Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
LUSC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg26958806	chr6:27640298	NA	0.67	5.75	0.3	1.96e-8	Depression;
LUSC	cis	rs12476592	0.602	rs2121351	chr2:63828361	G/A	cg10828910	chr2:63850056	LOC388955	0.5	5.81	0.3	1.49e-8	Childhood ear infection;
LUSC	cis	rs1863824	0.625	rs7091192	chr10:88167456	A/G	cg07322936	chr10:88137208	NA	-0.67	-9.63	-0.47	1.52e-19	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	20.89	0.75	1.43e-62	Prudent dietary pattern;
LUSC	cis	rs11690935	0.655	rs12052995	chr2:172537212	A/G	cg13550731	chr2:172543902	DYNC1I2	0.59	9.34	0.46	1.39e-18	Schizophrenia;
LUSC	cis	rs2835872	0.965	rs857946	chr21:39009303	A/T	cg20424643	chr21:39039972	KCNJ6	0.38	5.88	0.31	1.02e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg21775007	chr8:11205619	TDH	0.47	6.74	0.35	7e-11	Myopia (pathological);
LUSC	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg05147244	chr20:61493195	TCFL5	0.89	6.68	0.34	9.98e-11	Obesity-related traits;
LUSC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg02269571	chr22:50332266	NA	0.58	8.83	0.43	6.13e-17	Schizophrenia;
LUSC	cis	rs10489525	0.560	rs10858062	chr1:115602563	A/G	cg01522456	chr1:115632236	TSPAN2	0.51	7.52	0.38	5.19e-13	Autism;
LUSC	cis	rs3761218	0.668	rs6052079	chr20:3774209	G/T	cg02737268	chr20:3780182	CDC25B	0.36	6.9	0.35	2.58e-11	Bipolar disorder;
LUSC	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg14227996	chr4:17616232	MED28	0.8	8.14	0.41	7.99e-15	Opioid sensitivity;
LUSC	trans	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.38	-0.33	5.96e-10	Bladder cancer;
LUSC	trans	rs6982636	0.967	rs2954031	chr8:126491733	G/T	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.32	-6.25	-0.32	1.28e-9	Lipid metabolism phenotypes;
LUSC	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	7.12	0.36	6.54e-12	Ovarian reserve;
LUSC	cis	rs6556937	0.627	rs4590196	chr5:95997285	G/T	cg01741836	chr5:95996644	CAST	0.43	6.02	0.31	4.61e-9	Blood protein levels;
LUSC	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg04455712	chr21:45112962	RRP1B	0.46	8.65	0.43	2.23e-16	Mean corpuscular volume;
LUSC	cis	rs478607	0.831	rs59739006	chr11:64415903	C/T	cg19131476	chr11:64387923	NRXN2	0.34	6.06	0.31	3.76e-9	Urate levels;
LUSC	cis	rs6740322	0.948	rs6715072	chr2:43562230	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.93	-0.31	7.56e-9	Coronary artery disease;
LUSC	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg08085267	chr17:45401833	C17orf57	0.52	8.39	0.42	1.39e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs9929218	1.000	rs67359183	chr16:68814204	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.09	-0.55	3.58e-28	Colorectal cancer;
LUSC	trans	rs6480314	0.542	rs12572954	chr10:70030523	G/T	cg04882175	chr6:131122610	NA	-0.54	-6.15	-0.32	2.17e-9	Optic nerve measurement (disc area);
LUSC	cis	rs12541635	0.966	rs12544362	chr8:106976344	A/C	cg10147462	chr8:107024639	NA	0.56	9.8	0.47	4.11e-20	Age of smoking initiation;
LUSC	cis	rs887829	0.570	rs10168155	chr2:234596836	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.28	-0.33	1.04e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs4356932	0.967	rs4478212	chr4:76958899	A/G	cg00809888	chr4:76862425	NAAA	0.34	5.75	0.3	1.98e-8	Blood protein levels;
LUSC	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg06096015	chr1:231504339	EGLN1	0.53	9.06	0.44	1.11e-17	Hemoglobin concentration;
LUSC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2637266	1.000	rs2894337	chr10:78344871	C/T	cg18941641	chr10:78392320	NA	0.38	7.07	0.36	8.85e-12	Pulmonary function;
LUSC	cis	rs1863824	0.625	rs11202023	chr10:88165453	C/T	cg07322936	chr10:88137208	NA	-0.67	-9.82	-0.47	3.54e-20	Schizophrenia;
LUSC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.5	-0.34	2.86e-10	Joint mobility (Beighton score);
LUSC	cis	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg09307838	chr4:120376055	NA	-0.47	-7.23	-0.37	3.42e-12	Diastolic blood pressure;
LUSC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg08219700	chr8:58056026	NA	0.46	6.03	0.31	4.26e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg00495681	chr13:53174319	NA	0.8	15.51	0.65	2.93e-41	Lewy body disease;
LUSC	cis	rs2652834	0.851	rs4633662	chr15:63424286	G/A	cg05507819	chr15:63340323	TPM1	0.45	5.78	0.3	1.72e-8	HDL cholesterol;
LUSC	cis	rs11585357	0.793	rs112597506	chr1:17628832	A/G	cg08277548	chr1:17600880	PADI3	-0.6	-6.26	-0.32	1.17e-9	Hair shape;
LUSC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg24829409	chr8:58192753	C8orf71	-0.59	-6.54	-0.34	2.36e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs920590	0.643	rs2083641	chr8:19660217	A/C	cg03894339	chr8:19674705	INTS10	0.41	5.85	0.31	1.15e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12519773	0.597	rs4342312	chr5:92477890	C/A	cg18783429	chr5:92414398	NA	0.34	7.34	0.37	1.63e-12	Migraine;
LUSC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.68	-11.29	-0.53	2.85e-25	Systemic lupus erythematosus;
LUSC	cis	rs859767	0.540	rs17789633	chr2:135386474	G/T	cg12500956	chr2:135428796	TMEM163	0.27	6.51	0.34	2.72e-10	Neuroticism;
LUSC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.6	0.43	3.23e-16	Lung cancer;
LUSC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.54	0.57	8.07e-30	White blood cell count;
LUSC	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg16586182	chr3:47516702	SCAP	0.49	7.26	0.37	2.76e-12	Colorectal cancer;
LUSC	cis	rs4561483	0.831	rs33648	chr16:11979622	G/A	cg08843971	chr16:11963173	GSPT1	-0.45	-6.41	-0.33	4.83e-10	Testicular germ cell tumor;
LUSC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.81e-10	Bipolar disorder;
LUSC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg02475777	chr4:1388615	CRIPAK	0.44	6.5	0.34	2.92e-10	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg11062466	chr8:58055876	NA	0.7	8.6	0.43	3.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs13006833	0.668	rs291466	chr2:191184475	A/G	cg21644426	chr2:191273491	MFSD6	0.43	6.14	0.32	2.41e-9	Urinary metabolites;
LUSC	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-10.05	-0.48	6e-21	Morning vs. evening chronotype;
LUSC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg12963246	chr6:28129442	ZNF389	-0.52	-7.34	-0.37	1.68e-12	Depression;
LUSC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg06784218	chr1:46089804	CCDC17	0.5	9.72	0.47	7.96e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3771570	1.000	rs56363214	chr2:242227157	A/G	cg21155796	chr2:242212141	HDLBP	0.68	7.51	0.38	5.46e-13	Prostate cancer;
LUSC	cis	rs7267979	0.714	rs2474763	chr20:25241295	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	12.25	0.56	9.31e-29	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.7	11.44	0.53	8.42e-26	Blood protein levels;
LUSC	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-7.07	-0.36	8.88e-12	Alzheimer's disease (late onset);
LUSC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg06637938	chr14:75390232	RPS6KL1	0.5	7.85	0.39	5.57e-14	Height;
LUSC	trans	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg20935933	chr6:143382018	AIG1	0.51	7.43	0.38	8.96e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08045932	chr20:61659980	NA	0.56	9.62	0.47	1.67e-19	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg18964960	chr10:1102726	WDR37	0.47	6.55	0.34	2.17e-10	Response to angiotensin II receptor blocker therapy;
LUSC	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg25214090	chr10:38739885	LOC399744	0.54	7.91	0.4	3.85e-14	Corneal astigmatism;
LUSC	cis	rs977987	0.872	rs1542864	chr16:75471378	G/A	cg03315344	chr16:75512273	CHST6	0.53	10.32	0.49	7.71e-22	Dupuytren's disease;
LUSC	cis	rs9807989	0.801	rs11123925	chr2:102977511	G/A	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.5e-9	Asthma;
LUSC	cis	rs12220238	1.000	rs7904207	chr10:75884474	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	7.69	0.39	1.65e-13	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs977987	0.800	rs11645329	chr16:75336679	C/G	cg03315344	chr16:75512273	CHST6	0.48	8.9	0.44	3.61e-17	Dupuytren's disease;
LUSC	cis	rs7264396	0.836	rs1886695	chr20:34180535	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.52	7.56	0.38	3.84e-13	Total cholesterol levels;
LUSC	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg24558204	chr6:135376177	HBS1L	0.57	8.55	0.42	4.48e-16	Red blood cell count;
LUSC	cis	rs9811920	0.809	rs766778	chr3:99751480	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	5.97	0.31	6.08e-9	Axial length;
LUSC	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg24692254	chr21:30365293	RNF160	-0.54	-6.7	-0.34	8.77e-11	Cognitive test performance;
LUSC	cis	rs16910800	0.906	rs2449436	chr11:23204720	G/T	cg20040320	chr11:23191996	NA	0.44	6.52	0.34	2.58e-10	Cancer;
LUSC	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.64	0.39	2.25e-13	Iron status biomarkers;
LUSC	cis	rs354225	0.544	rs3796019	chr2:54807279	G/A	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	cis	rs3768617	0.811	rs12738377	chr1:183031256	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.61	0.43	3.01e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-5.9	-0.31	8.98e-9	Cutaneous nevi;
LUSC	cis	rs7712401	0.715	rs395981	chr5:122347911	C/T	cg19077854	chr5:122220652	SNX24	-0.41	-8.85	-0.44	5.29e-17	Mean platelet volume;
LUSC	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg23752985	chr2:85803571	VAMP8	-0.31	-6.48	-0.33	3.31e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	0.79	11.91	0.55	1.72e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-5.89	-0.31	9.39e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg18232548	chr7:50535776	DDC	-0.59	-8.59	-0.43	3.39e-16	Systemic sclerosis;
LUSC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg00825309	chr19:58991885	ZNF446	-0.52	-7.62	-0.38	2.64e-13	Uric acid clearance;
LUSC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06558623	chr16:89946397	TCF25	1.11	9.73	0.47	7.07e-20	Skin colour saturation;
LUSC	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	7.62	0.38	2.59e-13	Myopia (pathological);
LUSC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.91	15.59	0.65	1.52e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11214589	0.747	rs10502172	chr11:113199146	C/T	cg14159747	chr11:113255604	NA	0.26	6.42	0.33	4.68e-10	Neuroticism;
LUSC	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	7.58	0.38	3.41e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-0.82	-12.37	-0.56	3.44e-29	Blood protein levels;
LUSC	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.23	-0.45	3.29e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4834770	1.000	rs1397613	chr4:120242929	G/T	cg24375607	chr4:120327624	NA	0.41	5.84	0.3	1.26e-8	Blood protein levels;
LUSC	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg15744005	chr10:104629667	AS3MT	-0.34	-7.17	-0.37	4.94e-12	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg08523384	chr5:141488047	NDFIP1	-0.51	-7.21	-0.37	3.71e-12	Crohn's disease;
LUSC	cis	rs3126085	0.935	rs11583524	chr1:152161657	T/C	cg26876637	chr1:152193138	HRNR	-0.45	-5.96	-0.31	6.29e-9	Atopic dermatitis;
LUSC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg26408565	chr15:76604113	ETFA	0.53	8.77	0.43	9.05e-17	Blood metabolite levels;
LUSC	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg15839431	chr19:19639596	YJEFN3	0.61	6.6	0.34	1.63e-10	Bipolar disorder;
LUSC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg12564285	chr5:131593104	PDLIM4	-0.35	-6.51	-0.34	2.75e-10	Blood metabolite levels;
LUSC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	13.13	0.58	4.86e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg13010344	chr12:123464640	ARL6IP4	0.44	5.97	0.31	6.06e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg09034736	chr1:150693464	HORMAD1	0.4	5.73	0.3	2.2e-8	Melanoma;
LUSC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg27284194	chr4:1044797	NA	0.37	6.05	0.31	3.88e-9	Obesity-related traits;
LUSC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg07507251	chr3:52567010	NT5DC2	-0.32	-6.16	-0.32	2.07e-9	Bipolar disorder;
LUSC	trans	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.36	-0.33	6.48e-10	Bladder cancer;
LUSC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg05347473	chr6:146136440	FBXO30	0.52	8.54	0.42	4.68e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.48	-5.89	-0.31	9.6e-9	Iron status biomarkers;
LUSC	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.8	-0.35	4.79e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg08499158	chr17:42289980	UBTF	-0.56	-8.96	-0.44	2.37e-17	Total body bone mineral density;
LUSC	cis	rs859767	0.501	rs6705916	chr2:135397569	C/T	cg12500956	chr2:135428796	TMEM163	-0.27	-6.49	-0.33	3.07e-10	Neuroticism;
LUSC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	1.04	20.17	0.74	1.03e-59	Menopause (age at onset);
LUSC	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg04990556	chr1:26633338	UBXN11	0.85	11.21	0.52	5.72e-25	Obesity-related traits;
LUSC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg24209194	chr3:40518798	ZNF619	0.42	5.69	0.3	2.76e-8	Renal cell carcinoma;
LUSC	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg08079166	chr15:68083412	MAP2K5	0.41	8.47	0.42	8.02e-16	Restless legs syndrome;
LUSC	cis	rs3862435	0.572	rs2589969	chr15:90908051	T/C	cg22089800	chr15:90895588	ZNF774	0.58	6.3	0.33	9.47e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs4443100	1.000	rs4443100	chr22:23372864	C/G	cg14186256	chr22:23484241	RTDR1	0.47	5.9	0.31	8.73e-9	Serum parathyroid hormone levels;
LUSC	cis	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg05084668	chr3:125655381	ALG1L	-0.74	-10.88	-0.51	8.21e-24	Blood pressure (smoking interaction);
LUSC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg16228356	chr17:43848958	NA	-0.27	-6.28	-0.33	1.03e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg00376283	chr12:123451042	ABCB9	-0.65	-7.67	-0.39	1.91e-13	Neutrophil percentage of white cells;
LUSC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg02269571	chr22:50332266	NA	-0.55	-8.2	-0.41	5.16e-15	Schizophrenia;
LUSC	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-8.59	-0.43	3.4e-16	Systemic lupus erythematosus;
LUSC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg27432699	chr2:27873401	GPN1	-0.58	-8.68	-0.43	1.72e-16	Total body bone mineral density;
LUSC	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg01028140	chr2:1542097	TPO	-0.61	-8.28	-0.41	2.9e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.4e-10	Ulcerative colitis;
LUSC	trans	rs629535	0.679	rs62511660	chr8:70157089	G/A	cg21567404	chr3:27674614	NA	-0.93	-13.48	-0.59	2.32e-33	Dupuytren's disease;
LUSC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg00343986	chr7:65444356	GUSB	0.44	6.73	0.35	7.5e-11	Aortic root size;
LUSC	cis	rs7923609	0.871	rs7898861	chr10:65319678	T/C	cg01631684	chr10:65280961	REEP3	0.41	6.05	0.31	3.79e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.02e-14	Corneal astigmatism;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg05412045	chr2:3337680	TSSC1	-0.36	-5.98	-0.31	5.82e-9	N-glycan levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00293631	chr22:28315337	LOC284900;PITPNB	-0.4	-6.2	-0.32	1.71e-9	Electrocardiographic conduction measures;
LUSC	cis	rs68170813	0.652	rs6976759	chr7:107158506	A/G	cg02696742	chr7:106810147	HBP1	-0.64	-8.63	-0.43	2.46e-16	Coronary artery disease;
LUSC	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-0.92	-17.96	-0.7	6.13e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg25019033	chr10:957182	NA	-0.53	-6.0	-0.31	5.01e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	trans	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg25214090	chr10:38739885	LOC399744	0.57	8.17	0.41	6.24e-15	Corneal astigmatism;
LUSC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg09796270	chr17:17721594	SREBF1	-0.45	-8.24	-0.41	3.89e-15	Total body bone mineral density;
LUSC	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg15501526	chr10:2543763	NA	0.56	9.89	0.48	2.09e-20	Age-related hearing impairment;
LUSC	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.68	-7.65	-0.39	2.11e-13	Yeast infection;
LUSC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg20891283	chr12:69753455	YEATS4	0.65	10.16	0.49	2.71e-21	Blood protein levels;
LUSC	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg22431228	chr1:16359049	CLCNKA	-0.39	-7.1	-0.36	7.66e-12	Dilated cardiomyopathy;
LUSC	cis	rs17193922	0.876	rs17194040	chr16:53550898	C/T	cg09728985	chr16:53543985	NA	-0.4	-6.81	-0.35	4.53e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.93	12.09	0.55	3.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.51	7.94	0.4	3.2e-14	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg05425664	chr17:57184151	TRIM37	-0.57	-8.34	-0.42	1.96e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg07424592	chr7:64974309	NA	-0.41	-5.81	-0.3	1.45e-8	Calcium levels;
LUSC	cis	rs6977940	0.730	rs73033432	chr7:2891037	C/T	cg19731401	chr7:2775893	GNA12	0.69	7.54	0.38	4.62e-13	White matter integrity;
LUSC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg20243544	chr17:37824526	PNMT	0.5	7.11	0.36	6.96e-12	Asthma;
LUSC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.64	-10.53	-0.5	1.43e-22	Longevity;
LUSC	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg20503657	chr10:835505	NA	0.82	11.66	0.54	1.36e-26	Eosinophil percentage of granulocytes;
LUSC	cis	rs4363385	0.597	rs6679201	chr1:152976840	C/A	cg25856811	chr1:152973957	SPRR3	-0.34	-5.7	-0.3	2.69e-8	Inflammatory skin disease;
LUSC	cis	rs5770917	1.000	rs2269385	chr22:51010939	G/A	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.59	-5.7	-0.3	2.66e-8	Narcolepsy;
LUSC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	10.5	0.5	1.71e-22	Cognitive test performance;
LUSC	cis	rs271674	1.000	rs271674	chr17:47978986	A/G	cg05310240	chr17:47979069	NA	-0.38	-7.5	-0.38	5.88e-13	White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy;
LUSC	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg21963583	chr11:68658836	MRPL21	-0.4	-6.57	-0.34	1.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08280861	chr8:58055591	NA	0.52	5.73	0.3	2.21e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6084875	0.840	rs2065705	chr20:4719407	A/G	cg26097573	chr20:4721490	PRNT	0.31	5.77	0.3	1.78e-8	Systemic lupus erythematosus;
LUSC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg10729496	chr3:10149963	C3orf24	-0.49	-6.19	-0.32	1.77e-9	Alzheimer's disease;
LUSC	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.28	-0.41	2.9e-15	Response to antipsychotic treatment;
LUSC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-10.17	-0.49	2.45e-21	Monocyte count;
LUSC	cis	rs11605924	0.901	rs6485644	chr11:45855998	C/T	ch.11.939596F	chr11:45881766	CRY2	-0.5	-7.4	-0.38	1.13e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs926938	0.527	rs6680112	chr1:115548915	G/C	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.3	-0.33	9.18e-10	Autism;
LUSC	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.98	-0.36	1.64e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg22903471	chr2:27725779	GCKR	0.37	6.31	0.33	8.83e-10	Total body bone mineral density;
LUSC	cis	rs2692947	0.644	rs772175	chr2:96944553	G/A	cg23100626	chr2:96804247	ASTL	0.29	6.83	0.35	4.11e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.8	-0.35	4.88e-11	Lung cancer;
LUSC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	0.94	18.56	0.71	2.36e-53	Cognitive function;
LUSC	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg12473912	chr3:136751656	NA	0.4	7.17	0.37	4.99e-12	Neuroticism;
LUSC	cis	rs7177699	0.557	rs34372090	chr15:79110735	C/T	cg00540400	chr15:79124168	NA	-0.46	-7.98	-0.4	2.32e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs55728055	0.661	rs9619215	chr22:32042732	A/G	cg01338084	chr22:32026380	PISD	0.77	5.88	0.31	9.77e-9	Age-related hearing impairment;
LUSC	cis	rs75804782	0.521	rs55657931	chr2:239422072	A/G	cg18131467	chr2:239335373	ASB1	-0.69	-6.63	-0.34	1.37e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs4363385	0.818	rs4284210	chr1:152985711	G/A	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.09	-0.36	7.87e-12	Inflammatory skin disease;
LUSC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.58	-5.66	-0.3	3.3e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.4	-5.99	-0.31	5.42e-9	Menarche (age at onset);
LUSC	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-9.58	-0.46	2.32e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.7	0.3	2.59e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg07424592	chr7:64974309	NA	0.7	6.2	0.32	1.67e-9	Diabetic kidney disease;
LUSC	cis	rs240764	0.658	rs9399685	chr6:101204318	C/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.24	-0.32	1.32e-9	Neuroticism;
LUSC	cis	rs7524258	0.835	rs2412150	chr1:7303343	A/C	cg07173049	chr1:7289937	CAMTA1	0.35	7.32	0.37	1.82e-12	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg11663144	chr21:46675770	NA	-0.43	-7.37	-0.37	1.35e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg16797656	chr11:68205561	LRP5	0.35	6.0	0.31	5.2e-9	Total body bone mineral density;
LUSC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg13607699	chr17:42295918	UBTF	0.53	8.18	0.41	5.97e-15	Total body bone mineral density;
LUSC	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg26597838	chr10:835615	NA	0.56	7.33	0.37	1.74e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg16647868	chr5:131706066	SLC22A5	0.39	6.03	0.31	4.23e-9	Acylcarnitine levels;
LUSC	cis	rs7681440	0.647	rs6824979	chr4:90819407	C/G	cg15133208	chr4:90757351	SNCA	0.35	5.89	0.31	9.44e-9	Dementia with Lewy bodies;
LUSC	cis	rs11645898	0.935	rs72787094	chr16:72192613	C/A	cg14768367	chr16:72042858	DHODH	-0.64	-6.99	-0.36	1.47e-11	Blood protein levels;
LUSC	cis	rs859767	0.501	rs10928507	chr2:135396631	C/T	cg12500956	chr2:135428796	TMEM163	0.28	6.68	0.34	9.8e-11	Neuroticism;
LUSC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg04632378	chr13:21900426	NA	0.32	5.89	0.31	9.6e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	trans	rs9944715	0.834	rs9949494	chr18:43811300	T/C	cg01718231	chr17:29326311	RNF135	-0.5	-7.01	-0.36	1.29e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.53	-11.22	-0.52	5.31e-25	Vitamin D levels;
LUSC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg17948913	chr5:572064	NA	0.36	6.08	0.32	3.32e-9	Obesity-related traits;
LUSC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg05313129	chr8:58192883	C8orf71	-0.52	-5.9	-0.31	9.1e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg08975724	chr8:8085496	FLJ10661	0.47	7.09	0.36	7.88e-12	Mood instability;
LUSC	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg05738196	chr6:26577821	NA	0.77	13.68	0.6	3.8e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs11608355	0.545	rs33997929	chr12:109912064	C/T	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg05084668	chr3:125655381	ALG1L	-0.79	-12.02	-0.55	6.76e-28	Blood pressure (smoking interaction);
LUSC	cis	rs10904908	1.000	rs7903259	chr10:17259642	C/G	cg01003015	chr10:17271136	VIM	0.43	6.37	0.33	6.27e-10	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.25	-0.41	3.75e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg20016023	chr10:99160130	RRP12	-0.32	-7.95	-0.4	2.92e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs73001065	0.818	rs10500212	chr19:19723215	C/T	cg03709012	chr19:19516395	GATAD2A	0.89	7.12	0.36	6.51e-12	LDL cholesterol;
LUSC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg02807482	chr3:125708958	NA	-0.52	-6.5	-0.33	2.98e-10	Blood pressure (smoking interaction);
LUSC	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg15997130	chr1:24165203	NA	0.57	9.2	0.45	3.86e-18	Immature fraction of reticulocytes;
LUSC	cis	rs10992471	0.603	rs1980848	chr9:95248571	A/G	cg14631576	chr9:95140430	CENPP	0.34	6.17	0.32	2e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22029157	chr1:209979665	IRF6	0.75	11.17	0.52	7.96e-25	Cleft lip with or without cleft palate;
LUSC	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg03585969	chr10:35415529	CREM	0.64	9.06	0.44	1.14e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg08600765	chr20:34638493	LOC647979	-0.67	-7.64	-0.39	2.25e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg23649088	chr2:200775458	C2orf69	-0.54	-6.96	-0.36	1.85e-11	Schizophrenia;
LUSC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg12463550	chr7:65579703	CRCP	0.56	8.35	0.42	1.79e-15	Aortic root size;
LUSC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg07424592	chr7:64974309	NA	0.65	5.77	0.3	1.85e-8	Diabetic kidney disease;
LUSC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg07936489	chr17:37558343	FBXL20	0.69	9.58	0.46	2.38e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs9283706	0.608	rs13171572	chr5:66334552	T/A	cg11590213	chr5:66331682	MAST4	0.44	6.42	0.33	4.75e-10	Coronary artery disease;
LUSC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg23630131	chr7:65973040	NA	-0.21	-5.71	-0.3	2.52e-8	Aortic root size;
LUSC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.73	-10.03	-0.48	7.03e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.83	0.63	1.46e-38	Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00432041	chr8:67341355	RRS1	0.44	6.74	0.35	6.93e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10100465	0.961	rs6469699	chr8:118644899	A/C	cg09430518	chr8:118662568	NA	-0.3	-5.71	-0.3	2.43e-8	Leprosy;
LUSC	trans	rs12210905	0.844	rs7773336	chr6:26993555	A/G	cg11837749	chr1:55047332	ACOT11	0.55	6.0	0.31	5.25e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg19774624	chr17:42201019	HDAC5	-0.81	-13.73	-0.6	2.59e-34	Total body bone mineral density;
LUSC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg14019146	chr3:50243930	SLC38A3	0.37	8.52	0.42	5.56e-16	Body mass index;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg00761861	chr14:68141669	VTI1B	0.38	5.96	0.31	6.45e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg18350739	chr11:68623251	NA	-0.36	-6.54	-0.34	2.32e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs16937	0.711	rs4951172	chr1:205137578	A/G	cg00857998	chr1:205179979	DSTYK	-0.46	-6.47	-0.33	3.48e-10	Schizophrenia;
LUSC	cis	rs2694528	0.623	rs3857238	chr5:60066325	C/G	cg11474532	chr5:59995715	DEPDC1B	-0.6	-6.19	-0.32	1.72e-9	Parkinson's disease;
LUSC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg04287289	chr16:89883240	FANCA	0.77	6.23	0.32	1.42e-9	Skin colour saturation;
LUSC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg00343986	chr7:65444356	GUSB	0.43	6.55	0.34	2.22e-10	Aortic root size;
LUSC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21984481	chr17:79567631	NPLOC4	0.55	10.62	0.5	6.59e-23	Eye color traits;
LUSC	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	8.05	0.4	1.49e-14	Height;
LUSC	cis	rs1595825	0.732	rs74885211	chr2:198419911	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.27	-0.32	1.15e-9	Ulcerative colitis;
LUSC	trans	rs1493916	0.837	rs8088362	chr18:31413016	A/G	cg27147174	chr7:100797783	AP1S1	-0.56	-8.69	-0.43	1.63e-16	Life satisfaction;
LUSC	cis	rs12776158	0.901	rs57805780	chr10:71216455	A/C	cg12610070	chr10:71211762	TSPAN15	-0.46	-6.05	-0.31	3.9e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs16867321	0.639	rs13028421	chr2:181444035	G/T	cg23363182	chr2:181467187	NA	0.57	9.2	0.45	4.03e-18	Obesity;
LUSC	cis	rs4588572	0.686	rs2362823	chr5:77693623	A/G	cg11547950	chr5:77652471	NA	0.51	7.54	0.38	4.47e-13	Triglycerides;
LUSC	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg02454025	chr1:11042201	C1orf127	1.03	18.59	0.71	1.77e-53	Ewing sarcoma;
LUSC	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg24375607	chr4:120327624	NA	0.79	12.05	0.55	5.19e-28	Corneal astigmatism;
LUSC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.32	0.53	2.37e-25	Colorectal cancer;
LUSC	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg22878388	chr2:105853796	NA	-0.33	-6.02	-0.31	4.68e-9	Type 2 diabetes;
LUSC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg06637938	chr14:75390232	RPS6KL1	0.53	8.46	0.42	8.44e-16	Height;
LUSC	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg20283391	chr11:68216788	NA	-0.51	-7.33	-0.37	1.71e-12	Total body bone mineral density;
LUSC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.45	6.68	0.34	1.01e-10	Tumor biomarkers;
LUSC	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg05519781	chr21:40033154	ERG	0.62	10.03	0.48	7.47e-21	Coronary artery disease;
LUSC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-6.31	-0.33	9.06e-10	Monocyte count;
LUSC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg23985595	chr17:80112537	CCDC57	-0.3	-5.71	-0.3	2.55e-8	Life satisfaction;
LUSC	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg02175503	chr12:58329896	NA	0.48	6.98	0.36	1.57e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11764359	chr7:65958608	NA	0.58	8.62	0.43	2.82e-16	Aortic root size;
LUSC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11645453	chr3:52864694	ITIH4	-0.42	-10.37	-0.49	5.15e-22	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11800820	0.536	rs10802409	chr1:246632031	C/T	cg16700716	chr1:246684329	NA	0.34	5.65	0.3	3.37e-8	Obesity-related traits;
LUSC	cis	rs56146971	0.763	rs55950330	chr14:91872978	C/T	cg10511902	chr14:91842949	CCDC88C	0.46	5.97	0.31	6.14e-9	Alzheimer disease and age of onset;
LUSC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg05425664	chr17:57184151	TRIM37	-0.54	-8.01	-0.4	1.87e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7561273	0.586	rs7580772	chr2:24357657	T/C	cg20701182	chr2:24300061	SF3B14	0.46	5.87	0.31	1.05e-8	Quantitative traits;
LUSC	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-1.06	-12.8	-0.57	8.48e-31	Schizophrenia;
LUSC	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	13.19	0.59	2.96e-32	Mean platelet volume;
LUSC	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.83	0.3	1.3e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg24634471	chr8:143751801	JRK	0.6	8.99	0.44	1.83e-17	Schizophrenia;
LUSC	cis	rs1847202	0.859	rs7634316	chr3:72941452	C/G	cg25664220	chr3:72788482	NA	0.38	6.27	0.32	1.13e-9	Motion sickness;
LUSC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg13206674	chr6:150067644	NUP43	0.56	8.89	0.44	3.91e-17	Lung cancer;
LUSC	cis	rs9837602	0.935	rs17392948	chr3:99754498	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	5.82	0.3	1.36e-8	Breast cancer;
LUSC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.7	9.84	0.47	3.06e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs2346177	0.846	rs6714738	chr2:46646164	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-8.73	-0.43	1.2e-16	HDL cholesterol;
LUSC	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg26384229	chr12:38710491	ALG10B	0.72	11.42	0.53	1.02e-25	Morning vs. evening chronotype;
LUSC	cis	rs728616	0.558	rs35547640	chr10:82139150	C/T	cg05935833	chr10:81318306	SFTPA2	-0.43	-5.87	-0.31	1.08e-8	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs516243	0.841	rs6540944	chr1:10740405	C/T	cg02903756	chr1:10750680	CASZ1	-0.51	-9.11	-0.45	7.87e-18	Migraine - clinic-based;
LUSC	cis	rs6750047	0.605	rs1374191	chr2:38265420	T/G	cg07380506	chr2:38303506	CYP1B1	-0.45	-6.28	-0.33	1.02e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg04362960	chr10:104952993	NT5C2	0.5	6.29	0.33	9.94e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9815354	1.000	rs2128834	chr3:41862645	A/G	cg03022575	chr3:42003672	ULK4	0.56	6.7	0.34	8.72e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg00757033	chr12:89920650	WDR51B	0.6	10.33	0.49	7.01e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6681460	1.000	rs6680876	chr1:67129482	G/A	cg02459107	chr1:67143332	SGIP1	0.48	9.04	0.44	1.34e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs9311676	0.656	rs55964615	chr3:58389120	A/T	cg26110898	chr3:58419937	PDHB	0.4	6.53	0.34	2.4e-10	Systemic lupus erythematosus;
LUSC	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg19610905	chr11:61596333	FADS2	-0.54	-7.61	-0.38	2.85e-13	Red cell distribution width;Mean platelet volume;
LUSC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.68	-10.52	-0.5	1.53e-22	Aortic root size;
LUSC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.7	12.1	0.55	3.36e-28	Prudent dietary pattern;
LUSC	cis	rs3771570	1.000	rs62193202	chr2:242303717	G/A	cg21155796	chr2:242212141	HDLBP	0.62	6.67	0.34	1.07e-10	Prostate cancer;
LUSC	cis	rs870825	0.616	rs28672716	chr4:185647345	G/A	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg16524733	chr11:117070046	TAGLN	0.42	7.19	0.37	4.35e-12	Blood protein levels;
LUSC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	14.99	0.63	3.42e-39	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.69	-0.34	9.34e-11	Lung cancer;
LUSC	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.69	-11.11	-0.52	1.28e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3942852	0.868	rs10769315	chr11:48110367	A/G	cg20307385	chr11:47447363	PSMC3	0.54	6.28	0.33	1.04e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6541297	0.699	rs4846916	chr1:230296492	G/A	cg05784532	chr1:230284198	GALNT2	0.58	6.68	0.34	9.94e-11	Coronary artery disease;
LUSC	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.33	0.62	1.18e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs597583	0.709	rs7940527	chr11:117398202	C/G	cg27161313	chr11:117392002	DSCAML1	0.38	6.7	0.34	9.04e-11	Putamen volume;
LUSC	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	0.8	9.91	0.48	1.86e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.39	-7.57	-0.38	3.79e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	14.39	0.62	7.35e-37	Platelet count;
LUSC	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg27284194	chr4:1044797	NA	0.56	7.73	0.39	1.31e-13	Recombination rate (females);
LUSC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg14403583	chr14:105418241	AHNAK2	-0.59	-9.83	-0.47	3.42e-20	Rheumatoid arthritis;
LUSC	cis	rs6961069	0.745	rs13233631	chr7:80270822	A/G	cg04458919	chr7:80252533	CD36	0.35	6.27	0.32	1.09e-9	Platelet count;
LUSC	cis	rs679087	1.000	rs302321	chr12:29928388	A/C	cg14258853	chr12:29935411	TMTC1	1.0	17.66	0.69	9.56e-50	Schizophrenia;
LUSC	cis	rs6494488	0.500	rs72744722	chr15:65020453	C/A	cg08069370	chr15:64387884	SNX1	-0.66	-5.78	-0.3	1.71e-8	Coronary artery disease;
LUSC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg26384229	chr12:38710491	ALG10B	0.76	12.49	0.56	1.28e-29	Heart rate;
LUSC	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg05985134	chr18:33552581	C18orf21	0.5	6.73	0.35	7.22e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg09034736	chr1:150693464	HORMAD1	0.46	6.71	0.34	8.14e-11	Melanoma;
LUSC	cis	rs4363385	0.818	rs6587719	chr1:152993409	G/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.5	-0.38	5.84e-13	Inflammatory skin disease;
LUSC	cis	rs61990749	0.597	rs2299930	chr14:78163722	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.54	-5.85	-0.3	1.16e-8	Fibroblast growth factor basic levels;
LUSC	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg24503407	chr1:205819492	PM20D1	-0.48	-6.37	-0.33	6.13e-10	Menarche (age at onset);
LUSC	cis	rs7615316	0.779	rs7627694	chr3:142100478	T/C	cg16271453	chr3:142027066	XRN1	-0.41	-7.18	-0.37	4.48e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg23093090	chr10:104574429	C10orf26	-0.49	-9.75	-0.47	6.13e-20	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg21643547	chr1:205240462	TMCC2	-0.49	-9.38	-0.46	1.03e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-0.95	-18.47	-0.71	5.46e-53	Brugada syndrome;
LUSC	cis	rs737008	0.922	rs2550475	chr16:11371986	C/T	cg00044050	chr16:11439710	C16orf75	0.57	8.92	0.44	3.03e-17	Obesity-related traits;
LUSC	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg14061069	chr19:46274453	DMPK	-0.52	-8.99	-0.44	1.81e-17	Coronary artery disease;
LUSC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg05738196	chr6:26577821	NA	0.53	8.32	0.41	2.23e-15	Schizophrenia;
LUSC	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg07587117	chr16:2239488	CASKIN1	-0.31	-5.65	-0.3	3.42e-8	Height;
LUSC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06634786	chr22:41940651	POLR3H	0.51	6.11	0.32	2.82e-9	Vitiligo;
LUSC	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg00225070	chr15:80189496	MTHFS	0.61	9.44	0.46	6.63e-19	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	0.88	12.29	0.56	7.03e-29	Vitiligo;
LUSC	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg06636001	chr8:8085503	FLJ10661	0.57	8.45	0.42	8.93e-16	Retinal vascular caliber;
LUSC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.17	-0.32	1.94e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.38	7.93	0.4	3.38e-14	Hemoglobin concentration;
LUSC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg09640425	chr7:158790006	NA	-0.4	-6.19	-0.32	1.78e-9	Facial morphology (factor 20);
LUSC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg14552801	chr7:65878734	NA	-0.46	-6.34	-0.33	7.34e-10	Aortic root size;
LUSC	cis	rs13082711	0.522	rs578501	chr3:27344963	A/G	cg02860705	chr3:27208620	NA	0.46	8.37	0.42	1.57e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs9937943	0.673	rs12922972	chr16:74494522	T/A	cg01733217	chr16:74700730	RFWD3	0.58	6.49	0.33	3.11e-10	Neutrophil percentage of white cells;
LUSC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg00129232	chr17:37814104	STARD3	-0.49	-7.38	-0.37	1.23e-12	Asthma;
LUSC	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-8.45	-0.42	9.42e-16	Monocyte percentage of white cells;
LUSC	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg11502198	chr6:26597334	ABT1	0.59	9.24	0.45	2.86e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg15704280	chr7:45808275	SEPT13	-1.01	-18.94	-0.72	7.57e-55	Height;
LUSC	trans	rs11165623	0.740	rs12126692	chr1:96889258	C/G	cg10631902	chr5:14652156	NA	0.54	8.77	0.43	9.45e-17	Hip circumference;Waist circumference;
LUSC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg07777115	chr5:623756	CEP72	-0.47	-5.77	-0.3	1.78e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg17264618	chr3:40429014	ENTPD3	0.3	6.18	0.32	1.85e-9	Renal cell carcinoma;
LUSC	trans	rs10511400	0.618	rs6438566	chr3:119870789	T/C	cg02809009	chr19:50354510	PTOV1	-0.68	-6.19	-0.32	1.81e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs6977660	0.714	rs10249477	chr7:19805388	T/A	cg07541023	chr7:19748670	TWISTNB	0.64	6.92	0.35	2.28e-11	Thyroid stimulating hormone;
LUSC	trans	rs7939886	0.920	rs1586014	chr11:55771540	C/T	cg15704280	chr7:45808275	SEPT13	0.85	7.39	0.37	1.21e-12	Myopia (pathological);
LUSC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12311346	chr5:56204834	C5orf35	-0.84	-13.02	-0.58	1.29e-31	Initial pursuit acceleration;
LUSC	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg18230493	chr5:56204884	C5orf35	-0.57	-9.1	-0.45	8.19e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.73	0.6	2.45e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.49	-7.07	-0.36	8.9e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9473147	0.543	rs9381578	chr6:47556634	C/T	cg20196966	chr6:47445060	CD2AP	0.41	5.75	0.3	2.07e-8	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15099667	chr2:219134699	PNKD;AAMP	0.49	6.73	0.35	7.29e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg26769984	chr7:1090371	C7orf50	0.71	10.21	0.49	1.79e-21	Bronchopulmonary dysplasia;
LUSC	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.25	-0.32	1.26e-9	Mood instability;
LUSC	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.69	10.47	0.5	2.2e-22	Corneal astigmatism;
LUSC	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg04586622	chr2:25135609	ADCY3	0.32	6.18	0.32	1.92e-9	Body mass index;
LUSC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg11812906	chr14:75593930	NEK9	0.66	11.31	0.53	2.47e-25	Height;
LUSC	cis	rs983392	0.709	rs7932740	chr11:59976111	G/A	cg20284999	chr11:59952153	MS4A6A	-0.38	-6.24	-0.32	1.29e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6489882	0.703	rs10774671	chr12:113357193	G/A	cg20102336	chr12:113376681	OAS3	-0.39	-5.77	-0.3	1.82e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg24531977	chr5:56204891	C5orf35	0.61	9.15	0.45	5.56e-18	Coronary artery disease;
LUSC	cis	rs5753037	0.702	rs140100	chr22:30128240	C/T	cg01021169	chr22:30184971	ASCC2	-0.34	-5.77	-0.3	1.85e-8	Type 1 diabetes;
LUSC	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg25797454	chr6:150327115	RAET1K	0.33	7.5	0.38	5.67e-13	Alopecia areata;
LUSC	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.64	0.47	1.41e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs6977660	0.714	rs10252965	chr7:19822385	A/C	cg07541023	chr7:19748670	TWISTNB	0.58	6.24	0.32	1.34e-9	Thyroid stimulating hormone;
LUSC	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg26394196	chr10:1453818	ADARB2	-0.39	-6.7	-0.34	8.94e-11	Radiation response;
LUSC	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg13390004	chr1:15929781	NA	0.41	6.85	0.35	3.63e-11	Systolic blood pressure;
LUSC	cis	rs4566357	1.000	rs2177598	chr2:227922900	T/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.75	-0.3	1.97e-8	Coronary artery disease;
LUSC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg02079420	chr8:82753780	SNX16	0.38	5.79	0.3	1.6e-8	Diastolic blood pressure;
LUSC	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg22601191	chr20:60968625	CABLES2	0.43	6.11	0.32	2.77e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03352830	chr11:487213	PTDSS2	0.66	8.44	0.42	1e-15	Body mass index;
LUSC	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.55e-13	Putamen volume;
LUSC	cis	rs877282	0.947	rs4133015	chr10:774131	T/C	cg17470449	chr10:769945	NA	0.5	7.14	0.36	5.94e-12	Uric acid levels;
LUSC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.7	-11.5	-0.53	5e-26	Cognitive function;
LUSC	cis	rs10450586	0.932	rs10767632	chr11:27318465	C/G	cg08958251	chr11:27270390	NA	0.35	5.75	0.3	2.07e-8	Total body bone mineral density;
LUSC	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg24375607	chr4:120327624	NA	0.78	11.63	0.54	1.74e-26	Corneal astigmatism;
LUSC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-6.7	-0.34	8.72e-11	Tonsillectomy;
LUSC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	9.66	0.47	1.21e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg05347473	chr6:146136440	FBXO30	0.53	9.23	0.45	3.29e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg13560548	chr3:10150139	C3orf24	0.55	7.84	0.39	6.05e-14	Alzheimer's disease;
LUSC	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg05738196	chr6:26577821	NA	0.79	14.91	0.63	6.82e-39	Intelligence (multi-trait analysis);
LUSC	trans	rs6725041	0.805	rs6745249	chr2:213130571	A/G	cg17386128	chr2:173420391	PDK1	-0.41	-6.06	-0.31	3.77e-9	QT interval (ambient particulate matter interaction);
LUSC	trans	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg19694781	chr19:47549865	TMEM160	-0.39	-6.2	-0.32	1.66e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg20935933	chr6:143382018	AIG1	0.5	7.27	0.37	2.61e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg22907277	chr7:1156413	C7orf50	0.45	6.8	0.35	4.95e-11	Longevity;Endometriosis;
LUSC	cis	rs2235649	0.663	rs6600168	chr16:1848927	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-5.96	-0.31	6.24e-9	Blood metabolite levels;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.65	-12.59	-0.57	5.4e-30	Longevity;Endometriosis;
LUSC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.52	7.27	0.37	2.56e-12	Gut microbiome composition (summer);
LUSC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg25072359	chr17:41440525	NA	0.6	8.57	0.42	4.01e-16	Menopause (age at onset);
LUSC	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.89	14.82	0.63	1.52e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg23711669	chr6:146136114	FBXO30	0.84	15.31	0.64	1.92e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg20744362	chr22:50050164	C22orf34	-0.37	-7.8	-0.39	8.18e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg26395211	chr5:140044315	WDR55	0.45	7.01	0.36	1.29e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7572644	0.640	rs4564736	chr2:28069543	A/T	cg27432699	chr2:27873401	GPN1	0.51	6.96	0.36	1.78e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg23711669	chr6:146136114	FBXO30	0.88	16.15	0.66	9.46e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04063615	chr12:132293388	NA	-0.36	-5.99	-0.31	5.3e-9	Migraine;
LUSC	cis	rs68092024	0.731	rs792841	chr3:99471308	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.38	0.33	5.94e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg24562669	chr7:97807699	LMTK2	0.4	7.0	0.36	1.43e-11	Breast cancer;
LUSC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11764359	chr7:65958608	NA	0.55	7.32	0.37	1.81e-12	Aortic root size;
LUSC	cis	rs7760949	0.889	rs9475807	chr6:13934597	T/C	cg27413430	chr6:13925136	RNF182	0.61	8.94	0.44	2.64e-17	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-9.27	-0.45	2.35e-18	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.500	rs9772760	chr8:57986999	G/C	cg22535103	chr8:58192502	C8orf71	-0.48	-6.46	-0.33	3.76e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs73200209	0.744	rs61939680	chr12:116493867	G/A	cg01776926	chr12:116560359	MED13L	-0.5	-5.94	-0.31	7.14e-9	Total body bone mineral density;
LUSC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.38	-5.78	-0.3	1.74e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.94	0.31	7.28e-9	Menopause (age at onset);
LUSC	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.77	11.16	0.52	8.86e-25	Corneal astigmatism;
LUSC	trans	rs7980799	0.649	rs2220059	chr12:33648630	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.95	-0.31	6.71e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs7712401	0.601	rs246320	chr5:122308581	A/G	cg19077854	chr5:122220652	SNX24	0.44	9.77	0.47	5.19e-20	Mean platelet volume;
LUSC	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	5.77	0.3	1.82e-8	Schizophrenia;
LUSC	cis	rs1858037	0.867	rs871974	chr2:65557287	C/T	cg08085232	chr2:65598271	SPRED2	0.43	6.58	0.34	1.83e-10	Rheumatoid arthritis;
LUSC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14298792	chr15:30685198	CHRFAM7A	-0.5	-6.06	-0.31	3.72e-9	Huntington's disease progression;
LUSC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.83	0.3	1.3e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg27170947	chr2:26402098	FAM59B	0.73	10.81	0.51	1.45e-23	Gut microbiome composition (summer);
LUSC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg18230493	chr5:56204884	C5orf35	-0.86	-13.12	-0.58	5.35e-32	Initial pursuit acceleration;
LUSC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg05393297	chr12:53359155	NA	-0.73	-11.3	-0.53	2.71e-25	Cancer (pleiotropy);
LUSC	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg13010199	chr12:38710504	ALG10B	0.68	10.62	0.5	6.57e-23	Bladder cancer;
LUSC	trans	rs12210905	0.925	rs11966939	chr6:27003749	T/C	cg11837749	chr1:55047332	ACOT11	0.59	6.3	0.33	9.16e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs7005380	0.556	rs35362581	chr8:120933868	G/C	cg21744203	chr8:120868354	DSCC1	0.48	5.85	0.3	1.2e-8	Interstitial lung disease;
LUSC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.71	11.55	0.53	3.34e-26	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	12.23	0.56	1.16e-28	Cognitive test performance;
LUSC	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	0.83	11.65	0.54	1.45e-26	Blood protein levels;
LUSC	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg05340658	chr4:99064831	C4orf37	0.68	11.4	0.53	1.23e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs62056376	0.607	rs7213556	chr17:32592915	C/A	cg19986872	chr5:131347773	ACSL6	-0.38	-5.98	-0.31	5.65e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs9905704	0.633	rs8068455	chr17:56589381	C/T	cg19466818	chr17:56409534	MIR142	0.37	6.89	0.35	2.72e-11	Testicular germ cell tumor;
LUSC	cis	rs4285028	0.747	rs11916169	chr3:121403211	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-12.85	-0.58	5.56e-31	Multiple sclerosis;
LUSC	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.37	-6.87	-0.35	3.15e-11	Coronary artery disease;
LUSC	trans	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg07393940	chr7:158741817	NA	0.36	6.57	0.34	1.98e-10	Life satisfaction;
LUSC	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1941023	0.584	rs10750937	chr11:60172087	C/T	cg08716584	chr11:60157161	MS4A7	-0.62	-11.34	-0.53	2.02e-25	Congenital heart disease (maternal effect);
LUSC	cis	rs10905065	0.829	rs2246399	chr10:5799286	T/A	cg11519256	chr10:5708881	ASB13	-0.41	-5.93	-0.31	7.45e-9	Menopause (age at onset);
LUSC	cis	rs4664304	0.658	rs2667012	chr2:160867553	G/T	cg03641300	chr2:160917029	PLA2R1	-0.36	-6.05	-0.31	3.87e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs1595825	0.891	rs10497810	chr2:198895732	C/T	cg00982548	chr2:198649783	BOLL	-0.54	-6.89	-0.35	2.72e-11	Ulcerative colitis;
LUSC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.93	0.48	1.54e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.82	-0.39	7.14e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg14668632	chr7:2872130	GNA12	-0.42	-6.2	-0.32	1.69e-9	Height;
LUSC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	0.97	18.01	0.7	3.7700000000000003e-51	Bone mineral density;
LUSC	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg13010199	chr12:38710504	ALG10B	0.7	10.68	0.5	4.37e-23	Bladder cancer;
LUSC	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg19875535	chr5:140030758	IK	0.51	8.18	0.41	5.84e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs73206853	0.841	rs73191825	chr12:110942205	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	6.44	0.33	4.21e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-9.43	-0.46	7.23e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4629710	0.534	rs6916881	chr6:131565153	C/T	cg12700074	chr6:131571435	AKAP7	-0.35	-5.86	-0.31	1.13e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.71	0.3	2.52e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7246967	0.673	rs35007247	chr19:22822923	C/T	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs6063312	1.000	rs6095261	chr20:47346494	C/A	cg18078177	chr20:47281410	PREX1	0.6	7.18	0.37	4.55e-12	Tonometry;
LUSC	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg00484396	chr16:3507460	NAT15	-0.46	-7.58	-0.38	3.53e-13	Body mass index (adult);
LUSC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03934478	chr11:495069	RNH1	0.82	9.89	0.48	2.07e-20	Body mass index;
LUSC	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg24130564	chr14:104152367	KLC1	-0.45	-6.22	-0.32	1.45e-9	Body mass index;
LUSC	cis	rs12541635	0.677	rs2029879	chr8:107024695	T/A	cg10147462	chr8:107024639	NA	0.68	14.15	0.61	5.93e-36	Age of smoking initiation;
LUSC	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg25930673	chr12:123319894	HIP1R	-0.66	-6.46	-0.33	3.65e-10	Schizophrenia;
LUSC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23158103	chr7:148848205	ZNF398	-0.43	-6.78	-0.35	5.4e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg11663144	chr21:46675770	NA	-0.39	-6.83	-0.35	4.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	7.25	0.37	2.87e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs34638657	0.732	rs12597010	chr16:82199971	G/A	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.47	-0.33	3.55e-10	Lung adenocarcinoma;
LUSC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-10.22	-0.49	1.58e-21	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06127414	chr17:1179309	NA	-0.37	-6.39	-0.33	5.47e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs13089785	1.000	rs2332682	chr3:123654633	C/T	cg20230305	chr3:123418791	MYLK	0.36	6.0	0.31	5.17e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg07395648	chr5:131743802	NA	-0.42	-6.91	-0.35	2.42e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg17366294	chr4:99064904	C4orf37	0.57	10.05	0.48	6.03e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg08508325	chr11:3079039	CARS	-0.54	-13.66	-0.6	4.64e-34	Longevity;
LUSC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-8.97	-0.44	2.24e-17	Chronic sinus infection;
LUSC	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-15.59	-0.65	1.42e-41	Primary sclerosing cholangitis;
LUSC	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg01528321	chr10:82214614	TSPAN14	0.84	12.2	0.56	1.44e-28	Post bronchodilator FEV1;
LUSC	cis	rs977987	0.654	rs8054194	chr16:75497160	G/T	cg03315344	chr16:75512273	CHST6	0.51	9.38	0.46	1.04e-18	Dupuytren's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14608199	chr11:2949963	PHLDA2	0.38	6.05	0.31	3.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25072359	chr17:41440525	NA	0.66	9.28	0.45	2.14e-18	Menopause (age at onset);
LUSC	cis	rs253664	0.897	rs1199328	chr3:138112107	G/A	cg25188949	chr3:137893707	DBR1	-0.49	-5.91	-0.31	8.26e-9	Body mass index;
LUSC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg20135002	chr11:47629003	NA	-0.51	-7.98	-0.4	2.41e-14	Subjective well-being;
LUSC	cis	rs72634258	0.786	rs9434992	chr1:8179392	G/T	cg26816564	chr1:7831052	VAMP3	0.47	6.17	0.32	1.92e-9	Inflammatory bowel disease;
LUSC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg20573242	chr4:122745356	CCNA2	0.63	9.38	0.46	1.06e-18	Type 2 diabetes;
LUSC	cis	rs6733011	0.644	rs6719634	chr2:99460614	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-5.67	-0.3	3.07e-8	Bipolar disorder;
LUSC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg12560992	chr17:57184187	TRIM37	0.8	14.01	0.61	2.07e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs7577696	0.785	rs11683842	chr2:32364131	G/A	cg02381751	chr2:32503542	YIPF4	-0.44	-6.22	-0.32	1.53e-9	Inflammatory biomarkers;
LUSC	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg07169764	chr2:136633963	MCM6	-0.6	-8.05	-0.4	1.47e-14	Mosquito bite size;
LUSC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs8008758	1.000	rs12432879	chr14:101688977	A/G	cg26224664	chr14:101693935	NA	0.26	5.66	0.3	3.33e-8	Body mass index (alcohol intake interaction);
LUSC	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.76	-13.71	-0.6	3e-34	Ulcerative colitis;
LUSC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg18230493	chr5:56204884	C5orf35	-0.76	-9.0	-0.44	1.81e-17	Type 2 diabetes;
LUSC	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg12179176	chr11:130786555	SNX19	0.52	7.81	0.39	7.61e-14	Schizophrenia;
LUSC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg09877947	chr5:131593287	PDLIM4	-0.47	-6.69	-0.34	9.34e-11	Breast cancer;
LUSC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-7.47	-0.38	7.17e-13	Chronic sinus infection;
LUSC	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg08999081	chr20:33150536	PIGU	-0.41	-7.56	-0.38	3.88e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs2273669	0.667	rs75263286	chr6:109350489	G/C	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	9.1e-9	Prostate cancer;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg23981150	chr1:161111090	NA	-0.4	-6.06	-0.31	3.71e-9	N-glycan levels;
LUSC	cis	rs73206853	0.841	rs73191836	chr12:110966177	G/T	cg12870014	chr12:110450643	ANKRD13A	0.68	6.44	0.33	4.21e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg00277334	chr10:82204260	NA	-0.49	-7.15	-0.36	5.4e-12	Post bronchodilator FEV1;
LUSC	cis	rs10489202	1.000	rs17556487	chr1:167889094	T/A	cg24449463	chr1:168025552	DCAF6	-0.55	-6.69	-0.34	9.61e-11	Schizophrenia;
LUSC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.6	8.43	0.42	1.05e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6967385	0.519	rs7795828	chr7:12347689	C/T	cg10578991	chr7:12443926	VWDE	0.41	6.04	0.31	4.04e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.87	0.4	5.1e-14	Prudent dietary pattern;
LUSC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg02269571	chr22:50332266	NA	-0.55	-8.22	-0.41	4.59e-15	Schizophrenia;
LUSC	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.88	17.08	0.68	1.87e-47	Diastolic blood pressure;
LUSC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg07741184	chr6:167504864	NA	0.37	6.72	0.35	7.82e-11	Crohn's disease;
LUSC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.68	10.29	0.49	9.06e-22	Smoking initiation;
LUSC	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg24634471	chr8:143751801	JRK	0.51	7.25	0.37	2.97e-12	Schizophrenia;
LUSC	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg04374321	chr14:90722782	PSMC1	-0.44	-6.63	-0.34	1.34e-10	Mortality in heart failure;
LUSC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg24154853	chr7:158122151	PTPRN2	0.45	8.9	0.44	3.74e-17	Calcium levels;
LUSC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg15103426	chr22:29168792	CCDC117	0.6	8.45	0.42	8.82e-16	Lymphocyte counts;
LUSC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg24209194	chr3:40518798	ZNF619	0.47	6.67	0.34	1.07e-10	Renal cell carcinoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07481335	chr14:65879396	FUT8;LOC645431	-0.42	-6.31	-0.33	8.81e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2348418	0.864	rs7957495	chr12:28717455	C/G	cg13890972	chr12:28721907	NA	0.34	5.98	0.31	5.62e-9	Lung function (FVC);Lung function (FEV1);
LUSC	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg10840412	chr1:235813424	GNG4	0.64	8.78	0.43	8.41e-17	Bipolar disorder;
LUSC	trans	rs9409565	0.658	rs2809768	chr9:97128369	G/A	cg05679027	chr9:99775184	HIATL2	0.45	6.36	0.33	6.65e-10	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs9297145	0.585	rs62473049	chr7:98777685	T/C	cg05967295	chr7:98741636	SMURF1	-0.64	-9.99	-0.48	9.74e-21	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg27432699	chr2:27873401	GPN1	0.8	15.0	0.63	3.04e-39	Oral cavity cancer;
LUSC	cis	rs67072384	0.792	rs7936968	chr11:72479681	T/C	cg04827223	chr11:72435913	ARAP1	-0.87	-6.44	-0.33	4.27e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	trans	rs2285002	0.579	rs4902317	chr14:65270024	A/G	cg22491548	chr7:128000861	PRRT4	-0.27	-6.03	-0.31	4.43e-9	Red cell distribution width;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05602200	chr16:89307410	NA	0.7	6.07	0.32	3.48e-9	Cognitive performance;
LUSC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg06784218	chr1:46089804	CCDC17	-0.51	-9.79	-0.47	4.55e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.77	-0.43	9.5e-17	Axial length;
LUSC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08219700	chr8:58056026	NA	-0.74	-8.77	-0.43	9.31e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg18825119	chr6:163149453	PACRG;PARK2	-0.35	-6.2	-0.32	1.67e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs61142792	0.590	rs747861	chr5:177037397	C/G	cg10940203	chr5:177434438	FAM153C	0.68	6.21	0.32	1.59e-9	Alzheimer disease and age of onset;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12112058	chr1:224622605	WDR26	0.41	6.02	0.31	4.63e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.48	-5.74	-0.3	2.11e-8	Skin aging (microtopography measurement);
LUSC	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg23283495	chr1:209979779	IRF6	0.63	7.81	0.39	7.65e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs7577696	0.597	rs212690	chr2:32437631	C/G	cg02381751	chr2:32503542	YIPF4	0.53	6.84	0.35	3.76e-11	Inflammatory biomarkers;
LUSC	cis	rs813218	0.585	rs9860514	chr3:99917359	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.31	-5.85	-0.3	1.18e-8	Orofacial clefts;
LUSC	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg27284194	chr4:1044797	NA	-0.56	-8.84	-0.44	5.75e-17	Recombination rate (females);
LUSC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg12463550	chr7:65579703	CRCP	0.5	6.96	0.36	1.76e-11	Aortic root size;
LUSC	cis	rs13394619	0.935	rs12468019	chr2:11725049	T/C	cg07314298	chr2:11723111	GREB1	-0.58	-10.6	-0.5	8.34e-23	Endometriosis;
LUSC	cis	rs4363385	0.818	rs441229	chr1:153015059	A/C	cg25856811	chr1:152973957	SPRR3	-0.34	-5.79	-0.3	1.62e-8	Inflammatory skin disease;
LUSC	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg25019033	chr10:957182	NA	-0.53	-6.87	-0.35	3.13e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs714027	1.000	rs6006356	chr22:30503171	G/A	cg11564601	chr22:30592435	NA	-0.37	-6.79	-0.35	5.22e-11	Lymphocyte counts;
LUSC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08219700	chr8:58056026	NA	0.72	8.47	0.42	8.07e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	0.94	9.27	0.45	2.33e-18	Plasma clusterin levels;
LUSC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.85	-0.44	5.31e-17	Platelet count;
LUSC	cis	rs597583	0.806	rs10892135	chr11:117392826	G/A	cg27161313	chr11:117392002	DSCAML1	-0.43	-7.38	-0.37	1.25e-12	Putamen volume;
LUSC	cis	rs7089973	0.966	rs55711292	chr10:116604870	T/G	cg23260525	chr10:116636907	FAM160B1	0.37	7.19	0.37	4.21e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg18478394	chr8:109455254	TTC35	0.41	6.35	0.33	6.94e-10	Dupuytren's disease;
LUSC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.41	-0.33	5.01e-10	Life satisfaction;
LUSC	trans	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg25482853	chr8:67687455	SGK3	1.02	16.3	0.67	2.4e-44	Ulcerative colitis;
LUSC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21643547	chr1:205240462	TMCC2	-0.49	-9.32	-0.45	1.63e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.85	-17.64	-0.69	1.12e-49	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg20701182	chr2:24300061	SF3B14	0.58	6.19	0.32	1.72e-9	Lymphocyte counts;
LUSC	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	8.68	0.43	1.75e-16	Retinal vascular caliber;
LUSC	cis	rs2625529	0.761	rs16956444	chr15:72271235	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.51	-0.38	5.46e-13	Red blood cell count;
LUSC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg01448562	chr3:133502909	NA	-0.65	-10.67	-0.5	4.48e-23	Iron status biomarkers;
LUSC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg04369109	chr6:150039330	LATS1	-0.57	-8.31	-0.41	2.43e-15	Lung cancer;
LUSC	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	6.46	0.33	3.77e-10	Height;
LUSC	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg13852791	chr20:30311386	BCL2L1	0.81	10.69	0.51	3.75e-23	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs4474465	1.000	rs2063727	chr11:78183882	T/A	cg27205649	chr11:78285834	NARS2	-0.49	-5.84	-0.3	1.23e-8	Alzheimer's disease (survival time);
LUSC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21862992	chr11:68658383	NA	0.5	8.15	0.41	7.23e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.59	9.61	0.47	1.82e-19	Aortic root size;
LUSC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	9.1	0.45	8.53e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4343996	0.754	rs7811286	chr7:3349521	C/T	cg21248987	chr7:3385318	SDK1	-0.36	-6.19	-0.32	1.8e-9	Motion sickness;
LUSC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg18904891	chr8:8559673	CLDN23	0.4	6.21	0.32	1.54e-9	Mood instability;
LUSC	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.64	9.72	0.47	7.68e-20	Breast cancer;
LUSC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	0.7	15.06	0.64	1.7e-39	Prudent dietary pattern;
LUSC	trans	rs11165623	0.792	rs2104236	chr1:96908690	C/T	cg10631902	chr5:14652156	NA	-0.57	-9.25	-0.45	2.69e-18	Hip circumference;Waist circumference;
LUSC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	7.04	0.36	1.09e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.01	-0.44	1.65e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg24642439	chr20:33292090	TP53INP2	-0.57	-8.61	-0.43	2.97e-16	Height;
LUSC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	0.79	14.5	0.62	2.66e-37	Gestational age at birth (maternal effect);
LUSC	cis	rs540254	0.578	rs4656271	chr1:160782942	A/G	cg20255094	chr1:160771763	LY9	0.56	6.75	0.35	6.45e-11	Blood protein levels;
LUSC	cis	rs12474201	0.822	rs897530	chr2:46948150	C/G	cg06386533	chr2:46925753	SOCS5	0.71	10.49	0.5	1.97e-22	Height;
LUSC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-1.11	-24.8	-0.81	9.96e-78	Height;
LUSC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg27170947	chr2:26402098	FAM59B	-0.63	-9.15	-0.45	5.98e-18	Gut microbiome composition (summer);
LUSC	cis	rs6845621	0.901	rs12331873	chr4:18930586	C/A	cg12196642	chr4:18937545	NA	-0.37	-6.76	-0.35	6.21e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg06558623	chr16:89946397	TCF25	0.97	10.31	0.49	8.08e-22	Skin colour saturation;
LUSC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08048268	chr3:133502702	NA	0.46	9.17	0.45	5.05e-18	Iron status biomarkers;
LUSC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg18681998	chr4:17616180	MED28	0.84	15.84	0.65	1.53e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg20607287	chr7:12443886	VWDE	-0.65	-6.42	-0.33	4.74e-10	Coronary artery disease;
LUSC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg15704280	chr7:45808275	SEPT13	0.78	9.76	0.47	5.96e-20	Coronary artery disease;
LUSC	cis	rs7402982	0.934	rs6598539	chr15:99204483	T/C	cg03437748	chr15:99193247	IGF1R	0.54	8.5	0.42	6.32e-16	Birth weight;
LUSC	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.7	10.65	0.5	5.42e-23	Corneal astigmatism;
LUSC	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg22431228	chr1:16359049	CLCNKA	0.32	6.42	0.33	4.6e-10	Dilated cardiomyopathy;
LUSC	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs4478858	0.684	rs7521463	chr1:31761936	T/A	cg00250761	chr1:31883323	NA	-0.33	-7.95	-0.4	2.9e-14	Alcohol dependence;
LUSC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15369054	chr17:80825471	TBCD	-0.36	-5.9	-0.31	8.93e-9	Breast cancer;
LUSC	trans	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg27411982	chr8:10470053	RP1L1	0.39	6.29	0.33	9.94e-10	Parkinson's disease;
LUSC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.3	0.33	9.19e-10	Bipolar disorder;
LUSC	cis	rs62458065	0.640	rs4141788	chr7:32519264	T/C	cg20159608	chr7:32802032	NA	-0.71	-8.67	-0.43	1.9e-16	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-1.03	-20.12	-0.74	1.48e-59	Height;
LUSC	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg06191203	chr2:152266755	RIF1	-0.43	-6.02	-0.31	4.67e-9	Lung cancer;
LUSC	cis	rs9399401	1.000	rs7756305	chr6:142670955	T/C	cg03128060	chr6:142623767	GPR126	0.33	5.94	0.31	7.09e-9	Chronic obstructive pulmonary disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25333225	chr19:40791658	AKT2	0.5	7.64	0.39	2.3e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	8.73	0.43	1.27e-16	Lung cancer in ever smokers;
LUSC	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg13902645	chr11:5959945	NA	-0.61	-8.48	-0.42	7.61e-16	DNA methylation (variation);
LUSC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg02655711	chr22:19163373	SLC25A1	0.76	14.74	0.63	3.11e-38	Metabolite levels;
LUSC	trans	rs10221833	1.000	rs441414	chr2:165675693	A/G	cg17870553	chr6:144292355	PLAGL1	0.62	6.06	0.31	3.63e-9	Response to statin therapy;
LUSC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	10.52	0.5	1.57e-22	Blood protein levels;
LUSC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg13535736	chr9:111863775	C9orf5	-0.43	-6.87	-0.35	3.15e-11	Menarche (age at onset);
LUSC	cis	rs11650494	0.516	rs2233660	chr17:47492366	C/T	cg08112188	chr17:47440006	ZNF652	-0.98	-7.96	-0.4	2.76e-14	Prostate cancer;
LUSC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg00310523	chr12:86230176	RASSF9	0.45	8.31	0.41	2.43e-15	Major depressive disorder;
LUSC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg21724239	chr8:58056113	NA	0.6	7.11	0.36	7e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-14.08	-0.61	1.1e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-7.5	-0.38	5.92e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06634786	chr22:41940651	POLR3H	0.51	6.05	0.31	3.96e-9	Vitiligo;
LUSC	cis	rs997295	0.713	rs10518739	chr15:68014971	A/G	cg08079166	chr15:68083412	MAP2K5	0.33	6.56	0.34	1.99e-10	Motion sickness;
LUSC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.11	-0.58	5.82e-32	Platelet count;
LUSC	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	0.58	9.3	0.45	1.96e-18	Breast cancer;
LUSC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg16797656	chr11:68205561	LRP5	0.37	6.16	0.32	2.13e-9	Total body bone mineral density;
LUSC	cis	rs7137828	0.837	rs653178	chr12:112007756	A/G	cg10833066	chr12:111807467	FAM109A	-0.33	-6.72	-0.35	7.87e-11	Glaucoma (primary open-angle);Coronary artery disease;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg17517138	chr11:73019481	ARHGEF17	1.03	8.92	0.44	3.05e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs4889609	0.834	rs72785520	chr16:31070778	C/T	cg02466173	chr16:30829666	NA	-0.5	-9.46	-0.46	5.63e-19	Response to metformin (IC50);
LUSC	cis	rs11605924	1.000	rs11605924	chr11:45873091	A/C	ch.11.939596F	chr11:45881766	CRY2	-0.55	-8.32	-0.41	2.34e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.41	-0.42	1.21e-15	Lymphocyte counts;
LUSC	cis	rs4746818	1.000	rs7916991	chr10:70895373	C/A	cg11621586	chr10:70884670	VPS26A	1.14	10.89	0.51	7.61e-24	Left atrial antero-posterior diameter;
LUSC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg16240275	chr20:61666158	NCRNA00029	0.41	9.04	0.44	1.29e-17	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg12564285	chr5:131593104	PDLIM4	0.5	8.9	0.44	3.6e-17	Acylcarnitine levels;
LUSC	cis	rs2274273	0.662	rs67958555	chr14:55670866	G/A	cg04306507	chr14:55594613	LGALS3	0.47	9.24	0.45	3.04e-18	Protein biomarker;
LUSC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-5.94	-0.31	7.11e-9	Breast cancer;
LUSC	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg09184832	chr6:79620586	NA	-0.42	-6.65	-0.34	1.19e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg05754148	chr16:3507555	NAT15	0.51	7.75	0.39	1.14e-13	Tuberculosis;
LUSC	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs27434	0.529	rs42443	chr5:96156224	G/A	cg16492584	chr5:96139282	ERAP1	-0.57	-7.6	-0.38	3.1e-13	Ankylosing spondylitis;
LUSC	trans	rs7944735	0.607	rs34895872	chr11:48021778	A/G	cg15704280	chr7:45808275	SEPT13	0.55	6.53	0.34	2.45e-10	Intraocular pressure;
LUSC	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg15711740	chr2:61764176	XPO1	-0.49	-7.78	-0.39	9.16e-14	Tuberculosis;
LUSC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-8.51	-0.42	6e-16	Menarche (age at onset);
LUSC	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg07080220	chr10:102295463	HIF1AN	0.59	7.64	0.39	2.24e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg05182265	chr7:156933206	UBE3C	0.49	7.39	0.37	1.22e-12	Body mass index;
LUSC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg15691649	chr6:25882328	NA	-0.38	-6.28	-0.32	1.06e-9	Blood metabolite levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05604720	chr8:90769698	RIPK2	0.47	6.37	0.33	6.31e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	1.36	11.7	0.54	1.01e-26	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs13315871	1.000	rs9824965	chr3:58433505	T/A	cg12435725	chr3:58293450	RPP14	-0.7	-6.93	-0.35	2.21e-11	Cholesterol, total;
LUSC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg10862848	chr6:42927986	GNMT	-0.29	-7.04	-0.36	1.08e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg08027265	chr7:2291960	NA	-0.37	-6.1	-0.32	3e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.86	0.44	4.97e-17	Motion sickness;
LUSC	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg18477163	chr1:228402036	OBSCN	-0.56	-10.38	-0.49	4.49e-22	Diastolic blood pressure;
LUSC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	11.75	0.54	6.64e-27	Personality dimensions;
LUSC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.53e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg09835421	chr16:68378352	PRMT7	-0.76	-8.49	-0.42	7.06e-16	Schizophrenia;
LUSC	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.72	-13.57	-0.6	1e-33	Ulcerative colitis;
LUSC	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg18129178	chr5:148520854	ABLIM3	-0.52	-8.08	-0.4	1.21e-14	Breast cancer;
LUSC	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.75	-0.3	1.97e-8	IgG glycosylation;
LUSC	trans	rs61931739	0.649	rs864173	chr12:33721422	A/C	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg25036284	chr2:26402008	FAM59B	-0.72	-9.96	-0.48	1.25e-20	Gut microbiome composition (summer);
LUSC	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg01119278	chr6:110721349	DDO	-0.44	-7.8	-0.39	7.79e-14	Platelet distribution width;
LUSC	cis	rs9905704	0.589	rs2680696	chr17:56473013	C/T	cg12560992	chr17:57184187	TRIM37	-0.5	-5.99	-0.31	5.45e-9	Testicular germ cell tumor;
LUSC	cis	rs11997175	0.692	rs6468202	chr8:33747720	C/A	ch.8.33884649F	chr8:33765107	NA	0.52	8.04	0.4	1.6e-14	Body mass index;
LUSC	cis	rs597583	0.806	rs4938397	chr11:117392337	G/T	cg27161313	chr11:117392002	DSCAML1	-0.42	-7.25	-0.37	2.93e-12	Putamen volume;
LUSC	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg08079166	chr15:68083412	MAP2K5	0.41	7.29	0.37	2.33e-12	Restless legs syndrome;
LUSC	cis	rs9323205	0.677	rs11620820	chr14:51734445	C/T	cg23942311	chr14:51606299	NA	-0.42	-8.02	-0.4	1.81e-14	Cancer;
LUSC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg27535305	chr1:53392650	SCP2	-0.39	-7.46	-0.38	7.42e-13	Monocyte count;
LUSC	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	5.97	0.31	6.22e-9	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg22676075	chr6:135203613	NA	-0.64	-9.83	-0.47	3.31e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13852536	chr9:32567045	NDUFB6	0.47	5.98	0.31	5.85e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs4588572	0.643	rs1560196	chr5:77701982	G/C	cg11547950	chr5:77652471	NA	0.51	7.37	0.37	1.33e-12	Triglycerides;
LUSC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.66	-11.66	-0.54	1.34e-26	Aortic root size;
LUSC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg07936489	chr17:37558343	FBXL20	0.71	9.84	0.47	3.13e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg06606381	chr12:133084897	FBRSL1	-0.67	-6.7	-0.34	8.95e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2019216	0.542	rs2221893	chr17:21930012	A/G	cg22648282	chr17:21454238	C17orf51	-0.53	-7.98	-0.4	2.44e-14	Pelvic organ prolapse;
LUSC	cis	rs909341	0.909	rs2257440	chr20:62328267	C/T	cg09650180	chr20:62225654	GMEB2	-0.45	-5.94	-0.31	7.04e-9	Atopic dermatitis;
LUSC	cis	rs12681287	0.517	rs7462883	chr8:87526790	G/A	cg27223183	chr8:87520930	FAM82B	-0.53	-7.04	-0.36	1.1e-11	Caudate activity during reward;
LUSC	cis	rs4478858	0.684	rs7549343	chr1:31752260	A/G	cg00250761	chr1:31883323	NA	-0.34	-8.15	-0.41	7.26e-15	Alcohol dependence;
LUSC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg18681998	chr4:17616180	MED28	0.84	15.65	0.65	8.27e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg03433033	chr1:76189801	ACADM	-0.43	-6.39	-0.33	5.51e-10	Daytime sleep phenotypes;
LUSC	cis	rs4903214	0.895	rs12433272	chr14:74715250	C/T	cg08255017	chr14:74727001	VSX2	-0.48	-6.49	-0.33	3.09e-10	Inflammatory bowel disease;
LUSC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	9.17	0.45	5.09e-18	Menopause (age at onset);
LUSC	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg22875332	chr1:76189707	ACADM	0.41	6.28	0.32	1.05e-9	Daytime sleep phenotypes;
LUSC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-1.03	-20.48	-0.75	5.94e-61	Height;
LUSC	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg03929089	chr4:120376271	NA	-0.66	-9.53	-0.46	3.47e-19	Height;
LUSC	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	7.68	0.39	1.82e-13	Iron status biomarkers;
LUSC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.43	-0.38	9.09e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg08623948	chr7:23221430	NUPL2	0.4	6.15	0.32	2.16e-9	Triglycerides;
LUSC	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg00376283	chr12:123451042	ABCB9	0.65	8.18	0.41	6.03e-15	Neutrophil percentage of white cells;
LUSC	cis	rs2067615	0.579	rs7975576	chr12:107132501	A/G	cg15890332	chr12:107067104	RFX4	0.34	6.14	0.32	2.4e-9	Heart rate;
LUSC	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg23950597	chr19:37808831	NA	-0.65	-7.77	-0.39	9.66e-14	Coronary artery calcification;
LUSC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.67	9.61	0.47	1.85e-19	Methadone dose in opioid dependence;
LUSC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03264133	chr6:25882463	NA	0.64	10.73	0.51	2.83e-23	Blood metabolite levels;
LUSC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg21548813	chr6:291882	DUSP22	-0.51	-7.8	-0.39	7.73e-14	Menopause (age at onset);
LUSC	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	0.97	15.59	0.65	1.44e-41	Dupuytren's disease;
LUSC	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg11584989	chr19:19387371	SF4	-0.52	-6.16	-0.32	2.05e-9	Bipolar disorder;
LUSC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg04602696	chr16:88846723	FAM38A	-0.46	-9.43	-0.46	7.08e-19	Glycated hemoglobin levels;
LUSC	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg21573476	chr21:45109991	RRP1B	-0.36	-5.75	-0.3	2.01e-8	Mean corpuscular volume;
LUSC	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.36	-0.42	1.75e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg05973401	chr12:123451056	ABCB9	-0.46	-6.49	-0.33	3.08e-10	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs240764	0.817	rs12199888	chr6:101154419	T/A	cg09795085	chr6:101329169	ASCC3	-0.41	-6.02	-0.31	4.68e-9	Neuroticism;
LUSC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg20135002	chr11:47629003	NA	-0.51	-8.11	-0.41	9.83e-15	Subjective well-being;
LUSC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg05872129	chr22:39784769	NA	-0.58	-9.97	-0.48	1.18e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg10596483	chr8:143751796	JRK	0.61	9.38	0.46	1.04e-18	Schizophrenia;
LUSC	trans	rs4714291	0.963	rs4714293	chr6:40009566	T/C	cg02267698	chr19:7991119	CTXN1	0.52	7.3	0.37	2.19e-12	Strep throat;
LUSC	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.53	-0.42	5.32e-16	Body mass index;
LUSC	cis	rs600231	0.571	rs10896000	chr11:65218018	A/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-9.04	-0.44	1.33e-17	Bone mineral density;
LUSC	cis	rs751728	0.965	rs9394165	chr6:33731408	G/A	cg25922239	chr6:33757077	LEMD2	0.53	8.04	0.4	1.61e-14	Crohn's disease;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg08128228	chr1:167191360	POU2F1	0.35	5.97	0.31	6.11e-9	Calcium levels;
LUSC	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-8.16	-0.41	6.75e-15	Bladder cancer;
LUSC	cis	rs711244	0.783	rs2110944	chr2:37090233	T/C	cg14987922	chr2:37194071	STRN	-0.45	-6.58	-0.34	1.84e-10	Mean platelet volume;
LUSC	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.53	0.53	4.22e-26	Ileal carcinoids;
LUSC	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.6	-9.63	-0.47	1.63e-19	Body mass index;
LUSC	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg02038168	chr22:39784481	NA	-0.48	-7.87	-0.4	4.98e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04741861	chr19:3531604	FZR1	-0.38	-6.18	-0.32	1.9e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg24375607	chr4:120327624	NA	0.75	10.76	0.51	2.15e-23	Corneal astigmatism;
LUSC	cis	rs4842666	0.915	rs6538195	chr12:90062376	G/A	cg00757033	chr12:89920650	WDR51B	0.5	7.15	0.36	5.35e-12	Blood pressure;
LUSC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-7.05	-0.36	1.01e-11	Obesity-related traits;
LUSC	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg05110241	chr16:68378359	PRMT7	-0.46	-5.85	-0.3	1.2e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs724744	0.679	rs1205929	chr6:22359126	T/C	cg13807341	chr11:118445984	ARCN1	-0.36	-6.09	-0.32	3.12e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg04827223	chr11:72435913	ARAP1	-0.88	-15.22	-0.64	4.31e-40	Body mass index;
LUSC	cis	rs34779708	0.733	rs4102764	chr10:35545392	T/C	cg03585969	chr10:35415529	CREM	0.53	7.37	0.37	1.38e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg09904177	chr6:26538194	HMGN4	-0.77	-5.7	-0.3	2.63e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg24558204	chr6:135376177	HBS1L	0.57	8.77	0.43	9.11e-17	Red blood cell count;
LUSC	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg02466173	chr16:30829666	NA	0.56	11.11	0.52	1.3e-24	Dementia with Lewy bodies;
LUSC	cis	rs7582720	1.000	rs114702158	chr2:203821793	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs17604090	1.000	rs73297441	chr7:29684363	T/C	cg19413766	chr7:29689036	LOC646762	-0.58	-6.76	-0.35	6.1e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.16	-0.52	8.53e-25	Bipolar disorder;
LUSC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg07061783	chr6:25882402	NA	0.36	5.84	0.3	1.25e-8	Blood metabolite levels;
LUSC	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg14413466	chr17:79170920	AZI1	-0.33	-6.34	-0.33	7.48e-10	Frontotemporal dementia;
LUSC	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg13010199	chr12:38710504	ALG10B	0.62	9.06	0.44	1.14e-17	Bladder cancer;
LUSC	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg02696742	chr7:106810147	HBP1	0.63	9.46	0.46	5.51e-19	Coronary artery disease;
LUSC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg12463550	chr7:65579703	CRCP	0.5	7.0	0.36	1.4e-11	Aortic root size;
LUSC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg05855489	chr10:104503620	C10orf26	0.58	9.32	0.45	1.66e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1451375	0.652	rs7779110	chr7:50625651	T/C	cg18232548	chr7:50535776	DDC	0.48	6.61	0.34	1.54e-10	Malaria;
LUSC	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-12.53	-0.57	8.75e-30	Total body bone mineral density;
LUSC	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-7.1	-0.36	7.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg01652190	chr22:50026171	C22orf34	-0.31	-6.39	-0.33	5.51e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg01657329	chr11:68192670	LRP5	-0.44	-6.62	-0.34	1.41e-10	Total body bone mineral density;
LUSC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg03146154	chr1:46216737	IPP	0.55	8.25	0.41	3.82e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.76e-12	Type 2 diabetes;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15533222	chr18:19285008	ABHD3	-0.44	-6.51	-0.34	2.76e-10	Electrocardiographic conduction measures;
LUSC	cis	rs926938	0.527	rs360665	chr1:115478503	A/T	cg12756093	chr1:115239321	AMPD1	0.46	6.95	0.36	1.89e-11	Autism;
LUSC	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-5.72	-0.3	2.32e-8	IgG glycosylation;
LUSC	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.79	-0.39	8.62e-14	Chronic sinus infection;
LUSC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg12560992	chr17:57184187	TRIM37	0.88	16.86	0.68	1.36e-46	Intelligence (multi-trait analysis);
LUSC	cis	rs2109514	0.840	rs13223362	chr7:116137006	G/A	cg12739419	chr7:116140593	CAV2	-0.27	-5.91	-0.31	8.39e-9	Prevalent atrial fibrillation;
LUSC	cis	rs9309473	0.948	rs10199224	chr2:73761446	C/G	cg20560298	chr2:73613845	ALMS1	-0.46	-6.51	-0.34	2.83e-10	Metabolite levels;
LUSC	cis	rs9653442	0.510	rs12712068	chr2:100764439	A/G	cg07810366	chr2:100720526	AFF3	-0.45	-7.76	-0.39	1.05e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs12681287	0.640	rs34794500	chr8:87449995	G/A	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg17469321	chr7:55412551	NA	-0.65	-10.44	-0.5	2.94e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg05855489	chr10:104503620	C10orf26	0.61	8.01	0.4	1.97e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg23649088	chr2:200775458	C2orf69	0.53	7.23	0.37	3.26e-12	Schizophrenia;
LUSC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg20295408	chr7:1910781	MAD1L1	-0.47	-6.7	-0.34	8.97e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4683142	0.518	rs4682801	chr3:46021218	G/T	cg08033130	chr3:45983597	CXCR6;FYCO1	0.39	6.16	0.32	2.13e-9	Methadone dose in opioid dependence;
LUSC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.81	0.39	7.4e-14	Prudent dietary pattern;
LUSC	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg11189052	chr15:85197271	WDR73	0.48	5.89	0.31	9.66e-9	Schizophrenia;
LUSC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg14433983	chr11:636460	DRD4	-0.35	-5.85	-0.31	1.15e-8	Systemic lupus erythematosus;
LUSC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg03060546	chr3:49711283	APEH	0.7	11.64	0.54	1.67e-26	Resting heart rate;
LUSC	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.8	13.51	0.59	1.77e-33	Metabolic syndrome;
LUSC	cis	rs427941	0.632	rs201505	chr7:101760287	T/C	cg06246474	chr7:101738831	CUX1	0.39	6.34	0.33	7.51e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg03929089	chr4:120376271	NA	-0.44	-6.01	-0.31	4.89e-9	HDL cholesterol;
LUSC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.63	11.22	0.52	5.2e-25	Extrinsic epigenetic age acceleration;
LUSC	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-1.0	-13.51	-0.59	1.68e-33	Orofacial clefts;
LUSC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-8.17	-0.41	6.43e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.74	0.3	2.17e-8	Bipolar disorder (body mass index interaction);
LUSC	trans	rs955423	1.000	rs1696952	chr5:165725049	G/T	cg05036173	chr2:108994528	SULT1C4	-0.27	-5.95	-0.31	6.67e-9	Body mass index;
LUSC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.79	-9.76	-0.47	6.02e-20	Refractive error;
LUSC	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg25801113	chr15:45476975	SHF	-0.32	-6.43	-0.33	4.34e-10	Uric acid levels;
LUSC	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg15017067	chr4:17643749	FAM184B	-0.35	-5.65	-0.3	3.51e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg02951883	chr7:2050386	MAD1L1	-0.46	-7.91	-0.4	3.9e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs7202877	0.656	rs3851736	chr16:75387332	T/C	cg04384234	chr16:75411784	CFDP1	-0.63	-8.86	-0.44	4.77e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs6987853	0.736	rs2923446	chr8:42404177	G/A	cg09913449	chr8:42400586	C8orf40	0.53	9.22	0.45	3.45e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg17330251	chr7:94953956	PON1	0.37	5.93	0.31	7.67e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg15704280	chr7:45808275	SEPT13	0.76	8.65	0.43	2.25e-16	Axial length;
LUSC	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg02023728	chr11:77925099	USP35	0.48	7.13	0.36	6.23e-12	Testicular germ cell tumor;
LUSC	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg18827107	chr12:86230957	RASSF9	-0.41	-5.98	-0.31	5.78e-9	Major depressive disorder;
LUSC	cis	rs1808579	0.935	rs7239575	chr18:21120035	C/T	cg14672496	chr18:21087552	C18orf8	-0.34	-5.94	-0.31	6.99e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs9811920	0.683	rs793439	chr3:99637783	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.38	5.66	0.3	3.21e-8	Axial length;
LUSC	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg17757837	chr7:157058334	UBE3C	-0.9	-14.74	-0.63	3.25e-38	Body mass index;
LUSC	cis	rs4474465	1.000	rs10899533	chr11:78208480	T/C	cg27205649	chr11:78285834	NARS2	0.51	6.0	0.31	5.16e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg05084668	chr3:125655381	ALG1L	-0.76	-11.83	-0.54	3.33e-27	Blood pressure (smoking interaction);
LUSC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg20573242	chr4:122745356	CCNA2	0.43	6.67	0.34	1.07e-10	Type 2 diabetes;
LUSC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.33	-0.41	2.1e-15	Lymphocyte counts;
LUSC	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.83	-0.43	6.08e-17	Response to antipsychotic treatment;
LUSC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg27432699	chr2:27873401	GPN1	-0.58	-8.68	-0.43	1.72e-16	Total body bone mineral density;
LUSC	trans	rs62238980	0.614	rs117195584	chr22:32390013	C/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	trans	rs12439619	0.921	rs4778672	chr15:82537354	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.57	8.71	0.43	1.38e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg22823121	chr1:150693482	HORMAD1	0.6	9.28	0.45	2.21e-18	Tonsillectomy;
LUSC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg13607699	chr17:42295918	UBTF	0.48	7.51	0.38	5.58e-13	Total body bone mineral density;
LUSC	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg22705602	chr4:152727874	NA	0.38	7.92	0.4	3.61e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.43	0.56	1.96e-29	Motion sickness;
LUSC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.84	-13.58	-0.6	9.75e-34	Menarche (age at onset);
LUSC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg14829155	chr15:31115871	NA	0.46	6.57	0.34	1.89e-10	Huntington's disease progression;
LUSC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.54	0.46	3.2e-19	Bipolar disorder;
LUSC	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg00343986	chr7:65444356	GUSB	0.39	5.74	0.3	2.14e-8	Aortic root size;
LUSC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-0.73	-11.79	-0.54	4.8e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg06422659	chr12:57481370	NAB2	0.37	6.13	0.32	2.44e-9	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	1.04	20.08	0.74	2.21e-59	Menopause (age at onset);
LUSC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg04450456	chr4:17643702	FAM184B	0.34	5.71	0.3	2.48e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg11859384	chr17:80120422	CCDC57	0.36	5.71	0.3	2.49e-8	Life satisfaction;
LUSC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg22535103	chr8:58192502	C8orf71	-0.67	-7.25	-0.37	2.97e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg23649088	chr2:200775458	C2orf69	-0.42	-6.3	-0.33	9.47e-10	QT interval;
LUSC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-6.72	-0.35	7.71e-11	Aortic root size;
LUSC	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg16070123	chr10:51489643	NA	-0.51	-8.09	-0.4	1.12e-14	Prostate-specific antigen levels;
LUSC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.39	0.56	2.97e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.84	-0.3	1.24e-8	Breast cancer;
LUSC	cis	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg24375607	chr4:120327624	NA	0.5	7.77	0.39	9.66e-14	Diastolic blood pressure;
LUSC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg16928487	chr17:17741425	SREBF1	-0.42	-8.29	-0.41	2.74e-15	Total body bone mineral density;
LUSC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg00149659	chr3:10157352	C3orf10	0.6	8.3	0.41	2.62e-15	Alzheimer's disease;
LUSC	cis	rs1775715	0.705	rs2778651	chr10:32106575	C/T	cg04359828	chr10:32216031	ARHGAP12	0.41	6.95	0.36	1.95e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4654899	0.802	rs3767247	chr1:21227338	T/C	cg02927042	chr1:21476669	EIF4G3	-0.36	-5.67	-0.3	3.01e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.73	11.8	0.54	4.2e-27	Schizophrenia;
LUSC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg06713675	chr4:122721982	EXOSC9	0.45	8.02	0.4	1.85e-14	Type 2 diabetes;
LUSC	cis	rs7075426	1.000	rs7075426	chr10:88216402	G/A	cg07322936	chr10:88137208	NA	-0.49	-7.31	-0.37	1.98e-12	Migraine without aura;
LUSC	cis	rs7428496	0.528	rs13065800	chr3:142251714	G/A	cg16271453	chr3:142027066	XRN1	-0.51	-8.77	-0.43	9.61e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs7923609	0.783	rs7100409	chr10:65330195	T/A	cg01631684	chr10:65280961	REEP3	0.4	5.97	0.31	6.15e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7131987	0.683	rs7954278	chr12:29459290	G/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.68	-0.34	9.99e-11	QT interval;
LUSC	cis	rs2273669	0.504	rs117426315	chr6:109450464	G/A	cg05315195	chr6:109294784	ARMC2	-0.55	-5.85	-0.3	1.18e-8	Prostate cancer;
LUSC	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.59	-9.67	-0.47	1.18e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg27588902	chr6:42928151	GNMT	-0.3	-6.47	-0.33	3.55e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg18904891	chr8:8559673	CLDN23	0.43	6.56	0.34	2.04e-10	Mood instability;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22266470	chr19:51014659	JOSD2	-0.41	-6.04	-0.31	4.11e-9	Electrocardiographic conduction measures;
LUSC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	9.23	0.45	3.17e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg19748678	chr4:122722346	EXOSC9	0.48	7.47	0.38	7.05e-13	Type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg17366294	chr4:99064904	C4orf37	0.57	9.94	0.48	1.47e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg00677455	chr12:58241039	CTDSP2	0.44	6.3	0.33	9.57e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg23202291	chr11:1979235	NA	0.43	6.53	0.34	2.4e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg15798862	chr7:76129360	DTX2	-0.51	-8.59	-0.43	3.4e-16	Multiple sclerosis;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg16182055	chr5:137879011	ETF1	0.64	6.13	0.32	2.47e-9	Body mass index;
LUSC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg17554472	chr22:41940697	POLR3H	-0.47	-5.79	-0.3	1.6e-8	Vitiligo;
LUSC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06112835	chr11:68658793	MRPL21	0.51	7.82	0.39	7.01e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.61	-9.1	-0.45	8.25e-18	Endometrial cancer;
LUSC	cis	rs6845621	0.901	rs7697728	chr4:18922514	C/T	cg12196642	chr4:18937545	NA	-0.34	-6.37	-0.33	6.1e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.74	-0.39	1.18e-13	Blood metabolite levels;
LUSC	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg04851639	chr8:1020857	NA	-0.4	-8.09	-0.4	1.1e-14	Schizophrenia;
LUSC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg26408565	chr15:76604113	ETFA	-0.5	-7.98	-0.4	2.42e-14	Blood metabolite levels;
LUSC	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	10.18	0.49	2.2e-21	Lymphocyte counts;
LUSC	cis	rs10504073	0.669	rs62507251	chr8:50028524	T/G	cg00325661	chr8:49890786	NA	0.61	9.5	0.46	4.19e-19	Blood metabolite ratios;
LUSC	cis	rs3818285	0.556	rs3758409	chr10:111669239	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.69	-9.78	-0.47	5.13e-20	Superior crus of antihelix expression;
LUSC	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	0.94	15.8	0.65	2.17e-42	Dilated cardiomyopathy;
LUSC	cis	rs11229555	0.874	rs11229512	chr11:58286105	T/C	cg15696309	chr11:58395628	NA	-0.71	-9.0	-0.44	1.77e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.25	0.32	1.28e-9	Bipolar disorder;
LUSC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg12311346	chr5:56204834	C5orf35	-0.63	-8.9	-0.44	3.65e-17	Coronary artery disease;
LUSC	cis	rs9326248	0.520	rs10892060	chr11:116881662	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.59	9.19	0.45	4.23e-18	Blood protein levels;
LUSC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg25174290	chr11:3078921	CARS	0.59	9.57	0.46	2.39e-19	Longevity;
LUSC	cis	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg05084668	chr3:125655381	ALG1L	-0.59	-8.29	-0.41	2.76e-15	Blood pressure (smoking interaction);
LUSC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg20887711	chr4:1340912	KIAA1530	0.51	7.91	0.4	3.8e-14	Obesity-related traits;
LUSC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	11.43	0.53	9.66e-26	Alzheimer's disease;
LUSC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg04511125	chr2:88470314	THNSL2	-0.44	-6.61	-0.34	1.52e-10	Response to metformin (IC50);
LUSC	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg02493740	chr2:85810744	VAMP5	-0.37	-6.64	-0.34	1.24e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12058391	chr8:63951472	GGH	-0.44	-6.36	-0.33	6.5e-10	Electrocardiographic conduction measures;
LUSC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg05025164	chr4:1340916	KIAA1530	0.46	7.07	0.36	9.08e-12	Obesity-related traits;
LUSC	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg25233709	chr10:116636983	FAM160B1	0.37	6.51	0.34	2.82e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg03676636	chr4:99064102	C4orf37	0.37	8.23	0.41	4.36e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg06784218	chr1:46089804	CCDC17	-0.5	-10.06	-0.48	5.91e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.34	0.37	1.65e-12	Bipolar disorder;
LUSC	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	0.6	9.45	0.46	6.13e-19	Breast cancer;
LUSC	cis	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg26958806	chr6:27640298	NA	0.77	6.55	0.34	2.23e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs9905704	0.918	rs302868	chr17:56752123	C/T	cg12560992	chr17:57184187	TRIM37	0.54	7.7	0.39	1.58e-13	Testicular germ cell tumor;
LUSC	trans	rs6480314	0.542	rs7079054	chr10:70026161	G/A	cg04882175	chr6:131122610	NA	-0.55	-6.34	-0.33	7.25e-10	Optic nerve measurement (disc area);
LUSC	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.68	11.63	0.54	1.78e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.59	0.43	3.5e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.56	-0.38	3.86e-13	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg16041611	chr6:43139680	SRF	0.46	7.52	0.38	5.07e-13	Triglycerides;
LUSC	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg24397884	chr7:158709396	WDR60	0.8	9.04	0.44	1.31e-17	Height;
LUSC	trans	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.15	-0.32	2.16e-9	Depression;
LUSC	cis	rs2970818	0.831	rs9971728	chr12:4601068	G/A	cg11146114	chr12:4671731	NA	-0.6	-5.97	-0.31	6.03e-9	Phosphorus levels;
LUSC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.7	-0.43	1.5e-16	Aortic root size;
LUSC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg02807482	chr3:125708958	NA	-0.54	-6.63	-0.34	1.38e-10	Blood pressure (smoking interaction);
LUSC	cis	rs2067615	0.599	rs1579808	chr12:107239947	A/G	cg15890332	chr12:107067104	RFX4	-0.33	-6.06	-0.31	3.72e-9	Heart rate;
LUSC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg22166914	chr1:53195759	ZYG11B	0.5	8.25	0.41	3.62e-15	Monocyte count;
LUSC	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg07741184	chr6:167504864	NA	0.4	7.01	0.36	1.34e-11	Crohn's disease;
LUSC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg10729496	chr3:10149963	C3orf24	0.49	6.45	0.33	3.96e-10	Alzheimer's disease;
LUSC	cis	rs9816226	0.938	rs55742087	chr3:185830488	C/T	cg00760338	chr3:185826511	ETV5	-0.69	-8.85	-0.44	5.13e-17	Obesity;Body mass index;
LUSC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.91	-14.99	-0.63	3.48e-39	Height;
LUSC	cis	rs9879311	0.966	rs6442165	chr3:10415108	A/C	cg11030744	chr3:10328490	GHRL;GHRLOS	0.48	7.88	0.4	4.82e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12956009	0.518	rs10163861	chr18:44820214	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.76	0.35	6.34e-11	Educational attainment (years of education);
LUSC	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg19789473	chr17:27170043	C17orf63	-0.3	-5.65	-0.3	3.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9815354	0.812	rs17215988	chr3:41851320	A/C	cg03022575	chr3:42003672	ULK4	0.85	8.56	0.42	4.04e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg12863693	chr15:85201151	NMB	0.37	7.3	0.37	2.17e-12	Schizophrenia;
LUSC	cis	rs6942756	0.806	rs6467237	chr7:128964831	A/G	cg02491457	chr7:128862824	NA	-0.48	-7.17	-0.37	4.95e-12	White matter hyperintensity burden;
LUSC	cis	rs654950	0.774	rs941972	chr1:42040740	T/C	cg06885757	chr1:42089581	HIVEP3	-0.42	-8.52	-0.42	5.71e-16	Airway imaging phenotypes;
LUSC	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg08330031	chr10:104623503	C10orf32	0.34	5.79	0.3	1.64e-8	Arsenic metabolism;
LUSC	cis	rs77633900	0.614	rs2439989	chr15:76883862	G/C	cg21673338	chr15:77095150	SCAPER	-0.72	-6.99	-0.36	1.48e-11	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs7911264	0.739	rs10786050	chr10:94367230	A/G	cg25093409	chr10:94429542	NA	0.36	6.21	0.32	1.59e-9	Inflammatory bowel disease;
LUSC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.62	5.82	0.3	1.4e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg04733989	chr22:42467013	NAGA	0.55	8.7	0.43	1.54e-16	Schizophrenia;
LUSC	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.77	11.2	0.52	6.24e-25	Corneal astigmatism;
LUSC	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg13615516	chr5:77269221	NA	-0.4	-6.65	-0.34	1.18e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6669072	0.869	rs7526803	chr1:91235725	A/G	cg08895590	chr1:91227319	NA	0.35	7.55	0.38	4.26e-13	Cognitive function;
LUSC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg13395646	chr4:1353034	KIAA1530	-0.63	-10.47	-0.5	2.21e-22	Longevity;
LUSC	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg02023728	chr11:77925099	USP35	0.47	7.12	0.36	6.7e-12	Testicular germ cell tumor;
LUSC	cis	rs317865	0.737	rs73234648	chr4:16193602	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.61	5.88	0.31	1e-8	Kidney disease (early stage) in type 1 diabetes;
LUSC	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.73	-10.19	-0.49	2.06e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	6.31	0.33	8.94e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.43	6.7	0.34	9e-11	Dupuytren's disease;
LUSC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg09699651	chr6:150184138	LRP11	0.41	6.48	0.33	3.3e-10	Testicular germ cell tumor;
LUSC	cis	rs1547553	1	rs1547553	chr18:77926197	C/A	cg14906638	chr18:78001859	PARD6G	-0.65	-7.41	-0.38	1.06e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg00339695	chr16:24857497	SLC5A11	0.37	6.59	0.34	1.69e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg21138405	chr5:131827807	IRF1	0.34	6.04	0.31	4.22e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs6543140	0.964	rs6736135	chr2:103064924	A/G	cg09003973	chr2:102972529	NA	0.54	6.98	0.36	1.58e-11	Blood protein levels;
LUSC	cis	rs2070433	1.000	rs2070433	chr21:47961386	G/A	cg12379764	chr21:47803548	PCNT	0.8	10.4	0.49	4.02e-22	Lymphocyte counts;
LUSC	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg05714579	chr10:131428358	MGMT	0.52	7.64	0.39	2.34e-13	Response to temozolomide;
LUSC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg21573476	chr21:45109991	RRP1B	-0.37	-6.01	-0.31	4.75e-9	Mean corpuscular volume;
LUSC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.91	14.45	0.62	4.09e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg11062466	chr8:58055876	NA	0.5	6.42	0.33	4.55e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg13073564	chr4:8508604	NA	0.35	6.34	0.33	7.5e-10	Response to antineoplastic agents;
LUSC	cis	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg07460842	chr6:66804631	NA	0.49	5.94	0.31	7.24e-9	Metabolite levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08209163	chr13:28024472	MTIF3	-0.48	-6.4	-0.33	5.36e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg11843238	chr5:131593191	PDLIM4	0.41	6.85	0.35	3.64e-11	Breast cancer;
LUSC	trans	rs7944735	0.938	rs59185955	chr11:47961566	G/C	cg03929089	chr4:120376271	NA	0.6	6.27	0.32	1.13e-9	Intraocular pressure;
LUSC	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg18302933	chr2:88491318	NA	-0.38	-7.52	-0.38	5.01e-13	Response to metformin (IC50);
LUSC	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg15485101	chr11:133734466	NA	0.41	7.52	0.38	5.16e-13	Childhood ear infection;
LUSC	cis	rs3770081	1.000	rs78650586	chr2:86190783	G/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.97	-6.28	-0.32	1.06e-9	Facial emotion recognition (sad faces);
LUSC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs57590327	0.503	rs7631052	chr3:81866235	C/A	cg07356753	chr3:81810745	GBE1	-0.64	-9.97	-0.48	1.15e-20	Extraversion;
LUSC	cis	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg17325771	chr7:75508891	RHBDD2	-0.42	-5.83	-0.3	1.34e-8	Eotaxin levels;
LUSC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg13206674	chr6:150067644	NUP43	0.62	9.97	0.48	1.16e-20	Lung cancer;
LUSC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg24250549	chr1:154909240	PMVK	0.6	9.76	0.47	5.94e-20	Prostate cancer;
LUSC	cis	rs9378688	1.000	rs72830182	chr6:2221488	C/T	cg12303981	chr6:2244766	GMDS	-0.55	-6.54	-0.34	2.37e-10	Caudate nucleus volume;
LUSC	cis	rs4594175	0.886	rs11157802	chr14:51622984	C/T	cg23942311	chr14:51606299	NA	0.31	5.98	0.31	5.79e-9	Cancer;
LUSC	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg27490568	chr2:178487706	NA	-0.38	-5.79	-0.3	1.66e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg12257692	chr3:49977190	RBM6	-0.22	-6.07	-0.32	3.38e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12367572	1.000	rs7295923	chr12:45269284	C/T	cg04608330	chr12:45269318	NELL2	-0.58	-9.3	-0.45	1.95e-18	Gut microbiome composition (summer);
LUSC	cis	rs6982240	0.514	rs7002268	chr8:142277340	A/G	cg27411547	chr8:142287226	NA	-0.49	-8.35	-0.42	1.86e-15	Tonsillectomy;
LUSC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg14552801	chr7:65878734	NA	-0.44	-6.22	-0.32	1.51e-9	Aortic root size;
LUSC	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg17127132	chr2:85788382	GGCX	0.43	6.2	0.32	1.71e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg04944784	chr2:26401820	FAM59B	0.67	8.96	0.44	2.41e-17	Gut microbiome composition (summer);
LUSC	cis	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg05084668	chr3:125655381	ALG1L	-0.59	-8.33	-0.41	2.07e-15	Blood pressure (smoking interaction);
LUSC	cis	rs11676348	0.772	rs7422358	chr2:218952778	C/T	cg06547715	chr2:218990976	CXCR2	0.34	6.62	0.34	1.45e-10	Ulcerative colitis;
LUSC	cis	rs6818397	1.000	rs6818397	chr4:3434885	A/C	cg08741688	chr4:3415352	RGS12	0.37	6.26	0.32	1.19e-9	LDL cholesterol levels;Total cholesterol levels;
LUSC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg08088566	chr11:430123	ANO9	0.57	6.7	0.34	8.64e-11	Body mass index;
LUSC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.48e-24	Aortic root size;
LUSC	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-6.83	-0.35	3.94e-11	Total cholesterol levels;
LUSC	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.71	-11.41	-0.53	1.12e-25	Breast size;
LUSC	trans	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.63	-0.34	1.34e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg23982607	chr1:1823379	GNB1	-0.73	-14.91	-0.63	6.6e-39	Body mass index;
LUSC	cis	rs4700695	0.719	rs40176	chr5:65464965	C/T	cg21114390	chr5:65439923	SFRS12	-0.65	-9.28	-0.45	2.12e-18	Facial morphology (factor 19);
LUSC	trans	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-9.67	-0.47	1.2e-19	Blood pressure (smoking interaction);
LUSC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg15704280	chr7:45808275	SEPT13	-0.56	-6.96	-0.36	1.85e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7707921	0.767	rs862241	chr5:81588011	G/A	cg15871215	chr5:81402204	ATG10	0.45	7.1	0.36	7.45e-12	Breast cancer;
LUSC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg15848620	chr12:58087721	OS9	0.45	5.74	0.3	2.18e-8	Multiple sclerosis;
LUSC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg23711669	chr6:146136114	FBXO30	0.9	16.67	0.67	8.1e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	9.05	0.44	1.24e-17	Menopause (age at onset);
LUSC	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.3	-0.41	2.58e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg07701084	chr6:150067640	NUP43	0.58	9.03	0.44	1.41e-17	Lung cancer;
LUSC	cis	rs738321	0.756	rs11570745	chr22:38513493	C/T	cg25457927	chr22:38595422	NA	-0.32	-6.11	-0.32	2.8e-9	Breast cancer;
LUSC	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg26876637	chr1:152193138	HRNR	0.46	6.62	0.34	1.46e-10	Atopic dermatitis;
LUSC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg12463550	chr7:65579703	CRCP	0.52	7.58	0.38	3.39e-13	Aortic root size;
LUSC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg02527881	chr3:46936655	PTH1R	-0.42	-7.49	-0.38	6.18e-13	Colorectal cancer;
LUSC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-10.32	-0.49	7.4e-22	Mood instability;
LUSC	cis	rs7582180	0.903	rs6755791	chr2:100895872	G/A	cg08017756	chr2:100939284	LONRF2	-0.36	-6.01	-0.31	4.77e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs9871760	1.000	rs9871760	chr3:126993099	C/A	cg17872838	chr13:52607339	UTP14C	0.35	6.23	0.32	1.44e-9	Whole-brain volume;
LUSC	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg08975724	chr8:8085496	FLJ10661	0.49	6.95	0.36	1.98e-11	Monocyte count;
LUSC	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg21535247	chr6:8435926	SLC35B3	-0.58	-8.8	-0.43	7.23e-17	Motion sickness;
LUSC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg03146154	chr1:46216737	IPP	0.52	7.99	0.4	2.28e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg17366294	chr4:99064904	C4orf37	0.54	9.48	0.46	4.75e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg20703242	chr1:230279135	GALNT2	0.62	8.74	0.43	1.12e-16	Coronary artery disease;
LUSC	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.29	-0.37	2.28e-12	Neuroticism;
LUSC	cis	rs12286929	0.669	rs11606837	chr11:115042837	C/T	cg04055981	chr11:115044050	NA	0.43	7.69	0.39	1.68e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.37	-6.12	-0.32	2.57e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg05025164	chr4:1340916	KIAA1530	0.52	8.34	0.41	2.03e-15	Longevity;
LUSC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19346786	chr7:2764209	NA	-0.43	-7.31	-0.37	2.05e-12	Height;
LUSC	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	0.58	9.25	0.45	2.71e-18	Breast cancer;
LUSC	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg12140854	chr5:148520817	ABLIM3	-0.4	-6.05	-0.31	3.95e-9	Breast cancer;
LUSC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.56	-0.38	3.9e-13	Bipolar disorder;
LUSC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg05368731	chr17:41323189	NBR1	-0.83	-13.79	-0.6	1.46e-34	Menopause (age at onset);
LUSC	cis	rs9837602	0.938	rs9873709	chr3:99711687	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.93	-0.31	7.43e-9	Breast cancer;
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg11235426	chr6:292522	DUSP22	-0.65	-10.53	-0.5	1.36e-22	Menopause (age at onset);
LUSC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg20203395	chr5:56204925	C5orf35	-0.78	-10.4	-0.49	4.07e-22	Initial pursuit acceleration;
LUSC	cis	rs9341808	0.718	rs2322631	chr6:80843956	A/C	cg08355045	chr6:80787529	NA	0.57	10.03	0.48	6.94e-21	Sitting height ratio;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02037503	chr14:23540729	ACIN1	0.59	8.21	0.41	4.89e-15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.74	14.41	0.62	6.18e-37	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.07	-0.32	3.41e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg23093090	chr10:104574429	C10orf26	-0.34	-6.03	-0.31	4.33e-9	Arsenic metabolism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03153608	chr11:64126457	RPS6KA4	-0.43	-6.3	-0.33	9.57e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg26441486	chr22:50317300	CRELD2	0.48	7.21	0.37	3.88e-12	Schizophrenia;
LUSC	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.81	0.65	1.92e-42	Bladder cancer;
LUSC	cis	rs6062509	0.965	rs6062506	chr20:62352389	T/G	cg21849932	chr20:62369462	LIME1	-0.4	-5.93	-0.31	7.59e-9	Prostate cancer;
LUSC	cis	rs9581857	0.547	rs9581877	chr13:28104321	T/A	cg22138327	chr13:27999177	GTF3A	0.66	7.03	0.36	1.18e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg11752832	chr7:134001865	SLC35B4	0.54	8.31	0.41	2.37e-15	Mean platelet volume;
LUSC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg14019146	chr3:50243930	SLC38A3	-0.33	-7.16	-0.36	5.01e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg01879757	chr17:41196368	BRCA1	-0.51	-8.03	-0.4	1.66e-14	Menopause (age at onset);
LUSC	cis	rs9815354	1.000	rs1717027	chr3:41987920	T/C	cg03022575	chr3:42003672	ULK4	-0.51	-5.74	-0.3	2.11e-8	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs17661538	0.614	rs34849615	chr10:18414460	A/T	cg03634479	chr10:18430412	CACNB2	0.63	6.88	0.35	2.9e-11	Response to antipsychotic treatment;
LUSC	cis	rs7760535	0.826	rs7753887	chr6:111855107	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.39	-7.25	-0.37	2.95e-12	Metabolic traits;
LUSC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg16414030	chr3:133502952	NA	-0.57	-9.25	-0.45	2.77e-18	Iron status biomarkers;
LUSC	cis	rs7903847	0.656	rs12412478	chr10:99134923	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-6.5	-0.34	2.95e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6688613	0.685	rs742048	chr1:166910145	A/C	cg07049167	chr1:166818506	POGK	-0.41	-6.1	-0.32	3.01e-9	Refractive astigmatism;
LUSC	cis	rs7089973	0.966	rs12775180	chr10:116639754	T/C	cg23260525	chr10:116636907	FAM160B1	0.38	7.37	0.37	1.39e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg20744362	chr22:50050164	C22orf34	0.36	6.66	0.34	1.1e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg12432903	chr7:1882776	MAD1L1	-0.49	-8.45	-0.42	8.85e-16	Bipolar disorder and schizophrenia;
LUSC	trans	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg20935933	chr6:143382018	AIG1	0.5	7.27	0.37	2.61e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg22532475	chr10:104410764	TRIM8	-0.32	-7.15	-0.36	5.59e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg00745463	chr17:30367425	LRRC37B	-0.83	-10.0	-0.48	8.87e-21	Hip circumference adjusted for BMI;
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg01238044	chr22:24384105	GSTT1	0.55	8.14	0.41	7.96e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg03790207	chr6:42947109	PEX6	-0.46	-7.06	-0.36	9.53e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11030122	0.702	rs10835399	chr11:3989182	G/A	cg18678763	chr11:4115507	RRM1	-0.45	-5.77	-0.3	1.82e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs16937	0.711	rs11240384	chr1:205172175	C/T	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.36e-10	Schizophrenia;
LUSC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05535760	chr7:792225	HEATR2	0.91	9.61	0.47	1.88e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg13683864	chr3:40499215	RPL14	-1.13	-21.27	-0.76	4.37e-64	Renal cell carcinoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14935078	chr19:17414399	ABHD8	0.42	6.58	0.34	1.81e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-10.38	-0.49	4.64e-22	Alzheimer's disease (late onset);
LUSC	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.71	-11.74	-0.54	6.95e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg06238570	chr21:40685208	BRWD1	0.48	7.33	0.37	1.79e-12	Cognitive function;
LUSC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg17178900	chr1:205818956	PM20D1	0.44	6.13	0.32	2.48e-9	Prostate-specific antigen levels;
LUSC	cis	rs4964805	0.865	rs11111796	chr12:104205928	C/T	cg02344784	chr12:104178138	NT5DC3	0.41	6.6	0.34	1.64e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg07952391	chr2:88470173	THNSL2	0.77	6.84	0.35	3.74e-11	Plasma clusterin levels;
LUSC	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg11019008	chr10:131425282	MGMT	0.4	6.2	0.32	1.68e-9	Response to temozolomide;
LUSC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg13206674	chr6:150067644	NUP43	0.6	9.54	0.46	3.08e-19	Lung cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25999486	chr13:76056030	TBC1D4	-0.39	-6.36	-0.33	6.5e-10	Electrocardiographic conduction measures;
LUSC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg02475777	chr4:1388615	CRIPAK	0.43	6.44	0.33	4.04e-10	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg10729496	chr3:10149963	C3orf24	0.61	7.88	0.4	4.77e-14	Alzheimer's disease;
LUSC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg09796270	chr17:17721594	SREBF1	-0.45	-7.9	-0.4	4.09e-14	Total body bone mineral density;
LUSC	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.6	-9.68	-0.47	1.04e-19	Body mass index;
LUSC	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.05	-0.36	1.06e-11	Blood metabolite levels;
LUSC	cis	rs1832871	0.521	rs62437409	chr6:158820221	G/C	cg07165851	chr6:158734300	TULP4	0.4	6.34	0.33	7.55e-10	Height;
LUSC	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg22907277	chr7:1156413	C7orf50	0.44	6.77	0.35	5.64e-11	Longevity;Endometriosis;
LUSC	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg04310649	chr10:35416472	CREM	-0.4	-6.24	-0.32	1.33e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs865483	0.895	rs853234	chr17:35843050	A/G	cg06716730	chr17:35851459	DUSP14	-0.26	-5.89	-0.31	9.24e-9	Monocyte count;
LUSC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg00750074	chr16:89608354	SPG7	-0.56	-10.19	-0.49	2.07e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg22907277	chr7:1156413	C7orf50	0.67	7.26	0.37	2.66e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9468199	0.505	rs72847381	chr6:27873931	G/A	cg08851530	chr6:28072375	NA	1.24	8.4	0.42	1.32e-15	Parkinson's disease;
LUSC	trans	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg06606381	chr12:133084897	FBRSL1	-1.08	-9.45	-0.46	6.26e-19	Depression;
LUSC	cis	rs79911532	0.515	rs10235228	chr7:75833282	G/A	cg03592824	chr7:75666768	STYXL1	0.59	5.97	0.31	6e-9	Mononucleosis;
LUSC	cis	rs9837602	0.938	rs9823908	chr3:99795507	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.03	-0.31	4.31e-9	Breast cancer;
LUSC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg06454157	chr6:167490870	NA	-0.24	-5.94	-0.31	7.24e-9	Crohn's disease;
LUSC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	6.54	0.34	2.32e-10	Obesity-related traits;
LUSC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.54	-0.42	4.72e-16	Bipolar disorder;
LUSC	cis	rs9815354	1.000	rs17063599	chr3:41861676	C/T	cg03022575	chr3:42003672	ULK4	0.59	6.55	0.34	2.18e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg15744005	chr10:104629667	AS3MT	0.31	6.54	0.34	2.34e-10	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-0.97	-16.38	-0.67	1.1e-44	Dilated cardiomyopathy;
LUSC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.91	-0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs11700980	0.551	rs58732433	chr21:30109534	C/T	cg14791747	chr16:20752902	THUMPD1	0.55	5.98	0.31	5.75e-9	QRS complex (12-leadsum);
LUSC	cis	rs10208940	0.764	rs7583649	chr2:68830939	T/C	cg12452813	chr2:68675892	NA	0.57	5.88	0.31	9.87e-9	Urate levels in lean individuals;
LUSC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs8077577	0.895	rs6502640	chr17:18122485	G/A	cg16794390	chr17:18148240	FLII	0.42	5.89	0.31	9.54e-9	Obesity-related traits;
LUSC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg23711669	chr6:146136114	FBXO30	0.87	15.63	0.65	1.03e-41	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17421506	chr11:18656159	SPTY2D1	0.45	6.67	0.34	1.04e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg20291162	chr17:40259547	DHX58	0.55	7.53	0.38	4.79e-13	Fibrinogen levels;
LUSC	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-20.18	-0.74	8.81e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg12463550	chr7:65579703	CRCP	-0.51	-7.46	-0.38	7.72e-13	Aortic root size;
LUSC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-1.02	-15.74	-0.65	3.94e-42	Parkinson's disease;
LUSC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg19046167	chr17:80928561	B3GNTL1	0.45	6.81	0.35	4.52e-11	Breast cancer;
LUSC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg00750074	chr16:89608354	SPG7	-0.63	-12.22	-0.56	1.24e-28	Multiple myeloma (IgH translocation);
LUSC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.01	-0.4	1.87e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg05347473	chr6:146136440	FBXO30	0.56	9.8	0.47	4.41e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg10360139	chr7:1886902	MAD1L1	-0.44	-6.91	-0.35	2.42e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg13565492	chr6:43139072	SRF	-0.47	-5.98	-0.31	5.72e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg11189052	chr15:85197271	WDR73	0.46	5.72	0.3	2.35e-8	Schizophrenia;
LUSC	cis	rs4654899	1.000	rs6426660	chr1:21361640	A/G	cg01072550	chr1:21505969	NA	-0.56	-8.54	-0.42	4.74e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6545883	0.655	rs11893880	chr2:61422019	C/T	cg15711740	chr2:61764176	XPO1	-0.4	-6.33	-0.33	7.72e-10	Tuberculosis;
LUSC	cis	rs9314614	0.899	rs2977802	chr8:6694845	C/G	cg27319216	chr8:6693540	XKR5	0.35	6.3	0.33	9.41e-10	IgA nephropathy;White blood cell count (basophil);
LUSC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.06	0.52	1.93e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg22862634	chr11:62369728	EML3;MTA2	-0.49	-7.19	-0.37	4.27e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg21854759	chr1:92012499	NA	-0.44	-5.75	-0.3	2.02e-8	Eosinophil percentage of white cells;
LUSC	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg18129178	chr5:148520854	ABLIM3	-0.66	-10.32	-0.49	7.39e-22	Breast cancer;
LUSC	cis	rs7561273	0.609	rs3795953	chr2:24345707	C/G	cg06627628	chr2:24431161	ITSN2	-0.51	-6.8	-0.35	4.71e-11	Quantitative traits;
LUSC	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg02569458	chr12:86230093	RASSF9	0.39	6.27	0.32	1.1e-9	Major depressive disorder;
LUSC	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.01	-0.4	1.89e-14	Glomerular filtration rate;
LUSC	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg11584989	chr19:19387371	SF4	0.58	7.02	0.36	1.22e-11	Bipolar disorder;
LUSC	cis	rs6681460	0.932	rs523188	chr1:67174422	A/G	cg02459107	chr1:67143332	SGIP1	0.49	9.12	0.45	7.4e-18	Presence of antiphospholipid antibodies;
LUSC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.68	-10.36	-0.49	5.28e-22	Aortic root size;
LUSC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg06713675	chr4:122721982	EXOSC9	-0.68	-12.08	-0.55	4.12e-28	Type 2 diabetes;
LUSC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg16680214	chr1:154839983	KCNN3	-0.45	-8.19	-0.41	5.67e-15	Prostate cancer;
LUSC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg11645453	chr3:52864694	ITIH4	0.35	8.11	0.41	9.43e-15	Bipolar disorder;
LUSC	trans	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg04995722	chr7:26192034	NFE2L3	-0.39	-6.37	-0.33	6.27e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg20243544	chr17:37824526	PNMT	0.41	6.38	0.33	6.03e-10	Self-reported allergy;
LUSC	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg08017756	chr2:100939284	LONRF2	-0.4	-7.35	-0.37	1.51e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg18904891	chr8:8559673	CLDN23	-0.41	-5.88	-0.31	1.01e-8	Mood instability;
LUSC	cis	rs722599	0.683	rs7160852	chr14:75239424	T/C	cg06637938	chr14:75390232	RPS6KL1	0.39	5.69	0.3	2.85e-8	IgG glycosylation;
LUSC	cis	rs9650315	0.516	rs79664732	chr8:57202790	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	6.86	0.35	3.39e-11	Height;
LUSC	cis	rs7216064	1.000	rs8081517	chr17:65845697	A/T	cg12091567	chr17:66097778	LOC651250	-0.73	-9.42	-0.46	7.94e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.71	11.02	0.52	2.65e-24	Aortic root size;
LUSC	cis	rs9928842	0.823	rs4888365	chr16:75282247	A/G	cg09066997	chr16:75300724	BCAR1	0.5	6.37	0.33	6.14e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs11645898	0.935	rs35370634	chr16:72184566	C/T	cg14768367	chr16:72042858	DHODH	-0.65	-7.11	-0.36	7.28e-12	Blood protein levels;
LUSC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs1595825	0.838	rs80172713	chr2:198508044	T/C	cg19156104	chr2:198669113	PLCL1	-0.46	-5.78	-0.3	1.69e-8	Ulcerative colitis;
LUSC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.67e-12	Motion sickness;
LUSC	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg00033643	chr7:134001901	SLC35B4	0.43	6.33	0.33	7.96e-10	Mean platelet volume;
LUSC	trans	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg07211511	chr3:129823064	LOC729375	-0.74	-9.59	-0.46	2.12e-19	Blood pressure (smoking interaction);
LUSC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg14092988	chr3:52407081	DNAH1	0.32	6.01	0.31	4.95e-9	Bipolar disorder;
LUSC	trans	rs12431204	0.932	rs2323637	chr13:38447640	T/A	cg25252598	chr12:6641602	NA	0.38	6.27	0.32	1.12e-9	Schizophrenia;
LUSC	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.92	12.13	0.55	2.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg05585544	chr11:47624801	NA	-0.42	-7.27	-0.37	2.63e-12	Subjective well-being;
LUSC	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg25427524	chr10:38739819	LOC399744	-0.49	-6.53	-0.34	2.4e-10	Obesity (extreme);
LUSC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg09650180	chr20:62225654	GMEB2	-0.66	-9.69	-0.47	1.03e-19	Glioblastoma;
LUSC	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg26384229	chr12:38710491	ALG10B	0.73	11.94	0.55	1.27e-27	Morning vs. evening chronotype;
LUSC	trans	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.55	-8.54	-0.42	4.78e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg13010199	chr12:38710504	ALG10B	0.5	7.71	0.39	1.47e-13	Morning vs. evening chronotype;
LUSC	cis	rs10207060	0.500	rs10181238	chr2:240709496	G/A	cg20333904	chr2:240724165	NA	-0.37	-6.28	-0.32	1.06e-9	Obesity-related traits;
LUSC	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	9.27	0.45	2.29e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-6.4	-0.33	5.27e-10	Reticulocyte count;
LUSC	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.87	0.35	3.1e-11	Breast cancer;
LUSC	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-6.23	-0.32	1.37e-9	Educational attainment;
LUSC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg09365446	chr1:150670422	GOLPH3L	0.52	7.77	0.39	9.46e-14	Melanoma;
LUSC	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg18478394	chr8:109455254	TTC35	0.42	6.53	0.34	2.38e-10	Dupuytren's disease;
LUSC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.03	0.44	1.44e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg07741184	chr6:167504864	NA	0.49	8.62	0.43	2.75e-16	Crohn's disease;
LUSC	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg19875535	chr5:140030758	IK	0.47	7.56	0.38	4.05e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-1.13	-17.64	-0.69	1.06e-49	Exhaled nitric oxide output;
LUSC	cis	rs2282802	0.685	rs2053055	chr5:139646776	C/T	cg26211634	chr5:139558579	C5orf32	0.45	8.62	0.43	2.79e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7178572	0.568	rs12907847	chr15:77493174	C/T	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg20503657	chr10:835505	NA	0.76	9.07	0.44	1.02e-17	Eosinophil percentage of granulocytes;
LUSC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-1.17	-16.85	-0.68	1.53e-46	Breast cancer;
LUSC	trans	rs17685	1.000	rs17685	chr7:75616105	G/A	cg19862616	chr7:65841803	NCRNA00174	0.9	13.02	0.58	1.29e-31	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.66	-0.54	1.41e-26	Mean corpuscular volume;
LUSC	cis	rs12928939	0.518	rs12445564	chr16:71943309	C/T	cg03805757	chr16:71968109	PKD1L3	-0.65	-9.76	-0.47	5.76e-20	Post bronchodilator FEV1;
LUSC	cis	rs4629180	0.701	rs10202801	chr2:102106670	T/C	cg04415270	chr2:102091202	RFX8	-0.45	-7.88	-0.4	4.73e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs6076065	0.723	rs2249943	chr20:23378098	A/G	cg11657817	chr20:23433608	CST11	0.43	8.03	0.4	1.7e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7582180	0.934	rs2309822	chr2:100900406	G/A	cg08017756	chr2:100939284	LONRF2	-0.34	-5.69	-0.3	2.84e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs950881	0.932	rs10179458	chr2:102934974	C/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.37	0.33	6.4e-10	Allergy;
LUSC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02353165	chr6:42928485	GNMT	0.68	11.84	0.54	3.07e-27	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg05625103	chr10:2543513	NA	0.47	6.76	0.35	6.24e-11	Age-related hearing impairment;
LUSC	trans	rs62238980	0.522	rs77418985	chr22:32380919	C/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20997706	chr15:74907203	CLK3	-0.43	-6.38	-0.33	5.82e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7771547	0.607	rs584196	chr6:36456243	G/C	cg07856975	chr6:36356162	ETV7	0.37	6.58	0.34	1.8e-10	Platelet distribution width;
LUSC	cis	rs12900413	0.687	rs7176981	chr15:90315757	A/G	cg24249390	chr15:90295951	MESP1	-0.37	-5.75	-0.3	2.05e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs2227930	0.506	rs1552340	chr3:142015590	A/G	cg16271453	chr3:142027066	XRN1	0.54	9.96	0.48	1.26e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Body mass index;
LUSC	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.7	-0.34	8.84e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	7.91	0.4	3.88e-14	Menarche (age at onset);
LUSC	trans	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg01620082	chr3:125678407	NA	-0.82	-7.32	-0.37	1.84e-12	Depression;
LUSC	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.37	1.18e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg11608241	chr8:8085544	FLJ10661	0.44	6.4	0.33	5.18e-10	Mood instability;
LUSC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg00945038	chr17:61921165	SMARCD2	0.39	5.77	0.3	1.81e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs727505	1.000	rs10226033	chr7:124521430	C/A	cg23710748	chr7:124431027	NA	-0.42	-7.54	-0.38	4.53e-13	Lewy body disease;
LUSC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.33	0.59	8.6e-33	Cognitive test performance;
LUSC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg21699342	chr2:239360505	ASB1	0.56	10.5	0.5	1.76e-22	Multiple system atrophy;
LUSC	trans	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg15704280	chr7:45808275	SEPT13	0.67	6.31	0.33	8.99e-10	Intraocular pressure;
LUSC	cis	rs11676348	0.808	rs4674267	chr2:219046437	C/T	cg00012203	chr2:219082015	ARPC2	-0.59	-9.47	-0.46	5.35e-19	Ulcerative colitis;
LUSC	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	7.11	0.36	7.16e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg13736514	chr6:26305472	NA	-0.49	-9.69	-0.47	1e-19	Educational attainment;
LUSC	cis	rs7659604	0.540	rs7698889	chr4:122671324	G/T	cg19748678	chr4:122722346	EXOSC9	-0.42	-6.2	-0.32	1.68e-9	Type 2 diabetes;
LUSC	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.87	14.09	0.61	1.09e-35	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg12559939	chr2:27858050	GPN1	0.39	6.05	0.31	3.98e-9	Oral cavity cancer;
LUSC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06634786	chr22:41940651	POLR3H	-0.57	-6.44	-0.33	4.05e-10	Vitiligo;
LUSC	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg08854313	chr1:11322531	MTOR	0.81	12.1	0.55	3.52e-28	Body mass index;
LUSC	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-6.83	-0.35	3.91e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs983392	0.679	rs764859	chr11:59978255	C/G	cg24026212	chr11:59952134	MS4A6A	-0.35	-5.95	-0.31	6.86e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.52	-0.46	3.57e-19	Total cholesterol levels;
LUSC	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg06808227	chr14:105710500	BRF1	-0.72	-11.57	-0.53	2.91e-26	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg02403541	chr12:121454288	C12orf43	0.61	8.7	0.43	1.53e-16	N-glycan levels;
LUSC	cis	rs61931739	0.635	rs6488185	chr12:33933127	G/C	cg06521331	chr12:34319734	NA	-0.4	-6.69	-0.34	9.58e-11	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08280861	chr8:58055591	NA	0.54	6.3	0.33	9.15e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg08601574	chr20:25228251	PYGB	0.43	6.51	0.34	2.83e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg16339924	chr4:17578868	LAP3	0.54	8.14	0.41	7.69e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01029676	chr3:122785968	PDIA5	-0.34	-5.96	-0.31	6.45e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1507153	0.702	rs7740665	chr6:79353465	C/T	cg05283184	chr6:79620031	NA	-0.42	-7.38	-0.37	1.29e-12	Sjögren's syndrome;
LUSC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg17443473	chr1:3703550	LRRC47	0.32	5.65	0.3	3.36e-8	Red cell distribution width;
LUSC	cis	rs72960926	0.744	rs11758445	chr6:74979953	T/A	cg03266952	chr6:74778945	NA	-0.87	-7.19	-0.37	4.34e-12	Metabolite levels (MHPG);
LUSC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg24324837	chr19:49891574	CCDC155	0.44	5.82	0.3	1.36e-8	Multiple sclerosis;
LUSC	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg00083937	chr22:51039805	MAPK8IP2	0.5	8.41	0.42	1.18e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1866706	0.896	rs7945921	chr11:12875794	C/A	cg25843174	chr11:12811716	TEAD1	-0.28	-5.72	-0.3	2.36e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg05714579	chr10:131428358	MGMT	0.45	6.25	0.32	1.26e-9	Response to temozolomide;
LUSC	cis	rs1904096	0.506	rs6841121	chr4:95222995	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.42	-0.42	1.15e-15	Type 2 diabetes;
LUSC	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.85	9.79	0.47	4.53e-20	Breast cancer;
LUSC	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg08017756	chr2:100939284	LONRF2	-0.44	-8.27	-0.41	3.33e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9487051	0.698	rs11153168	chr6:109629420	A/T	cg01475377	chr6:109611718	NA	-0.37	-5.73	-0.3	2.25e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg09941381	chr10:64027924	RTKN2	0.4	7.4	0.38	1.1e-12	Rheumatoid arthritis;
LUSC	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.56	9.3	0.45	1.86e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg16393715	chr7:1948819	MAD1L1	0.37	6.33	0.33	7.88e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	trans	rs4714291	0.748	rs3008829	chr6:39953963	C/T	cg02267698	chr19:7991119	CTXN1	-0.53	-7.57	-0.38	3.58e-13	Strep throat;
LUSC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg17968037	chr7:100024898	ZCWPW1	-0.41	-6.14	-0.32	2.39e-9	Platelet count;
LUSC	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.9e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.91	-0.35	2.4e-11	Menopause (age at onset);
LUSC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg04518342	chr5:131593106	PDLIM4	-0.41	-6.95	-0.36	1.88e-11	Breast cancer;
LUSC	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.94	-0.31	7.31e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg13531842	chr10:38383804	ZNF37A	0.42	5.73	0.3	2.22e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	12.99	0.58	1.67e-31	Blood protein levels;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg04234412	chr22:24373322	LOC391322	-0.87	-14.13	-0.61	7.23e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs974417	0.508	rs986066	chr6:97342489	C/T	cg10979063	chr6:97285822	GPR63	0.42	6.71	0.34	8.31e-11	Body mass index;
LUSC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg24881330	chr22:46731750	TRMU	0.87	8.8	0.43	7.38e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.92	0.31	8e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2425143	0.908	rs58448091	chr20:34325470	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.16	-0.32	2.04e-9	Blood protein levels;
LUSC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg17264618	chr3:40429014	ENTPD3	0.33	6.79	0.35	5.05e-11	Renal cell carcinoma;
LUSC	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.84	0.3	1.23e-8	Breast cancer;
LUSC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	1.13	22.35	0.77	2.74e-68	Total cholesterol levels;
LUSC	cis	rs3784262	0.542	rs2899611	chr15:58327347	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.67	-0.3	3.12e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg00173435	chr12:106696525	TCP11L2	0.61	8.91	0.44	3.32e-17	Tourette syndrome;
LUSC	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg05855489	chr10:104503620	C10orf26	-0.69	-10.2	-0.49	1.86e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg17279839	chr7:150038598	RARRES2	0.42	6.78	0.35	5.45e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2766692	1.000	rs2766690	chr14:100682154	A/G	cg14866419	chr14:100704911	YY1	-0.46	-5.86	-0.31	1.12e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	0.91	15.04	0.64	2.2e-39	Breast cancer;
LUSC	trans	rs2055729	0.710	rs112406488	chr8:9736362	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	6.19	0.32	1.79e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs4919694	1.000	rs4917379	chr10:104752831	A/T	cg04362960	chr10:104952993	NT5C2	1.17	13.66	0.6	4.81e-34	Arsenic metabolism;
LUSC	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-7.07	-0.36	9.06e-12	Monocyte percentage of white cells;
LUSC	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg03859395	chr2:55845619	SMEK2	0.87	16.06	0.66	1.99e-43	Metabolic syndrome;
LUSC	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg15595755	chr5:1867978	NA	0.38	6.3	0.33	9.61e-10	Cardiovascular disease risk factors;
LUSC	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg19784903	chr17:45786737	TBKBP1	-0.43	-6.28	-0.33	1.05e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg15605315	chr1:45957053	TESK2	0.45	7.06	0.36	9.83e-12	High light scatter reticulocyte count;
LUSC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.13	15.93	0.66	6.52e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg19694781	chr19:47549865	TMEM160	0.59	9.52	0.46	3.59e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg22563815	chr15:78856949	CHRNA5	-0.23	-5.64	-0.3	3.58e-8	Sudden cardiac arrest;
LUSC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.68	-0.39	1.79e-13	Personality dimensions;
LUSC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.0	0.36	1.42e-11	Bipolar disorder;
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg23131131	chr22:24373011	LOC391322	-0.49	-7.1	-0.36	7.67e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.74	-0.3	2.09e-8	IgG glycosylation;
LUSC	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-9.12	-0.45	7.32e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg06521331	chr12:34319734	NA	0.38	6.52	0.34	2.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg10729496	chr3:10149963	C3orf24	0.57	7.74	0.39	1.21e-13	Alzheimer's disease;
LUSC	cis	rs7590368	0.962	rs13431633	chr2:10960225	T/C	cg15705551	chr2:10952987	PDIA6	0.58	8.0	0.4	2.11e-14	Educational attainment (years of education);
LUSC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.79	-0.43	8.32e-17	Aortic root size;
LUSC	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-7.74	-0.39	1.17e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7180079	0.925	rs11071789	chr15:64596057	C/T	cg08069370	chr15:64387884	SNX1	0.53	5.72	0.3	2.32e-8	Monocyte count;
LUSC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg17691542	chr6:26056736	HIST1H1C	0.54	8.11	0.41	9.42e-15	Height;
LUSC	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg22709100	chr7:91322751	NA	0.46	6.75	0.35	6.62e-11	Breast cancer;
LUSC	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg22907277	chr7:1156413	C7orf50	0.72	10.22	0.49	1.63e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7605827	0.930	rs10172344	chr2:15521591	A/G	cg19274914	chr2:15703543	NA	0.46	8.98	0.44	2.03e-17	Educational attainment (years of education);
LUSC	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg20744362	chr22:50050164	C22orf34	0.38	7.32	0.37	1.87e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7168353	0.948	rs10520720	chr15:93634724	A/G	cg12595281	chr15:93633172	RGMA	-0.48	-7.56	-0.38	3.89e-13	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.47	-0.91	7.9e-131	Myeloid white cell count;
LUSC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg25019033	chr10:957182	NA	-0.53	-6.9	-0.35	2.61e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs757081	0.506	rs11529609	chr11:17063790	G/A	cg15084286	chr11:17036142	PLEKHA7	0.49	6.42	0.33	4.6e-10	Systolic blood pressure;
LUSC	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg00071950	chr4:10020882	SLC2A9	0.5	8.4	0.42	1.28e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg21573476	chr21:45109991	RRP1B	-0.42	-6.75	-0.35	6.5500000000000006e-11	Mean corpuscular volume;
LUSC	cis	rs11608355	1.000	rs10850134	chr12:109861454	G/C	cg05360138	chr12:110035743	NA	0.47	6.35	0.33	6.87e-10	Neuroticism;
LUSC	cis	rs4356932	0.935	rs4345214	chr4:76954169	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg13206674	chr6:150067644	NUP43	0.57	8.99	0.44	1.91e-17	Lung cancer;
LUSC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg03146154	chr1:46216737	IPP	-0.57	-8.11	-0.41	9.92e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6543140	0.964	rs10193485	chr2:103089573	T/C	cg09003973	chr2:102972529	NA	0.54	6.83	0.35	4.07e-11	Blood protein levels;
LUSC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg08888203	chr3:10149979	C3orf24	0.66	9.07	0.44	1.06e-17	Alzheimer's disease;
LUSC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg09034736	chr1:150693464	HORMAD1	0.49	7.17	0.37	4.82e-12	Melanoma;
LUSC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.54	9.5	0.46	4.09e-19	Osteoporosis;
LUSC	cis	rs983392	0.667	rs631853	chr11:59944898	T/G	cg24026212	chr11:59952134	MS4A6A	0.34	6.2	0.32	1.71e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg22907277	chr7:1156413	C7orf50	0.72	7.67	0.39	1.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs500891	1.000	rs869288	chr6:84190216	A/T	cg08257003	chr6:84140564	ME1	0.34	7.06	0.36	9.77e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs11030122	0.673	rs66596383	chr11:3979745	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.71	-0.3	2.54e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg06784218	chr1:46089804	CCDC17	0.48	9.5	0.46	4.33e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg01657329	chr11:68192670	LRP5	-0.45	-7.1	-0.36	7.74e-12	Total body bone mineral density;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25336731	chr2:70520884	SNRPG	-0.52	-6.92	-0.35	2.31e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg06713675	chr4:122721982	EXOSC9	-0.69	-12.06	-0.55	4.59e-28	Type 2 diabetes;
LUSC	cis	rs2857891	0.862	rs957747	chr11:6966814	A/G	cg04053776	chr11:6947353	ZNF215	0.49	6.87	0.35	3.14e-11	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg09904177	chr6:26538194	HMGN4	-0.54	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg09754948	chr16:28834200	ATXN2L	0.44	6.43	0.33	4.51e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2241584	0.507	rs2913897	chr5:175921783	A/G	cg24735937	chr5:175843923	CLTB	-0.35	-6.23	-0.32	1.43e-9	Menopause (age at onset);
LUSC	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.75	-11.77	-0.54	5.4e-27	Dilated cardiomyopathy;
LUSC	cis	rs977987	0.762	rs1364079	chr16:75393131	C/A	cg04384234	chr16:75411784	CFDP1	-0.45	-7.46	-0.38	7.38e-13	Dupuytren's disease;
LUSC	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	12.4	0.56	2.66e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs10097669	0.634	rs2725065	chr8:4437566	C/T	cg16451306	chr5:71475356	MAP1B	0.29	5.97	0.31	5.98e-9	Trans fatty acid levels;
LUSC	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02176678	chr2:219576539	TTLL4	0.64	11.79	0.54	4.45e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg17764715	chr19:33622953	WDR88	0.6	8.33	0.41	2.08e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg27535305	chr1:53392650	SCP2	-0.38	-6.88	-0.35	2.9e-11	Monocyte count;
LUSC	cis	rs9311676	0.632	rs11130643	chr3:58423288	G/A	cg13750441	chr3:58318267	PXK	0.34	6.71	0.34	8.48e-11	Systemic lupus erythematosus;
LUSC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21862992	chr11:68658383	NA	0.48	7.69	0.39	1.71e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.74	0.65	3.85e-42	Morning vs. evening chronotype;
LUSC	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg22676075	chr6:135203613	NA	-0.56	-8.94	-0.44	2.64e-17	Red blood cell count;
LUSC	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg05855489	chr10:104503620	C10orf26	0.59	9.36	0.46	1.2e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg15083037	chr5:83017644	HAPLN1	-0.61	-7.72	-0.39	1.37e-13	Prostate cancer;
LUSC	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg00677455	chr12:58241039	CTDSP2	0.5	6.82	0.35	4.4e-11	Multiple sclerosis;
LUSC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.24	0.52	4.63e-25	Prudent dietary pattern;
LUSC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg11062466	chr8:58055876	NA	0.69	8.4	0.42	1.34e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg26528668	chr16:1614120	IFT140	0.44	7.25	0.37	2.93e-12	Coronary artery disease;
LUSC	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	1.01	13.91	0.61	4.95e-35	Exhaled nitric oxide levels;
LUSC	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg15073853	chr19:18549131	ISYNA1	-0.31	-5.72	-0.3	2.4e-8	Breast cancer;
LUSC	cis	rs7851660	0.809	rs7036589	chr9:100657720	A/T	cg13688889	chr9:100608707	NA	0.54	8.29	0.41	2.77e-15	Strep throat;
LUSC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg00031303	chr3:195681400	NA	-0.68	-9.76	-0.47	5.99e-20	Pancreatic cancer;
LUSC	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg00105475	chr2:10696890	NA	0.38	6.35	0.33	6.94e-10	Prostate cancer;
LUSC	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg05784532	chr1:230284198	GALNT2	0.54	8.26	0.41	3.52e-15	Coronary artery disease;
LUSC	cis	rs11756438	0.546	rs9489497	chr6:118999636	T/C	cg18833306	chr6:118973337	C6orf204	0.36	5.73	0.3	2.2e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	6.84	0.35	3.73e-11	Menarche (age at onset);
LUSC	cis	rs7808935	0.958	rs10486567	chr7:27976563	G/A	cg22168087	chr7:27702803	HIBADH	0.52	6.54	0.34	2.29e-10	Prostate cancer;
LUSC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	13.83	0.6	1.02e-34	Smoking behavior;
LUSC	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg17173187	chr15:85201210	NMB	0.51	9.69	0.47	9.71e-20	Schizophrenia;
LUSC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.87	0.4	4.99e-14	Prudent dietary pattern;
LUSC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.83	-0.47	3.36e-20	Gut microbiome composition (summer);
LUSC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.13	0.36	6.34e-12	Bipolar disorder;
LUSC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg25233709	chr10:116636983	FAM160B1	0.37	6.64	0.34	1.24e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21643547	chr1:205240462	TMCC2	-0.52	-10.11	-0.48	3.84e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	0.95	18.06	0.7	2.27e-51	Bone mineral density;
LUSC	cis	rs698813	0.674	rs6759891	chr2:44496005	C/T	cg00619915	chr2:44497795	NA	-0.51	-6.95	-0.36	1.88e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg18230493	chr5:56204884	C5orf35	-0.62	-9.55	-0.46	2.88e-19	Coronary artery disease;
LUSC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg11494091	chr17:61959527	GH2	0.38	6.24	0.32	1.31e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	8.93	0.44	2.91e-17	Monocyte percentage of white cells;
LUSC	cis	rs4141404	0.923	rs2413035	chr22:31600460	A/G	cg22777020	chr22:31556080	RNF185	-0.44	-5.72	-0.3	2.34e-8	Paclitaxel-induced neuropathy;
LUSC	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	11.04	0.52	2.31e-24	Hypertriglyceridemia;
LUSC	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.46	9.61	0.47	1.86e-19	Airflow obstruction;
LUSC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12756686	chr19:29218302	NA	0.46	5.81	0.3	1.42e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs2282802	0.685	rs12717951	chr5:139589309	A/G	cg26211634	chr5:139558579	C5orf32	0.43	8.03	0.4	1.63e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg12463550	chr7:65579703	CRCP	0.51	7.39	0.37	1.2e-12	Aortic root size;
LUSC	cis	rs11997175	0.545	rs7839592	chr8:33666662	T/C	ch.8.33884649F	chr8:33765107	NA	0.5	7.19	0.37	4.32e-12	Body mass index;
LUSC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.63	-0.43	2.57e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.85	0.54	2.87e-27	Personality dimensions;
LUSC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg17691542	chr6:26056736	HIST1H1C	0.52	7.85	0.39	5.8e-14	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08470185	chr1:1334798	CCNL2;LOC148413	-0.39	-6.24	-0.32	1.29e-9	Electrocardiographic conduction measures;
LUSC	cis	rs59698941	0.943	rs10491278	chr5:132220436	A/C	cg02081065	chr5:132209139	LEAP2	-0.65	-6.75	-0.35	6.45e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.5	7.67	0.39	1.84e-13	Eosinophil percentage of white cells;
LUSC	cis	rs10761482	0.861	rs10761490	chr10:62108666	T/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.1	-0.36	7.67e-12	Schizophrenia;
LUSC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg27284194	chr4:1044797	NA	0.35	5.83	0.3	1.32e-8	Obesity-related traits;
LUSC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	14.24	0.61	2.83e-36	Platelet count;
LUSC	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg06197492	chr11:2016605	H19	-0.37	-6.19	-0.32	1.79e-9	DNA methylation (variation);
LUSC	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg23229984	chr5:148520753	ABLIM3	0.41	6.45	0.33	3.99e-10	Breast cancer;
LUSC	cis	rs290268	1.000	rs188313	chr9:93548302	C/T	cg02608019	chr9:93564028	SYK	0.54	8.98	0.44	1.98e-17	Platelet count;
LUSC	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-7.54	-0.38	4.39e-13	Response to antipsychotic treatment;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg21030970	chr17:45798741	NA	0.37	6.27	0.32	1.14e-9	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23932593	chr6:133135524	RPS12;SNORD101	-0.52	-6.5	-0.34	2.98e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs56283067	0.671	rs1028608	chr6:44681721	C/T	cg18551225	chr6:44695536	NA	-0.42	-7.36	-0.37	1.48e-12	Total body bone mineral density;
LUSC	cis	rs68170813	0.559	rs80341862	chr7:106934731	C/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.98	-0.48	1.09e-20	Coronary artery disease;
LUSC	cis	rs6740322	1.000	rs11693666	chr2:43562479	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.44	6.15	0.32	2.17e-9	Coronary artery disease;
LUSC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06850241	chr22:41845214	NA	0.3	5.77	0.3	1.84e-8	Vitiligo;
LUSC	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.03	-23.32	-0.79	4.71e-72	Ulcerative colitis;
LUSC	cis	rs113835537	0.529	rs117112180	chr11:66293273	A/G	cg24851651	chr11:66362959	CCS	0.52	7.41	0.38	1.05e-12	Airway imaging phenotypes;
LUSC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	1.08	17.76	0.7	3.61e-50	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10493773	1.000	rs55654440	chr1:86176158	G/C	cg17807903	chr1:86174739	ZNHIT6	-0.44	-9.35	-0.46	1.28e-18	Urate levels in overweight individuals;
LUSC	cis	rs12210905	1.000	rs7757680	chr6:27005840	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-6.01	-0.31	4.74e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg06917634	chr15:78832804	PSMA4	-0.51	-5.95	-0.31	6.63e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg02487422	chr3:49467188	NICN1	0.45	7.08	0.36	8.66e-12	Resting heart rate;
LUSC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg04369109	chr6:150039330	LATS1	-0.53	-7.66	-0.39	2.03e-13	Lung cancer;
LUSC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg17366294	chr4:99064904	C4orf37	0.55	9.59	0.46	2.1e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg08645402	chr16:4508243	NA	-0.42	-6.88	-0.35	2.9e-11	Schizophrenia;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg00535420	chr2:238875533	UBE2F	0.43	6.1	0.32	2.86e-9	Mosquito bite size;
LUSC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	10.48	0.5	2.16e-22	Cognitive test performance;
LUSC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg12365402	chr11:9010492	NRIP3	-0.49	-9.15	-0.45	5.85e-18	Hemoglobin concentration;
LUSC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg08219700	chr8:58056026	NA	0.44	5.75	0.3	2.01e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg10909506	chr17:38081995	ORMDL3	0.32	5.75	0.3	2.04e-8	Self-reported allergy;
LUSC	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-0.8	-9.76	-0.47	5.85e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10774877	chr13:102068989	NALCN	-0.39	-6.12	-0.32	2.59e-9	Triglycerides;
LUSC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg10130564	chr11:117069849	TAGLN	0.31	6.0	0.31	5.07e-9	Blood protein levels;
LUSC	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg10253484	chr15:75165896	SCAMP2	-0.59	-8.29	-0.41	2.85e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs5770917	1.000	rs2073605	chr22:51008850	A/G	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.61	-5.9	-0.31	8.76e-9	Narcolepsy;
LUSC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.32	-5.93	-0.31	7.69e-9	IgG glycosylation;
LUSC	cis	rs4789693	0.938	rs4789694	chr17:80428099	A/C	cg04308225	chr17:80449738	NA	-0.48	-7.68	-0.39	1.81e-13	Glucocorticoid-induced osteonecrosis;
LUSC	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	14.08	0.61	1.14e-35	Exhaled nitric oxide levels;
LUSC	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs73416724	1.000	rs76649578	chr6:43388024	A/G	cg26312998	chr6:43337775	ZNF318	0.53	6.15	0.32	2.23e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.45	6.3	0.33	9.48e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.89	0.61	6.08e-35	Platelet count;
LUSC	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.72	11.06	0.52	1.99e-24	Alcohol dependence;
LUSC	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	0.84	14.2	0.61	3.77e-36	Prostate cancer;
LUSC	cis	rs4566357	0.595	rs1320406	chr2:227920474	C/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.61	-0.38	2.86e-13	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	0.93	16.11	0.66	1.32e-43	Menopause (age at onset);
LUSC	trans	rs629535	0.814	rs56301437	chr8:70108518	C/T	cg21567404	chr3:27674614	NA	-0.98	-15.88	-0.66	1.02e-42	Dupuytren's disease;
LUSC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg18904891	chr8:8559673	CLDN23	0.61	8.47	0.42	7.74e-16	Obesity-related traits;
LUSC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg16606324	chr3:10149918	C3orf24	-0.53	-7.42	-0.38	9.95e-13	Alzheimer's disease;
LUSC	cis	rs2708377	0.858	rs68045377	chr12:11294452	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.81	7.88	0.4	4.71e-14	Bitter taste perception;
LUSC	trans	rs12200782	0.932	rs72844476	chr6:26574150	C/T	cg11837749	chr1:55047332	ACOT11	0.57	6.14	0.32	2.32e-9	Small cell lung carcinoma;
LUSC	cis	rs13315871	0.929	rs11720747	chr3:58267833	G/A	cg12435725	chr3:58293450	RPP14	-0.82	-7.88	-0.4	4.7e-14	Cholesterol, total;
LUSC	cis	rs72792276	0.818	rs3805610	chr5:127487719	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.32	0.33	8.61e-10	Red cell distribution width;
LUSC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg13798780	chr7:105162888	PUS7	0.54	6.03	0.31	4.24e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.86	-15.07	-0.64	1.58e-39	Cognitive function;
LUSC	cis	rs1595825	0.891	rs2045244	chr2:198506466	C/T	cg19156104	chr2:198669113	PLCL1	-0.46	-5.78	-0.3	1.69e-8	Ulcerative colitis;
LUSC	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg16482183	chr6:26056742	HIST1H1C	0.63	9.07	0.44	1.01e-17	Iron status biomarkers;
LUSC	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.34	-0.37	1.65e-12	Psoriasis;
LUSC	cis	rs8092503	1.000	rs2015502	chr18:52489982	A/G	cg12377874	chr18:52495404	RAB27B	-0.34	-6.29	-0.33	1.01e-9	Childhood body mass index;
LUSC	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg22089800	chr15:90895588	ZNF774	0.52	7.48	0.38	6.67e-13	Rheumatoid arthritis;
LUSC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg16898833	chr6:26189333	HIST1H4D	0.64	6.14	0.32	2.39e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-1.15	-18.63	-0.71	1.22e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7202877	0.610	rs468079	chr16:75428474	G/A	cg04384234	chr16:75411784	CFDP1	0.69	9.97	0.48	1.11e-20	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.44	7.47	0.38	7.18e-13	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg26816564	chr1:7831052	VAMP3	0.44	5.73	0.3	2.21e-8	Inflammatory bowel disease;
LUSC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg24399712	chr22:39784796	NA	-0.64	-11.85	-0.54	2.84e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg27572855	chr1:25598939	RHD	-0.42	-7.5	-0.38	5.92e-13	Erythrocyte sedimentation rate;
LUSC	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg24631222	chr15:78858424	CHRNA5	0.68	9.08	0.44	9.58e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg09796270	chr17:17721594	SREBF1	0.43	7.65	0.39	2.17e-13	Total body bone mineral density;
LUSC	cis	rs500891	0.525	rs1170484	chr6:84038522	A/G	cg08257003	chr6:84140564	ME1	0.33	7.8	0.39	7.82e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs7605827	0.897	rs11682528	chr2:15533183	T/C	cg19274914	chr2:15703543	NA	0.48	9.34	0.46	1.39e-18	Educational attainment (years of education);
LUSC	cis	rs3733418	0.799	rs13110766	chr4:165956628	C/T	cg06481168	chr4:165878055	C4orf39;TRIM61	-0.45	-5.79	-0.3	1.6e-8	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.05	0.48	6.03e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.79	11.8	0.54	4.37e-27	Corneal astigmatism;
LUSC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.03	0.58	1.12e-31	Cognitive test performance;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10007002	chr8:38126881	PPAPDC1B	-0.4	-5.96	-0.31	6.46e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg03806693	chr22:41940476	POLR3H	-0.76	-11.0	-0.52	3.06e-24	Vitiligo;
LUSC	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.59	0.34	1.7e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.89	12.55	0.57	7.02e-30	Ileal carcinoids;
LUSC	trans	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg21659725	chr3:3221576	CRBN	0.69	8.29	0.41	2.82e-15	Menarche (age at onset);
LUSC	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs35995292	0.927	rs4720308	chr7:38914285	A/C	cg19327137	chr7:38886074	VPS41	0.34	5.71	0.3	2.47e-8	Subjective well-being (multi-trait analysis);
LUSC	cis	rs72772090	0.539	rs72775810	chr5:96185307	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.79	-0.35	5.01e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs3125734	0.633	rs4979754	chr10:64048959	G/A	cg19640130	chr10:64028056	RTKN2	-0.39	-6.8	-0.35	4.7e-11	Rheumatoid arthritis;
LUSC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg23601416	chr22:19950040	COMT	0.29	6.09	0.32	3.16e-9	Blood metabolite levels;
LUSC	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.71	-11.97	-0.55	9.97e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs524023	0.957	rs12365089	chr11:64364735	A/T	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.69	-0.3	2.71e-8	Urate levels in obese individuals;
LUSC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18854424	chr1:2615690	NA	0.49	9.85	0.47	2.88e-20	Ulcerative colitis;
LUSC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg19230755	chr7:65878503	NA	-0.42	-6.0	-0.31	5.22e-9	Aortic root size;
LUSC	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg26384229	chr12:38710491	ALG10B	0.72	11.29	0.53	3.03e-25	Morning vs. evening chronotype;
LUSC	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg04310649	chr10:35416472	CREM	-0.43	-6.64	-0.34	1.29e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2692947	0.727	rs2692950	chr2:96673524	T/C	cg22654517	chr2:96458247	NA	0.3	5.85	0.3	1.16e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.58	-10.24	-0.49	1.4e-21	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg05082376	chr22:42548792	NA	-0.38	-5.67	-0.3	3.09e-8	Schizophrenia;
LUSC	trans	rs1459104	0.789	rs28896554	chr11:54812637	C/T	cg15704280	chr7:45808275	SEPT13	0.75	6.55	0.34	2.23e-10	Body mass index;
LUSC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11645453	chr3:52864694	ITIH4	0.33	7.81	0.39	7.22e-14	Bipolar disorder;
LUSC	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.81	14.09	0.61	1.06e-35	Metabolic syndrome;
LUSC	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg10978503	chr1:24200527	CNR2	0.47	11.12	0.52	1.18e-24	Immature fraction of reticulocytes;
LUSC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg04455712	chr21:45112962	RRP1B	0.45	8.5	0.42	6.21e-16	Mean corpuscular volume;
LUSC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg14004847	chr7:1930337	MAD1L1	-0.58	-9.11	-0.45	7.51e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs4343996	0.727	rs4722696	chr7:3374580	C/G	cg21248987	chr7:3385318	SDK1	-0.35	-6.04	-0.31	4.12e-9	Motion sickness;
LUSC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.62	-0.5	6.98e-23	Obesity-related traits;
LUSC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg12963246	chr6:28129442	ZNF389	0.4	6.22	0.32	1.53e-9	Parkinson's disease;
LUSC	cis	rs72829446	0.556	rs10048219	chr17:7403792	C/T	cg02795151	chr17:7402630	POLR2A	0.63	7.81	0.39	7.61e-14	Androgen levels;
LUSC	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg24375607	chr4:120327624	NA	0.79	11.71	0.54	8.83e-27	Corneal astigmatism;
LUSC	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg01943577	chr7:158741284	NA	-0.39	-5.7	-0.3	2.6e-8	Height;
LUSC	cis	rs757110	0.590	rs7484027	chr11:17368381	T/A	cg01251548	chr11:17372745	DKFZp686O24166	0.34	6.54	0.34	2.29e-10	Type 2 diabetes;
LUSC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg06238570	chr21:40685208	BRWD1	0.47	7.25	0.37	2.94e-12	Cognitive function;
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg00024416	chr22:24240387	NA	-0.33	-5.69	-0.3	2.81e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.44	-0.42	9.51e-16	Cystic fibrosis severity;
LUSC	cis	rs9399401	0.626	rs1928528	chr6:142779109	T/G	cg04461802	chr6:142623433	GPR126	0.46	5.9	0.31	8.82e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs295140	1.000	rs11888462	chr2:201160499	G/T	cg04283868	chr2:201171347	SPATS2L	0.45	6.85	0.35	3.58e-11	QT interval;
LUSC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.38	0.37	1.3e-12	Bipolar disorder;
LUSC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg24829409	chr8:58192753	C8orf71	-0.45	-5.67	-0.3	3.05e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2267681	0.565	rs6464800	chr7:139518480	A/G	cg14116596	chr7:139528673	TBXAS1	0.38	6.63	0.34	1.34e-10	Cervical cancer;
LUSC	trans	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg21659725	chr3:3221576	CRBN	0.42	6.16	0.32	2.06e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg07578070	chr6:150326732	RAET1K	0.39	5.99	0.31	5.43e-9	Alopecia areata;
LUSC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg27432699	chr2:27873401	GPN1	-0.58	-8.67	-0.43	1.84e-16	Total body bone mineral density;
LUSC	cis	rs9815354	0.812	rs60659106	chr3:41949569	G/C	cg03022575	chr3:42003672	ULK4	0.81	8.49	0.42	6.81e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs8099014	0.906	rs4940695	chr18:56106483	T/G	cg12907477	chr18:56117327	MIR122	0.43	6.36	0.33	6.77e-10	Platelet count;
LUSC	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg13647721	chr17:30228624	UTP6	-0.68	-7.84	-0.39	5.94e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-6.85	-0.35	3.63e-11	Neutrophil percentage of white cells;
LUSC	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg24450063	chr1:156163899	SLC25A44	1.15	23.5	0.79	8.98e-73	Testicular germ cell tumor;
LUSC	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg12454169	chr2:30669597	LCLAT1	0.6	8.0	0.4	2.03e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs6750047	0.647	rs62136320	chr2:38275953	T/G	cg07380506	chr2:38303506	CYP1B1	0.47	6.54	0.34	2.27e-10	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg17971929	chr21:40555470	PSMG1	0.65	7.99	0.4	2.23e-14	Cognitive function;
LUSC	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg25039879	chr17:56429692	SUPT4H1	-0.47	-6.81	-0.35	4.58e-11	Cognitive test performance;
LUSC	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.34	-0.37	1.65e-12	Psoriasis;
LUSC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg21475434	chr5:93447410	FAM172A	0.76	9.17	0.45	5.12e-18	Diabetic retinopathy;
LUSC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg16989086	chr20:62203971	PRIC285	0.46	6.53	0.34	2.47e-10	Glioblastoma;
LUSC	trans	rs2262909	0.962	rs439574	chr19:22232024	A/C	cg17074339	chr11:11642133	GALNTL4	-0.4	-6.17	-0.32	1.95e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7539542	0.556	rs10732292	chr1:202891366	T/C	cg19681188	chr1:202830198	LOC148709	0.41	6.11	0.32	2.85e-9	Mean platelet volume;
LUSC	cis	rs72949976	1.000	rs72949976	chr2:214034104	C/T	cg08319019	chr2:214017104	IKZF2	-0.62	-9.61	-0.47	1.87e-19	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.71	-12.31	-0.56	5.71e-29	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs7113850	0.541	rs77868378	chr11:24233684	C/T	ch.11.24196551F	chr11:24239977	NA	1.01	9.09	0.45	8.71e-18	Bone fracture in osteoporosis;
LUSC	cis	rs2294693	0.945	rs742494	chr6:41007835	A/T	cg14769373	chr6:40998127	UNC5CL	-0.54	-7.23	-0.37	3.27e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6690583	0.623	rs12030730	chr1:85454109	C/G	cg22153463	chr1:85462885	MCOLN2	0.61	5.88	0.31	1.02e-8	Serum sulfate level;
LUSC	cis	rs2795502	0.564	rs11239842	chr10:43444882	A/G	cg08461752	chr10:43522343	NA	-0.55	-6.45	-0.33	3.85e-10	Blood protein levels;
LUSC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg05738196	chr6:26577821	NA	0.82	15.84	0.66	1.48e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs6714710	0.603	rs13023980	chr2:98502987	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.56	0.42	4.18e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs1865721	0.804	rs72977816	chr18:73146779	A/T	cg26385618	chr18:73139727	C18orf62	-0.52	-9.66	-0.47	1.24e-19	Intelligence;
LUSC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg03732007	chr1:2071316	PRKCZ	0.54	9.88	0.48	2.28e-20	Height;
LUSC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg03354898	chr7:1950403	MAD1L1	-0.31	-5.94	-0.31	7.04e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg08999081	chr20:33150536	PIGU	-0.41	-7.56	-0.38	3.88e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-7.29	-0.37	2.23e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg11584989	chr19:19387371	SF4	-0.64	-7.6	-0.38	2.99e-13	Bipolar disorder;
LUSC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-10.08	-0.48	4.74e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.3	-5.66	-0.3	3.27e-8	Lymphocyte counts;
LUSC	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg05343316	chr1:45956843	TESK2	0.65	8.91	0.44	3.31e-17	Platelet count;
LUSC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg17990871	chr1:1677678	SLC35E2	-0.41	-6.33	-0.33	7.81e-10	Body mass index;
LUSC	cis	rs11209185	0.509	rs9436356	chr1:68447202	A/G	cg22082780	chr1:68452167	NA	0.44	7.23	0.37	3.27e-12	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg06532163	chr17:45867833	NA	0.33	6.27	0.32	1.1e-9	IgG glycosylation;
LUSC	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg23173402	chr1:227635558	NA	0.6	7.19	0.37	4.24e-12	Major depressive disorder;
LUSC	cis	rs7927771	0.524	rs10742814	chr11:47554337	G/A	cg20307385	chr11:47447363	PSMC3	0.44	6.46	0.33	3.7e-10	Subjective well-being;
LUSC	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.81	-0.47	4e-20	Migraine;Coronary artery disease;
LUSC	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg19773385	chr1:10388646	KIF1B	-0.5	-8.68	-0.43	1.82e-16	Hepatocellular carcinoma;
LUSC	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg03732007	chr1:2071316	PRKCZ	0.49	7.79	0.39	8.55e-14	Height;
LUSC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg06784218	chr1:46089804	CCDC17	0.48	9.2	0.45	3.91e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs9300255	0.679	rs10846507	chr12:123786492	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-5.64	-0.3	3.55e-8	Neutrophil percentage of white cells;
LUSC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg05585544	chr11:47624801	NA	-0.41	-7.29	-0.37	2.3e-12	Subjective well-being;
LUSC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg18758796	chr5:131593413	PDLIM4	0.34	5.83	0.3	1.31e-8	Blood metabolite levels;
LUSC	cis	rs730566	0.640	rs6442112	chr3:48316034	A/G	cg11946769	chr3:48343235	NME6	0.49	6.39	0.33	5.47e-10	Prion diseases;
LUSC	cis	rs7943203	0.539	rs12226046	chr11:108335940	G/C	cg04873221	chr11:107992290	ACAT1	-0.39	-5.77	-0.3	1.77e-8	Red blood cell count;Mean corpuscular volume;
LUSC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	1.9e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.09	-0.4	1.12e-14	Total cholesterol levels;
LUSC	cis	rs2235649	0.666	rs2076429	chr16:1817935	A/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.47	5.88	0.31	1.01e-8	Blood metabolite levels;
LUSC	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg09904177	chr6:26538194	HMGN4	-0.71	-12.72	-0.57	1.76e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg17509989	chr5:176798049	RGS14	0.72	9.1	0.45	8.34e-18	Urate levels in lean individuals;
LUSC	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg02569458	chr12:86230093	RASSF9	0.51	8.34	0.42	1.95e-15	Major depressive disorder;
LUSC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg06008330	chr7:65541103	ASL	-0.4	-6.2	-0.32	1.66e-9	Aortic root size;
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg23131131	chr22:24373011	LOC391322	-0.5	-7.24	-0.37	3.06e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg00982548	chr2:198649783	BOLL	-0.57	-7.29	-0.37	2.32e-12	Ulcerative colitis;
LUSC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.78	-0.35	5.48e-11	Neutrophil percentage of white cells;
LUSC	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-7.42	-0.38	9.97e-13	Schizophrenia;
LUSC	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	7.02	0.36	1.24e-11	Ovarian reserve;
LUSC	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg03676636	chr4:99064102	C4orf37	0.3	6.48	0.33	3.32e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.25	0.37	2.92e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7659604	0.540	rs10012775	chr4:122676878	T/C	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.91	-0.31	8.47e-9	Type 2 diabetes;
LUSC	trans	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg11398623	chr21:37499189	NA	0.26	5.96	0.31	6.31e-9	Breast cancer;
LUSC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-1.07	-25.94	-0.82	4.9e-82	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.15	-0.49	2.88e-21	Obesity-related traits;
LUSC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.63	14.56	0.62	1.53e-37	Prostate cancer;
LUSC	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.71	10.85	0.51	1.08e-23	Smoking initiation;
LUSC	cis	rs6429082	0.818	rs834198	chr1:235671987	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	8.33	0.41	2.17e-15	Adiposity;
LUSC	trans	rs1325195	0.537	rs2636289	chr1:179169815	T/A	cg11624085	chr17:8464688	MYH10	0.43	6.38	0.33	5.94e-10	IgE grass sensitization;
LUSC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-1.06	-23.74	-0.79	1.09e-73	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.09	16.34	0.67	1.63e-44	Gut microbiome composition (summer);
LUSC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.74e-40	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.43	0.33	4.35e-10	Corneal astigmatism;
LUSC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.78	-0.35	5.4e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03526160	chr20:43586170	TOMM34	0.34	5.96	0.31	6.45e-9	Electrocardiographic conduction measures;
LUSC	cis	rs12210905	0.925	rs12190201	chr6:27001458	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.74e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg22029157	chr1:209979665	IRF6	0.71	8.65	0.43	2.19e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs9469578	0.892	rs73743333	chr6:33714042	G/A	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-7.98	-0.4	2.44e-14	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg18402987	chr7:1209562	NA	0.72	7.76	0.39	1.07e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs9473924	1.000	rs9473932	chr6:50857995	G/A	cg22375689	chr19:34175036	CHST8	0.38	6.15	0.32	2.27e-9	Body mass index;
LUSC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg12863693	chr15:85201151	NMB	-0.34	-7.06	-0.36	9.82e-12	Schizophrenia;
LUSC	cis	rs6494488	0.500	rs72742999	chr15:65010510	G/A	cg08069370	chr15:64387884	SNX1	-0.66	-5.78	-0.3	1.71e-8	Coronary artery disease;
LUSC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg22834771	chr12:69754056	YEATS4	-0.52	-7.78	-0.39	9.09e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs3849570	0.925	rs13091492	chr3:81891476	A/G	cg07356753	chr3:81810745	GBE1	-0.63	-9.75	-0.47	6.21e-20	Waist circumference;Body mass index;
LUSC	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg13010199	chr12:38710504	ALG10B	0.66	10.22	0.49	1.61e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06558623	chr16:89946397	TCF25	1.1	9.73	0.47	7.28e-20	Skin colour saturation;
LUSC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	10.22	0.49	1.57e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg26528668	chr16:1614120	IFT140	0.45	7.63	0.39	2.44e-13	Coronary artery disease;
LUSC	cis	rs12618769	0.652	rs3769708	chr2:99187650	T/C	cg10123293	chr2:99228465	UNC50	0.47	7.52	0.38	5.11e-13	Bipolar disorder;
LUSC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg03233332	chr7:66118400	NA	0.41	6.05	0.31	3.95e-9	Aortic root size;
LUSC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-1.0	-19.84	-0.74	1.95e-58	Menopause (age at onset);
LUSC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg22618164	chr12:122356400	WDR66	0.62	9.23	0.45	3.21e-18	Mean corpuscular volume;
LUSC	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg08917208	chr2:24149416	ATAD2B	0.91	10.01	0.48	8.69e-21	Lymphocyte counts;
LUSC	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.86	-0.44	4.73e-17	Response to antipsychotic treatment;
LUSC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg02018176	chr4:1364513	KIAA1530	0.47	8.16	0.41	6.75e-15	Obesity-related traits;
LUSC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg17971929	chr21:40555470	PSMG1	0.53	8.33	0.41	2.19e-15	Cognitive function;
LUSC	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg10547527	chr2:198650123	BOLL	-0.49	-5.72	-0.3	2.32e-8	Ulcerative colitis;
LUSC	cis	rs6546550	0.935	rs60207187	chr2:70093910	G/A	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.17	-0.37	4.97e-12	Prevalent atrial fibrillation;
LUSC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	11.12	0.52	1.19e-24	Bone mineral density;
LUSC	cis	rs7712401	0.601	rs418229	chr5:122341664	T/C	cg19077854	chr5:122220652	SNX24	-0.43	-9.25	-0.45	2.68e-18	Mean platelet volume;
LUSC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg11941060	chr3:133502564	NA	0.55	8.28	0.41	2.92e-15	Iron status biomarkers;
LUSC	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg19773385	chr1:10388646	KIF1B	-0.5	-8.74	-0.43	1.19e-16	Hepatocellular carcinoma;
LUSC	cis	rs17001868	0.568	rs470113	chr22:40729614	A/G	cg07138101	chr22:40742427	ADSL	0.6	7.25	0.37	2.87e-12	Mammographic density (dense area);
LUSC	cis	rs16867321	0.614	rs12693245	chr2:181445110	T/C	cg23363182	chr2:181467187	NA	0.57	9.2	0.45	4.03e-18	Obesity;
LUSC	trans	rs12637928	0.518	rs6767880	chr3:110151810	T/C	cg17371621	chr15:61264283	RORA	0.38	6.44	0.33	4.19e-10	Neuroticism;
LUSC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.21e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21293242	chr8:11204541	TDH	0.32	5.97	0.31	6.23e-9	Retinal vascular caliber;
LUSC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.59	-10.81	-0.51	1.51e-23	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7119	0.717	rs8033067	chr15:77825495	G/T	cg27398640	chr15:77910606	LINGO1	-0.32	-6.68	-0.34	9.78e-11	Type 2 diabetes;
LUSC	trans	rs979233	0.502	rs276242	chr5:42060518	C/G	cg07010552	chr17:7358735	CHRNB1	-0.41	-5.95	-0.31	6.62e-9	Systemic lupus erythematosus;
LUSC	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg03342759	chr3:160939853	NMD3	-0.52	-8.75	-0.43	1.1e-16	Morning vs. evening chronotype;
LUSC	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-7.14	-0.36	5.89e-12	Blood metabolite levels;
LUSC	cis	rs2625529	0.652	rs2957728	chr15:72236432	G/T	cg16672083	chr15:72433130	SENP8	0.49	8.15	0.41	7.45e-15	Red blood cell count;
LUSC	cis	rs4853525	0.923	rs7582941	chr2:191728900	A/T	cg11845111	chr2:191398756	TMEM194B	-0.41	-6.05	-0.31	3.83e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg08392591	chr16:89556376	ANKRD11	0.43	6.38	0.33	5.82e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs17102423	1.000	rs4902364	chr14:65602006	G/A	cg11161011	chr14:65562177	MAX	-0.65	-10.09	-0.48	4.6e-21	Obesity-related traits;
LUSC	cis	rs6028335	0.502	rs8114962	chr20:37635979	A/G	cg27552599	chr20:37590471	DHX35	0.45	7.51	0.38	5.57e-13	Alcohol and nicotine co-dependence;
LUSC	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.6	-9.63	-0.47	1.63e-19	Body mass index;
LUSC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-9.07	-0.44	1e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs4851254	0.660	rs60697219	chr2:100699507	G/A	cg07810366	chr2:100720526	AFF3	-0.46	-6.16	-0.32	2.05e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs983392	0.679	rs1019671	chr11:60008151	T/C	cg20284999	chr11:59952153	MS4A6A	-0.35	-5.75	-0.3	2.03e-8	Alzheimer's disease (late onset);
LUSC	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg13010199	chr12:38710504	ALG10B	0.54	8.05	0.4	1.48e-14	Morning vs. evening chronotype;
LUSC	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg08601574	chr20:25228251	PYGB	0.5	7.7	0.39	1.56e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg00277334	chr10:82204260	NA	-0.54	-7.57	-0.38	3.69e-13	Post bronchodilator FEV1;
LUSC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg13114125	chr14:105738426	BRF1	-0.91	-16.06	-0.66	1.98e-43	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg26668828	chr6:292823	DUSP22	-0.73	-12.25	-0.56	9.81e-29	Menopause (age at onset);
LUSC	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.42	-5.7	-0.3	2.58e-8	Height;
LUSC	cis	rs12545109	0.613	rs6998873	chr8:57299697	A/G	cg09654669	chr8:57350985	NA	0.46	6.13	0.32	2.51e-9	Obesity-related traits;
LUSC	trans	rs11700980	0.551	rs56166203	chr21:30109607	G/C	cg14791747	chr16:20752902	THUMPD1	0.56	6.15	0.32	2.24e-9	QRS complex (12-leadsum);
LUSC	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	0.93	12.62	0.57	3.86e-30	Primary sclerosing cholangitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03150463	chr7:108166687	PNPLA8	-0.42	-6.18	-0.32	1.87e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	6.96	0.36	1.79e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13184582	chr1:169075593	ATP1B1	-0.41	-6.03	-0.31	4.45e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2835872	0.758	rs1787396	chr21:39036487	A/C	cg20424643	chr21:39039972	KCNJ6	-0.45	-7.57	-0.38	3.65e-13	Electroencephalographic traits in alcoholism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13927387	chr11:101980807	YAP1	-0.38	-5.98	-0.31	5.72e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.62	7.3	0.37	2.17e-12	Crohn's disease;
LUSC	cis	rs35000415	0.938	rs17339836	chr7:128681062	C/T	cg19972273	chr7:128594194	NA	0.67	6.75	0.35	6.46e-11	Systemic lupus erythematosus;
LUSC	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.84	-0.3	1.25e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LUSC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.8	-14.53	-0.62	2.15e-37	Cognitive function;
LUSC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg03859395	chr2:55845619	SMEK2	-0.68	-10.48	-0.5	2.05e-22	Metabolic syndrome;
LUSC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg24399712	chr22:39784796	NA	-0.63	-11.83	-0.54	3.33e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs9547692	1.000	rs9531991	chr13:37470945	A/G	cg01493522	chr13:37497338	NA	-0.44	-6.35	-0.33	7.07e-10	Coronary artery disease;
LUSC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-9.28	-0.45	2.18e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs2835872	0.727	rs2835831	chr21:38987233	T/C	cg20424643	chr21:39039972	KCNJ6	0.37	5.71	0.3	2.51e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13126279	chr21:47581558	C21orf56	-0.56	-8.67	-0.43	1.86e-16	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg18187862	chr3:45730750	SACM1L	0.55	7.04	0.36	1.11e-11	Primary sclerosing cholangitis;
LUSC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg09877947	chr5:131593287	PDLIM4	0.55	9.05	0.44	1.17e-17	Acylcarnitine levels;
LUSC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00149659	chr3:10157352	C3orf10	0.97	12.89	0.58	4.01e-31	Alzheimer's disease;
LUSC	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg01420254	chr6:26195488	NA	0.66	7.31	0.37	2.05e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	11.91	0.55	1.71e-27	Coronary artery disease;
LUSC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	0.9	12.63	0.57	3.59e-30	Vitiligo;
LUSC	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg03342759	chr3:160939853	NMD3	-0.52	-7.38	-0.37	1.24e-12	Parkinson's disease;
LUSC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg24060327	chr5:131705240	SLC22A5	-0.43	-7.15	-0.36	5.49e-12	Blood metabolite levels;
LUSC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg03188948	chr7:1209495	NA	0.62	6.43	0.33	4.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.03e-17	Prudent dietary pattern;
LUSC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg18825076	chr15:78729989	IREB2	-0.49	-7.64	-0.39	2.28e-13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg26441486	chr22:50317300	CRELD2	-0.53	-8.01	-0.4	1.93e-14	Schizophrenia;
LUSC	trans	rs11997175	0.583	rs4739562	chr8:33844064	C/T	cg00636124	chr16:27215281	JMJD5	-0.45	-6.14	-0.32	2.35e-9	Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07182965	chr18:71815169	FBXO15;C18orf55	-0.4	-6.2	-0.32	1.7e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10489525	0.550	rs6659415	chr1:115632211	C/T	cg01522456	chr1:115632236	TSPAN2	0.71	10.48	0.5	2.08e-22	Autism;
LUSC	cis	rs1322512	0.917	rs2623942	chr6:152951118	T/A	cg27316956	chr6:152958899	SYNE1	-0.36	-6.14	-0.32	2.28e-9	Tonometry;
LUSC	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg16989719	chr2:238392110	NA	-0.42	-7.12	-0.36	6.7e-12	Prostate cancer;
LUSC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg08798685	chr6:27730294	NA	0.54	5.8	0.3	1.52e-8	Depression;
LUSC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg16325326	chr1:53192061	ZYG11B	-0.99	-19.96	-0.74	6.94e-59	Monocyte count;
LUSC	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg22532475	chr10:104410764	TRIM8	-0.4	-8.38	-0.42	1.47e-15	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11677416	1.000	rs1516790	chr2:113531291	G/A	cg27083787	chr2:113543245	IL1A	0.46	7.27	0.37	2.57e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg06917634	chr15:78832804	PSMA4	0.81	14.35	0.62	1.08e-36	Sudden cardiac arrest;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00510360	chr3:108308232	KIAA1524;DZIP3	0.45	6.23	0.32	1.39e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs68170813	0.559	rs12535258	chr7:106971050	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.64	-0.47	1.47e-19	Coronary artery disease;
LUSC	cis	rs9905704	0.681	rs1860262	chr17:56580997	T/C	cg19466818	chr17:56409534	MIR142	0.38	6.99	0.36	1.53e-11	Testicular germ cell tumor;
LUSC	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg05283184	chr6:79620031	NA	-0.57	-11.52	-0.53	4.53e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg25922239	chr6:33757077	LEMD2	0.53	8.01	0.4	1.99e-14	Crohn's disease;
LUSC	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg24130564	chr14:104152367	KLC1	0.45	6.31	0.33	9.04e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs12893668	0.703	rs4906335	chr14:104021141	C/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.59	-0.34	1.75e-10	Reticulocyte count;
LUSC	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg27661571	chr11:113659931	NA	-0.53	-6.31	-0.33	8.71e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-8.91	-0.44	3.36e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9326248	0.689	rs4516002	chr11:116999059	A/G	cg26566898	chr11:117069891	TAGLN	0.43	6.08	0.32	3.21e-9	Blood protein levels;
LUSC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg24879335	chr3:133465180	TF	0.46	7.91	0.4	3.93e-14	Iron status biomarkers (transferrin levels);
LUSC	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.33	7.66	0.39	2.05e-13	Coronary artery disease;
LUSC	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg23649088	chr2:200775458	C2orf69	-0.53	-6.46	-0.33	3.79e-10	Schizophrenia;
LUSC	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.48	-0.33	3.38e-10	Fear of minor pain;
LUSC	cis	rs7246967	0.673	rs16994997	chr19:22879610	T/G	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs1697139	1.000	rs1697139	chr5:66511535	A/G	cg11553311	chr5:66541588	NA	0.31	5.84	0.3	1.27e-8	Breast cancer;
LUSC	cis	rs73200209	0.744	rs17426676	chr12:116595512	T/C	cg01776926	chr12:116560359	MED13L	-0.51	-6.13	-0.32	2.45e-9	Total body bone mineral density;
LUSC	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg08508325	chr11:3079039	CARS	0.38	8.66	0.43	2e-16	Calcium levels;
LUSC	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.83	0.51	1.26e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.94	-0.35	2.11e-11	Electroencephalogram traits;
LUSC	cis	rs10911363	0.659	rs2275676	chr1:183430822	C/G	cg09173681	chr1:183549694	NCF2	-0.63	-11.19	-0.52	6.48e-25	Systemic lupus erythematosus;
LUSC	cis	rs11608355	0.618	rs12227736	chr12:109796637	G/A	cg19025524	chr12:109796872	NA	-0.49	-8.91	-0.44	3.46e-17	Neuroticism;
LUSC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.28	0.37	2.45e-12	Mean platelet volume;
LUSC	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg18478394	chr8:109455254	TTC35	0.41	6.29	0.33	9.7e-10	Dupuytren's disease;
LUSC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg03909863	chr11:638404	DRD4	-0.4	-5.86	-0.31	1.09e-8	Systemic lupus erythematosus;
LUSC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs2274273	0.624	rs7159824	chr14:55772536	C/T	cg04306507	chr14:55594613	LGALS3	0.49	10.03	0.48	7.04e-21	Protein biomarker;
LUSC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg02221750	chr19:17393354	ANKLE1	-0.89	-14.03	-0.61	1.7000000000000001e-35	Systemic lupus erythematosus;
LUSC	cis	rs9811920	0.535	rs1610509	chr3:99474327	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.3	5.84	0.3	1.23e-8	Axial length;
LUSC	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs1256061	0.603	rs960069	chr14:64745002	C/T	cg21174375	chr14:64681225	SYNE2	0.35	6.3	0.33	9.23e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg05785598	chr3:49045655	WDR6	0.32	5.85	0.3	1.18e-8	Parkinson's disease;
LUSC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg25258033	chr6:167368657	RNASET2	0.44	6.61	0.34	1.53e-10	Crohn's disease;
LUSC	cis	rs1160297	0.576	rs10206560	chr2:53089060	G/C	cg07782112	chr2:53107842	NA	0.4	6.47	0.33	3.53e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs240768	1.000	rs2398133	chr6:101004751	A/G	cg12253828	chr6:101329408	ASCC3	0.84	5.74	0.3	2.11e-8	Economic and political preferences (immigration/crime);
LUSC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-1.05	-20.64	-0.75	1.33e-61	Height;
LUSC	cis	rs4839421	0.934	rs12046828	chr1:111017477	C/G	cg06880108	chr1:111021908	CYMP	0.45	7.5	0.38	5.91e-13	Response to bupropion in depression;
LUSC	cis	rs10754283	0.935	rs1934046	chr1:90119290	A/T	cg21401794	chr1:90099060	LRRC8C	-0.64	-9.16	-0.45	5.23e-18	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg16524733	chr11:117070046	TAGLN	0.3	5.65	0.3	3.47e-8	Blood protein levels;
LUSC	cis	rs713477	0.692	rs8019270	chr14:55907172	C/G	cg13175173	chr14:55914753	NA	-0.31	-6.16	-0.32	2.13e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.73	0.3	2.25e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg05738196	chr6:26577821	NA	0.82	15.84	0.66	1.48e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.41e-10	Alzheimer's disease (late onset);
LUSC	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.52	0.38	5.1e-13	Rheumatoid arthritis;
LUSC	cis	rs4478858	0.735	rs10914344	chr1:31769025	T/C	cg00250761	chr1:31883323	NA	-0.33	-8.0	-0.4	2.07e-14	Alcohol dependence;
LUSC	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg03948781	chr1:205179583	DSTYK	0.33	6.43	0.33	4.38e-10	Red blood cell count;
LUSC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg16414030	chr3:133502952	NA	-0.39	-5.85	-0.3	1.17e-8	Iron status biomarkers;
LUSC	cis	rs2625529	0.652	rs2929525	chr15:72287856	G/A	cg16672083	chr15:72433130	SENP8	0.5	8.26	0.41	3.38e-15	Red blood cell count;
LUSC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20135002	chr11:47629003	NA	-0.49	-7.66	-0.39	2.01e-13	Subjective well-being;
LUSC	cis	rs7759001	0.857	rs6456777	chr6:27365994	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg15704280	chr7:45808275	SEPT13	0.73	8.3	0.41	2.64e-15	Axial length;
LUSC	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs12530845	0.887	rs4492299	chr7:135315690	T/G	cg23117316	chr7:135346802	PL-5283	-0.57	-9.27	-0.45	2.4e-18	Red blood cell traits;
LUSC	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg17173187	chr15:85201210	NMB	0.51	9.66	0.47	1.24e-19	Schizophrenia;
LUSC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg06637938	chr14:75390232	RPS6KL1	0.52	8.2	0.41	5.08e-15	Height;
LUSC	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.41	-7.05	-0.36	1e-11	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.05	13.89	0.61	5.97e-35	Uric acid levels;
LUSC	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	0.95	17.85	0.7	1.59e-50	Bone mineral density;
LUSC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg21724239	chr8:58056113	NA	0.74	6.34	0.33	7.54e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2303282	0.933	rs4783941	chr16:56511736	C/T	cg00500540	chr16:56394104	NA	0.46	7.4	0.38	1.14e-12	Breast cancer;
LUSC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg00990874	chr7:1149470	C7orf50	-0.59	-8.09	-0.4	1.15e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.08	-17.53	-0.69	3.03e-49	Homoarginine levels;
LUSC	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg11822372	chr1:151115635	SEMA6C	0.36	5.74	0.3	2.09e-8	Childhood ear infection;
LUSC	cis	rs9463078	0.565	rs10948183	chr6:44880881	T/C	cg25276700	chr6:44698697	NA	0.29	6.06	0.31	3.72e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs4588572	0.644	rs6870646	chr5:77741082	G/A	cg11547950	chr5:77652471	NA	-0.46	-6.74	-0.35	7.08e-11	Triglycerides;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10598066	chr11:44087808	ACCS	-0.49	-7.47	-0.38	7.1e-13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg15073853	chr19:18549131	ISYNA1	-0.33	-5.98	-0.31	5.66e-9	Breast cancer;
LUSC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg00945038	chr17:61921165	SMARCD2	0.5	8.83	0.44	5.87e-17	Prudent dietary pattern;
LUSC	cis	rs1413885	0.549	rs1334879	chr1:65846051	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	6.77	0.35	5.79e-11	Anticoagulant levels;
LUSC	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.15	-0.45	5.61e-18	Neuroticism;
LUSC	cis	rs2073300	0.826	rs6048809	chr20:23443788	C/T	cg09953122	chr20:23471693	CST8	-0.73	-6.86	-0.35	3.41e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg05926928	chr17:57297772	GDPD1	-0.9	-10.32	-0.49	7.58e-22	Opioid sensitivity;
LUSC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.98	-14.21	-0.61	3.53e-36	Initial pursuit acceleration;
LUSC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	0.77	13.53	0.6	1.44e-33	Cognitive function;
LUSC	cis	rs11625487	0.645	rs8006951	chr14:77965304	G/A	cg16049707	chr14:77965284	ISM2	0.6	8.58	0.42	3.72e-16	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs2348418	0.864	rs7960369	chr12:28714502	T/C	cg13890972	chr12:28721907	NA	-0.34	-5.81	-0.3	1.49e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	7.51	0.38	5.46e-13	Schizophrenia;
LUSC	cis	rs10072221	0.836	rs4254886	chr5:75706939	T/C	cg03132911	chr5:75698732	IQGAP2	0.36	6.08	0.32	3.36e-9	Mean platelet volume;
LUSC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.94	-0.35	2.09e-11	Lung cancer;
LUSC	trans	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg19862616	chr7:65841803	NCRNA00174	0.89	10.25	0.49	1.26e-21	Eotaxin levels;
LUSC	cis	rs9549260	0.816	rs964901	chr13:41248698	C/T	cg21288729	chr13:41239152	FOXO1	0.58	8.7	0.43	1.56e-16	Red blood cell count;
LUSC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg25214090	chr10:38739885	LOC399744	0.48	7.14	0.36	6.01e-12	Corneal astigmatism;
LUSC	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg01420254	chr6:26195488	NA	0.64	6.96	0.36	1.79e-11	Gout;Renal underexcretion gout;
LUSC	cis	rs10779751	0.734	rs2039840	chr1:11125866	G/A	cg04508216	chr1:11107452	MASP2	0.33	5.87	0.31	1.03e-8	Body mass index;
LUSC	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.78	-15.0	-0.63	3.1e-39	Endometriosis;
LUSC	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg04450456	chr4:17643702	FAM184B	0.39	6.54	0.34	2.34e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10193935	0.901	rs12615383	chr2:42610551	A/G	cg27598129	chr2:42591480	NA	0.62	8.26	0.41	3.52e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12530845	1.000	rs77068811	chr7:135334571	A/G	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.48	7.48	0.38	6.64e-13	Schizophrenia;
LUSC	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg00321850	chr1:175162397	KIAA0040	0.44	7.42	0.38	1.01e-12	Alcohol dependence;
LUSC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11764359	chr7:65958608	NA	-0.69	-11.1	-0.52	1.42e-24	Aortic root size;
LUSC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.84	11.01	0.52	2.85e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg21775007	chr8:11205619	TDH	0.47	6.83	0.35	4.05e-11	Myopia (pathological);
LUSC	cis	rs11756438	0.572	rs2638529	chr6:119006459	T/C	cg21191810	chr6:118973309	C6orf204	0.34	5.76	0.3	1.91e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg03477792	chr4:77819574	ANKRD56	-0.58	-8.45	-0.42	9.27e-16	Emphysema distribution in smoking;
LUSC	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg07959070	chr22:50026188	C22orf34	-0.36	-7.41	-0.38	1.05e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.23	0.32	1.42e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs5758511	0.773	rs73165164	chr22:42355549	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.43	7.13	0.36	6.12e-12	Birth weight;
LUSC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.29e-12	Tonsillectomy;
LUSC	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-0.85	-13.28	-0.59	1.26e-32	Triglycerides;
LUSC	cis	rs7827545	1.000	rs6578229	chr8:135562453	T/G	cg17885191	chr8:135476712	NA	0.56	8.33	0.41	2.07e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs4356932	0.902	rs28548768	chr4:76972755	T/C	cg00809888	chr4:76862425	NAAA	0.34	5.78	0.3	1.75e-8	Blood protein levels;
LUSC	cis	rs13082711	0.911	rs4973770	chr3:27425815	C/T	cg02860705	chr3:27208620	NA	0.49	8.38	0.42	1.53e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg13798912	chr7:905769	UNC84A	-0.57	-5.89	-0.31	9.23e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg11102782	chr19:18549136	ISYNA1	-0.36	-6.84	-0.35	3.89e-11	Breast cancer;
LUSC	cis	rs9473147	0.602	rs9296567	chr6:47553402	G/A	cg12968598	chr6:47444699	CD2AP	0.52	7.98	0.4	2.3e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg22681709	chr2:178499509	PDE11A	-0.59	-11.79	-0.54	4.53e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs11989744	0.500	rs7826517	chr8:23568841	G/A	cg03492747	chr16:86543808	FOXF1	-0.64	-11.12	-0.52	1.23e-24	Waist-hip ratio;
LUSC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg21918786	chr6:109611834	NA	-0.41	-7.06	-0.36	9.89e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs981844	0.712	rs10009854	chr4:154741785	C/T	cg14289246	chr4:154710475	SFRP2	-0.44	-6.13	-0.32	2.5e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg09796270	chr17:17721594	SREBF1	-0.45	-7.95	-0.4	2.89e-14	Total body bone mineral density;
LUSC	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg04352962	chr1:209979756	IRF6	0.56	6.65	0.34	1.19e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs78663649	0.708	rs115656720	chr19:16622921	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	-0.89	-6.53	-0.34	2.47e-10	White blood cell count;
LUSC	cis	rs2979489	0.786	rs1106352	chr8:30404671	C/T	cg26383811	chr8:30366931	RBPMS	-0.49	-7.71	-0.39	1.42e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.37	1.18e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg21918786	chr6:109611834	NA	-0.34	-5.84	-0.3	1.24e-8	Reticulocyte fraction of red cells;
LUSC	trans	rs6076960	0.846	rs6053962	chr20:6176915	A/G	cg21095983	chr6:86352623	SYNCRIP	0.41	6.33	0.33	7.92e-10	Smooth-surface caries;
LUSC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.72	-0.3	2.37e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg23306229	chr2:178417860	TTC30B	0.53	6.01	0.31	4.88e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.09	-0.48	4.43e-21	Obesity-related traits;
LUSC	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg01657329	chr11:68192670	LRP5	0.5	6.64	0.34	1.24e-10	Bone mineral density (spine);
LUSC	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg00277334	chr10:82204260	NA	-0.59	-9.81	-0.47	4.05e-20	Post bronchodilator FEV1;
LUSC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg00933542	chr6:150070202	PCMT1	0.33	6.77	0.35	5.98e-11	Lung cancer;
LUSC	cis	rs500891	0.597	rs9449619	chr6:84168161	A/G	cg08257003	chr6:84140564	ME1	0.35	8.41	0.42	1.25e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08859206	chr1:53392774	SCP2	0.5	8.51	0.42	6.03e-16	Monocyte count;
LUSC	cis	rs9807841	0.544	rs10407692	chr19:10770783	A/G	cg09936142	chr19:10668400	KRI1	-0.4	-6.46	-0.33	3.74e-10	Inflammatory skin disease;
LUSC	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.29	0.53	3.03e-25	Eye color traits;
LUSC	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Smoking initiation;
LUSC	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg01966878	chr4:90757139	SNCA	-0.35	-6.05	-0.31	3.97e-9	Dementia with Lewy bodies;
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-8.12	-0.41	8.88e-15	Lymphocyte counts;
LUSC	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg11621586	chr10:70884670	VPS26A	1.09	14.25	0.61	2.52e-36	Left atrial antero-posterior diameter;
LUSC	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg21191810	chr6:118973309	C6orf204	0.38	6.85	0.35	3.67e-11	Electrocardiographic conduction measures;
LUSC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg02782426	chr3:40428986	ENTPD3	-0.3	-5.89	-0.31	9.39e-9	Renal cell carcinoma;
LUSC	cis	rs1881396	0.531	rs72613829	chr2:27902987	C/T	cg27432699	chr2:27873401	GPN1	0.63	7.54	0.38	4.62e-13	Nonalcoholic fatty liver disease;
LUSC	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg13902645	chr11:5959945	NA	-0.56	-7.86	-0.4	5.2e-14	DNA methylation (variation);
LUSC	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg27426351	chr10:43362370	NA	-0.43	-6.0	-0.31	5.26e-9	Blood protein levels;
LUSC	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.77	-0.43	9.54e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg04756594	chr16:24857601	SLC5A11	-0.5	-7.36	-0.37	1.42e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-6.88	-0.35	2.95e-11	Height;
LUSC	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg27171569	chr16:83987465	OSGIN1	-0.64	-11.14	-0.52	1.03e-24	Pursuit maintenance gain;
LUSC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	13.5	0.59	1.88e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg24634471	chr8:143751801	JRK	0.51	7.25	0.37	2.97e-12	Schizophrenia;
LUSC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	0.95	12.71	0.57	1.86e-30	Eosinophil percentage of granulocytes;
LUSC	cis	rs1044826	0.956	rs13086868	chr3:139239644	A/G	cg00490450	chr3:139108681	COPB2	0.54	6.96	0.36	1.85e-11	Obesity-related traits;
LUSC	cis	rs3755132	0.568	rs16862882	chr2:15808632	C/G	cg12888861	chr2:15731646	DDX1	0.49	5.85	0.31	1.15e-8	Wilms tumor;
LUSC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	0.99	14.14	0.61	6.88e-36	Vitiligo;
LUSC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.8	-0.39	8.06e-14	Height;
LUSC	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-6.17	-0.32	1.93e-9	Bipolar disorder;
LUSC	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-6.51	-0.34	2.73e-10	High light scatter reticulocyte count;
LUSC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg01097406	chr16:89675127	NA	-0.38	-7.63	-0.39	2.41e-13	Vitiligo;
LUSC	cis	rs9341808	0.538	rs7747327	chr6:81035774	G/T	cg08355045	chr6:80787529	NA	-0.43	-7.32	-0.37	1.84e-12	Sitting height ratio;
LUSC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.2	-0.32	1.62e-9	Life satisfaction;
LUSC	cis	rs3771570	1.000	rs56052835	chr2:242243251	T/G	cg21155796	chr2:242212141	HDLBP	0.67	7.52	0.38	5.23e-13	Prostate cancer;
LUSC	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg27432699	chr2:27873401	GPN1	0.82	15.29	0.64	2.21e-40	Oral cavity cancer;
LUSC	cis	rs57920188	0.640	rs4478781	chr1:4086827	C/T	cg20703997	chr1:4087676	NA	0.6	8.24	0.41	3.92e-15	Interleukin-17 levels;
LUSC	cis	rs806215	0.951	rs327521	chr7:127249143	G/A	cg25922125	chr7:127225783	GCC1	0.5	6.46	0.33	3.78e-10	Type 2 diabetes;
LUSC	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.65	-0.43	2.19e-16	Axial length;
LUSC	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg12002119	chr2:101014098	CHST10	0.35	5.88	0.31	1.02e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.7	-0.47	8.88e-20	Coronary artery disease;
LUSC	cis	rs295140	0.934	rs74853338	chr2:201171651	C/T	cg04283868	chr2:201171347	SPATS2L	0.44	6.63	0.34	1.36e-10	QT interval;
LUSC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg05347473	chr6:146136440	FBXO30	-0.66	-11.37	-0.53	1.55e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.88	0.31	9.85e-9	Menopause (age at onset);
LUSC	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.74	12.54	0.57	8.27e-30	Alcohol dependence;
LUSC	trans	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg17264618	chr3:40429014	ENTPD3	0.34	7.32	0.37	1.87e-12	Renal cell carcinoma;
LUSC	cis	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg06521331	chr12:34319734	NA	0.39	6.06	0.31	3.61e-9	Morning vs. evening chronotype;
LUSC	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg09904177	chr6:26538194	HMGN4	0.75	14.03	0.61	1.84e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs922692	0.773	rs2869861	chr15:79076744	A/G	cg00540400	chr15:79124168	NA	-0.41	-7.06	-0.36	9.95e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg09654669	chr8:57350985	NA	-0.5	-6.28	-0.33	1.04e-9	Obesity-related traits;
LUSC	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg05347473	chr6:146136440	FBXO30	-0.39	-6.55	-0.34	2.17e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg00316803	chr15:76480434	C15orf27	-0.4	-6.8	-0.35	4.95e-11	Blood metabolite levels;
LUSC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-12.75	-0.57	1.32e-30	Chronic sinus infection;
LUSC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg13683864	chr3:40499215	RPL14	1.13	23.04	0.78	5.38e-71	Renal cell carcinoma;
LUSC	cis	rs10779751	0.734	rs7533211	chr1:11132965	G/C	cg08854313	chr1:11322531	MTOR	0.8	12.36	0.56	3.82e-29	Body mass index;
LUSC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	11.0	0.52	3.11e-24	Bone mineral density;
LUSC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-8.82	-0.43	6.32e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	trans	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg13565492	chr6:43139072	SRF	-0.57	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg15147215	chr3:52552868	STAB1	-0.32	-6.21	-0.32	1.56e-9	Bipolar disorder;
LUSC	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg26816564	chr1:7831052	VAMP3	0.97	13.38	0.59	5.36e-33	Inflammatory bowel disease;
LUSC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg13939156	chr17:80058883	NA	0.35	7.15	0.36	5.64e-12	Life satisfaction;
LUSC	trans	rs7939886	0.920	rs77391761	chr11:55814896	G/C	cg15704280	chr7:45808275	SEPT13	0.83	6.92	0.35	2.38e-11	Myopia (pathological);
LUSC	cis	rs7605827	0.930	rs11685629	chr2:15662271	A/T	cg19274914	chr2:15703543	NA	0.46	8.89	0.44	3.78e-17	Educational attainment (years of education);
LUSC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.66	-10.17	-0.49	2.51e-21	Menarche (age at onset);
LUSC	cis	rs7712401	0.601	rs30059	chr5:122297509	G/A	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15506890	chr2:3487001	NA	-0.57	-9.38	-0.46	1.06e-18	Neurofibrillary tangles;
LUSC	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.88	0.6	6.63e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9549260	0.755	rs2755219	chr13:41169625	A/G	cg21288729	chr13:41239152	FOXO1	0.59	8.94	0.44	2.71e-17	Red blood cell count;
LUSC	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg04287289	chr16:89883240	FANCA	0.5	7.42	0.38	9.91e-13	Vitiligo;
LUSC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg04025307	chr7:1156635	C7orf50	0.46	6.18	0.32	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg05347473	chr6:146136440	FBXO30	0.59	9.73	0.47	7.37e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	9.32	0.45	1.68e-18	Height;
LUSC	cis	rs2303282	0.716	rs2550307	chr16:56414131	A/G	cg00500540	chr16:56394104	NA	-0.44	-7.57	-0.38	3.6e-13	Breast cancer;
LUSC	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	12.47	0.56	1.46e-29	Primary sclerosing cholangitis;
LUSC	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg05738196	chr6:26577821	NA	0.79	15.3	0.64	1.98e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg18479299	chr3:125709523	NA	-0.52	-5.92	-0.31	7.97e-9	Blood pressure (smoking interaction);
LUSC	cis	rs2667011	0.534	rs12692581	chr2:160857482	G/A	cg06573604	chr2:160760825	LY75	-0.48	-7.24	-0.37	3.07e-12	Bilirubin levels;
LUSC	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg01989461	chr14:81687754	GTF2A1	0.74	13.65	0.6	5.14e-34	Schizophrenia;
LUSC	cis	rs7000551	0.751	rs896379	chr8:22374200	C/T	cg12081754	chr8:22256438	SLC39A14	0.45	6.84	0.35	3.73e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs977987	0.806	rs8056236	chr16:75448273	C/T	cg03315344	chr16:75512273	CHST6	0.48	8.92	0.44	3.16e-17	Dupuytren's disease;
LUSC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg00409905	chr10:38381863	ZNF37A	-0.34	-6.0	-0.31	5.21e-9	Extrinsic epigenetic age acceleration;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25986360	chr19:41169216	NA	-0.43	-6.13	-0.32	2.51e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	8.98	0.44	2.09e-17	Post bronchodilator FEV1;
LUSC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg09365446	chr1:150670422	GOLPH3L	0.46	6.93	0.35	2.16e-11	Melanoma;
LUSC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	0.98	14.16	0.61	5.38e-36	Vitiligo;
LUSC	cis	rs858239	0.541	rs4624924	chr7:23168843	A/C	cg23682824	chr7:23144976	KLHL7	0.4	5.76	0.3	1.96e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg12863693	chr15:85201151	NMB	0.41	8.61	0.43	2.99e-16	Schizophrenia;
LUSC	cis	rs9296092	0.560	rs7765263	chr6:33525559	A/G	cg13560919	chr6:33536144	NA	-0.84	-16.34	-0.67	1.67e-44	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.54	-8.02	-0.4	1.76e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg16342193	chr10:102329863	NA	-0.37	-6.71	-0.34	8.37e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg25214090	chr10:38739885	LOC399744	0.48	7.03	0.36	1.16e-11	Corneal astigmatism;
LUSC	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg24851651	chr11:66362959	CCS	-0.36	-5.73	-0.3	2.25e-8	Educational attainment (years of education);
LUSC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07080220	chr10:102295463	HIF1AN	0.64	8.46	0.42	8.63e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9581857	0.725	rs9581853	chr13:28016236	T/C	cg22138327	chr13:27999177	GTF3A	0.81	9.21	0.45	3.78e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs3772130	0.962	rs9841595	chr3:121483326	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.13	0.48	3.38e-21	Cognitive performance;
LUSC	cis	rs2041895	0.509	rs10861674	chr12:107304037	A/G	cg13944111	chr12:107296891	NA	0.38	6.7	0.34	8.68e-11	Glaucoma (low intraocular pressure);
LUSC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.45	-8.0	-0.4	2.01e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.81	0.35	4.44e-11	Rheumatoid arthritis;
LUSC	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.74	0.35	6.99e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.48	0.33	3.28e-10	Axial length;
LUSC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs7561273	0.609	rs3795953	chr2:24345707	C/G	cg20701182	chr2:24300061	SF3B14	0.46	5.87	0.31	1.05e-8	Quantitative traits;
LUSC	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg04117972	chr1:227635322	NA	0.82	8.42	0.42	1.11e-15	Major depressive disorder;
LUSC	cis	rs1113500	0.933	rs4590700	chr1:108638344	G/T	cg11967332	chr1:108735228	SLC25A24	0.39	5.95	0.31	6.59e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg00033643	chr7:134001901	SLC35B4	0.43	6.57	0.34	1.97e-10	Mean platelet volume;
LUSC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.9	0.44	3.74e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.07	-0.36	8.87e-12	Schizophrenia;
LUSC	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg07169764	chr2:136633963	MCM6	1.06	14.16	0.61	5.57e-36	Corneal structure;
LUSC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg08677398	chr8:58056175	NA	0.44	6.05	0.31	3.87e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.1	-0.45	8.23e-18	Bipolar disorder;
LUSC	cis	rs62400317	0.826	rs11963924	chr6:45306562	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.72	-0.39	1.35e-13	Total body bone mineral density;
LUSC	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg09165964	chr15:75287851	SCAMP5	-0.46	-6.8	-0.35	4.95e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	trans	rs62238980	0.614	rs73391051	chr22:32475878	G/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12084011	chr7:107220368	BCAP29	-0.37	-6.01	-0.31	4.74e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.82	-15.21	-0.64	4.55e-40	Dental caries;
LUSC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.76	-12.21	-0.56	1.38e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg11941060	chr3:133502564	NA	-0.46	-6.68	-0.34	1.02e-10	Iron status biomarkers;
LUSC	cis	rs9653442	0.545	rs11123814	chr2:100767082	A/G	cg07810366	chr2:100720526	AFF3	-0.45	-7.65	-0.39	2.21e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	5.88	0.31	1.02e-8	Mean platelet volume;
LUSC	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.28	-0.41	2.91e-15	Type 2 diabetes;
LUSC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.36	-6.35	-0.33	7.18e-10	Longevity;Endometriosis;
LUSC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	7.86	0.4	5.41e-14	Schizophrenia;
LUSC	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.34	-0.37	1.65e-12	Heart rate;
LUSC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.01	0.31	4.91e-9	Menopause (age at onset);
LUSC	cis	rs9462027	0.606	rs2038841	chr6:34738203	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.91	-0.31	8.62e-9	Systemic lupus erythematosus;
LUSC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg26395211	chr5:140044315	WDR55	-0.39	-6.0	-0.31	5.16e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.49	7.08	0.36	8.76e-12	Coronary heart disease;
LUSC	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg05709478	chr1:6581295	PLEKHG5	-0.51	-6.03	-0.31	4.3e-9	Body mass index;
LUSC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg00334542	chr7:100209784	MOSPD3	-0.49	-5.99	-0.31	5.52e-9	Other erythrocyte phenotypes;
LUSC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08048268	chr3:133502702	NA	-0.46	-9.04	-0.44	1.26e-17	Iron status biomarkers;
LUSC	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg04539111	chr16:67997858	SLC12A4	-0.42	-5.86	-0.31	1.09e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.5	-6.99	-0.36	1.5e-11	Renal function-related traits (BUN);
LUSC	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-7.1	-0.36	7.39e-12	Neuroticism;
LUSC	cis	rs7804356	1.000	rs3801819	chr7:26866698	T/G	cg03456212	chr7:26904342	SKAP2	-0.56	-6.44	-0.33	4.07e-10	Type 1 diabetes;
LUSC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg00944433	chr1:107599041	PRMT6	0.38	6.96	0.36	1.83e-11	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.79	-0.39	8.33e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs9311676	0.609	rs1126551	chr3:58416535	C/T	cg13750441	chr3:58318267	PXK	0.35	6.83	0.35	4.14e-11	Systemic lupus erythematosus;
LUSC	trans	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg26384229	chr12:38710491	ALG10B	0.59	9.42	0.46	7.54e-19	Morning vs. evening chronotype;
LUSC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg00800038	chr16:89945340	TCF25	-0.75	-6.52	-0.34	2.56e-10	Skin colour saturation;
LUSC	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg05527609	chr1:210001259	C1orf107	0.67	9.59	0.46	2.08e-19	Orofacial clefts;
LUSC	cis	rs12594515	1.000	rs56412446	chr15:45996424	A/G	cg06207120	chr15:45996521	NA	0.39	5.86	0.31	1.11e-8	Waist circumference;Weight;
LUSC	cis	rs9650315	0.570	rs7460090	chr8:57194163	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.48	0.38	6.47e-13	Height;
LUSC	cis	rs7590368	0.774	rs3932106	chr2:10916408	C/T	cg15705551	chr2:10952987	PDIA6	0.49	6.46	0.33	3.74e-10	Educational attainment (years of education);
LUSC	trans	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07362569	chr17:61921086	SMARCD2	0.35	6.87	0.35	3.13e-11	Prudent dietary pattern;
LUSC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02463440	chr8:22132932	PIWIL2	0.44	7.96	0.4	2.81e-14	Hypertriglyceridemia;
LUSC	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.95	14.99	0.63	3.3e-39	Multiple sclerosis;
LUSC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25072359	chr17:41440525	NA	0.66	9.42	0.46	7.64e-19	Menopause (age at onset);
LUSC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg14092988	chr3:52407081	DNAH1	0.31	6.17	0.32	2.03e-9	Bipolar disorder;
LUSC	cis	rs3812762	0.879	rs4929910	chr11:8784869	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.4	7.21	0.37	3.88e-12	Hypospadias;
LUSC	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg17385448	chr1:15911702	AGMAT	0.37	5.86	0.31	1.08e-8	Systolic blood pressure;
LUSC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg07716408	chr11:68623521	NA	-0.34	-6.68	-0.34	1e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg01251360	chr16:68772225	CDH1	-0.27	-6.35	-0.33	7e-10	Colorectal cancer;
LUSC	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg19468946	chr17:37922297	IKZF3	-0.43	-6.82	-0.35	4.17e-11	Self-reported allergy;
LUSC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg09455208	chr3:40491958	NA	0.5	9.31	0.45	1.82e-18	Renal cell carcinoma;
LUSC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.99	0.31	5.49e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg06028605	chr16:24865363	SLC5A11	0.49	8.58	0.42	3.75e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg02176678	chr2:219576539	TTLL4	-0.66	-12.89	-0.58	4.08e-31	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg24006582	chr15:45444508	DUOX1	-0.61	-8.96	-0.44	2.41e-17	Uric acid levels;
LUSC	cis	rs3820928	0.874	rs10182307	chr2:227875360	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.53	-0.38	4.78e-13	Pulmonary function;
LUSC	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg24692254	chr21:30365293	RNF160	-0.54	-7.86	-0.4	5.38e-14	Dental caries;
LUSC	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg17507749	chr15:85114479	UBE2QP1	0.56	6.96	0.36	1.8e-11	Schizophrenia;
LUSC	cis	rs78545713	0.536	rs56119218	chr6:26225881	C/A	cg23601095	chr6:26197514	HIST1H3D	0.64	5.76	0.3	1.87e-8	Iron status biomarkers (total iron binding capacity);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26505822	chr15:25684203	UBE3A	-0.43	-6.49	-0.33	3.14e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs143000161	1	rs143000161	chr2:165710540	A/T	cg03182029	chr2:165697222	COBLL1	0.72	6.61	0.34	1.48e-10	Heschl's gyrus morphology;
LUSC	cis	rs6076065	0.723	rs2281429	chr20:23399544	A/T	cg11657817	chr20:23433608	CST11	0.42	8.07	0.4	1.28e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg03433033	chr1:76189801	ACADM	-0.42	-6.19	-0.32	1.81e-9	Daytime sleep phenotypes;
LUSC	cis	rs7246967	0.611	rs117717959	chr19:22828678	C/T	cg23217946	chr19:22817039	ZNF492	0.45	6.04	0.31	4.09e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7582720	1.000	rs72934518	chr2:203937908	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.65	0.43	2.2e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.69	0.3	2.75e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg02423579	chr7:2872169	GNA12	-0.46	-6.37	-0.33	6.17e-10	Height;
LUSC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.79	0.35	5e-11	Tonsillectomy;
LUSC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg20203395	chr5:56204925	C5orf35	-0.79	-10.38	-0.49	4.48e-22	Initial pursuit acceleration;
LUSC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg07636037	chr3:49044803	WDR6	0.43	6.26	0.32	1.21e-9	Resting heart rate;
LUSC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08219700	chr8:58056026	NA	0.59	6.95	0.36	1.87e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7561273	0.609	rs10189243	chr2:24293756	C/T	cg20701182	chr2:24300061	SF3B14	0.45	5.77	0.3	1.76e-8	Quantitative traits;
LUSC	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.64	0.39	2.25e-13	Iron status biomarkers;
LUSC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg00933542	chr6:150070202	PCMT1	0.32	6.76	0.35	6.15e-11	Lung cancer;
LUSC	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg27284194	chr4:1044797	NA	0.5	8.02	0.4	1.75e-14	Recombination rate (males);
LUSC	trans	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-7.4	-0.38	1.15e-12	Menarche (age at onset);
LUSC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-18.67	-0.71	8.72e-54	Height;
LUSC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg04756594	chr16:24857601	SLC5A11	0.49	7.26	0.37	2.8e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.88	-0.51	8.12e-24	Schizophrenia;
LUSC	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg23306229	chr2:178417860	TTC30B	0.44	5.72	0.3	2.41e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07080220	chr10:102295463	HIF1AN	-0.68	-8.46	-0.42	8.65e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2262909	0.962	rs390730	chr19:22233509	C/A	cg11619707	chr19:22235551	ZNF257	-0.38	-5.7	-0.3	2.7e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18492804	chr14:54976994	CGRRF1	0.47	6.44	0.33	4.25e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9341808	0.500	rs806851	chr6:81030831	A/C	cg08355045	chr6:80787529	NA	-0.41	-7.09	-0.36	7.9e-12	Sitting height ratio;
LUSC	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg25173405	chr17:45401733	C17orf57	-0.38	-6.03	-0.31	4.26e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7000551	0.725	rs2461486	chr8:22392008	T/C	cg12081754	chr8:22256438	SLC39A14	0.42	6.2	0.32	1.64e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg20406979	chr6:167373233	NA	-0.26	-6.12	-0.32	2.58e-9	Crohn's disease;
LUSC	cis	rs9677476	0.818	rs9973675	chr2:232095484	G/A	cg07929768	chr2:232055508	NA	0.35	6.56	0.34	1.99e-10	Food antigen IgG levels;
LUSC	cis	rs713477	0.967	rs1572613	chr14:55909897	C/T	cg13175173	chr14:55914753	NA	-0.32	-6.74	-0.35	7.01e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs6700896	0.864	rs11208691	chr1:66092570	A/G	cg04111102	chr1:66153794	NA	0.31	6.87	0.35	3.14e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg17470449	chr10:769945	NA	0.55	7.68	0.39	1.81e-13	Uric acid levels;
LUSC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	14.52	0.62	2.21e-37	Platelet count;
LUSC	cis	rs950881	0.932	rs3771175	chr2:102960210	A/T	cg20060108	chr2:102954350	IL1RL1	-0.46	-6.02	-0.31	4.64e-9	Allergy;
LUSC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.92	0.4	3.59e-14	Colorectal cancer;
LUSC	cis	rs17685	1.000	rs17685	chr7:75616105	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-6.14	-0.32	2.39e-9	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	10.12	0.48	3.61e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1178968	0.792	rs1880948	chr7:72722981	G/A	cg25889504	chr7:72793014	NA	0.58	7.74	0.39	1.19e-13	Triglyceride levels;
LUSC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.83	-0.51	1.23e-23	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08280861	chr8:58055591	NA	0.54	5.94	0.31	6.98e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs72901758	0.669	rs17641275	chr17:76247796	A/C	cg25512537	chr17:76250053	NA	-0.37	-6.84	-0.35	3.79e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	10.98	0.51	3.81e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.6	-0.34	1.58e-10	Reticulocyte count;
LUSC	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg15605315	chr1:45957053	TESK2	0.38	5.65	0.3	3.36e-8	Platelet count;
LUSC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4474465	0.920	rs10128743	chr11:78214673	C/T	cg27205649	chr11:78285834	NARS2	-0.53	-6.0	-0.31	5.03e-9	Alzheimer's disease (survival time);
LUSC	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.25	-0.91	3.51e-130	Myeloid white cell count;
LUSC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs7189233	0.550	rs4784312	chr16:53498402	T/C	cg09728985	chr16:53543985	NA	-0.3	-5.71	-0.3	2.55e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6599077	1.000	rs6808614	chr3:40097000	T/C	cg13683864	chr3:40499215	RPL14	-0.59	-7.56	-0.38	3.95e-13	Sleep-related phenotypes;
LUSC	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg22676075	chr6:135203613	NA	0.56	8.8	0.43	7.35e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg05805236	chr11:65401703	PCNXL3	0.4	6.79	0.35	5.06e-11	Acne (severe);
LUSC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.54	-8.64	-0.43	2.36e-16	Longevity;Endometriosis;
LUSC	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg02403541	chr12:121454288	C12orf43	0.61	9.51	0.46	3.95e-19	Subjective well-being;Cardiovascular disease risk factors;
LUSC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.87	0.35	3.07e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg20701182	chr2:24300061	SF3B14	0.54	5.73	0.3	2.2e-8	Lymphocyte counts;
LUSC	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg03585969	chr10:35415529	CREM	0.66	9.47	0.46	5.19e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg10911889	chr6:126070802	HEY2	0.42	6.39	0.33	5.59e-10	Brugada syndrome;
LUSC	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14240646	chr10:27532245	ACBD5	0.6	7.61	0.38	2.85e-13	Breast cancer;
LUSC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg04414720	chr1:150670196	GOLPH3L	0.49	7.54	0.38	4.57e-13	Melanoma;
LUSC	cis	rs76878669	0.561	rs7110944	chr11:66118217	C/T	cg18002602	chr11:66138449	SLC29A2	-0.48	-8.44	-0.42	9.66e-16	Educational attainment (years of education);
LUSC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg13535736	chr9:111863775	C9orf5	-0.43	-6.73	-0.35	7.3e-11	Menarche (age at onset);
LUSC	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg15704280	chr7:45808275	SEPT13	-0.63	-7.68	-0.39	1.83e-13	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs4942242	0.626	rs7986998	chr13:44209916	G/A	cg19169023	chr15:41853346	TYRO3	0.57	8.75	0.43	1.05e-16	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-7.58	-0.38	3.48e-13	Fear of minor pain;
LUSC	trans	rs72674100	1.000	rs9998866	chr4:97987273	C/A	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg00933542	chr6:150070202	PCMT1	0.32	6.71	0.34	8.26e-11	Lung cancer;
LUSC	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg23029597	chr12:123009494	RSRC2	-0.74	-9.58	-0.46	2.27e-19	Body mass index;
LUSC	trans	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.74	-0.35	7.03e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs2736345	0.788	rs2618476	chr8:11352541	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.75	0.35	6.54e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LUSC	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-7.74	-0.39	1.18e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg25281562	chr12:121454272	C12orf43	0.46	5.86	0.31	1.12e-8	N-glycan levels;
LUSC	cis	rs4363385	0.818	rs1415965	chr1:153002750	G/A	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.9	-0.4	4e-14	Inflammatory skin disease;
LUSC	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg12559939	chr2:27858050	GPN1	-0.4	-6.24	-0.32	1.32e-9	Oral cavity cancer;
LUSC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg25019033	chr10:957182	NA	-0.51	-6.42	-0.33	4.77e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg24130564	chr14:104152367	KLC1	-0.71	-11.47	-0.53	6.71e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.48	-0.42	7.36e-16	Total cholesterol levels;
LUSC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg09796270	chr17:17721594	SREBF1	-0.46	-8.17	-0.41	6.52e-15	Total body bone mineral density;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.85	-15.33	-0.64	1.57e-40	Menarche (age at onset);
LUSC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg07148914	chr20:33460835	GGT7	-0.52	-8.1	-0.41	1.02e-14	Glomerular filtration rate (creatinine);
LUSC	trans	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg01620082	chr3:125678407	NA	-0.65	-6.72	-0.35	8.04e-11	Breast cancer;
LUSC	cis	rs6546550	0.901	rs10205487	chr2:70151471	C/T	cg02498382	chr2:70120550	SNRNP27	0.3	7.28	0.37	2.34e-12	Prevalent atrial fibrillation;
LUSC	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.73	14.21	0.61	3.48e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg17366294	chr4:99064904	C4orf37	0.58	10.38	0.49	4.47e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg26513180	chr16:89883248	FANCA	-0.67	-6.73	-0.35	7.35e-11	Skin colour saturation;
LUSC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg00750074	chr16:89608354	SPG7	-0.57	-10.21	-0.49	1.78e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg03709012	chr19:19516395	GATAD2A	-0.81	-12.78	-0.57	9.92e-31	Tonsillectomy;
LUSC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.44e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg05623727	chr3:50126028	RBM5	-0.35	-6.64	-0.34	1.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10193935	0.901	rs2286702	chr2:42555473	C/T	cg27598129	chr2:42591480	NA	-0.6	-8.17	-0.41	6.36e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7560272	0.723	rs13386124	chr2:73771695	C/G	cg20560298	chr2:73613845	ALMS1	-0.38	-6.08	-0.32	3.29e-9	Schizophrenia;
LUSC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg03461704	chr1:205818484	PM20D1	0.39	6.67	0.34	1.08e-10	Menarche (age at onset);
LUSC	cis	rs7084921	0.809	rs11594585	chr10:101811166	C/G	cg11888571	chr10:102027403	CWF19L1	-0.41	-5.66	-0.3	3.23e-8	Bone mineral density;
LUSC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-7.69	-0.39	1.63e-13	Personality dimensions;
LUSC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg20887711	chr4:1340912	KIAA1530	-0.49	-7.3	-0.37	2.16e-12	Obesity-related traits;
LUSC	cis	rs668210	0.793	rs1204011	chr11:65741086	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.56	-7.08	-0.36	8.6e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs977987	0.778	rs12445726	chr16:75465575	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.4e-11	Dupuytren's disease;
LUSC	cis	rs7584330	0.554	rs74001384	chr2:238424530	T/C	cg14458575	chr2:238380390	NA	0.44	5.77	0.3	1.78e-8	Prostate cancer;
LUSC	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg12927641	chr6:109611667	NA	-0.37	-6.38	-0.33	5.82e-10	Reticulocyte fraction of red cells;
LUSC	trans	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.4	0.42	1.29e-15	Diabetic kidney disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04250489	chr11:63535821	C11orf95	-0.43	-6.53	-0.34	2.43e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.52	-6.09	-0.32	3.13e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg20991723	chr1:152506922	NA	0.51	8.99	0.44	1.87e-17	Hair morphology;
LUSC	trans	rs61931739	0.649	rs864614	chr12:33725409	C/A	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg24296786	chr1:45957014	TESK2	0.46	6.76	0.35	6.29e-11	High light scatter reticulocyte count;
LUSC	cis	rs9443189	0.526	rs10943250	chr6:76208445	C/G	cg01950844	chr6:76311363	SENP6	0.66	6.71	0.34	8.2e-11	Prostate cancer;
LUSC	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg13010199	chr12:38710504	ALG10B	0.55	8.48	0.42	7.46e-16	Morning vs. evening chronotype;
LUSC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg24562669	chr7:97807699	LMTK2	0.35	6.19	0.32	1.8e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.33	-0.49	6.91e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.92	0.31	8.14e-9	Menopause (age at onset);
LUSC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg23887609	chr12:130822674	PIWIL1	0.49	7.27	0.37	2.65e-12	Menopause (age at onset);
LUSC	cis	rs2019216	0.521	rs2175657	chr17:21908494	T/G	cg22648282	chr17:21454238	C17orf51	-0.52	-7.74	-0.39	1.17e-13	Pelvic organ prolapse;
LUSC	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg03585969	chr10:35415529	CREM	0.58	8.54	0.42	4.68e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg02782426	chr3:40428986	ENTPD3	-0.34	-6.35	-0.33	7.02e-10	Renal cell carcinoma;
LUSC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.7	12.65	0.57	3.19e-30	Aortic root size;
LUSC	cis	rs4654899	0.802	rs2167811	chr1:21194510	A/G	cg01072550	chr1:21505969	NA	0.45	6.61	0.34	1.57e-10	Superior frontal gyrus grey matter volume;
LUSC	trans	rs1486139	1.000	rs1385935	chr7:46266402	A/G	cg17534202	chr9:96721102	NA	-0.35	-6.15	-0.32	2.26e-9	Select biomarker traits;
LUSC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg12639453	chr1:2035780	PRKCZ	-0.31	-6.41	-0.33	4.99e-10	Height;
LUSC	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg14530993	chr4:882597	GAK	0.72	7.42	0.38	1e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs35000415	0.938	rs17424602	chr7:128687940	A/G	cg19972273	chr7:128594194	NA	0.57	5.92	0.31	7.92e-9	Systemic lupus erythematosus;
LUSC	trans	rs2262909	0.962	rs17459246	chr19:22278121	T/C	cg17074339	chr11:11642133	GALNTL4	0.44	6.76	0.35	6.13e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1595825	1.000	rs7582715	chr2:198874310	T/G	cg00982548	chr2:198649783	BOLL	-0.49	-6.15	-0.32	2.15e-9	Ulcerative colitis;
LUSC	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg03732007	chr1:2071316	PRKCZ	0.47	7.62	0.38	2.68e-13	Height;
LUSC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-8.51	-0.42	5.84e-16	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs62055045	0.528	rs7194638	chr16:71573818	A/G	cg15281710	chr15:96890452	NA	-0.43	-6.46	-0.33	3.67e-10	Schizophrenia;
LUSC	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg05855489	chr10:104503620	C10orf26	0.49	7.45	0.38	8.2e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg09307838	chr4:120376055	NA	0.76	11.04	0.52	2.31e-24	Corneal astigmatism;
LUSC	cis	rs7523273	0.606	rs7144	chr1:207967719	A/G	cg22525895	chr1:207977042	MIR29B2	-0.4	-6.52	-0.34	2.59e-10	Schizophrenia;
LUSC	cis	rs9534288	0.913	rs9534299	chr13:46625586	A/T	cg15192986	chr13:46630673	CPB2	-0.73	-11.17	-0.52	8.18e-25	Blood protein levels;
LUSC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg15145296	chr3:125709740	NA	-0.58	-6.56	-0.34	2.03e-10	Blood pressure (smoking interaction);
LUSC	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg23791538	chr6:167370224	RNASET2	0.5	8.24	0.41	4.02e-15	Crohn's disease;
LUSC	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg24130564	chr14:104152367	KLC1	0.46	6.62	0.34	1.44e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg27411982	chr8:10470053	RP1L1	-0.41	-5.82	-0.3	1.35e-8	Neuroticism;
LUSC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-11.86	-0.54	2.61e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg02660097	chr11:68866761	NA	0.43	6.14	0.32	2.36e-9	Blond vs. brown hair color;
LUSC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg13531842	chr10:38383804	ZNF37A	-0.43	-6.71	-0.34	8.54e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg01884057	chr2:25150051	NA	0.42	9.13	0.45	6.57e-18	Body mass index;
LUSC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.75	13.19	0.59	2.77e-32	Colorectal cancer;
LUSC	cis	rs1577917	0.816	rs12664099	chr6:86648572	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.41	-5.96	-0.31	6.47e-9	Response to antipsychotic treatment;
LUSC	cis	rs427941	0.703	rs201447	chr7:101738384	C/A	cg06246474	chr7:101738831	CUX1	0.41	6.71	0.34	8.45e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.63	-0.43	2.54e-16	Aortic root size;
LUSC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg22823121	chr1:150693482	HORMAD1	0.5	7.32	0.37	1.85e-12	Melanoma;
LUSC	cis	rs11158026	0.628	rs8023187	chr14:55381662	T/C	cg04306507	chr14:55594613	LGALS3	0.34	6.18	0.32	1.92e-9	Parkinson's disease;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	1.02	23.13	0.78	2.42e-71	Menarche (age at onset);
LUSC	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg22777020	chr22:31556080	RNF185	-0.45	-5.79	-0.3	1.6e-8	Colorectal cancer;
LUSC	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg17848003	chr1:3704513	LRRC47	0.31	5.73	0.3	2.2e-8	Red cell distribution width;
LUSC	cis	rs9660992	0.626	rs9326600	chr1:205245268	G/A	cg00857998	chr1:205179979	DSTYK	0.52	8.08	0.4	1.17e-14	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs4737010	0.511	rs7006871	chr8:41670952	A/G	cg08923054	chr8:41654455	ANK1	0.34	6.11	0.32	2.74e-9	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg27537053	chr1:44069790	PTPRF	0.43	6.55	0.34	2.14e-10	Cognitive function;Information processing speed;
LUSC	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.06	-0.36	9.78e-12	Coronary artery disease;
LUSC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.04	21.0	0.75	5.16e-63	Cognitive function;
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.54	-8.27	-0.41	3.22e-15	Longevity;Endometriosis;
LUSC	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.44e-17	Iron status biomarkers;
LUSC	cis	rs9303542	0.694	rs8071207	chr17:46584016	T/C	cg09704116	chr17:46666958	LOC404266	0.31	5.95	0.31	6.69e-9	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs909002	0.789	rs3817398	chr1:32119431	C/T	cg01639898	chr1:32083012	HCRTR1	-0.32	-7.66	-0.39	2.1e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-10.46	-0.5	2.35e-22	Bladder cancer;
LUSC	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg24642439	chr20:33292090	TP53INP2	-0.52	-7.78	-0.39	8.86e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15664640	chr17:80829946	TBCD	0.5	8.89	0.44	4e-17	Breast cancer;
LUSC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	8.09e-13	Motion sickness;
LUSC	cis	rs11608355	0.521	rs6606709	chr12:109846714	A/C	cg19025524	chr12:109796872	NA	-0.4	-7.36	-0.37	1.41e-12	Neuroticism;
LUSC	trans	rs9409565	0.826	rs639276	chr9:97206737	G/T	cg05679027	chr9:99775184	HIATL2	-0.49	-7.0	-0.36	1.43e-11	Colorectal cancer (alcohol consumption interaction);
LUSC	trans	rs11165623	0.543	rs6656866	chr1:97002238	T/C	cg10631902	chr5:14652156	NA	-0.42	-6.21	-0.32	1.55e-9	Hip circumference;Waist circumference;
LUSC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-13.68	-0.6	3.77e-34	Total body bone mineral density;
LUSC	trans	rs72674100	1.000	rs4145376	chr4:97994304	C/T	cg16405019	chr1:18959625	PAX7	-0.61	-6.41	-0.33	5.09e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg07393940	chr7:158741817	NA	-0.38	-6.79	-0.35	5.02e-11	Life satisfaction;
LUSC	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg22117172	chr7:91764530	CYP51A1	0.32	5.71	0.3	2.49e-8	Breast cancer;
LUSC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg11247378	chr22:39784982	NA	-0.6	-10.47	-0.5	2.26e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg23791538	chr6:167370224	RNASET2	0.41	6.53	0.34	2.52e-10	Crohn's disease;
LUSC	cis	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg07460842	chr6:66804631	NA	0.7	8.15	0.41	7.18e-15	Type 2 diabetes;
LUSC	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.93	12.08	0.55	4.03e-28	Exhaled nitric oxide output;
LUSC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	trans	rs9929218	0.817	rs3114399	chr16:68713385	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-13.11	-0.58	5.78e-32	Colorectal cancer;
LUSC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg06784218	chr1:46089804	CCDC17	0.53	10.28	0.49	1.01e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg11645453	chr3:52864694	ITIH4	0.32	7.55	0.38	4.18e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2668423	0.502	rs7254913	chr19:1388320	A/G	cg02639931	chr19:1387894	NDUFS7	0.69	15.04	0.64	2.21e-39	Nonalcoholic fatty liver disease;
LUSC	cis	rs7584330	0.554	rs10190935	chr2:238435482	G/A	cg14458575	chr2:238380390	NA	0.48	5.97	0.31	6.06e-9	Prostate cancer;
LUSC	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	0.98	12.03	0.55	6.09e-28	Nonalcoholic fatty liver disease;
LUSC	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg17252645	chr8:143867129	LY6D	0.38	6.79	0.35	5.28e-11	Urinary tract infection frequency;
LUSC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08280861	chr8:58055591	NA	0.54	6.39	0.33	5.53e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg23172400	chr8:95962367	TP53INP1	0.32	6.4	0.33	5.22e-10	Type 2 diabetes;
LUSC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg25039879	chr17:56429692	SUPT4H1	0.66	8.88	0.44	4.12e-17	Cognitive test performance;
LUSC	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.78	-0.35	5.56e-11	Uric acid levels;
LUSC	cis	rs11756438	0.572	rs2638541	chr6:119003743	A/T	cg18833306	chr6:118973337	C6orf204	0.37	5.89	0.31	9.22e-9	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs34638657	0.833	rs4889479	chr16:82201474	T/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.38	-0.33	5.78e-10	Lung adenocarcinoma;
LUSC	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.86	14.0	0.61	2.4e-35	Bladder cancer;
LUSC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.72	12.25	0.56	9.7e-29	Alcohol dependence;
LUSC	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.4	-5.72	-0.3	2.33e-8	Lung cancer;
LUSC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-0.94	-14.06	-0.61	1.41e-35	Blood trace element (Zn levels);
LUSC	cis	rs4604732	0.642	rs4266925	chr1:247639165	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.36	5.85	0.31	1.15e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	12.42	0.56	2.27e-29	Cognitive test performance;
LUSC	cis	rs41271473	0.948	rs12144495	chr1:228810937	G/T	cg10167378	chr1:228756711	NA	-0.59	-7.22	-0.37	3.55e-12	Chronic lymphocytic leukemia;
LUSC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg03684893	chr10:554711	DIP2C	-0.37	-6.81	-0.35	4.64e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs7572644	0.766	rs1506535	chr2:28174081	G/A	cg27432699	chr2:27873401	GPN1	0.52	6.45	0.33	3.94e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	1.1	16.32	0.67	1.88e-44	Alzheimer's disease;
LUSC	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg24562669	chr7:97807699	LMTK2	0.43	7.32	0.37	1.83e-12	Breast cancer;
LUSC	cis	rs11039100	0.850	rs34161300	chr11:5830740	G/C	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6736093	0.932	rs77096506	chr2:112657554	T/G	cg12686935	chr2:112915763	FBLN7	-0.39	-5.99	-0.31	5.37e-9	Coronary artery disease;
LUSC	cis	rs79387448	0.638	rs11465698	chr2:103054577	T/C	cg09003973	chr2:102972529	NA	0.98	9.98	0.48	1.08e-20	Gut microbiota (bacterial taxa);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13445258	chr3:128369860	RPN1	0.44	6.58	0.34	1.87e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.06	-0.4	1.37e-14	Morning vs. evening chronotype;
LUSC	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg13256891	chr4:100009986	ADH5	0.51	6.97	0.36	1.65e-11	Alcohol dependence;
LUSC	cis	rs7605827	0.930	rs6733647	chr2:15542159	A/G	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg11812906	chr14:75593930	NEK9	-0.41	-6.11	-0.32	2.76e-9	Neuroticism;
LUSC	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-5.9	-0.31	8.86e-9	Schizophrenia;
LUSC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg25767906	chr1:53392781	SCP2	-0.52	-9.57	-0.46	2.42e-19	Monocyte count;
LUSC	cis	rs3924048	0.559	rs6541039	chr1:12626261	T/C	cg00291366	chr1:12616550	NA	0.32	7.41	0.38	1.03e-12	Optic cup area;
LUSC	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg17470449	chr10:769945	NA	0.52	7.08	0.36	8.38e-12	Uric acid levels;
LUSC	cis	rs2073300	1.000	rs6132620	chr20:23436654	A/G	cg09953122	chr20:23471693	CST8	-0.67	-6.15	-0.32	2.17e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12594515	0.935	rs8042519	chr15:45996341	G/C	cg06207120	chr15:45996521	NA	0.39	5.89	0.31	9.36e-9	Waist circumference;Weight;
LUSC	cis	rs7580658	0.817	rs6761447	chr2:128074573	A/T	cg09760422	chr2:128146352	NA	-0.29	-6.22	-0.32	1.47e-9	Protein C levels;
LUSC	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.86	-0.4	5.4e-14	Retinal vascular caliber;
LUSC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	0.87	14.83	0.63	1.38e-38	Tonsillectomy;
LUSC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.26e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.32	-0.37	1.84e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg26875233	chr11:93583750	C11orf90	-0.31	-6.05	-0.31	3.91e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs2274273	0.967	rs10147667	chr14:55570849	C/T	cg04306507	chr14:55594613	LGALS3	-0.53	-11.86	-0.54	2.47e-27	Protein biomarker;
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13012494	chr21:47604986	C21orf56	-0.54	-8.32	-0.41	2.29e-15	Testicular germ cell tumor;
LUSC	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.63	-0.47	1.55e-19	Multiple sclerosis;
LUSC	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg01884057	chr2:25150051	NA	-0.47	-10.78	-0.51	1.9e-23	Body mass index;
LUSC	cis	rs60695258	0.550	rs340648	chr4:87940940	A/G	cg10685359	chr4:87814065	C4orf36	0.34	6.1	0.32	2.94e-9	Hematocrit;
LUSC	cis	rs981844	0.689	rs7666762	chr4:154684197	C/T	cg14289246	chr4:154710475	SFRP2	-0.52	-7.43	-0.38	9.38e-13	Response to statins (LDL cholesterol change);
LUSC	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg09904177	chr6:26538194	HMGN4	0.66	11.7	0.54	1.01e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg24687639	chr15:41576060	LOC729082	0.51	6.41	0.33	4.82e-10	Cognitive function;Information processing speed;
LUSC	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg07679836	chr6:33548423	BAK1	0.32	5.71	0.3	2.46e-8	Platelet count;
LUSC	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg05887092	chr17:76393375	PGS1	-0.48	-8.44	-0.42	9.67e-16	HDL cholesterol levels;
LUSC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg08392591	chr16:89556376	ANKRD11	0.52	8.15	0.41	7.44e-15	Multiple myeloma (IgH translocation);
LUSC	cis	rs9311676	0.609	rs55845662	chr3:58424899	A/C	cg26110898	chr3:58419937	PDHB	0.39	6.33	0.33	7.88e-10	Systemic lupus erythematosus;
LUSC	cis	rs62400317	0.826	rs17209769	chr6:45321205	C/A	cg18551225	chr6:44695536	NA	-0.43	-7.25	-0.37	2.9e-12	Total body bone mineral density;
LUSC	cis	rs4891159	0.548	rs654754	chr18:74143695	T/C	cg24786174	chr18:74118243	ZNF516	0.94	20.12	0.74	1.48e-59	Longevity;
LUSC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg00945038	chr17:61921165	SMARCD2	0.54	9.56	0.46	2.58e-19	Prudent dietary pattern;
LUSC	cis	rs7202877	0.611	rs56092808	chr16:75312716	A/T	cg04384234	chr16:75411784	CFDP1	-0.65	-8.79	-0.43	8.13e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9473147	0.843	rs12202615	chr6:47618171	T/C	cg12968598	chr6:47444699	CD2AP	0.39	5.89	0.31	9.5e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	12.94	0.58	2.49e-31	Lung cancer in ever smokers;
LUSC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg00745463	chr17:30367425	LRRC37B	-0.75	-8.66	-0.43	1.98e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg00677455	chr12:58241039	CTDSP2	0.71	10.71	0.51	3.23e-23	Multiple sclerosis;
LUSC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg13175981	chr1:150552382	MCL1	0.46	6.17	0.32	2.02e-9	Blood protein levels;
LUSC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg01125463	chr6:42946178	PEX6	-0.36	-5.92	-0.31	7.95e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg07167872	chr1:205819463	PM20D1	-0.39	-5.83	-0.3	1.33e-8	Prostate-specific antigen levels;
LUSC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg04450456	chr4:17643702	FAM184B	-0.33	-5.68	-0.3	2.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg05738196	chr6:26577821	NA	0.77	14.31	0.62	1.51e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	7.38	0.37	1.26e-12	Schizophrenia;
LUSC	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg18825076	chr15:78729989	IREB2	-0.45	-6.1	-0.32	2.87e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg09021430	chr5:549028	NA	0.42	7.47	0.38	7.25e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg04362960	chr10:104952993	NT5C2	0.65	9.41	0.46	8.54e-19	Arsenic metabolism;
LUSC	cis	rs1595825	0.891	rs58409972	chr2:198897061	A/T	cg10547527	chr2:198650123	BOLL	-0.51	-6.06	-0.31	3.69e-9	Ulcerative colitis;
LUSC	cis	rs12210905	1.000	rs115268625	chr6:26948229	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-5.96	-0.31	6.57e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg18681998	chr4:17616180	MED28	0.77	13.73	0.6	2.53e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg25456477	chr12:86230367	RASSF9	0.43	7.69	0.39	1.69e-13	Major depressive disorder;
LUSC	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg07173049	chr1:7289937	CAMTA1	0.34	6.98	0.36	1.55e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg02951883	chr7:2050386	MAD1L1	-0.47	-8.14	-0.41	8.15e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11764359	chr7:65958608	NA	0.61	9.33	0.45	1.46e-18	Calcium levels;
LUSC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg00745463	chr17:30367425	LRRC37B	-0.79	-9.17	-0.45	4.91e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.87	0.31	1.06e-8	Rheumatoid arthritis;
LUSC	cis	rs7241530	0.662	rs12454883	chr18:75902642	G/A	cg14642773	chr18:75888474	NA	0.39	6.02	0.31	4.59e-9	Educational attainment (years of education);
LUSC	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg01884057	chr2:25150051	NA	0.46	10.75	0.51	2.33e-23	Body mass index;
LUSC	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg18681998	chr4:17616180	MED28	-0.82	-13.99	-0.61	2.58e-35	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.36	-0.56	3.71e-29	Rheumatoid arthritis;
LUSC	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.99	0.36	1.52e-11	Testicular germ cell tumor;
LUSC	cis	rs17286411	0.750	rs12444594	chr16:71941912	A/T	cg03805757	chr16:71968109	PKD1L3	0.44	7.16	0.36	5.31e-12	Blood protein levels;
LUSC	cis	rs77972916	0.505	rs6719754	chr2:43526386	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.45	-5.7	-0.3	2.58e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7000551	0.715	rs2469745	chr8:22343464	C/T	cg12081754	chr8:22256438	SLC39A14	0.4	6.13	0.32	2.52e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4363385	0.720	rs1134220	chr1:152976306	T/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.82	-0.39	6.89e-14	Inflammatory skin disease;
LUSC	cis	rs7247513	1.000	rs7247513	chr19:12691185	C/T	cg01871581	chr19:12707946	ZNF490	-0.57	-9.0	-0.44	1.79e-17	Bipolar disorder;
LUSC	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs6456156	0.774	rs6908364	chr6:167527296	C/T	cg07741184	chr6:167504864	NA	-0.35	-6.34	-0.33	7.32e-10	Primary biliary cholangitis;
LUSC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23221052	chr5:179740743	GFPT2	-0.65	-10.52	-0.5	1.51e-22	Height;
LUSC	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.84	-14.89	-0.63	8.37e-39	Ulcerative colitis;
LUSC	cis	rs9311676	0.632	rs11130642	chr3:58420042	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.4	0.33	5.22e-10	Systemic lupus erythematosus;
LUSC	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19717773	chr7:2847554	GNA12	-0.37	-6.06	-0.31	3.58e-9	Height;
LUSC	cis	rs963731	0.649	rs10779924	chr2:39208057	G/T	cg04010122	chr2:39346883	SOS1	-0.78	-5.7	-0.3	2.71e-8	Corticobasal degeneration;
LUSC	cis	rs9534288	0.830	rs2296641	chr13:46632226	A/C	cg15192986	chr13:46630673	CPB2	-0.8	-12.69	-0.57	2.14e-30	Blood protein levels;
LUSC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.55	-0.34	2.14e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06481639	chr22:41940642	POLR3H	0.49	5.72	0.3	2.38e-8	Vitiligo;
LUSC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.57	0.38	3.61e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg03538708	chr1:25844672	NA	-0.34	-5.83	-0.3	1.3e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg16339924	chr4:17578868	LAP3	0.61	9.16	0.45	5.45e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.76	-0.35	6.26e-11	Monocyte percentage of white cells;
LUSC	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.62	-8.93	-0.44	2.9e-17	Superior crus of antihelix expression;
LUSC	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg06606381	chr12:133084897	FBRSL1	-0.88	-9.18	-0.45	4.69e-18	Depression;
LUSC	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg23950597	chr19:37808831	NA	-0.57	-7.02	-0.36	1.27e-11	Coronary artery calcification;
LUSC	cis	rs6546550	0.835	rs3752781	chr2:70124316	T/A	cg02498382	chr2:70120550	SNRNP27	-0.28	-6.82	-0.35	4.39e-11	Prevalent atrial fibrillation;
LUSC	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.6	-0.38	3.04e-13	Retinal vascular caliber;
LUSC	cis	rs7172677	1.000	rs72730601	chr15:75421720	A/T	cg14664628	chr15:75095509	CSK	0.46	6.05	0.31	3.83e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg24375607	chr4:120327624	NA	0.78	11.59	0.54	2.39e-26	Corneal astigmatism;
LUSC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg11965913	chr1:205819406	PM20D1	0.51	7.62	0.38	2.64e-13	Prostate-specific antigen levels;
LUSC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg06238570	chr21:40685208	BRWD1	-0.56	-8.91	-0.44	3.33e-17	Menarche (age at onset);
LUSC	cis	rs8102476	0.846	rs11083450	chr19:38754239	T/C	cg14131526	chr19:38747285	PPP1R14A	-0.32	-5.73	-0.3	2.19e-8	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg19812747	chr11:111475976	SIK2	0.5	6.81	0.35	4.44e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	5.78	0.3	1.69e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs34638657	0.732	rs7205534	chr16:82201618	C/T	cg09439754	chr16:82129088	HSD17B2	-0.38	-6.29	-0.33	1e-9	Lung adenocarcinoma;
LUSC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.65	10.86	0.51	9.66e-24	Bone mineral density;
LUSC	cis	rs10761482	0.500	rs1574466	chr10:62294392	C/T	cg18175470	chr10:62150864	ANK3	-0.47	-6.92	-0.35	2.34e-11	Schizophrenia;
LUSC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg06238570	chr21:40685208	BRWD1	0.47	7.19	0.37	4.15e-12	Cognitive function;
LUSC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.61	9.95	0.48	1.38e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg10756647	chr7:56101905	PSPH	0.85	8.32	0.41	2.24e-15	Diabetic kidney disease;
LUSC	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.14	-0.32	2.4e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7177699	0.534	rs56683682	chr15:79112524	G/T	cg15571903	chr15:79123663	NA	-0.32	-5.84	-0.3	1.26e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2273669	0.667	rs11752532	chr6:109335969	C/G	cg05315195	chr6:109294784	ARMC2	-0.53	-5.89	-0.31	9.28e-9	Prostate cancer;
LUSC	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg24147428	chr11:65409760	SIPA1	-0.55	-7.76	-0.39	1.08e-13	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg04374321	chr14:90722782	PSMC1	-0.68	-10.28	-0.49	1.03e-21	Mortality in heart failure;
LUSC	trans	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.36	-0.33	6.45e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs629535	0.821	rs680993	chr8:70050247	G/A	cg21567404	chr3:27674614	NA	0.96	15.06	0.64	1.7e-39	Dupuytren's disease;
LUSC	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg19773385	chr1:10388646	KIF1B	-0.54	-8.39	-0.42	1.41e-15	Hepatocellular carcinoma;
LUSC	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg10512202	chr3:45649293	LIMD1	0.35	5.74	0.3	2.18e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg00277334	chr10:82204260	NA	0.5	7.29	0.37	2.21e-12	Post bronchodilator FEV1;
LUSC	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg23795048	chr12:9217529	LOC144571	0.34	5.88	0.31	1.02e-8	Sjögren's syndrome;
LUSC	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.71	11.7	0.54	9.51e-27	Lung cancer;
LUSC	trans	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg10756647	chr7:56101905	PSPH	0.87	8.94	0.44	2.62e-17	Diabetic kidney disease;
LUSC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg21724239	chr8:58056113	NA	0.59	7.3	0.37	2.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-8.14	-0.41	7.79e-15	Schizophrenia;
LUSC	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg14121845	chr20:25566513	NINL	0.31	5.66	0.3	3.21e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24110177	chr3:50126178	RBM5	0.57	9.21	0.45	3.63e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg17757837	chr7:157058334	UBE3C	0.82	13.3	0.59	1.14e-32	Body mass index;
LUSC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg17279839	chr7:150038598	RARRES2	0.48	7.48	0.38	6.65e-13	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25026754	chr15:65426128	PDCD7	-0.5	-6.6	-0.34	1.6e-10	Hepatitis;
LUSC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	6.06	0.31	3.58e-9	Tonsillectomy;
LUSC	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg02493740	chr2:85810744	VAMP5	-0.37	-6.64	-0.34	1.28e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-5.97	-0.31	6.07e-9	Depression;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg09774198	chr13:33160713	PDS5B	0.41	6.6	0.34	1.6e-10	Triglycerides;
LUSC	cis	rs6494488	0.500	rs112691501	chr15:64919260	T/C	cg08069370	chr15:64387884	SNX1	-0.66	-5.78	-0.3	1.7e-8	Coronary artery disease;
LUSC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.66	-10.96	-0.51	4.44e-24	Prudent dietary pattern;
LUSC	trans	rs1459104	0.714	rs67321261	chr11:54911368	A/G	cg15704280	chr7:45808275	SEPT13	0.74	6.28	0.32	1.04e-9	Body mass index;
LUSC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11644478	chr21:40555479	PSMG1	0.95	18.81	0.72	2.45e-54	Cognitive function;
LUSC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.9	0.31	9.02e-9	Menopause (age at onset);
LUSC	cis	rs2540226	0.761	rs10206408	chr2:39980482	G/A	cg23576258	chr2:39999331	THUMPD2	0.36	6.22	0.32	1.47e-9	Personality dimensions;
LUSC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg09796270	chr17:17721594	SREBF1	0.39	6.78	0.35	5.35e-11	Total body bone mineral density;
LUSC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs7186831	1	rs7186831	chr16:75473155	G/A	cg03315344	chr16:75512273	CHST6	0.5	9.65	0.47	1.32e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg25019033	chr10:957182	NA	-0.52	-5.81	-0.3	1.44e-8	Eosinophil percentage of granulocytes;
LUSC	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-14.1	-0.61	9.26e-36	Exhaled nitric oxide levels;
LUSC	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	0.86	14.03	0.61	1.79e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs12530845	1.000	rs12530845	chr7:135329978	T/C	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg25801113	chr15:45476975	SHF	0.3	6.17	0.32	1.95e-9	Uric acid levels;
LUSC	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg10356904	chr22:49881777	NA	-0.29	-5.9	-0.31	8.69e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1395	1.000	rs1275538	chr2:27441397	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	7.29	0.37	2.3e-12	Blood metabolite levels;
LUSC	trans	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.37	-0.33	6.31e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03904897	chr3:130612806	ATP2C1	-0.41	-6.12	-0.32	2.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg03929089	chr4:120376271	NA	0.66	6.22	0.32	1.47e-9	Intraocular pressure;
LUSC	cis	rs12541635	0.677	rs6469026	chr8:107006356	T/C	cg10147462	chr8:107024639	NA	0.66	13.81	0.6	1.21e-34	Age of smoking initiation;
LUSC	cis	rs113835537	0.529	rs2305533	chr11:66298623	A/C	cg24851651	chr11:66362959	CCS	0.54	7.86	0.4	5.2e-14	Airway imaging phenotypes;
LUSC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg22823121	chr1:150693482	HORMAD1	0.59	9.05	0.44	1.17e-17	Tonsillectomy;
LUSC	cis	rs9796	0.727	rs12101934	chr15:41353079	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.03	-0.4	1.73e-14	Menopause (age at onset);
LUSC	cis	rs12912251	1.000	rs7163869	chr15:38988391	G/C	cg01338139	chr15:38987640	C15orf53	-0.5	-6.8	-0.35	4.89e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg01528321	chr10:82214614	TSPAN14	0.84	12.92	0.58	2.91e-31	Post bronchodilator FEV1;
LUSC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.65e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg11247378	chr22:39784982	NA	-0.65	-12.89	-0.58	3.93e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs9517320	1.000	rs7996629	chr13:99128037	C/T	cg20487152	chr13:99095054	FARP1	0.35	6.44	0.33	4.08e-10	Longevity;
LUSC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.6	8.64	0.43	2.38e-16	Migraine;Coronary artery disease;
LUSC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	6.57	0.34	1.95e-10	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6496667	0.642	rs12148876	chr15:91065208	G/A	cg03599575	chr15:90893182	GABARAPL3	0.39	5.7	0.3	2.69e-8	Rheumatoid arthritis;
LUSC	cis	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg06521331	chr12:34319734	NA	-0.42	-6.56	-0.34	2.08e-10	Morning vs. evening chronotype;
LUSC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg19318889	chr4:1322082	MAEA	0.44	7.06	0.36	9.44e-12	Obesity-related traits;
LUSC	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg05973401	chr12:123451056	ABCB9	0.51	6.92	0.35	2.27e-11	Neutrophil percentage of white cells;
LUSC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03576123	chr11:487126	PTDSS2	-0.89	-9.92	-0.48	1.65e-20	Body mass index;
LUSC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg01765077	chr12:122356316	WDR66	0.49	6.73	0.35	7.54e-11	Mean corpuscular volume;
LUSC	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.53	-0.42	5.21e-16	Total cholesterol levels;
LUSC	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg05044414	chr3:183734942	ABCC5	0.2	6.88	0.35	3.01e-11	Anterior chamber depth;
LUSC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg01283332	chr5:1856932	NA	-0.33	-6.34	-0.33	7.28e-10	Cardiovascular disease risk factors;
LUSC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg23791538	chr6:167370224	RNASET2	-0.43	-6.95	-0.36	1.93e-11	Crohn's disease;
LUSC	cis	rs6977660	0.714	rs10224920	chr7:19816173	A/T	cg05791153	chr7:19748676	TWISTNB	0.67	7.23	0.37	3.37e-12	Thyroid stimulating hormone;
LUSC	trans	rs4714291	0.963	rs847743	chr6:40087154	C/G	cg02267698	chr19:7991119	CTXN1	0.54	7.6	0.38	2.95e-13	Strep throat;
LUSC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg26380479	chr7:97908229	NA	-0.27	-5.87	-0.31	1.04e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg03213289	chr20:61660250	NA	0.66	12.81	0.57	7.61e-31	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-8.14	-0.41	7.81e-15	Morning vs. evening chronotype;
LUSC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.45	-7.98	-0.4	2.4e-14	Longevity;Endometriosis;
LUSC	cis	rs9400467	0.528	rs240954	chr6:111659822	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.93	-0.35	2.19e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs3916	1.000	rs3916	chr12:121177272	G/C	cg27246729	chr12:121163418	ACADS	0.45	6.53	0.34	2.51e-10	Urinary metabolites (H-NMR features);
LUSC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.62	0.47	1.75e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs983392	0.755	rs1441586	chr11:59856028	T/C	cg24026212	chr11:59952134	MS4A6A	-0.32	-5.68	-0.3	2.97e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg22532475	chr10:104410764	TRIM8	-0.25	-6.01	-0.31	4.97e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.0	-0.31	5.11e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9473147	0.516	rs9349415	chr6:47551861	T/C	cg12968598	chr6:47444699	CD2AP	0.52	7.93	0.4	3.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs12900413	0.562	rs28557101	chr15:90298149	C/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.9	-0.31	8.68e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg13010199	chr12:38710504	ALG10B	0.56	8.27	0.41	3.18e-15	Morning vs. evening chronotype;
LUSC	cis	rs9815354	0.812	rs4299460	chr3:41952445	A/C	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.55e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg27494647	chr7:150038898	RARRES2	0.51	7.83	0.39	6.69e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3087591	0.960	rs4795587	chr17:29587917	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.64	-9.2	-0.45	4.12e-18	Hip circumference;
LUSC	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	9.02	0.44	1.52e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7572644	0.662	rs13402420	chr2:28271435	T/G	cg27432699	chr2:27873401	GPN1	-0.52	-7.03	-0.36	1.2e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.01	0.44	1.59e-17	Motion sickness;
LUSC	cis	rs739496	0.542	rs7316698	chr12:111790511	C/T	cg10833066	chr12:111807467	FAM109A	0.61	11.92	0.55	1.55e-27	Platelet count;
LUSC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg05855489	chr10:104503620	C10orf26	-0.64	-9.51	-0.46	3.8e-19	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.67	-0.34	1.04e-10	Resting heart rate;
LUSC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00166722	chr3:10149974	C3orf24	-0.6	-8.48	-0.42	7.15e-16	Alzheimer's disease;
LUSC	cis	rs2219968	0.828	rs4739190	chr8:78928417	A/G	cg00738934	chr8:78996279	NA	-0.41	-7.24	-0.37	3.06e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg18209359	chr17:80159595	CCDC57	-0.36	-5.82	-0.3	1.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18876405	chr7:65276391	NA	-0.56	-8.67	-0.43	1.96e-16	Aortic root size;
LUSC	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg23029597	chr12:123009494	RSRC2	-0.74	-9.58	-0.46	2.27e-19	Body mass index;
LUSC	cis	rs72802342	0.541	rs185052	chr16:75467063	C/T	cg03315344	chr16:75512273	CHST6	-0.45	-6.5	-0.34	2.94e-10	Advanced age-related macular degeneration;
LUSC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.74	7.4	0.38	1.14e-12	Initial pursuit acceleration;
LUSC	cis	rs6696846	0.630	rs11240373	chr1:205135600	A/C	cg00857998	chr1:205179979	DSTYK	0.68	10.21	0.49	1.83e-21	Red blood cell count;
LUSC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.45	6.1	0.32	2.92e-9	Multiple sclerosis;
LUSC	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.72	-0.43	1.32e-16	Axial length;
LUSC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.65	-10.07	-0.48	5.38e-21	Obesity-related traits;
LUSC	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.7	-0.43	1.51e-16	Response to antipsychotic treatment;
LUSC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	14.13	0.61	7.23e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg01966878	chr4:90757139	SNCA	-0.42	-6.03	-0.31	4.37e-9	Neuroticism;
LUSC	cis	rs73198271	0.515	rs1589613	chr8:8626940	T/C	cg01851573	chr8:8652454	MFHAS1	0.62	7.34	0.37	1.61e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2652834	0.851	rs2652819	chr15:63431175	A/G	cg05507819	chr15:63340323	TPM1	0.47	6.04	0.31	4.08e-9	HDL cholesterol;
LUSC	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg25643088	chr3:52874325	TMEM110	0.4	6.01	0.31	4.9e-9	Schizophrenia;
LUSC	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	0.9	17.43	0.69	7.75e-49	Metabolite levels;
LUSC	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg08847533	chr14:75593920	NEK9	-0.79	-13.69	-0.6	3.7e-34	Height;
LUSC	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg24130564	chr14:104152367	KLC1	0.45	6.51	0.34	2.72e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg22815214	chr1:201083145	CACNA1S	0.43	5.9	0.31	8.71e-9	Permanent tooth development;
LUSC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg11764359	chr7:65958608	NA	0.51	6.6	0.34	1.58e-10	Aortic root size;
LUSC	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	7.18	0.37	4.69e-12	Ovarian reserve;
LUSC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.68	-9.46	-0.46	5.56e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09877593	chr5:10564514	ANKRD33B	-0.41	-6.5	-0.34	2.86e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Depression;
LUSC	cis	rs68170813	0.559	rs7804979	chr7:106999453	C/G	cg02696742	chr7:106810147	HBP1	-0.61	-9.29	-0.45	2.08e-18	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15709087	chr19:33793161	CEBPA;LOC80054	0.44	6.15	0.32	2.21e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7605827	0.538	rs62120660	chr2:15659613	T/C	cg19274914	chr2:15703543	NA	0.47	9.19	0.45	4.24e-18	Educational attainment (years of education);
LUSC	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg14092571	chr14:90743983	NA	0.36	5.9	0.31	8.78e-9	Mortality in heart failure;
LUSC	trans	rs11088226	0.681	rs2409456	chr21:33929374	G/A	cg09050820	chr6:167586206	TCP10L2	0.74	9.73	0.47	7.17e-20	Gastritis;
LUSC	cis	rs138918	0.771	rs138934	chr22:43566924	A/C	cg08909806	chr22:43548696	TSPO	0.34	5.89	0.31	9.29e-9	Monocyte count;
LUSC	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg02997394	chr19:33096574	ANKRD27	0.79	8.95	0.44	2.44e-17	Eosinophilic esophagitis;
LUSC	cis	rs2274273	0.967	rs11622740	chr14:55617844	G/A	cg04306507	chr14:55594613	LGALS3	0.54	11.95	0.55	1.23e-27	Protein biomarker;
LUSC	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21659725	chr3:3221576	CRBN	-0.52	-8.34	-0.42	2.04e-15	Body mass index;
LUSC	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg20203395	chr5:56204925	C5orf35	-0.52	-7.62	-0.38	2.7e-13	Coronary artery disease;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18000306	chr6:288505	NA	0.33	6.23	0.32	1.43e-9	Menopause (age at onset);
LUSC	cis	rs2273669	0.667	rs12196024	chr6:109302258	C/T	cg05315195	chr6:109294784	ARMC2	-0.53	-5.94	-0.31	7.15e-9	Prostate cancer;
LUSC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg03188948	chr7:1209495	NA	0.46	6.18	0.32	1.87e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9394152	0.845	rs7747216	chr6:33476718	A/G	cg13560919	chr6:33536144	NA	-0.59	-10.93	-0.51	5.64e-24	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.94	0.55	1.29e-27	Exhaled nitric oxide output;
LUSC	trans	rs6480314	0.542	rs61854804	chr10:70015576	C/T	cg04882175	chr6:131122610	NA	-0.55	-6.22	-0.32	1.49e-9	Optic nerve measurement (disc area);
LUSC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.2	13.69	0.6	3.51e-34	Diabetic kidney disease;
LUSC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg18404041	chr3:52824283	ITIH1	0.44	7.84	0.39	6.21e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg25767906	chr1:53392781	SCP2	-0.34	-5.66	-0.3	3.33e-8	Monocyte count;
LUSC	cis	rs6426558	0.537	rs4653813	chr1:227461510	G/C	cg10327440	chr1:227177885	CDC42BPA	0.55	7.41	0.38	1.05e-12	Neutrophil percentage of white cells;
LUSC	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.26	0.52	3.74e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2262909	0.962	rs73021832	chr19:22316144	G/C	cg17074339	chr11:11642133	GALNTL4	0.43	6.62	0.34	1.42e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02513392	chr12:112601463	C12orf51	-0.72	-6.46	-0.33	3.73e-10	Cognitive performance;
LUSC	cis	rs72634258	0.945	rs225131	chr1:8095486	T/C	cg00042356	chr1:8021962	PARK7	0.61	7.65	0.39	2.19e-13	Inflammatory bowel disease;
LUSC	cis	rs12681287	0.547	rs56752411	chr8:87515156	C/T	cg00550725	chr8:87521180	FAM82B	0.44	5.75	0.3	2.07e-8	Caudate activity during reward;
LUSC	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg11247378	chr22:39784982	NA	0.41	6.24	0.32	1.36e-9	IgG glycosylation;
LUSC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21643547	chr1:205240462	TMCC2	-0.5	-9.3	-0.45	1.95e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg16423285	chr20:60520624	NA	-0.47	-5.82	-0.3	1.38e-8	Body mass index;
LUSC	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg00376283	chr12:123451042	ABCB9	0.68	8.74	0.43	1.12e-16	Neutrophil percentage of white cells;
LUSC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-8.2	-0.41	5.29e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg13010199	chr12:38710504	ALG10B	0.41	6.03	0.31	4.33e-9	Morning vs. evening chronotype;
LUSC	trans	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.59e-15	Diabetic kidney disease;
LUSC	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg26816564	chr1:7831052	VAMP3	1.08	14.73	0.63	3.37e-38	Inflammatory bowel disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25129346	chr5:68665436	TAF9;RAD17	-0.44	-6.77	-0.35	5.92e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7572644	0.699	rs7602328	chr2:28235184	G/A	cg27432699	chr2:27873401	GPN1	-0.52	-7.02	-0.36	1.28e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18312812	chr19:2900898	ZNF57	-0.45	-6.62	-0.34	1.43e-10	Hepatitis;
LUSC	cis	rs4664308	1.000	rs17341301	chr2:160902420	G/A	cg03641300	chr2:160917029	PLA2R1	-0.64	-10.71	-0.51	3.35e-23	Idiopathic membranous nephropathy;
LUSC	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg27471124	chr11:109292789	C11orf87	0.42	7.35	0.37	1.56e-12	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.82	-13.04	-0.58	1.06e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs7939886	0.920	rs74699881	chr11:55913852	A/T	cg15704280	chr7:45808275	SEPT13	0.8	6.49	0.33	3.19e-10	Myopia (pathological);
LUSC	trans	rs7737355	1.000	rs7737355	chr5:130604811	T/A	cg07715041	chr7:99302981	CYP3A7	-0.38	-6.1	-0.32	3.01e-9	Life satisfaction;
LUSC	cis	rs6577655	0.517	rs2241893	chr8:135586659	C/T	cg17885191	chr8:135476712	NA	0.6	7.76	0.39	1.06e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.46	7.52	0.38	5.02e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg11062466	chr8:58055876	NA	0.66	8.52	0.42	5.58e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.42	-0.38	9.66e-13	Myopia (pathological);
LUSC	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.37	-0.46	1.15e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg10560079	chr2:191398806	TMEM194B	-0.65	-8.06	-0.4	1.41e-14	Diastolic blood pressure;
LUSC	cis	rs3820928	1.000	rs4675120	chr2:227774888	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.96	-0.4	2.8e-14	Pulmonary function;
LUSC	cis	rs6967385	0.560	rs2192833	chr7:12355303	A/T	cg20607287	chr7:12443886	VWDE	0.45	6.8	0.35	4.88e-11	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7589342	0.745	rs933793	chr2:106511846	C/T	cg16077055	chr2:106428750	NCK2	-0.35	-6.61	-0.34	1.48e-10	Addiction;
LUSC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.45	0.33	3.89e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-7.4	-0.38	1.14e-12	Morning vs. evening chronotype;
LUSC	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.52	7.99	0.4	2.24e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.38	-0.33	5.93e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg12935359	chr14:103987150	CKB	-0.58	-9.0	-0.44	1.69e-17	Body mass index;
LUSC	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg00310523	chr12:86230176	RASSF9	0.36	6.47	0.33	3.4e-10	Major depressive disorder;
LUSC	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg03859395	chr2:55845619	SMEK2	0.87	16.02	0.66	2.98e-43	Metabolic syndrome;
LUSC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05535760	chr7:792225	HEATR2	0.81	9.46	0.46	5.75e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs6500395	1.000	rs9930365	chr16:48682154	A/C	cg04672837	chr16:48644449	N4BP1	0.45	6.8	0.35	4.69e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg25206134	chr2:45395956	NA	0.6	7.06	0.36	9.76e-12	Bipolar disorder;
LUSC	cis	rs6722750	0.716	rs6546058	chr2:64421702	A/G	cg22352474	chr2:64371530	PELI1	-0.54	-7.98	-0.4	2.31e-14	Neuroticism;
LUSC	cis	rs983392	0.805	rs11230184	chr11:59965789	G/A	cg20284999	chr11:59952153	MS4A6A	-0.39	-6.37	-0.33	6.25e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg13206674	chr6:150067644	NUP43	0.59	9.28	0.45	2.26e-18	Lung cancer;
LUSC	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg13010199	chr12:38710504	ALG10B	0.6	9.42	0.46	7.95e-19	Bladder cancer;
LUSC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg03188948	chr7:1209495	NA	0.68	7.14	0.36	5.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	6.42	0.33	4.65e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7712401	0.720	rs12109791	chr5:122146831	C/T	cg19077854	chr5:122220652	SNX24	0.35	8.03	0.4	1.72e-14	Mean platelet volume;
LUSC	trans	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg26043149	chr18:55253948	FECH	0.49	7.65	0.39	2.23e-13	Bone mineral density;
LUSC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg26338869	chr17:61819248	STRADA	-0.41	-6.02	-0.31	4.66e-9	Prudent dietary pattern;
LUSC	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.37	1.18e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs807669	0.504	rs8141941	chr22:19166263	G/A	cg02655711	chr22:19163373	SLC25A1	0.57	10.42	0.5	3.35e-22	Metabolite levels;
LUSC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg14784868	chr12:69753453	YEATS4	0.67	9.97	0.48	1.16e-20	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.54	-14.59	-0.62	1.18e-37	Urate levels in overweight individuals;
LUSC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg15704280	chr7:45808275	SEPT13	-0.91	-13.24	-0.59	1.93e-32	Coronary artery disease;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg19995800	chr19:45873596	ERCC2	0.44	5.99	0.31	5.54e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.78	-12.94	-0.58	2.53e-31	Aortic root size;
LUSC	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg00579200	chr11:133705235	NA	-0.39	-5.7	-0.3	2.58e-8	Childhood ear infection;
LUSC	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg15556689	chr8:8085844	FLJ10661	0.57	8.71	0.43	1.39e-16	Neuroticism;
LUSC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	0.97	13.23	0.59	2.1e-32	Eosinophil percentage of granulocytes;
LUSC	cis	rs8040855	0.599	rs4577058	chr15:85726458	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.82	0.35	4.25e-11	Bulimia nervosa;
LUSC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg04369109	chr6:150039330	LATS1	-0.57	-8.39	-0.42	1.37e-15	Lung cancer;
LUSC	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg21775007	chr8:11205619	TDH	-0.65	-10.26	-0.49	1.22e-21	Retinal vascular caliber;
LUSC	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg11266682	chr4:10021025	SLC2A9	0.47	8.43	0.42	1.06e-15	Bone mineral density;
LUSC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg10664184	chr19:17420304	DDA1	0.47	6.16	0.32	2.04e-9	Systemic lupus erythematosus;
LUSC	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg16558253	chr16:72132732	DHX38	-0.37	-5.92	-0.31	8.15e-9	Fibrinogen levels;
LUSC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg02167203	chr6:41068553	NFYA;LOC221442	-0.43	-6.59	-0.34	1.75e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20307385	chr11:47447363	PSMC3	0.43	5.78	0.3	1.72e-8	Subjective well-being;
LUSC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg08859206	chr1:53392774	SCP2	-0.42	-6.86	-0.35	3.29e-11	Monocyte count;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04260258	chr11:65386128	PCNXL3	-0.38	-5.96	-0.31	6.41e-9	Asthma;
LUSC	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg16579770	chr16:72058938	DHODH	0.34	5.73	0.3	2.26e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg19920283	chr7:105172520	RINT1	0.6	6.35	0.33	7.01e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg21770322	chr7:97807741	LMTK2	0.41	7.12	0.36	6.82e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg26380479	chr7:97908229	NA	-0.28	-6.08	-0.32	3.21e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg08601574	chr20:25228251	PYGB	0.38	5.81	0.3	1.48e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8016982	0.634	rs1035948	chr14:81682392	C/T	cg01989461	chr14:81687754	GTF2A1	0.73	13.22	0.59	2.28e-32	Schizophrenia;
LUSC	cis	rs13223928	0.592	rs4722439	chr7:3155858	C/T	cg19214707	chr7:3157722	NA	0.43	8.85	0.44	5.38e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.18	-0.52	7.38e-25	Mean corpuscular volume;
LUSC	cis	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg05299278	chr17:33885742	SLFN14	0.3	6.49	0.33	3.01e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg25456477	chr12:86230367	RASSF9	0.44	7.73	0.39	1.29e-13	Major depressive disorder;
LUSC	cis	rs5758265	1	rs5758265	chr22:41617897	G/A	cg03806693	chr22:41940476	POLR3H	-0.5	-6.94	-0.36	2e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg00990874	chr7:1149470	C7orf50	0.62	8.28	0.41	2.96e-15	Bronchopulmonary dysplasia;
LUSC	trans	rs7833787	0.759	rs4921964	chr8:18679795	A/C	cg25885280	chr11:70760166	SHANK2	0.26	6.45	0.33	3.9e-10	Obesity-related traits;
LUSC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg23791538	chr6:167370224	RNASET2	-0.39	-6.05	-0.31	3.94e-9	Crohn's disease;
LUSC	cis	rs184065563	1	rs184065563	chr6:45144224	G/A	cg18551225	chr6:44695536	NA	-0.42	-6.96	-0.36	1.84e-11	Total body bone mineral density (age over 60);Total body bone mineral density;
LUSC	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg27490568	chr2:178487706	NA	-0.47	-6.77	-0.35	5.63e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.73	0.47	7.14e-20	Bipolar disorder;
LUSC	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg13755796	chr4:20253514	NA	-0.42	-6.61	-0.34	1.55e-10	Life satisfaction;
LUSC	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.85	-0.35	3.48e-11	Morning vs. evening chronotype;
LUSC	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg02527881	chr3:46936655	PTH1R	0.41	7.02	0.36	1.22e-11	Colorectal cancer;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg27094323	chr7:1216898	NA	-0.47	-8.42	-0.42	1.11e-15	Longevity;Endometriosis;
LUSC	trans	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg18187862	chr3:45730750	SACM1L	0.52	6.84	0.35	3.74e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.36	-0.33	6.81e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-8.34	-0.41	2.03e-15	Breast cancer;
LUSC	cis	rs4964805	0.526	rs934845	chr12:104185257	T/G	cg02344784	chr12:104178138	NT5DC3	0.45	8.7	0.43	1.56e-16	Attention deficit hyperactivity disorder;
LUSC	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.75	-0.6	2.03e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg08807101	chr21:30365312	RNF160	-0.67	-10.46	-0.5	2.35e-22	Pancreatic cancer;
LUSC	cis	rs7815909	0.609	rs6474057	chr8:57209655	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.79	0.39	8.63e-14	Height;
LUSC	cis	rs11166629	0.502	rs2467030	chr8:135665361	A/G	cg27224718	chr8:135614730	ZFAT	0.49	7.38	0.37	1.28e-12	Smoking quantity;
LUSC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg15448220	chr1:150897856	SETDB1	0.41	6.18	0.32	1.84e-9	Melanoma;
LUSC	cis	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg05299278	chr17:33885742	SLFN14	0.3	6.55	0.34	2.14e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.78	-10.7	-0.51	3.54e-23	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-6.78	-0.35	5.61e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg19077165	chr18:44547161	KATNAL2	-0.4	-6.06	-0.31	3.63e-9	Personality dimensions;
LUSC	cis	rs4786125	0.665	rs1873704	chr16:6907021	C/G	cg03623568	chr16:6915990	A2BP1	-0.5	-8.02	-0.4	1.8e-14	Heart rate variability traits (SDNN);
LUSC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg02423579	chr7:2872169	GNA12	-0.43	-5.96	-0.31	6.52e-9	Height;
LUSC	cis	rs11229555	0.645	rs7929028	chr11:58188258	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg03433033	chr1:76189801	ACADM	-0.45	-6.81	-0.35	4.64e-11	Daytime sleep phenotypes;
LUSC	trans	rs4811340	0.562	rs4809911	chr20:51178696	G/T	cg15736553	chr3:11610338	VGLL4	-0.33	-5.95	-0.31	6.7e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg14440974	chr22:39074834	NA	-0.38	-6.37	-0.33	6.21e-10	Menopause (age at onset);
LUSC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.08	-0.36	8.53e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11209185	0.509	rs2419044	chr1:68421087	C/T	cg22082780	chr1:68452167	NA	0.42	6.62	0.34	1.45e-10	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-8.63	-0.43	2.48e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs6942756	1.000	rs2402945	chr7:128956256	C/A	cg02491457	chr7:128862824	NA	-0.47	-6.31	-0.33	9.1e-10	White matter hyperintensity burden;
LUSC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	1.03	17.97	0.7	5.47e-51	Testicular germ cell tumor;
LUSC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg16434002	chr17:42200994	HDAC5	-0.46	-6.43	-0.33	4.32e-10	Total body bone mineral density;
LUSC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg16606324	chr3:10149918	C3orf24	0.59	8.55	0.42	4.49e-16	Alzheimer's disease;
LUSC	cis	rs7147624	0.573	rs10148699	chr14:66199662	G/A	cg03016385	chr14:66212404	NA	-0.78	-8.29	-0.41	2.79e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4589502	1.000	rs75502100	chr15:67131417	T/C	cg12317470	chr15:67143691	NA	0.67	6.02	0.31	4.6e-9	Lung cancer (smoking interaction);
LUSC	trans	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.53	-0.34	2.39e-10	Bladder cancer;
LUSC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-7.74	-0.39	1.17e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs629535	0.911	rs490165	chr8:70014976	A/G	cg21567404	chr3:27674614	NA	-0.95	-15.49	-0.65	3.59e-41	Dupuytren's disease;
LUSC	cis	rs73206853	0.764	rs73191812	chr12:110910279	G/A	cg12870014	chr12:110450643	ANKRD13A	0.67	6.47	0.33	3.57e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg09359103	chr1:154839909	KCNN3	-0.71	-16.53	-0.67	2.9e-45	Prostate cancer;
LUSC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs4363385	0.818	rs684305	chr1:153006242	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.45e-8	Inflammatory skin disease;
LUSC	cis	rs7577696	0.606	rs212747	chr2:32414704	A/G	cg02381751	chr2:32503542	YIPF4	0.54	7.16	0.36	5.15e-12	Inflammatory biomarkers;
LUSC	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg00012203	chr2:219082015	ARPC2	0.58	9.7	0.47	9.04e-20	Ulcerative colitis;
LUSC	cis	rs7712401	0.601	rs30047	chr5:122270524	G/A	cg19077854	chr5:122220652	SNX24	0.41	8.94	0.44	2.64e-17	Mean platelet volume;
LUSC	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	0.58	9.25	0.45	2.71e-18	Breast cancer;
LUSC	cis	rs9309473	1.000	rs7582606	chr2:73813945	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.49	-0.33	3.18e-10	Metabolite levels;
LUSC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.41	6.06	0.31	3.6e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg14092571	chr14:90743983	NA	-0.35	-5.71	-0.3	2.45e-8	Mortality in heart failure;
LUSC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg02580895	chr19:2754563	NA	-0.47	-7.1	-0.36	7.55e-12	Total cholesterol levels;
LUSC	trans	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg10756647	chr7:56101905	PSPH	0.85	8.29	0.41	2.87e-15	Diabetic kidney disease;
LUSC	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg27467552	chr22:50353597	PIM3	-0.41	-7.08	-0.36	8.64e-12	Ulcerative colitis;
LUSC	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.26e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6580649	0.831	rs1635528	chr12:48395900	C/T	cg05342945	chr12:48394962	COL2A1	-0.43	-5.69	-0.3	2.73e-8	Lung cancer;
LUSC	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg27490568	chr2:178487706	NA	0.38	5.77	0.3	1.84e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2737618	0.674	rs2821332	chr1:200085714	A/T	cg21825944	chr1:200113062	NR5A2	-0.31	-5.92	-0.31	8.19e-9	Uric acid levels;
LUSC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.96	0.36	1.86e-11	Aortic root size;
LUSC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.34	0.59	7.64e-33	Platelet count;
LUSC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-7.22	-0.37	3.59e-12	Total body bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05238905	chr6:149867353	PPIL4	-0.5	-7.51	-0.38	5.41e-13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.97	-0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	13.76	0.6	1.96e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.67	0.3	3.13e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs950881	0.932	rs13431828	chr2:102954653	C/T	cg20060108	chr2:102954350	IL1RL1	0.45	5.9	0.31	8.86e-9	Allergy;
LUSC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	6.86	0.35	3.43e-11	Multiple sclerosis;
LUSC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg25456477	chr12:86230367	RASSF9	0.4	7.08	0.36	8.54e-12	Major depressive disorder;
LUSC	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg12552261	chr5:112820674	MCC	0.44	7.07	0.36	8.94e-12	Type 2 diabetes;
LUSC	trans	rs1864729	0.688	rs1476132	chr8:98305993	A/G	cg08679828	chr8:102218111	ZNF706	-0.8	-6.54	-0.34	2.37e-10	Estradiol plasma levels (breast cancer);
LUSC	cis	rs243505	0.528	rs6977453	chr7:148474746	A/G	cg09806900	chr7:148480153	CUL1	0.65	9.75	0.47	6.21e-20	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7129220	0.858	rs7930218	chr11:10234712	G/T	cg06252276	chr11:34852392	NA	-0.55	-5.96	-0.31	6.49e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg17173187	chr15:85201210	NMB	0.37	6.37	0.33	6.23e-10	Schizophrenia;
LUSC	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg11473876	chr11:109292803	C11orf87	0.41	6.58	0.34	1.78e-10	Schizophrenia;
LUSC	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg13010199	chr12:38710504	ALG10B	0.55	8.27	0.41	3.16e-15	Morning vs. evening chronotype;
LUSC	trans	rs890100	0.867	rs1978530	chr2:56743753	A/G	cg08299783	chr2:48920986	GTF2A1L;LHCGR	0.32	6.28	0.32	1.04e-9	Gut microbiome composition (summer);
LUSC	cis	rs7799006	0.606	rs34262822	chr7:2304275	C/T	cg08027265	chr7:2291960	NA	-0.62	-11.03	-0.52	2.55e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg22117172	chr7:91764530	CYP51A1	0.33	5.81	0.3	1.49e-8	Breast cancer;
LUSC	cis	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg27411982	chr8:10470053	RP1L1	0.49	7.8	0.39	8.18e-14	Neuroticism;
LUSC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.77	0.3	1.8e-8	Lung cancer;
LUSC	cis	rs7923609	0.905	rs10740129	chr10:65250808	G/A	cg01631684	chr10:65280961	REEP3	-0.42	-6.44	-0.33	4.07e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.25	-0.49	1.27e-21	Platelet count;
LUSC	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg18850127	chr7:39170497	POU6F2	0.41	5.98	0.31	5.62e-9	IgG glycosylation;
LUSC	cis	rs1864400	0.641	rs61845681	chr10:43733180	T/C	cg15436174	chr10:43711423	RASGEF1A	0.41	6.26	0.32	1.15e-9	Hirschsprung disease;
LUSC	trans	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg05839875	chr5:39203190	FYB	-0.32	-6.03	-0.31	4.39e-9	Prostate cancer;
LUSC	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg04362960	chr10:104952993	NT5C2	0.61	9.57	0.46	2.39e-19	Arsenic metabolism;
LUSC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.12	15.13	0.64	9.18e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-14.16	-0.61	5.52e-36	Monocyte count;
LUSC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.5	-6.84	-0.35	3.88e-11	Mean platelet volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08039701	chr5:74063125	NSA2;GFM2	-0.49	-6.36	-0.33	6.5e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg04508216	chr1:11107452	MASP2	0.31	5.67	0.3	3.17e-8	Body mass index;
LUSC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg11645453	chr3:52864694	ITIH4	0.35	7.97	0.4	2.5e-14	Bipolar disorder;
LUSC	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg18964960	chr10:1102726	WDR37	-0.45	-6.13	-0.32	2.54e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs2692947	0.727	rs1657502	chr2:96795608	A/C	cg23100626	chr2:96804247	ASTL	0.26	6.57	0.34	1.94e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.63	-7.79	-0.39	8.31e-14	Yeast infection;
LUSC	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg13683864	chr3:40499215	RPL14	-1.01	-16.92	-0.68	7.96e-47	Renal cell carcinoma;
LUSC	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg10167463	chr7:75959203	YWHAG	-0.65	-9.74	-0.47	6.73e-20	Multiple sclerosis;
LUSC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-6.18	-0.32	1.82e-9	Total body bone mineral density;
LUSC	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.26	0.45	2.47e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.38	-5.81	-0.3	1.47e-8	Myopia;
LUSC	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg25206134	chr2:45395956	NA	-0.54	-6.29	-0.33	9.78e-10	Bipolar disorder;
LUSC	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.61	0.65	1.27e-41	Bladder cancer;
LUSC	cis	rs6076065	0.748	rs999068	chr20:23376483	G/A	cg11657817	chr20:23433608	CST11	0.53	11.03	0.52	2.42e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg06212747	chr3:49208901	KLHDC8B	0.43	5.83	0.3	1.33e-8	Parkinson's disease;
LUSC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg27165867	chr14:105738592	BRF1	-0.5	-7.35	-0.37	1.57e-12	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25946216	chr14:74253857	C14orf43	-0.4	-6.11	-0.32	2.73e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg03188948	chr7:1209495	NA	0.61	7.25	0.37	2.85e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs1325195	0.920	rs2816210	chr1:179193932	C/T	cg11624085	chr17:8464688	MYH10	0.44	6.97	0.36	1.7e-11	IgE grass sensitization;
LUSC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9807989	0.507	rs1592458	chr2:103031749	A/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.72e-12	Asthma;
LUSC	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg08975724	chr8:8085496	FLJ10661	0.53	7.7	0.39	1.51e-13	Mood instability;
LUSC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg06219351	chr7:158114137	PTPRN2	0.49	8.86	0.44	4.81e-17	Calcium levels;
LUSC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg25036284	chr2:26402008	FAM59B	0.66	9.82	0.47	3.63e-20	Gut microbiome composition (summer);
LUSC	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	1.09	17.17	0.68	8.31e-48	Exhaled nitric oxide output;
LUSC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg22535103	chr8:58192502	C8orf71	-0.79	-8.06	-0.4	1.36e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg13334819	chr7:99746414	C7orf59	0.49	6.5	0.34	2.96e-10	Coronary artery disease;
LUSC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg14552801	chr7:65878734	NA	0.45	6.34	0.33	7.34e-10	Aortic root size;
LUSC	cis	rs2901656	0.875	rs7516301	chr1:172372260	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.29	5.65	0.3	3.43e-8	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg24375607	chr4:120327624	NA	0.78	11.69	0.54	1.1e-26	Corneal astigmatism;
LUSC	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg00405596	chr8:11794950	NA	0.35	5.76	0.3	1.88e-8	Myopia (pathological);
LUSC	cis	rs3770081	1.000	rs2303339	chr2:86346180	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	1.05	7.18	0.37	4.42e-12	Facial emotion recognition (sad faces);
LUSC	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg05163923	chr11:71159392	DHCR7	0.71	11.0	0.52	3.1e-24	Vitamin D levels;
LUSC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18357526	chr6:26021779	HIST1H4A	0.44	6.95	0.36	1.98e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg05621596	chr22:47072043	GRAMD4	-0.54	-8.62	-0.43	2.75e-16	Urate levels in obese individuals;
LUSC	trans	rs1941687	0.831	rs1353168	chr18:31359762	A/G	cg27147174	chr7:100797783	AP1S1	-0.48	-7.03	-0.36	1.14e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.74	-0.39	1.2e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.5	-0.46	4.34e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs17001868	0.892	rs73167023	chr22:40799954	T/C	cg07138101	chr22:40742427	ADSL	0.55	5.69	0.3	2.81e-8	Mammographic density (dense area);
LUSC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg15448220	chr1:150897856	SETDB1	0.43	6.22	0.32	1.45e-9	Melanoma;
LUSC	cis	rs4499344	0.526	rs8100915	chr19:33032310	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.8	-10.68	-0.5	4.31e-23	Mean platelet volume;
LUSC	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.07	20.81	0.75	2.88e-62	Cognitive ability;
LUSC	cis	rs11209002	0.614	rs7519768	chr1:67555522	C/T	cg02640540	chr1:67518911	SLC35D1	0.65	9.21	0.45	3.77e-18	Crohn's disease;
LUSC	cis	rs9815354	1.000	rs6768563	chr3:41865541	G/A	cg03022575	chr3:42003672	ULK4	0.59	6.57	0.34	1.97e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs12681287	0.752	rs4288357	chr8:87251833	C/T	cg27223183	chr8:87520930	FAM82B	-0.45	-5.76	-0.3	1.87e-8	Caudate activity during reward;
LUSC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg03209412	chr4:183728196	NA	0.46	7.05	0.36	1.04e-11	Pediatric autoimmune diseases;
LUSC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	cis	rs2359239	0.519	rs8007145	chr14:75185748	T/A	cg08847533	chr14:75593920	NEK9	0.48	6.92	0.35	2.36e-11	Neuroticism (multi-trait analysis);
LUSC	cis	rs7572644	0.766	rs13021285	chr2:28085347	T/C	cg27432699	chr2:27873401	GPN1	0.51	6.42	0.33	4.57e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9513627	1.000	rs73556172	chr13:100121684	A/G	cg25919922	chr13:100150906	NA	-0.8	-6.96	-0.36	1.83e-11	Obesity-related traits;
LUSC	cis	rs3744061	0.520	rs9908979	chr17:74645486	T/G	cg27546012	chr17:74684504	MXRA7	-0.38	-6.69	-0.34	9.45e-11	Retinal arteriolar caliber;
LUSC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.71	11.51	0.53	4.99e-26	Coronary artery disease;
LUSC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg18351406	chr4:77819688	ANKRD56	0.59	8.57	0.42	3.99e-16	Emphysema distribution in smoking;
LUSC	cis	rs1385374	0.858	rs11059927	chr12:129294333	T/C	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.8	-0.35	4.96e-11	Systemic lupus erythematosus;
LUSC	cis	rs394563	0.602	rs409099	chr6:149766863	T/G	cg11245181	chr6:149772854	ZC3H12D	-0.3	-6.57	-0.34	1.95e-10	Dupuytren's disease;
LUSC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06112835	chr11:68658793	MRPL21	0.48	7.51	0.38	5.32e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	10.84	0.51	1.13e-23	Prudent dietary pattern;
LUSC	cis	rs4363385	0.747	rs4240867	chr1:152954921	A/G	cg00922841	chr1:152955080	SPRR1A	0.44	7.89	0.4	4.36e-14	Inflammatory skin disease;
LUSC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg21293242	chr8:11204541	TDH	0.34	6.4	0.33	5.32e-10	Retinal vascular caliber;
LUSC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg18904891	chr8:8559673	CLDN23	0.55	7.56	0.38	3.95e-13	Obesity-related traits;
LUSC	cis	rs6688613	0.729	rs10918603	chr1:166936503	T/C	cg07049167	chr1:166818506	POGK	0.43	5.77	0.3	1.79e-8	Refractive astigmatism;
LUSC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	0.95	18.32	0.71	2.18e-52	Heart rate;
LUSC	cis	rs977987	0.843	rs6564259	chr16:75447393	T/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.62	-0.34	1.4e-10	Dupuytren's disease;
LUSC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg18538332	chr22:24372958	LOC391322	-0.4	-7.36	-0.37	1.45e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-1.04	-19.98	-0.74	5.38e-59	Height;
LUSC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg06740227	chr12:86229804	RASSF9	-0.44	-7.09	-0.36	7.89e-12	Major depressive disorder;
LUSC	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.89	0.66	9.43e-43	Bladder cancer;
LUSC	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg18721089	chr20:30220636	NA	-0.35	-5.94	-0.31	7.09e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-9.91	-0.48	1.88e-20	Chronic sinus infection;
LUSC	trans	rs11696501	0.739	rs4812933	chr20:44230792	C/A	cg03272292	chr12:48577362	C12orf68	0.52	6.1	0.32	2.87e-9	Brain structure;
LUSC	cis	rs12118280	0.581	rs545593	chr1:108720242	G/A	cg11967332	chr1:108735228	SLC25A24	-0.52	-6.79	-0.35	5.06e-11	Myeloid white cell count;
LUSC	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg24130564	chr14:104152367	KLC1	-0.5	-7.18	-0.37	4.49e-12	Body mass index;
LUSC	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.81	12.17	0.55	1.9e-28	Cognitive ability;
LUSC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg24130564	chr14:104152367	KLC1	-0.42	-6.15	-0.32	2.2e-9	Body mass index;
LUSC	cis	rs7246967	0.551	rs16998998	chr19:22911116	T/C	cg23217946	chr19:22817039	ZNF492	0.46	6.22	0.32	1.48e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21028142	chr17:79581711	NPLOC4	0.33	7.76	0.39	1.03e-13	Eye color traits;
LUSC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg00857998	chr1:205179979	DSTYK	0.6	9.06	0.44	1.11e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg06627628	chr2:24431161	ITSN2	0.59	8.49	0.42	6.83e-16	Asthma;
LUSC	cis	rs17014483	0.749	rs2924348	chr4:89632910	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.68	5.97	0.31	5.92e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7246967	0.673	rs4933017	chr19:22812980	T/C	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs3772130	1.000	rs2070180	chr3:121351338	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-9.56	-0.46	2.77e-19	Cognitive performance;
LUSC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.97	20.13	0.74	1.38e-59	Subjective well-being;
LUSC	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg17420585	chr12:42539391	GXYLT1	-0.38	-7.25	-0.37	2.94e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2282802	0.685	rs62385161	chr5:139635747	T/C	cg26211634	chr5:139558579	C5orf32	0.44	8.3	0.41	2.59e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.67	10.62	0.5	7.03e-23	Body mass index (adult);
LUSC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26314531	chr2:26401878	FAM59B	-0.73	-10.21	-0.49	1.79e-21	Gut microbiome composition (summer);
LUSC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs427941	0.632	rs201475	chr7:101745883	G/T	cg06246474	chr7:101738831	CUX1	0.39	6.42	0.33	4.68e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs41271473	1.000	rs41270189	chr1:228878888	C/T	cg10167378	chr1:228756711	NA	0.54	6.59	0.34	1.72e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg05347473	chr6:146136440	FBXO30	0.6	10.6	0.5	7.93e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-8.1	-0.41	1.03e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.96	0.31	6.45e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg20135002	chr11:47629003	NA	-0.46	-7.53	-0.38	4.77e-13	Subjective well-being;
LUSC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-6.15	-0.32	2.24e-9	Multiple sclerosis;
LUSC	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.05	-0.4	1.52e-14	Retinal vascular caliber;
LUSC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.43	0.33	4.51e-10	Obesity-related traits;
LUSC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg06784218	chr1:46089804	CCDC17	0.54	10.91	0.51	6.6e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg02038168	chr22:39784481	NA	-0.48	-7.81	-0.39	7.41e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs2463822	0.507	rs72919442	chr11:62028707	A/G	cg06239285	chr11:62104954	ASRGL1	-0.57	-5.81	-0.3	1.49e-8	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg00945038	chr17:61921165	SMARCD2	0.38	5.74	0.3	2.14e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg08847533	chr14:75593920	NEK9	-0.82	-15.11	-0.64	1.17e-39	Height;
LUSC	cis	rs6577655	0.517	rs2315835	chr8:135589854	A/G	cg17885191	chr8:135476712	NA	0.59	7.8	0.39	8.22e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg20203395	chr5:56204925	C5orf35	-0.6	-8.29	-0.41	2.7e-15	Initial pursuit acceleration;
LUSC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg13395646	chr4:1353034	KIAA1530	-0.8	-13.59	-0.6	8.35e-34	Obesity-related traits;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.87	-15.46	-0.65	4.84e-41	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12361290	chr11:129149358	NA	-0.52	-6.55	-0.34	2.16e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg16359550	chr11:109292809	C11orf87	0.37	6.37	0.33	6.29e-10	Schizophrenia;
LUSC	cis	rs2857891	0.817	rs2857901	chr11:6980511	A/G	cg14883916	chr11:6947541	ZNF215	0.45	5.83	0.3	1.29e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.71	-0.57	1.82e-30	Alzheimer's disease;
LUSC	cis	rs9341808	1.000	rs9341808	chr6:80953257	C/A	cg08355045	chr6:80787529	NA	0.51	8.94	0.44	2.7e-17	Sitting height ratio;
LUSC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg05347473	chr6:146136440	FBXO30	0.47	7.61	0.38	2.88e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.68	8.55	0.42	4.36e-16	Schizophrenia;
LUSC	cis	rs713477	0.631	rs7145182	chr14:55905231	C/G	cg13175173	chr14:55914753	NA	-0.29	-5.9	-0.31	8.84e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-0.89	-13.28	-0.59	1.29e-32	Asthma;
LUSC	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02176678	chr2:219576539	TTLL4	-0.74	-14.3	-0.62	1.62e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6545883	0.825	rs7578139	chr2:61564121	G/A	cg15711740	chr2:61764176	XPO1	0.42	6.54	0.34	2.32e-10	Tuberculosis;
LUSC	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg03522245	chr20:25566470	NINL	0.36	5.84	0.3	1.24e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.28	-0.37	2.45e-12	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg12856521	chr11:46389249	DGKZ	0.47	6.77	0.35	5.74e-11	Leprosy;
LUSC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg17724175	chr1:150552817	MCL1	0.37	6.79	0.35	5.02e-11	Tonsillectomy;
LUSC	trans	rs28647808	0.786	rs4962135	chr9:136256630	C/T	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.28	0.41	2.91e-15	Tonsillectomy;
LUSC	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.03	0.74	3.56e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg27411982	chr8:10470053	RP1L1	0.39	6.04	0.31	4.05e-9	Neuroticism;
LUSC	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg22875332	chr1:76189707	ACADM	-0.43	-6.54	-0.34	2.31e-10	Daytime sleep phenotypes;
LUSC	cis	rs3820928	0.874	rs10178731	chr2:227874232	C/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.26	-0.37	2.67e-12	Pulmonary function;
LUSC	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg14036092	chr11:66035641	RAB1B	-0.41	-5.86	-0.31	1.12e-8	Gout;
LUSC	trans	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg07817883	chr1:32538562	TMEM39B	-0.59	-7.32	-0.37	1.81e-12	Monocyte percentage of white cells;
LUSC	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg24375607	chr4:120327624	NA	-0.74	-11.04	-0.52	2.27e-24	Corneal astigmatism;
LUSC	cis	rs73195822	0.527	rs55728229	chr12:111169374	T/A	cg12870014	chr12:110450643	ANKRD13A	0.66	7.25	0.37	2.98e-12	Itch intensity from mosquito bite;
LUSC	cis	rs78545713	0.502	rs57145038	chr6:26311510	A/C	cg13736514	chr6:26305472	NA	-0.45	-5.9	-0.31	8.98e-9	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg21856205	chr7:94953877	PON1	-0.36	-5.72	-0.3	2.33e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg04733989	chr22:42467013	NAGA	0.56	8.64	0.43	2.4e-16	Schizophrenia;
LUSC	cis	rs11822910	0.737	rs2584858	chr11:57207077	C/T	cg00522883	chr11:57194120	SLC43A3	0.39	6.26	0.32	1.18e-9	Platelet distribution width;
LUSC	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg20587970	chr11:113659929	NA	-1.12	-15.37	-0.64	1.06e-40	Hip circumference adjusted for BMI;
LUSC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg06618935	chr21:46677482	NA	-0.4	-8.13	-0.41	8.35e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg16329650	chr2:213403929	ERBB4	0.86	18.45	0.71	6.91e-53	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4901869	0.902	rs2162491	chr14:59296247	C/T	cg02291164	chr14:59296302	NA	0.58	11.49	0.53	5.43e-26	Panic disorder;
LUSC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg09365446	chr1:150670422	GOLPH3L	0.47	6.82	0.35	4.25e-11	Melanoma;
LUSC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.59	-9.15	-0.45	5.96e-18	Pulmonary function;
LUSC	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.41	-0.38	1.04e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg05313129	chr8:58192883	C8orf71	-0.51	-5.7	-0.3	2.65e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg02493740	chr2:85810744	VAMP5	-0.33	-5.86	-0.31	1.08e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	1.04	19.54	0.73	3.11e-57	Menopause (age at onset);
LUSC	cis	rs2235649	0.704	rs1742425	chr16:1904524	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.46	-5.68	-0.3	2.98e-8	Blood metabolite levels;
LUSC	trans	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg03886242	chr7:26192032	NFE2L3	0.41	6.53	0.34	2.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg08085267	chr17:45401833	C17orf57	-0.44	-6.45	-0.33	3.95e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.68	0.34	9.71e-11	Menopause (age at onset);
LUSC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg09165964	chr15:75287851	SCAMP5	-1.01	-15.29	-0.64	2.16e-40	Blood trace element (Zn levels);
LUSC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.28e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19518452	chr22:21336528	LZTR1	-0.42	-6.08	-0.32	3.23e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg05623727	chr3:50126028	RBM5	0.34	6.39	0.33	5.71e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	0.97	13.24	0.59	1.84e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg24375607	chr4:120327624	NA	0.77	11.62	0.54	1.97e-26	Corneal astigmatism;
LUSC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg17264618	chr3:40429014	ENTPD3	0.3	6.12	0.32	2.65e-9	Renal cell carcinoma;
LUSC	cis	rs7572644	0.639	rs17006242	chr2:28001051	A/C	cg27432699	chr2:27873401	GPN1	-0.53	-6.95	-0.36	1.92e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg01528321	chr10:82214614	TSPAN14	0.82	12.42	0.56	2.14e-29	Post bronchodilator FEV1;
LUSC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg25039879	chr17:56429692	SUPT4H1	-0.65	-8.87	-0.44	4.54e-17	Cognitive test performance;
LUSC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg00677455	chr12:58241039	CTDSP2	0.59	7.92	0.4	3.64e-14	Multiple sclerosis;
LUSC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.45	-0.33	3.88e-10	Lung cancer;
LUSC	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs6684514	0.845	rs12138564	chr1:156291600	G/T	cg16558208	chr1:156270281	VHLL	0.36	5.76	0.3	1.9e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUSC	cis	rs2282802	0.685	rs2337082	chr5:139649201	G/A	cg26211634	chr5:139558579	C5orf32	0.44	8.14	0.41	7.78e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-1.0	-17.66	-0.69	9.05e-50	Body mass index;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26018965	chr1:183604789	ARPC5;RGL1	-0.49	-6.55	-0.34	2.24e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg24375607	chr4:120327624	NA	0.75	11.05	0.52	2.18e-24	Corneal astigmatism;
LUSC	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg04995722	chr7:26192034	NFE2L3	0.38	6.2	0.32	1.67e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs35484700	1	rs35484700	chr4:55498781	CG/C	cg18836493	chr4:55524333	KIT	-0.34	-5.68	-0.3	2.94e-8	White blood cell count;
LUSC	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.68	0.34	1.01e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg16339924	chr4:17578868	LAP3	0.54	8.0	0.4	2.03e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg05347473	chr6:146136440	FBXO30	0.46	7.99	0.4	2.16e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg08975724	chr8:8085496	FLJ10661	0.47	6.87	0.35	3.09e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2857891	0.862	rs957747	chr11:6966814	A/G	cg14883916	chr11:6947541	ZNF215	0.46	5.88	0.31	9.84e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg00531865	chr16:30841666	NA	-0.33	-5.92	-0.31	7.91e-9	Dementia with Lewy bodies;
LUSC	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg10596483	chr8:143751796	JRK	0.51	7.5	0.38	5.74e-13	Schizophrenia;
LUSC	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.37	-6.06	-0.31	3.76e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg20573242	chr4:122745356	CCNA2	0.66	10.54	0.5	1.26e-22	Type 2 diabetes;
LUSC	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg25233709	chr10:116636983	FAM160B1	0.37	6.56	0.34	2.09e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21240523	chr9:130965902	CIZ1;DNM1	0.45	6.82	0.35	4.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6424115	0.679	rs2267961	chr1:24071048	A/G	cg10978503	chr1:24200527	CNR2	-0.47	-9.36	-0.46	1.22e-18	Immature fraction of reticulocytes;
LUSC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	8.88	0.44	4.19e-17	Schizophrenia;
LUSC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg06453172	chr10:134556979	INPP5A	-0.49	-6.11	-0.32	2.78e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg26876637	chr1:152193138	HRNR	0.44	6.4	0.33	5.27e-10	Atopic dermatitis;
LUSC	cis	rs1941023	0.503	rs10792269	chr11:60117126	C/T	cg08716584	chr11:60157161	MS4A7	-0.59	-11.27	-0.52	3.41e-25	Congenital heart disease (maternal effect);
LUSC	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.62	-0.38	2.66e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.51	-9.4	-0.46	8.87e-19	Longevity;Endometriosis;
LUSC	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg21665744	chr7:39171113	POU6F2	0.44	6.78	0.35	5.34e-11	IgG glycosylation;
LUSC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.72	-10.13	-0.48	3.18e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg15704280	chr7:45808275	SEPT13	0.71	6.73	0.35	7.39e-11	Axial length;
LUSC	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg23711669	chr6:146136114	FBXO30	0.85	15.01	0.63	2.9e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.65	-12.27	-0.56	7.97e-29	Age-related hearing impairment;
LUSC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg06008330	chr7:65541103	ASL	-0.4	-6.24	-0.32	1.31e-9	Aortic root size;
LUSC	trans	rs10432489	0.708	rs4436925	chr2:181755933	T/C	cg04744134	chr19:8408128	KANK3	-0.8	-6.42	-0.33	4.8e-10	QT interval;
LUSC	cis	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg06521331	chr12:34319734	NA	0.37	6.3	0.33	9.33e-10	Morning vs. evening chronotype;
LUSC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg02018176	chr4:1364513	KIAA1530	0.51	8.83	0.44	5.97e-17	Obesity-related traits;
LUSC	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg22532475	chr10:104410764	TRIM8	-0.34	-7.55	-0.38	4.14e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg12963246	chr6:28129442	ZNF389	0.41	6.5	0.33	3e-10	Parkinson's disease;
LUSC	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.73	-12.85	-0.58	5.45e-31	White blood cell count (basophil);
LUSC	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.57	-7.5	-0.38	5.94e-13	Red cell distribution width;
LUSC	cis	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg06521331	chr12:34319734	NA	0.4	6.42	0.33	4.58e-10	Morning vs. evening chronotype;
LUSC	cis	rs4919087	0.926	rs10882884	chr10:99025611	T/A	cg25902810	chr10:99078978	FRAT1	0.46	6.57	0.34	1.9e-10	Monocyte count;
LUSC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.56	-8.62	-0.43	2.68e-16	Melanoma;
LUSC	cis	rs7173743	0.756	rs6495337	chr15:79125689	C/G	cg00540400	chr15:79124168	NA	-0.36	-6.29	-0.33	9.85e-10	Coronary artery disease;
LUSC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg00383909	chr3:49044727	WDR6	0.41	5.73	0.3	2.23e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg02527881	chr3:46936655	PTH1R	-0.39	-6.76	-0.35	6.22e-11	Colorectal cancer;
LUSC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-9.29	-0.45	2.08e-18	Monocyte percentage of white cells;
LUSC	cis	rs1113500	0.730	rs1777456	chr1:108588472	G/A	cg06207961	chr1:108661230	NA	-0.31	-5.95	-0.31	6.65e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg18402987	chr7:1209562	NA	0.71	7.66	0.39	2.03e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg03060546	chr3:49711283	APEH	0.74	12.1	0.55	3.54e-28	Resting heart rate;
LUSC	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg27284194	chr4:1044797	NA	0.59	8.97	0.44	2.1e-17	Recombination rate (females);
LUSC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg25036284	chr2:26402008	FAM59B	0.74	10.17	0.49	2.35e-21	Gut microbiome composition (summer);
LUSC	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg15704280	chr7:45808275	SEPT13	0.66	7.22	0.37	3.61e-12	Axial length;
LUSC	cis	rs757081	0.667	rs17473243	chr11:17266259	G/A	cg15432903	chr11:17409602	KCNJ11	-0.36	-5.75	-0.3	2.02e-8	Systolic blood pressure;
LUSC	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg00857998	chr1:205179979	DSTYK	0.59	8.87	0.44	4.36e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs62238980	0.614	rs118010731	chr22:32376308	G/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg18681998	chr4:17616180	MED28	0.86	15.61	0.65	1.18e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg04369109	chr6:150039330	LATS1	-0.54	-7.45	-0.38	8.03e-13	Lung cancer;
LUSC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.66	11.13	0.52	1.13e-24	Bone mineral density;
LUSC	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.88	-11.63	-0.54	1.74e-26	Mean corpuscular hemoglobin;
LUSC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg03929089	chr4:120376271	NA	-0.7	-8.57	-0.42	3.8e-16	Coronary artery disease;
LUSC	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-6.97	-0.36	1.67e-11	Neuroticism;
LUSC	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg16342193	chr10:102329863	NA	-0.35	-6.28	-0.32	1.08e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.94	-0.4	3.19e-14	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg11845111	chr2:191398756	TMEM194B	0.86	11.02	0.52	2.76e-24	Diastolic blood pressure;
LUSC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs4664304	0.772	rs6737904	chr2:160872526	G/C	cg23995753	chr2:160760732	LY75	-0.34	-6.4	-0.33	5.21e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.02	-0.36	1.21e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.69	-12.04	-0.55	5.48e-28	Prudent dietary pattern;
LUSC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.68	10.95	0.51	4.91e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7188861	0.689	rs12600282	chr16:11401866	G/T	cg00044050	chr16:11439710	C16orf75	0.6	6.49	0.33	3.19e-10	HDL cholesterol;
LUSC	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg22681709	chr2:178499509	PDE11A	-0.51	-9.14	-0.45	6.01e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg23034840	chr1:205782522	SLC41A1	0.66	9.67	0.47	1.12e-19	Menarche (age at onset);
LUSC	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg16230307	chr14:35515116	FAM177A1	0.76	9.35	0.46	1.32e-18	Psoriasis;
LUSC	cis	rs12545109	0.879	rs2609994	chr8:57365844	A/G	cg09654669	chr8:57350985	NA	-0.57	-7.46	-0.38	7.7e-13	Obesity-related traits;
LUSC	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.77	-12.39	-0.56	2.84e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4566357	0.615	rs3769645	chr2:227913717	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.2	-0.41	5.4e-15	Coronary artery disease;
LUSC	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg19628046	chr18:33552617	C18orf21	0.52	6.29	0.33	9.87e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.62	-5.75	-0.3	2.07e-8	Narcolepsy;
LUSC	cis	rs34638657	0.732	rs11866711	chr16:82201038	A/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.33	-0.33	7.89e-10	Lung adenocarcinoma;
LUSC	cis	rs7605827	0.930	rs10189403	chr2:15635664	T/A	cg19274914	chr2:15703543	NA	0.47	9.12	0.45	7.34e-18	Educational attainment (years of education);
LUSC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg12963246	chr6:28129442	ZNF389	0.52	7.17	0.37	4.94e-12	Depression;
LUSC	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg09238746	chr17:78121135	EIF4A3	-0.65	-9.94	-0.48	1.47e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs6967385	0.604	rs10258470	chr7:12331516	A/G	cg20607287	chr7:12443886	VWDE	0.37	5.82	0.3	1.38e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg08847533	chr14:75593920	NEK9	-0.84	-14.99	-0.63	3.37e-39	Height;
LUSC	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg19592336	chr6:28129416	ZNF389	0.44	5.87	0.31	1.04e-8	Parkinson's disease;
LUSC	cis	rs9549260	0.569	rs117615233	chr13:41309223	G/A	cg21288729	chr13:41239152	FOXO1	0.56	6.2	0.32	1.71e-9	Red blood cell count;
LUSC	cis	rs7179456	0.593	rs514049	chr15:59042363	A/C	cg05156742	chr15:59063176	FAM63B	-0.49	-7.62	-0.38	2.63e-13	Asperger disorder;
LUSC	cis	rs1983891	0.954	rs1886816	chr6:41544494	A/G	cg20194872	chr6:41519635	FOXP4	0.37	6.49	0.33	3.11e-10	Prostate cancer;
LUSC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.72	11.26	0.52	3.69e-25	Aortic root size;
LUSC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg13607699	chr17:42295918	UBTF	0.52	8.23	0.41	4.32e-15	Total body bone mineral density;
LUSC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg23711669	chr6:146136114	FBXO30	0.87	16.09	0.66	1.53e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg02696742	chr7:106810147	HBP1	-0.63	-9.66	-0.47	1.24e-19	Coronary artery disease;
LUSC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-9.62	-0.47	1.75e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs16910800	0.731	rs16910759	chr11:23192131	C/G	cg20040320	chr11:23191996	NA	-0.59	-7.63	-0.39	2.4e-13	Cancer;
LUSC	trans	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.99	-0.31	5.47e-9	Dementia with Lewy bodies;
LUSC	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg20991723	chr1:152506922	NA	0.51	9.74	0.47	6.76e-20	Hair morphology;
LUSC	cis	rs4631830	0.812	rs11593361	chr10:51539156	A/G	cg16070123	chr10:51489643	NA	-0.48	-7.57	-0.38	3.59e-13	Prostate-specific antigen levels;
LUSC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-7.46	-0.38	7.72e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.48	7.93	0.4	3.26e-14	Alcohol dependence;
LUSC	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs6545883	0.826	rs2694617	chr2:61537214	G/A	cg15711740	chr2:61764176	XPO1	0.44	6.92	0.35	2.3e-11	Tuberculosis;
LUSC	cis	rs1790761	0.967	rs1790753	chr11:67201008	C/T	cg24690094	chr11:67383802	NA	-0.32	-6.03	-0.31	4.35e-9	Mean corpuscular volume;
LUSC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.45	6.16	0.32	2.15e-9	Renal function-related traits (BUN);
LUSC	cis	rs11048434	0.761	rs12827988	chr12:9130287	A/G	cg13575925	chr12:9217583	LOC144571	0.34	6.18	0.32	1.92e-9	Sjögren's syndrome;
LUSC	cis	rs7264396	1.000	rs224409	chr20:34124920	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.37	-0.37	1.31e-12	Total cholesterol levels;
LUSC	cis	rs7315438	0.629	rs4767324	chr12:115920020	A/T	cg24172291	chr12:115889509	NA	-0.34	-5.67	-0.3	3.17e-8	Colorectal cancer;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03633073	chr16:89437518	ANKRD11	-0.34	-5.97	-0.31	5.9e-9	Asthma;
LUSC	cis	rs7315438	0.560	rs12829606	chr12:115889424	G/A	cg24172291	chr12:115889509	NA	-0.37	-6.25	-0.32	1.22e-9	Colorectal cancer;
LUSC	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg18825076	chr15:78729989	IREB2	-0.45	-6.13	-0.32	2.53e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg03563238	chr19:33554763	RHPN2	-0.41	-6.56	-0.34	2.09e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs5758511	0.773	rs9680671	chr22:42351477	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.46	-5.7	-0.3	2.68e-8	Birth weight;
LUSC	cis	rs76419734	0.510	rs2553461	chr4:106731410	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.57	-6.56	-0.34	2.05e-10	Post bronchodilator FEV1;
LUSC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.09	-0.36	8.28e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.67	10.61	0.5	7.13e-23	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg08645402	chr16:4508243	NA	0.52	8.82	0.43	6.66e-17	Schizophrenia;
LUSC	cis	rs12532214	0.724	rs79042841	chr7:3160660	T/C	cg19214707	chr7:3157722	NA	-0.48	-7.65	-0.39	2.13e-13	Itch intensity from mosquito bite;
LUSC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.57	-10.13	-0.48	3.24e-21	Extrinsic epigenetic age acceleration;
LUSC	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.23	-0.41	4.17e-15	Systolic blood pressure;
LUSC	cis	rs7178572	0.568	rs11854193	chr15:77458136	C/A	cg22256960	chr15:77711686	NA	-0.5	-7.95	-0.4	2.97e-14	Type 2 diabetes;
LUSC	cis	rs273573	1.000	rs273559	chr11:30923223	C/T	cg14844989	chr11:31128820	NA	0.36	5.72	0.3	2.34e-8	Total body bone mineral density;
LUSC	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg11502198	chr6:26597334	ABT1	0.7	11.83	0.54	3.39e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs7804356	1.000	rs10236221	chr7:26884671	A/T	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg26102564	chr10:131424627	MGMT	0.36	5.69	0.3	2.74e-8	Response to temozolomide;
LUSC	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg18232548	chr7:50535776	DDC	-0.45	-6.42	-0.33	4.65e-10	Systemic sclerosis;
LUSC	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg20991723	chr1:152506922	NA	0.54	10.25	0.49	1.33e-21	Hair morphology;
LUSC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg01416388	chr22:39784598	NA	-0.41	-6.82	-0.35	4.25e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.17	0.37	4.94e-12	Cognitive ability;
LUSC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg06238570	chr21:40685208	BRWD1	-0.6	-10.13	-0.48	3.39e-21	Cognitive function;
LUSC	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg09876464	chr15:85330779	ZNF592	0.36	6.77	0.35	5.7e-11	P wave terminal force;
LUSC	cis	rs73416724	1.000	rs4714675	chr6:43287893	T/C	cg26312998	chr6:43337775	ZNF318	-0.54	-6.27	-0.32	1.11e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg13206674	chr6:150067644	NUP43	0.55	8.15	0.41	7.32e-15	Lung cancer;
LUSC	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00321850	chr1:175162397	KIAA0040	-0.45	-7.72	-0.39	1.39e-13	Alcohol dependence;
LUSC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg25019033	chr10:957182	NA	-0.5	-6.45	-0.33	4.01e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.93	15.98	0.66	4.19e-43	Morning vs. evening chronotype;
LUSC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg06238570	chr21:40685208	BRWD1	0.47	7.38	0.37	1.27e-12	Cognitive function;
LUSC	cis	rs6845621	0.901	rs7684274	chr4:18920249	C/A	cg12196642	chr4:18937545	NA	-0.36	-6.76	-0.35	6.11e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg21724239	chr8:58056113	NA	0.77	9.21	0.45	3.76e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	10.56	0.5	1.14e-22	Cognitive test performance;
LUSC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg12863693	chr15:85201151	NMB	-0.26	-5.78	-0.3	1.67e-8	P wave terminal force;
LUSC	cis	rs2901656	0.967	rs4916186	chr1:172396020	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.31	6.13	0.32	2.44e-9	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg20016023	chr10:99160130	RRP12	-0.33	-8.1	-0.41	1.04e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs80282103	0.764	rs7093915	chr10:1107341	A/G	cg18964960	chr10:1102726	WDR37	-0.67	-6.17	-0.32	1.95e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00149659	chr3:10157352	C3orf10	0.91	13.04	0.58	1.03e-31	Alzheimer's disease;
LUSC	cis	rs2455601	1.000	rs11042114	chr11:8919889	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-7.85	-0.39	5.64e-14	Schizophrenia;
LUSC	cis	rs7614311	0.731	rs56263032	chr3:63863022	G/A	cg22134162	chr3:63841271	THOC7	-0.49	-6.07	-0.32	3.43e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.86	15.58	0.65	1.6e-41	Menarche (age at onset);
LUSC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg03036452	chr22:46663545	TTC38	0.54	5.89	0.31	9.38e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24531977	chr5:56204891	C5orf35	-0.8	-11.83	-0.54	3.29e-27	Coronary artery disease;
LUSC	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg27411982	chr8:10470053	RP1L1	0.49	7.32	0.37	1.82e-12	Neuroticism;
LUSC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-6.9	-0.35	2.59e-11	Alzheimer's disease (late onset);
LUSC	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg18357645	chr12:58087776	OS9	0.55	8.34	0.42	1.95e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7760949	0.963	rs1330117	chr6:13920926	C/T	cg27413430	chr6:13925136	RNF182	0.54	8.04	0.4	1.58e-14	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.68	-0.43	1.75e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg18681998	chr4:17616180	MED28	0.77	13.88	0.6	6.68e-35	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	10.54	0.5	1.27e-22	Menopause (age at onset);
LUSC	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg09699651	chr6:150184138	LRP11	0.46	7.32	0.37	1.82e-12	Testicular germ cell tumor;
LUSC	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg13334819	chr7:99746414	C7orf59	-0.43	-5.82	-0.3	1.36e-8	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02622885	chr11:14913424	CYP2R1	0.42	6.09	0.32	3.12e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs57590327	0.503	rs13073613	chr3:81888512	C/A	cg07356753	chr3:81810745	GBE1	-0.65	-10.18	-0.49	2.19e-21	Extraversion;
LUSC	trans	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg13010199	chr12:38710504	ALG10B	0.4	6.31	0.33	8.95e-10	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	0.95	12.17	0.55	1.93e-28	Vitiligo;
LUSC	cis	rs6076065	0.723	rs8183442	chr20:23415563	C/T	cg11657817	chr20:23433608	CST11	0.41	7.31	0.37	1.98e-12	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg12311346	chr5:56204834	C5orf35	-0.61	-9.32	-0.45	1.66e-18	Coronary artery disease;
LUSC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.67	9.88	0.48	2.22e-20	Methadone dose in opioid dependence;
LUSC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg07701084	chr6:150067640	NUP43	0.55	8.19	0.41	5.63e-15	Lung cancer;
LUSC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.82	-0.3	1.42e-8	Parkinson's disease;
LUSC	cis	rs28655083	0.529	rs285019	chr16:77099450	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.42	6.73	0.35	7.57e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7189233	0.550	rs4783811	chr16:53483376	A/G	cg09728985	chr16:53543985	NA	-0.32	-6.04	-0.31	4.06e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg02269571	chr22:50332266	NA	0.78	8.46	0.42	8.77e-16	Schizophrenia;
LUSC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg16372103	chr5:203701	NA	0.44	5.77	0.3	1.76e-8	Breast cancer;
LUSC	cis	rs6732160	0.510	rs57825971	chr2:73384796	C/G	cg24220031	chr2:73402428	NA	-0.26	-6.05	-0.31	3.89e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18099408	chr3:52552593	STAB1	-0.4	-6.92	-0.35	2.26e-11	Bipolar disorder;
LUSC	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19096424	chr1:120255104	PHGDH	0.44	6.07	0.32	3.48e-9	Blood metabolite levels;
LUSC	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg12884169	chr21:40033163	ERG	0.61	12.48	0.56	1.35e-29	Coronary artery disease;
LUSC	trans	rs72674100	1.000	rs10027971	chr4:97967340	T/C	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg05805236	chr11:65401703	PCNXL3	0.41	6.87	0.35	3.16e-11	Acne (severe);
LUSC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg01802117	chr1:53393560	SCP2	-0.43	-7.25	-0.37	2.88e-12	Monocyte count;
LUSC	trans	rs1325195	0.881	rs2816185	chr1:179117740	C/T	cg11624085	chr17:8464688	MYH10	0.43	7.08	0.36	8.7e-12	IgE grass sensitization;
LUSC	cis	rs6669072	0.804	rs1307511	chr1:91312880	T/G	cg08895590	chr1:91227319	NA	0.33	7.14	0.36	5.72e-12	Cognitive function;
LUSC	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg05738196	chr6:26577821	NA	-0.52	-5.76	-0.3	1.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg23630131	chr7:65973040	NA	-0.2	-5.64	-0.3	3.55e-8	Aortic root size;
LUSC	trans	rs6601327	0.540	rs6982148	chr8:9581070	G/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.6	-0.34	1.57e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg00106254	chr7:1943704	MAD1L1	-0.41	-5.89	-0.31	9.36e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-6.98	-0.36	1.57e-11	Longevity;Endometriosis;
LUSC	trans	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.52	0.38	4.99e-13	Ulcerative colitis;
LUSC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg13395646	chr4:1353034	KIAA1530	0.58	8.88	0.44	4.07e-17	Obesity-related traits;
LUSC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg00945038	chr17:61921165	SMARCD2	0.4	6.07	0.32	3.45e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg20790798	chr5:1857306	NA	-0.49	-8.52	-0.42	5.68e-16	Cardiovascular disease risk factors;
LUSC	cis	rs9943753	0.508	rs2075433	chr12:109833920	A/G	cg19025524	chr12:109796872	NA	-0.38	-6.98	-0.36	1.59e-11	HDL cholesterol;
LUSC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg12463550	chr7:65579703	CRCP	0.57	8.49	0.42	6.88e-16	Aortic root size;
LUSC	trans	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg26811252	chr16:29126840	RRN3P2	0.57	9.03	0.44	1.41e-17	Menopause (age at onset);
LUSC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	0.51	8.17	0.41	6.59e-15	Uric acid clearance;
LUSC	cis	rs6960043	0.818	rs1974620	chr7:15065467	A/G	cg19272540	chr7:15055459	NA	0.28	6.93	0.35	2.15e-11	Type 2 diabetes;
LUSC	cis	rs644148	0.836	rs2686774	chr19:44999827	T/C	cg15540054	chr19:45004280	ZNF180	-0.63	-9.36	-0.46	1.18e-18	Personality dimensions;
LUSC	cis	rs12760731	0.565	rs12026482	chr1:178155861	G/A	cg00404053	chr1:178313656	RASAL2	0.66	6.8	0.35	4.85e-11	Obesity-related traits;
LUSC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg04362960	chr10:104952993	NT5C2	-0.52	-6.15	-0.32	2.23e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg22823121	chr1:150693482	HORMAD1	0.59	9.08	0.44	1e-17	Tonsillectomy;
LUSC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10802521	chr3:52805072	NEK4	-0.52	-8.38	-0.42	1.51e-15	Bipolar disorder;
LUSC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.7	9.11	0.45	7.86e-18	Menarche (age at onset);
LUSC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg16797656	chr11:68205561	LRP5	0.36	6.06	0.31	3.62e-9	Total body bone mineral density;
LUSC	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg19622623	chr12:86230825	RASSF9	-0.43	-6.03	-0.31	4.27e-9	Major depressive disorder;
LUSC	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg22467129	chr15:76604101	ETFA	-0.47	-7.24	-0.37	3.05e-12	Blood metabolite levels;
LUSC	cis	rs11997175	0.574	rs10954931	chr8:33631066	A/T	ch.8.33884649F	chr8:33765107	NA	0.52	8.52	0.42	5.64e-16	Body mass index;
LUSC	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg21775007	chr8:11205619	TDH	-0.65	-10.3	-0.49	9.02e-22	Retinal vascular caliber;
LUSC	trans	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.41	-0.33	4.96e-10	Blood trace element (Cu levels);
LUSC	cis	rs3772130	0.962	rs9822949	chr3:121541239	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	10.13	0.48	3.31e-21	Cognitive performance;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23624671	chr1:63833285	ALG6	-0.4	-5.98	-0.31	5.71e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-8.45	-0.42	9.32e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-1.01	-20.01	-0.74	4.04e-59	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg20821713	chr7:1055600	C7orf50	-0.46	-6.83	-0.35	4e-11	Bronchopulmonary dysplasia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13682704	chr9:131549543	TBC1D13	-0.42	-6.22	-0.32	1.51e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.06	-0.64	1.78e-39	Lymphocyte percentage of white cells;
LUSC	trans	rs6445525	1.000	rs6445525	chr3:65993104	C/G	cg12639933	chr12:57626296	SHMT2	-0.35	-6.34	-0.33	7.49e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	12.78	0.57	9.84e-31	Cognitive test performance;
LUSC	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg17691542	chr6:26056736	HIST1H1C	0.59	8.07	0.4	1.3e-14	Iron status biomarkers;
LUSC	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg04240660	chr16:89714849	CHMP1A	0.41	6.43	0.33	4.3e-10	Hemoglobin concentration;
LUSC	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg00564555	chr16:1970112	NA	0.37	6.36	0.33	6.54e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12799349	chr18:9475500	RALBP1	-0.53	-6.18	-0.32	1.88e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.84	12.97	0.58	1.93e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6433857	0.536	rs1901750	chr2:181350739	C/T	cg23363182	chr2:181467187	NA	-0.44	-7.18	-0.37	4.61e-12	Body mass index;
LUSC	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.92	15.51	0.65	2.92e-41	Bladder cancer;
LUSC	cis	rs714027	1.000	rs2412975	chr22:30540590	T/C	cg11564601	chr22:30592435	NA	-0.37	-6.81	-0.35	4.67e-11	Lymphocyte counts;
LUSC	cis	rs2324229	0.927	rs1180195	chr6:83960862	C/T	cg08257003	chr6:84140564	ME1	0.31	7.07	0.36	8.83e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg08859206	chr1:53392774	SCP2	-0.54	-9.02	-0.44	1.47e-17	Monocyte count;
LUSC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg23102388	chr7:1867652	MAD1L1	-0.32	-5.81	-0.3	1.5e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs597583	0.664	rs4936384	chr11:117398591	C/T	cg27161313	chr11:117392002	DSCAML1	-0.43	-7.2	-0.37	3.96e-12	Putamen volume;
LUSC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg25319279	chr11:5960081	NA	-0.41	-5.72	-0.3	2.4e-8	DNA methylation (variation);
LUSC	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.69	-11.18	-0.52	7.13e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.6	-0.43	3.2e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs7980799	0.649	rs1994135	chr12:33682405	T/C	cg26384229	chr12:38710491	ALG10B	0.53	7.63	0.39	2.44e-13	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg03465714	chr1:152285911	FLG	-0.41	-5.71	-0.3	2.54e-8	Atopic dermatitis;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg02773601	chr12:57623994	SHMT2	-0.5	-6.22	-0.32	1.49e-9	Neuroticism;
LUSC	cis	rs4851254	0.660	rs74340261	chr2:100696827	C/T	cg07810366	chr2:100720526	AFF3	-0.45	-6.02	-0.31	4.59e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9400467	0.528	rs455726	chr6:111699368	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg20283391	chr11:68216788	NA	-0.6	-8.41	-0.42	1.24e-15	Total body bone mineral density;
LUSC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg16423285	chr20:60520624	NA	0.63	8.06	0.4	1.35e-14	Body mass index;
LUSC	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.35e-12	Asthma (childhood onset);
LUSC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24838063	chr12:130822603	PIWIL1	-0.63	-10.05	-0.48	6.13e-21	Menopause (age at onset);
LUSC	cis	rs2692947	0.832	rs4907212	chr2:96410048	T/A	cg22654517	chr2:96458247	NA	0.37	7.48	0.38	6.63e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4443100	0.670	rs9612225	chr22:23406619	G/A	cg21100191	chr22:23484243	RTDR1	0.56	7.07	0.36	9e-12	Serum parathyroid hormone levels;
LUSC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg12310025	chr6:25882481	NA	-0.48	-8.98	-0.44	2.06e-17	Blood metabolite levels;
LUSC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg15649852	chr7:65879115	NA	0.42	5.85	0.31	1.15e-8	Aortic root size;
LUSC	trans	rs800082	0.698	rs1178943	chr3:144391772	T/G	cg24215973	chr2:240111563	HDAC4	-0.72	-10.41	-0.49	3.63e-22	Smoking behavior;
LUSC	cis	rs9434723	0.844	rs2268174	chr1:9300668	C/A	cg04199779	chr1:9294473	H6PD	0.51	6.02	0.31	4.5e-9	Height;
LUSC	cis	rs1461503	0.932	rs56778812	chr11:122840491	C/T	cg27398637	chr11:122830231	C11orf63	-0.41	-6.54	-0.34	2.29e-10	Menarche (age at onset);
LUSC	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-10.5	-0.5	1.71e-22	Bladder cancer;
LUSC	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg16342193	chr10:102329863	NA	-0.36	-6.19	-0.32	1.74e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs17030434	0.953	rs12639885	chr4:154700374	G/A	cg14289246	chr4:154710475	SFRP2	-0.51	-6.64	-0.34	1.28e-10	Electrocardiographic conduction measures;
LUSC	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.2	-0.49	1.9e-21	Eye color traits;
LUSC	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg02493740	chr2:85810744	VAMP5	0.32	5.72	0.3	2.43e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg02782426	chr3:40428986	ENTPD3	0.39	7.43	0.38	9.35e-13	Renal cell carcinoma;
LUSC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg27631724	chr1:11040367	C1orf127	0.56	10.92	0.51	6.1e-24	Ewing sarcoma;
LUSC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.88	14.1	0.61	9.28e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs62400317	0.723	rs1329709	chr6:44974956	G/T	cg18551225	chr6:44695536	NA	-0.43	-6.89	-0.35	2.83e-11	Total body bone mineral density;
LUSC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg25258033	chr6:167368657	RNASET2	0.47	7.42	0.38	9.92e-13	Crohn's disease;
LUSC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg24675658	chr1:53192096	ZYG11B	0.75	12.88	0.58	4.33e-31	Monocyte count;
LUSC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg04267008	chr7:1944627	MAD1L1	-0.46	-6.97	-0.36	1.74e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1950626	0.743	rs1956734	chr14:101399830	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.35	-6.31	-0.33	8.91e-10	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg12463550	chr7:65579703	CRCP	0.45	6.71	0.34	8.11e-11	Aortic root size;
LUSC	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg20744362	chr22:50050164	C22orf34	0.35	6.29	0.33	9.69e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.84	0.3	1.21e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg16049864	chr8:95962084	TP53INP1	-0.68	-13.49	-0.59	2.08e-33	Type 2 diabetes;
LUSC	cis	rs7191700	0.836	rs28502009	chr16:11426541	G/A	cg00044050	chr16:11439710	C16orf75	0.58	8.55	0.42	4.56e-16	Multiple sclerosis;
LUSC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg15605315	chr1:45957053	TESK2	0.5	8.48	0.42	7.48e-16	High light scatter reticulocyte count;
LUSC	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.09	-16.28	-0.67	2.81e-44	Uric acid levels;
LUSC	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg11344533	chr11:111475393	SIK2	-0.49	-6.66	-0.34	1.14e-10	Primary sclerosing cholangitis;
LUSC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg14696996	chr19:15285081	NOTCH3	0.96	8.62	0.43	2.65e-16	Pulse pressure;
LUSC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg05805236	chr11:65401703	PCNXL3	-0.38	-5.79	-0.3	1.62e-8	Breast cancer;
LUSC	trans	rs4714291	0.802	rs911818	chr6:39988816	C/A	cg02267698	chr19:7991119	CTXN1	-0.53	-7.85	-0.39	5.68e-14	Strep throat;
LUSC	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg20991723	chr1:152506922	NA	-0.51	-9.57	-0.46	2.46e-19	Hair morphology;
LUSC	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg26924012	chr15:45694286	SPATA5L1	0.78	12.36	0.56	3.65e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg24110177	chr3:50126178	RBM5	-0.42	-6.7	-0.34	9e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg16989719	chr2:238392110	NA	-0.4	-6.89	-0.35	2.76e-11	Prostate cancer;
LUSC	cis	rs1322512	0.917	rs2758769	chr6:152986717	G/A	cg27316956	chr6:152958899	SYNE1	0.37	6.32	0.33	8.37e-10	Tonometry;
LUSC	trans	rs1949829	0.826	rs4947595	chr7:51537062	G/T	cg20941110	chr15:83953819	BNC1	0.55	6.01	0.31	4.98e-9	Wegener's granulomatosis;
LUSC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.08	-0.4	1.22e-14	Longevity;
LUSC	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg13755796	chr4:20253514	NA	-0.41	-6.4	-0.33	5.28e-10	Life satisfaction;
LUSC	cis	rs9818941	0.824	rs9838352	chr3:157760461	C/A	cg08654915	chr3:157813417	NA	-0.32	-7.49	-0.38	6.2e-13	Height;
LUSC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg06521852	chr22:38141419	TRIOBP	0.41	6.16	0.32	2.04e-9	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg22029157	chr1:209979665	IRF6	-0.78	-9.37	-0.46	1.13e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg03146154	chr1:46216737	IPP	0.56	8.39	0.42	1.39e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg03522245	chr20:25566470	NINL	0.36	5.88	0.31	9.79e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.59	-0.34	1.73e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-9.27	-0.45	2.38e-18	Bone mineral density;
LUSC	trans	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg25214090	chr10:38739885	LOC399744	0.45	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg22800045	chr5:56110881	MAP3K1	0.77	9.96	0.48	1.24e-20	Initial pursuit acceleration;
LUSC	cis	rs977987	0.872	rs4887825	chr16:75472422	C/A	cg03315344	chr16:75512273	CHST6	0.5	9.65	0.47	1.32e-19	Dupuytren's disease;
LUSC	trans	rs1486139	0.967	rs13234885	chr7:46290701	C/A	cg17534202	chr9:96721102	NA	-0.37	-6.63	-0.34	1.3100000000000001e-10	Select biomarker traits;
LUSC	cis	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg03522245	chr20:25566470	NINL	0.35	5.67	0.3	3.12e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg25237894	chr2:233734115	C2orf82	-0.37	-6.93	-0.35	2.18e-11	Coronary artery disease;
LUSC	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg09537434	chr19:41945824	ATP5SL	-0.87	-15.12	-0.64	1.01e-39	Height;
LUSC	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.82	-0.35	4.35e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg10483660	chr13:112241077	NA	-0.31	-5.68	-0.3	3e-8	Hepatitis;
LUSC	cis	rs590121	0.830	rs615896	chr11:75275301	T/C	cg26104986	chr11:75275303	SERPINH1	-0.28	-5.75	-0.3	2.02e-8	Coronary artery disease;
LUSC	cis	rs6500395	1.000	rs11076578	chr16:48714520	C/G	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg26893861	chr17:41843967	DUSP3	1.0	14.9	0.63	7.8e-39	Triglycerides;
LUSC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg08888203	chr3:10149979	C3orf24	0.64	8.98	0.44	2.07e-17	Alzheimer's disease;
LUSC	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg01416388	chr22:39784598	NA	-0.42	-6.89	-0.35	2.75e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6599077	0.802	rs17075717	chr3:40139432	G/C	cg13683864	chr3:40499215	RPL14	-0.52	-6.57	-0.34	1.94e-10	Sleep-related phenotypes;
LUSC	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.79	11.58	0.54	2.77e-26	Corneal astigmatism;
LUSC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg25456477	chr12:86230367	RASSF9	0.35	6.25	0.32	1.24e-9	Major depressive disorder;
LUSC	cis	rs2274273	1.000	rs7160110	chr14:55594635	A/G	cg04306507	chr14:55594613	LGALS3	0.57	13.06	0.58	9.13e-32	Protein biomarker;
LUSC	trans	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg10756647	chr7:56101905	PSPH	0.88	8.91	0.44	3.39e-17	Diabetic kidney disease;
LUSC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	22.61	0.78	2.65e-69	Prudent dietary pattern;
LUSC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08219700	chr8:58056026	NA	0.64	8.1	0.41	1.03e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs17597773	0.527	rs2484698	chr1:221086065	A/T	cg16008148	chr1:221062819	NA	-0.38	-6.97	-0.36	1.72e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9398803	0.865	rs2130603	chr6:126826819	A/C	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	2.02e-9	Male-pattern baldness;
LUSC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg03060546	chr3:49711283	APEH	0.73	11.98	0.55	9.72e-28	Resting heart rate;
LUSC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.47	-7.19	-0.37	4.2e-12	Vitiligo;
LUSC	cis	rs7580658	0.724	rs6712213	chr2:127998230	G/A	cg09760422	chr2:128146352	NA	-0.31	-6.86	-0.35	3.3e-11	Protein C levels;
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg04234412	chr22:24373322	LOC391322	-0.94	-16.72	-0.68	4.98e-46	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg03342759	chr3:160939853	NMD3	-0.44	-6.3	-0.33	9.36e-10	Parkinson's disease;
LUSC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-7.44	-0.38	8.71e-13	Chronic sinus infection;
LUSC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	0.95	18.81	0.72	2.51e-54	Cognitive function;
LUSC	cis	rs72827839	0.516	rs72833458	chr17:45938051	A/G	cg23391107	chr17:45924227	SP6	0.43	7.68	0.39	1.78e-13	Ease of getting up in the morning;
LUSC	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg25801113	chr15:45476975	SHF	0.34	6.85	0.35	3.49e-11	Uric acid levels;
LUSC	trans	rs76248362	0.867	rs74657221	chr13:24431809	G/C	cg26511321	chr7:27196790	HOXA7	-0.57	-5.99	-0.31	5.48e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02398342	chr17:80708632	TBCD;FN3K	-0.47	-7.56	-0.38	3.96e-13	Glycated hemoglobin levels;
LUSC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg11663144	chr21:46675770	NA	0.43	7.63	0.39	2.45e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg21890820	chr11:65308645	LTBP3	0.5	7.41	0.38	1.03e-12	Bone mineral density;
LUSC	cis	rs9650657	0.682	rs6989160	chr8:10705360	A/C	cg27411982	chr8:10470053	RP1L1	-0.4	-6.53	-0.34	2.42e-10	Neuroticism;
LUSC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg06641503	chr3:48959341	ARIH2	-0.39	-5.94	-0.31	7.17e-9	Parkinson's disease;
LUSC	trans	rs2055729	1.000	rs2055729	chr8:9792662	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.25	-0.32	1.26e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg05855489	chr10:104503620	C10orf26	0.61	9.8	0.47	4.43e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs17433780	0.964	rs12146148	chr1:89471892	C/T	cg09516651	chr1:89888402	LOC400759	0.49	8.21	0.41	4.91e-15	Carotid intima media thickness;
LUSC	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg17294928	chr15:75287854	SCAMP5	0.41	5.81	0.3	1.49e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.15	-0.32	2.18e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg13798780	chr7:105162888	PUS7	0.56	6.19	0.32	1.81e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs16854884	0.770	rs951865	chr3:143812677	G/A	cg06585982	chr3:143692056	C3orf58	0.44	6.49	0.33	3.18e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs2227930	0.506	rs7623785	chr3:142119140	T/C	cg16271453	chr3:142027066	XRN1	-0.54	-9.63	-0.47	1.61e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs17433780	0.808	rs7541867	chr1:89513537	G/A	cg09516651	chr1:89888402	LOC400759	0.61	11.66	0.54	1.34e-26	Carotid intima media thickness;
LUSC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg16325326	chr1:53192061	ZYG11B	0.81	14.3	0.62	1.62e-36	Monocyte count;
LUSC	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg03585969	chr10:35415529	CREM	0.62	8.97	0.44	2.2e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.63	7.75	0.39	1.1e-13	Lung function (FEV1/FVC);
LUSC	cis	rs6736093	1.000	rs13006203	chr2:112661150	G/A	cg12686935	chr2:112915763	FBLN7	-0.39	-5.99	-0.31	5.37e-9	Coronary artery disease;
LUSC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.48	0.42	7.57e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs981844	0.857	rs62325140	chr4:154714161	C/A	cg14289246	chr4:154710475	SFRP2	0.48	6.08	0.32	3.28e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.75	9.51	0.46	3.99e-19	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.71	12.53	0.57	8.86e-30	White blood cell count (basophil);
LUSC	cis	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg06521331	chr12:34319734	NA	-0.46	-7.33	-0.37	1.72e-12	Morning vs. evening chronotype;
LUSC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg06028605	chr16:24865363	SLC5A11	-0.4	-6.37	-0.33	6.39e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07080220	chr10:102295463	HIF1AN	0.68	9.3	0.45	1.86e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg21951975	chr1:209979733	IRF6	0.62	8.2	0.41	5.31e-15	Cleft lip with or without cleft palate;
LUSC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-6.95	-0.36	1.93e-11	Blood metabolite levels;
LUSC	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg00152838	chr16:24741724	TNRC6A	-0.43	-5.65	-0.3	3.5e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg23281280	chr6:28129359	ZNF389	0.44	5.8	0.3	1.52e-8	Parkinson's disease;
LUSC	cis	rs1322512	0.917	rs1322510	chr6:152984361	G/C	cg27316956	chr6:152958899	SYNE1	0.37	6.28	0.33	1.04e-9	Tonometry;
LUSC	cis	rs4380275	1.000	rs4450634	chr2:773257	G/A	cg21665850	chr2:731073	NA	0.42	6.75	0.35	6.49e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg24397884	chr7:158709396	WDR60	0.78	8.95	0.44	2.56e-17	Height;
LUSC	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg24634471	chr8:143751801	JRK	0.6	9.09	0.45	8.71e-18	Schizophrenia;
LUSC	cis	rs1983170	0.741	rs6685054	chr1:92018238	T/G	cg25838465	chr1:92012736	NA	0.41	5.74	0.3	2.18e-8	Eosinophil percentage of white cells;
LUSC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.86	14.19	0.61	4.34e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.7	-12.17	-0.55	1.85e-28	Dental caries;
LUSC	cis	rs17401966	0.540	rs4846199	chr1:10283961	A/G	cg19773385	chr1:10388646	KIF1B	-0.37	-6.46	-0.33	3.61e-10	Hepatocellular carcinoma;
LUSC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25072359	chr17:41440525	NA	0.65	9.38	0.46	1.06e-18	Menopause (age at onset);
LUSC	cis	rs11229555	0.645	rs11229431	chr11:58181253	A/G	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs752010	0.875	rs11210501	chr1:42091634	T/C	cg06885757	chr1:42089581	HIVEP3	0.45	8.98	0.44	2.09e-17	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21028142	chr17:79581711	NPLOC4	0.35	8.4	0.42	1.26e-15	Eye color traits;
LUSC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11764359	chr7:65958608	NA	-0.68	-10.97	-0.51	4.2e-24	Aortic root size;
LUSC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg25456477	chr12:86230367	RASSF9	0.43	7.67	0.39	1.9e-13	Major depressive disorder;
LUSC	cis	rs4919687	0.550	rs12780827	chr10:104467954	T/C	cg05855489	chr10:104503620	C10orf26	0.71	11.37	0.53	1.53e-25	Colorectal cancer;
LUSC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg19729930	chr2:74357872	NA	0.88	16.75	0.68	3.82e-46	Gestational age at birth (maternal effect);
LUSC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg22508957	chr16:3507546	NAT15	0.85	10.83	0.51	1.3e-23	Tuberculosis;
LUSC	cis	rs2354432	0.599	rs4950423	chr1:146854539	T/C	cg25205988	chr1:146714368	CHD1L	0.84	7.53	0.38	4.92e-13	Mitochondrial DNA levels;
LUSC	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg03060546	chr3:49711283	APEH	0.55	7.39	0.38	1.16e-12	Resting heart rate;
LUSC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg25258033	chr6:167368657	RNASET2	0.45	6.81	0.35	4.5e-11	Crohn's disease;
LUSC	cis	rs41271473	0.687	rs7535661	chr1:228887667	C/T	cg10167378	chr1:228756711	NA	0.48	6.37	0.33	6.1e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg17469321	chr7:55412551	NA	0.65	10.58	0.5	9.39e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9467773	0.572	rs3846846	chr6:26445039	A/G	cg09904177	chr6:26538194	HMGN4	-0.57	-8.72	-0.43	1.3e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9403521	0.673	rs3934959	chr6:143979710	A/G	cg18240653	chr6:144019428	PHACTR2	-0.52	-6.58	-0.34	1.83e-10	Obesity-related traits;
LUSC	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg17507749	chr15:85114479	UBE2QP1	0.66	8.1	0.41	1.04e-14	Schizophrenia;
LUSC	trans	rs13011075	0.919	rs17601498	chr2:68611712	A/G	cg14221825	chr19:46271408	SIX5	0.42	6.06	0.31	3.74e-9	Mean corpuscular volume;
LUSC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg04155289	chr7:94953770	PON1	-0.34	-5.66	-0.3	3.2e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.4	-5.96	-0.31	6.27e-9	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg27398817	chr8:82754497	SNX16	0.66	8.41	0.42	1.18e-15	Diastolic blood pressure;
LUSC	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg17830980	chr10:43048298	ZNF37B	-0.42	-6.55	-0.34	2.23e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.23	-14.54	-0.62	1.89e-37	Gout;
LUSC	cis	rs911119	0.955	rs8121405	chr20:23605226	G/A	cg16589663	chr20:23618590	CST3	0.57	6.82	0.35	4.18e-11	Chronic kidney disease;
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.72	-15.06	-0.64	1.7e-39	Longevity;Endometriosis;
LUSC	cis	rs662064	0.962	rs2781232	chr1:10544388	T/C	cg20482658	chr1:10539492	PEX14	-0.34	-6.89	-0.35	2.8e-11	Asthma;
LUSC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg21770322	chr7:97807741	LMTK2	0.42	7.2	0.37	4.05e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13006833	0.668	rs2582735	chr2:191143798	T/C	cg21644426	chr2:191273491	MFSD6	0.47	6.6	0.34	1.61e-10	Urinary metabolites;
LUSC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.85	11.06	0.52	1.91e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg20887711	chr4:1340912	KIAA1530	-0.45	-6.9	-0.35	2.56e-11	Obesity-related traits;
LUSC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.36	0.37	1.4e-12	Cognitive ability;
LUSC	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-9.45	-0.46	6.34e-19	Morning vs. evening chronotype;
LUSC	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg12863693	chr15:85201151	NMB	0.38	7.27	0.37	2.52e-12	Schizophrenia;
LUSC	cis	rs6982240	0.514	rs10093988	chr8:142260995	T/C	cg27411547	chr8:142287226	NA	-0.47	-7.9	-0.4	4e-14	Tonsillectomy;
LUSC	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg11057378	chr10:81107060	PPIF	0.34	5.81	0.3	1.49e-8	Height;
LUSC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg08132940	chr7:1081526	C7orf50	-0.51	-6.14	-0.32	2.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	10.28	0.49	9.82e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs11168618	0.904	rs11495273	chr12:48929190	A/T	cg24011408	chr12:48396354	COL2A1	0.39	6.33	0.33	7.83e-10	Adiponectin levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26233468	chr1:155145786	TRIM46;KRTCAP2	-0.43	-6.45	-0.33	3.93e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg06784218	chr1:46089804	CCDC17	0.29	5.83	0.3	1.31e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs9398803	0.796	rs1361107	chr6:126767511	A/C	cg19875578	chr6:126661172	C6orf173	0.43	6.32	0.33	8.59e-10	Male-pattern baldness;
LUSC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01341218	chr17:43662625	NA	-0.76	-11.16	-0.52	8.84e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg02018176	chr4:1364513	KIAA1530	0.46	6.45	0.33	3.82e-10	Recombination rate (females);
LUSC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	10.53	0.5	1.44e-22	Homoarginine levels;
LUSC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-6.01	-0.31	4.94e-9	Huntington's disease progression;
LUSC	cis	rs2267681	0.583	rs764745	chr7:139529928	G/C	cg14116596	chr7:139528673	TBXAS1	0.36	6.14	0.32	2.29e-9	Cervical cancer;
LUSC	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg07169764	chr2:136633963	MCM6	1.03	16.16	0.66	8.21e-44	Corneal structure;
LUSC	cis	rs113352275	1	rs113352275	chr15:78840567	C/T	cg18825076	chr15:78729989	IREB2	0.44	5.72	0.3	2.31e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg00484396	chr16:3507460	NAT15	-0.47	-7.01	-0.36	1.29e-11	Body mass index (adult);
LUSC	cis	rs977987	0.835	rs8046109	chr16:75360096	A/G	cg03315344	chr16:75512273	CHST6	0.51	9.91	0.48	1.78e-20	Dupuytren's disease;
LUSC	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg11584989	chr19:19387371	SF4	0.59	6.99	0.36	1.46e-11	Bipolar disorder;
LUSC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.72	-11.65	-0.54	1.51e-26	Colorectal cancer;
LUSC	trans	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg15556689	chr8:8085844	FLJ10661	0.42	6.28	0.32	1.08e-9	Retinal vascular caliber;
LUSC	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg10523679	chr1:76189770	ACADM	-0.49	-7.07	-0.36	9.34e-12	Daytime sleep phenotypes;
LUSC	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg07169764	chr2:136633963	MCM6	0.54	7.27	0.37	2.51e-12	Mosquito bite size;
LUSC	cis	rs72960926	0.744	rs72964291	chr6:74891874	C/G	cg03266952	chr6:74778945	NA	-0.8	-6.32	-0.33	8.53e-10	Metabolite levels (MHPG);
LUSC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg05347473	chr6:146136440	FBXO30	0.5	8.45	0.42	9.26e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg03342759	chr3:160939853	NMD3	-0.4	-5.83	-0.3	1.27e-8	Morning vs. evening chronotype;
LUSC	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	0.95	17.95	0.7	6.57e-51	Bone mineral density;
LUSC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.39	0.46	9.37e-19	Bipolar disorder;
LUSC	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07988820	chr12:82153109	PPFIA2	-0.42	-6.18	-0.32	1.92e-9	Resting heart rate;
LUSC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg19622623	chr12:86230825	RASSF9	-0.44	-6.32	-0.33	8.47e-10	Major depressive disorder;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.94	-18.11	-0.7	1.46e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg21770322	chr7:97807741	LMTK2	0.42	7.28	0.37	2.41e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.92	-0.35	2.28e-11	Menopause (age at onset);
LUSC	trans	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg20935933	chr6:143382018	AIG1	0.51	7.43	0.38	8.96e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18099408	chr3:52552593	STAB1	0.4	6.38	0.33	5.94e-10	Bipolar disorder;
LUSC	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg05519781	chr21:40033154	ERG	-0.78	-13.86	-0.6	8.16e-35	Coronary artery disease;
LUSC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.14	0.45	6.26e-18	Motion sickness;
LUSC	trans	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-7.07	-0.36	9.28e-12	Retinal vascular caliber;
LUSC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11764359	chr7:65958608	NA	0.68	10.85	0.51	1.06e-23	Aortic root size;
LUSC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.75	-0.35	6.51e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg17366294	chr4:99064904	C4orf37	0.55	9.57	0.46	2.54e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7264396	0.887	rs224347	chr20:34037523	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.65	-0.34	1.22e-10	Total cholesterol levels;
LUSC	trans	rs12236890	0.561	rs7862467	chr9:3181278	A/C	cg14780649	chr1:43534197	NA	0.3	6.37	0.33	6.28e-10	Monobrow thickness;
LUSC	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg00074818	chr8:8560427	CLDN23	0.59	9.95	0.48	1.32e-20	Obesity-related traits;
LUSC	cis	rs3820928	0.874	rs6707265	chr2:227849255	T/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.01	-0.4	1.97e-14	Pulmonary function;
LUSC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg20295408	chr7:1910781	MAD1L1	0.42	5.83	0.3	1.33e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg09323728	chr8:95962352	TP53INP1	0.35	6.61	0.34	1.53e-10	Type 2 diabetes;
LUSC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg04166393	chr7:2884313	GNA12	0.42	5.66	0.3	3.24e-8	Height;
LUSC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg20406979	chr6:167373233	NA	0.25	5.81	0.3	1.49e-8	Crohn's disease;
LUSC	trans	rs2514895	0.660	rs7925424	chr11:127113326	G/A	cg22738642	chr12:43137977	NA	0.5	6.26	0.32	1.17e-9	IgG glycosylation;
LUSC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg15445000	chr17:37608096	MED1	0.39	6.68	0.34	9.87e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.23	0.32	1.4e-9	Total body bone mineral density;
LUSC	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-16.85	-0.68	1.49e-46	Primary sclerosing cholangitis;
LUSC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	ch.11.42038R	chr11:967971	AP2A2	0.44	6.6	0.34	1.6e-10	Alzheimer's disease (late onset);
LUSC	cis	rs73198271	0.515	rs74841285	chr8:8635450	C/T	cg01851573	chr8:8652454	MFHAS1	0.58	6.53	0.34	2.49e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-8.52	-0.42	5.58e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.23e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12980942	0.872	rs7257583	chr19:41788117	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.58	6.28	0.33	1.03e-9	Coronary artery disease;
LUSC	cis	rs4851254	0.961	rs11680586	chr2:100746207	G/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.66	-0.3	3.34e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.88	-12.69	-0.57	2.2e-30	Initial pursuit acceleration;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18825258	chr8:26435354	DPYSL2	0.75	5.96	0.31	6.32e-9	Cognitive performance;
LUSC	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg22875332	chr1:76189707	ACADM	-0.42	-6.36	-0.33	6.65e-10	Daytime sleep phenotypes;
LUSC	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08704250	chr15:31115839	NA	-0.59	-9.2	-0.45	3.95e-18	Huntington's disease progression;
LUSC	cis	rs4478858	0.684	rs7515988	chr1:31731061	C/T	cg00250761	chr1:31883323	NA	0.35	8.55	0.42	4.41e-16	Alcohol dependence;
LUSC	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.85	-14.67	-0.63	5.73e-38	Cognitive function;
LUSC	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg27284194	chr4:1044797	NA	-0.56	-8.28	-0.41	2.99e-15	Recombination rate (females);
LUSC	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.77	-0.35	5.91e-11	Response to antipsychotic treatment;
LUSC	trans	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg10756647	chr7:56101905	PSPH	0.83	8.12	0.41	9.12e-15	Diabetic kidney disease;
LUSC	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.5	-0.53	5.15e-26	Mean corpuscular volume;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18516985	chr5:159846223	SLU7	0.79	6.32	0.33	8.37e-10	Cognitive performance;
LUSC	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.99	0.36	1.51e-11	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg21724239	chr8:58056113	NA	0.62	7.28	0.37	2.45e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-9.11	-0.45	7.82e-18	Bipolar disorder;
LUSC	cis	rs73206853	0.688	rs60971459	chr12:110702051	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	6.54	0.34	2.31e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg02454025	chr1:11042201	C1orf127	1.04	19.33	0.73	2.07e-56	Ewing sarcoma;
LUSC	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.7	-11.55	-0.53	3.33e-26	Sudden cardiac arrest;
LUSC	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg11019008	chr10:131425282	MGMT	-0.47	-7.07	-0.36	8.86e-12	Response to temozolomide;
LUSC	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-8.68	-0.43	1.78e-16	Morning vs. evening chronotype;
LUSC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg17971929	chr21:40555470	PSMG1	-0.67	-10.82	-0.51	1.39e-23	Cognitive function;
LUSC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg04155289	chr7:94953770	PON1	-0.34	-5.76	-0.3	1.89e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg03676636	chr4:99064102	C4orf37	0.36	7.84	0.39	6.15e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs722599	0.683	rs7142898	chr14:75254310	A/T	cg08847533	chr14:75593920	NEK9	0.44	6.18	0.32	1.85e-9	IgG glycosylation;
LUSC	cis	rs9534288	0.742	rs1977395	chr13:46638131	C/T	cg15192986	chr13:46630673	CPB2	-0.77	-11.56	-0.53	3.19e-26	Blood protein levels;
LUSC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.57	0.34	1.88e-10	Lung cancer;
LUSC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	7.05	0.36	1.02e-11	Schizophrenia;
LUSC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg03909863	chr11:638404	DRD4	-0.4	-5.87	-0.31	1.06e-8	Systemic lupus erythematosus;
LUSC	cis	rs1858037	0.867	rs4671660	chr2:65576436	C/A	cg08085232	chr2:65598271	SPRED2	-0.4	-5.93	-0.31	7.68e-9	Rheumatoid arthritis;
LUSC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.49	7.48	0.38	6.71e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg21775007	chr8:11205619	TDH	-0.48	-6.54	-0.34	2.3e-10	Triglycerides;
LUSC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	1.24	15.22	0.64	4.1e-40	Opioid sensitivity;
LUSC	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.8	-0.43	7.69e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6500395	0.962	rs11648101	chr16:48714178	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.4	0.33	5.13e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.95	0.51	4.95e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg20503657	chr10:835505	NA	0.89	12.32	0.56	5.37e-29	Eosinophil percentage of granulocytes;
LUSC	cis	rs617219	0.889	rs2121107	chr5:78468004	C/T	cg24856658	chr5:78533917	JMY	-0.3	-5.75	-0.3	1.98e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg15605315	chr1:45957053	TESK2	-0.42	-6.53	-0.34	2.47e-10	High light scatter reticulocyte count;
LUSC	cis	rs611744	0.870	rs640068	chr8:109158002	A/G	cg18478394	chr8:109455254	TTC35	0.4	5.9	0.31	9.12e-9	Dupuytren's disease;
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.9	17.74	0.7	4.53e-50	Menarche (age at onset);
LUSC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg00074818	chr8:8560427	CLDN23	0.59	9.95	0.48	1.35e-20	Obesity-related traits;
LUSC	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg17366294	chr4:99064904	C4orf37	0.59	10.45	0.5	2.62e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7727544	0.582	rs10052046	chr5:131544466	G/T	cg24060327	chr5:131705240	SLC22A5	-0.35	-5.72	-0.3	2.39e-8	Blood metabolite levels;
LUSC	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg15432903	chr11:17409602	KCNJ11	0.61	10.83	0.51	1.26e-23	Type 2 diabetes;
LUSC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	12.16	0.55	2.1e-28	Menopause (age at onset);
LUSC	cis	rs12760731	0.641	rs12038910	chr1:178444907	C/T	cg00404053	chr1:178313656	RASAL2	0.58	6.36	0.33	6.6e-10	Obesity-related traits;
LUSC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg17366294	chr4:99064904	C4orf37	0.54	8.8	0.43	7.33e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4631830	0.863	rs2611508	chr10:51518047	T/A	cg10326726	chr10:51549505	MSMB	-0.35	-5.92	-0.31	8.04e-9	Prostate-specific antigen levels;
LUSC	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg18753928	chr3:113234510	CCDC52	-0.52	-8.01	-0.4	1.99e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-0.9	-16.84	-0.68	1.65e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.04	-0.36	1.07e-11	Major depressive disorder;
LUSC	cis	rs2859741	0.546	rs2134846	chr1:37500723	G/A	cg09363841	chr1:37513479	NA	-0.38	-7.15	-0.36	5.35e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs2274459	0.841	rs13204162	chr6:33696131	C/T	cg06253072	chr6:33679850	C6orf125	0.5	6.0	0.31	5.28e-9	Obesity (extreme);
LUSC	cis	rs7538876	0.935	rs6586542	chr1:17763566	C/G	cg07965774	chr1:17746286	RCC2	-0.3	-5.7	-0.3	2.68e-8	Basal cell carcinoma;
LUSC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg07424592	chr7:64974309	NA	-0.64	-5.84	-0.3	1.26e-8	Diabetic kidney disease;
LUSC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg22709100	chr7:91322751	NA	0.4	5.81	0.3	1.48e-8	Breast cancer;
LUSC	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.78	0.35	5.31e-11	Height;
LUSC	trans	rs12200782	1.000	rs12200782	chr6:26403036	C/G	cg11837749	chr1:55047332	ACOT11	0.56	5.99	0.31	5.31e-9	Small cell lung carcinoma;
LUSC	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22857025	chr5:266934	NA	-1.18	-13.92	-0.61	4.6e-35	Breast cancer;
LUSC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02034447	chr16:89574710	SPG7	-0.43	-6.57	-0.34	1.93e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg00814883	chr7:100076585	TSC22D4	-0.46	-5.68	-0.3	2.89e-8	Lung function (FEV1/FVC);
LUSC	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg16070123	chr10:51489643	NA	-0.58	-9.57	-0.46	2.56e-19	Prostate-specific antigen levels;
LUSC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg07362569	chr17:61921086	SMARCD2	-0.29	-5.78	-0.3	1.73e-8	Prudent dietary pattern;
LUSC	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.32	-0.37	1.84e-12	Bipolar disorder;
LUSC	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg22029157	chr1:209979665	IRF6	0.57	6.48	0.33	3.21e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg00815214	chr21:47717953	NA	-0.35	-5.72	-0.3	2.33e-8	Testicular germ cell tumor;
LUSC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.38	-0.46	1.06e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg05585544	chr11:47624801	NA	0.4	7.01	0.36	1.33e-11	Subjective well-being;
LUSC	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg00405596	chr8:11794950	NA	0.36	6.0	0.31	5e-9	Myopia (pathological);
LUSC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	0.7	7.02	0.36	1.26e-11	Prostate cancer;
LUSC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg06494592	chr3:125709126	NA	-0.52	-5.93	-0.31	7.44e-9	Blood pressure (smoking interaction);
LUSC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg09034736	chr1:150693464	HORMAD1	0.45	6.48	0.33	3.36e-10	Melanoma;
LUSC	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg26668713	chr11:65405903	SIPA1	0.61	6.83	0.35	4.1e-11	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	trans	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.64	-0.34	1.27e-10	Monocyte count;
LUSC	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.83	-0.35	4.03e-11	Triglycerides;
LUSC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03021120	chr16:50402374	BRD7	-0.43	-6.55	-0.34	2.19e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg07701084	chr6:150067640	NUP43	0.58	8.87	0.44	4.56e-17	Lung cancer;
LUSC	cis	rs4494114	1.000	rs4388668	chr1:39360730	A/T	cg25970120	chr1:39325951	RRAGC	-0.41	-6.36	-0.33	6.61e-10	Blood protein levels;
LUSC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.28	-0.49	9.98e-22	Platelet count;
LUSC	cis	rs2346177	0.874	rs35462976	chr2:46649049	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.61	-0.38	2.89e-13	HDL cholesterol;
LUSC	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.4	-0.46	9.2e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg05110241	chr16:68378359	PRMT7	-0.43	-5.82	-0.3	1.35e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg11871910	chr12:69753446	YEATS4	0.61	8.28	0.41	3.03e-15	Response to diuretic therapy;
LUSC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg13010199	chr12:38710504	ALG10B	0.69	10.75	0.51	2.46e-23	Heart rate;
LUSC	trans	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg01620082	chr3:125678407	NA	-0.82	-7.65	-0.39	2.2e-13	Depression;
LUSC	cis	rs11031096	0.678	rs10767872	chr11:4184239	T/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.85	-0.3	1.2e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	0.93	8.06	0.4	1.33e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg08975724	chr8:8085496	FLJ10661	0.49	7.1	0.36	7.49e-12	Myopia (pathological);
LUSC	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg26384229	chr12:38710491	ALG10B	0.59	8.84	0.44	5.5e-17	Heart rate;
LUSC	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg01528321	chr10:82214614	TSPAN14	0.96	14.51	0.62	2.39e-37	Post bronchodilator FEV1;
LUSC	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg14458575	chr2:238380390	NA	0.58	6.82	0.35	4.36e-11	Prostate cancer;
LUSC	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg27661571	chr11:113659931	NA	0.58	6.77	0.35	5.78e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg02527881	chr3:46936655	PTH1R	0.4	7.11	0.36	6.89e-12	Colorectal cancer;
LUSC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.3	-0.33	9.36e-10	Lung cancer;
LUSC	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg20628663	chr10:43360327	NA	-0.77	-11.37	-0.53	1.57e-25	Blood protein levels;
LUSC	trans	rs12043259	1.000	rs12410154	chr1:204849156	G/T	cg23865240	chr7:27134109	HOXA1	-0.57	-6.01	-0.31	4.87e-9	Addiction;
LUSC	cis	rs1832871	0.672	rs13437296	chr6:158762819	A/C	cg07165851	chr6:158734300	TULP4	0.46	6.95	0.36	1.98e-11	Height;
LUSC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-13.85	-0.6	8.42e-35	Extrinsic epigenetic age acceleration;
LUSC	trans	rs1941687	0.800	rs1845387	chr18:31358940	T/G	cg27147174	chr7:100797783	AP1S1	-0.47	-6.97	-0.36	1.66e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs2652834	0.904	rs2729826	chr15:63360446	C/G	cg05507819	chr15:63340323	TPM1	-0.68	-8.73	-0.43	1.23e-16	HDL cholesterol;
LUSC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg12963246	chr6:28129442	ZNF389	0.59	8.18	0.41	6.19e-15	Parkinson's disease;
LUSC	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg03522245	chr20:25566470	NINL	-0.35	-5.68	-0.3	2.89e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg02175503	chr12:58329896	NA	0.66	10.82	0.51	1.33e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs9403521	0.673	rs7748882	chr6:143991712	T/C	cg18240653	chr6:144019428	PHACTR2	-0.52	-6.83	-0.35	3.91e-11	Obesity-related traits;
LUSC	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg16339924	chr4:17578868	LAP3	0.51	7.6	0.38	3.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg19196401	chr6:110721138	DDO	-0.42	-7.75	-0.39	1.12e-13	Platelet distribution width;
LUSC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg23791538	chr6:167370224	RNASET2	-0.43	-6.95	-0.36	1.93e-11	Crohn's disease;
LUSC	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	0.96	9.14	0.45	6.02e-18	Plasma clusterin levels;
LUSC	cis	rs4356932	1.000	rs6820370	chr4:76952278	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.77	0.3	1.78e-8	Blood protein levels;
LUSC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg20476274	chr7:133979776	SLC35B4	0.87	16.89	0.68	1.02e-46	Mean platelet volume;
LUSC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-0.79	-9.6	-0.46	2.04e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg03585969	chr10:35415529	CREM	0.61	8.82	0.43	6.41e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg13010199	chr12:38710504	ALG10B	0.57	8.6	0.43	3.06e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.39	-6.59	-0.34	1.71e-10	DNA methylation (variation);
LUSC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg23649088	chr2:200775458	C2orf69	0.55	7.38	0.37	1.26e-12	Schizophrenia;
LUSC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.25	0.41	3.79e-15	Tonsillectomy;
LUSC	cis	rs7588746	0.571	rs10931896	chr2:201148076	C/T	cg23649088	chr2:200775458	C2orf69	-0.41	-5.85	-0.31	1.14e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs977987	0.806	rs72787160	chr16:75445162	G/C	cg03315344	chr16:75512273	CHST6	0.48	8.96	0.44	2.4e-17	Dupuytren's disease;
LUSC	trans	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.37	0.42	1.6e-15	Diabetic kidney disease;
LUSC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg07741184	chr6:167504864	NA	0.4	7.13	0.36	6.37e-12	Crohn's disease;
LUSC	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.43	6.33	0.33	7.95e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	6.03	0.31	4.29e-9	Breast cancer;
LUSC	cis	rs1595825	1.000	rs1595825	chr2:198875464	G/A	cg00982548	chr2:198649783	BOLL	-0.49	-6.15	-0.32	2.15e-9	Ulcerative colitis;
LUSC	cis	rs1395	0.778	rs12465084	chr2:27414203	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.26	0.37	2.73e-12	Blood metabolite levels;
LUSC	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.45	-0.5	2.56e-22	Eye color traits;
LUSC	cis	rs7552167	0.789	rs6424162	chr1:24512576	T/C	cg01960748	chr1:24522592	NA	-0.69	-10.22	-0.49	1.63e-21	Psoriasis vulgaris;
LUSC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.23	0.37	3.42e-12	Bipolar disorder;
LUSC	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.7	-0.39	1.54e-13	Neuroticism;
LUSC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg05347473	chr6:146136440	FBXO30	0.62	10.47	0.5	2.25e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.19	0.64	5.67e-40	Bladder cancer;
LUSC	cis	rs17407555	0.606	rs3775945	chr4:10011996	A/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-6.22	-0.32	1.5e-9	Schizophrenia (age at onset);
LUSC	cis	rs1461503	0.966	rs7110154	chr11:122843300	A/G	cg27398637	chr11:122830231	C11orf63	-0.4	-6.5	-0.34	2.93e-10	Menarche (age at onset);
LUSC	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg05855489	chr10:104503620	C10orf26	-0.49	-7.38	-0.37	1.27e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.82	-0.43	6.25e-17	Response to antipsychotic treatment;
LUSC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg03806693	chr22:41940476	POLR3H	0.99	13.79	0.6	1.53e-34	Vitiligo;
LUSC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg07148914	chr20:33460835	GGT7	0.55	8.59	0.43	3.32e-16	Height;
LUSC	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	0.86	13.75	0.6	2.06e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg01657329	chr11:68192670	LRP5	0.46	7.38	0.37	1.26e-12	Total body bone mineral density;
LUSC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg23630131	chr7:65973040	NA	0.21	5.73	0.3	2.25e-8	Aortic root size;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg21176326	chr7:148788010	ZNF786	0.41	6.23	0.32	1.38e-9	N-glycan levels;
LUSC	cis	rs314370	0.570	rs314324	chr7:100433794	C/T	cg10426581	chr7:100472382	SRRT	0.49	7.63	0.39	2.44e-13	Resting heart rate;
LUSC	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.71e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg20891283	chr12:69753455	YEATS4	0.65	9.58	0.46	2.35e-19	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs9929218	0.954	rs12924033	chr16:68822599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-11.08	-0.52	1.63e-24	Colorectal cancer;
LUSC	cis	rs34779708	0.702	rs35969476	chr10:35544318	G/A	cg03585969	chr10:35415529	CREM	0.56	7.79	0.39	8.66e-14	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs36405	0.500	rs8011906	chr14:72359795	C/G	cg23396177	chr14:72358413	NA	-0.35	-6.65	-0.34	1.2e-10	Yang-deficiency constitution;
LUSC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg23788917	chr6:8435910	SLC35B3	0.51	7.48	0.38	6.83e-13	Motion sickness;
LUSC	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg21890820	chr11:65308645	LTBP3	0.47	7.1	0.36	7.78e-12	Bone mineral density;
LUSC	cis	rs7178572	0.743	rs62009090	chr15:77837055	T/G	cg22256960	chr15:77711686	NA	-0.46	-7.23	-0.37	3.32e-12	Type 2 diabetes;
LUSC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg07636037	chr3:49044803	WDR6	0.43	6.26	0.32	1.21e-9	Resting heart rate;
LUSC	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.09	0.4	1.15e-14	Axial length;
LUSC	cis	rs2625529	0.652	rs2929513	chr15:72229180	G/A	cg16672083	chr15:72433130	SENP8	0.5	8.28	0.41	2.95e-15	Red blood cell count;
LUSC	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg26384229	chr12:38710491	ALG10B	-0.79	-13.28	-0.59	1.33e-32	Morning vs. evening chronotype;
LUSC	cis	rs8063160	0.756	rs71396951	chr16:89726593	G/C	cg07984980	chr16:89898383	SPIRE2	0.87	6.78	0.35	5.44e-11	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LUSC	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg11214544	chr1:2391121	NA	-0.36	-6.08	-0.32	3.29e-9	Schizophrenia;
LUSC	cis	rs10465746	0.905	rs1324484	chr1:84382844	T/C	cg10977910	chr1:84465055	TTLL7	0.42	6.08	0.32	3.29e-9	Obesity-related traits;
LUSC	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg17366294	chr4:99064904	C4orf37	0.52	9.2	0.45	3.87e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg19875535	chr5:140030758	IK	0.47	7.56	0.38	4.05e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg13175981	chr1:150552382	MCL1	0.4	5.7	0.3	2.57e-8	Tonsillectomy;
LUSC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg16606324	chr3:10149918	C3orf24	0.65	9.65	0.47	1.38e-19	Alzheimer's disease;
LUSC	cis	rs3818285	0.959	rs3740137	chr10:111630917	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.92	-0.4	3.55e-14	Superior crus of antihelix expression;
LUSC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg07741184	chr6:167504864	NA	0.39	6.92	0.35	2.27e-11	Primary biliary cholangitis;
LUSC	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7561273	0.609	rs2080727	chr2:24350907	A/G	cg20701182	chr2:24300061	SF3B14	0.46	5.87	0.31	1.05e-8	Quantitative traits;
LUSC	cis	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg21775007	chr8:11205619	TDH	0.47	6.69	0.34	9.25e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs8014204	0.533	rs12889955	chr14:75172999	G/A	cg06637938	chr14:75390232	RPS6KL1	0.53	8.28	0.41	3.1e-15	Caffeine consumption;
LUSC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.63	-9.85	-0.47	2.84e-20	Iron status biomarkers;
LUSC	cis	rs4356932	0.691	rs4282209	chr4:76919536	A/G	cg00809888	chr4:76862425	NAAA	0.36	5.74	0.3	2.13e-8	Blood protein levels;
LUSC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg04518342	chr5:131593106	PDLIM4	0.41	7.89	0.4	4.4e-14	Blood metabolite levels;
LUSC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	0.84	11.33	0.53	2.16e-25	Eosinophil percentage of granulocytes;
LUSC	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.14	-0.41	7.7e-15	Bone mineral density;
LUSC	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg25206134	chr2:45395956	NA	0.56	6.44	0.33	4.13e-10	Bipolar disorder;
LUSC	cis	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg06521331	chr12:34319734	NA	-0.49	-8.13	-0.41	8.54e-15	Morning vs. evening chronotype;
LUSC	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.87	-0.35	3.12e-11	Daytime sleep phenotypes;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg10881360	chr1:24069720	TCEB3	0.49	5.95	0.31	6.61e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1832871	0.965	rs10945541	chr6:158740218	A/G	cg07165851	chr6:158734300	TULP4	-0.34	-5.83	-0.3	1.3e-8	Height;
LUSC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.86	-12.09	-0.55	3.81e-28	Initial pursuit acceleration;
LUSC	trans	rs12043259	1.000	rs12239873	chr1:204825808	C/G	cg23865240	chr7:27134109	HOXA1	-0.53	-6.01	-0.31	4.8e-9	Addiction;
LUSC	cis	rs7072216	0.727	rs7915108	chr10:100164441	T/C	cg26618903	chr10:100175079	PYROXD2	-0.46	-8.44	-0.42	1e-15	Metabolite levels;
LUSC	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	9.04	0.44	1.26e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg00064840	chr7:4784485	FOXK1	-0.3	-5.91	-0.31	8.46e-9	Mosquito bite size;
LUSC	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18876405	chr7:65276391	NA	0.55	8.65	0.43	2.22e-16	Aortic root size;
LUSC	cis	rs6546886	0.912	rs10200470	chr2:74284687	A/G	cg14702570	chr2:74259524	NA	-0.31	-5.77	-0.3	1.8e-8	Dialysis-related mortality;
LUSC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-5.75	-0.3	2.03e-8	Vitiligo;
LUSC	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg06360820	chr2:242988706	NA	-0.93	-10.14	-0.49	3.12e-21	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14497545	chr4:140754475	MAML3	-0.42	-7.43	-0.38	9e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21659725	chr3:3221576	CRBN	0.63	10.4	0.49	3.93e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg07621104	chr11:117668040	DSCAML1	0.49	6.36	0.33	6.76e-10	Myopia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19782173	chr5:76383047	LOC728723;ZBED3	0.51	7.18	0.37	4.56e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.42	6.58	0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11645453	chr3:52864694	ITIH4	0.34	7.99	0.4	2.15e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	8.87	0.44	4.45e-17	Menarche (age at onset);
LUSC	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg15819921	chr19:927150	ARID3A	-0.42	-6.38	-0.33	5.85e-10	Life satisfaction;
LUSC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg16797656	chr11:68205561	LRP5	0.36	5.97	0.31	5.96e-9	Total body bone mineral density;
LUSC	cis	rs17253792	0.822	rs75399477	chr14:56174413	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.9	-0.35	2.66e-11	Putamen volume;
LUSC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg03354898	chr7:1950403	MAD1L1	-0.32	-6.3	-0.33	9.32e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	0.97	15.38	0.64	9.67e-41	Dupuytren's disease;
LUSC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg18404041	chr3:52824283	ITIH1	0.4	7.2	0.37	3.96e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.47	-5.87	-0.31	1.05e-8	Iron status biomarkers;
LUSC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.54	-10.18	-0.49	2.29e-21	Longevity;Endometriosis;
LUSC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg02782426	chr3:40428986	ENTPD3	0.42	7.95	0.4	2.87e-14	Renal cell carcinoma;
LUSC	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg17691542	chr6:26056736	HIST1H1C	0.53	7.38	0.37	1.26e-12	Iron status biomarkers;
LUSC	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg12011299	chr4:100065546	ADH4	-0.73	-10.43	-0.5	3.05e-22	Alcohol dependence;
LUSC	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs7582720	1.000	rs72932781	chr2:203697278	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.73	0.43	1.22e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg01251360	chr16:68772225	CDH1	-0.28	-6.53	-0.34	2.51e-10	Colorectal cancer;
LUSC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.66	8.97	0.44	2.22e-17	High light scatter reticulocyte count;
LUSC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg11941060	chr3:133502564	NA	-0.51	-7.92	-0.4	3.5e-14	Iron status biomarkers;
LUSC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.76	-0.3	1.89e-8	Personality dimensions;
LUSC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg14440974	chr22:39074834	NA	-0.35	-5.86	-0.31	1.11e-8	Menopause (age at onset);
LUSC	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.01	-0.36	1.29e-11	Blood metabolite levels;
LUSC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg20790798	chr5:1857306	NA	-0.48	-8.28	-0.41	3.05e-15	Cardiovascular disease risk factors;
LUSC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg05313129	chr8:58192883	C8orf71	-0.51	-6.52	-0.34	2.54e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14082963	chr4:89444434	PIGY	0.39	6.57	0.34	1.92e-10	Triglycerides;
LUSC	cis	rs73206853	0.764	rs7312139	chr12:110985442	C/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.26	0.37	2.76e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg17340268	chr14:105411764	AHNAK2	-0.41	-6.48	-0.33	3.36e-10	Rheumatoid arthritis;
LUSC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg01017244	chr2:74357527	NA	0.69	13.33	0.59	8.68e-33	Gestational age at birth (maternal effect);
LUSC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg08917208	chr2:24149416	ATAD2B	0.53	5.88	0.31	1e-8	Lymphocyte counts;
LUSC	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg06937882	chr20:24974362	C20orf3	-0.41	-6.93	-0.35	2.21e-11	Blood protein levels;
LUSC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg18904891	chr8:8559673	CLDN23	0.57	8.28	0.41	3.06e-15	Obesity-related traits;
LUSC	trans	rs1973993	0.689	rs67544133	chr1:96971241	G/A	cg10631902	chr5:14652156	NA	-0.43	-6.23	-0.32	1.41e-9	Weight;
LUSC	trans	rs12200782	1.000	rs6456741	chr6:26617058	C/T	cg11837749	chr1:55047332	ACOT11	0.57	5.98	0.31	5.64e-9	Small cell lung carcinoma;
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	0.89	16.3	0.67	2.43e-44	Menarche (age at onset);
LUSC	trans	rs2694917	0.680	rs2638314	chr12:56866334	T/A	cg19051015	chr17:46697414	NA	0.4	6.14	0.32	2.34e-9	Blood metabolite ratios;
LUSC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.61	-0.43	2.96e-16	Breast cancer;
LUSC	cis	rs2625529	0.878	rs4777478	chr15:72279085	T/C	cg16672083	chr15:72433130	SENP8	-0.51	-7.37	-0.37	1.34e-12	Red blood cell count;
LUSC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.17	0.52	7.97e-25	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg17366294	chr4:99064904	C4orf37	0.6	10.6	0.5	8.12e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	7.54	0.38	4.55e-13	Schizophrenia;
LUSC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.29	-0.33	1.02e-9	Life satisfaction;
LUSC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-11.93	-0.55	1.42e-27	Mean corpuscular volume;
LUSC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06022373	chr22:39101656	GTPBP1	0.84	14.02	0.61	1.86e-35	Menopause (age at onset);
LUSC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-0.96	-9.14	-0.45	6.02e-18	Plasma clusterin levels;
LUSC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.23	0.56	1.11e-28	Menopause (age at onset);
LUSC	cis	rs7605827	0.930	rs4668447	chr2:15516166	T/C	cg19274914	chr2:15703543	NA	0.46	8.86	0.44	4.71e-17	Educational attainment (years of education);
LUSC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs67072384	0.901	rs2886366	chr11:72455207	G/C	cg04827223	chr11:72435913	ARAP1	-0.78	-6.8	-0.35	4.98e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs354225	0.544	rs10187447	chr2:54806711	A/T	cg01766943	chr2:54829624	SPTBN1	0.49	7.94	0.4	3.16e-14	Schizophrenia;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg27566289	chr17:48133890	ITGA3	0.39	6.11	0.32	2.82e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs13126513	0.519	rs959247	chr4:100556984	A/G	cg05468953	chr4:100565104	NA	0.36	6.91	0.35	2.5e-11	Metabolite levels (MHPG);
LUSC	cis	rs1044826	1.000	rs9835241	chr3:139234555	A/G	cg00490450	chr3:139108681	COPB2	0.52	6.72	0.34	8.03e-11	Obesity-related traits;
LUSC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg20406979	chr6:167373233	NA	-0.25	-5.66	-0.3	3.2e-8	Crohn's disease;
LUSC	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg01483505	chr11:975446	AP2A2	0.4	5.67	0.3	3.08e-8	Alzheimer's disease (late onset);
LUSC	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg00376283	chr12:123451042	ABCB9	-0.69	-7.78	-0.39	9.37e-14	Neutrophil percentage of white cells;
LUSC	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07988820	chr12:82153109	PPFIA2	-0.41	-6.09	-0.32	3.1e-9	Resting heart rate;
LUSC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg15848620	chr12:58087721	OS9	-0.57	-8.18	-0.41	6.1e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg13453750	chr1:205783389	SLC41A1	-0.33	-6.41	-0.33	5.09e-10	Menarche (age at onset);
LUSC	cis	rs926938	0.505	rs2878573	chr1:115521602	A/G	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.41	-0.33	5.05e-10	Autism;
LUSC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg11062466	chr8:58055876	NA	0.51	6.61	0.34	1.51e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg00784671	chr22:46762841	CELSR1	-0.54	-6.79	-0.35	5.18e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10392	0.516	rs4141892	chr20:37590758	T/C	cg27552599	chr20:37590471	DHX35	0.45	7.36	0.37	1.4e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs1957429	0.614	rs117722345	chr14:65381464	C/G	cg23373153	chr14:65346875	NA	-0.98	-7.73	-0.39	1.3e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg02782426	chr3:40428986	ENTPD3	0.35	6.55	0.34	2.2e-10	Renal cell carcinoma;
LUSC	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.95	-0.44	2.46e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7903847	0.642	rs6584128	chr10:99171926	G/T	cg08345082	chr10:99160200	RRP12	0.37	7.56	0.38	4.03e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.67	-0.39	1.89e-13	Blood metabolite levels;
LUSC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg19230755	chr7:65878503	NA	-0.42	-5.88	-0.31	1.01e-8	Aortic root size;
LUSC	cis	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg01881094	chr2:180872142	CWC22	1.06	12.67	0.57	2.59e-30	Schizophrenia;
LUSC	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.74	14.68	0.63	5.59e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1609391	0.543	rs9828009	chr3:136631275	C/T	cg15507776	chr3:136538369	TMEM22	0.51	8.36	0.42	1.71e-15	Neuroticism;
LUSC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18099408	chr3:52552593	STAB1	-0.38	-6.78	-0.35	5.55e-11	Electroencephalogram traits;
LUSC	cis	rs977987	0.806	rs35263058	chr16:75391937	T/C	cg03315344	chr16:75512273	CHST6	0.5	9.59	0.46	2.19e-19	Dupuytren's disease;
LUSC	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg24558204	chr6:135376177	HBS1L	0.59	9.09	0.45	9.11e-18	Red blood cell count;
LUSC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.61	12.65	0.57	3.12e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.81	0.43	6.94e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.41	-6.76	-0.35	6.15e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7804356	1.000	rs3823930	chr7:26856525	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.14	-0.32	2.4e-9	Type 1 diabetes;
LUSC	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg15571903	chr15:79123663	NA	0.35	6.39	0.33	5.42e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg21856205	chr7:94953877	PON1	-0.35	-5.65	-0.3	3.44e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6845621	0.901	rs207293	chr4:18919345	G/C	cg12196642	chr4:18937545	NA	-0.34	-6.36	-0.33	6.61e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9653442	0.593	rs2309811	chr2:100862359	A/G	cg22139774	chr2:100720529	AFF3	-0.4	-6.6	-0.34	1.64e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2692947	0.740	rs4907280	chr2:96402126	A/G	cg23100626	chr2:96804247	ASTL	0.29	6.83	0.35	3.97e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg19554555	chr3:13937349	NA	-0.39	-5.91	-0.31	8.62e-9	Ovarian reserve;
LUSC	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-9.96	-0.48	1.28e-20	Coffee consumption (cups per day);
LUSC	cis	rs4268898	0.722	rs34565113	chr2:24423076	G/T	cg06627628	chr2:24431161	ITSN2	0.6	8.36	0.42	1.77e-15	Asthma;
LUSC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-6.8	-0.35	4.8e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2067615	0.560	rs10431462	chr12:107106546	G/A	cg15890332	chr12:107067104	RFX4	0.33	6.02	0.31	4.66e-9	Heart rate;
LUSC	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg07169764	chr2:136633963	MCM6	1.15	17.44	0.69	6.87e-49	Corneal structure;
LUSC	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	0.94	11.64	0.54	1.65e-26	Nonalcoholic fatty liver disease;
LUSC	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg26897989	chr16:1907736	C16orf73	-0.38	-6.25	-0.32	1.26e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.71	0.39	1.46e-13	Ulcerative colitis;
LUSC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg24250549	chr1:154909240	PMVK	0.64	10.73	0.51	2.82e-23	Prostate cancer;
LUSC	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.63	11.1	0.52	1.43e-24	Ulcerative colitis;
LUSC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg18099408	chr3:52552593	STAB1	0.38	6.68	0.34	9.94e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg24642439	chr20:33292090	TP53INP2	0.53	8.13	0.41	8.37e-15	Coronary artery disease;
LUSC	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.35	-0.49	5.87e-22	Eye color traits;
LUSC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	0.92	15.38	0.64	1.02e-40	Breast cancer;
LUSC	cis	rs9341808	0.718	rs9343971	chr6:80882056	C/T	cg08355045	chr6:80787529	NA	0.58	10.07	0.48	5.33e-21	Sitting height ratio;
LUSC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.42	0.42	1.16e-15	Tonsillectomy;
LUSC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg06212747	chr3:49208901	KLHDC8B	0.44	6.05	0.31	3.95e-9	Parkinson's disease;
LUSC	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg17623882	chr6:41773611	USP49	-0.62	-10.52	-0.5	1.58e-22	Menarche (age at onset);
LUSC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg22907277	chr7:1156413	C7orf50	0.63	7.0	0.36	1.38e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.83	-0.35	4.11e-11	Crohn's disease;
LUSC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	cis	rs11971779	0.680	rs11768023	chr7:139054395	T/A	cg07862535	chr7:139043722	LUC7L2	0.59	7.63	0.39	2.51e-13	Diisocyanate-induced asthma;
LUSC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg03233332	chr7:66118400	NA	-0.42	-6.1	-0.32	2.88e-9	Aortic root size;
LUSC	cis	rs981844	0.775	rs62323977	chr4:154746141	G/A	cg14289246	chr4:154710475	SFRP2	0.47	6.21	0.32	1.59e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg01733217	chr16:74700730	RFWD3	0.75	12.29	0.56	6.92e-29	Testicular germ cell tumor;
LUSC	cis	rs3824867	0.881	rs4752829	chr11:47396654	G/A	cg20307385	chr11:47447363	PSMC3	-0.65	-9.13	-0.45	6.79e-18	Mean corpuscular hemoglobin;
LUSC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs9323205	0.723	rs61987304	chr14:51741213	A/G	cg23942311	chr14:51606299	NA	-0.42	-7.91	-0.4	3.73e-14	Cancer;
LUSC	cis	rs7809950	1.000	rs3801948	chr7:107238447	A/T	cg23024343	chr7:107201750	COG5	-0.55	-8.64	-0.43	2.39e-16	Coronary artery disease;
LUSC	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg04374321	chr14:90722782	PSMC1	-0.44	-6.64	-0.34	1.26e-10	Mortality in heart failure;
LUSC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	10.86	0.51	9.73e-24	Prudent dietary pattern;
LUSC	cis	rs243505	0.898	rs243524	chr7:148418181	A/C	cg09806900	chr7:148480153	CUL1	-0.44	-6.39	-0.33	5.65e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6669072	0.679	rs3896732	chr1:91313672	A/G	cg08895590	chr1:91227319	NA	0.32	6.92	0.35	2.37e-11	Cognitive function;
LUSC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg26769984	chr7:1090371	C7orf50	0.56	7.43	0.38	9.3e-13	Bronchopulmonary dysplasia;
LUSC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg03929089	chr4:120376271	NA	-0.94	-16.25	-0.66	3.8e-44	Height;
LUSC	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.41	-0.33	4.95e-10	Neuroticism;
LUSC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg06740227	chr12:86229804	RASSF9	0.39	6.15	0.32	2.22e-9	Major depressive disorder;
LUSC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg00310523	chr12:86230176	RASSF9	0.54	10.06	0.48	5.63e-21	Major depressive disorder;
LUSC	cis	rs6977660	1.000	rs12531373	chr7:19816825	A/C	cg05791153	chr7:19748676	TWISTNB	0.54	6.06	0.31	3.66e-9	Thyroid stimulating hormone;
LUSC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg06238570	chr21:40685208	BRWD1	-0.62	-10.5	-0.5	1.74e-22	Cognitive function;
LUSC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg05082376	chr22:42548792	NA	0.42	6.21	0.32	1.58e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04324509	chr3:101295624	PCNP	0.49	6.2	0.32	1.68e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg02344993	chr17:57696989	CLTC	0.49	7.29	0.37	2.3e-12	Hemoglobin concentration;
LUSC	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg18683606	chr7:100471612	SRRT	0.44	5.87	0.31	1.07e-8	Resting heart rate;
LUSC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-9.99	-0.48	9.62e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6690583	0.573	rs75119114	chr1:85451385	A/C	cg11262906	chr1:85462892	MCOLN2	0.68	6.56	0.34	1.99e-10	Serum sulfate level;
LUSC	cis	rs62400317	0.762	rs62436369	chr6:44867539	C/G	cg18551225	chr6:44695536	NA	-0.46	-7.44	-0.38	8.7e-13	Total body bone mineral density;
LUSC	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg23625390	chr15:77176239	SCAPER	-0.65	-9.87	-0.48	2.56e-20	Blood metabolite levels;
LUSC	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg27284194	chr4:1044797	NA	0.58	8.93	0.44	2.81e-17	Recombination rate (females);
LUSC	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg21545522	chr1:205238299	TMCC2	0.47	8.76	0.43	9.86e-17	Red blood cell count;
LUSC	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg24375607	chr4:120327624	NA	0.78	11.54	0.53	3.88e-26	Corneal astigmatism;
LUSC	cis	rs9311676	0.656	rs62258134	chr3:58398447	C/T	cg13750441	chr3:58318267	PXK	0.35	6.68	0.34	1.02e-10	Systemic lupus erythematosus;
LUSC	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg24060327	chr5:131705240	SLC22A5	0.48	8.18	0.41	5.94e-15	Blood metabolite levels;
LUSC	cis	rs2901656	0.677	rs1063412	chr1:172410967	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.39	8.15	0.41	7.53e-15	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg25258033	chr6:167368657	RNASET2	0.37	5.76	0.3	1.91e-8	Primary biliary cholangitis;
LUSC	cis	rs7640424	0.721	rs162064	chr3:107824061	G/T	cg09227934	chr3:107805635	CD47	-0.38	-6.0	-0.31	5.15e-9	Body mass index;
LUSC	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg07148914	chr20:33460835	GGT7	-0.58	-8.8	-0.43	7.21e-17	Height;
LUSC	cis	rs12476592	0.714	rs262492	chr2:63844685	G/A	cg10828910	chr2:63850056	LOC388955	0.54	6.39	0.33	5.58e-10	Childhood ear infection;
LUSC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg20283391	chr11:68216788	NA	-0.56	-7.9	-0.4	4.18e-14	Total body bone mineral density;
LUSC	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.09e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg00933542	chr6:150070202	PCMT1	0.29	5.93	0.31	7.45e-9	Lung cancer;
LUSC	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg03433033	chr1:76189801	ACADM	-0.49	-7.5	-0.38	5.97e-13	Daytime sleep phenotypes;
LUSC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	9.64	0.47	1.47e-19	Mean platelet volume;
LUSC	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg11395062	chr17:14139857	CDRT15	0.4	6.04	0.31	4.01e-9	Temperament;
LUSC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08677398	chr8:58056175	NA	0.54	7.38	0.37	1.24e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.74	0.84	1.09e-88	Chronic sinus infection;
LUSC	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-7.97	-0.4	2.62e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs13082711	0.911	rs13077400	chr3:27473066	A/G	cg02860705	chr3:27208620	NA	0.44	7.28	0.37	2.34e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs73206853	0.764	rs73206868	chr12:110816835	G/T	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg25214090	chr10:38739885	LOC399744	0.42	6.3	0.33	9.58e-10	Corneal astigmatism;
LUSC	cis	rs7512552	0.839	rs2647373	chr1:150320570	G/C	cg15654264	chr1:150340011	RPRD2	0.69	11.59	0.54	2.51e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08048268	chr3:133502702	NA	-0.48	-9.29	-0.45	2.11e-18	Iron status biomarkers;
LUSC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06022373	chr22:39101656	GTPBP1	0.76	11.93	0.55	1.43e-27	Menopause (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11227645	chr1:224544764	CNIH4	-0.49	-6.73	-0.35	7.49e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10754283	0.934	rs6684676	chr1:90102173	C/T	cg21401794	chr1:90099060	LRRC8C	0.65	9.79	0.47	4.51e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08439880	chr3:133502540	NA	-0.38	-6.95	-0.36	1.97e-11	Iron status biomarkers;
LUSC	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg05343316	chr1:45956843	TESK2	0.66	9.01	0.44	1.62e-17	Platelet count;
LUSC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	5.76	0.3	1.93e-8	Schizophrenia;
LUSC	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-1.23	-16.37	-0.67	1.18e-44	Hip circumference adjusted for BMI;
LUSC	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.55	-8.76	-0.43	9.73e-17	Schizophrenia;
LUSC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.88	-11.27	-0.52	3.51e-25	Chronic sinus infection;
LUSC	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg01028140	chr2:1542097	TPO	-0.6	-8.02	-0.4	1.86e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg01119278	chr6:110721349	DDO	-0.47	-8.34	-0.42	1.93e-15	Platelet distribution width;
LUSC	cis	rs722599	0.683	rs7145246	chr14:75242394	A/T	cg08847533	chr14:75593920	NEK9	-0.46	-6.39	-0.33	5.48e-10	IgG glycosylation;
LUSC	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg13390004	chr1:15929781	NA	0.4	6.5	0.33	2.99e-10	Systolic blood pressure;
LUSC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.78	0.3	1.72e-8	Menopause (age at onset);
LUSC	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg09307838	chr4:120376055	NA	0.7	10.03	0.48	7.31e-21	Corneal astigmatism;
LUSC	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-6.68	-0.34	9.83e-11	Homocysteine levels;
LUSC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg15595755	chr5:1867978	NA	0.45	8.15	0.41	7.3e-15	Cardiovascular disease risk factors;
LUSC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg14789911	chr21:47582049	C21orf56	0.39	6.22	0.32	1.48e-9	Testicular germ cell tumor;
LUSC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11764359	chr7:65958608	NA	-0.69	-11.1	-0.52	1.42e-24	Aortic root size;
LUSC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.57	-8.91	-0.44	3.38e-17	Alzheimer's disease (late onset);
LUSC	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg25214090	chr10:38739885	LOC399744	0.54	8.05	0.4	1.44e-14	Corneal astigmatism;
LUSC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg11941060	chr3:133502564	NA	-0.54	-8.41	-0.42	1.18e-15	Iron status biomarkers;
LUSC	trans	rs61931739	0.817	rs866515	chr12:34215479	A/G	cg26384229	chr12:38710491	ALG10B	0.54	8.61	0.43	2.89e-16	Morning vs. evening chronotype;
LUSC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg18350739	chr11:68623251	NA	-0.37	-6.36	-0.33	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs16854884	0.632	rs1466941	chr3:143670131	A/G	cg06585982	chr3:143692056	C3orf58	0.52	8.13	0.41	8.4e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.01	-22.2	-0.77	1.04e-67	Ulcerative colitis;
LUSC	cis	rs73198271	0.562	rs76960788	chr8:8674049	C/T	cg01851573	chr8:8652454	MFHAS1	0.67	8.61	0.43	2.93e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.64	11.0	0.52	3.11e-24	Bone mineral density;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08811349	chr8:124286482	ZHX1	0.46	6.43	0.33	4.4e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.45	-8.21	-0.41	4.86e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs17155006	0.563	rs451416	chr7:107738531	A/G	cg05962710	chr7:107745446	LAMB4	-0.36	-6.3	-0.33	9.63e-10	Pneumococcal bacteremia;
LUSC	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg04733989	chr22:42467013	NAGA	-0.4	-6.58	-0.34	1.77e-10	Cognitive function;
LUSC	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg23298862	chr7:158159286	PTPRN2	0.32	5.68	0.3	2.87e-8	Response to amphetamines;
LUSC	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg02269571	chr22:50332266	NA	-0.48	-7.27	-0.37	2.63e-12	Schizophrenia;
LUSC	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08219700	chr8:58056026	NA	0.7	7.95	0.4	2.95e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322817	0.691	rs2499667	chr6:105319125	G/A	cg02098413	chr6:105308735	HACE1	0.27	5.8	0.3	1.52e-8	Thyroid stimulating hormone;
LUSC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.44	-7.49	-0.38	6.29e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4443100	0.670	rs13054331	chr22:23407063	G/A	cg21100191	chr22:23484243	RTDR1	0.56	7.0	0.36	1.37e-11	Serum parathyroid hormone levels;
LUSC	cis	rs3741151	0.686	rs11235809	chr11:73290163	A/G	cg17517138	chr11:73019481	ARHGEF17	0.76	7.07	0.36	8.94e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.8	-0.35	4.88e-11	Menopause (age at onset);
LUSC	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg06671706	chr8:8559999	CLDN23	0.46	6.29	0.33	1.02e-9	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.64	0.6	5.64e-34	Platelet count;
LUSC	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg24579218	chr15:68104479	NA	-0.4	-6.69	-0.34	9.64e-11	Restless legs syndrome;
LUSC	cis	rs295140	1.000	rs3739121	chr2:201171014	G/C	cg04283868	chr2:201171347	SPATS2L	0.44	6.63	0.34	1.36e-10	QT interval;
LUSC	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg17376030	chr22:41985996	PMM1	-0.42	-5.68	-0.3	2.93e-8	Vitiligo;
LUSC	cis	rs240764	0.621	rs6570930	chr6:101181258	C/A	cg09795085	chr6:101329169	ASCC3	-0.43	-6.32	-0.33	8.54e-10	Neuroticism;
LUSC	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.64	8.62	0.43	2.79e-16	Menarche (age at onset);
LUSC	cis	rs7072216	0.763	rs12763326	chr10:100167396	A/G	cg26618903	chr10:100175079	PYROXD2	0.44	8.23	0.41	4.26e-15	Metabolite levels;
LUSC	cis	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg21775007	chr8:11205619	TDH	-0.44	-6.02	-0.31	4.52e-9	Neuroticism;
LUSC	cis	rs62432291	0.681	rs386818	chr6:159660255	T/C	cg14500486	chr6:159655392	FNDC1	-0.54	-6.06	-0.31	3.76e-9	Joint mobility (Beighton score);
LUSC	cis	rs9868809	0.881	rs57334642	chr3:48666795	C/T	cg00383909	chr3:49044727	WDR6	1.0	8.42	0.42	1.14e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.61	9.21	0.45	3.79e-18	Blood protein levels;
LUSC	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg05082376	chr22:42548792	NA	-0.4	-6.65	-0.34	1.22e-10	Cognitive function;
LUSC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg05347473	chr6:146136440	FBXO30	0.59	10.32	0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg15704280	chr7:45808275	SEPT13	-0.62	-8.17	-0.41	6.64e-15	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs1015291	0.708	rs1586839	chr12:19998176	C/A	cg01501474	chr7:55323552	NA	-0.45	-5.97	-0.31	6.09e-9	Diastolic blood pressure;
LUSC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg15335139	chr3:50242325	SLC38A3	-0.26	-5.71	-0.3	2.56e-8	Body mass index;
LUSC	cis	rs3857536	0.813	rs2188589	chr6:66939570	C/T	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	trans	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.17	-0.32	2.03e-9	Triglycerides;
LUSC	cis	rs9341808	0.754	rs9294173	chr6:80991630	T/A	cg08355045	chr6:80787529	NA	0.55	9.81	0.47	4.08e-20	Sitting height ratio;
LUSC	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg05343316	chr1:45956843	TESK2	0.65	8.91	0.44	3.31e-17	Platelet count;
LUSC	cis	rs500891	0.574	rs3798890	chr6:84119361	G/A	cg08257003	chr6:84140564	ME1	0.34	7.6	0.38	3.06e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg04310649	chr10:35416472	CREM	0.4	6.26	0.32	1.18e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg08999081	chr20:33150536	PIGU	0.38	6.9	0.35	2.68e-11	Height;
LUSC	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg24375607	chr4:120327624	NA	0.52	8.3	0.41	2.62e-15	Diastolic blood pressure;
LUSC	cis	rs1568889	0.592	rs11828877	chr11:28384030	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.55	6.68	0.34	1.02e-10	Bipolar disorder;
LUSC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06112835	chr11:68658793	MRPL21	0.52	7.92	0.4	3.5e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg03790207	chr6:42947109	PEX6	-0.45	-6.93	-0.35	2.14e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.52	-0.34	2.67e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9309473	0.950	rs6735946	chr2:73790058	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.45	-0.33	4.02e-10	Metabolite levels;
LUSC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06112835	chr11:68658793	MRPL21	0.51	7.58	0.38	3.39e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg22823121	chr1:150693482	HORMAD1	-0.56	-8.09	-0.4	1.08e-14	Melanoma;
LUSC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.61	8.09	0.4	1.1e-14	High light scatter reticulocyte count;
LUSC	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.7	10.91	0.51	6.34e-24	Breast cancer;
LUSC	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg04117972	chr1:227635322	NA	0.75	7.37	0.37	1.33e-12	Major depressive disorder;
LUSC	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21775007	chr8:11205619	TDH	0.7	11.29	0.53	2.85e-25	Retinal vascular caliber;
LUSC	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg22705602	chr4:152727874	NA	0.34	7.07	0.36	9.2e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1256061	0.603	rs1256037	chr14:64743301	G/A	cg23250157	chr14:64679961	SYNE2	0.32	5.71	0.3	2.56e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs1865721	0.804	rs3745084	chr18:73142510	T/G	cg26385618	chr18:73139727	C18orf62	-0.54	-9.92	-0.48	1.66e-20	Intelligence;
LUSC	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg00540400	chr15:79124168	NA	0.46	8.1	0.41	1.06e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7937682	0.593	rs1113851	chr11:111354161	G/A	cg09085632	chr11:111637200	PPP2R1B	0.44	5.87	0.31	1.04e-8	Primary sclerosing cholangitis;
LUSC	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg19628046	chr18:33552617	C18orf21	0.48	5.76	0.3	1.92e-8	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.57	-9.38	-0.46	1.06e-18	Aortic root size;
LUSC	cis	rs6882046	0.513	rs454214	chr5:88003403	A/G	cg22951263	chr5:87985283	NA	0.43	7.06	0.36	9.61e-12	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LUSC	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.87	14.76	0.63	2.57e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11764359	chr7:65958608	NA	-0.63	-9.44	-0.46	6.48e-19	Aortic root size;
LUSC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00166722	chr3:10149974	C3orf24	0.58	7.81	0.39	7.42e-14	Alzheimer's disease;
LUSC	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg11502198	chr6:26597334	ABT1	0.6	9.37	0.46	1.09e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg23625390	chr15:77176239	SCAPER	-0.61	-8.65	-0.43	2.22e-16	Blood metabolite levels;
LUSC	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.34	-0.33	7.51e-10	Systolic blood pressure;
LUSC	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.87	0.35	3.06e-11	Rheumatoid arthritis;
LUSC	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.21	-0.32	1.58e-9	Bipolar disorder;
LUSC	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg17757837	chr7:157058334	UBE3C	0.84	13.53	0.59	1.49e-33	Body mass index;
LUSC	cis	rs1519814	1.000	rs12678023	chr8:121123494	G/A	cg22335954	chr8:121166405	COL14A1	-0.41	-5.65	-0.3	3.44e-8	Breast cancer;
LUSC	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.96	-12.45	-0.56	1.77e-29	Exhaled nitric oxide output;
LUSC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg18758796	chr5:131593413	PDLIM4	0.44	7.07	0.36	9.24e-12	Breast cancer;
LUSC	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg09307838	chr4:120376055	NA	0.64	9.64	0.47	1.4e-19	Educational attainment;
LUSC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.81	13.73	0.6	2.58e-34	Blood protein levels;
LUSC	cis	rs1018697	1.000	rs11191397	chr10:104558274	C/A	cg04362960	chr10:104952993	NT5C2	0.46	6.41	0.33	5.1e-10	Colorectal adenoma (advanced);
LUSC	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg08000102	chr2:233561755	GIGYF2	0.68	11.26	0.52	3.82e-25	Coronary artery disease;
LUSC	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg27068330	chr11:65405492	SIPA1	-0.74	-10.28	-0.49	9.83e-22	Acne (severe);
LUSC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.38	6.6	0.34	1.62e-10	Obesity-related traits;
LUSC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11645453	chr3:52864694	ITIH4	0.35	8.09	0.4	1.09e-14	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.96	0.77	8.44e-67	Prudent dietary pattern;
LUSC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	15.94	0.66	6e-43	Platelet count;
LUSC	cis	rs977987	0.835	rs1010630	chr16:75328591	G/T	cg04384234	chr16:75411784	CFDP1	-0.41	-6.68	-0.34	9.98e-11	Dupuytren's disease;
LUSC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.17	0.37	4.8e-12	Platelet count;
LUSC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	11.13	0.52	1.12e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.72	9.28	0.45	2.12e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-6.28	-0.33	1.04e-9	Fear of minor pain;
LUSC	trans	rs17266958	1.000	rs17083747	chr9:83292983	A/C	cg01905489	chr1:26616534	UBXN11	-0.59	-6.46	-0.33	3.62e-10	Preschool internalizing problems;
LUSC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg25174290	chr11:3078921	CARS	0.57	8.58	0.42	3.72e-16	Type 2 diabetes;
LUSC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.98	-0.4	2.39e-14	Mean platelet volume;
LUSC	cis	rs1957429	0.614	rs17883073	chr14:65404059	G/A	cg23373153	chr14:65346875	NA	-0.98	-7.74	-0.39	1.16e-13	Pediatric areal bone mineral density (radius);
LUSC	trans	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg19694781	chr19:47549865	TMEM160	-0.39	-6.2	-0.32	1.67e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21659725	chr3:3221576	CRBN	-0.58	-8.2	-0.41	5.33e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.61	-0.47	1.89e-19	Coronary artery disease;
LUSC	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg23029597	chr12:123009494	RSRC2	-0.71	-9.45	-0.46	6.22e-19	Body mass index;
LUSC	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14019695	chr9:139328340	INPP5E	-0.5	-9.67	-0.47	1.18e-19	Monocyte percentage of white cells;
LUSC	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.1	-17.98	-0.7	4.8e-51	Primary sclerosing cholangitis;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10797726	chr6:82957093	IBTK	0.4	6.14	0.32	2.32e-9	Triglycerides;
LUSC	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg20368463	chr18:77673604	PQLC1	0.68	9.85	0.47	2.82e-20	Schizophrenia;
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg17372223	chr3:52568218	NT5DC2	0.4	6.34	0.33	7.56e-10	Electroencephalogram traits;
LUSC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs10761482	0.954	rs10994305	chr10:62085999	A/C	cg18175470	chr10:62150864	ANK3	-0.49	-6.86	-0.35	3.27e-11	Schizophrenia;
LUSC	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg23625390	chr15:77176239	SCAPER	-0.62	-8.66	-0.43	2.04e-16	Blood metabolite levels;
LUSC	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	8.09	0.4	1.1e-14	Response to antipsychotic treatment;
LUSC	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg11584989	chr19:19387371	SF4	-0.55	-6.31	-0.33	8.61e-10	Bipolar disorder;
LUSC	cis	rs3764563	0.877	rs4646526	chr19:15729773	A/G	cg20725493	chr19:15740067	CYP4F8	-0.6	-6.59	-0.34	1.67e-10	Inflammatory biomarkers;
LUSC	cis	rs75804782	0.521	rs56340711	chr2:239440080	A/T	cg18131467	chr2:239335373	ASB1	-0.67	-6.01	-0.31	4.73e-9	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg13565492	chr6:43139072	SRF	-0.63	-6.63	-0.34	1.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg24579218	chr15:68104479	NA	0.39	6.37	0.33	6.42e-10	Restless legs syndrome;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.91	18.84	0.72	1.91e-54	Menarche (age at onset);
LUSC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17173187	chr15:85201210	NMB	0.47	8.85	0.44	5.16e-17	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg17366294	chr4:99064904	C4orf37	0.55	9.59	0.46	2.07e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.75	-0.35	6.47e-11	Alzheimer's disease (late onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08120389	chr17:19881268	AKAP10	-0.46	-6.08	-0.32	3.3e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs2270927	0.510	rs246814	chr5:75599208	C/T	cg13563193	chr19:33072644	PDCD5	0.74	6.02	0.31	4.54e-9	Mean corpuscular volume;
LUSC	cis	rs7561273	0.586	rs7589717	chr2:24357463	G/A	cg20701182	chr2:24300061	SF3B14	0.46	5.87	0.31	1.05e-8	Quantitative traits;
LUSC	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	6.58	0.34	1.87e-10	Joint mobility (Beighton score);
LUSC	trans	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg24313572	chr1:56050060	NA	-0.29	-6.1	-0.32	2.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.8	-0.65	2.19e-42	Height;
LUSC	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg17173187	chr15:85201210	NMB	-0.37	-6.29	-0.33	9.98e-10	Schizophrenia;
LUSC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12516959	chr21:47718080	NA	-0.36	-6.09	-0.32	3.11e-9	Testicular germ cell tumor;
LUSC	cis	rs7188861	0.724	rs34437200	chr16:11391710	G/A	cg00044050	chr16:11439710	C16orf75	0.57	6.35	0.33	7.17e-10	HDL cholesterol;
LUSC	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg08755490	chr11:65554678	OVOL1	0.4	5.84	0.3	1.24e-8	Acne (severe);
LUSC	cis	rs951266	0.505	rs11639372	chr15:78966655	C/T	cg00540400	chr15:79124168	NA	-0.33	-5.74	-0.3	2.11e-8	Post bronchodilator FEV1/FVC ratio in COPD;Pre bronchodilator FEV1;Pre bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg21100191	chr22:23484243	RTDR1	0.93	16.05	0.66	2.35e-43	Bone mineral density;
LUSC	cis	rs243505	0.559	rs2072408	chr7:148508197	A/G	cg09806900	chr7:148480153	CUL1	0.66	9.88	0.48	2.29e-20	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg18850127	chr7:39170497	POU6F2	0.67	11.0	0.52	3.09e-24	IgG glycosylation;
LUSC	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.61	-0.47	1.84e-19	Morning vs. evening chronotype;
LUSC	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg00198436	chr1:120839380	FAM72B	0.41	6.17	0.32	1.96e-9	Schizophrenia;
LUSC	cis	rs7215564	0.908	rs34384177	chr17:78667040	A/T	cg09596252	chr17:78655493	RPTOR	0.52	5.67	0.3	3.1e-8	Myopia (pathological);
LUSC	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg05347473	chr6:146136440	FBXO30	0.54	9.24	0.45	2.91e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-7.13	-0.36	6.2e-12	Lung cancer;
LUSC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg14983838	chr19:29218262	NA	0.56	6.53	0.34	2.49e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	trans	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg18335740	chr13:41363409	SLC25A15	-0.57	-8.64	-0.43	2.34e-16	Lewy body disease;
LUSC	cis	rs870825	0.616	rs9631782	chr4:185626379	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.77e-32	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06295032	chr4:113206875	TIFA	-0.44	-6.8	-0.35	4.72e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg09455208	chr3:40491958	NA	0.53	9.39	0.46	9.85e-19	Renal cell carcinoma;
LUSC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.8	0.39	7.87e-14	Gut microbiome composition (summer);
LUSC	cis	rs10392	0.543	rs56660421	chr20:37559329	G/T	cg27552599	chr20:37590471	DHX35	0.46	7.32	0.37	1.92e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg19592336	chr6:28129416	ZNF389	0.51	6.67	0.34	1.06e-10	Parkinson's disease;
LUSC	trans	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg18335740	chr13:41363409	SLC25A15	0.47	6.88	0.35	2.93e-11	Lewy body disease;
LUSC	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg11845111	chr2:191398756	TMEM194B	-0.85	-10.7	-0.51	3.51e-23	Diastolic blood pressure;
LUSC	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.38	0.33	5.9e-10	Morning vs. evening chronotype;
LUSC	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg00071950	chr4:10020882	SLC2A9	0.51	8.48	0.42	7.55e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg15704280	chr7:45808275	SEPT13	-0.57	-7.11	-0.36	7.14e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10992471	0.603	rs10761163	chr9:95313287	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.81	-0.35	4.48e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg05360138	chr12:110035743	NA	0.88	10.35	0.49	5.75e-22	Neuroticism;
LUSC	cis	rs500891	0.525	rs6454321	chr6:84050941	A/G	cg08257003	chr6:84140564	ME1	0.34	8.09	0.4	1.08e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs4072705	0.585	rs7852843	chr9:127233823	C/T	cg13476313	chr9:127244764	NR5A1	-0.34	-6.69	-0.34	9.33e-11	Menarche (age at onset);
LUSC	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg08213375	chr14:104286397	PPP1R13B	0.52	10.31	0.49	8.03e-22	Schizophrenia;
LUSC	cis	rs7202877	0.561	rs7202083	chr16:75383727	G/T	cg04384234	chr16:75411784	CFDP1	-0.6	-7.13	-0.36	6.32e-12	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.77	-0.35	5.91e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg23711669	chr6:146136114	FBXO30	0.85	15.19	0.64	5.38e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs4474465	0.790	rs10793331	chr11:78270000	C/T	cg27205649	chr11:78285834	NARS2	0.52	6.24	0.32	1.29e-9	Alzheimer's disease (survival time);
LUSC	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-0.93	-17.69	-0.7	6.87e-50	Headache;
LUSC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.98	0.31	5.64e-9	Lung cancer;
LUSC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg05802129	chr4:122689817	NA	-0.52	-8.64	-0.43	2.3e-16	Type 2 diabetes;
LUSC	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-0.89	-12.48	-0.56	1.36e-29	Dilated cardiomyopathy;
LUSC	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	12.64	0.57	3.34e-30	Electrocardiographic conduction measures;
LUSC	cis	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05901451	chr6:126070800	HEY2	0.57	8.57	0.42	3.94e-16	Endometrial cancer;
LUSC	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg05340658	chr4:99064831	C4orf37	0.44	6.85	0.35	3.55e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	0.7	11.2	0.52	6.03e-25	Blood metabolite ratios;
LUSC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18932078	chr1:2524107	MMEL1	-0.31	-6.93	-0.35	2.21e-11	Ulcerative colitis;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11930279	chr12:12022652	ETV6	-0.81	-6.57	-0.34	1.89e-10	Cognitive performance;
LUSC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg11861562	chr11:117069780	TAGLN	-0.44	-7.96	-0.4	2.64e-14	Blood protein levels;
LUSC	cis	rs9517320	0.967	rs9517317	chr13:99125711	G/C	cg20487152	chr13:99095054	FARP1	0.34	6.4	0.33	5.25e-10	Longevity;
LUSC	cis	rs13315871	0.929	rs35376204	chr3:58325563	T/C	cg20936604	chr3:58311152	NA	-0.77	-7.27	-0.37	2.56e-12	Cholesterol, total;
LUSC	trans	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-7.09	-0.36	8.11e-12	Menarche (age at onset);
LUSC	cis	rs7527798	0.592	rs6671969	chr1:207839667	C/T	cg09232269	chr1:207846808	CR1L	-0.27	-5.79	-0.3	1.64e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg02569458	chr12:86230093	RASSF9	-0.47	-7.93	-0.4	3.34e-14	Major depressive disorder;
LUSC	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg03168497	chr17:48586147	MYCBPAP	0.49	6.42	0.33	4.6e-10	Visceral fat;
LUSC	cis	rs7246967	0.611	rs73022711	chr19:22875404	G/A	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg25664220	chr3:72788482	NA	-0.69	-11.29	-0.53	3.05e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg03929089	chr4:120376271	NA	-0.94	-16.25	-0.66	3.8e-44	Height;
LUSC	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.84	-0.44	5.55e-17	Monocyte percentage of white cells;
LUSC	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg09904177	chr6:26538194	HMGN4	-0.72	-6.72	-0.35	7.96e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg05425664	chr17:57184151	TRIM37	-0.51	-7.61	-0.38	2.84e-13	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg25174290	chr11:3078921	CARS	-0.42	-6.21	-0.32	1.61e-9	Calcium levels;
LUSC	cis	rs73206853	0.841	rs7971568	chr12:110780612	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	6.43	0.33	4.37e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.59	9.74	0.47	6.88e-20	Bone mineral density;
LUSC	cis	rs240768	0.826	rs117366009	chr6:100959054	G/A	cg12253828	chr6:101329408	ASCC3	0.84	5.85	0.31	1.15e-8	Economic and political preferences (immigration/crime);
LUSC	cis	rs3770081	1.000	rs76052260	chr2:86328727	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.92	-0.35	2.37e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg12463550	chr7:65579703	CRCP	0.55	8.1	0.41	1.05e-14	Aortic root size;
LUSC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg03233332	chr7:66118400	NA	-0.42	-6.08	-0.32	3.25e-9	Aortic root size;
LUSC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.37	0.37	1.35e-12	Bipolar disorder;
LUSC	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg26874229	chr2:105853672	NA	-0.32	-5.99	-0.31	5.32e-9	Type 2 diabetes;
LUSC	cis	rs778371	0.834	rs778364	chr2:233777859	A/G	cg08000102	chr2:233561755	GIGYF2	0.54	6.85	0.35	3.58e-11	Schizophrenia;
LUSC	cis	rs68170813	0.652	rs17482543	chr7:107169174	C/G	cg02696742	chr7:106810147	HBP1	-0.64	-8.63	-0.43	2.46e-16	Coronary artery disease;
LUSC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg03732007	chr1:2071316	PRKCZ	0.6	11.25	0.52	3.94e-25	Height;
LUSC	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg16346588	chr10:242978	ZMYND11	-0.39	-5.69	-0.3	2.79e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg16928487	chr17:17741425	SREBF1	-0.45	-9.06	-0.44	1.11e-17	Total body bone mineral density;
LUSC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg12257692	chr3:49977190	RBM6	-0.26	-7.41	-0.38	1.05e-12	Body mass index;
LUSC	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg13010199	chr12:38710504	ALG10B	0.53	7.92	0.4	3.56e-14	Morning vs. evening chronotype;
LUSC	cis	rs4363385	0.747	rs12048412	chr1:152977092	A/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.84	-0.39	6.02e-14	Inflammatory skin disease;
LUSC	cis	rs921665	0.831	rs6751452	chr2:3183930	T/G	cg16434511	chr2:3151078	NA	-0.59	-6.35	-0.33	6.99e-10	World class endurance athleticism;
LUSC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg13699009	chr12:122356056	WDR66	0.51	7.9	0.4	4.12e-14	Mean corpuscular volume;
LUSC	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg27124370	chr19:33622961	WDR88	0.52	6.71	0.34	8.59e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg13385521	chr17:29058706	SUZ12P	0.59	6.03	0.31	4.41e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg14458575	chr2:238380390	NA	0.68	12.06	0.55	4.8e-28	Prostate cancer;
LUSC	cis	rs2637266	0.967	rs2579748	chr10:78328313	T/C	cg18941641	chr10:78392320	NA	0.38	6.9	0.35	2.66e-11	Pulmonary function;
LUSC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.09	-0.36	7.88e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	8.94	0.44	2.69e-17	Total body bone mineral density;
LUSC	cis	rs7577696	0.752	rs12618002	chr2:32347715	A/T	cg02381751	chr2:32503542	YIPF4	-0.43	-5.86	-0.31	1.13e-8	Inflammatory biomarkers;
LUSC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.64	-0.6	5.38e-34	Chronic sinus infection;
LUSC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-13.62	-0.6	6.89e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg17480646	chr11:65405466	SIPA1	-0.45	-5.83	-0.3	1.3e-8	Acne (severe);
LUSC	cis	rs6752107	0.512	rs1372097	chr2:234227047	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	6.77	0.35	5.77e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg11189052	chr15:85197271	WDR73	0.48	5.96	0.31	6.31e-9	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.62	6.57	0.34	1.96e-10	Schizophrenia;
LUSC	cis	rs9303542	0.625	rs8064626	chr17:46567851	G/A	cg09704116	chr17:46666958	LOC404266	-0.38	-6.42	-0.33	4.76e-10	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs4704187	0.687	rs6864485	chr5:74497984	T/C	cg03227963	chr5:74354835	NA	0.3	6.64	0.34	1.24e-10	Response to amphetamines;
LUSC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	8.9	0.44	3.59e-17	Bipolar disorder;
LUSC	trans	rs72834455	0.925	rs72834469	chr2:119518903	T/A	cg02397686	chr17:73851076	WBP2	-0.65	-6.09	-0.32	3.19e-9	Tonsillectomy;
LUSC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	12.23	0.56	1.16e-28	Cognitive test performance;
LUSC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19346786	chr7:2764209	NA	-0.51	-8.6	-0.43	3.22e-16	Height;
LUSC	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg24910161	chr17:38119198	GSDMA	0.28	6.2	0.32	1.65e-9	Asthma and hay fever;
LUSC	cis	rs2109514	0.967	rs10271007	chr7:116145849	A/G	cg12739419	chr7:116140593	CAV2	-0.28	-6.3	-0.33	9.42e-10	Prevalent atrial fibrillation;
LUSC	cis	rs679087	0.932	rs10843506	chr12:29930883	G/A	cg14258853	chr12:29935411	TMTC1	0.85	14.64	0.63	7.49e-38	Schizophrenia;
LUSC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg20891283	chr12:69753455	YEATS4	0.43	5.77	0.3	1.77e-8	Response to diuretic therapy;
LUSC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg02153584	chr22:29168773	CCDC117	0.66	10.72	0.51	3.16e-23	Lymphocyte counts;
LUSC	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg01884057	chr2:25150051	NA	0.47	11.19	0.52	6.54e-25	Body mass index;
LUSC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg24829409	chr8:58192753	C8orf71	-0.57	-6.08	-0.32	3.31e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg10253484	chr15:75165896	SCAMP2	0.45	6.22	0.32	1.45e-9	Systemic lupus erythematosus;
LUSC	cis	rs3924048	0.559	rs4075303	chr1:12626593	C/G	cg23650765	chr1:12612165	NA	0.29	5.73	0.3	2.27e-8	Optic cup area;
LUSC	cis	rs655601	1.000	rs655601	chr5:180226673	G/T	cg13724780	chr5:180237085	MGAT1	-0.58	-5.83	-0.3	1.31e-8	Quantitative traits;
LUSC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	7.99	0.4	2.2e-14	Menarche (age at onset);
LUSC	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg03474202	chr17:45855739	NA	0.3	6.9	0.35	2.6e-11	IgG glycosylation;
LUSC	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.65	-0.43	2.17e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs17540621	1.000	rs115360269	chr2:47232527	C/T	cg23978866	chr2:47230407	TTC7A	-0.97	-6.63	-0.34	1.38e-10	Response to statin therapy;
LUSC	cis	rs7833986	0.501	rs2667983	chr8:56894087	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	11.16	0.52	8.31e-25	Height;
LUSC	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.47	-0.42	7.8e-16	Response to antipsychotic treatment;
LUSC	cis	rs1595825	0.786	rs75415672	chr2:198535679	G/A	cg19156104	chr2:198669113	PLCL1	-0.46	-5.73	-0.3	2.23e-8	Ulcerative colitis;
LUSC	trans	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg27661571	chr11:113659931	NA	-0.56	-6.61	-0.34	1.52e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	1.23	19.55	0.73	2.84e-57	Corneal structure;
LUSC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg07212818	chr11:638076	DRD4	-0.42	-7.03	-0.36	1.16e-11	Systemic lupus erythematosus;
LUSC	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.43	-7.77	-0.39	9.76e-14	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg05294307	chr14:35346193	BAZ1A	-0.58	-6.65	-0.34	1.23e-10	Psoriasis;
LUSC	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.83	14.24	0.61	2.86e-36	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs3755132	0.929	rs6708314	chr2:15745211	T/C	cg12888861	chr2:15731646	DDX1	0.5	7.27	0.37	2.55e-12	Wilms tumor;
LUSC	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.08	0.64	1.48e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	0.91	15.69	0.65	5.96e-42	Heart rate;
LUSC	cis	rs4343996	0.692	rs34148253	chr7:3454978	A/G	cg21248987	chr7:3385318	SDK1	0.36	5.89	0.31	9.35e-9	Motion sickness;
LUSC	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg04374321	chr14:90722782	PSMC1	0.73	11.62	0.54	1.91e-26	Mortality in heart failure;
LUSC	cis	rs9815354	1.000	rs1716644	chr3:41968028	A/G	cg03022575	chr3:42003672	ULK4	-0.58	-6.4	-0.33	5.41e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25072359	chr17:41440525	NA	0.66	9.42	0.46	7.64e-19	Menopause (age at onset);
LUSC	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg05925327	chr15:68127851	NA	-0.42	-6.3	-0.33	9.14e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	trans	rs72674100	0.881	rs72874647	chr4:97964813	A/G	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.68	-10.88	-0.51	8.47e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs977987	0.898	rs12918797	chr16:75493810	T/C	cg04384234	chr16:75411784	CFDP1	-0.48	-7.87	-0.4	5.05e-14	Dupuytren's disease;
LUSC	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg04374321	chr14:90722782	PSMC1	0.71	11.54	0.53	3.65e-26	Mortality in heart failure;
LUSC	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg04851639	chr8:1020857	NA	-0.37	-7.91	-0.4	3.82e-14	Schizophrenia;
LUSC	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.87	-14.3	-0.62	1.62e-36	Schizophrenia;
LUSC	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-10.11	-0.48	3.97e-21	Schizophrenia;
LUSC	cis	rs2688608	0.967	rs1815076	chr10:75659886	C/T	cg23231163	chr10:75533350	FUT11	-0.37	-5.96	-0.31	6.57e-9	Inflammatory bowel disease;
LUSC	cis	rs9283706	0.594	rs7734953	chr5:66349943	G/T	cg11590213	chr5:66331682	MAST4	0.49	7.22	0.37	3.44e-12	Coronary artery disease;
LUSC	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg02640540	chr1:67518911	SLC35D1	0.6	8.62	0.43	2.66e-16	Lymphocyte percentage of white cells;
LUSC	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg25457927	chr22:38595422	NA	-0.41	-8.08	-0.4	1.16e-14	Cutaneous nevi;
LUSC	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg11693508	chr17:37793320	STARD3	0.51	6.46	0.33	3.81e-10	Bipolar disorder;
LUSC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.86	-0.47	2.61e-20	Bipolar disorder;
LUSC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg21132104	chr15:45694354	SPATA5L1	0.57	7.97	0.4	2.54e-14	Homoarginine levels;
LUSC	cis	rs9341808	0.935	rs2322633	chr6:80845989	C/T	cg08355045	chr6:80787529	NA	-0.49	-8.66	-0.43	1.99e-16	Sitting height ratio;
LUSC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-6.17	-0.32	2.03e-9	Total body bone mineral density;
LUSC	trans	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18876405	chr7:65276391	NA	-0.55	-9.09	-0.45	9.05e-18	Aortic root size;
LUSC	cis	rs9796	0.866	rs1678750	chr15:41410705	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.04	-0.4	1.55e-14	Menopause (age at onset);
LUSC	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg13010199	chr12:38710504	ALG10B	0.7	10.93	0.51	5.81e-24	Bladder cancer;
LUSC	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.95	12.31	0.56	5.59e-29	Exhaled nitric oxide output;
LUSC	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.42	-5.88	-0.31	9.82e-9	Height;
LUSC	cis	rs16912285	0.748	rs12786638	chr11:24346006	A/G	ch.11.24196551F	chr11:24239977	NA	0.85	8.32	0.41	2.31e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg15691649	chr6:25882328	NA	-0.6	-8.9	-0.44	3.74e-17	Urate levels;
LUSC	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg17848003	chr1:3704513	LRRC47	0.31	6.01	0.31	4.86e-9	Red cell distribution width;
LUSC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg23630131	chr7:65973040	NA	-0.21	-5.9	-0.31	8.71e-9	Aortic root size;
LUSC	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg04117972	chr1:227635322	NA	0.61	6.56	0.34	2e-10	Major depressive disorder;
LUSC	cis	rs354225	0.544	rs3796017	chr2:54807452	T/A	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.47	-0.33	3.56e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.25	0.59	1.67e-32	Chronic sinus infection;
LUSC	trans	rs76248362	1.000	rs9510907	chr13:24435564	A/C	cg26511321	chr7:27196790	HOXA7	0.54	6.24	0.32	1.35e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs6723226	0.721	rs10172510	chr2:32620888	A/G	cg02381751	chr2:32503542	YIPF4	0.48	6.98	0.36	1.57e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.79	-13.29	-0.59	1.17e-32	Aortic root size;
LUSC	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg08917208	chr2:24149416	ATAD2B	-0.54	-6.1	-0.32	2.99e-9	Lymphocyte counts;
LUSC	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.08	-0.44	9.93e-18	Depression;
LUSC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25072359	chr17:41440525	NA	0.64	9.21	0.45	3.69e-18	Menopause (age at onset);
LUSC	cis	rs79387448	0.745	rs17027421	chr2:103159882	A/G	cg09003973	chr2:102972529	NA	0.88	8.56	0.42	4.18e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg24558204	chr6:135376177	HBS1L	0.68	10.82	0.51	1.32e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs6977660	0.943	rs10240816	chr7:19819620	A/C	cg07541023	chr7:19748670	TWISTNB	0.51	5.81	0.3	1.49e-8	Thyroid stimulating hormone;
LUSC	cis	rs2067615	0.524	rs10778500	chr12:107074410	T/A	cg15890332	chr12:107067104	RFX4	0.36	6.33	0.33	7.72e-10	Heart rate;
LUSC	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.28	0.53	3.13e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg05855489	chr10:104503620	C10orf26	-0.49	-7.47	-0.38	7.25e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2274273	0.870	rs10142547	chr14:55763963	T/C	cg04306507	chr14:55594613	LGALS3	0.56	13.23	0.59	2.05e-32	Protein biomarker;
LUSC	cis	rs757278	0.526	rs10272233	chr7:117309974	G/A	cg10524701	chr7:117356490	CTTNBP2	0.4	5.75	0.3	1.99e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs6494488	0.500	rs77463022	chr15:65064841	G/A	cg08069370	chr15:64387884	SNX1	-0.65	-5.91	-0.31	8.23e-9	Coronary artery disease;
LUSC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	6.17	0.32	1.97e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg20573242	chr4:122745356	CCNA2	0.59	8.68	0.43	1.8e-16	Type 2 diabetes;
LUSC	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg13256891	chr4:100009986	ADH5	-0.48	-6.42	-0.33	4.69e-10	Alcohol dependence;
LUSC	trans	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg25214090	chr10:38739885	LOC399744	0.45	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs7923452	1.000	rs7923452	chr10:30751171	T/C	cg25182066	chr10:30743637	MAP3K8	0.56	6.61	0.34	1.51e-10	Itch intensity from mosquito bite;
LUSC	cis	rs13315871	0.929	rs9837903	chr3:58301906	A/T	cg20936604	chr3:58311152	NA	-0.71	-6.73	-0.35	7.52e-11	Cholesterol, total;
LUSC	cis	rs295140	0.586	rs4673904	chr2:201163454	A/T	cg04283868	chr2:201171347	SPATS2L	0.42	6.38	0.33	6.04e-10	QT interval;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg13293757	chr3:48487975	ATRIP	0.63	6.05	0.31	3.95e-9	Body mass index;
LUSC	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.27e-8	Breast cancer;
LUSC	cis	rs13082711	0.522	rs6551192	chr3:27343376	C/T	cg02860705	chr3:27208620	NA	0.45	8.33	0.41	2.07e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.27e-8	Breast cancer;
LUSC	trans	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg11062466	chr8:58055876	NA	0.46	6.23	0.32	1.4e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs981844	0.712	rs1037654	chr4:154750300	C/G	cg14289246	chr4:154710475	SFRP2	-0.46	-6.32	-0.33	8.22e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg17168535	chr8:21777572	XPO7	0.67	10.34	0.49	6.42e-22	Mean corpuscular volume;
LUSC	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-9.19	-0.45	4.4e-18	Axial length;
LUSC	cis	rs17030434	1.000	rs12645134	chr4:154713430	T/C	cg14289246	chr4:154710475	SFRP2	-0.52	-6.91	-0.35	2.48e-11	Electrocardiographic conduction measures;
LUSC	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg20503657	chr10:835505	NA	0.73	9.19	0.45	4.2e-18	Eosinophil percentage of granulocytes;
LUSC	trans	rs2262909	0.853	rs56207853	chr19:22292357	C/T	cg17074339	chr11:11642133	GALNTL4	0.43	6.64	0.34	1.3e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg05340658	chr4:99064831	C4orf37	0.62	9.0	0.44	1.68e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg16482183	chr6:26056742	HIST1H1C	0.46	6.82	0.35	4.18e-11	Height;
LUSC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg27068330	chr11:65405492	SIPA1	-0.46	-5.88	-0.31	1.02e-8	Breast cancer;
LUSC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg08677398	chr8:58056175	NA	0.43	5.66	0.3	3.24e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg09365446	chr1:150670422	GOLPH3L	0.47	6.88	0.35	3.03e-11	Melanoma;
LUSC	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg09324608	chr17:30823087	MYO1D	0.35	5.85	0.3	1.2e-8	Schizophrenia;
LUSC	cis	rs7582180	1.000	rs10865039	chr2:100907351	A/G	cg08017756	chr2:100939284	LONRF2	-0.36	-6.0	-0.31	5.2e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7577696	0.512	rs212691	chr2:32438075	G/A	cg02381751	chr2:32503542	YIPF4	0.53	6.84	0.35	3.76e-11	Inflammatory biomarkers;
LUSC	cis	rs12760731	0.565	rs34676994	chr1:178054513	A/T	cg00404053	chr1:178313656	RASAL2	0.75	6.89	0.35	2.76e-11	Obesity-related traits;
LUSC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg12963246	chr6:28129442	ZNF389	0.52	7.12	0.36	6.72e-12	Depression;
LUSC	cis	rs2932538	0.744	rs6537742	chr1:113085197	G/T	cg22162597	chr1:113214053	CAPZA1	0.63	8.3	0.41	2.61e-15	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08219700	chr8:58056026	NA	0.66	7.82	0.39	7.08e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2798269	0.831	rs11148157	chr13:22137608	A/T	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.04	-0.31	4.15e-9	PR segment;
LUSC	trans	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg25214090	chr10:38739885	LOC399744	-0.37	-6.0	-0.31	5.03e-9	Diastolic blood pressure;
LUSC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-11.04	-0.52	2.27e-24	Glomerular filtration rate (creatinine);
LUSC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06544989	chr22:39130855	UNC84B	0.38	6.76	0.35	6.02e-11	Menopause (age at onset);
LUSC	cis	rs8114671	1.000	rs8114671	chr20:33789142	C/A	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.93	-0.31	7.41e-9	Height;
LUSC	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg26384229	chr12:38710491	ALG10B	0.73	11.38	0.53	1.4e-25	Morning vs. evening chronotype;
LUSC	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.59	-0.34	1.73e-10	Recombination measurement;
LUSC	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg13073564	chr4:8508604	NA	0.37	7.05	0.36	1.05e-11	Response to antineoplastic agents;
LUSC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg13047869	chr3:10149882	C3orf24	0.61	8.47	0.42	7.71e-16	Alzheimer's disease;
LUSC	cis	rs9311676	0.656	rs11130634	chr3:58379123	A/C	cg13750441	chr3:58318267	PXK	0.36	7.06	0.36	9.88e-12	Systemic lupus erythematosus;
LUSC	cis	rs4988958	0.584	rs7589142	chr2:103024660	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.72e-12	Asthma (childhood onset);
LUSC	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg25237894	chr2:233734115	C2orf82	0.35	6.5	0.33	2.96e-10	Coronary artery disease;
LUSC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg21361702	chr7:150065534	REPIN1	0.58	8.35	0.42	1.86e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg06792262	chr3:44622596	ZNF167	0.33	5.68	0.3	2.98e-8	Depressive symptoms;
LUSC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg25019033	chr10:957182	NA	-0.53	-6.75	-0.35	6.68e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.56	-0.42	4.33e-16	Metabolite levels;
LUSC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.71	-0.39	1.43e-13	Joint mobility (Beighton score);
LUSC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.24	0.52	4.35e-25	Menopause (age at onset);
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.7	-0.43	1.52e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs17253792	0.822	rs78824140	chr14:56042715	G/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.92	-0.35	2.29e-11	Putamen volume;
LUSC	cis	rs9039	1.000	rs9932208	chr16:9218267	T/C	cg08831531	chr16:9218945	NA	-0.66	-10.44	-0.5	2.78e-22	Menopause (age at onset);
LUSC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg26354017	chr1:205819088	PM20D1	0.43	6.15	0.32	2.19e-9	Menarche (age at onset);
LUSC	cis	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg02972257	chr16:68554789	NA	-0.48	-6.07	-0.32	3.39e-9	Ulcerative colitis;
LUSC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18404041	chr3:52824283	ITIH1	-0.58	-11.52	-0.53	4.35e-26	Bipolar disorder;
LUSC	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs4363385	0.588	rs6660878	chr1:153027068	A/G	cg25856811	chr1:152973957	SPRR3	-0.36	-5.96	-0.31	6.27e-9	Inflammatory skin disease;
LUSC	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg21045802	chr8:109455806	TTC35	0.46	7.12	0.36	6.47e-12	Dupuytren's disease;
LUSC	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.22e-13	Corneal astigmatism;
LUSC	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg13010199	chr12:38710504	ALG10B	0.7	11.97	0.55	1.04e-27	Heart rate;
LUSC	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg03522245	chr20:25566470	NINL	-0.35	-5.72	-0.3	2.36e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs700651	0.789	rs1371663	chr2:198900305	C/T	cg00792783	chr2:198669748	PLCL1	-0.43	-5.71	-0.3	2.5e-8	Intracranial aneurysm;
LUSC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg05738196	chr6:26577821	NA	0.53	8.32	0.41	2.23e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg13390004	chr1:15929781	NA	0.42	6.98	0.36	1.61e-11	Systolic blood pressure;
LUSC	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.22	0.37	3.53e-12	Blood metabolite levels;
LUSC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg22963979	chr7:1858916	MAD1L1	-0.7	-11.74	-0.54	7.13e-27	Bipolar disorder and schizophrenia;
LUSC	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg16586182	chr3:47516702	SCAP	-0.52	-7.99	-0.4	2.18e-14	Colorectal cancer;
LUSC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6733011	0.518	rs12712033	chr2:99457973	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-5.69	-0.3	2.74e-8	Bipolar disorder;
LUSC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg20243544	chr17:37824526	PNMT	0.48	6.1	0.32	3e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs68170813	0.652	rs117775624	chr7:107124113	C/T	cg02696742	chr7:106810147	HBP1	-0.64	-8.39	-0.42	1.39e-15	Coronary artery disease;
LUSC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.98	0.48	1.09e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.52	10.41	0.49	3.65e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.78	0.3	1.74e-8	Menopause (age at onset);
LUSC	cis	rs7789940	0.904	rs6953281	chr7:75946943	C/T	cg10167463	chr7:75959203	YWHAG	-0.63	-9.32	-0.45	1.61e-18	Multiple sclerosis;
LUSC	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg18232548	chr7:50535776	DDC	-0.58	-8.63	-0.43	2.48e-16	Systemic sclerosis;
LUSC	trans	rs747782	0.527	rs76142260	chr11:48331068	T/C	cg15704280	chr7:45808275	SEPT13	0.77	6.58	0.34	1.84e-10	Intraocular pressure;
LUSC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.91	0.31	8.45e-9	Lung cancer;
LUSC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg08125733	chr17:73851984	WBP2	0.47	6.48	0.33	3.23e-10	White matter hyperintensity burden;
LUSC	cis	rs11031096	0.621	rs11031159	chr11:4179695	T/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.82	-0.3	1.38e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg05110241	chr16:68378359	PRMT7	0.54	6.38	0.33	5.78e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3820928	0.874	rs1114562	chr2:227788592	T/C	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.01	-0.4	1.99e-14	Pulmonary function;
LUSC	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg13798780	chr7:105162888	PUS7	0.56	6.12	0.32	2.55e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg24060327	chr5:131705240	SLC22A5	-0.53	-8.78	-0.43	8.66e-17	Acylcarnitine levels;
LUSC	cis	rs67696533	0.588	rs6141743	chr20:31107399	C/G	cg13636640	chr20:31349939	DNMT3B	0.46	6.17	0.32	1.95e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs12980942	0.591	rs3760660	chr19:41769025	A/T	cg25627403	chr19:41769009	HNRNPUL1	0.69	7.22	0.37	3.45e-12	Coronary artery disease;
LUSC	trans	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg21659725	chr3:3221576	CRBN	0.68	8.24	0.41	3.83e-15	Menarche (age at onset);
LUSC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg19774624	chr17:42201019	HDAC5	-0.45	-6.47	-0.33	3.57e-10	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs78707713	0.512	rs12412776	chr10:71179502	G/A	cg12610070	chr10:71211762	TSPAN15	-0.52	-9.74	-0.47	6.63e-20	Venous thromboembolism;
LUSC	trans	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg12966876	chr2:111873850	ACOXL	0.32	6.0	0.31	5.13e-9	Bipolar disorder;
LUSC	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	cis	rs8112211	0.911	rs60071299	chr19:38850246	G/A	cg14299480	chr19:38876666	GGN	-0.37	-6.29	-0.33	9.87e-10	Blood protein levels;
LUSC	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg26384229	chr12:38710491	ALG10B	0.73	11.48	0.53	5.99e-26	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg03806693	chr22:41940476	POLR3H	-0.83	-12.27	-0.56	8.06e-29	Vitiligo;
LUSC	cis	rs9905704	0.846	rs11079356	chr17:56864242	C/A	cg12560992	chr17:57184187	TRIM37	0.58	8.38	0.42	1.5e-15	Testicular germ cell tumor;
LUSC	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg27147174	chr7:100797783	AP1S1	-0.66	-10.78	-0.51	1.89e-23	Life satisfaction;
LUSC	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18854424	chr1:2615690	NA	0.49	9.67	0.47	1.15e-19	Ulcerative colitis;
LUSC	cis	rs1007190	0.764	rs8070598	chr17:42876865	T/C	cg15406952	chr17:42872593	NA	-0.59	-6.18	-0.32	1.84e-9	DNA methylation (variation);
LUSC	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.64	-6.5	-0.34	2.86e-10	Lung cancer in ever smokers;
LUSC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg02423579	chr7:2872169	GNA12	-0.41	-6.31	-0.33	8.91e-10	Height;
LUSC	cis	rs4285028	0.603	rs79312528	chr3:121608997	T/C	cg11130432	chr3:121712080	ILDR1	-0.65	-9.64	-0.47	1.41e-19	Multiple sclerosis;
LUSC	cis	rs1882538	0.506	rs7805858	chr7:133126589	G/T	cg10665199	chr7:133106180	EXOC4	0.54	7.43	0.38	9.17e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs3772130	0.923	rs13090798	chr3:121482768	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.13	0.48	3.38e-21	Cognitive performance;
LUSC	cis	rs1957429	0.901	rs1957432	chr14:65352796	A/G	cg23373153	chr14:65346875	NA	0.89	11.18	0.52	7.39e-25	Pediatric areal bone mineral density (radius);
LUSC	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.11	-0.36	7.15e-12	Bipolar disorder;
LUSC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg00310523	chr12:86230176	RASSF9	0.49	9.39	0.46	9.64e-19	Major depressive disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18732869	chr19:6739680	TRIP10	-0.51	-6.69	-0.34	9.55e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg03894339	chr8:19674705	INTS10	0.48	6.48	0.33	3.2e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg17264618	chr3:40429014	ENTPD3	0.36	7.43	0.38	9.09e-13	Renal cell carcinoma;
LUSC	cis	rs17014483	0.749	rs3017899	chr4:89643997	C/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.66	5.75	0.3	1.98e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg06096015	chr1:231504339	EGLN1	0.55	9.93	0.48	1.55e-20	Hemoglobin concentration;
LUSC	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.56	-8.41	-0.42	1.23e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg02800362	chr5:177631904	HNRNPAB	0.83	12.38	0.56	3.21e-29	Obesity-related traits;
LUSC	cis	rs12912251	0.947	rs12899449	chr15:38995491	A/G	cg01338139	chr15:38987640	C15orf53	-0.49	-6.9	-0.35	2.68e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs73129298	0.551	rs6012790	chr20:48601580	A/G	cg25655593	chr20:48599521	SNAI1	0.59	6.36	0.33	6.69e-10	Inflammatory skin disease;
LUSC	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg00383909	chr3:49044727	WDR6	-0.85	-7.74	-0.39	1.18e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19709743	chr11:118230230	UBE4A	-0.47	-6.0	-0.31	5.26e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg18306943	chr3:40428807	ENTPD3	0.4	5.96	0.31	6.5e-9	Renal cell carcinoma;
LUSC	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg12483005	chr1:23474871	LUZP1	0.42	6.63	0.34	1.37e-10	Height;
LUSC	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg27284194	chr4:1044797	NA	0.53	8.14	0.41	7.97e-15	Recombination rate (females);
LUSC	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg00376283	chr12:123451042	ABCB9	0.65	8.3	0.41	2.63e-15	Neutrophil percentage of white cells;
LUSC	trans	rs7170930	0.618	rs55882547	chr15:66542766	T/C	cg06396762	chr16:3202609	NA	-0.72	-5.98	-0.31	5.75e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg12463550	chr7:65579703	CRCP	0.42	6.01	0.31	4.93e-9	Aortic root size;
LUSC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg11766577	chr21:47581405	C21orf56	-0.42	-6.14	-0.32	2.29e-9	Testicular germ cell tumor;
LUSC	cis	rs859767	0.812	rs842358	chr2:135345109	C/T	cg12500956	chr2:135428796	TMEM163	0.26	5.8	0.3	1.5e-8	Neuroticism;
LUSC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg00343986	chr7:65444356	GUSB	0.4	5.91	0.31	8.22e-9	Aortic root size;
LUSC	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg05738196	chr6:26577821	NA	0.67	11.16	0.52	8.39e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg19682013	chr15:45996608	NA	0.39	6.0	0.31	5.09e-9	Waist circumference;Weight;
LUSC	cis	rs968567	0.689	rs61897795	chr11:61618169	A/G	cg00603274	chr11:61596626	FADS2	-0.54	-6.78	-0.35	5.48e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs9341808	0.667	rs6938280	chr6:80897782	G/A	cg08355045	chr6:80787529	NA	0.47	8.13	0.41	8.26e-15	Sitting height ratio;
LUSC	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg18479299	chr3:125709523	NA	-0.48	-5.65	-0.3	3.42e-8	Blood pressure (smoking interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20894246	chr22:41682263	RANGAP1	0.47	6.53	0.34	2.47e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6433857	0.657	rs2368178	chr2:181501938	T/C	cg23363182	chr2:181467187	NA	-0.52	-8.38	-0.42	1.49e-15	Body mass index;
LUSC	cis	rs3087591	0.919	rs9913470	chr17:29566575	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.55	-7.88	-0.4	4.55e-14	Hip circumference;
LUSC	cis	rs500891	0.645	rs7751382	chr6:84176515	A/G	cg08257003	chr6:84140564	ME1	0.32	7.28	0.37	2.45e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs4474465	1.000	rs10793316	chr11:78211928	C/A	cg27205649	chr11:78285834	NARS2	0.49	5.69	0.3	2.74e-8	Alzheimer's disease (survival time);
LUSC	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg13902645	chr11:5959945	NA	-0.57	-7.9	-0.4	4.07e-14	DNA methylation (variation);
LUSC	trans	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg20587970	chr11:113659929	NA	-0.62	-8.82	-0.43	6.25e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03352830	chr11:487213	PTDSS2	0.68	8.61	0.43	2.91e-16	Body mass index;
LUSC	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg03929089	chr4:120376271	NA	-0.6	-6.25	-0.32	1.22e-9	D-dimer levels;
LUSC	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg25801113	chr15:45476975	SHF	0.34	7.04	0.36	1.13e-11	Uric acid levels;
LUSC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	9.46	0.46	5.67e-19	Menopause (age at onset);
LUSC	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.19	-0.37	4.3e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg08088566	chr11:430123	ANO9	0.67	7.64	0.39	2.34e-13	Body mass index;
LUSC	cis	rs3760982	0.585	rs68073292	chr19:44291401	T/C	cg11993925	chr19:44307056	LYPD5	0.35	7.63	0.39	2.55e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg10120925	chr2:223520811	FARSB	0.78	6.1	0.32	2.91e-9	Cognitive performance;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11520162	chr1:2517947	C1orf93	-0.42	-6.33	-0.33	7.85e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg13010199	chr12:38710504	ALG10B	0.58	9.27	0.45	2.37e-18	Morning vs. evening chronotype;
LUSC	cis	rs10465746	0.935	rs12406984	chr1:84416215	C/G	cg10977910	chr1:84465055	TTLL7	0.43	6.3	0.33	9.25e-10	Obesity-related traits;
LUSC	trans	rs979233	0.502	rs276260	chr5:42066357	G/A	cg07010552	chr17:7358735	CHRNB1	-0.42	-6.02	-0.31	4.47e-9	Systemic lupus erythematosus;
LUSC	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg00898013	chr13:113819073	PROZ	-0.62	-8.97	-0.44	2.14e-17	Platelet distribution width;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19777004	chr4:49526489	NA	-0.34	-6.02	-0.31	4.56e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	0.99	13.84	0.6	9.92e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg21724239	chr8:58056113	NA	0.69	8.88	0.44	4.09e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg09408571	chr1:101003634	GPR88	0.32	6.41	0.33	4.89e-10	Monocyte count;
LUSC	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg09915433	chr19:53449742	NA	-0.64	-10.3	-0.49	8.38e-22	Psoriasis;
LUSC	cis	rs4740619	0.619	rs10810527	chr9:16043350	C/G	cg14451791	chr9:16040625	NA	0.31	6.11	0.32	2.74e-9	Body mass index;
LUSC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg10018233	chr7:150070692	REPIN1	0.4	7.14	0.36	6e-12	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-8.65	-0.43	2.17e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg17507749	chr15:85114479	UBE2QP1	0.53	5.94	0.31	7.04e-9	Schizophrenia;
LUSC	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	9.02	0.44	1.46e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18404041	chr3:52824283	ITIH1	-0.62	-12.01	-0.55	7.56e-28	Bipolar disorder;
LUSC	cis	rs1775715	0.870	rs1775735	chr10:32255846	A/G	cg04359828	chr10:32216031	ARHGAP12	0.38	6.24	0.32	1.33e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.7	0.47	9.45e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg06028605	chr16:24865363	SLC5A11	0.54	8.0	0.4	2.03e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg24006582	chr15:45444508	DUOX1	-0.6	-8.67	-0.43	1.84e-16	Uric acid levels;
LUSC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs9646944	0.501	rs10174323	chr2:103012781	C/A	cg20060108	chr2:102954350	IL1RL1	0.48	6.51	0.34	2.73e-10	Blood protein levels;
LUSC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-10.12	-0.48	3.46e-21	Electroencephalogram traits;
LUSC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg15445000	chr17:37608096	MED1	0.4	6.76	0.35	6.29e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2067615	0.579	rs1073261	chr12:107135942	A/G	cg15890332	chr12:107067104	RFX4	0.34	6.21	0.32	1.59e-9	Heart rate;
LUSC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.36	0.37	1.48e-12	Cognitive ability;
LUSC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg12463550	chr7:65579703	CRCP	-0.45	-6.46	-0.33	3.62e-10	Aortic root size;
LUSC	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg24375607	chr4:120327624	NA	0.81	11.98	0.55	9.13e-28	Corneal astigmatism;
LUSC	cis	rs54211	0.808	rs5757608	chr22:39694622	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.59	5.92	0.31	7.96e-9	Sudden cardiac arrest;
LUSC	cis	rs6700896	0.500	rs7518632	chr1:66103350	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	6.29	0.33	9.97e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs13221852	0.659	rs1554499	chr7:3415818	G/A	cg21248987	chr7:3385318	SDK1	0.36	6.06	0.31	3.65e-9	Acute graft versus host disease in bone marrow transplantation (donor effect);
LUSC	trans	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg27411982	chr8:10470053	RP1L1	0.43	7.07	0.36	8.96e-12	Mood instability;
LUSC	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg12863693	chr15:85201151	NMB	-0.39	-8.18	-0.41	5.99e-15	Schizophrenia;
LUSC	cis	rs62400317	0.859	rs6919813	chr6:45159177	C/T	cg18551225	chr6:44695536	NA	-0.45	-7.19	-0.37	4.17e-12	Total body bone mineral density;
LUSC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.89	0.55	2.01e-27	Prudent dietary pattern;
LUSC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26314531	chr2:26401878	FAM59B	-0.68	-9.18	-0.45	4.53e-18	Gut microbiome composition (summer);
LUSC	trans	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg10756647	chr7:56101905	PSPH	0.86	8.34	0.42	1.97e-15	Diabetic kidney disease;
LUSC	cis	rs10761482	0.861	rs10761492	chr10:62108901	A/C	cg18175470	chr10:62150864	ANK3	-0.5	-7.05	-0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs68170813	0.652	rs6976759	chr7:107158506	A/G	cg24556660	chr7:106842632	COG5;HBP1	-0.45	-5.65	-0.3	3.52e-8	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg04369109	chr6:150039330	LATS1	-0.58	-8.6	-0.43	3.25e-16	Lung cancer;
LUSC	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg19116668	chr7:99932089	PMS2L1	0.34	5.99	0.31	5.31e-9	Coronary artery disease;
LUSC	cis	rs981844	0.712	rs1037649	chr4:154737796	G/A	cg14289246	chr4:154710475	SFRP2	-0.45	-6.26	-0.32	1.15e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg07862535	chr7:139043722	LUC7L2	-0.49	-6.02	-0.31	4.62e-9	Diisocyanate-induced asthma;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00157987	chr14:65347345	NA	-0.44	-6.08	-0.32	3.37e-9	Hepatitis;
LUSC	cis	rs180358	0.588	rs1263167	chr11:116677723	A/G	cg08985259	chr11:116699649	APOC3	0.3	5.92	0.31	7.82e-9	Multiple sclerosis (severity);
LUSC	cis	rs7739264	0.544	rs6456266	chr6:19791284	C/T	cg02404759	chr6:19790362	NA	-0.44	-6.8	-0.35	4.9e-11	Endometriosis;
LUSC	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg02176678	chr2:219576539	TTLL4	0.6	10.96	0.51	4.43e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	6.1	0.32	2.92e-9	Height;
LUSC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.28	-5.72	-0.3	2.31e-8	Dupuytren's disease;
LUSC	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.93	-0.48	1.58e-20	Total cholesterol levels;
LUSC	trans	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg17712092	chr4:129076599	LARP1B	-0.79	-11.65	-0.54	1.46e-26	Eosinophil percentage of white cells;
LUSC	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.55	-10.73	-0.51	2.79e-23	Educational attainment;
LUSC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06112835	chr11:68658793	MRPL21	0.52	8.2	0.41	5.38e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg15485101	chr11:133734466	NA	0.4	7.37	0.37	1.35e-12	Childhood ear infection;
LUSC	cis	rs55883249	1.000	rs10495573	chr2:9712160	T/G	cg23886495	chr2:9695866	ADAM17	0.5	5.76	0.3	1.92e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg25011763	chr5:6727354	POLS	-0.34	-5.77	-0.3	1.84e-8	Menopause (age at onset);
LUSC	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg17691542	chr6:26056736	HIST1H1C	0.6	8.12	0.41	8.79e-15	Iron status biomarkers;
LUSC	cis	rs4631830	0.896	rs7088225	chr10:51522120	T/C	cg20129853	chr10:51489980	NA	0.34	6.87	0.35	3.13e-11	Prostate-specific antigen levels;
LUSC	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg22777020	chr22:31556080	RNF185	-0.46	-5.82	-0.3	1.35e-8	Colorectal cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19163074	chr7:65112434	INTS4L2	0.5	6.91	0.35	2.51e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg08975724	chr8:8085496	FLJ10661	0.42	5.97	0.31	6.04e-9	Retinal vascular caliber;
LUSC	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-1.03	-21.06	-0.76	2.93e-63	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg21238619	chr17:78079768	GAA	0.4	7.51	0.38	5.43e-13	Yeast infection;
LUSC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.67	-8.54	-0.42	4.97e-16	Diastolic blood pressure;
LUSC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg15649852	chr7:65879115	NA	0.41	5.78	0.3	1.69e-8	Aortic root size;
LUSC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.52	-0.38	5.02e-13	Personality dimensions;
LUSC	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg02569458	chr12:86230093	RASSF9	0.49	8.2	0.41	5.16e-15	Major depressive disorder;
LUSC	cis	rs2279817	0.913	rs2270979	chr1:18023290	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.52	7.38	0.37	1.27e-12	Neuroticism;
LUSC	cis	rs116988415	0.584	rs2269308	chr14:65244950	G/A	cg25083366	chr14:65239357	SPTB	0.57	6.02	0.31	4.65e-9	Daytime sleep phenotypes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27576415	chr15:41709087	RTF1	0.43	6.27	0.32	1.1e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg12560992	chr17:57184187	TRIM37	0.59	10.02	0.48	7.54e-21	Testicular germ cell tumor;
LUSC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg20821713	chr7:1055600	C7orf50	-0.52	-6.79	-0.35	5e-11	Bronchopulmonary dysplasia;
LUSC	trans	rs2018683	0.707	rs917218	chr7:28975122	A/C	cg19402173	chr7:128379420	CALU	-0.46	-6.95	-0.36	1.96e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg17633681	chr16:88106987	BANP	0.5	9.19	0.45	4.38e-18	Menopause (age at onset);
LUSC	cis	rs9398803	0.713	rs6921183	chr6:126869029	A/T	cg19875578	chr6:126661172	C6orf173	0.39	5.72	0.3	2.32e-8	Male-pattern baldness;
LUSC	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg03563238	chr19:33554763	RHPN2	-0.41	-6.56	-0.34	2.09e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7178572	0.625	rs12905285	chr15:77845812	T/C	cg22256960	chr15:77711686	NA	-0.44	-7.07	-0.36	8.88e-12	Type 2 diabetes;
LUSC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.46	-7.75	-0.39	1.1e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg10909506	chr17:38081995	ORMDL3	0.33	5.95	0.31	6.59e-9	Self-reported allergy;
LUSC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg14552801	chr7:65878734	NA	0.37	5.65	0.3	3.47e-8	Aortic root size;
LUSC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.42	0.33	4.65e-10	Obesity-related traits;
LUSC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.8	12.78	0.57	1e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg05729581	chr11:3078854	CARS	-0.51	-7.65	-0.39	2.17e-13	Longevity;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24327541	chr19:8570921	NA	-0.57	-6.91	-0.35	2.48e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs2742234	0.910	rs2505511	chr10:43641029	T/A	cg02780029	chr10:43622663	RET	-0.34	-6.17	-0.32	1.95e-9	Hirschsprung disease;
LUSC	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg09307838	chr4:120376055	NA	0.75	10.98	0.51	3.78e-24	Corneal astigmatism;
LUSC	cis	rs6429082	0.627	rs2016437	chr1:235539355	T/G	cg26050004	chr1:235667680	B3GALNT2	-0.5	-6.87	-0.35	3.11e-11	Adiposity;
LUSC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg11663144	chr21:46675770	NA	0.43	7.52	0.38	5.26e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg26384229	chr12:38710491	ALG10B	0.72	11.29	0.53	2.92e-25	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.75	-0.35	6.58e-11	Lung cancer;
LUSC	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg03465714	chr1:152285911	FLG	-0.42	-5.85	-0.3	1.17e-8	Atopic dermatitis;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09284703	chr19:36207534	MLL4;ZBTB32	0.77	6.34	0.33	7.32e-10	Cognitive performance;
LUSC	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg04310649	chr10:35416472	CREM	-0.42	-6.59	-0.34	1.74e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6906287	0.647	rs12194555	chr6:118819212	C/A	cg21191810	chr6:118973309	C6orf204	0.32	5.74	0.3	2.16e-8	Electrocardiographic conduction measures;
LUSC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg07424592	chr7:64974309	NA	-0.63	-5.66	-0.3	3.26e-8	Diabetic kidney disease;
LUSC	cis	rs11031096	0.655	rs34295904	chr11:4206701	C/A	cg18678763	chr11:4115507	RRM1	-0.41	-5.77	-0.3	1.78e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9283706	0.673	rs2006323	chr5:66305992	T/C	cg11590213	chr5:66331682	MAST4	0.45	6.75	0.35	6.45e-11	Coronary artery disease;
LUSC	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1823874	1.000	rs1823874	chr15:100357435	T/C	cg16400843	chr15:100339927	C15orf51	0.41	8.29	0.41	2.87e-15	IgG glycosylation;
LUSC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs600626	0.636	rs11236517	chr11:75452721	T/C	cg24262691	chr11:75473276	NA	0.5	6.77	0.35	5.8200000000000003e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.4	-7.62	-0.38	2.64e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg06108461	chr20:60628389	TAF4	-0.66	-8.67	-0.43	1.91e-16	Obesity-related traits;
LUSC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg14416269	chr4:6271139	WFS1	0.54	11.13	0.52	1.14e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg03732007	chr1:2071316	PRKCZ	-0.51	-8.51	-0.42	5.91e-16	Height;
LUSC	cis	rs10208940	0.920	rs11886343	chr2:68750336	G/A	cg12452813	chr2:68675892	NA	0.56	5.81	0.3	1.45e-8	Urate levels in lean individuals;
LUSC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg13206674	chr6:150067644	NUP43	0.6	9.18	0.45	4.69e-18	Lung cancer;
LUSC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg07703079	chr11:430292	ANO9	0.6	6.52	0.34	2.66e-10	Body mass index;
LUSC	cis	rs3741151	0.773	rs7110369	chr11:73160946	C/A	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.8	12.18	0.55	1.76e-28	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.88	-0.31	1.01e-8	Recombination rate (females);
LUSC	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	7.15	0.36	5.38e-12	Rheumatoid arthritis;
LUSC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg04944784	chr2:26401820	FAM59B	-0.67	-9.4	-0.46	9.16e-19	Gut microbiome composition (summer);
LUSC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg21665744	chr7:39171113	POU6F2	0.49	7.78	0.39	8.99e-14	IgG glycosylation;
LUSC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg20887711	chr4:1340912	KIAA1530	0.44	6.69	0.34	9.7e-11	Obesity-related traits;
LUSC	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	0.96	14.32	0.62	1.3e-36	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg01176363	chr20:62369445	LIME1	-0.47	-7.14	-0.36	5.85e-12	Prostate cancer;
LUSC	cis	rs9463078	0.683	rs1418433	chr6:44752568	C/T	cg25276700	chr6:44698697	NA	0.29	5.74	0.3	2.14e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs10992471	0.580	rs12341093	chr9:95234182	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.68	-0.39	1.78e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.72	11.13	0.52	1.13e-24	Alcohol dependence;
LUSC	cis	rs2179367	0.600	rs11155654	chr6:149763137	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.33	-5.71	-0.3	2.48e-8	Dupuytren's disease;
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.58	9.81	0.47	3.86e-20	Lymphocyte counts;
LUSC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg05805236	chr11:65401703	PCNXL3	0.37	5.84	0.3	1.26e-8	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs2179367	0.600	rs9498353	chr6:149760996	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.35	-5.87	-0.31	1.03e-8	Dupuytren's disease;
LUSC	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg11244672	chr19:19639970	YJEFN3	-0.55	-6.91	-0.35	2.49e-11	Bipolar disorder;
LUSC	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.33e-21	Lymphocyte counts;
LUSC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg19774624	chr17:42201019	HDAC5	0.71	10.31	0.49	7.74e-22	Total body bone mineral density;
LUSC	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg13010199	chr12:38710504	ALG10B	0.71	10.95	0.51	4.69e-24	Morning vs. evening chronotype;
LUSC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg08499158	chr17:42289980	UBTF	0.39	6.5	0.33	2.99e-10	Total body bone mineral density;
LUSC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.73	0.43	1.26e-16	Prudent dietary pattern;
LUSC	cis	rs6545883	0.859	rs62149714	chr2:61603869	T/G	cg15711740	chr2:61764176	XPO1	0.41	6.26	0.32	1.19e-9	Tuberculosis;
LUSC	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg01990225	chr2:97406019	LMAN2L	-1.09	-7.42	-0.38	9.98e-13	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs926938	0.527	rs360667	chr1:115481451	C/G	cg01522456	chr1:115632236	TSPAN2	0.42	6.6	0.34	1.59e-10	Autism;
LUSC	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg26384229	chr12:38710491	ALG10B	0.68	10.98	0.51	3.73e-24	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6545883	0.895	rs2177961	chr2:61560264	T/C	cg15711740	chr2:61764176	XPO1	0.46	7.24	0.37	3.14e-12	Tuberculosis;
LUSC	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	5.96	0.31	6.32e-9	IgG glycosylation;
LUSC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25072359	chr17:41440525	NA	0.65	9.08	0.45	9.46e-18	Menopause (age at onset);
LUSC	cis	rs2742417	1.000	rs2673025	chr3:45760483	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-6.11	-0.32	2.79e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	0.58	9.28	0.45	2.15e-18	Breast cancer;
LUSC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg05084668	chr3:125655381	ALG1L	-0.49	-6.9	-0.35	2.55e-11	Blood pressure (smoking interaction);
LUSC	trans	rs7939886	0.920	rs7940563	chr11:55875133	C/T	cg03929089	chr4:120376271	NA	0.73	6.06	0.31	3.74e-9	Myopia (pathological);
LUSC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg24250549	chr1:154909240	PMVK	0.64	10.4	0.49	3.92e-22	Prostate cancer;
LUSC	cis	rs1595825	1.000	rs1440090	chr2:198879297	T/G	cg00982548	chr2:198649783	BOLL	-0.49	-6.15	-0.32	2.15e-9	Ulcerative colitis;
LUSC	cis	rs1595825	0.891	rs59990242	chr2:198895868	G/A	cg10547527	chr2:198650123	BOLL	-0.52	-6.25	-0.32	1.23e-9	Ulcerative colitis;
LUSC	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg00495681	chr13:53174319	NA	0.42	6.07	0.32	3.38e-9	Lewy body disease;
LUSC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg24829409	chr8:58192753	C8orf71	-0.47	-5.68	-0.3	2.89e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2692947	0.726	rs13009727	chr2:96769883	C/G	cg22654517	chr2:96458247	NA	-0.35	-6.72	-0.35	7.65e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs727505	0.607	rs17387591	chr7:124799471	A/G	cg23710748	chr7:124431027	NA	-0.37	-6.56	-0.34	2.05e-10	Lewy body disease;
LUSC	cis	rs859767	0.704	rs9287437	chr2:135357502	C/T	cg12500956	chr2:135428796	TMEM163	-0.27	-6.35	-0.33	7.13e-10	Neuroticism;
LUSC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg12463550	chr7:65579703	CRCP	-0.42	-6.17	-0.32	1.98e-9	Aortic root size;
LUSC	cis	rs4964805	0.626	rs869993	chr12:104175138	A/T	cg02344784	chr12:104178138	NT5DC3	0.45	7.17	0.37	4.76e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg13939156	chr17:80058883	NA	-0.33	-6.42	-0.33	4.68e-10	Life satisfaction;
LUSC	cis	rs2969070	0.831	rs10279360	chr7:2503998	T/C	cg03277898	chr7:2518824	NA	-0.27	-5.82	-0.3	1.35e-8	Diastolic blood pressure;
LUSC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg11812906	chr14:75593930	NEK9	-0.63	-10.39	-0.49	4.35e-22	Height;
LUSC	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg17052675	chr2:3827356	NA	-0.57	-11.33	-0.53	2.12e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.49	-9.77	-0.47	5.35e-20	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg21869046	chr19:41225005	ITPKC	0.49	6.71	0.34	8.51e-11	Kawasaki disease;
LUSC	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.53	8.53	0.42	5.12e-16	Response to antipsychotic treatment;
LUSC	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.73	11.69	0.54	1.03e-26	Dilated cardiomyopathy;
LUSC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg08470875	chr2:26401718	FAM59B	-0.71	-9.62	-0.47	1.64e-19	Gut microbiome composition (summer);
LUSC	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg11984989	chr7:158649758	WDR60	1.01	8.57	0.42	4.02e-16	Hippocampal volume;
LUSC	cis	rs17767294	0.708	rs113741085	chr6:27849982	C/A	cg08851530	chr6:28072375	NA	1.18	7.77	0.39	9.45e-14	Parkinson's disease;
LUSC	cis	rs2857891	0.817	rs2638102	chr11:6968610	T/C	cg04053776	chr11:6947353	ZNF215	0.42	5.94	0.31	6.99e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg08085267	chr17:45401833	C17orf57	0.54	8.85	0.44	5.16e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs193541	0.556	rs30024	chr5:122285160	A/G	cg19077854	chr5:122220652	SNX24	0.4	8.57	0.42	3.96e-16	Glucose homeostasis traits;
LUSC	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg24642439	chr20:33292090	TP53INP2	0.45	6.45	0.33	4.04e-10	Height;
LUSC	cis	rs804280	0.662	rs11784693	chr8:11610674	C/T	cg26752888	chr8:11627280	NEIL2	0.45	6.03	0.31	4.36e-9	Myopia (pathological);
LUSC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.6	0.38	3.03e-13	Bipolar disorder;
LUSC	cis	rs6005807	0.719	rs16986398	chr22:28815629	A/C	cg12565055	chr22:29076175	TTC28	0.53	5.8	0.3	1.56e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs9326248	0.861	rs1871757	chr11:117030581	A/T	cg16524733	chr11:117070046	TAGLN	0.37	5.93	0.31	7.36e-9	Blood protein levels;
LUSC	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg02421172	chr7:1938701	MAD1L1	0.43	5.67	0.3	3.02e-8	Bipolar disorder;
LUSC	cis	rs12618769	0.597	rs72821946	chr2:99142411	G/C	cg10123293	chr2:99228465	UNC50	0.45	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg02466173	chr16:30829666	NA	-0.52	-10.2	-0.49	1.98e-21	Dementia with Lewy bodies;
LUSC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg00255919	chr5:131827918	IRF1	0.43	8.25	0.41	3.62e-15	Asthma (sex interaction);
LUSC	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg26338869	chr17:61819248	STRADA	0.42	5.96	0.31	6.53e-9	Prudent dietary pattern;
LUSC	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.85	0.3	1.18e-8	Breast cancer;
LUSC	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg23306229	chr2:178417860	TTC30B	0.54	6.06	0.31	3.69e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.0	0.52	3.07e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.61	-0.43	2.96e-16	Response to antipsychotic treatment;
LUSC	cis	rs17155006	0.664	rs451252	chr7:107738948	G/A	cg05962710	chr7:107745446	LAMB4	-0.36	-6.3	-0.33	9.63e-10	Pneumococcal bacteremia;
LUSC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.6	-0.34	1.64e-10	High light scatter reticulocyte count;
LUSC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg25039879	chr17:56429692	SUPT4H1	0.7	9.56	0.46	2.65e-19	Cognitive test performance;
LUSC	cis	rs10761482	0.817	rs4948404	chr10:62108202	C/T	cg18175470	chr10:62150864	ANK3	-0.51	-7.31	-0.37	2e-12	Schizophrenia;
LUSC	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.4	-0.38	1.13e-12	Triglycerides;
LUSC	cis	rs2078087	0.522	rs503243	chr1:183222013	A/G	cg13843938	chr1:183241246	NMNAT2	-0.37	-6.08	-0.32	3.32e-9	Obesity-related traits;
LUSC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.45	-6.96	-0.36	1.84e-11	IgG glycosylation;
LUSC	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg01528321	chr10:82214614	TSPAN14	0.87	13.27	0.59	1.39e-32	Post bronchodilator FEV1;
LUSC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	5.99	0.31	5.53e-9	Breast cancer;
LUSC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg05313129	chr8:58192883	C8orf71	-0.51	-5.65	-0.3	3.44e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.75	-0.35	6.52e-11	Lung cancer;
LUSC	trans	rs72674100	1.000	rs76587581	chr4:97932962	A/G	cg09670535	chr1:18959427	PAX7	-0.64	-6.14	-0.32	2.39e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.26	-0.32	1.2e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7572733	0.534	rs1401092	chr2:198792320	C/A	cg00792783	chr2:198669748	PLCL1	-0.44	-5.86	-0.31	1.13e-8	Dermatomyositis;
LUSC	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg15654264	chr1:150340011	RPRD2	0.61	10.09	0.48	4.38e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03264133	chr6:25882463	NA	0.42	7.26	0.37	2.74e-12	Blood metabolite levels;
LUSC	cis	rs7605827	0.930	rs1469016	chr2:15687627	A/G	cg19274914	chr2:15703543	NA	0.46	8.83	0.44	5.83e-17	Educational attainment (years of education);
LUSC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg20607287	chr7:12443886	VWDE	-0.61	-6.43	-0.33	4.45e-10	Coronary artery disease;
LUSC	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg06096015	chr1:231504339	EGLN1	0.53	9.08	0.45	9.57e-18	Hemoglobin concentration;
LUSC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg23788917	chr6:8435910	SLC35B3	0.51	7.55	0.38	4.28e-13	Motion sickness;
LUSC	cis	rs6690583	0.573	rs7547317	chr1:85456961	T/G	cg11262906	chr1:85462892	MCOLN2	0.7	6.47	0.33	3.56e-10	Serum sulfate level;
LUSC	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-0.88	-12.76	-0.57	1.24e-30	Uric acid levels;
LUSC	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg13010199	chr12:38710504	ALG10B	-0.64	-11.02	-0.52	2.75e-24	Heart rate;
LUSC	trans	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg15556689	chr8:8085844	FLJ10661	0.46	6.91	0.35	2.5e-11	Retinal vascular caliber;
LUSC	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.4	5.93	0.31	7.6e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg04518342	chr5:131593106	PDLIM4	0.41	7.89	0.4	4.4e-14	Blood metabolite levels;
LUSC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg03929089	chr4:120376271	NA	-0.94	-16.17	-0.66	7.44e-44	Height;
LUSC	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg05738196	chr6:26577821	NA	-0.52	-5.76	-0.3	1.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg13498757	chr1:152161927	NA	0.35	5.88	0.31	1e-8	Inflammatory skin disease;
LUSC	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.79	-0.39	8.69e-14	Response to antipsychotic treatment;
LUSC	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg00677455	chr12:58241039	CTDSP2	-0.42	-6.12	-0.32	2.69e-9	Multiple sclerosis;
LUSC	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg04310649	chr10:35416472	CREM	-0.42	-6.61	-0.34	1.49e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg09163369	chr1:210001066	C1orf107	0.52	5.88	0.31	9.88e-9	Orofacial clefts;
LUSC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15664640	chr17:80829946	TBCD	-0.73	-12.72	-0.57	1.67e-30	Breast cancer;
LUSC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-9.74	-0.47	6.61e-20	Platelet count;
LUSC	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.2	0.56	1.4e-28	Height;
LUSC	cis	rs6570726	0.516	rs10484700	chr6:145728933	C/T	cg23711669	chr6:146136114	FBXO30	0.45	7.07	0.36	9.04e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12410462	0.581	rs113827839	chr1:227547180	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.66	-6.47	-0.33	3.44e-10	Major depressive disorder;
LUSC	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.37	-9.16	-0.45	5.43e-18	Diastolic blood pressure;
LUSC	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg07679836	chr6:33548423	BAK1	0.51	8.09	0.4	1.12e-14	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUSC	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg10518572	chr11:65560635	OVOL1	-0.25	-5.75	-0.3	1.97e-8	Acne (severe);
LUSC	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.77	0.3	1.82e-8	Tonsillectomy;
LUSC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg15445000	chr17:37608096	MED1	-0.4	-6.85	-0.35	3.46e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.82	-0.35	4.33e-11	Monocyte percentage of white cells;
LUSC	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg21775007	chr8:11205619	TDH	-0.64	-9.95	-0.48	1.39e-20	Retinal vascular caliber;
LUSC	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.45	-6.38	-0.33	5.97e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs5762813	0.524	rs5752815	chr22:29230733	C/A	cg02153584	chr22:29168773	CCDC117	0.54	6.36	0.33	6.54e-10	Hematocrit;Hemoglobin concentration;
LUSC	trans	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg08975724	chr8:8085496	FLJ10661	0.52	7.7	0.39	1.55e-13	Mood instability;
LUSC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	ch.11.42038R	chr11:967971	AP2A2	0.54	8.19	0.41	5.79e-15	Alzheimer's disease (late onset);
LUSC	cis	rs748404	0.723	rs512431	chr15:43541939	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.48	-7.6	-0.38	3.07e-13	Lung cancer;
LUSC	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.97	-0.36	1.7e-11	Response to antipsychotic treatment;
LUSC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg17173187	chr15:85201210	NMB	0.37	6.55	0.34	2.19e-10	Schizophrenia;
LUSC	trans	rs72792513	1.000	rs76240659	chr2:22916507	T/G	cg05844895	chr16:88969569	CBFA2T3	0.52	6.07	0.32	3.4e-9	Hepatitis B;
LUSC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg02269571	chr22:50332266	NA	0.59	8.71	0.43	1.44e-16	Schizophrenia;
LUSC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	0.98	14.13	0.61	7.04e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg13010199	chr12:38710504	ALG10B	-0.54	-8.54	-0.42	4.93e-16	Morning vs. evening chronotype;
LUSC	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg08999081	chr20:33150536	PIGU	0.38	6.9	0.35	2.68e-11	Height;
LUSC	trans	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.26	-0.32	1.19e-9	Blood trace element (Cu levels);
LUSC	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg16339924	chr4:17578868	LAP3	0.54	8.11	0.41	9.69e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07677032	chr17:61819896	STRADA	0.53	8.91	0.44	3.42e-17	Prudent dietary pattern;
LUSC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	1.03	17.94	0.7	7.26e-51	Parkinson's disease;
LUSC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.09e-30	Aortic root size;
LUSC	trans	rs11935423	0.778	rs28647519	chr4:100500775	C/T	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.05	-0.31	3.97e-9	Gut microbiome composition (summer);
LUSC	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17467752	chr17:38218738	THRA	0.81	13.63	0.6	6.01e-34	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.83	-0.47	3.46e-20	Hemoglobin concentration;
LUSC	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.97	21.74	0.77	6.65e-66	Longevity;
LUSC	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg12908607	chr1:44402522	ARTN	-0.49	-7.59	-0.38	3.15e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.82	-13.93	-0.61	4.23e-35	Bladder cancer;
LUSC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg15320075	chr8:145703422	NA	-0.44	-6.98	-0.36	1.62e-11	Age at first birth;
LUSC	cis	rs2658782	0.951	rs72972364	chr11:93122128	C/T	cg15737290	chr11:93063684	CCDC67	-0.62	-7.3	-0.37	2.12e-12	Pulmonary function decline;
LUSC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg27535305	chr1:53392650	SCP2	-0.38	-6.97	-0.36	1.7e-11	Monocyte count;
LUSC	cis	rs7828089	0.522	rs4872484	chr8:22255859	C/T	cg12081754	chr8:22256438	SLC39A14	0.87	13.85	0.6	8.99e-35	Verbal declarative memory;
LUSC	cis	rs59698941	0.943	rs55767930	chr5:132203952	G/A	cg02081065	chr5:132209139	LEAP2	-0.65	-6.75	-0.35	6.57e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg19812747	chr11:111475976	SIK2	-0.49	-6.8	-0.35	4.81e-11	Primary sclerosing cholangitis;
LUSC	cis	rs4654899	0.865	rs12130841	chr1:21067051	C/T	cg01072550	chr1:21505969	NA	-0.47	-7.04	-0.36	1.1e-11	Superior frontal gyrus grey matter volume;
LUSC	trans	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-12.19	-0.55	1.55e-28	Colorectal cancer;
LUSC	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	0.67	6.69	0.34	9.16e-11	Prostate cancer;
LUSC	trans	rs6600671	1.000	rs1986111	chr1:121204788	C/T	cg00646200	chr1:148855367	NA	0.46	7.31	0.37	1.94e-12	Hip geometry;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25411849	chr6:89855994	PM20D2	-0.54	-6.87	-0.35	3.13e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7520050	0.966	rs785479	chr1:46492144	C/T	cg06784218	chr1:46089804	CCDC17	-0.29	-5.66	-0.3	3.22e-8	Red blood cell count;Reticulocyte count;
LUSC	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg15704280	chr7:45808275	SEPT13	0.67	7.4	0.38	1.14e-12	Axial length;
LUSC	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg00383909	chr3:49044727	WDR6	1.09	9.27	0.45	2.41e-18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg27266027	chr21:40555129	PSMG1	0.41	5.98	0.31	5.88e-9	Cognitive function;
LUSC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-7.38	-0.37	1.3e-12	Colorectal cancer;
LUSC	cis	rs2540226	0.935	rs2716729	chr2:39954770	G/A	cg23576258	chr2:39999331	THUMPD2	0.34	5.67	0.3	3.09e-8	Personality dimensions;
LUSC	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg18105134	chr13:113819100	PROZ	0.65	9.62	0.47	1.65e-19	Platelet distribution width;
LUSC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg16584290	chr5:462447	EXOC3	-0.37	-6.43	-0.33	4.39e-10	Cystic fibrosis severity;
LUSC	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.73	10.36	0.49	5.62e-22	Corneal astigmatism;
LUSC	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	1.13	19.75	0.73	4.46e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs500891	0.553	rs3798884	chr6:84136112	C/A	cg08257003	chr6:84140564	ME1	0.37	9.17	0.45	5.06e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg11645453	chr3:52864694	ITIH4	0.35	7.99	0.4	2.28e-14	Bipolar disorder;
LUSC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg27532560	chr4:187881888	NA	-0.39	-6.39	-0.33	5.65e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg05132306	chr1:1846340	CALML6	-0.34	-8.55	-0.42	4.62e-16	Body mass index;
LUSC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.46	-9.73	-0.47	7.07e-20	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.46	-0.38	7.41e-13	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1113500	0.836	rs1618973	chr1:108586767	T/C	cg11967332	chr1:108735228	SLC25A24	-0.38	-5.81	-0.3	1.47e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg06223162	chr1:101003688	GPR88	0.49	9.35	0.46	1.26e-18	Monocyte count;
LUSC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg06713675	chr4:122721982	EXOSC9	0.39	6.36	0.33	6.57e-10	Type 2 diabetes;
LUSC	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	6.0	0.31	5.1e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	12.28	0.56	7.28e-29	Cognitive test performance;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13677111	chr13:37574825	ALG5;EXOSC8	-0.42	-6.29	-0.33	1.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6700559	0.740	rs4072554	chr1:200649366	A/G	cg07804481	chr1:200639085	DDX59	0.41	5.77	0.3	1.85e-8	Coronary artery disease;
LUSC	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg08134877	chr2:44394819	PPM1B	0.41	5.83	0.3	1.3e-8	Height;
LUSC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg23630131	chr7:65973040	NA	-0.21	-5.91	-0.31	8.46e-9	Aortic root size;
LUSC	cis	rs2235649	0.789	rs9929803	chr16:1852748	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.44	-6.02	-0.31	4.57e-9	Blood metabolite levels;
LUSC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-1.1	-16.2	-0.66	5.91e-44	Initial pursuit acceleration;
LUSC	trans	rs2392780	0.667	rs424281	chr8:128339426	G/A	cg10195415	chr17:73887371	TRIM65	0.42	6.65	0.34	1.18e-10	Breast cancer (early onset);
LUSC	cis	rs96067	0.772	rs1033891	chr1:36608402	A/G	cg24686825	chr1:36642396	MAP7D1	-0.57	-7.66	-0.39	2.05e-13	Corneal structure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27449864	chr7:73133982	STX1A	-0.41	-6.22	-0.32	1.5e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.16	0.77	1.43e-67	Prudent dietary pattern;
LUSC	cis	rs6076065	0.748	rs2295239	chr20:23387550	C/T	cg11657817	chr20:23433608	CST11	0.53	11.03	0.52	2.42e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg26924012	chr15:45694286	SPATA5L1	-1.12	-20.18	-0.74	9.3e-60	Homoarginine levels;
LUSC	cis	rs9399401	0.667	rs34018047	chr6:142790873	G/C	cg04461802	chr6:142623433	GPR126	0.46	5.92	0.31	7.8e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.64	0.57	3.49e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.51	0.38	5.48e-13	Iron status biomarkers;
LUSC	cis	rs4595586	0.679	rs4768471	chr12:39325960	G/A	cg26384229	chr12:38710491	ALG10B	0.46	6.4	0.33	5.21e-10	Morning vs. evening chronotype;
LUSC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg09365446	chr1:150670422	GOLPH3L	0.49	7.26	0.37	2.73e-12	Melanoma;
LUSC	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg02023728	chr11:77925099	USP35	0.49	6.92	0.35	2.39e-11	Testicular germ cell tumor;
LUSC	cis	rs7582720	1.000	rs72934751	chr2:203747522	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg23758822	chr17:41437982	NA	1.02	15.44	0.65	5.55e-41	Menopause (age at onset);
LUSC	cis	rs9473147	0.543	rs9349417	chr6:47580657	A/G	cg20196966	chr6:47445060	CD2AP	0.43	6.08	0.32	3.24e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg09165964	chr15:75287851	SCAMP5	-0.47	-6.84	-0.35	3.69e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs500891	0.553	rs7770573	chr6:84137756	G/T	cg08257003	chr6:84140564	ME1	0.37	9.17	0.45	5.06e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.9	-0.4	4.05e-14	Blood metabolite levels;
LUSC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg27588902	chr6:42928151	GNMT	-0.27	-5.94	-0.31	7.29e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg00343986	chr7:65444356	GUSB	0.44	6.3	0.33	9.48e-10	Aortic root size;
LUSC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	13.51	0.59	1.71e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg26408565	chr15:76604113	ETFA	-0.5	-8.0	-0.4	2.04e-14	Blood metabolite levels;
LUSC	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg26898376	chr11:64110657	CCDC88B	0.33	6.2	0.32	1.67e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs10986311	0.862	rs11791290	chr9:127096347	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.43	6.81	0.35	4.45e-11	Vitiligo;
LUSC	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg05973401	chr12:123451056	ABCB9	0.52	6.49	0.33	3.19e-10	Neutrophil percentage of white cells;
LUSC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03934478	chr11:495069	RNH1	0.82	9.83	0.47	3.29e-20	Body mass index;
LUSC	cis	rs6545883	0.868	rs2427885	chr2:61816777	A/G	cg15711740	chr2:61764176	XPO1	-0.47	-7.41	-0.38	1.06e-12	Tuberculosis;
LUSC	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.86	-0.47	2.63e-20	Migraine;Coronary artery disease;
LUSC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08219700	chr8:58056026	NA	0.7	7.95	0.4	2.95e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7615316	0.779	rs6440078	chr3:142070495	C/T	cg16271453	chr3:142027066	XRN1	-0.41	-7.19	-0.37	4.4e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg16586182	chr3:47516702	SCAP	0.52	8.13	0.41	8.41e-15	Colorectal cancer;
LUSC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg27398817	chr8:82754497	SNX16	-0.47	-6.36	-0.33	6.47e-10	Diastolic blood pressure;
LUSC	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg23815491	chr16:72088622	HP	0.37	6.54	0.34	2.28e-10	Fibrinogen levels;
LUSC	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg08392591	chr16:89556376	ANKRD11	0.39	5.72	0.3	2.42e-8	Multiple myeloma (IgH translocation);
LUSC	trans	rs72674100	0.737	rs2865752	chr4:97992784	T/C	cg09670535	chr1:18959427	PAX7	-0.61	-6.23	-0.32	1.41e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-7.94	-0.4	3.09e-14	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg25664220	chr3:72788482	NA	-0.69	-11.4	-0.53	1.19e-25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.26	-0.37	2.73e-12	Blood metabolite levels;
LUSC	cis	rs9420	0.961	rs11606396	chr11:57435211	C/T	cg23127183	chr11:57508653	C11orf31	-0.58	-8.85	-0.44	5.14e-17	Schizophrenia;
LUSC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.52	-11.05	-0.52	2.05e-24	Type 2 diabetes;
LUSC	cis	rs2239815	0.515	rs12170231	chr22:29237824	C/T	cg02153584	chr22:29168773	CCDC117	0.55	6.34	0.33	7.34e-10	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg08017756	chr2:100939284	LONRF2	-0.43	-8.06	-0.4	1.4e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg24578937	chr1:2090814	PRKCZ	0.38	7.69	0.39	1.61e-13	Coronary artery disease;
LUSC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg03938978	chr2:103052716	IL18RAP	0.36	6.99	0.36	1.53e-11	Asthma;
LUSC	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.48	0.5	2.07e-22	Colorectal cancer;
LUSC	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg12856521	chr11:46389249	DGKZ	0.41	6.38	0.33	6.02e-10	Leprosy;
LUSC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg04176532	chr22:50317003	CRELD2	-0.4	-5.78	-0.3	1.71e-8	Schizophrenia;
LUSC	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	7.06	0.36	9.98e-12	Rheumatoid arthritis;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg15104066	chr12:90102578	LOC338758	-0.37	-6.04	-0.31	4e-9	Triglycerides;
LUSC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg17279839	chr7:150038598	RARRES2	0.44	7.02	0.36	1.24e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3857536	0.813	rs1891600	chr6:66941645	G/C	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs7712401	0.601	rs386602	chr5:122321957	T/G	cg19077854	chr5:122220652	SNX24	-0.44	-9.58	-0.46	2.28e-19	Mean platelet volume;
LUSC	cis	rs12681287	0.640	rs8635	chr8:87479810	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-6.97	-0.36	1.74e-11	Caudate activity during reward;
LUSC	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg17385448	chr1:15911702	AGMAT	0.37	6.32	0.33	8.16e-10	Systolic blood pressure;
LUSC	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg21153622	chr11:89784906	NA	-0.39	-6.16	-0.32	2.13e-9	HDL cholesterol;
LUSC	cis	rs3741151	0.773	rs73542976	chr11:73127471	A/G	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg14154082	chr13:112174009	NA	0.38	7.78	0.39	9e-14	Menarche (age at onset);
LUSC	trans	rs800082	1.000	rs9289678	chr3:144307096	C/T	cg24215973	chr2:240111563	HDAC4	0.47	7.23	0.37	3.33e-12	Smoking behavior;
LUSC	cis	rs12422267	0.536	rs11246933	chr12:132610314	G/A	cg09764611	chr12:132620959	NA	-0.56	-8.07	-0.4	1.24e-14	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg13531842	chr10:38383804	ZNF37A	-0.48	-7.42	-0.38	9.51e-13	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.19	-0.52	6.61e-25	Alzheimer's disease;
LUSC	cis	rs12618769	0.597	rs3754881	chr2:99132093	G/A	cg10123293	chr2:99228465	UNC50	0.45	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	cis	rs62103177	0.564	rs3930043	chr18:77723832	G/A	cg02751453	chr18:77725136	HSBP1L1	-0.47	-6.17	-0.32	1.95e-9	Opioid sensitivity;
LUSC	cis	rs17824933	0.848	rs11230560	chr11:60771077	G/A	cg16817237	chr11:60793675	NA	0.39	6.3	0.33	9.26e-10	Multiple sclerosis;
LUSC	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg18002602	chr11:66138449	SLC29A2	-0.46	-8.1	-0.41	1.02e-14	Educational attainment (years of education);
LUSC	cis	rs2219968	0.798	rs4397393	chr8:78937569	G/C	cg00738934	chr8:78996279	NA	-0.42	-7.55	-0.38	4.31e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08048268	chr3:133502702	NA	-0.46	-8.79	-0.43	7.92e-17	Iron status biomarkers;
LUSC	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02176678	chr2:219576539	TTLL4	0.66	12.7	0.57	2.1000000000000002e-30	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10761482	0.861	rs4245587	chr10:62101589	G/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg08000102	chr2:233561755	GIGYF2	-0.5	-7.69	-0.39	1.61e-13	Coronary artery disease;
LUSC	trans	rs13011075	0.844	rs17530191	chr2:68621338	G/T	cg14221825	chr19:46271408	SIX5	0.42	6.04	0.31	4.16e-9	Mean corpuscular volume;
LUSC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg13047869	chr3:10149882	C3orf24	0.56	7.73	0.39	1.24e-13	Alzheimer's disease;
LUSC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-1.21	-13.48	-0.59	2.22e-33	Diabetic kidney disease;
LUSC	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg05784532	chr1:230284198	GALNT2	0.54	8.04	0.4	1.6e-14	Coronary artery disease;
LUSC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11764359	chr7:65958608	NA	0.68	10.89	0.51	7.59e-24	Aortic root size;
LUSC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.61	8.55	0.42	4.57e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12474201	0.588	rs3768719	chr2:46987935	T/G	cg06386533	chr2:46925753	SOCS5	0.48	6.93	0.35	2.15e-11	Height;
LUSC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.43	0.46	7e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.39	0.37	1.2e-12	Schizophrenia;
LUSC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.95	-0.31	6.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs977987	0.800	rs12922951	chr16:75355096	C/G	cg03315344	chr16:75512273	CHST6	0.53	10.12	0.48	3.61e-21	Dupuytren's disease;
LUSC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.17	-0.41	6.52e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2694528	1.000	rs929780	chr5:60189026	C/G	cg11474532	chr5:59995715	DEPDC1B	-0.71	-6.77	-0.35	5.85e-11	Parkinson's disease;
LUSC	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg17294928	chr15:75287854	SCAMP5	-0.76	-6.68	-0.34	1.01e-10	Lung cancer;
LUSC	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg05714579	chr10:131428358	MGMT	0.52	7.97	0.4	2.46e-14	Response to temozolomide;
LUSC	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg22491629	chr6:157744540	C6orf35	-0.92	-10.94	-0.51	5.17e-24	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.81	12.95	0.58	2.24e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15541040	chr2:3486749	NA	-0.58	-9.1	-0.45	8.15e-18	Neurofibrillary tangles;
LUSC	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg01028140	chr2:1542097	TPO	-0.6	-7.98	-0.4	2.45e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs6496667	0.683	rs2589973	chr15:90892293	C/T	cg10434728	chr15:90938212	IQGAP1	0.34	6.35	0.33	6.96e-10	Rheumatoid arthritis;
LUSC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21984481	chr17:79567631	NPLOC4	-0.59	-11.22	-0.52	5.11e-25	Eye color traits;
LUSC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08677398	chr8:58056175	NA	0.52	6.4	0.33	5.13e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg20811857	chr17:78079795	GAA	0.34	6.2	0.32	1.62e-9	Yeast infection;
LUSC	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg12884169	chr21:40033163	ERG	0.6	11.94	0.55	1.36e-27	Coronary artery disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02510388	chr3:182511451	ATP11B	0.68	6.4	0.33	5.34e-10	Cognitive performance;
LUSC	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.07	-22.54	-0.78	4.9e-69	Ulcerative colitis;
LUSC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg09021430	chr5:549028	NA	-0.55	-7.17	-0.37	4.85e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.39	-0.42	1.43e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg03611598	chr17:48586076	MYCBPAP	0.46	5.94	0.31	7.26e-9	Visceral fat;
LUSC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg18904891	chr8:8559673	CLDN23	0.41	6.31	0.33	9.06e-10	Mood instability;
LUSC	cis	rs2274459	0.841	rs3818526	chr6:33660973	T/C	cg06253072	chr6:33679850	C6orf125	0.48	5.76	0.3	1.89e-8	Obesity (extreme);
LUSC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg18225595	chr11:63971243	STIP1	0.42	6.75	0.35	6.52e-11	Platelet count;
LUSC	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg03465714	chr1:152285911	FLG	-0.41	-5.75	-0.3	2e-8	Atopic dermatitis;
LUSC	cis	rs7577851	0.625	rs56250322	chr2:69546480	G/A	cg10773587	chr2:69614142	GFPT1	0.59	6.3	0.33	9.29e-10	Parkinson's disease (age of onset);
LUSC	cis	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg21775007	chr8:11205619	TDH	0.46	6.61	0.34	1.55e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.88	-16.45	-0.67	5.76e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg27411982	chr8:10470053	RP1L1	0.4	6.18	0.32	1.91e-9	Neuroticism;
LUSC	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg09904177	chr6:26538194	HMGN4	-0.7	-6.65	-0.34	1.17e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.34	-0.37	1.65e-12	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg23630131	chr7:65973040	NA	0.21	5.81	0.3	1.43e-8	Aortic root size;
LUSC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	cis	rs73206853	0.686	rs73194039	chr12:111179153	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	6.67	0.34	1.08e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg04733989	chr22:42467013	NAGA	0.61	9.48	0.46	4.84e-19	Schizophrenia;
LUSC	cis	rs981844	0.775	rs17371468	chr4:154759826	G/C	cg14289246	chr4:154710475	SFRP2	0.5	6.67	0.34	1.09e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	0.64	13.66	0.6	4.71e-34	Prudent dietary pattern;
LUSC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg23630131	chr7:65973040	NA	0.2	5.74	0.3	2.1e-8	Aortic root size;
LUSC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg23719950	chr11:63933701	MACROD1	-0.35	-5.68	-0.3	2.98e-8	Platelet count;
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.38	6.11	0.32	2.7e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs13385	0.773	rs10067578	chr5:139558496	G/T	cg26211634	chr5:139558579	C5orf32	0.45	6.54	0.34	2.25e-10	Atrial fibrillation;
LUSC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.09	-0.32	3.16e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	29.27	0.85	3.41e-94	Chronic sinus infection;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16987101	chr1:226297828	NA	-0.55	-6.72	-0.35	7.81e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg07424592	chr7:64974309	NA	-0.4	-5.7	-0.3	2.7e-8	Calcium levels;
LUSC	cis	rs6076065	0.748	rs6048784	chr20:23382652	A/T	cg11657817	chr20:23433608	CST11	0.53	11.03	0.52	2.42e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs3087591	0.960	rs2905869	chr17:29519016	C/A	cg24425628	chr17:29625626	OMG;NF1	0.55	8.0	0.4	2.02e-14	Hip circumference;
LUSC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg05861140	chr6:150128134	PCMT1	-0.4	-6.31	-0.33	8.8e-10	Lung cancer;
LUSC	cis	rs926938	0.527	rs360672	chr1:115483836	C/T	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.41	-0.33	5.03e-10	Autism;
LUSC	cis	rs11608355	0.506	rs11066471	chr12:109828039	T/C	cg19025524	chr12:109796872	NA	-0.5	-9.09	-0.45	9.2e-18	Neuroticism;
LUSC	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg08601574	chr20:25228251	PYGB	0.49	7.55	0.38	4.23e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9811920	0.695	rs1287284	chr3:99516962	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-5.69	-0.3	2.85e-8	Axial length;
LUSC	cis	rs9296095	0.607	rs9366824	chr6:33521577	C/T	cg14003231	chr6:33640908	ITPR3	0.38	6.66	0.34	1.13e-10	Platelet count;
LUSC	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	0.92	8.03	0.4	1.65e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-17.88	-0.7	1.27e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11051970	0.877	rs2728671	chr12:32589715	T/A	cg24626660	chr12:32551988	NA	0.33	5.66	0.3	3.2e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg21535247	chr6:8435926	SLC35B3	0.57	9.0	0.44	1.69e-17	Motion sickness;
LUSC	cis	rs12760731	0.623	rs10913549	chr1:178383657	C/G	cg00404053	chr1:178313656	RASAL2	0.48	5.75	0.3	2.04e-8	Obesity-related traits;
LUSC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.48	-6.92	-0.35	2.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs77633900	0.772	rs8031672	chr15:76700553	T/C	cg21673338	chr15:77095150	SCAPER	0.65	5.88	0.31	9.92e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg26536354	chr8:144654954	C8orf73	0.64	7.32	0.37	1.88e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg03709012	chr19:19516395	GATAD2A	1.02	12.32	0.56	5.32e-29	Nonalcoholic fatty liver disease;
LUSC	trans	rs450533	0.541	rs433201	chr4:107851275	G/A	cg19546012	chr19:752860	C19orf21	-0.29	-6.22	-0.32	1.52e-9	Cancer;
LUSC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.6	-0.38	3.06e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11301069	chr17:8027502	HES7	-0.48	-6.27	-0.32	1.14e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg06238570	chr21:40685208	BRWD1	0.48	7.45	0.38	8.14e-13	Cognitive function;
LUSC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg18131467	chr2:239335373	ASB1	0.75	11.26	0.52	3.87e-25	Multiple system atrophy;
LUSC	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg03585969	chr10:35415529	CREM	0.65	9.34	0.45	1.45e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs698813	0.572	rs13424464	chr2:44482263	A/C	cg00619915	chr2:44497795	NA	-0.53	-7.35	-0.37	1.51e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg18230493	chr5:56204884	C5orf35	-0.78	-11.0	-0.52	3.09e-24	Initial pursuit acceleration;
LUSC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg03929089	chr4:120376271	NA	-0.49	-6.91	-0.35	2.47e-11	HDL cholesterol;
LUSC	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg15704280	chr7:45808275	SEPT13	-0.82	-11.51	-0.53	4.93e-26	Coronary artery disease;
LUSC	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg24851651	chr11:66362959	CCS	-0.38	-6.08	-0.32	3.34e-9	Educational attainment (years of education);
LUSC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg03289416	chr15:75166202	SCAMP2	0.45	6.81	0.35	4.65e-11	Breast cancer;
LUSC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg25767906	chr1:53392781	SCP2	0.39	6.66	0.34	1.12e-10	Monocyte count;
LUSC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg03146154	chr1:46216737	IPP	-0.55	-8.29	-0.41	2.87e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg06219351	chr7:158114137	PTPRN2	-0.53	-8.41	-0.42	1.24e-15	Response to amphetamines;
LUSC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg09877947	chr5:131593287	PDLIM4	-0.44	-6.62	-0.34	1.44e-10	Breast cancer;
LUSC	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg25575065	chr22:51066394	ARSA	-0.42	-5.93	-0.31	7.46e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg12002119	chr2:101014098	CHST10	0.34	5.68	0.3	2.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg15557168	chr22:42548783	NA	0.38	6.37	0.33	6.22e-10	Cognitive function;
LUSC	trans	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.74	-0.35	7.03e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg04455712	chr21:45112962	RRP1B	0.44	8.43	0.42	1.05e-15	Mean corpuscular volume;
LUSC	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg07828340	chr4:882639	GAK	-1.06	-11.64	-0.54	1.65e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-8.15	-0.41	7.5e-15	Schizophrenia;
LUSC	cis	rs1941023	0.567	rs955019	chr11:60174250	C/T	cg08716584	chr11:60157161	MS4A7	-0.56	-10.5	-0.5	1.75e-22	Congenital heart disease (maternal effect);
LUSC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.78	0.35	5.34e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2658782	0.724	rs2605626	chr11:93253903	A/G	cg15737290	chr11:93063684	CCDC67	0.58	6.91	0.35	2.42e-11	Pulmonary function decline;
LUSC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	15.63	0.65	9.98e-42	Platelet count;
LUSC	cis	rs17253792	0.822	rs12100949	chr14:56040787	T/C	cg01858014	chr14:56050164	KTN1	-0.76	-6.24	-0.32	1.32e-9	Putamen volume;
LUSC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg23601095	chr6:26197514	HIST1H3D	0.72	7.32	0.37	1.86e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg07274523	chr3:49395745	GPX1	0.67	10.37	0.49	5.13e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg02569458	chr12:86230093	RASSF9	-0.57	-9.69	-0.47	1.03e-19	Major depressive disorder;
LUSC	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.42	6.58	0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs1371867	0.846	rs2453624	chr8:101230523	A/G	cg06636551	chr8:101224915	SPAG1	0.47	8.76	0.43	9.83e-17	Atrioventricular conduction;
LUSC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.76	-0.43	9.95e-17	Lung cancer;
LUSC	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg06740227	chr12:86229804	RASSF9	0.39	6.09	0.32	3.05e-9	Major depressive disorder;
LUSC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg14440974	chr22:39074834	NA	-0.39	-6.42	-0.33	4.58e-10	Menopause (age at onset);
LUSC	cis	rs73195822	0.614	rs55946973	chr12:111214936	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	7.06	0.36	9.82e-12	Itch intensity from mosquito bite;
LUSC	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-5.84	-0.3	1.27e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg03929089	chr4:120376271	NA	0.82	11.14	0.52	9.93e-25	Coronary artery disease;
LUSC	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg12002119	chr2:101014098	CHST10	0.34	5.74	0.3	2.11e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg21770322	chr7:97807741	LMTK2	0.42	7.26	0.37	2.7e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg22532475	chr10:104410764	TRIM8	0.26	6.14	0.32	2.32e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10392	0.543	rs58414555	chr20:37554152	A/C	cg27552599	chr20:37590471	DHX35	0.45	7.26	0.37	2.74e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs7246657	0.551	rs28462002	chr19:37634462	A/G	cg23950597	chr19:37808831	NA	-0.57	-6.08	-0.32	3.34e-9	Coronary artery calcification;
LUSC	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg08676812	chr11:65308423	LTBP3	1.06	6.8	0.35	4.71e-11	Height;
LUSC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.06e-17	Prudent dietary pattern;
LUSC	cis	rs17604090	0.775	rs10225523	chr7:29689735	C/A	cg19413766	chr7:29689036	LOC646762	-0.56	-7.12	-0.36	6.67e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg14582100	chr15:45693742	SPATA5L1	0.59	10.52	0.5	1.53e-22	Homoarginine levels;
LUSC	trans	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg13010199	chr12:38710504	ALG10B	-0.45	-7.09	-0.36	8.27e-12	Morning vs. evening chronotype;
LUSC	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg07169764	chr2:136633963	MCM6	1.18	17.48	0.69	4.99e-49	Corneal structure;
LUSC	cis	rs17152411	1.000	rs7092008	chr10:126638226	G/A	cg07906193	chr10:126599966	NA	0.42	5.81	0.3	1.48e-8	Height;
LUSC	cis	rs7267979	0.816	rs422148	chr20:25512604	G/C	cg14121845	chr20:25566513	NINL	0.31	5.7	0.3	2.63e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	14.53	0.62	2.01e-37	Platelet count;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15583014	chr1:65468659	NA	0.78	6.35	0.33	7.1e-10	Cognitive performance;
LUSC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26314531	chr2:26401878	FAM59B	0.74	10.06	0.48	5.92e-21	Gut microbiome composition (summer);
LUSC	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg10253484	chr15:75165896	SCAMP2	0.5	6.7	0.34	8.73e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs11650494	0.908	rs77247327	chr17:47411493	T/C	cg08112188	chr17:47440006	ZNF652	1.22	10.05	0.48	6.07e-21	Prostate cancer;
LUSC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg11645453	chr3:52864694	ITIH4	0.36	8.63	0.43	2.5e-16	Bipolar disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05610379	chr10:123734658	NSMCE4A	-0.53	-6.42	-0.33	4.8e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.34	0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06879705	chr2:99771525	LIPT1;TSGA10	0.74	6.26	0.32	1.21e-9	Cognitive performance;
LUSC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6066835	1.000	rs6066829	chr20:47351630	G/T	cg18078177	chr20:47281410	PREX1	-0.69	-6.72	-0.34	7.99e-11	Multiple myeloma;
LUSC	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg15605315	chr1:45957053	TESK2	-0.44	-6.77	-0.35	5.93e-11	High light scatter reticulocyte count;
LUSC	cis	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg21775007	chr8:11205619	TDH	0.8	12.66	0.57	2.73e-30	Retinal vascular caliber;
LUSC	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg15485101	chr11:133734466	NA	0.4	7.3	0.37	2.14e-12	Childhood ear infection;
LUSC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	1.03	19.45	0.73	7.3e-57	Menopause (age at onset);
LUSC	cis	rs4494114	0.967	rs9438976	chr1:39353386	C/T	cg25970120	chr1:39325951	RRAGC	-0.4	-6.19	-0.32	1.8e-9	Blood protein levels;
LUSC	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg09654669	chr8:57350985	NA	-0.57	-7.81	-0.39	7.71e-14	Obesity-related traits;
LUSC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.54	6.61	0.34	1.53e-10	Renal function-related traits (BUN);
LUSC	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.93	-0.31	7.4e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg20476274	chr7:133979776	SLC35B4	0.78	13.61	0.6	7.29e-34	Mean platelet volume;
LUSC	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.49	-7.32	-0.37	1.87e-12	Cognitive test performance;
LUSC	cis	rs2235649	0.833	rs9939694	chr16:1852760	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-6.13	-0.32	2.55e-9	Blood metabolite levels;
LUSC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg26818010	chr10:134567672	INPP5A	-0.87	-11.25	-0.52	4.2e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7834588	0.523	rs9298067	chr8:63806223	G/A	cg20602954	chr8:63776762	NKAIN3	0.42	6.15	0.32	2.24e-9	Response to Vitamin E supplementation;
LUSC	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg25930673	chr12:123319894	HIP1R	-0.63	-6.23	-0.32	1.41e-9	Schizophrenia;
LUSC	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	0.89	12.81	0.57	8e-31	Uric acid levels;
LUSC	cis	rs460214	0.528	rs6517474	chr21:40023133	G/A	cg21578987	chr21:40029669	ERG	0.4	6.2	0.32	1.67e-9	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.58	-7.91	-0.4	3.75e-14	Longevity;Endometriosis;
LUSC	cis	rs2115630	0.791	rs2008262	chr15:85305270	C/T	cg17173187	chr15:85201210	NMB	-0.3	-6.14	-0.32	2.33e-9	P wave terminal force;
LUSC	trans	rs1325195	0.879	rs9727861	chr1:179092612	A/C	cg11624085	chr17:8464688	MYH10	-0.43	-7.2	-0.37	4.05e-12	IgE grass sensitization;
LUSC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg05863683	chr7:1912471	MAD1L1	0.3	5.7	0.3	2.67e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs6120849	0.754	rs6120828	chr20:33674460	A/G	cg24642439	chr20:33292090	TP53INP2	0.59	6.62	0.34	1.4e-10	Protein C levels;
LUSC	cis	rs7608623	0.773	rs11125168	chr2:23922383	C/T	cg08917208	chr2:24149416	ATAD2B	-0.43	-5.88	-0.31	9.75e-9	Obesity-related traits;
LUSC	cis	rs2262909	0.962	rs425781	chr19:22229306	A/G	cg11619707	chr19:22235551	ZNF257	-0.38	-5.7	-0.3	2.7e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg13256891	chr4:100009986	ADH5	0.46	6.39	0.33	5.61e-10	Alcohol dependence;
LUSC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.05e-10	Life satisfaction;
LUSC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg16228356	chr17:43848958	NA	0.25	5.81	0.3	1.48e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs5758511	0.773	rs9680671	chr22:42351477	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.43	7.08	0.36	8.49e-12	Birth weight;
LUSC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg16569376	chr16:15982511	C16orf63	0.79	6.14	0.32	2.33e-9	Cognitive performance;
LUSC	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.62	-0.34	1.39e-10	QT interval;
LUSC	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg09835421	chr16:68378352	PRMT7	-0.54	-5.94	-0.31	7.01e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg17757837	chr7:157058334	UBE3C	0.82	13.3	0.59	1.14e-32	Body mass index;
LUSC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg26446133	chr18:72167187	CNDP2	-0.6	-8.08	-0.4	1.19e-14	Mononucleosis;
LUSC	cis	rs9399401	0.667	rs12213892	chr6:142702234	A/G	cg03128060	chr6:142623767	GPR126	0.61	9.98	0.48	1.1e-20	Chronic obstructive pulmonary disease;
LUSC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19905802	chr11:62554200	TMEM179B;TAF6L	-0.5	-6.47	-0.33	3.55e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2109514	0.840	rs6953982	chr7:116129290	C/T	cg12739419	chr7:116140593	CAV2	-0.27	-5.77	-0.3	1.77e-8	Prevalent atrial fibrillation;
LUSC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg04362960	chr10:104952993	NT5C2	-0.53	-6.55	-0.34	2.17e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	6.3	0.33	9.61e-10	Iron status biomarkers;
LUSC	cis	rs9937943	0.512	rs13335886	chr16:74577161	C/G	cg01733217	chr16:74700730	RFWD3	-0.63	-8.15	-0.41	7.4e-15	Neutrophil percentage of white cells;
LUSC	trans	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.4	-0.33	5.26e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12136530	0.774	rs4911996	chr1:19765205	C/G	cg01832549	chr1:19774989	CAPZB	0.31	5.68	0.3	2.87e-8	Lead levels in blood;
LUSC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg00033643	chr7:134001901	SLC35B4	0.47	7.27	0.37	2.58e-12	Mean platelet volume;
LUSC	cis	rs240764	0.853	rs12374612	chr6:100955752	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-5.99	-0.31	5.53e-9	Neuroticism;
LUSC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03526776	chr6:41159608	TREML2	0.5	10.46	0.5	2.36e-22	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg14552801	chr7:65878734	NA	0.36	5.71	0.3	2.48e-8	Aortic root size;
LUSC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg10130564	chr11:117069849	TAGLN	-0.38	-6.53	-0.34	2.43e-10	Blood protein levels;
LUSC	cis	rs7236492	0.577	rs7236190	chr18:77198217	T/C	cg15644404	chr18:77186268	NFATC1	-0.5	-6.91	-0.35	2.41e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs17154702	0.506	rs74525088	chr8:8628413	A/T	cg01851573	chr8:8652454	MFHAS1	0.59	6.99	0.36	1.45e-11	Neurocognitive impairment in HIV-1 infection (continuous);
LUSC	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg23093090	chr10:104574429	C10orf26	0.35	6.46	0.33	3.61e-10	Arsenic metabolism;
LUSC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08280861	chr8:58055591	NA	0.53	6.86	0.35	3.35e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7215564	0.908	rs2316060	chr17:78663728	T/C	cg09596252	chr17:78655493	RPTOR	0.53	5.85	0.31	1.15e-8	Myopia (pathological);
LUSC	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-7.31	-0.37	2.01e-12	Bone mineral density;
LUSC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg07936489	chr17:37558343	FBXL20	0.68	9.9	0.48	1.94e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.36	-0.33	6.74e-10	Total body bone mineral density;
LUSC	cis	rs4561483	0.801	rs8061189	chr16:11951749	C/G	cg08843971	chr16:11963173	GSPT1	0.49	7.3	0.37	2.17e-12	Testicular germ cell tumor;
LUSC	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg09469691	chr10:81107165	PPIF	0.65	9.62	0.47	1.66e-19	Height;
LUSC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg10434728	chr15:90938212	IQGAP1	-0.44	-8.96	-0.44	2.33e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs853679	0.607	rs201002	chr6:27808192	A/G	cg01620082	chr3:125678407	NA	-0.65	-7.13	-0.36	6.42e-12	Depression;
LUSC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg25036284	chr2:26402008	FAM59B	-0.77	-11.38	-0.53	1.46e-25	Gut microbiome composition (summer);
LUSC	trans	rs1927790	0.667	rs7981845	chr13:96942533	C/T	cg03198741	chr6:1003969	LOC285768	-0.39	-5.95	-0.31	6.79e-9	Body mass index;
LUSC	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05731713	chr7:157510257	PTPRN2	0.47	8.94	0.44	2.68e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	6.04	0.31	4.22e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg02336364	chr1:24764700	NIPAL3	0.34	6.16	0.32	2.1e-9	Response to interferon beta in multiple sclerosis;
LUSC	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21385522	chr1:16154831	NA	0.56	8.82	0.43	6.67e-17	Systolic blood pressure;
LUSC	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08109568	chr15:31115862	NA	0.56	6.97	0.36	1.69e-11	Huntington's disease progression;
LUSC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg06028605	chr16:24865363	SLC5A11	-0.52	-9.14	-0.45	6.32e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg11214544	chr1:2391121	NA	-0.33	-5.68	-0.3	2.9e-8	Schizophrenia;
LUSC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg15649852	chr7:65879115	NA	-0.42	-5.72	-0.3	2.41e-8	Aortic root size;
LUSC	cis	rs7267979	0.565	rs6107060	chr20:25592476	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.71	12.84	0.58	5.79e-31	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg27661571	chr11:113659931	NA	-0.67	-7.74	-0.39	1.22e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs2019216	0.500	rs6565385	chr17:21897646	C/A	cg22648282	chr17:21454238	C17orf51	-0.52	-7.84	-0.39	6.27e-14	Pelvic organ prolapse;
LUSC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.16	0.55	2.03e-28	Motion sickness;
LUSC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-14.28	-0.62	1.95e-36	Chronic sinus infection;
LUSC	cis	rs10979	0.965	rs9496679	chr6:143896741	G/T	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg14019146	chr3:50243930	SLC38A3	0.52	12.7	0.57	1.97e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19717773	chr7:2847554	GNA12	-0.38	-6.02	-0.31	4.59e-9	Height;
LUSC	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg04374321	chr14:90722782	PSMC1	0.77	12.46	0.56	1.64e-29	Mortality in heart failure;
LUSC	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	11.25	0.52	4.24e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg17971929	chr21:40555470	PSMG1	-0.51	-7.57	-0.38	3.62e-13	Menarche (age at onset);
LUSC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg00750074	chr16:89608354	SPG7	-0.47	-8.21	-0.41	4.95e-15	Multiple myeloma (IgH translocation);
LUSC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	8.94	0.44	2.77e-17	Height;
LUSC	cis	rs3106136	0.967	rs2632399	chr4:95153741	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.93	-0.31	7.72e-9	Capecitabine sensitivity;
LUSC	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg22117172	chr7:91764530	CYP51A1	0.34	5.98	0.31	5.68e-9	Breast cancer;
LUSC	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg12863693	chr15:85201151	NMB	0.4	8.02	0.4	1.79e-14	Schizophrenia;
LUSC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg12564285	chr5:131593104	PDLIM4	-0.47	-8.04	-0.4	1.6e-14	Blood metabolite levels;
LUSC	cis	rs4919687	0.550	rs11191371	chr10:104459897	G/C	cg04362960	chr10:104952993	NT5C2	0.47	6.82	0.35	4.17e-11	Colorectal cancer;
LUSC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg05585544	chr11:47624801	NA	-0.41	-7.32	-0.37	1.86e-12	Subjective well-being;
LUSC	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.31	-5.79	-0.3	1.6e-8	Oropharynx cancer;
LUSC	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg17168535	chr8:21777572	XPO7	0.67	10.3	0.49	8.44e-22	Mean corpuscular volume;
LUSC	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.6	-6.39	-0.33	5.52e-10	Fibroblast growth factor basic levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07085396	chr18:12325516	TUBB6	0.46	6.43	0.33	4.44e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg22868518	chr11:507468	RNH1	-0.59	-5.8	-0.3	1.56e-8	Body mass index;
LUSC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.29	0.33	9.79e-10	Bipolar disorder;
LUSC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg07167872	chr1:205819463	PM20D1	0.52	7.9	0.4	3.94e-14	Prostate-specific antigen levels;
LUSC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11764359	chr7:65958608	NA	-0.54	-7.11	-0.36	7.23e-12	Aortic root size;
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.55	-8.0	-0.4	2.1e-14	Renal function-related traits (BUN);
LUSC	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07636037	chr3:49044803	WDR6	-0.69	-8.92	-0.44	3.02e-17	Menarche (age at onset);
LUSC	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg23795048	chr12:9217529	LOC144571	0.34	5.84	0.3	1.27e-8	Sjögren's syndrome;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16265552	chr3:113667068	ZDHHC23	0.43	6.11	0.32	2.84e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg03585969	chr10:35415529	CREM	0.63	9.39	0.46	9.85e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11971779	0.715	rs10265	chr7:139026152	T/G	cg23387468	chr7:139079360	LUC7L2	0.4	6.05	0.31	3.97e-9	Diisocyanate-induced asthma;
LUSC	cis	rs62027291	0.948	rs62007172	chr15:77306741	G/A	cg26408565	chr15:76604113	ETFA	0.52	6.21	0.32	1.55e-9	Plateletcrit;
LUSC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg03522245	chr20:25566470	NINL	0.53	7.66	0.39	2.09e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.26	0.32	1.19e-9	Height;
LUSC	trans	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.43	-6.12	-0.32	2.61e-9	Platelet distribution width;
LUSC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg05313129	chr8:58192883	C8orf71	-0.49	-6.77	-0.35	5.9e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	1.18	12.44	0.56	1.89e-29	Diabetic kidney disease;
LUSC	cis	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-8.23	-0.41	4.13e-15	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7119	0.635	rs59745219	chr15:77884130	A/G	cg27398640	chr15:77910606	LINGO1	0.36	8.57	0.42	3.93e-16	Type 2 diabetes;
LUSC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.59	0.6	8.31e-34	Platelet count;
LUSC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.91	-0.35	2.5e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs17095355	0.786	rs58096078	chr10:111734286	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.57	-7.31	-0.37	2.01e-12	Biliary atresia;
LUSC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.38	6.56	0.34	2.1e-10	Depressive symptoms;
LUSC	cis	rs858239	0.730	rs858289	chr7:23248158	C/T	cg05407003	chr7:23246146	NA	-0.38	-5.74	-0.3	2.1e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg25427524	chr10:38739819	LOC399744	0.48	6.21	0.32	1.61e-9	Obesity (extreme);
LUSC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg20476274	chr7:133979776	SLC35B4	0.88	17.04	0.68	2.81e-47	Mean platelet volume;
LUSC	trans	rs10497394	0.959	rs962782	chr2:174302988	G/T	cg03531853	chr9:86535572	KIF27	-0.58	-6.03	-0.31	4.43e-9	Otitis media (chronic/recurrent);
LUSC	cis	rs983392	0.836	rs7935829	chr11:59942815	A/G	cg24026212	chr11:59952134	MS4A6A	-0.37	-6.26	-0.32	1.2e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg06713675	chr4:122721982	EXOSC9	-0.69	-12.02	-0.55	6.45e-28	Type 2 diabetes;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10150615	chr22:24372951	LOC391322	-0.35	-5.93	-0.31	7.37e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08677398	chr8:58056175	NA	0.52	6.87	0.35	3.18e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1152591	0.543	rs1152592	chr14:64676098	A/G	cg21174375	chr14:64681225	SYNE2	0.33	6.01	0.31	4.85e-9	Atrial fibrillation;
LUSC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg19318889	chr4:1322082	MAEA	0.45	7.41	0.38	1.04e-12	Obesity-related traits;
LUSC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-9.62	-0.47	1.71e-19	Longevity;
LUSC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg03929089	chr4:120376271	NA	0.66	6.25	0.32	1.23e-9	Intraocular pressure;
LUSC	cis	rs7216064	1.000	rs4790908	chr17:65852907	T/G	cg12091567	chr17:66097778	LOC651250	-0.72	-9.39	-0.46	9.94e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg13119609	chr19:45449297	APOC2	0.33	5.74	0.3	2.09e-8	Blood protein levels;
LUSC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06221963	chr1:154839813	KCNN3	0.59	13.07	0.58	8e-32	Prostate cancer;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.57	9.55	0.46	2.87e-19	Lymphocyte counts;
LUSC	cis	rs12791968	0.527	rs12279115	chr11:45014587	G/C	cg11846598	chr11:44996168	LOC221122	-0.53	-6.15	-0.32	2.21e-9	Inhibitory control;
LUSC	trans	rs6982636	0.765	rs6982502	chr8:126479362	C/T	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.32	-6.02	-0.31	4.51e-9	Lipid metabolism phenotypes;
LUSC	cis	rs10740039	0.516	rs7477771	chr10:62355728	T/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.89	-0.35	2.83e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-9.41	-0.46	8.12e-19	Schizophrenia;
LUSC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg07395648	chr5:131743802	NA	0.42	6.01	0.31	4.97e-9	Blood metabolite levels;
LUSC	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-5.76	-0.3	1.89e-8	Breast cancer;
LUSC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16680214	chr1:154839983	KCNN3	-0.53	-10.03	-0.48	7.38e-21	Prostate cancer;
LUSC	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.73	-10.15	-0.49	2.77e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs116988415	0.584	rs1875054	chr14:65255066	G/A	cg00114569	chr14:65239327	SPTB	0.67	7.08	0.36	8.72e-12	Daytime sleep phenotypes;
LUSC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03576123	chr11:487126	PTDSS2	-0.99	-10.56	-0.5	1.11e-22	Body mass index;
LUSC	cis	rs17401966	0.540	rs7546368	chr1:10418826	G/A	cg19773385	chr1:10388646	KIF1B	-0.36	-6.32	-0.33	8.28e-10	Hepatocellular carcinoma;
LUSC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg10729496	chr3:10149963	C3orf24	0.58	7.71	0.39	1.48e-13	Alzheimer's disease;
LUSC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg12310025	chr6:25882481	NA	0.44	7.66	0.39	2.05e-13	Blood metabolite levels;
LUSC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg12863693	chr15:85201151	NMB	0.4	8.33	0.41	2.16e-15	Schizophrenia;
LUSC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg06740227	chr12:86229804	RASSF9	0.43	6.83	0.35	4.04e-11	Major depressive disorder;
LUSC	cis	rs11166629	1.000	rs4909332	chr8:135646340	T/C	cg27224718	chr8:135614730	ZFAT	0.65	10.68	0.5	4.28e-23	Smoking quantity;
LUSC	cis	rs1044826	1.000	rs3821545	chr3:139182971	C/G	cg00490450	chr3:139108681	COPB2	0.5	6.42	0.33	4.79e-10	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7246967	0.673	rs8103875	chr19:22866862	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg08270630	chr22:50330655	NA	0.4	5.93	0.31	7.52e-9	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06711307	chr19:10362455	MRPL4	-0.43	-6.49	-0.33	3.09e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg26304593	chr6:42947056	PEX6	-0.49	-7.36	-0.37	1.46e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.55	-6.6	-0.34	1.62e-10	Body mass index;
LUSC	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg17633681	chr16:88106987	BANP	0.53	10.16	0.49	2.64e-21	Menopause (age at onset);
LUSC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	8.77	0.43	9.47e-17	Longevity;
LUSC	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg03254818	chr6:169586852	NA	-0.45	-6.31	-0.33	8.67e-10	Pulse pressure;
LUSC	trans	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-7.39	-0.38	1.16e-12	Aortic root size;
LUSC	cis	rs2078087	0.522	rs75394497	chr1:183215798	C/A	cg13843938	chr1:183241246	NMNAT2	0.44	6.64	0.34	1.24e-10	Obesity-related traits;
LUSC	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg06552810	chr11:31128660	NA	-0.41	-7.23	-0.37	3.34e-12	Red blood cell count;
LUSC	cis	rs9549260	0.755	rs4429172	chr13:41189143	C/A	cg21288729	chr13:41239152	FOXO1	0.59	8.95	0.44	2.45e-17	Red blood cell count;
LUSC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg14004847	chr7:1930337	MAD1L1	-0.57	-8.85	-0.44	5.37e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs858239	0.601	rs4140959	chr7:23170776	C/T	cg23682824	chr7:23144976	KLHL7	0.4	5.79	0.3	1.65e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.27	5.84	0.3	1.27e-8	Electroencephalogram traits;
LUSC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg15649852	chr7:65879115	NA	-0.41	-5.76	-0.3	1.96e-8	Aortic root size;
LUSC	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg04749549	chr19:17459798	NA	-0.32	-5.84	-0.3	1.26e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUSC	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.55	5.7	0.3	2.68e-8	Smoking behavior;
LUSC	cis	rs4363385	0.530	rs10888529	chr1:153050654	G/T	cg25856811	chr1:152973957	SPRR3	-0.37	-6.14	-0.32	2.39e-9	Inflammatory skin disease;
LUSC	cis	rs7804356	1.000	rs3801825	chr7:26856959	T/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.14	-0.32	2.4e-9	Type 1 diabetes;
LUSC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-6.25	-0.32	1.27e-9	Height;
LUSC	cis	rs28374715	0.510	rs8034073	chr15:41545613	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.66	-11.35	-0.53	1.85e-25	Ulcerative colitis;
LUSC	cis	rs7432375	0.610	rs28458819	chr3:136522314	A/G	cg15507776	chr3:136538369	TMEM22	0.44	7.32	0.37	1.86e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg17294928	chr15:75287854	SCAMP5	-0.93	-13.47	-0.59	2.47e-33	Blood trace element (Zn levels);
LUSC	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.19	0.32	1.77e-9	Total body bone mineral density;
LUSC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg15790184	chr11:494944	RNH1	0.54	5.81	0.3	1.46e-8	Body mass index;
LUSC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg03146154	chr1:46216737	IPP	0.56	8.42	0.42	1.1e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg07701084	chr6:150067640	NUP43	0.58	9.09	0.45	9.32e-18	Lung cancer;
LUSC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg13393036	chr8:95962371	TP53INP1	0.44	8.6	0.43	3.05e-16	Type 2 diabetes;
LUSC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg07741184	chr6:167504864	NA	0.39	6.95	0.36	1.96e-11	Primary biliary cholangitis;
LUSC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.29	-0.41	2.71e-15	Obesity-related traits;
LUSC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg07701084	chr6:150067640	NUP43	0.51	7.27	0.37	2.65e-12	Lung cancer;
LUSC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg02023728	chr11:77925099	USP35	0.46	6.68	0.34	9.77e-11	Testicular germ cell tumor;
LUSC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg11752832	chr7:134001865	SLC35B4	-0.6	-9.63	-0.47	1.61e-19	Mean platelet volume;
LUSC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg25258033	chr6:167368657	RNASET2	0.39	6.28	0.32	1.07e-9	Crohn's disease;
LUSC	cis	rs6834538	0.597	rs4834291	chr4:113482718	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.38	6.2	0.32	1.62e-9	Free thyroxine concentration;
LUSC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12826209	chr6:26865740	GUSBL1	0.78	9.84	0.47	3.21e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg17724175	chr1:150552817	MCL1	0.37	6.79	0.35	5.02e-11	Tonsillectomy;
LUSC	trans	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.35	-0.49	5.81e-22	Hemoglobin concentration;
LUSC	cis	rs912057	1.000	rs912056	chr6:6736197	A/T	cg06612196	chr6:6737390	NA	0.54	10.06	0.48	5.67e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg09835421	chr16:68378352	PRMT7	-0.81	-8.86	-0.44	4.73e-17	Schizophrenia;
LUSC	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg13256891	chr4:100009986	ADH5	0.49	7.3	0.37	2.17e-12	Alcohol dependence;
LUSC	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg00898013	chr13:113819073	PROZ	0.54	8.04	0.4	1.59e-14	Platelet distribution width;
LUSC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-9.0	-0.44	1.72e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg15423357	chr2:25149977	NA	0.4	7.76	0.39	1.04e-13	Body mass index in non-asthmatics;
LUSC	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.68	-11.44	-0.53	8.86e-26	Caffeine consumption;
LUSC	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.53	8.33	0.41	2.19e-15	Colorectal cancer;
LUSC	cis	rs2742234	0.554	rs1254963	chr10:43696086	C/T	cg15436174	chr10:43711423	RASGEF1A	0.43	7.0	0.36	1.41e-11	Hirschsprung disease;
LUSC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg13319975	chr6:146136371	FBXO30	0.46	6.91	0.35	2.46e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6496044	0.568	rs1982742	chr15:86068750	A/G	cg13263323	chr15:86062960	AKAP13	-0.37	-6.04	-0.31	4.14e-9	Interstitial lung disease;
LUSC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg22166914	chr1:53195759	ZYG11B	0.68	11.49	0.53	5.62e-26	Monocyte count;
LUSC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg23711669	chr6:146136114	FBXO30	-0.83	-15.28	-0.64	2.37e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg05347473	chr6:146136440	FBXO30	0.49	8.3	0.41	2.7e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-9.86	-0.47	2.75e-20	Mood instability;
LUSC	trans	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg06636001	chr8:8085503	FLJ10661	0.46	6.4	0.33	5.3e-10	Monocyte count;
LUSC	trans	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg06606381	chr12:133084897	FBRSL1	-0.64	-7.13	-0.36	6.15e-12	Depression;
LUSC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.16	0.36	5.3e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs3924048	0.559	rs6541038	chr1:12626210	G/T	cg00291366	chr1:12616550	NA	0.33	7.58	0.38	3.36e-13	Optic cup area;
LUSC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-5.99	-0.31	5.35e-9	Lung cancer;
LUSC	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.55	11.0	0.52	3.3e-24	Coronary artery disease;
LUSC	cis	rs9297145	0.761	rs12534399	chr7:98746401	A/G	cg05967295	chr7:98741636	SMURF1	0.99	14.84	0.63	1.34e-38	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18374471	chr6:131384607	EPB41L2	-0.46	-7.08	-0.36	8.76e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.22	0.32	1.5e-9	Schizophrenia;
LUSC	trans	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-8.84	-0.44	5.76e-17	Depression;
LUSC	cis	rs12200782	1.000	rs6456742	chr6:26617075	T/C	cg11502198	chr6:26597334	ABT1	-0.76	-5.8	-0.3	1.53e-8	Small cell lung carcinoma;
LUSC	cis	rs6076065	0.723	rs7269627	chr20:23362727	A/T	cg11657817	chr20:23433608	CST11	0.42	7.99	0.4	2.19e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs72634258	0.842	rs6577463	chr1:8169485	T/G	cg00042356	chr1:8021962	PARK7	-0.59	-7.17	-0.37	4.76e-12	Inflammatory bowel disease;
LUSC	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg15485101	chr11:133734466	NA	0.39	6.95	0.36	1.95e-11	Childhood ear infection;
LUSC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg01770232	chr7:22766155	IL6	0.41	5.92	0.31	7.96e-9	Lung cancer;
LUSC	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.75	-14.12	-0.61	7.8e-36	Ulcerative colitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03666316	chr5:76012246	F2R	0.42	6.38	0.33	5.98e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11158026	0.575	rs8008150	chr14:55421436	G/T	cg04306507	chr14:55594613	LGALS3	0.36	6.42	0.33	4.8e-10	Parkinson's disease;
LUSC	trans	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg06521331	chr12:34319734	NA	0.4	6.36	0.33	6.46e-10	Bladder cancer;
LUSC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg16606324	chr3:10149918	C3orf24	0.62	8.87	0.44	4.41e-17	Alzheimer's disease;
LUSC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg02018176	chr4:1364513	KIAA1530	0.52	9.16	0.45	5.47e-18	Obesity-related traits;
LUSC	cis	rs6977660	0.714	rs28605851	chr7:19815219	G/A	cg07541023	chr7:19748670	TWISTNB	0.66	7.21	0.37	3.71e-12	Thyroid stimulating hormone;
LUSC	cis	rs654950	0.776	rs2759252	chr1:42021854	G/A	cg06885757	chr1:42089581	HIVEP3	-0.45	-8.72	-0.43	1.32e-16	Airway imaging phenotypes;
LUSC	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg27266060	chr8:22091797	NA	0.39	7.18	0.37	4.61e-12	Hypertriglyceridemia;
LUSC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg16586182	chr3:47516702	SCAP	-0.52	-7.99	-0.4	2.18e-14	Colorectal cancer;
LUSC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg05368731	chr17:41323189	NBR1	0.93	15.61	0.65	1.19e-41	Menopause (age at onset);
LUSC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.81	-0.43	6.8e-17	Lung cancer;
LUSC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.52	0.46	3.59e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs77633900	0.614	rs157757	chr15:76855927	G/C	cg21673338	chr15:77095150	SCAPER	-0.78	-7.05	-0.36	1.03e-11	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg20701182	chr2:24300061	SF3B14	0.74	7.3	0.37	2.15e-12	Lymphocyte counts;
LUSC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg04455712	chr21:45112962	RRP1B	0.48	9.09	0.45	8.9e-18	Mean corpuscular volume;
LUSC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg25039879	chr17:56429692	SUPT4H1	0.66	8.88	0.44	4.07e-17	Cognitive test performance;
LUSC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg08975724	chr8:8085496	FLJ10661	0.59	9.03	0.44	1.39e-17	Systolic blood pressure;
LUSC	cis	rs12973672	0.812	rs12979792	chr19:35748706	A/G	cg12095397	chr19:35769544	USF2	0.43	6.53	0.34	2.45e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg07541023	chr7:19748670	TWISTNB	0.67	7.32	0.37	1.88e-12	Thyroid stimulating hormone;
LUSC	trans	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.6	0.38	3.08e-13	Ulcerative colitis;
LUSC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21963583	chr11:68658836	MRPL21	0.55	8.28	0.41	3.08e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4499344	0.730	rs377044	chr19:33105951	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.8	12.31	0.56	5.87e-29	Mean platelet volume;
LUSC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	7.59	0.38	3.1400000000000003e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6060960	0.502	rs6089110	chr20:30486907	A/T	cg06102403	chr20:30458708	TTLL9;DUSP15	0.44	5.78	0.3	1.75e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19748678	chr4:122722346	EXOSC9	-0.48	-7.29	-0.37	2.29e-12	Type 2 diabetes;
LUSC	cis	rs62577244	0.645	rs12001733	chr9:138431675	G/T	cg14582108	chr9:138439003	OBP2A	0.41	7.81	0.39	7.3e-14	Subcutaneous adipose tissue (sex interaction);Subcutaneous adipose tissue;
LUSC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg13560548	chr3:10150139	C3orf24	0.48	6.9	0.35	2.69e-11	Alzheimer's disease;
LUSC	cis	rs2273669	0.667	rs79285264	chr6:109318279	G/T	cg05315195	chr6:109294784	ARMC2	-0.55	-5.87	-0.31	1.03e-8	Prostate cancer;
LUSC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg02018176	chr4:1364513	KIAA1530	0.51	8.7	0.43	1.53e-16	Obesity-related traits;
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-7.04	-0.36	1.08e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs72772090	0.539	rs111237997	chr5:96114953	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-6.55	-0.34	2.11e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6940638	0.956	rs12190473	chr6:27024687	C/T	cg09904177	chr6:26538194	HMGN4	-0.46	-5.7	-0.3	2.66e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7605827	0.866	rs2032692	chr2:15616847	A/G	cg19274914	chr2:15703543	NA	0.45	8.55	0.42	4.36e-16	Educational attainment (years of education);
LUSC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.54	-7.69	-0.39	1.62e-13	Tuberculosis;
LUSC	cis	rs2249625	0.545	rs10498880	chr6:72882183	G/T	cg18830697	chr6:72922368	RIMS1	0.37	7.42	0.38	9.84e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg17800788	chr1:21766015	NBPF3	0.3	5.81	0.3	1.49e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs1371867	0.846	rs2919471	chr8:101232701	T/C	cg00191853	chr8:101177733	SPAG1	0.41	6.61	0.34	1.5e-10	Atrioventricular conduction;
LUSC	trans	rs28595532	0.557	rs12498329	chr4:119311524	C/T	cg26518628	chr1:97050305	NA	-0.6	-6.86	-0.35	3.44e-11	Cannabis dependence symptom count;
LUSC	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg12483005	chr1:23474871	LUZP1	0.41	6.5	0.34	2.89e-10	Height;
LUSC	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg21775007	chr8:11205619	TDH	-0.47	-7.18	-0.37	4.67e-12	Neuroticism;
LUSC	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg11608241	chr8:8085544	FLJ10661	-0.47	-6.51	-0.34	2.77e-10	Neuroticism;
LUSC	cis	rs6840360	1.000	rs7439465	chr4:152594814	C/T	cg22705602	chr4:152727874	NA	0.28	5.66	0.3	3.29e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2303282	0.716	rs2219776	chr16:56399289	G/C	cg00500540	chr16:56394104	NA	-0.44	-7.55	-0.38	4.1e-13	Breast cancer;
LUSC	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg02466173	chr16:30829666	NA	0.56	11.11	0.52	1.3e-24	Dementia with Lewy bodies;
LUSC	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg25251562	chr2:3704773	ALLC	-0.39	-6.97	-0.36	1.71e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.61	-0.38	2.74e-13	Joint mobility (Beighton score);
LUSC	cis	rs12286929	0.609	rs45614535	chr11:115090866	G/A	cg04055981	chr11:115044050	NA	0.37	6.63	0.34	1.39e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22270384	chr19:12848240	ASNA1	0.46	6.48	0.33	3.34e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg10130564	chr11:117069849	TAGLN	0.31	6.0	0.31	5.24e-9	Blood protein levels;
LUSC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.7	12.69	0.57	2.16e-30	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	19.1	0.72	1.79e-55	Chronic sinus infection;
LUSC	cis	rs11608355	0.508	rs11066394	chr12:109799212	C/A	cg19025524	chr12:109796872	NA	-0.47	-8.59	-0.43	3.47e-16	Neuroticism;
LUSC	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg05110241	chr16:68378359	PRMT7	-0.45	-5.96	-0.31	6.5e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg15110403	chr19:17392923	ANKLE1	-0.59	-7.94	-0.4	3.09e-14	Systemic lupus erythematosus;
LUSC	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg12935359	chr14:103987150	CKB	0.65	10.51	0.5	1.67e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs4499344	0.633	rs259258	chr19:33152523	A/G	cg22980127	chr19:33182716	NUDT19	-0.44	-6.45	-0.33	3.88e-10	Mean platelet volume;
LUSC	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg19773385	chr1:10388646	KIF1B	-0.54	-8.32	-0.41	2.24e-15	Hepatocellular carcinoma;
LUSC	cis	rs2267137	0.868	rs5763178	chr22:29773869	A/G	cg07256473	chr22:29710276	RASL10A	0.39	7.39	0.37	1.19e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg18964960	chr10:1102726	WDR37	-0.46	-6.21	-0.32	1.58e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs7605827	0.866	rs11689153	chr2:15533899	A/G	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15433164	chr3:25824899	NGLY1	-0.49	-6.69	-0.34	9.49e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg04998671	chr14:104000505	TRMT61A	-0.46	-7.18	-0.37	4.47e-12	Coronary artery disease;
LUSC	cis	rs9650315	0.866	rs13272414	chr8:57183609	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.88	0.35	3.02e-11	Height;
LUSC	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.75	0.73	4.73e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg25019033	chr10:957182	NA	-0.5	-6.56	-0.34	2e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg22963979	chr7:1858916	MAD1L1	-0.56	-8.78	-0.43	8.5e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-0.88	-16.78	-0.68	2.87e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.69	10.37	0.49	5.1e-22	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg13263323	chr15:86062960	AKAP13	-0.35	-5.81	-0.3	1.45e-8	Coronary artery disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04575144	chr19:4067379	ZBTB7A	-0.49	-6.71	-0.34	8.37e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg26338869	chr17:61819248	STRADA	0.42	6.18	0.32	1.83e-9	Prudent dietary pattern;
LUSC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	1.06	11.67	0.54	1.23e-26	Hip circumference adjusted for BMI;
LUSC	cis	rs7584330	0.554	rs7573177	chr2:238444467	C/T	cg14458575	chr2:238380390	NA	-0.46	-6.21	-0.32	1.57e-9	Prostate cancer;
LUSC	cis	rs73206853	0.764	rs58535454	chr12:111003457	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	7.54	0.38	4.6e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg24733560	chr20:60626293	TAF4	0.44	7.96	0.4	2.66e-14	Body mass index;
LUSC	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg12072164	chr19:44306565	LYPD5	0.29	6.45	0.33	3.85e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs2580764	0.566	rs2968827	chr2:55297629	C/G	cg09592903	chr2:55203963	RTN4	0.46	9.13	0.45	6.74e-18	Mean platelet volume;
LUSC	cis	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg20936604	chr3:58311152	NA	0.65	6.56	0.34	2.08e-10	Cholesterol, total;
LUSC	cis	rs11971779	0.680	rs7808740	chr7:139028955	G/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.2	0.32	1.64e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg01528321	chr10:82214614	TSPAN14	0.89	13.66	0.6	4.65e-34	Post bronchodilator FEV1;
LUSC	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07988820	chr12:82153109	PPFIA2	0.45	6.58	0.34	1.84e-10	Resting heart rate;
LUSC	cis	rs12530845	0.524	rs7795267	chr7:135308455	C/G	cg23117316	chr7:135346802	PL-5283	-0.56	-8.88	-0.44	4.11e-17	Red blood cell traits;
LUSC	cis	rs61990749	0.597	rs6574391	chr14:78208121	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	6.59	0.34	1.76e-10	Fibroblast growth factor basic levels;
LUSC	trans	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.11	-0.32	2.83e-9	Depression;
LUSC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.44	6.69	0.34	9.59e-11	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	11.26	0.52	3.72e-25	Lymphocyte counts;
LUSC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.52e-8	Extrinsic epigenetic age acceleration;
LUSC	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg14343924	chr8:8086146	FLJ10661	0.44	6.04	0.31	4.1e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg10426581	chr7:100472382	SRRT	0.86	12.47	0.56	1.43e-29	Resting heart rate;
LUSC	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg04586622	chr2:25135609	ADCY3	0.39	8.19	0.41	5.74e-15	Body mass index;
LUSC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg21285383	chr16:89894308	SPIRE2	0.33	6.9	0.35	2.64e-11	Vitiligo;
LUSC	cis	rs4704187	0.687	rs28376290	chr5:74454706	C/T	cg03227963	chr5:74354835	NA	0.31	6.8	0.35	4.74e-11	Response to amphetamines;
LUSC	trans	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg25214090	chr10:38739885	LOC399744	0.47	6.86	0.35	3.32e-11	Corneal astigmatism;
LUSC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg27121462	chr16:89883253	FANCA	0.56	9.12	0.45	6.95e-18	Vitiligo;
LUSC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08219700	chr8:58056026	NA	0.69	8.22	0.41	4.58e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2625529	0.617	rs7175373	chr15:72203517	G/T	cg16672083	chr15:72433130	SENP8	0.46	7.77	0.39	9.52e-14	Red blood cell count;
LUSC	cis	rs10276381	1.000	rs10263857	chr7:28187284	C/G	cg23620719	chr7:28220237	JAZF1	0.59	6.55	0.34	2.15e-10	Crohn's disease;
LUSC	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg03342759	chr3:160939853	NMD3	-0.52	-7.46	-0.38	7.72e-13	Parkinson's disease;
LUSC	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg18132916	chr6:79620363	NA	-0.38	-5.71	-0.3	2.45e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg24130564	chr14:104152367	KLC1	-0.47	-6.72	-0.35	7.97e-11	Body mass index;
LUSC	cis	rs3857536	0.842	rs2188591	chr6:66939511	A/T	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg20203395	chr5:56204925	C5orf35	-0.58	-8.39	-0.42	1.39e-15	Coronary artery disease;
LUSC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.65	-0.47	1.32e-19	Bipolar disorder;
LUSC	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg18681998	chr4:17616180	MED28	0.78	13.71	0.6	3.02e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.27	-0.62	2.03e-36	Eye color traits;
LUSC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.72	-11.05	-0.52	2.15e-24	Aortic root size;
LUSC	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.55	0.42	4.42e-16	Coffee consumption (cups per day);
LUSC	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg20476274	chr7:133979776	SLC35B4	-0.71	-12.09	-0.55	3.59e-28	Mean platelet volume;
LUSC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.09	0.48	4.38e-21	Electroencephalogram traits;
LUSC	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg14169450	chr9:139327907	INPP5E	0.42	7.28	0.37	2.45e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-8.8	-0.43	7.34e-17	Chronic sinus infection;
LUSC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg08888203	chr3:10149979	C3orf24	0.63	8.07	0.4	1.25e-14	Alzheimer's disease;
LUSC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.54	-8.04	-0.4	1.53e-14	Gut microbiome composition (summer);
LUSC	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	19.01	0.72	3.91e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg21659725	chr3:3221576	CRBN	-0.68	-7.85	-0.39	5.77e-14	Menarche (age at onset);
LUSC	cis	rs4380275	1.000	rs4359695	chr2:774214	G/C	cg21665850	chr2:731073	NA	0.42	6.75	0.35	6.49e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	trans	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg07393940	chr7:158741817	NA	-0.35	-6.18	-0.32	1.89e-9	Life satisfaction;
LUSC	cis	rs59698941	0.891	rs72799497	chr5:132291148	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.31	-0.33	8.88e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.45	-8.07	-0.4	1.25e-14	Glomerular filtration rate;
LUSC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg07741184	chr6:167504864	NA	0.44	7.73	0.39	1.29e-13	Crohn's disease;
LUSC	trans	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04565464	chr8:145669602	NFKBIL2	-0.39	-6.54	-0.34	2.35e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg24687543	chr11:63912206	MACROD1	0.46	5.73	0.3	2.24e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg08079166	chr15:68083412	MAP2K5	0.35	6.19	0.32	1.8e-9	Obesity;
LUSC	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg12062639	chr20:23401060	NAPB	0.98	8.38	0.42	1.5e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.63	-0.34	1.34e-10	Platelet count;
LUSC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.39	-6.19	-0.32	1.81e-9	Personality dimensions;
LUSC	cis	rs12493885	0.818	rs61791544	chr3:153767504	T/A	cg17054900	chr3:154042577	DHX36	-0.54	-5.8	-0.3	1.51e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.82	-0.3	1.41e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg02574844	chr11:5959923	NA	-0.49	-6.89	-0.35	2.72e-11	DNA methylation (variation);
LUSC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg13206674	chr6:150067644	NUP43	0.62	10.12	0.48	3.53e-21	Lung cancer;
LUSC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg21724239	chr8:58056113	NA	0.55	6.37	0.33	6.25e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg16606324	chr3:10149918	C3orf24	0.62	9.38	0.46	1.05e-18	Alzheimer's disease;
LUSC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg03806693	chr22:41940476	POLR3H	1.01	13.99	0.61	2.56e-35	Vitiligo;
LUSC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg23625390	chr15:77176239	SCAPER	0.47	7.2	0.37	4.12e-12	Blood metabolite levels;
LUSC	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg21775007	chr8:11205619	TDH	0.82	13.79	0.6	1.53e-34	Retinal vascular caliber;
LUSC	cis	rs11690935	0.632	rs17581284	chr2:172659376	C/T	cg13550731	chr2:172543902	DYNC1I2	0.57	8.95	0.44	2.53e-17	Schizophrenia;
LUSC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.15	0.32	2.27e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg01884057	chr2:25150051	NA	0.39	8.72	0.43	1.37e-16	Body mass index in non-asthmatics;
LUSC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	7.57	0.38	3.63e-13	Multiple sclerosis;
LUSC	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06544989	chr22:39130855	UNC84B	0.34	6.0	0.31	5.19e-9	Menopause (age at onset);
LUSC	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg04362960	chr10:104952993	NT5C2	0.57	8.21	0.41	5.05e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	8.55	0.42	4.38e-16	Obesity-related traits;
LUSC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg19622623	chr12:86230825	RASSF9	-0.42	-5.82	-0.3	1.4e-8	Major depressive disorder;
LUSC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02018176	chr4:1364513	KIAA1530	0.55	10.06	0.48	5.73e-21	Longevity;
LUSC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00149659	chr3:10157352	C3orf10	1.1	14.91	0.63	7.05e-39	Alzheimer's disease;
LUSC	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg13852791	chr20:30311386	BCL2L1	0.96	14.88	0.63	9.14e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs11112613	0.938	rs2374513	chr12:106007300	C/T	cg03607813	chr12:105948248	NA	0.68	9.08	0.45	9.54e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs17125944	0.686	rs7147258	chr14:53337664	G/T	cg00686598	chr14:53173677	PSMC6	-0.69	-6.71	-0.34	8.47e-11	Alzheimer's disease (late onset);
LUSC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg06453172	chr10:134556979	INPP5A	-0.49	-6.11	-0.32	2.78e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	9.8	0.47	4.26e-20	Personality dimensions;
LUSC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg10609677	chr17:41278573	BRCA1;NBR2	0.35	5.71	0.3	2.54e-8	Menopause (age at onset);
LUSC	cis	rs73198271	0.628	rs11781258	chr8:8589758	A/G	cg01851573	chr8:8652454	MFHAS1	0.46	5.83	0.3	1.29e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6967385	0.560	rs10434998	chr7:12348375	C/T	cg20607287	chr7:12443886	VWDE	0.5	7.51	0.38	5.53e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.56	-11.15	-0.52	8.99e-25	Asthma (sex interaction);
LUSC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg06494592	chr3:125709126	NA	-0.52	-6.01	-0.31	4.85e-9	Blood pressure (smoking interaction);
LUSC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg10792982	chr14:105748885	BRF1	0.49	9.04	0.44	1.3e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10186029	0.509	rs6435756	chr2:213941279	C/G	cg08319019	chr2:214017104	IKZF2	-0.41	-6.02	-0.31	4.48e-9	Systemic sclerosis;
LUSC	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.63	-0.43	2.59e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6840360	0.718	rs2136960	chr4:152746189	A/G	cg22705602	chr4:152727874	NA	0.29	6.26	0.32	1.21e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.76	-11.69	-0.54	1.11e-26	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg05855489	chr10:104503620	C10orf26	0.63	8.73	0.43	1.25e-16	Arsenic metabolism;
LUSC	cis	rs7267979	0.545	rs6050426	chr20:25178265	C/G	cg08601574	chr20:25228251	PYGB	0.47	7.04	0.36	1.13e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.53	-8.07	-0.4	1.28e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.77	-0.35	5.87e-11	Morning vs. evening chronotype;
LUSC	cis	rs9837602	0.938	rs10511177	chr3:99724873	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-6.3	-0.33	9.55e-10	Breast cancer;
LUSC	cis	rs1113500	0.933	rs3909076	chr1:108631760	T/C	cg06207961	chr1:108661230	NA	0.4	7.45	0.38	8.2e-13	Growth-regulated protein alpha levels;
LUSC	trans	rs2262909	0.719	rs12461632	chr19:22245089	G/A	cg05197062	chr11:11642011	GALNTL4	0.57	7.89	0.4	4.28e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg01283332	chr5:1856932	NA	-0.32	-6.12	-0.32	2.68e-9	Cardiovascular disease risk factors;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20231940	chr2:129075198	HS6ST1	0.67	5.94	0.31	7.03e-9	Cognitive performance;
LUSC	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg12386194	chr3:101231763	SENP7	0.63	8.74	0.43	1.12e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg27284194	chr4:1044797	NA	-0.59	-8.51	-0.42	5.91e-16	Recombination rate (females);
LUSC	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg21045802	chr8:109455806	TTC35	0.48	7.13	0.36	6.36e-12	Dupuytren's disease;
LUSC	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg26384229	chr12:38710491	ALG10B	0.72	11.22	0.52	5.39e-25	Morning vs. evening chronotype;
LUSC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg15448220	chr1:150897856	SETDB1	0.4	5.88	0.31	1e-8	Melanoma;
LUSC	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg05234568	chr11:5960015	NA	-0.63	-8.89	-0.44	3.78e-17	DNA methylation (variation);
LUSC	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg05738196	chr6:26577821	NA	0.79	14.86	0.63	1.05e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg04287289	chr16:89883240	FANCA	0.77	13.15	0.58	4.12e-32	Vitiligo;
LUSC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	12.38	0.56	3.24e-29	Cognitive test performance;
LUSC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs7264396	1.000	rs224435	chr20:34154087	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.19	-0.37	4.16e-12	Total cholesterol levels;
LUSC	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg12863693	chr15:85201151	NMB	0.34	6.97	0.36	1.73e-11	Schizophrenia;
LUSC	cis	rs72960926	0.744	rs72950563	chr6:74912043	G/C	cg03266952	chr6:74778945	NA	-0.78	-6.22	-0.32	1.5e-9	Metabolite levels (MHPG);
LUSC	cis	rs7215564	0.908	rs34199628	chr17:78661675	A/G	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	trans	rs3857536	0.813	rs2093253	chr6:66937702	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.81	-14.84	-0.63	1.33e-38	Dental caries;
LUSC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg12564285	chr5:131593104	PDLIM4	0.34	6.27	0.32	1.09e-9	Blood metabolite levels;
LUSC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg18479299	chr3:125709523	NA	-0.51	-5.77	-0.3	1.76e-8	Blood pressure (smoking interaction);
LUSC	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg01884057	chr2:25150051	NA	0.44	10.0	0.48	9.07e-21	Body mass index in non-asthmatics;
LUSC	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg17691542	chr6:26056736	HIST1H1C	0.45	6.78	0.35	5.42e-11	Height;
LUSC	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.75	14.64	0.63	7.48e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg03563238	chr19:33554763	RHPN2	-0.39	-6.16	-0.32	2.14e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.78	11.36	0.53	1.62e-25	Multiple sclerosis;
LUSC	trans	rs2562456	0.793	rs11672341	chr19:21507304	A/G	cg00806126	chr19:22604979	ZNF98	-0.42	-5.99	-0.31	5.56e-9	Pain;
LUSC	trans	rs9944715	1.000	rs8094070	chr18:43849640	G/A	cg01718231	chr17:29326311	RNF135	-0.53	-7.51	-0.38	5.6e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11556929	chr2:240323605	HDAC4	-0.43	-6.23	-0.32	1.4e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.17	0.37	4.87e-12	Mean platelet volume;
LUSC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15664640	chr17:80829946	TBCD	0.63	11.19	0.52	6.99e-25	Breast cancer;
LUSC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00339695	chr16:24857497	SLC5A11	0.61	9.65	0.47	1.37e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	1.04	21.05	0.76	3.17e-63	Cognitive function;
LUSC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg12288994	chr5:1860383	NA	0.29	6.27	0.32	1.1e-9	Cardiovascular disease risk factors;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05329982	chr11:62359210	TUT1	0.41	6.41	0.33	5.08e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg00999904	chr2:3704751	ALLC	-0.44	-6.76	-0.35	6.12e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.96	-0.31	6.34e-9	Platelet count;
LUSC	cis	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05901451	chr6:126070800	HEY2	0.57	8.79	0.43	8.07e-17	Endometrial cancer;
LUSC	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	0.57	9.05	0.44	1.24e-17	Breast cancer;
LUSC	cis	rs6882046	0.513	rs628158	chr5:88041781	G/A	cg22951263	chr5:87985283	NA	-0.47	-7.67	-0.39	1.88e-13	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LUSC	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg27661571	chr11:113659931	NA	-0.63	-7.36	-0.37	1.41e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg02018176	chr4:1364513	KIAA1530	0.44	6.11	0.32	2.72e-9	Recombination rate (females);
LUSC	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg05855489	chr10:104503620	C10orf26	0.58	9.41	0.46	8.41e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs8170	0.603	rs10259	chr19:17430915	G/A	cg04749549	chr19:17459798	NA	-0.33	-5.96	-0.31	6.25e-9	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUSC	cis	rs17401966	0.522	rs4845930	chr1:10319049	G/A	cg19773385	chr1:10388646	KIF1B	-0.37	-6.44	-0.33	4.16e-10	Hepatocellular carcinoma;
LUSC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg16606324	chr3:10149918	C3orf24	0.57	8.34	0.42	1.98e-15	Alzheimer's disease;
LUSC	cis	rs524023	1.000	rs11602903	chr11:64358241	A/T	cg19131476	chr11:64387923	NRXN2	-0.38	-10.1	-0.48	4.3e-21	Urate levels in obese individuals;
LUSC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06634786	chr22:41940651	POLR3H	0.49	6.05	0.31	3.88e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18758796	chr5:131593413	PDLIM4	-0.5	-8.28	-0.41	3.03e-15	Acylcarnitine levels;
LUSC	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg11584989	chr19:19387371	SF4	0.59	6.99	0.36	1.46e-11	Bipolar disorder;
LUSC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg10018233	chr7:150070692	REPIN1	0.38	6.75	0.35	6.37e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10754283	0.967	rs1934045	chr1:90107799	A/C	cg21401794	chr1:90099060	LRRC8C	-0.63	-9.46	-0.46	5.59e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg08219700	chr8:58056026	NA	0.5	6.2	0.32	1.7e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	7.05	0.36	1.03e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs62055045	0.528	rs57342394	chr16:71562859	G/A	cg15281710	chr15:96890452	NA	-0.46	-6.69	-0.34	9.43e-11	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg24642844	chr7:1081250	C7orf50	-0.79	-10.44	-0.5	2.9e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg23283495	chr1:209979779	IRF6	0.44	7.16	0.36	5.23e-12	Monobrow;
LUSC	trans	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg10756647	chr7:56101905	PSPH	0.88	8.45	0.42	8.8e-16	Diabetic kidney disease;
LUSC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	1.06	17.28	0.69	3.09e-48	Parkinson's disease;
LUSC	cis	rs1858037	0.836	rs2576923	chr2:65633884	A/G	cg08085232	chr2:65598271	SPRED2	0.42	6.16	0.32	2.12e-9	Rheumatoid arthritis;
LUSC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg00945038	chr17:61921165	SMARCD2	0.54	9.52	0.46	3.65e-19	Prudent dietary pattern;
LUSC	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg15541040	chr2:3486749	NA	-0.52	-7.6	-0.38	3.1e-13	Neurofibrillary tangles;
LUSC	cis	rs13315871	1.000	rs11715445	chr3:58343888	T/C	cg12435725	chr3:58293450	RPP14	-0.74	-7.81	-0.39	7.27e-14	Cholesterol, total;
LUSC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.33	-0.33	7.7e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.47	-8.16	-0.41	6.97e-15	Longevity;Endometriosis;
LUSC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.9	0.35	2.56e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg21770322	chr7:97807741	LMTK2	0.41	6.97	0.36	1.71e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9443189	0.570	rs529383	chr6:76297847	T/G	cg01950844	chr6:76311363	SENP6	0.67	6.21	0.32	1.54e-9	Prostate cancer;
LUSC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.75	-0.35	6.73e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	7.08	0.36	8.38e-12	Platelet count;
LUSC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg05855489	chr10:104503620	C10orf26	-0.65	-9.58	-0.46	2.31e-19	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	8.85	0.44	5.03e-17	Cognitive test performance;
LUSC	cis	rs2236918	0.664	rs1776158	chr1:242017658	C/T	cg17736920	chr1:242011382	EXO1	0.4	6.3	0.33	9.5e-10	Menopause (age at onset);
LUSC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.31	-0.53	2.44e-25	Alzheimer's disease;
LUSC	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg22508957	chr16:3507546	NAT15	-0.41	-6.63	-0.34	1.37e-10	Body mass index (adult);
LUSC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg08859206	chr1:53392774	SCP2	-0.46	-7.57	-0.38	3.73e-13	Monocyte count;
LUSC	cis	rs3812762	0.871	rs2173999	chr11:8778077	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.34	5.84	0.3	1.24e-8	Hypospadias;
LUSC	cis	rs7246967	0.673	rs4244915	chr19:22854138	C/T	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg05776053	chr2:74358815	NA	0.47	7.39	0.37	1.17e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs11051970	0.661	rs188979	chr12:32569684	G/T	cg02745156	chr12:32552066	NA	0.39	7.1	0.36	7.54e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg05187965	chr10:45406764	TMEM72	-0.37	-8.5	-0.42	6.42e-16	Mean corpuscular volume;
LUSC	cis	rs735860	0.700	rs209524	chr6:53213226	G/C	cg10236188	chr6:53219634	NA	0.39	5.82	0.3	1.42e-8	Glaucoma;
LUSC	cis	rs12956009	0.518	rs4574017	chr18:44891703	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.44	0.33	4.13e-10	Educational attainment (years of education);
LUSC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg14895029	chr7:2775587	GNA12	-0.41	-6.35	-0.33	6.89e-10	Height;
LUSC	cis	rs17094222	0.504	rs11190661	chr10:102452136	C/T	cg26540559	chr10:102447443	NA	0.52	8.85	0.44	5.07e-17	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs72674100	1.000	rs4075858	chr4:97991815	A/G	cg09670535	chr1:18959427	PAX7	0.66	6.72	0.35	7.71e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11644478	chr21:40555479	PSMG1	-0.61	-9.53	-0.46	3.45e-19	Menarche (age at onset);
LUSC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg06454157	chr6:167490870	NA	-0.3	-7.03	-0.36	1.19e-11	Crohn's disease;
LUSC	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg20608306	chr11:116969690	SIK3	-0.39	-7.24	-0.37	3.06e-12	Blood protein levels;
LUSC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg06221963	chr1:154839813	KCNN3	-0.6	-13.28	-0.59	1.34e-32	Prostate cancer;
LUSC	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg00579200	chr11:133705235	NA	-0.41	-5.97	-0.31	6.07e-9	Childhood ear infection;
LUSC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg06784218	chr1:46089804	CCDC17	0.54	11.13	0.52	1.06e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12136530	0.744	rs34929465	chr1:19777950	G/A	cg01832549	chr1:19774989	CAPZB	-0.33	-6.1	-0.32	2.96e-9	Lead levels in blood;
LUSC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23158103	chr7:148848205	ZNF398	-0.45	-6.88	-0.35	2.9e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11764359	chr7:65958608	NA	-0.78	-12.75	-0.57	1.29e-30	Aortic root size;
LUSC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg01765077	chr12:122356316	WDR66	0.57	8.01	0.4	1.94e-14	Mean corpuscular volume;
LUSC	cis	rs1775715	0.737	rs2808078	chr10:32172552	C/T	cg26784012	chr10:32216390	ARHGAP12	0.46	7.86	0.4	5.38e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.44	0.38	8.35e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-14.97	-0.63	3.94e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22857025	chr5:266934	NA	-1.2	-14.11	-0.61	8.51e-36	Breast cancer;
LUSC	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-0.88	-15.75	-0.65	3.49e-42	Height;
LUSC	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg22283653	chr8:49824208	NA	0.33	6.54	0.34	2.3e-10	Sudden cardiac arrest;
LUSC	cis	rs6736093	0.862	rs35382200	chr2:112780716	G/C	cg12686935	chr2:112915763	FBLN7	-0.4	-6.29	-0.33	1.01e-9	Coronary artery disease;
LUSC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.48	-6.54	-0.34	2.34e-10	Neutrophil percentage of white cells;
LUSC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg10596483	chr8:143751796	JRK	0.61	9.4	0.46	9.2e-19	Schizophrenia;
LUSC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg11062466	chr8:58055876	NA	0.47	6.43	0.33	4.34e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg03161606	chr19:29218774	NA	0.51	5.96	0.31	6.3e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs7528419	0.591	rs4970837	chr1:109822008	G/T	cg00908766	chr1:109817496	CELSR2	0.57	9.57	0.46	2.56e-19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUSC	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg13010199	chr12:38710504	ALG10B	0.53	7.95	0.4	2.82e-14	Morning vs. evening chronotype;
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.39	5.99	0.31	5.56e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg19230755	chr7:65878503	NA	-0.41	-5.82	-0.3	1.37e-8	Aortic root size;
LUSC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg03146154	chr1:46216737	IPP	0.56	8.5	0.42	6.44e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg27165867	chr14:105738592	BRF1	-0.52	-7.62	-0.38	2.61e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg23093090	chr10:104574429	C10orf26	-0.38	-6.55	-0.34	2.22e-10	Arsenic metabolism;
LUSC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg12257692	chr3:49977190	RBM6	-0.24	-6.6	-0.34	1.66e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7929679	0.521	rs10836304	chr11:34794024	C/T	cg06937548	chr11:34938143	PDHX;APIP	-0.39	-5.69	-0.3	2.76e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg07169764	chr2:136633963	MCM6	1.18	17.48	0.69	4.99e-49	Corneal structure;
LUSC	cis	rs12575480	0.672	rs74048171	chr11:2093603	C/A	cg15541987	chr11:2077307	NA	-0.46	-7.11	-0.36	7.2e-12	Pursuit maintenance gain;
LUSC	cis	rs7804356	0.569	rs112164743	chr7:26859172	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	2.01e-9	Type 1 diabetes;
LUSC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	0.83	10.52	0.5	1.47e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg25206134	chr2:45395956	NA	0.58	6.3	0.33	9.55e-10	Bipolar disorder;
LUSC	cis	rs9487051	0.735	rs455839	chr6:109524221	G/A	cg01475377	chr6:109611718	NA	-0.34	-5.79	-0.3	1.65e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg09877947	chr5:131593287	PDLIM4	0.51	7.88	0.4	4.63e-14	Acylcarnitine levels;
LUSC	cis	rs4566357	0.557	rs2272201	chr2:227912551	T/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.27	-0.41	3.17e-15	Coronary artery disease;
LUSC	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg00540400	chr15:79124168	NA	-0.47	-8.16	-0.41	7.06e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs17253792	0.822	rs17685078	chr14:56127202	T/C	cg01858014	chr14:56050164	KTN1	-0.79	-6.68	-0.34	9.73e-11	Putamen volume;
LUSC	cis	rs3737883	1.000	rs11579558	chr1:203032038	G/T	cg00805880	chr1:203045044	PPFIA4	-0.29	-5.81	-0.3	1.43e-8	Early onset atrial fibrillation;
LUSC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg01416388	chr22:39784598	NA	0.44	7.0	0.36	1.4e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7830933	1.000	rs7830933	chr8:23603324	A/G	cg04349084	chr8:23602677	NA	0.37	5.88	0.31	9.79e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUSC	cis	rs59698941	0.943	rs4705980	chr5:132286084	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs11785693	0.909	rs62489557	chr8:4968371	A/G	cg26367366	chr8:4980734	NA	0.84	8.69	0.43	1.6e-16	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.43e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg22676075	chr6:135203613	NA	0.53	8.49	0.42	6.96e-16	Red blood cell count;
LUSC	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.45	0.33	3.86e-10	Menopause (age at onset);
LUSC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg13647721	chr17:30228624	UTP6	-0.65	-6.78	-0.35	5.44e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg19717773	chr7:2847554	GNA12	-0.39	-7.02	-0.36	1.24e-11	Height;
LUSC	trans	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	0.44	6.58	0.34	1.82e-10	Platelet distribution width;
LUSC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.37	0.56	3.46e-29	Prudent dietary pattern;
LUSC	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg12615879	chr12:58013172	SLC26A10	0.32	7.4	0.38	1.14e-12	Multiple sclerosis;
LUSC	cis	rs2304069	0.659	rs216141	chr5:149443994	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.42	-5.71	-0.3	2.49e-8	HIV-1 control;
LUSC	trans	rs4714291	0.963	rs847759	chr6:40024483	G/A	cg02267698	chr19:7991119	CTXN1	0.53	7.23	0.37	3.33e-12	Strep throat;
LUSC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.91	-0.31	8.25e-9	Neuroticism;
LUSC	cis	rs6845621	0.870	rs6818287	chr4:18934459	G/A	cg12196642	chr4:18937545	NA	-0.36	-6.66	-0.34	1.11e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	1.06	17.05	0.68	2.56e-47	Parkinson's disease;
LUSC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg10130564	chr11:117069849	TAGLN	-0.38	-6.56	-0.34	2.03e-10	Blood protein levels;
LUSC	cis	rs2652834	0.851	rs11071721	chr15:63350218	T/C	cg05507819	chr15:63340323	TPM1	0.67	8.43	0.42	1.03e-15	HDL cholesterol;
LUSC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.2	0.41	5.41e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg01251360	chr16:68772225	CDH1	0.26	6.24	0.32	1.3e-9	Colorectal cancer;
LUSC	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.59	-0.34	1.67e-10	Axial length;
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.66	10.19	0.49	2.14e-21	Lymphocyte counts;
LUSC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.78	-0.3	1.68e-8	Platelet count;
LUSC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	0.59	9.36	0.46	1.22e-18	Breast cancer;
LUSC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.78	-11.3	-0.53	2.62e-25	Alzheimer's disease;
LUSC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg05025164	chr4:1340916	KIAA1530	0.41	6.12	0.32	2.59e-9	Obesity-related traits;
LUSC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg13047869	chr3:10149882	C3orf24	0.43	6.45	0.33	3.84e-10	Alzheimer's disease;
LUSC	cis	rs7705502	1.000	rs56163845	chr5:173373948	A/G	cg18693985	chr5:173351052	CPEB4	-0.37	-5.83	-0.3	1.3e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs9473147	0.516	rs9369695	chr6:47440565	C/A	cg12968598	chr6:47444699	CD2AP	0.53	7.85	0.39	5.65e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.72	-0.39	1.37e-13	Bone mineral density;
LUSC	cis	rs9399401	0.667	rs34018047	chr6:142790873	G/C	cg03128060	chr6:142623767	GPR126	0.58	9.61	0.47	1.8e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25072359	chr17:41440525	NA	0.65	9.22	0.45	3.32e-18	Menopause (age at onset);
LUSC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.81	-14.44	-0.62	4.5e-37	Cognitive function;
LUSC	cis	rs17253792	0.822	rs77250916	chr14:56042208	A/G	cg01858014	chr14:56050164	KTN1	-0.89	-7.04	-0.36	1.1e-11	Putamen volume;
LUSC	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg08917208	chr2:24149416	ATAD2B	0.56	6.36	0.33	6.82e-10	Lymphocyte counts;
LUSC	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg19773385	chr1:10388646	KIF1B	-0.53	-8.21	-0.41	4.91e-15	Hepatocellular carcinoma;
LUSC	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.38	-0.33	5.93e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg00405596	chr8:11794950	NA	0.35	5.79	0.3	1.64e-8	Myopia (pathological);
LUSC	cis	rs354225	0.512	rs6744586	chr2:54930467	C/T	cg26097391	chr2:54893211	SPTBN1	0.46	6.06	0.31	3.76e-9	Schizophrenia;
LUSC	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.52	8.54	0.42	4.94e-16	IgG glycosylation;
LUSC	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.97	-0.44	2.15e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-12.87	-0.58	4.63e-31	Platelet count;
LUSC	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg00898013	chr13:113819073	PROZ	-0.54	-7.64	-0.39	2.31e-13	Platelet distribution width;
LUSC	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg07930552	chr6:133119739	C6orf192	0.78	8.1	0.4	1.08e-14	Type 2 diabetes nephropathy;
LUSC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg04414720	chr1:150670196	GOLPH3L	0.51	8.0	0.4	2.08e-14	Melanoma;
LUSC	cis	rs10740039	0.734	rs10821815	chr10:62404601	G/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.86	-0.35	3.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13089785	1.000	rs13081955	chr3:123600144	A/G	cg02558132	chr3:123411198	MYLK	0.36	6.16	0.32	2.1e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9420	0.961	rs7116341	chr11:57481155	G/A	cg23127183	chr11:57508653	C11orf31	-0.58	-8.91	-0.44	3.41e-17	Schizophrenia;
LUSC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg02167203	chr6:41068553	NFYA;LOC221442	-0.41	-6.27	-0.32	1.13e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg23978390	chr7:1156363	C7orf50	0.42	6.05	0.31	3.97e-9	Longevity;Endometriosis;
LUSC	trans	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg25214090	chr10:38739885	LOC399744	0.43	6.53	0.34	2.51e-10	Corneal astigmatism;
LUSC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-1.25	-13.99	-0.61	2.56e-35	Diabetic kidney disease;
LUSC	cis	rs7523050	0.643	rs34572569	chr1:109401856	A/T	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	trans	rs9944715	0.954	rs7228365	chr18:43817832	A/G	cg01718231	chr17:29326311	RNF135	-0.54	-7.74	-0.39	1.16e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09455096	chr2:61765470	XPO1	0.44	6.27	0.32	1.13e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg08736216	chr1:53307985	ZYG11A	0.28	5.67	0.3	3.15e-8	Monocyte count;
LUSC	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.42	-0.33	4.82e-10	Blood metabolite levels;
LUSC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	0.96	12.9	0.58	3.55e-31	Eosinophil percentage of granulocytes;
LUSC	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg16346588	chr10:242978	ZMYND11	0.43	5.82	0.3	1.39e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs1941023	0.584	rs2241921	chr11:60164302	C/T	cg08716584	chr11:60157161	MS4A7	-0.65	-12.12	-0.55	2.81e-28	Congenital heart disease (maternal effect);
LUSC	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg12473912	chr3:136751656	NA	0.39	6.81	0.35	4.51e-11	Neuroticism;
LUSC	cis	rs6845621	0.553	rs60895903	chr4:18857218	T/C	cg12196642	chr4:18937545	NA	-0.31	-5.78	-0.3	1.72e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg06627628	chr2:24431161	ITSN2	-0.73	-9.93	-0.48	1.61e-20	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg27284194	chr4:1044797	NA	0.5	7.59	0.38	3.29e-13	Recombination rate (females);
LUSC	cis	rs9837602	1.000	rs10212525	chr3:99713377	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.89	-0.31	9.26e-9	Breast cancer;
LUSC	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg03585969	chr10:35415529	CREM	0.6	8.75	0.43	1.08e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg03929089	chr4:120376271	NA	-0.58	-7.46	-0.38	7.43e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7771547	0.573	rs621796	chr6:36472259	A/T	cg07856975	chr6:36356162	ETV7	0.38	6.65	0.34	1.2e-10	Platelet distribution width;
LUSC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06850241	chr22:41845214	NA	0.31	5.8	0.3	1.56e-8	Vitiligo;
LUSC	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs9462027	0.651	rs7748203	chr6:34812054	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.82	-0.3	1.35e-8	Systemic lupus erythematosus;
LUSC	cis	rs4974559	0.739	rs2335937	chr4:1321516	C/A	cg02980000	chr4:1222292	CTBP1	0.97	9.05	0.44	1.17e-17	Systolic blood pressure;
LUSC	cis	rs60695258	0.550	rs340636	chr4:87930760	T/G	cg10685359	chr4:87814065	C4orf36	0.34	6.04	0.31	4.09e-9	Hematocrit;
LUSC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg06046430	chr4:77819534	ANKRD56	-0.48	-7.16	-0.36	5.32e-12	Emphysema distribution in smoking;
LUSC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.53	-7.06	-0.36	9.9e-12	Homoarginine levels;
LUSC	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg19920283	chr7:105172520	RINT1	0.58	6.11	0.32	2.75e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg00495681	chr13:53174319	NA	0.42	6.27	0.32	1.14e-9	Lewy body disease;
LUSC	cis	rs722599	0.715	rs2300598	chr14:75359229	T/C	cg08847533	chr14:75593920	NEK9	-0.47	-6.73	-0.35	7.6e-11	IgG glycosylation;
LUSC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg20608306	chr11:116969690	SIK3	0.41	6.87	0.35	3.08e-11	Blood protein levels;
LUSC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg13607699	chr17:42295918	UBTF	0.75	13.86	0.6	8.11e-35	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs3125734	0.534	rs10821973	chr10:64052337	G/A	cg19640130	chr10:64028056	RTKN2	-0.39	-6.8	-0.35	4.72e-11	Rheumatoid arthritis;
LUSC	cis	rs13401104	0.796	rs10929171	chr2:237115622	G/A	cg19324714	chr2:237145437	ASB18	0.43	5.65	0.3	3.43e-8	Educational attainment;
LUSC	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg21211680	chr2:198530	NA	-0.67	-7.1	-0.36	7.45e-12	Blood protein levels;
LUSC	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg25258033	chr6:167368657	RNASET2	-0.36	-5.79	-0.3	1.63e-8	Graves' disease;
LUSC	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	6.26	0.32	1.17e-9	Schizophrenia;
LUSC	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg24634471	chr8:143751801	JRK	0.5	6.95	0.36	1.88e-11	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg14092988	chr3:52407081	DNAH1	-0.28	-5.7	-0.3	2.66e-8	Bipolar disorder;
LUSC	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg04374321	chr14:90722782	PSMC1	-0.43	-6.44	-0.33	4.11e-10	Mortality in heart failure;
LUSC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg07424592	chr7:64974309	NA	-0.63	-5.66	-0.3	3.31e-8	Diabetic kidney disease;
LUSC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg18758796	chr5:131593413	PDLIM4	-0.42	-6.51	-0.34	2.77e-10	Blood metabolite levels;
LUSC	cis	rs13315871	0.929	rs11130627	chr3:58315749	G/A	cg12435725	chr3:58293450	RPP14	-0.74	-7.16	-0.36	5.16e-12	Cholesterol, total;
LUSC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.8	-12.64	-0.57	3.36e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	1.21	13.5	0.59	1.92e-33	Diabetic kidney disease;
LUSC	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg24578937	chr1:2090814	PRKCZ	-0.44	-9.86	-0.47	2.77e-20	Height;
LUSC	cis	rs897984	0.609	rs55979739	chr16:31049155	A/G	cg02466173	chr16:30829666	NA	-0.54	-10.3	-0.49	8.9e-22	Dementia with Lewy bodies;
LUSC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.2	0.32	1.67e-9	Total body bone mineral density;
LUSC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg27535305	chr1:53392650	SCP2	-0.37	-6.33	-0.33	7.72e-10	Monocyte count;
LUSC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg18681998	chr4:17616180	MED28	-0.84	-15.64	-0.65	9.77e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.74	0.43	1.13e-16	Menopause (age at onset);
LUSC	cis	rs10276381	0.786	rs73089302	chr7:28187134	G/A	cg23620719	chr7:28220237	JAZF1	0.59	6.55	0.34	2.15e-10	Crohn's disease;
LUSC	trans	rs12914656	0.556	rs8027956	chr15:86655875	A/C	cg27136844	chr3:147142355	NA	-0.39	-6.11	-0.32	2.77e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg21672276	chr3:44754072	ZNF502	-0.38	-6.0	-0.31	5.26e-9	Depressive symptoms;
LUSC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg20790798	chr5:1857306	NA	-0.51	-8.7	-0.43	1.48e-16	Cardiovascular disease risk factors;
LUSC	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.46	-0.33	3.61e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.69	-0.57	2.24e-30	Platelet count;
LUSC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg09655341	chr17:79618100	PDE6G	-0.29	-6.59	-0.34	1.67e-10	Eye color traits;
LUSC	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.83	0.43	6.08e-17	Lung cancer in ever smokers;
LUSC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	11.7	0.54	1e-26	Monocyte percentage of white cells;
LUSC	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.71	10.71	0.51	3.44e-23	Smoking initiation;
LUSC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.58e-8	Life satisfaction;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.7	10.57	0.5	9.88e-23	Lymphocyte counts;
LUSC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg09455208	chr3:40491958	NA	0.52	9.42	0.46	7.87e-19	Renal cell carcinoma;
LUSC	cis	rs2692947	0.800	rs61409777	chr2:96581373	C/A	cg23100626	chr2:96804247	ASTL	0.26	6.39	0.33	5.48e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.84	-0.44	5.62e-17	Metabolite levels;
LUSC	cis	rs3106136	0.527	rs10016806	chr4:95158495	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.36	-0.42	1.68e-15	Capecitabine sensitivity;
LUSC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg10523860	chr14:103875565	MARK3	-0.39	-6.51	-0.34	2.72e-10	Body mass index;
LUSC	cis	rs10266483	0.921	rs687547	chr7:63744929	A/G	cg24201672	chr7:64023550	ZNF680	-0.48	-6.33	-0.33	7.83e-10	Response to statin therapy;
LUSC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.31	0.41	2.37e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg15997130	chr1:24165203	NA	0.52	8.58	0.42	3.67e-16	Immature fraction of reticulocytes;
LUSC	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02176678	chr2:219576539	TTLL4	-0.6	-10.91	-0.51	6.45e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg01181863	chr3:195395398	SDHAP2	-0.6	-8.16	-0.41	7.12e-15	Pancreatic cancer;
LUSC	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg08508325	chr11:3079039	CARS	0.38	8.61	0.43	2.95e-16	Calcium levels;
LUSC	cis	rs2573652	0.722	rs12903458	chr15:100542673	T/G	cg00587665	chr15:100533223	ADAMTS17	-0.37	-6.65	-0.34	1.2e-10	Height;
LUSC	cis	rs17155006	0.691	rs413412	chr7:107745399	A/G	cg05962710	chr7:107745446	LAMB4	-0.36	-6.37	-0.33	6.44e-10	Pneumococcal bacteremia;
LUSC	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.5	-7.69	-0.39	1.65e-13	Cognitive test performance;
LUSC	cis	rs41271473	1.000	rs11583565	chr1:228880135	C/T	cg16512390	chr1:228756714	NA	0.5	6.04	0.31	4.05e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg21963583	chr11:68658836	MRPL21	0.56	8.66	0.43	2.09e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg08975724	chr8:8085496	FLJ10661	0.43	6.47	0.33	3.41e-10	Retinal vascular caliber;
LUSC	cis	rs7106204	1.000	rs4244512	chr11:24217355	A/G	ch.11.24196551F	chr11:24239977	NA	-0.99	-10.26	-0.49	1.18e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7605827	0.930	rs10184585	chr2:15683091	G/A	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.77e-16	Educational attainment (years of education);
LUSC	cis	rs59104589	0.617	rs73002114	chr2:242280924	G/A	cg14842376	chr2:242211374	HDLBP	0.52	5.95	0.31	6.85e-9	Fibrinogen levels;
LUSC	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg01528321	chr10:82214614	TSPAN14	0.9	13.83	0.6	1.05e-34	Post bronchodilator FEV1;
LUSC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg03732007	chr1:2071316	PRKCZ	-0.52	-9.21	-0.45	3.64e-18	Height;
LUSC	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg05043794	chr9:111880884	C9orf5	-0.32	-6.79	-0.35	5.01e-11	Menarche (age at onset);
LUSC	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg26022315	chr17:47021804	SNF8	0.37	5.75	0.3	2.02e-8	Type 2 diabetes;
LUSC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-8.91	-0.44	3.33e-17	Gut microbiome composition (summer);
LUSC	cis	rs6669072	1.000	rs6676886	chr1:91244343	C/G	cg08895590	chr1:91227319	NA	0.39	8.54	0.42	4.97e-16	Cognitive function;
LUSC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg05347473	chr6:146136440	FBXO30	-0.53	-9.23	-0.45	3.12e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11048434	0.736	rs2377672	chr12:9112414	A/G	cg13575925	chr12:9217583	LOC144571	0.35	6.43	0.33	4.51e-10	Sjögren's syndrome;
LUSC	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg00277334	chr10:82204260	NA	-0.5	-7.38	-0.37	1.28e-12	Post bronchodilator FEV1;
LUSC	trans	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg25482853	chr8:67687455	SGK3	1.12	15.85	0.66	1.36e-42	Obesity-related traits;
LUSC	cis	rs9650657	0.871	rs7814142	chr8:10637552	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.56	-0.34	2.11e-10	Neuroticism;
LUSC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg13939156	chr17:80058883	NA	-0.33	-6.39	-0.33	5.53e-10	Life satisfaction;
LUSC	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg04998671	chr14:104000505	TRMT61A	0.44	6.98	0.36	1.64e-11	Coronary artery disease;
LUSC	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg22029157	chr1:209979665	IRF6	0.77	9.48	0.46	4.95e-19	Cleft lip with or without cleft palate;
LUSC	trans	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg26811252	chr16:29126840	RRN3P2	0.56	8.92	0.44	3.23e-17	Menopause (age at onset);
LUSC	cis	rs7264396	1.000	rs224433	chr20:34153850	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.83	-0.35	3.98e-11	Total cholesterol levels;
LUSC	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.16	0.49	2.55e-21	Lymphocyte counts;
LUSC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.74	-10.72	-0.51	3.1e-23	Glomerular filtration rate;
LUSC	cis	rs983392	0.667	rs632185	chr11:59951433	A/G	cg02771260	chr11:59836817	MS4A3	0.35	6.08	0.32	3.27e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7945718	1.000	rs12269900	chr11:12748518	G/A	cg25843174	chr11:12811716	TEAD1	0.32	7.04	0.36	1.09e-11	Educational attainment (years of education);
LUSC	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg25237894	chr2:233734115	C2orf82	-0.36	-6.81	-0.35	4.67e-11	Coronary artery disease;
LUSC	cis	rs10779751	0.734	rs2791658	chr1:11127871	A/G	cg08854313	chr1:11322531	MTOR	0.81	12.1	0.55	3.52e-28	Body mass index;
LUSC	cis	rs7572644	0.723	rs35679500	chr2:28019966	T/C	cg27432699	chr2:27873401	GPN1	0.57	7.17	0.37	4.98e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg04455712	chr21:45112962	RRP1B	0.44	8.59	0.43	3.28e-16	Mean corpuscular volume;
LUSC	cis	rs12760731	0.623	rs10465514	chr1:178334035	G/T	cg00404053	chr1:178313656	RASAL2	0.47	5.75	0.3	2.03e-8	Obesity-related traits;
LUSC	cis	rs9399401	0.925	rs9496374	chr6:142735221	G/C	cg03128060	chr6:142623767	GPR126	0.34	6.1	0.32	2.95e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	9.14	0.45	6.4e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs2708977	0.637	rs687950	chr2:97069612	C/G	cg01950434	chr2:97203154	ARID5A	0.44	6.04	0.31	4.16e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg22624212	chr21:44298959	WDR4	0.39	5.96	0.31	6.32e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs668210	0.793	rs586921	chr11:65747701	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.56	-7.08	-0.36	8.32e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg16447950	chr5:562315	NA	-0.59	-7.06	-0.36	9.96e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10189230	0.935	rs1864461	chr2:222347615	A/G	cg14652038	chr2:222343519	EPHA4	0.36	6.38	0.33	5.83e-10	Urate levels in lean individuals;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25420398	chr3:133968920	RYK	-0.38	-6.23	-0.32	1.4e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9815354	0.812	rs73071222	chr3:41986896	C/T	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.72e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg14092988	chr3:52407081	DNAH1	0.31	5.97	0.31	5.95e-9	Bipolar disorder;
LUSC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21016266	chr12:122356598	WDR66	0.57	8.58	0.42	3.71e-16	Mean corpuscular volume;
LUSC	cis	rs870825	0.860	rs28696121	chr4:185598743	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	12.67	0.57	2.58e-30	Blood protein levels;
LUSC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.44	-5.92	-0.31	7.93e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9807989	0.839	rs6543123	chr2:102977196	C/T	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.5e-9	Asthma;
LUSC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.04	-0.48	6.9299999999999992e-21	Platelet count;
LUSC	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg10596483	chr8:143751796	JRK	0.51	7.44	0.38	8.76e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg19052272	chr2:3704530	ALLC	0.45	7.95	0.4	2.91e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.38	-0.33	5.79e-10	Monocyte count;
LUSC	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.54e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs2901656	0.591	rs9425304	chr1:172371151	C/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.31	6.0	0.31	5.11e-9	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs4474465	0.646	rs7937417	chr11:78284470	A/G	cg27205649	chr11:78285834	NARS2	0.56	6.78	0.35	5.39e-11	Alzheimer's disease (survival time);
LUSC	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg08917208	chr2:24149416	ATAD2B	0.56	6.36	0.33	6.82e-10	Lymphocyte counts;
LUSC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.63	9.8	0.47	4.22e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.48	6.46	0.33	3.74e-10	Renal function-related traits (BUN);
LUSC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg05347473	chr6:146136440	FBXO30	0.48	7.81	0.39	7.5e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg06238570	chr21:40685208	BRWD1	0.46	7.19	0.37	4.25e-12	Cognitive function;
LUSC	cis	rs12681287	0.511	rs7839601	chr8:87503839	G/C	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg03676636	chr4:99064102	C4orf37	0.29	6.13	0.32	2.49e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg19052272	chr2:3704530	ALLC	-0.49	-8.19	-0.41	5.6e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.99	0.44	1.91e-17	Lung cancer;
LUSC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg24060327	chr5:131705240	SLC22A5	-0.52	-8.69	-0.43	1.61e-16	Breast cancer;
LUSC	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.48	-5.87	-0.31	1.04e-8	Neutrophil percentage of white cells;
LUSC	cis	rs2282300	0.739	rs1222221	chr11:30342738	A/G	cg25418670	chr11:30344373	C11orf46	-0.6	-8.68	-0.43	1.78e-16	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18099408	chr3:52552593	STAB1	-0.41	-6.93	-0.35	2.17e-11	Bipolar disorder;
LUSC	cis	rs1534166	0.507	rs3811657	chr3:133474607	C/T	cg01448562	chr3:133502909	NA	0.51	5.7	0.3	2.57e-8	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg01966878	chr4:90757139	SNCA	-0.36	-6.26	-0.32	1.2e-9	Dementia with Lewy bodies;
LUSC	cis	rs3740713	0.669	rs113003553	chr11:18410861	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.47	-5.77	-0.3	1.85e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs6066835	1.000	rs2223684	chr20:47354880	A/C	cg18078177	chr20:47281410	PREX1	0.7	6.17	0.32	1.99e-9	Multiple myeloma;
LUSC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25072359	chr17:41440525	NA	0.64	8.97	0.44	2.23e-17	Menopause (age at onset);
LUSC	trans	rs984440	0.534	rs984441	chr8:139077477	C/T	cg03334052	chr1:168888044	NA	0.41	6.42	0.33	4.7e-10	Obesity-related traits;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10178905	chr15:63796301	USP3	-0.45	-6.02	-0.31	4.61e-9	Hepatitis;
LUSC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06634786	chr22:41940651	POLR3H	0.52	6.04	0.31	4.17e-9	Vitiligo;
LUSC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg03342759	chr3:160939853	NMD3	-0.48	-6.27	-0.32	1.09e-9	Parkinson's disease;
LUSC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg18240062	chr17:79603768	NPLOC4	0.69	12.9	0.58	3.69e-31	Eye color traits;
LUSC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg03948781	chr1:205179583	DSTYK	0.3	5.67	0.3	3.04e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg03146154	chr1:46216737	IPP	-0.5	-7.24	-0.37	3.08e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg08859206	chr1:53392774	SCP2	0.46	7.75	0.39	1.13e-13	Monocyte count;
LUSC	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.6	-6.34	-0.33	7.44e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.61	-0.43	2.88e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.27	-0.41	3.25e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg20976159	chr1:228193529	WNT3A	0.28	5.79	0.3	1.59e-8	Diastolic blood pressure;
LUSC	cis	rs11112613	0.609	rs17037380	chr12:106036708	C/T	cg03607813	chr12:105948248	NA	0.63	8.02	0.4	1.8e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	trans	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.11	-0.32	2.77e-9	Depression;
LUSC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg09367891	chr1:107599246	PRMT6	0.52	8.15	0.41	7.44e-15	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.72	0.6	2.68e-34	Alzheimer's disease;
LUSC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg15103426	chr22:29168792	CCDC117	0.48	6.36	0.33	6.61e-10	Lymphocyte counts;
LUSC	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg10840412	chr1:235813424	GNG4	0.59	7.54	0.38	4.41e-13	Bipolar disorder;
LUSC	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	7.07	0.36	8.99e-12	Cognitive test performance;
LUSC	cis	rs16910800	1.000	rs16910800	chr11:23202785	C/T	cg20040320	chr11:23191996	NA	-0.44	-6.35	-0.33	6.87e-10	Cancer;
LUSC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg19729930	chr2:74357872	NA	0.89	16.82	0.68	2e-46	Gestational age at birth (maternal effect);
LUSC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.75	-12.63	-0.57	3.75e-30	Body mass index;
LUSC	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	0.5	7.18	0.37	4.69e-12	Breast cancer;
LUSC	cis	rs4363385	0.818	rs557553	chr1:153010370	T/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.2	-0.37	4.14e-12	Inflammatory skin disease;
LUSC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg26695010	chr11:65641043	EFEMP2	-0.47	-6.83	-0.35	4.02e-11	Eosinophil percentage of white cells;
LUSC	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.55	-8.99	-0.44	1.88e-17	Itch intensity from mosquito bite;
LUSC	cis	rs6942756	1.000	rs7778277	chr7:128978805	C/T	cg02491457	chr7:128862824	NA	-0.47	-6.31	-0.33	9.1e-10	White matter hyperintensity burden;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01915076	chr12:49393228	DDN	-0.51	-6.19	-0.32	1.71e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	6.88	0.35	2.93e-11	Educational attainment;
LUSC	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-7.68	-0.39	1.78e-13	Morning vs. evening chronotype;
LUSC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg27284194	chr4:1044797	NA	-0.36	-5.81	-0.3	1.44e-8	Obesity-related traits;
LUSC	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg18002602	chr11:66138449	SLC29A2	0.45	8.12	0.41	8.95e-15	Educational attainment (years of education);
LUSC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg21475434	chr5:93447410	FAM172A	-0.71	-8.79	-0.43	8.1e-17	Diabetic retinopathy;
LUSC	cis	rs6495367	1.000	rs1961579	chr15:79380516	G/A	cg17916960	chr15:79447300	NA	0.35	6.6	0.34	1.64e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg18105134	chr13:113819100	PROZ	-0.69	-9.77	-0.47	5.23e-20	Platelet distribution width;
LUSC	trans	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg05373962	chr22:49881684	NA	-0.4	-8.36	-0.42	1.77e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg00750074	chr16:89608354	SPG7	-0.58	-10.5	-0.5	1.77e-22	Multiple myeloma (IgH translocation);
LUSC	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg05855489	chr10:104503620	C10orf26	0.6	9.67	0.47	1.11e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs10911363	0.549	rs12742245	chr1:183446922	T/A	cg09173681	chr1:183549694	NCF2	0.63	11.37	0.53	1.54e-25	Systemic lupus erythematosus;
LUSC	cis	rs10746514	0.804	rs11122429	chr1:232261532	G/A	cg09506761	chr1:232265262	NA	-0.57	-9.61	-0.47	1.77e-19	Response to statin therapy;
LUSC	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg15704280	chr7:45808275	SEPT13	-0.63	-7.68	-0.39	1.83e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg09034736	chr1:150693464	HORMAD1	0.44	6.15	0.32	2.19e-9	Melanoma;
LUSC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg24813613	chr7:1882135	MAD1L1	-0.42	-6.92	-0.35	2.29e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg04155231	chr12:9217510	LOC144571	0.3	5.7	0.3	2.67e-8	Sjögren's syndrome;
LUSC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg01420254	chr6:26195488	NA	0.64	7.28	0.37	2.35e-12	Gout;Renal underexcretion gout;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09132500	chr16:3156381	NA	0.45	6.07	0.32	3.53e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.88	-0.51	8.12e-24	Schizophrenia;
LUSC	cis	rs56399783	0.803	rs7811164	chr7:2822416	G/A	cg19731401	chr7:2775893	GNA12	0.63	8.6	0.43	3.06e-16	Childhood ear infection;
LUSC	cis	rs11608355	1.000	rs7958625	chr12:109869218	A/T	cg05360138	chr12:110035743	NA	0.47	6.36	0.33	6.68e-10	Neuroticism;
LUSC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.59	0.5	8.56e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	trans	rs1728785	0.901	rs7194664	chr16:68643313	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.78	0.39	9.06e-14	Ulcerative colitis;
LUSC	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.42	-0.38	9.65e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.61e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.88	-10.72	-0.51	3.02e-23	Lung cancer in ever smokers;
LUSC	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.49	7.01	0.36	1.35e-11	Coronary heart disease;
LUSC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	10.86	0.51	9.9e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4704187	0.687	rs4447963	chr5:74376309	A/C	cg03227963	chr5:74354835	NA	0.31	6.67	0.34	1.09e-10	Response to amphetamines;
LUSC	trans	rs71435601	0.628	rs494315	chr2:21400950	C/T	cg20757404	chr19:378427	NA	0.37	5.96	0.31	6.28e-9	Cholesterol, total;
LUSC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg17264618	chr3:40429014	ENTPD3	0.32	6.79	0.35	5.03e-11	Renal cell carcinoma;
LUSC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg20573242	chr4:122745356	CCNA2	0.63	9.16	0.45	5.39e-18	Type 2 diabetes;
LUSC	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg14458575	chr2:238380390	NA	0.65	11.57	0.53	2.91e-26	Prostate cancer;
LUSC	cis	rs11809207	0.903	rs17257148	chr1:26526348	G/C	cg19633962	chr1:26362018	EXTL1	-0.48	-5.82	-0.3	1.4e-8	Height;
LUSC	trans	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.29	0.49	9.05e-22	Mean corpuscular volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03560797	chr7:106301641	FLJ36031	-0.44	-6.63	-0.34	1.36e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.06	-0.36	9.79e-12	Lung cancer;
LUSC	cis	rs6426558	0.514	rs3754418	chr1:227348473	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.53	-7.4	-0.38	1.12e-12	Neutrophil percentage of white cells;
LUSC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.9	0.31	8.84e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg09876464	chr15:85330779	ZNF592	0.36	6.67	0.34	1.07e-10	P wave terminal force;
LUSC	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg09165964	chr15:75287851	SCAMP5	-0.93	-8.84	-0.44	5.7e-17	Lung cancer;
LUSC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg13939156	chr17:80058883	NA	-0.35	-7.04	-0.36	1.13e-11	Life satisfaction;
LUSC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg18230493	chr5:56204884	C5orf35	-0.65	-10.25	-0.49	1.28e-21	Coronary artery disease;
LUSC	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg05082376	chr22:42548792	NA	-0.37	-6.26	-0.32	1.18e-9	Cognitive function;
LUSC	cis	rs2387326	0.717	rs10829336	chr10:129943532	T/C	cg16087940	chr10:129947807	NA	-0.39	-5.81	-0.3	1.48e-8	Select biomarker traits;
LUSC	cis	rs1113500	0.565	rs1777455	chr1:108590288	C/A	cg06207961	chr1:108661230	NA	-0.35	-5.68	-0.3	2.98e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs3741151	0.773	rs73544767	chr11:73204619	C/T	cg17517138	chr11:73019481	ARHGEF17	0.98	8.36	0.42	1.77e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs4845570	0.834	rs13376155	chr1:151721270	A/G	cg07092448	chr1:151763213	TDRKH	-1.05	-10.92	-0.51	6.32e-24	Coronary artery disease;
LUSC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg25554036	chr4:6271136	WFS1	0.59	12.29	0.56	6.97e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs4343996	0.934	rs4320450	chr7:3372308	G/C	cg21248987	chr7:3385318	SDK1	-0.4	-6.75	-0.35	6.69e-11	Motion sickness;
LUSC	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg03465714	chr1:152285911	FLG	-0.42	-5.79	-0.3	1.64e-8	Atopic dermatitis;
LUSC	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg21951975	chr1:209979733	IRF6	0.57	6.9	0.35	2.68e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16346588	chr10:242978	ZMYND11	0.4	5.67	0.3	3.15e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs3741151	0.773	rs73544711	chr11:73164870	T/A	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-11.0	-0.52	3.09e-24	Response to antipsychotic treatment;
LUSC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg22834771	chr12:69754056	YEATS4	-0.43	-6.23	-0.32	1.37e-9	Blood protein levels;
LUSC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg01879757	chr17:41196368	BRCA1	-0.45	-6.98	-0.36	1.58e-11	Menopause (age at onset);
LUSC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg05552183	chr6:42928497	GNMT	-0.47	-8.1	-0.41	1.07e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs41271473	1.000	rs11580020	chr1:228880466	A/G	cg10167378	chr1:228756711	NA	-0.55	-6.66	-0.34	1.15e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.77	-0.35	5.74e-11	Alzheimer's disease (late onset);
LUSC	cis	rs10737909	0.510	rs12025158	chr1:15539259	A/G	cg21012057	chr1:15538911	TMEM51	0.51	8.87	0.44	4.37e-17	Migraine;
LUSC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.88	-14.34	-0.62	1.08e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs2786098	0.656	rs12563879	chr1:197528805	T/A	cg16005942	chr6:160526640	IGF2R	0.51	6.03	0.31	4.34e-9	Asthma;
LUSC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg01620082	chr3:125678407	NA	-0.85	-7.28	-0.37	2.42e-12	Depression;
LUSC	cis	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg06521331	chr12:34319734	NA	-0.48	-8.04	-0.4	1.53e-14	Morning vs. evening chronotype;
LUSC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg02018176	chr4:1364513	KIAA1530	-0.57	-9.84	-0.47	3.17e-20	Obesity-related traits;
LUSC	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.67	10.76	0.51	2.3e-23	Schizophrenia;
LUSC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg08847533	chr14:75593920	NEK9	0.85	15.8	0.65	2.15e-42	Height;
LUSC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg14019146	chr3:50243930	SLC38A3	0.31	6.59	0.34	1.69e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg05738196	chr6:26577821	NA	0.78	14.99	0.63	3.4e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg09367891	chr1:107599246	PRMT6	-0.5	-7.95	-0.4	2.84e-14	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.82	0.54	3.72e-27	Prudent dietary pattern;
LUSC	cis	rs9467711	0.516	rs1165168	chr6:25859508	A/C	cg08501292	chr6:25962987	TRIM38	0.57	5.8	0.3	1.53e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg22166914	chr1:53195759	ZYG11B	-0.71	-12.23	-0.56	1.11e-28	Monocyte count;
LUSC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg14092988	chr3:52407081	DNAH1	0.31	6.18	0.32	1.85e-9	Bipolar disorder;
LUSC	cis	rs6060717	0.536	rs6058364	chr20:34507890	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.74	-0.3	2.13e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-5.69	-0.3	2.75e-8	IgG glycosylation;
LUSC	cis	rs921665	0.681	rs6548169	chr2:3183752	A/G	cg02624386	chr2:3182749	NA	0.63	6.34	0.33	7.32e-10	World class endurance athleticism;
LUSC	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.7	-10.32	-0.49	7.64e-22	Vitiligo;
LUSC	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg13902645	chr11:5959945	NA	0.52	7.75	0.39	1.12e-13	DNA methylation (variation);
LUSC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.72	-9.93	-0.48	1.56e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg12310025	chr6:25882481	NA	-0.44	-7.73	-0.39	1.25e-13	Blood metabolite levels;
LUSC	cis	rs997295	0.713	rs17243334	chr15:68013079	A/G	cg08079166	chr15:68083412	MAP2K5	-0.34	-6.7	-0.34	9.08e-11	Motion sickness;
LUSC	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg27631724	chr1:11040367	C1orf127	0.54	9.56	0.46	2.75e-19	Ewing sarcoma;
LUSC	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg25024717	chr12:54324583	NA	-0.38	-6.67	-0.34	1.07e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	0.82	10.34	0.49	6.17e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs2932538	0.922	rs6537745	chr1:113154080	T/C	cg22162597	chr1:113214053	CAPZA1	0.53	7.54	0.38	4.39e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-10.6	-0.5	8.04e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs2979489	0.699	rs7840356	chr8:30406251	G/A	cg26383811	chr8:30366931	RBPMS	0.48	7.58	0.38	3.43e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg14552801	chr7:65878734	NA	-0.43	-5.89	-0.31	9.49e-9	Aortic root size;
LUSC	cis	rs921968	0.613	rs2710251	chr2:219543433	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-10.24	-0.49	1.42e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1808579	0.904	rs1652348	chr18:21147509	C/T	cg14672496	chr18:21087552	C18orf8	0.38	6.78	0.35	5.56e-11	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs7605827	0.897	rs4668899	chr2:15511575	C/A	cg19274914	chr2:15703543	NA	0.46	8.95	0.44	2.45e-17	Educational attainment (years of education);
LUSC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	8.14	0.41	7.67e-15	Homoarginine levels;
LUSC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.82	14.21	0.61	3.48e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7572644	0.640	rs4666024	chr2:28072979	C/G	cg27432699	chr2:27873401	GPN1	-0.55	-7.62	-0.38	2.68e-13	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg00310523	chr12:86230176	RASSF9	0.47	8.47	0.42	7.74e-16	Major depressive disorder;
LUSC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.75	-0.35	6.52e-11	Lung cancer;
LUSC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg21361702	chr7:150065534	REPIN1	0.51	6.54	0.34	2.32e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	cis	rs17030434	0.954	rs10000558	chr4:154766835	A/T	cg14289246	chr4:154710475	SFRP2	-0.48	-6.32	-0.33	8.33e-10	Electrocardiographic conduction measures;
LUSC	cis	rs17125944	1.000	rs17125944	chr14:53400629	C/T	cg00686598	chr14:53173677	PSMC6	-0.79	-6.9	-0.35	2.56e-11	Alzheimer's disease (late onset);
LUSC	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs9905704	0.681	rs1860262	chr17:56580997	T/C	cg12560992	chr17:57184187	TRIM37	-0.51	-5.98	-0.31	5.73e-9	Testicular germ cell tumor;
LUSC	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg13072238	chr3:49761600	GMPPB	-0.69	-8.19	-0.41	5.44e-15	Menarche (age at onset);
LUSC	cis	rs11608355	0.515	rs12822282	chr12:109923207	G/A	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	trans	rs7737355	1.000	rs6872972	chr5:130621533	C/T	cg07715041	chr7:99302981	CYP3A7	-0.39	-6.14	-0.32	2.3e-9	Life satisfaction;
LUSC	cis	rs939658	0.967	rs7171067	chr15:79452727	G/T	cg17916960	chr15:79447300	NA	0.48	9.62	0.47	1.64e-19	Refractive error;
LUSC	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg10356904	chr22:49881777	NA	-0.33	-7.39	-0.37	1.21e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg08079166	chr15:68083412	MAP2K5	0.4	7.16	0.36	5.1e-12	Restless legs syndrome;
LUSC	trans	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg21775007	chr8:11205619	TDH	0.46	6.73	0.35	7.52e-11	Mood instability;
LUSC	cis	rs2458413	0.522	rs2514657	chr8:105331215	T/C	cg04554929	chr8:105342491	NA	-0.36	-6.38	-0.33	6.02e-10	Paget's disease;
LUSC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg22963979	chr7:1858916	MAD1L1	-0.58	-8.97	-0.44	2.17e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg20607798	chr8:58055168	NA	0.53	6.03	0.31	4.36e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg18512352	chr11:47633146	NA	-0.47	-9.31	-0.45	1.69e-18	Subjective well-being;
LUSC	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg26384229	chr12:38710491	ALG10B	0.67	10.54	0.5	1.29e-22	Morning vs. evening chronotype;
LUSC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.4	0.53	1.16e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs1941687	0.765	rs11874521	chr18:31391966	G/A	cg27147174	chr7:100797783	AP1S1	-0.45	-6.48	-0.33	3.27e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg14584255	chr6:163149320	PACRG;PARK2	-0.34	-6.52	-0.34	2.66e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs4720118	1.000	rs11972278	chr7:33431364	C/T	cg18659248	chr10:3679062	NA	-0.35	-6.02	-0.31	4.65e-9	Leprosy;
LUSC	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.35	-0.37	1.52e-12	Type 2 diabetes;
LUSC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	0.9	14.75	0.63	2.98e-38	Breast cancer;
LUSC	cis	rs500891	0.525	rs6917851	chr6:84064190	A/C	cg08257003	chr6:84140564	ME1	-0.32	-7.15	-0.36	5.68e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs6693567	0.526	rs834239	chr1:150375458	C/A	cg15654264	chr1:150340011	RPRD2	0.44	7.16	0.36	5.09e-12	Migraine;
LUSC	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.66	-0.39	2.07e-13	Acne (severe);
LUSC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg22906224	chr7:99728672	NA	0.56	8.16	0.41	7.13e-15	Coronary artery disease;
LUSC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00166722	chr3:10149974	C3orf24	0.55	7.5	0.38	5.83e-13	Alzheimer's disease;
LUSC	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.74	-0.47	6.99e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg05973401	chr12:123451056	ABCB9	0.56	8.2	0.41	5.16e-15	Platelet count;
LUSC	trans	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg04995722	chr7:26192034	NFE2L3	-0.42	-6.54	-0.34	2.32e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg18402987	chr7:1209562	NA	0.73	7.84	0.39	5.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs9910292	0.591	rs1076198	chr17:31350133	G/T	cg03789507	chr8:136667083	NA	0.48	6.11	0.32	2.83e-9	Mosquito bite size;
LUSC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg00012203	chr2:219082015	ARPC2	-0.7	-11.58	-0.54	2.72e-26	Colorectal cancer;
LUSC	cis	rs2548003	0.518	rs2548006	chr5:28732126	C/T	cg22863700	chr5:28928346	NA	-0.47	-6.57	-0.34	1.95e-10	Hip geometry;
LUSC	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.65	0.34	1.17e-10	Menarche (age at onset);
LUSC	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg20203395	chr5:56204925	C5orf35	-0.49	-7.33	-0.37	1.78e-12	Breast cancer;Breast cancer (early onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08763126	chr6:109416997	C6orf182	0.45	5.98	0.31	5.83e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7903847	0.612	rs72838764	chr10:99142107	T/C	cg20016023	chr10:99160130	RRP12	-0.28	-6.15	-0.32	2.17e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs17255340	0.520	rs1145913	chr6:83993928	A/C	cg08257003	chr6:84140564	ME1	0.32	7.89	0.4	4.39e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.54	9.5	0.46	4.09e-19	Osteoporosis;
LUSC	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.8	-0.35	4.79e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg02389323	chr16:88786976	FAM38A	1.13	10.71	0.51	3.41e-23	Plateletcrit;
LUSC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg02951883	chr7:2050386	MAD1L1	-0.46	-7.92	-0.4	3.47e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg06521331	chr12:34319734	NA	-0.46	-7.21	-0.37	3.82e-12	Morning vs. evening chronotype;
LUSC	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg18132916	chr6:79620363	NA	-0.38	-5.84	-0.3	1.23e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.23	-0.45	3.16e-18	Morning vs. evening chronotype;
LUSC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg08888203	chr3:10149979	C3orf24	0.6	8.62	0.43	2.68e-16	Alzheimer's disease;
LUSC	cis	rs6460942	0.908	rs73677570	chr7:12280329	T/C	cg06484146	chr7:12443880	VWDE	-0.54	-5.84	-0.3	1.25e-8	Coronary artery disease;
LUSC	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg17507749	chr15:85114479	UBE2QP1	0.54	6.5	0.34	2.86e-10	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg06618935	chr21:46677482	NA	-0.39	-7.64	-0.39	2.28e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.21	0.59	2.34e-32	Total body bone mineral density;
LUSC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg19774624	chr17:42201019	HDAC5	-0.78	-11.81	-0.54	4.03e-27	Total body bone mineral density;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00781875	chr1:156252398	TMEM79;SMG5	0.4	6.01	0.31	4.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7580658	0.963	rs9789510	chr2:128137012	G/A	cg09760422	chr2:128146352	NA	-0.33	-7.17	-0.37	4.89e-12	Protein C levels;
LUSC	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg09754948	chr16:28834200	ATXN2L	0.45	6.45	0.33	3.87e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg04518342	chr5:131593106	PDLIM4	0.34	6.18	0.32	1.92e-9	Blood metabolite levels;
LUSC	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.27e-20	Coronary artery disease;
LUSC	cis	rs9925964	0.967	rs14235	chr16:31121793	G/A	cg02466173	chr16:30829666	NA	0.34	6.31	0.33	9.07e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08677398	chr8:58056175	NA	0.57	6.89	0.35	2.79e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.82	-0.43	6.25e-17	Response to antipsychotic treatment;
LUSC	trans	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg19894588	chr14:64061835	NA	-0.55	-7.29	-0.37	2.27e-12	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg22437258	chr11:111473054	SIK2	0.49	6.52	0.34	2.6e-10	Primary sclerosing cholangitis;
LUSC	cis	rs2820315	0.931	rs2644114	chr1:201864830	A/G	cg10061532	chr1:201886748	LMOD1	-0.27	-6.1	-0.32	2.98e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg11871910	chr12:69753446	YEATS4	0.46	6.02	0.31	4.67e-9	Response to diuretic therapy;
LUSC	trans	rs2840044	0.517	rs2124247	chr17:33885468	G/A	cg19694781	chr19:47549865	TMEM160	-0.42	-6.73	-0.35	7.62e-11	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg09021430	chr5:549028	NA	-0.54	-7.06	-0.36	9.57e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.58	9.31	0.45	1.74e-18	Aortic root size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03448396	chr3:38495949	LOC100128640;ACVR2B	0.39	6.11	0.32	2.81e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg11764359	chr7:65958608	NA	0.74	11.65	0.54	1.5e-26	Aortic root size;
LUSC	cis	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg20368463	chr18:77673604	PQLC1	0.69	6.98	0.36	1.57e-11	Opioid sensitivity;
LUSC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.38	5.89	0.31	9.29e-9	Platelet count;
LUSC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg23978390	chr7:1156363	C7orf50	0.53	6.39	0.33	5.67e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg00631329	chr6:26305371	NA	0.32	5.66	0.3	3.33e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9311676	0.632	rs6785572	chr3:58361517	A/G	cg13750441	chr3:58318267	PXK	-0.32	-6.23	-0.32	1.41e-9	Systemic lupus erythematosus;
LUSC	cis	rs1957429	0.634	rs59000318	chr14:65419473	C/A	cg23373153	chr14:65346875	NA	-0.88	-9.18	-0.45	4.73e-18	Pediatric areal bone mineral density (radius);
LUSC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06634786	chr22:41940651	POLR3H	0.49	5.72	0.3	2.34e-8	Vitiligo;
LUSC	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.2	0.32	1.67e-9	Systolic blood pressure;
LUSC	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	7.89	0.4	4.49e-14	Menarche (age at onset);
LUSC	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg11861562	chr11:117069780	TAGLN	0.33	6.35	0.33	7.23e-10	Blood protein levels;
LUSC	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg01884057	chr2:25150051	NA	0.42	9.13	0.45	6.57e-18	Body mass index;
LUSC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.19	13.56	0.6	1.16e-33	Diabetic kidney disease;
LUSC	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg27661571	chr11:113659931	NA	0.59	6.41	0.33	4.92e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs11785693	0.862	rs11778367	chr8:4988398	T/C	cg26367366	chr8:4980734	NA	0.77	9.11	0.45	7.89e-18	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs2235544	0.565	rs928441	chr1:54473368	C/A	cg25741118	chr1:54482237	LDLRAD1	-0.28	-6.14	-0.32	2.4e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.71	-9.73	-0.47	7.58e-20	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg04576048	chr1:205797593	PM20D1	0.34	6.13	0.32	2.51e-9	Menarche (age at onset);
LUSC	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.62	0.34	1.43e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9512730	0.517	rs1967772	chr13:28036062	G/A	cg08193333	chr13:27998609	GTF3A	0.45	5.65	0.3	3.44e-8	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg22117172	chr7:91764530	CYP51A1	0.33	5.81	0.3	1.49e-8	Breast cancer;
LUSC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg00800038	chr16:89945340	TCF25	-0.57	-6.14	-0.32	2.33e-9	Skin colour saturation;
LUSC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg12560992	chr17:57184187	TRIM37	-0.83	-15.32	-0.64	1.65e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs4776059	0.798	rs28368342	chr15:52921573	A/G	cg24008177	chr15:52972085	KIAA1370	-0.34	-6.26	-0.32	1.2e-9	Schizophrenia;
LUSC	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg18854424	chr1:2615690	NA	0.49	9.67	0.47	1.15e-19	Ulcerative colitis;
LUSC	cis	rs2742234	0.504	rs7093409	chr10:43740067	A/G	cg15436174	chr10:43711423	RASGEF1A	0.38	6.78	0.35	5.41e-11	Hirschsprung disease;
LUSC	cis	rs2742417	1.000	rs2673065	chr3:45771222	C/T	cg04837898	chr3:45731254	SACM1L	-0.37	-6.18	-0.32	1.9e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.47	-0.33	3.56e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg22709100	chr7:91322751	NA	0.39	5.74	0.3	2.13e-8	Breast cancer;
LUSC	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg06885757	chr1:42089581	HIVEP3	0.47	9.83	0.47	3.52e-20	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.32	0.37	1.82e-12	Motion sickness;
LUSC	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg17168535	chr8:21777572	XPO7	0.81	14.59	0.62	1.19e-37	Mean corpuscular volume;
LUSC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-1.14	-18.49	-0.71	4.69e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs3931020	0.688	rs525487	chr1:75217420	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.64	-8.43	-0.42	1.02e-15	Resistin levels;
LUSC	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg01475377	chr6:109611718	NA	-0.42	-7.65	-0.39	2.23e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg15448220	chr1:150897856	SETDB1	0.44	6.42	0.33	4.7e-10	Melanoma;
LUSC	cis	rs9311676	0.656	rs3191903	chr3:58382846	C/T	cg13750441	chr3:58318267	PXK	0.34	6.67	0.34	1.04e-10	Systemic lupus erythematosus;
LUSC	cis	rs4589502	1.000	rs2414925	chr15:67129986	A/G	cg09911534	chr15:67153556	NA	-0.61	-6.64	-0.34	1.3e-10	Lung cancer (smoking interaction);
LUSC	cis	rs6906287	0.647	rs2213856	chr6:118806793	C/T	cg21191810	chr6:118973309	C6orf204	0.33	5.9	0.31	8.9e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.5	10.1	0.48	4.13e-21	Anterior chamber depth;
LUSC	cis	rs983392	0.709	rs56273223	chr11:59984676	A/C	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.09	-0.32	3.18e-9	Alzheimer's disease (late onset);
LUSC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06022373	chr22:39101656	GTPBP1	0.74	11.63	0.54	1.84e-26	Menopause (age at onset);
LUSC	cis	rs939574	0.790	rs2276635	chr2:220087441	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.89	6.14	0.32	2.39e-9	Platelet distribution width;
LUSC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg00033643	chr7:134001901	SLC35B4	0.46	7.27	0.37	2.62e-12	Mean platelet volume;
LUSC	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg06060754	chr5:176797920	RGS14	-0.62	-8.75	-0.43	1.09e-16	Urate levels in lean individuals;
LUSC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9420	0.961	rs11229131	chr11:57562525	G/A	cg02958346	chr11:57425731	CLP1	-0.44	-6.44	-0.33	4.22e-10	Schizophrenia;
LUSC	cis	rs3106136	0.967	rs17310526	chr4:95222227	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.25	-0.32	1.29e-9	Capecitabine sensitivity;
LUSC	trans	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg14791747	chr16:20752902	THUMPD1	-0.42	-6.45	-0.33	4e-10	Dental caries;
LUSC	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.7	10.46	0.5	2.42e-22	Smoking initiation;
LUSC	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg23649088	chr2:200775458	C2orf69	0.48	6.68	0.34	1.01e-10	Schizophrenia;
LUSC	trans	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.38	0.33	5.76e-10	Monocyte count;
LUSC	cis	rs240764	0.817	rs240143	chr6:101080621	G/A	cg09795085	chr6:101329169	ASCC3	0.42	6.04	0.31	4.03e-9	Neuroticism;
LUSC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-9.1	-0.45	8.13e-18	Gut microbiome composition (summer);
LUSC	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg02487331	chr1:146550467	NA	-0.42	-7.41	-0.38	1.07e-12	HIV-1 control;
LUSC	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg06219351	chr7:158114137	PTPRN2	-0.51	-9.23	-0.45	3.15e-18	Calcium levels;
LUSC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.24	-0.32	1.32e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg26874229	chr2:105853672	NA	-0.34	-6.06	-0.31	3.66e-9	Type 2 diabetes;
LUSC	cis	rs79387448	0.745	rs17027430	chr2:103163237	T/C	cg09003973	chr2:102972529	NA	0.89	8.62	0.43	2.69e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs3849570	0.695	rs1851930	chr3:81895318	T/G	cg07356753	chr3:81810745	GBE1	-0.58	-8.98	-0.44	2.08e-17	Waist circumference;Body mass index;
LUSC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg04414720	chr1:150670196	GOLPH3L	0.5	7.36	0.37	1.49e-12	Urate levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10968375	chr5:55008210	SLC38A9	-0.45	-6.58	-0.34	1.78e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2236918	0.710	rs2526700	chr1:242019999	C/A	cg17736920	chr1:242011382	EXO1	0.41	6.44	0.33	4.25e-10	Menopause (age at onset);
LUSC	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg23176889	chr5:176863531	GRK6	-0.69	-14.24	-0.61	2.71e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg07169764	chr2:136633963	MCM6	-1.11	-16.32	-0.67	2.01e-44	Corneal structure;
LUSC	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg13175981	chr1:150552382	MCL1	0.45	5.8	0.3	1.52e-8	Urate levels;
LUSC	cis	rs11642862	0.685	rs79974799	chr16:30996795	C/T	cg02466173	chr16:30829666	NA	-0.61	-6.47	-0.33	3.42e-10	Tonsillectomy;
LUSC	cis	rs193541	0.593	rs154517	chr5:122189825	A/T	cg19077854	chr5:122220652	SNX24	0.37	7.82	0.39	7.01e-14	Glucose homeostasis traits;
LUSC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg21724239	chr8:58056113	NA	0.8	8.44	0.42	9.52e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg07507251	chr3:52567010	NT5DC2	0.31	6.12	0.32	2.65e-9	Bipolar disorder;
LUSC	cis	rs11645898	0.810	rs72787060	chr16:72105371	T/C	cg14768367	chr16:72042858	DHODH	-0.69	-7.54	-0.38	4.37e-13	Blood protein levels;
LUSC	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.5	7.73	0.39	1.27e-13	Cognitive test performance;
LUSC	trans	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg25214090	chr10:38739885	LOC399744	0.42	6.58	0.34	1.79e-10	Diastolic blood pressure;
LUSC	cis	rs7712401	0.601	rs30029	chr5:122283170	A/C	cg19077854	chr5:122220652	SNX24	-0.4	-9.01	-0.44	1.58e-17	Mean platelet volume;
LUSC	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.02	-0.31	4.72e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3771570	1.000	rs56222556	chr2:242364119	G/A	cg21155796	chr2:242212141	HDLBP	0.62	6.69	0.34	9.6e-11	Prostate cancer;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04650641	chr22:41697410	ZC3H7B	-0.49	-6.41	-0.33	4.99e-10	Hepatitis;
LUSC	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg12620499	chr2:216877984	MREG	0.66	10.5	0.5	1.79e-22	Alcohol dependence;
LUSC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg26380479	chr7:97908229	NA	-0.27	-6.04	-0.31	4.06e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.1	0.32	2.91e-9	IgG glycosylation;
LUSC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg06784218	chr1:46089804	CCDC17	-0.56	-11.07	-0.52	1.85e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg00945038	chr17:61921165	SMARCD2	0.38	5.67	0.3	3.13e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg23260525	chr10:116636907	FAM160B1	0.43	8.99	0.44	1.86e-17	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs11051970	0.918	rs76930558	chr12:32538839	A/C	cg02745156	chr12:32552066	NA	0.44	6.92	0.35	2.36e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	8.31	0.41	2.38e-15	Neuroticism;
LUSC	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-13.75	-0.6	2.13e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg23173402	chr1:227635558	NA	0.56	6.28	0.32	1.07e-9	Major depressive disorder;
LUSC	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg24558204	chr6:135376177	HBS1L	0.58	8.8	0.43	7.47e-17	Red blood cell count;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg05064044	chr6:292385	DUSP22	-0.73	-11.69	-0.54	1.11e-26	Menopause (age at onset);
LUSC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg22709100	chr7:91322751	NA	0.4	5.8	0.3	1.55e-8	Breast cancer;
LUSC	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg04989706	chr14:50066350	PPIL5	-0.45	-6.1	-0.32	2.89e-9	Carotid intima media thickness;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06097977	chr7:150924442	ABCF2	0.44	5.98	0.31	5.9e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg24631222	chr15:78858424	CHRNA5	0.64	8.37	0.42	1.62e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg08501292	chr6:25962987	TRIM38	0.63	5.81	0.3	1.47e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3784262	1.000	rs11071356	chr15:58240518	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.99	-0.31	5.54e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs184065563	1	rs184065563	chr6:45144224	G/A	cg20913747	chr6:44695427	NA	-0.46	-7.43	-0.38	8.91e-13	Total body bone mineral density (age over 60);Total body bone mineral density;
LUSC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.86	-0.35	3.27e-11	Lung cancer;
LUSC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.91	-0.48	1.81e-20	Platelet count;
LUSC	cis	rs73206853	0.563	rs34378671	chr12:111163204	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	7.52	0.38	5.1e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg15704280	chr7:45808275	SEPT13	0.81	7.73	0.39	1.27e-13	Axial length;
LUSC	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.36	-0.42	1.78e-15	Rheumatoid arthritis;
LUSC	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg23711669	chr6:146136114	FBXO30	0.87	16.13	0.66	1.08e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09969830	chr16:103646	SNRNP25;POLR3K	-0.43	-6.23	-0.32	1.39e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11809207	1.000	rs11809207	chr1:26521140	G/A	cg00300879	chr1:26503847	CNKSR1	0.3	5.82	0.3	1.34e-8	Height;
LUSC	cis	rs2658782	0.654	rs2605623	chr11:93249359	A/G	cg15737290	chr11:93063684	CCDC67	0.6	7.48	0.38	6.69e-13	Pulmonary function decline;
LUSC	trans	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg25482853	chr8:67687455	SGK3	0.79	11.22	0.52	5.33e-25	Obesity-related traits;
LUSC	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg09904177	chr6:26538194	HMGN4	0.67	6.34	0.33	7.59e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7215564	0.908	rs4889883	chr17:78664374	C/A	cg23238734	chr17:78661607	RPTOR	0.48	6.12	0.32	2.63e-9	Myopia (pathological);
LUSC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg09455208	chr3:40491958	NA	0.57	10.18	0.49	2.24e-21	Renal cell carcinoma;
LUSC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.6	7.65	0.39	2.17e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.4	0.56	2.61e-29	Prudent dietary pattern;
LUSC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg26039829	chr8:22132926	PIWIL2	0.44	8.15	0.41	7.24e-15	Hypertriglyceridemia;
LUSC	trans	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg05059571	chr16:84539110	KIAA1609	-0.47	-8.92	-0.44	3.1e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg12826209	chr6:26865740	GUSBL1	0.53	7.68	0.39	1.8e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.69	0.39	1.65e-13	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06626126	chr3:168865097	MECOM	-0.36	-6.03	-0.31	4.31e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4363385	0.693	rs368076	chr1:153046514	A/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.39	-0.37	1.19e-12	Inflammatory skin disease;
LUSC	cis	rs6987853	0.830	rs2272685	chr8:42354102	C/T	cg09913449	chr8:42400586	C8orf40	-0.41	-6.76	-0.35	6.35e-11	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.8	-13.0	-0.58	1.56e-31	Aortic root size;
LUSC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	8.98	0.44	2.02e-17	Height;
LUSC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg03161606	chr19:29218774	NA	0.52	6.78	0.35	5.45e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg05082376	chr22:42548792	NA	-0.4	-6.62	-0.34	1.45e-10	Cognitive function;
LUSC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.62	6.04	0.31	4.07e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1322512	0.917	rs2758783	chr6:153010415	A/G	cg27316956	chr6:152958899	SYNE1	0.36	6.19	0.32	1.76e-9	Tonometry;
LUSC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16405210	chr4:1374714	KIAA1530	-0.59	-9.24	-0.45	3e-18	Longevity;
LUSC	cis	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg01251360	chr16:68772225	CDH1	-0.25	-5.84	-0.3	1.23e-8	Colorectal cancer;
LUSC	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg11984989	chr7:158649758	WDR60	-0.99	-17.38	-0.69	1.19e-48	Height;
LUSC	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-5.8	-0.3	1.53e-8	Eosinophil percentage of white cells;
LUSC	trans	rs208520	0.779	rs208451	chr6:66906155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-12.9	-0.58	3.55e-31	Exhaled nitric oxide output;
LUSC	trans	rs6600671	1.000	rs4844381	chr1:121184898	C/T	cg00646200	chr1:148855367	NA	0.47	7.46	0.38	7.43e-13	Hip geometry;
LUSC	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg26893861	chr17:41843967	DUSP3	1.11	23.99	0.8	1.25e-74	Triglycerides;
LUSC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg04944784	chr2:26401820	FAM59B	0.78	11.21	0.52	5.48e-25	Gut microbiome composition (summer);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12568633	chr10:73533407	CDH23;C10orf54	-0.44	-6.05	-0.31	3.84e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12519773	0.526	rs4551051	chr5:92518724	T/C	cg18783429	chr5:92414398	NA	0.33	7.22	0.37	3.44e-12	Migraine;
LUSC	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg02574844	chr11:5959923	NA	-0.46	-6.42	-0.33	4.8e-10	DNA methylation (variation);
LUSC	trans	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.41	-0.33	4.96e-10	Blood trace element (Cu levels);
LUSC	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.58	-0.42	3.56e-16	Systolic blood pressure;
LUSC	cis	rs2294693	0.891	rs4714420	chr6:40992799	T/C	cg14769373	chr6:40998127	UNC5CL	-0.48	-7.0	-0.36	1.45e-11	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg03213289	chr20:61660250	NA	0.68	13.98	0.61	2.78e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6076065	0.651	rs6114085	chr20:23419276	T/A	cg11657817	chr20:23433608	CST11	0.41	7.45	0.38	7.97e-13	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs72792513	1.000	rs2339576	chr2:22920859	C/T	cg05844895	chr16:88969569	CBFA2T3	0.5	6.2	0.32	1.69e-9	Hepatitis B;
LUSC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg20891283	chr12:69753455	YEATS4	0.64	9.47	0.46	5.44e-19	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg25428297	chr7:1022841	CYP2W1	0.28	5.69	0.3	2.78e-8	Longevity;Endometriosis;
LUSC	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg26384229	chr12:38710491	ALG10B	0.73	11.48	0.53	5.99e-26	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg07701084	chr6:150067640	NUP43	0.58	9.04	0.44	1.31e-17	Lung cancer;
LUSC	trans	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg09781936	chr22:19749961	TBX1	-0.34	-6.01	-0.31	4.74e-9	Inflammatory bowel disease;
LUSC	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg25258033	chr6:167368657	RNASET2	-0.37	-6.16	-0.32	2.06e-9	Crohn's disease;
LUSC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg12463550	chr7:65579703	CRCP	-0.43	-6.36	-0.33	6.61e-10	Aortic root size;
LUSC	cis	rs4953318	0.619	rs12105417	chr2:46361255	A/C	cg12428440	chr2:46370979	PRKCE	0.46	7.74	0.39	1.18e-13	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg16339924	chr4:17578868	LAP3	0.51	7.6	0.38	3.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg04995722	chr7:26192034	NFE2L3	-0.42	-6.45	-0.33	3.83e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg17554472	chr22:41940697	POLR3H	0.48	5.96	0.31	6.35e-9	Vitiligo;
LUSC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.75	0.7	4.07e-50	Chronic sinus infection;
LUSC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24549020	chr5:56110836	MAP3K1	0.48	5.81	0.3	1.45e-8	Initial pursuit acceleration;
LUSC	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg15423357	chr2:25149977	NA	0.35	6.42	0.33	4.64e-10	Body mass index;
LUSC	trans	rs198712	0.505	rs198311	chr7:24191762	T/C	cg06529468	chr19:10676722	KRI1	0.38	6.1	0.32	2.89e-9	Aggressive periodontitis (sex interaction);
LUSC	trans	rs459571	0.834	rs379417	chr9:136890704	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-12.48	-0.56	1.34e-29	Platelet distribution width;
LUSC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22307029	chr19:49891270	CCDC155	0.61	7.78	0.39	9.21e-14	Multiple sclerosis;
LUSC	cis	rs7094131	0.523	rs10828322	chr10:22876002	G/A	cg19500236	chr10:22911537	PIP4K2A	0.35	6.01	0.31	4.98e-9	Obesity-related traits;
LUSC	cis	rs1983891	1.000	rs2104506	chr6:41533579	C/A	cg20194872	chr6:41519635	FOXP4	0.35	6.08	0.32	3.34e-9	Prostate cancer;
LUSC	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.92	-0.31	7.86e-9	Neutrophil percentage of white cells;
LUSC	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg19640130	chr10:64028056	RTKN2	-0.41	-7.5	-0.38	5.67e-13	Rheumatoid arthritis;
LUSC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06112835	chr11:68658793	MRPL21	-0.5	-7.85	-0.39	5.84e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-8.12	-0.41	8.96e-15	Lymphocyte counts;
LUSC	cis	rs74181299	0.964	rs2540948	chr2:65284623	T/C	cg05010058	chr2:65284262	CEP68	0.3	5.84	0.3	1.21e-8	Pulse pressure;
LUSC	cis	rs6426558	0.502	rs6697665	chr1:227474665	T/C	cg10327440	chr1:227177885	CDC42BPA	0.54	7.23	0.37	3.38e-12	Neutrophil percentage of white cells;
LUSC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.56	11.17	0.52	7.79e-25	Asthma (sex interaction);
LUSC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.81	14.65	0.63	7.13e-38	Blood protein levels;
LUSC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	0.64	13.4	0.59	4.4e-33	Prudent dietary pattern;
LUSC	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg16584290	chr5:462447	EXOC3	0.47	8.29	0.41	2.85e-15	Cystic fibrosis severity;
LUSC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.88e-11	Primary biliary cholangitis;
LUSC	cis	rs9322817	0.653	rs9399896	chr6:105216969	A/G	cg02098413	chr6:105308735	HACE1	-0.28	-5.76	-0.3	1.9e-8	Thyroid stimulating hormone;
LUSC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18357526	chr6:26021779	HIST1H4A	0.45	7.01	0.36	1.31e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	6.81	0.35	4.45e-11	Schizophrenia;
LUSC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg14668632	chr7:2872130	GNA12	-0.47	-6.89	-0.35	2.73e-11	Height;
LUSC	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg05187965	chr10:45406764	TMEM72	-0.38	-9.0	-0.44	1.75e-17	Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.03	20.93	0.75	9.51e-63	Cognitive function;
LUSC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.4	-6.5	-0.34	2.91e-10	Longevity;Endometriosis;
LUSC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg03806693	chr22:41940476	POLR3H	0.99	14.13	0.61	7.12e-36	Vitiligo;
LUSC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	12.96	0.58	2.16e-31	Platelet count;
LUSC	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg19997662	chr15:101784653	CHSY1	-0.43	-6.07	-0.32	3.49e-9	Corneal structure;
LUSC	cis	rs3771570	1.000	rs73018141	chr2:242221570	G/A	cg21155796	chr2:242212141	HDLBP	0.68	7.51	0.38	5.46e-13	Prostate cancer;
LUSC	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-0.85	-14.49	-0.62	3.04e-37	Headache;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21099776	chr17:17739742	SREBF1	0.4	6.04	0.31	4.11e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg15798862	chr7:76129360	DTX2	0.44	7.12	0.36	6.57e-12	Multiple sclerosis;
LUSC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg22800045	chr5:56110881	MAP3K1	0.45	6.37	0.33	6.29e-10	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs6688613	0.729	rs2072742	chr1:166929673	A/G	cg07049167	chr1:166818506	POGK	0.43	5.77	0.3	1.79e-8	Refractive astigmatism;
LUSC	cis	rs72781680	0.756	rs2551337	chr2:24006886	C/T	cg08917208	chr2:24149416	ATAD2B	0.63	7.16	0.36	5.01e-12	Lymphocyte counts;
LUSC	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.93	15.96	0.66	5.05e-43	Bladder cancer;
LUSC	trans	rs4714291	0.963	rs12194361	chr6:40116264	T/G	cg02267698	chr19:7991119	CTXN1	-0.52	-7.24	-0.37	3.18e-12	Strep throat;
LUSC	trans	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg25214090	chr10:38739885	LOC399744	0.53	7.8	0.39	7.9e-14	Corneal astigmatism;
LUSC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg07741184	chr6:167504864	NA	0.33	5.97	0.31	5.98e-9	Crohn's disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16553447	chr15:77197883	NA	-0.42	-6.05	-0.31	3.85e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg01176363	chr20:62369445	LIME1	-0.47	-7.09	-0.36	8.05e-12	Prostate cancer;
LUSC	cis	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg24375607	chr4:120327624	NA	0.48	7.36	0.37	1.41e-12	Diastolic blood pressure;
LUSC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg26380479	chr7:97908229	NA	-0.27	-6.06	-0.31	3.65e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg12927641	chr6:109611667	NA	-0.34	-5.72	-0.3	2.42e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs2279817	0.780	rs1124447	chr1:18007598	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.13	-0.32	2.54e-9	Neuroticism;
LUSC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04850017	chr11:63683019	RCOR2	0.3	6.03	0.31	4.28e-9	Pulse pressure;
LUSC	cis	rs2625529	0.824	rs12593134	chr15:72303007	G/C	cg16672083	chr15:72433130	SENP8	-0.51	-7.44	-0.38	8.7e-13	Red blood cell count;
LUSC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg15017067	chr4:17643749	FAM184B	0.35	5.87	0.31	1.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg20744362	chr22:50050164	C22orf34	0.38	7.96	0.4	2.68e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1784581	0.651	rs1784590	chr6:162389462	C/A	cg17173639	chr6:162384350	PARK2	-0.68	-12.13	-0.55	2.54e-28	Itch intensity from mosquito bite;
LUSC	trans	rs747782	0.527	rs7113857	chr11:48141859	G/T	cg15704280	chr7:45808275	SEPT13	0.7	6.49	0.33	3.05e-10	Intraocular pressure;
LUSC	cis	rs13385	0.769	rs17118759	chr5:139617407	A/G	cg26211634	chr5:139558579	C5orf32	0.44	6.86	0.35	3.4e-11	Atrial fibrillation;
LUSC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.7	10.95	0.51	4.71e-24	Aortic root size;
LUSC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg06637938	chr14:75390232	RPS6KL1	0.53	8.61	0.43	2.95e-16	Height;
LUSC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.49	-6.73	-0.35	7.34e-11	Renal function-related traits (BUN);
LUSC	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg23306229	chr2:178417860	TTC30B	0.55	5.96	0.31	6.4e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	0.93	16.17	0.66	7.55e-44	Menopause (age at onset);
LUSC	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18854424	chr1:2615690	NA	-0.49	-9.72	-0.47	8.17e-20	Ulcerative colitis;
LUSC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	0.93	16.02	0.66	3e-43	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27656486	chr14:105635239	JAG2	-0.41	-6.01	-0.31	4.8e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.14	-20.35	-0.74	1.94e-60	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.14e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-0.95	-14.07	-0.61	1.2e-35	Initial pursuit acceleration;
LUSC	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg18357645	chr12:58087776	OS9	0.43	6.46	0.33	3.73e-10	Multiple sclerosis;
LUSC	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg11887960	chr12:57824829	NA	0.55	7.07	0.36	9.13e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg00376283	chr12:123451042	ABCB9	0.58	7.51	0.38	5.49e-13	Neutrophil percentage of white cells;
LUSC	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.09	-0.36	8.12e-12	Blood metabolite levels;
LUSC	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg22529645	chr1:3704559	LRRC47	0.37	6.38	0.33	6.03e-10	Red cell distribution width;
LUSC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg02423579	chr7:2872169	GNA12	-0.42	-6.43	-0.33	4.52e-10	Height;
LUSC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg08888203	chr3:10149979	C3orf24	0.59	8.21	0.41	4.83e-15	Alzheimer's disease;
LUSC	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	11.01	0.52	2.94e-24	Hypertriglyceridemia;
LUSC	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg19774624	chr17:42201019	HDAC5	-0.73	-10.41	-0.5	3.56e-22	Total body bone mineral density;
LUSC	cis	rs7759001	0.857	rs1022518	chr6:27364886	A/G	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs4566357	1.000	rs6436650	chr2:227925097	C/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-6.04	-0.31	4.1e-9	Coronary artery disease;
LUSC	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg10018233	chr7:150070692	REPIN1	0.36	6.31	0.33	8.64e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.63	10.55	0.5	1.24e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.78	11.26	0.52	3.88e-25	Corneal astigmatism;
LUSC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg12257692	chr3:49977190	RBM6	-0.26	-7.41	-0.38	1.03e-12	Body mass index;
LUSC	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.67	10.4	0.49	3.99e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg04518342	chr5:131593106	PDLIM4	0.36	6.5	0.34	2.88e-10	Blood metabolite levels;
LUSC	cis	rs10203711	1.000	rs6731675	chr2:239566943	T/C	cg14580085	chr2:239553406	NA	0.41	6.93	0.35	2.24e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-10.94	-0.51	5.23e-24	Response to antipsychotic treatment;
LUSC	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg24375607	chr4:120327624	NA	0.79	11.78	0.54	5.25e-27	Corneal astigmatism;
LUSC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.28	0.64	2.42e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9815354	0.812	rs17218441	chr3:41987044	A/G	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.72e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg22676075	chr6:135203613	NA	0.47	7.37	0.37	1.39e-12	Red blood cell count;
LUSC	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg26597838	chr10:835615	NA	0.91	12.38	0.56	3.2e-29	Eosinophil percentage of granulocytes;
LUSC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.66	-10.56	-0.5	1.09e-22	Height;
LUSC	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg07148914	chr20:33460835	GGT7	0.54	8.38	0.42	1.53e-15	Height;
LUSC	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg00277334	chr10:82204260	NA	-0.49	-6.77	-0.35	5.89e-11	Post bronchodilator FEV1;
LUSC	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg05805236	chr11:65401703	PCNXL3	-0.63	-10.33	-0.49	6.71e-22	Acne (severe);
LUSC	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg24634471	chr8:143751801	JRK	0.49	7.14	0.36	5.85e-12	Schizophrenia;
LUSC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	5.94	0.31	7e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg08859206	chr1:53392774	SCP2	0.55	9.63	0.47	1.62e-19	Monocyte count;
LUSC	cis	rs12101261	1.000	rs12101255	chr14:81451052	C/T	cg06600135	chr14:81408086	NA	0.43	6.31	0.33	8.74e-10	Graves' disease;
LUSC	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg25930673	chr12:123319894	HIP1R	-0.72	-7.24	-0.37	3.14e-12	Schizophrenia;
LUSC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03352830	chr11:487213	PTDSS2	0.69	8.58	0.42	3.67e-16	Body mass index;
LUSC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07923666	chr12:49932857	KCNH3	-0.5	-6.15	-0.32	2.23e-9	Resting heart rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25913761	chr15:90727560	SEMA4B	0.43	6.85	0.35	3.61e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg22907277	chr7:1156413	C7orf50	0.72	10.44	0.5	2.92e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg05738196	chr6:26577821	NA	0.51	5.91	0.31	8.44e-9	Small cell lung carcinoma;
LUSC	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg03599575	chr15:90893182	GABARAPL3	-0.34	-5.69	-0.3	2.8e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.74	11.8	0.54	4.16e-27	Aortic root size;
LUSC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg06494592	chr3:125709126	NA	-0.52	-5.85	-0.3	1.16e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg05347473	chr6:146136440	FBXO30	0.46	7.97	0.4	2.52e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg22029157	chr1:209979665	IRF6	0.79	10.04	0.48	6.88e-21	Cleft lip with or without cleft palate;
LUSC	cis	rs7577696	0.597	rs2280968	chr2:32290040	G/T	cg02381751	chr2:32503542	YIPF4	-0.51	-6.88	-0.35	2.89e-11	Inflammatory biomarkers;
LUSC	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg06532163	chr17:45867833	NA	0.35	6.53	0.34	2.51e-10	IgG glycosylation;
LUSC	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg20734569	chr3:48348370	SPINK8	-0.46	-7.81	-0.39	7.43e-14	Coronary artery disease;
LUSC	trans	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.85	-0.35	3.67e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs67072384	0.786	rs58424437	chr11:72448256	C/T	cg04827223	chr11:72435913	ARAP1	-0.79	-7.25	-0.37	2.93e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	1.14	19.67	0.73	9.55e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg22535103	chr8:58192502	C8orf71	-0.52	-6.1	-0.32	2.94e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg23634087	chr20:50721797	ZFP64	0.74	6.72	0.35	7.72e-11	Cognitive performance;
LUSC	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg10840412	chr1:235813424	GNG4	0.68	9.13	0.45	6.54e-18	Bipolar disorder;
LUSC	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg10596483	chr8:143751796	JRK	0.61	9.4	0.46	9.11e-19	Schizophrenia;
LUSC	cis	rs4654899	0.758	rs2874367	chr1:21324491	A/C	cg01072550	chr1:21505969	NA	0.47	7.3	0.37	2.19e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-0.93	-14.02	-0.61	1.89e-35	Breast cancer;
LUSC	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg07274523	chr3:49395745	GPX1	0.67	10.52	0.5	1.5e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs2688608	0.839	rs2675662	chr10:75599127	A/G	cg23231163	chr10:75533350	FUT11	0.37	5.78	0.3	1.72e-8	Inflammatory bowel disease;
LUSC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg21573476	chr21:45109991	RRP1B	-0.42	-6.84	-0.35	3.69e-11	Mean corpuscular volume;
LUSC	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg09092052	chr15:45571596	NA	0.46	6.36	0.33	6.52e-10	Glomerular filtration rate;
LUSC	trans	rs11696501	0.694	rs7266372	chr20:44266635	T/C	cg03272292	chr12:48577362	C12orf68	0.49	5.98	0.31	5.75e-9	Brain structure;
LUSC	cis	rs1440088	0.732	rs13386066	chr2:198371687	C/T	cg00982548	chr2:198649783	BOLL	0.49	6.28	0.33	1.02e-9	Ulcerative colitis;
LUSC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg06618935	chr21:46677482	NA	-0.4	-7.67	-0.39	1.92e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2354432	0.607	rs7511989	chr1:146720160	A/G	cg25205988	chr1:146714368	CHD1L	-1.01	-9.45	-0.46	6.1e-19	Mitochondrial DNA levels;
LUSC	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.01	0.52	2.93e-24	Hypertriglyceridemia;
LUSC	cis	rs7605827	0.930	rs11675921	chr2:15569376	C/T	cg19274914	chr2:15703543	NA	-0.44	-8.29	-0.41	2.79e-15	Educational attainment (years of education);
LUSC	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.26e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs61990749	0.597	rs2267761	chr14:78147849	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.61	-6.55	-0.34	2.15e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs3087591	0.683	rs757375	chr17:29717879	C/G	cg24425628	chr17:29625626	OMG;NF1	0.48	7.33	0.37	1.7e-12	Hip circumference;
LUSC	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.73	10.66	0.5	5.08e-23	Corneal astigmatism;
LUSC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg05340658	chr4:99064831	C4orf37	0.43	6.84	0.35	3.74e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.34	-6.27	-0.32	1.14e-9	Monocyte percentage of white cells;
LUSC	cis	rs9906944	0.624	rs2411759	chr17:47071074	C/T	cg14634687	chr17:47094252	IGF2BP1	0.26	5.87	0.31	1.05e-8	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.59	7.93	0.4	3.41e-14	Response to diuretic therapy;
LUSC	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	6.73	0.35	7.37e-11	Lung cancer;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg15227302	chr7:135195347	CNOT4	0.39	5.96	0.31	6.55e-9	Schizophrenia;
LUSC	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.71	-10.12	-0.48	3.62e-21	Corneal astigmatism;
LUSC	cis	rs477692	1.000	rs479478	chr10:131428959	G/A	cg11019008	chr10:131425282	MGMT	0.4	6.0	0.31	5.17e-9	Response to temozolomide;
LUSC	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg07382826	chr16:28625726	SULT1A1	0.27	5.75	0.3	2.06e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7542375	0.655	rs4846670	chr1:221069017	G/T	cg16008148	chr1:221062819	NA	0.35	5.7	0.3	2.66e-8	Obesity-related traits;
LUSC	cis	rs1595825	0.891	rs80178661	chr2:198582442	A/G	cg00982548	chr2:198649783	BOLL	-0.52	-6.67	-0.34	1.07e-10	Ulcerative colitis;
LUSC	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	6.56	0.34	2.02e-10	Iron status biomarkers;
LUSC	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg00191853	chr8:101177733	SPAG1	-0.38	-6.36	-0.33	6.71e-10	Atrioventricular conduction;
LUSC	cis	rs16854884	0.837	rs989665	chr3:143792854	C/T	cg06585982	chr3:143692056	C3orf58	0.47	6.99	0.36	1.53e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg01528321	chr10:82214614	TSPAN14	0.85	12.98	0.58	1.85e-31	Post bronchodilator FEV1;
LUSC	cis	rs12474201	0.832	rs11695058	chr2:46978349	A/G	cg06386533	chr2:46925753	SOCS5	0.67	9.86	0.47	2.76e-20	Height;
LUSC	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.45	0.33	4.01e-10	Corneal astigmatism;
LUSC	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg09307838	chr4:120376055	NA	0.76	11.0	0.52	3.07e-24	Corneal astigmatism;
LUSC	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg06191203	chr2:152266755	RIF1	-0.43	-5.87	-0.31	1.04e-8	Lung cancer;
LUSC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.91	17.28	0.69	3.13e-48	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg05926928	chr17:57297772	GDPD1	-0.48	-6.71	-0.34	8.57e-11	Schizophrenia;
LUSC	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.46	0.53	7.04e-26	Eye color traits;
LUSC	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg03342759	chr3:160939853	NMD3	-0.41	-5.98	-0.31	5.71e-9	Morning vs. evening chronotype;
LUSC	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.48	7.18	0.37	4.47e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18932078	chr1:2524107	MMEL1	0.28	6.22	0.32	1.51e-9	Ulcerative colitis;
LUSC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.74	11.8	0.54	4.16e-27	Aortic root size;
LUSC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg11843238	chr5:131593191	PDLIM4	0.34	5.71	0.3	2.46e-8	Breast cancer;
LUSC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08280861	chr8:58055591	NA	0.57	7.2	0.37	3.94e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg05738196	chr6:26577821	NA	0.79	15.24	0.64	3.59e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg03060546	chr3:49711283	APEH	0.54	7.8	0.39	8.06e-14	Menarche (age at onset);
LUSC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg13683864	chr3:40499215	RPL14	-1.14	-19.9	-0.74	1.12e-58	Renal cell carcinoma;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg06877462	chr1:205807181	PM20D1	0.53	9.91	0.48	1.79e-20	Menarche (age at onset);
LUSC	cis	rs4964805	0.913	rs3812803	chr12:104200460	T/C	cg02344784	chr12:104178138	NT5DC3	0.43	6.96	0.36	1.85e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg21782813	chr7:2030301	MAD1L1	0.37	6.05	0.31	3.84e-9	Schizophrenia;
LUSC	trans	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.63	0.5	6.24e-23	Mean corpuscular volume;
LUSC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg13126279	chr21:47581558	C21orf56	-0.4	-5.78	-0.3	1.75e-8	Testicular germ cell tumor;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09113513	chr11:12695910	TEAD1	-0.36	-6.13	-0.32	2.53e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg14769373	chr6:40998127	UNC5CL	-0.56	-8.04	-0.4	1.54e-14	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg15448220	chr1:150897856	SETDB1	0.42	5.78	0.3	1.73e-8	Melanoma;
LUSC	cis	rs4363385	0.530	rs61815714	chr1:152921380	C/T	cg00922841	chr1:152955080	SPRR1A	-0.37	-6.06	-0.31	3.67e-9	Inflammatory skin disease;
LUSC	cis	rs5167	0.601	rs73047694	chr19:45497852	G/A	cg25746394	chr19:45450501	APOC2	0.31	5.77	0.3	1.83e-8	Blood protein levels;
LUSC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg12963246	chr6:28129442	ZNF389	0.55	7.66	0.39	1.98e-13	Parkinson's disease;
LUSC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06850241	chr22:41845214	NA	0.31	5.8	0.3	1.56e-8	Vitiligo;
LUSC	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg11245181	chr6:149772854	ZC3H12D	0.28	5.95	0.31	6.88e-9	Dupuytren's disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05972000	chr8:67525501	MYBL1	-0.4	-6.1	-0.32	2.99e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9549260	0.564	rs4941990	chr13:41299857	A/C	cg21288729	chr13:41239152	FOXO1	0.53	7.95	0.4	3e-14	Red blood cell count;
LUSC	cis	rs12760731	0.720	rs722321	chr1:178420220	C/T	cg00404053	chr1:178313656	RASAL2	0.62	6.56	0.34	2.09e-10	Obesity-related traits;
LUSC	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.77	13.41	0.59	4.13e-33	Calcium levels;
LUSC	cis	rs17401966	0.540	rs4846199	chr1:10283961	A/G	cg17425144	chr1:10567563	PEX14	-0.33	-5.78	-0.3	1.69e-8	Hepatocellular carcinoma;
LUSC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg05347473	chr6:146136440	FBXO30	-0.59	-10.56	-0.5	1.11e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06002616	chr8:101225028	SPAG1	-0.46	-7.47	-0.38	7.11e-13	Atrioventricular conduction;
LUSC	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg06937882	chr20:24974362	C20orf3	-0.44	-7.49	-0.38	6.07e-13	Blood protein levels;
LUSC	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg05985134	chr18:33552581	C18orf21	-0.57	-7.83	-0.39	6.73e-14	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg03342759	chr3:160939853	NMD3	-0.55	-8.04	-0.4	1.62e-14	Parkinson's disease;
LUSC	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.54	0.42	4.83e-16	Lung cancer in ever smokers;
LUSC	cis	rs13253111	0.624	rs7012030	chr8:28096346	C/T	cg26534493	chr8:28060551	NA	0.38	6.91	0.35	2.47e-11	Childhood body mass index;
LUSC	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg22491629	chr6:157744540	C6orf35	-0.9	-10.97	-0.51	4.22e-24	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg09467607	chr2:36825704	FEZ2	-0.52	-10.95	-0.51	4.95e-24	Height;
LUSC	trans	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	10.67	0.5	4.48e-23	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9436747	0.714	rs1186403	chr1:66000533	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.44	-5.94	-0.31	7.35e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs11051970	0.879	rs1500874	chr12:32589407	G/A	cg02745156	chr12:32552066	NA	0.43	7.29	0.37	2.29e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg19774624	chr17:42201019	HDAC5	-0.66	-10.41	-0.5	3.5e-22	Total body bone mineral density;
LUSC	cis	rs909685	1.000	rs2069235	chr22:39747780	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.48	6.89	0.35	2.75e-11	Rheumatoid arthritis;
LUSC	cis	rs16854884	1.000	rs11924473	chr3:143787075	C/G	cg06585982	chr3:143692056	C3orf58	0.47	6.58	0.34	1.85e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs1506636	1.000	rs2299984	chr7:123356921	G/T	cg03229431	chr7:123269106	ASB15	0.64	10.49	0.5	1.97e-22	Plateletcrit;Platelet count;
LUSC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg02158880	chr13:53174818	NA	0.4	5.92	0.31	7.86e-9	Lewy body disease;
LUSC	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg08000102	chr2:233561755	GIGYF2	0.81	14.11	0.61	8.92e-36	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26314531	chr2:26401878	FAM59B	-0.7	-9.6	-0.47	1.92e-19	Gut microbiome composition (summer);
LUSC	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg03585969	chr10:35415529	CREM	0.6	8.74	0.43	1.12e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg02569458	chr12:86230093	RASSF9	-0.36	-5.87	-0.31	1.07e-8	Major depressive disorder;
LUSC	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg03563238	chr19:33554763	RHPN2	-0.37	-6.34	-0.33	7.24e-10	Bone properties (heel);
LUSC	cis	rs7043114	0.525	rs8067	chr9:95218829	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.37	-6.65	-0.34	1.18e-10	Height;
LUSC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.2	0.37	3.93e-12	Platelet count;
LUSC	cis	rs7215564	0.818	rs34754307	chr17:78652758	C/G	cg23238734	chr17:78661607	RPTOR	0.49	6.28	0.32	1.08e-9	Myopia (pathological);
LUSC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.58	-10.03	-0.48	6.94e-21	Blood metabolite levels;
LUSC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg16405210	chr4:1374714	KIAA1530	-0.56	-8.61	-0.43	3.02e-16	Obesity-related traits;
LUSC	cis	rs860295	0.812	rs12407800	chr1:155760742	A/C	cg08949192	chr1:155289623	RUSC1;FDPS	-0.35	-5.72	-0.3	2.41e-8	Body mass index;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09672082	chr5:271577	PDCD6	-0.51	-6.02	-0.31	4.47e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg18721089	chr20:30220636	NA	-0.37	-5.82	-0.3	1.41e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg18538332	chr22:24372958	LOC391322	-0.47	-8.31	-0.41	2.41e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9640161	0.830	rs11972067	chr7:150071605	G/A	cg10018233	chr7:150070692	REPIN1	0.45	9.06	0.44	1.13e-17	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-10.68	-0.5	4.17e-23	Monocyte percentage of white cells;
LUSC	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg04310649	chr10:35416472	CREM	-0.43	-6.59	-0.34	1.73e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13223928	0.658	rs67519056	chr7:3157176	G/C	cg19214707	chr7:3157722	NA	-0.54	-10.82	-0.51	1.37e-23	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2742417	1.000	rs938362	chr3:45746365	T/C	cg09608765	chr3:45636137	LIMD1	-0.38	-7.51	-0.38	5.48e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs2652822	1.000	rs2652822	chr15:63422772	C/T	cg02713581	chr15:63449717	RPS27L	-0.38	-6.11	-0.32	2.74e-9	Metabolic traits;
LUSC	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.77	-12.92	-0.58	3.06e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs11935423	0.778	rs2866164	chr4:100490943	C/G	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.1	-0.32	3e-9	Gut microbiome composition (summer);
LUSC	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg06002616	chr8:101225028	SPAG1	0.46	7.56	0.38	4.05e-13	Atrioventricular conduction;
LUSC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg18190219	chr22:46762943	CELSR1	-0.42	-5.69	-0.3	2.78e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	10.83	0.51	1.23e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6977660	0.619	rs10223937	chr7:19787697	C/T	cg05791153	chr7:19748676	TWISTNB	0.67	7.27	0.37	2.65e-12	Thyroid stimulating hormone;
LUSC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg04944784	chr2:26401820	FAM59B	0.7	8.98	0.44	2.07e-17	Gut microbiome composition (summer);
LUSC	cis	rs4619890	0.528	rs62289337	chr4:7877939	G/A	cg24250820	chr4:7887609	AFAP1	0.36	6.15	0.32	2.17e-9	Glaucoma (primary open-angle);
LUSC	cis	rs7043114	0.525	rs4744134	chr9:95246833	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.35	6.25	0.32	1.24e-9	Height;
LUSC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.4	0.38	1.13e-12	Schizophrenia;
LUSC	cis	rs71636778	0.543	rs36109400	chr1:27247822	G/A	cg12203394	chr1:27248618	NUDC	0.53	5.65	0.3	3.47e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg15445000	chr17:37608096	MED1	0.39	6.78	0.35	5.4e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg18402987	chr7:1209562	NA	0.74	8.02	0.4	1.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg18681998	chr4:17616180	MED28	0.9	17.51	0.69	3.65e-49	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6556937	0.562	rs6897588	chr5:96003149	T/G	cg07690455	chr5:95997198	CAST	0.47	6.52	0.34	2.54e-10	Blood protein levels;
LUSC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18131467	chr2:239335373	ASB1	1.05	24.68	0.8	2.76e-77	Multiple system atrophy;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11117577	chr8:125551212	TATDN1;NDUFB9	-0.53	-7.04	-0.36	1.07e-11	Hepatitis;
LUSC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg03264133	chr6:25882463	NA	-0.34	-5.77	-0.3	1.84e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg04455712	chr21:45112962	RRP1B	0.46	8.64	0.43	2.31e-16	Mean corpuscular volume;
LUSC	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg00999904	chr2:3704751	ALLC	-0.33	-6.0	-0.31	5.01e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg19196401	chr6:110721138	DDO	0.41	7.69	0.39	1.61e-13	Platelet distribution width;
LUSC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg00376283	chr12:123451042	ABCB9	0.83	13.16	0.58	3.69e-32	Platelet count;
LUSC	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.66	-9.81	-0.47	3.97e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.15	10.47	0.5	2.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg10411590	chr13:21900810	NA	0.3	6.04	0.31	4.04e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs2289328	0.882	rs7164606	chr15:40645133	G/A	cg13931752	chr15:40660718	DISP2	0.47	6.36	0.33	6.61e-10	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-0.82	-11.26	-0.52	3.87e-25	Diastolic blood pressure;
LUSC	cis	rs977987	0.966	rs62060551	chr16:75502312	A/C	cg03315344	chr16:75512273	CHST6	0.55	10.7	0.51	3.58e-23	Dupuytren's disease;
LUSC	cis	rs9314323	0.862	rs7813520	chr8:26263260	C/T	cg13160058	chr8:26243215	BNIP3L	-0.41	-7.44	-0.38	8.49e-13	Red cell distribution width;
LUSC	cis	rs699	0.556	rs2478525	chr1:230865350	C/G	cg07502417	chr1:230849801	AGT	0.26	6.41	0.33	5.03e-10	Coronary artery disease;
LUSC	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.31	6.08	0.32	3.33e-9	Schizophrenia;
LUSC	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.07e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2230307	0.572	rs17122001	chr1:100628311	A/T	cg24955406	chr1:100503596	HIAT1	0.6	6.44	0.33	4.14e-10	Carotid intima media thickness;
LUSC	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg03585969	chr10:35415529	CREM	0.58	8.39	0.42	1.34e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs73198271	0.653	rs10087633	chr8:8660444	A/G	cg01851573	chr8:8652454	MFHAS1	0.48	8.13	0.41	8.32e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg13395646	chr4:1353034	KIAA1530	0.49	6.93	0.35	2.16e-11	Obesity-related traits;
LUSC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg06238570	chr21:40685208	BRWD1	-0.62	-10.38	-0.49	4.53e-22	Cognitive function;
LUSC	cis	rs6736093	0.966	rs74182850	chr2:112681337	C/T	cg12686935	chr2:112915763	FBLN7	-0.37	-5.9	-0.31	8.73e-9	Coronary artery disease;
LUSC	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg13390004	chr1:15929781	NA	0.41	6.88	0.35	3.03e-11	Systolic blood pressure;
LUSC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.64	8.0	0.4	2.02e-14	Lung function (FEV1/FVC);
LUSC	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg11502198	chr6:26597334	ABT1	0.6	9.37	0.46	1.12e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg15145296	chr3:125709740	NA	-0.56	-6.24	-0.32	1.29e-9	Blood pressure (smoking interaction);
LUSC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg15147215	chr3:52552868	STAB1	-0.32	-6.33	-0.33	7.69e-10	Electroencephalogram traits;
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg27094323	chr7:1216898	NA	-0.45	-7.62	-0.38	2.7e-13	Longevity;Endometriosis;
LUSC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.78	10.81	0.51	1.43e-23	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg10560079	chr2:191398806	TMEM194B	-0.68	-8.64	-0.43	2.45e-16	Diastolic blood pressure;
LUSC	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg03340356	chr1:67600835	NA	-0.39	-5.83	-0.3	1.27e-8	Psoriasis;
LUSC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-17.43	-0.69	7.38e-49	Monocyte count;
LUSC	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg27426351	chr10:43362370	NA	-0.43	-6.0	-0.31	5.26e-9	Blood protein levels;
LUSC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg25036284	chr2:26402008	FAM59B	-0.71	-9.77	-0.47	5.35e-20	Gut microbiome composition (summer);
LUSC	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	11.23	0.52	4.73e-25	Platelet count;
LUSC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.3	0.33	9.26e-10	Schizophrenia;
LUSC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg13560548	chr3:10150139	C3orf24	0.53	7.2	0.37	3.99e-12	Alzheimer's disease;
LUSC	cis	rs12220238	1.000	rs7083534	chr10:75955672	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.3	0.37	2.12e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.65	-10.94	-0.51	5.34e-24	Lung cancer;
LUSC	cis	rs68170813	0.559	rs12536603	chr7:107002573	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.56	-0.46	2.74e-19	Coronary artery disease;
LUSC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	17.1	0.68	1.62e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.07	-0.32	3.43e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1007190	0.881	rs71373521	chr17:42949442	C/T	cg15406952	chr17:42872593	NA	0.55	5.67	0.3	3.05e-8	DNA methylation (variation);
LUSC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg03146154	chr1:46216737	IPP	0.5	7.51	0.38	5.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg08501292	chr6:25962987	TRIM38	0.66	5.69	0.3	2.78e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8038465	0.638	rs7495543	chr15:73955133	G/C	cg15420318	chr15:73925796	NPTN	0.61	10.61	0.5	7.53e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs11971779	0.616	rs11771715	chr7:139027496	T/C	cg07862535	chr7:139043722	LUC7L2	0.53	6.58	0.34	1.84e-10	Diisocyanate-induced asthma;
LUSC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg04414720	chr1:150670196	GOLPH3L	0.56	9.1	0.45	8.47e-18	Tonsillectomy;
LUSC	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.88	15.08	0.64	1.52e-39	Morning vs. evening chronotype;
LUSC	cis	rs2859741	0.546	rs2102087	chr1:37482849	G/A	cg09363841	chr1:37513479	NA	-0.4	-7.69	-0.39	1.69e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	0.93	17.66	0.69	8.89e-50	Headache;
LUSC	cis	rs7973719	1.000	rs12828040	chr12:7326541	T/C	cg07052231	chr12:7363540	PEX5	0.53	9.17	0.45	4.89e-18	IgG glycosylation;
LUSC	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg26647111	chr11:31128758	NA	-0.41	-6.0	-0.31	5.27e-9	Red blood cell count;
LUSC	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg03213289	chr20:61660250	NA	0.58	9.65	0.47	1.38e-19	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg03585969	chr10:35415529	CREM	0.65	9.25	0.45	2.78e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg21535247	chr6:8435926	SLC35B3	-0.61	-9.47	-0.46	5.21e-19	Motion sickness;
LUSC	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg27539214	chr16:67997921	SLC12A4	-0.6	-7.42	-0.38	9.57e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg13010199	chr12:38710504	ALG10B	0.67	10.22	0.49	1.58e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4363385	0.747	rs1611760	chr1:152957573	T/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.78	-0.39	9.11e-14	Inflammatory skin disease;
LUSC	cis	rs2835872	0.931	rs10483038	chr21:39024771	T/C	cg20424643	chr21:39039972	KCNJ6	0.48	7.11	0.36	7.14e-12	Electroencephalographic traits in alcoholism;
LUSC	cis	rs240764	0.853	rs11155496	chr6:100988939	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.08	-0.32	3.38e-9	Neuroticism;
LUSC	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08645402	chr16:4508243	NA	0.5	8.41	0.42	1.24e-15	Schizophrenia;
LUSC	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg06064525	chr11:970664	AP2A2	-0.29	-5.68	-0.3	2.94e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg03676636	chr4:99064102	C4orf37	0.37	8.04	0.4	1.58e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg08847533	chr14:75593920	NEK9	0.84	15.45	0.65	5.43e-41	Height;
LUSC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-6.66	-0.34	1.11e-10	Mean corpuscular volume;
LUSC	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.66e-9	Response to antipsychotic treatment;
LUSC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08470875	chr2:26401718	FAM59B	-0.65	-8.86	-0.44	4.68e-17	Gut microbiome composition (summer);
LUSC	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg10523679	chr1:76189770	ACADM	0.47	6.86	0.35	3.43e-11	Daytime sleep phenotypes;
LUSC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	1.02	17.67	0.7	8.45e-50	Parkinson's disease;
LUSC	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg15744005	chr10:104629667	AS3MT	-0.29	-6.22	-0.32	1.46e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs12410462	0.581	rs77430808	chr1:227540880	C/T	cg04117972	chr1:227635322	NA	0.6	6.82	0.35	4.41e-11	Major depressive disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01249180	chr5:95997867	CAST	0.42	6.31	0.33	8.89e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg22907277	chr7:1156413	C7orf50	0.68	7.31	0.37	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03532510	chr1:224544720	CNIH4	-0.43	-6.4	-0.33	5.26e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg26384229	chr12:38710491	ALG10B	0.5	7.15	0.36	5.4e-12	Morning vs. evening chronotype;
LUSC	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg07169764	chr2:136633963	MCM6	1.16	16.34	0.67	1.58e-44	Corneal structure;
LUSC	cis	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg17469321	chr7:55412551	NA	0.65	10.63	0.5	6.09e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg00677455	chr12:58241039	CTDSP2	0.54	6.92	0.35	2.26e-11	Multiple sclerosis;
LUSC	trans	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.75	-10.17	-0.49	2.38e-21	Blood trace element (Cu levels);
LUSC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-5.79	-0.3	1.66e-8	Systolic blood pressure;
LUSC	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg15423357	chr2:25149977	NA	0.37	7.19	0.37	4.29e-12	Body mass index in non-asthmatics;
LUSC	cis	rs7428496	0.510	rs13072346	chr3:142300002	G/A	cg16271453	chr3:142027066	XRN1	-0.48	-8.13	-0.41	8.33e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs10746514	1.000	rs61835640	chr1:232245014	G/A	cg09506761	chr1:232265262	NA	0.46	7.35	0.37	1.57e-12	Response to statin therapy;
LUSC	trans	rs724744	0.742	rs1205933	chr6:22358361	G/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.07	-0.32	3.43e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs9815354	0.516	rs115135603	chr3:42031622	T/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg14092571	chr14:90743983	NA	-0.88	-18.4	-0.71	1.03e-52	Gut microbiota (bacterial taxa);
LUSC	cis	rs35883536	0.566	rs10783141	chr1:101043897	G/A	cg06223162	chr1:101003688	GPR88	-0.48	-9.12	-0.45	7.32e-18	Monocyte count;
LUSC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02475777	chr4:1388615	CRIPAK	-0.6	-8.94	-0.44	2.65e-17	Longevity;
LUSC	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.9	12.15	0.55	2.14e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs250677	0.522	rs10045726	chr5:148352990	C/T	cg18129178	chr5:148520854	ABLIM3	0.54	7.6	0.38	2.97e-13	Breast cancer;
LUSC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg24250549	chr1:154909240	PMVK	0.56	8.7	0.43	1.57e-16	Prostate cancer;
LUSC	cis	rs16854884	0.657	rs1867609	chr3:143752916	A/G	cg06585982	chr3:143692056	C3orf58	0.5	7.91	0.4	3.89e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	6.07	0.32	3.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs4654899	0.758	rs6697284	chr1:21295599	G/A	cg01072550	chr1:21505969	NA	-0.53	-8.08	-0.4	1.23e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg05623727	chr3:50126028	RBM5	-0.32	-5.94	-0.31	7.12e-9	Menarche (age at onset);
LUSC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg18758796	chr5:131593413	PDLIM4	0.44	7.23	0.37	3.26e-12	Breast cancer;
LUSC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg15445000	chr17:37608096	MED1	0.39	6.64	0.34	1.3e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg05714579	chr10:131428358	MGMT	0.4	5.64	0.3	3.54e-8	Response to temozolomide;
LUSC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs16867321	0.950	rs4667228	chr2:181498824	T/A	cg23363182	chr2:181467187	NA	-0.44	-5.74	-0.3	2.16e-8	Obesity;
LUSC	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06022373	chr22:39101656	GTPBP1	0.82	13.25	0.59	1.72e-32	Menopause (age at onset);
LUSC	cis	rs6484504	0.532	rs7121949	chr11:31288160	G/T	cg26647111	chr11:31128758	NA	-0.41	-5.86	-0.31	1.12e-8	Red blood cell count;
LUSC	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.13	0.41	8.56e-15	Axial length;
LUSC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg08470875	chr2:26401718	FAM59B	-0.7	-9.13	-0.45	6.74e-18	Gut microbiome composition (summer);
LUSC	trans	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg24247370	chr13:99142703	STK24	-0.34	-6.3	-0.33	9.6e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22590775	chr19:49891494	CCDC155	0.57	8.28	0.41	3.06e-15	Multiple sclerosis;
LUSC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg14773178	chr5:1868261	NA	0.31	5.8	0.3	1.5e-8	Cardiovascular disease risk factors;
LUSC	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg12620499	chr2:216877984	MREG	0.92	15.42	0.64	6.74e-41	Alcohol dependence;
LUSC	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg24675056	chr1:15929824	NA	0.48	8.33	0.41	2.17e-15	Systolic blood pressure;
LUSC	cis	rs10875746	0.951	rs58865997	chr12:48566873	G/A	cg13454099	chr12:49076203	C12orf41	-0.51	-5.95	-0.31	6.91e-9	Longevity (90 years and older);
LUSC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07507251	chr3:52567010	NT5DC2	-0.42	-7.58	-0.38	3.46e-13	Bipolar disorder;
LUSC	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg02527881	chr3:46936655	PTH1R	-0.39	-6.85	-0.35	3.66e-11	Colorectal cancer;
LUSC	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg18904891	chr8:8559673	CLDN23	0.59	8.1	0.41	1.03e-14	Obesity-related traits;
LUSC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg19539972	chr4:7069911	GRPEL1	0.71	8.67	0.43	1.87e-16	Monocyte percentage of white cells;
LUSC	trans	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg06521331	chr12:34319734	NA	-0.39	-5.95	-0.31	6.77e-9	Bladder cancer;
LUSC	cis	rs7582180	0.817	rs7559464	chr2:100906323	A/G	cg08017756	chr2:100939284	LONRF2	-0.35	-5.82	-0.3	1.39e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.26	-0.32	1.2e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3770081	1.000	rs58365138	chr2:86213105	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.04	-6.7	-0.34	8.99e-11	Facial emotion recognition (sad faces);
LUSC	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg13042288	chr15:90349979	ANPEP	-0.41	-6.27	-0.32	1.13e-9	Uric acid levels;
LUSC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg04352962	chr1:209979756	IRF6	0.54	7.16	0.36	5.32e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23158103	chr7:148848205	ZNF398	-0.42	-6.56	-0.34	2.11e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.31e-41	Bladder cancer;
LUSC	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg11584989	chr19:19387371	SF4	0.62	7.39	0.38	1.16e-12	Bipolar disorder;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	0.54	9.23	0.45	3.21e-18	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg17330251	chr7:94953956	PON1	-0.37	-5.86	-0.31	1.1e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg26220594	chr1:19110978	NA	-0.34	-5.71	-0.3	2.54e-8	Knee osteoarthritis;
LUSC	cis	rs997295	0.554	rs28568344	chr15:68096527	A/G	cg08079166	chr15:68083412	MAP2K5	0.37	7.78	0.39	9.09e-14	Motion sickness;
LUSC	cis	rs727505	0.954	rs67146030	chr7:124561790	T/G	cg23710748	chr7:124431027	NA	-0.42	-7.42	-0.38	9.76e-13	Lewy body disease;
LUSC	cis	rs6700896	0.897	rs7518710	chr1:66168238	G/A	cg04111102	chr1:66153794	NA	-0.33	-6.97	-0.36	1.68e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg11062466	chr8:58055876	NA	0.65	8.96	0.44	2.3e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs354225	0.544	rs13399656	chr2:54802696	T/G	cg01766943	chr2:54829624	SPTBN1	0.49	7.84	0.39	6.04e-14	Schizophrenia;
LUSC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23158103	chr7:148848205	ZNF398	-0.49	-7.87	-0.4	4.86e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2617583	0.967	rs2550947	chr5:1450506	T/C	cg07148919	chr5:1466943	LPCAT1	0.39	5.92	0.31	7.94e-9	Breast cancer;
LUSC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg05347473	chr6:146136440	FBXO30	0.53	9.04	0.44	1.3e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1790761	0.505	rs7941648	chr11:67347595	C/T	cg24690094	chr11:67383802	NA	-0.3	-5.75	-0.3	1.98e-8	Mean corpuscular volume;
LUSC	cis	rs3820928	1.000	rs10167422	chr2:227777554	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.96	-0.4	2.8e-14	Pulmonary function;
LUSC	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg07937631	chr13:79184529	NA	-0.42	-6.85	-0.35	3.5e-11	Large artery stroke;
LUSC	cis	rs6977940	0.818	rs11769302	chr7:2898839	C/T	cg19731401	chr7:2775893	GNA12	0.66	7.95	0.4	3e-14	White matter integrity;
LUSC	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.64	-10.04	-0.48	6.54e-21	Brugada syndrome;
LUSC	cis	rs2230307	0.536	rs581097	chr1:100515920	C/T	cg24955406	chr1:100503596	HIAT1	0.57	6.15	0.32	2.23e-9	Carotid intima media thickness;
LUSC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg06263672	chr7:65235340	NA	0.43	6.17	0.32	1.97e-9	Calcium levels;
LUSC	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg16423285	chr20:60520624	NA	0.94	13.06	0.58	8.84e-32	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1564271	0.553	rs9334138	chr10:26978929	G/A	cg13837822	chr10:26931731	LOC731789	0.45	9.73	0.47	7.27e-20	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUSC	cis	rs11625487	1.000	rs11625487	chr14:77961609	G/C	cg20045696	chr14:77926864	AHSA1	0.45	6.03	0.31	4.39e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs7827545	1.000	rs1372659	chr8:135566779	T/A	cg17885191	chr8:135476712	NA	0.57	8.5	0.42	6.26e-16	Hypertension (SNP x SNP interaction);
LUSC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg26335602	chr6:28129616	ZNF389	0.46	6.34	0.33	7.57e-10	Parkinson's disease;
LUSC	cis	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24549020	chr5:56110836	MAP3K1	0.49	5.7	0.3	2.69e-8	Initial pursuit acceleration;
LUSC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg02931644	chr1:25747376	RHCE	0.32	5.79	0.3	1.59e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs926938	0.505	rs360593	chr1:115472265	T/G	cg12756093	chr1:115239321	AMPD1	0.46	7.04	0.36	1.13e-11	Autism;
LUSC	cis	rs2425143	1.000	rs4504072	chr20:34448773	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.98	-0.31	5.8e-9	Blood protein levels;
LUSC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg20135002	chr11:47629003	NA	-0.52	-8.29	-0.41	2.81e-15	Subjective well-being;
LUSC	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg05468064	chr22:46423449	NA	0.43	6.61	0.34	1.5e-10	Dupuytren's disease;
LUSC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.65	-0.5	5.44e-23	Aortic root size;
LUSC	trans	rs6076960	0.811	rs6053960	chr20:6176778	T/C	cg17788362	chr6:86352627	SYNCRIP	0.4	5.98	0.31	5.81e-9	Smooth-surface caries;
LUSC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg04369109	chr6:150039330	LATS1	-0.6	-8.83	-0.43	6.2e-17	Lung cancer;
LUSC	cis	rs62400317	0.859	rs11964844	chr6:45258823	T/A	cg18551225	chr6:44695536	NA	-0.42	-7.05	-0.36	1.03e-11	Total body bone mineral density;
LUSC	cis	rs2303282	0.865	rs446167	chr16:56559465	G/A	cg00500540	chr16:56394104	NA	0.43	6.96	0.36	1.8e-11	Breast cancer;
LUSC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg23711669	chr6:146136114	FBXO30	0.87	15.93	0.66	6.54e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20546810	chr20:2489835	ZNF343	0.8	6.17	0.32	1.97e-9	Cognitive performance;
LUSC	trans	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg02679955	chr17:73521473	LLGL2	0.4	5.94	0.31	7.01e-9	Mood instability;
LUSC	cis	rs4851254	0.660	rs4851244	chr2:100671449	C/T	cg07810366	chr2:100720526	AFF3	0.43	5.91	0.31	8.4e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10203711	1.000	rs6713610	chr2:239566874	C/A	cg14580085	chr2:239553406	NA	0.41	6.93	0.35	2.24e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg00277334	chr10:82204260	NA	-0.5	-6.86	-0.35	3.37e-11	Post bronchodilator FEV1;
LUSC	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs11039798	1.000	rs9667626	chr11:48485877	T/C	cg15704280	chr7:45808275	SEPT13	0.71	6.62	0.34	1.46e-10	Axial length;
LUSC	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg13010344	chr12:123464640	ARL6IP4	0.47	6.43	0.33	4.31e-10	Neutrophil percentage of white cells;
LUSC	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.16	0.52	8.54e-25	Hypertriglyceridemia;
LUSC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg09034736	chr1:150693464	HORMAD1	0.48	6.91	0.35	2.44e-11	Tonsillectomy;
LUSC	cis	rs617219	0.889	rs10069036	chr5:78469223	A/T	cg24856658	chr5:78533917	JMY	-0.3	-5.75	-0.3	1.98e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.86	14.25	0.61	2.62e-36	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg15605315	chr1:45957053	TESK2	0.5	8.48	0.42	7.48e-16	High light scatter reticulocyte count;
LUSC	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg09085632	chr11:111637200	PPP2R1B	0.45	6.34	0.33	7.65e-10	Primary sclerosing cholangitis;
LUSC	cis	rs2274273	0.624	rs11848575	chr14:55755788	A/G	cg04306507	chr14:55594613	LGALS3	0.48	9.85	0.47	2.9e-20	Protein biomarker;
LUSC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg21285383	chr16:89894308	SPIRE2	0.34	7.09	0.36	7.96e-12	Vitiligo;
LUSC	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9400467	0.528	rs465795	chr6:111676443	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Blood metabolite levels;Amino acid levels;
LUSC	trans	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg04995722	chr7:26192034	NFE2L3	-0.36	-5.96	-0.31	6.23e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg26335602	chr6:28129616	ZNF389	0.45	6.13	0.32	2.43e-9	Depression;
LUSC	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg23306229	chr2:178417860	TTC30B	0.51	5.66	0.3	3.3e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.87	14.82	0.63	1.59e-38	Bladder cancer;
LUSC	cis	rs4888262	0.508	rs4544266	chr16:74660993	C/A	cg01733217	chr16:74700730	RFWD3	0.73	11.71	0.54	8.82e-27	Testicular germ cell tumor;
LUSC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.98	-0.36	1.63e-11	Colorectal cancer;
LUSC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg05941027	chr17:61774174	LIMD2	0.22	5.79	0.3	1.64e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg05585544	chr11:47624801	NA	-0.42	-7.14	-0.36	5.74e-12	Subjective well-being;
LUSC	cis	rs9788721	0.836	rs17483721	chr15:78733731	C/T	cg18825076	chr15:78729989	IREB2	0.56	9.2	0.45	3.91e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs2282300	0.696	rs12578061	chr11:30249365	T/A	cg06241208	chr11:30344200	C11orf46	-0.44	-5.65	-0.3	3.52e-8	Morning vs. evening chronotype;
LUSC	cis	rs10754283	0.967	rs4658130	chr1:90113447	G/C	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs11126435	0.641	rs6709863	chr2:74746080	C/T	cg04255230	chr2:74727010	LBX2	0.43	6.88	0.35	2.88e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg04374321	chr14:90722782	PSMC1	0.76	12.04	0.55	5.82e-28	Mortality in heart failure;
LUSC	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.92	15.75	0.65	3.5e-42	Bladder cancer;
LUSC	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg11887960	chr12:57824829	NA	0.54	6.8	0.35	4.89e-11	Obesity-related traits;
LUSC	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg14689365	chr7:158441557	NCAPG2	0.53	7.55	0.38	4.24e-13	Height;
LUSC	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.19	0.32	1.72e-9	Lymphocyte counts;
LUSC	cis	rs17253792	0.731	rs8008528	chr14:56062052	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.96	-0.36	1.81e-11	Putamen volume;
LUSC	cis	rs7587476	0.601	rs13021937	chr2:215673937	C/T	cg04004882	chr2:215674386	BARD1	-0.53	-7.37	-0.37	1.34e-12	Neuroblastoma;
LUSC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg16325326	chr1:53192061	ZYG11B	-0.98	-20.0	-0.74	4.61e-59	Monocyte count;
LUSC	cis	rs7246967	0.604	rs8107322	chr19:22897432	A/C	cg23217946	chr19:22817039	ZNF492	0.41	5.68	0.3	2.93e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.34	-0.42	2.01e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	5.89	0.31	9.39e-9	Personality dimensions;
LUSC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg03579872	chr1:53393473	SCP2	0.39	5.75	0.3	2.01e-8	Monocyte count;
LUSC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg06238570	chr21:40685208	BRWD1	0.52	7.96	0.4	2.75e-14	Cognitive function;
LUSC	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-6.33	-0.33	7.89e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg13010199	chr12:38710504	ALG10B	0.4	5.78	0.3	1.69e-8	Morning vs. evening chronotype;
LUSC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.84	0.35	3.83e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg05340658	chr4:99064831	C4orf37	-0.47	-7.45	-0.38	8.22e-13	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9467773	0.572	rs2076029	chr6:26390830	T/C	cg09904177	chr6:26538194	HMGN4	-0.52	-7.75	-0.39	1.1e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs8077577	0.895	rs62072468	chr17:18118179	A/G	cg16794390	chr17:18148240	FLII	0.41	5.75	0.3	2.01e-8	Obesity-related traits;
LUSC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg04450456	chr4:17643702	FAM184B	0.35	5.81	0.3	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg16576597	chr16:28551801	NUPR1	0.28	5.76	0.3	1.92e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.58	9.7	0.47	9.12e-20	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.57	0.38	3.75e-13	Blood metabolite levels;
LUSC	cis	rs134594	0.961	rs134599	chr22:29472863	G/A	cg03665785	chr22:29458676	C22orf31	0.28	5.75	0.3	1.96e-8	Birth weight;
LUSC	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg00277334	chr10:82204260	NA	0.48	6.5	0.33	2.99e-10	Post bronchodilator FEV1;
LUSC	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.77	11.09	0.52	1.49e-24	Corneal astigmatism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23071962	chr2:12856964	TRIB2	-0.49	-6.09	-0.32	3.15e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11077815	0.815	rs7223304	chr17:74447090	C/T	cg06840243	chr17:74442338	UBE2O	-0.35	-6.23	-0.32	1.42e-9	Lymphocyte counts;
LUSC	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.59	-8.04	-0.4	1.6e-14	Red cell distribution width;
LUSC	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg00757033	chr12:89920650	WDR51B	0.52	8.87	0.44	4.45e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg22638593	chr5:131593259	PDLIM4	0.42	6.24	0.32	1.31e-9	Breast cancer;
LUSC	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg11871910	chr12:69753446	YEATS4	0.45	5.86	0.31	1.13e-8	Response to diuretic therapy;
LUSC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03452623	chr4:187889614	NA	0.52	7.83	0.39	6.39e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3820068	0.608	rs12091750	chr1:16042766	T/C	cg24675056	chr1:15929824	NA	0.41	6.84	0.35	3.9e-11	Systolic blood pressure;
LUSC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg22834771	chr12:69754056	YEATS4	-0.45	-6.46	-0.33	3.72e-10	Blood protein levels;
LUSC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.58	0.46	2.27e-19	Bipolar disorder;
LUSC	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg14092571	chr14:90743983	NA	-0.35	-5.83	-0.3	1.29e-8	Mortality in heart failure;
LUSC	cis	rs10761482	0.500	rs4540900	chr10:62308734	C/T	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.58e-12	Schizophrenia;
LUSC	cis	rs2708977	0.730	rs596069	chr2:97076642	C/T	cg01950434	chr2:97203154	ARID5A	0.47	6.72	0.34	7.98e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg15605315	chr1:45957053	TESK2	-0.39	-5.98	-0.31	5.67e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	12.07	0.55	4.52e-28	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg18904891	chr8:8559673	CLDN23	-0.41	-6.28	-0.32	1.05e-9	Mood instability;
LUSC	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg13736514	chr6:26305472	NA	-0.46	-9.19	-0.45	4.3e-18	Educational attainment;
LUSC	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg25730555	chr22:47059586	GRAMD4	0.44	6.96	0.36	1.79e-11	Urate levels in obese individuals;
LUSC	cis	rs12980942	0.748	rs35501756	chr19:41823497	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.14	0.32	2.37e-9	Coronary artery disease;
LUSC	trans	rs17767294	0.522	rs78037434	chr6:27848898	A/T	cg23539494	chr17:65276751	NA	0.76	6.31	0.33	8.83e-10	Parkinson's disease;
LUSC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg18827107	chr12:86230957	RASSF9	0.45	6.86	0.35	3.4e-11	Major depressive disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20204401	chr17:78010341	CCDC40;TBC1D16	-0.43	-6.31	-0.33	9.01e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.72	13.06	0.58	8.81e-32	Platelet distribution width;
LUSC	cis	rs36715	1.000	rs36702	chr5:127552723	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	6.67	0.34	1.04e-10	Breast cancer;
LUSC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg00343986	chr7:65444356	GUSB	-0.41	-6.07	-0.32	3.41e-9	Aortic root size;
LUSC	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg11861562	chr11:117069780	TAGLN	0.35	6.81	0.35	4.51e-11	Blood protein levels;
LUSC	cis	rs10740039	0.810	rs1442543	chr10:62373462	T/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.89	-0.35	2.85e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-5.95	-0.31	6.62e-9	Monocyte count;
LUSC	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg26597838	chr10:835615	NA	-0.49	-6.68	-0.34	1.02e-10	Response to angiotensin II receptor blocker therapy;
LUSC	trans	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.35	0.49	5.71e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg02782426	chr3:40428986	ENTPD3	0.41	7.71	0.39	1.41e-13	Renal cell carcinoma;
LUSC	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg09092052	chr15:45571596	NA	0.46	6.34	0.33	7.51e-10	Glomerular filtration rate;
LUSC	cis	rs2797160	0.515	rs9375409	chr6:125972798	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-5.88	-0.31	9.89e-9	Endometrial cancer;
LUSC	cis	rs2562152	0.654	rs216600	chr16:110165	T/C	cg02949481	chr16:131562	MPG	0.48	5.78	0.3	1.69e-8	Glioblastoma;
LUSC	trans	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg25482853	chr8:67687455	SGK3	0.79	10.99	0.52	3.39e-24	Obesity-related traits;
LUSC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.48	0.38	6.75e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.86	-0.31	1.1e-8	IgG glycosylation;
LUSC	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg12620499	chr2:216877984	MREG	0.98	17.83	0.7	1.88e-50	Alcohol dependence;
LUSC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.03	0.31	4.3e-9	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.47	-7.97	-0.4	2.58e-14	Vitiligo;
LUSC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.9	14.52	0.62	2.26e-37	Systemic lupus erythematosus;
LUSC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08645402	chr16:4508243	NA	0.52	8.82	0.43	6.66e-17	Schizophrenia;
LUSC	cis	rs500891	0.525	rs9800770	chr6:84070313	C/T	cg08257003	chr6:84140564	ME1	0.35	8.49	0.42	6.69e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.65	-10.08	-0.48	4.75e-21	Obesity-related traits;
LUSC	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg20587970	chr11:113659929	NA	-1.27	-15.95	-0.66	5.89e-43	Hip circumference adjusted for BMI;
LUSC	cis	rs2860975	1.000	rs11188133	chr10:96772015	G/A	cg09036531	chr10:96991505	NA	-0.41	-5.72	-0.3	2.35e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg08601574	chr20:25228251	PYGB	0.42	6.29	0.33	9.95e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg27411982	chr8:10470053	RP1L1	0.49	7.66	0.39	1.99e-13	Monocyte count;
LUSC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg04287289	chr16:89883240	FANCA	0.54	8.4	0.42	1.26e-15	Vitiligo;
LUSC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg08213375	chr14:104286397	PPP1R13B	0.46	8.28	0.41	2.9e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg02772935	chr3:125709198	NA	-0.48	-5.76	-0.3	1.91e-8	Blood pressure (smoking interaction);
LUSC	cis	rs30380	0.632	rs27045	chr5:96138861	C/T	cg16492584	chr5:96139282	ERAP1	-0.58	-7.83	-0.39	6.65e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg14440974	chr22:39074834	NA	0.34	5.72	0.3	2.31e-8	Menopause (age at onset);
LUSC	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg14500267	chr11:67383377	NA	0.35	6.6	0.34	1.66e-10	Mean corpuscular volume;
LUSC	cis	rs10170846	1.000	rs10170846	chr2:223517705	C/G	cg25565276	chr2:223520875	FARSB	-0.67	-10.05	-0.48	6.17e-21	Schizophrenia (inflammation and infection response interaction);
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg22331096	chr8:128749328	MYC	0.39	6.1	0.32	2.87e-9	Schizophrenia (age at onset);
LUSC	cis	rs7707921	1.000	rs1019806	chr5:81551659	G/A	cg15871215	chr5:81402204	ATG10	0.44	6.43	0.33	4.35e-10	Breast cancer;
LUSC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.7	-0.34	9.12e-11	Alzheimer's disease (late onset);
LUSC	trans	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg10756647	chr7:56101905	PSPH	0.86	8.51	0.42	6.01e-16	Gout;
LUSC	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg10483660	chr13:112241077	NA	0.36	6.15	0.32	2.18e-9	Menarche (age at onset);
LUSC	cis	rs7315438	0.560	rs12824482	chr12:115888507	C/T	cg24172291	chr12:115889509	NA	-0.34	-5.82	-0.3	1.41e-8	Colorectal cancer;
LUSC	cis	rs9916302	0.821	rs11078916	chr17:37746307	T/C	cg07936489	chr17:37558343	FBXL20	-0.55	-7.34	-0.37	1.61e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs9311676	0.656	rs62258093	chr3:58371745	T/C	cg13750441	chr3:58318267	PXK	0.35	6.7	0.34	9.04e-11	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.77	-12.73	-0.57	1.56e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-7.46	-0.38	7.78e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-7.97	-0.4	2.52e-14	Bone mineral density;
LUSC	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg24130564	chr14:104152367	KLC1	-0.51	-7.42	-0.38	9.85e-13	Body mass index;
LUSC	trans	rs9380880	0.826	rs2273062	chr6:39550935	C/A	cg19893670	chr10:60097505	UBE2D1	0.65	5.96	0.31	6.24e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	0.58	9.13	0.45	6.85e-18	Breast cancer;
LUSC	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg00898013	chr13:113819073	PROZ	-0.57	-8.06	-0.4	1.38e-14	Platelet distribution width;
LUSC	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg14154082	chr13:112174009	NA	0.37	7.68	0.39	1.77e-13	Menarche (age at onset);
LUSC	trans	rs1941687	0.797	rs9953948	chr18:31399399	G/A	cg27147174	chr7:100797783	AP1S1	-0.44	-6.34	-0.33	7.57e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	1.05	19.04	0.72	3.07e-55	Menopause (age at onset);
LUSC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg18512352	chr11:47633146	NA	-0.46	-9.19	-0.45	4.42e-18	Subjective well-being;
LUSC	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.01	-0.31	4.99e-9	Retinal vascular caliber;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg16162350	chr3:168867412	MECOM	0.74	6.53	0.34	2.45e-10	Body mass index;
LUSC	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.8	12.93	0.58	2.67e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-0.81	-16.0	-0.66	3.69e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg13607699	chr17:42295918	UBTF	0.49	7.71	0.39	1.43e-13	Total body bone mineral density;
LUSC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg17264618	chr3:40429014	ENTPD3	-0.31	-6.47	-0.33	3.55e-10	Renal cell carcinoma;
LUSC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg09877947	chr5:131593287	PDLIM4	0.48	7.81	0.39	7.72e-14	Breast cancer;
LUSC	cis	rs6681460	0.932	rs602513	chr1:67177270	G/A	cg02459107	chr1:67143332	SGIP1	0.49	9.12	0.45	7.42e-18	Presence of antiphospholipid antibodies;
LUSC	cis	rs6982240	0.514	rs10481414	chr8:142275326	T/C	cg00131261	chr8:142287264	NA	-0.36	-6.05	-0.31	3.99e-9	Tonsillectomy;
LUSC	trans	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg13565492	chr6:43139072	SRF	-0.57	-6.05	-0.31	3.93e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg07930552	chr6:133119739	C6orf192	0.73	9.48	0.46	5e-19	Type 2 diabetes nephropathy;
LUSC	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg07606381	chr6:8435919	SLC35B3	-0.71	-11.44	-0.53	8.44e-26	Motion sickness;
LUSC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1775715	0.737	rs2799015	chr10:32107712	C/T	cg04359828	chr10:32216031	ARHGAP12	0.41	6.95	0.36	1.95e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.39	-5.79	-0.3	1.58e-8	Schizophrenia;
LUSC	cis	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05901451	chr6:126070800	HEY2	0.56	8.46	0.42	8.35e-16	Endometrial cancer;
LUSC	cis	rs6723226	0.699	rs805830	chr2:32501475	T/C	cg02381751	chr2:32503542	YIPF4	0.62	9.19	0.45	4.35e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.89	0.61	6.08e-35	Platelet count;
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23978390	chr7:1156363	C7orf50	0.5	7.1	0.36	7.49e-12	Longevity;Endometriosis;
LUSC	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg06092702	chr1:163392909	NA	-0.47	-7.82	-0.39	7.14e-14	Motion sickness;
LUSC	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg23505145	chr19:12996616	KLF1	0.64	10.77	0.51	2.08e-23	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1971762	0.583	rs1864448	chr12:54087856	T/G	cg23533419	chr12:54090519	NA	-0.38	-6.2	-0.32	1.64e-9	Height;
LUSC	cis	rs2354432	0.607	rs1530336	chr1:146685121	G/A	cg25205988	chr1:146714368	CHD1L	1.08	8.58	0.42	3.65e-16	Mitochondrial DNA levels;
LUSC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.55	7.97	0.4	2.51e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1775715	0.737	rs2799017	chr10:32203460	A/G	cg26784012	chr10:32216390	ARHGAP12	0.47	7.91	0.4	3.91e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg14343924	chr8:8086146	FLJ10661	-0.38	-5.69	-0.3	2.73e-8	Mood instability;
LUSC	cis	rs897080	0.552	rs1067326	chr2:44628605	T/A	cg00619915	chr2:44497795	NA	-0.41	-5.8	-0.3	1.54e-8	Height;
LUSC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg18827107	chr12:86230957	RASSF9	-0.44	-6.56	-0.34	2.07e-10	Major depressive disorder;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg27050229	chr1:856693	NA	0.5	6.03	0.31	4.45e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9547692	1.000	rs9531993	chr13:37475197	G/C	cg01493522	chr13:37497338	NA	-0.42	-6.23	-0.32	1.37e-9	Coronary artery disease;
LUSC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg22532475	chr10:104410764	TRIM8	0.3	6.0	0.31	5.1e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg18904891	chr8:8559673	CLDN23	0.59	8.15	0.41	7.49e-15	Obesity-related traits;
LUSC	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.74	11.09	0.52	1.54e-24	Eosinophil percentage of white cells;
LUSC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-6.43	-0.33	4.33e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg19812747	chr11:111475976	SIK2	0.55	7.72	0.39	1.39e-13	Primary sclerosing cholangitis;
LUSC	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg04896959	chr15:78267971	NA	0.51	10.78	0.51	1.95e-23	Coronary artery disease or large artery stroke;
LUSC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg20283391	chr11:68216788	NA	-0.55	-8.13	-0.41	8.23e-15	Total body bone mineral density;
LUSC	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs6084875	0.840	rs2422936	chr20:4720830	C/T	cg07258627	chr20:4721683	PRNT	-0.34	-6.07	-0.32	3.4e-9	Systemic lupus erythematosus;
LUSC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg01416388	chr22:39784598	NA	-0.44	-6.79	-0.35	5.15e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs629535	0.734	rs542288	chr8:70057149	G/T	cg21567404	chr3:27674614	NA	-0.95	-15.52	-0.65	2.84e-41	Dupuytren's disease;
LUSC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06634786	chr22:41940651	POLR3H	-0.5	-6.24	-0.32	1.29e-9	Vitiligo;
LUSC	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.14	0.41	8.12e-15	Coffee consumption (cups per day);
LUSC	cis	rs597583	0.806	rs2276339	chr11:117395481	G/A	cg27161313	chr11:117392002	DSCAML1	-0.42	-7.06	-0.36	9.78e-12	Putamen volume;
LUSC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg26102564	chr10:131424627	MGMT	0.4	6.29	0.33	9.76e-10	Response to temozolomide;
LUSC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg25036284	chr2:26402008	FAM59B	0.77	11.34	0.53	1.89e-25	Gut microbiome composition (summer);
LUSC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.25	0.52	4.18e-25	Menopause (age at onset);
LUSC	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg06219351	chr7:158114137	PTPRN2	-0.54	-8.37	-0.42	1.65e-15	Response to amphetamines;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22559669	chr4:99580121	TSPAN5	-0.4	-6.08	-0.32	3.35e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg20129853	chr10:51489980	NA	-0.35	-7.0	-0.36	1.38e-11	Prostate-specific antigen levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21362455	chr6:24495072	ALDH5A1	0.78	6.26	0.32	1.17e-9	Cognitive performance;
LUSC	trans	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg02800362	chr5:177631904	HNRNPAB	0.88	13.12	0.58	5.45e-32	Obesity-related traits;
LUSC	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg17120908	chr11:65337727	SSSCA1	-0.54	-9.3	-0.45	1.9e-18	Bone mineral density;
LUSC	trans	rs890448	0.796	rs1426541	chr4:102356859	C/T	cg05120309	chr14:100485494	NA	-0.36	-5.96	-0.31	6.38e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg04369109	chr6:150039330	LATS1	-0.55	-8.1	-0.41	1.07e-14	Lung cancer;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.57	-9.52	-0.46	3.5e-19	Lymphocyte counts;
LUSC	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.69	11.66	0.54	1.33e-26	Colorectal cancer;
LUSC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg06784218	chr1:46089804	CCDC17	0.55	11.17	0.52	7.91e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg20503657	chr10:835505	NA	0.54	7.17	0.37	4.71e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg04727924	chr7:799746	HEATR2	-0.54	-6.52	-0.34	2.67e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9646944	0.501	rs36049530	chr2:103079988	T/C	cg20060108	chr2:102954350	IL1RL1	0.45	6.08	0.32	3.22e-9	Blood protein levels;
LUSC	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg03060546	chr3:49711283	APEH	0.63	7.53	0.38	4.92e-13	Menarche (age at onset);
LUSC	cis	rs4363385	0.510	rs11576797	chr1:153049417	T/C	cg25856811	chr1:152973957	SPRR3	-0.39	-6.35	-0.33	6.9e-10	Inflammatory skin disease;
LUSC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg17724175	chr1:150552817	MCL1	0.37	6.75	0.35	6.64e-11	Tonsillectomy;
LUSC	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg00310523	chr12:86230176	RASSF9	0.38	6.91	0.35	2.48e-11	Major depressive disorder;
LUSC	cis	rs7605827	0.930	rs4668919	chr2:15662171	C/T	cg19274914	chr2:15703543	NA	0.45	8.69	0.43	1.69e-16	Educational attainment (years of education);
LUSC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg12463550	chr7:65579703	CRCP	-0.45	-6.7	-0.34	9.11e-11	Aortic root size;
LUSC	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg26384229	chr12:38710491	ALG10B	0.73	11.94	0.55	1.27e-27	Morning vs. evening chronotype;
LUSC	cis	rs4561483	0.831	rs8052900	chr16:11940390	T/C	cg08843971	chr16:11963173	GSPT1	0.41	6.0	0.31	5.23e-9	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg13939156	chr17:80058883	NA	0.35	7.15	0.36	5.4e-12	Life satisfaction;
LUSC	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg15704280	chr7:45808275	SEPT13	-0.46	-6.29	-0.33	1e-9	HDL cholesterol;
LUSC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.83	13.94	0.61	3.99e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.46	-6.22	-0.32	1.45e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	trans	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg01620082	chr3:125678407	NA	-0.69	-7.05	-0.36	1.06e-11	Breast cancer;
LUSC	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.06	16.59	0.67	1.7e-45	Exhaled nitric oxide output;
LUSC	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg13514129	chr1:39547527	MACF1	0.71	11.81	0.54	4.07e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg03146154	chr1:46216737	IPP	-0.38	-5.86	-0.31	1.11e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs2354432	0.607	rs1890039	chr1:146681951	T/C	cg25205988	chr1:146714368	CHD1L	1.08	8.58	0.42	3.65e-16	Mitochondrial DNA levels;
LUSC	cis	rs55665837	1.000	rs10832254	chr11:14434698	A/G	cg19336497	chr11:14380999	RRAS2	-0.37	-7.51	-0.38	5.34e-13	Vitamin D levels;
LUSC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg16414030	chr3:133502952	NA	-0.41	-6.44	-0.33	4.16e-10	Iron status biomarkers;
LUSC	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg16576597	chr16:28551801	NUPR1	0.34	6.77	0.35	5.67e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg15485101	chr11:133734466	NA	0.38	6.91	0.35	2.43e-11	Childhood ear infection;
LUSC	cis	rs151234	0.676	rs151320	chr16:28568678	A/G	cg01378222	chr16:28622494	SULT1A1	0.59	7.97	0.4	2.53e-14	Platelet distribution width;
LUSC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg24642844	chr7:1081250	C7orf50	-0.78	-10.24	-0.49	1.34e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	7.77	0.39	9.53e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17125944	0.686	rs7160582	chr14:53341445	G/T	cg00686598	chr14:53173677	PSMC6	0.79	6.85	0.35	3.63e-11	Alzheimer's disease (late onset);
LUSC	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg09165964	chr15:75287851	SCAMP5	-0.48	-6.94	-0.36	2e-11	Caffeine consumption;
LUSC	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg03128945	chr5:622914	CEP72	-0.47	-6.7	-0.34	8.81e-11	Obesity-related traits;
LUSC	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg09904177	chr6:26538194	HMGN4	-0.79	-5.88	-0.31	1e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6750047	0.585	rs4670235	chr2:38272528	C/T	cg07380506	chr2:38303506	CYP1B1	0.45	6.11	0.32	2.71e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs11039100	0.765	rs72896130	chr11:5834405	C/T	cg05234568	chr11:5960015	NA	-0.51	-5.68	-0.3	2.95e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg05283184	chr6:79620031	NA	-0.57	-11.83	-0.54	3.38e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-13.87	-0.6	7.04e-35	Intelligence (multi-trait analysis);
LUSC	trans	rs1941687	0.563	rs1586987	chr18:31338661	A/G	cg27147174	chr7:100797783	AP1S1	-0.56	-8.9	-0.44	3.61e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg24558204	chr6:135376177	HBS1L	0.68	10.46	0.5	2.49e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.63	10.55	0.5	1.17e-22	Blood metabolite levels;
LUSC	cis	rs7043114	0.525	rs1053441	chr9:95147840	T/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.51	-0.34	2.72e-10	Height;
LUSC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg04450456	chr4:17643702	FAM184B	-0.39	-6.3	-0.33	9.3e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg08917208	chr2:24149416	ATAD2B	0.56	6.44	0.33	4.27e-10	Lymphocyte counts;
LUSC	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg24375607	chr4:120327624	NA	0.76	12.23	0.56	1.14e-28	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.65	9.13	0.45	6.68e-18	Iron status biomarkers;
LUSC	trans	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-8.53	-0.42	5.13e-16	Obesity-related traits;
LUSC	cis	rs9309473	0.583	rs11899517	chr2:73573261	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-7.72	-0.39	1.33e-13	Metabolite levels;
LUSC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg18306943	chr3:40428807	ENTPD3	0.38	5.73	0.3	2.25e-8	Renal cell carcinoma;
LUSC	cis	rs9427116	0.502	rs6699825	chr1:154582970	A/G	cg17218026	chr1:154582156	ADAR	0.56	10.06	0.48	5.92e-21	Blood protein levels;
LUSC	cis	rs3126085	0.935	rs1390490	chr1:152161354	T/C	cg26876637	chr1:152193138	HRNR	0.44	5.92	0.31	7.94e-9	Atopic dermatitis;
LUSC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg09877947	chr5:131593287	PDLIM4	0.59	10.02	0.48	7.64e-21	Acylcarnitine levels;
LUSC	cis	rs4308124	0.708	rs6716091	chr2:111991133	C/T	cg04571233	chr2:111982156	NA	-0.53	-6.95	-0.36	1.98e-11	Vitiligo;
LUSC	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg04362960	chr10:104952993	NT5C2	0.58	9.38	0.46	1.04e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg16797656	chr11:68205561	LRP5	0.37	6.05	0.31	3.96e-9	Total body bone mineral density;
LUSC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg15790184	chr11:494944	RNH1	0.42	6.42	0.33	4.69e-10	Systemic lupus erythematosus;
LUSC	cis	rs4964805	0.672	rs4964823	chr12:104181420	A/T	cg02344784	chr12:104178138	NT5DC3	0.42	6.6	0.34	1.57e-10	Attention deficit hyperactivity disorder;
LUSC	trans	rs9650657	0.769	rs2116093	chr8:10613299	C/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.01	-0.31	4.82e-9	Neuroticism;
LUSC	cis	rs7923609	0.936	rs10740125	chr10:65209609	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.03e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs629535	0.590	rs62513426	chr8:70136843	T/G	cg21567404	chr3:27674614	NA	-0.93	-13.53	-0.6	1.45e-33	Dupuytren's disease;
LUSC	cis	rs7814319	0.966	rs10112328	chr8:97254372	C/T	cg20787634	chr8:97240163	UQCRB	0.33	5.73	0.3	2.22e-8	Lung function (FVC);
LUSC	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.88	0.44	4.07e-17	Lung cancer in ever smokers;
LUSC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08219700	chr8:58056026	NA	0.64	7.88	0.4	4.52e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg05472934	chr7:22766657	IL6	0.5	7.84	0.39	6.13e-14	Lung cancer;
LUSC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.74	-0.43	1.18e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7267979	0.844	rs4815413	chr20:25359229	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-16.94	-0.68	6.65e-47	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.62	6.55	0.34	2.16e-10	Schizophrenia;
LUSC	trans	rs6601327	0.613	rs11785458	chr8:9506810	T/C	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.17	-0.32	2.01e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs4356932	0.691	rs2242473	chr4:76878956	G/A	cg00809888	chr4:76862425	NAAA	-0.36	-5.72	-0.3	2.31e-8	Blood protein levels;
LUSC	cis	rs9837602	0.938	rs1017968	chr3:99787011	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.91	-0.31	8.57e-9	Breast cancer;
LUSC	trans	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg19694781	chr19:47549865	TMEM160	0.59	9.52	0.46	3.59e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs6700896	0.866	rs6588158	chr1:66160621	T/C	cg04111102	chr1:66153794	NA	-0.34	-7.42	-0.38	1e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6977940	0.512	rs6461600	chr7:2816537	C/T	cg14895029	chr7:2775587	GNA12	0.45	5.66	0.3	3.29e-8	White matter integrity;
LUSC	cis	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg01585723	chr16:33734837	NA	0.35	5.68	0.3	2.88e-8	Menopause (age at onset);
LUSC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.35	0.46	1.3e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24549020	chr5:56110836	MAP3K1	0.48	5.71	0.3	2.46e-8	Initial pursuit acceleration;
LUSC	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg06547715	chr2:218990976	CXCR2	-0.34	-6.76	-0.35	6.12e-11	Ulcerative colitis;
LUSC	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg08999081	chr20:33150536	PIGU	0.33	5.81	0.3	1.42e-8	Height;
LUSC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg24675658	chr1:53192096	ZYG11B	0.58	9.11	0.45	7.92e-18	Monocyte count;
LUSC	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	8.46	0.42	8.63e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg25182066	chr10:30743637	MAP3K8	-0.4	-6.0	-0.31	5.16e-9	Inflammatory bowel disease;
LUSC	cis	rs7799006	0.606	rs878534	chr7:2314652	G/A	cg02951883	chr7:2050386	MAD1L1	-0.36	-5.85	-0.3	1.2e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12292205	chr6:26970375	C6orf41	-0.58	-7.16	-0.36	5.14e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.83	0.39	6.53e-14	Prudent dietary pattern;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00668442	chr16:2318234	RNPS1	0.77	6.08	0.32	3.35e-9	Cognitive performance;
LUSC	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg18132916	chr6:79620363	NA	0.39	5.88	0.31	9.86e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg23283495	chr1:209979779	IRF6	0.64	9.3	0.45	1.96e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg23231163	chr10:75533350	FUT11	-0.38	-6.32	-0.33	8.41e-10	Inflammatory bowel disease;
LUSC	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.77	-10.43	-0.5	3.05e-22	Coronary artery disease;
LUSC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg17968037	chr7:100024898	ZCWPW1	-0.43	-6.14	-0.32	2.32e-9	Platelet count;
LUSC	cis	rs9283706	0.689	rs1030231	chr5:66317265	A/G	cg11590213	chr5:66331682	MAST4	0.48	6.8	0.35	4.95e-11	Coronary artery disease;
LUSC	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08109568	chr15:31115862	NA	-0.54	-7.45	-0.38	7.93e-13	Huntington's disease progression;
LUSC	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg20608306	chr11:116969690	SIK3	0.36	6.78	0.35	5.58e-11	Blood protein levels;
LUSC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.93	11.83	0.54	3.2e-27	Menarche (age at onset);
LUSC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.56e-24	Aortic root size;
LUSC	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg22089800	chr15:90895588	ZNF774	0.51	7.55	0.38	4.29e-13	Rheumatoid arthritis;
LUSC	trans	rs2665103	0.715	rs16973457	chr15:82563991	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.5	-0.34	2.89e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg22864355	chr14:105225861	SIVA1	-0.36	-6.02	-0.31	4.63e-9	Schizophrenia (age at onset);
LUSC	cis	rs1160297	0.576	rs13030509	chr2:53110287	T/A	cg07782112	chr2:53107842	NA	0.39	6.47	0.33	3.55e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs4400599	1.000	rs4540651	chr1:154128672	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.99	-0.31	5.38e-9	Platelet distribution width;
LUSC	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg07701084	chr6:150067640	NUP43	0.49	7.39	0.37	1.22e-12	Lung cancer;
LUSC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg04155289	chr7:94953770	PON1	-0.34	-5.68	-0.3	2.96e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.67	11.81	0.54	3.97e-27	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.42	0.56	2.19e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs11264799	0.520	rs2779159	chr1:157550357	C/T	cg18268488	chr1:157545234	FCRL4	0.39	7.63	0.39	2.42e-13	IgA nephropathy;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13162328	chr8:22462125	KIAA1967	0.76	6.02	0.31	4.68e-9	Cognitive performance;
LUSC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg22535103	chr8:58192502	C8orf71	-0.72	-7.89	-0.4	4.31e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.43	6.57	0.34	1.93e-10	Brugada syndrome;
LUSC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-9.49	-0.46	4.49e-19	Gut microbiome composition (summer);
LUSC	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-9.09	-0.45	9.03e-18	Coronary artery disease;
LUSC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	14.14	0.61	6.79e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.24	0.37	3.09e-12	Mean platelet volume;
LUSC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	8.45	0.42	9.05e-16	Menarche (age at onset);
LUSC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg12463550	chr7:65579703	CRCP	0.45	6.58	0.34	1.84e-10	Aortic root size;
LUSC	cis	rs16976116	0.901	rs7165491	chr15:55500455	A/C	cg11288833	chr15:55489084	RSL24D1	0.47	5.69	0.3	2.73e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg16576597	chr16:28551801	NUPR1	0.29	5.77	0.3	1.82e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs8040855	0.825	rs3964197	chr15:85721912	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.42	-6.39	-0.33	5.72e-10	Bulimia nervosa;
LUSC	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.7	-0.39	1.6e-13	Glomerular filtration rate;
LUSC	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg17385448	chr1:15911702	AGMAT	0.37	6.31	0.33	8.9e-10	Systolic blood pressure;
LUSC	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg09904177	chr6:26538194	HMGN4	-0.78	-5.94	-0.31	6.98e-9	Depression;
LUSC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.19	-13.56	-0.6	1.16e-33	Diabetic kidney disease;
LUSC	cis	rs934734	0.967	rs17534670	chr2:65615428	A/G	cg08085232	chr2:65598271	SPRED2	0.39	5.99	0.31	5.29e-9	Rheumatoid arthritis;
LUSC	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg00852783	chr1:26633632	UBXN11	0.6	9.31	0.45	1.78e-18	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs17407555	0.606	rs73229818	chr4:10019884	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-6.2	-0.32	1.68e-9	Schizophrenia (age at onset);
LUSC	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	0.29	5.92	0.31	8.2e-9	Cystic fibrosis severity;
LUSC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13770153	chr20:60521292	NA	0.73	9.94	0.48	1.4e-20	Body mass index;
LUSC	cis	rs9560113	1.000	rs9560106	chr13:112179605	A/G	cg14154082	chr13:112174009	NA	0.36	7.56	0.38	4.03e-13	Menarche (age at onset);
LUSC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.27	-0.37	2.61e-12	Alzheimer's disease (late onset);
LUSC	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.57	9.5	0.46	4.29e-19	Bone mineral density;
LUSC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-1.04	-19.43	-0.73	8.39e-57	Menopause (age at onset);
LUSC	cis	rs6500395	1.000	rs8052196	chr16:48691644	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.69	13.11	0.58	6.01e-32	Gestational age at birth (maternal effect);
LUSC	trans	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg13565492	chr6:43139072	SRF	-0.59	-6.72	-0.35	7.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg00933542	chr6:150070202	PCMT1	0.32	6.79	0.35	5.15e-11	Lung cancer;
LUSC	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg06637938	chr14:75390232	RPS6KL1	0.65	10.68	0.5	4.19e-23	Caffeine consumption;
LUSC	trans	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg26043149	chr18:55253948	FECH	-0.43	-6.6	-0.34	1.64e-10	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs3820928	0.874	rs2228557	chr2:227872182	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.55	-0.38	4.06e-13	Pulmonary function;
LUSC	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg03585969	chr10:35415529	CREM	0.61	8.87	0.44	4.62e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg07169764	chr2:136633963	MCM6	1.05	15.67	0.65	7.33e-42	Corneal structure;
LUSC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg06454157	chr6:167490870	NA	-0.27	-6.64	-0.34	1.28e-10	Primary biliary cholangitis;
LUSC	cis	rs6700559	0.740	rs11582610	chr1:200645101	C/T	cg07804481	chr1:200639085	DDX59	0.41	5.77	0.3	1.85e-8	Coronary artery disease;
LUSC	cis	rs7605827	0.897	rs4140714	chr2:15515723	T/A	cg19274914	chr2:15703543	NA	0.47	9.07	0.44	1.03e-17	Educational attainment (years of education);
LUSC	cis	rs12931792	0.687	rs8057425	chr16:30182541	T/C	cg17640201	chr16:30407289	ZNF48	0.63	10.23	0.49	1.46e-21	Tonsillectomy;
LUSC	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.34	-7.36	-0.37	1.4e-12	Dupuytren's disease;
LUSC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00166722	chr3:10149974	C3orf24	0.6	8.39	0.42	1.4e-15	Alzheimer's disease;
LUSC	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg17366294	chr4:99064904	C4orf37	0.59	10.56	0.5	1.07e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12618769	0.597	rs4599165	chr2:99144483	G/A	cg10123293	chr2:99228465	UNC50	0.46	7.54	0.38	4.34e-13	Bipolar disorder;
LUSC	trans	rs12495832	0.778	rs12635085	chr3:147933337	A/T	cg23651585	chr7:70252448	AUTS2	0.72	6.68	0.34	1.01e-10	Chin dimples;
LUSC	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg21854759	chr1:92012499	NA	-0.49	-6.88	-0.35	3.04e-11	Eosinophil percentage of white cells;
LUSC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18099408	chr3:52552593	STAB1	-0.38	-6.17	-0.32	1.92e-9	Bipolar disorder;
LUSC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg14552801	chr7:65878734	NA	-0.45	-6.44	-0.33	4.23e-10	Aortic root size;
LUSC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg27631724	chr1:11040367	C1orf127	0.55	10.65	0.5	5.36e-23	Ewing sarcoma;
LUSC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg05025164	chr4:1340916	KIAA1530	0.42	6.34	0.33	7.36e-10	Obesity-related traits;
LUSC	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.45	-9.88	-0.48	2.25e-20	Urate levels in overweight individuals;
LUSC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg10018233	chr7:150070692	REPIN1	0.4	6.7	0.34	8.7e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg06521331	chr12:34319734	NA	-0.45	-7.23	-0.37	3.3e-12	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg13010199	chr12:38710504	ALG10B	0.58	9.27	0.45	2.32e-18	Morning vs. evening chronotype;
LUSC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	14.03	0.61	1.83e-35	Smoking behavior;
LUSC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.53	0.42	5.04e-16	Prudent dietary pattern;
LUSC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08859206	chr1:53392774	SCP2	0.5	8.66	0.43	2e-16	Monocyte count;
LUSC	cis	rs11158026	0.603	rs8009997	chr14:55421911	A/C	cg04306507	chr14:55594613	LGALS3	0.34	5.96	0.31	6.24e-9	Parkinson's disease;
LUSC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg06784218	chr1:46089804	CCDC17	0.54	11.06	0.52	1.88e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3820928	1.000	rs4675116	chr2:227769607	A/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.73	-0.39	1.3e-13	Pulmonary function;
LUSC	cis	rs11608355	0.960	rs10774691	chr12:109859830	C/T	cg05360138	chr12:110035743	NA	0.47	6.35	0.33	6.87e-10	Neuroticism;
LUSC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-11.07	-0.52	1.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg09184832	chr6:79620586	NA	0.43	7.12	0.36	6.62e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg20119798	chr7:94954144	PON1	-0.33	-5.66	-0.3	3.28e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg01884057	chr2:25150051	NA	0.42	9.15	0.45	5.56e-18	Body mass index;
LUSC	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.54	-8.99	-0.44	1.83e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2742417	1.000	rs1534876	chr3:45741257	G/T	cg04837898	chr3:45731254	SACM1L	-0.35	-5.86	-0.31	1.08e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs508618	1.000	rs508618	chr1:231532312	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-6.6	-0.34	1.63e-10	Red blood cell count;
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg17541715	chr7:1216824	NA	-0.39	-6.14	-0.32	2.32e-9	Longevity;Endometriosis;
LUSC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	0.88	16.45	0.67	5.83e-45	Gestational age at birth (maternal effect);
LUSC	trans	rs330048	0.509	rs36111783	chr8:9145588	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.27	0.32	1.13e-9	Systemic lupus erythematosus;
LUSC	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.42	5.95	0.31	6.74e-9	Lung cancer;
LUSC	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.6	9.1	0.45	8.3e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg16606324	chr3:10149918	C3orf24	0.65	9.52	0.46	3.55e-19	Alzheimer's disease;
LUSC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.44	0.38	8.45e-13	Bipolar disorder;
LUSC	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg19743168	chr1:23544995	NA	0.4	7.96	0.4	2.78e-14	Height;
LUSC	cis	rs9815354	0.767	rs17281609	chr3:41833432	G/A	cg03022575	chr3:42003672	ULK4	0.86	8.67	0.43	1.97e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.16	-0.52	8.29e-25	Coffee consumption (cups per day);
LUSC	cis	rs9905704	0.846	rs304298	chr17:56839689	G/A	cg12560992	chr17:57184187	TRIM37	0.58	8.38	0.42	1.5e-15	Testicular germ cell tumor;
LUSC	cis	rs600626	0.636	rs11236518	chr11:75453066	C/T	cg24262691	chr11:75473276	NA	0.48	6.5	0.34	2.85e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg07777115	chr5:623756	CEP72	-0.45	-5.65	-0.3	3.5e-8	Obesity-related traits;
LUSC	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4629710	0.645	rs34601891	chr6:131551238	C/T	cg12606694	chr6:131520996	AKAP7	0.62	9.37	0.46	1.12e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg05313129	chr8:58192883	C8orf71	-0.5	-6.78	-0.35	5.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.39	0.53	1.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg20283391	chr11:68216788	NA	-0.57	-8.23	-0.41	4.21e-15	Total body bone mineral density;
LUSC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.41	-0.38	1.03e-12	Aortic root size;
LUSC	cis	rs2625529	0.627	rs12902661	chr15:72480158	T/G	cg16672083	chr15:72433130	SENP8	-0.5	-7.29	-0.37	2.31e-12	Red blood cell count;
LUSC	cis	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg24375607	chr4:120327624	NA	0.49	7.29	0.37	2.21e-12	Diastolic blood pressure;
LUSC	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg13390004	chr1:15929781	NA	0.41	6.53	0.34	2.44e-10	Systolic blood pressure;
LUSC	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg05342945	chr12:48394962	COL2A1	-0.45	-6.01	-0.31	4.94e-9	Lung cancer;
LUSC	trans	rs7520050	0.966	rs11589562	chr1:46466721	C/T	cg12165782	chr19:1675947	NA	-0.34	-5.99	-0.31	5.57e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg00933542	chr6:150070202	PCMT1	0.3	6.07	0.32	3.4e-9	Lung cancer;
LUSC	cis	rs16949788	1.000	rs78288367	chr15:66772721	C/T	cg08120210	chr15:66682733	MAP2K1	-0.63	-6.52	-0.34	2.61e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg11247378	chr22:39784982	NA	-0.64	-12.36	-0.56	3.67e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs926392	0.932	rs6513589	chr20:37686585	A/G	cg27552599	chr20:37590471	DHX35	0.33	5.71	0.3	2.54e-8	Dialysis-related mortality;
LUSC	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.69	-0.34	9.56e-11	Blood metabolite levels;
LUSC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg06145435	chr7:1022769	CYP2W1	0.27	5.66	0.3	3.19e-8	Longevity;Endometriosis;
LUSC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	8.16	0.41	6.87e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg19628046	chr18:33552617	C18orf21	0.51	6.1	0.32	2.94e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs34891900	0.507	rs2587084	chr22:18140644	T/G	cg19898043	chr22:18121309	BCL2L13	0.39	5.98	0.31	5.84e-9	Sum neutrophil eosinophil counts;
LUSC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.38	7.94	0.4	3.01e-14	Hemoglobin concentration;
LUSC	trans	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg07393940	chr7:158741817	NA	0.39	7.09	0.36	8.09e-12	Life satisfaction;
LUSC	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.79	-0.43	8.09e-17	Response to antipsychotic treatment;
LUSC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg04369109	chr6:150039330	LATS1	-0.56	-8.22	-0.41	4.62e-15	Lung cancer;
LUSC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	14.05	0.61	1.44e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10779751	1.000	rs2300094	chr1:11266044	C/T	cg08854313	chr1:11322531	MTOR	0.91	16.1	0.66	1.5e-43	Body mass index;
LUSC	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg13736514	chr6:26305472	NA	-0.45	-8.94	-0.44	2.72e-17	Educational attainment;
LUSC	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg07148914	chr20:33460835	GGT7	0.54	8.4	0.42	1.29e-15	Height;
LUSC	cis	rs7804356	1.000	rs3213853	chr7:26893524	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.12	-0.32	2.56e-9	Type 1 diabetes;
LUSC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.65	-11.63	-0.54	1.83e-26	Aortic root size;
LUSC	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg14675211	chr2:100938903	LONRF2	0.37	5.72	0.3	2.42e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-9.83	-0.47	3.49e-20	Blood metabolite levels;
LUSC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg18681998	chr4:17616180	MED28	0.84	15.62	0.65	1.13e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.04	-0.36	1.12e-11	Bipolar disorder;
LUSC	cis	rs72960926	0.590	rs72959617	chr6:74993963	G/A	cg03266952	chr6:74778945	NA	-0.8	-6.78	-0.35	5.51e-11	Metabolite levels (MHPG);
LUSC	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg09654669	chr8:57350985	NA	-0.62	-8.46	-0.42	8.51e-16	Obesity-related traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02335971	chr8:121457381	MTBP;MRPL13	-0.38	-6.13	-0.32	2.41e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6736093	0.966	rs13027171	chr2:112686988	G/A	cg12686935	chr2:112915763	FBLN7	-0.37	-5.91	-0.31	8.29e-9	Coronary artery disease;
LUSC	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg05043794	chr9:111880884	C9orf5	-0.31	-6.49	-0.33	3.1e-10	Menarche (age at onset);
LUSC	cis	rs12989701	0.778	rs7583814	chr2:127863029	C/T	cg08168897	chr2:127865431	BIN1	0.7	8.73	0.43	1.27e-16	Alzheimer's disease (late onset);
LUSC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	0.68	10.94	0.51	5.03e-24	Height;
LUSC	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Bladder cancer;
LUSC	cis	rs57920188	0.584	rs12062024	chr1:4089259	A/T	cg20703997	chr1:4087676	NA	-0.58	-8.75	-0.43	1.09e-16	Interleukin-17 levels;
LUSC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg06784218	chr1:46089804	CCDC17	0.48	9.63	0.47	1.62e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.72	-0.39	1.33e-13	Response to antipsychotic treatment;
LUSC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg03146154	chr1:46216737	IPP	0.56	8.37	0.42	1.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg05019905	chr6:29894831	HCG4P6	0.45	6.26	0.32	1.15e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11686214	chr19:59084984	MZF1;LOC100131691	0.47	6.79	0.35	5.29e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg05863683	chr7:1912471	MAD1L1	0.31	6.11	0.32	2.77e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg16586182	chr3:47516702	SCAP	-0.5	-7.78	-0.39	9.14e-14	Colorectal cancer;
LUSC	trans	rs7618314	0.504	rs2715694	chr3:108541143	C/T	cg23542590	chr3:56717769	C3orf63	-0.56	-6.01	-0.31	4.77e-9	Airway responsiveness in chronic obstructive pulmonary disease;
LUSC	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-7.28	-0.37	2.47e-12	Menarche (age at onset);
LUSC	cis	rs2625529	0.617	rs7175792	chr15:72431883	C/G	cg16672083	chr15:72433130	SENP8	-0.49	-8.31	-0.41	2.46e-15	Red blood cell count;
LUSC	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg16342193	chr10:102329863	NA	-0.35	-6.14	-0.32	2.35e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.56	-8.89	-0.44	3.89e-17	Brugada syndrome;
LUSC	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg03806693	chr22:41940476	POLR3H	-0.54	-7.87	-0.4	5.07e-14	Neuroticism;
LUSC	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-1.16	-16.1	-0.66	1.42e-43	Hip circumference adjusted for BMI;
LUSC	cis	rs2708977	0.901	rs6753667	chr2:97160382	G/A	cg01950434	chr2:97203154	ARID5A	-0.54	-8.15	-0.41	7.24e-15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg03676636	chr4:99064102	C4orf37	0.27	5.84	0.3	1.24e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6969780	1.000	rs73071548	chr7:27147430	A/G	cg26364809	chr7:27145159	NA	-0.61	-6.02	-0.31	4.7e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.46	6.55	0.34	2.21e-10	Gut microbiome composition (summer);
LUSC	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg11822372	chr1:151115635	SEMA6C	0.57	8.92	0.44	3.16e-17	Childhood ear infection;
LUSC	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg07936489	chr17:37558343	FBXL20	0.83	10.41	0.5	3.52e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.7	0.3	2.64e-8	Menopause (age at onset);
LUSC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.78	0.63	2.16e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg25258033	chr6:167368657	RNASET2	0.47	7.84	0.39	6.15e-14	Crohn's disease;
LUSC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg02931644	chr1:25747376	RHCE	0.38	6.91	0.35	2.53e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.89	14.89	0.63	8.25e-39	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6545883	0.859	rs35760550	chr2:61603865	T/A	cg15711740	chr2:61764176	XPO1	0.41	6.26	0.32	1.19e-9	Tuberculosis;
LUSC	cis	rs939658	0.626	rs11636901	chr15:79446292	T/C	cg17916960	chr15:79447300	NA	-0.45	-8.75	-0.43	1.09e-16	Refractive error;
LUSC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg10729496	chr3:10149963	C3orf24	0.54	7.17	0.37	4.98e-12	Alzheimer's disease;
LUSC	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg20026190	chr17:76395443	PGS1	0.34	5.83	0.3	1.28e-8	HDL cholesterol levels;
LUSC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.49	0.42	6.97e-16	Prudent dietary pattern;
LUSC	cis	rs2797160	0.547	rs9388442	chr6:125972608	G/C	cg05901451	chr6:126070800	HEY2	-0.41	-5.88	-0.31	9.89e-9	Endometrial cancer;
LUSC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg11905131	chr22:24372483	LOC391322	0.43	5.84	0.3	1.23e-8	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg27539214	chr16:67997921	SLC12A4	-0.42	-6.03	-0.31	4.33e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04020590	chr13:113978800	GRTP1	-0.39	-6.02	-0.31	4.6e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg06618935	chr21:46677482	NA	-0.37	-7.54	-0.38	4.6e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.46	0.33	3.67e-10	Corneal astigmatism;
LUSC	cis	rs56161922	1.000	rs72468035	chr1:207812405	C/T	cg11752769	chr1:207818423	CR1L	-0.69	-5.72	-0.3	2.31e-8	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg11871910	chr12:69753446	YEATS4	0.83	14.58	0.62	1.34e-37	Blood protein levels;
LUSC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg13319975	chr6:146136371	FBXO30	-0.51	-7.58	-0.38	3.35e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs78366141	0.649	rs78959409	chr4:89659712	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.93	7.0	0.36	1.37e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg07211511	chr3:129823064	LOC729375	-0.53	-6.08	-0.32	3.25e-9	Blood pressure (smoking interaction);
LUSC	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg24881330	chr22:46731750	TRMU	0.89	6.51	0.34	2.71e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9581857	0.685	rs9581856	chr13:28025615	G/C	cg22138327	chr13:27999177	GTF3A	0.81	9.21	0.45	3.79e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg03146154	chr1:46216737	IPP	-0.51	-7.73	-0.39	1.3e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	9.27	0.45	2.38e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.68	-10.99	-0.52	3.42e-24	Sudden cardiac arrest;
LUSC	cis	rs7091068	0.518	rs4919436	chr10:95461475	C/T	cg20715218	chr10:95462985	C10orf4	0.47	5.97	0.31	6.1e-9	Urinary tract infection frequency;
LUSC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.61	-8.54	-0.42	4.94e-16	Diastolic blood pressure;
LUSC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.23	-13.96	-0.61	3.38e-35	Gout;
LUSC	cis	rs7173743	0.934	rs7168915	chr15:79128889	C/T	cg00540400	chr15:79124168	NA	0.35	6.04	0.31	4.14e-9	Coronary artery disease;
LUSC	cis	rs7572644	0.665	rs4420671	chr2:28039300	G/C	cg27432699	chr2:27873401	GPN1	0.56	7.02	0.36	1.23e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9815354	0.857	rs9852020	chr3:41830206	G/A	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-0.9	-16.74	-0.68	4.08e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs68170813	0.652	rs56949084	chr7:107157387	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-8.63	-0.43	2.46e-16	Coronary artery disease;
LUSC	cis	rs10779751	0.960	rs4845860	chr1:11324193	A/G	cg08854313	chr1:11322531	MTOR	0.85	14.29	0.62	1.73e-36	Body mass index;
LUSC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.72	-0.3	2.43e-8	Tonsillectomy;
LUSC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg11645453	chr3:52864694	ITIH4	0.32	7.38	0.37	1.25e-12	Electroencephalogram traits;
LUSC	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg15595755	chr5:1867978	NA	0.39	6.25	0.32	1.25e-9	Cardiovascular disease risk factors;
LUSC	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-0.91	-13.12	-0.58	5.25e-32	Red blood cell traits;
LUSC	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.69	-0.34	9.53e-11	Monocyte percentage of white cells;
LUSC	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.0	-0.44	1.8e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg18512352	chr11:47633146	NA	0.47	9.44	0.46	6.79e-19	Subjective well-being;
LUSC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg12412775	chr1:25698385	RHCE	-0.29	-6.07	-0.32	3.44e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs2070433	1.000	rs2839306	chr21:47954219	G/T	cg12379764	chr21:47803548	PCNT	-0.76	-10.38	-0.49	4.56e-22	Lymphocyte counts;
LUSC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg22800045	chr5:56110881	MAP3K1	0.46	5.99	0.31	5.41e-9	Coronary artery disease;
LUSC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22509189	chr2:225307070	NA	-0.48	-6.21	-0.32	1.59e-9	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg26587870	chr6:27730563	NA	-0.61	-6.04	-0.31	4.14e-9	Depression;
LUSC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg26408565	chr15:76604113	ETFA	-0.47	-7.49	-0.38	6.07e-13	Blood metabolite levels;
LUSC	cis	rs62400317	0.859	rs10456546	chr6:45217424	C/T	cg18551225	chr6:44695536	NA	-0.46	-7.64	-0.39	2.28e-13	Total body bone mineral density;
LUSC	cis	rs380904	0.519	rs10102146	chr8:144649156	G/A	cg13399544	chr8:144649678	C8orf73	0.45	6.81	0.35	4.52e-11	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg15103426	chr22:29168792	CCDC117	0.6	8.35	0.42	1.87e-15	Lymphocyte counts;
LUSC	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg26597838	chr10:835615	NA	0.57	7.49	0.38	6.05e-13	Eosinophil percentage of granulocytes;
LUSC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	-0.36	-5.81	-0.3	1.43e-8	Menopause (age at onset);
LUSC	cis	rs9341808	0.591	rs6454147	chr6:80916328	G/A	cg08355045	chr6:80787529	NA	0.48	8.34	0.42	1.95e-15	Sitting height ratio;
LUSC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg07507251	chr3:52567010	NT5DC2	0.34	6.71	0.34	8.33e-11	Bipolar disorder;
LUSC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.52	-0.46	3.57e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs981844	0.712	rs6855082	chr4:154754039	A/G	cg14289246	chr4:154710475	SFRP2	-0.46	-6.26	-0.32	1.16e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.22	0.56	1.26e-28	Motion sickness;
LUSC	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg23649088	chr2:200775458	C2orf69	-0.57	-6.8	-0.35	4.76e-11	Schizophrenia;
LUSC	cis	rs59698941	0.943	rs41298946	chr5:132268390	A/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg25258033	chr6:167368657	RNASET2	0.36	5.66	0.3	3.2e-8	Primary biliary cholangitis;
LUSC	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg05855489	chr10:104503620	C10orf26	-0.7	-10.01	-0.48	8.51e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg06713675	chr4:122721982	EXOSC9	0.38	6.07	0.32	3.41e-9	Type 2 diabetes;
LUSC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.76	-10.26	-0.49	1.16e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg24812749	chr6:127587940	RNF146	0.73	10.48	0.5	2.02e-22	Breast cancer;
LUSC	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg05234568	chr11:5960015	NA	0.53	8.02	0.4	1.75e-14	DNA methylation (variation);
LUSC	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg04036182	chr15:45458818	NA	0.35	5.75	0.3	2.01e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg04036182	chr15:45458818	NA	-0.35	-5.74	-0.3	2.14e-8	Glomerular filtration rate;
LUSC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.53	-10.02	-0.48	7.92e-21	Longevity;Endometriosis;
LUSC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.61	8.55	0.42	4.57e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg16680214	chr1:154839983	KCNN3	-0.52	-9.76	-0.47	5.77e-20	Prostate cancer;
LUSC	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.01	0.31	4.76e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2147959	0.941	rs7524236	chr1:228630395	C/T	cg18477163	chr1:228402036	OBSCN	0.44	6.1	0.32	2.88e-9	Adult asthma;
LUSC	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg18825076	chr15:78729989	IREB2	0.47	6.32	0.33	8.41e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.74e-19	Body mass index;
LUSC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.08	0.52	1.72e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg10207240	chr12:122356781	WDR66	0.46	6.52	0.34	2.55e-10	Mean corpuscular volume;
LUSC	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg07929629	chr2:241523174	NA	0.62	10.62	0.5	6.62e-23	Bipolar disorder;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.48	8.02	0.4	1.82e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-1.17	-17.95	-0.7	6.46e-51	Corneal structure;
LUSC	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg03684893	chr10:554711	DIP2C	-0.45	-8.29	-0.41	2.82e-15	Psychosis in Alzheimer's disease;
LUSC	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.71e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	0.64	13.62	0.6	6.4e-34	Prudent dietary pattern;
LUSC	cis	rs12474201	0.925	rs1058157	chr2:46988275	G/A	cg06386533	chr2:46925753	SOCS5	0.72	10.63	0.5	6.14e-23	Height;
LUSC	cis	rs9534288	1.000	rs9534288	chr13:46605441	T/C	cg15192986	chr13:46630673	CPB2	-0.75	-11.81	-0.54	4.06e-27	Blood protein levels;
LUSC	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg25643088	chr3:52874325	TMEM110	-0.39	-5.84	-0.3	1.24e-8	Schizophrenia;
LUSC	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg20283391	chr11:68216788	NA	-0.61	-8.51	-0.42	5.97e-16	Total body bone mineral density (age 0-15);
LUSC	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg16230307	chr14:35515116	FAM177A1	0.78	10.01	0.48	8.72e-21	Psoriasis;
LUSC	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-19.83	-0.74	2.2e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg23750338	chr8:142222470	SLC45A4	0.58	11.26	0.52	3.68e-25	Immature fraction of reticulocytes;
LUSC	cis	rs67366981	1.000	rs59262654	chr14:77712261	A/G	cg22824376	chr14:77648248	TMEM63C	0.65	6.19	0.32	1.75e-9	Obsessive-compulsive symptoms;
LUSC	cis	rs3106136	1.000	rs2632401	chr4:95147055	C/G	cg11021082	chr4:95130006	SMARCAD1	0.34	6.03	0.31	4.29e-9	Capecitabine sensitivity;
LUSC	cis	rs3760982	0.967	rs3760984	chr19:44286762	C/T	cg11993925	chr19:44307056	LYPD5	0.28	6.28	0.33	1.03e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.34	-0.33	7.4e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.49	7.63	0.39	2.46e-13	Prudent dietary pattern;
LUSC	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.37	-0.33	6.31e-10	Retinal vascular caliber;
LUSC	cis	rs9517302	0.615	rs9517306	chr13:99097962	T/C	cg22223119	chr13:99095684	FARP1	-0.68	-9.67	-0.47	1.2e-19	Obesity-related traits;
LUSC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.4	-7.24	-0.37	3.12e-12	Longevity;Endometriosis;
LUSC	cis	rs4474465	0.607	rs7930161	chr11:78268878	C/A	cg27205649	chr11:78285834	NARS2	0.56	6.55	0.34	2.12e-10	Alzheimer's disease (survival time);
LUSC	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	9.48	0.46	4.9e-19	Lung cancer;
LUSC	trans	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	10.09	0.48	4.34e-21	Colorectal cancer;
LUSC	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	6.99	0.36	1.48e-11	Iron status biomarkers;
LUSC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg06784218	chr1:46089804	CCDC17	0.53	10.53	0.5	1.41e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg13047869	chr3:10149882	C3orf24	-0.59	-7.93	-0.4	3.32e-14	Alzheimer's disease;
LUSC	cis	rs2279817	0.818	rs11582250	chr1:17994234	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-6.13	-0.32	2.51e-9	Neuroticism;
LUSC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg16339924	chr4:17578868	LAP3	0.55	8.45	0.42	8.91e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg17173187	chr15:85201210	NMB	0.35	6.26	0.32	1.19e-9	Schizophrenia;
LUSC	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg00012203	chr2:219082015	ARPC2	-0.7	-11.58	-0.54	2.78e-26	Colorectal cancer;
LUSC	cis	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg06521331	chr12:34319734	NA	-0.36	-5.88	-0.31	9.85e-9	Morning vs. evening chronotype;
LUSC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg18240062	chr17:79603768	NPLOC4	0.59	10.09	0.48	4.43e-21	Eye color traits;
LUSC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg00431813	chr7:1051703	C7orf50	0.36	5.83	0.3	1.31e-8	Longevity;Endometriosis;
LUSC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg09877947	chr5:131593287	PDLIM4	0.45	7.14	0.36	5.84e-12	Breast cancer;
LUSC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg06287003	chr12:125626642	AACS	0.37	6.35	0.33	6.89e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg18904891	chr8:8559673	CLDN23	0.53	7.51	0.38	5.61e-13	Obesity-related traits;
LUSC	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs4654899	0.833	rs10916919	chr1:21317524	A/G	cg02927042	chr1:21476669	EIF4G3	0.36	5.83	0.3	1.31e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg21782813	chr7:2030301	MAD1L1	0.45	7.34	0.37	1.68e-12	Schizophrenia;
LUSC	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg13072238	chr3:49761600	GMPPB	-0.38	-6.26	-0.32	1.19e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg09455208	chr3:40491958	NA	0.56	10.52	0.5	1.54e-22	Renal cell carcinoma;
LUSC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg08132940	chr7:1081526	C7orf50	-0.51	-5.93	-0.31	7.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.96	-0.4	2.67e-14	Morning vs. evening chronotype;
LUSC	trans	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg10756647	chr7:56101905	PSPH	0.88	8.43	0.42	1.02e-15	Diabetic kidney disease;
LUSC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg02951883	chr7:2050386	MAD1L1	-0.59	-11.17	-0.52	8.06e-25	Bipolar disorder and schizophrenia;
LUSC	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg04362960	chr10:104952993	NT5C2	0.61	9.53	0.46	3.35e-19	Arsenic metabolism;
LUSC	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg09904177	chr6:26538194	HMGN4	-0.7	-6.46	-0.33	3.79e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.56	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg22437258	chr11:111473054	SIK2	0.43	5.68	0.3	2.96e-8	Primary sclerosing cholangitis;
LUSC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg26874229	chr2:105853672	NA	-0.32	-5.76	-0.3	1.95e-8	Type 2 diabetes;
LUSC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	0.97	14.02	0.61	1.89e-35	Vitiligo;
LUSC	cis	rs6977660	0.882	rs7781975	chr7:19849629	A/G	cg07541023	chr7:19748670	TWISTNB	0.5	5.8	0.3	1.53e-8	Thyroid stimulating hormone;
LUSC	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg16558253	chr16:72132732	DHX38	-0.42	-6.4	-0.33	5.2e-10	Fibrinogen levels;
LUSC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs10927875	0.619	rs2013019	chr1:16129320	T/C	cg21385522	chr1:16154831	NA	-0.61	-9.84	-0.47	3.1e-20	Dilated cardiomyopathy;
LUSC	cis	rs4478137	0.501	rs6828820	chr4:164230540	C/T	cg06758707	chr4:164254230	NPY1R	-0.48	-6.67	-0.34	1.09e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.52	6.86	0.35	3.28e-11	Blood protein levels;
LUSC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg06784218	chr1:46089804	CCDC17	0.49	9.69	0.47	9.94e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg00191853	chr8:101177733	SPAG1	-0.41	-6.59	-0.34	1.68e-10	Atrioventricular conduction;
LUSC	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03611598	chr17:48586076	MYCBPAP	0.47	5.92	0.31	8.01e-9	Visceral fat;
LUSC	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.9	13.27	0.59	1.38e-32	Coronary artery disease;
LUSC	cis	rs3857536	0.842	rs2188590	chr6:66939534	A/G	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg25427524	chr10:38739819	LOC399744	0.43	5.8	0.3	1.54e-8	Obesity (extreme);
LUSC	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg05340658	chr4:99064831	C4orf37	0.59	8.19	0.41	5.62e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg01657329	chr11:68192670	LRP5	-0.44	-7.11	-0.36	6.87e-12	Total body bone mineral density;
LUSC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg18681998	chr4:17616180	MED28	-0.87	-15.17	-0.64	6.53e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg16230307	chr14:35515116	FAM177A1	0.77	8.68	0.43	1.74e-16	Psoriasis;
LUSC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22307029	chr19:49891270	CCDC155	0.67	9.43	0.46	7.02e-19	Multiple sclerosis;
LUSC	cis	rs4664304	0.802	rs17830307	chr2:160871799	T/C	cg03641300	chr2:160917029	PLA2R1	-0.37	-5.99	-0.31	5.52e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg00684032	chr4:1343700	KIAA1530	-0.38	-6.51	-0.34	2.7e-10	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17024643	chr1:214725274	PTPN14	0.43	6.46	0.33	3.81e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg18187862	chr3:45730750	SACM1L	-0.53	-6.6	-0.34	1.57e-10	Primary sclerosing cholangitis;
LUSC	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-7.3	-0.37	2.07e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4363385	0.719	rs6664823	chr1:152933424	A/C	cg07796016	chr1:152779584	LCE1C	-0.49	-6.99	-0.36	1.52e-11	Inflammatory skin disease;
LUSC	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	0.8	11.78	0.54	4.85e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	trans	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg13010199	chr12:38710504	ALG10B	0.42	6.76	0.35	6.11e-11	Morning vs. evening chronotype;
LUSC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg01448562	chr3:133502909	NA	-0.36	-5.69	-0.3	2.72e-8	Iron status biomarkers;
LUSC	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.82	18.82	0.72	2.22e-54	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg11859384	chr17:80120422	CCDC57	-0.36	-5.66	-0.3	3.23e-8	Life satisfaction;
LUSC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg06494592	chr3:125709126	NA	-0.49	-5.66	-0.3	3.27e-8	Blood pressure (smoking interaction);
LUSC	cis	rs9650315	0.866	rs35587857	chr8:57167248	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	6.87	0.35	3.07e-11	Height;
LUSC	trans	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	6.67	0.34	1.04e-10	Retinal vascular caliber;
LUSC	trans	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.88	0.35	2.9e-11	Endometrial cancer;
LUSC	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs11955175	1.000	rs79575541	chr5:40672422	C/G	cg05478818	chr5:40835740	RPL37	0.72	5.95	0.31	6.65e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4423214	0.840	rs1123007	chr11:71185357	G/A	cg05163923	chr11:71159392	DHCR7	-0.76	-9.76	-0.47	5.62e-20	Vitamin D levels;
LUSC	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg17294928	chr15:75287854	SCAMP5	-0.7	-5.98	-0.31	5.73e-9	Lung cancer;
LUSC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg03579872	chr1:53393473	SCP2	-0.39	-5.87	-0.31	1.05e-8	Monocyte count;
LUSC	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg18825076	chr15:78729989	IREB2	-0.48	-6.82	-0.35	4.3e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg15711740	chr2:61764176	XPO1	-0.47	-7.36	-0.37	1.43e-12	Tuberculosis;
LUSC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03517284	chr6:25882590	NA	0.44	7.78	0.39	9.2e-14	Blood metabolite levels;
LUSC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	ch.11.42038R	chr11:967971	AP2A2	0.44	6.68	0.34	1.02e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4740619	0.619	rs1328280	chr9:16030903	C/T	cg14451791	chr9:16040625	NA	0.36	7.02	0.36	1.22e-11	Body mass index;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	0.99	23.34	0.79	3.81e-72	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg17366294	chr4:99064904	C4orf37	0.6	10.63	0.5	6.42e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg06454157	chr6:167490870	NA	-0.25	-6.03	-0.31	4.28e-9	Crohn's disease;
LUSC	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.71	-11.88	-0.54	2.2e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg10253484	chr15:75165896	SCAMP2	0.43	5.8	0.3	1.56e-8	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg04851639	chr8:1020857	NA	-0.37	-7.78	-0.39	8.96e-14	Schizophrenia;
LUSC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.84	-15.65	-0.65	8.92e-42	Dental caries;
LUSC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg07741184	chr6:167504864	NA	-0.35	-6.42	-0.33	4.59e-10	Crohn's disease;
LUSC	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg24006582	chr15:45444508	DUOX1	0.65	9.45	0.46	6.3e-19	Uric acid levels;
LUSC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg16545954	chr1:2118288	C1orf86	0.37	7.19	0.37	4.18e-12	Height;
LUSC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg19592336	chr6:28129416	ZNF389	0.47	6.19	0.32	1.75e-9	Depression;
LUSC	cis	rs7072216	0.763	rs9787550	chr10:100169051	C/T	cg26618903	chr10:100175079	PYROXD2	-0.48	-8.79	-0.43	7.99e-17	Metabolite levels;
LUSC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08439880	chr3:133502540	NA	-0.35	-6.34	-0.33	7.26e-10	Iron status biomarkers;
LUSC	cis	rs35883536	0.587	rs2809799	chr1:101036516	A/G	cg06223162	chr1:101003688	GPR88	0.49	9.27	0.45	2.44e-18	Monocyte count;
LUSC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg25258033	chr6:167368657	RNASET2	0.45	6.81	0.35	4.5e-11	Crohn's disease;
LUSC	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg13798780	chr7:105162888	PUS7	0.56	6.15	0.32	2.23e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-9.19	-0.45	4.42e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6733011	0.581	rs4851162	chr2:99466659	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-5.68	-0.3	2.92e-8	Bipolar disorder;
LUSC	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg10604040	chr11:65559109	OVOL1	0.31	5.72	0.3	2.34e-8	Acne (severe);
LUSC	cis	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg05084668	chr3:125655381	ALG1L	-0.62	-8.99	-0.44	1.88e-17	Blood pressure (smoking interaction);
LUSC	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.86	0.54	2.63e-27	Cognitive ability;
LUSC	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.82	-14.22	-0.61	3.17e-36	Ulcerative colitis;
LUSC	cis	rs3772130	1.000	rs11721318	chr3:121429485	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.64	9.28	0.45	2.14e-18	Cognitive performance;
LUSC	cis	rs9309473	0.519	rs1083922	chr2:73704003	A/G	cg20560298	chr2:73613845	ALMS1	0.44	6.78	0.35	5.59e-11	Metabolite levels;
LUSC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03576123	chr11:487126	PTDSS2	-0.95	-10.54	-0.5	1.29e-22	Body mass index;
LUSC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg00933542	chr6:150070202	PCMT1	0.3	6.0	0.31	5.27e-9	Lung cancer;
LUSC	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg15556689	chr8:8085844	FLJ10661	0.56	8.47	0.42	7.64e-16	Neuroticism;
LUSC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	0.99	13.72	0.6	2.7200000000000002e-34	Vitiligo;
LUSC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.52	-0.38	4.96e-13	Bipolar disorder and schizophrenia;
LUSC	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg15704280	chr7:45808275	SEPT13	0.74	8.4	0.42	1.26e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.52e-8	Breast cancer;
LUSC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg15448220	chr1:150897856	SETDB1	0.38	5.66	0.3	3.19e-8	Tonsillectomy;
LUSC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.07e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg20135002	chr11:47629003	NA	0.48	7.47	0.38	7.13e-13	Subjective well-being;
LUSC	cis	rs308403	0.608	rs309362	chr4:123658154	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	10.68	0.5	4.34e-23	Blood protein levels;
LUSC	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg17168535	chr8:21777572	XPO7	0.82	14.88	0.63	9.25e-39	Mean corpuscular volume;
LUSC	cis	rs7681440	0.626	rs2289515	chr4:90816790	T/A	cg20003494	chr4:90757398	SNCA	-0.35	-5.85	-0.3	1.16e-8	Dementia with Lewy bodies;
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	0.42	6.92	0.35	2.29e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg14004847	chr7:1930337	MAD1L1	-0.57	-8.65	-0.43	2.26e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.72	0.35	7.81e-11	Aortic root size;
LUSC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg26513180	chr16:89883248	FANCA	-0.58	-8.75	-0.43	1.05e-16	Vitiligo;
LUSC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.19	0.49	2.08e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2235544	0.565	rs928443	chr1:54473516	C/T	cg25741118	chr1:54482237	LDLRAD1	0.29	6.09	0.32	3.07e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg12473912	chr3:136751656	NA	0.38	6.68	0.34	1e-10	Neuroticism;
LUSC	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg03676636	chr4:99064102	C4orf37	0.36	8.01	0.4	1.97e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6545883	0.860	rs6545847	chr2:61445333	C/T	cg15711740	chr2:61764176	XPO1	0.45	6.96	0.36	1.85e-11	Tuberculosis;
LUSC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg16545954	chr1:2118288	C1orf86	0.38	7.45	0.38	8.29e-13	Height;
LUSC	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg13010199	chr12:38710504	ALG10B	0.55	8.49	0.42	6.68e-16	Morning vs. evening chronotype;
LUSC	cis	rs9650657	0.707	rs6984744	chr8:10616265	A/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.08	-0.32	3.26e-9	Neuroticism;
LUSC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg26373071	chr5:1325741	CLPTM1L	0.44	8.18	0.41	5.88e-15	Lung cancer;
LUSC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg20712883	chr12:51590929	POU6F1	0.46	6.65	0.34	1.19e-10	Cisplatin-induced ototoxicity;
LUSC	cis	rs17253792	0.822	rs76819679	chr14:56134672	C/G	cg01858014	chr14:56050164	KTN1	-0.77	-6.57	-0.34	1.95e-10	Putamen volume;
LUSC	cis	rs7512552	0.803	rs11582423	chr1:150493925	C/G	cg15654264	chr1:150340011	RPRD2	0.59	9.52	0.46	3.53e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17467752	chr17:38218738	THRA	-0.51	-7.2	-0.37	4.05e-12	White blood cell count;
LUSC	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg14500267	chr11:67383377	NA	-0.35	-6.13	-0.32	2.41e-9	Mean corpuscular volume;
LUSC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg14416269	chr4:6271139	WFS1	0.54	11.38	0.53	1.35e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg01620082	chr3:125678407	NA	-0.69	-7.05	-0.36	1.06e-11	Breast cancer;
LUSC	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.69	-10.24	-0.49	1.42e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg19719311	chr1:51443992	NA	0.34	6.39	0.33	5.65e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg25554036	chr4:6271136	WFS1	0.51	9.11	0.45	7.51e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	8.18	0.41	6.17e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg25482853	chr8:67687455	SGK3	1.1	15.5	0.65	3.27e-41	Obesity-related traits;
LUSC	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg09469691	chr10:81107165	PPIF	0.63	9.21	0.45	3.65e-18	Height;
LUSC	cis	rs2224391	0.628	rs2753238	chr6:5252795	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.48	-6.66	-0.34	1.15e-10	Height;
LUSC	cis	rs6977660	0.714	rs728156	chr7:19826309	G/C	cg07541023	chr7:19748670	TWISTNB	0.6	6.3	0.33	9.45e-10	Thyroid stimulating hormone;
LUSC	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg22029157	chr1:209979665	IRF6	0.72	8.9	0.44	3.5e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg07169764	chr2:136633963	MCM6	0.89	12.05	0.55	5.37e-28	Corneal structure;
LUSC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg08807101	chr21:30365312	RNF160	0.72	11.46	0.53	7.28e-26	Selective IgA deficiency;
LUSC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg03563238	chr19:33554763	RHPN2	-0.39	-6.24	-0.32	1.3e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.47	6.29	0.33	9.83e-10	Renal function-related traits (BUN);
LUSC	cis	rs12210905	1.000	rs72843613	chr6:27138467	G/A	cg11502198	chr6:26597334	ABT1	-0.79	-5.66	-0.3	3.22e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg05084668	chr3:125655381	ALG1L	-0.76	-11.47	-0.53	6.5e-26	Blood pressure (smoking interaction);
LUSC	cis	rs9807989	0.765	rs6751977	chr2:102967430	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.85	0.3	1.19e-8	Asthma;
LUSC	cis	rs934734	0.967	rs1866051	chr2:65602149	T/C	cg08085232	chr2:65598271	SPRED2	-0.37	-5.81	-0.3	1.49e-8	Rheumatoid arthritis;
LUSC	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.49	-11.77	-0.54	5.48e-27	Urate levels in overweight individuals;
LUSC	cis	rs2346177	0.844	rs4953365	chr2:46644946	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-7.76	-0.39	1.07e-13	HDL cholesterol;
LUSC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24110177	chr3:50126178	RBM5	0.66	11.46	0.53	7.41e-26	Body mass index;
LUSC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg11366901	chr6:160182831	ACAT2	0.81	11.23	0.52	4.73e-25	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.01	-0.36	1.31e-11	Blood metabolite levels;
LUSC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-0.8	-15.5	-0.65	3.24e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg14552801	chr7:65878734	NA	-0.37	-5.87	-0.31	1.08e-8	Aortic root size;
LUSC	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg09092052	chr15:45571596	NA	0.46	6.42	0.33	4.63e-10	Glomerular filtration rate;
LUSC	cis	rs9677476	0.909	rs13408391	chr2:232124127	G/T	cg07929768	chr2:232055508	NA	0.34	6.28	0.33	1.04e-9	Food antigen IgG levels;
LUSC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg26769984	chr7:1090371	C7orf50	0.56	7.84	0.39	6.14e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.82	-0.43	6.39e-17	Response to antipsychotic treatment;
LUSC	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg15654264	chr1:150340011	RPRD2	-0.65	-11.03	-0.52	2.44e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07343612	chr16:622815	PIGQ	-0.78	-13.43	-0.59	3.49e-33	Height;
LUSC	cis	rs16854884	0.586	rs7639366	chr3:143752034	T/G	cg06585982	chr3:143692056	C3orf58	0.52	8.27	0.41	3.23e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs11630290	0.702	rs73444597	chr15:64126503	C/T	cg12036633	chr15:63758958	NA	-0.57	-6.32	-0.33	8.52e-10	Iris characteristics;
LUSC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-6.73	-0.35	7.23e-11	Mean platelet volume;
LUSC	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg00852783	chr1:26633632	UBXN11	0.49	8.68	0.43	1.76e-16	Obesity-related traits;
LUSC	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg00376283	chr12:123451042	ABCB9	0.65	8.3	0.41	2.63e-15	Neutrophil percentage of white cells;
LUSC	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.74	14.38	0.62	8e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg04362960	chr10:104952993	NT5C2	0.61	9.81	0.47	3.95e-20	Arsenic metabolism;
LUSC	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg24558204	chr6:135376177	HBS1L	0.57	8.77	0.43	9.29e-17	Red blood cell count;
LUSC	trans	rs72674100	1.000	rs28523751	chr4:97964750	T/A	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg24112000	chr20:60950667	NA	-0.41	-8.04	-0.4	1.58e-14	Colorectal cancer;
LUSC	cis	rs4664304	0.770	rs55860731	chr2:160875437	C/T	cg03641300	chr2:160917029	PLA2R1	-0.36	-5.89	-0.31	9.46e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg20684491	chr1:25596433	NA	0.39	6.1	0.32	2.88e-9	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs11031096	0.503	rs10835604	chr11:4109709	A/T	cg18678763	chr11:4115507	RRM1	-0.51	-6.86	-0.35	3.43e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	8.22	0.41	4.5e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg23029597	chr12:123009494	RSRC2	-0.67	-8.73	-0.43	1.21e-16	Body mass index;
LUSC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg00409905	chr10:38381863	ZNF37A	-0.33	-5.72	-0.3	2.37e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7474896	1.000	rs11011339	chr10:37996346	C/A	cg25427524	chr10:38739819	LOC399744	-0.51	-5.77	-0.3	1.8e-8	Obesity (extreme);
LUSC	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg24642844	chr7:1081250	C7orf50	-0.58	-5.84	-0.3	1.23e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.51	0.38	5.43e-13	Prudent dietary pattern;
LUSC	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg15423357	chr2:25149977	NA	-0.44	-9.31	-0.45	1.71e-18	Body mass index in non-asthmatics;
LUSC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.4	-7.47	-0.38	7.17e-13	Coronary artery disease;
LUSC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg11062466	chr8:58055876	NA	0.67	7.7	0.39	1.53e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7246967	0.673	rs8102172	chr19:22870019	G/A	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs11153730	0.503	rs283045	chr6:118628476	C/G	cg21191810	chr6:118973309	C6orf204	0.34	5.83	0.3	1.32e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUSC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg08859206	chr1:53392774	SCP2	-0.56	-9.93	-0.48	1.55e-20	Monocyte count;
LUSC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg03188948	chr7:1209495	NA	0.66	7.09	0.36	8.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg03351412	chr1:154909251	PMVK	0.54	8.32	0.41	2.24e-15	Prostate cancer;
LUSC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03526776	chr6:41159608	TREML2	-0.45	-8.71	-0.43	1.48e-16	Alzheimer's disease (late onset);
LUSC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg22166914	chr1:53195759	ZYG11B	0.68	11.6	0.54	2.19e-26	Monocyte count;
LUSC	cis	rs3770081	1.000	rs3770087	chr2:86267068	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.8	-5.95	-0.31	6.7e-9	Facial emotion recognition (sad faces);
LUSC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.22	0.32	1.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg17127132	chr2:85788382	GGCX	0.41	5.89	0.31	9.31e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21984481	chr17:79567631	NPLOC4	0.74	15.59	0.65	1.42e-41	Eye color traits;
LUSC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg15649852	chr7:65879115	NA	-0.43	-5.81	-0.3	1.48e-8	Aortic root size;
LUSC	cis	rs698813	0.604	rs1988663	chr2:44492753	C/T	cg00619915	chr2:44497795	NA	-0.54	-7.48	-0.38	6.57e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs7828089	0.935	rs1568569	chr8:22249943	T/G	cg12081754	chr8:22256438	SLC39A14	0.62	9.64	0.47	1.46e-19	Verbal declarative memory;
LUSC	trans	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.87	0.35	3.2e-11	Endometrial cancer;
LUSC	cis	rs11583043	0.575	rs12759611	chr1:101587145	T/G	cg11406453	chr1:101602562	NA	-0.4	-6.82	-0.35	4.29e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs12101261	0.536	rs2371463	chr14:81457788	G/A	cg06600135	chr14:81408086	NA	0.46	6.96	0.36	1.79e-11	Graves' disease;
LUSC	cis	rs9837602	1.000	rs7627991	chr3:99808338	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.51	6.28	0.32	1.08e-9	Breast cancer;
LUSC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.99	-0.4	2.17e-14	Mean platelet volume;
LUSC	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.33	-21.02	-0.75	4.35e-63	Type 1 diabetes nephropathy;
LUSC	cis	rs4704187	0.687	rs4389672	chr5:74368642	G/T	cg03227963	chr5:74354835	NA	0.33	7.23	0.37	3.26e-12	Response to amphetamines;
LUSC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg00409905	chr10:38381863	ZNF37A	-0.39	-6.63	-0.34	1.36e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9308433	0.529	rs17022608	chr1:214500907	A/C	cg06198575	chr1:214491504	SMYD2	0.45	6.87	0.35	3.11e-11	IgG glycosylation;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11060661	chr22:24314208	DDT;DDTL	0.4	6.7	0.34	8.98e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg07701084	chr6:150067640	NUP43	0.57	8.87	0.44	4.63e-17	Lung cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03630847	chr5:172385878	LOC100268168;RPL26L1	0.74	6.01	0.31	4.81e-9	Cognitive performance;
LUSC	cis	rs9886651	0.935	rs4582525	chr8:128800947	A/G	cg07795030	chr8:128802207	NA	-0.34	-6.08	-0.32	3.35e-9	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LUSC	trans	rs61931739	0.635	rs1825746	chr12:33939984	C/T	cg13010199	chr12:38710504	ALG10B	0.4	6.05	0.31	3.88e-9	Morning vs. evening chronotype;
LUSC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg02569458	chr12:86230093	RASSF9	0.52	8.57	0.42	3.81e-16	Major depressive disorder;
LUSC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.47	-8.32	-0.41	2.23e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.46	7.42	0.38	9.53e-13	Resistin levels;
LUSC	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg16745616	chr19:8428856	ANGPTL4	-0.4	-6.03	-0.31	4.41e-9	HDL cholesterol;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01794563	chr14:102430985	DYNC1H1	-0.39	-6.01	-0.31	4.85e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs34638657	0.732	rs12597171	chr16:82200119	A/G	cg09439754	chr16:82129088	HSD17B2	0.35	5.76	0.3	1.87e-8	Lung adenocarcinoma;
LUSC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12756686	chr19:29218302	NA	0.59	6.86	0.35	3.26e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.73	-11.46	-0.53	7.13e-26	Dilated cardiomyopathy;
LUSC	cis	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.7	-0.3	2.63e-8	Resting heart rate;
LUSC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg18477163	chr1:228402036	OBSCN	-0.57	-10.59	-0.5	8.66e-23	Diastolic blood pressure;
LUSC	cis	rs62400317	0.859	rs10948212	chr6:45156933	A/C	cg18551225	chr6:44695536	NA	-0.45	-7.22	-0.37	3.47e-12	Total body bone mineral density;
LUSC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg11965913	chr1:205819406	PM20D1	0.88	16.95	0.68	5.97e-47	Menarche (age at onset);
LUSC	cis	rs28580297	1	rs28580297	chr4:119427957	C/G	cg02775129	chr4:119771670	NA	-0.56	-6.06	-0.31	3.71e-9	Body mass index;
LUSC	trans	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04565464	chr8:145669602	NFKBIL2	0.37	6.05	0.31	3.87e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs35306767	0.623	rs36062650	chr10:1142571	T/C	cg20503657	chr10:835505	NA	0.46	6.03	0.31	4.34e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg16325326	chr1:53192061	ZYG11B	-0.92	-18.08	-0.7	2.05e-51	Monocyte count;
LUSC	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg27087555	chr16:88793112	FAM38A	-1.42	-13.09	-0.58	7.12e-32	Plateletcrit;
LUSC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg19812747	chr11:111475976	SIK2	-0.55	-8.14	-0.41	7.93e-15	Primary sclerosing cholangitis;
LUSC	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg25482853	chr8:67687455	SGK3	1.12	16.14	0.66	1.01e-43	Obesity-related traits;
LUSC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg22903471	chr2:27725779	GCKR	-0.4	-6.84	-0.35	3.67e-11	Total body bone mineral density;
LUSC	cis	rs686320	1.000	rs679643	chr11:65250590	C/A	cg21890820	chr11:65308645	LTBP3	0.77	7.76	0.39	1.05e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs1419980	0.673	rs10772553	chr12:7768089	G/A	cg10578777	chr12:7781093	NA	-0.57	-6.25	-0.32	1.27e-9	HDL cholesterol levels;
LUSC	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg19116668	chr7:99932089	PMS2L1	0.35	6.12	0.32	2.68e-9	Coronary artery disease;
LUSC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg00012203	chr2:219082015	ARPC2	-0.7	-11.44	-0.53	8.34e-26	Colorectal cancer;
LUSC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.52e-9	Menopause (age at onset);
LUSC	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg17595323	chr11:93583763	C11orf90	-0.31	-5.78	-0.3	1.75e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14829155	chr15:31115871	NA	0.71	11.03	0.52	2.47e-24	Huntington's disease progression;
LUSC	cis	rs9644630	0.932	rs4273861	chr8:19352703	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.37	6.96	0.36	1.84e-11	Oropharynx cancer;
LUSC	trans	rs4720118	0.967	rs4723288	chr7:33487086	C/T	cg18659248	chr10:3679062	NA	-0.35	-6.03	-0.31	4.28e-9	Leprosy;
LUSC	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg11901034	chr3:128598214	ACAD9	-0.39	-6.03	-0.31	4.3e-9	IgG glycosylation;
LUSC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg08219700	chr8:58056026	NA	0.5	6.18	0.32	1.84e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg11247378	chr22:39784982	NA	-0.65	-13.06	-0.58	8.8e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg09092052	chr15:45571596	NA	0.46	6.36	0.33	6.52e-10	Glomerular filtration rate;
LUSC	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs3771570	1.000	rs73004354	chr2:242356239	G/T	cg21155796	chr2:242212141	HDLBP	0.61	6.57	0.34	1.9e-10	Prostate cancer;
LUSC	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg06462663	chr19:18546047	ISYNA1	0.45	7.63	0.39	2.54e-13	Breast cancer;
LUSC	cis	rs3764021	0.870	rs10743819	chr12:9876768	A/C	cg20894963	chr12:9885564	CLECL1	0.35	7.1	0.36	7.57e-12	Type 1 diabetes;
LUSC	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg08079166	chr15:68083412	MAP2K5	-0.4	-7.33	-0.37	1.78e-12	Restless legs syndrome;
LUSC	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.09	-17.12	-0.68	1.32e-47	Primary sclerosing cholangitis;
LUSC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg25344623	chr2:136566232	LCT	0.38	5.73	0.3	2.27e-8	Mosquito bite size;
LUSC	cis	rs4917833	0.789	rs11189618	chr10:100219519	G/A	cg19043522	chr10:100227446	HPSE2	0.4	5.71	0.3	2.53e-8	Pediatric bone mineral density (femoral neck);
LUSC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	9.84	0.47	3.12e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs870825	0.616	rs4519838	chr4:185628457	A/G	cg04058563	chr4:185651563	MLF1IP	0.88	13.14	0.58	4.44e-32	Blood protein levels;
LUSC	cis	rs11997175	0.715	rs7012923	chr8:33630937	A/C	ch.8.33884649F	chr8:33765107	NA	0.41	6.65	0.34	1.19e-10	Body mass index;
LUSC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00166722	chr3:10149974	C3orf24	0.6	8.2	0.41	5.37e-15	Alzheimer's disease;
LUSC	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg15423357	chr2:25149977	NA	0.44	8.97	0.44	2.11e-17	Body mass index;
LUSC	cis	rs240768	1.000	rs240157	chr6:101062677	T/C	cg12253828	chr6:101329408	ASCC3	0.83	5.73	0.3	2.27e-8	Economic and political preferences (immigration/crime);
LUSC	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg11901034	chr3:128598214	ACAD9	-0.39	-6.26	-0.32	1.18e-9	IgG glycosylation;
LUSC	cis	rs939574	1.000	rs45488900	chr2:220116509	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.09	8.72	0.43	1.31e-16	Platelet distribution width;
LUSC	cis	rs6558174	0.965	rs4072394	chr8:22490800	C/T	cg03733263	chr8:22462867	KIAA1967	0.45	6.01	0.31	4.74e-9	Breast cancer;
LUSC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg07424592	chr7:64974309	NA	-0.64	-5.73	-0.3	2.24e-8	Diabetic kidney disease;
LUSC	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg13042288	chr15:90349979	ANPEP	-0.48	-7.01	-0.36	1.31e-11	Uric acid levels;
LUSC	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.51	0.56	1.01e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs2857891	0.817	rs2638095	chr11:6979915	C/T	cg04053776	chr11:6947353	ZNF215	0.42	5.78	0.3	1.72e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg10840412	chr1:235813424	GNG4	0.47	6.02	0.31	4.71e-9	Bipolar disorder;
LUSC	cis	rs4664308	1.000	rs17831251	chr2:160914156	C/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.35	-0.53	1.8e-25	Idiopathic membranous nephropathy;
LUSC	trans	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg10756647	chr7:56101905	PSPH	1.01	6.53	0.34	2.51e-10	Diabetic kidney disease;
LUSC	cis	rs3126085	0.935	rs7537637	chr1:152223335	T/A	cg26876637	chr1:152193138	HRNR	0.44	6.2	0.32	1.7e-9	Atopic dermatitis;
LUSC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg21280719	chr6:42927975	GNMT	-0.32	-7.82	-0.39	7.14e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17650050	chr22:19419470	HIRA;MRPL40	-0.43	-6.65	-0.34	1.17e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7178572	0.568	rs11857294	chr15:77596725	C/T	cg22256960	chr15:77711686	NA	-0.51	-8.04	-0.4	1.63e-14	Type 2 diabetes;
LUSC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.57	-8.38	-0.42	1.51e-15	Obesity-related traits;
LUSC	cis	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg26958806	chr6:27640298	NA	0.8	6.56	0.34	2.04e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs62380364	0.602	rs650702	chr5:88055313	G/A	cg22951263	chr5:87985283	NA	-0.46	-7.53	-0.38	4.89e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	5.91	0.31	8.23e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg24060327	chr5:131705240	SLC22A5	-0.37	-6.0	-0.31	5.14e-9	Blood metabolite levels;
LUSC	trans	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs67072384	0.901	rs67288233	chr11:72458361	G/A	cg04827223	chr11:72435913	ARAP1	-0.74	-6.39	-0.33	5.61e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs9341808	0.519	rs4446525	chr6:81024053	C/T	cg08355045	chr6:80787529	NA	-0.42	-7.15	-0.36	5.59e-12	Sitting height ratio;
LUSC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg17724175	chr1:150552817	MCL1	-0.37	-6.79	-0.35	5.14e-11	Tonsillectomy;
LUSC	trans	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg04995722	chr7:26192034	NFE2L3	0.37	6.17	0.32	1.97e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12618769	1.000	rs55934348	chr2:99246885	T/C	cg10123293	chr2:99228465	UNC50	0.42	5.75	0.3	1.96e-8	Bipolar disorder;
LUSC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-11.93	-0.55	1.4e-27	Platelet count;
LUSC	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.11	15.45	0.65	5.38e-41	Uric acid levels;
LUSC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg06600287	chr1:53387719	ECHDC2	-0.28	-5.73	-0.3	2.26e-8	Monocyte count;
LUSC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg17376030	chr22:41985996	PMM1	0.46	5.85	0.31	1.15e-8	Vitiligo;
LUSC	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg23093090	chr10:104574429	C10orf26	-0.36	-6.6	-0.34	1.57e-10	Arsenic metabolism;
LUSC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.39	0.53	1.25e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.56	7.89	0.4	4.21e-14	Iron status biomarkers;
LUSC	cis	rs2742234	0.541	rs61845684	chr10:43744983	T/C	cg07801480	chr10:43725741	RASGEF1A	-0.39	-5.66	-0.3	3.26e-8	Hirschsprung disease;
LUSC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26314531	chr2:26401878	FAM59B	-0.7	-9.79	-0.47	4.64e-20	Gut microbiome composition (summer);
LUSC	cis	rs2742234	0.554	rs1270015	chr10:43698240	G/T	cg15436174	chr10:43711423	RASGEF1A	0.44	6.97	0.36	1.68e-11	Hirschsprung disease;
LUSC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg24503407	chr1:205819492	PM20D1	0.42	5.65	0.3	3.51e-8	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.76	-13.74	-0.6	2.24e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11644478	chr21:40555479	PSMG1	-0.62	-9.7	-0.47	9.15e-20	Menarche (age at onset);
LUSC	cis	rs12545109	0.879	rs2576580	chr8:57365828	G/C	cg09654669	chr8:57350985	NA	-0.57	-7.46	-0.38	7.7e-13	Obesity-related traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07135601	chr12:110906630	GPN3;C12orf24	-0.42	-6.26	-0.32	1.21e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg06028605	chr16:24865363	SLC5A11	0.59	8.58	0.42	3.75e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3087591	0.708	rs2854319	chr17:29694054	G/C	cg24425628	chr17:29625626	OMG;NF1	0.49	7.16	0.36	5.13e-12	Hip circumference;
LUSC	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg09307838	chr4:120376055	NA	-0.67	-9.79	-0.47	4.56e-20	Corneal astigmatism;
LUSC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg11871910	chr12:69753446	YEATS4	-0.92	-17.48	-0.69	4.62e-49	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg23791538	chr6:167370224	RNASET2	-0.43	-6.95	-0.36	1.93e-11	Crohn's disease;
LUSC	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg22467129	chr15:76604101	ETFA	0.44	6.98	0.36	1.62e-11	Blood metabolite levels;
LUSC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg05861140	chr6:150128134	PCMT1	-0.45	-7.17	-0.37	4.83e-12	Lung cancer;
LUSC	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.73	14.19	0.61	4.47e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	trans	rs62238980	0.614	rs4820062	chr22:32392437	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs11734570	0.581	rs4461531	chr4:38603576	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.48	6.03	0.31	4.41e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg15557168	chr22:42548783	NA	-0.47	-7.31	-0.37	2.03e-12	Schizophrenia;
LUSC	cis	rs13082711	0.911	rs6797389	chr3:27502070	G/T	cg02860705	chr3:27208620	NA	0.5	8.35	0.42	1.86e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs601339	1.000	rs1798219	chr12:123180061	A/C	cg11919336	chr12:123188078	GPR109A	0.43	6.52	0.34	2.64e-10	Adiponectin levels;
LUSC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08704250	chr15:31115839	NA	-0.57	-8.78	-0.43	8.33e-17	Huntington's disease progression;
LUSC	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.13	0.48	3.31e-21	Coffee consumption (cups per day);
LUSC	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.11	-29.49	-0.85	5.51e-95	Myeloid white cell count;
LUSC	cis	rs10203711	0.966	rs6713626	chr2:239566896	C/T	cg14580085	chr2:239553406	NA	0.41	6.93	0.35	2.24e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg01689657	chr7:91764605	CYP51A1	0.34	6.13	0.32	2.52e-9	Breast cancer;
LUSC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-7.03	-0.36	1.15e-11	Chronic sinus infection;
LUSC	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg16950941	chr11:66035639	RAB1B	0.51	7.4	0.38	1.09e-12	Gout;
LUSC	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg07810366	chr2:100720526	AFF3	-0.43	-7.16	-0.36	5.29e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23158103	chr7:148848205	ZNF398	-0.45	-7.29	-0.37	2.28e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg15448220	chr1:150897856	SETDB1	0.43	6.23	0.32	1.43e-9	Melanoma;
LUSC	cis	rs2652834	0.851	rs1566660	chr15:63429258	C/G	cg05507819	chr15:63340323	TPM1	0.44	5.74	0.3	2.16e-8	HDL cholesterol;
LUSC	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg16743903	chr16:89593216	SPG7	-0.41	-5.72	-0.3	2.32e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Bladder cancer;
LUSC	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg01028140	chr2:1542097	TPO	-0.6	-8.14	-0.41	7.81e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.67	-10.45	-0.5	2.63e-22	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	trans	rs7939886	0.920	rs1586014	chr11:55771540	C/T	cg03929089	chr4:120376271	NA	0.79	6.79	0.35	5.1e-11	Myopia (pathological);
LUSC	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg05110241	chr16:68378359	PRMT7	-0.82	-8.37	-0.42	1.55e-15	Schizophrenia;
LUSC	cis	rs116975820	0.697	rs11181433	chr12:42733559	A/G	cg01256987	chr12:42539512	GXYLT1	-0.46	-6.01	-0.31	4.88e-9	PR interval in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg14196790	chr5:131705035	SLC22A5	0.5	8.52	0.42	5.4e-16	Blood metabolite levels;
LUSC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.67	-10.16	-0.49	2.61e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg06145435	chr7:1022769	CYP2W1	0.34	7.37	0.37	1.38e-12	Longevity;Endometriosis;
LUSC	cis	rs2235649	0.833	rs9939766	chr16:1852808	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-6.13	-0.32	2.55e-9	Blood metabolite levels;
LUSC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg09455208	chr3:40491958	NA	0.59	10.09	0.48	4.36e-21	Renal cell carcinoma;
LUSC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg06212747	chr3:49208901	KLHDC8B	0.48	5.88	0.31	9.74e-9	Menarche (age at onset);
LUSC	cis	rs727505	0.607	rs59635547	chr7:124796371	A/C	cg23710748	chr7:124431027	NA	-0.39	-6.77	-0.35	5.67e-11	Lewy body disease;
LUSC	cis	rs8099014	1.000	rs9319929	chr18:56115825	A/C	cg12907477	chr18:56117327	MIR122	0.43	6.81	0.35	4.5e-11	Platelet count;
LUSC	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.67e-24	Hypertriglyceridemia;
LUSC	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg04586622	chr2:25135609	ADCY3	0.32	6.18	0.32	1.92e-9	Body mass index;
LUSC	cis	rs12545109	0.800	rs2118260	chr8:57393481	T/C	cg09654669	chr8:57350985	NA	-0.51	-6.78	-0.35	5.55e-11	Obesity-related traits;
LUSC	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg07621104	chr11:117668040	DSCAML1	0.51	6.82	0.35	4.18e-11	Myopia;
LUSC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg08859206	chr1:53392774	SCP2	0.46	7.64	0.39	2.33e-13	Monocyte count;
LUSC	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.68	-10.91	-0.51	6.54e-24	Retinal vascular caliber;
LUSC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg15145296	chr3:125709740	NA	-0.59	-6.67	-0.34	1.06e-10	Blood pressure (smoking interaction);
LUSC	cis	rs2109514	0.902	rs1007751	chr7:116110055	A/T	cg12739419	chr7:116140593	CAV2	-0.27	-5.94	-0.31	7.3e-9	Prevalent atrial fibrillation;
LUSC	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg18825119	chr6:163149453	PACRG;PARK2	-0.35	-6.23	-0.32	1.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.68	-0.3	2.93e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9311676	0.618	rs11130639	chr3:58406004	G/T	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.3e-10	Systemic lupus erythematosus;
LUSC	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg08917208	chr2:24149416	ATAD2B	0.99	10.11	0.48	4.01e-21	Lymphocyte counts;
LUSC	cis	rs4964805	0.913	rs36034617	chr12:104203615	G/C	cg02344784	chr12:104178138	NT5DC3	0.43	6.93	0.35	2.2e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.69	0.54	1.04e-26	Prudent dietary pattern;
LUSC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs72634258	0.554	rs35123409	chr1:7878568	C/T	cg26816564	chr1:7831052	VAMP3	0.96	12.48	0.56	1.37e-29	Inflammatory bowel disease;
LUSC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.63	-0.34	1.32e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg22467129	chr15:76604101	ETFA	-0.51	-8.25	-0.41	3.8e-15	Blood metabolite levels;
LUSC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg10523860	chr14:103875565	MARK3	0.4	6.48	0.33	3.3e-10	Body mass index;
LUSC	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg06917634	chr15:78832804	PSMA4	0.43	6.13	0.32	2.54e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs1524927	0.933	rs11769570	chr7:96359716	C/G	cg03808172	chr7:96339361	SHFM1	0.43	6.53	0.34	2.48e-10	Total body bone mineral density;
LUSC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.45e-9	Menopause (age at onset);
LUSC	cis	rs8056893	0.569	rs9935025	chr16:68307447	C/T	cg02226672	chr16:68398533	SMPD3	-0.29	-5.67	-0.3	3.02e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	trans	rs1459104	0.866	rs34179570	chr11:54823141	C/T	cg03929089	chr4:120376271	NA	0.7	6.08	0.32	3.27e-9	Body mass index;
LUSC	cis	rs1595825	0.891	rs4491721	chr2:198521407	C/G	cg00982548	chr2:198649783	BOLL	-0.52	-6.63	-0.34	1.34e-10	Ulcerative colitis;
LUSC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg01475377	chr6:109611718	NA	-0.42	-7.4	-0.38	1.13e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg25208724	chr1:156163844	SLC25A44	1.11	24.06	0.8	6.29e-75	Testicular germ cell tumor;
LUSC	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg23093090	chr10:104574429	C10orf26	-0.47	-5.76	-0.3	1.94e-8	Arsenic metabolism;
LUSC	cis	rs9807989	0.507	rs1035129	chr2:103019785	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.72e-12	Asthma;
LUSC	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.46	-0.42	8.73e-16	Heart rate;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg16523621	chr5:172721053	NA	0.73	6.56	0.34	2.11e-10	Cognitive performance;
LUSC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg09640425	chr7:158790006	NA	-0.41	-6.47	-0.33	3.53e-10	Facial morphology (factor 20);
LUSC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg20887711	chr4:1340912	KIAA1530	-0.41	-6.48	-0.33	3.19e-10	Obesity-related traits;
LUSC	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg13390004	chr1:15929781	NA	0.42	7.04	0.36	1.07e-11	Systolic blood pressure;
LUSC	cis	rs1322512	0.917	rs2800651	chr6:152976421	C/A	cg27316956	chr6:152958899	SYNE1	-0.37	-6.3	-0.33	9.2e-10	Tonometry;
LUSC	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg09092052	chr15:45571596	NA	0.45	6.3	0.33	9.44e-10	Glomerular filtration rate;
LUSC	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg04310649	chr10:35416472	CREM	-0.44	-6.56	-0.34	2.03e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.23	0.37	3.3e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6961069	0.749	rs4316098	chr7:80259988	C/T	cg04458919	chr7:80252533	CD36	0.37	6.68	0.34	1.02e-10	Platelet count;
LUSC	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg26384229	chr12:38710491	ALG10B	0.74	11.9	0.55	1.78e-27	Morning vs. evening chronotype;
LUSC	trans	rs7772697	0.508	rs13217006	chr6:149375716	C/G	cg22609380	chr12:98849379	NA	0.34	6.02	0.31	4.54e-9	Diabetic retinopathy;
LUSC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg09323728	chr8:95962352	TP53INP1	-0.38	-7.74	-0.39	1.2e-13	Type 2 diabetes;
LUSC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.53	-9.39	-0.46	9.4e-19	Bipolar disorder;
LUSC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg19875535	chr5:140030758	IK	0.54	8.95	0.44	2.48e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9815354	0.812	rs57209010	chr3:41854743	A/T	cg03022575	chr3:42003672	ULK4	0.83	8.75	0.43	1.07e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6750795	0.602	rs1667317	chr2:232412036	T/C	cg19187155	chr2:232395269	NMUR1	0.77	11.05	0.52	2.08e-24	Height;
LUSC	cis	rs11637445	0.603	rs1478941	chr15:68127141	A/G	cg08079166	chr15:68083412	MAP2K5	0.35	7.05	0.36	1.04e-11	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-8.98	-0.44	2.06e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	0.99	14.14	0.61	6.88e-36	Vitiligo;
LUSC	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg15557168	chr22:42548783	NA	-0.41	-7.01	-0.36	1.33e-11	Cognitive function;
LUSC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.26	34.21	0.88	3.37e-111	Chronic sinus infection;
LUSC	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.98	-0.36	1.58e-11	Response to antipsychotic treatment;
LUSC	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg05621596	chr22:47072043	GRAMD4	0.53	8.68	0.43	1.75e-16	Urate levels in obese individuals;
LUSC	cis	rs3733606	0.538	rs11734099	chr4:6891435	G/A	cg05012661	chr4:6891264	NA	0.59	8.35	0.42	1.82e-15	Platelet count;
LUSC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg03806693	chr22:41940476	POLR3H	-0.86	-12.34	-0.56	4.3e-29	Vitiligo;
LUSC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.64	9.76	0.47	5.84e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9650315	0.706	rs36112366	chr8:57138676	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.7	0.39	1.53e-13	Height;
LUSC	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg17845761	chr1:175162550	KIAA0040	-0.31	-6.0	-0.31	5.07e-9	Alcohol dependence;
LUSC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.65	9.67	0.47	1.12e-19	Blood protein levels;
LUSC	cis	rs28448403	1	rs28448403	chr8:11305564	G/A	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.33	-5.74	-0.3	2.1e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs80282103	0.618	rs1079389	chr10:1161980	A/G	cg18964960	chr10:1102726	WDR37	0.7	5.84	0.3	1.22e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs11608355	0.552	rs2304549	chr12:109794875	A/G	cg19025524	chr12:109796872	NA	-0.48	-9.16	-0.45	5.49e-18	Neuroticism;
LUSC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.91	-0.4	3.78e-14	Blood metabolite levels;
LUSC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg19622623	chr12:86230825	RASSF9	-0.46	-6.62	-0.34	1.48e-10	Major depressive disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23307708	chr5:133561976	PPP2CA	-0.49	-6.2	-0.32	1.65e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7119	0.651	rs12917044	chr15:77850146	A/G	cg27398640	chr15:77910606	LINGO1	0.32	6.86	0.35	3.3e-11	Type 2 diabetes;
LUSC	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07636037	chr3:49044803	WDR6	-0.69	-9.2	-0.45	4.05e-18	Menarche (age at onset);
LUSC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg18225595	chr11:63971243	STIP1	0.58	9.44	0.46	6.74e-19	Platelet count;
LUSC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg17366294	chr4:99064904	C4orf37	0.54	9.6	0.47	1.91e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2625529	0.761	rs11853268	chr15:72238973	T/C	cg16672083	chr15:72433130	SENP8	-0.51	-7.49	-0.38	6.37e-13	Red blood cell count;
LUSC	cis	rs76878669	0.561	rs10791876	chr11:66169646	C/T	cg18002602	chr11:66138449	SLC29A2	-0.49	-8.8	-0.43	7.57e-17	Educational attainment (years of education);
LUSC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.72	12.13	0.55	2.61e-28	Motion sickness;
LUSC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.4	-0.49	3.84e-22	Hemoglobin concentration;
LUSC	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg12310025	chr6:25882481	NA	-0.34	-5.72	-0.3	2.41e-8	Height;
LUSC	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.65	-9.41	-0.46	8.6e-19	Bipolar disorder;
LUSC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg02269571	chr22:50332266	NA	-0.51	-7.53	-0.38	4.88e-13	Schizophrenia;
LUSC	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg03517284	chr6:25882590	NA	-0.32	-5.71	-0.3	2.49e-8	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23000811	chr4:2464397	NA	-0.38	-6.18	-0.32	1.91e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg20848291	chr7:100343083	ZAN	-0.67	-9.26	-0.45	2.5e-18	Other erythrocyte phenotypes;
LUSC	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg13010199	chr12:38710504	ALG10B	0.66	9.97	0.48	1.11e-20	Bladder cancer;
LUSC	trans	rs895636	1.000	rs895636	chr2:45188353	A/G	cg26822602	chr1:247418074	VN1R5	0.41	6.12	0.32	2.61e-9	Metabolite levels;Fasting plasma glucose;
LUSC	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg05966235	chr16:28915196	ATP2A1	0.34	5.96	0.31	6.43e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-1.23	-13.41	-0.59	4.23e-33	Diabetic kidney disease;
LUSC	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg02018176	chr4:1364513	KIAA1530	0.44	6.05	0.31	3.91e-9	Recombination rate (females);
LUSC	cis	rs1018836	0.663	rs4735190	chr8:91509601	A/G	cg16814680	chr8:91681699	NA	-0.71	-10.89	-0.51	7.52e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg23985595	chr17:80112537	CCDC57	-0.3	-5.91	-0.31	8.55e-9	Life satisfaction;
LUSC	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg23691781	chr1:28212827	C1orf38	0.31	7.43	0.38	8.99e-13	Corneal astigmatism;
LUSC	cis	rs28655083	0.529	rs1847161	chr16:77097796	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	6.99	0.36	1.5e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg23788917	chr6:8435910	SLC35B3	0.51	7.56	0.38	3.86e-13	Motion sickness;
LUSC	cis	rs17407555	0.697	rs73212821	chr4:10069451	T/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-6.48	-0.33	3.27e-10	Schizophrenia (age at onset);
LUSC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03264133	chr6:25882463	NA	-0.42	-7.28	-0.37	2.42e-12	Blood metabolite levels;
LUSC	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg02023728	chr11:77925099	USP35	-0.44	-6.56	-0.34	2.1e-10	Testicular germ cell tumor;
LUSC	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-7.57	-0.38	3.63e-13	Neuroticism;
LUSC	cis	rs6545883	0.868	rs7574631	chr2:61825142	T/G	cg15711740	chr2:61764176	XPO1	-0.46	-7.31	-0.37	1.97e-12	Tuberculosis;
LUSC	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg03060546	chr3:49711283	APEH	0.59	8.22	0.41	4.42e-15	Resting heart rate;
LUSC	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.75	-0.39	1.1e-13	Neuroticism;
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22029157	chr1:209979665	IRF6	0.84	17.31	0.69	2.38e-48	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg11502198	chr6:26597334	ABT1	0.72	12.19	0.56	1.53e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg00898013	chr13:113819073	PROZ	-0.6	-8.48	-0.42	7.38e-16	Platelet distribution width;
LUSC	trans	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg06606381	chr12:133084897	FBRSL1	-0.56	-6.55	-0.34	2.16e-10	Depression;
LUSC	cis	rs7580658	0.929	rs13029237	chr2:128147854	C/T	cg09760422	chr2:128146352	NA	-0.33	-7.3	-0.37	2.12e-12	Protein C levels;
LUSC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.86	14.36	0.62	9.18e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg19318889	chr4:1322082	MAEA	-0.54	-8.76	-0.43	1.02e-16	Obesity-related traits;
LUSC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg04850211	chr1:228464232	OBSCN	0.32	5.77	0.3	1.78e-8	Diastolic blood pressure;
LUSC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg22823121	chr1:150693482	HORMAD1	0.5	7.44	0.38	8.47e-13	Melanoma;
LUSC	cis	rs9815354	0.812	rs73073358	chr3:41842527	G/A	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg09165964	chr15:75287851	SCAMP5	-0.93	-8.66	-0.43	2.11e-16	Lung cancer;
LUSC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.79	14.68	0.63	5.37e-38	Dental caries;
LUSC	cis	rs4077515	0.870	rs11793497	chr9:139271850	A/G	cg14169450	chr9:139327907	INPP5E	0.42	7.53	0.38	4.81e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs9409565	0.826	rs4612412	chr9:97208627	C/G	cg05679027	chr9:99775184	HIATL2	-0.5	-7.2	-0.37	4e-12	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.15	-0.36	5.49e-12	Major depressive disorder;
LUSC	cis	rs73206853	0.620	rs55845219	chr12:111164875	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	6.69	0.34	9.64e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1595825	0.891	rs76308665	chr2:198518062	C/T	cg19156104	chr2:198669113	PLCL1	-0.46	-5.75	-0.3	2.02e-8	Ulcerative colitis;
LUSC	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg08017756	chr2:100939284	LONRF2	-0.39	-7.21	-0.37	3.8e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg18681998	chr4:17616180	MED28	0.84	15.2	0.64	4.81e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6543140	0.964	rs10200081	chr2:103091556	T/C	cg09003973	chr2:102972529	NA	0.54	6.83	0.35	4.07e-11	Blood protein levels;
LUSC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.33	-0.33	7.74e-10	Vitiligo;
LUSC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.75	0.43	1.09e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg08888203	chr3:10149979	C3orf24	0.59	8.2	0.41	5.23e-15	Alzheimer's disease;
LUSC	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.25	-27.39	-0.83	2.17e-87	Exhaled nitric oxide output;
LUSC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg22508957	chr16:3507546	NAT15	-0.4	-5.7	-0.3	2.66e-8	Body mass index (adult);
LUSC	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg00290607	chr11:67383545	NA	0.35	6.58	0.34	1.81e-10	Mean corpuscular volume;
LUSC	trans	rs1941687	0.505	rs9956918	chr18:31315878	C/G	cg27147174	chr7:100797783	AP1S1	0.51	7.71	0.39	1.47e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-8.21	-0.41	4.95e-15	Aortic root size;
LUSC	cis	rs9039	1.000	rs17567434	chr16:9221447	C/G	cg08831531	chr16:9218945	NA	-0.65	-9.82	-0.47	3.59e-20	Menopause (age at onset);
LUSC	cis	rs642803	0.551	rs1308020	chr11:65497558	G/A	cg27068330	chr11:65405492	SIPA1	0.55	7.54	0.38	4.38e-13	Urate levels;
LUSC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.59	-5.76	-0.3	1.91e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.46	-5.79	-0.3	1.63e-8	Renal function-related traits (BUN);
LUSC	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg17143192	chr8:8559678	CLDN23	0.39	5.93	0.31	7.46e-9	Mood instability;
LUSC	cis	rs6882046	0.513	rs676096	chr5:88035887	C/T	cg22951263	chr5:87985283	NA	-0.45	-7.25	-0.37	2.85e-12	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LUSC	cis	rs593982	1.000	rs665191	chr11:65493658	G/A	cg08755490	chr11:65554678	OVOL1	1.43	15.16	0.64	7.19e-40	Atopic dermatitis;
LUSC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg03388025	chr16:89894329	SPIRE2	0.33	7.01	0.36	1.35e-11	Vitiligo;
LUSC	cis	rs6690583	0.623	rs12042160	chr1:85504516	A/G	cg11262906	chr1:85462892	MCOLN2	0.64	6.03	0.31	4.23e-9	Serum sulfate level;
LUSC	cis	rs7094131	0.523	rs10741008	chr10:22882344	T/G	cg19500236	chr10:22911537	PIP4K2A	0.36	6.23	0.32	1.38e-9	Obesity-related traits;
LUSC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-11.63	-0.54	1.72e-26	Platelet count;
LUSC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg10518572	chr11:65560635	OVOL1	-0.26	-6.0	-0.31	5.05e-9	Acne (severe);
LUSC	cis	rs2580764	0.565	rs2919129	chr2:55216545	G/T	cg20993754	chr2:55226987	RTN4	-0.33	-5.65	-0.3	3.39e-8	Mean platelet volume;
LUSC	cis	rs9814567	0.752	rs4634170	chr3:134335471	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.48	-0.56	1.33e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21984481	chr17:79567631	NPLOC4	0.58	11.22	0.52	5.07e-25	Eye color traits;
LUSC	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg15819921	chr19:927150	ARID3A	-0.43	-6.44	-0.33	4.06e-10	Life satisfaction;
LUSC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg27432699	chr2:27873401	GPN1	-0.59	-8.9	-0.44	3.72e-17	Menopause (age at onset);
LUSC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg23791538	chr6:167370224	RNASET2	-0.41	-6.51	-0.34	2.74e-10	Crohn's disease;
LUSC	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.48	0.46	4.86e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg10253484	chr15:75165896	SCAMP2	-0.49	-6.63	-0.34	1.33e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg12257692	chr3:49977190	RBM6	0.25	6.82	0.35	4.23e-11	Body mass index;
LUSC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00376283	chr12:123451042	ABCB9	0.68	8.54	0.42	4.8e-16	Neutrophil percentage of white cells;
LUSC	cis	rs12369635	1.000	rs11060121	chr12:129564206	C/T	cg01909103	chr12:129572610	TMEM132D	-0.6	-5.72	-0.3	2.41e-8	Schizophrenia (inflammation and infection response interaction);
LUSC	trans	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-9.22	-0.45	3.34e-18	Depression;
LUSC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-8.85	-0.44	5.14e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg23625390	chr15:77176239	SCAPER	-0.66	-10.26	-0.49	1.16e-21	Blood metabolite levels;
LUSC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	6.81	0.35	4.42e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1461503	0.534	rs7944405	chr11:122816099	A/G	cg27398637	chr11:122830231	C11orf63	-0.41	-6.75	-0.35	6.47e-11	Menarche (age at onset);
LUSC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg20891283	chr12:69753455	YEATS4	0.63	9.58	0.46	2.27e-19	Blood protein levels;
LUSC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg13256891	chr4:100009986	ADH5	-0.43	-6.0	-0.31	5.06e-9	Alcohol dependence;
LUSC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg22823121	chr1:150693482	HORMAD1	0.49	7.03	0.36	1.17e-11	Melanoma;
LUSC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25072359	chr17:41440525	NA	0.64	9.04	0.44	1.26e-17	Menopause (age at onset);
LUSC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg25427524	chr10:38739819	LOC399744	0.43	5.74	0.3	2.09e-8	Obesity (extreme);
LUSC	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg23188684	chr11:67383651	NA	0.34	6.01	0.31	4.86e-9	Mean corpuscular volume;
LUSC	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.05	-0.4	1.43e-14	Neuroticism;
LUSC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg11871910	chr12:69753446	YEATS4	0.9	16.75	0.68	3.71e-46	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.74	-11.1	-0.52	1.37e-24	Vitiligo;
LUSC	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.5	-0.34	2.93e-10	Recombination measurement;
LUSC	cis	rs3820928	0.874	rs2276593	chr2:227898434	A/G	cg11843606	chr2:227700838	RHBDD1	0.55	7.83	0.39	6.55e-14	Pulmonary function;
LUSC	cis	rs6076065	0.723	rs2424550	chr20:23394669	C/T	cg11657817	chr20:23433608	CST11	0.44	8.19	0.41	5.54e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg14893161	chr1:205819251	PM20D1	0.48	6.49	0.33	3.02e-10	Menarche (age at onset);
LUSC	cis	rs1775715	0.678	rs2778649	chr10:32146803	C/G	cg18675610	chr10:32216311	ARHGAP12	0.32	6.91	0.35	2.39e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs7243066	0.577	rs9957564	chr18:11296178	A/G	cg26633107	chr2:14774086	FAM84A	-0.48	-6.57	-0.34	1.91e-10	Dental caries;
LUSC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg06453172	chr10:134556979	INPP5A	-0.49	-6.02	-0.31	4.48e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs8179	0.593	rs17164683	chr7:92286980	C/T	cg15732164	chr7:92237376	CDK6	-0.42	-6.15	-0.32	2.22e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs2130392	0.892	rs11728389	chr4:185622046	C/T	cg04058563	chr4:185651563	MLF1IP	-0.41	-6.6	-0.34	1.63e-10	Kawasaki disease;
LUSC	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg14092571	chr14:90743983	NA	-0.35	-5.67	-0.3	3.12e-8	Mortality in heart failure;
LUSC	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg26384229	chr12:38710491	ALG10B	0.69	10.88	0.51	8.48e-24	Morning vs. evening chronotype;
LUSC	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg07148914	chr20:33460835	GGT7	0.47	6.99	0.36	1.55e-11	Height;
LUSC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg01879757	chr17:41196368	BRCA1	-0.47	-7.18	-0.37	4.54e-12	Menopause (age at onset);
LUSC	cis	rs1018836	0.608	rs7821069	chr8:91465548	C/G	cg16814680	chr8:91681699	NA	-0.48	-7.11	-0.36	6.97e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg00277334	chr10:82204260	NA	-0.48	-6.35	-0.33	6.97e-10	Post bronchodilator FEV1;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg16649755	chr6:88412160	NCRNA00120;AKIRIN2	0.36	6.17	0.32	2e-9	Triglycerides;
LUSC	cis	rs1864400	0.605	rs12360493	chr10:43718613	A/G	cg02780029	chr10:43622663	RET	0.35	6.03	0.31	4.37e-9	Hirschsprung disease;
LUSC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg17366294	chr4:99064904	C4orf37	0.59	10.56	0.5	1.12e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	13.29	0.59	1.19e-32	Blood protein levels;
LUSC	trans	rs10432489	0.708	rs4416179	chr2:181751896	T/C	cg04744134	chr19:8408128	KANK3	-0.81	-6.36	-0.33	6.68e-10	QT interval;
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10150615	chr22:24372951	LOC391322	-0.43	-7.23	-0.37	3.22e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg16624210	chr5:671434	TPPP	0.48	5.84	0.3	1.24e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs77633900	0.614	rs2585730	chr15:76989344	A/G	cg21673338	chr15:77095150	SCAPER	-0.77	-8.04	-0.4	1.56e-14	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg07862535	chr7:139043722	LUC7L2	-0.54	-6.87	-0.35	3.18e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.45	-0.33	3.91e-10	Bipolar disorder;
LUSC	cis	rs9443645	0.507	rs9352633	chr6:79462623	C/G	cg05283184	chr6:79620031	NA	-0.37	-7.0	-0.36	1.39e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg20607287	chr7:12443886	VWDE	-0.65	-6.45	-0.33	4.01e-10	Coronary artery disease;
LUSC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg11871910	chr12:69753446	YEATS4	0.83	14.65	0.63	7.16e-38	Blood protein levels;
LUSC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11764359	chr7:65958608	NA	0.68	10.89	0.51	7.59e-24	Aortic root size;
LUSC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg05585544	chr11:47624801	NA	-0.42	-7.26	-0.37	2.71e-12	Subjective well-being;
LUSC	trans	rs1486139	0.967	rs1903671	chr7:46282312	G/A	cg17534202	chr9:96721102	NA	-0.37	-6.56	-0.34	2.01e-10	Select biomarker traits;
LUSC	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg19875535	chr5:140030758	IK	0.49	8.14	0.41	7.85e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg07936489	chr17:37558343	FBXL20	0.71	9.91	0.48	1.88e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg06637938	chr14:75390232	RPS6KL1	0.52	8.25	0.41	3.72e-15	Height;
LUSC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg18681998	chr4:17616180	MED28	0.76	13.57	0.6	1.07e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg27068330	chr11:65405492	SIPA1	0.77	10.63	0.5	6.34e-23	Acne (severe);
LUSC	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg09085632	chr11:111637200	PPP2R1B	0.99	14.52	0.62	2.26e-37	Primary sclerosing cholangitis;
LUSC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg23985595	chr17:80112537	CCDC57	-0.33	-6.51	-0.34	2.77e-10	Life satisfaction;
LUSC	cis	rs4601821	0.895	rs1055075	chr11:113239512	T/C	cg14159747	chr11:113255604	NA	0.26	5.96	0.31	6.36e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg22907277	chr7:1156413	C7orf50	0.73	11.0	0.52	3.14e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13315871	1.000	rs71311873	chr3:58447106	C/A	cg20936604	chr3:58311152	NA	-0.72	-6.77	-0.35	5.83e-11	Cholesterol, total;
LUSC	cis	rs4925114	0.568	rs11656775	chr17:17654319	A/G	cg09796270	chr17:17721594	SREBF1	-0.43	-7.27	-0.37	2.6e-12	Body mass index;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.65	9.98	0.48	1.02e-20	Lymphocyte counts;
LUSC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg11645453	chr3:52864694	ITIH4	0.35	8.1	0.41	1.07e-14	Bipolar disorder;
LUSC	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg12573674	chr2:1569213	NA	-0.56	-7.51	-0.38	5.52e-13	IgG glycosylation;
LUSC	cis	rs8018808	0.935	rs11159263	chr14:77930188	G/C	cg20045696	chr14:77926864	AHSA1	0.34	5.76	0.3	1.95e-8	Myeloid white cell count;
LUSC	cis	rs62400317	0.859	rs10948204	chr6:45124300	T/C	cg20913747	chr6:44695427	NA	-0.46	-7.49	-0.38	6.35e-13	Total body bone mineral density;
LUSC	cis	rs56399783	0.901	rs73049341	chr7:2812255	G/C	cg14895029	chr7:2775587	GNA12	0.47	5.82	0.3	1.41e-8	Childhood ear infection;
LUSC	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg24531977	chr5:56204891	C5orf35	-0.57	-8.51	-0.42	6.03e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs983392	0.836	rs12453	chr11:59945745	T/C	cg02771260	chr11:59836817	MS4A3	-0.37	-5.96	-0.31	6.38e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.33	-0.33	8.02e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs981844	0.816	rs74549610	chr4:154710464	C/G	cg14289246	chr4:154710475	SFRP2	0.49	6.0	0.31	5.18e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg25019033	chr10:957182	NA	-0.5	-6.19	-0.32	1.81e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg15145296	chr3:125709740	NA	-0.56	-6.31	-0.33	8.95e-10	Blood pressure (smoking interaction);
LUSC	cis	rs11605924	1.000	rs12794698	chr11:45871861	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.52	-7.87	-0.4	4.93e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.35	-0.42	1.78e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.68	10.84	0.51	1.15e-23	Heart rate;
LUSC	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg17410650	chr12:54324560	NA	-0.58	-10.14	-0.49	2.97e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24549020	chr5:56110836	MAP3K1	0.43	5.74	0.3	2.18e-8	Initial pursuit acceleration;
LUSC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	14.49	0.62	2.83e-37	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg03929089	chr4:120376271	NA	0.64	7.35	0.37	1.58e-12	Axial length;
LUSC	cis	rs10740039	0.883	rs10994446	chr10:62399191	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg10578777	chr12:7781093	NA	0.59	6.47	0.33	3.44e-10	HDL cholesterol levels;
LUSC	trans	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.25	0.41	3.64e-15	Ulcerative colitis;
LUSC	cis	rs55665837	1.000	rs11023223	chr11:14457112	A/G	cg19336497	chr11:14380999	RRAS2	-0.37	-7.47	-0.38	7.25e-13	Vitamin D levels;
LUSC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.13	0.58	4.89e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25536300	chr19:797459	PTBP1	-0.52	-6.13	-0.32	2.49e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs2562456	0.833	rs56187954	chr19:21528060	T/A	cg00806126	chr19:22604979	ZNF98	-0.43	-6.12	-0.32	2.66e-9	Pain;
LUSC	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg10911889	chr6:126070802	HEY2	0.41	6.23	0.32	1.38e-9	Brugada syndrome;
LUSC	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.91	-0.4	3.93e-14	Total cholesterol levels;
LUSC	trans	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg26043149	chr18:55253948	FECH	-0.45	-7.02	-0.36	1.23e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg13789015	chr9:136890014	NCRNA00094	0.7	12.69	0.57	2.29e-30	Platelet distribution width;
LUSC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg01802117	chr1:53393560	SCP2	-0.37	-6.12	-0.32	2.55e-9	Monocyte count;
LUSC	trans	rs7556897	0.720	rs10177876	chr2:228664003	A/G	cg07776931	chr3:126135051	CCDC37	-0.28	-5.96	-0.31	6.42e-9	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10911232	0.526	rs41475048	chr1:183058452	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.54	-7.15	-0.36	5.62e-12	Hypertriglyceridemia;
LUSC	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.55	-0.34	2.18e-10	Neuroticism;
LUSC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.95	-0.4	2.98e-14	Chronic sinus infection;
LUSC	cis	rs2227564	0.620	rs11000785	chr10:75575963	T/C	cg23231163	chr10:75533350	FUT11	-0.45	-6.5	-0.34	2.94e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4363385	0.626	rs11205179	chr1:153021399	A/G	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.4	-0.33	5.37e-10	Inflammatory skin disease;
LUSC	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg21548813	chr6:291882	DUSP22	-0.5	-7.57	-0.38	3.77e-13	Menopause (age at onset);
LUSC	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	0.69	12.03	0.55	6e-28	Gut microbiome composition (winter);
LUSC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg22467129	chr15:76604101	ETFA	-0.44	-6.88	-0.35	3.01e-11	Blood metabolite levels;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg23712970	chr14:23540735	ACIN1	0.53	6.34	0.33	7.38e-10	Cognitive function;Information processing speed;
LUSC	cis	rs17001868	0.568	rs9611316	chr22:40737027	A/G	cg07138101	chr22:40742427	ADSL	0.63	7.67	0.39	1.85e-13	Mammographic density (dense area);
LUSC	cis	rs8092503	1.000	rs3764512	chr18:52495324	G/T	cg12377874	chr18:52495404	RAB27B	0.33	5.66	0.3	3.32e-8	Childhood body mass index;
LUSC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg27535305	chr1:53392650	SCP2	-0.37	-6.89	-0.35	2.83e-11	Monocyte count;
LUSC	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.02e-14	Corneal astigmatism;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg23690033	chr15:37393574	MEIS2	-0.48	-6.56	-0.34	2.01e-10	Hepatitis;
LUSC	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.26	0.64	2.91e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	7.46	0.38	7.65e-13	Colorectal cancer;
LUSC	cis	rs8060686	0.858	rs10468274	chr16:67922342	C/T	cg26727032	chr16:67993705	SLC12A4	-0.37	-5.7	-0.3	2.65e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.77	0.3	1.8e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.45	-0.33	3.82e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03352830	chr11:487213	PTDSS2	0.76	8.77	0.43	9.13e-17	Body mass index;
LUSC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22968622	chr17:43663579	NA	-0.78	-12.09	-0.55	3.8e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9362426	1.000	rs6930076	chr6:88088654	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	6.16	0.32	2.06e-9	Depressive episodes in bipolar disorder;
LUSC	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg21643547	chr1:205240462	TMCC2	-0.48	-9.12	-0.45	7.17e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg04315214	chr1:2043799	PRKCZ	0.46	9.4	0.46	9.12e-19	Height;
LUSC	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg03676636	chr4:99064102	C4orf37	0.36	7.89	0.4	4.25e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7903847	0.656	rs7895695	chr10:99167255	A/G	cg20016023	chr10:99160130	RRP12	0.25	5.65	0.3	3.52e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	7.94	0.4	3e-14	Multiple sclerosis;
LUSC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.74	11.02	0.52	2.64e-24	Multiple sclerosis;
LUSC	cis	rs7681440	0.647	rs6814221	chr4:90805501	C/T	cg20003494	chr4:90757398	SNCA	-0.36	-5.97	-0.31	5.92e-9	Dementia with Lewy bodies;
LUSC	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-20.01	-0.74	4.09e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg23093090	chr10:104574429	C10orf26	0.4	6.52	0.34	2.66e-10	Arsenic metabolism;
LUSC	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg27471124	chr11:109292789	C11orf87	0.43	7.46	0.38	7.34e-13	Schizophrenia;
LUSC	cis	rs12903285	1	rs12903285	chr15:78778953	A/G	cg18825076	chr15:78729989	IREB2	-0.43	-6.93	-0.35	2.12e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs727505	1.000	rs28392553	chr7:124442944	C/T	cg23710748	chr7:124431027	NA	-0.41	-7.36	-0.37	1.45e-12	Lewy body disease;
LUSC	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg23711669	chr6:146136114	FBXO30	0.81	14.85	0.63	1.16e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg22655196	chr4:3374909	RGS12	0.31	5.92	0.31	7.94e-9	Serum sulfate level;
LUSC	cis	rs73001065	0.636	rs28720066	chr19:19572220	G/T	cg03709012	chr19:19516395	GATAD2A	0.92	8.49	0.42	6.86e-16	LDL cholesterol;
LUSC	cis	rs2425143	0.818	rs73902932	chr20:34489009	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.69	-0.3	2.77e-8	Blood protein levels;
LUSC	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg11473876	chr11:109292803	C11orf87	0.34	5.72	0.3	2.4e-8	Schizophrenia;
LUSC	cis	rs1355223	0.867	rs11821793	chr11:34681462	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-5.65	-0.3	3.53e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg07507251	chr3:52567010	NT5DC2	-0.35	-6.54	-0.34	2.29e-10	Bipolar disorder;
LUSC	cis	rs7189233	1.000	rs16952251	chr16:53483138	A/G	cg09728985	chr16:53543985	NA	-0.31	-5.7	-0.3	2.64e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs7939886	0.920	rs7950386	chr11:55931513	C/T	cg03929089	chr4:120376271	NA	0.8	6.07	0.32	3.54e-9	Myopia (pathological);
LUSC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg07716408	chr11:68623521	NA	-0.31	-5.96	-0.31	6.4e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg21545522	chr1:205238299	TMCC2	0.46	8.55	0.42	4.49e-16	Red blood cell count;
LUSC	cis	rs62400317	0.762	rs10948176	chr6:44833913	A/G	cg20913747	chr6:44695427	NA	-0.47	-7.31	-0.37	1.96e-12	Total body bone mineral density;
LUSC	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg05519781	chr21:40033154	ERG	-0.63	-10.27	-0.49	1.07e-21	Coronary artery disease;
LUSC	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg17810781	chr1:201082982	CACNA1S	0.35	6.57	0.34	1.98e-10	Permanent tooth development;
LUSC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg11494091	chr17:61959527	GH2	0.39	6.8	0.35	4.75e-11	Height;
LUSC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg03146154	chr1:46216737	IPP	0.5	7.43	0.38	9.1e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.74	-0.43	1.14e-16	Mood instability;
LUSC	cis	rs11018904	0.906	rs35286339	chr11:89965679	A/G	cg26028595	chr11:89956573	CHORDC1	-0.51	-6.14	-0.32	2.39e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs71636778	0.543	rs10493037	chr1:27248645	A/G	cg12203394	chr1:27248618	NUDC	0.53	5.65	0.3	3.47e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg08470875	chr2:26401718	FAM59B	-0.69	-9.46	-0.46	5.73e-19	Gut microbiome composition (summer);
LUSC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg12311346	chr5:56204834	C5orf35	-0.6	-9.35	-0.46	1.29e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14442939	chr10:27389572	ANKRD26	0.89	10.13	0.48	3.43e-21	Breast cancer;
LUSC	cis	rs4356932	1.000	rs7689664	chr4:76963351	T/A	cg00809888	chr4:76862425	NAAA	0.35	5.92	0.31	7.78e-9	Blood protein levels;
LUSC	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	1.1	18.43	0.71	8.08e-53	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	0.92	15.23	0.64	3.94e-40	Breast cancer;
LUSC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg14789911	chr21:47582049	C21orf56	-0.36	-5.72	-0.3	2.39e-8	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg07701084	chr6:150067640	NUP43	0.54	8.15	0.41	7.58e-15	Lung cancer;
LUSC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg04369109	chr6:150039330	LATS1	-0.6	-8.67	-0.43	1.93e-16	Lung cancer;
LUSC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg18681998	chr4:17616180	MED28	0.85	16.11	0.66	1.26e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.77	-13.8	-0.6	1.41e-34	Cognitive function;
LUSC	trans	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg06606381	chr12:133084897	FBRSL1	-0.45	-5.96	-0.31	6.36e-9	Depression;
LUSC	cis	rs56283067	0.886	rs56110323	chr6:44679934	G/A	cg18551225	chr6:44695536	NA	-0.46	-7.9	-0.4	4.18e-14	Total body bone mineral density;
LUSC	cis	rs354225	0.554	rs4374410	chr2:54819088	G/T	cg26097391	chr2:54893211	SPTBN1	0.44	6.62	0.34	1.41e-10	Schizophrenia;
LUSC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22496380	chr5:211416	CCDC127	-0.87	-9.48	-0.46	5.06e-19	Breast cancer;
LUSC	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg24130564	chr14:104152367	KLC1	0.49	7.41	0.38	1.08e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg26536354	chr8:144654954	C8orf73	0.67	7.3	0.37	2.18e-12	Attention deficit hyperactivity disorder;
LUSC	trans	rs7939886	0.764	rs11227350	chr11:55912289	T/C	cg15704280	chr7:45808275	SEPT13	0.83	6.64	0.34	1.27e-10	Myopia (pathological);
LUSC	cis	rs6546550	0.867	rs1048266	chr2:70132676	A/G	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	11.32	0.53	2.25e-25	Lung cancer in ever smokers;
LUSC	cis	rs6740322	0.793	rs9808360	chr2:43546835	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-7.35	-0.37	1.54e-12	Coronary artery disease;
LUSC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	13.0	0.58	1.49e-31	Monocyte percentage of white cells;
LUSC	cis	rs4704187	0.687	rs1592948	chr5:74504152	G/A	cg03227963	chr5:74354835	NA	0.31	6.76	0.35	6.31e-11	Response to amphetamines;
LUSC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg08773314	chr2:239334832	ASB1	0.42	8.91	0.44	3.45e-17	Multiple system atrophy;
LUSC	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg11812906	chr14:75593930	NEK9	-0.42	-6.34	-0.33	7.66e-10	Neuroticism;
LUSC	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-7.56	-0.38	3.81e-13	Parkinson's disease;
LUSC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg11218175	chr11:495084	RNH1	0.53	5.81	0.3	1.44e-8	Body mass index;
LUSC	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg24375607	chr4:120327624	NA	0.77	11.32	0.53	2.32e-25	Corneal astigmatism;
LUSC	trans	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg14227996	chr4:17616232	MED28	-0.59	-6.34	-0.33	7.49e-10	Opioid sensitivity;
LUSC	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs8014204	0.566	rs11629369	chr14:75162021	G/A	cg06637938	chr14:75390232	RPS6KL1	0.53	8.34	0.42	2.03e-15	Caffeine consumption;
LUSC	cis	rs2354432	0.556	rs66501488	chr1:146853992	T/C	cg25205988	chr1:146714368	CHD1L	-0.9	-7.58	-0.38	3.38e-13	Mitochondrial DNA levels;
LUSC	cis	rs62400317	0.762	rs12211922	chr6:44847210	A/G	cg20913747	chr6:44695427	NA	-0.48	-7.43	-0.38	9.13e-13	Total body bone mineral density;
LUSC	trans	rs1325195	0.568	rs17362081	chr1:179092741	A/C	cg11624085	chr17:8464688	MYH10	-0.43	-6.54	-0.34	2.27e-10	IgE grass sensitization;
LUSC	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg04450456	chr4:17643702	FAM184B	0.4	6.45	0.33	4e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg15383120	chr6:291909	DUSP22	-0.48	-7.45	-0.38	7.86e-13	Menopause (age at onset);
LUSC	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg07169764	chr2:136633963	MCM6	1.2	17.84	0.7	1.71e-50	Corneal structure;
LUSC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.33	2.98e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg06521331	chr12:34319734	NA	0.41	6.45	0.33	3.83e-10	Morning vs. evening chronotype;
LUSC	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg06917634	chr15:78832804	PSMA4	-0.48	-5.97	-0.31	6.23e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.61	-0.34	1.56e-10	Longevity;Endometriosis;
LUSC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg04025307	chr7:1156635	C7orf50	0.44	6.94	0.36	2.04e-11	Longevity;Endometriosis;
LUSC	cis	rs2979489	0.891	rs2915592	chr8:30396417	C/T	cg26383811	chr8:30366931	RBPMS	-0.51	-8.18	-0.41	6.19e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs7903847	0.620	rs954149	chr10:99122936	G/A	cg20016023	chr10:99160130	RRP12	-0.34	-8.21	-0.41	4.79e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.37	5.68	0.3	2.88e-8	Ulcerative colitis;
LUSC	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-9.19	-0.45	4.25e-18	Myeloid white cell count;
LUSC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg07395648	chr5:131743802	NA	-0.4	-6.1	-0.32	2.9e-9	Breast cancer;
LUSC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.82	-14.95	-0.63	4.93e-39	Cognitive function;
LUSC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg25036284	chr2:26402008	FAM59B	-0.67	-9.55	-0.46	2.8e-19	Gut microbiome composition (summer);
LUSC	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.61	0.5	7.28e-23	Colorectal cancer;
LUSC	trans	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.81	-0.39	7.71e-14	Morning vs. evening chronotype;
LUSC	cis	rs72772090	0.634	rs17401901	chr5:96091925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.74	-8.36	-0.42	1.74e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg07393940	chr7:158741817	NA	-0.54	-8.25	-0.41	3.77e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs977987	0.806	rs35937717	chr16:75331567	C/A	cg04384234	chr16:75411784	CFDP1	-0.4	-6.52	-0.34	2.66e-10	Dupuytren's disease;
LUSC	trans	rs337939	0.634	rs9542440	chr13:71193499	T/C	cg11446651	chr17:27407276	MYO18A	-0.35	-6.07	-0.32	3.41e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.69	10.69	0.5	3.99e-23	Aortic root size;
LUSC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg20573242	chr4:122745356	CCNA2	0.42	6.45	0.33	3.9e-10	Type 2 diabetes;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg19078334	chr9:113019254	TXN	-0.57	-6.64	-0.34	1.25e-10	Height;
LUSC	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg10978503	chr1:24200527	CNR2	0.54	13.3	0.59	1.11e-32	Immature fraction of reticulocytes;
LUSC	trans	rs4148689	1.000	rs2283057	chr7:117202484	C/G	cg10450175	chr16:88689712	ZC3H18	0.46	6.03	0.31	4.38e-9	Gout;
LUSC	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg24686825	chr1:36642396	MAP7D1	0.49	7.54	0.38	4.59e-13	Corneal structure;
LUSC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg13206674	chr6:150067644	NUP43	0.61	9.77	0.47	5.32e-20	Lung cancer;
LUSC	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.61	12.63	0.57	3.64e-30	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs612683	0.694	rs6688166	chr1:101000717	G/C	cg06223162	chr1:101003688	GPR88	0.52	9.57	0.46	2.52e-19	Breast cancer;
LUSC	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9311676	0.609	rs62258133	chr3:58398318	C/G	cg13750441	chr3:58318267	PXK	0.35	6.68	0.34	1.02e-10	Systemic lupus erythematosus;
LUSC	cis	rs9905704	0.836	rs12952429	chr17:56843070	C/T	cg12560992	chr17:57184187	TRIM37	0.58	8.4	0.42	1.27e-15	Testicular germ cell tumor;
LUSC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg07741184	chr6:167504864	NA	0.39	7.03	0.36	1.18e-11	Crohn's disease;
LUSC	cis	rs2806561	0.780	rs4655142	chr1:23333728	T/C	cg19743168	chr1:23544995	NA	-0.38	-7.94	-0.4	3.07e-14	Height;
LUSC	cis	rs12318506	0.826	rs17804612	chr12:75671271	T/C	cg04728562	chr12:75699417	CAPS2	-0.76	-5.95	-0.31	6.65e-9	Coronary artery calcification;
LUSC	cis	rs17604090	0.938	rs28457783	chr7:29687058	T/G	cg19413766	chr7:29689036	LOC646762	-0.63	-7.43	-0.38	8.91e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs11051970	0.655	rs10771942	chr12:32528488	G/A	cg02745156	chr12:32552066	NA	0.37	6.69	0.34	9.37e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25072359	chr17:41440525	NA	0.66	9.44	0.46	6.54e-19	Menopause (age at onset);
LUSC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg19592336	chr6:28129416	ZNF389	0.47	6.19	0.32	1.75e-9	Parkinson's disease;
LUSC	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.82	-19.84	-0.74	1.9e-58	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs524023	0.874	rs495130	chr11:64449307	C/T	cg19131476	chr11:64387923	NRXN2	-0.38	-10.61	-0.5	7.33e-23	Urate levels in obese individuals;
LUSC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg12963246	chr6:28129442	ZNF389	0.49	6.65	0.34	1.21e-10	Depression;
LUSC	cis	rs713477	0.505	rs1953740	chr14:55886717	G/A	cg13175173	chr14:55914753	NA	-0.32	-6.0	-0.31	5.1e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg05855489	chr10:104503620	C10orf26	0.47	7.3	0.37	2.08e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08280861	chr8:58055591	NA	0.54	6.39	0.33	5.53e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7246967	0.673	rs7245540	chr19:22881504	C/G	cg23217946	chr19:22817039	ZNF492	0.42	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg05941027	chr17:61774174	LIMD2	0.22	5.65	0.3	3.4e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs17490626	0.533	rs5030925	chr10:71211150	A/C	cg14388049	chr10:71211838	TSPAN15	-0.33	-5.99	-0.31	5.28e-9	Thrombosis;
LUSC	cis	rs3736594	0.918	rs9967838	chr2:27968454	A/C	cg27432699	chr2:27873401	GPN1	-0.64	-9.08	-0.45	9.56e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg02038168	chr22:39784481	NA	-0.48	-8.0	-0.4	2.09e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs853679	0.505	rs200992	chr6:27814677	A/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.01	-0.4	1.9e-14	Depression;
LUSC	trans	rs6841433	0.615	rs13147485	chr4:115473477	T/G	cg01865118	chr8:29204221	DUSP4	-0.51	-5.97	-0.31	5.93e-9	Hemoglobin concentration;
LUSC	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg14458575	chr2:238380390	NA	0.69	11.77	0.54	5.54e-27	Prostate cancer;
LUSC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg10351095	chr21:47802916	PCNT	0.43	6.12	0.32	2.64e-9	Testicular germ cell tumor;
LUSC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg08888203	chr3:10149979	C3orf24	0.64	9.11	0.45	7.58e-18	Alzheimer's disease;
LUSC	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.9	-0.35	2.69e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.6	0.38	2.92e-13	Vitiligo;
LUSC	cis	rs2692947	0.696	rs2969490	chr2:96803904	A/G	cg23100626	chr2:96804247	ASTL	0.26	6.36	0.33	6.53e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg19743168	chr1:23544995	NA	0.39	7.68	0.39	1.83e-13	Height;
LUSC	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg06740227	chr12:86229804	RASSF9	-0.38	-6.16	-0.32	2.1e-9	Major depressive disorder;
LUSC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg22920501	chr2:26401640	FAM59B	-0.73	-10.73	-0.51	2.84e-23	Gut microbiome composition (summer);
LUSC	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.9	-0.4	4.1e-14	Blood metabolite levels;
LUSC	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.56	-0.34	2.08e-10	Type 2 diabetes;
LUSC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.8	0.39	8.09e-14	Parkinson's disease;
LUSC	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg08807101	chr21:30365312	RNF160	0.48	7.24	0.37	3.15e-12	Pancreatic cancer;
LUSC	cis	rs6785206	0.892	rs2712429	chr3:128336221	A/C	cg16766828	chr3:128327626	NA	-0.69	-7.66	-0.39	2.04e-13	Lymphocyte percentage of white cells;
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.3	6.01	0.31	4.83e-9	Lymphocyte counts;
LUSC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.81	-0.43	6.75e-17	Platelet count;
LUSC	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg05714579	chr10:131428358	MGMT	0.53	8.08	0.4	1.2e-14	Response to temozolomide;
LUSC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-0.88	-12.75	-0.57	1.35e-30	Initial pursuit acceleration;
LUSC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21984481	chr17:79567631	NPLOC4	-0.57	-10.9	-0.51	7.43e-24	Eye color traits;
LUSC	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-7.99	-0.4	2.23e-14	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7605827	0.930	rs7586201	chr2:15575735	G/A	cg19274914	chr2:15703543	NA	0.48	9.21	0.45	3.65e-18	Educational attainment (years of education);
LUSC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg27124370	chr19:33622961	WDR88	0.53	7.59	0.38	3.15e-13	Colorectal cancer;
LUSC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.27	0.59	1.45e-32	Chronic sinus infection;
LUSC	cis	rs72627509	0.857	rs781658	chr4:57779567	G/A	cg26694713	chr4:57773883	REST	0.52	6.33	0.33	8.05e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg27494647	chr7:150038898	RARRES2	0.46	7.35	0.37	1.55e-12	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.35	0.49	5.89e-22	Morning vs. evening chronotype;
LUSC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	trans	rs2769967	0.624	rs273439	chr9:81917213	C/T	cg21715903	chr6:51275527	NA	0.35	6.01	0.31	4.85e-9	Inattentive symptoms;
LUSC	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg05527609	chr1:210001259	C1orf107	-0.86	-11.96	-0.55	1.07e-27	Orofacial clefts;
LUSC	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg17848003	chr1:3704513	LRRC47	0.32	5.83	0.3	1.32e-8	Red cell distribution width;
LUSC	cis	rs651907	0.712	rs796410	chr3:101610189	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.48	6.82	0.35	4.36e-11	Colorectal cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16739845	chr14:92040772	C14orf184	-0.39	-5.98	-0.31	5.79e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg16339924	chr4:17578868	LAP3	0.55	8.42	0.42	1.11e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg21775007	chr8:11205619	TDH	0.46	6.55	0.34	2.18e-10	Myopia (pathological);
LUSC	cis	rs3820068	0.577	rs9728986	chr1:16040603	G/A	cg13390004	chr1:15929781	NA	0.41	6.79	0.35	5.02e-11	Systolic blood pressure;
LUSC	cis	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg02972257	chr16:68554789	NA	-0.49	-6.3	-0.33	9.24e-10	Ulcerative colitis;
LUSC	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.79	-0.35	5.15e-11	Putamen volume;
LUSC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	10.79	0.51	1.69e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2108225	0.967	rs6466189	chr7:107448516	C/T	cg18560240	chr7:107437656	SLC26A3	-0.39	-5.96	-0.31	6.42e-9	Ulcerative colitis;
LUSC	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7560272	0.723	rs7585119	chr2:73724679	A/T	cg20560298	chr2:73613845	ALMS1	-0.47	-7.23	-0.37	3.3e-12	Schizophrenia;
LUSC	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	10.58	0.5	9.48e-23	Eye color traits;
LUSC	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg18404041	chr3:52824283	ITIH1	-0.42	-7.61	-0.38	2.9e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.4	-7.29	-0.37	2.29e-12	Longevity;Endometriosis;
LUSC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.5	7.09	0.36	7.86e-12	Tonsillectomy;
LUSC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg03146154	chr1:46216737	IPP	0.55	8.21	0.41	5.01e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24549020	chr5:56110836	MAP3K1	0.44	5.95	0.31	6.76e-9	Initial pursuit acceleration;
LUSC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg04398451	chr17:18023971	MYO15A	-0.46	-7.4	-0.38	1.1e-12	Total body bone mineral density;
LUSC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg14664628	chr15:75095509	CSK	-0.54	-7.97	-0.4	2.61e-14	Breast cancer;
LUSC	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg10621924	chr7:39171070	POU6F2	0.42	6.26	0.32	1.21e-9	IgG glycosylation;
LUSC	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg08668359	chr10:1443807	ADARB2	0.41	6.2	0.32	1.66e-9	Radiation response;
LUSC	cis	rs2652834	0.851	rs1976433	chr15:63426912	T/G	cg05507819	chr15:63340323	TPM1	0.45	5.82	0.3	1.37e-8	HDL cholesterol;
LUSC	trans	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.1	-0.32	2.89e-9	Mood instability;
LUSC	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.63	0.47	1.54e-19	Arsenic metabolism;
LUSC	cis	rs13082711	0.911	rs923940	chr3:27459341	C/G	cg02860705	chr3:27208620	NA	0.49	8.3	0.41	2.69e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs13202913	0.837	rs6906678	chr6:151772395	A/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.65	-5.75	-0.3	2.04e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs2282300	0.637	rs7941828	chr11:30430331	C/T	cg25418670	chr11:30344373	C11orf46	-0.4	-6.33	-0.33	8.04e-10	Morning vs. evening chronotype;
LUSC	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg17420585	chr12:42539391	GXYLT1	-0.39	-7.66	-0.39	1.99e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	1.12	15.06	0.64	1.78e-39	Nonalcoholic fatty liver disease;
LUSC	cis	rs8062405	0.690	rs4787458	chr16:28531287	A/G	cg16576597	chr16:28551801	NUPR1	0.31	6.01	0.31	4.99e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs12210905	0.688	rs12209905	chr6:27404592	C/G	cg08851530	chr6:28072375	NA	0.93	5.77	0.3	1.77e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg23625390	chr15:77176239	SCAPER	0.53	8.54	0.42	4.89e-16	Blood metabolite levels;
LUSC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg06671706	chr8:8559999	CLDN23	0.5	6.68	0.34	9.98e-11	Obesity-related traits;
LUSC	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg00290607	chr11:67383545	NA	0.37	6.86	0.35	3.28e-11	Mean corpuscular volume;
LUSC	cis	rs11785693	0.862	rs11774099	chr8:4988218	C/T	cg26367366	chr8:4980734	NA	0.77	9.15	0.45	5.72e-18	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg22153745	chr1:153894579	GATAD2B	-0.55	-8.61	-0.43	2.85e-16	Total cholesterol levels;
LUSC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.67	-8.62	-0.43	2.65e-16	Huntington's disease progression;
LUSC	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg02023728	chr11:77925099	USP35	-0.45	-6.7	-0.34	8.67e-11	Testicular germ cell tumor;
LUSC	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg24110177	chr3:50126178	RBM5	0.42	6.66	0.34	1.1e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.89	-0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.66	6.05	0.31	3.93e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	1.02	17.51	0.69	3.61e-49	Parkinson's disease;
LUSC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg07701084	chr6:150067640	NUP43	0.57	8.88	0.44	4.29e-17	Lung cancer;
LUSC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg11608241	chr8:8085544	FLJ10661	0.43	6.37	0.33	6.43e-10	Mood instability;
LUSC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.83	14.35	0.62	1.02e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg15691649	chr6:25882328	NA	-0.48	-7.4	-0.38	1.12e-12	Blood metabolite levels;
LUSC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg09367891	chr1:107599246	PRMT6	-0.56	-8.69	-0.43	1.71e-16	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.47	8.18	0.41	6.18e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg23950597	chr19:37808831	NA	-0.65	-7.91	-0.4	3.9e-14	Coronary artery calcification;
LUSC	cis	rs2607426	0.581	rs2604866	chr19:41318757	C/G	cg05508168	chr19:41255947	C19orf54;SNRPA	0.81	6.52	0.34	2.64e-10	Blood protein levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25999486	chr13:76056030	TBC1D4	0.4	6.13	0.32	2.52e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4243830	1.000	rs34757678	chr1:6583270	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.9	8.76	0.43	9.71e-17	Body mass index;
LUSC	cis	rs6480314	1.000	rs6480314	chr10:69967447	G/A	cg06988349	chr10:69991859	ATOH7	-0.35	-5.71	-0.3	2.48e-8	Optic nerve measurement (disc area);
LUSC	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-10.06	-0.48	5.62e-21	Morning vs. evening chronotype;
LUSC	trans	rs12310956	0.510	rs11052882	chr12:33890017	T/C	cg13010199	chr12:38710504	ALG10B	0.44	6.8	0.35	4.74e-11	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9398803	0.865	rs1490388	chr6:126835655	C/T	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	1.97e-9	Male-pattern baldness;
LUSC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg01879757	chr17:41196368	BRCA1	-0.4	-6.03	-0.31	4.43e-9	Menopause (age at onset);
LUSC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.56	8.87	0.44	4.54e-17	Cognitive function;
LUSC	cis	rs2230307	0.505	rs641458	chr1:100578672	G/C	cg24955406	chr1:100503596	HIAT1	-0.63	-6.68	-0.34	1.01e-10	Carotid intima media thickness;
LUSC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg13918804	chr1:2043761	PRKCZ	0.27	5.66	0.3	3.25e-8	Height;
LUSC	cis	rs7512552	0.803	rs3738487	chr1:150477061	C/T	cg15654264	chr1:150340011	RPRD2	0.65	10.68	0.5	4.27e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg22800045	chr5:56110881	MAP3K1	0.42	5.71	0.3	2.48e-8	Coronary artery disease;
LUSC	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg07211511	chr3:129823064	LOC729375	-1.16	-17.55	-0.69	2.51e-49	Blood pressure (smoking interaction);
LUSC	cis	rs9039	1.000	rs17652208	chr16:9196463	C/T	cg08831531	chr16:9218945	NA	-0.69	-10.19	-0.49	2.13e-21	Menopause (age at onset);
LUSC	cis	rs11229555	0.645	rs11229428	chr11:58180382	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.9	-0.4	4.14e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1878931	0.615	rs6501171	chr16:3402610	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.85	15.86	0.66	1.24e-42	Body mass index (adult);
LUSC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1065852	0.510	rs5758666	chr22:42632833	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.39	7.0	0.36	1.45e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs1355223	0.573	rs1901830	chr11:34725028	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.13	-0.32	2.55e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg07343612	chr16:622815	PIGQ	0.43	5.88	0.31	9.7e-9	Height;
LUSC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg10755058	chr3:40428713	ENTPD3	0.35	5.9	0.31	8.88e-9	Renal cell carcinoma;
LUSC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.9	0.44	3.66e-17	Lung cancer;
LUSC	cis	rs834811	0.797	rs2633365	chr7:135879797	A/G	cg01726295	chr7:135938950	NA	0.39	6.77	0.35	5.85e-11	Post-traumatic stress disorder;
LUSC	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg13010199	chr12:38710504	ALG10B	0.59	9.66	0.47	1.26e-19	Morning vs. evening chronotype;
LUSC	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg15556689	chr8:8085844	FLJ10661	0.62	8.71	0.43	1.39e-16	Neuroticism;
LUSC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg02487422	chr3:49467188	NICN1	0.47	7.48	0.38	6.58e-13	Resting heart rate;
LUSC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.41	0.33	5.09e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg22681709	chr2:178499509	PDE11A	0.52	9.38	0.46	1.04e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg08683831	chr4:1404607	NA	0.36	6.11	0.32	2.83e-9	Obesity-related traits;
LUSC	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg20744362	chr22:50050164	C22orf34	0.4	8.37	0.42	1.64e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9815354	0.812	rs7652506	chr3:42060235	C/T	cg03022575	chr3:42003672	ULK4	0.58	6.61	0.34	1.54e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg11062466	chr8:58055876	NA	0.47	6.39	0.33	5.41e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	11.5	0.53	5.03e-26	Menarche (age at onset);
LUSC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23158103	chr7:148848205	ZNF398	-0.45	-7.0	-0.36	1.41e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2455601	0.744	rs7938995	chr11:8975675	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.52	-0.34	2.55e-10	Schizophrenia;
LUSC	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg23229984	chr5:148520753	ABLIM3	0.38	6.13	0.32	2.54e-9	Breast cancer;
LUSC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	cis	rs400736	0.930	rs408320	chr1:8085328	T/C	cg25007680	chr1:8021821	PARK7	0.58	9.11	0.45	7.58e-18	Response to antidepressants and depression;
LUSC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg22834771	chr12:69754056	YEATS4	-0.44	-6.3	-0.33	9.42e-10	Blood protein levels;
LUSC	cis	rs12900413	0.687	rs12902786	chr15:90304376	G/A	cg24249390	chr15:90295951	MESP1	-0.38	-5.9	-0.31	9.05e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg14539990	chr9:140728301	EHMT1	-0.38	-5.96	-0.31	6.36e-9	Educational attainment (years of education);
LUSC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg27170947	chr2:26402098	FAM59B	0.66	9.8	0.47	4.17e-20	Gut microbiome composition (summer);
LUSC	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg18477163	chr1:228402036	OBSCN	0.57	9.51	0.46	3.79e-19	Diastolic blood pressure;
LUSC	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg13010199	chr12:38710504	ALG10B	0.69	10.65	0.5	5.27e-23	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg21053147	chr12:120880522	NA	0.51	6.16	0.32	2.11e-9	Type 1 diabetes nephropathy;
LUSC	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.42	-0.69	8.59e-49	Exhaled nitric oxide output;
LUSC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg05373962	chr22:49881684	NA	-0.39	-9.11	-0.45	7.67e-18	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs727505	0.607	rs67454509	chr7:124792500	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.83	-0.35	4.01e-11	Lewy body disease;
LUSC	trans	rs1015213	0.609	rs117452492	chr8:52817651	A/G	cg26618441	chr5:140213825	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA5;PCDHA3;PCDHA4	-0.87	-6.09	-0.32	3.14e-9	Glaucoma (primary angle closure);
LUSC	cis	rs56161922	0.818	rs55638397	chr1:207856040	G/A	cg11752769	chr1:207818423	CR1L	-0.69	-5.84	-0.3	1.21e-8	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs8048576	0.512	rs8063863	chr16:84400850	C/T	cg03548384	chr16:84403863	ATP2C2	-0.41	-6.26	-0.32	1.2e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6704644	0.719	rs2228939	chr2:234371351	G/A	cg05711037	chr2:234359783	DGKD	0.57	5.65	0.3	3.5e-8	Bilirubin levels;
LUSC	trans	rs783147	0.500	rs4252130	chr6:161153080	A/C	cg15416064	chr12:49209402	NA	-0.47	-6.57	-0.34	1.91e-10	Lp (a) levels;
LUSC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg24733560	chr20:60626293	TAF4	0.37	5.91	0.31	8.66e-9	Body mass index;
LUSC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg12310025	chr6:25882481	NA	-0.5	-9.06	-0.44	1.09e-17	Blood metabolite levels;
LUSC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg02475777	chr4:1388615	CRIPAK	0.43	6.39	0.33	5.68e-10	Obesity-related traits;
LUSC	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg06271696	chr7:157225062	NA	-0.43	-8.34	-0.42	1.99e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-14.94	-0.63	5.08e-39	Vitiligo;
LUSC	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg05855489	chr10:104503620	C10orf26	-0.49	-7.45	-0.38	7.85e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg06784218	chr1:46089804	CCDC17	0.49	9.73	0.47	7.32e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.35	-0.42	1.81e-15	Response to antipsychotic treatment;
LUSC	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg15744005	chr10:104629667	AS3MT	-0.34	-6.95	-0.36	1.92e-11	Immature fraction of reticulocytes;Schizophrenia;
LUSC	trans	rs236907	0.859	rs10913684	chr1:171758758	A/G	cg13482142	chr2:234261155	NA	0.48	6.05	0.31	3.8e-9	Mean platelet volume;
LUSC	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18932078	chr1:2524107	MMEL1	-0.32	-6.93	-0.35	2.13e-11	Ulcerative colitis;
LUSC	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.55	-8.76	-0.43	9.98e-17	Schizophrenia;
LUSC	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.44	6.89	0.35	2.75e-11	Colorectal cancer;
LUSC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.52	0.34	2.55e-10	Bipolar disorder;
LUSC	cis	rs2963155	0.518	rs853176	chr5:142636456	A/G	cg17617527	chr5:142782415	NR3C1	-0.72	-8.86	-0.44	4.72e-17	Breast cancer;
LUSC	trans	rs11088226	0.846	rs2154501	chr21:33926451	G/A	cg09050820	chr6:167586206	TCP10L2	0.67	10.13	0.48	3.3e-21	Gastritis;
LUSC	cis	rs4853525	0.522	rs1860167	chr2:191582387	G/A	cg11845111	chr2:191398756	TMEM194B	-0.42	-5.77	-0.3	1.82e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg21427119	chr20:30132790	HM13	-0.44	-5.77	-0.3	1.82e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg17691542	chr6:26056736	HIST1H1C	0.53	8.07	0.4	1.24e-14	Height;
LUSC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg22823121	chr1:150693482	HORMAD1	-0.46	-6.85	-0.35	3.47e-11	Tonsillectomy;
LUSC	cis	rs3862435	0.572	rs76176014	chr15:90923962	G/A	cg22089800	chr15:90895588	ZNF774	0.59	6.26	0.32	1.21e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg23815491	chr16:72088622	HP	0.32	5.71	0.3	2.49e-8	Fibrinogen levels;
LUSC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00677455	chr12:58241039	CTDSP2	0.69	10.98	0.52	3.62e-24	Multiple sclerosis;
LUSC	trans	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg21659725	chr3:3221576	CRBN	0.69	8.23	0.41	4.34e-15	Menarche (age at onset);
LUSC	cis	rs1808579	0.935	rs1140458	chr18:21119777	G/A	cg14672496	chr18:21087552	C18orf8	0.36	6.23	0.32	1.37e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg24069376	chr3:38537580	EXOG	0.42	8.13	0.41	8.32e-15	Electrocardiographic conduction measures;
LUSC	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg00898013	chr13:113819073	PROZ	0.55	8.23	0.41	4.22e-15	Platelet distribution width;
LUSC	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.74	-11.97	-0.55	1.03e-27	Body mass index;
LUSC	trans	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg27411982	chr8:10470053	RP1L1	0.47	7.52	0.38	5.1e-13	Mood instability;
LUSC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.08	-0.32	3.22e-9	Total body bone mineral density;
LUSC	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07080220	chr10:102295463	HIF1AN	0.69	9.5	0.46	4.15e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6681460	1.000	rs1562217	chr1:67073566	C/T	cg02459107	chr1:67143332	SGIP1	-0.5	-9.35	-0.46	1.35e-18	Presence of antiphospholipid antibodies;
LUSC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	0.93	15.74	0.65	3.73e-42	Menopause (age at onset);
LUSC	cis	rs4704187	0.687	rs10058460	chr5:74498715	C/T	cg03227963	chr5:74354835	NA	0.31	6.76	0.35	6.31e-11	Response to amphetamines;
LUSC	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg06937882	chr20:24974362	C20orf3	-0.41	-6.94	-0.36	2.02e-11	Blood protein levels;
LUSC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg04369109	chr6:150039330	LATS1	-0.55	-8.09	-0.4	1.1e-14	Lung cancer;
LUSC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg03676636	chr4:99064102	C4orf37	0.38	8.92	0.44	3.17e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.7	10.66	0.5	5e-23	Aortic root size;
LUSC	cis	rs11756438	0.572	rs902779	chr6:119000593	A/C	cg18833306	chr6:118973337	C6orf204	0.36	5.79	0.3	1.59e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg12856521	chr11:46389249	DGKZ	0.4	6.29	0.33	1e-9	Leprosy;
LUSC	cis	rs12681287	0.547	rs9942792	chr8:87509046	C/T	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg25456477	chr12:86230367	RASSF9	0.35	6.21	0.32	1.56e-9	Major depressive disorder;
LUSC	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg06627628	chr2:24431161	ITSN2	-0.68	-9.47	-0.46	5.18e-19	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg24060327	chr5:131705240	SLC22A5	-0.52	-8.66	-0.43	2.08e-16	Breast cancer;
LUSC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg23978390	chr7:1156363	C7orf50	0.5	5.9	0.31	9.1e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.57	8.31	0.41	2.52e-15	Personality dimensions;
LUSC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	13.98	0.61	2.7e-35	Platelet count;
LUSC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg03790207	chr6:42947109	PEX6	-0.46	-6.88	-0.35	2.89e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1847202	0.859	rs6771288	chr3:72939471	A/G	cg25664220	chr3:72788482	NA	-0.38	-7.01	-0.36	1.3e-11	Motion sickness;
LUSC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.38	7.15	0.36	5.66e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg08773314	chr2:239334832	ASB1	0.44	9.54	0.46	3.22e-19	Multiple system atrophy;
LUSC	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	1.03	15.05	0.64	1.87e-39	Orofacial clefts;
LUSC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg02951883	chr7:2050386	MAD1L1	-0.62	-12.06	-0.55	4.77e-28	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg06671706	chr8:8559999	CLDN23	0.47	6.4	0.33	5.34e-10	Obesity-related traits;
LUSC	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg01028140	chr2:1542097	TPO	-0.53	-8.64	-0.43	2.29e-16	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg21775007	chr8:11205619	TDH	-0.45	-6.28	-0.32	1.03e-9	Myopia (pathological);
LUSC	trans	rs10946292	0.656	rs3012449	chr6:170436735	A/T	cg17832364	chr10:94847294	NA	0.38	6.31	0.33	8.63e-10	Obesity-related traits;
LUSC	trans	rs72674100	1.000	rs28417914	chr4:97988227	G/T	cg09670535	chr1:18959427	PAX7	-0.56	-6.01	-0.31	4.76e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg23791538	chr6:167370224	RNASET2	0.41	6.7	0.34	8.84e-11	Crohn's disease;
LUSC	cis	rs6469656	0.803	rs6983032	chr8:117705416	C/T	cg24004040	chr8:117650383	NA	-0.44	-6.44	-0.33	4.13e-10	Colorectal cancer;
LUSC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.75	0.54	6.47e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9462027	0.606	rs7759227	chr6:34728230	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.74	-0.3	2.08e-8	Systemic lupus erythematosus;
LUSC	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg10326726	chr10:51549505	MSMB	-0.35	-6.12	-0.32	2.58e-9	Prostate-specific antigen levels;
LUSC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.85	-14.19	-0.61	4.47e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.04	-0.58	1.08e-31	Alzheimer's disease;
LUSC	trans	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.21	0.45	3.77e-18	Resting heart rate;
LUSC	cis	rs10876993	0.622	rs7978394	chr12:58091695	C/A	cg18357645	chr12:58087776	OS9	0.58	8.65	0.43	2.28e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08280861	chr8:58055591	NA	0.57	6.2	0.32	1.67e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2235649	0.623	rs8048162	chr16:1848918	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-5.96	-0.31	6.24e-9	Blood metabolite levels;
LUSC	cis	rs9902453	0.934	rs4343336	chr17:28488236	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.19	0.41	5.67e-15	Coffee consumption (cups per day);
LUSC	cis	rs4363385	0.550	rs2050673	chr1:152923698	C/T	cg00922841	chr1:152955080	SPRR1A	-0.39	-6.4	-0.33	5.27e-10	Inflammatory skin disease;
LUSC	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg08975724	chr8:8085496	FLJ10661	0.46	6.64	0.34	1.26e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs79911532	0.515	rs113056502	chr7:75667901	G/A	cg03592824	chr7:75666768	STYXL1	0.7	6.83	0.35	4.03e-11	Mononucleosis;
LUSC	trans	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg13565492	chr6:43139072	SRF	-0.57	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs612683	0.602	rs12565245	chr1:101019326	T/G	cg06223162	chr1:101003688	GPR88	0.52	9.64	0.47	1.5e-19	Breast cancer;
LUSC	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg22676075	chr6:135203613	NA	0.48	7.51	0.38	5.47e-13	Reticulocyte count;High light scatter reticulocyte count;
LUSC	cis	rs9653442	0.900	rs4851269	chr2:100830348	C/T	cg22139774	chr2:100720529	AFF3	0.45	8.09	0.4	1.09e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg04865166	chr7:105162814	PUS7	0.51	5.84	0.3	1.25e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg05110241	chr16:68378359	PRMT7	-0.82	-8.92	-0.44	3.04e-17	Schizophrenia;
LUSC	cis	rs9837602	1.000	rs7610486	chr3:99732564	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.23	0.32	1.43e-9	Breast cancer;
LUSC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.97	-16.61	-0.67	1.39e-45	Body mass index;
LUSC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.13	0.48	3.25e-21	Intelligence (multi-trait analysis);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27328858	chr13:74709379	KLF12	0.43	6.0	0.31	5.15e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs73198271	0.740	rs11781430	chr8:8651733	G/C	cg01851573	chr8:8652454	MFHAS1	0.52	8.33	0.41	2.08e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg02079420	chr8:82753780	SNX16	0.43	7.37	0.37	1.39e-12	Diastolic blood pressure;
LUSC	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg13057898	chr1:3703894	LRRC47	0.46	7.89	0.4	4.42e-14	Red cell distribution width;
LUSC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg25039879	chr17:56429692	SUPT4H1	0.68	9.14	0.45	6.1e-18	Cognitive test performance;
LUSC	cis	rs7605827	0.930	rs11682580	chr2:15533272	T/C	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.63	9.58	0.46	2.33e-19	Type 2 diabetes;
LUSC	cis	rs10100465	0.961	rs1383176	chr8:118666943	G/C	cg09430518	chr8:118662568	NA	-0.3	-5.68	-0.3	2.95e-8	Leprosy;
LUSC	trans	rs800082	0.516	rs1178896	chr3:144240689	A/T	cg24215973	chr2:240111563	HDAC4	0.44	6.78	0.35	5.37e-11	Smoking behavior;
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg27094323	chr7:1216898	NA	-0.47	-8.28	-0.41	2.96e-15	Longevity;Endometriosis;
LUSC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg02269571	chr22:50332266	NA	-0.57	-8.59	-0.43	3.41e-16	Schizophrenia;
LUSC	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg18904891	chr8:8559673	CLDN23	0.53	7.6	0.38	3.05e-13	Obesity-related traits;
LUSC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg12257692	chr3:49977190	RBM6	0.24	6.73	0.35	7.19e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg07195126	chr1:160370843	VANGL2	0.48	7.37	0.37	1.37e-12	Breast size;
LUSC	cis	rs7923452	0.938	rs34930615	chr10:30761051	G/A	cg25182066	chr10:30743637	MAP3K8	0.58	6.94	0.35	2.09e-11	Itch intensity from mosquito bite;
LUSC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg04455712	chr21:45112962	RRP1B	0.47	9.01	0.44	1.67e-17	Mean corpuscular volume;
LUSC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg17143192	chr8:8559678	CLDN23	0.66	9.26	0.45	2.46e-18	Obesity-related traits;
LUSC	cis	rs6692729	0.933	rs2236914	chr1:227078721	A/T	cg10327440	chr1:227177885	CDC42BPA	0.49	6.88	0.35	2.89e-11	Electrodermal activity;
LUSC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.24	-0.37	3.12e-12	Colorectal cancer;
LUSC	trans	rs9929218	1.000	rs28450087	chr16:68803726	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.5	-0.53	5.24e-26	Colorectal cancer;
LUSC	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg21231944	chr12:82153410	PPFIA2	-0.39	-6.16	-0.32	2.07e-9	Resting heart rate;
LUSC	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg23711669	chr6:146136114	FBXO30	0.74	12.94	0.58	2.44e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	10.75	0.51	2.35e-23	Mood instability;
LUSC	cis	rs12940923	0.935	rs11871743	chr17:56368825	A/C	cg19466818	chr17:56409534	MIR142	-0.39	-6.87	-0.35	3.19e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg27170947	chr2:26402098	FAM59B	0.74	10.86	0.51	9.5e-24	Mean corpuscular hemoglobin;
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11905131	chr22:24372483	LOC391322	-0.53	-8.87	-0.44	4.66e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg11663144	chr21:46675770	NA	-0.41	-7.19	-0.37	4.39e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg11502198	chr6:26597334	ABT1	0.72	12.06	0.55	4.92e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg13560548	chr3:10150139	C3orf24	0.52	7.25	0.37	2.85e-12	Alzheimer's disease;
LUSC	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-9.08	-0.44	9.63e-18	Depression;
LUSC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg02454025	chr1:11042201	C1orf127	0.92	17.94	0.7	7.02e-51	Ewing sarcoma;
LUSC	cis	rs7095944	0.614	rs11245354	chr10:126450125	C/A	cg08799069	chr10:126477246	METTL10	-0.42	-6.56	-0.34	2.04e-10	Asthma;
LUSC	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07636037	chr3:49044803	WDR6	0.69	9.2	0.45	4.05e-18	Menarche (age at onset);
LUSC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.69	-0.39	1.72e-13	Tonsillectomy;
LUSC	cis	rs73001065	0.901	rs3794991	chr19:19610596	C/T	cg03709012	chr19:19516395	GATAD2A	0.94	7.27	0.37	2.61e-12	LDL cholesterol;
LUSC	cis	rs9931543	0.714	rs9923469	chr16:56289608	T/C	cg00991179	chr16:56000067	NA	-0.34	-5.89	-0.31	9.29e-9	Subjective well-being;
LUSC	cis	rs739496	0.542	rs10849937	chr12:111792427	A/G	cg10833066	chr12:111807467	FAM109A	0.61	11.82	0.54	3.53e-27	Platelet count;
LUSC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg05785598	chr3:49045655	WDR6	0.38	6.48	0.33	3.37e-10	Parkinson's disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05874476	chr15:43802882	TP53BP1	0.47	6.42	0.33	4.56e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs55720021	1	rs55720021	chr19:49144241	G/T	cg06677660	chr19:49140777	SEC1;DBP	0.44	5.65	0.3	3.45e-8	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
LUSC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.59	9.5	0.46	4.06e-19	Aortic root size;
LUSC	cis	rs804280	1.000	rs804281	chr8:11611865	A/G	cg00262122	chr8:11665843	FDFT1	0.41	5.9	0.31	9.13e-9	Myopia (pathological);
LUSC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg25258033	chr6:167368657	RNASET2	0.46	7.67	0.39	1.91e-13	Crohn's disease;
LUSC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg06238570	chr21:40685208	BRWD1	0.54	7.99	0.4	2.18e-14	Cognitive function;
LUSC	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg06714761	chr1:201096289	NA	0.42	7.85	0.39	5.54e-14	Permanent tooth development;
LUSC	cis	rs7577851	0.625	rs72826573	chr2:69567272	C/A	cg10773587	chr2:69614142	GFPT1	0.58	6.23	0.32	1.38e-9	Parkinson's disease (age of onset);
LUSC	cis	rs8018808	0.935	rs12433766	chr14:77930293	C/T	cg20045696	chr14:77926864	AHSA1	0.34	5.76	0.3	1.95e-8	Myeloid white cell count;
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg25703541	chr22:24373054	LOC391322	-0.89	-14.4	-0.62	6.77e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs7582180	0.903	rs2309825	chr2:100905101	A/C	cg08017756	chr2:100939284	LONRF2	-0.35	-5.96	-0.31	6.39e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7189233	0.955	rs8058684	chr16:53515118	G/A	cg04059762	chr16:53544020	NA	-0.32	-5.79	-0.3	1.67e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11039100	1.000	rs4474469	chr11:5828849	T/C	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22790142	chr14:24769116	C14orf21;DHRS1	-0.41	-6.0	-0.31	5.06e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2137920	0.891	rs2254629	chr10:50236629	T/A	cg27141751	chr10:50231850	C10orf72	0.38	5.73	0.3	2.28e-8	Migraine with aura;
LUSC	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg23283495	chr1:209979779	IRF6	0.7	8.25	0.41	3.6e-15	Cleft lip with or without cleft palate;
LUSC	cis	rs7173743	0.784	rs11072811	chr15:79132330	G/T	cg00540400	chr15:79124168	NA	-0.37	-6.59	-0.34	1.76e-10	Coronary artery disease;
LUSC	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg10596483	chr8:143751796	JRK	0.52	7.57	0.38	3.79e-13	Schizophrenia;
LUSC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.78	-12.23	-0.56	1.15e-28	Pancreatic cancer;
LUSC	trans	rs7580332	0.565	rs4832572	chr2:18540192	A/G	cg15951870	chr17:45925060	SP6	-0.34	-6.0	-0.31	5.18e-9	Amyotrophic lateral sclerosis;
LUSC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg02018176	chr4:1364513	KIAA1530	0.53	9.24	0.45	2.99e-18	Obesity-related traits;
LUSC	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg16512390	chr1:228756714	NA	0.7	8.89	0.44	4.03e-17	Chronic lymphocytic leukemia;
LUSC	cis	rs72781680	0.784	rs72798406	chr2:24180144	T/C	cg08917208	chr2:24149416	ATAD2B	0.61	6.96	0.36	1.82e-11	Lymphocyte counts;
LUSC	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.81	17.57	0.69	2.11e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4664304	1.000	rs4664304	chr2:160794008	A/G	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.32	-0.33	8.24e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4851254	0.626	rs71413861	chr2:100673501	A/G	cg22139774	chr2:100720529	AFF3	-0.44	-5.82	-0.3	1.37e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg01294253	chr9:136912663	BRD3	0.35	6.02	0.31	4.69e-9	Platelet distribution width;
LUSC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg23711669	chr6:146136114	FBXO30	0.7	12.18	0.55	1.69e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23158103	chr7:148848205	ZNF398	-0.44	-7.0	-0.36	1.43e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.76	-13.34	-0.59	7.85e-33	Cognitive function;
LUSC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg09367891	chr1:107599246	PRMT6	0.51	7.91	0.4	3.7e-14	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg01689657	chr7:91764605	CYP51A1	0.35	6.3	0.33	9.48e-10	Breast cancer;
LUSC	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg18811423	chr2:55921094	PNPT1	0.8	13.04	0.58	1.06e-31	Metabolic syndrome;
LUSC	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	7.19	0.37	4.21e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg17554472	chr22:41940697	POLR3H	-0.48	-5.76	-0.3	1.89e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg08888203	chr3:10149979	C3orf24	0.65	9.23	0.45	3.07e-18	Alzheimer's disease;
LUSC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg11062466	chr8:58055876	NA	0.5	6.81	0.35	4.69e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6733011	0.582	rs2280256	chr2:99449174	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-7.3	-0.37	2.12e-12	Bipolar disorder;
LUSC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	0.93	15.91	0.66	8.22e-43	Menopause (age at onset);
LUSC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.48	7.29	0.37	2.24e-12	Menarche (age at onset);
LUSC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg18451016	chr1:38461880	NA	-0.5	-6.86	-0.35	3.38e-11	Coronary artery disease;
LUSC	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg02569458	chr12:86230093	RASSF9	0.42	6.68	0.34	9.98e-11	Major depressive disorder;
LUSC	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg11502198	chr6:26597334	ABT1	0.59	9.32	0.45	1.69e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.92	0.4	3.59e-14	Colorectal cancer;
LUSC	cis	rs10792830	0.707	rs579406	chr11:85657759	A/C	cg07180834	chr11:85838833	NA	-0.3	-5.8	-0.3	1.56e-8	Psychosis and Alzheimer's disease;
LUSC	cis	rs4853525	0.522	rs62179715	chr2:191570072	C/T	cg11845111	chr2:191398756	TMEM194B	-0.43	-5.69	-0.3	2.8e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg13010199	chr12:38710504	ALG10B	-0.49	-7.5	-0.38	5.78e-13	Morning vs. evening chronotype;
LUSC	cis	rs7241530	0.689	rs6506735	chr18:75888482	C/T	cg14642773	chr18:75888474	NA	-0.37	-6.29	-0.33	1.02e-9	Educational attainment (years of education);
LUSC	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg02175503	chr12:58329896	NA	0.65	10.84	0.51	1.12e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.38	-9.16	-0.45	5.46e-18	Diastolic blood pressure;
LUSC	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg05623727	chr3:50126028	RBM5	-0.35	-6.66	-0.34	1.1e-10	Body mass index;
LUSC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.62	-11.14	-0.52	1e-24	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.39	-0.33	5.72e-10	Lung cancer;
LUSC	cis	rs35264875	0.851	rs7933746	chr11:68867722	A/G	cg02660097	chr11:68866761	NA	0.39	6.22	0.32	1.49e-9	Blond vs. brown hair color;
LUSC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg20684491	chr1:25596433	NA	0.42	6.6	0.34	1.66e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs11690935	0.632	rs34242651	chr2:172553999	G/A	cg13550731	chr2:172543902	DYNC1I2	0.6	9.54	0.46	3.22e-19	Schizophrenia;
LUSC	cis	rs1983891	0.908	rs2148342	chr6:41519522	G/A	cg20194872	chr6:41519635	FOXP4	0.33	5.91	0.31	8.35e-9	Prostate cancer;
LUSC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.67e-12	Motion sickness;
LUSC	trans	rs1459104	0.925	rs35473011	chr11:54881353	G/A	cg03929089	chr4:120376271	NA	0.68	6.03	0.31	4.28e-9	Body mass index;
LUSC	cis	rs4144743	0.877	rs7223766	chr17:45326734	T/G	cg18085866	chr17:45331354	ITGB3	-0.75	-7.79	-0.39	8.26e-14	Body mass index;
LUSC	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg19508488	chr2:152266495	RIF1	0.48	6.57	0.34	1.88e-10	Lung cancer;
LUSC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-6.02	-0.31	4.47e-9	Huntington's disease progression;
LUSC	cis	rs9807989	0.507	rs7605284	chr2:103044175	T/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.06	0.36	9.92e-12	Asthma;
LUSC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.15	-0.32	2.26e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9905704	0.874	rs304265	chr17:56749298	C/T	cg12560992	chr17:57184187	TRIM37	0.54	7.73	0.39	1.28e-13	Testicular germ cell tumor;
LUSC	cis	rs13242816	0.881	rs17138706	chr7:116109019	A/G	cg16553024	chr7:116138462	CAV2	-0.54	-5.92	-0.31	7.84e-9	P wave duration;
LUSC	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg25457927	chr22:38595422	NA	-0.42	-8.92	-0.44	3.05e-17	Cutaneous nevi;
LUSC	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg16346588	chr10:242978	ZMYND11	-0.43	-5.77	-0.3	1.83e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs6500395	0.926	rs1039344	chr16:48577569	A/G	cg04672837	chr16:48644449	N4BP1	0.43	6.28	0.32	1.05e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg24088639	chr11:34937564	PDHX;APIP	0.42	6.25	0.32	1.26e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.0	-0.4	2.14e-14	Glomerular filtration rate;
LUSC	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg17366294	chr4:99064904	C4orf37	0.54	9.33	0.45	1.47e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-5.81	-0.3	1.48e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg20406979	chr6:167373233	NA	0.25	5.81	0.3	1.49e-8	Crohn's disease;
LUSC	cis	rs12980942	1.000	rs34945449	chr19:41819824	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.01	0.31	4.79e-9	Coronary artery disease;
LUSC	cis	rs3105593	0.637	rs3098168	chr15:50751050	T/C	cg08437265	chr15:50716283	USP8	0.4	5.9	0.31	8.91e-9	QT interval;
LUSC	cis	rs2273669	0.667	rs12153822	chr6:109315115	T/C	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg12463550	chr7:65579703	CRCP	-0.47	-7.1	-0.36	7.5e-12	Aortic root size;
LUSC	cis	rs7246967	0.551	rs7257333	chr19:22881149	C/T	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg26924012	chr15:45694286	SPATA5L1	1.13	20.84	0.75	2.15e-62	Homoarginine levels;
LUSC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg22482690	chr17:47019901	SNF8	-0.34	-6.13	-0.32	2.5e-9	Type 2 diabetes;
LUSC	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg00277334	chr10:82204260	NA	-0.44	-6.32	-0.33	8.18e-10	Post bronchodilator FEV1;
LUSC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	9.39	0.46	9.42e-19	Mean platelet volume;
LUSC	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg23601095	chr6:26197514	HIST1H3D	0.7	7.53	0.38	4.89e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	7.37	0.37	1.37e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.56	0.5	1.13e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg20908204	chr19:46285434	DMPK	0.42	8.32	0.41	2.35e-15	Coronary artery disease;
LUSC	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg12863693	chr15:85201151	NMB	0.42	8.76	0.43	1.02e-16	Schizophrenia;
LUSC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.55	-12.69	-0.57	2.18e-30	Height;
LUSC	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.15	0.64	7.82e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.65	-0.43	2.19e-16	Total cholesterol levels;
LUSC	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.74	-11.82	-0.54	3.48e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6987853	0.933	rs2974353	chr8:42409165	A/C	cg09913449	chr8:42400586	C8orf40	0.49	8.14	0.41	7.77e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.88	15.08	0.64	1.52e-39	Resting heart rate;
LUSC	trans	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg04995722	chr7:26192034	NFE2L3	0.41	6.41	0.33	5.01e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs877282	0.947	rs957642	chr10:773966	C/T	cg17470449	chr10:769945	NA	0.52	7.32	0.37	1.86e-12	Uric acid levels;
LUSC	cis	rs7246967	0.673	rs8102006	chr19:22870103	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs3755132	0.929	rs55668395	chr2:15748423	T/C	cg12888861	chr2:15731646	DDX1	0.5	7.3	0.37	2.16e-12	Wilms tumor;
LUSC	cis	rs9392556	0.829	rs7744628	chr6:4119996	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	0.36	6.25	0.32	1.26e-9	Blood metabolite levels;
LUSC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg20276088	chr3:133502917	NA	0.44	6.63	0.34	1.38e-10	Iron status biomarkers;
LUSC	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.9	15.46	0.65	4.87e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs554111	0.636	rs10916935	chr1:21432112	T/C	cg01072550	chr1:21505969	NA	0.38	5.82	0.3	1.41e-8	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs7923609	0.967	rs7095571	chr10:65150959	T/G	cg01631684	chr10:65280961	REEP3	-0.4	-6.18	-0.32	1.89e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1864729	0.688	rs1540434	chr8:98305351	A/G	cg08679828	chr8:102218111	ZNF706	-0.79	-6.56	-0.34	2.07e-10	Estradiol plasma levels (breast cancer);
LUSC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg11861562	chr11:117069780	TAGLN	0.44	7.92	0.4	3.58e-14	Blood protein levels;
LUSC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg21251018	chr6:28226885	NKAPL	0.33	6.38	0.33	5.97e-10	Pubertal anthropometrics;
LUSC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg16928487	chr17:17741425	SREBF1	-0.37	-7.03	-0.36	1.19e-11	Total body bone mineral density;
LUSC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg13206674	chr6:150067644	NUP43	0.49	7.34	0.37	1.61e-12	Lung cancer;
LUSC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-1.03	-20.07	-0.74	2.43e-59	Height;
LUSC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.58e-8	Life satisfaction;
LUSC	cis	rs2303282	0.716	rs7187714	chr16:56467264	A/T	cg00500540	chr16:56394104	NA	-0.43	-7.38	-0.37	1.27e-12	Breast cancer;
LUSC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg06784218	chr1:46089804	CCDC17	0.54	11.06	0.52	1.88e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg06462663	chr19:18546047	ISYNA1	0.49	8.44	0.42	9.45e-16	Breast cancer;
LUSC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg04317338	chr11:64019027	PLCB3	0.66	7.32	0.37	1.89e-12	Mean platelet volume;
LUSC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg22823121	chr1:150693482	HORMAD1	0.56	8.05	0.4	1.45e-14	Urate levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21654404	chr12:118814431	SUDS3	-0.48	-6.2	-0.32	1.64e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg08975724	chr8:8085496	FLJ10661	0.48	6.95	0.36	1.87e-11	Neuroticism;
LUSC	cis	rs2479724	0.591	rs2479726	chr6:41898096	A/G	cg17623882	chr6:41773611	USP49	-0.5	-6.59	-0.34	1.73e-10	Menarche (age at onset);
LUSC	trans	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	7.44	0.38	8.86e-13	Menarche (age at onset);
LUSC	cis	rs4654899	0.865	rs6693020	chr1:21378057	A/G	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.09	-0.32	3.06e-9	Superior frontal gyrus grey matter volume;
LUSC	trans	rs6601327	0.573	rs13278824	chr8:9646119	T/A	cg15556689	chr8:8085844	FLJ10661	0.48	7.16	0.36	5.02e-12	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.98	0.31	5.76e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg18758796	chr5:131593413	PDLIM4	-0.42	-6.74	-0.35	6.98e-11	Breast cancer;
LUSC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.26	-0.49	1.23e-21	Electroencephalogram traits;
LUSC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg16228356	chr17:43848958	NA	-0.28	-6.37	-0.33	6.32e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg22535103	chr8:58192502	C8orf71	-0.67	-7.25	-0.37	2.97e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	0.81	15.55	0.65	2.06e-41	Gut microbiome composition (winter);
LUSC	trans	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	-0.67	-8.7	-0.43	1.59e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg18721089	chr20:30220636	NA	-0.37	-5.85	-0.3	1.19e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs11264799	0.581	rs2758680	chr1:157543746	C/T	cg18268488	chr1:157545234	FCRL4	0.37	6.91	0.35	2.46e-11	IgA nephropathy;
LUSC	cis	rs68170813	0.559	rs2894459	chr7:106960166	C/T	cg02696742	chr7:106810147	HBP1	-0.61	-8.96	-0.44	2.41e-17	Coronary artery disease;
LUSC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.43	-6.2	-0.32	1.64e-9	Longevity;Endometriosis;
LUSC	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg10645314	chr2:3704589	ALLC	-0.47	-8.0	-0.4	2.08e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg21770322	chr7:97807741	LMTK2	0.41	7.08	0.36	8.48e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg27411982	chr8:10470053	RP1L1	0.43	6.27	0.32	1.1e-9	Neuroticism;
LUSC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg18306943	chr3:40428807	ENTPD3	0.37	5.76	0.3	1.89e-8	Renal cell carcinoma;
LUSC	cis	rs2414856	0.504	rs72742986	chr15:64987229	T/C	cg08069370	chr15:64387884	SNX1	-0.68	-5.9	-0.31	8.97e-9	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs2455601	0.744	rs11042107	chr11:8905871	G/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.5	-7.9	-0.4	4.09e-14	Schizophrenia;
LUSC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg22618164	chr12:122356400	WDR66	0.61	9.03	0.44	1.43e-17	Mean corpuscular volume;
LUSC	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.01	-0.36	1.35e-11	Reticulocyte fraction of red cells;
LUSC	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs9807989	0.765	rs6751977	chr2:102967430	T/C	cg09003973	chr2:102972529	NA	0.45	6.19	0.32	1.8e-9	Asthma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11237535	chr17:78075184	GAA	-0.41	-6.07	-0.32	3.41e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	1.02	24.18	0.8	2.34e-75	Menarche (age at onset);
LUSC	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg23093090	chr10:104574429	C10orf26	-0.41	-7.33	-0.37	1.72e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3755132	0.929	rs16862822	chr2:15772958	G/A	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	cis	rs7760535	0.930	rs7742244	chr6:111852662	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.47	-0.33	3.42e-10	Metabolic traits;
LUSC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15664640	chr17:80829946	TBCD	-0.72	-13.28	-0.59	1.27e-32	Breast cancer;
LUSC	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg13390004	chr1:15929781	NA	0.41	7.06	0.36	9.46e-12	Systolic blood pressure;
LUSC	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-7.13	-0.36	6.21e-12	Morning vs. evening chronotype;
LUSC	cis	rs911119	0.955	rs6048933	chr20:23595637	T/G	cg16589663	chr20:23618590	CST3	0.61	7.22	0.37	3.62e-12	Chronic kidney disease;
LUSC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.35	-0.8	4.97e-76	Height;
LUSC	cis	rs7241530	0.636	rs28491529	chr18:75889301	A/G	cg14642773	chr18:75888474	NA	0.36	6.01	0.31	4.91e-9	Educational attainment (years of education);
LUSC	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg12559939	chr2:27858050	GPN1	0.4	6.3	0.33	9.64e-10	Oral cavity cancer;
LUSC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.46	-0.38	7.78e-13	Aortic root size;
LUSC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg15556689	chr8:8085844	FLJ10661	0.7	11.28	0.53	3.12e-25	Joint mobility (Beighton score);
LUSC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg11812906	chr14:75593930	NEK9	0.66	11.23	0.52	4.9e-25	Height;
LUSC	cis	rs4948275	0.550	rs7082786	chr10:63176990	C/A	cg02461363	chr10:63212496	TMEM26	-0.35	-5.7	-0.3	2.69e-8	Night sleep phenotypes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01869960	chr2:136289456	R3HDM1;ZRANB3	-0.46	-6.08	-0.32	3.33e-9	Hepatitis;
LUSC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820928	0.874	rs1917123	chr2:227889783	T/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.58	-0.38	3.42e-13	Pulmonary function;
LUSC	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg01733217	chr16:74700730	RFWD3	-0.87	-16.1	-0.66	1.47e-43	Multiple myeloma;
LUSC	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg03676636	chr4:99064102	C4orf37	0.36	8.01	0.4	1.99e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1005224	0.889	rs10132250	chr14:76124380	C/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.63	-8.65	-0.43	2.25e-16	Large artery stroke;
LUSC	cis	rs12681287	0.546	rs12546802	chr8:87499335	T/A	cg27223183	chr8:87520930	FAM82B	-0.55	-7.24	-0.37	3.19e-12	Caudate activity during reward;
LUSC	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg21775007	chr8:11205619	TDH	0.45	6.47	0.33	3.41e-10	Neuroticism;
LUSC	cis	rs714027	0.585	rs41170	chr22:30421066	C/T	cg11564601	chr22:30592435	NA	0.33	5.82	0.3	1.36e-8	Lymphocyte counts;
LUSC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06481639	chr22:41940642	POLR3H	-0.51	-6.14	-0.32	2.41e-9	Vitiligo;
LUSC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.67	-0.34	1.09e-10	Crohn's disease;
LUSC	trans	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg06606381	chr12:133084897	FBRSL1	-1.08	-9.49	-0.46	4.57e-19	Depression;
LUSC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg01973587	chr1:228161476	NA	0.44	8.04	0.4	1.62e-14	Diastolic blood pressure;
LUSC	cis	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg21775007	chr8:11205619	TDH	-0.53	-7.47	-0.38	7.28e-13	Neuroticism;
LUSC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg06636551	chr8:101224915	SPAG1	-0.4	-7.41	-0.38	1.06e-12	Atrioventricular conduction;
LUSC	cis	rs921665	0.749	rs4854133	chr2:3199626	C/T	cg02624386	chr2:3182749	NA	0.56	6.12	0.32	2.66e-9	World class endurance athleticism;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg01238044	chr22:24384105	GSTT1	-0.63	-10.14	-0.49	3.05e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.9	0.61	5.47e-35	Breast cancer;
LUSC	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.72	-13.41	-0.59	4.11e-33	Platelet distribution width;
LUSC	cis	rs9646944	0.501	rs10210176	chr2:103079516	A/C	cg20060108	chr2:102954350	IL1RL1	-0.44	-6.08	-0.32	3.25e-9	Blood protein levels;
LUSC	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg19468946	chr17:37922297	IKZF3	-0.43	-6.83	-0.35	3.97e-11	Self-reported allergy;
LUSC	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.9	15.74	0.65	3.85e-42	Morning vs. evening chronotype;
LUSC	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.45	-0.5	2.56e-22	Eye color traits;
LUSC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg00701064	chr4:6280414	WFS1	0.59	14.2	0.61	3.93e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg09034736	chr1:150693464	HORMAD1	0.4	5.71	0.3	2.5e-8	Melanoma;
LUSC	cis	rs500891	0.525	rs10943930	chr6:84060858	A/T	cg08257003	chr6:84140564	ME1	0.34	8.4	0.42	1.33e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg21775007	chr8:11205619	TDH	0.44	5.96	0.31	6.53e-9	Monocyte count;
LUSC	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	9.89	0.48	2.13e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.43	-9.0	-0.44	1.75e-17	Airflow obstruction;
LUSC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.65	-11.6	-0.54	2.18e-26	Aortic root size;
LUSC	cis	rs7589342	0.566	rs7589589	chr2:106391154	C/G	cg14210321	chr2:106509881	NCK2	-0.43	-6.22	-0.32	1.51e-9	Addiction;
LUSC	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg18833306	chr6:118973337	C6orf204	-0.46	-5.83	-0.3	1.34e-8	Diastolic blood pressure;
LUSC	cis	rs7180079	0.620	rs11071796	chr15:64712608	A/G	cg08069370	chr15:64387884	SNX1	0.51	5.64	0.3	3.55e-8	Monocyte count;
LUSC	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg12863693	chr15:85201151	NMB	0.36	7.06	0.36	9.44e-12	Schizophrenia;
LUSC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg18681998	chr4:17616180	MED28	0.9	17.84	0.7	1.85e-50	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.35	0.49	5.71e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.67	9.97	0.48	1.12e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs7804356	1.000	rs61354389	chr7:26868343	C/T	cg03456212	chr7:26904342	SKAP2	-0.56	-6.44	-0.33	4.23e-10	Type 1 diabetes;
LUSC	cis	rs9611519	1.000	rs5751069	chr22:41627775	C/G	cg03806693	chr22:41940476	POLR3H	-0.51	-6.93	-0.35	2.14e-11	Neuroticism;
LUSC	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg03433033	chr1:76189801	ACADM	-0.45	-6.78	-0.35	5.41e-11	Daytime sleep phenotypes;
LUSC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.84	15.46	0.65	4.71e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs5009270	0.512	rs1024412	chr7:112247758	A/G	cg23628563	chr7:112262597	NA	0.43	6.01	0.31	4.75e-9	Osteoarthritis (hip);
LUSC	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg16576083	chr14:105354267	KIAA0284	0.53	9.57	0.46	2.57e-19	IgG glycosylation;
LUSC	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.99	0.31	5.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	6.1	0.32	2.9e-9	Tonsillectomy;
LUSC	cis	rs8092503	1.000	rs7231263	chr18:52493167	A/T	cg12377874	chr18:52495404	RAB27B	-0.31	-5.73	-0.3	2.21e-8	Childhood body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27353073	chr11:76092311	PRKRIR	0.44	6.13	0.32	2.48e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16238933	chr4:668052	ATP5I	0.41	6.52	0.34	2.53e-10	Asthma;
LUSC	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg07930552	chr6:133119739	C6orf192	0.95	8.5	0.42	6.4e-16	Type 2 diabetes nephropathy;
LUSC	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.8	-0.43	7.57e-17	Coffee consumption (cups per day);
LUSC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg14403583	chr14:105418241	AHNAK2	-0.58	-9.66	-0.47	1.28e-19	Rheumatoid arthritis;
LUSC	cis	rs4363385	0.818	rs4576617	chr1:152985729	G/A	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.09	-0.36	7.87e-12	Inflammatory skin disease;
LUSC	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.74	-12.52	-0.57	9.6e-30	White blood cell count (basophil);
LUSC	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.42	6.54	0.34	2.26e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg04518342	chr5:131593106	PDLIM4	0.32	5.72	0.3	2.33e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg22920501	chr2:26401640	FAM59B	-0.79	-11.76	-0.54	5.97e-27	Gut microbiome composition (summer);
LUSC	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.45	-0.42	9.17e-16	Neuroticism;
LUSC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg15605315	chr1:45957053	TESK2	0.48	7.99	0.4	2.28e-14	High light scatter reticulocyte count;
LUSC	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg05855489	chr10:104503620	C10orf26	0.59	9.44	0.46	6.45e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-15.92	-0.66	7.51e-43	Gut microbiome composition (summer);
LUSC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg27572855	chr1:25598939	RHD	0.41	7.27	0.37	2.55e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.69	-0.47	9.96e-20	Hemoglobin concentration;
LUSC	cis	rs9818941	0.824	rs7427551	chr3:157725242	C/T	cg08654915	chr3:157813417	NA	-0.31	-7.28	-0.37	2.39e-12	Height;
LUSC	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg19628046	chr18:33552617	C18orf21	0.51	6.19	0.32	1.78e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs11997175	0.583	rs4386938	chr8:33673156	A/G	ch.8.33884649F	chr8:33765107	NA	0.44	6.53	0.34	2.51e-10	Body mass index;
LUSC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.63	8.44	0.42	9.92e-16	High light scatter reticulocyte count;
LUSC	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17691542	chr6:26056736	HIST1H1C	0.98	12.67	0.57	2.66e-30	Iron status biomarkers;
LUSC	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.14	-0.41	7.95e-15	Bone mineral density;
LUSC	cis	rs7923609	0.934	rs7923544	chr10:65182256	T/G	cg01631684	chr10:65280961	REEP3	-0.42	-6.42	-0.33	4.74e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg03340356	chr1:67600835	NA	0.44	6.82	0.35	4.25e-11	Psoriasis;
LUSC	cis	rs6494488	0.500	rs72741315	chr15:64713525	T/C	cg08069370	chr15:64387884	SNX1	-0.65	-5.67	-0.3	3.09e-8	Coronary artery disease;
LUSC	cis	rs10080237	0.564	rs2490232	chr6:80814802	C/T	cg08355045	chr6:80787529	NA	-0.54	-9.73	-0.47	7.12e-20	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUSC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08470875	chr2:26401718	FAM59B	0.74	9.9	0.48	1.99e-20	Gut microbiome composition (summer);
LUSC	cis	rs9311676	0.632	rs62258078	chr3:58363432	G/A	cg13750441	chr3:58318267	PXK	0.34	6.63	0.34	1.33e-10	Systemic lupus erythematosus;
LUSC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg14440974	chr22:39074834	NA	-0.36	-5.92	-0.31	7.79e-9	Menopause (age at onset);
LUSC	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-11.81	-0.54	4.04e-27	Colorectal cancer;
LUSC	cis	rs7590368	0.715	rs72779466	chr2:10963180	T/A	cg15705551	chr2:10952987	PDIA6	0.57	6.24	0.32	1.32e-9	Educational attainment (years of education);
LUSC	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg13256891	chr4:100009986	ADH5	-0.5	-6.47	-0.33	3.53e-10	Alcohol dependence;
LUSC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-7.22	-0.37	3.59e-12	Lung cancer;
LUSC	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg05340658	chr4:99064831	C4orf37	0.57	9.48	0.46	4.88e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg02023728	chr11:77925099	USP35	0.47	7.12	0.36	6.7e-12	Testicular germ cell tumor;
LUSC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.37	0.33	6.13e-10	Aortic root size;
LUSC	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg18825076	chr15:78729989	IREB2	-0.5	-7.78	-0.39	8.98e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg19468946	chr17:37922297	IKZF3	-0.43	-6.89	-0.35	2.82e-11	Self-reported allergy;
LUSC	cis	rs9815354	1.000	rs6805880	chr3:41865397	A/G	cg03022575	chr3:42003672	ULK4	0.59	6.55	0.34	2.2e-10	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg25214090	chr10:38739885	LOC399744	0.43	6.52	0.34	2.53e-10	Corneal astigmatism;
LUSC	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg03676636	chr4:99064102	C4orf37	0.29	5.69	0.3	2.85e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-9.69	-0.47	1e-19	Morning vs. evening chronotype;
LUSC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg00941745	chr8:109261117	EIF3E	0.48	7.63	0.39	2.42e-13	Triglycerides;
LUSC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg05043794	chr9:111880884	C9orf5	-0.36	-7.71	-0.39	1.42e-13	Menarche (age at onset);
LUSC	cis	rs7180079	0.620	rs6494481	chr15:64849904	G/T	cg08069370	chr15:64387884	SNX1	-0.51	-5.75	-0.3	1.97e-8	Monocyte count;
LUSC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.53	0.46	3.45e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12681287	0.640	rs13280468	chr8:87338452	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.29	-0.37	2.29e-12	Caudate activity during reward;
LUSC	cis	rs7605827	0.930	rs2160692	chr2:15637496	C/G	cg19274914	chr2:15703543	NA	0.46	8.87	0.44	4.51e-17	Educational attainment (years of education);
LUSC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.92	-0.44	3.05e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg04450456	chr4:17643702	FAM184B	0.4	6.75	0.35	6.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1018836	0.544	rs2142145	chr8:91460670	A/G	cg16814680	chr8:91681699	NA	-0.48	-6.87	-0.35	3.24e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg18681998	chr4:17616180	MED28	0.83	14.86	0.63	1.03e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12592908	chr6:36954170	MTCH1	-0.45	-5.99	-0.31	5.38e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg09904177	chr6:26538194	HMGN4	-0.74	-6.85	-0.35	3.47e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17095355	0.901	rs11194947	chr10:111763731	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.33	-0.37	1.79e-12	Biliary atresia;
LUSC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26314531	chr2:26401878	FAM59B	-0.67	-8.87	-0.44	4.63e-17	Gut microbiome composition (summer);
LUSC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.8	-0.65	2.29e-42	Gut microbiome composition (summer);
LUSC	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg13660082	chr14:53194042	PSMC6	-0.78	-6.82	-0.35	4.38e-11	Alzheimer's disease (late onset);
LUSC	trans	rs12637928	0.580	rs4682589	chr3:110211781	G/A	cg17371621	chr15:61264283	RORA	0.36	6.08	0.32	3.29e-9	Neuroticism;
LUSC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg22823121	chr1:150693482	HORMAD1	0.46	6.6	0.34	1.64e-10	Melanoma;
LUSC	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg01966878	chr4:90757139	SNCA	-0.36	-6.21	-0.32	1.61e-9	Dementia with Lewy bodies;
LUSC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.78	-14.57	-0.62	1.39e-37	Longevity;
LUSC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.66	0.6	4.84e-34	Platelet count;
LUSC	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg27068330	chr11:65405492	SIPA1	0.62	9.33	0.45	1.54e-18	Acne (severe);
LUSC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg07424592	chr7:64974309	NA	0.69	6.18	0.32	1.88e-9	Diabetic kidney disease;
LUSC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08280861	chr8:58055591	NA	0.53	5.83	0.3	1.31e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg11812906	chr14:75593930	NEK9	0.67	11.64	0.54	1.61e-26	Height;
LUSC	cis	rs8048589	0.558	rs35208076	chr16:12228169	C/T	cg02910054	chr16:12241554	SNX29	0.46	5.87	0.31	1.03e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg04455712	chr21:45112962	RRP1B	0.45	8.62	0.43	2.73e-16	Mean corpuscular volume;
LUSC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.68	11.42	0.53	1.01e-25	Systemic lupus erythematosus;
LUSC	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.39	-0.46	9.83e-19	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg20849893	chr7:64541193	NA	-0.65	-5.68	-0.3	2.99e-8	Diabetic kidney disease;
LUSC	cis	rs12476592	0.543	rs1446569	chr2:63818314	C/G	cg10828910	chr2:63850056	LOC388955	0.5	5.81	0.3	1.49e-8	Childhood ear infection;
LUSC	cis	rs6500395	1.000	rs9938633	chr16:48682093	G/C	cg04672837	chr16:48644449	N4BP1	0.45	6.8	0.35	4.69e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.74	10.31	0.49	7.84e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.6	0.47	1.95e-19	Bipolar disorder;
LUSC	cis	rs9807841	0.592	rs3810155	chr19:10764867	C/G	cg17710535	chr19:10819994	QTRT1	0.41	6.78	0.35	5.45e-11	Inflammatory skin disease;
LUSC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg09034736	chr1:150693464	HORMAD1	0.46	6.59	0.34	1.7e-10	Blood protein levels;
LUSC	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg05855489	chr10:104503620	C10orf26	0.52	8.02	0.4	1.76e-14	Arsenic metabolism;
LUSC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-9.17	-0.45	4.88e-18	Chronic sinus infection;
LUSC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg01802117	chr1:53393560	SCP2	-0.36	-5.95	-0.31	6.76e-9	Monocyte count;
LUSC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.79	0.51	1.7e-23	Menopause (age at onset);
LUSC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18854424	chr1:2615690	NA	0.53	10.87	0.51	9.06e-24	Ulcerative colitis;
LUSC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12016809	chr21:47604291	C21orf56	-0.46	-6.88	-0.35	3.04e-11	Testicular germ cell tumor;
LUSC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	9.0	0.44	1.69e-17	Total body bone mineral density;
LUSC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg08132940	chr7:1081526	C7orf50	-0.5	-5.92	-0.31	7.78e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs662064	0.692	rs12129512	chr1:10572967	G/T	cg20482658	chr1:10539492	PEX14	0.32	5.92	0.31	7.81e-9	Asthma;
LUSC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.96	16.26	0.66	3.22e-44	Breast cancer;
LUSC	cis	rs11690935	0.550	rs4280427	chr2:172813218	G/A	cg13550731	chr2:172543902	DYNC1I2	0.48	7.24	0.37	3.11e-12	Schizophrenia;
LUSC	trans	rs450533	0.718	rs440960	chr4:107826866	A/G	cg19546012	chr19:752860	C19orf21	-0.31	-5.95	-0.31	6.77e-9	Cancer;
LUSC	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg09307838	chr4:120376055	NA	-0.6	-8.85	-0.44	5.24e-17	Corneal astigmatism;
LUSC	cis	rs2625529	0.824	rs11072338	chr15:72245447	T/C	cg16672083	chr15:72433130	SENP8	-0.52	-7.65	-0.39	2.1e-13	Red blood cell count;
LUSC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg11941060	chr3:133502564	NA	0.53	8.11	0.41	9.96e-15	Iron status biomarkers;
LUSC	cis	rs9378688	0.654	rs2505661	chr6:2326285	G/A	cg12303981	chr6:2244766	GMDS	-0.41	-5.79	-0.3	1.63e-8	Caudate nucleus volume;
LUSC	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg07837209	chr13:79184101	NA	0.45	6.67	0.34	1.05e-10	Large artery stroke;
LUSC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg11845111	chr2:191398756	TMEM194B	-0.55	-9.21	-0.45	3.76e-18	Pulse pressure;
LUSC	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.7	-0.6	3.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg24375607	chr4:120327624	NA	0.69	10.52	0.5	1.56e-22	Corneal astigmatism;
LUSC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg06046430	chr4:77819534	ANKRD56	0.49	7.16	0.36	5.01e-12	Emphysema distribution in smoking;
LUSC	trans	rs6982636	0.967	rs2954029	chr8:126490972	A/T	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.33	-6.27	-0.32	1.13e-9	Lipid metabolism phenotypes;
LUSC	cis	rs2050392	1.000	rs7077496	chr10:30692028	G/A	cg18806716	chr10:30721971	MAP3K8	0.45	7.46	0.38	7.6e-13	Inflammatory bowel disease;
LUSC	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-9.35	-0.46	1.34e-18	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11764359	chr7:65958608	NA	-0.69	-11.11	-0.52	1.25e-24	Aortic root size;
LUSC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg18350739	chr11:68623251	NA	-0.4	-7.14	-0.36	5.7e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg00757033	chr12:89920650	WDR51B	0.59	9.83	0.47	3.49e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg26395211	chr5:140044315	WDR55	-0.37	-5.68	-0.3	2.99e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.33	-0.45	1.47e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg25258033	chr6:167368657	RNASET2	-0.47	-7.95	-0.4	2.87e-14	Crohn's disease;
LUSC	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg17252645	chr8:143867129	LY6D	0.37	6.46	0.33	3.67e-10	Urinary tract infection frequency;
LUSC	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg20283391	chr11:68216788	NA	-0.61	-8.42	-0.42	1.15e-15	Total body bone mineral density;
LUSC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg06718696	chr17:78121285	EIF4A3	0.45	6.4	0.33	5.16e-10	Yeast infection;
LUSC	trans	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg26043149	chr18:55253948	FECH	0.49	7.24	0.37	3.02e-12	Bone mineral density;
LUSC	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.51	-0.42	5.83e-16	Systolic blood pressure;
LUSC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg07936489	chr17:37558343	FBXL20	-0.7	-9.59	-0.46	2.05e-19	Glomerular filtration rate (creatinine);
LUSC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.94	15.05	0.64	1.94e-39	Coronary artery disease;
LUSC	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg22601191	chr20:60968625	CABLES2	0.45	6.29	0.33	9.99e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg06623918	chr6:96969491	KIAA0776	0.79	9.68	0.47	1.1e-19	Migraine;Coronary artery disease;
LUSC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg02782426	chr3:40428986	ENTPD3	0.42	7.78	0.39	8.91e-14	Renal cell carcinoma;
LUSC	cis	rs12618769	0.597	rs4851136	chr2:99060873	A/T	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.14e-13	Bipolar disorder;
LUSC	cis	rs7178572	0.568	rs1191196	chr15:77646504	C/T	cg22256960	chr15:77711686	NA	0.49	7.8	0.39	8.08e-14	Type 2 diabetes;
LUSC	cis	rs936229	0.861	rs3935077	chr15:75120211	C/G	cg14664628	chr15:75095509	CSK	-1.0	-16.58	-0.67	1.86e-45	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs2562456	0.833	rs1932087	chr19:21521427	G/A	cg00806126	chr19:22604979	ZNF98	-0.43	-6.0	-0.31	5.12e-9	Pain;
LUSC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg03188948	chr7:1209495	NA	0.71	7.58	0.38	3.37e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg23711669	chr6:146136114	FBXO30	-0.83	-15.16	-0.64	7.12e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4474465	0.688	rs7942527	chr11:78280322	A/G	cg27205649	chr11:78285834	NARS2	0.59	7.39	0.37	1.23e-12	Alzheimer's disease (survival time);
LUSC	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg03585969	chr10:35415529	CREM	0.62	8.97	0.44	2.2e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1865721	0.771	rs6566093	chr18:73136682	T/C	cg26385618	chr18:73139727	C18orf62	-0.55	-10.1	-0.48	4.25e-21	Intelligence;
LUSC	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.54	-10.77	-0.51	2.03e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs9462027	0.628	rs2815004	chr6:34636268	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.08	-0.32	3.24e-9	Systemic lupus erythematosus;
LUSC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.01	-0.52	2.85e-24	Bipolar disorder;
LUSC	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg10018233	chr7:150070692	REPIN1	0.35	6.24	0.32	1.31e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.55	-8.01	-0.4	1.96e-14	Iron status biomarkers;
LUSC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg03146154	chr1:46216737	IPP	-0.56	-8.41	-0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs483180	0.512	rs1163251	chr1:120209755	T/C	cg19096424	chr1:120255104	PHGDH	-0.47	-6.54	-0.34	2.35e-10	Macular telangiectasia type 2;
LUSC	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg05855489	chr10:104503620	C10orf26	0.46	6.42	0.33	4.78e-10	Arsenic metabolism;
LUSC	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg17691542	chr6:26056736	HIST1H1C	0.39	5.8	0.3	1.57e-8	Schizophrenia;
LUSC	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.36e-8	Visceral adipose tissue adjusted for BMI;
LUSC	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.3	-0.33	9.39e-10	Daytime sleep phenotypes;
LUSC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg27633287	chr12:130766243	NA	-0.32	-6.18	-0.32	1.9e-9	Menopause (age at onset);
LUSC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg18850127	chr7:39170497	POU6F2	0.62	9.41	0.46	8.52e-19	IgG glycosylation;
LUSC	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg21798802	chr22:38057573	PDXP	0.48	10.44	0.5	2.77e-22	Fat distribution (HIV);
LUSC	trans	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.84	0.44	5.54e-17	Diabetic kidney disease;
LUSC	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg15704280	chr7:45808275	SEPT13	-0.64	-7.12	-0.36	6.59e-12	Axial length;
LUSC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.47	7.89	0.4	4.5e-14	Lymphocyte counts;
LUSC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.08	15.15	0.64	7.97e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg12337884	chr13:114819908	RASA3	0.49	6.8	0.35	4.74e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg09877947	chr5:131593287	PDLIM4	0.42	6.98	0.36	1.57e-11	Blood metabolite levels;
LUSC	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.42	0.64	7.02e-41	Morning vs. evening chronotype;
LUSC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.44	6.24	0.32	1.33e-9	Osteoporosis;
LUSC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg13647721	chr17:30228624	UTP6	0.62	6.07	0.32	3.43e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg15654264	chr1:150340011	RPRD2	0.61	10.09	0.48	4.38e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg22823121	chr1:150693482	HORMAD1	0.49	7.05	0.36	1.04e-11	Melanoma;
LUSC	cis	rs12928939	0.815	rs12448022	chr16:71724369	T/C	cg03805757	chr16:71968109	PKD1L3	-0.4	-5.93	-0.31	7.44e-9	Post bronchodilator FEV1;
LUSC	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg12863693	chr15:85201151	NMB	0.36	7.07	0.36	9.13e-12	Schizophrenia;
LUSC	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg17652424	chr22:38574118	PLA2G6	-0.3	-6.43	-0.33	4.3e-10	Cutaneous nevi;
LUSC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg01579765	chr21:45077557	HSF2BP	-0.51	-10.77	-0.51	2.11e-23	Mean corpuscular volume;
LUSC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg19230755	chr7:65878503	NA	0.41	5.75	0.3	2e-8	Aortic root size;
LUSC	cis	rs9341808	0.718	rs4437429	chr6:80828592	A/G	cg08355045	chr6:80787529	NA	0.56	9.85	0.47	2.85e-20	Sitting height ratio;
LUSC	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg12935359	chr14:103987150	CKB	0.66	10.73	0.51	2.73e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs68092024	0.731	rs792840	chr3:99471251	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.34	-6.15	-0.32	2.25e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg03804128	chr16:635623	NA	0.33	6.53	0.34	2.4e-10	Height;
LUSC	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.26	-0.41	3.4e-15	Response to antipsychotic treatment;
LUSC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg13699009	chr12:122356056	WDR66	0.5	7.72	0.39	1.35e-13	Mean corpuscular volume;
LUSC	cis	rs7577696	0.597	rs7556942	chr2:32295694	G/A	cg02381751	chr2:32503542	YIPF4	-0.51	-6.88	-0.35	2.89e-11	Inflammatory biomarkers;
LUSC	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg24558204	chr6:135376177	HBS1L	0.59	9.22	0.45	3.33e-18	Red blood cell count;
LUSC	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.42	0.53	9.82e-26	Eye color traits;
LUSC	cis	rs7712401	0.601	rs30055	chr5:122301079	T/G	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs7084921	0.608	rs12773948	chr10:101865115	T/A	cg02250046	chr10:101825185	CPN1	-0.34	-6.24	-0.32	1.32e-9	Bone mineral density;
LUSC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg02423579	chr7:2872169	GNA12	-0.44	-6.19	-0.32	1.8e-9	Height;
LUSC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg06618935	chr21:46677482	NA	-0.29	-5.8	-0.3	1.5e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg05340658	chr4:99064831	C4orf37	0.57	9.41	0.46	8.36e-19	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25291907	chr18:19321706	MIB1	0.77	6.96	0.36	1.78e-11	Cognitive performance;
LUSC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg07424592	chr7:64974309	NA	0.66	5.8	0.3	1.55e-8	Diabetic kidney disease;
LUSC	trans	rs1973993	0.967	rs10489741	chr1:96942406	G/A	cg10631902	chr5:14652156	NA	0.56	9.76	0.47	5.7e-20	Weight;
LUSC	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg18209359	chr17:80159595	CCDC57	0.39	6.5	0.33	2.99e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs73198271	0.694	rs114184516	chr8:8647082	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.32	-0.33	8.29e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	ch.16.48423040F	chr16:49865539	NA	0.4	5.99	0.31	5.45e-9	N-glycan levels;
LUSC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg15839431	chr19:19639596	YJEFN3	-0.43	-5.89	-0.31	9.64e-9	Tonsillectomy;
LUSC	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg13298116	chr11:62369859	EML3;MTA2	-0.51	-7.9	-0.4	4e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3764021	0.870	rs2401391	chr12:9878583	T/C	cg20894963	chr12:9885564	CLECL1	0.34	6.95	0.36	1.98e-11	Type 1 diabetes;
LUSC	cis	rs4776059	0.798	rs1080731	chr15:52920658	C/T	cg24008177	chr15:52972085	KIAA1370	0.33	6.33	0.33	7.78e-10	Schizophrenia;
LUSC	cis	rs6025261	0.761	rs6092390	chr20:55510339	C/T	cg04763273	chr20:55502381	NA	0.33	5.87	0.31	1.05e-8	Verbal memory performance (delayed recall level);
LUSC	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg07169764	chr2:136633963	MCM6	1.16	17.83	0.7	1.99e-50	Corneal structure;
LUSC	cis	rs1983891	1.000	rs4714485	chr6:41536587	T/G	cg20194872	chr6:41519635	FOXP4	0.37	6.61	0.34	1.48e-10	Prostate cancer;
LUSC	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.51	-0.38	5.55e-13	Systemic lupus erythematosus;
LUSC	cis	rs73058052	0.935	rs3745474	chr19:50086806	C/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.5	5.78	0.3	1.72e-8	Fibrinogen levels;
LUSC	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg13256891	chr4:100009986	ADH5	0.5	7.34	0.37	1.62e-12	Alcohol dependence;
LUSC	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg03676636	chr4:99064102	C4orf37	0.29	6.16	0.32	2.07e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg24692254	chr21:30365293	RNF160	0.69	10.78	0.51	1.87e-23	Pancreatic cancer;
LUSC	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg18102446	chr2:218934044	RUFY4	-0.36	-5.75	-0.3	2e-8	Ulcerative colitis;
LUSC	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18252515	chr7:66147081	NA	-0.57	-7.83	-0.39	6.42e-14	Corneal structure;
LUSC	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg21479132	chr6:26055353	NA	0.63	5.84	0.3	1.23e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12472274	0.648	rs67102443	chr2:239084602	A/G	cg17459225	chr2:239074497	NA	0.52	8.66	0.43	2.06e-16	Phospholipid levels (plasma);
LUSC	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg25214090	chr10:38739885	LOC399744	0.54	8.05	0.4	1.44e-14	Corneal astigmatism;
LUSC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg18225595	chr11:63971243	STIP1	0.63	10.62	0.5	6.96e-23	Platelet count;
LUSC	cis	rs10740039	0.516	rs9731224	chr10:62343148	G/A	cg18175470	chr10:62150864	ANK3	-0.47	-6.98	-0.36	1.62e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	0.91	16.06	0.66	2.01e-43	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.78	0.3	1.7e-8	Rheumatoid arthritis;
LUSC	cis	rs9807989	0.839	rs4988958	chr2:102968285	T/C	cg09003973	chr2:102972529	NA	0.44	6.01	0.31	4.83e-9	Asthma;
LUSC	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg05738196	chr6:26577821	NA	-0.5	-6.03	-0.31	4.33e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg02475777	chr4:1388615	CRIPAK	-0.42	-6.17	-0.32	1.98e-9	Obesity-related traits;
LUSC	cis	rs7705502	1.000	rs72812817	chr5:173356748	A/G	cg18693985	chr5:173351052	CPEB4	-0.38	-6.02	-0.31	4.66e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	6.2	0.32	1.71e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs939658	1.000	rs8031019	chr15:79458512	C/T	cg17916960	chr15:79447300	NA	-0.49	-9.82	-0.47	3.67e-20	Refractive error;
LUSC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg17948913	chr5:572064	NA	0.38	6.27	0.32	1.09e-9	Obesity-related traits;
LUSC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.37	0.37	1.34e-12	Prudent dietary pattern;
LUSC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.69	11.46	0.53	7.01e-26	Heart rate;
LUSC	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-0.76	-10.76	-0.51	2.21e-23	Platelet distribution width;
LUSC	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.07	-0.44	1.05e-17	Monocyte percentage of white cells;
LUSC	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg00321850	chr1:175162397	KIAA0040	-0.44	-7.48	-0.38	6.64e-13	Alcohol dependence;
LUSC	cis	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.55	-0.38	4.09e-13	Morning vs. evening chronotype;
LUSC	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05901451	chr6:126070800	HEY2	0.77	12.5	0.56	1.13e-29	Endometrial cancer;
LUSC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18876405	chr7:65276391	NA	-0.56	-8.81	-0.43	7.03e-17	Aortic root size;
LUSC	cis	rs7598759	0.712	rs10933372	chr2:232332325	G/A	cg19187155	chr2:232395269	NMUR1	0.49	7.2	0.37	3.96e-12	Noise-induced hearing loss;
LUSC	cis	rs3740713	0.669	rs113003553	chr11:18410861	T/C	cg07915343	chr11:18477680	LDHAL6A	-0.46	-5.84	-0.3	1.26e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs57046232	0.552	rs6133306	chr20:6333294	T/G	cg17788362	chr6:86352627	SYNCRIP	0.42	5.96	0.31	6.34e-9	Colorectal cancer;
LUSC	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg05084668	chr3:125655381	ALG1L	-0.79	-11.95	-0.55	1.26e-27	Blood pressure (smoking interaction);
LUSC	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg04450456	chr4:17643702	FAM184B	0.37	6.39	0.33	5.7e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17001868	0.568	rs74424549	chr22:40736938	A/C	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.91	-0.51	6.58e-24	Schizophrenia;
LUSC	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg06547715	chr2:218990976	CXCR2	0.33	6.49	0.33	3.04e-10	Ulcerative colitis;
LUSC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.88	0.48	2.3e-20	Bipolar disorder;
LUSC	trans	rs1792738	0.592	rs1792736	chr18:53849110	A/G	cg08471173	chr2:171012543	NA	0.36	6.0	0.31	5.22e-9	Systolic blood pressure (cigarette smoking interaction);
LUSC	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg13813247	chr22:41461852	NA	-0.37	-6.75	-0.35	6.38e-11	Neuroticism;
LUSC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg26769984	chr7:1090371	C7orf50	0.58	8.06	0.4	1.34e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-7.04	-0.36	1.09e-11	Fear of minor pain;
LUSC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg18351406	chr4:77819688	ANKRD56	0.58	8.31	0.41	2.44e-15	Emphysema distribution in smoking;
LUSC	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.21	-0.49	1.83e-21	Eye color traits;
LUSC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg07507251	chr3:52567010	NT5DC2	0.34	6.54	0.34	2.27e-10	Bipolar disorder;
LUSC	cis	rs4776059	1.000	rs11853917	chr15:52922054	T/C	cg25063058	chr15:52860530	ARPP19	0.42	5.93	0.31	7.42e-9	Schizophrenia;
LUSC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-8.95	-0.44	2.6e-17	Bipolar disorder and schizophrenia;
LUSC	trans	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.06	0.31	3.73e-9	Corneal astigmatism;
LUSC	cis	rs939574	0.722	rs72955435	chr2:220087354	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.9	6.19	0.32	1.72e-9	Platelet distribution width;
LUSC	trans	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg18187862	chr3:45730750	SACM1L	-0.52	-6.39	-0.33	5.68e-10	Primary sclerosing cholangitis;
LUSC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg19196401	chr6:110721138	DDO	-0.46	-8.62	-0.43	2.69e-16	Platelet distribution width;
LUSC	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg13010199	chr12:38710504	ALG10B	-0.49	-7.44	-0.38	8.53e-13	Morning vs. evening chronotype;
LUSC	cis	rs3931020	0.657	rs277368	chr1:75230606	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	-0.46	-5.79	-0.3	1.62e-8	Resistin levels;
LUSC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg18681998	chr4:17616180	MED28	0.85	15.95	0.66	5.78e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.01	-0.4	1.89e-14	Glomerular filtration rate;
LUSC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs67696533	0.600	rs1868385	chr20:31111293	C/T	cg13636640	chr20:31349939	DNMT3B	0.48	6.54	0.34	2.38e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg12863693	chr15:85201151	NMB	0.39	8.07	0.4	1.29e-14	Schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg15057251	chr18:32621312	MAPRE2	0.47	6.46	0.33	3.62e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.89	0.31	9.48e-9	Rheumatoid arthritis;
LUSC	trans	rs7951105	0.737	rs12279184	chr11:39251206	T/C	cg24085930	chr3:21832523	NA	0.49	6.05	0.31	3.94e-9	Free thyroxine concentration;
LUSC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg26380479	chr7:97908229	NA	-0.26	-5.88	-0.31	1.02e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs30380	0.666	rs26512	chr5:96128400	G/T	cg16492584	chr5:96139282	ERAP1	-0.53	-7.23	-0.37	3.22e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2688608	0.905	rs2633300	chr10:75656647	A/C	cg17411546	chr10:75410026	SYNPO2L	-0.46	-6.84	-0.35	3.77e-11	Inflammatory bowel disease;
LUSC	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.12	24.2	0.8	1.88e-75	Schizophrenia;
LUSC	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.07	-22.54	-0.78	4.9e-69	Ulcerative colitis;
LUSC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg21770322	chr7:97807741	LMTK2	0.4	6.91	0.35	2.41e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.61	9.97	0.48	1.16e-20	Brugada syndrome;
LUSC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg13393036	chr8:95962371	TP53INP1	-0.47	-10.34	-0.49	6.17e-22	Type 2 diabetes;
LUSC	cis	rs758324	0.648	rs31474	chr5:131405027	A/G	cg14196790	chr5:131705035	SLC22A5	-0.43	-6.31	-0.33	8.91e-10	Alzheimer's disease in APOE e4- carriers;
LUSC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg11062466	chr8:58055876	NA	0.51	6.48	0.33	3.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg10645314	chr2:3704589	ALLC	-0.35	-6.13	-0.32	2.43e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs74181299	0.964	rs1009358	chr2:65276452	C/T	cg05010058	chr2:65284262	CEP68	-0.31	-6.26	-0.32	1.16e-9	Pulse pressure;
LUSC	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-6.0	-0.31	5.2e-9	Parkinson's disease;
LUSC	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg24375607	chr4:120327624	NA	0.75	11.23	0.52	4.96e-25	Corneal astigmatism;
LUSC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg11843238	chr5:131593191	PDLIM4	0.39	6.53	0.34	2.44e-10	Blood metabolite levels;
LUSC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	8.84	0.44	5.69e-17	Menarche (age at onset);
LUSC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.14e-30	Aortic root size;
LUSC	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.19	16.05	0.66	2.2e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg21775007	chr8:11205619	TDH	-0.69	-10.87	-0.51	8.91e-24	Retinal vascular caliber;
LUSC	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg06627628	chr2:24431161	ITSN2	-0.61	-7.4	-0.38	1.09e-12	Lymphocyte counts;
LUSC	trans	rs6561151	0.681	rs7995955	chr13:44434836	C/G	cg12856521	chr11:46389249	DGKZ	0.75	9.56	0.46	2.63e-19	Crohn's disease;
LUSC	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg13010199	chr12:38710504	ALG10B	0.42	6.14	0.32	2.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs4919687	0.550	rs7907503	chr10:104440050	C/T	cg05855489	chr10:104503620	C10orf26	0.7	11.31	0.53	2.52e-25	Colorectal cancer;
LUSC	cis	rs11229555	0.645	rs12800531	chr11:58180099	C/T	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg18477163	chr1:228402036	OBSCN	-0.56	-10.36	-0.49	5.41e-22	Diastolic blood pressure;
LUSC	cis	rs12220238	1.000	rs10824085	chr10:75911984	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.31	0.37	2.04e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg14895029	chr7:2775587	GNA12	-0.38	-5.82	-0.3	1.4e-8	Height;
LUSC	cis	rs909002	0.800	rs7549590	chr1:32109849	G/A	cg01639898	chr1:32083012	HCRTR1	0.32	7.68	0.39	1.8e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.51	10.22	0.49	1.58e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs11088226	0.801	rs2833886	chr21:33923872	C/A	cg09050820	chr6:167586206	TCP10L2	0.65	9.88	0.48	2.28e-20	Gastritis;
LUSC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.13	0.55	2.73e-28	Colorectal cancer;
LUSC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-12.36	-0.56	3.62e-29	Platelet count;
LUSC	cis	rs7945718	0.775	rs10500759	chr11:12822588	A/G	cg25843174	chr11:12811716	TEAD1	-0.31	-7.18	-0.37	4.44e-12	Educational attainment (years of education);
LUSC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg12311346	chr5:56204834	C5orf35	-0.63	-9.17	-0.45	5.01e-18	Coronary artery disease;
LUSC	cis	rs11209002	0.695	rs10889653	chr1:67560897	A/G	cg02640540	chr1:67518911	SLC35D1	0.66	6.61	0.34	1.5e-10	Crohn's disease;
LUSC	cis	rs2637266	1.000	rs12251434	chr10:78345468	C/A	cg18941641	chr10:78392320	NA	0.38	7.07	0.36	8.85e-12	Pulmonary function;
LUSC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.66	0.39	2.02e-13	Height;
LUSC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg17515076	chr17:73810948	UNK	-0.37	-6.22	-0.32	1.52e-9	White matter hyperintensity burden;
LUSC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18357526	chr6:26021779	HIST1H4A	0.4	6.3	0.33	9.2e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6714710	0.603	rs17489984	chr2:98421364	A/G	cg26665480	chr2:98280029	ACTR1B	0.61	8.91	0.44	3.25e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs6840360	1.000	rs6834095	chr4:152603278	C/T	cg22705602	chr4:152727874	NA	-0.28	-5.91	-0.31	8.54e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs62027291	1.000	rs112503392	chr15:77275646	C/T	cg26408565	chr15:76604113	ETFA	0.54	6.4	0.33	5.37e-10	Plateletcrit;
LUSC	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg20701182	chr2:24300061	SF3B14	0.89	11.69	0.54	1.08e-26	Lymphocyte counts;
LUSC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg08508325	chr11:3079039	CARS	-0.48	-11.12	-0.52	1.16e-24	Type 2 diabetes;
LUSC	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg22153463	chr1:85462885	MCOLN2	0.64	6.08	0.32	3.37e-9	Serum sulfate level;
LUSC	trans	rs9784649	1.000	rs3933895	chr5:25004929	A/T	cg08600765	chr20:34638493	LOC647979	-0.55	-6.45	-0.33	4.01e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg16329650	chr2:213403929	ERBB4	0.86	18.45	0.71	6.91e-53	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg21361702	chr7:150065534	REPIN1	0.49	6.4	0.33	5.3e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.04	21.51	0.76	5.11e-65	Height;
LUSC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg04362960	chr10:104952993	NT5C2	-0.61	-9.57	-0.46	2.45e-19	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg03733263	chr8:22462867	KIAA1967	0.89	15.6	0.65	1.36e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.22	-0.37	3.57e-12	Major depressive disorder;
LUSC	trans	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg25214090	chr10:38739885	LOC399744	0.43	6.41	0.33	5.04e-10	Corneal astigmatism;
LUSC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.77	0.35	5.97e-11	Tonsillectomy;
LUSC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.16	0.52	8.67e-25	Menopause (age at onset);
LUSC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg12658694	chr1:38397304	INPP5B	-0.49	-6.53	-0.34	2.52e-10	Coronary artery disease;
LUSC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg04414720	chr1:150670196	GOLPH3L	0.51	8.0	0.4	2.08e-14	Melanoma;
LUSC	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.69	-0.3	2.79e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11645453	chr3:52864694	ITIH4	0.4	8.71	0.43	1.4e-16	Bipolar disorder;
LUSC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.74	-0.35	6.81e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24110177	chr3:50126178	RBM5	-0.55	-9.05	-0.44	1.22e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg22638593	chr5:131593259	PDLIM4	0.44	6.28	0.33	1.05e-9	Acylcarnitine levels;
LUSC	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg17749961	chr2:30669863	LCLAT1	0.62	7.33	0.37	1.76e-12	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg14416269	chr4:6271139	WFS1	0.54	11.4	0.53	1.2e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2540226	1.000	rs2540226	chr2:39959060	G/T	cg23576258	chr2:39999331	THUMPD2	-0.34	-5.81	-0.3	1.45e-8	Personality dimensions;
LUSC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg11764359	chr7:65958608	NA	-0.78	-12.81	-0.57	7.69e-31	Aortic root size;
LUSC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.66	0.34	1.15e-10	Menopause (age at onset);
LUSC	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	7.23	0.37	3.22e-12	Resting heart rate;
LUSC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg06618935	chr21:46677482	NA	-0.39	-7.97	-0.4	2.48e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.78e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs7621025	0.500	rs1965107	chr3:136648643	T/A	cg15507776	chr3:136538369	TMEM22	0.61	8.42	0.42	1.13e-15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUSC	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	0.7	7.02	0.36	1.26e-11	Prostate cancer;
LUSC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg23791538	chr6:167370224	RNASET2	-0.41	-6.77	-0.35	5.65e-11	Crohn's disease;
LUSC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg14440974	chr22:39074834	NA	-0.38	-6.2	-0.32	1.69e-9	Menopause (age at onset);
LUSC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg11941060	chr3:133502564	NA	-0.52	-8.0	-0.4	2.11e-14	Iron status biomarkers;
LUSC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.46	-7.51	-0.38	5.42e-13	Breast cancer;
LUSC	cis	rs977987	0.806	rs12924920	chr16:75440133	G/A	cg04384234	chr16:75411784	CFDP1	-0.41	-6.58	-0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25951256	chr10:38645740	HSD17B7P2	-0.41	-5.97	-0.31	6.17e-9	Breast cancer;
LUSC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-14.08	-0.61	1.14e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs909002	0.830	rs10914461	chr1:32113217	G/A	cg01639898	chr1:32083012	HCRTR1	0.3	7.38	0.37	1.3e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2172802	0.659	rs2343251	chr4:62492671	C/A	cg04118610	chr4:62707027	LPHN3	0.45	6.1	0.32	2.97e-9	Partial epilepsies;
LUSC	cis	rs8050755	0.649	rs2516737	chr16:2101749	A/G	cg04515572	chr16:2107413	TSC2	0.69	6.94	0.35	2.09e-11	Major depressive disorder;
LUSC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.28	0.45	2.14e-18	Motion sickness;
LUSC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg14668632	chr7:2872130	GNA12	-0.49	-7.24	-0.37	3.17e-12	Height;
LUSC	cis	rs7605827	0.930	rs1024870	chr2:15625846	T/C	cg19274914	chr2:15703543	NA	0.46	8.82	0.43	6.51e-17	Educational attainment (years of education);
LUSC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg04369109	chr6:150039330	LATS1	-0.58	-8.44	-0.42	9.96e-16	Lung cancer;
LUSC	cis	rs9921338	0.961	rs56136462	chr16:11415595	A/G	cg00044050	chr16:11439710	C16orf75	-0.5	-6.73	-0.35	7.37e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	7.83	0.39	6.71e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-34.56	-0.88	2.43e-112	Myeloid white cell count;
LUSC	cis	rs231513	0.769	rs537169	chr17:41976740	G/A	cg26893861	chr17:41843967	DUSP3	-0.51	-6.06	-0.31	3.74e-9	Cognitive function;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04079722	chr16:30569728	ZNF764	-0.42	-6.08	-0.32	3.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14685339	chr14:77787351	POMT2;GSTZ1	0.48	6.66	0.34	1.13e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg03146154	chr1:46216737	IPP	0.5	7.44	0.38	8.46e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10203711	0.933	rs7584327	chr2:239584203	A/T	cg14580085	chr2:239553406	NA	0.39	6.47	0.33	3.56e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs76878669	0.538	rs2282530	chr11:66177952	C/T	cg18002602	chr11:66138449	SLC29A2	-0.49	-8.64	-0.43	2.38e-16	Educational attainment (years of education);
LUSC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg18240062	chr17:79603768	NPLOC4	0.71	12.97	0.58	1.96e-31	Eye color traits;
LUSC	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg02336364	chr1:24764700	NIPAL3	-0.33	-5.92	-0.31	8.05e-9	Response to interferon beta in multiple sclerosis;
LUSC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg13047869	chr3:10149882	C3orf24	0.55	7.84	0.39	6.12e-14	Alzheimer's disease;
LUSC	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg05855489	chr10:104503620	C10orf26	0.62	8.91	0.44	3.28e-17	Arsenic metabolism;
LUSC	trans	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg25214090	chr10:38739885	LOC399744	0.52	7.56	0.38	3.94e-13	Corneal astigmatism;
LUSC	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg11887960	chr12:57824829	NA	0.48	6.47	0.33	3.46e-10	Obesity-related traits;
LUSC	cis	rs9473147	0.516	rs9349416	chr6:47551938	G/A	cg20196966	chr6:47445060	CD2AP	0.41	5.75	0.3	2.07e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21016266	chr12:122356598	WDR66	0.62	9.42	0.46	7.85e-19	Mean corpuscular volume;
LUSC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-11.74	-0.54	7.34e-27	Monocyte count;
LUSC	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg21827317	chr3:136751795	NA	0.38	6.78	0.35	5.46e-11	Neuroticism;
LUSC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg12560992	chr17:57184187	TRIM37	-0.71	-12.61	-0.57	4.42e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg12179176	chr11:130786555	SNX19	0.77	13.32	0.59	8.95e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06387980	chr19:17416471	MRPL34	0.76	6.49	0.33	3.15e-10	Cognitive performance;
LUSC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs10266483	0.774	rs28580000	chr7:63801909	A/G	cg24201672	chr7:64023550	ZNF680	0.44	5.8	0.3	1.53e-8	Response to statin therapy;
LUSC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg16339924	chr4:17578868	LAP3	0.64	10.17	0.49	2.39e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg07549590	chr16:15018862	NA	-0.44	-7.26	-0.37	2.71e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs10022260	1	rs10022260	chr4:83793921	C/T	cg00595051	chr4:83955429	COPS4	-0.4	-6.79	-0.35	5.18e-11	Adult asthma;
LUSC	cis	rs911119	0.818	rs56077567	chr20:23591087	T/C	cg16589663	chr20:23618590	CST3	0.57	6.79	0.35	5.12e-11	Chronic kidney disease;
LUSC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs7939886	0.920	rs7113835	chr11:55947007	C/T	cg15704280	chr7:45808275	SEPT13	0.89	6.88	0.35	3e-11	Myopia (pathological);
LUSC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg00310523	chr12:86230176	RASSF9	0.52	9.83	0.47	3.52e-20	Major depressive disorder;
LUSC	cis	rs9650315	0.706	rs11985751	chr8:57137439	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	7.45	0.38	7.9e-13	Height;
LUSC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg21573476	chr21:45109991	RRP1B	-0.43	-6.89	-0.35	2.71e-11	Mean corpuscular volume;
LUSC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg25039879	chr17:56429692	SUPT4H1	0.72	9.79	0.47	4.62e-20	Cognitive test performance;
LUSC	cis	rs10497399	0.730	rs7558967	chr2:174111412	C/T	cg22854985	chr2:174082101	ZAK	-0.51	-5.96	-0.31	6.27e-9	Adiponectin levels;
LUSC	cis	rs4363385	0.747	rs1415971	chr1:152965779	T/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.66	-0.39	2.08e-13	Inflammatory skin disease;
LUSC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg27284194	chr4:1044797	NA	0.34	5.84	0.3	1.22e-8	Obesity-related traits;
LUSC	trans	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.94	-0.4	3.04e-14	Morning vs. evening chronotype;
LUSC	trans	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg17343622	chr17:76704594	CYTH1	-0.4	-6.26	-0.32	1.15e-9	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg05082376	chr22:42548792	NA	0.42	6.21	0.32	1.58e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.88	-17.2	-0.69	6.43e-48	Menarche (age at onset);
LUSC	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg21427119	chr20:30132790	HM13	-0.47	-6.9	-0.35	2.59e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg13256891	chr4:100009986	ADH5	0.48	7.11	0.36	7.05e-12	Alcohol dependence;
LUSC	trans	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.75e-10	Corneal astigmatism;
LUSC	cis	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg00049323	chr5:472564	LOC25845	0.39	5.98	0.31	5.61e-9	Cystic fibrosis severity;
LUSC	trans	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg19694781	chr19:47549865	TMEM160	-0.39	-6.2	-0.32	1.67e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.23	-0.37	3.28e-12	Morning vs. evening chronotype;
LUSC	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.38	-0.37	1.27e-12	Bipolar disorder;
LUSC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.72	-0.47	7.99e-20	Gut microbiome composition (summer);
LUSC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg13770153	chr20:60521292	NA	-0.43	-6.02	-0.31	4.63e-9	Body mass index;
LUSC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg02753203	chr1:228287806	NA	0.73	12.91	0.58	3.34e-31	Diastolic blood pressure;
LUSC	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg17173187	chr15:85201210	NMB	0.48	8.78	0.43	8.71e-17	Schizophrenia;
LUSC	trans	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg07663200	chr17:42030104	NA	-0.37	-6.17	-0.32	1.99e-9	Post bronchodilator FEV1;
LUSC	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-10.09	-0.48	4.66e-21	Migraine;Coronary artery disease;
LUSC	cis	rs9473147	0.516	rs10456570	chr6:47559451	A/G	cg12968598	chr6:47444699	CD2AP	0.52	7.93	0.4	3.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg05110241	chr16:68378359	PRMT7	-0.51	-6.14	-0.32	2.37e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg15423357	chr2:25149977	NA	0.43	8.63	0.43	2.53e-16	Body mass index;
LUSC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg13319975	chr6:146136371	FBXO30	-0.53	-8.05	-0.4	1.5e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23137483	chr22:41682341	RANGAP1	0.46	6.46	0.33	3.6e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg00579200	chr11:133705235	NA	-0.4	-5.98	-0.31	5.83e-9	Childhood ear infection;
LUSC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-12.88	-0.58	4.15e-31	Chronic sinus infection;
LUSC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	0.93	17.67	0.7	8.11e-50	Cognitive function;
LUSC	trans	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12516959	chr21:47718080	NA	0.35	5.67	0.3	3.1e-8	Testicular germ cell tumor;
LUSC	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.6	-0.38	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg27535305	chr1:53392650	SCP2	0.36	6.73	0.35	7.3e-11	Monocyte count;
LUSC	cis	rs2742417	0.967	rs2742441	chr3:45748429	G/A	cg09608765	chr3:45636137	LIMD1	-0.38	-7.51	-0.38	5.48e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg27588902	chr6:42928151	GNMT	-0.3	-6.55	-0.34	2.24e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg23241863	chr10:102295624	HIF1AN	0.48	5.74	0.3	2.18e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08859206	chr1:53392774	SCP2	-0.56	-9.64	-0.47	1.48e-19	Monocyte count;
LUSC	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg12483005	chr1:23474871	LUZP1	0.42	6.18	0.32	1.84e-9	Height;
LUSC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg21153622	chr11:89784906	NA	-0.46	-7.19	-0.37	4.37e-12	Coronary artery disease;
LUSC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg04518342	chr5:131593106	PDLIM4	-0.52	-9.42	-0.46	7.49e-19	Acylcarnitine levels;
LUSC	cis	rs12911832	1.000	rs4774310	chr15:58985164	T/G	cg05156742	chr15:59063176	FAM63B	0.47	6.63	0.34	1.36e-10	Schizophrenia;
LUSC	cis	rs1014246	0.848	rs11197799	chr10:118457650	C/T	cg14919929	chr10:118506882	NA	0.46	7.25	0.37	2.91e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs10754283	0.901	rs4520403	chr1:90112840	T/G	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11764359	chr7:65958608	NA	-0.79	-12.98	-0.58	1.74e-31	Aortic root size;
LUSC	cis	rs950881	0.932	rs72823621	chr2:102925435	C/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.29	0.33	1.02e-9	Allergy;
LUSC	trans	rs9929218	1.000	rs8056538	chr16:68802282	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.86	-0.54	2.63e-27	Colorectal cancer;
LUSC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4704187	0.663	rs1477935	chr5:74448494	C/T	cg03227963	chr5:74354835	NA	0.32	6.91	0.35	2.44e-11	Response to amphetamines;
LUSC	cis	rs2290159	1.000	rs2290159	chr3:12628920	G/C	cg23032965	chr3:12705835	RAF1	0.6	7.57	0.38	3.69e-13	Cholesterol, total;
LUSC	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg12560992	chr17:57184187	TRIM37	-0.71	-12.13	-0.55	2.62e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg27661571	chr11:113659931	NA	-0.57	-7.05	-0.36	1e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg27588902	chr6:42928151	GNMT	0.26	5.76	0.3	1.91e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs72772090	0.539	rs11739020	chr5:96113838	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.72	7.88	0.4	4.81e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg13615516	chr5:77269221	NA	0.39	6.49	0.33	3.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg13531842	chr10:38383804	ZNF37A	0.44	6.2	0.32	1.69e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg13647721	chr17:30228624	UTP6	0.6	6.24	0.32	1.31e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg16342193	chr10:102329863	NA	-0.34	-6.28	-0.32	1.08e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg13628971	chr7:2884303	GNA12	-0.41	-6.07	-0.32	3.47e-9	Height;
LUSC	cis	rs1950626	0.623	rs4402490	chr14:101445453	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.4	-7.49	-0.38	6.01e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg26618903	chr10:100175079	PYROXD2	-0.46	-8.68	-0.43	1.8e-16	Metabolite levels;
LUSC	cis	rs11702148	0.552	rs2154583	chr21:34888940	T/G	cg14850771	chr21:34775459	IFNGR2	0.4	5.88	0.31	9.95e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg17330251	chr7:94953956	PON1	-0.41	-6.74	-0.35	6.82e-11	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs12956009	0.559	rs1893787	chr18:44856030	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	6.24	0.32	1.35e-9	Educational attainment (years of education);
LUSC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg06008330	chr7:65541103	ASL	-0.39	-6.03	-0.31	4.35e-9	Aortic root size;
LUSC	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg03522245	chr20:25566470	NINL	0.35	5.78	0.3	1.68e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg01020399	chr1:249153122	ZNF692	0.42	6.06	0.31	3.77e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.29	-0.41	2.74e-15	Cystic fibrosis severity;
LUSC	cis	rs9427116	0.531	rs35504625	chr1:154599778	C/G	cg17218026	chr1:154582156	ADAR	0.59	10.45	0.5	2.66e-22	Blood protein levels;
LUSC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07677032	chr17:61819896	STRADA	0.54	8.94	0.44	2.69e-17	Prudent dietary pattern;
LUSC	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg27129171	chr3:47204927	SETD2	0.69	11.48	0.53	6.36e-26	Colorectal cancer;
LUSC	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.32e-11	Uric acid levels;
LUSC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.16	-0.36	5.04e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs983392	0.709	rs11230194	chr11:59980315	C/G	cg02771260	chr11:59836817	MS4A3	-0.36	-5.92	-0.31	8.12e-9	Alzheimer's disease (late onset);
LUSC	cis	rs13385	0.769	rs56997077	chr5:139558412	C/T	cg26211634	chr5:139558579	C5orf32	0.45	6.3	0.33	9.46e-10	Atrial fibrillation;
LUSC	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.69	-0.6	3.65e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg26579491	chr7:65878976	NA	0.4	5.68	0.3	2.91e-8	Aortic root size;
LUSC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg06064525	chr11:970664	AP2A2	-0.48	-10.56	-0.5	1.08e-22	Alzheimer's disease (late onset);
LUSC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs6967385	0.560	rs12539290	chr7:12344101	T/G	cg06484146	chr7:12443880	VWDE	0.45	6.81	0.35	4.46e-11	Response to taxane treatment (placlitaxel);
LUSC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg01283332	chr5:1856932	NA	-0.34	-6.35	-0.33	7.22e-10	Cardiovascular disease risk factors;
LUSC	cis	rs4654899	0.680	rs2305463	chr1:21180181	C/T	cg01072550	chr1:21505969	NA	0.48	7.2	0.37	3.92e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg18357645	chr12:58087776	OS9	-0.43	-5.96	-0.31	6.38e-9	Multiple sclerosis;
LUSC	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07080220	chr10:102295463	HIF1AN	0.66	9.05	0.44	1.25e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.26	0.37	2.66e-12	Morning vs. evening chronotype;
LUSC	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg02023728	chr11:77925099	USP35	0.46	6.7	0.34	8.82e-11	Testicular germ cell tumor;
LUSC	cis	rs7180079	1.000	rs8029682	chr15:64628534	C/T	cg08069370	chr15:64387884	SNX1	0.57	6.28	0.32	1.05e-9	Monocyte count;
LUSC	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs9784649	0.771	rs72755810	chr5:25039139	A/C	cg08600765	chr20:34638493	LOC647979	-0.56	-7.31	-0.37	1.98e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9875589	0.509	rs9867041	chr3:14014615	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	6.9	0.35	2.64e-11	Ovarian reserve;
LUSC	cis	rs57994353	0.578	rs10448340	chr9:139320069	A/C	cg14169450	chr9:139327907	INPP5E	0.37	6.07	0.32	3.43e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUSC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg22920501	chr2:26401640	FAM59B	-0.75	-10.64	-0.5	5.79e-23	Gut microbiome composition (summer);
LUSC	cis	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg08112188	chr17:47440006	ZNF652	1.39	11.35	0.53	1.76e-25	Prostate cancer;
LUSC	trans	rs4942242	0.512	rs9533551	chr13:44187120	G/C	cg19169023	chr15:41853346	TYRO3	-0.67	-10.13	-0.48	3.24e-21	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6429082	0.715	rs2131924	chr1:235580928	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.53	-7.4	-0.38	1.14e-12	Adiposity;
LUSC	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg22875332	chr1:76189707	ACADM	-0.42	-6.24	-0.32	1.35e-9	Daytime sleep phenotypes;
LUSC	cis	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg20368463	chr18:77673604	PQLC1	0.8	14.04	0.61	1.59e-35	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUSC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg13206674	chr6:150067644	NUP43	0.57	9.08	0.44	9.89e-18	Lung cancer;
LUSC	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg05110241	chr16:68378359	PRMT7	-0.85	-9.27	-0.45	2.36e-18	Schizophrenia;
LUSC	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.95	0.4	2.89e-14	Colorectal cancer;
LUSC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg26689682	chr12:9723402	NA	-0.42	-5.83	-0.3	1.29e-8	IgG glycosylation;
LUSC	cis	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg09307838	chr4:120376055	NA	-0.48	-7.29	-0.37	2.29e-12	Diastolic blood pressure;
LUSC	cis	rs7605827	0.930	rs2160693	chr2:15654669	A/T	cg19274914	chr2:15703543	NA	0.46	8.81	0.43	6.91e-17	Educational attainment (years of education);
LUSC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg08888203	chr3:10149979	C3orf24	0.68	9.35	0.46	1.27e-18	Alzheimer's disease;
LUSC	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg13813247	chr22:41461852	NA	-0.35	-6.39	-0.33	5.47e-10	Neuroticism;
LUSC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg05084668	chr3:125655381	ALG1L	-0.51	-7.13	-0.36	6.09e-12	Blood pressure (smoking interaction);
LUSC	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.68	11.73	0.54	7.63e-27	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs751728	1.000	rs2395449	chr6:33728755	T/A	cg25922239	chr6:33757077	LEMD2	0.52	7.65	0.39	2.11e-13	Crohn's disease;
LUSC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg10645314	chr2:3704589	ALLC	-0.73	-11.69	-0.54	1.05e-26	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg02493740	chr2:85810744	VAMP5	-0.49	-8.62	-0.43	2.68e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.95	-0.31	6.6e-9	Tonsillectomy;
LUSC	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.56	-0.42	4.25e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12190007	0.514	rs2984462	chr6:169843903	A/T	cg15038512	chr6:170123185	PHF10	-0.39	-6.38	-0.33	5.79e-10	Obesity-related traits;
LUSC	cis	rs4474465	0.920	rs7947824	chr11:78223731	C/G	cg27205649	chr11:78285834	NARS2	0.53	6.08	0.32	3.31e-9	Alzheimer's disease (survival time);
LUSC	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg13798780	chr7:105162888	PUS7	0.58	6.32	0.33	8.2e-10	Bipolar disorder (body mass index interaction);
LUSC	trans	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg13565492	chr6:43139072	SRF	-0.57	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs440932	1.000	rs440932	chr8:9026929	T/C	cg06636001	chr8:8085503	FLJ10661	0.42	5.96	0.31	6.38e-9	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.75	-0.73	4.73e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg03806693	chr22:41940476	POLR3H	-0.63	-9.21	-0.45	3.59e-18	Vitiligo;
LUSC	cis	rs8048589	0.604	rs12929519	chr16:12207439	A/G	cg02910054	chr16:12241554	SNX29	-0.47	-6.45	-0.33	3.89e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.84	14.45	0.62	4.06e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.5	-0.34	2.87e-10	Mood instability;
LUSC	trans	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg17675199	chr6:35436792	RPL10A	-0.42	-6.16	-0.32	2.14e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg25457927	chr22:38595422	NA	0.41	8.57	0.42	3.85e-16	Cutaneous nevi;
LUSC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg24562669	chr7:97807699	LMTK2	0.36	6.3	0.33	9.49e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11764359	chr7:65958608	NA	-0.68	-10.93	-0.51	5.47e-24	Aortic root size;
LUSC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg10857441	chr5:6722123	POLS	-0.42	-7.81	-0.39	7.23e-14	Menopause (age at onset);
LUSC	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	8.34	0.42	1.94e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg17469321	chr7:55412551	NA	0.64	10.19	0.49	2.02e-21	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg26897989	chr16:1907736	C16orf73	-0.42	-6.63	-0.34	1.37e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs11690935	0.531	rs62183800	chr2:172867273	C/T	cg13550731	chr2:172543902	DYNC1I2	0.53	7.96	0.4	2.7e-14	Schizophrenia;
LUSC	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.14	0.41	7.79e-15	Coffee consumption (cups per day);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg25953220	chr6:159240552	EZR	0.4	6.11	0.32	2.81e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	cis	rs2274273	0.744	rs8011808	chr14:55823344	A/T	cg04306507	chr14:55594613	LGALS3	0.56	13.05	0.58	9.37e-32	Protein biomarker;
LUSC	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg21775007	chr8:11205619	TDH	-0.49	-7.14	-0.36	5.77e-12	Neuroticism;
LUSC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	6.33	0.33	7.69e-10	Schizophrenia;
LUSC	trans	rs28647808	0.786	rs28590601	chr9:136256224	G/A	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.19	16.32	0.67	1.92e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg21775007	chr8:11205619	TDH	-0.46	-6.74	-0.35	6.85e-11	Neuroticism;
LUSC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08677398	chr8:58056175	NA	0.58	7.01	0.36	1.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg08680598	chr22:49984980	NA	-0.32	-6.07	-0.32	3.44e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.75	-11.08	-0.52	1.72e-24	Glomerular filtration rate;
LUSC	cis	rs1160297	0.634	rs10179810	chr2:53096145	T/A	cg07782112	chr2:53107842	NA	0.43	6.99	0.36	1.51e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.9	-0.35	2.69e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg02023728	chr11:77925099	USP35	0.46	6.83	0.35	4.05e-11	Testicular germ cell tumor;
LUSC	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg00990874	chr7:1149470	C7orf50	-0.51	-6.45	-0.33	3.98e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg09365446	chr1:150670422	GOLPH3L	-0.49	-7.67	-0.39	1.92e-13	Tonsillectomy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06911843	chr21:38639729	DSCR3	0.51	7.16	0.36	5.31e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg22834771	chr12:69754056	YEATS4	0.51	7.71	0.39	1.45e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs5167	0.566	rs35080293	chr19:45496624	T/G	cg13119609	chr19:45449297	APOC2	0.34	5.67	0.3	3.01e-8	Blood protein levels;
LUSC	cis	rs17125944	0.615	rs2357944	chr14:53305573	T/G	cg00686598	chr14:53173677	PSMC6	-0.66	-5.73	-0.3	2.23e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg17366294	chr4:99064904	C4orf37	0.52	8.32	0.41	2.26e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg00376283	chr12:123451042	ABCB9	0.71	10.93	0.51	5.64e-24	Neutrophil percentage of white cells;
LUSC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-0.81	-11.13	-0.52	1.06e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	7.95e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg26898376	chr11:64110657	CCDC88B	0.31	5.78	0.3	1.69e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	8.11	0.41	9.78e-15	Iron status biomarkers;
LUSC	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.71	-11.91	-0.55	1.71e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg02018176	chr4:1364513	KIAA1530	0.52	8.87	0.44	4.63e-17	Obesity-related traits;
LUSC	trans	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg10756647	chr7:56101905	PSPH	0.85	8.34	0.42	2.04e-15	Diabetic kidney disease;
LUSC	cis	rs3743266	0.613	rs10851681	chr15:60732138	C/T	cg21667061	chr15:60772094	NARG2	0.36	6.15	0.32	2.23e-9	Menarche (age at onset);
LUSC	cis	rs4834770	1.000	rs4834770	chr4:120241849	A/G	cg24375607	chr4:120327624	NA	0.4	5.75	0.3	1.97e-8	Blood protein levels;
LUSC	cis	rs73206853	0.764	rs73194012	chr12:111100627	T/C	cg12870014	chr12:110450643	ANKRD13A	0.7	7.55	0.38	4.26e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg02931644	chr1:25747376	RHCE	0.39	7.1	0.36	7.58e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs7177699	0.557	rs8035093	chr15:79120670	T/C	cg00540400	chr15:79124168	NA	0.45	7.94	0.4	3.17e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs73001065	0.591	rs56273306	chr19:19621004	T/C	cg03709012	chr19:19516395	GATAD2A	0.97	8.79	0.43	8.08e-17	LDL cholesterol;
LUSC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg17633681	chr16:88106987	BANP	0.5	9.24	0.45	2.89e-18	Menopause (age at onset);
LUSC	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg05855489	chr10:104503620	C10orf26	0.49	7.57	0.38	3.79e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg20935933	chr6:143382018	AIG1	0.5	7.32	0.37	1.92e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg00033643	chr7:134001901	SLC35B4	0.43	6.39	0.33	5.42e-10	Mean platelet volume;
LUSC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.33	0.45	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg13010199	chr12:38710504	ALG10B	0.66	9.93	0.48	1.57e-20	Bladder cancer;
LUSC	cis	rs1035144	0.506	rs7150858	chr14:81280425	T/C	cg06600135	chr14:81408086	NA	-0.53	-8.01	-0.4	1.99e-14	Male sexual orientation;
LUSC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07677032	chr17:61819896	STRADA	0.54	9.03	0.44	1.36e-17	Prudent dietary pattern;
LUSC	cis	rs400736	0.526	rs10864329	chr1:8164460	G/A	cg25007680	chr1:8021821	PARK7	-0.41	-6.15	-0.32	2.27e-9	Response to antidepressants and depression;
LUSC	trans	rs1997103	0.798	rs12154964	chr7:55414041	G/A	cg20935933	chr6:143382018	AIG1	0.5	7.33	0.37	1.73e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg23205692	chr1:25664452	TMEM50A	0.42	6.22	0.32	1.51e-9	Erythrocyte sedimentation rate;
LUSC	trans	rs17597773	0.638	rs7544735	chr1:220998913	A/G	cg25786136	chr2:222575520	NA	-0.39	-5.99	-0.31	5.28e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg03732007	chr1:2071316	PRKCZ	0.37	5.83	0.3	1.27e-8	Coronary artery disease;
LUSC	cis	rs6541297	0.645	rs4846918	chr1:230300586	A/G	cg20703242	chr1:230279135	GALNT2	-0.48	-5.81	-0.3	1.48e-8	Coronary artery disease;
LUSC	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg14343924	chr8:8086146	FLJ10661	0.42	6.04	0.31	4.04e-9	Acne (severe);
LUSC	cis	rs9494145	0.531	rs9399136	chr6:135402339	T/C	cg24558204	chr6:135376177	HBS1L	0.48	6.03	0.31	4.44e-9	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg03526776	chr6:41159608	TREML2	0.33	6.39	0.33	5.57e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.23	-0.41	4.35e-15	Coronary artery disease;
LUSC	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg21918786	chr6:109611834	NA	-0.36	-6.02	-0.31	4.66e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs4356932	1.000	rs4583787	chr4:76955069	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg23942311	chr14:51606299	NA	0.52	11.75	0.54	6.28e-27	Cancer;
LUSC	cis	rs9837602	0.938	rs1021341	chr3:99786289	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.55	0.34	2.17e-10	Breast cancer;
LUSC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.41	0.46	8.16e-19	Prudent dietary pattern;
LUSC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.63	0.47	1.59e-19	Bipolar disorder;
LUSC	cis	rs73206853	0.764	rs6606685	chr12:110881986	C/G	cg12870014	chr12:110450643	ANKRD13A	0.5	5.9	0.31	9.03e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	cis	rs4805834	0.668	rs17272183	chr19:33321213	A/G	cg00891608	chr19:33463040	C19orf40;CCDC123	-0.57	-5.64	-0.3	3.54e-8	Creatinine levels;
LUSC	cis	rs9648716	0.515	rs38719	chr7:140693894	G/T	cg23214464	chr7:140373596	ADCK2	0.75	6.21	0.32	1.54e-9	Type 2 diabetes;
LUSC	trans	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-12.52	-0.57	9.69e-30	Colorectal cancer;
LUSC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg25039879	chr17:56429692	SUPT4H1	0.72	9.78	0.47	5.07e-20	Cognitive test performance;
LUSC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg02782426	chr3:40428986	ENTPD3	0.41	7.69	0.39	1.65e-13	Renal cell carcinoma;
LUSC	cis	rs11608355	0.515	rs4766606	chr12:109934390	C/G	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg03806693	chr22:41940476	POLR3H	-1.02	-13.77	-0.6	1.74e-34	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.61	8.33	0.41	2.15e-15	Chronic sinus infection;
LUSC	cis	rs9815354	0.812	rs56983571	chr3:41994473	T/C	cg03022575	chr3:42003672	ULK4	0.85	8.86	0.44	4.72e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg09904177	chr6:26538194	HMGN4	0.69	11.91	0.55	1.76e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg18180107	chr4:99064573	C4orf37	0.41	5.7	0.3	2.62e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg04369109	chr6:150039330	LATS1	0.56	8.36	0.42	1.68e-15	Lung cancer;
LUSC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.79	-0.35	5.25e-11	Lung cancer;
LUSC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	0.94	19.11	0.72	1.61e-55	Cognitive function;
LUSC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg21770322	chr7:97807741	LMTK2	0.4	7.01	0.36	1.31e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.73	-0.39	1.31e-13	Glomerular filtration rate;
LUSC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg02269571	chr22:50332266	NA	-0.57	-8.73	-0.43	1.25e-16	Schizophrenia;
LUSC	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg05501817	chr11:14380813	RRAS2	0.45	7.06	0.36	9.92e-12	Vitamin D levels;
LUSC	cis	rs4356932	0.967	rs4859605	chr4:76965822	C/G	cg00809888	chr4:76862425	NAAA	0.34	5.68	0.3	2.94e-8	Blood protein levels;
LUSC	cis	rs12210905	0.800	rs12209651	chr6:26660925	A/C	cg11502198	chr6:26597334	ABT1	-0.74	-5.77	-0.3	1.8e-8	Hip circumference adjusted for BMI;
LUSC	trans	rs4650994	0.525	rs2493848	chr1:178547838	T/A	cg05059571	chr16:84539110	KIAA1609	0.48	9.2	0.45	4.08e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg24642439	chr20:33292090	TP53INP2	0.72	11.58	0.54	2.64e-26	Coronary artery disease;
LUSC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.55	-0.34	2.15e-10	Breast cancer;
LUSC	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg03806693	chr22:41940476	POLR3H	-0.49	-6.78	-0.35	5.59e-11	Neuroticism;
LUSC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg15145296	chr3:125709740	NA	-0.58	-6.56	-0.34	2.03e-10	Blood pressure (smoking interaction);
LUSC	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg23029597	chr12:123009494	RSRC2	-0.75	-9.32	-0.45	1.69e-18	Body mass index;
LUSC	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.52	-0.34	2.53e-10	Arsenic metabolism;
LUSC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-6.13	-0.32	2.44e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6580649	0.941	rs757556	chr12:48502493	C/T	cg24011408	chr12:48396354	COL2A1	-0.45	-6.1	-0.32	2.9e-9	Lung cancer;
LUSC	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg23283495	chr1:209979779	IRF6	0.44	7.16	0.36	5.23e-12	Monobrow;
LUSC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg25456477	chr12:86230367	RASSF9	0.44	7.87	0.4	4.98e-14	Major depressive disorder;
LUSC	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg08601574	chr20:25228251	PYGB	0.43	6.51	0.34	2.74e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs5770872	0.511	rs56168974	chr22:50831338	A/G	cg09860653	chr1:19970708	NBL1	-0.6	-8.43	-0.42	1.07e-15	Tonsillectomy;
LUSC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00149659	chr3:10157352	C3orf10	0.92	12.89	0.58	3.82e-31	Alzheimer's disease;
LUSC	trans	rs2301573	0.584	rs1136553	chr3:129366963	G/T	cg06813419	chr1:211502171	TRAF5	0.44	5.99	0.31	5.41e-9	Hip circumference;
LUSC	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.5	-0.42	6.29e-16	Response to antipsychotic treatment;
LUSC	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg13010199	chr12:38710504	ALG10B	0.52	7.71	0.39	1.46e-13	Morning vs. evening chronotype;
LUSC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg17330251	chr7:94953956	PON1	-0.39	-6.47	-0.33	3.59e-10	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg17279839	chr7:150038598	RARRES2	0.44	7.02	0.36	1.24e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	9.39	0.46	9.94e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg06784218	chr1:46089804	CCDC17	0.29	5.83	0.3	1.31e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.8	0.3	1.52e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10779751	0.690	rs743577	chr1:11119135	G/A	cg08854313	chr1:11322531	MTOR	0.8	11.81	0.54	3.86e-27	Body mass index;
LUSC	cis	rs2455601	0.638	rs2248245	chr11:8988350	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-6.35	-0.33	7.11e-10	Schizophrenia;
LUSC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.42	5.82	0.3	1.35e-8	Renal function-related traits (BUN);
LUSC	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.71	-0.39	1.42e-13	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25719439	chr16:89788035	C16orf7;ZNF276	-0.4	-6.14	-0.32	2.32e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9398803	0.830	rs1361109	chr6:126771143	C/T	cg19875578	chr6:126661172	C6orf173	0.41	5.93	0.31	7.72e-9	Male-pattern baldness;
LUSC	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg19336497	chr11:14380999	RRAS2	0.4	7.11	0.36	7.1e-12	Mitochondrial DNA levels;
LUSC	cis	rs2970818	0.831	rs2907494	chr12:4642184	G/A	cg11146114	chr12:4671731	NA	-0.59	-6.33	-0.33	7.79e-10	Phosphorus levels;
LUSC	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg14664628	chr15:75095509	CSK	-0.54	-7.96	-0.4	2.7e-14	Breast cancer;
LUSC	cis	rs1506636	1.000	rs656425	chr7:123424525	A/C	cg03229431	chr7:123269106	ASB15	0.65	10.68	0.5	4.29e-23	Plateletcrit;Platelet count;
LUSC	cis	rs11696845	0.712	rs6130685	chr20:43366730	T/G	cg25301532	chr20:43378953	KCNK15	0.35	6.18	0.32	1.89e-9	Obesity-related traits;
LUSC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.12	-0.32	2.63e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg01528321	chr10:82214614	TSPAN14	1.07	16.7	0.67	6.18e-46	Post bronchodilator FEV1;
LUSC	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.39	6.09	0.32	3.1e-9	Height;
LUSC	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg03929089	chr4:120376271	NA	0.71	6.74	0.35	7.11e-11	Axial length;
LUSC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg14019146	chr3:50243930	SLC38A3	0.35	7.88	0.4	4.57e-14	Body mass index;
LUSC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg26304593	chr6:42947056	PEX6	-0.49	-7.36	-0.37	1.46e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg09455208	chr3:40491958	NA	0.49	8.49	0.42	6.77e-16	Renal cell carcinoma;
LUSC	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg21028142	chr17:79581711	NPLOC4	0.32	7.53	0.38	4.81e-13	Eye color traits;
LUSC	cis	rs3087591	0.592	rs2342054	chr17:29724708	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	6.88	0.35	3.03e-11	Hip circumference;
LUSC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg09796270	chr17:17721594	SREBF1	0.43	7.65	0.39	2.17e-13	Total body bone mineral density;
LUSC	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.2	0.49	1.93e-21	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23331932	chr10:99894438	C10orf28	-0.47	-6.92	-0.35	2.25e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08109568	chr15:31115862	NA	-0.54	-7.79	-0.39	8.5e-14	Huntington's disease progression;
LUSC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg24209194	chr3:40518798	ZNF619	0.44	5.91	0.31	8.25e-9	Renal cell carcinoma;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03899609	chr16:29911630	SEZ6L2;ASPHD1	0.77	6.18	0.32	1.91e-9	Cognitive performance;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19794706	chr14:75643232	TMED10	-0.51	-6.18	-0.32	1.85e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.86	-0.31	1.14e-8	Retinal vascular caliber;
LUSC	cis	rs2742417	0.603	rs2742370	chr3:45782098	T/C	cg04837898	chr3:45731254	SACM1L	-0.46	-7.5	-0.38	5.97e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg08917208	chr2:24149416	ATAD2B	0.99	10.34	0.49	6.45e-22	Lymphocyte counts;
LUSC	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg20703242	chr1:230279135	GALNT2	0.55	8.47	0.42	7.77e-16	Coronary artery disease;
LUSC	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg05925327	chr15:68127851	NA	-0.38	-5.86	-0.31	1.09e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.93	-13.49	-0.59	2.03e-33	Initial pursuit acceleration;
LUSC	trans	rs4714291	0.925	rs847750	chr6:40074250	G/A	cg02267698	chr19:7991119	CTXN1	0.54	7.63	0.39	2.41e-13	Strep throat;
LUSC	cis	rs7075426	0.512	rs9633738	chr10:88183796	T/A	cg07322936	chr10:88137208	NA	-0.57	-7.82	-0.39	7.15e-14	Migraine without aura;
LUSC	cis	rs7202877	0.656	rs4888394	chr16:75413709	T/C	cg04384234	chr16:75411784	CFDP1	-0.65	-9.05	-0.44	1.18e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs6500395	0.962	rs9938126	chr16:48572121	A/T	cg04672837	chr16:48644449	N4BP1	0.45	6.52	0.34	2.66e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.66	-0.43	2.05e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	ch.11.42038R	chr11:967971	AP2A2	-0.51	-7.53	-0.38	4.83e-13	Alzheimer's disease (late onset);
LUSC	cis	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg20368463	chr18:77673604	PQLC1	-0.62	-6.64	-0.34	1.29e-10	Opioid sensitivity;
LUSC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg01973587	chr1:228161476	NA	-0.4	-7.24	-0.37	3.09e-12	Diastolic blood pressure;
LUSC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg09034736	chr1:150693464	HORMAD1	-0.4	-5.75	-0.3	2.05e-8	Tonsillectomy;
LUSC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg07424592	chr7:64974309	NA	0.66	5.83	0.3	1.32e-8	Diabetic kidney disease;
LUSC	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg01819759	chr13:79234251	RNF219	-0.55	-7.79	-0.39	8.43e-14	Large artery stroke;
LUSC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.7	12.35	0.56	4.07e-29	Dental caries;
LUSC	cis	rs10489202	1.000	rs34774552	chr1:168032245	G/A	cg24449463	chr1:168025552	DCAF6	-0.58	-7.24	-0.37	3.16e-12	Schizophrenia;
LUSC	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg27068330	chr11:65405492	SIPA1	-0.65	-9.42	-0.46	7.55e-19	Non-alcoholic fatty liver disease histology (lobular);
LUSC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg14829360	chr17:73884958	NA	-0.35	-5.75	-0.3	1.96e-8	White matter hyperintensity burden;
LUSC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg17366294	chr4:99064904	C4orf37	0.54	9.48	0.46	4.75e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.88	0.31	9.86e-9	Breast cancer;
LUSC	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	8.24	0.41	4e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06481639	chr22:41940642	POLR3H	-0.53	-6.04	-0.31	4.02e-9	Vitiligo;
LUSC	cis	rs4588572	0.643	rs13155648	chr5:77755343	A/G	cg11547950	chr5:77652471	NA	-0.55	-7.79	-0.39	8.27e-14	Triglycerides;
LUSC	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg25418670	chr11:30344373	C11orf46	-0.65	-9.28	-0.45	2.19e-18	Morning vs. evening chronotype;
LUSC	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6489882	0.867	rs4766675	chr12:113365453	A/T	cg20102336	chr12:113376681	OAS3	-0.46	-5.99	-0.31	5.45e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs76878669	0.538	rs2282530	chr11:66177952	C/T	cg24851651	chr11:66362959	CCS	0.4	6.14	0.32	2.31e-9	Educational attainment (years of education);
LUSC	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-7.71	-0.39	1.43e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg05855489	chr10:104503620	C10orf26	0.52	8.02	0.4	1.85e-14	Arsenic metabolism;
LUSC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.34	0.46	1.4e-18	Bipolar disorder;
LUSC	cis	rs1775715	0.870	rs11008702	chr10:32244818	T/G	cg04359828	chr10:32216031	ARHGAP12	0.38	6.34	0.33	7.58e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg03676636	chr4:99064102	C4orf37	0.34	7.23	0.37	3.24e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg25258033	chr6:167368657	RNASET2	-0.49	-8.15	-0.41	7.19e-15	Crohn's disease;
LUSC	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg15556689	chr8:8085844	FLJ10661	0.57	8.61	0.43	2.98e-16	Myopia (pathological);
LUSC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-7.1	-0.36	7.45e-12	Alzheimer's disease (late onset);
LUSC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg06096015	chr1:231504339	EGLN1	0.57	10.05	0.48	6.02e-21	Hemoglobin concentration;
LUSC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	ch.11.42038R	chr11:967971	AP2A2	0.55	8.46	0.42	8.36e-16	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg15839431	chr19:19639596	YJEFN3	0.61	6.42	0.33	4.71e-10	Bipolar disorder;
LUSC	cis	rs4809219	1	rs4809219	chr20:62303115	C/A	cg16989086	chr20:62203971	PRIC285	-0.53	-7.31	-0.37	1.95e-12	Atopic dermatitis;
LUSC	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg11019008	chr10:131425282	MGMT	0.43	6.58	0.34	1.85e-10	Response to temozolomide;
LUSC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02187348	chr16:89574699	SPG7	0.57	9.28	0.45	2.25e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs7614311	0.636	rs56165216	chr3:63916620	C/T	cg22134162	chr3:63841271	THOC7	-0.44	-5.71	-0.3	2.44e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-16.22	-0.66	4.64e-44	Cognitive function;
LUSC	cis	rs136211	0.599	rs9610497	chr22:36767359	C/T	cg10790723	chr22:36903033	FOXRED2	0.41	6.12	0.32	2.63e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg19468946	chr17:37922297	IKZF3	-0.39	-6.04	-0.31	4.16e-9	Eosinophil percentage of white cells;
LUSC	cis	rs6920965	0.509	rs654213	chr6:126149127	C/T	cg05901451	chr6:126070800	HEY2	0.4	5.72	0.3	2.41e-8	High light scatter reticulocyte count;
LUSC	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg05147244	chr20:61493195	TCFL5	0.93	6.86	0.35	3.27e-11	Obesity-related traits;
LUSC	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg02158880	chr13:53174818	NA	0.57	10.02	0.48	7.84e-21	Lewy body disease;
LUSC	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.57	-0.38	3.6e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg16325326	chr1:53192061	ZYG11B	0.86	15.3	0.64	2.12e-40	Monocyte count;
LUSC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg10729496	chr3:10149963	C3orf24	0.58	7.69	0.39	1.61e-13	Alzheimer's disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20180585	chr22:41777755	TEF	0.79	6.93	0.35	2.24e-11	Cognitive performance;
LUSC	cis	rs2235649	0.833	rs9929262	chr16:1851928	T/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-5.96	-0.31	6.47e-9	Blood metabolite levels;
LUSC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-10.42	-0.5	3.26e-22	Monocyte count;
LUSC	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg00982548	chr2:198649783	BOLL	-0.54	-6.58	-0.34	1.87e-10	Ulcerative colitis;
LUSC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg20368463	chr18:77673604	PQLC1	0.5	7.13	0.36	6.28e-12	Schizophrenia;
LUSC	cis	rs113835537	0.627	rs11227534	chr11:66336171	C/A	cg24851651	chr11:66362959	CCS	0.57	8.75	0.43	1.05e-16	Airway imaging phenotypes;
LUSC	cis	rs28595532	0.702	rs72670238	chr4:119322751	C/T	cg02775129	chr4:119771670	NA	-0.7	-5.82	-0.3	1.39e-8	Cannabis dependence symptom count;
LUSC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg11812906	chr14:75593930	NEK9	0.64	10.48	0.5	2.02e-22	Height;
LUSC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg27165867	chr14:105738592	BRF1	0.52	7.81	0.39	7.32e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9653442	0.500	rs72819191	chr2:100826572	A/G	cg22139774	chr2:100720529	AFF3	0.47	7.46	0.38	7.44e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg16339924	chr4:17578868	LAP3	0.57	8.82	0.43	6.49e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg04865166	chr7:105162814	PUS7	0.52	5.69	0.3	2.78e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.86	14.59	0.62	1.22e-37	Bladder cancer;
LUSC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg05347473	chr6:146136440	FBXO30	0.45	7.57	0.38	3.57e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12815613	1.000	rs55913575	chr12:121405288	G/A	cg02403541	chr12:121454288	C12orf43	-0.46	-5.87	-0.31	1.06e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4692589	0.606	rs11943813	chr4:170938243	T/C	cg19918862	chr4:170955249	NA	0.38	6.95	0.36	1.9e-11	Anxiety disorder;
LUSC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg02951883	chr7:2050386	MAD1L1	-0.45	-7.74	-0.39	1.18e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg00049323	chr5:472564	LOC25845	-0.41	-6.41	-0.33	4.84e-10	Cystic fibrosis severity;
LUSC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg27494647	chr7:150038898	RARRES2	0.44	6.82	0.35	4.28e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08109568	chr15:31115862	NA	-0.59	-8.15	-0.41	7.48e-15	Huntington's disease progression;
LUSC	cis	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg06521331	chr12:34319734	NA	-0.38	-6.37	-0.33	6.31e-10	Morning vs. evening chronotype;
LUSC	cis	rs7215564	0.908	rs2316062	chr17:78663558	C/T	cg23238734	chr17:78661607	RPTOR	0.47	6.1	0.32	2.98e-9	Myopia (pathological);
LUSC	cis	rs12220238	0.915	rs10824074	chr10:75876457	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	7.71	0.39	1.41e-13	Soluble interleukin-2 receptor subunit alpha;
LUSC	trans	rs1728785	0.681	rs4783647	chr16:68558048	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.55	-6.7	-0.34	8.94e-11	Ulcerative colitis;
LUSC	trans	rs13011075	0.919	rs2241947	chr2:68615395	C/T	cg23843053	chr4:110736631	GAR1	0.45	5.97	0.31	6.19e-9	Mean corpuscular volume;
LUSC	trans	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg01620082	chr3:125678407	NA	-0.79	-6.87	-0.35	3.14e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9649465	0.561	rs600081	chr7:123414591	A/T	cg03229431	chr7:123269106	ASB15	0.48	7.76	0.39	1.03e-13	Migraine;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18777999	chr3:115377360	GAP43	-0.42	-5.94	-0.31	7e-9	Hepatitis;
LUSC	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg05340658	chr4:99064831	C4orf37	-0.44	-6.95	-0.36	1.94e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-7.13	-0.36	6.26e-12	Alzheimer's disease (late onset);
LUSC	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg05973401	chr12:123451056	ABCB9	-0.54	-7.94	-0.4	3.04e-14	Platelet count;
LUSC	trans	rs9944715	0.954	rs7231430	chr18:43823472	C/T	cg01718231	chr17:29326311	RNF135	0.49	7.12	0.36	6.66e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg00310523	chr12:86230176	RASSF9	0.45	8.3	0.41	2.62e-15	Major depressive disorder;
LUSC	cis	rs11608355	1.000	rs10774690	chr12:109859682	G/A	cg19025524	chr12:109796872	NA	-0.39	-6.0	-0.31	5.26e-9	Neuroticism;
LUSC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.65	0.34	1.18e-10	Lung cancer;
LUSC	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg17127132	chr2:85788382	GGCX	0.45	6.96	0.36	1.82e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg12463550	chr7:65579703	CRCP	0.51	7.52	0.38	5.19e-13	Aortic root size;
LUSC	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg24578937	chr1:2090814	PRKCZ	0.58	12.99	0.58	1.62e-31	Height;
LUSC	cis	rs7095944	0.614	rs7898003	chr10:126451385	G/A	cg08799069	chr10:126477246	METTL10	-0.42	-6.56	-0.34	2.04e-10	Asthma;
LUSC	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg11161011	chr14:65562177	MAX	-0.71	-10.78	-0.51	1.95e-23	Obesity-related traits;
LUSC	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg14154082	chr13:112174009	NA	0.38	7.96	0.4	2.63e-14	Menarche (age at onset);
LUSC	cis	rs7577696	0.785	rs2886393	chr2:32371562	G/C	cg02381751	chr2:32503542	YIPF4	-0.44	-6.2	-0.32	1.63e-9	Inflammatory biomarkers;
LUSC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.25	0.41	3.79e-15	Melanoma;
LUSC	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg14416269	chr4:6271139	WFS1	0.45	8.36	0.42	1.78e-15	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.97	-16.7	-0.67	5.98e-46	Body mass index;
LUSC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg10207240	chr12:122356781	WDR66	0.48	6.8	0.35	4.92e-11	Mean corpuscular volume;
LUSC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.71	11.57	0.54	2.81e-26	Coronary artery disease;
LUSC	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg24375607	chr4:120327624	NA	0.75	11.05	0.52	2.18e-24	Corneal astigmatism;
LUSC	trans	rs62238980	0.614	rs116862462	chr22:32470463	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.49	0.59	2.02e-33	Cognitive test performance;
LUSC	cis	rs4974559	0.947	rs28418481	chr4:1330975	C/G	cg02980000	chr4:1222292	CTBP1	0.66	7.79	0.39	8.78e-14	Systolic blood pressure;
LUSC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg16339924	chr4:17578868	LAP3	0.62	9.39	0.46	9.43e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.27	0.62	2.12e-36	Exhaled nitric oxide levels;
LUSC	trans	rs11165623	0.564	rs6593612	chr1:97002041	C/A	cg10631902	chr5:14652156	NA	-0.42	-6.21	-0.32	1.55e-9	Hip circumference;Waist circumference;
LUSC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg01097406	chr16:89675127	NA	0.46	9.48	0.46	4.85e-19	Vitiligo;
LUSC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.59	-5.76	-0.3	1.91e-8	Cerebrospinal P-tau181p levels;
LUSC	trans	rs72674100	1.000	rs10016960	chr4:97989075	T/A	cg16405019	chr1:18959625	PAX7	-0.61	-6.44	-0.33	4.04e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg15083037	chr5:83017644	HAPLN1	0.57	7.68	0.39	1.74e-13	Prostate cancer;
LUSC	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg19743168	chr1:23544995	NA	0.43	8.19	0.41	5.53e-15	Height;
LUSC	cis	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg06521331	chr12:34319734	NA	-0.36	-5.98	-0.31	5.61e-9	Morning vs. evening chronotype;
LUSC	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg22709100	chr7:91322751	NA	0.43	6.48	0.33	3.37e-10	Breast cancer;
LUSC	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg12856521	chr11:46389249	DGKZ	-0.4	-6.09	-0.32	3.18e-9	Leprosy;
LUSC	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.24	0.45	2.94e-18	Coffee consumption (cups per day);
LUSC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	trans	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg18187862	chr3:45730750	SACM1L	0.55	7.01	0.36	1.36e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg27631724	chr1:11040367	C1orf127	0.56	10.92	0.51	6.1e-24	Ewing sarcoma;
LUSC	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg08999081	chr20:33150536	PIGU	0.37	6.84	0.35	3.89e-11	Height;
LUSC	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	9.6	0.46	2.01e-19	Total cholesterol levels;
LUSC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg18240062	chr17:79603768	NPLOC4	0.69	12.86	0.58	4.98e-31	Eye color traits;
LUSC	cis	rs6690583	0.623	rs6679539	chr1:85479457	G/T	cg22153463	chr1:85462885	MCOLN2	-0.58	-5.76	-0.3	1.88e-8	Serum sulfate level;
LUSC	cis	rs1506636	1.000	rs2896332	chr7:123297223	A/T	cg03229431	chr7:123269106	ASB15	-0.65	-10.62	-0.5	6.66e-23	Plateletcrit;Platelet count;
LUSC	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg13206674	chr6:150067644	NUP43	0.43	6.46	0.33	3.62e-10	Lung cancer;
LUSC	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg05343316	chr1:45956843	TESK2	0.61	8.51	0.42	5.84e-16	Platelet count;
LUSC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.11	17.08	0.68	1.84e-47	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg04398451	chr17:18023971	MYO15A	0.55	8.96	0.44	2.36e-17	Total body bone mineral density;
LUSC	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg00898013	chr13:113819073	PROZ	-0.57	-8.06	-0.4	1.38e-14	Platelet distribution width;
LUSC	trans	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.81	-0.35	4.66e-11	Morning vs. evening chronotype;
LUSC	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	0.91	17.91	0.7	9.05e-51	Metabolite levels;
LUSC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.98	-0.31	5.63e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg09184832	chr6:79620586	NA	-0.43	-6.96	-0.36	1.83e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg12751644	chr20:60527061	NA	0.38	6.59	0.34	1.68e-10	Obesity-related traits;
LUSC	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	11.44	0.53	8.24e-26	Coronary artery disease;
LUSC	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg24631222	chr15:78858424	CHRNA5	-0.82	-10.78	-0.51	1.93e-23	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2273669	0.667	rs4509156	chr6:109308952	A/C	cg05315195	chr6:109294784	ARMC2	0.52	5.88	0.31	1.02e-8	Prostate cancer;
LUSC	cis	rs7712401	0.562	rs377316	chr5:122259875	G/C	cg19077854	chr5:122220652	SNX24	0.42	9.27	0.45	2.4e-18	Mean platelet volume;
LUSC	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-0.56	-8.65	-0.43	2.21e-16	Breast cancer;
LUSC	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg03929089	chr4:120376271	NA	0.74	6.91	0.35	2.4e-11	Axial length;
LUSC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-7.05	-0.36	1.05e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-6.41	-0.33	5.09e-10	Response to antipsychotic treatment;
LUSC	cis	rs2227930	0.506	rs9859834	chr3:142106351	A/T	cg16271453	chr3:142027066	XRN1	-0.54	-9.85	-0.47	2.8e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs1609391	0.543	rs6800690	chr3:136623026	G/A	cg15507776	chr3:136538369	TMEM22	0.5	8.25	0.41	3.79e-15	Neuroticism;
LUSC	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs3850699	0.651	rs35485301	chr10:104370827	C/T	cg04362960	chr10:104952993	NT5C2	0.53	6.7	0.34	8.78e-11	Prostate cancer;
LUSC	cis	rs10266483	0.654	rs6962076	chr7:64019592	C/T	cg24201672	chr7:64023550	ZNF680	0.52	6.94	0.35	2.1e-11	Response to statin therapy;
LUSC	cis	rs7572644	0.639	rs3792253	chr2:28002002	T/C	cg27432699	chr2:27873401	GPN1	0.55	7.06	0.36	9.59e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03709012	chr19:19516395	GATAD2A	-0.51	-7.36	-0.37	1.43e-12	Tonsillectomy;
LUSC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg21951975	chr1:209979733	IRF6	-0.52	-8.95	-0.44	2.6e-17	Monobrow;
LUSC	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg17279839	chr7:150038598	RARRES2	0.43	6.6	0.34	1.61e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs868036	0.681	rs28376010	chr15:68063739	G/T	cg08079166	chr15:68083412	MAP2K5	0.39	6.71	0.34	8.56e-11	Restless legs syndrome;
LUSC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.27	-0.49	1.06e-21	Gut microbiome composition (summer);
LUSC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg23985595	chr17:80112537	CCDC57	0.34	6.49	0.33	3.03e-10	Life satisfaction;
LUSC	cis	rs7074356	0.522	rs1591958	chr10:82062661	G/A	cg27171509	chr10:82033454	MAT1A	-0.3	-6.05	-0.31	3.85e-9	Borderline personality disorder;
LUSC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg05754148	chr16:3507555	NAT15	-0.84	-9.07	-0.44	1.03e-17	Tuberculosis;
LUSC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg04850211	chr1:228464232	OBSCN	0.32	5.68	0.3	2.92e-8	Diastolic blood pressure;
LUSC	cis	rs12493885	0.628	rs61790906	chr3:153653953	T/G	cg17054900	chr3:154042577	DHX36	-0.54	-5.66	-0.3	3.23e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs16937	0.557	rs11240386	chr1:205175401	G/T	cg00857998	chr1:205179979	DSTYK	0.46	6.38	0.33	5.75e-10	Schizophrenia;
LUSC	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs5009270	0.553	rs6947690	chr7:112233386	C/G	cg23628563	chr7:112262597	NA	0.43	5.87	0.31	1.03e-8	Osteoarthritis (hip);
LUSC	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg07080220	chr10:102295463	HIF1AN	0.68	8.57	0.42	3.86e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.5	0.33	2.97e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	0.94	12.73	0.57	1.58e-30	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg24375607	chr4:120327624	NA	0.79	11.69	0.54	1.03e-26	Corneal astigmatism;
LUSC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg12935359	chr14:103987150	CKB	0.54	8.37	0.42	1.58e-15	Body mass index;
LUSC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg14552801	chr7:65878734	NA	0.38	5.91	0.31	8.41e-9	Aortic root size;
LUSC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.29	0.45	1.97e-18	Bipolar disorder;
LUSC	trans	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.51	0.42	6.1e-16	Diabetic kidney disease;
LUSC	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg04374321	chr14:90722782	PSMC1	0.68	10.47	0.5	2.33e-22	Mortality in heart failure;
LUSC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	7.8	0.39	7.99e-14	Cognitive test performance;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11963883	chr10:70715832	DDX21	0.46	6.06	0.31	3.68e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.62	-0.43	2.75e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs4704187	0.687	rs10036527	chr5:74481837	T/C	cg03227963	chr5:74354835	NA	0.3	6.54	0.34	2.32e-10	Response to amphetamines;
LUSC	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg05784532	chr1:230284198	GALNT2	0.49	7.41	0.38	1.06e-12	Coronary artery disease;
LUSC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-8.16	-0.41	6.95e-15	Personality dimensions;
LUSC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.65	14.38	0.62	7.99e-37	Hemoglobin concentration;
LUSC	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg13010199	chr12:38710504	ALG10B	0.63	9.11	0.45	7.63e-18	Morning vs. evening chronotype;
LUSC	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg23950597	chr19:37808831	NA	-0.62	-7.43	-0.38	9.32e-13	Coronary artery calcification;
LUSC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08392591	chr16:89556376	ANKRD11	-0.45	-6.98	-0.36	1.56e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-12.84	-0.57	5.96e-31	Platelet count;
LUSC	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg26874229	chr2:105853672	NA	-0.32	-6.0	-0.31	5.19e-9	Type 2 diabetes;
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.56	9.32	0.45	1.61e-18	Lymphocyte counts;
LUSC	cis	rs654950	0.840	rs647146	chr1:41986286	G/A	cg06885757	chr1:42089581	HIVEP3	0.39	7.76	0.39	1.02e-13	Airway imaging phenotypes;
LUSC	trans	rs11723530	0.507	rs4692762	chr4:170814209	G/C	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.28	-0.32	1.03e-9	Myopia (pathological);
LUSC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg13206674	chr6:150067644	NUP43	0.59	9.19	0.45	4.2e-18	Lung cancer;
LUSC	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.72	-12.92	-0.58	3.14e-31	Brugada syndrome;
LUSC	cis	rs6546886	0.957	rs4371381	chr2:74246613	T/C	cg14702570	chr2:74259524	NA	-0.3	-5.66	-0.3	3.34e-8	Dialysis-related mortality;
LUSC	trans	rs34421088	0.576	rs2572436	chr8:11099209	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.31	-0.37	1.96e-12	Neuroticism;
LUSC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg00800038	chr16:89945340	TCF25	0.59	6.34	0.33	7.52e-10	Skin colour saturation;
LUSC	cis	rs965513	1.000	rs7032019	chr9:100548144	G/A	cg13688889	chr9:100608707	NA	-0.54	-8.05	-0.4	1.45e-14	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.69	0.63	4.78e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg17031739	chr1:67600172	NA	0.36	5.72	0.3	2.35e-8	Psoriasis;
LUSC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg04450456	chr4:17643702	FAM184B	0.39	6.6	0.34	1.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs78572108	0.925	rs13431578	chr2:42264301	G/A	cg00607755	chr2:42274082	PKDCC	0.36	6.48	0.33	3.34e-10	Total body bone mineral density;
LUSC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	1.21	16.6	0.67	1.46e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg16359550	chr11:109292809	C11orf87	0.32	5.78	0.3	1.74e-8	Schizophrenia;
LUSC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg08847533	chr14:75593920	NEK9	0.86	16.11	0.66	1.35e-43	Height;
LUSC	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg06636001	chr8:8085503	FLJ10661	0.47	6.87	0.35	3.08e-11	Neuroticism;
LUSC	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg13852791	chr20:30311386	BCL2L1	0.95	14.83	0.63	1.45e-38	Mean corpuscular hemoglobin;
LUSC	cis	rs4474465	1.000	rs7935180	chr11:78169785	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.66	-0.3	3.32e-8	Alzheimer's disease (survival time);
LUSC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg22535103	chr8:58192502	C8orf71	0.7	7.24	0.37	3.18e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.23	26.97	0.83	7.47e-86	Exhaled nitric oxide output;
LUSC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-7.96	-0.4	2.76e-14	Longevity;
LUSC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.66	8.0	0.4	2.01e-14	Lung function (FEV1/FVC);
LUSC	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg05283184	chr6:79620031	NA	-0.57	-12.2	-0.56	1.41e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.04	-0.48	6.92e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg22705602	chr4:152727874	NA	-0.39	-8.37	-0.42	1.58e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg17800788	chr1:21766015	NBPF3	0.34	6.3	0.33	9.37e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg21918786	chr6:109611834	NA	-0.39	-6.55	-0.34	2.21e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs11971779	0.680	rs4732379	chr7:139122814	T/C	cg07862535	chr7:139043722	LUC7L2	0.6	7.64	0.39	2.25e-13	Diisocyanate-induced asthma;
LUSC	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg20129853	chr10:51489980	NA	-0.34	-6.82	-0.35	4.31e-11	Prostate-specific antigen levels;
LUSC	cis	rs7818345	0.967	rs13255946	chr8:19275354	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.37	6.99	0.36	1.49e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg12940439	chr1:67600707	NA	-0.37	-6.09	-0.32	3.13e-9	Psoriasis;
LUSC	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.66	11.73	0.54	7.75e-27	Itch intensity from mosquito bite;
LUSC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg09555818	chr19:45449301	APOC2	-0.47	-8.56	-0.42	4.29e-16	Blood protein levels;
LUSC	trans	rs34844492	0.744	rs17072704	chr3:65271885	C/T	cg21674010	chr15:58844583	LIPC	0.67	6.45	0.33	3.93e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.71	9.55	0.46	2.84e-19	Gut microbiome composition (summer);
LUSC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg22907277	chr7:1156413	C7orf50	-0.47	-7.36	-0.37	1.48e-12	Longevity;Endometriosis;
LUSC	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.47	-0.33	3.41e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.42	-0.62	5.29e-37	Schizophrenia;
LUSC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg07701084	chr6:150067640	NUP43	0.53	7.8	0.39	7.88e-14	Lung cancer;
LUSC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg13607699	chr17:42295918	UBTF	0.47	7.45	0.38	8.21e-13	Total body bone mineral density;
LUSC	cis	rs13315871	0.929	rs13080398	chr3:58300282	A/G	cg20936604	chr3:58311152	NA	-0.71	-6.73	-0.35	7.52e-11	Cholesterol, total;
LUSC	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg08999081	chr20:33150536	PIGU	0.45	8.16	0.41	6.79e-15	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.66	0.39	2.01e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg14007221	chr9:37651177	FRMPD1	0.42	6.43	0.33	4.54e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg27284194	chr4:1044797	NA	0.59	8.69	0.43	1.6e-16	Recombination rate (females);
LUSC	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg19812747	chr11:111475976	SIK2	-0.48	-6.55	-0.34	2.16e-10	Primary sclerosing cholangitis;
LUSC	trans	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.27	-0.45	2.45e-18	Depression;
LUSC	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg22782873	chr19:19639568	YJEFN3	-0.53	-6.48	-0.33	3.38e-10	Bipolar disorder;
LUSC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg14416269	chr4:6271139	WFS1	-0.47	-10.29	-0.49	9.47e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04004882	chr2:215674386	BARD1	0.48	6.37	0.33	6.34e-10	Neuroblastoma;
LUSC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg15468180	chr1:107600409	PRMT6	0.36	5.88	0.31	9.93e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg26335602	chr6:28129616	ZNF389	0.43	5.77	0.3	1.79e-8	Depression;
LUSC	cis	rs1957429	0.614	rs1957416	chr14:65369329	C/T	cg23373153	chr14:65346875	NA	-1.01	-8.51	-0.42	6.09e-16	Pediatric areal bone mineral density (radius);
LUSC	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg05373962	chr22:49881684	NA	-0.44	-10.5	-0.5	1.81e-22	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg17330251	chr7:94953956	PON1	-0.37	-5.96	-0.31	6.32e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg24813613	chr7:1882135	MAD1L1	-0.46	-7.82	-0.39	7.09e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg00012203	chr2:219082015	ARPC2	0.76	13.61	0.6	7.57e-34	Colorectal cancer;
LUSC	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07080220	chr10:102295463	HIF1AN	0.68	9.27	0.45	2.37e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg17470449	chr10:769945	NA	0.53	7.31	0.37	1.98e-12	Uric acid levels;
LUSC	cis	rs4253772	0.872	rs45576734	chr22:46638365	A/G	cg24881330	chr22:46731750	TRMU	0.63	5.85	0.31	1.15e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.38	0.33	5.95e-10	Menopause (age at onset);
LUSC	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.94	-0.35	2.06e-11	Response to antipsychotic treatment;
LUSC	cis	rs4363385	0.818	rs4845512	chr1:152995241	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.11	-0.36	7.08e-12	Inflammatory skin disease;
LUSC	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg01733217	chr16:74700730	RFWD3	0.98	21.94	0.77	1.05e-66	Multiple myeloma;
LUSC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg24101359	chr6:42928495	GNMT	0.35	5.8	0.3	1.5e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6500395	0.962	rs11647046	chr16:48623217	T/C	cg04672837	chr16:48644449	N4BP1	0.49	7.02	0.36	1.26e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg02018176	chr4:1364513	KIAA1530	0.53	9.2	0.45	3.96e-18	Obesity-related traits;
LUSC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg19318889	chr4:1322082	MAEA	0.42	6.94	0.36	2.01e-11	Obesity-related traits;
LUSC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg10792982	chr14:105748885	BRF1	0.5	9.14	0.45	6.23e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7173743	0.756	rs4539564	chr15:79128499	G/A	cg00540400	chr15:79124168	NA	0.35	5.99	0.31	5.29e-9	Coronary artery disease;
LUSC	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg05182265	chr7:156933206	UBE3C	0.59	9.67	0.47	1.17e-19	Body mass index;
LUSC	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg24130564	chr14:104152367	KLC1	-0.47	-6.82	-0.35	4.31e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg04455712	chr21:45112962	RRP1B	0.44	8.3	0.41	2.56e-15	Mean corpuscular volume;
LUSC	cis	rs909341	0.830	rs1623866	chr20:62333022	G/A	cg09650180	chr20:62225654	GMEB2	-0.45	-5.83	-0.3	1.32e-8	Atopic dermatitis;
LUSC	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg26395211	chr5:140044315	WDR55	0.38	5.77	0.3	1.77e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg18755752	chr8:142205143	DENND3	-0.51	-6.86	-0.35	3.38e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg19920283	chr7:105172520	RINT1	0.62	6.94	0.36	2.04e-11	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg18827107	chr12:86230957	RASSF9	-0.46	-6.97	-0.36	1.74e-11	Major depressive disorder;
LUSC	cis	rs1030268	0.620	rs2160746	chr7:133478204	G/C	cg10665199	chr7:133106180	EXOC4	0.54	5.89	0.31	9.6e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	0.64	13.62	0.6	6.4e-34	Prudent dietary pattern;
LUSC	cis	rs6942756	0.774	rs2566885	chr7:128917587	C/T	cg02491457	chr7:128862824	NA	0.49	7.23	0.37	3.26e-12	White matter hyperintensity burden;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06404838	chr11:117015391	PAFAH1B2	-0.44	-6.69	-0.34	9.7e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg23887609	chr12:130822674	PIWIL1	0.49	7.34	0.37	1.64e-12	Menopause (age at onset);
LUSC	cis	rs9687065	1.000	rs17722209	chr5:148406386	A/G	cg23229984	chr5:148520753	ABLIM3	-0.38	-5.79	-0.3	1.58e-8	Diastolic blood pressure;
LUSC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.31	0.56	5.66e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg15557168	chr22:42548783	NA	0.45	6.76	0.35	6.2e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg18540374	chr18:9102459	NDUFV2	-0.45	-6.71	-0.34	8.12e-11	Triglycerides;
LUSC	cis	rs36093844	0.752	rs17744606	chr11:85565450	C/T	cg25872744	chr11:85566296	CCDC83	-0.45	-5.78	-0.3	1.68e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg17845761	chr1:175162550	KIAA0040	-0.31	-6.01	-0.31	4.76e-9	Alcohol dependence;
LUSC	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg26597838	chr10:835615	NA	0.49	6.76	0.35	6.03e-11	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.58	0.34	1.86e-10	Lung cancer;
LUSC	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg08213375	chr14:104286397	PPP1R13B	0.52	10.25	0.49	1.3e-21	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26314531	chr2:26401878	FAM59B	-0.68	-9.1	-0.45	8.35e-18	Gut microbiome composition (summer);
LUSC	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07169764	chr2:136633963	MCM6	-0.74	-10.0	-0.48	8.98e-21	Mosquito bite size;
LUSC	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07080220	chr10:102295463	HIF1AN	-0.59	-8.1	-0.41	1.02e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg16339924	chr4:17578868	LAP3	0.54	8.32	0.41	2.32e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-8.17	-0.41	6.38e-15	Axial length;
LUSC	cis	rs2667011	0.818	rs1397709	chr2:160852712	G/T	cg06573604	chr2:160760825	LY75	-0.5	-6.5	-0.33	3.01e-10	Bilirubin levels;
LUSC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18932078	chr1:2524107	MMEL1	-0.28	-6.06	-0.31	3.77e-9	Ulcerative colitis;
LUSC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg18350739	chr11:68623251	NA	0.39	7.15	0.36	5.51e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs55665837	1.000	rs11023224	chr11:14457739	G/A	cg19336497	chr11:14380999	RRAS2	-0.37	-7.47	-0.38	6.93e-13	Vitamin D levels;
LUSC	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg05283184	chr6:79620031	NA	-0.57	-11.82	-0.54	3.53e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.17	-0.37	4.89e-12	Alzheimer's disease (late onset);
LUSC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg07936489	chr17:37558343	FBXL20	-0.7	-9.54	-0.46	3.1400000000000002e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg26924012	chr15:45694286	SPATA5L1	1.14	20.94	0.75	9e-63	Homoarginine levels;
LUSC	cis	rs2637266	0.783	rs864676	chr10:78509385	A/G	cg18941641	chr10:78392320	NA	0.39	7.14	0.36	5.99e-12	Pulmonary function;
LUSC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg26408565	chr15:76604113	ETFA	-0.5	-7.98	-0.4	2.41e-14	Blood metabolite levels;
LUSC	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg23127183	chr11:57508653	C11orf31	-0.58	-8.91	-0.44	3.41e-17	Schizophrenia;
LUSC	cis	rs10979	0.571	rs9386039	chr6:143916992	A/T	cg25407410	chr6:143891975	LOC285740	0.56	6.8	0.35	4.88e-11	Hypospadias;
LUSC	cis	rs1322512	1.000	rs1744379	chr6:152942844	C/A	cg27316956	chr6:152958899	SYNE1	-0.35	-5.79	-0.3	1.66e-8	Tonometry;
LUSC	cis	rs6554196	0.508	rs999020	chr4:55524304	T/C	cg18836493	chr4:55524333	KIT	-0.43	-7.43	-0.38	9.34e-13	Monocyte count;
LUSC	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-1.15	-18.29	-0.71	2.9e-52	Exhaled nitric oxide output;
LUSC	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg27661571	chr11:113659931	NA	-0.52	-6.19	-0.32	1.73e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg22153745	chr1:153894579	GATAD2B	-0.53	-8.1	-0.41	1.07e-14	Total cholesterol levels;
LUSC	cis	rs7315438	0.578	rs2384649	chr12:115884454	C/T	cg24172291	chr12:115889509	NA	-0.33	-5.71	-0.3	2.55e-8	Colorectal cancer;
LUSC	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg07148914	chr20:33460835	GGT7	0.56	8.52	0.42	5.56e-16	Height;
LUSC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18357526	chr6:26021779	HIST1H4A	0.41	6.02	0.31	4.54e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.6	-8.59	-0.43	3.38e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6669072	0.605	rs34304726	chr1:91257997	T/C	cg08895590	chr1:91227319	NA	-0.28	-5.99	-0.31	5.47e-9	Cognitive function;
LUSC	trans	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg24644049	chr4:85504048	CDS1	0.69	7.03	0.36	1.15e-11	Skin colour saturation;
LUSC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg04369109	chr6:150039330	LATS1	-0.53	-7.9	-0.4	3.96e-14	Lung cancer;
LUSC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg13047869	chr3:10149882	C3orf24	-0.64	-7.77	-0.39	1e-13	Alzheimer's disease;
LUSC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.24	0.37	3.09e-12	Mean platelet volume;
LUSC	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg22705602	chr4:152727874	NA	-0.3	-6.44	-0.33	4.19e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg21433313	chr16:3507492	NAT15	0.7	11.47	0.53	6.47e-26	Tuberculosis;
LUSC	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.41	-6.04	-0.31	4.01e-9	Schizophrenia;
LUSC	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-7.61	-0.38	2.84e-13	Neuroticism;
LUSC	cis	rs11955175	1.000	rs78855960	chr5:40657221	C/G	cg05478818	chr5:40835740	RPL37	0.7	5.72	0.3	2.37e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08219700	chr8:58056026	NA	0.64	7.88	0.4	4.52e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg22705602	chr4:152727874	NA	-0.32	-6.54	-0.34	2.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7904985	0.961	rs12355013	chr10:88114538	A/G	cg07322936	chr10:88137208	NA	0.54	6.97	0.36	1.7e-11	Barrett's esophagus;
LUSC	cis	rs17030434	0.906	rs4145339	chr4:154710481	C/T	cg14289246	chr4:154710475	SFRP2	-0.52	-6.66	-0.34	1.11e-10	Electrocardiographic conduction measures;
LUSC	trans	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg24644049	chr4:85504048	CDS1	0.88	7.53	0.38	4.81e-13	Skin colour saturation;
LUSC	trans	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.15	-0.32	2.19e-9	Depression;
LUSC	cis	rs9807989	0.773	rs72823661	chr2:102968716	G/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.91	0.31	8.63e-9	Asthma;
LUSC	cis	rs308403	0.530	rs13135766	chr4:123664427	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.75	-9.89	-0.48	2.1e-20	Blood protein levels;
LUSC	cis	rs6545883	0.965	rs7421663	chr2:61753786	C/T	cg15711740	chr2:61764176	XPO1	-0.5	-7.97	-0.4	2.55e-14	Tuberculosis;
LUSC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.95	-19.99	-0.74	5.2e-59	Post bronchodilator FEV1;
LUSC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.76	10.04	0.48	6.77e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg13206674	chr6:150067644	NUP43	0.6	9.54	0.46	3.08e-19	Lung cancer;
LUSC	cis	rs6445967	0.530	rs12486031	chr3:58409679	G/A	cg23715586	chr3:58305044	RPP14	0.42	7.14	0.36	5.81e-12	Platelet count;
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.53	-9.68	-0.47	1.07e-19	Longevity;Endometriosis;
LUSC	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg08213375	chr14:104286397	PPP1R13B	0.54	11.03	0.52	2.41e-24	Schizophrenia;
LUSC	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg13660082	chr14:53194042	PSMC6	-0.78	-6.81	-0.35	4.55e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg26924012	chr15:45694286	SPATA5L1	1.13	20.81	0.75	2.85e-62	Homoarginine levels;
LUSC	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg00255919	chr5:131827918	IRF1	0.35	6.75	0.35	6.41e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.51e-14	Prudent dietary pattern;
LUSC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg04369109	chr6:150039330	LATS1	-0.54	-7.83	-0.39	6.34e-14	Lung cancer;
LUSC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg02807482	chr3:125708958	NA	-0.54	-6.65	-0.34	1.16e-10	Blood pressure (smoking interaction);
LUSC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.47	-7.36	-0.37	1.43e-12	Alzheimer's disease (late onset);
LUSC	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg15556689	chr8:8085844	FLJ10661	0.58	8.74	0.43	1.19e-16	Neuroticism;
LUSC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.35	-5.72	-0.3	2.39e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06634786	chr22:41940651	POLR3H	-0.5	-5.89	-0.31	9.64e-9	Vitiligo;
LUSC	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg27539214	chr16:67997921	SLC12A4	-0.5	-6.72	-0.35	7.83e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs34638657	0.646	rs72628279	chr16:82199664	A/C	cg09439754	chr16:82129088	HSD17B2	-0.4	-6.73	-0.35	7.52e-11	Lung adenocarcinoma;
LUSC	cis	rs11031096	0.679	rs12292515	chr11:4206385	T/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.75	-0.3	2.02e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27109131	chr3:14165888	TMEM43;CHCHD4	-0.42	-5.97	-0.31	6.11e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg20200200	chr1:18807388	KLHDC7A	-0.33	-6.82	-0.35	4.36e-11	Breast cancer;
LUSC	cis	rs6750047	0.625	rs336036	chr2:38261143	C/T	cg07380506	chr2:38303506	CYP1B1	-0.44	-6.18	-0.32	1.91e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg16070123	chr10:51489643	NA	-0.52	-8.25	-0.41	3.65e-15	Prostate-specific antigen levels;
LUSC	cis	rs10761482	0.861	rs1473404	chr10:62102316	A/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06634786	chr22:41940651	POLR3H	0.51	5.95	0.31	6.94e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7577696	0.597	rs17011801	chr2:32298072	A/T	cg02381751	chr2:32503542	YIPF4	-0.51	-6.88	-0.35	2.89e-11	Inflammatory biomarkers;
LUSC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg02038168	chr22:39784481	NA	-0.49	-7.89	-0.4	4.5e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg09509183	chr1:209979624	IRF6	0.52	6.21	0.32	1.61e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	6.99	0.36	1.46e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg27068330	chr11:65405492	SIPA1	-0.64	-9.02	-0.44	1.54e-17	Acne (severe);
LUSC	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg04310649	chr10:35416472	CREM	-0.43	-6.64	-0.34	1.27e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg21100191	chr22:23484243	RTDR1	0.91	15.54	0.65	2.29e-41	Bone mineral density;
LUSC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.44e-9	Aortic root size;
LUSC	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg19196401	chr6:110721138	DDO	-0.47	-8.84	-0.44	5.67e-17	Platelet distribution width;
LUSC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg12310025	chr6:25882481	NA	-0.5	-9.06	-0.44	1.09e-17	Blood metabolite levels;
LUSC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg15017067	chr4:17643749	FAM184B	0.35	5.76	0.3	1.96e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg12257692	chr3:49977190	RBM6	-0.26	-7.32	-0.37	1.82e-12	Body mass index;
LUSC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg05472934	chr7:22766657	IL6	0.54	8.47	0.42	7.64e-16	Lung cancer;
LUSC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.46	-6.73	-0.35	7.2e-11	Menarche (age at onset);
LUSC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg07636037	chr3:49044803	WDR6	0.44	6.38	0.33	5.9e-10	Resting heart rate;
LUSC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg27532560	chr4:187881888	NA	-0.35	-5.83	-0.3	1.31e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg19875535	chr5:140030758	IK	0.48	7.76	0.39	1.01e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.79	-0.3	1.62e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs757081	0.606	rs679201	chr11:17200891	T/C	cg15432903	chr11:17409602	KCNJ11	-0.38	-5.89	-0.31	9.56e-9	Systolic blood pressure;
LUSC	cis	rs11031096	0.678	rs1442727	chr11:4188188	G/T	cg18678763	chr11:4115507	RRM1	0.41	5.9	0.31	9.15e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.53	-8.11	-0.41	9.55e-15	Lymphocyte counts;
LUSC	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg20933634	chr6:27740509	NA	0.43	5.93	0.31	7.46e-9	Parkinson's disease;
LUSC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs870825	0.616	rs4263438	chr4:185624238	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg13073564	chr4:8508604	NA	-0.44	-8.26	-0.41	3.47e-15	Response to antineoplastic agents;
LUSC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6733011	0.628	rs10188156	chr2:99465875	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.76	-0.35	6.12e-11	Bipolar disorder;
LUSC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.65	7.99	0.4	2.24e-14	Lung function (FEV1/FVC);
LUSC	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg19792802	chr11:65647270	CTSW	-0.41	-6.28	-0.32	1.05e-9	Crohn's disease;
LUSC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg27588902	chr6:42928151	GNMT	-0.3	-6.6	-0.34	1.57e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg00277334	chr10:82204260	NA	-0.52	-7.74	-0.39	1.21e-13	Post bronchodilator FEV1;
LUSC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.76	-11.99	-0.55	8.98e-28	Tonsillectomy;
LUSC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-0.97	-13.98	-0.61	2.89e-35	Initial pursuit acceleration;
LUSC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg25036284	chr2:26402008	FAM59B	-0.74	-10.65	-0.5	5.23e-23	Gut microbiome composition (summer);
LUSC	cis	rs9914544	0.545	rs8067882	chr17:18807131	A/G	cg26378065	chr17:18585709	ZNF286B	0.41	5.75	0.3	2.01e-8	Educational attainment (years of education);
LUSC	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg08601574	chr20:25228251	PYGB	0.42	6.5	0.33	3e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	6.67	0.34	1.05e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9359856	0.956	rs6912680	chr6:90300010	T/G	cg13799429	chr6:90582589	CASP8AP2	0.56	6.44	0.33	4.08e-10	Bipolar disorder;
LUSC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	8.95	0.44	2.45e-17	Menopause (age at onset);
LUSC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	6.07	0.32	3.55e-9	Height;
LUSC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg12564285	chr5:131593104	PDLIM4	0.32	5.68	0.3	3.01e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg27124370	chr19:33622961	WDR88	0.57	7.41	0.38	1.03e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg27144592	chr16:783916	NARFL	0.65	10.0	0.48	8.94e-21	Height;
LUSC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.68	-8.84	-0.44	5.66e-17	Menarche (age at onset);
LUSC	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.31	0.41	2.49e-15	Homoarginine levels;
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	0.36	5.71	0.3	2.55e-8	Lymphocyte counts;
LUSC	trans	rs11241130	0.669	rs26043	chr5:111013218	A/C	cg24626752	chr13:88328274	SLITRK5	0.72	6.13	0.32	2.43e-9	Obesity-related traits;
LUSC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg07703079	chr11:430292	ANO9	0.7	7.12	0.36	6.72e-12	Body mass index;
LUSC	cis	rs3741151	1.000	rs7125978	chr11:73039229	G/A	cg17517138	chr11:73019481	ARHGEF17	0.97	9.08	0.44	1e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg05585544	chr11:47624801	NA	-0.42	-7.36	-0.37	1.45e-12	Subjective well-being;
LUSC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg25174290	chr11:3078921	CARS	0.59	9.44	0.46	6.52e-19	Longevity;
LUSC	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg05043794	chr9:111880884	C9orf5	-0.35	-7.16	-0.36	5.05e-12	Menarche (age at onset);
LUSC	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg01420254	chr6:26195488	NA	0.7	7.46	0.38	7.56e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs2742417	0.603	rs2742374	chr3:45784082	T/C	cg04837898	chr3:45731254	SACM1L	-0.46	-7.46	-0.38	7.62e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.77	-0.47	5.32e-20	Gut microbiome composition (summer);
LUSC	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg20135002	chr11:47629003	NA	-0.43	-7.04	-0.36	1.12e-11	Subjective well-being;
LUSC	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg06532163	chr17:45867833	NA	0.34	6.34	0.33	7.6e-10	IgG glycosylation;
LUSC	cis	rs79387448	0.745	rs72995626	chr2:103162580	T/C	cg09003973	chr2:102972529	NA	0.89	8.62	0.43	2.69e-16	Gut microbiota (bacterial taxa);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg17598997	chr1:45672616	ZSWIM5	0.39	6.55	0.34	2.15e-10	Triglycerides;
LUSC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg21724239	chr8:58056113	NA	0.66	7.4	0.38	1.14e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.7	-10.95	-0.51	4.95e-24	Aortic root size;
LUSC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg03732007	chr1:2071316	PRKCZ	-0.53	-9.47	-0.46	5.11e-19	Height;
LUSC	cis	rs9818941	1.000	rs9818941	chr3:157686457	G/A	cg08654915	chr3:157813417	NA	-0.24	-6.08	-0.32	3.37e-9	Height;
LUSC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg13206674	chr6:150067644	NUP43	0.59	9.47	0.46	5.47e-19	Lung cancer;
LUSC	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.61	-0.34	1.51e-10	Uric acid levels;
LUSC	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg13319975	chr6:146136371	FBXO30	0.45	6.99	0.36	1.51e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.42	-7.72	-0.39	1.39e-13	Glomerular filtration rate;
LUSC	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg05472934	chr7:22766657	IL6	0.38	6.04	0.31	4.02e-9	Lung cancer;
LUSC	cis	rs11677416	1.000	rs2856836	chr2:113532083	A/G	cg27083787	chr2:113543245	IL1A	0.48	7.39	0.37	1.17e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs56283067	0.847	rs2128543	chr6:44685552	G/A	cg20913747	chr6:44695427	NA	-0.44	-7.32	-0.37	1.9e-12	Total body bone mineral density;
LUSC	trans	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.13	-0.32	2.49e-9	Bladder cancer;
LUSC	cis	rs2075165	0.935	rs933489	chr1:156235120	T/C	cg20302342	chr1:156215951	PAQR6	0.32	6.06	0.31	3.57e-9	Tonsillectomy;
LUSC	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg09754948	chr16:28834200	ATXN2L	0.42	6.11	0.32	2.78e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg26043149	chr18:55253948	FECH	0.51	7.52	0.38	4.96e-13	Bone mineral density;
LUSC	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg13010199	chr12:38710504	ALG10B	0.55	8.45	0.42	9.2e-16	Morning vs. evening chronotype;
LUSC	cis	rs13092825	1.000	rs13074313	chr3:113273634	A/C	cg18753928	chr3:113234510	CCDC52	0.38	5.75	0.3	2.02e-8	Dental caries;
LUSC	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.76	-0.39	1.07e-13	Pulmonary function;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25470731	chr5:132112891	SEPT8	0.71	6.52	0.34	2.54e-10	Cognitive performance;
LUSC	cis	rs7584330	0.554	rs3751110	chr2:238427142	T/C	cg16989719	chr2:238392110	NA	-0.43	-6.2	-0.32	1.65e-9	Prostate cancer;
LUSC	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-7.49	-0.38	6.32e-13	Atrioventricular conduction;
LUSC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs4144743	1.000	rs7208170	chr17:45330759	G/A	cg18085866	chr17:45331354	ITGB3	-0.74	-7.72	-0.39	1.38e-13	Body mass index;
LUSC	cis	rs7538876	0.903	rs7528427	chr1:17746273	C/T	cg07965774	chr1:17746286	RCC2	0.33	6.2	0.32	1.64e-9	Basal cell carcinoma;
LUSC	cis	rs11158026	0.757	rs8012152	chr14:55425567	T/C	cg04306507	chr14:55594613	LGALS3	0.33	6.4	0.33	5.17e-10	Parkinson's disease;
LUSC	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg17764715	chr19:33622953	WDR88	0.6	8.33	0.41	2.08e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	0.87	16.63	0.67	1.17e-45	Dental caries;
LUSC	cis	rs4654899	0.897	rs10916856	chr1:21082074	A/C	cg01072550	chr1:21505969	NA	-0.48	-7.09	-0.36	7.8e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs259282	0.851	rs174083	chr19:33141180	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.87	14.26	0.62	2.23e-36	Schizophrenia;
LUSC	cis	rs4663866	0.901	rs34040298	chr2:239191607	T/C	cg16914508	chr2:239161102	PER2	0.69	7.62	0.38	2.58e-13	Irritable bowel syndrome;
LUSC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg02534363	chr3:47050950	NBEAL2	0.35	5.75	0.3	2.07e-8	Colorectal cancer;
LUSC	cis	rs8113142	0.614	rs11083646	chr19:29214739	C/T	cg04546413	chr19:29218101	NA	0.43	5.93	0.31	7.76e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg23625390	chr15:77176239	SCAPER	-0.66	-9.83	-0.47	3.49e-20	Blood metabolite levels;
LUSC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg16346588	chr10:242978	ZMYND11	0.41	5.9	0.31	9.1e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg05373962	chr22:49881684	NA	-0.41	-9.99	-0.48	9.53e-21	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.81	-13.32	-0.59	9.42e-33	Bladder cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17735028	chr1:19283102	IFFO2	-0.37	-6.0	-0.31	5.25e-9	Electrocardiographic conduction measures;
LUSC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.74	-0.39	1.2e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.21	-0.37	3.86e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.83	-0.3	1.28e-8	Resting heart rate;
LUSC	cis	rs2637266	1.000	rs7897348	chr10:78359620	G/A	cg18941641	chr10:78392320	NA	0.38	7.08	0.36	8.29e-12	Pulmonary function;
LUSC	trans	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg20935933	chr6:143382018	AIG1	0.51	7.43	0.38	8.96e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg25039879	chr17:56429692	SUPT4H1	0.69	9.17	0.45	5.1e-18	Cognitive test performance;
LUSC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg03060546	chr3:49711283	APEH	-0.61	-6.86	-0.35	3.31e-11	Menarche (age at onset);
LUSC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.95	0.36	1.97e-11	Cystic fibrosis severity;
LUSC	cis	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg02972257	chr16:68554789	NA	-0.53	-6.6	-0.34	1.64e-10	Ulcerative colitis;
LUSC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg16606324	chr3:10149918	C3orf24	0.6	8.59	0.43	3.26e-16	Alzheimer's disease;
LUSC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg16339924	chr4:17578868	LAP3	0.51	7.63	0.39	2.41e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5771069	0.896	rs137862	chr22:50446550	C/A	cg27467552	chr22:50353597	PIM3	-0.41	-6.97	-0.36	1.75e-11	Ulcerative colitis;
LUSC	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg04850211	chr1:228464232	OBSCN	-0.36	-6.12	-0.32	2.69e-9	Diastolic blood pressure;
LUSC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.97	0.36	1.7e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg21251018	chr6:28226885	NKAPL	0.31	5.84	0.3	1.22e-8	Pubertal anthropometrics;
LUSC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg07777115	chr5:623756	CEP72	-0.46	-5.9	-0.31	9.16e-9	Obesity-related traits;
LUSC	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.23	0.37	3.29e-12	Blood metabolite levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04434696	chr7:128379324	CALU	0.7	6.03	0.31	4.35e-9	Cognitive performance;
LUSC	trans	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.76	-0.35	6.16e-11	Monocyte count;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg06680201	chr11:71824165	C11orf51	0.36	6.22	0.32	1.47e-9	Tuberculosis;
LUSC	cis	rs2932538	0.922	rs12401734	chr1:113071834	A/G	cg22162597	chr1:113214053	CAPZA1	0.7	10.07	0.48	5.48e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg11608241	chr8:8085544	FLJ10661	0.39	5.64	0.3	3.56e-8	Joint mobility (Beighton score);
LUSC	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg04586622	chr2:25135609	ADCY3	0.36	7.3	0.37	2.1e-12	Body mass index in non-asthmatics;
LUSC	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg08085267	chr17:45401833	C17orf57	0.45	6.75	0.35	6.5e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1124376	0.935	rs9855900	chr3:20147172	C/T	cg05072819	chr3:20081367	KAT2B	0.66	7.53	0.38	4.7e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg06740227	chr12:86229804	RASSF9	0.38	6.06	0.31	3.6e-9	Major depressive disorder;
LUSC	cis	rs9921338	0.961	rs7198849	chr16:11373301	C/T	cg00044050	chr16:11439710	C16orf75	-0.48	-6.73	-0.35	7.59e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.07	0.58	8.33e-32	Prudent dietary pattern;
LUSC	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg24631222	chr15:78858424	CHRNA5	0.62	8.76	0.43	1.01e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg23625390	chr15:77176239	SCAPER	-0.62	-9.51	-0.46	3.79e-19	Blood metabolite levels;
LUSC	cis	rs6690583	0.623	rs12041012	chr1:85515644	G/A	cg11262906	chr1:85462892	MCOLN2	0.69	6.22	0.32	1.51e-9	Serum sulfate level;
LUSC	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.71	0.51	3.22e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg03342759	chr3:160939853	NMD3	-0.48	-6.64	-0.34	1.27e-10	Parkinson's disease;
LUSC	cis	rs9914544	0.545	rs8067882	chr17:18807131	A/G	cg26306683	chr17:18585705	ZNF286B	0.42	5.95	0.31	6.65e-9	Educational attainment (years of education);
LUSC	cis	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg20307385	chr11:47447363	PSMC3	0.53	6.25	0.32	1.27e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg17420585	chr12:42539391	GXYLT1	-0.34	-6.52	-0.34	2.61e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs497273	0.512	rs1177585	chr12:121325321	C/T	cg02419362	chr12:121203948	SPPL3	-0.43	-7.83	-0.39	6.7e-14	Systemic lupus erythematosus;
LUSC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.14	17.32	0.69	2.01e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7759001	0.857	rs1883404	chr6:27350381	A/T	cg18711553	chr6:27366782	ZNF391	-0.41	-5.96	-0.31	6.24e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.85	-11.39	-0.53	1.25e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg24296786	chr1:45957014	TESK2	0.54	8.26	0.41	3.53e-15	High light scatter reticulocyte count;
LUSC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg12463550	chr7:65579703	CRCP	0.51	7.34	0.37	1.6e-12	Aortic root size;
LUSC	trans	rs2694917	0.632	rs2638315	chr12:56865056	C/G	cg19051015	chr17:46697414	NA	0.41	6.44	0.33	4.09e-10	Blood metabolite ratios;
LUSC	cis	rs4132509	1.000	rs10927050	chr1:243805907	A/G	cg21452805	chr1:244014465	NA	0.52	6.08	0.32	3.34e-9	RR interval (heart rate);
LUSC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg20848291	chr7:100343083	ZAN	-0.57	-6.93	-0.35	2.14e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg09904177	chr6:26538194	HMGN4	-0.75	-6.61	-0.34	1.51e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg20476274	chr7:133979776	SLC35B4	0.83	15.15	0.64	7.91e-40	Mean platelet volume;
LUSC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	9.91e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg05729581	chr11:3078854	CARS	0.39	5.7	0.3	2.67e-8	Calcium levels;
LUSC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16405210	chr4:1374714	KIAA1530	-0.83	-13.64	-0.6	5.54e-34	Longevity;
LUSC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg02772935	chr3:125709198	NA	-0.47	-6.08	-0.32	3.22e-9	Blood pressure (smoking interaction);
LUSC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg20887711	chr4:1340912	KIAA1530	0.49	7.21	0.37	3.85e-12	Obesity-related traits;
LUSC	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg05340658	chr4:99064831	C4orf37	-0.44	-6.95	-0.36	1.94e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9469578	0.792	rs79297236	chr6:33713930	T/C	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.7	-0.43	1.5e-16	Uric acid levels;
LUSC	cis	rs1891275	0.509	rs76313529	chr10:93443076	T/C	cg07889827	chr10:93443413	NA	-0.38	-8.35	-0.42	1.86e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6977660	0.714	rs10224920	chr7:19816173	A/T	cg07541023	chr7:19748670	TWISTNB	0.62	6.77	0.35	5.83e-11	Thyroid stimulating hormone;
LUSC	trans	rs2587949	0.571	rs2587916	chr3:4185379	T/C	cg15139668	chr4:4577005	NA	-0.43	-5.96	-0.31	6.24e-9	Periodontitis (DPAL);
LUSC	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg13256891	chr4:100009986	ADH5	0.51	6.96	0.36	1.79e-11	Smoking initiation;
LUSC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.88	-0.31	9.73e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg08213375	chr14:104286397	PPP1R13B	0.37	6.42	0.33	4.76e-10	Reticulocyte count;
LUSC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.88	-0.31	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6574644	1.000	rs6574639	chr14:81771541	C/T	cg01989461	chr14:81687754	GTF2A1	0.47	5.66	0.3	3.21e-8	Obesity-related traits;
LUSC	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.83	14.41	0.62	6.14e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs754133	0.964	rs894738	chr12:54417525	C/T	cg10005224	chr12:54424964	HOXC4;HOXC5	0.39	7.69	0.39	1.68e-13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
LUSC	cis	rs9311676	0.656	rs11708895	chr3:58403042	T/C	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.3e-10	Systemic lupus erythematosus;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14293776	chr19:12371199	NA	-0.48	-6.43	-0.33	4.34e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg24687543	chr11:63912206	MACROD1	0.48	5.84	0.3	1.26e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg16447950	chr5:562315	NA	-0.52	-6.88	-0.35	3e-11	Obesity-related traits;
LUSC	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg24642439	chr20:33292090	TP53INP2	0.5	7.45	0.38	8.24e-13	Height;
LUSC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.46	-0.42	8.76e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg06740227	chr12:86229804	RASSF9	0.39	6.1	0.32	2.98e-9	Major depressive disorder;
LUSC	cis	rs7614311	0.636	rs73117057	chr3:63915689	A/G	cg22134162	chr3:63841271	THOC7	-0.49	-6.1	-0.32	3.02e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg20991723	chr1:152506922	NA	0.48	8.93	0.44	2.85e-17	Hair morphology;
LUSC	cis	rs113835537	0.529	rs11227501	chr11:66274072	T/C	cg24851651	chr11:66362959	CCS	0.53	8.02	0.4	1.8e-14	Airway imaging phenotypes;
LUSC	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg22709100	chr7:91322751	NA	-0.39	-5.83	-0.3	1.32e-8	Breast cancer;
LUSC	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg16342193	chr10:102329863	NA	-0.34	-6.16	-0.32	2.12e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs1941687	0.563	rs7238931	chr18:31334993	G/A	cg27147174	chr7:100797783	AP1S1	-0.56	-8.87	-0.44	4.36e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg02153584	chr22:29168773	CCDC117	0.62	8.6	0.43	3.07e-16	Lymphocyte counts;
LUSC	trans	rs4724055	0.793	rs473147	chr7:41606407	G/T	cg23476065	chr7:151106043	WDR86	0.72	6.22	0.32	1.51e-9	Non-substance related behavioral disinhibition;
LUSC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg04944784	chr2:26401820	FAM59B	0.65	8.86	0.44	4.89e-17	Gut microbiome composition (summer);
LUSC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg01097406	chr16:89675127	NA	-0.34	-6.78	-0.35	5.4e-11	Vitiligo;
LUSC	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg11584989	chr19:19387371	SF4	0.58	6.97	0.36	1.74e-11	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6546537	0.550	rs72837959	chr2:69780762	C/T	cg10773587	chr2:69614142	GFPT1	-0.42	-6.66	-0.34	1.14e-10	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	6.77	0.35	5.96e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.47	-0.33	3.39e-10	Reticulocyte count;
LUSC	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.24	0.52	4.45e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg23711669	chr6:146136114	FBXO30	0.9	17.22	0.69	5.08e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.35	6.53	0.34	2.4e-10	Monocyte percentage of white cells;
LUSC	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.72	-11.95	-0.55	1.22e-27	Retinal vascular caliber;
LUSC	cis	rs4974559	0.739	rs28429103	chr4:1320023	G/A	cg02980000	chr4:1222292	CTBP1	1.04	9.63	0.47	1.54e-19	Systolic blood pressure;
LUSC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.7	11.58	0.54	2.64e-26	Heart rate;
LUSC	cis	rs3770081	1.000	rs12620810	chr2:86391481	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.04	-7.32	-0.37	1.86e-12	Facial emotion recognition (sad faces);
LUSC	cis	rs1044826	1.000	rs1586863	chr3:139138242	C/G	cg00490450	chr3:139108681	COPB2	0.55	7.32	0.37	1.82e-12	Obesity-related traits;
LUSC	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.94	-0.31	7.19e-9	Reticulocyte count;
LUSC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg09359103	chr1:154839909	KCNN3	-0.7	-15.74	-0.65	3.87e-42	Prostate cancer;
LUSC	cis	rs2979489	1.000	rs2979469	chr8:30285091	C/G	cg26383811	chr8:30366931	RBPMS	0.43	6.49	0.33	3.09e-10	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs858239	0.570	rs10271613	chr7:23162586	G/A	cg23682824	chr7:23144976	KLHL7	0.38	5.67	0.3	3.03e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg18132916	chr6:79620363	NA	-0.38	-5.81	-0.3	1.44e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg11764359	chr7:65958608	NA	0.52	6.85	0.35	3.5e-11	Aortic root size;
LUSC	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg26395211	chr5:140044315	WDR55	-0.37	-5.78	-0.3	1.74e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs79911532	0.515	rs113229120	chr7:75748581	C/T	cg03592824	chr7:75666768	STYXL1	0.67	6.39	0.33	5.7e-10	Mononucleosis;
LUSC	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.94	-21.04	-0.76	3.45e-63	Longevity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00394725	chr7:75024729	TRIM74;TRIM73	0.38	6.23	0.32	1.42e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-0.82	-12.46	-0.56	1.59e-29	Gut microbiome composition (summer);
LUSC	trans	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg26384229	chr12:38710491	ALG10B	0.56	8.85	0.44	5.37e-17	Morning vs. evening chronotype;
LUSC	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	0.8	9.85	0.47	2.9e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs7215564	0.908	rs34547024	chr17:78661373	C/G	cg09596252	chr17:78655493	RPTOR	0.54	5.94	0.31	7.02e-9	Myopia (pathological);
LUSC	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.0	0.36	1.39e-11	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.07	15.31	0.64	1.78e-40	Uric acid levels;
LUSC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	8.56	0.42	4.23e-16	Coronary artery disease;
LUSC	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg26395211	chr5:140044315	WDR55	0.45	6.93	0.35	2.14e-11	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs4363385	0.626	rs6664183	chr1:153064002	A/G	cg17486066	chr1:34330045	HMGB4;CSMD2	0.29	5.95	0.31	6.92e-9	Inflammatory skin disease;
LUSC	cis	rs6087990	0.871	rs1007122	chr20:31346001	C/T	cg13636640	chr20:31349939	DNMT3B	0.95	19.5	0.73	4.47e-57	Ulcerative colitis;
LUSC	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	0.97	7.93	0.4	3.23e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg12432903	chr7:1882776	MAD1L1	0.53	6.7	0.34	9.1e-11	Bipolar disorder;
LUSC	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.38	6.16	0.32	2.05e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg13535736	chr9:111863775	C9orf5	-0.39	-6.41	-0.33	4.93e-10	Menarche (age at onset);
LUSC	trans	rs72674100	1.000	rs28572591	chr4:97986135	G/A	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26981251	chr19:59055609	TRIM28	-0.41	-6.06	-0.31	3.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg03342759	chr3:160939853	NMD3	-0.57	-9.81	-0.47	4.11e-20	Morning vs. evening chronotype;
LUSC	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg09754948	chr16:28834200	ATXN2L	0.41	5.86	0.31	1.13e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.65	10.98	0.52	3.69e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	8.07	0.4	1.3e-14	Multiple sclerosis;
LUSC	cis	rs7827545	1.000	rs7008158	chr8:135565982	T/C	cg17885191	chr8:135476712	NA	0.56	8.35	0.42	1.87e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.52	8.63	0.43	2.51e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-0.73	-11.79	-0.54	4.7e-27	Height;
LUSC	cis	rs3741798	1.000	rs61922054	chr12:12499472	A/G	cg08615371	chr12:12503544	MANSC1	1.09	11.16	0.52	8.68e-25	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg20608306	chr11:116969690	SIK3	0.37	6.97	0.36	1.73e-11	Blood protein levels;
LUSC	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07080220	chr10:102295463	HIF1AN	0.59	7.86	0.4	5.23e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg02574844	chr11:5959923	NA	-0.45	-6.22	-0.32	1.51e-9	DNA methylation (variation);
LUSC	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg20587970	chr11:113659929	NA	-1.3	-16.35	-0.67	1.49e-44	Hip circumference adjusted for BMI;
LUSC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg18451016	chr1:38461880	NA	-0.48	-6.91	-0.35	2.47e-11	Coronary artery disease;
LUSC	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg11502198	chr6:26597334	ABT1	0.62	9.85	0.47	2.95e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg06521331	chr12:34319734	NA	-0.4	-6.09	-0.32	3.07e-9	Bladder cancer;
LUSC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.51	-0.42	5.88e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg14668632	chr7:2872130	GNA12	-0.45	-6.68	-0.34	9.86e-11	Height;
LUSC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg03605463	chr16:89740564	NA	0.6	9.41	0.46	8.23e-19	Vitiligo;
LUSC	cis	rs12541635	0.966	rs2059943	chr8:107071607	G/T	cg10147462	chr8:107024639	NA	0.53	9.59	0.46	2.12e-19	Age of smoking initiation;
LUSC	cis	rs1535500	0.967	rs11756070	chr6:39282748	G/A	cg06347083	chr6:39282316	KCNK17	-0.29	-6.27	-0.32	1.14e-9	Type 2 diabetes;
LUSC	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg16359550	chr11:109292809	C11orf87	0.34	5.99	0.31	5.43e-9	Schizophrenia;
LUSC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06850241	chr22:41845214	NA	0.35	6.29	0.33	9.8e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg03676636	chr4:99064102	C4orf37	0.36	7.72	0.39	1.36e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs500891	0.553	rs1112483	chr6:84112033	G/A	cg08257003	chr6:84140564	ME1	0.34	7.6	0.38	3.06e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03352830	chr11:487213	PTDSS2	0.71	8.55	0.42	4.65e-16	Body mass index;
LUSC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	6.81	0.35	4.54e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2625529	0.652	rs7497104	chr15:72154000	C/T	cg16672083	chr15:72433130	SENP8	-0.48	-8.11	-0.41	9.49e-15	Red blood cell count;
LUSC	cis	rs2262909	0.962	rs4932952	chr19:22246788	G/A	cg11619707	chr19:22235551	ZNF257	0.39	5.83	0.3	1.29e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6496044	0.611	rs8026938	chr15:86069118	G/T	cg13263323	chr15:86062960	AKAP13	0.37	5.96	0.31	6.44e-9	Interstitial lung disease;
LUSC	cis	rs1790761	0.505	rs7941395	chr11:67347417	A/G	cg24690094	chr11:67383802	NA	-0.3	-5.71	-0.3	2.46e-8	Mean corpuscular volume;
LUSC	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg09835421	chr16:68378352	PRMT7	-0.56	-6.31	-0.33	8.67e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10905065	0.862	rs9423948	chr10:5742491	G/A	cg11519256	chr10:5708881	ASB13	0.41	6.03	0.31	4.26e-9	Menopause (age at onset);
LUSC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03517284	chr6:25882590	NA	-0.52	-9.88	-0.48	2.37e-20	Blood metabolite levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00323305	chr3:24537182	THRB	0.7	5.99	0.31	5.55e-9	Cognitive performance;
LUSC	cis	rs10208940	0.920	rs6742045	chr2:68811850	G/A	cg12452813	chr2:68675892	NA	0.59	6.08	0.32	3.21e-9	Urate levels in lean individuals;
LUSC	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg19640130	chr10:64028056	RTKN2	-0.4	-7.1	-0.36	7.61e-12	Rheumatoid arthritis;
LUSC	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg21466736	chr12:48725269	NA	-0.29	-5.84	-0.3	1.21e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs4589502	0.614	rs17273637	chr15:67193084	C/T	cg09911534	chr15:67153556	NA	-0.59	-5.73	-0.3	2.21e-8	Lung cancer (smoking interaction);
LUSC	cis	rs7267979	0.586	rs6050432	chr20:25184028	T/C	cg08601574	chr20:25228251	PYGB	0.44	6.68	0.34	1e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4911259	0.552	rs2014837	chr20:31461082	C/T	cg13636640	chr20:31349939	DNMT3B	0.78	14.96	0.63	4.23e-39	Inflammatory bowel disease;
LUSC	cis	rs4363385	0.693	rs6656812	chr1:152930254	C/T	cg07796016	chr1:152779584	LCE1C	0.42	6.08	0.32	3.3e-9	Inflammatory skin disease;
LUSC	cis	rs1395	0.778	rs34618115	chr2:27418289	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.27	0.37	2.64e-12	Blood metabolite levels;
LUSC	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg23711669	chr6:146136114	FBXO30	0.83	14.52	0.62	2.22e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.6	10.32	0.49	7.29e-22	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	8.84	0.44	5.53e-17	Lung cancer in ever smokers;
LUSC	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	13.53	0.59	1.49e-33	Lymphocyte percentage of white cells;
LUSC	cis	rs4730250	0.707	rs80095766	chr7:106901394	G/T	cg02696742	chr7:106810147	HBP1	-0.63	-9.64	-0.47	1.45e-19	Osteoarthritis;
LUSC	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.91	-0.35	2.41e-11	Coronary artery disease;
LUSC	cis	rs859767	0.501	rs1568120	chr2:135406890	A/G	cg12500956	chr2:135428796	TMEM163	-0.27	-6.29	-0.33	9.76e-10	Neuroticism;
LUSC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg23262073	chr20:60523788	NA	-0.42	-6.07	-0.32	3.45e-9	Body mass index;
LUSC	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.53	-0.38	4.91e-13	Retinal vascular caliber;
LUSC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	0.88	15.29	0.64	2.2e-40	Gestational age at birth (maternal effect);
LUSC	cis	rs1712517	0.744	rs4293063	chr10:105052976	G/T	cg05636881	chr10:105038444	INA	0.39	6.32	0.33	8.31e-10	Migraine;
LUSC	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg11342453	chr6:26196699	NA	0.55	5.78	0.3	1.7e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs7584330	0.518	rs11884238	chr2:238424671	T/G	cg16989719	chr2:238392110	NA	-0.4	-5.84	-0.3	1.27e-8	Prostate cancer;
LUSC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.56	0.34	2.05e-10	Schizophrenia;
LUSC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.76	13.71	0.6	3.13e-34	Calcium levels;
LUSC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08219700	chr8:58056026	NA	0.64	8.19	0.41	5.6e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg26354017	chr1:205819088	PM20D1	0.43	5.75	0.3	2.02e-8	Menarche (age at onset);
LUSC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg07701084	chr6:150067640	NUP43	0.57	8.69	0.43	1.6e-16	Lung cancer;
LUSC	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.56	-0.34	2.01e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9361491	0.508	rs7773448	chr6:79417356	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.66	-0.3	3.34e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg15445000	chr17:37608096	MED1	-0.39	-6.75	-0.35	6.68e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.65	-10.25	-0.49	1.28e-21	Menarche (age at onset);
LUSC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg16558253	chr16:72132732	DHX38	-0.41	-6.32	-0.33	8.5e-10	Fibrinogen levels;
LUSC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg06454157	chr6:167490870	NA	-0.25	-5.96	-0.31	6.44e-9	Crohn's disease;
LUSC	trans	rs1922233	0.843	rs6854368	chr4:92365952	T/A	cg24250684	chr1:219729030	NA	-0.32	-6.0	-0.31	5.17e-9	Gut microbiome composition (summer and winter);
LUSC	cis	rs12618769	0.597	rs17033136	chr2:99149404	C/T	cg10123293	chr2:99228465	UNC50	-0.46	-7.65	-0.39	2.1e-13	Bipolar disorder;
LUSC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04267008	chr7:1944627	MAD1L1	0.42	6.15	0.32	2.27e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg15445000	chr17:37608096	MED1	-0.4	-6.44	-0.33	4.04e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs9359856	0.600	rs1179899	chr6:90320258	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-8.17	-0.41	6.36e-15	Bipolar disorder;
LUSC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg25319279	chr11:5960081	NA	-0.39	-6.01	-0.31	4.83e-9	DNA methylation (variation);
LUSC	cis	rs1595825	0.891	rs7585709	chr2:198883682	C/T	cg00982548	chr2:198649783	BOLL	-0.54	-6.93	-0.35	2.2e-11	Ulcerative colitis;
LUSC	cis	rs10465746	0.780	rs2147392	chr1:84404154	C/A	cg10977910	chr1:84465055	TTLL7	0.45	6.54	0.34	2.29e-10	Obesity-related traits;
LUSC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg05425664	chr17:57184151	TRIM37	0.54	8.01	0.4	1.88e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs427941	0.632	rs201480	chr7:101747575	A/G	cg06246474	chr7:101738831	CUX1	0.39	6.39	0.33	5.42e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7582720	1.000	rs72932558	chr2:203847325	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.35	0.42	1.88e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-7.23	-0.37	3.22e-12	Menopause (age at onset);
LUSC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.82	-13.18	-0.59	3.04e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg09835421	chr16:68378352	PRMT7	-0.75	-8.42	-0.42	1.13e-15	Schizophrenia;
LUSC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.45	-7.96	-0.4	2.78e-14	Eosinophil percentage of white cells;
LUSC	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg21251018	chr6:28226885	NKAPL	0.31	5.95	0.31	6.94e-9	Cardiac Troponin-T levels;
LUSC	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.24	0.52	4.42e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg27074582	chr2:240114406	HDAC4	0.44	7.0	0.36	1.38e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg17168535	chr8:21777572	XPO7	-0.59	-8.74	-0.43	1.19e-16	Mean corpuscular volume;
LUSC	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg08975724	chr8:8085496	FLJ10661	0.42	5.97	0.31	6.03e-9	Joint mobility (Beighton score);
LUSC	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.72	-13.53	-0.59	1.51e-33	Ulcerative colitis;
LUSC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6429082	0.715	rs2153204	chr1:235580382	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-7.95	-0.4	2.89e-14	Adiposity;
LUSC	cis	rs72634258	0.740	rs4489581	chr1:8174495	A/C	cg26816564	chr1:7831052	VAMP3	-0.44	-5.76	-0.3	1.96e-8	Inflammatory bowel disease;
LUSC	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg05340658	chr4:99064831	C4orf37	-0.46	-7.27	-0.37	2.5e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.61	-8.44	-0.42	1.01e-15	Mean platelet volume;
LUSC	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-6.66	-0.34	1.11e-10	Bipolar disorder;
LUSC	trans	rs656319	0.513	rs6985941	chr8:9983179	C/T	cg21775007	chr8:11205619	TDH	-0.47	-6.44	-0.33	4.19e-10	Myopia (pathological);
LUSC	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.29	-0.33	1.01e-9	Triglycerides;
LUSC	cis	rs4764124	0.646	rs2075268	chr12:14956476	A/G	cg19759883	chr12:14956454	WBP11;C12orf60	0.38	5.86	0.31	1.14e-8	Pubertal anthropometrics;
LUSC	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg22875332	chr1:76189707	ACADM	-0.42	-6.49	-0.33	3.14e-10	Daytime sleep phenotypes;
LUSC	cis	rs7575217	0.697	rs6727703	chr2:101698533	G/T	cg23907051	chr2:101730305	TBC1D8	0.28	7.61	0.38	2.76e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg12463550	chr7:65579703	CRCP	0.48	6.69	0.34	9.43e-11	Aortic root size;
LUSC	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg10253484	chr15:75165896	SCAMP2	0.39	5.67	0.3	3.07e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs28830936	0.934	rs3959569	chr15:42115747	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.88	-0.31	1.01e-8	Diastolic blood pressure;
LUSC	cis	rs9644630	0.897	rs17128525	chr8:19364006	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.33	-6.42	-0.33	4.65e-10	Oropharynx cancer;
LUSC	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2882667	0.898	rs6863347	chr5:138361135	C/T	cg04439458	chr5:138467593	SIL1	-0.39	-7.81	-0.39	7.32e-14	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6696846	0.515	rs10900450	chr1:205106238	C/G	cg00857998	chr1:205179979	DSTYK	0.48	6.81	0.35	4.45e-11	Red blood cell count;
LUSC	cis	rs7589342	0.839	rs12995333	chr2:106436366	A/C	cg16077055	chr2:106428750	NCK2	-0.37	-7.14	-0.36	5.97e-12	Addiction;
LUSC	cis	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg21775007	chr8:11205619	TDH	-0.58	-7.74	-0.39	1.23e-13	Triglycerides;
LUSC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.98	0.4	2.38e-14	Parkinson's disease;
LUSC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-1.01	-14.63	-0.62	8.61e-38	Initial pursuit acceleration;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11296937	chr11:64084966	PRDX5;TRMT112	-0.5	-6.47	-0.33	3.45e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg17420585	chr12:42539391	GXYLT1	-0.38	-7.44	-0.38	8.78e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	0.82	12.46	0.56	1.59e-29	Gut microbiome composition (summer);
LUSC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.81	0.3	1.43e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-0.53	-7.96	-0.4	2.69e-14	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21326301	chr3:180397115	CCDC39	0.41	5.94	0.31	7.05e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-0.99	-14.45	-0.62	4.26e-37	Initial pursuit acceleration;
LUSC	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg25124228	chr12:125621409	AACS	-0.57	-8.95	-0.44	2.55e-17	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3764021	0.870	rs10844622	chr12:9885082	G/A	cg20894963	chr12:9885564	CLECL1	0.34	6.98	0.36	1.64e-11	Type 1 diabetes;
LUSC	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg23992470	chr4:843637	GAK	0.53	5.66	0.3	3.22e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg16558253	chr16:72132732	DHX38	-0.41	-5.7	-0.3	2.63e-8	Blood protein levels;
LUSC	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg19637330	chr1:19110922	NA	-0.39	-5.76	-0.3	1.95e-8	Knee osteoarthritis;
LUSC	cis	rs6484504	0.779	rs16921914	chr11:31210771	G/A	cg06552810	chr11:31128660	NA	-0.41	-6.4	-0.33	5.13e-10	Red blood cell count;
LUSC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg23985595	chr17:80112537	CCDC57	0.32	6.22	0.32	1.45e-9	Life satisfaction;
LUSC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg06808227	chr14:105710500	BRF1	-0.68	-10.44	-0.5	2.91e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg19920283	chr7:105172520	RINT1	0.58	6.11	0.32	2.71e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg08213375	chr14:104286397	PPP1R13B	0.52	10.4	0.49	3.86e-22	Schizophrenia;
LUSC	trans	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-9.08	-0.44	9.63e-18	Depression;
LUSC	cis	rs722599	0.683	rs7145246	chr14:75242394	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.4	-5.69	-0.3	2.84e-8	IgG glycosylation;
LUSC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	0.62	7.2	0.37	3.95e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7586879	0.796	rs11684619	chr2:25078859	G/A	cg01884057	chr2:25150051	NA	0.39	8.03	0.4	1.63e-14	Body mass index;
LUSC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08219700	chr8:58056026	NA	0.63	7.97	0.4	2.45e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg04990556	chr1:26633338	UBXN11	0.88	11.64	0.54	1.61e-26	Obesity-related traits;
LUSC	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg05187965	chr10:45406764	TMEM72	-0.36	-8.38	-0.42	1.49e-15	Mean corpuscular volume;
LUSC	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21659725	chr3:3221576	CRBN	-0.64	-10.53	-0.5	1.4e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg15423357	chr2:25149977	NA	0.31	6.02	0.31	4.57e-9	Breast cancer;
LUSC	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.4	-5.92	-0.31	8.14e-9	Blood metabolite levels;
LUSC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg03146154	chr1:46216737	IPP	0.5	7.41	0.38	1.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs497273	0.553	rs508595	chr12:121198891	C/G	cg02419362	chr12:121203948	SPPL3	0.43	7.9	0.4	4.05e-14	Systemic lupus erythematosus;
LUSC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg25258033	chr6:167368657	RNASET2	0.39	6.3	0.33	9.49e-10	Crohn's disease;
LUSC	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg06547715	chr2:218990976	CXCR2	-0.32	-6.43	-0.33	4.46e-10	Ulcerative colitis;
LUSC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg20476274	chr7:133979776	SLC35B4	0.85	15.9	0.66	9.04e-43	Mean platelet volume;
LUSC	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-6.04	-0.31	4.06e-9	Parkinson's disease;
LUSC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg02187348	chr16:89574699	SPG7	0.49	7.48	0.38	6.67e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg13334819	chr7:99746414	C7orf59	0.5	6.68	0.34	9.99e-11	Coronary artery disease;
LUSC	cis	rs62400317	0.762	rs17423748	chr6:44943982	T/C	cg20913747	chr6:44695427	NA	-0.46	-7.2	-0.37	3.91e-12	Total body bone mineral density;
LUSC	cis	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.41	-6.1	-0.32	3e-9	IgG glycosylation;
LUSC	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-10.38	-0.49	4.68e-22	Menopause (age at onset);
LUSC	cis	rs911119	1.000	rs13041070	chr20:23614261	G/A	cg16589663	chr20:23618590	CST3	0.6	7.03	0.36	1.15e-11	Chronic kidney disease;
LUSC	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.64	0.47	1.43e-19	Coffee consumption (cups per day);
LUSC	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	11.64	0.54	1.65e-26	Menarche (age at onset);
LUSC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.6	-9.47	-0.46	5.4e-19	HDL cholesterol;
LUSC	cis	rs9398803	0.865	rs9385400	chr6:126764190	G/T	cg19875578	chr6:126661172	C6orf173	-0.39	-5.81	-0.3	1.42e-8	Male-pattern baldness;
LUSC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.52	0.46	3.68e-19	Bipolar disorder;
LUSC	cis	rs829883	0.763	rs249843	chr12:98870987	G/A	cg25150519	chr12:98850993	NA	0.78	13.62	0.6	6.8e-34	Colorectal adenoma (advanced);
LUSC	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg02640540	chr1:67518911	SLC35D1	-0.5	-7.18	-0.37	4.43e-12	Lymphocyte percentage of white cells;
LUSC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg04455712	chr21:45112962	RRP1B	0.45	8.46	0.42	8.61e-16	Mean corpuscular volume;
LUSC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	7.97	0.4	2.54e-14	Homoarginine levels;
LUSC	cis	rs2637266	0.626	rs724113	chr10:78557309	C/T	cg18941641	chr10:78392320	NA	0.38	7.03	0.36	1.19e-11	Pulmonary function;
LUSC	cis	rs727505	0.866	rs67724276	chr7:124719719	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.89	-0.35	2.79e-11	Lewy body disease;
LUSC	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg17644776	chr2:200775616	C2orf69	0.39	6.24	0.32	1.29e-9	Osteoporosis;
LUSC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.55	-8.68	-0.43	1.83e-16	Personality dimensions;
LUSC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18876405	chr7:65276391	NA	0.5	6.88	0.35	2.93e-11	Corneal structure;
LUSC	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-6.94	-0.36	2.02e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.38	-0.42	1.49e-15	Total cholesterol levels;
LUSC	cis	rs2067615	0.524	rs754184	chr12:107117521	A/G	cg15890332	chr12:107067104	RFX4	0.34	6.11	0.32	2.8e-9	Heart rate;
LUSC	cis	rs10979	1.000	rs9376760	chr6:143886969	C/T	cg25407410	chr6:143891975	LOC285740	-0.7	-11.21	-0.52	5.61e-25	Hypospadias;
LUSC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg06028605	chr16:24865363	SLC5A11	0.44	8.01	0.4	1.97e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg00757033	chr12:89920650	WDR51B	0.59	10.4	0.49	3.99e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4589502	0.920	rs77518050	chr15:67138089	T/C	cg09911534	chr15:67153556	NA	-0.69	-6.93	-0.35	2.15e-11	Lung cancer (smoking interaction);
LUSC	cis	rs113835537	0.529	rs2279864	chr11:66247844	G/A	cg24851651	chr11:66362959	CCS	0.54	8.02	0.4	1.77e-14	Airway imaging phenotypes;
LUSC	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-10.72	-0.51	3.01e-23	Mean corpuscular volume;
LUSC	cis	rs11209002	0.592	rs7551197	chr1:67588090	A/T	cg02640540	chr1:67518911	SLC35D1	0.58	8.16	0.41	7.01e-15	Crohn's disease;
LUSC	cis	rs870825	0.549	rs28579266	chr4:185627262	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.77e-32	Blood protein levels;
LUSC	cis	rs859767	0.501	rs12691869	chr2:135407641	T/C	cg12500956	chr2:135428796	TMEM163	-0.27	-6.44	-0.33	4.25e-10	Neuroticism;
LUSC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg16606324	chr3:10149918	C3orf24	0.62	9.12	0.45	7.2e-18	Alzheimer's disease;
LUSC	cis	rs4423214	0.592	rs7120029	chr11:71198957	G/A	cg05163923	chr11:71159392	DHCR7	-0.7	-7.32	-0.37	1.82e-12	Vitamin D levels;
LUSC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg05299278	chr17:33885742	SLFN14	0.29	6.44	0.33	4.09e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg27129171	chr3:47204927	SETD2	0.72	12.42	0.56	2.16e-29	Colorectal cancer;
LUSC	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg25214090	chr10:38739885	LOC399744	0.52	7.75	0.39	1.15e-13	Corneal astigmatism;
LUSC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.61	-6.19	-0.32	1.77e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg04871131	chr7:94954202	PON1	-0.37	-5.89	-0.31	9.34e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs17401966	0.867	rs6696056	chr1:10305992	C/A	cg19773385	chr1:10388646	KIF1B	-0.53	-9.18	-0.45	4.63e-18	Hepatocellular carcinoma;
LUSC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11645453	chr3:52864694	ITIH4	0.35	8.2	0.41	5.41e-15	Electroencephalogram traits;
LUSC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08677398	chr8:58056175	NA	0.52	6.08	0.32	3.29e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg16482183	chr6:26056742	HIST1H1C	0.42	6.08	0.32	3.28e-9	Height;
LUSC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg15147215	chr3:52552868	STAB1	0.3	5.98	0.31	5.77e-9	Bipolar disorder;
LUSC	cis	rs4363385	0.818	rs10888525	chr1:153000215	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.11	-0.36	7.29e-12	Inflammatory skin disease;
LUSC	cis	rs10170846	0.893	rs11692810	chr2:223544096	A/C	cg25565276	chr2:223520875	FARSB	-0.58	-8.62	-0.43	2.79e-16	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs7712401	0.755	rs27740	chr5:122204772	A/T	cg19077854	chr5:122220652	SNX24	-0.35	-8.5	-0.42	6.27e-16	Mean platelet volume;
LUSC	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg02196730	chr15:80188777	MTHFS	0.4	6.03	0.31	4.39e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg12552261	chr5:112820674	MCC	-0.44	-6.96	-0.36	1.77e-11	Type 2 diabetes;
LUSC	cis	rs7973719	0.865	rs1057225	chr12:7363574	C/G	cg07052231	chr12:7363540	PEX5	0.52	9.02	0.44	1.53e-17	IgG glycosylation;
LUSC	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg15704280	chr7:45808275	SEPT13	0.71	6.66	0.34	1.1e-10	Intraocular pressure;
LUSC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg15448220	chr1:150897856	SETDB1	0.38	5.83	0.3	1.28e-8	Melanoma;
LUSC	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.42	6.66	0.34	1.16e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs4654899	0.865	rs10493006	chr1:21375904	G/A	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.18	-0.32	1.88e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg05805236	chr11:65401703	PCNXL3	-0.48	-7.64	-0.39	2.32e-13	Non-alcoholic fatty liver disease histology (lobular);
LUSC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg23978390	chr7:1156363	C7orf50	0.49	5.68	0.3	2.86e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg04539111	chr16:67997858	SLC12A4	-0.45	-6.11	-0.32	2.71e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg09021430	chr5:549028	NA	-0.56	-7.67	-0.39	1.96e-13	Obesity-related traits;
LUSC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03517284	chr6:25882590	NA	-0.41	-7.2	-0.37	3.92e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2242663	0.705	rs551708	chr11:66486143	T/C	cg18002602	chr11:66138449	SLC29A2	0.38	6.59	0.34	1.68e-10	Bipolar disorder;
LUSC	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg24399712	chr22:39784796	NA	-0.51	-7.11	-0.36	6.88e-12	IgG glycosylation;
LUSC	trans	rs7939886	0.920	rs11227222	chr11:55876393	G/T	cg03929089	chr4:120376271	NA	-0.71	-6.09	-0.32	3.18e-9	Myopia (pathological);
LUSC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg15557168	chr22:42548783	NA	0.46	7.14	0.36	5.78e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg12560992	chr17:57184187	TRIM37	0.83	15.26	0.64	2.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.83	-11.19	-0.52	6.78e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg08048268	chr3:133502702	NA	-0.41	-7.41	-0.38	1.07e-12	Iron status biomarkers;
LUSC	trans	rs7286472	0.748	rs13057320	chr22:34365442	C/T	cg12297329	chr5:152029980	NA	-0.61	-6.32	-0.33	8.56e-10	Blood pressure measurement (cold pressor test);
LUSC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24110177	chr3:50126178	RBM5	-0.61	-10.47	-0.5	2.29e-22	Body mass index;
LUSC	trans	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.69	-10.7	-0.51	3.53e-23	Aortic root size;
LUSC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg13206674	chr6:150067644	NUP43	0.62	9.69	0.47	1.01e-19	Lung cancer;
LUSC	cis	rs60154123	0.730	rs10779528	chr1:210457378	C/T	cg22029157	chr1:209979665	IRF6	0.52	5.96	0.31	6.32e-9	Coronary artery disease;
LUSC	cis	rs9487051	0.735	rs351756	chr6:109538773	A/G	cg12927641	chr6:109611667	NA	0.35	5.79	0.3	1.61e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7189233	0.911	rs8057808	chr16:53520613	G/A	cg04059762	chr16:53544020	NA	-0.34	-6.09	-0.32	3.09e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11198358	chr17:47928494	NA	0.71	6.25	0.32	1.24e-9	Cognitive performance;
LUSC	trans	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg17675199	chr6:35436792	RPL10A	-0.4	-5.95	-0.31	6.75e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg04362960	chr10:104952993	NT5C2	-0.62	-9.87	-0.48	2.52e-20	Arsenic metabolism;
LUSC	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg01191920	chr7:158217561	PTPRN2	0.46	9.26	0.45	2.62e-18	Obesity-related traits;
LUSC	cis	rs9837602	1.000	rs17379739	chr3:99724792	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.96	-0.31	6.33e-9	Breast cancer;
LUSC	cis	rs36093844	0.747	rs17817314	chr11:85594972	T/C	cg16165120	chr11:85566439	CCDC83	-0.39	-5.65	-0.3	3.42e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg04944784	chr2:26401820	FAM59B	-0.75	-10.88	-0.51	8.22e-24	Gut microbiome composition (summer);
LUSC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg06740227	chr12:86229804	RASSF9	-0.41	-6.68	-0.34	1.02e-10	Major depressive disorder;
LUSC	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg04352962	chr1:209979756	IRF6	0.55	6.37	0.33	6.41e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.11	-0.32	2.84e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg13010199	chr12:38710504	ALG10B	0.54	8.24	0.41	3.83e-15	Heart rate;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg08172044	chr6:126070462	HEY2	0.75	6.35	0.33	7.01e-10	Cognitive performance;
LUSC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg12560992	chr17:57184187	TRIM37	-0.85	-15.42	-0.64	6.9e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg05347473	chr6:146136440	FBXO30	0.52	8.87	0.44	4.42e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg25797454	chr6:150327115	RAET1K	0.32	7.31	0.37	1.99e-12	Alopecia areata;
LUSC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.32	-5.92	-0.31	8.13e-9	IgG glycosylation;
LUSC	cis	rs7827545	1.000	rs1372660	chr8:135566788	C/G	cg17885191	chr8:135476712	NA	0.57	8.55	0.42	4.4e-16	Hypertension (SNP x SNP interaction);
LUSC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg13770153	chr20:60521292	NA	-0.63	-8.38	-0.42	1.45e-15	Body mass index;
LUSC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg16606324	chr3:10149918	C3orf24	0.63	9.16	0.45	5.37e-18	Alzheimer's disease;
LUSC	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.83	-0.3	1.32e-8	Coronary artery disease;
LUSC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg12463550	chr7:65579703	CRCP	-0.44	-6.27	-0.32	1.1e-9	Aortic root size;
LUSC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg08270630	chr22:50330655	NA	-0.43	-6.39	-0.33	5.55e-10	Schizophrenia;
LUSC	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg22709100	chr7:91322751	NA	0.39	5.8	0.3	1.55e-8	Breast cancer;
LUSC	trans	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-6.8	-0.35	4.92e-11	Monocyte count;
LUSC	cis	rs113835537	0.529	rs11227512	chr11:66281291	T/C	cg24851651	chr11:66362959	CCS	0.53	7.93	0.4	3.42e-14	Airway imaging phenotypes;
LUSC	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg24011408	chr12:48396354	COL2A1	-0.53	-8.72	-0.43	1.35e-16	Plateletcrit;
LUSC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg18305652	chr10:134549665	INPP5A	0.44	6.75	0.35	6.37e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-6.64	-0.34	1.27e-10	Morning vs. evening chronotype;
LUSC	cis	rs4132509	0.744	rs6687181	chr1:243878518	C/T	cg21452805	chr1:244014465	NA	0.63	6.89	0.35	2.74e-11	RR interval (heart rate);
LUSC	cis	rs73198271	0.562	rs75525911	chr8:8659359	C/A	cg01851573	chr8:8652454	MFHAS1	0.67	8.93	0.44	2.9e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.67	10.8	0.51	1.61e-23	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9322817	0.691	rs6907016	chr6:105211360	G/A	cg02098413	chr6:105308735	HACE1	-0.28	-5.78	-0.3	1.73e-8	Thyroid stimulating hormone;
LUSC	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg07828024	chr6:149772892	ZC3H12D	-0.32	-6.92	-0.35	2.3e-11	Dupuytren's disease;
LUSC	cis	rs9479482	0.678	rs3903885	chr6:150364128	G/A	cg00432049	chr6:150390894	ULBP3	-0.29	-6.38	-0.33	6.07e-10	Alopecia areata;
LUSC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg08847533	chr14:75593920	NEK9	-0.78	-13.37	-0.59	5.91e-33	Height;
LUSC	cis	rs4680	1.000	rs165722	chr22:19949013	C/T	cg22546130	chr22:19950026	COMT	0.26	5.74	0.3	2.12e-8	Blood metabolite levels;
LUSC	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg03929089	chr4:120376271	NA	0.74	6.91	0.35	2.4e-11	Axial length;
LUSC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.44	6.49	0.33	3.06e-10	Systemic lupus erythematosus;
LUSC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.2	-0.37	3.9e-12	Bipolar disorder;
LUSC	cis	rs9948	0.655	rs3731940	chr2:97377883	A/G	cg01990225	chr2:97406019	LMAN2L	0.75	5.68	0.3	3e-8	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs4704187	0.687	rs6885071	chr5:74460045	A/G	cg03227963	chr5:74354835	NA	0.32	6.83	0.35	4.02e-11	Response to amphetamines;
LUSC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg10755058	chr3:40428713	ENTPD3	0.34	5.73	0.3	2.19e-8	Renal cell carcinoma;
LUSC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08677398	chr8:58056175	NA	0.58	7.01	0.36	1.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg09877947	chr5:131593287	PDLIM4	0.44	6.92	0.35	2.26e-11	Breast cancer;
LUSC	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg15133208	chr4:90757351	SNCA	-0.5	-7.44	-0.38	8.32e-13	Neuroticism;
LUSC	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg04539111	chr16:67997858	SLC12A4	-0.43	-5.96	-0.31	6.47e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4363385	0.588	rs1577960	chr1:153025687	G/A	cg25856811	chr1:152973957	SPRR3	-0.36	-6.01	-0.31	4.88e-9	Inflammatory skin disease;
LUSC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.17	-0.32	1.98e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg19592336	chr6:28129416	ZNF389	0.44	5.75	0.3	2.01e-8	Parkinson's disease;
LUSC	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg01616529	chr11:638424	DRD4	-0.35	-6.02	-0.31	4.64e-9	Systemic lupus erythematosus;
LUSC	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg23711669	chr6:146136114	FBXO30	0.85	15.24	0.64	3.52e-40	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs62238980	0.614	rs117358438	chr22:32374532	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg10057126	chr4:77819792	ANKRD56	0.48	6.78	0.35	5.45e-11	Emphysema distribution in smoking;
LUSC	cis	rs11785693	0.862	rs11786595	chr8:5001621	T/G	cg26367366	chr8:4980734	NA	0.73	8.38	0.42	1.46e-15	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs1461503	0.868	rs10790543	chr11:122838311	A/C	cg27398637	chr11:122830231	C11orf63	-0.4	-6.34	-0.33	7.32e-10	Menarche (age at onset);
LUSC	trans	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.27	-0.32	1.12e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs7189233	0.955	rs8044205	chr16:53515093	T/C	cg09728985	chr16:53543985	NA	-0.34	-6.21	-0.32	1.55e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.69	11.87	0.54	2.4e-27	White blood cell count (basophil);
LUSC	cis	rs9534288	0.830	rs7987953	chr13:46634395	C/T	cg15192986	chr13:46630673	CPB2	-0.8	-12.65	-0.57	3.2e-30	Blood protein levels;
LUSC	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg13010344	chr12:123464640	ARL6IP4	-0.46	-5.72	-0.3	2.41e-8	Neutrophil percentage of white cells;
LUSC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.18	0.32	1.82e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg21361702	chr7:150065534	REPIN1	0.58	9.09	0.45	8.96e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	10.0	0.48	9.34e-21	Lymphocyte counts;
LUSC	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.41	-0.33	4.92e-10	High light scatter reticulocyte count;
LUSC	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg26875233	chr11:93583750	C11orf90	-0.3	-5.86	-0.31	1.13e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg20608306	chr11:116969690	SIK3	0.34	6.35	0.33	7.2e-10	Blood protein levels;
LUSC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.14	0.41	7.71e-15	Menarche (age at onset);
LUSC	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.05	-0.4	1.43e-14	Neuroticism;
LUSC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg24642439	chr20:33292090	TP53INP2	0.46	7.12	0.36	6.84e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg19774624	chr17:42201019	HDAC5	-0.46	-6.69	-0.34	9.28e-11	Total body bone mineral density;
LUSC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg02018176	chr4:1364513	KIAA1530	0.46	8.08	0.4	1.17e-14	Obesity-related traits;
LUSC	cis	rs965469	0.779	rs6051683	chr20:3237822	G/C	cg25506879	chr20:3388711	C20orf194	-0.49	-5.68	-0.3	2.88e-8	IFN-related cytopenia;
LUSC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.79	-0.43	8.19e-17	Bipolar disorder;
LUSC	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg26061582	chr7:22766209	IL6	0.48	6.98	0.36	1.56e-11	Lung cancer;
LUSC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.59	-9.68	-0.47	1.05e-19	Intelligence (multi-trait analysis);
LUSC	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.54	-0.42	4.88e-16	Depression;
LUSC	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg02549819	chr16:58548995	SETD6	0.96	9.0	0.44	1.74e-17	Schizophrenia;
LUSC	cis	rs11030122	0.632	rs4910596	chr11:4084604	A/G	cg08557956	chr11:4115526	RRM1	-0.46	-6.02	-0.31	4.66e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg19592336	chr6:28129416	ZNF389	0.47	6.19	0.32	1.75e-9	Depression;
LUSC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18876405	chr7:65276391	NA	0.52	7.81	0.39	7.33e-14	Aortic root size;
LUSC	trans	rs6828577	0.732	rs34983100	chr4:119454442	C/T	cg26518628	chr1:97050305	NA	-0.54	-7.85	-0.39	5.73e-14	Perioperative myocardial infarction in coronary artery bypass surgery;
LUSC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg21724239	chr8:58056113	NA	0.76	8.32	0.41	2.31e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs754466	0.651	rs11002322	chr10:79649653	G/T	cg17075019	chr10:79541650	NA	-0.74	-11.73	-0.54	7.4e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg05425664	chr17:57184151	TRIM37	-0.55	-8.14	-0.41	8.19e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs3857536	0.813	rs6455084	chr6:66935658	A/T	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg05941027	chr17:61774174	LIMD2	-0.22	-5.9	-0.31	8.69e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs974417	0.529	rs7771745	chr6:97345233	G/A	cg10979063	chr6:97285822	GPR63	0.41	6.67	0.34	1.04e-10	Body mass index;
LUSC	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg04374321	chr14:90722782	PSMC1	0.75	12.12	0.55	2.92e-28	Mortality in heart failure;
LUSC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg04414720	chr1:150670196	GOLPH3L	0.57	9.22	0.45	3.31e-18	Tonsillectomy;
LUSC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg01879757	chr17:41196368	BRCA1	-0.47	-7.2	-0.37	3.93e-12	Menopause (age at onset);
LUSC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.67	0.54	1.26e-26	Prudent dietary pattern;
LUSC	trans	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg02800362	chr5:177631904	HNRNPAB	0.83	12.44	0.56	1.95e-29	Obesity-related traits;
LUSC	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg24375607	chr4:120327624	NA	0.74	10.89	0.51	7.53e-24	Corneal astigmatism;
LUSC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg17971929	chr21:40555470	PSMG1	0.78	13.51	0.59	1.8e-33	Cognitive function;
LUSC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg08270630	chr22:50330655	NA	-0.43	-6.43	-0.33	4.45e-10	Schizophrenia;
LUSC	cis	rs12980942	0.810	rs35812313	chr19:41789178	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.59	6.44	0.33	4.28e-10	Coronary artery disease;
LUSC	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.83	0.51	1.26e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs7241530	0.662	rs4799009	chr18:75910320	C/G	cg14642773	chr18:75888474	NA	0.39	5.76	0.3	1.92e-8	Educational attainment (years of education);
LUSC	cis	rs7681440	0.583	rs2737023	chr4:90739505	T/C	cg06632027	chr4:90757378	SNCA	-0.36	-5.69	-0.3	2.71e-8	Dementia with Lewy bodies;
LUSC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg17911788	chr17:44343683	NA	-0.31	-6.06	-0.31	3.64e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.63	0.34	1.35e-10	Neuroticism;
LUSC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08048268	chr3:133502702	NA	0.43	8.34	0.42	1.98e-15	Iron status biomarkers;
LUSC	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg12863693	chr15:85201151	NMB	0.39	8.23	0.41	4.23e-15	Schizophrenia;
LUSC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.72	-0.35	7.71e-11	Blood protein levels;
LUSC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg09877947	chr5:131593287	PDLIM4	0.5	7.86	0.4	5.37e-14	Acylcarnitine levels;
LUSC	cis	rs68170813	0.559	rs1121312	chr7:106927820	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.8	-0.47	4.33e-20	Coronary artery disease;
LUSC	cis	rs356992	0.874	rs168565	chr2:60744331	A/G	cg08426369	chr2:60753602	BCL11A	0.43	5.88	0.31	9.91e-9	Educational attainment (years of education);
LUSC	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg11887960	chr12:57824829	NA	0.54	6.79	0.35	5.04e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-1.24	-13.61	-0.6	7.37e-34	Diabetic kidney disease;
LUSC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.84	-0.35	3.9e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs17253792	0.822	rs112238223	chr14:56056144	C/A	cg01858014	chr14:56050164	KTN1	-0.87	-6.96	-0.36	1.81e-11	Putamen volume;
LUSC	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg13575925	chr12:9217583	LOC144571	0.33	6.09	0.32	3.14e-9	Sjögren's syndrome;
LUSC	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg27205649	chr11:78285834	NARS2	0.53	6.46	0.33	3.72e-10	Alzheimer's disease (survival time);
LUSC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.78	-0.3	1.7e-8	Lung cancer;
LUSC	cis	rs12928939	0.769	rs34680964	chr16:71658594	G/A	cg03805757	chr16:71968109	PKD1L3	-0.41	-5.84	-0.3	1.22e-8	Post bronchodilator FEV1;
LUSC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg03146154	chr1:46216737	IPP	-0.51	-7.59	-0.38	3.28e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9581857	0.547	rs9581868	chr13:28070682	C/T	cg22138327	chr13:27999177	GTF3A	0.8	8.21	0.41	4.85e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg15103426	chr22:29168792	CCDC117	0.45	5.89	0.31	9.3e-9	Lymphocyte counts;
LUSC	cis	rs874628	0.686	rs72999447	chr19:18236947	G/A	cg00493341	chr19:18228948	MAST3	0.45	6.04	0.31	4.01e-9	Multiple sclerosis;
LUSC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	14.86	0.63	1.07e-38	Platelet count;
LUSC	cis	rs13082711	0.554	rs9310843	chr3:27371260	A/G	cg02860705	chr3:27208620	NA	0.51	9.05	0.44	1.23e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg01652190	chr22:50026171	C22orf34	-0.31	-6.32	-0.33	8.42e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs62344088	1.000	rs7715867	chr5:129059	C/T	cg22857025	chr5:266934	NA	-0.99	-7.1	-0.36	7.53e-12	Asthma (childhood onset);
LUSC	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg13535736	chr9:111863775	C9orf5	-0.41	-6.87	-0.35	3.23e-11	Menarche (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12028816	chr17:7232827	NEURL4	0.77	6.05	0.31	3.89e-9	Cognitive performance;
LUSC	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg22777020	chr22:31556080	RNF185	-0.44	-5.66	-0.3	3.24e-8	Colorectal cancer;
LUSC	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg01557791	chr16:72042693	DHODH	-0.46	-6.84	-0.35	3.89e-11	Fibrinogen levels;
LUSC	cis	rs2281845	0.560	rs12079819	chr1:201085420	G/A	cg22815214	chr1:201083145	CACNA1S	0.47	7.01	0.36	1.33e-11	Permanent tooth development;
LUSC	cis	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05901451	chr6:126070800	HEY2	0.57	8.64	0.43	2.36e-16	Endometrial cancer;
LUSC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.81	14.87	0.63	1.01e-38	Blood protein levels;
LUSC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-9.17	-0.45	5.15e-18	Mood instability;
LUSC	cis	rs7572644	0.699	rs1458398	chr2:28219941	A/G	cg27432699	chr2:27873401	GPN1	-0.51	-6.95	-0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs12310956	0.532	rs2087270	chr12:33850109	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.21	0.37	3.76e-12	Morning vs. evening chronotype;
LUSC	cis	rs16910800	0.731	rs16910754	chr11:23192015	A/G	cg20040320	chr11:23191996	NA	0.62	7.77	0.39	1.01e-13	Cancer;
LUSC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	0.94	13.86	0.6	8.14e-35	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg21775007	chr8:11205619	TDH	0.76	12.43	0.56	2.05e-29	Retinal vascular caliber;
LUSC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.06	0.31	3.68e-9	Menopause (age at onset);
LUSC	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	trans	rs1223397	0.938	rs13205692	chr6:13291560	C/T	cg13974761	chr1:152670598	LCE2A	0.37	6.07	0.32	3.51e-9	Blood pressure;
LUSC	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.92	-0.44	3.24e-17	Monocyte percentage of white cells;
LUSC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-6.82	-0.35	4.19e-11	Personality dimensions;
LUSC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.52	-7.67	-0.39	1.94e-13	Total body bone mineral density;
LUSC	cis	rs6076065	0.548	rs1112819	chr20:23323987	A/G	cg11657817	chr20:23433608	CST11	0.5	9.92	0.48	1.75e-20	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14094063	chr7:140624470	BRAF	0.45	6.8	0.35	4.76e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.58	10.7	0.51	3.69e-23	Bone mineral density;
LUSC	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg04998671	chr14:104000505	TRMT61A	-0.43	-6.63	-0.34	1.33e-10	Coronary artery disease;
LUSC	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	0.91	15.85	0.66	1.46e-42	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg21427119	chr20:30132790	HM13	-0.36	-5.67	-0.3	3.14e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.77	-11.97	-0.55	1.05e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg09165964	chr15:75287851	SCAMP5	-1.16	-19.7	-0.73	7.33e-58	Blood trace element (Zn levels);
LUSC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.87	-11.77	-0.54	5.62e-27	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs67539049	1.000	rs73207500	chr8:11293502	T/G	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.4	-6.13	-0.32	2.51e-9	Itch intensity from mosquito bite;
LUSC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg02153584	chr22:29168773	CCDC117	0.65	10.49	0.5	1.89e-22	Lymphocyte counts;
LUSC	cis	rs727505	0.954	rs59283092	chr7:124678282	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.79	-0.35	5.21e-11	Lewy body disease;
LUSC	cis	rs1957429	0.520	rs230718	chr14:65318943	A/G	cg23373153	chr14:65346875	NA	-0.81	-7.4	-0.38	1.15e-12	Pediatric areal bone mineral density (radius);
LUSC	cis	rs6693567	0.565	rs12739706	chr1:150261653	C/G	cg15654264	chr1:150340011	RPRD2	-0.45	-7.29	-0.37	2.25e-12	Migraine;
LUSC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.87	0.35	3.2e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg01802117	chr1:53393560	SCP2	-0.37	-6.02	-0.31	4.52e-9	Monocyte count;
LUSC	cis	rs16857609	0.628	rs1478585	chr2:218334784	C/T	cg03013118	chr2:218375971	DIRC3	-0.29	-5.7	-0.3	2.6e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
LUSC	cis	rs17162190	0.698	rs12094989	chr1:26848386	A/G	cg17456097	chr1:26900765	RPS6KA1	-0.42	-6.02	-0.31	4.71e-9	Mean corpuscular volume;
LUSC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	7.75	0.39	1.14e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22496380	chr5:211416	CCDC127	-0.81	-8.54	-0.42	4.82e-16	Breast cancer;
LUSC	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg12091567	chr17:66097778	LOC651250	-0.75	-9.35	-0.46	1.27e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-1.02	-24.92	-0.81	3.39e-78	Urate levels in lean individuals;
LUSC	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg24375607	chr4:120327624	NA	0.79	12.03	0.55	6.08e-28	Corneal astigmatism;
LUSC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.52e-9	Menopause (age at onset);
LUSC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg16339924	chr4:17578868	LAP3	0.59	9.06	0.44	1.15e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4443100	0.792	rs9612223	chr22:23389142	T/G	cg14186256	chr22:23484241	RTDR1	0.52	6.43	0.33	4.44e-10	Serum parathyroid hormone levels;
LUSC	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg24375607	chr4:120327624	NA	-0.63	-10.05	-0.48	6.3e-21	Corneal astigmatism;
LUSC	trans	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.37	-0.33	6.38e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg04287289	chr16:89883240	FANCA	-0.42	-6.18	-0.32	1.82e-9	Vitiligo;
LUSC	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07080220	chr10:102295463	HIF1AN	0.67	9.04	0.44	1.3e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg16473166	chr22:50639996	SELO	-0.59	-7.89	-0.4	4.27e-14	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LUSC	cis	rs6987853	0.931	rs3099936	chr8:42384331	C/T	cg09913449	chr8:42400586	C8orf40	-0.5	-8.38	-0.42	1.47e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.46	-0.33	3.75e-10	Vitiligo;
LUSC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-1.05	-14.61	-0.62	9.69e-38	Vitiligo;
LUSC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg17279839	chr7:150038598	RARRES2	0.49	7.28	0.37	2.46e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg15534755	chr11:117069859	TAGLN	-0.35	-5.98	-0.31	5.83e-9	Blood protein levels;
LUSC	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg19875535	chr5:140030758	IK	-0.48	-7.82	-0.39	6.95e-14	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg06914050	chr7:56119237	PSPH;CCT6A	0.41	6.22	0.32	1.47e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs6977660	0.714	rs12537283	chr7:19817658	G/T	cg07541023	chr7:19748670	TWISTNB	0.62	6.71	0.34	8.21e-11	Thyroid stimulating hormone;
LUSC	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	11.66	0.54	1.37e-26	Coronary artery disease;
LUSC	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.14	-0.45	6.2e-18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	trans	rs10090774	0.965	rs11785430	chr8:142009527	A/G	cg16477744	chr7:157367142	PTPRN2;MIR153-2	0.28	6.09	0.32	3.19e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs12900413	0.603	rs12907030	chr15:90301439	C/T	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.56e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg18209359	chr17:80159595	CCDC57	0.39	6.44	0.33	4.06e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-1.17	-16.86	-0.68	1.46e-46	Breast cancer;
LUSC	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg24375607	chr4:120327624	NA	0.8	11.95	0.55	1.22e-27	Corneal astigmatism;
LUSC	cis	rs4629180	0.727	rs10188564	chr2:102101064	C/A	cg04415270	chr2:102091202	RFX8	-0.55	-8.67	-0.43	1.84e-16	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	0.6	9.41	0.46	8.58e-19	Breast cancer;
LUSC	cis	rs10489202	0.686	rs12754453	chr1:167844896	A/T	cg24449463	chr1:168025552	DCAF6	-0.55	-6.27	-0.32	1.1e-9	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10477989	chr11:68039601	C11orf24	0.47	7.51	0.38	5.43e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg21280719	chr6:42927975	GNMT	-0.31	-7.76	-0.39	1.02e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.8	13.35	0.59	7.22e-33	Systolic blood pressure;
LUSC	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg20587970	chr11:113659929	NA	-1.16	-13.14	-0.58	4.33e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.9	0.48	2e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7178572	0.568	rs4886862	chr15:77652368	T/C	cg22256960	chr15:77711686	NA	-0.5	-8.07	-0.4	1.26e-14	Type 2 diabetes;
LUSC	cis	rs977987	0.806	rs4888416	chr16:75449176	C/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.66	-0.34	1.15e-10	Dupuytren's disease;
LUSC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.8	13.16	0.58	3.68e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs35264875	0.808	rs2305498	chr11:68866914	G/A	cg02660097	chr11:68866761	NA	0.43	6.6	0.34	1.6e-10	Blond vs. brown hair color;
LUSC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg06784218	chr1:46089804	CCDC17	0.55	11.09	0.52	1.49e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg05110241	chr16:68378359	PRMT7	-0.58	-6.72	-0.35	7.89e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.63	0.39	2.51e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg06917634	chr15:78832804	PSMA4	-0.43	-5.84	-0.3	1.26e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	trans	rs79040073	0.911	rs11638981	chr15:49321529	A/G	cg12040278	chr2:37572396	QPCT	-0.42	-6.02	-0.31	4.66e-9	Lung cancer in ever smokers;
LUSC	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg08345082	chr10:99160200	RRP12	-0.33	-6.79	-0.35	5.16e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.47	-0.33	3.57e-10	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg11244813	chr1:145039882	PDE4DIP	0.36	5.96	0.31	6.51e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1832871	0.672	rs9456295	chr6:158772078	G/A	cg07165851	chr6:158734300	TULP4	0.47	7.16	0.36	5.2e-12	Height;
LUSC	trans	rs4718428	0.705	rs4718430	chr7:66432024	G/T	cg18876405	chr7:65276391	NA	0.5	6.53	0.34	2.46e-10	Corneal structure;
LUSC	cis	rs6058796	1.000	rs9636547	chr20:31262033	T/A	cg13636640	chr20:31349939	DNMT3B	0.53	5.67	0.3	3.13e-8	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.71	0.34	8.42e-11	Tonsillectomy;
LUSC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-13.3	-0.59	1.15e-32	Chronic sinus infection;
LUSC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg22437258	chr11:111473054	SIK2	-0.43	-5.65	-0.3	3.35e-8	Primary sclerosing cholangitis;
LUSC	cis	rs1160297	0.643	rs13031599	chr2:53075902	T/C	cg07782112	chr2:53107842	NA	0.4	6.39	0.33	5.73e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs500891	0.525	rs12529407	chr6:84062581	C/T	cg08257003	chr6:84140564	ME1	-0.34	-8.3	-0.41	2.69e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.68	0.57	2.38e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	8.09	0.4	1.1e-14	Bipolar disorder;
LUSC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21028142	chr17:79581711	NPLOC4	0.35	8.24	0.41	4.03e-15	Eye color traits;
LUSC	cis	rs870825	1.000	rs9995633	chr4:185584441	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.67	0.54	1.3e-26	Blood protein levels;
LUSC	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06636551	chr8:101224915	SPAG1	-0.43	-8.0	-0.4	2.12e-14	Atrioventricular conduction;
LUSC	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg03806693	chr22:41940476	POLR3H	-0.96	-13.04	-0.58	1.08e-31	Vitiligo;
LUSC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg12927641	chr6:109611667	NA	-0.43	-7.5	-0.38	5.64e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs3857536	0.813	rs7757647	chr6:66947207	A/G	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs66716358	0.800	rs10838255	chr11:44320172	C/T	cg02785814	chr11:44338707	NA	-0.41	-6.15	-0.32	2.23e-9	Monobrow;
LUSC	trans	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.57	0.5	1.01e-22	Mean corpuscular volume;
LUSC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.57	-8.23	-0.41	4.36e-15	Obesity-related traits;
LUSC	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	0.57	8.61	0.43	2.86e-16	Breast cancer;
LUSC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg12463550	chr7:65579703	CRCP	0.44	6.23	0.32	1.38e-9	Aortic root size;
LUSC	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg05163923	chr11:71159392	DHCR7	-0.76	-9.95	-0.48	1.32e-20	Vitamin D levels;
LUSC	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg21211680	chr2:198530	NA	0.66	7.45	0.38	7.91e-13	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22737917	chr5:73936437	ENC1	-0.4	-6.01	-0.31	4.82e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg05925327	chr15:68127851	NA	-0.48	-7.03	-0.36	1.21e-11	Restless legs syndrome;
LUSC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg12143784	chr7:64541923	NA	0.42	6.55	0.34	2.21e-10	Calcium levels;
LUSC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08219700	chr8:58056026	NA	0.64	8.25	0.41	3.65e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6977660	0.941	rs5017192	chr7:19820114	C/T	cg05791153	chr7:19748676	TWISTNB	0.52	5.78	0.3	1.69e-8	Thyroid stimulating hormone;
LUSC	cis	rs7215564	0.818	rs35059200	chr17:78661619	T/C	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg11845111	chr2:191398756	TMEM194B	-0.81	-11.01	-0.52	2.86e-24	Diastolic blood pressure;
LUSC	cis	rs6120849	0.708	rs6087659	chr20:33606383	C/A	cg24642439	chr20:33292090	TP53INP2	0.62	6.8	0.35	4.74e-11	Protein C levels;
LUSC	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg20283391	chr11:68216788	NA	-0.6	-8.4	-0.42	1.25e-15	Total body bone mineral density;
LUSC	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-6.53	-0.34	2.48e-10	Homocysteine levels;
LUSC	cis	rs4356932	0.691	rs9307050	chr4:76905649	G/A	cg00809888	chr4:76862425	NAAA	0.37	5.88	0.31	9.75e-9	Blood protein levels;
LUSC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg07424592	chr7:64974309	NA	0.69	6.07	0.32	3.4e-9	Diabetic kidney disease;
LUSC	cis	rs6060717	0.536	rs6060666	chr20:34478954	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.67	-0.3	3.14e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg12310025	chr6:25882481	NA	-0.5	-9.06	-0.44	1.09e-17	Blood metabolite levels;
LUSC	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg24375607	chr4:120327624	NA	0.78	11.52	0.53	4.39e-26	Corneal astigmatism;
LUSC	cis	rs6847149	0.929	rs4698752	chr4:110780964	A/G	cg07850274	chr4:110748770	RRH	0.56	7.95	0.4	2.98e-14	Exercise treadmill test traits;
LUSC	cis	rs4713675	0.546	rs10947430	chr6:33658534	G/A	cg14003231	chr6:33640908	ITPR3	0.31	5.96	0.31	6.39e-9	Plateletcrit;
LUSC	trans	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.3	-0.33	9.38e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.64e-11	Morning vs. evening chronotype;
LUSC	trans	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg06636001	chr8:8085503	FLJ10661	0.44	6.37	0.33	6.14e-10	Retinal vascular caliber;
LUSC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg05340658	chr4:99064831	C4orf37	0.44	6.92	0.35	2.25e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg07716408	chr11:68623521	NA	-0.34	-6.65	-0.34	1.23e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg20744362	chr22:50050164	C22orf34	0.36	6.66	0.34	1.1e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg09904177	chr6:26538194	HMGN4	-0.48	-7.56	-0.38	3.93e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg00898013	chr13:113819073	PROZ	-0.53	-7.9	-0.4	4e-14	Platelet distribution width;
LUSC	cis	rs7255374	0.566	rs7255904	chr19:41529020	C/T	cg20630647	chr19:41531805	NA	0.38	6.37	0.33	6.2e-10	DDT metabolite (p,p'-DDE levels);
LUSC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.57	0.57	6.4e-30	Prudent dietary pattern;
LUSC	trans	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg18187862	chr3:45730750	SACM1L	-0.51	-6.17	-0.32	1.99e-9	Primary sclerosing cholangitis;
LUSC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg24733560	chr20:60626293	TAF4	0.4	6.52	0.34	2.58e-10	Body mass index;
LUSC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18099408	chr3:52552593	STAB1	0.42	7.22	0.37	3.55e-12	Bipolar disorder;
LUSC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg18230493	chr5:56204884	C5orf35	0.76	12.7	0.57	2.05e-30	Initial pursuit acceleration;
LUSC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg22823121	chr1:150693482	HORMAD1	0.49	7.0	0.36	1.37e-11	Melanoma;
LUSC	trans	rs877282	0.898	rs12356744	chr10:757477	G/C	cg13042288	chr15:90349979	ANPEP	-0.47	-6.51	-0.34	2.71e-10	Uric acid levels;
LUSC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2289583	0.544	rs1867153	chr15:75271229	C/T	cg14664628	chr15:75095509	CSK	0.44	5.99	0.31	5.36e-9	Systemic lupus erythematosus;
LUSC	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9463078	0.665	rs4714816	chr6:44715168	T/C	cg25276700	chr6:44698697	NA	0.31	6.34	0.33	7.59e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7572644	0.699	rs7595847	chr2:28173043	T/A	cg27432699	chr2:27873401	GPN1	-0.51	-6.95	-0.36	1.89e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs11785400	0.793	rs12546978	chr8:143750205	T/A	cg10596483	chr8:143751796	JRK	-0.51	-7.31	-0.37	1.98e-12	Schizophrenia;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg15130241	chr1:1334814	CCNL2;LOC148413	0.36	6.06	0.31	3.77e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.25	0.32	1.28e-9	Menopause (age at onset);
LUSC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg13395646	chr4:1353034	KIAA1530	-0.79	-13.54	-0.6	1.32e-33	Obesity-related traits;
LUSC	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg00310523	chr12:86230176	RASSF9	0.35	6.37	0.33	6.28e-10	Major depressive disorder;
LUSC	cis	rs4237845	0.680	rs10877033	chr12:58283731	T/C	cg02175503	chr12:58329896	NA	0.59	9.29	0.45	1.99e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg19622623	chr12:86230825	RASSF9	-0.43	-6.19	-0.32	1.8e-9	Major depressive disorder;
LUSC	cis	rs6969780	0.915	rs886339	chr7:27190670	A/C	cg26364809	chr7:27145159	NA	0.53	5.92	0.31	7.97e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg23950597	chr19:37808831	NA	-0.63	-7.77	-0.39	9.76e-14	Coronary artery calcification;
LUSC	trans	rs9944715	0.954	rs36191490	chr18:43839653	C/T	cg01718231	chr17:29326311	RNF135	-0.51	-7.09	-0.36	8.1e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs9467773	0.609	rs12663780	chr6:26397573	T/C	cg05738196	chr6:26577821	NA	-0.47	-6.72	-0.35	7.73e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.94	-0.35	2.08e-11	Neutrophil count;
LUSC	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg23950597	chr19:37808831	NA	-0.64	-7.72	-0.39	1.35e-13	Coronary artery calcification;
LUSC	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.86	0.31	1.13e-8	Tonsillectomy;Mean corpuscular volume;
LUSC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06558623	chr16:89946397	TCF25	0.95	10.21	0.49	1.82e-21	Skin colour saturation;
LUSC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg05623727	chr3:50126028	RBM5	-0.34	-6.29	-0.33	9.97e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	0.8	14.01	0.61	2.13e-35	Cognitive function;
LUSC	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.56	9.29	0.45	2.06e-18	Breast cancer;
LUSC	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.57	-7.78	-0.39	8.92e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.12	0.32	2.65e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	6.96	0.36	1.78e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9888739	0.668	rs9933520	chr16:31343386	A/G	cg15817542	chr16:31343056	ITGAM	-0.53	-7.13	-0.36	6.08e-12	Systemic lupus erythematosus;
LUSC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg07414643	chr4:187882934	NA	0.55	10.1	0.48	4.14e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7084921	0.608	rs12780510	chr10:101865881	T/C	cg11888571	chr10:102027403	CWF19L1	-0.42	-5.84	-0.3	1.27e-8	Bone mineral density;
LUSC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-1.19	-13.96	-0.61	3.37e-35	Diabetic kidney disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14347670	chr6:41908995	CCND3	0.49	7.22	0.37	3.62e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg14092988	chr3:52407081	DNAH1	0.41	7.34	0.37	1.66e-12	Bipolar disorder;
LUSC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg24675658	chr1:53192096	ZYG11B	0.58	9.11	0.45	7.6e-18	Monocyte count;
LUSC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12756686	chr19:29218302	NA	0.68	9.63	0.47	1.54e-19	Methadone dose in opioid dependence;
LUSC	trans	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07923666	chr12:49932857	KCNH3	-0.52	-6.51	-0.34	2.74e-10	Resting heart rate;
LUSC	cis	rs4964805	0.683	rs12424737	chr12:104196221	A/C	cg02344784	chr12:104178138	NT5DC3	0.46	8.83	0.44	5.86e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.65	-0.3	3.35e-8	Life satisfaction;
LUSC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg08088566	chr11:430123	ANO9	0.61	7.12	0.36	6.5e-12	Body mass index;
LUSC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.45	-7.66	-0.39	1.99e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg26513180	chr16:89883248	FANCA	-0.53	-7.84	-0.39	6.09e-14	Vitiligo;
LUSC	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg03929089	chr4:120376271	NA	0.65	6.08	0.32	3.36e-9	Axial length;
LUSC	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg23231163	chr10:75533350	FUT11	-0.43	-6.93	-0.35	2.21e-11	Inflammatory bowel disease;
LUSC	trans	rs11039798	1.000	rs12280020	chr11:48618844	G/C	cg15704280	chr7:45808275	SEPT13	0.68	6.41	0.33	4.99e-10	Axial length;
LUSC	trans	rs1459104	0.777	rs116287458	chr11:54916623	G/A	cg15704280	chr7:45808275	SEPT13	0.69	5.97	0.31	6.07e-9	Body mass index;
LUSC	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	0.98	10.97	0.51	4.05e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg05283184	chr6:79620031	NA	0.51	10.26	0.49	1.15e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg07507251	chr3:52567010	NT5DC2	0.31	6.14	0.32	2.33e-9	Bipolar disorder;
LUSC	cis	rs10979	0.965	rs9496674	chr6:143886106	G/T	cg25407410	chr6:143891975	LOC285740	-0.74	-12.09	-0.55	3.66e-28	Hypospadias;
LUSC	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg01579765	chr21:45077557	HSF2BP	0.45	9.62	0.47	1.63e-19	Mean corpuscular volume;
LUSC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.62	12.77	0.57	1.08e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1832871	0.644	rs56180963	chr6:158773990	G/A	cg07165851	chr6:158734300	TULP4	0.48	7.32	0.37	1.87e-12	Height;
LUSC	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg19920283	chr7:105172520	RINT1	0.6	6.38	0.33	5.9e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.54	10.25	0.49	1.27e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs55728055	0.661	rs7286496	chr22:31983760	G/A	cg01338084	chr22:32026380	PISD	0.93	6.78	0.35	5.4e-11	Age-related hearing impairment;
LUSC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	6.28	0.33	1.04e-9	Lung cancer;
LUSC	cis	rs3849570	1.000	rs6548773	chr3:81840222	C/T	cg07356753	chr3:81810745	GBE1	0.7	11.56	0.53	3.2e-26	Waist circumference;Body mass index;
LUSC	cis	rs911119	1.000	rs734801	chr20:23612791	A/G	cg16589663	chr20:23618590	CST3	0.58	6.88	0.35	2.94e-11	Chronic kidney disease;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg17819983	chr9:140189914	NA	0.4	6.3	0.33	9.16e-10	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg26043149	chr18:55253948	FECH	-0.54	-8.11	-0.41	9.44e-15	Bone mineral density;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23414580	chr4:4145323	NA	0.39	5.95	0.31	6.69e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.77	-11.82	-0.54	3.46e-27	Menarche (age at onset);
LUSC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg21862992	chr11:68658383	NA	0.5	8.08	0.4	1.19e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs61931739	0.649	rs815047	chr12:33726459	C/T	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	trans	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg13565492	chr6:43139072	SRF	-0.73	-10.83	-0.51	1.25e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	3.96e-12	Motion sickness;
LUSC	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg17385448	chr1:15911702	AGMAT	0.37	5.84	0.3	1.23e-8	Systolic blood pressure;
LUSC	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19653624	chr11:20408972	PRMT3	-0.68	-8.71	-0.43	1.41e-16	Pursuit maintenance gain;
LUSC	cis	rs60695258	0.512	rs2053770	chr4:87908085	C/T	cg10685359	chr4:87814065	C4orf36	0.33	5.81	0.3	1.49e-8	Hematocrit;
LUSC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	6.26	0.32	1.21e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg15445000	chr17:37608096	MED1	-0.39	-6.69	-0.34	9.47e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg20368463	chr18:77673604	PQLC1	-0.5	-7.21	-0.37	3.73e-12	Schizophrenia;
LUSC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg00509249	chr6:109615579	CCDC162	-0.32	-5.73	-0.3	2.24e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs68170813	0.652	rs74374590	chr7:107172470	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-8.63	-0.43	2.46e-16	Coronary artery disease;
LUSC	cis	rs6977660	1.000	rs2892940	chr7:19794750	G/A	cg05791153	chr7:19748676	TWISTNB	0.66	7.34	0.37	1.68e-12	Thyroid stimulating hormone;
LUSC	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.78	12.81	0.57	7.56e-31	Morning vs. evening chronotype;
LUSC	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.26	-0.37	2.65e-12	Bipolar disorder;
LUSC	cis	rs6700896	0.966	rs3790439	chr1:66085574	T/A	cg04111102	chr1:66153794	NA	0.32	7.07	0.36	8.85e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7560272	0.549	rs2421554	chr2:73806202	A/T	cg20560298	chr2:73613845	ALMS1	-0.43	-6.51	-0.34	2.74e-10	Schizophrenia;
LUSC	cis	rs11630290	0.592	rs12324556	chr15:64160951	G/A	cg12036633	chr15:63758958	NA	0.54	6.93	0.35	2.19e-11	Iris characteristics;
LUSC	cis	rs17828380	0.920	rs35893526	chr15:63455686	C/T	cg05507819	chr15:63340323	TPM1	-0.75	-6.12	-0.32	2.61e-9	Social communication problems;
LUSC	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-7.5	-0.38	5.92e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs2798269	1.000	rs12430902	chr13:22146005	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.39	-5.94	-0.31	7.18e-9	PR segment;
LUSC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg21535247	chr6:8435926	SLC35B3	0.56	8.45	0.42	8.88e-16	Motion sickness;
LUSC	cis	rs2766692	1.000	rs4905941	chr14:100725438	A/G	cg14866419	chr14:100704911	YY1	0.46	6.08	0.32	3.22e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg11050988	chr7:1952600	MAD1L1	-0.32	-6.11	-0.32	2.76e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg04369109	chr6:150039330	LATS1	-0.56	-8.31	-0.41	2.47e-15	Lung cancer;
LUSC	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.6	-0.43	3.13e-16	Neuroticism;
LUSC	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg22117172	chr7:91764530	CYP51A1	0.32	5.74	0.3	2.15e-8	Breast cancer;
LUSC	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.5	7.21	0.37	3.75e-12	Coronary heart disease;
LUSC	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.9	15.61	0.65	1.27e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4474465	1.000	rs12280198	chr11:78161361	C/T	cg27205649	chr11:78285834	NARS2	-0.53	-6.26	-0.32	1.16e-9	Alzheimer's disease (survival time);
LUSC	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.59	-9.66	-0.47	1.26e-19	Breast size;
LUSC	cis	rs17095355	0.818	rs4275548	chr10:111910971	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.33	-0.37	1.74e-12	Biliary atresia;
LUSC	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg05340658	chr4:99064831	C4orf37	0.44	6.9	0.35	2.57e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2637266	1.000	rs17384253	chr10:78342391	A/G	cg18941641	chr10:78392320	NA	0.39	7.08	0.36	8.42e-12	Pulmonary function;
LUSC	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg09904177	chr6:26538194	HMGN4	0.65	11.67	0.54	1.3e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg16414030	chr3:133502952	NA	-0.42	-6.22	-0.32	1.49e-9	Iron status biomarkers;
LUSC	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.45	-0.42	9.26e-16	Retinal vascular caliber;
LUSC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01256987	chr12:42539512	GXYLT1	-0.6	-12.79	-0.57	9.16e-31	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2667011	0.512	rs10177852	chr2:160820410	T/C	cg06573604	chr2:160760825	LY75	-0.45	-6.63	-0.34	1.32e-10	Bilirubin levels;
LUSC	cis	rs911119	0.913	rs6048922	chr20:23578116	G/C	cg16589663	chr20:23618590	CST3	0.6	7.02	0.36	1.21e-11	Chronic kidney disease;
LUSC	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.24	-0.41	4.03e-15	Neuroticism;
LUSC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg03146154	chr1:46216737	IPP	0.51	7.48	0.38	6.55e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg21775007	chr8:11205619	TDH	-0.43	-6.22	-0.32	1.45e-9	Mood instability;
LUSC	cis	rs662064	0.928	rs685746	chr1:10537437	C/G	cg20482658	chr1:10539492	PEX14	-0.3	-6.28	-0.32	1.07e-9	Asthma;
LUSC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03934478	chr11:495069	RNH1	0.85	10.24	0.49	1.37e-21	Body mass index;
LUSC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs9309473	0.615	rs62149774	chr2:73787652	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.56	-0.34	2.1e-10	Metabolite levels;
LUSC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg23590916	chr17:43697445	MGC57346	-0.48	-6.51	-0.34	2.7e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.7	-0.43	1.57e-16	Mood instability;
LUSC	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg15549821	chr19:49342101	PLEKHA4	-0.52	-6.12	-0.32	2.61e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg03806693	chr22:41940476	POLR3H	1.0	14.25	0.62	2.41e-36	Vitiligo;
LUSC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.97	0.31	6.13e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg11645453	chr3:52864694	ITIH4	-0.31	-7.48	-0.38	6.7e-13	Electroencephalogram traits;
LUSC	cis	rs66887589	0.870	rs2389875	chr4:120557014	G/T	cg09307838	chr4:120376055	NA	-0.51	-7.54	-0.38	4.53e-13	Diastolic blood pressure;
LUSC	cis	rs9283706	0.594	rs7717020	chr5:66353322	A/C	cg11590213	chr5:66331682	MAST4	0.48	7.07	0.36	9.12e-12	Coronary artery disease;
LUSC	cis	rs754133	0.964	rs894737	chr12:54418143	A/C	cg10005224	chr12:54424964	HOXC4;HOXC5	0.43	8.61	0.43	3.03e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
LUSC	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg00321850	chr1:175162397	KIAA0040	0.41	7.22	0.37	3.5e-12	Alcohol dependence;
LUSC	cis	rs11785693	0.862	rs11786186	chr8:4999059	G/C	cg26367366	chr8:4980734	NA	0.8	9.4	0.46	8.84e-19	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg02772935	chr3:125709198	NA	-0.48	-5.84	-0.3	1.23e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.55	-8.19	-0.41	5.5e-15	Lymphocyte counts;
LUSC	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.2	0.59	2.54e-32	Blood protein levels;
LUSC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.62	0.43	2.64e-16	Menarche (age at onset);
LUSC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.87	11.6	0.54	2.35e-26	Mean corpuscular hemoglobin;
LUSC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg06784218	chr1:46089804	CCDC17	0.56	11.62	0.54	1.92e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	6.09	0.32	3.04e-9	Menopause (age at onset);
LUSC	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg09173681	chr1:183549694	NCF2	0.65	11.52	0.53	4.42e-26	Systemic lupus erythematosus;
LUSC	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg26395211	chr5:140044315	WDR55	0.45	7.02	0.36	1.22e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg02487422	chr3:49467188	NICN1	0.47	7.36	0.37	1.45e-12	Resting heart rate;
LUSC	cis	rs2294693	0.945	rs13216361	chr6:41007046	C/T	cg14769373	chr6:40998127	UNC5CL	-0.54	-7.23	-0.37	3.27e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs80282103	0.764	rs12268949	chr10:1104257	A/G	cg18964960	chr10:1102726	WDR37	0.71	6.31	0.33	9.01e-10	Glomerular filtration rate (creatinine);
LUSC	trans	rs1409005	1.000	rs76093584	chr13:79154632	C/T	cg04653021	chr3:122514541	DIRC2	0.47	6.04	0.31	4.05e-9	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg18196295	chr10:418757	DIP2C	-0.46	-7.26	-0.37	2.77e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg26893861	chr17:41843967	DUSP3	0.86	13.17	0.58	3.36e-32	Triglycerides;
LUSC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg26677194	chr12:130822605	PIWIL1	0.59	8.8	0.43	7.28e-17	Menopause (age at onset);
LUSC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.4	-6.13	-0.32	2.42e-9	Lymphocyte counts;
LUSC	cis	rs7809950	1.000	rs3801954	chr7:107117048	C/T	cg23024343	chr7:107201750	COG5	-0.55	-8.85	-0.44	5.22e-17	Coronary artery disease;
LUSC	cis	rs72634258	0.945	rs28624	chr1:8084355	G/T	cg26816564	chr1:7831052	VAMP3	-0.46	-6.2	-0.32	1.69e-9	Inflammatory bowel disease;
LUSC	cis	rs4728302	0.559	rs12707093	chr7:133200817	C/T	cg10665199	chr7:133106180	EXOC4	0.53	7.29	0.37	2.23e-12	Intelligence;Intelligence (multi-trait analysis);
LUSC	cis	rs113835537	0.529	rs78999944	chr11:66251228	C/G	cg24851651	chr11:66362959	CCS	0.54	8.02	0.4	1.77e-14	Airway imaging phenotypes;
LUSC	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg14664628	chr15:75095509	CSK	-0.68	-10.25	-0.49	1.26e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.64	8.64	0.43	2.28e-16	Body mass index;
LUSC	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.48	-6.43	-0.33	4.34e-10	Diabetic retinopathy;
LUSC	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg26162295	chr17:38119207	GSDMA	-0.28	-6.33	-0.33	8.07e-10	Myeloid white cell count;
LUSC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg05313129	chr8:58192883	C8orf71	-0.52	-5.9	-0.31	9.1e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12980942	0.872	rs7256416	chr19:41787931	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.59	6.49	0.33	3.13e-10	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.63	0.5	6.47e-23	Menopause (age at onset);
LUSC	cis	rs981844	0.712	rs897610	chr4:154755439	C/A	cg14289246	chr4:154710475	SFRP2	-0.45	-6.22	-0.32	1.45e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs12545109	0.571	rs4314648	chr8:57276937	G/A	cg09654669	chr8:57350985	NA	-0.47	-5.97	-0.31	6.2e-9	Obesity-related traits;
LUSC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg13902645	chr11:5959945	NA	-0.54	-8.27	-0.41	3.28e-15	DNA methylation (variation);
LUSC	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.8	-17.95	-0.7	6.6e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4319547	0.506	rs2062488	chr12:122804256	C/T	cg23029597	chr12:123009494	RSRC2	0.54	6.91	0.35	2.52e-11	Body mass index;
LUSC	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.95	-18.22	-0.71	5.41e-52	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg09904177	chr6:26538194	HMGN4	0.76	14.16	0.61	5.54e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg19920283	chr7:105172520	RINT1	0.6	6.35	0.33	7.01e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg11871910	chr12:69753446	YEATS4	0.71	11.97	0.55	1.05e-27	Blood protein levels;
LUSC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg01416388	chr22:39784598	NA	-0.45	-7.61	-0.38	2.76e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg21361702	chr7:150065534	REPIN1	0.53	6.99	0.36	1.49e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.55	8.55	0.42	4.61e-16	Schizophrenia;
LUSC	trans	rs2562456	0.833	rs552800	chr19:21484642	G/A	cg00806126	chr19:22604979	ZNF98	0.4	6.2	0.32	1.67e-9	Pain;
LUSC	cis	rs6840360	1.000	rs4696104	chr4:152600451	A/G	cg22705602	chr4:152727874	NA	-0.27	-5.7	-0.3	2.6e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs2458413	0.903	rs2669448	chr8:105372324	T/G	cg04554929	chr8:105342491	NA	0.33	5.74	0.3	2.08e-8	Paget's disease;
LUSC	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg17173187	chr15:85201210	NMB	0.47	8.87	0.44	4.36e-17	Schizophrenia;
LUSC	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg05714579	chr10:131428358	MGMT	0.45	6.24	0.32	1.32e-9	Response to temozolomide;
LUSC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg21724239	chr8:58056113	NA	0.61	7.21	0.37	3.7e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs28655083	0.529	rs285018	chr16:77099065	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.42	6.74	0.35	6.79e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg10909506	chr17:38081995	ORMDL3	-0.34	-5.97	-0.31	6.07e-9	Self-reported allergy;
LUSC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.02	-0.36	1.26e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.79	-0.39	8.31e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.48	-9.02	-0.44	1.46e-17	Axial length;
LUSC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg14500267	chr11:67383377	NA	0.34	6.43	0.33	4.44e-10	Mean corpuscular volume;
LUSC	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg04362960	chr10:104952993	NT5C2	0.62	9.85	0.47	2.95e-20	Arsenic metabolism;
LUSC	trans	rs11696501	0.588	rs6073831	chr20:44279550	A/T	cg03272292	chr12:48577362	C12orf68	0.48	6.0	0.31	5.1e-9	Brain structure;
LUSC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg25258033	chr6:167368657	RNASET2	0.47	7.69	0.39	1.63e-13	Crohn's disease;
LUSC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg26335602	chr6:28129616	ZNF389	0.45	6.18	0.32	1.84e-9	Depression;
LUSC	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg07817648	chr10:79422355	NA	-0.56	-7.38	-0.37	1.29e-12	Bone mineral density;
LUSC	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg08085267	chr17:45401833	C17orf57	-0.54	-8.64	-0.43	2.4e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11764359	chr7:65958608	NA	-0.63	-9.62	-0.47	1.67e-19	Aortic root size;
LUSC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg04450456	chr4:17643702	FAM184B	0.39	6.61	0.34	1.51e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs73206853	0.764	rs16940881	chr12:110937818	G/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs8067287	0.597	rs7223652	chr17:16864559	C/T	cg26910001	chr17:16838321	NA	0.38	5.98	0.31	5.61e-9	Diabetic kidney disease;
LUSC	cis	rs7523273	0.606	rs2488252	chr1:207938228	C/T	cg22525895	chr1:207977042	MIR29B2	0.41	6.69	0.34	9.54e-11	Schizophrenia;
LUSC	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg04283868	chr2:201171347	SPATS2L	-0.42	-6.17	-0.32	1.99e-9	QT interval;
LUSC	cis	rs9311676	0.656	rs55727087	chr3:58404547	G/A	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.11e-10	Systemic lupus erythematosus;
LUSC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12756686	chr19:29218302	NA	0.66	9.77	0.47	5.41e-20	Methadone dose in opioid dependence;
LUSC	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg19773385	chr1:10388646	KIF1B	-0.48	-8.46	-0.42	8.72e-16	Hepatocellular carcinoma;
LUSC	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg18302933	chr2:88491318	NA	-0.35	-6.64	-0.34	1.3e-10	Response to metformin (IC50);
LUSC	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg18209359	chr17:80159595	CCDC57	0.37	6.01	0.31	4.87e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.79	0.35	5.02e-11	Tonsillectomy;
LUSC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	14.07	0.61	1.23e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06544989	chr22:39130855	UNC84B	0.34	5.8	0.3	1.53e-8	Menopause (age at onset);
LUSC	trans	rs6480314	0.542	rs10998044	chr10:70029265	A/G	cg04882175	chr6:131122610	NA	-0.55	-6.3	-0.33	9.45e-10	Optic nerve measurement (disc area);
LUSC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	0.96	17.76	0.7	3.72e-50	Heart rate;
LUSC	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg25237894	chr2:233734115	C2orf82	0.35	6.51	0.34	2.78e-10	Coronary artery disease;
LUSC	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg25755851	chr1:9335794	NA	-0.82	-13.44	-0.59	3.11e-33	Eosinophil percentage of white cells;
LUSC	cis	rs34366173	1	rs34366173	chr15:63998914	CTT/C	cg12036633	chr15:63758958	NA	-0.39	-5.66	-0.3	3.19e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.04	21.3	0.76	3.4e-64	Cognitive function;
LUSC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.87	0.6	7.37e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.47e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-5.9	-0.31	9.06e-9	Vitiligo;
LUSC	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg10978503	chr1:24200527	CNR2	0.45	10.11	0.48	3.84e-21	Immature fraction of reticulocytes;
LUSC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg06074448	chr4:187884817	NA	-0.41	-6.85	-0.35	3.49e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg24812749	chr6:127587940	RNF146	-0.7	-10.07	-0.48	5.4e-21	Breast cancer;
LUSC	cis	rs6736093	0.966	rs870761	chr2:112745290	A/T	cg12686935	chr2:112915763	FBLN7	-0.37	-5.96	-0.31	6.32e-9	Coronary artery disease;
LUSC	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg08085267	chr17:45401833	C17orf57	-0.6	-9.96	-0.48	1.28e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20361001	chr2:9563570	ITGB1BP1;CPSF3	-0.45	-6.57	-0.34	1.97e-10	Electrocardiographic conduction measures;
LUSC	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg05163923	chr11:71159392	DHCR7	-0.76	-9.95	-0.48	1.32e-20	Vitamin D levels;
LUSC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.38	-0.33	5.89e-10	Extrinsic epigenetic age acceleration;
LUSC	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-6.89	-0.35	2.81e-11	Monocyte count;
LUSC	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg19875535	chr5:140030758	IK	0.38	5.79	0.3	1.66e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg09904177	chr6:26538194	HMGN4	0.75	14.27	0.62	2.07e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg06238570	chr21:40685208	BRWD1	-0.63	-10.46	-0.5	2.5e-22	Cognitive function;
LUSC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.39	0.33	5.71e-10	Lung cancer;
LUSC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg05585544	chr11:47624801	NA	-0.42	-7.3	-0.37	2.07e-12	Subjective well-being;
LUSC	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg12011299	chr4:100065546	ADH4	-0.72	-10.42	-0.5	3.38e-22	Alcohol dependence;
LUSC	trans	rs4148689	0.951	rs2027944	chr7:117187659	T/C	cg10450175	chr16:88689712	ZC3H18	0.46	5.99	0.31	5.37e-9	Gout;
LUSC	cis	rs250677	0.522	rs55732303	chr5:148392538	C/T	cg18129178	chr5:148520854	ABLIM3	-0.53	-7.75	-0.39	1.13e-13	Breast cancer;
LUSC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg11189052	chr15:85197271	WDR73	0.47	5.84	0.3	1.26e-8	Schizophrenia;
LUSC	cis	rs6496667	0.558	rs10459677	chr15:91042399	A/C	cg10434728	chr15:90938212	IQGAP1	-0.35	-6.57	-0.34	1.94e-10	Rheumatoid arthritis;
LUSC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg06363034	chr20:62225388	GMEB2	-0.46	-7.81	-0.39	7.64e-14	Glioblastoma;
LUSC	cis	rs73001065	0.636	rs11668104	chr19:19426181	G/A	cg03709012	chr19:19516395	GATAD2A	0.92	8.48	0.42	7.55e-16	LDL cholesterol;
LUSC	cis	rs10761482	0.690	rs4406773	chr10:62104574	A/G	cg18175470	chr10:62150864	ANK3	-0.49	-7.07	-0.36	9.31e-12	Schizophrenia;
LUSC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-7.33	-0.37	1.71e-12	Menarche (age at onset);
LUSC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.7	0.39	1.54e-13	Prudent dietary pattern;
LUSC	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg03676636	chr4:99064102	C4orf37	0.37	8.04	0.4	1.58e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs13089785	0.725	rs2222822	chr3:123604788	T/A	cg02558132	chr3:123411198	MYLK	0.36	6.07	0.32	3.5e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg05717871	chr11:638507	DRD4	-0.35	-6.1	-0.32	3.01e-9	Systemic lupus erythematosus;
LUSC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg18225595	chr11:63971243	STIP1	0.6	9.9	0.48	1.98e-20	Platelet count;
LUSC	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg13628971	chr7:2884303	GNA12	0.38	5.72	0.3	2.36e-8	Height;
LUSC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs6424115	1.000	rs7521961	chr1:24157634	C/T	cg15997130	chr1:24165203	NA	-0.56	-9.19	-0.45	4.43e-18	Immature fraction of reticulocytes;
LUSC	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg17467752	chr17:38218738	THRA	-0.5	-6.97	-0.36	1.69e-11	White blood cell count;
LUSC	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-0.97	-15.59	-0.65	1.43e-41	Dupuytren's disease;
LUSC	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg03474202	chr17:45855739	NA	-0.29	-6.62	-0.34	1.44e-10	IgG glycosylation;
LUSC	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.51	0.59	1.83e-33	Morning vs. evening chronotype;
LUSC	cis	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg06521331	chr12:34319734	NA	-0.46	-7.69	-0.39	1.71e-13	Morning vs. evening chronotype;
LUSC	cis	rs2629540	0.765	rs12221075	chr10:126534855	G/A	cg08799069	chr10:126477246	METTL10	-0.52	-7.78	-0.39	9.23e-14	Cocaine dependence;
LUSC	cis	rs4713675	0.565	rs3818530	chr6:33661222	C/G	cg14003231	chr6:33640908	ITPR3	0.31	6.1	0.32	2.97e-9	Plateletcrit;
LUSC	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg21770322	chr7:97807741	LMTK2	0.55	10.04	0.48	6.79e-21	Breast cancer;
LUSC	cis	rs500891	0.693	rs1013317	chr6:83979611	C/T	cg08257003	chr6:84140564	ME1	0.34	7.03	0.36	1.18e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18876405	chr7:65276391	NA	-0.55	-8.77	-0.43	9.11e-17	Aortic root size;
LUSC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.24	14.24	0.61	2.72e-36	Diabetic kidney disease;
LUSC	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18252515	chr7:66147081	NA	-0.58	-7.99	-0.4	2.16e-14	Corneal structure;
LUSC	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg06462663	chr19:18546047	ISYNA1	0.48	8.24	0.41	3.95e-15	Breast cancer;
LUSC	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg13010199	chr12:38710504	ALG10B	0.66	9.98	0.48	1.02e-20	Bladder cancer;
LUSC	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00149659	chr3:10157352	C3orf10	0.98	14.52	0.62	2.16e-37	Alzheimer's disease;
LUSC	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg12091567	chr17:66097778	LOC651250	-0.74	-9.4	-0.46	9.15e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg25456477	chr12:86230367	RASSF9	0.33	5.8	0.3	1.55e-8	Major depressive disorder;
LUSC	cis	rs701145	0.585	rs1609205	chr3:153793923	G/A	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	cis	rs10806425	0.524	rs1394220	chr6:91019304	A/C	cg06866423	chr6:90926672	BACH2	0.41	6.6	0.34	1.63e-10	Celiac disease;
LUSC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg25019033	chr10:957182	NA	-0.52	-6.51	-0.34	2.81e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02176678	chr2:219576539	TTLL4	0.64	11.6	0.54	2.25e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs72772090	0.539	rs11740375	chr5:96112897	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.67	-6.93	-0.35	2.24e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10911363	0.592	rs4047798	chr1:183421406	C/T	cg09173681	chr1:183549694	NCF2	-0.62	-11.07	-0.52	1.84e-24	Systemic lupus erythematosus;
LUSC	trans	rs8040855	0.965	rs4843027	chr15:85715123	G/A	cg00988175	chr11:59481031	OR10V1	-0.3	-6.56	-0.34	2.02e-10	Bulimia nervosa;
LUSC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg21862992	chr11:68658383	NA	0.51	8.09	0.4	1.11e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.0	-0.52	3.3e-24	Mean corpuscular volume;
LUSC	trans	rs1493916	0.777	rs1845385	chr18:31318336	T/C	cg27147174	chr7:100797783	AP1S1	-0.54	-8.49	-0.42	6.74e-16	Life satisfaction;
LUSC	cis	rs56399783	0.901	rs73033407	chr7:2878857	G/C	cg14895029	chr7:2775587	GNA12	0.57	6.42	0.33	4.64e-10	Childhood ear infection;
LUSC	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg22906224	chr7:99728672	NA	0.47	6.58	0.34	1.86e-10	Coronary artery disease;
LUSC	cis	rs7927771	0.560	rs4752858	chr11:47685829	C/T	cg20307385	chr11:47447363	PSMC3	-0.43	-6.28	-0.33	1.04e-9	Subjective well-being;
LUSC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg04553112	chr3:125709451	NA	-0.48	-5.82	-0.3	1.41e-8	Blood pressure (smoking interaction);
LUSC	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg12863693	chr15:85201151	NMB	0.41	8.54	0.42	4.82e-16	Schizophrenia;
LUSC	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg07169764	chr2:136633963	MCM6	0.87	11.91	0.55	1.67e-27	Corneal structure;
LUSC	cis	rs4363385	0.818	rs561143	chr1:153010734	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs3768617	0.811	rs10911233	chr1:183052585	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.75	0.43	1.08e-16	Fuchs's corneal dystrophy;
LUSC	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.02e-14	Corneal astigmatism;
LUSC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg14019146	chr3:50243930	SLC38A3	0.31	6.96	0.36	1.81e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10193935	0.901	rs17029411	chr2:42479149	G/A	cg27598129	chr2:42591480	NA	-0.57	-7.82	-0.39	6.99e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs983392	0.709	rs11601689	chr11:59996266	G/C	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.11	-0.32	2.85e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7705502	0.962	rs1976074	chr5:173384663	T/A	cg18693985	chr5:173351052	CPEB4	-0.39	-6.23	-0.32	1.37e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg17911788	chr17:44343683	NA	0.29	5.68	0.3	2.98e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.4	-6.02	-0.31	4.55e-9	HDL cholesterol;
LUSC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg08499158	chr17:42289980	UBTF	0.4	6.21	0.32	1.59e-9	Total body bone mineral density;
LUSC	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg06640241	chr16:89574553	SPG7	-0.39	-5.71	-0.3	2.47e-8	Hemoglobin concentration;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14893161	chr1:205819251	PM20D1	-0.87	-16.69	-0.67	6.72e-46	Menarche (age at onset);
LUSC	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg20991723	chr1:152506922	NA	0.49	9.19	0.45	4.2e-18	Hair morphology;
LUSC	cis	rs11608355	1.000	rs11611370	chr12:109870291	A/G	cg05360138	chr12:110035743	NA	-0.45	-6.21	-0.32	1.54e-9	Neuroticism;
LUSC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06112835	chr11:68658793	MRPL21	0.52	7.88	0.4	4.61e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs3857536	0.813	rs7743965	chr6:66941346	C/G	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.73	-10.93	-0.51	5.52e-24	Menarche (age at onset);
LUSC	cis	rs2540226	0.935	rs2716730	chr2:39955834	T/C	cg23576258	chr2:39999331	THUMPD2	0.35	5.85	0.3	1.16e-8	Personality dimensions;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.49	-7.1	-0.36	7.58e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.33	-0.33	7.91e-10	Dupuytren's disease;
LUSC	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg01528321	chr10:82214614	TSPAN14	1.06	16.23	0.66	4.3e-44	Post bronchodilator FEV1;
LUSC	cis	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg09085632	chr11:111637200	PPP2R1B	0.5	6.97	0.36	1.67e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.88	15.08	0.64	1.52e-39	Bladder cancer;
LUSC	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg23711669	chr6:146136114	FBXO30	0.87	16.14	0.66	9.98e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18932078	chr1:2524107	MMEL1	0.32	7.14	0.36	5.89e-12	Ulcerative colitis;
LUSC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.29e-12	Tonsillectomy;
LUSC	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg01557791	chr16:72042693	DHODH	-0.48	-7.08	-0.36	8.4e-12	Fibrinogen levels;
LUSC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg02487422	chr3:49467188	NICN1	0.42	6.12	0.32	2.65e-9	Parkinson's disease;
LUSC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	7.91	0.4	3.9e-14	Height;
LUSC	cis	rs9549260	0.599	rs12870023	chr13:41244222	T/A	cg21288729	chr13:41239152	FOXO1	0.62	9.52	0.46	3.52e-19	Red blood cell count;
LUSC	cis	rs34526934	0.566	rs9141	chr2:177037970	T/C	cg26754761	chr2:177040938	NA	-0.41	-7.96	-0.4	2.63e-14	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	16.2	0.66	5.64e-44	Platelet count;
LUSC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg20283391	chr11:68216788	NA	-0.57	-8.17	-0.41	6.57e-15	Total body bone mineral density;
LUSC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13012494	chr21:47604986	C21orf56	0.45	6.6	0.34	1.6e-10	Testicular germ cell tumor;
LUSC	cis	rs4730250	0.554	rs76257331	chr7:106916279	G/A	cg02696742	chr7:106810147	HBP1	-0.55	-7.4	-0.38	1.13e-12	Osteoarthritis;
LUSC	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg24375607	chr4:120327624	NA	0.77	11.34	0.53	1.95e-25	Corneal astigmatism;
LUSC	cis	rs912057	1.000	rs1294414	chr6:6740366	A/G	cg06612196	chr6:6737390	NA	0.53	9.84	0.47	3.17e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg20302533	chr7:39170763	POU6F2	0.53	8.32	0.41	2.29e-15	IgG glycosylation;
LUSC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg12963246	chr6:28129442	ZNF389	0.52	7.12	0.36	6.72e-12	Depression;
LUSC	trans	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg26384229	chr12:38710491	ALG10B	0.56	9.07	0.44	1.06e-17	Morning vs. evening chronotype;
LUSC	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg21605333	chr4:119757512	SEC24D	0.88	8.09	0.4	1.12e-14	Cannabis dependence symptom count;
LUSC	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg09904177	chr6:26538194	HMGN4	-0.45	-6.07	-0.32	3.38e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg12257692	chr3:49977190	RBM6	-0.24	-6.57	-0.34	1.97e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg21798802	chr22:38057573	PDXP	-0.49	-10.82	-0.51	1.38e-23	Fat distribution (HIV);
LUSC	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.8e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs16895831	0.519	rs62414629	chr6:42598898	G/A	cg10605015	chr6:42532144	UBR2	-0.48	-5.69	-0.3	2.85e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg11632617	chr15:75315747	PPCDC	-0.53	-6.9	-0.35	2.65e-11	Blood trace element (Zn levels);
LUSC	cis	rs7124681	0.565	rs2203712	chr11:47534964	T/C	cg20307385	chr11:47447363	PSMC3	0.44	6.45	0.33	4.04e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg02175503	chr12:58329896	NA	0.4	5.73	0.3	2.27e-8	Multiple sclerosis;
LUSC	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg03522245	chr20:25566470	NINL	0.35	5.67	0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg05872129	chr22:39784769	NA	0.59	10.39	0.49	4.27e-22	Intelligence (multi-trait analysis);
LUSC	trans	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg24644049	chr4:85504048	CDS1	0.88	7.56	0.38	3.9e-13	Skin colour saturation;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08228715	chr17:79895357	PYCR1	-0.45	-7.02	-0.36	1.22e-11	Electrocardiographic conduction measures;
LUSC	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	6.58	0.34	1.78e-10	Lung cancer in ever smokers;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg02679291	chr19:48248902	GLTSCR2	0.36	6.06	0.31	3.75e-9	Mosquito bite size;
LUSC	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-25.58	-0.81	1.08e-80	Exhaled nitric oxide output;
LUSC	cis	rs11158026	0.526	rs3783639	chr14:55348666	T/C	cg04306507	chr14:55594613	LGALS3	0.4	6.45	0.33	3.94e-10	Parkinson's disease;
LUSC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.02	0.36	1.25e-11	Parkinson's disease;
LUSC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08470875	chr2:26401718	FAM59B	0.68	9.16	0.45	5.31e-18	Gut microbiome composition (summer);
LUSC	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg03576123	chr11:487126	PTDSS2	-0.45	-5.81	-0.3	1.45e-8	Systemic lupus erythematosus;
LUSC	cis	rs11642862	1.000	rs11645367	chr16:30770074	C/T	cg02466173	chr16:30829666	NA	-0.71	-7.59	-0.38	3.31e-13	Tonsillectomy;
LUSC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg08392591	chr16:89556376	ANKRD11	0.4	6.0	0.31	5.24e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.68	0.3	2.9e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg05985134	chr18:33552581	C18orf21	0.52	7.04	0.36	1.13e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs10779751	0.666	rs77270747	chr1:11214584	A/C	cg08854313	chr1:11322531	MTOR	-0.85	-13.21	-0.59	2.48e-32	Body mass index;
LUSC	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg25208724	chr1:156163844	SLC25A44	1.04	21.37	0.76	1.86e-64	Testicular germ cell tumor;
LUSC	cis	rs10843647	1.000	rs973483	chr12:30325893	T/G	cg12718339	chr12:29936407	TMTC1	-0.35	-5.87	-0.31	1.03e-8	Glucose homeostasis traits;
LUSC	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.22	0.71	5.32e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7590368	0.706	rs56268818	chr2:10956011	C/T	cg15705551	chr2:10952987	PDIA6	0.52	5.71	0.3	2.5e-8	Educational attainment (years of education);
LUSC	cis	rs61935443	0.720	rs892493	chr12:95283943	T/C	cg21533806	chr12:95267307	NA	0.51	6.35	0.33	7.08e-10	Schizophrenia;
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.47	7.32	0.37	1.83e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg14343924	chr8:8086146	FLJ10661	-0.45	-6.23	-0.32	1.43e-9	Monocyte count;
LUSC	cis	rs4666002	0.956	rs13020949	chr2:27836605	C/T	cg27432699	chr2:27873401	GPN1	0.41	5.82	0.3	1.35e-8	Phospholipid levels (plasma);
LUSC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg13962466	chr20:25176127	ENTPD6	-0.38	-6.05	-0.31	3.85e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg00310523	chr12:86230176	RASSF9	0.4	7.18	0.37	4.67e-12	Major depressive disorder;
LUSC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg04455712	chr21:45112962	RRP1B	0.43	8.14	0.41	7.98e-15	Mean corpuscular volume;
LUSC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.28	0.45	2.23e-18	Prudent dietary pattern;
LUSC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg05347473	chr6:146136440	FBXO30	0.63	10.93	0.51	5.81e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg10253484	chr15:75165896	SCAMP2	-0.5	-7.57	-0.38	3.59e-13	Breast cancer;
LUSC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg13047869	chr3:10149882	C3orf24	0.56	7.91	0.4	3.79e-14	Alzheimer's disease;
LUSC	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg18357645	chr12:58087776	OS9	0.38	5.77	0.3	1.85e-8	Multiple sclerosis;
LUSC	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg05714579	chr10:131428358	MGMT	-0.77	-11.67	-0.54	1.23e-26	Response to temozolomide;
LUSC	cis	rs7202877	0.706	rs247437	chr16:75431275	T/G	cg04384234	chr16:75411784	CFDP1	0.67	9.53	0.46	3.35e-19	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg24130564	chr14:104152367	KLC1	-0.49	-7.07	-0.36	9.18e-12	Body mass index;
LUSC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg08219700	chr8:58056026	NA	0.43	5.68	0.3	2.99e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-8.99	-0.44	1.92e-17	HDL cholesterol;
LUSC	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg04287289	chr16:89883240	FANCA	-0.5	-7.56	-0.38	3.85e-13	Vitiligo;
LUSC	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg02153584	chr22:29168773	CCDC117	0.65	10.32	0.49	7.39e-22	Lymphocyte counts;
LUSC	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg08017756	chr2:100939284	LONRF2	-0.45	-8.28	-0.41	3.01e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10843647	1.000	rs5010726	chr12:30337487	C/T	cg12718339	chr12:29936407	TMTC1	0.35	5.77	0.3	1.84e-8	Glucose homeostasis traits;
LUSC	cis	rs11605924	0.692	rs877412	chr11:45897651	A/C	ch.11.939596F	chr11:45881766	CRY2	0.66	10.13	0.48	3.24e-21	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.52	10.26	0.49	1.2e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg13010199	chr12:38710504	ALG10B	0.71	10.85	0.51	1.03e-23	Bladder cancer;
LUSC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg16362232	chr11:430036	ANO9	0.61	7.76	0.39	1.03e-13	Body mass index;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg18263451	chr1:25573180	C1orf63	0.41	6.07	0.32	3.51e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg17143192	chr8:8559678	CLDN23	0.39	6.06	0.31	3.71e-9	Mood instability;
LUSC	cis	rs16949788	1.000	rs75532475	chr15:66832466	A/G	cg08120210	chr15:66682733	MAP2K1	-0.61	-6.28	-0.33	1.04e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg21053147	chr12:120880522	NA	0.51	6.2	0.32	1.65e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg11663144	chr21:46675770	NA	-0.41	-7.12	-0.36	6.84e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg23649088	chr2:200775458	C2orf69	0.48	6.69	0.34	9.49e-11	Schizophrenia;
LUSC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg12560992	chr17:57184187	TRIM37	0.83	15.26	0.64	2.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7818345	0.637	rs3923920	chr8:19359184	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.3	-5.65	-0.3	3.4e-8	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg08773314	chr2:239334832	ASB1	0.42	9.26	0.45	2.63e-18	Multiple system atrophy;
LUSC	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg13334819	chr7:99746414	C7orf59	-0.5	-6.73	-0.35	7.41e-11	Coronary artery disease;
LUSC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg14196790	chr5:131705035	SLC22A5	0.45	7.38	0.37	1.24e-12	Breast cancer;Mosquito bite size;
LUSC	cis	rs4285028	0.747	rs11928871	chr3:121483388	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-12.24	-0.56	1.03e-28	Multiple sclerosis;
LUSC	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg26395211	chr5:140044315	WDR55	0.46	7.13	0.36	6.16e-12	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	8.49	0.42	7.01e-16	Type 2 diabetes;
LUSC	cis	rs4144743	1.000	rs34492688	chr17:45321622	C/A	cg18085866	chr17:45331354	ITGB3	-0.75	-8.11	-0.41	9.69e-15	Body mass index;
LUSC	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg09654669	chr8:57350985	NA	-0.57	-7.83	-0.39	6.46e-14	Obesity-related traits;
LUSC	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg08079166	chr15:68083412	MAP2K5	-0.47	-9.87	-0.48	2.57e-20	Restless legs syndrome;
LUSC	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg01028140	chr2:1542097	TPO	-0.61	-8.28	-0.41	2.9e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-8.15	-0.41	7.21e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg08888203	chr3:10149979	C3orf24	0.59	8.21	0.41	4.83e-15	Alzheimer's disease;
LUSC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg20684491	chr1:25596433	NA	0.4	6.28	0.33	1.04e-9	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg26338869	chr17:61819248	STRADA	0.41	5.95	0.31	6.66e-9	Prudent dietary pattern;
LUSC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg12386194	chr3:101231763	SENP7	0.64	8.95	0.44	2.44e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg24562669	chr7:97807699	LMTK2	0.34	5.93	0.31	7.39e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs735539	0.645	rs7326068	chr13:21209512	A/G	cg04906043	chr13:21280425	IL17D	0.37	6.16	0.32	2.11e-9	Dental caries;
LUSC	cis	rs9811920	0.535	rs704574	chr3:99483773	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.3	5.84	0.3	1.27e-8	Axial length;
LUSC	cis	rs9326248	0.769	rs499910	chr11:116763034	G/A	cg20608306	chr11:116969690	SIK3	0.39	6.36	0.33	6.76e-10	Blood protein levels;
LUSC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg13628971	chr7:2884303	GNA12	0.48	6.69	0.34	9.7e-11	Height;
LUSC	cis	rs7589342	0.831	rs10169998	chr2:106452253	A/G	cg14210321	chr2:106509881	NCK2	-0.54	-8.06	-0.4	1.38e-14	Addiction;
LUSC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.73	0.35	7.39e-11	Tonsillectomy;
LUSC	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg02023728	chr11:77925099	USP35	0.47	6.97	0.36	1.68e-11	Testicular germ cell tumor;
LUSC	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg09184832	chr6:79620586	NA	-0.44	-7.2	-0.37	3.94e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs72792513	1.000	rs72798597	chr2:22909794	C/T	cg05844895	chr16:88969569	CBFA2T3	0.53	6.22	0.32	1.52e-9	Hepatitis B;
LUSC	trans	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg26043149	chr18:55253948	FECH	0.51	7.55	0.38	4.18e-13	Bone mineral density;
LUSC	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg11102782	chr19:18549136	ISYNA1	-0.36	-6.89	-0.35	2.82e-11	Breast cancer;
LUSC	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17916960	chr15:79447300	NA	-0.53	-10.55	-0.5	1.22e-22	Refractive error;
LUSC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.58	8.94	0.44	2.74e-17	Longevity;
LUSC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg22508957	chr16:3507546	NAT15	0.65	10.86	0.51	9.8599999999999993e-24	Tuberculosis;
LUSC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg20243544	chr17:37824526	PNMT	0.52	7.4	0.38	1.12e-12	Asthma;
LUSC	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg23241863	chr10:102295624	HIF1AN	0.46	5.85	0.3	1.18e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10207060	0.500	rs4365487	chr2:240706803	T/C	cg07506560	chr2:240697449	NA	0.45	6.92	0.35	2.34e-11	Obesity-related traits;
LUSC	cis	rs983392	0.667	rs583791	chr11:59947252	C/T	cg24026212	chr11:59952134	MS4A6A	0.34	6.23	0.32	1.43e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg17366294	chr4:99064904	C4orf37	0.54	8.89	0.44	3.93e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg00012203	chr2:219082015	ARPC2	-0.76	-13.09	-0.58	6.86e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg27165867	chr14:105738592	BRF1	-0.55	-8.03	-0.4	1.7e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8114671	0.527	rs3736802	chr20:33604042	T/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-6.85	-0.35	3.54e-11	Height;
LUSC	cis	rs13006833	0.668	rs906916	chr2:191166212	G/A	cg21644426	chr2:191273491	MFSD6	0.43	6.27	0.32	1.09e-9	Urinary metabolites;
LUSC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg14416269	chr4:6271139	WFS1	-0.53	-11.37	-0.53	1.47e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg01119278	chr6:110721349	DDO	-0.45	-7.96	-0.4	2.62e-14	Platelet distribution width;
LUSC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00339695	chr16:24857497	SLC5A11	0.39	6.72	0.34	8.02e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.64	-13.55	-0.6	1.18e-33	Monocyte percentage of white cells;
LUSC	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg21095983	chr6:86352623	SYNCRIP	0.53	8.47	0.42	7.8e-16	Smooth-surface caries;
LUSC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.25	-0.32	1.23e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26142380	chr17:27276017	PHF12	0.44	6.05	0.31	3.83e-9	Neuroticism;
LUSC	cis	rs67981189	0.593	rs9323557	chr14:71470840	C/T	cg15816911	chr14:71606274	NA	-0.37	-6.52	-0.34	2.58e-10	Schizophrenia;
LUSC	cis	rs847577	1.000	rs847577	chr7:97694858	T/A	cg21770322	chr7:97807741	LMTK2	-0.51	-9.16	-0.45	5.3e-18	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02185053	chr8:130952137	FAM49B	-0.43	-6.55	-0.34	2.13e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.93	0.58	2.8e-31	Chronic sinus infection;
LUSC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg20406979	chr6:167373233	NA	0.26	6.24	0.32	1.34e-9	Crohn's disease;
LUSC	cis	rs11051970	0.877	rs2651360	chr12:32588920	C/T	cg02745156	chr12:32552066	NA	0.43	7.3	0.37	2.16e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03264133	chr6:25882463	NA	0.39	6.37	0.33	6.29e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg14552801	chr7:65878734	NA	0.38	5.9	0.31	8.97e-9	Aortic root size;
LUSC	cis	rs2625529	0.617	rs62023343	chr15:72174963	C/A	cg16672083	chr15:72433130	SENP8	0.48	7.93	0.4	3.38e-14	Red blood cell count;
LUSC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg22963979	chr7:1858916	MAD1L1	-0.56	-8.71	-0.43	1.4e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs73198271	0.562	rs112717383	chr8:8663216	T/C	cg01851573	chr8:8652454	MFHAS1	0.62	7.89	0.4	4.28e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05025164	chr4:1340916	KIAA1530	0.63	9.61	0.47	1.77e-19	Longevity;
LUSC	cis	rs2073300	1.000	rs6036418	chr20:23449698	A/G	cg09953122	chr20:23471693	CST8	-0.64	-5.83	-0.3	1.3e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg21775007	chr8:11205619	TDH	0.51	7.47	0.38	6.97e-13	Neuroticism;
LUSC	trans	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg14791747	chr16:20752902	THUMPD1	-0.44	-6.17	-0.32	1.92e-9	Pancreatic cancer;
LUSC	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.62	-0.34	1.39e-10	QT interval;
LUSC	trans	rs997154	0.655	rs7147394	chr14:23411054	C/G	cg08043656	chr13:52419383	FLJ37307	0.42	6.01	0.31	4.83e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUSC	cis	rs897984	0.568	rs4889653	chr16:30895713	C/T	cg02466173	chr16:30829666	NA	0.51	8.48	0.42	7.29e-16	Dementia with Lewy bodies;
LUSC	cis	rs9815354	0.812	rs73083333	chr3:41927505	G/A	cg03022575	chr3:42003672	ULK4	0.82	8.8	0.43	7.29e-17	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg02800362	chr5:177631904	HNRNPAB	0.88	13.11	0.58	5.56e-32	Obesity-related traits;
LUSC	trans	rs4811340	0.600	rs6063829	chr20:51173570	G/A	cg15736553	chr3:11610338	VGLL4	-0.34	-6.06	-0.31	3.74e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.62	9.83	0.47	3.52e-20	Alcohol dependence;
LUSC	cis	rs9296092	0.517	rs6911036	chr6:33471652	C/G	cg13560919	chr6:33536144	NA	-0.78	-13.33	-0.59	8.65e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.5	0.34	2.94e-10	Lung cancer;
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.78	11.85	0.54	2.76e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-13.04	-0.58	1.02e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs983392	0.667	rs624663	chr11:59945065	C/T	cg20284999	chr11:59952153	MS4A6A	0.35	6.08	0.32	3.34e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10465746	0.725	rs980417	chr1:84365331	C/A	cg10977910	chr1:84465055	TTLL7	0.51	7.29	0.37	2.21e-12	Obesity-related traits;
LUSC	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.63	7.39	0.37	1.18e-12	Schizophrenia;
LUSC	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg26408565	chr15:76604113	ETFA	-0.47	-7.42	-0.38	9.75e-13	Blood metabolite levels;
LUSC	cis	rs4478037	0.822	rs9868526	chr3:33124269	A/G	cg19404215	chr3:33155277	CRTAP	-0.8	-9.34	-0.46	1.4e-18	Major depressive disorder;
LUSC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08704250	chr15:31115839	NA	0.39	6.12	0.32	2.68e-9	Huntington's disease progression;
LUSC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg11752832	chr7:134001865	SLC35B4	0.55	8.61	0.43	2.94e-16	Mean platelet volume;
LUSC	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg05855489	chr10:104503620	C10orf26	-0.71	-10.46	-0.5	2.47e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg18225595	chr11:63971243	STIP1	0.49	6.08	0.32	3.24e-9	Mean platelet volume;
LUSC	cis	rs4938330	0.512	rs4938327	chr11:116906728	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-6.65	-0.34	1.17e-10	Blood protein levels;
LUSC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	1.14	22.08	0.77	2.89e-67	Total cholesterol levels;
LUSC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg02931644	chr1:25747376	RHCE	0.35	6.41	0.33	5.01e-10	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg04374321	chr14:90722782	PSMC1	-0.67	-10.23	-0.49	1.52e-21	Mortality in heart failure;
LUSC	cis	rs909674	0.734	rs1005522	chr22:39845898	C/A	cg05872129	chr22:39784769	NA	-0.52	-8.03	-0.4	1.65e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs8030485	0.756	rs2102999	chr15:79410710	C/T	cg17916960	chr15:79447300	NA	-0.37	-6.66	-0.34	1.15e-10	Left ventricle wall thickness;
LUSC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg24675658	chr1:53192096	ZYG11B	-0.67	-11.08	-0.52	1.7e-24	Monocyte count;
LUSC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg10207240	chr12:122356781	WDR66	0.44	6.16	0.32	2.05e-9	Mean corpuscular volume;
LUSC	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg05855489	chr10:104503620	C10orf26	0.53	8.11	0.41	9.87e-15	Arsenic metabolism;
LUSC	cis	rs9583531	0.891	rs7999536	chr13:111382199	G/A	cg24331049	chr13:111365604	ING1	0.65	7.37	0.37	1.37e-12	Coronary artery disease;
LUSC	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg13334819	chr7:99746414	C7orf59	0.5	6.71	0.34	8.38e-11	Coronary artery disease;
LUSC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.66	14.89	0.63	8.34e-39	Hemoglobin concentration;
LUSC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.56	-0.42	4.11e-16	Bipolar disorder;
LUSC	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg08975724	chr8:8085496	FLJ10661	0.56	8.22	0.41	4.65e-15	Mood instability;
LUSC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg07741184	chr6:167504864	NA	-0.39	-6.93	-0.35	2.22e-11	Crohn's disease;
LUSC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg09640425	chr7:158790006	NA	-0.52	-8.2	-0.41	5.4e-15	Facial morphology (factor 20);
LUSC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.88	12.15	0.55	2.15e-28	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg14830002	chr1:247616686	OR2B11	0.49	7.05	0.36	1.05e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.77	0.43	9e-17	Prudent dietary pattern;
LUSC	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg24130564	chr14:104152367	KLC1	-0.48	-6.87	-0.35	3.19e-11	Body mass index;
LUSC	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg02903104	chr8:1507517	DLGAP2	0.35	6.8	0.35	4.87e-11	Lung cancer;
LUSC	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg13042288	chr15:90349979	ANPEP	-0.48	-6.91	-0.35	2.46e-11	Uric acid levels;
LUSC	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg04362960	chr10:104952993	NT5C2	0.66	9.45	0.46	6.02e-19	Arsenic metabolism;
LUSC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg04414720	chr1:150670196	GOLPH3L	0.56	8.94	0.44	2.78e-17	Urate levels;
LUSC	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg10356904	chr22:49881777	NA	-0.3	-6.76	-0.35	6.13e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07051718	chr19:1438596	RPS15	0.43	6.03	0.31	4.37e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.78	-0.7	2.97e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4443100	1.000	rs4443100	chr22:23372864	C/G	cg21100191	chr22:23484243	RTDR1	0.5	6.1	0.32	3e-9	Serum parathyroid hormone levels;
LUSC	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	0.97	15.56	0.65	1.96e-41	Dupuytren's disease;
LUSC	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg19743168	chr1:23544995	NA	0.4	7.89	0.4	4.25e-14	Height;
LUSC	cis	rs813218	0.625	rs793484	chr3:99491508	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.3	-5.7	-0.3	2.58e-8	Orofacial clefts;
LUSC	cis	rs7315438	0.600	rs1874894	chr12:115886306	C/T	cg24172291	chr12:115889509	NA	-0.36	-6.14	-0.32	2.36e-9	Colorectal cancer;
LUSC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-6.66	-0.34	1.1e-10	Colorectal cancer;
LUSC	cis	rs9796	0.505	rs28665387	chr15:41532869	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.57	-0.42	3.98e-16	Menopause (age at onset);
LUSC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg18350739	chr11:68623251	NA	-0.39	-6.8	-0.35	4.88e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	10.66	0.5	4.82e-23	Homoarginine levels;
LUSC	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg24675056	chr1:15929824	NA	0.49	8.5	0.42	6.3e-16	Systolic blood pressure;
LUSC	cis	rs617219	0.889	rs12659618	chr5:78465660	G/A	cg24856658	chr5:78533917	JMY	-0.3	-5.75	-0.3	1.98e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.59	8.72	0.43	1.36e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg02782426	chr3:40428986	ENTPD3	-0.39	-7.61	-0.38	2.76e-13	Renal cell carcinoma;
LUSC	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg22139774	chr2:100720529	AFF3	-0.47	-8.12	-0.41	9.11e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	trans	rs10946292	0.706	rs3013256	chr6:170434737	C/G	cg17832364	chr10:94847294	NA	0.39	6.45	0.33	3.95e-10	Obesity-related traits;
LUSC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	13.12	0.58	5.47e-32	Monocyte percentage of white cells;
LUSC	cis	rs9309473	0.950	rs6546854	chr2:73834034	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.42	-0.33	4.75e-10	Metabolite levels;
LUSC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg11764359	chr7:65958608	NA	-0.51	-6.57	-0.34	1.94e-10	Aortic root size;
LUSC	trans	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg20935933	chr6:143382018	AIG1	0.5	7.08	0.36	8.38e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs12101261	0.536	rs724170	chr14:81457940	G/A	cg06600135	chr14:81408086	NA	0.46	6.96	0.36	1.79e-11	Graves' disease;
LUSC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.86	0.51	9.5e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg03060546	chr3:49711283	APEH	0.72	12.18	0.55	1.79e-28	Resting heart rate;
LUSC	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg12473912	chr3:136751656	NA	0.39	6.82	0.35	4.24e-11	Neuroticism;
LUSC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg16325326	chr1:53192061	ZYG11B	0.7	11.44	0.53	8.58e-26	Monocyte count;
LUSC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.56	0.34	2.09e-10	Menopause (age at onset);
LUSC	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg03342759	chr3:160939853	NMD3	-0.44	-6.31	-0.33	8.8e-10	Parkinson's disease;
LUSC	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg20607287	chr7:12443886	VWDE	-0.58	-6.03	-0.31	4.37e-9	Coronary artery disease;
LUSC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg13114125	chr14:105738426	BRF1	-0.95	-16.13	-0.66	1.07e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg05527609	chr1:210001259	C1orf107	-0.8	-10.07	-0.48	5.22e-21	Orofacial clefts;
LUSC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg00033643	chr7:134001901	SLC35B4	0.46	7.28	0.37	2.44e-12	Mean platelet volume;
LUSC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.82	13.97	0.61	3.12e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg02018176	chr4:1364513	KIAA1530	0.46	6.53	0.34	2.46e-10	Recombination rate (females);
LUSC	cis	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg02508848	chr16:68573721	ZFP90	-0.43	-5.73	-0.3	2.23e-8	Ulcerative colitis;
LUSC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg20203395	chr5:56204925	C5orf35	-0.75	-10.17	-0.49	2.51e-21	Initial pursuit acceleration;
LUSC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg16558253	chr16:72132732	DHX38	-0.41	-6.32	-0.33	8.5e-10	Fibrinogen levels;
LUSC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg23093090	chr10:104574429	C10orf26	-0.45	-8.06	-0.4	1.37e-14	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6693567	0.565	rs7544900	chr1:150262333	A/C	cg15654264	chr1:150340011	RPRD2	-0.45	-7.29	-0.37	2.25e-12	Migraine;
LUSC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg09655341	chr17:79618100	PDE6G	-0.29	-6.64	-0.34	1.29e-10	Eye color traits;
LUSC	cis	rs11997175	0.646	rs4733177	chr8:33691754	A/G	ch.8.33884649F	chr8:33765107	NA	0.45	6.65	0.34	1.21e-10	Body mass index;
LUSC	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg12432903	chr7:1882776	MAD1L1	0.52	6.32	0.33	8.26e-10	Bipolar disorder;
LUSC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg23978390	chr7:1156363	C7orf50	0.44	6.25	0.32	1.25e-9	Longevity;Endometriosis;
LUSC	cis	rs607541	0.764	rs629466	chr15:45934745	A/T	cg26924012	chr15:45694286	SPATA5L1	0.55	5.86	0.31	1.1e-8	Obesity-related traits;
LUSC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg23649088	chr2:200775458	C2orf69	-0.53	-6.46	-0.33	3.79e-10	Schizophrenia;
LUSC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.12	0.52	1.15e-24	Menopause (age at onset);
LUSC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.56	11.17	0.52	7.79e-25	Asthma (sex interaction);
LUSC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg10792982	chr14:105748885	BRF1	-0.45	-8.04	-0.4	1.52e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-17.06	-0.68	2.23e-47	Primary sclerosing cholangitis;
LUSC	cis	rs2742234	0.541	rs1879310	chr10:43734775	A/G	cg07801480	chr10:43725741	RASGEF1A	-0.39	-5.91	-0.31	8.49e-9	Hirschsprung disease;
LUSC	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg26727032	chr16:67993705	SLC12A4	-0.45	-6.75	-0.35	6.58e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	11.0	0.52	3.27e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs17621444	0.522	rs4752366	chr10:121763304	G/A	cg02041677	chr10:121771263	NA	-0.33	-6.23	-0.32	1.4e-9	IgG glycosylation;
LUSC	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.41	-0.33	4.92e-10	High light scatter reticulocyte count;
LUSC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.28	0.56	7.31e-29	Prudent dietary pattern;
LUSC	trans	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.71	-0.34	8.22e-11	Monocyte count;
LUSC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.54	-9.55	-0.46	2.87e-19	Bipolar disorder;
LUSC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg04455712	chr21:45112962	RRP1B	0.45	8.42	0.42	1.15e-15	Mean corpuscular volume;
LUSC	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.18	0.61	4.72e-36	Exhaled nitric oxide levels;
LUSC	trans	rs72674100	1.000	rs4145376	chr4:97994304	C/T	cg09670535	chr1:18959427	PAX7	-0.61	-6.23	-0.32	1.41e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg19875535	chr5:140030758	IK	0.46	7.32	0.37	1.91e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg18827107	chr12:86230957	RASSF9	-0.41	-5.99	-0.31	5.43e-9	Major depressive disorder;
LUSC	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg07701084	chr6:150067640	NUP43	0.47	7.03	0.36	1.18e-11	Testicular germ cell tumor;
LUSC	cis	rs9921338	0.961	rs17605444	chr16:11413589	A/C	cg00044050	chr16:11439710	C16orf75	-0.52	-7.13	-0.36	6.41e-12	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg18827107	chr12:86230957	RASSF9	-0.45	-6.77	-0.35	5.7e-11	Major depressive disorder;
LUSC	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	10.69	0.5	3.94e-23	Blood protein levels;
LUSC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-17.53	-0.69	3.14e-49	Body mass index;
LUSC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10802521	chr3:52805072	NEK4	-0.53	-8.53	-0.42	5.07e-16	Bipolar disorder;
LUSC	cis	rs983392	0.803	rs56189574	chr11:59933492	A/G	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.36	-0.33	6.81e-10	Alzheimer's disease (late onset);
LUSC	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.86	0.4	5.28e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1997103	0.954	rs6593236	chr7:55410992	C/T	cg17469321	chr7:55412551	NA	0.66	10.59	0.5	8.59e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26354017	chr1:205819088	PM20D1	0.85	15.21	0.64	4.58e-40	Menarche (age at onset);
LUSC	cis	rs10193935	1.000	rs13424523	chr2:42413562	T/G	cg27598129	chr2:42591480	NA	-0.61	-8.05	-0.4	1.48e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8133932	0.564	rs452797	chr21:47348455	C/G	cg14185626	chr21:47401492	COL6A1	-0.44	-5.65	-0.3	3.37e-8	Schizophrenia;
LUSC	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.67	6.53	0.34	2.44e-10	Initial pursuit acceleration;
LUSC	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	7.24	0.37	3.04e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg05187965	chr10:45406764	TMEM72	-0.31	-6.79	-0.35	5.2e-11	Mean corpuscular volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18009376	chr17:80056900	FASN	-0.41	-5.98	-0.31	5.88e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6669072	0.679	rs1766163	chr1:91314510	C/T	cg08895590	chr1:91227319	NA	-0.32	-6.83	-0.35	4.06e-11	Cognitive function;
LUSC	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg12963866	chr19:57752005	ZNF805	0.41	5.87	0.31	1.08e-8	Hyperactive-impulsive symptoms;
LUSC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg24829409	chr8:58192753	C8orf71	-0.49	-5.69	-0.3	2.78e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg03522245	chr20:25566470	NINL	-0.36	-5.83	-0.3	1.33e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3862435	0.706	rs2525999	chr15:90970571	A/G	cg22089800	chr15:90895588	ZNF774	0.58	6.24	0.32	1.3e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg11530693	chr1:120165357	ZNF697	0.69	11.07	0.52	1.75e-24	Systemic lupus erythematosus;
LUSC	cis	rs7572644	0.629	rs28662360	chr2:28208920	A/G	cg27432699	chr2:27873401	GPN1	-0.51	-6.86	-0.35	3.28e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.96	0.44	2.42e-17	Schizophrenia;
LUSC	cis	rs1190552	0.846	rs12883789	chr14:102954621	G/A	cg18135206	chr14:102964638	TECPR2	0.46	5.69	0.3	2.73e-8	Blood protein levels;
LUSC	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg05340658	chr4:99064831	C4orf37	-0.57	-8.44	-0.42	9.6e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.89	0.4	4.28e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-7.09	-0.36	7.98e-12	Homocysteine levels;
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	0.98	21.07	0.76	2.68e-63	Menarche (age at onset);
LUSC	cis	rs6840360	1.000	rs1366909	chr4:152588421	A/C	cg22705602	chr4:152727874	NA	-0.27	-5.79	-0.3	1.63e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg26335602	chr6:28129616	ZNF389	0.46	6.3	0.33	9.21e-10	Depression;
LUSC	cis	rs9427116	0.702	rs9427108	chr1:154607914	G/A	cg17218026	chr1:154582156	ADAR	0.56	9.92	0.48	1.69e-20	Blood protein levels;
LUSC	trans	rs61931739	0.635	rs1852225	chr12:33963004	C/T	cg13010199	chr12:38710504	ALG10B	0.4	6.03	0.31	4.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg17376030	chr22:41985996	PMM1	0.43	5.67	0.3	3.06e-8	Vitiligo;
LUSC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg27432699	chr2:27873401	GPN1	-0.48	-7.09	-0.36	7.82e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs977987	0.806	rs7188231	chr16:75436561	T/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.04	-0.36	1.08e-11	Dupuytren's disease;
LUSC	cis	rs9905704	0.718	rs8072379	chr17:56615997	C/A	cg19466818	chr17:56409534	MIR142	0.35	6.54	0.34	2.31e-10	Testicular germ cell tumor;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23415442	chr10:88855540	GLUD1;FAM35A	0.46	6.26	0.32	1.16e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05890377	chr2:74357713	NA	-0.68	-12.63	-0.57	3.75e-30	Gestational age at birth (maternal effect);
LUSC	cis	rs11614062	1.000	rs11614062	chr12:93956672	A/T	cg18151635	chr12:93972918	NA	-0.58	-7.8	-0.39	7.79e-14	Height;
LUSC	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg21211680	chr2:198530	NA	0.68	7.31	0.37	2e-12	Blood protein levels;
LUSC	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg10018233	chr7:150070692	REPIN1	0.4	7.11	0.36	6.9e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	10.57	0.5	9.82e-23	Response to antipsychotic treatment;
LUSC	cis	rs909002	0.800	rs968335	chr1:32085776	G/A	cg01639898	chr1:32083012	HCRTR1	0.31	7.5	0.38	5.73e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.872	rs1559339	chr16:75318646	A/G	cg03315344	chr16:75512273	CHST6	0.5	9.61	0.47	1.86e-19	Dupuytren's disease;
LUSC	trans	rs867371	1.000	rs13380317	chr15:82506790	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.37	6.1	0.32	3e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.56	-0.38	3.86e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	10.47	0.5	2.29e-22	Hip circumference adjusted for BMI;
LUSC	cis	rs701145	0.585	rs62276841	chr3:153783645	C/T	cg17054900	chr3:154042577	DHX36	-0.73	-7.44	-0.38	8.72e-13	Coronary artery disease;
LUSC	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg21918786	chr6:109611834	NA	-0.38	-6.51	-0.34	2.78e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.76	-17.13	-0.68	1.19e-47	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10743315	0.778	rs1586843	chr12:19354550	T/C	cg02471346	chr12:19282374	PLEKHA5	-0.46	-5.83	-0.3	1.33e-8	Gut microbiota (bacterial taxa);
LUSC	cis	rs4889855	0.585	rs72855201	chr17:78530597	A/G	cg16591659	chr17:78472290	NA	0.32	5.9	0.31	9.14e-9	Fractional excretion of uric acid;
LUSC	cis	rs354225	0.544	rs10169954	chr2:54808117	C/G	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08859206	chr1:53392774	SCP2	-0.52	-8.94	-0.44	2.75e-17	Monocyte count;
LUSC	cis	rs4964805	0.657	rs4964814	chr12:104189384	A/C	cg02344784	chr12:104178138	NT5DC3	-0.44	-8.58	-0.42	3.66e-16	Attention deficit hyperactivity disorder;
LUSC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.89	-13.72	-0.6	2.82e-34	Platelet count;
LUSC	trans	rs11165623	0.602	rs7517055	chr1:97007781	C/G	cg10631902	chr5:14652156	NA	-0.42	-6.41	-0.33	4.93e-10	Hip circumference;Waist circumference;
LUSC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.39e-8	Aortic root size;
LUSC	cis	rs4561483	0.603	rs11544193	chr16:12009304	C/A	cg08843971	chr16:11963173	GSPT1	0.43	6.57	0.34	1.96e-10	Testicular germ cell tumor;
LUSC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.85	0.63	1.2e-38	Platelet count;
LUSC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.78	12.78	0.57	1.04e-30	Aortic root size;
LUSC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg14019146	chr3:50243930	SLC38A3	0.37	8.42	0.42	1.12e-15	Body mass index;
LUSC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg09359103	chr1:154839909	KCNN3	-0.72	-16.47	-0.67	5.04e-45	Prostate cancer;
LUSC	cis	rs2279817	1.000	rs2354290	chr1:18019861	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.51	7.29	0.37	2.2e-12	Neuroticism;
LUSC	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg18806716	chr10:30721971	MAP3K8	0.46	7.48	0.38	6.62e-13	Inflammatory bowel disease;
LUSC	cis	rs2073300	1.000	rs2207989	chr20:23446014	T/G	cg09953122	chr20:23471693	CST8	-0.75	-6.87	-0.35	3.15e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03517284	chr6:25882590	NA	-0.46	-8.19	-0.41	5.6e-15	Blood metabolite levels;
LUSC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg11843238	chr5:131593191	PDLIM4	0.39	7.18	0.37	4.66e-12	Blood metabolite levels;
LUSC	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg00105475	chr2:10696890	NA	0.38	6.24	0.32	1.35e-9	Prostate cancer;
LUSC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg16606324	chr3:10149918	C3orf24	0.66	9.85	0.47	2.82e-20	Alzheimer's disease;
LUSC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg06784218	chr1:46089804	CCDC17	0.55	11.1	0.52	1.36e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13082711	0.911	rs17019809	chr3:27509080	A/G	cg02860705	chr3:27208620	NA	0.47	7.96	0.4	2.67e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg13852791	chr20:30311386	BCL2L1	0.7	7.22	0.37	3.49e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg09165964	chr15:75287851	SCAMP5	0.52	7.59	0.38	3.32e-13	Breast cancer;
LUSC	cis	rs9427116	0.502	rs7531982	chr1:154596122	A/T	cg17218026	chr1:154582156	ADAR	0.57	10.15	0.49	2.76e-21	Blood protein levels;
LUSC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg14092988	chr3:52407081	DNAH1	0.32	6.31	0.33	8.9e-10	Bipolar disorder;
LUSC	cis	rs1506636	1.000	rs12706545	chr7:123348744	C/T	cg03229431	chr7:123269106	ASB15	-0.6	-9.99	-0.48	1.01e-20	Plateletcrit;Platelet count;
LUSC	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg05283184	chr6:79620031	NA	-0.58	-12.34	-0.56	4.25e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs7851660	0.809	rs10984230	chr9:100660284	C/T	cg13688889	chr9:100608707	NA	-0.56	-8.66	-0.43	2.08e-16	Strep throat;
LUSC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg22705602	chr4:152727874	NA	-0.34	-7.41	-0.38	1.01e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg16928487	chr17:17741425	SREBF1	-0.35	-6.87	-0.35	3.13e-11	Total body bone mineral density;
LUSC	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg07080220	chr10:102295463	HIF1AN	0.61	8.12	0.41	9.34e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg12463550	chr7:65579703	CRCP	0.48	6.79	0.35	5.09e-11	Aortic root size;
LUSC	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg13042288	chr15:90349979	ANPEP	-0.5	-6.94	-0.36	2.01e-11	Uric acid levels;
LUSC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg18240062	chr17:79603768	NPLOC4	0.57	9.82	0.47	3.6e-20	Eye color traits;
LUSC	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.88	15.08	0.64	1.52e-39	Bladder cancer;
LUSC	cis	rs79387448	0.745	rs6749440	chr2:103101846	C/T	cg09003973	chr2:102972529	NA	0.88	8.73	0.43	1.23e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.53	-0.34	2.44e-10	Platelet count;
LUSC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg09359103	chr1:154839909	KCNN3	-0.7	-16.24	-0.66	4.09e-44	Prostate cancer;
LUSC	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg05425664	chr17:57184151	TRIM37	-0.48	-7.42	-0.38	9.62e-13	Testicular germ cell tumor;
LUSC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg01448562	chr3:133502909	NA	-0.52	-7.75	-0.39	1.12e-13	Iron status biomarkers;
LUSC	cis	rs9311676	0.609	rs62258080	chr3:58367493	G/A	cg26110898	chr3:58419937	PDHB	0.44	7.2	0.37	4.01e-12	Systemic lupus erythematosus;
LUSC	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	0.94	15.6	0.65	1.37e-41	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs7589342	0.660	rs7571132	chr2:106398913	C/T	cg14210321	chr2:106509881	NCK2	-0.42	-6.01	-0.31	4.93e-9	Addiction;
LUSC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg27432699	chr2:27873401	GPN1	-0.57	-8.48	-0.42	7.41e-16	Menopause (age at onset);
LUSC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06481639	chr22:41940642	POLR3H	-0.53	-6.18	-0.32	1.85e-9	Vitiligo;
LUSC	cis	rs7949030	0.780	rs3017666	chr11:62404417	A/T	cg11742103	chr11:62369870	EML3;MTA2	-0.48	-8.21	-0.41	4.75e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12145833	0.538	rs9803701	chr1:243391634	T/C	cg02356786	chr1:243265016	LOC731275	-0.63	-5.7	-0.3	2.66e-8	Obesity (early onset extreme);
LUSC	cis	rs11828289	0.607	rs79308902	chr11:23163835	G/A	cg20040320	chr11:23191996	NA	-0.63	-6.35	-0.33	7e-10	Cancer;
LUSC	cis	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg06521331	chr12:34319734	NA	0.39	6.11	0.32	2.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-7.05	-0.36	1.02e-11	Alzheimer's disease (late onset);
LUSC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.6	8.19	0.41	5.42e-15	High light scatter reticulocyte count;
LUSC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg13770153	chr20:60521292	NA	-0.61	-8.39	-0.42	1.43e-15	Body mass index;
LUSC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-7.09	-0.36	7.82e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg04586622	chr2:25135609	ADCY3	0.4	8.35	0.42	1.81e-15	Body mass index in non-asthmatics;
LUSC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg25039879	chr17:56429692	SUPT4H1	0.72	9.24	0.45	2.97e-18	Cognitive test performance;
LUSC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	15.98	0.66	4.41e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs657452	0.722	rs1185222	chr1:49958961	C/T	cg20501355	chr17:48785009	ANKRD40	0.39	6.2	0.32	1.68e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg16606324	chr3:10149918	C3orf24	0.59	8.66	0.43	1.98e-16	Alzheimer's disease;
LUSC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg15445000	chr17:37608096	MED1	-0.39	-6.71	-0.34	8.49e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg05973401	chr12:123451056	ABCB9	0.51	6.97	0.36	1.69e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg13798780	chr7:105162888	PUS7	0.55	5.95	0.31	6.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg06552810	chr11:31128660	NA	-0.4	-7.13	-0.36	6.38e-12	Red blood cell count;
LUSC	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.56e-22	Colorectal cancer;
LUSC	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg20487152	chr13:99095054	FARP1	-0.42	-7.02	-0.36	1.25e-11	Neuroticism;
LUSC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.95	0.44	2.52e-17	Prudent dietary pattern;
LUSC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg11645453	chr3:52864694	ITIH4	0.33	7.24	0.37	3.11e-12	Bipolar disorder;
LUSC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg20701182	chr2:24300061	SF3B14	0.88	11.35	0.53	1.86e-25	Lymphocyte counts;
LUSC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg15352829	chr14:105391018	PLD4	-0.43	-8.98	-0.44	1.99e-17	Rheumatoid arthritis;
LUSC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	10.91	0.51	6.39e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.79	0.35	5.08e-11	IgG glycosylation;
LUSC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg19622623	chr12:86230825	RASSF9	-0.45	-6.4	-0.33	5.37e-10	Major depressive disorder;
LUSC	trans	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-6.43	-0.33	4.45e-10	Monocyte count;
LUSC	cis	rs965469	1.000	rs2281500	chr20:3262824	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-6.07	-0.32	3.49e-9	IFN-related cytopenia;
LUSC	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg08917208	chr2:24149416	ATAD2B	1.01	10.61	0.5	7.29e-23	Lymphocyte counts;
LUSC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg21573476	chr21:45109991	RRP1B	-0.4	-6.52	-0.34	2.55e-10	Mean corpuscular volume;
LUSC	cis	rs7106204	0.800	rs6484026	chr11:24214633	G/A	ch.11.24196551F	chr11:24239977	NA	1.12	13.79	0.6	1.49e-34	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6565180	0.507	rs4471699	chr16:30320307	G/T	cg17640201	chr16:30407289	ZNF48	-0.64	-10.71	-0.51	3.22e-23	Tonsillectomy;
LUSC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.67	0.43	1.97e-16	Lung cancer in ever smokers;
LUSC	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg17470449	chr10:769945	NA	0.5	6.9	0.35	2.7e-11	Uric acid levels;
LUSC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg00376283	chr12:123451042	ABCB9	0.83	13.0	0.58	1.47e-31	Platelet count;
LUSC	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.5	-6.64	-0.34	1.26e-10	Corneal astigmatism;
LUSC	cis	rs10779751	1.000	rs2016559	chr1:11269917	G/T	cg08854313	chr1:11322531	MTOR	0.86	14.93	0.63	5.89e-39	Body mass index;
LUSC	cis	rs2692947	0.740	rs4907280	chr2:96402126	A/G	cg22654517	chr2:96458247	NA	0.37	6.92	0.35	2.38e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg18683606	chr7:100471612	SRRT	0.45	5.96	0.31	6.4e-9	Resting heart rate;
LUSC	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.46	9.67	0.47	1.13e-19	Airflow obstruction;
LUSC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg04673462	chr1:38461896	NA	0.5	8.34	0.42	1.93e-15	Coronary artery disease;
LUSC	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.42	-6.65	-0.34	1.23e-10	Educational attainment;
LUSC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14159672	chr1:205819179	PM20D1	-0.41	-5.89	-0.31	9.53e-9	Parkinson's disease;
LUSC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs7215564	0.730	rs2171023	chr17:78608913	A/T	cg23238734	chr17:78661607	RPTOR	0.46	6.11	0.32	2.73e-9	Myopia (pathological);
LUSC	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg24069376	chr3:38537580	EXOG	0.39	7.31	0.37	1.96e-12	Schizophrenia;
LUSC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg06221963	chr1:154839813	KCNN3	-0.6	-13.15	-0.58	4.23e-32	Prostate cancer;
LUSC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.77	0.39	9.52e-14	Major depressive disorder;
LUSC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.46	7.08	0.36	8.38e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg04369109	chr6:150039330	LATS1	-0.56	-8.2	-0.41	5.37e-15	Lung cancer;
LUSC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg01879757	chr17:41196368	BRCA1	-0.39	-5.96	-0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs1358748	0.555	rs2815389	chr1:67536583	C/G	cg02640540	chr1:67518911	SLC35D1	0.66	6.69	0.34	9.24e-11	Tuberculosis;
LUSC	trans	rs80093141	0.575	rs62001076	chr14:39358792	G/C	cg08262584	chr8:54154426	OPRK1	0.43	6.08	0.32	3.32e-9	Common carotid intima-media thickness in HIV infection;
LUSC	cis	rs12422267	0.536	rs12303540	chr12:132609679	A/G	cg09764611	chr12:132620959	NA	0.6	8.85	0.44	5.11e-17	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.41e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg03983476	chr2:10830698	NOL10	-0.37	-5.69	-0.3	2.71e-8	Prostate cancer;
LUSC	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.08	0.4	1.22e-14	Height;
LUSC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg10755058	chr3:40428713	ENTPD3	-0.33	-5.79	-0.3	1.64e-8	Renal cell carcinoma;
LUSC	cis	rs9356171	0.540	rs2207441	chr6:164325217	G/A	cg25752492	chr6:164341247	NA	-0.38	-6.53	-0.34	2.52e-10	Diisocyanate-induced asthma;
LUSC	cis	rs965469	0.948	rs2236094	chr20:3260368	C/G	cg25506879	chr20:3388711	C20orf194	0.52	5.86	0.31	1.08e-8	IFN-related cytopenia;
LUSC	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	1.15	13.83	0.6	1.01e-34	Arsenic metabolism;
LUSC	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg08085267	chr17:45401833	C17orf57	-0.54	-8.54	-0.42	4.71e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg13010199	chr12:38710504	ALG10B	0.56	8.42	0.42	1.11e-15	Morning vs. evening chronotype;
LUSC	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-9.52	-0.46	3.74e-19	Response to antipsychotic treatment;
LUSC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg07395648	chr5:131743802	NA	-0.45	-7.16	-0.36	5.21e-12	Breast cancer;Mosquito bite size;
LUSC	cis	rs4597304	1	rs4597304	chr16:85055741	G/C	cg01715842	chr16:85045600	ZDHHC7	-0.5	-7.09	-0.36	8.01e-12	Dysphagia;
LUSC	cis	rs738321	0.794	rs6001026	chr22:38545363	C/T	cg25457927	chr22:38595422	NA	-0.42	-8.15	-0.41	7.45e-15	Breast cancer;
LUSC	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg05182265	chr7:156933206	UBE3C	0.59	9.67	0.47	1.17e-19	Body mass index;
LUSC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg13114125	chr14:105738426	BRF1	-0.9	-15.57	-0.65	1.73e-41	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.7	11.96	0.55	1.13e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs9630182	0.520	rs2290035	chr11:13407771	T/A	cg00234616	chr2:74740572	TLX2	0.3	6.09	0.32	3.03e-9	Bone mineral density;
LUSC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg15335139	chr3:50242325	SLC38A3	-0.26	-5.71	-0.3	2.5e-8	Body mass index;
LUSC	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.35e-12	Asthma;
LUSC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg03909863	chr11:638404	DRD4	-0.42	-6.02	-0.31	4.59e-9	Systemic lupus erythematosus;
LUSC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg06454157	chr6:167490870	NA	-0.28	-6.75	-0.35	6.53e-11	Primary biliary cholangitis;
LUSC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg12863693	chr15:85201151	NMB	0.34	7.01	0.36	1.34e-11	Schizophrenia;
LUSC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg13319975	chr6:146136371	FBXO30	0.51	7.65	0.39	2.16e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.59	-5.69	-0.3	2.84e-8	Narcolepsy;
LUSC	cis	rs11229555	0.645	rs11530830	chr11:58252992	C/G	cg15696309	chr11:58395628	NA	0.66	8.01	0.4	1.99e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7586879	0.828	rs1865688	chr2:25108245	C/G	cg01884057	chr2:25150051	NA	0.41	8.61	0.43	3.02e-16	Body mass index;
LUSC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg22681709	chr2:178499509	PDE11A	-0.34	-6.21	-0.32	1.57e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19717773	chr7:2847554	GNA12	-0.35	-5.87	-0.31	1.08e-8	Height;
LUSC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg03806693	chr22:41940476	POLR3H	-0.99	-13.97	-0.61	2.95e-35	Vitiligo;
LUSC	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	trans	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.59	-0.34	1.71e-10	Triglycerides;
LUSC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.52	-7.12	-0.36	6.86e-12	Mean platelet volume;
LUSC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg03146154	chr1:46216737	IPP	0.53	7.86	0.4	5.39e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1775715	0.870	rs7095322	chr10:32248491	C/T	cg18675610	chr10:32216311	ARHGAP12	-0.28	-5.89	-0.31	9.32e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10779751	0.734	rs2261317	chr1:11124979	A/G	cg08854313	chr1:11322531	MTOR	0.81	12.1	0.55	3.52e-28	Body mass index;
LUSC	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg15790184	chr11:494944	RNH1	0.42	6.21	0.32	1.61e-9	Systemic lupus erythematosus;
LUSC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.77	14.56	0.62	1.51e-37	Longevity;
LUSC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06022373	chr22:39101656	GTPBP1	0.84	14.01	0.61	2.07e-35	Menopause (age at onset);
LUSC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.72	-0.3	2.43e-8	Tonsillectomy;
LUSC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.7	10.58	0.5	9.36e-23	Aortic root size;
LUSC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg00012203	chr2:219082015	ARPC2	0.89	17.23	0.69	4.76e-48	Colorectal cancer;
LUSC	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.64	-0.34	1.24e-10	Response to antipsychotic treatment;
LUSC	trans	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg03886242	chr7:26192032	NFE2L3	-0.42	-6.66	-0.34	1.11e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg13620615	chr21:40555724	PSMG1	0.52	6.19	0.32	1.81e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg14552801	chr7:65878734	NA	0.45	6.34	0.33	7.34e-10	Aortic root size;
LUSC	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg16230307	chr14:35515116	FAM177A1	0.74	8.78	0.43	8.84e-17	Psoriasis;
LUSC	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.38	-0.33	5.93e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7212590	0.618	rs7219051	chr17:58032710	G/A	cg10252138	chr17:58120427	NA	-0.8	-7.53	-0.38	4.68e-13	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10150615	chr22:24372951	LOC391322	-0.41	-6.54	-0.34	2.31e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg17143192	chr8:8559678	CLDN23	0.62	9.06	0.44	1.12e-17	Obesity-related traits;
LUSC	cis	rs10979	0.964	rs9321922	chr6:143895231	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg21724239	chr8:58056113	NA	-0.81	-8.97	-0.44	2.13e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg05025164	chr4:1340916	KIAA1530	0.43	6.43	0.33	4.39e-10	Obesity-related traits;
LUSC	cis	rs714027	0.585	rs41156	chr22:30404653	T/C	cg11564601	chr22:30592435	NA	-0.34	-5.9	-0.31	9.1e-9	Lymphocyte counts;
LUSC	cis	rs8064299	0.597	rs6501736	chr17:72775358	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.92	18.2	0.71	6.83e-52	Monocyte count;
LUSC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg23093090	chr10:104574429	C10orf26	-0.37	-7.1	-0.36	7.73e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg23711669	chr6:146136114	FBXO30	0.86	16.1	0.66	1.47e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg22089800	chr15:90895588	ZNF774	0.64	9.68	0.47	1.05e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg13010199	chr12:38710504	ALG10B	0.53	7.97	0.4	2.47e-14	Morning vs. evening chronotype;
LUSC	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg12432903	chr7:1882776	MAD1L1	0.53	6.7	0.34	9.1e-11	Bipolar disorder;
LUSC	cis	rs13242816	1.000	rs55803834	chr7:116103141	C/T	cg16553024	chr7:116138462	CAV2	-0.53	-5.81	-0.3	1.46e-8	P wave duration;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg21444639	chr1:171711847	VAMP4	0.43	6.38	0.33	5.9e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.24	-0.56	1.06e-28	Mean corpuscular volume;
LUSC	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg08355456	chr11:67383691	NA	0.36	6.68	0.34	1.03e-10	Mean corpuscular volume;
LUSC	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	0.77	10.97	0.51	4.21e-24	Response to hepatitis C treatment;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14433247	chr12:14923044	NA	-0.42	-6.24	-0.32	1.31e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.99	-0.4	2.18e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs983392	0.709	rs1426250	chr11:60001325	A/G	cg02771260	chr11:59836817	MS4A3	-0.37	-5.96	-0.31	6.5e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg21175976	chr8:11421337	BLK	-0.38	-6.55	-0.34	2.24e-10	Systolic blood pressure;
LUSC	cis	rs9677476	0.909	rs7562116	chr2:232108246	A/G	cg07929768	chr2:232055508	NA	0.35	6.44	0.33	4.21e-10	Food antigen IgG levels;
LUSC	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg09491104	chr22:46646882	C22orf40	-0.67	-7.0	-0.36	1.42e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	6.47	0.33	3.46e-10	Lung cancer in ever smokers;
LUSC	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg23093090	chr10:104574429	C10orf26	-0.47	-5.76	-0.3	1.94e-8	Arsenic metabolism;
LUSC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg02018176	chr4:1364513	KIAA1530	-0.58	-9.97	-0.48	1.13e-20	Obesity-related traits;
LUSC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg24250549	chr1:154909240	PMVK	0.55	8.72	0.43	1.38e-16	Prostate cancer;
LUSC	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.14	-0.41	7.68e-15	Retinal vascular caliber;
LUSC	cis	rs6429082	0.715	rs2131923	chr1:235580821	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-7.83	-0.39	6.38e-14	Adiposity;
LUSC	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	6.05	0.31	3.78e-9	Neuroticism;
LUSC	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg00982548	chr2:198649783	BOLL	-0.54	-6.63	-0.34	1.33e-10	Ulcerative colitis;
LUSC	cis	rs240764	0.621	rs11155623	chr6:101184373	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.4	-0.33	5.21e-10	Neuroticism;
LUSC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.11	0.64	1.18e-39	Platelet count;
LUSC	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.44	-0.33	4.21e-10	Dupuytren's disease;
LUSC	cis	rs4363385	0.747	rs4845330	chr1:152981505	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.33e-13	Inflammatory skin disease;
LUSC	cis	rs7927771	0.524	rs7943464	chr11:47886639	T/A	cg20307385	chr11:47447363	PSMC3	0.47	6.86	0.35	3.42e-11	Subjective well-being;
LUSC	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.75	-0.47	6.45e-20	Coronary artery disease;
LUSC	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg06287003	chr12:125626642	AACS	-0.36	-5.66	-0.3	3.24e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg09034736	chr1:150693464	HORMAD1	-0.4	-5.75	-0.3	2.05e-8	Tonsillectomy;
LUSC	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg17764715	chr19:33622953	WDR88	-0.59	-8.12	-0.41	9.04e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	5.92	0.31	7.92e-9	Personality dimensions;
LUSC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.51	-7.02	-0.36	1.21e-11	Renal function-related traits (BUN);
LUSC	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21659725	chr3:3221576	CRBN	0.54	8.74	0.43	1.17e-16	Body mass index;
LUSC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg12560992	chr17:57184187	TRIM37	0.82	14.77	0.63	2.39e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg04013166	chr16:89971882	TCF25	-0.63	-7.28	-0.37	2.35e-12	Skin colour saturation;
LUSC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg09417038	chr21:47716443	C21orf57	-0.41	-6.54	-0.34	2.27e-10	Testicular germ cell tumor;
LUSC	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.64	8.51	0.42	6.03e-16	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs12210905	0.688	rs78285097	chr6:27374644	G/C	cg08851530	chr6:28072375	NA	0.97	6.41	0.33	4.91e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg17507749	chr15:85114479	UBE2QP1	0.56	6.39	0.33	5.58e-10	Schizophrenia;
LUSC	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg03526459	chr1:146549940	NA	0.41	7.27	0.37	2.53e-12	HIV-1 control;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24542492	chr17:61818870	STRADA	-0.51	-6.72	-0.35	7.68e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.74	12.0	0.55	8.09e-28	Cognitive function;
LUSC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-1.05	-15.3	-0.64	1.96e-40	Vitiligo;
LUSC	cis	rs10207060	0.500	rs10181238	chr2:240709496	G/A	cg07506560	chr2:240697449	NA	0.48	7.35	0.37	1.56e-12	Obesity-related traits;
LUSC	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.45e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg08847533	chr14:75593920	NEK9	-0.39	-5.71	-0.3	2.47e-8	Caffeine consumption;
LUSC	cis	rs2346177	0.846	rs6714738	chr2:46646164	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.35	5.95	0.31	6.66e-9	HDL cholesterol;
LUSC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.08e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	12.09	0.55	3.72e-28	Ileal carcinoids;
LUSC	cis	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.36	-0.33	6.81e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs8048589	0.526	rs71388721	chr16:12212164	G/A	cg02910054	chr16:12241554	SNX29	0.5	7.02	0.36	1.26e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs12922317	0.927	rs12923439	chr16:12073958	C/T	cg08843971	chr16:11963173	GSPT1	-0.39	-5.69	-0.3	2.84e-8	Schizophrenia;
LUSC	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg21366198	chr4:185655624	MLF1IP	0.42	5.91	0.31	8.36e-9	Kawasaki disease;
LUSC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.4	-6.41	-0.33	5.01e-10	Systemic lupus erythematosus;
LUSC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg01448562	chr3:133502909	NA	-0.67	-10.98	-0.51	3.83e-24	Iron status biomarkers;
LUSC	trans	rs61931739	0.612	rs1906136	chr12:33905293	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.66	0.39	2.1e-13	Morning vs. evening chronotype;
LUSC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00152838	chr16:24741724	TNRC6A	-0.46	-5.71	-0.3	2.55e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06481639	chr22:41940642	POLR3H	-0.51	-6.14	-0.32	2.41e-9	Vitiligo;
LUSC	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.36	0.42	1.71e-15	Arsenic metabolism;
LUSC	cis	rs2688608	0.904	rs2675669	chr10:75653872	C/T	cg17411546	chr10:75410026	SYNPO2L	-0.43	-6.42	-0.33	4.66e-10	Inflammatory bowel disease;
LUSC	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg02023728	chr11:77925099	USP35	0.49	6.88	0.35	3.02e-11	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg21535247	chr6:8435926	SLC35B3	-0.64	-8.75	-0.43	1.1e-16	Motion sickness;
LUSC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg27427491	chr17:78079615	GAA	-0.36	-6.94	-0.35	2.09e-11	Yeast infection;
LUSC	cis	rs7582720	1.000	rs72934707	chr2:203707878	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	8.16	0.41	7.08e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.14	12.3	0.56	6.26e-29	Lung cancer in ever smokers;
LUSC	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg09307838	chr4:120376055	NA	0.67	9.49	0.46	4.49e-19	Corneal astigmatism;
LUSC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg13770153	chr20:60521292	NA	-0.61	-8.39	-0.42	1.43e-15	Body mass index;
LUSC	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg17085576	chr10:5658249	NA	-0.46	-6.79	-0.35	5.06e-11	Breast cancer;
LUSC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg22166914	chr1:53195759	ZYG11B	0.56	9.12	0.45	6.96e-18	Monocyte count;
LUSC	cis	rs7818345	0.967	rs7006702	chr8:19272533	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.28	0.37	2.35e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg27588902	chr6:42928151	GNMT	-0.29	-6.49	-0.33	3.11e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	8.19	0.41	5.74e-15	Height;
LUSC	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.59	-8.36	-0.42	1.71e-15	Hip circumference;
LUSC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg11941060	chr3:133502564	NA	-0.46	-6.63	-0.34	1.32e-10	Iron status biomarkers;
LUSC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	0.91	16.53	0.67	2.89e-45	Cognitive function;
LUSC	cis	rs1953600	0.870	rs1049550	chr10:81926702	G/A	cg04850286	chr10:81895943	PLAC9	-0.35	-6.01	-0.31	4.91e-9	Sarcoidosis;
LUSC	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg06207120	chr15:45996521	NA	0.39	5.99	0.31	5.51e-9	Waist circumference;Weight;
LUSC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.45e-8	Aortic root size;
LUSC	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg02903104	chr8:1507517	DLGAP2	0.33	6.52	0.34	2.65e-10	Lung cancer;
LUSC	cis	rs12210905	0.565	rs9689239	chr6:26881879	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.64	-5.66	-0.3	3.25e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	7.02	0.36	1.23e-11	Motion sickness;
LUSC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08439880	chr3:133502540	NA	-0.33	-6.01	-0.31	4.89e-9	Iron status biomarkers;
LUSC	cis	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg05084668	chr3:125655381	ALG1L	-0.75	-11.12	-0.52	1.15e-24	Blood pressure (smoking interaction);
LUSC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-1.1	-22.36	-0.77	2.43e-68	Coronary artery disease;
LUSC	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-6.99	-0.36	1.55e-11	Bipolar disorder;
LUSC	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.12	-18.16	-0.7	9.73e-52	Primary sclerosing cholangitis;
LUSC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.43	-7.08	-0.36	8.79e-12	Platelet count;
LUSC	trans	rs9929218	0.954	rs9929239	chr16:68821126	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.42	-0.53	9.9e-26	Colorectal cancer;
LUSC	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.49	7.07	0.36	8.98e-12	Coronary heart disease;
LUSC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08704250	chr15:31115839	NA	-0.6	-9.34	-0.46	1.41e-18	Huntington's disease progression;
LUSC	cis	rs7178572	0.524	rs12914128	chr15:77493875	T/C	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	cis	rs7577851	0.716	rs67481136	chr2:69668004	C/A	cg10773587	chr2:69614142	GFPT1	0.57	6.23	0.32	1.38e-9	Parkinson's disease (age of onset);
LUSC	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.62	-0.34	1.44e-10	Fear of minor pain;
LUSC	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.83	-13.9	-0.61	5.41e-35	Bladder cancer;
LUSC	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg08645402	chr16:4508243	NA	0.45	6.77	0.35	5.89e-11	Schizophrenia;
LUSC	cis	rs2548003	0.518	rs2554901	chr5:28733310	T/C	cg22863700	chr5:28928346	NA	0.45	6.22	0.32	1.45e-9	Hip geometry;
LUSC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg24209194	chr3:40518798	ZNF619	0.47	6.59	0.34	1.73e-10	Renal cell carcinoma;
LUSC	trans	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg18187862	chr3:45730750	SACM1L	0.56	7.06	0.36	9.52e-12	Primary sclerosing cholangitis;
LUSC	cis	rs10193935	0.901	rs92303	chr2:42656337	A/G	cg27598129	chr2:42591480	NA	0.57	7.94	0.4	3.01e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-7.01	-0.36	1.29e-11	Menarche (age at onset);
LUSC	trans	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg25214090	chr10:38739885	LOC399744	0.41	6.35	0.33	6.98e-10	Corneal astigmatism;
LUSC	cis	rs9921338	0.961	rs7187870	chr16:11431919	T/C	cg00044050	chr16:11439710	C16orf75	-0.5	-6.69	-0.34	9.4e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg18825076	chr15:78729989	IREB2	0.48	6.31	0.33	8.8e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg05043794	chr9:111880884	C9orf5	-0.35	-7.55	-0.38	4.16e-13	Menarche (age at onset);
LUSC	cis	rs4776059	0.798	rs2414167	chr15:52907428	A/G	cg24008177	chr15:52972085	KIAA1370	-0.33	-5.92	-0.31	7.93e-9	Schizophrenia;
LUSC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg11859384	chr17:80120422	CCDC57	-0.36	-5.68	-0.3	2.94e-8	Life satisfaction;
LUSC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.39	0.67	1.04e-44	Platelet count;
LUSC	trans	rs6496932	0.774	rs12901648	chr15:85951718	G/T	cg02291556	chr1:47656140	PDZK1IP1	0.43	6.2	0.32	1.67e-9	Central corneal thickness;Corneal structure;
LUSC	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg26395211	chr5:140044315	WDR55	-0.37	-5.65	-0.3	3.4e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs17750015	0.733	rs7506986	chr18:54404558	C/T	cg18434998	chr18:54306185	TXNL1	-0.47	-7.5	-0.38	5.69e-13	Depression and alcohol dependence;
LUSC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg13319975	chr6:146136371	FBXO30	0.47	7.25	0.37	2.91e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs73195822	0.614	rs11834902	chr12:111219809	C/A	cg12870014	chr12:110450643	ANKRD13A	0.68	6.61	0.34	1.5e-10	Itch intensity from mosquito bite;
LUSC	cis	rs2692947	0.683	rs2315416	chr2:96558477	C/T	cg22654517	chr2:96458247	NA	0.38	7.58	0.38	3.45e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6714710	0.603	rs11681535	chr2:98488949	G/C	cg26665480	chr2:98280029	ACTR1B	0.59	8.68	0.43	1.73e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg00191853	chr8:101177733	SPAG1	-0.41	-6.56	-0.34	2.08e-10	Atrioventricular conduction;
LUSC	cis	rs2067615	0.524	rs10778503	chr12:107090616	C/T	cg15890332	chr12:107067104	RFX4	0.35	6.15	0.32	2.24e-9	Heart rate;
LUSC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg04518342	chr5:131593106	PDLIM4	0.32	5.66	0.3	3.28e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg07167872	chr1:205819463	PM20D1	-0.43	-5.84	-0.3	1.21e-8	Menarche (age at onset);
LUSC	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07080220	chr10:102295463	HIF1AN	0.67	9.17	0.45	4.96e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.19	0.59	2.82e-32	Blood protein levels;
LUSC	cis	rs2625529	0.652	rs2278987	chr15:72409769	T/C	cg16672083	chr15:72433130	SENP8	0.49	8.14	0.41	7.93e-15	Red blood cell count;
LUSC	cis	rs9811920	0.965	rs9289981	chr3:99868104	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.38	5.65	0.3	3.41e-8	Axial length;
LUSC	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-11.0	-0.52	3.09e-24	Response to antipsychotic treatment;
LUSC	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg24069376	chr3:38537580	EXOG	0.42	8.21	0.41	4.88e-15	Electrocardiographic conduction measures;
LUSC	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	5.98	0.31	5.86e-9	Rheumatoid arthritis;
LUSC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.23	-0.49	1.52e-21	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg11062466	chr8:58055876	NA	0.61	7.5	0.38	5.71e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg04455712	chr21:45112962	RRP1B	0.45	8.53	0.42	5.06e-16	Mean corpuscular volume;
LUSC	cis	rs2219968	0.798	rs9657126	chr8:78942271	T/C	cg00738934	chr8:78996279	NA	-0.4	-7.22	-0.37	3.56e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	8.86	0.44	4.85e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs12545109	0.879	rs1581129	chr8:57377476	T/C	cg09654669	chr8:57350985	NA	-0.57	-7.46	-0.38	7.7e-13	Obesity-related traits;
LUSC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16680214	chr1:154839983	KCNN3	-0.58	-11.29	-0.53	3.05e-25	Prostate cancer;
LUSC	cis	rs4843185	0.667	rs4143865	chr16:85716612	T/A	cg05245094	chr16:85669572	KIAA0182	0.43	6.13	0.32	2.53e-9	Platelet distribution width;
LUSC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.15	0.49	2.87e-21	Electroencephalogram traits;
LUSC	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg00495681	chr13:53174319	NA	0.79	15.57	0.65	1.72e-41	Lewy body disease;
LUSC	cis	rs5771069	0.896	rs137862	chr22:50446550	C/A	cg03721641	chr22:50451245	IL17REL	0.29	5.9	0.31	9.02e-9	Ulcerative colitis;
LUSC	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg24692254	chr21:30365293	RNF160	-0.53	-8.06	-0.4	1.33e-14	Selective IgA deficiency;
LUSC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-13.7	-0.6	3.17e-34	Chronic sinus infection;
LUSC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg20398880	chr6:41068722	NFYA;LOC221442	0.39	6.05	0.31	3.96e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7805747	0.961	rs10224002	chr7:151415041	C/T	cg17611936	chr7:151411526	PRKAG2	-0.49	-6.97	-0.36	1.67e-11	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUSC	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg21153622	chr11:89784906	NA	-0.4	-6.19	-0.32	1.75e-9	HDL cholesterol;
LUSC	trans	rs724744	0.660	rs1737234	chr6:22351804	T/C	cg13807341	chr11:118445984	ARCN1	-0.36	-6.15	-0.32	2.18e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg03433033	chr1:76189801	ACADM	-0.39	-5.66	-0.3	3.35e-8	Daytime sleep phenotypes;
LUSC	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg21045802	chr8:109455806	TTC35	0.43	6.62	0.34	1.45e-10	Dupuytren's disease;
LUSC	cis	rs6120849	0.754	rs6120793	chr20:33604407	T/C	cg24642439	chr20:33292090	TP53INP2	0.62	6.82	0.35	4.29e-11	Protein C levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13862631	chr4:78979894	FRAS1	0.43	6.08	0.32	3.25e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.44	5.91	0.31	8.32e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6546537	0.550	rs12617329	chr2:69781530	C/A	cg10773587	chr2:69614142	GFPT1	-0.42	-6.66	-0.34	1.14e-10	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg24562669	chr7:97807699	LMTK2	0.34	5.95	0.31	6.83e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.48	-0.38	6.73e-13	Depression;
LUSC	cis	rs7771547	0.607	rs6923993	chr6:36427276	A/G	cg07856975	chr6:36356162	ETV7	0.34	5.98	0.31	5.9e-9	Platelet distribution width;
LUSC	cis	rs7804356	1.000	rs12540045	chr7:26863174	C/G	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.05e-9	Type 1 diabetes;
LUSC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg00033643	chr7:134001901	SLC35B4	0.45	7.02	0.36	1.22e-11	Mean platelet volume;
LUSC	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg19875535	chr5:140030758	IK	0.49	8.11	0.41	9.5e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2070488	0.560	rs1381798	chr3:38437471	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.66	-9.88	-0.48	2.29e-20	Electrocardiographic conduction measures;
LUSC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.72	12.97	0.58	1.89e-31	Prudent dietary pattern;
LUSC	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg24812749	chr6:127587940	RNF146	0.49	7.16	0.36	5.1e-12	Breast cancer;
LUSC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg06671706	chr8:8559999	CLDN23	0.51	6.96	0.36	1.8e-11	Obesity-related traits;
LUSC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.2	-0.32	1.7e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	23.48	0.79	1.08e-72	Colorectal cancer;
LUSC	cis	rs73206853	0.841	rs73191815	chr12:110914698	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	6.44	0.33	4.21e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	6.31	0.33	8.76e-10	Blood metabolite levels;
LUSC	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg24375607	chr4:120327624	NA	0.69	10.58	0.5	9.66e-23	Corneal astigmatism;
LUSC	cis	rs56283067	0.887	rs12198016	chr6:44771708	C/T	cg18551225	chr6:44695536	NA	-0.45	-6.99	-0.36	1.47e-11	Total body bone mineral density;
LUSC	cis	rs4499344	0.531	rs863905	chr19:33146403	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.7	10.44	0.5	2.84e-22	Mean platelet volume;
LUSC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg08200582	chr11:442649	ANO9	-0.57	-6.04	-0.31	4.22e-9	Body mass index;
LUSC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg21770322	chr7:97807741	LMTK2	0.41	7.27	0.37	2.51e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.73	-0.35	7.19e-11	Alzheimer's disease (late onset);
LUSC	trans	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg07211511	chr3:129823064	LOC729375	-0.78	-10.17	-0.49	2.36e-21	Blood pressure (smoking interaction);
LUSC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg11941060	chr3:133502564	NA	-0.52	-8.07	-0.4	1.25e-14	Iron status biomarkers;
LUSC	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg00631329	chr6:26305371	NA	-0.46	-9.23	-0.45	3.18e-18	Educational attainment;
LUSC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.32	0.33	8.38e-10	Menopause (age at onset);
LUSC	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17467752	chr17:38218738	THRA	-0.5	-7.05	-0.36	1.05e-11	White blood cell count (basophil);White blood cell count;
LUSC	cis	rs6893807	0.778	rs7721099	chr5:87936379	A/G	cg02225085	chr5:87975992	LOC645323	-0.46	-5.67	-0.3	3.11e-8	Body mass index;
LUSC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg18230493	chr5:56204884	C5orf35	-0.91	-13.32	-0.59	9.56e-33	Initial pursuit acceleration;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg06441968	chr1:40627537	RLF	0.52	6.43	0.33	4.43e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-8.13	-0.41	8.56e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs834811	0.865	rs844327	chr7:135898043	G/T	cg01726295	chr7:135938950	NA	0.34	6.07	0.32	3.47e-9	Post-traumatic stress disorder;
LUSC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs10927875	0.619	rs2013019	chr1:16129320	T/C	cg22431228	chr1:16359049	CLCNKA	0.31	6.34	0.33	7.39e-10	Dilated cardiomyopathy;
LUSC	trans	rs6982636	1.000	rs6982636	chr8:126479315	G/A	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.34	-6.43	-0.33	4.46e-10	Lipid metabolism phenotypes;
LUSC	cis	rs7605827	0.866	rs2160696	chr2:15518983	A/T	cg19274914	chr2:15703543	NA	0.45	8.73	0.43	1.27e-16	Educational attainment (years of education);
LUSC	cis	rs9341808	0.718	rs3805922	chr6:80891989	A/G	cg08355045	chr6:80787529	NA	0.58	10.07	0.48	5.31e-21	Sitting height ratio;
LUSC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg09021430	chr5:549028	NA	-0.57	-7.67	-0.39	1.92e-13	Obesity-related traits;
LUSC	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg06360820	chr2:242988706	NA	-0.83	-9.58	-0.46	2.22e-19	Obesity-related traits;
LUSC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.82	10.74	0.51	2.54e-23	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg07424592	chr7:64974309	NA	0.7	6.05	0.31	3.99e-9	Diabetic kidney disease;
LUSC	cis	rs11676348	0.755	rs62183956	chr2:219046122	C/T	cg06547715	chr2:218990976	CXCR2	-0.31	-6.24	-0.32	1.31e-9	Ulcerative colitis;
LUSC	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg23711669	chr6:146136114	FBXO30	-0.49	-7.37	-0.37	1.38e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg20701182	chr2:24300061	SF3B14	0.76	7.72	0.39	1.39e-13	Lymphocyte counts;
LUSC	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg26384229	chr12:38710491	ALG10B	-0.67	-10.25	-0.49	1.32e-21	Bladder cancer;
LUSC	trans	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.81e-10	Life satisfaction;
LUSC	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg16386425	chr10:429943	DIP2C	0.41	6.0	0.31	5.08e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg24562669	chr7:97807699	LMTK2	0.35	6.22	0.32	1.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.79	-10.76	-0.51	2.31e-23	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg03676636	chr4:99064102	C4orf37	0.33	7.19	0.37	4.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15664640	chr17:80829946	TBCD	-0.74	-13.43	-0.59	3.66e-33	Breast cancer;
LUSC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg21951975	chr1:209979733	IRF6	0.61	7.89	0.4	4.43e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg10483660	chr13:112241077	NA	-0.31	-5.77	-0.3	1.81e-8	Hepatitis;
LUSC	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.76	-11.29	-0.53	3.04e-25	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg05738196	chr6:26577821	NA	-0.6	-7.03	-0.36	1.15e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg25039879	chr17:56429692	SUPT4H1	0.66	8.81	0.43	6.99e-17	Cognitive test performance;
LUSC	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg11344533	chr11:111475393	SIK2	0.44	5.76	0.3	1.93e-8	Primary sclerosing cholangitis;
LUSC	cis	rs9648716	0.515	rs62485390	chr7:140662686	T/G	cg23214464	chr7:140373596	ADCK2	0.67	5.86	0.31	1.12e-8	Type 2 diabetes;
LUSC	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg03859395	chr2:55845619	SMEK2	-0.64	-9.07	-0.44	1e-17	Metabolic syndrome;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	ch.6.143706070F	chr6:143664377	NA	0.38	6.24	0.32	1.34e-9	Triglycerides;
LUSC	trans	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg16660971	chr17:78860029	RPTOR	0.37	6.01	0.31	4.78e-9	Major depressive disorder;
LUSC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.1	0.32	2.85e-9	Schizophrenia;
LUSC	cis	rs3931020	0.688	rs405445	chr1:75221150	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	-0.45	-5.78	-0.3	1.68e-8	Resistin levels;
LUSC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg09877947	chr5:131593287	PDLIM4	0.5	7.85	0.39	5.84e-14	Acylcarnitine levels;
LUSC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.4	-5.85	-0.3	1.19e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9323205	0.953	rs7141012	chr14:51600948	C/G	cg23942311	chr14:51606299	NA	-0.47	-9.11	-0.45	7.51e-18	Cancer;
LUSC	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg13042288	chr15:90349979	ANPEP	-0.48	-6.93	-0.35	2.21e-11	Uric acid levels;
LUSC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg05347473	chr6:146136440	FBXO30	-0.59	-10.32	-0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6681460	0.899	rs1280280	chr1:67173903	G/A	cg02459107	chr1:67143332	SGIP1	0.46	8.53	0.42	5.14e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs921665	0.680	rs7591433	chr2:3180126	A/C	cg16434511	chr2:3151078	NA	-0.64	-6.86	-0.35	3.31e-11	World class endurance athleticism;
LUSC	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	7.08	0.36	8.72e-12	Protein C levels;
LUSC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg04850211	chr1:228464232	OBSCN	0.31	5.68	0.3	2.95e-8	Diastolic blood pressure;
LUSC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg01416388	chr22:39784598	NA	-0.43	-7.27	-0.37	2.56e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	8.16	0.41	6.89e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg06606381	chr12:133084897	FBRSL1	-0.97	-8.42	-0.42	1.13e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9948	0.655	rs6758151	chr2:97388884	A/G	cg01990225	chr2:97406019	LMAN2L	-1.09	-8.29	-0.41	2.9e-15	Erectile dysfunction and prostate cancer treatment;
LUSC	trans	rs953492	0.591	rs10803123	chr1:243377892	T/A	cg25284624	chr1:224180302	NA	-0.43	-6.63	-0.34	1.35e-10	Diastolic blood pressure;
LUSC	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg08680598	chr22:49984980	NA	-0.33	-6.14	-0.32	2.39e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg02117656	chr17:79614917	TSPAN10	-0.31	-5.82	-0.3	1.41e-8	Eye color traits;
LUSC	cis	rs877282	0.853	rs10904545	chr10:757100	G/A	cg17470449	chr10:769945	NA	0.51	6.9	0.35	2.59e-11	Uric acid levels;
LUSC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	7.47	0.38	7.22e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg19318889	chr4:1322082	MAEA	0.43	5.73	0.3	2.28e-8	Recombination rate (females);
LUSC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.94	0.44	2.75e-17	Prudent dietary pattern;
LUSC	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg07169764	chr2:136633963	MCM6	1.23	19.09	0.72	1.82e-55	Corneal structure;
LUSC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg05025164	chr4:1340916	KIAA1530	0.41	6.11	0.32	2.8e-9	Obesity-related traits;
LUSC	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg10792982	chr14:105748885	BRF1	0.43	7.6	0.38	2.94e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2346177	0.844	rs12991646	chr2:46643831	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.36	6.23	0.32	1.43e-9	HDL cholesterol;
LUSC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.72	12.16	0.55	2.03e-28	Motion sickness;
LUSC	cis	rs889512	0.731	rs3743614	chr16:75280958	C/T	cg04987608	chr16:75300043	BCAR1	-0.54	-6.54	-0.34	2.26e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.79	-10.43	-0.5	3.06e-22	Refractive error;
LUSC	cis	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg02972257	chr16:68554789	NA	-0.5	-6.36	-0.33	6.76e-10	Ulcerative colitis;
LUSC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg11342453	chr6:26196699	NA	-0.54	-5.73	-0.3	2.27e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-1.02	-20.77	-0.75	4.34e-62	Dilated cardiomyopathy;
LUSC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg25036284	chr2:26402008	FAM59B	0.72	10.36	0.49	5.33e-22	Gut microbiome composition (summer);
LUSC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg13206674	chr6:150067644	NUP43	0.62	10.01	0.48	8.43e-21	Lung cancer;
LUSC	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg25174290	chr11:3078921	CARS	-0.4	-5.92	-0.31	7.88e-9	Calcium levels;
LUSC	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg23711669	chr6:146136114	FBXO30	0.86	15.36	0.64	1.19e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	1.02	19.7	0.73	7.26e-58	Menopause (age at onset);
LUSC	cis	rs7789940	0.904	rs12531348	chr7:75937191	G/C	cg10167463	chr7:75959203	YWHAG	-0.59	-8.48	-0.42	7.37e-16	Multiple sclerosis;
LUSC	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.94	-0.44	2.73e-17	Gut microbiome composition (summer);
LUSC	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg19767477	chr5:127420684	SLC12A2	-0.43	-5.7	-0.3	2.58e-8	Ileal carcinoids;
LUSC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.96	0.51	4.45e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg20701182	chr2:24300061	SF3B14	0.58	6.19	0.32	1.72e-9	Lymphocyte counts;
LUSC	cis	rs921665	0.680	rs76494865	chr2:3191204	G/A	cg02624386	chr2:3182749	NA	0.59	6.61	0.34	1.56e-10	World class endurance athleticism;
LUSC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg14668632	chr7:2872130	GNA12	-0.42	-6.15	-0.32	2.26e-9	Height;
LUSC	cis	rs9837602	0.935	rs9875640	chr3:99729091	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.21	0.32	1.57e-9	Breast cancer;
LUSC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-6.39	-0.33	5.61e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9311676	0.632	rs62258126	chr3:58396114	T/C	cg26110898	chr3:58419937	PDHB	0.4	6.42	0.33	4.6e-10	Systemic lupus erythematosus;
LUSC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg13206674	chr6:150067644	NUP43	0.6	9.53	0.46	3.38e-19	Lung cancer;
LUSC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg11871910	chr12:69753446	YEATS4	0.95	17.8	0.7	2.59e-50	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2273669	0.667	rs114481082	chr6:109280932	G/A	cg05315195	chr6:109294784	ARMC2	-0.59	-6.61	-0.34	1.55e-10	Prostate cancer;
LUSC	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg18196295	chr10:418757	DIP2C	0.36	5.65	0.3	3.44e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs11645898	0.935	rs4788611	chr16:72175256	A/G	cg14768367	chr16:72042858	DHODH	-0.65	-7.11	-0.36	7.28e-12	Blood protein levels;
LUSC	cis	rs7523050	0.730	rs12726126	chr1:109436128	A/G	cg08274380	chr1:109419600	GPSM2	1.13	11.51	0.53	4.76e-26	Fat distribution (HIV);
LUSC	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.69	-11.08	-0.52	1.61e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg09323728	chr8:95962352	TP53INP1	-0.4	-7.93	-0.4	3.44e-14	Type 2 diabetes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19518383	chr11:64577818	MEN1	-0.43	-6.21	-0.32	1.58e-9	Hepatitis;
LUSC	cis	rs1322512	0.876	rs1159357	chr6:153029300	G/A	cg27316956	chr6:152958899	SYNE1	0.35	5.85	0.3	1.16e-8	Tonometry;
LUSC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg23788917	chr6:8435910	SLC35B3	0.51	7.56	0.38	3.85e-13	Motion sickness;
LUSC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg09034736	chr1:150693464	HORMAD1	0.45	6.48	0.33	3.36e-10	Melanoma;
LUSC	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg12002119	chr2:101014098	CHST10	0.35	5.88	0.31	1.02e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6942756	1.000	rs12111832	chr7:128889025	G/C	cg02491457	chr7:128862824	NA	-0.52	-7.42	-0.38	9.94e-13	White matter hyperintensity burden;
LUSC	cis	rs12594515	1.000	rs8029209	chr15:45993489	A/G	cg06207120	chr15:45996521	NA	0.38	5.71	0.3	2.53e-8	Waist circumference;Weight;
LUSC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.79	0.78	5.11e-70	Prudent dietary pattern;
LUSC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.67	0.43	1.91e-16	Prudent dietary pattern;
LUSC	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg03678062	chr6:149772716	ZC3H12D	0.3	6.22	0.32	1.45e-9	Dupuytren's disease;
LUSC	trans	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg12856521	chr11:46389249	DGKZ	0.42	6.53	0.34	2.48e-10	Leprosy;
LUSC	cis	rs2742417	0.624	rs2673029	chr3:45758867	A/G	cg04837898	chr3:45731254	SACM1L	-0.42	-6.82	-0.35	4.36e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1865721	0.771	rs72975985	chr18:73127648	C/T	cg26385618	chr18:73139727	C18orf62	-0.54	-9.7	-0.47	8.93e-20	Intelligence;
LUSC	cis	rs926938	0.618	rs6693491	chr1:115371061	A/G	cg12756093	chr1:115239321	AMPD1	-0.53	-8.06	-0.4	1.42e-14	Autism;
LUSC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg10556349	chr10:835070	NA	0.56	6.44	0.33	4.08e-10	Eosinophil percentage of granulocytes;
LUSC	trans	rs1347297	0.614	rs7589679	chr2:179282437	T/C	cg14011486	chr1:26737247	LIN28	0.46	7.18	0.37	4.57e-12	Alzheimer disease and age of onset;
LUSC	cis	rs56283067	0.578	rs12201563	chr6:45359394	T/C	cg20913747	chr6:44695427	NA	-0.46	-6.72	-0.35	7.77e-11	Total body bone mineral density;
LUSC	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.68	0.3	2.9e-8	Self-reported allergy;
LUSC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-10.91	-0.51	6.82e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg05347473	chr6:146136440	FBXO30	0.55	9.44	0.46	6.44e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg04374321	chr14:90722782	PSMC1	0.75	12.08	0.55	4e-28	Mortality in heart failure;
LUSC	cis	rs6545883	0.708	rs2518936	chr2:61792342	T/C	cg15711740	chr2:61764176	XPO1	-0.39	-6.15	-0.32	2.17e-9	Tuberculosis;
LUSC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg02931644	chr1:25747376	RHCE	0.37	6.81	0.35	4.45e-11	Plateletcrit;Mean corpuscular volume;
LUSC	trans	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg10756647	chr7:56101905	PSPH	0.84	8.72	0.43	1.32e-16	Diabetic kidney disease;
LUSC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg11941060	chr3:133502564	NA	-0.5	-7.79	-0.39	8.43e-14	Iron status biomarkers;
LUSC	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg23752985	chr2:85803571	VAMP8	0.33	6.38	0.33	5.92e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-7.22	-0.37	3.47e-12	Mean platelet volume;
LUSC	cis	rs2625529	0.617	rs11630170	chr15:72448451	C/T	cg16672083	chr15:72433130	SENP8	0.5	8.07	0.4	1.29e-14	Red blood cell count;
LUSC	cis	rs1577917	0.637	rs1838957	chr6:86565056	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.29	-0.33	9.98e-10	Response to antipsychotic treatment;
LUSC	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.63	0.39	2.49e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg11244672	chr19:19639970	YJEFN3	0.64	8.0	0.4	2.09e-14	Bipolar disorder;
LUSC	trans	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.42	6.12	0.32	2.69e-9	Corneal astigmatism;
LUSC	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg26394196	chr10:1453818	ADARB2	-0.37	-6.36	-0.33	6.48e-10	Radiation response;
LUSC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg22166914	chr1:53195759	ZYG11B	0.66	11.12	0.52	1.2e-24	Monocyte count;
LUSC	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.54	0.57	7.75e-30	Height;
LUSC	cis	rs8049634	0.720	rs11864916	chr16:84228305	C/G	cg07804857	chr16:84208222	LRRC50	-0.32	-5.9	-0.31	8.84e-9	Small cell lung carcinoma;
LUSC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg16606324	chr3:10149918	C3orf24	0.62	9.06	0.44	1.15e-17	Alzheimer's disease;
LUSC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg18350739	chr11:68623251	NA	-0.38	-6.38	-0.33	5.75e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg05043794	chr9:111880884	C9orf5	-0.38	-7.88	-0.4	4.51e-14	Menarche (age at onset);
LUSC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg16680214	chr1:154839983	KCNN3	0.45	8.11	0.41	9.58e-15	Prostate cancer;
LUSC	cis	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg06521331	chr12:34319734	NA	0.38	6.4	0.33	5.32e-10	Morning vs. evening chronotype;
LUSC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg11843238	chr5:131593191	PDLIM4	-0.38	-6.18	-0.32	1.87e-9	Blood metabolite levels;
LUSC	cis	rs793571	0.566	rs1648532	chr15:59076778	G/C	cg05156742	chr15:59063176	FAM63B	0.56	8.44	0.42	9.48e-16	Schizophrenia;
LUSC	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18932078	chr1:2524107	MMEL1	-0.31	-6.84	-0.35	3.79e-11	Ulcerative colitis;
LUSC	trans	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg07393940	chr7:158741817	NA	0.37	6.58	0.34	1.84e-10	Life satisfaction;
LUSC	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg20628663	chr10:43360327	NA	-0.77	-11.37	-0.53	1.57e-25	Blood protein levels;
LUSC	cis	rs1113500	0.933	rs1419003	chr1:108616955	A/C	cg11967332	chr1:108735228	SLC25A24	0.4	5.88	0.31	1.01e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs7772486	0.558	rs2142980	chr6:146080679	G/A	cg13319975	chr6:146136371	FBXO30	0.67	9.48	0.46	5.01e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769707	0.605	rs2071900	chr22:50052175	A/G	cg20744362	chr22:50050164	C22orf34	0.39	7.29	0.37	2.27e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.35	-5.67	-0.3	3.06e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg15133208	chr4:90757351	SNCA	-0.53	-8.1	-0.41	1.04e-14	Neuroticism;
LUSC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg06784218	chr1:46089804	CCDC17	0.49	9.41	0.46	8.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg05714579	chr10:131428358	MGMT	0.49	7.39	0.37	1.21e-12	Response to temozolomide;
LUSC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg22143856	chr6:28129313	ZNF389	0.41	5.68	0.3	2.98e-8	Parkinson's disease;
LUSC	cis	rs17767294	0.708	rs72848754	chr6:27878458	T/A	cg08851530	chr6:28072375	NA	1.31	8.29	0.41	2.8e-15	Parkinson's disease;
LUSC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.2	0.61	3.9e-36	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9837602	0.872	rs34996634	chr3:99738219	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.72	-0.3	2.37e-8	Breast cancer;
LUSC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg12463550	chr7:65579703	CRCP	0.5	6.99	0.36	1.46e-11	Aortic root size;
LUSC	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg04624458	chr1:1913527	KIAA1751	0.36	5.97	0.31	6.12e-9	Severe influenza A (H1N1) infection;
LUSC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg21984481	chr17:79567631	NPLOC4	-0.53	-9.8	-0.47	4.43e-20	Eye color traits;
LUSC	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg05425664	chr17:57184151	TRIM37	0.56	8.5	0.42	6.49e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg15448220	chr1:150897856	SETDB1	0.43	6.23	0.32	1.43e-9	Melanoma;
LUSC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg12257692	chr3:49977190	RBM6	-0.25	-7.14	-0.36	5.92e-12	Body mass index;
LUSC	trans	rs1376359	0.503	rs584481	chr1:103250184	T/C	cg17154563	chr19:40477487	PSMC4	0.48	6.04	0.31	4.03e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs55665837	0.961	rs12795972	chr11:14443775	C/T	cg19336497	chr11:14380999	RRAS2	-0.37	-7.53	-0.38	4.9e-13	Vitamin D levels;
LUSC	cis	rs11247915	0.501	rs34209692	chr1:26608782	C/T	cg04990556	chr1:26633338	UBXN11	-0.53	-7.24	-0.37	3.15e-12	Obesity-related traits;
LUSC	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.47	-6.57	-0.34	1.93e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg21782813	chr7:2030301	MAD1L1	0.55	9.98	0.48	1.04e-20	Bipolar disorder and schizophrenia;
LUSC	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg06462663	chr19:18546047	ISYNA1	0.48	8.16	0.41	6.81e-15	Breast cancer;
LUSC	cis	rs868036	1.000	rs9972436	chr15:68098027	G/C	cg08079166	chr15:68083412	MAP2K5	0.4	8.32	0.41	2.2e-15	Restless legs syndrome;
LUSC	cis	rs367615	0.506	rs2914684	chr5:108775110	C/T	cg17395555	chr5:108820864	NA	-0.52	-9.75	-0.47	6.13e-20	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs7712401	0.791	rs6595409	chr5:122113756	G/A	cg19077854	chr5:122220652	SNX24	0.35	7.87	0.4	5.01e-14	Mean platelet volume;
LUSC	cis	rs2303282	0.664	rs2440472	chr16:56436824	A/G	cg00500540	chr16:56394104	NA	-0.39	-6.69	-0.34	9.34e-11	Breast cancer;
LUSC	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg20243544	chr17:37824526	PNMT	0.58	8.26	0.41	3.46e-15	Asthma;
LUSC	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.7	-0.51	3.49e-23	Schizophrenia;
LUSC	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.69	-11.18	-0.52	7.13e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	9.16	0.45	5.48e-18	Menarche (age at onset);
LUSC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg15790184	chr11:494944	RNH1	0.54	6.17	0.32	1.96e-9	Body mass index;
LUSC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.71	13.18	0.59	3.08e-32	Height;
LUSC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	0.83	13.39	0.59	4.9e-33	Menopause (age at onset);
LUSC	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg07828340	chr4:882639	GAK	1.07	11.42	0.53	1.01e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.41	6.05	0.31	3.92e-9	Longevity;Endometriosis;
LUSC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg04450456	chr4:17643702	FAM184B	-0.41	-6.67	-0.34	1.06e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3849570	0.555	rs6790351	chr3:82008988	C/T	cg07356753	chr3:81810745	GBE1	-0.42	-6.07	-0.32	3.41e-9	Waist circumference;Body mass index;
LUSC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg24578937	chr1:2090814	PRKCZ	-0.42	-9.13	-0.45	6.71e-18	Height;
LUSC	cis	rs12681287	0.640	rs12541793	chr8:87462558	G/A	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-0.59	-9.29	-0.45	1.98e-18	Breast cancer;
LUSC	cis	rs713587	0.571	rs475868	chr2:25318059	A/G	cg01884057	chr2:25150051	NA	-0.26	-5.72	-0.3	2.31e-8	Body mass index in non-asthmatics;
LUSC	cis	rs2677744	0.626	rs868547	chr15:91498760	G/A	cg20750528	chr15:91474456	HDDC3;UNC45A	-0.32	-5.65	-0.3	3.37e-8	Attention deficit hyperactivity disorder;
LUSC	cis	rs10743315	0.643	rs12578443	chr12:19321893	G/C	cg02471346	chr12:19282374	PLEKHA5	0.67	6.74	0.35	7.07e-11	Gut microbiota (bacterial taxa);
LUSC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg09904177	chr6:26538194	HMGN4	-0.5	-5.78	-0.3	1.74e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg05855489	chr10:104503620	C10orf26	0.59	9.61	0.47	1.81e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.71	10.81	0.51	1.48e-23	Smoking initiation;
LUSC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.82	0.3	1.41e-8	Breast cancer;
LUSC	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg05729581	chr11:3078854	CARS	0.4	5.97	0.31	6.03e-9	Calcium levels;
LUSC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.53	0.42	5.16e-16	Motion sickness;
LUSC	cis	rs981844	0.857	rs41320045	chr4:154720615	A/T	cg10279832	chr4:154682576	RNF175	0.39	5.86	0.31	1.11e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs1692580	0.870	rs263532	chr1:2164116	T/C	cg21194808	chr1:2205498	SKI	0.36	5.76	0.3	1.91e-8	Coronary artery disease;
LUSC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14829155	chr15:31115871	NA	-0.72	-10.7	-0.51	3.74e-23	Huntington's disease progression;
LUSC	cis	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg18131467	chr2:239335373	ASB1	-0.75	-6.67	-0.34	1.04e-10	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.48	-0.38	6.57e-13	Retinal vascular caliber;
LUSC	cis	rs9398803	0.865	rs9398809	chr6:126789144	C/T	cg19875578	chr6:126661172	C6orf173	0.42	6.18	0.32	1.9e-9	Male-pattern baldness;
LUSC	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-7.01	-0.36	1.33e-11	Homocysteine levels;
LUSC	cis	rs2286885	1.000	rs2286886	chr9:129246177	T/C	cg15282417	chr9:129245246	FAM125B	0.38	6.34	0.33	7.26e-10	Intraocular pressure;
LUSC	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg04455712	chr21:45112962	RRP1B	0.42	7.94	0.4	3.02e-14	Mean corpuscular volume;
LUSC	trans	rs1941687	0.583	rs8091977	chr18:31359414	T/C	cg27147174	chr7:100797783	AP1S1	-0.52	-8.28	-0.41	3.04e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17467752	chr17:38218738	THRA	0.77	12.47	0.56	1.47e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg03676636	chr4:99064102	C4orf37	0.36	7.92	0.4	3.52e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg02153584	chr22:29168773	CCDC117	-0.58	-8.72	-0.43	1.3e-16	Lymphocyte counts;
LUSC	cis	rs67072384	1.000	rs5008485	chr11:72455152	C/T	cg04827223	chr11:72435913	ARAP1	-0.78	-6.8	-0.35	4.98e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs28655083	0.843	rs1502433	chr16:77087101	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	7.08	0.36	8.57e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg23758822	chr17:41437982	NA	1.01	19.87	0.74	1.5e-58	Menopause (age at onset);
LUSC	cis	rs7005380	0.556	rs4073559	chr8:120917443	G/C	cg21744203	chr8:120868354	DSCC1	-0.48	-5.84	-0.3	1.26e-8	Interstitial lung disease;
LUSC	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg09699651	chr6:150184138	LRP11	0.46	7.27	0.37	2.54e-12	Testicular germ cell tumor;
LUSC	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg13010199	chr12:38710504	ALG10B	0.68	10.65	0.5	5.32e-23	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg18477163	chr1:228402036	OBSCN	-0.55	-10.16	-0.49	2.62e-21	Diastolic blood pressure;
LUSC	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg27284194	chr4:1044797	NA	0.59	8.79	0.43	7.77e-17	Recombination rate (females);
LUSC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg06219351	chr7:158114137	PTPRN2	0.49	8.85	0.44	5.26e-17	Calcium levels;
LUSC	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg18404041	chr3:52824283	ITIH1	-0.57	-9.6	-0.46	2.04e-19	Schizophrenia;
LUSC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg05347473	chr6:146136440	FBXO30	0.65	11.39	0.53	1.29e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Bladder cancer;
LUSC	cis	rs9467711	0.516	rs1165163	chr6:25863487	G/C	cg08501292	chr6:25962987	TRIM38	0.57	5.9	0.31	8.86e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1044826	0.553	rs295469	chr3:139212900	G/A	cg00490450	chr3:139108681	COPB2	0.43	6.2	0.32	1.67e-9	Obesity-related traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21864845	chr1:1208426	UBE2J2	0.47	6.75	0.35	6.44e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.49	-6.89	-0.35	2.8e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-13.8	-0.6	1.3600000000000001e-34	Hemoglobin concentration;
LUSC	trans	rs7181230	1.000	rs7181230	chr15:40360741	A/G	cg22705835	chr10:65332833	REEP3	-0.43	-7.68	-0.39	1.76e-13	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18404041	chr3:52824283	ITIH1	-0.62	-12.3	-0.56	6.21e-29	Bipolar disorder;
LUSC	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg04998671	chr14:104000505	TRMT61A	-0.44	-6.85	-0.35	3.48e-11	Coronary artery disease;
LUSC	cis	rs9815354	0.812	rs113528686	chr3:41951547	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.55e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg25319279	chr11:5960081	NA	-0.39	-6.19	-0.32	1.76e-9	DNA methylation (variation);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg17746833	chr17:39805051	NA	0.39	6.13	0.32	2.48e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7851660	0.935	rs10818124	chr9:100603008	C/T	cg13688889	chr9:100608707	NA	-0.61	-10.38	-0.49	4.54e-22	Strep throat;
LUSC	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg21775007	chr8:11205619	TDH	-0.64	-10.41	-0.49	3.61e-22	Retinal vascular caliber;
LUSC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.79	-0.35	5.15e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg09877947	chr5:131593287	PDLIM4	0.51	7.94	0.4	3.2e-14	Acylcarnitine levels;
LUSC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg09469691	chr10:81107165	PPIF	0.67	10.56	0.5	1.12e-22	Height;
LUSC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg12442385	chr7:1034912	NA	-0.34	-5.84	-0.3	1.21e-8	Longevity;Endometriosis;
LUSC	cis	rs1775715	0.677	rs2808105	chr10:32110907	C/T	cg26784012	chr10:32216390	ARHGAP12	0.44	7.39	0.37	1.21e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs11610422	1.000	rs12824814	chr12:31414473	G/T	cg02734259	chr12:9559402	NA	-0.6	-6.39	-0.33	5.69e-10	Coronary artery disease;
LUSC	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.7	-10.03	-0.48	7.22e-21	Vitiligo;
LUSC	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg04727924	chr7:799746	HEATR2	-0.54	-6.46	-0.33	3.79e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs12137294	0.866	rs1077883	chr1:205210415	G/T	cg00857998	chr1:205179979	DSTYK	0.39	5.73	0.3	2.25e-8	Red cell distribution width;
LUSC	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg04036182	chr15:45458818	NA	0.35	5.75	0.3	2.02e-8	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg27275811	chr11:74457193	NA	-0.61	-6.15	-0.32	2.17e-9	Type 2 diabetes nephropathy;
LUSC	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg17385448	chr1:15911702	AGMAT	0.37	5.86	0.31	1.08e-8	Systolic blood pressure;
LUSC	cis	rs8081395	0.769	rs12449331	chr17:57883646	T/C	cg18434674	chr17:58106139	NA	-0.27	-5.92	-0.31	8.01e-9	White blood cell count;
LUSC	cis	rs965469	1.000	rs6051702	chr20:3251924	A/C	cg25506879	chr20:3388711	C20orf194	-0.54	-6.28	-0.33	1.04e-9	IFN-related cytopenia;
LUSC	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3820928	0.874	rs13383070	chr2:227904939	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.87	-0.4	5.01e-14	Pulmonary function;
LUSC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.7	12.59	0.57	5.27e-30	Aortic root size;
LUSC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.63	-0.34	1.33e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg02772935	chr3:125709198	NA	-0.48	-5.76	-0.3	1.94e-8	Blood pressure (smoking interaction);
LUSC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.1	-0.41	1.07e-14	Lung cancer;
LUSC	trans	rs877282	0.735	rs111609055	chr10:826539	A/G	cg13042288	chr15:90349979	ANPEP	-0.4	-6.02	-0.31	4.53e-9	Uric acid levels;
LUSC	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg02807482	chr3:125708958	NA	-0.49	-5.79	-0.3	1.61e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7804356	1.000	rs3801833	chr7:26852212	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg22117172	chr7:91764530	CYP51A1	0.33	5.83	0.3	1.28e-8	Breast cancer;
LUSC	cis	rs4240897	0.935	rs2236055	chr1:12042261	A/G	cg13216073	chr1:12042593	MFN2	0.42	7.56	0.38	3.88e-13	Tuberculosis;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg08128889	chr17:80828176	TBCD	-0.45	-7.12	-0.36	6.82e-12	N-glycan levels;
LUSC	cis	rs722599	0.683	rs2058918	chr14:75288518	A/G	cg08847533	chr14:75593920	NEK9	0.43	5.97	0.31	6.06e-9	IgG glycosylation;
LUSC	cis	rs79149102	0.737	rs75128970	chr15:75181397	C/T	cg09165964	chr15:75287851	SCAMP5	-0.88	-6.53	-0.34	2.48e-10	Lung cancer;
LUSC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg05585544	chr11:47624801	NA	-0.42	-7.31	-0.37	2.04e-12	Subjective well-being;
LUSC	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg09165964	chr15:75287851	SCAMP5	0.85	8.01	0.4	1.89e-14	Lung cancer;
LUSC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg04518342	chr5:131593106	PDLIM4	0.4	7.31	0.37	1.94e-12	Breast cancer;
LUSC	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg23625390	chr15:77176239	SCAPER	-0.62	-8.81	-0.43	7.12e-17	Blood metabolite levels;
LUSC	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg04398451	chr17:18023971	MYO15A	0.46	7.32	0.37	1.81e-12	Total body bone mineral density;
LUSC	cis	rs7560272	0.723	rs780391	chr2:73703904	C/T	cg20560298	chr2:73613845	ALMS1	0.45	7.14	0.36	5.99e-12	Schizophrenia;
LUSC	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	0.88	13.69	0.6	3.44e-34	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.66	11.36	0.53	1.63e-25	Myeloid white cell count;
LUSC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg06636001	chr8:8085503	FLJ10661	0.59	9.08	0.45	9.34e-18	Mood instability;
LUSC	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg19156104	chr2:198669113	PLCL1	-0.46	-5.71	-0.3	2.44e-8	Ulcerative colitis;
LUSC	cis	rs9515201	0.774	rs9521739	chr13:111038803	A/G	cg05272587	chr13:111038400	COL4A2	-0.35	-5.71	-0.3	2.52e-8	White matter hyperintensity burden;
LUSC	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg05347473	chr6:146136440	FBXO30	0.52	8.82	0.43	6.43e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg12564285	chr5:131593104	PDLIM4	-0.33	-6.0	-0.31	5.18e-9	Breast cancer;Mosquito bite size;
LUSC	trans	rs72674100	0.737	rs2865752	chr4:97992784	T/C	cg16405019	chr1:18959625	PAX7	-0.61	-6.41	-0.33	5.09e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg15423357	chr2:25149977	NA	0.45	9.02	0.44	1.52e-17	Body mass index;
LUSC	cis	rs4356932	0.935	rs115936805	chr4:76968068	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.86	0.31	1.11e-8	Blood protein levels;
LUSC	cis	rs3772130	0.564	rs4420917	chr3:121567863	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.83	13.54	0.6	1.29e-33	Cognitive performance;
LUSC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg23649088	chr2:200775458	C2orf69	0.59	7.35	0.37	1.56e-12	Schizophrenia;
LUSC	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg09044154	chr16:88155775	NA	-0.55	-7.36	-0.37	1.48e-12	Menopause (age at onset);
LUSC	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg24558204	chr6:135376177	HBS1L	0.55	8.34	0.42	2.02e-15	Red blood cell count;
LUSC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.63	0.62	8.8e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4919694	1.000	rs77505796	chr10:104647774	A/T	cg04362960	chr10:104952993	NT5C2	1.18	13.48	0.59	2.26e-33	Arsenic metabolism;
LUSC	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg21427119	chr20:30132790	HM13	-0.46	-6.38	-0.33	5.78e-10	Mean corpuscular hemoglobin;
LUSC	trans	rs4450131	0.522	rs17152232	chr10:126398927	A/G	cg09091424	chr11:67057304	ANKRD13D	0.42	6.07	0.32	3.5e-9	White blood cell count (basophil);
LUSC	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-7.92	-0.4	3.48e-14	Morning vs. evening chronotype;
LUSC	cis	rs4919087	0.962	rs3740522	chr10:99019144	C/T	cg25902810	chr10:99078978	FRAT1	0.46	6.57	0.34	1.9e-10	Monocyte count;
LUSC	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.73	10.28	0.49	1.02e-21	Corneal astigmatism;
LUSC	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.82	-0.43	6.55e-17	Uric acid levels;
LUSC	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.69	-0.39	1.64e-13	Blood metabolite levels;
LUSC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg27170947	chr2:26402098	FAM59B	0.72	10.82	0.51	1.41e-23	Gut microbiome composition (summer);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04275194	chr2:219433691	USP37;RQCD1	0.45	7.71	0.39	1.48e-13	Triglycerides;
LUSC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg16928487	chr17:17741425	SREBF1	0.37	7.13	0.36	6.28e-12	Total body bone mineral density;
LUSC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23158103	chr7:148848205	ZNF398	-0.5	-8.17	-0.41	6.41e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.25	-0.45	2.85e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-10.34	-0.49	6.48e-22	Schizophrenia;
LUSC	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg17470449	chr10:769945	NA	0.53	7.41	0.38	1.05e-12	Uric acid levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27585405	chr16:475496	RAB11FIP3	-0.41	-6.08	-0.32	3.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg09184832	chr6:79620586	NA	0.43	6.63	0.34	1.35e-10	Left atrial antero-posterior diameter;
LUSC	cis	rs7789940	0.904	rs61294900	chr7:75937212	A/T	cg10167463	chr7:75959203	YWHAG	-0.59	-8.48	-0.42	7.37e-16	Multiple sclerosis;
LUSC	cis	rs9649213	0.574	rs17436977	chr7:97883459	T/C	cg26380479	chr7:97908229	NA	-0.27	-5.81	-0.3	1.44e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs6596100	0.554	rs12515756	chr5:132238880	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.29	-0.33	9.7e-10	Breast cancer;
LUSC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs10140922	0.864	rs72666622	chr14:35820138	T/A	cg07166546	chr14:35805898	NA	-0.26	-6.11	-0.32	2.76e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9644630	0.696	rs35736969	chr8:19319620	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.5	8.2	0.41	5.3e-15	Oropharynx cancer;
LUSC	cis	rs67072384	0.892	rs7104664	chr11:72444450	C/T	cg04827223	chr11:72435913	ARAP1	-0.82	-7.76	-0.39	1.04e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs34779708	0.931	rs3740083	chr10:35320383	C/T	cg04310649	chr10:35416472	CREM	-0.4	-6.07	-0.32	3.45e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs965513	1.000	rs1443438	chr9:100550028	T/C	cg13688889	chr9:100608707	NA	-0.54	-7.97	-0.4	2.58e-14	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-7.15	-0.36	5.48e-12	Homocysteine levels;
LUSC	trans	rs9929218	0.954	rs9646284	chr16:68791306	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-11.29	-0.53	2.99e-25	Colorectal cancer;
LUSC	cis	rs17095355	0.901	rs9783184	chr10:111760499	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.35	-0.37	1.53e-12	Biliary atresia;
LUSC	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.72	-0.39	1.33e-13	Response to antipsychotic treatment;
LUSC	trans	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	8.5	0.42	6.31e-16	Type 2 diabetes;
LUSC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.51	6.2	0.32	1.7e-9	Multiple sclerosis;
LUSC	cis	rs4363385	0.693	rs576941	chr1:153040165	A/G	cg00922841	chr1:152955080	SPRR1A	0.42	7.31	0.37	1.97e-12	Inflammatory skin disease;
LUSC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg27398817	chr8:82754497	SNX16	0.6	7.43	0.38	9.41e-13	Diastolic blood pressure;
LUSC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.72	-0.34	8.09e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10761482	0.861	rs7073512	chr10:62109926	T/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.05	-0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg24642439	chr20:33292090	TP53INP2	0.5	7.46	0.38	7.71e-13	Height;
LUSC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg02782426	chr3:40428986	ENTPD3	0.39	7.48	0.38	6.78e-13	Renal cell carcinoma;
LUSC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg19468946	chr17:37922297	IKZF3	-0.44	-6.93	-0.35	2.22e-11	Self-reported allergy;
LUSC	cis	rs10761482	0.566	rs4505011	chr10:62200308	T/C	cg18175470	chr10:62150864	ANK3	-0.54	-7.63	-0.39	2.45e-13	Schizophrenia;
LUSC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg17330251	chr7:94953956	PON1	-0.36	-5.64	-0.3	3.57e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.62	8.43	0.42	1.02e-15	Adiposity;
LUSC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg06212747	chr3:49208901	KLHDC8B	0.44	5.69	0.3	2.76e-8	Parkinson's disease;
LUSC	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg04155231	chr12:9217510	LOC144571	0.3	5.68	0.3	2.93e-8	Sjögren's syndrome;
LUSC	cis	rs2227564	0.729	rs2675674	chr10:75652682	G/A	cg23231163	chr10:75533350	FUT11	-0.42	-5.92	-0.31	8.17e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9921338	0.961	rs9302459	chr16:11420339	G/T	cg00044050	chr16:11439710	C16orf75	0.46	6.09	0.32	3.03e-9	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs2348418	0.864	rs7304540	chr12:28713422	C/G	cg13890972	chr12:28721907	NA	-0.34	-5.81	-0.3	1.48e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs405956	0.932	rs9654624	chr6:105584895	G/C	cg22580625	chr6:105627791	POPDC3	-0.59	-5.77	-0.3	1.84e-8	QT interval;
LUSC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg04455712	chr21:45112962	RRP1B	0.44	8.33	0.41	2.17e-15	Mean corpuscular volume;
LUSC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.53	7.81	0.39	7.45e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg20203395	chr5:56204925	C5orf35	-0.77	-10.27	-0.49	1.12e-21	Initial pursuit acceleration;
LUSC	cis	rs72829446	0.530	rs66616380	chr17:7380188	C/A	cg02795151	chr17:7402630	POLR2A	0.61	7.4	0.38	1.13e-12	Androgen levels;
LUSC	cis	rs4566357	1.000	rs7567789	chr2:227922104	T/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.76	-0.3	1.87e-8	Coronary artery disease;
LUSC	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.43	6.56	0.34	2.08e-10	Dupuytren's disease;
LUSC	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg01652190	chr22:50026171	C22orf34	-0.31	-6.39	-0.33	5.51e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg04362960	chr10:104952993	NT5C2	0.6	9.53	0.46	3.28e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-6.17	-0.32	1.98e-9	Vitiligo;
LUSC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18876405	chr7:65276391	NA	0.56	8.89	0.44	3.85e-17	Aortic root size;
LUSC	trans	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg08975724	chr8:8085496	FLJ10661	0.43	6.09	0.32	3.06e-9	Retinal vascular caliber;
LUSC	cis	rs4974559	0.501	rs1732115	chr4:1244416	C/T	cg02980000	chr4:1222292	CTBP1	1.0	10.04	0.48	6.65e-21	Systolic blood pressure;
LUSC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.77	0.3	1.81e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg06784218	chr1:46089804	CCDC17	-0.48	-9.21	-0.45	3.67e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.89	-0.31	9.61e-9	Ulcerative colitis;
LUSC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06022373	chr22:39101656	GTPBP1	0.84	13.98	0.61	2.65e-35	Menopause (age at onset);
LUSC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg16447950	chr5:562315	NA	-0.55	-6.63	-0.34	1.35e-10	Obesity-related traits;
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-7.99	-0.4	2.23e-14	Lymphocyte counts;
LUSC	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.68	-11.35	-0.53	1.82e-25	Caffeine consumption;
LUSC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg27535305	chr1:53392650	SCP2	-0.41	-8.1	-0.41	1.05e-14	Monocyte count;
LUSC	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.26	-0.32	1.18e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg06600287	chr1:53387719	ECHDC2	-0.28	-5.69	-0.3	2.73e-8	Monocyte count;
LUSC	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.69	-10.24	-0.49	1.4e-21	Metabolic syndrome;
LUSC	cis	rs78545713	0.649	rs77727979	chr6:26222026	T/A	cg23601095	chr6:26197514	HIST1H3D	0.67	5.68	0.3	2.87e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg24375607	chr4:120327624	NA	0.76	11.36	0.53	1.69e-25	Corneal astigmatism;
LUSC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg14552801	chr7:65878734	NA	0.38	5.84	0.3	1.24e-8	Aortic root size;
LUSC	cis	rs4363385	0.693	rs310102	chr1:153042423	T/C	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.24	-0.37	3.13e-12	Inflammatory skin disease;
LUSC	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	17.64	0.69	1.13e-49	Body mass index (adult);
LUSC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg02753203	chr1:228287806	NA	0.73	12.91	0.58	3.34e-31	Diastolic blood pressure;
LUSC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21028142	chr17:79581711	NPLOC4	-0.32	-7.79	-0.39	8.41e-14	Eye color traits;
LUSC	cis	rs62458065	0.850	rs28693551	chr7:32469387	G/A	cg20159608	chr7:32802032	NA	-0.63	-7.5	-0.38	5.76e-13	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg14433983	chr11:636460	DRD4	-0.35	-5.88	-0.31	9.78e-9	Systemic lupus erythematosus;
LUSC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24110177	chr3:50126178	RBM5	-0.67	-11.5	-0.53	5.03e-26	Body mass index;
LUSC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.83	-15.1	-0.64	1.25e-39	Cognitive function;
LUSC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg16797656	chr11:68205561	LRP5	0.36	6.06	0.31	3.66e-9	Total body bone mineral density;
LUSC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg03354898	chr7:1950403	MAD1L1	0.35	6.85	0.35	3.55e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg22676075	chr6:135203613	NA	0.49	7.44	0.38	8.37e-13	Red blood cell count;
LUSC	trans	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg16660971	chr17:78860029	RPTOR	0.37	5.97	0.31	5.95e-9	Major depressive disorder;
LUSC	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg03585969	chr10:35415529	CREM	0.6	8.77	0.43	9.27e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs17401966	1.000	rs1049887	chr1:10460485	T/C	cg19773385	chr1:10388646	KIF1B	-0.53	-7.97	-0.4	2.49e-14	Hepatocellular carcinoma;
LUSC	cis	rs6545883	0.895	rs4430924	chr2:61703856	A/G	cg15711740	chr2:61764176	XPO1	-0.42	-6.26	-0.32	1.17e-9	Tuberculosis;
LUSC	cis	rs9462027	0.583	rs7755982	chr6:34715297	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.9	-0.31	9.02e-9	Systemic lupus erythematosus;
LUSC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9788721	0.836	rs17405217	chr15:78731149	C/T	cg18825076	chr15:78729989	IREB2	-0.63	-10.25	-0.49	1.32e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.74	-14.23	-0.61	3.13e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg11752832	chr7:134001865	SLC35B4	0.56	8.67	0.43	1.86e-16	Mean platelet volume;
LUSC	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs6424115	0.679	rs2267961	chr1:24071048	A/G	cg15997130	chr1:24165203	NA	-0.48	-6.75	-0.35	6.61e-11	Immature fraction of reticulocytes;
LUSC	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg20703242	chr1:230279135	GALNT2	0.52	8.2	0.41	5.39e-15	Coronary artery disease;
LUSC	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.57	-0.46	2.4e-19	Systolic blood pressure;
LUSC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.31	-0.41	2.51e-15	Obesity-related traits;
LUSC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg04455712	chr21:45112962	RRP1B	0.43	8.05	0.4	1.47e-14	Mean corpuscular volume;
LUSC	cis	rs1443512	0.704	rs4759308	chr12:54329031	A/T	cg25024717	chr12:54324583	NA	-0.39	-6.74	-0.35	6.86e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs2637266	0.967	rs2579760	chr10:78321768	A/C	cg18941641	chr10:78392320	NA	0.37	6.75	0.35	6.47e-11	Pulmonary function;
LUSC	cis	rs7614311	0.636	rs3821902	chr3:63941697	T/G	cg22134162	chr3:63841271	THOC7	-0.47	-5.96	-0.31	6.34e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.61	0.5	7.28e-23	Colorectal cancer;
LUSC	trans	rs6561151	0.681	rs17653353	chr13:44421746	A/G	cg12856521	chr11:46389249	DGKZ	0.79	9.62	0.47	1.67e-19	Crohn's disease;
LUSC	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg08213375	chr14:104286397	PPP1R13B	0.52	10.23	0.49	1.55e-21	Schizophrenia;
LUSC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	22.71	0.78	1.1e-69	Height;
LUSC	cis	rs77633900	0.685	rs2469556	chr15:76650148	G/A	cg21673338	chr15:77095150	SCAPER	-0.72	-6.22	-0.32	1.5e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg12935359	chr14:103987150	CKB	-0.56	-8.48	-0.42	7.62e-16	Body mass index;
LUSC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.19	15.48	0.65	4.17e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2346177	0.811	rs4953373	chr2:46652145	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.35	5.95	0.31	6.82e-9	HDL cholesterol;
LUSC	cis	rs11229555	0.874	rs11601687	chr11:58338628	T/C	cg15696309	chr11:58395628	NA	-0.7	-9.06	-0.44	1.12e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg15448220	chr1:150897856	SETDB1	0.43	6.24	0.32	1.35e-9	Melanoma;
LUSC	cis	rs2387326	0.717	rs10829342	chr10:129944493	C/T	cg16087940	chr10:129947807	NA	-0.39	-6.0	-0.31	5e-9	Select biomarker traits;
LUSC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9309473	0.519	rs2421574	chr2:73908767	C/G	cg20560298	chr2:73613845	ALMS1	0.41	6.18	0.32	1.83e-9	Metabolite levels;
LUSC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.39	0.37	1.21e-12	Schizophrenia;
LUSC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	0.79	13.2	0.59	2.61e-32	Gestational age at birth (maternal effect);
LUSC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg05347473	chr6:146136440	FBXO30	0.53	9.06	0.44	1.13e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg22903657	chr4:1355424	KIAA1530	-0.35	-6.0	-0.31	5.02e-9	Obesity-related traits;
LUSC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg03354898	chr7:1950403	MAD1L1	-0.37	-7.0	-0.36	1.43e-11	Schizophrenia;
LUSC	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg13390004	chr1:15929781	NA	0.42	6.86	0.35	3.25e-11	Systolic blood pressure;
LUSC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06634786	chr22:41940651	POLR3H	0.51	6.11	0.32	2.82e-9	Vitiligo;
LUSC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.77	14.68	0.63	5.42e-38	Monocyte count;
LUSC	cis	rs3770081	1.000	rs3731819	chr2:86368641	C/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.86	-0.35	3.43e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs6987853	0.787	rs12677427	chr8:42414226	T/A	cg09913449	chr8:42400586	C8orf40	0.53	9.22	0.45	3.48e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg10483660	chr13:112241077	NA	-0.31	-5.68	-0.3	2.99e-8	Hepatitis;
LUSC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.51	7.43	0.38	9.21e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs1904096	0.506	rs7439869	chr4:95173779	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.31	-0.41	2.41e-15	Type 2 diabetes;
LUSC	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg27068330	chr11:65405492	SIPA1	-0.76	-10.98	-0.51	3.78e-24	Acne (severe);
LUSC	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.3	-0.33	9.35e-10	Bipolar disorder;
LUSC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg21699342	chr2:239360505	ASB1	0.57	10.59	0.5	8.38e-23	Multiple system atrophy;
LUSC	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-6.48	-0.33	3.39e-10	Response to antipsychotic treatment;
LUSC	cis	rs12681287	0.640	rs13253515	chr8:87458596	T/A	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs7463659	0.904	rs7826572	chr8:135433805	G/T	cg17885191	chr8:135476712	NA	-0.4	-5.67	-0.3	3.15e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4417855	0.665	rs7653032	chr3:187413388	G/A	cg19198148	chr3:187451818	BCL6	0.56	9.78	0.47	4.99e-20	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.62	0.47	1.65e-19	Bipolar disorder;
LUSC	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg00376283	chr12:123451042	ABCB9	0.68	7.67	0.39	1.89e-13	Neutrophil percentage of white cells;
LUSC	cis	rs7715806	0.500	rs17649332	chr5:75003878	T/C	cg19683494	chr5:74908142	NA	0.58	7.75	0.39	1.15e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.46e-23	Gut microbiome composition (summer);
LUSC	cis	rs4919694	1.000	rs77318450	chr10:104733098	A/G	cg04362960	chr10:104952993	NT5C2	1.15	13.45	0.59	2.87e-33	Arsenic metabolism;
LUSC	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	9.44	0.46	6.76e-19	Lung cancer in ever smokers;
LUSC	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg07936489	chr17:37558343	FBXL20	0.77	9.55	0.46	2.96e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs10782582	0.609	rs1251584	chr1:76424440	C/T	cg10523679	chr1:76189770	ACADM	0.4	5.69	0.3	2.84e-8	Daytime sleep phenotypes;
LUSC	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg17252645	chr8:143867129	LY6D	0.37	6.61	0.34	1.55e-10	Urinary tract infection frequency;
LUSC	cis	rs9462027	0.628	rs6924898	chr6:34811199	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.82	-0.3	1.35e-8	Systemic lupus erythematosus;
LUSC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg17971929	chr21:40555470	PSMG1	0.54	8.48	0.42	7.21e-16	Cognitive function;
LUSC	cis	rs6733011	0.518	rs12712033	chr2:99457973	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.78	-0.35	5.61e-11	Bipolar disorder;
LUSC	cis	rs13315871	0.929	rs13097873	chr3:58267924	C/T	cg12435725	chr3:58293450	RPP14	-0.78	-7.71	-0.39	1.45e-13	Cholesterol, total;
LUSC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg06784218	chr1:46089804	CCDC17	0.47	9.31	0.45	1.81e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg15534020	chr5:154320467	MRPL22	0.37	6.06	0.31	3.67e-9	Schizophrenia;
LUSC	cis	rs921665	0.748	rs11677991	chr2:3185321	G/A	cg16434511	chr2:3151078	NA	-0.53	-6.35	-0.33	7.11e-10	World class endurance athleticism;
LUSC	trans	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg21775007	chr8:11205619	TDH	0.44	6.6	0.34	1.61e-10	Mood instability;
LUSC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9831754	1.000	rs9855903	chr3:78347988	C/A	cg06138941	chr3:78371609	NA	-0.75	-10.03	-0.48	7.14e-21	Calcium levels;
LUSC	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg00852783	chr1:26633632	UBXN11	-0.47	-5.82	-0.3	1.37e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	7.96	0.4	2.63e-14	Homoarginine levels;
LUSC	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg06917634	chr15:78832804	PSMA4	-0.48	-6.02	-0.31	4.65e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18854424	chr1:2615690	NA	0.5	9.97	0.48	1.12e-20	Ulcerative colitis;
LUSC	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.01	-0.36	1.35e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg08807101	chr21:30365312	RNF160	-0.53	-7.9	-0.4	4.17e-14	Dental caries;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18075040	chr12:96337100	AMDHD1;CCDC38	-0.55	-6.73	-0.35	7.56e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.44	-7.0	-0.36	1.41e-11	Bipolar disorder;
LUSC	cis	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.37e-9	Ulcerative colitis;
LUSC	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg16476235	chr8:21771668	DOK2	0.24	5.68	0.3	2.89e-8	Mean corpuscular volume;
LUSC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.49	0.46	4.39e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs1113500	0.614	rs11185243	chr1:108597141	T/C	cg11967332	chr1:108735228	SLC25A24	0.42	5.82	0.3	1.35e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg25457927	chr22:38595422	NA	-0.42	-8.92	-0.44	3.05e-17	Cutaneous nevi;
LUSC	cis	rs11676348	0.774	rs11683524	chr2:218984604	G/A	cg00012203	chr2:219082015	ARPC2	-0.53	-8.08	-0.4	1.19e-14	Ulcerative colitis;
LUSC	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.94	-0.44	2.7e-17	Total cholesterol levels;
LUSC	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg12311346	chr5:56204834	C5orf35	-0.55	-8.32	-0.41	2.23e-15	Coronary artery disease;
LUSC	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.19e-33	Morning vs. evening chronotype;
LUSC	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg07661805	chr8:143867942	LY6D	-0.25	-5.82	-0.3	1.37e-8	Urinary tract infection frequency;
LUSC	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg07080220	chr10:102295463	HIF1AN	0.68	8.74	0.43	1.19e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg11062466	chr8:58055876	NA	0.58	7.3	0.37	2.12e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	10.92	0.51	5.95e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2124969	0.548	rs983916	chr2:161015066	T/G	cg03641300	chr2:160917029	PLA2R1	-0.47	-5.7	-0.3	2.7e-8	Waist circumference adjusted for body mass index;
LUSC	cis	rs9463078	0.817	rs9369523	chr6:44908728	T/C	cg25276700	chr6:44698697	NA	-0.31	-6.1	-0.32	2.86e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg24331049	chr13:111365604	ING1	-0.52	-6.84	-0.35	3.86e-11	Coronary artery disease;
LUSC	cis	rs6998277	0.830	rs12543046	chr8:103603809	A/G	cg10187029	chr8:103597600	NA	-0.79	-12.46	-0.56	1.64e-29	Migraine;
LUSC	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg11244672	chr19:19639970	YJEFN3	-0.55	-6.91	-0.35	2.49e-11	Bipolar disorder;
LUSC	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg22029157	chr1:209979665	IRF6	0.78	9.2	0.45	4.04e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs968451	1.000	rs17000962	chr22:39680187	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.7	8.9	0.44	3.7e-17	Primary biliary cholangitis;
LUSC	trans	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg06606381	chr12:133084897	FBRSL1	-0.9	-7.6	-0.38	3.06e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.08	-0.4	1.19e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg23711669	chr6:146136114	FBXO30	-0.91	-17.36	-0.69	1.44e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg15534755	chr11:117069859	TAGLN	0.34	5.91	0.31	8.33e-9	Blood protein levels;
LUSC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg25258033	chr6:167368657	RNASET2	-0.46	-7.78	-0.39	9e-14	Crohn's disease;
LUSC	cis	rs3931020	0.688	rs455032	chr1:75196488	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	-0.46	-5.92	-0.31	8.17e-9	Resistin levels;
LUSC	cis	rs865483	0.895	rs853208	chr17:35826456	C/A	cg06716730	chr17:35851459	DUSP14	0.28	6.18	0.32	1.91e-9	Monocyte count;
LUSC	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg23241863	chr10:102295624	HIF1AN	0.48	5.72	0.3	2.38e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-15.75	-0.65	3.57e-42	Height;
LUSC	cis	rs7923609	0.783	rs7907451	chr10:65328740	T/A	cg01631684	chr10:65280961	REEP3	0.4	5.97	0.31	6.17e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.85	-0.51	1.05e-23	Alcohol dependence;
LUSC	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	9.18	0.45	4.63e-18	Mood instability;
LUSC	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg22709100	chr7:91322751	NA	-0.39	-5.68	-0.3	2.94e-8	Breast cancer;
LUSC	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg26727032	chr16:67993705	SLC12A4	0.38	5.76	0.3	1.89e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.51e-14	Prudent dietary pattern;
LUSC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg12310025	chr6:25882481	NA	-0.41	-7.28	-0.37	2.45e-12	Height;
LUSC	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg10167378	chr1:228756711	NA	0.74	9.51	0.46	3.81e-19	Chronic lymphocytic leukemia;
LUSC	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg04362960	chr10:104952993	NT5C2	0.58	8.5	0.42	6.52e-16	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg01483505	chr11:975446	AP2A2	0.4	5.76	0.3	1.92e-8	Alzheimer's disease (late onset);
LUSC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.65	-0.34	1.17e-10	Menarche (age at onset);
LUSC	cis	rs9341808	0.718	rs9448886	chr6:80825901	C/T	cg08355045	chr6:80787529	NA	0.56	9.85	0.47	2.85e-20	Sitting height ratio;
LUSC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg17143192	chr8:8559678	CLDN23	0.64	9.1	0.45	8.37e-18	Obesity-related traits;
LUSC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08677398	chr8:58056175	NA	0.52	6.01	0.31	4.77e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.72	-0.43	1.38e-16	Bipolar disorder;
LUSC	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02176678	chr2:219576539	TTLL4	0.65	11.5	0.53	5.29e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg05966235	chr16:28915196	ATP2A1	0.34	5.96	0.31	6.43e-9	Tonsillectomy;Mean corpuscular volume;
LUSC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg02153584	chr22:29168773	CCDC117	-0.52	-7.85	-0.39	5.88e-14	Lymphocyte counts;
LUSC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.64	0.57	3.49e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	6.9	0.35	2.62e-11	Melanoma;
LUSC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.33	-0.33	8.09e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs669446	0.533	rs6429638	chr1:44211010	A/G	cg15962314	chr1:44399869	ARTN	0.24	5.65	0.3	3.46e-8	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg26384229	chr12:38710491	ALG10B	0.71	11.18	0.52	7.25e-25	Morning vs. evening chronotype;
LUSC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	6.16	0.32	2.14e-9	Tonsillectomy;
LUSC	cis	rs6733011	0.600	rs1356424	chr2:99425838	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-6.98	-0.36	1.57e-11	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg24829409	chr8:58192753	C8orf71	-0.5	-6.1	-0.32	2.86e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg13722127	chr7:150037890	RARRES2	0.4	5.92	0.31	7.83e-9	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs6601327	0.736	rs4840426	chr8:9408978	G/T	cg15556689	chr8:8085844	FLJ10661	0.43	6.06	0.31	3.76e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	cis	rs6596100	0.538	rs66481372	chr5:132179592	T/A	cg02081065	chr5:132209139	LEAP2	-0.62	-6.02	-0.31	4.62e-9	Breast cancer;
LUSC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.24	0.52	4.63e-25	Prudent dietary pattern;
LUSC	cis	rs1971762	0.583	rs7979659	chr12:54086579	A/G	cg23533419	chr12:54090519	NA	-0.37	-6.04	-0.31	4.12e-9	Height;
LUSC	cis	rs9807841	0.592	rs10401513	chr19:10778763	A/T	cg17710535	chr19:10819994	QTRT1	0.42	6.87	0.35	3.21e-11	Inflammatory skin disease;
LUSC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	ch.11.42038R	chr11:967971	AP2A2	0.44	6.62	0.34	1.45e-10	Alzheimer's disease (late onset);
LUSC	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg22482690	chr17:47019901	SNF8	0.38	7.01	0.36	1.35e-11	Type 2 diabetes;
LUSC	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.37	1.18e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	0.98	21.34	0.76	2.33e-64	Menarche (age at onset);
LUSC	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-10.75	-0.51	2.34e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs3820928	0.874	rs6718057	chr2:227834349	T/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.42	-0.38	9.97e-13	Pulmonary function;
LUSC	trans	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg04995722	chr7:26192034	NFE2L3	-0.43	-6.64	-0.34	1.24e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16266895	chr12:101674004	UTP20	0.42	6.11	0.32	2.83e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg02038168	chr22:39784481	NA	-0.47	-7.27	-0.37	2.54e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs8018808	0.935	rs4903584	chr14:77934758	A/G	cg20045696	chr14:77926864	AHSA1	0.34	5.76	0.3	1.95e-8	Myeloid white cell count;
LUSC	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg17173187	chr15:85201210	NMB	0.39	6.79	0.35	5.22e-11	Schizophrenia;
LUSC	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	13.16	0.58	3.88e-32	Lung cancer in ever smokers;
LUSC	trans	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg02800362	chr5:177631904	HNRNPAB	0.87	12.81	0.57	8.07e-31	Obesity-related traits;
LUSC	cis	rs2559856	1.000	rs10745921	chr12:102087193	A/G	cg12924262	chr12:102091054	CHPT1	0.43	6.04	0.31	4e-9	Blood protein levels;
LUSC	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg11984989	chr7:158649758	WDR60	1.14	13.69	0.6	3.45e-34	Height;
LUSC	cis	rs1832871	1.000	rs1832871	chr6:158722034	C/T	cg07165851	chr6:158734300	TULP4	0.36	6.29	0.33	9.99e-10	Height;
LUSC	cis	rs7615316	0.844	rs13075471	chr3:142191659	T/C	cg16271453	chr3:142027066	XRN1	-0.38	-6.53	-0.34	2.42e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg19743168	chr1:23544995	NA	0.46	9.11	0.45	8.03e-18	Height;
LUSC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03576123	chr11:487126	PTDSS2	-0.95	-10.54	-0.5	1.29e-22	Body mass index;
LUSC	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg15145296	chr3:125709740	NA	-0.5	-5.75	-0.3	2e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg12002119	chr2:101014098	CHST10	0.34	5.74	0.3	2.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	0.85	13.95	0.61	3.77e-35	Tonsillectomy;
LUSC	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-8.19	-0.41	5.68e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7084921	0.608	rs11597561	chr10:101863041	T/C	cg02250046	chr10:101825185	CPN1	-0.35	-6.33	-0.33	7.9e-10	Bone mineral density;
LUSC	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg18352616	chr4:3374830	RGS12	0.3	5.95	0.31	6.73e-9	Serum sulfate level;
LUSC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg12463550	chr7:65579703	CRCP	0.57	8.47	0.42	7.7e-16	Aortic root size;
LUSC	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg26195577	chr20:24973756	C20orf3	1.11	18.17	0.71	8.49e-52	Blood protein levels;
LUSC	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg15423357	chr2:25149977	NA	0.37	7.19	0.37	4.31e-12	Body mass index in non-asthmatics;
LUSC	trans	rs335206	0.542	rs55981521	chr5:122477177	C/T	cg01368872	chr15:91498139	RCCD1	-0.45	-6.07	-0.32	3.42e-9	QRS duration;
LUSC	cis	rs859767	0.709	rs7575742	chr2:135429002	A/G	cg12500956	chr2:135428796	TMEM163	-0.27	-6.11	-0.32	2.76e-9	Neuroticism;
LUSC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg17366294	chr4:99064904	C4orf37	0.55	9.77	0.47	5.18e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.83	-0.3	1.3e-8	Bipolar disorder;
LUSC	cis	rs13082711	0.911	rs7644466	chr3:27515271	C/G	cg02860705	chr3:27208620	NA	0.46	7.61	0.38	2.79e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	10.93	0.51	5.6e-24	Response to antipsychotic treatment;
LUSC	cis	rs57590327	0.503	rs2049415	chr3:81901887	A/T	cg07356753	chr3:81810745	GBE1	-0.66	-10.49	-0.5	2e-22	Extraversion;
LUSC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg20573242	chr4:122745356	CCNA2	0.43	6.6	0.34	1.62e-10	Type 2 diabetes;
LUSC	cis	rs6840360	0.642	rs2709842	chr4:152370637	C/T	cg20465933	chr4:152376761	FAM160A1	-0.32	-5.74	-0.3	2.1e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10186029	0.509	rs13425936	chr2:213940346	C/T	cg08319019	chr2:214017104	IKZF2	-0.42	-6.12	-0.32	2.64e-9	Systemic sclerosis;
LUSC	cis	rs2932538	0.885	rs6661642	chr1:113090109	T/C	cg22162597	chr1:113214053	CAPZA1	0.7	10.11	0.48	3.74e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	trans	rs1459104	0.866	rs12804916	chr11:54831763	G/A	cg03929089	chr4:120376271	NA	0.74	6.38	0.33	5.96e-10	Body mass index;
LUSC	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg19773385	chr1:10388646	KIF1B	-0.53	-8.19	-0.41	5.74e-15	Hepatocellular carcinoma;
LUSC	trans	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.08	-0.32	3.28e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs59698941	0.943	rs67162224	chr5:132289372	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs9309473	0.687	rs12465867	chr2:73612102	C/T	cg20560298	chr2:73613845	ALMS1	-0.59	-8.68	-0.43	1.78e-16	Metabolite levels;
LUSC	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg12863693	chr15:85201151	NMB	0.37	7.52	0.38	4.96e-13	Schizophrenia;
LUSC	trans	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg13565492	chr6:43139072	SRF	-0.63	-6.63	-0.34	1.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25072359	chr17:41440525	NA	0.62	9.05	0.44	1.2e-17	Menopause (age at onset);
LUSC	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg04117972	chr1:227635322	NA	0.73	7.6	0.38	2.92e-13	Major depressive disorder;
LUSC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15664640	chr17:80829946	TBCD	-0.73	-12.62	-0.57	4.09e-30	Breast cancer;
LUSC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg23711669	chr6:146136114	FBXO30	-0.89	-16.79	-0.68	2.69e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg06917634	chr15:78832804	PSMA4	0.49	6.18	0.32	1.86e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg06784218	chr1:46089804	CCDC17	0.55	11.12	0.52	1.19e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg17279839	chr7:150038598	RARRES2	0.51	7.37	0.37	1.33e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg12463550	chr7:65579703	CRCP	0.42	6.03	0.31	4.28e-9	Aortic root size;
LUSC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg00033643	chr7:134001901	SLC35B4	0.47	7.35	0.37	1.53e-12	Mean platelet volume;
LUSC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg07701084	chr6:150067640	NUP43	0.52	7.4	0.38	1.12e-12	Lung cancer;
LUSC	cis	rs16854884	0.657	rs34683397	chr3:143723559	C/T	cg06585982	chr3:143692056	C3orf58	0.46	7.12	0.36	6.6e-12	Economic and political preferences (feminism/equality);
LUSC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.68	-9.99	-0.48	1.02e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs9535307	1.000	rs9535307	chr13:50291842	A/C	cg04663916	chr13:50265991	EBPL	0.49	5.71	0.3	2.44e-8	Obesity-related traits;
LUSC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg22903471	chr2:27725779	GCKR	-0.4	-6.94	-0.36	1.99e-11	Total body bone mineral density;
LUSC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg23711669	chr6:146136114	FBXO30	0.83	14.82	0.63	1.57e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg01294253	chr9:136912663	BRD3	0.33	5.74	0.3	2.08e-8	Platelet distribution width;
LUSC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg12463550	chr7:65579703	CRCP	0.52	7.64	0.39	2.32e-13	Aortic root size;
LUSC	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg00012203	chr2:219082015	ARPC2	-0.55	-8.23	-0.41	4.19e-15	Colorectal cancer;
LUSC	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg13010199	chr12:38710504	ALG10B	0.48	7.28	0.37	2.47e-12	Heart rate;
LUSC	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg00277334	chr10:82204260	NA	-0.48	-6.6	-0.34	1.65e-10	Post bronchodilator FEV1;
LUSC	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg00757033	chr12:89920650	WDR51B	0.6	10.33	0.49	7.01e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.63	11.41	0.53	1.14e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.42	-0.38	9.83e-13	Reticulocyte count;
LUSC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	0.88	15.31	0.64	1.86e-40	Gestational age at birth (maternal effect);
LUSC	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg24531977	chr5:56204891	C5orf35	-0.59	-8.63	-0.43	2.49e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	15.51	0.65	3.02e-41	Platelet count;
LUSC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.11e-11	Crohn's disease;
LUSC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg12403142	chr1:92012408	NA	0.4	6.33	0.33	8.11e-10	Breast cancer;
LUSC	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-16.65	-0.67	9.68e-46	Exhaled nitric oxide output;
LUSC	cis	rs68170813	0.559	rs77605964	chr7:106962948	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.46	-0.46	5.6e-19	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18131467	chr2:239335373	ASB1	1.05	24.64	0.8	4.06e-77	Multiple system atrophy;
LUSC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg06637938	chr14:75390232	RPS6KL1	0.52	8.29	0.41	2.85e-15	Height;
LUSC	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg17168535	chr8:21777572	XPO7	0.82	15.11	0.64	1.14e-39	Mean corpuscular volume;
LUSC	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg11502198	chr6:26597334	ABT1	0.73	12.25	0.56	9.63e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg22681709	chr2:178499509	PDE11A	-0.55	-10.45	-0.5	2.67e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg24675056	chr1:15929824	NA	-0.39	-6.42	-0.33	4.75e-10	Systolic blood pressure;
LUSC	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.33	0.33	7.94e-10	Corneal astigmatism;
LUSC	cis	rs6546550	0.867	rs7592647	chr2:70139134	C/T	cg02498382	chr2:70120550	SNRNP27	-0.28	-6.83	-0.35	4.13e-11	Prevalent atrial fibrillation;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13114696	chr21:47808953	PCNT	0.51	6.62	0.34	1.47e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.93	-0.31	7.53e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.94	0.31	7.2e-9	Menopause (age at onset);
LUSC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg06618935	chr21:46677482	NA	-0.37	-7.33	-0.37	1.75e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.56	10.33	0.49	6.79e-22	Bone mineral density;
LUSC	cis	rs3820928	0.874	rs13385711	chr2:227830414	G/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.42	-0.38	9.97e-13	Pulmonary function;
LUSC	cis	rs2274273	0.805	rs8012156	chr14:55552500	G/T	cg04306507	chr14:55594613	LGALS3	0.51	11.07	0.52	1.75e-24	Protein biomarker;
LUSC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.55	9.42	0.46	7.68e-19	IgG glycosylation;
LUSC	cis	rs7474896	1.000	rs734512	chr10:37973072	C/T	cg25427524	chr10:38739819	LOC399744	0.52	5.86	0.31	1.1e-8	Obesity (extreme);
LUSC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-13.0	-0.58	1.54e-31	Platelet count;
LUSC	cis	rs10186029	0.676	rs10497991	chr2:213968775	G/A	cg08319019	chr2:214017104	IKZF2	0.6	8.76	0.43	9.95e-17	Systemic sclerosis;
LUSC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	8.59	0.43	3.41e-16	Total body bone mineral density;
LUSC	cis	rs6845621	1.000	rs6845621	chr4:18866169	G/A	cg12196642	chr4:18937545	NA	-0.32	-6.09	-0.32	3.18e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg07424592	chr7:64974309	NA	0.68	6.01	0.31	4.75e-9	Diabetic kidney disease;
LUSC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg04369109	chr6:150039330	LATS1	-0.56	-7.79	-0.39	8.3e-14	Lung cancer;
LUSC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-8.92	-0.44	3.07e-17	Gut microbiome composition (summer);
LUSC	trans	rs11264799	0.765	rs12125713	chr1:157636657	A/G	cg25498969	chr3:136062740	STAG1	-0.24	-5.95	-0.31	6.9e-9	IgA nephropathy;
LUSC	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg03605463	chr16:89740564	NA	-0.39	-5.78	-0.3	1.68e-8	Vitiligo;
LUSC	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg06131755	chr6:160182447	ACAT2	0.6	8.27	0.41	3.27e-15	Iron status biomarkers;
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07157834	chr1:205819609	PM20D1	0.85	15.25	0.64	3.19e-40	Menarche (age at onset);
LUSC	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg11502198	chr6:26597334	ABT1	-0.69	-11.7	-0.54	9.85e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg05855489	chr10:104503620	C10orf26	-0.49	-7.42	-0.38	9.5e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs17407555	0.821	rs4292329	chr4:10144459	C/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-5.66	-0.3	3.18e-8	Schizophrenia (age at onset);
LUSC	cis	rs9837602	1.000	rs9833980	chr3:99767096	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.15	0.32	2.19e-9	Breast cancer;
LUSC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg14552801	chr7:65878734	NA	-0.44	-6.11	-0.32	2.79e-9	Aortic root size;
LUSC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg15704280	chr7:45808275	SEPT13	-0.98	-16.61	-0.67	1.43e-45	Height;
LUSC	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.69	0.65	5.76e-42	Bladder cancer;
LUSC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg11843238	chr5:131593191	PDLIM4	-0.5	-8.56	-0.42	4.14e-16	Acylcarnitine levels;
LUSC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg09165964	chr15:75287851	SCAMP5	0.52	7.59	0.38	3.32e-13	Breast cancer;
LUSC	cis	rs7923609	0.967	rs10509189	chr10:65264126	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.44	-0.33	4.07e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.72	11.83	0.54	3.35e-27	Longevity;
LUSC	cis	rs34421088	0.506	rs7813424	chr8:11144517	G/A	cg21775007	chr8:11205619	TDH	0.5	7.07	0.36	9.06e-12	Neuroticism;
LUSC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs72772090	0.539	rs67140788	chr5:96116286	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-6.78	-0.35	5.49e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg05064044	chr6:292385	DUSP22	-0.52	-7.75	-0.39	1.09e-13	Menopause (age at onset);
LUSC	cis	rs16976116	0.901	rs56328329	chr15:55502977	A/T	cg11288833	chr15:55489084	RSL24D1	0.51	6.16	0.32	2.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7129556	0.520	rs10793257	chr11:77309533	T/C	cg12586386	chr11:77299805	AQP11	0.22	5.64	0.3	3.56e-8	Weight loss (gastric bypass surgery);
LUSC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg11663144	chr21:46675770	NA	-0.41	-7.14	-0.36	5.99e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	13.25	0.59	1.72e-32	Alzheimer's disease;
LUSC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg17221980	chr6:117996486	NUS1	0.36	6.11	0.32	2.82e-9	Triglycerides;
LUSC	cis	rs202011557	1	rs202011557	chr2:102913642	A/AAAAC	cg20060108	chr2:102954350	IL1RL1	0.48	5.68	0.3	2.96e-8	Asthma;
LUSC	cis	rs710865	0.723	rs710870	chr1:19549759	G/A	cg13387374	chr1:19411106	UBR4	0.5	7.66	0.39	2.07e-13	Brain structure;
LUSC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06850241	chr22:41845214	NA	0.31	5.73	0.3	2.23e-8	Vitiligo;
LUSC	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	9.51	0.46	4.03e-19	Lung cancer in ever smokers;
LUSC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg09650180	chr20:62225654	GMEB2	-0.68	-9.76	-0.47	5.63e-20	Glioblastoma;
LUSC	cis	rs3740713	1.000	rs73440625	chr11:18470800	A/G	cg15463284	chr11:18477534	LDHAL6A	-0.5	-5.73	-0.3	2.21e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg11218175	chr11:495084	RNH1	0.53	5.69	0.3	2.77e-8	Body mass index;
LUSC	cis	rs2050392	1.000	rs2265185	chr10:30691777	A/C	cg18806716	chr10:30721971	MAP3K8	-0.47	-7.59	-0.38	3.25e-13	Inflammatory bowel disease;
LUSC	cis	rs1808579	0.935	rs4800162	chr18:21117419	G/T	cg14672496	chr18:21087552	C18orf8	0.36	6.23	0.32	1.37e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs13315871	0.929	rs77487951	chr3:58290892	G/A	cg20936604	chr3:58311152	NA	-0.71	-6.33	-0.33	7.74e-10	Cholesterol, total;
LUSC	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.47	7.67	0.39	1.9e-13	Alcohol dependence;
LUSC	trans	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.69	-0.39	1.71e-13	Morning vs. evening chronotype;
LUSC	cis	rs7122539	0.646	rs627330	chr11:66602099	C/T	cg24851651	chr11:66362959	CCS	0.55	9.69	0.47	9.57e-20	HIV-1 susceptibility;
LUSC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg07777115	chr5:623756	CEP72	-0.45	-5.74	-0.3	2.16e-8	Obesity-related traits;
LUSC	trans	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg14791747	chr16:20752902	THUMPD1	-0.42	-6.42	-0.33	4.65e-10	Dental caries;
LUSC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg18758796	chr5:131593413	PDLIM4	0.47	7.82	0.39	7.05e-14	Acylcarnitine levels;
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.61	-11.32	-0.53	2.37e-25	Longevity;Endometriosis;
LUSC	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-0.82	-16.53	-0.67	2.75e-45	Gut microbiota (bacterial taxa);
LUSC	cis	rs2414856	0.510	rs72756978	chr15:64572492	T/C	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs9463078	0.605	rs9472416	chr6:44950963	T/C	cg25276700	chr6:44698697	NA	0.29	6.05	0.31	3.94e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg11812906	chr14:75593930	NEK9	0.62	10.17	0.49	2.36e-21	Height;
LUSC	cis	rs7584330	0.554	rs3751107	chr2:238427251	G/A	cg16989719	chr2:238392110	NA	-0.43	-6.24	-0.32	1.34e-9	Prostate cancer;
LUSC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg11645453	chr3:52864694	ITIH4	0.26	5.95	0.31	6.74e-9	Bipolar disorder;
LUSC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	9.64	0.47	1.43e-19	Eosinophil percentage of white cells;
LUSC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg09509183	chr1:209979624	IRF6	0.43	5.84	0.3	1.26e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.61	8.09	0.4	1.1e-14	High light scatter reticulocyte count;
LUSC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg13047869	chr3:10149882	C3orf24	0.57	7.9	0.4	4.11e-14	Alzheimer's disease;
LUSC	cis	rs6674970	0.966	rs10788800	chr1:151104950	G/A	cg11822372	chr1:151115635	SEMA6C	0.54	8.4	0.42	1.32e-15	Childhood ear infection;
LUSC	cis	rs9902453	0.726	rs3110494	chr17:27976597	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.15	0.52	9.7e-25	Coffee consumption (cups per day);
LUSC	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg00042356	chr1:8021962	PARK7	0.6	7.0	0.36	1.41e-11	Inflammatory bowel disease;
LUSC	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg02153584	chr22:29168773	CCDC117	0.58	8.26	0.41	3.38e-15	Lymphocyte counts;
LUSC	cis	rs3760982	0.813	rs10426528	chr19:44299298	A/G	cg11993925	chr19:44307056	LYPD5	0.32	7.17	0.37	4.81e-12	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11764359	chr7:65958608	NA	0.68	10.85	0.51	1.06e-23	Aortic root size;
LUSC	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg17830980	chr10:43048298	ZNF37B	0.41	6.51	0.34	2.81e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6062509	0.895	rs6062497	chr20:62336258	C/T	cg01176363	chr20:62369445	LIME1	-0.47	-6.94	-0.36	1.99e-11	Prostate cancer;
LUSC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg10609677	chr17:41278573	BRCA1;NBR2	0.35	5.71	0.3	2.54e-8	Menopause (age at onset);
LUSC	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg02696742	chr7:106810147	HBP1	-0.64	-9.58	-0.46	2.35e-19	Coronary artery disease;
LUSC	cis	rs62408225	1.000	rs2089126	chr6:90970212	A/G	cg06866423	chr6:90926672	BACH2	0.4	5.8	0.3	1.58e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg08601574	chr20:25228251	PYGB	0.42	6.29	0.33	9.95e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11866815	0.739	rs35050910	chr16:394483	T/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.4	6.14	0.32	2.38e-9	Body mass index;
LUSC	cis	rs12618769	0.597	rs7593615	chr2:99030598	C/A	cg10123293	chr2:99228465	UNC50	0.46	7.85	0.39	5.69e-14	Bipolar disorder;
LUSC	trans	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg27661571	chr11:113659931	NA	0.51	5.95	0.31	6.61e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4363385	0.747	rs1999886	chr1:152955522	T/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.78	-0.39	9.11e-14	Inflammatory skin disease;
LUSC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.12	-0.66	1.22e-43	Monocyte count;
LUSC	cis	rs11191205	0.865	rs11191161	chr10:103726528	C/T	cg15320455	chr10:103880129	LDB1	-0.55	-6.45	-0.33	4.01e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg26668828	chr6:292823	DUSP22	-0.49	-7.14	-0.36	5.86e-12	Menopause (age at onset);
LUSC	cis	rs12618769	0.597	rs3769719	chr2:99124404	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.48	0.38	6.81e-13	Bipolar disorder;
LUSC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg09359103	chr1:154839909	KCNN3	-0.7	-16.24	-0.66	4.09e-44	Prostate cancer;
LUSC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg27572855	chr1:25598939	RHD	0.45	8.33	0.41	2.06e-15	Erythrocyte sedimentation rate;
LUSC	cis	rs6977660	0.562	rs12112698	chr7:19781431	A/G	cg07541023	chr7:19748670	TWISTNB	0.61	6.47	0.33	3.46e-10	Thyroid stimulating hormone;
LUSC	cis	rs9837602	1.000	rs9833980	chr3:99767096	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	5.64	0.3	3.56e-8	Breast cancer;
LUSC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg13560548	chr3:10150139	C3orf24	0.51	7.32	0.37	1.85e-12	Alzheimer's disease;
LUSC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11764359	chr7:65958608	NA	0.54	6.97	0.36	1.75e-11	Aortic root size;
LUSC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg25456477	chr12:86230367	RASSF9	-0.32	-5.69	-0.3	2.83e-8	Major depressive disorder;
LUSC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg06697600	chr4:7070879	GRPEL1	-0.45	-7.31	-0.37	1.97e-12	Monocyte percentage of white cells;
LUSC	cis	rs4845570	1.000	rs4845579	chr1:151770138	C/T	cg07092448	chr1:151763213	TDRKH	-1.27	-17.53	-0.69	3.03e-49	Coronary artery disease;
LUSC	cis	rs9815354	0.638	rs12634670	chr3:41875299	G/C	cg03022575	chr3:42003672	ULK4	0.84	8.86	0.44	4.79e-17	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs7939886	0.920	rs11231794	chr11:55765776	T/C	cg15704280	chr7:45808275	SEPT13	0.78	6.57	0.34	1.94e-10	Myopia (pathological);
LUSC	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg03563238	chr19:33554763	RHPN2	-0.4	-6.33	-0.33	7.81e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.41	5.95	0.31	6.68e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.03	0.58	1.12e-31	Chronic sinus infection;
LUSC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg05347473	chr6:146136440	FBXO30	0.4	6.75	0.35	6.37e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs67981189	0.593	rs221919	chr14:71588229	A/G	cg15816911	chr14:71606274	NA	-0.33	-5.76	-0.3	1.86e-8	Schizophrenia;
LUSC	cis	rs9581857	0.547	rs9581878	chr13:28104552	T/A	cg22138327	chr13:27999177	GTF3A	0.67	7.24	0.37	3.08e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg11619707	chr19:22235551	ZNF257	0.39	5.87	0.31	1.04e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7212590	0.748	rs7211208	chr17:57957109	A/C	cg10252138	chr17:58120427	NA	-0.76	-7.02	-0.36	1.24e-11	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg14440974	chr22:39074834	NA	-0.37	-6.09	-0.32	3.17e-9	Menopause (age at onset);
LUSC	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.6	-0.34	1.65e-10	Joint mobility (Beighton score);
LUSC	trans	rs7980799	0.649	rs1601003	chr12:33689436	A/T	cg26384229	chr12:38710491	ALG10B	0.57	8.17	0.41	6.38e-15	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg06521852	chr22:38141419	TRIOBP	-0.35	-5.67	-0.3	3.1e-8	Glioblastoma;Glioma;
LUSC	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.45	-0.42	8.9e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg04374321	chr14:90722782	PSMC1	0.74	11.58	0.54	2.72e-26	Mortality in heart failure;
LUSC	cis	rs9399401	0.626	rs12664563	chr6:142785201	A/G	cg03128060	chr6:142623767	GPR126	0.58	9.61	0.47	1.76e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg15711740	chr2:61764176	XPO1	-0.43	-6.51	-0.34	2.7e-10	Tuberculosis;
LUSC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs57920188	0.535	rs7412438	chr1:4095581	C/G	cg20703997	chr1:4087676	NA	0.56	7.97	0.4	2.62e-14	Interleukin-17 levels;
LUSC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg23985595	chr17:80112537	CCDC57	-0.31	-5.99	-0.31	5.51e-9	Life satisfaction;
LUSC	cis	rs2742417	0.532	rs2742424	chr3:45735218	A/G	cg09608765	chr3:45636137	LIMD1	0.35	6.44	0.33	4.21e-10	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg00945038	chr17:61921165	SMARCD2	-0.46	-7.82	-0.39	7.15e-14	Prudent dietary pattern;
LUSC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	0.82	12.46	0.56	1.59e-29	Gut microbiome composition (summer);
LUSC	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.91	-0.31	8.57e-9	Resting heart rate;
LUSC	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg25344623	chr2:136566232	LCT	0.4	5.98	0.31	5.74e-9	Mosquito bite size;
LUSC	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg08999081	chr20:33150536	PIGU	0.32	5.65	0.3	3.51e-8	Height;
LUSC	cis	rs477692	0.569	rs1771448	chr10:131296201	A/G	cg05714579	chr10:131428358	MGMT	-0.39	-5.73	-0.3	2.19e-8	Response to temozolomide;
LUSC	cis	rs3736594	0.918	rs9677663	chr2:27972445	G/A	cg27432699	chr2:27873401	GPN1	-0.64	-9.07	-0.44	1.07e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg04450456	chr4:17643702	FAM184B	0.39	6.78	0.35	5.59e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg10578991	chr7:12443926	VWDE	-0.47	-5.71	-0.3	2.53e-8	Coronary artery disease;
LUSC	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00631329	chr6:26305371	NA	-0.47	-9.36	-0.46	1.25e-18	Educational attainment;
LUSC	cis	rs6500395	1.000	rs2883475	chr16:48560315	C/T	cg04672837	chr16:48644449	N4BP1	0.44	6.42	0.33	4.56e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9314323	0.698	rs1064807	chr8:26236978	C/T	cg11498726	chr8:26250323	BNIP3L	-0.46	-6.7	-0.34	9.02e-11	Red cell distribution width;
LUSC	cis	rs7582720	1.000	rs116678869	chr2:203819471	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg24130564	chr14:104152367	KLC1	0.45	6.53	0.34	2.43e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.2	-0.41	5.08e-15	Neuroticism;
LUSC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg07636037	chr3:49044803	WDR6	0.43	6.18	0.32	1.84e-9	Resting heart rate;
LUSC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.55	8.74	0.43	1.19e-16	Aortic root size;
LUSC	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg19116668	chr7:99932089	PMS2L1	0.34	5.95	0.31	6.8e-9	Coronary artery disease;
LUSC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.72	12.14	0.55	2.35e-28	Motion sickness;
LUSC	cis	rs3812762	0.917	rs2873297	chr11:8791227	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.39	6.63	0.34	1.35e-10	Hypospadias;
LUSC	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg08854313	chr1:11322531	MTOR	0.83	14.56	0.62	1.52e-37	Body mass index;
LUSC	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg01884057	chr2:25150051	NA	0.46	11.1	0.52	1.46e-24	Body mass index in non-asthmatics;
LUSC	cis	rs9788721	0.967	rs72740955	chr15:78849779	C/T	cg18825076	chr15:78729989	IREB2	-0.5	-7.6	-0.38	2.93e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.56	-9.02	-0.44	1.48e-17	Schizophrenia;
LUSC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-8.53	-0.42	5.21e-16	Chronic sinus infection;
LUSC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.34	-0.42	1.93e-15	Neuroticism;
LUSC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.7	11.34	0.53	1.97e-25	Coronary artery disease;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23690355	chr15:44719213	CTDSPL2	0.44	6.69	0.34	9.34e-11	Triglycerides;
LUSC	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg20811857	chr17:78079795	GAA	0.29	5.66	0.3	3.18e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	trans	rs6480314	0.542	rs17231637	chr10:70029894	C/T	cg04882175	chr6:131122610	NA	0.51	5.99	0.31	5.43e-9	Optic nerve measurement (disc area);
LUSC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.29e-12	Tonsillectomy;
LUSC	trans	rs11700980	0.551	rs2832012	chr21:30110932	C/T	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.41e-9	QRS complex (12-leadsum);
LUSC	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg25922239	chr6:33757077	LEMD2	0.53	7.83	0.39	6.45e-14	Crohn's disease;
LUSC	cis	rs11645898	0.810	rs72787085	chr16:72182564	C/T	cg14768367	chr16:72042858	DHODH	-0.65	-7.11	-0.36	7.28e-12	Blood protein levels;
LUSC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.19	-0.37	4.37e-12	Blood protein levels;
LUSC	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg11584989	chr19:19387371	SF4	0.59	6.99	0.36	1.46e-11	Bipolar disorder;
LUSC	cis	rs17253792	0.822	rs79291233	chr14:56065302	G/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.96	-0.36	1.81e-11	Putamen volume;
LUSC	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg15654264	chr1:150340011	RPRD2	0.61	10.04	0.48	6.57e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.26	-0.32	1.2e-9	Morning vs. evening chronotype;
LUSC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg13114125	chr14:105738426	BRF1	-0.92	-14.78	-0.63	2.28e-38	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.18	0.58	3.19e-32	Cognitive test performance;
LUSC	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg13206674	chr6:150067644	NUP43	0.6	9.45	0.46	6.24e-19	Lung cancer;
LUSC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	11.42	0.53	1.04e-25	Coronary artery disease;
LUSC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg15556689	chr8:8085844	FLJ10661	0.65	10.36	0.49	5.51e-22	Mood instability;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22713327	chr12:120703336	PXN	-0.49	-6.27	-0.32	1.09e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg11062466	chr8:58055876	NA	-0.73	-8.85	-0.44	5.2e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg15133208	chr4:90757351	SNCA	-0.57	-8.74	-0.43	1.12e-16	Neuroticism;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12904531	chr11:67572716	LOC645332	0.76	6.18	0.32	1.91e-9	Cognitive performance;
LUSC	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg23260525	chr10:116636907	FAM160B1	0.4	8.21	0.41	4.95e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	6.37	0.33	6.36e-10	Mean platelet volume;
LUSC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg18225595	chr11:63971243	STIP1	-0.57	-9.19	-0.45	4.35e-18	Platelet count;
LUSC	cis	rs75920871	0.528	rs12274465	chr11:116957189	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-6.1	-0.32	2.9e-9	Subjective well-being;
LUSC	cis	rs4285028	0.696	rs3915060	chr3:121712980	C/T	cg11130432	chr3:121712080	ILDR1	0.71	11.61	0.54	2.08e-26	Multiple sclerosis;
LUSC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg09650180	chr20:62225654	GMEB2	-0.66	-9.53	-0.46	3.46e-19	Glioblastoma;
LUSC	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17467752	chr17:38218738	THRA	-0.5	-7.0	-0.36	1.37e-11	White blood cell count;
LUSC	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg03678062	chr6:149772716	ZC3H12D	0.33	6.83	0.35	3.93e-11	Dupuytren's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00252696	chr1:31769601	ZCCHC17;SNRNP40	-0.46	-6.02	-0.31	4.58e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.67	11.48	0.53	5.96e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4776059	1.000	rs35372377	chr15:52882281	G/A	cg25063058	chr15:52860530	ARPP19	0.45	6.18	0.32	1.9e-9	Schizophrenia;
LUSC	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg20129853	chr10:51489980	NA	-0.36	-7.56	-0.38	3.84e-13	Prostate-specific antigen levels;
LUSC	cis	rs7561273	0.586	rs6545264	chr2:24310105	A/G	cg20701182	chr2:24300061	SF3B14	0.5	6.47	0.33	3.57e-10	Quantitative traits;
LUSC	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-11.51	-0.53	4.74e-26	Total body bone mineral density;
LUSC	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg08975724	chr8:8085496	FLJ10661	0.55	8.21	0.41	4.91e-15	Mood instability;
LUSC	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs3820068	0.608	rs7552400	chr1:16035892	A/G	cg13390004	chr1:15929781	NA	0.41	6.79	0.35	5.02e-11	Systolic blood pressure;
LUSC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg24733560	chr20:60626293	TAF4	0.44	8.05	0.4	1.47e-14	Body mass index;
LUSC	cis	rs7264396	0.836	rs6088880	chr20:34165582	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.52	7.77	0.39	9.46e-14	Total cholesterol levels;
LUSC	trans	rs445114	0.509	rs432523	chr8:128337927	A/T	cg10195415	chr17:73887371	TRIM65	0.42	6.73	0.35	7.51e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	0.8	14.01	0.61	2.13e-35	Cognitive function;
LUSC	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg01475377	chr6:109611718	NA	-0.44	-7.84	-0.39	6.06e-14	Reticulocyte fraction of red cells;
LUSC	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg09876464	chr15:85330779	ZNF592	0.36	6.67	0.34	1.07e-10	P wave terminal force;
LUSC	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-9.32	-0.45	1.58e-18	Bone mineral density;
LUSC	cis	rs7119038	0.818	rs76704408	chr11:118683327	G/T	cg19308663	chr11:118741387	NA	0.34	5.93	0.31	7.36e-9	Sjögren's syndrome;
LUSC	cis	rs4499344	0.658	rs10415040	chr19:33052706	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.79	-10.17	-0.49	2.46e-21	Mean platelet volume;
LUSC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg18305652	chr10:134549665	INPP5A	-0.42	-6.49	-0.33	3.13e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.72	-0.35	7.76e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg04315214	chr1:2043799	PRKCZ	-0.38	-7.47	-0.38	7.08e-13	Height;
LUSC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.55	-8.02	-0.4	1.86e-14	Alzheimer's disease (late onset);
LUSC	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	13.87	0.6	7.44e-35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg02073558	chr3:44770973	ZNF501	0.56	8.91	0.44	3.39e-17	Depressive symptoms;
LUSC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg13560548	chr3:10150139	C3orf24	0.52	7.12	0.36	6.49e-12	Alzheimer's disease;
LUSC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.79	-0.57	9.51e-31	Chronic sinus infection;
LUSC	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg13334819	chr7:99746414	C7orf59	-0.5	-6.73	-0.35	7.41e-11	Coronary artery disease;
LUSC	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.33	-7.3	-0.37	2.12e-12	Dupuytren's disease;
LUSC	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.75	-12.36	-0.56	3.69e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg03258749	chr1:151040405	MLLT11	-0.38	-6.22	-0.32	1.5e-9	Childhood ear infection;
LUSC	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg23752985	chr2:85803571	VAMP8	0.32	6.2	0.32	1.7e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	8.12	0.41	9.31e-15	Height;
LUSC	cis	rs11997175	0.624	rs7465686	chr8:33718321	G/A	ch.8.33884649F	chr8:33765107	NA	0.42	5.91	0.31	8.61e-9	Body mass index;
LUSC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.68	-9.46	-0.46	5.56e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg15445000	chr17:37608096	MED1	0.39	6.74	0.35	6.89e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.64	-10.07	-0.48	5.22e-21	Osteoporosis;
LUSC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.58	9.34	0.45	1.45e-18	Aortic root size;
LUSC	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.87	0.4	4.92e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg02018176	chr4:1364513	KIAA1530	0.47	6.42	0.33	4.72e-10	Recombination rate (females);
LUSC	cis	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg08501292	chr6:25962987	TRIM38	0.67	5.69	0.3	2.72e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg13683864	chr3:40499215	RPL14	-0.77	-12.77	-0.57	1.1e-30	Renal cell carcinoma;
LUSC	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.51	10.22	0.49	1.58e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg23711669	chr6:146136114	FBXO30	0.85	15.47	0.65	4.32e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	0.59	8.99	0.44	1.82e-17	Breast cancer;
LUSC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg05729581	chr11:3078854	CARS	-0.53	-7.9	-0.4	4.01e-14	Type 2 diabetes;
LUSC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg20203395	chr5:56204925	C5orf35	-0.56	-7.81	-0.39	7.65e-14	Initial pursuit acceleration;
LUSC	cis	rs1506636	0.962	rs7811830	chr7:123320183	G/C	cg03229431	chr7:123269106	ASB15	-0.64	-10.57	-0.5	1.05e-22	Plateletcrit;Platelet count;
LUSC	cis	rs1461503	0.966	rs10892938	chr11:122841921	A/C	cg27398637	chr11:122830231	C11orf63	-0.41	-6.53	-0.34	2.4e-10	Menarche (age at onset);
LUSC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg07701084	chr6:150067640	NUP43	0.55	8.33	0.41	2.1e-15	Lung cancer;
LUSC	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.67	8.33	0.41	2.08e-15	Schizophrenia;
LUSC	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg18512352	chr11:47633146	NA	-0.43	-8.9	-0.44	3.56e-17	Subjective well-being;
LUSC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg19592336	chr6:28129416	ZNF389	0.47	6.19	0.32	1.75e-9	Depression;
LUSC	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.27	-0.32	1.13e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg03690763	chr11:133734501	NA	0.31	5.69	0.3	2.82e-8	Childhood ear infection;
LUSC	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	5.87	0.31	1.04e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg17507749	chr15:85114479	UBE2QP1	0.71	9.32	0.45	1.62e-18	Schizophrenia;
LUSC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg07424592	chr7:64974309	NA	-0.45	-6.29	-0.33	9.76e-10	Calcium levels;
LUSC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.7	-0.43	1.57e-16	Bipolar disorder;
LUSC	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	5.76	0.3	1.94e-8	Educational attainment;
LUSC	cis	rs17253792	0.915	rs78498383	chr14:56177585	C/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.86	-0.35	3.35e-11	Putamen volume;
LUSC	cis	rs11166629	0.883	rs11778878	chr8:135599220	C/T	cg27224718	chr8:135614730	ZFAT	-0.61	-9.9	-0.48	2.02e-20	Smoking quantity;
LUSC	cis	rs1595825	0.891	rs79745588	chr2:198516835	G/A	cg19156104	chr2:198669113	PLCL1	-0.46	-5.84	-0.3	1.24e-8	Ulcerative colitis;
LUSC	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.5	7.83	0.39	6.75e-14	Cognitive test performance;
LUSC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg17340268	chr14:105411764	AHNAK2	-0.38	-6.12	-0.32	2.58e-9	Rheumatoid arthritis;
LUSC	cis	rs7804356	1.000	rs3801812	chr7:26887615	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg22709100	chr7:91322751	NA	0.39	5.86	0.31	1.13e-8	Breast cancer;
LUSC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg06008330	chr7:65541103	ASL	0.4	6.19	0.32	1.76e-9	Aortic root size;
LUSC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg21361702	chr7:150065534	REPIN1	0.49	6.53	0.34	2.42e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg08000102	chr2:233561755	GIGYF2	0.8	13.0	0.58	1.44e-31	Schizophrenia;
LUSC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.72	11.96	0.55	1.12e-27	Longevity;
LUSC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18357526	chr6:26021779	HIST1H4A	0.46	7.24	0.37	3.06e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs17095355	1.000	rs12254785	chr10:111699607	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.6	-0.38	2.95e-13	Biliary atresia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09775628	chr19:1479573	C19orf25	0.73	6.02	0.31	4.67e-9	Cognitive performance;
LUSC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.92	0.31	7.89e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs701145	0.938	rs165275	chr3:153991875	T/C	cg17054900	chr3:154042577	DHX36	0.82	8.52	0.42	5.56e-16	Coronary artery disease;
LUSC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16405210	chr4:1374714	KIAA1530	-0.66	-10.69	-0.51	3.78e-23	Longevity;
LUSC	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg25206134	chr2:45395956	NA	0.58	6.33	0.33	7.73e-10	Bipolar disorder;
LUSC	trans	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg03886242	chr7:26192032	NFE2L3	-0.37	-6.08	-0.32	3.32e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs77956314	0.818	rs12296869	chr12:117431203	G/A	cg02017074	chr12:117425053	FBXW8	-0.66	-6.57	-0.34	1.88e-10	Subcortical brain region volumes;Hippocampal volume;
LUSC	cis	rs6688613	0.649	rs11584352	chr1:166850372	T/C	cg07049167	chr1:166818506	POGK	0.48	6.72	0.35	7.69e-11	Refractive astigmatism;
LUSC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg13047869	chr3:10149882	C3orf24	0.57	7.9	0.4	4.11e-14	Alzheimer's disease;
LUSC	cis	rs13315871	0.929	rs13097873	chr3:58267924	C/T	cg20936604	chr3:58311152	NA	-0.75	-6.97	-0.36	1.7e-11	Cholesterol, total;
LUSC	cis	rs7772486	0.558	rs2142980	chr6:146080679	G/A	cg05347473	chr6:146136440	FBXO30	-0.6	-9.27	-0.45	2.3e-18	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-8.61	-0.43	2.9e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.63	10.2	0.49	1.89e-21	Prostate cancer;
LUSC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.7	12.58	0.57	5.73e-30	Prudent dietary pattern;
LUSC	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg04362960	chr10:104952993	NT5C2	0.59	9.4	0.46	9.21e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.64	0.63	8.06e-38	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.88	15.14	0.64	8.97e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11608355	0.515	rs12833054	chr12:109890955	G/A	cg05360138	chr12:110035743	NA	0.81	8.76	0.43	1.02e-16	Neuroticism;
LUSC	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg12863693	chr15:85201151	NMB	0.35	6.8	0.35	4.73e-11	Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21956150	chr19:1438388	RPS15	-0.53	-6.81	-0.35	4.43e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7582720	1.000	rs72934710	chr2:203709776	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	8.0	0.4	2.12e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg14416269	chr4:6271139	WFS1	0.54	11.47	0.53	6.76e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs62238980	0.614	rs117017176	chr22:32400725	T/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.8	-0.43	7.25e-17	Total cholesterol levels;
LUSC	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.49	0.5	1.98e-22	Colorectal cancer;
LUSC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg17294928	chr15:75287854	SCAMP5	0.41	5.99	0.31	5.56e-9	Breast cancer;
LUSC	cis	rs9322817	0.691	rs9391249	chr6:105343433	T/A	cg02098413	chr6:105308735	HACE1	0.28	5.96	0.31	6.43e-9	Thyroid stimulating hormone;
LUSC	cis	rs977987	0.806	rs8054769	chr16:75401113	T/C	cg04384234	chr16:75411784	CFDP1	-0.42	-6.94	-0.36	2e-11	Dupuytren's disease;
LUSC	cis	rs7180079	0.502	rs8033972	chr15:64524980	G/A	cg02848875	chr15:64387786	SNX1	-0.41	-8.0	-0.4	2.02e-14	Monocyte count;
LUSC	cis	rs7119	0.931	rs62009087	chr15:77833064	C/T	cg27398640	chr15:77910606	LINGO1	-0.32	-7.22	-0.37	3.58e-12	Type 2 diabetes;
LUSC	cis	rs1775715	0.707	rs2065443	chr10:32164236	C/G	cg18675610	chr10:32216311	ARHGAP12	0.3	6.65	0.34	1.19e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg09365446	chr1:150670422	GOLPH3L	0.47	7.01	0.36	1.33e-11	Melanoma;
LUSC	cis	rs72781680	0.821	rs17038360	chr2:24095798	A/G	cg08917208	chr2:24149416	ATAD2B	0.6	6.98	0.36	1.59e-11	Lymphocyte counts;
LUSC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg17264618	chr3:40429014	ENTPD3	0.31	6.78	0.35	5.39e-11	Renal cell carcinoma;
LUSC	cis	rs240764	0.658	rs12194255	chr6:101168439	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-6.03	-0.31	4.42e-9	Neuroticism;
LUSC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg21433313	chr16:3507492	NAT15	0.65	10.84	0.51	1.14e-23	Tuberculosis;
LUSC	cis	rs727505	1.000	rs59294613	chr7:124554267	C/A	cg23710748	chr7:124431027	NA	-0.4	-7.15	-0.36	5.64e-12	Lewy body disease;
LUSC	cis	rs10450586	0.863	rs7126943	chr11:27303937	A/G	cg08958251	chr11:27270390	NA	-0.36	-5.78	-0.3	1.76e-8	Total body bone mineral density;
LUSC	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs600231	0.613	rs12803915	chr11:65211979	G/A	cg17120908	chr11:65337727	SSSCA1	-0.67	-9.33	-0.45	1.46e-18	Bone mineral density;
LUSC	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg00376283	chr12:123451042	ABCB9	0.72	10.08	0.48	5.06e-21	Neutrophil percentage of white cells;
LUSC	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg00321850	chr1:175162397	KIAA0040	0.45	7.35	0.37	1.52e-12	Alcohol dependence;
LUSC	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg23601095	chr6:26197514	HIST1H3D	0.69	7.46	0.38	7.54e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg18904891	chr8:8559673	CLDN23	0.56	7.76	0.39	1.04e-13	Obesity-related traits;
LUSC	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg23505145	chr19:12996616	KLF1	0.65	10.82	0.51	1.38e-23	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg04833646	chr19:10679720	CDKN2D	1.15	16.63	0.67	1.2e-45	Red cell distribution width;
LUSC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.67	0.34	1.06e-10	Neutrophil percentage of white cells;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18825258	chr8:26435354	DPYSL2	-0.42	-6.04	-0.31	4.09e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg12365402	chr11:9010492	NRIP3	-0.48	-8.98	-0.44	1.98e-17	Hemoglobin concentration;
LUSC	cis	rs9341835	0.518	rs9344168	chr6:64169682	G/A	cg03326410	chr6:64151739	NA	-0.37	-6.01	-0.31	4.85e-9	Schizophrenia;
LUSC	cis	rs4280164	0.578	rs17184689	chr14:24794440	A/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.57	-7.45	-0.38	8.28e-13	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs4561483	0.582	rs35063476	chr16:12044301	A/G	cg08843971	chr16:11963173	GSPT1	-0.42	-5.98	-0.31	5.8e-9	Testicular germ cell tumor;
LUSC	cis	rs2239815	0.515	rs5762849	chr22:29238086	G/A	cg02153584	chr22:29168773	CCDC117	0.55	6.34	0.33	7.34e-10	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	cis	rs8056893	0.714	rs7192234	chr16:68391189	C/G	cg02226672	chr16:68398533	SMPD3	0.33	5.85	0.31	1.15e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg07541023	chr7:19748670	TWISTNB	0.81	8.03	0.4	1.67e-14	Thyroid stimulating hormone;
LUSC	cis	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg06521331	chr12:34319734	NA	-0.52	-8.45	-0.42	9.35e-16	Morning vs. evening chronotype;
LUSC	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21659725	chr3:3221576	CRBN	-0.53	-8.33	-0.41	2.1e-15	Body mass index;
LUSC	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.9	0.61	5.49e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	6.63	0.34	1.36e-10	Menarche (age at onset);
LUSC	cis	rs3099143	1.000	rs901008	chr15:77097018	C/A	cg21673338	chr15:77095150	SCAPER	-0.79	-7.59	-0.38	3.29e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg26441486	chr22:50317300	CRELD2	0.53	8.07	0.4	1.27e-14	Schizophrenia;
LUSC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg12560992	chr17:57184187	TRIM37	0.82	14.75	0.63	2.92e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs9905704	0.560	rs2526375	chr17:56429094	A/G	cg19466818	chr17:56409534	MIR142	-0.37	-6.54	-0.34	2.26e-10	Testicular germ cell tumor;
LUSC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg22437258	chr11:111473054	SIK2	0.5	6.83	0.35	4.12e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-8.33	-0.41	2.14e-15	Schizophrenia;
LUSC	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg08079166	chr15:68083412	MAP2K5	-0.42	-8.57	-0.42	3.98e-16	Restless legs syndrome;
LUSC	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg08601574	chr20:25228251	PYGB	-0.42	-6.51	-0.34	2.68e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs377070	0.966	rs368931	chr4:123631597	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.47	6.84	0.35	3.82e-11	Mosquito bite size;
LUSC	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg09904177	chr6:26538194	HMGN4	0.79	6.25	0.32	1.24e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.39	-0.56	2.98e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg22166914	chr1:53195759	ZYG11B	0.68	11.37	0.53	1.55e-25	Monocyte count;
LUSC	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg14458575	chr2:238380390	NA	0.67	11.5	0.53	5.33e-26	Prostate cancer;
LUSC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg11645453	chr3:52864694	ITIH4	0.35	7.88	0.4	4.52e-14	Bipolar disorder;
LUSC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg04267008	chr7:1944627	MAD1L1	-0.51	-7.73	-0.39	1.24e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.68	-0.47	1.07e-19	Multiple sclerosis;
LUSC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	1.06	20.25	0.74	4.64e-60	Menopause (age at onset);
LUSC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21862992	chr11:68658383	NA	0.5	7.98	0.4	2.35e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.68	-11.29	-0.53	2.91e-25	Cognitive function;
LUSC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg04111992	chr7:158790115	NA	-0.45	-7.19	-0.37	4.2e-12	Facial morphology (factor 20);
LUSC	cis	rs4478858	0.611	rs7527645	chr1:31763787	T/C	cg00250761	chr1:31883323	NA	-0.33	-7.95	-0.4	2.9e-14	Alcohol dependence;
LUSC	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg21951975	chr1:209979733	IRF6	0.59	7.01	0.36	1.3e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg15571903	chr15:79123663	NA	0.33	6.02	0.31	4.57e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs3850699	0.651	rs35485301	chr10:104370827	C/T	cg05855489	chr10:104503620	C10orf26	0.71	9.49	0.46	4.54e-19	Prostate cancer;
LUSC	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg26395211	chr5:140044315	WDR55	-0.37	-5.72	-0.3	2.43e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.58	11.94	0.55	1.29e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18876405	chr7:65276391	NA	0.53	8.2	0.41	5.2e-15	Aortic root size;
LUSC	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg12573674	chr2:1569213	NA	-0.56	-7.97	-0.4	2.61e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	0.93	12.71	0.57	1.81e-30	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	0.94	13.57	0.6	1.01e-33	Vitiligo;
LUSC	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-1.14	-20.32	-0.74	2.42e-60	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg13010344	chr12:123464640	ARL6IP4	0.49	6.44	0.33	4.06e-10	Neutrophil percentage of white cells;
LUSC	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-7.12	-0.36	6.5e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg17143192	chr8:8559678	CLDN23	-0.37	-5.77	-0.3	1.82e-8	Mood instability;
LUSC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg24634471	chr8:143751801	JRK	0.6	9.06	0.44	1.13e-17	Schizophrenia;
LUSC	cis	rs7043114	0.525	rs10283572	chr9:95133074	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.58	-0.34	1.85e-10	Height;
LUSC	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg04111992	chr7:158790115	NA	-0.47	-7.5	-0.38	5.69e-13	Facial morphology (factor 20);
LUSC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs56399783	0.901	rs12540539	chr7:2873294	C/T	cg19731401	chr7:2775893	GNA12	0.68	9.05	0.44	1.19e-17	Childhood ear infection;
LUSC	cis	rs7589342	0.536	rs10167046	chr2:106386764	A/G	cg09152813	chr2:106391379	NCK2	-0.37	-6.07	-0.32	3.43e-9	Addiction;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09644986	chr12:6644356	GAPDH	-0.48	-7.07	-0.36	9.1e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-0.56	-9.31	-0.45	1.76e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg04414720	chr1:150670196	GOLPH3L	0.51	7.87	0.4	5.1e-14	Melanoma;
LUSC	cis	rs2573652	0.674	rs11630583	chr15:100543355	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.35	-6.25	-0.32	1.22e-9	Height;
LUSC	cis	rs4666002	0.956	rs34502053	chr2:27854524	G/A	cg27432699	chr2:27873401	GPN1	0.43	5.85	0.3	1.2e-8	Phospholipid levels (plasma);
LUSC	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.63	-8.53	-0.42	5.09e-16	Primary sclerosing cholangitis;
LUSC	trans	rs12310956	0.510	rs2054867	chr12:33835462	C/G	cg13010199	chr12:38710504	ALG10B	-0.47	-7.35	-0.37	1.51e-12	Morning vs. evening chronotype;
LUSC	trans	rs1347297	0.526	rs919177	chr2:179258923	C/T	cg14011486	chr1:26737247	LIN28	0.42	6.62	0.34	1.4e-10	Alzheimer disease and age of onset;
LUSC	cis	rs12956009	0.583	rs7240132	chr18:44858634	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.42	-6.26	-0.32	1.15e-9	Educational attainment (years of education);
LUSC	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.68	-0.47	1.06e-19	Morning vs. evening chronotype;
LUSC	cis	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.78	-0.3	1.74e-8	Resting heart rate;
LUSC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg02569458	chr12:86230093	RASSF9	-0.48	-7.95	-0.4	2.87e-14	Major depressive disorder;
LUSC	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg13770153	chr20:60521292	NA	-0.61	-8.4	-0.42	1.32e-15	Body mass index;
LUSC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg20295408	chr7:1910781	MAD1L1	-0.49	-6.88	-0.35	3.05e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	9.75	0.47	6.12e-20	Eotaxin levels;
LUSC	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.72	11.93	0.55	1.37e-27	Monocyte count;
LUSC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.63	-0.39	2.43e-13	Aortic root size;
LUSC	cis	rs6499755	0.932	rs1370386	chr16:55340167	G/C	cg02859129	chr16:55357253	IRX6	0.36	6.07	0.32	3.52e-9	Hypospadias;
LUSC	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg16797656	chr11:68205561	LRP5	0.37	6.05	0.31	3.96e-9	Total body bone mineral density (age 0-15);
LUSC	cis	rs12155623	1.000	rs12155623	chr8:49812201	A/T	cg22283653	chr8:49824208	NA	-0.38	-8.09	-0.4	1.08e-14	Sudden cardiac arrest;
LUSC	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg20933634	chr6:27740509	NA	0.42	6.12	0.32	2.63e-9	Parkinson's disease;
LUSC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-8.29	-0.41	2.82e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1113500	0.897	rs11185263	chr1:108639804	C/G	cg06207961	chr1:108661230	NA	0.42	7.71	0.39	1.42e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg22618164	chr12:122356400	WDR66	0.55	7.8	0.39	8.09e-14	Mean corpuscular volume;
LUSC	cis	rs3018712	0.532	rs2513282	chr11:68418311	A/C	cg22747802	chr11:68417633	NA	-0.41	-5.65	-0.3	3.5e-8	Total body bone mineral density;
LUSC	cis	rs9400467	0.528	rs6568680	chr6:111776164	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.97	-0.36	1.73e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs2798269	1.000	rs4770172	chr13:22123676	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.1	-0.32	2.93e-9	PR segment;
LUSC	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg26850624	chr5:429559	AHRR	-0.42	-8.18	-0.41	6.16e-15	Cystic fibrosis severity;
LUSC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg11247378	chr22:39784982	NA	-0.64	-12.57	-0.57	6.06e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg09835421	chr16:68378352	PRMT7	-0.57	-6.28	-0.32	1.08e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg03354898	chr7:1950403	MAD1L1	0.32	6.36	0.33	6.53e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.92	0.35	2.31e-11	Testicular germ cell tumor;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15202378	chr1:180199443	LHX4	0.46	6.6	0.34	1.62e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg06197492	chr11:2016605	H19	0.36	5.84	0.3	1.22e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg02017074	chr12:117425053	FBXW8	0.7	8.03	0.4	1.69e-14	Subcortical brain region volumes;Hippocampal volume;
LUSC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg24733560	chr20:60626293	TAF4	0.41	6.7	0.34	8.69e-11	Body mass index;
LUSC	cis	rs4660306	0.677	rs6429566	chr1:45941852	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-6.1	-0.32	2.93e-9	Homocysteine levels;
LUSC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg24101359	chr6:42928495	GNMT	0.37	6.07	0.32	3.5e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg14664628	chr15:75095509	CSK	-0.76	-12.18	-0.55	1.71e-28	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs778371	0.834	rs778363	chr2:233778896	A/G	cg08000102	chr2:233561755	GIGYF2	-0.56	-7.09	-0.36	8.09e-12	Schizophrenia;
LUSC	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg27661571	chr11:113659931	NA	-0.69	-7.91	-0.4	3.77e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg16329650	chr2:213403929	ERBB4	0.64	9.01	0.44	1.6e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg02428538	chr16:24856791	SLC5A11	0.5	5.76	0.3	1.88e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.67	-0.43	1.93e-16	Bipolar disorder and schizophrenia;
LUSC	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.47	0.33	3.46e-10	Corneal astigmatism;
LUSC	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg27068330	chr11:65405492	SIPA1	-0.74	-10.3	-0.49	8.46e-22	Acne (severe);
LUSC	cis	rs35079168	0.701	rs3132296	chr9:137302631	C/T	cg14344989	chr9:137329237	RXRA	-0.37	-6.05	-0.31	3.9e-9	Intelligence;
LUSC	trans	rs34421088	0.532	rs2736388	chr8:11159588	T/C	cg06636001	chr8:8085503	FLJ10661	0.44	6.36	0.33	6.71e-10	Neuroticism;
LUSC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.88	-0.81	4.68e-78	Height;
LUSC	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg23260525	chr10:116636907	FAM160B1	0.4	7.92	0.4	3.51e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg12463550	chr7:65579703	CRCP	0.53	7.66	0.39	2e-13	Aortic root size;
LUSC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg12310025	chr6:25882481	NA	-0.35	-5.75	-0.3	1.99e-8	Height;
LUSC	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg13010199	chr12:38710504	ALG10B	0.49	7.53	0.38	4.89e-13	Morning vs. evening chronotype;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg26406571	chr11:2422425	TSSC4	0.61	6.13	0.32	2.51e-9	Body mass index;
LUSC	cis	rs4631830	0.863	rs2611508	chr10:51518047	T/A	cg16070123	chr10:51489643	NA	-0.51	-8.05	-0.4	1.47e-14	Prostate-specific antigen levels;
LUSC	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.15	-0.36	5.35e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7264396	0.887	rs224343	chr20:34036699	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.51	-0.34	2.74e-10	Total cholesterol levels;
LUSC	cis	rs1595825	0.891	rs1992313	chr2:198896766	T/C	cg10547527	chr2:198650123	BOLL	-0.52	-6.25	-0.32	1.23e-9	Ulcerative colitis;
LUSC	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	cis	rs2302729	0.860	rs6489375	chr12:2777768	A/G	cg19945202	chr12:2788847	CACNA1C	-0.37	-5.65	-0.3	3.35e-8	Sleep quality;
LUSC	trans	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.92	0.61	4.72e-35	Alzheimer's disease;
LUSC	cis	rs6714788	0.565	rs7599083	chr2:100658077	G/A	cg22139774	chr2:100720529	AFF3	-0.38	-6.04	-0.31	4.17e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg07423050	chr13:99094983	FARP1	-0.48	-9.04	-0.44	1.32e-17	Longevity;
LUSC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg04315214	chr1:2043799	PRKCZ	0.44	8.97	0.44	2.24e-17	Height;
LUSC	trans	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg18187862	chr3:45730750	SACM1L	0.54	6.47	0.33	3.5e-10	Primary sclerosing cholangitis;
LUSC	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg19784903	chr17:45786737	TBKBP1	-0.42	-6.56	-0.34	2.05e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg25214090	chr10:38739885	LOC399744	0.46	6.88	0.35	3.03e-11	Corneal astigmatism;
LUSC	cis	rs7712401	0.562	rs30046	chr5:122271233	G/C	cg19077854	chr5:122220652	SNX24	0.41	8.98	0.44	1.95e-17	Mean platelet volume;
LUSC	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.32	0.45	1.64e-18	Lung cancer in ever smokers;
LUSC	cis	rs11030122	0.673	rs10767767	chr11:4003678	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.91	-0.31	8.37e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg05738196	chr6:26577821	NA	0.79	15.24	0.64	3.63e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.9	0.51	6.96e-24	Monocyte percentage of white cells;
LUSC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg17971929	chr21:40555470	PSMG1	0.49	7.4	0.38	1.13e-12	Menarche (age at onset);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00934312	chr7:149570931	ATP6V0E2;LOC401431	-0.4	-6.02	-0.31	4.56e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg10596483	chr8:143751796	JRK	0.61	9.52	0.46	3.68e-19	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg18681998	chr4:17616180	MED28	0.9	17.87	0.7	1.39e-50	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg04362960	chr10:104952993	NT5C2	0.52	6.56	0.34	2.07e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10779751	1.000	rs4845856	chr1:11274547	T/C	cg08854313	chr1:11322531	MTOR	0.91	16.0	0.66	3.48e-43	Body mass index;
LUSC	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg05343316	chr1:45956843	TESK2	-0.57	-8.27	-0.41	3.3e-15	Platelet count;
LUSC	cis	rs11031096	0.738	rs9937	chr11:4159457	A/G	cg18678763	chr11:4115507	RRM1	0.39	5.78	0.3	1.7e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.66	-0.5	4.97e-23	Monocyte count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14783567	chr1:244211067	NA	-0.38	-6.26	-0.32	1.18e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10761482	0.861	rs1350633	chr10:62111910	T/C	cg18175470	chr10:62150864	ANK3	-0.51	-7.25	-0.37	2.99e-12	Schizophrenia;
LUSC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg09796270	chr17:17721594	SREBF1	0.44	7.94	0.4	3.14e-14	Total body bone mineral density;
LUSC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg02534363	chr3:47050950	NBEAL2	0.37	6.01	0.31	4.78e-9	Colorectal cancer;
LUSC	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-10.64	-0.5	5.73e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs11229555	0.645	rs11229445	chr11:58199458	G/A	cg15696309	chr11:58395628	NA	-0.6	-7.42	-0.38	9.52e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11997175	0.545	rs5005657	chr8:33668913	C/G	ch.8.33884649F	chr8:33765107	NA	0.5	7.17	0.37	4.86e-12	Body mass index;
LUSC	trans	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg07817883	chr1:32538562	TMEM39B	-0.58	-6.73	-0.35	7.27e-11	Monocyte percentage of white cells;
LUSC	cis	rs11785693	0.862	rs62491169	chr8:4986425	C/A	cg26367366	chr8:4980734	NA	0.79	9.34	0.46	1.4e-18	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs4654899	1.000	rs12133780	chr1:21270808	G/A	cg01072550	chr1:21505969	NA	-0.54	-8.13	-0.41	8.21e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.56	-0.34	2.03e-10	Menarche (age at onset);
LUSC	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg05855489	chr10:104503620	C10orf26	0.59	9.53	0.46	3.31e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.91	0.4	3.73e-14	Prudent dietary pattern;
LUSC	cis	rs5758511	0.514	rs2899354	chr22:42554409	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.6	10.18	0.49	2.17e-21	Birth weight;
LUSC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg02269571	chr22:50332266	NA	0.58	8.61	0.43	2.88e-16	Schizophrenia;
LUSC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg25369027	chr8:103666178	KLF10	0.45	6.38	0.33	5.81e-10	Mosquito bite size;
LUSC	cis	rs75804782	0.581	rs72987336	chr2:239365345	T/C	cg18131467	chr2:239335373	ASB1	-0.73	-6.63	-0.34	1.36e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.39	0.33	5.69e-10	Sudden cardiac arrest;
LUSC	cis	rs6545883	0.525	rs1729658	chr2:61373520	C/T	cg15711740	chr2:61764176	XPO1	-0.38	-6.17	-0.32	1.96e-9	Tuberculosis;
LUSC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg07395648	chr5:131743802	NA	0.43	7.08	0.36	8.43e-12	Blood metabolite levels;
LUSC	trans	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg07393940	chr7:158741817	NA	-0.38	-6.96	-0.36	1.86e-11	Life satisfaction;
LUSC	cis	rs2742417	1.000	rs2742447	chr3:45763977	C/T	cg09608765	chr3:45636137	LIMD1	-0.36	-7.06	-0.36	9.54e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9462027	0.628	rs10947532	chr6:34780315	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.75	-0.3	2.03e-8	Systemic lupus erythematosus;
LUSC	cis	rs7927771	0.524	rs10838782	chr11:47877800	A/G	cg20307385	chr11:47447363	PSMC3	0.47	6.84	0.35	3.82e-11	Subjective well-being;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17107073	chr14:69951322	FLJ44817	0.41	5.97	0.31	5.94e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg08213375	chr14:104286397	PPP1R13B	0.38	6.24	0.32	1.29e-9	Reticulocyte count;
LUSC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg04414720	chr1:150670196	GOLPH3L	0.54	8.46	0.42	8.59e-16	Melanoma;
LUSC	cis	rs4664304	0.966	rs925411	chr2:160745785	G/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.31	-0.33	8.83e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01524091	chr6:44281032	AARS2	-0.5	-6.67	-0.34	1.08e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00149659	chr3:10157352	C3orf10	0.92	11.72	0.54	8.44e-27	Alzheimer's disease;
LUSC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg08683831	chr4:1404607	NA	0.35	5.94	0.31	7.03e-9	Obesity-related traits;
LUSC	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg21545522	chr1:205238299	TMCC2	0.48	9.07	0.44	1.07e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg13010199	chr12:38710504	ALG10B	0.58	9.23	0.45	3.24e-18	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.2	0.52	6.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9309473	0.519	rs6746971	chr2:73669462	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.17	-0.37	4.93e-12	Metabolite levels;
LUSC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	9.09	0.45	8.88e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.29	-0.37	2.26e-12	Monocyte count;
LUSC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg13609457	chr4:120235615	NA	-0.41	-5.8	-0.3	1.51e-8	Corneal astigmatism;
LUSC	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg03676636	chr4:99064102	C4orf37	0.33	7.08	0.36	8.35e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg07393940	chr7:158741817	NA	0.37	6.6	0.34	1.62e-10	Life satisfaction;
LUSC	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-8.45	-0.42	8.92e-16	Body mass index;
LUSC	cis	rs7572644	0.640	rs4632296	chr2:28024984	T/C	cg27432699	chr2:27873401	GPN1	0.56	7.3	0.37	2.09e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25072359	chr17:41440525	NA	0.68	9.58	0.46	2.24e-19	Menopause (age at onset);
LUSC	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg19875535	chr5:140030758	IK	0.48	7.13	0.36	6.16e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs73416724	1.000	rs111467122	chr6:43334547	C/T	cg26312998	chr6:43337775	ZNF318	0.57	6.62	0.34	1.4e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg24110177	chr3:50126178	RBM5	0.51	8.08	0.4	1.23e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg05340658	chr4:99064831	C4orf37	-0.43	-6.86	-0.35	3.3e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs240764	0.817	rs12214151	chr6:101159516	G/T	cg09795085	chr6:101329169	ASCC3	-0.42	-6.12	-0.32	2.61e-9	Neuroticism;
LUSC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	13.18	0.58	3.15e-32	Alzheimer's disease;
LUSC	cis	rs11123610	0.679	rs34705357	chr2:3716032	C/T	cg25251562	chr2:3704773	ALLC	-0.42	-6.85	-0.35	3.53e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.85	-0.35	3.62e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11971779	0.793	rs9632774	chr7:139137562	C/T	cg07862535	chr7:139043722	LUC7L2	0.51	6.33	0.33	7.85e-10	Diisocyanate-induced asthma;
LUSC	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg24631222	chr15:78858424	CHRNA5	0.54	6.11	0.32	2.73e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg04369109	chr6:150039330	LATS1	-0.56	-8.29	-0.41	2.88e-15	Lung cancer;
LUSC	cis	rs11031096	0.683	rs10835729	chr11:4210847	T/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.71	-0.3	2.5e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg00677455	chr12:58241039	CTDSP2	0.59	8.36	0.42	1.67e-15	Multiple sclerosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16483426	chr12:110151678	C12orf34	-0.42	-6.26	-0.32	1.18e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs71537559	1	rs71537559	chr6:27309779	G/C	cg01620082	chr3:125678407	NA	-0.76	-6.83	-0.35	3.98e-11	Squamous cell lung carcinoma;
LUSC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg16339924	chr4:17578868	LAP3	0.62	9.4	0.46	9.06e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs77633900	0.614	rs2469244	chr15:76884127	G/A	cg21673338	chr15:77095150	SCAPER	-0.72	-6.99	-0.36	1.48e-11	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.81	0.35	4.44e-11	Rheumatoid arthritis;
LUSC	cis	rs7215564	0.908	rs34384177	chr17:78667040	A/T	cg23238734	chr17:78661607	RPTOR	0.49	6.43	0.33	4.46e-10	Myopia (pathological);
LUSC	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg23601095	chr6:26197514	HIST1H3D	0.7	7.53	0.38	4.89e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs4622329	0.615	rs7954630	chr12:102290154	G/A	cg23541617	chr12:102225335	GNPTAB	0.26	6.07	0.32	3.51e-9	Systemic lupus erythematosus;
LUSC	trans	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-7.99	-0.4	2.22e-14	Menarche (age at onset);
LUSC	cis	rs6750047	0.868	rs1431332	chr2:38280253	G/A	cg07380506	chr2:38303506	CYP1B1	0.49	6.87	0.35	3.12e-11	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.46	0.33	3.78e-10	Renal cell carcinoma;
LUSC	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.21	-0.41	4.76e-15	Response to antipsychotic treatment;
LUSC	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	5.93	0.31	7.38e-9	IgG glycosylation;
LUSC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-1.03	-20.07	-0.74	2.43e-59	Height;
LUSC	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg16339924	chr4:17578868	LAP3	0.59	9.02	0.44	1.47e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	10.96	0.51	4.44e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs67072384	1.000	rs7125722	chr11:72449716	G/A	cg04827223	chr11:72435913	ARAP1	-0.78	-6.71	-0.34	8.4e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs6733011	0.500	rs6755640	chr2:99445917	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-5.86	-0.31	1.14e-8	Bipolar disorder;
LUSC	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.71	-12.39	-0.56	2.81e-29	White blood cell count (basophil);
LUSC	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.71	11.91	0.55	1.64e-27	Longevity;
LUSC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg04352962	chr1:209979756	IRF6	0.55	6.46	0.33	3.73e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg07424592	chr7:64974309	NA	-0.66	-5.72	-0.3	2.42e-8	Diabetic kidney disease;
LUSC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-13.62	-0.6	6.89e-34	Intelligence (multi-trait analysis);
LUSC	trans	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.52	-0.34	2.64e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg06238570	chr21:40685208	BRWD1	-0.53	-8.16	-0.41	6.74e-15	Menarche (age at onset);
LUSC	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg13256891	chr4:100009986	ADH5	0.51	6.96	0.36	1.79e-11	Smoking initiation;
LUSC	cis	rs7216064	0.700	rs4791295	chr17:65997317	G/A	cg12091567	chr17:66097778	LOC651250	-0.82	-10.95	-0.51	4.64e-24	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21518248	chr2:162101506	NA	0.45	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg24562669	chr7:97807699	LMTK2	0.48	8.56	0.42	4.18e-16	Breast cancer;
LUSC	cis	rs2637266	1.000	rs2395387	chr10:78357029	T/C	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.8	-0.39	7.77e-14	Glomerular filtration rate;
LUSC	cis	rs3803170	0.513	rs11065888	chr12:111828663	G/C	cg10833066	chr12:111807467	FAM109A	0.39	7.24	0.37	3.19e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs4144743	1.000	rs4541130	chr17:45321037	G/A	cg18085866	chr17:45331354	ITGB3	-0.8	-8.43	-0.42	1.05e-15	Body mass index;
LUSC	cis	rs2143950	0.512	rs77772792	chr14:35520127	C/G	cg16230307	chr14:35515116	FAM177A1	-0.43	-5.83	-0.3	1.31e-8	Atopic dermatitis;
LUSC	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06636551	chr8:101224915	SPAG1	-0.44	-8.03	-0.4	1.63e-14	Atrioventricular conduction;
LUSC	cis	rs686320	1.000	rs616599	chr11:65254025	T/G	cg21890820	chr11:65308645	LTBP3	0.8	7.81	0.39	7.38e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg20887711	chr4:1340912	KIAA1530	0.45	6.68	0.34	9.71e-11	Obesity-related traits;
LUSC	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg07856975	chr6:36356162	ETV7	-0.35	-6.3	-0.33	9.53e-10	Platelet distribution width;
LUSC	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg03585969	chr10:35415529	CREM	0.59	8.8	0.43	7.47e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1113500	0.509	rs17020915	chr1:108647006	G/T	cg11967332	chr1:108735228	SLC25A24	0.42	5.73	0.3	2.22e-8	Growth-regulated protein alpha levels;
LUSC	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg27411982	chr8:10470053	RP1L1	0.41	6.32	0.33	8.43e-10	Neuroticism;
LUSC	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg19196401	chr6:110721138	DDO	-0.46	-8.73	-0.43	1.28e-16	Platelet distribution width;
LUSC	cis	rs7577851	0.953	rs6760776	chr2:69738790	T/C	cg10773587	chr2:69614142	GFPT1	0.47	5.73	0.3	2.3e-8	Parkinson's disease (age of onset);
LUSC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg04017836	chr7:65315216	NA	-0.37	-5.95	-0.31	6.75e-9	Height;
LUSC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	7.9	0.4	4.16e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.47	-0.56	1.51e-29	Alzheimer's disease;
LUSC	cis	rs9322817	0.540	rs2034823	chr6:105219573	A/T	cg02098413	chr6:105308735	HACE1	-0.28	-5.7	-0.3	2.59e-8	Thyroid stimulating hormone;
LUSC	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.54	-0.5	1.26e-22	Eye color traits;
LUSC	trans	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs12510870	0.511	rs3822100	chr4:74309472	C/G	cg01940055	chr4:146018582	ANAPC10;ABCE1	0.37	6.07	0.32	3.38e-9	Iris color (b* coordinate);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03571684	chr8:94753266	RBM12B	-0.41	-6.05	-0.31	3.94e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg21141812	chr3:48556323	PFKFB4	0.33	5.69	0.3	2.72e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs7605827	0.930	rs13410044	chr2:15602535	A/G	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.37e-17	Educational attainment (years of education);
LUSC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18131467	chr2:239335373	ASB1	1.06	25.42	0.81	4.43e-80	Multiple system atrophy;
LUSC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25072359	chr17:41440525	NA	0.58	8.33	0.41	2.14e-15	Menopause (age at onset);
LUSC	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg27068330	chr11:65405492	SIPA1	0.62	9.33	0.45	1.54e-18	Acne (severe);
LUSC	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg00784671	chr22:46762841	CELSR1	-0.54	-6.79	-0.35	5.18e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg18404041	chr3:52824283	ITIH1	-0.57	-9.59	-0.46	2.19e-19	Schizophrenia;
LUSC	cis	rs1953600	0.668	rs751740	chr10:81912179	T/C	cg00277334	chr10:82204260	NA	0.41	6.32	0.33	8.29e-10	Sarcoidosis;
LUSC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg24562669	chr7:97807699	LMTK2	0.34	5.98	0.31	5.9e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11764359	chr7:65958608	NA	-0.49	-7.24	-0.37	3.11e-12	Calcium levels;
LUSC	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg15744005	chr10:104629667	AS3MT	-0.34	-6.89	-0.35	2.75e-11	Arsenic metabolism;
LUSC	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg15395560	chr15:45543142	SLC28A2	0.33	5.66	0.3	3.25e-8	Uric acid levels;
LUSC	cis	rs9928842	0.882	rs6564241	chr16:75263974	T/C	cg09066997	chr16:75300724	BCAR1	0.54	6.37	0.33	6.12e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg27094323	chr7:1216898	NA	-0.38	-6.56	-0.34	2.1e-10	Longevity;Endometriosis;
LUSC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.69	0.3	2.81e-8	Self-reported allergy;
LUSC	cis	rs80130819	0.748	rs7953726	chr12:48611757	A/G	cg24011408	chr12:48396354	COL2A1	0.47	5.88	0.31	1.01e-8	Prostate cancer;
LUSC	cis	rs1595825	0.732	rs114972685	chr2:198437829	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.23	-0.32	1.36e-9	Ulcerative colitis;
LUSC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg13206674	chr6:150067644	NUP43	-0.6	-9.74	-0.47	6.86e-20	Lung cancer;
LUSC	cis	rs4654899	0.758	rs6426665	chr1:21382205	T/C	cg01072550	chr1:21505969	NA	-0.51	-7.82	-0.39	6.9e-14	Superior frontal gyrus grey matter volume;
LUSC	trans	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg07393940	chr7:158741817	NA	-0.38	-6.83	-0.35	4.05e-11	Life satisfaction;
LUSC	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.38	-7.43	-0.38	9.26e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs988712	0.672	rs16917237	chr11:27702383	A/C	cg10635145	chr11:27742435	BDNF	0.44	5.79	0.3	1.62e-8	Obesity;
LUSC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.27	0.56	8.02e-29	Cognitive test performance;
LUSC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-9.46	-0.46	5.81e-19	Chronic sinus infection;
LUSC	cis	rs2294693	0.945	rs932399	chr6:41011266	C/T	cg14769373	chr6:40998127	UNC5CL	-0.57	-7.33	-0.37	1.76e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs2617583	0.509	rs13089	chr5:1462732	G/C	cg13982541	chr5:1466431	LPCAT1	0.41	5.85	0.3	1.18e-8	Breast cancer;
LUSC	trans	rs12883384	1.000	rs2416009	chr14:47405018	A/T	cg09323092	chr16:921072	LMF1	0.32	6.06	0.31	3.76e-9	Neuroticism;
LUSC	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg01528321	chr10:82214614	TSPAN14	0.9	13.31	0.59	1.02e-32	Post bronchodilator FEV1;
LUSC	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg18132916	chr6:79620363	NA	-0.38	-5.69	-0.3	2.82e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.72e-12	Asthma (childhood onset);
LUSC	cis	rs4664308	0.935	rs4520993	chr2:160937673	G/A	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.62	-0.54	1.97e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.4	5.96	0.31	6.59e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.01	0.55	7.43e-28	Colorectal cancer;
LUSC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.62	8.31	0.41	2.42e-15	High light scatter reticulocyte count;
LUSC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg23625390	chr15:77176239	SCAPER	0.43	6.37	0.33	6.44e-10	Blood metabolite levels;
LUSC	trans	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.57e-15	Diabetic kidney disease;
LUSC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-6.9	-0.35	2.61e-11	Neuroticism;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10894697	chr10:115439008	CASP7	-0.48	-7.02	-0.36	1.26e-11	Electrocardiographic conduction measures;
LUSC	cis	rs12912251	0.947	rs7171233	chr15:38988760	T/A	cg01338139	chr15:38987640	C15orf53	-0.5	-6.83	-0.35	3.95e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg14345882	chr6:26364793	BTN3A2	0.6	5.69	0.3	2.81e-8	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27067419	chr5:54830434	PPAP2A;RNF138P1	-0.5	-6.2	-0.32	1.64e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4786125	0.665	rs1565633	chr16:6919428	G/C	cg03623568	chr16:6915990	A2BP1	-0.5	-8.39	-0.42	1.38e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs7605827	0.930	rs1996517	chr2:15517330	T/C	cg19274914	chr2:15703543	NA	0.45	8.73	0.43	1.27e-16	Educational attainment (years of education);
LUSC	cis	rs9467773	0.595	rs9366657	chr6:26434914	C/G	cg05738196	chr6:26577821	NA	0.54	8.13	0.41	8.44e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.35	5.68	0.3	2.99e-8	Systemic lupus erythematosus;
LUSC	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg01448562	chr3:133502909	NA	-0.53	-8.3	-0.41	2.67e-15	Ankle injury;
LUSC	cis	rs2692947	0.550	rs12623771	chr2:96633504	A/G	cg23100626	chr2:96804247	ASTL	0.23	5.74	0.3	2.1e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7523273	0.853	rs7537216	chr1:208006429	A/T	cg22525895	chr1:207977042	MIR29B2	-0.38	-5.66	-0.3	3.33e-8	Schizophrenia;
LUSC	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg23625390	chr15:77176239	SCAPER	0.47	7.23	0.37	3.23e-12	Blood metabolite levels;
LUSC	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg19628046	chr18:33552617	C18orf21	0.51	5.96	0.31	6.29e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg00945038	chr17:61921165	SMARCD2	0.54	9.64	0.47	1.4e-19	Prudent dietary pattern;
LUSC	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg15556689	chr8:8085844	FLJ10661	0.68	10.78	0.51	1.9e-23	Mood instability;
LUSC	cis	rs6960043	0.818	rs6967891	chr7:15065074	T/C	cg19272540	chr7:15055459	NA	-0.31	-7.66	-0.39	2.02e-13	Type 2 diabetes;
LUSC	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21659725	chr3:3221576	CRBN	0.62	10.21	0.49	1.78e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg03678062	chr6:149772716	ZC3H12D	0.3	6.03	0.31	4.38e-9	Dupuytren's disease;
LUSC	cis	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-8.36	-0.42	1.77e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg18357645	chr12:58087776	OS9	0.56	8.58	0.43	3.53e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg25124228	chr12:125621409	AACS	0.45	6.9	0.35	2.67e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-10.1	-0.48	4.1e-21	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg06552810	chr11:31128660	NA	-0.4	-6.95	-0.36	1.93e-11	Red blood cell count;
LUSC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg26659404	chr1:25747437	RHCE	-0.28	-5.86	-0.31	1.08e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.67	-0.54	1.26e-26	Coffee consumption (cups per day);
LUSC	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg14500267	chr11:67383377	NA	0.3	5.68	0.3	2.91e-8	Mean corpuscular volume;
LUSC	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg05234568	chr11:5960015	NA	-0.58	-8.28	-0.41	3.1e-15	DNA methylation (variation);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16326979	chr8:107670161	OXR1	-0.39	-5.97	-0.31	6.23e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg18135555	chr8:22132992	PIWIL2	0.39	7.82	0.39	7.14e-14	Hypertriglyceridemia;
LUSC	cis	rs2677744	0.688	rs2239293	chr15:91450350	G/A	cg23684204	chr15:91497937	RCCD1	0.43	5.94	0.31	7e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.37	0.62	8.94e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs8133932	0.654	rs375971	chr21:47338854	C/G	cg14185626	chr21:47401492	COL6A1	-0.46	-5.88	-0.31	1.01e-8	Schizophrenia;
LUSC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00149659	chr3:10157352	C3orf10	-1.16	-15.15	-0.64	8.09e-40	Alzheimer's disease;
LUSC	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg07862535	chr7:139043722	LUC7L2	0.54	6.75	0.35	6.59e-11	Diisocyanate-induced asthma;
LUSC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg09165964	chr15:75287851	SCAMP5	-0.91	-8.56	-0.42	4.25e-16	Lung cancer;
LUSC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg09998033	chr7:158218633	PTPRN2	-0.59	-9.64	-0.47	1.4e-19	Obesity-related traits;
LUSC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1957429	0.520	rs230723	chr14:65316017	C/T	cg23373153	chr14:65346875	NA	-0.83	-7.65	-0.39	2.18e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg17173187	chr15:85201210	NMB	0.38	6.65	0.34	1.21e-10	Schizophrenia;
LUSC	cis	rs7577696	0.924	rs212760	chr2:32429222	A/G	cg02381751	chr2:32503542	YIPF4	0.4	5.79	0.3	1.6e-8	Inflammatory biomarkers;
LUSC	cis	rs12200782	1.000	rs12205909	chr6:26630999	G/A	cg11502198	chr6:26597334	ABT1	-0.76	-5.8	-0.3	1.53e-8	Small cell lung carcinoma;
LUSC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg20607798	chr8:58055168	NA	0.57	5.78	0.3	1.7e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg11663144	chr21:46675770	NA	-0.33	-5.74	-0.3	2.15e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	5.96e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13215566	0.929	rs35007480	chr6:89924201	A/G	cg08400210	chr6:89908154	GABRR1	0.46	5.88	0.31	9.95e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg02187348	chr16:89574699	SPG7	0.5	7.77	0.39	9.65e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	12.79	0.57	9.23e-31	Hip circumference adjusted for BMI;
LUSC	cis	rs4363385	0.510	rs7541328	chr1:152894142	C/G	cg00922841	chr1:152955080	SPRR1A	-0.36	-5.88	-0.31	1.02e-8	Inflammatory skin disease;
LUSC	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	14.4	0.62	6.68e-37	Lymphocyte percentage of white cells;
LUSC	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg08017756	chr2:100939284	LONRF2	-0.43	-8.09	-0.4	1.13e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-7.45	-0.38	7.87e-13	Morning vs. evening chronotype;
LUSC	cis	rs3820928	0.845	rs13384342	chr2:227805010	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.03	-0.4	1.67e-14	Pulmonary function;
LUSC	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg08999081	chr20:33150536	PIGU	0.55	10.87	0.51	9.32e-24	Coronary artery disease;
LUSC	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg12924262	chr12:102091054	CHPT1	-0.42	-6.03	-0.31	4.34e-9	Blood protein levels;
LUSC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg20607798	chr8:58055168	NA	0.54	5.82	0.3	1.39e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7640424	0.620	rs17231503	chr3:107817299	C/T	cg09227934	chr3:107805635	CD47	-0.53	-7.64	-0.39	2.29e-13	Body mass index;
LUSC	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg04374321	chr14:90722782	PSMC1	-0.7	-10.51	-0.5	1.66e-22	Mortality in heart failure;
LUSC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg11812906	chr14:75593930	NEK9	0.63	10.55	0.5	1.22e-22	Height;
LUSC	trans	rs12145833	0.538	rs12026408	chr1:243366805	G/A	cg25284624	chr1:224180302	NA	0.7	6.63	0.34	1.36e-10	Obesity (early onset extreme);
LUSC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg13939156	chr17:80058883	NA	0.34	6.55	0.34	2.14e-10	Life satisfaction;
LUSC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	12.06	0.55	4.63e-28	Colorectal cancer;
LUSC	cis	rs778371	0.723	rs11689851	chr2:233567342	A/G	cg08000102	chr2:233561755	GIGYF2	0.82	12.92	0.58	2.93e-31	Schizophrenia;
LUSC	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg07173049	chr1:7289937	CAMTA1	0.37	7.69	0.39	1.62e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg00745463	chr17:30367425	LRRC37B	0.57	7.26	0.37	2.74e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.5	7.68	0.39	1.73e-13	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg05973401	chr12:123451056	ABCB9	0.54	6.67	0.34	1.06e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1712517	0.524	rs1712509	chr10:105013870	G/T	cg04362960	chr10:104952993	NT5C2	-0.53	-7.12	-0.36	6.77e-12	Migraine;
LUSC	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg16230307	chr14:35515116	FAM177A1	0.7	9.19	0.45	4.4e-18	Psoriasis;
LUSC	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg15485101	chr11:133734466	NA	0.38	7.17	0.37	4.98e-12	Childhood ear infection;
LUSC	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg21775007	chr8:11205619	TDH	-0.48	-6.95	-0.36	1.94e-11	Triglycerides;
LUSC	trans	rs10096351	0.574	rs684254	chr8:128338693	G/A	cg10195415	chr17:73887371	TRIM65	0.41	6.64	0.34	1.3100000000000001e-10	Breast cancer;
LUSC	cis	rs11229555	0.645	rs4594017	chr11:58194788	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3771570	0.901	rs62190413	chr2:242417950	G/A	cg21155796	chr2:242212141	HDLBP	0.61	6.86	0.35	3.35e-11	Prostate cancer;
LUSC	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.84	-0.44	5.49e-17	Monocyte percentage of white cells;
LUSC	cis	rs11642862	1.000	rs75500538	chr16:30782449	G/A	cg02466173	chr16:30829666	NA	-0.71	-7.59	-0.38	3.31e-13	Tonsillectomy;
LUSC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12379764	chr21:47803548	PCNT	-0.5	-7.15	-0.36	5.39e-12	Testicular germ cell tumor;
LUSC	cis	rs7804356	0.859	rs2391362	chr7:26907123	T/C	cg03456212	chr7:26904342	SKAP2	-0.57	-6.51	-0.34	2.76e-10	Type 1 diabetes;
LUSC	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.4	-0.46	8.69e-19	Schizophrenia;
LUSC	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg22467129	chr15:76604101	ETFA	-0.44	-6.86	-0.35	3.27e-11	Blood metabolite levels;
LUSC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg08088566	chr11:430123	ANO9	0.62	7.2	0.37	3.89e-12	Body mass index;
LUSC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg21699342	chr2:239360505	ASB1	0.56	10.3	0.49	8.39e-22	Multiple system atrophy;
LUSC	trans	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.63	-10.02	-0.48	8.04e-21	Endometrial cancer;
LUSC	cis	rs738322	0.810	rs4820325	chr22:38599978	G/A	cg17652424	chr22:38574118	PLA2G6	0.28	5.69	0.3	2.79e-8	Cutaneous nevi;
LUSC	cis	rs9359856	0.510	rs6937244	chr6:90468465	C/A	cg13799429	chr6:90582589	CASP8AP2	0.91	10.87	0.51	8.88e-24	Bipolar disorder;
LUSC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.99	0.31	5.57e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	9.69	0.47	1.02e-19	Personality dimensions;
LUSC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg09021430	chr5:549028	NA	-0.55	-7.57	-0.38	3.64e-13	Obesity-related traits;
LUSC	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg18827107	chr12:86230957	RASSF9	-0.4	-5.99	-0.31	5.31e-9	Major depressive disorder;
LUSC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12379764	chr21:47803548	PCNT	-0.43	-6.0	-0.31	5.12e-9	Testicular germ cell tumor;
LUSC	cis	rs9815354	0.767	rs73830585	chr3:42003698	T/A	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.21e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg12311346	chr5:56204834	C5orf35	-0.61	-9.41	-0.46	8.33e-19	Coronary artery disease;
LUSC	cis	rs7589342	0.536	rs10198057	chr2:106392799	A/C	cg09152813	chr2:106391379	NCK2	0.39	6.35	0.33	7.16e-10	Addiction;
LUSC	trans	rs13113518	0.812	rs12500601	chr4:56317656	T/C	cg07140194	chr2:73150236	EMX1	0.6	6.1	0.32	2.9e-9	Height;
LUSC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg19318889	chr4:1322082	MAEA	0.47	8.06	0.4	1.4e-14	Longevity;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19168507	chr11:107436485	ALKBH8	0.46	5.95	0.31	6.91e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00321850	chr1:175162397	KIAA0040	0.46	7.83	0.39	6.5e-14	Alcohol dependence;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24048372	chr5:93954560	C5orf36;ANKRD32	-0.55	-6.85	-0.35	3.46e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.72	10.24	0.49	1.43e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg09904177	chr6:26538194	HMGN4	0.65	11.7	0.54	9.83e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-8.52	-0.42	5.64e-16	Chronic sinus infection;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05970768	chr5:171682616	UBTD2	0.55	6.73	0.35	7.42e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg23601095	chr6:26197514	HIST1H3D	0.65	7.19	0.37	4.21e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg25072359	chr17:41440525	NA	0.6	8.66	0.43	2e-16	Menopause (age at onset);
LUSC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-14.65	-0.63	7.28e-38	Vitiligo;
LUSC	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg21293242	chr8:11204541	TDH	0.32	6.06	0.31	3.65e-9	Retinal vascular caliber;
LUSC	trans	rs12317459	0.591	rs11115437	chr12:83204590	G/A	cg10237817	chr1:154519846	TDRD10	0.31	6.14	0.32	2.28e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg04369109	chr6:150039330	LATS1	-0.54	-7.97	-0.4	2.48e-14	Lung cancer;
LUSC	trans	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg02030672	chr11:45687055	CHST1	0.41	6.24	0.32	1.33e-9	Obesity-related traits;
LUSC	cis	rs897080	0.552	rs1067405	chr2:44674861	T/C	cg00619915	chr2:44497795	NA	-0.46	-6.59	-0.34	1.66e-10	Height;
LUSC	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-8.04	-0.4	1.56e-14	Schizophrenia;
LUSC	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22857025	chr5:266934	NA	-1.19	-13.96	-0.61	3.19e-35	Breast cancer;
LUSC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg17971929	chr21:40555470	PSMG1	0.71	11.18	0.52	7.56e-25	Cognitive function;
LUSC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg19622623	chr12:86230825	RASSF9	0.4	5.75	0.3	2.02e-8	Major depressive disorder;
LUSC	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg19824325	chr16:58548873	SETD6	0.94	9.13	0.45	6.5e-18	Schizophrenia;
LUSC	cis	rs2979489	0.786	rs2979514	chr8:30399461	A/C	cg26383811	chr8:30366931	RBPMS	-0.51	-8.18	-0.41	6.19e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs3744061	0.557	rs4261577	chr17:74648566	T/C	cg27546012	chr17:74684504	MXRA7	-0.38	-6.53	-0.34	2.52e-10	Retinal arteriolar caliber;
LUSC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg07716408	chr11:68623521	NA	-0.32	-6.29	-0.33	9.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg13683864	chr3:40499215	RPL14	0.76	12.0	0.55	8.23e-28	Renal cell carcinoma;
LUSC	trans	rs2288327	1.000	rs3731746	chr2:179430997	G/A	cg14011486	chr1:26737247	LIN28	0.47	5.99	0.31	5.53e-9	Atrial fibrillation;
LUSC	trans	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg18187862	chr3:45730750	SACM1L	0.52	6.78	0.35	5.56e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg01884057	chr2:25150051	NA	0.48	11.39	0.53	1.31e-25	Body mass index;
LUSC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg03233332	chr7:66118400	NA	-0.42	-6.09	-0.32	3.02e-9	Aortic root size;
LUSC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg05347473	chr6:146136440	FBXO30	0.52	8.65	0.43	2.21e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg23752985	chr2:85803571	VAMP8	0.34	7.45	0.38	8.02e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.09	-0.32	3.05e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg19682013	chr15:45996608	NA	0.39	5.82	0.3	1.41e-8	Waist circumference;Weight;
LUSC	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg10857441	chr5:6722123	POLS	-0.44	-8.08	-0.4	1.19e-14	Menopause (age at onset);
LUSC	cis	rs7043114	0.525	rs7847929	chr9:95154244	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.63	-0.34	1.38e-10	Height;
LUSC	cis	rs6087990	0.965	rs2424899	chr20:31343543	A/C	cg13636640	chr20:31349939	DNMT3B	1.03	23.38	0.79	2.71e-72	Ulcerative colitis;
LUSC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.46	6.09	0.32	3.14e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12519773	0.597	rs4308464	chr5:92468867	G/C	cg18783429	chr5:92414398	NA	0.34	7.42	0.38	9.81e-13	Migraine;
LUSC	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg25801113	chr15:45476975	SHF	0.33	6.81	0.35	4.54e-11	Uric acid levels;
LUSC	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	5.99	0.31	5.55e-9	Schizophrenia;
LUSC	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	11.29	0.53	2.92e-25	Mean corpuscular hemoglobin;
LUSC	cis	rs28530618	0.580	rs4607010	chr20:31255271	G/C	cg13636640	chr20:31349939	DNMT3B	-0.43	-5.75	-0.3	1.97e-8	Birth weight;
LUSC	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	7.8	0.39	8.14e-14	Lung cancer;
LUSC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	12.66	0.57	2.89e-30	Platelet count;
LUSC	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg19920283	chr7:105172520	RINT1	0.58	6.12	0.32	2.65e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-7.61	-0.38	2.91e-13	Chronic sinus infection;
LUSC	cis	rs6785206	0.730	rs9861429	chr3:128425749	A/G	cg16766828	chr3:128327626	NA	-0.68	-7.5	-0.38	5.79e-13	Lymphocyte percentage of white cells;
LUSC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg16362232	chr11:430036	ANO9	0.6	7.87	0.4	4.86e-14	Body mass index;
LUSC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	0.94	15.86	0.66	1.24e-42	Menopause (age at onset);
LUSC	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg23569941	chr2:219139048	TMBIM1;PNKD	-0.37	-5.94	-0.31	7.31e-9	Ulcerative colitis;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.91	17.99	0.7	4.44e-51	Menarche (age at onset);
LUSC	cis	rs13315871	1.000	rs71311855	chr3:58320507	A/G	cg12435725	chr3:58293450	RPP14	-0.72	-7.18	-0.37	4.66e-12	Cholesterol, total;
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.68	10.5	0.5	1.75e-22	Lymphocyte counts;
LUSC	cis	rs3755132	0.929	rs2302935	chr2:15753482	C/G	cg12888861	chr2:15731646	DDX1	0.52	7.48	0.38	6.45e-13	Wilms tumor;
LUSC	cis	rs13082711	0.911	rs923941	chr3:27458914	A/G	cg02860705	chr3:27208620	NA	0.52	8.71	0.43	1.44e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs11785693	0.862	rs6994323	chr8:4996786	T/A	cg26367366	chr8:4980734	NA	0.73	8.61	0.43	2.9e-16	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs1062746	0.544	rs8059287	chr16:87332956	G/A	cg02258303	chr16:87377426	FBXO31	-0.53	-7.9	-0.4	4.15e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs4363385	0.747	rs4845333	chr1:152982877	G/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.33e-13	Inflammatory skin disease;
LUSC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg09323728	chr8:95962352	TP53INP1	0.37	7.08	0.36	8.39e-12	Type 2 diabetes;
LUSC	cis	rs116988415	0.584	rs2269308	chr14:65244950	G/A	cg00114569	chr14:65239327	SPTB	0.6	6.55	0.34	2.23e-10	Daytime sleep phenotypes;
LUSC	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg10596483	chr8:143751796	JRK	0.51	7.31	0.37	1.95e-12	Schizophrenia;
LUSC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg12463550	chr7:65579703	CRCP	0.5	6.97	0.36	1.7e-11	Aortic root size;
LUSC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-7.14	-0.36	5.87e-12	Blood metabolite levels;
LUSC	cis	rs4690686	1.000	rs2278904	chr4:177248622	C/G	cg17059388	chr4:177262070	NA	-0.35	-6.9	-0.35	2.64e-11	Essential tremor;
LUSC	cis	rs4363385	0.747	rs2339495	chr1:152975116	A/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.76	-0.39	1.05e-13	Inflammatory skin disease;
LUSC	trans	rs9392918	0.967	rs9379130	chr6:7702659	C/G	cg12631351	chr5:80256738	RASGRF2	0.35	6.06	0.31	3.59e-9	Height;
LUSC	cis	rs2274273	0.529	rs10131562	chr14:55847015	G/A	cg04306507	chr14:55594613	LGALS3	0.47	9.45	0.46	6.31e-19	Protein biomarker;
LUSC	cis	rs6087990	0.735	rs2424915	chr20:31378448	C/T	cg13636640	chr20:31349939	DNMT3B	0.86	16.76	0.68	3.37e-46	Ulcerative colitis;
LUSC	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.74	11.51	0.53	4.7e-26	Retinal vascular caliber;
LUSC	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg16797656	chr11:68205561	LRP5	0.38	6.21	0.32	1.58e-9	Total body bone mineral density;
LUSC	trans	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.81e-10	Life satisfaction;
LUSC	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg19773385	chr1:10388646	KIF1B	-0.49	-8.37	-0.42	1.57e-15	Hepatocellular carcinoma;
LUSC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.38	-6.43	-0.33	4.51e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg22709100	chr7:91322751	NA	-0.38	-5.72	-0.3	2.37e-8	Breast cancer;
LUSC	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg17294928	chr15:75287854	SCAMP5	0.43	6.21	0.32	1.54e-9	Breast cancer;
LUSC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.66	0.39	2.02e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.73	14.11	0.61	8.53e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.34	0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg21775007	chr8:11205619	TDH	-0.68	-10.68	-0.5	4.35e-23	Retinal vascular caliber;
LUSC	cis	rs77633900	0.614	rs280024	chr15:77034518	A/C	cg21673338	chr15:77095150	SCAPER	-0.82	-8.07	-0.4	1.26e-14	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs4589502	1.000	rs75502100	chr15:67131417	T/C	cg09911534	chr15:67153556	NA	-0.69	-7.34	-0.37	1.67e-12	Lung cancer (smoking interaction);
LUSC	cis	rs9888739	0.800	rs1143683	chr16:31336888	A/G	cg15817542	chr16:31343056	ITGAM	0.47	6.63	0.34	1.39e-10	Systemic lupus erythematosus;
LUSC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg16647868	chr5:131706066	SLC22A5	-0.39	-5.77	-0.3	1.77e-8	Breast cancer;
LUSC	cis	rs7246657	0.653	rs10406612	chr19:37716611	C/T	cg23950597	chr19:37808831	NA	-0.61	-6.32	-0.33	8.32e-10	Coronary artery calcification;
LUSC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg05347473	chr6:146136440	FBXO30	-0.6	-10.43	-0.5	3.17e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4499344	0.730	rs2545357	chr19:33104610	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.06	0.58	9.33e-32	Mean platelet volume;
LUSC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.88	0.48	2.3e-20	Bipolar disorder;
LUSC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg11941060	chr3:133502564	NA	-0.46	-6.62	-0.34	1.4e-10	Iron status biomarkers;
LUSC	cis	rs9646944	0.501	rs10186052	chr2:103079608	G/A	cg20060108	chr2:102954350	IL1RL1	0.45	6.18	0.32	1.91e-9	Blood protein levels;
LUSC	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg16482183	chr6:26056742	HIST1H1C	0.44	6.57	0.34	1.92e-10	Height;
LUSC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6688613	0.685	rs4657613	chr1:166870878	A/G	cg07049167	chr1:166818506	POGK	0.44	6.73	0.35	7.52e-11	Refractive astigmatism;
LUSC	cis	rs2625529	0.642	rs2200056	chr15:72302667	T/C	cg16672083	chr15:72433130	SENP8	-0.52	-7.49	-0.38	6.03e-13	Red blood cell count;
LUSC	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg22676075	chr6:135203613	NA	0.54	8.55	0.42	4.6e-16	Red blood cell count;
LUSC	trans	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.09	-0.32	3.17e-9	Monocyte count;
LUSC	trans	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg13565492	chr6:43139072	SRF	-0.41	-5.99	-0.31	5.45e-9	Longevity;Endometriosis;
LUSC	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg24692254	chr21:30365293	RNF160	0.78	13.63	0.6	6.17e-34	Dental caries;
LUSC	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.35	5.81	0.3	1.48e-8	IgG glycosylation;
LUSC	trans	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg21659725	chr3:3221576	CRBN	-0.71	-7.8	-0.39	7.78e-14	Menarche (age at onset);
LUSC	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg18825076	chr15:78729989	IREB2	0.47	6.54	0.34	2.29e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg12963866	chr19:57752005	ZNF805	-0.39	-5.78	-0.3	1.73e-8	Hyperactive-impulsive symptoms;
LUSC	cis	rs2298450	0.717	rs9974041	chr21:37634873	G/A	cg02919814	chr21:37666008	DOPEY2	-0.51	-7.34	-0.37	1.67e-12	Schizophrenia;
LUSC	cis	rs7599312	0.586	rs7571561	chr2:213386267	T/C	cg16329650	chr2:213403929	ERBB4	0.52	7.56	0.38	3.92e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg03233332	chr7:66118400	NA	0.42	6.02	0.31	4.64e-9	Aortic root size;
LUSC	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg05283184	chr6:79620031	NA	-0.56	-11.88	-0.54	2.27e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-0.99	-17.08	-0.68	1.85e-47	Height;
LUSC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	9.58	0.46	2.32e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg09904177	chr6:26538194	HMGN4	0.64	11.43	0.53	9.16e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg10978503	chr1:24200527	CNR2	0.54	13.21	0.59	2.32e-32	Immature fraction of reticulocytes;
LUSC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg16060761	chr17:80687452	NA	0.42	6.59	0.34	1.75e-10	Breast cancer;
LUSC	cis	rs7605827	0.930	rs4571032	chr2:15685038	A/G	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.82e-16	Educational attainment (years of education);
LUSC	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	19.01	0.72	3.91e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	13.65	0.6	5.02e-34	Platelet count;
LUSC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg20573242	chr4:122745356	CCNA2	0.53	7.85	0.39	5.6e-14	Type 2 diabetes;
LUSC	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.77	12.03	0.55	6.19e-28	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg07169764	chr2:136633963	MCM6	1.05	16.74	0.68	4.06e-46	Corneal structure;
LUSC	cis	rs6460942	0.908	rs74801929	chr7:12232715	C/G	cg06484146	chr7:12443880	VWDE	-0.56	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg12463550	chr7:65579703	CRCP	0.52	7.51	0.38	5.47e-13	Aortic root size;
LUSC	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg17691542	chr6:26056736	HIST1H1C	0.54	8.11	0.41	9.7e-15	Height;
LUSC	cis	rs367943	0.712	rs13157609	chr5:112683583	G/A	cg12552261	chr5:112820674	MCC	0.39	6.37	0.33	6.4e-10	Type 2 diabetes;
LUSC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg13607699	chr17:42295918	UBTF	-0.48	-7.64	-0.39	2.37e-13	Total body bone mineral density;
LUSC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg08949735	chr16:89699720	DPEP1	-0.24	-5.87	-0.31	1.04e-8	Vitiligo;
LUSC	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07636037	chr3:49044803	WDR6	0.69	8.83	0.43	6.21e-17	Menarche (age at onset);
LUSC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg18402987	chr7:1209562	NA	0.7	7.64	0.39	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.22	-0.32	1.51e-9	Neuroticism;
LUSC	trans	rs2302464	1.000	rs73125993	chr4:15730513	T/C	cg17675199	chr6:35436792	RPL10A	-0.88	-6.15	-0.32	2.26e-9	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg23711669	chr6:146136114	FBXO30	0.84	15.05	0.64	1.97e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.45	-0.42	8.97e-16	Mood instability;
LUSC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-10.27	-0.49	1.07e-21	Longevity;Endometriosis;
LUSC	cis	rs3791556	0.898	rs3791549	chr2:240109024	A/G	cg03281426	chr2:240109471	HDAC4	-0.56	-8.23	-0.41	4.16e-15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2274273	0.588	rs7155054	chr14:55750662	A/G	cg04306507	chr14:55594613	LGALS3	0.47	9.59	0.46	2.15e-19	Protein biomarker;
LUSC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-6.03	-0.31	4.38e-9	Vitiligo;
LUSC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg02038168	chr22:39784481	NA	0.45	6.7	0.34	9.04e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	0.7	6.97	0.36	1.74e-11	Prostate cancer;
LUSC	trans	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.56e-13	Motion sickness;
LUSC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.91	0.44	3.4e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6960043	1.000	rs12666046	chr7:15050381	A/G	cg19272540	chr7:15055459	NA	-0.31	-7.41	-0.38	1.01e-12	Type 2 diabetes;
LUSC	cis	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.63	-0.39	2.42e-13	Morning vs. evening chronotype;
LUSC	cis	rs4704187	0.687	rs10942729	chr5:74364300	C/T	cg03227963	chr5:74354835	NA	0.32	7.13	0.36	6.4e-12	Response to amphetamines;
LUSC	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg06532163	chr17:45867833	NA	0.35	6.53	0.34	2.51e-10	IgG glycosylation;
LUSC	cis	rs7818345	0.935	rs6991212	chr8:19276522	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.37	7.12	0.36	6.47e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg17420585	chr12:42539391	GXYLT1	-0.32	-5.97	-0.31	6.02e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.89	-18.22	-0.71	5.27e-52	Monocyte count;
LUSC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg10360139	chr7:1886902	MAD1L1	-0.38	-5.76	-0.3	1.91e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs597583	0.671	rs4938401	chr11:117399605	T/G	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.02	-0.4	1.81e-14	Putamen volume;
LUSC	trans	rs6787172	1.000	rs6787172	chr3:158187811	T/G	cg23275840	chr4:47708675	CORIN	-0.27	-6.03	-0.31	4.45e-9	Subjective well-being;
LUSC	cis	rs611744	0.870	rs633794	chr8:109174702	A/G	cg18478394	chr8:109455254	TTC35	0.43	6.39	0.33	5.65e-10	Dupuytren's disease;
LUSC	cis	rs10992471	0.603	rs12341817	chr9:95252152	C/T	cg14631576	chr9:95140430	CENPP	-0.33	-5.96	-0.31	6.48e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	trans	rs4714291	0.925	rs847784	chr6:40053272	A/G	cg02267698	chr19:7991119	CTXN1	0.54	7.52	0.38	5.19e-13	Strep throat;
LUSC	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg26102564	chr10:131424627	MGMT	0.38	5.94	0.31	7.21e-9	Response to temozolomide;
LUSC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.64	0.6	5.79e-34	Cognitive test performance;
LUSC	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.69	-10.06	-0.48	5.62e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	trans	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.99	-0.31	5.47e-9	Dementia with Lewy bodies;
LUSC	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-20.51	-0.75	4.63e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg27170947	chr2:26402098	FAM59B	-0.7	-10.76	-0.51	2.21e-23	Gut microbiome composition (summer);
LUSC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg03676636	chr4:99064102	C4orf37	0.38	8.09	0.4	1.14e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg13010199	chr12:38710504	ALG10B	0.67	10.36	0.49	5.56e-22	Heart rate;
LUSC	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg05738196	chr6:26577821	NA	0.83	16.11	0.66	1.29e-43	Intelligence (multi-trait analysis);
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg04234412	chr22:24373322	LOC391322	-0.87	-14.96	-0.63	4.27e-39	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.45	6.65	0.34	1.16e-10	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg13334819	chr7:99746414	C7orf59	0.5	6.76	0.35	6.07e-11	Coronary artery disease;
LUSC	trans	rs724744	0.742	rs1737224	chr6:22355309	T/C	cg13807341	chr11:118445984	ARCN1	-0.36	-6.07	-0.32	3.43e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg20848291	chr7:100343083	ZAN	-0.55	-8.03	-0.4	1.72e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg07424592	chr7:64974309	NA	-0.64	-5.72	-0.3	2.33e-8	Diabetic kidney disease;
LUSC	cis	rs9472414	0.510	rs7746032	chr6:44708613	A/T	cg20913747	chr6:44695427	NA	0.38	5.77	0.3	1.81e-8	Height;
LUSC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg25319279	chr11:5960081	NA	-0.39	-6.04	-0.31	4.07e-9	DNA methylation (variation);
LUSC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-1.01	-17.18	-0.68	7.55e-48	Body mass index;
LUSC	cis	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg05084668	chr3:125655381	ALG1L	-0.76	-11.44	-0.53	8.62e-26	Blood pressure (smoking interaction);
LUSC	cis	rs6840360	1.000	rs6849050	chr4:152599902	C/T	cg22705602	chr4:152727874	NA	-0.27	-5.74	-0.3	2.14e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	9.3	0.45	1.94e-18	Mood instability;
LUSC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg19717773	chr7:2847554	GNA12	-0.32	-5.77	-0.3	1.84e-8	Height;
LUSC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg02153584	chr22:29168773	CCDC117	0.59	8.91	0.44	3.47e-17	Lymphocyte counts;
LUSC	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg18932078	chr1:2524107	MMEL1	0.31	6.74	0.35	6.76e-11	Ulcerative colitis;
LUSC	cis	rs4930561	0.765	rs4930564	chr11:67983281	C/T	cg16338278	chr11:67432957	ALDH3B2	-0.36	-5.89	-0.31	9.38e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg03060546	chr3:49711283	APEH	0.7	11.63	0.54	1.78e-26	Resting heart rate;
LUSC	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg10547527	chr2:198650123	BOLL	-0.49	-5.79	-0.3	1.65e-8	Ulcerative colitis;
LUSC	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg22961513	chr11:14280813	SPON1	-0.35	-5.82	-0.3	1.39e-8	Mitochondrial DNA levels;
LUSC	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg23601095	chr6:26197514	HIST1H3D	0.71	7.35	0.37	1.57e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-7.13	-0.36	6.16e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7605827	0.930	rs11691392	chr2:15498781	C/T	cg19274914	chr2:15703543	NA	0.45	8.51	0.42	6.15e-16	Educational attainment (years of education);
LUSC	cis	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.58	-0.34	1.86e-10	Morning vs. evening chronotype;
LUSC	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg25482853	chr8:67687455	SGK3	1.2	17.23	0.69	4.62e-48	Lung disease severity in cystic fibrosis;
LUSC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg14668632	chr7:2872130	GNA12	-0.41	-6.22	-0.32	1.5e-9	Height;
LUSC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg05373962	chr22:49881684	NA	-0.41	-9.73	-0.47	7.4e-20	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.71	-11.17	-0.52	7.69e-25	Alcohol dependence;
LUSC	cis	rs7408868	1.000	rs7250232	chr19:15277199	C/T	cg14696996	chr19:15285081	NOTCH3	0.94	7.81	0.39	7.61e-14	Pulse pressure;
LUSC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg09904177	chr6:26538194	HMGN4	0.76	14.14	0.61	6.7e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg06808227	chr14:105710500	BRF1	0.71	11.45	0.53	7.98e-26	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13941441	chr2:190649374	PMS1;ORMDL1	0.47	6.42	0.33	4.78e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	0.94	15.3	0.64	1.96e-40	Parkinson's disease;
LUSC	cis	rs55871839	0.643	rs7004274	chr8:59810378	T/A	cg07426533	chr8:59803705	TOX	-0.37	-5.93	-0.31	7.5e-9	Pneumonia;
LUSC	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg25801113	chr15:45476975	SHF	-0.33	-6.48	-0.33	3.28e-10	Uric acid levels;
LUSC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg07424592	chr7:64974309	NA	0.7	6.2	0.32	1.67e-9	Diabetic kidney disease;
LUSC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.5	0.56	1.14e-29	Motion sickness;
LUSC	cis	rs6733011	0.519	rs12712037	chr2:99463025	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.01	-0.31	4.84e-9	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.28e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg08773314	chr2:239334832	ASB1	0.43	9.27	0.45	2.35e-18	Multiple system atrophy;
LUSC	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg00262122	chr8:11665843	FDFT1	-0.44	-6.66	-0.34	1.12e-10	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg08027265	chr7:2291960	NA	0.35	5.65	0.3	3.41e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.94	-13.51	-0.59	1.68e-33	Initial pursuit acceleration;
LUSC	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg21095983	chr6:86352623	SYNCRIP	0.5	8.07	0.4	1.25e-14	Smooth-surface caries;
LUSC	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.98	0.44	2e-17	Lung cancer in ever smokers;
LUSC	cis	rs6693567	0.526	rs3818978	chr1:150266338	T/A	cg09579323	chr1:150459698	TARS2	-0.41	-5.77	-0.3	1.83e-8	Migraine;
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.6	10.09	0.48	4.37e-21	Lymphocyte counts;
LUSC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9467160	0.520	rs2753910	chr6:24442473	C/T	cg20631270	chr6:24437470	GPLD1	-0.39	-6.16	-0.32	2.13e-9	Liver enzyme levels;
LUSC	cis	rs11126435	0.565	rs715407	chr2:74765693	G/T	cg04255230	chr2:74727010	LBX2	0.4	5.87	0.31	1.08e-8	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7043114	0.525	rs12353096	chr9:95031144	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.37	-6.21	-0.32	1.57e-9	Height;
LUSC	cis	rs35995292	0.553	rs2392605	chr7:38924670	T/C	cg19327137	chr7:38886074	VPS41	0.54	10.22	0.49	1.65e-21	Subjective well-being (multi-trait analysis);
LUSC	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg05855489	chr10:104503620	C10orf26	0.61	9.8	0.47	4.43e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs710216	0.752	rs841848	chr1:43402545	G/A	cg03128534	chr1:43423976	SLC2A1	0.45	5.68	0.3	2.95e-8	Red cell distribution width;
LUSC	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg22029157	chr1:209979665	IRF6	0.52	8.21	0.41	4.96e-15	Monobrow;
LUSC	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg22349387	chr12:9600060	DDX12	-0.37	-5.65	-0.3	3.39e-8	Breast size;
LUSC	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg16535667	chr11:65410126	SIPA1	-0.46	-6.05	-0.31	3.82e-9	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg08048268	chr3:133502702	NA	-0.41	-7.42	-0.38	9.57e-13	Iron status biomarkers;
LUSC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-7.05	-0.36	1.05e-11	Total body bone mineral density;
LUSC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg20503657	chr10:835505	NA	1.05	13.48	0.59	2.19e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.9	0.31	9.03e-9	Menopause (age at onset);
LUSC	cis	rs4253772	0.872	rs45528736	chr22:46638312	A/G	cg18190219	chr22:46762943	CELSR1	-0.48	-5.81	-0.3	1.45e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10582045	chr15:43477796	CCNDBP1	-0.48	-6.27	-0.32	1.09e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg14500267	chr11:67383377	NA	-0.32	-5.81	-0.3	1.44e-8	Mean corpuscular volume;
LUSC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg08677398	chr8:58056175	NA	0.44	5.86	0.31	1.11e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19346786	chr7:2764209	NA	-0.46	-7.92	-0.4	3.5e-14	Height;
LUSC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg22535103	chr8:58192502	C8orf71	-0.62	-7.32	-0.37	1.85e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs17021463	0.934	rs28403447	chr4:95257753	G/A	cg11021082	chr4:95130006	SMARCAD1	0.41	7.67	0.39	1.84e-13	Testicular germ cell tumor;
LUSC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg26566898	chr11:117069891	TAGLN	0.48	8.3	0.41	2.63e-15	Blood protein levels;
LUSC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg23719950	chr11:63933701	MACROD1	-0.62	-8.07	-0.4	1.26e-14	Mean platelet volume;
LUSC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg13114125	chr14:105738426	BRF1	-0.92	-16.04	-0.66	2.55e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4619890	0.528	rs28437157	chr4:7874435	C/A	cg24250820	chr4:7887609	AFAP1	0.36	6.1	0.32	2.88e-9	Glaucoma (primary open-angle);
LUSC	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	11.4	0.53	1.17e-25	Colorectal cancer;
LUSC	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg00310523	chr12:86230176	RASSF9	0.46	8.4	0.42	1.32e-15	Major depressive disorder;
LUSC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.09e-18	Menopause (age at onset);
LUSC	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.11	15.06	0.64	1.73e-39	Lung cancer in ever smokers;
LUSC	cis	rs17540621	0.744	rs114700821	chr2:47185714	C/T	cg23978866	chr2:47230407	TTC7A	-0.9	-6.69	-0.34	9.42e-11	Response to statin therapy;
LUSC	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg17691542	chr6:26056736	HIST1H1C	-0.5	-7.19	-0.37	4.37e-12	Iron status biomarkers;
LUSC	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.6	9.59	0.46	2.2e-19	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26386436	chr14:90084672	FOXN3	0.4	6.06	0.31	3.75e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs73206853	0.563	rs16940950	chr12:111136459	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	7.36	0.37	1.45e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7561273	0.609	rs6545285	chr2:24340029	T/C	cg20701182	chr2:24300061	SF3B14	0.45	5.83	0.3	1.32e-8	Quantitative traits;
LUSC	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg14689365	chr7:158441557	NCAPG2	0.53	7.59	0.38	3.25e-13	Height;
LUSC	cis	rs1178968	1.000	rs1178959	chr7:72777093	T/C	cg25889504	chr7:72793014	NA	0.6	7.77	0.39	9.92e-14	Triglyceride levels;
LUSC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg15605315	chr1:45957053	TESK2	0.51	8.44	0.42	1e-15	High light scatter reticulocyte count;
LUSC	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg08601574	chr20:25228251	PYGB	0.41	6.21	0.32	1.61e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.97	0.4	2.55e-14	Electroencephalogram traits;
LUSC	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.56e-22	Hypertriglyceridemia;
LUSC	cis	rs6554196	0.525	rs2237036	chr4:55526175	G/C	cg18836493	chr4:55524333	KIT	-0.44	-7.55	-0.38	4.2e-13	Monocyte count;
LUSC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26314531	chr2:26401878	FAM59B	-0.7	-9.75	-0.47	6.29e-20	Gut microbiome composition (summer);
LUSC	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg10818794	chr15:86012489	AKAP13	0.41	6.49	0.33	3.13e-10	Coronary artery disease;
LUSC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.95	0.36	1.94e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg09307838	chr4:120376055	NA	0.71	10.61	0.5	7.43e-23	Corneal astigmatism;
LUSC	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.77	-0.35	5.76e-11	Monocyte percentage of white cells;
LUSC	trans	rs9944715	0.911	rs7230995	chr18:43786822	G/A	cg01718231	chr17:29326311	RNF135	-0.54	-7.66	-0.39	2.03e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg03806693	chr22:41940476	POLR3H	-0.73	-10.48	-0.5	2.04e-22	Vitiligo;
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg01238044	chr22:24384105	GSTT1	-0.62	-9.95	-0.48	1.3e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg13852791	chr20:30311386	BCL2L1	0.73	8.39	0.42	1.35e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.9	0.44	3.62e-17	Lung cancer;
LUSC	cis	rs7527798	0.571	rs11118237	chr1:207818719	G/A	cg09232269	chr1:207846808	CR1L	-0.31	-6.46	-0.33	3.68e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg04414720	chr1:150670196	GOLPH3L	0.49	7.77	0.39	9.49e-14	Melanoma;
LUSC	cis	rs73206853	0.841	rs9783428	chr12:111068096	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	7.17	0.37	4.73e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7577696	0.752	rs12995952	chr2:32373298	C/T	cg02381751	chr2:32503542	YIPF4	-0.41	-5.67	-0.3	3.14e-8	Inflammatory biomarkers;
LUSC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20307385	chr11:47447363	PSMC3	-0.45	-5.95	-0.31	6.79e-9	Subjective well-being;
LUSC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.63	-0.34	1.32e-10	Aortic root size;
LUSC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg20135002	chr11:47629003	NA	-0.5	-7.78	-0.39	9.27e-14	Subjective well-being;
LUSC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg22834771	chr12:69754056	YEATS4	-0.49	-7.37	-0.37	1.31e-12	Blood protein levels;
LUSC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg00033643	chr7:134001901	SLC35B4	0.44	6.72	0.35	7.83e-11	Mean platelet volume;
LUSC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg04518342	chr5:131593106	PDLIM4	0.45	7.89	0.4	4.3e-14	Breast cancer;
LUSC	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg19743168	chr1:23544995	NA	0.43	8.03	0.4	1.68e-14	Height;
LUSC	cis	rs3126085	0.935	rs3126091	chr1:152307338	T/C	cg26876637	chr1:152193138	HRNR	-0.44	-6.02	-0.31	4.67e-9	Atopic dermatitis;
LUSC	cis	rs10746514	0.833	rs10864720	chr1:232271232	C/T	cg09506761	chr1:232265262	NA	-0.57	-9.72	-0.47	7.91e-20	Response to statin therapy;
LUSC	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg09654669	chr8:57350985	NA	-0.56	-7.78	-0.39	9.24e-14	Obesity-related traits;
LUSC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08219700	chr8:58056026	NA	0.69	7.93	0.4	3.34e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg16342193	chr10:102329863	NA	-0.35	-6.22	-0.32	1.53e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7584330	0.554	rs62186170	chr2:238425883	C/T	cg16989719	chr2:238392110	NA	-0.43	-6.2	-0.32	1.65e-9	Prostate cancer;
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.75	-16.85	-0.68	1.51e-46	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg21775007	chr8:11205619	TDH	0.43	6.24	0.32	1.32e-9	Neuroticism;
LUSC	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.55	10.65	0.5	5.16e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18876405	chr7:65276391	NA	0.48	6.59	0.34	1.73e-10	Corneal structure;
LUSC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.42	-6.15	-0.32	2.17e-9	Schizophrenia;
LUSC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg16586182	chr3:47516702	SCAP	-0.49	-7.59	-0.38	3.1400000000000003e-13	Colorectal cancer;
LUSC	cis	rs2236918	1.000	rs1629051	chr1:242026344	A/G	cg17736920	chr1:242011382	EXO1	-0.45	-7.26	-0.37	2.68e-12	Menopause (age at onset);
LUSC	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg12179176	chr11:130786555	SNX19	0.56	8.87	0.44	4.57e-17	Schizophrenia;
LUSC	cis	rs701145	0.585	rs1358405	chr3:153810992	A/G	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.38	5.94	0.31	6.98e-9	Lymphocyte counts;
LUSC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15541040	chr2:3486749	NA	-0.58	-9.21	-0.45	3.59e-18	Neurofibrillary tangles;
LUSC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg25039879	chr17:56429692	SUPT4H1	0.67	8.95	0.44	2.48e-17	Cognitive test performance;
LUSC	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg09323728	chr8:95962352	TP53INP1	0.3	5.92	0.31	8.17e-9	Type 2 diabetes;
LUSC	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg05519781	chr21:40033154	ERG	0.77	13.33	0.59	8.19e-33	Coronary artery disease;
LUSC	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg06627628	chr2:24431161	ITSN2	-0.86	-12.09	-0.55	3.55e-28	Asthma;
LUSC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg18306943	chr3:40428807	ENTPD3	0.38	5.73	0.3	2.2e-8	Renal cell carcinoma;
LUSC	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg04827223	chr11:72435913	ARAP1	0.66	8.73	0.43	1.28e-16	Type 2 diabetes;
LUSC	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.74	0.43	1.17e-16	Coffee consumption (cups per day);
LUSC	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg14438399	chr17:27053147	TLCD1	0.52	5.75	0.3	2.05e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.71	-12.37	-0.56	3.47e-29	White blood cell count (basophil);
LUSC	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.73	12.03	0.55	6.29e-28	Metabolic syndrome;
LUSC	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg17757837	chr7:157058334	UBE3C	0.82	13.01	0.58	1.35e-31	Body mass index;
LUSC	trans	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg00599273	chr12:58146742	CDK4	0.31	5.96	0.31	6.44e-9	Multiple sclerosis;
LUSC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg20891558	chr2:74357851	NA	0.85	15.52	0.65	2.67e-41	Gestational age at birth (maternal effect);
LUSC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	4.73e-15	Homoarginine levels;
LUSC	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg15839431	chr19:19639596	YJEFN3	0.65	7.27	0.37	2.63e-12	Bipolar disorder;
LUSC	cis	rs12541635	0.677	rs7819501	chr8:107006962	C/T	cg10147462	chr8:107024639	NA	-0.67	-13.67	-0.6	4.34e-34	Age of smoking initiation;
LUSC	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg06917634	chr15:78832804	PSMA4	-0.48	-5.98	-0.31	5.88e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg05855489	chr10:104503620	C10orf26	0.6	9.68	0.47	1.05e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg13385521	chr17:29058706	SUZ12P	0.65	6.26	0.32	1.18e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.14	-0.32	2.28e-9	IgG glycosylation;
LUSC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.72	-0.39	1.4e-13	Aortic root size;
LUSC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	10.79	0.51	1.81e-23	Homoarginine levels;
LUSC	cis	rs17255340	0.539	rs1144194	chr6:83978378	G/A	cg08257003	chr6:84140564	ME1	0.32	7.72	0.39	1.37e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.86	-0.31	1.08e-8	Aortic root size;
LUSC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg20887711	chr4:1340912	KIAA1530	0.43	6.55	0.34	2.13e-10	Obesity-related traits;
LUSC	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg05340658	chr4:99064831	C4orf37	0.61	8.89	0.44	3.83e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7177699	0.526	rs7165042	chr15:79123338	C/G	cg00540400	chr15:79124168	NA	0.43	7.51	0.38	5.44e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg08558340	chr7:100472263	SRRT	0.5	6.23	0.32	1.37e-9	Resting heart rate;
LUSC	cis	rs6087990	0.735	rs2424920	chr20:31385452	T/C	cg13636640	chr20:31349939	DNMT3B	0.9	18.2	0.71	6.72e-52	Ulcerative colitis;
LUSC	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg24675056	chr1:15929824	NA	0.47	8.07	0.4	1.32e-14	Systolic blood pressure;
LUSC	cis	rs7582720	1.000	rs72936332	chr2:204056678	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.29	0.41	2.71e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09241243	chr14:64970743	ZBTB25;ZBTB1	0.45	6.01	0.31	4.94e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06077733	chr10:60094879	UBE2D1	-0.44	-6.65	-0.34	1.17e-10	Electrocardiographic conduction measures;
LUSC	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg00204512	chr16:28754710	NA	0.32	5.67	0.3	3.15e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg24331049	chr13:111365604	ING1	-0.63	-8.49	-0.42	6.97e-16	Coronary artery disease;
LUSC	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg20016023	chr10:99160130	RRP12	-0.31	-7.55	-0.38	4.1e-13	Monocyte percentage of white cells;
LUSC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg01448562	chr3:133502909	NA	-0.65	-10.61	-0.5	7.25e-23	Iron status biomarkers;
LUSC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.79	9.79	0.47	4.75e-20	Body mass index;
LUSC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg17178900	chr1:205818956	PM20D1	-0.49	-7.42	-0.38	9.63e-13	Menarche (age at onset);
LUSC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg05861140	chr6:150128134	PCMT1	0.4	6.46	0.33	3.77e-10	Lung cancer;
LUSC	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.52	-0.46	3.57e-19	Total cholesterol levels;
LUSC	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg13902645	chr11:5959945	NA	-0.57	-8.08	-0.4	1.22e-14	DNA methylation (variation);
LUSC	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.71e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg26168224	chr5:2018326	NA	-0.48	-7.99	-0.4	2.24e-14	Gut microbiome composition (winter);
LUSC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg13628971	chr7:2884303	GNA12	0.5	6.92	0.35	2.38e-11	Height;
LUSC	cis	rs3784262	0.679	rs11071366	chr15:58334244	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-6.71	-0.34	8.23e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	trans	rs953492	0.583	rs10803125	chr1:243380376	G/C	cg25284624	chr1:224180302	NA	-0.44	-6.8	-0.35	4.95e-11	Diastolic blood pressure;
LUSC	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.55	9.35	0.46	1.33e-18	IgG glycosylation;
LUSC	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg20701182	chr2:24300061	SF3B14	0.77	7.74	0.39	1.17e-13	Lymphocyte counts;
LUSC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-6.42	-0.33	4.59e-10	Bipolar disorder;
LUSC	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg14092571	chr14:90743983	NA	0.37	6.18	0.32	1.85e-9	Mortality in heart failure;
LUSC	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.47	-6.0	-0.31	5.26e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1451375	0.698	rs10899748	chr7:50646089	G/A	cg18232548	chr7:50535776	DDC	0.45	6.2	0.32	1.7e-9	Malaria;
LUSC	cis	rs6942756	0.806	rs2718115	chr7:128871532	A/G	cg02491457	chr7:128862824	NA	0.54	8.13	0.41	8.51e-15	White matter hyperintensity burden;
LUSC	cis	rs6977660	0.714	rs10270204	chr7:19819544	C/T	cg07541023	chr7:19748670	TWISTNB	0.59	6.33	0.33	7.76e-10	Thyroid stimulating hormone;
LUSC	cis	rs7582720	1.000	rs72926772	chr2:203804289	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs10193935	0.901	rs2286701	chr2:42555636	T/C	cg27598129	chr2:42591480	NA	-0.6	-8.17	-0.41	6.36e-15	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg15556689	chr8:8085844	FLJ10661	0.58	8.88	0.44	4.07e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.3	0.56	5.99e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs2046867	0.818	rs62249875	chr3:72911858	G/A	cg25664220	chr3:72788482	NA	-0.62	-10.83	-0.51	1.27e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg06627628	chr2:24431161	ITSN2	0.82	12.21	0.56	1.33e-28	Asthma;
LUSC	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.02	0.31	4.65e-9	Corneal astigmatism;
LUSC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg16584290	chr5:462447	EXOC3	0.44	7.72	0.39	1.32e-13	Cystic fibrosis severity;
LUSC	cis	rs7119	0.651	rs12902072	chr15:77848732	T/C	cg27398640	chr15:77910606	LINGO1	-0.33	-6.79	-0.35	5.05e-11	Type 2 diabetes;
LUSC	cis	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg20936604	chr3:58311152	NA	-0.67	-6.63	-0.34	1.37e-10	Cholesterol, total;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05588757	chr2:95825608	ZNF514	-0.48	-5.97	-0.31	6.15e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg16512390	chr1:228756714	NA	0.73	9.66	0.47	1.25e-19	Chronic lymphocytic leukemia;
LUSC	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07636037	chr3:49044803	WDR6	-0.67	-8.63	-0.43	2.63e-16	Menarche (age at onset);
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg00767846	chr2:170655407	SSB	0.4	6.31	0.33	8.94e-10	Eotaxin levels;
LUSC	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-7.0	-0.36	1.44e-11	Blood metabolite levels;
LUSC	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.79	-0.47	4.54e-20	Total cholesterol levels;
LUSC	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.07	-0.44	1.06e-17	Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21724239	chr8:58056113	NA	0.79	9.06	0.44	1.13e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg22961513	chr11:14280813	SPON1	0.34	5.7	0.3	2.65e-8	Mitochondrial DNA levels;
LUSC	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.65	-8.23	-0.41	4.31e-15	Body mass index;
LUSC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg13206674	chr6:150067644	NUP43	0.62	9.97	0.48	1.16e-20	Lung cancer;
LUSC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs977987	0.815	rs11646677	chr16:75408981	T/C	cg04384234	chr16:75411784	CFDP1	-0.45	-7.44	-0.38	8.86e-13	Dupuytren's disease;
LUSC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg04315214	chr1:2043799	PRKCZ	0.4	8.09	0.4	1.15e-14	Height;
LUSC	cis	rs7799006	0.929	rs35791351	chr7:2269248	C/T	cg12823233	chr7:2316876	SNX8	-0.34	-5.89	-0.31	9.33e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.37	6.94	0.36	2.01e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg02018176	chr4:1364513	KIAA1530	0.51	8.83	0.44	5.97e-17	Obesity-related traits;
LUSC	cis	rs68170813	0.559	rs10953536	chr7:107021691	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.38	-0.46	1.02e-18	Coronary artery disease;
LUSC	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg09462578	chr12:12878428	APOLD1	-0.53	-6.53	-0.34	2.43e-10	Systemic lupus erythematosus;
LUSC	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00321850	chr1:175162397	KIAA0040	-0.45	-7.72	-0.39	1.39e-13	Alcohol dependence;
LUSC	trans	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.46	0.33	3.7e-10	Resting heart rate;
LUSC	cis	rs6489882	0.510	rs61478890	chr12:113364375	A/G	cg20102336	chr12:113376681	OAS3	-0.41	-5.89	-0.31	9.59e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs829883	0.724	rs11109507	chr12:98904160	C/T	cg25150519	chr12:98850993	NA	0.62	8.51	0.42	5.92e-16	Colorectal adenoma (advanced);
LUSC	cis	rs6700896	0.931	rs2889195	chr1:66156730	C/T	cg04111102	chr1:66153794	NA	0.32	7.14	0.36	6.01e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs68170813	0.641	rs75639044	chr7:107092631	A/C	cg02696742	chr7:106810147	HBP1	-0.66	-9.66	-0.47	1.21e-19	Coronary artery disease;
LUSC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg12560992	chr17:57184187	TRIM37	0.89	16.62	0.67	1.3e-45	Intelligence (multi-trait analysis);
LUSC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg20203395	chr5:56204925	C5orf35	-0.55	-7.69	-0.39	1.67e-13	Coronary artery disease;
LUSC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg00339695	chr16:24857497	SLC5A11	-0.58	-8.57	-0.42	3.84e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg15934090	chr1:100435551	SLC35A3	0.48	8.27	0.41	3.25e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg24503407	chr1:205819492	PM20D1	-0.47	-6.25	-0.32	1.22e-9	Menarche (age at onset);
LUSC	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg19743168	chr1:23544995	NA	0.45	9.82	0.47	3.57e-20	Height;
LUSC	trans	rs1982346	1.000	rs2544426	chr4:106717797	C/T	cg01484487	chr2:74726892	LBX2	-0.47	-5.95	-0.31	6.64e-9	Lung function (FEV1);
LUSC	cis	rs500891	0.693	rs767144	chr6:83976802	G/T	cg08257003	chr6:84140564	ME1	0.35	7.75	0.39	1.11e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs4629180	0.675	rs10184144	chr2:102104978	C/T	cg04415270	chr2:102091202	RFX8	-0.45	-7.88	-0.4	4.79e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7289126	0.868	rs2267377	chr22:38629519	T/C	cg25457927	chr22:38595422	NA	-0.29	-5.87	-0.31	1.04e-8	Mammographic density (dense area);Percent mammographic density;
LUSC	cis	rs72781680	0.821	rs12616257	chr2:24135034	A/G	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg27129171	chr3:47204927	SETD2	0.7	11.75	0.54	6.42e-27	Colorectal cancer;
LUSC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg24642844	chr7:1081250	C7orf50	-0.79	-10.39	-0.49	4.39e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs4691139	0.903	rs10434177	chr4:165915531	A/T	cg11630554	chr4:165878136	TRIM61;C4orf39	-0.5	-5.74	-0.3	2.09e-8	Ovarian cancer in BRCA1 mutation carriers;
LUSC	cis	rs11168618	0.904	rs7137866	chr12:48922802	T/C	cg24011408	chr12:48396354	COL2A1	0.4	6.43	0.33	4.29e-10	Adiponectin levels;
LUSC	cis	rs4704187	0.687	rs10035303	chr5:74505495	A/C	cg03227963	chr5:74354835	NA	0.3	6.64	0.34	1.24e-10	Response to amphetamines;
LUSC	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	1.09	15.83	0.65	1.75e-42	Uric acid levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10949322	chr10:35379230	CUL2	-0.4	-6.09	-0.32	3.13e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg03929089	chr4:120376271	NA	-0.52	-7.29	-0.37	2.32e-12	HDL cholesterol;
LUSC	cis	rs6845621	0.870	rs58618798	chr4:18905039	G/A	cg12196642	chr4:18937545	NA	-0.34	-6.46	-0.33	3.79e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg21361702	chr7:150065534	REPIN1	0.47	6.29	0.33	9.71e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs983392	0.679	rs10736701	chr11:60031476	C/T	cg24026212	chr11:59952134	MS4A6A	0.36	6.32	0.33	8.42e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7818345	0.967	rs7015440	chr8:19276991	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.37	7.12	0.36	6.47e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.57	9.07	0.44	1.03e-17	Lymphocyte counts;
LUSC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-6.19	-0.32	1.78e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg05791153	chr7:19748676	TWISTNB	0.77	8.29	0.41	2.82e-15	Thyroid stimulating hormone;
LUSC	trans	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.96	-0.36	1.85e-11	Myopia (pathological);
LUSC	cis	rs7173743	0.756	rs8035039	chr15:79129823	A/G	cg00540400	chr15:79124168	NA	0.36	6.36	0.33	6.71e-10	Coronary artery disease;
LUSC	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.73	10.97	0.51	3.98e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg20406979	chr6:167373233	NA	0.26	6.13	0.32	2.5e-9	Crohn's disease;
LUSC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.65	-8.41	-0.42	1.17e-15	Huntington's disease progression;
LUSC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	0.76	12.53	0.57	8.86e-30	Cognitive function;
LUSC	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg24375607	chr4:120327624	NA	0.53	8.09	0.4	1.11e-14	Diastolic blood pressure;
LUSC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg25894440	chr7:65020034	NA	0.39	6.17	0.32	1.94e-9	Calcium levels;
LUSC	trans	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.62	-10.11	-0.48	3.93e-21	Mean corpuscular volume;
LUSC	cis	rs17253792	0.915	rs76952651	chr14:56188994	G/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.14	-0.36	5.71e-12	Putamen volume;
LUSC	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg05347473	chr6:146136440	FBXO30	0.55	9.49	0.46	4.62e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg27170947	chr2:26402098	FAM59B	-0.65	-9.4	-0.46	9.24e-19	Gut microbiome composition (summer);
LUSC	cis	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg09307838	chr4:120376055	NA	0.46	6.9	0.35	2.54e-11	Corneal astigmatism;
LUSC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	7.93	0.4	3.34e-14	Renal cell carcinoma;
LUSC	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.73	-0.39	1.28e-13	Glomerular filtration rate;
LUSC	cis	rs4619890	0.528	rs62289336	chr4:7877661	T/C	cg24250820	chr4:7887609	AFAP1	0.36	6.15	0.32	2.17e-9	Glaucoma (primary open-angle);
LUSC	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14169450	chr9:139327907	INPP5E	0.45	8.06	0.4	1.33e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg00049323	chr5:472564	LOC25845	-0.43	-6.71	-0.34	8.18e-11	Cystic fibrosis severity;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12287025	chr11:44087605	ACCS	-0.39	-5.96	-0.31	6.35e-9	Electrocardiographic conduction measures;
LUSC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08859206	chr1:53392774	SCP2	-0.54	-9.67	-0.47	1.17e-19	Monocyte count;
LUSC	cis	rs977987	0.966	rs8055490	chr16:75497135	C/T	cg04384234	chr16:75411784	CFDP1	-0.49	-8.14	-0.41	7.8e-15	Dupuytren's disease;
LUSC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.47	-0.38	7.12e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.78	-10.45	-0.5	2.75e-22	Initial pursuit acceleration;
LUSC	trans	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg18187862	chr3:45730750	SACM1L	-0.55	-7.01	-0.36	1.29e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg22431228	chr1:16359049	CLCNKA	0.4	8.4	0.42	1.33e-15	Systolic blood pressure;
LUSC	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg25214090	chr10:38739885	LOC399744	0.5	7.39	0.37	1.19e-12	Corneal astigmatism;
LUSC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg07741184	chr6:167504864	NA	0.39	6.88	0.35	2.9e-11	Primary biliary cholangitis;
LUSC	cis	rs12618769	0.652	rs72823794	chr2:99216593	T/A	cg10123293	chr2:99228465	UNC50	0.47	7.6	0.38	2.98e-13	Bipolar disorder;
LUSC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg13206674	chr6:150067644	NUP43	0.62	10.05	0.48	6.38e-21	Lung cancer;
LUSC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.7	10.85	0.51	1.04e-23	Aortic root size;
LUSC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg02475777	chr4:1388615	CRIPAK	-0.4	-6.1	-0.32	3.01e-9	Obesity-related traits;
LUSC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.33	-0.49	7.12e-22	Platelet count;
LUSC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	19.1	0.72	1.79e-55	Chronic sinus infection;
LUSC	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-22.83	-0.78	3.76e-70	Ulcerative colitis;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01585723	chr16:33734837	NA	0.45	7.7	0.39	1.6e-13	Menopause (age at onset);
LUSC	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.23	-0.45	3.12e-18	Monocyte percentage of white cells;
LUSC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.94	0.31	7.17e-9	Menopause (age at onset);
LUSC	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-17.61	-0.69	1.4e-49	Primary sclerosing cholangitis;
LUSC	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg13775593	chr10:823151	NA	-0.3	-6.15	-0.32	2.17e-9	Uric acid levels;
LUSC	cis	rs12681287	0.517	rs13249753	chr8:87513216	A/G	cg27223183	chr8:87520930	FAM82B	-0.57	-7.6	-0.38	2.99e-13	Caudate activity during reward;
LUSC	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg09904177	chr6:26538194	HMGN4	-0.74	-6.95	-0.36	1.9e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg20243544	chr17:37824526	PNMT	0.43	6.48	0.33	3.25e-10	Self-reported allergy;
LUSC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg25456477	chr12:86230367	RASSF9	-0.39	-7.02	-0.36	1.27e-11	Major depressive disorder;
LUSC	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.3	6.13	0.32	2.45e-9	Schizophrenia;
LUSC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg19748678	chr4:122722346	EXOSC9	0.48	7.47	0.38	7.05e-13	Type 2 diabetes;
LUSC	cis	rs136211	0.640	rs9306310	chr22:36758258	G/A	cg16924664	chr22:36878180	TXN2	0.4	5.98	0.31	5.62e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs4919087	0.923	rs11189037	chr10:98974707	C/G	cg25902810	chr10:99078978	FRAT1	0.46	6.58	0.34	1.84e-10	Monocyte count;
LUSC	cis	rs2607426	0.681	rs8109099	chr19:41282509	T/A	cg05508168	chr19:41255947	C19orf54;SNRPA	-0.9	-7.07	-0.36	9.1e-12	Blood protein levels;
LUSC	cis	rs3770081	1.000	rs2278087	chr2:86281946	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.84	-0.35	3.84e-11	Facial emotion recognition (sad faces);
LUSC	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg13010199	chr12:38710504	ALG10B	0.69	10.83	0.51	1.27e-23	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.7	11.87	0.54	2.29e-27	Motion sickness;
LUSC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg14019146	chr3:50243930	SLC38A3	-0.33	-7.35	-0.37	1.51e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.818	rs1048296	chr1:153012240	A/C	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg25174290	chr11:3078921	CARS	-0.59	-9.56	-0.46	2.67e-19	Longevity;
LUSC	cis	rs354225	0.553	rs7564719	chr2:54829731	A/C	cg01766943	chr2:54829624	SPTBN1	0.47	7.63	0.39	2.51e-13	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs600231	0.542	rs10896009	chr11:65246054	A/G	cg17120908	chr11:65337727	SSSCA1	0.68	9.53	0.46	3.39e-19	Bone mineral density;
LUSC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg05313129	chr8:58192883	C8orf71	-0.51	-5.79	-0.3	1.64e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs17029056	0.527	rs35490701	chr2:42158374	A/G	cg25815440	chr2:42134162	NA	0.33	6.69	0.34	9.35e-11	Breast cancer;
LUSC	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg27432699	chr2:27873401	GPN1	0.8	15.0	0.63	3.04e-39	Oral cavity cancer;
LUSC	cis	rs3741151	0.656	rs73550316	chr11:73299799	G/A	cg17517138	chr11:73019481	ARHGEF17	0.93	8.08	0.4	1.19e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs4285028	0.948	rs12637351	chr3:121694412	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.72	9.33	0.45	1.57e-18	Multiple sclerosis;
LUSC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05792022	chr13:41239732	FOXO1	0.48	7.25	0.37	2.99e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.85	-14.02	-0.61	1.89e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg02466173	chr16:30829666	NA	-0.6	-11.24	-0.52	4.47e-25	Multiple myeloma;
LUSC	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17916960	chr15:79447300	NA	-0.53	-10.67	-0.5	4.59e-23	Refractive error;
LUSC	cis	rs7605827	0.836	rs13019322	chr2:15511270	G/A	cg19274914	chr2:15703543	NA	0.46	8.95	0.44	2.45e-17	Educational attainment (years of education);
LUSC	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg23711669	chr6:146136114	FBXO30	0.84	15.07	0.64	1.66e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg14196790	chr5:131705035	SLC22A5	0.48	8.18	0.41	6.2e-15	Blood metabolite levels;
LUSC	cis	rs4356932	1.000	rs4535358	chr4:76974409	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.83	0.3	1.33e-8	Blood protein levels;
LUSC	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg17252645	chr8:143867129	LY6D	0.38	6.68	0.34	1.01e-10	Urinary tract infection frequency;
LUSC	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg08847533	chr14:75593920	NEK9	0.5	7.21	0.37	3.87e-12	Caffeine consumption;
LUSC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg14004847	chr7:1930337	MAD1L1	-0.56	-8.57	-0.42	3.77e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg09876464	chr15:85330779	ZNF592	0.36	6.56	0.34	2.06e-10	P wave terminal force;
LUSC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.63	10.06	0.48	5.51e-21	Longevity;
LUSC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02187348	chr16:89574699	SPG7	-0.6	-9.98	-0.48	1.05e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg21770322	chr7:97807741	LMTK2	0.57	10.37	0.49	5.03e-22	Breast cancer;
LUSC	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg11584989	chr19:19387371	SF4	0.57	6.78	0.35	5.44e-11	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg03676636	chr4:99064102	C4orf37	0.37	8.1	0.4	1.08e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs10489202	1.000	rs34058770	chr1:168057399	C/A	cg24449463	chr1:168025552	DCAF6	-0.58	-7.13	-0.36	6.4e-12	Schizophrenia;
LUSC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg00049323	chr5:472564	LOC25845	-0.43	-6.71	-0.34	8.18e-11	Cystic fibrosis severity;
LUSC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg23093090	chr10:104574429	C10orf26	-0.38	-7.19	-0.37	4.16e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs308403	0.509	rs1849431	chr4:123674762	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.94	16.05	0.66	2.3e-43	Blood protein levels;
LUSC	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg14186256	chr22:23484241	RTDR1	0.94	17.06	0.68	2.19e-47	Bone mineral density;
LUSC	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg10857441	chr5:6722123	POLS	0.44	8.12	0.41	8.97e-15	Menopause (age at onset);
LUSC	cis	rs10189230	0.967	rs13026659	chr2:222353014	C/T	cg14652038	chr2:222343519	EPHA4	0.34	6.0	0.31	5.23e-9	Urate levels in lean individuals;
LUSC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg11632617	chr15:75315747	PPCDC	-0.5	-6.58	-0.34	1.86e-10	Blood trace element (Zn levels);
LUSC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg00677455	chr12:58241039	CTDSP2	0.61	8.48	0.42	7.56e-16	Multiple sclerosis;
LUSC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.37	0.62	8.94e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg08499158	chr17:42289980	UBTF	0.42	6.38	0.33	6.04e-10	Total body bone mineral density;
LUSC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg25811766	chr13:21894605	NA	0.63	7.78	0.39	9.04e-14	White matter hyperintensity burden;
LUSC	cis	rs2742234	0.541	rs7098236	chr10:43740508	T/C	cg02780029	chr10:43622663	RET	0.34	5.75	0.3	2.07e-8	Hirschsprung disease;
LUSC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.76	-0.35	6.32e-11	Platelet count;
LUSC	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg04545296	chr12:48745243	ZNF641	0.37	6.68	0.34	1.01e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg02574844	chr11:5959923	NA	-0.4	-5.76	-0.3	1.95e-8	DNA methylation (variation);
LUSC	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-6.22	-0.32	1.52e-9	Bipolar disorder;
LUSC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18404041	chr3:52824283	ITIH1	-0.61	-11.94	-0.55	1.36e-27	Bipolar disorder;
LUSC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19717773	chr7:2847554	GNA12	-0.39	-6.07	-0.31	3.57e-9	Height;
LUSC	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg08132940	chr7:1081526	C7orf50	-0.48	-5.97	-0.31	6.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg22852734	chr6:133119734	C6orf192	1.17	14.03	0.61	1.8e-35	Type 2 diabetes nephropathy;
LUSC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg22618164	chr12:122356400	WDR66	0.6	8.97	0.44	2.13e-17	Mean corpuscular volume;
LUSC	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg12927641	chr6:109611667	NA	-0.35	-5.85	-0.3	1.19e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs722599	0.715	rs12147629	chr14:75307588	A/G	cg08847533	chr14:75593920	NEK9	-0.43	-6.07	-0.32	3.43e-9	IgG glycosylation;
LUSC	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg23093090	chr10:104574429	C10orf26	-0.4	-6.79	-0.35	5.05e-11	Arsenic metabolism;
LUSC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg11871910	chr12:69753446	YEATS4	0.82	14.42	0.62	5.7e-37	Blood protein levels;
LUSC	trans	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-6.79	-0.35	5.19e-11	Menarche (age at onset);
LUSC	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg13010199	chr12:38710504	ALG10B	-0.51	-7.66	-0.39	2.03e-13	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs295140	0.903	rs3820888	chr2:201180023	T/C	cg04283868	chr2:201171347	SPATS2L	0.41	6.15	0.32	2.27e-9	QT interval;
LUSC	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg09904177	chr6:26538194	HMGN4	0.73	13.26	0.59	1.51e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg17652424	chr22:38574118	PLA2G6	-0.31	-6.66	-0.34	1.1e-10	Cutaneous nevi;
LUSC	cis	rs8061121	0.706	rs8048835	chr16:87188551	A/T	cg10047845	chr16:87184939	NA	0.52	5.7	0.3	2.69e-8	Congenital left-sided heart lesions;
LUSC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.4	-5.83	-0.3	1.3e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg05147244	chr20:61493195	TCFL5	0.95	7.5	0.38	6e-13	Obesity-related traits;
LUSC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg00376283	chr12:123451042	ABCB9	0.7	9.84	0.47	3.03e-20	Neutrophil percentage of white cells;
LUSC	cis	rs6546537	0.571	rs4852274	chr2:69780637	G/A	cg10773587	chr2:69614142	GFPT1	-0.44	-6.92	-0.35	2.25e-11	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs4730250	0.707	rs257373	chr7:106798290	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.1	-0.45	8.66e-18	Osteoarthritis;
LUSC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg23711669	chr6:146136114	FBXO30	0.83	15.19	0.64	5.29e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	0.6	9.54	0.46	3.18e-19	Breast cancer;
LUSC	trans	rs7939886	0.920	rs17150038	chr11:55863414	A/T	cg03929089	chr4:120376271	NA	0.73	6.06	0.31	3.74e-9	Myopia (pathological);
LUSC	trans	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg25214090	chr10:38739885	LOC399744	0.49	7.07	0.36	8.92e-12	Corneal astigmatism;
LUSC	trans	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-9.0	-0.44	1.77e-17	Obesity-related traits;
LUSC	cis	rs1160297	0.585	rs12713230	chr2:53090138	A/G	cg07782112	chr2:53107842	NA	0.4	6.44	0.33	4.27e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs2224391	1.000	rs2753248	chr6:5262154	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.47	-6.72	-0.35	7.76e-11	Height;
LUSC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg01765077	chr12:122356316	WDR66	0.54	7.69	0.39	1.68e-13	Mean corpuscular volume;
LUSC	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg05425664	chr17:57184151	TRIM37	-0.46	-7.07	-0.36	9.25e-12	Testicular germ cell tumor;
LUSC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.27	-5.64	-0.3	3.54e-8	Lung cancer;
LUSC	cis	rs7923609	0.967	rs10761758	chr10:65172747	A/T	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.01e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg10911889	chr6:126070802	HEY2	0.44	6.67	0.34	1.06e-10	Brugada syndrome;
LUSC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg08270630	chr22:50330655	NA	-0.42	-6.25	-0.32	1.25e-9	Schizophrenia;
LUSC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg02951883	chr7:2050386	MAD1L1	-0.42	-7.2	-0.37	4.1e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.37	-0.53	1.57e-25	Mean corpuscular volume;
LUSC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.13	-0.32	2.42e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3947	1.000	rs709821	chr8:11702594	G/C	cg00262122	chr8:11665843	FDFT1	-0.47	-5.67	-0.3	3.08e-8	Blood protein levels;
LUSC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg00033643	chr7:134001901	SLC35B4	0.44	6.73	0.35	7.57e-11	Mean platelet volume;
LUSC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg22834771	chr12:69754056	YEATS4	-0.49	-7.33	-0.37	1.71e-12	Blood protein levels;
LUSC	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg24579218	chr15:68104479	NA	-0.39	-6.51	-0.34	2.7e-10	Restless legs syndrome;
LUSC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.18	0.41	5.91e-15	Height;
LUSC	trans	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg01620082	chr3:125678407	NA	-0.78	-6.87	-0.35	3.13e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26384229	chr12:38710491	ALG10B	0.88	15.21	0.64	4.78e-40	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.25	0.37	3e-12	Platelet count;
LUSC	cis	rs2070433	0.851	rs8129793	chr21:47925719	T/C	cg12379764	chr21:47803548	PCNT	0.69	9.11	0.45	7.74e-18	Lymphocyte counts;
LUSC	cis	rs6087990	0.806	rs6141814	chr20:31368960	C/A	cg13636640	chr20:31349939	DNMT3B	0.89	17.61	0.69	1.43e-49	Ulcerative colitis;
LUSC	cis	rs7215564	0.908	rs2316063	chr17:78663360	G/A	cg23238734	chr17:78661607	RPTOR	0.47	6.1	0.32	2.98e-9	Myopia (pathological);
LUSC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-1.04	-15.37	-0.64	1.09e-40	Initial pursuit acceleration;
LUSC	cis	rs870825	0.616	rs6552802	chr4:185620751	C/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs3768617	0.811	rs4350171	chr1:182982148	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.42	0.42	1.12e-15	Fuchs's corneal dystrophy;
LUSC	cis	rs7944735	0.508	rs4752877	chr11:47886165	C/A	cg20307385	chr11:47447363	PSMC3	-0.55	-5.67	-0.3	3.06e-8	Intraocular pressure;
LUSC	cis	rs8040855	0.627	rs1532776	chr15:85624614	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-5.92	-0.31	8.12e-9	Bulimia nervosa;
LUSC	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg13042288	chr15:90349979	ANPEP	-0.49	-6.82	-0.35	4.39e-11	Uric acid levels;
LUSC	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-0.83	-15.31	-0.64	1.87e-40	Longevity;
LUSC	trans	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg14791747	chr16:20752902	THUMPD1	-0.4	-6.14	-0.32	2.33e-9	Dental caries;
LUSC	cis	rs11650494	0.908	rs11658111	chr17:47383994	C/T	cg08112188	chr17:47440006	ZNF652	1.17	10.21	0.49	1.71e-21	Prostate cancer;
LUSC	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg06917634	chr15:78832804	PSMA4	-0.59	-7.25	-0.37	2.85e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.17e-20	Major depressive disorder;
LUSC	cis	rs10823500	0.545	rs7082562	chr10:71945684	A/G	cg26699283	chr10:71892715	AIFM2	-0.36	-5.7	-0.3	2.7e-8	Blood protein levels;
LUSC	cis	rs11264799	0.765	rs67070092	chr1:157622973	T/A	cg18268488	chr1:157545234	FCRL4	0.33	5.74	0.3	2.13e-8	IgA nephropathy;
LUSC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg00745463	chr17:30367425	LRRC37B	-0.79	-9.21	-0.45	3.67e-18	Hip circumference adjusted for BMI;
LUSC	trans	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.19	-0.32	1.73e-9	Bladder cancer;
LUSC	cis	rs6714710	0.603	rs7421146	chr2:98552271	G/C	cg26665480	chr2:98280029	ACTR1B	0.63	9.11	0.45	7.76e-18	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg03161606	chr19:29218774	NA	0.6	8.84	0.44	5.41e-17	Methadone dose in opioid dependence;
LUSC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.78	-0.35	5.6e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	1.22	16.53	0.67	2.92e-45	Eosinophil percentage of granulocytes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04000159	chr8:54755598	ATP6V1H	0.48	7.32	0.37	1.83e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg11645453	chr3:52864694	ITIH4	0.37	8.66	0.43	2.06e-16	Bipolar disorder;
LUSC	trans	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg26043149	chr18:55253948	FECH	0.49	7.24	0.37	3.02e-12	Bone mineral density;
LUSC	cis	rs1953600	0.870	rs1049550	chr10:81926702	G/A	cg00277334	chr10:82204260	NA	-0.44	-6.92	-0.35	2.36e-11	Sarcoidosis;
LUSC	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21659725	chr3:3221576	CRBN	0.62	10.21	0.49	1.78e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg09953122	chr20:23471693	CST8	0.65	5.92	0.31	8.07e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7527798	0.592	rs10863437	chr1:207817612	T/C	cg09232269	chr1:207846808	CR1L	-0.3	-6.38	-0.33	5.88e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg24375607	chr4:120327624	NA	0.76	12.17	0.55	1.85e-28	Corneal astigmatism;
LUSC	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg10596483	chr8:143751796	JRK	0.52	7.46	0.38	7.78e-13	Schizophrenia;
LUSC	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg25456477	chr12:86230367	RASSF9	0.4	6.91	0.35	2.45e-11	Major depressive disorder;
LUSC	cis	rs6545883	0.826	rs777590	chr2:61417145	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.68	-0.34	1.03e-10	Tuberculosis;
LUSC	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg01528321	chr10:82214614	TSPAN14	1.1	12.06	0.55	4.95e-28	Post bronchodilator FEV1;
LUSC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg26354017	chr1:205819088	PM20D1	0.45	7.09	0.36	8.18e-12	Menarche (age at onset);
LUSC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-6.29	-0.33	9.97e-10	Electroencephalogram traits;
LUSC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg22532475	chr10:104410764	TRIM8	0.25	6.05	0.31	3.85e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.51	0.53	4.93e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.39	-0.49	4.39e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-20.34	-0.74	2.17e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg20243544	chr17:37824526	PNMT	-0.46	-5.67	-0.3	3.1e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg15744005	chr10:104629667	AS3MT	-0.32	-6.19	-0.32	1.75e-9	Arsenic metabolism;
LUSC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	7.96	0.4	2.74e-14	Mood instability;
LUSC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	0.98	13.47	0.59	2.48e-33	Cisplatin-induced ototoxicity;
LUSC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg20887711	chr4:1340912	KIAA1530	0.41	6.26	0.32	1.18e-9	Obesity-related traits;
LUSC	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.78	13.51	0.59	1.7e-33	Metabolic syndrome;
LUSC	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.57	9.35	0.46	1.27e-18	Schizophrenia;
LUSC	cis	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg06521331	chr12:34319734	NA	-0.4	-6.81	-0.35	4.54e-11	Morning vs. evening chronotype;
LUSC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.69e-9	Aortic root size;
LUSC	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg25214090	chr10:38739885	LOC399744	-0.5	-7.71	-0.39	1.45e-13	Corneal astigmatism;
LUSC	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.29	-0.49	9.26e-22	Eye color traits;
LUSC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg18681998	chr4:17616180	MED28	0.84	15.51	0.65	3.01e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.83	0.3	1.34e-8	Breast cancer;
LUSC	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14019695	chr9:139328340	INPP5E	-0.5	-10.08	-0.48	5.05e-21	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg25214090	chr10:38739885	LOC399744	0.58	8.47	0.42	8.08e-16	Corneal astigmatism;
LUSC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg05025164	chr4:1340916	KIAA1530	0.46	7.06	0.36	9.77e-12	Obesity-related traits;
LUSC	cis	rs6700896	0.864	rs6588153	chr1:66092017	T/A	cg04111102	chr1:66153794	NA	0.32	7.01	0.36	1.29e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02453779	chr11:105948520	AASDHPPT;KBTBD3	-0.49	-6.19	-0.32	1.79e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	7.92	0.4	3.59e-14	Menarche (age at onset);
LUSC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.77	-0.43	9.28e-17	Uric acid levels;
LUSC	trans	rs6601327	0.518	rs13264850	chr8:9575331	A/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.29	-0.33	1e-9	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg16011800	chr17:1958478	HIC1	0.43	6.02	0.31	4.66e-9	Lymphocyte counts;Red cell distribution width;
LUSC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg18512352	chr11:47633146	NA	-0.47	-9.72	-0.47	7.72e-20	Subjective well-being;
LUSC	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	6.03	0.31	4.24e-9	Retinal vascular caliber;
LUSC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg06096015	chr1:231504339	EGLN1	0.56	9.98	0.48	1.07e-20	Hemoglobin concentration;
LUSC	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg08477640	chr19:41863820	B9D2	0.5	7.65	0.39	2.13e-13	Migraine;Coronary artery disease;
LUSC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.74	-0.35	6.96e-11	Monocyte count;
LUSC	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg24375607	chr4:120327624	NA	0.79	11.85	0.54	2.9e-27	Corneal astigmatism;
LUSC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08645402	chr16:4508243	NA	0.53	9.05	0.44	1.17e-17	Schizophrenia;
LUSC	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-0.98	-18.71	-0.72	6.21e-54	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7759001	0.857	rs10080569	chr6:27363076	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.67	0.3	3.1e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.48	-8.93	-0.44	2.94e-17	Urinary metabolites;
LUSC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.76	13.54	0.6	1.34e-33	Aortic root size;
LUSC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14829155	chr15:31115871	NA	-0.57	-7.9	-0.4	4e-14	Huntington's disease progression;
LUSC	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-8.97	-0.44	2.17e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg18230493	chr5:56204884	C5orf35	-0.6	-9.38	-0.46	1.03e-18	Coronary artery disease;
LUSC	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg14227996	chr4:17616232	MED28	0.82	7.87	0.4	4.98e-14	Opioid sensitivity;
LUSC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg14552801	chr7:65878734	NA	0.38	5.76	0.3	1.96e-8	Aortic root size;
LUSC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.7	10.83	0.51	1.22e-23	Aortic root size;
LUSC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg09359103	chr1:154839909	KCNN3	-0.7	-16.24	-0.66	4.09e-44	Prostate cancer;
LUSC	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.7	0.65	5.43e-42	Morning vs. evening chronotype;
LUSC	cis	rs6494488	0.500	rs72744734	chr15:65042312	C/A	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg03342759	chr3:160939853	NMD3	-0.49	-8.16	-0.41	6.68e-15	Morning vs. evening chronotype;
LUSC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg08213375	chr14:104286397	PPP1R13B	0.42	7.11	0.36	7.04e-12	Reticulocyte count;
LUSC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg08847533	chr14:75593920	NEK9	-0.84	-15.37	-0.64	1.1e-40	Height;
LUSC	cis	rs2742417	0.603	rs2742449	chr3:45764544	T/C	cg10512202	chr3:45649293	LIMD1	0.35	5.88	0.31	9.96e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs10740039	0.516	rs10740032	chr10:62322385	C/T	cg18175470	chr10:62150864	ANK3	-0.45	-6.89	-0.35	2.87e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.56	0.46	2.7e-19	Menarche (age at onset);
LUSC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg25767906	chr1:53392781	SCP2	-0.5	-9.11	-0.45	7.51e-18	Monocyte count;
LUSC	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg24375607	chr4:120327624	NA	0.76	11.19	0.52	6.99e-25	Corneal astigmatism;
LUSC	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03352830	chr11:487213	PTDSS2	0.68	8.54	0.42	4.67e-16	Body mass index;
LUSC	cis	rs34734847	0.787	rs7976497	chr12:121135467	T/C	cg27246729	chr12:121163418	ACADS	0.42	6.71	0.34	8.13e-11	Mean corpuscular volume;
LUSC	trans	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-12.35	-0.56	3.9e-29	Colorectal cancer;
LUSC	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.47	-6.36	-0.33	6.49e-10	Neutrophil percentage of white cells;
LUSC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg00677455	chr12:58241039	CTDSP2	0.61	8.57	0.42	3.9e-16	Multiple sclerosis;
LUSC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.39	6.15	0.32	2.2e-9	Electroencephalogram traits;
LUSC	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg13385521	chr17:29058706	SUZ12P	0.6	5.86	0.31	1.09e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18854424	chr1:2615690	NA	-0.5	-9.71	-0.47	8.48e-20	Ulcerative colitis;
LUSC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11645453	chr3:52864694	ITIH4	0.34	8.08	0.4	1.23e-14	Electroencephalogram traits;
LUSC	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg23093090	chr10:104574429	C10orf26	-0.36	-6.68	-0.34	1e-10	Arsenic metabolism;
LUSC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg09826364	chr7:158789723	NA	-0.38	-5.98	-0.31	5.83e-9	Facial morphology (factor 20);
LUSC	trans	rs7765175	0.598	rs1388219	chr6:113620699	C/T	cg03745386	chr12:29534188	ERGIC2	-0.38	-6.0	-0.31	5.24e-9	Coronary artery calcification;
LUSC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.43	0.5	3.23e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg25767906	chr1:53392781	SCP2	-0.62	-11.99	-0.55	8.4e-28	Monocyte count;
LUSC	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg03676636	chr4:99064102	C4orf37	0.3	6.11	0.32	2.75e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1476679	0.927	rs2405442	chr7:99971313	T/C	cg19116668	chr7:99932089	PMS2L1	0.44	7.82	0.39	6.95e-14	Alzheimer's disease (late onset);
LUSC	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.66	-9.06	-0.44	1.16e-17	Large artery stroke;
LUSC	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg07169764	chr2:136633963	MCM6	0.54	7.29	0.37	2.21e-12	Mosquito bite size;
LUSC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00166722	chr3:10149974	C3orf24	0.64	8.8	0.43	7.45e-17	Alzheimer's disease;
LUSC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.4	-0.33	5.3e-10	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.38	-0.33	5.91e-10	Mood instability;
LUSC	cis	rs16895831	0.519	rs4379287	chr6:42592486	T/C	cg10605015	chr6:42532144	UBR2	0.48	5.69	0.3	2.85e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg11019008	chr10:131425282	MGMT	0.41	5.91	0.31	8.46e-9	Response to temozolomide;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.49	-7.07	-0.36	8.9e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg00495681	chr13:53174319	NA	0.77	14.43	0.62	4.87e-37	Lewy body disease;
LUSC	cis	rs35883536	0.647	rs1855630	chr1:101039979	C/G	cg06223162	chr1:101003688	GPR88	-0.47	-8.88	-0.44	4.3e-17	Monocyte count;
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-8.03	-0.4	1.71e-14	Lymphocyte counts;
LUSC	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg11262906	chr1:85462892	MCOLN2	-0.73	-9.25	-0.45	2.68e-18	Serum sulfate level;
LUSC	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg07080220	chr10:102295463	HIF1AN	0.6	7.64	0.39	2.38e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg24675056	chr1:15929824	NA	0.43	7.6	0.38	3.02e-13	Systolic blood pressure;
LUSC	cis	rs612683	0.602	rs2030048	chr1:101006577	C/T	cg06223162	chr1:101003688	GPR88	-0.51	-9.5	-0.46	4.14e-19	Breast cancer;
LUSC	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg26597838	chr10:835615	NA	0.81	11.31	0.53	2.58e-25	Eosinophil percentage of granulocytes;
LUSC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.58	-9.18	-0.45	4.78e-18	Total body bone mineral density;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06434480	chr5:74632940	HMGCR	0.47	6.43	0.33	4.39e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg14829155	chr15:31115871	NA	0.45	6.27	0.32	1.09e-9	Huntington's disease progression;
LUSC	cis	rs4722585	0.533	rs3753097	chr7:26198207	A/G	cg07876897	chr7:26191696	NFE2L3	0.46	6.9	0.35	2.62e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUSC	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg24375607	chr4:120327624	NA	0.75	11.26	0.52	3.74e-25	Corneal astigmatism;
LUSC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.61	9.65	0.47	1.36e-19	Pulse pressure;
LUSC	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18252515	chr7:66147081	NA	-0.58	-7.98	-0.4	2.31e-14	Corneal structure;
LUSC	cis	rs1775715	0.769	rs2808102	chr10:32117749	A/T	cg18675610	chr10:32216311	ARHGAP12	0.31	6.58	0.34	1.8e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg02569458	chr12:86230093	RASSF9	0.55	9.21	0.45	3.79e-18	Major depressive disorder;
LUSC	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg07169764	chr2:136633963	MCM6	1.18	17.44	0.69	6.88e-49	Corneal structure;
LUSC	cis	rs2354432	0.607	rs6694347	chr1:146751140	T/C	cg25205988	chr1:146714368	CHD1L	-1.0	-9.35	-0.46	1.26e-18	Mitochondrial DNA levels;
LUSC	cis	rs2688419	0.545	rs6550719	chr3:23072185	C/G	cg00327796	chr3:23032191	NA	-0.42	-7.35	-0.37	1.53e-12	Type 2 diabetes;
LUSC	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.88	12.64	0.57	3.48e-30	Coronary artery disease;
LUSC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.68	-11.26	-0.52	3.79e-25	Cognitive function;
LUSC	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-1.11	-15.3	-0.64	1.99e-40	Hip circumference adjusted for BMI;
LUSC	cis	rs9296092	0.538	rs75652975	chr6:33516251	C/T	cg13560919	chr6:33536144	NA	-0.82	-15.66	-0.65	7.89e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg26668828	chr6:292823	DUSP22	-0.54	-8.18	-0.41	5.92e-15	Menopause (age at onset);
LUSC	cis	rs6060717	0.654	rs8122716	chr20:34607001	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-5.74	-0.3	2.16e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg05347473	chr6:146136440	FBXO30	0.54	9.25	0.45	2.77e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.64	10.53	0.5	1.45e-22	Height;
LUSC	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg23202291	chr11:1979235	NA	0.41	6.66	0.34	1.11e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg17376030	chr22:41985996	PMM1	-0.48	-5.9	-0.31	8.71e-9	Vitiligo;
LUSC	cis	rs9677476	0.863	rs12478335	chr2:232064967	C/A	cg07929768	chr2:232055508	NA	0.37	7.0	0.36	1.41e-11	Food antigen IgG levels;
LUSC	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-8.94	-0.44	2.75e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2004776	0.656	rs11122587	chr1:230867100	C/G	cg07502417	chr1:230849801	AGT	0.25	5.77	0.3	1.85e-8	Diastolic blood pressure;
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.67	-11.22	-0.52	5.24e-25	Longevity;Endometriosis;
LUSC	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg23625390	chr15:77176239	SCAPER	0.46	6.83	0.35	3.92e-11	Blood metabolite levels;
LUSC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.67	9.54	0.46	3.15e-19	Methadone dose in opioid dependence;
LUSC	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.16	-0.36	5.15e-12	Response to antipsychotic treatment;
LUSC	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg06937882	chr20:24974362	C20orf3	0.45	7.86	0.4	5.28e-14	Blood protein levels;
LUSC	cis	rs9650657	0.836	rs6601523	chr8:10635141	C/T	cg27411982	chr8:10470053	RP1L1	-0.36	-5.76	-0.3	1.96e-8	Neuroticism;
LUSC	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg06781209	chr11:61594997	FADS2	-0.42	-6.73	-0.35	7.29e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg16240275	chr20:61666158	NCRNA00029	0.41	9.08	0.45	9.54e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.79	0.3	1.6e-8	Breast cancer;
LUSC	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.58	0.38	3.44e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg13010199	chr12:38710504	ALG10B	0.46	6.49	0.33	3.11e-10	Morning vs. evening chronotype;
LUSC	cis	rs62027291	0.583	rs62027297	chr15:77281674	A/T	cg26408565	chr15:76604113	ETFA	0.44	5.96	0.31	6.45e-9	Plateletcrit;
LUSC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.67	0.54	1.23e-26	Hip circumference adjusted for BMI;
LUSC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg03188948	chr7:1209495	NA	0.66	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.77	-0.39	9.55e-14	Height;
LUSC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg24829409	chr8:58192753	C8orf71	-0.59	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	8.97	0.44	2.11e-17	Iron status biomarkers;
LUSC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg08676812	chr11:65308423	LTBP3	0.94	6.57	0.34	1.89e-10	Height;
LUSC	cis	rs12137294	0.866	rs1172156	chr1:205220087	C/T	cg00857998	chr1:205179979	DSTYK	0.4	5.86	0.31	1.13e-8	Red cell distribution width;
LUSC	cis	rs68170813	0.605	rs75659533	chr7:107134987	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.21	-0.45	3.77e-18	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.64	11.18	0.52	7.59e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7809950	1.000	rs2293658	chr7:107270567	C/T	cg23024343	chr7:107201750	COG5	-0.55	-8.84	-0.44	5.52e-17	Coronary artery disease;
LUSC	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg21918786	chr6:109611834	NA	-0.36	-6.19	-0.32	1.8e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg04414720	chr1:150670196	GOLPH3L	0.56	9.1	0.45	8.47e-18	Tonsillectomy;
LUSC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg01879757	chr17:41196368	BRCA1	-0.46	-7.0	-0.36	1.44e-11	Menopause (age at onset);
LUSC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.21	-13.94	-0.61	4.07e-35	Diabetic kidney disease;
LUSC	cis	rs1355223	0.573	rs7125773	chr11:34723573	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.55	-0.34	2.12e-10	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg10792982	chr14:105748885	BRF1	0.45	8.08	0.4	1.19e-14	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.33	0.53	2.1e-25	Mean corpuscular volume;
LUSC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg10792982	chr14:105748885	BRF1	0.52	9.42	0.46	7.45e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7113850	0.541	rs7107667	chr11:24224091	T/A	ch.11.24196551F	chr11:24239977	NA	1.0	8.93	0.44	2.94e-17	Bone fracture in osteoporosis;
LUSC	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs2652834	0.898	rs10162675	chr15:63370358	T/C	cg05507819	chr15:63340323	TPM1	-0.67	-8.06	-0.4	1.35e-14	HDL cholesterol;
LUSC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.76	10.84	0.51	1.13e-23	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.41	-0.33	4.97e-10	Uric acid levels;
LUSC	cis	rs71636778	0.543	rs17162330	chr1:27236212	A/G	cg12203394	chr1:27248618	NUDC	0.54	5.71	0.3	2.52e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-6.04	-0.31	4.03e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg18187862	chr3:45730750	SACM1L	0.54	7.06	0.36	9.6e-12	Primary sclerosing cholangitis;
LUSC	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg21433313	chr16:3507492	NAT15	0.79	9.94	0.48	1.41e-20	Tuberculosis;
LUSC	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	5.93	0.31	7.49e-9	Schizophrenia;
LUSC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.64	-10.12	-0.48	3.65e-21	Height;
LUSC	cis	rs6489882	0.867	rs7298184	chr12:113368249	C/A	cg20102336	chr12:113376681	OAS3	-0.42	-6.13	-0.32	2.44e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-7.97	-0.4	2.54e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg02569458	chr12:86230093	RASSF9	0.58	9.91	0.48	1.9e-20	Major depressive disorder;
LUSC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg18230493	chr5:56204884	C5orf35	0.64	10.66	0.5	5.13e-23	Initial pursuit acceleration;
LUSC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	0.88	12.29	0.56	7.03e-29	Vitiligo;
LUSC	cis	rs1044826	0.642	rs4683464	chr3:139196961	C/T	cg00490450	chr3:139108681	COPB2	0.46	6.99	0.36	1.5e-11	Obesity-related traits;
LUSC	trans	rs961253	0.556	rs6054140	chr20:6331643	A/G	cg17788362	chr6:86352627	SYNCRIP	0.41	5.98	0.31	5.82e-9	Colorectal cancer;
LUSC	cis	rs2742417	0.967	rs2742462	chr3:45774696	G/A	cg04837898	chr3:45731254	SACM1L	-0.38	-6.41	-0.33	4.88e-10	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.89	-0.31	9.46e-9	Tonsillectomy;
LUSC	cis	rs1775715	0.870	rs7095322	chr10:32248491	C/T	cg04359828	chr10:32216031	ARHGAP12	-0.39	-6.62	-0.34	1.45e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs11229555	0.645	rs11229459	chr11:58208025	G/A	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6500395	0.928	rs2080509	chr16:48690915	T/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg05738196	chr6:26577821	NA	-0.48	-7.06	-0.36	9.54e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg19678392	chr7:94953810	PON1	-0.35	-5.65	-0.3	3.36e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg02423579	chr7:2872169	GNA12	-0.4	-6.39	-0.33	5.45e-10	Height;
LUSC	cis	rs4654899	0.802	rs6685306	chr1:21219050	C/T	cg01072550	chr1:21505969	NA	-0.52	-7.59	-0.38	3.15e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg14004847	chr7:1930337	MAD1L1	-0.54	-8.12	-0.41	9.3e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg12473912	chr3:136751656	NA	0.38	6.83	0.35	3.97e-11	Neuroticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21611145	chr19:13261629	IER2;STX10	0.46	7.19	0.37	4.19e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1595825	0.732	rs77615390	chr2:198454790	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.36	-0.33	6.8e-10	Ulcerative colitis;
LUSC	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-7.47	-0.38	6.91e-13	Morning vs. evening chronotype;
LUSC	trans	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg14227996	chr4:17616232	MED28	0.57	6.4	0.33	5.22e-10	Opioid sensitivity;
LUSC	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg25237894	chr2:233734115	C2orf82	0.34	6.38	0.33	6.03e-10	Coronary artery disease;
LUSC	trans	rs1922233	0.891	rs28508157	chr4:92410988	C/T	cg24250684	chr1:219729030	NA	-0.33	-6.42	-0.33	4.69e-10	Gut microbiome composition (summer and winter);
LUSC	cis	rs25645	0.502	rs7207600	chr17:38091660	G/A	cg26162295	chr17:38119207	GSDMA	-0.29	-6.53	-0.34	2.43e-10	Myeloid white cell count;
LUSC	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg26384229	chr12:38710491	ALG10B	0.54	8.71	0.43	1.46e-16	Morning vs. evening chronotype;
LUSC	cis	rs55882075	0.690	rs12374485	chr5:179131395	G/C	cg14593053	chr5:179126677	CANX	0.49	7.88	0.4	4.7e-14	Monocyte percentage of white cells;
LUSC	cis	rs10761482	0.813	rs2061489	chr10:62103196	A/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.1	0.41	1.01e-14	Homoarginine levels;
LUSC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg21535247	chr6:8435926	SLC35B3	0.57	8.7	0.43	1.48e-16	Motion sickness;
LUSC	trans	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg20935933	chr6:143382018	AIG1	0.5	7.33	0.37	1.71e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6545883	0.791	rs2600665	chr2:61405795	G/T	cg15711740	chr2:61764176	XPO1	-0.4	-5.97	-0.31	6.2e-9	Tuberculosis;
LUSC	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg05501817	chr11:14380813	RRAS2	0.56	8.76	0.43	9.7e-17	Sense of smell;
LUSC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg14829155	chr15:31115871	NA	0.46	6.67	0.34	1.07e-10	Huntington's disease progression;
LUSC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.79	-12.42	-0.56	2.15e-29	Pancreatic cancer;
LUSC	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg00376283	chr12:123451042	ABCB9	0.64	8.15	0.41	7.56e-15	Neutrophil percentage of white cells;
LUSC	trans	rs9960767	0.803	rs10401120	chr18:53192498	A/G	cg26244646	chr17:59391924	BCAS3	-0.51	-6.16	-0.32	2.1e-9	Schizophrenia;
LUSC	cis	rs1775715	0.677	rs2808105	chr10:32110907	C/T	cg03015672	chr10:32216066	ARHGAP12	0.33	5.84	0.3	1.22e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs57590327	0.503	rs2372905	chr3:81504592	C/G	cg07356753	chr3:81810745	GBE1	0.44	5.85	0.31	1.15e-8	Extraversion;
LUSC	cis	rs9879311	0.966	rs6442165	chr3:10415108	A/C	cg08489410	chr3:10329245	GHRL;GHRLOS	0.44	7.06	0.36	9.55e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg11861562	chr11:117069780	TAGLN	0.34	6.59	0.34	1.75e-10	Blood protein levels;
LUSC	cis	rs939658	0.935	rs2204069	chr15:79449335	A/G	cg17916960	chr15:79447300	NA	0.49	9.95	0.48	1.39e-20	Refractive error;
LUSC	cis	rs2446066	0.799	rs76805893	chr12:53830119	G/C	cg20730629	chr12:53886622	MAP3K12	-0.42	-5.72	-0.3	2.4e-8	Red blood cell count;
LUSC	trans	rs1325195	0.537	rs1325194	chr1:179071918	G/T	cg11624085	chr17:8464688	MYH10	-0.44	-6.59	-0.34	1.71e-10	IgE grass sensitization;
LUSC	trans	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.71	-0.34	8.43e-11	Depression;
LUSC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg12560992	chr17:57184187	TRIM37	0.84	15.44	0.65	5.6e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11645453	chr3:52864694	ITIH4	0.33	7.83	0.39	6.46e-14	Electroencephalogram traits;
LUSC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg19230755	chr7:65878503	NA	-0.41	-5.75	-0.3	2e-8	Aortic root size;
LUSC	cis	rs4363385	0.747	rs1577964	chr1:152961784	C/A	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.31	-0.37	1.95e-12	Inflammatory skin disease;
LUSC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg22903657	chr4:1355424	KIAA1530	-0.36	-6.02	-0.31	4.68e-9	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg16482183	chr6:26056742	HIST1H1C	0.87	11.64	0.54	1.66e-26	Iron status biomarkers;
LUSC	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	5.85	0.31	1.14e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg06022373	chr22:39101656	GTPBP1	0.83	13.39	0.59	5.01e-33	Menopause (age at onset);
LUSC	cis	rs1152591	0.562	rs1262242	chr14:64653869	C/T	cg21174375	chr14:64681225	SYNE2	0.34	6.18	0.32	1.86e-9	Atrial fibrillation;
LUSC	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg05163923	chr11:71159392	DHCR7	0.74	10.98	0.52	3.66e-24	Vitamin D levels;
LUSC	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.44	-7.9	-0.4	4.05e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg04362960	chr10:104952993	NT5C2	0.58	9.07	0.44	1.03e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4499344	0.604	rs259245	chr19:33145106	A/G	cg22980127	chr19:33182716	NUDT19	-0.43	-6.28	-0.33	1.03e-9	Mean platelet volume;
LUSC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg14582100	chr15:45693742	SPATA5L1	0.54	9.23	0.45	3.18e-18	Homoarginine levels;
LUSC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg03929089	chr4:120376271	NA	-0.96	-16.62	-0.67	1.28e-45	Height;
LUSC	cis	rs17401966	0.522	rs912962	chr1:10348712	G/T	cg17425144	chr1:10567563	PEX14	0.34	6.17	0.32	2.01e-9	Hepatocellular carcinoma;
LUSC	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.42	-6.76	-0.35	6.16e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04267008	chr7:1944627	MAD1L1	0.42	6.11	0.32	2.7e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg05805236	chr11:65401703	PCNXL3	0.65	10.75	0.51	2.39e-23	Acne (severe);
LUSC	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg09469691	chr10:81107165	PPIF	0.58	8.77	0.43	9.21e-17	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18339838	chr7:108210215	THAP5;DNAJB9	-0.43	-6.28	-0.32	1.08e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg22166914	chr1:53195759	ZYG11B	0.54	8.83	0.43	6.21e-17	Monocyte count;
LUSC	cis	rs80130819	0.748	rs2932095	chr12:48658212	C/T	cg24011408	chr12:48396354	COL2A1	0.46	5.84	0.3	1.22e-8	Prostate cancer;
LUSC	cis	rs1577917	0.839	rs12216103	chr6:86571128	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.29	-0.33	9.98e-10	Response to antipsychotic treatment;
LUSC	cis	rs62400317	0.686	rs860741	chr6:44808435	G/A	cg18551225	chr6:44695536	NA	0.45	7.49	0.38	6.39e-13	Total body bone mineral density;
LUSC	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg22601191	chr20:60968625	CABLES2	0.55	9.38	0.46	1.03e-18	Colorectal cancer;
LUSC	cis	rs939658	1.000	rs17175798	chr15:79463960	A/G	cg17916960	chr15:79447300	NA	0.51	10.28	0.49	9.81e-22	Refractive error;
LUSC	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg14917874	chr2:235941519	SH3BP4	-0.54	-8.55	-0.42	4.56e-16	Dialysis-related mortality;
LUSC	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg04374321	chr14:90722782	PSMC1	0.76	12.13	0.55	2.61e-28	Mortality in heart failure;
LUSC	cis	rs2688608	0.933	rs2633307	chr10:75653881	G/A	cg17411546	chr10:75410026	SYNPO2L	-0.46	-6.84	-0.35	3.89e-11	Inflammatory bowel disease;
LUSC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26314531	chr2:26401878	FAM59B	-0.66	-9.12	-0.45	7.39e-18	Gut microbiome composition (summer);
LUSC	cis	rs7246967	0.673	rs55684269	chr19:22924547	C/T	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.04e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs3750965	0.959	rs4930265	chr11:68855954	A/G	cg06818126	chr11:68850279	TPCN2	-0.44	-6.58	-0.34	1.86e-10	Hair color;
LUSC	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.95	-10.77	-0.51	2.08e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs870825	0.616	rs28450662	chr4:185638900	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	13.74	0.6	2.31e-34	Blood protein levels;
LUSC	cis	rs6987853	0.933	rs2974341	chr8:42398302	T/A	cg09913449	chr8:42400586	C8orf40	0.49	8.26	0.41	3.35e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.89	0.6	6.36e-35	Cognitive test performance;
LUSC	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.69	10.41	0.49	3.68e-22	Corneal astigmatism;
LUSC	cis	rs3947	0.813	rs1293316	chr8:11690915	A/G	cg00262122	chr8:11665843	FDFT1	-0.48	-5.87	-0.31	1.04e-8	Blood protein levels;
LUSC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg04166393	chr7:2884313	GNA12	0.45	5.98	0.31	5.82e-9	Height;
LUSC	trans	rs1146849	0.671	rs1254236	chr13:72879259	C/T	cg00555393	chr10:15077929	NA	0.33	6.07	0.32	3.43e-9	Facial emotion recognition (sad faces);
LUSC	cis	rs9308433	0.569	rs1353718	chr1:214459652	A/T	cg06198575	chr1:214491504	SMYD2	0.44	6.75	0.35	6.57e-11	IgG glycosylation;
LUSC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg21573476	chr21:45109991	RRP1B	-0.36	-5.79	-0.3	1.6e-8	Mean corpuscular volume;
LUSC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg02569458	chr12:86230093	RASSF9	0.57	9.75	0.47	6.49e-20	Major depressive disorder;
LUSC	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg16230307	chr14:35515116	FAM177A1	0.78	9.88	0.48	2.39e-20	Psoriasis;
LUSC	cis	rs6754311	0.593	rs6755383	chr2:136416941	C/T	cg07169764	chr2:136633963	MCM6	0.57	7.47	0.38	6.93e-13	Mosquito bite size;
LUSC	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg07828340	chr4:882639	GAK	0.42	5.78	0.3	1.76e-8	Systemic sclerosis;
LUSC	trans	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.29	0.37	2.26e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.73	11.41	0.53	1.14e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9807989	0.524	rs7591246	chr2:102999403	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.27e-12	Asthma;
LUSC	trans	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg02030672	chr11:45687055	CHST1	0.45	6.74	0.35	6.89e-11	Obesity-related traits;
LUSC	cis	rs6967385	0.583	rs7811925	chr7:12351245	C/T	cg20607287	chr7:12443886	VWDE	0.4	5.95	0.31	6.72e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg02176678	chr2:219576539	TTLL4	-0.58	-10.17	-0.49	2.38e-21	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg26513180	chr16:89883248	FANCA	0.9	17.58	0.69	1.92e-49	Vitiligo;
LUSC	cis	rs3741798	1.000	rs61922027	chr12:12486444	C/T	cg08615371	chr12:12503544	MANSC1	1.07	10.76	0.51	2.28e-23	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg06238570	chr21:40685208	BRWD1	-0.63	-11.0	-0.52	3.14e-24	Cognitive function;
LUSC	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg02176678	chr2:219576539	TTLL4	0.54	9.63	0.47	1.56e-19	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9800506	0.584	rs2011361	chr6:35524394	T/A	cg03566752	chr6:35512600	NA	0.34	7.71	0.39	1.42e-13	Neutrophil percentage of granulocytes;
LUSC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.86	-14.36	-0.62	9.24e-37	Schizophrenia;
LUSC	cis	rs67072384	0.901	rs11235586	chr11:72476025	C/G	cg04827223	chr11:72435913	ARAP1	-0.77	-5.84	-0.3	1.24e-8	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg24375607	chr4:120327624	NA	0.75	11.48	0.53	6.19e-26	Corneal astigmatism;
LUSC	cis	rs243505	1.000	rs243512	chr7:148430062	C/T	cg09806900	chr7:148480153	CUL1	-0.49	-6.94	-0.35	2.06e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.91	15.31	0.64	1.88e-40	Bladder cancer;
LUSC	trans	rs2562456	0.833	rs55920089	chr19:21520693	A/T	cg00806126	chr19:22604979	ZNF98	-0.43	-6.15	-0.32	2.25e-9	Pain;
LUSC	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg16797656	chr11:68205561	LRP5	0.37	6.14	0.32	2.34e-9	Total body bone mineral density;
LUSC	cis	rs1950626	0.833	rs12892225	chr14:101415413	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.44	0.38	8.76e-13	Pelvic organ prolapse (moderate/severe);
LUSC	trans	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg14227996	chr4:17616232	MED28	-0.55	-6.25	-0.32	1.23e-9	Opioid sensitivity;
LUSC	cis	rs62209	0.752	rs11256941	chr10:11017020	G/T	cg26901096	chr10:10994189	LOC254312	0.39	6.16	0.32	2.1e-9	Alzheimer's disease (late onset);
LUSC	cis	rs977987	0.806	rs6564252	chr16:75388940	C/T	cg03315344	chr16:75512273	CHST6	0.51	9.65	0.47	1.31e-19	Dupuytren's disease;
LUSC	cis	rs6565180	1.000	rs11862806	chr16:30364071	A/G	cg17640201	chr16:30407289	ZNF48	-0.87	-15.42	-0.64	6.95e-41	Tonsillectomy;
LUSC	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.37	-5.66	-0.3	3.23e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9322817	0.691	rs2486141	chr6:105299930	G/A	cg02098413	chr6:105308735	HACE1	0.27	5.68	0.3	2.95e-8	Thyroid stimulating hormone;
LUSC	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg15571903	chr15:79123663	NA	0.34	6.19	0.32	1.81e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs6563842	0.563	rs9603786	chr13:41316364	G/A	cg21288729	chr13:41239152	FOXO1	0.52	7.71	0.39	1.42e-13	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUSC	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg23544223	chr18:12777786	NA	-0.59	-6.11	-0.32	2.77e-9	Inflammatory skin disease;
LUSC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg10018233	chr7:150070692	REPIN1	-0.36	-6.38	-0.33	5.95e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg14440974	chr22:39074834	NA	-0.4	-6.62	-0.34	1.46e-10	Menopause (age at onset);
LUSC	cis	rs13202913	0.779	rs9383896	chr6:151768495	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	5.67	0.3	3.12e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg11062466	chr8:58055876	NA	0.58	8.25	0.41	3.76e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg05347473	chr6:146136440	FBXO30	-0.54	-9.27	-0.45	2.3e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	6.95	0.36	1.96e-11	Bipolar disorder;
LUSC	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg17279839	chr7:150038598	RARRES2	0.54	8.15	0.41	7.57e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs16854884	0.657	rs6440210	chr3:143705763	A/G	cg06585982	chr3:143692056	C3orf58	0.48	7.38	0.37	1.23e-12	Economic and political preferences (feminism/equality);
LUSC	cis	rs7616215	0.519	rs2133664	chr3:46101774	T/A	cg19145607	chr3:45983792	CXCR6;FYCO1	0.32	5.72	0.3	2.39e-8	Behcet's disease;
LUSC	cis	rs12681287	0.547	rs13261956	chr8:87478765	G/A	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.36	6.24e-12	Caudate activity during reward;
LUSC	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg11244672	chr19:19639970	YJEFN3	-0.55	-6.7	-0.34	9.01e-11	Bipolar disorder;
LUSC	cis	rs12530845	0.945	rs59664351	chr7:135314717	C/A	cg23117316	chr7:135346802	PL-5283	-0.57	-9.93	-0.48	1.61e-20	Red blood cell traits;
LUSC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg24733560	chr20:60626293	TAF4	0.4	6.45	0.33	3.98e-10	Body mass index;
LUSC	cis	rs11997175	0.546	rs11778519	chr8:33615873	G/A	ch.8.33884649F	chr8:33765107	NA	0.51	8.12	0.41	9.29e-15	Body mass index;
LUSC	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg27661571	chr11:113659931	NA	-0.57	-6.31	-0.33	8.73e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg08392591	chr16:89556376	ANKRD11	0.47	7.24	0.37	3.03e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.25	0.52	4.16e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg21699342	chr2:239360505	ASB1	-0.42	-6.05	-0.31	3.91e-9	Multiple system atrophy;
LUSC	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg09877947	chr5:131593287	PDLIM4	0.38	6.3	0.33	9.24e-10	Blood metabolite levels;
LUSC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg21361702	chr7:150065534	REPIN1	0.45	6.28	0.33	1.03e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-6.52	-0.34	2.6200000000000003e-10	Lung cancer;
LUSC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg13902645	chr11:5959945	NA	0.56	8.91	0.44	3.38e-17	DNA methylation (variation);
LUSC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg11608241	chr8:8085544	FLJ10661	-0.5	-7.18	-0.37	4.55e-12	Neuroticism;
LUSC	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg13010199	chr12:38710504	ALG10B	0.56	7.7	0.39	1.59e-13	Resting heart rate;
LUSC	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg23711669	chr6:146136114	FBXO30	0.82	14.38	0.62	8.11e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4499344	0.730	rs2868150	chr19:33098875	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	trans	rs9467603	0.925	rs3949215	chr6:25777497	A/T	cg06606381	chr12:133084897	FBRSL1	0.59	5.95	0.31	6.9e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4474465	0.850	rs10793322	chr11:78242615	T/C	cg27205649	chr11:78285834	NARS2	0.51	6.07	0.32	3.48e-9	Alzheimer's disease (survival time);
LUSC	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	12.1	0.55	3.51e-28	Electrocardiographic conduction measures;
LUSC	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg21466736	chr12:48725269	NA	-0.33	-5.73	-0.3	2.21e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg18132916	chr6:79620363	NA	-0.39	-5.92	-0.31	8.18e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7084921	0.533	rs12765091	chr10:101855231	G/C	cg02250046	chr10:101825185	CPN1	-0.34	-6.12	-0.32	2.63e-9	Bone mineral density;
LUSC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.95	0.4	2.88e-14	Electroencephalogram traits;
LUSC	cis	rs4964805	0.657	rs1866294	chr12:104186795	A/G	cg02344784	chr12:104178138	NT5DC3	0.46	8.81	0.43	6.71e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg23649088	chr2:200775458	C2orf69	0.49	6.71	0.34	8.6e-11	Schizophrenia;
LUSC	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg01851573	chr8:8652454	MFHAS1	0.53	8.45	0.42	8.97e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2414856	0.510	rs72757000	chr15:64613476	A/G	cg08069370	chr15:64387884	SNX1	-0.77	-6.56	-0.34	2.06e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg24558204	chr6:135376177	HBS1L	0.68	10.65	0.5	5.53e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.31	5.86	0.31	1.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg19046167	chr17:80928561	B3GNTL1	0.5	7.09	0.36	7.81e-12	Glycated hemoglobin levels;
LUSC	cis	rs7808935	0.768	rs757138	chr7:27989403	T/G	cg22168087	chr7:27702803	HIBADH	0.46	5.97	0.31	5.99e-9	Prostate cancer;
LUSC	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.65	0.3	3.35e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	6.01	0.31	4.84e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg02466173	chr16:30829666	NA	-0.6	-10.79	-0.51	1.73e-23	Multiple myeloma;
LUSC	cis	rs9837602	1.000	rs13064704	chr3:99767541	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.89	-0.31	9.61e-9	Breast cancer;
LUSC	trans	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.21	-0.32	1.62e-9	Monocyte count;
LUSC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.49	-0.33	3.04e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11060661	chr22:24314208	DDT;DDTL	0.41	6.81	0.35	4.49e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.64	0.39	2.29e-13	Prudent dietary pattern;
LUSC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-11.88	-0.54	2.19e-27	Body mass index;
LUSC	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.45	-6.41	-0.33	4.95e-10	Reticulocyte count;
LUSC	cis	rs7809950	0.798	rs10281535	chr7:107229618	T/G	cg23024343	chr7:107201750	COG5	0.55	8.62	0.43	2.68e-16	Coronary artery disease;
LUSC	cis	rs11208691	0.513	rs72480644	chr1:66159417	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	5.88	0.31	9.88e-9	Lymphocyte percentage of white cells;
LUSC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg00933542	chr6:150070202	PCMT1	0.31	6.52	0.34	2.67e-10	Lung cancer;
LUSC	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg22709100	chr7:91322751	NA	-0.4	-5.83	-0.3	1.3e-8	Breast cancer;
LUSC	cis	rs3820068	0.608	rs12734937	chr1:16047726	T/C	cg13390004	chr1:15929781	NA	0.41	6.59	0.34	1.73e-10	Systolic blood pressure;
LUSC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg12463550	chr7:65579703	CRCP	0.5	7.03	0.36	1.15e-11	Aortic root size;
LUSC	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg04865166	chr7:105162814	PUS7	0.52	5.92	0.31	7.79e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.86e-12	Blood metabolite levels;
LUSC	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.06	0.36	9.89e-12	Morning vs. evening chronotype;
LUSC	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg10978503	chr1:24200527	CNR2	0.47	10.89	0.51	7.57e-24	Immature fraction of reticulocytes;
LUSC	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg00105475	chr2:10696890	NA	0.37	6.09	0.32	3.03e-9	Prostate cancer;
LUSC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg06454157	chr6:167490870	NA	-0.28	-6.87	-0.35	3.1e-11	Primary biliary cholangitis;
LUSC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg16606324	chr3:10149918	C3orf24	0.59	7.88	0.4	4.61e-14	Alzheimer's disease;
LUSC	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg06219351	chr7:158114137	PTPRN2	-0.53	-9.67	-0.47	1.16e-19	Calcium levels;
LUSC	cis	rs6692729	0.931	rs2855562	chr1:227081850	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.45	-6.17	-0.32	1.97e-9	Electrodermal activity;
LUSC	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg27432699	chr2:27873401	GPN1	-0.88	-17.68	-0.7	8.07e-50	Oral cavity cancer;
LUSC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.14	0.36	5.83e-12	Major depressive disorder;
LUSC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.01	-0.4	2e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg07741184	chr6:167504864	NA	0.48	8.19	0.41	5.46e-15	Crohn's disease;
LUSC	cis	rs713477	0.524	rs4901560	chr14:55888533	C/T	cg13175173	chr14:55914753	NA	0.32	6.01	0.31	4.93e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg22777020	chr22:31556080	RNF185	-0.45	-5.79	-0.3	1.6e-8	Colorectal cancer;
LUSC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.7	-12.66	-0.57	2.88e-30	Aortic root size;
LUSC	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg03732007	chr1:2071316	PRKCZ	-0.5	-8.73	-0.43	1.23e-16	Height;
LUSC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00152838	chr16:24741724	TNRC6A	-0.46	-5.73	-0.3	2.2e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg00825309	chr19:58991885	ZNF446	-0.49	-7.07	-0.36	9.18e-12	Uric acid clearance;
LUSC	trans	rs979233	0.502	rs276240	chr5:42059928	A/G	cg07010552	chr17:7358735	CHRNB1	0.44	6.3	0.33	9.56e-10	Systemic lupus erythematosus;
LUSC	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.82	-0.3	1.41e-8	Bipolar disorder;
LUSC	cis	rs1775715	0.675	rs2808085	chr10:32148599	C/T	cg18675610	chr10:32216311	ARHGAP12	0.3	6.57	0.34	1.95e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs41271473	0.898	rs55730631	chr1:228865663	C/A	cg10167378	chr1:228756711	NA	0.58	6.96	0.36	1.77e-11	Chronic lymphocytic leukemia;
LUSC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg11871910	chr12:69753446	YEATS4	0.67	10.4	0.49	4.03e-22	Blood protein levels;
LUSC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg24503407	chr1:205819492	PM20D1	-0.54	-8.52	-0.42	5.6e-16	Menarche (age at onset);
LUSC	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg07828340	chr4:882639	GAK	0.96	9.8	0.47	4.19e-20	Parkinson's disease;
LUSC	cis	rs73206853	0.563	rs9706102	chr12:111185391	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	6.91	0.35	2.49e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7247513	0.797	rs3815914	chr19:12760664	T/C	cg01871581	chr19:12707946	ZNF490	-0.5	-7.35	-0.37	1.56e-12	Bipolar disorder;
LUSC	cis	rs16958440	0.867	rs2117373	chr18:44671834	C/T	cg17192377	chr18:44677553	HDHD2	0.67	7.08	0.36	8.51e-12	Sitting height ratio;
LUSC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg14552801	chr7:65878734	NA	0.38	5.94	0.31	7.28e-9	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15996282	chr5:36152109	LMBRD2;SKP2	-0.41	-5.96	-0.31	6.25e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs668210	0.793	rs1151514	chr11:65758854	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.59	7.82	0.39	6.97e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9462027	0.628	rs28675115	chr6:34732514	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.91	-0.31	8.62e-9	Systemic lupus erythematosus;
LUSC	cis	rs6700896	0.500	rs2186245	chr1:66118064	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	6.36	0.33	6.62e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08677398	chr8:58056175	NA	0.52	7.2	0.37	4.08e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.59	7.85	0.39	5.74e-14	High light scatter reticulocyte count;
LUSC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg00684032	chr4:1343700	KIAA1530	0.33	5.83	0.3	1.28e-8	Obesity-related traits;
LUSC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-6.24	-0.32	1.33e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6688613	0.545	rs10800270	chr1:166827602	A/T	cg07049167	chr1:166818506	POGK	0.55	7.83	0.39	6.55e-14	Refractive astigmatism;
LUSC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	0.88	16.45	0.67	5.83e-45	Gestational age at birth (maternal effect);
LUSC	cis	rs2299587	0.689	rs1847154	chr8:17780338	A/G	cg01800426	chr8:17659068	MTUS1	-0.43	-5.78	-0.3	1.7e-8	Economic and political preferences;
LUSC	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.53	8.18	0.41	6.18e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.8	-0.51	1.62e-23	Glomerular filtration rate;
LUSC	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.51	10.19	0.49	2e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg12463550	chr7:65579703	CRCP	0.48	7.2	0.37	4.03e-12	Aortic root size;
LUSC	cis	rs713587	0.935	rs4430895	chr2:25161386	C/T	cg04586622	chr2:25135609	ADCY3	0.32	6.45	0.33	4e-10	Body mass index in non-asthmatics;
LUSC	cis	rs231513	1.000	rs231499	chr17:41973507	C/T	cg26893861	chr17:41843967	DUSP3	0.52	6.19	0.32	1.72e-9	Cognitive function;
LUSC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21984481	chr17:79567631	NPLOC4	-0.57	-10.89	-0.51	7.97e-24	Eye color traits;
LUSC	cis	rs9462027	0.628	rs9469886	chr6:34758824	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.11e-8	Systemic lupus erythematosus;
LUSC	cis	rs1784581	0.588	rs9295179	chr6:162420546	G/A	cg17173639	chr6:162384350	PARK2	0.57	9.91	0.48	1.8e-20	Itch intensity from mosquito bite;
LUSC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg21433313	chr16:3507492	NAT15	0.65	10.97	0.51	4.16e-24	Tuberculosis;
LUSC	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg21862992	chr11:68658383	NA	-0.34	-5.72	-0.3	2.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12210905	0.688	rs114843651	chr6:27449611	A/G	cg08851530	chr6:28072375	NA	0.97	6.01	0.31	4.99e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.24	0.52	4.53e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.47	-7.04	-0.36	1.08e-11	Height;
LUSC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg24154853	chr7:158122151	PTPRN2	0.45	8.8	0.43	7.55e-17	Calcium levels;
LUSC	cis	rs12999616	0.817	rs35321033	chr2:98327812	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	6.05	0.31	3.91e-9	Colorectal cancer;
LUSC	cis	rs12900413	0.687	rs10152954	chr15:90307442	T/C	cg24249390	chr15:90295951	MESP1	-0.38	-6.0	-0.31	5e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.71	0.51	3.24e-23	Menopause (age at onset);
LUSC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg26304593	chr6:42947056	PEX6	-0.54	-8.49	-0.42	6.8e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21545522	chr1:205238299	TMCC2	0.5	9.36	0.46	1.21e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg13390004	chr1:15929781	NA	0.42	7.0	0.36	1.43e-11	Systolic blood pressure;
LUSC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08564027	chr20:61660810	NA	0.9	17.01	0.68	3.71e-47	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg04450456	chr4:17643702	FAM184B	0.35	5.8	0.3	1.56e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13089785	1.000	rs13071800	chr3:123626813	C/A	cg19611163	chr3:123411211	MYLK	0.34	5.77	0.3	1.84e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	7.19	0.37	4.39e-12	Platelet count;
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.9	17.74	0.7	4.53e-50	Menarche (age at onset);
LUSC	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.85	-0.35	3.55e-11	Response to antipsychotic treatment;
LUSC	trans	rs1486139	1.000	rs4464869	chr7:46284640	A/G	cg17534202	chr9:96721102	NA	-0.37	-6.5	-0.34	2.86e-10	Select biomarker traits;
LUSC	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-6.02	-0.31	4.63e-9	Fear of minor pain;
LUSC	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.21	0.32	1.58e-9	Total body bone mineral density;
LUSC	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.64	-0.34	1.24e-10	Response to antipsychotic treatment;
LUSC	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg03806693	chr22:41940476	POLR3H	-0.91	-12.72	-0.57	1.7e-30	Vitiligo;
LUSC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg02951883	chr7:2050386	MAD1L1	-0.46	-7.72	-0.39	1.39e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs1557765	0.527	rs2018218	chr11:17390855	A/G	cg15432903	chr11:17409602	KCNJ11	0.43	7.6	0.38	2.96e-13	Body mass index;Social communication problems;
LUSC	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg04691961	chr3:161091175	C3orf57	-0.35	-5.97	-0.31	6.09e-9	Morning vs. evening chronotype;
LUSC	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg23840854	chr1:161414152	NA	0.9	10.79	0.51	1.73e-23	Rheumatoid arthritis;
LUSC	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs12900413	0.687	rs62023459	chr15:90308231	A/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.87	-0.31	1.03e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs7582720	1.000	rs75166090	chr2:203692760	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.64	0.43	2.43e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg24578937	chr1:2090814	PRKCZ	-0.43	-9.55	-0.46	2.78e-19	Height;
LUSC	cis	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg21775007	chr8:11205619	TDH	-0.49	-7.26	-0.37	2.66e-12	Retinal vascular caliber;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg05131766	chr16:47495110	PHKB;ITFG1	0.4	6.24	0.32	1.33e-9	Educational attainment (years of education);
LUSC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg08742575	chr21:47604166	C21orf56	0.45	6.59	0.34	1.7e-10	Testicular germ cell tumor;
LUSC	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg02023728	chr11:77925099	USP35	0.46	6.97	0.36	1.71e-11	Testicular germ cell tumor;
LUSC	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg00579200	chr11:133705235	NA	-0.39	-5.86	-0.31	1.14e-8	Childhood ear infection;
LUSC	trans	rs7939886	0.920	rs11227212	chr11:55873334	A/G	cg03929089	chr4:120376271	NA	0.73	6.06	0.31	3.74e-9	Myopia (pathological);
LUSC	trans	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07923666	chr12:49932857	KCNH3	-0.52	-6.51	-0.34	2.74e-10	Resting heart rate;
LUSC	cis	rs12136530	0.774	rs10442642	chr1:19773818	A/G	cg01832549	chr1:19774989	CAPZB	-0.33	-5.92	-0.31	7.96e-9	Lead levels in blood;
LUSC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg12463550	chr7:65579703	CRCP	0.57	8.46	0.42	8.25e-16	Aortic root size;
LUSC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg00509249	chr6:109615579	CCDC162	-0.32	-5.85	-0.3	1.19e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg17211192	chr8:82754475	SNX16	-0.76	-10.05	-0.48	6.13e-21	Diastolic blood pressure;
LUSC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg06784218	chr1:46089804	CCDC17	0.55	11.08	0.52	1.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4474465	1.000	rs6592779	chr11:78197283	G/C	cg27205649	chr11:78285834	NARS2	-0.55	-6.3	-0.33	9.65e-10	Alzheimer's disease (survival time);
LUSC	cis	rs4919687	0.550	rs11191371	chr10:104459897	G/C	cg05855489	chr10:104503620	C10orf26	0.71	11.55	0.53	3.39e-26	Colorectal cancer;
LUSC	trans	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg07393940	chr7:158741817	NA	-0.51	-8.2	-0.41	5.11e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-15.47	-0.65	4.49e-41	Primary sclerosing cholangitis;
LUSC	cis	rs897984	0.568	rs4889651	chr16:30895545	C/T	cg02466173	chr16:30829666	NA	-0.51	-8.4	-0.42	1.32e-15	Dementia with Lewy bodies;
LUSC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.79	0.6	1.44e-34	Platelet count;
LUSC	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg20734569	chr3:48348370	SPINK8	-0.47	-7.9	-0.4	4.12e-14	Coronary artery disease;
LUSC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg02248941	chr16:2239361	CASKIN1	0.42	7.97	0.4	2.52e-14	Height;
LUSC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg03526776	chr6:41159608	TREML2	0.33	6.12	0.32	2.67e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7940866	0.874	rs7112616	chr11:130805334	T/C	cg12179176	chr11:130786555	SNX19	0.62	9.39	0.46	9.33e-19	Schizophrenia;
LUSC	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.31	0.41	2.49e-15	Homoarginine levels;
LUSC	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	7.66	0.39	2.06e-13	Retinal vascular caliber;
LUSC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg12412775	chr1:25698385	RHCE	-0.31	-6.4	-0.33	5.3e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs10186029	0.676	rs10804213	chr2:213964399	G/A	cg08319019	chr2:214017104	IKZF2	0.6	8.86	0.44	4.71e-17	Systemic sclerosis;
LUSC	cis	rs7712401	0.755	rs1545697	chr5:122102277	T/C	cg19077854	chr5:122220652	SNX24	0.35	7.8	0.39	7.8500000000000006e-14	Mean platelet volume;
LUSC	cis	rs2652822	0.967	rs4775633	chr15:63437746	G/A	cg02713581	chr15:63449717	RPS27L	0.42	6.63	0.34	1.36e-10	Metabolic traits;
LUSC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg01765077	chr12:122356316	WDR66	0.55	7.64	0.39	2.34e-13	Mean corpuscular volume;
LUSC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13770153	chr20:60521292	NA	-0.62	-8.39	-0.42	1.36e-15	Body mass index;
LUSC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg21535247	chr6:8435926	SLC35B3	0.58	9.01	0.44	1.65e-17	Motion sickness;
LUSC	cis	rs34638657	0.827	rs3829548	chr16:82206238	C/G	cg07918374	chr16:82182319	MPHOSPH6	-0.6	-6.07	-0.32	3.41e-9	Lung adenocarcinoma;
LUSC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg00310523	chr12:86230176	RASSF9	0.52	9.83	0.47	3.52e-20	Major depressive disorder;
LUSC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg06713675	chr4:122721982	EXOSC9	-0.72	-12.31	-0.56	5.85e-29	Type 2 diabetes;
LUSC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.49	0.5	1.95e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg26384229	chr12:38710491	ALG10B	-0.58	-9.22	-0.45	3.42e-18	Morning vs. evening chronotype;
LUSC	trans	rs1941687	0.797	rs6507071	chr18:31393333	C/T	cg27147174	chr7:100797783	AP1S1	-0.44	-6.41	-0.33	4.82e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.58	-7.2	-0.37	4.07e-12	Iron status biomarkers;
LUSC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.12e-18	Menopause (age at onset);
LUSC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.4	5.96	0.31	6.34e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	8.81	0.43	6.73e-17	Height;
LUSC	cis	rs2255336	0.748	rs60110638	chr12:10597311	A/T	cg16084090	chr12:10586130	KLRC2	-0.45	-5.8	-0.3	1.53e-8	Blood protein levels;
LUSC	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg22532475	chr10:104410764	TRIM8	-0.33	-7.32	-0.37	1.92e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9355610	0.609	rs7772112	chr6:167408896	G/A	cg23791538	chr6:167370224	RNASET2	0.44	6.15	0.32	2.2e-9	Graves' disease;
LUSC	cis	rs500891	0.645	rs1180188	chr6:83967295	A/T	cg08257003	chr6:84140564	ME1	0.3	6.7	0.34	8.8e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs6754311	0.593	rs10928542	chr2:136410299	G/A	cg07169764	chr2:136633963	MCM6	0.55	7.25	0.37	2.94e-12	Mosquito bite size;
LUSC	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg25828445	chr12:7781288	NA	0.62	6.59	0.34	1.67e-10	HDL cholesterol levels;
LUSC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg25174290	chr11:3078921	CARS	0.54	7.97	0.4	2.59e-14	Longevity;
LUSC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg06145435	chr7:1022769	CYP2W1	0.3	6.37	0.33	6.23e-10	Longevity;Endometriosis;
LUSC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3741151	0.686	rs7944346	chr11:73244230	C/T	cg17517138	chr11:73019481	ARHGEF17	0.79	7.52	0.38	5.1e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg00579200	chr11:133705235	NA	-0.39	-5.92	-0.31	8.19e-9	Childhood ear infection;
LUSC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg02475777	chr4:1388615	CRIPAK	0.44	6.5	0.34	2.92e-10	Obesity-related traits;
LUSC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08219700	chr8:58056026	NA	0.69	7.91	0.4	3.7e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs7939886	0.920	rs4612826	chr11:55948005	C/A	cg03929089	chr4:120376271	NA	0.82	6.22	0.32	1.53e-9	Myopia (pathological);
LUSC	cis	rs4664304	1.000	rs57771571	chr2:160767804	G/C	cg03641300	chr2:160917029	PLA2R1	-0.41	-6.78	-0.35	5.41e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg18132916	chr6:79620363	NA	-0.38	-5.81	-0.3	1.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6424115	0.545	rs11576333	chr1:24065770	C/T	cg15997130	chr1:24165203	NA	-0.45	-6.28	-0.33	1.04e-9	Immature fraction of reticulocytes;
LUSC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.83	0.3	1.31e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg06637938	chr14:75390232	RPS6KL1	0.53	8.62	0.43	2.76e-16	Height;
LUSC	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg23711669	chr6:146136114	FBXO30	0.88	16.36	0.67	1.34e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.2	-0.32	1.65e-9	Bipolar disorder;
LUSC	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.92	0.48	1.75e-20	Migraine;Coronary artery disease;
LUSC	trans	rs1532331	0.548	rs6894506	chr5:43169096	C/T	cg17870909	chr21:47566968	FTCD	0.25	5.96	0.31	6.28e-9	Menarche (age at onset);
LUSC	cis	rs56283067	0.887	rs62437973	chr6:44761978	G/A	cg18551225	chr6:44695536	NA	-0.48	-7.61	-0.38	2.8e-13	Total body bone mineral density;
LUSC	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg05738196	chr6:26577821	NA	-0.47	-6.12	-0.32	2.69e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.68	10.62	0.5	6.72e-23	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg00376283	chr12:123451042	ABCB9	0.69	9.81	0.47	3.82e-20	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg11062466	chr8:58055876	NA	0.66	8.57	0.42	3.86e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4654899	0.865	rs61779075	chr1:21417027	T/C	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.3	-0.33	9.29e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.38	-0.33	5.93e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.47	0.38	7.01e-13	Motion sickness;
LUSC	cis	rs73206853	0.620	rs73194035	chr12:111165793	A/G	cg12870014	chr12:110450643	ANKRD13A	0.82	6.97	0.36	1.67e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs11229555	0.645	rs11229427	chr11:58180275	A/C	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-6.65	-0.34	1.17e-10	Morning vs. evening chronotype;
LUSC	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21293242	chr8:11204541	TDH	0.34	6.3	0.33	9.19e-10	Retinal vascular caliber;
LUSC	cis	rs2708977	0.699	rs631746	chr2:97065499	A/G	cg01950434	chr2:97203154	ARID5A	-0.49	-6.64	-0.34	1.28e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg17971929	chr21:40555470	PSMG1	-0.47	-7.13	-0.36	6.12e-12	Menarche (age at onset);
LUSC	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg17294928	chr15:75287854	SCAMP5	-0.77	-8.86	-0.44	4.7e-17	Blood trace element (Zn levels);
LUSC	cis	rs2237234	0.580	rs7763910	chr6:26472655	C/T	cg09904177	chr6:26538194	HMGN4	-0.48	-7.46	-0.38	7.39e-13	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg13918937	chr19:4670319	C19orf10	0.42	6.67	0.34	1.03e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.87	-0.35	3.17e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg02380750	chr20:61661411	NA	0.34	5.93	0.31	7.57e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg24250549	chr1:154909240	PMVK	0.64	10.36	0.49	5.26e-22	Prostate cancer;
LUSC	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg16586182	chr3:47516702	SCAP	-0.52	-7.99	-0.4	2.18e-14	Colorectal cancer;
LUSC	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg26647111	chr11:31128758	NA	-0.42	-6.05	-0.31	3.81e-9	Red blood cell count;
LUSC	cis	rs1007190	0.764	rs758020	chr17:42872579	C/A	cg15406952	chr17:42872593	NA	-0.59	-6.13	-0.32	2.45e-9	DNA methylation (variation);
LUSC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06850241	chr22:41845214	NA	-0.31	-5.7	-0.3	2.7e-8	Vitiligo;
LUSC	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg20573242	chr4:122745356	CCNA2	-0.45	-6.74	-0.35	7.12e-11	Type 2 diabetes;
LUSC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.46	-6.82	-0.35	4.33e-11	Bipolar disorder;
LUSC	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg05941027	chr17:61774174	LIMD2	0.23	5.88	0.31	9.69e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg12751644	chr20:60527061	NA	-0.34	-6.18	-0.32	1.88e-9	Body mass index;
LUSC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.9	0.58	3.43e-31	Alzheimer's disease;
LUSC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.15	0.32	2.21e-9	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	9.87	0.48	2.52e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.64	-0.47	1.42e-19	Bone mineral density;
LUSC	cis	rs2710642	0.678	rs11125946	chr2:63298150	C/T	cg17519650	chr2:63277830	OTX1	-0.52	-7.19	-0.37	4.2e-12	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs9549260	0.753	rs2297628	chr13:41233905	T/C	cg21288729	chr13:41239152	FOXO1	0.56	6.29	0.33	9.83e-10	Red blood cell count;
LUSC	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.87	0.31	1.06e-8	Morning vs. evening chronotype;
LUSC	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.62	-0.47	1.63e-19	Neuroticism;
LUSC	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	0.88	13.15	0.58	4.22e-32	Obesity-related traits;
LUSC	cis	rs2398893	1.000	rs10993017	chr9:96760384	C/T	cg14459158	chr9:96720562	NA	-0.31	-5.96	-0.31	6.36e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.51	-0.34	2.79e-10	Bipolar disorder;
LUSC	trans	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg06521331	chr12:34319734	NA	-0.38	-5.95	-0.31	6.7e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg23950597	chr19:37808831	NA	-0.63	-7.53	-0.38	4.71e-13	Coronary artery calcification;
LUSC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg06740227	chr12:86229804	RASSF9	-0.44	-7.05	-0.36	1.02e-11	Major depressive disorder;
LUSC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	0.92	15.1	0.64	1.27e-39	Breast cancer;
LUSC	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg17810781	chr1:201082982	CACNA1S	0.31	5.92	0.31	7.79e-9	Permanent tooth development;
LUSC	cis	rs7937682	0.564	rs10891277	chr11:111373103	A/G	cg09085632	chr11:111637200	PPP2R1B	0.46	6.07	0.32	3.47e-9	Primary sclerosing cholangitis;
LUSC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg00074818	chr8:8560427	CLDN23	0.59	9.92	0.48	1.71e-20	Obesity-related traits;
LUSC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-1.12	-25.08	-0.81	8.21e-79	Height;
LUSC	cis	rs2540226	0.655	rs2716681	chr2:39932862	G/A	cg23576258	chr2:39999331	THUMPD2	0.35	5.84	0.3	1.21e-8	Personality dimensions;
LUSC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg06618935	chr21:46677482	NA	-0.39	-7.6	-0.38	3.05e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6733011	0.500	rs6755640	chr2:99445917	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.39	-0.33	5.55e-10	Bipolar disorder;
LUSC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03517284	chr6:25882590	NA	0.4	6.74	0.35	6.84e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg13393036	chr8:95962371	TP53INP1	-0.47	-9.69	-0.47	9.74e-20	Type 2 diabetes;
LUSC	cis	rs9811920	0.715	rs1017967	chr3:99905803	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.32	6.15	0.32	2.16e-9	Axial length;
LUSC	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07636037	chr3:49044803	WDR6	0.7	9.42	0.46	7.44e-19	Menarche (age at onset);
LUSC	trans	rs1015291	0.708	rs1586838	chr12:19998182	A/G	cg01501474	chr7:55323552	NA	-0.45	-5.97	-0.31	6.09e-9	Diastolic blood pressure;
LUSC	cis	rs7178572	1.000	rs12910361	chr15:77782335	A/G	cg22256960	chr15:77711686	NA	-0.55	-9.25	-0.45	2.74e-18	Type 2 diabetes;
LUSC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg22823121	chr1:150693482	HORMAD1	0.59	9.05	0.44	1.23e-17	Tonsillectomy;
LUSC	cis	rs6546550	0.713	rs6718517	chr2:70018462	T/C	cg02498382	chr2:70120550	SNRNP27	-0.26	-6.37	-0.33	6.2e-10	Prevalent atrial fibrillation;
LUSC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg02782426	chr3:40428986	ENTPD3	-0.35	-6.59	-0.34	1.7e-10	Renal cell carcinoma;
LUSC	cis	rs2200578	0.786	rs62158261	chr2:99563210	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.62	7.31	0.37	1.93e-12	IgG glycosylation;
LUSC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03576123	chr11:487126	PTDSS2	-0.96	-10.59	-0.5	8.69e-23	Body mass index;
LUSC	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.71	11.1	0.52	1.44e-24	Alcohol dependence;
LUSC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg08277548	chr1:17600880	PADI3	-0.62	-6.52	-0.34	2.56e-10	Hair shape;
LUSC	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg07741184	chr6:167504864	NA	0.51	8.73	0.43	1.2e-16	Crohn's disease;
LUSC	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg15423357	chr2:25149977	NA	0.45	9.13	0.45	6.59e-18	Body mass index;
LUSC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-10.09	-0.48	4.63e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs701145	0.938	rs355770	chr3:154040273	G/A	cg17054900	chr3:154042577	DHX36	0.83	8.63	0.43	2.47e-16	Coronary artery disease;
LUSC	cis	rs7681423	1.000	rs2066861	chr4:155527436	C/T	cg20735720	chr4:155535218	FGG	-0.46	-6.58	-0.34	1.84e-10	Fibrinogen;
LUSC	cis	rs2932538	0.961	rs6690292	chr1:113188419	C/T	cg22162597	chr1:113214053	CAPZA1	-0.52	-7.43	-0.38	9.27e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10900049	chr2:8849962	NA	0.4	5.96	0.31	6.55e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.61	-5.74	-0.3	2.09e-8	Narcolepsy;
LUSC	trans	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.27	0.32	1.09e-9	Corneal astigmatism;
LUSC	trans	rs1325195	0.520	rs2636288	chr1:179227845	T/C	cg11624085	chr17:8464688	MYH10	0.45	6.93	0.35	2.18e-11	IgE grass sensitization;
LUSC	cis	rs1975974	0.935	rs41361749	chr17:21732693	A/G	cg18423549	chr17:21743878	NA	0.54	8.23	0.41	4.2e-15	Psoriasis;
LUSC	cis	rs2230307	0.572	rs6677080	chr1:100633469	A/T	cg24955406	chr1:100503596	HIAT1	0.57	5.9	0.31	9.09e-9	Carotid intima media thickness;
LUSC	cis	rs6012953	0.845	rs968701	chr20:49195248	G/A	cg13958625	chr20:49123093	NA	-0.27	-5.97	-0.31	6.1e-9	Vitiligo;
LUSC	cis	rs7572644	0.766	rs56046821	chr2:28234701	T/A	cg27432699	chr2:27873401	GPN1	-0.52	-6.53	-0.34	2.44e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg02136620	chr5:178986620	RUFY1	0.38	5.86	0.31	1.13e-8	Lung cancer;
LUSC	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg17366294	chr4:99064904	C4orf37	0.52	9.2	0.45	3.87e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg08200582	chr11:442649	ANO9	-0.53	-6.0	-0.31	5.06e-9	Body mass index;
LUSC	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg24006582	chr15:45444508	DUOX1	-0.6	-8.77	-0.43	9.28e-17	Uric acid levels;
LUSC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg16434002	chr17:42200994	HDAC5	0.44	5.98	0.31	5.87e-9	Total body bone mineral density;
LUSC	cis	rs7605827	0.930	rs11691286	chr2:15558580	G/T	cg19274914	chr2:15703543	NA	0.46	8.92	0.44	3.15e-17	Educational attainment (years of education);
LUSC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.33	0.37	1.78e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-7.99	-0.4	2.26e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.7	10.95	0.51	4.71e-24	Aortic root size;
LUSC	cis	rs10992471	0.580	rs10992366	chr9:95317214	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.84	-0.35	3.73e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2637266	0.935	rs2579774	chr10:78402253	T/C	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.94e-13	Pulmonary function;
LUSC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg10018233	chr7:150070692	REPIN1	0.37	6.49	0.33	3.07e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg11812906	chr14:75593930	NEK9	-0.67	-11.56	-0.53	3.21e-26	Height;
LUSC	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs6845621	0.835	rs10005486	chr4:18935783	G/T	cg12196642	chr4:18937545	NA	-0.36	-6.76	-0.35	6.14e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.52	0.59	1.57e-33	Platelet count;
LUSC	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	1.15	9.62	0.47	1.72e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg06636001	chr8:8085503	FLJ10661	0.48	7.42	0.38	9.95e-13	Mood instability;
LUSC	cis	rs9581857	0.725	rs9319366	chr13:28017722	C/T	cg22138327	chr13:27999177	GTF3A	0.81	9.21	0.45	3.78e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg07169764	chr2:136633963	MCM6	-1.07	-15.97	-0.66	4.53e-43	Corneal structure;
LUSC	trans	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.47	-6.27	-0.32	1.13e-9	Corneal astigmatism;
LUSC	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg00376283	chr12:123451042	ABCB9	0.65	8.3	0.41	2.63e-15	Neutrophil percentage of white cells;
LUSC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.66	-9.44	-0.46	6.4e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.36e-8	Lung cancer;
LUSC	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg21775007	chr8:11205619	TDH	-0.47	-6.88	-0.35	3.05e-11	Neuroticism;
LUSC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs7508679	1.000	rs7508679	chr19:7222832	A/G	cg00428638	chr19:7224713	INSR	0.35	7.62	0.38	2.63e-13	Hypothyroidism;
LUSC	cis	rs58235267	0.656	rs13410889	chr2:63087778	T/C	cg17519650	chr2:63277830	OTX1	0.71	9.8	0.47	4.13e-20	Prostate-specific antigen levels (conditioned on lead SNPs);
LUSC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg17971929	chr21:40555470	PSMG1	-0.47	-7.13	-0.36	6.08e-12	Menarche (age at onset);
LUSC	trans	rs7939886	0.920	rs17150038	chr11:55863414	A/T	cg15704280	chr7:45808275	SEPT13	0.79	6.65	0.34	1.23e-10	Myopia (pathological);
LUSC	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-9.59	-0.46	2.05e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg25767906	chr1:53392781	SCP2	-0.58	-11.28	-0.53	3.33e-25	Monocyte count;
LUSC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03576123	chr11:487126	PTDSS2	-0.92	-10.35	-0.49	5.78e-22	Body mass index;
LUSC	cis	rs1788820	0.917	rs4800489	chr18:21125942	A/G	cg14672496	chr18:21087552	C18orf8	0.4	6.36	0.33	6.63e-10	Body mass index;
LUSC	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg26876637	chr1:152193138	HRNR	0.45	6.66	0.34	1.16e-10	Atopic dermatitis;
LUSC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg02951883	chr7:2050386	MAD1L1	0.37	6.26	0.32	1.15e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.31	6.25	0.32	1.25e-9	Schizophrenia;
LUSC	trans	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg13206674	chr6:150067644	NUP43	0.59	9.24	0.45	2.87e-18	Lung cancer;
LUSC	cis	rs4363385	0.776	rs1890284	chr1:152942190	G/A	cg07796016	chr1:152779584	LCE1C	-0.46	-6.4	-0.33	5.34e-10	Inflammatory skin disease;
LUSC	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.71	11.07	0.52	1.75e-24	Alcohol dependence;
LUSC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg07424592	chr7:64974309	NA	-0.69	-6.09	-0.32	3.03e-9	Diabetic kidney disease;
LUSC	trans	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg14227996	chr4:17616232	MED28	0.55	6.19	0.32	1.77e-9	Opioid sensitivity;
LUSC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.49	-6.44	-0.33	4.06e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg24631222	chr15:78858424	CHRNA5	0.62	8.76	0.43	1.01e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.16	0.61	5.72e-36	Platelet count;
LUSC	cis	rs6714710	0.603	rs11678591	chr2:98541001	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.43	0.42	1.04e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-0.56	-8.69	-0.43	1.63e-16	Breast cancer;
LUSC	cis	rs7428496	0.528	rs13066441	chr3:142239107	A/C	cg16271453	chr3:142027066	XRN1	-0.51	-8.95	-0.44	2.6e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs7605827	0.930	rs13024104	chr2:15603346	T/C	cg19274914	chr2:15703543	NA	0.47	9.14	0.45	6.12e-18	Educational attainment (years of education);
LUSC	cis	rs7202877	0.706	rs2059257	chr16:75396376	G/A	cg03315344	chr16:75512273	CHST6	0.43	6.35	0.33	7.12e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs16854884	0.632	rs34071449	chr3:143662861	C/T	cg06585982	chr3:143692056	C3orf58	0.47	7.24	0.37	3.11e-12	Economic and political preferences (feminism/equality);
LUSC	cis	rs7104764	0.507	rs7111364	chr11:258542	G/C	cg00562011	chr11:252351	PSMD13	-0.51	-6.64	-0.34	1.26e-10	Menarche (age at onset);
LUSC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg04398451	chr17:18023971	MYO15A	0.5	7.9	0.4	4.04e-14	Total body bone mineral density;
LUSC	cis	rs9420	0.925	rs78587207	chr11:57654991	T/G	cg02958346	chr11:57425731	CLP1	-0.45	-6.28	-0.33	1.04e-9	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.05	-0.31	3.89e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg13560548	chr3:10150139	C3orf24	0.48	6.6	0.34	1.6e-10	Alzheimer's disease;
LUSC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15541040	chr2:3486749	NA	-0.58	-8.92	-0.44	3.07e-17	Neurofibrillary tangles;
LUSC	cis	rs3770081	1.000	rs78646493	chr2:86283195	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.94	-6.99	-0.36	1.51e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.32	-0.41	2.27e-15	Lymphocyte counts;
LUSC	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.78	-10.94	-0.51	5.29e-24	Cognitive ability;
LUSC	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg21775007	chr8:11205619	TDH	0.82	13.75	0.6	2.2e-34	Retinal vascular caliber;
LUSC	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg17691542	chr6:26056736	HIST1H1C	0.4	5.95	0.31	6.7e-9	Schizophrenia;
LUSC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg12463550	chr7:65579703	CRCP	0.63	5.7	0.3	2.58e-8	Gout;
LUSC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg20203395	chr5:56204925	C5orf35	-0.55	-7.5	-0.38	5.88e-13	Type 2 diabetes;
LUSC	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg24687543	chr11:63912206	MACROD1	0.46	5.94	0.31	7.22e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.67	-0.34	1.08e-10	Monocyte percentage of white cells;
LUSC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00149659	chr3:10157352	C3orf10	0.92	12.88	0.58	4.25e-31	Alzheimer's disease;
LUSC	cis	rs7200543	0.583	rs4985149	chr16:15147338	A/T	cg03427771	chr16:15082598	PDXDC1	-0.41	-5.85	-0.31	1.15e-8	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	trans	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg06521331	chr12:34319734	NA	0.39	6.15	0.32	2.17e-9	Bladder cancer;
LUSC	cis	rs12681287	0.640	rs12679811	chr8:87465370	T/C	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08219700	chr8:58056026	NA	0.64	7.88	0.4	4.52e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2230307	0.536	rs687513	chr1:100598867	C/T	cg24955406	chr1:100503596	HIAT1	-0.64	-6.65	-0.34	1.22e-10	Carotid intima media thickness;
LUSC	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg10645314	chr2:3704589	ALLC	-0.51	-7.75	-0.39	1.14e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.4	5.75	0.3	2.04e-8	Lung cancer;
LUSC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.92	-13.66	-0.6	4.71e-34	Alzheimer's disease;
LUSC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.3	-0.45	1.86e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg11887960	chr12:57824829	NA	0.54	6.74	0.35	7.11e-11	Obesity-related traits;
LUSC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg21285383	chr16:89894308	SPIRE2	0.33	6.76	0.35	6.21e-11	Vitiligo;
LUSC	cis	rs7809950	0.834	rs3801946	chr7:107242995	T/A	cg23024343	chr7:107201750	COG5	0.57	9.02	0.44	1.54e-17	Coronary artery disease;
LUSC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg16405210	chr4:1374714	KIAA1530	-0.56	-8.68	-0.43	1.73e-16	Obesity-related traits;
LUSC	cis	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg02972257	chr16:68554789	NA	-0.5	-6.35	-0.33	7.04e-10	Ulcerative colitis;
LUSC	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg18357645	chr12:58087776	OS9	0.51	7.64	0.39	2.33e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.73	-0.3	2.24e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26314531	chr2:26401878	FAM59B	0.66	8.43	0.42	1.02e-15	Gut microbiome composition (summer);
LUSC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7215564	0.908	rs35071767	chr17:78652575	A/G	cg09596252	chr17:78655493	RPTOR	0.56	6.05	0.31	3.85e-9	Myopia (pathological);
LUSC	cis	rs3931020	0.657	rs10890142	chr1:75179129	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.46	5.76	0.3	1.91e-8	Resistin levels;
LUSC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.33	-0.49	7.12e-22	Platelet count;
LUSC	cis	rs2227564	0.620	rs11000787	chr10:75584383	T/C	cg23231163	chr10:75533350	FUT11	-0.43	-6.29	-0.33	1.02e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2742234	0.578	rs2742241	chr10:43625223	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.15	-0.36	5.38e-12	Hirschsprung disease;
LUSC	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18932078	chr1:2524107	MMEL1	0.32	7.08	0.36	8.45e-12	Ulcerative colitis;
LUSC	cis	rs9900062	1.000	rs9900062	chr17:62739574	G/A	cg02598441	chr17:62777298	LOC146880	-0.61	-6.64	-0.34	1.28e-10	QT interval;
LUSC	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg05347473	chr6:146136440	FBXO30	0.5	8.45	0.42	9.26e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg01420254	chr6:26195488	NA	0.66	7.31	0.37	2.05e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg18099408	chr3:52552593	STAB1	-0.36	-6.0	-0.31	5.16e-9	Electroencephalogram traits;
LUSC	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg03342759	chr3:160939853	NMD3	-0.48	-8.18	-0.41	5.8e-15	Morning vs. evening chronotype;
LUSC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg25456477	chr12:86230367	RASSF9	0.43	7.71	0.39	1.41e-13	Major depressive disorder;
LUSC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg17330251	chr7:94953956	PON1	-0.41	-6.63	-0.34	1.35e-10	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.16	0.36	5.07e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11612902	chr7:98476174	TRRAP	-0.5	-6.1	-0.32	2.93e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	15.73	0.65	4.3e-42	Platelet count;
LUSC	cis	rs36051895	0.623	rs6476952	chr9:5236924	T/C	cg02405213	chr9:5042618	JAK2	-0.58	-8.42	-0.42	1.12e-15	Pediatric autoimmune diseases;
LUSC	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.62	-0.57	4.01e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg02023728	chr11:77925099	USP35	0.44	6.64	0.34	1.3e-10	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-6.27	-0.32	1.09e-9	Lung cancer;
LUSC	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.35	-0.33	7.01e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.69	-0.34	9.63e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.15	0.32	2.22e-9	Corneal astigmatism;
LUSC	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg15997130	chr1:24165203	NA	0.52	8.62	0.43	2.63e-16	Immature fraction of reticulocytes;
LUSC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg27170947	chr2:26402098	FAM59B	0.71	11.01	0.52	2.92e-24	Gut microbiome composition (summer);
LUSC	trans	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	6.15	0.32	2.24e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3845702	0.736	rs9288045	chr2:180814194	G/A	cg01881094	chr2:180872142	CWC22	-1.06	-12.75	-0.57	1.27e-30	Schizophrenia;
LUSC	cis	rs2835872	0.828	rs2835836	chr21:38989187	A/C	cg20424643	chr21:39039972	KCNJ6	0.4	6.28	0.32	1.08e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.85	0.35	3.5e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg05855489	chr10:104503620	C10orf26	0.63	8.2	0.41	5.12e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs117352156	0.882	rs10826545	chr10:29236395	A/G	cg06394621	chr10:29236369	NA	0.43	5.76	0.3	1.87e-8	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs4704187	0.687	rs2335134	chr5:74478843	A/C	cg03227963	chr5:74354835	NA	0.29	6.43	0.33	4.38e-10	Response to amphetamines;
LUSC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	0.89	17.19	0.69	6.71e-48	Cognitive function;
LUSC	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.76	-0.43	9.87e-17	Response to antipsychotic treatment;
LUSC	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg08807101	chr21:30365312	RNF160	-0.51	-6.86	-0.35	3.36e-11	Cognitive test performance;
LUSC	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg02403541	chr12:121454288	C12orf43	-0.73	-11.19	-0.52	6.81e-25	Metabolic traits;LDL cholesterol;
LUSC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg10621924	chr7:39171070	POU6F2	0.5	7.81	0.39	7.37e-14	IgG glycosylation;
LUSC	cis	rs4588572	0.570	rs2362832	chr5:77795843	A/G	cg11547950	chr5:77652471	NA	-0.57	-8.12	-0.41	9.18e-15	Triglycerides;
LUSC	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.6	-8.28	-0.41	2.91e-15	Body mass index (adult);
LUSC	cis	rs13006833	0.668	rs291462	chr2:191181678	T/C	cg21644426	chr2:191273491	MFSD6	0.43	6.16	0.32	2.13e-9	Urinary metabolites;
LUSC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg12463550	chr7:65579703	CRCP	0.51	7.48	0.38	6.42e-13	Aortic root size;
LUSC	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.47	8.79	0.43	8.25e-17	Bone mineral density;
LUSC	cis	rs9900062	0.546	rs2676294	chr17:62710764	A/G	cg02598441	chr17:62777298	LOC146880	0.52	6.82	0.35	4.39e-11	QT interval;
LUSC	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.18e-10	Subjective well-being;
LUSC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-1.19	-12.67	-0.57	2.71e-30	Diabetic kidney disease;
LUSC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg26441486	chr22:50317300	CRELD2	0.52	7.95	0.4	2.85e-14	Schizophrenia;
LUSC	cis	rs701145	0.938	rs357504	chr3:153956857	A/C	cg17054900	chr3:154042577	DHX36	0.78	8.61	0.43	2.95e-16	Coronary artery disease;
LUSC	cis	rs6977660	0.714	rs10229108	chr7:19824253	G/A	cg05791153	chr7:19748676	TWISTNB	0.67	6.98	0.36	1.55e-11	Thyroid stimulating hormone;
LUSC	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg17366294	chr4:99064904	C4orf37	0.52	7.39	0.37	1.19e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg23791538	chr6:167370224	RNASET2	0.53	8.86	0.44	4.87e-17	Crohn's disease;
LUSC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg22638593	chr5:131593259	PDLIM4	-0.41	-5.82	-0.3	1.39e-8	Blood metabolite levels;
LUSC	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg00677455	chr12:58241039	CTDSP2	0.62	9.28	0.45	2.19e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs1493916	0.837	rs11876492	chr18:31413804	T/C	cg27147174	chr7:100797783	AP1S1	-0.57	-9.03	-0.44	1.37e-17	Life satisfaction;
LUSC	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.57	-11.8	-0.54	4.27e-27	Sense of smell;
LUSC	cis	rs17155006	0.746	rs402264	chr7:107748337	G/A	cg05962710	chr7:107745446	LAMB4	-0.36	-6.52	-0.34	2.57e-10	Pneumococcal bacteremia;
LUSC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.12	-0.32	2.62e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.74	-0.39	1.18e-13	Schizophrenia;
LUSC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21545522	chr1:205238299	TMCC2	0.5	9.48	0.46	4.76e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs12973672	0.812	rs10421504	chr19:35764701	C/G	cg12095397	chr19:35769544	USF2	0.44	6.67	0.34	1.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg21496419	chr19:44306685	LYPD5	0.32	6.72	0.34	8.08e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg16339924	chr4:17578868	LAP3	0.48	7.25	0.37	2.89e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg02423579	chr7:2872169	GNA12	-0.49	-7.0	-0.36	1.39e-11	Height;
LUSC	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs11264799	0.603	rs10489674	chr1:157566019	G/A	cg18268488	chr1:157545234	FCRL4	0.33	5.9	0.31	8.76e-9	IgA nephropathy;
LUSC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg18827107	chr12:86230957	RASSF9	0.46	6.96	0.36	1.86e-11	Major depressive disorder;
LUSC	trans	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg14791747	chr16:20752902	THUMPD1	-0.41	-5.96	-0.31	6.3e-9	Pancreatic cancer;
LUSC	trans	rs7939886	0.920	rs1481926	chr11:55973281	C/T	cg03929089	chr4:120376271	NA	0.82	6.07	0.32	3.41e-9	Myopia (pathological);
LUSC	cis	rs853679	0.527	rs9461443	chr6:28194629	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.81	-0.3	1.44e-8	Depression;
LUSC	cis	rs6688613	0.694	rs1476347	chr1:166815587	G/T	cg07049167	chr1:166818506	POGK	0.55	8.17	0.41	6.32e-15	Refractive astigmatism;
LUSC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg02931644	chr1:25747376	RHCE	0.32	5.89	0.31	9.58e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs7586879	0.828	rs4077677	chr2:25122798	G/C	cg01884057	chr2:25150051	NA	0.42	8.8	0.43	7.49e-17	Body mass index;
LUSC	cis	rs6690583	0.623	rs1371141	chr1:85455372	C/A	cg22153463	chr1:85462885	MCOLN2	0.61	5.91	0.31	8.56e-9	Serum sulfate level;
LUSC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26314531	chr2:26401878	FAM59B	-0.66	-9.12	-0.45	7.39e-18	Gut microbiome composition (summer);
LUSC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.6	0.46	2.01e-19	Mean platelet volume;
LUSC	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg18306943	chr3:40428807	ENTPD3	0.4	6.09	0.32	3.13e-9	Renal cell carcinoma;
LUSC	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg24110177	chr3:50126178	RBM5	-0.47	-7.58	-0.38	3.52e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs57046232	0.552	rs1571216	chr20:6316328	A/C	cg21095983	chr6:86352623	SYNCRIP	-0.51	-7.58	-0.38	3.38e-13	Colorectal cancer;
LUSC	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg06346307	chr22:19949965	COMT	-0.33	-6.69	-0.34	9.6e-11	Blood metabolite levels;
LUSC	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-6.17	-0.32	1.96e-9	Fear of minor pain;
LUSC	cis	rs12122100	0.696	rs12733095	chr1:146545741	C/T	cg03526459	chr1:146549940	NA	-0.41	-6.63	-0.34	1.38e-10	HIV-1 control;
LUSC	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg25801113	chr15:45476975	SHF	0.3	6.24	0.32	1.32e-9	Uric acid levels;
LUSC	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg15485101	chr11:133734466	NA	0.42	7.65	0.39	2.13e-13	Childhood ear infection;
LUSC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg05373962	chr22:49881684	NA	-0.43	-10.28	-0.49	1.04e-21	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg19640130	chr10:64028056	RTKN2	-0.4	-7.07	-0.36	9.11e-12	Rheumatoid arthritis;
LUSC	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-6.32	-0.33	8.47e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg11062466	chr8:58055876	NA	0.48	6.03	0.31	4.34e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02034447	chr16:89574710	SPG7	0.43	6.44	0.33	4.25e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs9905704	0.609	rs72828712	chr17:56897404	A/T	cg12560992	chr17:57184187	TRIM37	0.51	5.87	0.31	1.07e-8	Testicular germ cell tumor;
LUSC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg17264618	chr3:40429014	ENTPD3	0.37	7.54	0.38	4.56e-13	Renal cell carcinoma;
LUSC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-1.18	-13.0	-0.58	1.52e-31	Diabetic kidney disease;
LUSC	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg24011408	chr12:48396354	COL2A1	0.58	7.76	0.39	1.06e-13	Lung cancer;
LUSC	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.25	-0.45	2.79e-18	Acne (severe);
LUSC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg02475777	chr4:1388615	CRIPAK	0.44	6.73	0.35	7.29e-11	Longevity;
LUSC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20796294	chr1:220219430	EPRS	-0.53	-6.74	-0.35	7.16e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs2835872	0.965	rs857947	chr21:39008539	C/T	cg20424643	chr21:39039972	KCNJ6	-0.39	-6.03	-0.31	4.26e-9	Electroencephalographic traits in alcoholism;
LUSC	trans	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-6.88	-0.35	2.94e-11	Menarche (age at onset);
LUSC	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	0.9	14.1	0.61	9.62e-36	Bladder cancer;
LUSC	cis	rs4499344	0.633	rs166311	chr19:33161246	A/G	cg22980127	chr19:33182716	NUDT19	-0.43	-6.38	-0.33	5.77e-10	Mean platelet volume;
LUSC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.35	-5.68	-0.3	2.97e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7605827	0.930	rs10929365	chr2:15531626	G/A	cg19274914	chr2:15703543	NA	0.48	9.34	0.46	1.39e-18	Educational attainment (years of education);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04184946	chr16:53537260	AKTIP	0.5	6.76	0.35	6.02e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg13531842	chr10:38383804	ZNF37A	-0.45	-6.98	-0.36	1.57e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06656553	chr16:89960601	TCF25	-0.63	-5.7	-0.3	2.68e-8	Skin colour saturation;
LUSC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.42	-6.17	-0.32	1.97e-9	Corneal astigmatism;
LUSC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.28	-0.45	2.26e-18	Gut microbiome composition (summer);
LUSC	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg11879182	chr18:77439856	CTDP1	0.72	11.35	0.53	1.79e-25	Monocyte count;
LUSC	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg08601574	chr20:25228251	PYGB	0.43	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg02574844	chr11:5959923	NA	-0.44	-6.33	-0.33	7.94e-10	DNA methylation (variation);
LUSC	cis	rs6696846	0.515	rs11240364	chr1:205105917	C/G	cg00857998	chr1:205179979	DSTYK	0.47	6.6	0.34	1.57e-10	Red blood cell count;
LUSC	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	0.89	13.13	0.58	5.06e-32	Obesity-related traits;
LUSC	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg21770322	chr7:97807741	LMTK2	0.56	10.25	0.49	1.34e-21	Prostate cancer (SNP x SNP interaction);Prostate cancer;
LUSC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.92	11.69	0.54	1.1e-26	Menarche (age at onset);
LUSC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.34	-0.67	1.59e-44	Height;
LUSC	cis	rs9359856	0.623	rs1179907	chr6:90324849	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.83	-10.41	-0.49	3.79e-22	Bipolar disorder;
LUSC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	15.03	0.64	2.39e-39	Platelet count;
LUSC	cis	rs11608355	1.000	rs11611370	chr12:109870291	A/G	cg19025524	chr12:109796872	NA	0.36	5.68	0.3	2.87e-8	Neuroticism;
LUSC	cis	rs6076065	0.548	rs1112818	chr20:23323936	G/A	cg11657817	chr20:23433608	CST11	0.49	9.75	0.47	6.21e-20	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg13770153	chr20:60521292	NA	-0.68	-9.51	-0.46	3.81e-19	Body mass index;
LUSC	cis	rs12493885	0.818	rs73158491	chr3:153764112	T/C	cg17054900	chr3:154042577	DHX36	-0.75	-7.65	-0.39	2.18e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-0.93	-16.1	-0.66	1.45e-43	Height;
LUSC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg00933542	chr6:150070202	PCMT1	0.3	6.0	0.31	5.27e-9	Lung cancer;
LUSC	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg13010344	chr12:123464640	ARL6IP4	0.48	7.82	0.39	7.01e-14	Platelet count;
LUSC	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg01629716	chr15:45996671	NA	0.4	5.98	0.31	5.77e-9	Waist circumference;Weight;
LUSC	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.69e-9	Response to antipsychotic treatment;
LUSC	cis	rs644148	0.785	rs118112019	chr19:44965091	T/G	cg15540054	chr19:45004280	ZNF180	0.46	6.25	0.32	1.27e-9	Personality dimensions;
LUSC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.71	-0.34	8.11e-11	Total body bone mineral density;
LUSC	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg19773385	chr1:10388646	KIF1B	-0.57	-9.74	-0.47	6.71e-20	Hepatocellular carcinoma;
LUSC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg11584989	chr19:19387371	SF4	0.51	6.5	0.34	2.94e-10	Tonsillectomy;
LUSC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg06784218	chr1:46089804	CCDC17	0.53	11.03	0.52	2.54e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg11189052	chr15:85197271	WDR73	0.5	6.43	0.33	4.31e-10	Schizophrenia;
LUSC	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg13813247	chr22:41461852	NA	-0.38	-6.79	-0.35	5.18e-11	Neuroticism;
LUSC	cis	rs10779751	0.960	rs1883965	chr1:11322156	A/G	cg08854313	chr1:11322531	MTOR	0.85	14.39	0.62	7.28e-37	Body mass index;
LUSC	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.31	-0.33	8.73e-10	Resting heart rate;
LUSC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg15839431	chr19:19639596	YJEFN3	0.41	5.89	0.31	9.23e-9	Tonsillectomy;
LUSC	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg27284194	chr4:1044797	NA	0.59	8.26	0.41	3.55e-15	Recombination rate (females);
LUSC	cis	rs17255340	0.511	rs6930990	chr6:84066749	A/C	cg08257003	chr6:84140564	ME1	0.35	8.62	0.43	2.66e-16	Platelet-derived growth factor BB levels;
LUSC	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.96	-0.68	5.59e-47	Exhaled nitric oxide output;
LUSC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19346786	chr7:2764209	NA	-0.48	-8.02	-0.4	1.84e-14	Height;
LUSC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-10.42	-0.5	3.26e-22	Monocyte count;
LUSC	cis	rs7572644	0.699	rs1902966	chr2:28189280	G/A	cg27432699	chr2:27873401	GPN1	-0.51	-6.95	-0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.48	-7.57	-0.38	3.57e-13	Alzheimer's disease (late onset);
LUSC	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.36e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24763869	chr17:3572311	TMEM93;TAX1BP3	0.47	6.98	0.36	1.56e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg23262073	chr20:60523788	NA	-0.36	-5.66	-0.3	3.25e-8	Body mass index;
LUSC	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.49	-8.94	-0.44	2.71e-17	Eosinophil percentage of white cells;
LUSC	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg24558204	chr6:135376177	HBS1L	0.66	9.89	0.48	2.06e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.43e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.72	-6.72	-0.35	7.85e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg06917634	chr15:78832804	PSMA4	-0.57	-7.11	-0.36	6.98e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs10432489	0.708	rs4436925	chr2:181755933	T/C	cg25678491	chr13:101327172	TMTC4	-0.77	-6.03	-0.31	4.41e-9	QT interval;
LUSC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg21862992	chr11:68658383	NA	0.51	8.13	0.41	8.56e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.58	-0.34	1.82e-10	Bladder cancer;
LUSC	cis	rs6496044	0.568	rs6496065	chr15:86075372	C/T	cg13263323	chr15:86062960	AKAP13	-0.37	-6.16	-0.32	2.06e-9	Interstitial lung disease;
LUSC	cis	rs10761482	0.769	rs4948403	chr10:62107662	A/T	cg18175470	chr10:62150864	ANK3	-0.51	-7.24	-0.37	3.06e-12	Schizophrenia;
LUSC	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	12.09	0.55	3.72e-28	Ileal carcinoids;
LUSC	trans	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg01620082	chr3:125678407	NA	-0.87	-7.55	-0.38	4.28e-13	Depression;
LUSC	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg21770322	chr7:97807741	LMTK2	0.47	8.03	0.4	1.65e-14	Breast cancer;
LUSC	cis	rs1577917	0.958	rs1816937	chr6:86557251	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg22834771	chr12:69754056	YEATS4	-0.41	-5.79	-0.3	1.6e-8	Blood protein levels;
LUSC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.8	10.5	0.5	1.74e-22	Schizophrenia;
LUSC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.92	0.51	6.12e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg09904177	chr6:26538194	HMGN4	0.67	11.34	0.53	2.01e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.45	0.38	8.3e-13	Bipolar disorder;
LUSC	cis	rs7572644	0.760	rs10190494	chr2:28131243	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-7.01	-0.36	1.33e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg15485101	chr11:133734466	NA	0.35	6.3	0.33	9.3e-10	Childhood ear infection;
LUSC	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg00784671	chr22:46762841	CELSR1	-0.63	-7.02	-0.36	1.27e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg16576083	chr14:105354267	KIAA0284	-0.52	-9.06	-0.44	1.13e-17	IgG glycosylation;
LUSC	cis	rs2067615	0.579	rs10861667	chr12:107194776	T/G	cg15890332	chr12:107067104	RFX4	0.36	6.57	0.34	1.89e-10	Heart rate;
LUSC	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg09491104	chr22:46646882	C22orf40	-0.7	-7.46	-0.38	7.57e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4499344	0.730	rs259286	chr19:33164759	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	13.37	0.59	5.94e-33	Mean platelet volume;
LUSC	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.68	10.38	0.49	4.51e-22	Smoking initiation;
LUSC	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg22508957	chr16:3507546	NAT15	0.84	10.81	0.51	1.45e-23	Tuberculosis;
LUSC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg17507749	chr15:85114479	UBE2QP1	0.68	8.58	0.42	3.61e-16	Schizophrenia;
LUSC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.73	0.54	7.69e-27	Alzheimer's disease;
LUSC	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.76	-14.57	-0.62	1.45e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg14154082	chr13:112174009	NA	0.38	7.88	0.4	4.53e-14	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.28	0.53	3.25e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg26335602	chr6:28129616	ZNF389	0.42	5.7	0.3	2.63e-8	Depression;
LUSC	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-9.69	-0.47	1e-19	Hemoglobin concentration;
LUSC	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	15.22	0.64	4.09e-40	Lymphocyte percentage of white cells;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg24341944	chr3:157827791	RSRC1	0.35	6.49	0.33	3.11e-10	Tuberculosis;
LUSC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.82	0.3	1.36e-8	Menopause (age at onset);
LUSC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg21724239	chr8:58056113	NA	0.55	6.55	0.34	2.19e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11039100	0.850	rs11039168	chr11:5844723	C/A	cg13902645	chr11:5959945	NA	-0.54	-5.99	-0.31	5.41e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg01416388	chr22:39784598	NA	-0.46	-7.59	-0.38	3.28e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg20090143	chr19:45452003	APOC2	0.49	9.61	0.47	1.85e-19	Blood protein levels;
LUSC	cis	rs1385374	0.858	rs10847696	chr12:129297153	G/A	cg09035930	chr12:129282057	SLC15A4	-0.62	-6.87	-0.35	3.22e-11	Systemic lupus erythematosus;
LUSC	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg01119278	chr6:110721349	DDO	0.48	8.66	0.43	1.99e-16	Platelet distribution width;
LUSC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg04727924	chr7:799746	HEATR2	-0.56	-6.66	-0.34	1.15e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg24675658	chr1:53192096	ZYG11B	-0.53	-8.33	-0.41	2.14e-15	Monocyte count;
LUSC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg07870213	chr5:140052090	DND1	-0.78	-11.61	-0.54	2.04e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg03732007	chr1:2071316	PRKCZ	-0.53	-9.47	-0.46	5.17e-19	Height;
LUSC	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg08079166	chr15:68083412	MAP2K5	0.36	6.06	0.31	3.68e-9	Obesity;
LUSC	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg15028160	chr19:49622717	PPFIA3;C19orf73	0.43	6.18	0.32	1.87e-9	Platelet distribution width;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06876710	chr8:26148870	PPP2R2A	0.77	6.38	0.33	5.84e-10	Cognitive performance;
LUSC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.58	10.76	0.51	2.21e-23	Bone mineral density;
LUSC	cis	rs4629710	0.592	rs67399092	chr6:131582936	G/A	cg12700074	chr6:131571435	AKAP7	-0.34	-5.67	-0.3	3.15e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg11494091	chr17:61959527	GH2	0.39	6.63	0.34	1.38e-10	Height;
LUSC	cis	rs71403859	0.667	rs12924650	chr16:71705908	C/T	cg08717414	chr16:71523259	ZNF19	-0.66	-7.49	-0.38	6.23e-13	Post bronchodilator FEV1;
LUSC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg09455208	chr3:40491958	NA	0.58	10.23	0.49	1.51e-21	Renal cell carcinoma;
LUSC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.37	5.67	0.3	3.05e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.73	0.54	7.94e-27	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7615316	0.934	rs7634158	chr3:142227902	T/C	cg16271453	chr3:142027066	XRN1	-0.4	-6.87	-0.35	3.22e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19717773	chr7:2847554	GNA12	-0.35	-5.66	-0.3	3.23e-8	Height;
LUSC	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg00383909	chr3:49044727	WDR6	1.14	10.32	0.49	7.24e-22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	8.53	0.42	5.16e-16	Motion sickness;
LUSC	cis	rs117352156	0.943	rs10826544	chr10:29234961	C/A	cg06394621	chr10:29236369	NA	-0.44	-5.68	-0.3	2.94e-8	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg06547715	chr2:218990976	CXCR2	0.33	6.5	0.33	3e-10	Ulcerative colitis;
LUSC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg15704280	chr7:45808275	SEPT13	-0.98	-15.8	-0.65	2.19e-42	Height;
LUSC	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8099014	1.000	rs11152073	chr18:56108266	A/T	cg12907477	chr18:56117327	MIR122	0.44	7.17	0.37	5.01e-12	Platelet count;
LUSC	cis	rs117352156	0.943	rs17760150	chr10:29213844	A/G	cg06394621	chr10:29236369	NA	-0.48	-6.44	-0.33	4.06e-10	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg16325326	chr1:53192061	ZYG11B	0.97	18.99	0.72	4.69e-55	Monocyte count;
LUSC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.41	-0.33	4.96e-10	Life satisfaction;
LUSC	cis	rs12220238	0.908	rs73284278	chr10:76011751	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.61	6.77	0.35	5.65e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.05	-0.44	1.22e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7202877	0.610	rs1010631	chr16:75328590	C/G	cg03315344	chr16:75512273	CHST6	0.4	5.84	0.3	1.21e-8	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.55	-0.38	4.27e-13	Hemoglobin concentration;
LUSC	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg04455712	chr21:45112962	RRP1B	0.48	9.01	0.44	1.6e-17	Mean corpuscular volume;
LUSC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg07507251	chr3:52567010	NT5DC2	0.36	7.23	0.37	3.31e-12	Bipolar disorder;
LUSC	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg09179987	chr1:167433047	CD247	0.36	5.9	0.31	8.84e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.45	-0.33	3.91e-10	Fear of minor pain;
LUSC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08439880	chr3:133502540	NA	-0.33	-5.91	-0.31	8.39e-9	Iron status biomarkers;
LUSC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg03146154	chr1:46216737	IPP	0.52	7.79	0.39	8.3e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3750965	0.806	rs7107680	chr11:68859894	C/T	cg06818126	chr11:68850279	TPCN2	-0.45	-6.63	-0.34	1.32e-10	Hair color;
LUSC	cis	rs2901656	0.629	rs10752946	chr1:172376632	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.36	7.29	0.37	2.31e-12	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg14440974	chr22:39074834	NA	-0.37	-6.09	-0.32	3.17e-9	Menopause (age at onset);
LUSC	cis	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg05299278	chr17:33885742	SLFN14	0.3	6.23	0.32	1.39e-9	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg01193554	chr1:41846683	NA	-0.29	-6.07	-0.32	3.52e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.23	-0.49	1.46e-21	Gut microbiome composition (summer);
LUSC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg09491104	chr22:46646882	C22orf40	-0.64	-7.38	-0.37	1.3e-12	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg27411982	chr8:10470053	RP1L1	0.51	7.87	0.4	4.87e-14	Monocyte count;
LUSC	cis	rs877282	0.898	rs12356744	chr10:757477	G/C	cg17470449	chr10:769945	NA	0.52	6.97	0.36	1.72e-11	Uric acid levels;
LUSC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg25767906	chr1:53392781	SCP2	0.71	14.15	0.61	6.14e-36	Monocyte count;
LUSC	cis	rs9796	0.870	rs72737704	chr15:41323575	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.99	-0.36	1.51e-11	Menopause (age at onset);
LUSC	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.18	-0.37	4.64e-12	Morning vs. evening chronotype;
LUSC	cis	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg21775007	chr8:11205619	TDH	0.47	6.66	0.34	1.11e-10	Neuroticism;
LUSC	cis	rs240764	0.658	rs9390685	chr6:101224725	A/T	cg09795085	chr6:101329169	ASCC3	0.43	6.12	0.32	2.62e-9	Neuroticism;
LUSC	cis	rs508618	0.731	rs11805033	chr1:231546452	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.56	6.83	0.35	4.01e-11	Red blood cell count;
LUSC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-7.03	-0.36	1.21e-11	Monocyte percentage of white cells;
LUSC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.64	-0.39	2.27e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg14458575	chr2:238380390	NA	0.58	6.76	0.35	6.35e-11	Prostate cancer;
LUSC	cis	rs11955175	1.000	rs2228058	chr5:40681254	C/T	cg05478818	chr5:40835740	RPL37	0.71	5.73	0.3	2.24e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.57	0.57	6.1e-30	Motion sickness;
LUSC	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.59	0.43	3.35e-16	Coffee consumption (cups per day);
LUSC	cis	rs7580658	0.895	rs4662580	chr2:128102806	C/A	cg09760422	chr2:128146352	NA	-0.3	-6.36	-0.33	6.57e-10	Protein C levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26439015	chr5:1111863	SLC12A7	-0.39	-6.0	-0.31	5.06e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.76	-0.35	6.16e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2011503	0.509	rs76347963	chr19:19780145	C/T	cg11584989	chr19:19387371	SF4	0.51	5.82	0.3	1.41e-8	Bipolar disorder;
LUSC	cis	rs6484504	0.600	rs2616815	chr11:31327316	C/T	cg06552810	chr11:31128660	NA	0.39	6.81	0.35	4.65e-11	Red blood cell count;
LUSC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg15557168	chr22:42548783	NA	-0.43	-6.76	-0.35	5.99e-11	Schizophrenia;
LUSC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg14552801	chr7:65878734	NA	0.37	5.71	0.3	2.49e-8	Aortic root size;
LUSC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg16928487	chr17:17741425	SREBF1	-0.42	-8.26	-0.41	3.45e-15	Total body bone mineral density;
LUSC	cis	rs2067615	0.579	rs7297592	chr12:107223969	G/T	cg15890332	chr12:107067104	RFX4	0.34	6.02	0.31	4.6e-9	Heart rate;
LUSC	cis	rs3956705	0.762	rs13311608	chr7:32999601	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.5	-7.2	-0.37	4.11e-12	Red cell distribution width;
LUSC	cis	rs8028182	0.525	rs9920028	chr15:75927717	G/A	cg20655648	chr15:75932815	IMP3	0.42	5.69	0.3	2.81e-8	Sudden cardiac arrest;
LUSC	trans	rs1941687	0.764	rs4799357	chr18:31366442	T/C	cg27147174	chr7:100797783	AP1S1	-0.54	-8.4	-0.42	1.28e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs28595532	0.546	rs17516389	chr4:119239267	T/C	cg02775129	chr4:119771670	NA	-0.65	-5.69	-0.3	2.83e-8	Cannabis dependence symptom count;
LUSC	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg26068271	chr17:76253126	NA	0.62	10.8	0.51	1.64e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg24558204	chr6:135376177	HBS1L	0.69	10.72	0.51	3.17e-23	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg24675658	chr1:53192096	ZYG11B	0.76	13.04	0.58	1.07e-31	Monocyte count;
LUSC	cis	rs6120849	0.662	rs6060300	chr20:33780970	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	6.17	0.32	1.95e-9	Protein C levels;
LUSC	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg18825076	chr15:78729989	IREB2	0.46	6.31	0.33	8.94e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs72634258	0.945	rs17367289	chr1:8053135	C/T	cg26816564	chr1:7831052	VAMP3	-0.42	-6.01	-0.31	4.78e-9	Inflammatory bowel disease;
LUSC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25072359	chr17:41440525	NA	0.65	9.39	0.46	9.5e-19	Menopause (age at onset);
LUSC	cis	rs2742417	0.603	rs1468542	chr3:45779136	A/T	cg04837898	chr3:45731254	SACM1L	0.45	7.61	0.38	2.89e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.24	-0.32	1.29e-9	Morning vs. evening chronotype;
LUSC	cis	rs2658782	0.906	rs2658791	chr11:93198983	T/C	cg15737290	chr11:93063684	CCDC67	0.68	8.34	0.42	2.01e-15	Pulmonary function decline;
LUSC	cis	rs9359856	0.564	rs56281344	chr6:90445393	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.43	-0.42	1.02e-15	Bipolar disorder;
LUSC	cis	rs7605827	0.808	rs13001585	chr2:15517790	T/C	cg19274914	chr2:15703543	NA	0.45	8.73	0.43	1.27e-16	Educational attainment (years of education);
LUSC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	0.91	17.57	0.69	2.11e-49	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.33	-0.41	2.13e-15	Body mass index;
LUSC	cis	rs7072216	0.763	rs10883092	chr10:100167276	A/C	cg26618903	chr10:100175079	PYROXD2	-0.46	-8.71	-0.43	1.39e-16	Metabolite levels;
LUSC	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06636551	chr8:101224915	SPAG1	-0.45	-8.26	-0.41	3.35e-15	Atrioventricular conduction;
LUSC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25072359	chr17:41440525	NA	0.64	9.06	0.44	1.15e-17	Menopause (age at onset);
LUSC	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.4	5.78	0.3	1.68e-8	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg21770322	chr7:97807741	LMTK2	0.42	7.3	0.37	2.08e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8064299	0.597	rs7210318	chr17:72783385	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.93	19.27	0.73	3.7e-56	Monocyte count;
LUSC	cis	rs73193808	0.639	rs2832248	chr21:30556981	C/T	cg03476357	chr21:30257390	N6AMT1	0.46	6.22	0.32	1.5e-9	Coronary artery disease;
LUSC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg21856205	chr7:94953877	PON1	-0.35	-5.8	-0.3	1.58e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg23260525	chr10:116636907	FAM160B1	0.49	10.57	0.5	1.02e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.5	7.2	0.37	3.99e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-6.14	-0.32	2.39e-9	Crohn's disease;
LUSC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg20476274	chr7:133979776	SLC35B4	0.87	16.82	0.68	2e-46	Mean platelet volume;
LUSC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg12463550	chr7:65579703	CRCP	-0.51	-7.33	-0.37	1.74e-12	Aortic root size;
LUSC	trans	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.26	-0.32	1.17e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs7939886	0.920	rs1031978	chr11:55965641	G/T	cg15704280	chr7:45808275	SEPT13	0.89	6.81	0.35	4.56e-11	Myopia (pathological);
LUSC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg08847533	chr14:75593920	NEK9	0.84	15.4	0.64	8.01e-41	Height;
LUSC	trans	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg21659725	chr3:3221576	CRBN	-0.68	-7.85	-0.39	5.77e-14	Menarche (age at onset);
LUSC	cis	rs73206853	0.609	rs7306167	chr12:110892449	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg21775007	chr8:11205619	TDH	-0.7	-11.17	-0.52	8.2e-25	Retinal vascular caliber;
LUSC	trans	rs11933661	0.528	rs1022008	chr4:130966269	C/G	cg07526618	chr12:54070131	ATP5G2	0.39	6.18	0.32	1.84e-9	Alcohol dependence;
LUSC	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg06636001	chr8:8085503	FLJ10661	0.74	10.4	0.49	4.1e-22	Red cell distribution width;
LUSC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.75	-0.35	6.36e-11	Lung cancer;
LUSC	cis	rs11031096	0.683	rs55898672	chr11:4189284	G/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.76	-0.3	1.96e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs750134	0.818	rs55873675	chr12:109034165	T/C	cg23338993	chr2:234600423	UGT1A10;UGT1A6;UGT1A9;UGT1A7;UGT1A8	0.45	5.96	0.31	6.54e-9	Low high density lipoprotein cholesterol levels;
LUSC	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.76	-0.35	6.27e-11	Neuroticism;
LUSC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg11752832	chr7:134001865	SLC35B4	0.53	7.96	0.4	2.71e-14	Mean platelet volume;
LUSC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.15	-0.32	2.16e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11051970	0.879	rs73081911	chr12:32539124	C/G	cg02745156	chr12:32552066	NA	0.44	6.99	0.36	1.48e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4629180	0.959	rs11896771	chr2:102098328	T/C	cg01388757	chr2:102091195	RFX8	-0.44	-6.88	-0.35	2.97e-11	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.7	10.99	0.52	3.46e-24	Alcohol dependence;
LUSC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.59	-0.38	3.12e-13	Aortic root size;
LUSC	cis	rs4280164	0.945	rs3181384	chr14:24786976	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.59	-7.22	-0.37	3.54e-12	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg01125463	chr6:42946178	PEX6	-0.36	-5.79	-0.3	1.65e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg07382826	chr16:28625726	SULT1A1	0.28	6.0	0.31	5.18e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg15557168	chr22:42548783	NA	-0.33	-5.67	-0.3	3.03e-8	Cognitive function;
LUSC	cis	rs9311676	0.632	rs6774357	chr3:58361530	A/C	cg26110898	chr3:58419937	PDHB	0.41	6.64	0.34	1.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg06671706	chr8:8559999	CLDN23	0.5	6.47	0.33	3.56e-10	Obesity-related traits;
LUSC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg10556349	chr10:835070	NA	0.56	6.23	0.32	1.41e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18876405	chr7:65276391	NA	-0.55	-8.78	-0.43	8.51e-17	Aortic root size;
LUSC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg12257692	chr3:49977190	RBM6	0.24	6.57	0.34	1.93e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg04725166	chr1:7887271	PER3	-0.44	-5.91	-0.31	8.39e-9	Crohn's disease;
LUSC	trans	rs8002861	0.664	rs9525873	chr13:44482204	T/C	cg12856521	chr11:46389249	DGKZ	0.43	6.31	0.33	8.95e-10	Leprosy;
LUSC	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.23	-26.94	-0.83	9.87e-86	Exhaled nitric oxide output;
LUSC	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg25730555	chr22:47059586	GRAMD4	0.46	7.03	0.36	1.18e-11	Urate levels in obese individuals;
LUSC	cis	rs701145	0.537	rs1727952	chr3:153871565	C/T	cg17054900	chr3:154042577	DHX36	0.69	6.76	0.35	6.15e-11	Coronary artery disease;
LUSC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg08847533	chr14:75593920	NEK9	0.83	14.37	0.62	8.46e-37	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27470012	chr16:48643924	N4BP1	-0.4	-5.97	-0.31	6.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.65	0.5	5.24e-23	Mean corpuscular volume;
LUSC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg27633287	chr12:130766243	NA	0.31	5.69	0.3	2.85e-8	Menopause (age at onset);
LUSC	cis	rs7577851	0.672	rs67938413	chr2:69645422	C/T	cg10773587	chr2:69614142	GFPT1	0.58	7.05	0.36	1.05e-11	Parkinson's disease (age of onset);
LUSC	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.64	0.39	2.25e-13	Iron status biomarkers;
LUSC	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.17	0.37	4.75e-12	Morning vs. evening chronotype;
LUSC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg26958806	chr6:27640298	NA	0.68	5.76	0.3	1.93e-8	Depression;
LUSC	trans	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07923666	chr12:49932857	KCNH3	-0.49	-6.09	-0.32	3.05e-9	Resting heart rate;
LUSC	cis	rs7216064	1.000	rs8074078	chr17:65838743	A/C	cg12091567	chr17:66097778	LOC651250	-0.74	-9.55	-0.46	2.86e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs8126001	0.548	rs4431000	chr20:62715548	C/A	cg03642690	chr20:62727907	OPRL1	-0.33	-5.84	-0.3	1.24e-8	Pulse pressure;Mean corpuscular volume;
LUSC	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg18721089	chr20:30220636	NA	-0.35	-6.07	-0.31	3.56e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	1.08	14.32	0.62	1.3e-36	Uric acid levels;
LUSC	cis	rs1160297	0.576	rs1376567	chr2:53098515	C/G	cg07782112	chr2:53107842	NA	0.4	6.48	0.33	3.31e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7605827	0.930	rs2049718	chr2:15518589	A/G	cg19274914	chr2:15703543	NA	-0.44	-8.41	-0.42	1.22e-15	Educational attainment (years of education);
LUSC	cis	rs2124969	0.548	rs62175391	chr2:161022588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.47	-5.7	-0.3	2.7e-8	Waist circumference adjusted for body mass index;
LUSC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	13.92	0.61	4.85e-35	Alzheimer's disease;
LUSC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg14784868	chr12:69753453	YEATS4	0.63	9.18	0.45	4.66e-18	Blood protein levels;
LUSC	cis	rs5769707	0.681	rs8137111	chr22:50043750	G/A	cg05373962	chr22:49881684	NA	-0.41	-8.49	-0.42	6.93e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs12200782	1.000	rs72843802	chr6:26517515	C/T	cg18180407	chr1:55047736	ACOT11	0.48	5.97	0.31	6.12e-9	Small cell lung carcinoma;
LUSC	cis	rs12474201	0.928	rs12999586	chr2:46938736	C/T	cg06386533	chr2:46925753	SOCS5	0.78	11.84	0.54	3.17e-27	Height;
LUSC	cis	rs6723226	0.708	rs2754513	chr2:32782763	G/A	cg02381751	chr2:32503542	YIPF4	0.57	8.46	0.42	8.46e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg16049707	chr14:77965284	ISM2	-0.54	-7.54	-0.38	4.36e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs240764	0.658	rs3811078	chr6:101247503	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-6.65	-0.34	1.18e-10	Neuroticism;
LUSC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg17366294	chr4:99064904	C4orf37	0.56	9.88	0.48	2.35e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2392780	0.536	rs377649	chr8:128337241	G/T	cg10897648	chr18:56338258	MALT1	-0.42	-6.39	-0.33	5.72e-10	Breast cancer (early onset);
LUSC	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg17470723	chr8:74884337	TCEB1	0.52	8.06	0.4	1.33e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.99	-0.44	1.83e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs61990749	0.597	rs9788540	chr14:78132172	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.57	-6.21	-0.32	1.58e-9	Fibroblast growth factor basic levels;
LUSC	cis	rs2970818	0.731	rs11063170	chr12:4575084	A/T	cg11146114	chr12:4671731	NA	-0.64	-6.25	-0.32	1.23e-9	Phosphorus levels;
LUSC	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg26384229	chr12:38710491	ALG10B	0.54	7.65	0.39	2.19e-13	Morning vs. evening chronotype;
LUSC	trans	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-6.89	-0.35	2.86e-11	Menarche (age at onset);
LUSC	cis	rs757081	0.667	rs569780	chr11:17206745	C/T	cg15432903	chr11:17409602	KCNJ11	-0.38	-5.85	-0.3	1.18e-8	Systolic blood pressure;
LUSC	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	0.87	13.29	0.59	1.19e-32	Pulmonary function decline;
LUSC	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg04310649	chr10:35416472	CREM	-0.43	-6.56	-0.34	1.99e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg20908204	chr19:46285434	DMPK	-0.36	-6.71	-0.34	8.2e-11	Coronary artery disease;
LUSC	cis	rs9341808	0.529	rs2322765	chr6:81064596	A/G	cg08355045	chr6:80787529	NA	0.44	7.51	0.38	5.6e-13	Sitting height ratio;
LUSC	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.88	0.6	6.88e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1322512	0.917	rs1744377	chr6:152943484	T/C	cg27316956	chr6:152958899	SYNE1	-0.36	-5.87	-0.31	1.05e-8	Tonometry;
LUSC	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg19508488	chr2:152266495	RIF1	0.54	7.74	0.39	1.21e-13	Lung cancer;
LUSC	cis	rs9818941	0.955	rs4362677	chr3:157667357	A/G	cg08654915	chr3:157813417	NA	0.24	5.85	0.31	1.14e-8	Height;
LUSC	cis	rs11608355	0.846	rs4766471	chr12:109853462	G/A	cg05360138	chr12:110035743	NA	0.61	8.19	0.41	5.79e-15	Neuroticism;
LUSC	cis	rs1865721	0.804	rs72977818	chr18:73146852	T/C	cg26385618	chr18:73139727	C18orf62	-0.52	-9.62	-0.47	1.71e-19	Intelligence;
LUSC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-9.6	-0.46	2.04e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs983392	0.679	rs603648	chr11:60012673	A/T	cg24026212	chr11:59952134	MS4A6A	0.36	6.3	0.33	9.17e-10	Alzheimer's disease (late onset);
LUSC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg07870213	chr5:140052090	DND1	0.77	11.42	0.53	9.74e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs2637266	1.000	rs12774835	chr10:78352226	C/G	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg03859395	chr2:55845619	SMEK2	-0.63	-8.81	-0.43	7.08e-17	Metabolic syndrome;
LUSC	cis	rs10992471	0.639	rs10821008	chr9:95487497	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.34	-0.33	7.67e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-0.88	-18.58	-0.71	2.09e-53	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg21770322	chr7:97807741	LMTK2	0.41	7.07	0.36	9.1e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6961069	0.777	rs1953299	chr7:80265625	T/G	cg04458919	chr7:80252533	CD36	0.36	6.45	0.33	3.95e-10	Platelet count;
LUSC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.58	9.44	0.46	6.57e-19	Aortic root size;
LUSC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg24110177	chr3:50126178	RBM5	0.51	7.98	0.4	2.44e-14	Menarche (age at onset);
LUSC	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg17294928	chr15:75287854	SCAMP5	0.43	6.19	0.32	1.81e-9	Breast cancer;
LUSC	trans	rs10432489	0.708	rs6730421	chr2:181755815	A/G	cg04744134	chr19:8408128	KANK3	-0.74	-6.14	-0.32	2.33e-9	QT interval;
LUSC	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg16576597	chr16:28551801	NUPR1	0.33	6.61	0.34	1.48e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg13683864	chr3:40499215	RPL14	-0.96	-16.8	-0.68	2.35e-46	Renal cell carcinoma;
LUSC	cis	rs4474465	1.000	rs7128417	chr11:78205974	C/G	cg27205649	chr11:78285834	NARS2	0.51	5.91	0.31	8.55e-9	Alzheimer's disease (survival time);
LUSC	trans	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg14791747	chr16:20752902	THUMPD1	-0.42	-6.41	-0.33	4.97e-10	Dental caries;
LUSC	cis	rs6076065	0.723	rs6137924	chr20:23366171	C/G	cg11657817	chr20:23433608	CST11	0.43	8.07	0.4	1.25e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg17376030	chr22:41985996	PMM1	-0.44	-5.71	-0.3	2.47e-8	Vitiligo;
LUSC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg24060327	chr5:131705240	SLC22A5	-0.53	-8.26	-0.41	3.48e-15	Acylcarnitine levels;
LUSC	cis	rs73195822	0.614	rs11065717	chr12:111208823	A/C	cg12870014	chr12:110450643	ANKRD13A	0.65	6.91	0.35	2.49e-11	Itch intensity from mosquito bite;
LUSC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg00815214	chr21:47717953	NA	0.37	5.86	0.31	1.13e-8	Testicular germ cell tumor;
LUSC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg03188948	chr7:1209495	NA	0.72	8.19	0.41	5.71e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.84	-0.35	3.88e-11	Menopause (age at onset);
LUSC	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	1.06	15.15	0.64	7.78e-40	Uric acid levels;
LUSC	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg21293242	chr8:11204541	TDH	0.32	6.06	0.31	3.62e-9	Retinal vascular caliber;
LUSC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg24209194	chr3:40518798	ZNF619	0.4	5.64	0.3	3.56e-8	Renal cell carcinoma;
LUSC	trans	rs7243066	0.577	rs9957564	chr18:11296178	A/G	cg23062198	chr2:14774063	FAM84A	-0.47	-6.24	-0.32	1.29e-9	Dental caries;
LUSC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg21782813	chr7:2030301	MAD1L1	-0.5	-8.37	-0.42	1.56e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs2236918	0.710	rs2526702	chr1:242017983	G/A	cg17736920	chr1:242011382	EXO1	0.43	6.8	0.35	4.79e-11	Menopause (age at onset);
LUSC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg06238570	chr21:40685208	BRWD1	-0.57	-8.85	-0.44	5.02e-17	Menarche (age at onset);
LUSC	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.49	-7.45	-0.38	7.92e-13	Menarche (age at onset);
LUSC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg13206674	chr6:150067644	NUP43	0.63	10.24	0.49	1.38e-21	Lung cancer;
LUSC	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.4	-6.27	-0.32	1.14e-9	IgG glycosylation;
LUSC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-0.8	-15.66	-0.65	7.98e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-6.88	-0.35	3.01e-11	Blood metabolite levels;
LUSC	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg13010199	chr12:38710504	ALG10B	0.55	8.42	0.42	1.13e-15	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.69	-0.39	1.71e-13	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.58	0.46	2.24e-19	Bipolar disorder;
LUSC	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-11.25	-0.52	4.13e-25	Alcohol dependence;
LUSC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg02660097	chr11:68866761	NA	0.43	6.1	0.32	2.9e-9	Blond vs. brown hair color;
LUSC	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg13010199	chr12:38710504	ALG10B	0.55	8.36	0.42	1.74e-15	Morning vs. evening chronotype;
LUSC	cis	rs897080	0.515	rs1067334	chr2:44626633	A/G	cg00619915	chr2:44497795	NA	-0.41	-5.8	-0.3	1.54e-8	Height;
LUSC	cis	rs2274273	0.682	rs7151224	chr14:55517262	G/A	cg04306507	chr14:55594613	LGALS3	0.49	10.52	0.5	1.55e-22	Protein biomarker;
LUSC	cis	rs9420	0.961	rs11605731	chr11:57524089	C/G	cg23127183	chr11:57508653	C11orf31	-0.57	-8.81	-0.43	6.86e-17	Schizophrenia;
LUSC	trans	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg06606381	chr12:133084897	FBRSL1	-1.03	-8.88	-0.44	4.15e-17	Depression;
LUSC	cis	rs7107174	1.000	rs2511157	chr11:77972632	G/A	cg02023728	chr11:77925099	USP35	0.52	7.2	0.37	4.11e-12	Testicular germ cell tumor;
LUSC	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg06197492	chr11:2016605	H19	0.4	6.49	0.33	3.07e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg05738196	chr6:26577821	NA	0.76	13.52	0.59	1.66e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.45	-0.33	3.95e-10	Retinal vascular caliber;
LUSC	cis	rs7712401	0.601	rs30027	chr5:122283390	T/C	cg19077854	chr5:122220652	SNX24	0.43	9.7	0.47	9.4e-20	Mean platelet volume;
LUSC	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	7.38	0.37	1.24e-12	Response to antipsychotic treatment;
LUSC	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg13010199	chr12:38710504	ALG10B	0.69	11.81	0.54	3.94e-27	Heart rate;
LUSC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.08	-0.4	1.19e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg07636037	chr3:49044803	WDR6	0.45	6.59	0.34	1.72e-10	Resting heart rate;
LUSC	cis	rs8092503	1.000	rs3764515	chr18:52494397	G/T	cg12377874	chr18:52495404	RAB27B	0.33	5.99	0.31	5.54e-9	Childhood body mass index;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05856122	chr11:6633491	TAF10	-0.37	-6.01	-0.31	4.88e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg04455712	chr21:45112962	RRP1B	0.45	8.53	0.42	5.06e-16	Mean corpuscular volume;
LUSC	trans	rs2840044	1.000	rs225259	chr17:33958168	A/G	cg19694781	chr19:47549865	TMEM160	-0.58	-9.31	-0.45	1.71e-18	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-0.82	-15.82	-0.65	1.77e-42	Gut microbiome composition (winter);
LUSC	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.61	0.5	7.28e-23	Colorectal cancer;
LUSC	trans	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg26043149	chr18:55253948	FECH	-0.46	-7.05	-0.36	1.02e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.62	9.97	0.48	1.15e-20	Blood metabolite ratios;
LUSC	cis	rs7590368	0.683	rs12471762	chr2:10958258	C/T	cg15705551	chr2:10952987	PDIA6	0.59	6.36	0.33	6.56e-10	Educational attainment (years of education);
LUSC	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.44	7.23	0.37	3.4e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs12681287	0.673	rs2976178	chr8:87332552	C/G	cg27223183	chr8:87520930	FAM82B	-0.51	-6.62	-0.34	1.43e-10	Caudate activity during reward;
LUSC	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.49	0.75	5.16e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs887829	0.588	rs4663971	chr2:234674252	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.77	-0.39	9.71e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg13010199	chr12:38710504	ALG10B	0.69	10.76	0.51	2.21e-23	Bladder cancer;
LUSC	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg26566898	chr11:117069891	TAGLN	0.38	7.28	0.37	2.48e-12	Blood protein levels;
LUSC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.09	0.55	3.55e-28	Colorectal cancer;
LUSC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg03806693	chr22:41940476	POLR3H	0.99	13.85	0.6	9.09e-35	Vitiligo;
LUSC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.55	0.34	2.18e-10	Menarche (age at onset);
LUSC	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg27489772	chr12:121021490	NA	0.6	8.03	0.4	1.68e-14	Type 1 diabetes nephropathy;
LUSC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26314531	chr2:26401878	FAM59B	0.74	10.04	0.48	6.81e-21	Gut microbiome composition (summer);
LUSC	cis	rs1172822	0.698	rs2384687	chr19:55831188	A/G	cg04391588	chr19:55832610	TMEM150B	0.29	5.77	0.3	1.84e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg03233332	chr7:66118400	NA	-0.41	-6.05	-0.31	3.89e-9	Aortic root size;
LUSC	cis	rs2820315	0.867	rs2820323	chr1:201883160	G/A	cg10061532	chr1:201886748	LMOD1	0.28	6.44	0.33	4.11e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs7113850	0.541	rs7107940	chr11:24233228	G/A	ch.11.24196551F	chr11:24239977	NA	0.97	9.05	0.44	1.2e-17	Bone fracture in osteoporosis;
LUSC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06481639	chr22:41940642	POLR3H	-0.49	-5.7	-0.3	2.61e-8	Vitiligo;
LUSC	cis	rs9311676	0.632	rs11719192	chr3:58431817	C/G	cg13750441	chr3:58318267	PXK	0.35	6.84	0.35	3.88e-11	Systemic lupus erythematosus;
LUSC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07157834	chr1:205819609	PM20D1	0.53	8.68	0.43	1.76e-16	Menarche (age at onset);
LUSC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.52	0.57	9.28e-30	Motion sickness;
LUSC	cis	rs4285028	0.747	rs9808981	chr3:121429561	G/A	cg11130432	chr3:121712080	ILDR1	-0.53	-7.79	-0.39	8.81e-14	Multiple sclerosis;
LUSC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg20203395	chr5:56204925	C5orf35	-0.56	-8.05	-0.4	1.49e-14	Coronary artery disease;
LUSC	cis	rs11997175	0.740	rs6991071	chr8:33814103	G/A	ch.8.33884649F	chr8:33765107	NA	0.53	8.17	0.41	6.33e-15	Body mass index;
LUSC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg16606324	chr3:10149918	C3orf24	0.59	8.47	0.42	7.78e-16	Alzheimer's disease;
LUSC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08280861	chr8:58055591	NA	0.54	6.3	0.33	9.15e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.9	-0.35	2.62e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6457821	1.000	rs56987668	chr6:35319253	T/C	cg06087101	chr6:35551932	FKBP5	0.65	5.95	0.31	6.86e-9	Height;
LUSC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.31	-0.41	2.42e-15	Gut microbiome composition (summer);
LUSC	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.4	-5.65	-0.3	3.51e-8	Bipolar disorder;
LUSC	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.83	-15.23	-0.64	3.98e-40	Longevity;
LUSC	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg26195577	chr20:24973756	C20orf3	1.11	18.48	0.71	5e-53	Blood protein levels;
LUSC	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.32	-18.36	-0.71	1.51e-52	Hip circumference adjusted for BMI;
LUSC	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.64	-0.47	1.41e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08736216	chr1:53307985	ZYG11A	0.3	6.06	0.31	3.77e-9	Monocyte count;
LUSC	cis	rs10761482	0.954	rs10740022	chr10:62062686	A/G	cg18175470	chr10:62150864	ANK3	0.46	6.59	0.34	1.73e-10	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.68	11.63	0.54	1.78e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg06808227	chr14:105710500	BRF1	-0.66	-10.21	-0.49	1.82e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.9	12.12	0.55	2.84e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg17691542	chr6:26056736	HIST1H1C	0.56	7.84	0.39	6.1e-14	Iron status biomarkers;
LUSC	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg12179176	chr11:130786555	SNX19	-0.86	-14.47	-0.62	3.42e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs6674970	1.000	rs6656450	chr1:151089602	A/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.43	-5.84	-0.3	1.25e-8	Childhood ear infection;
LUSC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg21856205	chr7:94953877	PON1	-0.36	-5.72	-0.3	2.32e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg02158880	chr13:53174818	NA	0.58	10.12	0.48	3.68e-21	Lewy body disease;
LUSC	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.43	-8.32	-0.41	2.25e-15	Colorectal cancer;
LUSC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg01689657	chr7:91764605	CYP51A1	0.33	6.0	0.31	5.28e-9	Breast cancer;
LUSC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg04287289	chr16:89883240	FANCA	0.57	8.85	0.44	5.02e-17	Vitiligo;
LUSC	cis	rs6818397	1.000	rs6818397	chr4:3434885	A/C	cg11522145	chr4:3412961	RGS12	0.29	5.7	0.3	2.68e-8	LDL cholesterol levels;Total cholesterol levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02621988	chr17:2498631	PAFAH1B1	0.38	6.34	0.33	7.52e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9341835	0.772	rs9449233	chr6:64138234	G/T	cg00787780	chr6:64151745	NA	-0.34	-5.78	-0.3	1.72e-8	Schizophrenia;
LUSC	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg03859395	chr2:55845619	SMEK2	-0.71	-10.9	-0.51	6.98e-24	Metabolic syndrome;
LUSC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.61e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg03342759	chr3:160939853	NMD3	-0.42	-6.83	-0.35	3.91e-11	Morning vs. evening chronotype;
LUSC	cis	rs1832871	0.711	rs9456266	chr6:158714422	A/G	cg07165851	chr6:158734300	TULP4	0.5	7.66	0.39	2.05e-13	Height;
LUSC	cis	rs6752107	0.967	rs3792109	chr2:234184417	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.72	11.97	0.55	1.06e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9472414	0.510	rs227845	chr6:44695338	C/A	cg20913747	chr6:44695427	NA	0.39	5.79	0.3	1.63e-8	Height;
LUSC	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg23422044	chr7:1970798	MAD1L1	-0.61	-6.21	-0.32	1.62e-9	Bipolar disorder;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23142935	chr16:22385308	CDR2	-0.42	-6.74	-0.35	7.08e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg22705602	chr4:152727874	NA	0.32	6.77	0.35	5.65e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7181230	1.000	rs28534747	chr15:40374269	T/C	cg00868766	chr15:40364524	NA	0.33	5.69	0.3	2.71e-8	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg22709100	chr7:91322751	NA	0.4	5.91	0.31	8.61e-9	Breast cancer;
LUSC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.42	5.97	0.31	6.16e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7223966	0.655	rs6504165	chr17:61630076	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.4	5.66	0.3	3.27e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7216064	0.953	rs9890629	chr17:65871559	G/A	cg12091567	chr17:66097778	LOC651250	-0.73	-9.37	-0.46	1.13e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7264396	0.943	rs6060448	chr20:34112192	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.38	5.93	0.31	7.58e-9	Total cholesterol levels;
LUSC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg07701084	chr6:150067640	NUP43	0.58	8.9	0.44	3.74e-17	Lung cancer;
LUSC	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg05373962	chr22:49881684	NA	-0.4	-8.44	-0.42	1.01e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg19792802	chr11:65647270	CTSW	0.45	6.53	0.34	2.42e-10	Crohn's disease;
LUSC	cis	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg02972257	chr16:68554789	NA	-0.51	-6.26	-0.32	1.21e-9	Ulcerative colitis;
LUSC	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.47	8.27	0.41	3.14e-15	HDL cholesterol;
LUSC	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg07148914	chr20:33460835	GGT7	0.54	8.25	0.41	3.63e-15	Height;
LUSC	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg09184832	chr6:79620586	NA	-0.43	-6.96	-0.36	1.76e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.24e-19	Prudent dietary pattern;
LUSC	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg15704280	chr7:45808275	SEPT13	-0.54	-7.55	-0.38	4.19e-13	HDL cholesterol;
LUSC	cis	rs7572644	0.766	rs12997202	chr2:28250389	A/G	cg27432699	chr2:27873401	GPN1	0.52	6.48	0.33	3.22e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg08179530	chr6:36648295	CDKN1A	-0.56	-8.04	-0.4	1.54e-14	Coronary artery disease;
LUSC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.23	0.32	1.39e-9	Obesity-related traits;
LUSC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg12658694	chr1:38397304	INPP5B	-0.56	-9.5	-0.46	4.09e-19	Coronary artery disease;
LUSC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg08219700	chr8:58056026	NA	0.45	5.81	0.3	1.49e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg00105475	chr2:10696890	NA	0.35	5.92	0.31	7.8e-9	Prostate cancer;
LUSC	cis	rs7799006	0.527	rs6967286	chr7:2212758	C/A	cg08027265	chr7:2291960	NA	-0.36	-5.93	-0.31	7.56e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-1.19	-12.97	-0.58	2.03e-31	Diabetic kidney disease;
LUSC	cis	rs1451375	0.698	rs11238214	chr7:50636018	A/G	cg18232548	chr7:50535776	DDC	0.51	7.76	0.39	1.01e-13	Malaria;
LUSC	trans	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.57	-9.7	-0.47	8.87e-20	Mean corpuscular volume;
LUSC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg25809561	chr17:30822961	MYO1D	0.47	8.37	0.42	1.56e-15	Schizophrenia;
LUSC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg08270630	chr22:50330655	NA	-0.4	-6.07	-0.32	3.4e-9	Schizophrenia;
LUSC	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	0.99	13.29	0.59	1.19e-32	Uric acid levels;
LUSC	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg00071950	chr4:10020882	SLC2A9	0.5	7.88	0.4	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg24088639	chr11:34937564	PDHX;APIP	-0.46	-6.84	-0.35	3.81e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs11676855	0.893	rs6431329	chr2:235934338	C/T	cg14917874	chr2:235941519	SH3BP4	0.51	8.68	0.43	1.81e-16	Dialysis-related mortality;
LUSC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-1.03	-9.66	-0.47	1.23e-19	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-7.29	-0.37	2.2e-12	Retinal vascular caliber;
LUSC	cis	rs9646944	0.501	rs10172116	chr2:103087573	C/T	cg20060108	chr2:102954350	IL1RL1	0.44	5.87	0.31	1.07e-8	Blood protein levels;
LUSC	cis	rs9462027	0.606	rs2395606	chr6:34778486	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.75	-0.3	2.03e-8	Systemic lupus erythematosus;
LUSC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg24250549	chr1:154909240	PMVK	-0.57	-9.15	-0.45	5.95e-18	Prostate cancer;
LUSC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08677398	chr8:58056175	NA	0.51	6.75	0.35	6.43e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20149956	chr1:249132233	ZNF672	-0.52	-6.72	-0.35	7.99e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg15704280	chr7:45808275	SEPT13	-0.84	-11.72	-0.54	8.17e-27	Coronary artery disease;
LUSC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.05	-0.4	1.45e-14	Bipolar disorder;
LUSC	cis	rs865483	0.861	rs1063215	chr17:35874936	A/G	cg06716730	chr17:35851459	DUSP14	0.26	5.87	0.31	1.05e-8	Monocyte count;
LUSC	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg27124370	chr19:33622961	WDR88	0.52	6.66	0.34	1.14e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg07930552	chr6:133119739	C6orf192	0.85	10.66	0.5	5.07e-23	Type 2 diabetes nephropathy;
LUSC	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg19875535	chr5:140030758	IK	0.44	6.96	0.36	1.8e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1549118	0.595	rs28613643	chr14:78332161	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.43	-5.74	-0.3	2.16e-8	Resting heart rate;
LUSC	trans	rs403814	0.938	rs3898848	chr18:6294119	C/T	cg05469346	chr5:174115696	NA	-0.44	-6.1	-0.32	2.9e-9	Hypertension;
LUSC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg24399712	chr22:39784796	NA	-0.58	-9.26	-0.45	2.6e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg23711669	chr6:146136114	FBXO30	0.87	15.93	0.66	6.54e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg23649088	chr2:200775458	C2orf69	0.49	7.4	0.38	1.15e-12	Osteoporosis;
LUSC	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	0.88	13.86	0.6	7.72e-35	Blood protein levels;
LUSC	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.38	-0.33	5.86e-10	Daytime sleep phenotypes;
LUSC	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.82	-13.23	-0.59	1.99e-32	Schizophrenia;
LUSC	trans	rs3858145	0.588	rs61854837	chr10:70042370	C/G	cg04882175	chr6:131122610	NA	-0.67	-8.42	-0.42	1.09e-15	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUSC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg20503657	chr10:835505	NA	0.51	7.01	0.36	1.35e-11	Response to angiotensin II receptor blocker therapy;
LUSC	trans	rs7939886	0.844	rs12421584	chr11:55937410	G/A	cg03929089	chr4:120376271	NA	0.8	6.07	0.32	3.54e-9	Myopia (pathological);
LUSC	cis	rs1448094	0.617	rs2221319	chr12:86468064	C/A	cg00310523	chr12:86230176	RASSF9	-0.35	-6.27	-0.32	1.14e-9	Major depressive disorder;
LUSC	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg12081754	chr8:22256438	SLC39A14	0.76	11.87	0.54	2.28e-27	Verbal declarative memory;
LUSC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.82	13.38	0.59	5.26e-33	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg08017756	chr2:100939284	LONRF2	-0.47	-8.64	-0.43	2.36e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg01765077	chr12:122356316	WDR66	0.51	7.38	0.37	1.28e-12	Mean corpuscular volume;
LUSC	cis	rs3820068	0.608	rs9660255	chr1:16031891	T/G	cg13390004	chr1:15929781	NA	0.41	6.79	0.35	5.02e-11	Systolic blood pressure;
LUSC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg00033643	chr7:134001901	SLC35B4	0.47	7.35	0.37	1.53e-12	Mean platelet volume;
LUSC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18932078	chr1:2524107	MMEL1	0.33	7.31	0.37	2.03e-12	Ulcerative colitis;
LUSC	cis	rs3820928	1.000	rs1346618	chr2:227771988	C/T	cg11843606	chr2:227700838	RHBDD1	0.51	7.59	0.38	3.19e-13	Pulmonary function;
LUSC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03264133	chr6:25882463	NA	-0.5	-9.14	-0.45	6.03e-18	Blood metabolite levels;
LUSC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	0.99	13.98	0.61	2.67e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-5.73	-0.3	2.2e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-8.86	-0.44	4.7e-17	Response to antipsychotic treatment;
LUSC	cis	rs9473147	0.516	rs9381579	chr6:47556680	C/T	cg20196966	chr6:47445060	CD2AP	0.41	5.75	0.3	2.07e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg00945038	chr17:61921165	SMARCD2	-0.52	-9.15	-0.45	5.79e-18	Prudent dietary pattern;
LUSC	cis	rs753778	0.559	rs2288997	chr8:142200731	A/G	cg18755752	chr8:142205143	DENND3	0.62	9.09	0.45	8.84e-18	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.57	8.11	0.41	9.92e-15	Resting heart rate;
LUSC	cis	rs11051970	0.636	rs2651368	chr12:32561506	T/C	cg02745156	chr12:32552066	NA	0.37	6.82	0.35	4.3e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg20821713	chr7:1055600	C7orf50	-0.58	-7.76	-0.39	1.04e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs981844	0.712	rs921882	chr4:154752878	A/C	cg14289246	chr4:154710475	SFRP2	-0.46	-6.3	-0.33	9.19e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs8099014	0.816	rs8099343	chr18:56110071	C/T	cg12907477	chr18:56117327	MIR122	0.44	7.02	0.36	1.28e-11	Platelet count;
LUSC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06481639	chr22:41940642	POLR3H	-0.54	-5.97	-0.31	6.16e-9	Vitiligo;
LUSC	cis	rs9341835	0.772	rs9294196	chr6:64135193	A/G	cg00787780	chr6:64151745	NA	0.34	5.77	0.3	1.81e-8	Schizophrenia;
LUSC	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.73	-13.24	-0.59	1.88e-32	Schizophrenia;
LUSC	cis	rs9837602	1.000	rs62285478	chr3:99822135	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.31	0.33	8.81e-10	Breast cancer;
LUSC	cis	rs250677	0.522	rs56309414	chr5:148376026	C/G	cg18129178	chr5:148520854	ABLIM3	-0.5	-7.29	-0.37	2.21e-12	Breast cancer;
LUSC	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg03929089	chr4:120376271	NA	0.72	6.77	0.35	5.71e-11	Axial length;
LUSC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	1.0	18.55	0.71	2.64e-53	Cognitive function;
LUSC	cis	rs7712401	0.601	rs154502	chr5:122207046	C/T	cg19077854	chr5:122220652	SNX24	0.42	9.66	0.47	1.26e-19	Mean platelet volume;
LUSC	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.6	13.63	0.6	6e-34	Height;
LUSC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.59	7.88	0.4	4.54e-14	High light scatter reticulocyte count;
LUSC	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg11984989	chr7:158649758	WDR60	1.11	13.54	0.6	1.3e-33	Height;
LUSC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.64	10.16	0.49	2.64e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23409613	chr14:53196849	STYX	-0.5	-6.14	-0.32	2.29e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg15468180	chr1:107600409	PRMT6	0.38	6.02	0.31	4.53e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.02	-0.31	4.49e-9	Platelet count;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-0.43	-7.23	-0.37	3.22e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg15744005	chr10:104629667	AS3MT	-0.28	-5.93	-0.31	7.63e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1775715	0.737	rs2799018	chr10:32202069	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.76	0.35	6.05e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9810089	0.967	rs7372313	chr3:135872958	G/C	cg12473912	chr3:136751656	NA	0.33	5.68	0.3	3.01e-8	Gestational age at birth (child effect);
LUSC	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg11244672	chr19:19639970	YJEFN3	0.61	7.59	0.38	3.3e-13	Bipolar disorder;
LUSC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg25174290	chr11:3078921	CARS	0.59	8.94	0.44	2.79e-17	Longevity;
LUSC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	0.94	18.89	0.72	1.15e-54	Cognitive function;
LUSC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg04733989	chr22:42467013	NAGA	-0.62	-9.72	-0.47	7.81e-20	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1486139	1.000	rs6463322	chr7:46283138	T/C	cg17534202	chr9:96721102	NA	-0.37	-6.56	-0.34	2.01e-10	Select biomarker traits;
LUSC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.03	-0.31	4.28e-9	Platelet count;
LUSC	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.59	-0.62	1.21e-37	Schizophrenia;
LUSC	trans	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.41	-0.33	5.05e-10	Monocyte count;
LUSC	cis	rs597583	0.715	rs1940040	chr11:117393294	G/C	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.53	-0.42	4.99e-16	Putamen volume;
LUSC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-14.99	-0.63	3.24e-39	Gut microbiome composition (summer);
LUSC	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.97	-0.31	6.08e-9	Type 2 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25198656	chr7:5013641	RNF216L	-0.53	-6.09	-0.32	3.04e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.03	-0.31	4.39e-9	Resting heart rate;
LUSC	trans	rs12200782	1.000	rs12201802	chr6:26398664	G/A	cg11837749	chr1:55047332	ACOT11	0.59	6.15	0.32	2.19e-9	Small cell lung carcinoma;
LUSC	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg05738196	chr6:26577821	NA	-0.45	-6.58	-0.34	1.87e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg11693508	chr17:37793320	STARD3	0.66	8.07	0.4	1.27e-14	Bipolar disorder;
LUSC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg26441486	chr22:50317300	CRELD2	0.53	8.07	0.4	1.27e-14	Schizophrenia;
LUSC	cis	rs7119	0.679	rs12914932	chr15:77839051	G/A	cg27398640	chr15:77910606	LINGO1	-0.32	-6.5	-0.34	2.87e-10	Type 2 diabetes;
LUSC	cis	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg02972257	chr16:68554789	NA	-0.49	-6.35	-0.33	7.09e-10	Ulcerative colitis;
LUSC	cis	rs367615	0.537	rs431669	chr5:108663115	G/A	cg17395555	chr5:108820864	NA	0.55	9.62	0.47	1.72e-19	Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-1.03	-19.82	-0.74	2.49e-58	Height;
LUSC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg26380479	chr7:97908229	NA	-0.26	-5.77	-0.3	1.78e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg06784218	chr1:46089804	CCDC17	-0.55	-11.25	-0.52	4.05e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg06917634	chr15:78832804	PSMA4	-0.49	-6.02	-0.31	4.58e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-6.95	-0.36	1.98e-11	Chronic sinus infection;
LUSC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg11247378	chr22:39784982	NA	-0.65	-13.23	-0.59	2.05e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs2635047	0.811	rs17723754	chr18:44771481	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	5.93	0.31	7.62e-9	Educational attainment;
LUSC	cis	rs4499344	0.664	rs7258278	chr19:33099523	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	12.91	0.58	3.4e-31	Mean platelet volume;
LUSC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg20302533	chr7:39170763	POU6F2	0.55	9.19	0.45	4.35e-18	IgG glycosylation;
LUSC	trans	rs2299682	0.826	rs16995976	chr20:9482637	C/T	cg16619378	chr17:14207530	HS3ST3B1;MGC12916	-0.6	-6.0	-0.31	5.09e-9	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg09904177	chr6:26538194	HMGN4	-0.78	-5.74	-0.3	2.12e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg27398640	chr15:77910606	LINGO1	-0.28	-5.81	-0.3	1.42e-8	Type 2 diabetes;
LUSC	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.12	0.32	2.57e-9	Corneal astigmatism;
LUSC	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14298792	chr15:30685198	CHRFAM7A	-0.69	-8.87	-0.44	4.43e-17	Huntington's disease progression;
LUSC	cis	rs9420	0.884	rs589914	chr11:57661032	A/G	cg23127183	chr11:57508653	C11orf31	0.51	7.22	0.37	3.44e-12	Schizophrenia;
LUSC	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg22437258	chr11:111473054	SIK2	0.54	7.68	0.39	1.75e-13	Primary sclerosing cholangitis;
LUSC	cis	rs7681423	1.000	rs2066854	chr4:155535181	T/A	cg20735720	chr4:155535218	FGG	-0.47	-6.84	-0.35	3.79e-11	Fibrinogen;
LUSC	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.79	0.3	1.6e-8	Breast cancer;
LUSC	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.43	6.07	0.32	3.4e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs9811920	0.893	rs9814549	chr3:99892190	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.33	-6.18	-0.32	1.88e-9	Axial length;
LUSC	cis	rs7538876	0.903	rs1324368	chr1:17752000	A/G	cg07965774	chr1:17746286	RCC2	0.33	6.23	0.32	1.37e-9	Basal cell carcinoma;
LUSC	trans	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg07393940	chr7:158741817	NA	0.36	6.43	0.33	4.46e-10	Life satisfaction;
LUSC	cis	rs10754283	0.967	rs10754285	chr1:90116587	A/G	cg21401794	chr1:90099060	LRRC8C	0.48	6.27	0.32	1.1e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.54	-0.34	2.32e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg03354898	chr7:1950403	MAD1L1	0.43	8.83	0.44	6.05e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg00106254	chr7:1943704	MAD1L1	-0.4	-5.74	-0.3	2.09e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.78	-0.7	2.97e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg22920501	chr2:26401640	FAM59B	0.77	11.26	0.52	3.73e-25	Gut microbiome composition (summer);
LUSC	trans	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg03886242	chr7:26192032	NFE2L3	-0.41	-6.26	-0.32	1.22e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.66	-11.21	-0.52	5.47e-25	Caffeine consumption;
LUSC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	9.46	0.46	5.68e-19	Motion sickness;
LUSC	cis	rs11030122	0.661	rs4910877	chr11:4062153	A/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.66	-0.3	3.19e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.26	14.54	0.62	1.94e-37	Gout;
LUSC	cis	rs6750047	0.609	rs2121259	chr2:38269475	T/C	cg07380506	chr2:38303506	CYP1B1	0.44	6.03	0.31	4.26e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg01125463	chr6:42946178	PEX6	-0.36	-5.97	-0.31	6.19e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg25801113	chr15:45476975	SHF	0.32	6.44	0.33	4.13e-10	Uric acid levels;
LUSC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg16606324	chr3:10149918	C3orf24	0.59	8.55	0.42	4.49e-16	Alzheimer's disease;
LUSC	cis	rs12545109	0.765	rs2576589	chr8:57425647	C/T	cg09654669	chr8:57350985	NA	-0.49	-6.01	-0.31	4.77e-9	Obesity-related traits;
LUSC	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.11e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6906287	0.669	rs2184402	chr6:118935341	T/C	cg21191810	chr6:118973309	C6orf204	0.32	5.91	0.31	8.23e-9	Electrocardiographic conduction measures;
LUSC	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	cis	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg21775007	chr8:11205619	TDH	-0.49	-7.03	-0.36	1.21e-11	Systolic blood pressure;
LUSC	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg01028140	chr2:1542097	TPO	-0.37	-5.97	-0.31	6.12e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-10.56	-0.5	1.14e-22	Schizophrenia;
LUSC	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.6	-0.34	1.66e-10	Retinal vascular caliber;
LUSC	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg01256987	chr12:42539512	GXYLT1	-0.38	-7.11	-0.36	7.07e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs2262909	0.962	rs73019842	chr19:22249909	T/G	cg17074339	chr11:11642133	GALNTL4	0.47	7.17	0.37	4.94e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg24006582	chr15:45444508	DUOX1	-0.6	-8.77	-0.43	9.28e-17	Uric acid levels;
LUSC	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg27432699	chr2:27873401	GPN1	0.79	14.44	0.62	4.64e-37	Oral cavity cancer;
LUSC	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg22906224	chr7:99728672	NA	-0.5	-6.94	-0.35	2.09e-11	Coronary artery disease;
LUSC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.26	-0.32	1.21e-9	Sudden cardiac arrest;
LUSC	cis	rs4253772	0.938	rs41329344	chr22:46636930	C/T	cg09491104	chr22:46646882	C22orf40	-0.62	-6.62	-0.34	1.47e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs6460942	0.591	rs7800823	chr7:12378697	G/T	cg06484146	chr7:12443880	VWDE	-0.46	-6.14	-0.32	2.37e-9	Coronary artery disease;
LUSC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	15.92	0.66	7.28e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16410656	chr11:35965504	LDLRAD3	-0.46	-6.04	-0.31	4.22e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.85	11.36	0.53	1.62e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.14	0.45	6.18e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6500395	0.962	rs9921737	chr16:48589873	G/T	cg04672837	chr16:48644449	N4BP1	0.43	6.17	0.32	1.94e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs2665103	0.715	rs7403041	chr15:82580182	A/C	cg18393722	chr15:85113863	UBE2QP1	0.45	7.03	0.36	1.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg21963583	chr11:68658836	MRPL21	0.56	8.66	0.43	2.09e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg22907277	chr7:1156413	C7orf50	0.72	7.61	0.38	2.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.18	0.77	1.27e-67	Prudent dietary pattern;
LUSC	cis	rs4443100	0.792	rs9612223	chr22:23389142	T/G	cg21100191	chr22:23484243	RTDR1	0.55	6.6	0.34	1.62e-10	Serum parathyroid hormone levels;
LUSC	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.91	15.42	0.64	7e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg18758796	chr5:131593413	PDLIM4	0.44	7.44	0.38	8.46e-13	Breast cancer;
LUSC	cis	rs7605827	0.930	rs9287664	chr2:15597116	A/G	cg19274914	chr2:15703543	NA	-0.48	-9.42	-0.46	7.41e-19	Educational attainment (years of education);
LUSC	cis	rs870825	0.860	rs2705895	chr4:185598404	C/T	cg04058563	chr4:185651563	MLF1IP	-0.79	-12.08	-0.55	4.06e-28	Blood protein levels;
LUSC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg05738196	chr6:26577821	NA	0.48	7.04	0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7949030	1.000	rs3018561	chr11:62392229	C/A	cg11742103	chr11:62369870	EML3;MTA2	-0.48	-8.08	-0.4	1.23e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	9.26	0.45	2.48e-18	Lung cancer in ever smokers;
LUSC	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg17470723	chr8:74884337	TCEB1	0.5	7.38	0.37	1.23e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg02772935	chr3:125709198	NA	-0.48	-5.81	-0.3	1.49e-8	Blood pressure (smoking interaction);
LUSC	trans	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.81	12.12	0.55	2.97e-28	Colorectal cancer;
LUSC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-0.88	-16.78	-0.68	2.87e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	0.88	13.29	0.59	1.19e-32	Blood protein levels;
LUSC	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07080220	chr10:102295463	HIF1AN	-0.55	-7.76	-0.39	1.07e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg20243544	chr17:37824526	PNMT	0.39	6.11	0.32	2.75e-9	Self-reported allergy;
LUSC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg15145296	chr3:125709740	NA	-0.58	-6.41	-0.33	4.91e-10	Blood pressure (smoking interaction);
LUSC	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg14092571	chr14:90743983	NA	-0.35	-5.71	-0.3	2.45e-8	Mortality in heart failure;
LUSC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs911119	1.000	rs6036476	chr20:23610308	C/G	cg16589663	chr20:23618590	CST3	0.59	6.95	0.36	1.88e-11	Chronic kidney disease;
LUSC	cis	rs6494488	0.500	rs111858590	chr15:65063622	C/A	cg08069370	chr15:64387884	SNX1	-0.65	-5.85	-0.31	1.15e-8	Coronary artery disease;
LUSC	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg17719053	chr1:75198211	TYW3;CRYZ	0.39	5.69	0.3	2.78e-8	Resistin levels;
LUSC	cis	rs9807989	0.507	rs6755905	chr2:103048207	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.06	0.36	9.98e-12	Asthma;
LUSC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg24250549	chr1:154909240	PMVK	0.66	11.1	0.52	1.36e-24	Prostate cancer;
LUSC	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg08888203	chr3:10149979	C3orf24	0.46	7.0	0.36	1.41e-11	Alzheimer's disease;
LUSC	cis	rs9311676	0.656	rs56028017	chr3:58372508	C/T	cg26110898	chr3:58419937	PDHB	0.41	6.69	0.34	9.67e-11	Systemic lupus erythematosus;
LUSC	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07080220	chr10:102295463	HIF1AN	0.67	9.41	0.46	8.22e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.26	-0.49	1.18e-21	Platelet count;
LUSC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-8.32	-0.41	2.21e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg18753928	chr3:113234510	CCDC52	-0.54	-8.21	-0.41	4.85e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg19318889	chr4:1322082	MAEA	0.43	5.66	0.3	3.22e-8	Recombination rate (females);
LUSC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg08508325	chr11:3079039	CARS	-0.53	-13.82	-0.6	1.15e-34	Longevity;
LUSC	cis	rs11971779	0.715	rs11772771	chr7:139058803	T/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.03	0.36	1.16e-11	Diisocyanate-induced asthma;
LUSC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14298792	chr15:30685198	CHRFAM7A	-0.46	-5.66	-0.3	3.32e-8	Huntington's disease progression;
LUSC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	0.93	20.17	0.74	9.82e-60	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6942756	0.876	rs28636722	chr7:129015151	C/T	cg02491457	chr7:128862824	NA	-0.41	-5.95	-0.31	6.64e-9	White matter hyperintensity burden;
LUSC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.33	0.53	2.21e-25	Menopause (age at onset);
LUSC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg16339924	chr4:17578868	LAP3	0.59	9.15	0.45	5.86e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg19418458	chr7:158789849	NA	0.63	10.61	0.5	7.41e-23	Facial morphology (factor 20);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg00476814	chr22:19974536	ARVCF	0.38	6.46	0.33	3.64e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg24562669	chr7:97807699	LMTK2	0.35	6.06	0.31	3.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg24011408	chr12:48396354	COL2A1	0.48	8.06	0.4	1.42e-14	Platelet count;
LUSC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg23985595	chr17:80112537	CCDC57	-0.3	-5.7	-0.3	2.64e-8	Life satisfaction;
LUSC	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.38	-0.37	1.25e-12	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.85	-0.3	1.2e-8	Recombination rate (females);
LUSC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg13685833	chr1:53393034	SCP2	-0.37	-5.67	-0.3	3.08e-8	Monocyte count;
LUSC	cis	rs3760982	0.935	rs10422990	chr19:44295273	C/T	cg11993925	chr19:44307056	LYPD5	0.28	6.06	0.31	3.68e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg17420585	chr12:42539391	GXYLT1	-0.39	-7.78	-0.39	9.23e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg06271696	chr7:157225062	NA	-0.39	-7.66	-0.39	2.09e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg18825119	chr6:163149453	PACRG;PARK2	-0.36	-6.48	-0.33	3.22e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg27494647	chr7:150038898	RARRES2	0.46	6.91	0.35	2.52e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg10729496	chr3:10149963	C3orf24	0.52	6.96	0.36	1.76e-11	Alzheimer's disease;
LUSC	cis	rs28655083	0.550	rs598340	chr16:77102504	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.39	6.26	0.32	1.21e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	8.61	0.43	2.83e-16	Schizophrenia;
LUSC	cis	rs7923609	0.936	rs10822160	chr10:65112796	T/G	cg01631684	chr10:65280961	REEP3	-0.41	-6.31	-0.33	8.98e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg00745463	chr17:30367425	LRRC37B	-0.87	-10.22	-0.49	1.66e-21	Hip circumference adjusted for BMI;
LUSC	cis	rs10193935	0.901	rs222486	chr2:42649664	C/T	cg27598129	chr2:42591480	NA	-0.59	-8.06	-0.4	1.38e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg25214090	chr10:38739885	LOC399744	0.43	6.47	0.33	3.54e-10	Corneal astigmatism;
LUSC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.69	0.43	1.66e-16	Prudent dietary pattern;
LUSC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15664640	chr17:80829946	TBCD	-0.62	-8.34	-0.42	1.94e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUSC	cis	rs1775715	0.677	rs2808074	chr10:32179184	A/C	cg26784012	chr10:32216390	ARHGAP12	0.46	7.84	0.39	6.15e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg12575136	chr18:32820987	ZNF397	0.53	9.47	0.46	5.11e-19	White blood cell count;
LUSC	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg12140854	chr5:148520817	ABLIM3	-0.42	-6.17	-0.32	2.01e-9	Breast cancer;
LUSC	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg23649088	chr2:200775458	C2orf69	-0.52	-8.05	-0.4	1.5e-14	Osteoporosis;
LUSC	cis	rs977987	0.931	rs11641430	chr16:75495276	T/C	cg03315344	chr16:75512273	CHST6	0.52	9.8	0.47	4.44e-20	Dupuytren's disease;
LUSC	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg02466173	chr16:30829666	NA	-0.57	-10.48	-0.5	2.16e-22	Multiple myeloma;
LUSC	cis	rs13089785	0.725	rs2222822	chr3:123604788	T/A	cg19611163	chr3:123411211	MYLK	0.35	5.85	0.3	1.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-11.9	-0.55	1.77e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg23630131	chr7:65973040	NA	-0.21	-5.8	-0.3	1.55e-8	Aortic root size;
LUSC	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg22709100	chr7:91322751	NA	-0.39	-5.8	-0.3	1.56e-8	Breast cancer;
LUSC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	0.83	11.94	0.55	1.26e-27	Breast cancer;
LUSC	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.01	-20.42	-0.75	9.81e-61	Ulcerative colitis;
LUSC	cis	rs1891275	0.509	rs34190234	chr10:93443074	A/C	cg07889827	chr10:93443413	NA	-0.38	-8.35	-0.42	1.86e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg08493051	chr2:3487164	NA	-0.52	-8.29	-0.41	2.75e-15	Neurofibrillary tangles;
LUSC	cis	rs17125944	0.615	rs12587286	chr14:53304751	C/T	cg00686598	chr14:53173677	PSMC6	0.92	7.65	0.39	2.15e-13	Alzheimer's disease (late onset);
LUSC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.5	-7.07	-0.36	8.9e-12	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.28	-0.41	2.98e-15	Morning vs. evening chronotype;
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-8.08	-0.4	1.16e-14	Longevity;Endometriosis;
LUSC	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	0.94	13.31	0.59	1.05e-32	Primary sclerosing cholangitis;
LUSC	cis	rs753274	0.650	rs72998945	chr19:14418441	C/A	cg25450033	chr19:14444658	NA	0.34	5.84	0.3	1.25e-8	Tumor necrosis factor beta levels;
LUSC	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21984481	chr17:79567631	NPLOC4	-0.72	-14.88	-0.63	9e-39	Eye color traits;
LUSC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg25174290	chr11:3078921	CARS	0.59	9.47	0.46	5.12e-19	Longevity;
LUSC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21028142	chr17:79581711	NPLOC4	0.34	8.33	0.41	2.11e-15	Eye color traits;
LUSC	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg22618164	chr12:122356400	WDR66	0.55	8.0	0.4	2.01e-14	Mean corpuscular volume;
LUSC	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.61	-9.21	-0.45	3.72e-18	Morning vs. evening chronotype;
LUSC	trans	rs67133203	0.904	rs12830073	chr12:51419381	G/A	cg17484237	chr5:156536107	HAVCR2	0.44	5.97	0.31	6.1e-9	Urinary tract infection frequency;
LUSC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg23205692	chr1:25664452	TMEM50A	0.39	5.83	0.3	1.33e-8	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg20135002	chr11:47629003	NA	-0.44	-7.08	-0.36	8.5e-12	Subjective well-being;
LUSC	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg03732007	chr1:2071316	PRKCZ	0.48	7.65	0.39	2.18e-13	Height;
LUSC	cis	rs77741769	1.000	rs77741769	chr12:121363835	C/T	cg02419362	chr12:121203948	SPPL3	0.35	5.85	0.3	1.2e-8	Mean corpuscular volume;
LUSC	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg05110241	chr16:68378359	PRMT7	-0.56	-6.51	-0.34	2.7e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg27411982	chr8:10470053	RP1L1	0.4	6.09	0.32	3.15e-9	Mood instability;
LUSC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.89	-18.1	-0.7	1.6e-51	Intelligence (multi-trait analysis);
LUSC	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg05855489	chr10:104503620	C10orf26	0.6	9.57	0.46	2.47e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06028605	chr16:24865363	SLC5A11	-0.68	-10.81	-0.51	1.45e-23	Intelligence (multi-trait analysis);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg14498460	chr14:104129107	KLC1	-0.39	-6.33	-0.33	8.1e-10	N-glycan levels;
LUSC	cis	rs9807989	0.765	rs6704565	chr2:102967431	G/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.85	0.3	1.19e-8	Asthma;
LUSC	cis	rs10949834	0.517	rs810536	chr7:73504233	G/A	cg07137043	chr7:73588983	EIF4H	0.52	6.27	0.32	1.12e-9	Verbal memory performance (residualized delayed recall change);
LUSC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg02772935	chr3:125709198	NA	-0.48	-5.86	-0.31	1.12e-8	Blood pressure (smoking interaction);
LUSC	cis	rs4964805	1.000	rs4964806	chr12:104192760	C/T	cg02344784	chr12:104178138	NT5DC3	0.45	7.15	0.36	5.34e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs6494488	0.500	rs72741307	chr15:64700223	G/A	cg08069370	chr15:64387884	SNX1	-0.65	-5.71	-0.3	2.54e-8	Coronary artery disease;
LUSC	trans	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.68e-9	Depression;
LUSC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg02569458	chr12:86230093	RASSF9	0.42	6.67	0.34	1.09e-10	Major depressive disorder;
LUSC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg05082376	chr22:42548792	NA	-0.43	-6.43	-0.33	4.34e-10	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg03676636	chr4:99064102	C4orf37	-0.34	-7.6	-0.38	3.09e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.25	0.52	4.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg04414720	chr1:150670196	GOLPH3L	0.53	8.26	0.41	3.52e-15	Melanoma;
LUSC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.8	11.62	0.54	1.91e-26	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs977987	0.806	rs4887824	chr16:75441613	T/C	cg03315344	chr16:75512273	CHST6	0.48	8.94	0.44	2.8e-17	Dupuytren's disease;
LUSC	trans	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg21659725	chr3:3221576	CRBN	-0.68	-7.85	-0.39	5.77e-14	Menarche (age at onset);
LUSC	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.34	-0.37	1.69e-12	Neuroticism;
LUSC	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.68	-11.3	-0.53	2.71e-25	Caffeine consumption;
LUSC	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-15.19	-0.64	5.5e-40	Exhaled nitric oxide output;
LUSC	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg02423579	chr7:2872169	GNA12	-0.42	-6.6	-0.34	1.61e-10	Height;
LUSC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg27170947	chr2:26402098	FAM59B	0.65	9.56	0.46	2.73e-19	Gut microbiome composition (summer);
LUSC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg03351412	chr1:154909251	PMVK	0.55	8.85	0.44	5.3e-17	Prostate cancer;
LUSC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12311346	chr5:56204834	C5orf35	-0.84	-12.95	-0.58	2.23e-31	Initial pursuit acceleration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22317537	chr8:144099822	LY6E;LOC100133669	0.42	6.36	0.33	6.56e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg13319975	chr6:146136371	FBXO30	0.48	7.23	0.37	3.33e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07677032	chr17:61819896	STRADA	0.55	9.2	0.45	4.08e-18	Prudent dietary pattern;
LUSC	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg13010199	chr12:38710504	ALG10B	0.43	6.49	0.33	3.18e-10	Morning vs. evening chronotype;
LUSC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg06238570	chr21:40685208	BRWD1	0.45	6.92	0.35	2.29e-11	Cognitive function;
LUSC	cis	rs4443100	0.958	rs9608066	chr22:23387172	A/G	cg21100191	chr22:23484243	RTDR1	0.47	5.69	0.3	2.8e-8	Serum parathyroid hormone levels;
LUSC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.24	-0.37	3.02e-12	Bipolar disorder;
LUSC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.53	0.57	8.85e-30	Motion sickness;
LUSC	cis	rs7119038	0.818	rs10892288	chr11:118644694	A/G	cg19308663	chr11:118741387	NA	0.37	6.33	0.33	7.82e-10	Sjögren's syndrome;
LUSC	cis	rs80282103	0.764	rs10047382	chr10:1102868	T/C	cg18964960	chr10:1102726	WDR37	0.73	6.71	0.34	8.45e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg18105134	chr13:113819100	PROZ	-0.7	-10.1	-0.48	4.04e-21	Platelet distribution width;
LUSC	cis	rs11997175	0.600	rs4739590	chr8:33802686	A/G	ch.8.33884649F	chr8:33765107	NA	0.4	6.31	0.33	8.68e-10	Body mass index;
LUSC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg17173187	chr15:85201210	NMB	0.37	6.44	0.33	4.09e-10	Bipolar disorder lithium response (categorical) or schizophrenia;
LUSC	cis	rs11229555	0.609	rs7128459	chr11:58179291	C/T	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg02023728	chr11:77925099	USP35	0.52	7.27	0.37	2.52e-12	Testicular germ cell tumor;
LUSC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.67	8.57	0.42	3.82e-16	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	0.99	19.43	0.73	8.48e-57	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg08601574	chr20:25228251	PYGB	0.39	5.96	0.31	6.48e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg08807101	chr21:30365312	RNF160	0.5	7.44	0.38	8.77e-13	Pancreatic cancer;
LUSC	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg25427524	chr10:38739819	LOC399744	0.42	5.67	0.3	3.04e-8	Obesity (extreme);
LUSC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.97	-0.51	4.1e-24	Aortic root size;
LUSC	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg05182265	chr7:156933206	UBE3C	0.58	9.39	0.46	9.77e-19	Body mass index;
LUSC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg01528321	chr10:82214614	TSPAN14	0.62	9.02	0.44	1.54e-17	Post bronchodilator FEV1;
LUSC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg09359103	chr1:154839909	KCNN3	-0.58	-12.02	-0.55	6.79e-28	Prostate cancer;
LUSC	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.79	0.3	1.64e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg05555928	chr11:63887634	MACROD1	0.33	5.77	0.3	1.79e-8	Platelet count;
LUSC	cis	rs11209185	0.545	rs12030775	chr1:68421189	A/T	cg22082780	chr1:68452167	NA	0.4	6.81	0.35	4.47e-11	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.9	-0.35	2.57e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.82	-0.3	1.39e-8	Bipolar disorder;
LUSC	cis	rs6500395	1.000	rs7187513	chr16:48591638	T/C	cg04672837	chr16:48644449	N4BP1	0.43	6.47	0.33	3.44e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6961069	0.585	rs62461689	chr7:80245769	G/C	cg04458919	chr7:80252533	CD36	-0.39	-6.88	-0.35	2.9e-11	Platelet count;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26140352	chr6:83777368	DOPEY1	0.75	6.51	0.34	2.75e-10	Cognitive performance;
LUSC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg16624210	chr5:671434	TPPP	0.5	6.54	0.34	2.35e-10	Obesity-related traits;
LUSC	cis	rs3916	0.641	rs2393749	chr12:121131891	C/T	cg27246729	chr12:121163418	ACADS	0.39	6.13	0.32	2.43e-9	Urinary metabolites (H-NMR features);
LUSC	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg11984989	chr7:158649758	WDR60	-0.99	-17.05	-0.68	2.43e-47	Height;
LUSC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.59	8.78	0.43	8.59e-17	Alzheimer's disease;
LUSC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg00129232	chr17:37814104	STARD3	-0.41	-5.85	-0.3	1.18e-8	Asthma;
LUSC	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg00745463	chr17:30367425	LRRC37B	-0.48	-6.33	-0.33	8.01e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs8113142	0.614	rs73028023	chr19:29134072	C/T	cg04546413	chr19:29218101	NA	0.43	5.91	0.31	8.41e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg11584989	chr19:19387371	SF4	-0.62	-7.26	-0.37	2.72e-12	Bipolar disorder;
LUSC	cis	rs6961069	0.742	rs3211849	chr7:80283323	A/G	cg04458919	chr7:80252533	CD36	-0.34	-6.08	-0.32	3.34e-9	Platelet count;
LUSC	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg06623918	chr6:96969491	KIAA0776	-0.83	-12.1	-0.55	3.35e-28	Migraine;Coronary artery disease;
LUSC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.47	-7.07	-0.36	8.91e-12	Alzheimer's disease (late onset);
LUSC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	11.32	0.53	2.22e-25	Colorectal cancer;
LUSC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg01879757	chr17:41196368	BRCA1	-0.46	-6.9	-0.35	2.59e-11	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.32e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs56399783	0.614	rs116929101	chr7:2760325	G/A	cg19731401	chr7:2775893	GNA12	0.71	8.3	0.41	2.59e-15	Childhood ear infection;
LUSC	cis	rs9715521	0.677	rs17493148	chr4:59861895	T/C	cg11281224	chr4:60001000	NA	-0.51	-6.97	-0.36	1.73e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9905704	0.633	rs917016	chr17:56454156	C/T	cg12560992	chr17:57184187	TRIM37	-0.48	-5.66	-0.3	3.18e-8	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.63	-0.39	2.43e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.21	0.45	3.72e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4363385	0.747	rs9659623	chr1:152965158	C/T	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.43	-0.38	9.16e-13	Inflammatory skin disease;
LUSC	cis	rs56145559	1	rs56145559	chr2:73623439	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-6.65	-0.34	1.16e-10	Schizophrenia;
LUSC	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg24006582	chr15:45444508	DUOX1	-0.61	-8.96	-0.44	2.4e-17	Uric acid levels;
LUSC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg04369109	chr6:150039330	LATS1	-0.54	-7.78	-0.39	9.26e-14	Lung cancer;
LUSC	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg21521518	chr4:53727714	RASL11B	0.44	5.85	0.3	1.19e-8	Optic nerve measurement (cup area);
LUSC	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg25206134	chr2:45395956	NA	-0.55	-6.55	-0.34	2.13e-10	Bipolar disorder;
LUSC	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.07	-0.36	8.87e-12	Schizophrenia;
LUSC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-0.84	-9.09	-0.45	9.11e-18	Breast cancer;
LUSC	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg17376030	chr22:41985996	PMM1	-0.47	-5.76	-0.3	1.89e-8	Cannabis dependence symptom count;
LUSC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg02951883	chr7:2050386	MAD1L1	-0.35	-5.94	-0.31	7.07e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg24399712	chr22:39784796	NA	-0.61	-10.86	-0.51	1.01e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs7651511	0.651	rs7632308	chr3:141196260	T/C	cg00789793	chr3:141329863	RASA2	0.38	5.76	0.3	1.88e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15369054	chr17:80825471	TBCD	0.68	11.24	0.52	4.42e-25	Breast cancer;
LUSC	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.54	-0.46	3.03e-19	Total cholesterol levels;
LUSC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg18240062	chr17:79603768	NPLOC4	0.6	10.32	0.49	7.26e-22	Eye color traits;
LUSC	cis	rs17253792	0.822	rs74051609	chr14:56171132	G/A	cg01858014	chr14:56050164	KTN1	-0.7	-6.2	-0.32	1.63e-9	Putamen volume;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07229938	chr10:124907600	HMX2	-0.37	-6.07	-0.32	3.39e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.61	8.11	0.41	9.99e-15	High light scatter reticulocyte count;
LUSC	cis	rs7911264	0.739	rs7071905	chr10:94386122	T/G	cg25093409	chr10:94429542	NA	0.36	6.21	0.32	1.59e-9	Inflammatory bowel disease;
LUSC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs3925075	1.000	rs55742763	chr16:31340368	G/A	cg02846316	chr16:31340340	ITGAM	0.36	6.63	0.34	1.33e-10	IgA nephropathy;
LUSC	cis	rs2652834	0.851	rs2652795	chr15:63409265	T/C	cg05507819	chr15:63340323	TPM1	0.46	5.94	0.31	7.3e-9	HDL cholesterol;
LUSC	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg02951883	chr7:2050386	MAD1L1	0.45	6.35	0.33	6.95e-10	Neuroticism;
LUSC	trans	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg19676328	chr12:49525230	TUBA1B	-0.54	-8.69	-0.43	1.62e-16	Total cholesterol levels;
LUSC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg13531842	chr10:38383804	ZNF37A	-0.48	-7.47	-0.38	7.1e-13	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26314531	chr2:26401878	FAM59B	0.75	10.1	0.48	4.27e-21	Gut microbiome composition (summer);
LUSC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg16339924	chr4:17578868	LAP3	-0.58	-8.69	-0.43	1.63e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg06636001	chr8:8085503	FLJ10661	0.5	7.16	0.36	5.12e-12	Systemic lupus erythematosus;
LUSC	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg04362960	chr10:104952993	NT5C2	0.59	9.33	0.45	1.51e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.83	14.48	0.62	3.23e-37	Metabolic syndrome;
LUSC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-10.24	-0.49	1.38e-21	Gut microbiome composition (summer);
LUSC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg11843238	chr5:131593191	PDLIM4	0.36	6.67	0.34	1.05e-10	Blood metabolite levels;
LUSC	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-8.11	-0.41	9.67e-15	Parkinson's disease;
LUSC	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg09184832	chr6:79620586	NA	-0.44	-7.0	-0.36	1.39e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs877282	0.533	rs10904565	chr10:819991	G/T	cg22713356	chr15:30763199	NA	0.72	9.41	0.46	8.34e-19	Uric acid levels;
LUSC	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg22705602	chr4:152727874	NA	-0.35	-7.76	-0.39	1.02e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.82	0.39	7.02e-14	Prudent dietary pattern;
LUSC	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg15744005	chr10:104629667	AS3MT	-0.37	-7.54	-0.38	4.38e-13	Arsenic metabolism;
LUSC	cis	rs3740713	1.000	rs1848048	chr11:18468996	T/C	cg07915343	chr11:18477680	LDHAL6A	-0.54	-6.74	-0.35	6.85e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg15105969	chr2:36825350	FEZ2	-0.43	-5.81	-0.3	1.45e-8	Height;
LUSC	trans	rs11700980	1.000	rs35893000	chr21:30123965	C/T	cg05609335	chr17:75789393	NA	0.41	6.32	0.33	8.58e-10	QRS complex (12-leadsum);
LUSC	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	10.45	0.5	2.73e-22	Coffee consumption (cups per day);
LUSC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg00255919	chr5:131827918	IRF1	0.43	8.28	0.41	3.11e-15	Asthma (sex interaction);
LUSC	cis	rs859767	0.779	rs6430528	chr2:135395348	A/G	cg12500956	chr2:135428796	TMEM163	-0.27	-6.22	-0.32	1.48e-9	Neuroticism;
LUSC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	1.03	19.51	0.73	4.23e-57	Menopause (age at onset);
LUSC	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg23950597	chr19:37808831	NA	-0.63	-7.68	-0.39	1.82e-13	Coronary artery calcification;
LUSC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18301423	chr5:131593218	PDLIM4	0.47	7.38	0.37	1.26e-12	Acylcarnitine levels;
LUSC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.44	6.27	0.32	1.09e-9	Breast cancer;
LUSC	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg00898013	chr13:113819073	PROZ	-0.55	-8.04	-0.4	1.61e-14	Platelet distribution width;
LUSC	trans	rs970548	0.738	rs61854124	chr10:46077158	T/C	cg20477318	chr10:51623047	TIMM23	0.58	5.96	0.31	6.38e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	10.02	0.48	7.97e-21	Lymphocyte counts;
LUSC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13012494	chr21:47604986	C21orf56	0.4	5.82	0.3	1.35e-8	Testicular germ cell tumor;
LUSC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg09359103	chr1:154839909	KCNN3	-0.58	-12.02	-0.55	6.79e-28	Prostate cancer;
LUSC	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.83	-0.39	6.41e-14	Retinal vascular caliber;
LUSC	trans	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg13565492	chr6:43139072	SRF	-0.6	-7.07	-0.36	9.1e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-6.84	-0.35	3.82e-11	Height;
LUSC	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg08000102	chr2:233561755	GIGYF2	0.79	12.38	0.56	3.07e-29	Schizophrenia;
LUSC	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	trans	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg13565492	chr6:43139072	SRF	-0.73	-10.83	-0.51	1.25e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	5.74	0.3	2.12e-8	Neutrophil percentage of white cells;
LUSC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.86	-0.44	4.7e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg24675658	chr1:53192096	ZYG11B	-0.59	-9.32	-0.45	1.67e-18	Monocyte count;
LUSC	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg06627628	chr2:24431161	ITSN2	-0.74	-10.35	-0.49	5.96e-22	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs6489882	0.902	rs4767037	chr12:113372804	A/C	cg20102336	chr12:113376681	OAS3	-0.42	-6.03	-0.31	4.29e-9	Chronic lymphocytic leukemia;
LUSC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg12041069	chr6:45341222	RUNX2;SUPT3H	-0.4	-6.36	-0.33	6.6e-10	Breast cancer;
LUSC	cis	rs35000415	0.688	rs13232316	chr7:128715299	A/T	cg19972273	chr7:128594194	NA	0.54	5.83	0.3	1.34e-8	Systemic lupus erythematosus;
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg04352962	chr1:209979756	IRF6	0.63	10.96	0.51	4.42e-24	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg22143856	chr6:28129313	ZNF389	0.41	5.68	0.3	2.98e-8	Parkinson's disease;
LUSC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg20243544	chr17:37824526	PNMT	0.5	7.2	0.37	4.09e-12	Asthma;
LUSC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.71	12.72	0.57	1.68e-30	Prudent dietary pattern;
LUSC	cis	rs10465746	0.967	rs12118434	chr1:84328629	C/T	cg10977910	chr1:84465055	TTLL7	0.43	6.27	0.32	1.11e-9	Obesity-related traits;
LUSC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg17264618	chr3:40429014	ENTPD3	0.3	6.6	0.34	1.66e-10	Renal cell carcinoma;
LUSC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-5.94	-0.31	7.02e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.44	0.46	6.65e-19	Bipolar disorder;
LUSC	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg21709803	chr11:61594965	FADS2	-0.36	-5.78	-0.3	1.67e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg22681709	chr2:178499509	PDE11A	-0.6	-12.03	-0.55	6.02e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.63	-10.31	-0.49	8.04e-22	Itch intensity from mosquito bite;
LUSC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12794691	chr3:111805077	C3orf52	0.75	5.96	0.31	6.41e-9	Cognitive performance;
LUSC	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg06636001	chr8:8085503	FLJ10661	0.53	7.93	0.4	3.44e-14	Retinal vascular caliber;
LUSC	cis	rs12791968	0.765	rs12226848	chr11:45009204	C/T	cg11846598	chr11:44996168	LOC221122	-0.55	-7.7	-0.39	1.59e-13	Inhibitory control;
LUSC	cis	rs4664304	0.802	rs3792175	chr2:160862804	T/A	cg23995753	chr2:160760732	LY75	-0.32	-5.95	-0.31	6.73e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg02269571	chr22:50332266	NA	-0.57	-8.59	-0.43	3.41e-16	Schizophrenia;
LUSC	cis	rs9311676	0.656	rs62258093	chr3:58371745	T/C	cg26110898	chr3:58419937	PDHB	0.41	6.69	0.34	9.67e-11	Systemic lupus erythematosus;
LUSC	cis	rs34638657	0.732	rs12102917	chr16:82196808	G/A	cg09439754	chr16:82129088	HSD17B2	-0.4	-6.68	-0.34	1.02e-10	Lung adenocarcinoma;
LUSC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg11766577	chr21:47581405	C21orf56	-0.56	-8.78	-0.43	8.84e-17	Testicular germ cell tumor;
LUSC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg17420585	chr12:42539391	GXYLT1	-0.36	-6.8	-0.35	4.82e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg03676636	chr4:99064102	C4orf37	0.33	7.11	0.36	6.98e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2742417	1.000	rs2673036	chr3:45752471	C/T	cg09608765	chr3:45636137	LIMD1	-0.38	-7.53	-0.38	4.87e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs3771570	0.901	rs4675944	chr2:242430170	C/T	cg21155796	chr2:242212141	HDLBP	0.61	7.09	0.36	7.88e-12	Prostate cancer;
LUSC	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.83	-0.43	6.12e-17	Monocyte percentage of white cells;
LUSC	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg19875535	chr5:140030758	IK	-0.54	-8.88	-0.44	4.13e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg24578937	chr1:2090814	PRKCZ	0.57	12.95	0.58	2.37e-31	Height;
LUSC	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.66	0.54	1.35e-26	Cognitive ability;
LUSC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg04518342	chr5:131593106	PDLIM4	0.45	8.21	0.41	5e-15	Breast cancer;
LUSC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	9.76	0.47	5.8e-20	Eosinophil percentage of white cells;
LUSC	cis	rs7833986	1.000	rs61690651	chr8:57096661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	8.87	0.44	4.64e-17	Height;
LUSC	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs17255340	0.577	rs13197603	chr6:84075113	C/T	cg08257003	chr6:84140564	ME1	0.32	7.35	0.37	1.49e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.68	-0.3	2.93e-8	Alzheimer's disease (survival time);
LUSC	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg10523679	chr1:76189770	ACADM	-0.49	-7.16	-0.36	5.33e-12	Daytime sleep phenotypes;
LUSC	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg26769984	chr7:1090371	C7orf50	0.57	7.21	0.37	3.84e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg03161606	chr19:29218774	NA	0.51	6.0	0.31	5.03e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs1298908	0.639	rs2994388	chr10:82034262	A/G	cg01528321	chr10:82214614	TSPAN14	-0.57	-8.21	-0.41	4.74e-15	Diabetic kidney disease;
LUSC	cis	rs17014483	0.749	rs2924935	chr4:89640567	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.65	5.75	0.3	2.07e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.12e-9	Menopause (age at onset);
LUSC	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.61	9.25	0.45	2.7e-18	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg20406979	chr6:167373233	NA	0.25	5.96	0.31	6.39e-9	Crohn's disease;
LUSC	cis	rs926392	0.896	rs1569538	chr20:37685216	A/G	cg27552599	chr20:37590471	DHX35	-0.33	-5.84	-0.3	1.23e-8	Dialysis-related mortality;
LUSC	cis	rs11642862	1.000	rs112234000	chr16:30778808	G/A	cg02466173	chr16:30829666	NA	-0.71	-7.59	-0.38	3.31e-13	Tonsillectomy;
LUSC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg11845111	chr2:191398756	TMEM194B	0.56	9.37	0.46	1.16e-18	Pulse pressure;
LUSC	cis	rs983392	0.559	rs1426249	chr11:60002261	C/A	cg20284999	chr11:59952153	MS4A6A	-0.36	-5.97	-0.31	6e-9	Alzheimer's disease (late onset);
LUSC	trans	rs6445525	0.967	rs6792662	chr3:65996707	G/C	cg12639933	chr12:57626296	SHMT2	0.34	6.18	0.32	1.85e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10761482	0.500	rs7080540	chr10:62298586	A/T	cg18175470	chr10:62150864	ANK3	-0.5	-7.23	-0.37	3.25e-12	Schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20956373	chr1:22109557	USP48	-0.43	-6.08	-0.32	3.34e-9	Electrocardiographic conduction measures;
LUSC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05165339	chr4:1420672	NA	0.29	6.5	0.33	2.98e-10	Longevity;
LUSC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17261708	chr5:176794207	RGS14	0.34	5.97	0.31	5.95e-9	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg15556689	chr8:8085844	FLJ10661	0.68	10.76	0.51	2.23e-23	Joint mobility (Beighton score);
LUSC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.01	-0.4	1.87e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg07741184	chr6:167504864	NA	0.37	6.72	0.35	7.82e-11	Crohn's disease;
LUSC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg05855489	chr10:104503620	C10orf26	0.58	9.35	0.46	1.33e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs17739794	0.517	rs6559193	chr8:775451	C/T	cg07178994	chr8:816998	NA	-0.39	-5.84	-0.3	1.25e-8	Clozapine-induced cytotoxicity;
LUSC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06028605	chr16:24865363	SLC5A11	-0.69	-10.95	-0.51	4.66e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9318086	0.935	rs2025701	chr13:24440581	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.4	6.09	0.32	3.05e-9	Myopia (pathological);
LUSC	cis	rs3824867	0.959	rs4237544	chr11:47454271	G/T	cg20307385	chr11:47447363	PSMC3	-0.63	-9.29	-0.45	2e-18	Mean corpuscular hemoglobin;
LUSC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.93	0.35	2.16e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg07817883	chr1:32538562	TMEM39B	-0.57	-6.73	-0.35	7.39e-11	Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg18825076	chr15:78729989	IREB2	0.44	6.13	0.32	2.46e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg13042288	chr15:90349979	ANPEP	0.48	7.12	0.36	6.61e-12	Uric acid levels;
LUSC	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg27432699	chr2:27873401	GPN1	0.83	15.87	0.66	1.14e-42	Oral cavity cancer;
LUSC	cis	rs9807989	0.811	rs11689730	chr2:102969984	C/A	cg09003973	chr2:102972529	NA	0.44	6.04	0.31	4.15e-9	Asthma;
LUSC	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06002616	chr8:101225028	SPAG1	0.47	8.1	0.41	1.04e-14	Atrioventricular conduction;
LUSC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg21782813	chr7:2030301	MAD1L1	0.57	10.02	0.48	7.5e-21	Bipolar disorder and schizophrenia;
LUSC	trans	rs7495211	0.529	rs11247364	chr15:98623984	A/T	cg08901157	chr15:56033728	PRTG	0.34	5.98	0.31	5.86e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7181230	0.961	rs7183977	chr15:40377092	C/T	cg22705835	chr10:65332833	REEP3	0.4	6.86	0.35	3.27e-11	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg00484396	chr16:3507460	NAT15	-0.89	-10.55	-0.5	1.23e-22	Tuberculosis;
LUSC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8014204	0.762	rs12891131	chr14:75240090	A/G	cg06637938	chr14:75390232	RPS6KL1	0.51	8.01	0.4	1.95e-14	Caffeine consumption;
LUSC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg02891314	chr5:179741120	GFPT2	-0.65	-10.62	-0.5	7.07e-23	Height;
LUSC	cis	rs7508679	1.000	rs4804411	chr19:7222377	G/C	cg09779027	chr19:7224513	INSR	0.43	9.37	0.46	1.09e-18	Hypothyroidism;
LUSC	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-7.38	-0.37	1.29e-12	Axial length;
LUSC	cis	rs1950626	0.750	rs12895798	chr14:101442793	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.77	0.39	9.82e-14	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs62103177	0.564	rs3930042	chr18:77723843	G/A	cg20368463	chr18:77673604	PQLC1	0.73	7.51	0.38	5.47e-13	Opioid sensitivity;
LUSC	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg18825076	chr15:78729989	IREB2	-0.46	-6.26	-0.32	1.2e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.48	0.69	4.89e-49	Chronic sinus infection;
LUSC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg01765077	chr12:122356316	WDR66	0.52	7.27	0.37	2.58e-12	Mean corpuscular volume;
LUSC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.7	12.12	0.55	2.81e-28	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25072359	chr17:41440525	NA	0.65	9.38	0.46	1.06e-18	Menopause (age at onset);
LUSC	cis	rs4654899	0.758	rs4457549	chr1:21487231	A/G	cg01072550	chr1:21505969	NA	0.53	8.07	0.4	1.28e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04978709	chr7:75101039	POM121C	0.47	6.96	0.36	1.77e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg03188948	chr7:1209495	NA	0.47	6.21	0.32	1.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg01237263	chr17:21179546	NA	0.42	6.47	0.33	3.5e-10	N-glycan levels;
LUSC	cis	rs6076065	0.644	rs1056394	chr20:23337422	G/A	cg11657817	chr20:23433608	CST11	0.44	8.24	0.41	3.88e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.45	6.74	0.35	6.97e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg04545296	chr12:48745243	ZNF641	0.3	5.74	0.3	2.17e-8	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs1044826	1.000	rs964227	chr3:139156093	C/A	cg00490450	chr3:139108681	COPB2	0.53	6.95	0.36	1.94e-11	Obesity-related traits;
LUSC	cis	rs77372450	0.636	rs10052322	chr5:157014420	C/A	cg25387487	chr5:157003181	ADAM19	-0.5	-5.83	-0.3	1.28e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg09835421	chr16:68378352	PRMT7	-0.54	-6.15	-0.32	2.18e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25072359	chr17:41440525	NA	0.64	9.15	0.45	5.64e-18	Menopause (age at onset);
LUSC	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg18105134	chr13:113819100	PROZ	-0.7	-9.96	-0.48	1.22e-20	Platelet distribution width;
LUSC	cis	rs9296092	0.500	rs9461885	chr6:33521069	G/T	cg13560919	chr6:33536144	NA	-0.82	-15.74	-0.65	3.89e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.2	0.64	4.94e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12946454	0.621	rs11651809	chr17:43255681	C/G	cg10701640	chr17:43249399	NA	0.52	12.37	0.56	3.42e-29	Systolic blood pressure;
LUSC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.71	11.06	0.52	1.87e-24	Aortic root size;
LUSC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.42	-7.01	-0.36	1.3e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg15117754	chr3:10150083	C3orf24	0.44	5.66	0.3	3.32e-8	Alzheimer's disease;
LUSC	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg21132104	chr15:45694354	SPATA5L1	0.41	5.94	0.31	7.1e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg00343986	chr7:65444356	GUSB	0.46	6.94	0.35	2.09e-11	Aortic root size;
LUSC	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg05347473	chr6:146136440	FBXO30	-0.38	-6.3	-0.33	9.35e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg17143192	chr8:8559678	CLDN23	0.56	8.14	0.41	7.92e-15	Obesity-related traits;
LUSC	cis	rs41307935	0.822	rs71636786	chr1:27177925	T/A	cg25841309	chr1:27248983	NUDC	-0.65	-5.81	-0.3	1.42e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg15704280	chr7:45808275	SEPT13	-0.46	-6.29	-0.33	1e-9	HDL cholesterol;
LUSC	cis	rs1185460	0.967	rs1307145	chr11:118950217	C/G	cg23280166	chr11:118938394	VPS11	0.47	7.27	0.37	2.55e-12	Coronary artery disease;
LUSC	trans	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.96	19.57	0.73	2.38e-57	Colorectal cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16925090	chr11:101785516	KIAA1377;ANGPTL5	0.49	7.21	0.37	3.83e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg09092052	chr15:45571596	NA	-0.46	-6.28	-0.33	1.03e-9	Glomerular filtration rate;
LUSC	cis	rs2798269	0.668	rs1200055	chr13:22086127	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.02	-0.31	4.56e-9	PR segment;
LUSC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.83	-0.3	1.33e-8	Platelet count;
LUSC	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg14154082	chr13:112174009	NA	0.38	7.95	0.4	2.97e-14	Menarche (age at onset);
LUSC	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg18105134	chr13:113819100	PROZ	0.57	6.97	0.36	1.75e-11	Blood protein levels;
LUSC	cis	rs9788721	0.967	rs55853698	chr15:78857939	T/G	cg06917634	chr15:78832804	PSMA4	-0.48	-6.37	-0.33	6.11e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg00012203	chr2:219082015	ARPC2	0.89	17.23	0.69	4.71e-48	Colorectal cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05736393	chr2:74775957	LOXL3	0.45	6.87	0.35	3.19e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19433769	chr4:2420260	ZFYVE28	-0.39	-5.99	-0.31	5.46e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg20573242	chr4:122745356	CCNA2	0.44	6.76	0.35	6.05e-11	Type 2 diabetes;
LUSC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-5.69	-0.3	2.85e-8	Vitiligo;
LUSC	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg23505145	chr19:12996616	KLF1	0.64	10.29	0.49	9.57e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-0.91	-14.09	-0.61	1.06e-35	Prostate cancer;
LUSC	trans	rs2786098	0.656	rs12116519	chr1:197565337	C/T	cg16005942	chr6:160526640	IGF2R	0.5	6.02	0.31	4.61e-9	Asthma;
LUSC	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg23029597	chr12:123009494	RSRC2	-0.68	-8.8	-0.43	7.39e-17	Body mass index;
LUSC	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg14675211	chr2:100938903	LONRF2	0.37	5.76	0.3	1.89e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.3	-7.5	-0.38	5.75e-13	Lymphocyte counts;
LUSC	cis	rs79149102	0.737	rs113915655	chr15:75219722	T/C	cg09165964	chr15:75287851	SCAMP5	-0.9	-6.76	-0.35	6.21e-11	Lung cancer;
LUSC	cis	rs55728055	0.661	rs62237772	chr22:31964975	A/C	cg01338084	chr22:32026380	PISD	0.93	6.77	0.35	5.67e-11	Age-related hearing impairment;
LUSC	trans	rs2786098	0.656	rs12125739	chr1:197529577	T/G	cg16005942	chr6:160526640	IGF2R	0.51	6.08	0.32	3.31e-9	Asthma;
LUSC	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg05738196	chr6:26577821	NA	0.53	8.41	0.42	1.25e-15	Schizophrenia;
LUSC	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg09184832	chr6:79620586	NA	-0.45	-7.35	-0.37	1.57e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg13535736	chr9:111863775	C9orf5	-0.43	-7.1	-0.36	7.64e-12	Menarche (age at onset);
LUSC	cis	rs12493885	0.818	rs73160504	chr3:153773384	C/T	cg17054900	chr3:154042577	DHX36	-0.74	-7.55	-0.38	4.06e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7945718	0.967	rs10831904	chr11:12760937	A/G	cg25843174	chr11:12811716	TEAD1	0.32	7.06	0.36	9.72e-12	Educational attainment (years of education);
LUSC	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.5	-0.34	2.9e-10	Retinal vascular caliber;
LUSC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg13319975	chr6:146136371	FBXO30	0.49	7.39	0.37	1.19e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-10.3	-0.49	8.75e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.76	-0.35	6.27e-11	Morning vs. evening chronotype;
LUSC	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg00631329	chr6:26305371	NA	0.43	7.7	0.39	1.52e-13	Mosquito bite size;
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg16132339	chr22:24313637	DDTL;DDT	0.4	6.35	0.33	6.96e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg05283184	chr6:79620031	NA	-0.46	-8.4	-0.42	1.34e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg05163923	chr11:71159392	DHCR7	0.7	10.85	0.51	1.05e-23	Vitamin D levels;
LUSC	trans	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg26043149	chr18:55253948	FECH	0.49	7.24	0.37	3.02e-12	Bone mineral density;
LUSC	cis	rs11209002	0.614	rs7552205	chr1:67551741	C/A	cg02640540	chr1:67518911	SLC35D1	0.64	9.0	0.44	1.78e-17	Crohn's disease;
LUSC	trans	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Depression;
LUSC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg13047869	chr3:10149882	C3orf24	0.63	8.73	0.43	1.21e-16	Alzheimer's disease;
LUSC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	6.84	0.35	3.68e-11	Schizophrenia;
LUSC	trans	rs2975734	0.676	rs4841299	chr8:10112593	A/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.33	-0.33	7.9e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs11971779	0.680	rs4732370	chr7:139077240	A/C	cg07862535	chr7:139043722	LUC7L2	-0.54	-6.75	-0.35	6.59e-11	Diisocyanate-induced asthma;
LUSC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	0.73	9.97	0.48	1.14e-20	Gut microbiome composition (summer);
LUSC	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg19622623	chr12:86230825	RASSF9	-0.41	-5.66	-0.3	3.31e-8	Major depressive disorder;
LUSC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	0.99	13.72	0.6	2.7200000000000002e-34	Vitiligo;
LUSC	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg19257562	chr1:2043853	PRKCZ	0.32	6.46	0.33	3.77e-10	Height;
LUSC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg06808227	chr14:105710500	BRF1	-0.68	-10.42	-0.5	3.37e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs17095355	0.901	rs61881586	chr10:111758419	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.35	-0.37	1.53e-12	Biliary atresia;
LUSC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg00857998	chr1:205179979	DSTYK	0.67	10.68	0.5	4.31e-23	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	0.9	16.31	0.67	2.14e-44	Cognitive function;
LUSC	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.12	-0.45	7.12e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.59	0.57	5.28e-30	Prudent dietary pattern;
LUSC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21016266	chr12:122356598	WDR66	0.6	8.83	0.44	5.82e-17	Mean corpuscular volume;
LUSC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg25456477	chr12:86230367	RASSF9	0.34	5.74	0.3	2.16e-8	Major depressive disorder;
LUSC	cis	rs1538970	0.962	rs9429158	chr1:45821393	A/G	cg05343316	chr1:45956843	TESK2	0.59	8.22	0.41	4.53e-15	Platelet count;
LUSC	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-7.59	-0.38	3.15e-13	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs13242816	1.000	rs55833477	chr7:116110375	C/G	cg16553024	chr7:116138462	CAV2	-0.54	-5.92	-0.31	7.84e-9	P wave duration;
LUSC	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.12	0.74	1.49e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg00343986	chr7:65444356	GUSB	-0.48	-7.2	-0.37	3.97e-12	Aortic root size;
LUSC	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg11161011	chr14:65562177	MAX	-0.71	-10.78	-0.51	1.95e-23	Obesity-related traits;
LUSC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg13798780	chr7:105162888	PUS7	-0.53	-6.0	-0.31	4.99e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs3772130	0.923	rs7649092	chr3:121561950	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	9.98	0.48	1.09e-20	Cognitive performance;
LUSC	cis	rs793571	0.502	rs387812	chr15:59074786	T/C	cg05156742	chr15:59063176	FAM63B	0.55	8.74	0.43	1.14e-16	Schizophrenia;
LUSC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg21770322	chr7:97807741	LMTK2	0.43	7.38	0.37	1.26e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs13126694	0.650	rs10028808	chr4:158860640	T/C	cg07447742	chr13:49793170	MLNR	-0.29	-6.09	-0.32	3.07e-9	Blood osmolality (transformed sodium);
LUSC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg08470875	chr2:26401718	FAM59B	-0.69	-9.37	-0.46	1.16e-18	Gut microbiome composition (summer);
LUSC	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg17595323	chr11:93583763	C11orf90	-0.31	-5.67	-0.3	3.09e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-7.95	-0.4	2.87e-14	Major depressive disorder;
LUSC	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg05294307	chr14:35346193	BAZ1A	-0.57	-7.05	-0.36	1.03e-11	Psoriasis;
LUSC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08280861	chr8:58055591	NA	0.54	6.44	0.33	4.06e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg04352962	chr1:209979756	IRF6	0.49	6.3	0.33	9.27e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.82	14.29	0.62	1.77e-36	Blood protein levels;
LUSC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	7.47	0.38	7.28e-13	Breast cancer;
LUSC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg03146154	chr1:46216737	IPP	-0.51	-7.36	-0.37	1.47e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs17604090	1.000	rs17661938	chr7:29693378	C/T	cg19413766	chr7:29689036	LOC646762	-0.62	-7.46	-0.38	7.31e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	trans	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.1	-0.32	2.97e-9	Depression;
LUSC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.8	9.81	0.47	4.05e-20	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9318086	0.712	rs9318099	chr13:24442462	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.43	-6.56	-0.34	2.11e-10	Myopia (pathological);
LUSC	cis	rs7589342	0.839	rs1465641	chr2:106438936	C/T	cg16077055	chr2:106428750	NCK2	0.37	7.0	0.36	1.43e-11	Addiction;
LUSC	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg18232548	chr7:50535776	DDC	0.52	7.0	0.36	1.39e-11	Malaria;
LUSC	trans	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg16724585	chr3:197361211	NA	-0.6	-8.45	-0.42	9.04e-16	Pancreatic cancer;
LUSC	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg04310649	chr10:35416472	CREM	-0.41	-6.32	-0.33	8.17e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.94	19.71	0.73	6.5e-58	Ulcerative colitis;
LUSC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.65	0.3	3.37e-8	Self-reported allergy;
LUSC	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg17366294	chr4:99064904	C4orf37	0.59	10.51	0.5	1.68e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg16447950	chr5:562315	NA	-0.57	-7.04	-0.36	1.12e-11	Obesity-related traits;
LUSC	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg13010199	chr12:38710504	ALG10B	-0.56	-8.82	-0.43	6.69e-17	Morning vs. evening chronotype;
LUSC	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg23711669	chr6:146136114	FBXO30	-0.84	-15.22	-0.64	4.21e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.61	9.71	0.47	8.65e-20	Alcohol dependence;
LUSC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11764359	chr7:65958608	NA	0.68	11.06	0.52	2e-24	Aortic root size;
LUSC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.35	-0.37	1.51e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg14582100	chr15:45693742	SPATA5L1	0.58	10.56	0.5	1.11e-22	Homoarginine levels;
LUSC	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg02158880	chr13:53174818	NA	0.39	5.99	0.31	5.46e-9	Lewy body disease;
LUSC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.31	-0.41	2.51e-15	Obesity-related traits;
LUSC	cis	rs28647808	0.786	rs28458971	chr9:136255736	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs11622475	0.580	rs36026329	chr14:104351661	T/A	cg12183467	chr14:104352244	NA	-0.5	-10.1	-0.48	4.19e-21	Bipolar disorder;
LUSC	cis	rs16976116	0.901	rs1061821	chr15:55496111	T/C	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	13.52	0.59	1.6e-33	Menarche (age at onset);
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	11.13	0.52	1.1e-24	Lymphocyte counts;
LUSC	cis	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg06521331	chr12:34319734	NA	0.39	5.74	0.3	2.14e-8	Resting heart rate;
LUSC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.6	-0.43	3.08e-16	Personality dimensions;
LUSC	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg08079166	chr15:68083412	MAP2K5	0.36	6.2	0.32	1.7e-9	Obesity;
LUSC	cis	rs240764	0.658	rs9322183	chr6:101225121	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.33	-0.33	8e-10	Neuroticism;
LUSC	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.37	-5.8	-0.3	1.55e-8	Diastolic blood pressure;
LUSC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-9.74	-0.47	6.52e-20	Schizophrenia;
LUSC	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg12002119	chr2:101014098	CHST10	-0.35	-5.86	-0.31	1.1e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs73206853	0.688	rs57837519	chr12:110961082	C/T	cg12870014	chr12:110450643	ANKRD13A	0.49	5.86	0.31	1.11e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg00049323	chr5:472564	LOC25845	-0.41	-6.16	-0.32	2.07e-9	Cystic fibrosis severity;
LUSC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.58	9.33	0.45	1.47e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs9886428	1.000	rs34062482	chr8:14115734	A/C	cg19037007	chr20:741798	C20orf54	-0.4	-6.29	-0.33	9.78e-10	IgG glycosylation;
LUSC	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-7.47	-0.38	7.11e-13	Atrioventricular conduction;
LUSC	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.15	0.49	2.74e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	0.61	9.61	0.47	1.78e-19	Breast cancer;
LUSC	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg20991723	chr1:152506922	NA	0.53	9.76	0.47	5.9e-20	Hair morphology;
LUSC	cis	rs12493885	0.818	rs55681005	chr3:153759257	G/T	cg17054900	chr3:154042577	DHX36	-0.75	-7.65	-0.39	2.18e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg24578937	chr1:2090814	PRKCZ	-0.44	-9.86	-0.47	2.77e-20	Height;
LUSC	cis	rs6728642	0.708	rs56807297	chr2:97861340	A/C	cg26665480	chr2:98280029	ACTR1B	-0.73	-5.73	-0.3	2.19e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg00129232	chr17:37814104	STARD3	-0.43	-6.36	-0.33	6.8e-10	Asthma;
LUSC	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg27124370	chr19:33622961	WDR88	0.53	6.69	0.34	9.21e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7973719	0.966	rs1450962	chr12:7320545	A/G	cg07052231	chr12:7363540	PEX5	0.52	8.84	0.44	5.49e-17	IgG glycosylation;
LUSC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg04871131	chr7:94954202	PON1	-0.38	-6.08	-0.32	3.2e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg27588902	chr6:42928151	GNMT	-0.3	-6.6	-0.34	1.65e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs377070	0.934	rs309396	chr4:123614282	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.47	6.79	0.35	5.04e-11	Mosquito bite size;
LUSC	cis	rs2235649	0.592	rs7197113	chr16:1969483	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-5.65	-0.3	3.51e-8	Blood metabolite levels;
LUSC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg11062466	chr8:58055876	NA	0.72	8.93	0.44	2.94e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11645453	chr3:52864694	ITIH4	0.34	8.09	0.4	1.13e-14	Bipolar disorder;
LUSC	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-7.27	-0.37	2.52e-12	Total body bone mineral density;
LUSC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.34	-5.64	-0.3	3.55e-8	Personality dimensions;
LUSC	cis	rs12530845	1.000	rs4291211	chr7:135335373	C/T	cg23117316	chr7:135346802	PL-5283	-0.57	-9.73	-0.47	7.38e-20	Red blood cell traits;
LUSC	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg25427524	chr10:38739819	LOC399744	-0.49	-6.8	-0.35	4.98e-11	Obesity (extreme);
LUSC	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	0.97	11.95	0.55	1.16e-27	Nonalcoholic fatty liver disease;
LUSC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.72	-0.35	7.86e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.07	0.32	3.49e-9	Recombination rate (females);
LUSC	cis	rs7215564	0.908	rs35646299	chr17:78653506	T/G	cg09596252	chr17:78655493	RPTOR	0.56	6.05	0.31	3.85e-9	Myopia (pathological);
LUSC	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg08645402	chr16:4508243	NA	0.53	8.18	0.41	6.1e-15	Schizophrenia;
LUSC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg27094323	chr7:1216898	NA	-0.36	-6.31	-0.33	8.92e-10	Longevity;Endometriosis;
LUSC	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg20503657	chr10:835505	NA	0.85	12.05	0.55	5.19e-28	Eosinophil percentage of granulocytes;
LUSC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.08	-0.36	8.62e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg23711669	chr6:146136114	FBXO30	0.82	14.37	0.62	8.27e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-8.75	-0.43	1.1e-16	Lymphocyte counts;
LUSC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.35	-7.53	-0.38	4.67e-13	Cystic fibrosis severity;
LUSC	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	6.45	0.33	3.92e-10	Height;
LUSC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15506890	chr2:3487001	NA	-0.58	-9.5	-0.46	4.21e-19	Neurofibrillary tangles;
LUSC	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg22089800	chr15:90895588	ZNF774	0.54	7.88	0.4	4.76e-14	Rheumatoid arthritis;
LUSC	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg11502198	chr6:26597334	ABT1	0.7	11.72	0.54	8.63e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg05425664	chr17:57184151	TRIM37	0.55	7.75	0.39	1.08e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs11608355	1.000	rs9669684	chr12:109860644	C/T	cg19025524	chr12:109796872	NA	-0.38	-5.96	-0.31	6.58e-9	Neuroticism;
LUSC	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.88	11.88	0.55	2.12e-27	Mean corpuscular hemoglobin;
LUSC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg17971929	chr21:40555470	PSMG1	-0.63	-10.27	-0.49	1.12e-21	Cognitive function;
LUSC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg10360139	chr7:1886902	MAD1L1	-0.45	-6.96	-0.36	1.83e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7674212	0.539	rs6533056	chr4:104120997	T/C	cg16532752	chr4:104119610	CENPE	-0.47	-6.8	-0.35	4.81e-11	Type 2 diabetes;
LUSC	cis	rs3087591	0.919	rs2012581	chr17:29560800	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.6	-8.75	-0.43	1.09e-16	Hip circumference;
LUSC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg05082376	chr22:42548792	NA	0.43	6.5	0.33	2.98e-10	Schizophrenia;
LUSC	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg11645453	chr3:52864694	ITIH4	0.37	8.32	0.41	2.23e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	0.6	9.22	0.45	3.41e-18	Breast cancer;
LUSC	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg02951883	chr7:2050386	MAD1L1	-0.37	-6.22	-0.32	1.52e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2273669	0.588	rs114414265	chr6:109306489	C/A	cg05315195	chr6:109294784	ARMC2	-0.55	-6.21	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.03	-0.52	2.41e-24	Bipolar disorder;
LUSC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg20135002	chr11:47629003	NA	-0.52	-8.16	-0.41	7.03e-15	Subjective well-being;
LUSC	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg09307838	chr4:120376055	NA	0.69	9.98	0.48	1.05e-20	Corneal astigmatism;
LUSC	cis	rs2806974	0.608	rs1322938	chr13:53731757	A/G	cg14823544	chr13:53775958	NA	-0.33	-5.68	-0.3	2.96e-8	Trans fatty acid levels;
LUSC	cis	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg26958806	chr6:27640298	NA	0.83	6.57	0.34	1.94e-10	Depression;
LUSC	trans	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg10756647	chr7:56101905	PSPH	-0.82	-8.16	-0.41	6.72e-15	Diabetic kidney disease;
LUSC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.71	-0.43	1.38e-16	Bipolar disorder;
LUSC	cis	rs6494488	0.500	rs72742987	chr15:64993757	T/C	cg08069370	chr15:64387884	SNX1	-0.68	-5.9	-0.31	8.97e-9	Coronary artery disease;
LUSC	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg20307385	chr11:47447363	PSMC3	-0.43	-5.66	-0.3	3.24e-8	Neuroticism;
LUSC	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-1.03	-14.46	-0.62	3.7e-37	Exhaled nitric oxide output;
LUSC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-13.0	-0.58	1.54e-31	Platelet count;
LUSC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.65	14.11	0.61	8.97e-36	Hemoglobin concentration;
LUSC	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg24881330	chr22:46731750	TRMU	0.68	8.26	0.41	3.54e-15	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg10253484	chr15:75165896	SCAMP2	0.49	7.24	0.37	3.12e-12	Breast cancer;
LUSC	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.79	-12.39	-0.56	2.84e-29	Schizophrenia;
LUSC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg00310523	chr12:86230176	RASSF9	0.49	9.26	0.45	2.64e-18	Major depressive disorder;
LUSC	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	trans	rs236907	0.859	rs12730717	chr1:171756515	C/T	cg13482142	chr2:234261155	NA	0.48	5.96	0.31	6.35e-9	Mean platelet volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08484668	chr6:157472027	ARID1B	0.47	6.75	0.35	6.49e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg03146154	chr1:46216737	IPP	0.52	7.65	0.39	2.11e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg14844989	chr11:31128820	NA	0.37	5.81	0.3	1.47e-8	Red blood cell count;
LUSC	cis	rs921665	1.000	rs921665	chr2:3174321	A/G	cg16434511	chr2:3151078	NA	-0.48	-5.82	-0.3	1.41e-8	World class endurance athleticism;
LUSC	cis	rs1882538	0.538	rs7803848	chr7:133108547	C/T	cg10665199	chr7:133106180	EXOC4	0.55	7.95	0.4	2.9e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg12641515	chr19:46296257	DMWD	0.48	7.21	0.37	3.84e-12	Coronary artery disease;
LUSC	cis	rs4474465	0.850	rs7117513	chr11:78206418	T/G	cg27205649	chr11:78285834	NARS2	0.51	5.91	0.31	8.55e-9	Alzheimer's disease (survival time);
LUSC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.34	0.59	7.79e-33	Cognitive test performance;
LUSC	cis	rs8133932	0.608	rs403192	chr21:47360641	C/T	cg14185626	chr21:47401492	COL6A1	-0.45	-5.69	-0.3	2.81e-8	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.57	9.86	0.47	2.63e-20	White blood cell count (basophil);White blood cell count;
LUSC	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg24558204	chr6:135376177	HBS1L	0.56	8.5	0.42	6.4e-16	Red blood cell count;
LUSC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.17	0.58	3.43e-32	Chronic sinus infection;
LUSC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg22532475	chr10:104410764	TRIM8	-0.34	-6.59	-0.34	1.67e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg26335602	chr6:28129616	ZNF389	0.65	5.98	0.31	5.69e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg07923666	chr12:49932857	KCNH3	-0.49	-6.08	-0.32	3.33e-9	Resting heart rate;
LUSC	cis	rs2299587	0.585	rs2285304	chr8:17797931	T/A	cg01800426	chr8:17659068	MTUS1	-0.49	-6.54	-0.34	2.33e-10	Economic and political preferences;
LUSC	cis	rs7833986	1.000	rs7833986	chr8:57100149	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.54	8.43	0.42	1.04e-15	Height;
LUSC	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg05887092	chr17:76393375	PGS1	0.54	9.77	0.47	5.3e-20	HDL cholesterol levels;
LUSC	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg05585544	chr11:47624801	NA	-0.4	-6.93	-0.35	2.24e-11	Subjective well-being;
LUSC	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg26677194	chr12:130822605	PIWIL1	0.58	8.72	0.43	1.31e-16	Menopause (age at onset);
LUSC	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg13514129	chr1:39547527	MACF1	0.72	11.83	0.54	3.36e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs12530845	0.887	rs78641973	chr7:135324311	C/T	cg23117316	chr7:135346802	PL-5283	-0.57	-9.07	-0.44	1.01e-17	Red blood cell traits;
LUSC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg05347473	chr6:146136440	FBXO30	0.42	7.22	0.37	3.47e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg11584989	chr19:19387371	SF4	0.57	6.78	0.35	5.44e-11	Bipolar disorder;
LUSC	cis	rs6693567	0.545	rs2275246	chr1:150460168	A/G	cg15654264	chr1:150340011	RPRD2	0.43	6.93	0.35	2.16e-11	Migraine;
LUSC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.59	0.5	8.51e-23	Alzheimer's disease;
LUSC	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.61	0.65	1.27e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9473147	0.516	rs9296561	chr6:47488938	G/A	cg20196966	chr6:47445060	CD2AP	0.42	5.83	0.3	1.31e-8	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09352908	chr3:37017749	NA	0.5	6.03	0.31	4.45e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-6.44	-0.33	4.13e-10	Monocyte count;
LUSC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.67	-12.72	-0.57	1.66e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg07701084	chr6:150067640	NUP43	0.46	6.88	0.35	3.01e-11	Testicular germ cell tumor;
LUSC	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	8.54	0.42	4.96e-16	Retinal vascular caliber;
LUSC	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg05340658	chr4:99064831	C4orf37	0.59	7.91	0.4	3.82e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	11.01	0.52	2.87e-24	Coffee consumption (cups per day);
LUSC	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.55	9.86	0.47	2.68e-20	Bone mineral density;
LUSC	cis	rs654950	0.743	rs115951861	chr1:41992488	C/T	cg06885757	chr1:42089581	HIVEP3	-0.37	-7.28	-0.37	2.38e-12	Airway imaging phenotypes;
LUSC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg21770322	chr7:97807741	LMTK2	0.41	7.06	0.36	9.5e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6845621	0.901	rs4697202	chr4:18920624	A/G	cg12196642	chr4:18937545	NA	-0.34	-6.47	-0.33	3.48e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg14668632	chr7:2872130	GNA12	-0.46	-6.71	-0.34	8.2e-11	Height;
LUSC	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg22508957	chr16:3507546	NAT15	0.44	6.21	0.32	1.56e-9	Body mass index (adult);
LUSC	trans	rs11723530	0.538	rs6419975	chr4:170807934	T/G	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.17	-0.32	2e-9	Myopia (pathological);
LUSC	cis	rs12618769	1.000	rs72825732	chr2:99259778	T/C	cg10123293	chr2:99228465	UNC50	0.43	5.96	0.31	6.29e-9	Bipolar disorder;
LUSC	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg13319975	chr6:146136371	FBXO30	0.51	7.6	0.38	2.98e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.89	0.44	3.86e-17	Schizophrenia;
LUSC	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg24642439	chr20:33292090	TP53INP2	-0.5	-7.48	-0.38	6.76e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.56	-11.56	-0.53	3.23e-26	Sense of smell;
LUSC	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	0.91	17.89	0.7	1.14e-50	Metabolite levels;
LUSC	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg23649088	chr2:200775458	C2orf69	0.49	6.77	0.35	5.85e-11	Schizophrenia;
LUSC	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg21775007	chr8:11205619	TDH	0.78	12.6	0.57	4.65e-30	Retinal vascular caliber;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24517800	chr6:42989357	C6orf153	-0.44	-6.53	-0.34	2.49e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg08916839	chr5:415575	AHRR	0.76	7.11	0.36	6.97e-12	Fat distribution (HIV);
LUSC	cis	rs6733011	0.628	rs1983352	chr2:99454227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.56	-0.34	2.01e-10	Bipolar disorder;
LUSC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.73	-0.57	1.58e-30	Alzheimer's disease;
LUSC	cis	rs3820928	0.874	rs6717168	chr2:227901342	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.81	-0.39	7.61e-14	Pulmonary function;
LUSC	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg26384229	chr12:38710491	ALG10B	0.72	11.37	0.53	1.52e-25	Morning vs. evening chronotype;
LUSC	cis	rs981844	1.000	rs62325105	chr4:154673846	T/C	cg14289246	chr4:154710475	SFRP2	0.5	6.44	0.33	4.05e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg23625390	chr15:77176239	SCAPER	0.5	7.67	0.39	1.92e-13	Blood metabolite levels;
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.93	19.08	0.72	2.06e-55	Menarche (age at onset);
LUSC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.88	0.51	8.56e-24	Bladder cancer;
LUSC	cis	rs11158026	0.757	rs72715573	chr14:55459571	C/T	cg04306507	chr14:55594613	LGALS3	0.37	7.19	0.37	4.15e-12	Parkinson's disease;
LUSC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg11062466	chr8:58055876	NA	0.66	8.67	0.43	1.93e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg16339924	chr4:17578868	LAP3	0.55	7.7	0.39	1.52e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13082711	0.871	rs73046194	chr3:27454558	C/T	cg02860705	chr3:27208620	NA	0.5	8.54	0.42	4.67e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13126279	chr21:47581558	C21orf56	-0.5	-7.52	-0.38	4.98e-13	Testicular germ cell tumor;
LUSC	cis	rs9549260	0.755	rs9577091	chr13:41227865	G/A	cg21288729	chr13:41239152	FOXO1	0.64	9.97	0.48	1.12e-20	Red blood cell count;
LUSC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg25703541	chr22:24373054	LOC391322	0.81	14.24	0.61	2.85e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05360402	chr5:110848191	STARD4	0.42	6.45	0.33	3.92e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.76	-14.31	-0.62	1.43e-36	Ulcerative colitis;
LUSC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.66	-0.39	2.04e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs701145	0.585	rs1713810	chr3:153876826	C/T	cg17054900	chr3:154042577	DHX36	-0.53	-5.69	-0.3	2.82e-8	Coronary artery disease;
LUSC	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg12559939	chr2:27858050	GPN1	0.39	6.03	0.31	4.39e-9	Oral cavity cancer;
LUSC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg17376030	chr22:41985996	PMM1	-0.48	-5.99	-0.31	5.37e-9	Vitiligo;
LUSC	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.9	-0.35	2.58e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5758511	0.573	rs5996069	chr22:42201185	T/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-7.47	-0.38	7.22e-13	Birth weight;
LUSC	cis	rs12220238	1.000	rs10824106	chr10:75958408	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.6	-6.51	-0.34	2.74e-10	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.75	0.39	1.1e-13	Parkinson's disease;
LUSC	cis	rs2307022	0.586	rs10852441	chr16:68385439	T/A	cg02226672	chr16:68398533	SMPD3	0.3	5.69	0.3	2.81e-8	Body mass index;
LUSC	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg05855489	chr10:104503620	C10orf26	0.49	7.36	0.37	1.46e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs3736594	0.513	rs78170284	chr2:27835082	G/A	cg27432699	chr2:27873401	GPN1	0.65	8.55	0.42	4.5e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs2487048	0.725	rs2246293	chr9:107690838	C/G	cg14019050	chr9:107690770	ABCA1	0.27	5.67	0.3	3.17e-8	Intraocular pressure;
LUSC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg11657440	chr19:46296263	DMWD	0.88	16.75	0.68	3.92e-46	Coronary artery disease;
LUSC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg23887609	chr12:130822674	PIWIL1	0.49	7.34	0.37	1.64e-12	Menopause (age at onset);
LUSC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg21251018	chr6:28226885	NKAPL	0.32	6.02	0.31	4.65e-9	Cardiac Troponin-T levels;
LUSC	cis	rs926938	0.584	rs1286558	chr1:115357587	C/T	cg12756093	chr1:115239321	AMPD1	0.48	7.17	0.37	4.86e-12	Autism;
LUSC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	12.21	0.56	1.32e-28	Colorectal cancer;
LUSC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-0.64	-13.19	-0.59	2.96e-32	Prudent dietary pattern;
LUSC	cis	rs1775715	0.870	rs1251407	chr10:32238325	A/G	cg18675610	chr10:32216311	ARHGAP12	0.29	6.2	0.32	1.69e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs11051970	0.879	rs2243815	chr12:32576158	C/T	cg24626660	chr12:32551988	NA	0.33	5.7	0.3	2.69e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.29	-0.33	9.77e-10	Aortic root size;
LUSC	cis	rs9549260	0.592	rs9315783	chr13:41289164	T/C	cg21288729	chr13:41239152	FOXO1	0.55	8.3	0.41	2.7e-15	Red blood cell count;
LUSC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.69	11.23	0.52	4.65e-25	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg20302533	chr7:39170763	POU6F2	0.55	9.13	0.45	6.58e-18	IgG glycosylation;
LUSC	cis	rs10986311	0.775	rs7857897	chr9:127118550	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.46	7.32	0.37	1.89e-12	Vitiligo;
LUSC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg00310523	chr12:86230176	RASSF9	-0.43	-7.91	-0.4	3.85e-14	Major depressive disorder;
LUSC	cis	rs238295	0.805	rs6053500	chr20:5542683	A/G	cg15842884	chr20:5591925	RP5-1022P6.2	-0.43	-5.83	-0.3	1.33e-8	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs6961069	0.538	rs3211886	chr7:80289439	A/G	cg04458919	chr7:80252533	CD36	0.38	6.49	0.33	3.04e-10	Platelet count;
LUSC	cis	rs6700896	0.500	rs1938496	chr1:66100915	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	6.07	0.32	3.56e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg06637938	chr14:75390232	RPS6KL1	0.58	9.16	0.45	5.54e-18	Caffeine consumption;
LUSC	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg18904891	chr8:8559673	CLDN23	0.6	7.9	0.4	4.13e-14	Obesity-related traits;
LUSC	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg16482183	chr6:26056742	HIST1H1C	0.58	8.02	0.4	1.86e-14	Iron status biomarkers;
LUSC	cis	rs6076065	0.612	rs11905630	chr20:23326165	G/C	cg11657817	chr20:23433608	CST11	0.44	8.17	0.41	6.46e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	0.58	9.29	0.45	1.98e-18	Breast cancer;
LUSC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg16339924	chr4:17578868	LAP3	0.57	8.75	0.43	1.11e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg12463550	chr7:65579703	CRCP	-0.55	-8.03	-0.4	1.68e-14	Aortic root size;
LUSC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg24881330	chr22:46731750	TRMU	0.78	7.22	0.37	3.53e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4851254	0.660	rs4851250	chr2:100729293	T/C	cg07810366	chr2:100720526	AFF3	-0.45	-5.89	-0.31	9.37e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7202877	0.706	rs247425	chr16:75460402	C/T	cg04384234	chr16:75411784	CFDP1	0.7	9.72	0.47	7.98e-20	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7615316	1.000	rs6802774	chr3:142351466	G/C	cg16271453	chr3:142027066	XRN1	-0.34	-5.82	-0.3	1.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4663866	0.901	rs3739066	chr2:239184124	G/T	cg16914508	chr2:239161102	PER2	0.68	7.24	0.37	3.04e-12	Irritable bowel syndrome;
LUSC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg27432699	chr2:27873401	GPN1	-0.57	-8.45	-0.42	9.25e-16	Total body bone mineral density;
LUSC	cis	rs7532866	0.885	rs7552065	chr1:26731951	G/T	cg17456097	chr1:26900765	RPS6KA1	-0.43	-6.24	-0.32	1.3e-9	Height;
LUSC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06112835	chr11:68658793	MRPL21	0.49	7.35	0.37	1.57e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg14552801	chr7:65878734	NA	-0.36	-5.68	-0.3	2.91e-8	Aortic root size;
LUSC	cis	rs16895831	0.519	rs12210135	chr6:42570156	G/T	cg10605015	chr6:42532144	UBR2	-0.48	-5.88	-0.31	9.83e-9	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	6.38	0.33	5.95e-10	Bipolar disorder;
LUSC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg16049864	chr8:95962084	TP53INP1	-0.68	-13.49	-0.59	2.08e-33	Type 2 diabetes;
LUSC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.66	-11.66	-0.54	1.34e-26	Aortic root size;
LUSC	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.6	13.83	0.6	1.07e-34	Height;
LUSC	cis	rs727505	1.000	rs10246424	chr7:124494861	A/G	cg23710748	chr7:124431027	NA	-0.41	-7.4	-0.38	1.11e-12	Lewy body disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04616222	chr10:99078965	FRAT1	-0.44	-6.74	-0.35	7.04e-11	Electrocardiographic conduction measures;
LUSC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.53	7.95	0.4	2.87e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.31e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg12310025	chr6:25882481	NA	0.43	7.42	0.38	9.99e-13	Blood metabolite levels;
LUSC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg16447950	chr5:562315	NA	-0.55	-6.69	-0.34	9.35e-11	Obesity-related traits;
LUSC	cis	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg24459738	chr19:57751996	ZNF805	-0.52	-7.69	-0.39	1.67e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs9905704	0.681	rs4277402	chr17:56581651	C/G	cg12560992	chr17:57184187	TRIM37	-0.49	-5.8	-0.3	1.57e-8	Testicular germ cell tumor;
LUSC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.91	17.18	0.68	7.46e-48	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.7	-0.39	1.53e-13	Systolic blood pressure;
LUSC	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	0.93	17.68	0.7	7.64e-50	Headache;
LUSC	cis	rs76878669	0.606	rs2282531	chr11:66099494	C/T	cg24851651	chr11:66362959	CCS	0.4	6.43	0.33	4.36e-10	Educational attainment (years of education);
LUSC	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg18352616	chr4:3374830	RGS12	0.29	5.75	0.3	2.06e-8	Serum sulfate level;
LUSC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg20135002	chr11:47629003	NA	-0.52	-8.13	-0.41	8.23e-15	Subjective well-being;
LUSC	cis	rs2708377	0.799	rs977474	chr12:11284772	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg14552801	chr7:65878734	NA	0.38	5.74	0.3	2.14e-8	Aortic root size;
LUSC	cis	rs7011049	1.000	rs72640848	chr8:53836225	A/G	cg26025543	chr8:53854495	NA	0.5	5.93	0.31	7.37e-9	Systolic blood pressure;
LUSC	trans	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg25214090	chr10:38739885	LOC399744	0.51	7.19	0.37	4.36e-12	Corneal astigmatism;
LUSC	cis	rs3770081	1.000	rs17027011	chr2:86406556	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.87	-6.33	-0.33	7.7e-10	Facial emotion recognition (sad faces);
LUSC	cis	rs73206853	0.841	rs17619763	chr12:110645829	C/T	cg12870014	chr12:110450643	ANKRD13A	0.7	6.64	0.34	1.26e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg18755752	chr8:142205143	DENND3	-0.52	-8.01	-0.4	1.99e-14	Immature fraction of reticulocytes;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12756303	chr2:74692479	MOGS	0.38	6.57	0.34	1.89e-10	Asthma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26904999	chr6:166796588	BRP44L	-0.42	-6.42	-0.33	4.58e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.48	-0.53	6.14e-26	Mean corpuscular volume;
LUSC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.75	-0.51	2.45e-23	Chronic sinus infection;
LUSC	cis	rs136211	0.599	rs9610497	chr22:36767359	C/T	cg21778268	chr22:36877729	TXN2	-0.41	-5.86	-0.31	1.1e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg15556689	chr8:8085844	FLJ10661	0.6	9.07	0.44	1.03e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	7.39	0.37	1.18e-12	Response to antipsychotic treatment;
LUSC	cis	rs977987	0.843	rs62062564	chr16:75442622	G/A	cg03315344	chr16:75512273	CHST6	0.53	10.19	0.49	2.13e-21	Dupuytren's disease;
LUSC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg04155289	chr7:94953770	PON1	-0.34	-5.69	-0.3	2.72e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2806561	0.754	rs750354	chr1:23297406	T/C	cg19743168	chr1:23544995	NA	-0.38	-7.91	-0.4	3.79e-14	Height;
LUSC	cis	rs6580649	0.941	rs7312326	chr12:48480643	G/A	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg11887960	chr12:57824829	NA	-0.52	-6.62	-0.34	1.48e-10	Obesity-related traits;
LUSC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg04546413	chr19:29218101	NA	0.71	11.45	0.53	7.9e-26	Methadone dose in opioid dependence;
LUSC	trans	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.41	-0.33	5.05e-10	Monocyte count;
LUSC	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg06219351	chr7:158114137	PTPRN2	-0.52	-8.26	-0.41	3.46e-15	Response to amphetamines;
LUSC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg17330251	chr7:94953956	PON1	-0.36	-5.86	-0.31	1.08e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9462027	0.628	rs34141614	chr6:34777031	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.75	-0.3	2.03e-8	Systemic lupus erythematosus;
LUSC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg20887711	chr4:1340912	KIAA1530	0.43	6.37	0.33	6.12e-10	Obesity-related traits;
LUSC	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg13010199	chr12:38710504	ALG10B	0.55	8.48	0.42	7.46e-16	Morning vs. evening chronotype;
LUSC	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-12.87	-0.58	4.48e-31	Total body bone mineral density;
LUSC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7202877	0.656	rs4888374	chr16:75322228	T/C	cg04384234	chr16:75411784	CFDP1	-0.63	-8.83	-0.44	5.84e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	trans	rs7493138	0.967	rs61984307	chr14:29017635	T/G	cg10573181	chr4:170533618	NEK1	0.41	6.05	0.31	3.97e-9	Longevity;
LUSC	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg19920283	chr7:105172520	RINT1	0.6	6.35	0.33	7.01e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.88	-11.22	-0.52	5.29e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs4746818	1.000	rs7893492	chr10:70960448	C/T	cg11621586	chr10:70884670	VPS26A	-1.15	-11.44	-0.53	8.66e-26	Left atrial antero-posterior diameter;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg06098346	chr12:48499667	PFKM;SENP1	-0.46	-6.11	-0.32	2.77e-9	Cognitive function;Information processing speed;
LUSC	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg08601574	chr20:25228251	PYGB	-0.43	-6.49	-0.33	3.02e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9581857	0.579	rs76657892	chr13:27997604	A/G	cg22138327	chr13:27999177	GTF3A	0.83	9.37	0.46	1.1e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg15626777	chr1:38157909	CDCA8	0.43	6.26	0.32	1.18e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg27170947	chr2:26402098	FAM59B	-0.63	-9.15	-0.45	5.98e-18	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg17366294	chr4:99064904	C4orf37	0.59	10.55	0.5	1.17e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs983392	0.805	rs10897011	chr11:59961427	G/A	cg02771260	chr11:59836817	MS4A3	-0.36	-5.79	-0.3	1.61e-8	Alzheimer's disease (late onset);
LUSC	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-6.31	-0.33	9.01e-10	Parkinson's disease;
LUSC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg18305652	chr10:134549665	INPP5A	0.46	6.99	0.36	1.49e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-6.65	-0.34	1.21e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg22709100	chr7:91322751	NA	0.42	6.14	0.32	2.39e-9	Breast cancer;
LUSC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21171335	chr12:122356390	WDR66	0.63	9.27	0.45	2.34e-18	Mean corpuscular volume;
LUSC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg13206674	chr6:150067644	NUP43	0.61	9.65	0.47	1.39e-19	Lung cancer;
LUSC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg12257692	chr3:49977190	RBM6	0.24	6.61	0.34	1.53e-10	Body mass index;
LUSC	cis	rs6733011	0.519	rs11900176	chr2:99463536	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.42	5.8	0.3	1.58e-8	Bipolar disorder;
LUSC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	0.93	16.12	0.66	1.16e-43	Menopause (age at onset);
LUSC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.37	-0.33	6.35e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg20003494	chr4:90757398	SNCA	-0.33	-5.71	-0.3	2.5e-8	Dementia with Lewy bodies;
LUSC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg17366294	chr4:99064904	C4orf37	0.54	9.5	0.46	4.34e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.42	0.33	4.68e-10	Corneal astigmatism;
LUSC	cis	rs6977660	0.714	rs12672257	chr7:19813466	C/T	cg05791153	chr7:19748676	TWISTNB	0.7	7.4	0.38	1.12e-12	Thyroid stimulating hormone;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg15242686	chr22:24348715	GSTTP1	0.47	7.52	0.38	4.96e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs17092148	1.000	rs7271289	chr20:33397303	C/T	cg16810054	chr20:33298113	TP53INP2	0.43	6.81	0.35	4.68e-11	Neuroticism;
LUSC	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg18357645	chr12:58087776	OS9	0.55	8.29	0.41	2.83e-15	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg21775007	chr8:11205619	TDH	-0.45	-6.42	-0.33	4.58e-10	Mood instability;
LUSC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.12	-0.32	2.62e-9	Alzheimer's disease (late onset);
LUSC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg20821713	chr7:1055600	C7orf50	0.55	7.44	0.38	8.71e-13	Bronchopulmonary dysplasia;
LUSC	trans	rs4518370	1.000	rs4518370	chr5:82180306	A/G	cg14564229	chr9:119748106	ASTN2	-0.38	-5.98	-0.31	5.81e-9	Osteoarthritis biomarkers;
LUSC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg27398817	chr8:82754497	SNX16	-0.47	-6.36	-0.33	6.61e-10	Diastolic blood pressure;
LUSC	cis	rs35883536	0.647	rs59667512	chr1:101046712	C/T	cg06223162	chr1:101003688	GPR88	-0.47	-8.62	-0.43	2.66e-16	Monocyte count;
LUSC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg04025307	chr7:1156635	C7orf50	0.44	6.11	0.32	2.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11645453	chr3:52864694	ITIH4	0.35	8.11	0.41	9.81e-15	Electroencephalogram traits;
LUSC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13242816	1.000	rs12706090	chr7:116104045	A/G	cg16553024	chr7:116138462	CAV2	0.53	5.81	0.3	1.46e-8	P wave duration;
LUSC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg21724239	chr8:58056113	NA	0.54	6.6	0.34	1.63e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg03929089	chr4:120376271	NA	0.6	6.41	0.33	5.03e-10	Axial length;
LUSC	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.08	-0.36	8.32e-12	Mood instability;
LUSC	cis	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.77	-0.3	1.77e-8	Resting heart rate;
LUSC	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg22852734	chr6:133119734	C6orf192	1.32	10.76	0.51	2.26e-23	Type 2 diabetes nephropathy;
LUSC	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg24397884	chr7:158709396	WDR60	0.61	9.51	0.46	3.82e-19	Height;
LUSC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg23630131	chr7:65973040	NA	-0.21	-5.77	-0.3	1.81e-8	Aortic root size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06972182	chr14:56047764	C14orf33;KTN1	0.4	6.06	0.31	3.71e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg00310523	chr12:86230176	RASSF9	0.45	8.34	0.42	2.01e-15	Major depressive disorder;
LUSC	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg21775007	chr8:11205619	TDH	0.44	6.04	0.31	4.02e-9	Neuroticism;
LUSC	trans	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg18187862	chr3:45730750	SACM1L	0.6	7.77	0.39	9.8e-14	Primary sclerosing cholangitis;
LUSC	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg10351095	chr21:47802916	PCNT	-0.43	-6.12	-0.32	2.57e-9	Testicular germ cell tumor;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg10673984	chr17:58677844	PPM1D	0.38	6.4	0.33	5.16e-10	Educational attainment (years of education);
LUSC	cis	rs6445797	0.632	rs11130538	chr3:56700769	A/G	cg13792233	chr3:56591045	CCDC66	0.4	5.69	0.3	2.83e-8	Gastritis;
LUSC	cis	rs68092024	0.704	rs793487	chr3:99495422	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	6.62	0.34	1.42e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg16482183	chr6:26056742	HIST1H1C	0.66	9.22	0.45	3.37e-18	Iron status biomarkers;
LUSC	cis	rs9473147	0.516	rs4715018	chr6:47441871	T/C	cg12968598	chr6:47444699	CD2AP	0.53	8.06	0.4	1.35e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7017697	0.507	rs10113140	chr8:19684745	A/C	cg03894339	chr8:19674705	INTS10	-0.5	-6.87	-0.35	3.23e-11	Breast cancer;
LUSC	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.32	-6.08	-0.32	3.24e-9	Monocyte percentage of white cells;
LUSC	cis	rs11958404	0.932	rs72816587	chr5:157434144	T/A	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs7818345	1.000	rs4618712	chr8:19302621	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.37	7.13	0.36	6.35e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg05855489	chr10:104503620	C10orf26	0.49	7.47	0.38	7.01e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.34	-6.43	-0.33	4.35e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12318506	0.826	rs11180433	chr12:75661470	T/C	cg04728562	chr12:75699417	CAPS2	-0.77	-5.93	-0.31	7.49e-9	Coronary artery calcification;
LUSC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.37	-0.37	1.35e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	1.36	11.7	0.54	1.01e-26	Cognitive function;
LUSC	cis	rs9341808	0.718	rs9352801	chr6:80817468	G/T	cg08355045	chr6:80787529	NA	0.56	9.6	0.46	2.04e-19	Sitting height ratio;
LUSC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07677032	chr17:61819896	STRADA	0.53	8.91	0.44	3.42e-17	Prudent dietary pattern;
LUSC	cis	rs4851254	0.618	rs35730185	chr2:100648085	G/A	cg22139774	chr2:100720529	AFF3	-0.44	-5.79	-0.3	1.65e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs17102423	0.964	rs8015330	chr14:65602183	C/T	cg11161011	chr14:65562177	MAX	-0.65	-10.11	-0.48	3.81e-21	Obesity-related traits;
LUSC	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.14	0.41	7.7e-15	Myopia (pathological);
LUSC	cis	rs983392	0.805	rs7933805	chr11:59967526	A/G	cg20284999	chr11:59952153	MS4A6A	-0.4	-6.72	-0.35	7.69e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg11645453	chr3:52864694	ITIH4	0.59	14.12	0.61	7.82e-36	Schizophrenia;
LUSC	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg10483660	chr13:112241077	NA	-0.31	-5.68	-0.3	3e-8	Hepatitis;
LUSC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg12560992	chr17:57184187	TRIM37	-0.9	-17.69	-0.7	6.85e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg06064525	chr11:970664	AP2A2	0.49	10.89	0.51	7.88e-24	Alzheimer's disease (late onset);
LUSC	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6961069	0.538	rs3211871	chr7:80287358	A/G	cg04458919	chr7:80252533	CD36	-0.39	-6.51	-0.34	2.81e-10	Platelet count;
LUSC	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	0.78	11.63	0.54	1.74e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	trans	rs4942242	1.000	rs9533572	chr13:44234265	A/C	cg19169023	chr15:41853346	TYRO3	-0.44	-7.44	-0.38	8.36e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	10.78	0.51	1.84e-23	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg27284194	chr4:1044797	NA	0.59	8.79	0.43	7.77e-17	Recombination rate (females);
LUSC	trans	rs57046232	0.552	rs6038445	chr20:6329093	A/G	cg21095983	chr6:86352623	SYNCRIP	0.5	7.35	0.37	1.49e-12	Colorectal cancer;
LUSC	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg01620082	chr3:125678407	NA	-0.81	-7.79	-0.39	8.42e-14	Depression;
LUSC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	15.03	0.64	2.29e-39	Platelet count;
LUSC	cis	rs13242816	1.000	rs35800776	chr7:116110069	C/A	cg16553024	chr7:116138462	CAV2	-0.54	-5.83	-0.3	1.32e-8	P wave duration;
LUSC	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg18721089	chr20:30220636	NA	-0.37	-6.2	-0.32	1.63e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg21890820	chr11:65308645	LTBP3	1.4	9.45	0.46	6.03e-19	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16284459	chr7:91510405	MTERF	0.38	6.05	0.31	3.9e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg11632617	chr15:75315747	PPCDC	-0.5	-6.45	-0.33	4.03e-10	Blood trace element (Zn levels);
LUSC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25072359	chr17:41440525	NA	-0.61	-9.04	-0.44	1.34e-17	Menopause (age at onset);
LUSC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.57	0.46	2.39e-19	Bipolar disorder;
LUSC	cis	rs9341808	0.683	rs9359409	chr6:80826897	C/G	cg08355045	chr6:80787529	NA	0.56	9.85	0.47	2.85e-20	Sitting height ratio;
LUSC	cis	rs7178572	0.889	rs869301	chr15:77830633	T/C	cg22256960	chr15:77711686	NA	-0.52	-8.46	-0.42	8.69e-16	Type 2 diabetes;
LUSC	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg03676636	chr4:99064102	C4orf37	0.3	5.87	0.31	1.03e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2067615	0.524	rs7959062	chr12:107107334	G/T	cg15890332	chr12:107067104	RFX4	0.35	6.24	0.32	1.34e-9	Heart rate;
LUSC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	7.44	0.38	8.66e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23544223	chr18:12777786	NA	0.59	6.25	0.32	1.26e-9	Inflammatory skin disease;
LUSC	cis	rs73206853	0.925	rs61106808	chr12:110876009	C/G	cg12870014	chr12:110450643	ANKRD13A	0.5	5.9	0.31	9.03e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs1347297	0.526	rs728005	chr2:179251006	C/T	cg14011486	chr1:26737247	LIN28	0.43	6.7	0.34	8.69e-11	Alzheimer disease and age of onset;
LUSC	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg03563238	chr19:33554763	RHPN2	0.4	6.42	0.33	4.68e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.66	0.69	9.01e-50	Chronic sinus infection;
LUSC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.71	10.08	0.48	4.93e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs2840044	0.711	rs225301	chr17:33922411	T/A	cg19694781	chr19:47549865	TMEM160	-0.8	-12.34	-0.56	4.4e-29	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06002616	chr8:101225028	SPAG1	0.42	6.85	0.35	3.49e-11	Atrioventricular conduction;
LUSC	cis	rs11955175	1.000	rs11954632	chr5:40674929	C/G	cg05478818	chr5:40835740	RPL37	0.7	5.77	0.3	1.81e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.41	-0.42	1.21e-15	Lung cancer;
LUSC	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg15819921	chr19:927150	ARID3A	-0.42	-6.21	-0.32	1.59e-9	Life satisfaction;
LUSC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg16325326	chr1:53192061	ZYG11B	1.04	21.76	0.77	5.48e-66	Monocyte count;
LUSC	trans	rs1941687	0.797	rs1493917	chr18:31392833	G/A	cg27147174	chr7:100797783	AP1S1	-0.45	-6.56	-0.34	2.04e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-6.18	-0.32	1.91e-9	IgG glycosylation;
LUSC	cis	rs6736093	0.966	rs11676040	chr2:112713115	T/C	cg12686935	chr2:112915763	FBLN7	-0.36	-5.81	-0.3	1.45e-8	Coronary artery disease;
LUSC	cis	rs950173	1.000	rs950173	chr2:172570419	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.82	-7.53	-0.38	4.68e-13	Hippocampal volume;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18000306	chr6:288505	NA	-0.34	-6.48	-0.33	3.27e-10	Menopause (age at onset);
LUSC	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg04362960	chr10:104952993	NT5C2	-0.48	-5.74	-0.3	2.18e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.15	0.36	5.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg10018233	chr7:150070692	REPIN1	0.38	6.66	0.34	1.15e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06850241	chr22:41845214	NA	-0.3	-5.65	-0.3	3.38e-8	Vitiligo;
LUSC	cis	rs76525880	0.538	rs9221	chr17:46675813	C/T	cg06593406	chr17:46696139	NA	-0.69	-5.87	-0.31	1.07e-8	Colorectal or endometrial cancer;
LUSC	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.13	-0.36	6.1e-12	Morning vs. evening chronotype;
LUSC	cis	rs3740713	1.000	rs1848048	chr11:18468996	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.56	-6.77	-0.35	5.8e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg13319975	chr6:146136371	FBXO30	-0.47	-7.24	-0.37	3.19e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.68	-10.77	-0.51	2.11e-23	Menarche (age at onset);
LUSC	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-12.01	-0.55	7.02e-28	Platelet distribution width;
LUSC	cis	rs1957429	0.520	rs72625644	chr14:65342282	A/T	cg23373153	chr14:65346875	NA	-0.9	-7.84	-0.39	5.92e-14	Pediatric areal bone mineral density (radius);
LUSC	cis	rs2540226	0.816	rs4670957	chr2:39980652	C/T	cg23576258	chr2:39999331	THUMPD2	0.36	6.2	0.32	1.69e-9	Personality dimensions;
LUSC	cis	rs6424115	1.000	rs4649115	chr1:24155731	A/G	cg15997130	chr1:24165203	NA	-0.56	-9.2	-0.45	3.94e-18	Immature fraction of reticulocytes;
LUSC	cis	rs3857536	0.741	rs9363558	chr6:66937260	C/T	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg25036284	chr2:26402008	FAM59B	-0.74	-10.51	-0.5	1.66e-22	Gut microbiome composition (summer);
LUSC	cis	rs870825	0.616	rs10022818	chr4:185619282	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	13.39	0.59	5.13e-33	Blood protein levels;
LUSC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.64	10.48	0.5	2.07e-22	Hemoglobin concentration;
LUSC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.6	12.55	0.57	7.26e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs58785573	1.000	rs58785573	chr4:38653773	A/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.41	6.18	0.32	1.91e-9	Lymphocyte percentage of white cells;
LUSC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25072359	chr17:41440525	NA	0.66	9.42	0.46	7.64e-19	Menopause (age at onset);
LUSC	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg02023728	chr11:77925099	USP35	0.4	6.22	0.32	1.52e-9	Testicular germ cell tumor;
LUSC	cis	rs7851660	0.874	rs7868534	chr9:100632606	G/A	cg13688889	chr9:100608707	NA	-0.56	-8.91	-0.44	3.48e-17	Strep throat;
LUSC	cis	rs1113500	0.897	rs2336127	chr1:108640870	G/A	cg06207961	chr1:108661230	NA	0.42	7.8	0.39	7.93e-14	Growth-regulated protein alpha levels;
LUSC	cis	rs231513	0.906	rs1642611	chr17:41997712	T/C	cg26893861	chr17:41843967	DUSP3	-0.59	-6.28	-0.33	1.02e-9	Cognitive function;
LUSC	cis	rs8099014	1.000	rs4640266	chr18:56131865	T/G	cg12907477	chr18:56117327	MIR122	0.44	6.86	0.35	3.35e-11	Platelet count;
LUSC	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg25251562	chr2:3704773	ALLC	-0.49	-6.56	-0.34	2.07e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7000551	0.581	rs2293145	chr8:22262654	A/T	cg12081754	chr8:22256438	SLC39A14	0.94	14.61	0.62	9.98e-38	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs28647808	0.881	rs41297211	chr9:136260721	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg18240062	chr17:79603768	NPLOC4	0.56	9.75	0.47	6.3e-20	Eye color traits;
LUSC	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg12165864	chr7:66369176	NA	-0.53	-7.14	-0.36	5.85e-12	Corneal structure;
LUSC	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg06552810	chr11:31128660	NA	-0.4	-7.13	-0.36	6.38e-12	Red blood cell count;
LUSC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	12.78	0.57	9.84e-31	Cognitive test performance;
LUSC	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg16576597	chr16:28551801	NUPR1	0.33	6.57	0.34	1.91e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg13010199	chr12:38710504	ALG10B	-0.51	-7.7	-0.39	1.53e-13	Morning vs. evening chronotype;
LUSC	cis	rs7605827	0.930	rs6431708	chr2:15638175	C/T	cg19274914	chr2:15703543	NA	0.46	8.84	0.44	5.74e-17	Educational attainment (years of education);
LUSC	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.02	-0.36	1.27e-11	Alzheimer's disease (late onset);
LUSC	trans	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg07923666	chr12:49932857	KCNH3	-0.49	-6.16	-0.32	2.09e-9	Resting heart rate;
LUSC	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg24579218	chr15:68104479	NA	-0.37	-6.63	-0.34	1.34e-10	Restless legs syndrome;
LUSC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg05585544	chr11:47624801	NA	-0.41	-7.16	-0.36	5.05e-12	Subjective well-being;
LUSC	cis	rs4343996	0.701	rs13224926	chr7:3386594	C/T	cg21248987	chr7:3385318	SDK1	-0.35	-5.91	-0.31	8.42e-9	Motion sickness;
LUSC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06022373	chr22:39101656	GTPBP1	0.79	12.22	0.56	1.2e-28	Menopause (age at onset);
LUSC	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.79	11.9	0.55	1.79e-27	Cognitive ability;
LUSC	trans	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.67	11.66	0.54	1.39e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg13010199	chr12:38710504	ALG10B	-0.5	-7.96	-0.4	2.68e-14	Morning vs. evening chronotype;
LUSC	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.88	17.38	0.69	1.19e-48	Ulcerative colitis;
LUSC	cis	rs7582720	0.943	rs115628302	chr2:203690047	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.98	0.4	2.35e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs6076960	0.684	rs3909041	chr20:6249598	C/G	cg17788362	chr6:86352627	SYNCRIP	0.44	6.29	0.33	9.71e-10	Smooth-surface caries;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.85	-15.02	-0.63	2.49e-39	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7809950	0.637	rs2701685	chr7:107299584	A/G	cg23024343	chr7:107201750	COG5	0.53	8.08	0.4	1.19e-14	Coronary artery disease;
LUSC	cis	rs4478858	0.735	rs6676682	chr1:31809816	C/T	cg00250761	chr1:31883323	NA	-0.36	-8.91	-0.44	3.33e-17	Alcohol dependence;
LUSC	cis	rs2227930	0.506	rs1485393	chr3:142052616	A/G	cg16271453	chr3:142027066	XRN1	-0.55	-9.98	-0.48	1.06e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs4938330	0.680	rs4938329	chr11:116928112	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-6.24	-0.32	1.34e-9	Blood protein levels;
LUSC	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg22681709	chr2:178499509	PDE11A	-0.52	-7.04	-0.36	1.1e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg01879757	chr17:41196368	BRCA1	0.45	7.17	0.37	4.89e-12	Menopause (age at onset);
LUSC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-6.03	-0.31	4.37e-9	Longevity;
LUSC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg12963246	chr6:28129442	ZNF389	0.52	7.18	0.37	4.53e-12	Depression;
LUSC	cis	rs11608355	0.515	rs11609630	chr12:109918934	C/T	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs7712401	0.601	rs30026	chr5:122284568	T/C	cg19077854	chr5:122220652	SNX24	0.44	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17474694	chr1:100315971	AGL	-0.42	-6.4	-0.33	5.15e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4494114	0.967	rs7532880	chr1:39297734	T/C	cg25970120	chr1:39325951	RRAGC	-0.43	-6.6	-0.34	1.59e-10	Blood protein levels;
LUSC	cis	rs738321	0.757	rs4821748	chr22:38541936	G/A	cg25457927	chr22:38595422	NA	-0.42	-8.01	-0.4	1.93e-14	Breast cancer;
LUSC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg02951883	chr7:2050386	MAD1L1	-0.62	-12.05	-0.55	5.11e-28	Bipolar disorder and schizophrenia;
LUSC	trans	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg21051086	chr3:73046214	PPP4R2	-0.52	-7.93	-0.4	3.23e-14	Pancreatic cancer;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg07325562	chr11:65150083	SLC25A45	0.49	6.92	0.35	2.38e-11	Cognitive function;Information processing speed;
LUSC	cis	rs8067354	0.872	rs7224006	chr17:57896338	C/T	cg02344993	chr17:57696989	CLTC	-0.37	-5.65	-0.3	3.42e-8	Hemoglobin concentration;
LUSC	cis	rs75804782	0.521	rs72993056	chr2:239404671	G/T	cg18131467	chr2:239335373	ASB1	-0.68	-6.28	-0.33	1.03e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg08807101	chr21:30365312	RNF160	-0.55	-7.39	-0.37	1.18e-12	Cognitive test performance;
LUSC	cis	rs1572438	0.896	rs9405366	chr6:858296	A/C	cg13447295	chr6:887704	NA	-0.46	-6.26	-0.32	1.15e-9	Aging;
LUSC	cis	rs12594515	1.000	rs12594515	chr15:45985071	C/G	cg01629716	chr15:45996671	NA	-0.39	-5.81	-0.3	1.48e-8	Waist circumference;Weight;
LUSC	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg14830002	chr1:247616686	OR2B11	0.52	7.44	0.38	8.47e-13	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	1.0	15.01	0.63	2.71e-39	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg25233709	chr10:116636983	FAM160B1	0.43	7.51	0.38	5.4e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs138544659	1	rs138544659	chr15:78900701	T/G	cg18825076	chr15:78729989	IREB2	-0.51	-7.91	-0.4	3.77e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	8.41	0.42	1.25e-15	Menarche (age at onset);
LUSC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.57	-9.52	-0.46	3.61e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg06640241	chr16:89574553	SPG7	0.39	5.7	0.3	2.7e-8	Hemoglobin concentration;
LUSC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg08680598	chr22:49984980	NA	-0.34	-6.25	-0.32	1.24e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6545883	0.895	rs2256617	chr2:61679924	A/G	cg15711740	chr2:61764176	XPO1	-0.45	-6.79	-0.35	5.13e-11	Tuberculosis;
LUSC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs2267681	0.583	rs10253277	chr7:139525978	A/G	cg14116596	chr7:139528673	TBXAS1	0.37	6.38	0.33	5.86e-10	Cervical cancer;
LUSC	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg16482183	chr6:26056742	HIST1H1C	0.56	8.34	0.42	2.02e-15	Height;
LUSC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg25039879	chr17:56429692	SUPT4H1	0.66	8.88	0.44	4.12e-17	Cognitive test performance;
LUSC	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg11161011	chr14:65562177	MAX	-0.7	-10.88	-0.51	8.62e-24	Obesity-related traits;
LUSC	cis	rs10203711	0.705	rs4286234	chr2:239616695	G/C	cg14580085	chr2:239553406	NA	0.42	6.92	0.35	2.31e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.34	-0.46	1.38e-18	Acne (severe);
LUSC	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg25233709	chr10:116636983	FAM160B1	0.39	6.75	0.35	6.65e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.74	-0.3	2.14e-8	Monocyte count;
LUSC	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg20703242	chr1:230279135	GALNT2	0.57	8.7	0.43	1.55e-16	Coronary artery disease;
LUSC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	0.91	15.15	0.64	7.89e-40	Breast cancer;
LUSC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.83	13.72	0.6	2.84e-34	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg10483660	chr13:112241077	NA	-0.31	-5.68	-0.3	2.99e-8	Hepatitis;
LUSC	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg01528321	chr10:82214614	TSPAN14	0.89	13.59	0.6	8.81e-34	Post bronchodilator FEV1;
LUSC	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg13397359	chr6:42928475	GNMT	0.43	5.9	0.31	8.84e-9	Blood protein levels;
LUSC	cis	rs477692	1.000	rs4750759	chr10:131436603	G/A	cg11019008	chr10:131425282	MGMT	-0.39	-5.81	-0.3	1.44e-8	Response to temozolomide;
LUSC	cis	rs10887741	1.000	rs12761361	chr10:89427203	G/C	cg24243914	chr10:89418206	PAPSS2	0.33	6.04	0.31	4.19e-9	Exercise (leisure time);
LUSC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.03	0.77	4.68e-67	Prudent dietary pattern;
LUSC	cis	rs17540621	1.000	rs115086675	chr2:47232247	C/T	cg23978866	chr2:47230407	TTC7A	-0.97	-6.63	-0.34	1.38e-10	Response to statin therapy;
LUSC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg04733989	chr22:42467013	NAGA	0.64	9.88	0.48	2.31e-20	Schizophrenia;
LUSC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg17971929	chr21:40555470	PSMG1	-0.62	-10.05	-0.48	6.07e-21	Cognitive function;
LUSC	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg19773385	chr1:10388646	KIF1B	-0.51	-8.81	-0.43	6.93e-17	Hepatocellular carcinoma;
LUSC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg15445000	chr17:37608096	MED1	-0.38	-6.55	-0.34	2.15e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.15	-0.36	5.58e-12	Bipolar disorder;
LUSC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg20295408	chr7:1910781	MAD1L1	-0.47	-6.88	-0.35	2.94e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23376446	chr14:100752258	NA	0.45	6.04	0.31	4.19e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.3e-11	Uric acid levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18217172	chr6:139309321	REPS1	-0.44	-6.81	-0.35	4.44e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg24531977	chr5:56204891	C5orf35	-0.58	-8.6	-0.43	3.09e-16	Coronary artery disease;
LUSC	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.58	9.54	0.46	3.05e-19	Breast cancer;
LUSC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg08859206	chr1:53392774	SCP2	-0.42	-6.8	-0.35	4.75e-11	Monocyte count;
LUSC	cis	rs7394190	0.748	rs60632610	chr10:75415677	C/T	cg07699608	chr10:75541558	CHCHD1	0.49	5.65	0.3	3.43e-8	Incident atrial fibrillation;
LUSC	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg15704280	chr7:45808275	SEPT13	0.7	6.53	0.34	2.48e-10	Intraocular pressure;
LUSC	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	14.75	0.63	2.93e-38	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg07061783	chr6:25882402	NA	-0.38	-5.86	-0.31	1.12e-8	Blood metabolite levels;
LUSC	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg09835421	chr16:68378352	PRMT7	-0.44	-5.78	-0.3	1.69e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs295140	0.773	rs13007517	chr2:201129729	C/T	cg04283868	chr2:201171347	SPATS2L	0.41	5.95	0.31	6.78e-9	QT interval;
LUSC	cis	rs9296092	0.521	rs9461886	chr6:33526770	T/C	cg13560919	chr6:33536144	NA	-0.85	-16.44	-0.67	6.54e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg13175981	chr1:150552382	MCL1	0.48	6.56	0.34	2.08e-10	Tonsillectomy;
LUSC	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg07148914	chr20:33460835	GGT7	0.49	7.28	0.37	2.45e-12	Height;
LUSC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.5	7.29	0.37	2.25e-12	Total body bone mineral density;
LUSC	cis	rs2078087	0.522	rs3768594	chr1:183212171	G/T	cg13843938	chr1:183241246	NMNAT2	0.38	6.15	0.32	2.22e-9	Obesity-related traits;
LUSC	cis	rs965604	1.000	rs4887057	chr15:78760918	G/A	cg18825076	chr15:78729989	IREB2	0.42	6.77	0.35	5.79e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg21100191	chr22:23484243	RTDR1	0.92	15.75	0.65	3.49e-42	Bone mineral density;
LUSC	trans	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg02800362	chr5:177631904	HNRNPAB	0.87	12.86	0.58	5.05e-31	Obesity-related traits;
LUSC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg19812747	chr11:111475976	SIK2	-0.55	-7.79	-0.39	8.47e-14	Primary sclerosing cholangitis;
LUSC	cis	rs62432291	0.681	rs439126	chr6:159656632	T/C	cg14500486	chr6:159655392	FNDC1	-0.52	-5.84	-0.3	1.22e-8	Joint mobility (Beighton score);
LUSC	cis	rs6696846	0.515	rs12739846	chr1:205096895	T/C	cg00857998	chr1:205179979	DSTYK	0.46	6.55	0.34	2.2e-10	Red blood cell count;
LUSC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg18538332	chr22:24372958	LOC391322	0.43	6.49	0.33	3.16e-10	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs4851254	0.660	rs56037757	chr2:100690130	A/G	cg07810366	chr2:100720526	AFF3	-0.46	-6.16	-0.32	2.05e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs116988415	0.584	rs74859785	chr14:65249684	C/T	cg25083366	chr14:65239357	SPTB	0.63	6.74	0.35	6.9e-11	Daytime sleep phenotypes;
LUSC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg12963246	chr6:28129442	ZNF389	0.48	6.73	0.35	7.46e-11	Depression;
LUSC	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg19116668	chr7:99932089	PMS2L1	0.33	5.7	0.3	2.64e-8	Coronary artery disease;
LUSC	cis	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg06521331	chr12:34319734	NA	0.43	6.85	0.35	3.57e-11	Morning vs. evening chronotype;
LUSC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg04944784	chr2:26401820	FAM59B	-0.7	-9.84	-0.47	3.15e-20	Gut microbiome composition (summer);
LUSC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg11766577	chr21:47581405	C21orf56	-0.41	-5.85	-0.3	1.19e-8	Testicular germ cell tumor;
LUSC	cis	rs701145	0.585	rs1727957	chr3:153870407	G/A	cg17054900	chr3:154042577	DHX36	0.69	6.76	0.35	6.15e-11	Coronary artery disease;
LUSC	cis	rs11039100	0.607	rs1032649	chr11:5782773	A/T	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16246410	chr2:157189316	NR4A2	-0.4	-6.02	-0.31	4.72e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg14403583	chr14:105418241	AHNAK2	-0.58	-9.64	-0.47	1.48e-19	Rheumatoid arthritis;
LUSC	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg26769984	chr7:1090371	C7orf50	0.44	6.5	0.33	2.98e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs7605827	0.930	rs4668449	chr2:15530141	T/C	cg19274914	chr2:15703543	NA	0.47	9.08	0.44	1e-17	Educational attainment (years of education);
LUSC	trans	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg08975724	chr8:8085496	FLJ10661	0.43	6.22	0.32	1.47e-9	Retinal vascular caliber;
LUSC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21545522	chr1:205238299	TMCC2	0.52	9.87	0.48	2.58e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7945718	0.875	rs9888258	chr11:12782716	A/G	cg25843174	chr11:12811716	TEAD1	0.32	7.26	0.37	2.68e-12	Educational attainment (years of education);
LUSC	cis	rs7729723	0.539	rs6895528	chr5:137810944	A/C	cg19169342	chr5:137827400	NA	-0.27	-5.9	-0.31	9.01e-9	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
LUSC	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs308447	0.516	rs6815982	chr4:123677472	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.85	-11.63	-0.54	1.77e-26	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-6.77	-0.35	5.7e-11	Major depressive disorder;
LUSC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.7	9.46	0.46	5.87e-19	Gut microbiome composition (summer);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00097626	chr1:205782249	SLC41A1	-0.4	-6.06	-0.31	3.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg11608241	chr8:8085544	FLJ10661	0.4	5.75	0.3	2.03e-8	Mood instability;
LUSC	cis	rs10886558	0.662	rs10886560	chr10:121759608	A/G	cg02041677	chr10:121771263	NA	0.33	5.72	0.3	2.37e-8	Shingles;
LUSC	cis	rs2074585	0.517	rs11635361	chr15:91081791	G/T	cg10434728	chr15:90938212	IQGAP1	-0.37	-6.91	-0.35	2.41e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.97	-0.31	6.07e-9	Resting heart rate;
LUSC	cis	rs6500395	1.000	rs4785247	chr16:48687732	A/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg09654669	chr8:57350985	NA	-0.57	-7.92	-0.4	3.57e-14	Obesity-related traits;
LUSC	cis	rs738322	0.574	rs28653361	chr22:38570700	C/A	cg25457927	chr22:38595422	NA	-0.36	-7.13	-0.36	6.36e-12	Cutaneous nevi;
LUSC	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.36	-5.71	-0.3	2.56e-8	Prion diseases;
LUSC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg07701084	chr6:150067640	NUP43	0.53	7.85	0.39	5.88e-14	Lung cancer;
LUSC	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg06637938	chr14:75390232	RPS6KL1	0.65	11.0	0.52	3.23e-24	Caffeine consumption;
LUSC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg13393036	chr8:95962371	TP53INP1	-0.44	-9.06	-0.44	1.15e-17	Type 2 diabetes;
LUSC	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg03732007	chr1:2071316	PRKCZ	0.47	7.51	0.38	5.29e-13	Height;
LUSC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.4	-5.82	-0.3	1.38e-8	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-8.2	-0.41	5.16e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11676348	0.774	rs13397673	chr2:219047782	A/G	cg06547715	chr2:218990976	CXCR2	0.3	5.9	0.31	8.8e-9	Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-0.93	-20.0	-0.74	4.48e-59	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-6.38	-0.33	5.87e-10	Tuberculosis;
LUSC	cis	rs6723226	0.638	rs6543657	chr2:32705085	T/C	cg02381751	chr2:32503542	YIPF4	0.55	8.54	0.42	4.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg01579765	chr21:45077557	HSF2BP	-0.51	-10.92	-0.51	6.15e-24	Mean corpuscular volume;
LUSC	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg02023728	chr11:77925099	USP35	0.49	7.02	0.36	1.24e-11	Testicular germ cell tumor;
LUSC	trans	rs62458065	0.850	rs7785999	chr7:32461262	G/T	cg00845942	chr12:64062724	DPY19L2	-0.52	-6.09	-0.32	3.02e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg12823233	chr7:2316876	SNX8	-0.45	-7.76	-0.39	1.01e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs2786098	0.656	rs10922257	chr1:197545720	G/A	cg16005942	chr6:160526640	IGF2R	0.51	6.09	0.32	3.12e-9	Asthma;
LUSC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg18225595	chr11:63971243	STIP1	0.51	6.31	0.33	8.81e-10	Mean platelet volume;
LUSC	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.64	0.34	1.3e-10	IgG glycosylation;
LUSC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg11062466	chr8:58055876	NA	0.67	7.68	0.39	1.81e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg06454157	chr6:167490870	NA	-0.28	-6.58	-0.34	1.78e-10	Primary biliary cholangitis;
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg17541715	chr7:1216824	NA	-0.39	-6.23	-0.32	1.41e-9	Longevity;Endometriosis;
LUSC	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg08085267	chr17:45401833	C17orf57	0.53	7.53	0.38	4.89e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12379764	chr21:47803548	PCNT	-0.42	-5.82	-0.3	1.38e-8	Testicular germ cell tumor;
LUSC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg07395648	chr5:131743802	NA	-0.39	-5.76	-0.3	1.95e-8	Breast cancer;
LUSC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11645453	chr3:52864694	ITIH4	0.37	8.64	0.43	2.35e-16	Bipolar disorder;
LUSC	cis	rs1044826	0.692	rs188421	chr3:139234066	A/C	cg15131784	chr3:139108705	COPB2	-0.38	-6.18	-0.32	1.87e-9	Obesity-related traits;
LUSC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-1.02	-17.01	-0.68	3.4e-47	Systemic lupus erythematosus;
LUSC	trans	rs6600671	1.000	rs4844607	chr1:121184059	C/T	cg00646200	chr1:148855367	NA	-0.44	-6.91	-0.35	2.47e-11	Hip geometry;
LUSC	cis	rs35079168	0.735	rs1887309	chr9:137308242	A/G	cg24164254	chr9:137329341	RXRA	0.39	6.53	0.34	2.44e-10	Intelligence;
LUSC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.44	-0.33	4.26e-10	Aortic root size;
LUSC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07677032	chr17:61819896	STRADA	0.53	8.47	0.42	7.74e-16	Prudent dietary pattern;
LUSC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.48e-28	Motion sickness;
LUSC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg04369109	chr6:150039330	LATS1	-0.54	-7.99	-0.4	2.19e-14	Lung cancer;
LUSC	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg11244672	chr19:19639970	YJEFN3	-0.6	-7.3	-0.37	2.13e-12	Bipolar disorder;
LUSC	cis	rs400736	0.729	rs2493215	chr1:8007716	C/T	cg25007680	chr1:8021821	PARK7	0.47	6.99	0.36	1.48e-11	Response to antidepressants and depression;
LUSC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg22029157	chr1:209979665	IRF6	0.6	9.88	0.48	2.29e-20	Monobrow;
LUSC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.65	0.86	4.24e-99	Chronic sinus infection;
LUSC	trans	rs6601327	0.613	rs4612345	chr8:9580001	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.58	-0.34	1.83e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs10484885	0.690	rs292236	chr6:90528422	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.91	-10.69	-0.5	3.82e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.49	8.47	0.42	8.11e-16	HDL cholesterol;
LUSC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg13770153	chr20:60521292	NA	-0.64	-9.0	-0.44	1.7e-17	Body mass index;
LUSC	cis	rs4478858	0.735	rs4531329	chr1:31817810	A/T	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg09975044	chr14:104007538	NA	-0.36	-5.66	-0.3	3.21e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	1.03	18.37	0.71	1.37e-52	Parkinson's disease;
LUSC	cis	rs4363385	0.740	rs1697428	chr1:153015761	C/A	cg25856811	chr1:152973957	SPRR3	-0.36	-5.99	-0.31	5.45e-9	Inflammatory skin disease;
LUSC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg10909506	chr17:38081995	ORMDL3	0.33	5.78	0.3	1.68e-8	Self-reported allergy;
LUSC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg22563815	chr15:78856949	CHRNA5	0.26	6.31	0.33	8.74e-10	Sudden cardiac arrest;
LUSC	cis	rs6681460	0.649	rs4655494	chr1:67002876	G/A	cg02459107	chr1:67143332	SGIP1	0.37	6.18	0.32	1.92e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg05925327	chr15:68127851	NA	-0.4	-6.4	-0.33	5.35e-10	Restless legs syndrome;
LUSC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg14668632	chr7:2872130	GNA12	-0.48	-7.11	-0.36	7.27e-12	Height;
LUSC	cis	rs6845621	0.727	rs34295055	chr4:18909184	C/A	cg12196642	chr4:18937545	NA	-0.33	-6.27	-0.32	1.1e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	trans	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg26043149	chr18:55253948	FECH	0.47	7.22	0.37	3.56e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg02023728	chr11:77925099	USP35	0.45	6.3	0.33	9.6e-10	Testicular germ cell tumor;
LUSC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg06219351	chr7:158114137	PTPRN2	-0.52	-9.51	-0.46	3.88e-19	Calcium levels;
LUSC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.47	0.42	7.84e-16	Tonsillectomy;
LUSC	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.62	9.93	0.48	1.51e-20	Blood metabolite ratios;
LUSC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-1.05	-15.17	-0.64	6.42e-40	Vitiligo;
LUSC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.83	14.28	0.62	1.86e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg03709012	chr19:19516395	GATAD2A	0.76	11.7	0.54	1e-26	Tonsillectomy;
LUSC	trans	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.01	21.19	0.76	8.89e-64	Colorectal cancer;
LUSC	trans	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg12856521	chr11:46389249	DGKZ	0.4	6.34	0.33	7.43e-10	Leprosy;
LUSC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg09035930	chr12:129282057	SLC15A4	0.74	16.34	0.67	1.65e-44	Systemic lupus erythematosus;
LUSC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg10621924	chr7:39171070	POU6F2	0.42	6.24	0.32	1.35e-9	IgG glycosylation;
LUSC	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg17075019	chr10:79541650	NA	-0.76	-12.26	-0.56	8.47e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19717773	chr7:2847554	GNA12	-0.38	-5.88	-0.31	1.01e-8	Height;
LUSC	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg16359550	chr11:109292809	C11orf87	0.34	5.99	0.31	5.43e-9	Schizophrenia;
LUSC	trans	rs12692738	0.526	rs422265	chr2:165630796	C/T	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg12560992	chr17:57184187	TRIM37	0.81	15.09	0.64	1.3e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.25	0.52	4.16e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs3740713	1.000	rs76599129	chr11:18471627	T/A	cg15463284	chr11:18477534	LDHAL6A	-0.5	-5.72	-0.3	2.37e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg17252645	chr8:143867129	LY6D	0.37	6.61	0.34	1.55e-10	Urinary tract infection frequency;
LUSC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.88	-0.54	2.18e-27	Chronic sinus infection;
LUSC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.57	0.38	3.73e-13	Parkinson's disease;
LUSC	cis	rs2273669	0.667	rs16822	chr6:109307710	G/A	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs12900413	0.562	rs11631438	chr15:90300620	C/T	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.56e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg09955084	chr16:413813	NA	0.26	5.72	0.3	2.35e-8	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.57	-0.5	1.02e-22	Eye color traits;
LUSC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg08742575	chr21:47604166	C21orf56	0.46	7.01	0.36	1.3e-11	Testicular germ cell tumor;
LUSC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.56	10.49	0.5	1.91e-22	Bone mineral density;
LUSC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg03579872	chr1:53393473	SCP2	0.39	5.67	0.3	3.15e-8	Monocyte count;
LUSC	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg08085267	chr17:45401833	C17orf57	-0.55	-8.55	-0.42	4.52e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg21724239	chr8:58056113	NA	0.8	8.59	0.43	3.29e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs34779708	0.733	rs61449529	chr10:35543914	T/C	cg03585969	chr10:35415529	CREM	0.56	7.79	0.39	8.66e-14	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3741151	0.773	rs58334887	chr11:73171510	A/C	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.76	12.2	0.56	1.44e-28	Menopause (age at onset);
LUSC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg16989086	chr20:62203971	PRIC285	0.47	6.54	0.34	2.27e-10	Glioblastoma;
LUSC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.45	7.3	0.37	2.14e-12	Pulse pressure;
LUSC	cis	rs12145833	0.538	rs10926977	chr1:243411367	T/G	cg02356786	chr1:243265016	LOC731275	0.67	5.99	0.31	5.57e-9	Obesity (early onset extreme);
LUSC	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg27489772	chr12:121021490	NA	-0.6	-7.72	-0.39	1.32e-13	Type 1 diabetes nephropathy;
LUSC	cis	rs7923609	0.967	rs3999089	chr10:65203808	C/T	cg01631684	chr10:65280961	REEP3	0.41	6.32	0.33	8.39e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg23795048	chr12:9217529	LOC144571	0.33	5.79	0.3	1.62e-8	Sjögren's syndrome;
LUSC	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg04989706	chr14:50066350	PPIL5	-0.44	-5.77	-0.3	1.79e-8	Carotid intima media thickness;
LUSC	cis	rs75804782	0.690	rs56198112	chr2:239348887	A/G	cg18131467	chr2:239335373	ASB1	-0.73	-6.63	-0.34	1.37e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg08888203	chr3:10149979	C3orf24	0.62	8.65	0.43	2.17e-16	Alzheimer's disease;
LUSC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg06238570	chr21:40685208	BRWD1	0.48	7.33	0.37	1.77e-12	Cognitive function;
LUSC	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs4144743	0.528	rs12940207	chr17:45352194	G/T	cg18085866	chr17:45331354	ITGB3	-0.74	-6.45	-0.33	3.89e-10	Body mass index;
LUSC	cis	rs11229555	0.598	rs1893902	chr11:58190747	A/G	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2235649	0.663	rs12596160	chr16:1848784	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.46	-6.11	-0.32	2.76e-9	Blood metabolite levels;
LUSC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08219700	chr8:58056026	NA	0.65	7.64	0.39	2.26e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg21775007	chr8:11205619	TDH	-0.65	-10.27	-0.49	1.07e-21	Retinal vascular caliber;
LUSC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg12963246	chr6:28129442	ZNF389	0.49	6.73	0.35	7.47e-11	Depression;
LUSC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg12412775	chr1:25698385	RHCE	-0.29	-5.93	-0.31	7.5e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	1.21	16.49	0.67	4.13e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs2625529	0.668	rs8192386	chr15:72513148	A/C	cg16672083	chr15:72433130	SENP8	0.49	7.36	0.37	1.45e-12	Red blood cell count;
LUSC	cis	rs9837602	1.000	rs35521705	chr3:99716690	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.89	-0.31	9.26e-9	Breast cancer;
LUSC	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg22676075	chr6:135203613	NA	0.47	7.33	0.37	1.72e-12	Red blood cell count;
LUSC	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-7.58	-0.38	3.44e-13	Atrioventricular conduction;
LUSC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg09365446	chr1:150670422	GOLPH3L	0.54	8.35	0.42	1.9e-15	Tonsillectomy;
LUSC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg02527881	chr3:46936655	PTH1R	-0.67	-12.22	-0.56	1.24e-28	Birth weight;
LUSC	cis	rs3847687	1.000	rs3847687	chr12:131525053	C/T	cg13586425	chr12:131519906	GPR133	-0.26	-5.92	-0.31	7.84e-9	Longevity;
LUSC	cis	rs9322817	0.617	rs9391242	chr6:105231257	G/A	cg02098413	chr6:105308735	HACE1	-0.27	-5.65	-0.3	3.39e-8	Thyroid stimulating hormone;
LUSC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg11062466	chr8:58055876	NA	0.58	8.24	0.41	3.97e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg03806693	chr22:41940476	POLR3H	-0.55	-7.46	-0.38	7.69e-13	Neuroticism;
LUSC	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-7.77	-0.39	9.79e-14	Reticulocyte count;
LUSC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.61	0.34	1.52e-10	Personality dimensions;
LUSC	trans	rs34546498	1	rs34546498	chr6:26961280	C/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-8.49	-0.42	7e-16	Breast cancer;
LUSC	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.73	10.31	0.49	7.81e-22	Corneal astigmatism;
LUSC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08722720	chr15:34331557	AVEN;CHRM5	0.47	6.58	0.34	1.86e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.39	-0.37	1.15e-12	Triglycerides;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21432158	chr12:104530941	NFYB	0.39	6.06	0.31	3.7e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg05347473	chr6:146136440	FBXO30	0.41	6.84	0.35	3.78e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg13042288	chr15:90349979	ANPEP	-0.46	-6.57	-0.34	1.89e-10	Uric acid levels;
LUSC	cis	rs710216	0.917	rs3754223	chr1:43419091	A/T	cg22176566	chr1:43424700	SLC2A1	0.43	6.06	0.31	3.7e-9	Red cell distribution width;
LUSC	cis	rs12410462	0.581	rs7541809	chr1:227547299	G/A	cg04117972	chr1:227635322	NA	0.62	6.74	0.35	7.04e-11	Major depressive disorder;
LUSC	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg09754948	chr16:28834200	ATXN2L	0.43	6.35	0.33	7.17e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg11843238	chr5:131593191	PDLIM4	-0.4	-6.54	-0.34	2.32e-10	Blood metabolite levels;
LUSC	cis	rs9039	0.513	rs9937906	chr16:9203871	A/G	cg08831531	chr16:9218945	NA	-0.45	-7.28	-0.37	2.47e-12	Menopause (age at onset);
LUSC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg04450456	chr4:17643702	FAM184B	0.35	5.8	0.3	1.56e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs57920188	0.585	rs12126679	chr1:4072921	C/T	cg20703997	chr1:4087676	NA	0.6	8.35	0.42	1.8e-15	Interleukin-17 levels;
LUSC	cis	rs897984	0.762	rs7206511	chr16:30950352	G/A	cg02466173	chr16:30829666	NA	0.57	11.46	0.53	7.28e-26	Dementia with Lewy bodies;
LUSC	trans	rs11039798	1.000	rs10160423	chr11:48457227	G/T	cg15704280	chr7:45808275	SEPT13	0.66	6.02	0.31	4.48e-9	Axial length;
LUSC	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.68	-0.34	1.01e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9649213	0.574	rs17436977	chr7:97883459	T/C	cg24562669	chr7:97807699	LMTK2	0.38	6.45	0.33	3.95e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7615316	0.902	rs9820770	chr3:142175019	A/G	cg16271453	chr3:142027066	XRN1	-0.41	-7.04	-0.36	1.07e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs57920188	0.535	rs12129515	chr1:4094101	G/A	cg20703997	chr1:4087676	NA	0.55	7.76	0.39	1.04e-13	Interleukin-17 levels;
LUSC	cis	rs10838532	0.515	rs72904370	chr11:46040015	G/C	cg24204282	chr11:45944920	GYLTL1B	0.44	5.85	0.3	1.17e-8	Axial length;
LUSC	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.84	-14.53	-0.62	2.07e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg16405210	chr4:1374714	KIAA1530	0.52	7.92	0.4	3.48e-14	Obesity-related traits;
LUSC	cis	rs72799341	1.000	rs72799341	chr16:30936743	G/A	cg02466173	chr16:30829666	NA	-0.51	-7.78	-0.39	8.92e-14	Diastolic blood pressure;
LUSC	cis	rs2224391	0.540	rs1570085	chr6:5253063	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-6.76	-0.35	6.08e-11	Height;
LUSC	trans	rs9393777	0.920	rs13212562	chr6:27300310	A/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.99	-0.36	1.53e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg23978390	chr7:1156363	C7orf50	0.43	6.28	0.32	1.06e-9	Longevity;Endometriosis;
LUSC	trans	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.65	0.39	2.18e-13	Ulcerative colitis;
LUSC	trans	rs1493916	0.807	rs10775455	chr18:31310761	A/C	cg27147174	chr7:100797783	AP1S1	-0.53	-8.01	-0.4	1.91e-14	Life satisfaction;
LUSC	cis	rs1443512	0.947	rs1822438	chr12:54342326	A/C	cg17410650	chr12:54324560	NA	-0.43	-6.77	-0.35	5.8200000000000003e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	trans	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg06521331	chr12:34319734	NA	-0.39	-6.0	-0.31	5.25e-9	Bladder cancer;
LUSC	cis	rs4631830	0.863	rs2611489	chr10:51524889	C/T	cg20129853	chr10:51489980	NA	-0.34	-7.0	-0.36	1.44e-11	Prostate-specific antigen levels;
LUSC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg20243544	chr17:37824526	PNMT	0.47	6.01	0.31	4.83e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.25	0.37	2.93e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.21	-13.94	-0.61	4.07e-35	Diabetic kidney disease;
LUSC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26314531	chr2:26401878	FAM59B	-0.67	-9.29	-0.45	1.99e-18	Gut microbiome composition (summer);
LUSC	cis	rs11229555	0.609	rs11229451	chr11:58201687	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg09365446	chr1:150670422	GOLPH3L	0.49	7.17	0.37	4.8e-12	Melanoma;
LUSC	cis	rs6424115	0.545	rs11576333	chr1:24065770	C/T	cg10978503	chr1:24200527	CNR2	-0.44	-8.6	-0.43	3.05e-16	Immature fraction of reticulocytes;
LUSC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg13395646	chr4:1353034	KIAA1530	0.59	9.04	0.44	1.32e-17	Obesity-related traits;
LUSC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.86	-0.54	2.57e-27	Chronic sinus infection;
LUSC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg06212747	chr3:49208901	KLHDC8B	0.46	6.22	0.32	1.48e-9	Parkinson's disease;
LUSC	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg12292205	chr6:26970375	C6orf41	-0.67	-9.09	-0.45	8.93e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg13114125	chr14:105738426	BRF1	0.91	15.46	0.65	5.01e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs57590327	0.503	rs9874464	chr3:81505488	C/G	cg07356753	chr3:81810745	GBE1	-0.47	-6.19	-0.32	1.76e-9	Extraversion;
LUSC	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg05283184	chr6:79620031	NA	-0.57	-12.12	-0.55	2.96e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.49	-0.38	6.15e-13	Aortic root size;
LUSC	cis	rs9462027	0.628	rs9469909	chr6:34813077	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.75	-0.3	1.97e-8	Systemic lupus erythematosus;
LUSC	cis	rs117352156	0.943	rs10763675	chr10:29211930	A/G	cg06394621	chr10:29236369	NA	-0.47	-6.37	-0.33	6.16e-10	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.11e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1018697	1.000	rs7909612	chr10:104561456	G/A	cg04362960	chr10:104952993	NT5C2	0.47	6.45	0.33	3.99e-10	Colorectal adenoma (advanced);
LUSC	cis	rs1983170	0.808	rs4658230	chr1:92019325	T/C	cg25838465	chr1:92012736	NA	0.42	5.91	0.31	8.39e-9	Eosinophil percentage of white cells;
LUSC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg24578937	chr1:2090814	PRKCZ	0.45	10.22	0.49	1.64e-21	Height;
LUSC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg15017067	chr4:17643749	FAM184B	-0.36	-5.8	-0.3	1.51e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg05784532	chr1:230284198	GALNT2	0.49	7.39	0.38	1.16e-12	Coronary artery disease;
LUSC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-12.37	-0.56	3.47e-29	Total body bone mineral density;
LUSC	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg22676075	chr6:135203613	NA	0.47	7.29	0.37	2.32e-12	Red blood cell count;
LUSC	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg20283391	chr11:68216788	NA	-0.62	-8.6	-0.43	3.23e-16	Total body bone mineral density;
LUSC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg16031515	chr1:205743344	RAB7L1	-0.28	-5.98	-0.31	5.72e-9	Menarche (age at onset);
LUSC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.77	0.57	1.06e-30	Motion sickness;
LUSC	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg08213375	chr14:104286397	PPP1R13B	0.52	10.25	0.49	1.29e-21	Schizophrenia;
LUSC	cis	rs2230307	0.572	rs621212	chr1:100559281	T/C	cg24955406	chr1:100503596	HIAT1	0.59	6.44	0.33	4.1e-10	Carotid intima media thickness;
LUSC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg08499158	chr17:42289980	UBTF	-0.37	-6.08	-0.32	3.2e-9	Total body bone mineral density;
LUSC	cis	rs9513627	0.915	rs80270035	chr13:100121784	C/T	cg25919922	chr13:100150906	NA	-0.8	-6.96	-0.36	1.83e-11	Obesity-related traits;
LUSC	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg04398451	chr17:18023971	MYO15A	-0.44	-7.13	-0.36	6.2e-12	Total body bone mineral density;
LUSC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.91	-14.62	-0.62	9.2e-38	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.68	-0.47	1.07e-19	Multiple sclerosis;
LUSC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg13010344	chr12:123464640	ARL6IP4	0.44	6.61	0.34	1.55e-10	Neutrophil percentage of white cells;
LUSC	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg26876637	chr1:152193138	HRNR	0.47	6.69	0.34	9.42e-11	Atopic dermatitis;
LUSC	trans	rs2840044	1.000	rs225277	chr17:33973311	G/A	cg19694781	chr19:47549865	TMEM160	-0.57	-9.11	-0.45	7.65e-18	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg10840412	chr1:235813424	GNG4	0.45	5.95	0.31	6.8e-9	Bipolar disorder;
LUSC	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg20503657	chr10:835505	NA	0.8	11.08	0.52	1.71e-24	Eosinophil percentage of granulocytes;
LUSC	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg00792783	chr2:198669748	PLCL1	0.43	5.7	0.3	2.66e-8	Dermatomyositis;
LUSC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg06484146	chr7:12443880	VWDE	-0.69	-7.35	-0.37	1.53e-12	Coronary artery disease;
LUSC	trans	rs1325195	0.881	rs2486995	chr1:179098475	C/T	cg11624085	chr17:8464688	MYH10	0.44	7.3	0.37	2.08e-12	IgE grass sensitization;
LUSC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg19302996	chr17:73780495	UNK	0.54	8.18	0.41	6.21e-15	White matter hyperintensity burden;
LUSC	trans	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg06521331	chr12:34319734	NA	0.4	6.23	0.32	1.37e-9	Bladder cancer;
LUSC	trans	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04565464	chr8:145669602	NFKBIL2	0.37	6.06	0.31	3.7e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4704187	0.687	rs6858969	chr5:74379281	T/C	cg03227963	chr5:74354835	NA	0.32	6.76	0.35	6.08e-11	Response to amphetamines;
LUSC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg01125463	chr6:42946178	PEX6	-0.37	-6.03	-0.31	4.27e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4343996	0.934	rs4722655	chr7:3342895	C/A	cg21248987	chr7:3385318	SDK1	0.39	6.67	0.34	1.09e-10	Motion sickness;
LUSC	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.77	-0.47	5.45e-20	Multiple sclerosis;
LUSC	cis	rs4356932	0.967	rs6856958	chr4:76952356	T/G	cg00809888	chr4:76862425	NAAA	0.35	5.77	0.3	1.78e-8	Blood protein levels;
LUSC	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg01629716	chr15:45996671	NA	0.4	5.87	0.31	1.05e-8	Waist circumference;Weight;
LUSC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg04369109	chr6:150039330	LATS1	-0.57	-8.34	-0.42	1.91e-15	Lung cancer;
LUSC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.73	-9.6	-0.47	1.93e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.6	0.34	1.61e-10	Resting heart rate;
LUSC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10802521	chr3:52805072	NEK4	-0.57	-8.96	-0.44	2.39e-17	Bipolar disorder;
LUSC	cis	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg06521331	chr12:34319734	NA	-0.41	-6.33	-0.33	8.04e-10	Morning vs. evening chronotype;
LUSC	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg03929089	chr4:120376271	NA	0.68	7.66	0.39	2.09e-13	Axial length;
LUSC	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg24642439	chr20:33292090	TP53INP2	0.4	5.84	0.3	1.23e-8	Height;
LUSC	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg17691542	chr6:26056736	HIST1H1C	0.38	5.73	0.3	2.21e-8	Schizophrenia;
LUSC	cis	rs1355223	0.573	rs1597961	chr11:34727114	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.13	-0.32	2.55e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg07701084	chr6:150067640	NUP43	0.58	9.04	0.44	1.33e-17	Lung cancer;
LUSC	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg12292205	chr6:26970375	C6orf41	-0.63	-7.57	-0.38	3.72e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs60695258	0.550	rs4693800	chr4:87915620	C/G	cg10685359	chr4:87814065	C4orf36	0.33	5.98	0.31	5.83e-9	Hematocrit;
LUSC	cis	rs57502260	0.704	rs72936599	chr11:68320405	G/A	cg20283391	chr11:68216788	NA	-0.62	-5.83	-0.3	1.29e-8	Total body bone mineral density (age 45-60);
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg02506360	chr16:46963989	GPT2	0.37	5.95	0.31	6.7e-9	Educational attainment (years of education);
LUSC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg11608241	chr8:8085544	FLJ10661	0.41	6.07	0.32	3.55e-9	Mood instability;
LUSC	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-8.16	-0.41	6.81e-15	Morning vs. evening chronotype;
LUSC	cis	rs11264799	0.520	rs1885561	chr1:157548669	T/A	cg18268488	chr1:157545234	FCRL4	0.39	7.67	0.39	1.92e-13	IgA nephropathy;
LUSC	trans	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04565464	chr8:145669602	NFKBIL2	0.36	6.05	0.31	3.98e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4704187	0.687	rs6896474	chr5:74453818	C/G	cg03227963	chr5:74354835	NA	-0.3	-5.77	-0.3	1.77e-8	Response to amphetamines;
LUSC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-14.82	-0.63	1.57e-38	Total body bone mineral density;
LUSC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.61	11.67	0.54	1.29e-26	Pulse pressure;
LUSC	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg17366294	chr4:99064904	C4orf37	0.59	10.45	0.5	2.62e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg16325326	chr1:53192061	ZYG11B	0.81	14.0	0.61	2.39e-35	Monocyte count;
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.3	6.07	0.32	3.48e-9	Lymphocyte counts;
LUSC	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg04492858	chr10:133558786	NA	0.39	6.66	0.34	1.14e-10	Survival in rectal cancer;
LUSC	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg09835421	chr16:68378352	PRMT7	-0.52	-5.93	-0.31	7.45e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs500891	0.553	rs6941094	chr6:84138485	C/A	cg08257003	chr6:84140564	ME1	0.37	9.17	0.45	5.06e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.47	-8.4	-0.42	1.27e-15	Eosinophil percentage of white cells;
LUSC	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg15654264	chr1:150340011	RPRD2	0.61	10.09	0.48	4.38e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg11887960	chr12:57824829	NA	0.52	6.54	0.34	2.29e-10	Obesity-related traits;
LUSC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.14e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg04176532	chr22:50317003	CRELD2	-0.35	-5.68	-0.3	2.92e-8	Schizophrenia;
LUSC	cis	rs7011049	1.000	rs6988927	chr8:53837496	T/C	cg26025543	chr8:53854495	NA	0.52	6.17	0.32	1.95e-9	Systolic blood pressure;
LUSC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18876405	chr7:65276391	NA	0.56	8.82	0.43	6.35e-17	Aortic root size;
LUSC	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg03060546	chr3:49711283	APEH	-0.61	-7.17	-0.37	4.92e-12	Menarche (age at onset);
LUSC	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg02176678	chr2:219576539	TTLL4	-0.55	-9.78	-0.47	4.92e-20	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.85	-0.44	5.02e-17	Axial length;
LUSC	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.97	0.51	4.04e-24	Monocyte percentage of white cells;
LUSC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.79	13.29	0.59	1.24e-32	Monocyte count;
LUSC	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.66	9.42	0.46	7.73e-19	Inflammatory bowel disease;
LUSC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg05872129	chr22:39784769	NA	-0.59	-11.12	-0.52	1.21e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24110177	chr3:50126178	RBM5	0.6	9.95	0.48	1.35e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg15103426	chr22:29168792	CCDC117	0.46	5.94	0.31	7.06e-9	Lymphocyte counts;
LUSC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	7.91	0.4	3.87e-14	Menarche (age at onset);
LUSC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg12564285	chr5:131593104	PDLIM4	0.42	7.68	0.39	1.74e-13	Breast cancer;
LUSC	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.41	-6.42	-0.33	4.6e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg27086020	chr5:148206096	ADRB2	0.75	6.02	0.31	4.59e-9	Cognitive performance;
LUSC	cis	rs7945705	0.875	rs11042059	chr11:8795080	G/A	cg12365402	chr11:9010492	NRIP3	0.45	7.99	0.4	2.21e-14	Hemoglobin concentration;
LUSC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg27535305	chr1:53392650	SCP2	0.36	6.73	0.35	7.39e-11	Monocyte count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24491766	chr7:21985706	CDCA7L	-0.4	-5.95	-0.31	6.75e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs174449	0.603	rs174460	chr11:61657110	C/T	cg01500311	chr11:61656094	FADS3	0.44	7.93	0.4	3.41e-14	Trans fatty acid levels;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg12748915	chr4:95373019	PDLIM5	0.4	6.33	0.33	7.81e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs9403521	1.000	rs9403521	chr6:143994199	C/T	cg18240653	chr6:144019428	PHACTR2	0.51	6.2	0.32	1.65e-9	Obesity-related traits;
LUSC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-6.9	-0.35	2.65e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9311676	0.632	rs11925533	chr3:58429908	G/A	cg26110898	chr3:58419937	PDHB	0.41	6.69	0.34	9.7e-11	Systemic lupus erythematosus;
LUSC	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.11	25.84	0.82	1.22e-81	Schizophrenia;
LUSC	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg23750338	chr8:142222470	SLC45A4	0.45	8.26	0.41	3.5e-15	Immature fraction of reticulocytes;
LUSC	cis	rs8113142	0.614	rs4805257	chr19:29130465	A/G	cg04546413	chr19:29218101	NA	-0.43	-6.1	-0.32	2.96e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9837602	1.000	rs9873878	chr3:99711816	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.89	-0.31	9.26e-9	Breast cancer;
LUSC	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.69	-0.3	2.85e-8	Recombination rate (females);
LUSC	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.45	-0.33	3.97e-10	Uric acid levels;
LUSC	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	8.37	0.42	1.61e-15	Adiposity;
LUSC	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg13010199	chr12:38710504	ALG10B	-0.6	-9.33	-0.45	1.56e-18	Morning vs. evening chronotype;
LUSC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg06784218	chr1:46089804	CCDC17	-0.58	-11.51	-0.53	4.83e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg23752985	chr2:85803571	VAMP8	0.33	7.06	0.36	9.61e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6939532	0.522	rs4712980	chr6:26355758	G/T	cg09904177	chr6:26538194	HMGN4	0.44	6.11	0.32	2.77e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-8.13	-0.41	8.64e-15	Axial length;
LUSC	cis	rs6840360	1.000	rs1105536	chr4:152605027	C/T	cg22705602	chr4:152727874	NA	-0.27	-5.74	-0.3	2.15e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs75804782	0.641	rs59499060	chr2:239341411	C/T	cg18131467	chr2:239335373	ASB1	-0.72	-6.56	-0.34	2.07e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg20887711	chr4:1340912	KIAA1530	0.43	6.71	0.34	8.33e-11	Obesity-related traits;
LUSC	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg03342759	chr3:160939853	NMD3	-0.44	-6.84	-0.35	3.76e-11	Morning vs. evening chronotype;
LUSC	cis	rs34421088	0.506	rs2409755	chr8:11169983	G/A	cg21293242	chr8:11204541	TDH	0.31	5.8	0.3	1.54e-8	Neuroticism;
LUSC	cis	rs11605924	0.901	rs11607883	chr11:45839709	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.48	-7.11	-0.36	6.9e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-9.36	-0.46	1.22e-18	Coffee consumption (cups per day);
LUSC	cis	rs68092024	0.704	rs704575	chr3:99486075	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-6.14	-0.32	2.31e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs1385374	0.800	rs12321679	chr12:129284791	G/A	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.78	-0.35	5.5e-11	Systemic lupus erythematosus;
LUSC	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg21361702	chr7:150065534	REPIN1	0.45	6.32	0.33	8.59e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg16339924	chr4:17578868	LAP3	0.51	7.58	0.38	3.42e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12413816	0.818	rs35567671	chr10:13769722	C/A	cg16485048	chr10:13749193	FRMD4A	0.44	7.28	0.37	2.36e-12	Red cell distribution width;
LUSC	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg14414819	chr6:37225644	TMEM217;TBC1D22B	0.46	6.1	0.32	2.91e-9	Cognitive function;Information processing speed;
LUSC	cis	rs829883	0.724	rs1439774	chr12:98907692	C/T	cg25150519	chr12:98850993	NA	-0.64	-8.7	-0.43	1.53e-16	Colorectal adenoma (advanced);
LUSC	cis	rs16949788	1.000	rs7182169	chr15:66748213	C/A	cg08120210	chr15:66682733	MAP2K1	-0.62	-6.2	-0.32	1.65e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7809950	0.648	rs114452520	chr7:107176780	C/T	cg23024343	chr7:107201750	COG5	-0.56	-8.77	-0.43	9.38e-17	Coronary artery disease;
LUSC	cis	rs72792276	1.000	rs13357283	chr5:127423114	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	8.8	0.43	7.27e-17	Red cell distribution width;
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.61	-11.51	-0.53	4.92e-26	Longevity;Endometriosis;
LUSC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg05313129	chr8:58192883	C8orf71	-0.49	-6.77	-0.35	5.9e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.83	0.63	1.46e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6426558	0.537	rs10495253	chr1:227471820	A/T	cg10327440	chr1:227177885	CDC42BPA	0.54	7.2	0.37	3.97e-12	Neutrophil percentage of white cells;
LUSC	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14442939	chr10:27389572	ANKRD26	0.89	10.1	0.48	4.15e-21	Breast cancer;
LUSC	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06002616	chr8:101225028	SPAG1	-0.46	-7.49	-0.38	6.19e-13	Atrioventricular conduction;
LUSC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.91	0.35	2.49e-11	Parkinson's disease;
LUSC	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg22676075	chr6:135203613	NA	-0.72	-12.5	-0.56	1.16e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.43	0.78	1.26e-68	Prudent dietary pattern;
LUSC	trans	rs2262909	0.962	rs4932952	chr19:22246788	G/A	cg05197062	chr11:11642011	GALNTL4	0.56	7.88	0.4	4.75e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg23791538	chr6:167370224	RNASET2	0.5	8.37	0.42	1.65e-15	Crohn's disease;
LUSC	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg19812747	chr11:111475976	SIK2	0.53	7.53	0.38	4.72e-13	Primary sclerosing cholangitis;
LUSC	cis	rs887829	0.531	rs4338954	chr2:234593931	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.31	-0.33	8.87e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	trans	rs1941687	0.732	rs3744888	chr18:31402594	A/G	cg27147174	chr7:100797783	AP1S1	-0.43	-6.44	-0.33	4.21e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs2734839	0.964	rs1107162	chr11:113289037	A/G	cg14159747	chr11:113255604	NA	-0.3	-7.55	-0.38	4.3e-13	Information processing speed;
LUSC	cis	rs10986311	0.706	rs7851278	chr9:127102939	T/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.42	6.74	0.35	6.82e-11	Vitiligo;
LUSC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.51	0.38	5.34e-13	Prudent dietary pattern;
LUSC	cis	rs9796	0.870	rs4244584	chr15:41259523	A/G	cg18705301	chr15:41695430	NDUFAF1	0.44	7.62	0.38	2.61e-13	Menopause (age at onset);
LUSC	cis	rs4450131	0.569	rs3824801	chr10:126356840	T/G	cg20435097	chr10:126320824	FAM53B	0.24	6.15	0.32	2.26e-9	White blood cell count (basophil);
LUSC	cis	rs3087591	0.919	rs2018624	chr17:29560777	T/G	cg24425628	chr17:29625626	OMG;NF1	-0.55	-7.92	-0.4	3.46e-14	Hip circumference;
LUSC	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	10.02	0.48	7.77e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.46	6.5	0.34	2.94e-10	Eosinophil percentage of white cells;
LUSC	cis	rs73200209	0.744	rs61562746	chr12:116456445	A/C	cg01776926	chr12:116560359	MED13L	-0.51	-5.96	-0.31	6.56e-9	Total body bone mineral density;
LUSC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg09021430	chr5:549028	NA	-0.6	-9.39	-0.46	9.86e-19	Obesity-related traits;
LUSC	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg19622623	chr12:86230825	RASSF9	-0.41	-5.68	-0.3	2.86e-8	Major depressive disorder;
LUSC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.18	-0.52	7.42e-25	Alzheimer's disease;
LUSC	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg15704280	chr7:45808275	SEPT13	0.64	8.34	0.42	1.95e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg18196295	chr10:418757	DIP2C	0.38	6.17	0.32	1.93e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg22907277	chr7:1156413	C7orf50	0.62	9.54	0.46	3.1e-19	Longevity;Endometriosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09852601	chr17:72732955	RAB37	-0.48	-6.45	-0.33	3.98e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg10248733	chr19:16607483	C19orf44;CALR3	-0.55	-6.35	-0.33	6.89e-10	Lymphocyte percentage of white cells;
LUSC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	4.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.65	11.09	0.52	1.58e-24	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg12677248	chr5:167913319	RARS	0.48	6.19	0.32	1.78e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg07741184	chr6:167504864	NA	-0.36	-6.54	-0.34	2.36e-10	Crohn's disease;
LUSC	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg13256891	chr4:100009986	ADH5	-0.43	-6.0	-0.31	5.06e-9	Alcohol dependence;
LUSC	cis	rs4654899	0.743	rs61778528	chr1:21059837	C/T	cg01072550	chr1:21505969	NA	-0.48	-7.05	-0.36	1.05e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs240764	0.817	rs239211	chr6:101144965	A/C	cg09795085	chr6:101329169	ASCC3	0.42	6.12	0.32	2.55e-9	Neuroticism;
LUSC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg00339695	chr16:24857497	SLC5A11	0.41	7.02	0.36	1.23e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg07741184	chr6:167504864	NA	0.38	6.77	0.35	5.65e-11	Primary biliary cholangitis;
LUSC	trans	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.07	-0.32	3.46e-9	Monocyte count;
LUSC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg25566285	chr7:158114605	PTPRN2	0.31	5.85	0.3	1.2e-8	Calcium levels;
LUSC	trans	rs60843830	0.550	rs300751	chr2:209063	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.41	6.55	0.34	2.18e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.84	-0.3	1.25e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.87	0.35	3.08e-11	IgG glycosylation;
LUSC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg15147215	chr3:52552868	STAB1	-0.29	-5.76	-0.3	1.93e-8	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769707	0.681	rs739236	chr22:50041602	A/G	cg20744362	chr22:50050164	C22orf34	0.37	6.85	0.35	3.55e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.22	-0.32	1.47e-9	Blood trace element (Cu levels);
LUSC	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg24375607	chr4:120327624	NA	0.78	11.52	0.53	4.39e-26	Corneal astigmatism;
LUSC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.82	0.35	4.17e-11	Platelet count;
LUSC	trans	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg06521331	chr12:34319734	NA	-0.39	-6.0	-0.31	5.25e-9	Bladder cancer;
LUSC	cis	rs6987853	0.602	rs2974337	chr8:42390873	C/T	cg09913449	chr8:42400586	C8orf40	0.45	7.57	0.38	3.68e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg20503657	chr10:835505	NA	1.23	15.71	0.65	4.86e-42	Eosinophil percentage of granulocytes;
LUSC	cis	rs3106136	0.967	rs3106135	chr4:95138308	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.12	-0.32	2.68e-9	Capecitabine sensitivity;
LUSC	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg02660097	chr11:68866761	NA	0.43	6.01	0.31	4.82e-9	Blond vs. brown hair color;
LUSC	cis	rs11971779	0.715	rs55714903	chr7:139074590	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	7.37	0.37	1.32e-12	Diisocyanate-induced asthma;
LUSC	cis	rs4908769	0.624	rs6678140	chr1:8436802	C/T	cg00546117	chr1:8445545	RERE	0.29	5.93	0.31	7.74e-9	Allergy;
LUSC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg09359103	chr1:154839909	KCNN3	-0.72	-17.43	-0.69	7.33e-49	Prostate cancer;
LUSC	cis	rs6960043	0.818	rs2191349	chr7:15064309	G/T	cg19272540	chr7:15055459	NA	-0.32	-7.79	-0.39	8.77e-14	Type 2 diabetes;
LUSC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg02018176	chr4:1364513	KIAA1530	0.53	9.63	0.47	1.52e-19	Longevity;
LUSC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg05729581	chr11:3078854	CARS	-0.53	-8.31	-0.41	2.35e-15	Longevity;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg27094323	chr7:1216898	NA	-0.45	-7.81	-0.39	7.33e-14	Longevity;Endometriosis;
LUSC	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg13390004	chr1:15929781	NA	0.41	6.9	0.35	2.66e-11	Systolic blood pressure;
LUSC	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21293242	chr8:11204541	TDH	0.33	6.24	0.32	1.3e-9	Retinal vascular caliber;
LUSC	cis	rs11779988	0.571	rs208053	chr8:17825327	G/A	cg01800426	chr8:17659068	MTUS1	-0.49	-5.99	-0.31	5.46e-9	Breast cancer;
LUSC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg07716408	chr11:68623521	NA	-0.32	-6.36	-0.33	6.6e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.33e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg22676075	chr6:135203613	NA	-0.61	-9.71	-0.47	8.64e-20	Red blood cell count;
LUSC	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg01528321	chr10:82214614	TSPAN14	0.62	9.3	0.45	1.9e-18	Post bronchodilator FEV1;
LUSC	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg22349387	chr12:9600060	DDX12	-0.43	-6.99	-0.36	1.49e-11	Breast size;
LUSC	cis	rs10193935	0.901	rs6720837	chr2:42463173	A/T	cg27598129	chr2:42591480	NA	-0.56	-7.9	-0.4	3.97e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11649653	0.502	rs11864054	chr16:30846134	G/A	cg02466173	chr16:30829666	NA	-0.48	-9.34	-0.46	1.36e-18	Triglycerides;
LUSC	trans	rs2055729	0.645	rs62489486	chr8:9741925	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	6.61	0.34	1.55e-10	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.88	0.44	4.22e-17	Brugada syndrome;
LUSC	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.58	0.34	1.81e-10	Corneal astigmatism;
LUSC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06028605	chr16:24865363	SLC5A11	0.7	11.23	0.52	4.73e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	10.09	0.48	4.47e-21	Coffee consumption (cups per day);
LUSC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03934478	chr11:495069	RNH1	0.83	10.05	0.48	6.3e-21	Body mass index;
LUSC	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.1	-0.36	7.71e-12	Response to antipsychotic treatment;
LUSC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg04414720	chr1:150670196	GOLPH3L	0.5	8.23	0.41	4.35e-15	Tonsillectomy;
LUSC	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg13057898	chr1:3703894	LRRC47	0.52	9.03	0.44	1.45e-17	Red cell distribution width;
LUSC	cis	rs3099143	1.000	rs4541044	chr15:77173193	C/T	cg21673338	chr15:77095150	SCAPER	0.81	7.7	0.39	1.56e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg04398451	chr17:18023971	MYO15A	-0.49	-7.9	-0.4	3.99e-14	Total body bone mineral density;
LUSC	trans	rs7951105	1.000	rs12271653	chr11:39247083	T/C	cg24085930	chr3:21832523	NA	0.49	6.06	0.31	3.58e-9	Free thyroxine concentration;
LUSC	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.83	0.39	6.66e-14	Colorectal cancer;
LUSC	cis	rs11583043	0.708	rs12734559	chr1:101563001	G/A	cg11406453	chr1:101602562	NA	-0.4	-6.76	-0.35	6.13e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg15704280	chr7:45808275	SEPT13	-0.82	-10.42	-0.5	3.43e-22	Coronary artery disease;
LUSC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-11.66	-0.54	1.32e-26	Chronic sinus infection;
LUSC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg16928487	chr17:17741425	SREBF1	-0.43	-8.49	-0.42	6.87e-16	Total body bone mineral density;
LUSC	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.05e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4132509	0.793	rs12037013	chr1:243784207	G/A	cg21452805	chr1:244014465	NA	0.64	6.19	0.32	1.78e-9	RR interval (heart rate);
LUSC	cis	rs8038465	0.638	rs12594175	chr15:73973186	C/T	cg15420318	chr15:73925796	NPTN	0.59	10.06	0.48	5.73e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg24112000	chr20:60950667	NA	0.38	7.22	0.37	3.49e-12	Colorectal cancer;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13340481	chr17:27275985	PHF12	0.45	6.04	0.31	4.04e-9	Neuroticism;
LUSC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-13.47	-0.59	2.54e-33	Total body bone mineral density;
LUSC	cis	rs870825	0.616	rs28444118	chr4:185621692	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs3087591	0.919	rs7406870	chr17:29590617	G/A	cg24425628	chr17:29625626	OMG;NF1	0.65	9.24	0.45	3.06e-18	Hip circumference;
LUSC	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg16359550	chr11:109292809	C11orf87	0.36	6.39	0.33	5.73e-10	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19682514	chr1:61549327	NFIA	-0.39	-6.02	-0.31	4.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg21963583	chr11:68658836	MRPL21	0.56	8.34	0.42	1.94e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs61931739	0.649	rs815043	chr12:33722599	C/T	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg02428538	chr16:24856791	SLC5A11	0.5	5.72	0.3	2.32e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg06238570	chr21:40685208	BRWD1	0.6	10.12	0.48	3.5e-21	Cognitive function;
LUSC	cis	rs6690583	0.623	rs55721024	chr1:85454447	A/C	cg22153463	chr1:85462885	MCOLN2	0.62	6.0	0.31	5.12e-9	Serum sulfate level;
LUSC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg12310025	chr6:25882481	NA	0.41	6.79	0.35	5.02e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.03	-0.36	1.16e-11	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg06636001	chr8:8085503	FLJ10661	0.71	11.94	0.55	1.35e-27	Mood instability;
LUSC	cis	rs6546550	0.904	rs3771537	chr2:70038792	A/C	cg02498382	chr2:70120550	SNRNP27	-0.28	-6.78	-0.35	5.51e-11	Prevalent atrial fibrillation;
LUSC	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg13852791	chr20:30311386	BCL2L1	0.97	12.49	0.56	1.27e-29	Mean corpuscular hemoglobin;
LUSC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-7.32	-0.37	1.86e-12	Schizophrenia;
LUSC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.62	0.62	8.89e-38	Platelet count;
LUSC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.97	-0.36	1.74e-11	Lung cancer;
LUSC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg22907277	chr7:1156413	C7orf50	0.72	7.61	0.38	2.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg19592336	chr6:28129416	ZNF389	-0.51	-6.81	-0.35	4.6e-11	Parkinson's disease;
LUSC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	15.98	0.66	4.41e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg17366294	chr4:99064904	C4orf37	0.53	8.27	0.41	3.15e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg20503657	chr10:835505	NA	0.63	7.93	0.4	3.38e-14	Eosinophil percentage of granulocytes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22813821	chr12:72148853	RAB21	-0.41	-6.1	-0.32	2.9e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg01256987	chr12:42539512	GXYLT1	0.35	6.4	0.33	5.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.5	-8.49	-0.42	6.76e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9395066	0.545	rs1831310	chr6:44976725	G/A	cg25276700	chr6:44698697	NA	0.29	6.03	0.31	4.31e-9	Height;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18722919	chr20:13619583	TASP1	0.71	5.98	0.31	5.64e-9	Cognitive performance;
LUSC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg10729496	chr3:10149963	C3orf24	0.56	6.97	0.36	1.7e-11	Alzheimer's disease;
LUSC	cis	rs12940923	0.810	rs7215408	chr17:56366106	T/G	cg19466818	chr17:56409534	MIR142	-0.39	-6.86	-0.35	3.35e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs12617721	0.874	rs3754890	chr2:99088624	C/T	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs367943	0.673	rs7708084	chr5:112732692	G/T	cg12552261	chr5:112820674	MCC	0.36	6.04	0.31	4.21e-9	Type 2 diabetes;
LUSC	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg04586622	chr2:25135609	ADCY3	0.4	8.37	0.42	1.58e-15	Body mass index;
LUSC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.2	-0.37	3.93e-12	Platelet count;
LUSC	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07328417	chr8:28558817	EXTL3	0.72	6.03	0.31	4.28e-9	Cognitive performance;
LUSC	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.08	0.32	3.24e-9	Recombination rate (females);
LUSC	cis	rs909341	0.680	rs2427534	chr20:62366478	A/G	cg09650180	chr20:62225654	GMEB2	-0.46	-5.98	-0.31	5.74e-9	Atopic dermatitis;
LUSC	cis	rs10392	0.706	rs72623596	chr20:37585212	T/C	cg27552599	chr20:37590471	DHX35	0.46	5.85	0.3	1.17e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	trans	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08439880	chr3:133502540	NA	0.35	6.26	0.32	1.17e-9	Iron status biomarkers;
LUSC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg09034736	chr1:150693464	HORMAD1	0.42	5.8	0.3	1.55e-8	Melanoma;
LUSC	cis	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.49	-6.17	-0.32	2e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg05044414	chr3:183734942	ABCC5	0.19	6.37	0.33	6.44e-10	Anterior chamber depth;
LUSC	trans	rs2262909	1.000	rs436039	chr19:22214873	T/C	cg05197062	chr11:11642011	GALNTL4	-0.51	-7.08	-0.36	8.34e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.64	-8.16	-0.41	6.95e-15	Body mass index;
LUSC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.48	0.62	3.21e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3847687	0.869	rs11061300	chr12:131523261	G/A	cg13586425	chr12:131519906	GPR133	-0.26	-5.92	-0.31	7.9e-9	Longevity;
LUSC	cis	rs9462027	0.628	rs3734264	chr6:34831866	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.68	-0.3	2.98e-8	Systemic lupus erythematosus;
LUSC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg14440974	chr22:39074834	NA	-0.35	-5.9	-0.31	8.75e-9	Menopause (age at onset);
LUSC	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg05585544	chr11:47624801	NA	0.42	7.3	0.37	2.17e-12	Subjective well-being;
LUSC	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg16586182	chr3:47516702	SCAP	-0.52	-8.11	-0.41	1e-14	Colorectal cancer;
LUSC	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	7.56	0.38	3.8e-13	Neuroticism;
LUSC	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg22532475	chr10:104410764	TRIM8	0.25	5.93	0.31	7.44e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs780094	0.500	rs4666002	chr2:27840640	G/C	cg27432699	chr2:27873401	GPN1	0.42	5.93	0.31	7.49e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.98	-0.36	1.63e-11	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg04450456	chr4:17643702	FAM184B	0.38	6.48	0.33	3.2e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.23	-0.32	1.39e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7586879	0.752	rs11683748	chr2:25130434	C/T	cg01884057	chr2:25150051	NA	0.42	8.82	0.43	6.26e-17	Body mass index;
LUSC	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg06360820	chr2:242988706	NA	-0.91	-9.85	-0.47	2.81e-20	Obesity-related traits;
LUSC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg16325326	chr1:53192061	ZYG11B	-0.99	-19.96	-0.74	6.94e-59	Monocyte count;
LUSC	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg13010199	chr12:38710504	ALG10B	-0.65	-10.25	-0.49	1.3e-21	Bladder cancer;
LUSC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.22	0.32	1.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg14343924	chr8:8086146	FLJ10661	0.44	6.24	0.32	1.34e-9	Neuroticism;
LUSC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg07424592	chr7:64974309	NA	0.63	5.67	0.3	3.15e-8	Diabetic kidney disease;
LUSC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg03948781	chr1:205179583	DSTYK	0.31	5.94	0.31	7.05e-9	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.13	0.52	1.06e-24	Fuchs's corneal dystrophy;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg16218377	chr11:34073324	CAPRIN1	-0.51	-6.11	-0.32	2.81e-9	Height;
LUSC	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs2679649	1.000	rs2684269	chr6:122354077	T/A	cg00167820	chr8:131663355	NA	0.54	6.32	0.33	8.59e-10	Subcutaneous adipose tissue;
LUSC	cis	rs9473147	0.543	rs1872505	chr6:47480975	C/G	cg20196966	chr6:47445060	CD2AP	0.42	5.83	0.3	1.31e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg26338869	chr17:61819248	STRADA	0.42	6.1	0.32	2.91e-9	Prudent dietary pattern;
LUSC	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg13789015	chr9:136890014	NCRNA00094	0.67	12.62	0.57	4.16e-30	Platelet distribution width;
LUSC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg05425664	chr17:57184151	TRIM37	0.54	7.98	0.4	2.31e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06080224	chr7:107204581	COG5;DUS4L	-0.42	-5.95	-0.31	6.69e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7572733	0.534	rs10931794	chr2:198776140	C/T	cg00792783	chr2:198669748	PLCL1	-0.45	-6.03	-0.31	4.46e-9	Dermatomyositis;
LUSC	cis	rs12210905	0.622	rs116198502	chr6:26915015	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.67	-5.85	-0.3	1.18e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg00945038	chr17:61921165	SMARCD2	0.38	5.76	0.3	1.95e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-7.51	-0.38	5.43e-13	Mood instability;
LUSC	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg14664628	chr15:75095509	CSK	-1.02	-17.47	-0.69	5.21e-49	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs11051970	0.918	rs7309706	chr12:32538208	A/T	cg02745156	chr12:32552066	NA	0.44	6.93	0.35	2.24e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6754311	0.593	rs313518	chr2:136439090	C/T	cg07169764	chr2:136633963	MCM6	0.55	7.29	0.37	2.32e-12	Mosquito bite size;
LUSC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.38	0.33	5.95e-10	Menopause (age at onset);
LUSC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.69	0.3	2.74e-8	Personality dimensions;
LUSC	cis	rs1160297	0.576	rs13002328	chr2:53085447	A/C	cg07782112	chr2:53107842	NA	0.39	6.36	0.33	6.73e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg05425664	chr17:57184151	TRIM37	-0.53	-7.98	-0.4	2.33e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7709377	0.620	rs11960815	chr5:115500207	A/C	cg23108291	chr5:115420582	COMMD10	0.42	6.02	0.31	4.61e-9	Metabolite levels  (X-11787);
LUSC	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg18404041	chr3:52824283	ITIH1	0.4	7.12	0.36	6.55e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-14.01	-0.61	2.17e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg16405210	chr4:1374714	KIAA1530	-0.56	-8.61	-0.43	2.9e-16	Obesity-related traits;
LUSC	trans	rs11039798	1.000	rs7102865	chr11:48458361	A/C	cg15704280	chr7:45808275	SEPT13	0.66	6.02	0.31	4.48e-9	Axial length;
LUSC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg00745463	chr17:30367425	LRRC37B	-0.64	-7.81	-0.39	7.55e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg26338869	chr17:61819248	STRADA	0.43	6.17	0.32	1.92e-9	Prudent dietary pattern;
LUSC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-7.27	-0.37	2.56e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	7.05	0.36	1.06e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg12940439	chr1:67600707	NA	0.36	6.16	0.32	2.08e-9	Psoriasis;
LUSC	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.5	-0.34	2.86e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs2857891	0.909	rs56372435	chr11:6938658	T/C	cg14883916	chr11:6947541	ZNF215	0.46	5.96	0.31	6.39e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg22907277	chr7:1156413	C7orf50	0.72	10.06	0.48	5.71e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs308403	0.509	rs9990804	chr4:123671984	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.94	17.0	0.68	4.05e-47	Blood protein levels;
LUSC	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg08213375	chr14:104286397	PPP1R13B	0.4	6.92	0.35	2.33e-11	Reticulocyte count;
LUSC	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg04896959	chr15:78267971	NA	0.51	10.75	0.51	2.33e-23	Coronary artery disease or large artery stroke;
LUSC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg26898376	chr11:64110657	CCDC88B	0.33	5.93	0.31	7.68e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	1.0	13.97	0.61	3.14e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg22166914	chr1:53195759	ZYG11B	0.62	9.94	0.48	1.47e-20	Monocyte count;
LUSC	cis	rs7605827	0.930	rs4668905	chr2:15543776	C/A	cg19274914	chr2:15703543	NA	0.47	9.08	0.44	9.67e-18	Educational attainment (years of education);
LUSC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg04871131	chr7:94954202	PON1	-0.38	-6.08	-0.32	3.2e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg25019033	chr10:957182	NA	-0.51	-6.35	-0.33	6.96e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg10857441	chr5:6722123	POLS	-0.47	-9.15	-0.45	5.67e-18	Menopause (age at onset);
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	0.93	17.97	0.7	5.5e-51	Menarche (age at onset);
LUSC	cis	rs3087591	0.708	rs2525569	chr17:29675971	T/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.0	0.36	1.44e-11	Hip circumference;
LUSC	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg23625390	chr15:77176239	SCAPER	-0.63	-9.46	-0.46	5.78e-19	Blood metabolite levels;
LUSC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg06784218	chr1:46089804	CCDC17	0.48	9.34	0.46	1.39e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg02176678	chr2:219576539	TTLL4	-0.54	-9.56	-0.46	2.72e-19	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg12419862	chr22:24373484	LOC391322	-0.86	-13.97	-0.61	2.91e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg04545296	chr12:48745243	ZNF641	0.37	6.72	0.35	7.87e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg10756647	chr7:56101905	PSPH	-0.84	-8.42	-0.42	1.14e-15	Diabetic kidney disease;
LUSC	cis	rs1395	1.000	rs1659685	chr2:27420690	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.39	-6.47	-0.33	3.47e-10	Blood metabolite levels;
LUSC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg03146154	chr1:46216737	IPP	0.54	7.73	0.39	1.27e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6484504	0.576	rs208103	chr11:31167400	A/G	cg06552810	chr11:31128660	NA	-0.38	-6.84	-0.35	3.71e-11	Red blood cell count;
LUSC	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg10560079	chr2:191398806	TMEM194B	-0.73	-8.95	-0.44	2.43e-17	Diastolic blood pressure;
LUSC	cis	rs7572644	0.766	rs12614744	chr2:28269702	T/A	cg27432699	chr2:27873401	GPN1	0.53	6.59	0.34	1.68e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg05855489	chr10:104503620	C10orf26	0.54	8.21	0.41	5.02e-15	Arsenic metabolism;
LUSC	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg15704280	chr7:45808275	SEPT13	0.6	8.82	0.43	6.42e-17	Coronary artery disease;
LUSC	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg03929089	chr4:120376271	NA	0.74	6.91	0.35	2.4e-11	Axial length;
LUSC	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg20991723	chr1:152506922	NA	0.49	9.01	0.44	1.57e-17	Hair morphology;
LUSC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.94	-0.36	2.05e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg02018176	chr4:1364513	KIAA1530	0.51	8.73	0.43	1.2e-16	Obesity-related traits;
LUSC	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg20283391	chr11:68216788	NA	-0.56	-8.25	-0.41	3.82e-15	Bone mineral density (spine);
LUSC	cis	rs9650315	0.866	rs34035722	chr8:57197333	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	7.13	0.36	6.25e-12	Height;
LUSC	cis	rs4566357	0.615	rs12474622	chr2:227912793	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.27	-0.41	3.17e-15	Coronary artery disease;
LUSC	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg12744634	chr1:26560303	CCDC21	0.39	5.84	0.3	1.25e-8	Obesity-related traits;
LUSC	trans	rs4811340	0.572	rs6068254	chr20:51180440	T/C	cg15736553	chr3:11610338	VGLL4	-0.33	-5.95	-0.31	6.7e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs9341808	0.727	rs10943697	chr6:80931506	A/C	cg08355045	chr6:80787529	NA	0.58	10.04	0.48	6.79e-21	Sitting height ratio;
LUSC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.21	0.37	3.81e-12	Monocyte count;
LUSC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg08847533	chr14:75593920	NEK9	0.86	16.04	0.66	2.53e-43	Height;
LUSC	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.89	0.35	2.71e-11	Rheumatoid arthritis;
LUSC	cis	rs7215564	0.818	rs34756632	chr17:78618859	C/T	cg23238734	chr17:78661607	RPTOR	0.46	5.83	0.3	1.32e-8	Myopia (pathological);
LUSC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs134594	1.000	rs134601	chr22:29473495	G/T	cg03665785	chr22:29458676	C22orf31	0.28	5.79	0.3	1.66e-8	Birth weight;
LUSC	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.6	-9.64	-0.47	1.48e-19	Body mass index;
LUSC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg21285383	chr16:89894308	SPIRE2	0.34	7.25	0.37	2.89e-12	Vitiligo;
LUSC	cis	rs6542838	0.641	rs12478574	chr2:99476369	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.37	-0.33	6.11e-10	Fear of minor pain;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg21583850	chr1:112532802	KCND3	0.44	6.36	0.33	6.69e-10	Mosquito bite size;
LUSC	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg08017756	chr2:100939284	LONRF2	-0.45	-8.36	-0.42	1.72e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg04851639	chr8:1020857	NA	-0.35	-7.03	-0.36	1.19e-11	Schizophrenia;
LUSC	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg17127132	chr2:85788382	GGCX	0.45	7.16	0.36	5.07e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs34891900	0.507	rs12167823	chr22:18124362	G/A	cg08824373	chr22:18117835	NA	-0.44	-6.74	-0.35	7.05e-11	Sum neutrophil eosinophil counts;
LUSC	cis	rs13315871	0.929	rs2056120	chr3:58309436	A/T	cg12435725	chr3:58293450	RPP14	-0.67	-6.78	-0.35	5.31e-11	Cholesterol, total;
LUSC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg11645453	chr3:52864694	ITIH4	0.36	8.68	0.43	1.79e-16	Bipolar disorder;
LUSC	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg25214090	chr10:38739885	LOC399744	0.53	7.97	0.4	2.55e-14	Corneal astigmatism;
LUSC	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg04586622	chr2:25135609	ADCY3	0.32	6.09	0.32	3.15e-9	Body mass index;
LUSC	cis	rs6076065	0.723	rs2424530	chr20:23369354	A/G	cg11657817	chr20:23433608	CST11	0.42	7.97	0.4	2.62e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg13010199	chr12:38710504	ALG10B	0.7	10.69	0.5	3.98e-23	Bladder cancer;
LUSC	cis	rs6933660	0.610	rs71549125	chr6:151770796	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.84	-13.18	-0.58	3.11e-32	Menarche (age at onset);
LUSC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg23172400	chr8:95962367	TP53INP1	0.37	6.78	0.35	5.5e-11	Type 2 diabetes;
LUSC	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg24397884	chr7:158709396	WDR60	0.77	8.51	0.42	6.14e-16	Height;
LUSC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg12560992	chr17:57184187	TRIM37	-0.88	-17.25	-0.69	3.97e-48	Intelligence (multi-trait analysis);
LUSC	cis	rs7712401	0.580	rs383262	chr5:122345684	C/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.25	-0.45	2.68e-18	Mean platelet volume;
LUSC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.72e-10	Bipolar disorder;
LUSC	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg23303369	chr20:44641161	MMP9	0.35	5.96	0.31	6.49e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	1.1	14.56	0.62	1.57e-37	Nonalcoholic fatty liver disease;
LUSC	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	6.6	0.34	1.59e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg09044154	chr16:88155775	NA	-0.57	-7.82	-0.39	6.89e-14	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21117768	chr2:85829779	TMEM150A	-0.41	-6.2	-0.32	1.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11264799	0.539	rs12125930	chr1:157577086	A/G	cg18268488	chr1:157545234	FCRL4	0.37	6.88	0.35	2.97e-11	IgA nephropathy;
LUSC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg18827107	chr12:86230957	RASSF9	-0.47	-6.99	-0.36	1.55e-11	Major depressive disorder;
LUSC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg12927641	chr6:109611667	NA	-0.39	-6.76	-0.35	6.03e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs7945718	0.875	rs9888178	chr11:12782643	C/T	cg25843174	chr11:12811716	TEAD1	0.32	7.3	0.37	2.16e-12	Educational attainment (years of education);
LUSC	cis	rs4654899	0.644	rs6669077	chr1:21290520	A/C	cg01072550	chr1:21505969	NA	-0.53	-8.08	-0.4	1.23e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg21775007	chr8:11205619	TDH	0.41	5.89	0.31	9.29e-9	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg20243544	chr17:37824526	PNMT	0.39	5.84	0.3	1.26e-8	Self-reported allergy;
LUSC	cis	rs11031096	0.727	rs2056853	chr11:4142172	C/T	cg18678763	chr11:4115507	RRM1	-0.49	-7.27	-0.37	2.5e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg15309053	chr8:964076	NA	0.33	6.58	0.34	1.84e-10	Schizophrenia;
LUSC	cis	rs6429082	0.715	rs2172718	chr1:235580727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-7.83	-0.39	6.38e-14	Adiposity;
LUSC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.85	-15.01	-0.63	2.77e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	6.85	0.35	3.66e-11	Morning vs. evening chronotype;
LUSC	trans	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.51	-8.15	-0.41	7.16e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.41	-0.33	4.97e-10	Uric acid levels;
LUSC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg13628971	chr7:2884303	GNA12	0.49	6.75	0.35	6.7e-11	Height;
LUSC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg06064525	chr11:970664	AP2A2	-0.48	-10.4	-0.49	3.79e-22	Alzheimer's disease (late onset);
LUSC	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg14092571	chr14:90743983	NA	-0.87	-18.47	-0.71	5.29e-53	Gut microbiota (bacterial taxa);
LUSC	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.09	-0.48	4.41e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg02018176	chr4:1364513	KIAA1530	0.45	7.71	0.39	1.45e-13	Obesity-related traits;
LUSC	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17507749	chr15:85114479	UBE2QP1	0.57	7.22	0.37	3.59e-12	Schizophrenia;
LUSC	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg08999081	chr20:33150536	PIGU	0.37	6.57	0.34	1.92e-10	Height;
LUSC	cis	rs17095355	1.000	rs12267704	chr10:111722008	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.49	-0.38	6.22e-13	Biliary atresia;
LUSC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg26898376	chr11:64110657	CCDC88B	0.35	6.82	0.35	4.37e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.54	0.57	8.07e-30	White blood cell count;
LUSC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	8.32	0.41	2.25e-15	Colorectal cancer;
LUSC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.01	-0.44	1.67e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg09509183	chr1:209979624	IRF6	0.43	5.73	0.3	2.25e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg14092988	chr3:52407081	DNAH1	0.3	5.81	0.3	1.46e-8	Bipolar disorder;
LUSC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg16606324	chr3:10149918	C3orf24	0.62	8.87	0.44	4.41e-17	Alzheimer's disease;
LUSC	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.76	12.34	0.56	4.43e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs5758511	0.773	rs62240999	chr22:42355563	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.31	0.37	1.95e-12	Birth weight;
LUSC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.34	0.33	7.36e-10	Obesity-related traits;
LUSC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg18099408	chr3:52552593	STAB1	0.35	5.67	0.3	3.16e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.47	-6.48	-0.33	3.28e-10	Reticulocyte count;
LUSC	cis	rs2219968	0.743	rs7833315	chr8:78931987	T/C	cg00738934	chr8:78996279	NA	-0.42	-7.53	-0.38	4.74e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.58	-0.34	1.79e-10	Reticulocyte count;
LUSC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	12.01	0.55	7.4e-28	Monocyte percentage of white cells;
LUSC	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg01028140	chr2:1542097	TPO	-0.49	-6.9	-0.35	2.56e-11	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.77	16.08	0.66	1.68e-43	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg22681709	chr2:178499509	PDE11A	0.51	9.37	0.46	1.11e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs981844	1.000	rs72731672	chr4:154664925	G/T	cg10279832	chr4:154682576	RNF175	-0.4	-5.77	-0.3	1.76e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs4919087	1.000	rs10882898	chr10:99087330	G/A	cg25902810	chr10:99078978	FRAT1	-0.46	-6.73	-0.35	7.24e-11	Monocyte count;
LUSC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg25214090	chr10:38739885	LOC399744	0.54	8.06	0.4	1.36e-14	Corneal astigmatism;
LUSC	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.09	-0.4	1.11e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01256987	chr12:42539512	GXYLT1	-0.59	-12.43	-0.56	2.07e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg13073564	chr4:8508604	NA	0.47	9.16	0.45	5.17e-18	Response to antineoplastic agents;
LUSC	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.05	-0.31	3.91e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.27	-0.41	3.16e-15	Schizophrenia;
LUSC	cis	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg05299278	chr17:33885742	SLFN14	-0.31	-6.38	-0.33	5.88e-10	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs4474465	0.850	rs4559714	chr11:78257302	C/T	cg27205649	chr11:78285834	NARS2	0.52	6.2	0.32	1.7e-9	Alzheimer's disease (survival time);
LUSC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06544989	chr22:39130855	UNC84B	0.34	5.89	0.31	9.37e-9	Menopause (age at onset);
LUSC	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg24375607	chr4:120327624	NA	0.75	11.05	0.52	2.18e-24	Corneal astigmatism;
LUSC	cis	rs1941023	0.584	rs6591578	chr11:60158649	G/A	cg08716584	chr11:60157161	MS4A7	-0.62	-11.28	-0.53	3.11e-25	Congenital heart disease (maternal effect);
LUSC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.4	-6.74	-0.35	6.87e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg02086790	chr16:375327	AXIN1	-0.34	-5.91	-0.31	8.24e-9	Bone mineral density (spine);Bone mineral density;
LUSC	trans	rs1800594	1	rs1800594	chr1:169510524	A/G	cg16792071	chr10:134842795	NA	0.29	5.95	0.31	6.75e-9	Ischemic stroke;
LUSC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg14019146	chr3:50243930	SLC38A3	0.31	6.72	0.35	7.94e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg18827107	chr12:86230957	RASSF9	-0.43	-6.4	-0.33	5.11e-10	Major depressive disorder;
LUSC	cis	rs12928939	0.727	rs8053623	chr16:71647529	A/G	cg03805757	chr16:71968109	PKD1L3	-0.4	-5.81	-0.3	1.47e-8	Post bronchodilator FEV1;
LUSC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg18827107	chr12:86230957	RASSF9	-0.47	-6.99	-0.36	1.55e-11	Major depressive disorder;
LUSC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-9.44	-0.46	6.38e-19	Type 2 diabetes;
LUSC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg18681998	chr4:17616180	MED28	-0.82	-14.09	-0.61	1.02e-35	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg21775007	chr8:11205619	TDH	0.46	6.69	0.34	9.61e-11	Mood instability;
LUSC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7633857	0.512	rs745707	chr3:160652672	G/T	cg03342759	chr3:160939853	NMD3	-0.41	-6.19	-0.32	1.72e-9	Educational attainment (years of education);
LUSC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.96	0.48	1.2e-20	Bipolar disorder;
LUSC	cis	rs6445967	0.530	rs12495722	chr3:58401595	C/T	cg23715586	chr3:58305044	RPP14	0.42	7.18	0.37	4.61e-12	Platelet count;
LUSC	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.07e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg14668632	chr7:2872130	GNA12	0.44	6.29	0.33	1.02e-9	Height;
LUSC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg21856205	chr7:94953877	PON1	-0.36	-5.73	-0.3	2.29e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg17264618	chr3:40429014	ENTPD3	0.34	6.05	0.31	3.89e-9	Renal cell carcinoma;
LUSC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg05425664	chr17:57184151	TRIM37	-0.52	-7.83	-0.39	6.51e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs75920871	0.528	rs10892071	chr11:116954565	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.46	-0.33	3.68e-10	Subjective well-being;
LUSC	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.5	-5.72	-0.3	2.33e-8	Red blood cell traits;
LUSC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18932078	chr1:2524107	MMEL1	0.31	6.88	0.35	2.93e-11	Ulcerative colitis;
LUSC	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg12365402	chr11:9010492	NRIP3	0.46	8.02	0.4	1.75e-14	Hemoglobin concentration;
LUSC	trans	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg15934090	chr1:100435551	SLC35A3	0.4	5.99	0.31	5.42e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4629180	1.000	rs908133	chr2:102092374	A/C	cg01388757	chr2:102091195	RFX8	-0.44	-7.01	-0.36	1.33e-11	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6690583	0.562	rs6688354	chr1:85520854	A/G	cg11262906	chr1:85462892	MCOLN2	0.68	6.32	0.33	8.43e-10	Serum sulfate level;
LUSC	cis	rs2282032	0.527	rs2282033	chr14:90769635	G/T	cg14092571	chr14:90743983	NA	-0.45	-7.74	-0.39	1.19e-13	Longevity;
LUSC	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg24147428	chr11:65409760	SIPA1	-0.54	-7.65	-0.39	2.2e-13	Blood pressure (age interaction);
LUSC	cis	rs17401966	0.540	rs6541084	chr1:10285447	A/G	cg17425144	chr1:10567563	PEX14	-0.34	-6.05	-0.31	3.83e-9	Hepatocellular carcinoma;
LUSC	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	6.24	0.32	1.35e-9	Lymphocyte counts;
LUSC	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg02176678	chr2:219576539	TTLL4	-0.59	-10.58	-0.5	9.39e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2324229	0.828	rs1180238	chr6:83943666	G/A	cg08257003	chr6:84140564	ME1	0.27	6.23	0.32	1.37e-9	Platelet-derived growth factor BB levels;
LUSC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.14e-30	Aortic root size;
LUSC	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Smoking initiation;
LUSC	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.22	-0.32	1.48e-9	Neutrophil percentage of white cells;
LUSC	trans	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg18187862	chr3:45730750	SACM1L	0.56	7.06	0.36	9.52e-12	Primary sclerosing cholangitis;
LUSC	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg26384229	chr12:38710491	ALG10B	0.93	15.61	0.65	1.21e-41	Bladder cancer;
LUSC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg15445000	chr17:37608096	MED1	-0.39	-6.8	-0.35	4.94e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg25214090	chr10:38739885	LOC399744	-0.42	-6.55	-0.34	2.21e-10	Corneal astigmatism;
LUSC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	13.87	0.6	7.19e-35	Platelet count;
LUSC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg18850127	chr7:39170497	POU6F2	0.68	11.0	0.52	3.13e-24	IgG glycosylation;
LUSC	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.11	-0.36	7.29e-12	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs67366981	1.000	rs57178676	chr14:77704595	A/C	cg22824376	chr14:77648248	TMEM63C	0.68	6.39	0.33	5.43e-10	Obsessive-compulsive symptoms;
LUSC	cis	rs2637266	1.000	rs4979784	chr10:78355476	T/A	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg16325326	chr1:53192061	ZYG11B	0.93	17.63	0.69	1.17e-49	Monocyte count;
LUSC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg19774624	chr17:42201019	HDAC5	0.82	14.05	0.61	1.43e-35	Total body bone mineral density;
LUSC	cis	rs17253792	0.822	rs74609892	chr14:56053002	G/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	8.91e-12	Putamen volume;
LUSC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg14004847	chr7:1930337	MAD1L1	0.55	8.65	0.43	2.2e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg14668632	chr7:2872130	GNA12	-0.45	-6.52	-0.34	2.66e-10	Height;
LUSC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	7.39	0.37	1.17e-12	Mood instability;
LUSC	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg24675056	chr1:15929824	NA	0.42	6.85	0.35	3.57e-11	Systolic blood pressure;
LUSC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg11871910	chr12:69753446	YEATS4	0.6	8.08	0.4	1.17e-14	Response to diuretic therapy;
LUSC	cis	rs4842666	0.915	rs73437358	chr12:90072076	G/A	cg00757033	chr12:89920650	WDR51B	0.5	7.13	0.36	6.44e-12	Blood pressure;
LUSC	trans	rs8055236	0.564	rs7187443	chr16:83197057	C/G	cg27022570	chr14:50155261	POLE2	0.44	5.96	0.31	6.5e-9	Coronary heart disease;
LUSC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg18512352	chr11:47633146	NA	0.46	9.33	0.45	1.56e-18	Subjective well-being;
LUSC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg00033643	chr7:134001901	SLC35B4	0.43	6.64	0.34	1.3100000000000001e-10	Mean platelet volume;
LUSC	cis	rs983392	0.805	rs11230180	chr11:59961486	A/C	cg02771260	chr11:59836817	MS4A3	0.39	5.84	0.3	1.22e-8	Alzheimer's disease (late onset);
LUSC	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg25319279	chr11:5960081	NA	-0.48	-6.53	-0.34	2.49e-10	DNA methylation (variation);
LUSC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.82	0.35	4.33e-11	Renal cell carcinoma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06199468	chr16:58163354	C16orf80	-0.44	-6.45	-0.33	3.85e-10	Electrocardiographic conduction measures;
LUSC	cis	rs2019216	0.542	rs8073228	chr17:21909838	C/G	cg22648282	chr17:21454238	C17orf51	-0.53	-7.8	-0.39	8.14e-14	Pelvic organ prolapse;
LUSC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00149659	chr3:10157352	C3orf10	0.88	12.31	0.56	5.78e-29	Alzheimer's disease;
LUSC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.74	-13.19	-0.59	2.77e-32	Personality dimensions;
LUSC	cis	rs2932538	0.922	rs7551933	chr1:113086706	C/T	cg22162597	chr1:113214053	CAPZA1	-0.62	-9.3	-0.45	1.93e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs983392	0.755	rs569046	chr11:59911161	C/G	cg24026212	chr11:59952134	MS4A6A	-0.31	-5.71	-0.3	2.45e-8	Alzheimer's disease (late onset);
LUSC	cis	rs9296092	0.517	rs62405895	chr6:33471969	G/T	cg13560919	chr6:33536144	NA	-0.82	-13.93	-0.61	4.42e-35	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg03060546	chr3:49711283	APEH	0.72	12.14	0.55	2.46e-28	Resting heart rate;
LUSC	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg06462663	chr19:18546047	ISYNA1	-0.45	-7.97	-0.4	2.61e-14	Breast cancer;
LUSC	cis	rs11645898	0.935	rs4788615	chr16:72192372	G/A	cg14768367	chr16:72042858	DHODH	-0.66	-7.24	-0.37	3.2e-12	Blood protein levels;
LUSC	cis	rs6546886	0.912	rs9309478	chr2:74305203	G/C	cg14702570	chr2:74259524	NA	-0.3	-5.8	-0.3	1.56e-8	Dialysis-related mortality;
LUSC	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg21951975	chr1:209979733	IRF6	0.56	6.86	0.35	3.26e-11	Coronary artery disease;
LUSC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg11871910	chr12:69753446	YEATS4	0.83	14.62	0.62	8.94e-38	Blood protein levels;
LUSC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg20608306	chr11:116969690	SIK3	0.39	6.38	0.33	5.81e-10	Blood protein levels;
LUSC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.38e-12	Motion sickness;
LUSC	cis	rs12220238	1.000	rs12252705	chr10:75984863	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.0	0.36	1.39e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg13073564	chr4:8508604	NA	0.34	6.28	0.32	1.08e-9	Response to antineoplastic agents;
LUSC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03352830	chr11:487213	PTDSS2	0.72	8.68	0.43	1.82e-16	Body mass index;
LUSC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg23985595	chr17:80112537	CCDC57	-0.31	-5.94	-0.31	7.08e-9	Life satisfaction;
LUSC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg04450456	chr4:17643702	FAM184B	0.39	6.47	0.33	3.46e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.67	0.54	1.29e-26	Coffee consumption (cups per day);
LUSC	cis	rs2658782	0.615	rs2605615	chr11:93233068	G/A	cg15737290	chr11:93063684	CCDC67	0.63	8.12	0.41	9.26e-15	Pulmonary function decline;
LUSC	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg06917634	chr15:78832804	PSMA4	-0.44	-5.92	-0.31	7.96e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg05623727	chr3:50126028	RBM5	-0.33	-6.18	-0.32	1.87e-9	Body mass index;
LUSC	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg18240062	chr17:79603768	NPLOC4	0.79	15.37	0.64	1.04e-40	Eye color traits;
LUSC	cis	rs939658	1.000	rs939658	chr15:79451869	A/G	cg17916960	chr15:79447300	NA	0.47	9.33	0.45	1.54e-18	Refractive error;
LUSC	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg23029597	chr12:123009494	RSRC2	0.74	9.36	0.46	1.24e-18	Body mass index;
LUSC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg06263672	chr7:65235340	NA	0.44	6.34	0.33	7.28e-10	Calcium levels;
LUSC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.52	8.13	0.41	8.77e-15	Longevity;Endometriosis;
LUSC	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.49	0.33	3.11e-10	Morning vs. evening chronotype;
LUSC	trans	rs8022206	0.740	rs1950764	chr14:68343363	G/A	cg15809352	chr2:121748218	GLI2	0.46	6.67	0.34	1.08e-10	Platelet count;Mean platelet volume;
LUSC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11645453	chr3:52864694	ITIH4	0.33	7.64	0.39	2.35e-13	Bipolar disorder;
LUSC	cis	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg07460842	chr6:66804631	NA	0.49	5.97	0.31	6.2e-9	Metabolite levels;
LUSC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.11	0.36	7.1e-12	Bipolar disorder;
LUSC	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg14196790	chr5:131705035	SLC22A5	0.47	7.74	0.39	1.21e-13	Blood metabolite levels;
LUSC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.51	10.1	0.48	4.02e-21	Monocyte percentage of white cells;
LUSC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg20243544	chr17:37824526	PNMT	0.58	8.28	0.41	3.06e-15	Asthma;
LUSC	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg07862535	chr7:139043722	LUC7L2	-0.54	-6.75	-0.35	6.59e-11	Diisocyanate-induced asthma;
LUSC	trans	rs870142	0.883	rs73203671	chr4:4641587	G/A	cg04017672	chr1:182359056	GLUL	0.4	5.99	0.31	5.39e-9	Congenital heart disease;
LUSC	cis	rs4889855	0.516	rs4890041	chr17:78521114	A/T	cg16591659	chr17:78472290	NA	0.31	5.68	0.3	2.99e-8	Fractional excretion of uric acid;
LUSC	cis	rs9921338	0.961	rs7206749	chr16:11376922	T/C	cg00044050	chr16:11439710	C16orf75	-0.5	-6.97	-0.36	1.74e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg19812747	chr11:111475976	SIK2	0.54	7.57	0.38	3.65e-13	Primary sclerosing cholangitis;
LUSC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg06521331	chr12:34319734	NA	-0.47	-8.04	-0.4	1.55e-14	Morning vs. evening chronotype;
LUSC	cis	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg09307838	chr4:120376055	NA	0.52	7.81	0.39	7.33e-14	Diastolic blood pressure;
LUSC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-10.16	-0.49	2.59e-21	Longevity;Endometriosis;
LUSC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg00944433	chr1:107599041	PRMT6	-0.36	-6.66	-0.34	1.15e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg04511125	chr2:88470314	THNSL2	-0.43	-6.45	-0.33	3.91e-10	Response to metformin (IC50);
LUSC	trans	rs10096351	0.550	rs78015822	chr8:128336740	A/G	cg10897648	chr18:56338258	MALT1	-0.42	-6.24	-0.32	1.33e-9	Breast cancer;
LUSC	trans	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg11887960	chr12:57824829	NA	0.54	6.74	0.35	7.11e-11	Obesity-related traits;
LUSC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	0.83	13.64	0.6	5.74e-34	Menopause (age at onset);
LUSC	cis	rs17095355	1.000	rs975442	chr10:111705895	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.62	-0.38	2.6e-13	Biliary atresia;
LUSC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg23711669	chr6:146136114	FBXO30	0.77	12.42	0.56	2.28e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg12559939	chr2:27858050	GPN1	-0.41	-6.26	-0.32	1.2e-9	Oral cavity cancer;
LUSC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.81	-0.51	1.5e-23	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg22139774	chr2:100720529	AFF3	-0.52	-9.09	-0.45	9.3e-18	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg00049323	chr5:472564	LOC25845	-0.44	-6.8	-0.35	4.79e-11	Cystic fibrosis severity;
LUSC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02187348	chr16:89574699	SPG7	0.61	10.13	0.48	3.21e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs2635047	0.811	rs28471970	chr18:44788439	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	5.7	0.3	2.68e-8	Educational attainment;
LUSC	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg20302533	chr7:39170763	POU6F2	0.49	7.94	0.4	3.19e-14	IgG glycosylation;
LUSC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg17971929	chr21:40555470	PSMG1	0.79	13.69	0.6	3.66e-34	Cognitive function;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26468205	chr20:62886904	PCMTD2	-0.51	-6.08	-0.32	3.37e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.09	-0.32	3.13e-9	Joint mobility (Beighton score);
LUSC	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg22800045	chr5:56110881	MAP3K1	0.45	6.35	0.33	6.95e-10	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.41	-6.43	-0.33	4.36e-10	Mean platelet volume;
LUSC	cis	rs9311676	0.656	rs6799077	chr3:58404096	C/T	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.11e-10	Systemic lupus erythematosus;
LUSC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.11	-0.41	9.71e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg08219700	chr8:58056026	NA	0.47	6.18	0.32	1.83e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg15309053	chr8:964076	NA	0.4	8.03	0.4	1.66e-14	Schizophrenia;
LUSC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg10263370	chr3:44754102	ZNF502	-0.37	-5.88	-0.31	1.01e-8	Depressive symptoms;
LUSC	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg09835421	chr16:68378352	PRMT7	-0.46	-5.77	-0.3	1.83e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg09479241	chr17:27052676	TLCD1	0.44	6.24	0.32	1.35e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7246657	0.722	rs2927742	chr19:38133618	T/C	cg23950597	chr19:37808831	NA	0.49	5.67	0.3	3.11e-8	Coronary artery calcification;
LUSC	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg05887092	chr17:76393375	PGS1	0.6	11.41	0.53	1.12e-25	HDL cholesterol levels;
LUSC	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg07169764	chr2:136633963	MCM6	1.03	16.47	0.67	4.8e-45	Corneal structure;
LUSC	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.31	-18.22	-0.71	5.26e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.43	-6.02	-0.31	4.63e-9	Lung cancer;
LUSC	cis	rs372883	0.935	rs1153295	chr21:30704080	T/G	cg24692254	chr21:30365293	RNF160	-0.41	-5.7	-0.3	2.57e-8	Pancreatic cancer;
LUSC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	6.41	0.33	4.97e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg13114125	chr14:105738426	BRF1	-0.96	-16.4	-0.67	9.45e-45	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg18402987	chr7:1209562	NA	0.55	5.98	0.31	5.65e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.64	-0.3	3.56e-8	Coronary artery disease;
LUSC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg05347473	chr6:146136440	FBXO30	0.46	7.99	0.4	2.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9633740	0.578	rs7084416	chr10:82304297	G/A	cg01528321	chr10:82214614	TSPAN14	-0.72	-6.98	-0.36	1.56e-11	Post bronchodilator FEV1;
LUSC	cis	rs2227564	0.729	rs2688616	chr10:75650652	G/C	cg23231163	chr10:75533350	FUT11	-0.43	-5.88	-0.31	9.97e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg00343986	chr7:65444356	GUSB	-0.38	-5.73	-0.3	2.29e-8	Aortic root size;
LUSC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.17	0.55	1.94e-28	Prudent dietary pattern;
LUSC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg26513180	chr16:89883248	FANCA	-0.85	-13.77	-0.6	1.75e-34	Vitiligo;
LUSC	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg21466736	chr12:48725269	NA	0.34	6.1	0.32	2.97e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg18357645	chr12:58087776	OS9	0.55	8.34	0.42	1.95e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg11062466	chr8:58055876	NA	0.61	7.5	0.38	5.71e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs13401104	0.796	rs1968708	chr2:237110654	G/A	cg19324714	chr2:237145437	ASB18	0.43	5.79	0.3	1.6e-8	Educational attainment;
LUSC	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg12863693	chr15:85201151	NMB	0.38	8.08	0.4	1.17e-14	Schizophrenia;
LUSC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.47	6.0	0.31	5.1e-9	Renal function-related traits (BUN);
LUSC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-7.05	-0.36	1.01e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1506636	1.000	rs666266	chr7:123417759	A/G	cg03229431	chr7:123269106	ASB15	0.65	10.68	0.5	4.29e-23	Plateletcrit;Platelet count;
LUSC	cis	rs72634258	0.699	rs12128234	chr1:8170219	T/C	cg00042356	chr1:8021962	PARK7	-0.59	-7.17	-0.37	4.76e-12	Inflammatory bowel disease;
LUSC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg10130564	chr11:117069849	TAGLN	0.39	6.66	0.34	1.16e-10	Blood protein levels;
LUSC	cis	rs7267979	0.745	rs6132845	chr20:25547767	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.74	14.86	0.63	1.09e-38	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs73195822	0.667	rs73194062	chr12:111223294	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	6.7	0.34	9.1e-11	Itch intensity from mosquito bite;
LUSC	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg00012203	chr2:219082015	ARPC2	-0.58	-9.43	-0.46	7.27e-19	Ulcerative colitis;
LUSC	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg00376283	chr12:123451042	ABCB9	0.65	8.3	0.41	2.63e-15	Neutrophil percentage of white cells;
LUSC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg24130564	chr14:104152367	KLC1	-0.4	-5.7	-0.3	2.66e-8	Body mass index;
LUSC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg08088566	chr11:430123	ANO9	0.66	7.32	0.37	1.82e-12	Body mass index;
LUSC	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg03585969	chr10:35415529	CREM	-0.59	-8.94	-0.44	2.77e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2324229	0.828	rs1180185	chr6:83970313	T/G	cg08257003	chr6:84140564	ME1	0.34	8.01	0.4	1.97e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs2637266	0.655	rs846595	chr10:78531300	C/T	cg18941641	chr10:78392320	NA	0.39	7.08	0.36	8.35e-12	Pulmonary function;
LUSC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg09436375	chr6:42928200	GNMT	-0.29	-6.82	-0.35	4.27e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11583043	0.667	rs4617425	chr1:101543205	C/A	cg11406453	chr1:101602562	NA	-0.4	-6.68	-0.34	9.91e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.06	-0.36	9.46e-12	Coronary artery disease;
LUSC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.46	-0.33	3.6e-10	Life satisfaction;
LUSC	cis	rs6005807	0.545	rs12169120	chr22:29005302	A/C	cg12565055	chr22:29076175	TTC28	0.54	5.79	0.3	1.62e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg04398451	chr17:18023971	MYO15A	0.51	8.11	0.41	9.49e-15	Total body bone mineral density;
LUSC	cis	rs4698790	0.914	rs7671905	chr4:110722886	T/C	cg07850274	chr4:110748770	RRH	0.4	6.17	0.32	1.98e-9	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUSC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg06784218	chr1:46089804	CCDC17	0.51	9.72	0.47	7.88e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg07424592	chr7:64974309	NA	-0.64	-5.73	-0.3	2.24e-8	Diabetic kidney disease;
LUSC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.98	0.36	1.57e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg04155231	chr12:9217510	LOC144571	0.3	5.73	0.3	2.3e-8	Sjögren's syndrome;
LUSC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.84	0.44	5.53e-17	Schizophrenia;
LUSC	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg13072238	chr3:49761600	GMPPB	-0.59	-7.82	-0.39	6.94e-14	Menarche (age at onset);
LUSC	cis	rs10761482	0.813	rs7083624	chr10:62121239	G/C	cg18175470	chr10:62150864	ANK3	-0.51	-7.31	-0.37	2.03e-12	Schizophrenia;
LUSC	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg07701084	chr6:150067640	NUP43	0.46	6.93	0.35	2.23e-11	Testicular germ cell tumor;
LUSC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg13010344	chr12:123464640	ARL6IP4	-0.5	-8.09	-0.4	1.15e-14	Platelet count;
LUSC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00149659	chr3:10157352	C3orf10	0.94	12.69	0.57	2.21e-30	Alzheimer's disease;
LUSC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg13647721	chr17:30228624	UTP6	0.54	5.91	0.31	8.42e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs796825	0.530	rs1492272	chr3:119962322	G/C	cg21790991	chr3:120137480	FSTL1	-0.34	-5.98	-0.31	5.68e-9	HIV-1 susceptibility;
LUSC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg13072238	chr3:49761600	GMPPB	-0.65	-7.74	-0.39	1.17e-13	Menarche (age at onset);
LUSC	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg00834899	chr3:194121120	GP5	0.66	12.7	0.57	2.04e-30	Platelet distribution width;
LUSC	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg26384229	chr12:38710491	ALG10B	0.72	11.31	0.53	2.59e-25	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.41	6.19	0.32	1.75e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1018697	1.000	rs2150928	chr10:104550985	G/A	cg04362960	chr10:104952993	NT5C2	0.47	6.48	0.33	3.29e-10	Colorectal adenoma (advanced);
LUSC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	0.95	16.07	0.66	1.92e-43	Menopause (age at onset);
LUSC	cis	rs6060717	0.610	rs2590964	chr20:34613376	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.32	-0.33	8.6e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.88	0.4	4.55e-14	Total body bone mineral density;
LUSC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg25258033	chr6:167368657	RNASET2	0.49	7.99	0.4	2.17e-14	Crohn's disease;
LUSC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.44	6.52	0.34	2.54e-10	Systemic lupus erythematosus;
LUSC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.02	20.15	0.74	1.14e-59	Cognitive function;
LUSC	cis	rs9436747	0.585	rs6662904	chr1:65997740	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.45	6.13	0.32	2.52e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	9.27	0.45	2.43e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3812762	0.843	rs2292046	chr11:8807179	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.39	6.86	0.35	3.32e-11	Hypospadias;
LUSC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg10523679	chr1:76189770	ACADM	-0.47	-6.71	-0.34	8.21e-11	Daytime sleep phenotypes;
LUSC	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg20933634	chr6:27740509	NA	0.4	5.87	0.31	1.06e-8	Parkinson's disease;
LUSC	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg14458575	chr2:238380390	NA	0.68	11.54	0.53	3.84e-26	Prostate cancer;
LUSC	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	6.64	0.34	1.24e-10	Menarche (age at onset);
LUSC	cis	rs12681287	0.547	rs7461366	chr8:87511685	C/T	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	trans	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg26384229	chr12:38710491	ALG10B	0.59	9.42	0.46	7.54e-19	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg22166914	chr1:53195759	ZYG11B	-0.55	-8.77	-0.43	9.2e-17	Monocyte count;
LUSC	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg19875535	chr5:140030758	IK	0.51	8.37	0.42	1.55e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs554111	0.593	rs4654906	chr1:21509642	A/T	cg01072550	chr1:21505969	NA	-0.39	-5.82	-0.3	1.37e-8	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg10645314	chr2:3704589	ALLC	0.49	7.88	0.4	4.66e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg04576048	chr1:205797593	PM20D1	0.34	6.13	0.32	2.51e-9	Menarche (age at onset);
LUSC	cis	rs12618769	0.597	rs72821951	chr2:99157009	A/C	cg10123293	chr2:99228465	UNC50	0.47	7.58	0.38	3.39e-13	Bipolar disorder;
LUSC	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.99	0.31	5.32e-9	Schizophrenia;
LUSC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08859206	chr1:53392774	SCP2	-0.51	-8.75	-0.43	1.07e-16	Monocyte count;
LUSC	cis	rs7523273	0.606	rs2761430	chr1:207912408	G/A	cg22525895	chr1:207977042	MIR29B2	0.41	6.71	0.34	8.42e-11	Schizophrenia;
LUSC	trans	rs7374394	1.000	rs2301052	chr3:184953662	C/T	cg08270206	chr16:56623390	MT3	-0.47	-6.04	-0.31	4.14e-9	Cognitive performance;
LUSC	trans	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg11887960	chr12:57824829	NA	0.54	6.74	0.35	7.11e-11	Obesity-related traits;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg11235426	chr6:292522	DUSP22	-0.66	-10.55	-0.5	1.18e-22	Menopause (age at onset);
LUSC	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg09835421	chr16:68378352	PRMT7	-0.7	-7.49	-0.38	6.14e-13	Magnesium levels;
LUSC	cis	rs7804356	1.000	rs1327989	chr7:26833563	C/T	cg03456212	chr7:26904342	SKAP2	-0.55	-6.53	-0.34	2.46e-10	Type 1 diabetes;
LUSC	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg05855489	chr10:104503620	C10orf26	0.6	8.86	0.44	4.83e-17	Arsenic metabolism;
LUSC	cis	rs12369635	1.000	rs73159540	chr12:129559421	C/T	cg01909103	chr12:129572610	TMEM132D	-0.6	-5.69	-0.3	2.82e-8	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs7000551	0.751	rs1116084	chr8:22395309	C/T	cg12081754	chr8:22256438	SLC39A14	0.42	5.85	0.31	1.15e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg01238044	chr22:24384105	GSTT1	-0.54	-7.89	-0.4	4.41e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg03146154	chr1:46216737	IPP	0.56	8.32	0.41	2.35e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	6.18e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	0.57	8.78	0.43	8.71e-17	Breast cancer;
LUSC	cis	rs4478137	0.501	rs6828399	chr4:164228471	T/C	cg06758707	chr4:164254230	NPY1R	-0.52	-6.95	-0.36	1.91e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs427941	0.703	rs201446	chr7:101738323	C/G	cg06246474	chr7:101738831	CUX1	0.41	6.71	0.34	8.45e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg05347473	chr6:146136440	FBXO30	0.48	7.9	0.4	4.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg20026190	chr17:76395443	PGS1	0.46	8.2	0.41	5.33e-15	HDL cholesterol levels;
LUSC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07677032	chr17:61819896	STRADA	0.52	8.63	0.43	2.54e-16	Prudent dietary pattern;
LUSC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg14993813	chr1:46806288	NSUN4	-0.53	-7.33	-0.37	1.77e-12	Menopause (age at onset);
LUSC	cis	rs59698941	0.943	rs55746968	chr5:132298188	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	trans	rs12210905	0.925	rs10946896	chr6:26988576	A/G	cg11837749	chr1:55047332	ACOT11	0.57	6.09	0.32	3.07e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7605827	0.930	rs13017972	chr2:15699739	A/G	cg19274914	chr2:15703543	NA	0.48	9.24	0.45	2.91e-18	Educational attainment (years of education);
LUSC	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.14	0.36	5.87e-12	IgG glycosylation;
LUSC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg07741184	chr6:167504864	NA	0.34	6.13	0.32	2.45e-9	Crohn's disease;
LUSC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07677032	chr17:61819896	STRADA	0.54	8.93	0.44	2.86e-17	Prudent dietary pattern;
LUSC	cis	rs12493885	0.818	rs11928425	chr3:153773565	G/T	cg17054900	chr3:154042577	DHX36	-0.54	-5.76	-0.3	1.89e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg06287003	chr12:125626642	AACS	-0.39	-6.81	-0.35	4.55e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg18478394	chr8:109455254	TTC35	0.43	6.79	0.35	5.05e-11	Dupuytren's disease;
LUSC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.85	14.01	0.61	2.17e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg11494091	chr17:61959527	GH2	0.4	6.85	0.35	3.62e-11	Height;
LUSC	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.55	-0.6	1.2e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg22907277	chr7:1156413	C7orf50	0.46	7.17	0.37	4.82e-12	Longevity;Endometriosis;
LUSC	cis	rs360798	0.532	rs2421816	chr2:63075033	C/A	cg17519650	chr2:63277830	OTX1	0.47	6.44	0.33	4.08e-10	Coronary artery disease;
LUSC	trans	rs9929218	0.559	rs11642362	chr16:68811307	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.96	18.93	0.72	8.39e-55	Colorectal cancer;
LUSC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.73	-12.49	-0.56	1.22e-29	Height;
LUSC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg05425664	chr17:57184151	TRIM37	0.52	7.76	0.39	1.04e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.1	-0.36	7.78e-12	Bipolar disorder;
LUSC	trans	rs800082	0.802	rs2717380	chr3:144256908	A/T	cg24215973	chr2:240111563	HDAC4	0.41	6.15	0.32	2.21e-9	Smoking behavior;
LUSC	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-7.05	-0.36	1.02e-11	Blood metabolite levels;
LUSC	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg18230493	chr5:56204884	C5orf35	-0.56	-8.76	-0.43	9.83e-17	Coronary artery disease;
LUSC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.26	0.41	3.48e-15	Hemoglobin concentration;
LUSC	trans	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-9.82	-0.47	3.59e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-9.82	-0.47	3.55e-20	Morning vs. evening chronotype;
LUSC	cis	rs3087591	0.708	rs17885030	chr17:29655218	C/T	cg24425628	chr17:29625626	OMG;NF1	0.47	7.05	0.36	1.06e-11	Hip circumference;
LUSC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg22903471	chr2:27725779	GCKR	-0.42	-7.05	-0.36	1.02e-11	Total body bone mineral density;
LUSC	cis	rs2985684	0.841	rs2281836	chr14:50065717	G/C	cg04989706	chr14:50066350	PPIL5	-0.49	-6.31	-0.33	8.83e-10	Carotid intima media thickness;
LUSC	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg12615879	chr12:58013172	SLC26A10	0.36	8.33	0.41	2.05e-15	Multiple sclerosis;
LUSC	cis	rs2282300	0.653	rs12800124	chr11:30239865	A/G	cg06241208	chr11:30344200	C11orf46	-0.44	-5.65	-0.3	3.52e-8	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08219700	chr8:58056026	NA	0.56	7.69	0.39	1.62e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg22903471	chr2:27725779	GCKR	-0.41	-6.96	-0.36	1.8e-11	Total body bone mineral density;
LUSC	cis	rs12137294	0.866	rs1172156	chr1:205220087	C/T	cg21643547	chr1:205240462	TMCC2	-0.35	-6.36	-0.33	6.53e-10	Red cell distribution width;
LUSC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.95	-0.36	1.96e-11	Blood metabolite levels;
LUSC	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.84	0.3	1.25e-8	Breast cancer;
LUSC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg11965913	chr1:205819406	PM20D1	0.59	10.26	0.49	1.17e-21	Menarche (age at onset);
LUSC	cis	rs11677416	1.000	rs6542093	chr2:113528536	G/A	cg27083787	chr2:113543245	IL1A	0.44	6.97	0.36	1.65e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs6060717	0.610	rs2590965	chr20:34613120	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	6.63	0.34	1.36e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg10596483	chr8:143751796	JRK	0.54	7.64	0.39	2.37e-13	Schizophrenia;
LUSC	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg25173405	chr17:45401733	C17orf57	0.38	6.05	0.31	3.96e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg17724175	chr1:150552817	MCL1	0.35	6.23	0.32	1.44e-9	Melanoma;
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.52	-8.75	-0.43	1.09e-16	Lymphocyte counts;
LUSC	cis	rs8060686	0.623	rs2418736	chr16:68154862	A/G	cg26727032	chr16:67993705	SLC12A4	0.38	5.87	0.31	1.05e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg04362960	chr10:104952993	NT5C2	0.59	9.36	0.46	1.22e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg13119609	chr19:45449297	APOC2	0.34	5.79	0.3	1.61e-8	Blood protein levels;
LUSC	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg27661571	chr11:113659931	NA	-0.61	-6.87	-0.35	3.15e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg27284194	chr4:1044797	NA	0.58	8.64	0.43	2.4e-16	Recombination rate (females);
LUSC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.89	-0.4	4.44e-14	Obesity-related traits;
LUSC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg10596483	chr8:143751796	JRK	-0.6	-9.23	-0.45	3.19e-18	Schizophrenia;
LUSC	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	9.69	0.47	9.99e-20	Lymphocyte counts;
LUSC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.45	0.46	5.94e-19	Bipolar disorder;
LUSC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.66	-11.05	-0.52	2.09e-24	Tuberculosis;
LUSC	cis	rs7953508	0.750	rs7977788	chr12:93982332	G/A	cg18151635	chr12:93972918	NA	-0.55	-7.91	-0.4	3.91e-14	Pubertal anthropometrics;
LUSC	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs6736093	0.796	rs34240639	chr2:112809951	T/A	cg12686935	chr2:112915763	FBLN7	-0.4	-6.35	-0.33	7.12e-10	Coronary artery disease;
LUSC	cis	rs73198271	0.960	rs10503392	chr8:8609555	G/C	cg01851573	chr8:8652454	MFHAS1	0.6	8.32	0.41	2.28e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs9969804	0.782	rs10761169	chr9:95515033	T/C	cg25594165	chr10:83637420	NRG3	0.32	6.09	0.32	3.04e-9	Height;
LUSC	cis	rs6460942	0.908	rs79175014	chr7:12245378	T/G	cg06484146	chr7:12443880	VWDE	-0.59	-5.87	-0.31	1.02e-8	Coronary artery disease;
LUSC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.75	-0.3	1.97e-8	Monocyte count;
LUSC	cis	rs6543140	0.964	rs1035126	chr2:103019981	C/T	cg09003973	chr2:102972529	NA	0.57	7.44	0.38	8.7e-13	Blood protein levels;
LUSC	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg24375607	chr4:120327624	NA	-0.63	-10.12	-0.48	3.51e-21	Corneal astigmatism;
LUSC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg06784218	chr1:46089804	CCDC17	-0.56	-10.93	-0.51	5.46e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.63	0.34	1.34e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg18827107	chr12:86230957	RASSF9	-0.41	-5.99	-0.31	5.43e-9	Major depressive disorder;
LUSC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	0.92	15.23	0.64	3.94e-40	Breast cancer;
LUSC	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.08	0.52	1.71e-24	Hypertriglyceridemia;
LUSC	cis	rs2235544	0.565	rs635045	chr1:54469109	A/G	cg25741118	chr1:54482237	LDLRAD1	0.29	6.06	0.31	3.64e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-6.67	-0.34	1.05e-10	Longevity;Endometriosis;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg25703541	chr22:24373054	LOC391322	-0.89	-14.49	-0.62	2.83e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg22166914	chr1:53195759	ZYG11B	0.63	10.29	0.49	9.68e-22	Monocyte count;
LUSC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg20283391	chr11:68216788	NA	-0.58	-8.13	-0.41	8.67e-15	Total body bone mineral density;
LUSC	cis	rs4901869	0.931	rs12891570	chr14:59334338	T/A	cg02291164	chr14:59296302	NA	0.58	10.98	0.51	3.78e-24	Panic disorder;
LUSC	cis	rs1568889	0.838	rs6484359	chr11:28262328	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	12.94	0.58	2.53e-31	Bipolar disorder;
LUSC	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg17757837	chr7:157058334	UBE3C	0.82	13.01	0.58	1.35e-31	Body mass index;
LUSC	cis	rs10992471	0.630	rs10453241	chr9:95198887	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.86	-0.35	3.32e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg07703079	chr11:430292	ANO9	0.67	6.91	0.35	2.45e-11	Body mass index;
LUSC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg12257692	chr3:49977190	RBM6	0.24	6.69	0.34	9.53e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg02508848	chr16:68573721	ZFP90	-0.42	-5.75	-0.3	2.07e-8	Ulcerative colitis;
LUSC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	8.94	0.44	2.76e-17	Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11489602	chr10:32345426	KIF5B	-0.46	-6.13	-0.32	2.54e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07677032	chr17:61819896	STRADA	0.54	8.88	0.44	4.33e-17	Prudent dietary pattern;
LUSC	cis	rs7172677	1.000	rs4479194	chr15:75422131	C/T	cg14664628	chr15:75095509	CSK	-0.44	-5.82	-0.3	1.41e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg14664628	chr15:75095509	CSK	0.57	8.95	0.44	2.51e-17	Breast cancer;
LUSC	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.74	0.43	1.15e-16	Menopause (age at onset);
LUSC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	14.25	0.61	2.49e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg01420254	chr6:26195488	NA	0.66	7.31	0.37	2.05e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg07803811	chr1:43423981	SLC2A1	0.41	6.27	0.32	1.09e-9	Red cell distribution width;
LUSC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg11645453	chr3:52864694	ITIH4	0.31	7.12	0.36	6.56e-12	Bipolar disorder;
LUSC	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg16339924	chr4:17578868	LAP3	0.5	7.57	0.38	3.57e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17102423	0.685	rs4899161	chr14:65540901	G/A	cg11161011	chr14:65562177	MAX	-0.76	-11.16	-0.52	8.75e-25	Obesity-related traits;
LUSC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.2	22.43	0.78	1.32e-68	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg16524733	chr11:117070046	TAGLN	0.45	7.9	0.4	4.11e-14	Blood protein levels;
LUSC	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg01973587	chr1:228161476	NA	0.38	6.29	0.33	9.73e-10	Parkinson's disease;
LUSC	cis	rs1881396	0.531	rs4665386	chr2:27935352	C/A	cg27432699	chr2:27873401	GPN1	0.68	7.94	0.4	3.03e-14	Nonalcoholic fatty liver disease;
LUSC	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg09462578	chr12:12878428	APOLD1	-0.63	-7.29	-0.37	2.3e-12	Systemic lupus erythematosus;
LUSC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg16606324	chr3:10149918	C3orf24	0.68	9.78	0.47	5.03e-20	Alzheimer's disease;
LUSC	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.18	0.32	1.82e-9	Systolic blood pressure;
LUSC	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg13334819	chr7:99746414	C7orf59	0.5	6.73	0.35	7.39e-11	Coronary artery disease;
LUSC	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.73	-0.7	4.71e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.99	-0.4	2.18e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.48	0.56	1.36e-29	Motion sickness;
LUSC	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.82	-0.35	4.23e-11	Response to antipsychotic treatment;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg08548315	chr1:81609992	NA	0.38	6.09	0.32	3.09e-9	Cognitive function;Information processing speed;
LUSC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg04352962	chr1:209979756	IRF6	0.53	6.31	0.33	9.08e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	6.28	0.32	1.08e-9	Tonsillectomy;
LUSC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.7	-0.43	1.51e-16	Lung cancer;
LUSC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.22	-14.04	-0.61	1.61e-35	Diabetic kidney disease;
LUSC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.92	-0.31	7.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11025559	0.643	rs11025570	chr11:20481109	T/A	cg19653624	chr11:20408972	PRMT3	-0.74	-8.59	-0.43	3.47e-16	Pursuit maintenance gain;
LUSC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.43	-0.33	4.52e-10	Lung cancer;
LUSC	trans	rs1997103	0.954	rs9649854	chr7:55410213	G/A	cg20935933	chr6:143382018	AIG1	0.5	7.28	0.37	2.42e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2742234	0.955	rs2503849	chr10:43672776	G/A	cg02780029	chr10:43622663	RET	-0.33	-5.98	-0.31	5.75e-9	Hirschsprung disease;
LUSC	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg01884057	chr2:25150051	NA	0.47	11.11	0.52	1.3e-24	Body mass index;
LUSC	trans	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.34	-0.33	7.61e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs17604090	0.793	rs17150665	chr7:29688860	T/G	cg19413766	chr7:29689036	LOC646762	-0.56	-7.01	-0.36	1.36e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs7771547	0.642	rs668499	chr6:36496379	A/G	cg07856975	chr6:36356162	ETV7	0.36	6.2	0.32	1.7e-9	Platelet distribution width;
LUSC	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg01966878	chr4:90757139	SNCA	-0.34	-5.85	-0.3	1.18e-8	Dementia with Lewy bodies;
LUSC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg09044154	chr16:88155775	NA	0.55	7.53	0.38	4.81e-13	Menopause (age at onset);
LUSC	cis	rs4947962	0.617	rs1558543	chr7:55135512	C/T	cg23757825	chr7:55092271	EGFR	-0.57	-6.69	-0.34	9.67e-11	Subjective response to lithium treatment;
LUSC	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.42	-0.62	5.29e-37	Schizophrenia;
LUSC	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.12	0.32	2.63e-9	Corneal astigmatism;
LUSC	cis	rs27434	0.583	rs34764	chr5:96155229	A/G	cg16492584	chr5:96139282	ERAP1	-0.58	-7.91	-0.4	3.9e-14	Ankylosing spondylitis;
LUSC	trans	rs6956675	0.830	rs4585626	chr7:62671592	C/G	cg01314568	chr7:57830625	NA	0.42	5.97	0.31	6.01e-9	Obesity-related traits;
LUSC	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.72	-0.47	7.9e-20	Coronary artery disease;
LUSC	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	0.85	13.38	0.59	5.28e-33	Blood protein levels;
LUSC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.69	-16.09	-0.66	1.52e-43	Prostate cancer;
LUSC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-0.93	-15.59	-0.65	1.53e-41	Body mass index;
LUSC	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.21	0.32	1.58e-9	Total body bone mineral density;
LUSC	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.43	0.64	6.56e-41	Bladder cancer;
LUSC	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg25457927	chr22:38595422	NA	0.32	6.34	0.33	7.43e-10	Cutaneous nevi;
LUSC	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-28.87	-0.84	8.9e-93	Myeloid white cell count;
LUSC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg07716408	chr11:68623521	NA	-0.33	-6.25	-0.32	1.27e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.67	11.39	0.53	1.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.37	5.75	0.3	2.07e-8	Lymphocyte counts;
LUSC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg00599273	chr12:58146742	CDK4	0.31	5.85	0.3	1.18e-8	Multiple sclerosis;
LUSC	cis	rs12618769	0.652	rs3769701	chr2:99195111	A/C	cg10123293	chr2:99228465	UNC50	0.48	7.76	0.39	1.01e-13	Bipolar disorder;
LUSC	cis	rs7804356	0.953	rs7785832	chr7:26852760	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg19592336	chr6:28129416	ZNF389	0.48	6.29	0.33	9.69e-10	Depression;
LUSC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-0.87	-9.49	-0.46	4.54e-19	Breast cancer;
LUSC	cis	rs4631830	0.863	rs2843549	chr10:51521247	C/A	cg20129853	chr10:51489980	NA	-0.32	-6.39	-0.33	5.63e-10	Prostate-specific antigen levels;
LUSC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg04121214	chr22:50244548	NA	-0.34	-5.74	-0.3	2.14e-8	Schizophrenia;
LUSC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05025164	chr4:1340916	KIAA1530	0.65	9.98	0.48	1.08e-20	Longevity;
LUSC	cis	rs8064299	0.597	rs9893035	chr17:72783798	A/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.94	19.3	0.73	2.66e-56	Monocyte count;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11554771	chr1:6305590	HES3	0.41	5.94	0.31	6.98e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg03146154	chr1:46216737	IPP	-0.55	-8.23	-0.41	4.16e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06481639	chr22:41940642	POLR3H	-0.5	-5.69	-0.3	2.78e-8	Vitiligo;
LUSC	cis	rs7512552	0.966	rs10788873	chr1:150250534	T/A	cg15654264	chr1:150340011	RPRD2	-0.61	-9.92	-0.48	1.76e-20	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg15145296	chr3:125709740	NA	-0.56	-6.73	-0.35	7.36e-11	Blood pressure (smoking interaction);
LUSC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg23283495	chr1:209979779	IRF6	-0.54	-8.61	-0.43	2.94e-16	Monobrow;
LUSC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg17173187	chr15:85201210	NMB	0.48	8.78	0.43	8.71e-17	Schizophrenia;
LUSC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg05360949	chr19:41903737	BCKDHA;EXOSC5	0.41	5.68	0.3	3e-8	Height;
LUSC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg17143192	chr8:8559678	CLDN23	0.61	8.95	0.44	2.52e-17	Obesity-related traits;
LUSC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-1.13	-23.13	-0.78	2.47e-71	Height;
LUSC	cis	rs6494488	0.500	rs11854894	chr15:65020245	G/C	cg08069370	chr15:64387884	SNX1	-0.65	-5.92	-0.31	7.91e-9	Coronary artery disease;
LUSC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg18200150	chr17:30822561	MYO1D	-0.34	-7.15	-0.36	5.44e-12	Schizophrenia;
LUSC	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg19792802	chr11:65647270	CTSW	-0.41	-6.28	-0.32	1.05e-9	Crohn's disease;
LUSC	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.39	-0.42	1.35e-15	Coffee consumption (cups per day);
LUSC	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.57	-8.0	-0.4	2.06e-14	Schizophrenia;
LUSC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs79387448	0.745	rs7576324	chr2:103142994	G/A	cg09003973	chr2:102972529	NA	0.82	8.12	0.41	9.02e-15	Gut microbiota (bacterial taxa);
LUSC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.19e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6060717	0.610	rs1891154	chr20:34617129	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-6.35	-0.33	7.18e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs7216064	0.861	rs73352810	chr17:65875184	G/A	cg12091567	chr17:66097778	LOC651250	-0.73	-9.37	-0.46	1.13e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-13.85	-0.6	8.4e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22590775	chr19:49891494	CCDC155	0.57	7.55	0.38	4.1e-13	Multiple sclerosis;
LUSC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14298792	chr15:30685198	CHRFAM7A	0.64	8.4	0.42	1.31e-15	Huntington's disease progression;
LUSC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	13.51	0.59	1.76e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	cis	rs9650315	0.777	rs5027179	chr8:57179633	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	6.82	0.35	4.17e-11	Height;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27026005	chr19:50380748	TBC1D17;AKT1S1	-0.53	-6.32	-0.33	8.13e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06571993	chr7:98579529	TRRAP	-0.81	-6.83	-0.35	3.98e-11	Cognitive performance;
LUSC	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg18721089	chr20:30220636	NA	-0.36	-6.19	-0.32	1.74e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg14696996	chr19:15285081	NOTCH3	1.02	9.37	0.46	1.1e-18	Pulse pressure;
LUSC	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg12165864	chr7:66369176	NA	-0.53	-7.15	-0.36	5.51e-12	Corneal structure;
LUSC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg04414720	chr1:150670196	GOLPH3L	0.47	6.86	0.35	3.32e-11	Melanoma;
LUSC	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg21211680	chr2:198530	NA	-0.54	-6.68	-0.34	9.72e-11	Blood protein levels;
LUSC	cis	rs2629540	0.847	rs12247543	chr10:126419743	G/C	cg08799069	chr10:126477246	METTL10	0.66	9.48	0.46	5.02e-19	Cocaine dependence;
LUSC	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg00792783	chr2:198669748	PLCL1	0.44	5.94	0.31	7.12e-9	Dermatomyositis;
LUSC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg03233332	chr7:66118400	NA	0.4	5.87	0.31	1.06e-8	Aortic root size;
LUSC	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg04539111	chr16:67997858	SLC12A4	-0.44	-6.08	-0.32	3.37e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17772535	chr12:65153236	GNS	-0.51	-6.0	-0.31	5.06e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.37	0.46	1.16e-18	Lung cancer in ever smokers;
LUSC	cis	rs7572733	0.534	rs2060488	chr2:198751637	T/G	cg00792783	chr2:198669748	PLCL1	0.46	6.15	0.32	2.17e-9	Dermatomyositis;
LUSC	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg20587970	chr11:113659929	NA	-1.04	-13.87	-0.6	7.41e-35	Hip circumference adjusted for BMI;
LUSC	trans	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg02030672	chr11:45687055	CHST1	0.55	8.9	0.44	3.7e-17	Obesity-related traits;
LUSC	cis	rs4474465	0.915	rs10899504	chr11:78157983	C/A	cg27205649	chr11:78285834	NARS2	-0.49	-5.85	-0.3	1.18e-8	Alzheimer's disease (survival time);
LUSC	cis	rs8102476	0.773	rs11668070	chr19:38748913	G/A	cg14131526	chr19:38747285	PPP1R14A	-0.35	-6.12	-0.32	2.68e-9	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11645453	chr3:52864694	ITIH4	0.35	8.2	0.41	5.41e-15	Electroencephalogram traits;
LUSC	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg13319975	chr6:146136371	FBXO30	-0.68	-10.51	-0.5	1.65e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg02551604	chr5:131831745	NA	-0.42	-6.62	-0.34	1.39e-10	Asthma (sex interaction);
LUSC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg09877947	chr5:131593287	PDLIM4	0.36	6.06	0.31	3.61e-9	Blood metabolite levels;
LUSC	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.0	-0.36	1.38e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08736216	chr1:53307985	ZYG11A	-0.28	-6.03	-0.31	4.3e-9	Monocyte count;
LUSC	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	6.09	0.32	3.11e-9	Lung cancer in ever smokers;
LUSC	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg00074818	chr8:8560427	CLDN23	0.58	9.85	0.47	2.86e-20	Obesity-related traits;
LUSC	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg01620082	chr3:125678407	NA	-0.78	-7.2	-0.37	4.02e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15369054	chr17:80825471	TBCD	0.39	6.38	0.33	5.85e-10	Breast cancer;
LUSC	trans	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg26043149	chr18:55253948	FECH	0.46	7.23	0.37	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.66	-9.63	-0.47	1.59e-19	Refractive error;
LUSC	cis	rs10492096	0.947	rs10849484	chr12:6637941	C/T	cg13857086	chr12:6580257	VAMP1	0.63	7.56	0.38	3.81e-13	Hip geometry;
LUSC	cis	rs701145	1.000	rs355784	chr3:153986371	A/C	cg17054900	chr3:154042577	DHX36	0.82	8.49	0.42	7.02e-16	Coronary artery disease;
LUSC	cis	rs3916	0.662	rs2138249	chr12:121124142	A/C	cg27246729	chr12:121163418	ACADS	0.39	6.12	0.32	2.59e-9	Urinary metabolites (H-NMR features);
LUSC	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-8.39	-0.42	1.41e-15	Axial length;
LUSC	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22496380	chr5:211416	CCDC127	-0.85	-8.77	-0.43	9.3e-17	Breast cancer;
LUSC	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.52	-0.46	3.62e-19	Coronary artery disease;
LUSC	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg17173187	chr15:85201210	NMB	0.36	6.18	0.32	1.9e-9	Schizophrenia;
LUSC	trans	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg19694781	chr19:47549865	TMEM160	-0.41	-6.54	-0.34	2.28e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs62400317	0.859	rs10948220	chr6:45236654	A/G	cg20913747	chr6:44695427	NA	-0.47	-7.65	-0.39	2.2e-13	Total body bone mineral density;
LUSC	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg25214090	chr10:38739885	LOC399744	-0.52	-7.84	-0.39	6.04e-14	Corneal astigmatism;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg10963375	chr1:205815865	PM20D1	0.32	5.67	0.3	3.14e-8	Menarche (age at onset);
LUSC	cis	rs34734847	0.842	rs696337	chr12:121159380	T/C	cg27246729	chr12:121163418	ACADS	0.41	6.51	0.34	2.75e-10	Mean corpuscular volume;
LUSC	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg10645314	chr2:3704589	ALLC	-0.37	-6.56	-0.34	2.02e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg06454157	chr6:167490870	NA	-0.27	-6.64	-0.34	1.28e-10	Primary biliary cholangitis;
LUSC	cis	rs2932538	0.885	rs6691025	chr1:113177070	G/T	cg22162597	chr1:113214053	CAPZA1	-0.7	-9.97	-0.48	1.14e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	16.33	0.67	1.77e-44	Platelet count;
LUSC	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg05985134	chr18:33552581	C18orf21	0.53	7.26	0.37	2.74e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs10254118	0.757	rs7788086	chr7:133135206	C/T	cg10665199	chr7:133106180	EXOC4	0.59	7.98	0.4	2.35e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg03732007	chr1:2071316	PRKCZ	-0.54	-9.55	-0.46	2.89e-19	Height;
LUSC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.55	0.42	4.56e-16	Motion sickness;
LUSC	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.26	-0.37	2.67e-12	Neuroticism;
LUSC	cis	rs977987	0.778	rs4888409	chr16:75436231	A/T	cg04384234	chr16:75411784	CFDP1	-0.41	-6.58	-0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs2522056	1.000	rs757105	chr5:131795663	C/T	cg24060327	chr5:131705240	SLC22A5	0.45	5.96	0.31	6.39e-9	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18876405	chr7:65276391	NA	-0.54	-8.57	-0.42	3.82e-16	Aortic root size;
LUSC	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg26898376	chr11:64110657	CCDC88B	0.31	5.78	0.3	1.69e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg03859395	chr2:55845619	SMEK2	0.88	15.88	0.66	1.07e-42	Metabolic syndrome;
LUSC	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg08779649	chr13:50194554	NA	0.4	6.83	0.35	3.95e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg13813247	chr22:41461852	NA	-0.36	-6.38	-0.33	6.06e-10	Neuroticism;
LUSC	cis	rs4363385	0.791	rs489323	chr1:153006047	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.43e-12	Inflammatory skin disease;
LUSC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.15	-0.36	5.34e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs11264799	0.603	rs12133056	chr1:157585751	G/T	cg18268488	chr1:157545234	FCRL4	0.36	6.62	0.34	1.41e-10	IgA nephropathy;
LUSC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.71	12.08	0.55	3.9e-28	Heart rate;
LUSC	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg27661571	chr11:113659931	NA	0.6	6.43	0.33	4.36e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13673779	chr18:48723081	MEX3C	-0.36	-5.97	-0.31	5.9e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7621025	0.675	rs34602896	chr3:136346385	A/G	cg15507776	chr3:136538369	TMEM22	-0.43	-5.8	-0.3	1.53e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUSC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.36	-6.05	-0.31	3.95e-9	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs7178572	0.568	rs11630689	chr15:77520094	C/T	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	cis	rs7615316	0.779	rs9871402	chr3:142024351	A/C	cg16271453	chr3:142027066	XRN1	-0.38	-6.55	-0.34	2.23e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.82	0.68	2.11e-46	Exhaled nitric oxide output;
LUSC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg07936489	chr17:37558343	FBXL20	0.72	9.94	0.48	1.47e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg08508325	chr11:3079039	CARS	-0.53	-13.35	-0.59	6.94e-33	Longevity;
LUSC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg00990874	chr7:1149470	C7orf50	-0.45	-5.87	-0.31	1.05e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg13047869	chr3:10149882	C3orf24	0.57	8.04	0.4	1.54e-14	Alzheimer's disease;
LUSC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14829155	chr15:31115871	NA	-0.72	-10.66	-0.5	5.02e-23	Huntington's disease progression;
LUSC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg17747265	chr1:1875780	NA	0.46	8.6	0.43	3.04e-16	Body mass index;
LUSC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg14196790	chr5:131705035	SLC22A5	0.43	7.17	0.37	4.76e-12	Blood metabolite levels;
LUSC	cis	rs10489525	0.583	rs1967711	chr1:115630967	C/T	cg01522456	chr1:115632236	TSPAN2	0.7	10.23	0.49	1.52e-21	Autism;
LUSC	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg23950597	chr19:37808831	NA	-0.63	-7.8	-0.39	8.08e-14	Coronary artery calcification;
LUSC	cis	rs13315871	0.929	rs13077539	chr3:58267846	T/C	cg20936604	chr3:58311152	NA	-0.75	-6.97	-0.36	1.7e-11	Cholesterol, total;
LUSC	cis	rs7246657	0.653	rs10402050	chr19:37688958	A/T	cg23950597	chr19:37808831	NA	-0.62	-6.38	-0.33	5.75e-10	Coronary artery calcification;
LUSC	cis	rs754466	1.000	rs56256440	chr10:79698207	A/G	cg17075019	chr10:79541650	NA	-0.63	-8.17	-0.41	6.23e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg02117656	chr17:79614917	TSPAN10	-0.3	-5.67	-0.3	3.16e-8	Eye color traits;
LUSC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg23649088	chr2:200775458	C2orf69	0.77	13.69	0.6	3.59e-34	Osteoporosis;
LUSC	cis	rs243505	0.898	rs243537	chr7:148408278	A/G	cg09806900	chr7:148480153	CUL1	-0.48	-6.8	-0.35	4.74e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4285028	0.747	rs7623901	chr3:121529011	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.9	12.59	0.57	5e-30	Multiple sclerosis;
LUSC	trans	rs9944715	1.000	rs9944836	chr18:43831380	C/T	cg01718231	chr17:29326311	RNF135	0.52	7.37	0.37	1.37e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.57	-0.34	1.94e-10	Schizophrenia;
LUSC	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4595586	0.679	rs1156706	chr12:39372641	G/A	cg26384229	chr12:38710491	ALG10B	0.43	5.83	0.3	1.27e-8	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.58	0.38	3.4e-13	Bipolar disorder;
LUSC	cis	rs4713118	0.869	rs9283880	chr6:27715243	A/C	cg20933634	chr6:27740509	NA	0.42	5.9	0.31	9.13e-9	Parkinson's disease;
LUSC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg19747945	chr6:42946146	PEX6	-0.35	-5.68	-0.3	2.98e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1568889	0.838	rs4614434	chr11:28302234	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	13.11	0.58	5.77e-32	Bipolar disorder;
LUSC	cis	rs7106204	1.000	rs12798139	chr11:24220907	A/G	ch.11.24196551F	chr11:24239977	NA	0.99	9.97	0.48	1.12e-20	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg00757033	chr12:89920650	WDR51B	0.59	10.15	0.49	2.74e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2302729	0.545	rs10161275	chr12:2771018	A/G	cg19945202	chr12:2788847	CACNA1C	-0.42	-7.17	-0.37	4.75e-12	Sleep quality;
LUSC	trans	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-6.84	-0.35	3.85e-11	Menarche (age at onset);
LUSC	cis	rs11676348	0.772	rs12471105	chr2:218950209	G/A	cg06547715	chr2:218990976	CXCR2	0.32	6.2	0.32	1.65e-9	Ulcerative colitis;
LUSC	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.89	12.43	0.56	1.98e-29	Ileal carcinoids;
LUSC	cis	rs68170813	0.652	rs6957186	chr7:107200592	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.46	-5.72	-0.3	2.4e-8	Coronary artery disease;
LUSC	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg01528321	chr10:82214614	TSPAN14	0.92	14.09	0.61	1.02e-35	Post bronchodilator FEV1;
LUSC	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg09904177	chr6:26538194	HMGN4	0.57	8.91	0.44	3.43e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg09035930	chr12:129282057	SLC15A4	0.6	10.22	0.49	1.65e-21	Systemic lupus erythematosus;
LUSC	cis	rs4601821	0.858	rs4938012	chr11:113259654	A/G	cg14159747	chr11:113255604	NA	0.26	6.1	0.32	2.92e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg11608241	chr8:8085544	FLJ10661	0.44	6.74	0.35	7.05e-11	Mood instability;
LUSC	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg25214090	chr10:38739885	LOC399744	0.6	8.81	0.43	6.84e-17	Corneal astigmatism;
LUSC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg03146154	chr1:46216737	IPP	0.56	8.34	0.42	2.02e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.76	11.12	0.52	1.15e-24	Corneal astigmatism;
LUSC	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg23601095	chr6:26197514	HIST1H3D	0.69	7.46	0.38	7.54e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg24006582	chr15:45444508	DUOX1	-0.6	-8.67	-0.43	1.84e-16	Uric acid levels;
LUSC	cis	rs11997175	0.603	rs716584	chr8:33779748	C/G	ch.8.33884649F	chr8:33765107	NA	0.42	6.29	0.33	1e-9	Body mass index;
LUSC	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg20891283	chr12:69753455	YEATS4	0.44	5.77	0.3	1.82e-8	Response to diuretic therapy;
LUSC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg15445000	chr17:37608096	MED1	-0.42	-7.14	-0.36	5.98e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg23188684	chr11:67383651	NA	0.35	6.18	0.32	1.92e-9	Mean corpuscular volume;
LUSC	cis	rs3936840	0.647	rs942024	chr14:102979463	C/T	cg18135206	chr14:102964638	TECPR2	0.48	6.49	0.33	3.07e-10	Plateletcrit;
LUSC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg23815491	chr16:72088622	HP	0.34	5.97	0.31	6.12e-9	Fibrinogen levels;
LUSC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg24813613	chr7:1882135	MAD1L1	-0.44	-7.31	-0.37	1.99e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.69	10.36	0.49	5.28e-22	Alcohol dependence;
LUSC	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.21	-0.37	3.87e-12	Bipolar disorder;
LUSC	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg26395211	chr5:140044315	WDR55	-0.37	-5.78	-0.3	1.74e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1044826	0.642	rs6771831	chr3:139177585	C/T	cg15131784	chr3:139108705	COPB2	0.41	6.66	0.34	1.12e-10	Obesity-related traits;
LUSC	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg06484146	chr7:12443880	VWDE	-0.68	-7.26	-0.37	2.76e-12	Coronary artery disease;
LUSC	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg08975724	chr8:8085496	FLJ10661	0.53	8.0	0.4	2.07e-14	Systolic blood pressure;
LUSC	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg21681030	chr2:46777652	RHOQ	0.51	7.94	0.4	3.08e-14	Height;
LUSC	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg08017756	chr2:100939284	LONRF2	-0.44	-7.8	-0.39	7.92e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg17173187	chr15:85201210	NMB	0.37	6.5	0.33	3e-10	Schizophrenia;
LUSC	cis	rs62400317	0.762	rs6908606	chr6:44998888	A/G	cg18551225	chr6:44695536	NA	-0.42	-6.76	-0.35	6.21e-11	Total body bone mineral density;
LUSC	cis	rs17092148	0.887	rs2144956	chr20:33145868	G/A	cg16810054	chr20:33298113	TP53INP2	-0.36	-5.72	-0.3	2.31e-8	Neuroticism;
LUSC	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg26384229	chr12:38710491	ALG10B	-0.6	-9.2	-0.45	4.07e-18	Morning vs. evening chronotype;
LUSC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg04166393	chr7:2884313	GNA12	0.43	5.74	0.3	2.14e-8	Height;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05797538	chr16:56554066	BBS2	0.75	6.01	0.31	4.79e-9	Cognitive performance;
LUSC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.44	-7.28	-0.37	2.43e-12	IgG glycosylation;
LUSC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06873352	chr17:61820015	STRADA	0.54	8.22	0.41	4.53e-15	Height;
LUSC	cis	rs7289126	0.966	rs2284072	chr22:38633666	A/C	cg25457927	chr22:38595422	NA	-0.29	-5.73	-0.3	2.2e-8	Mammographic density (dense area);Percent mammographic density;
LUSC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg16339924	chr4:17578868	LAP3	0.55	8.48	0.42	7.61e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg01416388	chr22:39784598	NA	-0.42	-6.94	-0.35	2.11e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-9.76	-0.47	5.99e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2227564	0.620	rs4746148	chr10:75534488	C/T	cg23231163	chr10:75533350	FUT11	-0.46	-6.72	-0.35	7.97e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg16576597	chr16:28551801	NUPR1	0.33	6.57	0.34	1.99e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg26043149	chr18:55253948	FECH	-0.53	-7.57	-0.38	3.74e-13	Bone mineral density;
LUSC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25809561	chr17:30822961	MYO1D	-0.44	-8.25	-0.41	3.74e-15	Schizophrenia;
LUSC	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg21427119	chr20:30132790	HM13	-0.44	-6.52	-0.34	2.67e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-9.22	-0.45	3.46e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg06454157	chr6:167490870	NA	-0.25	-5.71	-0.3	2.52e-8	Crohn's disease;
LUSC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg02018176	chr4:1364513	KIAA1530	0.45	7.42	0.38	9.56e-13	Obesity-related traits;
LUSC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg12310025	chr6:25882481	NA	-0.41	-7.28	-0.37	2.43e-12	Height;
LUSC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.65	8.33	0.41	2.1e-15	Lung function (FEV1/FVC);
LUSC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg08975724	chr8:8085496	FLJ10661	0.47	7.05	0.36	1.01e-11	Mood instability;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16755220	chr16:12070685	RUNDC2A	-0.46	-6.4	-0.33	5.27e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	trans	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.83	-0.39	6.54e-14	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.69	13.09	0.58	6.74e-32	Height;
LUSC	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.76	10.54	0.5	1.33e-22	Corneal astigmatism;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg20364735	chr6:13615554	NOL7	0.4	6.1	0.32	2.9e-9	Schizophrenia (age at onset);
LUSC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.34	0.49	6.15e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12980942	0.810	rs16958999	chr19:41825186	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.08	0.32	3.22e-9	Coronary artery disease;
LUSC	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.27e-20	Coronary artery disease;
LUSC	cis	rs73206853	0.841	rs55864430	chr12:110932355	G/T	cg12870014	chr12:110450643	ANKRD13A	0.68	6.44	0.33	4.21e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00934597	chr7:893267	UNC84A	-0.48	-7.15	-0.36	5.64e-12	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg17376030	chr22:41985996	PMM1	-0.46	-5.88	-0.31	1.02e-8	Vitiligo;
LUSC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg14552801	chr7:65878734	NA	-0.45	-6.51	-0.34	2.77e-10	Aortic root size;
LUSC	cis	rs7246967	0.611	rs7250285	chr19:22837108	C/T	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs548987	0.507	rs3757132	chr6:25832691	C/T	cg03517284	chr6:25882590	NA	-0.38	-5.7	-0.3	2.62e-8	Homocysteine levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22728371	chr5:32313149	MTMR12	-0.53	-6.49	-0.33	3.07e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.65	14.25	0.61	2.45e-36	Hemoglobin concentration;
LUSC	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.73	-0.7	4.95e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9283706	0.608	rs71626484	chr5:66334502	A/T	cg11590213	chr5:66331682	MAST4	0.44	6.42	0.33	4.75e-10	Coronary artery disease;
LUSC	cis	rs6541297	0.645	rs2103827	chr1:230298285	T/A	cg05784532	chr1:230284198	GALNT2	0.55	6.56	0.34	2.1e-10	Coronary artery disease;
LUSC	cis	rs981844	0.735	rs17371573	chr4:154765216	G/A	cg14289246	chr4:154710475	SFRP2	0.51	6.83	0.35	4.02e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.35	0.53	1.8e-25	Alzheimer's disease;
LUSC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg08742575	chr21:47604166	C21orf56	0.39	5.74	0.3	2.12e-8	Testicular germ cell tumor;
LUSC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02187348	chr16:89574699	SPG7	0.46	7.11	0.36	7.08e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs2354432	0.607	rs1530335	chr1:146685288	T/C	cg25205988	chr1:146714368	CHD1L	1.08	8.58	0.42	3.65e-16	Mitochondrial DNA levels;
LUSC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08677398	chr8:58056175	NA	0.44	6.36	0.33	6.82e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03041860	chr2:208489911	FAM119A	0.45	6.73	0.35	7.2e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6599077	0.642	rs2257066	chr3:40087981	G/T	cg13683864	chr3:40499215	RPL14	-0.44	-6.41	-0.33	4.88e-10	Sleep-related phenotypes;
LUSC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg17077180	chr1:38461687	NA	-0.45	-6.55	-0.34	2.14e-10	Coronary artery disease;
LUSC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.31	0.53	2.45e-25	Menopause (age at onset);
LUSC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg15147215	chr3:52552868	STAB1	-0.36	-7.11	-0.36	6.89e-12	Bipolar disorder;
LUSC	trans	rs1486139	1.000	rs4286853	chr7:46284924	A/G	cg17534202	chr9:96721102	NA	-0.36	-6.48	-0.33	3.3e-10	Select biomarker traits;
LUSC	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg21366198	chr4:185655624	MLF1IP	-0.46	-6.59	-0.34	1.72e-10	Kawasaki disease;
LUSC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.1	-0.58	6.15e-32	Platelet count;
LUSC	cis	rs12618769	0.652	rs4851144	chr2:99220707	T/C	cg10123293	chr2:99228465	UNC50	0.47	7.71	0.39	1.48e-13	Bipolar disorder;
LUSC	cis	rs907683	0.635	rs11691617	chr2:220295167	C/T	cg15015639	chr2:220282977	DES	0.3	7.18	0.37	4.59e-12	Resting heart rate;
LUSC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg12463550	chr7:65579703	CRCP	-0.52	-7.54	-0.38	4.43e-13	Aortic root size;
LUSC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg27535305	chr1:53392650	SCP2	-0.4	-7.57	-0.38	3.57e-13	Monocyte count;
LUSC	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.53	0.34	2.4e-10	IgG glycosylation;
LUSC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg15556689	chr8:8085844	FLJ10661	0.69	11.71	0.54	9.3e-27	Mood instability;
LUSC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg05082376	chr22:42548792	NA	0.43	6.53	0.34	2.43e-10	Schizophrenia;
LUSC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10802521	chr3:52805072	NEK4	-0.5	-7.95	-0.4	3e-14	Electroencephalogram traits;
LUSC	trans	rs11700980	1.000	rs56288550	chr21:30131840	T/C	cg05609335	chr17:75789393	NA	0.42	6.36	0.33	6.45e-10	QRS complex (12-leadsum);
LUSC	cis	rs6977660	0.714	rs6954046	chr7:19820388	G/A	cg07541023	chr7:19748670	TWISTNB	0.58	6.32	0.33	8.51e-10	Thyroid stimulating hormone;
LUSC	cis	rs73206853	0.764	rs7953794	chr12:111081197	A/G	cg12870014	chr12:110450643	ANKRD13A	0.71	8.17	0.41	6.43e-15	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs427941	0.703	rs201440	chr7:101735599	C/T	cg06246474	chr7:101738831	CUX1	0.41	6.7	0.34	8.72e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg09408571	chr1:101003634	GPR88	0.31	5.78	0.3	1.72e-8	Breast cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13040021	chr20:5093911	C20orf30	0.47	6.53	0.34	2.39e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10744422	0.748	rs1671688	chr12:123255733	A/T	cg25930673	chr12:123319894	HIP1R	-0.58	-5.96	-0.31	6.41e-9	Schizophrenia;
LUSC	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg07169764	chr2:136633963	MCM6	-0.57	-7.67	-0.39	1.95e-13	Mosquito bite size;
LUSC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg23711669	chr6:146136114	FBXO30	0.89	17.09	0.68	1.7e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg04369109	chr6:150039330	LATS1	-0.56	-8.2	-0.41	5.13e-15	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14280377	chr14:39639762	TRAPPC6B	-0.42	-6.26	-0.32	1.18e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12541635	0.677	rs34872724	chr8:107033071	C/T	cg10147462	chr8:107024639	NA	-0.68	-14.17	-0.61	5.19e-36	Age of smoking initiation;
LUSC	cis	rs10489202	0.632	rs12410730	chr1:168069477	T/C	cg24449463	chr1:168025552	DCAF6	-0.69	-10.43	-0.5	3.05e-22	Schizophrenia;
LUSC	cis	rs722599	0.748	rs11623342	chr14:75347937	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.92	-0.31	8.12e-9	IgG glycosylation;
LUSC	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-17.5	-0.69	3.98e-49	Primary sclerosing cholangitis;
LUSC	cis	rs1775715	0.707	rs2808079	chr10:32167385	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.78	0.35	5.33e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg00310523	chr12:86230176	RASSF9	0.37	6.69	0.34	9.54e-11	Major depressive disorder;
LUSC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.68	-11.77	-0.54	5.42e-27	Menarche (age at onset);
LUSC	cis	rs6120849	0.754	rs6087667	chr20:33651887	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.63	0.34	1.35e-10	Protein C levels;
LUSC	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.46	-5.69	-0.3	2.79e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg23093090	chr10:104574429	C10orf26	0.35	6.47	0.33	3.5e-10	Arsenic metabolism;
LUSC	cis	rs1867631	0.565	rs10749764	chr1:67149706	G/C	cg02459107	chr1:67143332	SGIP1	0.34	5.84	0.3	1.25e-8	Menopause (age at onset);
LUSC	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg26384229	chr12:38710491	ALG10B	0.73	11.47	0.53	6.77e-26	Morning vs. evening chronotype;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10141938	chr7:26240087	HNRNPA2B1;CBX3	0.44	6.51	0.34	2.72e-10	Triglycerides;
LUSC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg07636037	chr3:49044803	WDR6	0.59	6.25	0.32	1.28e-9	Menarche (age at onset);
LUSC	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg05738196	chr6:26577821	NA	0.83	15.96	0.66	4.91e-43	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	6.36	0.33	6.63e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs16866061	0.517	rs7594223	chr2:225472985	T/C	cg12698349	chr2:225449008	CUL3	0.49	7.27	0.37	2.62e-12	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg20988073	chr3:125900093	ALDH1L1	-0.33	-6.56	-0.34	2.08e-10	Metabolite levels;
LUSC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	9.86	0.47	2.73e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg12552261	chr5:112820674	MCC	-0.43	-6.95	-0.36	1.98e-11	Type 2 diabetes;
LUSC	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg15556689	chr8:8085844	FLJ10661	0.58	8.32	0.41	2.33e-15	Monocyte count;
LUSC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg00945038	chr17:61921165	SMARCD2	0.54	9.36	0.46	1.17e-18	Prudent dietary pattern;
LUSC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg15103426	chr22:29168792	CCDC117	0.46	6.03	0.31	4.39e-9	Lymphocyte counts;
LUSC	cis	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg06521331	chr12:34319734	NA	-0.46	-7.59	-0.38	3.33e-13	Morning vs. evening chronotype;
LUSC	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg14664628	chr15:75095509	CSK	0.47	6.25	0.32	1.28e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9346649	0.616	rs7740995	chr6:168492221	G/A	cg02770688	chr6:168491649	NA	0.51	9.71	0.47	8.45e-20	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs7712401	0.601	rs246322	chr5:122307269	C/T	cg19077854	chr5:122220652	SNX24	-0.42	-9.65	-0.47	1.3e-19	Mean platelet volume;
LUSC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	11.86	0.54	2.68e-27	Prudent dietary pattern;
LUSC	cis	rs10097731	0.908	rs77317991	chr8:82032468	C/T	cg25230327	chr8:82042993	NA	-0.45	-6.61	-0.34	1.57e-10	Serum total protein level;
LUSC	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg03909863	chr11:638404	DRD4	-0.41	-6.19	-0.32	1.81e-9	Systemic lupus erythematosus;
LUSC	cis	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg26958806	chr6:27640298	NA	0.8	6.56	0.34	2.04e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19244751	chr21:35747585	FAM165B	-0.48	-6.53	-0.34	2.44e-10	Hepatitis;
LUSC	cis	rs9318086	0.663	rs2312295	chr13:24457744	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.45	6.79	0.35	5.02e-11	Myopia (pathological);
LUSC	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg15997130	chr1:24165203	NA	0.39	6.33	0.33	7.97e-10	Immature fraction of reticulocytes;
LUSC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg16060761	chr17:80687452	NA	-0.42	-6.56	-0.34	2.05e-10	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08105748	chr6:57086875	RAB23	-0.44	-6.67	-0.34	1.05e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.29	-0.41	2.71e-15	Coffee consumption (cups per day);
LUSC	cis	rs1886644	1.000	rs1886644	chr1:85350658	A/C	cg08479277	chr1:85350632	LPAR3	0.52	8.22	0.41	4.58e-15	Glucose homeostasis traits;
LUSC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.81	-0.39	7.43e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs61931739	0.963	rs12310956	chr12:33970682	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.98	-0.36	1.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg24296786	chr1:45957014	TESK2	0.41	5.84	0.3	1.25e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg26354017	chr1:205819088	PM20D1	0.53	8.65	0.43	2.2e-16	Menarche (age at onset);
LUSC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg04450456	chr4:17643702	FAM184B	0.4	6.91	0.35	2.53e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg24579218	chr15:68104479	NA	-0.36	-6.19	-0.32	1.74e-9	Obesity;
LUSC	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg24130564	chr14:104152367	KLC1	-0.71	-11.28	-0.53	3.13e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg13114125	chr14:105738426	BRF1	-0.92	-16.14	-0.66	1.01e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.24	-0.56	1.05e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.15	-0.32	2.24e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6599077	0.802	rs11720413	chr3:40141857	C/G	cg13683864	chr3:40499215	RPL14	-0.53	-7.08	-0.36	8.41e-12	Sleep-related phenotypes;
LUSC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14829155	chr15:31115871	NA	-0.72	-10.7	-0.51	3.74e-23	Huntington's disease progression;
LUSC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg26695010	chr11:65641043	EFEMP2	0.41	5.74	0.3	2.14e-8	Breast cancer;
LUSC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.67	-16.23	-0.66	4.39e-44	Prostate cancer;
LUSC	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.68	0.5	4.16e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	1.05	13.04	0.58	1.07e-31	Nonalcoholic fatty liver disease;
LUSC	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg21775007	chr8:11205619	TDH	-0.52	-7.56	-0.38	3.9e-13	Triglycerides;
LUSC	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg25206134	chr2:45395956	NA	0.57	6.55	0.34	2.14e-10	Bipolar disorder;
LUSC	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg15556689	chr8:8085844	FLJ10661	0.55	8.15	0.41	7.29e-15	Monocyte count;
LUSC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.43	-6.51	-0.34	2.75e-10	Prudent dietary pattern;
LUSC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg24060327	chr5:131705240	SLC22A5	-0.67	-11.71	-0.54	8.72e-27	Blood metabolite levels;
LUSC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.49	-0.38	6.39e-13	Lymphocyte counts;
LUSC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg23281280	chr6:28129359	ZNF389	0.45	6.04	0.31	4.09e-9	Parkinson's disease;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg10699731	chr19:12780957	C19orf56;MORG1	0.37	6.01	0.31	4.98e-9	Mosquito bite size;
LUSC	trans	rs2736337	0.530	rs2003422	chr8:11303137	G/C	cg15556689	chr8:8085844	FLJ10661	0.43	6.07	0.32	3.41e-9	Rheumatoid arthritis;
LUSC	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-6.69	-0.34	9.2e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg22482690	chr17:47019901	SNF8	-0.34	-6.13	-0.32	2.51e-9	Type 2 diabetes;
LUSC	cis	rs57590327	0.716	rs3772891	chr3:81776760	A/G	cg07356753	chr3:81810745	GBE1	0.62	8.56	0.42	4.3e-16	Extraversion;
LUSC	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg15309053	chr8:964076	NA	0.38	7.85	0.39	5.78e-14	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12753558	chr1:247464072	ZNF496	0.45	6.07	0.32	3.56e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7192380	0.639	rs2917666	chr16:69763960	C/G	cg00738113	chr16:70207722	CLEC18C	0.31	6.28	0.33	1.04e-9	Sjögren's syndrome;
LUSC	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-6.99	-0.36	1.53e-11	Menarche (age at onset);
LUSC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	6.88	0.35	3.05e-11	Schizophrenia;
LUSC	cis	rs78572108	0.858	rs61473148	chr2:42259707	C/A	cg00607755	chr2:42274082	PKDCC	0.37	6.55	0.34	2.13e-10	Total body bone mineral density;
LUSC	trans	rs6957923	0.655	rs6949019	chr7:23594050	A/G	ch.2.47844995F	chr2:47991493	NA	0.38	6.24	0.32	1.35e-9	Height;
LUSC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg04844267	chr4:1394941	NA	0.33	6.57	0.34	1.97e-10	Obesity-related traits;
LUSC	cis	rs3741151	0.773	rs73543000	chr11:73151774	T/C	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.74	0.35	6.78e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9467773	0.595	rs6907924	chr6:26438817	T/G	cg05738196	chr6:26577821	NA	-0.52	-7.72	-0.39	1.37e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6545883	0.929	rs10190332	chr2:61619267	T/G	cg15711740	chr2:61764176	XPO1	0.42	6.53	0.34	2.43e-10	Tuberculosis;
LUSC	trans	rs17039065	1.000	rs17039068	chr4:109385975	C/A	cg07444054	chr2:108107501	NA	0.41	6.12	0.32	2.59e-9	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08677398	chr8:58056175	NA	0.55	6.95	0.36	1.94e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg02018176	chr4:1364513	KIAA1530	0.55	9.75	0.47	6.15e-20	Obesity-related traits;
LUSC	cis	rs9399401	0.667	rs7757571	chr6:142702589	A/C	cg03128060	chr6:142623767	GPR126	0.61	9.98	0.48	1.1e-20	Chronic obstructive pulmonary disease;
LUSC	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	7.56	0.38	4.03e-13	Resistin levels;
LUSC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-0.8	-9.77	-0.47	5.27e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs1595825	0.786	rs74652956	chr2:198754247	C/T	cg00982548	chr2:198649783	BOLL	-0.56	-7.02	-0.36	1.24e-11	Ulcerative colitis;
LUSC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.47	7.76	0.39	1.06e-13	Vitiligo;
LUSC	cis	rs7799006	0.755	rs2256545	chr7:2291943	G/A	cg08027265	chr7:2291960	NA	-0.64	-11.65	-0.54	1.45e-26	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3824867	0.920	rs7101772	chr11:47449378	A/G	cg20307385	chr11:47447363	PSMC3	-0.64	-9.52	-0.46	3.67e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.88	-10.38	-0.49	4.65e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.85	13.97	0.61	2.94e-35	Bladder cancer;
LUSC	cis	rs2303282	0.716	rs2587872	chr16:56412696	T/C	cg00500540	chr16:56394104	NA	-0.44	-7.69	-0.39	1.7e-13	Breast cancer;
LUSC	cis	rs6066835	1.000	rs742645	chr20:47323655	G/A	cg18078177	chr20:47281410	PREX1	0.75	6.1	0.32	2.87e-9	Multiple myeloma;
LUSC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00166722	chr3:10149974	C3orf24	0.53	7.36	0.37	1.41e-12	Alzheimer's disease;
LUSC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg06640241	chr16:89574553	SPG7	0.89	16.11	0.66	1.28e-43	Multiple myeloma (IgH translocation);
LUSC	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg15423357	chr2:25149977	NA	0.45	9.03	0.44	1.37e-17	Body mass index in non-asthmatics;
LUSC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.54	0.34	2.28e-10	Bipolar disorder;
LUSC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.99	0.44	1.87e-17	Motion sickness;
LUSC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.11	14.54	0.62	1.83e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.5e-24	Aortic root size;
LUSC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02018176	chr4:1364513	KIAA1530	-0.72	-12.94	-0.58	2.63e-31	Longevity;
LUSC	cis	rs55871839	0.619	rs6471756	chr8:59802159	A/G	cg07426533	chr8:59803705	TOX	-0.36	-5.75	-0.3	2.07e-8	Pneumonia;
LUSC	cis	rs12540874	0.965	rs9791887	chr7:50661170	A/C	cg18232548	chr7:50535776	DDC	-0.43	-6.02	-0.31	4.5e-9	Systemic sclerosis;
LUSC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.63	9.72	0.47	7.61e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg21775007	chr8:11205619	TDH	-0.65	-10.2	-0.49	1.94e-21	Retinal vascular caliber;
LUSC	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg14154082	chr13:112174009	NA	0.37	7.7	0.39	1.54e-13	Menarche (age at onset);
LUSC	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.83	-0.39	6.41e-14	Retinal vascular caliber;
LUSC	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-8.66	-0.43	2.03e-16	Body mass index;
LUSC	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg05347473	chr6:146136440	FBXO30	0.51	8.53	0.42	5.03e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg00277334	chr10:82204260	NA	-0.51	-7.41	-0.38	1.05e-12	Post bronchodilator FEV1;
LUSC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-6.02	-0.31	4.68e-9	Major depressive disorder;
LUSC	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.74	-0.47	6.99e-20	Migraine;Coronary artery disease;
LUSC	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs4808199	0.649	rs34755166	chr19:19665581	G/A	cg03709012	chr19:19516395	GATAD2A	0.91	10.03	0.48	7.4e-21	Nonalcoholic fatty liver disease;
LUSC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.66	-0.43	2.1e-16	Lung cancer;
LUSC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.71	-11.09	-0.52	1.47e-24	Menarche (age at onset);
LUSC	cis	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg23231163	chr10:75533350	FUT11	-0.38	-6.13	-0.32	2.44e-9	Inflammatory bowel disease;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg08399230	chr16:4665037	FAM100A	0.35	5.96	0.31	6.57e-9	Schizophrenia (age at onset);
LUSC	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg08847533	chr14:75593920	NEK9	-0.49	-7.09	-0.36	7.96e-12	IgG glycosylation;
LUSC	cis	rs7584330	0.554	rs3751111	chr2:238426953	G/T	cg16989719	chr2:238392110	NA	-0.43	-6.2	-0.32	1.65e-9	Prostate cancer;
LUSC	cis	rs62400317	0.859	rs10456122	chr6:45163057	C/G	cg20913747	chr6:44695427	NA	-0.48	-7.67	-0.39	1.91e-13	Total body bone mineral density;
LUSC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08109568	chr15:31115862	NA	0.73	11.12	0.52	1.2e-24	Huntington's disease progression;
LUSC	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.12	0.36	6.78e-12	Morning vs. evening chronotype;
LUSC	cis	rs9815354	0.761	rs17280777	chr3:41806167	C/T	cg03022575	chr3:42003672	ULK4	0.83	8.52	0.42	5.39e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg09517075	chr8:22133004	PIWIL2	0.41	8.16	0.41	6.69e-15	Hypertriglyceridemia;
LUSC	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	6.31	0.33	8.94e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3772130	0.962	rs1318472	chr3:121556899	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	10.0	0.48	9e-21	Cognitive performance;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03552398	chr14:89021307	PTPN21	0.41	6.07	0.32	3.46e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.06	0.52	1.99e-24	Prudent dietary pattern;
LUSC	cis	rs11645898	1.000	rs72791115	chr16:72207315	T/C	cg14768367	chr16:72042858	DHODH	-0.63	-7.0	-0.36	1.38e-11	Blood protein levels;
LUSC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.41	-5.94	-0.31	7.13e-9	Tonsillectomy;
LUSC	cis	rs3931020	0.688	rs525487	chr1:75217420	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	-0.44	-5.71	-0.3	2.5e-8	Resistin levels;
LUSC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.5	-5.74	-0.3	2.15e-8	Schizophrenia;
LUSC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg21280719	chr6:42927975	GNMT	-0.34	-8.51	-0.42	5.99e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg03060546	chr3:49711283	APEH	0.7	11.67	0.54	1.23e-26	Resting heart rate;
LUSC	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.84	-0.35	3.69e-11	Retinal vascular caliber;
LUSC	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg22532475	chr10:104410764	TRIM8	0.25	5.95	0.31	6.71e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7759001	0.857	rs980962	chr6:27361008	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.69	0.3	2.77e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg18099408	chr3:52552593	STAB1	0.37	6.2	0.32	1.63e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.15	10.47	0.5	2.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.62	-9.47	-0.46	5.11e-19	Metabolite levels;
LUSC	cis	rs7572644	0.662	rs6706209	chr2:28101938	C/T	cg27432699	chr2:27873401	GPN1	-0.49	-6.58	-0.34	1.85e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg12292205	chr6:26970375	C6orf41	-0.51	-8.48	-0.42	7.18e-16	Schizophrenia;
LUSC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg13319975	chr6:146136371	FBXO30	0.48	7.31	0.37	1.99e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg24130564	chr14:104152367	KLC1	-0.41	-5.75	-0.3	1.98e-8	Body mass index;
LUSC	cis	rs1979679	0.573	rs6487694	chr12:28727734	T/C	cg13890972	chr12:28721907	NA	-0.4	-5.86	-0.31	1.09e-8	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg03433033	chr1:76189801	ACADM	-0.48	-7.14	-0.36	5.8e-12	Daytime sleep phenotypes;
LUSC	cis	rs7178572	0.568	rs1493700	chr15:77629060	T/C	cg22256960	chr15:77711686	NA	-0.5	-8.04	-0.4	1.57e-14	Type 2 diabetes;
LUSC	cis	rs7267979	0.789	rs2260197	chr20:25284343	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.75	15.04	0.64	2.08e-39	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs9929218	0.954	rs35444713	chr16:68824492	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.09	-0.52	1.54e-24	Colorectal cancer;
LUSC	cis	rs3741151	0.892	rs2027763	chr11:73035799	A/G	cg17517138	chr11:73019481	ARHGEF17	0.83	7.98	0.4	2.35e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1113500	0.933	rs10881498	chr1:108634984	C/A	cg11967332	chr1:108735228	SLC25A24	0.39	5.92	0.31	7.86e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg13010199	chr12:38710504	ALG10B	0.62	9.48	0.46	4.72e-19	Bladder cancer;
LUSC	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg25251562	chr2:3704773	ALLC	-0.49	-7.44	-0.38	8.43e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7267979	0.844	rs6083851	chr20:25401235	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.78	-16.35	-0.67	1.41e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg09835421	chr16:68378352	PRMT7	-0.54	-6.08	-0.32	3.32e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg05519781	chr21:40033154	ERG	0.77	13.32	0.59	9.59e-33	Coronary artery disease;
LUSC	cis	rs1775715	0.737	rs11008695	chr10:32216887	T/G	cg04359828	chr10:32216031	ARHGAP12	0.39	6.75	0.35	6.52e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs250677	0.522	rs10038913	chr5:148354224	A/G	cg12140854	chr5:148520817	ABLIM3	0.36	5.99	0.31	5.57e-9	Breast cancer;
LUSC	cis	rs1865721	0.804	rs3826652	chr18:73142153	C/T	cg26385618	chr18:73139727	C18orf62	0.54	10.6	0.5	8.3300000000000006e-23	Intelligence;
LUSC	cis	rs4363385	0.720	rs1970328	chr1:152975829	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-5.65	-0.3	3.43e-8	Inflammatory skin disease;
LUSC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg24675658	chr1:53192096	ZYG11B	-0.53	-8.33	-0.41	2.18e-15	Monocyte count;
LUSC	cis	rs7113850	0.541	rs4536215	chr11:24245374	C/A	ch.11.24196551F	chr11:24239977	NA	1.01	9.09	0.45	9.05e-18	Bone fracture in osteoporosis;
LUSC	cis	rs4974559	0.739	rs3817604	chr4:1291337	C/T	cg02980000	chr4:1222292	CTBP1	1.02	9.13	0.45	6.93e-18	Systolic blood pressure;
LUSC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg07395648	chr5:131743802	NA	-0.39	-5.8	-0.3	1.53e-8	Breast cancer;
LUSC	cis	rs2282300	0.739	rs1222219	chr11:30344345	G/C	cg25418670	chr11:30344373	C11orf46	-0.65	-9.25	-0.45	2.7e-18	Morning vs. evening chronotype;
LUSC	cis	rs10489525	0.599	rs2335724	chr1:115608444	T/C	cg17147537	chr1:115611705	TSPAN2	0.3	6.08	0.32	3.36e-9	Autism;
LUSC	cis	rs9677476	0.818	rs16827879	chr2:232092301	C/T	cg07929768	chr2:232055508	NA	0.34	6.4	0.33	5.36e-10	Food antigen IgG levels;
LUSC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.03	0.48	6.98e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	9.88	0.48	2.32e-20	Menopause (age at onset);
LUSC	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg13010199	chr12:38710504	ALG10B	-0.46	-7.01	-0.36	1.35e-11	Bladder cancer;
LUSC	cis	rs1557765	0.527	rs10832782	chr11:17397273	G/C	cg15432903	chr11:17409602	KCNJ11	0.46	7.86	0.4	5.27e-14	Body mass index;Social communication problems;
LUSC	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg24011408	chr12:48396354	COL2A1	0.51	6.87	0.35	3.21e-11	Lung cancer;
LUSC	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.55	0.5	1.22e-22	Lymphocyte counts;
LUSC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg11871910	chr12:69753446	YEATS4	0.64	9.3	0.45	1.88e-18	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.55	7.97	0.4	2.51e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.33	-0.45	1.46e-18	Type 2 diabetes;
LUSC	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg04362960	chr10:104952993	NT5C2	0.57	8.22	0.41	4.65e-15	Arsenic metabolism;
LUSC	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg13010199	chr12:38710504	ALG10B	0.56	8.51	0.42	5.98e-16	Morning vs. evening chronotype;
LUSC	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg15819921	chr19:927150	ARID3A	-0.43	-6.36	-0.33	6.54e-10	Life satisfaction;
LUSC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs2742417	1.000	rs2673034	chr3:45755138	A/G	cg18779283	chr3:45636154	LIMD1	-0.34	-5.9	-0.31	8.79e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7605827	0.930	rs11676115	chr2:15602962	G/A	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs10072221	0.836	rs55995866	chr5:75701344	A/G	cg03132911	chr5:75698732	IQGAP2	0.38	6.44	0.33	4.25e-10	Mean platelet volume;
LUSC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.31	0.37	1.99e-12	Motion sickness;
LUSC	trans	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg03886242	chr7:26192032	NFE2L3	0.37	6.26	0.32	1.18e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg09021430	chr5:549028	NA	-0.55	-7.57	-0.38	3.64e-13	Obesity-related traits;
LUSC	cis	rs76878669	0.561	rs10791872	chr11:66138434	C/G	cg18002602	chr11:66138449	SLC29A2	-0.48	-8.45	-0.42	9.19e-16	Educational attainment (years of education);
LUSC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00166722	chr3:10149974	C3orf24	-0.59	-8.45	-0.42	8.98e-16	Alzheimer's disease;
LUSC	cis	rs1178968	1.000	rs4717755	chr7:72761178	T/G	cg25889504	chr7:72793014	NA	0.52	6.79	0.35	5.28e-11	Triglyceride levels;
LUSC	cis	rs2346177	0.875	rs1447565	chr2:46643682	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.37	6.27	0.32	1.11e-9	HDL cholesterol;
LUSC	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg15962314	chr1:44399869	ARTN	-0.29	-6.35	-0.33	6.95e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg05340658	chr4:99064831	C4orf37	0.59	8.75	0.43	1.05e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg02493740	chr2:85810744	VAMP5	-0.37	-6.51	-0.34	2.73e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.59	0.38	3.26e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg01475377	chr6:109611718	NA	-0.43	-7.78	-0.39	8.93e-14	Reticulocyte fraction of red cells;
LUSC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg07701084	chr6:150067640	NUP43	0.58	8.97	0.44	2.22e-17	Lung cancer;
LUSC	cis	rs2835872	0.793	rs2835835	chr21:38989072	G/A	cg20424643	chr21:39039972	KCNJ6	0.36	5.69	0.3	2.84e-8	Electroencephalographic traits in alcoholism;
LUSC	trans	rs13196614	0.697	rs35007635	chr6:149021587	T/C	cg01343097	chr1:248284971	OR2M1P	0.41	5.96	0.31	6.57e-9	Migraine;
LUSC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.55	0.34	2.22e-10	Schizophrenia;
LUSC	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg24375607	chr4:120327624	NA	-0.7	-10.98	-0.51	3.79e-24	Corneal astigmatism;
LUSC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg15335117	chr5:41925216	FBXO4	0.37	6.08	0.32	3.35e-9	Breast cancer;
LUSC	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg25019033	chr10:957182	NA	-0.51	-6.35	-0.33	7.22e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs250677	0.522	rs10040598	chr5:148365720	C/A	cg18129178	chr5:148520854	ABLIM3	0.54	7.6	0.38	3.07e-13	Breast cancer;
LUSC	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg18105134	chr13:113819100	PROZ	0.65	9.62	0.47	1.67e-19	Platelet distribution width;
LUSC	cis	rs7799006	0.606	rs12535174	chr7:2310974	C/T	cg08027265	chr7:2291960	NA	-0.62	-10.99	-0.52	3.33e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg02487422	chr3:49467188	NICN1	0.43	6.82	0.35	4.32e-11	Resting heart rate;
LUSC	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg24558204	chr6:135376177	HBS1L	-0.63	-9.07	-0.44	1.03e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.89	0.31	9.52e-9	Menopause (age at onset);
LUSC	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg00579200	chr11:133705235	NA	-0.41	-5.93	-0.31	7.69e-9	Childhood ear infection;
LUSC	cis	rs1788820	0.833	rs1429934	chr18:21162288	C/T	cg14672496	chr18:21087552	C18orf8	0.43	6.78	0.35	5.5e-11	Body mass index;
LUSC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg08859206	chr1:53392774	SCP2	-0.44	-7.2	-0.37	4.11e-12	Monocyte count;
LUSC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06634786	chr22:41940651	POLR3H	-0.49	-6.02	-0.31	4.65e-9	Vitiligo;
LUSC	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg13256891	chr4:100009986	ADH5	0.46	6.39	0.33	5.71e-10	Alcohol dependence;
LUSC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25072359	chr17:41440525	NA	0.65	9.22	0.45	3.32e-18	Menopause (age at onset);
LUSC	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.9	12.12	0.55	2.84e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg15445000	chr17:37608096	MED1	0.4	6.76	0.35	6.31e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg19046167	chr17:80928561	B3GNTL1	0.5	7.06	0.36	9.96e-12	Glycated hemoglobin levels;
LUSC	cis	rs4631830	0.733	rs4512771	chr10:51540906	C/A	cg10326726	chr10:51549505	MSMB	-0.34	-5.66	-0.3	3.34e-8	Prostate-specific antigen levels;
LUSC	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg05340658	chr4:99064831	C4orf37	0.64	9.46	0.46	5.59e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1461503	0.868	rs11602682	chr11:122842315	A/T	cg27398637	chr11:122830231	C11orf63	-0.39	-6.18	-0.32	1.86e-9	Menarche (age at onset);
LUSC	cis	rs11676348	0.873	rs10210012	chr2:219013334	G/A	cg00012203	chr2:219082015	ARPC2	-0.55	-8.5	-0.42	6.33e-16	Ulcerative colitis;
LUSC	cis	rs981844	0.922	rs2118863	chr4:154657579	C/T	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	6.96	0.36	1.85e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg25110126	chr1:46999211	NA	-0.54	-7.36	-0.37	1.47e-12	Monobrow;
LUSC	cis	rs7727544	0.582	rs3828675	chr5:131546868	G/A	cg14196790	chr5:131705035	SLC22A5	0.45	7.43	0.38	9.24e-13	Blood metabolite levels;
LUSC	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg13256891	chr4:100009986	ADH5	0.51	6.97	0.36	1.65e-11	Alcohol dependence;
LUSC	cis	rs2607426	0.681	rs2257613	chr19:41284004	C/T	cg05508168	chr19:41255947	C19orf54;SNRPA	0.88	6.79	0.35	5.16e-11	Blood protein levels;
LUSC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05776053	chr2:74358815	NA	0.45	7.13	0.36	6.06e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs1322512	0.917	rs1744382	chr6:152942064	A/G	cg27316956	chr6:152958899	SYNE1	-0.34	-5.64	-0.3	3.54e-8	Tonometry;
LUSC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg01616529	chr11:638424	DRD4	-0.34	-5.8	-0.3	1.58e-8	Systemic lupus erythematosus;
LUSC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg14829360	chr17:73884958	NA	-0.35	-5.82	-0.3	1.39e-8	White matter hyperintensity burden;
LUSC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg02038168	chr22:39784481	NA	-0.5	-8.35	-0.42	1.85e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg23649088	chr2:200775458	C2orf69	0.54	7.36	0.37	1.45e-12	Schizophrenia;
LUSC	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg14844989	chr11:31128820	NA	0.4	6.14	0.32	2.34e-9	Red blood cell count;
LUSC	cis	rs12891047	0.804	rs10141638	chr14:68318593	T/A	cg20999565	chr14:68265668	ZFYVE26	0.39	5.86	0.31	1.11e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs13385	0.769	rs36050010	chr5:139569859	C/A	cg26211634	chr5:139558579	C5orf32	0.44	6.29	0.33	9.75e-10	Atrial fibrillation;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg18538332	chr22:24372958	LOC391322	-0.47	-8.33	-0.41	2.09e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10188299	chr14:67982149	TMEM229B	0.49	6.59	0.34	1.77e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg12863693	chr15:85201151	NMB	0.33	6.87	0.35	3.19e-11	Schizophrenia;
LUSC	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg17470449	chr10:769945	NA	0.51	7.07	0.36	9.06e-12	Uric acid levels;
LUSC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg11766577	chr21:47581405	C21orf56	-0.42	-6.17	-0.32	1.98e-9	Testicular germ cell tumor;
LUSC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15664640	chr17:80829946	TBCD	-0.75	-13.55	-0.6	1.27e-33	Breast cancer;
LUSC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11645453	chr3:52864694	ITIH4	-0.31	-7.28	-0.37	2.44e-12	Bipolar disorder;
LUSC	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg20243544	chr17:37824526	PNMT	0.5	7.07	0.36	9.22e-12	Asthma;
LUSC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	0.49	7.75	0.39	1.12e-13	Uric acid clearance;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08843538	chr2:210288784	MAP2	-0.34	-5.99	-0.31	5.53e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1712517	0.771	rs11191666	chr10:105127278	A/G	cg05636881	chr10:105038444	INA	0.4	6.73	0.35	7.41e-11	Migraine;
LUSC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs17362650	0.686	rs12474540	chr2:9699313	C/T	cg23886495	chr2:9695866	ADAM17	0.45	6.36	0.33	6.72e-10	Alcohol dependence (age at onset);
LUSC	cis	rs9815354	0.680	rs75308766	chr3:42031894	G/A	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.4	-0.38	1.12e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg16006841	chr5:176797999	RGS14	0.64	10.36	0.49	5.33e-22	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.8	-11.89	-0.55	2.06e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg06627628	chr2:24431161	ITSN2	0.63	9.31	0.45	1.7e-18	Asthma;
LUSC	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg03929089	chr4:120376271	NA	-0.45	-6.18	-0.32	1.92e-9	HDL cholesterol;
LUSC	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg11502198	chr6:26597334	ABT1	0.59	9.37	0.46	1.15e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs72634258	0.503	rs2794666	chr1:7822009	A/G	cg26816564	chr1:7831052	VAMP3	0.96	13.58	0.6	9.88e-34	Inflammatory bowel disease;
LUSC	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg06937882	chr20:24974362	C20orf3	0.42	7.0	0.36	1.43e-11	Blood protein levels;
LUSC	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg21770322	chr7:97807741	LMTK2	0.56	10.08	0.48	4.99e-21	Breast cancer;
LUSC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25072359	chr17:41440525	NA	0.66	9.45	0.46	6.08e-19	Menopause (age at onset);
LUSC	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg23691781	chr1:28212827	C1orf38	0.32	7.81	0.39	7.4e-14	Corneal astigmatism;
LUSC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg08219700	chr8:58056026	NA	0.48	6.28	0.32	1.07e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00475322	chr7:917719	C7orf20	0.45	6.63	0.34	1.37e-10	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs983392	0.679	rs764859	chr11:59978255	C/G	cg02771260	chr11:59836817	MS4A3	-0.36	-5.79	-0.3	1.58e-8	Alzheimer's disease (late onset);
LUSC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.75	14.33	0.62	1.24e-36	Monocyte count;
LUSC	cis	rs5770917	1.000	rs2269384	chr22:51011115	C/T	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.59	-5.7	-0.3	2.66e-8	Narcolepsy;
LUSC	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-6.09	-0.32	3.13e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg17757837	chr7:157058334	UBE3C	-0.91	-15.16	-0.64	7.01e-40	Body mass index;
LUSC	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg03585969	chr10:35415529	CREM	0.64	9.53	0.46	3.46e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg26587870	chr6:27730563	NA	-0.67	-6.07	-0.32	3.54e-9	Depression;
LUSC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.27	0.45	2.33e-18	Prudent dietary pattern;
LUSC	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	6.08	0.32	3.34e-9	Breast cancer;
LUSC	cis	rs4144027	0.904	rs10438242	chr14:104345075	C/T	cg12183467	chr14:104352244	NA	-0.29	-5.93	-0.31	7.77e-9	Blood metabolite levels;
LUSC	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg00784671	chr22:46762841	CELSR1	-0.54	-6.57	-0.34	1.88e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg11764359	chr7:65958608	NA	0.53	6.88	0.35	2.9e-11	Aortic root size;
LUSC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg05425664	chr17:57184151	TRIM37	0.54	8.01	0.4	1.87e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22913584	chr5:81046758	SSBP2	0.48	6.75	0.35	6.59e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12618769	0.652	rs1062847	chr2:99226173	T/A	cg10123293	chr2:99228465	UNC50	0.47	7.6	0.38	2.98e-13	Bipolar disorder;
LUSC	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg04865166	chr7:105162814	PUS7	0.52	5.66	0.3	3.24e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6960043	0.738	rs4721400	chr7:15059906	G/A	cg19272540	chr7:15055459	NA	0.33	8.05	0.4	1.49e-14	Type 2 diabetes;
LUSC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.56	-0.34	2e-10	Menarche (age at onset);
LUSC	cis	rs593982	0.920	rs1151501	chr11:65484883	A/G	cg08755490	chr11:65554678	OVOL1	1.53	12.92	0.58	3e-31	Atopic dermatitis;
LUSC	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg04586622	chr2:25135609	ADCY3	0.42	8.93	0.44	2.89e-17	Body mass index;
LUSC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg13560548	chr3:10150139	C3orf24	-0.51	-6.78	-0.35	5.47e-11	Alzheimer's disease;
LUSC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg04727924	chr7:799746	HEATR2	-0.53	-6.48	-0.33	3.27e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg14196790	chr5:131705035	SLC22A5	-0.45	-7.53	-0.38	4.81e-13	Blood metabolite levels;
LUSC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.86	-16.15	-0.66	9.28e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.39	6.12	0.32	2.67e-9	Electroencephalogram traits;
LUSC	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg04310649	chr10:35416472	CREM	-0.43	-6.59	-0.34	1.73e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg25815440	chr2:42134162	NA	-0.26	-5.97	-0.31	5.96e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs73200209	0.744	rs59619030	chr12:116475001	T/C	cg01776926	chr12:116560359	MED13L	-0.5	-5.97	-0.31	6.1e-9	Total body bone mineral density;
LUSC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.76	0.39	1.04e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg01475377	chr6:109611718	NA	-0.41	-7.38	-0.37	1.24e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs7246967	0.611	rs57013651	chr19:22863027	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs9506514	0.712	rs11838795	chr13:21258328	T/C	cg04906043	chr13:21280425	IL17D	-0.3	-5.66	-0.3	3.31e-8	Coronary artery calcification;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03328750	chr5:142150401	ARHGAP26	0.44	6.34	0.33	7.25e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15557168	chr22:42548783	NA	0.37	6.34	0.33	7.48e-10	Cognitive function;
LUSC	trans	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg05926928	chr17:57297772	GDPD1	-0.89	-10.31	-0.49	8.13e-22	Opioid sensitivity;
LUSC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.98	-0.4	2.39e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg03115019	chr17:80708279	FN3K	0.48	5.75	0.3	2e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUSC	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg16342193	chr10:102329863	NA	-0.34	-6.17	-0.32	1.98e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9807989	0.839	rs4851565	chr2:102971481	C/A	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.67e-9	Asthma;
LUSC	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg22852734	chr6:133119734	C6orf192	1.34	10.57	0.5	1.05e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg13319975	chr6:146136371	FBXO30	-0.71	-11.06	-0.52	1.96e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg02782426	chr3:40428986	ENTPD3	0.41	7.71	0.39	1.41e-13	Renal cell carcinoma;
LUSC	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22496380	chr5:211416	CCDC127	-0.85	-8.77	-0.43	9.3e-17	Breast cancer;
LUSC	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg12698349	chr2:225449008	CUL3	0.85	14.02	0.61	1.99e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs9831754	1.000	rs3946823	chr3:78353052	G/A	cg06138941	chr3:78371609	NA	-0.76	-10.07	-0.48	5.17e-21	Calcium levels;
LUSC	cis	rs7220401	0.789	rs3760456	chr17:27948844	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-9.58	-0.46	2.27e-19	Coronary artery disease;
LUSC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18404041	chr3:52824283	ITIH1	-0.62	-12.01	-0.55	7.56e-28	Bipolar disorder;
LUSC	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg24531977	chr5:56204891	C5orf35	-0.55	-8.08	-0.4	1.19e-14	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg09436375	chr6:42928200	GNMT	-0.29	-6.82	-0.35	4.33e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10802521	chr3:52805072	NEK4	-0.56	-9.11	-0.45	7.82e-18	Bipolar disorder;
LUSC	cis	rs367615	0.512	rs246105	chr5:108672946	C/T	cg17395555	chr5:108820864	NA	0.54	9.6	0.46	2.02e-19	Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs2048656	0.570	rs7814635	chr8:9646620	G/A	cg15556689	chr8:8085844	FLJ10661	0.46	6.59	0.34	1.7e-10	Schizophrenia;
LUSC	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.54	-0.46	3.21e-19	Neuroticism;
LUSC	cis	rs17095355	1.000	rs3862006	chr10:111750764	A/G	cg00817464	chr10:111662876	XPNPEP1	0.6	7.76	0.39	1.08e-13	Biliary atresia;
LUSC	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.88	-0.44	4.11e-17	Response to antipsychotic treatment;
LUSC	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg04545296	chr12:48745243	ZNF641	0.37	6.72	0.35	7.87e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg02187348	chr16:89574699	SPG7	0.48	7.4	0.38	1.12e-12	Multiple myeloma (IgH translocation);
LUSC	trans	rs9860340	0.770	rs7631474	chr3:87643214	C/T	cg03644585	chr7:884825	UNC84A	0.42	6.01	0.31	4.84e-9	Electroencephalographic traits in alcoholism;
LUSC	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg15556689	chr8:8085844	FLJ10661	0.57	8.7	0.43	1.53e-16	Retinal vascular caliber;
LUSC	cis	rs2067615	0.579	rs66716938	chr12:107196825	T/C	cg15890332	chr12:107067104	RFX4	0.34	6.18	0.32	1.91e-9	Heart rate;
LUSC	cis	rs9677476	1.000	rs6711312	chr2:232122348	T/C	cg07929768	chr2:232055508	NA	0.3	5.7	0.3	2.69e-8	Food antigen IgG levels;
LUSC	cis	rs7615316	0.934	rs13093869	chr3:142319213	G/C	cg16271453	chr3:142027066	XRN1	-0.36	-6.12	-0.32	2.58e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg11859384	chr17:80120422	CCDC57	0.37	5.87	0.31	1.06e-8	Life satisfaction;
LUSC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg07701084	chr6:150067640	NUP43	0.57	8.7	0.43	1.49e-16	Lung cancer;
LUSC	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg20503657	chr10:835505	NA	0.58	7.62	0.38	2.7e-13	Eosinophil percentage of granulocytes;
LUSC	cis	rs7804356	1.000	rs3823932	chr7:26853980	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	trans	rs3857536	0.813	rs4710581	chr6:66939954	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.81	0.51	1.49e-23	Morning vs. evening chronotype;
LUSC	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg01256987	chr12:42539512	GXYLT1	0.34	6.11	0.32	2.73e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08439880	chr3:133502540	NA	-0.33	-6.0	-0.31	5.26e-9	Iron status biomarkers;
LUSC	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg25173405	chr17:45401733	C17orf57	-0.37	-5.78	-0.3	1.75e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg04374321	chr14:90722782	PSMC1	0.68	10.52	0.5	1.52e-22	Mortality in heart failure;
LUSC	trans	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg14791747	chr16:20752902	THUMPD1	-0.4	-6.07	-0.32	3.44e-9	Dental caries;
LUSC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg12564285	chr5:131593104	PDLIM4	0.56	10.64	0.5	6.04e-23	Acylcarnitine levels;
LUSC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05165339	chr4:1420672	NA	-0.28	-6.3	-0.33	9.57e-10	Longevity;
LUSC	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg26816564	chr1:7831052	VAMP3	0.5	6.15	0.32	2.18e-9	Inflammatory bowel disease;
LUSC	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.17e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs12989701	1.000	rs13004848	chr2:127887560	C/T	cg08168897	chr2:127865431	BIN1	-0.69	-8.52	-0.42	5.71e-16	Alzheimer's disease (late onset);
LUSC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg13397359	chr6:42928475	GNMT	0.57	9.5	0.46	4.34e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7927771	0.524	rs4752860	chr11:47705015	C/A	cg20307385	chr11:47447363	PSMC3	-0.43	-6.3	-0.33	9.19e-10	Subjective well-being;
LUSC	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg15605315	chr1:45957053	TESK2	-0.42	-6.65	-0.34	1.19e-10	High light scatter reticulocyte count;
LUSC	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg13010199	chr12:38710504	ALG10B	0.47	7.3	0.37	2.17e-12	Morning vs. evening chronotype;
LUSC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00166722	chr3:10149974	C3orf24	0.62	8.7	0.43	1.52e-16	Alzheimer's disease;
LUSC	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-6.76	-0.35	6.22e-11	Colorectal cancer;
LUSC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21963583	chr11:68658836	MRPL21	0.55	8.66	0.43	2.04e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.84	-14.12	-0.61	8.07e-36	Height;
LUSC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.75	0.43	1.09e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2273669	0.667	rs116189763	chr6:109302894	T/C	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg27121462	chr16:89883253	FANCA	0.53	8.29	0.41	2.76e-15	Vitiligo;
LUSC	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.49	0.75	5.16e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg03342759	chr3:160939853	NMD3	-0.48	-8.18	-0.41	5.8e-15	Morning vs. evening chronotype;
LUSC	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg26566898	chr11:117069891	TAGLN	0.37	7.02	0.36	1.28e-11	Blood protein levels;
LUSC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.77	7.46	0.38	7.35e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06481639	chr22:41940642	POLR3H	0.48	5.76	0.3	1.93e-8	Vitiligo;
LUSC	cis	rs1322512	0.874	rs2254037	chr6:153016317	G/C	cg27316956	chr6:152958899	SYNE1	0.36	6.19	0.32	1.81e-9	Tonometry;
LUSC	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg17764715	chr19:33622953	WDR88	0.59	7.95	0.4	2.96e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.68	-11.34	-0.53	1.88e-25	Caffeine consumption;
LUSC	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.86	-0.31	1.11e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs72634258	0.842	rs4325151	chr1:8168917	T/A	cg00042356	chr1:8021962	PARK7	-0.58	-7.05	-0.36	1.06e-11	Inflammatory bowel disease;
LUSC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg14664628	chr15:75095509	CSK	-0.53	-7.99	-0.4	2.17e-14	Breast cancer;
LUSC	cis	rs9467773	0.609	rs12663780	chr6:26397573	T/C	cg09904177	chr6:26538194	HMGN4	-0.54	-8.04	-0.4	1.59e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg04369109	chr6:150039330	LATS1	-0.56	-8.28	-0.41	3.03e-15	Lung cancer;
LUSC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26314531	chr2:26401878	FAM59B	-0.68	-9.32	-0.45	1.67e-18	Gut microbiome composition (summer);
LUSC	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg22029157	chr1:209979665	IRF6	0.57	6.48	0.33	3.21e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg04287289	chr16:89883240	FANCA	-0.42	-6.05	-0.31	3.99e-9	Vitiligo;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04225523	chr3:133292095	CDV3	0.41	6.04	0.31	4.07e-9	Triglycerides;
LUSC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.92	12.05	0.55	5.3e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs80130819	0.688	rs7305418	chr12:48586112	A/G	cg24011408	chr12:48396354	COL2A1	0.44	5.67	0.3	3.1e-8	Prostate cancer;
LUSC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg09021430	chr5:549028	NA	-0.57	-7.67	-0.39	1.92e-13	Obesity-related traits;
LUSC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.81	13.5	0.59	1.91e-33	Aortic root size;
LUSC	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg09238746	chr17:78121135	EIF4A3	0.53	8.17	0.41	6.55e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs10170310	1.000	rs6720716	chr2:139268802	A/G	cg10095539	chr2:139258744	SPOPL	0.33	5.89	0.31	9.45e-9	Response to antipsychotic treatment;
LUSC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20419410	chr7:155089803	INSIG1	-0.43	-6.36	-0.33	6.78e-10	Electrocardiographic conduction measures;
LUSC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-10.28	-0.49	1.05e-21	Mood instability;
LUSC	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg05340658	chr4:99064831	C4orf37	0.63	10.02	0.48	7.77e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg07389463	chr12:132296394	NA	-0.46	-8.87	-0.44	4.59e-17	Migraine;
LUSC	cis	rs3087591	0.960	rs1801052	chr17:29508775	C/T	cg24425628	chr17:29625626	OMG;NF1	0.56	8.13	0.41	8.72e-15	Hip circumference;
LUSC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg24879335	chr3:133465180	TF	0.45	7.82	0.39	7.1e-14	Iron status biomarkers (transferrin levels);
LUSC	cis	rs3126085	0.825	rs4845428	chr1:152225261	T/C	cg26876637	chr1:152193138	HRNR	0.44	6.19	0.32	1.73e-9	Atopic dermatitis;
LUSC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	cis	rs1160297	0.601	rs1864534	chr2:53109005	G/T	cg07782112	chr2:53107842	NA	0.39	6.48	0.33	3.27e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg24397884	chr7:158709396	WDR60	0.62	9.38	0.46	1.02e-18	Height;
LUSC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg06028605	chr16:24865363	SLC5A11	-0.51	-9.01	-0.44	1.6e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	ch.2.1636738F	chr2:72222117	NA	-0.41	-6.31	-0.33	9.02e-10	Electrocardiographic conduction measures;
LUSC	cis	rs513349	1.000	rs210145	chr6:33547440	G/C	cg07679836	chr6:33548423	BAK1	0.33	5.86	0.31	1.12e-8	Platelet count;
LUSC	trans	rs3857536	0.706	rs1418854	chr6:66893284	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.4	-0.33	5.35e-10	Blood trace element (Cu levels);
LUSC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg13175981	chr1:150552382	MCL1	0.55	7.8	0.39	8.03e-14	Tonsillectomy;
LUSC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg06808227	chr14:105710500	BRF1	-0.67	-10.39	-0.49	4.17e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.77	-12.55	-0.57	7.5e-30	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16405210	chr4:1374714	KIAA1530	-0.63	-10.37	-0.49	4.93e-22	Longevity;
LUSC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg03351412	chr1:154909251	PMVK	0.53	8.39	0.42	1.42e-15	Prostate cancer;
LUSC	cis	rs6961069	0.527	rs3211827	chr7:80279460	A/C	cg04458919	chr7:80252533	CD36	-0.39	-6.72	-0.35	7.79e-11	Platelet count;
LUSC	cis	rs7000551	0.642	rs2449328	chr8:22375043	A/G	cg12081754	chr8:22256438	SLC39A14	0.44	6.55	0.34	2.21e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg20936695	chr7:66093774	KCTD7	-0.62	-5.97	-0.31	5.97e-9	Diabetic kidney disease;
LUSC	cis	rs7072216	0.922	rs4539242	chr10:100148058	T/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-5.75	-0.3	2e-8	Metabolite levels;
LUSC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg07061783	chr6:25882402	NA	-0.38	-5.86	-0.31	1.08e-8	Blood metabolite levels;
LUSC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg03146154	chr1:46216737	IPP	0.52	7.67	0.39	1.9e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24786498	chr4:53578478	SNORA26;KIAA0114	-0.4	-5.97	-0.31	6.11e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01035107	chr19:48281693	SEPW1	-0.45	-6.71	-0.34	8.25e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6545883	0.929	rs9679557	chr2:61709349	C/A	cg15711740	chr2:61764176	XPO1	-0.44	-6.69	-0.34	9.64e-11	Tuberculosis;
LUSC	cis	rs6681460	0.649	rs10889625	chr1:67007235	T/C	cg02459107	chr1:67143332	SGIP1	0.38	6.42	0.33	4.68e-10	Presence of antiphospholipid antibodies;
LUSC	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02725935	chr1:120612404	NOTCH2	-0.43	-6.31	-0.33	8.81e-10	Electrocardiographic conduction measures;
LUSC	trans	rs5770872	0.521	rs7511047	chr22:50816619	A/G	cg09860653	chr1:19970708	NBL1	-0.48	-7.15	-0.36	5.59e-12	Tonsillectomy;
LUSC	cis	rs11158026	0.603	rs11846514	chr14:55440340	A/C	cg04306507	chr14:55594613	LGALS3	0.4	7.47	0.38	7e-13	Parkinson's disease;
LUSC	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	0.63	8.56	0.42	4.09e-16	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs1577917	0.916	rs4706252	chr6:86555180	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg04944784	chr2:26401820	FAM59B	0.78	11.21	0.52	5.48e-25	Gut microbiome composition (summer);
LUSC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.78	-0.72	3.21e-54	Height;
LUSC	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.89	-0.31	9.5e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2652834	0.950	rs2729787	chr15:63401493	G/T	cg05507819	chr15:63340323	TPM1	0.66	7.95	0.4	2.84e-14	HDL cholesterol;
LUSC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.77	13.9	0.61	5.55e-35	Iron status biomarkers;
LUSC	cis	rs1823874	0.581	rs11855419	chr15:100327480	A/G	cg16400843	chr15:100339927	C15orf51	-0.37	-6.75	-0.35	6.45e-11	IgG glycosylation;
LUSC	cis	rs2731664	0.792	rs2545795	chr5:176887106	A/C	cg23176889	chr5:176863531	GRK6	-0.64	-12.99	-0.58	1.7e-31	Intelligence (multi-trait analysis);
LUSC	trans	rs1376359	0.537	rs471949	chr1:103255403	A/G	cg17154563	chr19:40477487	PSMC4	0.48	6.04	0.31	4.22e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6982636	1.000	rs2980853	chr8:126478350	G/T	cg13325919	chr3:181432053	SOX2;SOX2OT	0.33	6.35	0.33	7.09e-10	Lipid metabolism phenotypes;
LUSC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	cis	rs77741769	0.529	rs12579868	chr12:121207147	C/T	cg02419362	chr12:121203948	SPPL3	0.46	8.55	0.42	4.63e-16	Mean corpuscular volume;
LUSC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg12463550	chr7:65579703	CRCP	0.45	6.58	0.34	1.84e-10	Aortic root size;
LUSC	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg14343924	chr8:8086146	FLJ10661	0.45	5.94	0.31	7.24e-9	Neuroticism;
LUSC	trans	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg18187862	chr3:45730750	SACM1L	0.54	7.0	0.36	1.39e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9309473	0.607	rs1851546	chr2:73591127	C/A	cg20560298	chr2:73613845	ALMS1	-0.59	-8.88	-0.44	4.12e-17	Metabolite levels;
LUSC	cis	rs8058578	0.633	rs113448632	chr16:30898219	C/T	cg02466173	chr16:30829666	NA	-0.53	-8.68	-0.43	1.83e-16	Multiple myeloma;
LUSC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-6.23	-0.32	1.42e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	13.76	0.6	1.96e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6750047	0.546	rs1367696	chr2:38286914	C/T	cg07380506	chr2:38303506	CYP1B1	0.5	6.89	0.35	2.83e-11	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs4654899	0.758	rs35913932	chr1:21423025	G/T	cg01072550	chr1:21505969	NA	-0.51	-7.78	-0.39	9.1e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg25456477	chr12:86230367	RASSF9	0.43	7.69	0.39	1.65e-13	Major depressive disorder;
LUSC	trans	rs4811340	0.600	rs6068250	chr20:51179959	A/G	cg15736553	chr3:11610338	VGLL4	-0.33	-5.95	-0.31	6.7e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg22868518	chr11:507468	RNH1	-0.63	-5.87	-0.31	1.08e-8	Body mass index;
LUSC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg02269571	chr22:50332266	NA	-0.55	-8.12	-0.41	9.15e-15	Schizophrenia;
LUSC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.32	0.41	2.31e-15	Prudent dietary pattern;
LUSC	cis	rs713477	0.935	rs12888181	chr14:55906082	A/C	cg13175173	chr14:55914753	NA	-0.32	-6.77	-0.35	5.7e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-10.17	-0.49	2.45e-21	Morning vs. evening chronotype;
LUSC	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg00277334	chr10:82204260	NA	-0.58	-8.84	-0.44	5.72e-17	Post bronchodilator FEV1;
LUSC	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg08999081	chr20:33150536	PIGU	0.38	6.76	0.35	6.24e-11	Height;
LUSC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg13175981	chr1:150552382	MCL1	0.47	6.62	0.34	1.43e-10	Tonsillectomy;
LUSC	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg17385448	chr1:15911702	AGMAT	0.36	5.92	0.31	8.13e-9	Systolic blood pressure;
LUSC	trans	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg07393940	chr7:158741817	NA	-0.37	-6.66	-0.34	1.15e-10	Life satisfaction;
LUSC	cis	rs7119	0.717	rs7176307	chr15:77816684	G/C	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs7809950	0.953	rs28687365	chr7:107106712	A/C	cg23024343	chr7:107201750	COG5	-0.54	-8.69	-0.43	1.69e-16	Coronary artery disease;
LUSC	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	cis	rs16854884	0.558	rs60367530	chr3:143719294	G/A	cg01302019	chr3:143689584	C3orf58	-0.35	-5.81	-0.3	1.44e-8	Economic and political preferences (feminism/equality);
LUSC	cis	rs12545109	0.800	rs2610058	chr8:57409120	G/A	cg09654669	chr8:57350985	NA	-0.52	-6.66	-0.34	1.1e-10	Obesity-related traits;
LUSC	cis	rs6977660	1.000	rs6974669	chr7:19793296	T/A	cg05791153	chr7:19748676	TWISTNB	0.66	7.42	0.38	9.92e-13	Thyroid stimulating hormone;
LUSC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.65	0.39	2.17e-13	Parkinson's disease;
LUSC	cis	rs909341	0.859	rs3208008	chr20:62326110	A/C	cg09650180	chr20:62225654	GMEB2	0.46	5.99	0.31	5.51e-9	Atopic dermatitis;
LUSC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg11752832	chr7:134001865	SLC35B4	0.55	8.7	0.43	1.52e-16	Mean platelet volume;
LUSC	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg17173187	chr15:85201210	NMB	0.5	9.39	0.46	9.83e-19	Schizophrenia;
LUSC	trans	rs2392780	0.896	rs17465317	chr8:128356670	C/T	cg10897648	chr18:56338258	MALT1	-0.4	-6.13	-0.32	2.44e-9	Breast cancer (early onset);
LUSC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg15110403	chr19:17392923	ANKLE1	-0.6	-8.33	-0.41	2.11e-15	Systemic lupus erythematosus;
LUSC	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.61	-0.38	2.79e-13	Pulmonary function;
LUSC	cis	rs7621025	0.664	rs6439657	chr3:136494639	C/T	cg15507776	chr3:136538369	TMEM22	-0.41	-5.73	-0.3	2.2e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUSC	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg25457927	chr22:38595422	NA	0.49	10.51	0.5	1.69e-22	Cutaneous nevi;
LUSC	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg09307838	chr4:120376055	NA	0.71	10.61	0.5	7.43e-23	Corneal astigmatism;
LUSC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg13535736	chr9:111863775	C9orf5	-0.43	-6.88	-0.35	2.94e-11	Menarche (age at onset);
LUSC	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg02423579	chr7:2872169	GNA12	-0.37	-5.73	-0.3	2.21e-8	Height;
LUSC	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.5	-8.15	-0.41	7.45e-15	Platelet count;
LUSC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.17	0.32	1.95e-9	Menopause (age at onset);
LUSC	cis	rs9309473	0.950	rs6546849	chr2:73831037	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-6.63	-0.34	1.37e-10	Metabolite levels;
LUSC	cis	rs9837602	1.000	rs2291494	chr3:99781805	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.37	5.68	0.3	2.98e-8	Breast cancer;
LUSC	cis	rs59104589	0.617	rs60614486	chr2:242274998	C/G	cg14842376	chr2:242211374	HDLBP	0.59	6.56	0.34	2.01e-10	Fibrinogen levels;
LUSC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.26	-0.41	3.38e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7524258	0.868	rs4243824	chr1:7289777	G/A	cg07173049	chr1:7289937	CAMTA1	0.36	7.5	0.38	5.89e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.94	0.4	3.06e-14	Bipolar disorder;
LUSC	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg26384229	chr12:38710491	ALG10B	-0.67	-10.46	-0.5	2.35e-22	Bladder cancer;
LUSC	cis	rs7580658	0.963	rs6732279	chr2:128089540	G/T	cg09760422	chr2:128146352	NA	-0.33	-7.14	-0.36	6e-12	Protein C levels;
LUSC	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.24	0.37	3.16e-12	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg05313129	chr8:58192883	C8orf71	-0.5	-6.51	-0.34	2.8e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg22823121	chr1:150693482	HORMAD1	0.51	7.89	0.4	4.49e-14	Tonsillectomy;
LUSC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.78	14.38	0.62	7.93e-37	Osteoporosis;
LUSC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.71	0.34	8.51e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.22	-0.41	4.54e-15	Response to antipsychotic treatment;
LUSC	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.82	0.51	1.33e-23	Morning vs. evening chronotype;
LUSC	cis	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg22729335	chr19:2427816	TIMM13	1.07	19.06	0.72	2.49e-55	Cortisol levels (saliva);
LUSC	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg12365402	chr11:9010492	NRIP3	-0.45	-8.34	-0.42	2.01e-15	Hemoglobin concentration;
LUSC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.95	0.31	6.61e-9	Menopause (age at onset);
LUSC	cis	rs4363385	0.818	rs4845514	chr1:153000820	T/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.92	-0.4	3.59e-14	Inflammatory skin disease;
LUSC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	6.04	0.31	4.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg13798780	chr7:105162888	PUS7	0.57	6.08	0.32	3.37e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.68	11.73	0.54	7.63e-27	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08677398	chr8:58056175	NA	0.52	6.87	0.35	3.24e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg05347473	chr6:146136440	FBXO30	0.56	9.49	0.46	4.63e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg18904891	chr8:8559673	CLDN23	-0.38	-5.88	-0.31	9.98e-9	Mood instability;
LUSC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.71	0.6	2.94e-34	Platelet count;
LUSC	trans	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.57	-8.72	-0.43	1.31e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7511006	1.000	rs7290710	chr22:50677454	C/T	cg16473166	chr22:50639996	SELO	0.58	7.73	0.39	1.27e-13	Obesity-related traits;
LUSC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg23205692	chr1:25664452	TMEM50A	0.41	6.19	0.32	1.8e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01570182	chr17:44337453	NA	-0.69	-10.43	-0.5	3.03e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg03599575	chr15:90893182	GABARAPL3	0.33	5.93	0.31	7.59e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.72	-0.35	7.84e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.81	13.42	0.59	3.94e-33	Pediatric autoimmune diseases;
LUSC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg08219700	chr8:58056026	NA	0.47	6.2	0.32	1.67e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg20573242	chr4:122745356	CCNA2	0.64	9.22	0.45	3.55e-18	Type 2 diabetes;
LUSC	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs73198271	0.960	rs11776546	chr8:8609181	T/G	cg01851573	chr8:8652454	MFHAS1	0.6	8.33	0.41	2.08e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.39	-0.33	5.51e-10	Daytime sleep phenotypes;
LUSC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg06877462	chr1:205807181	PM20D1	-0.39	-6.97	-0.36	1.66e-11	Menarche (age at onset);
LUSC	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg06462663	chr19:18546047	ISYNA1	0.47	8.01	0.4	1.95e-14	Breast cancer;
LUSC	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg06636001	chr8:8085503	FLJ10661	0.67	10.88	0.51	8.52e-24	Neuroticism;
LUSC	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.66	9.78	0.47	4.94e-20	Menarche (age at onset);
LUSC	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg16482183	chr6:26056742	HIST1H1C	0.56	8.13	0.41	8.45e-15	Iron status biomarkers;
LUSC	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg17385448	chr1:15911702	AGMAT	0.37	5.78	0.3	1.76e-8	Systolic blood pressure;
LUSC	cis	rs983392	0.680	rs11230201	chr11:59996994	C/G	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.16	-0.32	2.04e-9	Alzheimer's disease (late onset);
LUSC	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg15934090	chr1:100435551	SLC35A3	0.48	8.32	0.41	2.27e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg25482853	chr8:67687455	SGK3	1.12	15.79	0.65	2.41e-42	Obesity-related traits;
LUSC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.09e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.4	-6.79	-0.35	5e-11	Extrinsic epigenetic age acceleration;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07754938	chr3:48885314	PRKAR2A	-0.45	-6.84	-0.35	3.81e-11	Electrocardiographic conduction measures;
LUSC	cis	rs11958404	0.932	rs72816581	chr5:157432591	T/A	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg23625390	chr15:77176239	SCAPER	0.52	8.1	0.41	1.02e-14	Blood metabolite levels;
LUSC	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg27284194	chr4:1044797	NA	0.58	8.61	0.43	2.92e-16	Recombination rate (females);
LUSC	cis	rs981844	0.775	rs72733610	chr4:154732336	A/G	cg14289246	chr4:154710475	SFRP2	0.47	6.29	0.33	9.72e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs10871290	0.881	rs3863436	chr16:74468038	T/C	cg01733217	chr16:74700730	RFWD3	-0.62	-8.99	-0.44	1.92e-17	Breast cancer;
LUSC	cis	rs7072216	0.727	rs942809	chr10:100168001	G/A	cg26618903	chr10:100175079	PYROXD2	-0.46	-8.71	-0.43	1.39e-16	Metabolite levels;
LUSC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg09640425	chr7:158790006	NA	0.42	6.44	0.33	4.09e-10	Facial morphology (factor 20);
LUSC	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg03894339	chr8:19674705	INTS10	0.58	7.7	0.39	1.59e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.16	-0.41	6.74e-15	Type 2 diabetes;
LUSC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg17366294	chr4:99064904	C4orf37	0.54	8.66	0.43	2.08e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11229555	0.645	rs4579945	chr11:58190873	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.44	-7.61	-0.38	2.87e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-17.88	-0.7	1.27e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg16386425	chr10:429943	DIP2C	-0.43	-6.87	-0.35	3.18e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs1595825	0.891	rs16824264	chr2:198675917	T/C	cg00982548	chr2:198649783	BOLL	-0.6	-7.44	-0.38	8.52e-13	Ulcerative colitis;
LUSC	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg01475377	chr6:109611718	NA	-0.38	-6.67	-0.34	1.04e-10	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
LUSC	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21643547	chr1:205240462	TMCC2	0.5	9.55	0.46	2.98e-19	Platelet count;
LUSC	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg15073853	chr19:18549131	ISYNA1	-0.31	-5.69	-0.3	2.78e-8	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24262715	chr15:44038991	PDIA3;CATSPER2P1	0.38	6.13	0.32	2.47e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs116988415	0.584	rs75851540	chr14:65262909	C/T	cg25083366	chr14:65239357	SPTB	0.67	6.9	0.35	2.64e-11	Daytime sleep phenotypes;
LUSC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.81	13.64	0.6	5.83e-34	Aortic root size;
LUSC	cis	rs2629540	0.889	rs4962699	chr10:126477209	A/G	cg08799069	chr10:126477246	METTL10	-0.72	-11.3	-0.53	2.63e-25	Cocaine dependence;
LUSC	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg21770322	chr7:97807741	LMTK2	0.46	7.85	0.39	5.81e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9462027	0.628	rs1998702	chr6:34741917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.31	-5.66	-0.3	3.33e-8	Systemic lupus erythematosus;
LUSC	cis	rs7586879	0.828	rs13428789	chr2:25087643	C/T	cg04586622	chr2:25135609	ADCY3	0.3	5.74	0.3	2.09e-8	Body mass index;
LUSC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	12.48	0.56	1.38e-29	Cognitive test performance;
LUSC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25072359	chr17:41440525	NA	0.69	9.65	0.47	1.36e-19	Menopause (age at onset);
LUSC	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg24631222	chr15:78858424	CHRNA5	-0.67	-9.03	-0.44	1.39e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg20891283	chr12:69753455	YEATS4	0.43	5.69	0.3	2.74e-8	Response to diuretic therapy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23922560	chr14:37117375	NA	0.44	6.47	0.33	3.47e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.03	20.49	0.75	5.09e-61	Cognitive function;
LUSC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg20476274	chr7:133979776	SLC35B4	0.83	15.25	0.64	3.17e-40	Mean platelet volume;
LUSC	cis	rs7799006	0.606	rs878534	chr7:2314652	G/A	cg12823233	chr7:2316876	SNX8	-0.45	-7.63	-0.39	2.41e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg18196295	chr10:418757	DIP2C	-0.51	-8.36	-0.42	1.71e-15	Psychosis in Alzheimer's disease;
LUSC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-10.03	-0.48	7.13e-21	Hemoglobin concentration;
LUSC	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.51	-0.46	3.89e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7267979	0.740	rs2259961	chr20:25282626	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.77	16.24	0.66	4.1e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10779751	0.734	rs1211575	chr1:11118390	G/A	cg08854313	chr1:11322531	MTOR	0.77	11.33	0.53	2.18e-25	Body mass index;
LUSC	trans	rs62103177	0.673	rs36087369	chr18:77589596	C/G	cg05926928	chr17:57297772	GDPD1	1.03	12.92	0.58	3.01e-31	Opioid sensitivity;
LUSC	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	8.09	0.4	1.09e-14	Response to antipsychotic treatment;
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg25703541	chr22:24373054	LOC391322	-1.0	-18.23	-0.71	4.8e-52	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg03465714	chr1:152285911	FLG	-0.4	-5.83	-0.3	1.34e-8	Atopic dermatitis;
LUSC	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg24851651	chr11:66362959	CCS	-0.53	-8.54	-0.42	4.91e-16	Bipolar disorder;
LUSC	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.82	0.35	4.38e-11	Height;
LUSC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg13319975	chr6:146136371	FBXO30	0.5	7.52	0.38	5.18e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1595825	0.891	rs59990242	chr2:198895868	G/A	cg00982548	chr2:198649783	BOLL	-0.54	-6.89	-0.35	2.72e-11	Ulcerative colitis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17121955	chr11:6411382	SMPD1	-0.51	-6.82	-0.35	4.16e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg11502198	chr6:26597334	ABT1	0.59	8.82	0.43	6.52e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg05941027	chr17:61774174	LIMD2	0.22	5.7	0.3	2.66e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg23985595	chr17:80112537	CCDC57	-0.31	-6.01	-0.31	4.74e-9	Life satisfaction;
LUSC	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17467752	chr17:38218738	THRA	0.53	7.9	0.4	3.97e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs73001065	0.818	rs16996185	chr19:19720788	G/T	cg03709012	chr19:19516395	GATAD2A	-0.88	-7.15	-0.36	5.53e-12	LDL cholesterol;
LUSC	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg25801113	chr15:45476975	SHF	0.36	7.27	0.37	2.55e-12	Uric acid levels;
LUSC	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.94	-0.44	2.7e-17	Total cholesterol levels;
LUSC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg22823121	chr1:150693482	HORMAD1	0.5	7.21	0.37	3.67e-12	Melanoma;
LUSC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg04518342	chr5:131593106	PDLIM4	-0.53	-9.46	-0.46	5.69e-19	Acylcarnitine levels;
LUSC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg22834771	chr12:69754056	YEATS4	-0.53	-8.07	-0.4	1.27e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.18	-0.41	5.98e-15	Joint mobility (Beighton score);
LUSC	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg19875535	chr5:140030758	IK	-0.47	-7.69	-0.39	1.64e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.22	-0.32	1.48e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2629540	0.806	rs10901812	chr10:126419384	A/G	cg08799069	chr10:126477246	METTL10	-0.62	-8.81	-0.43	6.71e-17	Cocaine dependence;
LUSC	cis	rs1113500	0.897	rs10785832	chr1:108638899	G/A	cg11967332	chr1:108735228	SLC25A24	0.39	5.93	0.31	7.44e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs2274273	0.624	rs7140628	chr14:55760681	A/C	cg04306507	chr14:55594613	LGALS3	0.49	10.03	0.48	7.04e-21	Protein biomarker;
LUSC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg07952391	chr2:88470173	THNSL2	0.77	6.84	0.35	3.74e-11	Plasma clusterin levels;
LUSC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg03609598	chr5:56110824	MAP3K1	-0.41	-5.9	-0.31	8.97e-9	Initial pursuit acceleration;
LUSC	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg26408565	chr15:76604113	ETFA	-0.47	-7.42	-0.38	9.75e-13	Blood metabolite levels;
LUSC	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg07169764	chr2:136633963	MCM6	1.09	16.22	0.66	4.72e-44	Corneal structure;
LUSC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.11	0.45	7.98e-18	Motion sickness;
LUSC	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg20607287	chr7:12443886	VWDE	-0.65	-6.34	-0.33	7.48e-10	Coronary artery disease;
LUSC	trans	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg06753689	chr10:1034030	GTPBP4	-0.6	-5.97	-0.31	6.09e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.16	-0.36	5.08e-12	Coronary artery disease;
LUSC	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg07169764	chr2:136633963	MCM6	-0.74	-9.97	-0.48	1.19e-20	Mosquito bite size;
LUSC	cis	rs4851254	0.660	rs58683655	chr2:100686519	G/C	cg07810366	chr2:100720526	AFF3	-0.46	-6.16	-0.32	2.05e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.7	0.3	2.64e-8	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07677032	chr17:61819896	STRADA	0.52	8.79	0.43	8.03e-17	Prudent dietary pattern;
LUSC	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg24069376	chr3:38537580	EXOG	0.38	7.34	0.37	1.69e-12	Electrocardiographic conduction measures;
LUSC	trans	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg25835954	chr13:50160062	RCBTB1	0.55	7.81	0.39	7.71e-14	Cortisol levels (saliva);
LUSC	cis	rs2067615	0.524	rs10467029	chr12:107078448	C/T	cg15890332	chr12:107067104	RFX4	0.36	6.24	0.32	1.35e-9	Heart rate;
LUSC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.06	0.44	1.12e-17	Monocyte percentage of white cells;
LUSC	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg22705602	chr4:152727874	NA	-0.33	-6.71	-0.34	8.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg09184832	chr6:79620586	NA	-0.42	-6.82	-0.35	4.28e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg04455712	chr21:45112962	RRP1B	0.48	9.02	0.44	1.45e-17	Mean corpuscular volume;
LUSC	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03713592	chr11:72463424	ARAP1	0.74	8.74	0.43	1.12e-16	Type 2 diabetes;
LUSC	cis	rs10979	0.597	rs9484776	chr6:143906325	T/C	cg25407410	chr6:143891975	LOC285740	-0.68	-8.33	-0.41	2.16e-15	Hypospadias;
LUSC	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg04833646	chr19:10679720	CDKN2D	1.06	14.03	0.61	1.72e-35	Red cell distribution width;
LUSC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.1	16.88	0.68	1.19e-46	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg02175503	chr12:58329896	NA	0.49	7.13	0.36	6.28e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.898	rs11253353	chr10:766862	C/A	cg13042288	chr15:90349979	ANPEP	-0.46	-6.1	-0.32	2.89e-9	Uric acid levels;
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.37	-5.97	-0.31	6.16e-9	Longevity;Endometriosis;
LUSC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg04287289	chr16:89883240	FANCA	0.78	6.24	0.32	1.29e-9	Skin colour saturation;
LUSC	cis	rs7605827	0.866	rs34815739	chr2:15533375	A/G	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	6.24	0.32	1.35e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.57	-8.44	-0.42	1.01e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9395066	0.545	rs4714830	chr6:44955528	C/T	cg25276700	chr6:44698697	NA	0.29	5.8	0.3	1.53e-8	Height;
LUSC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg10729496	chr3:10149963	C3orf24	0.51	6.77	0.35	5.8200000000000003e-11	Alzheimer's disease;
LUSC	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg00784671	chr22:46762841	CELSR1	-0.49	-5.96	-0.31	6.49e-9	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04686114	chr12:57081832	PTGES3	-0.47	-6.23	-0.32	1.41e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg07636037	chr3:49044803	WDR6	0.9	12.05	0.55	4.99e-28	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg02493740	chr2:85810744	VAMP5	-0.33	-5.83	-0.3	1.29e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg23625390	chr15:77176239	SCAPER	-0.65	-9.96	-0.48	1.21e-20	Blood metabolite levels;
LUSC	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg03788504	chr6:150331562	NA	-0.26	-5.84	-0.3	1.22e-8	Alopecia areata;
LUSC	cis	rs16854884	0.586	rs2011080	chr3:143756149	T/G	cg06585982	chr3:143692056	C3orf58	0.51	8.25	0.41	3.6e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg20607798	chr8:58055168	NA	0.57	5.78	0.3	1.7e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs72674100	1.000	rs7656873	chr4:97964668	A/G	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg26395211	chr5:140044315	WDR55	0.46	7.1	0.36	7.64e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg02018176	chr4:1364513	KIAA1530	0.5	8.54	0.42	4.76e-16	Obesity-related traits;
LUSC	trans	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg13565492	chr6:43139072	SRF	-0.63	-6.63	-0.34	1.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg05347473	chr6:146136440	FBXO30	0.49	8.19	0.41	5.64e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.35	0.59	7.08e-33	Cognitive test performance;
LUSC	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-10.3	-0.49	8.6e-22	Body mass index;
LUSC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.6	-0.34	1.59e-10	Life satisfaction;
LUSC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.32	-0.37	1.84e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg27124370	chr19:33622961	WDR88	0.56	7.97	0.4	2.53e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg18721089	chr20:30220636	NA	-0.39	-6.15	-0.32	2.2e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg21433313	chr16:3507492	NAT15	0.41	5.78	0.3	1.69e-8	Body mass index (adult);
LUSC	cis	rs701145	0.878	rs442480	chr3:153992952	T/A	cg17054900	chr3:154042577	DHX36	0.84	8.49	0.42	6.84e-16	Coronary artery disease;
LUSC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.61	0.62	1.05e-37	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.49	0.5	1.96e-22	Lymphocyte counts;
LUSC	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg11742103	chr11:62369870	EML3;MTA2	-0.48	-8.36	-0.42	1.71e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg00310523	chr12:86230176	RASSF9	-0.43	-7.91	-0.4	3.85e-14	Major depressive disorder;
LUSC	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.2	-0.32	1.62e-9	Bipolar disorder;
LUSC	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.59	0.5	8.87e-23	Hypertriglyceridemia;
LUSC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.68	-12.13	-0.55	2.74e-28	Aortic root size;
LUSC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg06028605	chr16:24865363	SLC5A11	0.47	8.5	0.42	6.31e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg10845886	chr2:3471009	TTC15	-0.58	-7.52	-0.38	5.21e-13	Neurofibrillary tangles;
LUSC	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg06462663	chr19:18546047	ISYNA1	0.49	8.36	0.42	1.74e-15	Breast cancer;
LUSC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg07701084	chr6:150067640	NUP43	0.53	7.93	0.4	3.23e-14	Lung cancer;
LUSC	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.14	0.41	8.16e-15	Axial length;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06935581	chr16:451865	DECR2	0.69	5.97	0.31	6.16e-9	Cognitive performance;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21898799	chr19:49122504	RPL18;SPHK2	-0.41	-6.01	-0.31	4.93e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg12463550	chr7:65579703	CRCP	0.5	7.03	0.36	1.17e-11	Aortic root size;
LUSC	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg10253484	chr15:75165896	SCAMP2	0.41	5.8	0.3	1.51e-8	Systemic lupus erythematosus;
LUSC	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg07621104	chr11:117668040	DSCAML1	0.45	5.92	0.31	8.12e-9	Myopia;
LUSC	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg13010199	chr12:38710504	ALG10B	0.48	7.49	0.38	6.31e-13	Morning vs. evening chronotype;
LUSC	cis	rs1210638	0.706	rs2518798	chr22:18970403	T/C	cg12798833	chr22:18958832	DGCR5	-0.31	-5.83	-0.3	1.31e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg02574844	chr11:5959923	NA	-0.41	-5.82	-0.3	1.4e-8	DNA methylation (variation);
LUSC	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.9	0.61	5.49e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.27	0.32	1.13e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg04518342	chr5:131593106	PDLIM4	-0.36	-6.62	-0.34	1.41e-10	Breast cancer;
LUSC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg13206674	chr6:150067644	NUP43	0.61	9.65	0.47	1.4e-19	Lung cancer;
LUSC	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg26384229	chr12:38710491	ALG10B	0.57	8.5	0.42	6.44e-16	Bladder cancer;
LUSC	trans	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg07211511	chr3:129823064	LOC729375	-0.74	-9.62	-0.47	1.65e-19	Blood pressure (smoking interaction);
LUSC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg02018176	chr4:1364513	KIAA1530	0.47	8.21	0.41	4.75e-15	Obesity-related traits;
LUSC	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7202877	0.706	rs4887813	chr16:75312494	A/G	cg04384234	chr16:75411784	CFDP1	-0.66	-8.99	-0.44	1.84e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	14.89	0.63	7.94e-39	Total body bone mineral density;
LUSC	cis	rs189798	0.807	rs12785	chr8:8994936	A/T	cg15556689	chr8:8085844	FLJ10661	0.47	6.21	0.32	1.59e-9	Myopia (pathological);
LUSC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.46	0.46	5.71e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2637266	1.000	rs2395389	chr10:78357701	C/T	cg18941641	chr10:78392320	NA	0.38	6.93	0.35	2.18e-11	Pulmonary function;
LUSC	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg03806693	chr22:41940476	POLR3H	0.84	12.06	0.55	4.75e-28	Vitiligo;
LUSC	cis	rs9283706	0.608	rs10065036	chr5:66338084	G/A	cg11590213	chr5:66331682	MAST4	0.46	6.77	0.35	5.74e-11	Coronary artery disease;
LUSC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg03909863	chr11:638404	DRD4	-0.41	-6.18	-0.32	1.84e-9	Systemic lupus erythematosus;
LUSC	trans	rs72674100	1.000	rs10016008	chr4:97974457	A/G	cg16405019	chr1:18959625	PAX7	-0.58	-6.3	-0.33	9.4e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg23711669	chr6:146136114	FBXO30	-0.91	-17.88	-0.7	1.27e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.26	-0.37	2.75e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	cis	rs30380	0.632	rs26489	chr5:96133427	C/T	cg16492584	chr5:96139282	ERAP1	-0.56	-7.56	-0.38	3.96e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg07460842	chr6:66804631	NA	-0.74	-9.93	-0.48	1.51e-20	Blood trace element (Cu levels);
LUSC	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg20701182	chr2:24300061	SF3B14	0.74	7.28	0.37	2.4e-12	Lymphocyte counts;
LUSC	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.92	0.35	2.34e-11	IgG glycosylation;
LUSC	trans	rs9784649	1.000	rs56156666	chr5:24999440	A/T	cg08600765	chr20:34638493	LOC647979	-0.53	-6.35	-0.33	6.94e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg05340658	chr4:99064831	C4orf37	0.44	7.0	0.36	1.41e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.8	-0.47	4.39e-20	Platelet count;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg15082645	chr12:121148294	UNC119B	0.39	6.16	0.32	2.1e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg26353448	chr1:248524236	OR2T4	-0.3	-5.81	-0.3	1.48e-8	Common traits (Other);
LUSC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.54e-17	Motion sickness;
LUSC	cis	rs12208915	0.945	rs12214796	chr6:79561068	T/C	cg05283184	chr6:79620031	NA	0.46	5.97	0.31	5.97e-9	Left atrial antero-posterior diameter;
LUSC	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg22681709	chr2:178499509	PDE11A	-0.47	-8.36	-0.42	1.68e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-7.63	-0.39	2.4e-13	Morning vs. evening chronotype;
LUSC	cis	rs2147959	0.941	rs10916317	chr1:228645063	A/G	cg18477163	chr1:228402036	OBSCN	-0.44	-6.0	-0.31	5.14e-9	Adult asthma;
LUSC	trans	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg14791747	chr16:20752902	THUMPD1	0.71	9.39	0.46	9.69e-19	Cognitive test performance;
LUSC	cis	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg26958806	chr6:27640298	NA	0.71	5.68	0.3	2.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9549260	0.755	rs7338669	chr13:41200091	C/T	cg21288729	chr13:41239152	FOXO1	-0.59	-9.21	-0.45	3.57e-18	Red blood cell count;
LUSC	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.71	-8.37	-0.42	1.59e-15	Refractive error;
LUSC	cis	rs9473147	0.503	rs9473123	chr6:47475339	G/A	cg12968598	chr6:47444699	CD2AP	0.52	7.9	0.4	4.13e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.31e-41	Bladder cancer;
LUSC	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg11584989	chr19:19387371	SF4	0.57	6.92	0.35	2.31e-11	Bipolar disorder;
LUSC	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.56	0.46	2.6e-19	Lung cancer in ever smokers;
LUSC	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg17173187	chr15:85201210	NMB	0.48	8.9	0.44	3.51e-17	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg13206674	chr6:150067644	NUP43	0.6	9.7	0.47	9.47e-20	Lung cancer;
LUSC	cis	rs77741769	0.529	rs909053	chr12:121237668	G/A	cg02419362	chr12:121203948	SPPL3	0.46	8.54	0.42	4.69e-16	Mean corpuscular volume;
LUSC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21171335	chr12:122356390	WDR66	-0.5	-7.37	-0.37	1.35e-12	Mean corpuscular volume;
LUSC	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg00012203	chr2:219082015	ARPC2	-0.71	-11.74	-0.54	7.24e-27	Colorectal cancer;
LUSC	cis	rs7605827	0.930	rs1549015	chr2:15616458	T/C	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs9473147	0.516	rs7749167	chr6:47493940	G/A	cg12968598	chr6:47444699	CD2AP	0.53	7.97	0.4	2.49e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg15556689	chr8:8085844	FLJ10661	0.64	10.2	0.49	1.92e-21	Mood instability;
LUSC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg22800045	chr5:56110881	MAP3K1	0.44	6.14	0.32	2.35e-9	Coronary artery disease;
LUSC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg09365446	chr1:150670422	GOLPH3L	0.48	7.2	0.37	4.1e-12	Melanoma;
LUSC	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg06219351	chr7:158114137	PTPRN2	-0.54	-9.85	-0.47	2.89e-20	Calcium levels;
LUSC	cis	rs4478858	0.698	rs4949385	chr1:31793256	C/T	cg00250761	chr1:31883323	NA	-0.35	-8.75	-0.43	1.09e-16	Alcohol dependence;
LUSC	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.6	9.49	0.46	4.56e-19	Morning vs. evening chronotype;
LUSC	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg16482183	chr6:26056742	HIST1H1C	1.01	12.86	0.58	4.88e-31	Iron status biomarkers;
LUSC	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg15744005	chr10:104629667	AS3MT	-0.28	-5.89	-0.31	9.43e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg15819921	chr19:927150	ARID3A	-0.44	-6.54	-0.34	2.29e-10	Life satisfaction;
LUSC	cis	rs4499344	0.604	rs259287	chr19:33164859	C/T	cg22980127	chr19:33182716	NUDT19	-0.42	-6.3	-0.33	9.55e-10	Mean platelet volume;
LUSC	trans	rs17742757	0.521	rs2736324	chr8:11328182	C/G	cg15556689	chr8:8085844	FLJ10661	0.47	5.99	0.31	5.54e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg13010199	chr12:38710504	ALG10B	-0.53	-8.23	-0.41	4.11e-15	Morning vs. evening chronotype;
LUSC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.95	-0.31	6.75e-9	Tonsillectomy;
LUSC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg21644426	chr2:191273491	MFSD6	0.62	9.78	0.47	4.81e-20	Pulse pressure;
LUSC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.76	13.3	0.59	1.09e-32	Age at first birth;
LUSC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg10729496	chr3:10149963	C3orf24	0.55	7.31	0.37	2e-12	Alzheimer's disease;
LUSC	cis	rs12801636	0.512	rs11227247	chr11:65422853	A/C	cg27068330	chr11:65405492	SIPA1	0.58	5.73	0.3	2.26e-8	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg02508848	chr16:68573721	ZFP90	0.43	6.01	0.31	4.92e-9	Ulcerative colitis;
LUSC	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg08847533	chr14:75593920	NEK9	-0.66	-10.85	-0.51	1.06e-23	Coronary artery disease;
LUSC	cis	rs1538970	0.962	rs3219489	chr1:45797505	C/G	cg05343316	chr1:45956843	TESK2	0.58	7.91	0.4	3.73e-14	Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11227075	chr10:52750930	PRKG1	0.4	6.3	0.33	9.26e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28655083	0.529	rs285023	chr16:77099783	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.39	6.26	0.32	1.16e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9443189	0.615	rs6453829	chr6:76268509	C/T	cg01950844	chr6:76311363	SENP6	0.68	6.95	0.36	1.96e-11	Prostate cancer;
LUSC	cis	rs5009270	0.553	rs2188548	chr7:112235267	C/T	cg27282281	chr7:112262583	NA	0.43	5.8	0.3	1.57e-8	Osteoarthritis (hip);
LUSC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg19230755	chr7:65878503	NA	-0.41	-5.82	-0.3	1.37e-8	Aortic root size;
LUSC	cis	rs1595825	0.732	rs2340687	chr2:198460040	T/G	cg00982548	chr2:198649783	BOLL	-0.52	-6.36	-0.33	6.8e-10	Ulcerative colitis;
LUSC	cis	rs2413583	0.591	rs12483879	chr22:39719148	C/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.73	7.11	0.36	7.08e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.06	-0.4	1.37e-14	Type 2 diabetes;
LUSC	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg03859395	chr2:55845619	SMEK2	0.85	15.18	0.64	5.99e-40	Metabolic syndrome;
LUSC	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg00540400	chr15:79124168	NA	-0.48	-8.43	-0.42	1.04e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg13535736	chr9:111863775	C9orf5	-0.35	-5.79	-0.3	1.66e-8	Menarche (age at onset);
LUSC	trans	rs800082	0.839	rs62275528	chr3:144293687	T/C	cg24215973	chr2:240111563	HDAC4	-0.44	-6.61	-0.34	1.49e-10	Smoking behavior;
LUSC	cis	rs2742234	0.590	rs2435339	chr10:43642173	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.36	-0.37	1.49e-12	Hirschsprung disease;
LUSC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.59e-9	Menopause (age at onset);
LUSC	cis	rs4629180	0.540	rs6747670	chr2:102130368	T/C	cg04415270	chr2:102091202	RFX8	-0.43	-7.49	-0.38	6.2e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg02428538	chr16:24856791	SLC5A11	0.52	6.0	0.31	5.28e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg00376283	chr12:123451042	ABCB9	0.66	8.26	0.41	3.5e-15	Neutrophil percentage of white cells;
LUSC	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg16230307	chr14:35515116	FAM177A1	0.78	10.0	0.48	8.96e-21	Psoriasis;
LUSC	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg14830002	chr1:247616686	OR2B11	0.49	7.05	0.36	1.05e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg04362960	chr10:104952993	NT5C2	0.6	9.59	0.46	2.18e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7809950	1.000	rs10274041	chr7:107261556	C/T	cg23024343	chr7:107201750	COG5	0.54	8.44	0.42	9.52e-16	Coronary artery disease;
LUSC	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	5.9	0.31	8.85e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg05425664	chr17:57184151	TRIM37	-0.5	-7.41	-0.38	1.02e-12	Testicular germ cell tumor;
LUSC	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.69	10.48	0.5	2.02e-22	Corneal astigmatism;
LUSC	trans	rs12165098	0.636	rs4581776	chr18:36747024	G/C	cg23858286	chr9:138135095	NA	-0.42	-6.14	-0.32	2.28e-9	Sleep duration;
LUSC	cis	rs7178572	0.539	rs12594346	chr15:77671966	A/T	cg22256960	chr15:77711686	NA	0.51	7.47	0.38	6.85e-13	Type 2 diabetes;
LUSC	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg23752985	chr2:85803571	VAMP8	0.3	6.37	0.33	6.28e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg06462663	chr19:18546047	ISYNA1	0.44	7.24	0.37	3.02e-12	Breast cancer;
LUSC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	0.93	17.84	0.7	1.83e-50	Heart rate;
LUSC	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.39	-0.42	1.41e-15	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6977660	0.653	rs28537170	chr7:19814239	T/G	cg05791153	chr7:19748676	TWISTNB	0.8	8.08	0.4	1.16e-14	Thyroid stimulating hormone;
LUSC	cis	rs243505	0.898	rs243536	chr7:148409941	C/T	cg09806900	chr7:148480153	CUL1	0.44	6.37	0.33	6.38e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg03526776	chr6:41159608	TREML2	0.32	6.07	0.32	3.44e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.22	-0.49	1.68e-21	Eye color traits;
LUSC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11764359	chr7:65958608	NA	0.68	10.88	0.51	8.15e-24	Aortic root size;
LUSC	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg01256987	chr12:42539512	GXYLT1	-0.41	-7.56	-0.38	3.98e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg16405210	chr4:1374714	KIAA1530	0.55	8.87	0.44	4.49e-17	Obesity-related traits;
LUSC	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.62	-9.47	-0.46	5.11e-19	Metabolite levels;
LUSC	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.42	-7.04	-0.36	1.08e-11	Prion diseases;
LUSC	trans	rs7737355	1.000	rs6876350	chr5:130604109	G/T	cg07715041	chr7:99302981	CYP3A7	-0.38	-6.11	-0.32	2.82e-9	Life satisfaction;
LUSC	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.72	0.35	8.08e-11	Corneal astigmatism;
LUSC	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg05347473	chr6:146136440	FBXO30	0.52	8.79	0.43	8.2e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg16482183	chr6:26056742	HIST1H1C	0.47	6.95	0.36	1.89e-11	Height;
LUSC	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg09796270	chr17:17721594	SREBF1	-0.42	-7.3	-0.37	2.11e-12	Total body bone mineral density;
LUSC	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg16586182	chr3:47516702	SCAP	0.52	8.13	0.41	8.41e-15	Colorectal cancer;
LUSC	cis	rs12530134	0.519	rs3920484	chr6:170746081	A/G	cg16453901	chr6:170730693	NA	-0.93	-6.17	-0.32	1.97e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.2	13.62	0.6	6.4e-34	Diabetic kidney disease;
LUSC	trans	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg26384229	chr12:38710491	ALG10B	0.57	9.05	0.44	1.16e-17	Morning vs. evening chronotype;
LUSC	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg05887092	chr17:76393375	PGS1	-0.58	-11.14	-0.52	9.76e-25	HDL cholesterol levels;
LUSC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg02807482	chr3:125708958	NA	-0.52	-6.56	-0.34	2.03e-10	Blood pressure (smoking interaction);
LUSC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg00945038	chr17:61921165	SMARCD2	0.38	5.67	0.3	3.01e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.74	10.76	0.51	2.3e-23	Corneal astigmatism;
LUSC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15556689	chr8:8085844	FLJ10661	0.75	12.3	0.56	5.97e-29	Systolic blood pressure;
LUSC	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg27284194	chr4:1044797	NA	0.59	8.84	0.44	5.8e-17	Recombination rate (females);
LUSC	cis	rs3136441	1.000	rs4752947	chr11:46901156	A/T	cg01183595	chr11:46746236	F2	0.38	5.67	0.3	3.12e-8	HDL cholesterol;
LUSC	cis	rs79387448	0.564	rs77375846	chr2:103155075	T/C	cg09003973	chr2:102972529	NA	1.0	9.4	0.46	8.76e-19	Gut microbiota (bacterial taxa);
LUSC	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg22709100	chr7:91322751	NA	0.46	6.71	0.34	8.29e-11	Breast cancer;
LUSC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg16414030	chr3:133502952	NA	-0.38	-6.04	-0.31	4.16e-9	Iron status biomarkers;
LUSC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg16482183	chr6:26056742	HIST1H1C	0.53	7.81	0.39	7.32e-14	Height;
LUSC	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg05855489	chr10:104503620	C10orf26	-0.69	-9.87	-0.48	2.54e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.71	0.34	8.49e-11	IgG glycosylation;
LUSC	cis	rs977987	0.843	rs2059256	chr16:75395835	G/T	cg03315344	chr16:75512273	CHST6	0.53	10.39	0.49	4.42e-22	Dupuytren's disease;
LUSC	cis	rs2932538	0.922	rs7527076	chr1:113150481	G/A	cg22162597	chr1:113214053	CAPZA1	0.69	9.99	0.48	9.74e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg07395648	chr5:131743802	NA	0.4	5.82	0.3	1.34e-8	Breast cancer;
LUSC	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.19	0.52	6.82e-25	Coffee consumption (cups per day);
LUSC	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg03585969	chr10:35415529	CREM	0.65	9.25	0.45	2.78e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg14675211	chr2:100938903	LONRF2	0.37	5.75	0.3	2.06e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2857891	0.697	rs1004754	chr11:6946248	T/C	cg04053776	chr11:6947353	ZNF215	0.53	7.65	0.39	2.17e-13	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11905131	chr22:24372483	LOC391322	-0.57	-9.39	-0.46	9.43e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg00933542	chr6:150070202	PCMT1	0.3	6.18	0.32	1.83e-9	Lung cancer;
LUSC	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-0.9	-16.53	-0.67	2.76e-45	Heart rate;
LUSC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.38	0.42	1.54e-15	Prudent dietary pattern;
LUSC	trans	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg06636001	chr8:8085503	FLJ10661	0.43	6.03	0.31	4.23e-9	Schizophrenia;
LUSC	cis	rs7681440	0.583	rs2737035	chr4:90777213	C/T	cg06632027	chr4:90757378	SNCA	-0.37	-5.75	-0.3	1.99e-8	Dementia with Lewy bodies;
LUSC	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.09	-0.52	1.52e-24	Mean corpuscular volume;
LUSC	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	7.96	0.4	2.74e-14	Axial length;
LUSC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05776053	chr2:74358815	NA	0.46	6.7	0.34	8.91e-11	Gestational age at birth (maternal effect);
LUSC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg21724239	chr8:58056113	NA	0.77	9.21	0.45	3.76e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg13114125	chr14:105738426	BRF1	-0.9	-15.55	-0.65	2.03e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	6.78	0.35	5.42e-11	Height;
LUSC	trans	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-6.08	-0.32	3.25e-9	Morning vs. evening chronotype;
LUSC	cis	rs61931739	0.591	rs4931764	chr12:33979423	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.81	-0.35	4.58e-11	Morning vs. evening chronotype;
LUSC	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg16928487	chr17:17741425	SREBF1	-0.44	-8.59	-0.43	3.27e-16	Total body bone mineral density;
LUSC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg07701084	chr6:150067640	NUP43	0.53	7.95	0.4	2.83e-14	Lung cancer;
LUSC	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg17764715	chr19:33622953	WDR88	-0.48	-6.55	-0.34	2.14e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg21951975	chr1:209979733	IRF6	0.54	6.71	0.34	8.37e-11	Coronary artery disease;
LUSC	cis	rs11214589	0.651	rs12360992	chr11:113262900	A/C	cg14159747	chr11:113255604	NA	0.29	7.56	0.38	3.98e-13	Neuroticism;
LUSC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg11663144	chr21:46675770	NA	-0.42	-7.34	-0.37	1.59e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7709377	0.574	rs1508875	chr5:115496470	C/T	cg23108291	chr5:115420582	COMMD10	-0.42	-6.03	-0.31	4.4e-9	Metabolite levels  (X-11787);
LUSC	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg06207120	chr15:45996521	NA	0.39	6.01	0.31	4.87e-9	Waist circumference;Weight;
LUSC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg20476274	chr7:133979776	SLC35B4	0.82	14.95	0.63	4.64e-39	Mean platelet volume;
LUSC	cis	rs2235649	0.833	rs2011088	chr16:1850091	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.1	-0.32	2.85e-9	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs739496	1.000	rs739496	chr12:111887659	A/G	cg10833066	chr12:111807467	FAM109A	0.31	5.72	0.3	2.41e-8	Platelet count;
LUSC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg02569458	chr12:86230093	RASSF9	0.39	6.2	0.32	1.63e-9	Major depressive disorder;
LUSC	cis	rs36093844	0.800	rs17817331	chr11:85595338	A/G	cg25872744	chr11:85566296	CCDC83	0.45	6.01	0.31	4.84e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.56	8.02	0.4	1.86e-14	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg08200582	chr11:442649	ANO9	-0.52	-5.72	-0.3	2.43e-8	Body mass index;
LUSC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-7.66	-0.39	1.97e-13	Longevity;Endometriosis;
LUSC	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg11530693	chr1:120165357	ZNF697	0.69	10.79	0.51	1.79e-23	Systemic lupus erythematosus;
LUSC	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg21827317	chr3:136751795	NA	0.39	7.12	0.36	6.45e-12	Neuroticism;
LUSC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg26784012	chr10:32216390	ARHGAP12	0.45	7.59	0.38	3.19e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.4	-0.42	1.26e-15	Body mass index;
LUSC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16405210	chr4:1374714	KIAA1530	-0.59	-9.48	-0.46	5.04e-19	Longevity;
LUSC	trans	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg17830980	chr10:43048298	ZNF37B	-0.44	-7.05	-0.36	1.06e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.54	0.34	2.25e-10	IgG glycosylation;
LUSC	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21775007	chr8:11205619	TDH	0.71	11.36	0.53	1.72e-25	Retinal vascular caliber;
LUSC	cis	rs2188554	0.583	rs2213958	chr7:117241394	A/T	cg10524701	chr7:117356490	CTTNBP2	0.4	5.75	0.3	1.99e-8	Esophageal adenocarcinoma;
LUSC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg23601095	chr6:26197514	HIST1H3D	0.72	7.33	0.37	1.71e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs10465746	0.967	rs12732697	chr1:84349283	A/G	cg10977910	chr1:84465055	TTLL7	0.44	6.29	0.33	9.9e-10	Obesity-related traits;
LUSC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	8.92	0.44	3.22e-17	Monocyte count;
LUSC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg10978503	chr1:24200527	CNR2	-0.53	-12.99	-0.58	1.6e-31	Immature fraction of reticulocytes;
LUSC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg26116260	chr4:7069785	GRPEL1	1.16	18.16	0.7	9.53e-52	Monocyte percentage of white cells;
LUSC	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.53	-8.04	-0.4	1.62e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9535307	0.929	rs942032	chr13:50251145	T/G	cg04663916	chr13:50265991	EBPL	0.49	5.7	0.3	2.63e-8	Obesity-related traits;
LUSC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	9.21	0.45	3.7e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs2348418	0.715	rs1355471	chr12:28721725	A/G	cg13890972	chr12:28721907	NA	0.38	6.88	0.35	2.92e-11	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs3087591	1.000	rs2854322	chr17:29699416	C/T	cg24425628	chr17:29625626	OMG;NF1	0.6	8.78	0.43	8.55e-17	Hip circumference;
LUSC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg00012203	chr2:219082015	ARPC2	-0.7	-11.59	-0.54	2.53e-26	Colorectal cancer;
LUSC	cis	rs61990749	0.544	rs176962	chr14:78185510	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	6.41	0.33	4.9e-10	Fibroblast growth factor basic levels;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg23037186	chr1:16971262	MST1P2	0.38	5.95	0.31	6.94e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	6.52	0.34	2.66e-10	Menarche (age at onset);
LUSC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.44	6.2	0.32	1.71e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-6.08	-0.32	3.33e-9	Schizophrenia;
LUSC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg23711669	chr6:146136114	FBXO30	0.87	16.34	0.67	1.68e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-1.23	-13.28	-0.59	1.37e-32	Diabetic kidney disease;
LUSC	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg16576597	chr16:28551801	NUPR1	0.33	6.63	0.34	1.3100000000000001e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2274273	0.870	rs7158768	chr14:55763612	A/C	cg04306507	chr14:55594613	LGALS3	0.56	13.23	0.59	2.05e-32	Protein biomarker;
LUSC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-7.46	-0.38	7.4e-13	Mean platelet volume;
LUSC	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg09904177	chr6:26538194	HMGN4	-0.7	-6.85	-0.35	3.65e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg20283391	chr11:68216788	NA	-0.58	-8.19	-0.41	5.48e-15	Total body bone mineral density;
LUSC	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.69	12.78	0.57	1.04e-30	Metabolite levels;
LUSC	cis	rs3760982	0.585	rs4803659	chr19:44290235	C/T	cg11993925	chr19:44307056	LYPD5	0.35	7.57	0.38	3.76e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg16666935	chr13:31736119	HSPH1	-0.48	-5.99	-0.31	5.3300000000000004e-09	Neuroticism;
LUSC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg23711669	chr6:146136114	FBXO30	0.9	16.98	0.68	4.57e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg08392591	chr16:89556376	ANKRD11	0.47	7.23	0.37	3.39e-12	Multiple myeloma (IgH translocation);
LUSC	trans	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.22	-0.32	1.47e-9	Morning vs. evening chronotype;
LUSC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg12516959	chr21:47718080	NA	-0.37	-6.11	-0.32	2.85e-9	Testicular germ cell tumor;
LUSC	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg20487152	chr13:99095054	FARP1	-0.41	-6.96	-0.36	1.78e-11	Longevity;
LUSC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26314531	chr2:26401878	FAM59B	-0.68	-9.1	-0.45	8.35e-18	Gut microbiome composition (summer);
LUSC	cis	rs1113500	0.933	rs4517375	chr1:108638330	A/C	cg11967332	chr1:108735228	SLC25A24	-0.39	-6.01	-0.31	4.83e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg14552801	chr7:65878734	NA	-0.44	-6.18	-0.32	1.85e-9	Aortic root size;
LUSC	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg13010199	chr12:38710504	ALG10B	0.66	9.86	0.47	2.65e-20	Bladder cancer;
LUSC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08859206	chr1:53392774	SCP2	0.51	8.67	0.43	1.96e-16	Monocyte count;
LUSC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.57	-0.46	2.51e-19	Subjective well-being;
LUSC	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.46	-0.42	8.29e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-11.13	-0.52	1.13e-24	Chronic sinus infection;
LUSC	cis	rs9309473	0.519	rs13027816	chr2:73897691	C/T	cg20560298	chr2:73613845	ALMS1	0.47	7.01	0.36	1.3e-11	Metabolite levels;
LUSC	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.27	-0.41	3.16e-15	Schizophrenia;
LUSC	trans	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg06521331	chr12:34319734	NA	-0.4	-6.17	-0.32	2e-9	Bladder cancer;
LUSC	cis	rs7712401	0.601	rs390234	chr5:122331523	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.2	-0.45	4.07e-18	Mean platelet volume;
LUSC	cis	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg06521331	chr12:34319734	NA	-0.45	-7.38	-0.37	1.29e-12	Morning vs. evening chronotype;
LUSC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg18230493	chr5:56204884	C5orf35	0.73	11.56	0.53	3.12e-26	Initial pursuit acceleration;
LUSC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.15	0.41	7.33e-15	Homoarginine levels;
LUSC	cis	rs858239	0.601	rs3735228	chr7:23170427	T/G	cg23682824	chr7:23144976	KLHL7	0.39	5.67	0.3	3.11e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg16989719	chr2:238392110	NA	-0.52	-6.75	-0.35	6.41e-11	Prostate cancer;
LUSC	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.84	-0.35	3.68e-11	Response to antipsychotic treatment;
LUSC	cis	rs231513	0.954	rs231493	chr17:41976998	G/C	cg26893861	chr17:41843967	DUSP3	-0.51	-6.06	-0.31	3.74e-9	Cognitive function;
LUSC	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg08213375	chr14:104286397	PPP1R13B	0.53	10.51	0.5	1.69e-22	Schizophrenia;
LUSC	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg05393297	chr12:53359155	NA	-0.7	-10.51	-0.5	1.65e-22	Cancer (pleiotropy);
LUSC	cis	rs911119	0.955	rs6114201	chr20:23607231	T/A	cg16589663	chr20:23618590	CST3	0.57	6.86	0.35	3.3e-11	Chronic kidney disease;
LUSC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg08847533	chr14:75593920	NEK9	-0.8	-13.47	-0.59	2.46e-33	Height;
LUSC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg01579765	chr21:45077557	HSF2BP	-0.56	-11.65	-0.54	1.43e-26	Mean corpuscular volume;
LUSC	cis	rs57920188	0.535	rs10915664	chr1:4093700	G/A	cg20703997	chr1:4087676	NA	0.56	7.97	0.4	2.62e-14	Interleukin-17 levels;
LUSC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg22166914	chr1:53195759	ZYG11B	0.56	9.03	0.44	1.44e-17	Monocyte count;
LUSC	cis	rs4722585	0.533	rs757371	chr7:26199207	A/G	cg07876897	chr7:26191696	NFE2L3	0.45	6.64	0.34	1.3100000000000001e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUSC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg04455712	chr21:45112962	RRP1B	0.46	8.87	0.44	4.59e-17	Mean corpuscular volume;
LUSC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg06008330	chr7:65541103	ASL	0.42	6.55	0.34	2.19e-10	Aortic root size;
LUSC	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg11502198	chr6:26597334	ABT1	-0.5	-7.25	-0.37	2.91e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.56	-0.38	3.86e-13	Body mass index;
LUSC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg03188948	chr7:1209495	NA	0.66	6.93	0.35	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs6433857	0.536	rs1971134	chr2:181351532	G/A	cg23363182	chr2:181467187	NA	-0.44	-7.05	-0.36	1.04e-11	Body mass index;
LUSC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	11.78	0.54	5.23e-27	Ileal carcinoids;
LUSC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg05347473	chr6:146136440	FBXO30	0.58	10.14	0.49	3.06e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg01802117	chr1:53393560	SCP2	-0.42	-7.07	-0.36	9.26e-12	Monocyte count;
LUSC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.03	-0.44	1.39e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg06238570	chr21:40685208	BRWD1	0.48	7.35	0.37	1.53e-12	Cognitive function;
LUSC	cis	rs7659604	0.502	rs10212738	chr4:122675724	G/A	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.91	-0.31	8.47e-9	Type 2 diabetes;
LUSC	cis	rs897984	0.542	rs7294	chr16:31102321	A/G	cg02466173	chr16:30829666	NA	0.48	8.99	0.44	1.86e-17	Dementia with Lewy bodies;
LUSC	cis	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg20159608	chr7:32802032	NA	-0.71	-9.23	-0.45	3.21e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg18099408	chr3:52552593	STAB1	0.35	6.0	0.31	5.23e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg23942311	chr14:51606299	NA	0.49	11.44	0.53	8.76e-26	Cancer;
LUSC	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.57	-0.34	1.89e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg19418458	chr7:158789849	NA	-0.65	-11.12	-0.52	1.16e-24	Facial morphology (factor 20);
LUSC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.94	-14.98	-0.63	3.56e-39	Coronary artery disease;
LUSC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg24060327	chr5:131705240	SLC22A5	-0.66	-11.55	-0.53	3.41e-26	Breast cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06622468	chr19:10491460	TYK2	-0.47	-6.4	-0.33	5.36e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs909341	0.909	rs1151622	chr20:62365556	A/G	cg09650180	chr20:62225654	GMEB2	-0.45	-5.81	-0.3	1.48e-8	Atopic dermatitis;
LUSC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg13683864	chr3:40499215	RPL14	-1.2	-18.3	-0.71	2.6e-52	Renal cell carcinoma;
LUSC	cis	rs4706831	0.625	rs638056	chr6:80980808	G/A	cg08355045	chr6:80787529	NA	-0.4	-6.9	-0.35	2.66e-11	Joint mobility (Beighton score);
LUSC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg02023728	chr11:77925099	USP35	0.48	6.81	0.35	4.5e-11	Testicular germ cell tumor;
LUSC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg01802117	chr1:53393560	SCP2	-0.38	-6.21	-0.32	1.6e-9	Monocyte count;
LUSC	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06138422	chr12:133338013	ANKLE2	-0.48	-6.32	-0.33	8.33e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg03609598	chr5:56110824	MAP3K1	-0.42	-5.97	-0.31	5.96e-9	Initial pursuit acceleration;
LUSC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg23758822	chr17:41437982	NA	1.01	19.41	0.73	1.04e-56	Menopause (age at onset);
LUSC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg23982607	chr1:1823379	GNB1	-0.71	-14.64	-0.63	7.87e-38	Body mass index;
LUSC	cis	rs4629180	0.917	rs7560926	chr2:102125098	C/A	cg01388757	chr2:102091195	RFX8	0.48	7.64	0.39	2.39e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7605827	0.897	rs6431698	chr2:15540156	G/C	cg19274914	chr2:15703543	NA	0.46	8.96	0.44	2.28e-17	Educational attainment (years of education);
LUSC	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.46	-6.16	-0.32	2.11e-9	Schizophrenia;
LUSC	trans	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg07211511	chr3:129823064	LOC729375	-0.75	-10.4	-0.49	3.9e-22	Blood pressure (smoking interaction);
LUSC	cis	rs9831754	1.000	rs112170848	chr3:78359996	G/A	cg06138941	chr3:78371609	NA	-0.76	-10.05	-0.48	6.05e-21	Calcium levels;
LUSC	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg16482183	chr6:26056742	HIST1H1C	0.47	6.9	0.35	2.61e-11	Height;
LUSC	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg08048268	chr3:133502702	NA	-0.37	-7.04	-0.36	1.12e-11	Ankle injury;
LUSC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg05623727	chr3:50126028	RBM5	0.31	5.81	0.3	1.43e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.63	9.31	0.45	1.71e-18	Platelet distribution width;
LUSC	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.46	-6.23	-0.32	1.4e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.82	0.47	3.55e-20	Lung cancer;
LUSC	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg17173187	chr15:85201210	NMB	0.53	9.95	0.48	1.3e-20	Schizophrenia;
LUSC	cis	rs9323205	0.871	rs8008599	chr14:51670057	A/G	cg23942311	chr14:51606299	NA	0.41	8.06	0.4	1.39e-14	Cancer;
LUSC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg06238570	chr21:40685208	BRWD1	0.49	7.54	0.38	4.47e-13	Cognitive function;
LUSC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-6.11	-0.32	2.72e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08677398	chr8:58056175	NA	0.52	6.08	0.32	3.29e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7759001	0.857	rs10807021	chr6:27356925	T/G	cg18711553	chr6:27366782	ZNF391	0.39	5.78	0.3	1.73e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.18	30.04	0.85	5.97e-97	Testicular germ cell tumor;
LUSC	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg08017756	chr2:100939284	LONRF2	-0.45	-8.51	-0.42	6.11e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14442939	chr10:27389572	ANKRD26	0.9	9.51	0.46	3.81e-19	Breast cancer;
LUSC	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg08330031	chr10:104623503	C10orf32	0.31	5.67	0.3	3.04e-8	Arsenic metabolism;
LUSC	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.82	-0.3	1.37e-8	IgG glycosylation;
LUSC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg24209194	chr3:40518798	ZNF619	0.44	6.07	0.31	3.56e-9	Renal cell carcinoma;
LUSC	cis	rs7180079	1.000	rs55700118	chr15:64529455	G/T	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs9677476	0.908	rs7598478	chr2:232115887	C/T	cg07929768	chr2:232055508	NA	0.31	5.78	0.3	1.7e-8	Food antigen IgG levels;
LUSC	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.77	-10.87	-0.51	8.9e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4812048	0.793	rs7266693	chr20:57593158	T/C	cg14073986	chr20:57617431	SLMO2	0.67	6.45	0.33	3.94e-10	Mean platelet volume;
LUSC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg21856205	chr7:94953877	PON1	-0.35	-5.73	-0.3	2.26e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.84	-0.35	3.85e-11	Recombination measurement;
LUSC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg09034736	chr1:150693464	HORMAD1	0.44	6.16	0.32	2.05e-9	Melanoma;
LUSC	cis	rs7561273	0.609	rs6545285	chr2:24340029	T/C	cg06627628	chr2:24431161	ITSN2	-0.51	-6.84	-0.35	3.83e-11	Quantitative traits;
LUSC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	11.79	0.54	4.55e-27	Cognitive test performance;
LUSC	cis	rs7178572	0.568	rs12916731	chr15:77507021	C/T	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	cis	rs68170813	0.652	rs8180747	chr7:107106308	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-8.5	-0.42	6.49e-16	Coronary artery disease;
LUSC	cis	rs75804782	0.641	rs56134361	chr2:239318905	A/G	cg18131467	chr2:239335373	ASB1	-0.74	-6.64	-0.34	1.28e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.16	0.45	5.34e-18	Prudent dietary pattern;
LUSC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg09455208	chr3:40491958	NA	0.58	10.25	0.49	1.31e-21	Renal cell carcinoma;
LUSC	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-8.32	-0.41	2.34e-15	Systolic blood pressure;
LUSC	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg25214090	chr10:38739885	LOC399744	0.53	7.59	0.38	3.3e-13	Corneal astigmatism;
LUSC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg16447950	chr5:562315	NA	-0.59	-7.01	-0.36	1.29e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg13683864	chr3:40499215	RPL14	-0.97	-16.59	-0.67	1.71e-45	Renal cell carcinoma;
LUSC	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg22571038	chr17:48585470	MYCBPAP	-0.48	-6.19	-0.32	1.78e-9	Visceral fat;
LUSC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01272058	chr19:40926777	NA	0.47	6.99	0.36	1.5e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg09904177	chr6:26538194	HMGN4	-0.39	-5.69	-0.3	2.76e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg24342717	chr2:85555507	TGOLN2	-0.74	-11.93	-0.55	1.44e-27	Ear protrusion;
LUSC	cis	rs2692947	0.759	rs11687113	chr2:96658588	A/G	cg22654517	chr2:96458247	NA	0.31	6.01	0.31	4.89e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg05234568	chr11:5960015	NA	-0.61	-8.56	-0.42	4.04e-16	DNA methylation (variation);
LUSC	trans	rs72674100	1.000	rs4075858	chr4:97991815	A/G	cg16405019	chr1:18959625	PAX7	0.65	6.78	0.35	5.33e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg05360949	chr19:41903737	BCKDHA;EXOSC5	0.41	5.66	0.3	3.22e-8	Height;
LUSC	cis	rs713477	0.967	rs10150596	chr14:55916167	A/G	cg13175173	chr14:55914753	NA	0.3	6.42	0.33	4.74e-10	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23593958	chr10:35415966	CREM	-0.49	-6.11	-0.32	2.72e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg08085267	chr17:45401833	C17orf57	-0.46	-6.69	-0.34	9.41e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.39	0.46	9.37e-19	Bipolar disorder;
LUSC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.75	-0.51	2.45e-23	Chronic sinus infection;
LUSC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg12311346	chr5:56204834	C5orf35	0.56	8.62	0.43	2.71e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs400736	0.576	rs10864328	chr1:8164456	G/C	cg25007680	chr1:8021821	PARK7	-0.41	-6.15	-0.32	2.27e-9	Response to antidepressants and depression;
LUSC	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg09201001	chr11:18656081	SPTY2D1	0.92	15.2	0.64	4.91e-40	Breast cancer;
LUSC	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-8.19	-0.41	5.43e-15	Morning vs. evening chronotype;
LUSC	cis	rs7210086	0.768	rs4072716	chr17:70640933	T/C	cg04206342	chr17:70636940	NA	-0.35	-5.82	-0.3	1.4e-8	Ulcerative colitis;
LUSC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg11189052	chr15:85197271	WDR73	-0.63	-9.89	-0.48	2.15e-20	Schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15942720	chr14:51706980	TMX1	-0.4	-5.99	-0.31	5.53e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg01657329	chr11:68192670	LRP5	-0.4	-5.76	-0.3	1.92e-8	Total body bone mineral density;
LUSC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg25019033	chr10:957182	NA	-0.5	-6.2	-0.32	1.63e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs7923452	0.688	rs117895480	chr10:30788921	A/G	cg18806716	chr10:30721971	MAP3K8	0.57	6.27	0.32	1.14e-9	Itch intensity from mosquito bite;
LUSC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.38	6.18	0.32	1.9e-9	Electroencephalogram traits;
LUSC	cis	rs1788820	0.917	rs1788762	chr18:21132571	G/C	cg14672496	chr18:21087552	C18orf8	0.4	6.53	0.34	2.4e-10	Body mass index;
LUSC	trans	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.86	-0.4	5.34e-14	Morning vs. evening chronotype;
LUSC	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.82	-10.2	-0.49	1.94e-21	Body mass index;
LUSC	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg09455208	chr3:40491958	NA	0.45	8.07	0.4	1.25e-14	Renal cell carcinoma;
LUSC	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg25457927	chr22:38595422	NA	-0.4	-7.86	-0.39	5.5e-14	Cutaneous nevi;
LUSC	cis	rs4631830	0.863	rs2926494	chr10:51517356	T/C	cg10326726	chr10:51549505	MSMB	-0.35	-5.81	-0.3	1.42e-8	Prostate-specific antigen levels;
LUSC	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg20302533	chr7:39170763	POU6F2	0.51	7.91	0.4	3.72e-14	IgG glycosylation;
LUSC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg05805236	chr11:65401703	PCNXL3	0.37	5.89	0.31	9.23e-9	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	trans	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.6	0.85	2.14e-95	Chronic sinus infection;
LUSC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18099408	chr3:52552593	STAB1	0.41	7.1	0.36	7.57e-12	Bipolar disorder;
LUSC	cis	rs12476592	0.602	rs10469945	chr2:63816776	T/C	cg10828910	chr2:63850056	LOC388955	0.5	5.81	0.3	1.49e-8	Childhood ear infection;
LUSC	cis	rs1009647	0.645	rs17742719	chr14:55855596	A/C	cg04306507	chr14:55594613	LGALS3	-0.4	-6.28	-0.32	1.08e-9	Testicular germ cell tumor;
LUSC	cis	rs57920188	0.585	rs12117500	chr1:4072315	G/A	cg20703997	chr1:4087676	NA	0.6	8.35	0.42	1.8e-15	Interleukin-17 levels;
LUSC	cis	rs10203711	0.933	rs11695877	chr2:239585797	T/A	cg14580085	chr2:239553406	NA	0.39	6.47	0.33	3.56e-10	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs72674100	1.000	rs28483048	chr4:97990804	C/A	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg13175981	chr1:150552382	MCL1	0.47	6.49	0.33	3.14e-10	Tonsillectomy;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22470056	chr3:49947811	MON1A	-0.35	-6.05	-0.31	3.89e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg05347473	chr6:146136440	FBXO30	0.57	10.06	0.48	5.62e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg07936489	chr17:37558343	FBXL20	0.72	9.96	0.48	1.28e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs73206853	0.563	rs73194050	chr12:111200634	T/C	cg12870014	chr12:110450643	ANKRD13A	0.65	6.92	0.35	2.32e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs11088226	0.681	rs8131384	chr21:33944127	C/T	cg09050820	chr6:167586206	TCP10L2	0.72	9.27	0.45	2.38e-18	Gastritis;
LUSC	trans	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg10756647	chr7:56101905	PSPH	0.75	7.66	0.39	2.08e-13	Diabetic kidney disease;
LUSC	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs34779708	0.931	rs12261654	chr10:35322024	G/A	cg03585969	chr10:35415529	CREM	0.61	8.82	0.43	6.24e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4964805	0.954	rs11111785	chr12:104189056	A/G	cg02344784	chr12:104178138	NT5DC3	0.45	7.15	0.36	5.34e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs2637266	1.000	rs2130799	chr10:78322922	C/T	cg18941641	chr10:78392320	NA	0.36	6.51	0.34	2.68e-10	Pulmonary function;
LUSC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg00990874	chr7:1149470	C7orf50	-0.54	-6.94	-0.36	2.04e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg26513180	chr16:89883248	FANCA	0.79	6.38	0.33	5.88e-10	Skin colour saturation;
LUSC	cis	rs12367572	0.620	rs1857924	chr12:45344212	T/G	cg04608330	chr12:45269318	NELL2	-0.39	-6.01	-0.31	4.98e-9	Gut microbiome composition (summer);
LUSC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg05084668	chr3:125655381	ALG1L	-0.51	-7.12	-0.36	6.65e-12	Blood pressure (smoking interaction);
LUSC	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg01028140	chr2:1542097	TPO	-0.6	-8.03	-0.4	1.64e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg22638593	chr5:131593259	PDLIM4	0.41	6.06	0.31	3.6e-9	Breast cancer;
LUSC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.67	-11.02	-0.52	2.72e-24	Cognitive function;
LUSC	cis	rs62408225	1.000	rs62408227	chr6:90965171	A/G	cg06866423	chr6:90926672	BACH2	0.39	5.68	0.3	2.9e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.63	-0.43	2.6e-16	Response to antipsychotic treatment;
LUSC	cis	rs10761482	0.861	rs7089563	chr10:62109898	C/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.05	-0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs7584330	0.554	rs1343768	chr2:238444881	G/A	cg14458575	chr2:238380390	NA	0.43	5.68	0.3	3e-8	Prostate cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24975666	chr17:80416629	NARF	-0.53	-7.03	-0.36	1.2e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-8.92	-0.44	3.04e-17	Obesity-related traits;
LUSC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.45	-7.12	-0.36	6.52e-12	Alzheimer's disease (late onset);
LUSC	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg06636551	chr8:101224915	SPAG1	-0.4	-7.41	-0.38	1.03e-12	Atrioventricular conduction;
LUSC	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg24375607	chr4:120327624	NA	0.79	11.98	0.55	9.22e-28	Corneal astigmatism;
LUSC	cis	rs6845621	0.901	rs1452554	chr4:18920164	A/G	cg12196642	chr4:18937545	NA	0.38	7.06	0.36	9.58e-12	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg00945038	chr17:61921165	SMARCD2	0.52	8.73	0.43	1.23e-16	Prudent dietary pattern;
LUSC	cis	rs4478858	0.684	rs10798837	chr1:31719340	C/T	cg00250761	chr1:31883323	NA	-0.33	-8.03	-0.4	1.71e-14	Alcohol dependence;
LUSC	cis	rs9815354	0.638	rs17284933	chr3:42029835	T/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg06197492	chr11:2016605	H19	0.43	7.37	0.37	1.37e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg27661571	chr11:113659931	NA	0.47	5.95	0.31	6.86e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg27068330	chr11:65405492	SIPA1	-0.75	-10.33	-0.49	7.02e-22	Acne (severe);
LUSC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg11766577	chr21:47581405	C21orf56	-0.45	-6.83	-0.35	4.12e-11	Testicular germ cell tumor;
LUSC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.45	-0.46	6.09e-19	Electroencephalogram traits;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00092273	chr8:124780287	FAM91A1	-0.52	-6.98	-0.36	1.6e-11	Hepatitis;
LUSC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg01097406	chr16:89675127	NA	-0.34	-6.7	-0.34	8.66e-11	Vitiligo;
LUSC	cis	rs13385	0.769	rs13163983	chr5:139622572	A/C	cg26211634	chr5:139558579	C5orf32	0.46	7.04	0.36	1.09e-11	Atrial fibrillation;
LUSC	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-10.42	-0.5	3.44e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg23950597	chr19:37808831	NA	-0.64	-7.74	-0.39	1.17e-13	Coronary artery calcification;
LUSC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg21724239	chr8:58056113	NA	0.8	8.32	0.41	2.34e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs911119	0.866	rs4815223	chr20:23577112	C/A	cg16589663	chr20:23618590	CST3	0.6	7.1	0.36	7.4e-12	Chronic kidney disease;
LUSC	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg24851651	chr11:66362959	CCS	-0.38	-6.08	-0.32	3.34e-9	Educational attainment (years of education);
LUSC	cis	rs4474465	0.688	rs4945300	chr11:78282632	T/C	cg27205649	chr11:78285834	NARS2	0.58	7.18	0.37	4.53e-12	Alzheimer's disease (survival time);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19372772	chr2:264904	ACP1;SH3YL1	0.54	7.4	0.38	1.1e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.82	13.35	0.59	7.11e-33	Testicular germ cell tumor;
LUSC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.46	0.33	3.71e-10	Alzheimer's disease (late onset);
LUSC	cis	rs735539	0.521	rs2585895	chr13:21396967	A/T	cg04906043	chr13:21280425	IL17D	-0.39	-5.68	-0.3	2.89e-8	Dental caries;
LUSC	trans	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg07393940	chr7:158741817	NA	-0.37	-6.7	-0.34	8.81e-11	Life satisfaction;
LUSC	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg00852783	chr1:26633632	UBXN11	-0.49	-5.8	-0.3	1.52e-8	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs35892873	0.703	rs7615776	chr3:126060617	G/A	cg15490784	chr3:126061950	KLF15	0.3	5.73	0.3	2.19e-8	Male-pattern baldness;
LUSC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg10253484	chr15:75165896	SCAMP2	-0.46	-6.55	-0.34	2.21e-10	Breast cancer;
LUSC	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.75	8.15	0.41	7.55e-15	Yeast infection;
LUSC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.62	-0.34	1.46e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03038380	chr15:78591716	WDR61	0.44	6.0	0.31	5.13e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg26335602	chr6:28129616	ZNF389	0.43	5.75	0.3	1.98e-8	Depression;
LUSC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.92	-0.4	3.52e-14	Joint mobility (Beighton score);
LUSC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.86	0.31	1.13e-8	Tonsillectomy;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg09033563	chr22:24373618	LOC391322	-0.64	-9.7	-0.47	9.08e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9300255	0.679	rs10846507	chr12:123786492	G/T	cg13010344	chr12:123464640	ARL6IP4	-0.51	-6.59	-0.34	1.69e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2274273	0.624	rs8003279	chr14:55864130	A/G	cg04306507	chr14:55594613	LGALS3	0.46	8.53	0.42	5e-16	Protein biomarker;
LUSC	cis	rs4363385	0.510	rs6677674	chr1:153037601	A/G	cg00922841	chr1:152955080	SPRR1A	-0.35	-5.9	-0.31	9.08e-9	Inflammatory skin disease;
LUSC	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.22	-0.32	1.48e-9	Response to antipsychotic treatment;
LUSC	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg00540400	chr15:79124168	NA	0.45	8.06	0.4	1.4e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7188861	0.724	rs1794019	chr16:11379775	T/C	cg00044050	chr16:11439710	C16orf75	0.59	6.56	0.34	2.01e-10	HDL cholesterol;
LUSC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	13.63	0.6	5.98e-34	Chronic sinus infection;
LUSC	cis	rs1950626	0.716	rs34572720	chr14:101447150	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.76	0.39	1.03e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg24112000	chr20:60950667	NA	0.36	6.82	0.35	4.3e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg06008330	chr7:65541103	ASL	0.4	6.17	0.32	1.96e-9	Aortic root size;
LUSC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg09365446	chr1:150670422	GOLPH3L	0.46	7.02	0.36	1.24e-11	Tonsillectomy;
LUSC	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.1	-0.32	2.87e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg00277334	chr10:82204260	NA	-0.49	-7.06	-0.36	9.93e-12	Post bronchodilator FEV1;
LUSC	cis	rs1564271	1.000	rs1197422	chr10:27012078	A/G	cg13837822	chr10:26931731	LOC731789	0.45	8.89	0.44	3.97e-17	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUSC	cis	rs62400317	0.859	rs62400313	chr6:45256366	A/T	cg20913747	chr6:44695427	NA	-0.46	-7.45	-0.38	8.27e-13	Total body bone mineral density;
LUSC	cis	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs9633740	0.842	rs1870140	chr10:82246749	A/G	cg01528321	chr10:82214614	TSPAN14	1.07	10.56	0.5	1.1e-22	Post bronchodilator FEV1;
LUSC	cis	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg21775007	chr8:11205619	TDH	0.45	6.34	0.33	7.26e-10	Neuroticism;
LUSC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.56	-8.79	-0.43	8.01e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-10.34	-0.49	6.22e-22	Monocyte percentage of white cells;
LUSC	cis	rs925255	0.901	rs906805	chr2:28604879	A/G	cg01273330	chr2:28605224	NA	-0.42	-6.94	-0.36	2e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs41271951	0.512	rs79122717	chr1:151093526	G/A	cg11822372	chr1:151115635	SEMA6C	-0.78	-7.18	-0.37	4.51e-12	Blood protein levels;
LUSC	cis	rs612683	0.602	rs2030048	chr1:101006577	C/T	cg09408571	chr1:101003634	GPR88	-0.3	-5.81	-0.3	1.45e-8	Breast cancer;
LUSC	trans	rs2736345	0.788	rs998683	chr8:11353000	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.85	-0.35	3.62e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LUSC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.49	6.04	0.31	4.1e-9	Renal function-related traits (BUN);
LUSC	cis	rs4474465	1.000	rs10899509	chr11:78170811	C/T	cg27205649	chr11:78285834	NARS2	-0.5	-5.87	-0.31	1.04e-8	Alzheimer's disease (survival time);
LUSC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg05347473	chr6:146136440	FBXO30	0.54	9.41	0.46	8.08e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.35	0.33	6.88e-10	Menopause (age at onset);
LUSC	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.29	0.67	2.62e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.82	-15.9	-0.66	8.57e-43	Inflammatory bowel disease;
LUSC	cis	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.8	-0.35	4.96e-11	Morning vs. evening chronotype;
LUSC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg24209194	chr3:40518798	ZNF619	0.45	6.14	0.32	2.32e-9	Renal cell carcinoma;
LUSC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.54	-9.42	-0.46	7.85e-19	Homoarginine levels;
LUSC	cis	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg06521331	chr12:34319734	NA	-0.46	-7.33	-0.37	1.73e-12	Morning vs. evening chronotype;
LUSC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg12257692	chr3:49977190	RBM6	0.24	6.73	0.35	7.19e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.78	-12.55	-0.57	7.46e-30	Aortic root size;
LUSC	trans	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.33	-0.33	7.77e-10	Triglycerides;
LUSC	cis	rs701145	0.537	rs357479	chr3:153891489	A/G	cg17054900	chr3:154042577	DHX36	0.71	7.3	0.37	2.16e-12	Coronary artery disease;
LUSC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg00042356	chr1:8021962	PARK7	0.81	8.95	0.44	2.45e-17	Inflammatory bowel disease;
LUSC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg16414030	chr3:133502952	NA	-0.42	-6.47	-0.33	3.49e-10	Iron status biomarkers;
LUSC	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg06636001	chr8:8085503	FLJ10661	0.55	8.24	0.41	4.03e-15	Myopia (pathological);
LUSC	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.13	-0.32	2.47e-9	Resting heart rate;
LUSC	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg03929089	chr4:120376271	NA	0.59	6.44	0.33	4.04e-10	Axial length;
LUSC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg01973587	chr1:228161476	NA	0.45	8.09	0.4	1.15e-14	Diastolic blood pressure;
LUSC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.87	-12.64	-0.57	3.45e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg01475377	chr6:109611718	NA	-0.44	-8.07	-0.4	1.28e-14	Reticulocyte fraction of red cells;
LUSC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg12963246	chr6:28129442	ZNF389	0.43	6.15	0.32	2.26e-9	Depression;
LUSC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18854424	chr1:2615690	NA	-0.49	-9.78	-0.47	5.1e-20	Ulcerative colitis;
LUSC	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg02175503	chr12:58329896	NA	-0.77	-13.81	-0.6	1.28e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.82	-0.35	4.38e-11	Systolic blood pressure;
LUSC	cis	rs6681460	0.800	rs481681	chr1:67194378	G/A	cg02459107	chr1:67143332	SGIP1	-0.47	-8.61	-0.43	2.98e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs12618769	0.543	rs2278211	chr2:99149946	G/A	cg10123293	chr2:99228465	UNC50	0.46	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg21573476	chr21:45109991	RRP1B	-0.38	-6.07	-0.32	3.48e-9	Mean corpuscular volume;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14086791	chr11:69489770	ORAOV1	0.44	5.98	0.31	5.69e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg08847533	chr14:75593920	NEK9	-0.79	-13.55	-0.6	1.2e-33	Height;
LUSC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.45	-8.27	-0.41	3.14e-15	Eosinophil percentage of white cells;
LUSC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg09034736	chr1:150693464	HORMAD1	0.46	6.77	0.35	5.7e-11	Melanoma;
LUSC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.63	-5.9	-0.31	8.74e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg06784218	chr1:46089804	CCDC17	-0.32	-6.16	-0.32	2.04e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs11645898	0.687	rs56129242	chr16:72098260	C/G	cg14768367	chr16:72042858	DHODH	-0.53	-6.15	-0.32	2.16e-9	Blood protein levels;
LUSC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg03522245	chr20:25566470	NINL	0.36	5.85	0.3	1.17e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.13	-0.45	6.87e-18	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07677032	chr17:61819896	STRADA	0.53	8.93	0.44	2.87e-17	Prudent dietary pattern;
LUSC	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18252515	chr7:66147081	NA	-0.54	-7.52	-0.38	4.96e-13	Corneal structure;
LUSC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.4	-6.41	-0.33	5.01e-10	Systemic lupus erythematosus;
LUSC	cis	rs7215564	0.908	rs2316060	chr17:78663728	T/C	cg23238734	chr17:78661607	RPTOR	0.47	6.1	0.32	2.98e-9	Myopia (pathological);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg06370133	chr2:113914844	NA	0.48	6.23	0.32	1.39e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg00105475	chr2:10696890	NA	0.38	6.27	0.32	1.11e-9	Prostate cancer;
LUSC	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg05855489	chr10:104503620	C10orf26	0.58	9.42	0.46	7.51e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	5.81	0.3	1.49e-8	Breast cancer;
LUSC	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg27411982	chr8:10470053	RP1L1	-0.45	-6.71	-0.34	8.52e-11	Morning vs. evening chronotype;
LUSC	trans	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04565464	chr8:145669602	NFKBIL2	0.4	6.47	0.33	3.41e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.55	-5.96	-0.31	6.41e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg22903657	chr4:1355424	KIAA1530	-0.48	-8.02	-0.4	1.77e-14	Obesity-related traits;
LUSC	trans	rs9650657	0.707	rs2005309	chr8:10652170	T/C	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.37	-0.33	6.15e-10	Neuroticism;
LUSC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg19539972	chr4:7069911	GRPEL1	-0.74	-9.12	-0.45	7.21e-18	Monocyte percentage of white cells;
LUSC	cis	rs1983170	0.808	rs2219393	chr1:92016577	C/T	cg25838465	chr1:92012736	NA	0.43	6.07	0.32	3.41e-9	Eosinophil percentage of white cells;
LUSC	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.63	9.65	0.47	1.34e-19	Corneal astigmatism;
LUSC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.36e-22	Alzheimer's disease (late onset);
LUSC	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	6.06	0.31	3.73e-9	Obesity;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25733915	chr17:40829168	PLEKHH3	0.47	6.53	0.34	2.47e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg20703242	chr1:230279135	GALNT2	0.52	8.2	0.41	5.22e-15	Coronary artery disease;
LUSC	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg21466736	chr12:48725269	NA	-0.33	-5.76	-0.3	1.92e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs7607369	0.536	rs6436091	chr2:219669141	T/C	cg02176678	chr2:219576539	TTLL4	-0.52	-9.15	-0.45	5.72e-18	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg06784218	chr1:46089804	CCDC17	0.47	9.27	0.45	2.3e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-0.96	-11.43	-0.53	9.26e-26	Corneal structure;
LUSC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg19748678	chr4:122722346	EXOSC9	0.48	7.49	0.38	6.4e-13	Type 2 diabetes;
LUSC	cis	rs12980942	0.810	rs3745295	chr19:41785282	T/G	cg25627403	chr19:41769009	HNRNPUL1	0.59	6.49	0.33	3.13e-10	Coronary artery disease;
LUSC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg05347473	chr6:146136440	FBXO30	-0.45	-7.88	-0.4	4.55e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg14227996	chr4:17616232	MED28	0.75	7.56	0.38	4.01e-13	Opioid sensitivity;
LUSC	cis	rs7107174	1.000	rs2511185	chr11:77982496	C/A	cg02023728	chr11:77925099	USP35	0.45	6.83	0.35	4.13e-11	Testicular germ cell tumor;
LUSC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.91	-0.31	8.42e-9	Total body bone mineral density;
LUSC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-11.92	-0.55	1.5e-27	Mean corpuscular volume;
LUSC	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg07169764	chr2:136633963	MCM6	1.13	18.3	0.71	2.67e-52	Corneal structure;
LUSC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.8	11.48	0.53	6.05e-26	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.77	-0.63	2.46e-38	Schizophrenia;
LUSC	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.88	-0.31	9.79e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg26659404	chr1:25747437	RHCE	0.28	5.94	0.31	7.19e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg23625390	chr15:77176239	SCAPER	-0.66	-10.08	-0.48	4.7e-21	Blood metabolite levels;
LUSC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg26408565	chr15:76604113	ETFA	-0.49	-7.87	-0.4	4.85e-14	Blood metabolite levels;
LUSC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg21724239	chr8:58056113	NA	0.56	6.86	0.35	3.37e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	10.57	0.5	9.9e-23	Blood protein levels;
LUSC	cis	rs7289126	1.000	rs5995558	chr22:38647639	A/G	cg25457927	chr22:38595422	NA	-0.29	-5.68	-0.3	2.98e-8	Mammographic density (dense area);Percent mammographic density;
LUSC	cis	rs9513627	1.000	rs2390279	chr13:100208705	A/G	cg25919922	chr13:100150906	NA	-0.73	-6.26	-0.32	1.17e-9	Obesity-related traits;
LUSC	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	1.01	13.85	0.6	8.57e-35	Uric acid levels;
LUSC	trans	rs7721647	0.520	rs13355661	chr5:90811629	C/A	cg15140562	chr3:48659193	TMEM89	-0.41	-6.03	-0.31	4.24e-9	Breast cancer;
LUSC	cis	rs7804356	1.000	rs73065517	chr7:26830555	T/C	cg03456212	chr7:26904342	SKAP2	-0.55	-6.52	-0.34	2.57e-10	Type 1 diabetes;
LUSC	trans	rs6828577	0.560	rs2631147	chr4:119455854	C/T	cg26518628	chr1:97050305	NA	0.48	7.21	0.37	3.75e-12	Perioperative myocardial infarction in coronary artery bypass surgery;
LUSC	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg04310649	chr10:35416472	CREM	0.41	6.48	0.33	3.2e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg24375607	chr4:120327624	NA	0.76	12.17	0.55	1.85e-28	Corneal astigmatism;
LUSC	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg08755490	chr11:65554678	OVOL1	0.41	5.91	0.31	8.32e-9	Acne (severe);
LUSC	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg17507749	chr15:85114479	UBE2QP1	0.65	8.15	0.41	7.64e-15	Schizophrenia;
LUSC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg00701064	chr4:6280414	WFS1	0.5	10.42	0.5	3.27e-22	Cisplatin-induced ototoxicity;
LUSC	cis	rs4363385	0.553	rs41263664	chr1:152974063	G/A	cg25856811	chr1:152973957	SPRR3	-0.36	-6.04	-0.31	4.02e-9	Inflammatory skin disease;
LUSC	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg16898833	chr6:26189333	HIST1H4D	0.64	5.92	0.31	8e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	7.55	0.38	4.17e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	0.94	17.57	0.69	2.06e-49	Headache;
LUSC	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg05738196	chr6:26577821	NA	-0.54	-5.81	-0.3	1.48e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1044826	1.000	rs9289578	chr3:139200514	G/A	cg00490450	chr3:139108681	COPB2	0.51	6.79	0.35	5.07e-11	Obesity-related traits;
LUSC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.74	-12.61	-0.57	4.48e-30	Height;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05160915	chr11:111749944	FDXACB1;C11orf1	-0.47	-6.13	-0.32	2.42e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg16339924	chr4:17578868	LAP3	0.51	7.6	0.38	3.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg15133208	chr4:90757351	SNCA	0.52	8.02	0.4	1.81e-14	Neuroticism;
LUSC	cis	rs35883536	0.626	rs11799819	chr1:101049382	G/A	cg06223162	chr1:101003688	GPR88	-0.47	-8.68	-0.43	1.78e-16	Monocyte count;
LUSC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg02038168	chr22:39784481	NA	-0.5	-8.21	-0.41	4.96e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg26769984	chr7:1090371	C7orf50	0.7	10.64	0.5	5.85e-23	Bronchopulmonary dysplasia;
LUSC	cis	rs11608355	1.000	rs10850134	chr12:109861454	G/C	cg19025524	chr12:109796872	NA	-0.38	-5.96	-0.31	6.58e-9	Neuroticism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17072271	chr17:73400970	GRB2	-0.45	-6.78	-0.35	5.5e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg01097406	chr16:89675127	NA	0.46	9.36	0.46	1.2e-18	Vitiligo;
LUSC	cis	rs1609391	0.561	rs9817967	chr3:136629490	G/A	cg15507776	chr3:136538369	TMEM22	0.51	8.36	0.42	1.71e-15	Neuroticism;
LUSC	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg18002602	chr11:66138449	SLC29A2	0.45	7.98	0.4	2.43e-14	Educational attainment (years of education);
LUSC	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.01	-0.4	1.89e-14	Glomerular filtration rate;
LUSC	cis	rs4766646	0.542	rs4766635	chr12:110276914	A/G	cg10794374	chr12:110278745	NA	0.27	5.85	0.3	1.15e-8	Metabolite levels (MHPG);
LUSC	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg07701084	chr6:150067640	NUP43	0.47	7.03	0.36	1.18e-11	Lung cancer;
LUSC	trans	rs7916697	0.593	rs10762198	chr10:70023053	A/G	cg04882175	chr6:131122610	NA	0.46	6.02	0.31	4.47e-9	Optic disc area;
LUSC	cis	rs6882046	0.513	rs2431391	chr5:88046590	C/T	cg22951263	chr5:87985283	NA	-0.47	-7.72	-0.39	1.39e-13	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LUSC	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg26597838	chr10:835615	NA	0.98	13.76	0.6	1.85e-34	Eosinophil percentage of granulocytes;
LUSC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg19318889	chr4:1322082	MAEA	0.48	7.83	0.39	6.66e-14	Obesity-related traits;
LUSC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg05802129	chr4:122689817	NA	-0.5	-8.12	-0.41	9.17e-15	Type 2 diabetes;
LUSC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	8.99	0.44	1.88e-17	Motion sickness;
LUSC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08859206	chr1:53392774	SCP2	0.51	8.74	0.43	1.14e-16	Monocyte count;
LUSC	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg20608306	chr11:116969690	SIK3	0.35	6.52	0.34	2.61e-10	Blood protein levels;
LUSC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg27535305	chr1:53392650	SCP2	0.36	6.73	0.35	7.3e-11	Monocyte count;
LUSC	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.57	-11.78	-0.54	5.12e-27	Sense of smell;
LUSC	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg21064579	chr19:49206444	FUT2	0.46	8.65	0.43	2.24e-16	Dietary macronutrient intake;
LUSC	cis	rs2425143	1.000	rs8115150	chr20:34397189	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.93	-0.31	7.7e-9	Blood protein levels;
LUSC	cis	rs1878931	0.615	rs6501171	chr16:3402610	T/A	cg00484396	chr16:3507460	NAT15	-0.35	-5.82	-0.3	1.36e-8	Body mass index (adult);
LUSC	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg11502198	chr6:26597334	ABT1	0.69	11.3	0.53	2.71e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg23711669	chr6:146136114	FBXO30	-0.82	-14.69	-0.63	5.14e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.71	-0.34	8.54e-11	Lung cancer;
LUSC	cis	rs4953318	1.000	rs4953318	chr2:46355051	A/C	cg12428440	chr2:46370979	PRKCE	0.38	6.73	0.35	7.36e-11	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.04	0.31	4.13e-9	Menopause (age at onset);
LUSC	cis	rs7712401	0.601	rs30069	chr5:122293026	A/G	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg09875802	chr5:133340681	VDAC1	0.47	6.27	0.32	1.12e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07080220	chr10:102295463	HIF1AN	0.7	9.42	0.46	7.7e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7264396	0.887	rs224363	chr20:34062710	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-5.89	-0.31	9.54e-9	Total cholesterol levels;
LUSC	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.7e-32	Blood protein levels;
LUSC	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg05973401	chr12:123451056	ABCB9	0.5	6.68	0.34	1.02e-10	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg05340658	chr4:99064831	C4orf37	-0.44	-6.91	-0.35	2.44e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg27124370	chr19:33622961	WDR88	0.53	6.8	0.35	4.84e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg02569458	chr12:86230093	RASSF9	0.5	8.24	0.41	4.04e-15	Major depressive disorder;
LUSC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18357526	chr6:26021779	HIST1H4A	0.4	6.36	0.33	6.69e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg01741372	chr11:783889	NA	0.45	7.99	0.4	2.21e-14	Breast cancer;
LUSC	cis	rs7000551	0.751	rs2443494	chr8:22372262	C/G	cg12081754	chr8:22256438	SLC39A14	0.42	6.27	0.32	1.11e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs16974263	1.000	rs16974263	chr19:40913539	A/G	cg14150973	chr19:40950431	SERTAD3	-0.7	-7.02	-0.36	1.23e-11	Otitis media;Otitis media (chronic);Otitis media (recurrent);
LUSC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.61	-9.2	-0.45	3.87e-18	Blood protein levels;
LUSC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg00631329	chr6:26305371	NA	0.33	5.74	0.3	2.13e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg08847533	chr14:75593920	NEK9	-0.54	-8.08	-0.4	1.23e-14	Neuroticism;
LUSC	trans	rs9914544	0.545	rs8067882	chr17:18807131	A/G	cg04702396	chr17:15466718	FAM18B2	0.45	6.95	0.36	1.87e-11	Educational attainment (years of education);
LUSC	cis	rs17253792	0.822	rs10137885	chr14:56173590	A/G	cg01858014	chr14:56050164	KTN1	-0.74	-6.34	-0.33	7.62e-10	Putamen volume;
LUSC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg13628971	chr7:2884303	GNA12	0.43	6.49	0.33	3.17e-10	Height;
LUSC	cis	rs11166629	1.000	rs6577713	chr8:135645592	C/A	cg21672855	chr8:135614777	ZFAT	0.35	5.66	0.3	3.22e-8	Smoking quantity;
LUSC	cis	rs9549260	0.755	rs9566553	chr13:41174231	A/G	cg21288729	chr13:41239152	FOXO1	0.58	8.84	0.44	5.5e-17	Red blood cell count;
LUSC	cis	rs8016982	0.963	rs2099108	chr14:81675420	C/G	cg01989461	chr14:81687754	GTF2A1	0.57	8.54	0.42	4.86e-16	Schizophrenia;
LUSC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg27588902	chr6:42928151	GNMT	-0.3	-6.56	-0.34	2.05e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	0.7	10.88	0.51	8.63e-24	Blood metabolite ratios;
LUSC	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	13.19	0.59	2.77e-32	Lung cancer in ever smokers;
LUSC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.48	-7.68	-0.39	1.73e-13	Alzheimer's disease (late onset);
LUSC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg20887711	chr4:1340912	KIAA1530	0.46	7.1	0.36	7.5e-12	Obesity-related traits;
LUSC	cis	rs62458065	0.850	rs62458098	chr7:32471129	G/A	cg20159608	chr7:32802032	NA	-0.66	-7.83	-0.39	6.35e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg05425664	chr17:57184151	TRIM37	-0.5	-7.41	-0.38	1.02e-12	Testicular germ cell tumor;
LUSC	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	0.91	17.84	0.7	1.74e-50	Metabolite levels;
LUSC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12956009	0.583	rs16952069	chr18:44904220	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.38	0.33	6.05e-10	Educational attainment (years of education);
LUSC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00290607	chr11:67383545	NA	0.46	8.79	0.43	7.95e-17	Mean corpuscular volume;
LUSC	trans	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-6.04	-0.31	4.04e-9	Morning vs. evening chronotype;
LUSC	cis	rs16910800	0.731	rs59845980	chr11:23191511	T/G	cg20040320	chr11:23191996	NA	-0.59	-7.63	-0.39	2.4e-13	Cancer;
LUSC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg07741184	chr6:167504864	NA	-0.35	-6.39	-0.33	5.46e-10	Crohn's disease;
LUSC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.72	13.55	0.6	1.27e-33	Gestational age at birth (maternal effect);
LUSC	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-8.43	-0.42	1.05e-15	Morning vs. evening chronotype;
LUSC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg09455208	chr3:40491958	NA	-0.55	-9.87	-0.48	2.49e-20	Renal cell carcinoma;
LUSC	cis	rs6681460	0.932	rs603750	chr1:67177488	A/G	cg02459107	chr1:67143332	SGIP1	0.48	8.96	0.44	2.34e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	0.96	15.49	0.65	3.57e-41	Parkinson's disease;
LUSC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.48	-0.42	7.37e-16	Bipolar disorder and schizophrenia;
LUSC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.75	-0.8	1.56e-77	Height;
LUSC	cis	rs8008758	0.963	rs10132271	chr14:101688874	C/T	cg26224664	chr14:101693935	NA	-0.27	-5.7	-0.3	2.61e-8	Body mass index (alcohol intake interaction);
LUSC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18301423	chr5:131593218	PDLIM4	0.47	7.46	0.38	7.75e-13	Acylcarnitine levels;
LUSC	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg21775007	chr8:11205619	TDH	-0.71	-11.23	-0.52	4.88e-25	Retinal vascular caliber;
LUSC	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.94	0.36	2.02e-11	Height;
LUSC	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg09835421	chr16:68378352	PRMT7	-0.53	-6.01	-0.31	4.86e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg25124228	chr12:125621409	AACS	-0.45	-7.37	-0.37	1.37e-12	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15541040	chr2:3486749	NA	-0.58	-9.1	-0.45	8.1e-18	Neurofibrillary tangles;
LUSC	cis	rs2798269	0.902	rs12869776	chr13:22103294	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-5.77	-0.3	1.84e-8	PR segment;
LUSC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-7.38	-0.37	1.24e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.79	11.95	0.55	1.2e-27	Lymphocyte counts;
LUSC	cis	rs11153147	0.502	rs75772189	chr6:109416369	C/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.84	-0.3	1.22e-8	Mean corpuscular volume;
LUSC	cis	rs6977660	0.714	rs6945753	chr7:19814255	A/G	cg07541023	chr7:19748670	TWISTNB	0.66	7.21	0.37	3.71e-12	Thyroid stimulating hormone;
LUSC	cis	rs6433857	0.657	rs6756509	chr2:181500273	T/C	cg23363182	chr2:181467187	NA	-0.52	-8.4	-0.42	1.28e-15	Body mass index;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13036321	chr4:166248467	SC4MOL	-0.42	-6.31	-0.33	8.78e-10	Electrocardiographic conduction measures;
LUSC	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.25	-17.72	-0.7	5.52e-50	Hip circumference adjusted for BMI;
LUSC	cis	rs1832871	0.655	rs4292552	chr6:158722888	G/A	cg07165851	chr6:158734300	TULP4	0.5	7.76	0.39	1.03e-13	Height;
LUSC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg18681998	chr4:17616180	MED28	0.89	15.31	0.64	1.79e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg09469691	chr10:81107165	PPIF	0.65	9.72	0.47	7.73e-20	Height;
LUSC	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg09654669	chr8:57350985	NA	-0.58	-7.84	-0.39	5.98e-14	Obesity-related traits;
LUSC	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg14844989	chr11:31128820	NA	-0.37	-5.79	-0.3	1.67e-8	Red blood cell count;
LUSC	cis	rs3099143	1.000	rs4886831	chr15:77106801	T/C	cg21673338	chr15:77095150	SCAPER	0.78	7.71	0.39	1.43e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg21361702	chr7:150065534	REPIN1	0.46	6.29	0.33	1.01e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.77	-12.95	-0.58	2.23e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7572644	0.723	rs13019037	chr2:28024642	C/T	cg27432699	chr2:27873401	GPN1	0.59	7.6	0.38	2.96e-13	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg16447950	chr5:562315	NA	-0.58	-7.3	-0.37	2.1e-12	Obesity-related traits;
LUSC	cis	rs113835537	0.597	rs3737525	chr11:66306355	A/G	cg24851651	chr11:66362959	CCS	0.51	7.49	0.38	6.26e-13	Airway imaging phenotypes;
LUSC	cis	rs2797160	0.967	rs80303782	chr6:126004193	C/T	cg05901451	chr6:126070800	HEY2	-0.56	-8.15	-0.41	7.47e-15	Endometrial cancer;
LUSC	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.25	-0.32	1.24e-9	Neuroticism;
LUSC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	8.83	0.43	6.15e-17	Total body bone mineral density;
LUSC	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6594499	0.872	rs6859041	chr5:110435231	G/A	cg04022379	chr5:110408740	TSLP	0.43	6.47	0.33	3.54e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.93	0.35	2.14e-11	Platelet count;
LUSC	cis	rs9311676	0.656	rs56384862	chr3:58395863	A/G	cg13750441	chr3:58318267	PXK	0.35	6.78	0.35	5.59e-11	Systemic lupus erythematosus;
LUSC	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg22709100	chr7:91322751	NA	0.44	6.44	0.33	4.17e-10	Breast cancer;
LUSC	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.44	-0.33	4.16e-10	Platelet count;
LUSC	trans	rs3857536	0.813	rs1029401	chr6:66952268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-5.99	-0.31	5.34e-9	Blood trace element (Cu levels);
LUSC	cis	rs11209002	1.000	rs10732838	chr1:67577955	C/T	cg02640540	chr1:67518911	SLC35D1	0.69	7.58	0.38	3.42e-13	Crohn's disease;
LUSC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg25767906	chr1:53392781	SCP2	0.69	13.43	0.59	3.53e-33	Monocyte count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10704137	chr6:25732153	NA	0.52	6.35	0.33	7.1e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg13010199	chr12:38710504	ALG10B	0.49	7.34	0.37	1.65e-12	Heart rate;
LUSC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg16524733	chr11:117070046	TAGLN	-0.41	-7.25	-0.37	2.92e-12	Blood protein levels;
LUSC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg09455208	chr3:40491958	NA	0.59	10.13	0.48	3.39e-21	Renal cell carcinoma;
LUSC	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg16070123	chr10:51489643	NA	-0.52	-8.25	-0.41	3.65e-15	Prostate-specific antigen levels;
LUSC	cis	rs477692	1.000	rs7475154	chr10:131440584	C/T	cg11019008	chr10:131425282	MGMT	-0.4	-5.97	-0.31	6.05e-9	Response to temozolomide;
LUSC	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg00310523	chr12:86230176	RASSF9	-0.41	-7.41	-0.38	1.04e-12	Major depressive disorder;
LUSC	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg17757837	chr7:157058334	UBE3C	0.83	13.32	0.59	9.03e-33	Body mass index;
LUSC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg01097406	chr16:89675127	NA	-0.34	-6.7	-0.34	8.95e-11	Vitiligo;
LUSC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-1.07	-16.62	-0.67	1.31e-45	Initial pursuit acceleration;
LUSC	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.36	0.53	1.62e-25	Coffee consumption (cups per day);
LUSC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg07217954	chr7:1067459	C7orf50	0.52	5.67	0.3	3.02e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.66	10.62	0.5	6.68e-23	Longevity;
LUSC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.82	-13.78	-0.6	1.69e-34	Aortic root size;
LUSC	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.71	-11.17	-0.52	7.69e-25	Alcohol dependence;
LUSC	cis	rs2109514	0.902	rs717957	chr7:116113107	G/C	cg12739419	chr7:116140593	CAV2	-0.27	-5.92	-0.31	7.84e-9	Prevalent atrial fibrillation;
LUSC	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg18232548	chr7:50535776	DDC	-0.61	-9.06	-0.44	1.12e-17	Systemic sclerosis;
LUSC	cis	rs9815354	0.812	rs73071338	chr3:41824328	G/A	cg03022575	chr3:42003672	ULK4	0.85	8.67	0.43	1.91e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg18681998	chr4:17616180	MED28	0.81	14.6	0.62	1.07e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg23719950	chr11:63933701	MACROD1	-0.59	-7.17	-0.37	4.9e-12	Mean platelet volume;
LUSC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg02475777	chr4:1388615	CRIPAK	0.4	5.81	0.3	1.43e-8	Obesity-related traits;
LUSC	cis	rs716595	1.000	rs2050996	chr10:111993697	G/C	cg13996003	chr10:112034540	MXI1	-0.7	-5.81	-0.3	1.42e-8	Normalized brain volume;
LUSC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06022373	chr22:39101656	GTPBP1	-0.79	-11.96	-0.55	1.15e-27	Menopause (age at onset);
LUSC	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg01733217	chr16:74700730	RFWD3	0.74	12.24	0.56	1.05e-28	Testicular germ cell tumor;
LUSC	cis	rs1577917	0.570	rs114854865	chr6:86554236	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	cis	rs7577851	0.715	rs6708008	chr2:69618072	G/T	cg10773587	chr2:69614142	GFPT1	0.58	6.48	0.33	3.24e-10	Parkinson's disease (age of onset);
LUSC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.76	-11.85	-0.54	2.77e-27	Tonsillectomy;
LUSC	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.45	-0.5	2.64e-22	Eye color traits;
LUSC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg23625390	chr15:77176239	SCAPER	0.53	8.14	0.41	7.77e-15	Blood metabolite levels;
LUSC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg05973401	chr12:123451056	ABCB9	0.52	7.13	0.36	6.38e-12	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs17030434	1.000	rs17030434	chr4:154703596	A/G	cg14289246	chr4:154710475	SFRP2	-0.53	-7.06	-0.36	9.68e-12	Electrocardiographic conduction measures;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04422289	chr4:48833305	OCIAD1	0.52	6.93	0.35	2.22e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4908769	0.624	rs894875	chr1:8432136	C/T	cg00546117	chr1:8445545	RERE	0.3	5.93	0.31	7.58e-9	Allergy;
LUSC	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.76	-11.96	-0.55	1.09e-27	Schizophrenia;
LUSC	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg06637938	chr14:75390232	RPS6KL1	0.65	10.68	0.5	4.38e-23	Caffeine consumption;
LUSC	cis	rs1044826	1.000	rs13092507	chr3:139152480	A/G	cg00490450	chr3:139108681	COPB2	0.55	7.24	0.37	3.1e-12	Obesity-related traits;
LUSC	trans	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-9.51	-0.46	3.95e-19	Morning vs. evening chronotype;
LUSC	cis	rs983392	0.805	rs1834550	chr11:59959843	T/C	cg24026212	chr11:59952134	MS4A6A	-0.37	-6.26	-0.32	1.21e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.85	-0.51	1.03e-23	Alzheimer's disease (late onset);
LUSC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg07332563	chr6:291687	DUSP22	-0.52	-7.98	-0.4	2.37e-14	Menopause (age at onset);
LUSC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg24154853	chr7:158122151	PTPRN2	-0.42	-8.26	-0.41	3.55e-15	Calcium levels;
LUSC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg09359103	chr1:154839909	KCNN3	-0.7	-16.3	-0.67	2.36e-44	Prostate cancer;
LUSC	trans	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg13010199	chr12:38710504	ALG10B	0.41	6.48	0.33	3.28e-10	Morning vs. evening chronotype;
LUSC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.45	6.49	0.33	3.13e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.67	-10.17	-0.49	2.36e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs73198271	0.613	rs11249892	chr8:8657240	C/T	cg01851573	chr8:8652454	MFHAS1	0.46	7.45	0.38	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg09365446	chr1:150670422	GOLPH3L	0.55	8.44	0.42	9.59e-16	Tonsillectomy;
LUSC	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg18477163	chr1:228402036	OBSCN	0.57	9.59	0.46	2.12e-19	Diastolic blood pressure;
LUSC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg12365402	chr11:9010492	NRIP3	-0.52	-10.02	-0.48	7.57e-21	Hemoglobin concentration;
LUSC	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.73	-0.43	1.23e-16	Total cholesterol levels;
LUSC	trans	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.66	-0.34	1.12e-10	Endometrial cancer;
LUSC	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.29	6.5	0.34	2.95e-10	Coronary artery disease;
LUSC	trans	rs6693295	0.625	rs6680215	chr1:246347153	G/A	cg22732515	chr19:44031385	ETHE1	0.44	5.94	0.31	7.06e-9	Migraine - clinic-based;Migraine with aura;
LUSC	cis	rs9815354	0.638	rs73075241	chr3:42058045	C/T	cg03022575	chr3:42003672	ULK4	0.78	7.85	0.39	5.64e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00149659	chr3:10157352	C3orf10	0.89	12.15	0.55	2.18e-28	Alzheimer's disease;
LUSC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.22	0.56	1.25e-28	Prudent dietary pattern;
LUSC	cis	rs6750047	0.691	rs336032	chr2:38264788	T/C	cg07380506	chr2:38303506	CYP1B1	-0.43	-5.92	-0.31	8.2e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg01097406	chr16:89675127	NA	0.48	9.87	0.48	2.53e-20	Vitiligo;
LUSC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg01765077	chr12:122356316	WDR66	0.55	7.75	0.39	1.1e-13	Mean corpuscular volume;
LUSC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.26	0.32	1.19e-9	Mean platelet volume;
LUSC	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.46	-0.33	3.67e-10	Mood instability;
LUSC	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg11344533	chr11:111475393	SIK2	0.47	6.34	0.33	7.53e-10	Primary sclerosing cholangitis;
LUSC	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg02018176	chr4:1364513	KIAA1530	0.44	6.49	0.33	3.18e-10	Recombination rate (females);
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg08701551	chr17:66287507	ARSG;SLC16A6	-0.45	-6.08	-0.32	3.37e-9	Height;
LUSC	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.68	13.03	0.58	1.18e-31	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.75	-0.8	1.56e-77	Height;
LUSC	trans	rs853679	0.599	rs202906	chr6:28011652	C/T	cg06606381	chr12:133084897	FBRSL1	0.62	6.95	0.36	1.91e-11	Depression;
LUSC	trans	rs62238980	0.522	rs118120290	chr22:32399262	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg03342759	chr3:160939853	NMD3	-0.45	-6.23	-0.32	1.41e-9	Parkinson's disease;
LUSC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg07424592	chr7:64974309	NA	0.69	6.07	0.32	3.41e-9	Diabetic kidney disease;
LUSC	cis	rs6495367	1.000	rs6495367	chr15:79375347	C/T	cg17916960	chr15:79447300	NA	0.34	6.41	0.33	5.01e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.68	12.13	0.55	2.6e-28	Aortic root size;
LUSC	cis	rs6456156	0.774	rs1012657	chr6:167525142	A/C	cg07741184	chr6:167504864	NA	-0.34	-5.9	-0.31	8.82e-9	Primary biliary cholangitis;
LUSC	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg06917634	chr15:78832804	PSMA4	-0.48	-5.94	-0.31	7.15e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg08975724	chr8:8085496	FLJ10661	0.5	7.47	0.38	7.2e-13	Neuroticism;
LUSC	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg13319975	chr6:146136371	FBXO30	0.47	7.24	0.37	3.19e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg21724239	chr8:58056113	NA	0.81	9.65	0.47	1.4e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.77	0.3	1.81e-8	Cerebrospinal P-tau181p levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15649193	chr19:14640403	TECR;MIR639	0.74	6.21	0.32	1.58e-9	Cognitive performance;
LUSC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.62	9.26	0.45	2.59e-18	Longevity;
LUSC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.81	-0.35	4.59e-11	Lung cancer;
LUSC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.85	-0.31	1.15e-8	Tonsillectomy;
LUSC	cis	rs6987853	0.787	rs2923437	chr8:42425399	A/C	cg09913449	chr8:42400586	C8orf40	0.54	9.56	0.46	2.6e-19	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg23950597	chr19:37808831	NA	-0.65	-7.91	-0.4	3.9e-14	Coronary artery calcification;
LUSC	cis	rs2932538	0.922	rs9429694	chr1:113158289	G/A	cg22162597	chr1:113214053	CAPZA1	0.69	9.92	0.48	1.67e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs8014204	0.736	rs2111705	chr14:75261641	G/A	cg06637938	chr14:75390232	RPS6KL1	0.51	7.9	0.4	3.94e-14	Caffeine consumption;
LUSC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.22	0.37	3.5e-12	Platelet count;
LUSC	cis	rs250677	0.524	rs183140	chr5:148438803	G/T	cg18129178	chr5:148520854	ABLIM3	-0.57	-9.28	-0.45	2.17e-18	Breast cancer;
LUSC	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.41	0.53	1.1e-25	Eye color traits;
LUSC	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg01528321	chr10:82214614	TSPAN14	0.98	14.61	0.62	1.03e-37	Post bronchodilator FEV1;
LUSC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	16.15	0.66	8.92e-44	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.38	5.68	0.3	2.89e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.87	-15.46	-0.65	4.63e-41	Cognitive function;
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.53	7.3	0.37	2.06e-12	Renal function-related traits (BUN);
LUSC	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg27411982	chr8:10470053	RP1L1	-0.37	-5.93	-0.31	7.5e-9	Retinal vascular caliber;
LUSC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.71	0.47	8.46e-20	Bipolar disorder;
LUSC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg22166914	chr1:53195759	ZYG11B	-0.62	-10.29	-0.49	9.65e-22	Monocyte count;
LUSC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg26441486	chr22:50317300	CRELD2	-0.54	-8.27	-0.41	3.21e-15	Schizophrenia;
LUSC	cis	rs4499344	0.730	rs417823	chr19:33104561	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.01	0.58	1.39e-31	Mean platelet volume;
LUSC	cis	rs11997175	0.546	rs13282996	chr8:33596397	C/T	ch.8.33884649F	chr8:33765107	NA	0.48	7.7	0.39	1.54e-13	Body mass index;
LUSC	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.92	-0.44	3.05e-17	Coffee consumption (cups per day);
LUSC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.06	0.58	8.72e-32	Cognitive test performance;
LUSC	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg04267008	chr7:1944627	MAD1L1	-0.39	-5.77	-0.3	1.78e-8	Schizophrenia;
LUSC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22496380	chr5:211416	CCDC127	-0.74	-8.57	-0.42	3.87e-16	Breast cancer;
LUSC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs7605827	0.791	rs7604881	chr2:15476735	T/A	cg19274914	chr2:15703543	NA	0.44	8.43	0.42	1.08e-15	Educational attainment (years of education);
LUSC	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg21775007	chr8:11205619	TDH	0.47	6.61	0.34	1.54e-10	Myopia (pathological);
LUSC	cis	rs963731	0.522	rs1454222	chr2:39215895	C/A	cg04010122	chr2:39346883	SOS1	-0.79	-5.73	-0.3	2.2e-8	Corticobasal degeneration;
LUSC	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg05855489	chr10:104503620	C10orf26	0.6	9.68	0.47	1.1e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs977987	0.931	rs7195161	chr16:75495572	T/C	cg04384234	chr16:75411784	CFDP1	-0.48	-7.83	-0.39	6.46e-14	Dupuytren's disease;
LUSC	cis	rs2303282	0.716	rs2966205	chr16:56446612	C/T	cg00500540	chr16:56394104	NA	-0.44	-7.65	-0.39	2.14e-13	Breast cancer;
LUSC	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg23625390	chr15:77176239	SCAPER	-0.55	-7.7	-0.39	1.5700000000000001e-13	Blood metabolite levels;
LUSC	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg05805236	chr11:65401703	PCNXL3	-0.63	-10.52	-0.5	1.47e-22	Acne (severe);
LUSC	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg13385521	chr17:29058706	SUZ12P	0.69	6.79	0.35	5.27e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.7	-0.43	1.58e-16	Platelet count;
LUSC	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg10253484	chr15:75165896	SCAMP2	-0.46	-6.61	-0.34	1.49e-10	Breast cancer;
LUSC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.49e-10	Extrinsic epigenetic age acceleration;
LUSC	trans	rs9393777	0.844	rs28360634	chr6:27332891	T/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-9.05	-0.44	1.21e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg12560992	chr17:57184187	TRIM37	-0.64	-10.59	-0.5	9e-23	Testicular germ cell tumor;
LUSC	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.85	0.3	1.16e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg16230307	chr14:35515116	FAM177A1	0.81	10.11	0.48	3.77e-21	Psoriasis;
LUSC	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg14416269	chr4:6271139	WFS1	0.56	12.24	0.56	1.01e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg20203395	chr5:56204925	C5orf35	-0.5	-7.49	-0.38	6.14e-13	Coronary artery disease;
LUSC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.71	-10.0	-0.48	9.07e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs2679649	1.000	rs2679646	chr6:122352143	A/G	cg00167820	chr8:131663355	NA	0.55	6.42	0.33	4.79e-10	Subcutaneous adipose tissue;
LUSC	cis	rs6005807	0.640	rs2013784	chr22:28923933	C/T	cg12565055	chr22:29076175	TTC28	-0.53	-5.76	-0.3	1.93e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg12751644	chr20:60527061	NA	-0.35	-6.2	-0.32	1.69e-9	Body mass index;
LUSC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.53	-8.35	-0.42	1.87e-15	Melanoma;
LUSC	trans	rs17641971	0.899	rs818557	chr8:49984515	G/C	cg15678142	chr1:167411538	CD247	0.4	6.0	0.31	5.08e-9	Blood metabolite levels;
LUSC	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06022373	chr22:39101656	GTPBP1	0.76	12.31	0.56	5.79e-29	Menopause (age at onset);
LUSC	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15664640	chr17:80829946	TBCD	0.53	9.33	0.45	1.56e-18	Breast cancer;
LUSC	cis	rs6960043	0.818	rs10950550	chr7:15063923	T/G	cg19272540	chr7:15055459	NA	0.33	8.01	0.4	1.91e-14	Type 2 diabetes;
LUSC	cis	rs238295	0.805	rs1983694	chr20:5574134	T/C	cg15842884	chr20:5591925	RP5-1022P6.2	-0.44	-5.95	-0.31	6.87e-9	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.46	-0.5	2.51e-22	Eye color traits;
LUSC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg17173187	chr15:85201210	NMB	0.37	6.56	0.34	2.08e-10	Schizophrenia;
LUSC	cis	rs3812762	0.871	rs10734637	chr11:8788225	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.37	6.36	0.33	6.54e-10	Hypospadias;
LUSC	trans	rs17495987	1.000	rs17495987	chr7:7899965	A/G	cg25844211	chr1:229761456	URB2;TAF5L	0.46	5.98	0.31	5.7e-9	Tonsillectomy;
LUSC	cis	rs9341808	0.718	rs2179842	chr6:80979053	T/C	cg08355045	chr6:80787529	NA	0.56	9.78	0.47	4.95e-20	Sitting height ratio;
LUSC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg24644049	chr4:85504048	CDS1	0.87	7.49	0.38	6.2e-13	Skin colour saturation;
LUSC	cis	rs877282	1.000	rs7100358	chr10:773681	G/A	cg17470449	chr10:769945	NA	0.49	6.88	0.35	2.93e-11	Uric acid levels;
LUSC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.07e-17	Prudent dietary pattern;
LUSC	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-39.49	-0.91	6.94e-128	Myeloid white cell count;
LUSC	cis	rs11676348	0.805	rs12694428	chr2:218958820	G/A	cg00012203	chr2:219082015	ARPC2	-0.52	-7.96	-0.4	2.7e-14	Ulcerative colitis;
LUSC	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg16579770	chr16:72058938	DHODH	0.34	5.73	0.3	2.24e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg12940439	chr1:67600707	NA	0.37	6.11	0.32	2.71e-9	Psoriasis;
LUSC	trans	rs2727405	1.000	rs2727405	chr11:13090942	G/A	cg19779488	chr5:171679572	UBTD2	0.42	6.05	0.31	3.82e-9	Obesity-related traits;
LUSC	cis	rs2932538	0.922	rs7522110	chr1:113072914	A/C	cg22162597	chr1:113214053	CAPZA1	0.72	10.22	0.49	1.58e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.47	7.02	0.36	1.23e-11	Cognitive test performance;
LUSC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	trans	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.41	-0.33	5.05e-10	Monocyte count;
LUSC	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg05347473	chr6:146136440	FBXO30	-0.48	-8.1	-0.41	1.01e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg06151567	chr1:17765735	RCC2	0.39	6.01	0.31	4.82e-9	Schizophrenia;
LUSC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.78	-0.3	1.71e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-0.9	-16.96	-0.68	5.43e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7246967	0.673	rs12985495	chr19:22930378	A/G	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.04e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg04511125	chr2:88470314	THNSL2	0.64	5.87	0.31	1.07e-8	Plasma clusterin levels;
LUSC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg05347473	chr6:146136440	FBXO30	0.57	9.83	0.47	3.39e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg00132208	chr4:10120780	NA	0.35	5.71	0.3	2.49e-8	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg02023728	chr11:77925099	USP35	0.45	6.83	0.35	4.06e-11	Testicular germ cell tumor;
LUSC	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.67	-10.32	-0.49	7.33e-22	Morning vs. evening chronotype;
LUSC	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg17252645	chr8:143867129	LY6D	-0.55	-10.55	-0.5	1.2e-22	Urinary tract infection frequency;
LUSC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-0.82	-14.19	-0.61	4.12e-36	Longevity;
LUSC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-8.57	-0.42	3.92e-16	Lymphocyte counts;
LUSC	cis	rs2067615	0.599	rs10778508	chr12:107159405	A/G	cg19260189	chr12:106995001	RFX4	-0.22	-5.69	-0.3	2.83e-8	Heart rate;
LUSC	cis	rs7172677	1.000	rs8032261	chr15:75424012	A/T	cg14664628	chr15:75095509	CSK	-0.44	-5.8	-0.3	1.55e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.87	-0.35	3.14e-11	Bipolar disorder;
LUSC	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.86	0.51	9.62e-24	Bladder cancer;
LUSC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	0.65	13.73	0.6	2.61e-34	Prudent dietary pattern;
LUSC	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg06060754	chr5:176797920	RGS14	0.56	8.96	0.44	2.38e-17	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.14e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-1.12	-15.55	-0.65	2.16e-41	Hip circumference adjusted for BMI;
LUSC	cis	rs225245	0.817	rs225302	chr17:33922396	C/T	cg05299278	chr17:33885742	SLFN14	0.31	6.93	0.35	2.22e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17691542	chr6:26056736	HIST1H1C	0.98	12.62	0.57	3.96e-30	Iron status biomarkers;
LUSC	cis	rs3857536	0.813	rs6455083	chr6:66935406	T/C	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs2637266	1.000	rs12251862	chr10:78367929	A/G	cg18941641	chr10:78392320	NA	0.4	7.35	0.37	1.54e-12	Pulmonary function;
LUSC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg06740227	chr12:86229804	RASSF9	-0.36	-5.7	-0.3	2.61e-8	Major depressive disorder;
LUSC	trans	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg05084668	chr3:125655381	ALG1L	-0.49	-6.98	-0.36	1.64e-11	Blood pressure (smoking interaction);
LUSC	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	6.57	0.34	1.94e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs6982240	0.514	rs1865247	chr8:142274654	A/T	cg27411547	chr8:142287226	NA	-0.48	-8.13	-0.41	8.27e-15	Tonsillectomy;
LUSC	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.46	0.5	2.53e-22	Schizophrenia;
LUSC	cis	rs9811920	0.928	rs9865713	chr3:99870299	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.33	6.2	0.32	1.64e-9	Axial length;
LUSC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg10207240	chr12:122356781	WDR66	0.45	6.55	0.34	2.2e-10	Mean corpuscular volume;
LUSC	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg01966878	chr4:90757139	SNCA	-0.42	-5.96	-0.31	6.24e-9	Neuroticism;
LUSC	cis	rs4663866	1.000	rs71426509	chr2:239175334	A/C	cg16914508	chr2:239161102	PER2	0.68	7.15	0.36	5.4e-12	Irritable bowel syndrome;
LUSC	cis	rs7267979	0.789	rs6083841	chr20:25384564	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.76	-15.27	-0.64	2.7e-40	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10743315	0.557	rs17505123	chr12:19301353	G/A	cg02471346	chr12:19282374	PLEKHA5	0.86	6.8	0.35	4.76e-11	Gut microbiota (bacterial taxa);
LUSC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg00310523	chr12:86230176	RASSF9	-0.51	-9.9	-0.48	1.91e-20	Major depressive disorder;
LUSC	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg15309053	chr8:964076	NA	0.41	8.29	0.41	2.81e-15	Schizophrenia;
LUSC	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg17764715	chr19:33622953	WDR88	-0.58	-8.07	-0.4	1.32e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs724744	0.680	rs1318602	chr6:22357342	A/G	cg13807341	chr11:118445984	ARCN1	-0.35	-5.94	-0.31	6.98e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg05501817	chr11:14380813	RRAS2	-0.59	-9.36	-0.46	1.22e-18	Sense of smell;
LUSC	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg09307838	chr4:120376055	NA	-0.6	-8.89	-0.44	3.85e-17	Corneal astigmatism;
LUSC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg04455712	chr21:45112962	RRP1B	0.48	8.89	0.44	3.85e-17	Mean corpuscular volume;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21800906	chr11:32914818	QSER1	0.44	6.21	0.32	1.55e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg08975724	chr8:8085496	FLJ10661	0.53	7.91	0.4	3.89e-14	Mood instability;
LUSC	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg13319975	chr6:146136371	FBXO30	0.49	7.42	0.38	9.85e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg04749549	chr19:17459798	NA	-0.31	-5.76	-0.3	1.94e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUSC	cis	rs2286503	0.839	rs2270105	chr7:22862467	G/A	cg11367502	chr7:22862612	TOMM7	0.46	6.26	0.32	1.17e-9	Fibrinogen;
LUSC	cis	rs11997175	0.624	rs17701219	chr8:33728795	T/A	ch.8.33884649F	chr8:33765107	NA	0.49	7.32	0.37	1.89e-12	Body mass index;
LUSC	cis	rs57920188	0.535	rs4295856	chr1:4094842	C/T	cg20703997	chr1:4087676	NA	0.55	7.76	0.39	1.04e-13	Interleukin-17 levels;
LUSC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.52	-0.42	5.5e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg15962314	chr1:44399869	ARTN	0.24	5.86	0.31	1.12e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-7.37	-0.37	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11971779	0.680	rs28579232	chr7:139073116	C/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs710216	0.957	rs3738514	chr1:43426591	A/G	cg03128534	chr1:43423976	SLC2A1	-0.49	-6.56	-0.34	2.03e-10	Red cell distribution width;
LUSC	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.08	0.36	8.52e-12	Schizophrenia;
LUSC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg22663859	chr13:21900854	NA	0.29	5.69	0.3	2.78e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs10193935	0.901	rs10201586	chr2:42622594	C/G	cg27598129	chr2:42591480	NA	-0.61	-8.21	-0.41	4.98e-15	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg15704280	chr7:45808275	SEPT13	-0.51	-7.18	-0.37	4.51e-12	HDL cholesterol;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18110333	chr6:292329	DUSP22	-0.73	-12.1	-0.55	3.44e-28	Menopause (age at onset);
LUSC	trans	rs6600671	0.967	rs12069545	chr1:121172203	A/G	cg08727972	chr1:148025634	NBPF14	0.45	6.25	0.32	1.24e-9	Hip geometry;
LUSC	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	0.56	8.55	0.42	4.54e-16	Breast cancer;
LUSC	trans	rs6601327	0.571	rs7838571	chr8:9647796	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	7.1	0.36	7.66e-12	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg09835421	chr16:68378352	PRMT7	-0.59	-6.21	-0.32	1.55e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7589342	0.536	rs17201484	chr2:106394809	C/G	cg14210321	chr2:106509881	NCK2	-0.4	-5.72	-0.3	2.33e-8	Addiction;
LUSC	cis	rs7617773	0.817	rs11130163	chr3:48312658	T/C	cg20734569	chr3:48348370	SPINK8	-0.44	-7.69	-0.39	1.68e-13	Coronary artery disease;
LUSC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg11062466	chr8:58055876	NA	0.75	9.1	0.45	8.12e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg15790184	chr11:494944	RNH1	0.49	7.53	0.38	4.71e-13	Systemic lupus erythematosus;
LUSC	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg01448562	chr3:133502909	NA	0.59	9.31	0.45	1.79e-18	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs7903847	0.642	rs7078782	chr10:99168604	C/T	cg08345082	chr10:99160200	RRP12	-0.35	-7.27	-0.37	2.51e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.74	-0.39	1.21e-13	Chronic sinus infection;
LUSC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	6.07	0.32	3.53e-9	Schizophrenia;
LUSC	cis	rs4730250	0.640	rs7783562	chr7:106917438	G/T	cg02696742	chr7:106810147	HBP1	-0.49	-5.89	-0.31	9.32e-9	Osteoarthritis;
LUSC	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	5.91	0.31	8.26e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg23029597	chr12:123009494	RSRC2	-0.75	-9.52	-0.46	3.6e-19	Body mass index;
LUSC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.39	0.67	1.04e-44	Platelet count;
LUSC	trans	rs28588043	0.550	rs61816051	chr1:170953276	T/C	cg07135042	chr19:56905152	ZNF582	-0.62	-6.3	-0.33	9.37e-10	Number of children (6+ vs. 0 or 1);
LUSC	cis	rs727505	0.954	rs2239532	chr7:124405676	A/C	cg23710748	chr7:124431027	NA	-0.42	-7.54	-0.38	4.44e-13	Lewy body disease;
LUSC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08677398	chr8:58056175	NA	0.51	6.68	0.34	9.95e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg12463550	chr7:65579703	CRCP	0.57	8.47	0.42	7.7e-16	Aortic root size;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg17994390	chr8:95565953	KIAA1429	0.46	6.31	0.33	8.86e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs9356171	0.572	rs13198847	chr6:164326504	T/C	cg25752492	chr6:164341247	NA	-0.38	-6.6	-0.34	1.64e-10	Diisocyanate-induced asthma;
LUSC	cis	rs1419980	0.586	rs10845548	chr12:7777657	T/A	cg25828445	chr12:7781288	NA	-0.62	-6.49	-0.33	3.04e-10	HDL cholesterol levels;
LUSC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg11494091	chr17:61959527	GH2	0.38	6.57	0.34	1.96e-10	Height;
LUSC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg12463550	chr7:65579703	CRCP	-0.52	-7.55	-0.38	4.17e-13	Aortic root size;
LUSC	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg27471124	chr11:109292789	C11orf87	0.43	7.61	0.38	2.86e-13	Schizophrenia;
LUSC	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg09408571	chr1:101003634	GPR88	-0.31	-5.75	-0.3	2.01e-8	Breast cancer;
LUSC	cis	rs6977660	0.714	rs17141945	chr7:19805056	T/A	cg07541023	chr7:19748670	TWISTNB	0.64	6.92	0.35	2.28e-11	Thyroid stimulating hormone;
LUSC	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	6.36	0.33	6.75e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs965513	0.901	rs1877431	chr9:100534147	C/T	cg13688889	chr9:100608707	NA	0.4	5.91	0.31	8.66e-9	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg12856521	chr11:46389249	DGKZ	-0.38	-6.0	-0.31	5.21e-9	Leprosy;
LUSC	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.52	0.5	1.5e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2274273	0.624	rs78205412	chr14:55781250	G/A	cg04306507	chr14:55594613	LGALS3	0.48	9.7	0.47	9.23e-20	Protein biomarker;
LUSC	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.55	0.34	2.18e-10	Corneal astigmatism;
LUSC	cis	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg17469321	chr7:55412551	NA	0.66	10.63	0.5	6.52e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.69	-0.51	3.79e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs9314323	0.692	rs6557914	chr8:26208744	G/C	cg13160058	chr8:26243215	BNIP3L	-0.4	-7.02	-0.36	1.26e-11	Red cell distribution width;
LUSC	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-0.68	-6.84	-0.35	3.85e-11	Prostate cancer;
LUSC	cis	rs10740039	0.516	rs2393646	chr10:62319434	G/A	cg18175470	chr10:62150864	ANK3	-0.45	-6.89	-0.35	2.87e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg24881330	chr22:46731750	TRMU	0.65	7.96	0.4	2.75e-14	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg26338869	chr17:61819248	STRADA	0.4	5.73	0.3	2.21e-8	Prudent dietary pattern;
LUSC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg13395646	chr4:1353034	KIAA1530	0.62	9.93	0.48	1.53e-20	Obesity-related traits;
LUSC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.49	-0.33	3.11e-10	Platelet count;
LUSC	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg06552810	chr11:31128660	NA	-0.4	-7.16	-0.36	5.12e-12	Red blood cell count;
LUSC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13732083	chr21:47605072	C21orf56	0.47	6.91	0.35	2.48e-11	Testicular germ cell tumor;
LUSC	cis	rs2795502	0.630	rs4948698	chr10:43539459	A/G	cg08461752	chr10:43522343	NA	0.57	7.34	0.37	1.64e-12	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.55	0.5	1.17e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg09365446	chr1:150670422	GOLPH3L	0.51	7.5	0.38	5.68e-13	Melanoma;
LUSC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.2	-0.72	6.74e-56	Height;
LUSC	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg14458575	chr2:238380390	NA	0.68	12.24	0.56	1.06e-28	Prostate cancer;
LUSC	cis	rs7264396	1.000	rs6060479	chr20:34165723	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.5	7.35	0.37	1.54e-12	Total cholesterol levels;
LUSC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.22	-0.49	1.65e-21	Hemoglobin concentration;
LUSC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06850241	chr22:41845214	NA	-0.3	-5.73	-0.3	2.26e-8	Vitiligo;
LUSC	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg16339924	chr4:17578868	LAP3	0.6	9.05	0.44	1.23e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.22	-0.41	4.66e-15	Neuroticism;
LUSC	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	0.58	9.29	0.45	2.01e-18	Breast cancer;
LUSC	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg01858014	chr14:56050164	KTN1	-0.82	-7.11	-0.36	7.29e-12	Putamen volume;
LUSC	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.6	-0.34	1.6e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.81	-0.43	6.92e-17	Bipolar disorder;
LUSC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg18402987	chr7:1209562	NA	0.72	7.69	0.39	1.67e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg20129853	chr10:51489980	NA	0.37	7.54	0.38	4.58e-13	Prostate-specific antigen levels;
LUSC	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg11693508	chr17:37793320	STARD3	0.56	6.81	0.35	4.6e-11	Bipolar disorder;
LUSC	trans	rs10411161	0.657	rs67462252	chr19:52382851	T/C	cg22319618	chr22:45562946	NUP50	-0.5	-5.94	-0.31	6.97e-9	Breast cancer;
LUSC	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg24675056	chr1:15929824	NA	0.46	7.91	0.4	3.85e-14	Systolic blood pressure;
LUSC	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg13755796	chr4:20253514	NA	0.44	6.54	0.34	2.34e-10	Life satisfaction;
LUSC	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg09835421	chr16:68378352	PRMT7	-0.54	-6.08	-0.32	3.32e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg19894588	chr14:64061835	NA	-0.52	-6.75	-0.35	6.5500000000000006e-11	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg06454157	chr6:167490870	NA	-0.28	-6.71	-0.34	8.57e-11	Primary biliary cholangitis;
LUSC	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg07862535	chr7:139043722	LUC7L2	-0.57	-7.22	-0.37	3.54e-12	Diisocyanate-induced asthma;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg22946670	chr1:154909930	PMVK	0.35	5.96	0.31	6.54e-9	Triglycerides;
LUSC	cis	rs41271951	0.512	rs11204774	chr1:151062957	C/T	cg11822372	chr1:151115635	SEMA6C	-0.75	-7.2	-0.37	4.11e-12	Blood protein levels;
LUSC	cis	rs11603020	0.950	rs28362950	chr11:57371918	G/A	cg23127183	chr11:57508653	C11orf31	-0.47	-6.44	-0.33	4.23e-10	Blood protein levels;
LUSC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.6	0.54	2.24e-26	Menopause (age at onset);
LUSC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	trans	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg10756647	chr7:56101905	PSPH	-0.87	-8.55	-0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg24375607	chr4:120327624	NA	0.7	11.27	0.52	3.51e-25	Corneal astigmatism;
LUSC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg16989086	chr20:62203971	PRIC285	0.43	5.96	0.31	6.48e-9	Glioblastoma;
LUSC	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg08999081	chr20:33150536	PIGU	0.37	6.82	0.35	4.34e-11	Height;
LUSC	cis	rs6960043	0.818	rs10267273	chr7:15053589	A/G	cg19272540	chr7:15055459	NA	-0.34	-8.37	-0.42	1.63e-15	Type 2 diabetes;
LUSC	cis	rs1577917	0.629	rs6927475	chr6:86206773	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	6.91	0.35	2.46e-11	Response to antipsychotic treatment;
LUSC	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-8.05	-0.4	1.51e-14	Schizophrenia;
LUSC	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg12179176	chr11:130786555	SNX19	0.64	9.66	0.47	1.28e-19	Schizophrenia;
LUSC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg26677194	chr12:130822605	PIWIL1	0.59	8.77	0.43	9.52e-17	Menopause (age at onset);
LUSC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.76	-0.3	1.92e-8	Total body bone mineral density;
LUSC	cis	rs367943	0.712	rs1850407	chr5:112721569	C/A	cg12552261	chr5:112820674	MCC	0.37	6.12	0.32	2.69e-9	Type 2 diabetes;
LUSC	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg05082376	chr22:42548792	NA	-0.4	-6.66	-0.34	1.16e-10	Cognitive function;
LUSC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-6.64	-0.34	1.28e-10	Blood metabolite levels;
LUSC	trans	rs11681884	0.786	rs11897709	chr2:113809290	G/A	cg19632953	chr13:113635898	MCF2L	0.69	6.03	0.31	4.45e-9	Stroke;
LUSC	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg05360138	chr12:110035743	NA	0.56	6.97	0.36	1.73e-11	Neuroticism;
LUSC	cis	rs3740393	0.562	rs60459635	chr10:104500988	T/G	cg05855489	chr10:104503620	C10orf26	0.56	5.74	0.3	2.07e-8	Microalbuminuria;
LUSC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg15448220	chr1:150897856	SETDB1	0.43	6.33	0.33	8.02e-10	Melanoma;
LUSC	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg22029157	chr1:209979665	IRF6	0.71	8.47	0.42	7.71e-16	Coronary artery disease;
LUSC	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg24375607	chr4:120327624	NA	0.65	10.63	0.5	6.26e-23	Corneal astigmatism;
LUSC	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	trans	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg21659725	chr3:3221576	CRBN	-0.72	-8.2	-0.41	5.17e-15	Menarche (age at onset);
LUSC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.48	7.83	0.39	6.52e-14	Vitiligo;
LUSC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.48	6.03	0.31	4.34e-9	Multiple sclerosis;
LUSC	cis	rs67072384	1.000	rs2365441	chr11:72450226	T/C	cg04827223	chr11:72435913	ARAP1	-0.78	-6.71	-0.34	8.4e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.47e-8	Breast cancer;
LUSC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg24829409	chr8:58192753	C8orf71	0.52	5.98	0.31	5.6e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	0.69	11.04	0.52	2.2e-24	Blood metabolite ratios;
LUSC	trans	rs12210905	0.622	rs116198502	chr6:26915015	A/G	cg11837749	chr1:55047332	ACOT11	0.55	5.97	0.31	6.14e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25072359	chr17:41440525	NA	0.69	9.65	0.47	1.36e-19	Menopause (age at onset);
LUSC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg13206674	chr6:150067644	NUP43	0.59	9.28	0.45	2.26e-18	Lung cancer;
LUSC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.63	-10.19	-0.49	2.09e-21	Cognitive test performance;
LUSC	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg13736514	chr6:26305472	NA	-0.45	-8.91	-0.44	3.34e-17	Educational attainment;
LUSC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-0.88	-18.2	-0.71	6.32e-52	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18538332	chr22:24372958	LOC391322	-0.48	-8.65	-0.43	2.14e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	9.49	0.46	4.38e-19	Eotaxin levels;
LUSC	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg21770322	chr7:97807741	LMTK2	-0.49	-7.95	-0.4	2.97e-14	Breast cancer;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg09361219	chr2:61293079	KIAA1841	0.39	6.15	0.32	2.16e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg14696996	chr19:15285081	NOTCH3	0.99	9.07	0.44	1.06e-17	Pulse pressure;
LUSC	cis	rs72634258	0.945	rs7522911	chr1:8097145	C/T	cg00042356	chr1:8021962	PARK7	0.84	10.05	0.48	5.98e-21	Inflammatory bowel disease;
LUSC	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg03563238	chr19:33554763	RHPN2	-0.4	-6.47	-0.33	3.46e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg10604040	chr11:65559109	OVOL1	0.31	5.75	0.3	1.99e-8	Acne (severe);
LUSC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg07661805	chr8:143867942	LY6D	-0.25	-5.93	-0.31	7.69e-9	Urinary tract infection frequency;
LUSC	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg26395211	chr5:140044315	WDR55	-0.37	-5.7	-0.3	2.69e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4319547	0.688	rs6489158	chr12:123110365	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.52	-7.42	-0.38	9.66e-13	Body mass index;
LUSC	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	10.94	0.51	5.25e-24	Response to antipsychotic treatment;
LUSC	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg18827107	chr12:86230957	RASSF9	-0.45	-6.77	-0.35	5.7e-11	Major depressive disorder;
LUSC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-8.97	-0.44	2.1e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg05347473	chr6:146136440	FBXO30	-0.39	-6.55	-0.34	2.24e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg01528321	chr10:82214614	TSPAN14	1.16	19.38	0.73	1.38e-56	Post bronchodilator FEV1;
LUSC	cis	rs10108704	1.000	rs28463252	chr8:110360137	T/A	cg20147595	chr8:110349212	ENY2	-0.44	-5.75	-0.3	2.04e-8	Multiple system atrophy (pathologically confirmed);
LUSC	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.61	0.5	7.28e-23	Colorectal cancer;
LUSC	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg16230307	chr14:35515116	FAM177A1	0.78	9.88	0.48	2.39e-20	Psoriasis;
LUSC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg02931644	chr1:25747376	RHCE	0.39	7.18	0.37	4.61e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.76	13.57	0.6	1.04e-33	Age at first birth;
LUSC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-0.99	-16.75	-0.68	4e-46	Body mass index;
LUSC	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg13010199	chr12:38710504	ALG10B	0.64	9.82	0.47	3.64e-20	Bladder cancer;
LUSC	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg22709100	chr7:91322751	NA	-0.42	-6.12	-0.32	2.69e-9	Breast cancer;
LUSC	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg01851573	chr8:8652454	MFHAS1	0.54	8.22	0.41	4.59e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg21849932	chr20:62369462	LIME1	0.43	6.53	0.34	2.5e-10	Prostate cancer;
LUSC	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg20307385	chr11:47447363	PSMC3	0.45	6.5	0.34	2.91e-10	Subjective well-being;
LUSC	cis	rs7828089	0.875	rs6998575	chr8:22254499	C/T	cg12081754	chr8:22256438	SLC39A14	0.62	10.22	0.49	1.68e-21	Verbal declarative memory;
LUSC	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg07741184	chr6:167504864	NA	-0.34	-5.98	-0.31	5.59e-9	Crohn's disease;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04720665	chr1:245028075	HNRNPU	-0.41	-6.26	-0.32	1.15e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.61	0.6	7.09e-34	Cognitive test performance;
LUSC	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg01028140	chr2:1542097	TPO	-0.61	-9.12	-0.45	7.42e-18	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.5	0.34	2.86e-10	Morning vs. evening chronotype;
LUSC	trans	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Parkinson's disease;
LUSC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.68	0.47	1.08e-19	Bipolar disorder;
LUSC	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg10547527	chr2:198650123	BOLL	-0.5	-5.85	-0.3	1.16e-8	Ulcerative colitis;
LUSC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.87	16.84	0.68	1.7e-46	Mean platelet volume;
LUSC	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg23387468	chr7:139079360	LUC7L2	-0.4	-5.92	-0.31	8.12e-9	Diisocyanate-induced asthma;
LUSC	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg02822958	chr2:46747628	ATP6V1E2	-0.36	-6.05	-0.31	3.92e-9	Height;
LUSC	trans	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg14791747	chr16:20752902	THUMPD1	-0.4	-6.13	-0.32	2.47e-9	Dental caries;
LUSC	cis	rs713477	1.000	rs8010013	chr14:55884828	A/C	cg04306507	chr14:55594613	LGALS3	-0.34	-6.82	-0.35	4.32e-11	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg13010199	chr12:38710504	ALG10B	0.55	8.52	0.42	5.57e-16	Morning vs. evening chronotype;
LUSC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg09359103	chr1:154839909	KCNN3	-0.73	-17.4	-0.69	1.05e-48	Prostate cancer;
LUSC	cis	rs2455601	0.671	rs2568091	chr11:8986048	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.27	-0.32	1.14e-9	Schizophrenia;
LUSC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg00255919	chr5:131827918	IRF1	-0.42	-8.01	-0.4	1.97e-14	Asthma (sex interaction);
LUSC	cis	rs2798269	0.867	rs2761909	chr13:22116804	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.41	-6.32	-0.33	8.19e-10	PR segment;
LUSC	cis	rs17154702	0.510	rs7831224	chr8:8656647	C/T	cg01851573	chr8:8652454	MFHAS1	0.56	7.7	0.39	1.54e-13	Neurocognitive impairment in HIV-1 infection (continuous);
LUSC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg12560992	chr17:57184187	TRIM37	0.85	15.53	0.65	2.58e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs1443512	0.947	rs894739	chr12:54346869	T/C	cg17410650	chr12:54324560	NA	-0.44	-7.08	-0.36	8.37e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.16	0.49	2.56e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg17294928	chr15:75287854	SCAMP5	-0.76	-10.12	-0.48	3.67e-21	Blood trace element (Zn levels);
LUSC	cis	rs2742417	0.603	rs7631818	chr3:45775931	A/T	cg04837898	chr3:45731254	SACM1L	-0.46	-7.41	-0.38	1.08e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg13397359	chr6:42928475	GNMT	0.43	5.93	0.31	7.54e-9	Blood protein levels;
LUSC	cis	rs7804356	1.000	rs10272303	chr7:26827815	T/C	cg03456212	chr7:26904342	SKAP2	-0.56	-6.63	-0.34	1.36e-10	Type 1 diabetes;
LUSC	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg20744362	chr22:50050164	C22orf34	0.4	8.33	0.41	2.15e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg02951883	chr7:2050386	MAD1L1	-0.44	-7.45	-0.38	8.19e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg25838465	chr1:92012736	NA	0.45	6.19	0.32	1.8e-9	Eosinophil percentage of white cells;
LUSC	cis	rs1560104	0.709	rs9806831	chr16:12704395	A/G	cg02946846	chr16:12632861	SNX29	0.32	5.83	0.3	1.28e-8	Obesity-related traits;
LUSC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg15445000	chr17:37608096	MED1	0.4	6.7	0.34	8.76e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg19046167	chr17:80928561	B3GNTL1	0.44	6.94	0.36	1.99e-11	Breast cancer;
LUSC	cis	rs977987	0.806	rs2285225	chr16:75429252	T/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.02	-0.36	1.26e-11	Dupuytren's disease;
LUSC	cis	rs17001868	0.568	rs9607702	chr22:40739177	A/G	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg00857998	chr1:205179979	DSTYK	0.59	9.0	0.44	1.73e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs4729127	1.000	rs12673727	chr7:93987809	G/A	cg20086523	chr13:52378287	DHRS12	0.56	6.0	0.31	5.11e-9	Intelligence;
LUSC	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	0.92	15.91	0.66	8.08e-43	Menopause (age at onset);
LUSC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.74	-0.35	6.77e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	6.08	0.32	3.2e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg07395648	chr5:131743802	NA	-0.37	-5.71	-0.3	2.54e-8	Asthma (sex interaction);
LUSC	trans	rs61931739	0.635	rs7979207	chr12:33910566	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-6.13	-0.32	2.45e-9	Morning vs. evening chronotype;
LUSC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.56	-0.34	2.08e-10	Life satisfaction;
LUSC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg18240062	chr17:79603768	NPLOC4	0.58	10.19	0.49	2.01e-21	Eye color traits;
LUSC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg18512352	chr11:47633146	NA	0.48	9.98	0.48	1.03e-20	Subjective well-being;
LUSC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.83	0.35	3.98e-11	Platelet count;
LUSC	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.79	-14.05	-0.61	1.46e-35	Iron status biomarkers;
LUSC	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.85	-15.5	-0.65	3.37e-41	Caffeine consumption;
LUSC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg27532560	chr4:187881888	NA	-0.38	-6.27	-0.32	1.1e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.44	-5.98	-0.31	5.62e-9	Neutrophil percentage of white cells;
LUSC	cis	rs8048589	0.615	rs34098770	chr16:12237812	G/A	cg02910054	chr16:12241554	SNX29	0.51	6.3	0.33	9.22e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs2573652	0.657	rs2573668	chr15:100541776	C/T	cg00587665	chr15:100533223	ADAMTS17	0.39	6.92	0.35	2.25e-11	Height;
LUSC	cis	rs4363385	0.747	rs3753454	chr1:152973776	T/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.59	-0.38	3.15e-13	Inflammatory skin disease;
LUSC	cis	rs250677	0.522	rs62378210	chr5:148384885	G/A	cg18129178	chr5:148520854	ABLIM3	-0.51	-7.28	-0.37	2.42e-12	Breast cancer;
LUSC	cis	rs7520050	0.966	rs12049588	chr1:46472422	G/A	cg06784218	chr1:46089804	CCDC17	-0.29	-5.69	-0.3	2.78e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg07741184	chr6:167504864	NA	0.39	6.88	0.35	2.9e-11	Primary biliary cholangitis;
LUSC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg11752832	chr7:134001865	SLC35B4	0.6	9.38	0.46	1.04e-18	Mean platelet volume;
LUSC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-8.05	-0.4	1.49e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg22356347	chr1:167427500	CD247	-0.25	-5.81	-0.3	1.43e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg03453431	chr7:157225567	NA	-0.57	-10.42	-0.5	3.27e-22	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-7.11	-0.36	7.07e-12	Aortic root size;
LUSC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg15212455	chr7:39170539	POU6F2	0.65	11.19	0.52	6.8e-25	IgG glycosylation;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg00024416	chr22:24240387	NA	-0.32	-5.89	-0.31	9.24e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg21433313	chr16:3507492	NAT15	-0.41	-6.51	-0.34	2.71e-10	Body mass index (adult);
LUSC	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg23711669	chr6:146136114	FBXO30	0.83	14.71	0.63	4.06e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg15848620	chr12:58087721	OS9	-0.51	-7.37	-0.37	1.34e-12	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg23625390	chr15:77176239	SCAPER	-0.66	-10.06	-0.48	5.61e-21	Blood metabolite levels;
LUSC	cis	rs6574644	0.920	rs12146979	chr14:81780859	A/G	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04165764	chr17:48074112	NA	-0.4	-5.95	-0.31	6.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.37	5.83	0.3	1.34e-8	Vitiligo;
LUSC	cis	rs4343996	0.754	rs6965684	chr7:3348223	A/T	cg21248987	chr7:3385318	SDK1	0.37	6.37	0.33	6.31e-10	Motion sickness;
LUSC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg12463550	chr7:65579703	CRCP	0.42	6.03	0.31	4.41e-9	Aortic root size;
LUSC	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg00376283	chr12:123451042	ABCB9	0.64	8.15	0.41	7.56e-15	Neutrophil percentage of white cells;
LUSC	cis	rs10743315	0.557	rs78468792	chr12:19351592	T/A	cg02471346	chr12:19282374	PLEKHA5	0.78	6.28	0.33	1.02e-9	Gut microbiota (bacterial taxa);
LUSC	trans	rs2587949	0.550	rs1825509	chr3:4207147	C/T	cg15139668	chr4:4577005	NA	-0.41	-6.03	-0.31	4.27e-9	Periodontitis (DPAL);
LUSC	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg05340658	chr4:99064831	C4orf37	0.45	7.22	0.37	3.43e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-9.48	-0.46	4.76e-19	Morning vs. evening chronotype;
LUSC	cis	rs965469	1.000	rs1040727	chr20:3264292	G/A	cg25506879	chr20:3388711	C20orf194	-0.55	-5.93	-0.31	7.41e-9	IFN-related cytopenia;
LUSC	trans	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg05926928	chr17:57297772	GDPD1	-0.88	-10.12	-0.48	3.55e-21	Opioid sensitivity;
LUSC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg10130564	chr11:117069849	TAGLN	-0.38	-6.59	-0.34	1.71e-10	Blood protein levels;
LUSC	cis	rs4622329	0.552	rs4764669	chr12:102288250	G/A	cg23541617	chr12:102225335	GNPTAB	0.27	6.38	0.33	5.92e-10	Systemic lupus erythematosus;
LUSC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg06096015	chr1:231504339	EGLN1	0.56	9.84	0.47	3.23e-20	Hemoglobin concentration;
LUSC	cis	rs2835872	0.828	rs73220495	chr21:38989712	G/A	cg20424643	chr21:39039972	KCNJ6	0.37	5.78	0.3	1.74e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg03585969	chr10:35415529	CREM	0.64	8.96	0.44	2.3e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg00427296	chr17:8534932	MYH10	-0.55	-6.09	-0.32	3.04e-9	Blood protein levels;
LUSC	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg13010199	chr12:38710504	ALG10B	0.6	9.78	0.47	4.97e-20	Morning vs. evening chronotype;
LUSC	cis	rs752010	0.619	rs6702659	chr1:42112236	T/C	cg06885757	chr1:42089581	HIVEP3	0.57	11.75	0.54	6.68e-27	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs9462027	0.606	rs12201281	chr6:34681091	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.33	5.79	0.3	1.65e-8	Systemic lupus erythematosus;
LUSC	cis	rs7572644	0.680	rs12465012	chr2:28028191	C/T	cg27432699	chr2:27873401	GPN1	0.55	7.3	0.37	2.19e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.81	13.8	0.6	1.33e-34	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-8.88	-0.44	4.2e-17	Gut microbiome composition (summer);
LUSC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.25	-0.32	1.26e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs669446	0.533	rs28833034	chr1:44212942	A/G	cg15962314	chr1:44399869	ARTN	0.24	5.73	0.3	2.28e-8	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg15737290	chr11:93063684	CCDC67	0.66	8.09	0.4	1.15e-14	Pulmonary function decline;
LUSC	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.38	-0.42	1.49e-15	Response to antipsychotic treatment;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13389229	chr3:49449900	RHOA;TCTA	-0.45	-6.09	-0.32	3.09e-9	Hepatitis;
LUSC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg06713675	chr4:122721982	EXOSC9	-0.45	-7.96	-0.4	2.76e-14	Type 2 diabetes;
LUSC	cis	rs273573	0.961	rs163854	chr11:30964632	G/T	cg06552810	chr11:31128660	NA	0.33	5.73	0.3	2.23e-8	Total body bone mineral density;
LUSC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg24375607	chr4:120327624	NA	0.79	11.91	0.55	1.72e-27	Corneal astigmatism;
LUSC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg04398451	chr17:18023971	MYO15A	-0.44	-6.97	-0.36	1.68e-11	Total body bone mineral density;
LUSC	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg22777020	chr22:31556080	RNF185	-0.46	-5.84	-0.3	1.26e-8	Colorectal cancer;
LUSC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.75	9.31	0.45	1.77e-18	Gut microbiome composition (summer);
LUSC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg07701084	chr6:150067640	NUP43	0.53	8.14	0.41	8.16e-15	Lung cancer;
LUSC	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg02023728	chr11:77925099	USP35	0.46	6.7	0.34	8.82e-11	Testicular germ cell tumor;
LUSC	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.67	0.43	1.91e-16	Menopause (age at onset);
LUSC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.92	0.44	3.02e-17	Motion sickness;
LUSC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.19	-13.56	-0.6	1.16e-33	Diabetic kidney disease;
LUSC	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg21890820	chr11:65308645	LTBP3	-0.53	-7.93	-0.4	3.33e-14	Bone mineral density;
LUSC	cis	rs4474465	0.646	rs7927503	chr11:78280606	G/T	cg27205649	chr11:78285834	NARS2	0.58	7.18	0.37	4.52e-12	Alzheimer's disease (survival time);
LUSC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.1	0.48	4.25e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg26043149	chr18:55253948	FECH	-0.42	-6.58	-0.34	1.84e-10	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg23590916	chr17:43697445	MGC57346	-0.49	-6.58	-0.34	1.8e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg04362960	chr10:104952993	NT5C2	-0.65	-10.26	-0.49	1.19e-21	Arsenic metabolism;
LUSC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26314531	chr2:26401878	FAM59B	-0.7	-9.93	-0.48	1.56e-20	Gut microbiome composition (summer);
LUSC	cis	rs30380	0.632	rs26498	chr5:96138812	C/T	cg16492584	chr5:96139282	ERAP1	0.56	7.55	0.38	4.28e-13	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-5.99	-0.31	5.44e-9	Triglycerides;
LUSC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg23711669	chr6:146136114	FBXO30	-0.77	-13.82	-0.6	1.17e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9318086	0.687	rs9507182	chr13:24442365	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.42	6.36	0.33	6.71e-10	Myopia (pathological);
LUSC	cis	rs6704644	0.719	rs72980376	chr2:234373368	C/T	cg05711037	chr2:234359783	DGKD	0.66	6.49	0.33	3.14e-10	Bilirubin levels;
LUSC	cis	rs983392	0.836	rs72918674	chr11:59944580	C/T	cg20284999	chr11:59952153	MS4A6A	-0.38	-6.24	-0.32	1.29e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6740322	0.895	rs6738717	chr2:43573670	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-7.16	-0.36	5.05e-12	Coronary artery disease;
LUSC	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg03709012	chr19:19516395	GATAD2A	0.93	11.5	0.53	5.11e-26	Nonalcoholic fatty liver disease;
LUSC	cis	rs11166629	1.000	rs966659	chr8:135639045	C/T	cg27224718	chr8:135614730	ZFAT	-0.66	-10.93	-0.51	5.6e-24	Smoking quantity;
LUSC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg16545954	chr1:2118288	C1orf86	0.32	6.22	0.32	1.45e-9	Height;
LUSC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg13813247	chr22:41461852	NA	-0.36	-6.52	-0.34	2.53e-10	Neuroticism;
LUSC	cis	rs2798269	0.933	rs2476639	chr13:22137266	T/G	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.06	-0.31	3.72e-9	PR segment;
LUSC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg03060546	chr3:49711283	APEH	-0.44	-6.17	-0.32	1.93e-9	Menarche (age at onset);
LUSC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg04414720	chr1:150670196	GOLPH3L	0.56	9.11	0.45	7.62e-18	Tonsillectomy;
LUSC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16680214	chr1:154839983	KCNN3	-0.57	-11.1	-0.52	1.46e-24	Prostate cancer;
LUSC	cis	rs554111	0.656	rs6695218	chr1:21190512	A/C	cg01072550	chr1:21505969	NA	0.41	6.32	0.33	8.51e-10	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg00784671	chr22:46762841	CELSR1	-0.42	-5.69	-0.3	2.82e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg02038168	chr22:39784481	NA	-0.45	-6.84	-0.35	3.82e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg20991723	chr1:152506922	NA	0.5	9.35	0.46	1.32e-18	Hair morphology;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13602813	chr3:13920840	WNT7A	0.45	7.14	0.36	5.99e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg01884057	chr2:25150051	NA	0.43	9.76	0.47	5.79e-20	Body mass index in non-asthmatics;
LUSC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg11062466	chr8:58055876	NA	-0.65	-8.35	-0.42	1.87e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21862992	chr11:68658383	NA	0.45	7.23	0.37	3.32e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06873352	chr17:61820015	STRADA	0.56	8.72	0.43	1.35e-16	Height;
LUSC	cis	rs11031096	0.678	rs970329	chr11:4189803	G/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.76	-0.3	1.96e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4654899	0.680	rs11805006	chr1:21249603	C/T	cg01072550	chr1:21505969	NA	-0.54	-8.16	-0.41	7.05e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.51	-0.38	5.34e-13	Bipolar disorder;
LUSC	cis	rs72960926	0.744	rs72952257	chr6:74924073	A/G	cg03266952	chr6:74778945	NA	-0.84	-7.01	-0.36	1.34e-11	Metabolite levels (MHPG);
LUSC	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg26384229	chr12:38710491	ALG10B	0.73	11.38	0.53	1.4e-25	Morning vs. evening chronotype;
LUSC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg06454157	chr6:167490870	NA	-0.26	-6.26	-0.32	1.2e-9	Crohn's disease;
LUSC	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg00677455	chr12:58241039	CTDSP2	0.49	7.42	0.38	9.56e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.84	14.89	0.63	7.84e-39	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs8040855	0.965	rs11073990	chr15:85711301	C/T	cg00988175	chr11:59481031	OR10V1	0.29	6.24	0.32	1.35e-9	Bulimia nervosa;
LUSC	cis	rs9311676	0.656	rs4399910	chr3:58389809	A/G	cg13750441	chr3:58318267	PXK	0.35	6.76	0.35	6.2e-11	Systemic lupus erythematosus;
LUSC	cis	rs2625529	0.730	rs1481860	chr15:72241857	T/C	cg16672083	chr15:72433130	SENP8	0.5	7.99	0.4	2.24e-14	Red blood cell count;
LUSC	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.38	0.33	6.06e-10	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.68e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg26384229	chr12:38710491	ALG10B	0.88	14.82	0.63	1.57e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg20243544	chr17:37824526	PNMT	0.48	6.73	0.35	7.42e-11	Asthma;
LUSC	cis	rs1506636	0.962	rs2896335	chr7:123376855	A/T	cg03229431	chr7:123269106	ASB15	-0.65	-10.57	-0.5	9.99e-23	Plateletcrit;Platelet count;
LUSC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.64	-0.39	2.3e-13	Retinal vascular caliber;
LUSC	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.9	-0.4	4.2e-14	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2710642	0.671	rs13009169	chr2:63405218	G/A	cg17519650	chr2:63277830	OTX1	-0.5	-6.8	-0.35	4.72e-11	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg21782813	chr7:2030301	MAD1L1	0.47	8.04	0.4	1.55e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	1.04	22.7	0.78	1.14e-69	Testicular germ cell tumor;
LUSC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg08847533	chr14:75593920	NEK9	-0.8	-13.67	-0.6	4.11e-34	Height;
LUSC	cis	rs3809566	0.710	rs4075583	chr15:63340227	C/T	cg05507819	chr15:63340323	TPM1	0.46	6.41	0.33	5.07e-10	Platelet count;
LUSC	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg03585969	chr10:35415529	CREM	0.62	8.91	0.44	3.28e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.49	-0.33	3.17e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.43	5.82	0.3	1.41e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg20019720	chr6:154832845	CNKSR3	0.62	8.69	0.43	1.63e-16	Lipoprotein (a) levels;
LUSC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.9	0.44	3.61e-17	Lung cancer;
LUSC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg06784218	chr1:46089804	CCDC17	0.54	10.88	0.51	8.41e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.05	0.4	1.44e-14	Corneal astigmatism;
LUSC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00321850	chr1:175162397	KIAA0040	0.46	7.83	0.39	6.5e-14	Alcohol dependence;
LUSC	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg23598886	chr18:12777645	NA	-0.57	-5.7	-0.3	2.67e-8	Inflammatory skin disease;
LUSC	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	ch.11.42038R	chr11:967971	AP2A2	0.53	7.76	0.39	1.05e-13	Alzheimer's disease (late onset);
LUSC	cis	rs61931739	0.817	rs866515	chr12:34215479	A/G	cg06521331	chr12:34319734	NA	-0.38	-6.44	-0.33	4.28e-10	Morning vs. evening chronotype;
LUSC	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.9	0.66	8.5e-43	Bladder cancer;
LUSC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg27170947	chr2:26402098	FAM59B	0.73	10.81	0.51	1.45e-23	Gut microbiome composition (summer);
LUSC	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg25457927	chr22:38595422	NA	-0.4	-8.42	-0.42	1.11e-15	Cutaneous nevi;
LUSC	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg18904891	chr8:8559673	CLDN23	0.41	5.89	0.31	9.22e-9	Neuroticism;
LUSC	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg11189052	chr15:85197271	WDR73	-0.44	-6.36	-0.33	6.53e-10	P wave terminal force;
LUSC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg17366294	chr4:99064904	C4orf37	0.56	9.8	0.47	4.42e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg17366294	chr4:99064904	C4orf37	0.58	10.38	0.49	4.47e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg22709100	chr7:91322751	NA	-0.38	-5.72	-0.3	2.37e-8	Breast cancer;
LUSC	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg18351406	chr4:77819688	ANKRD56	0.46	6.39	0.33	5.46e-10	Emphysema distribution in smoking;
LUSC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.61	0.54	2.17e-26	Alzheimer's disease;
LUSC	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg18357645	chr12:58087776	OS9	-0.41	-5.76	-0.3	1.87e-8	Multiple sclerosis;
LUSC	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.55e-13	Putamen volume;
LUSC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.03	20.27	0.74	3.82e-60	Cognitive function;
LUSC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg10792982	chr14:105748885	BRF1	0.5	8.84	0.44	5.56e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4843185	0.576	rs380996	chr16:85728813	A/G	cg05245094	chr16:85669572	KIAA0182	-0.42	-6.45	-0.33	3.99e-10	Platelet distribution width;
LUSC	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg16070123	chr10:51489643	NA	-0.5	-7.99	-0.4	2.18e-14	Prostate-specific antigen levels;
LUSC	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg17410650	chr12:54324560	NA	-0.58	-10.18	-0.49	2.21e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs939658	0.683	rs8024572	chr15:79465600	A/G	cg17916960	chr15:79447300	NA	0.39	7.16	0.36	5.18e-12	Refractive error;
LUSC	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg06623918	chr6:96969491	KIAA0776	-0.84	-10.4	-0.49	3.86e-22	Migraine;Coronary artery disease;
LUSC	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg07817648	chr10:79422355	NA	0.5	7.13	0.36	6.36e-12	Bone mineral density;
LUSC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.65	0.76	1.42e-65	Prudent dietary pattern;
LUSC	cis	rs2742417	0.603	rs2742458	chr3:45767602	C/T	cg04837898	chr3:45731254	SACM1L	-0.45	-7.26	-0.37	2.66e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9650315	0.929	rs72656020	chr8:57166349	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	7.2	0.37	3.99e-12	Height;
LUSC	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.66	-11.39	-0.53	1.28e-25	Electrocardiographic conduction measures;
LUSC	cis	rs1107366	1.000	rs1107364	chr3:125904263	G/A	cg20988073	chr3:125900093	ALDH1L1	-0.3	-6.04	-0.31	4.02e-9	Metabolite levels;
LUSC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.49	7.81	0.39	7.54e-14	Resistin levels;
LUSC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg03146154	chr1:46216737	IPP	0.56	8.39	0.42	1.36e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4919687	0.577	rs12765459	chr10:104465687	G/C	cg04362960	chr10:104952993	NT5C2	0.49	6.67	0.34	1.08e-10	Colorectal cancer;
LUSC	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg04518342	chr5:131593106	PDLIM4	0.32	5.88	0.31	9.85e-9	Blood metabolite levels;
LUSC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg23625390	chr15:77176239	SCAPER	0.51	7.83	0.39	6.53e-14	Blood metabolite levels;
LUSC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.04	0.4	1.61e-14	Parkinson's disease;
LUSC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.62	12.64	0.57	3.5e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg27284194	chr4:1044797	NA	0.52	8.55	0.42	4.34e-16	Recombination rate (males);
LUSC	cis	rs2637266	0.935	rs1866890	chr10:78397073	C/T	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.95e-13	Pulmonary function;
LUSC	cis	rs6845621	0.745	rs11737348	chr4:18855589	G/C	cg12196642	chr4:18937545	NA	-0.31	-5.82	-0.3	1.39e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9304742	0.611	rs10415443	chr19:53464864	C/G	cg09915433	chr19:53449742	NA	-0.5	-7.87	-0.4	4.9e-14	Psoriasis;
LUSC	cis	rs929596	0.564	rs2602362	chr2:234516548	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-6.07	-0.32	3.45e-9	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg08999081	chr20:33150536	PIGU	0.38	6.8	0.35	4.87e-11	Height;
LUSC	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.08	15.38	0.64	9.93e-41	Uric acid levels;
LUSC	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.28	-0.37	2.41e-12	Morning vs. evening chronotype;
LUSC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg21770322	chr7:97807741	LMTK2	0.41	7.03	0.36	1.2e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg20573242	chr4:122745356	CCNA2	0.43	6.53	0.34	2.45e-10	Type 2 diabetes;
LUSC	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg03929089	chr4:120376271	NA	-0.58	-7.46	-0.38	7.43e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs1865721	0.958	rs11663060	chr18:73172806	T/C	cg26385618	chr18:73139727	C18orf62	-0.47	-7.87	-0.4	4.85e-14	Intelligence;
LUSC	cis	rs9905704	0.633	rs4793588	chr17:56471051	G/T	cg19466818	chr17:56409534	MIR142	0.33	6.13	0.32	2.42e-9	Testicular germ cell tumor;
LUSC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.58	0.38	3.46e-13	Bipolar disorder;
LUSC	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg10253484	chr15:75165896	SCAMP2	-0.54	-7.36	-0.37	1.46e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7903847	0.632	rs11189157	chr10:99113729	G/A	cg20016023	chr10:99160130	RRP12	-0.29	-6.25	-0.32	1.22e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg04455712	chr21:45112962	RRP1B	0.45	8.56	0.42	4.04e-16	Mean corpuscular volume;
LUSC	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg05555928	chr11:63887634	MACROD1	-0.52	-6.35	-0.33	7.06e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg17385448	chr1:15911702	AGMAT	0.35	6.01	0.31	4.81e-9	Systolic blood pressure;
LUSC	cis	rs6867913	0.709	rs2338874	chr5:141466926	G/A	cg23435118	chr5:141488016	NDFIP1	-0.44	-6.92	-0.35	2.29e-11	Asthma;
LUSC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg11764359	chr7:65958608	NA	0.52	6.7	0.34	8.95e-11	Aortic root size;
LUSC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg02773041	chr1:40204384	PPIE	0.5	7.47	0.38	7.15e-13	Blood protein levels;
LUSC	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg04362960	chr10:104952993	NT5C2	0.58	9.16	0.45	5.32e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23260255	chr3:187871479	LPP	0.47	6.85	0.35	3.63e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg12463550	chr7:65579703	CRCP	-0.55	-8.09	-0.4	1.11e-14	Aortic root size;
LUSC	cis	rs12618769	0.625	rs3769726	chr2:99105827	G/C	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs10779751	1.000	rs4845982	chr1:11271576	T/C	cg08854313	chr1:11322531	MTOR	0.86	14.99	0.63	3.25e-39	Body mass index;
LUSC	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.8	-12.95	-0.58	2.24e-31	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg16339924	chr4:17578868	LAP3	0.55	8.53	0.42	5.11e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23106890	chr6:49431067	CENPQ;MUT	-0.43	-6.32	-0.33	8.18e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg09455208	chr3:40491958	NA	-0.49	-8.47	-0.42	7.78e-16	Renal cell carcinoma;
LUSC	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg10370574	chr19:1840461	REXO1	0.55	7.96	0.4	2.67e-14	Bipolar disorder;
LUSC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg16339924	chr4:17578868	LAP3	0.57	8.79	0.43	8.02e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg16362232	chr11:430036	ANO9	0.64	8.11	0.41	9.91e-15	Body mass index;
LUSC	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	0.78	11.89	0.55	1.96e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg22382663	chr15:68346430	PIAS1	0.45	6.68	0.34	9.76e-11	Calcium levels;
LUSC	cis	rs17155006	0.612	rs435361	chr7:107738552	C/T	cg05962710	chr7:107745446	LAMB4	-0.36	-6.3	-0.33	9.63e-10	Pneumococcal bacteremia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25080152	chr8:128748155	MYC	0.44	6.72	0.35	8.03e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3916	1.000	rs1799958	chr12:121176083	G/A	cg02419362	chr12:121203948	SPPL3	0.36	5.65	0.3	3.5e-8	Urinary metabolites (H-NMR features);
LUSC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg23985595	chr17:80112537	CCDC57	0.3	5.79	0.3	1.66e-8	Life satisfaction;
LUSC	cis	rs2692947	0.526	rs58719199	chr2:96578247	G/A	cg22654517	chr2:96458247	NA	0.37	6.93	0.35	2.17e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10802521	chr3:52805072	NEK4	-0.52	-8.46	-0.42	8.21e-16	Bipolar disorder;
LUSC	cis	rs9650315	0.778	rs56181002	chr8:57158384	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	7.54	0.38	4.5e-13	Height;
LUSC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-6.36	-0.33	6.74e-10	Longevity;Endometriosis;
LUSC	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	13.2	0.59	2.59e-32	Systemic lupus erythematosus;
LUSC	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg17788362	chr6:86352627	SYNCRIP	0.52	7.61	0.38	2.75e-13	Smooth-surface caries;
LUSC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg16339924	chr4:17578868	LAP3	0.66	10.35	0.49	6e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00260888	chr20:30865478	KIF3B	0.43	6.93	0.35	2.18e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.45e-8	Lymphocyte counts;
LUSC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg02493740	chr2:85810744	VAMP5	-0.38	-7.02	-0.36	1.21e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.47	-5.85	-0.3	1.18e-8	Iron status biomarkers;
LUSC	trans	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg21659725	chr3:3221576	CRBN	0.66	7.57	0.38	3.62e-13	Menarche (age at onset);
LUSC	trans	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg01620082	chr3:125678407	NA	-0.86	-7.49	-0.38	6.36e-13	Depression;
LUSC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.62	-10.31	-0.49	8.31e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs79387448	1.000	rs79387448	chr2:103215410	C/T	cg09003973	chr2:102972529	NA	0.77	7.41	0.38	1.05e-12	Gut microbiota (bacterial taxa);
LUSC	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg17366294	chr4:99064904	C4orf37	0.6	10.76	0.51	2.18e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg15744005	chr10:104629667	AS3MT	-0.39	-7.98	-0.4	2.29e-14	Arsenic metabolism;
LUSC	cis	rs472402	0.580	rs3736316	chr5:6656210	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.54	-7.77	-0.39	9.73e-14	Response to amphetamines;
LUSC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg11062466	chr8:58055876	NA	0.47	6.28	0.32	1.07e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg17143192	chr8:8559678	CLDN23	-0.64	-9.42	-0.46	7.43e-19	Obesity-related traits;
LUSC	cis	rs909002	0.962	rs1474181	chr1:32136610	C/G	cg13919466	chr1:32135498	COL16A1	-0.34	-6.35	-0.33	7e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg24562669	chr7:97807699	LMTK2	0.37	6.45	0.33	3.99e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.96	0.61	3.35e-35	Platelet count;
LUSC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg16647868	chr5:131706066	SLC22A5	-0.38	-5.81	-0.3	1.45e-8	Breast cancer;
LUSC	cis	rs11209002	0.567	rs2755268	chr1:67539881	T/C	cg02640540	chr1:67518911	SLC35D1	0.62	8.59	0.43	3.33e-16	Crohn's disease;
LUSC	cis	rs1775715	0.707	rs2808073	chr10:32179275	A/G	cg04359828	chr10:32216031	ARHGAP12	0.37	6.31	0.33	8.87e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg25566285	chr7:158114605	PTPRN2	0.35	6.53	0.34	2.52e-10	Calcium levels;
LUSC	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.82	0.43	6.31e-17	Axial length;
LUSC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg22117172	chr7:91764530	CYP51A1	0.32	5.77	0.3	1.81e-8	Breast cancer;
LUSC	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg00101154	chr16:420108	MRPL28	-0.4	-6.13	-0.32	2.42e-9	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs12145833	0.596	rs12026068	chr1:243440352	A/G	cg02356786	chr1:243265016	LOC731275	0.66	6.32	0.33	8.59e-10	Obesity (early onset extreme);
LUSC	cis	rs9653442	0.545	rs10496344	chr2:100764125	C/T	cg22139774	chr2:100720529	AFF3	0.42	7.26	0.37	2.79e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg20744362	chr22:50050164	C22orf34	0.39	7.08	0.36	8.47e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	0.8	12.82	0.57	7.09e-31	Gestational age at birth (maternal effect);
LUSC	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.19	-0.37	4.36e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg00800038	chr16:89945340	TCF25	0.74	6.81	0.35	4.55e-11	Skin colour saturation;
LUSC	cis	rs4622329	0.636	rs4764670	chr12:102288867	A/G	cg23541617	chr12:102225335	GNPTAB	0.26	6.07	0.32	3.51e-9	Systemic lupus erythematosus;
LUSC	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg04218760	chr10:45406644	TMEM72	-0.28	-6.85	-0.35	3.52e-11	Mean corpuscular volume;
LUSC	cis	rs1712517	0.771	rs2292807	chr10:105155645	T/C	cg05636881	chr10:105038444	INA	0.42	7.04	0.36	1.13e-11	Migraine;
LUSC	cis	rs4474465	0.850	rs7942371	chr11:78219975	A/G	cg27205649	chr11:78285834	NARS2	0.49	5.69	0.3	2.74e-8	Alzheimer's disease (survival time);
LUSC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	12.55	0.57	7.26e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	7.19	0.37	4.21e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7605827	0.930	rs3792578	chr2:15534642	G/A	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg24881330	chr22:46731750	TRMU	0.73	5.98	0.31	5.59e-9	Body mass index;
LUSC	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg12310025	chr6:25882481	NA	-0.34	-5.88	-0.31	9.73e-9	Height;
LUSC	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	16.39	0.67	1.04e-44	Chronic sinus infection;
LUSC	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.7	14.56	0.62	1.52e-37	Systemic lupus erythematosus;
LUSC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.72	-12.05	-0.55	5.1e-28	Motion sickness;
LUSC	trans	rs1133146	1.000	rs1133146	chr19:53666660	A/G	cg04114473	chr14:102976357	ANKRD9	-0.39	-6.44	-0.33	4.06e-10	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs6977660	1.000	rs4719584	chr7:19823388	T/C	cg05791153	chr7:19748676	TWISTNB	0.52	5.75	0.3	2.01e-8	Thyroid stimulating hormone;
LUSC	cis	rs7615316	1.000	rs6440098	chr3:142355410	A/C	cg16271453	chr3:142027066	XRN1	0.35	6.24	0.32	1.29e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9398803	0.865	rs4559102	chr6:126773580	G/A	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	1.96e-9	Male-pattern baldness;
LUSC	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg17168535	chr8:21777572	XPO7	0.65	9.39	0.46	9.5e-19	Mean corpuscular volume;
LUSC	cis	rs7577851	0.579	rs67016706	chr2:69548495	T/G	cg10773587	chr2:69614142	GFPT1	0.59	6.36	0.33	6.58e-10	Parkinson's disease (age of onset);
LUSC	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg21545522	chr1:205238299	TMCC2	0.43	8.16	0.41	7.02e-15	Red blood cell count;
LUSC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	0.98	13.91	0.61	5.29e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg16393715	chr7:1948819	MAD1L1	0.37	6.36	0.33	6.82e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9815354	0.680	rs73073290	chr3:42027684	T/G	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg00982548	chr2:198649783	BOLL	-0.58	-7.27	-0.37	2.59e-12	Ulcerative colitis;
LUSC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10053473	chr17:62856997	LRRC37A3	-0.67	-10.5	-0.5	1.8e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.35	5.82	0.3	1.4e-8	Neutrophil percentage of white cells;
LUSC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg26380479	chr7:97908229	NA	-0.27	-6.14	-0.32	2.37e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs931127	0.658	rs7926512	chr11:65464487	T/A	cg05805236	chr11:65401703	PCNXL3	-0.41	-7.08	-0.36	8.52e-12	Systemic lupus erythematosus;
LUSC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.81	0.39	7.4e-14	Prudent dietary pattern;
LUSC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg00431813	chr7:1051703	C7orf50	-0.44	-7.11	-0.36	7.21e-12	Longevity;Endometriosis;
LUSC	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg24579218	chr15:68104479	NA	-0.36	-6.28	-0.32	1.05e-9	Restless legs syndrome;
LUSC	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg05343316	chr1:45956843	TESK2	-0.63	-8.79	-0.43	7.84e-17	Platelet count;
LUSC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.85	-0.44	5.26e-17	Gut microbiome composition (summer);
LUSC	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.51	-10.33	-0.49	7e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs968451	0.552	rs715505	chr22:39751251	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.54	6.72	0.34	8.07e-11	Primary biliary cholangitis;
LUSC	cis	rs806215	1.000	rs698406	chr7:127255285	C/G	cg25922125	chr7:127225783	GCC1	0.57	7.1	0.36	7.44e-12	Type 2 diabetes;
LUSC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-6.03	-0.31	4.38e-9	Vitiligo;
LUSC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.22	0.61	3.35e-36	Platelet count;
LUSC	cis	rs7615316	0.899	rs4597728	chr3:142200809	T/C	cg16271453	chr3:142027066	XRN1	-0.4	-6.87	-0.35	3.22e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4285028	0.796	rs12638492	chr3:121711763	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-9.01	-0.44	1.68e-17	Multiple sclerosis;
LUSC	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg08807101	chr21:30365312	RNF160	0.72	11.55	0.53	3.34e-26	Pancreatic cancer;
LUSC	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg02569458	chr12:86230093	RASSF9	0.41	6.68	0.34	1.03e-10	Major depressive disorder;
LUSC	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg13010199	chr12:38710504	ALG10B	0.63	9.82	0.47	3.75e-20	Bladder cancer;
LUSC	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	19.88	0.74	1.33e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12667521	chr19:29218732	NA	0.61	8.77	0.43	9.02e-17	Methadone dose in opioid dependence;
LUSC	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	6.91	0.35	2.42e-11	Height;
LUSC	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg24375607	chr4:120327624	NA	0.72	11.49	0.53	5.61e-26	Corneal astigmatism;
LUSC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg02269571	chr22:50332266	NA	0.59	8.71	0.43	1.44e-16	Schizophrenia;
LUSC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg05585544	chr11:47624801	NA	-0.42	-7.36	-0.37	1.45e-12	Subjective well-being;
LUSC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg15557168	chr22:42548783	NA	-0.45	-6.86	-0.35	3.26e-11	Schizophrenia;
LUSC	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.73	-11.49	-0.53	5.8e-26	Schizophrenia;
LUSC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-12.63	-0.57	3.54e-30	Extrinsic epigenetic age acceleration;
LUSC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg08508325	chr11:3079039	CARS	-0.5	-12.49	-0.56	1.18e-29	Longevity;
LUSC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	trans	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	0.58	9.25	0.45	2.71e-18	Breast cancer;
LUSC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg14004847	chr7:1930337	MAD1L1	-0.58	-8.88	-0.44	4.24e-17	Schizophrenia;
LUSC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg21951975	chr1:209979733	IRF6	0.4	6.67	0.34	1.04e-10	Monobrow;
LUSC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg23649088	chr2:200775458	C2orf69	-0.55	-7.49	-0.38	6.12e-13	Schizophrenia;
LUSC	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.84	-0.44	5.62e-17	Metabolite levels;
LUSC	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	7.05	0.36	1.06e-11	Mood instability;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg20160885	chr7:5013524	RNF216L	0.48	5.97	0.31	5.92e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11764359	chr7:65958608	NA	0.61	9.2	0.45	3.85e-18	Aortic root size;
LUSC	cis	rs965469	1.000	rs6037556	chr20:3317890	G/C	cg25506879	chr20:3388711	C20orf194	-0.51	-5.68	-0.3	2.97e-8	IFN-related cytopenia;
LUSC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg12257692	chr3:49977190	RBM6	-0.25	-6.94	-0.36	1.99e-11	Body mass index;
LUSC	cis	rs7953508	0.750	rs7310389	chr12:93976636	A/G	cg18151635	chr12:93972918	NA	-0.56	-8.0	-0.4	2.04e-14	Pubertal anthropometrics;
LUSC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg03060546	chr3:49711283	APEH	0.45	5.97	0.31	6.16e-9	Menarche (age at onset);
LUSC	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.62	10.04	0.48	6.47e-21	Blood metabolite ratios;
LUSC	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs3771570	0.901	rs10190033	chr2:242412358	A/C	cg21155796	chr2:242212141	HDLBP	0.5	5.92	0.31	7.84e-9	Prostate cancer;
LUSC	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg23719950	chr11:63933701	MACROD1	0.58	7.34	0.37	1.6e-12	Mean platelet volume;
LUSC	trans	rs9944275	0.799	rs7163690	chr15:97206581	A/C	cg18834029	chr10:103349097	POLL;RP11-529I10.4	-0.52	-5.98	-0.31	5.7e-9	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LUSC	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-7.17	-0.37	4.99e-12	Morning vs. evening chronotype;
LUSC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg00376283	chr12:123451042	ABCB9	0.69	9.81	0.47	3.98e-20	Neutrophil percentage of white cells;
LUSC	cis	rs7224314	1.000	rs7224314	chr17:65386214	A/C	cg01507342	chr17:65387096	PITPNC1	-0.46	-8.24	-0.41	3.98e-15	Diisocyanate-induced asthma;
LUSC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg17264618	chr3:40429014	ENTPD3	0.3	6.46	0.33	3.61e-10	Renal cell carcinoma;
LUSC	cis	rs2078087	0.831	rs10911291	chr1:183233815	G/A	cg13843938	chr1:183241246	NMNAT2	0.44	5.89	0.31	9.45e-9	Obesity-related traits;
LUSC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.85	-0.47	2.99e-20	Subjective well-being;
LUSC	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs7336332	0.598	rs76249173	chr13:28010445	A/G	cg22138327	chr13:27999177	GTF3A	0.8	10.02	0.48	7.6e-21	Weight;
LUSC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg26898376	chr11:64110657	CCDC88B	0.34	6.4	0.33	5.11e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.69	-0.39	1.61e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg09307838	chr4:120376055	NA	0.55	8.13	0.41	8.52e-15	Corneal astigmatism;
LUSC	cis	rs28647808	0.881	rs7042326	chr9:136266636	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22496380	chr5:211416	CCDC127	-0.74	-8.61	-0.43	2.96e-16	Breast cancer;
LUSC	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.8	0.39	8.05e-14	Coffee consumption (cups per day);
LUSC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-6.06	-0.31	3.7e-9	Personality dimensions;
LUSC	cis	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05901451	chr6:126070800	HEY2	0.58	8.59	0.43	3.43e-16	Endometrial cancer;
LUSC	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs12681287	0.640	rs12549332	chr8:87353392	G/A	cg27223183	chr8:87520930	FAM82B	-0.53	-7.02	-0.36	1.28e-11	Caudate activity during reward;
LUSC	cis	rs9311676	0.656	rs56198078	chr3:58392224	G/C	cg26110898	chr3:58419937	PDHB	0.4	6.48	0.33	3.23e-10	Systemic lupus erythematosus;
LUSC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16680214	chr1:154839983	KCNN3	-0.51	-9.31	-0.45	1.79e-18	Prostate cancer;
LUSC	cis	rs2219968	0.962	rs13263076	chr8:78970258	T/C	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.93	0.35	2.18e-11	Tonsillectomy;
LUSC	trans	rs11696501	0.688	rs4812955	chr20:44324638	G/C	cg03272292	chr12:48577362	C12orf68	0.5	5.96	0.31	6.31e-9	Brain structure;
LUSC	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.82	0.35	4.29e-11	Height;
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12379764	chr21:47803548	PCNT	0.49	7.12	0.36	6.49e-12	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.39	-0.33	5.47e-10	Lung cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17976829	chr10:131934431	GLRX3	0.48	7.32	0.37	1.9e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg23711669	chr6:146136114	FBXO30	-0.87	-16.34	-0.67	1.56e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-6.3	-0.33	9.52e-10	Body mass index;
LUSC	cis	rs12711979	0.513	rs4849991	chr2:3840545	T/G	cg17052675	chr2:3827356	NA	-0.37	-6.14	-0.32	2.29e-9	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs72627509	0.904	rs56281640	chr4:57765816	G/A	cg26694713	chr4:57773883	REST	0.52	6.29	0.33	1.01e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg08213375	chr14:104286397	PPP1R13B	0.47	8.55	0.42	4.52e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.83	-14.22	-0.61	3.14e-36	Menarche (age at onset);
LUSC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg16797656	chr11:68205561	LRP5	-0.39	-7.14	-0.36	5.87e-12	Total body bone mineral density;
LUSC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg18512352	chr11:47633146	NA	-0.48	-9.73	-0.47	7.33e-20	Subjective well-being;
LUSC	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.77	-0.43	9.28e-17	Uric acid levels;
LUSC	cis	rs1775715	0.870	rs1775731	chr10:32253512	A/G	cg18675610	chr10:32216311	ARHGAP12	0.29	6.0	0.31	5.11e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg21573476	chr21:45109991	RRP1B	-0.37	-5.92	-0.31	7.85e-9	Mean corpuscular volume;
LUSC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg02187348	chr16:89574699	SPG7	0.5	7.93	0.4	3.27e-14	Multiple myeloma (IgH translocation);
LUSC	trans	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04565464	chr8:145669602	NFKBIL2	0.39	6.36	0.33	6.55e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.45	-0.46	6.03e-19	Schizophrenia;
LUSC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg13628971	chr7:2884303	GNA12	0.48	6.8	0.35	4.84e-11	Height;
LUSC	cis	rs231513	0.911	rs537165	chr17:41976736	C/T	cg26893861	chr17:41843967	DUSP3	-0.51	-6.06	-0.31	3.74e-9	Cognitive function;
LUSC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg11247378	chr22:39784982	NA	-0.64	-12.82	-0.57	6.95e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg25039879	chr17:56429692	SUPT4H1	0.71	9.29	0.45	2.02e-18	Cognitive test performance;
LUSC	cis	rs6596100	0.538	rs17516673	chr5:132196711	C/T	cg02081065	chr5:132209139	LEAP2	-0.62	-5.9	-0.31	9.1e-9	Breast cancer;
LUSC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg23711669	chr6:146136114	FBXO30	0.88	16.24	0.66	4e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg11812906	chr14:75593930	NEK9	-0.63	-10.49	-0.5	2e-22	Height;
LUSC	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg26102564	chr10:131424627	MGMT	0.37	5.93	0.31	7.52e-9	Response to temozolomide;
LUSC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg16606324	chr3:10149918	C3orf24	0.64	8.92	0.44	3.07e-17	Alzheimer's disease;
LUSC	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg21775007	chr8:11205619	TDH	-0.65	-10.3	-0.49	9.02e-22	Retinal vascular caliber;
LUSC	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg04036182	chr15:45458818	NA	-0.36	-5.73	-0.3	2.22e-8	Glomerular filtration rate;
LUSC	cis	rs2348418	0.864	rs11049714	chr12:28714095	G/A	cg13890972	chr12:28721907	NA	-0.34	-5.81	-0.3	1.49e-8	Lung function (FVC);Lung function (FEV1);
LUSC	trans	rs7980799	0.591	rs10844614	chr12:33605702	A/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.36	-0.42	1.69e-15	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs2267681	0.544	rs2361644	chr7:139516316	G/A	cg14116596	chr7:139528673	TBXAS1	0.37	6.42	0.33	4.77e-10	Cervical cancer;
LUSC	trans	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg17675199	chr6:35436792	RPL10A	-0.4	-5.95	-0.31	6.67e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg04369109	chr6:150039330	LATS1	-0.52	-7.41	-0.38	1.06e-12	Lung cancer;
LUSC	cis	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg17469321	chr7:55412551	NA	0.65	10.63	0.5	6.09e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9790314	0.690	rs7614375	chr3:160851331	A/T	cg03342759	chr3:160939853	NMD3	-0.41	-6.73	-0.35	7.18e-11	Morning vs. evening chronotype;
LUSC	cis	rs9650657	0.644	rs6601535	chr8:10695652	G/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.25	-0.32	1.28e-9	Neuroticism;
LUSC	cis	rs1322512	1.000	rs2800634	chr6:153010414	G/A	cg27316956	chr6:152958899	SYNE1	0.34	5.97	0.31	6.01e-9	Tonometry;
LUSC	cis	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg27411982	chr8:10470053	RP1L1	-0.41	-6.66	-0.34	1.13e-10	Systolic blood pressure;
LUSC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.0	0.55	7.78e-28	Prudent dietary pattern;
LUSC	trans	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-5.95	-0.31	6.76e-9	Joint mobility (Beighton score);
LUSC	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.77	-0.3	1.81e-8	Coronary artery disease;
LUSC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.23e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg01879757	chr17:41196368	BRCA1	-0.45	-6.84	-0.35	3.68e-11	Menopause (age at onset);
LUSC	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs11018904	0.768	rs35389990	chr11:89978683	T/C	cg26138821	chr11:89956704	CHORDC1	-0.59	-6.71	-0.34	8.28e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.63	12.18	0.55	1.8e-28	Pulse pressure;
LUSC	cis	rs6599077	1.000	rs9842262	chr3:40095675	T/G	cg13683864	chr3:40499215	RPL14	-0.6	-7.66	-0.39	2.06e-13	Sleep-related phenotypes;
LUSC	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.06	-0.31	3.58e-9	Breast cancer;
LUSC	cis	rs4478858	0.663	rs11591060	chr1:31780012	G/A	cg00250761	chr1:31883323	NA	-0.35	-8.54	-0.42	4.8e-16	Alcohol dependence;
LUSC	cis	rs4363385	0.693	rs7556517	chr1:152925755	G/T	cg07796016	chr1:152779584	LCE1C	0.48	6.91	0.35	2.5e-11	Inflammatory skin disease;
LUSC	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg05985134	chr18:33552581	C18orf21	0.51	6.84	0.35	3.76e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.03	20.49	0.75	5.09e-61	Cognitive function;
LUSC	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg04155231	chr12:9217510	LOC144571	0.3	5.67	0.3	3.11e-8	Sjögren's syndrome;
LUSC	cis	rs983392	0.805	rs2123314	chr11:59966295	C/T	cg20284999	chr11:59952153	MS4A6A	0.4	6.93	0.35	2.24e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2303282	0.716	rs2966206	chr16:56441253	G/A	cg00500540	chr16:56394104	NA	-0.43	-7.33	-0.37	1.74e-12	Breast cancer;
LUSC	cis	rs56283067	0.847	rs10456536	chr6:44692995	G/C	cg20913747	chr6:44695427	NA	-0.49	-7.97	-0.4	2.54e-14	Total body bone mineral density;
LUSC	cis	rs796364	0.570	rs35733345	chr2:200647533	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-6.57	-0.34	1.96e-10	Schizophrenia;
LUSC	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs12545109	0.800	rs1530217	chr8:57408097	C/T	cg09654669	chr8:57350985	NA	-0.52	-6.66	-0.34	1.1e-10	Obesity-related traits;
LUSC	cis	rs6722750	0.901	rs6710681	chr2:64413221	A/G	cg22352474	chr2:64371530	PELI1	-0.45	-6.77	-0.35	5.71e-11	Neuroticism;
LUSC	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg08601574	chr20:25228251	PYGB	0.39	5.98	0.31	5.71e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08280861	chr8:58055591	NA	-0.58	-6.29	-0.33	9.87e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.9	17.74	0.7	4.53e-50	Menarche (age at onset);
LUSC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.67	0.6	4.14e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	5.9	0.31	8.79e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg16989719	chr2:238392110	NA	-0.41	-7.18	-0.37	4.43e-12	Prostate cancer;
LUSC	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.7e-12	Type 2 diabetes;
LUSC	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg16070123	chr10:51489643	NA	-0.5	-7.99	-0.4	2.21e-14	Prostate-specific antigen levels;
LUSC	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.51	-6.83	-0.35	3.98e-11	Response to bleomycin (chromatid breaks);
LUSC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.38	-0.37	1.25e-12	Electroencephalogram traits;
LUSC	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.86	0.4	5.28e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg21385522	chr1:16154831	NA	-0.56	-8.21	-0.41	5.04e-15	Systolic blood pressure;
LUSC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg18825119	chr6:163149453	PACRG;PARK2	-0.35	-6.2	-0.32	1.67e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg00684032	chr4:1343700	KIAA1530	0.36	6.18	0.32	1.91e-9	Obesity-related traits;
LUSC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg05738196	chr6:26577821	NA	0.78	14.06	0.61	1.32e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg22143856	chr6:28129313	ZNF389	0.42	5.78	0.3	1.73e-8	Parkinson's disease;
LUSC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg00106254	chr7:1943704	MAD1L1	-0.42	-6.01	-0.31	4.9e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg13607699	chr17:42295918	UBTF	-0.54	-8.46	-0.42	8.29e-16	Total body bone mineral density;
LUSC	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg23711669	chr6:146136114	FBXO30	0.73	12.89	0.58	3.92e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-0.96	-13.64	-0.6	5.69e-34	Vitiligo;
LUSC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg02487422	chr3:49467188	NICN1	0.41	5.79	0.3	1.64e-8	Parkinson's disease;
LUSC	cis	rs11051970	0.879	rs2728680	chr12:32583512	T/C	cg02745156	chr12:32552066	NA	0.43	7.29	0.37	2.29e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg07856975	chr6:36356162	ETV7	0.34	6.21	0.32	1.61e-9	Platelet distribution width;
LUSC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg11062466	chr8:58055876	NA	0.42	5.66	0.3	3.32e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg13010344	chr12:123464640	ARL6IP4	0.49	8.01	0.4	1.92e-14	Neutrophil percentage of white cells;
LUSC	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	0.97	15.28	0.64	2.54e-40	Dupuytren's disease;
LUSC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.11	0.36	7.26e-12	Mean platelet volume;
LUSC	cis	rs6987853	0.787	rs2974300	chr8:42440532	C/T	cg09913449	chr8:42400586	C8orf40	0.51	8.82	0.43	6.44e-17	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg03676636	chr4:99064102	C4orf37	0.36	7.84	0.39	6.16e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg00173435	chr12:106696525	TCP11L2	0.6	8.68	0.43	1.83e-16	Tourette syndrome;
LUSC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	0.93	12.69	0.57	2.24e-30	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs853679	1.000	rs853676	chr6:28299687	C/T	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.32	-0.33	8.28e-10	Depression;
LUSC	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg11887960	chr12:57824829	NA	0.54	6.8	0.35	4.89e-11	Obesity-related traits;
LUSC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-5.8	-0.3	1.58e-8	Tonsillectomy;
LUSC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg05855489	chr10:104503620	C10orf26	-0.76	-12.89	-0.58	3.99e-31	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg26304593	chr6:42947056	PEX6	-0.49	-7.4	-0.38	1.13e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	7.67	0.39	1.94e-13	Prudent dietary pattern;
LUSC	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg04586622	chr2:25135609	ADCY3	0.43	9.13	0.45	6.59e-18	Body mass index;
LUSC	cis	rs7220401	0.512	rs71371126	chr17:28002642	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-8.71	-0.43	1.39e-16	Coronary artery disease;
LUSC	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg03342759	chr3:160939853	NMD3	-0.43	-6.37	-0.33	6.25e-10	Kawasaki disease;
LUSC	cis	rs2540226	0.935	rs6731450	chr2:39977336	G/C	cg23576258	chr2:39999331	THUMPD2	0.34	5.72	0.3	2.35e-8	Personality dimensions;
LUSC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.72e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6967385	0.604	rs2883866	chr7:12332245	T/A	cg20607287	chr7:12443886	VWDE	0.36	5.67	0.3	3.12e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg19230755	chr7:65878503	NA	0.43	6.06	0.31	3.59e-9	Aortic root size;
LUSC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg15839431	chr19:19639596	YJEFN3	0.42	5.73	0.3	2.3e-8	Tonsillectomy;
LUSC	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	13.78	0.6	1.66e-34	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg08213375	chr14:104286397	PPP1R13B	0.35	5.93	0.31	7.49e-9	Reticulocyte count;
LUSC	trans	rs2262909	0.962	rs11673195	chr19:22313814	T/C	cg17074339	chr11:11642133	GALNTL4	0.43	6.64	0.34	1.24e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg25036284	chr2:26402008	FAM59B	-0.68	-9.85	-0.47	2.84e-20	Gut microbiome composition (summer);
LUSC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg13683864	chr3:40499215	RPL14	-1.14	-21.3	-0.76	3.44e-64	Renal cell carcinoma;
LUSC	cis	rs500891	0.525	rs1170346	chr6:84021751	C/T	cg08257003	chr6:84140564	ME1	0.34	7.74	0.39	1.19e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	7.84	0.39	6.01e-14	Coffee consumption (cups per day);
LUSC	cis	rs977987	0.835	rs4888379	chr16:75340231	A/T	cg03315344	chr16:75512273	CHST6	0.51	9.86	0.47	2.74e-20	Dupuytren's disease;
LUSC	trans	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.72	0.51	3.02e-23	Mean corpuscular volume;
LUSC	trans	rs2188420	0.745	rs1636804	chr7:106591791	T/C	cg04262465	chr14:101405693	SNORD113-6	-0.39	-5.99	-0.31	5.48e-9	Interferon gamma levels;
LUSC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2652834	0.718	rs8034620	chr15:63397155	C/T	cg05507819	chr15:63340323	TPM1	0.55	6.98	0.36	1.55e-11	HDL cholesterol;
LUSC	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg12559939	chr2:27858050	GPN1	0.4	6.31	0.33	8.83e-10	Oral cavity cancer;
LUSC	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg08847533	chr14:75593920	NEK9	-0.44	-6.25	-0.32	1.26e-9	IgG glycosylation;
LUSC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg11663144	chr21:46675770	NA	-0.42	-7.26	-0.37	2.72e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs73200209	0.744	rs17498802	chr12:116642212	T/G	cg01776926	chr12:116560359	MED13L	-0.51	-6.18	-0.32	1.9e-9	Total body bone mineral density;
LUSC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg03732007	chr1:2071316	PRKCZ	-0.56	-10.12	-0.48	3.51e-21	Height;
LUSC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-7.02	-0.36	1.21e-11	Alzheimer's disease (late onset);
LUSC	trans	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg10756647	chr7:56101905	PSPH	0.88	8.45	0.42	8.8e-16	Diabetic kidney disease;
LUSC	cis	rs1832871	1.000	rs705930	chr6:158711855	T/C	cg07165851	chr6:158734300	TULP4	0.37	6.35	0.33	6.94e-10	Height;
LUSC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.18	-0.32	1.87e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16204216	chr11:3818895	PGAP2;NUP98	-0.41	-6.16	-0.32	2.12e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.84	-0.3	1.22e-8	IgG glycosylation;
LUSC	cis	rs6942756	0.668	rs644723	chr7:129107881	C/T	cg02491457	chr7:128862824	NA	-0.4	-5.72	-0.3	2.35e-8	White matter hyperintensity burden;
LUSC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.79	-0.39	8.52e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-19.85	-0.74	1.77e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs17102423	0.896	rs11158577	chr14:65596490	A/G	cg11161011	chr14:65562177	MAX	-0.61	-9.25	-0.45	2.78e-18	Obesity-related traits;
LUSC	cis	rs17102423	0.661	rs11627540	chr14:65614892	C/T	cg11161011	chr14:65562177	MAX	-0.69	-9.18	-0.45	4.48e-18	Obesity-related traits;
LUSC	cis	rs2708977	0.637	rs583705	chr2:97068754	C/T	cg01950434	chr2:97203154	ARID5A	-0.45	-6.2	-0.32	1.71e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.46	6.88	0.35	2.93e-11	Schizophrenia;
LUSC	cis	rs7577851	1.000	rs6757825	chr2:69741801	C/T	cg10773587	chr2:69614142	GFPT1	0.49	5.67	0.3	3.04e-8	Parkinson's disease (age of onset);
LUSC	cis	rs68170813	0.652	rs116894096	chr7:107178477	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.45	-5.65	-0.3	3.52e-8	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg21280719	chr6:42927975	GNMT	-0.31	-7.84	-0.39	6.14e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs12594515	1.000	rs11855562	chr15:45995659	C/T	cg06207120	chr15:45996521	NA	0.39	5.86	0.31	1.11e-8	Waist circumference;Weight;
LUSC	cis	rs7605827	0.897	rs2380650	chr2:15533689	T/C	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	trans	rs9409565	0.826	rs4744345	chr9:97207669	G/A	cg05679027	chr9:99775184	HIATL2	-0.49	-7.0	-0.36	1.43e-11	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07667813	chr19:7985168	SNAPC2	-0.33	-6.16	-0.32	2.04e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs17253792	0.822	rs112418863	chr14:56114079	G/A	cg01858014	chr14:56050164	KTN1	-0.8	-6.58	-0.34	1.79e-10	Putamen volume;
LUSC	cis	rs4700695	0.719	rs153390	chr5:65431087	G/C	cg21114390	chr5:65439923	SFRS12	-0.62	-8.57	-0.42	3.9e-16	Facial morphology (factor 19);
LUSC	cis	rs6076065	0.723	rs6083095	chr20:23354090	C/T	cg11657817	chr20:23433608	CST11	0.42	7.92	0.4	3.62e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg21535247	chr6:8435926	SLC35B3	0.56	8.49	0.42	6.76e-16	Motion sickness;
LUSC	cis	rs9359856	0.510	rs2768940	chr6:90436319	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.9	-10.8	-0.51	1.58e-23	Bipolar disorder;
LUSC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg07424592	chr7:64974309	NA	0.66	5.8	0.3	1.55e-8	Diabetic kidney disease;
LUSC	cis	rs12618769	0.652	rs7595120	chr2:99231805	C/G	cg10123293	chr2:99228465	UNC50	0.46	7.52	0.38	5.16e-13	Bipolar disorder;
LUSC	cis	rs6599077	0.950	rs4676563	chr3:40105092	G/C	cg13683864	chr3:40499215	RPL14	-0.61	-7.6	-0.38	3.09e-13	Sleep-related phenotypes;
LUSC	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg10253484	chr15:75165896	SCAMP2	0.5	6.91	0.35	2.47e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg05084668	chr3:125655381	ALG1L	-0.49	-6.86	-0.35	3.26e-11	Blood pressure (smoking interaction);
LUSC	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg25214090	chr10:38739885	LOC399744	0.51	7.54	0.38	4.35e-13	Corneal astigmatism;
LUSC	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg22713356	chr15:30763199	NA	1.0	13.06	0.58	8.86e-32	Uric acid levels;
LUSC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg17971929	chr21:40555470	PSMG1	-0.5	-7.35	-0.37	1.5e-12	Menarche (age at onset);
LUSC	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.72	12.31	0.56	5.67e-29	Cognitive function;
LUSC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.53	0.38	4.76e-13	Colorectal cancer;
LUSC	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg07959070	chr22:50026188	C22orf34	-0.36	-7.39	-0.37	1.22e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9549260	0.617	rs9549266	chr13:41278409	C/G	cg21288729	chr13:41239152	FOXO1	0.59	6.57	0.34	1.89e-10	Red blood cell count;
LUSC	cis	rs11642862	0.901	rs112190455	chr16:30971437	C/T	cg02466173	chr16:30829666	NA	-0.63	-6.45	-0.33	3.9e-10	Tonsillectomy;
LUSC	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg12927641	chr6:109611667	NA	-0.34	-5.82	-0.3	1.38e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg18357645	chr12:58087776	OS9	0.52	7.77	0.39	9.44e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02018176	chr4:1364513	KIAA1530	0.71	13.59	0.6	8.57e-34	Longevity;
LUSC	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg13057898	chr1:3703894	LRRC47	0.5	8.97	0.44	2.23e-17	Red cell distribution width;
LUSC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs259282	0.813	rs259250	chr19:33149216	T/C	cg22980127	chr19:33182716	NUDT19	-0.43	-6.28	-0.32	1.06e-9	Schizophrenia;
LUSC	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.67	12.8	0.57	8.76e-31	Age-related hearing impairment;
LUSC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg05552183	chr6:42928497	GNMT	0.49	8.17	0.41	6.42e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1190552	0.846	rs3742437	chr14:102965047	G/A	cg18135206	chr14:102964638	TECPR2	0.48	5.89	0.31	9.54e-9	Blood protein levels;
LUSC	cis	rs11958404	0.932	rs76228149	chr5:157434486	G/A	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	6.55	0.34	2.17e-10	Mean platelet volume;
LUSC	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.89	0.35	2.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs73206853	0.686	rs73194021	chr12:111131893	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	6.73	0.35	7.61e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6690583	0.573	rs7547317	chr1:85456961	T/G	cg22153463	chr1:85462885	MCOLN2	0.62	5.7	0.3	2.68e-8	Serum sulfate level;
LUSC	cis	rs4954585	0.683	rs11678502	chr2:136994454	C/T	cg05194412	chr2:137003533	NA	0.38	6.99	0.36	1.49e-11	Colorectal cancer;
LUSC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	0.93	17.43	0.69	7.74e-49	Heart rate;
LUSC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg20684491	chr1:25596433	NA	0.38	5.99	0.31	5.34e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs4713675	0.565	rs2274458	chr6:33679596	A/C	cg14003231	chr6:33640908	ITPR3	0.29	5.68	0.3	2.93e-8	Plateletcrit;
LUSC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg26384229	chr12:38710491	ALG10B	0.57	8.23	0.41	4.3e-15	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg17764715	chr19:33622953	WDR88	0.58	7.86	0.4	5.25e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg01765077	chr12:122356316	WDR66	0.51	7.26	0.37	2.81e-12	Mean corpuscular volume;
LUSC	cis	rs597583	0.806	rs1941390	chr11:117396991	G/A	cg27161313	chr11:117392002	DSCAML1	-0.43	-7.19	-0.37	4.33e-12	Putamen volume;
LUSC	trans	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.16	0.32	2.09e-9	Corneal astigmatism;
LUSC	trans	rs75804782	0.580	rs72987332	chr2:239362529	G/T	cg01134436	chr17:81009848	B3GNTL1	0.64	6.16	0.32	2.14e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg08330031	chr10:104623503	C10orf32	0.31	5.66	0.3	3.32e-8	Arsenic metabolism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27535044	chr8:82633568	ZFAND1	-0.51	-6.3	-0.33	9.21e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.61	9.52	0.46	3.64e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs977987	0.806	rs4888411	chr16:75443183	T/A	cg03315344	chr16:75512273	CHST6	0.48	8.98	0.44	2.08e-17	Dupuytren's disease;
LUSC	trans	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.08	-0.32	3.31e-9	Depression;
LUSC	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.89	-0.4	4.34e-14	Glomerular filtration rate;
LUSC	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg18002602	chr11:66138449	SLC29A2	0.47	8.38	0.42	1.44e-15	Educational attainment (years of education);
LUSC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.09	-19.0	-0.72	4.48e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg13126279	chr21:47581558	C21orf56	-0.42	-6.17	-0.32	1.93e-9	Testicular germ cell tumor;
LUSC	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.31	-6.15	-0.32	2.17e-9	Hemoglobin concentration;
LUSC	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg18132916	chr6:79620363	NA	-0.37	-5.7	-0.3	2.6e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg27094323	chr7:1216898	NA	-0.43	-7.2	-0.37	3.97e-12	Longevity;Endometriosis;
LUSC	cis	rs11955175	1.000	rs11956741	chr5:40677576	G/C	cg05478818	chr5:40835740	RPL37	0.7	5.77	0.3	1.81e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs6692729	0.966	rs6674701	chr1:227007182	A/G	cg10327440	chr1:227177885	CDC42BPA	0.46	6.6	0.34	1.64e-10	Electrodermal activity;
LUSC	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg23625390	chr15:77176239	SCAPER	0.46	7.03	0.36	1.15e-11	Blood metabolite levels;
LUSC	cis	rs6545883	0.859	rs7561672	chr2:61519094	G/A	cg15711740	chr2:61764176	XPO1	0.44	6.78	0.35	5.44e-11	Tuberculosis;
LUSC	cis	rs9309473	0.500	rs12472502	chr2:73859184	C/T	cg20560298	chr2:73613845	ALMS1	0.46	6.93	0.35	2.13e-11	Metabolite levels;
LUSC	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg05340658	chr4:99064831	C4orf37	0.68	11.4	0.53	1.23e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23375783	chr17:73008576	ICT1	-0.5	-6.55	-0.34	2.19e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13770153	chr20:60521292	NA	-0.61	-8.28	-0.41	3.08e-15	Body mass index;
LUSC	cis	rs59698941	0.943	rs72799496	chr5:132290911	T/C	cg02081065	chr5:132209139	LEAP2	-0.66	-6.63	-0.34	1.33e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs10782582	0.609	rs5745469	chr1:76347394	G/A	cg03433033	chr1:76189801	ACADM	-0.39	-5.7	-0.3	2.6e-8	Daytime sleep phenotypes;
LUSC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg16989086	chr20:62203971	PRIC285	0.45	6.34	0.33	7.32e-10	Glioblastoma;
LUSC	cis	rs12760731	0.623	rs1985761	chr1:178438645	A/G	cg00404053	chr1:178313656	RASAL2	0.47	5.79	0.3	1.6e-8	Obesity-related traits;
LUSC	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg21827317	chr3:136751795	NA	0.38	6.9	0.35	2.63e-11	Neuroticism;
LUSC	cis	rs6722750	0.716	rs1554877	chr2:64418977	A/G	cg22352474	chr2:64371530	PELI1	-0.54	-8.2	-0.41	5.29e-15	Neuroticism;
LUSC	trans	rs853679	0.599	rs149943	chr6:28002388	G/A	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.15	-0.36	5.51e-12	Depression;
LUSC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg06808227	chr14:105710500	BRF1	-0.68	-10.69	-0.5	4e-23	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.27	0.41	3.21e-15	Menarche (age at onset);
LUSC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.65	0.57	3.17e-30	Prudent dietary pattern;
LUSC	cis	rs12618769	0.597	rs72819965	chr2:99023719	G/C	cg10123293	chr2:99228465	UNC50	0.48	8.1	0.41	1.01e-14	Bipolar disorder;
LUSC	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg12310025	chr6:25882481	NA	0.36	6.1	0.32	3.01e-9	Blood metabolite levels;
LUSC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-11.97	-0.55	1.04e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12973672	0.904	rs10424619	chr19:35768237	A/T	cg12095397	chr19:35769544	USF2	0.43	6.61	0.34	1.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg18825119	chr6:163149453	PACRG;PARK2	-0.36	-6.33	-0.33	7.75e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg05347473	chr6:146136440	FBXO30	0.45	7.44	0.38	8.78e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03870842	chr4:123843873	NUDT6;SPATA5	-0.45	-6.16	-0.32	2.05e-9	Hepatitis;
LUSC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.18	-0.41	6.08e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05535760	chr7:792225	HEATR2	0.95	9.78	0.47	5.07e-20	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.71	-0.3	2.52e-8	Total body bone mineral density;
LUSC	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg26384229	chr12:38710491	ALG10B	-0.54	-8.2	-0.41	5.33e-15	Bladder cancer;
LUSC	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.64	0.34	1.3e-10	IgG glycosylation;
LUSC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18404041	chr3:52824283	ITIH1	-0.56	-10.63	-0.5	6.41e-23	Bipolar disorder;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.62	-10.61	-0.5	7.4e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg11062466	chr8:58055876	NA	0.71	8.73	0.43	1.27e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.31	21.44	0.76	9.26e-65	Type 1 diabetes nephropathy;
LUSC	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg07148914	chr20:33460835	GGT7	0.47	6.93	0.35	2.22e-11	Height;
LUSC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21518248	chr2:162101506	NA	0.46	6.96	0.36	1.81e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs2677744	0.534	rs6496739	chr15:91494430	C/T	cg23684204	chr15:91497937	RCCD1	0.57	7.95	0.4	2.87e-14	Attention deficit hyperactivity disorder;
LUSC	cis	rs6906287	0.609	rs13191610	chr6:118945317	G/A	cg21191810	chr6:118973309	C6orf204	0.32	5.9	0.31	9.06e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg17724175	chr1:150552817	MCL1	0.36	6.48	0.33	3.39e-10	Blood protein levels;
LUSC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs2562456	0.833	rs62107547	chr19:21524047	A/C	cg00806126	chr19:22604979	ZNF98	-0.43	-6.19	-0.32	1.78e-9	Pain;
LUSC	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-6.36	-0.33	6.76e-10	Reticulocyte count;
LUSC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg13918804	chr1:2043761	PRKCZ	0.27	5.66	0.3	3.34e-8	Height;
LUSC	cis	rs4417855	0.665	rs9867557	chr3:187410568	G/A	cg19198148	chr3:187451818	BCL6	0.57	10.26	0.49	1.2e-21	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07636037	chr3:49044803	WDR6	-0.67	-8.65	-0.43	2.22e-16	Menarche (age at onset);
LUSC	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.56	8.46	0.42	8.5e-16	Blood protein levels;
LUSC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06634786	chr22:41940651	POLR3H	-0.49	-5.79	-0.3	1.6e-8	Vitiligo;
LUSC	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg13647721	chr17:30228624	UTP6	0.6	6.13	0.32	2.53e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg08470875	chr2:26401718	FAM59B	-0.67	-8.96	-0.44	2.32e-17	Gut microbiome composition (summer);
LUSC	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs887829	0.570	rs10445704	chr2:234600274	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.3	-0.33	9.47e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg06008330	chr7:65541103	ASL	-0.4	-6.22	-0.32	1.52e-9	Aortic root size;
LUSC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	0.93	13.08	0.58	7.49e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg06937882	chr20:24974362	C20orf3	-0.41	-6.94	-0.36	2.02e-11	Blood protein levels;
LUSC	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg12179176	chr11:130786555	SNX19	0.62	9.3	0.45	1.89e-18	Schizophrenia;
LUSC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg00310523	chr12:86230176	RASSF9	0.53	9.74	0.47	6.71e-20	Major depressive disorder;
LUSC	cis	rs77633900	0.772	rs2469554	chr15:76642700	G/C	cg21673338	chr15:77095150	SCAPER	-0.69	-5.93	-0.31	7.56e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg11211951	chr8:145729740	GPT	0.57	11.3	0.53	2.65e-25	Age at first birth;
LUSC	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg11789530	chr4:8429930	ACOX3	-0.57	-8.74	-0.43	1.12e-16	Response to antineoplastic agents;
LUSC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.7	-10.67	-0.5	4.75e-23	Aortic root size;
LUSC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	6.57	0.34	1.93e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg15605315	chr1:45957053	TESK2	-0.41	-6.58	-0.34	1.81e-10	High light scatter reticulocyte count;
LUSC	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg22709100	chr7:91322751	NA	0.39	5.77	0.3	1.8e-8	Breast cancer;
LUSC	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg25809561	chr17:30822961	MYO1D	0.55	9.62	0.47	1.68e-19	Schizophrenia;
LUSC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.33	-0.37	1.77e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-9.04	-0.44	1.27e-17	Response to antipsychotic treatment;
LUSC	cis	rs2677744	0.626	rs11207	chr15:91497239	C/T	cg23684204	chr15:91497937	RCCD1	0.57	7.86	0.39	5.47e-14	Attention deficit hyperactivity disorder;
LUSC	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg18932078	chr1:2524107	MMEL1	-0.29	-6.44	-0.33	4.15e-10	Ulcerative colitis;
LUSC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	13.25	0.59	1.67e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg01879757	chr17:41196368	BRCA1	-0.45	-6.84	-0.35	3.68e-11	Menopause (age at onset);
LUSC	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	0.79	11.52	0.53	4.27e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06022373	chr22:39101656	GTPBP1	0.84	13.96	0.61	3.35e-35	Menopause (age at onset);
LUSC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg15335139	chr3:50242325	SLC38A3	-0.27	-5.97	-0.31	5.96e-9	Body mass index;
LUSC	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg07274523	chr3:49395745	GPX1	0.35	5.65	0.3	3.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1050846	0.603	rs1050847	chr16:87443734	A/G	cg27585878	chr16:87386489	FBXO31	0.37	6.14	0.32	2.29e-9	Neuroticism;
LUSC	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg23752985	chr2:85803571	VAMP8	0.36	7.83	0.39	6.48e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.92	0.51	6.12e-24	Hypertriglyceridemia;
LUSC	cis	rs7119	0.667	rs2867312	chr15:77902293	A/G	cg27398640	chr15:77910606	LINGO1	-0.36	-8.67	-0.43	1.91e-16	Type 2 diabetes;
LUSC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg07806771	chr7:64541737	NA	0.47	6.68	0.34	9.93e-11	Calcium levels;
LUSC	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg04450456	chr4:17643702	FAM184B	0.4	6.31	0.33	8.84e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23395165	chr19:4483111	HDGF2	-0.4	-6.32	-0.33	8.5e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26943378	chr22:50689804	HDAC10	-0.46	-7.07	-0.36	9.34e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg25206134	chr2:45395956	NA	0.51	5.98	0.31	5.87e-9	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg08680598	chr22:49984980	NA	-0.34	-6.25	-0.32	1.26e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs977987	0.836	rs17685540	chr16:75323840	T/C	cg04384234	chr16:75411784	CFDP1	-0.38	-6.0	-0.31	5.04e-9	Dupuytren's disease;
LUSC	cis	rs28595532	0.748	rs55949457	chr4:119336174	A/G	cg21605333	chr4:119757512	SEC24D	0.97	8.07	0.4	1.26e-14	Cannabis dependence symptom count;
LUSC	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.35	-5.83	-0.3	1.34e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg27284194	chr4:1044797	NA	0.35	5.7	0.3	2.58e-8	Obesity-related traits;
LUSC	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg27411982	chr8:10470053	RP1L1	-0.37	-5.9	-0.31	8.72e-9	Retinal vascular caliber;
LUSC	cis	rs4664308	0.694	rs4665140	chr2:160890710	T/A	cg03641300	chr2:160917029	PLA2R1	-0.48	-8.0	-0.4	2.13e-14	Idiopathic membranous nephropathy;
LUSC	trans	rs1325195	0.770	rs965401	chr1:179133221	T/A	cg11624085	chr17:8464688	MYH10	0.42	6.73	0.35	7.5e-11	IgE grass sensitization;
LUSC	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg05855489	chr10:104503620	C10orf26	0.55	8.35	0.42	1.82e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.69	-12.32	-0.56	5.45e-29	Ulcerative colitis;
LUSC	cis	rs3126085	0.935	rs2338430	chr1:152214420	C/T	cg26876637	chr1:152193138	HRNR	-0.46	-6.44	-0.33	4.17e-10	Atopic dermatitis;
LUSC	cis	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.65	-0.3	3.52e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg01879757	chr17:41196368	BRCA1	-0.47	-7.34	-0.37	1.61e-12	Menopause (age at onset);
LUSC	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.42e-8	Life satisfaction;
LUSC	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.83	9.32	0.45	1.66e-18	Yeast infection;
LUSC	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg11245181	chr6:149772854	ZC3H12D	0.3	6.52	0.34	2.63e-10	Dupuytren's disease;
LUSC	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg04369109	chr6:150039330	LATS1	-0.4	-5.78	-0.3	1.67e-8	Testicular germ cell tumor;
LUSC	cis	rs11169552	0.510	rs12231317	chr12:51041005	G/A	cg12884762	chr12:50931848	DIP2B	-0.31	-5.67	-0.3	3.15e-8	Colorectal cancer;
LUSC	trans	rs9944715	0.954	rs4890629	chr18:43797564	A/G	cg01718231	chr17:29326311	RNF135	-0.48	-6.81	-0.35	4.66e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg24812749	chr6:127587940	RNF146	0.73	10.48	0.5	2.02e-22	Breast cancer;
LUSC	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg13010199	chr12:38710504	ALG10B	0.44	6.95	0.36	1.9e-11	Morning vs. evening chronotype;
LUSC	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg00339695	chr16:24857497	SLC5A11	0.35	6.24	0.32	1.34e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22307029	chr19:49891270	CCDC155	0.6	6.12	0.32	2.69e-9	Multiple sclerosis;
LUSC	cis	rs4737010	0.536	rs6474365	chr8:41662940	G/T	cg08923054	chr8:41654455	ANK1	0.37	6.48	0.33	3.22e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6977660	0.619	rs12534026	chr7:19788687	T/C	cg07541023	chr7:19748670	TWISTNB	0.59	6.73	0.35	7.39e-11	Thyroid stimulating hormone;
LUSC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg05639522	chr1:247681581	NA	-0.41	-5.65	-0.3	3.45e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.08	0.64	1.48e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs17621444	0.505	rs4237514	chr10:121811325	C/G	cg02041677	chr10:121771263	NA	-0.33	-6.37	-0.33	6.1e-10	IgG glycosylation;
LUSC	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg16850897	chr7:100343110	ZAN	0.36	5.83	0.3	1.3e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg20243544	chr17:37824526	PNMT	0.42	6.48	0.33	3.27e-10	Self-reported allergy;
LUSC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg20243544	chr17:37824526	PNMT	0.53	7.46	0.38	7.66e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg24558204	chr6:135376177	HBS1L	0.58	9.03	0.44	1.38e-17	Red blood cell count;
LUSC	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg02753203	chr1:228287806	NA	-0.88	-16.23	-0.66	4.53e-44	Parkinson's disease;
LUSC	cis	rs9807841	0.617	rs2229383	chr19:10794630	G/T	cg17710535	chr19:10819994	QTRT1	0.42	6.95	0.36	1.97e-11	Inflammatory skin disease;
LUSC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg15595755	chr5:1867978	NA	0.45	8.46	0.42	8.21e-16	Cardiovascular disease risk factors;
LUSC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg11344533	chr11:111475393	SIK2	-0.48	-6.35	-0.33	7.13e-10	Primary sclerosing cholangitis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19638132	chr11:59521665	STX3	-0.45	-6.44	-0.33	4.22e-10	Hepatitis;
LUSC	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg08000102	chr2:233561755	GIGYF2	-0.74	-11.06	-0.52	2e-24	Schizophrenia;
LUSC	cis	rs1808579	1.000	rs11663558	chr18:21133937	G/A	cg14672496	chr18:21087552	C18orf8	0.34	5.66	0.3	3.24e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs3126085	0.935	rs12746239	chr1:152246726	G/A	cg26876637	chr1:152193138	HRNR	-0.44	-5.91	-0.31	8.24e-9	Atopic dermatitis;
LUSC	cis	rs865483	0.929	rs9906140	chr17:35857151	A/G	cg06716730	chr17:35851459	DUSP14	-0.28	-6.36	-0.33	6.71e-10	Monocyte count;
LUSC	cis	rs36093844	0.800	rs75605851	chr11:85580031	T/G	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg05805236	chr11:65401703	PCNXL3	-0.56	-9.2	-0.45	3.92e-18	Acne (severe);
LUSC	cis	rs977987	0.872	rs4243111	chr16:75320827	C/T	cg03315344	chr16:75512273	CHST6	0.49	9.18	0.45	4.59e-18	Dupuytren's disease;
LUSC	cis	rs3790645	1.000	rs392814	chr1:26892009	T/C	cg17456097	chr1:26900765	RPS6KA1	0.43	6.18	0.32	1.84e-9	Glucose homeostasis traits;
LUSC	cis	rs1322512	1.000	rs2758785	chr6:153010878	C/T	cg27316956	chr6:152958899	SYNE1	0.35	6.04	0.31	4.21e-9	Tonometry;
LUSC	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg00432049	chr6:150390894	ULBP3	-0.27	-5.68	-0.3	2.86e-8	Alopecia areata;
LUSC	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg24634471	chr8:143751801	JRK	0.6	8.92	0.44	3.02e-17	Schizophrenia;
LUSC	cis	rs9473147	0.543	rs9473119	chr6:47450618	G/A	cg12968598	chr6:47444699	CD2AP	0.53	8.18	0.41	6.12e-15	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs11608355	0.545	rs6606723	chr12:109905044	C/G	cg05360138	chr12:110035743	NA	0.89	11.55	0.53	3.47e-26	Neuroticism;
LUSC	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-13.95	-0.61	3.51e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg00701064	chr4:6280414	WFS1	0.62	15.75	0.65	3.37e-42	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.76	11.74	0.54	7.12e-27	Platelet count;
LUSC	trans	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg06606381	chr12:133084897	FBRSL1	-0.77	-6.79	-0.35	5.27e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.57	-0.34	1.92e-10	Lung cancer;
LUSC	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg12756686	chr19:29218302	NA	0.53	6.15	0.32	2.2e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.76	-13.71	-0.6	3e-34	Ulcerative colitis;
LUSC	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.24	-0.32	1.3e-9	Bipolar disorder;
LUSC	cis	rs4423214	0.535	rs1540129	chr11:71129523	C/G	cg05163923	chr11:71159392	DHCR7	0.51	6.9	0.35	2.65e-11	Vitamin D levels;
LUSC	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg13319975	chr6:146136371	FBXO30	0.49	7.37	0.37	1.35e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04297576	chr16:85588660	NA	-0.44	-6.74	-0.35	6.83e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg12756686	chr19:29218302	NA	0.57	6.49	0.33	3.05e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg03388025	chr16:89894329	SPIRE2	0.33	6.64	0.34	1.25e-10	Vitiligo;
LUSC	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg19554555	chr3:13937349	NA	-0.39	-5.84	-0.3	1.25e-8	Ovarian reserve;
LUSC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg15534755	chr11:117069859	TAGLN	0.35	6.14	0.32	2.33e-9	Blood protein levels;
LUSC	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-8.82	-0.43	6.4e-17	Morning vs. evening chronotype;
LUSC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18357526	chr6:26021779	HIST1H4A	0.4	5.97	0.31	6.22e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs17095355	1.000	rs12263915	chr10:111744664	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.48	-0.38	6.7e-13	Biliary atresia;
LUSC	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.77	0.51	1.98e-23	Morning vs. evening chronotype;
LUSC	trans	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg24644049	chr4:85504048	CDS1	0.61	6.36	0.33	6.61e-10	Skin colour saturation;
LUSC	cis	rs4363385	0.510	rs10494282	chr1:152923762	G/C	cg25856811	chr1:152973957	SPRR3	-0.38	-6.12	-0.32	2.6e-9	Inflammatory skin disease;
LUSC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg00990874	chr7:1149470	C7orf50	-0.45	-6.35	-0.33	6.98e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs500891	0.533	rs4706178	chr6:84184472	A/G	cg08257003	chr6:84140564	ME1	0.33	8.04	0.4	1.54e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.25	0.56	9.35e-29	Motion sickness;
LUSC	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-1.16	-18.75	-0.72	4.22e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg10327440	chr1:227177885	CDC42BPA	-0.62	-6.11	-0.32	2.79e-9	Major depressive disorder;
LUSC	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.39	0.46	9.94e-19	Coffee consumption (cups per day);
LUSC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4654899	0.733	rs10799678	chr1:21322785	C/T	cg01072550	chr1:21505969	NA	-0.53	-8.18	-0.41	6.01e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg23711669	chr6:146136114	FBXO30	0.86	15.43	0.65	6.19e-41	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg13565492	chr6:43139072	SRF	-0.57	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg24296786	chr1:45957014	TESK2	0.54	8.34	0.42	1.92e-15	High light scatter reticulocyte count;
LUSC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.61	8.22	0.41	4.65e-15	Response to diuretic therapy;
LUSC	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg27490568	chr2:178487706	NA	-0.38	-5.76	-0.3	1.96e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg20203395	chr5:56204925	C5orf35	-0.54	-7.69	-0.39	1.65e-13	Coronary artery disease;
LUSC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg12432903	chr7:1882776	MAD1L1	-0.37	-5.89	-0.31	9.43e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg01620082	chr3:125678407	NA	-0.87	-7.55	-0.38	4.28e-13	Depression;
LUSC	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg21095983	chr6:86352623	SYNCRIP	0.5	7.63	0.39	2.44e-13	Smooth-surface caries;
LUSC	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg17173187	chr15:85201210	NMB	-0.32	-6.56	-0.34	2e-10	P wave terminal force;
LUSC	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.73	-12.89	-0.58	3.95e-31	Bipolar disorder;
LUSC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13012494	chr21:47604986	C21orf56	0.39	5.76	0.3	1.9e-8	Testicular germ cell tumor;
LUSC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.76	11.31	0.53	2.58e-25	Migraine;
LUSC	trans	rs747782	0.528	rs624348	chr11:48400795	G/A	cg03929089	chr4:120376271	NA	-0.64	-5.98	-0.31	5.65e-9	Intraocular pressure;
LUSC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	4.73e-15	Homoarginine levels;
LUSC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg22655196	chr4:3374909	RGS12	0.3	5.76	0.3	1.95e-8	Serum sulfate level;
LUSC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.63	10.68	0.5	4.18e-23	Blood metabolite levels;
LUSC	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg25019033	chr10:957182	NA	-0.58	-7.66	-0.39	2.04e-13	Eosinophil percentage of granulocytes;
LUSC	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg21775007	chr8:11205619	TDH	0.49	6.92	0.35	2.32e-11	Mood instability;
LUSC	cis	rs73198271	1.000	rs11774744	chr8:8607764	A/G	cg01851573	chr8:8652454	MFHAS1	0.57	8.08	0.4	1.22e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.76	-12.82	-0.57	7.37e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg11344533	chr11:111475393	SIK2	-0.47	-6.45	-0.33	3.83e-10	Primary sclerosing cholangitis;
LUSC	trans	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg21659725	chr3:3221576	CRBN	-0.51	-7.9	-0.4	4.08e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs701145	0.585	rs1620712	chr3:153790050	C/G	cg17054900	chr3:154042577	DHX36	0.54	5.73	0.3	2.3e-8	Coronary artery disease;
LUSC	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg24006582	chr15:45444508	DUOX1	-0.61	-9.03	-0.44	1.43e-17	Uric acid levels;
LUSC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg11366901	chr6:160182831	ACAT2	0.94	13.12	0.58	5.38e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg05738196	chr6:26577821	NA	0.79	15.32	0.64	1.73e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg26408565	chr15:76604113	ETFA	-0.43	-6.75	-0.35	6.62e-11	Blood metabolite levels;
LUSC	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.72e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9921338	1.000	rs8055427	chr16:11436883	T/A	cg00044050	chr16:11439710	C16orf75	-0.5	-6.67	-0.34	1.07e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs4629180	1.000	rs11123889	chr2:102107180	G/A	cg01388757	chr2:102091195	RFX8	0.47	7.6	0.38	3.06e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.9	0.77	1.58e-66	Prudent dietary pattern;
LUSC	cis	rs9653442	0.900	rs10194635	chr2:100834217	T/A	cg07810366	chr2:100720526	AFF3	-0.47	-8.11	-0.41	9.73e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.26	0.52	3.74e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06221963	chr1:154839813	KCNN3	-0.61	-13.83	-0.6	1.03e-34	Prostate cancer;
LUSC	cis	rs6728642	0.572	rs1320147	chr2:97600626	A/C	cg26665480	chr2:98280029	ACTR1B	0.74	7.49	0.38	6.13e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs3925075	0.764	rs8044482	chr16:31345752	T/C	cg02846316	chr16:31340340	ITGAM	0.36	6.61	0.34	1.56e-10	IgA nephropathy;
LUSC	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg03676636	chr4:99064102	C4orf37	0.35	7.82	0.39	6.97e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg19622623	chr12:86230825	RASSF9	-0.42	-6.01	-0.31	4.85e-9	Major depressive disorder;
LUSC	cis	rs12594515	1.000	rs56412446	chr15:45996424	A/G	cg01629716	chr15:45996671	NA	0.39	5.87	0.31	1.08e-8	Waist circumference;Weight;
LUSC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.87	0.4	4.98e-14	Major depressive disorder;
LUSC	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg01028140	chr2:1542097	TPO	-0.37	-5.97	-0.31	6.12e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg09904177	chr6:26538194	HMGN4	0.47	7.47	0.38	7.28e-13	Schizophrenia;
LUSC	cis	rs7605827	0.675	rs55977282	chr2:15691791	G/T	cg19274914	chr2:15703543	NA	-0.45	-8.05	-0.4	1.43e-14	Educational attainment (years of education);
LUSC	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg07080220	chr10:102295463	HIF1AN	0.7	8.39	0.42	1.39e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.67	0.6	4.14e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg21775007	chr8:11205619	TDH	-0.51	-7.55	-0.38	4.06e-13	Triglycerides;
LUSC	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg13010199	chr12:38710504	ALG10B	0.66	10.32	0.49	7.69e-22	Bladder cancer;
LUSC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.65	-10.38	-0.49	4.61e-22	Systemic lupus erythematosus;
LUSC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg06636001	chr8:8085503	FLJ10661	0.63	9.7	0.47	9e-20	Joint mobility (Beighton score);
LUSC	cis	rs701145	0.938	rs355780	chr3:153978289	C/T	cg17054900	chr3:154042577	DHX36	0.81	8.35	0.42	1.82e-15	Coronary artery disease;
LUSC	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg05472934	chr7:22766657	IL6	0.41	6.52	0.34	2.64e-10	Lung cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09564133	chr5:176738847	MXD3	0.44	6.48	0.33	3.24e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg09033563	chr22:24373618	LOC391322	-0.48	-6.78	-0.35	5.33e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.62	-11.94	-0.55	1.34e-27	Longevity;Endometriosis;
LUSC	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	1.09	17.17	0.68	8.31e-48	Exhaled nitric oxide output;
LUSC	trans	rs984440	0.600	rs6999788	chr8:139079319	T/A	cg03334052	chr1:168888044	NA	-0.41	-6.45	-0.33	3.9e-10	Obesity-related traits;
LUSC	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg07395648	chr5:131743802	NA	0.39	6.5	0.34	2.92e-10	Breast cancer;Mosquito bite size;
LUSC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg20818283	chr2:191399100	TMEM194B	0.49	7.35	0.37	1.5e-12	Pulse pressure;
LUSC	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg21045802	chr8:109455806	TTC35	-0.46	-7.08	-0.36	8.34e-12	Dupuytren's disease;
LUSC	cis	rs62400317	0.859	rs55779653	chr6:45265960	C/T	cg20913747	chr6:44695427	NA	-0.45	-7.42	-0.38	9.97e-13	Total body bone mineral density;
LUSC	cis	rs360798	0.512	rs2710637	chr2:63173450	G/A	cg17519650	chr2:63277830	OTX1	0.48	6.86	0.35	3.25e-11	Coronary artery disease;
LUSC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg22963979	chr7:1858916	MAD1L1	-0.56	-8.52	-0.42	5.7e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg14581129	chr12:53358946	NA	-0.61	-9.0	-0.44	1.79e-17	Prostate cancer;
LUSC	trans	rs2262909	0.962	rs56369285	chr19:22267185	T/C	cg05197062	chr11:11642011	GALNTL4	0.56	7.88	0.4	4.75e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs11923600	0.730	rs62285824	chr3:175891133	T/G	cg02188190	chr13:112894616	NA	0.45	6.37	0.33	6.1e-10	Height;
LUSC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.63	10.55	0.5	1.17e-22	Blood metabolite levels;
LUSC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg23262073	chr20:60523788	NA	-0.42	-5.96	-0.31	6.32e-9	Body mass index;
LUSC	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg06484146	chr7:12443880	VWDE	-0.73	-7.32	-0.37	1.89e-12	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg13206674	chr6:150067644	NUP43	0.61	9.82	0.47	3.55e-20	Lung cancer;
LUSC	cis	rs10904908	1.000	rs7903402	chr10:17259772	C/T	cg01003015	chr10:17271136	VIM	-0.43	-6.17	-0.32	2e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg21573476	chr21:45109991	RRP1B	-0.41	-6.62	-0.34	1.42e-10	Mean corpuscular volume;
LUSC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg20887711	chr4:1340912	KIAA1530	0.42	6.51	0.34	2.77e-10	Obesity-related traits;
LUSC	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg05973401	chr12:123451056	ABCB9	0.52	7.0	0.36	1.44e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.3e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04850017	chr11:63683019	RCOR2	0.29	5.79	0.3	1.6e-8	Pulse pressure;
LUSC	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg05855489	chr10:104503620	C10orf26	0.52	6.73	0.35	7.28e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6961069	0.621	rs13222488	chr7:80240508	A/T	cg04458919	chr7:80252533	CD36	-0.41	-7.2	-0.37	3.99e-12	Platelet count;
LUSC	trans	rs7739264	0.563	rs9465516	chr6:19771998	A/C	cg13431028	chr2:169073609	STK39	0.36	6.15	0.32	2.24e-9	Endometriosis;
LUSC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26314531	chr2:26401878	FAM59B	-0.66	-9.25	-0.45	2.84e-18	Gut microbiome composition (summer);
LUSC	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.08	-0.36	8.55e-12	Menopause (age at onset);
LUSC	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.63	9.58	0.46	2.31e-19	Mean corpuscular volume;
LUSC	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.92	15.65	0.65	8.39e-42	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg26043149	chr18:55253948	FECH	0.51	7.52	0.38	5.09e-13	Bone mineral density;
LUSC	cis	rs12462428	0.911	rs6512119	chr19:16665215	C/T	cg05286348	chr19:16641544	CHERP	-0.54	-6.17	-0.32	1.98e-9	Educational attainment (years of education);
LUSC	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.61	0.5	7.64e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg14169450	chr9:139327907	INPP5E	0.43	7.57	0.38	3.61e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg08499158	chr17:42289980	UBTF	-0.37	-6.0	-0.31	5.1e-9	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs10761482	0.500	rs1938538	chr10:62298233	T/C	cg18175470	chr10:62150864	ANK3	-0.5	-7.23	-0.37	3.25e-12	Schizophrenia;
LUSC	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.4	-0.53	1.15e-25	Coffee consumption (cups per day);
LUSC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26314531	chr2:26401878	FAM59B	-0.71	-10.02	-0.48	7.96e-21	Gut microbiome composition (summer);
LUSC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-9.19	-0.45	4.14e-18	Gut microbiome composition (summer);
LUSC	cis	rs472402	0.623	rs8192133	chr5:6636645	A/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.51	-7.69	-0.39	1.66e-13	Response to amphetamines;
LUSC	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.41	6.34	0.33	7.31e-10	Homocysteine levels;
LUSC	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.35	-0.46	1.34e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3772130	0.962	rs11707504	chr3:121496734	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.23	0.49	1.48e-21	Cognitive performance;
LUSC	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg10523679	chr1:76189770	ACADM	-0.48	-7.11	-0.36	7.03e-12	Daytime sleep phenotypes;
LUSC	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg04218760	chr10:45406644	TMEM72	-0.29	-6.88	-0.35	3.04e-11	Mean corpuscular volume;
LUSC	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19096424	chr1:120255104	PHGDH	0.44	6.03	0.31	4.29e-9	Blood metabolite levels;
LUSC	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg11846333	chr4:119757529	SEC24D	-0.75	-6.64	-0.34	1.27e-10	Cannabis dependence symptom count;
LUSC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02187348	chr16:89574699	SPG7	0.58	9.55	0.46	2.99e-19	Multiple myeloma (IgH translocation);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20297566	chr3:99979976	TBC1D23	0.47	6.97	0.36	1.68e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	ch.3.55501R	chr3:3184210	TRNT1	0.43	6.78	0.35	5.54e-11	Triglycerides;
LUSC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg06363034	chr20:62225388	GMEB2	-0.46	-7.71	-0.39	1.45e-13	Glioblastoma;
LUSC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg24154853	chr7:158122151	PTPRN2	0.44	8.77	0.43	9.32e-17	Calcium levels;
LUSC	cis	rs6500395	1.000	rs7202551	chr16:48728984	A/G	cg04672837	chr16:48644449	N4BP1	-0.47	-6.95	-0.36	1.9e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg22868518	chr11:507468	RNH1	-0.63	-6.2	-0.32	1.69e-9	Body mass index;
LUSC	cis	rs7799006	0.929	rs35791351	chr7:2269248	C/T	cg08027265	chr7:2291960	NA	-0.43	-7.4	-0.38	1.12e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg15103426	chr22:29168792	CCDC117	-0.44	-5.67	-0.3	3.03e-8	Lymphocyte counts;
LUSC	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.65	5.68	0.3	2.87e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg27170947	chr2:26402098	FAM59B	-0.65	-9.64	-0.47	1.49e-19	Gut microbiome composition (summer);
LUSC	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg26384229	chr12:38710491	ALG10B	0.75	11.85	0.54	2.85e-27	Morning vs. evening chronotype;
LUSC	cis	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg07460842	chr6:66804631	NA	-0.47	-6.85	-0.35	3.64e-11	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs4930561	0.739	rs10896303	chr11:67974292	C/A	cg16338278	chr11:67432957	ALDH3B2	0.4	6.75	0.35	6.73e-11	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg08067268	chr2:26466485	HADHB;HADHA	0.4	5.93	0.31	7.73e-9	Gut microbiome composition (summer);
LUSC	trans	rs11923600	0.793	rs11718762	chr3:175890798	G/T	cg02188190	chr13:112894616	NA	0.42	6.06	0.31	3.67e-9	Height;
LUSC	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21293242	chr8:11204541	TDH	0.34	6.38	0.33	5.92e-10	Retinal vascular caliber;
LUSC	cis	rs1451375	0.755	rs6969081	chr7:50624505	A/T	cg18232548	chr7:50535776	DDC	0.52	7.93	0.4	3.22e-14	Malaria;
LUSC	cis	rs7173743	0.756	rs11852830	chr15:79125429	A/T	cg00540400	chr15:79124168	NA	0.36	6.1	0.32	2.98e-9	Coronary artery disease;
LUSC	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-7.04	-0.36	1.1e-11	Fear of minor pain;
LUSC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg04944784	chr2:26401820	FAM59B	0.77	11.23	0.52	4.85e-25	Gut microbiome composition (summer);
LUSC	cis	rs472402	0.560	rs6874005	chr5:6624371	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.41	-5.91	-0.31	8.61e-9	Response to amphetamines;
LUSC	cis	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg21775007	chr8:11205619	TDH	0.51	7.14	0.36	5.93e-12	Neuroticism;
LUSC	cis	rs9653442	0.564	rs2164711	chr2:100775422	G/T	cg07810366	chr2:100720526	AFF3	-0.44	-7.61	-0.38	2.74e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg21427119	chr20:30132790	HM13	-0.38	-5.98	-0.31	5.75e-9	Subcortical brain region volumes;Putamen volume;
LUSC	trans	rs2262909	0.962	rs409439	chr19:22227432	C/T	cg05197062	chr11:11642011	GALNTL4	-0.56	-7.81	-0.39	7.34e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.28	-17.65	-0.69	1.05e-49	Hip circumference adjusted for BMI;
LUSC	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	6.04	0.31	4.01e-9	Neuroticism;
LUSC	cis	rs35883536	0.647	rs7535762	chr1:101047534	A/G	cg06223162	chr1:101003688	GPR88	-0.47	-8.81	-0.43	6.81e-17	Monocyte count;
LUSC	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-9.17	-0.45	4.88e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg22532475	chr10:104410764	TRIM8	-0.33	-7.32	-0.37	1.92e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg06462663	chr19:18546047	ISYNA1	0.48	8.12	0.41	9.32e-15	Breast cancer;
LUSC	trans	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg18187862	chr3:45730750	SACM1L	0.55	6.91	0.35	2.52e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11585357	0.895	rs2977305	chr1:17613737	A/T	cg08277548	chr1:17600880	PADI3	0.62	6.51	0.34	2.72e-10	Hair shape;
LUSC	trans	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg09904177	chr6:26538194	HMGN4	-0.8	-6.0	-0.31	5.13e-9	Depression;
LUSC	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.92	15.76	0.65	3.19e-42	Bladder cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25375453	chr3:14219857	LSM3;XPC	-0.42	-6.36	-0.33	6.68e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg08975724	chr8:8085496	FLJ10661	0.51	7.63	0.39	2.55e-13	Mood instability;
LUSC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg24562669	chr7:97807699	LMTK2	0.35	6.27	0.32	1.15e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.36	7.36	0.37	1.46e-12	Hemoglobin concentration;
LUSC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg25428297	chr7:1022841	CYP2W1	0.31	6.49	0.33	3.02e-10	Longevity;Endometriosis;
LUSC	cis	rs12973672	1.000	rs10421768	chr19:35772899	A/G	cg12095397	chr19:35769544	USF2	0.41	6.38	0.33	5.82e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	10.39	0.49	4.3e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.72	12.3	0.56	6.22e-29	Motion sickness;
LUSC	cis	rs7712401	0.755	rs13172043	chr5:122184759	G/A	cg19077854	chr5:122220652	SNX24	0.36	8.24	0.41	4.02e-15	Mean platelet volume;
LUSC	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg05347473	chr6:146136440	FBXO30	0.43	7.04	0.36	1.11e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.53	-8.37	-0.42	1.57e-15	Height;
LUSC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-7.99	-0.4	2.2e-14	Menarche (age at onset);
LUSC	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg16482183	chr6:26056742	HIST1H1C	0.57	8.03	0.4	1.68e-14	Iron status biomarkers;
LUSC	trans	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg11398623	chr21:37499189	NA	0.26	6.03	0.31	4.25e-9	Breast cancer;
LUSC	cis	rs7615316	1.000	rs7646880	chr3:142351930	C/T	cg16271453	chr3:142027066	XRN1	-0.35	-5.99	-0.31	5.54e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.27	0.45	2.34e-18	Prudent dietary pattern;
LUSC	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.73	11.05	0.52	2.14e-24	Alcohol dependence;
LUSC	cis	rs1593	0.734	rs4253407	chr4:187193308	A/T	cg09526685	chr4:187126073	CYP4V2	0.57	5.8	0.3	1.51e-8	Activated partial thromboplastin time;
LUSC	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.59	-8.68	-0.43	1.75e-16	Squamous cell carcinoma;
LUSC	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg20734569	chr3:48348370	SPINK8	-0.48	-8.13	-0.41	8.72e-15	Coronary artery disease;
LUSC	cis	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.13	-0.41	8.48e-15	Coronary artery disease;
LUSC	cis	rs151234	0.800	rs231974	chr16:28540322	A/T	cg01378222	chr16:28622494	SULT1A1	-0.61	-7.86	-0.4	5.37e-14	Platelet distribution width;
LUSC	cis	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg24375607	chr4:120327624	NA	-0.48	-7.47	-0.38	7.22e-13	Diastolic blood pressure;
LUSC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg24296786	chr1:45957014	TESK2	0.46	6.51	0.34	2.83e-10	Red blood cell count;Reticulocyte count;
LUSC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.19	16.51	0.67	3.48e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04578738	chr17:34136331	TAF15	0.44	6.28	0.32	1.06e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.83	0.3	1.28e-8	Menopause (age at onset);
LUSC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	9.63	0.47	1.53e-19	Eosinophil percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14677912	chr5:140019017	TMCO6	-0.37	-6.19	-0.32	1.8e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg17143192	chr8:8559678	CLDN23	0.64	9.29	0.45	2.01e-18	Obesity-related traits;
LUSC	cis	rs6120849	0.707	rs6120799	chr20:33614955	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	6.74	0.35	6.84e-11	Protein C levels;
LUSC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg18357645	chr12:58087776	OS9	0.53	8.0	0.4	2.09e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08677398	chr8:58056175	NA	0.58	6.95	0.36	1.96e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.37	6.46	0.33	3.62e-10	Primary biliary cholangitis;
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg24846343	chr22:24311635	DDTL	0.77	17.41	0.69	9.4e-49	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg05887092	chr17:76393375	PGS1	0.55	9.79	0.47	4.62e-20	HDL cholesterol levels;
LUSC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg23711669	chr6:146136114	FBXO30	0.75	13.38	0.59	5.42e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg24006582	chr15:45444508	DUOX1	-0.62	-9.22	-0.45	3.51e-18	Uric acid levels;
LUSC	cis	rs6845621	0.966	rs2048961	chr4:18861390	C/T	cg12196642	chr4:18937545	NA	-0.32	-5.99	-0.31	5.28e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg26115276	chr5:178977181	RUFY1	0.37	5.95	0.31	6.85e-9	Schizophrenia;
LUSC	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg05347473	chr6:146136440	FBXO30	0.52	8.67	0.43	1.87e-16	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg14895029	chr7:2775587	GNA12	-0.36	-5.69	-0.3	2.8e-8	Height;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg15057150	chr1:206680618	RASSF5	0.44	7.25	0.37	2.96e-12	Schizophrenia;
LUSC	trans	rs61931739	0.649	rs815046	chr12:33720602	C/T	cg26384229	chr12:38710491	ALG10B	0.43	6.24	0.32	1.36e-9	Morning vs. evening chronotype;
LUSC	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg09092052	chr15:45571596	NA	0.48	6.75	0.35	6.71e-11	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg05110241	chr16:68378359	PRMT7	-0.78	-8.89	-0.44	3.82e-17	Schizophrenia;
LUSC	trans	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg25214090	chr10:38739885	LOC399744	0.5	7.57	0.38	3.68e-13	Corneal astigmatism;
LUSC	cis	rs4664308	1.000	rs2175416	chr2:160904021	G/A	cg03641300	chr2:160917029	PLA2R1	-0.66	-11.21	-0.52	5.69e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.18	-0.45	4.65e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1413885	0.516	rs1591364	chr1:65842364	T/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.5	7.51	0.38	5.61e-13	Anticoagulant levels;
LUSC	cis	rs9837602	1.000	rs704582	chr3:99571926	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-5.89	-0.31	9.63e-9	Breast cancer;
LUSC	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.54	0.75	3.49e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10761482	0.861	rs4245588	chr10:62101746	A/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg11984989	chr7:158649758	WDR60	1.07	21.81	0.77	3.37e-66	Height;
LUSC	cis	rs7804356	0.953	rs3801822	chr7:26861201	T/C	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.05e-9	Type 1 diabetes;
LUSC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12311346	chr5:56204834	C5orf35	0.82	13.45	0.59	3.05e-33	Initial pursuit acceleration;
LUSC	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.5	7.61	0.38	2.87e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg19468946	chr17:37922297	IKZF3	-0.43	-6.82	-0.35	4.17e-11	Self-reported allergy;
LUSC	cis	rs4654899	0.865	rs957163	chr1:21416181	G/T	cg01072550	chr1:21505969	NA	-0.52	-7.6	-0.38	2.99e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg01733217	chr16:74700730	RFWD3	0.8	13.34	0.59	8.02e-33	Testicular germ cell tumor;
LUSC	cis	rs6693567	0.565	rs3754217	chr1:150480373	G/T	cg15654264	chr1:150340011	RPRD2	0.45	7.17	0.37	4.91e-12	Migraine;
LUSC	trans	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg09050820	chr6:167586206	TCP10L2	0.73	9.47	0.46	5.31e-19	Gastritis;
LUSC	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg17376030	chr22:41985996	PMM1	-0.42	-5.71	-0.3	2.56e-8	Vitiligo;
LUSC	cis	rs4776059	1.000	rs11853917	chr15:52922054	T/C	cg22715398	chr15:52968154	KIAA1370	-0.65	-9.54	-0.46	3.02e-19	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.54	0.76	3.92e-65	Prudent dietary pattern;
LUSC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg23788917	chr6:8435910	SLC35B3	0.51	7.62	0.38	2.58e-13	Motion sickness;
LUSC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.55	0.34	2.22e-10	Lung cancer;
LUSC	cis	rs11608355	0.846	rs61934479	chr12:109855111	A/G	cg19025524	chr12:109796872	NA	-0.39	-5.72	-0.3	2.35e-8	Neuroticism;
LUSC	cis	rs6700896	0.500	rs12130476	chr1:66124850	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.93	0.31	7.6e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.11	14.84	0.63	1.26e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-7.21	-0.37	3.69e-12	Response to antipsychotic treatment;
LUSC	cis	rs11958404	0.932	rs72818104	chr5:157437632	T/C	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg20628663	chr10:43360327	NA	-0.76	-11.4	-0.53	1.23e-25	Blood protein levels;
LUSC	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.49	-0.42	6.89e-16	Total cholesterol levels;
LUSC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13770153	chr20:60521292	NA	-0.64	-8.6	-0.43	3.17e-16	Body mass index;
LUSC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00149659	chr3:10157352	C3orf10	-0.83	-12.13	-0.55	2.64e-28	Alzheimer's disease;
LUSC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05535760	chr7:792225	HEATR2	0.91	9.61	0.47	1.88e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg03433033	chr1:76189801	ACADM	0.65	8.86	0.44	4.71e-17	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.01	-0.36	1.3e-11	Neuroticism;
LUSC	trans	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg06521331	chr12:34319734	NA	-0.39	-6.0	-0.31	5.25e-9	Bladder cancer;
LUSC	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18252515	chr7:66147081	NA	-0.57	-7.95	-0.4	2.87e-14	Corneal structure;
LUSC	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg24692254	chr21:30365293	RNF160	-0.54	-6.65	-0.34	1.23e-10	Cognitive test performance;
LUSC	trans	rs629535	1.000	rs644951	chr8:70009082	C/T	cg21567404	chr3:27674614	NA	-0.86	-13.03	-0.58	1.2e-31	Dupuytren's disease;
LUSC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg03146154	chr1:46216737	IPP	-0.51	-7.73	-0.39	1.3e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg10104451	chr8:143696006	ARC	-0.64	-9.07	-0.44	1.06e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.05	0.52	2.14e-24	Hypertriglyceridemia;
LUSC	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg20243544	chr17:37824526	PNMT	0.43	6.54	0.34	2.28e-10	Self-reported allergy;
LUSC	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.83	0.51	1.27e-23	Morning vs. evening chronotype;
LUSC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg17515076	chr17:73810948	UNK	-0.4	-6.72	-0.35	7.94e-11	White matter hyperintensity burden;
LUSC	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg07080220	chr10:102295463	HIF1AN	0.61	8.14	0.41	8.11e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg15147215	chr3:52552868	STAB1	-0.29	-5.83	-0.3	1.28e-8	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg08676812	chr11:65308423	LTBP3	1.06	6.8	0.35	4.71e-11	Height;
LUSC	cis	rs12101261	0.890	rs3783947	chr14:81449534	T/C	cg06600135	chr14:81408086	NA	0.42	6.33	0.33	7.96e-10	Graves' disease;
LUSC	cis	rs6977660	1.000	rs2107403	chr7:19819025	G/C	cg07541023	chr7:19748670	TWISTNB	0.51	5.82	0.3	1.37e-8	Thyroid stimulating hormone;
LUSC	trans	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg07923666	chr12:49932857	KCNH3	-0.49	-6.12	-0.32	2.55e-9	Resting heart rate;
LUSC	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg09184832	chr6:79620586	NA	-0.41	-6.3	-0.33	9.47e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg10253484	chr15:75165896	SCAMP2	-0.5	-7.57	-0.38	3.64e-13	Breast cancer;
LUSC	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg05340658	chr4:99064831	C4orf37	0.44	6.85	0.35	3.55e-11	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21415643	chr1:42127431	HIVEP3	-0.42	-6.16	-0.32	2.04e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7107174	0.892	rs1007837	chr11:77941076	A/G	cg02023728	chr11:77925099	USP35	0.48	6.84	0.35	3.78e-11	Testicular germ cell tumor;
LUSC	trans	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.86	0.47	2.6e-20	Mean corpuscular volume;
LUSC	trans	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg21659725	chr3:3221576	CRBN	0.72	8.76	0.43	1.01e-16	Menarche (age at onset);
LUSC	cis	rs1943345	1.000	rs1943345	chr11:82876270	G/T	cg07047830	chr11:82868014	PCF11	-0.51	-7.25	-0.37	2.93e-12	Obesity-related traits;
LUSC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10802521	chr3:52805072	NEK4	-0.57	-9.37	-0.46	1.13e-18	Electroencephalogram traits;
LUSC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg11764359	chr7:65958608	NA	-0.52	-6.78	-0.35	5.48e-11	Aortic root size;
LUSC	cis	rs2637266	0.905	rs1978925	chr10:78399879	C/T	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.94e-13	Pulmonary function;
LUSC	cis	rs2835872	0.698	rs2898318	chr21:38986690	C/G	cg20424643	chr21:39039972	KCNJ6	0.4	6.09	0.32	3.05e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.3	-0.49	8.36e-22	Hemoglobin concentration;
LUSC	cis	rs6845621	0.717	rs13114942	chr4:18843090	A/T	cg12196642	chr4:18937545	NA	-0.31	-5.7	-0.3	2.61e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg24101359	chr6:42928495	GNMT	0.36	5.9	0.31	8.69e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg21153622	chr11:89784906	NA	-0.39	-6.0	-0.31	5.01e-9	HDL cholesterol;
LUSC	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg20734569	chr3:48348370	SPINK8	-0.48	-8.29	-0.41	2.74e-15	Coronary artery disease;
LUSC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.74	-10.75	-0.51	2.36e-23	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs12210905	0.688	rs72839474	chr6:27324757	T/C	cg02699829	chr19:13216355	TRMT1	-0.56	-6.23	-0.32	1.39e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg15445000	chr17:37608096	MED1	-0.4	-6.73	-0.35	7.36e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg22189786	chr22:42395067	WBP2NL	0.43	5.78	0.3	1.72e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs939574	0.720	rs6714820	chr2:220071803	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.95	-8.17	-0.41	6.53e-15	Platelet distribution width;
LUSC	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg24399712	chr22:39784796	NA	0.41	6.84	0.35	3.74e-11	IgG glycosylation;
LUSC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg16325326	chr1:53192061	ZYG11B	0.95	17.75	0.7	3.99e-50	Monocyte count;
LUSC	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg00277334	chr10:82204260	NA	-0.45	-6.34	-0.33	7.39e-10	Post bronchodilator FEV1;
LUSC	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg20744362	chr22:50050164	C22orf34	0.42	8.68	0.43	1.79e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.79	-0.3	1.67e-8	Aortic root size;
LUSC	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg24375607	chr4:120327624	NA	0.69	10.26	0.49	1.17e-21	Corneal astigmatism;
LUSC	trans	rs1941687	0.831	rs11877286	chr18:31386764	T/C	cg27147174	chr7:100797783	AP1S1	-0.46	-6.84	-0.35	3.68e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs17604090	0.938	rs68072609	chr7:29682467	C/T	cg19413766	chr7:29689036	LOC646762	-0.62	-7.11	-0.36	7.3e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs2073300	1.000	rs6114142	chr20:23461082	A/G	cg09953122	chr20:23471693	CST8	-0.75	-7.29	-0.37	2.2e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg24558204	chr6:135376177	HBS1L	0.58	9.0	0.44	1.69e-17	Red blood cell count;
LUSC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.19	0.32	1.77e-9	Menopause (age at onset);
LUSC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs9517320	1.000	rs9517322	chr13:99126338	C/G	cg20487152	chr13:99095054	FARP1	0.34	6.35	0.33	6.84e-10	Longevity;
LUSC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06481639	chr22:41940642	POLR3H	0.5	5.77	0.3	1.81e-8	Vitiligo;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg23478354	chr19:59010761	SLC27A5	0.38	6.26	0.32	1.19e-9	Schizophrenia;
LUSC	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg20991723	chr1:152506922	NA	0.51	9.48	0.46	4.74e-19	Hair morphology;
LUSC	cis	rs977987	0.835	rs1010630	chr16:75328591	G/T	cg03315344	chr16:75512273	CHST6	0.51	9.6	0.47	1.91e-19	Dupuytren's disease;
LUSC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg13628971	chr7:2884303	GNA12	0.47	6.59	0.34	1.73e-10	Height;
LUSC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg17143192	chr8:8559678	CLDN23	0.37	5.73	0.3	2.29e-8	Mood instability;
LUSC	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg12863693	chr15:85201151	NMB	0.39	8.1	0.41	1.06e-14	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.82	14.91	0.63	6.87e-39	Cognitive function;
LUSC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.89	0.31	9.52e-9	Menopause (age at onset);
LUSC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg25039879	chr17:56429692	SUPT4H1	0.68	9.09	0.45	8.81e-18	Cognitive test performance;
LUSC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg08847533	chr14:75593920	NEK9	0.84	15.41	0.64	7.3400000000000005e-41	Height;
LUSC	cis	rs10193935	0.901	rs13384323	chr2:42631346	C/T	cg27598129	chr2:42591480	NA	-0.58	-7.96	-0.4	2.63e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.9	-0.35	2.69e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg21724239	chr8:58056113	NA	0.72	7.25	0.37	2.88e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.71	-11.44	-0.53	8.82e-26	Retinal vascular caliber;
LUSC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.39	0.46	9.37e-19	Bipolar disorder;
LUSC	cis	rs117851058	0.590	rs2607412	chr19:41268243	A/G	cg05508168	chr19:41255947	C19orf54;SNRPA	0.64	5.84	0.3	1.27e-8	Post bronchodilator FEV1;
LUSC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.56	-0.6	1.12e-33	Chronic sinus infection;
LUSC	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg06484146	chr7:12443880	VWDE	-0.74	-7.3	-0.37	2.18e-12	Coronary artery disease;
LUSC	cis	rs6426558	0.502	rs1929858	chr1:227220175	C/A	cg10327440	chr1:227177885	CDC42BPA	0.59	7.93	0.4	3.32e-14	Neutrophil percentage of white cells;
LUSC	cis	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg05084668	chr3:125655381	ALG1L	-0.42	-5.66	-0.3	3.33e-8	Blood pressure (smoking interaction);
LUSC	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg17470449	chr10:769945	NA	0.56	7.69	0.39	1.67e-13	Uric acid levels;
LUSC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.76	-0.39	1.04e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4363385	0.720	rs883810	chr1:152941345	T/C	cg00922841	chr1:152955080	SPRR1A	-0.4	-6.64	-0.34	1.3100000000000001e-10	Inflammatory skin disease;
LUSC	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6845621	0.901	rs1452555	chr4:18926504	G/A	cg12196642	chr4:18937545	NA	-0.36	-6.66	-0.34	1.11e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	trans	rs62458065	0.640	rs6950077	chr7:32502895	A/G	cg00845942	chr12:64062724	DPY19L2	0.55	6.75	0.35	6.43e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs2963155	0.518	rs853184	chr5:142640901	C/T	cg17617527	chr5:142782415	NR3C1	0.71	8.61	0.43	2.89e-16	Breast cancer;
LUSC	cis	rs7809950	0.773	rs62483722	chr7:107186349	C/T	cg23024343	chr7:107201750	COG5	-0.55	-8.7	-0.43	1.53e-16	Coronary artery disease;
LUSC	cis	rs77216612	1.000	rs77216612	chr12:12877983	A/G	cg09462578	chr12:12878428	APOLD1	-1.0	-17.1	-0.68	1.56e-47	Lymphocyte counts;
LUSC	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg11693508	chr17:37793320	STARD3	0.6	7.12	0.36	6.69e-12	Bipolar disorder;
LUSC	cis	rs1322512	0.917	rs2800624	chr6:153005247	G/A	cg27316956	chr6:152958899	SYNE1	0.36	6.11	0.32	2.76e-9	Tonometry;
LUSC	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg13393036	chr8:95962371	TP53INP1	-0.43	-9.16	-0.45	5.45e-18	Type 2 diabetes;
LUSC	cis	rs9902453	0.934	rs11080120	chr17:28507021	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.52	0.42	5.37e-16	Coffee consumption (cups per day);
LUSC	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg09904177	chr6:26538194	HMGN4	0.75	14.28	0.62	1.96e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs76878669	0.561	rs10896111	chr11:66115690	T/C	cg18002602	chr11:66138449	SLC29A2	-0.48	-8.44	-0.42	9.66e-16	Educational attainment (years of education);
LUSC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg05738196	chr6:26577821	NA	-0.59	-6.85	-0.35	3.53e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg26043149	chr18:55253948	FECH	0.47	7.16	0.36	5.06e-12	Bone mineral density;
LUSC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.78	13.84	0.6	9.54e-35	Longevity;
LUSC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.38	6.15	0.32	2.21e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-0.99	-16.83	-0.68	1.86e-46	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs757081	0.634	rs17472942	chr11:17094702	A/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-6.05	-0.31	3.98e-9	Systolic blood pressure;
LUSC	cis	rs4730250	0.581	rs3779500	chr7:106792704	T/C	cg02696742	chr7:106810147	HBP1	0.64	9.04	0.44	1.32e-17	Osteoarthritis;
LUSC	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg01528321	chr10:82214614	TSPAN14	1.09	17.18	0.68	7.64e-48	Post bronchodilator FEV1;
LUSC	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg23625390	chr15:77176239	SCAPER	0.46	7.04	0.36	1.09e-11	Blood metabolite levels;
LUSC	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg09184832	chr6:79620586	NA	-0.43	-7.02	-0.36	1.27e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1790761	0.967	rs1476792	chr11:67196237	A/G	cg24690094	chr11:67383802	NA	-0.32	-5.83	-0.3	1.29e-8	Mean corpuscular volume;
LUSC	cis	rs10761482	0.600	rs1572843	chr10:62226980	C/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.7	-0.34	8.77e-11	Schizophrenia;
LUSC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.31	-0.45	1.71e-18	Platelet count;
LUSC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03934478	chr11:495069	RNH1	0.81	9.94	0.48	1.41e-20	Body mass index;
LUSC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs701145	0.585	rs357476	chr3:153892844	A/G	cg10247383	chr3:153839028	SGEF	0.64	5.91	0.31	8.28e-9	Coronary artery disease;
LUSC	trans	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.07	0.52	1.78e-24	Mean corpuscular volume;
LUSC	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg18232548	chr7:50535776	DDC	-0.57	-8.47	-0.42	7.79e-16	Systemic sclerosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08163220	chr3:31574309	STT3B	0.47	6.88	0.35	2.9100000000000002e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg05347473	chr6:146136440	FBXO30	0.56	9.73	0.47	7.22e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.63	-0.34	1.38e-10	Monocyte percentage of white cells;
LUSC	cis	rs2274273	0.870	rs11625423	chr14:55795913	G/A	cg04306507	chr14:55594613	LGALS3	0.54	11.81	0.54	3.97e-27	Protein biomarker;
LUSC	cis	rs2901656	0.701	rs10911786	chr1:172448717	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.29	5.76	0.3	1.88e-8	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.69	10.25	0.49	1.27e-21	Corneal astigmatism;
LUSC	cis	rs7495132	0.526	rs60433006	chr15:91197475	C/T	cg05609160	chr15:91208370	NA	-0.4	-5.78	-0.3	1.69e-8	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs1788820	0.871	rs1623003	chr18:21165163	C/T	cg14672496	chr18:21087552	C18orf8	0.43	6.75	0.35	6.59e-11	Body mass index;
LUSC	cis	rs13040088	0.518	rs2427452	chr20:61577275	T/C	cg23096297	chr20:61557774	DIDO1	-0.71	-9.56	-0.46	2.72e-19	Menopause (age at onset);
LUSC	cis	rs17253792	1.000	rs17253792	chr14:56205030	T/C	cg01858014	chr14:56050164	KTN1	-0.89	-6.69	-0.34	9.39e-11	Putamen volume;
LUSC	cis	rs61931739	0.635	rs7138254	chr12:33914422	G/T	cg06521331	chr12:34319734	NA	-0.41	-6.67	-0.34	1.04e-10	Morning vs. evening chronotype;
LUSC	trans	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg16620390	chr12:125670262	NA	-0.47	-6.07	-0.32	3.5e-9	Thyroid stimulating hormone;
LUSC	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg12850546	chr22:42539477	CYP2D7P1	0.56	6.44	0.33	4.23e-10	Birth weight;
LUSC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9549260	0.755	rs9549252	chr13:41230141	A/G	cg21288729	chr13:41239152	FOXO1	0.56	8.29	0.41	2.77e-15	Red blood cell count;
LUSC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13770153	chr20:60521292	NA	-0.64	-8.6	-0.43	3.17e-16	Body mass index;
LUSC	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-6.06	-0.31	3.66e-9	Coronary artery disease;
LUSC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg04166393	chr7:2884313	GNA12	0.46	6.13	0.32	2.43e-9	Height;
LUSC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg12257692	chr3:49977190	RBM6	-0.27	-7.54	-0.38	4.6e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs3118233	1	rs3118233	chr16:68733646	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-12.31	-0.56	5.63e-29	Red cell distribution width;
LUSC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg02423579	chr7:2872169	GNA12	-0.46	-6.43	-0.33	4.41e-10	Height;
LUSC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg00012203	chr2:219082015	ARPC2	-0.71	-11.68	-0.54	1.18e-26	Colorectal cancer;
LUSC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6840360	0.582	rs1372976	chr4:152451453	G/A	cg20465933	chr4:152376761	FAM160A1	0.33	5.94	0.31	7.19e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-9.98	-0.48	1.07e-20	Gut microbiome composition (summer);
LUSC	trans	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg26043149	chr18:55253948	FECH	-0.44	-6.81	-0.35	4.65e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg27094323	chr7:1216898	NA	-0.35	-6.07	-0.32	3.49e-9	Longevity;Endometriosis;
LUSC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.52	8.53	0.42	5.25e-16	Immature fraction of reticulocytes;
LUSC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs136211	0.640	rs9610495	chr22:36760838	G/A	cg21778268	chr22:36877729	TXN2	-0.41	-5.79	-0.3	1.64e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg09839279	chr12:125627357	AACS	-0.34	-5.89	-0.31	9.5e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg12552261	chr5:112820674	MCC	-0.44	-7.01	-0.36	1.3e-11	Type 2 diabetes;
LUSC	cis	rs1832871	1.000	rs827858	chr6:158707396	T/C	cg07165851	chr6:158734300	TULP4	0.37	6.5	0.33	2.99e-10	Height;
LUSC	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg06547715	chr2:218990976	CXCR2	0.34	6.5	0.34	2.93e-10	Ulcerative colitis;
LUSC	cis	rs10927875	0.619	rs7546589	chr1:16129530	A/G	cg21385522	chr1:16154831	NA	-0.6	-9.74	-0.47	6.69e-20	Dilated cardiomyopathy;
LUSC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg15556689	chr8:8085844	FLJ10661	0.66	10.83	0.51	1.3e-23	Mood instability;
LUSC	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg11584989	chr19:19387371	SF4	0.57	6.78	0.35	5.44e-11	Bipolar disorder;
LUSC	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg24375607	chr4:120327624	NA	0.75	11.65	0.54	1.43e-26	Corneal astigmatism;
LUSC	cis	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg06521331	chr12:34319734	NA	0.38	6.47	0.33	3.55e-10	Morning vs. evening chronotype;
LUSC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg02782426	chr3:40428986	ENTPD3	0.41	7.8	0.39	8.21e-14	Renal cell carcinoma;
LUSC	cis	rs9796	0.835	rs11856848	chr15:41370961	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.04	-0.4	1.55e-14	Menopause (age at onset);
LUSC	cis	rs9420	0.961	rs12805841	chr11:57443842	G/A	cg02958346	chr11:57425731	CLP1	-0.44	-6.45	-0.33	4.02e-10	Schizophrenia;
LUSC	cis	rs859767	0.741	rs6430529	chr2:135433023	G/T	cg12500956	chr2:135428796	TMEM163	-0.29	-6.49	-0.33	3.19e-10	Neuroticism;
LUSC	cis	rs983392	1.000	rs920573	chr11:59924959	G/A	cg24026212	chr11:59952134	MS4A6A	-0.33	-5.65	-0.3	3.42e-8	Alzheimer's disease (late onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09828504	chr21:43279690	PRDM15	-0.4	-6.78	-0.35	5.5e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7043114	0.544	rs4302908	chr9:95321641	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.55	-0.34	2.14e-10	Height;
LUSC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg00945038	chr17:61921165	SMARCD2	-0.53	-9.31	-0.45	1.73e-18	Prudent dietary pattern;
LUSC	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.6	-0.47	1.95e-19	Migraine;Coronary artery disease;
LUSC	cis	rs9660992	1.000	rs1779410	chr1:205248759	A/G	cg00857998	chr1:205179979	DSTYK	0.44	6.6	0.34	1.61e-10	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.38	0.33	6.06e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg27494647	chr7:150038898	RARRES2	-0.57	-8.43	-0.42	1.04e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg03713592	chr11:72463424	ARAP1	0.59	7.66	0.39	1.96e-13	Type 2 diabetes;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg10346511	chr11:30344563	C11orf46	0.42	6.21	0.32	1.61e-9	Mosquito bite size;
LUSC	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg04310649	chr10:35416472	CREM	-0.4	-6.18	-0.32	1.83e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg02569458	chr12:86230093	RASSF9	0.52	8.36	0.42	1.67e-15	Major depressive disorder;
LUSC	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg15133208	chr4:90757351	SNCA	-0.55	-8.29	-0.41	2.77e-15	Neuroticism;
LUSC	cis	rs2274273	1.000	rs66871576	chr14:55629050	C/T	cg04306507	chr14:55594613	LGALS3	0.55	12.02	0.55	6.51e-28	Protein biomarker;
LUSC	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.69	10.34	0.49	6.47e-22	Dilated cardiomyopathy;
LUSC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg04352962	chr1:209979756	IRF6	0.5	6.78	0.35	5.51e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg04310649	chr10:35416472	CREM	-0.4	-6.19	-0.32	1.72e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg25233709	chr10:116636983	FAM160B1	0.44	7.89	0.4	4.28e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg06028605	chr16:24865363	SLC5A11	0.46	8.43	0.42	1.06e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-8.09	-0.4	1.09e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.58	-8.89	-0.44	3.88e-17	Schizophrenia;
LUSC	cis	rs7215564	0.908	rs4243241	chr17:78660502	A/C	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg03647239	chr10:116582469	FAM160B1	0.42	6.34	0.33	7.32e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg04287289	chr16:89883240	FANCA	-0.41	-6.0	-0.31	5.16e-9	Vitiligo;
LUSC	cis	rs11645898	1.000	rs72791117	chr16:72217385	T/C	cg14768367	chr16:72042858	DHODH	-0.55	-5.96	-0.31	6.48e-9	Blood protein levels;
LUSC	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg07640336	chr12:132677496	NA	0.43	8.54	0.42	4.99e-16	Anti-saccade response;
LUSC	cis	rs16917546	0.967	rs10995239	chr10:64388365	A/G	cg03961010	chr10:64397487	ZNF365	-0.42	-6.66	-0.34	1.1e-10	Basal cell carcinoma;
LUSC	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg11584989	chr19:19387371	SF4	0.62	7.5	0.38	5.74e-13	Bipolar disorder;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg12582022	chr3:112738401	C3orf17	0.52	6.63	0.34	1.33e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.55	5.78	0.3	1.74e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7216064	1.000	rs8067892	chr17:65837983	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-9.44	-0.46	6.6e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	trans	rs3847153	1.000	rs36061340	chr8:101807230	C/T	cg05884214	chr7:1712054	NA	0.63	5.99	0.31	5.4e-9	Premature ovarian failure;
LUSC	cis	rs3768617	0.868	rs20561	chr1:183105705	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	8.15	0.41	7.15e-15	Fuchs's corneal dystrophy;
LUSC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg09904177	chr6:26538194	HMGN4	0.47	7.48	0.38	6.76e-13	Schizophrenia;
LUSC	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs7075426	0.524	rs12411744	chr10:88245075	G/A	cg07322936	chr10:88137208	NA	0.42	6.02	0.31	4.49e-9	Migraine without aura;
LUSC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-6.21	-0.32	1.55e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg05707623	chr12:122985044	ZCCHC8	0.66	8.11	0.41	9.63e-15	Body mass index;
LUSC	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	1.06	15.09	0.64	1.33e-39	Uric acid levels;
LUSC	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg08000102	chr2:233561755	GIGYF2	-0.52	-8.17	-0.41	6.48e-15	Coronary artery disease;
LUSC	cis	rs6700896	0.966	rs10889570	chr1:66088084	C/G	cg04111102	chr1:66153794	NA	0.32	7.05	0.36	1.03e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.61	0.54	2.12e-26	Alzheimer's disease;
LUSC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg25019033	chr10:957182	NA	-0.5	-6.26	-0.32	1.18e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs7527798	1.000	rs2147021	chr1:207849214	A/G	cg09232269	chr1:207846808	CR1L	-0.32	-5.83	-0.3	1.3e-8	Erythrocyte sedimentation rate;
LUSC	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.22	-0.37	3.64e-12	Neuroticism;
LUSC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-9.53	-0.46	3.33e-19	Bipolar disorder;
LUSC	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg10701640	chr17:43249399	NA	0.47	10.0	0.48	8.96e-21	Height;
LUSC	cis	rs4499344	0.633	rs259256	chr19:33151802	C/T	cg22980127	chr19:33182716	NUDT19	-0.44	-6.51	-0.34	2.74e-10	Mean platelet volume;
LUSC	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg14895029	chr7:2775587	GNA12	-0.4	-6.06	-0.31	3.61e-9	Height;
LUSC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg24060327	chr5:131705240	SLC22A5	-0.67	-11.48	-0.53	6.2e-26	Acylcarnitine levels;
LUSC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.52	0.34	2.54e-10	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg01689657	chr7:91764605	CYP51A1	0.33	6.08	0.32	3.34e-9	Breast cancer;
LUSC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg05347473	chr6:146136440	FBXO30	0.54	9.27	0.45	2.43e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	0.99	13.96	0.61	3.29e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs10203711	1.000	rs6711116	chr2:239596636	T/G	cg14580085	chr2:239553406	NA	0.42	7.06	0.36	9.66e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-8.74	-0.43	1.15e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg01448562	chr3:133502909	NA	0.44	6.95	0.36	1.92e-11	Iron status biomarkers;
LUSC	cis	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.39	-0.33	5.57e-10	Morning vs. evening chronotype;
LUSC	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg18230493	chr5:56204884	C5orf35	-0.55	-8.7	-0.43	1.59e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg04310649	chr10:35416472	CREM	-0.41	-6.43	-0.33	4.53e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1005224	1.000	rs1158282	chr14:76172916	C/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.54	-7.14	-0.36	5.98e-12	Large artery stroke;
LUSC	cis	rs11018904	0.636	rs61903695	chr11:89922417	A/G	cg26028595	chr11:89956573	CHORDC1	-0.47	-5.76	-0.3	1.9e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs151234	0.741	rs151230	chr16:28583215	G/A	cg01378222	chr16:28622494	SULT1A1	-0.62	-8.34	-0.42	1.95e-15	Platelet distribution width;
LUSC	cis	rs6500395	1.000	rs11647048	chr16:48623227	T/G	cg04672837	chr16:48644449	N4BP1	0.49	7.02	0.36	1.26e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.51	-7.63	-0.39	2.51e-13	Menarche (age at onset);
LUSC	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg04450456	chr4:17643702	FAM184B	0.35	6.01	0.31	4.76e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12367572	1.000	rs7304472	chr12:45262324	A/G	cg04608330	chr12:45269318	NELL2	-0.59	-9.48	-0.46	4.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg12463550	chr7:65579703	CRCP	0.56	8.35	0.42	1.79e-15	Aortic root size;
LUSC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg21141812	chr3:48556323	PFKFB4	0.33	5.94	0.31	7.06e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.81	-0.39	7.64e-14	Blood metabolite levels;
LUSC	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg23950597	chr19:37808831	NA	-0.62	-7.32	-0.37	1.89e-12	Coronary artery calcification;
LUSC	cis	rs9905704	0.627	rs1267544	chr17:56643398	T/G	cg12560992	chr17:57184187	TRIM37	-0.53	-6.34	-0.33	7.56e-10	Testicular germ cell tumor;
LUSC	trans	rs10090774	0.965	rs13255947	chr8:141911445	T/C	cg16477744	chr7:157367142	PTPRN2;MIR153-2	0.28	6.08	0.32	3.28e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg13010199	chr12:38710504	ALG10B	0.53	7.92	0.4	3.45e-14	Morning vs. evening chronotype;
LUSC	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg21643547	chr1:205240462	TMCC2	-0.42	-7.58	-0.38	3.47e-13	Red blood cell count;
LUSC	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg05340658	chr4:99064831	C4orf37	0.58	7.74	0.39	1.2e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg00343986	chr7:65444356	GUSB	-0.48	-7.28	-0.37	2.37e-12	Aortic root size;
LUSC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.95	-0.36	1.98e-11	Blood metabolite levels;
LUSC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	13.5	0.59	1.97e-33	Platelet count;
LUSC	trans	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg25482853	chr8:67687455	SGK3	1.12	15.85	0.66	1.36e-42	Obesity-related traits;
LUSC	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg20608306	chr11:116969690	SIK3	0.37	6.97	0.36	1.73e-11	Blood protein levels;
LUSC	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg06636001	chr8:8085503	FLJ10661	0.6	9.1	0.45	8.61e-18	Mood instability;
LUSC	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg05973401	chr12:123451056	ABCB9	0.53	6.54	0.34	2.29e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg06784218	chr1:46089804	CCDC17	0.51	10.18	0.49	2.28e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.95	-0.4	2.84e-14	Morning vs. evening chronotype;
LUSC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg19077165	chr18:44547161	KATNAL2	0.42	6.41	0.33	4.9e-10	Personality dimensions;
LUSC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg08601574	chr20:25228251	PYGB	-0.43	-6.59	-0.34	1.71e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	16.91	0.68	8.92e-47	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg21775007	chr8:11205619	TDH	-0.57	-8.03	-0.4	1.66e-14	Triglycerides;
LUSC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg02269571	chr22:50332266	NA	-0.54	-8.0	-0.4	2.09e-14	Schizophrenia;
LUSC	trans	rs4729127	1.000	rs7799378	chr7:94007546	C/G	cg19987288	chr12:56122958	CD63	-0.52	-6.03	-0.31	4.31e-9	Intelligence;
LUSC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26354017	chr1:205819088	PM20D1	-0.78	-15.15	-0.64	8.11e-40	Monocyte percentage of white cells;
LUSC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.82	15.09	0.64	1.34e-39	Blood protein levels;
LUSC	cis	rs2857891	0.695	rs2857893	chr11:6983330	C/T	cg04053776	chr11:6947353	ZNF215	0.4	5.94	0.31	7.14e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21016266	chr12:122356598	WDR66	-0.6	-9.23	-0.45	3.1e-18	Mean corpuscular volume;
LUSC	cis	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg02972257	chr16:68554789	NA	0.45	5.96	0.31	6.47e-9	Colorectal cancer;
LUSC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg03526776	chr6:41159608	TREML2	0.33	6.44	0.33	4.24e-10	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg03233332	chr7:66118400	NA	0.41	6.0	0.31	5.17e-9	Aortic root size;
LUSC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg19230755	chr7:65878503	NA	-0.41	-5.71	-0.3	2.5e-8	Aortic root size;
LUSC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.14e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs272594	1.000	rs272595	chr8:81470769	A/G	cg01004056	chr1:230560318	NA	-0.43	-5.97	-0.31	6.16e-9	Neutrophil count;
LUSC	cis	rs10791097	0.728	rs10894265	chr11:130714613	T/C	cg12179176	chr11:130786555	SNX19	-0.67	-10.07	-0.48	5.46e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg14552801	chr7:65878734	NA	0.39	6.07	0.32	3.53e-9	Aortic root size;
LUSC	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg24851651	chr11:66362959	CCS	0.39	6.13	0.32	2.43e-9	Educational attainment (years of education);
LUSC	cis	rs2625529	0.824	rs7170461	chr15:72218599	C/A	cg16672083	chr15:72433130	SENP8	-0.52	-7.51	-0.38	5.28e-13	Red blood cell count;
LUSC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg23630131	chr7:65973040	NA	-0.2	-5.64	-0.3	3.55e-8	Aortic root size;
LUSC	cis	rs7589342	0.501	rs12995849	chr2:106443111	C/T	cg14210321	chr2:106509881	NCK2	-0.4	-6.0	-0.31	5.23e-9	Addiction;
LUSC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg06618935	chr21:46677482	NA	-0.42	-7.94	-0.4	3.02e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7432375	0.610	rs6793936	chr3:136509793	A/C	cg12473912	chr3:136751656	NA	0.32	5.7	0.3	2.59e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs2285002	0.745	rs229674	chr14:65281472	G/C	cg01253149	chr3:184321996	NA	-0.32	-6.23	-0.32	1.39e-9	Red cell distribution width;
LUSC	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg19875535	chr5:140030758	IK	0.5	8.24	0.41	3.98e-15	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg16605590	chr2:122494233	MKI67IP	0.42	6.45	0.33	3.91e-10	N-glycan levels;
LUSC	cis	rs7178572	0.962	rs12324627	chr15:77767539	A/G	cg22256960	chr15:77711686	NA	-0.55	-9.2	-0.45	4.07e-18	Type 2 diabetes;
LUSC	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-1.03	-22.33	-0.77	3.09e-68	Platelet distribution width;
LUSC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg27266027	chr21:40555129	PSMG1	0.42	6.17	0.32	1.99e-9	Cognitive function;
LUSC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.96e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg05025164	chr4:1340916	KIAA1530	0.46	7.07	0.36	9.08e-12	Obesity-related traits;
LUSC	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg05738196	chr6:26577821	NA	-0.48	-6.89	-0.35	2.74e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.48	-7.89	-0.4	4.38e-14	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs9400467	0.528	rs462432	chr6:111659755	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.85	-0.35	3.51e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs4665630	0.522	rs2712054	chr2:23956123	C/T	cg08063864	chr2:24346004	PFN4;LOC375190	0.78	7.38	0.37	1.29e-12	Hypertension;
LUSC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08439880	chr3:133502540	NA	-0.31	-5.82	-0.3	1.4e-8	Iron status biomarkers;
LUSC	trans	rs1547374	0.694	rs225349	chr21:43776890	C/T	cg09521743	chr10:75415752	SYNPO2L	0.5	9.07	0.44	1.03e-17	Pancreatic cancer;
LUSC	cis	rs9650657	0.601	rs10903330	chr8:10673104	C/T	cg27411982	chr8:10470053	RP1L1	0.35	5.69	0.3	2.78e-8	Neuroticism;
LUSC	trans	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg27411982	chr8:10470053	RP1L1	0.41	6.63	0.34	1.33e-10	Mood instability;
LUSC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12311346	chr5:56204834	C5orf35	-1.01	-14.65	-0.63	7.19e-38	Initial pursuit acceleration;
LUSC	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg20703242	chr1:230279135	GALNT2	0.61	8.48	0.42	7.51e-16	Coronary artery disease;
LUSC	cis	rs10465746	0.780	rs2389649	chr1:84379449	C/T	cg10977910	chr1:84465055	TTLL7	0.45	6.41	0.33	4.94e-10	Obesity-related traits;
LUSC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.63	-0.43	2.55e-16	Gut microbiome composition (summer);
LUSC	cis	rs9309473	1.000	rs1881245	chr2:73649928	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-6.35	-0.33	6.83e-10	Metabolite levels;
LUSC	cis	rs56804039	1.000	rs7017341	chr8:8381664	C/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.99	-0.36	1.54e-11	Cervical cancer;
LUSC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-1.12	-17.84	-0.7	1.74e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs250677	0.522	rs998304	chr5:148382365	C/A	cg18129178	chr5:148520854	ABLIM3	-0.51	-7.4	-0.38	1.11e-12	Breast cancer;
LUSC	cis	rs9323205	0.723	rs55980461	chr14:51737434	G/A	cg23942311	chr14:51606299	NA	-0.42	-7.95	-0.4	2.83e-14	Cancer;
LUSC	cis	rs679087	0.640	rs79708380	chr12:29909457	G/A	cg14258853	chr12:29935411	TMTC1	-1.01	-15.0	-0.63	2.92e-39	Schizophrenia;
LUSC	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.48	-0.33	3.21e-10	Uric acid levels;
LUSC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	9.62	0.47	1.65e-19	Height;
LUSC	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14240646	chr10:27532245	ACBD5	0.71	8.19	0.41	5.71e-15	Breast cancer;
LUSC	cis	rs6740322	0.948	rs6722694	chr2:43569798	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-6.19	-0.32	1.79e-9	Coronary artery disease;
LUSC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16680214	chr1:154839983	KCNN3	-0.56	-10.92	-0.51	6.29e-24	Prostate cancer;
LUSC	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.6	-9.62	-0.47	1.68e-19	Body mass index;
LUSC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.68	-8.56	-0.42	4.17e-16	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg00852783	chr1:26633632	UBXN11	0.49	8.74	0.43	1.17e-16	Obesity-related traits;
LUSC	cis	rs4356932	1.000	rs6850760	chr4:76951684	A/T	cg00809888	chr4:76862425	NAAA	0.38	6.42	0.33	4.72e-10	Blood protein levels;
LUSC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	10.48	0.5	2.16e-22	Cognitive test performance;
LUSC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg05585544	chr11:47624801	NA	-0.42	-7.26	-0.37	2.74e-12	Subjective well-being;
LUSC	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-1.14	-17.81	-0.7	2.27e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs1941023	0.584	rs2241920	chr11:60164204	A/G	cg08716584	chr11:60157161	MS4A7	0.6	10.63	0.5	6.06e-23	Congenital heart disease (maternal effect);
LUSC	cis	rs12410462	0.581	rs7543931	chr1:227550976	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.67	-6.43	-0.33	4.5e-10	Major depressive disorder;
LUSC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg23625390	chr15:77176239	SCAPER	0.59	9.22	0.45	3.51e-18	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.68	11.71	0.54	8.87e-27	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg04414720	chr1:150670196	GOLPH3L	0.52	8.31	0.41	2.42e-15	Melanoma;
LUSC	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg22705602	chr4:152727874	NA	-0.35	-7.48	-0.38	6.81e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17436476	chr1:62120002	NA	0.5	5.95	0.31	6.71e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	7.12	0.36	6.84e-12	Endometrial cancer;
LUSC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.81	-0.39	7.53e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg10756647	chr7:56101905	PSPH	0.87	8.4	0.42	1.31e-15	Diabetic kidney disease;
LUSC	cis	rs6690583	0.623	rs7522239	chr1:85484366	C/T	cg22153463	chr1:85462885	MCOLN2	0.6	5.96	0.31	6.35e-9	Serum sulfate level;
LUSC	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg26924012	chr15:45694286	SPATA5L1	1.13	19.81	0.73	2.73e-58	Homoarginine levels;
LUSC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg04141948	chr7:1023156	CYP2W1	0.3	6.26	0.32	1.2e-9	Longevity;Endometriosis;
LUSC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25072359	chr17:41440525	NA	0.66	9.42	0.46	7.64e-19	Menopause (age at onset);
LUSC	cis	rs3931020	0.657	rs277376	chr1:75242246	G/T	cg00121533	chr1:75199117	CRYZ;TYW3	-0.45	-5.77	-0.3	1.78e-8	Resistin levels;
LUSC	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg14092571	chr14:90743983	NA	-0.37	-6.16	-0.32	2.07e-9	Mortality in heart failure;
LUSC	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg24459738	chr19:57751996	ZNF805	-0.5	-7.35	-0.37	1.56e-12	Hyperactive-impulsive symptoms;
LUSC	cis	rs909341	0.710	rs3848669	chr20:62300811	G/T	cg09650180	chr20:62225654	GMEB2	0.46	5.97	0.31	6.2e-9	Atopic dermatitis;
LUSC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg19912559	chr1:40204330	PPIE	0.53	8.18	0.41	6.17e-15	Blood protein levels;
LUSC	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	8.34	0.42	2.02e-15	Height;
LUSC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg22823121	chr1:150693482	HORMAD1	0.48	6.92	0.35	2.26e-11	Melanoma;
LUSC	cis	rs12681287	0.604	rs6471316	chr8:87403587	G/C	cg27223183	chr8:87520930	FAM82B	0.55	7.45	0.38	8.05e-13	Caudate activity during reward;
LUSC	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg23093090	chr10:104574429	C10orf26	-0.37	-6.87	-0.35	3.08e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	9.53	0.46	3.4e-19	IgG glycosylation;
LUSC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg02423579	chr7:2872169	GNA12	-0.45	-6.35	-0.33	6.84e-10	Height;
LUSC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.73	0.35	7.5e-11	Aortic root size;
LUSC	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg23093090	chr10:104574429	C10orf26	-0.47	-5.76	-0.3	1.94e-8	Arsenic metabolism;
LUSC	cis	rs9653442	0.545	rs11123813	chr2:100765692	C/T	cg07810366	chr2:100720526	AFF3	-0.45	-7.79	-0.39	8.8e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7580658	0.864	rs4150441	chr2:128040915	T/C	cg09760422	chr2:128146352	NA	-0.28	-5.89	-0.31	9.64e-9	Protein C levels;
LUSC	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg06552810	chr11:31128660	NA	0.39	6.68	0.34	1.02e-10	Red blood cell count;
LUSC	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.59	-0.34	1.71e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg25664220	chr3:72788482	NA	0.61	9.82	0.47	3.8e-20	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg05714579	chr10:131428358	MGMT	-0.52	-7.97	-0.4	2.45e-14	Response to temozolomide;
LUSC	cis	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg21775007	chr8:11205619	TDH	-0.59	-9.34	-0.45	1.42e-18	Systolic blood pressure;
LUSC	cis	rs2579519	0.547	rs2463560	chr2:96595589	T/C	cg23100626	chr2:96804247	ASTL	0.23	5.75	0.3	2.05e-8	Diastolic blood pressure;
LUSC	cis	rs1775715	0.707	rs2808088	chr10:32146150	A/G	cg03015672	chr10:32216066	ARHGAP12	0.35	6.39	0.33	5.5e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1014246	1.000	rs2240706	chr10:118466297	C/G	cg14919929	chr10:118506882	NA	0.38	5.88	0.31	9.98e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs4253772	0.938	rs41355347	chr22:46637511	G/A	cg09491104	chr22:46646882	C22orf40	-0.64	-6.59	-0.34	1.75e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg22437258	chr11:111473054	SIK2	-0.45	-5.96	-0.31	6.25e-9	Primary sclerosing cholangitis;
LUSC	cis	rs3862435	0.706	rs2253425	chr15:90945759	G/A	cg22089800	chr15:90895588	ZNF774	0.55	5.96	0.31	6.34e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg08213375	chr14:104286397	PPP1R13B	0.52	10.25	0.49	1.29e-21	Schizophrenia;
LUSC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	0.65	9.48	0.46	5e-19	Methadone dose in opioid dependence;
LUSC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg03351412	chr1:154909251	PMVK	0.5	7.91	0.4	3.85e-14	Prostate cancer;
LUSC	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg13010199	chr12:38710504	ALG10B	0.48	7.28	0.37	2.47e-12	Heart rate;
LUSC	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg23711669	chr6:146136114	FBXO30	0.85	15.26	0.64	2.8e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg07701084	chr6:150067640	NUP43	0.53	7.99	0.4	2.25e-14	Lung cancer;
LUSC	cis	rs10484885	0.824	rs72919954	chr6:90515665	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.06	-0.4	1.35e-14	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg17294928	chr15:75287854	SCAMP5	-0.76	-10.18	-0.49	2.18e-21	Blood trace element (Zn levels);
LUSC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg27432699	chr2:27873401	GPN1	-0.58	-8.68	-0.43	1.72e-16	Total body bone mineral density;
LUSC	cis	rs1662342	1.000	rs1662343	chr18:3251994	A/G	cg00760847	chr18:3262519	MYL12B	-0.58	-5.68	-0.3	2.97e-8	QRS duration;
LUSC	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08645402	chr16:4508243	NA	0.49	8.11	0.41	9.74e-15	Schizophrenia;
LUSC	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg14844989	chr11:31128820	NA	-0.39	-5.93	-0.31	7.53e-9	Red blood cell count;
LUSC	cis	rs6920965	0.507	rs9385389	chr6:126215486	G/C	cg05901451	chr6:126070800	HEY2	-0.53	-7.62	-0.38	2.66e-13	High light scatter reticulocyte count;
LUSC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.8	-0.54	4.37e-27	Chronic sinus infection;
LUSC	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.69e-9	Response to antipsychotic treatment;
LUSC	cis	rs11039100	0.607	rs34670757	chr11:5783042	G/C	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs865483	0.860	rs2522968	chr17:35830300	G/A	cg06716730	chr17:35851459	DUSP14	0.28	6.18	0.32	1.91e-9	Monocyte count;
LUSC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-0.9	-16.73	-0.68	4.51e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10802521	chr3:52805072	NEK4	-0.54	-8.59	-0.43	3.47e-16	Bipolar disorder;
LUSC	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg22906224	chr7:99728672	NA	0.52	7.57	0.38	3.71e-13	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.9	0.44	3.71e-17	Lung cancer;
LUSC	cis	rs9487051	0.703	rs351755	chr6:109538073	G/A	cg01475377	chr6:109611718	NA	0.35	6.03	0.31	4.42e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg10756647	chr7:56101905	PSPH	-0.84	-8.39	-0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.7	-0.3	2.59e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg25258033	chr6:167368657	RNASET2	0.49	8.04	0.4	1.62e-14	Crohn's disease;
LUSC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg16414030	chr3:133502952	NA	-0.39	-5.85	-0.3	1.17e-8	Iron status biomarkers;
LUSC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg04455712	chr21:45112962	RRP1B	0.44	8.36	0.42	1.66e-15	Mean corpuscular volume;
LUSC	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.22	0.71	5.32e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-8.1	-0.41	1.03e-14	Morning vs. evening chronotype;
LUSC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg15485101	chr11:133734466	NA	0.43	7.61	0.38	2.75e-13	Childhood ear infection;
LUSC	cis	rs1256061	0.654	rs1256040	chr14:64738394	G/A	cg21174375	chr14:64681225	SYNE2	0.33	6.04	0.31	4.05e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg17469321	chr7:55412551	NA	0.65	9.62	0.47	1.69e-19	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg20203395	chr5:56204925	C5orf35	-0.67	-8.75	-0.43	1.08e-16	Initial pursuit acceleration;
LUSC	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg00982548	chr2:198649783	BOLL	-0.56	-7.07	-0.36	9.04e-12	Ulcerative colitis;
LUSC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg07701084	chr6:150067640	NUP43	0.51	7.64	0.39	2.37e-13	Lung cancer;
LUSC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg01256987	chr12:42539512	GXYLT1	-0.44	-8.08	-0.4	1.19e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.51	-0.42	5.95e-16	Menopause (age at onset);
LUSC	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	trans	rs6600671	0.966	rs6600664	chr1:121222436	G/A	cg00646200	chr1:148855367	NA	0.46	7.12	0.36	6.57e-12	Hip geometry;
LUSC	cis	rs6580649	0.598	rs1793913	chr12:48387025	T/A	cg24011408	chr12:48396354	COL2A1	0.5	6.36	0.33	6.75e-10	Lung cancer;
LUSC	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg17366294	chr4:99064904	C4orf37	0.55	8.51	0.42	5.79e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs113835537	0.529	rs11227500	chr11:66273233	T/C	cg24851651	chr11:66362959	CCS	0.54	8.14	0.41	7.9e-15	Airway imaging phenotypes;
LUSC	cis	rs28595532	0.623	rs71608363	chr4:119227259	T/C	cg21605333	chr4:119757512	SEC24D	0.73	6.13	0.32	2.46e-9	Cannabis dependence symptom count;
LUSC	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg25214090	chr10:38739885	LOC399744	0.5	7.39	0.37	1.19e-12	Corneal astigmatism;
LUSC	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	0.93	17.58	0.69	1.94e-49	Headache;
LUSC	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg16482183	chr6:26056742	HIST1H1C	0.44	6.56	0.34	2.03e-10	Height;
LUSC	cis	rs68170813	0.559	rs80017637	chr7:107050660	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.36	-0.46	1.25e-18	Coronary artery disease;
LUSC	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg07169764	chr2:136633963	MCM6	0.87	12.05	0.55	4.98e-28	Corneal structure;
LUSC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg20639618	chr4:183729073	NA	0.62	8.61	0.43	2.88e-16	Pediatric autoimmune diseases;
LUSC	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg03676636	chr4:99064102	C4orf37	0.31	6.14	0.32	2.39e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8078723	0.510	rs9898547	chr17:38136026	G/T	cg17467752	chr17:38218738	THRA	-0.52	-7.69	-0.39	1.63e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.48	9.35	0.46	1.27e-18	Eosinophil percentage of white cells;
LUSC	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06002616	chr8:101225028	SPAG1	-0.46	-7.56	-0.38	3.93e-13	Atrioventricular conduction;
LUSC	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg16405210	chr4:1374714	KIAA1530	0.47	5.77	0.3	1.8e-8	Recombination rate (females);
LUSC	cis	rs6736093	0.931	rs34974369	chr2:112683390	G/A	cg12686935	chr2:112915763	FBLN7	-0.37	-5.9	-0.31	8.73e-9	Coronary artery disease;
LUSC	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg02018176	chr4:1364513	KIAA1530	0.43	5.65	0.3	3.45e-8	Recombination rate (females);
LUSC	cis	rs829883	0.646	rs4762494	chr12:98933834	T/G	cg25150519	chr12:98850993	NA	-0.63	-8.71	-0.43	1.47e-16	Colorectal adenoma (advanced);
LUSC	cis	rs4700695	0.668	rs36837	chr5:65480007	C/A	cg21114390	chr5:65439923	SFRS12	-0.51	-7.4	-0.38	1.14e-12	Facial morphology (factor 19);
LUSC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg12432903	chr7:1882776	MAD1L1	-0.49	-8.45	-0.42	8.85e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg22852734	chr6:133119734	C6orf192	1.22	14.16	0.61	5.56e-36	Type 2 diabetes nephropathy;
LUSC	cis	rs4280164	0.887	rs2748543	chr14:24778674	C/A	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.61	-7.2	-0.37	4.04e-12	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg07460842	chr6:66804631	NA	1.03	14.22	0.61	3.16e-36	Exhaled nitric oxide levels;
LUSC	trans	rs2679649	1.000	rs2679643	chr6:122353149	T/C	cg00167820	chr8:131663355	NA	0.54	6.35	0.33	6.96e-10	Subcutaneous adipose tissue;
LUSC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg10360139	chr7:1886902	MAD1L1	-0.43	-6.46	-0.33	3.79e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1832871	0.541	rs11755760	chr6:158886742	A/G	cg07165851	chr6:158734300	TULP4	0.41	5.81	0.3	1.43e-8	Height;
LUSC	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg19773385	chr1:10388646	KIF1B	-0.55	-8.69	-0.43	1.6e-16	Hepatocellular carcinoma;
LUSC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	7.67	0.39	1.92e-13	Prudent dietary pattern;
LUSC	trans	rs75804782	0.581	rs72987336	chr2:239365345	T/C	cg01134436	chr17:81009848	B3GNTL1	0.63	6.12	0.32	2.67e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs17253792	0.915	rs28375514	chr14:56179941	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.86	-0.35	3.35e-11	Putamen volume;
LUSC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11764359	chr7:65958608	NA	-0.62	-9.4	-0.46	9.28e-19	Corneal structure;
LUSC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg21724239	chr8:58056113	NA	0.56	5.97	0.31	5.95e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg21782813	chr7:2030301	MAD1L1	0.4	6.54	0.34	2.25e-10	Schizophrenia;
LUSC	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg12826209	chr6:26865740	GUSBL1	0.68	7.67	0.39	1.85e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs11677416	1.000	rs1040193	chr2:113530099	C/T	cg27083787	chr2:113543245	IL1A	0.48	7.41	0.38	1.06e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg09307838	chr4:120376055	NA	0.58	8.64	0.43	2.41e-16	Corneal astigmatism;
LUSC	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg02023728	chr11:77925099	USP35	0.46	6.97	0.36	1.71e-11	Testicular germ cell tumor;
LUSC	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg27284194	chr4:1044797	NA	0.6	8.88	0.44	4.09e-17	Recombination rate (females);
LUSC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg12463550	chr7:65579703	CRCP	-0.42	-6.27	-0.32	1.14e-9	Aortic root size;
LUSC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg04775059	chr7:64541387	NA	0.48	7.02	0.36	1.24e-11	Calcium levels;
LUSC	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg23229984	chr5:148520753	ABLIM3	0.41	6.48	0.33	3.22e-10	Breast cancer;
LUSC	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.59	-10.47	-0.5	2.34e-22	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.7	0.3	2.65e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05890377	chr2:74357713	NA	0.73	13.59	0.6	8.73e-34	Gestational age at birth (maternal effect);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04301719	chr15:89164530	AEN	0.7	5.95	0.31	6.74e-9	Cognitive performance;
LUSC	trans	rs2055729	0.645	rs7828229	chr8:9742841	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.41	-0.33	5.04e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs1107366	0.513	rs35078897	chr3:125973767	T/C	cg01346077	chr3:125931526	NA	0.37	6.37	0.33	6.26e-10	Metabolite levels;
LUSC	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg02993010	chr8:124780839	FAM91A1	-0.47	-5.66	-0.3	3.32e-8	Pancreatic cancer;
LUSC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg26695010	chr11:65641043	EFEMP2	-0.48	-7.14	-0.36	6e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs939574	0.790	rs72955440	chr2:220091765	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	6.07	0.32	3.4e-9	Platelet distribution width;
LUSC	cis	rs701145	0.938	rs2971446	chr3:154073445	G/C	cg17054900	chr3:154042577	DHX36	0.78	7.98	0.4	2.43e-14	Coronary artery disease;
LUSC	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg13852791	chr20:30311386	BCL2L1	0.95	14.9	0.63	7.51e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg04775059	chr7:64541387	NA	-0.47	-6.8	-0.35	4.88e-11	Calcium levels;
LUSC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.44	-7.55	-0.38	4.14e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1832871	0.711	rs9459946	chr6:158707957	T/C	cg07165851	chr6:158734300	TULP4	0.51	7.91	0.4	3.75e-14	Height;
LUSC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-6.84	-0.35	3.89e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg17042849	chr6:26104293	HIST1H4C	-0.38	-5.66	-0.3	3.3e-8	Height;
LUSC	cis	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg20368463	chr18:77673604	PQLC1	-0.63	-6.72	-0.34	8.05e-11	Opioid sensitivity;
LUSC	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.7	-0.3	2.59e-8	Bipolar disorder;
LUSC	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg05738196	chr6:26577821	NA	0.82	15.81	0.65	2e-42	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08135327	chr2:134877962	NA	-0.49	-6.66	-0.34	1.16e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg07169764	chr2:136633963	MCM6	0.52	7.21	0.37	3.73e-12	Mosquito bite size;
LUSC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg08219700	chr8:58056026	NA	0.51	6.41	0.33	5e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6977940	0.558	rs11765473	chr7:2894800	C/G	cg19731401	chr7:2775893	GNA12	0.65	7.28	0.37	2.44e-12	White matter integrity;
LUSC	cis	rs9369695	0.842	rs9395262	chr6:47465267	T/C	cg12968598	chr6:47444699	CD2AP	0.53	8.0	0.4	2.1e-14	Reticulocyte count;
LUSC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg19774624	chr17:42201019	HDAC5	-0.82	-14.27	-0.62	2.15e-36	Total body bone mineral density;
LUSC	cis	rs2224391	0.628	rs9405261	chr6:5249702	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.48	-6.46	-0.33	3.59e-10	Height;
LUSC	cis	rs2742417	0.603	rs2064064	chr3:45759995	C/T	cg10512202	chr3:45649293	LIMD1	0.36	6.04	0.31	4.18e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23978390	chr7:1156363	C7orf50	0.48	6.79	0.35	5.15e-11	Longevity;Endometriosis;
LUSC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg23711669	chr6:146136114	FBXO30	0.91	17.67	0.7	8.33e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg05347473	chr6:146136440	FBXO30	0.52	8.64	0.43	2.32e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.72	12.66	0.57	2.87e-30	Colorectal cancer;
LUSC	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg07817648	chr10:79422355	NA	0.58	7.47	0.38	7.23e-13	Bone mineral density;
LUSC	cis	rs7799006	0.606	rs34417375	chr7:2315105	C/T	cg08027265	chr7:2291960	NA	-0.62	-10.98	-0.52	3.67e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.8	0.3	1.54e-8	Menopause (age at onset);
LUSC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.69	9.01	0.44	1.6e-17	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.89	0.51	7.97e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.81e-10	Bipolar disorder;
LUSC	trans	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.9	0.35	2.57e-11	Endometrial cancer;
LUSC	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg25828445	chr12:7781288	NA	0.58	5.97	0.31	6.18e-9	HDL cholesterol levels;
LUSC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg02079420	chr8:82753780	SNX16	0.42	7.2	0.37	4.01e-12	Diastolic blood pressure;
LUSC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg15445000	chr17:37608096	MED1	0.38	6.53	0.34	2.52e-10	Glomerular filtration rate (creatinine);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03525424	chr17:48238931	NA	0.5	6.68	0.34	1.02e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg08355456	chr11:67383691	NA	0.37	6.83	0.35	4.05e-11	Mean corpuscular volume;
LUSC	cis	rs9549260	0.564	rs7997896	chr13:41268823	T/A	cg21288729	chr13:41239152	FOXO1	0.53	7.97	0.4	2.6e-14	Red blood cell count;
LUSC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg03732007	chr1:2071316	PRKCZ	-0.51	-8.99	-0.44	1.81e-17	Height;
LUSC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg17554472	chr22:41940697	POLR3H	-0.47	-5.74	-0.3	2.18e-8	Vitiligo;
LUSC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	9.93	0.48	1.51e-20	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs73193808	0.639	rs2832237	chr21:30547683	C/G	cg03476357	chr21:30257390	N6AMT1	0.47	6.27	0.32	1.13e-9	Coronary artery disease;
LUSC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.63	11.19	0.52	6.5e-25	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg23262073	chr20:60523788	NA	-0.42	-6.38	-0.33	6.07e-10	Body mass index;
LUSC	cis	rs2798269	1.000	rs2761913	chr13:22135042	A/G	cg18095732	chr13:22033692	ZDHHC20	0.41	6.14	0.32	2.29e-9	PR segment;
LUSC	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg11941060	chr3:133502564	NA	-0.46	-6.52	-0.34	2.64e-10	Iron status biomarkers;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg26668828	chr6:292823	DUSP22	-0.73	-12.06	-0.55	4.58e-28	Menopause (age at onset);
LUSC	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg25457927	chr22:38595422	NA	-0.44	-9.18	-0.45	4.7e-18	Cutaneous nevi;
LUSC	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg18129178	chr5:148520854	ABLIM3	0.66	10.27	0.49	1.14e-21	Breast cancer;
LUSC	cis	rs10979	0.964	rs9496683	chr6:143898845	G/A	cg25407410	chr6:143891975	LOC285740	-0.75	-11.97	-0.55	1.06e-27	Hypospadias;
LUSC	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg09184832	chr6:79620586	NA	-0.43	-6.96	-0.36	1.76e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg09033563	chr22:24373618	LOC391322	-0.48	-6.78	-0.35	5.33e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg23711669	chr6:146136114	FBXO30	0.87	16.1	0.66	1.44e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9462027	0.606	rs205260	chr6:34563958	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.18	-0.32	1.91e-9	Systemic lupus erythematosus;
LUSC	trans	rs10242455	0.702	rs41385645	chr7:98974038	A/T	cg03698393	chr15:89438795	HAPLN3	-0.81	-6.17	-0.32	2e-9	Blood metabolite levels;
LUSC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg03647239	chr10:116582469	FAM160B1	0.49	7.97	0.4	2.55e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs7939886	0.920	rs1481926	chr11:55973281	C/T	cg15704280	chr7:45808275	SEPT13	0.9	6.77	0.35	5.86e-11	Myopia (pathological);
LUSC	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg05343316	chr1:45956843	TESK2	0.59	8.34	0.42	1.93e-15	Platelet count;
LUSC	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg01557791	chr16:72042693	DHODH	-0.52	-7.54	-0.38	4.42e-13	Fibrinogen levels;
LUSC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18402987	chr7:1209562	NA	0.43	5.69	0.3	2.74e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7771547	0.642	rs9470309	chr6:36509751	A/G	cg07856975	chr6:36356162	ETV7	0.37	6.42	0.33	4.65e-10	Platelet distribution width;
LUSC	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg21549285	chr21:42799141	MX1	-0.39	-5.95	-0.31	6.63e-9	IgG glycosylation;
LUSC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.87	-0.35	3.19e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg11871910	chr12:69753446	YEATS4	0.55	8.68	0.43	1.78e-16	Blood protein levels;
LUSC	cis	rs1113500	0.730	rs1618693	chr1:108591583	G/A	cg06207961	chr1:108661230	NA	-0.3	-5.65	-0.3	3.49e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.48	-8.89	-0.44	3.77e-17	Urinary metabolites;
LUSC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg27588902	chr6:42928151	GNMT	-0.3	-6.6	-0.34	1.65e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.99	0.31	5.5e-9	Menopause (age at onset);
LUSC	cis	rs9625935	0.700	rs9625921	chr22:30508275	C/G	cg11564601	chr22:30592435	NA	-0.33	-5.7	-0.3	2.65e-8	Tonsillectomy;
LUSC	cis	rs977987	0.843	rs12443904	chr16:75438770	C/T	cg03315344	chr16:75512273	CHST6	0.53	10.17	0.49	2.47e-21	Dupuytren's disease;
LUSC	cis	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.29	-0.41	2.79e-15	Morning vs. evening chronotype;
LUSC	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.5	6.83	0.35	3.91e-11	Corneal astigmatism;
LUSC	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg12559939	chr2:27858050	GPN1	0.41	6.4	0.33	5.27e-10	Oral cavity cancer;
LUSC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg21972741	chr5:435613	AHRR	0.36	6.8	0.35	4.8e-11	Cystic fibrosis severity;
LUSC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.72	-9.95	-0.48	1.35e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.86	-0.31	1.13e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs13233308	0.837	rs7793933	chr7:87416839	C/T	cg22633988	chr4:77610603	SHROOM3	-0.42	-6.3	-0.33	9.27e-10	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs28785552	0.554	rs11084178	chr19:53212361	C/T	cg10871876	chr19:53194124	ZNF83	0.36	5.72	0.3	2.31e-8	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs2625529	0.701	rs62025574	chr15:72236075	C/T	cg16672083	chr15:72433130	SENP8	-0.52	-7.51	-0.38	5.28e-13	Red blood cell count;
LUSC	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg15934090	chr1:100435551	SLC35A3	0.48	8.21	0.41	4.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6714788	0.565	rs7558817	chr2:100654482	C/A	cg07810366	chr2:100720526	AFF3	-0.39	-6.08	-0.32	3.25e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4845459	0.967	rs4112787	chr1:152551325	A/G	cg08895932	chr1:152778580	LCE1C	0.34	5.78	0.3	1.72e-8	Psoriasis;
LUSC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg01256987	chr12:42539512	GXYLT1	-0.44	-8.02	-0.4	1.83e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg17168535	chr8:21777572	XPO7	0.83	15.48	0.65	3.9e-41	Mean corpuscular volume;
LUSC	trans	rs3857536	0.813	rs4710580	chr6:66935200	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.21	0.49	1.77e-21	Lymphocyte counts;
LUSC	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.37	1.18e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs894344	0.650	rs16905182	chr8:135576794	C/A	cg17885191	chr8:135476712	NA	0.41	5.85	0.3	1.17e-8	Systolic blood pressure;
LUSC	cis	rs6460942	0.591	rs6942551	chr7:12338356	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-6.2	-0.32	1.64e-9	Coronary artery disease;
LUSC	cis	rs2219968	0.676	rs1586415	chr8:78840220	A/C	cg00738934	chr8:78996279	NA	-0.35	-5.94	-0.31	6.98e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg01943577	chr7:158741284	NA	-0.4	-5.76	-0.3	1.9e-8	Height;
LUSC	cis	rs2425143	1.000	rs11696369	chr20:34378629	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-5.72	-0.3	2.33e-8	Blood protein levels;
LUSC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.08	-0.32	3.35e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg12419862	chr22:24373484	LOC391322	0.8	10.21	0.49	1.78e-21	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg15744005	chr10:104629667	AS3MT	-0.34	-6.92	-0.35	2.31e-11	Arsenic metabolism;
LUSC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.44	0.42	1e-15	Parkinson's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21776568	chr13:95254007	GPR180	0.43	6.44	0.33	4.13e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg07959070	chr22:50026188	C22orf34	-0.32	-5.95	-0.31	6.72e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.32	-0.37	1.89e-12	Neuroticism;
LUSC	cis	rs713477	0.654	rs12886848	chr14:55911138	G/A	cg13175173	chr14:55914753	NA	-0.3	-6.12	-0.32	2.66e-9	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	11.45	0.53	8.02e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg02508848	chr16:68573721	ZFP90	-0.43	-6.02	-0.31	4.61e-9	Ulcerative colitis;
LUSC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg02534363	chr3:47050950	NBEAL2	0.38	6.17	0.32	2e-9	Colorectal cancer;
LUSC	cis	rs12973672	0.680	rs564117	chr19:35718938	C/T	cg12095397	chr19:35769544	USF2	0.39	5.8	0.3	1.5e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12737363	chr1:183604674	ARPC5;RGL1	0.45	6.51	0.34	2.81e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7075426	0.524	rs12779025	chr10:88188716	T/A	cg07322936	chr10:88137208	NA	0.42	5.73	0.3	2.23e-8	Migraine without aura;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22929219	chr22:35796023	MCM5	-0.46	-6.01	-0.31	4.75e-9	Hepatitis;
LUSC	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.75e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.91	0.31	8.37e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2544523	0.511	rs2544535	chr2:15906778	A/G	cg26669897	chr2:15909070	NA	0.33	7.09	0.36	7.88e-12	Asthma or chronic obstructive pulmonary disease;
LUSC	cis	rs4280164	0.551	rs1109152	chr14:24799024	G/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.61	-7.58	-0.38	3.51e-13	Parent of origin effect on language impairment (paternal);
LUSC	trans	rs7944735	0.832	rs7130876	chr11:48050995	A/G	cg03929089	chr4:120376271	NA	0.66	6.57	0.34	1.91e-10	Intraocular pressure;
LUSC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg09877947	chr5:131593287	PDLIM4	-0.53	-8.44	-0.42	9.5e-16	Acylcarnitine levels;
LUSC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg05025164	chr4:1340916	KIAA1530	0.53	8.21	0.41	4.9e-15	Longevity;
LUSC	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.27e-8	Breast cancer;
LUSC	trans	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-6.06	-0.31	3.66e-9	Morning vs. evening chronotype;
LUSC	cis	rs11608355	0.545	rs7139106	chr12:109908640	G/A	cg05360138	chr12:110035743	NA	0.89	11.55	0.53	3.47e-26	Neuroticism;
LUSC	cis	rs1957429	0.520	rs7144515	chr14:65333725	G/A	cg23373153	chr14:65346875	NA	-0.88	-8.1	-0.41	1.06e-14	Pediatric areal bone mineral density (radius);
LUSC	cis	rs9309473	0.519	rs1881246	chr2:73650122	T/A	cg20560298	chr2:73613845	ALMS1	0.48	7.41	0.38	1.02e-12	Metabolite levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02715291	chr4:54243685	FIP1L1	-0.45	-6.69	-0.34	9.65e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg06521331	chr12:34319734	NA	-0.45	-7.4	-0.38	1.13e-12	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23543263	chr13:22245177	FGF9	0.45	6.18	0.32	1.83e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg13010199	chr12:38710504	ALG10B	0.42	6.28	0.32	1.04e-9	Morning vs. evening chronotype;
LUSC	cis	rs7828089	0.935	rs896378	chr8:22262321	T/C	cg12081754	chr8:22256438	SLC39A14	0.53	8.28	0.41	2.96e-15	Verbal declarative memory;
LUSC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07677032	chr17:61819896	STRADA	0.54	9.05	0.44	1.17e-17	Prudent dietary pattern;
LUSC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.81	13.52	0.59	1.62e-33	Aortic root size;
LUSC	cis	rs1499972	0.941	rs6794831	chr3:117642484	C/A	cg07612923	chr3:117604196	NA	0.65	5.87	0.31	1.03e-8	Schizophrenia;
LUSC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-7.14	-0.36	5.79e-12	Total body bone mineral density;
LUSC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.38	6.6	0.34	1.62e-10	Obesity-related traits;
LUSC	cis	rs6500395	1.000	rs7185899	chr16:48714101	A/G	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg00750074	chr16:89608354	SPG7	-0.53	-9.62	-0.47	1.64e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg09034736	chr1:150693464	HORMAD1	0.44	5.98	0.31	5.83e-9	Melanoma;
LUSC	cis	rs500891	0.525	rs6900022	chr6:84109944	T/A	cg08257003	chr6:84140564	ME1	0.33	7.27	0.37	2.52e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg21545522	chr1:205238299	TMCC2	0.43	8.15	0.41	7.46e-15	Red blood cell count;
LUSC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg03146154	chr1:46216737	IPP	0.55	8.19	0.41	5.7e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg10556349	chr10:835070	NA	0.59	6.48	0.33	3.31e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.44	0.5	2.94e-22	Colorectal cancer;
LUSC	cis	rs977987	0.806	rs12930768	chr16:75464500	T/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.42e-11	Dupuytren's disease;
LUSC	cis	rs6845621	0.700	rs10008431	chr4:18934125	T/C	cg12196642	chr4:18937545	NA	-0.36	-6.57	-0.34	1.91e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg12751644	chr20:60527061	NA	-0.33	-5.91	-0.31	8.33e-9	Body mass index;
LUSC	trans	rs9987353	0.784	rs4841116	chr8:9130116	G/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.19	-0.32	1.72e-9	Recombination measurement;
LUSC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26314531	chr2:26401878	FAM59B	-0.66	-8.86	-0.44	4.92e-17	Gut microbiome composition (summer);
LUSC	cis	rs2425143	1.000	rs6060642	chr20:34449840	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.9	-0.31	9.06e-9	Blood protein levels;
LUSC	trans	rs2789047	0.920	rs2817952	chr6:121187100	C/G	cg27453922	chr7:148922355	ZNF282	0.39	6.16	0.32	2.08e-9	Peak creatinine levels in vancomycin therapy;
LUSC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	7.6	0.38	2.92e-13	Prudent dietary pattern;
LUSC	cis	rs7712401	0.601	rs187405	chr5:122294995	G/A	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11777782	chr19:18284937	IFI30	-0.45	-6.41	-0.33	4.83e-10	Hepatitis;
LUSC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs433852	0.898	rs376524	chr19:49116438	A/G	cg06677660	chr19:49140777	SEC1;DBP	-0.58	-6.96	-0.36	1.85e-11	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg05552183	chr6:42928497	GNMT	0.46	7.62	0.38	2.61e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.41	-0.46	8.5e-19	Chronic sinus infection;
LUSC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg14019146	chr3:50243930	SLC38A3	-0.33	-7.33	-0.37	1.73e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06636551	chr8:101224915	SPAG1	-0.44	-8.03	-0.4	1.63e-14	Atrioventricular conduction;
LUSC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg05623727	chr3:50126028	RBM5	0.32	5.97	0.31	6.05e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.89	-0.31	9.19e-9	Longevity;
LUSC	cis	rs7103648	0.695	rs12577643	chr11:47467172	A/T	cg20307385	chr11:47447363	PSMC3	0.89	14.54	0.62	1.84e-37	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg22963979	chr7:1858916	MAD1L1	-0.56	-8.54	-0.42	4.69e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.34	-6.2	-0.32	1.64e-9	Obesity-related traits;
LUSC	cis	rs3820928	0.874	rs2229813	chr2:227892720	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.55	-0.38	4.32e-13	Pulmonary function;
LUSC	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg21862992	chr11:68658383	NA	0.33	5.71	0.3	2.53e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	1.03	16.72	0.67	5.21e-46	Primary sclerosing cholangitis;
LUSC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg00933542	chr6:150070202	PCMT1	0.31	6.48	0.33	3.2e-10	Lung cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13735691	chr19:36103707	HAUS5	-0.41	-5.97	-0.31	6.07e-9	Electrocardiographic conduction measures;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11503359	chr11:73882148	C2CD3;PPME1	-0.43	-6.44	-0.33	4.16e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18932078	chr1:2524107	MMEL1	-0.32	-7.13	-0.36	6.33e-12	Ulcerative colitis;
LUSC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg03146154	chr1:46216737	IPP	-0.5	-7.24	-0.37	3.08e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.75	-10.7	-0.51	3.66e-23	Gut microbiome composition (summer);
LUSC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.69	11.42	0.53	9.91e-26	Systemic lupus erythematosus;
LUSC	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg04310649	chr10:35416472	CREM	-0.44	-6.58	-0.34	1.85e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7560272	0.538	rs13014700	chr2:73920121	C/G	cg20560298	chr2:73613845	ALMS1	0.38	5.81	0.3	1.5e-8	Schizophrenia;
LUSC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.62	-0.34	1.41e-10	Total body bone mineral density;
LUSC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.67	11.22	0.52	5.16e-25	Cognitive function;
LUSC	cis	rs3770081	1.000	rs60479377	chr2:86283948	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.93	-7.0	-0.36	1.39e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs7091068	0.671	rs1223296	chr10:95404621	T/C	cg20715218	chr10:95462985	C10orf4	-0.56	-6.18	-0.32	1.84e-9	Urinary tract infection frequency;
LUSC	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg00982548	chr2:198649783	BOLL	-0.58	-7.27	-0.37	2.59e-12	Ulcerative colitis;
LUSC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23661578	chr6:42981936	MEA1;KLHDC3	-0.43	-6.81	-0.35	4.5e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.66	10.35	0.49	5.84e-22	Longevity;
LUSC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.97	0.55	1.04e-27	Personality dimensions;
LUSC	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg22681709	chr2:178499509	PDE11A	0.35	6.6	0.34	1.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	0.96	16.31	0.67	2.17e-44	Menopause (age at onset);
LUSC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	12.22	0.56	1.18e-28	Colorectal cancer;
LUSC	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg06885757	chr1:42089581	HIVEP3	0.44	9.0	0.44	1.74e-17	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs4988958	0.565	rs6760621	chr2:102999952	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.27e-12	Asthma (childhood onset);
LUSC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	6.81	0.35	4.56e-11	Platelet count;
LUSC	trans	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg14791747	chr16:20752902	THUMPD1	0.75	9.91	0.48	1.8e-20	Cognitive test performance;
LUSC	cis	rs977987	0.835	rs4888380	chr16:75347690	T/C	cg03315344	chr16:75512273	CHST6	0.53	10.12	0.48	3.61e-21	Dupuytren's disease;
LUSC	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg23241863	chr10:102295624	HIF1AN	0.49	5.98	0.31	5.84e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.37	-0.33	6.16e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-8.8	-0.43	7.59e-17	Personality dimensions;
LUSC	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.95	0.31	6.85e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs3755132	0.929	rs2302930	chr2:15737343	A/G	cg12888861	chr2:15731646	DDX1	0.5	7.34	0.37	1.68e-12	Wilms tumor;
LUSC	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg07150166	chr2:30669952	LCLAT1	0.54	6.25	0.32	1.29e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg06219351	chr7:158114137	PTPRN2	0.49	8.84	0.44	5.59e-17	Calcium levels;
LUSC	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg05738196	chr6:26577821	NA	-0.59	-6.85	-0.35	3.48e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg24531977	chr5:56204891	C5orf35	-0.55	-8.16	-0.41	6.74e-15	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs68092024	0.704	rs793487	chr3:99495422	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.37	-7.2	-0.37	4.13e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs9469578	0.579	rs73743305	chr6:33667660	C/T	cg18708504	chr6:33715942	IP6K3	0.63	6.13	0.32	2.48e-9	Phosphorus levels;
LUSC	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12908607	chr1:44402522	ARTN	0.46	7.47	0.38	7.06e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg17252645	chr8:143867129	LY6D	-0.37	-6.57	-0.34	1.88e-10	Urinary tract infection frequency;
LUSC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.76	0.39	1.02e-13	Prudent dietary pattern;
LUSC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.66e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg16342193	chr10:102329863	NA	-0.34	-6.14	-0.32	2.35e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7605827	0.897	rs10202600	chr2:15514461	T/C	cg19274914	chr2:15703543	NA	0.46	8.86	0.44	4.71e-17	Educational attainment (years of education);
LUSC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.27	0.45	2.43e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg22117172	chr7:91764530	CYP51A1	-0.33	-5.88	-0.31	1e-8	Breast cancer;
LUSC	cis	rs9392556	0.829	rs676683	chr6:4127253	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-6.43	-0.33	4.52e-10	Blood metabolite levels;
LUSC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-0.92	-17.42	-0.69	8.41e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs800082	0.507	rs1121562	chr3:144259665	A/G	cg24215973	chr2:240111563	HDAC4	0.48	7.52	0.38	5.07e-13	Smoking behavior;
LUSC	cis	rs7267979	0.527	rs6083891	chr20:25574272	C/G	cg03522245	chr20:25566470	NINL	-0.39	-6.07	-0.32	3.38e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg25258033	chr6:167368657	RNASET2	0.38	5.82	0.3	1.38e-8	Primary biliary cholangitis;
LUSC	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg26384229	chr12:38710491	ALG10B	0.75	11.76	0.54	5.82e-27	Morning vs. evening chronotype;
LUSC	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-0.83	-15.24	-0.64	3.51e-40	Longevity;
LUSC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06221963	chr1:154839813	KCNN3	-0.61	-13.83	-0.6	1.06e-34	Prostate cancer;
LUSC	cis	rs9462027	0.651	rs7769820	chr6:34760228	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.11e-8	Systemic lupus erythematosus;
LUSC	trans	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg11887960	chr12:57824829	NA	0.52	6.49	0.33	3.12e-10	Obesity-related traits;
LUSC	cis	rs7804356	1.000	rs10272457	chr7:26888155	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs9318086	0.648	rs7331047	chr13:24467342	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.44	6.61	0.34	1.48e-10	Myopia (pathological);
LUSC	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg13010199	chr12:38710504	ALG10B	0.56	8.83	0.44	6.09e-17	Morning vs. evening chronotype;
LUSC	cis	rs7577851	0.716	rs72833923	chr2:69666626	C/G	cg10773587	chr2:69614142	GFPT1	0.57	6.23	0.32	1.38e-9	Parkinson's disease (age of onset);
LUSC	cis	rs240764	0.817	rs240147	chr6:101078300	G/A	cg09795085	chr6:101329169	ASCC3	0.42	6.04	0.31	4.03e-9	Neuroticism;
LUSC	cis	rs751728	0.664	rs943474	chr6:33749834	G/C	cg25922239	chr6:33757077	LEMD2	0.42	6.28	0.33	1.05e-9	Crohn's disease;
LUSC	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg02175503	chr12:58329896	NA	0.6	9.69	0.47	1.01e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs6752107	0.503	rs13002340	chr2:234234959	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	6.91	0.35	2.49e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg13699009	chr12:122356056	WDR66	0.46	7.11	0.36	7.23e-12	Mean corpuscular volume;
LUSC	cis	rs10484885	0.878	rs1328018	chr6:90297847	A/G	cg13799429	chr6:90582589	CASP8AP2	0.77	7.43	0.38	9.35e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg02423579	chr7:2872169	GNA12	0.47	6.49	0.33	3.02e-10	Height;
LUSC	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg20701182	chr2:24300061	SF3B14	0.75	7.46	0.38	7.57e-13	Birth weight;
LUSC	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg06484146	chr7:12443880	VWDE	-0.62	-6.24	-0.32	1.36e-9	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	0.92	16.06	0.66	2.14e-43	Menopause (age at onset);
LUSC	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg23649088	chr2:200775458	C2orf69	-0.57	-7.0	-0.36	1.41e-11	Schizophrenia;
LUSC	trans	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg06521331	chr12:34319734	NA	-0.39	-5.95	-0.31	6.67e-9	Bladder cancer;
LUSC	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.25	0.32	1.23e-9	Schizophrenia;
LUSC	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	6.71	0.34	8.58e-11	Schizophrenia;
LUSC	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg04310649	chr10:35416472	CREM	-0.4	-6.13	-0.32	2.5e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs62103177	0.568	rs2365388	chr18:77973702	G/T	cg05926928	chr17:57297772	GDPD1	0.7	6.89	0.35	2.81e-11	Opioid sensitivity;
LUSC	cis	rs6681460	0.966	rs7519747	chr1:67140723	T/C	cg02459107	chr1:67143332	SGIP1	0.49	9.18	0.45	4.59e-18	Presence of antiphospholipid antibodies;
LUSC	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.62	-0.43	2.75e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg14343924	chr8:8086146	FLJ10661	0.4	5.71	0.3	2.5e-8	Mood instability;
LUSC	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.88	-0.35	3.01e-11	Total cholesterol levels;
LUSC	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg05973401	chr12:123451056	ABCB9	0.53	7.88	0.4	4.69e-14	Platelet count;
LUSC	cis	rs714027	0.545	rs41161	chr22:30407652	T/C	cg11564601	chr22:30592435	NA	-0.35	-6.06	-0.31	3.76e-9	Lymphocyte counts;
LUSC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg09877947	chr5:131593287	PDLIM4	-0.46	-6.88	-0.35	3.01e-11	Breast cancer;
LUSC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	15.41	0.64	7.23e-41	Platelet count;
LUSC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.29	0.45	2.01e-18	Prudent dietary pattern;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg14031059	chr19:19626956	NDUFA13;TSSK6	0.43	5.99	0.31	5.56e-9	Mosquito bite size;
LUSC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	11.15	0.52	9.49e-25	Prudent dietary pattern;
LUSC	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg03563238	chr19:33554763	RHPN2	-0.41	-6.56	-0.34	2.09e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg04586622	chr2:25135609	ADCY3	0.42	9.0	0.44	1.8e-17	Body mass index;
LUSC	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg07173049	chr1:7289937	CAMTA1	0.33	6.74	0.35	6.81e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06544989	chr22:39130855	UNC84B	0.33	5.67	0.3	3.02e-8	Menopause (age at onset);
LUSC	cis	rs983392	0.805	rs7926729	chr11:59961786	C/T	cg02771260	chr11:59836817	MS4A3	-0.36	-5.82	-0.3	1.4e-8	Alzheimer's disease (late onset);
LUSC	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.51	7.73	0.39	1.27e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg21361702	chr7:150065534	REPIN1	0.56	7.98	0.4	2.39e-14	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg21687924	chr11:3400496	ZNF195	0.45	6.57	0.34	1.92e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs870825	0.616	rs67641203	chr4:185623845	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08392591	chr16:89556376	ANKRD11	0.5	7.66	0.39	2.02e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg14019695	chr9:139328340	INPP5E	0.42	8.06	0.4	1.41e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg05738196	chr6:26577821	NA	-0.48	-6.89	-0.35	2.82e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	19.54	0.73	3.02e-57	Prudent dietary pattern;
LUSC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg08888203	chr3:10149979	C3orf24	0.59	8.25	0.41	3.58e-15	Alzheimer's disease;
LUSC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.7	-10.81	-0.51	1.53e-23	Aortic root size;
LUSC	cis	rs4478858	0.746	rs7520439	chr1:31688721	G/C	cg00250761	chr1:31883323	NA	0.36	9.37	0.46	1.1e-18	Alcohol dependence;
LUSC	cis	rs9649213	0.614	rs10953254	chr7:97914305	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-9.96	-0.48	1.29e-20	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	7.77e-16	Aortic root size;
LUSC	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.26	0.56	8.64e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-5.87	-0.31	1.06e-8	Testicular germ cell tumor;
LUSC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg07636037	chr3:49044803	WDR6	0.43	6.26	0.32	1.21e-9	Resting heart rate;
LUSC	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg06671706	chr8:8559999	CLDN23	0.49	6.61	0.34	1.48e-10	Obesity-related traits;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23924007	chr4:140099401	NA	0.41	6.73	0.35	7.3e-11	Triglycerides;
LUSC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	0.62	9.07	0.44	1.05e-17	Gestational age at birth (maternal effect);
LUSC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.68	0.6	4.04e-34	Platelet count;
LUSC	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg24375607	chr4:120327624	NA	0.78	11.55	0.53	3.41e-26	Corneal astigmatism;
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.29	-7.52	-0.38	4.94e-13	Lymphocyte counts;
LUSC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21963583	chr11:68658836	MRPL21	0.56	8.34	0.42	1.93e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs926938	0.563	rs360661	chr1:115455280	G/A	cg12756093	chr1:115239321	AMPD1	0.41	6.16	0.32	2.04e-9	Autism;
LUSC	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg13514129	chr1:39547527	MACF1	0.71	11.83	0.54	3.24e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg22800045	chr5:56110881	MAP3K1	0.78	9.7	0.47	9.52e-20	Initial pursuit acceleration;
LUSC	trans	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg21775007	chr8:11205619	TDH	0.5	7.25	0.37	2.93e-12	Mood instability;
LUSC	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.51	10.24	0.49	1.4e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs4853525	0.923	rs13397788	chr2:191731503	G/A	cg11845111	chr2:191398756	TMEM194B	-0.39	-5.7	-0.3	2.64e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	trans	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.54	0.53	3.8e-26	Mean corpuscular volume;
LUSC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.67	0.39	1.93e-13	Obesity-related traits;
LUSC	cis	rs7814319	0.870	rs2292836	chr8:97239613	A/C	cg20787634	chr8:97240163	UQCRB	-0.34	-5.92	-0.31	7.9e-9	Lung function (FVC);
LUSC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg02569458	chr12:86230093	RASSF9	0.52	8.64	0.43	2.3e-16	Major depressive disorder;
LUSC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.66	11.41	0.53	1.06e-25	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2835872	0.828	rs111576572	chr21:38989564	A/G	cg20424643	chr21:39039972	KCNJ6	0.36	5.68	0.3	2.95e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs2273669	0.504	rs78662936	chr6:109449690	G/T	cg05315195	chr6:109294784	ARMC2	-0.55	-5.85	-0.3	1.18e-8	Prostate cancer;
LUSC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.05	24.35	0.8	5.28e-76	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg19418458	chr7:158789849	NA	-0.62	-10.26	-0.49	1.15e-21	Facial morphology (factor 20);
LUSC	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg15445000	chr17:37608096	MED1	-0.4	-6.79	-0.35	5.16e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg18477163	chr1:228402036	OBSCN	0.63	12.25	0.56	9.77e-29	Diastolic blood pressure;
LUSC	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg06627628	chr2:24431161	ITSN2	-0.75	-10.62	-0.5	6.77e-23	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26314531	chr2:26401878	FAM59B	0.73	10.06	0.48	5.58e-21	Gut microbiome composition (summer);
LUSC	cis	rs6901250	0.851	rs339313	chr6:117179501	C/T	cg12892004	chr6:117198278	RFX6	-0.45	-8.59	-0.43	3.3e-16	C-reactive protein levels;
LUSC	cis	rs1403694	0.695	rs5029969	chr3:186434405	G/T	cg12454167	chr3:186435060	KNG1	0.34	8.42	0.42	1.11e-15	Blood protein levels;
LUSC	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.03e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg22732515	chr19:44031385	ETHE1	0.63	10.37	0.49	4.93e-22	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.48	6.37	0.33	6.15e-10	Renal function-related traits (BUN);
LUSC	cis	rs1152591	0.669	rs2978381	chr14:64766652	T/C	cg21174375	chr14:64681225	SYNE2	0.32	5.83	0.3	1.29e-8	Atrial fibrillation;
LUSC	cis	rs7590368	1.000	rs7576898	chr2:10958956	A/G	cg15705551	chr2:10952987	PDIA6	0.58	8.0	0.4	2.11e-14	Educational attainment (years of education);
LUSC	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg24634471	chr8:143751801	JRK	0.6	8.88	0.44	4.24e-17	Schizophrenia;
LUSC	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg12002119	chr2:101014098	CHST10	-0.36	-5.93	-0.31	7.48e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs926938	0.563	rs360645	chr1:115427218	A/G	cg01522456	chr1:115632236	TSPAN2	-0.38	-5.92	-0.31	7.79e-9	Autism;
LUSC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg14456004	chr13:21872349	NA	0.42	6.09	0.32	3.09e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs11756438	0.546	rs9489497	chr6:118999636	T/C	cg21191810	chr6:118973309	C6orf204	0.35	5.91	0.31	8.34e-9	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs7944735	0.575	rs34972471	chr11:48050391	G/A	cg15704280	chr7:45808275	SEPT13	0.55	6.57	0.34	1.89e-10	Intraocular pressure;
LUSC	cis	rs4964805	1.000	rs34307072	chr12:104196304	G/A	cg02344784	chr12:104178138	NT5DC3	0.45	7.23	0.37	3.32e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg14403583	chr14:105418241	AHNAK2	-0.55	-9.33	-0.45	1.54e-18	Rheumatoid arthritis;
LUSC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	8.47	0.42	8.11e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12594515	1.000	rs11855562	chr15:45995659	C/T	cg19682013	chr15:45996608	NA	0.39	5.8	0.3	1.51e-8	Waist circumference;Weight;
LUSC	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg15704280	chr7:45808275	SEPT13	0.73	8.36	0.42	1.72e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg05731713	chr7:157510257	PTPRN2	0.41	7.32	0.37	1.9e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7592578	0.603	rs12476782	chr2:191472880	G/A	cg27211696	chr2:191398769	TMEM194B	-0.43	-5.67	-0.3	3.06e-8	Diastolic blood pressure;
LUSC	cis	rs7582720	1.000	rs72936873	chr2:203791333	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg27068330	chr11:65405492	SIPA1	0.63	9.52	0.46	3.74e-19	Acne (severe);
LUSC	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-0.9	-12.56	-0.57	6.66e-30	Orofacial clefts;
LUSC	cis	rs28647808	0.748	rs28721280	chr9:136267318	C/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.33	-0.33	8.06e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg24675056	chr1:15929824	NA	0.49	8.51	0.42	6.14e-16	Systolic blood pressure;
LUSC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg19077165	chr18:44547161	KATNAL2	0.42	6.39	0.33	5.53e-10	Personality dimensions;
LUSC	cis	rs72781680	0.664	rs2712076	chr2:23993366	T/C	cg08917208	chr2:24149416	ATAD2B	0.62	7.05	0.36	1.06e-11	Lymphocyte counts;
LUSC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg05347473	chr6:146136440	FBXO30	0.56	9.39	0.46	9.31e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg21100191	chr22:23484243	RTDR1	0.91	15.24	0.64	3.65e-40	Bone mineral density;
LUSC	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21775007	chr8:11205619	TDH	0.76	12.8	0.57	8.31e-31	Retinal vascular caliber;
LUSC	cis	rs1832871	0.672	rs56075516	chr6:158745752	G/A	cg07165851	chr6:158734300	TULP4	0.46	6.89	0.35	2.81e-11	Height;
LUSC	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.89	15.27	0.64	2.63e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg08999081	chr20:33150536	PIGU	0.37	6.56	0.34	2.06e-10	Height;
LUSC	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.48	-0.38	6.8e-13	Height;
LUSC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	9.71	0.47	8.71e-20	Personality dimensions;
LUSC	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.45	0.5	2.62e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.77	-11.95	-0.55	1.19e-27	Tonsillectomy;
LUSC	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg22482690	chr17:47019901	SNF8	0.4	7.52	0.38	5.04e-13	Type 2 diabetes;
LUSC	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg09307838	chr4:120376055	NA	0.64	9.64	0.47	1.4e-19	Educational attainment;
LUSC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.29	0.69	2.78e-48	Chronic sinus infection;
LUSC	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg24558204	chr6:135376177	HBS1L	0.57	8.46	0.42	8.44e-16	Red blood cell count;
LUSC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg23711669	chr6:146136114	FBXO30	0.81	14.04	0.61	1.6e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg08027265	chr7:2291960	NA	0.36	6.05	0.31	3.94e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.91	15.42	0.64	7e-41	Bladder cancer;
LUSC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg06145435	chr7:1022769	CYP2W1	0.3	6.18	0.32	1.89e-9	Longevity;Endometriosis;
LUSC	cis	rs7580658	0.895	rs4662722	chr2:128102569	T/C	cg09760422	chr2:128146352	NA	-0.3	-6.36	-0.33	6.57e-10	Protein C levels;
LUSC	cis	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg02972257	chr16:68554789	NA	-0.46	-6.09	-0.32	3.13e-9	Colorectal cancer;
LUSC	cis	rs76935404	0.736	rs57274441	chr19:41431422	T/G	cg04176888	chr19:41596066	CYP2A13	0.36	5.67	0.3	3.12e-8	nicotine metabolite ratio in current smokers;
LUSC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg04369109	chr6:150039330	LATS1	-0.6	-8.83	-0.43	6.2e-17	Lung cancer;
LUSC	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg25237894	chr2:233734115	C2orf82	0.36	6.65	0.34	1.23e-10	Coronary artery disease;
LUSC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg17294928	chr15:75287854	SCAMP5	0.41	6.0	0.31	5.18e-9	Breast cancer;
LUSC	cis	rs3733631	1.000	rs3733631	chr4:104641103	G/C	cg24090629	chr4:104641072	TACR3	-0.5	-6.4	-0.33	5.32e-10	Menarche (age at onset);
LUSC	cis	rs4889855	0.505	rs7501740	chr17:78610345	A/G	cg16591659	chr17:78472290	NA	-0.33	-5.82	-0.3	1.37e-8	Fractional excretion of uric acid;
LUSC	cis	rs11168618	0.870	rs7302209	chr12:48895384	T/C	cg24011408	chr12:48396354	COL2A1	0.4	6.38	0.33	5.93e-10	Adiponectin levels;
LUSC	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.73	-12.85	-0.58	5.33e-31	White blood cell count (basophil);
LUSC	cis	rs617219	0.889	rs56064275	chr5:78436952	C/T	cg24856658	chr5:78533917	JMY	-0.31	-5.79	-0.3	1.62e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	6.96	0.36	1.77e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg03522245	chr20:25566470	NINL	-0.36	-5.8	-0.3	1.56e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg18825076	chr15:78729989	IREB2	-0.45	-6.24	-0.32	1.3e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.81	-0.43	6.98e-17	Monocyte count;
LUSC	cis	rs2710642	0.849	rs4671450	chr2:62981869	C/A	cg17519650	chr2:63277830	OTX1	-0.52	-7.22	-0.37	3.63e-12	LDL cholesterol levels;LDL cholesterol;
LUSC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-1.03	-20.07	-0.74	2.43e-59	Height;
LUSC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg04850211	chr1:228464232	OBSCN	-0.33	-5.94	-0.31	7.25e-9	Diastolic blood pressure;
LUSC	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg26195577	chr20:24973756	C20orf3	1.12	18.1	0.7	1.58e-51	Blood protein levels;
LUSC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.91	-15.91	-0.66	8.13e-43	Cognitive function;
LUSC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg11498726	chr8:26250323	BNIP3L	-0.46	-6.61	-0.34	1.5e-10	Red cell distribution width;
LUSC	cis	rs10979	1.000	rs35354710	chr6:143886454	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-11.98	-0.55	9.52e-28	Hypospadias;
LUSC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg25726756	chr21:47582351	C21orf56	-0.33	-5.73	-0.3	2.2e-8	Testicular germ cell tumor;
LUSC	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.9	0.31	8.81e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.09	-0.36	8.16e-12	Neuroticism;
LUSC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg17366294	chr4:99064904	C4orf37	0.56	9.81	0.47	3.98e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg05283184	chr6:79620031	NA	-0.57	-12.14	-0.55	2.5e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9902453	0.967	rs3813034	chr17:28524804	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.95	0.44	2.58e-17	Coffee consumption (cups per day);
LUSC	cis	rs2147959	0.941	rs6426503	chr1:228651011	A/G	cg18477163	chr1:228402036	OBSCN	-0.43	-5.97	-0.31	6.22e-9	Adult asthma;
LUSC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg08508325	chr11:3079039	CARS	-0.5	-12.22	-0.56	1.27e-28	Longevity;
LUSC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg09021430	chr5:549028	NA	-0.53	-7.49	-0.38	6.08e-13	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-9.92	-0.48	1.72e-20	Bone mineral density;
LUSC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs9650315	0.810	rs36122101	chr8:57202560	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.31	0.37	1.93e-12	Height;
LUSC	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg25237894	chr2:233734115	C2orf82	0.35	6.42	0.33	4.6e-10	Coronary artery disease;
LUSC	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.74	0.47	6.81e-20	Coffee consumption (cups per day);
LUSC	cis	rs1775715	0.707	rs2808079	chr10:32167385	C/T	cg18675610	chr10:32216311	ARHGAP12	0.3	6.64	0.34	1.28e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.9	0.61	5.49e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg11161011	chr14:65562177	MAX	-0.81	-12.51	-0.56	1.01e-29	Obesity-related traits;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg24562927	chr17:4075322	ANKFY1	-0.4	-6.33	-0.33	7.92e-10	N-glycan levels;
LUSC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg08392591	chr16:89556376	ANKRD11	0.46	7.04	0.36	1.1e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs7202877	0.519	rs3743606	chr16:75335474	C/A	cg04384234	chr16:75411784	CFDP1	-0.6	-7.67	-0.39	1.96e-13	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7808935	0.914	rs67746093	chr7:27985524	C/G	cg22168087	chr7:27702803	HIBADH	0.57	6.77	0.35	5.87e-11	Prostate cancer;
LUSC	cis	rs1775715	0.835	rs11008701	chr10:32241096	A/G	cg26784012	chr10:32216390	ARHGAP12	0.36	5.76	0.3	1.91e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg07701084	chr6:150067640	NUP43	0.55	8.14	0.41	7.83e-15	Lung cancer;
LUSC	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.77	-0.43	8.96e-17	Monocyte percentage of white cells;
LUSC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg13206674	chr6:150067644	NUP43	0.6	9.5	0.46	4.09e-19	Lung cancer;
LUSC	trans	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg20587970	chr11:113659929	NA	-0.63	-8.76	-0.43	1.01e-16	Height;
LUSC	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg08601574	chr20:25228251	PYGB	0.43	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3740713	1.000	rs73440615	chr11:18467283	T/C	cg15463284	chr11:18477534	LDHAL6A	-0.5	-5.69	-0.3	2.72e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg08213375	chr14:104286397	PPP1R13B	0.38	6.24	0.32	1.29e-9	Reticulocyte count;
LUSC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg11062466	chr8:58055876	NA	0.43	5.79	0.3	1.63e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1983891	1.000	rs4714486	chr6:41542417	C/T	cg15051332	chr6:41514432	FOXP4	0.41	5.91	0.31	8.43e-9	Prostate cancer;
LUSC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg26335602	chr6:28129616	ZNF389	0.43	5.75	0.3	1.98e-8	Depression;
LUSC	cis	rs8027181	0.839	rs2277598	chr15:73027478	T/C	cg25632853	chr15:73088954	NA	0.31	6.18	0.32	1.87e-9	Triglyceride levels;
LUSC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.96	-13.89	-0.6	6.39e-35	Initial pursuit acceleration;
LUSC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.67	10.58	0.5	9.14e-23	Prudent dietary pattern;
LUSC	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg18681998	chr4:17616180	MED28	-0.74	-12.38	-0.56	3.01e-29	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2953174	0.938	rs2975764	chr2:241534381	A/G	cg07929629	chr2:241523174	NA	0.47	6.09	0.32	3.18e-9	Bipolar disorder;
LUSC	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg00898013	chr13:113819073	PROZ	-0.57	-8.12	-0.41	9.33e-15	Platelet distribution width;
LUSC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg21782813	chr7:2030301	MAD1L1	0.42	7.26	0.37	2.74e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg09835421	chr16:68378352	PRMT7	-0.61	-7.59	-0.38	3.25e-13	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg04989706	chr14:50066350	PPIL5	-0.46	-5.96	-0.31	6.27e-9	Carotid intima media thickness;
LUSC	cis	rs12295403	0.723	rs12787397	chr11:18687025	C/T	cg09887367	chr11:18690185	NA	-0.32	-5.73	-0.3	2.3e-8	Ovarian reserve;
LUSC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs13126513	0.519	rs7659550	chr4:100554402	G/T	cg05468953	chr4:100565104	NA	0.36	6.68	0.34	9.76e-11	Metabolite levels (MHPG);
LUSC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg02951883	chr7:2050386	MAD1L1	-0.37	-6.44	-0.33	4.28e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg14664628	chr15:75095509	CSK	0.43	6.07	0.32	3.43e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg03790207	chr6:42947109	PEX6	-0.45	-6.76	-0.35	6.08e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs8099014	1.000	rs7238719	chr18:56132195	T/C	cg12907477	chr18:56117327	MIR122	0.41	6.38	0.33	6.02e-10	Platelet count;
LUSC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg12365402	chr11:9010492	NRIP3	-0.49	-9.33	-0.45	1.5e-18	Hemoglobin concentration;
LUSC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg07701084	chr6:150067640	NUP43	0.56	8.35	0.42	1.84e-15	Lung cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11554525	chr8:33342681	MAK16	0.77	5.96	0.31	6.24e-9	Cognitive performance;
LUSC	cis	rs117352156	0.943	rs2368966	chr10:29214609	A/G	cg06394621	chr10:29236369	NA	0.47	6.34	0.33	7.38e-10	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs4664308	0.967	rs17241792	chr2:160915205	C/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.52	-0.53	4.37e-26	Idiopathic membranous nephropathy;
LUSC	trans	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg01620082	chr3:125678407	NA	-0.69	-7.05	-0.36	1.06e-11	Breast cancer;
LUSC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg22823121	chr1:150693482	HORMAD1	0.46	6.58	0.34	1.82e-10	Melanoma;
LUSC	cis	rs2625529	0.652	rs1481862	chr15:72245648	G/A	cg16672083	chr15:72433130	SENP8	0.48	8.06	0.4	1.34e-14	Red blood cell count;
LUSC	cis	rs67696533	0.711	rs1108445	chr20:31127647	A/G	cg13636640	chr20:31349939	DNMT3B	0.46	6.4	0.33	5.17e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg22496339	chr2:162101262	NA	0.49	7.07	0.36	9.32e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg20628663	chr10:43360327	NA	0.65	9.56	0.46	2.69e-19	Blood protein levels;
LUSC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg05347473	chr6:146136440	FBXO30	0.54	9.03	0.44	1.44e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3740540	0.507	rs942015	chr10:126289932	G/T	cg04949429	chr10:126290192	LHPP	0.36	7.65	0.39	2.18e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg05861140	chr6:150128134	PCMT1	-0.4	-6.32	-0.33	8.19e-10	Lung cancer;
LUSC	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-7.62	-0.38	2.63e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs8060686	0.623	rs6499163	chr16:68243486	G/T	cg26727032	chr16:67993705	SLC12A4	-0.42	-6.42	-0.33	4.71e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg07169764	chr2:136633963	MCM6	-0.6	-7.81	-0.39	7.66e-14	Mosquito bite size;
LUSC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg21782813	chr7:2030301	MAD1L1	0.58	10.31	0.49	8.12e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg00376283	chr12:123451042	ABCB9	0.65	8.16	0.41	7.13e-15	Neutrophil percentage of white cells;
LUSC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.58	0.34	1.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg03351412	chr1:154909251	PMVK	0.51	7.9	0.4	4.21e-14	Prostate cancer;
LUSC	cis	rs12681287	0.640	rs7830480	chr8:87403137	T/C	cg27223183	chr8:87520930	FAM82B	0.55	7.45	0.38	8.05e-13	Caudate activity during reward;
LUSC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg24562669	chr7:97807699	LMTK2	0.35	6.06	0.31	3.68e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.77	-0.39	1e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1712517	0.844	rs1163081	chr10:105029840	G/C	cg05636881	chr10:105038444	INA	0.39	6.56	0.34	2.03e-10	Migraine;
LUSC	cis	rs243505	1.000	rs243516	chr7:148426271	T/G	cg09806900	chr7:148480153	CUL1	-0.48	-6.94	-0.35	2.08e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4132509	0.793	rs10927047	chr1:243803677	A/T	cg21452805	chr1:244014465	NA	0.58	6.0	0.31	5.28e-9	RR interval (heart rate);
LUSC	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg04352962	chr1:209979756	IRF6	0.52	5.77	0.3	1.83e-8	Coronary artery disease;
LUSC	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg21775007	chr8:11205619	TDH	0.8	13.74	0.6	2.36e-34	Retinal vascular caliber;
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg22907277	chr7:1156413	C7orf50	0.48	7.2	0.37	4.14e-12	Longevity;Endometriosis;
LUSC	cis	rs708547	0.874	rs7674167	chr4:57721477	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.59	-7.78	-0.39	9.08e-14	Response to bleomycin (chromatid breaks);
LUSC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	12.65	0.57	3.13e-30	Cognitive test performance;
LUSC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.82	0.3	1.41e-8	Lung cancer;
LUSC	cis	rs6977940	0.730	rs11770451	chr7:2887990	G/T	cg19731401	chr7:2775893	GNA12	0.72	8.0	0.4	2.03e-14	White matter integrity;
LUSC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg26769984	chr7:1090371	C7orf50	0.55	8.79	0.43	7.97e-17	Bronchopulmonary dysplasia;
LUSC	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg25436886	chr3:127056972	NA	-0.49	-6.7	-0.34	8.94e-11	Interleukin-10 levels;Interleukin-13 levels;
LUSC	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg13319975	chr6:146136371	FBXO30	-0.38	-5.7	-0.3	2.63e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	11.83	0.54	3.41e-27	Nonalcoholic fatty liver disease;
LUSC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.24	0.37	3.13e-12	Mean platelet volume;
LUSC	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg11789530	chr4:8429930	ACOX3	0.55	8.79	0.43	7.76e-17	Response to antineoplastic agents;
LUSC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.56	-0.57	6.61e-30	Chronic sinus infection;
LUSC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg07741184	chr6:167504864	NA	0.37	6.72	0.35	7.82e-11	Crohn's disease;
LUSC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	cis	rs9612	1.000	rs12611034	chr19:44268678	C/T	cg08581076	chr19:44259116	C19orf61	0.48	5.92	0.31	8.17e-9	Exhaled nitric oxide output;
LUSC	cis	rs62400317	0.793	rs12210230	chr6:45344854	T/A	cg18551225	chr6:44695536	NA	-0.43	-7.18	-0.37	4.6e-12	Total body bone mineral density;
LUSC	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg01444801	chr10:135216882	MTG1	-0.49	-6.43	-0.33	4.52e-10	Systemic lupus erythematosus;
LUSC	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg22906224	chr7:99728672	NA	-0.5	-6.94	-0.35	2.09e-11	Coronary artery disease;
LUSC	cis	rs13242816	1.000	rs34234085	chr7:116114066	G/A	cg16553024	chr7:116138462	CAV2	-0.52	-5.71	-0.3	2.44e-8	P wave duration;
LUSC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.55	0.53	3.44e-26	Hip circumference adjusted for BMI;
LUSC	cis	rs10979	0.965	rs34373782	chr6:143888258	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg03146154	chr1:46216737	IPP	0.56	8.36	0.42	1.77e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg11789530	chr4:8429930	ACOX3	0.55	8.44	0.42	9.93e-16	Response to antineoplastic agents;
LUSC	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg03570417	chr12:132312461	MMP17	0.37	6.76	0.35	6.28e-11	Migraine;
LUSC	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg08213375	chr14:104286397	PPP1R13B	0.36	5.91	0.31	8.48e-9	Reticulocyte count;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg03699307	chr16:75600014	GABARAPL2	0.35	6.0	0.31	5.21e-9	Triglycerides;
LUSC	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-7.05	-0.36	1.02e-11	Blood metabolite levels;
LUSC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg08683831	chr4:1404607	NA	-0.32	-5.66	-0.3	3.3e-8	Obesity-related traits;
LUSC	cis	rs12367572	0.965	rs1506676	chr12:45237401	T/C	cg04608330	chr12:45269318	NELL2	-0.54	-8.51	-0.42	5.97e-16	Gut microbiome composition (summer);
LUSC	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21659725	chr3:3221576	CRBN	0.61	8.48	0.42	7.14e-16	Resting heart rate;
LUSC	cis	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg07460842	chr6:66804631	NA	-0.77	-10.42	-0.5	3.33e-22	Blood trace element (Cu levels);
LUSC	cis	rs7614311	0.731	rs3774727	chr3:63977875	A/G	cg22134162	chr3:63841271	THOC7	-0.49	-5.98	-0.31	5.68e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg12927641	chr6:109611667	NA	-0.41	-7.24	-0.37	3.02e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs796364	0.525	rs10931895	chr2:201143242	C/T	cg23649088	chr2:200775458	C2orf69	0.54	7.33	0.37	1.71e-12	Schizophrenia;
LUSC	cis	rs11756438	0.572	rs1771756	chr6:119018502	C/T	cg21191810	chr6:118973309	C6orf204	0.34	5.74	0.3	2.09e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs72960926	0.744	rs11756265	chr6:74901250	T/C	cg03266952	chr6:74778945	NA	-0.76	-6.05	-0.31	3.85e-9	Metabolite levels (MHPG);
LUSC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08219700	chr8:58056026	NA	0.63	8.08	0.4	1.19e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg22508957	chr16:3507546	NAT15	0.45	6.41	0.33	4.94e-10	Body mass index (adult);
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg00024416	chr22:24240387	NA	0.31	5.67	0.3	3.02e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg16586182	chr3:47516702	SCAP	-0.51	-8.0	-0.4	2.09e-14	Colorectal cancer;
LUSC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.67	-10.25	-0.49	1.33e-21	Menarche (age at onset);
LUSC	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg04374321	chr14:90722782	PSMC1	0.76	12.04	0.55	5.82e-28	Mortality in heart failure;
LUSC	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg00310523	chr12:86230176	RASSF9	-0.35	-6.35	-0.33	6.92e-10	Major depressive disorder;
LUSC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23158103	chr7:148848205	ZNF398	-0.48	-8.0	-0.4	2.13e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	trans	rs7893279	0.822	rs6415973	chr10:18715168	C/T	cg01840055	chr3:141338555	NA	0.5	5.99	0.31	5.41e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs55871839	0.708	rs13261666	chr8:59814666	G/T	cg07426533	chr8:59803705	TOX	-0.36	-5.8	-0.3	1.57e-8	Pneumonia;
LUSC	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg05855489	chr10:104503620	C10orf26	-0.68	-10.15	-0.49	2.8e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-8.21	-0.41	4.96e-15	Colorectal cancer;
LUSC	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg08601574	chr20:25228251	PYGB	-0.43	-6.63	-0.34	1.32e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs56399783	0.803	rs17132665	chr7:2802173	T/C	cg14895029	chr7:2775587	GNA12	0.51	6.1	0.32	2.96e-9	Childhood ear infection;
LUSC	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg07148914	chr20:33460835	GGT7	0.53	8.17	0.41	6.38e-15	Height;
LUSC	cis	rs870825	0.698	rs28412823	chr4:185638829	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.74	0.6	2.31e-34	Blood protein levels;
LUSC	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-8.68	-0.43	1.82e-16	Schizophrenia;
LUSC	cis	rs16854884	0.837	rs13083224	chr3:143801696	C/T	cg06585982	chr3:143692056	C3orf58	0.44	6.54	0.34	2.26e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg16743903	chr16:89593216	SPG7	-0.39	-6.06	-0.31	3.62e-9	Multiple myeloma (IgH translocation);
LUSC	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg13010199	chr12:38710504	ALG10B	0.51	7.68	0.39	1.83e-13	Morning vs. evening chronotype;
LUSC	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.72	-10.12	-0.48	3.56e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.09	0.4	1.12e-14	Homoarginine levels;
LUSC	cis	rs4409675	0.576	rs6565	chr1:28213157	T/C	cg23691781	chr1:28212827	C1orf38	0.32	7.61	0.38	2.83e-13	Corneal astigmatism;
LUSC	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg07423050	chr13:99094983	FARP1	-0.52	-9.41	-0.46	8.16e-19	Neuroticism;
LUSC	cis	rs11608355	0.532	rs7968387	chr12:109788019	A/C	cg19025524	chr12:109796872	NA	-0.44	-8.14	-0.41	7.81e-15	Neuroticism;
LUSC	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg13073564	chr4:8508604	NA	0.43	8.24	0.41	3.88e-15	Response to antineoplastic agents;
LUSC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	9.69	0.47	9.74e-20	Personality dimensions;
LUSC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg03060546	chr3:49711283	APEH	0.71	11.95	0.55	1.23e-27	Resting heart rate;
LUSC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	8.53	0.42	5.32e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.32	0.56	5.42e-29	Motion sickness;
LUSC	cis	rs12973672	1.000	rs10410675	chr19:35768828	T/C	cg12095397	chr19:35769544	USF2	0.44	6.91	0.35	2.42e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2607426	1.000	rs2607426	chr19:41274713	A/G	cg05508168	chr19:41255947	C19orf54;SNRPA	0.6	5.76	0.3	1.9e-8	Blood protein levels;
LUSC	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg25828445	chr12:7781288	NA	0.62	6.61	0.34	1.57e-10	HDL cholesterol levels;
LUSC	cis	rs4144743	0.702	rs16941733	chr17:45318289	T/C	cg18085866	chr17:45331354	ITGB3	-0.79	-7.64	-0.39	2.3e-13	Body mass index;
LUSC	cis	rs2742234	0.656	rs1864400	chr10:43610366	G/A	cg02780029	chr10:43622663	RET	-0.35	-5.99	-0.31	5.42e-9	Hirschsprung disease;
LUSC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.84	-13.67	-0.6	4.23e-34	Hip circumference adjusted for BMI;
LUSC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	8.81	0.43	6.73e-17	Height;
LUSC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg13206674	chr6:150067644	NUP43	0.59	9.47	0.46	5.18e-19	Lung cancer;
LUSC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg22920501	chr2:26401640	FAM59B	0.71	10.8	0.51	1.56e-23	Gut microbiome composition (summer);
LUSC	cis	rs12618769	0.652	rs76525766	chr2:99221088	A/G	cg10123293	chr2:99228465	UNC50	0.47	7.6	0.38	2.98e-13	Bipolar disorder;
LUSC	cis	rs911119	0.657	rs2145231	chr20:23625547	A/G	cg16589663	chr20:23618590	CST3	-0.52	-5.91	-0.31	8.55e-9	Chronic kidney disease;
LUSC	cis	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg02972257	chr16:68554789	NA	-0.5	-6.23	-0.32	1.4e-9	Ulcerative colitis;
LUSC	trans	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg24739457	chr1:205821442	NA	0.35	5.99	0.31	5.49e-9	Menarche (age at onset);
LUSC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg17376030	chr22:41985996	PMM1	-0.46	-5.72	-0.3	2.42e-8	Vitiligo;
LUSC	cis	rs141518190	1	rs141518190	chr15:78900647	A/G	cg18825076	chr15:78729989	IREB2	-0.51	-7.91	-0.4	3.77e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.91	0.61	5.12e-35	Cognitive test performance;
LUSC	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg25801113	chr15:45476975	SHF	0.34	6.85	0.35	3.49e-11	Uric acid levels;
LUSC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06112835	chr11:68658793	MRPL21	0.51	7.94	0.4	3.04e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-6.98	-0.36	1.61e-11	Breast cancer;
LUSC	cis	rs12900413	0.959	rs67279010	chr15:90318341	T/C	cg24249390	chr15:90295951	MESP1	-0.44	-6.55	-0.34	2.2e-10	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg05717871	chr11:638507	DRD4	-0.33	-5.84	-0.3	1.26e-8	Systemic lupus erythematosus;
LUSC	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.51	-0.34	2.79e-10	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4252134	0.959	rs4252093	chr6:161133685	A/G	cg00639886	chr12:54943102	PDE1B	-0.44	-6.3	-0.33	9.18e-10	Giant cell arteritis;
LUSC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.95	-0.31	6.78e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7953249	0.807	rs7310409	chr12:121424861	A/G	cg02403541	chr12:121454288	C12orf43	-0.61	-9.05	-0.44	1.17e-17	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs11971779	0.590	rs59602547	chr7:139117023	G/A	cg07862535	chr7:139043722	LUC7L2	0.6	7.62	0.39	2.56e-13	Diisocyanate-induced asthma;
LUSC	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg23649088	chr2:200775458	C2orf69	0.51	7.72	0.39	1.32e-13	Osteoporosis;
LUSC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg23985595	chr17:80112537	CCDC57	-0.3	-5.7	-0.3	2.64e-8	Life satisfaction;
LUSC	cis	rs432925	0.600	rs385862	chr16:344659	A/G	cg06233593	chr16:337645	AXIN1	0.44	8.18	0.41	6.13e-15	Morning vs. evening chronotype;
LUSC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-1.03	-15.7	-0.65	5.56e-42	Initial pursuit acceleration;
LUSC	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg22029157	chr1:209979665	IRF6	0.71	8.39	0.42	1.37e-15	Coronary artery disease;
LUSC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg05785598	chr3:49045655	WDR6	0.34	5.97	0.31	5.99e-9	Parkinson's disease;
LUSC	cis	rs3862435	0.764	rs9672149	chr15:91059224	T/A	cg22089800	chr15:90895588	ZNF774	-0.57	-5.74	-0.3	2.14e-8	Response to exercise (triglyceride level interaction);
LUSC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg24562669	chr7:97807699	LMTK2	0.35	6.08	0.32	3.21e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg11764359	chr7:65958608	NA	0.44	6.4	0.33	5.4e-10	Corneal structure;
LUSC	cis	rs17621444	0.505	rs11199145	chr10:121775105	C/T	cg02041677	chr10:121771263	NA	-0.34	-6.47	-0.33	3.53e-10	IgG glycosylation;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13566851	chr6:143857813	NA	0.45	6.84	0.35	3.7e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg06494592	chr3:125709126	NA	-0.53	-6.03	-0.31	4.35e-9	Blood pressure (smoking interaction);
LUSC	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg05084668	chr3:125655381	ALG1L	-0.82	-11.52	-0.53	4.58e-26	Blood pressure (smoking interaction);
LUSC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg09359103	chr1:154839909	KCNN3	-0.72	-16.45	-0.67	5.91e-45	Prostate cancer;
LUSC	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.51	-6.05	-0.31	3.99e-9	Body mass index;
LUSC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.37	-5.74	-0.3	2.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6714710	0.603	rs116309486	chr2:98493359	A/G	cg26665480	chr2:98280029	ACTR1B	0.61	8.9	0.44	3.72e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03001875	chr1:234614834	TARBP1	0.45	6.11	0.32	2.82e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7572644	0.699	rs7426295	chr2:28078994	G/A	cg27432699	chr2:27873401	GPN1	0.52	7.02	0.36	1.23e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.33	0.37	1.76e-12	Hip circumference adjusted for BMI;
LUSC	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.7	-0.43	1.57e-16	Retinal vascular caliber;
LUSC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.63	-0.47	1.53e-19	Joint mobility (Beighton score);
LUSC	cis	rs17095355	1.000	rs7067604	chr10:111734665	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.65	-7.91	-0.4	3.86e-14	Biliary atresia;
LUSC	cis	rs73206853	0.686	rs7139314	chr12:110923871	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21783428	chr6:3118692	BPHL	0.74	6.12	0.32	2.62e-9	Cognitive performance;
LUSC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	7.98	0.4	2.31e-14	Homoarginine levels;
LUSC	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg17385448	chr1:15911702	AGMAT	0.35	5.97	0.31	6.18e-9	Systolic blood pressure;
LUSC	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg05340658	chr4:99064831	C4orf37	-0.46	-7.16	-0.36	5.07e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.77	14.21	0.61	3.73e-36	Osteoporosis;
LUSC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg20476274	chr7:133979776	SLC35B4	0.81	14.17	0.61	5.17e-36	Mean platelet volume;
LUSC	cis	rs2455601	0.608	rs1368017	chr11:8867070	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-7.46	-0.38	7.49e-13	Schizophrenia;
LUSC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg00343986	chr7:65444356	GUSB	0.38	5.71	0.3	2.46e-8	Aortic root size;
LUSC	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg23173402	chr1:227635558	NA	0.6	7.14	0.36	5.98e-12	Major depressive disorder;
LUSC	cis	rs68170813	0.641	rs12539895	chr7:107091849	C/A	cg02696742	chr7:106810147	HBP1	-0.66	-9.66	-0.47	1.21e-19	Coronary artery disease;
LUSC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.79	0.47	4.62e-20	Bipolar disorder;
LUSC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6867913	0.561	rs9324864	chr5:141469000	A/G	cg23435118	chr5:141488016	NDFIP1	0.45	7.12	0.36	6.67e-12	Asthma;
LUSC	cis	rs71017072	1	rs71017072	chr7:19794295	G/GA	cg07541023	chr7:19748670	TWISTNB	0.6	6.57	0.34	1.91e-10	Rubella;
LUSC	cis	rs4776059	0.761	rs12594964	chr15:52900208	G/A	cg22715398	chr15:52968154	KIAA1370	0.66	8.37	0.42	1.57e-15	Schizophrenia;
LUSC	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg20701182	chr2:24300061	SF3B14	0.75	7.31	0.37	1.94e-12	Lymphocyte counts;
LUSC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	4.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs865483	0.929	rs853215	chr17:35861133	A/G	cg06716730	chr17:35851459	DUSP14	0.28	6.33	0.33	8.12e-10	Monocyte count;
LUSC	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg01028140	chr2:1542097	TPO	-0.37	-5.96	-0.31	6.44e-9	IgG glycosylation;
LUSC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.03	0.31	4.27e-9	Lung cancer;
LUSC	cis	rs6920965	0.507	rs12203025	chr6:126192034	C/T	cg05901451	chr6:126070800	HEY2	-0.54	-7.77	-0.39	9.74e-14	High light scatter reticulocyte count;
LUSC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.1e-30	Aortic root size;
LUSC	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg11473876	chr11:109292803	C11orf87	-0.42	-6.61	-0.34	1.54e-10	Schizophrenia;
LUSC	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.82	-13.55	-0.6	1.28e-33	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-17.99	-0.7	4.38e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg03342759	chr3:160939853	NMD3	-0.48	-7.92	-0.4	3.49e-14	Morning vs. evening chronotype;
LUSC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg04234412	chr22:24373322	LOC391322	0.77	9.54	0.46	3e-19	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg24531977	chr5:56204891	C5orf35	-0.6	-8.96	-0.44	2.34e-17	Coronary artery disease;
LUSC	cis	rs2324229	0.797	rs1180186	chr6:83968946	T/G	cg08257003	chr6:84140564	ME1	0.33	7.71	0.39	1.42e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg24468199	chr11:65410028	SIPA1	-0.54	-7.52	-0.38	4.99e-13	Blood pressure (age interaction);
LUSC	cis	rs6977660	0.660	rs10269891	chr7:19816063	T/C	cg07541023	chr7:19748670	TWISTNB	0.65	7.04	0.36	1.12e-11	Thyroid stimulating hormone;
LUSC	cis	rs708547	0.836	rs781554	chr4:57717537	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.57	-6.9	-0.35	2.64e-11	Response to bleomycin (chromatid breaks);
LUSC	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg09307838	chr4:120376055	NA	0.75	10.89	0.51	7.5e-24	Corneal astigmatism;
LUSC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-9.58	-0.46	2.36e-19	Morning vs. evening chronotype;
LUSC	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.41	6.83	0.35	3.95e-11	Cystic fibrosis severity;
LUSC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs1062746	0.544	rs3762182	chr16:87326113	A/G	cg02258303	chr16:87377426	FBXO31	0.51	7.67	0.39	1.93e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg08859206	chr1:53392774	SCP2	-0.43	-7.04	-0.36	1.09e-11	Monocyte count;
LUSC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg25039879	chr17:56429692	SUPT4H1	0.72	9.75	0.47	6.09e-20	Cognitive test performance;
LUSC	cis	rs10761482	1.000	rs10821720	chr10:62077056	A/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.36	-0.33	6.65e-10	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs1957429	0.901	rs59876171	chr14:65384429	C/T	cg23373153	chr14:65346875	NA	-1.04	-11.35	-0.53	1.85e-25	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg03676636	chr4:99064102	C4orf37	0.31	6.57	0.34	1.94e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg09092052	chr15:45571596	NA	0.45	6.26	0.32	1.18e-9	Glomerular filtration rate;
LUSC	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	8.96	0.44	2.34e-17	Iron status biomarkers;
LUSC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs7771547	0.642	rs629560	chr6:36511391	A/G	cg07856975	chr6:36356162	ETV7	0.36	6.31	0.33	8.95e-10	Platelet distribution width;
LUSC	cis	rs977987	0.806	rs12448947	chr16:75462954	G/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.39e-11	Dupuytren's disease;
LUSC	cis	rs11997175	0.609	rs4733459	chr8:33663793	T/C	ch.8.33884649F	chr8:33765107	NA	0.4	6.14	0.32	2.31e-9	Body mass index;
LUSC	cis	rs548181	0.611	rs1293672	chr11:125461034	A/G	cg03464685	chr11:125439445	EI24	1.28	13.82	0.6	1.1e-34	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg06784218	chr1:46089804	CCDC17	0.5	9.91	0.48	1.76e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12912251	1.000	rs35024396	chr15:38989770	G/A	cg01338139	chr15:38987640	C15orf53	-0.5	-6.9	-0.35	2.54e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg26695010	chr11:65641043	EFEMP2	0.46	6.68	0.34	1.02e-10	Eosinophil percentage of white cells;
LUSC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.14	-0.49	3.12e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6845621	0.754	rs7685547	chr4:18878333	G/A	cg12196642	chr4:18937545	NA	-0.33	-6.0	-0.31	5.16e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.84	-0.81	6.6900000000000005e-78	Height;
LUSC	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg21433313	chr16:3507492	NAT15	0.8	9.92	0.48	1.73e-20	Tuberculosis;
LUSC	cis	rs61931739	0.635	rs1352208	chr12:33932543	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.69	-0.34	9.58e-11	Morning vs. evening chronotype;
LUSC	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg13755796	chr4:20253514	NA	-0.42	-6.61	-0.34	1.48e-10	Life satisfaction;
LUSC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg06784218	chr1:46089804	CCDC17	0.49	9.49	0.46	4.67e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg24634471	chr8:143751801	JRK	0.59	9.01	0.44	1.67e-17	Schizophrenia;
LUSC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg07507251	chr3:52567010	NT5DC2	0.35	6.85	0.35	3.63e-11	Bipolar disorder;
LUSC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg27266060	chr8:22091797	NA	0.4	7.36	0.37	1.41e-12	Hypertriglyceridemia;
LUSC	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg18681998	chr4:17616180	MED28	0.86	15.68	0.65	6.75e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg21890820	chr11:65308645	LTBP3	0.78	7.76	0.39	1.06e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.01	-0.36	1.29e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.4	0.53	1.15e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2067615	0.599	rs10778508	chr12:107159405	A/G	cg15890332	chr12:107067104	RFX4	-0.33	-5.97	-0.31	5.93e-9	Heart rate;
LUSC	cis	rs365132	0.875	rs3923879	chr5:176355312	C/T	cg25401027	chr5:176370377	UIMC1	0.35	5.72	0.3	2.36e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg02158880	chr13:53174818	NA	-0.57	-10.08	-0.48	5.03e-21	Lewy body disease;
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.52	-8.75	-0.43	1.09e-16	Lymphocyte counts;
LUSC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg02951883	chr7:2050386	MAD1L1	-0.46	-8.08	-0.4	1.18e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.13	-0.45	6.92e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg07959070	chr22:50026188	C22orf34	-0.29	-5.9	-0.31	9.09e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg25457927	chr22:38595422	NA	-0.42	-8.92	-0.44	3.05e-17	Cutaneous nevi;
LUSC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg00343986	chr7:65444356	GUSB	-0.42	-6.46	-0.33	3.61e-10	Aortic root size;
LUSC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg15839431	chr19:19639596	YJEFN3	0.43	6.1	0.32	2.86e-9	Tonsillectomy;
LUSC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg24675658	chr1:53192096	ZYG11B	-0.72	-11.74	-0.54	6.94e-27	Monocyte count;
LUSC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg05973401	chr12:123451056	ABCB9	0.56	8.17	0.41	6.27e-15	Platelet count;
LUSC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08677398	chr8:58056175	NA	0.52	6.87	0.35	3.18e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	8.84	0.44	5.69e-17	Lung cancer;
LUSC	cis	rs57590327	0.503	rs13075250	chr3:81907952	T/C	cg07356753	chr3:81810745	GBE1	-0.65	-10.37	-0.49	4.88e-22	Extraversion;
LUSC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg14789911	chr21:47582049	C21orf56	-0.39	-6.23	-0.32	1.42e-9	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.18	0.55	1.77e-28	Motion sickness;
LUSC	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg18678763	chr11:4115507	RRM1	0.47	6.09	0.32	3.11e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg16339924	chr4:17578868	LAP3	0.58	9.05	0.44	1.18e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg21699342	chr2:239360505	ASB1	0.6	11.22	0.52	5.27e-25	Multiple system atrophy;
LUSC	cis	rs7149337	0.869	rs10137481	chr14:51694614	C/T	cg23942311	chr14:51606299	NA	0.48	10.51	0.5	1.65e-22	Cancer;
LUSC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg24154853	chr7:158122151	PTPRN2	0.45	8.8	0.43	7.55e-17	Calcium levels;
LUSC	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg02466173	chr16:30829666	NA	-0.59	-10.83	-0.51	1.28e-23	Multiple myeloma;
LUSC	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	9.63	0.47	1.51e-19	Body mass index;
LUSC	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	7.33	0.37	1.72e-12	Educational attainment;
LUSC	cis	rs4285028	0.699	rs1344279	chr3:121615679	G/A	cg11130432	chr3:121712080	ILDR1	-0.63	-9.48	-0.46	4.96e-19	Multiple sclerosis;
LUSC	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg06917634	chr15:78832804	PSMA4	-0.53	-6.59	-0.34	1.68e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	6.69	0.34	9.24e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs67539049	1.000	rs60320871	chr8:11297549	C/G	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.38	-5.81	-0.3	1.43e-8	Itch intensity from mosquito bite;
LUSC	cis	rs6977940	0.730	rs73033432	chr7:2891037	C/T	cg19346786	chr7:2764209	NA	0.53	5.76	0.3	1.93e-8	White matter integrity;
LUSC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.59	0.46	2.18e-19	Lung cancer;
LUSC	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.38	-0.33	5.78e-10	Response to antipsychotic treatment;
LUSC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg26408565	chr15:76604113	ETFA	-0.5	-8.03	-0.4	1.68e-14	Blood metabolite levels;
LUSC	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg24296786	chr1:45957014	TESK2	-0.47	-6.94	-0.36	2.01e-11	High light scatter reticulocyte count;
LUSC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg12463550	chr7:65579703	CRCP	0.57	8.47	0.42	7.7e-16	Aortic root size;
LUSC	trans	rs656319	0.669	rs56279061	chr8:9873980	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.2	-0.37	3.94e-12	Myopia (pathological);
LUSC	cis	rs4285028	0.948	rs12497349	chr3:121708517	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-9.18	-0.45	4.76e-18	Multiple sclerosis;
LUSC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-7.33	-0.37	1.76e-12	Mean platelet volume;
LUSC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg05861140	chr6:150128134	PCMT1	-0.45	-7.17	-0.37	4.83e-12	Lung cancer;
LUSC	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg08213375	chr14:104286397	PPP1R13B	0.52	10.48	0.5	2.03e-22	Schizophrenia;
LUSC	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg26752888	chr8:11627280	NEIL2	-0.41	-6.53	-0.34	2.42e-10	Myopia (pathological);
LUSC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22433210	chr17:43662623	NA	-0.72	-10.25	-0.49	1.34e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.82	0.39	7.02e-14	Prudent dietary pattern;
LUSC	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.89	-0.44	3.97e-17	Coffee consumption (cups per day);
LUSC	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg03684893	chr10:554711	DIP2C	0.35	6.31	0.33	8.64e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.77	12.06	0.55	4.9e-28	Heart rate;
LUSC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg20203395	chr5:56204925	C5orf35	-0.5	-7.38	-0.37	1.28e-12	Coronary artery disease;
LUSC	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	6.92	0.35	2.25e-11	Lung cancer in ever smokers;
LUSC	cis	rs6967385	0.538	rs10275154	chr7:12355002	T/C	cg06484146	chr7:12443880	VWDE	0.5	7.43	0.38	9.08e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg17366294	chr4:99064904	C4orf37	0.59	10.3	0.49	8.78e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg17366294	chr4:99064904	C4orf37	0.55	9.6	0.47	1.98e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4280164	0.945	rs11158635	chr14:24776769	G/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.6	-7.11	-0.36	7.27e-12	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	0.95	17.95	0.7	6.57e-51	Bone mineral density;
LUSC	cis	rs7106204	1.000	rs7110656	chr11:24216034	G/T	ch.11.24196551F	chr11:24239977	NA	0.99	9.66	0.47	1.26e-19	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6987853	0.830	rs9643888	chr8:42352007	T/C	cg09913449	chr8:42400586	C8orf40	-0.42	-6.85	-0.35	3.49e-11	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg20135002	chr11:47629003	NA	-0.48	-7.36	-0.37	1.4e-12	Subjective well-being;
LUSC	cis	rs3774830	0.685	rs73212741	chr4:5464450	G/C	cg26943120	chr4:5472116	STK32B	0.29	5.8	0.3	1.57e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg07148914	chr20:33460835	GGT7	0.56	8.46	0.42	8.69e-16	Height;
LUSC	cis	rs10740039	0.516	rs1975443	chr10:62321342	G/A	cg18175470	chr10:62150864	ANK3	-0.47	-6.95	-0.36	1.97e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.86	-0.35	3.38e-11	Monocyte percentage of white cells;
LUSC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg11859384	chr17:80120422	CCDC57	0.38	5.96	0.31	6.52e-9	Life satisfaction;
LUSC	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18854424	chr1:2615690	NA	-0.5	-9.86	-0.47	2.74e-20	Ulcerative colitis;
LUSC	cis	rs9326248	0.861	rs4938348	chr11:117021877	G/C	cg26566898	chr11:117069891	TAGLN	0.37	5.86	0.31	1.11e-8	Blood protein levels;
LUSC	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.61	-14.16	-0.61	5.7e-36	Sense of smell;
LUSC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	11.18	0.52	7.05e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg06521331	chr12:34319734	NA	-0.48	-7.77	-0.39	9.54e-14	Morning vs. evening chronotype;
LUSC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg22823121	chr1:150693482	HORMAD1	0.51	7.41	0.38	1.07e-12	Melanoma;
LUSC	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.92	0.51	6.12e-24	Hypertriglyceridemia;
LUSC	cis	rs4788815	1.000	rs4788815	chr16:71634811	A/T	cg00732059	chr16:71740210	PHLPP2	0.38	5.91	0.31	8.27e-9	Metabolite levels;
LUSC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.48	7.83	0.39	6.55e-14	Vitiligo;
LUSC	cis	rs1577917	0.804	rs2786854	chr6:86668740	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.26	-0.32	1.21e-9	Response to antipsychotic treatment;
LUSC	cis	rs870825	0.616	rs2310110	chr4:185647902	G/A	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23158103	chr7:148848205	ZNF398	-0.47	-7.71	-0.39	1.5e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.85	13.91	0.61	5e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg23102388	chr7:1867652	MAD1L1	-0.31	-5.93	-0.31	7.67e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg22729335	chr19:2427816	TIMM13	-0.48	-7.91	-0.4	3.82e-14	Cortisol levels (saliva);
LUSC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg22563815	chr15:78856949	CHRNA5	-0.25	-6.03	-0.31	4.42e-9	Sudden cardiac arrest;
LUSC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.28	5.65	0.3	3.44e-8	Cognitive function;
LUSC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-1.12	-24.54	-0.8	9.72e-77	Height;
LUSC	cis	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg06521331	chr12:34319734	NA	0.4	6.61	0.34	1.48e-10	Morning vs. evening chronotype;
LUSC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg15605315	chr1:45957053	TESK2	0.46	7.21	0.37	3.78e-12	High light scatter reticulocyte count;
LUSC	cis	rs2692947	0.770	rs12471925	chr2:96555522	C/A	cg23100626	chr2:96804247	ASTL	0.3	7.03	0.36	1.17e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg09365446	chr1:150670422	GOLPH3L	0.52	7.95	0.4	2.81e-14	Melanoma;
LUSC	trans	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg04995722	chr7:26192034	NFE2L3	0.37	6.15	0.32	2.24e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.13	-0.41	8.27e-15	Retinal vascular caliber;
LUSC	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg15704280	chr7:45808275	SEPT13	0.78	7.57	0.38	3.79e-13	Axial length;
LUSC	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg23505145	chr19:12996616	KLF1	0.64	10.98	0.51	3.62e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.86	14.0	0.61	2.4e-35	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg05855489	chr10:104503620	C10orf26	0.52	7.88	0.4	4.72e-14	Arsenic metabolism;
LUSC	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg17143192	chr8:8559678	CLDN23	0.63	9.07	0.44	1.02e-17	Obesity-related traits;
LUSC	trans	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg25482853	chr8:67687455	SGK3	1.11	15.56	0.65	1.88e-41	Obesity-related traits;
LUSC	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.36e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg14004847	chr7:1930337	MAD1L1	-0.57	-8.87	-0.44	4.51e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11764359	chr7:65958608	NA	-0.68	-10.96	-0.51	4.32e-24	Aortic root size;
LUSC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	12.1	0.55	3.43e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs12545109	0.800	rs2582404	chr8:57387368	C/T	cg09654669	chr8:57350985	NA	-0.51	-6.81	-0.35	4.61e-11	Obesity-related traits;
LUSC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.6	-8.89	-0.44	3.97e-17	Menarche (age at onset);
LUSC	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.62	9.39	0.46	9.41e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1335645	0.570	rs12406191	chr1:111639491	C/G	cg00321911	chr1:111669324	DRAM2	-0.59	-6.29	-0.33	9.92e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs983392	0.836	rs17602572	chr11:59948374	C/G	cg20284999	chr11:59952153	MS4A6A	-0.39	-6.57	-0.34	1.97e-10	Alzheimer's disease (late onset);
LUSC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg06671706	chr8:8559999	CLDN23	0.45	6.08	0.32	3.32e-9	Obesity-related traits;
LUSC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.7	-12.66	-0.57	2.88e-30	Aortic root size;
LUSC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg09650180	chr20:62225654	GMEB2	-0.66	-9.63	-0.47	1.51e-19	Glioblastoma;
LUSC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	0.81	12.76	0.57	1.21e-30	Gestational age at birth (maternal effect);
LUSC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.8	0.3	1.5e-8	Menopause (age at onset);
LUSC	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg25427524	chr10:38739819	LOC399744	-0.5	-6.53	-0.34	2.48e-10	Obesity (extreme);
LUSC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.85	-13.92	-0.61	4.79e-35	Menopause (age at onset);
LUSC	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg23711669	chr6:146136114	FBXO30	-0.82	-14.68	-0.63	5.49e-38	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16338201	chr18:9914940	VAPA	-0.39	-5.99	-0.31	5.54e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	10.75	0.51	2.31e-23	Homoarginine levels;
LUSC	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.7	0.54	9.61e-27	Ileal carcinoids;
LUSC	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg25237894	chr2:233734115	C2orf82	0.36	6.16	0.32	2.14e-9	Coronary artery disease;
LUSC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg26695010	chr11:65641043	EFEMP2	0.42	5.81	0.3	1.42e-8	Breast cancer;
LUSC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg05890377	chr2:74357713	NA	0.69	12.22	0.56	1.25e-28	Gestational age at birth (maternal effect);
LUSC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.48	-0.33	3.31e-10	Personality dimensions;
LUSC	cis	rs1358748	0.522	rs4655514	chr1:67550921	G/C	cg02640540	chr1:67518911	SLC35D1	0.62	6.4	0.33	5.25e-10	Tuberculosis;
LUSC	cis	rs28785552	0.931	rs10406850	chr19:53240807	A/C	cg22067481	chr19:53234126	ZNF611	-0.53	-7.35	-0.37	1.55e-12	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs35123781	1.000	rs9687282	chr5:139065988	T/G	cg00976381	chr5:138713954	SLC23A1	-0.38	-5.74	-0.3	2.17e-8	Schizophrenia;
LUSC	cis	rs7172677	1.000	rs4886658	chr15:75414536	A/C	cg14664628	chr15:75095509	CSK	-0.45	-5.8	-0.3	1.51e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg05738196	chr6:26577821	NA	0.8	15.21	0.64	4.74e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg27411982	chr8:10470053	RP1L1	-0.4	-6.01	-0.31	4.93e-9	Triglycerides;
LUSC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg13047869	chr3:10149882	C3orf24	0.57	7.9	0.4	4.11e-14	Alzheimer's disease;
LUSC	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg11019008	chr10:131425282	MGMT	0.42	6.4	0.33	5.19e-10	Response to temozolomide;
LUSC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	13.45	0.59	3.03e-33	Chronic sinus infection;
LUSC	cis	rs600626	0.578	rs11821808	chr11:75451187	C/T	cg24262691	chr11:75473276	NA	0.44	5.91	0.31	8.25e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg20887711	chr4:1340912	KIAA1530	0.39	5.67	0.3	3.16e-8	Obesity-related traits;
LUSC	cis	rs7605827	0.930	rs4668446	chr2:15516020	C/T	cg19274914	chr2:15703543	NA	0.47	9.07	0.44	1.03e-17	Educational attainment (years of education);
LUSC	cis	rs13088318	0.504	rs55759062	chr3:101202152	C/T	cg12386194	chr3:101231763	SENP7	0.38	5.77	0.3	1.82e-8	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7712401	0.601	rs404442	chr5:122344931	C/T	cg19077854	chr5:122220652	SNX24	-0.42	-9.19	-0.45	4.44e-18	Mean platelet volume;
LUSC	cis	rs7927771	0.524	rs7123952	chr11:47852057	T/C	cg20307385	chr11:47447363	PSMC3	0.45	6.55	0.34	2.17e-10	Subjective well-being;
LUSC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg00990874	chr7:1149470	C7orf50	-0.51	-5.92	-0.31	8.18e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg21856205	chr7:94953877	PON1	-0.36	-5.75	-0.3	2.06e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.7	0.3	2.59e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs72772090	0.539	rs3335	chr5:96115070	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-6.56	-0.34	2.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg20476274	chr7:133979776	SLC35B4	0.87	16.89	0.68	1.02e-46	Mean platelet volume;
LUSC	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg07701084	chr6:150067640	NUP43	0.48	7.06	0.36	9.88e-12	Testicular germ cell tumor;
LUSC	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg18512352	chr11:47633146	NA	-0.43	-9.2	-0.45	4.07e-18	Subjective well-being;
LUSC	trans	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg02800362	chr5:177631904	HNRNPAB	0.83	12.44	0.56	1.95e-29	Obesity-related traits;
LUSC	cis	rs6541297	0.645	rs2296065	chr1:230301776	G/A	cg20703242	chr1:230279135	GALNT2	0.48	5.73	0.3	2.2e-8	Coronary artery disease;
LUSC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg08888203	chr3:10149979	C3orf24	0.59	8.21	0.41	5.04e-15	Alzheimer's disease;
LUSC	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg25309564	chr22:51001381	C22orf41	0.45	6.21	0.32	1.58e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07677032	chr17:61819896	STRADA	0.54	9.03	0.44	1.36e-17	Prudent dietary pattern;
LUSC	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg08523384	chr5:141488047	NDFIP1	-0.51	-7.42	-0.38	9.93e-13	Crohn's disease;
LUSC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08280861	chr8:58055591	NA	0.58	6.74	0.35	6.86e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.47	-8.24	-0.41	3.87e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.03	0.44	1.44e-17	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.86	-0.81	6.04e-78	Height;
LUSC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.46	0.67	5.21e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs62027291	0.950	rs62027298	chr15:77282250	C/T	cg26408565	chr15:76604113	ETFA	0.51	6.12	0.32	2.65e-9	Plateletcrit;
LUSC	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg00191853	chr8:101177733	SPAG1	-0.39	-6.32	-0.33	8.17e-10	Atrioventricular conduction;
LUSC	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	0.99	20.1	0.74	1.78e-59	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-10.14	-0.48	3.18e-21	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs10432489	0.708	rs12328545	chr2:181771545	T/A	cg11196870	chr8:41386826	GINS4	0.93	6.32	0.33	8.44e-10	QT interval;
LUSC	cis	rs9650315	0.704	rs67742458	chr8:57170647	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.75	0.39	1.09e-13	Height;
LUSC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg18479299	chr3:125709523	NA	-0.51	-5.83	-0.3	1.33e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.44	-0.33	4.15e-10	Arsenic metabolism;
LUSC	cis	rs9309473	0.583	rs6709853	chr2:73576065	T/A	cg20560298	chr2:73613845	ALMS1	-0.51	-7.33	-0.37	1.7e-12	Metabolite levels;
LUSC	cis	rs3740540	0.530	rs2362507	chr10:126290820	A/G	cg04949429	chr10:126290192	LHPP	0.36	7.65	0.39	2.21e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6987853	0.966	rs2084709	chr8:42423190	A/G	cg09913449	chr8:42400586	C8orf40	0.51	8.84	0.44	5.49e-17	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-8.06	-0.4	1.41e-14	Aortic root size;
LUSC	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg07959070	chr22:50026188	C22orf34	-0.36	-7.39	-0.37	1.18e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02628353	chr7:26241504	HNRNPA2B1;CBX3	0.44	6.4	0.33	5.39e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs17401966	0.540	rs10864452	chr1:10395683	G/T	cg17425144	chr1:10567563	PEX14	-0.34	-5.96	-0.31	6.31e-9	Hepatocellular carcinoma;
LUSC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg05973401	chr12:123451056	ABCB9	0.52	7.01	0.36	1.32e-11	Neutrophil percentage of white cells;
LUSC	cis	rs1358748	0.522	rs6701962	chr1:67564857	A/T	cg02640540	chr1:67518911	SLC35D1	0.68	6.85	0.35	3.53e-11	Tuberculosis;
LUSC	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg21138405	chr5:131827807	IRF1	-0.34	-6.04	-0.31	4.22e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg18512352	chr11:47633146	NA	-0.46	-9.51	-0.46	3.86e-19	Subjective well-being;
LUSC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7586879	0.663	rs6760328	chr2:25077991	T/C	cg01884057	chr2:25150051	NA	0.35	7.05	0.36	1.01e-11	Body mass index;
LUSC	cis	rs778371	0.697	rs4973564	chr2:233718440	A/G	cg08000102	chr2:233561755	GIGYF2	-0.81	-13.88	-0.6	6.5e-35	Schizophrenia;
LUSC	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14240646	chr10:27532245	ACBD5	-0.66	-7.89	-0.4	4.35e-14	Breast cancer;
LUSC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.76	7.59	0.38	3.22e-13	Initial pursuit acceleration;
LUSC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg08859206	chr1:53392774	SCP2	0.39	6.52	0.34	2.58e-10	Monocyte count;
LUSC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.49	-8.31	-0.41	2.45e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg17554472	chr22:41940697	POLR3H	0.47	5.73	0.3	2.22e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg25039879	chr17:56429692	SUPT4H1	0.68	9.14	0.45	6.1e-18	Cognitive test performance;
LUSC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	13.83	0.6	1.06e-34	Platelet count;
LUSC	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg10547527	chr2:198650123	BOLL	0.5	5.87	0.31	1.04e-8	Ulcerative colitis;
LUSC	cis	rs2227564	0.794	rs2688607	chr10:75663736	C/T	cg17411546	chr10:75410026	SYNPO2L	0.45	5.69	0.3	2.78e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9392556	0.829	rs633290	chr6:4114788	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	0.35	6.29	0.33	1.02e-9	Blood metabolite levels;
LUSC	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.56e-22	Colorectal cancer;
LUSC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg05941027	chr17:61774174	LIMD2	0.21	5.79	0.3	1.62e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg01475377	chr6:109611718	NA	-0.42	-7.6	-0.38	3.11e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19346786	chr7:2764209	NA	0.47	8.25	0.41	3.57e-15	Height;
LUSC	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg02079420	chr8:82753780	SNX16	0.39	5.91	0.31	8.33e-9	Diastolic blood pressure;
LUSC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg08499158	chr17:42289980	UBTF	-0.53	-8.52	-0.42	5.5e-16	Total body bone mineral density;
LUSC	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg08213375	chr14:104286397	PPP1R13B	-0.53	-10.12	-0.48	3.59e-21	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11201273	chr8:38088865	DDHD2	-0.4	-6.32	-0.33	8.46e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg00564555	chr16:1970112	NA	-0.35	-5.97	-0.31	6.19e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7189233	0.531	rs1131220	chr16:53503934	G/A	cg09728985	chr16:53543985	NA	-0.33	-6.18	-0.32	1.91e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg13453750	chr1:205783389	SLC41A1	0.34	6.75	0.35	6.7e-11	Menarche (age at onset);
LUSC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.66	0.63	6.18e-38	Platelet count;
LUSC	cis	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg06521331	chr12:34319734	NA	-0.47	-7.77	-0.39	9.91e-14	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08677398	chr8:58056175	NA	0.53	6.5	0.33	2.97e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs977987	0.843	rs12149063	chr16:75451758	G/A	cg04384234	chr16:75411784	CFDP1	-0.41	-6.65	-0.34	1.23e-10	Dupuytren's disease;
LUSC	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.02	-20.93	-0.75	9.51e-63	Ulcerative colitis;
LUSC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06634786	chr22:41940651	POLR3H	0.52	5.89	0.31	9.31e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07677032	chr17:61819896	STRADA	0.52	8.78	0.43	8.47e-17	Prudent dietary pattern;
LUSC	trans	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg18335740	chr13:41363409	SLC25A15	-0.55	-8.46	-0.42	8.2e-16	Lewy body disease;
LUSC	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.64	10.59	0.5	8.6e-23	Morning vs. evening chronotype;
LUSC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs7605827	0.930	rs11674824	chr2:15537429	G/A	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	5.78	0.3	1.73e-8	Rheumatoid arthritis;
LUSC	cis	rs500891	0.553	rs12197490	chr6:84153255	G/A	cg08257003	chr6:84140564	ME1	0.37	9.19	0.45	4.35e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg23758822	chr17:41437982	NA	1.03	20.09	0.74	2.12e-59	Menopause (age at onset);
LUSC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21545522	chr1:205238299	TMCC2	0.49	9.13	0.45	6.85e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-6.24	-0.32	1.32e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2262909	0.962	rs408687	chr19:22231123	T/C	cg11619707	chr19:22235551	ZNF257	-0.38	-5.7	-0.3	2.7e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg25214090	chr10:38739885	LOC399744	0.43	6.53	0.34	2.51e-10	Corneal astigmatism;
LUSC	cis	rs10979	0.931	rs9484771	chr6:143896897	T/A	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24110177	chr3:50126178	RBM5	0.65	11.69	0.54	1.1e-26	Body mass index;
LUSC	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.66	11.76	0.54	5.88e-27	Itch intensity from mosquito bite;
LUSC	cis	rs1395	0.925	rs1659701	chr2:27414877	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.4	-6.68	-0.34	9.89e-11	Blood metabolite levels;
LUSC	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.88	-0.35	2.88e-11	Mood instability;
LUSC	trans	rs7893279	0.822	rs11014186	chr10:18714473	A/T	cg01840055	chr3:141338555	NA	0.5	6.04	0.31	4.15e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs2625529	0.701	rs2306490	chr15:72227837	A/G	cg16672083	chr15:72433130	SENP8	-0.52	-7.51	-0.38	5.54e-13	Red blood cell count;
LUSC	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg05855489	chr10:104503620	C10orf26	-0.54	-7.53	-0.38	4.76e-13	Arsenic metabolism;
LUSC	cis	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05901451	chr6:126070800	HEY2	0.76	12.41	0.56	2.33e-29	Endometrial cancer;
LUSC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06112835	chr11:68658793	MRPL21	0.52	7.95	0.4	2.82e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg03676636	chr4:99064102	C4orf37	0.36	7.91	0.4	3.77e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg26384229	chr12:38710491	ALG10B	0.56	8.61	0.43	2.98e-16	Morning vs. evening chronotype;
LUSC	cis	rs6500395	1.000	rs6500402	chr16:48687354	C/T	cg04672837	chr16:48644449	N4BP1	0.46	6.97	0.36	1.7e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg20302533	chr7:39170763	POU6F2	0.49	7.83	0.39	6.63e-14	IgG glycosylation;
LUSC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg25258033	chr6:167368657	RNASET2	0.43	6.74	0.35	6.76e-11	Crohn's disease;
LUSC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	0.88	12.29	0.56	7.03e-29	Vitiligo;
LUSC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	9.32	0.45	1.58e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg11764359	chr7:65958608	NA	0.55	7.39	0.37	1.17e-12	Aortic root size;
LUSC	cis	rs6545883	0.894	rs4672423	chr2:61435275	C/T	cg15711740	chr2:61764176	XPO1	0.46	7.2	0.37	3.94e-12	Tuberculosis;
LUSC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg20295408	chr7:1910781	MAD1L1	0.4	5.74	0.3	2.12e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs73129298	0.551	rs57655671	chr20:48598089	G/T	cg25655593	chr20:48599521	SNAI1	0.59	6.37	0.33	6.36e-10	Inflammatory skin disease;
LUSC	trans	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.47	-0.38	7e-13	Menarche (age at onset);
LUSC	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18854424	chr1:2615690	NA	-0.52	-10.6	-0.5	8.29e-23	Ulcerative colitis;
LUSC	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg00277334	chr10:82204260	NA	-0.59	-9.81	-0.47	4.05e-20	Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg11062466	chr8:58055876	NA	0.54	6.89	0.35	2.84e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg17652818	chr12:56727926	PAN2	0.45	6.29	0.33	9.67e-10	Mosquito bite size;
LUSC	cis	rs983392	0.709	rs11826180	chr11:59991333	T/C	cg02771260	chr11:59836817	MS4A3	-0.36	-5.97	-0.31	6.15e-9	Alzheimer's disease (late onset);
LUSC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg18132916	chr6:79620363	NA	-0.39	-5.99	-0.31	5.41e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg06008330	chr7:65541103	ASL	-0.4	-6.27	-0.32	1.13e-9	Aortic root size;
LUSC	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22455342	chr2:225449267	CUL3	0.44	6.04	0.31	4.08e-9	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs911119	0.913	rs6048928	chr20:23585988	A/G	cg16589663	chr20:23618590	CST3	0.62	7.67	0.39	1.89e-13	Chronic kidney disease;
LUSC	cis	rs61990749	0.597	rs10148373	chr14:78280199	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.68	6.79	0.35	5.15e-11	Fibroblast growth factor basic levels;
LUSC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg05425664	chr17:57184151	TRIM37	0.53	7.83	0.39	6.59e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg00531865	chr16:30841666	NA	-0.33	-6.02	-0.31	4.51e-9	Dementia with Lewy bodies;
LUSC	cis	rs12618769	0.652	rs2230388	chr2:99193496	C/T	cg10123293	chr2:99228465	UNC50	0.46	7.47	0.38	7.17e-13	Bipolar disorder;
LUSC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26326168	chr12:133405726	GOLGA3	0.43	7.11	0.36	7.02e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg08345082	chr10:99160200	RRP12	0.33	6.67	0.34	1.05e-10	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.47	-0.38	7.29e-13	Retinal vascular caliber;
LUSC	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.07e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.68	10.32	0.49	7.51e-22	Bladder cancer;
LUSC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg03354898	chr7:1950403	MAD1L1	-0.37	-7.22	-0.37	3.48e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg08742575	chr21:47604166	C21orf56	-0.48	-7.36	-0.37	1.43e-12	Testicular germ cell tumor;
LUSC	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg04374321	chr14:90722782	PSMC1	0.75	12.04	0.55	5.52e-28	Mortality in heart failure;
LUSC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs68170813	0.559	rs79978998	chr7:106845482	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.82	-0.47	3.71e-20	Coronary artery disease;
LUSC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg04518342	chr5:131593106	PDLIM4	0.42	7.25	0.37	2.83e-12	Breast cancer;
LUSC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg11843238	chr5:131593191	PDLIM4	0.4	6.66	0.34	1.16e-10	Acylcarnitine levels;
LUSC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-9.83	-0.47	3.34e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	1.0	12.62	0.57	4.07e-30	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.71	-12.08	-0.55	4.08e-28	Prudent dietary pattern;
LUSC	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg14092571	chr14:90743983	NA	-0.9	-18.84	-0.72	1.79e-54	Gut microbiota (bacterial taxa);
LUSC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.87	0.31	1.04e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.92	0.48	1.76e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7561273	0.561	rs35268318	chr2:24352824	A/T	cg06627628	chr2:24431161	ITSN2	-0.51	-6.8	-0.35	4.71e-11	Quantitative traits;
LUSC	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07080220	chr10:102295463	HIF1AN	0.68	9.42	0.46	7.78e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08645402	chr16:4508243	NA	0.53	8.95	0.44	2.43e-17	Schizophrenia;
LUSC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18404041	chr3:52824283	ITIH1	0.46	8.83	0.44	5.89e-17	Electroencephalogram traits;
LUSC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg00814883	chr7:100076585	TSC22D4	-0.66	-8.64	-0.43	2.36e-16	Platelet count;
LUSC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg03146154	chr1:46216737	IPP	0.51	7.66	0.39	2.08e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.7	-0.3	2.68e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg27121462	chr16:89883253	FANCA	0.55	8.87	0.44	4.58e-17	Vitiligo;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23250587	chr7:150929681	CHPF2	-0.42	-6.4	-0.33	5.27e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg00155535	chr12:132671473	NA	0.39	6.46	0.33	3.78e-10	Anti-saccade response;
LUSC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg27535305	chr1:53392650	SCP2	0.4	7.49	0.38	6.1e-13	Monocyte count;
LUSC	cis	rs7180079	1.000	rs4238425	chr15:64671193	C/A	cg02848875	chr15:64387786	SNX1	0.42	5.74	0.3	2.11e-8	Monocyte count;
LUSC	cis	rs4499344	0.730	rs434020	chr19:33104070	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg16362232	chr11:430036	ANO9	0.62	8.11	0.41	9.85e-15	Body mass index;
LUSC	cis	rs1797885	0.651	rs1552484	chr3:12580246	C/G	cg09856107	chr3:12701776	RAF1	-0.33	-5.92	-0.31	8.11e-9	Immature fraction of reticulocytes;
LUSC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.56	0.46	2.67e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13242816	1.000	rs35800921	chr7:116124041	G/A	cg16553024	chr7:116138462	CAV2	-0.52	-5.68	-0.3	2.89e-8	P wave duration;
LUSC	trans	rs71327718	1	rs71327718	chr3:125592857	C/G	cg07211511	chr3:129823064	LOC729375	-1.06	-12.97	-0.58	2.03e-31	Metabolite levels (HVA/5-HIAA ratio);
LUSC	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg05855489	chr10:104503620	C10orf26	-0.48	-7.35	-0.37	1.53e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs8141797	0.502	rs12484381	chr22:24577121	G/C	cg00411358	chr22:24577142	SUSD2	-0.5	-5.84	-0.3	1.23e-8	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14049380	chr3:52805078	NEK4	-0.42	-6.19	-0.32	1.78e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg18032502	chr11:1949113	TNNT3	0.32	5.68	0.3	2.99e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs35883536	0.647	rs34195036	chr1:101040429	C/A	cg06223162	chr1:101003688	GPR88	-0.48	-9.15	-0.45	5.79e-18	Monocyte count;
LUSC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg05941027	chr17:61774174	LIMD2	0.21	5.79	0.3	1.62e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg10523679	chr1:76189770	ACADM	0.45	6.46	0.33	3.72e-10	Daytime sleep phenotypes;
LUSC	cis	rs3925075	0.903	rs36100148	chr16:31345023	C/T	cg02846316	chr16:31340340	ITGAM	0.35	6.53	0.34	2.48e-10	IgA nephropathy;
LUSC	cis	rs6977660	0.714	rs9969171	chr7:19827328	T/C	cg05791153	chr7:19748676	TWISTNB	0.65	6.58	0.34	1.82e-10	Thyroid stimulating hormone;
LUSC	cis	rs738322	0.805	rs11570734	chr22:38518622	A/G	cg25457927	chr22:38595422	NA	-0.4	-7.85	-0.39	5.55e-14	Cutaneous nevi;
LUSC	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.51	10.12	0.48	3.48e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.18	-0.41	5.96e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg24250549	chr1:154909240	PMVK	0.64	10.53	0.5	1.42e-22	Prostate cancer;
LUSC	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg06623918	chr6:96969491	KIAA0776	0.8	9.95	0.48	1.37e-20	Migraine;Coronary artery disease;
LUSC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	1.22	16.19	0.66	6.1e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs12620999	1.000	rs10803655	chr2:238075551	C/T	cg23555395	chr2:238036564	NA	-0.47	-8.34	-0.41	2.03e-15	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg08270630	chr22:50330655	NA	-0.42	-6.29	-0.33	1e-9	Schizophrenia;
LUSC	trans	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg19402173	chr7:128379420	CALU	-0.47	-7.08	-0.36	8.32e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-9.6	-0.47	1.9e-19	Platelet distribution width;
LUSC	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.11	-20.23	-0.74	5.6e-60	Homoarginine levels;
LUSC	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24110177	chr3:50126178	RBM5	-0.55	-9.03	-0.44	1.35e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg17279839	chr7:150038598	RARRES2	-0.53	-7.93	-0.4	3.37e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	14.02	0.61	1.89e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1018836	0.631	rs9987164	chr8:91470910	T/G	cg16814680	chr8:91681699	NA	-0.56	-8.27	-0.41	3.28e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6500395	1.000	rs11643264	chr16:48558462	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.53	0.34	2.41e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3740713	1.000	rs1848048	chr11:18468996	T/C	cg15463284	chr11:18477534	LDHAL6A	-0.5	-5.73	-0.3	2.21e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06022373	chr22:39101656	GTPBP1	-0.72	-11.82	-0.54	3.6e-27	Menopause (age at onset);
LUSC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03264133	chr6:25882463	NA	-0.42	-7.25	-0.37	2.97e-12	Blood metabolite levels;
LUSC	cis	rs7091068	0.671	rs514120	chr10:95404400	G/A	cg20715218	chr10:95462985	C10orf4	-0.59	-6.78	-0.35	5.32e-11	Urinary tract infection frequency;
LUSC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg13010199	chr12:38710504	ALG10B	0.66	10.16	0.49	2.53e-21	Bladder cancer;
LUSC	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg10247383	chr3:153839028	SGEF	-0.48	-5.9	-0.31	8.75e-9	Coronary artery disease;
LUSC	cis	rs8040855	0.599	rs2342123	chr15:85725149	C/G	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-6.94	-0.35	2.11e-11	Bulimia nervosa;
LUSC	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg02569458	chr12:86230093	RASSF9	0.42	6.86	0.35	3.31e-11	Major depressive disorder;
LUSC	cis	rs240764	0.631	rs9322174	chr6:101204193	G/C	cg09795085	chr6:101329169	ASCC3	-0.44	-6.32	-0.33	8.3e-10	Neuroticism;
LUSC	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg16576597	chr16:28551801	NUPR1	0.32	6.53	0.34	2.39e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs5771242	0.518	rs67881086	chr22:50673439	G/A	cg16473166	chr22:50639996	SELO	0.69	9.56	0.46	2.77e-19	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LUSC	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	6.95	0.36	1.87e-11	Neuroticism;
LUSC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	15.73	0.65	4.3e-42	Platelet count;
LUSC	cis	rs9323205	0.765	rs2999386	chr14:51652628	G/T	cg23942311	chr14:51606299	NA	0.32	6.67	0.34	1.06e-10	Cancer;
LUSC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-6.8	-0.35	4.8e-11	Alzheimer's disease (late onset);
LUSC	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg18099408	chr3:52552593	STAB1	0.36	5.96	0.31	6.41e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6076065	0.748	rs6048750	chr20:23334192	T/G	cg11657817	chr20:23433608	CST11	0.53	10.68	0.5	4.37e-23	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg18681998	chr4:17616180	MED28	0.86	15.49	0.65	3.49e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg20734569	chr3:48348370	SPINK8	-0.47	-8.17	-0.41	6.44e-15	Coronary artery disease;
LUSC	cis	rs1524927	1.000	rs12704870	chr7:96331727	A/G	cg03808172	chr7:96339361	SHFM1	0.43	6.48	0.33	3.34e-10	Total body bone mineral density;
LUSC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	7.72	0.39	1.37e-13	Bipolar disorder;
LUSC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.28	0.59	1.28e-32	Cognitive test performance;
LUSC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg21361702	chr7:150065534	REPIN1	0.58	8.47	0.42	8.02e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7707921	0.881	rs112413913	chr5:81359709	A/G	cg15871215	chr5:81402204	ATG10	-0.45	-6.48	-0.33	3.3e-10	Breast cancer;
LUSC	cis	rs10426930	0.700	rs10413045	chr19:5024099	G/T	cg25246084	chr19:4971487	KDM4B	-0.34	-6.2	-0.32	1.65e-9	Monocyte percentage of white cells;
LUSC	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.65	11.36	0.53	1.66e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.92	-19.39	-0.73	1.24e-56	Longevity;
LUSC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	7.36	0.37	1.42e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs662064	0.890	rs1632108	chr1:10561923	C/T	cg20482658	chr1:10539492	PEX14	0.33	6.79	0.35	5.27e-11	Asthma;
LUSC	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg17652424	chr22:38574118	PLA2G6	0.28	5.95	0.31	6.68e-9	Cutaneous nevi;
LUSC	cis	rs738322	0.719	rs34066050	chr22:38612604	G/A	cg17652424	chr22:38574118	PLA2G6	0.28	5.81	0.3	1.45e-8	Cutaneous nevi;
LUSC	cis	rs7000551	0.688	rs2948145	chr8:22367792	T/C	cg12081754	chr8:22256438	SLC39A14	0.42	6.41	0.33	5.03e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1775715	0.835	rs12266771	chr10:32231380	G/A	cg26784012	chr10:32216390	ARHGAP12	0.42	6.93	0.35	2.19e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.76	-0.3	1.87e-8	Depression;
LUSC	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg07382826	chr16:28625726	SULT1A1	0.27	5.87	0.31	1.04e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg13010199	chr12:38710504	ALG10B	0.62	9.14	0.45	6.27e-18	Heart rate;
LUSC	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg02269571	chr22:50332266	NA	0.59	7.57	0.38	3.67e-13	Schizophrenia;
LUSC	cis	rs814295	0.736	rs78680773	chr2:27751562	A/C	cg27432699	chr2:27873401	GPN1	0.53	5.92	0.31	8.07e-9	Triglyceride levels;
LUSC	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg09165964	chr15:75287851	SCAMP5	-0.92	-8.08	-0.4	1.19e-14	Lung cancer;
LUSC	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg01191920	chr7:158217561	PTPRN2	0.46	9.22	0.45	3.55e-18	Obesity-related traits;
LUSC	trans	rs9380880	0.826	rs9380882	chr6:39547428	A/T	cg12580580	chr10:74544059	CCDC109A	0.59	6.68	0.34	9.96e-11	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-8.0	-0.4	2.05e-14	Lymphocyte counts;
LUSC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg00684032	chr4:1343700	KIAA1530	0.34	5.86	0.31	1.13e-8	Obesity-related traits;
LUSC	cis	rs9677476	0.909	rs13428369	chr2:232125632	T/C	cg07929768	chr2:232055508	NA	0.31	5.9	0.31	9.1e-9	Food antigen IgG levels;
LUSC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg07636037	chr3:49044803	WDR6	0.44	6.35	0.33	7.23e-10	Resting heart rate;
LUSC	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.75	-12.33	-0.56	5.01e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs9462027	0.583	rs9462022	chr6:34761684	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.77	-0.3	1.84e-8	Systemic lupus erythematosus;
LUSC	cis	rs2235649	0.833	rs9926962	chr16:1851826	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-6.09	-0.32	3.19e-9	Blood metabolite levels;
LUSC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.71	0.51	3.24e-23	Menopause (age at onset);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg04597389	chr17:79935740	ASPSCR1	0.45	6.07	0.32	3.54e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19717773	chr7:2847554	GNA12	-0.32	-5.65	-0.3	3.44e-8	Height;
LUSC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg06713675	chr4:122721982	EXOSC9	-0.45	-8.02	-0.4	1.86e-14	Type 2 diabetes;
LUSC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	29.27	0.85	3.41e-94	Chronic sinus infection;
LUSC	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-12.64	-0.57	3.43e-30	Total body bone mineral density;
LUSC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21862992	chr11:68658383	NA	0.51	8.15	0.41	7.21e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg02569458	chr12:86230093	RASSF9	0.52	8.36	0.42	1.67e-15	Major depressive disorder;
LUSC	cis	rs877282	0.755	rs2790388	chr10:786084	T/C	cg17470449	chr10:769945	NA	0.41	6.03	0.31	4.33e-9	Uric acid levels;
LUSC	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.58	9.7	0.47	9.23e-20	Bone mineral density;
LUSC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.82	-0.35	4.29e-11	Total body bone mineral density;
LUSC	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg14227996	chr4:17616232	MED28	0.8	7.86	0.4	5.18e-14	Opioid sensitivity;
LUSC	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg16850897	chr7:100343110	ZAN	-0.54	-7.55	-0.38	4.27e-13	Other erythrocyte phenotypes;
LUSC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg16362232	chr11:430036	ANO9	0.62	8.05	0.4	1.48e-14	Body mass index;
LUSC	cis	rs73206853	0.640	rs3825390	chr12:110976409	A/C	cg12870014	chr12:110450643	ANKRD13A	0.74	9.41	0.46	8.49e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs77633900	0.614	rs280033	chr15:77023099	G/A	cg21673338	chr15:77095150	SCAPER	-0.82	-8.07	-0.4	1.26e-14	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg05043794	chr9:111880884	C9orf5	-0.35	-7.48	-0.38	6.84e-13	Menarche (age at onset);
LUSC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg15445000	chr17:37608096	MED1	0.4	6.76	0.35	6.29e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg18225595	chr11:63971243	STIP1	0.54	7.18	0.37	4.49e-12	Mean platelet volume;
LUSC	cis	rs9653442	0.545	rs11123810	chr2:100759285	T/C	cg07810366	chr2:100720526	AFF3	-0.46	-7.78	-0.39	9.22e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg14019146	chr3:50243930	SLC38A3	0.33	7.23	0.37	3.41e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6736093	0.966	rs11679801	chr2:112712835	G/A	cg12686935	chr2:112915763	FBLN7	-0.37	-5.87	-0.31	1.02e-8	Coronary artery disease;
LUSC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.15	0.58	4.25e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.13	-0.36	6.22e-12	Major depressive disorder;
LUSC	trans	rs885518	0.636	rs10811612	chr9:21774167	C/G	cg06483441	chr5:102442571	GIN1	-0.64	-6.38	-0.33	5.79e-10	Lung adenocarcinoma;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.49	-8.44	-0.42	1.01e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg00857998	chr1:205179979	DSTYK	-0.52	-8.32	-0.41	2.2e-15	Red blood cell count;
LUSC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.8	0.3	1.5e-8	Menopause (age at onset);
LUSC	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg05373962	chr22:49881684	NA	-0.41	-8.45	-0.42	8.97e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9462027	0.628	rs4601124	chr6:34776910	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.75	-0.3	2.03e-8	Systemic lupus erythematosus;
LUSC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg04455712	chr21:45112962	RRP1B	0.44	8.28	0.41	3.06e-15	Mean corpuscular volume;
LUSC	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg23387468	chr7:139079360	LUC7L2	0.4	6.08	0.32	3.28e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1775715	0.870	rs11008702	chr10:32244818	T/G	cg18675610	chr10:32216311	ARHGAP12	0.27	5.76	0.3	1.96e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg07930552	chr6:133119739	C6orf192	-0.74	-9.87	-0.48	2.45e-20	Type 2 diabetes nephropathy;
LUSC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.43	-5.81	-0.3	1.48e-8	Diabetic retinopathy;
LUSC	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg08601574	chr20:25228251	PYGB	0.55	8.83	0.43	6.23e-17	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg03433033	chr1:76189801	ACADM	0.63	7.91	0.4	3.7e-14	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.6	-9.54	-0.46	3.15e-19	HDL cholesterol;
LUSC	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg13256891	chr4:100009986	ADH5	0.5	6.91	0.35	2.41e-11	Smoking initiation;
LUSC	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.84	-0.3	1.21e-8	Ileal carcinoids;
LUSC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg00033643	chr7:134001901	SLC35B4	0.47	7.39	0.37	1.19e-12	Mean platelet volume;
LUSC	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg17173187	chr15:85201210	NMB	-0.37	-6.85	-0.35	3.65e-11	Schizophrenia;
LUSC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08645402	chr16:4508243	NA	0.48	7.37	0.37	1.36e-12	Schizophrenia;
LUSC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg09877947	chr5:131593287	PDLIM4	0.42	6.96	0.36	1.76e-11	Blood metabolite levels;
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg22907277	chr7:1156413	C7orf50	0.57	8.91	0.44	3.25e-17	Longevity;Endometriosis;
LUSC	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg05283184	chr6:79620031	NA	-0.56	-11.8	-0.54	4.14e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	12.91	0.58	3.43e-31	Lung cancer in ever smokers;
LUSC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	9.31	0.45	1.75e-18	Total body bone mineral density;
LUSC	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg01557791	chr16:72042693	DHODH	0.51	7.42	0.38	9.69e-13	Fibrinogen levels;
LUSC	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg21427119	chr20:30132790	HM13	0.39	5.83	0.3	1.34e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.74	-0.35	6.77e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	11.84	0.54	2.97e-27	Height;
LUSC	cis	rs354225	0.584	rs10188545	chr2:54831875	A/G	cg01766943	chr2:54829624	SPTBN1	0.49	7.66	0.39	1.98e-13	Schizophrenia;
LUSC	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg20219074	chr11:18656078	SPTY2D1	0.73	10.97	0.51	3.96e-24	Breast cancer;
LUSC	cis	rs59698941	0.527	rs1910075	chr5:132180089	A/T	cg14825688	chr5:132208181	LEAP2	-0.44	-6.49	-0.33	3.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs72960926	0.744	rs72957986	chr6:74969096	A/C	cg03266952	chr6:74778945	NA	-0.8	-6.94	-0.36	2e-11	Metabolite levels (MHPG);
LUSC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg03351412	chr1:154909251	PMVK	0.46	7.08	0.36	8.74e-12	Prostate cancer;
LUSC	cis	rs897984	0.806	rs8052245	chr16:30916430	C/G	cg02466173	chr16:30829666	NA	0.56	11.47	0.53	6.6900000000000006e-26	Dementia with Lewy bodies;
LUSC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-0.89	-11.89	-0.55	2.02e-27	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg15534755	chr11:117069859	TAGLN	0.35	6.14	0.32	2.33e-9	Blood protein levels;
LUSC	trans	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.84	0.51	1.19e-23	Mean corpuscular volume;
LUSC	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg02269571	chr22:50332266	NA	-0.53	-7.87	-0.4	4.86e-14	Schizophrenia;
LUSC	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg17168535	chr8:21777572	XPO7	0.8	14.3	0.62	1.6e-36	Mean corpuscular volume;
LUSC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg26513180	chr16:89883248	FANCA	0.91	17.79	0.7	2.93e-50	Vitiligo;
LUSC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg26304593	chr6:42947056	PEX6	-0.51	-7.91	-0.4	3.84e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs17095355	1.000	rs921348	chr10:111707498	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.54	-0.38	4.61e-13	Biliary atresia;
LUSC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg05347473	chr6:146136440	FBXO30	0.59	10.32	0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12940923	1.000	rs2877875	chr17:56375765	C/T	cg19466818	chr17:56409534	MIR142	-0.37	-6.42	-0.33	4.77e-10	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs4499344	0.555	rs7250741	chr19:33033231	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.77	-10.31	-0.49	8.03e-22	Mean platelet volume;
LUSC	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg24375607	chr4:120327624	NA	0.64	9.51	0.46	3.89e-19	Educational attainment;
LUSC	trans	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg18187862	chr3:45730750	SACM1L	0.53	7.03	0.36	1.16e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg14019146	chr3:50243930	SLC38A3	-0.33	-7.18	-0.37	4.54e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg13010199	chr12:38710504	ALG10B	0.45	7.19	0.37	4.24e-12	Morning vs. evening chronotype;
LUSC	cis	rs4363385	0.720	rs1611754	chr1:152956415	A/T	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.43	-0.38	9.27e-13	Inflammatory skin disease;
LUSC	cis	rs1577917	0.958	rs12209668	chr6:86566517	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.65	0.34	1.22e-10	Corneal astigmatism;
LUSC	cis	rs1983891	0.865	rs10947980	chr6:41525739	A/G	cg20194872	chr6:41519635	FOXP4	0.35	5.99	0.31	5.35e-9	Prostate cancer;
LUSC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg19592336	chr6:28129416	ZNF389	0.48	6.3	0.33	9.46e-10	Depression;
LUSC	cis	rs3736594	0.918	rs12471347	chr2:27981655	G/C	cg27432699	chr2:27873401	GPN1	0.64	8.82	0.43	6.5e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg21132104	chr15:45694354	SPATA5L1	0.4	5.68	0.3	2.87e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg13628971	chr7:2884303	GNA12	0.48	6.72	0.35	7.74e-11	Height;
LUSC	cis	rs7523050	0.643	rs17621851	chr1:109400835	C/T	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	cis	rs1062746	0.834	rs9308347	chr16:87371752	C/T	cg02258303	chr16:87377426	FBXO31	-0.6	-10.07	-0.48	5.18e-21	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg08355456	chr11:67383691	NA	0.38	7.01	0.36	1.35e-11	Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg11062466	chr8:58055876	NA	0.66	8.97	0.44	2.22e-17	Developmental language disorder (linguistic errors);
LUSC	trans	rs12210905	1.000	rs12205628	chr6:27225959	C/A	cg11837749	chr1:55047332	ACOT11	0.58	5.98	0.31	5.64e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg08601574	chr20:25228251	PYGB	0.42	6.35	0.33	7.01e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	0.58	9.08	0.44	9.76e-18	Breast cancer;
LUSC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg20887711	chr4:1340912	KIAA1530	0.69	10.72	0.51	2.99e-23	Longevity;
LUSC	cis	rs16917546	0.967	rs10995256	chr10:64402434	G/T	cg03961010	chr10:64397487	ZNF365	-0.41	-6.5	-0.33	2.98e-10	Basal cell carcinoma;
LUSC	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg04310649	chr10:35416472	CREM	-0.42	-6.61	-0.34	1.52e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs13315871	1.000	rs11715445	chr3:58343888	T/C	cg20936604	chr3:58311152	NA	-0.72	-7.09	-0.36	8.14e-12	Cholesterol, total;
LUSC	trans	rs4714291	0.894	rs2253393	chr6:39953821	G/A	cg02267698	chr19:7991119	CTXN1	0.5	6.92	0.35	2.37e-11	Strep throat;
LUSC	cis	rs6714710	0.603	rs956039	chr2:98416848	C/A	cg26665480	chr2:98280029	ACTR1B	0.64	9.26	0.45	2.47e-18	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs9311676	0.632	rs11925533	chr3:58429908	G/A	cg13750441	chr3:58318267	PXK	0.35	6.84	0.35	3.88e-11	Systemic lupus erythematosus;
LUSC	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg00105475	chr2:10696890	NA	-0.36	-6.09	-0.32	3.15e-9	Prostate cancer;
LUSC	cis	rs17818399	0.533	rs4384837	chr2:46789514	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.36	5.78	0.3	1.68e-8	Height;
LUSC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg14949292	chr17:78079608	GAA	-0.31	-5.89	-0.31	9.42e-9	Yeast infection;
LUSC	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg01884057	chr2:25150051	NA	0.48	11.39	0.53	1.31e-25	Body mass index;
LUSC	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg12292205	chr6:26970375	C6orf41	-0.64	-9.24	-0.45	2.98e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg08975724	chr8:8085496	FLJ10661	0.42	6.04	0.31	4.02e-9	Neuroticism;
LUSC	cis	rs7638995	0.878	rs17005384	chr3:69181552	A/G	cg26574240	chr3:69171822	LMOD3	0.6	8.4	0.42	1.27e-15	Alzheimer's disease (late onset);
LUSC	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.85	-0.3	1.18e-8	Testicular germ cell tumor;
LUSC	cis	rs11677416	1.000	rs6542090	chr2:113524795	T/C	cg27083787	chr2:113543245	IL1A	0.44	6.78	0.35	5.4e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	trans	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg24247370	chr13:99142703	STK24	-0.32	-5.95	-0.31	6.69e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg20276088	chr3:133502917	NA	-0.42	-6.17	-0.32	2.02e-9	Iron status biomarkers;
LUSC	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-1.13	-17.56	-0.69	2.24e-49	Exhaled nitric oxide output;
LUSC	cis	rs17095355	1.000	rs6584962	chr10:111689904	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.57	-7.12	-0.36	6.59e-12	Biliary atresia;
LUSC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg17366294	chr4:99064904	C4orf37	0.56	9.93	0.48	1.54e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	6.32	0.33	8.57e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg09877947	chr5:131593287	PDLIM4	0.48	7.9	0.4	4.12e-14	Breast cancer;
LUSC	cis	rs56104184	0.779	rs4802513	chr19:49357656	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.92	-10.72	-0.51	2.98e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg18825076	chr15:78729989	IREB2	0.44	6.13	0.32	2.54e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1775715	0.651	rs2808033	chr10:32194127	A/T	cg18675610	chr10:32216311	ARHGAP12	0.31	6.67	0.34	1.07e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs911555	0.655	rs10149470	chr14:104017953	A/G	cg24130564	chr14:104152367	KLC1	-0.46	-7.06	-0.36	9.72e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg20283391	chr11:68216788	NA	-0.51	-7.39	-0.38	1.16e-12	Total body bone mineral density;
LUSC	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg19920283	chr7:105172520	RINT1	0.58	6.22	0.32	1.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg02423579	chr7:2872169	GNA12	0.46	6.78	0.35	5.35e-11	Height;
LUSC	cis	rs2637266	0.935	rs7900900	chr10:78367383	A/T	cg18941641	chr10:78392320	NA	0.39	7.22	0.37	3.64e-12	Pulmonary function;
LUSC	cis	rs2479724	0.591	rs4526183	chr6:41829267	T/C	cg17623882	chr6:41773611	USP49	-0.52	-6.79	-0.35	5.25e-11	Menarche (age at onset);
LUSC	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg11984989	chr7:158649758	WDR60	1.06	20.78	0.75	3.74e-62	Height;
LUSC	trans	rs724744	0.680	rs1205943	chr6:22356914	A/G	cg13807341	chr11:118445984	ARCN1	-0.36	-6.07	-0.32	3.43e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg10207240	chr12:122356781	WDR66	0.47	6.77	0.35	5.88e-11	Mean corpuscular volume;
LUSC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.24	0.41	3.92e-15	Prudent dietary pattern;
LUSC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.37	5.67	0.3	3.05e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg18538332	chr22:24372958	LOC391322	-0.43	-7.72	-0.39	1.36e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.47	-0.38	6.84e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg13206674	chr6:150067644	NUP43	0.62	10.12	0.48	3.53e-21	Lung cancer;
LUSC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28647808	0.881	rs7029386	chr9:136263736	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.41	0.46	8.16e-19	Prudent dietary pattern;
LUSC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg26116260	chr4:7069785	GRPEL1	-1.12	-12.87	-0.58	4.68e-31	Monocyte percentage of white cells;
LUSC	cis	rs1728785	0.681	rs4783647	chr16:68558048	G/A	cg02972257	chr16:68554789	NA	0.55	6.78	0.35	5.39e-11	Ulcerative colitis;
LUSC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg13175981	chr1:150552382	MCL1	0.44	5.75	0.3	2.04e-8	Urate levels;
LUSC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	0.92	15.38	0.64	1.02e-40	Breast cancer;
LUSC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.84	-13.97	-0.61	3.09e-35	Height;
LUSC	cis	rs4499344	0.521	rs259222	chr19:33136895	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	13.7	0.6	3.28e-34	Mean platelet volume;
LUSC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg23711669	chr6:146136114	FBXO30	0.89	16.79	0.68	2.69e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06481639	chr22:41940642	POLR3H	0.48	5.87	0.31	1.05e-8	Vitiligo;
LUSC	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg01420254	chr6:26195488	NA	0.71	7.39	0.37	1.23e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg21361702	chr7:150065534	REPIN1	0.51	6.5	0.33	2.97e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg13683864	chr3:40499215	RPL14	-1.02	-17.47	-0.69	5.06e-49	Renal cell carcinoma;
LUSC	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg24578937	chr1:2090814	PRKCZ	0.57	12.48	0.56	1.28e-29	Height;
LUSC	cis	rs2219968	1.000	rs13281300	chr8:78966585	A/G	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg16339924	chr4:17578868	LAP3	-0.56	-7.49	-0.38	6.12e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-8.9	-0.44	3.51e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.68	-12.09	-0.55	3.72e-28	Aortic root size;
LUSC	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.47	-0.42	7.8e-16	Response to antipsychotic treatment;
LUSC	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg04362960	chr10:104952993	NT5C2	1.17	13.39	0.59	5.02e-33	Arsenic metabolism;
LUSC	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg08645402	chr16:4508243	NA	0.51	8.69	0.43	1.65e-16	Schizophrenia;
LUSC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg21132104	chr15:45694354	SPATA5L1	-0.58	-8.14	-0.41	7.73e-15	Homoarginine levels;
LUSC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.1	15.88	0.66	1.04e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs73198271	0.562	rs964773	chr8:8651314	T/C	cg01851573	chr8:8652454	MFHAS1	0.6	8.29	0.41	2.81e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg04414720	chr1:150670196	GOLPH3L	0.45	6.53	0.34	2.44e-10	Tonsillectomy;
LUSC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg17747265	chr1:1875780	NA	-0.58	-12.02	-0.55	6.84e-28	Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14014471	chr1:178694459	RALGPS2	0.4	6.13	0.32	2.44e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg19653624	chr11:20408972	PRMT3	-0.7	-8.88	-0.44	4.28e-17	Pursuit maintenance gain;
LUSC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-6.8	-0.35	4.8e-11	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg27535305	chr1:53392650	SCP2	-0.4	-7.69	-0.39	1.62e-13	Monocyte count;
LUSC	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs67981189	0.593	rs10140917	chr14:71491820	T/C	cg15816911	chr14:71606274	NA	0.33	5.86	0.31	1.1e-8	Schizophrenia;
LUSC	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.5	-0.46	4.07e-19	Schizophrenia;
LUSC	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.28	0.32	1.06e-9	Neuroticism;
LUSC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.82	-13.01	-0.58	1.39e-31	Tonsillectomy;
LUSC	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg18132916	chr6:79620363	NA	-0.39	-6.01	-0.31	4.88e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7178572	0.568	rs7166927	chr15:77673459	A/G	cg22256960	chr15:77711686	NA	0.5	7.92	0.4	3.58e-14	Type 2 diabetes;
LUSC	cis	rs6845621	0.901	rs1377152	chr4:18922896	A/G	cg12196642	chr4:18937545	NA	-0.35	-6.62	-0.34	1.46e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	0.8	9.85	0.47	2.9e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg12382846	chr20:60892121	LAMA5	0.32	5.93	0.31	7.59e-9	Pelvic organ prolapse;
LUSC	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg15485101	chr11:133734466	NA	0.43	7.67	0.39	1.93e-13	Childhood ear infection;
LUSC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg13902645	chr11:5959945	NA	-0.6	-8.44	-0.42	9.71e-16	DNA methylation (variation);
LUSC	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.77	-0.43	9.28e-17	Uric acid levels;
LUSC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.62	-10.15	-0.49	2.78e-21	Iron status biomarkers;
LUSC	cis	rs2688608	0.869	rs2633308	chr10:75653904	A/T	cg17411546	chr10:75410026	SYNPO2L	-0.44	-6.68	-0.34	1.03e-10	Inflammatory bowel disease;
LUSC	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg01849466	chr14:104193079	ZFYVE21	0.51	8.39	0.42	1.42e-15	Schizophrenia;
LUSC	cis	rs10203711	0.933	rs1810139	chr2:239568154	A/C	cg14580085	chr2:239553406	NA	0.4	6.73	0.35	7.48e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg02176678	chr2:219576539	TTLL4	-0.57	-10.09	-0.48	4.66e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7180079	1.000	rs6494475	chr15:64634884	C/A	cg08069370	chr15:64387884	SNX1	0.55	5.99	0.31	5.37e-9	Monocyte count;
LUSC	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg05855489	chr10:104503620	C10orf26	0.58	9.69	0.47	1.02e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01555307	chr17:61044018	NA	-0.42	-6.29	-0.33	9.71e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg03351412	chr1:154909251	PMVK	0.53	8.35	0.42	1.9e-15	Prostate cancer;
LUSC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg27535305	chr1:53392650	SCP2	0.46	8.95	0.44	2.46e-17	Monocyte count;
LUSC	cis	rs7180079	0.620	rs2414856	chr15:65072461	A/G	cg08069370	chr15:64387884	SNX1	0.55	5.87	0.31	1.05e-8	Monocyte count;
LUSC	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg09796270	chr17:17721594	SREBF1	-0.42	-7.3	-0.37	2.11e-12	Total body bone mineral density;
LUSC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg04398451	chr17:18023971	MYO15A	0.57	9.56	0.46	2.63e-19	Total body bone mineral density;
LUSC	cis	rs7605827	0.780	rs34739027	chr2:15532146	C/A	cg19274914	chr2:15703543	NA	0.46	9.06	0.44	1.08e-17	Educational attainment (years of education);
LUSC	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	7.16	0.36	5.26e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg22029157	chr1:209979665	IRF6	0.72	9.02	0.44	1.48e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg13072238	chr3:49761600	GMPPB	0.69	8.78	0.43	8.71e-17	Menarche (age at onset);
LUSC	cis	rs4862307	0.754	rs6846007	chr4:184991604	A/G	cg06737308	chr4:185021514	ENPP6	-0.42	-6.56	-0.34	2.05e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUSC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.5	-7.1	-0.36	7.66e-12	Renal function-related traits (BUN);
LUSC	cis	rs9800506	1.000	rs9800506	chr6:35517390	G/T	cg03566752	chr6:35512600	NA	0.24	5.7	0.3	2.57e-8	Neutrophil percentage of granulocytes;
LUSC	cis	rs6494488	0.500	rs72742993	chr15:65006023	G/C	cg08069370	chr15:64387884	SNX1	-0.66	-5.77	-0.3	1.76e-8	Coronary artery disease;
LUSC	trans	rs11696501	0.739	rs6073821	chr20:44251791	A/G	cg03272292	chr12:48577362	C12orf68	0.49	5.99	0.31	5.29e-9	Brain structure;
LUSC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg03732007	chr1:2071316	PRKCZ	0.56	10.11	0.48	3.8e-21	Height;
LUSC	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	16.88	0.68	1.17e-46	Exhaled nitric oxide output;
LUSC	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg13010199	chr12:38710504	ALG10B	0.55	8.38	0.42	1.5e-15	Morning vs. evening chronotype;
LUSC	cis	rs9715521	0.775	rs67846233	chr4:59848576	G/A	cg11281224	chr4:60001000	NA	-0.46	-6.47	-0.33	3.55e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg02176678	chr2:219576539	TTLL4	-0.55	-9.78	-0.47	4.92e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-7.04	-0.36	1.09e-11	Asthma;
LUSC	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06636551	chr8:101224915	SPAG1	-0.43	-7.99	-0.4	2.2e-14	Atrioventricular conduction;
LUSC	cis	rs713477	1.000	rs7142204	chr14:55908436	G/T	cg13175173	chr14:55914753	NA	0.34	7.1	0.36	7.45e-12	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs10754283	0.934	rs10493829	chr1:90117833	T/C	cg21401794	chr1:90099060	LRRC8C	0.61	8.79	0.43	7.99e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg00933542	chr6:150070202	PCMT1	0.3	6.07	0.32	3.4e-9	Lung cancer;
LUSC	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg24503407	chr1:205819492	PM20D1	-0.42	-5.71	-0.3	2.56e-8	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg24375607	chr4:120327624	NA	0.69	10.58	0.5	9.19e-23	Corneal astigmatism;
LUSC	cis	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg26958806	chr6:27640298	NA	0.81	6.28	0.32	1.05e-9	Depression;
LUSC	cis	rs9361491	0.657	rs9448537	chr6:79437747	G/A	cg05283184	chr6:79620031	NA	-0.34	-6.2	-0.32	1.66e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3125734	0.633	rs6479804	chr10:64048327	T/C	cg09941381	chr10:64027924	RTKN2	-0.39	-7.06	-0.36	9.64e-12	Rheumatoid arthritis;
LUSC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg18479299	chr3:125709523	NA	-0.55	-6.89	-0.35	2.84e-11	Blood pressure (smoking interaction);
LUSC	cis	rs4964805	0.586	rs934846	chr12:104185297	C/T	cg02344784	chr12:104178138	NT5DC3	0.45	8.7	0.43	1.52e-16	Attention deficit hyperactivity disorder;
LUSC	cis	rs2115630	0.754	rs12595321	chr15:85331269	G/A	cg09876464	chr15:85330779	ZNF592	0.35	6.33	0.33	7.7e-10	P wave terminal force;
LUSC	cis	rs4704187	0.663	rs965735	chr5:74459220	A/G	cg03227963	chr5:74354835	NA	0.31	6.83	0.35	4.09e-11	Response to amphetamines;
LUSC	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.45	-7.02	-0.36	1.22e-11	Tonsillectomy;
LUSC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.67	11.93	0.55	1.38e-27	Aortic root size;
LUSC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	cis	rs2109514	0.840	rs2402080	chr7:116135016	G/C	cg12739419	chr7:116140593	CAV2	-0.28	-6.08	-0.32	3.32e-9	Prevalent atrial fibrillation;
LUSC	cis	rs9818941	0.956	rs4317052	chr3:157721994	C/T	cg08654915	chr3:157813417	NA	0.23	6.09	0.32	3.1e-9	Height;
LUSC	cis	rs9287719	0.774	rs4997811	chr2:10755538	T/C	cg03983476	chr2:10830698	NOL10	-0.38	-5.77	-0.3	1.83e-8	Prostate cancer;
LUSC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg13393036	chr8:95962371	TP53INP1	0.44	8.6	0.43	3.05e-16	Type 2 diabetes;
LUSC	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-1.06	-15.7	-0.65	5.45e-42	Exhaled nitric oxide output;
LUSC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg23719950	chr11:63933701	MACROD1	-0.61	-7.94	-0.4	3.13e-14	Mean platelet volume;
LUSC	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg11584989	chr19:19387371	SF4	0.59	7.07	0.36	8.9e-12	Bipolar disorder;
LUSC	cis	rs597583	0.664	rs3819210	chr11:117389517	A/G	cg27161313	chr11:117392002	DSCAML1	-0.49	-8.23	-0.41	4.13e-15	Putamen volume;
LUSC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg04518342	chr5:131593106	PDLIM4	0.47	8.62	0.43	2.64e-16	Blood metabolite levels;
LUSC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg27094323	chr7:1216898	NA	-0.38	-6.6	-0.34	1.57e-10	Longevity;Endometriosis;
LUSC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg00800038	chr16:89945340	TCF25	-0.65	-6.78	-0.35	5.47e-11	Skin colour saturation;
LUSC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg12564285	chr5:131593104	PDLIM4	0.33	5.84	0.3	1.25e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg09904177	chr6:26538194	HMGN4	-0.52	-8.27	-0.41	3.12e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7605827	0.930	rs4668923	chr2:15681227	G/A	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.77e-16	Educational attainment (years of education);
LUSC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg06784218	chr1:46089804	CCDC17	0.55	11.09	0.52	1.49e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg17633681	chr16:88106987	BANP	0.52	9.88	0.48	2.27e-20	Menopause (age at onset);
LUSC	trans	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-5.97	-0.31	6.07e-9	Depression;
LUSC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg00149659	chr3:10157352	C3orf10	0.64	9.07	0.44	1.04e-17	Alzheimer's disease;
LUSC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg04398451	chr17:18023971	MYO15A	-0.67	-11.53	-0.53	4.16e-26	Total body bone mineral density;
LUSC	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg16989719	chr2:238392110	NA	-0.39	-6.34	-0.33	7.63e-10	Prostate cancer;
LUSC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg13206674	chr6:150067644	NUP43	0.51	7.72	0.39	1.35e-13	Lung cancer;
LUSC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg23283495	chr1:209979779	IRF6	0.44	7.16	0.36	5.23e-12	Monobrow;
LUSC	cis	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.74	-0.35	6.92e-11	Morning vs. evening chronotype;
LUSC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.4	-6.71	-0.34	8.4e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg11502198	chr6:26597334	ABT1	0.59	9.37	0.46	1.15e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg03929089	chr4:120376271	NA	-0.58	-6.28	-0.32	1.04e-9	Axial length;
LUSC	cis	rs11971779	0.553	rs36002669	chr7:139113161	T/A	cg07862535	chr7:139043722	LUC7L2	0.56	6.98	0.36	1.61e-11	Diisocyanate-induced asthma;
LUSC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg23649088	chr2:200775458	C2orf69	0.59	7.35	0.37	1.56e-12	Schizophrenia;
LUSC	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-9.64	-0.47	1.45e-19	Coffee consumption (cups per day);
LUSC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.67e-12	Motion sickness;
LUSC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18099408	chr3:52552593	STAB1	-0.43	-7.65	-0.39	2.2e-13	Bipolar disorder;
LUSC	trans	rs9944715	0.954	rs8093407	chr18:43849464	A/G	cg01718231	chr17:29326311	RNF135	-0.53	-7.68	-0.39	1.75e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs62400317	0.859	rs114017772	chr6:45113862	T/C	cg20913747	chr6:44695427	NA	-0.46	-7.39	-0.37	1.21e-12	Total body bone mineral density;
LUSC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg01483505	chr11:975446	AP2A2	0.41	5.66	0.3	3.29e-8	Alzheimer's disease (late onset);
LUSC	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg03563238	chr19:33554763	RHPN2	-0.4	-6.43	-0.33	4.3e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-10.28	-0.49	1.02e-21	Morning vs. evening chronotype;
LUSC	cis	rs6906287	0.559	rs7751467	chr6:118893861	T/A	cg21191810	chr6:118973309	C6orf204	0.32	5.92	0.31	8.18e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-0.77	-12.22	-0.56	1.18e-28	Height;
LUSC	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.75	11.94	0.55	1.36e-27	Height;
LUSC	cis	rs7072216	0.922	rs942814	chr10:100151305	A/G	cg26618903	chr10:100175079	PYROXD2	-0.3	-5.95	-0.31	6.89e-9	Metabolite levels;
LUSC	cis	rs6543140	0.929	rs6742530	chr2:103082280	G/A	cg09003973	chr2:102972529	NA	0.54	6.84	0.35	3.74e-11	Blood protein levels;
LUSC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg16606324	chr3:10149918	C3orf24	-0.56	-8.63	-0.43	2.53e-16	Alzheimer's disease;
LUSC	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg00631329	chr6:26305371	NA	-0.48	-9.35	-0.46	1.27e-18	Educational attainment;
LUSC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg27068330	chr11:65405492	SIPA1	-0.47	-6.08	-0.32	3.2e-9	Breast cancer;
LUSC	cis	rs9463078	0.526	rs9472337	chr6:44711576	C/A	cg25276700	chr6:44698697	NA	0.3	6.26	0.32	1.19e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg06808227	chr14:105710500	BRF1	-0.65	-9.82	-0.47	3.77e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs34734847	1.000	rs35360964	chr12:121156290	T/C	cg27246729	chr12:121163418	ACADS	0.47	7.51	0.38	5.56e-13	Mean corpuscular volume;
LUSC	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg24375607	chr4:120327624	NA	0.69	10.92	0.51	6.06e-24	Educational attainment;
LUSC	cis	rs4654899	0.965	rs6692244	chr1:21396886	C/A	cg01072550	chr1:21505969	NA	-0.53	-8.06	-0.4	1.33e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg08499158	chr17:42289980	UBTF	0.56	8.98	0.44	2.02e-17	Total body bone mineral density;
LUSC	cis	rs3857536	0.813	rs2093253	chr6:66937702	A/G	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.8	-0.35	4.88e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.65	-11.43	-0.53	9.54e-26	Multiple sclerosis;
LUSC	trans	rs7170930	0.618	rs2899716	chr15:66538636	G/A	cg06396762	chr16:3202609	NA	-0.72	-5.97	-0.31	5.91e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	29.03	0.85	2.44e-93	Chronic sinus infection;
LUSC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg15428835	chr7:75027521	TRIM73;TRIM74	-0.4	-8.0	-0.4	2.09e-14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg26408565	chr15:76604113	ETFA	-0.5	-7.97	-0.4	2.49e-14	Blood metabolite levels;
LUSC	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg24060327	chr5:131705240	SLC22A5	0.48	6.72	0.35	7.78e-11	Lymphocyte counts;Fibrinogen;
LUSC	trans	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg25482853	chr8:67687455	SGK3	1.12	15.85	0.66	1.36e-42	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00149659	chr3:10157352	C3orf10	1.01	14.4	0.62	6.83e-37	Alzheimer's disease;
LUSC	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg22782873	chr19:19639568	YJEFN3	-0.49	-6.12	-0.32	2.56e-9	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6690583	1.000	rs2304641	chr1:85513398	C/T	cg11262906	chr1:85462892	MCOLN2	0.72	7.9	0.4	4.12e-14	Serum sulfate level;
LUSC	cis	rs17685	0.740	rs2286821	chr7:75611355	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.43	6.78	0.35	5.3e-11	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9534288	0.619	rs9526143	chr13:46675991	C/T	cg15192986	chr13:46630673	CPB2	-0.75	-10.77	-0.51	2.06e-23	Blood protein levels;
LUSC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg00310523	chr12:86230176	RASSF9	0.51	9.56	0.46	2.65e-19	Major depressive disorder;
LUSC	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg24011408	chr12:48396354	COL2A1	0.53	8.72	0.43	1.32e-16	Plateletcrit;
LUSC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg08219700	chr8:58056026	NA	0.56	6.75	0.35	6.65e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4853525	0.923	rs4853523	chr2:191732779	A/G	cg11845111	chr2:191398756	TMEM194B	-0.41	-6.05	-0.31	3.93e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	trans	rs3919583	0.579	rs3909481	chr5:86944417	A/G	cg01120514	chr4:25314414	ZCCHC4	0.59	6.62	0.34	1.41e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.11	0.48	3.78e-21	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07004357	chr22:18893614	DGCR6	0.45	6.56	0.34	2.04e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2692947	0.631	rs2312954	chr2:96772447	C/T	cg23100626	chr2:96804247	ASTL	-0.3	-7.05	-0.36	1.03e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4478858	0.735	rs6679393	chr1:31770944	T/C	cg00250761	chr1:31883323	NA	-0.33	-7.97	-0.4	2.59e-14	Alcohol dependence;
LUSC	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg07828024	chr6:149772892	ZC3H12D	0.34	7.24	0.37	3.14e-12	Dupuytren's disease;
LUSC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg07741184	chr6:167504864	NA	0.36	6.5	0.34	2.86e-10	Crohn's disease;
LUSC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg10523679	chr1:76189770	ACADM	0.86	11.41	0.53	1.11e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg07636037	chr3:49044803	WDR6	0.44	6.36	0.33	6.5e-10	Resting heart rate;
LUSC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.94	0.31	7.17e-9	Menopause (age at onset);
LUSC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	trans	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.71e-10	Life satisfaction;
LUSC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19717773	chr7:2847554	GNA12	-0.34	-5.82	-0.3	1.35e-8	Height;
LUSC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg14500267	chr11:67383377	NA	0.32	5.72	0.3	2.39e-8	Mean corpuscular volume;
LUSC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14159672	chr1:205819179	PM20D1	0.54	8.74	0.43	1.17e-16	Menarche (age at onset);
LUSC	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg13010199	chr12:38710504	ALG10B	0.7	11.84	0.54	2.97e-27	Heart rate;
LUSC	cis	rs2357013	0.752	rs35254490	chr2:53152835	G/A	cg07782112	chr2:53107842	NA	-0.41	-6.37	-0.33	6.09e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg06112835	chr11:68658793	MRPL21	-0.37	-6.15	-0.32	2.22e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg16339924	chr4:17578868	LAP3	0.5	7.35	0.37	1.54e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17621444	0.505	rs11199146	chr10:121777960	T/A	cg02041677	chr10:121771263	NA	-0.35	-6.42	-0.33	4.66e-10	IgG glycosylation;
LUSC	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.97	0.36	1.68e-11	Morning vs. evening chronotype;
LUSC	cis	rs909002	0.800	rs1056526	chr1:32084904	C/T	cg01639898	chr1:32083012	HCRTR1	0.31	7.55	0.38	4.22e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg14019146	chr3:50243930	SLC38A3	-0.36	-8.25	-0.41	3.72e-15	Body mass index;
LUSC	cis	rs13040088	0.872	rs2295481	chr20:61574727	C/T	cg23096297	chr20:61557774	DIDO1	0.81	10.57	0.5	9.85e-23	Menopause (age at onset);
LUSC	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg05234568	chr11:5960015	NA	-0.56	-8.15	-0.41	7.16e-15	DNA methylation (variation);
LUSC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg23711669	chr6:146136114	FBXO30	0.86	15.63	0.65	1.01e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2637266	1.000	rs6480827	chr10:78356333	T/G	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	trans	rs13011075	0.919	rs2070171	chr2:68613710	A/G	cg14221825	chr19:46271408	SIX5	-0.45	-6.48	-0.33	3.33e-10	Mean corpuscular volume;
LUSC	trans	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.16	-0.32	2.05e-9	Bladder cancer;
LUSC	cis	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.73	-0.35	7.4e-11	Morning vs. evening chronotype;
LUSC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.5	-8.11	-0.41	9.76e-15	Platelet count;
LUSC	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg22875332	chr1:76189707	ACADM	-0.41	-6.15	-0.32	2.23e-9	Daytime sleep phenotypes;
LUSC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.79	11.58	0.54	2.77e-26	Corneal astigmatism;
LUSC	cis	rs76878669	0.516	rs7104570	chr11:66159098	A/G	cg24851651	chr11:66362959	CCS	-0.37	-5.92	-0.31	8.11e-9	Educational attainment (years of education);
LUSC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg01097406	chr16:89675127	NA	-0.34	-6.77	-0.35	5.89e-11	Vitiligo;
LUSC	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg00898013	chr13:113819073	PROZ	0.54	8.25	0.41	3.7e-15	Platelet distribution width;
LUSC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	8.93	0.44	2.88e-17	Schizophrenia;
LUSC	cis	rs6967385	0.560	rs10248602	chr7:12347113	G/C	cg06484146	chr7:12443880	VWDE	0.52	7.71	0.39	1.42e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg26102564	chr10:131424627	MGMT	0.36	5.69	0.3	2.74e-8	Response to temozolomide;
LUSC	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26384229	chr12:38710491	ALG10B	0.91	15.77	0.65	2.76e-42	Morning vs. evening chronotype;
LUSC	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg05714579	chr10:131428358	MGMT	0.54	8.19	0.41	5.78e-15	Response to temozolomide;
LUSC	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg01557791	chr16:72042693	DHODH	-0.51	-6.62	-0.34	1.47e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg13565492	chr6:43139072	SRF	-0.63	-6.57	-0.34	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg00825309	chr19:58991885	ZNF446	-0.49	-7.1	-0.36	7.49e-12	Uric acid clearance;
LUSC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	ch.11.42038R	chr11:967971	AP2A2	0.43	6.4	0.33	5.39e-10	Alzheimer's disease (late onset);
LUSC	cis	rs12712073	0.845	rs6729966	chr2:100781566	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-7.05	-0.36	1.05e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4478858	0.647	rs1007013	chr1:31710270	C/T	cg00250761	chr1:31883323	NA	-0.34	-8.34	-0.42	1.95e-15	Alcohol dependence;
LUSC	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg23029597	chr12:123009494	RSRC2	-0.69	-8.95	-0.44	2.5e-17	Body mass index;
LUSC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.73	-12.17	-0.55	1.85e-28	Motion sickness;
LUSC	cis	rs1160297	0.575	rs6715857	chr2:53097395	T/G	cg07782112	chr2:53107842	NA	0.45	7.23	0.37	3.41e-12	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg10351095	chr21:47802916	PCNT	0.43	6.12	0.32	2.64e-9	Testicular germ cell tumor;
LUSC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg05425664	chr17:57184151	TRIM37	0.52	7.73	0.39	1.31e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg08773314	chr2:239334832	ASB1	0.48	10.24	0.49	1.39e-21	Multiple system atrophy;
LUSC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg08219700	chr8:58056026	NA	-0.46	-6.11	-0.32	2.77e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg02079420	chr8:82753780	SNX16	0.4	5.99	0.31	5.57e-9	Diastolic blood pressure;
LUSC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg25767906	chr1:53392781	SCP2	-0.64	-12.85	-0.58	5.48e-31	Monocyte count;
LUSC	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg24130564	chr14:104152367	KLC1	-0.48	-7.02	-0.36	1.28e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs55665837	1.000	rs10832271	chr11:14466919	C/G	cg05501817	chr11:14380813	RRAS2	-0.4	-6.54	-0.34	2.3e-10	Vitamin D levels;
LUSC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-7.14	-0.36	5.77e-12	Blood metabolite levels;
LUSC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg16339924	chr4:17578868	LAP3	0.54	8.0	0.4	2.06e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs35883536	0.647	rs11166485	chr1:101048805	G/C	cg06223162	chr1:101003688	GPR88	-0.48	-8.83	-0.44	5.88e-17	Monocyte count;
LUSC	cis	rs3772130	1.000	rs35988617	chr3:121432902	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.64	9.28	0.45	2.14e-18	Cognitive performance;
LUSC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.62	8.48	0.42	7.3e-16	Body mass index (adult);
LUSC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.24	-18.03	-0.7	3.19e-51	Type 1 diabetes nephropathy;
LUSC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg10729496	chr3:10149963	C3orf24	0.53	7.21	0.37	3.79e-12	Alzheimer's disease;
LUSC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg22532475	chr10:104410764	TRIM8	0.28	5.74	0.3	2.18e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.08	-0.4	1.19e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg00750074	chr16:89608354	SPG7	-0.45	-6.77	-0.35	5.96e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.65	14.37	0.62	8.8e-37	Hemoglobin concentration;
LUSC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg04518342	chr5:131593106	PDLIM4	0.45	7.85	0.39	5.88e-14	Breast cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13929079	chr12:49246153	DDX23	-0.46	-6.17	-0.32	2.01e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6601450	0.540	rs7824231	chr8:10273958	G/A	cg12940923	chr8:10282607	MSRA	-0.37	-6.7	-0.34	8.85e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg02972257	chr16:68554789	NA	-0.53	-6.76	-0.35	6.31e-11	Ulcerative colitis;
LUSC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.01	0.77	5.62e-67	Prudent dietary pattern;
LUSC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg07061783	chr6:25882402	NA	-0.38	-5.86	-0.31	1.12e-8	Blood metabolite levels;
LUSC	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	12.49	0.56	1.22e-29	Electrocardiographic conduction measures;
LUSC	trans	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg13010199	chr12:38710504	ALG10B	0.43	6.73	0.35	7.38e-11	Morning vs. evening chronotype;
LUSC	cis	rs4889855	0.556	rs56873925	chr17:78536611	C/T	cg16591659	chr17:78472290	NA	0.33	6.07	0.32	3.46e-9	Fractional excretion of uric acid;
LUSC	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.98	-0.36	1.59e-11	Fear of minor pain;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02501984	chr12:133263946	POLE;PXMP2	-0.58	-6.95	-0.36	1.93e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg00898013	chr13:113819073	PROZ	0.58	8.63	0.43	2.49e-16	Platelet distribution width;
LUSC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg10802521	chr3:52805072	NEK4	0.44	6.26	0.32	1.18e-9	Bipolar disorder;
LUSC	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg03806693	chr22:41940476	POLR3H	0.98	14.25	0.61	2.6e-36	Vitiligo;
LUSC	cis	rs9796	0.870	rs28501589	chr15:41282534	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.41	-7.17	-0.37	4.92e-12	Menopause (age at onset);
LUSC	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg04998671	chr14:104000505	TRMT61A	0.39	5.9	0.31	8.86e-9	Reticulocyte count;
LUSC	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.42	-0.38	9.53e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.09	-0.48	4.67e-21	Hemoglobin concentration;
LUSC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg13047869	chr3:10149882	C3orf24	0.56	7.72	0.39	1.37e-13	Alzheimer's disease;
LUSC	cis	rs7614311	0.636	rs66818634	chr3:63913222	G/A	cg22134162	chr3:63841271	THOC7	-0.48	-5.82	-0.3	1.42e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg05347473	chr6:146136440	FBXO30	-0.66	-11.37	-0.53	1.55e-25	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg24313572	chr1:56050060	NA	-0.31	-6.49	-0.33	3.13e-10	Morning vs. evening chronotype;
LUSC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.7	0.3	2.64e-8	Menopause (age at onset);
LUSC	cis	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.75	-0.3	2.05e-8	Resting heart rate;
LUSC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.55	0.34	2.2e-10	Menopause (age at onset);
LUSC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg01483505	chr11:975446	AP2A2	0.4	5.75	0.3	1.99e-8	Alzheimer's disease (late onset);
LUSC	cis	rs524023	0.874	rs504915	chr11:64464085	T/A	cg19131476	chr11:64387923	NRXN2	-0.38	-10.5	-0.5	1.77e-22	Urate levels in obese individuals;
LUSC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg19812747	chr11:111475976	SIK2	-0.53	-7.89	-0.4	4.28e-14	Primary sclerosing cholangitis;
LUSC	trans	rs17361889	0.752	rs4721485	chr7:16282473	G/A	cg11150683	chr12:114107765	NA	0.34	5.99	0.31	5.55e-9	Pediatric bone mineral content (hip);
LUSC	cis	rs10792830	0.900	rs580887	chr11:85831433	A/T	cg07180834	chr11:85838833	NA	-0.31	-6.11	-0.32	2.75e-9	Psychosis and Alzheimer's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00881440	chr7:2595255	C7orf27	-0.51	-6.14	-0.32	2.35e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2235544	0.565	rs928444	chr1:54473548	C/G	cg25741118	chr1:54482237	LDLRAD1	0.29	6.19	0.32	1.79e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs3862435	0.572	rs74480504	chr15:90924025	T/C	cg22089800	chr15:90895588	ZNF774	0.59	6.26	0.32	1.21e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg12552261	chr5:112820674	MCC	-0.44	-7.02	-0.36	1.25e-11	Type 2 diabetes;
LUSC	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg19508488	chr2:152266495	RIF1	-0.45	-6.51	-0.34	2.81e-10	Lung cancer;
LUSC	cis	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg24375607	chr4:120327624	NA	0.5	7.78	0.39	8.93e-14	Diastolic blood pressure;
LUSC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg03146154	chr1:46216737	IPP	0.49	7.33	0.37	1.74e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.7	-10.9	-0.51	6.9e-24	Aortic root size;
LUSC	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg02569458	chr12:86230093	RASSF9	0.43	6.91	0.35	2.46e-11	Major depressive disorder;
LUSC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-13.72	-0.6	2.75e-34	Total body bone mineral density;
LUSC	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg03929089	chr4:120376271	NA	-0.55	-6.24	-0.32	1.34e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6942756	1.000	rs67520056	chr7:128982075	A/G	cg02491457	chr7:128862824	NA	-0.47	-6.38	-0.33	6.02e-10	White matter hyperintensity burden;
LUSC	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.7	10.5	0.5	1.75e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs61774743	0.754	rs11581271	chr1:41835061	C/G	cg08462924	chr1:41848221	NA	0.37	6.26	0.32	1.2e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.92	12.13	0.55	2.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-7.47	-0.38	7.11e-13	Atrioventricular conduction;
LUSC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	1.03	19.9	0.74	1.11e-58	Cognitive function;
LUSC	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg02524346	chr8:600233	NA	-0.76	-6.75	-0.35	6.43e-11	IgG glycosylation;
LUSC	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg06219351	chr7:158114137	PTPRN2	-0.54	-8.24	-0.41	4.02e-15	Response to amphetamines;
LUSC	cis	rs7613051	0.945	rs7629880	chr3:33058811	C/T	cg19000631	chr3:33138515	GLB1;TMPPE	-0.48	-5.72	-0.3	2.31e-8	Atopic dermatitis;
LUSC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg18681998	chr4:17616180	MED28	0.83	15.02	0.63	2.55e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs460214	0.539	rs55819392	chr21:40038207	G/A	cg12884169	chr21:40033163	ERG	-0.37	-5.93	-0.31	7.46e-9	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.91	0.35	2.49e-11	Parkinson's disease;
LUSC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg12257692	chr3:49977190	RBM6	-0.26	-7.17	-0.37	4.71e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.59	0.38	3.31e-13	Ulcerative colitis;
LUSC	cis	rs3947	0.789	rs8005	chr8:11701096	A/C	cg00262122	chr8:11665843	FDFT1	0.52	7.05	0.36	1.06e-11	Blood protein levels;
LUSC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg00784671	chr22:46762841	CELSR1	-0.49	-6.68	-0.34	1.02e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg21361702	chr7:150065534	REPIN1	0.57	8.02	0.4	1.85e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg27432699	chr2:27873401	GPN1	-0.57	-8.45	-0.42	9.09e-16	Total body bone mineral density;
LUSC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12292205	chr6:26970375	C6orf41	-0.6	-7.36	-0.37	1.47e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs7726558	0.658	rs28943593	chr5:118877566	C/T	cg14402224	chr7:50570049	DDC	-0.48	-6.06	-0.31	3.67e-9	QT interval (sulfonylurea treatment interaction);
LUSC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg13206674	chr6:150067644	NUP43	0.58	8.94	0.44	2.69e-17	Lung cancer;
LUSC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg04369109	chr6:150039330	LATS1	-0.58	-8.56	-0.42	4.25e-16	Lung cancer;
LUSC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg07424592	chr7:64974309	NA	0.71	6.19	0.32	1.72e-9	Diabetic kidney disease;
LUSC	cis	rs11608355	0.515	rs2241204	chr12:109972037	G/A	cg05360138	chr12:110035743	NA	0.93	12.29	0.56	6.89e-29	Neuroticism;
LUSC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.74	-18.03	-0.7	3.19e-51	Prostate cancer;
LUSC	cis	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.45	5.82	0.3	1.41e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg11901034	chr3:128598214	ACAD9	-0.41	-6.5	-0.34	2.91e-10	IgG glycosylation;
LUSC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg10792982	chr14:105748885	BRF1	0.5	8.87	0.44	4.48e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg06238570	chr21:40685208	BRWD1	-0.54	-8.55	-0.42	4.58e-16	Menarche (age at onset);
LUSC	trans	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg04995722	chr7:26192034	NFE2L3	0.37	6.16	0.32	2.08e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.03	-0.36	1.2e-11	Triglycerides;
LUSC	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.18	-0.49	2.18e-21	Eye color traits;
LUSC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg04025307	chr7:1156635	C7orf50	0.42	6.77	0.35	5.97e-11	Longevity;Endometriosis;
LUSC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.86	16.48	0.67	4.59e-45	Mean platelet volume;
LUSC	cis	rs9807989	0.839	rs6749114	chr2:102967587	A/C	cg09003973	chr2:102972529	NA	0.44	5.99	0.31	5.43e-9	Asthma;
LUSC	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg09904177	chr6:26538194	HMGN4	0.76	14.16	0.61	5.54e-36	Intelligence (multi-trait analysis);
LUSC	trans	rs8022179	0.580	rs8013228	chr14:103842650	A/G	cg17675199	chr6:35436792	RPL10A	0.49	6.34	0.33	7.44e-10	Monocyte count;
LUSC	cis	rs67366981	0.925	rs41438045	chr14:77692781	A/T	cg22824376	chr14:77648248	TMEM63C	0.76	7.14	0.36	5.72e-12	Obsessive-compulsive symptoms;
LUSC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.74	9.68	0.47	1.03e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs3741151	1.000	rs7941454	chr11:73085336	C/T	cg17517138	chr11:73019481	ARHGEF17	0.9	7.87	0.4	4.86e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04565464	chr8:145669602	NFKBIL2	0.39	6.41	0.33	4.9e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg26695010	chr11:65641043	EFEMP2	-0.47	-7.15	-0.36	5.35e-12	Eosinophil percentage of white cells;
LUSC	cis	rs4561483	0.673	rs28279	chr16:11968555	A/C	cg08843971	chr16:11963173	GSPT1	0.51	8.01	0.4	1.99e-14	Testicular germ cell tumor;
LUSC	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg04036182	chr15:45458818	NA	0.34	5.66	0.3	3.2e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9937943	0.614	rs35148538	chr16:74613575	G/C	cg01733217	chr16:74700730	RFWD3	0.58	6.04	0.31	4.15e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.58	-0.42	3.69e-16	Response to antipsychotic treatment;
LUSC	cis	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg05299278	chr17:33885742	SLFN14	-0.3	-6.31	-0.33	8.91e-10	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs593982	1.000	rs576663	chr11:65498942	G/T	cg08755490	chr11:65554678	OVOL1	1.41	17.72	0.7	5.44e-50	Atopic dermatitis;
LUSC	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg23711669	chr6:146136114	FBXO30	0.77	13.91	0.61	5.14e-35	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.55	-0.34	2.19e-10	Neuroticism;
LUSC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg00800038	chr16:89945340	TCF25	-0.76	-6.58	-0.34	1.78e-10	Skin colour saturation;
LUSC	trans	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg10756647	chr7:56101905	PSPH	-0.83	-8.16	-0.41	7.1e-15	Diabetic kidney disease;
LUSC	trans	rs9944715	0.954	rs9952469	chr18:43812010	T/C	cg01718231	chr17:29326311	RNF135	-0.52	-7.35	-0.37	1.52e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg21775007	chr8:11205619	TDH	-0.48	-7.22	-0.37	3.6e-12	Neuroticism;
LUSC	cis	rs2303282	0.716	rs7203090	chr16:56444439	C/T	cg00500540	chr16:56394104	NA	-0.43	-7.32	-0.37	1.88e-12	Breast cancer;
LUSC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.44	0.33	4.14e-10	Lung cancer;
LUSC	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg12856521	chr11:46389249	DGKZ	0.41	6.33	0.33	7.96e-10	Leprosy;
LUSC	cis	rs17092148	0.887	rs6058077	chr20:33140999	G/A	cg16810054	chr20:33298113	TP53INP2	-0.36	-5.69	-0.3	2.73e-8	Neuroticism;
LUSC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-0.8	-11.08	-0.52	1.72e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.25	0.52	4.11e-25	Eye color traits;
LUSC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.68	12.02	0.55	6.86e-28	Aortic root size;
LUSC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg02018176	chr4:1364513	KIAA1530	0.52	9.06	0.44	1.13e-17	Obesity-related traits;
LUSC	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	7.25	0.37	2.87e-12	Lung cancer in ever smokers;
LUSC	cis	rs500891	0.525	rs1170466	chr6:84025802	C/T	cg08257003	chr6:84140564	ME1	0.33	7.11	0.36	6.96e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.5	-6.85	-0.35	3.57e-11	Renal function-related traits (BUN);
LUSC	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg21775007	chr8:11205619	TDH	-0.49	-6.69	-0.34	9.61e-11	Morning vs. evening chronotype;
LUSC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Depression;
LUSC	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05901451	chr6:126070800	HEY2	-0.59	-8.91	-0.44	3.44e-17	Endometrial cancer;
LUSC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-7.74	-0.39	1.21e-13	Prudent dietary pattern;
LUSC	cis	rs11229555	0.645	rs12274866	chr11:58177129	C/T	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg07741184	chr6:167504864	NA	0.49	8.55	0.42	4.6e-16	Crohn's disease;
LUSC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.79	0.35	5.23e-11	Aortic root size;
LUSC	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg06360820	chr2:242988706	NA	-0.83	-9.71	-0.47	8.58e-20	Obesity-related traits;
LUSC	cis	rs73206853	0.841	rs56017652	chr12:110931054	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2859741	0.546	rs2133910	chr1:37478785	G/T	cg09363841	chr1:37513479	NA	-0.4	-7.69	-0.39	1.64e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	trans	rs12637928	0.560	rs11706216	chr3:110220349	C/T	cg17371621	chr15:61264283	RORA	0.37	6.13	0.32	2.43e-9	Neuroticism;
LUSC	cis	rs4704187	0.595	rs7717337	chr5:74377001	T/C	cg03227963	chr5:74354835	NA	0.31	6.78	0.35	5.4e-11	Response to amphetamines;
LUSC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg00484396	chr16:3507460	NAT15	0.71	12.45	0.56	1.69e-29	Tuberculosis;
LUSC	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20045696	chr14:77926864	AHSA1	-0.48	-6.45	-0.33	3.99e-10	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg04166393	chr7:2884313	GNA12	0.42	5.92	0.31	8.2e-9	Height;
LUSC	cis	rs500891	0.818	rs13220730	chr6:84092546	T/C	cg08257003	chr6:84140564	ME1	0.33	6.91	0.35	2.5e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs10779751	0.770	rs2791643	chr1:11207269	C/T	cg08854313	chr1:11322531	MTOR	0.84	13.21	0.59	2.37e-32	Body mass index;
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01585723	chr16:33734837	NA	0.47	8.09	0.4	1.11e-14	Menopause (age at onset);
LUSC	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg13615516	chr5:77269221	NA	0.39	6.62	0.34	1.39e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg09307838	chr4:120376055	NA	0.63	9.47	0.46	5.11e-19	Corneal astigmatism;
LUSC	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.47	8.79	0.43	8.13e-17	Hemoglobin concentration;
LUSC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg11384718	chr3:121553940	IQCB1;EAF2	0.4	6.15	0.32	2.18e-9	Triglyceride levels;
LUSC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25072359	chr17:41440525	NA	0.64	9.02	0.44	1.51e-17	Menopause (age at onset);
LUSC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.39	0.42	1.43e-15	Parkinson's disease;
LUSC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg01097406	chr16:89675127	NA	-0.38	-7.73	-0.39	1.32e-13	Vitiligo;
LUSC	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.66	0.34	1.15e-10	Schizophrenia;
LUSC	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg18230493	chr5:56204884	C5orf35	0.5	7.95	0.4	2.94e-14	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg11901034	chr3:128598214	ACAD9	0.4	6.18	0.32	1.86e-9	IgG glycosylation;
LUSC	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-7.97	-0.4	2.52e-14	Parkinson's disease;
LUSC	cis	rs662064	0.852	rs616402	chr1:10566272	C/T	cg20482658	chr1:10539492	PEX14	0.28	5.86	0.31	1.12e-8	Asthma;
LUSC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg27535305	chr1:53392650	SCP2	-0.39	-7.46	-0.38	7.42e-13	Monocyte count;
LUSC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	7.96	0.4	2.63e-14	Homoarginine levels;
LUSC	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg22681709	chr2:178499509	PDE11A	-0.34	-6.19	-0.32	1.72e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg06238570	chr21:40685208	BRWD1	-0.52	-7.85	-0.39	5.83e-14	Menarche (age at onset);
LUSC	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg23992470	chr4:843637	GAK	0.58	6.29	0.33	1e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg20283391	chr11:68216788	NA	-0.53	-7.27	-0.37	2.53e-12	Total body bone mineral density;
LUSC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1505368	0.781	rs10197836	chr2:213274278	T/C	cg16329650	chr2:213403929	ERBB4	0.54	8.55	0.42	4.44e-16	Symmetrical dimethylarginine levels;
LUSC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.79	-14.41	-0.62	6.25e-37	Dental caries;
LUSC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg19592336	chr6:28129416	ZNF389	0.48	6.3	0.33	9.46e-10	Depression;
LUSC	cis	rs7188861	0.768	rs7184969	chr16:11397206	C/A	cg00044050	chr16:11439710	C16orf75	0.54	6.04	0.31	4.17e-9	HDL cholesterol;
LUSC	cis	rs672059	1.000	rs480132	chr1:183161779	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.06	0.4	1.37e-14	Hypertriglyceridemia;
LUSC	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg08017756	chr2:100939284	LONRF2	-0.47	-8.64	-0.43	2.36e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14945867	chr14:54908007	CNIH	0.45	6.17	0.32	1.95e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs679087	0.686	rs10843500	chr12:29918582	C/G	cg14258853	chr12:29935411	TMTC1	0.68	10.55	0.5	1.22e-22	Schizophrenia;
LUSC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg22638593	chr5:131593259	PDLIM4	0.39	5.76	0.3	1.91e-8	Breast cancer;
LUSC	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg12940439	chr1:67600707	NA	0.36	5.81	0.3	1.43e-8	Psoriasis;
LUSC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06636551	chr8:101224915	SPAG1	-0.44	-7.97	-0.4	2.5e-14	Atrioventricular conduction;
LUSC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.67	-10.43	-0.5	3.07e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.17	-0.52	7.89e-25	Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg18404041	chr3:52824283	ITIH1	-0.58	-9.62	-0.47	1.75e-19	Schizophrenia;
LUSC	cis	rs308403	0.568	rs13120869	chr4:123646152	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.8	10.22	0.49	1.61e-21	Blood protein levels;
LUSC	trans	rs10411161	0.702	rs8113685	chr19:52383890	C/T	cg22319618	chr22:45562946	NUP50	-0.49	-5.94	-0.31	6.97e-9	Breast cancer;
LUSC	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs655601	0.643	rs112702671	chr5:180220930	C/T	cg13724780	chr5:180237085	MGAT1	1.06	8.0	0.4	2.1e-14	Quantitative traits;
LUSC	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg13298116	chr11:62369859	EML3;MTA2	-0.52	-8.89	-0.44	3.75e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13242816	1.000	rs35364754	chr7:116109716	T/G	cg16553024	chr7:116138462	CAV2	-0.54	-5.92	-0.31	7.84e-9	P wave duration;
LUSC	cis	rs7818345	0.845	rs4256608	chr8:19267560	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	5.97	0.31	6.05e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg21856205	chr7:94953877	PON1	-0.35	-5.74	-0.3	2.09e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs73198271	0.562	rs55657655	chr8:8675491	G/A	cg01851573	chr8:8652454	MFHAS1	0.65	8.45	0.42	8.99e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg00757033	chr12:89920650	WDR51B	0.6	10.42	0.5	3.48e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg24313572	chr1:56050060	NA	-0.31	-6.33	-0.33	7.99e-10	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.43e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2067615	0.579	rs1811458	chr12:107203683	G/A	cg15890332	chr12:107067104	RFX4	0.34	6.18	0.32	1.91e-9	Heart rate;
LUSC	cis	rs116988415	0.584	rs77490765	chr14:65278537	T/G	cg00114569	chr14:65239327	SPTB	0.7	7.21	0.37	3.75e-12	Daytime sleep phenotypes;
LUSC	cis	rs2425143	0.514	rs8114246	chr20:34581979	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-6.3	-0.33	9.16e-10	Blood protein levels;
LUSC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-14.3	-0.62	1.55e-36	Chronic sinus infection;
LUSC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg23625390	chr15:77176239	SCAPER	0.46	7.02	0.36	1.25e-11	Blood metabolite levels;
LUSC	cis	rs10911363	0.615	rs9286848	chr1:183426249	C/G	cg09173681	chr1:183549694	NCF2	-0.63	-11.13	-0.52	1.12e-24	Systemic lupus erythematosus;
LUSC	cis	rs9309473	0.948	rs13392691	chr2:73748980	G/A	cg20560298	chr2:73613845	ALMS1	-0.51	-7.31	-0.37	2e-12	Metabolite levels;
LUSC	cis	rs17253792	0.822	rs113649689	chr14:56088065	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg22681709	chr2:178499509	PDE11A	-0.35	-6.48	-0.33	3.22e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg06212747	chr3:49208901	KLHDC8B	0.45	6.12	0.32	2.58e-9	Parkinson's disease;
LUSC	cis	rs2115536	0.692	rs6495451	chr15:80164053	C/T	cg02196730	chr15:80188777	MTHFS	0.4	6.01	0.31	4.8e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg08392591	chr16:89556376	ANKRD11	0.42	6.25	0.32	1.26e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	10.22	0.49	1.68e-21	Ileal carcinoids;
LUSC	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg26566898	chr11:117069891	TAGLN	0.36	7.02	0.36	1.24e-11	Blood protein levels;
LUSC	cis	rs8014204	0.781	rs10143492	chr14:75212114	G/C	cg08847533	chr14:75593920	NEK9	0.4	5.64	0.3	3.57e-8	Caffeine consumption;
LUSC	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.8	-0.43	7.27e-17	Monocyte percentage of white cells;
LUSC	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg09469691	chr10:81107165	PPIF	0.7	10.75	0.51	2.35e-23	Height;
LUSC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.74	11.15	0.52	9.56e-25	Type 2 diabetes;
LUSC	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg01884057	chr2:25150051	NA	0.46	10.58	0.5	9.55e-23	Body mass index;
LUSC	cis	rs3750965	0.959	rs2253658	chr11:68856804	C/G	cg06818126	chr11:68850279	TPCN2	-0.44	-6.42	-0.33	4.7e-10	Hair color;
LUSC	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg16359550	chr11:109292809	C11orf87	0.38	6.47	0.33	3.46e-10	Schizophrenia;
LUSC	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg13042288	chr15:90349979	ANPEP	-0.47	-6.73	-0.35	7.27e-11	Uric acid levels;
LUSC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg05623727	chr3:50126028	RBM5	-0.35	-6.55	-0.34	2.14e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg07148914	chr20:33460835	GGT7	-0.53	-8.1	-0.41	1.05e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg18758796	chr5:131593413	PDLIM4	0.47	7.78	0.39	9.31e-14	Acylcarnitine levels;
LUSC	cis	rs2637266	0.655	rs7902535	chr10:78460889	C/T	cg18941641	chr10:78392320	NA	0.34	5.96	0.31	6.58e-9	Pulmonary function;
LUSC	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	0.99	19.44	0.73	7.79e-57	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	1.06	17.28	0.69	3.12e-48	Testicular germ cell tumor;
LUSC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg00431813	chr7:1051703	C7orf50	-0.46	-7.55	-0.38	4.26e-13	Longevity;Endometriosis;
LUSC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.39	7.48	0.38	6.47e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg05313129	chr8:58192883	C8orf71	-0.5	-5.71	-0.3	2.44e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24845578	chr5:95170808	NA	-0.39	-6.28	-0.32	1.06e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.51	0.62	2.44e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12472274	0.646	rs35468889	chr2:239090959	G/A	cg17459225	chr2:239074497	NA	0.54	7.39	0.37	1.19e-12	Phospholipid levels (plasma);
LUSC	cis	rs6545883	0.801	rs778142	chr2:61681428	G/T	cg15711740	chr2:61764176	XPO1	-0.43	-6.41	-0.33	5.01e-10	Tuberculosis;
LUSC	trans	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg26043149	chr18:55253948	FECH	-0.46	-6.95	-0.36	1.88e-11	Bone mineral density;
LUSC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg18827107	chr12:86230957	RASSF9	-0.4	-5.99	-0.31	5.56e-9	Major depressive disorder;
LUSC	cis	rs16937	0.711	rs12130817	chr1:205140305	C/T	cg00857998	chr1:205179979	DSTYK	0.46	6.5	0.34	2.93e-10	Schizophrenia;
LUSC	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.7	-0.39	1.6e-13	Glomerular filtration rate;
LUSC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg03188948	chr7:1209495	NA	0.61	6.95	0.36	1.88e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs981844	0.736	rs1036614	chr4:154639105	G/A	cg14289246	chr4:154710475	SFRP2	0.47	5.83	0.3	1.32e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-9.5	-0.46	4.12e-19	Bladder cancer;
LUSC	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg14169450	chr9:139327907	INPP5E	0.44	7.94	0.4	3.07e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg19610905	chr11:61596333	FADS2	-0.55	-8.31	-0.41	2.39e-15	Trans fatty acid levels;
LUSC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Parkinson's disease;
LUSC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4132509	0.744	rs10927065	chr1:243914611	G/T	cg21452805	chr1:244014465	NA	0.6	6.75	0.35	6.49e-11	RR interval (heart rate);
LUSC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22433210	chr17:43662623	NA	-0.74	-10.81	-0.51	1.43e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs240993	0.595	rs3777911	chr6:111902480	G/C	cg22127309	chr6:111907043	TRAF3IP2	0.34	6.12	0.32	2.69e-9	Inflammatory skin disease;Psoriasis;
LUSC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg08499158	chr17:42289980	UBTF	0.4	6.23	0.32	1.41e-9	Total body bone mineral density;
LUSC	cis	rs7336332	0.598	rs45622135	chr13:28011594	T/C	cg22138327	chr13:27999177	GTF3A	0.81	10.14	0.49	2.98e-21	Weight;
LUSC	cis	rs11229555	0.645	rs7930547	chr11:58197616	A/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12618546	chr1:32817463	NA	-0.42	-6.57	-0.34	1.88e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	9.98	0.48	1.09e-20	Mean corpuscular volume;
LUSC	cis	rs796825	0.530	rs55861253	chr3:119986807	A/G	cg21790991	chr3:120137480	FSTL1	-0.34	-6.1	-0.32	2.93e-9	HIV-1 susceptibility;
LUSC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg06671706	chr8:8559999	CLDN23	0.47	6.4	0.33	5.34e-10	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12230071	chr15:65822924	PTPLAD1	0.46	6.86	0.35	3.33e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.67	11.96	0.55	1.11e-27	Mean corpuscular volume;
LUSC	cis	rs17253792	0.822	rs10483645	chr14:56103766	G/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.28e-10	Putamen volume;
LUSC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg15110403	chr19:17392923	ANKLE1	-0.52	-7.15	-0.36	5.67e-12	Systemic lupus erythematosus;
LUSC	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg26380479	chr7:97908229	NA	-0.28	-6.0	-0.31	5.07e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.66	-0.39	1.98e-13	Morning vs. evening chronotype;
LUSC	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.71	8.75	0.43	1.09e-16	Body mass index;
LUSC	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg05347473	chr6:146136440	FBXO30	-0.49	-8.27	-0.41	3.14e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4363385	0.747	rs1413849	chr1:152970233	C/A	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.46	-0.38	7.47e-13	Inflammatory skin disease;
LUSC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.2	13.62	0.6	6.4e-34	Diabetic kidney disease;
LUSC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-6.74	-0.35	7.02e-11	Alzheimer's disease (late onset);
LUSC	cis	rs6736093	0.763	rs11690440	chr2:112820109	G/A	cg12686935	chr2:112915763	FBLN7	-0.41	-6.52	-0.34	2.58e-10	Coronary artery disease;
LUSC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg00509249	chr6:109615579	CCDC162	-0.32	-5.85	-0.3	1.19e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg23649088	chr2:200775458	C2orf69	-0.53	-7.13	-0.36	6.41e-12	Schizophrenia;
LUSC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	6.48	0.33	3.22e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg03859395	chr2:55845619	SMEK2	0.87	16.19	0.66	6.22e-44	Metabolic syndrome;
LUSC	cis	rs2692947	0.667	rs4144055	chr2:96647856	G/T	cg22654517	chr2:96458247	NA	0.32	6.22	0.32	1.49e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg24558204	chr6:135376177	HBS1L	0.59	9.26	0.45	2.63e-18	Red blood cell count;
LUSC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg11663144	chr21:46675770	NA	-0.34	-5.65	-0.3	3.53e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3770081	1.000	rs74733602	chr2:86303442	T/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.08	-6.95	-0.36	1.94e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-6.27	-0.32	1.09e-9	IgG glycosylation;
LUSC	cis	rs13242816	1.000	rs34424131	chr7:116119002	G/A	cg16553024	chr7:116138462	CAV2	-0.52	-5.71	-0.3	2.44e-8	P wave duration;
LUSC	cis	rs7590368	1.000	rs55771723	chr2:10961902	T/C	cg15705551	chr2:10952987	PDIA6	0.58	8.0	0.4	2.11e-14	Educational attainment (years of education);
LUSC	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14240646	chr10:27532245	ACBD5	-0.66	-7.7	-0.39	1.55e-13	Breast cancer;
LUSC	cis	rs829883	0.664	rs1096148	chr12:98851005	A/G	cg25150519	chr12:98850993	NA	0.83	14.13	0.61	7.1e-36	Colorectal adenoma (advanced);
LUSC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg12564285	chr5:131593104	PDLIM4	-0.52	-9.42	-0.46	7.55e-19	Acylcarnitine levels;
LUSC	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.94	0.51	5.15e-24	Morning vs. evening chronotype;
LUSC	trans	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.66	-11.48	-0.53	6.18e-26	Mean corpuscular volume;
LUSC	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg06552810	chr11:31128660	NA	-0.42	-7.24	-0.37	3.07e-12	Red blood cell count;
LUSC	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.77	0.43	9.04e-17	Lung cancer in ever smokers;
LUSC	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	9.22	0.45	3.53e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.83	-15.55	-0.65	2.11e-41	Heart rate;
LUSC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	6.48	0.33	3.31e-10	Personality dimensions;
LUSC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.76	10.15	0.49	2.8e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg09650180	chr20:62225654	GMEB2	-0.67	-9.62	-0.47	1.68e-19	Glioblastoma;
LUSC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.77	-0.35	5.74e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2953174	0.786	rs2953145	chr2:241515596	C/G	cg07929629	chr2:241523174	NA	-0.48	-7.45	-0.38	7.93e-13	Bipolar disorder;
LUSC	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg10909506	chr17:38081995	ORMDL3	0.33	5.77	0.3	1.81e-8	Self-reported allergy;
LUSC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg01181863	chr3:195395398	SDHAP2	-0.61	-8.37	-0.42	1.64e-15	Pancreatic cancer;
LUSC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg05313129	chr8:58192883	C8orf71	-0.44	-6.18	-0.32	1.92e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2236918	0.932	rs1776178	chr1:242011534	C/T	cg17736920	chr1:242011382	EXO1	-0.45	-7.36	-0.37	1.44e-12	Menopause (age at onset);
LUSC	cis	rs72781680	0.706	rs72796108	chr2:23904990	C/A	cg20701182	chr2:24300061	SF3B14	0.72	6.99	0.36	1.54e-11	Lymphocyte counts;
LUSC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg03576123	chr11:487126	PTDSS2	-0.47	-5.77	-0.3	1.77e-8	Systemic lupus erythematosus;
LUSC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.19	-0.49	2.13e-21	Hemoglobin concentration;
LUSC	cis	rs500891	0.525	rs36116892	chr6:84087567	T/A	cg08257003	chr6:84140564	ME1	0.34	8.16	0.41	6.84e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.09	-0.4	1.1e-14	Lung cancer;
LUSC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg01125463	chr6:42946178	PEX6	-0.36	-5.84	-0.3	1.23e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg27446573	chr6:127587934	RNF146	0.64	10.28	0.49	1.03e-21	Breast cancer;
LUSC	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-13.89	-0.61	5.93e-35	Exhaled nitric oxide output;
LUSC	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg27489772	chr12:121021490	NA	0.58	7.75	0.39	1.11e-13	Type 1 diabetes nephropathy;
LUSC	cis	rs13082711	0.911	rs997680	chr3:27443638	G/A	cg02860705	chr3:27208620	NA	0.46	7.71	0.39	1.42e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg08470875	chr2:26401718	FAM59B	0.75	9.99	0.48	1e-20	Gut microbiome composition (summer);
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.47	-8.32	-0.41	2.32e-15	Longevity;Endometriosis;
LUSC	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg17385448	chr1:15911702	AGMAT	0.38	5.91	0.31	8.64e-9	Systolic blood pressure;
LUSC	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.26	-0.45	2.47e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg15839431	chr19:19639596	YJEFN3	-0.57	-6.13	-0.32	2.48e-9	Bipolar disorder;
LUSC	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg18904891	chr8:8559673	CLDN23	0.55	7.18	0.37	4.47e-12	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.32	0.77	3.6e-68	Prudent dietary pattern;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05407825	chr18:2571088	NDC80;METTL4	0.67	6.11	0.32	2.73e-9	Cognitive performance;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16717740	chr19:19612870	GATAD2A	0.38	6.04	0.31	4.17e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg04317338	chr11:64019027	PLCB3	0.68	7.75	0.39	1.12e-13	Attention deficit hyperactivity disorder;
LUSC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19717773	chr7:2847554	GNA12	-0.38	-6.2	-0.32	1.65e-9	Height;
LUSC	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.49	8.04	0.4	1.57e-14	Facial morphology (factor 20);
LUSC	cis	rs6977660	0.714	rs10270468	chr7:19810559	T/C	cg05791153	chr7:19748676	TWISTNB	0.66	7.04	0.36	1.11e-11	Thyroid stimulating hormone;
LUSC	cis	rs7017697	0.507	rs10112790	chr8:19684414	A/T	cg03894339	chr8:19674705	INTS10	-0.55	-7.2	-0.37	3.9e-12	Breast cancer;
LUSC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg06618935	chr21:46677482	NA	-0.37	-7.12	-0.36	6.83e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg11965913	chr1:205819406	PM20D1	-0.48	-6.7	-0.34	8.63e-11	Menarche (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11234017	chr17:42767172	CCDC43	0.44	6.53	0.34	2.46e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg00310523	chr12:86230176	RASSF9	-0.35	-6.3	-0.33	9.24e-10	Major depressive disorder;
LUSC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.55	9.01	0.44	1.57e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg04576048	chr1:205797593	PM20D1	0.33	6.05	0.31	3.88e-9	Menarche (age at onset);
LUSC	cis	rs4622329	0.615	rs4764676	chr12:102289957	T/C	cg23541617	chr12:102225335	GNPTAB	0.26	6.07	0.32	3.51e-9	Systemic lupus erythematosus;
LUSC	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.76	-0.35	6.1e-11	Monocyte percentage of white cells;
LUSC	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg13010199	chr12:38710504	ALG10B	0.67	10.27	0.49	1.1e-21	Bladder cancer;
LUSC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18876405	chr7:65276391	NA	0.54	8.23	0.41	4.27e-15	Aortic root size;
LUSC	cis	rs35883536	1.000	rs4907921	chr1:101128249	C/T	cg06223162	chr1:101003688	GPR88	0.32	5.79	0.3	1.62e-8	Monocyte count;
LUSC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg13334819	chr7:99746414	C7orf59	-0.43	-5.75	-0.3	2.01e-8	Coronary artery disease;
LUSC	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg12560992	chr17:57184187	TRIM37	-0.75	-11.78	-0.54	4.92e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs981844	0.740	rs1020702	chr4:154685712	A/C	cg14289246	chr4:154710475	SFRP2	-0.52	-7.41	-0.38	1.06e-12	Response to statins (LDL cholesterol change);
LUSC	cis	rs7674212	0.539	rs6854709	chr4:104129786	A/G	cg16532752	chr4:104119610	CENPE	-0.45	-6.86	-0.35	3.42e-11	Type 2 diabetes;
LUSC	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	1.01	11.41	0.53	1.14e-25	Type 2 diabetes;
LUSC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg00129232	chr17:37814104	STARD3	-0.41	-5.91	-0.31	8.22e-9	Asthma;
LUSC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg05347473	chr6:146136440	FBXO30	-0.57	-9.69	-0.47	1.01e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	13.79	0.6	1.44e-34	Smoking behavior;
LUSC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.62	-0.38	2.68e-13	Type 2 diabetes;
LUSC	trans	rs7939886	0.920	rs74459856	chr11:56027689	G/A	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg18352616	chr4:3374830	RGS12	0.31	6.12	0.32	2.61e-9	Serum sulfate level;
LUSC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg16325326	chr1:53192061	ZYG11B	0.88	15.8	0.65	2.19e-42	Monocyte count;
LUSC	cis	rs6977660	0.619	rs12530799	chr7:19782793	G/A	cg05791153	chr7:19748676	TWISTNB	0.69	7.18	0.37	4.5e-12	Thyroid stimulating hormone;
LUSC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg26335602	chr6:28129616	ZNF389	0.43	5.77	0.3	1.79e-8	Depression;
LUSC	cis	rs10498514	0.793	rs116953714	chr14:65054966	C/T	cg25134081	chr14:64931936	AKAP5	0.98	6.74	0.35	7.01e-11	Cognitive performance;
LUSC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg21724239	chr8:58056113	NA	0.78	9.38	0.46	1.06e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg13126279	chr21:47581558	C21orf56	-0.42	-6.17	-0.32	1.93e-9	Testicular germ cell tumor;
LUSC	trans	rs7939886	0.920	rs78769647	chr11:55965527	C/T	cg03929089	chr4:120376271	NA	0.81	6.11	0.32	2.73e-9	Myopia (pathological);
LUSC	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg02023728	chr11:77925099	USP35	0.52	7.01	0.36	1.3e-11	Testicular germ cell tumor;
LUSC	cis	rs10189230	0.904	rs13029372	chr2:222348434	A/G	cg14652038	chr2:222343519	EPHA4	0.37	6.45	0.33	3.94e-10	Urate levels in lean individuals;
LUSC	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg22431228	chr1:16359049	CLCNKA	-0.43	-8.86	-0.44	4.89e-17	Dilated cardiomyopathy;
LUSC	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.46	9.63	0.47	1.54e-19	Airflow obstruction;
LUSC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg06046430	chr4:77819534	ANKRD56	0.48	6.94	0.35	2.06e-11	Emphysema distribution in smoking;
LUSC	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg00852783	chr1:26633632	UBXN11	-0.5	-5.73	-0.3	2.21e-8	Obesity-related traits;
LUSC	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg01420254	chr6:26195488	NA	0.66	7.19	0.37	4.38e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs6977940	0.730	rs11768001	chr7:2887783	T/C	cg19731401	chr7:2775893	GNA12	0.7	7.58	0.38	3.54e-13	White matter integrity;
LUSC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.24	0.52	4.63e-25	Prudent dietary pattern;
LUSC	cis	rs7246967	0.551	rs7248993	chr19:22849152	G/C	cg23217946	chr19:22817039	ZNF492	0.49	6.87	0.35	3.18e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg08847533	chr14:75593920	NEK9	0.85	15.86	0.66	1.33e-42	Height;
LUSC	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg26876637	chr1:152193138	HRNR	0.43	6.06	0.31	3.62e-9	Atopic dermatitis;
LUSC	cis	rs4409675	0.576	rs2749110	chr1:28235010	T/C	cg23691781	chr1:28212827	C1orf38	0.33	7.92	0.4	3.62e-14	Corneal astigmatism;
LUSC	cis	rs6460942	0.908	rs112897715	chr7:12241541	T/C	cg06484146	chr7:12443880	VWDE	-0.6	-6.26	-0.32	1.21e-9	Coronary artery disease;
LUSC	cis	rs1712517	0.771	rs11191654	chr10:105077124	C/A	cg05636881	chr10:105038444	INA	0.39	6.39	0.33	5.47e-10	Migraine;
LUSC	cis	rs7011049	1.000	rs11997775	chr8:53833571	C/T	cg26025543	chr8:53854495	NA	-0.48	-5.92	-0.31	8.08e-9	Systolic blood pressure;
LUSC	cis	rs4704187	0.663	rs6889760	chr5:74503704	A/C	cg03227963	chr5:74354835	NA	0.3	6.64	0.34	1.24e-10	Response to amphetamines;
LUSC	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg05110241	chr16:68378359	PRMT7	-0.55	-6.39	-0.33	5.58e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.75	0.3	2.03e-8	Schizophrenia;
LUSC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg20476274	chr7:133979776	SLC35B4	0.87	16.89	0.68	1.02e-46	Mean platelet volume;
LUSC	cis	rs3862435	0.764	rs78896416	chr15:90993016	G/A	cg22089800	chr15:90895588	ZNF774	0.57	5.97	0.31	5.95e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg11843238	chr5:131593191	PDLIM4	-0.38	-6.3	-0.33	9.24e-10	Breast cancer;
LUSC	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg24596788	chr1:163392923	NA	-0.45	-7.59	-0.38	3.27e-13	Motion sickness;
LUSC	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.38e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	10.67	0.5	4.71e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6960043	0.818	rs10244051	chr7:15063833	T/G	cg19272540	chr7:15055459	NA	-0.31	-7.6	-0.38	2.92e-13	Type 2 diabetes;
LUSC	cis	rs7771547	0.573	rs547026	chr6:36398616	G/A	cg07856975	chr6:36356162	ETV7	0.34	6.17	0.32	1.93e-9	Platelet distribution width;
LUSC	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.56e-22	Colorectal cancer;
LUSC	cis	rs3812111	0.510	rs9372453	chr6:116583872	T/A	cg18828861	chr6:116576566	TSPYL4	0.38	6.74	0.35	7e-11	Age-related macular degeneration;
LUSC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.47	-8.4	-0.42	1.31e-15	Eosinophil percentage of white cells;
LUSC	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg26587870	chr6:27730563	NA	-0.61	-5.79	-0.3	1.62e-8	Breast cancer;
LUSC	cis	rs6674970	0.933	rs12134957	chr1:151045419	A/G	cg11822372	chr1:151115635	SEMA6C	0.54	8.2	0.41	5.39e-15	Childhood ear infection;
LUSC	cis	rs9900062	0.586	rs12600679	chr17:62687327	T/G	cg02598441	chr17:62777298	LOC146880	-0.54	-6.87	-0.35	3.17e-11	QT interval;
LUSC	trans	rs12543645	0.598	rs35338507	chr8:10277982	G/A	cg15556689	chr8:8085844	FLJ10661	0.46	6.25	0.32	1.27e-9	Schizophrenia;
LUSC	cis	rs10887741	0.690	rs11202503	chr10:89440749	T/G	cg13926569	chr10:89418898	PAPSS2	0.34	7.32	0.37	1.86e-12	Exercise (leisure time);
LUSC	cis	rs4601821	0.858	rs2298489	chr11:113235419	C/T	cg14159747	chr11:113255604	NA	-0.29	-6.81	-0.35	4.53e-11	Alcoholic chronic pancreatitis;
LUSC	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-9.0	-0.44	1.75e-17	HDL cholesterol;
LUSC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	13.42	0.59	3.99e-33	Cognitive test performance;
LUSC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg05340658	chr4:99064831	C4orf37	0.6	9.0	0.44	1.76e-17	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2262909	0.962	rs17459246	chr19:22278121	T/C	cg05197062	chr11:11642011	GALNTL4	0.54	7.58	0.38	3.39e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.75	0.6	2.12e-34	Platelet count;
LUSC	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.37	5.66	0.3	3.23e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs2652834	1.000	rs2652838	chr15:63396088	A/G	cg05507819	chr15:63340323	TPM1	0.67	8.2	0.41	5.33e-15	HDL cholesterol;
LUSC	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg24562669	chr7:97807699	LMTK2	0.39	6.73	0.35	7.47e-11	Breast cancer;
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg04025307	chr7:1156635	C7orf50	0.41	6.31	0.33	8.96e-10	Longevity;Endometriosis;
LUSC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg20849893	chr7:64541193	NA	-0.48	-7.08	-0.36	8.65e-12	Calcium levels;
LUSC	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.16	0.45	5.47e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.44	6.42	0.33	4.74e-10	Eosinophil percentage of white cells;
LUSC	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs9395066	0.545	rs3799979	chr6:44845514	A/G	cg25276700	chr6:44698697	NA	0.3	5.96	0.31	6.31e-9	Height;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14878842	chr13:113730426	MCF2L	0.43	6.23	0.32	1.41e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg16535667	chr11:65410126	SIPA1	-0.44	-6.09	-0.32	3.05e-9	Blood pressure (age interaction);
LUSC	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg18721089	chr20:30220636	NA	-0.35	-5.94	-0.31	7.09e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg00677455	chr12:58241039	CTDSP2	0.71	11.06	0.52	1.99e-24	Intelligence (multi-trait analysis);
LUSC	trans	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg19894588	chr14:64061835	NA	-0.52	-7.83	-0.39	6.34e-14	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg13114125	chr14:105738426	BRF1	-0.85	-14.23	-0.61	3.06e-36	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10193935	0.901	rs13393459	chr2:42463124	C/T	cg27598129	chr2:42591480	NA	-0.59	-7.88	-0.4	4.82e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg25767906	chr1:53392781	SCP2	-0.51	-9.09	-0.45	9.24e-18	Monocyte count;
LUSC	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg01557791	chr16:72042693	DHODH	-0.5	-6.48	-0.33	3.3e-10	Blood protein levels;
LUSC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15556689	chr8:8085844	FLJ10661	0.89	15.92	0.66	7.25e-43	Neuroticism;
LUSC	cis	rs2445762	0.600	rs12148492	chr15:51653193	A/C	cg07517944	chr15:51633816	GLDN	-0.4	-6.41	-0.33	4.98e-10	Hormone measurements;
LUSC	cis	rs6500395	1.000	rs7201196	chr16:48674030	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.8	0.35	4.86e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg23791538	chr6:167370224	RNASET2	0.52	8.67	0.43	1.87e-16	Crohn's disease;
LUSC	trans	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg19694781	chr19:47549865	TMEM160	-0.39	-6.2	-0.32	1.66e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.97	-0.44	2.14e-17	Monocyte percentage of white cells;
LUSC	cis	rs1808579	0.935	rs2435307	chr18:21127910	A/G	cg14672496	chr18:21087552	C18orf8	-0.33	-5.74	-0.3	2.17e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04074137	chr3:142720408	SR140	-0.41	-5.97	-0.31	6.18e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg04944784	chr2:26401820	FAM59B	-0.73	-10.7	-0.51	3.55e-23	Gut microbiome composition (summer);
LUSC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.77	-11.95	-0.55	1.19e-27	Tonsillectomy;
LUSC	trans	rs1493916	0.837	rs2123333	chr18:31410730	G/A	cg27147174	chr7:100797783	AP1S1	-0.55	-8.73	-0.43	1.21e-16	Life satisfaction;
LUSC	cis	rs1775715	0.870	rs3847415	chr10:32219456	G/T	cg18675610	chr10:32216311	ARHGAP12	0.28	6.18	0.32	1.92e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.79	0.54	4.46e-27	Personality dimensions;
LUSC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg14582100	chr15:45693742	SPATA5L1	0.56	10.5	0.5	1.84e-22	Homoarginine levels;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg23131131	chr22:24373011	LOC391322	-0.39	-5.71	-0.3	2.56e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg18758796	chr5:131593413	PDLIM4	0.33	5.66	0.3	3.18e-8	Blood metabolite levels;
LUSC	cis	rs72781680	0.716	rs2551326	chr2:23982378	T/C	cg08917208	chr2:24149416	ATAD2B	0.58	6.49	0.33	3.15e-10	Lymphocyte counts;
LUSC	cis	rs67366981	0.720	rs4447349	chr14:77685381	G/A	cg22824376	chr14:77648248	TMEM63C	0.88	8.54	0.42	4.76e-16	Obsessive-compulsive symptoms;
LUSC	trans	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg21659725	chr3:3221576	CRBN	0.42	6.17	0.32	2.02e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg26380479	chr7:97908229	NA	-0.27	-5.9	-0.31	8.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-13.52	-0.59	1.62e-33	Total body bone mineral density;
LUSC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg11812906	chr14:75593930	NEK9	-0.63	-10.39	-0.49	4.13e-22	Height;
LUSC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.68	10.96	0.51	4.42e-24	Menarche (age at onset);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15611150	chr3:133524362	SRPRB	0.38	6.09	0.32	3.11e-9	Asthma;
LUSC	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.03	0.52	2.51e-24	Colorectal cancer;
LUSC	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.37	0.49	5.04e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg00343986	chr7:65444356	GUSB	0.43	6.54	0.34	2.26e-10	Aortic root size;
LUSC	cis	rs2109514	0.902	rs28495552	chr7:116113744	C/G	cg12739419	chr7:116140593	CAV2	-0.27	-5.92	-0.31	7.84e-9	Prevalent atrial fibrillation;
LUSC	trans	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg11244813	chr1:145039882	PDE4DIP	0.37	6.11	0.32	2.76e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21724239	chr8:58056113	NA	0.86	9.61	0.47	1.83e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg18357645	chr12:58087776	OS9	0.54	8.28	0.41	2.96e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.6	13.87	0.6	7.29e-35	Height;
LUSC	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.21	-0.37	3.65e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs35883536	0.626	rs12135243	chr1:101092955	G/A	cg06223162	chr1:101003688	GPR88	-0.41	-7.26	-0.37	2.69e-12	Monocyte count;
LUSC	cis	rs55665837	1.000	rs12287715	chr11:14444575	G/A	cg05501817	chr11:14380813	RRAS2	-0.41	-6.61	-0.34	1.51e-10	Vitamin D levels;
LUSC	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg08601574	chr20:25228251	PYGB	0.41	6.25	0.32	1.22e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-0.66	-9.41	-0.46	8.54e-19	Platelet distribution width;
LUSC	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.37	-0.33	6.16e-10	Retinal vascular caliber;
LUSC	cis	rs9815354	0.812	rs73069240	chr3:41950973	A/T	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.55e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6977660	0.943	rs10274447	chr7:19850640	C/T	cg05791153	chr7:19748676	TWISTNB	0.52	5.97	0.31	6.23e-9	Thyroid stimulating hormone;
LUSC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs61931739	0.533	rs7970871	chr12:33917301	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.68	-0.34	9.84e-11	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	15.48	0.65	4.01e-41	Platelet count;
LUSC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg20476274	chr7:133979776	SLC35B4	0.81	14.06	0.61	1.36e-35	Mean platelet volume;
LUSC	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg10596483	chr8:143751796	JRK	-0.52	-7.47	-0.38	7.09e-13	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg18402987	chr7:1209562	NA	0.7	7.64	0.39	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24143933	chr1:212458162	PPP2R5A	0.44	6.8	0.35	4.83e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg04362960	chr10:104952993	NT5C2	0.49	6.27	0.32	1.11e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.31	-0.37	2.01e-12	Bipolar disorder;
LUSC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg08917208	chr2:24149416	ATAD2B	0.53	5.88	0.31	1e-8	Lymphocyte counts;
LUSC	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg19773385	chr1:10388646	KIF1B	-0.5	-8.47	-0.42	7.84e-16	Hepatocellular carcinoma;
LUSC	cis	rs7582180	1.000	rs7582180	chr2:100912463	C/T	cg08017756	chr2:100939284	LONRF2	0.38	6.34	0.33	7.61e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg24375607	chr4:120327624	NA	0.71	11.34	0.53	1.94e-25	Corneal astigmatism;
LUSC	trans	rs877282	0.583	rs11253441	chr10:828288	C/T	cg22713356	chr15:30763199	NA	-0.78	-10.37	-0.49	5.07e-22	Uric acid levels;
LUSC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7119167	0.686	rs6592519	chr11:73045074	T/C	cg17517138	chr11:73019481	ARHGEF17	0.49	5.71	0.3	2.49e-8	Blood protein levels;
LUSC	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg22139774	chr2:100720529	AFF3	-0.52	-8.97	-0.44	2.16e-17	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.1	24.44	0.8	2.23e-76	Schizophrenia;
LUSC	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg05373962	chr22:49881684	NA	-0.4	-8.46	-0.42	8.69e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11690935	0.731	rs10930491	chr2:172569824	A/G	cg13550731	chr2:172543902	DYNC1I2	0.59	9.36	0.46	1.23e-18	Schizophrenia;
LUSC	cis	rs7615316	0.779	rs4434160	chr3:142004728	A/G	cg16271453	chr3:142027066	XRN1	-0.4	-7.07	-0.36	8.91e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9549260	0.755	rs2151785	chr13:41243660	G/A	cg21288729	chr13:41239152	FOXO1	0.63	9.8	0.47	4.19e-20	Red blood cell count;
LUSC	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-6.56	-0.34	2.08e-10	Monocyte percentage of white cells;
LUSC	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	7.89	0.4	4.33e-14	Neuroticism;
LUSC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24110177	chr3:50126178	RBM5	0.55	9.0	0.44	1.77e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs983392	0.709	rs7939882	chr11:59973929	A/C	cg02771260	chr11:59836817	MS4A3	-0.36	-5.88	-0.31	9.77e-9	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg12463550	chr7:65579703	CRCP	0.57	8.52	0.42	5.72e-16	Aortic root size;
LUSC	cis	rs68092024	0.731	rs793480	chr3:99488364	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.36	-7.02	-0.36	1.28e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs6733011	0.500	rs7560696	chr2:99405800	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-7.09	-0.36	7.93e-12	Bipolar disorder;
LUSC	cis	rs500891	0.868	rs34941468	chr6:84139871	A/T	cg08257003	chr6:84140564	ME1	0.35	7.21	0.37	3.81e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs3099143	1.000	rs3106380	chr15:77104377	G/A	cg21673338	chr15:77095150	SCAPER	-0.78	-7.47	-0.38	7.09e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs4954585	0.708	rs6430612	chr2:137006198	C/T	cg05194412	chr2:137003533	NA	0.38	7.03	0.36	1.17e-11	Colorectal cancer;
LUSC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg00359181	chr2:38893519	GALM	-0.52	-6.02	-0.31	4.52e-9	5-HTT brain serotonin transporter levels;
LUSC	trans	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg19676328	chr12:49525230	TUBA1B	-0.53	-8.36	-0.42	1.7e-15	Total cholesterol levels;
LUSC	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg23691781	chr1:28212827	C1orf38	0.32	7.79	0.39	8.33e-14	Corneal astigmatism;
LUSC	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg19875535	chr5:140030758	IK	0.46	7.32	0.37	1.91e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4654899	0.865	rs10916951	chr1:21528835	A/G	cg01072550	chr1:21505969	NA	0.53	8.1	0.41	1.02e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg18721089	chr20:30220636	NA	-0.34	-5.81	-0.3	1.46e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs11168618	1.000	rs11168637	chr12:48953504	G/A	cg24011408	chr12:48396354	COL2A1	0.41	6.45	0.33	4e-10	Adiponectin levels;
LUSC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	-0.42	-6.6	-0.34	1.61e-10	Menopause (age at onset);
LUSC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg23625390	chr15:77176239	SCAPER	0.48	7.29	0.37	2.33e-12	Blood metabolite levels;
LUSC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg04287289	chr16:89883240	FANCA	0.78	13.7	0.6	3.2e-34	Vitiligo;
LUSC	cis	rs7804356	1.000	rs3823933	chr7:26853966	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs2637266	0.967	rs4608018	chr10:78376110	T/C	cg18941641	chr10:78392320	NA	0.38	6.94	0.36	2.04e-11	Pulmonary function;
LUSC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg12560992	chr17:57184187	TRIM37	-0.84	-15.24	-0.64	3.5e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-0.89	-17.75	-0.7	4.1e-50	Urate levels;
LUSC	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg03060546	chr3:49711283	APEH	0.59	8.08	0.4	1.2e-14	Resting heart rate;
LUSC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.39	0.33	5.67e-10	Alzheimer's disease (late onset);
LUSC	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg03684893	chr10:554711	DIP2C	-0.38	-6.91	-0.35	2.42e-11	Psychosis in Alzheimer's disease;
LUSC	trans	rs3960554	0.709	rs73138006	chr7:75769990	T/C	cg19862616	chr7:65841803	NCRNA00174	0.9	10.19	0.49	2.1e-21	Eotaxin levels;
LUSC	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg21211680	chr2:198530	NA	0.35	5.77	0.3	1.85e-8	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs4499344	0.633	rs259246	chr19:33146154	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.75	11.4	0.53	1.16e-25	Mean platelet volume;
LUSC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg17143192	chr8:8559678	CLDN23	0.37	5.76	0.3	1.89e-8	Mood instability;
LUSC	cis	rs7255045	0.742	rs7251196	chr19:12950863	C/T	cg21491176	chr19:12958399	MAST1	-0.34	-5.8	-0.3	1.5e-8	Mean corpuscular volume;
LUSC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg22920501	chr2:26401640	FAM59B	-0.8	-11.67	-0.54	1.27e-26	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-8.53	-0.42	5.32e-16	Prudent dietary pattern;
LUSC	trans	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg10756647	chr7:56101905	PSPH	0.87	8.39	0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs16937	0.711	rs10900467	chr1:205160074	G/A	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.36e-10	Schizophrenia;
LUSC	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.75	-12.1	-0.55	3.37e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg23711669	chr6:146136114	FBXO30	0.74	13.25	0.59	1.76e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg12463550	chr7:65579703	CRCP	-0.41	-5.98	-0.31	5.79e-9	Aortic root size;
LUSC	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg17517138	chr11:73019481	ARHGEF17	1.04	8.68	0.43	1.78e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.82	0.7	2.19e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs800082	0.647	rs6791653	chr3:144177094	T/G	cg24215973	chr2:240111563	HDAC4	0.41	6.1	0.32	2.96e-9	Smoking behavior;
LUSC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg02475777	chr4:1388615	CRIPAK	-0.47	-7.09	-0.36	7.98e-12	Obesity-related traits;
LUSC	cis	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.75	-0.35	6.42e-11	Morning vs. evening chronotype;
LUSC	trans	rs895636	0.898	rs10205310	chr2:45188646	A/G	cg19444027	chr12:57145625	PRIM1	0.53	6.31	0.33	8.83e-10	Metabolite levels;Fasting plasma glucose;
LUSC	cis	rs13385	0.769	rs34266577	chr5:139547797	C/T	cg26211634	chr5:139558579	C5orf32	0.45	6.3	0.33	9.46e-10	Atrial fibrillation;
LUSC	cis	rs57549656	0.799	rs2110120	chr19:2711413	A/G	cg06609049	chr19:2785107	THOP1	0.47	6.21	0.32	1.62e-9	Schizophrenia;
LUSC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg04518342	chr5:131593106	PDLIM4	0.45	8.34	0.42	1.91e-15	Breast cancer;
LUSC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	15.88	0.66	1.08e-42	Platelet count;
LUSC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg01125463	chr6:42946178	PEX6	-0.37	-6.01	-0.31	4.78e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-5.84	-0.3	1.26e-8	Vitiligo;
LUSC	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.72	-0.35	7.73e-11	Response to antipsychotic treatment;
LUSC	cis	rs75804782	0.641	rs3769124	chr2:239349362	G/A	cg18131467	chr2:239335373	ASB1	-0.73	-6.63	-0.34	1.37e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg17554472	chr22:41940697	POLR3H	-0.48	-5.77	-0.3	1.85e-8	Vitiligo;
LUSC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06634786	chr22:41940651	POLR3H	-0.52	-6.14	-0.32	2.33e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs637571	0.528	rs566266	chr11:65573587	A/C	cg17712092	chr4:129076599	LARP1B	-0.71	-10.28	-0.49	1.02e-21	Eosinophil percentage of white cells;
LUSC	cis	rs56283067	0.578	rs72862930	chr6:45361883	C/T	cg18551225	chr6:44695536	NA	-0.42	-6.35	-0.33	6.91e-10	Total body bone mineral density;
LUSC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.11	-0.41	9.95e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1775715	0.737	rs2799017	chr10:32203460	A/G	cg18675610	chr10:32216311	ARHGAP12	0.31	6.67	0.34	1.07e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg11019008	chr10:131425282	MGMT	0.42	6.31	0.33	8.88e-10	Response to temozolomide;
LUSC	cis	rs3125734	0.633	rs3902162	chr10:64041817	C/T	cg19640130	chr10:64028056	RTKN2	-0.4	-7.02	-0.36	1.25e-11	Rheumatoid arthritis;
LUSC	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg25809561	chr17:30822961	MYO1D	0.57	9.8	0.47	4.2e-20	Schizophrenia;
LUSC	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg08017634	chr8:144659831	NAPRT1	0.73	6.16	0.32	2.15e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg26566898	chr11:117069891	TAGLN	0.48	8.42	0.42	1.15e-15	Blood protein levels;
LUSC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs2625529	0.730	rs2957368	chr15:72329906	C/T	cg16672083	chr15:72433130	SENP8	-0.48	-7.82	-0.39	7.02e-14	Red blood cell count;
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.57	-8.86	-0.44	5e-17	Lymphocyte counts;
LUSC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg05855489	chr10:104503620	C10orf26	0.58	9.3	0.45	1.84e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg13939156	chr17:80058883	NA	0.33	6.43	0.33	4.45e-10	Life satisfaction;
LUSC	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg04374321	chr14:90722782	PSMC1	0.75	12.08	0.55	4e-28	Mortality in heart failure;
LUSC	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg15383120	chr6:291909	DUSP22	-0.46	-7.12	-0.36	6.57e-12	Menopause (age at onset);
LUSC	cis	rs12532214	0.690	rs74446924	chr7:3127245	C/T	cg19214707	chr7:3157722	NA	-0.42	-6.08	-0.32	3.3e-9	Itch intensity from mosquito bite;
LUSC	trans	rs656319	0.605	rs60278284	chr8:10003210	G/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.23	-0.37	3.3e-12	Myopia (pathological);
LUSC	cis	rs2019216	0.500	rs7210996	chr17:21917331	G/A	cg22648282	chr17:21454238	C17orf51	-0.51	-7.54	-0.38	4.43e-13	Pelvic organ prolapse;
LUSC	cis	rs3768617	0.966	rs10911253	chr1:183086190	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.74	0.43	1.16e-16	Fuchs's corneal dystrophy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08644993	chr1:153508755	S100A6	-0.38	-6.06	-0.31	3.66e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25072359	chr17:41440525	NA	0.65	9.39	0.46	9.7e-19	Menopause (age at onset);
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15109118	chr6:5431669	FARS2	0.48	7.05	0.36	1.03e-11	Neuroticism;
LUSC	cis	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	16.67	0.67	7.97e-46	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg27411982	chr8:10470053	RP1L1	-0.47	-7.22	-0.37	3.63e-12	Neuroticism;
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.4	-6.46	-0.33	3.78e-10	Longevity;Endometriosis;
LUSC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.63	9.25	0.45	2.82e-18	Blood protein levels;
LUSC	trans	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg22153745	chr1:153894579	GATAD2B	-0.53	-7.33	-0.37	1.77e-12	Total cholesterol levels;
LUSC	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg05805236	chr11:65401703	PCNXL3	-0.64	-10.46	-0.5	2.47e-22	Acne (severe);
LUSC	cis	rs1808579	1.000	rs891386	chr18:21103971	A/C	cg14672496	chr18:21087552	C18orf8	0.34	5.77	0.3	1.8e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg05501817	chr11:14380813	RRAS2	-0.47	-7.41	-0.38	1.05e-12	Vitamin D levels;
LUSC	cis	rs3947	0.855	rs1293327	chr8:11694986	G/A	cg00262122	chr8:11665843	FDFT1	-0.53	-6.55	-0.34	2.19e-10	Blood protein levels;
LUSC	cis	rs3540	0.960	rs28539372	chr15:91021412	T/A	cg10434728	chr15:90938212	IQGAP1	0.32	5.71	0.3	2.53e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-6.84	-0.35	3.75e-11	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02285715	chr20:61493179	TCFL5	-0.41	-6.01	-0.31	4.74e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.16	-0.32	2.13e-9	Life satisfaction;
LUSC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	9.27	0.45	2.37e-18	Motion sickness;
LUSC	cis	rs3820068	0.608	rs12091644	chr1:16044945	G/A	cg24675056	chr1:15929824	NA	0.43	6.95	0.36	1.94e-11	Systolic blood pressure;
LUSC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg01879757	chr17:41196368	BRCA1	-0.5	-8.05	-0.4	1.48e-14	Menopause (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04246999	chr16:71930048	KIAA0174	0.73	5.96	0.31	6.48e-9	Cognitive performance;
LUSC	cis	rs524023	0.914	rs11231845	chr11:64407419	G/A	cg19131476	chr11:64387923	NRXN2	-0.38	-10.48	-0.5	2.05e-22	Urate levels in obese individuals;
LUSC	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg17366294	chr4:99064904	C4orf37	0.58	10.39	0.49	4.16e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-0.41	-6.75	-0.35	6.46e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	0.92	15.67	0.65	7.13e-42	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg23262351	chr6:79576851	IRAK1BP1	-0.39	-5.95	-0.31	6.72e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg12963246	chr6:28129442	ZNF389	0.4	5.96	0.31	6.46e-9	Parkinson's disease;
LUSC	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.84	14.71	0.63	4.12e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.76	-13.45	-0.59	2.85e-33	Dental caries;
LUSC	cis	rs16917546	0.967	rs10995246	chr10:64391846	C/A	cg03961010	chr10:64397487	ZNF365	-0.43	-6.71	-0.34	8.44e-11	Basal cell carcinoma;
LUSC	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg20219074	chr11:18656078	SPTY2D1	0.72	10.87	0.51	9.28e-24	Breast cancer;
LUSC	cis	rs9928842	0.882	rs4737	chr16:75238103	A/G	cg09066997	chr16:75300724	BCAR1	-0.5	-6.07	-0.32	3.47e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs79911532	0.515	rs77381667	chr7:75663126	C/T	cg03592824	chr7:75666768	STYXL1	0.7	6.83	0.35	4.03e-11	Mononucleosis;
LUSC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg26897989	chr16:1907736	C16orf73	-0.42	-6.63	-0.34	1.37e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.07	14.26	0.62	2.27e-36	Uric acid levels;
LUSC	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg27165867	chr14:105738592	BRF1	-0.51	-7.14	-0.36	6.02e-12	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02902800	chr4:6784175	KIAA0232	-0.45	-6.02	-0.31	4.48e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg05738196	chr6:26577821	NA	0.82	15.81	0.65	1.93e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg07061783	chr6:25882402	NA	0.43	6.06	0.31	3.6e-9	Blood metabolite levels;
LUSC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.83	13.77	0.6	1.8e-34	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7106204	0.668	rs7119362	chr11:24218132	G/T	ch.11.24196551F	chr11:24239977	NA	1.13	14.35	0.62	9.89e-37	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg16342193	chr10:102329863	NA	-0.33	-6.1	-0.32	2.86e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs28785552	0.800	rs10853855	chr19:53232293	A/G	cg22067481	chr19:53234126	ZNF611	-0.51	-7.02	-0.36	1.23e-11	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg04455712	chr21:45112962	RRP1B	0.47	9.02	0.44	1.47e-17	Mean corpuscular volume;
LUSC	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg14036092	chr11:66035641	RAB1B	0.45	6.51	0.34	2.77e-10	Gout;
LUSC	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-15.21	-0.64	4.49e-40	Exhaled nitric oxide output;
LUSC	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg04310649	chr10:35416472	CREM	-0.41	-6.56	-0.34	2.03e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4921915	0.598	rs55686478	chr8:18250375	G/A	cg18736775	chr8:18248649	NAT2	-0.56	-6.07	-0.32	3.49e-9	Iron status biomarkers (transferrin levels);
LUSC	trans	rs877282	0.629	rs78997110	chr10:764388	A/G	cg22713356	chr15:30763199	NA	1.09	14.2	0.61	4.05e-36	Uric acid levels;
LUSC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08645402	chr16:4508243	NA	0.51	8.5	0.42	6.33e-16	Schizophrenia;
LUSC	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.06	0.31	3.61e-9	Corneal astigmatism;
LUSC	cis	rs9309473	0.632	rs7599076	chr2:73585519	G/T	cg20560298	chr2:73613845	ALMS1	-0.56	-8.09	-0.4	1.13e-14	Metabolite levels;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20557037	chr2:165698099	COBLL1	-0.42	-6.55	-0.34	2.22e-10	Triglycerides;
LUSC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.73	-0.39	1.25e-13	Type 2 diabetes;
LUSC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg08027265	chr7:2291960	NA	-0.4	-6.59	-0.34	1.74e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	14.2	0.61	3.89e-36	Mean platelet volume;
LUSC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg03579872	chr1:53393473	SCP2	-0.39	-5.87	-0.31	1.07e-8	Monocyte count;
LUSC	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	8.0	0.4	2.07e-14	Body mass index;
LUSC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.64	0.6	5.58e-34	Cognitive test performance;
LUSC	trans	rs9693857	0.520	rs4841163	chr8:9366178	C/G	cg27411982	chr8:10470053	RP1L1	0.41	6.26	0.32	1.17e-9	Systolic blood pressure;
LUSC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.13	0.55	2.54e-28	Cognitive test performance;
LUSC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg02187348	chr16:89574699	SPG7	0.61	9.91	0.48	1.88e-20	Multiple myeloma (IgH translocation);
LUSC	trans	rs1459104	0.866	rs67929427	chr11:54824182	C/T	cg15704280	chr7:45808275	SEPT13	0.75	6.55	0.34	2.23e-10	Body mass index;
LUSC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg12560992	chr17:57184187	TRIM37	0.87	15.71	0.65	5.05e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg14844989	chr11:31128820	NA	-0.39	-5.99	-0.31	5.29e-9	Red blood cell count;
LUSC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg05552183	chr6:42928497	GNMT	0.47	7.98	0.4	2.37e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.28	-0.32	1.08e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg09796270	chr17:17721594	SREBF1	-0.43	-7.55	-0.38	4.32e-13	Total body bone mineral density;
LUSC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg20887711	chr4:1340912	KIAA1530	0.44	6.64	0.34	1.28e-10	Obesity-related traits;
LUSC	cis	rs1376877	0.538	rs12474416	chr2:204226003	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.5	6.43	0.33	4.33e-10	Subclinical atherosclerosis traits (other);
LUSC	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg15704280	chr7:45808275	SEPT13	0.74	7.02	0.36	1.22e-11	Axial length;
LUSC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg16482183	chr6:26056742	HIST1H1C	0.53	7.81	0.39	7.32e-14	Height;
LUSC	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg19653624	chr11:20408972	PRMT3	0.63	8.25	0.41	3.61e-15	Pursuit maintenance gain;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14211646	chr1:26758996	DHDDS	0.41	6.27	0.32	1.1e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg22823121	chr1:150693482	HORMAD1	0.5	7.28	0.37	2.45e-12	Melanoma;
LUSC	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg27661571	chr11:113659931	NA	-0.52	-6.19	-0.32	1.73e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12667521	chr19:29218732	NA	0.58	7.24	0.37	3.04e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg12963246	chr6:28129442	ZNF389	0.53	7.4	0.38	1.11e-12	Depression;
LUSC	cis	rs7582720	1.000	rs72934554	chr2:203987806	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.61	0.43	2.86e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	13.66	0.6	4.78e-34	Platelet count;
LUSC	cis	rs7818345	0.967	rs10107416	chr8:19286253	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.35	-6.73	-0.35	7.58e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs7572644	0.699	rs6708889	chr2:28107692	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-6.86	-0.35	3.4e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg23436779	chr17:56769830	TEX14;RAD51C	-0.47	-5.82	-0.3	1.37e-8	Cognitive test performance;
LUSC	cis	rs10887741	0.624	rs9633742	chr10:89432286	A/G	cg13926569	chr10:89418898	PAPSS2	0.34	7.35	0.37	1.55e-12	Exercise (leisure time);
LUSC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	ch.11.42038R	chr11:967971	AP2A2	0.53	7.83	0.39	6.49e-14	Alzheimer's disease (late onset);
LUSC	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.65	10.16	0.49	2.68e-21	Alcohol dependence;
LUSC	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg23752985	chr2:85803571	VAMP8	-0.37	-7.95	-0.4	2.81e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.63	9.21	0.45	3.76e-18	Menarche (age at onset);
LUSC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	8.84	0.44	5.72e-17	Prudent dietary pattern;
LUSC	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg23950597	chr19:37808831	NA	-0.56	-6.57	-0.34	1.88e-10	Coronary artery calcification;
LUSC	trans	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg26384229	chr12:38710491	ALG10B	0.57	9.05	0.44	1.16e-17	Morning vs. evening chronotype;
LUSC	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg27411982	chr8:10470053	RP1L1	-0.54	-8.98	-0.44	1.95e-17	Neuroticism;
LUSC	cis	rs4654899	0.758	rs7556221	chr1:21455559	C/G	cg01072550	chr1:21505969	NA	-0.52	-8.01	-0.4	1.87e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10905065	0.861	rs10752069	chr10:5752403	A/G	cg11519256	chr10:5708881	ASB13	0.41	5.96	0.31	6.51e-9	Menopause (age at onset);
LUSC	cis	rs1595825	0.732	rs10198804	chr2:198461941	A/C	cg00982548	chr2:198649783	BOLL	-0.51	-6.46	-0.33	3.65e-10	Ulcerative colitis;
LUSC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg06096015	chr1:231504339	EGLN1	0.57	10.04	0.48	6.89e-21	Hemoglobin concentration;
LUSC	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg22153463	chr1:85462885	MCOLN2	-0.71	-9.59	-0.46	2.18e-19	Serum sulfate level;
LUSC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26314531	chr2:26401878	FAM59B	0.68	7.99	0.4	2.15e-14	Gut microbiome composition (summer);
LUSC	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg22709100	chr7:91322751	NA	-0.41	-5.92	-0.31	7.79e-9	Breast cancer;
LUSC	cis	rs3741151	1.000	rs75114310	chr11:73042047	C/T	cg17517138	chr11:73019481	ARHGEF17	1.15	9.74	0.47	7e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.42	-6.2	-0.32	1.69e-9	IgG glycosylation;
LUSC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg16240275	chr20:61666158	NCRNA00029	0.41	9.2	0.45	4.06e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.4	5.99	0.31	5.39e-9	Menopause (age at onset);
LUSC	cis	rs12931792	0.712	rs56399904	chr16:30166183	C/T	cg17640201	chr16:30407289	ZNF48	0.54	8.51	0.42	5.89e-16	Tonsillectomy;
LUSC	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg16099169	chr2:106886729	NA	-0.55	-7.08	-0.36	8.48e-12	Facial morphology (factor 23);
LUSC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs929596	0.564	rs2741028	chr2:234518914	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-6.37	-0.33	6.31e-10	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg24631222	chr15:78858424	CHRNA5	-0.65	-8.82	-0.43	6.63e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.89	15.27	0.64	2.63e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg13319975	chr6:146136371	FBXO30	0.48	7.3	0.37	2.09e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg15704280	chr7:45808275	SEPT13	0.64	7.23	0.37	3.22e-12	Axial length;
LUSC	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	10.02	0.48	7.9e-21	Lymphocyte counts;
LUSC	trans	rs7939886	0.920	rs2460212	chr11:55886155	C/T	cg15704280	chr7:45808275	SEPT13	-0.73	-6.2	-0.32	1.63e-9	Myopia (pathological);
LUSC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg13685833	chr1:53393034	SCP2	0.4	6.09	0.32	3.18e-9	Monocyte count;
LUSC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg00599273	chr12:58146742	CDK4	0.31	5.86	0.31	1.14e-8	Multiple sclerosis;
LUSC	cis	rs9549260	0.753	rs61963266	chr13:41171036	G/A	cg21288729	chr13:41239152	FOXO1	0.53	5.99	0.31	5.38e-9	Red blood cell count;
LUSC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.69	-0.34	9.49e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg07701084	chr6:150067640	NUP43	0.58	9.04	0.44	1.31e-17	Lung cancer;
LUSC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg03709012	chr19:19516395	GATAD2A	0.52	6.07	0.32	3.54e-9	Tonsillectomy;
LUSC	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	7.89	0.4	4.26e-14	Breast cancer;
LUSC	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.71	-11.91	-0.55	1.7e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs868036	0.958	rs3784709	chr15:68072275	C/T	cg05925327	chr15:68127851	NA	-0.32	-5.7	-0.3	2.57e-8	Restless legs syndrome;
LUSC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	6.01	0.31	4.85e-9	Tonsillectomy;
LUSC	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.59	0.5	8.82e-23	Colorectal cancer;
LUSC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.78	0.35	5.46e-11	Tonsillectomy;
LUSC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg05347473	chr6:146136440	FBXO30	0.49	8.22	0.41	4.64e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05901451	chr6:126070800	HEY2	0.57	8.56	0.42	4.25e-16	Endometrial cancer;
LUSC	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	5.71	0.3	2.51e-8	Breast cancer;
LUSC	cis	rs7707921	0.757	rs226198	chr5:81573992	C/T	cg15871215	chr5:81402204	ATG10	0.42	5.93	0.31	7.74e-9	Breast cancer;
LUSC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg24154853	chr7:158122151	PTPRN2	0.45	8.72	0.43	1.34e-16	Calcium levels;
LUSC	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.61	8.32	0.41	2.22e-15	Adiposity;
LUSC	cis	rs11229555	0.874	rs10896787	chr11:58285494	G/T	cg15696309	chr11:58395628	NA	-0.71	-8.88	-0.44	4.11e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.65	-10.06	-0.48	5.59e-21	Longevity;Endometriosis;
LUSC	cis	rs2109514	0.902	rs926197	chr7:116118330	A/C	cg12739419	chr7:116140593	CAV2	0.26	5.76	0.3	1.86e-8	Prevalent atrial fibrillation;
LUSC	cis	rs9399401	0.961	rs9389984	chr6:142652344	C/T	cg03128060	chr6:142623767	GPR126	0.32	5.8	0.3	1.56e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs7202877	0.706	rs1540	chr16:75481185	G/C	cg04384234	chr16:75411784	CFDP1	0.68	8.96	0.44	2.36e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.74	-0.51	2.59e-23	Chronic sinus infection;
LUSC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg15790184	chr11:494944	RNH1	0.57	6.13	0.32	2.43e-9	Body mass index;
LUSC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg22618164	chr12:122356400	WDR66	0.63	9.15	0.45	5.7e-18	Mean corpuscular volume;
LUSC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-7.85	-0.39	5.8e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg06028605	chr16:24865363	SLC5A11	0.68	9.5	0.46	4.3e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs1881396	0.947	rs8731	chr2:27873326	C/G	cg27432699	chr2:27873401	GPN1	0.64	8.61	0.43	3.03e-16	Nonalcoholic fatty liver disease;
LUSC	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg08017756	chr2:100939284	LONRF2	-0.43	-8.29	-0.41	2.76e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg17470723	chr8:74884337	TCEB1	0.52	8.19	0.41	5.44e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4462272	0.503	rs11593131	chr10:101843608	G/A	cg02250046	chr10:101825185	CPN1	-0.31	-5.72	-0.3	2.4e-8	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-6.64	-0.34	1.26e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg15252948	chr8:42698594	THAP1	0.5	6.07	0.32	3.41e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7106204	0.609	rs11821417	chr11:24279139	G/T	ch.11.24196551F	chr11:24239977	NA	0.72	5.97	0.31	6.08e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg17567195	chr5:167378696	ODZ2	-0.38	-6.03	-0.31	4.23e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg27539214	chr16:67997921	SLC12A4	-0.5	-6.72	-0.35	7.83e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.72	-13.42	-0.59	3.74e-33	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.33	0.37	1.8e-12	Motion sickness;
LUSC	cis	rs9296095	0.632	rs6914422	chr6:33534880	A/G	cg14003231	chr6:33640908	ITPR3	-0.39	-6.74	-0.35	6.77e-11	Platelet count;
LUSC	cis	rs7830933	0.780	rs6983481	chr8:23609009	G/T	cg04349084	chr8:23602677	NA	0.35	5.7	0.3	2.67e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUSC	cis	rs34638657	0.732	rs11859473	chr16:82201072	T/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.33	-0.33	7.89e-10	Lung adenocarcinoma;
LUSC	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.58	-0.42	3.56e-16	Systolic blood pressure;
LUSC	cis	rs9463078	0.547	rs1338908	chr6:44728812	C/T	cg25276700	chr6:44698697	NA	0.3	6.3	0.33	9.28e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.38	0.33	5.99e-10	Bipolar disorder;
LUSC	trans	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg19894588	chr14:64061835	NA	-0.55	-7.3	-0.37	2.1e-12	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg17366294	chr4:99064904	C4orf37	0.47	8.02	0.4	1.79e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg02187348	chr16:89574699	SPG7	0.38	5.73	0.3	2.22e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13770153	chr20:60521292	NA	-0.62	-8.39	-0.42	1.36e-15	Body mass index;
LUSC	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.62	0.34	1.46e-10	Morning vs. evening chronotype;
LUSC	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg03585969	chr10:35415529	CREM	0.62	8.98	0.44	2.08e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4253772	0.938	rs11704979	chr22:46632994	G/A	cg09491104	chr22:46646882	C22orf40	-0.62	-6.62	-0.34	1.47e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11229555	1.000	rs2276153	chr11:58407740	C/G	cg15696309	chr11:58395628	NA	-0.68	-8.92	-0.44	3.06e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08645402	chr16:4508243	NA	0.5	8.56	0.42	4.25e-16	Schizophrenia;
LUSC	cis	rs9462027	0.628	rs6937314	chr6:34799308	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.79	-0.3	1.6e-8	Systemic lupus erythematosus;
LUSC	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg04362960	chr10:104952993	NT5C2	0.58	8.37	0.42	1.64e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg12292205	chr6:26970375	C6orf41	0.38	6.0	0.31	5.08e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg02569458	chr12:86230093	RASSF9	-0.37	-5.88	-0.31	9.77e-9	Major depressive disorder;
LUSC	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg04450456	chr4:17643702	FAM184B	-0.41	-6.53	-0.34	2.45e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	0.92	18.72	0.72	5.7e-54	Dental caries;
LUSC	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg19875535	chr5:140030758	IK	0.37	5.67	0.3	3.1e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2625529	0.556	rs1552134	chr15:72232898	T/A	cg16672083	chr15:72433130	SENP8	0.49	8.08	0.4	1.21e-14	Red blood cell count;
LUSC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	0.96	19.19	0.72	7.61e-56	Cognitive function;
LUSC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg16447950	chr5:562315	NA	-0.59	-7.08	-0.36	8.42e-12	Lung disease severity in cystic fibrosis;
LUSC	trans	rs7980799	1.000	rs7980799	chr12:33576990	A/C	cg26384229	chr12:38710491	ALG10B	-0.45	-6.48	-0.33	3.29e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs829880	1.000	rs829880	chr12:98845331	G/T	cg25150519	chr12:98850993	NA	0.68	10.78	0.51	1.96e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg07701084	chr6:150067640	NUP43	0.56	8.43	0.42	1.07e-15	Lung cancer;
LUSC	trans	rs9929218	1.000	rs12596061	chr16:68807828	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.09	-0.55	3.58e-28	Colorectal cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13511387	chr3:11760609	VGLL4	-0.42	-6.18	-0.32	1.82e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17709503	chr2:99347854	MGAT4A	-0.4	-6.02	-0.31	4.51e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg18129178	chr5:148520854	ABLIM3	-0.69	-10.62	-0.5	6.72e-23	Breast cancer;
LUSC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.95	15.19	0.64	5.71e-40	Coronary artery disease;
LUSC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06112835	chr11:68658793	MRPL21	0.52	7.93	0.4	3.43e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	1.07	17.61	0.69	1.52e-49	Parkinson's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25628257	chr11:61559992	C11orf10;FEN1;MIR611	-0.42	-6.24	-0.32	1.32e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg13206674	chr6:150067644	NUP43	0.6	9.67	0.47	1.13e-19	Lung cancer;
LUSC	cis	rs6669072	0.565	rs10801830	chr1:91272173	G/A	cg08895590	chr1:91227319	NA	-0.27	-5.81	-0.3	1.48e-8	Cognitive function;
LUSC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-6.34	-0.33	7.33e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg20790798	chr5:1857306	NA	-0.5	-8.58	-0.43	3.6e-16	Cardiovascular disease risk factors;
LUSC	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.76	-0.39	1.05e-13	Retinal vascular caliber;
LUSC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg01879757	chr17:41196368	BRCA1	-0.46	-6.97	-0.36	1.72e-11	Menopause (age at onset);
LUSC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.68	-0.3	2.93e-8	Tonsillectomy;
LUSC	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg02403541	chr12:121454288	C12orf43	-0.61	-8.8	-0.43	7.35e-17	N-glycan levels;
LUSC	cis	rs73206853	0.764	rs56128816	chr12:110775609	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg05707623	chr12:122985044	ZCCHC8	0.67	8.16	0.41	6.75e-15	Body mass index;
LUSC	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg11584989	chr19:19387371	SF4	0.57	6.88	0.35	2.92e-11	Bipolar disorder;
LUSC	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-6.88	-0.35	2.89e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9398803	0.865	rs1907067	chr6:126837663	A/C	cg19875578	chr6:126661172	C6orf173	0.41	6.11	0.32	2.84e-9	Male-pattern baldness;
LUSC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg27284194	chr4:1044797	NA	0.39	6.3	0.33	9.25e-10	Longevity;
LUSC	cis	rs1030877	0.515	rs2576741	chr2:105897964	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.67	9.22	0.45	3.35e-18	Obesity-related traits;
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-8.0	-0.4	2.05e-14	Lymphocyte counts;
LUSC	cis	rs739496	0.542	rs7300400	chr12:111792179	A/C	cg10833066	chr12:111807467	FAM109A	0.61	11.97	0.55	1.05e-27	Platelet count;
LUSC	cis	rs6692729	0.933	rs2855559	chr1:227080459	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.5	-7.09	-0.36	7.94e-12	Electrodermal activity;
LUSC	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg17507749	chr15:85114479	UBE2QP1	0.56	6.39	0.33	5.58e-10	Schizophrenia;
LUSC	cis	rs9467773	0.526	rs9348710	chr6:26360486	A/C	cg05738196	chr6:26577821	NA	-0.49	-7.55	-0.38	4.21e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg07810366	chr2:100720526	AFF3	0.44	7.66	0.39	2.04e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg19046167	chr17:80928561	B3GNTL1	0.39	6.39	0.33	5.45e-10	Breast cancer;
LUSC	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.86	-0.35	3.32e-11	Monocyte percentage of white cells;
LUSC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.56	-9.04	-0.44	1.33e-17	Tonsillectomy;
LUSC	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg00530320	chr1:46809349	NSUN4	0.58	8.51	0.42	5.83e-16	Menopause (age at onset);
LUSC	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg02223005	chr5:693632	TPPP	0.47	6.19	0.32	1.73e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-8.92	-0.44	3.06e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.36	-0.37	1.46e-12	Personality dimensions;
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg16393715	chr7:1948819	MAD1L1	0.35	6.1	0.32	2.9e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg21475434	chr5:93447410	FAM172A	-0.42	-6.01	-0.31	4.92e-9	Diabetic retinopathy;
LUSC	trans	rs4252134	0.801	rs62436702	chr6:161196562	T/C	cg15416064	chr12:49209402	NA	-0.45	-6.11	-0.32	2.73e-9	Giant cell arteritis;
LUSC	cis	rs8112211	0.911	rs2286475	chr19:38847431	T/C	cg14299480	chr19:38876666	GGN	-0.35	-5.94	-0.31	7.12e-9	Blood protein levels;
LUSC	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.77e-22	Eye color traits;
LUSC	cis	rs6840360	0.967	rs6535812	chr4:152599374	C/A	cg22705602	chr4:152727874	NA	-0.27	-5.7	-0.3	2.66e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2297440	0.527	rs4809318	chr20:62264760	G/A	cg09650180	chr20:62225654	GMEB2	-0.67	-9.67	-0.47	1.12e-19	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUSC	cis	rs4700695	0.841	rs448454	chr5:65293462	G/A	cg21114390	chr5:65439923	SFRS12	0.49	6.03	0.31	4.23e-9	Facial morphology (factor 19);
LUSC	cis	rs427941	0.668	rs201461	chr7:101741625	T/C	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg25428297	chr7:1022841	CYP2W1	0.29	6.24	0.32	1.29e-9	Longevity;Endometriosis;
LUSC	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg03806693	chr22:41940476	POLR3H	-0.54	-7.23	-0.37	3.39e-12	Neuroticism;
LUSC	cis	rs9549260	0.755	rs17061491	chr13:41228210	T/A	cg21288729	chr13:41239152	FOXO1	0.64	9.95	0.48	1.38e-20	Red blood cell count;
LUSC	cis	rs1395	1.000	rs3769143	chr2:27450724	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.39	-6.45	-0.33	3.89e-10	Blood metabolite levels;
LUSC	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.76	-0.39	1.02e-13	Total cholesterol levels;
LUSC	cis	rs17253792	0.822	rs74935793	chr14:56143277	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-6.72	-0.35	7.8e-11	Putamen volume;
LUSC	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.67	-0.34	1.04e-10	Resting heart rate;
LUSC	cis	rs2860975	0.967	rs11188134	chr10:96774255	G/C	cg09036531	chr10:96991505	NA	-0.41	-5.66	-0.3	3.26e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.11	-0.36	6.97e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg16928487	chr17:17741425	SREBF1	-0.33	-6.27	-0.32	1.11e-9	Total body bone mineral density;
LUSC	cis	rs1403694	0.655	rs3806688	chr3:186434819	T/C	cg12454167	chr3:186435060	KNG1	0.34	8.44	0.42	9.55e-16	Blood protein levels;
LUSC	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg07173049	chr1:7289937	CAMTA1	0.37	7.64	0.39	2.38e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs983392	0.792	rs525794	chr11:59903287	A/G	cg20284999	chr11:59952153	MS4A6A	-0.32	-5.66	-0.3	3.3e-8	Alzheimer's disease (late onset);
LUSC	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-1.16	-15.97	-0.66	4.56e-43	Hip circumference adjusted for BMI;
LUSC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg06740227	chr12:86229804	RASSF9	0.43	6.73	0.35	7.2e-11	Major depressive disorder;
LUSC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-0.9	-18.4	-0.71	1.04e-52	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg23711669	chr6:146136114	FBXO30	0.73	13.12	0.58	5.29e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11677416	0.601	rs12469600	chr2:113572357	T/C	cg27083787	chr2:113543245	IL1A	0.45	6.52	0.34	2.6e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	0.94	18.17	0.71	8.64e-52	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6669072	0.565	rs12567901	chr1:91266119	G/A	cg08895590	chr1:91227319	NA	-0.27	-5.78	-0.3	1.68e-8	Cognitive function;
LUSC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg07703079	chr11:430292	ANO9	0.64	6.51	0.34	2.78e-10	Body mass index;
LUSC	cis	rs9395066	0.545	rs7749865	chr6:44918406	T/C	cg25276700	chr6:44698697	NA	0.3	6.1	0.32	2.88e-9	Height;
LUSC	cis	rs2019216	0.542	rs1987424	chr17:21874036	G/A	cg22648282	chr17:21454238	C17orf51	-0.52	-7.68	-0.39	1.8e-13	Pelvic organ prolapse;
LUSC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	0.93	17.83	0.7	1.93e-50	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.29	0.41	2.71e-15	Ulcerative colitis;
LUSC	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg06552810	chr11:31128660	NA	-0.42	-7.34	-0.37	1.61e-12	Red blood cell count;
LUSC	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.51	7.38	0.37	1.26e-12	Coronary heart disease;
LUSC	cis	rs3916	0.688	rs9204	chr12:121177778	A/G	cg21892295	chr12:121157589	UNC119B	-0.39	-6.49	-0.33	3.02e-10	Urinary metabolites (H-NMR features);
LUSC	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg05163923	chr11:71159392	DHCR7	0.7	10.87	0.51	9.28e-24	Vitamin D levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17660026	chr22:41252631	XPNPEP3;ST13	-0.5	-6.18	-0.32	1.9e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9815354	0.812	rs73073234	chr3:42012071	C/T	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.5e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9420	0.961	rs7117205	chr11:57641883	A/G	cg23127183	chr11:57508653	C11orf31	-0.53	-7.73	-0.39	1.28e-13	Schizophrenia;
LUSC	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg11645453	chr3:52864694	ITIH4	0.49	11.37	0.53	1.57e-25	Schizophrenia;
LUSC	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg05973401	chr12:123451056	ABCB9	0.52	6.43	0.33	4.36e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.61	9.71	0.47	8.65e-20	Alcohol dependence;
LUSC	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	7.04	0.36	1.12e-11	Homocysteine levels;
LUSC	cis	rs3770081	1.000	rs12328085	chr2:86262009	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.8	-5.68	-0.3	2.96e-8	Facial emotion recognition (sad faces);
LUSC	cis	rs981844	0.857	rs62325139	chr4:154712213	C/T	cg14289246	chr4:154710475	SFRP2	0.48	6.05	0.31	3.9e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg23788917	chr6:8435910	SLC35B3	-0.49	-7.05	-0.36	1.03e-11	Motion sickness;
LUSC	cis	rs6494488	0.500	rs67108203	chr15:65005952	C/T	cg08069370	chr15:64387884	SNX1	-0.61	-5.75	-0.3	1.98e-8	Coronary artery disease;
LUSC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10802521	chr3:52805072	NEK4	-0.56	-8.94	-0.44	2.71e-17	Bipolar disorder;
LUSC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg25456477	chr12:86230367	RASSF9	0.44	7.83	0.39	6.31e-14	Major depressive disorder;
LUSC	cis	rs1506636	1.000	rs615410	chr7:123437765	T/C	cg03229431	chr7:123269106	ASB15	0.64	10.43	0.5	3.15e-22	Plateletcrit;Platelet count;
LUSC	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg24375607	chr4:120327624	NA	0.75	11.09	0.52	1.57e-24	Corneal astigmatism;
LUSC	cis	rs6484504	0.600	rs10835763	chr11:31345574	G/A	cg06552810	chr11:31128660	NA	0.39	6.87	0.35	3.24e-11	Red blood cell count;
LUSC	cis	rs4144743	1.000	rs2317384	chr17:45329770	G/A	cg18085866	chr17:45331354	ITGB3	-0.74	-7.72	-0.39	1.38e-13	Body mass index;
LUSC	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg21521518	chr4:53727714	RASL11B	0.46	6.1	0.32	2.99e-9	Optic nerve measurement (cup area);
LUSC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg11752832	chr7:134001865	SLC35B4	0.56	8.79	0.43	7.94e-17	Mean platelet volume;
LUSC	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg27661571	chr11:113659931	NA	-0.53	-6.52	-0.34	2.65e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs12594515	1.000	rs12185095	chr15:45994635	G/T	cg01629716	chr15:45996671	NA	0.39	5.86	0.31	1.14e-8	Waist circumference;Weight;
LUSC	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg15744005	chr10:104629667	AS3MT	0.35	7.13	0.36	6.16e-12	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg16797656	chr11:68205561	LRP5	0.37	6.16	0.32	2.13e-9	Total body bone mineral density;
LUSC	cis	rs75920871	0.528	rs7484045	chr11:116946890	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.6	-0.34	1.65e-10	Subjective well-being;
LUSC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.99	-0.4	2.16e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01570182	chr17:44337453	NA	-0.66	-9.84	-0.47	3.08e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs12900413	0.687	rs12911196	chr15:90310734	G/C	cg24249390	chr15:90295951	MESP1	-0.37	-5.85	-0.3	1.17e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs6084875	0.840	rs6052816	chr20:4725086	T/C	cg07258627	chr20:4721683	PRNT	-0.35	-6.21	-0.32	1.57e-9	Systemic lupus erythematosus;
LUSC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.98	0.31	5.65e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg10523679	chr1:76189770	ACADM	-0.48	-7.0	-0.36	1.42e-11	Daytime sleep phenotypes;
LUSC	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg17764715	chr19:33622953	WDR88	0.6	8.23	0.41	4.15e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	10.66	0.5	5.11e-23	Coronary artery disease;
LUSC	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg20487152	chr13:99095054	FARP1	-0.41	-6.95	-0.36	1.97e-11	Longevity;
LUSC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.83	-10.29	-0.49	9.28e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg11764359	chr7:65958608	NA	-0.68	-10.33	-0.49	6.65e-22	Aortic root size;
LUSC	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg17173187	chr15:85201210	NMB	0.47	8.9	0.44	3.57e-17	Schizophrenia;
LUSC	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg25237894	chr2:233734115	C2orf82	0.34	6.23	0.32	1.43e-9	Coronary artery disease;
LUSC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg16325326	chr1:53192061	ZYG11B	-0.76	-12.81	-0.57	7.68e-31	Monocyte count;
LUSC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	13.5	0.59	1.88e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs9942416	0.601	rs114547168	chr5:74991903	A/G	cg19683494	chr5:74908142	NA	0.43	6.65	0.34	1.21e-10	Age-related disease endophenotypes;
LUSC	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg18132916	chr6:79620363	NA	0.39	5.91	0.31	8.56e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06481639	chr22:41940642	POLR3H	-0.51	-6.17	-0.32	1.98e-9	Vitiligo;
LUSC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg20608306	chr11:116969690	SIK3	0.4	6.74	0.35	7.08e-11	Blood protein levels;
LUSC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg15605315	chr1:45957053	TESK2	0.5	8.48	0.42	7.38e-16	High light scatter reticulocyte count;
LUSC	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg17366294	chr4:99064904	C4orf37	0.51	8.12	0.41	9.3e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg20607287	chr7:12443886	VWDE	-0.65	-6.48	-0.33	3.37e-10	Coronary artery disease;
LUSC	cis	rs6574644	1.000	rs4903977	chr14:81772095	T/C	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs1775715	0.707	rs2808087	chr10:32146444	C/G	cg03015672	chr10:32216066	ARHGAP12	0.35	6.39	0.33	5.5e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs17253792	0.822	rs45501402	chr14:56140115	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-6.72	-0.35	7.8e-11	Putamen volume;
LUSC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg24296786	chr1:45957014	TESK2	0.47	6.91	0.35	2.51e-11	High light scatter reticulocyte count;
LUSC	cis	rs7119	0.651	rs12902948	chr15:77849254	T/C	cg27398640	chr15:77910606	LINGO1	-0.34	-7.06	-0.36	9.97e-12	Type 2 diabetes;
LUSC	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.29	0.64	2.16e-40	Morning vs. evening chronotype;
LUSC	trans	rs7243066	0.529	rs1391471	chr18:11297066	A/G	cg26633107	chr2:14774086	FAM84A	-0.43	-6.07	-0.32	3.49e-9	Dental caries;
LUSC	cis	rs16910800	0.689	rs7128636	chr11:23164689	C/T	cg20040320	chr11:23191996	NA	-0.6	-7.58	-0.38	3.55e-13	Cancer;
LUSC	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08704250	chr15:31115839	NA	-0.45	-6.36	-0.33	6.57e-10	Huntington's disease progression;
LUSC	cis	rs6574644	1.000	rs1957545	chr14:81772981	C/G	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg05775895	chr3:12838266	CAND2	0.49	7.42	0.38	9.85e-13	QRS complex (12-leadsum);
LUSC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.22	0.32	1.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4363385	0.818	rs1415969	chr1:153006448	G/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.44e-12	Inflammatory skin disease;
LUSC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg05347473	chr6:146136440	FBXO30	0.5	8.45	0.42	8.8e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-20.32	-0.74	2.4e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-7.81	-0.39	7.63e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg07274523	chr3:49395745	GPX1	0.67	10.52	0.5	1.5e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.81	-14.25	-0.61	2.54e-36	Sudden cardiac arrest;
LUSC	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.85	0.47	2.88e-20	Lymphocyte counts;
LUSC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.86	0.51	1e-23	Schizophrenia;
LUSC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24110177	chr3:50126178	RBM5	-0.61	-10.46	-0.5	2.42e-22	Body mass index;
LUSC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23158103	chr7:148848205	ZNF398	-0.45	-7.28	-0.37	2.41e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg05084668	chr3:125655381	ALG1L	-0.48	-6.79	-0.35	5.06e-11	Blood pressure (smoking interaction);
LUSC	cis	rs7799006	0.895	rs3757437	chr7:2271980	C/T	cg12745145	chr7:2261452	MAD1L1	-0.29	-5.76	-0.3	1.88e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Depression;
LUSC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg17554472	chr22:41940697	POLR3H	0.49	5.98	0.31	5.86e-9	Vitiligo;
LUSC	cis	rs12410462	0.681	rs113316536	chr1:227547033	T/G	cg23173402	chr1:227635558	NA	0.55	6.39	0.33	5.42e-10	Major depressive disorder;
LUSC	cis	rs10740039	0.883	rs1867081	chr10:62386327	A/G	cg18175470	chr10:62150864	ANK3	-0.47	-7.0	-0.36	1.42e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg05863683	chr7:1912471	MAD1L1	0.3	5.69	0.3	2.74e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg11218175	chr11:495084	RNH1	0.53	5.71	0.3	2.51e-8	Body mass index;
LUSC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg22868518	chr11:507468	RNH1	-0.64	-5.85	-0.3	1.19e-8	Body mass index;
LUSC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg23985595	chr17:80112537	CCDC57	0.31	5.87	0.31	1.08e-8	Life satisfaction;
LUSC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.62	-0.5	6.83e-23	Alzheimer's disease;
LUSC	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg11812906	chr14:75593930	NEK9	0.66	11.37	0.53	1.56e-25	Height;
LUSC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.59e-9	Menopause (age at onset);
LUSC	cis	rs10911363	0.592	rs2702203	chr1:183462513	A/T	cg09173681	chr1:183549694	NCF2	0.66	12.24	0.56	1.08e-28	Systemic lupus erythematosus;
LUSC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.17	-0.37	4.74e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg06784218	chr1:46089804	CCDC17	-0.31	-6.17	-0.32	2.02e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs11630290	0.639	rs6494442	chr15:64166891	A/G	cg12036633	chr15:63758958	NA	0.5	6.06	0.31	3.73e-9	Iris characteristics;
LUSC	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg04586622	chr2:25135609	ADCY3	-0.43	-9.2	-0.45	4.07e-18	Body mass index;
LUSC	cis	rs877282	0.853	rs12777155	chr10:754731	G/C	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg03036452	chr22:46663545	TTC38	0.52	5.7	0.3	2.62e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg01416388	chr22:39784598	NA	-0.44	-7.31	-0.37	1.97e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2067615	0.507	rs10746064	chr12:107086245	G/T	cg15890332	chr12:107067104	RFX4	0.35	6.13	0.32	2.51e-9	Heart rate;
LUSC	cis	rs983392	0.678	rs1562990	chr11:60023087	C/A	cg02771260	chr11:59836817	MS4A3	0.36	5.93	0.31	7.76e-9	Alzheimer's disease (late onset);
LUSC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.11	0.32	2.79e-9	Schizophrenia;
LUSC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg09877947	chr5:131593287	PDLIM4	0.47	7.31	0.37	2.05e-12	Acylcarnitine levels;
LUSC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg05347473	chr6:146136440	FBXO30	-0.6	-10.6	-0.5	7.93e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg16359550	chr11:109292809	C11orf87	0.35	6.05	0.31	3.96e-9	Schizophrenia;
LUSC	cis	rs13082711	0.911	rs74279676	chr3:27512944	G/A	cg02860705	chr3:27208620	NA	0.49	8.2	0.41	5.1e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg24687543	chr11:63912206	MACROD1	0.44	5.87	0.31	1.07e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04125625	chr1:29564120	PTPRU	0.5	7.06	0.36	9.96e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs534126	1.000	rs9918515	chr7:142922662	C/T	cg04039957	chr7:143013207	CLCN1	-0.31	-6.0	-0.31	5.15e-9	Cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06064461	chr2:176032401	ATF2;MIR933	0.58	8.3	0.41	2.69e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03264133	chr6:25882463	NA	-0.5	-9.15	-0.45	5.97e-18	Blood metabolite levels;
LUSC	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg05340658	chr4:99064831	C4orf37	0.6	8.9	0.44	3.64e-17	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.11	0.41	9.89e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg02466173	chr16:30829666	NA	-0.56	-11.18	-0.52	7.23e-25	Dementia with Lewy bodies;
LUSC	cis	rs6580649	0.771	rs1034762	chr12:48389643	G/T	cg05342945	chr12:48394962	COL2A1	0.44	5.88	0.31	1.02e-8	Lung cancer;
LUSC	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg09491104	chr22:46646882	C22orf40	-0.66	-6.67	-0.34	1.06e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg04455712	chr21:45112962	RRP1B	0.46	8.7	0.43	1.58e-16	Mean corpuscular volume;
LUSC	cis	rs2279817	0.955	rs2270978	chr1:18023365	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.52	7.38	0.37	1.27e-12	Neuroticism;
LUSC	trans	rs198712	0.505	rs198319	chr7:24188766	T/C	cg06529468	chr19:10676722	KRI1	0.38	6.1	0.32	2.98e-9	Aggressive periodontitis (sex interaction);
LUSC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.65	-10.05	-0.48	6.28e-21	Menarche (age at onset);
LUSC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg23630131	chr7:65973040	NA	-0.2	-5.64	-0.3	3.55e-8	Aortic root size;
LUSC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg04450456	chr4:17643702	FAM184B	0.39	6.48	0.33	3.28e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg20243544	chr17:37824526	PNMT	0.52	7.41	0.38	1.02e-12	Asthma;
LUSC	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	7.42	0.38	9.78e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs662735	0.515	rs113026	chr11:30846842	G/A	cg14844989	chr11:31128820	NA	0.37	5.78	0.3	1.74e-8	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg12826209	chr6:26865740	GUSBL1	0.69	7.67	0.39	1.86e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.45	0.33	3.9e-10	Alzheimer's disease (late onset);
LUSC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg14583973	chr4:3374767	RGS12	0.38	8.0	0.4	2.01e-14	Serum sulfate level;
LUSC	cis	rs983392	0.803	rs56189574	chr11:59933492	A/G	cg20284999	chr11:59952153	MS4A6A	-0.36	-6.2	-0.32	1.63e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg20406979	chr6:167373233	NA	-0.26	-6.09	-0.32	3.09e-9	Crohn's disease;
LUSC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	0.91	18.67	0.71	9.05e-54	Dental caries;
LUSC	cis	rs10419226	0.555	rs3829671	chr19:18777667	T/C	cg22001208	chr19:18782374	NA	-0.38	-6.33	-0.33	7.77e-10	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Schizophrenia;
LUSC	cis	rs877282	0.583	rs11253425	chr10:815173	G/A	cg13775593	chr10:823151	NA	0.29	5.77	0.3	1.85e-8	Uric acid levels;
LUSC	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg19743168	chr1:23544995	NA	0.39	7.2	0.37	4.01e-12	Height;
LUSC	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg00191853	chr8:101177733	SPAG1	-0.39	-6.47	-0.33	3.49e-10	Atrioventricular conduction;
LUSC	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg19682013	chr15:45996608	NA	-0.39	-5.96	-0.31	6.31e-9	Waist circumference;Weight;
LUSC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg16447950	chr5:562315	NA	-0.52	-6.88	-0.35	3e-11	Obesity-related traits;
LUSC	trans	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg04995722	chr7:26192034	NFE2L3	-0.39	-6.01	-0.31	4.84e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10248839	0.518	rs34011864	chr7:29698499	G/A	cg19413766	chr7:29689036	LOC646762	-0.55	-7.41	-0.38	1.07e-12	Facial emotion recognition (angry faces);
LUSC	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg13010199	chr12:38710504	ALG10B	-0.55	-8.69	-0.43	1.69e-16	Morning vs. evening chronotype;
LUSC	cis	rs9653442	0.545	rs10496344	chr2:100764125	C/T	cg07810366	chr2:100720526	AFF3	0.45	7.72	0.39	1.36e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg14458575	chr2:238380390	NA	0.72	12.94	0.58	2.6e-31	Prostate cancer;
LUSC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-6.91	-0.35	2.47e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs67366981	0.841	rs55903932	chr14:77706389	T/C	cg22824376	chr14:77648248	TMEM63C	0.84	7.56	0.38	3.96e-13	Obsessive-compulsive symptoms;
LUSC	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg24375607	chr4:120327624	NA	0.74	11.0	0.52	3.27e-24	Corneal astigmatism;
LUSC	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg05768032	chr16:30646687	NA	0.4	5.96	0.31	6.32e-9	Multiple myeloma;
LUSC	cis	rs1595825	0.735	rs16827465	chr2:198945680	G/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.57	-0.34	1.88e-10	Ulcerative colitis;
LUSC	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg09408571	chr1:101003634	GPR88	0.35	6.93	0.35	2.23e-11	Monocyte count;
LUSC	trans	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg07393940	chr7:158741817	NA	0.53	8.39	0.42	1.36e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.77	-13.2	-0.59	2.57e-32	Height;
LUSC	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07080220	chr10:102295463	HIF1AN	0.66	9.05	0.44	1.17e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg00277334	chr10:82204260	NA	-0.52	-7.5	-0.38	5.66e-13	Post bronchodilator FEV1;
LUSC	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.65	-0.34	1.17e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg08027265	chr7:2291960	NA	-0.38	-6.25	-0.32	1.29e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	13.0	0.58	1.45e-31	Total body bone mineral density;
LUSC	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.37	0.33	6.33e-10	IgG glycosylation;
LUSC	cis	rs4380275	0.931	rs4538239	chr2:774238	C/T	cg21665850	chr2:731073	NA	0.42	6.75	0.35	6.49e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg05855489	chr10:104503620	C10orf26	-0.66	-8.34	-0.42	2.01e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs73001065	0.818	rs73004966	chr19:19716558	C/T	cg03709012	chr19:19516395	GATAD2A	0.89	7.18	0.37	4.56e-12	LDL cholesterol;
LUSC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.37	5.65	0.3	3.41e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.42	0.38	9.97e-13	Bipolar disorder;
LUSC	cis	rs7241530	0.662	rs7244039	chr18:75906601	T/C	cg14642773	chr18:75888474	NA	0.39	5.96	0.31	6.32e-9	Educational attainment (years of education);
LUSC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.69	-0.39	1.64e-13	Type 2 diabetes;
LUSC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00684032	chr4:1343700	KIAA1530	0.37	6.51	0.34	2.82e-10	Obesity-related traits;
LUSC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.84	-0.3	1.23e-8	Total body bone mineral density;
LUSC	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg04362960	chr10:104952993	NT5C2	1.1	12.9	0.58	3.57e-31	Arsenic metabolism;
LUSC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg05347473	chr6:146136440	FBXO30	0.51	8.52	0.42	5.7e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.88	0.6	6.55e-35	Cognitive test performance;
LUSC	cis	rs2692947	0.702	rs7604842	chr2:96777340	C/T	cg23100626	chr2:96804247	ASTL	-0.28	-6.58	-0.34	1.82e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg11663144	chr21:46675770	NA	-0.42	-7.38	-0.37	1.3e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	7.33	0.37	1.74e-12	Menarche (age at onset);
LUSC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg19912559	chr1:40204330	PPIE	0.53	8.18	0.41	6.17e-15	Blood protein levels;
LUSC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06505273	chr16:24850292	NA	0.4	5.65	0.3	3.43e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.73	12.14	0.55	2.45e-28	Alcohol dependence;
LUSC	cis	rs12891047	0.899	rs11847628	chr14:68284075	G/T	cg20999565	chr14:68265668	ZFYVE26	0.37	5.69	0.3	2.82e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.02	20.37	0.74	1.57e-60	Cognitive function;
LUSC	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg27284194	chr4:1044797	NA	0.6	9.03	0.44	1.43e-17	Recombination rate (females);
LUSC	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	5.96	0.31	6.32e-9	IgG glycosylation;
LUSC	cis	rs9473147	0.843	rs6904933	chr6:47628558	G/A	cg12968598	chr6:47444699	CD2AP	0.38	5.69	0.3	2.8e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs34891900	0.507	rs2535707	chr22:18181869	C/T	cg08824373	chr22:18117835	NA	0.42	6.36	0.33	6.45e-10	Sum neutrophil eosinophil counts;
LUSC	cis	rs73198271	0.960	rs73198287	chr8:8612786	C/T	cg01851573	chr8:8652454	MFHAS1	0.59	8.28	0.41	2.93e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg08499158	chr17:42289980	UBTF	-0.49	-8.24	-0.41	4.03e-15	Total body bone mineral density;
LUSC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg24675658	chr1:53192096	ZYG11B	0.58	9.11	0.45	7.6e-18	Monocyte count;
LUSC	cis	rs977987	0.931	rs1834013	chr16:75496163	G/T	cg03315344	chr16:75512273	CHST6	0.57	11.13	0.52	1.07e-24	Dupuytren's disease;
LUSC	cis	rs12210905	0.925	rs12212317	chr6:26986553	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.98	-0.31	5.84e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7707921	0.881	rs73134747	chr5:81378294	C/T	cg15871215	chr5:81402204	ATG10	-0.43	-6.25	-0.32	1.24e-9	Breast cancer;
LUSC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg00990874	chr7:1149470	C7orf50	-0.55	-6.92	-0.35	2.38e-11	Bronchopulmonary dysplasia;
LUSC	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.58	-0.34	1.86e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs290268	0.838	rs1319677	chr9:93565999	A/G	cg02608019	chr9:93564028	SYK	0.54	9.48	0.46	5.07e-19	Platelet count;
LUSC	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.56	0.6	1.12e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.89	-15.03	-0.64	2.24e-39	Schizophrenia;
LUSC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	9.65	0.47	1.37e-19	Height;
LUSC	cis	rs34891900	0.507	rs2535679	chr22:18202850	A/G	cg19898043	chr22:18121309	BCL2L13	0.38	5.85	0.3	1.19e-8	Sum neutrophil eosinophil counts;
LUSC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19717773	chr7:2847554	GNA12	-0.39	-6.19	-0.32	1.78e-9	Height;
LUSC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg22834771	chr12:69754056	YEATS4	-0.54	-8.08	-0.4	1.23e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9487051	0.773	rs421790	chr6:109543428	T/A	cg00509249	chr6:109615579	CCDC162	-0.34	-5.81	-0.3	1.42e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg16701003	chr16:89028210	CBFA2T3	0.35	6.18	0.32	1.86e-9	Social autistic-like traits;
LUSC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.45	-7.45	-0.38	7.79e-13	Pulse pressure;
LUSC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg16584290	chr5:462447	EXOC3	0.45	8.09	0.4	1.09e-14	Cystic fibrosis severity;
LUSC	cis	rs3087591	0.708	rs7505	chr17:29644852	G/A	cg24425628	chr17:29625626	OMG;NF1	0.45	6.86	0.35	3.32e-11	Hip circumference;
LUSC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg14558114	chr2:88469736	THNSL2	0.8	7.13	0.36	6.19e-12	Plasma clusterin levels;
LUSC	trans	rs2587949	0.615	rs795293	chr3:4185953	C/T	cg15139668	chr4:4577005	NA	-0.43	-6.2	-0.32	1.68e-9	Periodontitis (DPAL);
LUSC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	6.41	0.33	4.97e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	12.5	0.56	1.09e-29	Hip circumference adjusted for BMI;
LUSC	trans	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.78	0.51	1.86e-23	Mean corpuscular volume;
LUSC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg16928487	chr17:17741425	SREBF1	-0.37	-7.11	-0.36	7.27e-12	Total body bone mineral density;
LUSC	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.77	-13.7	-0.6	3.33e-34	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg19077165	chr18:44547161	KATNAL2	0.45	6.68	0.34	9.9e-11	Personality dimensions;
LUSC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg13902645	chr11:5959945	NA	-0.53	-8.1	-0.41	1.03e-14	DNA methylation (variation);
LUSC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg02428538	chr16:24856791	SLC5A11	-0.52	-5.98	-0.31	5.74e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg13010199	chr12:38710504	ALG10B	0.56	7.68	0.39	1.76e-13	Resting heart rate;
LUSC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	16.33	0.67	1.77e-44	Platelet count;
LUSC	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg05110241	chr16:68378359	PRMT7	-0.62	-6.65	-0.34	1.22e-10	Schizophrenia;
LUSC	cis	rs1030877	0.515	rs3828300	chr2:105901107	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.67	-8.08	-0.4	1.22e-14	Obesity-related traits;
LUSC	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.81	-0.43	7.2e-17	Monocyte percentage of white cells;
LUSC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	9.02	0.44	1.56e-17	Total body bone mineral density;
LUSC	cis	rs6977660	0.714	rs10252965	chr7:19822385	A/C	cg05791153	chr7:19748676	TWISTNB	0.64	6.74	0.35	6.97e-11	Thyroid stimulating hormone;
LUSC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18357526	chr6:26021779	HIST1H4A	0.37	5.86	0.31	1.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg20790798	chr5:1857306	NA	-0.5	-8.7	-0.43	1.52e-16	Cardiovascular disease risk factors;
LUSC	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-9.78	-0.47	4.92e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg21132104	chr15:45694354	SPATA5L1	0.57	8.19	0.41	5.77e-15	Homoarginine levels;
LUSC	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg11584989	chr19:19387371	SF4	0.68	8.02	0.4	1.86e-14	Bipolar disorder;
LUSC	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg06002616	chr8:101225028	SPAG1	-0.41	-6.82	-0.35	4.37e-11	Atrioventricular conduction;
LUSC	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg23093090	chr10:104574429	C10orf26	-0.34	-6.43	-0.33	4.52e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08724901	chr15:89089781	DET1	-0.44	-6.2	-0.32	1.62e-9	Hepatitis;
LUSC	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg13010199	chr12:38710504	ALG10B	0.68	10.76	0.51	2.25e-23	Bladder cancer;
LUSC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg20302342	chr1:156215951	PAQR6	0.32	6.17	0.32	1.99e-9	Tonsillectomy;
LUSC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg11752832	chr7:134001865	SLC35B4	0.6	9.52	0.46	3.57e-19	Mean platelet volume;
LUSC	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.65	10.82	0.51	1.38e-23	Alcohol dependence;
LUSC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	12.22	0.56	1.18e-28	Colorectal cancer;
LUSC	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg08213375	chr14:104286397	PPP1R13B	0.38	6.31	0.33	8.61e-10	Reticulocyte count;
LUSC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.49	7.33	0.37	1.79e-12	Renal function-related traits (BUN);
LUSC	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-16.42	-0.67	8.09e-45	Primary sclerosing cholangitis;
LUSC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg04317338	chr11:64019027	PLCB3	0.64	7.33	0.37	1.77e-12	Mean platelet volume;
LUSC	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.88	0.31	9.87e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-0.58	-9.19	-0.45	4.34e-18	Breast cancer;
LUSC	cis	rs2692947	0.673	rs2692894	chr2:96784934	T/G	cg23100626	chr2:96804247	ASTL	-0.3	-7.14	-0.36	6e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	1.0	14.01	0.61	2.08e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs4891159	0.527	rs690593	chr18:74160408	C/G	cg24786174	chr18:74118243	ZNF516	0.87	17.23	0.69	4.8e-48	Longevity;
LUSC	cis	rs7759001	0.857	rs4305708	chr6:27372303	T/G	cg18711553	chr6:27366782	ZNF391	0.39	5.73	0.3	2.25e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.63	8.41	0.42	1.21e-15	High light scatter reticulocyte count;
LUSC	cis	rs16854884	0.770	rs6782024	chr3:143816936	G/C	cg06585982	chr3:143692056	C3orf58	0.45	6.69	0.34	9.28e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg10909506	chr17:38081995	ORMDL3	0.34	6.07	0.32	3.55e-9	Self-reported allergy;
LUSC	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	0.57	9.09	0.45	8.87e-18	Breast cancer;
LUSC	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.45	-6.62	-0.34	1.42e-10	Immature fraction of reticulocytes;
LUSC	trans	rs1941687	0.831	rs55671114	chr18:31386284	C/A	cg27147174	chr7:100797783	AP1S1	-0.45	-6.67	-0.34	1.06e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.44	8.3	0.41	2.61e-15	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg13010199	chr12:38710504	ALG10B	-0.63	-10.7	-0.51	3.65e-23	Heart rate;
LUSC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg06784218	chr1:46089804	CCDC17	-0.52	-9.78	-0.47	5.14e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg23625390	chr15:77176239	SCAPER	-0.65	-10.06	-0.48	5.57e-21	Blood metabolite levels;
LUSC	cis	rs7681440	0.647	rs1442136	chr4:90819026	C/T	cg15133208	chr4:90757351	SNCA	0.36	6.2	0.32	1.63e-9	Dementia with Lewy bodies;
LUSC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg19230755	chr7:65878503	NA	-0.41	-5.74	-0.3	2.17e-8	Aortic root size;
LUSC	cis	rs7712401	0.601	rs39819	chr5:122301676	G/A	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	6.2	0.32	1.69e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11630290	0.592	rs8028348	chr15:64156465	A/G	cg12036633	chr15:63758958	NA	0.53	6.84	0.35	3.73e-11	Iris characteristics;
LUSC	cis	rs113835537	0.935	rs11550057	chr11:66392880	C/T	cg24851651	chr11:66362959	CCS	0.53	6.55	0.34	2.14e-10	Airway imaging phenotypes;
LUSC	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.78	-0.35	5.3e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LUSC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19346786	chr7:2764209	NA	-0.41	-7.05	-0.36	1e-11	Height;
LUSC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.7	0.39	1.61e-13	Major depressive disorder;
LUSC	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.72	-11.23	-0.52	4.82e-25	Alcohol dependence;
LUSC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg22166914	chr1:53195759	ZYG11B	0.48	7.61	0.38	2.74e-13	Monocyte count;
LUSC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg21951975	chr1:209979733	IRF6	0.4	6.67	0.34	1.08e-10	Monobrow;
LUSC	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.82	-0.43	6.58e-17	Response to antipsychotic treatment;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg23284646	chr4:17616339	MED28	0.5	6.31	0.33	9.01e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4363385	0.669	rs4845519	chr1:153003916	G/T	cg00922841	chr1:152955080	SPRR1A	0.43	7.61	0.38	2.76e-13	Inflammatory skin disease;
LUSC	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/G	cg20655648	chr15:75932815	IMP3	0.42	5.82	0.3	1.42e-8	Sudden cardiac arrest;
LUSC	trans	rs12210905	0.688	rs12196452	chr6:27344415	A/T	cg02699829	chr19:13216355	TRMT1	-0.56	-6.33	-0.33	7.7e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg00864171	chr11:67383662	NA	0.35	6.14	0.32	2.31e-9	Mean corpuscular volume;
LUSC	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.96	-0.36	1.86e-11	Aortic root size;
LUSC	cis	rs939658	0.683	rs11634726	chr15:79465894	A/G	cg17916960	chr15:79447300	NA	-0.44	-8.22	-0.41	4.56e-15	Refractive error;
LUSC	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg04455712	chr21:45112962	RRP1B	0.41	7.55	0.38	4.13e-13	Mean corpuscular volume;
LUSC	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg27631724	chr1:11040367	C1orf127	0.55	10.58	0.5	9.33e-23	Ewing sarcoma;
LUSC	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg03585969	chr10:35415529	CREM	0.62	8.93	0.44	2.97e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg12310025	chr6:25882481	NA	-0.47	-7.22	-0.37	3.47e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6969780	0.915	rs12666919	chr7:27189498	A/T	cg26364809	chr7:27145159	NA	0.53	5.92	0.31	7.97e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs983392	0.649	rs7936120	chr11:60000574	T/A	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.08	-0.32	3.22e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08470875	chr2:26401718	FAM59B	0.73	9.87	0.48	2.53e-20	Gut microbiome composition (summer);
LUSC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg13560548	chr3:10150139	C3orf24	-0.5	-6.97	-0.36	1.66e-11	Alzheimer's disease;
LUSC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06558623	chr16:89946397	TCF25	-0.83	-8.89	-0.44	3.93e-17	Skin colour saturation;
LUSC	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg11871910	chr12:69753446	YEATS4	-0.45	-5.96	-0.31	6.31e-9	Response to diuretic therapy;
LUSC	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03878208	chr11:72483293	STARD10	0.58	7.43	0.38	9.24e-13	Type 2 diabetes;
LUSC	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg23711669	chr6:146136114	FBXO30	0.85	15.18	0.64	6.02e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg12559939	chr2:27858050	GPN1	0.38	5.79	0.3	1.62e-8	Oral cavity cancer;
LUSC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg08773314	chr2:239334832	ASB1	-0.43	-9.32	-0.45	1.6e-18	Multiple system atrophy;
LUSC	cis	rs16976116	0.901	rs1061874	chr15:55496287	A/T	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg05082376	chr22:42548792	NA	-0.39	-5.82	-0.3	1.41e-8	Schizophrenia;
LUSC	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.73	-0.43	1.23e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7264396	0.667	rs224368	chr20:34070380	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-5.94	-0.31	7.13e-9	Total cholesterol levels;
LUSC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.45	5.99	0.31	5.34e-9	Renal function-related traits (BUN);
LUSC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.76	7.87	0.4	5.12e-14	Body mass index;
LUSC	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg09911534	chr15:67153556	NA	-0.6	-9.79	-0.47	4.54e-20	Lung cancer (smoking interaction);
LUSC	cis	rs4409675	0.548	rs1000432	chr1:28225119	T/C	cg23691781	chr1:28212827	C1orf38	0.31	7.43	0.38	9.31e-13	Corneal astigmatism;
LUSC	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg13047869	chr3:10149882	C3orf24	0.44	6.79	0.35	5.06e-11	Alzheimer's disease;
LUSC	cis	rs9902453	0.934	rs34433787	chr17:28496780	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.18	0.41	5.84e-15	Coffee consumption (cups per day);
LUSC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15541040	chr2:3486749	NA	-0.58	-9.1	-0.45	8.15e-18	Neurofibrillary tangles;
LUSC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg05347473	chr6:146136440	FBXO30	0.55	9.47	0.46	5.36e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.58	-0.42	3.69e-16	Rheumatoid arthritis;
LUSC	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.92	10.97	0.51	4.11e-24	Bipolar disorder;
LUSC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg11871910	chr12:69753446	YEATS4	0.93	17.13	0.68	1.14e-47	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg06191203	chr2:152266755	RIF1	0.53	7.33	0.37	1.75e-12	Lung cancer;
LUSC	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.51	-7.32	-0.37	1.9e-12	Lung cancer;
LUSC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.48	0.38	6.75e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg02475777	chr4:1388615	CRIPAK	0.41	6.11	0.32	2.76e-9	Obesity-related traits;
LUSC	cis	rs7188861	0.510	rs35307035	chr16:11402908	G/A	cg00044050	chr16:11439710	C16orf75	0.58	6.26	0.32	1.21e-9	HDL cholesterol;
LUSC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg12310025	chr6:25882481	NA	0.63	10.52	0.5	1.5e-22	Blood metabolite levels;
LUSC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg14092988	chr3:52407081	DNAH1	0.31	6.15	0.32	2.23e-9	Bipolar disorder;
LUSC	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.77e-22	Eye color traits;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13602798	chr17:8152519	PFAS;C17orf68	-0.44	-6.71	-0.34	8.32e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	0.97	13.45	0.59	2.98e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg12564285	chr5:131593104	PDLIM4	0.39	7.12	0.36	6.85e-12	Breast cancer;
LUSC	cis	rs870825	0.616	rs877276	chr4:185621249	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.59	-9.0	-0.44	1.79e-17	HDL cholesterol;
LUSC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg13319975	chr6:146136371	FBXO30	0.49	7.34	0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg09436375	chr6:42928200	GNMT	-0.29	-6.51	-0.34	2.8e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg23260525	chr10:116636907	FAM160B1	0.49	10.57	0.5	1.04e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.47	-0.33	3.51e-10	Monocyte count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12774482	chr13:50656354	DLEU1;DLEU2	-0.43	-6.89	-0.35	2.7e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg04365224	chr3:72788183	NA	-0.46	-5.76	-0.3	1.88e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.58	8.78	0.43	8.82e-17	Lymphocyte counts;
LUSC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.49	-0.38	6.39e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.7	-12.22	-0.56	1.21e-28	Aortic root size;
LUSC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	0.94	18.17	0.71	8.64e-52	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.68	-11.3	-0.53	2.71e-25	Caffeine consumption;
LUSC	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg27432699	chr2:27873401	GPN1	0.83	15.87	0.66	1.14e-42	Oral cavity cancer;
LUSC	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg17366294	chr4:99064904	C4orf37	0.56	9.85	0.47	2.83e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2274273	0.516	rs10137071	chr14:55370340	C/T	cg04306507	chr14:55594613	LGALS3	0.32	6.0	0.31	5.19e-9	Protein biomarker;
LUSC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg12560992	chr17:57184187	TRIM37	0.58	9.32	0.45	1.64e-18	Testicular germ cell tumor;
LUSC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg23711669	chr6:146136114	FBXO30	0.88	15.89	0.66	9.37e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-13.55	-0.6	1.28e-33	Morning vs. evening chronotype;
LUSC	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.61	8.02	0.4	1.8e-14	High light scatter reticulocyte count;
LUSC	cis	rs10875595	0.836	rs10062604	chr5:140661932	T/C	cg24830062	chr5:140700576	TAF7	-0.52	-6.31	-0.33	9.1e-10	Pulmonary function decline;
LUSC	cis	rs9297145	0.565	rs4729516	chr7:98745679	G/A	cg05967295	chr7:98741636	SMURF1	-0.64	-10.08	-0.48	4.9e-21	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg23625390	chr15:77176239	SCAPER	-0.65	-9.69	-0.47	9.8e-20	Blood metabolite levels;
LUSC	cis	rs9807989	0.507	rs6710528	chr2:103016142	A/G	cg03938978	chr2:103052716	IL18RAP	-0.37	-7.05	-0.36	1e-11	Asthma;
LUSC	cis	rs11024102	0.830	rs11024110	chr11:17028390	T/A	cg15084286	chr11:17036142	PLEKHA7	0.46	6.36	0.33	6.54e-10	Glaucoma (primary angle closure);
LUSC	cis	rs34375054	0.672	rs10400509	chr12:125592173	T/C	cg09839279	chr12:125627357	AACS	-0.35	-6.36	-0.33	6.79e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	1.3	11.92	0.55	1.51e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg21724239	chr8:58056113	NA	0.78	9.03	0.44	1.43e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs11229555	0.609	rs12270515	chr11:58217945	G/A	cg15696309	chr11:58395628	NA	-0.61	-7.43	-0.38	9e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg16070123	chr10:51489643	NA	0.55	9.19	0.45	4.36e-18	Prostate-specific antigen levels;
LUSC	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.74	-15.36	-0.64	1.13e-40	Recombination rate (males);
LUSC	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg13206674	chr6:150067644	NUP43	0.41	6.21	0.32	1.56e-9	Testicular germ cell tumor;
LUSC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg14668632	chr7:2872130	GNA12	-0.43	-6.7	-0.34	9.06e-11	Height;
LUSC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg06618935	chr21:46677482	NA	-0.38	-7.03	-0.36	1.18e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs698813	0.763	rs786615	chr2:44590608	T/C	cg00619915	chr2:44497795	NA	-0.42	-6.01	-0.31	4.9e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00166722	chr3:10149974	C3orf24	0.6	8.59	0.43	3.36e-16	Alzheimer's disease;
LUSC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06221963	chr1:154839813	KCNN3	-0.6	-13.65	-0.6	5.11e-34	Prostate cancer;
LUSC	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.64	-0.3	3.56e-8	Recombination rate (females);
LUSC	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg27147174	chr7:100797783	AP1S1	-0.65	-10.45	-0.5	2.64e-22	Life satisfaction;
LUSC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg05623727	chr3:50126028	RBM5	0.34	6.41	0.33	4.88e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.86	-0.44	4.78e-17	Response to antipsychotic treatment;
LUSC	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.67	-0.63	5.64e-38	Schizophrenia;
LUSC	cis	rs7804356	1.000	rs3801810	chr7:26892531	G/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.15	-0.32	2.27e-9	Type 1 diabetes;
LUSC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18404041	chr3:52824283	ITIH1	-0.63	-12.22	-0.56	1.19e-28	Bipolar disorder;
LUSC	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg01884057	chr2:25150051	NA	0.47	10.84	0.51	1.17e-23	Body mass index;
LUSC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg05347473	chr6:146136440	FBXO30	0.5	8.36	0.42	1.67e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6866614	0.627	rs27437	chr5:131436961	A/G	cg14196790	chr5:131705035	SLC22A5	0.41	6.67	0.34	1.07e-10	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05165339	chr4:1420672	NA	-0.29	-6.43	-0.33	4.37e-10	Longevity;
LUSC	cis	rs295140	0.656	rs3769472	chr2:201193373	G/A	cg04283868	chr2:201171347	SPATS2L	0.42	5.89	0.31	9.24e-9	QT interval;
LUSC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.29	-5.85	-0.31	1.14e-8	Total body bone mineral density;
LUSC	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg01620082	chr3:125678407	NA	-0.8	-7.23	-0.37	3.4e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg12463550	chr7:65579703	CRCP	0.44	6.37	0.33	6.16e-10	Aortic root size;
LUSC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg25272121	chr1:152190972	HRNR	-0.39	-6.73	-0.35	7.42e-11	Inflammatory skin disease;
LUSC	trans	rs12210905	0.925	rs72838262	chr6:27008517	G/C	cg11837749	chr1:55047332	ACOT11	0.59	6.29	0.33	1.02e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs10779751	0.734	rs1211575	chr1:11118390	G/A	cg04508216	chr1:11107452	MASP2	0.33	5.86	0.31	1.1e-8	Body mass index;
LUSC	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg11887960	chr12:57824829	NA	0.52	6.61	0.34	1.55e-10	Obesity-related traits;
LUSC	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg25174290	chr11:3078921	CARS	0.61	9.56	0.46	2.75e-19	Longevity;
LUSC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	7.75	0.39	1.14e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.78	-10.54	-0.5	1.25e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs950881	0.867	rs56179005	chr2:102974328	G/A	cg20060108	chr2:102954350	IL1RL1	0.47	6.08	0.32	3.37e-9	Allergy;
LUSC	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg13615516	chr5:77269221	NA	0.39	6.52	0.34	2.54e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg17366294	chr4:99064904	C4orf37	0.55	9.51	0.46	3.91e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4730250	0.707	rs10953537	chr7:107027905	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.37	-0.46	1.15e-18	Osteoarthritis;
LUSC	trans	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg20587970	chr11:113659929	NA	0.77	9.81	0.47	3.96e-20	Hip circumference adjusted for BMI;
LUSC	trans	rs12709013	0.636	rs1657161	chr16:58777138	C/T	cg19313373	chr1:162694184	DDR2	-0.35	-5.96	-0.31	6.55e-9	Blood metabolite ratios;
LUSC	cis	rs12210905	1.000	rs12213361	chr6:27138387	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.66	-0.3	3.22e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs7589728	0.844	rs77144652	chr2:88496684	G/A	cg04511125	chr2:88470314	THNSL2	0.68	6.33	0.33	7.78e-10	Plasma clusterin levels;
LUSC	cis	rs7119	0.717	rs12915548	chr15:77818042	A/G	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	trans	rs3960554	0.932	rs60717745	chr7:75846083	C/G	cg19862616	chr7:65841803	NCRNA00174	0.89	9.2	0.45	3.86e-18	Eotaxin levels;
LUSC	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg08523384	chr5:141488047	NDFIP1	-0.51	-7.19	-0.37	4.38e-12	Crohn's disease;
LUSC	cis	rs7923609	0.936	rs10761779	chr10:65274927	A/G	cg01631684	chr10:65280961	REEP3	-0.42	-6.56	-0.34	2.02e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg03676636	chr4:99064102	C4orf37	0.3	6.1	0.32	2.86e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2580764	0.566	rs2968795	chr2:55287989	G/A	cg09592903	chr2:55203963	RTN4	0.49	9.95	0.48	1.39e-20	Mean platelet volume;
LUSC	trans	rs931812	0.825	rs34235568	chr8:101895761	C/T	cg20993868	chr7:22813445	NA	0.58	10.03	0.48	7.32e-21	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg06521331	chr12:34319734	NA	-0.38	-6.55	-0.34	2.2e-10	Morning vs. evening chronotype;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03039008	chr3:150126185	TSC22D2	-0.41	-6.02	-0.31	4.56e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.19	-0.41	5.51e-15	Axial length;
LUSC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.64	8.36	0.42	1.71e-15	Huntington's disease progression;
LUSC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg10130564	chr11:117069849	TAGLN	0.38	6.59	0.34	1.68e-10	Blood protein levels;
LUSC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg22437258	chr11:111473054	SIK2	0.51	7.04	0.36	1.1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg20684491	chr1:25596433	NA	0.4	6.36	0.33	6.71e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg17211192	chr8:82754475	SNX16	-0.82	-11.22	-0.52	5.21e-25	Diastolic blood pressure;
LUSC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs9346649	0.591	rs1873338	chr6:168492087	T/C	cg02770688	chr6:168491649	NA	0.48	9.08	0.45	9.54e-18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs2286885	1.000	rs7851961	chr9:129249140	G/A	cg15282417	chr9:129245246	FAM125B	0.38	6.34	0.33	7.36e-10	Intraocular pressure;
LUSC	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg02574844	chr11:5959923	NA	-0.45	-6.24	-0.32	1.35e-9	DNA methylation (variation);
LUSC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-6.66	-0.34	1.11e-10	Mean corpuscular volume;
LUSC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg18230493	chr5:56204884	C5orf35	-0.55	-8.7	-0.43	1.57e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg00750074	chr16:89608354	SPG7	-0.55	-9.91	-0.48	1.83e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg21251018	chr6:28226885	NKAPL	-0.31	-5.84	-0.3	1.27e-8	Pubertal anthropometrics;
LUSC	trans	rs12210905	0.925	rs12200985	chr6:27004892	G/T	cg11837749	chr1:55047332	ACOT11	0.59	6.28	0.32	1.05e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.39	5.94	0.31	7.07e-9	Ulcerative colitis;
LUSC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.24	0.52	4.63e-25	Prudent dietary pattern;
LUSC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-9.37	-0.46	1.1e-18	Gut microbiome composition (summer);
LUSC	cis	rs500891	0.547	rs1145900	chr6:84038920	T/C	cg08257003	chr6:84140564	ME1	0.32	7.13	0.36	6.15e-12	Platelet-derived growth factor BB levels;
LUSC	trans	rs11696501	0.688	rs11696685	chr20:44295134	A/G	cg03272292	chr12:48577362	C12orf68	0.48	6.0	0.31	5.1e-9	Brain structure;
LUSC	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg25214090	chr10:38739885	LOC399744	0.56	8.16	0.41	7.08e-15	Corneal astigmatism;
LUSC	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg18512352	chr11:47633146	NA	-0.46	-9.22	-0.45	3.51e-18	Subjective well-being;
LUSC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	12.72	0.57	1.74e-30	Motion sickness;
LUSC	cis	rs9612	0.950	rs60649310	chr19:44269241	A/G	cg08581076	chr19:44259116	C19orf61	0.48	5.75	0.3	1.97e-8	Exhaled nitric oxide output;
LUSC	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg16797656	chr11:68205561	LRP5	0.38	6.22	0.32	1.52e-9	Total body bone mineral density;
LUSC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.67	11.14	0.52	9.98e-25	Cognitive function;
LUSC	cis	rs6681460	0.934	rs4655635	chr1:67068240	T/G	cg02459107	chr1:67143332	SGIP1	0.45	8.29	0.41	2.84e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs4629180	0.562	rs10198901	chr2:102127937	G/A	cg01388757	chr2:102091195	RFX8	-0.36	-6.41	-0.33	4.96e-10	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg17885191	chr8:135476712	NA	0.88	14.3	0.62	1.61e-36	Educational attainment;
LUSC	cis	rs73001065	1.000	rs56255430	chr19:19477877	A/C	cg03709012	chr19:19516395	GATAD2A	0.99	7.55	0.38	4.06e-13	LDL cholesterol;
LUSC	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg06462663	chr19:18546047	ISYNA1	0.5	8.56	0.42	4.2e-16	Breast cancer;
LUSC	cis	rs28489187	0.577	rs3920521	chr1:85848866	A/C	cg02862864	chr1:85742044	BCL10	-0.42	-5.77	-0.3	1.86e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LUSC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.18	15.2	0.64	5.15e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1018697	1.000	rs1018696	chr10:104549066	A/G	cg04362960	chr10:104952993	NT5C2	0.47	6.45	0.33	4.04e-10	Colorectal adenoma (advanced);
LUSC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg11494091	chr17:61959527	GH2	0.39	6.77	0.35	5.68e-11	Height;
LUSC	cis	rs2073300	1.000	rs2207988	chr20:23446000	C/A	cg09953122	chr20:23471693	CST8	-0.75	-6.87	-0.35	3.15e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs57786342	0.624	rs4899262	chr14:69283545	G/A	cg03189333	chr14:69283534	NA	-0.48	-5.99	-0.31	5.58e-9	Macrophage inflammatory protein 1a levels;
LUSC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg02951883	chr7:2050386	MAD1L1	-0.35	-6.09	-0.32	3.08e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg27411982	chr8:10470053	RP1L1	0.4	6.1	0.32	2.91e-9	Myopia (pathological);
LUSC	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg10547527	chr2:198650123	BOLL	-0.49	-5.72	-0.3	2.4e-8	Ulcerative colitis;
LUSC	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg24375607	chr4:120327624	NA	0.52	8.3	0.41	2.62e-15	Diastolic blood pressure;
LUSC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-9.71	-0.47	8.38e-20	Rheumatoid arthritis;
LUSC	trans	rs6982636	0.765	rs2001945	chr8:126477978	C/G	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.32	-6.31	-0.33	9.06e-10	Lipid metabolism phenotypes;
LUSC	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	0.72	10.61	0.5	7.35e-23	Vitiligo;
LUSC	cis	rs9309711	0.770	rs13409323	chr2:3488184	C/T	cg10845886	chr2:3471009	TTC15	-0.55	-7.03	-0.36	1.15e-11	Neurofibrillary tangles;
LUSC	cis	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg21775007	chr8:11205619	TDH	-0.51	-7.39	-0.37	1.17e-12	Triglycerides;
LUSC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.17	0.52	7.73e-25	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.44	0.38	8.34e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg15309053	chr8:964076	NA	0.35	7.16	0.36	5.03e-12	Schizophrenia;
LUSC	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg14631576	chr9:95140430	CENPP	-0.33	-5.93	-0.31	7.77e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg03806693	chr22:41940476	POLR3H	-0.85	-12.0	-0.55	8.2e-28	Vitiligo;
LUSC	cis	rs1044826	1.000	rs13060697	chr3:139101777	G/A	cg00490450	chr3:139108681	COPB2	0.55	7.39	0.37	1.22e-12	Obesity-related traits;
LUSC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg23283495	chr1:209979779	IRF6	-0.55	-9.2	-0.45	3.84e-18	Monobrow;
LUSC	cis	rs3892630	0.529	rs35300319	chr19:33409948	G/A	cg22980127	chr19:33182716	NUDT19	0.66	8.64	0.43	2.29e-16	Red blood cell traits;
LUSC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg16680214	chr1:154839983	KCNN3	-0.52	-9.76	-0.47	5.77e-20	Prostate cancer;
LUSC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg25258033	chr6:167368657	RNASET2	0.47	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	trans	rs1376359	0.537	rs538840	chr1:103260952	G/T	cg17154563	chr19:40477487	PSMC4	0.48	6.06	0.31	3.61e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.88	14.84	0.63	1.28e-38	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs11165623	0.585	rs55896436	chr1:96994162	G/A	cg10631902	chr5:14652156	NA	-0.41	-6.09	-0.32	3.12e-9	Hip circumference;Waist circumference;
LUSC	cis	rs68170813	0.559	rs58319984	chr7:106965794	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.87	-0.48	2.43e-20	Coronary artery disease;
LUSC	cis	rs2742234	0.541	rs10793426	chr10:43745280	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.39	-5.67	-0.3	3.06e-8	Hirschsprung disease;
LUSC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.66	-11.66	-0.54	1.34e-26	Aortic root size;
LUSC	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg18904891	chr8:8559673	CLDN23	0.6	8.08	0.4	1.2e-14	Obesity-related traits;
LUSC	cis	rs73206853	0.841	rs57216167	chr12:110940748	C/T	cg12870014	chr12:110450643	ANKRD13A	0.67	6.47	0.33	3.57e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg03522245	chr20:25566470	NINL	-0.35	-5.68	-0.3	2.89e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10097731	0.808	rs80141261	chr8:82034453	T/C	cg25230327	chr8:82042993	NA	-0.44	-6.5	-0.33	2.98e-10	Serum total protein level;
LUSC	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	7.02	0.36	1.24e-11	Ovarian reserve;
LUSC	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-9.3	-0.45	1.95e-18	Morning vs. evening chronotype;
LUSC	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg11789530	chr4:8429930	ACOX3	-0.42	-6.1	-0.32	2.95e-9	Response to antineoplastic agents;
LUSC	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg17127132	chr2:85788382	GGCX	0.45	7.05	0.36	1.05e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7520050	0.902	rs4626927	chr1:46248645	C/T	cg24296786	chr1:45957014	TESK2	0.42	5.88	0.31	9.75e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs7000551	0.642	rs2122880	chr8:22375042	C/A	cg12081754	chr8:22256438	SLC39A14	0.45	6.75	0.35	6.5500000000000006e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs7939886	0.920	rs17145425	chr11:55950030	A/G	cg03929089	chr4:120376271	NA	0.83	6.29	0.33	1e-9	Myopia (pathological);
LUSC	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg17376030	chr22:41985996	PMM1	-0.46	-6.06	-0.31	3.61e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg14791747	chr16:20752902	THUMPD1	0.71	9.43	0.46	6.88e-19	Cognitive test performance;
LUSC	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.76	-0.35	6.13e-11	Reticulocyte count;
LUSC	cis	rs1371867	0.846	rs2453624	chr8:101230523	A/G	cg00191853	chr8:101177733	SPAG1	0.41	6.64	0.34	1.27e-10	Atrioventricular conduction;
LUSC	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg15571903	chr15:79123663	NA	0.32	5.9	0.31	9.02e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs11997175	0.545	rs4733458	chr8:33661542	G/T	ch.8.33884649F	chr8:33765107	NA	0.49	7.29	0.37	2.2e-12	Body mass index;
LUSC	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg01092361	chr6:42185687	MRPS10	0.78	8.68	0.43	1.78e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg18402987	chr7:1209562	NA	0.71	7.85	0.39	5.89e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg18232548	chr7:50535776	DDC	-0.53	-7.33	-0.37	1.7e-12	Malaria;
LUSC	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg13010199	chr12:38710504	ALG10B	-0.5	-7.59	-0.38	3.32e-13	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg11502198	chr6:26597334	ABT1	0.72	12.01	0.55	7.53e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.19	-0.32	1.75e-9	Lung cancer;
LUSC	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg09307838	chr4:120376055	NA	0.57	8.59	0.43	3.46e-16	Diastolic blood pressure;
LUSC	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg06223162	chr1:101003688	GPR88	0.52	9.58	0.46	2.31e-19	Breast cancer;
LUSC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	10.09	0.48	4.6e-21	Bipolar disorder;
LUSC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg03146154	chr1:46216737	IPP	0.51	7.51	0.38	5.46e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg00042356	chr1:8021962	PARK7	0.83	9.81	0.47	3.83e-20	Inflammatory bowel disease;
LUSC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.29	0.45	2.03e-18	Monocyte percentage of white cells;
LUSC	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-7.38	-0.37	1.29e-12	Axial length;
LUSC	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg11871910	chr12:69753446	YEATS4	0.44	6.04	0.31	4.14e-9	Response to diuretic therapy;
LUSC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-12.69	-0.57	2.29e-30	Platelet count;
LUSC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	5.99	0.31	5.53e-9	Breast cancer;
LUSC	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1775715	0.870	rs1775735	chr10:32255846	A/G	cg03015672	chr10:32216066	ARHGAP12	0.33	5.69	0.3	2.85e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg04998671	chr14:104000505	TRMT61A	-0.47	-7.22	-0.37	3.51e-12	Coronary artery disease;
LUSC	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg02569458	chr12:86230093	RASSF9	0.49	8.22	0.41	4.69e-15	Major depressive disorder;
LUSC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.53	7.9	0.4	4.1e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg01097406	chr16:89675127	NA	-0.37	-7.42	-0.38	9.78e-13	Vitiligo;
LUSC	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg01657329	chr11:68192670	LRP5	-0.4	-5.77	-0.3	1.85e-8	Total body bone mineral density;
LUSC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	9.31	0.45	1.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg11845111	chr2:191398756	TMEM194B	0.84	10.73	0.51	2.73e-23	Diastolic blood pressure;
LUSC	cis	rs7705502	1.000	rs1564823	chr5:173383194	G/T	cg18693985	chr5:173351052	CPEB4	-0.4	-6.46	-0.33	3.75e-10	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg02022491	chr17:2323612	METT10D	-0.35	-5.99	-0.31	5.4e-9	N-glycan levels;
LUSC	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg18232548	chr7:50535776	DDC	0.55	7.35	0.37	1.52e-12	Malaria;
LUSC	cis	rs9341835	0.772	rs9341841	chr6:64135010	G/A	cg03326410	chr6:64151739	NA	-0.38	-6.26	-0.32	1.15e-9	Schizophrenia;
LUSC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg08975724	chr8:8085496	FLJ10661	0.65	9.92	0.48	1.72e-20	Systolic blood pressure;
LUSC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs1044826	0.619	rs57357132	chr3:139118358	A/T	cg00490450	chr3:139108681	COPB2	-0.5	-7.87	-0.4	4.85e-14	Obesity-related traits;
LUSC	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg15704280	chr7:45808275	SEPT13	-0.44	-6.01	-0.31	4.86e-9	HDL cholesterol;
LUSC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg27124370	chr19:33622961	WDR88	0.57	7.93	0.4	3.33e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.67	-0.47	1.19e-19	Multiple sclerosis;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg18538332	chr22:24372958	LOC391322	-0.46	-8.05	-0.4	1.48e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7180079	1.000	rs62024569	chr15:64496926	T/C	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg17264618	chr3:40429014	ENTPD3	0.34	6.92	0.35	2.37e-11	Renal cell carcinoma;
LUSC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.75	-0.54	6.51e-27	Mean corpuscular volume;
LUSC	cis	rs963731	0.649	rs1869514	chr2:39205796	C/T	cg04010122	chr2:39346883	SOS1	-0.78	-5.7	-0.3	2.71e-8	Corticobasal degeneration;
LUSC	trans	rs1864729	0.591	rs2635139	chr8:98301557	A/G	cg08679828	chr8:102218111	ZNF706	-0.67	-6.3	-0.33	9.28e-10	Estradiol plasma levels (breast cancer);
LUSC	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.63	10.03	0.48	7.4e-21	Morning vs. evening chronotype;
LUSC	cis	rs12449964	0.524	rs4925094	chr17:17569012	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-8.23	-0.41	4.28e-15	Coronary artery disease or ischemic stroke;
LUSC	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg19336497	chr11:14380999	RRAS2	-0.48	-8.94	-0.44	2.79e-17	Sense of smell;
LUSC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21984481	chr17:79567631	NPLOC4	-0.56	-10.71	-0.51	3.22e-23	Eye color traits;
LUSC	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	1.18	10.67	0.5	4.51e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg09491104	chr22:46646882	C22orf40	-0.7	-7.3	-0.37	2.14e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	7.97	0.4	2.54e-14	Homoarginine levels;
LUSC	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg13206674	chr6:150067644	NUP43	0.43	6.54	0.34	2.3e-10	Testicular germ cell tumor;
LUSC	cis	rs10045504	0.502	rs72746031	chr5:38743161	G/A	cg15396434	chr5:38725168	NA	-0.51	-5.67	-0.3	3.17e-8	Night sleep phenotypes;
LUSC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg24060327	chr5:131705240	SLC22A5	-0.65	-11.16	-0.52	8.27e-25	Breast cancer;
LUSC	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg11244672	chr19:19639970	YJEFN3	-0.61	-7.52	-0.38	5e-13	Bipolar disorder;
LUSC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg09085632	chr11:111637200	PPP2R1B	1.0	15.54	0.65	2.26e-41	Primary sclerosing cholangitis;
LUSC	cis	rs4363385	0.643	rs11576457	chr1:152918556	C/T	cg07796016	chr1:152779584	LCE1C	0.51	7.59	0.38	3.23e-13	Inflammatory skin disease;
LUSC	cis	rs7177699	0.526	rs7165733	chr15:79123505	G/A	cg00540400	chr15:79124168	NA	0.43	7.51	0.38	5.44e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs62408225	0.802	rs4706360	chr6:90913548	C/T	cg06866423	chr6:90926672	BACH2	0.46	7.03	0.36	1.21e-11	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9302635	0.678	rs8054585	chr16:72225314	G/A	cg01557791	chr16:72042693	DHODH	-0.41	-5.65	-0.3	3.42e-8	Blood protein levels;
LUSC	cis	rs6906287	0.625	rs9489355	chr6:118685314	A/G	cg21191810	chr6:118973309	C6orf204	0.37	6.76	0.35	6.11e-11	Electrocardiographic conduction measures;
LUSC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.44	-0.46	6.52e-19	Joint mobility (Beighton score);
LUSC	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg13852791	chr20:30311386	BCL2L1	0.92	13.81	0.6	1.2e-34	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg23093090	chr10:104574429	C10orf26	-0.37	-6.79	-0.35	5.01e-11	Arsenic metabolism;
LUSC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg00933542	chr6:150070202	PCMT1	0.29	5.93	0.31	7.45e-9	Lung cancer;
LUSC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-9.66	-0.47	1.29e-19	Rheumatoid arthritis;
LUSC	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg17385448	chr1:15911702	AGMAT	0.36	6.2	0.32	1.69e-9	Systolic blood pressure;
LUSC	cis	rs62408225	0.963	rs1321859	chr6:91011673	C/T	cg06866423	chr6:90926672	BACH2	0.41	5.99	0.31	5.3300000000000004e-09	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg19920283	chr7:105172520	RINT1	0.58	6.25	0.32	1.25e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs9510787	1.000	rs35520244	chr13:24190488	G/T	cg20646490	chr19:45971291	FOSB	-0.51	-5.99	-0.31	5.48e-9	Nasopharyngeal carcinoma;
LUSC	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg21775007	chr8:11205619	TDH	-0.68	-10.45	-0.5	2.66e-22	Retinal vascular caliber;
LUSC	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg24130564	chr14:104152367	KLC1	0.45	6.46	0.33	3.78e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs72674100	0.867	rs4292338	chr4:97963600	G/T	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg23630131	chr7:65973040	NA	-0.21	-6.07	-0.31	3.56e-9	Aortic root size;
LUSC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg07870213	chr5:140052090	DND1	-0.75	-11.28	-0.53	3.08e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg01851573	chr8:8652454	MFHAS1	0.53	8.42	0.42	1.09e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.58	-0.42	3.75e-16	Bladder cancer;
LUSC	cis	rs2219968	0.962	rs3884556	chr8:78939959	T/C	cg00738934	chr8:78996279	NA	0.4	7.15	0.36	5.57e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.53	-0.46	3.42e-19	Chronic sinus infection;
LUSC	cis	rs13385	0.813	rs6859064	chr5:139663301	A/T	cg26211634	chr5:139558579	C5orf32	0.44	6.13	0.32	2.46e-9	Atrial fibrillation;
LUSC	cis	rs894734	1.000	rs894734	chr12:54319727	A/G	cg17410650	chr12:54324560	NA	-0.4	-7.36	-0.37	1.48e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	cis	rs6961069	0.503	rs3211822	chr7:80278626	A/G	cg04458919	chr7:80252533	CD36	0.39	6.84	0.35	3.9e-11	Platelet count;
LUSC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.48e-28	Motion sickness;
LUSC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-12.39	-0.56	2.79e-29	Body mass index;
LUSC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg20135002	chr11:47629003	NA	-0.51	-8.04	-0.4	1.59e-14	Subjective well-being;
LUSC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.79	-13.88	-0.6	6.76e-35	Cognitive function;
LUSC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg17366294	chr4:99064904	C4orf37	0.59	10.52	0.5	1.5e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12313068	0.709	rs11829777	chr12:110503770	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	9.66	0.47	1.25e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs7212590	0.655	rs8072050	chr17:58010972	G/A	cg10252138	chr17:58120427	NA	-0.82	-7.64	-0.39	2.33e-13	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg02475777	chr4:1388615	CRIPAK	0.44	6.5	0.34	2.92e-10	Obesity-related traits;
LUSC	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg10978503	chr1:24200527	CNR2	0.53	12.93	0.58	2.88e-31	Immature fraction of reticulocytes;
LUSC	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg22482690	chr17:47019901	SNF8	0.4	7.48	0.38	6.49e-13	Type 2 diabetes;
LUSC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg08888203	chr3:10149979	C3orf24	0.59	8.21	0.41	4.83e-15	Alzheimer's disease;
LUSC	cis	rs7590368	0.715	rs12463454	chr2:10958235	G/A	cg15705551	chr2:10952987	PDIA6	0.57	6.23	0.32	1.41e-9	Educational attainment (years of education);
LUSC	cis	rs1775715	0.644	rs2799022	chr10:32137198	C/T	cg18675610	chr10:32216311	ARHGAP12	0.31	6.75	0.35	6.67e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg04218760	chr10:45406644	TMEM72	-0.29	-6.99	-0.36	1.49e-11	Mean corpuscular volume;
LUSC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.14	0.41	8.18e-15	Prudent dietary pattern;
LUSC	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg02825527	chr7:2087843	MAD1L1	-0.5	-5.73	-0.3	2.29e-8	Bipolar disorder;
LUSC	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg22491629	chr6:157744540	C6orf35	-0.88	-10.65	-0.5	5.24e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg08975724	chr8:8085496	FLJ10661	0.46	6.47	0.33	3.54e-10	Mean corpuscular volume;
LUSC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.45	0.42	8.88e-16	Motion sickness;
LUSC	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.61	-8.32	-0.41	2.32e-15	Red cell distribution width;
LUSC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-7.87	-0.4	4.95e-14	Neuroticism;
LUSC	cis	rs4974559	0.739	rs10012819	chr4:1324758	G/C	cg02980000	chr4:1222292	CTBP1	0.97	9.05	0.44	1.17e-17	Systolic blood pressure;
LUSC	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg27147174	chr7:100797783	AP1S1	-0.65	-10.24	-0.49	1.39e-21	Life satisfaction;
LUSC	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	1.1	18.31	0.71	2.31e-52	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg05340658	chr4:99064831	C4orf37	-0.44	-6.95	-0.36	1.94e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg08499158	chr17:42289980	UBTF	-0.58	-9.33	-0.45	1.5e-18	Total body bone mineral density;
LUSC	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg24562669	chr7:97807699	LMTK2	0.48	8.56	0.42	4.18e-16	Breast cancer;
LUSC	cis	rs2879627	0.504	rs6480583	chr10:53673125	C/T	cg06976598	chr10:53639124	PRKG1	0.43	5.7	0.3	2.61e-8	Coronary artery disease;
LUSC	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.6	9.49	0.46	4.6e-19	Morning vs. evening chronotype;
LUSC	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg18683606	chr7:100471612	SRRT	0.45	6.0	0.31	5.05e-9	Resting heart rate;
LUSC	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.42	-0.33	4.59e-10	Uric acid levels;
LUSC	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg09904177	chr6:26538194	HMGN4	0.75	14.15	0.61	5.95e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12756686	chr19:29218302	NA	0.68	9.28	0.45	2.12e-18	Methadone dose in opioid dependence;
LUSC	cis	rs7582180	0.903	rs7557977	chr2:100897573	G/A	cg08017756	chr2:100939284	LONRF2	-0.37	-6.18	-0.32	1.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg09034736	chr1:150693464	HORMAD1	0.41	5.75	0.3	1.96e-8	Melanoma;
LUSC	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9323205	0.677	rs8014210	chr14:51709802	T/C	cg23942311	chr14:51606299	NA	-0.42	-8.0	-0.4	2e-14	Cancer;
LUSC	cis	rs13315871	0.929	rs11717783	chr3:58267642	A/T	cg12435725	chr3:58293450	RPP14	-0.78	-7.71	-0.39	1.45e-13	Cholesterol, total;
LUSC	trans	rs28647808	0.881	rs28461467	chr9:136261288	G/A	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg00800038	chr16:89945340	TCF25	-0.75	-6.56	-0.34	2.09e-10	Skin colour saturation;
LUSC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg24829409	chr8:58192753	C8orf71	-0.47	-6.0	-0.31	5.11e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg22535103	chr8:58192502	C8orf71	-0.56	-6.74	-0.35	6.89e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23158103	chr7:148848205	ZNF398	-0.47	-7.92	-0.4	3.57e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-9.19	-0.45	4.25e-18	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs911119	1.000	rs3827143	chr20:23619617	A/G	cg16589663	chr20:23618590	CST3	0.6	7.08	0.36	8.36e-12	Chronic kidney disease;
LUSC	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg13393036	chr8:95962371	TP53INP1	-0.31	-6.18	-0.32	1.91e-9	Type 2 diabetes;
LUSC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg02153584	chr22:29168773	CCDC117	0.66	10.59	0.5	8.62e-23	Lymphocyte counts;
LUSC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg22482690	chr17:47019901	SNF8	0.38	7.01	0.36	1.35e-11	Type 2 diabetes;
LUSC	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg09479241	chr17:27052676	TLCD1	0.43	5.78	0.3	1.68e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg07930552	chr6:133119739	C6orf192	0.85	10.62	0.5	6.83e-23	Type 2 diabetes nephropathy;
LUSC	cis	rs4834770	0.685	rs4496567	chr4:120175625	A/T	cg24375607	chr4:120327624	NA	0.42	5.82	0.3	1.39e-8	Blood protein levels;
LUSC	cis	rs2219968	0.740	rs4478563	chr8:78919823	A/G	cg00738934	chr8:78996279	NA	0.32	5.67	0.3	3.11e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs500891	0.547	rs12195417	chr6:84173028	T/C	cg08257003	chr6:84140564	ME1	0.3	6.74	0.35	6.86e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs4812048	0.689	rs151356	chr20:57607949	G/A	cg14073986	chr20:57617431	SLMO2	0.5	5.76	0.3	1.93e-8	Mean platelet volume;
LUSC	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.75	-0.39	1.11e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2191566	0.960	rs2270196	chr19:44506623	A/G	cg03039196	chr19:44506973	ZNF230	-0.34	-5.65	-0.3	3.39e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg19743168	chr1:23544995	NA	0.4	7.89	0.4	4.25e-14	Height;
LUSC	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg10018233	chr7:150070692	REPIN1	0.37	6.43	0.33	4.29e-10	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg24247370	chr13:99142703	STK24	-0.34	-6.24	-0.32	1.35e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06873352	chr17:61820015	STRADA	0.56	8.63	0.43	2.6e-16	Height;
LUSC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	9.02	0.44	1.5e-17	Motion sickness;
LUSC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg17507749	chr15:85114479	UBE2QP1	0.68	8.72	0.43	1.36e-16	Schizophrenia;
LUSC	cis	rs2742234	0.541	rs60845448	chr10:43721462	C/T	cg15436174	chr10:43711423	RASGEF1A	0.44	7.06	0.36	9.75e-12	Hirschsprung disease;
LUSC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.25	0.37	2.92e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg08219700	chr8:58056026	NA	0.47	6.21	0.32	1.55e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg03806693	chr22:41940476	POLR3H	-1.0	-14.25	-0.61	2.51e-36	Vitiligo;
LUSC	trans	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.38	-0.33	5.77e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg03585969	chr10:35415529	CREM	-0.58	-8.57	-0.42	3.98e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.55	-0.34	2.2e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.67e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17030434	1.000	rs75083896	chr4:154719082	A/G	cg14289246	chr4:154710475	SFRP2	-0.53	-6.84	-0.35	3.69e-11	Electrocardiographic conduction measures;
LUSC	cis	rs1322512	0.917	rs911921	chr6:152992740	C/T	cg27316956	chr6:152958899	SYNE1	0.37	6.32	0.33	8.37e-10	Tonometry;
LUSC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg21573476	chr21:45109991	RRP1B	-0.37	-5.96	-0.31	6.34e-9	Mean corpuscular volume;
LUSC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-8.65	-0.43	2.18e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs17683430	0.557	rs4821012	chr22:32387985	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5.04e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.91	12.92	0.58	2.96e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.81	-0.3	1.49e-8	Type 2 diabetes;
LUSC	cis	rs926938	0.618	rs360617	chr1:115404099	G/A	cg01522456	chr1:115632236	TSPAN2	-0.4	-6.36	-0.33	6.64e-10	Autism;
LUSC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.14	0.41	8.18e-15	Prudent dietary pattern;
LUSC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg06212747	chr3:49208901	KLHDC8B	0.44	5.98	0.31	5.78e-9	Parkinson's disease;
LUSC	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg14675211	chr2:100938903	LONRF2	0.37	5.74	0.3	2.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10465746	0.935	rs6687372	chr1:84447634	C/T	cg10977910	chr1:84465055	TTLL7	0.44	6.37	0.33	6.11e-10	Obesity-related traits;
LUSC	cis	rs7809950	0.678	rs79902674	chr7:106866498	A/C	cg23024343	chr7:107201750	COG5	-0.66	-9.34	-0.46	1.35e-18	Coronary artery disease;
LUSC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg24690094	chr11:67383802	NA	0.44	8.74	0.43	1.11e-16	Mean corpuscular volume;
LUSC	cis	rs4363385	1.000	rs10888527	chr1:153001363	G/T	cg00922841	chr1:152955080	SPRR1A	0.48	8.18	0.41	6e-15	Inflammatory skin disease;
LUSC	cis	rs4953318	0.704	rs10495927	chr2:46352499	A/G	cg12428440	chr2:46370979	PRKCE	0.42	7.38	0.37	1.28e-12	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg14789911	chr21:47582049	C21orf56	-0.42	-6.59	-0.34	1.7e-10	Testicular germ cell tumor;
LUSC	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.06	13.11	0.58	5.81e-32	Sexual dysfunction (female);
LUSC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25072359	chr17:41440525	NA	0.65	9.39	0.46	9.33e-19	Menopause (age at onset);
LUSC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg09365446	chr1:150670422	GOLPH3L	-0.39	-5.75	-0.3	1.99e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg02086790	chr16:375327	AXIN1	-0.4	-6.15	-0.32	2.16e-9	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs7833986	0.941	rs13249175	chr8:57058706	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	9.02	0.44	1.55e-17	Height;
LUSC	trans	rs12286929	0.646	rs12805914	chr11:115019739	T/A	cg27361520	chr2:103038171	IL18RAP	0.3	5.97	0.31	6.11e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2742417	1.000	rs2673051	chr3:45732409	G/T	cg09608765	chr3:45636137	LIMD1	-0.36	-7.17	-0.37	4.83e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.33	-0.41	2.19e-15	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg13854012	chr2:162103682	NA	-0.45	-7.97	-0.4	2.58e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg05368731	chr17:41323189	NBR1	0.95	15.89	0.66	9.54e-43	Menopause (age at onset);
LUSC	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	6.17	0.32	1.96e-9	Educational attainment;
LUSC	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg18721089	chr20:30220636	NA	-0.35	-5.94	-0.31	7.09e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.97	-0.36	1.71e-11	Retinal vascular caliber;
LUSC	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	8.81	0.43	6.88e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg09127314	chr1:152161683	NA	-0.39	-5.65	-0.3	3.42e-8	Atopic dermatitis;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.65	9.75	0.47	6.44e-20	Lymphocyte counts;
LUSC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08677398	chr8:58056175	NA	0.54	6.39	0.33	5.43e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg07424592	chr7:64974309	NA	0.7	6.07	0.32	3.39e-9	Diabetic kidney disease;
LUSC	cis	rs897080	0.515	rs1067325	chr2:44628997	C/T	cg00619915	chr2:44497795	NA	-0.41	-5.8	-0.3	1.54e-8	Height;
LUSC	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg27539214	chr16:67997921	SLC12A4	-0.54	-7.52	-0.38	5.23e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-10.82	-0.51	1.39e-23	Response to antipsychotic treatment;
LUSC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg24642844	chr7:1081250	C7orf50	-0.69	-9.49	-0.46	4.43e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg11645453	chr3:52864694	ITIH4	0.35	8.24	0.41	3.87e-15	Bipolar disorder;
LUSC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-6.84	-0.35	3.9e-11	Parkinson's disease;
LUSC	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg25174290	chr11:3078921	CARS	-0.41	-6.19	-0.32	1.8e-9	Calcium levels;
LUSC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg18876405	chr7:65276391	NA	0.42	5.71	0.3	2.45e-8	Aortic root size;
LUSC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs911119	1.000	rs6036478	chr20:23611359	C/A	cg16589663	chr20:23618590	CST3	0.59	6.95	0.36	1.88e-11	Chronic kidney disease;
LUSC	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.55	0.5	1.18e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg22482690	chr17:47019901	SNF8	0.41	7.56	0.38	4.05e-13	Type 2 diabetes;
LUSC	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg22800045	chr5:56110881	MAP3K1	0.46	6.39	0.33	5.61e-10	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg10150615	chr22:24372951	LOC391322	-0.43	-6.76	-0.35	6e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.24	0.52	4.34e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10489202	0.683	rs7515429	chr1:168066659	A/G	cg24449463	chr1:168025552	DCAF6	-0.71	-10.61	-0.5	7.27e-23	Schizophrenia;
LUSC	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4664304	0.629	rs62175466	chr2:160852308	C/T	cg05371993	chr16:1458494	UNKL	0.41	6.01	0.31	4.74e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs977987	0.832	rs37597	chr16:75500275	T/G	cg03315344	chr16:75512273	CHST6	-0.5	-9.3	-0.45	1.87e-18	Dupuytren's disease;
LUSC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21171335	chr12:122356390	WDR66	0.59	8.79	0.43	8.12e-17	Mean corpuscular volume;
LUSC	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.83	-0.35	4.06e-11	Response to antipsychotic treatment;
LUSC	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.09	25.66	0.81	5.5e-81	Colorectal cancer;
LUSC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.91	17.28	0.69	3.13e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.26	-0.32	1.2e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1065852	0.510	rs5751247	chr22:42633054	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.41	7.22	0.37	3.43e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.65	0.39	2.11e-13	Prudent dietary pattern;
LUSC	cis	rs701145	0.585	rs357480	chr3:153891182	A/G	cg17054900	chr3:154042577	DHX36	0.71	7.3	0.37	2.16e-12	Coronary artery disease;
LUSC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-10.6	-0.5	8.23e-23	Monocyte count;
LUSC	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg06552810	chr11:31128660	NA	-0.4	-7.08	-0.36	8.78e-12	Red blood cell count;
LUSC	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg25427524	chr10:38739819	LOC399744	-0.49	-6.8	-0.35	4.81e-11	Obesity (extreme);
LUSC	cis	rs4253772	0.530	rs11090875	chr22:46785301	C/T	cg00784671	chr22:46762841	CELSR1	-0.59	-6.42	-0.33	4.81e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9420	0.961	rs682503	chr11:57640994	C/G	cg02958346	chr11:57425731	CLP1	0.47	6.66	0.34	1.15e-10	Schizophrenia;
LUSC	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg18357645	chr12:58087776	OS9	0.54	8.38	0.42	1.48e-15	Rheumatoid arthritis;
LUSC	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.74	-0.39	1.21e-13	Retinal vascular caliber;
LUSC	cis	rs4499344	0.622	rs4805767	chr19:33049056	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.77	-9.94	-0.48	1.46e-20	Mean platelet volume;
LUSC	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg17757837	chr7:157058334	UBE3C	-0.55	-6.27	-0.32	1.14e-9	Type 2 diabetes;
LUSC	cis	rs34734847	0.766	rs3794214	chr12:121168245	C/T	cg21892295	chr12:121157589	UNC119B	0.33	5.79	0.3	1.65e-8	Mean corpuscular volume;
LUSC	trans	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.44	5.98	0.31	5.61e-9	Corneal astigmatism;
LUSC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg10792982	chr14:105748885	BRF1	0.52	9.39	0.46	9.66e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4662750	0.580	rs4662743	chr2:128350808	A/G	cg06107159	chr2:128432243	LIMS2	0.33	5.83	0.3	1.32e-8	Renal cell carcinoma;
LUSC	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg03585969	chr10:35415529	CREM	-0.58	-8.59	-0.43	3.39e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.62	8.23	0.41	4.34e-15	High light scatter reticulocyte count;
LUSC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg20295408	chr7:1910781	MAD1L1	0.49	6.98	0.36	1.63e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs8017423	0.935	rs4643251	chr14:90669256	C/T	cg14092571	chr14:90743983	NA	0.36	5.71	0.3	2.53e-8	Mortality in heart failure;
LUSC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	0.83	14.09	0.61	1.01e-35	Tonsillectomy;
LUSC	cis	rs56283067	0.740	rs111810959	chr6:44709460	C/A	cg20913747	chr6:44695427	NA	-0.49	-8.22	-0.41	4.6e-15	Total body bone mineral density;
LUSC	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.01	0.44	1.62e-17	Menarche (age at onset);
LUSC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg04830146	chr17:31203787	MYO1D	0.37	5.79	0.3	1.64e-8	Schizophrenia;
LUSC	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs877282	0.898	rs10904546	chr10:757222	A/G	cg17470449	chr10:769945	NA	0.52	6.97	0.36	1.72e-11	Uric acid levels;
LUSC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21643547	chr1:205240462	TMCC2	0.5	9.38	0.46	1.02e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg05855489	chr10:104503620	C10orf26	-0.64	-8.65	-0.43	2.26e-16	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.77	0.3	1.85e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.7	0.51	3.49e-23	Coffee consumption (cups per day);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24053619	chr2:61293272	KIAA1841	0.46	6.37	0.33	6.42e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11971779	0.553	rs7799742	chr7:139051878	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg04691961	chr3:161091175	C3orf57	-0.35	-6.04	-0.31	4.14e-9	Morning vs. evening chronotype;
LUSC	cis	rs7084921	0.608	rs11597561	chr10:101863041	T/C	cg11888571	chr10:102027403	CWF19L1	-0.46	-6.28	-0.32	1.06e-9	Bone mineral density;
LUSC	cis	rs10419226	0.555	rs8100824	chr19:18749412	C/G	cg22001208	chr19:18782374	NA	-0.39	-6.49	-0.33	3.01e-10	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg18681998	chr4:17616180	MED28	0.8	14.29	0.62	1.69e-36	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs977987	0.806	rs7188231	chr16:75436561	T/C	cg03315344	chr16:75512273	CHST6	0.53	10.17	0.49	2.47e-21	Dupuytren's disease;
LUSC	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	0.87	11.49	0.53	5.73e-26	Menopause (age at onset);
LUSC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	8.56	0.42	4.04e-16	Height;
LUSC	cis	rs730566	0.640	rs6442112	chr3:48316034	A/G	cg21141812	chr3:48556323	PFKFB4	0.31	6.07	0.32	3.38e-9	Prion diseases;
LUSC	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.75	-0.47	6.15e-20	Mood instability;
LUSC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg08999081	chr20:33150536	PIGU	-0.4	-7.58	-0.38	3.53e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs9837602	0.938	rs34922392	chr3:99794730	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.06	-0.31	3.72e-9	Breast cancer;
LUSC	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg03948781	chr1:205179583	DSTYK	0.33	6.32	0.33	8.23e-10	Red blood cell count;
LUSC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	0.9	14.8	0.63	1.81e-38	Gestational age at birth (maternal effect);
LUSC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.4	0.33	5.4e-10	Menopause (age at onset);
LUSC	cis	rs3750965	0.839	rs921670	chr11:68871639	C/T	cg06818126	chr11:68850279	TPCN2	-0.46	-6.73	-0.35	7.23e-11	Hair color;
LUSC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg16524733	chr11:117070046	TAGLN	-0.44	-7.72	-0.39	1.37e-13	Blood protein levels;
LUSC	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg22681709	chr2:178499509	PDE11A	-0.42	-6.79	-0.35	5.04e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.4	-6.52	-0.34	2.58e-10	Longevity;Endometriosis;
LUSC	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.3	0.56	6.39e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	trans	rs9693857	0.518	rs7001721	chr8:9271410	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.1	-0.32	2.9e-9	Systolic blood pressure;
LUSC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs4851251	1.000	rs4851251	chr2:100753490	C/T	cg07810366	chr2:100720526	AFF3	0.48	7.05	0.36	1.06e-11	Educational attainment (years of education);
LUSC	cis	rs9420	0.961	rs2847308	chr11:57498232	C/T	cg23127183	chr11:57508653	C11orf31	0.53	8.17	0.41	6.49e-15	Schizophrenia;
LUSC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg23649088	chr2:200775458	C2orf69	0.58	7.93	0.4	3.31e-14	Schizophrenia;
LUSC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11764359	chr7:65958608	NA	0.69	11.09	0.52	1.48e-24	Aortic root size;
LUSC	cis	rs4654899	0.525	rs12035087	chr1:21471606	T/A	cg01072550	chr1:21505969	NA	0.53	8.11	0.41	9.73e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs73206853	0.563	rs7301769	chr12:111171026	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.51	0.38	5.32e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.58	0.5	9.15e-23	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg12806067	chr12:132554024	EP400	-0.4	-6.39	-0.33	5.57e-10	N-glycan levels;
LUSC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg27165867	chr14:105738592	BRF1	-0.52	-7.49	-0.38	6.12e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg27068330	chr11:65405492	SIPA1	-0.76	-10.88	-0.51	8.57e-24	Acne (severe);
LUSC	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg11693508	chr17:37793320	STARD3	-0.5	-6.61	-0.34	1.53e-10	Bipolar disorder;
LUSC	cis	rs9796	0.649	rs8035828	chr15:41467287	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.5	-0.42	6.62e-16	Menopause (age at onset);
LUSC	cis	rs4654899	0.833	rs10127757	chr1:21490045	A/G	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.21	-0.32	1.58e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg14346243	chr4:90757452	SNCA	-0.4	-5.71	-0.3	2.51e-8	Neuroticism;
LUSC	cis	rs7315438	0.600	rs11067601	chr12:115883429	C/T	cg24172291	chr12:115889509	NA	0.34	5.91	0.31	8.22e-9	Colorectal cancer;
LUSC	cis	rs9807841	0.670	rs8113002	chr19:10776606	A/T	cg17710535	chr19:10819994	QTRT1	0.43	6.99	0.36	1.49e-11	Inflammatory skin disease;
LUSC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg12310025	chr6:25882481	NA	-0.42	-6.91	-0.35	2.49e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.94	-0.31	7.3e-9	Resting heart rate;
LUSC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4450131	0.522	rs34336231	chr10:126355662	C/T	cg20435097	chr10:126320824	FAM53B	0.23	5.86	0.31	1.13e-8	White blood cell count (basophil);
LUSC	cis	rs11030122	0.632	rs714380	chr11:4059653	A/T	cg18678763	chr11:4115507	RRM1	-0.5	-6.64	-0.34	1.29e-10	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg19275040	chr1:35325496	C1orf212	0.44	6.42	0.33	4.74e-10	Mosquito bite size;
LUSC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.01	-15.07	-0.64	1.59e-39	Platelet count;
LUSC	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg07274523	chr3:49395745	GPX1	0.66	10.26	0.49	1.18e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.63	0.47	1.55e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08109568	chr15:31115862	NA	-0.58	-7.92	-0.4	3.52e-14	Huntington's disease progression;
LUSC	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg02466173	chr16:30829666	NA	-0.6	-10.87	-0.51	9.42e-24	Multiple myeloma;
LUSC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg11247378	chr22:39784982	NA	-0.66	-12.96	-0.58	2.05e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg04450003	chr12:50355995	AQP5	0.6	10.76	0.51	2.21e-23	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg06784218	chr1:46089804	CCDC17	0.5	10.11	0.48	3.73e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4654899	1.000	rs6669102	chr1:21355543	A/G	cg01072550	chr1:21505969	NA	-0.56	-8.49	-0.42	7.09e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.01	0.44	1.59e-17	Motion sickness;
LUSC	trans	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg26043149	chr18:55253948	FECH	-0.46	-7.13	-0.36	6.34e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7106204	0.748	rs11827778	chr11:24211321	G/A	ch.11.24196551F	chr11:24239977	NA	1.13	12.76	0.57	1.21e-30	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs500891	0.645	rs12204425	chr6:84162024	G/A	cg08257003	chr6:84140564	ME1	0.34	7.66	0.39	1.99e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs96067	0.805	rs4652902	chr1:36612955	C/A	cg24686825	chr1:36642396	MAP7D1	-0.71	-9.67	-0.47	1.18e-19	Corneal structure;
LUSC	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.21	-0.49	1.75e-21	Eye color traits;
LUSC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.88e-11	Primary biliary cholangitis;
LUSC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00321850	chr1:175162397	KIAA0040	0.46	7.83	0.39	6.5e-14	Alcohol dependence;
LUSC	cis	rs7582720	1.000	rs72934745	chr2:203744454	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11764359	chr7:65958608	NA	0.61	9.27	0.45	2.44e-18	Calcium levels;
LUSC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg06640241	chr16:89574553	SPG7	0.88	15.87	0.66	1.12e-42	Multiple myeloma (IgH translocation);
LUSC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.82	-0.3	1.4e-8	Monocyte count;
LUSC	cis	rs6460942	0.908	rs77894875	chr7:12248257	T/C	cg06484146	chr7:12443880	VWDE	-0.58	-6.02	-0.31	4.59e-9	Coronary artery disease;
LUSC	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg19567339	chr10:100142640	NA	0.38	5.67	0.3	3.1e-8	Metabolite levels;
LUSC	trans	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.75	-0.35	6.41e-11	Life satisfaction;
LUSC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-13.43	-0.59	3.55e-33	Hemoglobin concentration;
LUSC	cis	rs78545713	0.536	rs2179516	chr6:26229411	C/T	cg23601095	chr6:26197514	HIST1H3D	0.64	5.76	0.3	1.87e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg24531977	chr5:56204891	C5orf35	-0.72	-10.37	-0.49	4.9e-22	Coronary artery disease;
LUSC	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg10978503	chr1:24200527	CNR2	0.54	13.21	0.59	2.32e-32	Immature fraction of reticulocytes;
LUSC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.75	-0.39	1.09e-13	Mean platelet volume;
LUSC	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg19743168	chr1:23544995	NA	0.38	7.13	0.36	6.16e-12	Height;
LUSC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.82	14.21	0.61	3.48e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.82	-13.78	-0.6	1.69e-34	Aortic root size;
LUSC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg08888203	chr3:10149979	C3orf24	0.66	9.31	0.45	1.79e-18	Alzheimer's disease;
LUSC	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg04865166	chr7:105162814	PUS7	0.53	5.87	0.31	1.06e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-7.6	-0.38	3.1e-13	Schizophrenia;
LUSC	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg04998671	chr14:104000505	TRMT61A	-0.48	-6.71	-0.34	8.58e-11	Reticulocyte count;
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg25243455	chr2:114033360	PAX8;LOC440839	-0.34	-7.75	-0.39	1.13e-13	Lymphocyte counts;
LUSC	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg05784532	chr1:230284198	GALNT2	0.54	8.04	0.4	1.6e-14	Coronary artery disease;
LUSC	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg25019033	chr10:957182	NA	-0.58	-7.63	-0.39	2.55e-13	Eosinophil percentage of granulocytes;
LUSC	cis	rs7589342	0.792	rs13426321	chr2:106500280	G/A	cg14210321	chr2:106509881	NCK2	-0.6	-9.09	-0.45	9.21e-18	Addiction;
LUSC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg24578937	chr1:2090814	PRKCZ	0.45	9.95	0.48	1.32e-20	Height;
LUSC	cis	rs1847202	0.826	rs11922892	chr3:72952186	T/G	cg25664220	chr3:72788482	NA	-0.44	-7.94	-0.4	3.21e-14	Motion sickness;
LUSC	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.81	0.51	1.43e-23	Morning vs. evening chronotype;
LUSC	cis	rs9399401	0.884	rs263181	chr6:142862719	A/G	cg03128060	chr6:142623767	GPR126	0.32	5.93	0.31	7.55e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg09021430	chr5:549028	NA	0.43	7.62	0.38	2.65e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06481639	chr22:41940642	POLR3H	-0.53	-6.19	-0.32	1.77e-9	Vitiligo;
LUSC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg11657440	chr19:46296263	DMWD	0.87	16.17	0.66	7.44e-44	Coronary artery disease;
LUSC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg07061783	chr6:25882402	NA	-0.5	-6.81	-0.35	4.41e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	7.26	0.37	2.8e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	trans	rs4148689	0.904	rs12533524	chr7:117187461	T/C	cg10450175	chr16:88689712	ZC3H18	0.47	6.09	0.32	3.08e-9	Gout;
LUSC	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg00898013	chr13:113819073	PROZ	-0.56	-8.48	-0.42	7.34e-16	Platelet distribution width;
LUSC	cis	rs3768617	0.966	rs10797850	chr1:183094802	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.71	0.43	1.44e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs1178968	1.000	rs757938	chr7:72778573	A/G	cg25889504	chr7:72793014	NA	0.54	7.03	0.36	1.16e-11	Triglyceride levels;
LUSC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.46	6.71	0.34	8.59e-11	Schizophrenia;
LUSC	cis	rs2086824	0.702	rs3114891	chr16:89399455	A/G	cg02187348	chr16:89574699	SPG7	0.38	5.76	0.3	1.86e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs4700695	0.764	rs152993	chr5:65262968	A/T	cg21114390	chr5:65439923	SFRS12	0.49	5.64	0.3	3.56e-8	Facial morphology (factor 19);
LUSC	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg16383222	chr8:145688536	CYHR1	-0.35	-5.99	-0.31	5.5e-9	Age at first birth;
LUSC	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg15934090	chr1:100435551	SLC35A3	0.48	8.28	0.41	3.05e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3771570	1.000	rs73002147	chr2:242302934	T/C	cg21155796	chr2:242212141	HDLBP	0.62	6.67	0.34	1.07e-10	Prostate cancer;
LUSC	cis	rs7572644	0.664	rs12473340	chr2:28023797	G/A	cg27432699	chr2:27873401	GPN1	0.59	7.64	0.39	2.28e-13	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs4704187	0.687	rs1582504	chr5:74479545	C/T	cg03227963	chr5:74354835	NA	0.3	6.59	0.34	1.68e-10	Response to amphetamines;
LUSC	trans	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg21775007	chr8:11205619	TDH	-0.43	-6.13	-0.32	2.42e-9	Mood instability;
LUSC	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs2573652	1.000	rs2581341	chr15:100514494	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.43	-7.88	-0.4	4.54e-14	Height;
LUSC	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg00484396	chr16:3507460	NAT15	-0.37	-6.2	-0.32	1.65e-9	Body mass index (adult);
LUSC	trans	rs656319	0.625	rs34427895	chr8:9875221	G/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.93	-0.35	2.22e-11	Myopia (pathological);
LUSC	cis	rs6012953	0.967	rs6020585	chr20:49147492	T/C	cg13958625	chr20:49123093	NA	0.31	6.73	0.35	7.53e-11	Vitiligo;
LUSC	cis	rs7945718	0.905	rs4454698	chr11:12720560	A/G	cg25843174	chr11:12811716	TEAD1	-0.32	-7.03	-0.36	1.2e-11	Educational attainment (years of education);
LUSC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg04315214	chr1:2043799	PRKCZ	0.46	9.54	0.46	3.05e-19	Height;
LUSC	cis	rs11718455	0.548	rs9824340	chr3:43902170	A/G	cg08738300	chr3:44038990	NA	0.57	8.32	0.41	2.34e-15	Coronary artery disease;
LUSC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.3	-0.33	9.44e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.45	7.05	0.36	1.04e-11	Systolic blood pressure;
LUSC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14829155	chr15:31115871	NA	-0.57	-7.93	-0.4	3.23e-14	Huntington's disease progression;
LUSC	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg07423050	chr13:99094983	FARP1	-0.53	-9.68	-0.47	1.04e-19	Longevity;
LUSC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg10018233	chr7:150070692	REPIN1	0.4	7.28	0.37	2.48e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg23711669	chr6:146136114	FBXO30	0.87	15.5	0.65	3.27e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg06462663	chr19:18546047	ISYNA1	0.46	7.91	0.4	3.7e-14	Breast cancer;
LUSC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg09021430	chr5:549028	NA	-0.56	-7.62	-0.38	2.66e-13	Obesity-related traits;
LUSC	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg04374321	chr14:90722782	PSMC1	-0.66	-10.01	-0.48	8.62e-21	Mortality in heart failure;
LUSC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.58	-10.06	-0.48	5.56e-21	Obesity-related traits;
LUSC	cis	rs427941	0.632	rs201492	chr7:101754138	C/T	cg06246474	chr7:101738831	CUX1	0.39	6.32	0.33	8.19e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs9815354	0.812	rs73079360	chr3:41888372	T/A	cg03022575	chr3:42003672	ULK4	0.84	8.74	0.43	1.14e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg19773385	chr1:10388646	KIF1B	-0.55	-8.54	-0.42	4.65e-16	Hepatocellular carcinoma;
LUSC	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg13852791	chr20:30311386	BCL2L1	0.7	7.94	0.4	3.17e-14	Mean corpuscular hemoglobin;
LUSC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs7903847	0.642	rs10882911	chr10:99138064	A/C	cg08345082	chr10:99160200	RRP12	-0.37	-7.56	-0.38	3.89e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs870825	0.860	rs10015194	chr4:185598925	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	12.67	0.57	2.58e-30	Blood protein levels;
LUSC	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg00277334	chr10:82204260	NA	-0.53	-7.33	-0.37	1.73e-12	Post bronchodilator FEV1;
LUSC	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg16586182	chr3:47516702	SCAP	-0.51	-8.05	-0.4	1.47e-14	Colorectal cancer;
LUSC	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.52	-0.42	5.45e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg22532475	chr10:104410764	TRIM8	-0.25	-6.13	-0.32	2.43e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.03	0.44	1.37e-17	Motion sickness;
LUSC	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg00071950	chr4:10020882	SLC2A9	0.42	6.63	0.34	1.37e-10	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.06	-24.1	-0.8	4.7e-75	Ulcerative colitis;
LUSC	cis	rs908922	1.000	rs908922	chr1:152454591	C/T	cg20991723	chr1:152506922	NA	0.51	9.21	0.45	3.63e-18	Hair morphology;
LUSC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg12639453	chr1:2035780	PRKCZ	0.3	6.4	0.33	5.4e-10	Height;
LUSC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24549020	chr5:56110836	MAP3K1	0.49	5.76	0.3	1.93e-8	Initial pursuit acceleration;
LUSC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.65	11.32	0.53	2.22e-25	Aortic root size;
LUSC	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg23625390	chr15:77176239	SCAPER	-0.65	-10.02	-0.48	7.95e-21	Blood metabolite levels;
LUSC	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.87	-0.35	3.12e-11	Response to antipsychotic treatment;
LUSC	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg05294307	chr14:35346193	BAZ1A	-0.58	-6.65	-0.34	1.18e-10	Psoriasis;
LUSC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg06219351	chr7:158114137	PTPRN2	0.48	8.65	0.43	2.22e-16	Calcium levels;
LUSC	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg08017756	chr2:100939284	LONRF2	-0.47	-8.72	-0.43	1.34e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg12564285	chr5:131593104	PDLIM4	0.41	8.01	0.4	1.98e-14	Blood metabolite levels;
LUSC	cis	rs7799006	0.862	rs3757439	chr7:2272122	C/T	cg02951883	chr7:2050386	MAD1L1	-0.34	-5.81	-0.3	1.45e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg20587970	chr11:113659929	NA	-1.11	-13.48	-0.59	2.22e-33	Hip circumference adjusted for BMI;
LUSC	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg18795169	chr1:18902165	NA	-1.01	-24.4	-0.8	3.36e-76	Urate levels in lean individuals;
LUSC	cis	rs72960926	0.744	rs56077244	chr6:74920700	A/G	cg03266952	chr6:74778945	NA	-0.84	-7.09	-0.36	8.15e-12	Metabolite levels (MHPG);
LUSC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06850241	chr22:41845214	NA	0.31	5.8	0.3	1.56e-8	Vitiligo;
LUSC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg07936489	chr17:37558343	FBXL20	0.63	8.2	0.41	5.41e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.49	-0.5	1.89e-22	Alzheimer's disease;
LUSC	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.07	-0.48	5.32e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg15556689	chr8:8085844	FLJ10661	-0.7	-11.5	-0.53	5.06e-26	Joint mobility (Beighton score);
LUSC	cis	rs7709377	0.595	rs173813	chr5:115632671	A/C	cg23108291	chr5:115420582	COMMD10	-0.43	-6.11	-0.32	2.83e-9	Metabolite levels  (X-11787);
LUSC	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg08601574	chr20:25228251	PYGB	-0.41	-6.24	-0.32	1.33e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs10484761	0.529	rs6914427	chr6:40806615	T/A	cg20593826	chr1:59280370	NA	0.44	6.33	0.33	8.08e-10	Esophageal cancer;
LUSC	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg01420254	chr6:26195488	NA	0.65	7.24	0.37	3.03e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg11693508	chr17:37793320	STARD3	0.56	6.7	0.34	8.71e-11	Bipolar disorder;
LUSC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg08968635	chr6:28129556	ZNF389	0.45	5.67	0.3	3.06e-8	Parkinson's disease;
LUSC	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg10518543	chr12:38710700	ALG10B	0.41	5.79	0.3	1.66e-8	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg12463550	chr7:65579703	CRCP	0.42	6.04	0.31	4.08e-9	Aortic root size;
LUSC	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.05	-21.18	-0.76	1.05e-63	Ulcerative colitis;
LUSC	trans	rs72674100	1.000	rs28645642	chr4:97971149	C/T	cg16405019	chr1:18959625	PAX7	-0.58	-6.31	-0.33	8.97e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg05501817	chr11:14380813	RRAS2	-0.57	-9.02	-0.44	1.49e-17	Sense of smell;
LUSC	cis	rs6728642	0.803	rs11891458	chr2:97632450	G/T	cg26665480	chr2:98280029	ACTR1B	-0.65	-5.77	-0.3	1.76e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs11039100	1.000	rs11039100	chr11:5827003	C/T	cg13902645	chr11:5959945	NA	0.53	5.93	0.31	7.62e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.61	-9.62	-0.47	1.67e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3824867	0.879	rs4752837	chr11:47465955	G/A	cg20307385	chr11:47447363	PSMC3	0.64	9.48	0.46	4.83e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs4363385	0.747	rs946098	chr1:152975038	A/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.71	-0.39	1.44e-13	Inflammatory skin disease;
LUSC	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg00990874	chr7:1149470	C7orf50	-0.51	-5.94	-0.31	7.14e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs4851254	0.550	rs13402299	chr2:100659409	C/T	cg22139774	chr2:100720529	AFF3	-0.44	-5.75	-0.3	2.06e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg00945038	chr17:61921165	SMARCD2	0.4	6.02	0.31	4.67e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs865483	0.895	rs853191	chr17:35821758	A/T	cg06716730	chr17:35851459	DUSP14	0.28	6.3	0.33	9.49e-10	Monocyte count;
LUSC	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg06917634	chr15:78832804	PSMA4	0.52	6.47	0.33	3.58e-10	Post bronchodilator FEV1;
LUSC	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg04063615	chr12:132293388	NA	-0.37	-5.9	-0.31	9.1e-9	Migraine;
LUSC	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg02158880	chr13:53174818	NA	0.38	5.73	0.3	2.25e-8	Lewy body disease;
LUSC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg11812906	chr14:75593930	NEK9	0.65	11.13	0.52	1.1e-24	Height;
LUSC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.6	0.57	4.81e-30	Motion sickness;
LUSC	cis	rs7940866	0.903	rs1347283	chr11:130868583	T/G	cg12179176	chr11:130786555	SNX19	0.62	9.55	0.46	2.88e-19	Schizophrenia;
LUSC	cis	rs6750047	0.585	rs4670808	chr2:38267794	A/G	cg07380506	chr2:38303506	CYP1B1	0.43	5.95	0.31	6.7e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg18240062	chr17:79603768	NPLOC4	0.58	10.08	0.48	4.95e-21	Eye color traits;
LUSC	cis	rs6120849	0.573	rs3746429	chr20:33703607	A/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-5.73	-0.3	2.21e-8	Protein C levels;
LUSC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.01	0.77	5.62e-67	Prudent dietary pattern;
LUSC	trans	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg06521331	chr12:34319734	NA	-0.4	-6.19	-0.32	1.74e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.63	7.75	0.39	1.12e-13	Schizophrenia;
LUSC	trans	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg10756647	chr7:56101905	PSPH	0.85	8.34	0.42	2.04e-15	Diabetic kidney disease;
LUSC	cis	rs2969070	0.867	rs886626	chr7:2498052	A/C	cg03277898	chr7:2518824	NA	-0.29	-6.08	-0.32	3.24e-9	Diastolic blood pressure;
LUSC	trans	rs236907	0.814	rs2232825	chr1:171763549	C/T	cg13482142	chr2:234261155	NA	0.48	5.98	0.31	5.66e-9	Mean platelet volume;
LUSC	cis	rs3862435	0.764	rs16944453	chr15:90998905	G/A	cg22089800	chr15:90895588	ZNF774	0.55	5.78	0.3	1.76e-8	Response to exercise (triglyceride level interaction);
LUSC	cis	rs6967385	0.900	rs10278941	chr7:12364646	G/C	cg20607287	chr7:12443886	VWDE	0.4	5.86	0.31	1.09e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7923609	0.967	rs7076310	chr10:65135672	C/A	cg01631684	chr10:65280961	REEP3	-0.38	-5.89	-0.31	9.62e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	7.14	0.36	5.81e-12	Menarche (age at onset);
LUSC	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.67	-0.5	4.42e-23	Glomerular filtration rate;
LUSC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg11003573	chr3:44754125	ZNF502	-0.35	-5.68	-0.3	3.01e-8	Depressive symptoms;
LUSC	cis	rs524023	1.000	rs524023	chr11:64358265	C/T	cg19131476	chr11:64387923	NRXN2	0.37	9.84	0.47	3.17e-20	Urate levels in obese individuals;
LUSC	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.92	15.81	0.65	1.92e-42	Bladder cancer;
LUSC	trans	rs1223397	0.938	rs35549743	chr6:13294354	C/T	cg13974761	chr1:152670598	LCE2A	0.37	6.04	0.31	4.07e-9	Blood pressure;
LUSC	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.44	-0.42	9.64e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.08	15.25	0.64	3.22e-40	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs55910451	0.520	rs1858446	chr10:5852172	C/T	cg11519256	chr10:5708881	ASB13	0.48	6.06	0.31	3.59e-9	Breast cancer;
LUSC	cis	rs59698941	0.943	rs66628697	chr5:132252561	C/T	cg02081065	chr5:132209139	LEAP2	-0.64	-6.66	-0.34	1.1e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs7429990	0.965	rs1550914	chr3:47995168	A/C	cg20734569	chr3:48348370	SPINK8	-0.37	-6.26	-0.32	1.2e-9	Educational attainment (years of education);
LUSC	cis	rs9362426	0.672	rs12663865	chr6:88103149	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	5.79	0.3	1.65e-8	Depressive episodes in bipolar disorder;
LUSC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25072359	chr17:41440525	NA	0.65	9.39	0.46	9.33e-19	Menopause (age at onset);
LUSC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg16624210	chr5:671434	TPPP	0.49	6.27	0.32	1.12e-9	Obesity-related traits;
LUSC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg22906224	chr7:99728672	NA	0.6	8.76	0.43	1.01e-16	Coronary artery disease;
LUSC	cis	rs2445762	0.518	rs8043240	chr15:51635565	C/T	cg07517944	chr15:51633816	GLDN	0.37	6.65	0.34	1.21e-10	Hormone measurements;
LUSC	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg06627628	chr2:24431161	ITSN2	-0.6	-7.34	-0.37	1.69e-12	Lymphocyte counts;
LUSC	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.63	8.23	0.41	4.31e-15	Schizophrenia;
LUSC	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg04545296	chr12:48745243	ZNF641	0.34	6.17	0.32	1.98e-9	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs16854884	0.586	rs7650172	chr3:143729408	G/C	cg06585982	chr3:143692056	C3orf58	0.53	8.45	0.42	9.21e-16	Economic and political preferences (feminism/equality);
LUSC	cis	rs250677	0.522	rs17109208	chr5:148378475	G/A	cg18129178	chr5:148520854	ABLIM3	-0.51	-7.5	-0.38	5.69e-13	Breast cancer;
LUSC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22590775	chr19:49891494	CCDC155	0.61	8.79	0.43	8.23e-17	Multiple sclerosis;
LUSC	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.69	-0.34	9.58e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	7.28	0.37	2.36e-12	Mean platelet volume;
LUSC	cis	rs6494488	0.500	rs72741338	chr15:64761087	G/A	cg08069370	chr15:64387884	SNX1	-0.65	-5.75	-0.3	2.06e-8	Coronary artery disease;
LUSC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg10018233	chr7:150070692	REPIN1	0.38	6.72	0.35	7.85e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg22906224	chr7:99728672	NA	-0.49	-6.94	-0.35	2.11e-11	Coronary artery disease;
LUSC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg10556349	chr10:835070	NA	0.56	6.65	0.34	1.17e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg10556349	chr10:835070	NA	0.56	6.27	0.32	1.09e-9	Eosinophil percentage of granulocytes;
LUSC	trans	rs800082	0.501	rs9878902	chr3:144220319	A/T	cg24215973	chr2:240111563	HDAC4	0.49	7.59	0.38	3.24e-13	Smoking behavior;
LUSC	cis	rs16910800	0.731	rs35725172	chr11:23185968	G/A	cg20040320	chr11:23191996	NA	-0.59	-7.6	-0.38	3.11e-13	Cancer;
LUSC	cis	rs9311676	0.656	rs62258127	chr3:58397102	G/A	cg13750441	chr3:58318267	PXK	0.35	6.81	0.35	4.44e-11	Systemic lupus erythematosus;
LUSC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19346786	chr7:2764209	NA	-0.4	-7.1	-0.36	7.35e-12	Height;
LUSC	cis	rs1395	0.925	rs2580754	chr2:27398196	A/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.4	6.82	0.35	4.24e-11	Blood metabolite levels;
LUSC	trans	rs1973993	0.745	rs6683508	chr1:96955038	T/C	cg10631902	chr5:14652156	NA	-0.46	-6.74	-0.35	6.92e-11	Weight;
LUSC	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg05855489	chr10:104503620	C10orf26	0.53	8.09	0.4	1.11e-14	Arsenic metabolism;
LUSC	cis	rs6433857	0.536	rs7557023	chr2:181350474	G/A	cg23363182	chr2:181467187	NA	-0.44	-7.18	-0.37	4.61e-12	Body mass index;
LUSC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.97	0.51	3.92e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4722166	0.704	rs4321884	chr7:22741459	A/T	cg05472934	chr7:22766657	IL6	0.37	5.95	0.31	6.59e-9	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16827057	chr17:73257779	MRPS7;GGA3	-0.43	-6.34	-0.33	7.28e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21784498	chr17:26645922	TMEM97	-0.4	-5.99	-0.31	5.38e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs72960926	0.744	rs72954341	chr6:74947167	A/G	cg03266952	chr6:74778945	NA	-0.77	-6.77	-0.35	5.96e-11	Metabolite levels (MHPG);
LUSC	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.05	-0.31	3.97e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2398893	1.000	rs2398893	chr9:96758342	A/G	cg14459158	chr9:96720562	NA	0.32	6.15	0.32	2.24e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2286885	0.965	rs4837091	chr9:129244928	A/G	cg15282417	chr9:129245246	FAM125B	0.37	6.13	0.32	2.54e-9	Intraocular pressure;
LUSC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg02782426	chr3:40428986	ENTPD3	0.38	6.2	0.32	1.67e-9	Renal cell carcinoma;
LUSC	trans	rs34421088	0.506	rs2409755	chr8:11169983	G/A	cg15556689	chr8:8085844	FLJ10661	0.44	6.48	0.33	3.37e-10	Neuroticism;
LUSC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08219700	chr8:58056026	NA	0.7	7.95	0.4	2.95e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg25233709	chr10:116636983	FAM160B1	0.38	6.63	0.34	1.38e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg20848291	chr7:100343083	ZAN	0.39	6.05	0.31	3.89e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs6736093	0.966	rs34087685	chr2:112693010	G/C	cg12686935	chr2:112915763	FBLN7	-0.36	-5.84	-0.3	1.25e-8	Coronary artery disease;
LUSC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg16447950	chr5:562315	NA	-0.58	-7.11	-0.36	7.26e-12	Obesity-related traits;
LUSC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg23711669	chr6:146136114	FBXO30	0.83	14.71	0.63	4.06e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg26380479	chr7:97908229	NA	-0.27	-5.95	-0.31	6.69e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg25319279	chr11:5960081	NA	-0.39	-5.81	-0.3	1.42e-8	DNA methylation (variation);
LUSC	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg05855489	chr10:104503620	C10orf26	0.52	7.86	0.4	5.22e-14	Arsenic metabolism;
LUSC	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	0.98	14.62	0.62	9.25e-38	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs10992471	0.580	rs12341093	chr9:95234182	G/T	cg14631576	chr9:95140430	CENPP	-0.34	-6.17	-0.32	1.97e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs3755132	0.852	rs6431718	chr2:15747875	C/T	cg12888861	chr2:15731646	DDX1	0.5	7.27	0.37	2.55e-12	Wilms tumor;
LUSC	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg11621586	chr10:70884670	VPS26A	-1.12	-11.2	-0.52	6.16e-25	Left atrial antero-posterior diameter;
LUSC	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg04450456	chr4:17643702	FAM184B	0.39	6.54	0.34	2.34e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12195417	0.758	rs6454326	chr6:84115740	A/G	cg08257003	chr6:84140564	ME1	0.36	8.88	0.44	4.2e-17	Schizophrenia;
LUSC	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg10523679	chr1:76189770	ACADM	-0.46	-6.67	-0.34	1.04e-10	Daytime sleep phenotypes;
LUSC	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg03948781	chr1:205179583	DSTYK	-0.32	-6.1	-0.32	2.91e-9	Red blood cell count;
LUSC	cis	rs7615316	0.779	rs2862744	chr3:142105519	C/A	cg16271453	chr3:142027066	XRN1	-0.4	-7.11	-0.36	7.04e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.9	14.4	0.62	6.73e-37	Cisplatin-induced ototoxicity;
LUSC	cis	rs7246967	0.551	rs57775631	chr19:22814461	T/C	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	trans	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg25214090	chr10:38739885	LOC399744	0.59	8.52	0.42	5.67e-16	Corneal astigmatism;
LUSC	cis	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg06521852	chr22:38141419	TRIOBP	0.42	6.31	0.33	8.96e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.24	-0.37	3.14e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg08017756	chr2:100939284	LONRF2	-0.39	-6.57	-0.34	1.98e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07080220	chr10:102295463	HIF1AN	0.68	9.6	0.47	1.93e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	0.63	13.39	0.59	4.87e-33	Prudent dietary pattern;
LUSC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.65	0.57	3.1e-30	Motion sickness;
LUSC	trans	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg21361702	chr7:150065534	REPIN1	0.44	5.99	0.31	5.45e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.44	-0.38	8.85e-13	Psoriasis;
LUSC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg12564285	chr5:131593104	PDLIM4	0.47	8.54	0.42	4.98e-16	Blood metabolite levels;
LUSC	cis	rs2637266	0.507	rs2637250	chr10:78282063	T/C	cg18941641	chr10:78392320	NA	0.32	5.96	0.31	6.3e-9	Pulmonary function;
LUSC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25072359	chr17:41440525	NA	0.65	9.28	0.45	2.18e-18	Menopause (age at onset);
LUSC	cis	rs742132	0.527	rs12526321	chr6:25494503	A/G	cg03264133	chr6:25882463	NA	0.47	6.49	0.33	3.12e-10	Uric acid levels;
LUSC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg01879757	chr17:41196368	BRCA1	-0.46	-7.4	-0.38	1.14e-12	Menopause (age at onset);
LUSC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.32	-0.56	5.36e-29	Rheumatoid arthritis;
LUSC	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg08975724	chr8:8085496	FLJ10661	0.46	6.53	0.34	2.5e-10	Joint mobility (Beighton score);
LUSC	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg15133208	chr4:90757351	SNCA	-0.53	-8.27	-0.41	3.2e-15	Neuroticism;
LUSC	cis	rs9399401	0.667	rs6922607	chr6:142703483	A/G	cg03128060	chr6:142623767	GPR126	0.6	9.89	0.48	2.22e-20	Chronic obstructive pulmonary disease;
LUSC	cis	rs13082711	0.595	rs17681498	chr3:27331258	T/C	cg02860705	chr3:27208620	NA	0.74	12.38	0.56	3.2e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs6690583	0.623	rs2028304	chr1:85488030	G/A	cg11262906	chr1:85462892	MCOLN2	-0.66	-6.65	-0.34	1.23e-10	Serum sulfate level;
LUSC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg05785598	chr3:49045655	WDR6	0.33	5.84	0.3	1.22e-8	Parkinson's disease;
LUSC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg22906224	chr7:99728672	NA	0.55	8.1	0.41	1.01e-14	Coronary artery disease;
LUSC	cis	rs7605827	0.930	rs7579714	chr2:15686869	A/C	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.82e-16	Educational attainment (years of education);
LUSC	cis	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg03522245	chr20:25566470	NINL	-0.36	-5.73	-0.3	2.21e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.79	12.95	0.58	2.4e-31	Selective IgA deficiency;
LUSC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg07936489	chr17:37558343	FBXL20	-0.72	-9.84	-0.47	3.17e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.2	-0.32	1.68e-9	Bladder cancer;
LUSC	cis	rs509477	0.718	rs273346	chr18:32603056	G/T	cg23791764	chr18:32556832	MAPRE2	0.4	5.79	0.3	1.65e-8	Cerebrospinal fluid AB1-42 levels;
LUSC	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg07905836	chr2:113190072	RGPD8;RGPD5	0.8	8.83	0.43	6.23e-17	Yeast infection;
LUSC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg14552801	chr7:65878734	NA	0.45	6.34	0.33	7.34e-10	Aortic root size;
LUSC	cis	rs9831754	0.906	rs9869812	chr3:78385679	G/A	cg06138941	chr3:78371609	NA	-0.66	-8.99	-0.44	1.87e-17	Calcium levels;
LUSC	cis	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg09904177	chr6:26538194	HMGN4	-0.76	-5.96	-0.31	6.44e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03959472	chr4:170191358	SH3RF1	-0.44	-5.96	-0.31	6.49e-9	Hepatitis;
LUSC	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg06530960	chr19:49140787	SEC1;DBP	-0.55	-7.52	-0.38	5.14e-13	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.65	-0.39	2.17e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs6009527	1.000	rs2318942	chr22:49573505	G/A	cg12746016	chr22:49560550	NA	0.37	6.24	0.32	1.3e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg04539111	chr16:67997858	SLC12A4	-0.45	-5.92	-0.31	7.92e-9	HDL cholesterol;
LUSC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.56	0.38	3.9e-13	Colorectal cancer;
LUSC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	0.76	11.15	0.52	9.4e-25	Gut microbiome composition (summer);
LUSC	cis	rs7621025	0.500	rs4678275	chr3:136653683	C/T	cg15507776	chr3:136538369	TMEM22	0.59	8.34	0.42	1.99e-15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUSC	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.7	0.75	7.91e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-6.81	-0.35	4.57e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg17376030	chr22:41985996	PMM1	-0.46	-5.81	-0.3	1.45e-8	Vitiligo;
LUSC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.45	0.53	8.13e-26	Prudent dietary pattern;
LUSC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg09491104	chr22:46646882	C22orf40	-0.7	-7.38	-0.37	1.28e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg04315214	chr1:2043799	PRKCZ	-0.39	-7.74	-0.39	1.18e-13	Height;
LUSC	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg20703242	chr1:230279135	GALNT2	0.55	8.6	0.43	3.24e-16	Coronary artery disease;
LUSC	cis	rs6961069	0.503	rs3211834	chr7:80280117	A/C	cg04458919	chr7:80252533	CD36	0.39	6.66	0.34	1.11e-10	Platelet count;
LUSC	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg12002119	chr2:101014098	CHST10	0.36	6.06	0.31	3.77e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs17095355	1.000	rs12571872	chr10:111676114	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.64	-7.47	-0.38	6.94e-13	Biliary atresia;
LUSC	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg04990556	chr1:26633338	UBXN11	-0.45	-6.05	-0.31	3.93e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs983392	0.679	rs636317	chr11:60019150	C/T	cg20284999	chr11:59952153	MS4A6A	0.4	6.87	0.35	3.22e-11	Alzheimer's disease (late onset);
LUSC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.83	-0.35	4.1e-11	Lung cancer;
LUSC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.49	-0.38	6.26e-13	Blood metabolite levels;
LUSC	cis	rs73206853	0.841	rs73191840	chr12:110970457	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	6.47	0.33	3.57e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg22089800	chr15:90895588	ZNF774	0.65	9.74	0.47	6.63e-20	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs317865	0.748	rs73234656	chr4:16212702	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.6	5.76	0.3	1.94e-8	Kidney disease (early stage) in type 1 diabetes;
LUSC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg24250549	chr1:154909240	PMVK	0.64	10.4	0.49	3.92e-22	Prostate cancer;
LUSC	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg05805236	chr11:65401703	PCNXL3	-0.63	-10.33	-0.49	6.71e-22	Acne (severe);
LUSC	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg16230307	chr14:35515116	FAM177A1	0.81	10.21	0.49	1.73e-21	Psoriasis;
LUSC	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.32	-6.47	-0.33	3.46e-10	Schizophrenia;
LUSC	cis	rs1865721	0.771	rs7235563	chr18:73139335	C/G	cg26385618	chr18:73139727	C18orf62	-0.51	-8.93	-0.44	2.96e-17	Intelligence;
LUSC	cis	rs7615316	0.751	rs57177110	chr3:142139172	T/C	cg16271453	chr3:142027066	XRN1	-0.43	-7.46	-0.38	7.63e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg18225595	chr11:63971243	STIP1	0.63	10.13	0.48	3.22e-21	Platelet count;
LUSC	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg20991723	chr1:152506922	NA	0.52	9.91	0.48	1.86e-20	Hair morphology;
LUSC	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg16586182	chr3:47516702	SCAP	0.52	7.96	0.4	2.63e-14	Colorectal cancer;
LUSC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg09021430	chr5:549028	NA	-0.49	-6.93	-0.35	2.23e-11	Obesity-related traits;
LUSC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg13206674	chr6:150067644	NUP43	0.58	9.08	0.45	9.37e-18	Lung cancer;
LUSC	cis	rs4664308	1.000	rs6707458	chr2:160914540	G/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-10.68	-0.5	4.21e-23	Idiopathic membranous nephropathy;
LUSC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-7.74	-0.39	1.21e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9462027	0.585	rs2814976	chr6:34576237	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.52e-9	Systemic lupus erythematosus;
LUSC	cis	rs7527798	0.592	rs11118282	chr1:207832402	G/A	cg09232269	chr1:207846808	CR1L	-0.29	-6.21	-0.32	1.61e-9	Erythrocyte sedimentation rate;
LUSC	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.73	11.13	0.52	1.14e-24	Eosinophil percentage of white cells;
LUSC	cis	rs599083	0.793	rs471966	chr11:68173861	C/T	cg20283391	chr11:68216788	NA	0.48	6.53	0.34	2.39e-10	Bone mineral density (spine);
LUSC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-1.03	-20.07	-0.74	2.43e-59	Height;
LUSC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg16362232	chr11:430036	ANO9	0.6	7.87	0.4	4.86e-14	Body mass index;
LUSC	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg11189052	chr15:85197271	WDR73	0.48	5.87	0.31	1.04e-8	Schizophrenia;
LUSC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg24250549	chr1:154909240	PMVK	0.62	10.02	0.48	7.91e-21	Prostate cancer;
LUSC	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.71	-0.91	1.49e-128	Myeloid white cell count;
LUSC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	29.12	0.85	1.14e-93	Chronic sinus infection;
LUSC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-6.54	-0.34	2.26e-10	Body mass index;
LUSC	cis	rs2932538	0.922	rs6668533	chr1:113064468	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	9.76	0.47	5.68e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg05347473	chr6:146136440	FBXO30	0.53	9.01	0.44	1.61e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12973672	0.904	rs12974791	chr19:35767218	A/G	cg12095397	chr19:35769544	USF2	0.44	6.92	0.35	2.37e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg16606324	chr3:10149918	C3orf24	-0.58	-8.47	-0.42	7.82e-16	Alzheimer's disease;
LUSC	cis	rs4629710	0.592	rs4424112	chr6:131563788	C/T	cg12700074	chr6:131571435	AKAP7	-0.35	-5.76	-0.3	1.91e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg00290607	chr11:67383545	NA	0.37	6.93	0.35	2.22e-11	Mean corpuscular volume;
LUSC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2324229	0.754	rs1180234	chr6:83948473	G/T	cg08257003	chr6:84140564	ME1	0.28	6.78	0.35	5.51e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs790123	1.000	rs2650950	chr3:122382048	C/T	cg17380795	chr3:122379686	NA	0.35	5.74	0.3	2.15e-8	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg00310523	chr12:86230176	RASSF9	0.4	7.33	0.37	1.8e-12	Major depressive disorder;
LUSC	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.56	0.6	1.12e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs55720021	1	rs55720021	chr19:49144241	G/T	cg06530960	chr19:49140787	SEC1;DBP	0.5	6.67	0.34	1.09e-10	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
LUSC	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg06623918	chr6:96969491	KIAA0776	0.77	9.22	0.45	3.56e-18	Migraine;Coronary artery disease;
LUSC	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	3e-9	Prostate cancer;
LUSC	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg25061697	chr4:841865	NA	-0.39	-6.02	-0.31	4.67e-9	Bladder cancer;
LUSC	cis	rs1215050	0.904	rs1727285	chr4:98978821	G/A	cg05340658	chr4:99064831	C4orf37	-0.43	-6.57	-0.34	1.96e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs354225	0.584	rs13432302	chr2:54813938	A/C	cg26097391	chr2:54893211	SPTBN1	0.44	6.6	0.34	1.6e-10	Schizophrenia;
LUSC	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg14530993	chr4:882597	GAK	0.66	6.7	0.34	9.12e-11	Parkinson's disease;
LUSC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.57	-0.38	3.74e-13	Tonsillectomy;
LUSC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg25456477	chr12:86230367	RASSF9	-0.35	-6.18	-0.32	1.9e-9	Major depressive disorder;
LUSC	cis	rs7178572	0.889	rs7177055	chr15:77832762	A/G	cg22256960	chr15:77711686	NA	0.5	8.39	0.42	1.41e-15	Type 2 diabetes;
LUSC	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg14092571	chr14:90743983	NA	-0.89	-18.66	-0.71	9.62e-54	Gut microbiota (bacterial taxa);
LUSC	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg07169764	chr2:136633963	MCM6	-0.73	-9.86	-0.47	2.64e-20	Mosquito bite size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17964432	chr4:184020264	WWC2;C4orf38	-0.41	-6.39	-0.33	5.5e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1322512	0.622	rs2758796	chr6:152931766	G/A	cg27316956	chr6:152958899	SYNE1	-0.35	-5.85	-0.31	1.15e-8	Tonometry;
LUSC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg09655341	chr17:79618100	PDE6G	-0.28	-6.58	-0.34	1.81e-10	Eye color traits;
LUSC	trans	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg10756647	chr7:56101905	PSPH	0.87	8.43	0.42	1.06e-15	Diabetic kidney disease;
LUSC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg13206674	chr6:150067644	NUP43	0.57	9.09	0.45	9.1e-18	Lung cancer;
LUSC	trans	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg13010199	chr12:38710504	ALG10B	0.46	7.07	0.36	9.06e-12	Morning vs. evening chronotype;
LUSC	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg23750338	chr8:142222470	SLC45A4	-0.55	-10.59	-0.5	8.48e-23	Immature fraction of reticulocytes;
LUSC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg00310523	chr12:86230176	RASSF9	0.53	10.25	0.49	1.28e-21	Major depressive disorder;
LUSC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg22508957	chr16:3507546	NAT15	0.64	10.65	0.5	5.48e-23	Tuberculosis;
LUSC	cis	rs7178572	0.849	rs1005752	chr15:77818128	C/A	cg22256960	chr15:77711686	NA	-0.51	-8.42	-0.42	1.16e-15	Type 2 diabetes;
LUSC	cis	rs11247915	1.000	rs11247915	chr1:26650550	G/T	cg15628303	chr1:26608928	UBXN11	-0.35	-6.28	-0.33	1.03e-9	Obesity-related traits;
LUSC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg27532560	chr4:187881888	NA	-0.43	-6.95	-0.36	1.87e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.62	-0.43	2.79e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08736216	chr1:53307985	ZYG11A	-0.27	-5.79	-0.3	1.6e-8	Monocyte count;
LUSC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-10.97	-0.51	3.99e-24	Mean corpuscular volume;
LUSC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg14019146	chr3:50243930	SLC38A3	0.29	6.42	0.33	4.79e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21488398	chr2:70369791	NA	-0.41	-6.48	-0.33	3.3e-10	Electrocardiographic conduction measures;
LUSC	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.23	0.37	3.26e-12	Diisocyanate-induced asthma;
LUSC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.2	-0.32	1.69e-9	Cutaneous nevi;
LUSC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08280861	chr8:58055591	NA	0.54	5.94	0.31	6.98e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06850241	chr22:41845214	NA	0.32	5.83	0.3	1.28e-8	Vitiligo;
LUSC	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.91	0.4	3.71e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs34779708	0.733	rs12254018	chr10:35550641	T/A	cg03585969	chr10:35415529	CREM	0.53	7.37	0.37	1.32e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7589342	0.669	rs11895604	chr2:106536134	G/A	cg14210321	chr2:106509881	NCK2	-0.56	-8.55	-0.42	4.44e-16	Addiction;
LUSC	trans	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.6	0.43	3.05e-16	Resting heart rate;
LUSC	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg05973401	chr12:123451056	ABCB9	-0.54	-6.72	-0.34	8.09e-11	Neutrophil percentage of white cells;
LUSC	trans	rs12310956	0.510	rs2054867	chr12:33835462	C/G	cg26384229	chr12:38710491	ALG10B	-0.56	-8.93	-0.44	2.97e-17	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg26384229	chr12:38710491	ALG10B	0.57	9.05	0.44	1.24e-17	Morning vs. evening chronotype;
LUSC	cis	rs3820928	1.000	rs3820928	chr2:227773466	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.78	-0.39	8.85e-14	Pulmonary function;
LUSC	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14240646	chr10:27532245	ACBD5	0.7	8.12	0.41	9.18e-15	Breast cancer;
LUSC	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.99	-0.36	1.49e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	14.74	0.63	3.05e-38	Blood protein levels;
LUSC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18357526	chr6:26021779	HIST1H4A	0.43	6.7	0.34	8.69e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg20503657	chr10:835505	NA	0.78	9.42	0.46	7.61e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2273669	0.667	rs17070139	chr6:109358345	C/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	9.1e-9	Prostate cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03657485	chr18:12702964	PSMG2;CEP76	-0.4	-6.08	-0.32	3.32e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg08847533	chr14:75593920	NEK9	0.85	15.84	0.65	1.54e-42	Height;
LUSC	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.64	-0.34	1.28e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.94	0.31	7.2e-9	Menopause (age at onset);
LUSC	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.4	-0.38	1.15e-12	Psoriasis;
LUSC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.72	-10.11	-0.48	3.96e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs243505	0.762	rs10241408	chr7:148481488	G/A	cg09806900	chr7:148480153	CUL1	0.59	8.68	0.43	1.72e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.25	-14.44	-0.62	4.52e-37	Gout;
LUSC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg26441486	chr22:50317300	CRELD2	0.49	6.78	0.35	5.54e-11	Schizophrenia;
LUSC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.48	8.05	0.4	1.46e-14	Vitiligo;
LUSC	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg11502198	chr6:26597334	ABT1	0.7	11.83	0.54	3.39e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6740322	0.895	rs10196095	chr2:43571885	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.49	-6.81	-0.35	4.41e-11	Coronary artery disease;
LUSC	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.7	10.65	0.5	5.42e-23	Corneal astigmatism;
LUSC	cis	rs6840360	0.967	rs1511170	chr4:152701110	A/G	cg22705602	chr4:152727874	NA	-0.27	-5.74	-0.3	2.11e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.778	rs4888413	chr16:75443223	C/A	cg03315344	chr16:75512273	CHST6	0.48	8.98	0.44	2.08e-17	Dupuytren's disease;
LUSC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.57	-12.28	-0.56	7.65e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg04691961	chr3:161091175	C3orf57	-0.36	-6.24	-0.32	1.34e-9	Morning vs. evening chronotype;
LUSC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.14e-35	Breast cancer;
LUSC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.66	-12.3	-0.56	6.3e-29	Type 2 diabetes;
LUSC	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	13.27	0.59	1.39e-32	Post bronchodilator FEV1;
LUSC	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.5	-0.46	4.07e-19	Schizophrenia;
LUSC	cis	rs1564271	0.553	rs1616702	chr10:26989529	G/C	cg13837822	chr10:26931731	LOC731789	0.47	9.93	0.48	1.55e-20	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUSC	cis	rs968451	0.865	rs12627970	chr22:39721745	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.65	8.36	0.42	1.69e-15	Primary biliary cholangitis;
LUSC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg24675658	chr1:53192096	ZYG11B	0.75	12.9	0.58	3.69e-31	Monocyte count;
LUSC	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg14675211	chr2:100938903	LONRF2	0.37	5.76	0.3	1.94e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs78049276	0.736	rs6842241	chr4:148400819	C/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.54	-6.12	-0.32	2.68e-9	Pulse pressure;
LUSC	cis	rs4588572	0.643	rs6453391	chr5:77755035	T/C	cg11547950	chr5:77652471	NA	-0.56	-7.9	-0.4	4.04e-14	Triglycerides;
LUSC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.76	-0.51	2.13e-23	Alzheimer's disease (late onset);
LUSC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg04414720	chr1:150670196	GOLPH3L	0.53	8.5	0.42	6.19e-16	Tonsillectomy;
LUSC	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.69	-0.34	9.49e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg12658694	chr1:38397304	INPP5B	0.43	6.42	0.33	4.65e-10	Coronary artery disease;
LUSC	cis	rs7119	0.717	rs11636529	chr15:77816220	T/C	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-8.72	-0.43	1.33e-16	Lymphocyte counts;
LUSC	cis	rs13315871	1.000	rs9821570	chr3:58335919	C/G	cg20936604	chr3:58311152	NA	-0.73	-7.37	-0.37	1.31e-12	Cholesterol, total;
LUSC	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg16482183	chr6:26056742	HIST1H1C	0.64	8.64	0.43	2.41e-16	Iron status biomarkers;
LUSC	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg09184832	chr6:79620586	NA	-0.45	-7.29	-0.37	2.27e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.69	13.08	0.58	7.62e-32	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg06238570	chr21:40685208	BRWD1	-0.64	-10.63	-0.5	6.19e-23	Cognitive function;
LUSC	cis	rs4988958	0.527	rs11465641	chr2:103000868	T/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.27e-12	Asthma (childhood onset);
LUSC	cis	rs4363385	0.818	rs10788854	chr1:153002320	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.09	-0.36	8.12e-12	Inflammatory skin disease;
LUSC	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg18105134	chr13:113819100	PROZ	0.64	9.14	0.45	6.1e-18	Platelet distribution width;
LUSC	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg23306229	chr2:178417860	TTC30B	0.51	5.8	0.3	1.53e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	trans	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	7.28	0.37	2.43e-12	Menarche (age at onset);
LUSC	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.52e-8	Breast cancer;
LUSC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.58	-7.86	-0.4	5.33e-14	Mean platelet volume;
LUSC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg15848620	chr12:58087721	OS9	0.46	5.73	0.3	2.26e-8	Multiple sclerosis;
LUSC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	7.41	0.38	1.07e-12	Prudent dietary pattern;
LUSC	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.45	-7.47	-0.38	6.96e-13	Hirschsprung disease;
LUSC	cis	rs1790761	0.967	rs13859	chr11:67202156	C/T	cg24690094	chr11:67383802	NA	-0.33	-6.06	-0.31	3.62e-9	Mean corpuscular volume;
LUSC	cis	rs7586879	0.828	rs12986610	chr2:25106265	A/G	cg04586622	chr2:25135609	ADCY3	-0.31	-5.97	-0.31	6.2e-9	Body mass index;
LUSC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg11247378	chr22:39784982	NA	-0.56	-8.67	-0.43	1.89e-16	IgG glycosylation;
LUSC	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.24	-0.91	3.88e-130	Myeloid white cell count;
LUSC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg21963583	chr11:68658836	MRPL21	0.56	8.37	0.42	1.58e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg13175981	chr1:150552382	MCL1	0.53	7.4	0.38	1.09e-12	Tonsillectomy;
LUSC	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg00191853	chr8:101177733	SPAG1	-0.38	-6.36	-0.33	6.71e-10	Atrioventricular conduction;
LUSC	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.81	0.51	1.45e-23	Colorectal cancer;
LUSC	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.41	6.54	0.34	2.24e-10	Response to antipsychotic treatment;
LUSC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	6.41	0.33	4.97e-10	Schizophrenia;
LUSC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg19774624	chr17:42201019	HDAC5	-0.81	-12.77	-0.57	1.1e-30	Total body bone mineral density;
LUSC	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg06781209	chr11:61594997	FADS2	-0.42	-6.78	-0.35	5.41e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg11887960	chr12:57824829	NA	0.55	7.21	0.37	3.7e-12	Lung disease severity in cystic fibrosis;
LUSC	trans	rs17685	0.890	rs76021834	chr7:75607155	A/G	cg19862616	chr7:65841803	NCRNA00174	0.79	11.25	0.52	4.18e-25	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs9815354	0.680	rs73073262	chr3:42018443	G/T	cg03022575	chr3:42003672	ULK4	0.76	7.59	0.38	3.33e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10733682	0.633	rs869500	chr9:129465898	G/A	cg00232160	chr9:129468157	NA	0.43	7.71	0.39	1.45e-13	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	7.11	0.36	7.01e-12	Colorectal cancer;
LUSC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	0.63	13.44	0.59	3.14e-33	Prudent dietary pattern;
LUSC	cis	rs8050260	0.500	rs4783650	chr16:68558528	T/C	cg02972257	chr16:68554789	NA	0.56	6.97	0.36	1.73e-11	Plateletcrit;
LUSC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.17	0.41	6.43e-15	Melanoma;
LUSC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.26	-0.37	2.71e-12	Subjective well-being;
LUSC	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.24	-0.37	3.2e-12	Menopause (age at onset);
LUSC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg15145296	chr3:125709740	NA	-0.58	-6.52	-0.34	2.67e-10	Blood pressure (smoking interaction);
LUSC	cis	rs6580649	0.941	rs12580764	chr12:48453882	G/A	cg24011408	chr12:48396354	COL2A1	-0.46	-6.12	-0.32	2.56e-9	Lung cancer;
LUSC	cis	rs4474465	1.000	rs10899520	chr11:78183370	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.71	-0.3	2.51e-8	Alzheimer's disease (survival time);
LUSC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg04287289	chr16:89883240	FANCA	-0.41	-5.99	-0.31	5.48e-9	Vitiligo;
LUSC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg22823121	chr1:150693482	HORMAD1	-0.46	-7.06	-0.36	9.57e-12	Tonsillectomy;
LUSC	trans	rs4650994	0.544	rs2811314	chr1:178619183	C/T	cg05059571	chr16:84539110	KIAA1609	0.46	8.67	0.43	1.87e-16	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg00857998	chr1:205179979	DSTYK	0.52	7.83	0.39	6.47e-14	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg00610228	chr6:35695934	FKBP5;LOC285847	0.48	6.02	0.31	4.55e-9	Cognitive function;Information processing speed;
LUSC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.16	0.36	5.16e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2637266	1.000	rs10824425	chr10:78340310	C/G	cg18941641	chr10:78392320	NA	0.38	7.11	0.36	7.08e-12	Pulmonary function;
LUSC	cis	rs9311676	0.609	rs6770113	chr3:58379297	C/A	cg13750441	chr3:58318267	PXK	0.36	7.06	0.36	9.88e-12	Systemic lupus erythematosus;
LUSC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	11.47	0.53	6.88e-26	Menarche (age at onset);
LUSC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg18477163	chr1:228402036	OBSCN	-0.56	-10.49	-0.5	1.95e-22	Diastolic blood pressure;
LUSC	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg05784532	chr1:230284198	GALNT2	0.55	8.18	0.41	6.09e-15	Coronary artery disease;
LUSC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg16339924	chr4:17578868	LAP3	0.62	9.19	0.45	4.41e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg04450456	chr4:17643702	FAM184B	0.41	7.14	0.36	5.9e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04565464	chr8:145669602	NFKBIL2	0.37	6.07	0.32	3.44e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15541040	chr2:3486749	NA	-0.58	-8.92	-0.44	3.07e-17	Neurofibrillary tangles;
LUSC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg21132104	chr15:45694354	SPATA5L1	0.57	8.13	0.41	8.21e-15	Homoarginine levels;
LUSC	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	0.82	12.24	0.56	1.04e-28	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.71	11.34	0.53	2.02e-25	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.84	0.39	6.15e-14	Prudent dietary pattern;
LUSC	trans	rs7181230	0.885	rs8026641	chr15:40338861	C/T	cg22705835	chr10:65332833	REEP3	0.36	5.99	0.31	5.36e-9	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg12863693	chr15:85201151	NMB	0.42	8.65	0.43	2.14e-16	Schizophrenia;
LUSC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg06618935	chr21:46677482	NA	-0.36	-6.98	-0.36	1.55e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg12463550	chr7:65579703	CRCP	0.45	6.73	0.35	7.31e-11	Aortic root size;
LUSC	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.93	12.22	0.56	1.2e-28	Exhaled nitric oxide output;
LUSC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.5	6.13	0.32	2.43e-9	Renal function-related traits (BUN);
LUSC	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg11189052	chr15:85197271	WDR73	0.5	6.39	0.33	5.56e-10	Schizophrenia;
LUSC	cis	rs147499554	1	rs147499554	chr15:78900650	C/T	cg06917634	chr15:78832804	PSMA4	-0.44	-5.91	-0.31	8.24e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg20701182	chr2:24300061	SF3B14	0.74	7.48	0.38	6.68e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg03676636	chr4:99064102	C4orf37	0.38	7.91	0.4	3.85e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6977660	0.714	rs10276518	chr7:19781325	C/A	cg05791153	chr7:19748676	TWISTNB	0.76	7.51	0.38	5.62e-13	Thyroid stimulating hormone;
LUSC	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg20307385	chr11:47447363	PSMC3	0.45	6.52	0.34	2.68e-10	Subjective well-being;
LUSC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg20203395	chr5:56204925	C5orf35	-0.56	-7.89	-0.4	4.42e-14	Type 2 diabetes;
LUSC	cis	rs3106136	0.967	rs11722476	chr4:95170839	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.36	-6.32	-0.33	8.39e-10	Capecitabine sensitivity;
LUSC	cis	rs7945718	0.934	rs3993110	chr11:12794530	A/C	cg25843174	chr11:12811716	TEAD1	0.34	7.58	0.38	3.5e-13	Educational attainment (years of education);
LUSC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	12.96	0.58	2.16e-31	Platelet count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24686684	chr20:48330546	B4GALT5	-0.52	-6.26	-0.32	1.21e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9815354	0.904	rs9852991	chr3:41875455	C/A	cg03022575	chr3:42003672	ULK4	0.64	7.02	0.36	1.21e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2290159	0.752	rs5746182	chr3:12672550	A/G	cg23032965	chr3:12705835	RAF1	0.74	9.13	0.45	6.87e-18	Cholesterol, total;
LUSC	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.44	-8.04	-0.4	1.54e-14	Monocyte percentage of white cells;
LUSC	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg16989719	chr2:238392110	NA	0.38	6.58	0.34	1.77e-10	Prostate cancer;
LUSC	cis	rs1832871	0.672	rs12525675	chr6:158708749	A/T	cg07165851	chr6:158734300	TULP4	0.51	7.91	0.4	3.75e-14	Height;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11149768	chr20:4129361	SMOX	0.48	6.89	0.35	2.79e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	0.64	13.57	0.6	1.06e-33	Prudent dietary pattern;
LUSC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg12288994	chr5:1860383	NA	0.31	6.89	0.35	2.72e-11	Cardiovascular disease risk factors;
LUSC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	9.07	0.44	1.03e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7173743	1.000	rs11632020	chr15:79143759	C/T	cg00540400	chr15:79124168	NA	-0.34	-5.83	-0.3	1.3e-8	Coronary artery disease;
LUSC	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-6.05	-0.31	3.9e-9	Major depressive disorder;
LUSC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg23630131	chr7:65973040	NA	0.21	5.86	0.31	1.14e-8	Aortic root size;
LUSC	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.77	-0.35	5.91e-11	Response to antipsychotic treatment;
LUSC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg15017067	chr4:17643749	FAM184B	0.34	5.71	0.3	2.44e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg04013166	chr16:89971882	TCF25	0.65	7.5	0.38	5.98e-13	Skin colour saturation;
LUSC	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg26924012	chr15:45694286	SPATA5L1	0.79	12.43	0.56	2.13e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg21782813	chr7:2030301	MAD1L1	0.54	9.26	0.45	2.61e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs9517320	0.967	rs7997785	chr13:99127985	T/A	cg07423050	chr13:99094983	FARP1	0.34	6.33	0.33	8.08e-10	Longevity;
LUSC	cis	rs6901250	0.851	rs339322	chr6:117193356	T/C	cg12892004	chr6:117198278	RFX6	-0.44	-8.19	-0.41	5.5e-15	C-reactive protein levels;
LUSC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg15921436	chr17:44337874	NA	-0.73	-11.27	-0.52	3.58e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg22532475	chr10:104410764	TRIM8	-0.25	-6.01	-0.31	4.97e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1832871	1.000	rs827856	chr6:158705887	G/A	cg07165851	chr6:158734300	TULP4	0.37	6.44	0.33	4.26e-10	Height;
LUSC	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg01028140	chr2:1542097	TPO	-0.6	-8.14	-0.41	7.81e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg01475377	chr6:109611718	NA	-0.41	-7.26	-0.37	2.7e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs4423214	0.879	rs1792264	chr11:71150247	C/T	cg05163923	chr11:71159392	DHCR7	-0.68	-8.94	-0.44	2.65e-17	Vitamin D levels;
LUSC	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg08997352	chr12:9597637	DDX12	-0.6	-9.5	-0.46	4.24e-19	Breast size;
LUSC	cis	rs61823972	0.547	rs12048743	chr1:205114873	C/G	cg21545522	chr1:205238299	TMCC2	0.31	5.72	0.3	2.41e-8	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
LUSC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg11766577	chr21:47581405	C21orf56	-0.4	-5.74	-0.3	2.14e-8	Testicular germ cell tumor;
LUSC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg01420254	chr6:26195488	NA	0.68	7.52	0.38	5.21e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg13073564	chr4:8508604	NA	-0.45	-8.38	-0.42	1.48e-15	Response to antineoplastic agents;
LUSC	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg13390004	chr1:15929781	NA	0.42	6.98	0.36	1.61e-11	Systolic blood pressure;
LUSC	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.2e-13	Corneal astigmatism;
LUSC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg03146154	chr1:46216737	IPP	0.5	7.46	0.38	7.52e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg00577361	chr1:21112950	HP1BP3	0.62	6.06	0.31	3.64e-9	Body mass index;
LUSC	cis	rs6076065	0.692	rs6083111	chr20:23374667	A/G	cg11657817	chr20:23433608	CST11	0.42	7.99	0.4	2.19e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs4285028	0.948	rs12493408	chr3:121692119	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.73	-9.54	-0.46	3.15e-19	Multiple sclerosis;
LUSC	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg09654669	chr8:57350985	NA	-0.61	-8.16	-0.41	7.11e-15	Obesity-related traits;
LUSC	trans	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg15445000	chr17:37608096	MED1	-0.4	-6.79	-0.35	5.16e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs897984	0.542	rs73530203	chr16:31099859	G/A	cg02466173	chr16:30829666	NA	-0.48	-8.89	-0.44	3.76e-17	Dementia with Lewy bodies;
LUSC	cis	rs72960926	0.744	rs16884690	chr6:75046076	A/C	cg03266952	chr6:74778945	NA	-0.64	-6.14	-0.32	2.41e-9	Metabolite levels (MHPG);
LUSC	trans	rs2392780	0.667	rs424281	chr8:128339426	G/A	cg10897648	chr18:56338258	MALT1	-0.44	-6.59	-0.34	1.67e-10	Breast cancer (early onset);
LUSC	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg19610905	chr11:61596333	FADS2	-0.53	-7.91	-0.4	3.82e-14	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUSC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.91	15.9	0.66	8.53e-43	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs17286411	0.750	rs11075910	chr16:71936733	A/G	cg03805757	chr16:71968109	PKD1L3	0.42	6.96	0.36	1.79e-11	Blood protein levels;
LUSC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg15445000	chr17:37608096	MED1	0.4	6.77	0.35	5.76e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg15704280	chr7:45808275	SEPT13	-0.63	-7.68	-0.39	1.83e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs8067354	0.574	rs2526354	chr17:57976658	A/G	cg02344993	chr17:57696989	CLTC	0.48	6.74	0.35	6.76e-11	Hemoglobin concentration;
LUSC	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs7568458	0.704	rs10176176	chr2:85762048	A/T	cg02493740	chr2:85810744	VAMP5	-0.35	-6.18	-0.32	1.87e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg25019033	chr10:957182	NA	-0.53	-5.83	-0.3	1.28e-8	Eosinophil percentage of granulocytes;
LUSC	trans	rs10511400	0.541	rs10049256	chr3:119920683	G/T	cg02809009	chr19:50354510	PTOV1	-0.73	-6.52	-0.34	2.64e-10	Economic and political preferences (feminism/equality);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg24023618	chr6:114292459	HDAC2	0.46	6.95	0.36	1.95e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg08847335	chr10:891726	LARP4B	0.46	5.89	0.31	9.19e-9	Eosinophil percentage of granulocytes;
LUSC	trans	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg19894588	chr14:64061835	NA	0.54	7.68	0.39	1.75e-13	Glioblastoma;Glioma;
LUSC	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.72	14.63	0.62	8.52e-38	Recombination rate (males);
LUSC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg06784218	chr1:46089804	CCDC17	-0.57	-11.33	-0.53	2.14e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-7.73	-0.39	1.31e-13	Bladder cancer;
LUSC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg11663144	chr21:46675770	NA	-0.42	-7.25	-0.37	2.93e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg05623727	chr3:50126028	RBM5	-0.36	-6.62	-0.34	1.4e-10	Body mass index;
LUSC	cis	rs752010	0.841	rs58737163	chr1:42079821	G/T	cg06885757	chr1:42089581	HIVEP3	0.41	8.37	0.42	1.55e-15	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg12560992	chr17:57184187	TRIM37	-0.84	-15.41	-0.64	7.53e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.4	0.38	1.1e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg00898013	chr13:113819073	PROZ	-0.53	-7.91	-0.4	3.82e-14	Platelet distribution width;
LUSC	cis	rs4253772	0.530	rs28362161	chr22:46807439	C/T	cg24881330	chr22:46731750	TRMU	0.76	5.68	0.3	2.97e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg14917874	chr2:235941519	SH3BP4	0.46	7.64	0.39	2.38e-13	Dialysis-related mortality;
LUSC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg07716408	chr11:68623521	NA	-0.31	-5.76	-0.3	1.88e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg23172400	chr8:95962367	TP53INP1	-0.47	-9.59	-0.46	2.13e-19	Type 2 diabetes;
LUSC	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg26384229	chr12:38710491	ALG10B	0.5	7.2	0.37	3.91e-12	Morning vs. evening chronotype;
LUSC	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg06547715	chr2:218990976	CXCR2	0.33	6.5	0.34	2.92e-10	Ulcerative colitis;
LUSC	cis	rs3125734	0.719	rs10821972	chr10:64043735	G/A	cg09941381	chr10:64027924	RTKN2	-0.35	-6.26	-0.32	1.19e-9	Rheumatoid arthritis;
LUSC	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg16359550	chr11:109292809	C11orf87	0.33	5.95	0.31	6.88e-9	Schizophrenia;
LUSC	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.54	8.31	0.41	2.37e-15	Colorectal cancer;
LUSC	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.89	15.24	0.64	3.51e-40	Bladder cancer;
LUSC	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg05738196	chr6:26577821	NA	-0.65	-10.52	-0.5	1.56e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg26516362	chr5:178986906	RUFY1	-0.54	-9.88	-0.48	2.22e-20	Lung cancer;
LUSC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg14668632	chr7:2872130	GNA12	-0.45	-6.34	-0.33	7.54e-10	Height;
LUSC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.17	0.41	6.46e-15	Homoarginine levels;
LUSC	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg25258033	chr6:167368657	RNASET2	-0.4	-6.44	-0.33	4.28e-10	Crohn's disease;
LUSC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg25258033	chr6:167368657	RNASET2	0.39	6.26	0.32	1.16e-9	Crohn's disease;
LUSC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg09835421	chr16:68378352	PRMT7	-0.54	-5.92	-0.31	7.97e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg15212455	chr7:39170539	POU6F2	0.55	9.21	0.45	3.73e-18	IgG glycosylation;
LUSC	cis	rs17030434	0.954	rs6847810	chr4:154752789	C/T	cg14289246	chr4:154710475	SFRP2	-0.54	-7.21	-0.37	3.7e-12	Electrocardiographic conduction measures;
LUSC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg07395648	chr5:131743802	NA	0.37	5.8	0.3	1.52e-8	Asthma (sex interaction);
LUSC	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg05738196	chr6:26577821	NA	0.82	15.81	0.65	1.93e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg04871131	chr7:94954202	PON1	-0.38	-6.09	-0.32	3.12e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11674844	chr1:27216367	GPN2	0.53	7.27	0.37	2.53e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	6.56	0.34	2.02e-10	Schizophrenia;
LUSC	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.76	-12.62	-0.57	4.13e-30	Schizophrenia;
LUSC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg24060327	chr5:131705240	SLC22A5	0.69	11.35	0.53	1.86e-25	Blood metabolite levels;
LUSC	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.55	-0.42	4.55e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6546550	0.901	rs3732266	chr2:70057448	T/G	cg02498382	chr2:70120550	SNRNP27	-0.27	-6.31	-0.33	8.86e-10	Prevalent atrial fibrillation;
LUSC	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.55	-15.01	-0.63	2.84e-39	Urate levels in overweight individuals;
LUSC	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg22852734	chr6:133119734	C6orf192	1.09	13.26	0.59	1.53e-32	Type 2 diabetes nephropathy;
LUSC	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg24631222	chr15:78858424	CHRNA5	0.61	8.62	0.43	2.74e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg04117972	chr1:227635322	NA	0.64	5.91	0.31	8.23e-9	Major depressive disorder;
LUSC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.87	-0.31	1.03e-8	Alzheimer's disease (late onset);
LUSC	cis	rs11051970	0.879	rs2243815	chr12:32576158	C/T	cg02745156	chr12:32552066	NA	0.43	7.33	0.37	1.73e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6545883	0.839	rs778764	chr2:61785680	C/T	cg15711740	chr2:61764176	XPO1	-0.42	-6.49	-0.33	3.03e-10	Tuberculosis;
LUSC	cis	rs9341808	0.718	rs9448908	chr6:80898069	C/T	cg08355045	chr6:80787529	NA	0.59	10.3	0.49	8.61e-22	Sitting height ratio;
LUSC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg14773178	chr5:1868261	NA	0.32	5.88	0.31	1.01e-8	Cardiovascular disease risk factors;
LUSC	trans	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.09	-0.36	7.79e-12	Menarche (age at onset);
LUSC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg11764359	chr7:65958608	NA	0.54	7.12	0.36	6.5e-12	Aortic root size;
LUSC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	11.3	0.53	2.7e-25	Tonsillectomy;
LUSC	cis	rs13394619	1.000	rs2884374	chr2:11731846	C/T	cg07314298	chr2:11723111	GREB1	0.56	10.14	0.49	3.02e-21	Endometriosis;
LUSC	cis	rs834811	0.831	rs834810	chr7:135879825	T/C	cg01726295	chr7:135938950	NA	0.39	6.76	0.35	6.2e-11	Post-traumatic stress disorder;
LUSC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17167076	chr2:192109990	MYO1B	-0.36	-5.98	-0.31	5.72e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg05896524	chr21:47604654	C21orf56	0.42	6.23	0.32	1.4e-9	Testicular germ cell tumor;
LUSC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06544989	chr22:39130855	UNC84B	0.35	6.03	0.31	4.35e-9	Menopause (age at onset);
LUSC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-7.45	-0.38	8.07e-13	Lung function (FEV1/FVC);
LUSC	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-25.83	-0.82	1.29e-81	Exhaled nitric oxide output;
LUSC	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg13010199	chr12:38710504	ALG10B	0.54	8.46	0.42	8.75e-16	Morning vs. evening chronotype;
LUSC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg01483505	chr11:975446	AP2A2	0.4	5.67	0.3	3.03e-8	Alzheimer's disease (late onset);
LUSC	cis	rs17401966	0.540	rs7546368	chr1:10418826	G/A	cg17425144	chr1:10567563	PEX14	-0.34	-6.07	-0.32	3.45e-9	Hepatocellular carcinoma;
LUSC	cis	rs17021463	0.902	rs34465979	chr4:95257554	C/A	cg11021082	chr4:95130006	SMARCAD1	0.4	7.43	0.38	8.99e-13	Testicular germ cell tumor;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg13453750	chr1:205783389	SLC41A1	-0.32	-6.33	-0.33	7.74e-10	Menarche (age at onset);
LUSC	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg22906224	chr7:99728672	NA	0.46	6.4	0.33	5.29e-10	Coronary artery disease;
LUSC	cis	rs62400317	0.821	rs34455867	chr6:45172071	T/C	cg18551225	chr6:44695536	NA	-0.44	-7.21	-0.37	3.79e-12	Total body bone mineral density;
LUSC	cis	rs4363385	0.553	rs11580383	chr1:152942192	A/G	cg00922841	chr1:152955080	SPRR1A	-0.36	-6.06	-0.31	3.63e-9	Inflammatory skin disease;
LUSC	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg06552810	chr11:31128660	NA	-0.42	-7.39	-0.37	1.19e-12	Red blood cell count;
LUSC	cis	rs78572108	0.858	rs13384438	chr2:42265408	G/A	cg00607755	chr2:42274082	PKDCC	0.36	6.52	0.34	2.61e-10	Total body bone mineral density;
LUSC	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg17127132	chr2:85788382	GGCX	0.44	6.28	0.33	1.03e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	0.95	17.83	0.7	2.02e-50	Bone mineral density;
LUSC	cis	rs7589342	0.536	rs7563690	chr2:106396935	C/T	cg14210321	chr2:106509881	NCK2	-0.4	-5.74	-0.3	2.09e-8	Addiction;
LUSC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03934478	chr11:495069	RNH1	0.82	9.84	0.47	3.08e-20	Body mass index;
LUSC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg04546413	chr19:29218101	NA	0.71	11.39	0.53	1.26e-25	Methadone dose in opioid dependence;
LUSC	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg15556689	chr8:8085844	FLJ10661	0.56	8.43	0.42	1.05e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg09839279	chr12:125627357	AACS	-0.31	-5.72	-0.3	2.31e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg06223162	chr1:101003688	GPR88	0.48	9.09	0.45	8.67e-18	Monocyte count;
LUSC	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	13.28	0.59	1.37e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg00579200	chr11:133705235	NA	-0.39	-5.7	-0.3	2.58e-8	Childhood ear infection;
LUSC	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-5.77	-0.3	1.79e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg25811766	chr13:21894605	NA	0.62	9.61	0.47	1.83e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg15448220	chr1:150897856	SETDB1	0.4	5.72	0.3	2.34e-8	Melanoma;
LUSC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg00049323	chr5:472564	LOC25845	-0.48	-7.73	-0.39	1.28e-13	Cystic fibrosis severity;
LUSC	cis	rs57590327	0.503	rs4856350	chr3:81503374	G/A	cg07356753	chr3:81810745	GBE1	0.45	6.02	0.31	4.58e-9	Extraversion;
LUSC	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg00677455	chr12:58241039	CTDSP2	0.49	7.28	0.37	2.48e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs8032315	0.965	rs35346340	chr15:91427872	G/C	cg05469396	chr15:91419421	FURIN	-0.43	-6.83	-0.35	4.1e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.43	7.19	0.37	4.36e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.83	-0.39	6.5e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6545883	0.929	rs13413337	chr2:61747123	A/G	cg15711740	chr2:61764176	XPO1	-0.48	-7.56	-0.38	3.91e-13	Tuberculosis;
LUSC	cis	rs12545109	0.700	rs2670045	chr8:57393695	A/G	cg09654669	chr8:57350985	NA	-0.5	-6.69	-0.34	9.33e-11	Obesity-related traits;
LUSC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg22166914	chr1:53195759	ZYG11B	0.67	11.31	0.53	2.54e-25	Monocyte count;
LUSC	trans	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg19894588	chr14:64061835	NA	-0.48	-6.48	-0.33	3.21e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18876405	chr7:65276391	NA	-0.56	-8.82	-0.43	6.67e-17	Aortic root size;
LUSC	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.26	0.45	2.61e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6982240	0.569	rs6992278	chr8:142279383	C/G	cg27411547	chr8:142287226	NA	-0.48	-8.41	-0.42	1.18e-15	Tonsillectomy;
LUSC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	0.92	13.73	0.6	2.61e-34	Breast cancer;
LUSC	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.16	-0.32	2.07e-9	Resting heart rate;
LUSC	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.23e-28	Corneal astigmatism;
LUSC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg10909506	chr17:38081995	ORMDL3	0.33	5.87	0.31	1.02e-8	Self-reported allergy;
LUSC	cis	rs3087591	0.573	rs731758	chr17:29723000	C/G	cg24425628	chr17:29625626	OMG;NF1	0.45	6.67	0.34	1.09e-10	Hip circumference;
LUSC	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg23625390	chr15:77176239	SCAPER	-0.66	-9.95	-0.48	1.32e-20	Blood metabolite levels;
LUSC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-13.73	-0.6	2.43e-34	Hemoglobin concentration;
LUSC	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg03929089	chr4:120376271	NA	0.58	6.49	0.33	3.04e-10	Axial length;
LUSC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg03526776	chr6:41159608	TREML2	0.31	5.84	0.3	1.25e-8	Alzheimer's disease (late onset);
LUSC	trans	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg25284624	chr1:224180302	NA	-0.66	-6.59	-0.34	1.76e-10	Obesity (early onset extreme);
LUSC	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	8.72	0.43	1.37e-16	Lung cancer in ever smokers;
LUSC	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg26647111	chr11:31128758	NA	-0.43	-6.12	-0.32	2.58e-9	Red blood cell count;
LUSC	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg17075019	chr10:79541650	NA	-0.76	-12.26	-0.56	8.47e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9303280	0.754	rs3816470	chr17:37985801	A/G	cg20243544	chr17:37824526	PNMT	0.4	5.85	0.3	1.17e-8	Self-reported allergy;
LUSC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.57	0.5	9.83e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.55	-0.34	2.22e-10	Aortic root size;
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24739457	chr1:205821442	NA	0.36	6.2	0.32	1.63e-9	Menarche (age at onset);
LUSC	cis	rs4588572	0.643	rs1864172	chr5:77690945	T/C	cg11547950	chr5:77652471	NA	0.53	7.46	0.38	7.57e-13	Triglycerides;
LUSC	trans	rs1973993	0.967	rs6679458	chr1:96946253	G/T	cg10631902	chr5:14652156	NA	0.5	8.43	0.42	1.03e-15	Weight;
LUSC	cis	rs6750047	0.587	rs2163454	chr2:38279170	A/C	cg07380506	chr2:38303506	CYP1B1	0.47	6.48	0.33	3.23e-10	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs34891900	0.507	rs738133	chr22:18205557	C/T	cg19898043	chr22:18121309	BCL2L13	0.38	5.85	0.3	1.19e-8	Sum neutrophil eosinophil counts;
LUSC	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.62	-5.79	-0.3	1.59e-8	Major depressive disorder;
LUSC	cis	rs10203711	1.000	rs907108	chr2:239566285	T/C	cg14580085	chr2:239553406	NA	0.41	6.93	0.35	2.24e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs1881396	0.945	rs62141291	chr2:27784034	C/T	cg27432699	chr2:27873401	GPN1	0.67	8.88	0.44	4.15e-17	Nonalcoholic fatty liver disease;
LUSC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg11871910	chr12:69753446	YEATS4	0.68	10.44	0.5	2.93e-22	Blood protein levels;
LUSC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg18305652	chr10:134549665	INPP5A	0.46	6.83	0.35	4.01e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs2736340	0.539	rs9644687	chr8:11323025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.48	-0.38	6.61e-13	Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;Systemic lupus erythematosus;Kawasaki disease;Systemic lupus erythematosus or rheumatoid arthritis;
LUSC	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-8.39	-0.42	1.43e-15	Morning vs. evening chronotype;
LUSC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03264133	chr6:25882463	NA	0.38	6.29	0.33	9.97e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg15704280	chr7:45808275	SEPT13	-0.59	-7.3	-0.37	2.1e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg27170947	chr2:26402098	FAM59B	0.65	9.35	0.46	1.28e-18	Gut microbiome composition (summer);
LUSC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	0.92	19.44	0.73	7.64e-57	Dental caries;
LUSC	cis	rs11625487	0.515	rs12434419	chr14:77855617	G/A	cg20045696	chr14:77926864	AHSA1	-0.56	-8.85	-0.44	5.13e-17	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.21	-0.45	3.67e-18	Total cholesterol levels;
LUSC	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg22709100	chr7:91322751	NA	-0.4	-5.94	-0.31	6.99e-9	Breast cancer;
LUSC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg07148914	chr20:33460835	GGT7	0.47	6.93	0.35	2.24e-11	Height;
LUSC	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.5	7.08	0.36	8.82e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs35306767	0.623	rs36062650	chr10:1142571	T/C	cg26597838	chr10:835615	NA	0.48	6.19	0.32	1.79e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg04450456	chr4:17643702	FAM184B	0.4	6.91	0.35	2.53e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11756438	0.547	rs2798327	chr6:119005353	C/T	cg21191810	chr6:118973309	C6orf204	0.34	5.76	0.3	1.94e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7582720	1.000	rs6722332	chr2:203745327	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	0.98	13.49	0.59	2.08e-33	Vitiligo;
LUSC	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00338735	chr4:53728038	RASL11B	0.49	5.67	0.3	3.11e-8	Optic nerve measurement (cup area);
LUSC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg13607699	chr17:42295918	UBTF	0.48	7.51	0.38	5.58e-13	Total body bone mineral density;
LUSC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg08392591	chr16:89556376	ANKRD11	0.39	5.82	0.3	1.4e-8	Multiple myeloma (IgH translocation);
LUSC	trans	rs57046232	0.552	rs6038443	chr20:6328844	A/G	cg21095983	chr6:86352623	SYNCRIP	0.5	7.35	0.37	1.49e-12	Colorectal cancer;
LUSC	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg00191853	chr8:101177733	SPAG1	0.39	6.51	0.34	2.69e-10	Atrioventricular conduction;
LUSC	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-15.22	-0.64	4.25e-40	Heart rate;
LUSC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg04455712	chr21:45112962	RRP1B	0.49	9.19	0.45	4.25e-18	Mean corpuscular volume;
LUSC	cis	rs6445797	0.632	rs2029464	chr3:56661320	T/G	cg13792233	chr3:56591045	CCDC66	0.41	5.72	0.3	2.33e-8	Gastritis;
LUSC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg08999081	chr20:33150536	PIGU	0.46	8.24	0.41	3.95e-15	Coronary artery disease;
LUSC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg13206674	chr6:150067644	NUP43	0.61	9.77	0.47	5.34e-20	Lung cancer;
LUSC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg14668632	chr7:2872130	GNA12	-0.44	-6.45	-0.33	3.86e-10	Height;
LUSC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.82	-14.77	-0.63	2.34e-38	Sudden cardiac arrest;
LUSC	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg06207120	chr15:45996521	NA	0.4	6.15	0.32	2.17e-9	Waist circumference;Weight;
LUSC	trans	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg26043149	chr18:55253948	FECH	-0.44	-6.8	-0.35	4.9e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.15	-0.32	2.24e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6714788	0.565	rs12712063	chr2:100663281	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.82	-0.3	1.41e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4776059	1.000	rs11858743	chr15:52936330	G/A	cg22715398	chr15:52968154	KIAA1370	-0.65	-9.45	-0.46	6.08e-19	Schizophrenia;
LUSC	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg16524733	chr11:117070046	TAGLN	0.3	5.65	0.3	3.49e-8	Blood protein levels;
LUSC	cis	rs1395	1.000	rs1275501	chr2:27419282	A/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.41	-6.7	-0.34	8.62e-11	Blood metabolite levels;
LUSC	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg09904177	chr6:26538194	HMGN4	0.68	12.11	0.55	3.11e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg23625390	chr15:77176239	SCAPER	-0.65	-10.02	-0.48	7.62e-21	Blood metabolite levels;
LUSC	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg04539111	chr16:67997858	SLC12A4	-0.45	-6.03	-0.31	4.27e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg25767906	chr1:53392781	SCP2	-0.5	-9.16	-0.45	5.33e-18	Monocyte count;
LUSC	cis	rs2652822	1.000	rs1126308	chr15:63429086	G/T	cg02713581	chr15:63449717	RPS27L	-0.42	-6.78	-0.35	5.5e-11	Metabolic traits;
LUSC	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.69	0.6	3.62e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.5	-0.34	2.94e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg09359103	chr1:154839909	KCNN3	-0.69	-15.34	-0.64	1.47e-40	Prostate cancer;
LUSC	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.41	6.63	0.34	1.36e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg07741184	chr6:167504864	NA	0.4	7.01	0.36	1.3e-11	Primary biliary cholangitis;
LUSC	cis	rs6012953	1.000	rs6063533	chr20:49159399	C/T	cg13958625	chr20:49123093	NA	-0.3	-6.6	-0.34	1.61e-10	Vitiligo;
LUSC	cis	rs17155006	1.000	rs17155006	chr7:107757843	A/G	cg05962710	chr7:107745446	LAMB4	-0.32	-5.81	-0.3	1.44e-8	Pneumococcal bacteremia;
LUSC	cis	rs713477	0.654	rs11158040	chr14:55914607	T/C	cg13175173	chr14:55914753	NA	-0.29	-6.0	-0.31	5e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs1864400	0.696	rs2742239	chr10:43621712	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.34	-0.37	1.67e-12	Hirschsprung disease;
LUSC	cis	rs714027	0.565	rs2285667	chr22:30384104	T/A	cg11564601	chr22:30592435	NA	0.34	5.82	0.3	1.38e-8	Lymphocyte counts;
LUSC	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg18753928	chr3:113234510	CCDC52	-0.49	-7.34	-0.37	1.62e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg19046167	chr17:80928561	B3GNTL1	-0.47	-6.75	-0.35	6.48e-11	Glycated hemoglobin levels;
LUSC	cis	rs727505	0.866	rs3214004	chr7:124720929	T/C	cg23710748	chr7:124431027	NA	-0.4	-6.96	-0.36	1.79e-11	Lewy body disease;
LUSC	cis	rs1003719	0.715	rs8126941	chr21:38551542	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-10.0	-0.48	9.04e-21	Eye color traits;
LUSC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg24250549	chr1:154909240	PMVK	0.64	10.36	0.49	5.4e-22	Prostate cancer;
LUSC	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg00105475	chr2:10696890	NA	0.38	6.27	0.32	1.11e-9	Prostate cancer;
LUSC	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18854424	chr1:2615690	NA	0.51	10.34	0.49	6.28e-22	Ulcerative colitis;
LUSC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg11812906	chr14:75593930	NEK9	0.64	10.97	0.51	4.2e-24	Height;
LUSC	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.86	0.6	7.72e-35	Blood protein levels;
LUSC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	7.53	0.38	4.75e-13	Menarche (age at onset);
LUSC	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg14530993	chr4:882597	GAK	0.64	6.55	0.34	2.22e-10	Parkinson's disease;
LUSC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6732160	0.691	rs4536673	chr2:73413462	A/T	cg24220031	chr2:73402428	NA	-0.23	-5.81	-0.3	1.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg16482183	chr6:26056742	HIST1H1C	0.47	6.88	0.35	2.95e-11	Height;
LUSC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg17376030	chr22:41985996	PMM1	0.48	6.03	0.31	4.25e-9	Vitiligo;
LUSC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg08132940	chr7:1081526	C7orf50	-0.5	-6.15	-0.32	2.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg20818283	chr2:191399100	TMEM194B	0.43	6.76	0.35	6.15e-11	Pulse pressure;
LUSC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg09034736	chr1:150693464	HORMAD1	0.42	5.82	0.3	1.42e-8	Melanoma;
LUSC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24110177	chr3:50126178	RBM5	0.55	8.94	0.44	2.71e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg16989719	chr2:238392110	NA	-0.36	-6.31	-0.33	9.12e-10	Prostate cancer;
LUSC	cis	rs6725041	0.547	rs1394784	chr2:213209325	G/A	cg16329650	chr2:213403929	ERBB4	-0.42	-6.66	-0.34	1.15e-10	QT interval (ambient particulate matter interaction);
LUSC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg16928487	chr17:17741425	SREBF1	-0.36	-6.67	-0.34	1.05e-10	Total body bone mineral density;
LUSC	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg08000102	chr2:233561755	GIGYF2	-0.7	-11.58	-0.54	2.72e-26	Coronary artery disease;
LUSC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.79	-0.43	8.24e-17	Platelet count;
LUSC	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.31	-6.73	-0.35	7.49e-11	Dupuytren's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11277148	chr8:26371569	PNMA2	-0.56	-6.94	-0.36	2.1e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs1325195	0.507	rs10798652	chr1:179061427	A/G	cg11624085	chr17:8464688	MYH10	0.47	7.9	0.4	3.97e-14	IgE grass sensitization;
LUSC	cis	rs1443512	0.812	rs1867299	chr12:54329975	T/C	cg25024717	chr12:54324583	NA	-0.4	-6.9	-0.35	2.69e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	trans	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.44	6.58	0.34	1.85e-10	Endometrial cancer;
LUSC	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.08	0.52	1.68e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-8.91	-0.44	3.38e-17	Monocyte percentage of white cells;
LUSC	trans	rs156299	0.549	rs198316	chr7:24190531	A/T	cg06529468	chr19:10676722	KRI1	0.38	6.11	0.32	2.83e-9	Vitamin D levels;
LUSC	cis	rs11650494	0.908	rs8076023	chr17:47399633	C/G	cg08112188	chr17:47440006	ZNF652	1.2	10.63	0.5	6.08e-23	Prostate cancer;
LUSC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg04025307	chr7:1156635	C7orf50	0.42	6.76	0.35	6.14e-11	Longevity;Endometriosis;
LUSC	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.73	11.15	0.52	9.17e-25	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.93	-0.51	5.64e-24	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.95e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.49	6.22	0.32	1.46e-9	Multiple sclerosis;
LUSC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg18477163	chr1:228402036	OBSCN	0.63	12.24	0.56	1.05e-28	Diastolic blood pressure;
LUSC	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.31	-0.37	2.01e-12	Bipolar disorder;
LUSC	cis	rs2625529	0.617	rs2306576	chr15:72170686	C/T	cg16672083	chr15:72433130	SENP8	0.47	7.9	0.4	4.12e-14	Red blood cell count;
LUSC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.72	-0.3	2.43e-8	Tonsillectomy;
LUSC	cis	rs7215564	0.908	rs35151535	chr17:78661695	C/T	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs9467773	0.526	rs10946817	chr6:26364056	C/T	cg09904177	chr6:26538194	HMGN4	-0.5	-7.91	-0.4	3.73e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4280164	0.945	rs4981503	chr14:24786293	T/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.6	7.1	0.36	7.38e-12	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.64e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg27411982	chr8:10470053	RP1L1	-0.48	-7.37	-0.37	1.32e-12	Neuroticism;
LUSC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03517284	chr6:25882590	NA	-0.52	-9.67	-0.47	1.16e-19	Blood metabolite levels;
LUSC	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg22906224	chr7:99728672	NA	0.54	7.95	0.4	2.82e-14	Coronary artery disease;
LUSC	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.11	-28.89	-0.85	7.41e-93	Myeloid white cell count;
LUSC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg13175981	chr1:150552382	MCL1	0.44	5.76	0.3	1.91e-8	Blood protein levels;
LUSC	cis	rs6700896	0.500	rs2186246	chr1:66118009	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	6.36	0.33	6.62e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs877282	0.853	rs4579862	chr10:753298	A/C	cg13042288	chr15:90349979	ANPEP	-0.45	-6.29	-0.33	9.87e-10	Uric acid levels;
LUSC	cis	rs2348418	0.798	rs4930826	chr12:28727318	A/T	cg13890972	chr12:28721907	NA	-0.35	-5.93	-0.31	7.44e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg11130432	chr3:121712080	ILDR1	-0.63	-9.49	-0.46	4.55e-19	Multiple sclerosis;
LUSC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg05347473	chr6:146136440	FBXO30	0.53	8.91	0.44	3.27e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg09033563	chr22:24373618	LOC391322	-0.48	-6.78	-0.35	5.38e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg19812747	chr11:111475976	SIK2	-0.56	-8.11	-0.41	9.51e-15	Primary sclerosing cholangitis;
LUSC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.13	-0.41	8.71e-15	Chronic sinus infection;
LUSC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg00857998	chr1:205179979	DSTYK	0.55	8.48	0.42	7.29e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.59	0.34	1.7e-10	Lung cancer;
LUSC	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.93	19.36	0.73	1.53e-56	Monocyte count;
LUSC	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-8.62	-0.43	2.74e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	0.782	rs8113006	chr19:19669441	C/G	cg11244672	chr19:19639970	YJEFN3	0.44	5.91	0.31	8.52e-9	Bipolar disorder;
LUSC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-7.41	-0.38	1.07e-12	Colorectal cancer;
LUSC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg20821713	chr7:1055600	C7orf50	0.51	6.47	0.33	3.4e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg17031739	chr1:67600172	NA	0.46	7.17	0.37	4.72e-12	Psoriasis;
LUSC	cis	rs17604090	0.761	rs115923387	chr7:29720702	A/G	cg19413766	chr7:29689036	LOC646762	-0.65	-8.13	-0.41	8.39e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.44	-0.33	4.23e-10	Menopause (age at onset);
LUSC	cis	rs354225	0.544	rs10182836	chr2:54808504	T/G	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg09365446	chr1:150670422	GOLPH3L	-0.41	-5.94	-0.31	7.12e-9	Tonsillectomy;
LUSC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg15704280	chr7:45808275	SEPT13	0.67	6.23	0.32	1.38e-9	Axial length;
LUSC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.63	-8.11	-0.41	9.61e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15541609	chr14:100705844	YY1	0.62	6.08	0.32	3.36e-9	Cognitive performance;
LUSC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg26695010	chr11:65641043	EFEMP2	-0.48	-7.05	-0.36	1.04e-11	Eosinophil percentage of white cells;
LUSC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26818010	chr10:134567672	INPP5A	-0.79	-10.57	-0.5	1.05e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg03161606	chr19:29218774	NA	0.5	6.77	0.35	5.83e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs7122539	0.646	rs627330	chr11:66602099	C/T	cg18002602	chr11:66138449	SLC29A2	-0.33	-5.87	-0.31	1.08e-8	HIV-1 susceptibility;
LUSC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg23490090	chr17:78081364	GAA	-0.34	-5.78	-0.3	1.7e-8	Yeast infection;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg08305803	chr16:28565427	CCDC101	0.73	6.05	0.31	3.87e-9	Cognitive performance;
LUSC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.15e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg04310649	chr10:35416472	CREM	-0.43	-6.45	-0.33	3.94e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg27284194	chr4:1044797	NA	0.35	5.7	0.3	2.58e-8	Obesity-related traits;
LUSC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.29	-0.37	2.2e-12	Menopause (age at onset);
LUSC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg26408565	chr15:76604113	ETFA	-0.5	-8.05	-0.4	1.46e-14	Blood metabolite levels;
LUSC	cis	rs2235544	0.588	rs664758	chr1:54461263	C/T	cg25741118	chr1:54482237	LDLRAD1	0.33	7.61	0.38	2.84e-13	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg27124370	chr19:33622961	WDR88	-0.59	-7.72	-0.39	1.4e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg10729496	chr3:10149963	C3orf24	0.57	7.09	0.36	8.19e-12	Alzheimer's disease;
LUSC	cis	rs4851254	0.618	rs7572939	chr2:100654914	A/G	cg22139774	chr2:100720529	AFF3	-0.44	-5.75	-0.3	2.02e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	1.05	18.99	0.72	4.92e-55	Parkinson's disease;
LUSC	cis	rs9581857	0.547	rs9579087	chr13:28059780	G/A	cg22138327	chr13:27999177	GTF3A	0.81	8.38	0.42	1.49e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	9.04	0.44	1.28e-17	Menopause (age at onset);
LUSC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg02487422	chr3:49467188	NICN1	0.48	7.63	0.39	2.46e-13	Resting heart rate;
LUSC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.77	-7.0	-0.36	1.42e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg12463550	chr7:65579703	CRCP	-0.56	-8.35	-0.42	1.78e-15	Aortic root size;
LUSC	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg03585969	chr10:35415529	CREM	0.62	8.97	0.44	2.2e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg10645314	chr2:3704589	ALLC	-0.37	-6.47	-0.33	3.55e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg24397884	chr7:158709396	WDR60	-0.8	-9.06	-0.44	1.09e-17	Height;
LUSC	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg20713898	chr8:124780851	FAM91A1	-0.54	-7.49	-0.38	6.06e-13	Pancreatic cancer;
LUSC	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg12826209	chr6:26865740	GUSBL1	0.67	5.85	0.31	1.14e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6460942	0.591	rs62448726	chr7:12330881	A/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.98	-0.31	5.79e-9	Coronary artery disease;
LUSC	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg11019008	chr10:131425282	MGMT	0.39	6.02	0.31	4.58e-9	Response to temozolomide;
LUSC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.94	-19.27	-0.73	3.78e-56	Post bronchodilator FEV1;
LUSC	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.32	-0.33	8.52e-10	Bipolar disorder;
LUSC	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg05855489	chr10:104503620	C10orf26	-0.48	-7.35	-0.37	1.53e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg27411982	chr8:10470053	RP1L1	0.42	6.81	0.35	4.56e-11	Neuroticism;
LUSC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.5	0.34	2.96e-10	Menopause (age at onset);
LUSC	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.45	0.56	1.78e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.99	-0.36	1.55e-11	Schizophrenia;
LUSC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg11344533	chr11:111475393	SIK2	0.48	6.52	0.34	2.55e-10	Primary sclerosing cholangitis;
LUSC	trans	rs7939886	0.623	rs77065109	chr11:55906843	G/A	cg03929089	chr4:120376271	NA	0.76	6.1	0.32	2.93e-9	Myopia (pathological);
LUSC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg16006841	chr5:176797999	RGS14	0.63	9.91	0.48	1.87e-20	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs907683	0.559	rs4674394	chr2:220289870	C/T	cg15015639	chr2:220282977	DES	-0.31	-7.07	-0.36	9.11e-12	Resting heart rate;
LUSC	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg09365446	chr1:150670422	GOLPH3L	0.44	6.1	0.32	2.94e-9	Melanoma;
LUSC	trans	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-8.7	-0.43	1.5e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.71	13.23	0.59	2.04e-32	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUSC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg05347473	chr6:146136440	FBXO30	0.46	7.96	0.4	2.72e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6714788	0.546	rs12712062	chr2:100654307	A/T	cg07810366	chr2:100720526	AFF3	-0.39	-6.08	-0.32	3.25e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.85	11.51	0.53	4.93e-26	Mean corpuscular hemoglobin;
LUSC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-16.17	-0.66	7.42e-44	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg14791747	chr16:20752902	THUMPD1	-0.41	-6.21	-0.32	1.54e-9	Dental caries;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01460805	chr8:22549804	EGR3	-0.41	-5.96	-0.31	6.29e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2303282	0.933	rs34793257	chr16:56494071	C/T	cg00500540	chr16:56394104	NA	-0.45	-7.23	-0.37	3.42e-12	Breast cancer;
LUSC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.97	-0.4	2.61e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg19077165	chr18:44547161	KATNAL2	-0.37	-5.68	-0.3	2.94e-8	Personality dimensions;
LUSC	cis	rs8044995	0.563	rs3785127	chr16:68399590	C/G	cg09835421	chr16:68378352	PRMT7	-0.77	-8.61	-0.43	3.01e-16	Schizophrenia;
LUSC	cis	rs12760731	0.720	rs7548163	chr1:178306695	G/A	cg00404053	chr1:178313656	RASAL2	0.56	6.1	0.32	2.98e-9	Obesity-related traits;
LUSC	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg24375607	chr4:120327624	NA	0.79	11.67	0.54	1.27e-26	Corneal astigmatism;
LUSC	cis	rs9837602	1.000	rs1021103	chr3:99603230	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.39	-5.83	-0.3	1.28e-8	Breast cancer;
LUSC	cis	rs9378688	1.000	rs3778568	chr6:2225680	C/T	cg12303981	chr6:2244766	GMDS	-0.52	-6.27	-0.32	1.15e-9	Caudate nucleus volume;
LUSC	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg15432903	chr11:17409602	KCNJ11	0.61	10.79	0.51	1.68e-23	Type 2 diabetes;
LUSC	cis	rs356992	0.915	rs168562	chr2:60747192	T/C	cg08426369	chr2:60753602	BCL11A	0.44	6.05	0.31	3.86e-9	Educational attainment (years of education);
LUSC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.84	-0.44	5.44e-17	Monocyte count;
LUSC	trans	rs2490361	1.000	rs2490360	chr1:237326980	C/T	cg15653282	chr18:11689218	GNAL	0.39	6.02	0.31	4.68e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg22467129	chr15:76604101	ETFA	-0.52	-8.35	-0.42	1.9e-15	Blood metabolite levels;
LUSC	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg03983476	chr2:10830698	NOL10	-0.37	-5.71	-0.3	2.56e-8	Prostate cancer;
LUSC	cis	rs7805747	0.523	rs13239239	chr7:151423196	C/T	cg17611936	chr7:151411526	PRKAG2	-0.43	-5.86	-0.31	1.14e-8	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUSC	cis	rs12422267	0.536	rs12423631	chr12:132606886	C/T	cg09764611	chr12:132620959	NA	-0.58	-8.04	-0.4	1.59e-14	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs965513	1.000	rs7028661	chr9:100538470	A/G	cg13688889	chr9:100608707	NA	-0.57	-8.61	-0.43	2.88e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	7.26	0.37	2.8e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.83	-15.15	-0.64	8.08e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11051970	0.679	rs2651366	chr12:32560431	T/C	cg24626660	chr12:32551988	NA	0.31	5.7	0.3	2.7e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3125734	0.633	rs3852412	chr10:64050288	C/T	cg09941381	chr10:64027924	RTKN2	-0.39	-7.06	-0.36	9.64e-12	Rheumatoid arthritis;
LUSC	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg05738196	chr6:26577821	NA	0.81	15.89	0.66	9.79e-43	Intelligence (multi-trait analysis);
LUSC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06022373	chr22:39101656	GTPBP1	0.76	12.13	0.55	2.62e-28	Menopause (age at onset);
LUSC	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg03929089	chr4:120376271	NA	0.59	6.58	0.34	1.79e-10	Axial length;
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.46	7.77	0.39	1e-13	Lymphocyte counts;
LUSC	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	6.35	0.33	6.95e-10	Response to antipsychotic treatment;
LUSC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12016809	chr21:47604291	C21orf56	0.46	6.91	0.35	2.52e-11	Testicular germ cell tumor;
LUSC	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg25208724	chr1:156163844	SLC25A44	1.08	22.65	0.78	1.77e-69	Testicular germ cell tumor;
LUSC	cis	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.58	-0.42	3.62e-16	Bladder cancer;
LUSC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.42	-0.38	9.84e-13	Aortic root size;
LUSC	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg12927641	chr6:109611667	NA	-0.35	-5.87	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.88	-0.4	4.57e-14	Height;
LUSC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg17340268	chr14:105411764	AHNAK2	-0.4	-6.29	-0.33	9.71e-10	Rheumatoid arthritis;
LUSC	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-7.48	-0.38	6.52e-13	Fear of minor pain;
LUSC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg00431813	chr7:1051703	C7orf50	-0.43	-7.37	-0.37	1.31e-12	Longevity;Endometriosis;
LUSC	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-7.02	-0.36	1.28e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg25457927	chr22:38595422	NA	-0.35	-6.73	-0.35	7.45e-11	Cutaneous nevi;
LUSC	cis	rs4631830	0.900	rs7920517	chr10:51532621	G/A	cg20129853	chr10:51489980	NA	-0.35	-6.99	-0.36	1.49e-11	Prostate-specific antigen levels;
LUSC	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg05738196	chr6:26577821	NA	0.82	15.81	0.65	1.93e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs13401104	0.796	rs10929169	chr2:237115532	C/T	cg19324714	chr2:237145437	ASB18	0.43	5.65	0.3	3.35e-8	Educational attainment;
LUSC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg09367891	chr1:107599246	PRMT6	-0.5	-7.77	-0.39	1e-13	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg03806693	chr22:41940476	POLR3H	-0.95	-12.89	-0.58	3.97e-31	Vitiligo;
LUSC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg10556349	chr10:835070	NA	0.56	6.16	0.32	2.05e-9	Eosinophil percentage of granulocytes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03006338	chr19:4402502	CHAF1A	-0.45	-5.95	-0.31	6.85e-9	Hepatitis;
LUSC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.56e-24	Aortic root size;
LUSC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg13647721	chr17:30228624	UTP6	-0.63	-6.11	-0.32	2.85e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1355223	0.573	rs947501	chr11:34753375	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.16	-0.32	2.1e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg23260525	chr10:116636907	FAM160B1	0.4	8.18	0.41	5.96e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg24154853	chr7:158122151	PTPRN2	0.35	5.81	0.3	1.47e-8	Response to amphetamines;
LUSC	trans	rs72674100	1.000	rs28504129	chr4:97990879	G/A	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.66	-7.04	-0.36	1.07e-11	Ankle injury;
LUSC	cis	rs17253792	0.731	rs79483151	chr14:56048851	C/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	8.91e-12	Putamen volume;
LUSC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg23711669	chr6:146136114	FBXO30	0.72	12.66	0.57	2.78e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4974559	0.739	rs6599298	chr4:1298122	A/G	cg02980000	chr4:1222292	CTBP1	1.02	9.33	0.45	1.5e-18	Systolic blood pressure;
LUSC	trans	rs12145833	0.538	rs61833885	chr1:243397188	C/A	cg01826367	chr1:224180288	NA	0.7	6.3	0.33	9.36e-10	Obesity (early onset extreme);
LUSC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg16060761	chr17:80687452	NA	0.45	7.21	0.37	3.81e-12	Breast cancer;
LUSC	cis	rs2692947	0.759	rs1917890	chr2:96672001	C/T	cg22654517	chr2:96458247	NA	0.31	6.13	0.32	2.54e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg00012203	chr2:219082015	ARPC2	-0.75	-12.8	-0.57	8.66e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	10.85	0.51	1.06e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9314614	0.934	rs2980955	chr8:6694434	A/G	cg27319216	chr8:6693540	XKR5	-0.35	-6.35	-0.33	6.92e-10	IgA nephropathy;White blood cell count (basophil);
LUSC	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg10483660	chr13:112241077	NA	-0.31	-5.68	-0.3	2.99e-8	Hepatitis;
LUSC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	0.91	17.45	0.69	6.11e-49	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg23711669	chr6:146136114	FBXO30	0.71	11.49	0.53	5.85e-26	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.43	-5.86	-0.31	1.11e-8	Coronary artery disease;
LUSC	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg04733989	chr22:42467013	NAGA	0.41	6.52	0.34	2.54e-10	Cognitive function;
LUSC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg15147215	chr3:52552868	STAB1	-0.31	-6.16	-0.32	2.06e-9	Bipolar disorder;
LUSC	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg04240660	chr16:89714849	CHMP1A	-0.41	-6.48	-0.33	3.28e-10	Hemoglobin concentration;
LUSC	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg19875535	chr5:140030758	IK	0.5	8.28	0.41	3.06e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs17253792	0.822	rs10139905	chr14:56170031	T/C	cg01858014	chr14:56050164	KTN1	-0.71	-6.35	-0.33	6.97e-10	Putamen volume;
LUSC	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg06484146	chr7:12443880	VWDE	-0.69	-7.2	-0.37	4.01e-12	Coronary artery disease;
LUSC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-5.91	-0.31	8.41e-9	Crohn's disease;
LUSC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.38	0.33	5.95e-10	Menopause (age at onset);
LUSC	trans	rs2392780	0.596	rs283705	chr8:128317450	C/T	cg10897648	chr18:56338258	MALT1	-0.42	-6.24	-0.32	1.31e-9	Breast cancer (early onset);
LUSC	trans	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-8.7	-0.43	1.5e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg18230493	chr5:56204884	C5orf35	0.53	8.46	0.42	8.41e-16	Coronary artery disease;
LUSC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.91	11.87	0.54	2.36e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg25815440	chr2:42134162	NA	-0.27	-6.33	-0.33	8.07e-10	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs17604090	0.877	rs28516764	chr7:29685245	T/G	cg19413766	chr7:29689036	LOC646762	-0.58	-6.93	-0.35	2.12e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	trans	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.9	0.35	2.69e-11	Morning vs. evening chronotype;
LUSC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.8	-0.47	4.39e-20	Platelet count;
LUSC	cis	rs11031096	0.711	rs17283923	chr11:4173841	C/T	cg18678763	chr11:4115507	RRM1	-0.4	-5.68	-0.3	2.99e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg02551604	chr5:131831745	NA	-0.4	-6.27	-0.32	1.1e-9	Asthma (sex interaction);
LUSC	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.84	0.39	6.23e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg22875332	chr1:76189707	ACADM	-0.7	-9.59	-0.46	2.15e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs17401966	0.540	rs11121557	chr1:10448260	T/G	cg19773385	chr1:10388646	KIF1B	-0.37	-6.56	-0.34	2.02e-10	Hepatocellular carcinoma;
LUSC	trans	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg19862616	chr7:65841803	NCRNA00174	0.84	9.53	0.46	3.45e-19	Eotaxin levels;
LUSC	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.99	-0.44	1.88e-17	Response to antipsychotic treatment;
LUSC	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg15133208	chr4:90757351	SNCA	-0.34	-5.99	-0.31	5.45e-9	Dementia with Lewy bodies;
LUSC	cis	rs977987	0.806	rs766521	chr16:75424154	A/G	cg03315344	chr16:75512273	CHST6	-0.47	-8.99	-0.44	1.88e-17	Dupuytren's disease;
LUSC	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.48	0.5	2.15e-22	Lung cancer in ever smokers;
LUSC	trans	rs6869502	0.871	rs13354207	chr5:110151791	C/G	cg10196696	chr5:157247843	CLINT1	-0.41	-5.96	-0.31	6.48e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg20476274	chr7:133979776	SLC35B4	0.79	13.93	0.61	4.16e-35	Mean platelet volume;
LUSC	cis	rs1371867	0.846	rs2453624	chr8:101230523	A/G	cg06002616	chr8:101225028	SPAG1	0.47	7.65	0.39	2.16e-13	Atrioventricular conduction;
LUSC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03576123	chr11:487126	PTDSS2	-0.95	-10.54	-0.5	1.27e-22	Body mass index;
LUSC	trans	rs9944715	1.000	rs9952972	chr18:43842617	T/A	cg01718231	chr17:29326311	RNF135	-0.5	-6.95	-0.36	1.97e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs6546550	0.935	rs3214007	chr2:70098808	A/G	cg02498382	chr2:70120550	SNRNP27	-0.31	-7.62	-0.38	2.62e-13	Prevalent atrial fibrillation;
LUSC	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg08873628	chr1:175162347	KIAA0040	-0.43	-6.31	-0.33	8.92e-10	Diastolic blood pressure;
LUSC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg24881330	chr22:46731750	TRMU	0.88	8.87	0.44	4.44e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg14416269	chr4:6271139	WFS1	0.54	11.41	0.53	1.08e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.36	-0.37	1.47e-12	Menopause (age at onset);
LUSC	cis	rs11971779	0.680	rs7785903	chr7:139122643	T/C	cg07862535	chr7:139043722	LUC7L2	0.6	7.64	0.39	2.25e-13	Diisocyanate-induced asthma;
LUSC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg04166393	chr7:2884313	GNA12	0.4	5.8	0.3	1.57e-8	Height;
LUSC	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg18132916	chr6:79620363	NA	-0.39	-5.9	-0.31	8.72e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg17264618	chr3:40429014	ENTPD3	0.36	7.58	0.38	3.48e-13	Renal cell carcinoma;
LUSC	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg05585544	chr11:47624801	NA	-0.42	-7.15	-0.36	5.43e-12	Subjective well-being;
LUSC	cis	rs1044826	0.642	rs295478	chr3:139223135	G/A	cg00490450	chr3:139108681	COPB2	0.46	7.02	0.36	1.27e-11	Obesity-related traits;
LUSC	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg08345082	chr10:99160200	RRP12	-0.36	-7.3	-0.37	2.19e-12	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.33	0.33	8.04e-10	Corneal astigmatism;
LUSC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.72	0.65	4.67e-42	Platelet count;
LUSC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-1.04	-20.3	-0.74	2.97e-60	Height;
LUSC	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg26384229	chr12:38710491	ALG10B	-0.66	-10.17	-0.49	2.44e-21	Bladder cancer;
LUSC	trans	rs979233	0.502	rs10074493	chr5:42111968	C/T	cg07010552	chr17:7358735	CHRNB1	-0.4	-6.06	-0.31	3.74e-9	Systemic lupus erythematosus;
LUSC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	8.33	0.41	2.16e-15	Total body bone mineral density;
LUSC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.65	13.71	0.6	3.03e-34	Monocyte percentage of white cells;
LUSC	cis	rs116988415	0.584	rs2269307	chr14:65245007	G/A	cg00114569	chr14:65239327	SPTB	0.62	6.5	0.34	2.88e-10	Daytime sleep phenotypes;
LUSC	cis	rs6599077	0.950	rs9863161	chr3:40105336	T/C	cg13683864	chr3:40499215	RPL14	-0.61	-7.6	-0.38	3.09e-13	Sleep-related phenotypes;
LUSC	cis	rs7267979	0.565	rs4815432	chr20:25556403	A/C	cg03522245	chr20:25566470	NINL	-0.38	-5.98	-0.31	5.66e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg24006582	chr15:45444508	DUOX1	0.65	9.45	0.46	6.25e-19	Uric acid levels;
LUSC	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.55	0.38	4.06e-13	Iron status biomarkers;
LUSC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg04518342	chr5:131593106	PDLIM4	0.35	6.39	0.33	5.47e-10	Blood metabolite levels;
LUSC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg18827107	chr12:86230957	RASSF9	-0.46	-6.88	-0.35	3.04e-11	Major depressive disorder;
LUSC	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.09	-0.4	1.14e-14	Neuroticism;
LUSC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg06671706	chr8:8559999	CLDN23	-0.53	-6.97	-0.36	1.69e-11	Obesity-related traits;
LUSC	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-0.85	-15.63	-0.65	1.02e-41	Longevity;
LUSC	cis	rs6939532	0.522	rs13218591	chr6:26376832	T/C	cg05738196	chr6:26577821	NA	-0.44	-6.16	-0.32	2.05e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg02551604	chr5:131831745	NA	-0.41	-6.23	-0.32	1.37e-9	Asthma (sex interaction);
LUSC	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg23093090	chr10:104574429	C10orf26	-0.35	-6.49	-0.33	3.17e-10	Waist circumference;Hip circumference;
LUSC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg00343986	chr7:65444356	GUSB	0.44	6.73	0.35	7.5e-11	Aortic root size;
LUSC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg06453172	chr10:134556979	INPP5A	-0.5	-6.35	-0.33	6.9e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg04871131	chr7:94954202	PON1	-0.38	-6.12	-0.32	2.65e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg07741184	chr6:167504864	NA	-0.35	-6.39	-0.33	5.46e-10	Crohn's disease;
LUSC	cis	rs6580649	0.831	rs4760620	chr12:48559642	A/G	cg24011408	chr12:48396354	COL2A1	0.48	6.56	0.34	2e-10	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26500801	chr19:10613855	KEAP1	-0.39	-6.0	-0.31	5.22e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg24631222	chr15:78858424	CHRNA5	-0.66	-8.72	-0.43	1.34e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg04871131	chr7:94954202	PON1	0.38	6.77	0.35	5.63e-11	Paraoxonase activity;
LUSC	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg16576597	chr16:28551801	NUPR1	0.3	6.09	0.32	3.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg05887092	chr17:76393375	PGS1	0.54	9.77	0.47	5.57e-20	HDL cholesterol levels;
LUSC	cis	rs977987	0.836	rs34673655	chr16:75323559	T/C	cg03315344	chr16:75512273	CHST6	0.47	8.62	0.43	2.7e-16	Dupuytren's disease;
LUSC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.0	-0.36	1.44e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9434723	0.841	rs9435152	chr1:9308249	C/T	cg04199779	chr1:9294473	H6PD	0.56	6.23	0.32	1.38e-9	Height;
LUSC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.36e-8	Lung cancer;
LUSC	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg04310649	chr10:35416472	CREM	-0.42	-6.47	-0.33	3.4e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg06671706	chr8:8559999	CLDN23	0.49	6.43	0.33	4.36e-10	Obesity-related traits;
LUSC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg14552801	chr7:65878734	NA	0.38	5.93	0.31	7.68e-9	Aortic root size;
LUSC	cis	rs62027291	0.898	rs78138579	chr15:77308255	C/T	cg26408565	chr15:76604113	ETFA	0.51	6.15	0.32	2.27e-9	Plateletcrit;
LUSC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.03	-0.52	2.41e-24	Bipolar disorder;
LUSC	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-0.88	-13.13	-0.58	4.86e-32	Asthma;
LUSC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	0.95	13.81	0.6	1.29e-34	Vitiligo;
LUSC	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-6.56	-0.34	2.05e-10	Hemoglobin concentration;
LUSC	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg12863693	chr15:85201151	NMB	0.42	8.76	0.43	1.02e-16	Schizophrenia;
LUSC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg27170947	chr2:26402098	FAM59B	-0.72	-11.04	-0.52	2.26e-24	Gut microbiome composition (summer);
LUSC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.39	6.0	0.31	5.15e-9	Total body bone mineral density;
LUSC	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg11473876	chr11:109292803	C11orf87	-0.41	-6.71	-0.34	8.36e-11	Schizophrenia;
LUSC	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg04920474	chr2:44395004	PPM1B	0.62	8.02	0.4	1.79e-14	Height;
LUSC	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg12560992	chr17:57184187	TRIM37	0.58	9.32	0.45	1.65e-18	Testicular germ cell tumor;
LUSC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg04844267	chr4:1394941	NA	0.32	6.31	0.33	8.95e-10	Obesity-related traits;
LUSC	cis	rs4595586	0.756	rs7137139	chr12:39364013	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.85	0.35	3.66e-11	Morning vs. evening chronotype;
LUSC	cis	rs3931020	0.688	rs277396	chr1:75213648	A/C	cg21906852	chr1:75198582	TYW3;CRYZ	-0.44	-5.67	-0.3	3.15e-8	Resistin levels;
LUSC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg13175981	chr1:150552382	MCL1	0.44	6.06	0.31	3.6e-9	Urate levels;
LUSC	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.92e-20	Coronary artery disease;
LUSC	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.35	-0.42	1.82e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11676348	0.808	rs61700947	chr2:219046171	C/G	cg00012203	chr2:219082015	ARPC2	0.59	9.44	0.46	6.77e-19	Ulcerative colitis;
LUSC	cis	rs7267979	0.565	rs958075	chr20:25595123	C/T	cg03522245	chr20:25566470	NINL	-0.38	-6.0	-0.31	5.12e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4851254	0.660	rs56037757	chr2:100690130	A/G	cg22139774	chr2:100720529	AFF3	-0.43	-5.75	-0.3	1.99e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-8.2	-0.41	5.25e-15	Chronic sinus infection;
LUSC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg04287289	chr16:89883240	FANCA	-0.74	-12.05	-0.55	5.38e-28	Vitiligo;
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.52	-9.52	-0.46	3.63e-19	Longevity;Endometriosis;
LUSC	trans	rs867371	0.502	rs8025964	chr15:82521770	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.08	-0.32	3.27e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg24642439	chr20:33292090	TP53INP2	-0.42	-5.94	-0.31	6.99e-9	Height;
LUSC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.39	-6.04	-0.31	4.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-10.0	-0.48	8.85e-21	Personality dimensions;
LUSC	trans	rs853679	0.546	rs200490	chr6:27796935	G/T	cg06606381	chr12:133084897	FBRSL1	-0.73	-7.26	-0.37	2.66e-12	Depression;
LUSC	cis	rs6599077	0.950	rs9863428	chr3:40099571	T/C	cg13683864	chr3:40499215	RPL14	-0.59	-7.4	-0.38	1.11e-12	Sleep-related phenotypes;
LUSC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.54	-0.34	2.25e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	6.22	0.32	1.52e-9	Retinal vascular caliber;
LUSC	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg27661571	chr11:113659931	NA	-0.6	-7.12	-0.36	6.47e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg20887711	chr4:1340912	KIAA1530	0.7	10.79	0.51	1.76e-23	Longevity;
LUSC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.29	-5.97	-0.31	6.02e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.42	6.56	0.34	2.04e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14893161	chr1:205819251	PM20D1	0.47	6.56	0.34	2.03e-10	Parkinson's disease;
LUSC	cis	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg06521331	chr12:34319734	NA	0.39	6.42	0.33	4.76e-10	Morning vs. evening chronotype;
LUSC	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg16586182	chr3:47516702	SCAP	0.53	8.07	0.4	1.31e-14	Colorectal cancer;
LUSC	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg13010199	chr12:38710504	ALG10B	0.62	9.23	0.45	3.2e-18	Bladder cancer;
LUSC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.71	11.12	0.52	1.21e-24	Height;
LUSC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18876405	chr7:65276391	NA	-0.58	-9.36	-0.46	1.17e-18	Aortic root size;
LUSC	cis	rs753307	0.512	rs749776	chr19:49519058	T/C	cg20610492	chr19:49520450	LHB	-0.35	-5.8	-0.3	1.58e-8	Blood protein levels;
LUSC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.5	-6.96	-0.36	1.78e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.37	-0.42	1.6e-15	Response to antipsychotic treatment;
LUSC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg22823121	chr1:150693482	HORMAD1	0.5	7.21	0.37	3.67e-12	Melanoma;
LUSC	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.2	-0.45	4.01e-18	Extrinsic epigenetic age acceleration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24201109	chr6:16129407	MYLIP	0.44	6.02	0.31	4.55e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17467752	chr17:38218738	THRA	0.52	7.66	0.39	2.02e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg17294928	chr15:75287854	SCAMP5	-0.71	-6.51	-0.34	2.68e-10	Lung cancer;
LUSC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.33	-0.37	1.7e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs870825	0.655	rs28726376	chr4:185638954	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.55	0.6	1.23e-33	Blood protein levels;
LUSC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-7.26	-0.37	2.75e-12	Homoarginine levels;
LUSC	trans	rs2018683	0.707	rs2057957	chr7:28974626	A/C	cg19402173	chr7:128379420	CALU	0.48	7.37	0.37	1.35e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.66	0.57	2.9e-30	Motion sickness;
LUSC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg05457628	chr5:178986728	RUFY1	0.67	12.45	0.56	1.76e-29	Lung cancer;
LUSC	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	6.2	0.32	1.71e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	trans	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg25482853	chr8:67687455	SGK3	1.11	15.5	0.65	3.31e-41	Obesity-related traits;
LUSC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg06713675	chr4:122721982	EXOSC9	-0.46	-8.07	-0.4	1.27e-14	Type 2 diabetes;
LUSC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg18904891	chr8:8559673	CLDN23	0.6	8.0	0.4	2.11e-14	Obesity-related traits;
LUSC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.49	0.33	3.13e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg10862848	chr6:42927986	GNMT	-0.31	-7.5	-0.38	5.89e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	0.88	12.29	0.56	6.62e-29	Vitiligo;
LUSC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg22963979	chr7:1858916	MAD1L1	-0.74	-12.73	-0.57	1.57e-30	Bipolar disorder and schizophrenia;
LUSC	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg13575925	chr12:9217583	LOC144571	0.35	6.36	0.33	6.77e-10	Sjögren's syndrome;
LUSC	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg25214090	chr10:38739885	LOC399744	-0.5	-7.44	-0.38	8.43e-13	Corneal astigmatism;
LUSC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg16743903	chr16:89593216	SPG7	-0.4	-5.98	-0.31	5.59e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.01	0.31	4.88e-9	Menopause (age at onset);
LUSC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg17971929	chr21:40555470	PSMG1	0.63	7.61	0.38	2.83e-13	Cognitive function;
LUSC	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg05855489	chr10:104503620	C10orf26	0.68	11.35	0.53	1.78e-25	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6736093	0.966	rs3761699	chr2:112705290	G/A	cg12686935	chr2:112915763	FBLN7	-0.36	-5.81	-0.3	1.45e-8	Coronary artery disease;
LUSC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.38	-5.92	-0.31	8e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	10.19	0.49	2.11e-21	Mean corpuscular hemoglobin;
LUSC	cis	rs7590368	0.715	rs56263234	chr2:10959160	A/G	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	cis	rs10465746	0.682	rs882897	chr1:84426049	A/T	cg10977910	chr1:84465055	TTLL7	0.44	6.42	0.33	4.78e-10	Obesity-related traits;
LUSC	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg16797656	chr11:68205561	LRP5	0.38	6.25	0.32	1.27e-9	Total body bone mineral density;
LUSC	trans	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg25214090	chr10:38739885	LOC399744	0.41	6.29	0.33	9.72e-10	Corneal astigmatism;
LUSC	cis	rs1044826	1.000	rs13074208	chr3:139207151	A/G	cg00490450	chr3:139108681	COPB2	0.51	6.79	0.35	5.07e-11	Obesity-related traits;
LUSC	cis	rs4132509	0.744	rs10803156	chr1:243917776	G/C	cg21452805	chr1:244014465	NA	0.56	5.69	0.3	2.78e-8	RR interval (heart rate);
LUSC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.53	10.45	0.5	2.75e-22	Coronary artery disease;
LUSC	trans	rs2797160	0.967	rs28629380	chr6:126004197	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.38	-0.33	6.05e-10	Endometrial cancer;
LUSC	cis	rs7633770	0.786	rs1402148	chr3:46678295	C/T	cg11219411	chr3:46661640	NA	0.37	7.7	0.39	1.52e-13	Coronary artery disease;
LUSC	cis	rs2255336	0.938	rs2734414	chr12:10598802	A/T	cg16084090	chr12:10586130	KLRC2	0.45	6.05	0.31	3.79e-9	Blood protein levels;
LUSC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.63	-0.34	1.37e-10	Breast cancer;
LUSC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg12564285	chr5:131593104	PDLIM4	0.39	7.09	0.36	7.98e-12	Breast cancer;
LUSC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.59	-8.91	-0.44	3.26e-17	Alzheimer's disease;
LUSC	cis	rs1178968	1.000	rs4717756	chr7:72765458	C/G	cg25889504	chr7:72793014	NA	-0.56	-7.32	-0.37	1.91e-12	Triglyceride levels;
LUSC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg10207240	chr12:122356781	WDR66	0.48	7.0	0.36	1.39e-11	Mean platelet volume;
LUSC	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg09173681	chr1:183549694	NCF2	0.64	11.37	0.53	1.55e-25	Systemic lupus erythematosus;
LUSC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.55	0.46	2.98e-19	Personality dimensions;
LUSC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg12311346	chr5:56204834	C5orf35	-0.65	-10.12	-0.48	3.59e-21	Coronary artery disease;
LUSC	trans	rs62458065	0.640	rs28587905	chr7:32533054	C/T	cg00845942	chr12:64062724	DPY19L2	-0.6	-7.35	-0.37	1.5e-12	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.65	-8.03	-0.4	1.63e-14	Yeast infection;
LUSC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21862992	chr11:68658383	NA	0.52	8.02	0.4	1.74e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg10792982	chr14:105748885	BRF1	0.49	8.53	0.42	5.15e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	0.92	15.33	0.64	1.58e-40	Breast cancer;
LUSC	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.53	-11.22	-0.52	5.31e-25	Sense of smell;
LUSC	cis	rs11608355	0.508	rs12822899	chr12:109800978	A/G	cg19025524	chr12:109796872	NA	-0.47	-8.45	-0.42	9.19e-16	Neuroticism;
LUSC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11958404	0.860	rs6868839	chr5:157442196	T/G	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.86	0.6	7.72e-35	Blood protein levels;
LUSC	cis	rs4887059	1	rs4887059	chr15:78782095	C/T	cg18825076	chr15:78729989	IREB2	-0.43	-6.82	-0.35	4.31e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs2905347	0.757	rs2905318	chr7:22696653	A/C	cg09038599	chr8:57233391	SDR16C5	0.28	6.13	0.32	2.54e-9	Major depression and alcohol dependence;
LUSC	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg11941060	chr3:133502564	NA	-0.44	-6.29	-0.33	9.96e-10	Iron status biomarkers;
LUSC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg24375607	chr4:120327624	NA	0.71	11.35	0.53	1.83e-25	Corneal astigmatism;
LUSC	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.74	-10.65	-0.5	5.58e-23	Glomerular filtration rate;
LUSC	trans	rs2392780	0.536	rs620808	chr8:128335714	C/T	cg10195415	chr17:73887371	TRIM65	0.42	6.65	0.34	1.23e-10	Breast cancer (early onset);
LUSC	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg16482183	chr6:26056742	HIST1H1C	0.58	8.02	0.4	1.86e-14	Iron status biomarkers;
LUSC	trans	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg26043149	chr18:55253948	FECH	0.48	7.05	0.36	1.04e-11	Bone mineral density;
LUSC	cis	rs472402	0.580	rs11738248	chr5:6657494	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.53	-7.52	-0.38	5.2e-13	Response to amphetamines;
LUSC	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.36e-13	Type 2 diabetes;
LUSC	trans	rs4252134	0.881	rs4252107	chr6:161137518	T/C	cg00639886	chr12:54943102	PDE1B	-0.43	-6.17	-0.32	2.01e-9	Giant cell arteritis;
LUSC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg19266014	chr7:2183958	MAD1L1	-0.36	-6.17	-0.32	2.03e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg22532475	chr10:104410764	TRIM8	0.26	6.14	0.32	2.37e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11168618	0.810	rs35338015	chr12:48839401	C/T	cg24011408	chr12:48396354	COL2A1	0.38	6.07	0.32	3.48e-9	Adiponectin levels;
LUSC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	8.25	0.41	3.73e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-11.49	-0.53	5.69e-26	Schizophrenia;
LUSC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg07741184	chr6:167504864	NA	0.39	6.88	0.35	2.9e-11	Primary biliary cholangitis;
LUSC	cis	rs6460942	0.908	rs77799203	chr7:12264432	C/G	cg06484146	chr7:12443880	VWDE	-0.56	-5.84	-0.3	1.25e-8	Coronary artery disease;
LUSC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.23	14.08	0.61	1.1e-35	Diabetic kidney disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00660163	chr1:156052512	MEX3A	-0.43	-6.55	-0.34	2.19e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs394563	0.601	rs439495	chr6:149793224	A/G	cg11245181	chr6:149772854	ZC3H12D	0.35	7.03	0.36	1.2e-11	Dupuytren's disease;
LUSC	cis	rs9796	0.866	rs516156	chr15:41381257	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.04	-0.4	1.55e-14	Menopause (age at onset);
LUSC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.28	-5.87	-0.31	1.08e-8	Lung cancer;
LUSC	cis	rs9815354	1.000	rs9856088	chr3:41860482	G/T	cg03022575	chr3:42003672	ULK4	0.58	6.52	0.34	2.55e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg19610905	chr11:61596333	FADS2	0.42	5.77	0.3	1.82e-8	Neutrophil count;Sum basophil neutrophil counts;
LUSC	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.36	5.99	0.31	5.31e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg26408565	chr15:76604113	ETFA	-0.43	-6.85	-0.35	3.64e-11	Blood metabolite levels;
LUSC	cis	rs977987	0.624	rs59867374	chr16:75432682	G/A	cg04384234	chr16:75411784	CFDP1	-0.43	-6.9	-0.35	2.55e-11	Dupuytren's disease;
LUSC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2710642	0.888	rs2539985	chr2:63134507	T/A	cg17519650	chr2:63277830	OTX1	0.51	7.19	0.37	4.27e-12	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg08888203	chr3:10149979	C3orf24	0.66	9.31	0.45	1.79e-18	Alzheimer's disease;
LUSC	trans	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	7.1	0.36	7.44e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7582720	0.945	rs72934583	chr2:204009057	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.83	8.78	0.43	8.34e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.53	6.99	0.36	1.47e-11	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.72	-10.15	-0.49	2.92e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg17385448	chr1:15911702	AGMAT	0.37	5.86	0.31	1.08e-8	Systolic blood pressure;
LUSC	cis	rs11997175	0.583	rs7464599	chr8:33817572	G/A	ch.8.33884649F	chr8:33765107	NA	0.46	6.55	0.34	2.22e-10	Body mass index;
LUSC	cis	rs10740039	0.883	rs10761538	chr10:62409221	G/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.92	-0.35	2.38e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg07936489	chr17:37558343	FBXL20	-0.7	-9.98	-0.48	1.09e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg08079166	chr15:68083412	MAP2K5	0.48	8.04	0.4	1.57e-14	Restless legs syndrome;
LUSC	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg20628663	chr10:43360327	NA	-0.76	-11.4	-0.53	1.23e-25	Blood protein levels;
LUSC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.57	0.38	3.69e-13	Prudent dietary pattern;
LUSC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg24562669	chr7:97807699	LMTK2	0.36	6.27	0.32	1.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6121246	0.542	rs75694362	chr20:30450708	T/C	cg13852791	chr20:30311386	BCL2L1	0.68	6.51	0.34	2.79e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09326880	chr3:43147587	C3orf39	-0.48	-5.72	-0.3	2.33e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.14	0.36	5.96e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.93	-0.4	3.41e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.88	15.14	0.64	8.97e-40	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17712092	chr4:129076599	LARP1B	0.72	10.86	0.51	9.8599999999999993e-24	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.96	0.7	5.97e-51	Chronic sinus infection;
LUSC	cis	rs9650657	0.615	rs7012199	chr8:10696997	A/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.32	-0.33	8.37e-10	Neuroticism;
LUSC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg06145435	chr7:1022769	CYP2W1	0.3	6.19	0.32	1.77e-9	Longevity;Endometriosis;
LUSC	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.33	0.49	6.79e-22	Schizophrenia;
LUSC	trans	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg10756647	chr7:56101905	PSPH	0.88	8.45	0.42	8.8e-16	Diabetic kidney disease;
LUSC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg22508957	chr16:3507546	NAT15	-0.86	-10.67	-0.5	4.52e-23	Tuberculosis;
LUSC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.38	0.37	1.24e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg05425664	chr17:57184151	TRIM37	-0.49	-7.46	-0.38	7.68e-13	Testicular germ cell tumor;
LUSC	cis	rs3820068	0.544	rs7551750	chr1:16035008	T/C	cg13390004	chr1:15929781	NA	0.41	6.79	0.35	5.02e-11	Systolic blood pressure;
LUSC	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg00191853	chr8:101177733	SPAG1	-0.41	-6.53	-0.34	2.46e-10	Atrioventricular conduction;
LUSC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg19812747	chr11:111475976	SIK2	-0.55	-8.2	-0.41	5.19e-15	Primary sclerosing cholangitis;
LUSC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg21535247	chr6:8435926	SLC35B3	0.57	8.92	0.44	3.02e-17	Motion sickness;
LUSC	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-8.67	-0.43	1.93e-16	Response to antipsychotic treatment;
LUSC	trans	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.47	-0.38	6.98e-13	Menarche (age at onset);
LUSC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.79	12.71	0.57	1.81e-30	Aortic root size;
LUSC	trans	rs61931739	0.635	rs4442626	chr12:33912530	C/T	cg13010199	chr12:38710504	ALG10B	0.41	6.12	0.32	2.65e-9	Morning vs. evening chronotype;
LUSC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.85	0.7	1.69e-50	Chronic sinus infection;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04869497	chr17:20059225	CYTSB	0.48	6.49	0.33	3.08e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg04546413	chr19:29218101	NA	0.74	12.95	0.58	2.35e-31	Methadone dose in opioid dependence;
LUSC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.88	0.6	6.55e-35	Cognitive test performance;
LUSC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.44	-0.42	1e-15	Breast cancer;
LUSC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg05043794	chr9:111880884	C9orf5	-0.38	-7.85	-0.39	5.79e-14	Menarche (age at onset);
LUSC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg12386194	chr3:101231763	SENP7	0.53	7.47	0.38	7.18e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.51	8.04	0.4	1.6e-14	Schizophrenia;
LUSC	cis	rs10754283	0.967	rs10801757	chr1:90103080	A/G	cg21401794	chr1:90099060	LRRC8C	0.63	9.61	0.47	1.84e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.4	-0.33	5.2400000000000005e-10	Personality dimensions;
LUSC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg26335602	chr6:28129616	ZNF389	0.43	5.8	0.3	1.54e-8	Depression;
LUSC	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg05855489	chr10:104503620	C10orf26	0.64	9.26	0.45	2.47e-18	Arsenic metabolism;
LUSC	cis	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg21775007	chr8:11205619	TDH	-0.49	-6.89	-0.35	2.85e-11	Triglycerides;
LUSC	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg15997130	chr1:24165203	NA	-0.54	-8.79	-0.43	7.79e-17	Immature fraction of reticulocytes;
LUSC	cis	rs2299587	0.560	rs12718385	chr8:17781257	T/C	cg01800426	chr8:17659068	MTUS1	-0.49	-6.53	-0.34	2.4e-10	Economic and political preferences;
LUSC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg14949292	chr17:78079608	GAA	0.33	5.71	0.3	2.54e-8	Yeast infection;
LUSC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	9.06	0.44	1.1e-17	Total body bone mineral density;
LUSC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg11663144	chr21:46675770	NA	-0.41	-7.29	-0.37	2.3e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6690583	0.524	rs12045710	chr1:85451765	T/C	cg22153463	chr1:85462885	MCOLN2	0.62	6.0	0.31	5.12e-9	Serum sulfate level;
LUSC	cis	rs7572644	0.699	rs10175508	chr2:28213424	C/T	cg27432699	chr2:27873401	GPN1	-0.51	-6.95	-0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7605827	0.866	rs2276664	chr2:15701002	A/T	cg19274914	chr2:15703543	NA	0.46	8.64	0.43	2.33e-16	Educational attainment (years of education);
LUSC	trans	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-8.31	-0.41	2.44e-15	Obesity-related traits;
LUSC	cis	rs7809950	0.817	rs2204833	chr7:107283069	T/C	cg23024343	chr7:107201750	COG5	0.62	8.71	0.43	1.43e-16	Coronary artery disease;
LUSC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.23	-0.32	1.39e-9	Neutrophil percentage of white cells;
LUSC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg07806771	chr7:64541737	NA	0.42	5.99	0.31	5.43e-9	Calcium levels;
LUSC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.85	15.67	0.65	6.91e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg21171335	chr12:122356390	WDR66	0.62	9.33	0.45	1.51e-18	Mean corpuscular volume;
LUSC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.52	-0.34	2.63e-10	Life satisfaction;
LUSC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg04287289	chr16:89883240	FANCA	-0.42	-6.06	-0.31	3.61e-9	Vitiligo;
LUSC	cis	rs73206853	0.698	rs56327628	chr12:111117931	A/C	cg12870014	chr12:110450643	ANKRD13A	0.67	6.85	0.35	3.6e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.87	-0.31	1.05e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2692947	0.770	rs2315421	chr2:96497516	G/C	cg23100626	chr2:96804247	ASTL	0.26	6.47	0.33	3.53e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg26102564	chr10:131424627	MGMT	0.36	5.69	0.3	2.74e-8	Response to temozolomide;
LUSC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg15448220	chr1:150897856	SETDB1	0.38	5.69	0.3	2.84e-8	Urate levels;
LUSC	cis	rs10193935	0.901	rs6727657	chr2:42632117	A/G	cg27598129	chr2:42591480	NA	-0.6	-8.17	-0.41	6.63e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg23422044	chr7:1970798	MAD1L1	0.63	7.34	0.37	1.63e-12	Bipolar disorder;
LUSC	cis	rs11690935	0.569	rs62183770	chr2:172838117	C/G	cg13550731	chr2:172543902	DYNC1I2	0.5	7.44	0.38	8.64e-13	Schizophrenia;
LUSC	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg06606381	chr12:133084897	FBRSL1	-1.0	-8.84	-0.44	5.76e-17	Depression;
LUSC	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.6	7.39	0.37	1.21e-12	Mammographic density (dense area);
LUSC	cis	rs9581857	0.685	rs9319370	chr13:28042493	G/T	cg22138327	chr13:27999177	GTF3A	0.74	8.04	0.4	1.53e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg18230493	chr5:56204884	C5orf35	-0.58	-9.36	-0.46	1.22e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7923609	0.967	rs7085621	chr10:65208926	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.03e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs34421088	0.532	rs3808515	chr8:11156041	C/T	cg15556689	chr8:8085844	FLJ10661	0.41	6.08	0.32	3.23e-9	Neuroticism;
LUSC	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg08017756	chr2:100939284	LONRF2	-0.43	-8.06	-0.4	1.4e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	9.57	0.46	2.51e-19	Menopause (age at onset);
LUSC	cis	rs10875746	0.903	rs11168427	chr12:48538979	A/G	cg13454099	chr12:49076203	C12orf41	-0.52	-6.15	-0.32	2.17e-9	Longevity (90 years and older);
LUSC	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg05729581	chr11:3078854	CARS	0.4	5.82	0.3	1.36e-8	Calcium levels;
LUSC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg21361702	chr7:150065534	REPIN1	0.52	6.73	0.35	7.29e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg04111992	chr7:158790115	NA	-0.38	-5.87	-0.31	1.03e-8	Facial morphology (factor 20);
LUSC	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg03585969	chr10:35415529	CREM	0.59	8.83	0.44	6.06e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7106204	0.686	rs12791623	chr11:24277924	A/T	ch.11.24196551F	chr11:24239977	NA	0.73	6.0	0.31	5.01e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	1.14	17.51	0.69	3.64e-49	Corneal structure;
LUSC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg05776053	chr2:74358815	NA	0.46	7.24	0.37	3.06e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.71	-11.09	-0.52	1.47e-24	Menarche (age at onset);
LUSC	trans	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.73	-12.68	-0.57	2.33e-30	Brugada syndrome;
LUSC	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg27426351	chr10:43362370	NA	-0.43	-6.0	-0.31	5.26e-9	Blood protein levels;
LUSC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg11812906	chr14:75593930	NEK9	-0.64	-10.47	-0.5	2.32e-22	Height;
LUSC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg08847533	chr14:75593920	NEK9	-0.79	-13.55	-0.6	1.25e-33	Height;
LUSC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg21285383	chr16:89894308	SPIRE2	0.31	6.58	0.34	1.79e-10	Vitiligo;
LUSC	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg26566898	chr11:117069891	TAGLN	0.38	7.23	0.37	3.4e-12	Blood protein levels;
LUSC	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg17691542	chr6:26056736	HIST1H1C	0.59	8.19	0.41	5.46e-15	Iron status biomarkers;
LUSC	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-9.77	-0.47	5.53e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11039100	1.000	rs12362696	chr11:5828034	G/A	cg13902645	chr11:5959945	NA	-0.52	-5.84	-0.3	1.25e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-8.04	-0.4	1.62e-14	Mood instability;
LUSC	cis	rs55665837	1.000	rs11023229	chr11:14461001	G/C	cg19336497	chr11:14380999	RRAS2	-0.37	-7.47	-0.38	6.93e-13	Vitamin D levels;
LUSC	trans	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.42	6.55	0.34	2.21e-10	Cystic fibrosis severity;
LUSC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.53	10.45	0.5	2.74e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.42	-0.33	4.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6740322	0.748	rs6544634	chr2:43471528	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-6.53	-0.34	2.45e-10	Coronary artery disease;
LUSC	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg02018176	chr4:1364513	KIAA1530	0.45	6.29	0.33	9.9e-10	Recombination rate (females);
LUSC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs7147624	0.882	rs7141367	chr14:65938641	C/T	cg03016385	chr14:66212404	NA	-0.84	-9.36	-0.46	1.19e-18	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.62	12.64	0.57	3.5e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs4654899	0.802	rs6685306	chr1:21219050	C/T	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.01	-0.31	4.79e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg20821713	chr7:1055600	C7orf50	-0.53	-6.93	-0.35	2.13e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg03146154	chr1:46216737	IPP	-0.58	-8.39	-0.42	1.37e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg15704280	chr7:45808275	SEPT13	-0.57	-6.98	-0.36	1.64e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg21724239	chr8:58056113	NA	0.61	6.83	0.35	4.08e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg27411982	chr8:10470053	RP1L1	0.39	6.0	0.31	5.28e-9	Systolic blood pressure;
LUSC	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-5.96	-0.31	6.26e-9	Neuroticism;
LUSC	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	11.86	0.54	2.59e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	1.01	13.19	0.59	2.99e-32	Diabetic retinopathy;
LUSC	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.97	0.48	1.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.2e-28	Corneal astigmatism;
LUSC	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg09839279	chr12:125627357	AACS	-0.32	-5.66	-0.3	3.18e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg15744005	chr10:104629667	AS3MT	-0.28	-5.9	-0.31	8.93e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.98	-0.48	1.03e-20	Type 2 diabetes;
LUSC	cis	rs9815354	0.812	rs73073355	chr3:41842332	G/A	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg20476274	chr7:133979776	SLC35B4	-0.8	-14.64	-0.63	7.44e-38	Mean platelet volume;
LUSC	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg12573674	chr2:1569213	NA	-0.55	-6.09	-0.32	3.04e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7577696	0.925	rs12617290	chr2:32341408	A/G	cg02381751	chr2:32503542	YIPF4	-0.39	-5.66	-0.3	3.25e-8	Inflammatory biomarkers;
LUSC	cis	rs11229555	0.645	rs7117080	chr11:58178677	C/G	cg15696309	chr11:58395628	NA	-0.6	-7.48	-0.38	6.71e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs36093844	0.800	rs112468922	chr11:85576694	A/G	cg16165120	chr11:85566439	CCDC83	-0.4	-5.82	-0.3	1.41e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg05729581	chr11:3078854	CARS	0.4	5.86	0.31	1.11e-8	Calcium levels;
LUSC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10802521	chr3:52805072	NEK4	-0.54	-8.89	-0.44	3.84e-17	Bipolar disorder;
LUSC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.06e-9	Testicular germ cell tumor;
LUSC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.42	-0.33	4.6e-10	Total body bone mineral density;
LUSC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg02187348	chr16:89574699	SPG7	0.63	10.39	0.49	4.39e-22	Multiple myeloma (IgH translocation);
LUSC	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg13010199	chr12:38710504	ALG10B	0.52	7.75	0.39	1.1e-13	Morning vs. evening chronotype;
LUSC	cis	rs4664304	0.903	rs72957578	chr2:160754133	G/C	cg03641300	chr2:160917029	PLA2R1	-0.4	-6.48	-0.33	3.26e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg00277334	chr10:82204260	NA	-0.46	-6.53	-0.34	2.47e-10	Post bronchodilator FEV1;
LUSC	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.52	-0.42	5.45e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.48	-8.44	-0.42	9.46e-16	Blood metabolite levels;
LUSC	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg26384229	chr12:38710491	ALG10B	0.5	7.17	0.37	4.75e-12	Morning vs. evening chronotype;
LUSC	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg05555928	chr11:63887634	MACROD1	-0.5	-6.1	-0.32	2.93e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg03474202	chr17:45855739	NA	-0.29	-6.7	-0.34	8.99e-11	IgG glycosylation;
LUSC	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.52	-8.11	-0.41	1e-14	Platelet count;
LUSC	cis	rs10992471	0.603	rs11788523	chr9:95256593	G/A	cg14631576	chr9:95140430	CENPP	-0.33	-5.96	-0.31	6.48e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg24399712	chr22:39784796	NA	0.54	8.81	0.43	7.17e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg15595755	chr5:1867978	NA	0.46	8.29	0.41	2.86e-15	Cardiovascular disease risk factors;
LUSC	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.65	5.68	0.3	2.87e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03576123	chr11:487126	PTDSS2	-1.13	-11.88	-0.55	2.15e-27	Body mass index;
LUSC	cis	rs3760982	0.813	rs8111664	chr19:44295092	G/A	cg11993925	chr19:44307056	LYPD5	-0.31	-6.79	-0.35	5.11e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	trans	rs1459104	0.714	rs35789111	chr11:54926634	C/G	cg15704280	chr7:45808275	SEPT13	0.74	6.28	0.32	1.04e-9	Body mass index;
LUSC	cis	rs9807989	0.773	rs72823661	chr2:102968716	G/A	cg09003973	chr2:102972529	NA	0.44	6.01	0.31	4.83e-9	Asthma;
LUSC	cis	rs2067615	0.560	rs4964485	chr12:107121952	A/G	cg15890332	chr12:107067104	RFX4	0.34	6.15	0.32	2.22e-9	Heart rate;
LUSC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.8	-12.6	-0.57	4.65e-30	Menopause (age at onset);
LUSC	cis	rs2294693	0.853	rs9296350	chr6:40977623	G/A	cg14418226	chr6:40996092	UNC5CL	0.42	5.89	0.31	9.38e-9	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg20476274	chr7:133979776	SLC35B4	0.88	16.77	0.68	3.06e-46	Mean platelet volume;
LUSC	cis	rs80130819	0.515	rs72644846	chr12:48508283	A/G	cg24011408	chr12:48396354	COL2A1	-0.45	-6.19	-0.32	1.72e-9	Prostate cancer;
LUSC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	10.57	0.5	1.03e-22	Coffee consumption (cups per day);
LUSC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs62432291	0.681	rs2501176	chr6:159655383	A/G	cg14500486	chr6:159655392	FNDC1	-0.52	-5.84	-0.3	1.22e-8	Joint mobility (Beighton score);
LUSC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.19	0.37	4.23e-12	Mean platelet volume;
LUSC	cis	rs9419702	0.538	rs9322837	chr10:133539229	G/A	cg04492858	chr10:133558786	NA	0.42	6.98	0.36	1.57e-11	Survival in rectal cancer;
LUSC	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.74	0.51	2.65e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.44	-0.38	8.75e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg08508325	chr11:3079039	CARS	0.38	8.54	0.42	4.96e-16	Calcium levels;
LUSC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg06219351	chr7:158114137	PTPRN2	-0.53	-9.49	-0.46	4.53e-19	Calcium levels;
LUSC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg05802129	chr4:122689817	NA	-0.46	-8.14	-0.41	8.14e-15	Type 2 diabetes;
LUSC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg18681998	chr4:17616180	MED28	0.85	15.97	0.66	4.86e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg22467129	chr15:76604101	ETFA	-0.44	-7.02	-0.36	1.21e-11	Blood metabolite levels;
LUSC	cis	rs1160297	0.576	rs12713233	chr2:53116767	T/A	cg07782112	chr2:53107842	NA	0.45	7.32	0.37	1.81e-12	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.69e-9	Response to antipsychotic treatment;
LUSC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg25258033	chr6:167368657	RNASET2	0.37	5.83	0.3	1.28e-8	Primary biliary cholangitis;
LUSC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg01879757	chr17:41196368	BRCA1	-0.39	-5.83	-0.3	1.32e-8	Menopause (age at onset);
LUSC	trans	rs17039065	1.000	rs72889382	chr4:109391564	A/C	cg07444054	chr2:108107501	NA	0.42	6.17	0.32	1.93e-9	Gut microbiome composition (summer);
LUSC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg04398451	chr17:18023971	MYO15A	-0.48	-7.72	-0.39	1.34e-13	Total body bone mineral density;
LUSC	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.86	-0.4	5.34e-14	Mood instability;
LUSC	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg23277830	chr1:3704460	LRRC47	0.35	6.48	0.33	3.3e-10	Red cell distribution width;
LUSC	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg01733217	chr16:74700730	RFWD3	0.97	22.15	0.77	1.61e-67	Multiple myeloma;
LUSC	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg02476566	chr12:106696527	TCP11L2	0.53	6.74	0.35	6.82e-11	Tourette syndrome;
LUSC	cis	rs10886558	0.502	rs12573567	chr10:121825731	T/G	cg02041677	chr10:121771263	NA	-0.34	-6.14	-0.32	2.31e-9	Shingles;
LUSC	cis	rs2274273	0.805	rs10131926	chr14:55713246	T/C	cg04306507	chr14:55594613	LGALS3	0.58	13.72	0.6	2.79e-34	Protein biomarker;
LUSC	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.86	13.87	0.6	7.36e-35	Coronary artery disease;
LUSC	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg00982548	chr2:198649783	BOLL	0.57	7.25	0.37	2.89e-12	Ulcerative colitis;
LUSC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.9	0.44	3.53e-17	Menopause (age at onset);
LUSC	trans	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg21659725	chr3:3221576	CRBN	0.48	7.21	0.37	3.83e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7712401	0.601	rs62377424	chr5:122332322	G/A	cg19077854	chr5:122220652	SNX24	-0.43	-9.2	-0.45	4.07e-18	Mean platelet volume;
LUSC	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14240646	chr10:27532245	ACBD5	-0.66	-8.46	-0.42	8.79e-16	Breast cancer;
LUSC	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.63	-0.34	1.35e-10	Fear of minor pain;
LUSC	trans	rs62458065	0.850	rs28677012	chr7:32469811	C/A	cg00845942	chr12:64062724	DPY19L2	-0.52	-6.11	-0.32	2.84e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg12856521	chr11:46389249	DGKZ	0.4	6.13	0.32	2.54e-9	Leprosy;
LUSC	cis	rs6692729	0.931	rs1296171	chr1:227059606	C/G	cg10327440	chr1:227177885	CDC42BPA	0.49	7.09	0.36	8.19e-12	Electrodermal activity;
LUSC	cis	rs6445797	0.603	rs11706624	chr3:56584341	T/C	cg13792233	chr3:56591045	CCDC66	0.4	5.68	0.3	2.93e-8	Gastritis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25998680	chr6:43044239	PTK7	-0.4	-5.97	-0.31	6.14e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4622329	0.615	rs6539016	chr12:102290237	A/T	cg23541617	chr12:102225335	GNPTAB	0.26	6.07	0.32	3.51e-9	Systemic lupus erythematosus;
LUSC	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg18758796	chr5:131593413	PDLIM4	0.35	5.78	0.3	1.69e-8	Blood metabolite levels;
LUSC	cis	rs7586879	0.796	rs10187348	chr2:25078415	G/C	cg01884057	chr2:25150051	NA	0.38	7.89	0.4	4.27e-14	Body mass index;
LUSC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg07507251	chr3:52567010	NT5DC2	0.34	6.55	0.34	2.21e-10	Bipolar disorder;
LUSC	cis	rs17401966	0.522	rs912962	chr1:10348712	G/T	cg19773385	chr1:10388646	KIF1B	0.35	6.06	0.31	3.71e-9	Hepatocellular carcinoma;
LUSC	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14442939	chr10:27389572	ANKRD26	-0.88	-9.89	-0.48	2.12e-20	Breast cancer;
LUSC	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.57	7.43	0.38	8.99e-13	Multiple sclerosis;
LUSC	cis	rs77633900	0.614	rs12442966	chr15:76918290	G/T	cg21673338	chr15:77095150	SCAPER	0.68	6.87	0.35	3.17e-11	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19346786	chr7:2764209	NA	-0.37	-6.35	-0.33	6.96e-10	Height;
LUSC	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.3	0.53	2.74e-25	Coffee consumption (cups per day);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07600127	chr13:30881527	KATNAL1	0.44	6.05	0.31	3.85e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28830936	1.000	rs17734856	chr15:42045160	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.28	-5.99	-0.31	5.38e-9	Diastolic blood pressure;
LUSC	cis	rs4478858	0.735	rs11582342	chr1:31810681	A/G	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3862435	0.706	rs12594352	chr15:91002657	A/G	cg22089800	chr15:90895588	ZNF774	0.56	5.98	0.31	5.66e-9	Response to exercise (triglyceride level interaction);
LUSC	trans	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg26043149	chr18:55253948	FECH	0.51	7.52	0.38	5.1e-13	Bone mineral density;
LUSC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	0.64	13.37	0.59	5.97e-33	Prudent dietary pattern;
LUSC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.7	-0.47	9.44e-20	Gut microbiome composition (summer);
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20063963	chr1:204951166	NFASC	0.37	5.96	0.31	6.34e-9	Neuroticism;
LUSC	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg04058563	chr4:185651563	MLF1IP	0.44	7.15	0.36	5.56e-12	Kawasaki disease;
LUSC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg23719950	chr11:63933701	MACROD1	-0.38	-5.8	-0.3	1.55e-8	Platelet count;
LUSC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10802521	chr3:52805072	NEK4	-0.56	-9.11	-0.45	7.82e-18	Bipolar disorder;
LUSC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs62400317	0.859	rs12214749	chr6:45307906	A/G	cg20913747	chr6:44695427	NA	-0.47	-7.72	-0.39	1.35e-13	Total body bone mineral density;
LUSC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg15649852	chr7:65879115	NA	-0.41	-5.64	-0.3	3.53e-8	Aortic root size;
LUSC	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg24634471	chr8:143751801	JRK	0.59	8.88	0.44	4.09e-17	Schizophrenia;
LUSC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg22907277	chr7:1156413	C7orf50	0.72	7.68	0.39	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3849570	1.000	rs3772883	chr3:81802802	C/T	cg07356753	chr3:81810745	GBE1	-0.57	-9.04	-0.44	1.29e-17	Waist circumference;Body mass index;
LUSC	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg16850897	chr7:100343110	ZAN	-0.62	-8.65	-0.43	2.16e-16	Other erythrocyte phenotypes;
LUSC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg08859206	chr1:53392774	SCP2	0.55	9.48	0.46	5.03e-19	Monocyte count;
LUSC	cis	rs113835537	0.935	rs3867133	chr11:66451962	A/G	cg24851651	chr11:66362959	CCS	-0.46	-5.96	-0.31	6.26e-9	Airway imaging phenotypes;
LUSC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg08392591	chr16:89556376	ANKRD11	0.44	6.58	0.34	1.86e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg26647111	chr11:31128758	NA	-0.42	-6.16	-0.32	2.08e-9	Red blood cell count;
LUSC	trans	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-6.87	-0.35	3.11e-11	Menarche (age at onset);
LUSC	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.77	-0.47	5.55e-20	Hemoglobin concentration;
LUSC	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.29	6.02	0.31	4.65e-9	Hemoglobin concentration;
LUSC	cis	rs4704187	0.687	rs1363577	chr5:74463185	T/G	cg03227963	chr5:74354835	NA	0.32	6.83	0.35	4.02e-11	Response to amphetamines;
LUSC	cis	rs7173743	0.756	rs7169511	chr15:79128665	T/C	cg00540400	chr15:79124168	NA	0.35	5.99	0.31	5.29e-9	Coronary artery disease;
LUSC	cis	rs2108225	0.934	rs2283045	chr7:107440714	G/A	cg18560240	chr7:107437656	SLC26A3	-0.39	-5.96	-0.31	6.42e-9	Ulcerative colitis;
LUSC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg01689657	chr7:91764605	CYP51A1	0.33	6.03	0.31	4.29e-9	Breast cancer;
LUSC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	8.36	0.42	1.68e-15	Personality dimensions;
LUSC	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg16586182	chr3:47516702	SCAP	0.49	7.21	0.37	3.72e-12	QT interval;
LUSC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg02931644	chr1:25747376	RHCE	-0.37	-6.94	-0.36	2.04e-11	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg06671706	chr8:8559999	CLDN23	0.49	6.52	0.34	2.66e-10	Obesity-related traits;
LUSC	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg22705602	chr4:152727874	NA	-0.37	-7.97	-0.4	2.51e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs30380	0.632	rs26497	chr5:96138767	T/C	cg16492584	chr5:96139282	ERAP1	-0.57	-7.72	-0.39	1.33e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-6.17	-0.32	1.99e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-0.83	-15.3	-0.64	2.07e-40	Longevity;
LUSC	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg03647239	chr10:116582469	FAM160B1	0.41	6.18	0.32	1.86e-9	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.75	-10.95	-0.51	4.72e-24	Glomerular filtration rate;
LUSC	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	9.71	0.47	8.25e-20	Response to antipsychotic treatment;
LUSC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg10556349	chr10:835070	NA	0.55	6.21	0.32	1.53e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.27	-0.41	3.33e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg23306229	chr2:178417860	TTC30B	0.62	7.24	0.37	3.12e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg23435118	chr5:141488016	NDFIP1	-0.55	-7.94	-0.4	3.14e-14	Crohn's disease;
LUSC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg16240275	chr20:61666158	NCRNA00029	-0.28	-5.95	-0.31	6.9e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs36093844	0.800	rs17817355	chr11:85599945	C/A	cg25872744	chr11:85566296	CCDC83	-0.44	-5.65	-0.3	3.35e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs7615316	0.528	rs13078890	chr3:142350044	T/C	cg16271453	chr3:142027066	XRN1	-0.45	-7.92	-0.4	3.56e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg05738196	chr6:26577821	NA	-0.53	-7.93	-0.4	3.34e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg03465714	chr1:152285911	FLG	-0.41	-5.89	-0.31	9.28e-9	Atopic dermatitis;
LUSC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg11941060	chr3:133502564	NA	-0.42	-6.12	-0.32	2.68e-9	Iron status biomarkers;
LUSC	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-8.22	-0.41	4.4e-15	Body mass index;
LUSC	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg20503657	chr10:835505	NA	0.91	12.5	0.56	1.16e-29	Eosinophil percentage of granulocytes;
LUSC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.89	-12.72	-0.57	1.75e-30	Initial pursuit acceleration;
LUSC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg12463550	chr7:65579703	CRCP	-0.47	-6.96	-0.36	1.86e-11	Aortic root size;
LUSC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg04518342	chr5:131593106	PDLIM4	0.36	6.53	0.34	2.44e-10	Blood metabolite levels;
LUSC	cis	rs7589342	0.929	rs6719896	chr2:106428404	C/G	cg14210321	chr2:106509881	NCK2	0.55	8.41	0.42	1.23e-15	Addiction;
LUSC	cis	rs77741769	0.700	rs2701184	chr12:121353088	T/G	cg02403541	chr12:121454288	C12orf43	0.44	6.62	0.34	1.45e-10	Mean corpuscular volume;
LUSC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg04398451	chr17:18023971	MYO15A	0.57	9.41	0.46	8.44e-19	Total body bone mineral density;
LUSC	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg00540400	chr15:79124168	NA	-0.39	-6.95	-0.36	1.96e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg03678062	chr6:149772716	ZC3H12D	0.33	6.83	0.35	4.02e-11	Dupuytren's disease;
LUSC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg09021430	chr5:549028	NA	-0.57	-7.78	-0.39	9.19e-14	Obesity-related traits;
LUSC	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.31	0.49	7.81e-22	Morning vs. evening chronotype;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	0.96	20.05	0.74	3.02e-59	Menarche (age at onset);
LUSC	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.87	-0.35	3.06e-11	Response to antipsychotic treatment;
LUSC	cis	rs12760731	0.623	rs10913536	chr1:178315257	G/A	cg00404053	chr1:178313656	RASAL2	0.47	5.75	0.3	2.01e-8	Obesity-related traits;
LUSC	cis	rs78572108	0.800	rs4952574	chr2:42263822	T/C	cg00607755	chr2:42274082	PKDCC	0.36	6.48	0.33	3.34e-10	Total body bone mineral density;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01744215	chr16:9056616	USP7	0.85	6.61	0.34	1.49e-10	Cognitive performance;
LUSC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg12560992	chr17:57184187	TRIM37	0.88	16.79	0.68	2.54e-46	Intelligence (multi-trait analysis);
LUSC	cis	rs55871839	0.643	rs10109566	chr8:59800446	A/G	cg07426533	chr8:59803705	TOX	-0.36	-5.72	-0.3	2.36e-8	Pneumonia;
LUSC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg07701084	chr6:150067640	NUP43	0.51	7.48	0.38	6.59e-13	Lung cancer;
LUSC	cis	rs1483890	0.723	rs2007578	chr3:69408982	T/A	cg22125112	chr3:69402811	FRMD4B	0.4	5.67	0.3	3.06e-8	Resting heart rate;
LUSC	cis	rs10740039	0.842	rs7090892	chr10:62411851	A/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.79	-0.35	5.04e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.72	-0.35	7.63e-11	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.54	0.38	4.59e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10072221	0.836	rs10462540	chr5:75703257	G/A	cg03132911	chr5:75698732	IQGAP2	0.38	6.43	0.33	4.49e-10	Mean platelet volume;
LUSC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.12	0.58	5.22e-32	Cognitive test performance;
LUSC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.77	13.78	0.6	1.58e-34	Calcium levels;
LUSC	cis	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg02972257	chr16:68554789	NA	-0.53	-6.6	-0.34	1.64e-10	Ulcerative colitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08354699	chr15:63796895	USP3	0.43	6.51	0.34	2.7e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.3	0.69	2.6e-48	Chronic sinus infection;
LUSC	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg19554555	chr3:13937349	NA	-0.38	-5.71	-0.3	2.47e-8	Ovarian reserve;
LUSC	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.51	0.5	1.69e-22	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg17366294	chr4:99064904	C4orf37	0.55	9.77	0.47	5.18e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	7.44	0.38	8.62e-13	Axial length;
LUSC	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg14696996	chr19:15285081	NOTCH3	0.99	9.07	0.44	1.06e-17	Pulse pressure;
LUSC	trans	rs459571	0.916	rs467303	chr9:136904835	C/T	cg10765909	chr12:53715428	AAAS	-0.43	-6.22	-0.32	1.47e-9	Platelet distribution width;
LUSC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-8.93	-0.44	2.82e-17	Chronic sinus infection;
LUSC	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg12615879	chr12:58013172	SLC26A10	0.36	8.41	0.42	1.23e-15	Multiple sclerosis;
LUSC	cis	rs7246967	0.673	rs7249685	chr19:22882379	C/T	cg23217946	chr19:22817039	ZNF492	0.41	5.66	0.3	3.22e-8	Bronchopulmonary dysplasia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg03016446	chr10:74386166	CBARA1	0.39	6.31	0.33	8.8e-10	Triglycerides;
LUSC	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg05373962	chr22:49881684	NA	-0.44	-10.74	-0.51	2.5e-23	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs3820928	0.839	rs10197773	chr2:227824835	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.58	-0.38	3.41e-13	Pulmonary function;
LUSC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg03146154	chr1:46216737	IPP	0.53	7.75	0.39	1.09e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2625529	0.607	rs2912231	chr15:72567957	G/T	cg16672083	chr15:72433130	SENP8	-0.46	-6.7	-0.34	8.67e-11	Red blood cell count;
LUSC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.48	-6.44	-0.33	4.09e-10	Tonsillectomy;
LUSC	cis	rs10266483	0.843	rs667644	chr7:63750558	C/A	cg24201672	chr7:64023550	ZNF680	-0.43	-5.75	-0.3	1.98e-8	Response to statin therapy;
LUSC	cis	rs7809950	0.817	rs2253833	chr7:107205669	A/G	cg23024343	chr7:107201750	COG5	0.65	9.53	0.46	3.43e-19	Coronary artery disease;
LUSC	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.49	-8.1	-0.41	1.06e-14	Asthma;
LUSC	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.2e-13	Corneal astigmatism;
LUSC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg03146154	chr1:46216737	IPP	-0.55	-8.02	-0.4	1.79e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg16558253	chr16:72132732	DHX38	-0.41	-6.32	-0.33	8.5e-10	Fibrinogen levels;
LUSC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg27432699	chr2:27873401	GPN1	-0.53	-8.07	-0.4	1.32e-14	Total body bone mineral density;
LUSC	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg17127132	chr2:85788382	GGCX	0.43	6.13	0.32	2.42e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2019216	0.500	rs12938673	chr17:21941987	C/G	cg22648282	chr17:21454238	C17orf51	-0.5	-6.83	-0.35	4.12e-11	Pelvic organ prolapse;
LUSC	cis	rs1775715	0.870	rs11008700	chr10:32236937	A/G	cg04359828	chr10:32216031	ARHGAP12	0.38	6.47	0.33	3.5e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs500891	0.525	rs12215595	chr6:84055783	A/G	cg08257003	chr6:84140564	ME1	0.34	8.09	0.4	1.08e-14	Platelet-derived growth factor BB levels;
LUSC	trans	rs2262909	0.849	rs10420483	chr19:22190378	A/G	cg17074339	chr11:11642133	GALNTL4	-0.42	-6.27	-0.32	1.11e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7582720	1.000	rs72936842	chr2:203773686	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.38	0.42	1.49e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg04455712	chr21:45112962	RRP1B	0.46	8.61	0.43	2.95e-16	Mean corpuscular volume;
LUSC	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.76	11.3	0.53	2.7e-25	Corneal astigmatism;
LUSC	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg08079166	chr15:68083412	MAP2K5	0.41	7.29	0.37	2.33e-12	Restless legs syndrome;
LUSC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg20120165	chr17:48586569	MYCBPAP	-0.38	-6.2	-0.32	1.71e-9	Visceral fat;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19296258	chr17:78878799	RPTOR	-0.39	-6.38	-0.33	6.01e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg16447950	chr5:562315	NA	-0.58	-7.11	-0.36	7.26e-12	Obesity-related traits;
LUSC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg22963979	chr7:1858916	MAD1L1	-0.6	-9.44	-0.46	6.45e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs12210905	0.610	rs72845208	chr6:27395664	C/A	cg08851530	chr6:28072375	NA	0.93	5.77	0.3	1.77e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs11997175	0.646	rs28785323	chr8:33736104	C/G	ch.8.33884649F	chr8:33765107	NA	0.53	8.04	0.4	1.6e-14	Body mass index;
LUSC	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg16512390	chr1:228756714	NA	-0.53	-7.67	-0.39	1.95e-13	Chronic lymphocytic leukemia;
LUSC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg20135002	chr11:47629003	NA	-0.52	-8.14	-0.41	8.1e-15	Subjective well-being;
LUSC	cis	rs7107174	0.688	rs11237490	chr11:78135229	C/T	cg27205649	chr11:78285834	NARS2	-0.53	-6.05	-0.31	3.93e-9	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.79	-0.35	5.13e-11	Lung cancer;
LUSC	cis	rs7903847	0.656	rs74729163	chr10:99137287	A/C	cg20016023	chr10:99160130	RRP12	-0.31	-6.58	-0.34	1.81e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg11871910	chr12:69753446	YEATS4	0.84	14.83	0.63	1.4e-38	Blood protein levels;
LUSC	cis	rs6987853	0.563	rs2974302	chr8:42443119	C/G	cg09913449	chr8:42400586	C8orf40	0.43	7.17	0.37	4.98e-12	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg17443473	chr1:3703550	LRRC47	-0.33	-5.98	-0.31	5.78e-9	Red cell distribution width;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24739457	chr1:205821442	NA	0.36	6.21	0.32	1.54e-9	Menarche (age at onset);
LUSC	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg13072238	chr3:49761600	GMPPB	0.39	6.42	0.33	4.61e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg15147215	chr3:52552868	STAB1	-0.32	-6.32	-0.33	8.13e-10	Bipolar disorder;
LUSC	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg24634471	chr8:143751801	JRK	0.51	7.21	0.37	3.71e-12	Schizophrenia;
LUSC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg17264618	chr3:40429014	ENTPD3	0.31	6.69	0.34	9.31e-11	Renal cell carcinoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10994148	chr6:99797842	C6orf168	-0.42	-6.51	-0.34	2.73e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg13319975	chr6:146136371	FBXO30	0.5	7.52	0.38	5.18e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.48	-7.21	-0.37	3.65e-12	Neutrophil percentage of white cells;
LUSC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.78	0.3	1.69e-8	Menopause (age at onset);
LUSC	cis	rs80130819	0.748	rs1074174	chr12:48696720	A/G	cg24011408	chr12:48396354	COL2A1	0.44	5.68	0.3	2.86e-8	Prostate cancer;
LUSC	cis	rs12681287	0.640	rs28561640	chr8:87425638	G/A	cg27223183	chr8:87520930	FAM82B	0.55	7.52	0.38	4.95e-13	Caudate activity during reward;
LUSC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg04111992	chr7:158790115	NA	-0.39	-6.34	-0.33	7.35e-10	Facial morphology (factor 20);
LUSC	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	13.38	0.59	5.34e-33	Systemic lupus erythematosus;
LUSC	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	9.92	0.48	1.63e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg19640130	chr10:64028056	RTKN2	0.41	7.3	0.37	2.19e-12	Rheumatoid arthritis;
LUSC	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.06e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg13010199	chr12:38710504	ALG10B	0.45	6.35	0.33	6.97e-10	Morning vs. evening chronotype;
LUSC	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg23241863	chr10:102295624	HIF1AN	0.5	5.87	0.31	1.05e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7572733	0.534	rs1401095	chr2:198779867	C/T	cg00792783	chr2:198669748	PLCL1	-0.45	-6.07	-0.32	3.49e-9	Dermatomyositis;
LUSC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.24	0.41	4.07e-15	Hemoglobin concentration;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.8	13.77	0.6	1.84e-34	Menarche (age at onset);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg17392909	chr10:135187035	ECHS1	-0.47	-6.13	-0.32	2.54e-9	Cognitive function;Information processing speed;
LUSC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg22437258	chr11:111473054	SIK2	0.51	7.07	0.36	9.11e-12	Primary sclerosing cholangitis;
LUSC	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.41	-5.96	-0.31	6.29e-9	Platelet distribution width;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04351903	chr1:202162209	LGR6	0.46	6.86	0.35	3.26e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg00262122	chr8:11665843	FDFT1	-0.44	-6.74	-0.35	6.85e-11	Morning vs. evening chronotype;
LUSC	cis	rs9649465	0.522	rs662705	chr7:123431594	A/C	cg03229431	chr7:123269106	ASB15	0.48	7.68	0.39	1.76e-13	Migraine;
LUSC	cis	rs4845459	0.967	rs4845447	chr1:152590886	T/C	cg08895932	chr1:152778580	LCE1C	-0.36	-6.3	-0.33	9.62e-10	Psoriasis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26646903	chr3:186285208	TBCCD1	-0.44	-6.33	-0.33	7.96e-10	Hepatitis;
LUSC	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg03585969	chr10:35415529	CREM	0.6	8.74	0.43	1.12e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg20283391	chr11:68216788	NA	-0.61	-8.55	-0.42	4.43e-16	Total body bone mineral density;
LUSC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.51	-8.14	-0.41	8.17e-15	Platelet count;
LUSC	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.23	0.32	1.43e-9	Corneal astigmatism;
LUSC	cis	rs74181299	0.855	rs2723066	chr2:65279321	T/G	cg05010058	chr2:65284262	CEP68	0.31	6.11	0.32	2.75e-9	Pulse pressure;
LUSC	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg01557791	chr16:72042693	DHODH	0.57	9.13	0.45	6.88e-18	Prostate cancer;
LUSC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21984481	chr17:79567631	NPLOC4	-0.72	-15.07	-0.64	1.65e-39	Eye color traits;
LUSC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg25566285	chr7:158114605	PTPRN2	0.35	6.53	0.34	2.52e-10	Calcium levels;
LUSC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg05347473	chr6:146136440	FBXO30	0.48	8.08	0.4	1.16e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs240764	0.658	rs11155673	chr6:101243283	A/T	cg09795085	chr6:101329169	ASCC3	-0.46	-6.65	-0.34	1.18e-10	Neuroticism;
LUSC	cis	rs7123876	0.587	rs11604034	chr11:72364147	G/C	cg03713592	chr11:72463424	ARAP1	0.71	7.67	0.39	1.86e-13	Body mass index;
LUSC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg06027949	chr8:82754900	SNX16	-0.43	-5.81	-0.3	1.48e-8	Diastolic blood pressure;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10432423	chr10:51371707	LOC728407;PARG	0.46	6.01	0.31	4.96e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg02079420	chr8:82753780	SNX16	-0.41	-7.03	-0.36	1.13e-11	Diastolic blood pressure;
LUSC	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg09165964	chr15:75287851	SCAMP5	-0.73	-6.73	-0.35	7.21e-11	Lung cancer;
LUSC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg15557168	chr22:42548783	NA	0.38	6.38	0.33	6.04e-10	Cognitive function;
LUSC	cis	rs2154427	0.872	rs80098814	chr21:34133002	C/T	cg21871883	chr21:34145043	C21orf49;C21orf66	0.65	5.74	0.3	2.14e-8	Bilirubin levels;
LUSC	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.37	6.48	0.33	3.33e-10	Primary biliary cholangitis;
LUSC	cis	rs2046867	0.774	rs62249873	chr3:72907115	G/A	cg25664220	chr3:72788482	NA	-0.61	-9.76	-0.47	5.99e-20	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg21862992	chr11:68658383	NA	0.49	7.78	0.39	9.01e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg25208724	chr1:156163844	SLC25A44	1.02	20.47	0.75	6.66e-61	Testicular germ cell tumor;
LUSC	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.62	9.47	0.46	5.25e-19	Corneal astigmatism;
LUSC	cis	rs2290159	0.752	rs3773352	chr3:12651982	G/C	cg23032965	chr3:12705835	RAF1	0.74	8.95	0.44	2.58e-17	Cholesterol, total;
LUSC	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg22546130	chr22:19950026	COMT	-0.4	-8.65	-0.43	2.19e-16	Blood metabolite levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11557658	chr12:57914033	DDIT3	0.47	6.63	0.34	1.37e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1595825	1.000	rs1440091	chr2:198879457	C/T	cg00982548	chr2:198649783	BOLL	-0.48	-6.01	-0.31	4.72e-9	Ulcerative colitis;
LUSC	cis	rs13089785	1.000	rs13089785	chr3:123653909	A/C	cg19611163	chr3:123411211	MYLK	0.34	5.86	0.31	1.11e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	12.72	0.57	1.67e-30	Platelet count;
LUSC	cis	rs9420	0.961	rs11570190	chr11:57560452	A/C	cg23127183	chr11:57508653	C11orf31	-0.56	-8.61	-0.43	2.83e-16	Schizophrenia;
LUSC	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.51	-0.34	2.78e-10	Mood instability;
LUSC	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg25554036	chr4:6271136	WFS1	0.51	9.3	0.45	1.9e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.87	-0.4	4.92e-14	Blood metabolite levels;
LUSC	cis	rs865483	0.860	rs853220	chr17:35787666	C/T	cg06716730	chr17:35851459	DUSP14	0.27	5.88	0.31	9.89e-9	Monocyte count;
LUSC	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg26924012	chr15:45694286	SPATA5L1	0.73	10.57	0.5	9.9e-23	Glomerular filtration rate;
LUSC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg01416388	chr22:39784598	NA	-0.45	-7.6	-0.38	3.02e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg03522245	chr20:25566470	NINL	0.35	5.67	0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg05501817	chr11:14380813	RRAS2	-0.55	-8.68	-0.43	1.77e-16	Sense of smell;
LUSC	cis	rs4655537	0.568	rs4655783	chr1:66143044	T/C	cg04111102	chr1:66153794	NA	0.27	5.75	0.3	1.97e-8	Blood protein levels;
LUSC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	8.27	0.41	3.33e-15	Height;
LUSC	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.86	-0.44	4.93e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg06606381	chr12:133084897	FBRSL1	0.98	9.3	0.45	1.83e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs12928939	0.517	rs71384782	chr16:71978591	A/G	cg03805757	chr16:71968109	PKD1L3	-0.63	-9.53	-0.46	3.42e-19	Post bronchodilator FEV1;
LUSC	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg09904177	chr6:26538194	HMGN4	-0.51	-5.71	-0.3	2.45e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg18681998	chr4:17616180	MED28	0.78	13.85	0.6	8.79e-35	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11958404	0.932	rs6859470	chr5:157429505	T/G	cg05962755	chr5:157440814	NA	0.54	6.35	0.33	7.18e-10	IgG glycosylation;
LUSC	cis	rs9902453	0.834	rs9901694	chr17:28271645	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	10.55	0.5	1.18e-22	Coffee consumption (cups per day);
LUSC	trans	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17712092	chr4:129076599	LARP1B	-0.67	-10.38	-0.49	4.57e-22	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.75e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2361718	0.527	rs11150847	chr17:78153130	G/A	cg06718696	chr17:78121285	EIF4A3	0.45	6.33	0.33	7.8e-10	Yeast infection;
LUSC	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg09307838	chr4:120376055	NA	0.6	9.13	0.45	6.85e-18	Corneal astigmatism;
LUSC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg02269571	chr22:50332266	NA	-0.57	-8.54	-0.42	4.87e-16	Schizophrenia;
LUSC	cis	rs1595825	0.891	rs73061068	chr2:198908439	A/G	cg10547527	chr2:198650123	BOLL	-0.53	-6.29	-0.33	9.68e-10	Ulcerative colitis;
LUSC	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg11845111	chr2:191398756	TMEM194B	-0.67	-9.01	-0.44	1.64e-17	Diastolic blood pressure;
LUSC	cis	rs10986311	0.775	rs3758207	chr9:127132020	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.43	-7.08	-0.36	8.37e-12	Vitiligo;
LUSC	trans	rs11696501	0.739	rs6073835	chr20:44286454	C/T	cg03272292	chr12:48577362	C12orf68	0.48	6.0	0.31	5.2e-9	Brain structure;
LUSC	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg13660082	chr14:53194042	PSMC6	-0.78	-6.81	-0.35	4.55e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.74	0.3	2.17e-8	Self-reported allergy;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19355881	chr6:34759549	UHRF1BP1	-0.5	-6.41	-0.33	4.94e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11764359	chr7:65958608	NA	0.55	7.28	0.37	2.46e-12	Aortic root size;
LUSC	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg17385448	chr1:15911702	AGMAT	0.36	6.18	0.32	1.92e-9	Systolic blood pressure;
LUSC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg26587870	chr6:27730563	NA	-0.65	-6.04	-0.31	4.2e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4666002	0.636	rs2272406	chr2:27892023	A/T	cg27432699	chr2:27873401	GPN1	0.53	6.98	0.36	1.57e-11	Phospholipid levels (plasma);
LUSC	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg16482183	chr6:26056742	HIST1H1C	0.46	6.87	0.35	3.17e-11	Height;
LUSC	cis	rs6456156	0.811	rs975822	chr6:167516458	C/T	cg07741184	chr6:167504864	NA	-0.34	-5.88	-0.31	9.77e-9	Primary biliary cholangitis;
LUSC	cis	rs9902453	0.934	rs7223645	chr17:28491029	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.19	0.41	5.67e-15	Coffee consumption (cups per day);
LUSC	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg04827223	chr11:72435913	ARAP1	-0.77	-9.04	-0.44	1.31e-17	Type 2 diabetes;
LUSC	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg23625390	chr15:77176239	SCAPER	-0.45	-6.89	-0.35	2.75e-11	Blood metabolite levels;
LUSC	cis	rs11025559	0.773	rs10833334	chr11:20498640	T/C	cg19653624	chr11:20408972	PRMT3	-0.69	-8.45	-0.42	9.04e-16	Pursuit maintenance gain;
LUSC	cis	rs12900413	1.000	rs12900413	chr15:90321039	C/T	cg24249390	chr15:90295951	MESP1	0.42	6.34	0.33	7.42e-10	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs677665	0.537	rs72641832	chr1:9336116	C/A	cg25755851	chr1:9335794	NA	0.82	12.9	0.58	3.7e-31	Eosinophil percentage of white cells;
LUSC	cis	rs72781680	0.716	rs2551325	chr2:23979729	C/T	cg08917208	chr2:24149416	ATAD2B	0.6	6.68	0.34	1.01e-10	Lymphocyte counts;
LUSC	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg15556689	chr8:8085844	FLJ10661	0.5	7.32	0.37	1.89e-12	Neuroticism;
LUSC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.19	-0.49	2.06e-21	Monocyte count;
LUSC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg06064525	chr11:970664	AP2A2	0.48	10.67	0.5	4.55e-23	Alzheimer's disease (late onset);
LUSC	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.79	-12.56	-0.57	6.57e-30	Dilated cardiomyopathy;
LUSC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg25482853	chr8:67687455	SGK3	1.19	19.24	0.73	4.65e-56	Lung disease severity in cystic fibrosis;
LUSC	trans	rs11700980	0.551	rs11701759	chr21:30115571	C/T	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg12091567	chr17:66097778	LOC651250	-0.72	-9.17	-0.45	5.05e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	trans	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.71	-0.39	1.42e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg15744005	chr10:104629667	AS3MT	-0.28	-5.9	-0.31	8.88e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7246967	0.673	rs937078	chr19:22811667	G/A	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg12292205	chr6:26970375	C6orf41	-0.4	-5.94	-0.31	7.04e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg06484146	chr7:12443880	VWDE	-0.64	-6.3	-0.33	9.57e-10	Coronary artery disease;
LUSC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.64	-0.39	2.24e-13	Electroencephalogram traits;
LUSC	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg26668713	chr11:65405903	SIPA1	0.56	6.6	0.34	1.57e-10	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs4132509	1.000	rs73124169	chr1:243804939	T/C	cg21452805	chr1:244014465	NA	0.49	5.86	0.31	1.11e-8	RR interval (heart rate);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg22128035	chr2:47168977	MCFD2;TTC7A	0.46	6.35	0.33	6.93e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs72674100	1.000	rs17026376	chr4:97993847	G/A	cg16405019	chr1:18959625	PAX7	-0.61	-6.41	-0.33	5.09e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.78	-10.67	-0.5	4.69e-23	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2625529	0.775	rs4777466	chr15:72136872	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-7.77	-0.39	9.62e-14	Red blood cell count;
LUSC	trans	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.48	0.5	2.06e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs11031096	0.535	rs10767886	chr11:4218391	T/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.72	-0.3	2.37e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg12564285	chr5:131593104	PDLIM4	0.33	5.91	0.31	8.31e-9	Lung function (FEV1/FVC);
LUSC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.81	13.62	0.6	6.38e-34	Aortic root size;
LUSC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.09	0.48	4.64e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs240764	0.621	rs11155636	chr6:101201243	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-6.46	-0.33	3.67e-10	Neuroticism;
LUSC	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg05501817	chr11:14380813	RRAS2	-0.47	-7.41	-0.38	1.05e-12	Vitamin D levels;
LUSC	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg25208724	chr1:156163844	SLC25A44	1.03	20.96	0.75	7.5e-63	Testicular germ cell tumor;
LUSC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg09165964	chr15:75287851	SCAMP5	-1.07	-16.47	-0.67	4.95e-45	Blood trace element (Zn levels);
LUSC	cis	rs3744061	0.557	rs9889862	chr17:74647976	A/G	cg27546012	chr17:74684504	MXRA7	-0.37	-6.12	-0.32	2.56e-9	Retinal arteriolar caliber;
LUSC	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg03342759	chr3:160939853	NMD3	-0.48	-6.62	-0.34	1.43e-10	Parkinson's disease;
LUSC	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07080220	chr10:102295463	HIF1AN	-0.67	-9.09	-0.45	8.91e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs80130819	0.688	rs1552551	chr12:48643101	C/A	cg24011408	chr12:48396354	COL2A1	0.46	5.84	0.3	1.22e-8	Prostate cancer;
LUSC	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	1.07	15.38	0.64	1.01e-40	Uric acid levels;
LUSC	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg06552810	chr11:31128660	NA	-0.42	-7.4	-0.38	1.09e-12	Red blood cell count;
LUSC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg01973587	chr1:228161476	NA	0.47	8.49	0.42	6.91e-16	Diastolic blood pressure;
LUSC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-6.9	-0.35	2.55e-11	Lung cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25808892	chr17:6459352	PITPNM3	-0.49	-6.19	-0.32	1.72e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg02931644	chr1:25747376	RHCE	0.36	6.62	0.34	1.41e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs28830936	1.000	rs17677199	chr15:41954613	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.36	-0.33	6.8e-10	Diastolic blood pressure;
LUSC	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg13852791	chr20:30311386	BCL2L1	0.93	14.15	0.61	6.1e-36	Mean corpuscular hemoglobin;
LUSC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg03351412	chr1:154909251	PMVK	0.55	8.7	0.43	1.52e-16	Prostate cancer;
LUSC	cis	rs7927771	0.542	rs11039336	chr11:47706141	A/G	cg20307385	chr11:47447363	PSMC3	-0.43	-6.3	-0.33	9.19e-10	Subjective well-being;
LUSC	cis	rs1832871	0.672	rs9457337	chr6:158726292	C/T	cg07165851	chr6:158734300	TULP4	0.46	6.92	0.35	2.31e-11	Height;
LUSC	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg19920283	chr7:105172520	RINT1	0.58	6.22	0.32	1.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.42	-6.1	-0.32	2.9e-9	Platelet count;
LUSC	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg13010199	chr12:38710504	ALG10B	0.66	10.22	0.49	1.61e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs714027	1.000	rs2412971	chr22:30494371	G/A	cg11564601	chr22:30592435	NA	-0.37	-6.95	-0.36	1.91e-11	Lymphocyte counts;
LUSC	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg16558253	chr16:72132732	DHX38	-0.37	-5.83	-0.3	1.29e-8	Fibrinogen levels;
LUSC	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg00383909	chr3:49044727	WDR6	1.14	10.58	0.5	9.77e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4356932	1.000	rs6819597	chr4:76957171	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs4776059	0.959	rs4548810	chr15:52943814	C/T	cg22715398	chr15:52968154	KIAA1370	-0.59	-8.17	-0.41	6.55e-15	Schizophrenia;
LUSC	cis	rs10911363	0.571	rs6424897	chr1:183419203	T/C	cg09173681	chr1:183549694	NCF2	-0.64	-11.69	-0.54	1.06e-26	Systemic lupus erythematosus;
LUSC	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg15423357	chr2:25149977	NA	-0.4	-7.75	-0.39	1.12e-13	Body mass index;
LUSC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg02269571	chr22:50332266	NA	0.59	8.74	0.43	1.17e-16	Schizophrenia;
LUSC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg20399509	chr21:47717575	C21orf57	-0.42	-5.99	-0.31	5.55e-9	Testicular germ cell tumor;
LUSC	cis	rs75920871	0.528	rs682048	chr11:116828320	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.13	-0.32	2.52e-9	Subjective well-being;
LUSC	cis	rs36051895	0.632	rs7040922	chr9:5174829	A/G	cg02405213	chr9:5042618	JAK2	0.6	9.07	0.44	1.06e-17	Pediatric autoimmune diseases;
LUSC	cis	rs262150	0.851	rs2657326	chr7:158766262	C/T	cg04111992	chr7:158790115	NA	-0.37	-5.91	-0.31	8.33e-9	Facial morphology (factor 20);
LUSC	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.41	6.5	0.33	3e-10	Homocysteine levels;
LUSC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg10523679	chr1:76189770	ACADM	-0.43	-6.18	-0.32	1.85e-9	Daytime sleep phenotypes;
LUSC	cis	rs6500395	0.962	rs9937623	chr16:48571590	A/T	cg04672837	chr16:48644449	N4BP1	-0.44	-6.32	-0.33	8.36e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg14061069	chr19:46274453	DMPK	0.68	14.07	0.61	1.26e-35	Coronary artery disease;
LUSC	cis	rs11587682	0.760	rs12136802	chr1:150450204	T/C	cg11822372	chr1:151115635	SEMA6C	-0.43	-5.71	-0.3	2.48e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg06521331	chr12:34319734	NA	0.4	6.35	0.33	7.1e-10	Morning vs. evening chronotype;
LUSC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg13047869	chr3:10149882	C3orf24	0.61	8.2	0.41	5.3e-15	Alzheimer's disease;
LUSC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg11657440	chr19:46296263	DMWD	0.87	16.63	0.67	1.11e-45	Coronary artery disease;
LUSC	trans	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg06606381	chr12:133084897	FBRSL1	-0.48	-6.26	-0.32	1.17e-9	Depression;
LUSC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg03233332	chr7:66118400	NA	-0.43	-6.24	-0.32	1.35e-9	Aortic root size;
LUSC	cis	rs2219968	1.000	rs13255746	chr8:78954214	A/T	cg00738934	chr8:78996279	NA	0.35	6.28	0.32	1.08e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg05805236	chr11:65401703	PCNXL3	-0.65	-10.56	-0.5	1.12e-22	Acne (severe);
LUSC	cis	rs8063160	0.628	rs258322	chr16:89755903	C/T	cg07984980	chr16:89898383	SPIRE2	0.57	6.23	0.32	1.38e-9	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LUSC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14298792	chr15:30685198	CHRFAM7A	-0.51	-6.29	-0.33	9.95e-10	Huntington's disease progression;
LUSC	cis	rs3768617	1.000	rs1360704	chr1:183099380	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.61	-8.83	-0.43	6.07e-17	Fuchs's corneal dystrophy;
LUSC	cis	rs7246967	0.611	rs8108452	chr19:22853618	G/A	cg23217946	chr19:22817039	ZNF492	0.45	6.01	0.31	4.91e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg24399712	chr22:39784796	NA	-0.65	-12.05	-0.55	5.03e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7481584	0.961	rs729662	chr11:3028140	G/A	cg08508325	chr11:3079039	CARS	0.3	5.65	0.3	3.45e-8	Calcium levels;
LUSC	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg05373962	chr22:49881684	NA	-0.42	-8.77	-0.43	9.43e-17	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg27170947	chr2:26402098	FAM59B	-0.42	-5.75	-0.3	1.97e-8	Gut microbiome composition (summer);
LUSC	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	5.9	0.31	8.85e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg12365402	chr11:9010492	NRIP3	0.44	8.26	0.41	3.41e-15	Hemoglobin concentration;
LUSC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg24675658	chr1:53192096	ZYG11B	0.59	9.22	0.45	3.51e-18	Monocyte count;
LUSC	cis	rs7202877	0.706	rs247447	chr16:75486648	A/G	cg03315344	chr16:75512273	CHST6	-0.49	-6.89	-0.35	2.86e-11	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.25	0.32	1.25e-9	Monocyte percentage of white cells;
LUSC	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg01475377	chr6:109611718	NA	-0.41	-7.38	-0.37	1.24e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.48	0.53	6.19e-26	Prudent dietary pattern;
LUSC	cis	rs2444240	0.505	rs566935	chr11:120055477	C/G	cg04390734	chr11:120039366	NA	-0.31	-6.65	-0.34	1.19e-10	Corneal curvature;
LUSC	cis	rs977987	0.778	rs4888409	chr16:75436231	A/T	cg03315344	chr16:75512273	CHST6	0.48	8.94	0.44	2.8e-17	Dupuytren's disease;
LUSC	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg03647239	chr10:116582469	FAM160B1	0.45	7.45	0.38	8.05e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg05890377	chr2:74357713	NA	0.7	12.28	0.56	7.18e-29	Gestational age at birth (maternal effect);
LUSC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg17366294	chr4:99064904	C4orf37	0.54	9.49	0.46	4.52e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3772130	0.962	rs11715951	chr3:121522968	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.7	10.34	0.49	6.51e-22	Cognitive performance;
LUSC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.15	-0.32	2.26e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.51	6.23	0.32	1.44e-9	Multiple sclerosis;
LUSC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg14541582	chr5:601475	NA	-0.37	-5.71	-0.3	2.48e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9534288	0.699	rs9534321	chr13:46669032	A/G	cg15192986	chr13:46630673	CPB2	-0.72	-10.54	-0.5	1.29e-22	Blood protein levels;
LUSC	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg18005901	chr6:33739558	LEMD2	-0.39	-5.75	-0.3	2.03e-8	Schizophrenia;
LUSC	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.13e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg17211192	chr8:82754475	SNX16	-0.58	-8.21	-0.41	5.01e-15	Diastolic blood pressure;
LUSC	cis	rs6901250	0.788	rs571296	chr6:117092558	A/G	cg12892004	chr6:117198278	RFX6	-0.43	-7.83	-0.39	6.65e-14	C-reactive protein levels;
LUSC	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg17031739	chr1:67600172	NA	0.39	6.02	0.31	4.67e-9	Psoriasis;
LUSC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.86	-11.07	-0.52	1.83e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.48	6.97	0.36	1.65e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	6.57	0.34	1.92e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06002616	chr8:101225028	SPAG1	-0.46	-7.56	-0.38	3.93e-13	Atrioventricular conduction;
LUSC	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07256732	chr16:621771	PIGQ	-0.36	-6.54	-0.34	2.24e-10	Height;
LUSC	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg15556689	chr8:8085844	FLJ10661	0.56	8.52	0.42	5.66e-16	Mood instability;
LUSC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg00546932	chr16:1947055	NA	0.36	5.75	0.3	2e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.46	0.75	6.72e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.42	6.06	0.31	3.77e-9	Systemic lupus erythematosus;
LUSC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06634786	chr22:41940651	POLR3H	0.53	6.02	0.31	4.68e-9	Vitiligo;
LUSC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11644478	chr21:40555479	PSMG1	-0.59	-9.3	-0.45	1.88e-18	Menarche (age at onset);
LUSC	trans	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg25214090	chr10:38739885	LOC399744	0.44	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	trans	rs10492201	0.529	rs11177004	chr12:68409009	G/A	cg21566642	chr2:233284661	NA	-0.38	-5.98	-0.31	5.86e-9	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs1808579	0.870	rs11665096	chr18:21118025	G/C	cg14672496	chr18:21087552	C18orf8	0.36	6.3	0.33	9.52e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.21	-0.49	1.83e-21	Eye color traits;
LUSC	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg03342759	chr3:160939853	NMD3	-0.42	-6.83	-0.35	3.91e-11	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg02415014	chr8:143852576	LYNX1	-0.33	-7.71	-0.39	1.44e-13	Urinary tract infection frequency;
LUSC	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg21051086	chr3:73046214	PPP4R2	-0.52	-7.96	-0.4	2.63e-14	Pancreatic cancer;
LUSC	cis	rs2573652	1.000	rs1469828	chr15:100517210	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.43	-8.06	-0.4	1.41e-14	Height;
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg25703541	chr22:24373054	LOC391322	-0.87	-14.2	-0.61	3.93e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg22105103	chr4:187893119	NA	0.65	11.31	0.53	2.49e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg23992470	chr4:843637	GAK	0.53	5.66	0.3	3.33e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.41	-6.48	-0.33	3.26e-10	Bone mineral density (hip);Bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00037072	chr1:25573940	C1orf63	-0.41	-6.31	-0.33	8.87e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg10756647	chr7:56101905	PSPH	0.83	8.29	0.41	2.8e-15	Diabetic kidney disease;
LUSC	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg18753928	chr3:113234510	CCDC52	-0.52	-8.01	-0.4	1.99e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs11662586	1.000	rs11662586	chr18:77716171	A/C	cg20368463	chr18:77673604	PQLC1	0.58	7.1	0.36	7.77e-12	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUSC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg24250549	chr1:154909240	PMVK	0.6	9.81	0.47	3.81e-20	Prostate cancer;
LUSC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg02175503	chr12:58329896	NA	0.78	13.55	0.6	1.27e-33	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17783671	chr19:59070436	UBE2M;LOC100131691	-0.4	-6.03	-0.31	4.46e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg19894588	chr14:64061835	NA	0.54	7.25	0.37	2.93e-12	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg17279839	chr7:150038598	RARRES2	0.44	7.02	0.36	1.24e-11	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.83	0.68	1.93e-46	Exhaled nitric oxide output;
LUSC	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.71	0.51	3.22e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg23093090	chr10:104574429	C10orf26	-0.38	-7.18	-0.37	4.64e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg13010199	chr12:38710504	ALG10B	0.68	10.49	0.5	1.99e-22	Bladder cancer;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg11149768	chr20:4129361	SMOX	0.55	6.53	0.34	2.44e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs672059	1.000	rs652753	chr1:183156569	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.99	0.4	2.15e-14	Hypertriglyceridemia;
LUSC	cis	rs13418410	0.539	rs35866672	chr2:33842174	G/A	cg04131969	chr2:33951647	MYADML	-0.75	-10.99	-0.52	3.55e-24	Non-response to antidepressants and depression;
LUSC	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	0.87	13.15	0.58	4.13e-32	Triglycerides;
LUSC	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg20701182	chr2:24300061	SF3B14	0.74	7.48	0.38	6.68e-13	Lymphocyte counts;
LUSC	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.85	-0.44	5.17e-17	Total cholesterol levels;
LUSC	cis	rs870825	0.929	rs72689263	chr4:185590961	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	11.29	0.53	2.87e-25	Blood protein levels;
LUSC	cis	rs7241530	0.636	rs7242088	chr18:75903530	A/T	cg14642773	chr18:75888474	NA	0.38	5.91	0.31	8.67e-9	Educational attainment (years of education);
LUSC	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg16797656	chr11:68205561	LRP5	0.35	5.84	0.3	1.27e-8	Total body bone mineral density;
LUSC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg24851651	chr11:66362959	CCS	-0.52	-8.23	-0.41	4.24e-15	Bipolar disorder;
LUSC	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg10356904	chr22:49881777	NA	-0.3	-6.38	-0.33	6.04e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg11993925	chr19:44307056	LYPD5	0.35	7.59	0.38	3.12e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs4776059	0.798	rs10851520	chr15:52912978	C/G	cg24008177	chr15:52972085	KIAA1370	-0.34	-6.21	-0.32	1.62e-9	Schizophrenia;
LUSC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg03806693	chr22:41940476	POLR3H	-0.99	-14.23	-0.61	3.07e-36	Vitiligo;
LUSC	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg01420254	chr6:26195488	NA	0.71	7.5	0.38	5.86e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg08000102	chr2:233561755	GIGYF2	-0.69	-11.36	-0.53	1.66e-25	Coronary artery disease;
LUSC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg19748678	chr4:122722346	EXOSC9	0.5	7.67	0.39	1.86e-13	Type 2 diabetes;
LUSC	trans	rs12050412	1.000	rs12050412	chr14:83378003	G/T	cg08986871	chr7:100279334	GIGYF1	0.38	5.98	0.31	5.65e-9	Word reading;
LUSC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-12.87	-0.58	4.63e-31	Platelet count;
LUSC	trans	rs7939886	0.764	rs79601668	chr11:55753767	G/C	cg15704280	chr7:45808275	SEPT13	0.84	7.06	0.36	9.96e-12	Myopia (pathological);
LUSC	cis	rs11645898	0.872	rs7206422	chr16:72152652	C/T	cg14768367	chr16:72042858	DHODH	-0.62	-6.67	-0.34	1.08e-10	Blood protein levels;
LUSC	cis	rs977987	0.671	rs9922008	chr16:75335406	T/C	cg03315344	chr16:75512273	CHST6	0.53	9.76	0.47	5.76e-20	Dupuytren's disease;
LUSC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-11.3	-0.53	2.67e-25	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-0.89	-17.71	-0.7	5.65e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg04374321	chr14:90722782	PSMC1	-0.67	-10.3	-0.49	9e-22	Mortality in heart failure;
LUSC	cis	rs73206853	0.764	rs76044375	chr12:110901339	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.61	0.43	2.84e-16	Prudent dietary pattern;
LUSC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg22920501	chr2:26401640	FAM59B	0.79	9.74	0.47	6.82e-20	Gut microbiome composition (summer);
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.57	-9.0	-0.44	1.74e-17	Lymphocyte counts;
LUSC	trans	rs13011075	0.878	rs17602092	chr2:68620410	T/A	cg14221825	chr19:46271408	SIX5	0.44	6.24	0.32	1.35e-9	Mean corpuscular volume;
LUSC	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg21535942	chr1:75199100	CRYZ;TYW3	0.43	5.96	0.31	6.27e-9	Resistin levels;
LUSC	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.27	-0.41	3.16e-15	Schizophrenia;
LUSC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg14668632	chr7:2872130	GNA12	-0.43	-6.13	-0.32	2.43e-9	Height;
LUSC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg25767906	chr1:53392781	SCP2	-0.62	-12.0	-0.55	7.69e-28	Monocyte count;
LUSC	cis	rs1775715	0.674	rs2778670	chr10:32161676	G/A	cg04359828	chr10:32216031	ARHGAP12	0.4	6.87	0.35	3.07e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg03433033	chr1:76189801	ACADM	0.72	9.41	0.46	8.07e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg23711669	chr6:146136114	FBXO30	0.8	14.56	0.62	1.59e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg02574844	chr11:5959923	NA	-0.46	-6.34	-0.33	7.59e-10	DNA methylation (variation);
LUSC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.38	-7.02	-0.36	1.21e-11	Longevity;Endometriosis;
LUSC	cis	rs10992471	0.535	rs10117041	chr9:95282331	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.9	-0.35	2.68e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg09491104	chr22:46646882	C22orf40	-0.72	-7.44	-0.38	8.4e-13	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18579396	chr17:41623924	ETV4	0.4	6.31	0.33	8.84e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7095944	0.614	rs12570348	chr10:126438963	A/C	cg12521813	chr7:139477841	TBXAS1;HIPK2	-0.38	-5.94	-0.31	7.04e-9	Asthma;
LUSC	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1062753	0.771	rs932376	chr22:42614362	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.39	7.04	0.36	1.11e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs9399401	0.667	rs17071756	chr6:142715195	C/T	cg03128060	chr6:142623767	GPR126	-0.54	-9.04	-0.44	1.34e-17	Chronic obstructive pulmonary disease;
LUSC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg12751644	chr20:60527061	NA	-0.36	-6.54	-0.34	2.26e-10	Body mass index;
LUSC	cis	rs72772090	0.539	rs17405676	chr5:96182615	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-6.99	-0.36	1.53e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg13206674	chr6:150067644	NUP43	0.59	9.14	0.45	6.26e-18	Lung cancer;
LUSC	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	0.92	8.03	0.4	1.65e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg09835421	chr16:68378352	PRMT7	-0.52	-5.79	-0.3	1.59e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1124376	0.935	rs28716666	chr3:20148409	C/T	cg05072819	chr3:20081367	KAT2B	0.66	7.53	0.38	4.7e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-8.42	-0.42	1.12e-15	Coffee consumption (cups per day);
LUSC	cis	rs12681287	0.547	rs9942793	chr8:87509091	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg04586622	chr2:25135609	ADCY3	-0.34	-7.06	-0.36	9.76e-12	Body mass index;
LUSC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	trans	rs72674100	1.000	rs7656873	chr4:97964668	A/G	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6469656	0.892	rs10088177	chr8:117756957	G/A	cg24004040	chr8:117650383	NA	-0.4	-5.97	-0.31	5.95e-9	Colorectal cancer;
LUSC	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg13010199	chr12:38710504	ALG10B	-0.46	-6.9	-0.35	2.7e-11	Morning vs. evening chronotype;
LUSC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg13902645	chr11:5959945	NA	-0.6	-8.44	-0.42	9.71e-16	DNA methylation (variation);
LUSC	cis	rs2274459	0.841	rs10947432	chr6:33676556	A/G	cg06253072	chr6:33679850	C6orf125	-0.49	-6.07	-0.32	3.49e-9	Obesity (extreme);
LUSC	cis	rs2274273	0.774	rs9323278	chr14:55541574	C/G	cg04306507	chr14:55594613	LGALS3	0.5	10.77	0.51	1.99e-23	Protein biomarker;
LUSC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg12963246	chr6:28129442	ZNF389	0.52	7.17	0.37	4.94e-12	Depression;
LUSC	cis	rs16854884	0.683	rs6766544	chr3:143736659	G/T	cg06585982	chr3:143692056	C3orf58	0.5	7.93	0.4	3.36e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg15448220	chr1:150897856	SETDB1	0.4	5.87	0.31	1.02e-8	Melanoma;
LUSC	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg05340658	chr4:99064831	C4orf37	0.68	11.52	0.53	4.24e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg14895029	chr7:2775587	GNA12	0.36	5.91	0.31	8.63e-9	Height;
LUSC	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.72	-12.38	-0.56	3.15e-29	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.49	0.5	1.96e-22	Lymphocyte counts;
LUSC	cis	rs7945718	0.967	rs2241857	chr11:12815831	C/T	cg25843174	chr11:12811716	TEAD1	-0.33	-7.45	-0.38	8.15e-13	Educational attainment (years of education);
LUSC	cis	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg20368463	chr18:77673604	PQLC1	-0.63	-6.71	-0.34	8.51e-11	Opioid sensitivity;
LUSC	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg05738196	chr6:26577821	NA	0.44	5.77	0.3	1.84e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg18681998	chr4:17616180	MED28	0.85	15.49	0.65	3.6e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10744422	0.800	rs6489240	chr12:123275030	T/C	cg25930673	chr12:123319894	HIP1R	-0.6	-5.94	-0.31	7.08e-9	Schizophrenia;
LUSC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	0.83	13.59	0.6	8.92e-34	Longevity;
LUSC	trans	rs11088226	1.000	rs78679088	chr21:33910827	G/A	cg09050820	chr6:167586206	TCP10L2	0.53	6.7	0.34	9.05e-11	Gastritis;
LUSC	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg25801113	chr15:45476975	SHF	0.36	7.32	0.37	1.82e-12	Uric acid levels;
LUSC	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.7	0.75	7.91e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24201716	chr10:115933917	C10orf118;MIR2110	-0.37	-5.98	-0.31	5.65e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs17253792	1.000	rs28616134	chr14:56178802	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.86	-0.35	3.35e-11	Putamen volume;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25201359	chr7:158622466	ESYT2	-0.42	-5.96	-0.31	6.53e-9	Electrocardiographic conduction measures;
LUSC	cis	rs807669	0.525	rs9604934	chr22:19194868	C/T	cg02655711	chr22:19163373	SLC25A1	0.48	8.62	0.43	2.82e-16	Metabolite levels;
LUSC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg27535305	chr1:53392650	SCP2	-0.39	-7.19	-0.37	4.2e-12	Monocyte count;
LUSC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg26924012	chr15:45694286	SPATA5L1	1.13	20.89	0.75	1.35e-62	Homoarginine levels;
LUSC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20887711	chr4:1340912	KIAA1530	0.55	8.58	0.43	3.61e-16	Longevity;
LUSC	cis	rs4601821	0.522	rs754672	chr11:113249136	C/T	cg14159747	chr11:113255604	NA	0.29	7.22	0.37	3.6e-12	Alcoholic chronic pancreatitis;
LUSC	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg11584989	chr19:19387371	SF4	-0.53	-6.3	-0.33	9.26e-10	Bipolar disorder;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03738959	chr9:37904295	MCART1	-0.45	-5.96	-0.31	6.3e-9	Hepatitis;
LUSC	trans	rs17767294	0.708	rs113741085	chr6:27849982	C/A	cg23539494	chr17:65276751	NA	0.74	6.11	0.32	2.7e-9	Parkinson's disease;
LUSC	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg08345082	chr10:99160200	RRP12	-0.35	-7.17	-0.37	4.77e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9807989	0.801	rs11123925	chr2:102977511	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.74	0.3	2.08e-8	Asthma;
LUSC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg14895029	chr7:2775587	GNA12	-0.39	-5.87	-0.31	1.08e-8	Height;
LUSC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg10792982	chr14:105748885	BRF1	0.5	8.87	0.44	4.48e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-7.01	-0.36	1.33e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	8.93	0.44	2.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg08017756	chr2:100939284	LONRF2	0.43	7.96	0.4	2.7e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	9.02	0.44	1.52e-17	Response to bleomycin (chromatid breaks);
LUSC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg25174290	chr11:3078921	CARS	0.59	9.43	0.46	6.87e-19	Longevity;
LUSC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg15448220	chr1:150897856	SETDB1	0.4	5.87	0.31	1.02e-8	Melanoma;
LUSC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg05973401	chr12:123451056	ABCB9	0.54	6.67	0.34	1.06e-10	Neutrophil percentage of white cells;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20585088	chr3:182970927	MCF2L2;B3GNT5	0.42	6.52	0.34	2.59e-10	Triglycerides;
LUSC	cis	rs9625935	0.748	rs1468177	chr22:30544559	C/T	cg11564601	chr22:30592435	NA	0.35	6.23	0.32	1.38e-9	Tonsillectomy;
LUSC	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg11502198	chr6:26597334	ABT1	0.56	8.73	0.43	1.21e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg21545522	chr1:205238299	TMCC2	0.46	8.6	0.43	3.05e-16	Red blood cell count;
LUSC	cis	rs17102423	0.731	rs1957949	chr14:65542607	C/T	cg11161011	chr14:65562177	MAX	-0.66	-10.19	-0.49	2.08e-21	Obesity-related traits;
LUSC	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.07	14.17	0.61	5.24e-36	Uric acid levels;
LUSC	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg01294253	chr9:136912663	BRD3	0.34	5.77	0.3	1.8e-8	Platelet distribution width;
LUSC	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg10840412	chr1:235813424	GNG4	0.54	7.09	0.36	8.24e-12	Bipolar disorder;
LUSC	cis	rs2742417	0.603	rs7631818	chr3:45775931	A/T	cg10512202	chr3:45649293	LIMD1	0.36	6.07	0.32	3.55e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.41	-0.33	4.97e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg27121462	chr16:89883253	FANCA	0.54	8.65	0.43	2.27e-16	Vitiligo;
LUSC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs13089785	1.000	rs13088101	chr3:123625634	T/C	cg02558132	chr3:123411198	MYLK	0.34	5.81	0.3	1.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs41271473	1.000	rs72751929	chr1:228884358	A/G	cg16512390	chr1:228756714	NA	0.49	5.91	0.31	8.31e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg25173405	chr17:45401733	C17orf57	0.43	6.24	0.32	1.31e-9	Coronary artery disease;
LUSC	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.79	11.39	0.53	1.27e-25	Corneal astigmatism;
LUSC	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.39	-6.47	-0.33	3.47e-10	Prudent dietary pattern;
LUSC	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg18232548	chr7:50535776	DDC	0.55	7.47	0.38	7.2e-13	Malaria;
LUSC	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg09998033	chr7:158218633	PTPRN2	-0.43	-6.86	-0.35	3.32e-11	Obesity-related traits;
LUSC	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.68	-0.3	2.89e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg05738196	chr6:26577821	NA	0.79	15.3	0.64	1.98e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs56161922	1.000	rs57587123	chr1:207825415	A/G	cg11752769	chr1:207818423	CR1L	-0.71	-6.19	-0.32	1.75e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.19	-14.26	-0.62	2.33e-36	Diabetic kidney disease;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10150615	chr22:24372951	LOC391322	-0.38	-6.46	-0.33	3.75e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg18904891	chr8:8559673	CLDN23	0.38	5.97	0.31	6.05e-9	Mood instability;
LUSC	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.92	15.65	0.65	8.39e-42	Bladder cancer;
LUSC	cis	rs662064	0.748	rs2026792	chr1:10594790	A/G	cg20482658	chr1:10539492	PEX14	0.32	6.4	0.33	5.2400000000000005e-10	Asthma;
LUSC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.08e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg17173187	chr15:85201210	NMB	0.51	9.69	0.47	9.71e-20	Schizophrenia;
LUSC	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg03676636	chr4:99064102	C4orf37	0.37	7.99	0.4	2.15e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2282802	0.685	rs6889283	chr5:139653439	G/T	cg26211634	chr5:139558579	C5orf32	0.44	8.43	0.42	1.02e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7804356	1.000	rs10276471	chr7:26837940	C/G	cg03456212	chr7:26904342	SKAP2	-0.55	-6.47	-0.33	3.54e-10	Type 1 diabetes;
LUSC	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg05343316	chr1:45956843	TESK2	0.61	8.59	0.43	3.38e-16	Platelet count;
LUSC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs354225	0.544	rs13423873	chr2:54786677	A/G	cg26097391	chr2:54893211	SPTBN1	0.48	7.09	0.36	8.21e-12	Schizophrenia;
LUSC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	13.63	0.6	6.19e-34	Platelet count;
LUSC	cis	rs11586313	0.597	rs1590931	chr1:152861866	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.68	-0.3	2.94e-8	Vitamin D levels;
LUSC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.57	8.78	0.43	8.95e-17	Longevity;
LUSC	trans	rs1376359	0.537	rs570890	chr1:103279575	T/A	cg17154563	chr19:40477487	PSMC4	0.48	6.01	0.31	4.97e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg10664184	chr19:17420304	DDA1	0.46	6.0	0.31	5.19e-9	Systemic lupus erythematosus;
LUSC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.42	0.5	3.24e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.62	0.47	1.68e-19	Bipolar disorder;
LUSC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	0.93	15.91	0.66	7.9e-43	Menopause (age at onset);
LUSC	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.59	-8.88	-0.44	4.07e-17	Endometrial cancer;
LUSC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-0.8	-11.08	-0.52	1.72e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg13047869	chr3:10149882	C3orf24	0.6	8.27	0.41	3.15e-15	Alzheimer's disease;
LUSC	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg22681709	chr2:178499509	PDE11A	-0.52	-9.36	-0.46	1.21e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.71	0.51	3.28e-23	Bladder cancer;
LUSC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg11752832	chr7:134001865	SLC35B4	0.56	8.77	0.43	9.14e-17	Mean platelet volume;
LUSC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg10755058	chr3:40428713	ENTPD3	0.36	5.95	0.31	6.64e-9	Renal cell carcinoma;
LUSC	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.97	18.8	0.72	2.7e-54	Diastolic blood pressure;
LUSC	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg13789015	chr9:136890014	NCRNA00094	0.67	12.31	0.56	5.87e-29	Platelet distribution width;
LUSC	cis	rs9513627	0.920	rs73556201	chr13:100128753	C/G	cg25919922	chr13:100150906	NA	-0.75	-6.44	-0.33	4.11e-10	Obesity-related traits;
LUSC	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	ch.8.33884649F	chr8:33765107	NA	0.54	8.92	0.44	3.03e-17	Body mass index;
LUSC	cis	rs2274273	0.870	rs3783652	chr14:55854208	A/G	cg04306507	chr14:55594613	LGALS3	0.53	11.78	0.54	4.98e-27	Protein biomarker;
LUSC	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg06219351	chr7:158114137	PTPRN2	0.53	9.68	0.47	1.08e-19	Calcium levels;
LUSC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg24209194	chr3:40518798	ZNF619	0.42	5.76	0.3	1.87e-8	Renal cell carcinoma;
LUSC	trans	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg19894588	chr14:64061835	NA	-0.44	-6.33	-0.33	7.68e-10	Glioblastoma;Glioma;
LUSC	cis	rs10875746	0.951	rs2228500	chr12:48526712	A/G	cg13454099	chr12:49076203	C12orf41	0.53	6.15	0.32	2.16e-9	Longevity (90 years and older);
LUSC	cis	rs80130819	0.515	rs1793915	chr12:48386577	G/T	cg24011408	chr12:48396354	COL2A1	0.49	6.07	0.32	3.52e-9	Prostate cancer;
LUSC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg09359103	chr1:154839909	KCNN3	-0.7	-15.74	-0.65	3.87e-42	Prostate cancer;
LUSC	cis	rs240764	0.746	rs151572	chr6:101110984	C/T	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.69e-9	Neuroticism;
LUSC	cis	rs2235544	0.550	rs12075159	chr1:54470234	A/G	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.02e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg01416388	chr22:39784598	NA	-0.38	-6.3	-0.33	9.27e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs12050794	0.671	rs8192362	chr15:72519858	G/A	cg16672083	chr15:72433130	SENP8	0.47	7.85	0.39	5.73e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs963731	0.649	rs9679498	chr2:39218458	G/C	cg04010122	chr2:39346883	SOS1	-0.82	-5.89	-0.31	9.62e-9	Corticobasal degeneration;
LUSC	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg24375607	chr4:120327624	NA	0.72	11.34	0.53	1.99e-25	Corneal astigmatism;
LUSC	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg00484396	chr16:3507460	NAT15	0.55	7.97	0.4	2.56e-14	Body mass index (adult);
LUSC	cis	rs4666002	0.956	rs3749147	chr2:27851918	G/A	cg27432699	chr2:27873401	GPN1	0.42	5.8	0.3	1.51e-8	Phospholipid levels (plasma);
LUSC	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg04851639	chr8:1020857	NA	-0.36	-7.8	-0.39	7.96e-14	Schizophrenia;
LUSC	cis	rs701145	0.938	rs355747	chr3:153962973	T/C	cg17054900	chr3:154042577	DHX36	0.85	9.0	0.44	1.75e-17	Coronary artery disease;
LUSC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.55	-8.97	-0.44	2.15e-17	Menarche (age at onset);
LUSC	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17691542	chr6:26056736	HIST1H1C	0.99	12.8	0.57	8.78e-31	Iron status biomarkers;
LUSC	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.56e-22	Colorectal cancer;
LUSC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg15448220	chr1:150897856	SETDB1	-0.42	-6.19	-0.32	1.8e-9	Melanoma;
LUSC	cis	rs8064299	0.655	rs734232	chr17:72765731	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.51	8.3	0.41	2.53e-15	Monocyte count;
LUSC	cis	rs3106136	0.967	rs12645192	chr4:95181525	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.21	-0.32	1.59e-9	Capecitabine sensitivity;
LUSC	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.63	-6.48	-0.33	3.29e-10	Lung cancer in ever smokers;
LUSC	cis	rs394563	0.967	rs447025	chr6:149799128	A/C	cg11245181	chr6:149772854	ZC3H12D	-0.3	-6.53	-0.34	2.46e-10	Dupuytren's disease;
LUSC	cis	rs2224391	0.910	rs7752203	chr6:5260812	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.51	-7.36	-0.37	1.42e-12	Height;
LUSC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg21280719	chr6:42927975	GNMT	-0.32	-7.86	-0.39	5.46e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg11871910	chr12:69753446	YEATS4	0.83	14.58	0.62	1.34e-37	Blood protein levels;
LUSC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg13393036	chr8:95962371	TP53INP1	-0.46	-10.09	-0.48	4.61e-21	Type 2 diabetes;
LUSC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg20203395	chr5:56204925	C5orf35	-0.45	-6.75	-0.35	6.67e-11	Coronary artery disease;
LUSC	cis	rs6733011	0.628	rs6726156	chr2:99458607	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-5.99	-0.31	5.4e-9	Bipolar disorder;
LUSC	cis	rs9648716	0.515	rs38723	chr7:140695812	A/G	cg23214464	chr7:140373596	ADCK2	0.74	6.33	0.33	8.04e-10	Type 2 diabetes;
LUSC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.05	21.14	0.76	1.45e-63	Cognitive function;
LUSC	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg00383909	chr3:49044727	WDR6	1.04	9.56	0.46	2.68e-19	Cognitive function;
LUSC	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	10.68	0.5	4.13e-23	Coronary artery disease;
LUSC	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-5.84	-0.3	1.22e-8	Fear of minor pain;
LUSC	cis	rs78579285	0.622	rs4782322	chr16:88797669	T/G	cg01900006	chr16:88814613	FAM38A	0.61	6.84	0.35	3.88e-11	Joint mobility (Beighton score);
LUSC	cis	rs908922	0.702	rs569232	chr1:152526643	A/G	cg20991723	chr1:152506922	NA	0.48	8.51	0.42	6.06e-16	Hair morphology;
LUSC	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg03522245	chr20:25566470	NINL	0.35	5.69	0.3	2.81e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7683537	0.887	rs7678412	chr4:185648611	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Systemic lupus erythematosus;
LUSC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.34	6.62	0.34	1.47e-10	Schizophrenia;
LUSC	cis	rs11608355	0.545	rs1073779	chr12:109894721	C/T	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.1e-26	Neuroticism;
LUSC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.95	0.31	6.91e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.37	5.98	0.31	5.76e-9	Cystic fibrosis severity;
LUSC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg07507251	chr3:52567010	NT5DC2	0.33	6.37	0.33	6.25e-10	Bipolar disorder;
LUSC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.54	0.34	2.24e-10	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg01620082	chr3:125678407	NA	-0.69	-6.89	-0.35	2.78e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01726902	chr16:48419541	SIAH1	0.71	6.16	0.32	2.04e-9	Cognitive performance;
LUSC	cis	rs4964805	0.549	rs2292682	chr12:104156520	C/T	cg02344784	chr12:104178138	NT5DC3	0.39	6.11	0.32	2.71e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.35	-0.42	1.82e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs77741769	0.571	rs4454799	chr12:121317075	A/C	cg02419362	chr12:121203948	SPPL3	-0.46	-8.45	-0.42	9.34e-16	Mean corpuscular volume;
LUSC	trans	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg25214090	chr10:38739885	LOC399744	0.41	6.22	0.32	1.51e-9	Corneal astigmatism;
LUSC	cis	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.79	-0.39	8.8e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg04013166	chr16:89971882	TCF25	0.62	7.24	0.37	3.1e-12	Skin colour saturation;
LUSC	cis	rs12519773	0.501	rs4321736	chr5:92533363	C/T	cg18783429	chr5:92414398	NA	0.35	7.52	0.38	5.18e-13	Migraine;
LUSC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14829155	chr15:31115871	NA	-0.56	-7.8	-0.39	8.07e-14	Huntington's disease progression;
LUSC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.75	0.3	1.98e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs981844	0.712	rs4571310	chr4:154746832	T/C	cg14289246	chr4:154710475	SFRP2	-0.46	-6.32	-0.33	8.22e-10	Response to statins (LDL cholesterol change);
LUSC	trans	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	9.0	0.44	1.77e-17	Type 2 diabetes;
LUSC	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg14675211	chr2:100938903	LONRF2	0.37	5.73	0.3	2.29e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg07362569	chr17:61921086	SMARCD2	-0.37	-7.24	-0.37	3.04e-12	Prudent dietary pattern;
LUSC	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	6.67	0.34	1.03e-10	Resting heart rate;
LUSC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg25019033	chr10:957182	NA	-0.52	-5.9	-0.31	9.08e-9	Eosinophil percentage of granulocytes;
LUSC	trans	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg21659725	chr3:3221576	CRBN	-0.72	-8.2	-0.41	5.26e-15	Menarche (age at onset);
LUSC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.95	-0.31	6.6e-9	Tonsillectomy;
LUSC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg19774624	chr17:42201019	HDAC5	-0.81	-13.38	-0.59	5.26e-33	Total body bone mineral density;
LUSC	trans	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.14	0.32	2.31e-9	Corneal astigmatism;
LUSC	cis	rs12681287	0.927	rs2953517	chr8:87332013	C/T	cg27223183	chr8:87520930	FAM82B	-0.46	-6.03	-0.31	4.39e-9	Caudate activity during reward;
LUSC	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg05340658	chr4:99064831	C4orf37	0.66	10.96	0.51	4.56e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs61823972	0.527	rs4951182	chr1:205236233	A/C	cg21643547	chr1:205240462	TMCC2	0.3	5.66	0.3	3.24e-8	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
LUSC	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg04990556	chr1:26633338	UBXN11	-0.46	-5.99	-0.31	5.52e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4363385	0.818	rs11205176	chr1:153002481	A/G	cg25856811	chr1:152973957	SPRR3	-0.36	-5.94	-0.31	6.97e-9	Inflammatory skin disease;
LUSC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg24399712	chr22:39784796	NA	-0.62	-10.99	-0.52	3.34e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg27535305	chr1:53392650	SCP2	0.37	6.93	0.35	2.14e-11	Monocyte count;
LUSC	cis	rs56399783	0.901	rs11764225	chr7:2775607	G/A	cg14895029	chr7:2775587	GNA12	0.55	6.09	0.32	3.13e-9	Childhood ear infection;
LUSC	trans	rs4596713	0.508	rs12056979	chr9:71778946	A/G	cg25283916	chr1:242222868	NA	-0.29	-6.0	-0.31	5.05e-9	Headache;
LUSC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11645453	chr3:52864694	ITIH4	0.34	8.08	0.4	1.23e-14	Electroencephalogram traits;
LUSC	cis	rs6500395	1.000	rs12447645	chr16:48694440	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg05283184	chr6:79620031	NA	-0.46	-8.73	-0.43	1.26e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.63	0.5	6.09e-23	Mean corpuscular volume;
LUSC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg05738196	chr6:26577821	NA	-0.48	-7.11	-0.36	6.88e-12	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg13010199	chr12:38710504	ALG10B	0.54	8.3	0.41	2.53e-15	Morning vs. evening chronotype;
LUSC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg25838465	chr1:92012736	NA	-0.71	-14.32	-0.62	1.34e-36	Breast cancer;
LUSC	cis	rs2879627	0.560	rs2186146	chr10:53679200	C/G	cg06976598	chr10:53639124	PRKG1	0.46	5.85	0.31	1.15e-8	Coronary artery disease;
LUSC	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.96	-0.4	2.76e-14	Blood metabolite levels;
LUSC	cis	rs7246967	0.673	rs3853653	chr19:22871932	C/T	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs791888	0.858	rs1555434	chr10:89419143	G/C	cg13926569	chr10:89418898	PAPSS2	-0.37	-7.22	-0.37	3.56e-12	Magnesium levels;
LUSC	cis	rs1832871	0.643	rs7750656	chr6:158725907	C/T	cg07165851	chr6:158734300	TULP4	0.5	7.73	0.39	1.29e-13	Height;
LUSC	cis	rs7707921	0.723	rs226197	chr5:81574925	G/A	cg15871215	chr5:81402204	ATG10	0.46	7.03	0.36	1.14e-11	Breast cancer;
LUSC	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg15819921	chr19:927150	ARID3A	-0.44	-6.42	-0.33	4.77e-10	Life satisfaction;
LUSC	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg13010199	chr12:38710504	ALG10B	0.7	10.93	0.51	5.81e-24	Bladder cancer;
LUSC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg22823121	chr1:150693482	HORMAD1	0.46	6.6	0.34	1.64e-10	Melanoma;
LUSC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	8.91	0.44	3.34e-17	Total body bone mineral density;
LUSC	cis	rs6545883	0.894	rs4672436	chr2:61603357	A/C	cg15711740	chr2:61764176	XPO1	0.41	6.27	0.32	1.12e-9	Tuberculosis;
LUSC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg07701084	chr6:150067640	NUP43	0.54	8.15	0.41	7.58e-15	Lung cancer;
LUSC	cis	rs9650315	1.000	rs56261906	chr8:57158479	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	7.37	0.37	1.39e-12	Height;
LUSC	cis	rs2742234	0.541	rs10793424	chr10:43717116	G/T	cg15436174	chr10:43711423	RASGEF1A	0.44	7.06	0.36	9.75e-12	Hirschsprung disease;
LUSC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg00945038	chr17:61921165	SMARCD2	0.39	5.99	0.31	5.49e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9943753	0.525	rs983307	chr12:109815103	T/G	cg19025524	chr12:109796872	NA	-0.39	-7.12	-0.36	6.48e-12	HDL cholesterol;
LUSC	cis	rs2191566	0.959	rs7256345	chr19:44510905	T/G	cg03039196	chr19:44506973	ZNF230	0.36	5.93	0.31	7.69e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.5	-0.34	2.94e-10	Alzheimer's disease (late onset);
LUSC	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg24006582	chr15:45444508	DUOX1	-0.6	-8.69	-0.43	1.64e-16	Uric acid levels;
LUSC	cis	rs2282300	0.910	rs528292	chr11:30389710	A/G	cg25418670	chr11:30344373	C11orf46	0.51	7.16	0.36	5.23e-12	Morning vs. evening chronotype;
LUSC	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg00806126	chr19:22604979	ZNF98	0.37	5.71	0.3	2.43e-8	Pain;
LUSC	cis	rs1775715	0.707	rs2808094	chr10:32133756	T/C	cg03015672	chr10:32216066	ARHGAP12	0.35	6.27	0.32	1.13e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-8.91	-0.44	3.37e-17	Alzheimer's disease;
LUSC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg06074448	chr4:187884817	NA	-0.39	-6.49	-0.33	3.06e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-7.14	-0.36	5.93e-12	Aortic root size;
LUSC	trans	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg17830980	chr10:43048298	ZNF37B	0.54	7.59	0.38	3.13e-13	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg24812749	chr6:127587940	RNF146	0.73	10.42	0.5	3.3e-22	Breast cancer;
LUSC	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg06917634	chr15:78832804	PSMA4	-0.48	-5.97	-0.31	6.23e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-7.1	-0.36	7.33e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.79	0.63	2.05e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg17462356	chr17:80056334	FASN	-0.46	-6.21	-0.32	1.53e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2860975	1.000	rs7920659	chr10:96767924	T/C	cg09036531	chr10:96991505	NA	-0.4	-5.66	-0.3	3.24e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs7220711	0.967	rs1828720	chr17:41797692	A/C	cg26893861	chr17:41843967	DUSP3	0.42	5.75	0.3	2.05e-8	Bone mineral density (spine);Bone mineral density (hip);
LUSC	cis	rs6940638	0.956	rs72838268	chr6:27021173	A/G	cg05738196	chr6:26577821	NA	-0.5	-5.73	-0.3	2.25e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18426487	chr10:35379348	CUL2	-0.47	-6.18	-0.32	1.92e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg21963583	chr11:68658836	MRPL21	0.59	8.71	0.43	1.41e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg11502198	chr6:26597334	ABT1	0.69	11.61	0.54	2.11e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs983392	0.679	rs1026252	chr11:60030559	C/T	cg02771260	chr11:59836817	MS4A3	0.37	5.99	0.31	5.34e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9581857	0.579	rs77187836	chr13:27998646	C/A	cg22138327	chr13:27999177	GTF3A	0.83	9.36	0.46	1.23e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg10518543	chr12:38710700	ALG10B	-0.41	-5.67	-0.3	3.11e-8	Morning vs. evening chronotype;
LUSC	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg19875535	chr5:140030758	IK	0.47	7.7	0.39	1.54e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.52	8.02	0.4	1.83e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg23262351	chr6:79576851	IRAK1BP1	-0.37	-5.72	-0.3	2.41e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-9.64	-0.47	1.49e-19	Gut microbiome composition (summer);
LUSC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	7.91	0.4	3.87e-14	Menarche (age at onset);
LUSC	cis	rs9653442	0.545	rs4851257	chr2:100775297	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-7.09	-0.36	8.27e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00166722	chr3:10149974	C3orf24	0.54	7.43	0.38	8.88e-13	Alzheimer's disease;
LUSC	cis	rs7605827	0.897	rs1996516	chr2:15517246	G/A	cg19274914	chr2:15703543	NA	0.45	8.73	0.43	1.27e-16	Educational attainment (years of education);
LUSC	cis	rs13385	0.723	rs28722951	chr5:139609952	T/G	cg26211634	chr5:139558579	C5orf32	0.46	6.96	0.36	1.78e-11	Atrial fibrillation;
LUSC	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg03676636	chr4:99064102	C4orf37	0.36	7.91	0.4	3.77e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg13565492	chr6:43139072	SRF	-0.66	-9.67	-0.47	1.18e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs800082	0.839	rs17282884	chr3:144319905	C/T	cg24215973	chr2:240111563	HDAC4	0.41	6.22	0.32	1.52e-9	Smoking behavior;
LUSC	cis	rs1030268	0.640	rs12707092	chr7:133188145	C/G	cg10665199	chr7:133106180	EXOC4	0.6	6.9	0.35	2.66e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11997175	0.574	rs4364597	chr8:33653729	G/C	ch.8.33884649F	chr8:33765107	NA	0.52	8.45	0.42	8.95e-16	Body mass index;
LUSC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg23711669	chr6:146136114	FBXO30	0.76	13.67	0.6	4.22e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2731664	0.792	rs335452	chr5:176879671	C/T	cg23176889	chr5:176863531	GRK6	-0.69	-14.36	-0.62	9.47e-37	Intelligence (multi-trait analysis);
LUSC	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.5	-8.07	-0.4	1.27e-14	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg23758822	chr17:41437982	NA	1.06	19.99	0.74	4.88e-59	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05714094	chr11:117102988	RNF214;PCSK7	0.51	7.97	0.4	2.6e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg24434963	chr7:99006419	PDAP1;BUD31	0.75	5.95	0.31	6.85e-9	Cognitive performance;
LUSC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg15595755	chr5:1867978	NA	0.47	8.64	0.43	2.38e-16	Cardiovascular disease risk factors;
LUSC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg21361702	chr7:150065534	REPIN1	0.46	6.32	0.33	8.6e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg26587870	chr6:27730563	NA	-0.61	-5.79	-0.3	1.62e-8	Breast cancer;
LUSC	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg23029597	chr12:123009494	RSRC2	-0.74	-9.42	-0.46	7.52e-19	Body mass index;
LUSC	trans	rs1825630	1.000	rs1825630	chr3:59902801	C/T	cg17670512	chr17:80627720	RAB40B	-0.34	-6.09	-0.32	3.04e-9	Aortic root size;
LUSC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg13798912	chr7:905769	UNC84A	-0.58	-5.83	-0.3	1.29e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg03859395	chr2:55845619	SMEK2	0.7	11.26	0.52	3.77e-25	Metabolic syndrome;
LUSC	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-5.82	-0.3	1.36e-8	Testicular germ cell tumor;
LUSC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg24562669	chr7:97807699	LMTK2	0.34	5.95	0.31	6.83e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg02569458	chr12:86230093	RASSF9	-0.36	-5.72	-0.3	2.4e-8	Major depressive disorder;
LUSC	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.2e-13	Corneal astigmatism;
LUSC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.24	14.01	0.61	2.1e-35	Diabetic kidney disease;
LUSC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg07741184	chr6:167504864	NA	-0.39	-6.9	-0.35	2.57e-11	Crohn's disease;
LUSC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg09323728	chr8:95962352	TP53INP1	-0.33	-6.26	-0.32	1.19e-9	Type 2 diabetes;
LUSC	cis	rs3857067	1.000	rs3857068	chr4:95026494	C/G	cg11021082	chr4:95130006	SMARCAD1	0.32	6.02	0.31	4.54e-9	QT interval;
LUSC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg04414720	chr1:150670196	GOLPH3L	0.54	8.42	0.42	1.09e-15	Melanoma;
LUSC	cis	rs6840360	1.000	rs6839074	chr4:152603357	A/G	cg22705602	chr4:152727874	NA	0.27	5.65	0.3	3.49e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg08499158	chr17:42289980	UBTF	-0.5	-8.21	-0.41	4.77e-15	Total body bone mineral density;
LUSC	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg20608306	chr11:116969690	SIK3	0.37	6.8	0.35	4.7e-11	Blood protein levels;
LUSC	cis	rs6977660	0.660	rs10239332	chr7:19824465	A/G	cg07541023	chr7:19748670	TWISTNB	0.6	6.37	0.33	6.35e-10	Thyroid stimulating hormone;
LUSC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	1.03	19.78	0.73	3.52e-58	Cognitive function;
LUSC	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg13393036	chr8:95962371	TP53INP1	-0.31	-6.18	-0.32	1.91e-9	Type 2 diabetes;
LUSC	cis	rs4478858	0.735	rs7526095	chr1:31797581	C/T	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	trans	rs2786098	0.656	rs17622452	chr1:197560485	T/C	cg16005942	chr6:160526640	IGF2R	0.5	6.04	0.31	4.16e-9	Asthma;
LUSC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg16325326	chr1:53192061	ZYG11B	0.69	11.17	0.52	7.98e-25	Monocyte count;
LUSC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg00800038	chr16:89945340	TCF25	-0.75	-6.64	-0.34	1.26e-10	Skin colour saturation;
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg10360139	chr7:1886902	MAD1L1	-0.4	-5.97	-0.31	6.04e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08859206	chr1:53392774	SCP2	-0.54	-9.35	-0.46	1.34e-18	Monocyte count;
LUSC	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg13010199	chr12:38710504	ALG10B	0.57	8.14	0.41	8.11e-15	Bladder cancer;
LUSC	cis	rs2219968	0.700	rs12541492	chr8:78863766	C/G	cg00738934	chr8:78996279	NA	-0.36	-6.1	-0.32	2.99e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg27411982	chr8:10470053	RP1L1	0.41	6.24	0.32	1.31e-9	Mood instability;
LUSC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.79	0.43	7.84e-17	Lung cancer;
LUSC	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18854424	chr1:2615690	NA	0.52	10.81	0.51	1.52e-23	Ulcerative colitis;
LUSC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	13.41	0.59	4.06e-33	Platelet count;
LUSC	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.76	-0.39	1.06e-13	Retinal vascular caliber;
LUSC	cis	rs1712517	0.545	rs3740381	chr10:105046689	G/C	cg04362960	chr10:104952993	NT5C2	-0.49	-6.66	-0.34	1.1e-10	Migraine;
LUSC	cis	rs7264396	0.887	rs2236164	chr20:34097353	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.68	-0.34	9.98e-11	Total cholesterol levels;
LUSC	trans	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg21659725	chr3:3221576	CRBN	0.51	7.87	0.4	5.06e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg22906224	chr7:99728672	NA	-0.47	-6.52	-0.34	2.56e-10	Coronary artery disease;
LUSC	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.8	-0.3	1.53e-8	Ileal carcinoids;
LUSC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06850241	chr22:41845214	NA	-0.32	-6.01	-0.31	4.96e-9	Vitiligo;
LUSC	cis	rs7202877	0.561	rs8050662	chr16:75360734	A/G	cg03315344	chr16:75512273	CHST6	-0.41	-6.19	-0.32	1.74e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg18478394	chr8:109455254	TTC35	0.47	7.28	0.37	2.38e-12	Dupuytren's disease;
LUSC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg03351412	chr1:154909251	PMVK	0.51	7.98	0.4	2.45e-14	Prostate cancer;
LUSC	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg04586622	chr2:25135609	ADCY3	0.42	8.89	0.44	3.97e-17	Body mass index;
LUSC	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg00857998	chr1:205179979	DSTYK	0.61	9.74	0.47	6.63e-20	Red blood cell count;
LUSC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg20302342	chr1:156215951	PAQR6	0.32	6.2	0.32	1.67e-9	Tonsillectomy;
LUSC	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg08601574	chr20:25228251	PYGB	0.38	5.81	0.3	1.48e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9976767	0.637	rs9984108	chr21:43825628	T/G	cg23042151	chr21:43824109	UBASH3A	-0.35	-6.71	-0.34	8.39e-11	Type 1 diabetes;
LUSC	trans	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg01620082	chr3:125678407	NA	-0.59	-6.38	-0.33	5.96e-10	Depression;
LUSC	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21659725	chr3:3221576	CRBN	0.6	8.77	0.43	9.54e-17	Resting heart rate;
LUSC	cis	rs7180079	1.000	rs62021590	chr15:64521349	A/T	cg08069370	chr15:64387884	SNX1	-0.54	-5.85	-0.3	1.17e-8	Monocyte count;
LUSC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg03289416	chr15:75166202	SCAMP2	0.44	6.85	0.35	3.58e-11	Breast cancer;
LUSC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.83	-15.06	-0.64	1.77e-39	Total body bone mineral density;
LUSC	cis	rs4930561	0.714	rs7950451	chr11:67962406	C/A	cg16338278	chr11:67432957	ALDH3B2	0.4	6.73	0.35	7.35e-11	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs11608355	0.515	rs35691047	chr12:109932585	C/T	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg02466173	chr16:30829666	NA	0.55	11.16	0.52	8.55e-25	Dementia with Lewy bodies;
LUSC	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg00383909	chr3:49044727	WDR6	1.14	10.58	0.5	9.36e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-17.76	-0.7	3.74e-50	Primary sclerosing cholangitis;
LUSC	trans	rs7737355	0.947	rs10478980	chr5:130618247	C/T	cg07715041	chr7:99302981	CYP3A7	-0.39	-6.14	-0.32	2.3e-9	Life satisfaction;
LUSC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22433210	chr17:43662623	NA	0.75	10.94	0.51	5.08e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg21798802	chr22:38057573	PDXP	0.33	6.71	0.34	8.49e-11	Fat distribution (HIV);
LUSC	cis	rs6487679	0.526	rs7972426	chr12:9381254	C/T	cg08997352	chr12:9597637	DDX12	-0.4	-5.66	-0.3	3.21e-8	Non-alcoholic fatty liver disease histology (AST);
LUSC	cis	rs7512552	0.966	rs2147324	chr1:150255587	T/C	cg15654264	chr1:150340011	RPRD2	-0.6	-9.68	-0.47	1.11e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg25039879	chr17:56429692	SUPT4H1	0.39	5.83	0.3	1.3e-8	Cognitive test performance;
LUSC	trans	rs116988415	0.584	rs17180497	chr14:65269707	A/C	cg25021359	chr7:123315035	NA	-0.42	-6.13	-0.32	2.53e-9	Daytime sleep phenotypes;
LUSC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.05	0.55	5.22e-28	Motion sickness;
LUSC	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg10840412	chr1:235813424	GNG4	-0.6	-8.34	-0.42	1.92e-15	Bipolar disorder;
LUSC	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg06671706	chr8:8559999	CLDN23	0.43	5.93	0.31	7.58e-9	Obesity-related traits;
LUSC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	15.88	0.66	1.08e-42	Platelet count;
LUSC	cis	rs672059	1.000	rs479994	chr1:183161729	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.06	0.4	1.37e-14	Hypertriglyceridemia;
LUSC	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg21984481	chr17:79567631	NPLOC4	-0.59	-11.38	-0.53	1.45e-25	Eye color traits;
LUSC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	13.28	0.59	1.28e-32	Total body bone mineral density;
LUSC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg17845761	chr1:175162550	KIAA0040	0.31	5.93	0.31	7.53e-9	Alcohol dependence;
LUSC	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg05738196	chr6:26577821	NA	-0.54	-5.81	-0.3	1.48e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg00409905	chr10:38381863	ZNF37A	-0.34	-6.04	-0.31	4.06e-9	Extrinsic epigenetic age acceleration;
LUSC	trans	rs61931739	0.635	rs10743837	chr12:33982162	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.6	0.38	3.09e-13	Morning vs. evening chronotype;
LUSC	cis	rs983392	0.792	rs1303615	chr11:59885120	C/T	cg20284999	chr11:59952153	MS4A6A	-0.33	-5.84	-0.3	1.21e-8	Alzheimer's disease (late onset);
LUSC	cis	rs240764	0.817	rs240164	chr6:101044487	T/A	cg09795085	chr6:101329169	ASCC3	0.4	5.74	0.3	2.17e-8	Neuroticism;
LUSC	cis	rs3820068	0.608	rs10927840	chr1:16045250	A/G	cg17385448	chr1:15911702	AGMAT	0.37	5.96	0.31	6.28e-9	Systolic blood pressure;
LUSC	trans	rs4942242	0.640	rs9533563	chr13:44212127	A/G	cg19169023	chr15:41853346	TYRO3	-0.59	-8.71	-0.43	1.38e-16	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg03859395	chr2:55845619	SMEK2	0.86	16.16	0.66	8.48e-44	Metabolic syndrome;
LUSC	cis	rs7586879	0.789	rs11688754	chr2:25133885	C/T	cg01884057	chr2:25150051	NA	0.42	8.42	0.42	1.11e-15	Body mass index;
LUSC	cis	rs67696533	0.711	rs4911241	chr20:31140165	C/T	cg13636640	chr20:31349939	DNMT3B	0.46	6.24	0.32	1.33e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs9800506	0.584	rs6936583	chr6:35525925	G/A	cg03566752	chr6:35512600	NA	0.35	7.72	0.39	1.34e-13	Neutrophil percentage of granulocytes;
LUSC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg14784868	chr12:69753453	YEATS4	0.54	8.06	0.4	1.39e-14	Response to diuretic therapy;
LUSC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.22	0.32	1.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg26043149	chr18:55253948	FECH	0.45	6.98	0.36	1.61e-11	Bone mineral density;
LUSC	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg03340356	chr1:67600835	NA	0.4	6.68	0.34	9.97e-11	Psoriasis;
LUSC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.62	-0.43	2.69e-16	Obesity-related traits;
LUSC	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg09904177	chr6:26538194	HMGN4	0.69	12.34	0.56	4.53e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	6.97	0.36	1.72e-11	Tonsillectomy;
LUSC	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	12.02	0.55	6.89e-28	Nonalcoholic fatty liver disease;
LUSC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-6.87	-0.35	3.17e-11	Bipolar disorder;
LUSC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27286337	chr10:134555280	INPP5A	0.91	11.32	0.53	2.31e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2798269	0.966	rs2798268	chr13:22131690	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.13	-0.32	2.42e-9	PR segment;
LUSC	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg15744005	chr10:104629667	AS3MT	-0.28	-5.92	-0.31	8.11e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4665630	0.522	rs2551351	chr2:23914065	C/T	cg08063864	chr2:24346004	PFN4;LOC375190	-0.8	-7.21	-0.37	3.88e-12	Hypertension;
LUSC	trans	rs1325195	0.920	rs2816183	chr1:179116474	C/G	cg11624085	chr17:8464688	MYH10	0.43	7.08	0.36	8.7e-12	IgE grass sensitization;
LUSC	cis	rs1595825	0.838	rs73058883	chr2:198896255	C/T	cg00982548	chr2:198649783	BOLL	-0.54	-6.89	-0.35	2.72e-11	Ulcerative colitis;
LUSC	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.59	-9.45	-0.46	6.32e-19	Body mass index;
LUSC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg02475777	chr4:1388615	CRIPAK	0.43	6.42	0.33	4.81e-10	Obesity-related traits;
LUSC	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg13647721	chr17:30228624	UTP6	-0.68	-7.84	-0.39	5.94e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg01420254	chr6:26195488	NA	0.67	7.49	0.38	6.09e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs11051970	1.000	rs1872829	chr12:32535100	C/T	cg02745156	chr12:32552066	NA	0.46	7.51	0.38	5.47e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg03522245	chr20:25566470	NINL	0.35	5.7	0.3	2.66e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg09941381	chr10:64027924	RTKN2	-0.38	-7.05	-0.36	1.03e-11	Rheumatoid arthritis;
LUSC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12311346	chr5:56204834	C5orf35	0.83	13.75	0.6	2.09e-34	Initial pursuit acceleration;
LUSC	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg24375607	chr4:120327624	NA	0.76	11.01	0.52	2.89e-24	Corneal astigmatism;
LUSC	cis	rs2742417	1.000	rs2742389	chr3:45756683	G/C	cg09608765	chr3:45636137	LIMD1	-0.39	-7.81	-0.39	7.4e-14	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2235544	0.554	rs7540270	chr1:54484682	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.33	-7.61	-0.38	2.85e-13	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs2281558	0.833	rs55792313	chr20:25521255	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.61	9.2	0.45	4.07e-18	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg03188948	chr7:1209495	NA	0.61	6.38	0.33	5.97e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg07701084	chr6:150067640	NUP43	0.53	8.04	0.4	1.54e-14	Lung cancer;
LUSC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg26924012	chr15:45694286	SPATA5L1	1.14	20.94	0.75	9e-63	Homoarginine levels;
LUSC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg14440974	chr22:39074834	NA	-0.38	-6.31	-0.33	8.64e-10	Menopause (age at onset);
LUSC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-8.51	-0.42	6.15e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.67	11.25	0.52	4.08e-25	Gestational age at birth (maternal effect);
LUSC	cis	rs17639215	0.550	rs9679297	chr2:102914569	T/C	cg09003973	chr2:102972529	NA	0.57	7.23	0.37	3.39e-12	Serum protein levels (sST2);
LUSC	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02176678	chr2:219576539	TTLL4	0.58	10.63	0.5	6.37e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg24375607	chr4:120327624	NA	0.76	12.09	0.55	3.61e-28	Corneal astigmatism;
LUSC	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg05738196	chr6:26577821	NA	0.79	15.0	0.63	2.98e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg26695010	chr11:65641043	EFEMP2	-0.48	-6.96	-0.36	1.85e-11	Eosinophil percentage of white cells;
LUSC	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg17127132	chr2:85788382	GGCX	0.45	7.07	0.36	9.2e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg00898013	chr13:113819073	PROZ	-0.63	-8.82	-0.43	6.52e-17	Platelet distribution width;
LUSC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg02221750	chr19:17393354	ANKLE1	-0.92	-14.02	-0.61	2.02e-35	Systemic lupus erythematosus;
LUSC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg18225595	chr11:63971243	STIP1	0.47	5.77	0.3	1.82e-8	Mean platelet volume;
LUSC	cis	rs2230307	0.505	rs482873	chr1:100589757	C/T	cg24955406	chr1:100503596	HIAT1	-0.63	-6.65	-0.34	1.19e-10	Carotid intima media thickness;
LUSC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg26879891	chr1:152191343	HRNR	-0.38	-6.79	-0.35	5.24e-11	Inflammatory skin disease;
LUSC	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg04662567	chr6:169592167	NA	0.43	6.44	0.33	4.28e-10	Pulse pressure;
LUSC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	trans	rs9944715	0.911	rs9956574	chr18:43782203	C/T	cg01718231	chr17:29326311	RNF135	-0.55	-7.88	-0.4	4.55e-14	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg17264618	chr3:40429014	ENTPD3	0.29	6.07	0.32	3.46e-9	Renal cell carcinoma;
LUSC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	trans	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg13565492	chr6:43139072	SRF	-0.61	-6.37	-0.33	6.1e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.94	0.48	1.48e-20	Mean corpuscular volume;
LUSC	cis	rs5758511	0.573	rs2267438	chr22:42237565	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-7.53	-0.38	4.88e-13	Birth weight;
LUSC	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.17	0.37	4.82e-12	IgG glycosylation;
LUSC	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg23625390	chr15:77176239	SCAPER	0.65	10.01	0.48	8.38e-21	Blood metabolite levels;
LUSC	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg11965913	chr1:205819406	PM20D1	-0.41	-6.22	-0.32	1.45e-9	Prostate-specific antigen levels;
LUSC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	7.99	0.4	2.24e-14	Mean platelet volume;
LUSC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg19318889	chr4:1322082	MAEA	0.47	7.87	0.4	4.96e-14	Longevity;
LUSC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.1	-20.24	-0.74	5.13e-60	Homoarginine levels;
LUSC	cis	rs7527798	1.000	rs35728110	chr1:207821397	T/C	cg09232269	chr1:207846808	CR1L	-0.32	-5.67	-0.3	3.05e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs11997175	0.583	rs17780153	chr8:33789161	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	6.76	0.35	6.32e-11	Body mass index;
LUSC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg19077165	chr18:44547161	KATNAL2	0.41	6.18	0.32	1.84e-9	Personality dimensions;
LUSC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg04450456	chr4:17643702	FAM184B	0.39	6.46	0.33	3.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.98	-0.48	1.09e-20	Migraine;Coronary artery disease;
LUSC	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg10547527	chr2:198650123	BOLL	-0.5	-6.04	-0.31	4.1e-9	Ulcerative colitis;
LUSC	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg16950941	chr11:66035639	RAB1B	0.54	8.01	0.4	1.96e-14	Gout;
LUSC	trans	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg17675199	chr6:35436792	RPL10A	-0.42	-6.12	-0.32	2.57e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06513149	chr13:33002431	N4BP2L1	0.43	6.4	0.33	5.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10761482	0.861	rs10994310	chr10:62106169	C/T	cg18175470	chr10:62150864	ANK3	0.48	6.91	0.35	2.44e-11	Schizophrenia;
LUSC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg16006841	chr5:176797999	RGS14	0.65	10.5	0.5	1.79e-22	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9646944	0.501	rs12991737	chr2:103018128	T/A	cg20060108	chr2:102954350	IL1RL1	0.48	6.6	0.34	1.65e-10	Blood protein levels;
LUSC	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg04733989	chr22:42467013	NAGA	0.4	6.34	0.33	7.46e-10	Cognitive function;
LUSC	cis	rs11191205	0.954	rs11191191	chr10:103800979	G/A	cg15320455	chr10:103880129	LDB1	0.53	5.9	0.31	8.98e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12541635	0.899	rs1429676	chr8:107065790	G/A	cg10147462	chr8:107024639	NA	-0.54	-9.76	-0.47	6e-20	Age of smoking initiation;
LUSC	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg21385522	chr1:16154831	NA	-0.54	-8.52	-0.42	5.4e-16	Systolic blood pressure;
LUSC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg22963979	chr7:1858916	MAD1L1	0.53	8.21	0.41	4.93e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.62	9.93	0.48	1.51e-20	Blood metabolite ratios;
LUSC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg03929089	chr4:120376271	NA	-0.91	-14.96	-0.63	4.43e-39	Height;
LUSC	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg12310025	chr6:25882481	NA	-0.34	-5.74	-0.3	2.11e-8	Height;
LUSC	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg20135002	chr11:47629003	NA	-0.45	-6.9	-0.35	2.56e-11	Neuroticism;
LUSC	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.71	-10.37	-0.49	4.95e-22	Glomerular filtration rate;
LUSC	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.81	-0.43	6.88e-17	Coffee consumption (cups per day);
LUSC	cis	rs7224314	1.000	rs62084080	chr17:65387014	C/T	cg01507342	chr17:65387096	PITPNC1	-0.45	-7.93	-0.4	3.28e-14	Diisocyanate-induced asthma;
LUSC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	11.69	0.54	1.09e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10875746	0.903	rs11168414	chr12:48512331	C/T	cg13454099	chr12:49076203	C12orf41	-0.5	-5.89	-0.31	9.66e-9	Longevity (90 years and older);
LUSC	cis	rs240764	0.621	rs11752659	chr6:101212241	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.41	-0.33	5.02e-10	Neuroticism;
LUSC	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	13.19	0.59	2.77e-32	Lung cancer in ever smokers;
LUSC	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg27661571	chr11:113659931	NA	-0.7	-7.97	-0.4	2.45e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg27539214	chr16:67997921	SLC12A4	-0.46	-5.99	-0.31	5.44e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg01557791	chr16:72042693	DHODH	-0.47	-6.0	-0.31	5.11e-9	Blood protein levels;
LUSC	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg09904177	chr6:26538194	HMGN4	0.76	14.41	0.62	5.81e-37	Intelligence (multi-trait analysis);
LUSC	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg08975724	chr8:8085496	FLJ10661	0.45	6.67	0.34	1.09e-10	Retinal vascular caliber;
LUSC	cis	rs295140	1.000	rs7599609	chr2:201177653	G/A	cg04283868	chr2:201171347	SPATS2L	0.42	6.38	0.33	5.75e-10	QT interval;
LUSC	cis	rs9420	0.961	rs11606396	chr11:57435211	C/T	cg02958346	chr11:57425731	CLP1	-0.43	-6.21	-0.32	1.59e-9	Schizophrenia;
LUSC	cis	rs6960043	0.818	rs4719433	chr7:15065003	A/G	cg19272540	chr7:15055459	NA	-0.31	-7.71	-0.39	1.46e-13	Type 2 diabetes;
LUSC	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg19773385	chr1:10388646	KIF1B	-0.54	-8.29	-0.41	2.74e-15	Hepatocellular carcinoma;
LUSC	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg09092052	chr15:45571596	NA	0.46	6.37	0.33	6.18e-10	Glomerular filtration rate;
LUSC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg05347473	chr6:146136440	FBXO30	0.56	9.71	0.47	8.3e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg06917634	chr15:78832804	PSMA4	-0.7	-11.88	-0.54	2.22e-27	Sudden cardiac arrest;
LUSC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg24675658	chr1:53192096	ZYG11B	0.75	12.9	0.58	3.69e-31	Monocyte count;
LUSC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg15790184	chr11:494944	RNH1	0.54	6.17	0.32	2e-9	Body mass index;
LUSC	cis	rs7000551	0.689	rs7007673	chr8:22316687	G/T	cg12081754	chr8:22256438	SLC39A14	0.44	6.57	0.34	1.89e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-7.98	-0.4	2.41e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.46	-6.23	-0.32	1.4e-9	Monocyte count;
LUSC	trans	rs2262909	0.962	rs409835	chr19:22230671	T/C	cg17074339	chr11:11642133	GALNTL4	-0.46	-7.07	-0.36	9.1e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg23385854	chr11:62623264	SNORD27;SLC3A2;SNORD26;SNORD28;SNORD25;SNHG1	-0.41	-6.1	-0.32	2.89e-9	Calcium levels;
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.34	-0.42	1.94e-15	Lymphocyte counts;
LUSC	cis	rs17789174	0.951	rs12596553	chr16:85104752	G/T	cg01715842	chr16:85045600	ZDHHC7	-0.4	-5.64	-0.3	3.57e-8	Dysphagia;
LUSC	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg06713675	chr4:122721982	EXOSC9	0.37	6.0	0.31	4.99e-9	Type 2 diabetes;
LUSC	cis	rs870825	0.616	rs14969	chr4:185615764	C/A	cg04058563	chr4:185651563	MLF1IP	0.86	13.29	0.59	1.2e-32	Blood protein levels;
LUSC	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg15839431	chr19:19639596	YJEFN3	0.65	6.94	0.36	2.01e-11	Bipolar disorder;
LUSC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg21285383	chr16:89894308	SPIRE2	0.36	7.77	0.39	9.97e-14	Vitiligo;
LUSC	cis	rs2282300	0.739	rs1222208	chr11:30361377	A/C	cg25418670	chr11:30344373	C11orf46	-0.65	-9.34	-0.46	1.4e-18	Morning vs. evening chronotype;
LUSC	cis	rs642803	0.613	rs489574	chr11:65542739	C/T	cg27068330	chr11:65405492	SIPA1	0.58	7.82	0.39	6.93e-14	Urate levels;
LUSC	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.5	-0.46	4.09e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	0.77	11.36	0.53	1.68e-25	Gut microbiome composition (summer);
LUSC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.68	11.48	0.53	6.2e-26	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.54	-0.34	2.3e-10	Blood metabolite levels;
LUSC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.76	-0.3	1.96e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg13072238	chr3:49761600	GMPPB	0.63	7.65	0.39	2.14e-13	Menarche (age at onset);
LUSC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg16624210	chr5:671434	TPPP	0.5	6.47	0.33	3.58e-10	Obesity-related traits;
LUSC	cis	rs921665	0.831	rs2305491	chr2:3198175	C/T	cg02624386	chr2:3182749	NA	0.59	6.6	0.34	1.59e-10	World class endurance athleticism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17955752	chr17:79935872	ASPSCR1	-0.41	-6.02	-0.31	4.5e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	trans	rs2018683	0.600	rs6948880	chr7:29003478	C/T	cg19402173	chr7:128379420	CALU	-0.48	-7.29	-0.37	2.21e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg14019146	chr3:50243930	SLC38A3	0.31	6.78	0.35	5.6e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-16.38	-0.67	1.09e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21293242	chr8:11204541	TDH	0.32	5.91	0.31	8.66e-9	Retinal vascular caliber;
LUSC	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg17366294	chr4:99064904	C4orf37	0.6	10.65	0.5	5.59e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg14582100	chr15:45693742	SPATA5L1	0.44	7.98	0.4	2.38e-14	Glomerular filtration rate;
LUSC	cis	rs75920871	0.528	rs10082609	chr11:116949074	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.44	-0.33	4.19e-10	Subjective well-being;
LUSC	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg13852791	chr20:30311386	BCL2L1	0.96	14.98	0.63	3.73e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg23131131	chr22:24373011	LOC391322	-0.41	-5.79	-0.3	1.65e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11690935	0.632	rs34531723	chr2:172564094	A/C	cg13550731	chr2:172543902	DYNC1I2	0.6	9.6	0.46	2.03e-19	Schizophrenia;
LUSC	cis	rs9393777	0.778	rs67457459	chr6:27198343	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.81	-0.3	1.43e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs853679	0.546	rs200990	chr6:27815823	T/G	cg06606381	chr12:133084897	FBRSL1	-0.77	-7.75	-0.39	1.15e-13	Depression;
LUSC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.62	-9.72	-0.47	7.74e-20	Menarche (age at onset);
LUSC	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.18	-0.32	1.84e-9	Breast cancer;
LUSC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.58	7.85	0.39	5.83e-14	High light scatter reticulocyte count;
LUSC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg11843238	chr5:131593191	PDLIM4	0.39	7.18	0.37	4.66e-12	Blood metabolite levels;
LUSC	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg17366294	chr4:99064904	C4orf37	-0.51	-8.57	-0.42	4.01e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg04310649	chr10:35416472	CREM	-0.43	-6.74	-0.35	7.16e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg15110403	chr19:17392923	ANKLE1	-0.52	-7.29	-0.37	2.32e-12	Systemic lupus erythematosus;
LUSC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg24130564	chr14:104152367	KLC1	-0.42	-6.08	-0.32	3.38e-9	Body mass index;
LUSC	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg13319975	chr6:146136371	FBXO30	0.49	7.43	0.38	9.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg19747945	chr6:42946146	PEX6	-0.36	-5.88	-0.31	9.8e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07926531	chr1:33546695	ADC	-0.47	-6.13	-0.32	2.49e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs1325195	0.879	rs2791940	chr1:179115485	C/T	cg11624085	chr17:8464688	MYH10	0.42	6.89	0.35	2.76e-11	IgE grass sensitization;
LUSC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.71	0.39	1.41e-13	Vitiligo;
LUSC	cis	rs7804356	1.000	rs12532395	chr7:26841702	G/A	cg03456212	chr7:26904342	SKAP2	-0.55	-6.47	-0.33	3.54e-10	Type 1 diabetes;
LUSC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-6.77	-0.35	5.93e-11	Menopause (age at onset);
LUSC	cis	rs7580658	0.750	rs4497825	chr2:128061053	A/G	cg09760422	chr2:128146352	NA	-0.3	-6.8	-0.35	4.72e-11	Protein C levels;
LUSC	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg02423579	chr7:2872169	GNA12	-0.38	-5.75	-0.3	2.02e-8	Height;
LUSC	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	0.7	6.98	0.36	1.63e-11	Prostate cancer;
LUSC	cis	rs8038465	0.571	rs7176654	chr15:73999006	C/T	cg15420318	chr15:73925796	NPTN	-0.47	-7.66	-0.39	2.01e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7759001	0.817	rs1534937	chr6:27354335	A/T	cg18711553	chr6:27366782	ZNF391	0.39	5.78	0.3	1.73e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg23711669	chr6:146136114	FBXO30	-0.87	-16.34	-0.67	1.56e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg04998671	chr14:104000505	TRMT61A	-0.43	-6.53	-0.34	2.52e-10	Coronary artery disease;
LUSC	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.91	0.31	8.5e-9	Rheumatoid arthritis;
LUSC	cis	rs73195822	0.506	rs55948838	chr12:111142793	C/T	cg12870014	chr12:110450643	ANKRD13A	0.67	7.4	0.38	1.13e-12	Itch intensity from mosquito bite;
LUSC	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg06636551	chr8:101224915	SPAG1	-0.4	-7.41	-0.38	1.03e-12	Atrioventricular conduction;
LUSC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg19592336	chr6:28129416	ZNF389	0.45	6.0	0.31	5.12e-9	Depression;
LUSC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg09640425	chr7:158790006	NA	0.38	6.22	0.32	1.49e-9	Facial morphology (factor 20);
LUSC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg00343986	chr7:65444356	GUSB	0.47	7.04	0.36	1.08e-11	Aortic root size;
LUSC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	1.06	20.2	0.74	7.16e-60	Menopause (age at onset);
LUSC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.02	-0.36	1.21e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.03	-0.36	1.17e-11	Colorectal cancer;
LUSC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg12963246	chr6:28129442	ZNF389	0.49	6.65	0.34	1.21e-10	Depression;
LUSC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg21724239	chr8:58056113	NA	0.59	6.83	0.35	3.92e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg09650180	chr20:62225654	GMEB2	-0.66	-9.42	-0.46	7.76e-19	Glioblastoma;
LUSC	cis	rs56804039	1.000	rs67611618	chr8:8380939	T/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.96	-0.36	1.84e-11	Cervical cancer;
LUSC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21582582	chr3:182698605	DCUN1D1	0.47	8.38	0.42	1.51e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.68	11.27	0.52	3.61e-25	Heart rate;
LUSC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02187348	chr16:89574699	SPG7	0.65	10.74	0.51	2.56e-23	Multiple myeloma (IgH translocation);
LUSC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg12463550	chr7:65579703	CRCP	0.62	5.67	0.3	3.04e-8	Diabetic kidney disease;
LUSC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg02951883	chr7:2050386	MAD1L1	-0.35	-5.9	-0.31	8.73e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2370759	0.891	rs11592754	chr10:32619572	A/C	cg01819863	chr10:32635814	EPC1	1.06	11.03	0.52	2.54e-24	Sexual dysfunction (female);
LUSC	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg07828340	chr4:882639	GAK	-0.92	-10.22	-0.49	1.66e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg13397359	chr6:42928475	GNMT	0.56	9.49	0.46	4.38e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg23280166	chr11:118938394	VPS11	0.48	7.64	0.39	2.27e-13	Coronary artery disease;
LUSC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.61	-0.43	2.86e-16	Monocyte count;
LUSC	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-6.85	-0.35	3.53e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9612	1.000	rs3786954	chr19:44272346	A/G	cg08581076	chr19:44259116	C19orf61	0.49	6.18	0.32	1.86e-9	Exhaled nitric oxide output;
LUSC	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg06677660	chr19:49140777	SEC1;DBP	0.58	6.89	0.35	2.74e-11	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs16895831	0.583	rs62414592	chr6:42516867	G/A	cg10605015	chr6:42532144	UBR2	-0.51	-6.12	-0.32	2.64e-9	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-15.05	-0.64	1.86e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg03733263	chr8:22462867	KIAA1967	0.97	16.82	0.68	1.99e-46	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs2348418	0.831	rs2348416	chr12:28709216	C/G	cg13890972	chr12:28721907	NA	-0.37	-6.26	-0.32	1.21e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg25554036	chr4:6271136	WFS1	0.59	12.03	0.55	6.13e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg00701064	chr4:6280414	WFS1	0.59	14.6	0.62	1.11e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs11608355	0.597	rs9943699	chr12:109840876	G/C	cg19025524	chr12:109796872	NA	-0.47	-8.76	-0.43	9.63e-17	Neuroticism;
LUSC	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg05347473	chr6:146136440	FBXO30	0.54	9.24	0.45	2.91e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg20019720	chr6:154832845	CNKSR3	0.62	8.72	0.43	1.34e-16	Lipoprotein (a) levels;
LUSC	cis	rs6690583	0.623	rs12042910	chr1:85452580	G/A	cg22153463	chr1:85462885	MCOLN2	0.62	6.0	0.31	5.12e-9	Serum sulfate level;
LUSC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18131467	chr2:239335373	ASB1	1.03	24.53	0.8	1e-76	Multiple system atrophy;
LUSC	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.49	7.03	0.36	1.2e-11	Coronary heart disease;
LUSC	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg12573674	chr2:1569213	NA	-0.64	-8.84	-0.44	5.53e-17	Placebo response in major depressive disorder (% change in symptom score);
LUSC	trans	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg18187862	chr3:45730750	SACM1L	0.55	7.05	0.36	1.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg18827107	chr12:86230957	RASSF9	-0.5	-7.49	-0.38	6.22e-13	Major depressive disorder;
LUSC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	4.73e-15	Homoarginine levels;
LUSC	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg18964960	chr10:1102726	WDR37	-0.47	-6.31	-0.33	8.82e-10	Response to angiotensin II receptor blocker therapy;
LUSC	trans	rs6445525	0.967	rs6782159	chr3:65993782	C/G	cg04367164	chr11:76902992	MYO7A	-0.3	-5.98	-0.31	5.74e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2617583	0.967	rs2550946	chr5:1450513	A/G	cg07148919	chr5:1466943	LPCAT1	0.39	5.92	0.31	7.94e-9	Breast cancer;
LUSC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg14440974	chr22:39074834	NA	-0.37	-5.95	-0.31	6.66e-9	Menopause (age at onset);
LUSC	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg08277548	chr1:17600880	PADI3	-0.65	-7.22	-0.37	3.43e-12	Hair shape;
LUSC	cis	rs7523050	0.643	rs35662800	chr1:109400816	C/A	cg08274380	chr1:109419600	GPSM2	1.1	10.69	0.51	3.76e-23	Fat distribution (HIV);
LUSC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.58	-9.05	-0.44	1.19e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-7.06	-0.36	9.65e-12	Mean platelet volume;
LUSC	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02176678	chr2:219576539	TTLL4	-0.67	-13.25	-0.59	1.7e-32	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg15133208	chr4:90757351	SNCA	-0.55	-8.63	-0.43	2.6e-16	Neuroticism;
LUSC	cis	rs911119	0.955	rs35610040	chr20:23616469	T/C	cg16589663	chr20:23618590	CST3	0.6	6.99	0.36	1.48e-11	Chronic kidney disease;
LUSC	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg05738196	chr6:26577821	NA	0.68	11.5	0.53	5.01e-26	Intelligence (multi-trait analysis);
LUSC	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg10840412	chr1:235813424	GNG4	0.57	7.35	0.37	1.49e-12	Bipolar disorder;
LUSC	cis	rs2219968	0.962	rs6473079	chr8:78928787	A/G	cg00738934	chr8:78996279	NA	0.39	7.08	0.36	8.46e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg05729581	chr11:3078854	CARS	0.39	5.82	0.3	1.4e-8	Calcium levels;
LUSC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg05234568	chr11:5960015	NA	-0.61	-8.77	-0.43	9.07e-17	DNA methylation (variation);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10518340	chr6:97731094	MIR548H3;C6orf167	-0.43	-6.38	-0.33	5.77e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-0.96	-10.25	-0.49	1.29e-21	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9473147	0.543	rs13211285	chr6:47479618	C/T	cg12968598	chr6:47444699	CD2AP	0.53	7.97	0.4	2.49e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.37	-6.29	-0.33	1.02e-9	High light scatter reticulocyte count;
LUSC	cis	rs1448094	0.617	rs2221319	chr12:86468064	C/A	cg02569458	chr12:86230093	RASSF9	-0.35	-5.67	-0.3	3.09e-8	Major depressive disorder;
LUSC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg22823121	chr1:150693482	HORMAD1	0.58	8.97	0.44	2.13e-17	Tonsillectomy;
LUSC	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.54	-10.49	-0.5	1.96e-22	Educational attainment;
LUSC	cis	rs400736	0.894	rs172811	chr1:8039949	A/G	cg25007680	chr1:8021821	PARK7	0.58	9.18	0.45	4.47e-18	Response to antidepressants and depression;
LUSC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.0	0.58	1.55e-31	Prudent dietary pattern;
LUSC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12379764	chr21:47803548	PCNT	-0.5	-7.02	-0.36	1.28e-11	Testicular germ cell tumor;
LUSC	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg23840854	chr1:161414152	NA	-0.92	-11.2	-0.52	6.13e-25	Rheumatoid arthritis;
LUSC	trans	rs34421088	0.576	rs2572437	chr8:11098441	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.42	-0.33	4.78e-10	Neuroticism;
LUSC	trans	rs2055729	0.645	rs12543685	chr8:9747056	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	6.47	0.33	3.58e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs11792861	0.566	rs966466	chr9:111851333	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	7.08	0.36	8.49e-12	Menarche (age at onset);
LUSC	cis	rs727505	1.000	rs7777947	chr7:124436063	T/G	cg23710748	chr7:124431027	NA	-0.4	-7.25	-0.37	3.01e-12	Lewy body disease;
LUSC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg07747251	chr5:1868357	NA	0.3	5.71	0.3	2.44e-8	Cardiovascular disease risk factors;
LUSC	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg19554555	chr3:13937349	NA	-0.38	-5.71	-0.3	2.47e-8	Ovarian reserve;
LUSC	cis	rs931127	0.719	rs11227259	chr11:65459404	T/C	cg05805236	chr11:65401703	PCNXL3	-0.41	-7.17	-0.37	4.98e-12	Systemic lupus erythematosus;
LUSC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03576123	chr11:487126	PTDSS2	-1.01	-10.65	-0.5	5.17e-23	Body mass index;
LUSC	cis	rs10823500	0.777	rs10999196	chr10:71982305	T/C	cg02100629	chr10:71892760	AIFM2	-0.36	-5.86	-0.31	1.12e-8	Blood protein levels;
LUSC	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg10434728	chr15:90938212	IQGAP1	0.4	8.21	0.41	4.78e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7705502	1.000	rs966544	chr5:173350405	A/G	cg18693985	chr5:173351052	CPEB4	-0.37	-5.86	-0.31	1.13e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg08079166	chr15:68083412	MAP2K5	0.35	5.96	0.31	6.51e-9	Obesity;
LUSC	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.82	0.51	1.4e-23	Heart rate;
LUSC	trans	rs62458065	0.640	rs10274556	chr7:32513947	A/G	cg00845942	chr12:64062724	DPY19L2	-0.57	-6.91	-0.35	2.5e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg17385448	chr1:15911702	AGMAT	0.37	5.86	0.31	1.08e-8	Systolic blood pressure;
LUSC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg23887609	chr12:130822674	PIWIL1	0.49	7.34	0.37	1.64e-12	Menopause (age at onset);
LUSC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg24468199	chr11:65410028	SIPA1	0.37	5.74	0.3	2.09e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23564928	chr14:32030597	NUBPL	0.43	6.33	0.33	7.86e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg13114125	chr14:105738426	BRF1	-0.94	-16.08	-0.66	1.69e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7178572	0.568	rs11858641	chr15:77585820	C/T	cg22256960	chr15:77711686	NA	-0.5	-8.02	-0.4	1.83e-14	Type 2 diabetes;
LUSC	cis	rs2073300	1.000	rs6132631	chr20:23461848	T/C	cg09953122	chr20:23471693	CST8	-0.76	-7.49	-0.38	6.37e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg09904177	chr6:26538194	HMGN4	-0.71	-6.8	-0.35	4.92e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg10604040	chr11:65559109	OVOL1	0.31	5.72	0.3	2.34e-8	Acne (severe);
LUSC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.52	-7.96	-0.4	2.67e-14	Longevity;Endometriosis;
LUSC	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs13114435	0.723	rs3886768	chr4:183817324	A/G	cg00486011	chr4:183851557	NA	-0.32	-5.77	-0.3	1.85e-8	Obesity-related traits;
LUSC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg12463550	chr7:65579703	CRCP	0.56	8.38	0.42	1.53e-15	Aortic root size;
LUSC	cis	rs2012796	1.000	rs12436146	chr14:81821282	A/G	cg02996355	chr14:81879375	NA	0.5	7.24	0.37	3.08e-12	Night sleep phenotypes;
LUSC	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.43	6.6	0.34	1.58e-10	Dupuytren's disease;
LUSC	cis	rs12476592	0.602	rs262506	chr2:63863022	A/G	cg10828910	chr2:63850056	LOC388955	0.49	5.78	0.3	1.71e-8	Childhood ear infection;
LUSC	cis	rs9905704	0.918	rs9891129	chr17:56630474	T/C	cg12560992	chr17:57184187	TRIM37	-0.55	-7.81	-0.39	7.44e-14	Testicular germ cell tumor;
LUSC	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg14196790	chr5:131705035	SLC22A5	-0.42	-6.82	-0.35	4.3e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs483180	0.531	rs662243	chr1:120209564	A/C	cg19096424	chr1:120255104	PHGDH	0.47	6.58	0.34	1.83e-10	Macular telangiectasia type 2;
LUSC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	9.28	0.45	2.17e-18	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.13	0.58	4.77e-32	Prudent dietary pattern;
LUSC	cis	rs10823500	0.545	rs7082562	chr10:71945684	A/G	cg02100629	chr10:71892760	AIFM2	-0.36	-6.1	-0.32	2.91e-9	Blood protein levels;
LUSC	cis	rs7712401	0.601	rs246282	chr5:122225605	G/T	cg19077854	chr5:122220652	SNX24	0.4	8.76	0.43	9.9900000000000006e-17	Mean platelet volume;
LUSC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.63	-0.34	1.33e-10	Alzheimer's disease (late onset);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04915425	chr11:47236385	DDB2	-0.44	-6.04	-0.31	4.13e-9	Hepatitis;
LUSC	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg17691542	chr6:26056736	HIST1H1C	0.47	7.04	0.36	1.12e-11	Height;
LUSC	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg13010199	chr12:38710504	ALG10B	0.65	10.07	0.48	5.45e-21	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	0.98	15.66	0.65	7.7e-42	Dupuytren's disease;
LUSC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-1.08	-26.06	-0.82	1.7e-82	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.26	-27.67	-0.83	2e-88	Exhaled nitric oxide output;
LUSC	cis	rs6982240	0.514	rs10481414	chr8:142275326	T/C	cg27411547	chr8:142287226	NA	-0.47	-8.02	-0.4	1.77e-14	Tonsillectomy;
LUSC	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg10560079	chr2:191398806	TMEM194B	-0.74	-9.0	-0.44	1.73e-17	Diastolic blood pressure;
LUSC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg06096015	chr1:231504339	EGLN1	0.58	10.12	0.48	3.46e-21	Hemoglobin concentration;
LUSC	cis	rs1506636	0.962	rs10243279	chr7:123441262	T/A	cg03229431	chr7:123269106	ASB15	0.63	10.15	0.49	2.75e-21	Plateletcrit;Platelet count;
LUSC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg20476274	chr7:133979776	SLC35B4	0.87	16.82	0.68	2e-46	Mean platelet volume;
LUSC	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg21141812	chr3:48556323	PFKFB4	0.35	6.02	0.31	4.54e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg11473876	chr11:109292803	C11orf87	0.35	5.97	0.31	5.95e-9	Schizophrenia;
LUSC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg06740227	chr12:86229804	RASSF9	0.44	7.09	0.36	7.84e-12	Major depressive disorder;
LUSC	cis	rs7119167	0.686	rs12294659	chr11:73041007	G/A	cg17517138	chr11:73019481	ARHGEF17	0.5	5.85	0.3	1.16e-8	Blood protein levels;
LUSC	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg01973587	chr1:228161476	NA	-0.41	-7.23	-0.37	3.38e-12	Diastolic blood pressure;
LUSC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg12639453	chr1:2035780	PRKCZ	0.3	6.38	0.33	6.06e-10	Height;
LUSC	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg13010199	chr12:38710504	ALG10B	0.55	8.48	0.42	7.35e-16	Morning vs. evening chronotype;
LUSC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.76	-13.42	-0.59	3.81e-33	Dental caries;
LUSC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.92	0.4	3.59e-14	Colorectal cancer;
LUSC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg26695010	chr11:65641043	EFEMP2	-0.47	-6.93	-0.35	2.18e-11	Eosinophil percentage of white cells;
LUSC	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-18.27	-0.71	3.63e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9469578	1.000	rs6923565	chr6:33707112	G/A	cg18708504	chr6:33715942	IP6K3	0.72	9.01	0.44	1.58e-17	Phosphorus levels;
LUSC	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg02023728	chr11:77925099	USP35	0.44	6.41	0.33	5.04e-10	Testicular germ cell tumor;
LUSC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.15	-0.52	9.06e-25	Mean corpuscular volume;
LUSC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.48	-6.33	-0.33	8.07e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg20283391	chr11:68216788	NA	-0.61	-8.46	-0.42	8.4e-16	Total body bone mineral density;
LUSC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg22437258	chr11:111473054	SIK2	0.52	7.44	0.38	8.76e-13	Primary sclerosing cholangitis;
LUSC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	0.49	7.75	0.39	1.11e-13	Uric acid clearance;
LUSC	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-0.93	-8.41	-0.42	1.2e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2742234	0.794	rs17153156	chr10:43704637	C/G	cg02780029	chr10:43622663	RET	0.32	6.22	0.32	1.51e-9	Hirschsprung disease;
LUSC	trans	rs1268789	0.545	rs11730871	chr4:79368816	T/C	cg06112894	chr8:141469983	TRAPPC9	0.22	5.96	0.31	6.33e-9	Hair shape;Hair morphology;
LUSC	cis	rs897080	0.515	rs4953088	chr2:44564518	C/T	cg00619915	chr2:44497795	NA	0.4	5.89	0.31	9.52e-9	Height;
LUSC	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg02569458	chr12:86230093	RASSF9	0.47	7.47	0.38	6.9e-13	Major depressive disorder;
LUSC	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-6.35	-0.33	6.98e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08280861	chr8:58055591	NA	0.55	6.51	0.34	2.79e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-0.96	-12.87	-0.58	4.54e-31	Exhaled nitric oxide output;
LUSC	trans	rs10096351	0.528	rs74588857	chr8:128336741	C/T	cg10897648	chr18:56338258	MALT1	-0.42	-6.24	-0.32	1.33e-9	Breast cancer;
LUSC	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.31e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.47	-7.1	-0.36	7.72e-12	Neutrophil percentage of white cells;
LUSC	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.36	0.64	1.2e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs10492096	0.947	rs10849483	chr12:6635374	G/A	cg13857086	chr12:6580257	VAMP1	0.64	7.69	0.39	1.64e-13	Hip geometry;
LUSC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.54	-0.34	2.29e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs757081	0.667	rs17560341	chr11:17107163	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-6.02	-0.31	4.54e-9	Systolic blood pressure;
LUSC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg21665744	chr7:39171113	POU6F2	0.47	7.56	0.38	3.96e-13	IgG glycosylation;
LUSC	cis	rs11622475	0.677	rs7145372	chr14:104359121	A/G	cg12183467	chr14:104352244	NA	0.46	9.26	0.45	2.55e-18	Bipolar disorder;
LUSC	cis	rs3947	0.855	rs1296026	chr8:11697442	C/T	cg00262122	chr8:11665843	FDFT1	-0.48	-5.66	-0.3	3.32e-8	Blood protein levels;
LUSC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg06637938	chr14:75390232	RPS6KL1	0.54	8.62	0.43	2.76e-16	Height;
LUSC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg16339924	chr4:17578868	LAP3	0.58	8.72	0.43	1.36e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	8.96	0.44	2.3e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg02269571	chr22:50332266	NA	-0.57	-8.4	-0.42	1.26e-15	Schizophrenia;
LUSC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg11752832	chr7:134001865	SLC35B4	0.56	8.64	0.43	2.38e-16	Mean platelet volume;
LUSC	trans	rs1325195	0.537	rs2793807	chr1:179171713	C/T	cg11624085	chr17:8464688	MYH10	0.43	6.38	0.33	5.94e-10	IgE grass sensitization;
LUSC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg17366294	chr4:99064904	C4orf37	0.58	10.24	0.49	1.42e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-12.65	-0.57	3.18e-30	Body mass index;
LUSC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg07701084	chr6:150067640	NUP43	-0.55	-8.38	-0.42	1.46e-15	Lung cancer;
LUSC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.34	-6.98	-0.36	1.6e-11	Hemoglobin concentration;
LUSC	cis	rs10465746	0.967	rs11576870	chr1:84333301	G/A	cg10977910	chr1:84465055	TTLL7	0.45	6.38	0.33	5.91e-10	Obesity-related traits;
LUSC	cis	rs10761482	0.532	rs1938533	chr10:62234109	G/C	cg18175470	chr10:62150864	ANK3	-0.48	-6.77	-0.35	5.77e-11	Schizophrenia;
LUSC	trans	rs7178375	0.941	rs4779796	chr15:31208050	C/T	cg04373760	chr16:53404718	NA	0.64	8.8	0.43	7.58e-17	Hypertriglyceridemia;
LUSC	cis	rs7589342	0.831	rs13429270	chr2:106453060	C/T	cg14210321	chr2:106509881	NCK2	-0.54	-8.04	-0.4	1.58e-14	Addiction;
LUSC	cis	rs3849570	1.000	rs11915016	chr3:81833966	G/A	cg07356753	chr3:81810745	GBE1	-0.68	-11.09	-0.52	1.46e-24	Waist circumference;Body mass index;
LUSC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg06060754	chr5:176797920	RGS14	0.6	9.71	0.47	8.65e-20	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7615316	0.902	rs6770155	chr3:142308691	A/G	cg16271453	chr3:142027066	XRN1	-0.36	-6.12	-0.32	2.61e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	8.93	0.44	2.84e-17	Response to bleomycin (chromatid breaks);
LUSC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.1e-12	Motion sickness;
LUSC	cis	rs911119	0.913	rs13038990	chr20:23589053	C/T	cg16589663	chr20:23618590	CST3	0.56	6.77	0.35	5.68e-11	Chronic kidney disease;
LUSC	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg08645402	chr16:4508243	NA	-0.47	-7.26	-0.37	2.7e-12	Schizophrenia;
LUSC	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg19468946	chr17:37922297	IKZF3	-0.39	-6.22	-0.32	1.51e-9	Self-reported allergy;
LUSC	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg21100191	chr22:23484243	RTDR1	0.91	15.61	0.65	1.18e-41	Bone mineral density;
LUSC	trans	rs10016947	0.826	rs6821736	chr4:104267560	T/A	cg02356640	chr11:1501973	HCCA2	0.69	5.98	0.31	5.79e-9	Breast cancer;
LUSC	trans	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg25482853	chr8:67687455	SGK3	0.65	9.56	0.46	2.63e-19	Obesity-related traits;
LUSC	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg15556689	chr8:8085844	FLJ10661	0.56	7.89	0.4	4.31e-14	Neuroticism;
LUSC	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-0.9	-15.28	-0.64	2.44e-40	Headache;
LUSC	trans	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.66	-0.34	1.16e-10	Endometrial cancer;
LUSC	cis	rs12220238	1.000	rs1908331	chr10:75885817	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	7.69	0.39	1.65e-13	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs11630290	0.736	rs7183958	chr15:64155534	C/G	cg12036633	chr15:63758958	NA	-0.62	-6.85	-0.35	3.67e-11	Iris characteristics;
LUSC	cis	rs644148	0.836	rs2686776	chr19:45000366	T/C	cg15540054	chr19:45004280	ZNF180	-0.62	-9.16	-0.45	5.44e-18	Personality dimensions;
LUSC	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg15423357	chr2:25149977	NA	0.45	9.03	0.44	1.37e-17	Body mass index;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20769334	chr22:50913335	SBF1	-0.53	-7.01	-0.36	1.29e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg12615879	chr12:58013172	SLC26A10	-0.27	-5.77	-0.3	1.78e-8	Multiple sclerosis;
LUSC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.74	-0.65	3.74e-42	Gut microbiome composition (summer);
LUSC	cis	rs4144743	1.000	rs67080286	chr17:45322248	T/G	cg18085866	chr17:45331354	ITGB3	-0.73	-7.87	-0.4	4.93e-14	Body mass index;
LUSC	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg13390004	chr1:15929781	NA	0.4	6.56	0.34	2.09e-10	Systolic blood pressure;
LUSC	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs12712073	0.837	rs11692867	chr2:100759477	G/A	cg07810366	chr2:100720526	AFF3	-0.44	-7.53	-0.38	4.69e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg27411982	chr8:10470053	RP1L1	-0.49	-7.85	-0.39	5.89e-14	Neuroticism;
LUSC	cis	rs2652834	0.904	rs8032506	chr15:63371644	G/A	cg05507819	chr15:63340323	TPM1	-0.66	-7.93	-0.4	3.36e-14	HDL cholesterol;
LUSC	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg02023728	chr11:77925099	USP35	0.48	6.47	0.33	3.54e-10	Testicular germ cell tumor;
LUSC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg06627628	chr2:24431161	ITSN2	0.61	7.36	0.37	1.45e-12	Lymphocyte counts;
LUSC	cis	rs75920871	0.588	rs1815789	chr11:116834953	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-6.47	-0.33	3.57e-10	Subjective well-being;
LUSC	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg13798780	chr7:105162888	PUS7	0.58	6.32	0.33	8.2e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg00074818	chr8:8560427	CLDN23	0.59	9.8	0.47	4.21e-20	Obesity-related traits;
LUSC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg07217954	chr7:1067459	C7orf50	0.52	5.67	0.3	3.02e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs240764	0.645	rs454747	chr6:101055566	T/C	cg09795085	chr6:101329169	ASCC3	0.41	5.9	0.31	9.09e-9	Neuroticism;
LUSC	cis	rs11997175	0.574	rs4236733	chr8:33655582	G/A	ch.8.33884649F	chr8:33765107	NA	0.52	8.57	0.42	3.94e-16	Body mass index;
LUSC	cis	rs2073300	0.793	rs6114094	chr20:23434267	A/G	cg09953122	chr20:23471693	CST8	-0.69	-6.55	-0.34	2.13e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	14.3	0.62	1.66e-36	Platelet count;
LUSC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg04450456	chr4:17643702	FAM184B	0.38	6.46	0.33	3.77e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1775715	0.513	rs2808089	chr10:32145112	A/T	cg04359828	chr10:32216031	ARHGAP12	0.41	7.12	0.36	6.83e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg04450456	chr4:17643702	FAM184B	-0.41	-6.51	-0.34	2.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg00857998	chr1:205179979	DSTYK	0.61	9.82	0.47	3.76e-20	Red blood cell count;
LUSC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg15556689	chr8:8085844	FLJ10661	0.68	10.96	0.51	4.41e-24	Joint mobility (Beighton score);
LUSC	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	0.6	9.45	0.46	6.13e-19	Breast cancer;
LUSC	cis	rs4290604	0.748	rs4621125	chr2:238080214	G/A	cg23555395	chr2:238036564	NA	-0.51	-6.89	-0.35	2.81e-11	Asthma;
LUSC	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.58	9.7	0.47	9.12e-20	Bone mineral density;
LUSC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg03146154	chr1:46216737	IPP	0.56	8.35	0.42	1.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25072359	chr17:41440525	NA	0.66	9.44	0.46	6.54e-19	Menopause (age at onset);
LUSC	trans	rs2262909	0.962	rs390730	chr19:22233509	C/A	cg05197062	chr11:11642011	GALNTL4	-0.56	-7.81	-0.39	7.34e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg05313129	chr8:58192883	C8orf71	-0.58	-6.3	-0.33	9.65e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg05802129	chr4:122689817	NA	-0.48	-8.33	-0.41	2.06e-15	Type 2 diabetes;
LUSC	cis	rs4285028	0.948	rs12493408	chr3:121692119	C/A	cg11130432	chr3:121712080	ILDR1	-0.63	-9.56	-0.46	2.57e-19	Multiple sclerosis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11206763	chr12:56521692	ESYT1	0.52	7.3	0.37	2.09e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7408868	0.908	rs10418660	chr19:15278635	A/G	cg14696996	chr19:15285081	NOTCH3	0.97	9.33	0.45	1.56e-18	Pulse pressure;
LUSC	cis	rs354225	0.544	rs13403284	chr2:54805749	A/G	cg01766943	chr2:54829624	SPTBN1	0.48	7.61	0.38	2.89e-13	Schizophrenia;
LUSC	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg24459738	chr19:57751996	ZNF805	-0.5	-7.51	-0.38	5.36e-13	Hyperactive-impulsive symptoms;
LUSC	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.11	0.32	2.74e-9	Myopia (pathological);
LUSC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg23758822	chr17:41437982	NA	1.03	19.9	0.74	1.14e-58	Menopause (age at onset);
LUSC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg06808227	chr14:105710500	BRF1	-0.65	-9.82	-0.47	3.77e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6681460	0.549	rs7525509	chr1:67031968	C/T	cg02459107	chr1:67143332	SGIP1	0.31	5.69	0.3	2.85e-8	Presence of antiphospholipid antibodies;
LUSC	trans	rs2392780	0.512	rs373701	chr8:128334992	C/A	cg10195415	chr17:73887371	TRIM65	0.41	6.49	0.33	3.12e-10	Breast cancer (early onset);
LUSC	cis	rs13089785	0.965	rs12488058	chr3:123599681	C/T	cg02558132	chr3:123411198	MYLK	0.36	6.15	0.32	2.17e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg22532475	chr10:104410764	TRIM8	-0.32	-7.15	-0.36	5.59e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	0.69	11.04	0.52	2.2e-24	Blood metabolite ratios;
LUSC	trans	rs7944735	0.786	rs7123436	chr11:48013484	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.56	0.34	2.07e-10	Intraocular pressure;
LUSC	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg03599575	chr15:90893182	GABARAPL3	0.33	5.91	0.31	8.3e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs4704187	0.687	rs6888707	chr5:74442920	A/G	cg03227963	chr5:74354835	NA	0.31	6.77	0.35	5.75e-11	Response to amphetamines;
LUSC	trans	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.72	0.39	1.39e-13	Ulcerative colitis;
LUSC	cis	rs981844	0.740	rs7653960	chr4:154697430	T/G	cg14289246	chr4:154710475	SFRP2	-0.52	-7.16	-0.36	5.19e-12	Response to statins (LDL cholesterol change);
LUSC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg14416269	chr4:6271139	WFS1	0.54	11.37	0.53	1.53e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.85	-0.47	2.92e-20	Total cholesterol levels;
LUSC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.9	0.77	1.58e-66	Prudent dietary pattern;
LUSC	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg20587970	chr11:113659929	NA	-0.86	-10.81	-0.51	1.53e-23	Hip circumference adjusted for BMI;
LUSC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg03929089	chr4:120376271	NA	-0.94	-16.46	-0.67	5.66e-45	Height;
LUSC	cis	rs57549656	0.799	rs1001328	chr19:2712016	G/C	cg06609049	chr19:2785107	THOP1	0.49	6.31	0.33	8.64e-10	Schizophrenia;
LUSC	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	6.98	0.36	1.63e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.67	11.29	0.53	2.91e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16656864	chr17:27718261	TAOK1	0.48	7.05	0.36	1e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg03732007	chr1:2071316	PRKCZ	-0.53	-9.4	-0.46	9.09e-19	Height;
LUSC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg16797656	chr11:68205561	LRP5	0.4	7.17	0.37	4.72e-12	Total body bone mineral density;
LUSC	cis	rs908922	0.847	rs499697	chr1:152493154	A/G	cg20991723	chr1:152506922	NA	-0.51	-8.9	-0.44	3.55e-17	Hair morphology;
LUSC	cis	rs9905704	0.918	rs581903	chr17:56719197	C/T	cg12560992	chr17:57184187	TRIM37	0.55	7.85	0.39	5.74e-14	Testicular germ cell tumor;
LUSC	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg20734569	chr3:48348370	SPINK8	-0.46	-8.24	-0.41	3.91e-15	Coronary artery disease;
LUSC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-9.68	-0.47	1.11e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg15133208	chr4:90757351	SNCA	-0.53	-8.27	-0.41	3.2e-15	Neuroticism;
LUSC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	11.98	0.55	9.22e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs4356932	1.000	rs10003240	chr4:76955330	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs7605827	0.893	rs7572131	chr2:15691886	G/A	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.32e-17	Educational attainment (years of education);
LUSC	cis	rs60154123	0.772	rs614167	chr1:210425895	T/C	cg22029157	chr1:209979665	IRF6	0.59	6.03	0.31	4.23e-9	Coronary artery disease;
LUSC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg13206674	chr6:150067644	NUP43	0.59	9.05	0.44	1.19e-17	Lung cancer;
LUSC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.06	-16.96	-0.68	5.39e-47	Primary sclerosing cholangitis;
LUSC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.58	-0.46	2.23e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21862992	chr11:68658383	NA	0.49	7.84	0.39	6.24e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7215564	0.908	rs7501497	chr17:78660738	T/C	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.84	-15.46	-0.65	4.96e-41	Dental caries;
LUSC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg23791538	chr6:167370224	RNASET2	0.41	6.53	0.34	2.39e-10	Crohn's disease;
LUSC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.5	-8.31	-0.41	2.46e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.61	-0.34	1.52e-10	Response to antipsychotic treatment;
LUSC	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg17623882	chr6:41773611	USP49	-0.59	-10.1	-0.48	4.14e-21	Menarche (age at onset);
LUSC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg05717871	chr11:638507	DRD4	-0.36	-6.06	-0.31	3.76e-9	Systemic lupus erythematosus;
LUSC	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg02353165	chr6:42928485	GNMT	-0.46	-5.81	-0.3	1.49e-8	Blood protein levels;
LUSC	cis	rs6961069	0.585	rs12532196	chr7:80241570	T/C	cg04458919	chr7:80252533	CD36	-0.39	-6.91	-0.35	2.41e-11	Platelet count;
LUSC	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg05585544	chr11:47624801	NA	-0.36	-6.3	-0.33	9.37e-10	Subjective well-being;
LUSC	cis	rs28830936	0.966	rs2241522	chr15:42127734	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.69	-0.3	2.83e-8	Diastolic blood pressure;
LUSC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg17691542	chr6:26056736	HIST1H1C	0.52	7.85	0.39	5.8e-14	Height;
LUSC	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg10596483	chr8:143751796	JRK	0.61	9.4	0.46	9.11e-19	Schizophrenia;
LUSC	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.68	11.86	0.54	2.56e-27	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs9473147	0.516	rs9395279	chr6:47542864	C/T	cg02130027	chr6:47444894	CD2AP	0.35	5.65	0.3	3.39e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs36405	0.500	rs2109273	chr14:72360964	C/T	cg23396177	chr14:72358413	NA	-0.37	-6.97	-0.36	1.69e-11	Yang-deficiency constitution;
LUSC	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06656553	chr16:89960601	TCF25	-0.64	-5.66	-0.3	3.2e-8	Skin colour saturation;
LUSC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs354225	0.544	rs13399656	chr2:54802696	T/G	cg26097391	chr2:54893211	SPTBN1	0.43	6.33	0.33	7.75e-10	Schizophrenia;
LUSC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg06008330	chr7:65541103	ASL	-0.41	-6.31	-0.33	8.66e-10	Aortic root size;
LUSC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg18827107	chr12:86230957	RASSF9	-0.46	-6.96	-0.36	1.81e-11	Major depressive disorder;
LUSC	cis	rs2625529	0.824	rs12595228	chr15:72267215	T/C	cg16672083	chr15:72433130	SENP8	-0.51	-7.39	-0.37	1.19e-12	Red blood cell count;
LUSC	cis	rs2285947	1.000	rs6970597	chr7:21583519	C/A	cg04471919	chr7:21584483	DNAH11	0.35	7.74	0.39	1.16e-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	trans	rs61931739	0.817	rs866515	chr12:34215479	A/G	cg24313572	chr1:56050060	NA	-0.31	-6.41	-0.33	4.89e-10	Morning vs. evening chronotype;
LUSC	cis	rs295140	0.706	rs3769484	chr2:201172999	C/T	cg04283868	chr2:201171347	SPATS2L	0.43	6.18	0.32	1.82e-9	QT interval;
LUSC	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg01657329	chr11:68192670	LRP5	-0.42	-6.34	-0.33	7.46e-10	Total body bone mineral density;
LUSC	cis	rs662735	0.515	rs273612	chr11:30903063	C/T	cg14844989	chr11:31128820	NA	0.35	5.68	0.3	2.93e-8	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg05855489	chr10:104503620	C10orf26	0.53	8.11	0.41	9.87e-15	Arsenic metabolism;
LUSC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.77e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6500395	0.962	rs7499213	chr16:48680597	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.41	0.33	4.93e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07177001	chr8:22926478	TNFRSF10B	0.71	6.03	0.31	4.3e-9	Cognitive performance;
LUSC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.86	-0.35	3.27e-11	Lung cancer;
LUSC	cis	rs7809950	0.954	rs2520242	chr7:107136320	G/T	cg23024343	chr7:107201750	COG5	0.56	8.99	0.44	1.9e-17	Coronary artery disease;
LUSC	cis	rs7241530	0.595	rs12954372	chr18:75900263	C/A	cg14642773	chr18:75888474	NA	0.38	5.7	0.3	2.61e-8	Educational attainment (years of education);
LUSC	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	9.45	0.46	6e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs2882667	0.858	rs11959851	chr5:138421405	C/G	cg04439458	chr5:138467593	SIL1	-0.41	-7.98	-0.4	2.29e-14	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg04733989	chr22:42467013	NAGA	0.42	7.08	0.36	8.61e-12	Cognitive function;
LUSC	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg25173405	chr17:45401733	C17orf57	0.37	5.76	0.3	1.89e-8	Multiple sclerosis or amyotrophic lateral sclerosis;
LUSC	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.2	0.41	5.32e-15	Corneal astigmatism;
LUSC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22307029	chr19:49891270	CCDC155	0.69	9.55	0.46	2.9e-19	Multiple sclerosis;
LUSC	cis	rs4654899	1.000	rs6684976	chr1:21367501	G/A	cg01072550	chr1:21505969	NA	-0.56	-8.54	-0.42	4.74e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg05347473	chr6:146136440	FBXO30	0.41	6.79	0.35	5.11e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12620999	1.000	rs13004252	chr2:238035408	C/A	cg23555395	chr2:238036564	NA	-0.51	-8.12	-0.41	9.17e-15	Systemic lupus erythematosus;
LUSC	cis	rs7577696	0.525	rs2366547	chr2:32251109	G/A	cg02381751	chr2:32503542	YIPF4	-0.45	-6.07	-0.32	3.52e-9	Inflammatory biomarkers;
LUSC	cis	rs2652834	0.851	rs2729813	chr15:63412154	A/G	cg05507819	chr15:63340323	TPM1	0.46	5.94	0.31	7.3e-9	HDL cholesterol;
LUSC	cis	rs6484504	0.576	rs208071	chr11:31144996	C/T	cg26647111	chr11:31128758	NA	-0.42	-6.11	-0.32	2.7e-9	Red blood cell count;
LUSC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg12639453	chr1:2035780	PRKCZ	-0.3	-6.3	-0.33	9.13e-10	Height;
LUSC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg13206674	chr6:150067644	NUP43	0.62	9.73	0.47	7.45e-20	Lung cancer;
LUSC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.66	-9.18	-0.45	4.72e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg23281280	chr6:28129359	ZNF389	0.43	5.71	0.3	2.55e-8	Parkinson's disease;
LUSC	cis	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg21775007	chr8:11205619	TDH	-0.47	-6.49	-0.33	3.09e-10	Triglycerides;
LUSC	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs6728642	0.908	rs6731522	chr2:97647997	A/G	cg26665480	chr2:98280029	ACTR1B	-0.69	-5.97	-0.31	6.02e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg07274523	chr3:49395745	GPX1	0.67	10.27	0.49	1.11e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs12891047	0.901	rs11621019	chr14:68269435	T/C	cg20999565	chr14:68265668	ZFYVE26	0.38	5.67	0.3	3.06e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs6009527	0.711	rs8141990	chr22:49570455	T/G	cg12746016	chr22:49560550	NA	0.48	8.74	0.43	1.17e-16	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg25930673	chr12:123319894	HIP1R	-0.62	-6.11	-0.32	2.79e-9	Schizophrenia;
LUSC	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg25281562	chr12:121454272	C12orf43	-0.43	-5.69	-0.3	2.84e-8	Metabolic traits;LDL cholesterol;
LUSC	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.56	9.45	0.46	6.08e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7580658	0.724	rs6712446	chr2:127998399	G/T	cg09760422	chr2:128146352	NA	-0.3	-6.79	-0.35	5.27e-11	Protein C levels;
LUSC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg22823121	chr1:150693482	HORMAD1	0.59	9.05	0.44	1.17e-17	Tonsillectomy;
LUSC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg12463550	chr7:65579703	CRCP	-0.55	-8.23	-0.41	4.27e-15	Aortic root size;
LUSC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00908189	chr16:619842	PIGQ	0.66	10.21	0.49	1.81e-21	Height;
LUSC	cis	rs59698941	0.943	rs67422135	chr5:132222728	T/A	cg02081065	chr5:132209139	LEAP2	-0.65	-6.75	-0.35	6.45e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg02551604	chr5:131831745	NA	0.43	6.8	0.35	4.74e-11	Asthma (sex interaction);
LUSC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg00343986	chr7:65444356	GUSB	0.47	7.01	0.36	1.35e-11	Calcium levels;
LUSC	cis	rs710216	0.957	rs3738514	chr1:43426591	A/G	cg22176566	chr1:43424700	SLC2A1	-0.45	-6.0	-0.31	5.06e-9	Red cell distribution width;
LUSC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6674176	0.542	rs803675	chr1:44353237	G/A	cg15962314	chr1:44399869	ARTN	0.26	5.88	0.31	9.74e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2046867	0.818	rs62249874	chr3:72911202	G/C	cg25664220	chr3:72788482	NA	-0.62	-10.56	-0.5	1.07e-22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg03188948	chr7:1209495	NA	0.65	6.9	0.35	2.56e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg03909863	chr11:638404	DRD4	-0.4	-5.86	-0.31	1.13e-8	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.65	11.09	0.52	1.58e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11971779	0.838	rs4728468	chr7:139122978	G/A	cg07862535	chr7:139043722	LUC7L2	0.7	8.49	0.42	6.64e-16	Diisocyanate-induced asthma;
LUSC	cis	rs67696533	0.540	rs2889678	chr20:31189993	C/T	cg13636640	chr20:31349939	DNMT3B	-0.41	-5.92	-0.31	8.15e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.71	-12.05	-0.55	5.25e-28	Height;
LUSC	cis	rs1160297	0.609	rs10208858	chr2:53094982	G/A	cg07782112	chr2:53107842	NA	0.4	6.7	0.34	8.8e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs240764	0.578	rs723743	chr6:101237504	T/C	cg09795085	chr6:101329169	ASCC3	0.44	6.27	0.32	1.13e-9	Neuroticism;
LUSC	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg22563815	chr15:78856949	CHRNA5	0.25	6.13	0.32	2.5e-9	Sudden cardiac arrest;
LUSC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.64	10.16	0.49	2.64e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00251250	chr1:234746546	IRF2BP2	-0.4	-6.0	-0.31	5.21e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-17.37	-0.69	1.32e-48	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10761482	0.859	rs2199210	chr10:62094752	T/G	cg18175470	chr10:62150864	ANK3	-0.45	-6.71	-0.34	8.5e-11	Schizophrenia;
LUSC	trans	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg17712092	chr4:129076599	LARP1B	-0.71	-9.97	-0.48	1.18e-20	Breast cancer;
LUSC	cis	rs8133932	0.555	rs374331	chr21:47338218	A/G	cg14185626	chr21:47401492	COL6A1	-0.44	-5.68	-0.3	2.93e-8	Schizophrenia;
LUSC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg22823121	chr1:150693482	HORMAD1	0.53	7.95	0.4	2.9e-14	Melanoma;
LUSC	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg22437258	chr11:111473054	SIK2	0.5	6.91	0.35	2.49e-11	Primary sclerosing cholangitis;
LUSC	cis	rs16867335	1.000	rs2113786	chr2:181483250	C/T	cg23363182	chr2:181467187	NA	-0.48	-6.2	-0.32	1.66e-9	Survival in rectal cancer;
LUSC	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg24578937	chr1:2090814	PRKCZ	0.57	12.75	0.57	1.28e-30	Height;
LUSC	cis	rs3809566	0.637	rs8026047	chr15:63323347	C/G	cg05507819	chr15:63340323	TPM1	-0.47	-5.88	-0.31	9.78e-9	Platelet count;
LUSC	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.54	9.07	0.44	1.04e-17	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg22705602	chr4:152727874	NA	-0.31	-6.14	-0.32	2.34e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg16447950	chr5:562315	NA	-0.58	-7.3	-0.37	2.1e-12	Obesity-related traits;
LUSC	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg02176678	chr2:219576539	TTLL4	0.61	11.13	0.52	1.08e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2219968	1.000	rs13248763	chr8:78975616	G/A	cg00738934	chr8:78996279	NA	0.35	6.23	0.32	1.37e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	0.96	18.87	0.72	1.48e-54	Menarche (age at onset);
LUSC	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.3	-6.57	-0.34	1.91e-10	Dupuytren's disease;
LUSC	cis	rs2274273	0.840	rs1045002	chr14:55818517	T/A	cg04306507	chr14:55594613	LGALS3	0.53	11.64	0.54	1.66e-26	Protein biomarker;
LUSC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg04166393	chr7:2884313	GNA12	0.48	6.31	0.33	8.74e-10	Height;
LUSC	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg01191920	chr7:158217561	PTPRN2	-0.44	-9.08	-0.44	9.67e-18	Obesity-related traits;
LUSC	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg01657329	chr11:68192670	LRP5	-0.48	-7.43	-0.38	9.37e-13	Total body bone mineral density;
LUSC	cis	rs10740039	0.883	rs10994468	chr10:62426291	A/G	cg18175470	chr10:62150864	ANK3	-0.47	-7.09	-0.36	8.08e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.26e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs17105932	1.000	rs10890582	chr11:106631807	G/T	cg24932660	chr1:27709575	CD164L2	0.65	5.98	0.31	5.76e-9	Anxiety disorder;
LUSC	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg05043794	chr9:111880884	C9orf5	-0.33	-6.7	-0.34	9.06e-11	Menarche (age at onset);
LUSC	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg09835421	chr16:68378352	PRMT7	-0.44	-5.78	-0.3	1.74e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg11764359	chr7:65958608	NA	-0.68	-10.7	-0.51	3.74e-23	Aortic root size;
LUSC	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg08668359	chr10:1443807	ADARB2	0.41	6.15	0.32	2.16e-9	Radiation response;
LUSC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg06618935	chr21:46677482	NA	-0.37	-7.33	-0.37	1.75e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg19318889	chr4:1322082	MAEA	0.39	6.36	0.33	6.46e-10	Obesity-related traits;
LUSC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg13939156	chr17:80058883	NA	0.34	6.55	0.34	2.14e-10	Life satisfaction;
LUSC	cis	rs929596	0.564	rs2741034	chr2:234548814	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-6.11	-0.32	2.81e-9	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg14784868	chr12:69753453	YEATS4	0.62	8.7	0.43	1.55e-16	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg16325326	chr1:53192061	ZYG11B	0.78	14.03	0.61	1.72e-35	Monocyte count;
LUSC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg02572448	chr1:8763403	RERE	0.42	6.15	0.32	2.15e-9	Mosquito bite size;
LUSC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.86	0.35	3.37e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs3849570	0.695	rs9830445	chr3:81508063	T/G	cg07356753	chr3:81810745	GBE1	0.46	6.07	0.32	3.47e-9	Waist circumference;Body mass index;
LUSC	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg24812749	chr6:127587940	RNF146	0.7	9.92	0.48	1.75e-20	Breast cancer;
LUSC	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-9.16	-0.45	5.26e-18	Neuroticism;
LUSC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg13607699	chr17:42295918	UBTF	-0.4	-5.77	-0.3	1.77e-8	Total body bone mineral density;
LUSC	cis	rs10489202	0.955	rs17557162	chr1:167985950	A/T	cg24449463	chr1:168025552	DCAF6	0.59	7.64	0.39	2.26e-13	Schizophrenia;
LUSC	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.0	-0.36	1.45e-11	Blood metabolite levels;
LUSC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.82	14.02	0.61	2.03e-35	Blood protein levels;
LUSC	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg18478394	chr8:109455254	TTC35	0.45	6.8	0.35	4.91e-11	Dupuytren's disease;
LUSC	cis	rs7106204	1.000	rs4622259	chr11:24215789	A/G	ch.11.24196551F	chr11:24239977	NA	0.99	9.62	0.47	1.71e-19	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1413885	0.516	rs3818449	chr1:65844963	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	7.46	0.38	7.62e-13	Anticoagulant levels;
LUSC	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg23029597	chr12:123009494	RSRC2	0.75	9.5	0.46	4.15e-19	Body mass index;
LUSC	cis	rs9653442	0.564	rs7601892	chr2:100789490	G/A	cg07810366	chr2:100720526	AFF3	-0.43	-7.28	-0.37	2.43e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg05855489	chr10:104503620	C10orf26	0.53	8.12	0.41	9.19e-15	Arsenic metabolism;
LUSC	cis	rs722599	0.748	rs741096	chr14:75351487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.42	-6.15	-0.32	2.18e-9	IgG glycosylation;
LUSC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	0.62	7.18	0.37	4.62e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs35079168	0.923	rs11103473	chr9:137287629	A/T	cg13941235	chr9:137270186	RXRA	0.33	5.8	0.3	1.53e-8	Intelligence;
LUSC	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg09754948	chr16:28834200	ATXN2L	0.4	5.94	0.31	7.11e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg16339924	chr4:17578868	LAP3	-0.55	-7.95	-0.4	2.97e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg03188948	chr7:1209495	NA	0.57	6.14	0.32	2.37e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7572644	0.766	rs13004096	chr2:28087205	C/T	cg27432699	chr2:27873401	GPN1	0.52	6.47	0.33	3.5e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.48	0.5	2.17e-22	Schizophrenia;
LUSC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg15145296	chr3:125709740	NA	-0.59	-6.67	-0.34	1.06e-10	Blood pressure (smoking interaction);
LUSC	trans	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.1	-0.32	2.97e-9	Depression;
LUSC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.56	0.5	1.09e-22	Hip circumference adjusted for BMI;
LUSC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	1.21	16.25	0.66	3.52e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs4746818	0.793	rs2008541	chr10:70860599	A/G	cg11621586	chr10:70884670	VPS26A	0.9	8.95	0.44	2.45e-17	Left atrial antero-posterior diameter;
LUSC	cis	rs524023	1.000	rs3825018	chr11:64358809	G/A	cg19131476	chr11:64387923	NRXN2	-0.38	-10.1	-0.48	4.3e-21	Urate levels in obese individuals;
LUSC	trans	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg14458575	chr2:238380390	NA	0.87	15.13	0.64	9.15e-40	Prostate cancer;
LUSC	cis	rs75229567	0.717	rs74527680	chr12:70235392	A/G	cg10114359	chr12:70132523	RAB3IP	1.34	11.2	0.52	6.25e-25	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16116313	chr12:122255002	SETD1B	0.49	6.14	0.32	2.41e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.72	-9.91	-0.48	1.9e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.9	0.35	2.56e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.21	-0.49	1.83e-21	Gut microbiome composition (summer);
LUSC	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-7.91	-0.4	3.74e-14	Reticulocyte count;
LUSC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.45	-7.32	-0.37	1.83e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	0.92	15.35	0.64	1.35e-40	Breast cancer;
LUSC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg09034736	chr1:150693464	HORMAD1	-0.4	-5.73	-0.3	2.29e-8	Tonsillectomy;
LUSC	cis	rs7119	0.604	rs2667783	chr15:77862529	G/A	cg27398640	chr15:77910606	LINGO1	0.36	7.96	0.4	2.63e-14	Type 2 diabetes;
LUSC	cis	rs17095355	1.000	rs55683820	chr10:111665376	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.64	-7.47	-0.38	6.94e-13	Biliary atresia;
LUSC	cis	rs7074356	0.831	rs12764048	chr10:82148963	A/G	cg05935833	chr10:81318306	SFTPA2	-0.43	-5.67	-0.3	3.14e-8	Borderline personality disorder;
LUSC	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg05717871	chr11:638507	DRD4	-0.34	-5.9	-0.31	8.74e-9	Systemic lupus erythematosus;
LUSC	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.46	6.64	0.34	1.27e-10	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs362296	0.698	rs362266	chr4:3259632	C/G	cg14583973	chr4:3374767	RGS12	-0.3	-5.87	-0.31	1.05e-8	Parental longevity (mother's age at death);
LUSC	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg27147174	chr7:100797783	AP1S1	-0.65	-10.59	-0.5	8.47e-23	Life satisfaction;
LUSC	cis	rs1044826	1.000	rs9289576	chr3:139200326	G/A	cg00490450	chr3:139108681	COPB2	0.51	6.74	0.35	6.96e-11	Obesity-related traits;
LUSC	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	1.1	14.45	0.62	4.26e-37	Mitochondrial DNA levels;
LUSC	trans	rs6601327	0.606	rs4841204	chr8:9583407	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.49	-0.33	3.09e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.36	0.53	1.66e-25	Menopause (age at onset);
LUSC	cis	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg21775007	chr8:11205619	TDH	0.46	6.55	0.34	2.18e-10	Myopia (pathological);
LUSC	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg08807101	chr21:30365312	RNF160	-0.5	-6.75	-0.35	6.38e-11	Cognitive test performance;
LUSC	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg04374321	chr14:90722782	PSMC1	0.7	11.12	0.52	1.19e-24	Mortality in heart failure;
LUSC	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	1.01	13.91	0.61	4.95e-35	Exhaled nitric oxide levels;
LUSC	cis	rs400736	0.729	rs1546846	chr1:8004259	C/T	cg25007680	chr1:8021821	PARK7	-0.49	-7.22	-0.37	3.58e-12	Response to antidepressants and depression;
LUSC	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg08345082	chr10:99160200	RRP12	-0.36	-7.28	-0.37	2.45e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg04850211	chr1:228464232	OBSCN	0.39	7.31	0.37	2.02e-12	Diastolic blood pressure;
LUSC	trans	rs656319	0.580	rs13272793	chr8:10002027	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.34	-0.33	7.38e-10	Myopia (pathological);
LUSC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg08132940	chr7:1081526	C7orf50	-0.52	-6.07	-0.32	3.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	1.04	19.97	0.74	6.31e-59	Menopause (age at onset);
LUSC	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg19682013	chr15:45996608	NA	0.39	5.94	0.31	7.33e-9	Waist circumference;Weight;
LUSC	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	1.02	13.43	0.59	3.55e-33	Uric acid levels;
LUSC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg27427491	chr17:78079615	GAA	-0.36	-6.94	-0.36	2.02e-11	Yeast infection;
LUSC	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg16576597	chr16:28551801	NUPR1	0.29	5.75	0.3	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg05784532	chr1:230284198	GALNT2	-0.6	-8.48	-0.42	7.46e-16	Coronary artery disease;
LUSC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.58	-8.86	-0.44	4.84e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg27589368	chr17:43923255	LOC100128977;IMP5	-0.27	-5.9	-0.31	9.02e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg00102166	chr1:43425337	SLC2A1	-0.53	-7.68	-0.39	1.73e-13	Monocyte count;
LUSC	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.77	12.06	0.55	4.9e-28	Heart rate;
LUSC	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.74	11.57	0.54	2.83e-26	Menopause (age at onset);
LUSC	trans	rs61931739	0.649	rs815044	chr12:33722209	A/G	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs7589342	0.895	rs11901644	chr2:106432113	T/G	cg16077055	chr2:106428750	NCK2	0.39	7.3	0.37	2.06e-12	Addiction;
LUSC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg03563238	chr19:33554763	RHPN2	-0.33	-5.76	-0.3	1.9e-8	Colorectal cancer;
LUSC	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-15.62	-0.65	1.1e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg09998033	chr7:158218633	PTPRN2	-0.52	-8.5	-0.42	6.41e-16	Obesity-related traits;
LUSC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	22.39	0.77	1.82e-68	Height;
LUSC	cis	rs13040088	0.935	rs3787513	chr20:61573736	G/A	cg23096297	chr20:61557774	DIDO1	0.81	10.59	0.5	8.83e-23	Menopause (age at onset);
LUSC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg02269571	chr22:50332266	NA	0.59	8.74	0.43	1.17e-16	Schizophrenia;
LUSC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg05802129	chr4:122689817	NA	-0.36	-6.44	-0.33	4.17e-10	Type 2 diabetes;
LUSC	cis	rs7212590	0.748	rs8074176	chr17:57861995	G/A	cg10252138	chr17:58120427	NA	-0.72	-6.96	-0.36	1.76e-11	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.15	-0.32	2.19e-9	Depression;
LUSC	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.86	-12.9	-0.58	3.55e-31	Asthma;
LUSC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg09359103	chr1:154839909	KCNN3	0.68	15.83	0.65	1.75e-42	Prostate cancer;
LUSC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg03647239	chr10:116582469	FAM160B1	0.44	7.01	0.36	1.32e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.12	-0.45	7.26e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg05775895	chr3:12838266	CAND2	0.61	10.8	0.51	1.63e-23	QRS complex (12-leadsum);
LUSC	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg00191853	chr8:101177733	SPAG1	-0.38	-6.22	-0.32	1.48e-9	Atrioventricular conduction;
LUSC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	11.19	0.52	6.83e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg05373962	chr22:49881684	NA	-0.39	-8.64	-0.43	2.4e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.87	0.31	1.06e-8	Life satisfaction;
LUSC	cis	rs2070433	1.000	rs2839302	chr21:47952364	G/A	cg12379764	chr21:47803548	PCNT	0.79	10.25	0.49	1.26e-21	Lymphocyte counts;
LUSC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.71	13.83	0.6	1.03e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9464760	0.527	rs9476759	chr6:15158709	T/C	cg15799072	chr6:15248335	JARID2	0.52	5.86	0.31	1.08e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10992471	0.528	rs7860786	chr9:95245473	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.35	-6.13	-0.32	2.43e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg11812906	chr14:75593930	NEK9	0.66	11.33	0.53	2.04e-25	Height;
LUSC	cis	rs10193935	0.792	rs13423729	chr2:42492874	C/T	cg27598129	chr2:42591480	NA	-0.58	-7.94	-0.4	3.05e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6429082	0.846	rs2270538	chr1:235602404	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.62	-8.62	-0.43	2.68e-16	Adiposity;
LUSC	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.38	-0.42	1.49e-15	Response to antipsychotic treatment;
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.42	8.49e-16	Lymphocyte counts;
LUSC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.74	-0.35	6.85e-11	Crohn's disease;
LUSC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.58	10.7	0.51	3.69e-23	Bone mineral density;
LUSC	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-8.27	-0.41	3.12e-15	Schizophrenia;
LUSC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.8	0.3	1.5e-8	Menopause (age at onset);
LUSC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	8.18	0.41	5.88e-15	Mean platelet volume;
LUSC	trans	rs9929218	0.911	rs1075959	chr16:68832750	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.2	-0.52	6.2e-25	Colorectal cancer;
LUSC	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg00579200	chr11:133705235	NA	-0.39	-5.97	-0.31	6.21e-9	Childhood ear infection;
LUSC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg11752832	chr7:134001865	SLC35B4	0.53	7.97	0.4	2.48e-14	Mean platelet volume;
LUSC	cis	rs500891	0.574	rs12524862	chr6:84146655	C/T	cg08257003	chr6:84140564	ME1	0.38	9.14	0.45	6.37e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs2348418	0.966	rs7136139	chr12:28684020	T/A	cg13890972	chr12:28721907	NA	-0.34	-5.83	-0.3	1.28e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs1007190	0.764	rs4793153	chr17:42873792	T/C	cg15406952	chr17:42872593	NA	-0.59	-6.13	-0.32	2.45e-9	DNA methylation (variation);
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	0.95	19.76	0.73	4.32e-58	Menarche (age at onset);
LUSC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg22166914	chr1:53195759	ZYG11B	-0.71	-12.32	-0.56	5.33e-29	Monocyte count;
LUSC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg04287289	chr16:89883240	FANCA	0.8	14.3	0.62	1.56e-36	Vitiligo;
LUSC	cis	rs10992471	0.603	rs10118939	chr9:95293641	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-6.97	-0.36	1.72e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg23711669	chr6:146136114	FBXO30	0.7	12.24	0.56	1.03e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg20701182	chr2:24300061	SF3B14	0.74	7.28	0.37	2.4e-12	Lymphocyte counts;
LUSC	cis	rs6700896	0.931	rs10443261	chr1:66129121	T/C	cg04111102	chr1:66153794	NA	0.33	7.26	0.37	2.81e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg15145296	chr3:125709740	NA	-0.58	-6.56	-0.34	2.01e-10	Blood pressure (smoking interaction);
LUSC	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg20991723	chr1:152506922	NA	0.53	10.03	0.48	7.05e-21	Hair morphology;
LUSC	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.39	-0.42	1.36e-15	Total cholesterol levels;
LUSC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg23719950	chr11:63933701	MACROD1	-0.62	-7.99	-0.4	2.15e-14	Mean platelet volume;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03235119	chr5:176449645	ZNF346	-0.37	-6.53	-0.34	2.42e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg24375607	chr4:120327624	NA	-0.47	-7.25	-0.37	2.96e-12	Diastolic blood pressure;
LUSC	cis	rs11642862	0.710	rs17849880	chr16:30999198	C/T	cg02466173	chr16:30829666	NA	-0.61	-6.47	-0.33	3.42e-10	Tonsillectomy;
LUSC	cis	rs2455601	0.638	rs2742485	chr11:8986787	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-6.93	-0.35	2.23e-11	Schizophrenia;
LUSC	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg26384229	chr12:38710491	ALG10B	0.89	14.35	0.62	9.97e-37	Bladder cancer;
LUSC	cis	rs981844	1.000	rs2405430	chr4:154658391	A/G	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg26102564	chr10:131424627	MGMT	0.45	7.03	0.36	1.2e-11	Response to temozolomide;
LUSC	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	13.27	0.59	1.39e-32	Post bronchodilator FEV1;
LUSC	cis	rs9640161	0.783	rs2021871	chr7:150071156	T/C	cg10018233	chr7:150070692	REPIN1	0.45	9.06	0.44	1.13e-17	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.59	9.72	0.47	8.16e-20	Aortic root size;
LUSC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.99	-0.4	2.18e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11642862	1.000	rs11645175	chr16:30803299	C/T	cg02466173	chr16:30829666	NA	-0.69	-7.33	-0.37	1.8e-12	Tonsillectomy;
LUSC	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg07080220	chr10:102295463	HIF1AN	0.58	7.61	0.38	2.74e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.6	-5.7	-0.3	2.7e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18404041	chr3:52824283	ITIH1	-0.56	-10.88	-0.51	8.32e-24	Electroencephalogram traits;
LUSC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg05738196	chr6:26577821	NA	-0.52	-8.28	-0.41	2.94e-15	Schizophrenia;
LUSC	cis	rs113835537	0.529	rs11227503	chr11:66275242	G/C	cg24851651	chr11:66362959	CCS	0.54	8.03	0.4	1.66e-14	Airway imaging phenotypes;
LUSC	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.67	0.3	3.06e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg02466173	chr16:30829666	NA	-0.68	-16.27	-0.66	3.13e-44	Dementia with Lewy bodies;
LUSC	cis	rs896543	0.702	rs12692190	chr2:237496190	C/T	cg25295825	chr2:237489920	CXCR7	0.5	6.12	0.32	2.56e-9	Alcohol dependence (age at onset);
LUSC	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg25251562	chr2:3704773	ALLC	-0.48	-7.39	-0.38	1.15e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs73200209	0.744	rs17498480	chr12:116558916	A/T	cg01776926	chr12:116560359	MED13L	-0.47	-5.75	-0.3	2.04e-8	Total body bone mineral density;
LUSC	cis	rs17014483	0.749	rs2860422	chr4:89644931	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.66	5.75	0.3	1.98e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg18230493	chr5:56204884	C5orf35	-0.68	-10.24	-0.49	1.44e-21	Coronary artery disease;
LUSC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg22903657	chr4:1355424	KIAA1530	0.37	6.27	0.32	1.14e-9	Obesity-related traits;
LUSC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7582720	1.000	rs72932572	chr2:203859391	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	8.37	0.42	1.63e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg25214090	chr10:38739885	LOC399744	-0.53	-7.53	-0.38	4.78e-13	Corneal astigmatism;
LUSC	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.95	-0.31	6.74e-9	Neuroticism;
LUSC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.66	-0.43	2.08e-16	Total cholesterol levels;
LUSC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	13.24	0.59	1.94e-32	Monocyte percentage of white cells;
LUSC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.42	0.38	9.54e-13	Alzheimer's disease;
LUSC	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg06636001	chr8:8085503	FLJ10661	0.53	7.93	0.4	3.25e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08219700	chr8:58056026	NA	0.66	8.37	0.42	1.58e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.95	-0.31	6.78e-9	Type 2 diabetes;
LUSC	cis	rs2274273	0.806	rs7146752	chr14:55738907	A/G	cg04306507	chr14:55594613	LGALS3	0.57	13.34	0.59	7.9e-33	Protein biomarker;
LUSC	cis	rs8077577	0.836	rs58441148	chr17:18106498	T/A	cg16794390	chr17:18148240	FLII	0.41	5.88	0.31	9.85e-9	Obesity-related traits;
LUSC	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg24642439	chr20:33292090	TP53INP2	-0.5	-7.58	-0.38	3.4e-13	Coronary artery disease;
LUSC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg13531842	chr10:38383804	ZNF37A	-0.45	-6.98	-0.36	1.57e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg09479241	chr17:27052676	TLCD1	0.45	6.12	0.32	2.66e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs73206853	0.841	rs16940933	chr12:111102574	C/A	cg12870014	chr12:110450643	ANKRD13A	0.71	7.16	0.36	5.01e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.55	7.71	0.39	1.43e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9400467	0.528	rs457492	chr6:111641850	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.36	-0.33	6.48e-10	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs12681287	0.752	rs67615966	chr8:87255203	C/A	cg27223183	chr8:87520930	FAM82B	-0.45	-5.72	-0.3	2.33e-8	Caudate activity during reward;
LUSC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.04	21.37	0.76	1.82e-64	Cognitive function;
LUSC	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg24631222	chr15:78858424	CHRNA5	0.69	9.14	0.45	6.07e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.71	-9.96	-0.48	1.21e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs7538876	1.000	rs942457	chr1:17739586	G/A	cg07965774	chr1:17746286	RCC2	0.31	5.76	0.3	1.96e-8	Basal cell carcinoma;
LUSC	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg24375607	chr4:120327624	NA	-0.76	-11.09	-0.52	1.5e-24	Corneal astigmatism;
LUSC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg18512352	chr11:47633146	NA	-0.48	-9.77	-0.47	5.36e-20	Subjective well-being;
LUSC	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg23625390	chr15:77176239	SCAPER	-0.64	-9.66	-0.47	1.24e-19	Blood metabolite levels;
LUSC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	11.24	0.52	4.57e-25	Alzheimer's disease;
LUSC	cis	rs9581857	0.547	rs4612914	chr13:28049128	A/G	cg22138327	chr13:27999177	GTF3A	0.75	8.21	0.41	4.91e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg07741184	chr6:167504864	NA	0.49	8.62	0.43	2.75e-16	Crohn's disease;
LUSC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.83	13.06	0.58	9.2e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg06636001	chr8:8085503	FLJ10661	0.67	10.28	0.49	9.9700000000000009e-22	Neuroticism;
LUSC	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.43	-6.55	-0.34	2.21e-10	Schizophrenia;
LUSC	trans	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg18187862	chr3:45730750	SACM1L	0.55	7.05	0.36	1.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg13319975	chr6:146136371	FBXO30	-0.47	-7.08	-0.36	8.5e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg12863693	chr15:85201151	NMB	0.37	7.72	0.39	1.34e-13	Schizophrenia;
LUSC	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg14668632	chr7:2872130	GNA12	-0.46	-6.54	-0.34	2.29e-10	Height;
LUSC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg04844267	chr4:1394941	NA	0.32	6.31	0.33	9.05e-10	Obesity-related traits;
LUSC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg20887711	chr4:1340912	KIAA1530	0.44	6.64	0.34	1.28e-10	Obesity-related traits;
LUSC	cis	rs9309473	0.632	rs6546825	chr2:73592253	G/C	cg20560298	chr2:73613845	ALMS1	-0.54	-7.98	-0.4	2.33e-14	Metabolite levels;
LUSC	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg16386425	chr10:429943	DIP2C	0.39	5.73	0.3	2.26e-8	Psychosis in Alzheimer's disease;
LUSC	trans	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg13565492	chr6:43139072	SRF	-0.62	-6.56	-0.34	2.09e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12220238	1.000	rs10824103	chr10:75949415	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.88	0.35	2.93e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs9650315	0.929	rs5027176	chr8:57179749	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	6.82	0.35	4.17e-11	Height;
LUSC	cis	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg21775007	chr8:11205619	TDH	-0.49	-7.49	-0.38	6.03e-13	Systolic blood pressure;
LUSC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00684032	chr4:1343700	KIAA1530	0.37	6.51	0.34	2.82e-10	Obesity-related traits;
LUSC	cis	rs2249625	0.545	rs60835713	chr6:72880349	T/C	cg18830697	chr6:72922368	RIMS1	0.37	7.42	0.38	9.84e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-0.57	-8.08	-0.4	1.18e-14	IgG glycosylation;
LUSC	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg05527609	chr1:210001259	C1orf107	0.68	9.69	0.47	1.02e-19	Orofacial clefts;
LUSC	cis	rs859767	0.603	rs842359	chr2:135345568	G/C	cg12500956	chr2:135428796	TMEM163	0.26	6.09	0.32	3.09e-9	Neuroticism;
LUSC	cis	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg20368463	chr18:77673604	PQLC1	-0.6	-6.06	-0.31	3.74e-9	Opioid sensitivity;
LUSC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg18904891	chr8:8559673	CLDN23	-0.44	-6.7	-0.34	8.93e-11	Mood instability;
LUSC	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg01557791	chr16:72042693	DHODH	-0.46	-6.84	-0.35	3.81e-11	Fibrinogen levels;
LUSC	trans	rs13011075	0.919	rs17601687	chr2:68615899	A/G	cg14221825	chr19:46271408	SIX5	-0.46	-6.59	-0.34	1.75e-10	Mean corpuscular volume;
LUSC	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.39	-5.79	-0.3	1.58e-8	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.62	0.62	8.89e-38	Platelet count;
LUSC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg08873628	chr1:175162347	KIAA0040	0.39	5.75	0.3	2.06e-8	Alcohol dependence;
LUSC	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg10255544	chr17:80519551	FOXK2	0.36	5.8	0.3	1.56e-8	Reticulocyte fraction of red cells;
LUSC	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg08975724	chr8:8085496	FLJ10661	0.42	6.01	0.31	4.91e-9	Neuroticism;
LUSC	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg13010199	chr12:38710504	ALG10B	0.53	8.25	0.41	3.76e-15	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg08219700	chr8:58056026	NA	0.46	5.88	0.31	1e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg09509183	chr1:209979624	IRF6	0.44	5.95	0.31	6.69e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg27494647	chr7:150038898	RARRES2	0.47	7.19	0.37	4.35e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2274273	0.638	rs58269011	chr14:55684388	A/G	cg04306507	chr14:55594613	LGALS3	0.48	9.55	0.46	2.91e-19	Protein biomarker;
LUSC	trans	rs2262909	0.745	rs1989120	chr19:22205528	T/C	cg05197062	chr11:11642011	GALNTL4	-0.5	-6.94	-0.36	2.08e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.49	0.75	5.16e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-6.05	-0.31	3.87e-9	Coronary artery disease;
LUSC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18404041	chr3:52824283	ITIH1	-0.62	-12.32	-0.56	5.06e-29	Bipolar disorder;
LUSC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg00074818	chr8:8560427	CLDN23	0.59	9.72	0.47	8.05e-20	Obesity-related traits;
LUSC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18099408	chr3:52552593	STAB1	0.4	6.63	0.34	1.38e-10	Bipolar disorder;
LUSC	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg26102564	chr10:131424627	MGMT	0.45	7.15	0.36	5.61e-12	Response to temozolomide;
LUSC	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg22705602	chr4:152727874	NA	-0.32	-6.47	-0.33	3.41e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6580649	0.941	rs4760677	chr12:48449163	C/T	cg24011408	chr12:48396354	COL2A1	-0.46	-6.17	-0.32	1.95e-9	Lung cancer;
LUSC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg13319975	chr6:146136371	FBXO30	0.48	7.21	0.37	3.66e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs557514	1.000	rs557514	chr1:182404684	A/G	cg26135716	chr1:182360902	GLUL	0.5	7.31	0.37	2e-12	Common carotid intima-media thickness;
LUSC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.09	-0.4	1.12e-14	Type 2 diabetes;
LUSC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.44	6.45	0.33	3.9e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg09509183	chr1:209979624	IRF6	0.49	5.75	0.3	2.05e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg24450063	chr1:156163899	SLC25A44	1.15	23.13	0.78	2.56e-71	Testicular germ cell tumor;
LUSC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.63	7.85	0.39	5.6e-14	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	12.35	0.56	4.15e-29	Electrocardiographic conduction measures;
LUSC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg09640425	chr7:158790006	NA	-0.53	-8.56	-0.42	4.21e-16	Facial morphology (factor 20);
LUSC	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg21775007	chr8:11205619	TDH	-0.45	-6.47	-0.33	3.44e-10	Myopia (pathological);
LUSC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	5.8	0.3	1.52e-8	Breast cancer;
LUSC	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.88	0.35	3.04e-11	Rheumatoid arthritis;
LUSC	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg14893161	chr1:205819251	PM20D1	-0.47	-6.39	-0.33	5.57e-10	Menarche (age at onset);
LUSC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	12.93	0.58	2.65e-31	Platelet count;
LUSC	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg02023728	chr11:77925099	USP35	0.54	7.71	0.39	1.41e-13	Testicular germ cell tumor;
LUSC	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg25817165	chr18:72167213	CNDP2	-0.72	-8.39	-0.42	1.37e-15	Refractive error;
LUSC	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg23752985	chr2:85803571	VAMP8	0.33	6.36	0.33	6.62e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10208940	0.920	rs35002937	chr2:68753240	T/A	cg12452813	chr2:68675892	NA	0.56	5.81	0.3	1.45e-8	Urate levels in lean individuals;
LUSC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	6.54	0.34	2.27e-10	Tonsillectomy;
LUSC	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg10840412	chr1:235813424	GNG4	0.55	7.14	0.36	5.85e-12	Neuroticism;
LUSC	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06360820	chr2:242988706	NA	-0.72	-8.83	-0.43	6.1e-17	Obesity-related traits;
LUSC	cis	rs7707921	0.767	rs862242	chr5:81587566	C/T	cg15871215	chr5:81402204	ATG10	-0.45	-7.04	-0.36	1.1e-11	Breast cancer;
LUSC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.78	0.35	5.46e-11	Tonsillectomy;
LUSC	cis	rs6967385	0.560	rs10254029	chr7:12343148	G/C	cg06484146	chr7:12443880	VWDE	0.45	6.71	0.34	8.1e-11	Response to taxane treatment (placlitaxel);
LUSC	cis	rs11958404	1.000	rs72816538	chr5:157414303	A/G	cg05962755	chr5:157440814	NA	0.49	6.13	0.32	2.44e-9	IgG glycosylation;
LUSC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg17211192	chr8:82754475	SNX16	-0.58	-8.19	-0.41	5.42e-15	Diastolic blood pressure;
LUSC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.78	11.36	0.53	1.73e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-9.53	-0.46	3.33e-19	Bipolar disorder;
LUSC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21862992	chr11:68658383	NA	0.51	7.99	0.4	2.25e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	1.09	15.78	0.65	2.59e-42	Uric acid levels;
LUSC	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg03585969	chr10:35415529	CREM	0.62	9.23	0.45	3.12e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.8	0.39	7.92e-14	Iron status biomarkers;
LUSC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	0.64	13.57	0.6	1e-33	Prudent dietary pattern;
LUSC	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02176678	chr2:219576539	TTLL4	-0.67	-13.08	-0.58	7.21e-32	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg04374321	chr14:90722782	PSMC1	0.69	10.65	0.5	5.28e-23	Mortality in heart failure;
LUSC	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg22431228	chr1:16359049	CLCNKA	0.4	7.39	0.37	1.18e-12	Dilated cardiomyopathy;
LUSC	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg06092702	chr1:163392909	NA	-0.46	-7.63	-0.39	2.47e-13	Motion sickness;
LUSC	cis	rs17255340	0.539	rs1144185	chr6:84012619	A/G	cg08257003	chr6:84140564	ME1	0.32	7.59	0.38	3.28e-13	Platelet-derived growth factor BB levels;
LUSC	trans	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg18187862	chr3:45730750	SACM1L	0.56	7.23	0.37	3.34e-12	Primary sclerosing cholangitis;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21871407	chr14:50159882	KLHDC1	-0.42	-6.2	-0.32	1.71e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1034435	0.547	rs5768686	chr22:48899214	G/A	cg05992904	chr22:48892994	FAM19A5	-0.37	-6.58	-0.34	1.82e-10	Late-onset Alzheimer's disease;
LUSC	cis	rs193541	0.632	rs1903260	chr5:122135188	T/C	cg19077854	chr5:122220652	SNX24	0.37	7.56	0.38	3.94e-13	Glucose homeostasis traits;
LUSC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.62	-12.99	-0.58	1.64e-31	Monocyte percentage of white cells;
LUSC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.26	-0.41	3.41e-15	Bone mineral density;
LUSC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26314531	chr2:26401878	FAM59B	-0.69	-9.5	-0.46	4.2e-19	Gut microbiome composition (summer);
LUSC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.68	-9.95	-0.48	1.3e-20	Migraine;
LUSC	cis	rs56804039	1.000	rs56804039	chr8:8381029	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.27	-0.32	1.12e-9	Cervical cancer;
LUSC	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg10911889	chr6:126070802	HEY2	0.41	6.29	0.33	9.69e-10	Brugada syndrome;
LUSC	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg24313572	chr1:56050060	NA	-0.29	-6.04	-0.31	4.2e-9	Morning vs. evening chronotype;
LUSC	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg03060546	chr3:49711283	APEH	-0.62	-7.12	-0.36	6.76e-12	Menarche (age at onset);
LUSC	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.61e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg17366294	chr4:99064904	C4orf37	0.63	11.29	0.53	2.99e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg06917634	chr15:78832804	PSMA4	0.49	5.99	0.31	5.35e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.44	-0.33	4.28e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7615316	0.751	rs6772400	chr3:142152477	T/A	cg16271453	chr3:142027066	XRN1	-0.43	-7.42	-0.38	9.9e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2425143	1.000	rs6060524	chr20:34221155	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.12	-0.32	2.56e-9	Blood protein levels;
LUSC	cis	rs7804356	1.000	rs3801832	chr7:26852280	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-6.08	-0.32	3.23e-9	Type 1 diabetes;
LUSC	cis	rs4654899	0.897	rs10916859	chr1:21087956	A/G	cg01072550	chr1:21505969	NA	-0.45	-6.7	-0.34	9.04e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9341835	0.679	rs9344137	chr6:64156964	A/T	cg03326410	chr6:64151739	NA	-0.37	-5.98	-0.31	5.64e-9	Schizophrenia;
LUSC	cis	rs11585357	0.843	rs72633805	chr1:17617471	A/T	cg08277548	chr1:17600880	PADI3	-0.64	-6.62	-0.34	1.42e-10	Hair shape;
LUSC	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02176678	chr2:219576539	TTLL4	0.56	10.41	0.49	3.65e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg23625390	chr15:77176239	SCAPER	-0.61	-9.56	-0.46	2.6e-19	Blood metabolite levels;
LUSC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg06238570	chr21:40685208	BRWD1	0.48	7.54	0.38	4.59e-13	Cognitive function;
LUSC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg02951883	chr7:2050386	MAD1L1	-0.48	-8.56	-0.42	4.26e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg25801113	chr15:45476975	SHF	0.34	7.03	0.36	1.17e-11	Uric acid levels;
LUSC	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg12473912	chr3:136751656	NA	0.39	6.87	0.35	3.24e-11	Neuroticism;
LUSC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg11812906	chr14:75593930	NEK9	0.67	11.64	0.54	1.61e-26	Height;
LUSC	cis	rs4704187	0.687	rs7700965	chr5:74356857	T/C	cg03227963	chr5:74354835	NA	0.32	6.96	0.36	1.77e-11	Response to amphetamines;
LUSC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.92e-10	Life satisfaction;
LUSC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg20283391	chr11:68216788	NA	0.54	8.02	0.4	1.82e-14	Total body bone mineral density;
LUSC	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.64	-0.34	1.3e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg21573476	chr21:45109991	RRP1B	-0.43	-6.94	-0.36	2.04e-11	Mean corpuscular volume;
LUSC	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg06627628	chr2:24431161	ITSN2	-0.59	-7.24	-0.37	3.06e-12	Lymphocyte counts;
LUSC	cis	rs13315871	1.000	rs12330157	chr3:58364562	C/T	cg12435725	chr3:58293450	RPP14	-0.72	-7.16	-0.36	5.13e-12	Cholesterol, total;
LUSC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25072359	chr17:41440525	NA	0.65	9.22	0.45	3.32e-18	Menopause (age at onset);
LUSC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-8.35	-0.42	1.88e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg07741184	chr6:167504864	NA	-0.36	-6.59	-0.34	1.73e-10	Crohn's disease;
LUSC	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-9.05	-0.44	1.25e-17	Neuroticism;
LUSC	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.82	-0.39	7.17e-14	Blood metabolite levels;
LUSC	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg14631276	chr8:145163102	KIAA1875	-0.81	-7.18	-0.37	4.68e-12	Blood metabolite levels;
LUSC	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.93	0.4	3.39e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs10203711	1.000	rs10203711	chr2:239553368	C/T	cg14580085	chr2:239553406	NA	0.42	6.96	0.36	1.83e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg03806693	chr22:41940476	POLR3H	-0.66	-9.98	-0.48	1.07e-20	Vitiligo;
LUSC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.7	12.65	0.57	3.19e-30	Aortic root size;
LUSC	cis	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg05084668	chr3:125655381	ALG1L	-0.46	-5.91	-0.31	8.44e-9	Blood pressure (smoking interaction);
LUSC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.82	-14.52	-0.62	2.23e-37	Cognitive function;
LUSC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.01	-0.36	1.34e-11	Lung cancer;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg16606067	chr5:178977123	RUFY1	0.36	5.99	0.31	5.38e-9	Schizophrenia;
LUSC	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg19717773	chr7:2847554	GNA12	0.37	6.68	0.34	1.01e-10	Height;
LUSC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg19812747	chr11:111475976	SIK2	-0.57	-8.47	-0.42	7.76e-16	Primary sclerosing cholangitis;
LUSC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.53	-0.5	1.41e-22	Chronic sinus infection;
LUSC	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg08807101	chr21:30365312	RNF160	0.63	10.34	0.49	6.26e-22	Pancreatic cancer;
LUSC	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg00898013	chr13:113819073	PROZ	-0.55	-7.86	-0.39	5.42e-14	Platelet distribution width;
LUSC	cis	rs713477	0.967	rs12887653	chr14:55911030	T/A	cg13175173	chr14:55914753	NA	-0.32	-6.7	-0.34	8.86e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs1113500	0.799	rs1777459	chr1:108584999	G/C	cg06207961	chr1:108661230	NA	-0.37	-6.73	-0.35	7.57e-11	Growth-regulated protein alpha levels;
LUSC	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg12560992	chr17:57184187	TRIM37	-0.75	-11.35	-0.53	1.86e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs6942756	0.955	rs9641849	chr7:128899238	C/T	cg02491457	chr7:128862824	NA	-0.52	-7.37	-0.37	1.38e-12	White matter hyperintensity burden;
LUSC	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.76	11.06	0.52	2.01e-24	Corneal astigmatism;
LUSC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.9	0.35	2.56e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4961252	0.545	rs1107258	chr8:142104071	G/A	cg09914555	chr8:142094789	NA	-0.47	-7.15	-0.36	5.62e-12	Isovolumetric relaxation time;Response to interferon beta therapy;
LUSC	cis	rs7572644	0.713	rs12617171	chr2:28038799	C/T	cg27432699	chr2:27873401	GPN1	0.57	6.96	0.36	1.82e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg21775007	chr8:11205619	TDH	-0.44	-5.97	-0.31	6.09e-9	Monocyte count;
LUSC	cis	rs2540226	0.844	rs1035139	chr2:39999315	G/A	cg23576258	chr2:39999331	THUMPD2	0.34	5.73	0.3	2.24e-8	Personality dimensions;
LUSC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.75	-9.66	-0.47	1.26e-19	Gut microbiome composition (summer);
LUSC	trans	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg25214090	chr10:38739885	LOC399744	0.5	7.2	0.37	4.1e-12	Corneal astigmatism;
LUSC	trans	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg26043149	chr18:55253948	FECH	0.48	7.2	0.37	4.05e-12	Bone mineral density;
LUSC	cis	rs829883	0.664	rs829874	chr12:98840615	G/A	cg25150519	chr12:98850993	NA	0.8	13.41	0.59	4.3e-33	Colorectal adenoma (advanced);
LUSC	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.61	-9.85	-0.47	2.99e-20	Dilated cardiomyopathy;
LUSC	cis	rs3814231	0.531	rs11196446	chr10:115471016	A/C	cg24846397	chr10:115438155	CASP7	-0.33	-5.75	-0.3	2.01e-8	Vitiligo;
LUSC	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg00757033	chr12:89920650	WDR51B	0.6	10.4	0.49	4.04e-22	NT-proBNP levels in acute coronary syndrome;
LUSC	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg08017634	chr8:144659831	NAPRT1	0.7	6.06	0.31	3.64e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.75	-11.09	-0.52	1.51e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg14019146	chr3:50243930	SLC38A3	-0.37	-8.19	-0.41	5.67e-15	Body mass index;
LUSC	cis	rs7903847	0.642	rs7078782	chr10:99168604	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-7.45	-0.38	7.84e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-9.02	-0.44	1.55e-17	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-0.82	-11.77	-0.54	5.26e-27	Response to hepatitis C treatment;
LUSC	cis	rs62458065	1.000	rs6462363	chr7:32464759	T/G	cg20159608	chr7:32802032	NA	-0.57	-7.01	-0.36	1.34e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs1215050	0.904	rs165246	chr4:98688541	C/T	cg05340658	chr4:99064831	C4orf37	0.41	6.5	0.34	2.86e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.58	0.38	3.37e-13	Schizophrenia;
LUSC	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21659725	chr3:3221576	CRBN	-0.52	-8.38	-0.42	1.5e-15	Body mass index;
LUSC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.76	0.51	2.21e-23	Bone mineral density;
LUSC	cis	rs2599510	0.783	rs2038534	chr2:32659489	G/A	cg02381751	chr2:32503542	YIPF4	0.4	5.82	0.3	1.41e-8	Interleukin-18 levels;
LUSC	cis	rs9398803	0.713	rs9375447	chr6:126874091	A/G	cg19875578	chr6:126661172	C6orf173	0.39	5.64	0.3	3.54e-8	Male-pattern baldness;
LUSC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13012494	chr21:47604986	C21orf56	0.42	6.3	0.33	9.41e-10	Testicular germ cell tumor;
LUSC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg16928487	chr17:17741425	SREBF1	-0.43	-8.55	-0.42	4.5e-16	Total body bone mineral density;
LUSC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02018176	chr4:1364513	KIAA1530	0.55	9.94	0.48	1.46e-20	Longevity;
LUSC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg11062466	chr8:58055876	NA	0.72	6.96	0.36	1.76e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg03983476	chr2:10830698	NOL10	-0.37	-5.71	-0.3	2.56e-8	Prostate cancer;
LUSC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.8	12.95	0.58	2.42e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs983392	0.709	rs4492839	chr11:59986399	T/A	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.1	-0.32	2.9e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs2392780	0.512	rs594076	chr8:128334966	G/C	cg10195415	chr17:73887371	TRIM65	0.41	6.49	0.33	3.12e-10	Breast cancer (early onset);
LUSC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg23172400	chr8:95962367	TP53INP1	-0.3	-6.11	-0.32	2.79e-9	Type 2 diabetes;
LUSC	cis	rs7560272	0.538	rs13000788	chr2:73918312	C/T	cg20560298	chr2:73613845	ALMS1	0.4	6.13	0.32	2.54e-9	Schizophrenia;
LUSC	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg09307838	chr4:120376055	NA	0.7	10.17	0.49	2.4e-21	Corneal astigmatism;
LUSC	cis	rs12137294	0.866	rs896318	chr1:205205784	A/G	cg00857998	chr1:205179979	DSTYK	0.4	5.77	0.3	1.77e-8	Red cell distribution width;
LUSC	cis	rs9612	0.950	rs7256472	chr19:44246970	C/T	cg08581076	chr19:44259116	C19orf61	0.53	6.57	0.34	1.88e-10	Exhaled nitric oxide output;
LUSC	cis	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg06521331	chr12:34319734	NA	-0.47	-7.67	-0.39	1.95e-13	Morning vs. evening chronotype;
LUSC	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg23229984	chr5:148520753	ABLIM3	0.42	6.25	0.32	1.27e-9	Breast cancer;
LUSC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.51	0.5	1.63e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs79149102	0.737	rs12593975	chr15:75189591	G/A	cg09165964	chr15:75287851	SCAMP5	-0.88	-6.55	-0.34	2.12e-10	Lung cancer;
LUSC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg04414720	chr1:150670196	GOLPH3L	0.53	8.62	0.43	2.81e-16	Tonsillectomy;
LUSC	cis	rs73206853	0.620	rs17682482	chr12:111154788	C/G	cg12870014	chr12:110450643	ANKRD13A	0.68	6.54	0.34	2.36e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs983392	0.709	rs2081547	chr11:59989430	C/T	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.11	-0.32	2.78e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6445797	0.632	rs7626378	chr3:56602885	A/T	cg13792233	chr3:56591045	CCDC66	0.4	5.67	0.3	3.09e-8	Gastritis;
LUSC	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg05340658	chr4:99064831	C4orf37	0.57	9.52	0.46	3.59e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.69	-10.52	-0.5	1.49e-22	Menopause (age at onset);
LUSC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.73	0.39	1.26e-13	Bipolar disorder;
LUSC	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg00982548	chr2:198649783	BOLL	-0.56	-7.17	-0.37	4.94e-12	Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg20607798	chr8:58055168	NA	0.55	5.83	0.3	1.28e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6005807	0.719	rs58049055	chr22:29007850	A/G	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg16898833	chr6:26189333	HIST1H4D	0.62	5.84	0.3	1.24e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs79387448	0.638	rs116055209	chr2:103032189	C/T	cg09003973	chr2:102972529	NA	0.98	10.18	0.49	2.25e-21	Gut microbiota (bacterial taxa);
LUSC	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg23719950	chr11:63933701	MACROD1	-0.6	-7.25	-0.37	2.89e-12	Mean platelet volume;
LUSC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-12.17	-0.55	1.82e-28	Personality dimensions;
LUSC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.53	0.38	4.76e-13	Colorectal cancer;
LUSC	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg05283184	chr6:79620031	NA	-0.57	-12.14	-0.55	2.43e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-0.75	-13.22	-0.59	2.21e-32	Gut microbiome composition (winter);
LUSC	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.71	-12.37	-0.56	3.46e-29	White blood cell count (basophil);
LUSC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.01	0.31	4.91e-9	Menopause (age at onset);
LUSC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06634786	chr22:41940651	POLR3H	-0.51	-5.98	-0.31	5.74e-9	Vitiligo;
LUSC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.48	0.38	6.44e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.78	-13.03	-0.58	1.17e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg03342759	chr3:160939853	NMD3	-0.41	-6.06	-0.31	3.59e-9	Morning vs. evening chronotype;
LUSC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg00049323	chr5:472564	LOC25845	-0.43	-6.71	-0.34	8.18e-11	Cystic fibrosis severity;
LUSC	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11905131	chr22:24372483	LOC391322	-0.49	-8.21	-0.41	4.73e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.08	0.55	4.01e-28	Prudent dietary pattern;
LUSC	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg13010199	chr12:38710504	ALG10B	0.52	7.71	0.39	1.5e-13	Morning vs. evening chronotype;
LUSC	cis	rs2625529	0.526	rs8040828	chr15:72492779	C/A	cg16672083	chr15:72433130	SENP8	0.47	7.98	0.4	2.36e-14	Red blood cell count;
LUSC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05025164	chr4:1340916	KIAA1530	0.51	7.63	0.39	2.56e-13	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21115516	chr19:9251333	ZNF317	0.49	7.19	0.37	4.35e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs17433780	0.857	rs12140979	chr1:89467242	C/G	cg09516651	chr1:89888402	LOC400759	0.49	8.05	0.4	1.42e-14	Carotid intima media thickness;
LUSC	cis	rs1577917	0.959	rs2816822	chr6:86658292	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.26	-0.32	1.18e-9	Response to antipsychotic treatment;
LUSC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.59	8.06	0.4	1.34e-14	High light scatter reticulocyte count;
LUSC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.74	-0.35	6.77e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg04362960	chr10:104952993	NT5C2	0.59	8.84	0.44	5.52e-17	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg17971929	chr21:40555470	PSMG1	-0.54	-7.76	-0.39	1.02e-13	Menarche (age at onset);
LUSC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg03233332	chr7:66118400	NA	0.41	6.05	0.31	3.95e-9	Aortic root size;
LUSC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.83	13.64	0.6	5.67e-34	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.14	0.49	3.12e-21	Mean corpuscular volume;
LUSC	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.57	9.9	0.48	1.97e-20	Birth weight;
LUSC	cis	rs9443189	0.570	rs485906	chr6:76300550	A/C	cg01950844	chr6:76311363	SENP6	0.7	6.98	0.36	1.63e-11	Prostate cancer;
LUSC	cis	rs7084921	0.608	rs4475856	chr10:101833339	G/T	cg02250046	chr10:101825185	CPN1	-0.35	-6.46	-0.33	3.66e-10	Bone mineral density;
LUSC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg13535736	chr9:111863775	C9orf5	-0.4	-6.66	-0.34	1.12e-10	Menarche (age at onset);
LUSC	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg04837898	chr3:45731254	SACM1L	-0.35	-5.82	-0.3	1.41e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg12386194	chr3:101231763	SENP7	0.64	8.96	0.44	2.36e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.81	-0.35	4.62e-11	Bipolar disorder;
LUSC	cis	rs11031096	0.655	rs12275634	chr11:4211754	T/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.73	-0.3	2.29e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs16854884	0.739	rs56196484	chr3:143786160	G/T	cg06585982	chr3:143692056	C3orf58	0.49	7.47	0.38	7.24e-13	Economic and political preferences (feminism/equality);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07005090	chr11:59522827	STX3	-0.4	-6.0	-0.31	5.14e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg15133208	chr4:90757351	SNCA	-0.32	-5.66	-0.3	3.26e-8	Dementia with Lewy bodies;
LUSC	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg01528321	chr10:82214614	TSPAN14	0.91	14.23	0.61	2.92e-36	Post bronchodilator FEV1;
LUSC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg10253484	chr15:75165896	SCAMP2	-0.5	-7.59	-0.38	3.15e-13	Breast cancer;
LUSC	cis	rs7241530	0.662	rs71362787	chr18:75907482	G/A	cg14642773	chr18:75888474	NA	0.38	5.72	0.3	2.41e-8	Educational attainment (years of education);
LUSC	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg13852791	chr20:30311386	BCL2L1	0.84	10.24	0.49	1.43e-21	Mean corpuscular hemoglobin;
LUSC	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.44	0.33	4.04e-10	Corneal astigmatism;
LUSC	trans	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg21775007	chr8:11205619	TDH	0.47	6.89	0.35	2.71e-11	Mood instability;
LUSC	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg03684893	chr10:554711	DIP2C	-0.38	-6.83	-0.35	4.09e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs1005224	0.782	rs34882722	chr14:76153896	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.63	-8.53	-0.42	5.35e-16	Large artery stroke;
LUSC	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg13206674	chr6:150067644	NUP43	0.43	6.56	0.34	2.01e-10	Testicular germ cell tumor;
LUSC	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg11019008	chr10:131425282	MGMT	0.39	5.84	0.3	1.26e-8	Response to temozolomide;
LUSC	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg03522245	chr20:25566470	NINL	0.36	5.8	0.3	1.54e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg17173187	chr15:85201210	NMB	0.37	6.4	0.33	5.31e-10	Schizophrenia;
LUSC	cis	rs9549260	0.755	rs12585875	chr13:41199531	A/G	cg21288729	chr13:41239152	FOXO1	0.6	9.21	0.45	3.75e-18	Red blood cell count;
LUSC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.92	0.4	3.59e-14	Colorectal cancer;
LUSC	cis	rs4722585	0.533	rs12334205	chr7:26202490	G/A	cg07876897	chr7:26191696	NFE2L3	0.46	6.75	0.35	6.4e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUSC	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg11057378	chr10:81107060	PPIF	0.34	5.95	0.31	6.77e-9	Height;
LUSC	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg11553311	chr5:66541588	NA	0.33	6.24	0.32	1.33e-9	Breast cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00408597	chr11:9685941	SWAP70	-0.51	-6.06	-0.31	3.58e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg26678313	chr12:57521867	LRP1	0.41	6.19	0.32	1.79e-9	Metabolite levels (Pyroglutamine);
LUSC	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg27411982	chr8:10470053	RP1L1	0.4	6.18	0.32	1.84e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg21427119	chr20:30132790	HM13	-0.46	-6.65	-0.34	1.2e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs11971779	0.680	rs11765421	chr7:139025094	G/A	cg23387468	chr7:139079360	LUC7L2	0.42	6.34	0.33	7.65e-10	Diisocyanate-induced asthma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19649853	chr19:39341302	HNRNPL	0.45	6.51	0.34	2.78e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg07701084	chr6:150067640	NUP43	0.54	8.02	0.4	1.82e-14	Lung cancer;
LUSC	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg22676075	chr6:135203613	NA	0.46	7.31	0.37	2.04e-12	Red blood cell count;
LUSC	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg24558204	chr6:135376177	HBS1L	0.67	10.47	0.5	2.32e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.82	-13.78	-0.6	1.69e-34	Aortic root size;
LUSC	cis	rs73198271	0.628	rs76079102	chr8:8591553	A/T	cg01851573	chr8:8652454	MFHAS1	0.46	5.82	0.3	1.36e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg18187862	chr3:45730750	SACM1L	0.5	6.39	0.33	5.48e-10	Primary sclerosing cholangitis;
LUSC	trans	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.03	-0.36	1.19e-11	Triglycerides;
LUSC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25072359	chr17:41440525	NA	0.66	9.42	0.46	7.64e-19	Menopause (age at onset);
LUSC	cis	rs55665837	1.000	rs12804549	chr11:14437758	A/T	cg05501817	chr11:14380813	RRAS2	-0.4	-6.48	-0.33	3.35e-10	Vitamin D levels;
LUSC	trans	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg01294253	chr9:136912663	BRD3	0.34	5.9	0.31	8.89e-9	Platelet distribution width;
LUSC	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg00579200	chr11:133705235	NA	-0.39	-6.01	-0.31	4.87e-9	Childhood ear infection;
LUSC	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg05738196	chr6:26577821	NA	0.81	15.7	0.65	5.64e-42	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13292458	chr18:13726614	RNMT;C18orf19	0.45	6.09	0.32	3.1e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg05585544	chr11:47624801	NA	-0.41	-7.2	-0.37	3.91e-12	Subjective well-being;
LUSC	cis	rs6845621	0.901	rs207294	chr4:18918758	C/A	cg12196642	chr4:18937545	NA	-0.33	-6.27	-0.32	1.1e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg09877947	chr5:131593287	PDLIM4	0.42	6.83	0.35	4.03e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21171335	chr12:122356390	WDR66	-0.58	-8.78	-0.43	8.58e-17	Mean corpuscular volume;
LUSC	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg22875332	chr1:76189707	ACADM	-0.42	-6.22	-0.32	1.48e-9	Daytime sleep phenotypes;
LUSC	cis	rs11958404	0.932	rs113494689	chr5:157428078	G/T	cg05962755	chr5:157440814	NA	0.51	6.09	0.32	3.16e-9	IgG glycosylation;
LUSC	cis	rs113835537	0.529	rs7950790	chr11:66258053	G/A	cg24851651	chr11:66362959	CCS	0.53	8.0	0.4	2.03e-14	Airway imaging phenotypes;
LUSC	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	0.87	14.41	0.62	6.28e-37	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg21724239	chr8:58056113	NA	0.77	8.43	0.42	1.07e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9359856	0.623	rs1179903	chr6:90321736	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.83	-10.1	-0.48	4.02e-21	Bipolar disorder;
LUSC	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg09582351	chr12:29534625	ERGIC2	-0.31	-6.49	-0.33	3.11e-10	QT interval;
LUSC	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.1	-0.32	2.87e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6120849	0.754	rs6088667	chr20:33566722	A/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.22	0.32	1.44e-9	Protein C levels;
LUSC	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg06552810	chr11:31128660	NA	-0.42	-7.4	-0.38	1.14e-12	Red blood cell count;
LUSC	cis	rs10754283	0.967	rs10801759	chr1:90113745	A/G	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg06219351	chr7:158114137	PTPRN2	-0.52	-9.51	-0.46	3.88e-19	Calcium levels;
LUSC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07677032	chr17:61819896	STRADA	0.54	9.04	0.44	1.33e-17	Prudent dietary pattern;
LUSC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.73	-11.01	-0.52	2.9e-24	Menarche (age at onset);
LUSC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.59	-9.55	-0.46	2.82e-19	IgG glycosylation;
LUSC	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg24110177	chr3:50126178	RBM5	0.41	6.51	0.34	2.68e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg20307385	chr11:47447363	PSMC3	-0.46	-5.94	-0.31	7.15e-9	Subjective well-being;
LUSC	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs911119	1.000	rs3787498	chr20:23616781	C/T	cg16589663	chr20:23618590	CST3	0.6	6.99	0.36	1.48e-11	Chronic kidney disease;
LUSC	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg09307838	chr4:120376055	NA	0.74	10.76	0.51	2.22e-23	Corneal astigmatism;
LUSC	cis	rs17154702	0.524	rs2664041	chr8:8593144	A/G	cg01851573	chr8:8652454	MFHAS1	0.4	6.22	0.32	1.52e-9	Neurocognitive impairment in HIV-1 infection (continuous);
LUSC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.59	9.16	0.45	5.3e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs4938330	0.739	rs11216266	chr11:116950150	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.4	-0.33	5.21e-10	Blood protein levels;
LUSC	cis	rs6964587	0.621	rs38799	chr7:92045139	C/T	cg17063962	chr7:91808500	NA	-0.46	-6.92	-0.35	2.33e-11	Breast cancer;
LUSC	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg21775007	chr8:11205619	TDH	0.54	7.92	0.4	3.57e-14	Neuroticism;
LUSC	cis	rs11031096	0.702	rs1015998	chr11:4150869	G/A	cg18678763	chr11:4115507	RRM1	0.38	5.77	0.3	1.83e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4478137	0.501	rs6811330	chr4:164230038	G/T	cg06758707	chr4:164254230	NPY1R	-0.5	-6.84	-0.35	3.88e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	1.04	19.44	0.73	7.67e-57	Menopause (age at onset);
LUSC	cis	rs983392	0.709	rs7939882	chr11:59973929	A/C	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.16	-0.32	2.05e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg21880101	chr17:80066754	CCDC57	-0.31	-5.91	-0.31	8.52e-9	Life satisfaction;
LUSC	cis	rs56399783	0.901	rs17132741	chr7:2868997	C/T	cg19731401	chr7:2775893	GNA12	-0.63	-9.29	-0.45	2.06e-18	Childhood ear infection;
LUSC	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.72	-13.34	-0.59	7.96e-33	Ulcerative colitis;
LUSC	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	cg06064525	chr11:970664	AP2A2	-0.3	-5.9	-0.31	8.76e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg09034736	chr1:150693464	HORMAD1	0.4	5.72	0.3	2.34e-8	Melanoma;
LUSC	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12826209	chr6:26865740	GUSBL1	0.74	9.08	0.44	9.64e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.94	-14.72	-0.63	3.87e-38	Body mass index;
LUSC	cis	rs68170813	0.641	rs74524528	chr7:107090979	G/A	cg02696742	chr7:106810147	HBP1	-0.66	-9.66	-0.47	1.21e-19	Coronary artery disease;
LUSC	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg26384229	chr12:38710491	ALG10B	0.61	8.94	0.44	2.64e-17	Morning vs. evening chronotype;
LUSC	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.89	-0.35	2.81e-11	Response to antipsychotic treatment;
LUSC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	18.1	0.7	1.66e-51	Chronic sinus infection;
LUSC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg05347473	chr6:146136440	FBXO30	-0.59	-10.25	-0.49	1.3e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg12011299	chr4:100065546	ADH4	-0.41	-6.54	-0.34	2.29e-10	Alcohol dependence;
LUSC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg10018233	chr7:150070692	REPIN1	0.34	6.08	0.32	3.23e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg25237894	chr2:233734115	C2orf82	0.35	6.5	0.33	3.01e-10	Coronary artery disease;
LUSC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17509989	chr5:176798049	RGS14	-0.67	-10.73	-0.51	2.91e-23	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg18477163	chr1:228402036	OBSCN	-0.55	-10.16	-0.49	2.62e-21	Diastolic blood pressure;
LUSC	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.68	0.34	1.02e-10	Educational attainment;
LUSC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg19468946	chr17:37922297	IKZF3	-0.37	-5.85	-0.3	1.16e-8	Self-reported allergy;
LUSC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.41	-6.22	-0.32	1.48e-9	Menarche (age at onset);
LUSC	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-6.54	-0.34	2.28e-10	Arsenic metabolism;
LUSC	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg24375607	chr4:120327624	NA	0.76	12.2	0.56	1.45e-28	Corneal astigmatism;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg12352820	chr6:13616043	NOL7	0.33	6.23	0.32	1.4e-9	Tuberculosis;
LUSC	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.16	-0.41	7.11e-15	Joint mobility (Beighton score);
LUSC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.48	-9.0	-0.44	1.7e-17	Axial length;
LUSC	cis	rs12145833	0.596	rs61833913	chr1:243440028	C/G	cg02356786	chr1:243265016	LOC731275	0.66	6.32	0.33	8.59e-10	Obesity (early onset extreme);
LUSC	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.44	0.33	4.12e-10	IgG glycosylation;
LUSC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg10253484	chr15:75165896	SCAMP2	-0.44	-6.4	-0.33	5.31e-10	Breast cancer;
LUSC	cis	rs7220711	1.000	rs7220711	chr17:41789965	C/T	cg26893861	chr17:41843967	DUSP3	-0.42	-5.92	-0.31	7.97e-9	Bone mineral density (spine);Bone mineral density (hip);
LUSC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg04733989	chr22:42467013	NAGA	-0.61	-9.5	-0.46	4.27e-19	Schizophrenia;
LUSC	trans	rs62387962	1.000	rs62389053	chr5:157290951	C/T	cg09066361	chr7:126890254	GRM8	0.49	6.46	0.33	3.81e-10	Platelet distribution width;
LUSC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	15.63	0.65	9.98e-42	Platelet count;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg16199381	chr9:100396477	TSTD2;NCBP1	0.43	6.35	0.33	6.89e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.79	0.43	7.84e-17	Prudent dietary pattern;
LUSC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg03351412	chr1:154909251	PMVK	0.56	8.9	0.44	3.73e-17	Prostate cancer;
LUSC	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg21433313	chr16:3507492	NAT15	0.68	11.44	0.53	8.55e-26	Tuberculosis;
LUSC	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg05925327	chr15:68127851	NA	0.33	5.91	0.31	8.43e-9	Restless legs syndrome;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg24405498	chr19:1556284	MEX3D	-0.42	-6.3	-0.33	9.61e-10	N-glycan levels;
LUSC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.1	0.61	9.47e-36	Platelet count;
LUSC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg18827107	chr12:86230957	RASSF9	-0.48	-7.08	-0.36	8.82e-12	Major depressive disorder;
LUSC	cis	rs6445797	0.632	rs2291499	chr3:56658481	G/C	cg13792233	chr3:56591045	CCDC66	0.41	5.72	0.3	2.33e-8	Gastritis;
LUSC	trans	rs724744	0.742	rs1205919	chr6:22365242	G/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.01	-0.31	4.75e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg23093090	chr10:104574429	C10orf26	-0.45	-7.91	-0.4	3.82e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.52	0.53	4.36e-26	Prudent dietary pattern;
LUSC	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg09904177	chr6:26538194	HMGN4	0.65	11.7	0.54	9.83e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg10792982	chr14:105748885	BRF1	0.51	9.35	0.46	1.29e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg00898013	chr13:113819073	PROZ	-0.56	-8.07	-0.4	1.29e-14	Platelet distribution width;
LUSC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	6.3	0.33	9.29e-10	Tonsillectomy;
LUSC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg02428538	chr16:24856791	SLC5A11	-0.56	-5.85	-0.3	1.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg07936489	chr17:37558343	FBXL20	0.78	9.96	0.48	1.27e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9595066	0.627	rs4942287	chr13:44734696	C/T	cg04068111	chr13:44716778	NA	0.45	5.89	0.31	9.43e-9	Schizophrenia;
LUSC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	8.4	0.42	1.31e-15	Height;
LUSC	cis	rs6062509	0.839	rs3859579	chr20:62301795	A/G	cg27236539	chr20:62289627	RTEL1	0.53	7.07	0.36	8.87e-12	Prostate cancer;
LUSC	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg26536354	chr8:144654954	C8orf73	0.67	7.31	0.37	2.05e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Parkinson's disease;
LUSC	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.79	-11.9	-0.55	1.87e-27	Blood pressure (smoking interaction);
LUSC	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg01733217	chr16:74700730	RFWD3	0.8	13.34	0.59	8.02e-33	Testicular germ cell tumor;
LUSC	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg13010199	chr12:38710504	ALG10B	0.56	8.48	0.42	7.21e-16	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg24642439	chr20:33292090	TP53INP2	-0.48	-7.37	-0.37	1.35e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg03563238	chr19:33554763	RHPN2	-0.41	-6.49	-0.33	3.19e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs2389217	0.509	rs2389219	chr12:33722185	T/A	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg24579218	chr15:68104479	NA	0.35	5.97	0.31	5.94e-9	Motion sickness;
LUSC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg05861140	chr6:150128134	PCMT1	-0.44	-7.13	-0.36	6.26e-12	Lung cancer;
LUSC	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg23093090	chr10:104574429	C10orf26	-0.39	-6.99	-0.36	1.48e-11	Arsenic metabolism;
LUSC	trans	rs11696501	0.694	rs1487325	chr20:44258989	A/G	cg03272292	chr12:48577362	C12orf68	-0.51	-6.14	-0.32	2.31e-9	Brain structure;
LUSC	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.24e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.45	7.19	0.37	4.16e-12	Alcohol dependence;
LUSC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-9.64	-0.47	1.43e-19	Monocyte count;
LUSC	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-8.24	-0.41	3.91e-15	Blood pressure (smoking interaction);
LUSC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.76	-9.95	-0.48	1.31e-20	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg05347473	chr6:146136440	FBXO30	0.4	6.63	0.34	1.34e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3790645	1.000	rs34062688	chr1:26887150	A/G	cg17456097	chr1:26900765	RPS6KA1	0.41	6.01	0.31	4.9e-9	Glucose homeostasis traits;
LUSC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.46	-0.38	7.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg05347473	chr6:146136440	FBXO30	0.56	9.66	0.47	1.28e-19	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	ch.15.381296F	chr15:40219076	NA	0.44	6.26	0.32	1.19e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg15448220	chr1:150897856	SETDB1	0.41	6.02	0.31	4.61e-9	Melanoma;
LUSC	cis	rs62400317	0.859	rs17209636	chr6:45142517	T/G	cg18551225	chr6:44695536	NA	-0.43	-6.92	-0.35	2.37e-11	Total body bone mineral density;
LUSC	trans	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg26384229	chr12:38710491	ALG10B	0.56	8.78	0.43	8.54e-17	Morning vs. evening chronotype;
LUSC	cis	rs3833788	1	rs3833788	chr12:121151062	CTCTCTTG/C	cg21892295	chr12:121157589	UNC119B	-0.51	-9.33	-0.45	1.47e-18	Mean corpuscular hemoglobin;
LUSC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.82	0.39	6.95e-14	Prudent dietary pattern;
LUSC	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.07	14.26	0.62	2.27e-36	Uric acid levels;
LUSC	cis	rs34638657	0.789	rs2967363	chr16:82204132	C/G	cg09439754	chr16:82129088	HSD17B2	-0.4	-6.67	-0.34	1.05e-10	Lung adenocarcinoma;
LUSC	cis	rs11608355	0.810	rs2217972	chr12:109857612	C/T	cg19025524	chr12:109796872	NA	-0.38	-5.7	-0.3	2.6e-8	Neuroticism;
LUSC	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg00277334	chr10:82204260	NA	0.51	7.4	0.38	1.12e-12	Post bronchodilator FEV1;
LUSC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	13.39	0.59	5.09e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs12200782	1.000	rs72844495	chr6:26610640	T/C	cg11837749	chr1:55047332	ACOT11	0.57	5.98	0.31	5.64e-9	Small cell lung carcinoma;
LUSC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.82	0.35	4.24e-11	Tonsillectomy;
LUSC	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg02825527	chr7:2087843	MAD1L1	-0.51	-5.72	-0.3	2.34e-8	Bipolar disorder;
LUSC	cis	rs2274273	1.000	rs67098772	chr14:55595242	G/A	cg04306507	chr14:55594613	LGALS3	0.54	11.49	0.53	5.85e-26	Protein biomarker;
LUSC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22442454	chr1:209979470	IRF6	-0.43	-5.86	-0.31	1.12e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs11958404	1.000	rs9686690	chr5:157412103	C/T	cg05962755	chr5:157440814	NA	0.51	6.24	0.32	1.32e-9	IgG glycosylation;
LUSC	cis	rs11031096	0.754	rs4910886	chr11:4143721	G/T	cg18678763	chr11:4115507	RRM1	-0.51	-7.48	-0.38	6.46e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg04733989	chr22:42467013	NAGA	0.41	6.73	0.35	7.34e-11	Cognitive function;
LUSC	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg24375607	chr4:120327624	NA	-0.75	-11.36	-0.53	1.71e-25	Corneal astigmatism;
LUSC	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg06636001	chr8:8085503	FLJ10661	0.74	10.4	0.49	4.1e-22	Red cell distribution width;
LUSC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.86	-0.54	2.57e-27	Chronic sinus infection;
LUSC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.35	-0.33	6.93e-10	Arsenic metabolism;
LUSC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg14664628	chr15:75095509	CSK	-0.58	-8.99	-0.44	1.9e-17	Breast cancer;
LUSC	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.6	-9.69	-0.47	9.72e-20	Body mass index;
LUSC	cis	rs377070	0.934	rs309397	chr4:123614323	A/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.48	6.74	0.35	7.12e-11	Mosquito bite size;
LUSC	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.64	-7.79	-0.39	8.55e-14	Yeast infection;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03241282	chr3:197807491	LOC348840	0.46	6.17	0.32	2.02e-9	Neuroticism;
LUSC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.91	0.31	8.34e-9	Menopause (age at onset);
LUSC	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg00277334	chr10:82204260	NA	0.58	8.87	0.44	4.36e-17	Post bronchodilator FEV1;
LUSC	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23544223	chr18:12777786	NA	0.59	6.25	0.32	1.26e-9	Inflammatory skin disease;
LUSC	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.9	0.51	6.87e-24	Hypertriglyceridemia;
LUSC	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg25930673	chr12:123319894	HIP1R	-0.72	-7.12	-0.36	6.69e-12	Schizophrenia;
LUSC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02018176	chr4:1364513	KIAA1530	0.75	13.67	0.6	4.11e-34	Longevity;
LUSC	cis	rs3784262	0.967	rs12148907	chr15:58296450	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.93	-0.31	7.51e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.89	-0.48	2.14e-20	Joint mobility (Beighton score);
LUSC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10802521	chr3:52805072	NEK4	-0.56	-8.72	-0.43	1.33e-16	Bipolar disorder;
LUSC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg16405210	chr4:1374714	KIAA1530	0.55	8.23	0.41	4.21e-15	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg26338869	chr17:61819248	STRADA	0.42	6.06	0.31	3.7e-9	Prudent dietary pattern;
LUSC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg18225595	chr11:63971243	STIP1	0.54	9.21	0.45	3.81e-18	Platelet count;
LUSC	trans	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg18187862	chr3:45730750	SACM1L	0.54	7.09	0.36	8.05e-12	Primary sclerosing cholangitis;
LUSC	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg02023728	chr11:77925099	USP35	0.45	6.71	0.34	8.21e-11	Testicular germ cell tumor;
LUSC	cis	rs11030122	0.702	rs7950153	chr11:3951337	T/C	cg18678763	chr11:4115507	RRM1	-0.43	-5.67	-0.3	3.06e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg05738196	chr6:26577821	NA	0.82	15.84	0.66	1.48e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg00898013	chr13:113819073	PROZ	0.58	8.58	0.42	3.72e-16	Platelet distribution width;
LUSC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg04369109	chr6:150039330	LATS1	-0.58	-8.44	-0.42	9.96e-16	Lung cancer;
LUSC	cis	rs4601821	0.965	rs10891543	chr11:113255895	A/G	cg14159747	chr11:113255604	NA	0.25	5.93	0.31	7.68e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	9.27	0.45	2.37e-18	Motion sickness;
LUSC	cis	rs727505	1.000	rs720613	chr7:124452670	C/T	cg23710748	chr7:124431027	NA	-0.41	-7.36	-0.37	1.46e-12	Lewy body disease;
LUSC	cis	rs7605827	0.780	rs2287278	chr2:15667771	C/G	cg19274914	chr2:15703543	NA	0.46	9.06	0.44	1.12e-17	Educational attainment (years of education);
LUSC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg13206674	chr6:150067644	NUP43	0.64	10.5	0.5	1.8e-22	Lung cancer;
LUSC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08280861	chr8:58055591	NA	0.54	6.47	0.33	3.4e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9653442	0.593	rs10865036	chr2:100860595	A/G	cg07810366	chr2:100720526	AFF3	-0.39	-6.33	-0.33	7.84e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg15711740	chr2:61764176	XPO1	-0.48	-7.52	-0.38	5.04e-13	Tuberculosis;
LUSC	cis	rs8141797	0.901	rs176159	chr22:24514352	A/G	cg00411358	chr22:24577142	SUSD2	0.57	6.13	0.32	2.46e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg02423579	chr7:2872169	GNA12	-0.4	-6.14	-0.32	2.4e-9	Height;
LUSC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg13685833	chr1:53393034	SCP2	0.46	6.76	0.35	6.1e-11	Monocyte count;
LUSC	trans	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg21775007	chr8:11205619	TDH	0.44	6.15	0.32	2.27e-9	Neuroticism;
LUSC	cis	rs10875746	0.903	rs10875735	chr12:48463806	T/C	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.51	8.05	0.4	1.49e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg19773385	chr1:10388646	KIF1B	0.5	8.59	0.43	3.28e-16	Hepatocellular carcinoma;
LUSC	cis	rs6693567	0.545	rs4970922	chr1:150458094	C/A	cg15654264	chr1:150340011	RPRD2	0.43	6.92	0.35	2.34e-11	Migraine;
LUSC	cis	rs10504229	0.500	rs9772760	chr8:57986999	G/C	cg11062466	chr8:58055876	NA	0.38	5.68	0.3	2.98e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.11	-0.36	7.29e-12	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs34891900	0.507	rs9605364	chr22:18127437	G/A	cg19898043	chr22:18121309	BCL2L13	0.41	6.25	0.32	1.25e-9	Sum neutrophil eosinophil counts;
LUSC	cis	rs500891	0.525	rs6454320	chr6:84050814	C/T	cg08257003	chr6:84140564	ME1	0.34	8.09	0.4	1.08e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs5758511	0.773	rs62240997	chr22:42354567	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.44	7.24	0.37	3.08e-12	Birth weight;
LUSC	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.01	-0.36	1.3e-11	Colorectal cancer;
LUSC	cis	rs4474465	0.790	rs6592784	chr11:78234790	C/T	cg27205649	chr11:78285834	NARS2	0.53	6.14	0.32	2.34e-9	Alzheimer's disease (survival time);
LUSC	cis	rs62400317	0.859	rs72860105	chr6:45265201	A/T	cg20913747	chr6:44695427	NA	-0.45	-7.42	-0.38	9.97e-13	Total body bone mineral density;
LUSC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg03146154	chr1:46216737	IPP	-0.51	-7.42	-0.38	9.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg20935933	chr6:143382018	AIG1	-0.51	-7.57	-0.38	3.65e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1044826	1.000	rs13089007	chr3:139095587	T/C	cg00490450	chr3:139108681	COPB2	0.56	7.42	0.38	9.5e-13	Obesity-related traits;
LUSC	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.52	7.54	0.38	4.45e-13	Breast cancer;
LUSC	cis	rs6120849	0.754	rs6120788	chr20:33583716	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	6.85	0.35	3.52e-11	Protein C levels;
LUSC	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg00745463	chr17:30367425	LRRC37B	-0.76	-9.31	-0.45	1.78e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs12900413	0.645	rs28407340	chr15:90311864	C/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.82	-0.3	1.37e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg10729496	chr3:10149963	C3orf24	0.52	6.88	0.35	2.9100000000000002e-11	Alzheimer's disease;
LUSC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-5.97	-0.31	6.07e-9	Parkinson's disease;
LUSC	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg18721089	chr20:30220636	NA	0.36	6.18	0.32	1.88e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs2692947	0.702	rs2312955	chr2:96777168	T/G	cg22654517	chr2:96458247	NA	-0.32	-5.85	-0.3	1.19e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7759001	0.779	rs13215216	chr6:27346645	G/C	cg18711553	chr6:27366782	ZNF391	0.41	5.95	0.31	6.67e-9	Glomerular filtration rate (creatinine);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15539190	chr13:28024404	MTIF3	-0.4	-6.13	-0.32	2.5e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16983817	chr21:15399683	NA	-0.45	-6.49	-0.33	3.09e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg05985134	chr18:33552581	C18orf21	0.5	6.73	0.35	7.22e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs3741151	0.686	rs7935948	chr11:73219118	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.79	-7.51	-0.38	5.35e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.53	-6.22	-0.32	1.5e-9	Verbal memory performance (residualized delayed recall change);
LUSC	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg23795048	chr12:9217529	LOC144571	0.34	5.89	0.31	9.24e-9	Sjögren's syndrome;
LUSC	trans	rs1392935	0.831	rs11654419	chr17:49973935	C/T	cg17187048	chr2:122407283	CLASP1	-0.57	-6.09	-0.32	3.06e-9	Bacterial meningitis;
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.36	5.65	0.3	3.49e-8	Lymphocyte counts;
LUSC	cis	rs983392	0.678	rs7108663	chr11:60028142	C/T	cg02771260	chr11:59836817	MS4A3	0.37	6.1	0.32	2.95e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg21427119	chr20:30132790	HM13	-0.44	-6.18	-0.32	1.83e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg17911788	chr17:44343683	NA	-0.3	-5.88	-0.31	9.84e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08439880	chr3:133502540	NA	-0.36	-6.51	-0.34	2.73e-10	Iron status biomarkers;
LUSC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg14343924	chr8:8086146	FLJ10661	0.43	6.19	0.32	1.75e-9	Mood instability;
LUSC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg00033643	chr7:134001901	SLC35B4	0.45	6.95	0.36	1.92e-11	Mean platelet volume;
LUSC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg26513180	chr16:89883248	FANCA	0.79	6.38	0.33	5.88e-10	Skin colour saturation;
LUSC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg03233332	chr7:66118400	NA	-0.4	-5.92	-0.31	8.15e-9	Aortic root size;
LUSC	cis	rs7527798	1.000	rs12744104	chr1:207819000	G/A	cg09232269	chr1:207846808	CR1L	-0.32	-5.77	-0.3	1.84e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs1775715	0.811	rs1775741	chr10:32267284	C/T	cg04359828	chr10:32216031	ARHGAP12	-0.39	-6.49	-0.33	3.14e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs751728	0.626	rs6457741	chr6:33756026	C/T	cg25922239	chr6:33757077	LEMD2	0.42	6.25	0.32	1.24e-9	Crohn's disease;
LUSC	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg23260525	chr10:116636907	FAM160B1	0.39	7.99	0.4	2.23e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs1459104	0.866	rs35456973	chr11:54838812	C/A	cg03929089	chr4:120376271	NA	0.68	6.03	0.31	4.28e-9	Body mass index;
LUSC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg17264618	chr3:40429014	ENTPD3	0.34	7.18	0.37	4.56e-12	Renal cell carcinoma;
LUSC	cis	rs7605827	0.930	rs7598068	chr2:15596535	A/T	cg19274914	chr2:15703543	NA	0.47	8.98	0.44	2.02e-17	Educational attainment (years of education);
LUSC	cis	rs737008	0.922	rs376374	chr16:11370616	G/A	cg00044050	chr16:11439710	C16orf75	-0.55	-8.54	-0.42	4.82e-16	Obesity-related traits;
LUSC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg00990874	chr7:1149470	C7orf50	-0.54	-6.47	-0.33	3.57e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	10.84	0.51	1.16e-23	Lung cancer in ever smokers;
LUSC	trans	rs62238980	0.521	rs117792024	chr22:32379444	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg11062466	chr8:58055876	NA	0.46	6.1	0.32	2.86e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs77972916	0.611	rs11693190	chr2:43602415	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.73	-0.3	2.27e-8	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs11696501	0.688	rs6065851	chr20:44279034	C/T	cg03272292	chr12:48577362	C12orf68	0.48	6.0	0.31	5.1e-9	Brain structure;
LUSC	cis	rs8032315	0.862	rs7166599	chr15:91403674	A/G	cg05469396	chr15:91419421	FURIN	-0.37	-5.67	-0.3	3.1e-8	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.61	-0.38	2.84e-13	Depression;
LUSC	trans	rs116175374	0.793	rs114644732	chr2:31432074	G/C	cg15543616	chr12:5019024	KCNA1	-0.77	-6.01	-0.31	4.9e-9	Endometriosis;
LUSC	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.46	-0.42	8.29e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.49	7.48	0.38	6.62e-13	Eosinophil percentage of white cells;
LUSC	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.36	6.02	0.31	4.71e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg19592336	chr6:28129416	ZNF389	-0.47	-6.36	-0.33	6.5e-10	Depression;
LUSC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-10.32	-0.49	7.4e-22	Gut microbiome composition (summer);
LUSC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.86	-13.58	-0.6	9.19e-34	Cognitive test performance;
LUSC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.17	0.41	6.44e-15	Prudent dietary pattern;
LUSC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.98	0.4	2.38e-14	Parkinson's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13976219	chr19:7197166	INSR	-0.54	-6.87	-0.35	3.24e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.37	-0.59	5.8e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs3087591	0.636	rs736598	chr17:29720470	T/C	cg24425628	chr17:29625626	OMG;NF1	0.49	7.49	0.38	6.35e-13	Hip circumference;
LUSC	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.76	-11.59	-0.54	2.49e-26	Cognitive ability;
LUSC	cis	rs4343996	0.967	rs7785994	chr7:3351810	T/C	cg21248987	chr7:3385318	SDK1	-0.38	-6.52	-0.34	2.52e-10	Motion sickness;
LUSC	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21659725	chr3:3221576	CRBN	-0.52	-8.37	-0.42	1.61e-15	Body mass index;
LUSC	cis	rs17155006	0.746	rs429252	chr7:107745554	T/C	cg05962710	chr7:107745446	LAMB4	-0.36	-6.51	-0.34	2.68e-10	Pneumococcal bacteremia;
LUSC	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21775007	chr8:11205619	TDH	0.71	11.4	0.53	1.21e-25	Retinal vascular caliber;
LUSC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.1	0.52	1.39e-24	Alzheimer's disease;
LUSC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg08975724	chr8:8085496	FLJ10661	0.5	7.44	0.38	8.63e-13	Mood instability;
LUSC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	cis	rs7809950	0.954	rs2712193	chr7:107125885	A/C	cg23024343	chr7:107201750	COG5	-0.55	-8.81	-0.43	7.13e-17	Coronary artery disease;
LUSC	trans	rs9650657	0.648	rs7833945	chr8:10700266	T/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.28	-0.32	1.07e-9	Neuroticism;
LUSC	cis	rs2191566	0.821	rs59756444	chr19:44513656	C/G	cg03039196	chr19:44506973	ZNF230	0.35	5.65	0.3	3.43e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19346786	chr7:2764209	NA	-0.48	-7.88	-0.4	4.61e-14	Height;
LUSC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.8	-0.3	1.57e-8	Platelet count;
LUSC	cis	rs7241530	0.662	rs7235625	chr18:75906500	G/A	cg14642773	chr18:75888474	NA	0.39	5.96	0.31	6.32e-9	Educational attainment (years of education);
LUSC	cis	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg16850897	chr7:100343110	ZAN	0.37	5.92	0.31	7.9e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg04865166	chr7:105162814	PUS7	0.52	5.87	0.31	1.02e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg14634687	chr17:47094252	IGF2BP1	0.31	6.6	0.34	1.61e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg06238570	chr21:40685208	BRWD1	0.47	7.3	0.37	2.12e-12	Cognitive function;
LUSC	cis	rs17253792	0.915	rs28537145	chr14:56179119	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.86	-0.35	3.35e-11	Putamen volume;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg21931103	chr2:99771423	LIPT1;TSGA10	0.4	6.17	0.32	2.03e-9	Triglycerides;
LUSC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02034447	chr16:89574710	SPG7	0.4	6.05	0.31	3.95e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs380904	0.519	rs12541790	chr8:144643321	A/G	cg13399544	chr8:144649678	C8orf73	-0.44	-6.85	-0.35	3.58e-11	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06022373	chr22:39101656	GTPBP1	0.76	11.69	0.54	1.11e-26	Menopause (age at onset);
LUSC	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	1.01	13.91	0.61	4.95e-35	Exhaled nitric oxide levels;
LUSC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.25	0.32	1.28e-9	Menopause (age at onset);
LUSC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg06028605	chr16:24865363	SLC5A11	0.51	9.11	0.45	7.83e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg00321850	chr1:175162397	KIAA0040	-0.45	-7.82	-0.39	6.91e-14	Alcohol dependence;
LUSC	cis	rs11229555	1.000	rs11229555	chr11:58408687	G/T	cg15696309	chr11:58395628	NA	-0.66	-8.99	-0.44	1.83e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg14458575	chr2:238380390	NA	0.56	6.97	0.36	1.72e-11	Prostate cancer;
LUSC	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg20090143	chr19:45452003	APOC2	0.34	5.81	0.3	1.44e-8	Blood protein levels;
LUSC	cis	rs9398803	0.931	rs9375435	chr6:126661858	C/T	cg19875578	chr6:126661172	C6orf173	0.43	6.27	0.32	1.09e-9	Male-pattern baldness;
LUSC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg21951975	chr1:209979733	IRF6	0.55	8.23	0.41	4.3e-15	Cleft lip with or without cleft palate;
LUSC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07256732	chr16:621771	PIGQ	-0.36	-6.54	-0.34	2.33e-10	Height;
LUSC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08219700	chr8:58056026	NA	0.64	7.88	0.4	4.52e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.76	-12.17	-0.55	1.87e-28	Height;
LUSC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	12.03	0.55	6.07e-28	Chronic sinus infection;
LUSC	cis	rs4964805	0.865	rs4964289	chr12:104204191	G/A	cg02344784	chr12:104178138	NT5DC3	0.4	6.35	0.33	7.15e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.1	-0.32	2.86e-9	Mood instability;
LUSC	cis	rs7605827	0.897	rs11675604	chr2:15672901	C/T	cg19274914	chr2:15703543	NA	0.45	8.55	0.42	4.49e-16	Educational attainment (years of education);
LUSC	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	0.97	15.59	0.65	1.44e-41	Dupuytren's disease;
LUSC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.7	11.58	0.54	2.59e-26	Heart rate;
LUSC	cis	rs6594499	0.542	rs4530809	chr5:110462230	A/G	cg04022379	chr5:110408740	TSLP	0.57	8.62	0.43	2.69e-16	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20435150	chr7:2443076	CHST12	-0.48	-7.39	-0.37	1.21e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg15921436	chr17:44337874	NA	0.72	10.99	0.52	3.35e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.83	12.28	0.56	7.58e-29	Breast cancer;
LUSC	cis	rs7851660	0.809	rs7034648	chr9:100654093	C/A	cg13688889	chr9:100608707	NA	-0.53	-8.06	-0.4	1.36e-14	Strep throat;
LUSC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg03526776	chr6:41159608	TREML2	0.33	6.12	0.32	2.67e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.35	-6.6	-0.34	1.62e-10	Coronary artery disease;
LUSC	cis	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.4e-9	Ulcerative colitis;
LUSC	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.29	0.53	2.98e-25	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7527798	1.000	rs12745818	chr1:207819401	C/T	cg09232269	chr1:207846808	CR1L	-0.32	-5.77	-0.3	1.84e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg10556349	chr10:835070	NA	0.44	5.66	0.3	3.31e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs7605827	0.930	rs7590458	chr2:15601574	A/G	cg19274914	chr2:15703543	NA	-0.44	-8.47	-0.42	7.76e-16	Educational attainment (years of education);
LUSC	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	5.97	0.31	6.21e-9	Rheumatoid arthritis;
LUSC	cis	rs6961069	0.745	rs1527479	chr7:80272568	C/T	cg04458919	chr7:80252533	CD36	-0.33	-5.96	-0.31	6.37e-9	Platelet count;
LUSC	cis	rs10875746	0.859	rs3782910	chr12:48483507	T/C	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	1.97e-8	Longevity (90 years and older);
LUSC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg05234568	chr11:5960015	NA	-0.55	-8.0	-0.4	2.14e-14	DNA methylation (variation);
LUSC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg22823121	chr1:150693482	HORMAD1	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg18825076	chr15:78729989	IREB2	0.47	6.34	0.33	7.31e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.72	-0.39	1.35e-13	Lymphocyte counts;
LUSC	cis	rs965469	1.000	rs1040726	chr20:3264267	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-5.96	-0.31	6.56e-9	IFN-related cytopenia;
LUSC	trans	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg25214090	chr10:38739885	LOC399744	0.39	6.13	0.32	2.45e-9	Diastolic blood pressure;
LUSC	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg15704280	chr7:45808275	SEPT13	0.75	8.53	0.42	5.16e-16	Axial length;
LUSC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13732083	chr21:47605072	C21orf56	-0.4	-6.06	-0.31	3.71e-9	Testicular germ cell tumor;
LUSC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg20295408	chr7:1910781	MAD1L1	-0.53	-7.77	-0.39	9.86e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg16230307	chr14:35515116	FAM177A1	0.79	10.05	0.48	6.13e-21	Psoriasis;
LUSC	cis	rs3741151	0.881	rs12099129	chr11:73091318	T/G	cg17517138	chr11:73019481	ARHGEF17	1.04	8.78	0.43	8.62e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-8.14	-0.41	8.06e-15	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs28785552	0.897	rs34244888	chr19:53242228	T/A	cg10871876	chr19:53194124	ZNF83	0.56	8.65	0.43	2.15e-16	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.67	9.98	0.48	1.09e-20	Corneal astigmatism;
LUSC	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg08213375	chr14:104286397	PPP1R13B	0.52	10.19	0.49	2.11e-21	Schizophrenia;
LUSC	cis	rs4629180	0.593	rs6707517	chr2:102089878	C/T	cg04415270	chr2:102091202	RFX8	-0.55	-8.91	-0.44	3.44e-17	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.74	9.99	0.48	9.68e-21	Platelet count;
LUSC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg11502198	chr6:26597334	ABT1	0.64	10.07	0.48	5.3e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg07382826	chr16:28625726	SULT1A1	0.28	6.08	0.32	3.3e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2273669	0.667	rs76267985	chr6:109326183	A/T	cg05315195	chr6:109294784	ARMC2	-0.53	-5.94	-0.31	7.15e-9	Prostate cancer;
LUSC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10802521	chr3:52805072	NEK4	-0.51	-8.12	-0.41	9.1e-15	Bipolar disorder;
LUSC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg26441486	chr22:50317300	CRELD2	0.47	6.96	0.36	1.82e-11	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21780859	chr13:30002907	MTUS2	0.36	6.13	0.32	2.46e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs12692738	0.526	rs355872	chr2:165632206	T/C	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg07741184	chr6:167504864	NA	-0.36	-6.53	-0.34	2.41e-10	Crohn's disease;
LUSC	cis	rs2227564	0.672	rs2461864	chr10:75659872	A/T	cg23231163	chr10:75533350	FUT11	-0.43	-5.91	-0.31	8.36e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg23601416	chr22:19950040	COMT	0.44	9.19	0.45	4.38e-18	Blood metabolite levels;
LUSC	cis	rs11018904	0.906	rs12793836	chr11:89953493	C/T	cg26138821	chr11:89956704	CHORDC1	-0.58	-6.87	-0.35	3.19e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.68	11.49	0.53	5.71e-26	Heart rate;
LUSC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg09365446	chr1:150670422	GOLPH3L	0.54	8.17	0.41	6.27e-15	Urate levels;
LUSC	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg21366198	chr4:185655624	MLF1IP	-0.44	-6.24	-0.32	1.36e-9	Kawasaki disease;
LUSC	cis	rs6977660	0.943	rs10240816	chr7:19819620	A/C	cg05791153	chr7:19748676	TWISTNB	0.54	5.94	0.31	6.96e-9	Thyroid stimulating hormone;
LUSC	cis	rs2932538	0.922	rs12750023	chr1:113118329	G/A	cg22162597	chr1:113214053	CAPZA1	0.7	10.1	0.48	4.1e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg23711669	chr6:146136114	FBXO30	0.74	12.95	0.58	2.36e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.61	-0.38	2.74e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg00343986	chr7:65444356	GUSB	0.39	5.76	0.3	1.91e-8	Aortic root size;
LUSC	cis	rs9391997	0.568	rs1567900	chr6:433109	T/C	cg09757644	chr6:447497	NA	0.28	5.89	0.31	9.22e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg17143192	chr8:8559678	CLDN23	0.39	5.94	0.31	7.02e-9	Mood instability;
LUSC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg04155289	chr7:94953770	PON1	-0.35	-6.02	-0.31	4.7e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg12564285	chr5:131593104	PDLIM4	-0.32	-5.77	-0.3	1.83e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg09323728	chr8:95962352	TP53INP1	-0.37	-7.49	-0.38	6.31e-13	Type 2 diabetes;
LUSC	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	0.95	17.69	0.7	6.9e-50	Bone mineral density;
LUSC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	7.94	0.4	3.04e-14	Colorectal cancer;
LUSC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg22963979	chr7:1858916	MAD1L1	-0.56	-8.47	-0.42	7.85e-16	Schizophrenia;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg18064852	chr5:36690457	NA	0.39	6.46	0.33	3.62e-10	Mosquito bite size;
LUSC	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg24675056	chr1:15929824	NA	0.46	7.96	0.4	2.75e-14	Systolic blood pressure;
LUSC	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg03684893	chr10:554711	DIP2C	-0.38	-6.93	-0.35	2.24e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs2625529	0.701	rs12911154	chr15:72212653	G/A	cg16672083	chr15:72433130	SENP8	-0.52	-7.54	-0.38	4.35e-13	Red blood cell count;
LUSC	cis	rs2387326	0.717	rs10829339	chr10:129943681	C/T	cg16087940	chr10:129947807	NA	-0.4	-5.99	-0.31	5.41e-9	Select biomarker traits;
LUSC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg12863693	chr15:85201151	NMB	0.35	6.84	0.35	3.79e-11	Schizophrenia;
LUSC	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.28	20.98	0.75	6.38e-63	Type 1 diabetes nephropathy;
LUSC	cis	rs1957429	0.901	rs7143661	chr14:65378981	G/A	cg23373153	chr14:65346875	NA	1.03	11.29	0.53	2.92e-25	Pediatric areal bone mineral density (radius);
LUSC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg23711669	chr6:146136114	FBXO30	0.88	16.26	0.66	3.33e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.7	8.63	0.43	2.62e-16	Type 2 diabetes;
LUSC	cis	rs2273669	0.510	rs11757590	chr6:109370003	T/C	cg05315195	chr6:109294784	ARMC2	-0.52	-5.78	-0.3	1.7e-8	Prostate cancer;
LUSC	cis	rs12760731	0.720	rs1510266	chr1:178346771	A/T	cg00404053	chr1:178313656	RASAL2	-0.55	-6.34	-0.33	7.54e-10	Obesity-related traits;
LUSC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.93	-0.48	1.59e-20	Hemoglobin concentration;
LUSC	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	7.57	0.38	3.56e-13	Morning vs. evening chronotype;
LUSC	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg07828024	chr6:149772892	ZC3H12D	0.34	7.44	0.38	8.54e-13	Dupuytren's disease;
LUSC	cis	rs2742234	0.541	rs12416428	chr10:43708998	G/A	cg15436174	chr10:43711423	RASGEF1A	0.44	7.03	0.36	1.14e-11	Hirschsprung disease;
LUSC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg09835421	chr16:68378352	PRMT7	-0.55	-6.17	-0.32	1.92e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	7.72	0.39	1.37e-13	Lung function (FEV1/FVC);
LUSC	cis	rs10744422	1.000	rs4759381	chr12:123348480	G/A	cg25930673	chr12:123319894	HIP1R	-0.67	-6.74	-0.35	6.99e-11	Schizophrenia;
LUSC	cis	rs6681460	0.585	rs1359463	chr1:67169565	G/A	cg02459107	chr1:67143332	SGIP1	0.33	5.76	0.3	1.93e-8	Presence of antiphospholipid antibodies;
LUSC	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-7.1	-0.36	7.73e-12	Axial length;
LUSC	cis	rs4654899	1.000	rs6689819	chr1:21472395	A/T	cg01072550	chr1:21505969	NA	-0.55	-8.42	-0.42	1.16e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs968451	0.813	rs5757614	chr22:39717554	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	8.51	0.42	6.07e-16	Primary biliary cholangitis;
LUSC	cis	rs921665	0.749	rs4477952	chr2:3201249	G/A	cg02624386	chr2:3182749	NA	0.59	6.36	0.33	6.7e-10	World class endurance athleticism;
LUSC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.73	-0.43	1.25e-16	Aortic root size;
LUSC	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg02696742	chr7:106810147	HBP1	-0.63	-9.5	-0.46	4.06e-19	Coronary artery disease;
LUSC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg11752832	chr7:134001865	SLC35B4	0.61	9.6	0.46	2e-19	Mean platelet volume;
LUSC	cis	rs981844	0.712	rs1037648	chr4:154737877	T/C	cg14289246	chr4:154710475	SFRP2	-0.44	-6.17	-0.32	1.97e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg18825076	chr15:78729989	IREB2	-0.44	-6.13	-0.32	2.52e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10986311	0.832	rs10818951	chr9:127131062	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.39	6.23	0.32	1.4e-9	Vitiligo;
LUSC	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.36	-0.42	1.71e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.42	-6.96	-0.36	1.86e-11	Glomerular filtration rate;
LUSC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg12463550	chr7:65579703	CRCP	-0.47	-6.96	-0.36	1.84e-11	Aortic root size;
LUSC	cis	rs11229555	0.609	rs12291791	chr11:58186290	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.78	-0.39	9.19e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg24562669	chr7:97807699	LMTK2	0.4	6.85	0.35	3.66e-11	Breast cancer;
LUSC	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg04989706	chr14:50066350	PPIL5	-0.46	-6.21	-0.32	1.57e-9	Carotid intima media thickness;
LUSC	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg10523679	chr1:76189770	ACADM	-0.49	-7.06	-0.36	9.81e-12	Daytime sleep phenotypes;
LUSC	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg13010199	chr12:38710504	ALG10B	0.64	10.0	0.48	9.35e-21	Bladder cancer;
LUSC	cis	rs2274273	0.805	rs28660594	chr14:55846174	T/C	cg04306507	chr14:55594613	LGALS3	0.53	11.88	0.55	2.11e-27	Protein biomarker;
LUSC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg12560992	chr17:57184187	TRIM37	0.8	13.95	0.61	3.66e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.59	10.7	0.51	3.63e-23	Bone mineral density;
LUSC	cis	rs11971779	0.816	rs11979272	chr7:139074069	C/T	cg07862535	chr7:139043722	LUC7L2	0.74	8.31	0.41	2.47e-15	Diisocyanate-induced asthma;
LUSC	cis	rs834603	0.575	rs1704968	chr7:47468231	T/C	cg09696706	chr7:47479511	TNS3	0.32	5.75	0.3	2.01e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg15145296	chr3:125709740	NA	-0.59	-6.49	-0.33	3.19e-10	Blood pressure (smoking interaction);
LUSC	cis	rs6545883	0.929	rs12713436	chr2:61691260	T/C	cg15711740	chr2:61764176	XPO1	-0.46	-7.06	-0.36	9.62e-12	Tuberculosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13353472	chr19:39343117	HNRNPL	-0.53	-6.51	-0.34	2.8e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg13628971	chr7:2884303	GNA12	0.37	5.67	0.3	3.02e-8	Height;
LUSC	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.16	0.36	5.04e-12	Educational attainment;
LUSC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.69	-10.9	-0.51	6.91e-24	Monocyte percentage of white cells;
LUSC	cis	rs4662750	0.580	rs7558838	chr2:128351346	T/C	cg06107159	chr2:128432243	LIMS2	-0.32	-5.65	-0.3	3.48e-8	Renal cell carcinoma;
LUSC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg24838063	chr12:130822603	PIWIL1	0.68	10.48	0.5	2.08e-22	Menopause (age at onset);
LUSC	cis	rs9400467	0.528	rs1623806	chr6:111665071	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.87	-0.35	3.11e-11	Blood metabolite levels;Amino acid levels;
LUSC	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	8.27	0.41	3.25e-15	Retinal vascular caliber;
LUSC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06481639	chr22:41940642	POLR3H	-0.51	-6.14	-0.32	2.41e-9	Vitiligo;
LUSC	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg17385448	chr1:15911702	AGMAT	0.35	5.99	0.31	5.54e-9	Systolic blood pressure;
LUSC	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	6.37	0.33	6.43e-10	Schizophrenia;
LUSC	cis	rs1448094	0.565	rs80346149	chr12:86317542	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-5.67	-0.3	3.01e-8	Major depressive disorder;
LUSC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg21733973	chr7:65235735	NA	0.47	6.6	0.34	1.66e-10	Calcium levels;
LUSC	cis	rs7267979	0.816	rs6037158	chr20:25595466	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.8	16.68	0.67	7.39e-46	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14829155	chr15:31115871	NA	-0.72	-10.47	-0.5	2.24e-22	Huntington's disease progression;
LUSC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	1.03	18.74	0.72	4.56e-54	Menopause (age at onset);
LUSC	cis	rs2742234	0.910	rs2505511	chr10:43641029	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.36	-6.41	-0.33	4.92e-10	Hirschsprung disease;
LUSC	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.25	0.64	3.15e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs17034641	1.000	rs17034641	chr2:46372644	G/A	cg12428440	chr2:46370979	PRKCE	0.46	6.2	0.32	1.65e-9	Hemoglobin;Hematocrit;
LUSC	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.53	0.5	1.37e-22	Colorectal cancer;
LUSC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg18350739	chr11:68623251	NA	-0.37	-6.48	-0.33	3.24e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.37	-0.37	1.37e-12	Joint mobility (Beighton score);
LUSC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg16423285	chr20:60520624	NA	-0.47	-5.94	-0.31	6.99e-9	Body mass index;
LUSC	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.64	-9.44	-0.46	6.49e-19	Superior crus of antihelix expression;
LUSC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	1.04	19.19	0.72	7.41e-56	Menopause (age at onset);
LUSC	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg24562669	chr7:97807699	LMTK2	0.47	8.5	0.42	6.62e-16	Breast cancer;
LUSC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg11247378	chr22:39784982	NA	-0.66	-12.93	-0.58	2.78e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs79387448	0.745	rs7593444	chr2:103158561	G/A	cg09003973	chr2:102972529	NA	0.88	8.56	0.42	4.18e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.41	-5.93	-0.31	7.68e-9	Tonsillectomy;
LUSC	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg20701182	chr2:24300061	SF3B14	0.56	6.01	0.31	4.81e-9	Lymphocyte counts;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg17461462	chr8:627771	ERICH1	-0.75	-6.4	-0.33	5.39e-10	Cognitive performance;
LUSC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg15448220	chr1:150897856	SETDB1	0.42	6.06	0.31	3.68e-9	Melanoma;
LUSC	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg08085267	chr17:45401833	C17orf57	-0.51	-7.18	-0.37	4.58e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.73	-12.34	-0.56	4.27e-29	White blood cell count (basophil);
LUSC	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg27432699	chr2:27873401	GPN1	0.81	14.95	0.63	4.58e-39	Oral cavity cancer;
LUSC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg00684032	chr4:1343700	KIAA1530	0.36	6.64	0.34	1.24e-10	Longevity;
LUSC	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.02e-14	Corneal astigmatism;
LUSC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	7.43	0.38	9.1e-13	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg04450456	chr4:17643702	FAM184B	0.39	6.61	0.34	1.49e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg16482183	chr6:26056742	HIST1H1C	0.46	6.91	0.35	2.41e-11	Height;
LUSC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg01448562	chr3:133502909	NA	-0.5	-7.46	-0.38	7.63e-13	Iron status biomarkers;
LUSC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg17143192	chr8:8559678	CLDN23	0.65	9.05	0.44	1.21e-17	Obesity-related traits;
LUSC	trans	rs12510870	0.511	rs6834059	chr4:74301675	C/G	cg01940055	chr4:146018582	ANAPC10;ABCE1	0.39	6.54	0.34	2.35e-10	Iris color (b* coordinate);
LUSC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg23719950	chr11:63933701	MACROD1	-0.64	-8.2	-0.41	5.19e-15	Mean platelet volume;
LUSC	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg22437258	chr11:111473054	SIK2	0.53	7.15	0.36	5.55e-12	Primary sclerosing cholangitis;
LUSC	trans	rs11039798	0.920	rs12417899	chr11:49017552	G/A	cg15704280	chr7:45808275	SEPT13	0.86	7.18	0.37	4.49e-12	Axial length;
LUSC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg01973587	chr1:228161476	NA	-0.41	-7.4	-0.38	1.15e-12	Diastolic blood pressure;
LUSC	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-7.47	-0.38	7.11e-13	Atrioventricular conduction;
LUSC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.57	7.48	0.38	6.74e-13	Response to diuretic therapy;
LUSC	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg06484146	chr7:12443880	VWDE	-0.68	-7.08	-0.36	8.67e-12	Coronary artery disease;
LUSC	cis	rs11676348	0.772	rs11676275	chr2:218944808	G/A	cg06547715	chr2:218990976	CXCR2	0.31	6.01	0.31	4.74e-9	Ulcerative colitis;
LUSC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.48	7.96	0.4	2.79e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25632093	chr22:29999554	NF2	-0.4	-6.03	-0.31	4.26e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7192380	1.000	rs7192380	chr16:69704342	T/C	cg26679644	chr16:69762563	NA	0.35	6.2	0.32	1.65e-9	Sjögren's syndrome;
LUSC	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg21775007	chr8:11205619	TDH	0.43	6.08	0.32	3.26e-9	Mood instability;
LUSC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00475322	chr7:917719	C7orf20	0.45	6.59	0.34	1.68e-10	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs1538970	0.962	rs9429072	chr1:45810091	C/T	cg05343316	chr1:45956843	TESK2	-0.56	-7.88	-0.4	4.75e-14	Platelet count;
LUSC	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg10978503	chr1:24200527	CNR2	0.37	8.34	0.42	2.01e-15	Immature fraction of reticulocytes;
LUSC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1143633	0.566	rs12987491	chr2:113691499	G/A	cg06156847	chr2:113672199	IL1F7	0.29	6.34	0.33	7.31e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.64	-8.87	-0.44	4.64e-17	Body mass index;
LUSC	trans	rs1493916	0.748	rs4799355	chr18:31313124	G/T	cg27147174	chr7:100797783	AP1S1	-0.55	-8.74	-0.43	1.19e-16	Life satisfaction;
LUSC	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg05283184	chr6:79620031	NA	-0.57	-12.14	-0.55	2.33e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06850241	chr22:41845214	NA	0.3	5.77	0.3	1.84e-8	Vitiligo;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20908936	chr7:113726250	NA	-0.4	-5.97	-0.31	6.16e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg12463550	chr7:65579703	CRCP	-0.42	-6.46	-0.33	3.66e-10	Aortic root size;
LUSC	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg25214090	chr10:38739885	LOC399744	0.54	8.02	0.4	1.78e-14	Corneal astigmatism;
LUSC	cis	rs2017854	0.562	rs1583319	chr17:65500961	A/T	cg07622687	chr17:65503465	PITPNC1	0.44	7.63	0.39	2.49e-13	Pulmonary function;
LUSC	cis	rs3106136	0.934	rs34396188	chr4:95191292	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.18	-0.32	1.92e-9	Capecitabine sensitivity;
LUSC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08219700	chr8:58056026	NA	0.64	8.09	0.4	1.09e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-7.34	-0.37	1.64e-12	Parkinson's disease;
LUSC	cis	rs71636778	0.543	rs71636796	chr1:27243095	T/C	cg12203394	chr1:27248618	NUDC	0.53	5.65	0.3	3.36e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.49	0.56	1.21e-29	Motion sickness;
LUSC	cis	rs897080	0.515	rs698818	chr2:44709769	G/A	cg00619915	chr2:44497795	NA	-0.42	-6.01	-0.31	4.83e-9	Height;
LUSC	cis	rs5758511	0.773	rs7288749	chr22:42356430	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.51	-6.24	-0.32	1.34e-9	Birth weight;
LUSC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg11247378	chr22:39784982	NA	-0.66	-12.83	-0.57	6.31e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs3741151	0.773	rs73546720	chr11:73252409	C/T	cg17517138	chr11:73019481	ARHGEF17	0.97	8.12	0.41	8.78e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21643547	chr1:205240462	TMCC2	-0.52	-9.94	-0.48	1.43e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg03146154	chr1:46216737	IPP	0.5	7.43	0.38	9.1e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2625529	0.652	rs2899775	chr15:72268354	C/T	cg16672083	chr15:72433130	SENP8	0.48	7.92	0.4	3.52e-14	Red blood cell count;
LUSC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.71	12.72	0.57	1.68e-30	Prudent dietary pattern;
LUSC	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg08313168	chr12:7315531	NA	0.46	5.98	0.31	5.65e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg06092702	chr1:163392909	NA	0.41	6.87	0.35	3.06e-11	Motion sickness;
LUSC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg08219700	chr8:58056026	NA	0.46	6.02	0.31	4.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg06784218	chr1:46089804	CCDC17	0.35	5.99	0.31	5.39e-9	Platelet count;
LUSC	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg25214090	chr10:38739885	LOC399744	0.54	8.0	0.4	2.12e-14	Corneal astigmatism;
LUSC	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg21770322	chr7:97807741	LMTK2	0.44	7.74	0.39	1.22e-13	Breast cancer;
LUSC	trans	rs9847048	0.715	rs62271998	chr3:116370362	A/C	cg11621464	chr19:41120268	LTBP4	-0.61	-5.99	-0.31	5.32e-9	Gut microbiome composition (summer);
LUSC	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.78	13.24	0.59	1.94e-32	Platelet distribution width;
LUSC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	15.59	0.65	1.47e-41	Platelet count;
LUSC	cis	rs6543140	0.964	rs4851589	chr2:103077145	A/G	cg09003973	chr2:102972529	NA	0.53	7.01	0.36	1.34e-11	Blood protein levels;
LUSC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.95	-16.03	-0.66	2.64e-43	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03812724	chr21:15588363	RBM11	0.45	6.31	0.33	8.95e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg18758796	chr5:131593413	PDLIM4	-0.38	-6.46	-0.33	3.65e-10	Breast cancer;
LUSC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg11871910	chr12:69753446	YEATS4	0.63	8.34	0.42	1.97e-15	Response to diuretic therapy;
LUSC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.18	0.61	4.74e-36	Platelet count;
LUSC	cis	rs6693567	0.545	rs2133129	chr1:150355537	T/C	cg15654264	chr1:150340011	RPRD2	0.45	7.24	0.37	3.09e-12	Migraine;
LUSC	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg23950597	chr19:37808831	NA	-0.63	-7.38	-0.37	1.31e-12	Coronary artery calcification;
LUSC	cis	rs11648785	0.777	rs4433810	chr16:90098466	G/T	cg16611967	chr16:90144006	NA	0.47	6.13	0.32	2.48e-9	Tanning;
LUSC	cis	rs225245	0.755	rs226432	chr17:34043825	G/A	cg05299278	chr17:33885742	SLFN14	-0.29	-6.3	-0.33	9.54e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg12432903	chr7:1882776	MAD1L1	-0.39	-6.4	-0.33	5.19e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg13683864	chr3:40499215	RPL14	-1.01	-16.92	-0.68	7.96e-47	Renal cell carcinoma;
LUSC	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.54	11.01	0.52	2.88e-24	Glomerular filtration rate (creatinine);
LUSC	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs683250	1.000	rs523494	chr11:83312379	G/A	cg26617787	chr11:123396133	GRAMD1B	-0.31	-5.97	-0.31	5.96e-9	Subcortical brain region volumes;
LUSC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.78	-10.59	-0.5	8.39e-23	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg27432699	chr2:27873401	GPN1	0.79	14.87	0.63	9.46e-39	Oral cavity cancer;
LUSC	cis	rs2540226	0.816	rs12623545	chr2:39977565	T/C	cg23576258	chr2:39999331	THUMPD2	0.36	6.09	0.32	3.03e-9	Personality dimensions;
LUSC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.9	0.35	2.56e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg00990874	chr7:1149470	C7orf50	-0.54	-6.72	-0.35	7.74e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs6684514	1.000	rs12117903	chr1:156311165	G/T	cg16558208	chr1:156270281	VHLL	0.35	5.71	0.3	2.54e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUSC	cis	rs73198271	0.960	rs73198288	chr8:8613940	G/A	cg01851573	chr8:8652454	MFHAS1	0.59	8.43	0.42	1.04e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg26384229	chr12:38710491	ALG10B	0.73	11.91	0.55	1.7e-27	Morning vs. evening chronotype;
LUSC	cis	rs12912251	0.948	rs34281605	chr15:38989674	G/A	cg01338139	chr15:38987640	C15orf53	-0.51	-7.11	-0.36	7.04e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg06636551	chr8:101224915	SPAG1	-0.41	-7.5	-0.38	5.99e-13	Atrioventricular conduction;
LUSC	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg14500267	chr11:67383377	NA	0.32	6.14	0.32	2.29e-9	Mean corpuscular volume;
LUSC	trans	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg18187862	chr3:45730750	SACM1L	-0.5	-6.17	-0.32	1.95e-9	Primary sclerosing cholangitis;
LUSC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	15.92	0.66	7.26e-43	Platelet count;
LUSC	cis	rs12760731	0.720	rs12048834	chr1:178353998	A/G	cg00404053	chr1:178313656	RASAL2	0.64	6.59	0.34	1.76e-10	Obesity-related traits;
LUSC	cis	rs7072216	0.727	rs942808	chr10:100168102	C/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07677032	chr17:61819896	STRADA	0.54	8.72	0.43	1.3e-16	Prudent dietary pattern;
LUSC	cis	rs6460942	0.558	rs4330594	chr7:12278615	G/A	cg06484146	chr7:12443880	VWDE	-0.53	-5.72	-0.3	2.32e-8	Coronary artery disease;
LUSC	cis	rs11051970	0.879	rs2733682	chr12:32574608	G/A	cg02745156	chr12:32552066	NA	0.43	7.35	0.37	1.58e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg21775007	chr8:11205619	TDH	-0.55	-7.96	-0.4	2.68e-14	Neuroticism;
LUSC	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.79	14.41	0.62	6.2e-37	Platelet distribution width;
LUSC	cis	rs7605827	0.930	rs7577512	chr2:15623218	G/T	cg19274914	chr2:15703543	NA	0.46	8.87	0.44	4.51e-17	Educational attainment (years of education);
LUSC	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.78	11.19	0.52	6.99e-25	Corneal astigmatism;
LUSC	cis	rs9837602	1.000	rs10049383	chr3:99748548	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.2	0.32	1.64e-9	Breast cancer;
LUSC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg18404041	chr3:52824283	ITIH1	0.39	6.78	0.35	5.48e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.54	-9.46	-0.46	5.87e-19	IgG glycosylation;
LUSC	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg16359550	chr11:109292809	C11orf87	0.37	6.46	0.33	3.71e-10	Schizophrenia;
LUSC	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg24562669	chr7:97807699	LMTK2	0.48	8.56	0.42	4.31e-16	Breast cancer;
LUSC	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg08916839	chr5:415575	AHRR	0.76	7.18	0.37	4.43e-12	Fat distribution (HIV);
LUSC	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg21775007	chr8:11205619	TDH	-0.67	-10.57	-0.5	9.86e-23	Retinal vascular caliber;
LUSC	trans	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.34	0.62	1.09e-36	Exhaled nitric oxide levels;
LUSC	cis	rs790123	0.692	rs796892	chr3:122385402	C/T	cg00926285	chr3:122398533	PARP14	0.4	5.86	0.31	1.11e-8	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.65	-0.54	1.53e-26	Schizophrenia;
LUSC	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs454510	0.826	rs347903	chr1:120192431	C/T	cg16322792	chr1:120165303	ZNF697	0.34	5.66	0.3	3.3e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg05527609	chr1:210001259	C1orf107	0.67	9.59	0.46	2.09e-19	Orofacial clefts;
LUSC	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg20701182	chr2:24300061	SF3B14	0.49	6.28	0.33	1.04e-9	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg16434002	chr17:42200994	HDAC5	-0.45	-6.45	-0.33	3.95e-10	Total body bone mineral density;
LUSC	trans	rs6561151	0.681	rs2121037	chr13:44471317	C/T	cg12856521	chr11:46389249	DGKZ	0.74	9.23	0.45	3.25e-18	Crohn's disease;
LUSC	trans	rs2730260	0.867	rs2730264	chr7:158843109	A/G	cg06713098	chr7:45960367	IGFBP3	0.39	5.99	0.31	5.48e-9	Myopia (pathological);
LUSC	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg26513180	chr16:89883248	FANCA	-0.56	-8.69	-0.43	1.71e-16	Vitiligo;
LUSC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.01	-19.72	-0.73	6.2e-58	Cognitive function;
LUSC	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg05163923	chr11:71159392	DHCR7	0.75	11.19	0.52	6.57e-25	Vitamin D levels;
LUSC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg22437258	chr11:111473054	SIK2	0.51	7.08	0.36	8.78e-12	Primary sclerosing cholangitis;
LUSC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg05896524	chr21:47604654	C21orf56	0.4	5.8	0.3	1.52e-8	Testicular germ cell tumor;
LUSC	cis	rs2115536	0.704	rs2163005	chr15:80194480	A/G	cg00225070	chr15:80189496	MTHFS	0.57	7.96	0.4	2.62e-14	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg05313129	chr8:58192883	C8orf71	-0.5	-6.86	-0.35	3.28e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.7	12.62	0.57	3.9e-30	Prudent dietary pattern;
LUSC	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg13114125	chr14:105738426	BRF1	-0.86	-14.21	-0.61	3.63e-36	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs17001868	0.568	rs9611310	chr22:40733777	A/G	cg07138101	chr22:40742427	ADSL	0.64	7.62	0.38	2.72e-13	Mammographic density (dense area);
LUSC	cis	rs7493	0.950	rs7802171	chr7:95030321	A/G	cg04155289	chr7:94953770	PON1	-0.34	-5.68	-0.3	2.97e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.44	-5.98	-0.31	5.72e-9	Childhood ear infection;
LUSC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.91	0.31	8.27e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	10.5	0.5	1.79e-22	Monocyte percentage of white cells;
LUSC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.36	-0.33	6.46e-10	Total body bone mineral density;
LUSC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg09877947	chr5:131593287	PDLIM4	-0.45	-6.94	-0.36	2.02e-11	Breast cancer;
LUSC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	0.85	14.24	0.61	2.82e-36	Menopause (age at onset);
LUSC	cis	rs6580649	0.941	rs4589362	chr12:48478664	T/C	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.24e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg08484992	chr16:88977278	CBFA2T3	-0.33	-5.88	-0.31	1.02e-8	Social autistic-like traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16088692	chr2:170440797	PPIG	-0.41	-5.98	-0.31	5.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg06096015	chr1:231504339	EGLN1	0.56	9.79	0.47	4.46e-20	Hemoglobin concentration;
LUSC	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg20135002	chr11:47629003	NA	-0.49	-7.66	-0.39	2.09e-13	Subjective well-being;
LUSC	cis	rs6489882	0.867	rs7306205	chr12:113366899	A/G	cg20102336	chr12:113376681	OAS3	-0.39	-5.65	-0.3	3.46e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19346786	chr7:2764209	NA	-0.52	-8.68	-0.43	1.74e-16	Height;
LUSC	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg15934090	chr1:100435551	SLC35A3	-0.47	-7.84	-0.39	6.21e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.11	0.61	8.37e-36	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4481887	0.676	rs1544177	chr1:248524683	C/G	cg26353448	chr1:248524236	OR2T4	-0.31	-6.12	-0.32	2.61e-9	Common traits (Other);
LUSC	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg15432903	chr11:17409602	KCNJ11	0.61	10.83	0.51	1.26e-23	Type 2 diabetes;
LUSC	cis	rs6546550	0.935	rs4241261	chr2:70063660	A/G	cg02498382	chr2:70120550	SNRNP27	-0.28	-6.99	-0.36	1.54e-11	Prevalent atrial fibrillation;
LUSC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg15691649	chr6:25882328	NA	-0.37	-5.84	-0.3	1.26e-8	Blood metabolite levels;
LUSC	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg02428538	chr16:24856791	SLC5A11	-0.53	-6.11	-0.32	2.72e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg05347473	chr6:146136440	FBXO30	-0.56	-9.7	-0.47	9.34e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg12935359	chr14:103987150	CKB	0.54	8.37	0.42	1.58e-15	Body mass index;
LUSC	trans	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg02030672	chr11:45687055	CHST1	0.5	7.88	0.4	4.66e-14	Obesity-related traits;
LUSC	cis	rs7192380	0.737	rs7204433	chr16:69589924	A/G	cg00738113	chr16:70207722	CLEC18C	-0.28	-6.03	-0.31	4.33e-9	Sjögren's syndrome;
LUSC	cis	rs67539049	1.000	rs3021518	chr8:11296049	T/A	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.38	-5.77	-0.3	1.77e-8	Itch intensity from mosquito bite;
LUSC	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.48	-0.69	4.87e-49	Exhaled nitric oxide output;
LUSC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.69	11.76	0.54	6.19e-27	Prudent dietary pattern;
LUSC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg23283495	chr1:209979779	IRF6	0.44	7.16	0.36	5.23e-12	Monobrow;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15924583	chr3:47045470	NBEAL2	-0.38	-6.6	-0.34	1.57e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs4729127	1.000	rs8180725	chr7:94010953	G/C	cg19058453	chr19:9879420	ZNF846	0.59	5.99	0.31	5.45e-9	Intelligence;
LUSC	cis	rs7903847	0.642	rs10882909	chr10:99137998	G/C	cg08345082	chr10:99160200	RRP12	-0.38	-7.68	-0.39	1.72e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7589342	1.000	rs7589342	chr2:106433478	C/T	cg16077055	chr2:106428750	NCK2	0.38	7.26	0.37	2.75e-12	Addiction;
LUSC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01516881	chr6:292596	DUSP22	-0.55	-8.1	-0.41	1.06e-14	Menopause (age at onset);
LUSC	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg22709100	chr7:91322751	NA	-0.39	-5.66	-0.3	3.19e-8	Breast cancer;
LUSC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg09455208	chr3:40491958	NA	0.56	10.19	0.49	2e-21	Renal cell carcinoma;
LUSC	cis	rs1595825	1.000	rs1440087	chr2:198871476	G/C	cg19156104	chr2:198669113	PLCL1	-0.46	-5.68	-0.3	2.91e-8	Ulcerative colitis;
LUSC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.31	-0.41	2.42e-15	Gut microbiome composition (summer);
LUSC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.43	-0.38	9.29e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg07636037	chr3:49044803	WDR6	-0.52	-7.31	-0.37	2.01e-12	Prion diseases;
LUSC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg15691649	chr6:25882328	NA	-0.39	-6.37	-0.33	6.13e-10	Blood metabolite levels;
LUSC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg17264618	chr3:40429014	ENTPD3	0.31	6.13	0.32	2.5e-9	Renal cell carcinoma;
LUSC	cis	rs2667011	0.756	rs4401175	chr2:160842687	G/A	cg06573604	chr2:160760825	LY75	-0.49	-6.31	-0.33	8.97e-10	Bilirubin levels;
LUSC	cis	rs926938	0.583	rs12401670	chr1:115244337	C/T	cg12756093	chr1:115239321	AMPD1	-0.55	-7.87	-0.4	4.99e-14	Autism;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg00024416	chr22:24240387	NA	-0.33	-6.11	-0.32	2.78e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7215564	0.908	rs35374347	chr17:78642244	C/T	cg09596252	chr17:78655493	RPTOR	0.58	6.08	0.32	3.38e-9	Myopia (pathological);
LUSC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg12257692	chr3:49977190	RBM6	0.25	6.92	0.35	2.29e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06481639	chr22:41940642	POLR3H	0.5	5.72	0.3	2.42e-8	Vitiligo;
LUSC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg18404041	chr3:52824283	ITIH1	-0.4	-7.28	-0.37	2.41e-12	Electroencephalogram traits;
LUSC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg05313129	chr8:58192883	C8orf71	-0.51	-5.75	-0.3	1.99e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4629710	0.645	rs35561719	chr6:131551244	G/A	cg12700074	chr6:131571435	AKAP7	-0.36	-5.96	-0.31	6.33e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg09365446	chr1:150670422	GOLPH3L	-0.52	-7.56	-0.38	3.89e-13	Blood protein levels;
LUSC	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg04851639	chr8:1020857	NA	-0.4	-8.26	-0.41	3.56e-15	Schizophrenia;
LUSC	cis	rs66887589	0.934	rs4834792	chr4:120555696	T/A	cg24375607	chr4:120327624	NA	-0.47	-7.23	-0.37	3.27e-12	Diastolic blood pressure;
LUSC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06634786	chr22:41940651	POLR3H	-0.51	-5.97	-0.31	6.08e-9	Vitiligo;
LUSC	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg11502198	chr6:26597334	ABT1	0.64	10.07	0.48	5.31e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs9443645	0.810	rs7767711	chr6:79810700	G/A	cg05283184	chr6:79620031	NA	-0.54	-11.02	-0.52	2.75e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg26335602	chr6:28129616	ZNF389	0.44	5.94	0.31	6.98e-9	Parkinson's disease;
LUSC	cis	rs4253772	1.000	rs4253772	chr22:46627603	C/T	cg09491104	chr22:46646882	C22orf40	-0.63	-6.52	-0.34	2.57e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg05802129	chr4:122689817	NA	-0.5	-8.12	-0.41	9.17e-15	Type 2 diabetes;
LUSC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg16339924	chr4:17578868	LAP3	0.59	9.2	0.45	3.85e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1322512	0.611	rs1028651	chr6:152937865	T/C	cg27316956	chr6:152958899	SYNE1	-0.36	-5.94	-0.31	7.06e-9	Tonometry;
LUSC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-0.92	-17.29	-0.69	2.73e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs983392	0.679	rs1026255	chr11:60029949	A/G	cg20284999	chr11:59952153	MS4A6A	-0.39	-6.51	-0.34	2.77e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg03948781	chr1:205179583	DSTYK	0.33	6.46	0.33	3.63e-10	Red blood cell count;
LUSC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg03351412	chr1:154909251	PMVK	0.46	7.16	0.36	5.3e-12	Prostate cancer;
LUSC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg12257692	chr3:49977190	RBM6	-0.26	-7.33	-0.37	1.75e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg11632617	chr15:75315747	PPCDC	-0.52	-6.72	-0.35	7.75e-11	Blood trace element (Zn levels);
LUSC	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.84	-0.39	6.19e-14	Schizophrenia;
LUSC	cis	rs9283706	0.689	rs12517976	chr5:66321579	G/A	cg11590213	chr5:66331682	MAST4	0.47	6.75	0.35	6.56e-11	Coronary artery disease;
LUSC	cis	rs7247513	0.964	rs12979795	chr19:12717847	C/T	cg01871581	chr19:12707946	ZNF490	0.57	9.16	0.45	5.27e-18	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.78	0.77	4.41e-66	Prudent dietary pattern;
LUSC	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg17376030	chr22:41985996	PMM1	-0.42	-5.69	-0.3	2.76e-8	Vitiligo;
LUSC	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg02017074	chr12:117425053	FBXW8	0.66	7.55	0.38	4.13e-13	Subcortical brain region volumes;Hippocampal volume;
LUSC	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg23625390	chr15:77176239	SCAPER	-0.56	-8.85	-0.44	5.21e-17	Blood metabolite levels;
LUSC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-17.68	-0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11785693	0.862	rs73183618	chr8:4988340	T/C	cg26367366	chr8:4980734	NA	0.77	9.15	0.45	5.86e-18	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.32	0.37	1.89e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg02038168	chr22:39784481	NA	-0.48	-7.64	-0.39	2.36e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs11935423	0.778	rs6839296	chr4:100492817	G/A	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.1	-0.32	3e-9	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21724239	chr8:58056113	NA	0.81	8.84	0.44	5.66e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	8.8	0.43	7.21e-17	Menopause (age at onset);
LUSC	cis	rs1967309	0.625	rs730242	chr16:4070433	C/T	cg00061520	chr16:4070371	ADCY9	0.4	8.19	0.41	5.54e-15	Response to Dalcetrapib treatment in acute coronary syndrome;
LUSC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00631329	chr6:26305371	NA	0.45	8.87	0.44	4.62e-17	Educational attainment;
LUSC	cis	rs7408868	0.563	rs11085949	chr19:15296917	G/T	cg14696996	chr19:15285081	NOTCH3	0.78	7.86	0.4	5.32e-14	Pulse pressure;
LUSC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg02475777	chr4:1388615	CRIPAK	-0.41	-6.0	-0.31	5.1e-9	Obesity-related traits;
LUSC	trans	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg11887960	chr12:57824829	NA	0.47	6.47	0.33	3.48e-10	Obesity-related traits;
LUSC	cis	rs981844	1.000	rs2251639	chr4:154656410	T/C	cg14289246	chr4:154710475	SFRP2	0.5	6.26	0.32	1.2e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs7178572	0.568	rs62008452	chr15:77591007	A/G	cg22256960	chr15:77711686	NA	-0.51	-8.04	-0.4	1.63e-14	Type 2 diabetes;
LUSC	cis	rs10744422	0.800	rs2649902	chr12:123243687	G/A	cg25930673	chr12:123319894	HIP1R	-0.58	-5.98	-0.31	5.68e-9	Schizophrenia;
LUSC	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-1.14	-18.11	-0.7	1.5e-51	Exhaled nitric oxide output;
LUSC	cis	rs2235544	1.000	rs2235544	chr1:54375570	A/C	cg25741118	chr1:54482237	LDLRAD1	-0.28	-6.29	-0.33	1e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg17264618	chr3:40429014	ENTPD3	0.33	6.93	0.35	2.23e-11	Renal cell carcinoma;
LUSC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg05025164	chr4:1340916	KIAA1530	0.45	6.87	0.35	3.19e-11	Obesity-related traits;
LUSC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-9.96	-0.48	1.28e-20	Alzheimer's disease;
LUSC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg18681998	chr4:17616180	MED28	0.85	16.06	0.66	2.03e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9473147	0.516	rs1485780	chr6:47556630	A/C	cg20196966	chr6:47445060	CD2AP	0.41	5.75	0.3	2.07e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg25838465	chr1:92012736	NA	0.47	6.57	0.34	1.92e-10	Eosinophil percentage of white cells;
LUSC	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg12927641	chr6:109611667	NA	-0.34	-5.8	-0.3	1.52e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs2425143	1.000	rs7261284	chr20:34244104	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.21	-0.32	1.58e-9	Blood protein levels;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg16261398	chr11:1410750	BRSK2	0.31	6.01	0.31	4.73e-9	Metabolite levels (Pyroglutamine);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13098082	chr7:149290	NA	0.44	6.12	0.32	2.64e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6558174	0.930	rs12676084	chr8:22493350	C/T	cg03733263	chr8:22462867	KIAA1967	0.46	6.08	0.32	3.28e-9	Breast cancer;
LUSC	trans	rs75804782	0.641	rs72987328	chr2:239360097	C/T	cg01134436	chr17:81009848	B3GNTL1	0.66	6.41	0.33	4.82e-10	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg03886242	chr7:26192032	NFE2L3	0.37	6.17	0.32	1.99e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg19640130	chr10:64028056	RTKN2	0.43	7.61	0.38	2.8e-13	Rheumatoid arthritis;
LUSC	cis	rs2019216	0.542	rs3829569	chr17:21909222	T/C	cg22648282	chr17:21454238	C17orf51	-0.5	-7.42	-0.38	1e-12	Pelvic organ prolapse;
LUSC	cis	rs2742417	1.000	rs2742386	chr3:45756310	A/C	cg04837898	chr3:45731254	SACM1L	-0.34	-5.73	-0.3	2.26e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.79	-0.57	9.23e-31	Platelet count;
LUSC	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg23649088	chr2:200775458	C2orf69	0.58	8.41	0.42	1.21e-15	Schizophrenia;
LUSC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg07636037	chr3:49044803	WDR6	0.44	6.38	0.33	5.9e-10	Resting heart rate;
LUSC	cis	rs9815354	0.812	rs73073229	chr3:42007850	T/C	cg03022575	chr3:42003672	ULK4	0.82	8.57	0.42	3.93e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs62400317	0.762	rs12211922	chr6:44847210	A/G	cg18551225	chr6:44695536	NA	-0.47	-7.5	-0.38	5.71e-13	Total body bone mineral density;
LUSC	cis	rs9653442	0.863	rs10865035	chr2:100835734	A/G	cg07810366	chr2:100720526	AFF3	-0.46	-8.17	-0.41	6.53e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg22907277	chr7:1156413	C7orf50	0.72	10.48	0.5	2.17e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12541635	1.000	rs1540420	chr8:107088426	C/T	cg10147462	chr8:107024639	NA	-0.48	-8.76	-0.43	1.03e-16	Age of smoking initiation;
LUSC	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.67	-0.43	1.88e-16	Retinal vascular caliber;
LUSC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg06454157	chr6:167490870	NA	-0.3	-7.03	-0.36	1.19e-11	Crohn's disease;
LUSC	trans	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.54	-0.34	2.36e-10	Endometrial cancer;
LUSC	cis	rs62400317	0.762	rs756	chr6:44795772	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.28	-0.37	2.35e-12	Total body bone mineral density;
LUSC	cis	rs4588572	0.644	rs2115435	chr5:77723700	A/C	cg11547950	chr5:77652471	NA	-0.45	-6.73	-0.35	7.33e-11	Triglycerides;
LUSC	cis	rs9494145	0.680	rs9402686	chr6:135427817	G/A	cg22676075	chr6:135203613	NA	0.63	8.9	0.44	3.53e-17	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs7589342	0.536	rs7562892	chr2:106396212	C/T	cg14210321	chr2:106509881	NCK2	-0.4	-5.73	-0.3	2.28e-8	Addiction;
LUSC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-10.67	-0.5	4.43e-23	Bipolar disorder and schizophrenia;
LUSC	trans	rs629535	0.911	rs627382	chr8:70014081	C/T	cg21567404	chr3:27674614	NA	-0.96	-15.16	-0.64	6.97e-40	Dupuytren's disease;
LUSC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg08219700	chr8:58056026	NA	0.5	6.21	0.32	1.6e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg12639453	chr1:2035780	PRKCZ	0.32	6.88	0.35	2.93e-11	Height;
LUSC	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg03894339	chr8:19674705	INTS10	0.51	6.83	0.35	4.07e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg06521331	chr12:34319734	NA	-0.48	-7.67	-0.39	1.84e-13	Morning vs. evening chronotype;
LUSC	cis	rs7084921	0.579	rs11597870	chr10:101847857	T/C	cg02250046	chr10:101825185	CPN1	-0.35	-6.2	-0.32	1.63e-9	Bone mineral density;
LUSC	cis	rs7712401	0.541	rs6867714	chr5:122382059	T/G	cg19077854	chr5:122220652	SNX24	0.38	7.98	0.4	2.32e-14	Mean platelet volume;
LUSC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg15145296	chr3:125709740	NA	-0.58	-6.52	-0.34	2.63e-10	Blood pressure (smoking interaction);
LUSC	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg00277334	chr10:82204260	NA	-0.49	-6.71	-0.34	8.2e-11	Post bronchodilator FEV1;
LUSC	cis	rs1003719	0.591	rs2018521	chr21:38517264	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.52	-8.09	-0.4	1.12e-14	Eye color traits;
LUSC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.48	0.56	1.35e-29	Motion sickness;
LUSC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	0.9	13.18	0.58	3.2e-32	Breast cancer;
LUSC	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-20.08	-0.74	2.32e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2637266	1.000	rs7098929	chr10:78361194	T/G	cg18941641	chr10:78392320	NA	0.4	7.45	0.38	7.84e-13	Pulmonary function;
LUSC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-1.13	-24.98	-0.81	2.08e-78	Height;
LUSC	trans	rs28647808	0.786	rs28458971	chr9:136255736	C/T	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs4293296	0.525	rs75175834	chr14:54825714	T/C	cg02257953	chr14:54816093	NA	-0.45	-6.34	-0.33	7.57e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07988820	chr12:82153109	PPFIA2	0.42	5.98	0.31	5.71e-9	Resting heart rate;
LUSC	cis	rs6433857	0.505	rs16867320	chr2:181362312	A/G	cg23363182	chr2:181467187	NA	0.44	7.04	0.36	1.1e-11	Body mass index;
LUSC	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	11.56	0.53	3.19e-26	Ileal carcinoids;
LUSC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.57	0.78	3.62e-69	Prudent dietary pattern;
LUSC	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg22676075	chr6:135203613	NA	0.49	7.59	0.38	3.26e-13	Red blood cell count;
LUSC	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22307029	chr19:49891270	CCDC155	0.6	7.7	0.39	1.51e-13	Multiple sclerosis;
LUSC	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg21211680	chr2:198530	NA	0.73	8.23	0.41	4.28e-15	Blood protein levels;
LUSC	cis	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg06521331	chr12:34319734	NA	-0.46	-7.36	-0.37	1.45e-12	Morning vs. evening chronotype;
LUSC	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg16576597	chr16:28551801	NUPR1	0.34	6.88	0.35	2.9100000000000002e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg12179176	chr11:130786555	SNX19	0.62	9.66	0.47	1.27e-19	Schizophrenia;
LUSC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20135002	chr11:47629003	NA	-0.51	-7.88	-0.4	4.74e-14	Subjective well-being;
LUSC	cis	rs7809950	1.000	rs10276604	chr7:107216738	C/T	cg23024343	chr7:107201750	COG5	0.53	8.4	0.42	1.3e-15	Coronary artery disease;
LUSC	cis	rs920590	0.523	rs4464983	chr8:19680979	C/T	cg03894339	chr8:19674705	INTS10	-0.44	-6.26	-0.32	1.16e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7180079	1.000	rs8031895	chr15:64487863	C/A	cg08069370	chr15:64387884	SNX1	-0.52	-5.7	-0.3	2.67e-8	Monocyte count;
LUSC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25072359	chr17:41440525	NA	0.65	9.39	0.46	9.7e-19	Menopause (age at onset);
LUSC	cis	rs2070433	0.534	rs2839269	chr21:47891491	A/G	cg12379764	chr21:47803548	PCNT	0.61	8.77	0.43	9.46e-17	Lymphocyte counts;
LUSC	cis	rs10911363	0.592	rs2275675	chr1:183439483	C/T	cg09173681	chr1:183549694	NCF2	-0.65	-11.85	-0.54	2.91e-27	Systemic lupus erythematosus;
LUSC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.39	0.33	5.42e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.92e-20	Coronary artery disease;
LUSC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.57	7.67	0.39	1.86e-13	High light scatter reticulocyte count;
LUSC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg11632617	chr15:75315747	PPCDC	-0.53	-6.89	-0.35	2.78e-11	Blood trace element (Zn levels);
LUSC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg18110333	chr6:292329	DUSP22	-0.53	-7.87	-0.4	4.98e-14	Menopause (age at onset);
LUSC	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg23093090	chr10:104574429	C10orf26	0.34	6.26	0.32	1.15e-9	Arsenic metabolism;
LUSC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg26039829	chr8:22132926	PIWIL2	0.43	8.22	0.41	4.68e-15	Hypertriglyceridemia;
LUSC	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	9.47	0.46	5.47e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg17264618	chr3:40429014	ENTPD3	0.35	7.53	0.38	4.81e-13	Renal cell carcinoma;
LUSC	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.97	-0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.86	0.6	7.98e-35	Breast cancer;
LUSC	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg11887960	chr12:57824829	NA	0.58	7.11	0.36	7.27e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs929596	0.755	rs4148324	chr2:234672722	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.65	-11.04	-0.52	2.35e-24	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.44	0.5	2.94e-22	Colorectal cancer;
LUSC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg06713675	chr4:122721982	EXOSC9	-0.44	-7.77	-0.39	9.93e-14	Type 2 diabetes;
LUSC	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg18827107	chr12:86230957	RASSF9	-0.46	-6.83	-0.35	3.98e-11	Major depressive disorder;
LUSC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg06784218	chr1:46089804	CCDC17	0.52	10.63	0.5	6.36e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs734999	0.869	rs61054170	chr1:2498052	C/T	cg18854424	chr1:2615690	NA	0.47	9.71	0.47	8.81e-20	Ulcerative colitis;
LUSC	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg03948781	chr1:205179583	DSTYK	0.33	6.46	0.33	3.66e-10	Red blood cell count;
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.85	15.36	0.64	1.22e-40	Menarche (age at onset);
LUSC	cis	rs2273669	0.667	rs12374597	chr6:109346184	A/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.73	7.68	0.39	1.76e-13	Yeast infection;
LUSC	cis	rs2274273	0.870	rs61210954	chr14:55765402	T/C	cg04306507	chr14:55594613	LGALS3	0.56	13.14	0.58	4.36e-32	Protein biomarker;
LUSC	trans	rs12145833	0.665	rs78871868	chr1:243422322	C/T	cg01826367	chr1:224180288	NA	0.67	6.03	0.31	4.42e-9	Obesity (early onset extreme);
LUSC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg12863693	chr15:85201151	NMB	0.34	6.8	0.35	4.75e-11	Schizophrenia;
LUSC	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.46	-0.42	8.72e-16	Response to antipsychotic treatment;
LUSC	cis	rs2425143	1.000	rs733609	chr20:34393074	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.72	-0.3	2.41e-8	Blood protein levels;
LUSC	cis	rs240764	0.658	rs9322181	chr6:101221630	C/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.34	-0.33	7.43e-10	Neuroticism;
LUSC	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg03340356	chr1:67600835	NA	0.4	6.54	0.34	2.31e-10	Psoriasis;
LUSC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.79	0.35	5.24e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs7939886	0.920	rs76702940	chr11:55999305	G/A	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.97	0.36	1.73e-11	Bipolar disorder;
LUSC	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg14092571	chr14:90743983	NA	-0.36	-5.79	-0.3	1.64e-8	Mortality in heart failure;
LUSC	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.69	-0.34	9.63e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11360819	chr6:15663360	DTNBP1	-0.48	-6.66	-0.34	1.13e-10	Hepatitis;
LUSC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	6.09	0.32	3.13e-9	Height;
LUSC	cis	rs4706831	0.663	rs1984242	chr6:81051245	A/G	cg08355045	chr6:80787529	NA	0.48	8.22	0.41	4.5e-15	Joint mobility (Beighton score);
LUSC	trans	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg01620082	chr3:125678407	NA	-0.83	-7.4	-0.38	1.15e-12	Depression;
LUSC	cis	rs17401966	0.540	rs4846216	chr1:10447792	A/T	cg19773385	chr1:10388646	KIF1B	0.37	6.42	0.33	4.78e-10	Hepatocellular carcinoma;
LUSC	cis	rs516243	0.688	rs284312	chr1:10737226	C/T	cg02903756	chr1:10750680	CASZ1	-0.46	-8.05	-0.4	1.45e-14	Migraine - clinic-based;
LUSC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.69	-11.94	-0.55	1.28e-27	Dental caries;
LUSC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11890956	chr21:40555474	PSMG1	1.02	20.09	0.74	2.04e-59	Cognitive function;
LUSC	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.85	14.77	0.63	2.38e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs2273669	0.667	rs3734649	chr6:109294752	C/T	cg05315195	chr6:109294784	ARMC2	-0.58	-6.44	-0.33	4.09e-10	Prostate cancer;
LUSC	cis	rs1981331	1.000	rs75843712	chr21:47976115	A/G	cg17243659	chr21:48055224	PRMT2	0.86	6.21	0.32	1.61e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	trans	rs412658	0.704	rs8105767	chr19:22215441	A/G	cg05197062	chr11:11642011	GALNTL4	-0.41	-6.02	-0.31	4.6e-9	Telomere length;
LUSC	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.56	-7.72	-0.39	1.38e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	0.96	19.12	0.72	1.4e-55	Cognitive function;
LUSC	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-7.01	-0.36	1.29e-11	Cystic fibrosis severity;
LUSC	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg08807101	chr21:30365312	RNF160	-0.71	-11.22	-0.52	5.45e-25	Pancreatic cancer;
LUSC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.84	13.51	0.59	1.72e-33	Breast cancer;
LUSC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.3	0.56	6.22e-29	Motion sickness;
LUSC	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.68	-0.39	1.78e-13	Morning vs. evening chronotype;
LUSC	cis	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg03709012	chr19:19516395	GATAD2A	0.82	6.94	0.35	2.08e-11	LDL cholesterol;
LUSC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg05896524	chr21:47604654	C21orf56	0.51	7.75	0.39	1.13e-13	Testicular germ cell tumor;
LUSC	cis	rs7760949	0.889	rs9396262	chr6:13927418	C/T	cg27413430	chr6:13925136	RNF182	0.61	8.89	0.44	3.81e-17	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg22532475	chr10:104410764	TRIM8	-0.26	-6.07	-0.32	3.46e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg05855489	chr10:104503620	C10orf26	0.5	7.7	0.39	1.59e-13	Arsenic metabolism;
LUSC	cis	rs9309473	0.607	rs7567017	chr2:73596270	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-8.47	-0.42	8.05e-16	Metabolite levels;
LUSC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08109568	chr15:31115862	NA	-0.51	-7.29	-0.37	2.22e-12	Huntington's disease progression;
LUSC	cis	rs6500395	1.000	rs9933976	chr16:48590145	A/G	cg04672837	chr16:48644449	N4BP1	0.43	6.34	0.33	7.56e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg06263672	chr7:65235340	NA	-0.44	-6.41	-0.33	4.82e-10	Calcium levels;
LUSC	cis	rs72960926	0.744	rs1931272	chr6:74950681	C/T	cg03266952	chr6:74778945	NA	-0.84	-6.98	-0.36	1.57e-11	Metabolite levels (MHPG);
LUSC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06634786	chr22:41940651	POLR3H	0.52	5.94	0.31	7.26e-9	Vitiligo;
LUSC	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg04111992	chr7:158790115	NA	-0.49	-7.58	-0.38	3.41e-13	Facial morphology (factor 20);
LUSC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg18402987	chr7:1209562	NA	0.73	7.92	0.4	3.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.44	6.03	0.31	4.33e-9	Lung cancer;
LUSC	cis	rs3824867	0.879	rs10769267	chr11:47460098	C/T	cg20307385	chr11:47447363	PSMC3	0.65	9.66	0.47	1.27e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs727505	0.821	rs67167896	chr7:124614127	T/C	cg23710748	chr7:124431027	NA	-0.37	-6.54	-0.34	2.27e-10	Lewy body disease;
LUSC	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg18357645	chr12:58087776	OS9	0.41	6.22	0.32	1.49e-9	Multiple sclerosis;
LUSC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.59	0.38	3.26e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.24	-0.37	3.2e-12	Electroencephalogram traits;
LUSC	cis	rs11608355	0.545	rs2302704	chr12:109898797	A/G	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.9	-13.21	-0.59	2.44e-32	Initial pursuit acceleration;
LUSC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg09021430	chr5:549028	NA	-0.57	-7.76	-0.39	1.04e-13	Obesity-related traits;
LUSC	cis	rs77633900	0.614	rs2459360	chr15:76868664	C/T	cg21673338	chr15:77095150	SCAPER	-0.73	-7.19	-0.37	4.22e-12	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.67	-10.33	-0.49	6.6e-22	Brugada syndrome;
LUSC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg03929089	chr4:120376271	NA	-0.79	-10.1	-0.48	4.02e-21	Coronary artery disease;
LUSC	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.37	0.33	6.28e-10	Neuroticism;
LUSC	cis	rs17767294	0.541	rs72845050	chr6:27610070	A/C	cg08851530	chr6:28072375	NA	0.9	6.21	0.32	1.61e-9	Parkinson's disease;
LUSC	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	1.15	18.32	0.71	2.27e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs12677618	1.000	rs10092931	chr8:142307201	A/G	cg07140289	chr8:142299684	NA	0.35	5.74	0.3	2.15e-8	Plateletcrit;
LUSC	cis	rs8126001	0.573	rs7271530	chr20:62727915	A/G	cg03642690	chr20:62727907	OPRL1	0.32	5.69	0.3	2.85e-8	Pulse pressure;Mean corpuscular volume;
LUSC	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg01966878	chr4:90757139	SNCA	-0.43	-6.16	-0.32	2.05e-9	Neuroticism;
LUSC	cis	rs7523273	0.606	rs1962149	chr1:207956559	G/A	cg22525895	chr1:207977042	MIR29B2	-0.39	-6.12	-0.32	2.61e-9	Schizophrenia;
LUSC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-7.2	-0.37	3.92e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg26890010	chr1:70876953	CTH	0.43	6.21	0.32	1.58e-9	Triglycerides;
LUSC	cis	rs6693567	0.545	rs1260403	chr1:150303666	A/G	cg15654264	chr1:150340011	RPRD2	0.45	7.33	0.37	1.8e-12	Migraine;
LUSC	cis	rs3857536	0.813	rs9363554	chr6:66930183	A/G	cg07460842	chr6:66804631	NA	-0.47	-6.49	-0.33	3.18e-10	Blood trace element (Cu levels);
LUSC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg16584290	chr5:462447	EXOC3	-0.34	-5.81	-0.3	1.46e-8	Cystic fibrosis severity;
LUSC	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg13010199	chr12:38710504	ALG10B	0.55	8.36	0.42	1.73e-15	Morning vs. evening chronotype;
LUSC	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg05555928	chr11:63887634	MACROD1	-0.48	-6.09	-0.32	3.08e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.68	-0.3	2.87e-8	Eotaxin levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15283028	chr22:41601160	L3MBTL2	0.45	6.19	0.32	1.8e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7264396	0.887	rs736031	chr20:34048625	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.72	-0.35	7.94e-11	Total cholesterol levels;
LUSC	cis	rs874628	0.686	rs11666281	chr19:18234588	C/T	cg00493341	chr19:18228948	MAST3	0.47	6.31	0.33	8.81e-10	Multiple sclerosis;
LUSC	cis	rs7605827	0.930	rs6720900	chr2:15688281	T/C	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.32e-17	Educational attainment (years of education);
LUSC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg22823121	chr1:150693482	HORMAD1	0.47	6.71	0.34	8.59e-11	Melanoma;
LUSC	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.21	0.45	3.72e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg06637938	chr14:75390232	RPS6KL1	0.54	8.78	0.43	8.47e-17	Coronary artery disease;
LUSC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg09877947	chr5:131593287	PDLIM4	0.45	7.07	0.36	8.83e-12	Breast cancer;
LUSC	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg13010199	chr12:38710504	ALG10B	0.54	8.44	0.42	9.47e-16	Morning vs. evening chronotype;
LUSC	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	0.94	8.24	0.41	3.94e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18876405	chr7:65276391	NA	0.54	8.62	0.43	2.7e-16	Aortic root size;
LUSC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg12310025	chr6:25882481	NA	-0.45	-7.82	-0.39	7.19e-14	Blood metabolite levels;
LUSC	cis	rs4851254	0.660	rs60697219	chr2:100699507	G/A	cg22139774	chr2:100720529	AFF3	-0.43	-5.75	-0.3	1.99e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg03909863	chr11:638404	DRD4	-0.37	-5.7	-0.3	2.66e-8	Systemic lupus erythematosus;
LUSC	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg24375607	chr4:120327624	NA	0.69	10.92	0.51	6.06e-24	Corneal astigmatism;
LUSC	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg01420254	chr6:26195488	NA	0.71	7.5	0.38	5.86e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs2932538	0.922	rs6698030	chr1:113138318	G/A	cg22162597	chr1:113214053	CAPZA1	0.7	10.06	0.48	5.71e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01570182	chr17:44337453	NA	0.69	10.39	0.49	4.39e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9653442	0.522	rs4851274	chr2:100870862	T/C	cg22139774	chr2:100720529	AFF3	-0.37	-6.14	-0.32	2.39e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg23283495	chr1:209979779	IRF6	0.67	7.92	0.4	3.5e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.66	-12.03	-0.55	6.31e-28	Birth weight;
LUSC	cis	rs11785693	0.862	rs6994150	chr8:4996630	T/G	cg26367366	chr8:4980734	NA	0.71	8.43	0.42	1.02e-15	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg09877947	chr5:131593287	PDLIM4	0.42	6.98	0.36	1.57e-11	Blood metabolite levels;
LUSC	cis	rs6975373	0.730	rs1009528	chr7:4456304	G/T	cg10785373	chr7:4456119	NA	-0.6	-5.7	-0.3	2.58e-8	Borderline personality disorder;
LUSC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	10.1	0.48	4.12e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg20887711	chr4:1340912	KIAA1530	0.47	7.17	0.37	4.96e-12	Obesity-related traits;
LUSC	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.21	0.45	3.83e-18	Coffee consumption (cups per day);
LUSC	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg05163923	chr11:71159392	DHCR7	-0.77	-10.04	-0.48	6.5e-21	Vitamin D levels;
LUSC	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg25427524	chr10:38739819	LOC399744	0.43	5.75	0.3	2e-8	Obesity (extreme);
LUSC	trans	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08382705	chr11:45687319	CHST1	-0.49	-7.76	-0.39	1.04e-13	Height;
LUSC	trans	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg07393940	chr7:158741817	NA	0.51	8.42	0.42	1.13e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.11	-0.58	5.82e-32	Platelet count;
LUSC	cis	rs68092024	0.731	rs793480	chr3:99488364	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	6.34	0.33	7.66e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19346786	chr7:2764209	NA	-0.39	-6.85	-0.35	3.63e-11	Height;
LUSC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7169223	0.653	rs1564499	chr15:79084808	C/T	cg21242079	chr15:79101063	ADAMTS7	-0.39	-6.06	-0.31	3.73e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs6987853	0.933	rs2974339	chr8:42397529	T/C	cg09913449	chr8:42400586	C8orf40	0.49	8.26	0.41	3.35e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4988958	0.565	rs6732138	chr2:103009662	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.54e-12	Asthma (childhood onset);
LUSC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg00310523	chr12:86230176	RASSF9	0.46	8.5	0.42	6.35e-16	Major depressive disorder;
LUSC	cis	rs2200578	1.000	rs60025964	chr2:99880577	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.53	6.19	0.32	1.72e-9	IgG glycosylation;
LUSC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg22349387	chr12:9600060	DDX12	-0.44	-7.04	-0.36	1.12e-11	Breast size;
LUSC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25072359	chr17:41440525	NA	0.69	9.65	0.47	1.36e-19	Menopause (age at onset);
LUSC	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-7.77	-0.39	9.72e-14	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	6.61	0.34	1.49e-10	Bipolar disorder;
LUSC	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg13010199	chr12:38710504	ALG10B	0.68	11.24	0.52	4.31e-25	Heart rate;
LUSC	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg01503450	chr10:980765	NA	-0.39	-5.72	-0.3	2.34e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs870825	0.655	rs67798981	chr4:185619567	A/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg18538332	chr22:24372958	LOC391322	-0.47	-8.37	-0.42	1.62e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4654899	1.000	rs7537072	chr1:21434533	T/C	cg01072550	chr1:21505969	NA	-0.51	-7.79	-0.39	8.71e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg10862848	chr6:42927986	GNMT	-0.27	-6.34	-0.33	7.6e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg14773178	chr5:1868261	NA	0.31	5.69	0.3	2.74e-8	Cardiovascular disease risk factors;
LUSC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg06454157	chr6:167490870	NA	-0.24	-6.04	-0.31	4.19e-9	Crohn's disease;
LUSC	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg05855489	chr10:104503620	C10orf26	0.6	9.76	0.47	5.86e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg22681709	chr2:178499509	PDE11A	-0.45	-8.12	-0.41	9.28e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	15.98	0.66	4.1e-43	Platelet count;
LUSC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg02269571	chr22:50332266	NA	0.59	8.71	0.43	1.44e-16	Schizophrenia;
LUSC	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg02569458	chr12:86230093	RASSF9	0.48	7.66	0.39	2.03e-13	Major depressive disorder;
LUSC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.85	-14.33	-0.62	1.18e-36	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.65	0.47	1.38e-19	Bipolar disorder;
LUSC	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.87	14.25	0.61	2.49e-36	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2274273	1.000	rs10149435	chr14:55627489	C/T	cg04306507	chr14:55594613	LGALS3	0.54	11.89	0.55	2.02e-27	Protein biomarker;
LUSC	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.2	-0.37	4.06e-12	Systolic blood pressure;
LUSC	cis	rs6542838	0.641	rs6760065	chr2:99486318	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.08	-0.32	3.22e-9	Fear of minor pain;
LUSC	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg13334819	chr7:99746414	C7orf59	0.49	6.5	0.34	2.96e-10	Coronary artery disease;
LUSC	cis	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg15711740	chr2:61764176	XPO1	-0.5	-7.93	-0.4	3.26e-14	Tuberculosis;
LUSC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg05585544	chr11:47624801	NA	-0.42	-7.39	-0.37	1.21e-12	Subjective well-being;
LUSC	trans	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	7.1	0.36	7.44e-12	Menarche (age at onset);
LUSC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg13319975	chr6:146136371	FBXO30	-0.7	-10.73	-0.51	2.91e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7789940	1.000	rs76024966	chr7:75995021	C/T	cg10167463	chr7:75959203	YWHAG	-0.66	-9.96	-0.48	1.24e-20	Multiple sclerosis;
LUSC	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg22705602	chr4:152727874	NA	-0.39	-8.54	-0.42	4.8e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg12002119	chr2:101014098	CHST10	0.35	5.81	0.3	1.5e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9311676	0.632	rs11130631	chr3:58366128	G/C	cg26110898	chr3:58419937	PDHB	0.44	7.22	0.37	3.62e-12	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.78e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs4356932	1.000	rs6846814	chr4:76952288	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.78	0.3	1.69e-8	Blood protein levels;
LUSC	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.19	-0.41	5.66e-15	Axial length;
LUSC	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	8.52	0.42	5.39e-16	Schizophrenia;
LUSC	cis	rs61990749	0.597	rs176946	chr14:78178439	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.51	5.68	0.3	2.9e-8	Fibroblast growth factor basic levels;
LUSC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg20891283	chr12:69753455	YEATS4	0.44	6.02	0.31	4.53e-9	Response to diuretic therapy;
LUSC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg16414030	chr3:133502952	NA	0.35	5.77	0.3	1.86e-8	Iron status biomarkers;
LUSC	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg25237894	chr2:233734115	C2orf82	-0.34	-6.17	-0.32	1.99e-9	Coronary artery disease;
LUSC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg02221750	chr19:17393354	ANKLE1	-0.89	-13.67	-0.6	4.45e-34	Systemic lupus erythematosus;
LUSC	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg21890820	chr11:65308645	LTBP3	0.5	7.44	0.38	8.38e-13	Bone mineral density;
LUSC	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.45	0.33	4.02e-10	Testicular germ cell tumor;
LUSC	cis	rs9341835	0.510	rs2250179	chr6:64174559	T/G	cg03326410	chr6:64151739	NA	-0.36	-5.91	-0.31	8.32e-9	Schizophrenia;
LUSC	cis	rs1506636	1.000	rs619575	chr7:123393460	C/T	cg03229431	chr7:123269106	ASB15	-0.58	-9.33	-0.45	1.5e-18	Plateletcrit;Platelet count;
LUSC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.42	-0.46	7.51e-19	Chronic sinus infection;
LUSC	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	1.18	13.92	0.61	4.83e-35	Arsenic metabolism;
LUSC	trans	rs9975851	0.663	rs219685	chr21:27734660	A/G	cg13892514	chr2:241853394	NA	0.34	5.96	0.31	6.39e-9	Airflow obstruction;
LUSC	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg03676636	chr4:99064102	C4orf37	0.37	7.68	0.39	1.8e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1358748	0.522	rs1321153	chr1:67584824	T/C	cg02640540	chr1:67518911	SLC35D1	0.67	6.53	0.34	2.5e-10	Tuberculosis;
LUSC	cis	rs16867335	1.000	rs11899423	chr2:181483750	C/A	cg23363182	chr2:181467187	NA	-0.46	-6.1	-0.32	2.97e-9	Survival in rectal cancer;
LUSC	cis	rs9925964	0.967	rs889548	chr16:31137712	A/G	cg02466173	chr16:30829666	NA	-0.34	-6.18	-0.32	1.86e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg18721089	chr20:30220636	NA	-0.43	-6.93	-0.35	2.24e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg14552801	chr7:65878734	NA	0.45	6.53	0.34	2.5e-10	Aortic root size;
LUSC	cis	rs2067615	0.542	rs11113120	chr12:107203460	T/C	cg15890332	chr12:107067104	RFX4	0.34	6.21	0.32	1.61e-9	Heart rate;
LUSC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg19468946	chr17:37922297	IKZF3	-0.44	-6.91	-0.35	2.5e-11	Self-reported allergy;
LUSC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	8.91	0.44	3.33e-17	Prudent dietary pattern;
LUSC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg08999081	chr20:33150536	PIGU	0.43	7.98	0.4	2.4e-14	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1322512	0.874	rs2758802	chr6:152952542	A/G	cg27316956	chr6:152958899	SYNE1	-0.36	-6.18	-0.32	1.82e-9	Tonometry;
LUSC	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg11266682	chr4:10021025	SLC2A9	0.43	7.41	0.38	1.03e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1371867	0.810	rs3020182	chr8:101233008	T/C	cg00191853	chr8:101177733	SPAG1	0.4	6.47	0.33	3.47e-10	Atrioventricular conduction;
LUSC	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg12863693	chr15:85201151	NMB	0.34	6.78	0.35	5.31e-11	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.41	0.33	4.95e-10	Lung cancer;
LUSC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.72	0.39	1.32e-13	Total body bone mineral density;
LUSC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12667521	chr19:29218732	NA	0.61	8.78	0.43	8.57e-17	Methadone dose in opioid dependence;
LUSC	cis	rs4343996	0.720	rs2178630	chr7:3492208	T/C	cg21248987	chr7:3385318	SDK1	0.35	5.75	0.3	2.07e-8	Motion sickness;
LUSC	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg21385522	chr1:16154831	NA	-0.65	-10.75	-0.51	2.47e-23	Dilated cardiomyopathy;
LUSC	cis	rs7119	0.700	rs4886519	chr15:77893885	A/G	cg27398640	chr15:77910606	LINGO1	0.37	8.75	0.43	1.08e-16	Type 2 diabetes;
LUSC	cis	rs1506636	1.000	rs600774	chr7:123397831	C/T	cg03229431	chr7:123269106	ASB15	0.61	9.84	0.47	3.12e-20	Plateletcrit;Platelet count;
LUSC	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21775007	chr8:11205619	TDH	0.75	12.44	0.56	1.94e-29	Retinal vascular caliber;
LUSC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg22823121	chr1:150693482	HORMAD1	0.49	7.0	0.36	1.42e-11	Melanoma;
LUSC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg03351412	chr1:154909251	PMVK	0.55	8.7	0.43	1.52e-16	Prostate cancer;
LUSC	cis	rs2607426	0.681	rs2303723	chr19:41230995	A/G	cg05508168	chr19:41255947	C19orf54;SNRPA	0.92	7.08	0.36	8.81e-12	Blood protein levels;
LUSC	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.83	-0.39	6.69e-14	Blood metabolite levels;
LUSC	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.81	0.43	6.77e-17	Axial length;
LUSC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.12	15.13	0.64	9.18e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9921338	0.961	rs72773830	chr16:11412823	G/C	cg00044050	chr16:11439710	C16orf75	-0.5	-6.75	-0.35	6.64e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	7.64	0.39	2.28e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg12463550	chr7:65579703	CRCP	-0.56	-8.33	-0.41	2.14e-15	Aortic root size;
LUSC	cis	rs7589342	0.660	rs11124058	chr2:106400749	A/G	cg14210321	chr2:106509881	NCK2	-0.44	-6.09	-0.32	3.06e-9	Addiction;
LUSC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg11752832	chr7:134001865	SLC35B4	-0.48	-7.12	-0.36	6.49e-12	Mean platelet volume;
LUSC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg08680598	chr22:49984980	NA	-0.35	-6.52	-0.34	2.53e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02964845	chr11:64885336	ZNHIT2	-0.42	-6.14	-0.32	2.35e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11822910	1.000	rs11822910	chr11:57195917	G/A	cg00522883	chr11:57194120	SLC43A3	0.44	6.37	0.33	6.21e-10	Platelet distribution width;
LUSC	cis	rs62400317	0.859	rs72869118	chr6:45064626	T/C	cg18551225	chr6:44695536	NA	-0.42	-6.82	-0.35	4.17e-11	Total body bone mineral density;
LUSC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg06637938	chr14:75390232	RPS6KL1	0.51	7.87	0.4	5.01e-14	Height;
LUSC	cis	rs6456156	0.742	rs3093026	chr6:167532690	A/G	cg07741184	chr6:167504864	NA	0.32	5.76	0.3	1.87e-8	Primary biliary cholangitis;
LUSC	cis	rs12200560	0.505	rs1334318	chr6:97079610	A/G	cg06623918	chr6:96969491	KIAA0776	-0.48	-6.94	-0.36	2.02e-11	Coronary heart disease;
LUSC	cis	rs10754283	0.967	rs10737707	chr1:90119304	A/G	cg21401794	chr1:90099060	LRRC8C	0.61	8.78	0.43	8.66e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	ch.11.42038R	chr11:967971	AP2A2	0.42	6.11	0.32	2.78e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.7	-0.34	8.84e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg18225595	chr11:63971243	STIP1	0.51	6.31	0.33	8.93e-10	Mean platelet volume;
LUSC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.94	0.4	3.18e-14	Parkinson's disease;
LUSC	cis	rs600626	0.529	rs2008476	chr11:75470813	C/T	cg24262691	chr11:75473276	NA	0.51	6.64	0.34	1.3100000000000001e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs55665837	1.000	rs10832264	chr11:14459982	T/A	cg05501817	chr11:14380813	RRAS2	-0.41	-6.51	-0.34	2.72e-10	Vitamin D levels;
LUSC	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.25	0.71	4.19e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7089973	0.523	rs6585311	chr10:116733575	T/C	cg23260525	chr10:116636907	FAM160B1	0.3	5.78	0.3	1.73e-8	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg24881330	chr22:46731750	TRMU	0.84	7.3	0.37	2.11e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg20476274	chr7:133979776	SLC35B4	0.79	13.93	0.61	4.16e-35	Mean platelet volume;
LUSC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg07424592	chr7:64974309	NA	0.67	5.97	0.31	6.18e-9	Diabetic kidney disease;
LUSC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg17279839	chr7:150038598	RARRES2	0.4	6.13	0.32	2.46e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg22815214	chr1:201083145	CACNA1S	0.53	9.17	0.45	5.08e-18	Permanent tooth development;
LUSC	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg06627628	chr2:24431161	ITSN2	-0.47	-6.8	-0.35	4.87e-11	Venous thromboembolism (SNP x SNP interaction);
LUSC	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.43	-0.46	6.97e-19	Chronic sinus infection;
LUSC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg05347473	chr6:146136440	FBXO30	-0.51	-8.74	-0.43	1.19e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg22029157	chr1:209979665	IRF6	0.8	10.25	0.49	1.27e-21	Cleft lip with or without cleft palate;
LUSC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.02	-0.31	4.55e-9	Total body bone mineral density;
LUSC	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg09035930	chr12:129282057	SLC15A4	-0.6	-9.98	-0.48	1.06e-20	Systemic lupus erythematosus;
LUSC	cis	rs2742234	0.541	rs12416428	chr10:43708998	G/A	cg02780029	chr10:43622663	RET	0.34	5.66	0.3	3.23e-8	Hirschsprung disease;
LUSC	cis	rs9472414	0.771	rs1935549	chr6:44763188	C/T	cg20913747	chr6:44695427	NA	0.41	5.92	0.31	7.92e-9	Height;
LUSC	trans	rs11671005	0.504	rs7257669	chr19:59064939	T/C	cg22037779	chr5:139682734	PFDN1	-0.56	-7.19	-0.37	4.21e-12	Mean platelet volume;
LUSC	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg00999904	chr2:3704751	ALLC	0.53	8.79	0.43	7.76e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg01884057	chr2:25150051	NA	0.42	9.1	0.45	8.06e-18	Body mass index;
LUSC	trans	rs17266958	1.000	rs62576991	chr9:83299840	C/T	cg01905489	chr1:26616534	UBXN11	-0.51	-5.97	-0.31	6.06e-9	Preschool internalizing problems;
LUSC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.17	-0.32	1.96e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.45	0.56	1.73e-29	Motion sickness;
LUSC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg05973401	chr12:123451056	ABCB9	0.52	7.54	0.38	4.47e-13	Platelet count;
LUSC	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.86	-0.47	2.63e-20	Migraine;Coronary artery disease;
LUSC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg03709012	chr19:19516395	GATAD2A	0.76	11.7	0.54	1e-26	Tonsillectomy;
LUSC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg20276088	chr3:133502917	NA	-0.42	-6.13	-0.32	2.45e-9	Iron status biomarkers;
LUSC	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg06627628	chr2:24431161	ITSN2	-0.61	-9.0	-0.44	1.75e-17	Asthma;
LUSC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	1.06	20.2	0.74	7.16e-60	Menopause (age at onset);
LUSC	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.82	10.81	0.51	1.42e-23	Mean corpuscular volume;
LUSC	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.2	-0.41	5.06e-15	Response to antipsychotic treatment;
LUSC	cis	rs11209002	1.000	rs2863202	chr1:67584335	T/C	cg02640540	chr1:67518911	SLC35D1	0.68	7.37	0.37	1.4e-12	Crohn's disease;
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg13453750	chr1:205783389	SLC41A1	-0.33	-6.41	-0.33	5.09e-10	Menarche (age at onset);
LUSC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg01802117	chr1:53393560	SCP2	0.39	6.45	0.33	3.85e-10	Monocyte count;
LUSC	cis	rs76935404	0.899	rs73034465	chr19:41419075	A/G	cg04176888	chr19:41596066	CYP2A13	0.39	6.02	0.31	4.51e-9	nicotine metabolite ratio in current smokers;
LUSC	cis	rs295140	1.000	rs7559005	chr2:201161371	C/T	cg04283868	chr2:201171347	SPATS2L	0.43	6.58	0.34	1.83e-10	QT interval;
LUSC	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg17052675	chr2:3827356	NA	-0.58	-11.38	-0.53	1.42e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	6.35	0.33	7.14e-10	Schizophrenia;
LUSC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.54	-13.71	-0.6	3.07e-34	Longevity;
LUSC	trans	rs62458065	0.850	rs7808992	chr7:32470677	C/T	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.23	-0.32	1.42e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg25214090	chr10:38739885	LOC399744	0.49	7.53	0.38	4.82e-13	Corneal astigmatism;
LUSC	cis	rs7089973	0.932	rs17794346	chr10:116643095	C/T	cg23260525	chr10:116636907	FAM160B1	-0.34	-6.54	-0.34	2.31e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08704250	chr15:31115839	NA	0.41	6.25	0.32	1.28e-9	Huntington's disease progression;
LUSC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18404041	chr3:52824283	ITIH1	0.59	11.57	0.53	2.89e-26	Bipolar disorder;
LUSC	cis	rs240764	0.658	rs12213201	chr6:101176285	C/A	cg09795085	chr6:101329169	ASCC3	-0.44	-6.44	-0.33	4.08e-10	Neuroticism;
LUSC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08280861	chr8:58055591	NA	0.54	5.94	0.31	6.98e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12210905	0.541	rs62617138	chr6:27463766	C/A	cg08851530	chr6:28072375	NA	0.93	5.71	0.3	2.47e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	7.41	0.38	1.07e-12	Response to antipsychotic treatment;
LUSC	cis	rs524023	0.914	rs80841	chr11:64437490	T/C	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.71	-0.3	2.56e-8	Urate levels in obese individuals;
LUSC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg09034736	chr1:150693464	HORMAD1	0.53	7.62	0.38	2.72e-13	Tonsillectomy;
LUSC	cis	rs988712	0.705	rs1829469	chr11:27730556	A/G	cg10635145	chr11:27742435	BDNF	-0.48	-6.35	-0.33	7.05e-10	Obesity;
LUSC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	0.87	14.79	0.63	1.95e-38	Tonsillectomy;
LUSC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	0.91	15.38	0.64	9.64e-41	Menopause (age at onset);
LUSC	cis	rs4073221	0.929	rs7371812	chr3:18281071	C/T	cg07694806	chr3:18168406	NA	0.55	5.65	0.3	3.38e-8	Parkinson's disease;
LUSC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs13067593	1.000	rs67563589	chr3:188564574	G/C	cg17809494	chr3:188572244	LPP	0.45	6.26	0.32	1.18e-9	Immune reponse to smallpox (secreted IFN-alpha);
LUSC	cis	rs9788682	1.000	rs57064725	chr15:78833036	C/A	cg24631222	chr15:78858424	CHRNA5	0.81	11.54	0.53	3.89e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg12311346	chr5:56204834	C5orf35	-0.65	-10.16	-0.49	2.62e-21	Coronary artery disease;
LUSC	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg00745463	chr17:30367425	LRRC37B	-0.83	-9.07	-0.44	1.01e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg22676075	chr6:135203613	NA	-0.47	-7.45	-0.38	7.86e-13	Red blood cell count;
LUSC	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.57	-8.92	-0.44	3.21e-17	Lung cancer;
LUSC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg05234568	chr11:5960015	NA	-0.58	-9.56	-0.46	2.67e-19	DNA methylation (variation);
LUSC	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg24130564	chr14:104152367	KLC1	-0.48	-6.93	-0.35	2.14e-11	Body mass index;
LUSC	cis	rs2050392	0.829	rs306589	chr10:30723831	A/G	cg18806716	chr10:30721971	MAP3K8	-0.48	-8.01	-0.4	1.98e-14	Inflammatory bowel disease;
LUSC	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.52	-10.3	-0.49	8.66e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.44e-17	Iron status biomarkers;
LUSC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.68	0.7	7.58e-50	Chronic sinus infection;
LUSC	cis	rs9811920	0.809	rs6802817	chr3:99779264	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.35	-6.52	-0.34	2.6e-10	Axial length;
LUSC	cis	rs57549656	0.799	rs28628309	chr19:2712586	T/G	cg06609049	chr19:2785107	THOP1	0.49	6.39	0.33	5.45e-10	Schizophrenia;
LUSC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.21	0.69	5.93e-48	Chronic sinus infection;
LUSC	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg23649088	chr2:200775458	C2orf69	-0.54	-6.53	-0.34	2.39e-10	Schizophrenia;
LUSC	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg06697600	chr4:7070879	GRPEL1	-0.4	-6.56	-0.34	2.09e-10	Monocyte percentage of white cells;
LUSC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg13047869	chr3:10149882	C3orf24	0.56	7.89	0.4	4.32e-14	Alzheimer's disease;
LUSC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-1.06	-15.56	-0.65	1.88e-41	Vitiligo;
LUSC	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	6.07	0.32	3.46e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg17410650	chr12:54324560	NA	-0.57	-9.89	-0.48	2.18e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	0.77	12.62	0.57	3.88e-30	Cognitive function;
LUSC	cis	rs1577917	0.958	rs36035797	chr6:86562880	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.72	9.4	0.46	8.87e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.77	0.3	1.78e-8	Tonsillectomy;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23918991	chr4:103749251	UBE2D3	-0.48	-6.08	-0.32	3.27e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	9.96e-29	Motion sickness;
LUSC	cis	rs9549260	0.755	rs58919811	chr13:41226485	A/C	cg21288729	chr13:41239152	FOXO1	0.65	10.04	0.48	6.48e-21	Red blood cell count;
LUSC	cis	rs7215564	0.908	rs34135683	chr17:78652903	G/T	cg09596252	chr17:78655493	RPTOR	0.55	5.92	0.31	7.92e-9	Myopia (pathological);
LUSC	trans	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-8.62	-0.43	2.82e-16	Obesity-related traits;
LUSC	cis	rs1461503	0.966	rs10892936	chr11:122841720	G/A	cg27398637	chr11:122830231	C11orf63	-0.41	-6.52	-0.34	2.55e-10	Menarche (age at onset);
LUSC	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg00757033	chr12:89920650	WDR51B	0.59	10.22	0.49	1.69e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg26566898	chr11:117069891	TAGLN	0.38	7.24	0.37	3.1e-12	Blood protein levels;
LUSC	cis	rs644148	0.738	rs2686767	chr19:44995037	G/C	cg15540054	chr19:45004280	ZNF180	-0.5	-6.99	-0.36	1.46e-11	Personality dimensions;
LUSC	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.96	-0.61	3.22e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg05925327	chr15:68127851	NA	-0.47	-6.87	-0.35	3.16e-11	Restless legs syndrome;
LUSC	cis	rs4953076	0.573	rs920519	chr2:44452344	T/C	cg04920474	chr2:44395004	PPM1B	0.6	7.85	0.39	5.88e-14	Height;
LUSC	cis	rs6750047	1.000	rs6750047	chr2:38276549	A/G	cg07380506	chr2:38303506	CYP1B1	0.47	6.6	0.34	1.64e-10	Cutaneous malignant melanoma;Melanoma;
LUSC	trans	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg17567195	chr5:167378696	ODZ2	-0.38	-6.08	-0.32	3.27e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs12474201	0.928	rs7594523	chr2:46935791	G/C	cg06386533	chr2:46925753	SOCS5	0.75	11.33	0.53	2.07e-25	Height;
LUSC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.7	12.47	0.56	1.42e-29	Prudent dietary pattern;
LUSC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg25036284	chr2:26402008	FAM59B	-0.68	-9.47	-0.46	5.29e-19	Gut microbiome composition (summer);
LUSC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg20203395	chr5:56204925	C5orf35	-0.74	-10.1	-0.48	4.21e-21	Initial pursuit acceleration;
LUSC	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-10.14	-0.49	3.13e-21	Chronic sinus infection;
LUSC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg08847533	chr14:75593920	NEK9	0.82	14.5	0.62	2.71e-37	Height;
LUSC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg07424592	chr7:64974309	NA	-0.64	-5.72	-0.3	2.33e-8	Diabetic kidney disease;
LUSC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-10.1	-0.48	4.05e-21	Gut microbiome composition (summer);
LUSC	trans	rs330071	0.500	rs17662123	chr8:9246837	G/A	cg08975724	chr8:8085496	FLJ10661	0.41	6.11	0.32	2.73e-9	Acne (severe);
LUSC	cis	rs2708977	0.698	rs772159	chr2:97036439	G/A	cg01950434	chr2:97203154	ARID5A	-0.45	-5.99	-0.31	5.56e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs10979	0.964	rs35826562	chr6:143898672	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-11.79	-0.54	4.66e-27	Hypospadias;
LUSC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg08132940	chr7:1081526	C7orf50	-0.48	-6.04	-0.31	4.02e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg03929089	chr4:120376271	NA	0.54	6.74	0.35	6.85e-11	Intraocular pressure;
LUSC	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.87	15.49	0.65	3.75e-41	Metabolic syndrome;
LUSC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs75229567	0.541	rs775443	chr12:70122623	C/T	cg10114359	chr12:70132523	RAB3IP	-0.86	-8.38	-0.42	1.52e-15	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs1775715	0.737	rs11008695	chr10:32216887	T/G	cg26784012	chr10:32216390	ARHGAP12	0.44	7.44	0.38	8.73e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.56	-7.73	-0.39	1.29e-13	Renal function-related traits (BUN);
LUSC	cis	rs778371	0.676	rs921055	chr2:233697337	A/C	cg08000102	chr2:233561755	GIGYF2	-0.77	-12.2	-0.56	1.46e-28	Schizophrenia;
LUSC	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg04455712	chr21:45112962	RRP1B	0.47	8.82	0.43	6.42e-17	Mean corpuscular volume;
LUSC	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg04310649	chr10:35416472	CREM	-0.4	-6.12	-0.32	2.64e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7980799	0.935	rs7312012	chr12:33517984	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-5.99	-0.31	5.53e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs6545883	0.831	rs1186704	chr2:61672991	A/G	cg15711740	chr2:61764176	XPO1	-0.45	-6.99	-0.36	1.5e-11	Tuberculosis;
LUSC	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg03433033	chr1:76189801	ACADM	-0.48	-7.33	-0.37	1.8e-12	Daytime sleep phenotypes;
LUSC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg10755058	chr3:40428713	ENTPD3	0.36	5.98	0.31	5.63e-9	Renal cell carcinoma;
LUSC	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg05855489	chr10:104503620	C10orf26	-0.71	-11.68	-0.54	1.16e-26	Immature fraction of reticulocytes;Schizophrenia;
LUSC	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.58	0.5	9.58e-23	Morning vs. evening chronotype;
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.93	19.27	0.73	3.8e-56	Menarche (age at onset);
LUSC	trans	rs11610422	1.000	rs12824070	chr12:31414280	C/T	cg02734259	chr12:9559402	NA	-0.59	-6.35	-0.33	7.09e-10	Coronary artery disease;
LUSC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg05234568	chr11:5960015	NA	0.68	11.12	0.52	1.23e-24	DNA methylation (variation);
LUSC	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.71	-9.13	-0.45	6.47e-18	Childhood ear infection;
LUSC	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg23711669	chr6:146136114	FBXO30	0.81	14.85	0.63	1.16e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10193935	0.901	rs222479	chr2:42656857	T/G	cg27598129	chr2:42591480	NA	-0.56	-7.73	-0.39	1.27e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.72	13.29	0.59	1.16e-32	Metabolite levels;
LUSC	cis	rs7507204	0.906	rs11671513	chr19:3429937	C/T	cg08380311	chr19:3435252	NFIC	0.7	10.13	0.48	3.33e-21	Height;
LUSC	cis	rs1775715	0.737	rs2778650	chr10:32106851	A/G	cg18675610	chr10:32216311	ARHGAP12	0.29	6.34	0.33	7.56e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19346786	chr7:2764209	NA	-0.47	-7.78	-0.39	8.84e-14	Height;
LUSC	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg07150166	chr2:30669952	LCLAT1	0.64	6.9	0.35	2.66e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23158103	chr7:148848205	ZNF398	-0.48	-7.88	-0.4	4.66e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs8055236	0.564	rs4619382	chr16:83196518	T/C	cg27022570	chr14:50155261	POLE2	-0.44	-6.02	-0.31	4.53e-9	Coronary heart disease;
LUSC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg25019033	chr10:957182	NA	-0.51	-6.41	-0.33	5.04e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs11158026	0.603	rs943914	chr14:55440068	C/A	cg04306507	chr14:55594613	LGALS3	0.4	7.47	0.38	7e-13	Parkinson's disease;
LUSC	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.52	-0.34	2.67e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7809950	0.678	rs2107317	chr7:106899685	T/C	cg23024343	chr7:107201750	COG5	-0.66	-10.06	-0.48	5.78e-21	Coronary artery disease;
LUSC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-8.19	-0.41	5.55e-15	Height;
LUSC	cis	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.21	-0.41	4.95e-15	Coronary artery disease;
LUSC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	1.04	25.1	0.81	7.3e-79	Menarche (age at onset);
LUSC	trans	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.73	0.39	1.27e-13	Ulcerative colitis;
LUSC	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.32	-0.33	8.18e-10	Triglycerides;
LUSC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg25124228	chr12:125621409	AACS	-0.59	-9.87	-0.48	2.44e-20	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg15819921	chr19:927150	ARID3A	-0.43	-6.25	-0.32	1.28e-9	Life satisfaction;
LUSC	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.49	7.39	0.38	1.16e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26314531	chr2:26401878	FAM59B	0.74	10.09	0.48	4.67e-21	Gut microbiome composition (summer);
LUSC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg25039879	chr17:56429692	SUPT4H1	0.69	9.17	0.45	4.94e-18	Cognitive test performance;
LUSC	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg22532475	chr10:104410764	TRIM8	0.26	6.26	0.32	1.21e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg07701084	chr6:150067640	NUP43	0.55	8.39	0.42	1.37e-15	Lung cancer;
LUSC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	8.97	0.44	2.14e-17	Prudent dietary pattern;
LUSC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg12463550	chr7:65579703	CRCP	0.63	5.7	0.3	2.7e-8	Diabetic kidney disease;
LUSC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg19230755	chr7:65878503	NA	-0.43	-6.02	-0.31	4.48e-9	Aortic root size;
LUSC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg03146154	chr1:46216737	IPP	-0.51	-7.32	-0.37	1.84e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7759001	0.857	rs2206252	chr6:27358462	A/C	cg18711553	chr6:27366782	ZNF391	0.4	5.99	0.31	5.44e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs2652834	0.808	rs28583444	chr15:63357852	T/G	cg05507819	chr15:63340323	TPM1	0.69	8.66	0.43	2.03e-16	HDL cholesterol;
LUSC	cis	rs3741151	0.686	rs61516411	chr11:73302768	T/C	cg17517138	chr11:73019481	ARHGEF17	0.76	7.04	0.36	1.07e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.16	-0.52	8.86e-25	Alzheimer's disease;
LUSC	trans	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg25214090	chr10:38739885	LOC399744	0.44	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg06585982	chr3:143692056	C3orf58	0.41	6.44	0.33	4.23e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	1.1	14.47	0.62	3.47e-37	Nonalcoholic fatty liver disease;
LUSC	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.11	15.31	0.64	1.94e-40	Uric acid levels;
LUSC	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	1.14	19.9	0.74	1.2e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs243505	0.737	rs243513	chr7:148429806	G/A	cg09806900	chr7:148480153	CUL1	-0.52	-6.8	-0.35	4.95e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg18681998	chr4:17616180	MED28	0.82	15.41	0.64	7.26e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	6.07	0.32	3.42e-9	Schizophrenia;
LUSC	cis	rs7818345	1.000	rs11204041	chr8:19291371	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.99	0.36	1.49e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg23093090	chr10:104574429	C10orf26	-0.38	-6.52	-0.34	2.61e-10	Arsenic metabolism;
LUSC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21028142	chr17:79581711	NPLOC4	-0.32	-7.79	-0.39	8.41e-14	Eye color traits;
LUSC	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-7.78	-0.39	9.31e-14	Reticulocyte count;
LUSC	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg12365402	chr11:9010492	NRIP3	-0.41	-7.21	-0.37	3.82e-12	Hematocrit;
LUSC	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.65	9.87	0.48	2.53e-20	Height;
LUSC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.56	0.46	2.71e-19	Bipolar disorder;
LUSC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.24	0.41	3.98e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.07	0.36	9.17e-12	Morning vs. evening chronotype;
LUSC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg19046167	chr17:80928561	B3GNTL1	0.44	7.05	0.36	1.02e-11	Breast cancer;
LUSC	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg02951883	chr7:2050386	MAD1L1	0.44	5.9	0.31	8.92e-9	Bipolar disorder;
LUSC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13012494	chr21:47604986	C21orf56	0.49	7.55	0.38	4.06e-13	Testicular germ cell tumor;
LUSC	cis	rs6987853	0.661	rs6988493	chr8:42351328	C/T	cg09913449	chr8:42400586	C8orf40	-0.45	-7.51	-0.38	5.34e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg19318889	chr4:1322082	MAEA	0.52	8.75	0.43	1.1e-16	Obesity-related traits;
LUSC	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.41	5.74	0.3	2.09e-8	Multiple sclerosis;
LUSC	trans	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.69	0.39	1.67e-13	Ulcerative colitis;
LUSC	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg11861562	chr11:117069780	TAGLN	0.37	7.31	0.37	2e-12	Blood protein levels;
LUSC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.08	0.32	3.35e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1873147	0.731	rs12902152	chr15:63313968	T/C	cg12160578	chr15:63334699	TPM1	-0.46	-6.18	-0.32	1.92e-9	Orofacial clefts;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00482020	chr16:25026850	ARHGAP17	-0.43	-5.95	-0.31	6.82e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg24642439	chr20:33292090	TP53INP2	0.55	8.19	0.41	5.74e-15	Height;
LUSC	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	1.12	19.04	0.72	3.1e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2361718	0.590	rs4527052	chr17:78140910	A/G	cg23490090	chr17:78081364	GAA	-0.37	-6.23	-0.32	1.44e-9	Yeast infection;
LUSC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.71e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg11502198	chr6:26597334	ABT1	0.59	9.24	0.45	2.88e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg08847533	chr14:75593920	NEK9	0.83	14.52	0.62	2.18e-37	Height;
LUSC	cis	rs12776158	0.685	rs60677596	chr10:71216880	A/G	cg12610070	chr10:71211762	TSPAN15	-0.46	-5.93	-0.31	7.46e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.96	-11.82	-0.54	3.63e-27	Blood trace element (Zn levels);
LUSC	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.35	-0.42	1.82e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs740160	0.558	rs17161669	chr7:98908663	G/A	cg24650262	chr7:98904301	NA	0.6	6.32	0.33	8.28e-10	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg16606324	chr3:10149918	C3orf24	0.59	8.55	0.42	4.49e-16	Alzheimer's disease;
LUSC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg20849893	chr7:64541193	NA	-0.65	-5.74	-0.3	2.07e-8	Diabetic kidney disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04724115	chr22:39052386	LOC646851;CBY1	-0.45	-6.71	-0.34	8.53e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg11645453	chr3:52864694	ITIH4	0.35	8.16	0.41	6.91e-15	Bipolar disorder;
LUSC	trans	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg05267876	chr1:229644265	NUP133	-0.55	-6.15	-0.32	2.24e-9	Lung cancer in ever smokers;
LUSC	cis	rs9473147	0.543	rs9296558	chr6:47451883	C/T	cg12968598	chr6:47444699	CD2AP	0.54	8.19	0.41	5.64e-15	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs12530845	0.943	rs58577912	chr7:135329269	T/G	cg23117316	chr7:135346802	PL-5283	-0.58	-9.63	-0.47	1.55e-19	Red blood cell traits;
LUSC	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-8.72	-0.43	1.28e-16	Response to antipsychotic treatment;
LUSC	cis	rs9788721	0.836	rs1504550	chr15:78766250	A/G	cg18825076	chr15:78729989	IREB2	-0.61	-9.53	-0.46	3.26e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	trans	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg15704280	chr7:45808275	SEPT13	-0.56	-6.48	-0.33	3.23e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2219968	1.000	rs6473086	chr8:78974646	T/C	cg00738934	chr8:78996279	NA	0.37	6.86	0.35	3.39e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg19116668	chr7:99932089	PMS2L1	-0.33	-5.67	-0.3	3.17e-8	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11814312	chr17:76672156	CYTH1	0.46	6.39	0.33	5.64e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg23029597	chr12:123009494	RSRC2	-0.74	-9.84	-0.47	3.05e-20	Body mass index;
LUSC	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.31	-0.33	8.78e-10	Bipolar disorder;
LUSC	cis	rs6733011	0.604	rs12712035	chr2:99461298	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-6.38	-0.33	5.77e-10	Bipolar disorder;
LUSC	cis	rs73198271	0.599	rs10103169	chr8:8650698	T/A	cg01851573	chr8:8652454	MFHAS1	0.52	8.44	0.42	9.81e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19346786	chr7:2764209	NA	-0.39	-6.94	-0.35	2.09e-11	Height;
LUSC	cis	rs13082711	0.911	rs11708710	chr3:27457348	A/C	cg02860705	chr3:27208620	NA	0.52	8.71	0.43	1.44e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	trans	rs6600671	0.932	rs6600663	chr1:121222437	A/T	cg00646200	chr1:148855367	NA	0.46	7.12	0.36	6.57e-12	Hip geometry;
LUSC	trans	rs2262909	0.962	rs408687	chr19:22231123	T/C	cg17074339	chr11:11642133	GALNTL4	-0.46	-7.07	-0.36	9.1e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg23173402	chr1:227635558	NA	0.75	8.14	0.41	8.12e-15	Major depressive disorder;
LUSC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-6.98	-0.36	1.61e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	9.6	0.46	2.03e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg03948781	chr1:205179583	DSTYK	0.32	6.24	0.32	1.34e-9	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg04455712	chr21:45112962	RRP1B	-0.46	-8.69	-0.43	1.68e-16	Mean corpuscular volume;
LUSC	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.25	-0.41	3.73e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9341808	0.718	rs9343978	chr6:80971978	A/G	cg08355045	chr6:80787529	NA	0.56	9.76	0.47	5.61e-20	Sitting height ratio;
LUSC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	0.92	15.42	0.64	7.18e-41	Breast cancer;
LUSC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg02269571	chr22:50332266	NA	0.58	8.61	0.43	2.88e-16	Schizophrenia;
LUSC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	0.94	17.87	0.7	1.34e-50	Heart rate;
LUSC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.39	-7.45	-0.38	7.92e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg06360820	chr2:242988706	NA	-0.9	-9.61	-0.47	1.82e-19	Obesity-related traits;
LUSC	cis	rs7589342	0.801	rs13031068	chr2:106455021	A/G	cg16077055	chr2:106428750	NCK2	0.37	6.96	0.36	1.84e-11	Addiction;
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01171360	chr6:293285	DUSP22	-0.69	-11.15	-0.52	9.28e-25	Menopause (age at onset);
LUSC	trans	rs1941687	0.831	rs28402875	chr18:31351506	G/A	cg27147174	chr7:100797783	AP1S1	-0.47	-6.85	-0.35	3.46e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs7246967	0.673	rs7252925	chr19:22865808	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs500891	1.000	rs500891	chr6:84196790	A/G	cg08257003	chr6:84140564	ME1	-0.32	-6.63	-0.34	1.34e-10	Platelet-derived growth factor BB levels;
LUSC	trans	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg25482853	chr8:67687455	SGK3	0.8	11.24	0.52	4.47e-25	Obesity-related traits;
LUSC	cis	rs9796	0.870	rs12910027	chr15:41283817	A/T	cg18705301	chr15:41695430	NDUFAF1	0.47	8.26	0.41	3.44e-15	Menopause (age at onset);
LUSC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg20821713	chr7:1055600	C7orf50	-0.48	-7.85	-0.39	5.76e-14	Longevity;Endometriosis;
LUSC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	0.98	18.79	0.72	3e-54	Cognitive function;
LUSC	cis	rs6580649	0.882	rs7133249	chr12:48456823	C/T	cg24011408	chr12:48396354	COL2A1	-0.45	-6.07	-0.32	3.47e-9	Lung cancer;
LUSC	trans	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg26116260	chr4:7069785	GRPEL1	0.42	6.3	0.33	9.51e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs6546886	0.912	rs4241260	chr2:74293395	C/T	cg14702570	chr2:74259524	NA	-0.3	-5.68	-0.3	2.89e-8	Dialysis-related mortality;
LUSC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	12.18	0.55	1.66e-28	Nonalcoholic fatty liver disease;
LUSC	cis	rs9837602	1.000	rs34626154	chr3:99756312	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.09	0.32	3.14e-9	Breast cancer;
LUSC	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg22732515	chr19:44031385	ETHE1	0.66	10.69	0.5	3.87e-23	Fractional exhaled nitric oxide (childhood);
LUSC	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.86	-14.8	-0.63	1.77e-38	Morning vs. evening chronotype;
LUSC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.3	-6.19	-0.32	1.78e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg13660082	chr14:53194042	PSMC6	-0.78	-6.43	-0.33	4.36e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7181230	0.961	rs7183977	chr15:40377092	C/T	cg00868766	chr15:40364524	NA	-0.35	-6.1	-0.32	2.94e-9	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg00074818	chr8:8560427	CLDN23	0.59	9.95	0.48	1.33e-20	Obesity-related traits;
LUSC	cis	rs7851660	0.809	rs7022148	chr9:100660824	T/C	cg13688889	chr9:100608707	NA	-0.54	-8.44	-0.42	9.53e-16	Strep throat;
LUSC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg22508957	chr16:3507546	NAT15	0.93	10.44	0.5	2.86e-22	Tuberculosis;
LUSC	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	0.84	14.12	0.61	7.89e-36	Blood protein levels;
LUSC	cis	rs6499188	1.000	rs6499188	chr16:68674788	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.19	-0.32	1.77e-9	Ulcerative colitis;
LUSC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg03146154	chr1:46216737	IPP	-0.52	-7.71	-0.39	1.49e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3741151	0.686	rs73546735	chr11:73256797	C/T	cg17517138	chr11:73019481	ARHGEF17	0.97	8.12	0.41	8.78e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg20399509	chr21:47717575	C21orf57	-0.39	-5.96	-0.31	6.5e-9	Testicular germ cell tumor;
LUSC	cis	rs6740322	0.895	rs11684601	chr2:43574242	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-7.88	-0.4	4.75e-14	Coronary artery disease;
LUSC	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg20503657	chr10:835505	NA	0.98	13.9	0.61	5.53e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.43	0.53	9.29e-26	Prudent dietary pattern;
LUSC	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg06287003	chr12:125626642	AACS	-0.4	-6.13	-0.32	2.41e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06544989	chr22:39130855	UNC84B	0.37	6.36	0.33	6.56e-10	Menopause (age at onset);
LUSC	cis	rs9815354	0.812	rs17218504	chr3:41987278	A/G	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.72e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-0.77	-12.24	-0.56	1.03e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg15133208	chr4:90757351	SNCA	-0.32	-5.66	-0.3	3.23e-8	Dementia with Lewy bodies;
LUSC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg12011299	chr4:100065546	ADH4	-0.72	-10.42	-0.5	3.38e-22	Alcohol dependence;
LUSC	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.17	-0.37	4.84e-12	Type 2 diabetes;
LUSC	cis	rs2455601	0.679	rs2653559	chr11:8900394	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.91	-0.35	2.44e-11	Schizophrenia;
LUSC	trans	rs1135642	0.509	rs78111759	chr4:77807626	A/G	cg27323975	chr12:129436478	GLT1D1	-0.77	-6.02	-0.31	4.64e-9	Food addiction;
LUSC	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg23752985	chr2:85803571	VAMP8	0.36	7.87	0.4	5.05e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	11.27	0.53	3.36e-25	Total body bone mineral density;
LUSC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg24130564	chr14:104152367	KLC1	-0.42	-6.07	-0.32	3.38e-9	Body mass index;
LUSC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.91	0.61	5.26e-35	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg11812906	chr14:75593930	NEK9	-0.39	-5.69	-0.3	2.75e-8	Caffeine consumption;
LUSC	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg08975724	chr8:8085496	FLJ10661	0.5	7.36	0.37	1.4e-12	Mood instability;
LUSC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg20891558	chr2:74357851	NA	0.85	15.66	0.65	7.91e-42	Gestational age at birth (maternal effect);
LUSC	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg11502198	chr6:26597334	ABT1	0.59	9.37	0.46	1.15e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg23711669	chr6:146136114	FBXO30	0.73	12.76	0.57	1.22e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg10792982	chr14:105748885	BRF1	0.48	8.68	0.43	1.75e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6076065	0.548	rs6048742	chr20:23327584	T/C	cg11657817	chr20:23433608	CST11	0.51	10.14	0.49	3.08e-21	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs72674100	1.000	rs10005163	chr4:97959097	C/T	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg20935933	chr6:143382018	AIG1	0.5	7.33	0.37	1.71e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	0.99	13.79	0.6	1.42e-34	Eosinophil percentage of granulocytes;
LUSC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg27170947	chr2:26402098	FAM59B	-0.72	-11.04	-0.52	2.26e-24	Gut microbiome composition (summer);
LUSC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg13319975	chr6:146136371	FBXO30	0.7	11.14	0.52	9.86e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.68	-11.44	-0.53	8.62e-26	Caffeine consumption;
LUSC	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg21775007	chr8:11205619	TDH	-0.65	-10.26	-0.49	1.22e-21	Retinal vascular caliber;
LUSC	cis	rs12618769	0.947	rs72825711	chr2:99240243	A/T	cg10123293	chr2:99228465	UNC50	0.41	5.7	0.3	2.57e-8	Bipolar disorder;
LUSC	cis	rs13315871	0.929	rs9857333	chr3:58293551	G/C	cg12435725	chr3:58293450	RPP14	-0.69	-7.16	-0.36	5.24e-12	Cholesterol, total;
LUSC	cis	rs2734839	0.964	rs11214605	chr11:113300601	C/T	cg14159747	chr11:113255604	NA	0.23	5.72	0.3	2.31e-8	Information processing speed;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg03395511	chr6:291903	DUSP22	-0.7	-11.52	-0.53	4.49e-26	Menopause (age at onset);
LUSC	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.52	10.43	0.5	3.08e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg18721089	chr20:30220636	NA	-0.34	-5.95	-0.31	6.9e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.79	0.3	1.66e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11637445	0.677	rs4386088	chr15:68108913	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	7.21	0.37	3.84e-12	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.28	0.59	1.35e-32	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02986439	chr15:66545422	MEGF11	-0.41	-5.98	-0.31	5.77e-9	Hepatitis;
LUSC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg02475777	chr4:1388615	CRIPAK	0.45	6.68	0.34	1.02e-10	Obesity-related traits;
LUSC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24838063	chr12:130822603	PIWIL1	0.71	11.06	0.52	1.98e-24	Menopause (age at onset);
LUSC	cis	rs7267979	0.816	rs422148	chr20:25512604	G/C	cg03522245	chr20:25566470	NINL	0.36	5.82	0.3	1.38e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	6.87	0.35	3.17e-11	Height;
LUSC	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg07636037	chr3:49044803	WDR6	0.78	10.32	0.49	7.27e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg02176678	chr2:219576539	TTLL4	-0.57	-10.14	-0.48	3.18e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.44	-0.33	4.21e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg18352616	chr4:3374830	RGS12	0.34	7.09	0.36	8.12e-12	Serum sulfate level;
LUSC	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg00191853	chr8:101177733	SPAG1	0.37	6.32	0.33	8.45e-10	Atrioventricular conduction;
LUSC	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.28	-0.37	2.45e-12	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg27411982	chr8:10470053	RP1L1	0.39	6.16	0.32	2.06e-9	Mood instability;
LUSC	cis	rs12474201	0.928	rs12998753	chr2:46938385	A/G	cg06386533	chr2:46925753	SOCS5	0.76	11.34	0.53	1.89e-25	Height;
LUSC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg08270630	chr22:50330655	NA	0.41	6.13	0.32	2.44e-9	Schizophrenia;
LUSC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.87	-0.48	2.48e-20	Hemoglobin concentration;
LUSC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.75	-0.8	1.56e-77	Height;
LUSC	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg08213375	chr14:104286397	PPP1R13B	-0.53	-10.14	-0.49	2.96e-21	Schizophrenia;
LUSC	cis	rs500891	0.525	rs6454322	chr6:84057542	A/G	cg08257003	chr6:84140564	ME1	0.34	8.18	0.41	6.19e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg12463550	chr7:65579703	CRCP	0.56	8.29	0.41	2.86e-15	Aortic root size;
LUSC	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.89	0.51	7.63e-24	Hypertriglyceridemia;
LUSC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg12560992	chr17:57184187	TRIM37	-0.85	-15.42	-0.64	6.9e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg26384229	chr12:38710491	ALG10B	0.55	7.79	0.39	8.68e-14	Morning vs. evening chronotype;
LUSC	cis	rs2652834	1.000	rs2652835	chr15:63396408	T/C	cg05507819	chr15:63340323	TPM1	0.67	8.15	0.41	7.29e-15	HDL cholesterol;
LUSC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg12927641	chr6:109611667	NA	-0.43	-7.62	-0.38	2.71e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg06917634	chr15:78832804	PSMA4	0.72	11.56	0.53	3.08e-26	Sudden cardiac arrest;
LUSC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg08200582	chr11:442649	ANO9	-0.52	-6.1	-0.32	3.02e-9	Body mass index;
LUSC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13126279	chr21:47581558	C21orf56	0.54	8.47	0.42	8.07e-16	Testicular germ cell tumor;
LUSC	cis	rs77972916	0.561	rs4372955	chr2:43566146	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.95	-0.31	6.66e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2522056	1.000	rs2522050	chr5:131796609	C/T	cg24060327	chr5:131705240	SLC22A5	0.45	5.96	0.31	6.39e-9	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	0.85	13.64	0.6	5.63e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.85	0.35	3.61e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.71	-0.39	1.44e-13	Glomerular filtration rate;
LUSC	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg04310649	chr10:35416472	CREM	-0.44	-6.58	-0.34	1.85e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg23231163	chr10:75533350	FUT11	0.41	6.47	0.33	3.43e-10	Inflammatory bowel disease;
LUSC	cis	rs2637266	1.000	rs12262400	chr10:78386862	T/C	cg18941641	chr10:78392320	NA	0.4	7.33	0.37	1.79e-12	Pulmonary function;
LUSC	trans	rs62238980	0.614	rs77017871	chr22:32382145	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg03340356	chr1:67600835	NA	-0.43	-6.81	-0.35	4.57e-11	Psoriasis;
LUSC	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg20991723	chr1:152506922	NA	0.48	8.99	0.44	1.91e-17	Hair morphology;
LUSC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.8	0.6	1.3600000000000001e-34	Chronic sinus infection;
LUSC	cis	rs12928939	0.517	rs9940234	chr16:71964805	C/T	cg03805757	chr16:71968109	PKD1L3	-0.63	-9.69	-0.47	1.01e-19	Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs11958404	0.932	rs72816566	chr5:157427613	G/A	cg05962755	chr5:157440814	NA	0.51	6.18	0.32	1.89e-9	IgG glycosylation;
LUSC	cis	rs7715806	0.500	rs17649350	chr5:75006156	C/T	cg19683494	chr5:74908142	NA	-0.55	-7.54	-0.38	4.46e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26314531	chr2:26401878	FAM59B	0.67	8.72	0.43	1.36e-16	Gut microbiome composition (summer);
LUSC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg27535305	chr1:53392650	SCP2	-0.4	-7.5	-0.38	5.74e-13	Monocyte count;
LUSC	trans	rs7893279	0.749	rs4748464	chr10:18712258	C/A	cg01840055	chr3:141338555	NA	0.5	5.94	0.31	7.03e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg13453750	chr1:205783389	SLC41A1	-0.33	-6.41	-0.33	4.83e-10	Menarche (age at onset);
LUSC	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg20991723	chr1:152506922	NA	0.52	9.8	0.47	4.38e-20	Hair morphology;
LUSC	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg06197492	chr11:2016605	H19	-0.39	-6.58	-0.34	1.84e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg13699009	chr12:122356056	WDR66	0.48	7.49	0.38	6.33e-13	Mean corpuscular volume;
LUSC	cis	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg17469321	chr7:55412551	NA	0.66	10.62	0.5	6.87e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg01528321	chr10:82214614	TSPAN14	0.99	10.75	0.51	2.32e-23	Post bronchodilator FEV1;
LUSC	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.7	10.54	0.5	1.25e-22	Corneal astigmatism;
LUSC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-9.59	-0.46	2.14e-19	Longevity;Endometriosis;
LUSC	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg11843606	chr2:227700838	RHBDD1	-0.64	-10.12	-0.48	3.44e-21	Pulmonary function;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26847093	chr13:51483765	RNASEH2B	0.43	6.08	0.32	3.37e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	8.1	0.41	1.01e-14	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg11584989	chr19:19387371	SF4	0.59	6.99	0.36	1.46e-11	Bipolar disorder;
LUSC	cis	rs1692120	0.545	rs1812458	chr11:61408449	C/T	cg19838087	chr11:61442541	NA	-0.32	-5.97	-0.31	6.07e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg17366294	chr4:99064904	C4orf37	0.58	10.24	0.49	1.42e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg03676636	chr4:99064102	C4orf37	0.29	5.67	0.3	3.13e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9837602	0.938	rs9814359	chr3:99797013	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.99	-0.31	5.43e-9	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09739887	chr4:7105262	FLJ36777	0.41	6.09	0.32	3.04e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07923666	chr12:49932857	KCNH3	-0.53	-6.43	-0.33	4.54e-10	Resting heart rate;
LUSC	cis	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg09307838	chr4:120376055	NA	0.48	7.2	0.37	4.07e-12	Diastolic blood pressure;
LUSC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-1.04	-14.89	-0.63	8.23e-39	Vitiligo;
LUSC	cis	rs2235649	0.624	rs2076427	chr16:1817754	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.46	5.75	0.3	1.96e-8	Blood metabolite levels;
LUSC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02018176	chr4:1364513	KIAA1530	-0.67	-11.6	-0.54	2.36e-26	Obesity-related traits;
LUSC	cis	rs75920871	0.528	rs1241655	chr11:116837808	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.23	-0.32	1.4e-9	Subjective well-being;
LUSC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21724239	chr8:58056113	NA	0.81	8.84	0.44	5.66e-17	Developmental language disorder (linguistic errors);
LUSC	trans	rs11118993	0.936	rs11587643	chr1:206714520	G/A	cg25718223	chr19:13915877	ZSWIM4	-0.36	-6.05	-0.31	3.81e-9	Neurofibrillary tangles;
LUSC	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg26647111	chr11:31128758	NA	0.39	5.73	0.3	2.3e-8	Red blood cell count;
LUSC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg16558253	chr16:72132732	DHX38	-0.43	-6.49	-0.33	3.09e-10	Fibrinogen levels;
LUSC	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg24375607	chr4:120327624	NA	0.79	12.03	0.55	6.08e-28	Corneal astigmatism;
LUSC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg00784671	chr22:46762841	CELSR1	-0.48	-6.53	-0.34	2.42e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9399401	0.589	rs2294775	chr6:142766347	C/G	cg03128060	chr6:142623767	GPR126	0.48	8.83	0.44	5.86e-17	Chronic obstructive pulmonary disease;
LUSC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg13319975	chr6:146136371	FBXO30	0.51	7.63	0.39	2.49e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg00071950	chr4:10020882	SLC2A9	-0.57	-9.51	-0.46	3.99e-19	Bone mineral density;
LUSC	trans	rs11039798	0.920	rs12292685	chr11:48571032	G/T	cg15704280	chr7:45808275	SEPT13	0.69	6.51	0.34	2.81e-10	Axial length;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23214606	chr1:202976451	TMEM183A;TMEM183B	0.44	6.03	0.31	4.38e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10979	1.000	rs9484768	chr6:143887928	C/T	cg25407410	chr6:143891975	LOC285740	-0.75	-12.09	-0.55	3.8e-28	Hypospadias;
LUSC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-11.86	-0.54	2.59e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg15145296	chr3:125709740	NA	-0.54	-6.02	-0.31	4.57e-9	Blood pressure (smoking interaction);
LUSC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.32	-5.93	-0.31	7.69e-9	IgG glycosylation;
LUSC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08219700	chr8:58056026	NA	0.67	8.37	0.42	1.63e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs61869271	0.871	rs12098332	chr10:116728074	A/T	cg23260525	chr10:116636907	FAM160B1	0.32	6.38	0.33	5.75e-10	Tonsillectomy;
LUSC	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg27631724	chr1:11040367	C1orf127	0.54	9.4	0.46	8.69e-19	Ewing sarcoma;
LUSC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06873352	chr17:61820015	STRADA	-0.62	-10.74	-0.51	2.63e-23	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg12963246	chr6:28129442	ZNF389	0.56	7.89	0.4	4.28e-14	Parkinson's disease;
LUSC	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg06096015	chr1:231504339	EGLN1	0.55	9.63	0.47	1.56e-19	Hemoglobin concentration;
LUSC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.1	16.96	0.68	5.39e-47	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg02951883	chr7:2050386	MAD1L1	0.46	6.13	0.32	2.47e-9	Neuroticism;
LUSC	trans	rs6736587	0.744	rs11673910	chr2:81932861	T/C	cg14247332	chr9:132805979	FNBP1	0.44	6.0	0.31	5.2e-9	Orthostatic hypotension;
LUSC	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg17757837	chr7:157058334	UBE3C	0.81	12.99	0.58	1.68e-31	Body mass index;
LUSC	trans	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg06606381	chr12:133084897	FBRSL1	-0.72	-7.28	-0.37	2.47e-12	Breast cancer;
LUSC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	0.92	15.51	0.65	2.92e-41	Menopause (age at onset);
LUSC	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.69	-11.38	-0.53	1.42e-25	Colorectal cancer;
LUSC	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.77	11.2	0.52	6.25e-25	Corneal astigmatism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01656856	chr2:170551263	PHOSPHO2;KLHL23;C2orf77	0.42	6.07	0.32	3.5e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72960926	0.744	rs11754468	chr6:74932522	C/T	cg03266952	chr6:74778945	NA	-0.77	-6.79	-0.35	5.08e-11	Metabolite levels (MHPG);
LUSC	cis	rs6845621	0.840	rs6816238	chr4:18918968	T/C	cg12196642	chr4:18937545	NA	-0.33	-6.38	-0.33	5.78e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9815354	0.812	rs56728371	chr3:41999381	T/A	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.42	5.02e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg12365402	chr11:9010492	NRIP3	0.47	8.77	0.43	9.02e-17	Hemoglobin concentration;
LUSC	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg18721089	chr20:30220636	NA	-0.39	-6.02	-0.31	4.5e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg13390004	chr1:15929781	NA	0.38	6.49	0.33	3.04e-10	Systolic blood pressure;
LUSC	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.68	11.58	0.54	2.61e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg20203395	chr5:56204925	C5orf35	-0.71	-9.61	-0.47	1.79e-19	Initial pursuit acceleration;
LUSC	cis	rs11608355	0.515	rs2270361	chr12:109935894	G/C	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs977987	0.872	rs3743609	chr16:75467021	G/C	cg04384234	chr16:75411784	CFDP1	-0.45	-7.44	-0.38	8.59e-13	Dupuytren's disease;
LUSC	cis	rs7000551	0.700	rs2461480	chr8:22381839	C/T	cg12081754	chr8:22256438	SLC39A14	0.43	6.43	0.33	4.3e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4839421	0.966	rs6677767	chr1:111022475	C/T	cg06880108	chr1:111021908	CYMP	-0.43	-7.26	-0.37	2.73e-12	Response to bupropion in depression;
LUSC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg22834771	chr12:69754056	YEATS4	-0.43	-6.23	-0.32	1.41e-9	Blood protein levels;
LUSC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg21435336	chr19:17392852	ANKLE1	-0.47	-6.33	-0.33	7.67e-10	Systemic lupus erythematosus;
LUSC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg11843238	chr5:131593191	PDLIM4	0.38	6.52	0.34	2.54e-10	Breast cancer;
LUSC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21016266	chr12:122356598	WDR66	0.61	9.24	0.45	3.05e-18	Mean corpuscular volume;
LUSC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg00450029	chr8:599525	NA	-0.59	-5.69	-0.3	2.82e-8	IgG glycosylation;
LUSC	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg17652424	chr22:38574118	PLA2G6	-0.3	-6.63	-0.34	1.39e-10	Cutaneous nevi;
LUSC	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg27411982	chr8:10470053	RP1L1	-0.42	-6.56	-0.34	1.99e-10	Monocyte count;
LUSC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg22903471	chr2:27725779	GCKR	0.41	6.99	0.36	1.48e-11	Total body bone mineral density;
LUSC	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg07423050	chr13:99094983	FARP1	-0.56	-10.83	-0.51	1.3e-23	Longevity;
LUSC	cis	rs7246967	0.611	rs12973627	chr19:22867705	G/A	cg23217946	chr19:22817039	ZNF492	0.45	6.01	0.31	4.91e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg06096015	chr1:231504339	EGLN1	0.58	10.36	0.49	5.56e-22	Hemoglobin concentration;
LUSC	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg07929629	chr2:241523174	NA	-0.57	-10.86	-0.51	1e-23	Bipolar disorder;
LUSC	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg26195577	chr20:24973756	C20orf3	1.11	18.48	0.71	5e-53	Blood protein levels;
LUSC	cis	rs780094	0.500	rs13002853	chr2:27853245	C/G	cg27432699	chr2:27873401	GPN1	0.43	5.86	0.31	1.1e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg08000102	chr2:233561755	GIGYF2	-0.51	-8.09	-0.4	1.13e-14	Coronary artery disease;
LUSC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg06671706	chr8:8559999	CLDN23	0.5	6.8	0.35	4.85e-11	Obesity-related traits;
LUSC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg05313129	chr8:58192883	C8orf71	-0.51	-6.52	-0.34	2.59e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	0.57	9.07	0.44	1.02e-17	Breast cancer;
LUSC	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg14092571	chr14:90743983	NA	-0.36	-5.99	-0.31	5.48e-9	Mortality in heart failure;
LUSC	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.72	-13.48	-0.59	2.36e-33	Ulcerative colitis;
LUSC	cis	rs12050794	0.636	rs3759902	chr15:72525274	C/G	cg16672083	chr15:72433130	SENP8	0.47	7.87	0.4	5.04e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.7	-0.34	9.12e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1891275	0.515	rs1592051	chr10:93542186	A/G	cg07889827	chr10:93443413	NA	0.39	8.91	0.44	3.44e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs295140	1.000	rs1367857	chr2:201160765	T/C	cg04283868	chr2:201171347	SPATS2L	0.44	6.69	0.34	9.14e-11	QT interval;
LUSC	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.62	-0.43	2.64e-16	Retinal vascular caliber;
LUSC	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg10356904	chr22:49881777	NA	-0.33	-7.39	-0.37	1.21e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	6.24	0.32	1.35e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg07537917	chr2:241836409	C2orf54	-0.25	-5.72	-0.3	2.37e-8	Urinary metabolites;
LUSC	cis	rs7804356	0.817	rs4719882	chr7:26882252	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.12	-0.32	2.67e-9	Type 1 diabetes;
LUSC	cis	rs2607426	0.681	rs10420685	chr19:41235120	A/G	cg05508168	chr19:41255947	C19orf54;SNRPA	0.92	6.83	0.35	3.91e-11	Blood protein levels;
LUSC	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg14844989	chr11:31128820	NA	-0.37	-5.9	-0.31	8.97e-9	Red blood cell count;
LUSC	cis	rs2637266	0.714	rs6480835	chr10:78446863	T/C	cg18941641	chr10:78392320	NA	0.33	5.98	0.31	5.67e-9	Pulmonary function;
LUSC	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg07080220	chr10:102295463	HIF1AN	0.65	8.87	0.44	4.48e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.81	-15.0	-0.63	2.95e-39	Dental caries;
LUSC	trans	rs17086172	0.841	rs76610733	chr18:70268315	C/G	cg15710198	chr8:55370334	SOX17	-0.67	-6.11	-0.32	2.73e-9	Airflow obstruction;
LUSC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg11342453	chr6:26196699	NA	0.58	6.09	0.32	3.17e-9	Gout;Renal underexcretion gout;
LUSC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg16928487	chr17:17741425	SREBF1	-0.33	-6.16	-0.32	2.11e-9	Total body bone mineral density;
LUSC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.36	-0.56	3.64e-29	Type 2 diabetes;
LUSC	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg04414720	chr1:150670196	GOLPH3L	0.56	9.04	0.44	1.31e-17	Tonsillectomy;
LUSC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26314531	chr2:26401878	FAM59B	-0.59	-7.43	-0.38	8.92e-13	Gut microbiome composition (summer);
LUSC	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg11742103	chr11:62369870	EML3;MTA2	-0.46	-7.16	-0.36	5.02e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.75	0.39	1.08e-13	Bipolar disorder;
LUSC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	8.87	0.44	4.57e-17	Menopause (age at onset);
LUSC	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.96	0.36	1.79e-11	Endometrial cancer;
LUSC	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.69	-0.39	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg16339924	chr4:17578868	LAP3	0.52	7.83	0.39	6.34e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.16	-0.32	2.06e-9	Alcohol dependence;
LUSC	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	1.07	19.25	0.73	4.4e-56	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg18827107	chr12:86230957	RASSF9	0.4	5.99	0.31	5.43e-9	Major depressive disorder;
LUSC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.64	0.6	5.79e-34	Cognitive test performance;
LUSC	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg13010199	chr12:38710504	ALG10B	0.67	9.61	0.47	1.83e-19	Bladder cancer;
LUSC	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg12927641	chr6:109611667	NA	-0.35	-5.88	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg25258033	chr6:167368657	RNASET2	0.43	7.1	0.36	7.59e-12	Crohn's disease;
LUSC	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-21.72	-0.77	7.36e-66	Ulcerative colitis;
LUSC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.92	-16.66	-0.67	8.66e-46	Cognitive function;
LUSC	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	6.08	0.32	3.35e-9	Lung cancer in ever smokers;
LUSC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.72	11.82	0.54	3.51e-27	Coronary artery disease;
LUSC	trans	rs1325195	0.920	rs2793806	chr1:179180424	G/A	cg11624085	chr17:8464688	MYH10	0.44	6.84	0.35	3.75e-11	IgE grass sensitization;
LUSC	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	9.47	0.46	5.31e-19	Body mass index;
LUSC	cis	rs727505	0.954	rs28638102	chr7:124499480	A/C	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg05084668	chr3:125655381	ALG1L	-0.46	-5.91	-0.31	8.44e-9	Blood pressure (smoking interaction);
LUSC	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	0.82	12.36	0.56	3.58e-29	Resting heart rate;
LUSC	cis	rs6060717	0.536	rs6060664	chr20:34478884	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.67	-0.3	3.14e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	0.99	14.03	0.61	1.78e-35	Vitiligo;
LUSC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.82	12.94	0.58	2.44e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9807841	0.670	rs2738042	chr19:10790143	C/G	cg17710535	chr19:10819994	QTRT1	0.41	6.6	0.34	1.66e-10	Inflammatory skin disease;
LUSC	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg07936489	chr17:37558343	FBXL20	0.65	8.35	0.42	1.87e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg19812747	chr11:111475976	SIK2	-0.48	-6.84	-0.35	3.87e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg23241863	chr10:102295624	HIF1AN	-0.49	-6.08	-0.32	3.31e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs34293785	0.565	rs59710023	chr1:66137193	T/C	cg04111102	chr1:66153794	NA	0.34	7.38	0.37	1.29e-12	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
LUSC	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg23093090	chr10:104574429	C10orf26	-0.38	-7.15	-0.36	5.58e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg10483660	chr13:112241077	NA	0.37	6.57	0.34	1.95e-10	Menarche (age at onset);
LUSC	cis	rs4280164	0.945	rs2224122	chr14:24783414	G/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.6	-7.07	-0.36	9.32e-12	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-12.18	-0.55	1.73e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.39	-0.42	1.34e-15	Response to antipsychotic treatment;
LUSC	cis	rs6460942	0.591	rs4721080	chr7:12337785	T/C	cg06484146	chr7:12443880	VWDE	-0.58	-6.2	-0.32	1.67e-9	Coronary artery disease;
LUSC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	1.05	19.08	0.72	1.98e-55	Parkinson's disease;
LUSC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-7.29	-0.37	2.21e-12	Renal function-related traits (BUN);
LUSC	cis	rs7804356	1.000	rs10272190	chr7:26887942	T/A	cg03456212	chr7:26904342	SKAP2	-0.51	-5.91	-0.31	8.61e-9	Type 1 diabetes;
LUSC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.82	-0.3	1.41e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg24675658	chr1:53192096	ZYG11B	0.58	9.07	0.44	1.01e-17	Monocyte count;
LUSC	cis	rs61931739	0.513	rs10844698	chr12:33890158	C/T	cg06521331	chr12:34319734	NA	-0.36	-5.88	-0.31	1.02e-8	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	21.85	0.77	2.44e-66	Prudent dietary pattern;
LUSC	trans	rs853679	0.607	rs200489	chr6:27798257	T/C	cg01620082	chr3:125678407	NA	-0.73	-7.34	-0.37	1.65e-12	Depression;
LUSC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs12541635	0.966	rs2217391	chr8:107063126	A/G	cg10147462	chr8:107024639	NA	0.57	10.46	0.5	2.36e-22	Age of smoking initiation;
LUSC	trans	rs1751857	1.000	rs1782808	chr13:40976034	C/T	cg24642820	chr3:13462465	NUP210	0.62	5.97	0.31	6.16e-9	Body mass index (change over time) in chronic obstructive pulmonary disease;
LUSC	cis	rs2219968	1.000	rs35551201	chr8:78963968	G/A	cg00738934	chr8:78996279	NA	0.34	6.18	0.32	1.89e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg16743903	chr16:89593216	SPG7	-0.47	-6.57	-0.34	1.88e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.75	0.47	6.42e-20	Eosinophil percentage of white cells;
LUSC	cis	rs7804356	0.954	rs3801815	chr7:26881292	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.12	-0.32	2.58e-9	Type 1 diabetes;
LUSC	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg27205649	chr11:78285834	NARS2	-0.52	-5.69	-0.3	2.85e-8	Testicular germ cell tumor;
LUSC	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg07636037	chr3:49044803	WDR6	-0.66	-8.06	-0.4	1.4e-14	Menarche (age at onset);
LUSC	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	10.16	0.49	2.56e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg02428538	chr16:24856791	SLC5A11	-0.57	-6.3	-0.33	9.3e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-8.53	-0.42	5.13e-16	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.15	0.32	2.21e-9	Corneal astigmatism;
LUSC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg20203395	chr5:56204925	C5orf35	-0.47	-7.04	-0.36	1.12e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	0.7	11.08	0.52	1.6e-24	Blood metabolite ratios;
LUSC	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg25730555	chr22:47059586	GRAMD4	0.44	7.53	0.38	4.74e-13	Urate levels in obese individuals;
LUSC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg16325326	chr1:53192061	ZYG11B	-0.88	-16.04	-0.66	2.58e-43	Monocyte count;
LUSC	cis	rs4363385	0.510	rs61811902	chr1:153053464	A/G	cg25856811	chr1:152973957	SPRR3	-0.41	-6.64	-0.34	1.25e-10	Inflammatory skin disease;
LUSC	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg22676075	chr6:135203613	NA	0.72	11.11	0.52	1.32e-24	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1865721	0.771	rs72975986	chr18:73127649	A/G	cg26385618	chr18:73139727	C18orf62	-0.54	-9.7	-0.47	8.93e-20	Intelligence;
LUSC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08280861	chr8:58055591	NA	-0.57	-6.22	-0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08889044	chr22:42949946	SERHL2	0.44	6.85	0.35	3.46e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg06028605	chr16:24865363	SLC5A11	0.5	8.62	0.43	2.69e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg19556208	chr14:24630405	IRF9	0.38	6.16	0.32	2.15e-9	Triglycerides;
LUSC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.82	0.68	1.93e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs9359856	0.564	rs72915918	chr6:90430792	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.88	-8.68	-0.43	1.83e-16	Bipolar disorder;
LUSC	cis	rs9547692	0.938	rs12427600	chr13:37460648	C/T	cg01034396	chr13:37494802	SMAD9	-0.3	-5.79	-0.3	1.66e-8	Coronary artery disease;
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-7.96	-0.4	2.67e-14	Lymphocyte counts;
LUSC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26314531	chr2:26401878	FAM59B	-0.7	-9.2	-0.45	3.96e-18	Gut microbiome composition (summer);
LUSC	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg06197492	chr11:2016605	H19	0.36	5.85	0.3	1.19e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs7577696	0.785	rs11683110	chr2:32349813	T/C	cg02381751	chr2:32503542	YIPF4	-0.44	-6.22	-0.32	1.47e-9	Inflammatory biomarkers;
LUSC	cis	rs72781680	0.752	rs56343114	chr2:23900629	C/G	cg08917208	chr2:24149416	ATAD2B	0.85	8.96	0.44	2.37e-17	Lymphocyte counts;
LUSC	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg13010344	chr12:123464640	ARL6IP4	-0.46	-6.36	-0.33	6.57e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg01256987	chr12:42539512	GXYLT1	0.36	6.61	0.34	1.53e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.3e-10	Alzheimer's disease (late onset);
LUSC	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.65	-0.3	3.46e-8	Ileal carcinoids;
LUSC	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-1.14	-18.19	-0.71	7.14e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg13319975	chr6:146136371	FBXO30	0.5	7.44	0.38	8.58e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg07395648	chr5:131743802	NA	0.39	6.24	0.32	1.32e-9	Asthma (sex interaction);
LUSC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.05	0.44	1.22e-17	Motion sickness;
LUSC	cis	rs1080500	1.000	rs1080500	chr3:53175017	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-7.51	-0.38	5.29e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06112835	chr11:68658793	MRPL21	0.51	7.71	0.39	1.47e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6554196	0.508	rs3819386	chr4:55527374	T/C	cg18836493	chr4:55524333	KIT	-0.44	-7.6	-0.38	3e-13	Monocyte count;
LUSC	cis	rs2354432	0.607	rs68080346	chr1:146708484	T/C	cg25205988	chr1:146714368	CHD1L	-1.01	-8.99	-0.44	1.91e-17	Mitochondrial DNA levels;
LUSC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.7	0.3	2.67e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg21280719	chr6:42927975	GNMT	0.3	7.52	0.38	5.18e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg04691961	chr3:161091175	C3orf57	-0.35	-6.11	-0.32	2.74e-9	Morning vs. evening chronotype;
LUSC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg22709100	chr7:91322751	NA	0.4	5.77	0.3	1.8e-8	Breast cancer;
LUSC	cis	rs1595825	0.891	rs60582020	chr2:198520555	A/C	cg19156104	chr2:198669113	PLCL1	-0.45	-5.69	-0.3	2.74e-8	Ulcerative colitis;
LUSC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg06008330	chr7:65541103	ASL	-0.4	-6.27	-0.32	1.13e-9	Aortic root size;
LUSC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg07700843	chr1:2391317	NA	-0.36	-6.37	-0.33	6.16e-10	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.71	12.79	0.57	9.66e-31	Prudent dietary pattern;
LUSC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.5	0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.64	-10.99	-0.52	3.58e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-1.08	-15.78	-0.65	2.71e-42	Initial pursuit acceleration;
LUSC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg06618935	chr21:46677482	NA	-0.39	-7.74	-0.39	1.16e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06221963	chr1:154839813	KCNN3	-0.59	-12.99	-0.58	1.61e-31	Prostate cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13560760	chr9:139308792	PMPCA	-0.43	-6.93	-0.35	2.12e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.69	11.25	0.52	4.26e-25	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg08501292	chr6:25962987	TRIM38	0.66	6.05	0.31	3.97e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1030877	0.515	rs2576735	chr2:105888839	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.64	8.56	0.42	4.17e-16	Obesity-related traits;
LUSC	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg13256891	chr4:100009986	ADH5	-0.49	-6.37	-0.33	6.11e-10	Alcohol dependence;
LUSC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg18758796	chr5:131593413	PDLIM4	0.43	7.46	0.38	7.59e-13	Breast cancer;
LUSC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24110177	chr3:50126178	RBM5	-0.54	-8.8	-0.43	7.39e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg09835421	chr16:68378352	PRMT7	-0.75	-8.25	-0.41	3.72e-15	Schizophrenia;
LUSC	trans	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg25214090	chr10:38739885	LOC399744	0.43	6.58	0.34	1.77e-10	Corneal astigmatism;
LUSC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg12365402	chr11:9010492	NRIP3	-0.39	-6.73	-0.35	7.19e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.46	-0.42	8.33e-16	Response to antipsychotic treatment;
LUSC	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg07148914	chr20:33460835	GGT7	-0.55	-8.41	-0.42	1.25e-15	Height;
LUSC	cis	rs10911363	0.592	rs2702177	chr1:183450622	G/C	cg09173681	chr1:183549694	NCF2	0.66	12.24	0.56	1.08e-28	Systemic lupus erythematosus;
LUSC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg19318889	chr4:1322082	MAEA	0.42	7.02	0.36	1.26e-11	Obesity-related traits;
LUSC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg20243544	chr17:37824526	PNMT	0.47	5.97	0.31	5.98e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg09835421	chr16:68378352	PRMT7	-0.73	-7.63	-0.39	2.43e-13	Magnesium levels;
LUSC	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg11502198	chr6:26597334	ABT1	0.69	11.45	0.53	7.68e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs11785400	1.000	rs10108059	chr8:143750028	G/T	cg10596483	chr8:143751796	JRK	-0.6	-9.22	-0.45	3.54e-18	Schizophrenia;
LUSC	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.11	15.85	0.66	1.44e-42	Lung cancer in ever smokers;
LUSC	cis	rs11779988	0.545	rs208753	chr8:17814915	A/G	cg01800426	chr8:17659068	MTUS1	-0.47	-5.74	-0.3	2.13e-8	Breast cancer;
LUSC	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg20713898	chr8:124780851	FAM91A1	-0.54	-7.52	-0.38	5.18e-13	Pancreatic cancer;
LUSC	cis	rs877282	0.755	rs2486579	chr10:785647	G/A	cg17470449	chr10:769945	NA	0.41	6.03	0.31	4.33e-9	Uric acid levels;
LUSC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg12927641	chr6:109611667	NA	-0.43	-7.62	-0.38	2.71e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg26384229	chr12:38710491	ALG10B	0.58	8.66	0.43	2.11e-16	Heart rate;
LUSC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-7.14	-0.36	5.69e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg23711669	chr6:146136114	FBXO30	0.88	16.13	0.66	1.05e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.95	-0.36	1.97e-11	Mood instability;
LUSC	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg23127183	chr11:57508653	C11orf31	-0.53	-8.13	-0.41	8.55e-15	Schizophrenia;
LUSC	cis	rs4588572	0.643	rs10942857	chr5:77760241	A/G	cg11547950	chr5:77652471	NA	-0.56	-7.9	-0.4	4.03e-14	Triglycerides;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15152706	chr6:170615451	FAM120B	-0.4	-6.18	-0.32	1.87e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.52	9.51	0.46	3.79e-19	Bone mineral density;
LUSC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.38	-0.33	5.88e-10	Lung cancer;
LUSC	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg16482183	chr6:26056742	HIST1H1C	0.58	8.27	0.41	3.26e-15	Iron status biomarkers;
LUSC	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.64	9.76	0.47	5.69e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg16434002	chr17:42200994	HDAC5	-0.46	-6.44	-0.33	4.27e-10	Total body bone mineral density;
LUSC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15664640	chr17:80829946	TBCD	0.47	8.44	0.42	9.53e-16	Breast cancer;
LUSC	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg23173402	chr1:227635558	NA	0.68	6.57	0.34	1.93e-10	Major depressive disorder;
LUSC	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-13.39	-0.59	4.85e-33	Brugada syndrome;
LUSC	cis	rs977987	0.806	rs7188604	chr16:75451170	T/G	cg03315344	chr16:75512273	CHST6	0.48	8.91	0.44	3.47e-17	Dupuytren's disease;
LUSC	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg05340658	chr4:99064831	C4orf37	0.69	11.84	0.54	2.99e-27	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.47	-8.79	-0.43	7.93e-17	Monocyte percentage of white cells;
LUSC	trans	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.85	-0.35	3.53e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	5.71	0.3	2.47e-8	Educational attainment;
LUSC	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg02569458	chr12:86230093	RASSF9	0.48	7.57	0.38	3.66e-13	Major depressive disorder;
LUSC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg21770322	chr7:97807741	LMTK2	0.41	7.08	0.36	8.48e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg04995722	chr7:26192034	NFE2L3	-0.38	-6.02	-0.31	4.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg00540400	chr15:79124168	NA	0.45	8.06	0.4	1.41e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs1983170	0.808	rs6668067	chr1:92018613	G/A	cg25838465	chr1:92012736	NA	0.42	5.92	0.31	7.87e-9	Eosinophil percentage of white cells;
LUSC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg20406979	chr6:167373233	NA	0.26	6.21	0.32	1.61e-9	Crohn's disease;
LUSC	cis	rs6445967	0.569	rs7622497	chr3:58282673	A/C	cg13750441	chr3:58318267	PXK	-0.32	-5.65	-0.3	3.38e-8	Platelet count;
LUSC	trans	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.09	-0.32	3.07e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07677032	chr17:61819896	STRADA	0.54	9.05	0.44	1.17e-17	Prudent dietary pattern;
LUSC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg02782426	chr3:40428986	ENTPD3	0.32	6.06	0.31	3.72e-9	Renal cell carcinoma;
LUSC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06634786	chr22:41940651	POLR3H	-0.56	-6.52	-0.34	2.61e-10	Vitiligo;
LUSC	cis	rs73416724	1.000	rs75320251	chr6:43395101	G/A	cg26312998	chr6:43337775	ZNF318	0.56	6.67	0.34	1.09e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs73198271	0.694	rs115037021	chr8:8647080	A/C	cg01851573	chr8:8652454	MFHAS1	0.52	8.12	0.41	9.04e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs17155006	0.664	rs410866	chr7:107744543	C/T	cg05962710	chr7:107745446	LAMB4	0.34	5.87	0.31	1.03e-8	Pneumococcal bacteremia;
LUSC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg19257562	chr1:2043853	PRKCZ	0.31	6.06	0.31	3.73e-9	Height;
LUSC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.88	-0.35	2.94e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg08470875	chr2:26401718	FAM59B	-0.68	-8.85	-0.44	5.2e-17	Gut microbiome composition (summer);
LUSC	cis	rs7503807	0.967	rs12939549	chr17:78611724	C/T	cg09596252	chr17:78655493	RPTOR	-0.45	-7.65	-0.39	2.15e-13	Obesity;
LUSC	cis	rs7818345	0.845	rs11782540	chr8:19268251	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.32	6.16	0.32	2.1e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg00745463	chr17:30367425	LRRC37B	-0.47	-6.68	-0.34	1.01e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg06627628	chr2:24431161	ITSN2	0.81	12.16	0.55	2.08e-28	Asthma;
LUSC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	15.22	0.64	4.35e-40	Platelet count;
LUSC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg26695010	chr11:65641043	EFEMP2	-0.47	-7.09	-0.36	8.12e-12	Eosinophil percentage of white cells;
LUSC	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.38	-0.42	1.49e-15	Total cholesterol levels;
LUSC	cis	rs7106204	0.514	rs1443043	chr11:24251991	A/G	ch.11.24196551F	chr11:24239977	NA	0.92	10.2	0.49	1.98e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg06521331	chr12:34319734	NA	-0.37	-6.37	-0.33	6.39e-10	Morning vs. evening chronotype;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg20205542	chr3:183892600	AP2M1	0.46	6.3	0.33	9.17e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1595825	1.000	rs6434950	chr2:198869979	A/G	cg00982548	chr2:198649783	BOLL	-0.49	-6.15	-0.32	2.15e-9	Ulcerative colitis;
LUSC	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-8.21	-0.41	4.95e-15	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	7.67	0.39	1.92e-13	Prudent dietary pattern;
LUSC	cis	rs965513	1.000	rs1588635	chr9:100537802	A/C	cg13688889	chr9:100608707	NA	-0.63	-9.42	-0.46	7.83e-19	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg21770322	chr7:97807741	LMTK2	0.5	8.59	0.43	3.5e-16	Breast cancer;
LUSC	trans	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.23	0.32	1.39e-9	Corneal astigmatism;
LUSC	cis	rs1941023	0.503	rs10750936	chr11:60144180	G/A	cg08716584	chr11:60157161	MS4A7	-0.65	-12.39	-0.56	2.92e-29	Congenital heart disease (maternal effect);
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg01238044	chr22:24384105	GSTT1	-0.53	-7.35	-0.37	1.55e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22496380	chr5:211416	CCDC127	-0.86	-8.69	-0.43	1.6e-16	Breast cancer;
LUSC	cis	rs3849570	1.000	rs9826270	chr3:81841869	C/T	cg07356753	chr3:81810745	GBE1	-0.69	-11.09	-0.52	1.51e-24	Waist circumference;Body mass index;
LUSC	cis	rs4629710	0.592	rs9492877	chr6:131562577	C/G	cg12606694	chr6:131520996	AKAP7	0.62	9.42	0.46	7.5e-19	Multiple myeloma (IgH translocation);
LUSC	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg22491629	chr6:157744540	C6orf35	-0.9	-10.67	-0.5	4.68e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs2732480	0.538	rs2732462	chr12:48696384	A/G	cg04545296	chr12:48745243	ZNF641	0.35	6.38	0.33	6.03e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs10865541	0.902	rs12476309	chr2:3404845	C/T	cg15807143	chr2:3452624	TTC15	0.32	5.67	0.3	3.11e-8	Obesity-related traits;
LUSC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.78	0.43	8.48e-17	Prudent dietary pattern;
LUSC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08736216	chr1:53307985	ZYG11A	0.3	6.16	0.32	2.04e-9	Monocyte count;
LUSC	cis	rs295140	0.706	rs1347551	chr2:201186572	C/T	cg04283868	chr2:201171347	SPATS2L	0.4	5.65	0.3	3.45e-8	QT interval;
LUSC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg23788917	chr6:8435910	SLC35B3	-0.48	-6.99	-0.36	1.49e-11	Motion sickness;
LUSC	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-7.07	-0.36	9.1e-12	Fear of minor pain;
LUSC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg02569458	chr12:86230093	RASSF9	0.49	8.22	0.41	4.69e-15	Major depressive disorder;
LUSC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-6.83	-0.35	4.08e-11	Neuroticism;
LUSC	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.06	-24.08	-0.8	5.54e-75	Ulcerative colitis;
LUSC	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg27411982	chr8:10470053	RP1L1	0.41	6.28	0.32	1.08e-9	Mood instability;
LUSC	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg02023728	chr11:77925099	USP35	0.48	6.73	0.35	7.42e-11	Testicular germ cell tumor;
LUSC	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg23985595	chr17:80112537	CCDC57	-0.3	-5.68	-0.3	2.87e-8	Life satisfaction;
LUSC	cis	rs12986413	1.000	rs12986413	chr19:2170954	A/T	cg09261902	chr19:2140048	AP3D1	-0.32	-6.3	-0.33	9.48e-10	Height;
LUSC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg13319975	chr6:146136371	FBXO30	0.49	7.53	0.38	4.85e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9395066	0.527	rs1590864	chr6:44906151	C/A	cg25276700	chr6:44698697	NA	0.3	6.07	0.32	3.46e-9	Height;
LUSC	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg06287003	chr12:125626642	AACS	-0.41	-6.8	-0.35	4.79e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg00376283	chr12:123451042	ABCB9	-0.66	-7.74	-0.39	1.18e-13	Neutrophil percentage of white cells;
LUSC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	1.0	13.96	0.61	3.22e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs1044826	0.642	rs9859864	chr3:139091219	G/T	cg00490450	chr3:139108681	COPB2	-0.51	-8.14	-0.41	7.74e-15	Obesity-related traits;
LUSC	cis	rs7527798	0.501	rs12125256	chr1:207851361	C/T	cg09232269	chr1:207846808	CR1L	-0.29	-6.27	-0.32	1.14e-9	Erythrocyte sedimentation rate;
LUSC	trans	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg07923666	chr12:49932857	KCNH3	-0.49	-6.14	-0.32	2.29e-9	Resting heart rate;
LUSC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg19230755	chr7:65878503	NA	-0.4	-5.75	-0.3	2.06e-8	Aortic root size;
LUSC	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg05340658	chr4:99064831	C4orf37	0.59	9.73	0.47	7.5e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg17470449	chr10:769945	NA	0.53	7.12	0.36	6.81e-12	Uric acid levels;
LUSC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.62	-0.34	1.41e-10	Lung cancer;
LUSC	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.81	-0.6	1.26e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg14092988	chr3:52407081	DNAH1	0.32	5.9	0.31	8.93e-9	Bipolar disorder;
LUSC	cis	rs11166629	1.000	rs894349	chr8:135638055	T/C	cg21672855	chr8:135614777	ZFAT	0.36	5.91	0.31	8.3e-9	Smoking quantity;
LUSC	cis	rs73206853	0.686	rs73206895	chr12:110879968	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.94	0.4	3.18e-14	Ulcerative colitis;
LUSC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg12963246	chr6:28129442	ZNF389	0.39	6.07	0.32	3.54e-9	Cardiac Troponin-T levels;
LUSC	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg00012203	chr2:219082015	ARPC2	0.82	14.46	0.62	3.99e-37	Colorectal cancer;
LUSC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg02269571	chr22:50332266	NA	0.6	8.97	0.44	2.25e-17	Schizophrenia;
LUSC	trans	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.14	0.32	2.31e-9	Corneal astigmatism;
LUSC	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1595825	0.786	rs77773624	chr2:198514845	G/A	cg19156104	chr2:198669113	PLCL1	-0.46	-5.84	-0.3	1.24e-8	Ulcerative colitis;
LUSC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg24375607	chr4:120327624	NA	0.75	11.09	0.52	1.57e-24	Corneal astigmatism;
LUSC	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.61	-0.38	2.74e-13	Mood instability;
LUSC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.84	14.2	0.61	3.93e-36	Blood protein levels;
LUSC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.3	-0.45	1.91e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg12091567	chr17:66097778	LOC651250	-0.71	-9.45	-0.46	6.25e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	1.05	17.93	0.7	8.17e-51	Testicular germ cell tumor;
LUSC	cis	rs4363385	0.740	rs1338181	chr1:153010301	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.2	-0.37	4.14e-12	Inflammatory skin disease;
LUSC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg08270630	chr22:50330655	NA	0.4	5.9	0.31	8.78e-9	Schizophrenia;
LUSC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg16797656	chr11:68205561	LRP5	0.37	6.7	0.34	9e-11	Total body bone mineral density;
LUSC	trans	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04565464	chr8:145669602	NFKBIL2	0.4	6.53	0.34	2.44e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	8.03	0.4	1.7e-14	Ulcerative colitis;
LUSC	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg00129232	chr17:37814104	STARD3	-0.49	-7.32	-0.37	1.84e-12	Asthma;
LUSC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Parkinson's disease;
LUSC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg15704280	chr7:45808275	SEPT13	-1.02	-19.52	-0.73	3.57e-57	Height;
LUSC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg03806693	chr22:41940476	POLR3H	1.01	14.1	0.61	9.46e-36	Vitiligo;
LUSC	cis	rs7953249	0.807	rs7970695	chr12:121423376	G/A	cg02403541	chr12:121454288	C12orf43	-0.62	-9.08	-0.44	9.97e-18	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.48e-28	Motion sickness;
LUSC	cis	rs977987	0.872	rs4887825	chr16:75472422	C/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.11	-0.36	6.95e-12	Dupuytren's disease;
LUSC	cis	rs12618769	0.597	rs17031146	chr2:99036683	A/G	cg10123293	chr2:99228465	UNC50	0.46	7.73	0.39	1.27e-13	Bipolar disorder;
LUSC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg15110403	chr19:17392923	ANKLE1	-0.58	-7.97	-0.4	2.57e-14	Systemic lupus erythematosus;
LUSC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg22823121	chr1:150693482	HORMAD1	0.49	7.2	0.37	4.13e-12	Melanoma;
LUSC	cis	rs1568889	0.712	rs10835306	chr11:28302410	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	13.11	0.58	5.78e-32	Bipolar disorder;
LUSC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	16.05	0.66	2.26e-43	Platelet count;
LUSC	cis	rs59698941	0.943	rs73259116	chr5:132218461	A/G	cg02081065	chr5:132209139	LEAP2	-0.65	-6.76	-0.35	6.04e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg13918804	chr1:2043761	PRKCZ	0.27	5.81	0.3	1.48e-8	Height;
LUSC	trans	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.16	-0.32	2.15e-9	Triglycerides;
LUSC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.44	6.11	0.32	2.72e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1018836	0.632	rs2879361	chr8:91481909	C/T	cg16814680	chr8:91681699	NA	0.67	10.17	0.49	2.46e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg15839431	chr19:19639596	YJEFN3	0.42	5.73	0.3	2.3e-8	Tonsillectomy;
LUSC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.4	-0.38	1.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2190422	0.651	rs6945055	chr7:103086835	T/G	cg04218035	chr7:103086829	SLC26A5	0.31	6.08	0.32	3.21e-9	Morning vs. evening chronotype;
LUSC	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg10523679	chr1:76189770	ACADM	-0.48	-6.99	-0.36	1.48e-11	Daytime sleep phenotypes;
LUSC	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.97	0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.25	0.37	2.85e-12	Blood metabolite levels;
LUSC	cis	rs612683	0.824	rs17454919	chr1:100830370	A/G	cg06223162	chr1:101003688	GPR88	0.4	7.31	0.37	2.05e-12	Breast cancer;
LUSC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.02	0.44	1.51e-17	Menarche (age at onset);
LUSC	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg09904177	chr6:26538194	HMGN4	-0.73	-6.67	-0.34	1.05e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg24562669	chr7:97807699	LMTK2	0.4	6.78	0.35	5.32e-11	Breast cancer;
LUSC	cis	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg06521331	chr12:34319734	NA	-0.46	-7.33	-0.37	1.73e-12	Morning vs. evening chronotype;
LUSC	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg19773385	chr1:10388646	KIF1B	-0.54	-8.33	-0.41	2.08e-15	Hepatocellular carcinoma;
LUSC	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg01966878	chr4:90757139	SNCA	0.33	5.69	0.3	2.73e-8	Dementia with Lewy bodies;
LUSC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg04518342	chr5:131593106	PDLIM4	0.53	9.79	0.47	4.47e-20	Acylcarnitine levels;
LUSC	cis	rs1568889	0.838	rs11030220	chr11:28145769	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.7	0.57	2.01e-30	Bipolar disorder;
LUSC	cis	rs9311676	0.656	rs56097407	chr3:58378079	G/A	cg13750441	chr3:58318267	PXK	0.36	7.06	0.36	9.88e-12	Systemic lupus erythematosus;
LUSC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg06600287	chr1:53387719	ECHDC2	-0.28	-5.69	-0.3	2.71e-8	Monocyte count;
LUSC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg22823121	chr1:150693482	HORMAD1	0.56	8.46	0.42	8.54e-16	Melanoma;
LUSC	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg00376283	chr12:123451042	ABCB9	-0.66	-8.39	-0.42	1.4e-15	Neutrophil percentage of white cells;
LUSC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.42	-0.33	4.68e-10	Life satisfaction;
LUSC	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.59	-0.38	3.15e-13	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs11048434	0.736	rs1805761	chr12:9099533	T/C	cg13575925	chr12:9217583	LOC144571	0.34	6.25	0.32	1.29e-9	Sjögren's syndrome;
LUSC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg03477792	chr4:77819574	ANKRD56	0.61	8.7	0.43	1.52e-16	Emphysema distribution in smoking;
LUSC	cis	rs7091068	0.566	rs7909925	chr10:95507170	A/G	cg20715218	chr10:95462985	C10orf4	0.59	6.53	0.34	2.48e-10	Urinary tract infection frequency;
LUSC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.95	12.23	0.56	1.1e-28	Chronic sinus infection;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg18864399	chr15:73345368	NEO1	0.39	5.96	0.31	6.31e-9	Calcium levels;
LUSC	cis	rs2294693	0.945	rs11756893	chr6:41010058	A/C	cg14769373	chr6:40998127	UNC5CL	-0.54	-7.22	-0.37	3.59e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg05855489	chr10:104503620	C10orf26	0.6	9.44	0.46	6.77e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg14895029	chr7:2775587	GNA12	-0.41	-6.13	-0.32	2.53e-9	Height;
LUSC	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg09307838	chr4:120376055	NA	-0.59	-8.76	-0.43	9.86e-17	Corneal astigmatism;
LUSC	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg21385522	chr1:16154831	NA	-0.98	-18.46	-0.71	6.21e-53	Dilated cardiomyopathy;
LUSC	cis	rs57504626	1	rs57504626	chr19:19720399	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	7.15	0.36	5.53e-12	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05776053	chr2:74358815	NA	0.45	7.21	0.37	3.77e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg20129853	chr10:51489980	NA	0.36	7.45	0.38	7.84e-13	Prostate-specific antigen levels;
LUSC	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg00810483	chr4:3375144	RGS12	-0.31	-6.1	-0.32	2.9e-9	Serum sulfate level;
LUSC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg09365446	chr1:150670422	GOLPH3L	0.46	6.93	0.35	2.16e-11	Melanoma;
LUSC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg25036284	chr2:26402008	FAM59B	-0.68	-9.38	-0.46	1.06e-18	Gut microbiome composition (summer);
LUSC	cis	rs7712401	0.623	rs538424	chr5:122228763	G/A	cg19077854	chr5:122220652	SNX24	0.39	8.64	0.43	2.36e-16	Mean platelet volume;
LUSC	cis	rs4566357	0.930	rs13398295	chr2:227926873	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.89	-0.31	9.43e-9	Coronary artery disease;
LUSC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg21644426	chr2:191273491	MFSD6	0.61	9.72	0.47	8e-20	Pulse pressure;
LUSC	cis	rs2708377	0.929	rs2599415	chr12:11217237	G/A	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs3820928	0.874	rs13423046	chr2:227901805	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.89	-0.4	4.48e-14	Pulmonary function;
LUSC	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg03929089	chr4:120376271	NA	-0.6	-7.24	-0.37	3.14e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg23711669	chr6:146136114	FBXO30	0.93	18.04	0.7	2.89e-51	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13266717	chr20:62338881	ARFRP1;ZGPAT	-0.43	-6.5	-0.34	2.95e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.23	-0.32	1.41e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9650315	0.866	rs6474053	chr8:57169733	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.12	0.36	6.82e-12	Height;
LUSC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg12365402	chr11:9010492	NRIP3	-0.4	-6.81	-0.35	4.53e-11	Hemoglobin concentration;
LUSC	cis	rs7091068	0.522	rs866674	chr10:95487515	A/G	cg20715218	chr10:95462985	C10orf4	0.61	7.51	0.38	5.6e-13	Urinary tract infection frequency;
LUSC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg02896835	chr1:92012615	NA	-0.62	-11.13	-0.52	1.08e-24	Breast cancer;
LUSC	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg06547715	chr2:218990976	CXCR2	0.33	6.52	0.34	2.63e-10	Ulcerative colitis;
LUSC	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.55	0.46	2.87e-19	Schizophrenia;
LUSC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.4	5.83	0.3	1.33e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs8022206	0.891	rs1033686	chr14:68362510	A/G	cg15809352	chr2:121748218	GLI2	-0.44	-6.29	-0.33	9.84e-10	Platelet count;Mean platelet volume;
LUSC	cis	rs3741151	0.773	rs73544729	chr11:73183418	G/T	cg17517138	chr11:73019481	ARHGEF17	0.99	8.33	0.41	2.14e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg09655341	chr17:79618100	PDE6G	-0.27	-6.12	-0.32	2.64e-9	Eye color traits;
LUSC	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-7.11	-0.36	6.93e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.28	-0.32	1.06e-9	Retinal vascular caliber;
LUSC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.68	-10.44	-0.5	2.84e-22	Aortic root size;
LUSC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.61	-0.57	4.42e-30	Alzheimer's disease;
LUSC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.47	-7.92	-0.4	3.47e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg04362960	chr10:104952993	NT5C2	1.16	13.95	0.61	3.69e-35	Arsenic metabolism;
LUSC	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg21643547	chr1:205240462	TMCC2	-0.38	-7.04	-0.36	1.11e-11	Red blood cell count;
LUSC	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg00484396	chr16:3507460	NAT15	0.49	7.23	0.37	3.26e-12	Body mass index (adult);
LUSC	cis	rs6681460	0.565	rs1536112	chr1:67107225	C/T	cg02459107	chr1:67143332	SGIP1	-0.44	-8.27	-0.41	3.16e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.65	10.57	0.5	9.85e-23	Longevity;
LUSC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.79	0.51	1.7e-23	Bladder cancer;
LUSC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.08	20.92	0.75	1.06e-62	Cognitive ability;
LUSC	cis	rs7580658	0.963	rs867304	chr2:128078488	G/A	cg09760422	chr2:128146352	NA	-0.32	-7.24	-0.37	3.13e-12	Protein C levels;
LUSC	cis	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg06521331	chr12:34319734	NA	-0.41	-6.43	-0.33	4.4e-10	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg02176678	chr2:219576539	TTLL4	-0.57	-10.03	-0.48	7.16e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	7.49	0.38	6.31e-13	Initial pursuit acceleration;
LUSC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17509989	chr5:176798049	RGS14	0.69	10.99	0.52	3.4e-24	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg03188948	chr7:1209495	NA	0.64	6.9	0.35	2.56e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	7.2	0.37	4.1e-12	Motion sickness;
LUSC	cis	rs12042938	0.600	rs823161	chr1:231775017	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	6.13	0.32	2.43e-9	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg13047869	chr3:10149882	C3orf24	0.57	7.91	0.4	3.81e-14	Alzheimer's disease;
LUSC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.4	0.56	2.7e-29	Prudent dietary pattern;
LUSC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg14019146	chr3:50243930	SLC38A3	0.31	6.78	0.35	5.6e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg21775007	chr8:11205619	TDH	-0.49	-6.6	-0.34	1.6e-10	Neuroticism;
LUSC	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg09479241	chr17:27052676	TLCD1	0.44	5.9	0.31	8.93e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10802521	chr3:52805072	NEK4	-0.55	-8.98	-0.44	2.02e-17	Bipolar disorder;
LUSC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg03609598	chr5:56110824	MAP3K1	-0.42	-5.97	-0.31	5.96e-9	Initial pursuit acceleration;
LUSC	cis	rs7804356	1.000	rs10272603	chr7:26888277	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	trans	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-13.47	-0.59	2.5e-33	Brugada syndrome;
LUSC	trans	rs724744	0.772	rs1629125	chr6:22353431	A/G	cg13807341	chr11:118445984	ARCN1	-0.36	-6.19	-0.32	1.77e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs9650657	0.836	rs3905581	chr8:10603705	G/T	cg14992524	chr8:10586135	SOX7	-0.3	-5.65	-0.3	3.39e-8	Neuroticism;
LUSC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20135002	chr11:47629003	NA	-0.49	-7.66	-0.39	2.06e-13	Subjective well-being;
LUSC	cis	rs4561483	0.801	rs33660	chr16:11961858	A/G	cg08843971	chr16:11963173	GSPT1	-0.49	-7.59	-0.38	3.31e-13	Testicular germ cell tumor;
LUSC	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.46	0.53	7.16e-26	Eye color traits;
LUSC	cis	rs11958404	0.932	rs72816600	chr5:157436349	T/C	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs116988415	0.584	rs11622171	chr14:65258644	C/G	cg25083366	chr14:65239357	SPTB	0.68	6.83	0.35	4.1e-11	Daytime sleep phenotypes;
LUSC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.64	0.6	5.79e-34	Cognitive test performance;
LUSC	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg17279839	chr7:150038598	RARRES2	0.41	6.39	0.33	5.56e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.85	-0.47	2.99e-20	Hemoglobin concentration;
LUSC	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg13298116	chr11:62369859	EML3;MTA2	-0.51	-8.74	-0.43	1.18e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg25173405	chr17:45401733	C17orf57	-0.38	-6.03	-0.31	4.27e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.08	0.52	1.68e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg06238570	chr21:40685208	BRWD1	-0.55	-8.63	-0.43	2.55e-16	Menarche (age at onset);
LUSC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.02	0.36	1.27e-11	Mean platelet volume;
LUSC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-17.36	-0.69	1.44e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg00334542	chr7:100209784	MOSPD3	-0.48	-5.7	-0.3	2.61e-8	Other erythrocyte phenotypes;
LUSC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.03	-0.36	1.2e-11	Bipolar disorder;
LUSC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg25566285	chr7:158114605	PTPRN2	0.35	6.53	0.34	2.52e-10	Calcium levels;
LUSC	cis	rs17092148	0.945	rs6142237	chr20:33340993	C/T	cg16810054	chr20:33298113	TP53INP2	-0.41	-6.47	-0.33	3.42e-10	Neuroticism;
LUSC	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-0.65	-9.59	-0.46	2.1e-19	Platelet distribution width;
LUSC	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg04176472	chr15:90893244	GABARAPL3	0.35	6.02	0.31	4.53e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg14629032	chr9:94185528	NFIL3	0.38	6.08	0.32	3.3e-9	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg11645453	chr3:52864694	ITIH4	0.34	7.78	0.39	8.92e-14	Bipolar disorder;
LUSC	trans	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg06437703	chr8:37914619	EIF4EBP1	0.57	8.87	0.44	4.61e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg25566285	chr7:158114605	PTPRN2	-0.33	-6.22	-0.32	1.5e-9	Calcium levels;
LUSC	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg25206134	chr2:45395956	NA	0.56	6.42	0.33	4.61e-10	Bipolar disorder;
LUSC	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.61	-0.38	2.74e-13	Retinal vascular caliber;
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg23034840	chr1:205782522	SLC41A1	0.62	8.8	0.43	7.43e-17	Menarche (age at onset);
LUSC	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg08807101	chr21:30365312	RNF160	-0.53	-6.68	-0.34	9.85e-11	Cognitive test performance;
LUSC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.24	0.37	3.18e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs751728	0.664	rs12190029	chr6:33749152	T/A	cg25922239	chr6:33757077	LEMD2	0.43	6.48	0.33	3.22e-10	Crohn's disease;
LUSC	cis	rs16854884	0.586	rs6782789	chr3:143746691	G/A	cg06585982	chr3:143692056	C3orf58	0.52	8.29	0.41	2.86e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg06060754	chr5:176797920	RGS14	-0.61	-8.6	-0.43	3.13e-16	Urate levels in lean individuals;
LUSC	cis	rs9503598	0.636	rs7766753	chr6:3467708	A/C	cg00476032	chr6:3446245	SLC22A23	0.3	5.88	0.31	9.78e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg18904891	chr8:8559673	CLDN23	0.6	8.08	0.4	1.2e-14	Obesity-related traits;
LUSC	cis	rs308447	0.516	rs732676	chr4:123717476	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.84	11.44	0.53	8.46e-26	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg06636001	chr8:8085503	FLJ10661	0.45	6.78	0.35	5.53e-11	Joint mobility (Beighton score);
LUSC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.41	-5.94	-0.31	7.25e-9	Tonsillectomy;
LUSC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs977987	0.750	rs4888407	chr16:75432390	T/C	cg04384234	chr16:75411784	CFDP1	-0.42	-6.84	-0.35	3.73e-11	Dupuytren's disease;
LUSC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.61	-0.38	2.81e-13	Schizophrenia;
LUSC	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg07148914	chr20:33460835	GGT7	0.56	8.42	0.42	1.14e-15	Height;
LUSC	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.17	0.37	4.71e-12	Morning vs. evening chronotype;
LUSC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.35	-0.37	1.49e-12	Extrinsic epigenetic age acceleration;
LUSC	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	7.78	0.39	9.42e-14	Neuroticism;
LUSC	cis	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.87	-0.31	1.03e-8	Resting heart rate;
LUSC	cis	rs28647808	0.881	rs7040821	chr9:136263584	C/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.56	0.46	2.6e-19	Lung cancer in ever smokers;
LUSC	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg17168535	chr8:21777572	XPO7	-0.66	-11.0	-0.52	3.19e-24	Lung cancer in ever smokers;
LUSC	cis	rs7215564	0.908	rs4536520	chr17:78660239	C/T	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg21775007	chr8:11205619	TDH	0.46	6.46	0.33	3.75e-10	Neuroticism;
LUSC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg06713675	chr4:122721982	EXOSC9	-0.66	-11.68	-0.54	1.2e-26	Type 2 diabetes;
LUSC	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg24397884	chr7:158709396	WDR60	0.62	9.56	0.46	2.71e-19	Height;
LUSC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18932078	chr1:2524107	MMEL1	0.28	6.15	0.32	2.18e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs7800944	0.715	rs12540011	chr7:72991704	G/A	cg07452164	chr7:72993570	TBL2	0.47	6.7	0.34	8.62e-11	Coffee consumption (cups per day);
LUSC	cis	rs2299587	0.560	rs11987695	chr8:17781085	A/G	cg01800426	chr8:17659068	MTUS1	-0.48	-6.41	-0.33	4.82e-10	Economic and political preferences;
LUSC	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg24006582	chr15:45444508	DUOX1	0.66	9.5	0.46	4.32e-19	Uric acid levels;
LUSC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.75	12.41	0.56	2.44e-29	Coronary artery disease;
LUSC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg09796270	chr17:17721594	SREBF1	0.42	7.51	0.38	5.43e-13	Total body bone mineral density;
LUSC	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21775007	chr8:11205619	TDH	0.78	12.75	0.57	1.35e-30	Retinal vascular caliber;
LUSC	cis	rs2346177	0.875	rs1447565	chr2:46643682	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-8.83	-0.44	5.91e-17	HDL cholesterol;
LUSC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg05872129	chr22:39784769	NA	-0.58	-10.59	-0.5	8.65e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.07	20.47	0.75	6.13e-61	Cognitive ability;
LUSC	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg03563238	chr19:33554763	RHPN2	-0.41	-6.56	-0.34	2.09e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg17845761	chr1:175162550	KIAA0040	0.31	5.98	0.31	5.7e-9	Alcohol dependence;
LUSC	cis	rs3750965	1.000	rs7950657	chr11:68834831	G/A	cg06818126	chr11:68850279	TPCN2	-0.44	-6.25	-0.32	1.25e-9	Hair color;
LUSC	cis	rs9644630	0.672	rs4486225	chr8:19313404	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.48	8.01	0.4	1.96e-14	Oropharynx cancer;
LUSC	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg02493740	chr2:85810744	VAMP5	-0.32	-5.78	-0.3	1.72e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg20587970	chr11:113659929	NA	-1.35	-19.04	-0.72	3.02e-55	Hip circumference adjusted for BMI;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12787624	chr12:50677281	LIMA1	-0.41	-6.19	-0.32	1.78e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.3	-0.45	1.92e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs12618769	0.652	rs72823801	chr2:99235055	A/G	cg10123293	chr2:99228465	UNC50	0.46	7.54	0.38	4.42e-13	Bipolar disorder;
LUSC	cis	rs926938	0.618	rs360617	chr1:115404099	G/A	cg12756093	chr1:115239321	AMPD1	0.47	7.23	0.37	3.25e-12	Autism;
LUSC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg07414643	chr4:187882934	NA	0.56	10.7	0.51	3.67e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg23711669	chr6:146136114	FBXO30	0.71	12.28	0.56	7.14e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg23176889	chr5:176863531	GRK6	0.61	12.18	0.55	1.65e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg01973587	chr1:228161476	NA	0.45	8.09	0.4	1.15e-14	Diastolic blood pressure;
LUSC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.72	0.57	1.68e-30	Prudent dietary pattern;
LUSC	trans	rs1973993	0.903	rs2038646	chr1:96940371	C/G	cg10631902	chr5:14652156	NA	0.53	8.82	0.43	6.25e-17	Weight;
LUSC	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.46	8.22	0.41	4.44e-15	HDL cholesterol;
LUSC	cis	rs6733011	0.500	rs885115	chr2:99446445	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-6.15	-0.32	2.18e-9	Bipolar disorder;
LUSC	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg00677455	chr12:58241039	CTDSP2	0.72	11.19	0.52	6.61e-25	Multiple sclerosis;
LUSC	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-7.23	-0.37	3.3e-12	Morning vs. evening chronotype;
LUSC	cis	rs4680	0.737	rs2239393	chr22:19950428	A/G	cg22546130	chr22:19950026	COMT	-0.39	-8.42	-0.42	1.1e-15	Blood metabolite levels;
LUSC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg24060327	chr5:131705240	SLC22A5	0.66	10.98	0.51	3.75e-24	Breast cancer;
LUSC	trans	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.83	-0.39	6.63e-14	Morning vs. evening chronotype;
LUSC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg23985595	chr17:80112537	CCDC57	-0.31	-6.11	-0.32	2.82e-9	Life satisfaction;
LUSC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7424096	0.582	rs7600245	chr2:37220614	A/C	cg14987922	chr2:37194071	STRN	0.61	8.25	0.41	3.78e-15	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs12493885	0.769	rs61791540	chr3:153757041	G/A	cg17054900	chr3:154042577	DHX36	-0.67	-7.06	-0.36	9.76e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.38	0.33	5.95e-10	Menopause (age at onset);
LUSC	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg27411982	chr8:10470053	RP1L1	0.41	6.63	0.34	1.39e-10	Mood instability;
LUSC	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg15103426	chr22:29168792	CCDC117	-0.44	-5.73	-0.3	2.24e-8	Lymphocyte counts;
LUSC	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-17.83	-0.7	1.92e-50	Primary sclerosing cholangitis;
LUSC	cis	rs11039100	1.000	rs61875915	chr11:5828568	A/G	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2219968	0.740	rs7829841	chr8:78918716	G/T	cg00738934	chr8:78996279	NA	0.34	5.99	0.31	5.54e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs62238980	0.614	rs4821013	chr22:32388224	A/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs1775715	0.678	rs7096139	chr10:32217404	A/C	cg03015672	chr10:32216066	ARHGAP12	0.32	5.74	0.3	2.17e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg02403541	chr12:121454288	C12orf43	0.7	9.82	0.47	3.54e-20	N-glycan levels;
LUSC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.63	0.5	6.1e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs6773957	1.000	rs3774261	chr3:186571559	C/T	cg01963189	chr4:121613795	NA	0.33	6.14	0.32	2.3e-9	Adiponectin levels;
LUSC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg10547527	chr2:198650123	BOLL	-0.5	-5.79	-0.3	1.64e-8	Ulcerative colitis;
LUSC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg24531977	chr5:56204891	C5orf35	0.7	10.21	0.49	1.75e-21	Coronary artery disease;
LUSC	cis	rs7267979	0.528	rs34485039	chr20:25583763	G/T	cg03522245	chr20:25566470	NINL	-0.4	-6.09	-0.32	3.11e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg01416388	chr22:39784598	NA	-0.43	-6.67	-0.34	1.04e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs983392	0.678	rs4938933	chr11:60034429	C/T	cg24026212	chr11:59952134	MS4A6A	0.37	6.43	0.33	4.29e-10	Alzheimer's disease (late onset);
LUSC	trans	rs12524093	0.541	rs79673384	chr6:143040299	C/A	cg22454011	chr18:13611439	C18orf1	0.68	5.96	0.31	6.53e-9	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-1.15	-17.97	-0.7	5.57e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs3849570	1.000	rs3772882	chr3:81808602	C/A	cg07356753	chr3:81810745	GBE1	-0.57	-9.01	-0.44	1.59e-17	Waist circumference;Body mass index;
LUSC	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg16434002	chr17:42200994	HDAC5	0.46	6.75	0.35	6.63e-11	Total body bone mineral density;
LUSC	cis	rs9463078	0.605	rs17339124	chr6:44942577	C/G	cg25276700	chr6:44698697	NA	0.28	5.91	0.31	8.4e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs2392780	0.514	rs653605	chr8:128338847	G/T	cg10195415	chr17:73887371	TRIM65	0.41	6.64	0.34	1.3100000000000001e-10	Breast cancer (early onset);
LUSC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.39	0.37	1.21e-12	Schizophrenia;
LUSC	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07988820	chr12:82153109	PPFIA2	-0.42	-5.85	-0.3	1.18e-8	Resting heart rate;
LUSC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.23e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg10253484	chr15:75165896	SCAMP2	-0.51	-6.68	-0.34	1.03e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18876405	chr7:65276391	NA	0.54	8.47	0.42	8.18e-16	Aortic root size;
LUSC	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	8.52	0.42	5.74e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg14844989	chr11:31128820	NA	-0.37	-5.85	-0.3	1.18e-8	Red blood cell count;
LUSC	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg24375607	chr4:120327624	NA	0.75	11.04	0.52	2.35e-24	Corneal astigmatism;
LUSC	cis	rs4363385	0.642	rs58124215	chr1:152916375	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-6.95	-0.36	1.95e-11	Inflammatory skin disease;
LUSC	cis	rs10045504	0.502	rs57589709	chr5:38733853	C/T	cg15396434	chr5:38725168	NA	-0.52	-5.8	-0.3	1.5e-8	Night sleep phenotypes;
LUSC	trans	rs17039065	1.000	rs56717804	chr4:109394241	G/A	cg07444054	chr2:108107501	NA	0.43	6.3	0.33	9.24e-10	Gut microbiome composition (summer);
LUSC	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg17173187	chr15:85201210	NMB	0.37	5.89	0.31	9.64e-9	Schizophrenia;
LUSC	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg25801113	chr15:45476975	SHF	0.35	7.32	0.37	1.82e-12	Uric acid levels;
LUSC	cis	rs9359856	0.956	rs9362664	chr6:90307703	G/A	cg13799429	chr6:90582589	CASP8AP2	0.55	6.41	0.33	5.1e-10	Bipolar disorder;
LUSC	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg08917208	chr2:24149416	ATAD2B	0.55	6.26	0.32	1.17e-9	Lymphocyte counts;
LUSC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg05084668	chr3:125655381	ALG1L	-0.5	-7.12	-0.36	6.65e-12	Blood pressure (smoking interaction);
LUSC	cis	rs34779708	0.931	rs7923172	chr10:35309367	G/A	cg04310649	chr10:35416472	CREM	-0.4	-6.07	-0.32	3.45e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9648716	0.515	rs79007238	chr7:140651724	C/T	cg23214464	chr7:140373596	ADCK2	0.69	6.05	0.31	3.88e-9	Type 2 diabetes;
LUSC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-14.03	-0.61	1.77e-35	Hemoglobin concentration;
LUSC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg23788917	chr6:8435910	SLC35B3	0.52	7.77	0.39	9.8e-14	Motion sickness;
LUSC	cis	rs7923609	0.746	rs7070761	chr10:65317056	A/T	cg01631684	chr10:65280961	REEP3	0.41	6.05	0.31	3.84e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg24375607	chr4:120327624	NA	0.75	11.2	0.52	6.02e-25	Corneal astigmatism;
LUSC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg07404485	chr7:94953653	PON1	0.3	5.8	0.3	1.54e-8	Paraoxonase activity;
LUSC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.66	-0.39	2.1e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6977660	0.714	rs6976854	chr7:19818311	A/G	cg07541023	chr7:19748670	TWISTNB	0.6	6.51	0.34	2.7e-10	Thyroid stimulating hormone;
LUSC	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg13699009	chr12:122356056	WDR66	-0.4	-6.13	-0.32	2.46e-9	Mean corpuscular volume;
LUSC	cis	rs62408225	1.000	rs62408233	chr6:90976609	G/A	cg06866423	chr6:90926672	BACH2	0.42	5.96	0.31	6.26e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-0.83	-9.37	-0.46	1.12e-18	Diabetic kidney disease;
LUSC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.7	-10.7	-0.51	3.47e-23	Aortic root size;
LUSC	cis	rs4865169	0.934	rs12650737	chr4:57892475	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.37	-5.67	-0.3	3.1e-8	Breast cancer;
LUSC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.76	-0.47	5.72e-20	Gut microbiome composition (summer);
LUSC	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg02655711	chr22:19163373	SLC25A1	-0.6	-10.67	-0.5	4.73e-23	Metabolite levels;
LUSC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg02018176	chr4:1364513	KIAA1530	0.5	8.84	0.44	5.6e-17	Obesity-related traits;
LUSC	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg09307838	chr4:120376055	NA	0.5	7.48	0.38	6.54e-13	Diastolic blood pressure;
LUSC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06634786	chr22:41940651	POLR3H	-0.57	-6.44	-0.33	4.11e-10	Vitiligo;
LUSC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.44	6.0	0.31	5e-9	Renal function-related traits (BUN);
LUSC	trans	rs4711689	1.000	rs4711689	chr6:41692812	C/T	cg14182588	chr15:74754012	UBL7	-0.45	-6.13	-0.32	2.51e-9	Colorectal cancer;
LUSC	trans	rs931812	0.895	rs13251731	chr8:101902528	C/G	cg20993868	chr7:22813445	NA	0.63	11.34	0.53	1.98e-25	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg20129853	chr10:51489980	NA	0.36	7.45	0.38	7.84e-13	Prostate-specific antigen levels;
LUSC	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg27633287	chr12:130766243	NA	0.32	5.89	0.31	9.23e-9	Menopause (age at onset);
LUSC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg22535103	chr8:58192502	C8orf71	-0.75	-7.79	-0.39	8.27e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs984440	0.542	rs4909732	chr8:139079704	T/A	cg03334052	chr1:168888044	NA	0.41	6.45	0.33	3.95e-10	Obesity-related traits;
LUSC	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-1.01	-14.28	-0.62	1.98e-36	Exhaled nitric oxide output;
LUSC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg07424592	chr7:64974309	NA	0.64	5.87	0.31	1.07e-8	Diabetic kidney disease;
LUSC	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.27e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.6	-0.57	4.72e-30	Chronic sinus infection;
LUSC	cis	rs4253772	0.872	rs45552534	chr22:46638171	G/A	cg18190219	chr22:46762943	CELSR1	-0.48	-5.81	-0.3	1.45e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2262909	0.889	rs61268244	chr19:22310130	C/T	cg11619707	chr19:22235551	ZNF257	0.39	5.9	0.31	8.73e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.37	-6.42	-0.33	4.68e-10	Breast cancer;
LUSC	cis	rs7189233	1.000	rs62048520	chr16:53491095	C/A	cg09728985	chr16:53543985	NA	-0.33	-5.92	-0.31	8.05e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-8.84	-0.44	5.8e-17	Obesity-related traits;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.48	7.85	0.39	5.73e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06221963	chr1:154839813	KCNN3	-0.63	-14.77	-0.63	2.51e-38	Prostate cancer;
LUSC	cis	rs7264396	0.887	rs224370	chr20:34073379	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.34	-0.33	7.56e-10	Total cholesterol levels;
LUSC	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg15704280	chr7:45808275	SEPT13	0.63	8.45	0.42	9.4e-16	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg12524338	chr4:183729343	NA	0.68	8.62	0.43	2.81e-16	Pediatric autoimmune diseases;
LUSC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.46	6.75	0.35	6.52e-11	Eosinophil percentage of white cells;
LUSC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-11.85	-0.54	2.77e-27	Hemoglobin concentration;
LUSC	cis	rs4786125	0.706	rs8062094	chr16:6902585	A/G	cg03623568	chr16:6915990	A2BP1	-0.45	-7.83	-0.39	6.75e-14	Heart rate variability traits (SDNN);
LUSC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-1.05	-15.17	-0.64	6.42e-40	Vitiligo;
LUSC	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg05347473	chr6:146136440	FBXO30	0.5	8.45	0.42	9.18e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6484504	0.576	rs208067	chr11:31153578	C/T	cg06552810	chr11:31128660	NA	-0.41	-7.36	-0.37	1.44e-12	Red blood cell count;
LUSC	trans	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg25214090	chr10:38739885	LOC399744	0.49	7.53	0.38	4.82e-13	Corneal astigmatism;
LUSC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg00684032	chr4:1343700	KIAA1530	0.33	5.77	0.3	1.85e-8	Obesity-related traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26251069	chr18:657649	C18orf56;TYMS	-0.44	-6.32	-0.33	8.35e-10	Electrocardiographic conduction measures;
LUSC	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg00376283	chr12:123451042	ABCB9	0.68	7.82	0.39	7.13e-14	Allergy;
LUSC	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg15571903	chr15:79123663	NA	-0.32	-5.79	-0.3	1.64e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs76878669	0.561	rs7125752	chr11:66162419	C/T	cg18002602	chr11:66138449	SLC29A2	-0.47	-8.26	-0.41	3.54e-15	Educational attainment (years of education);
LUSC	trans	rs62238980	0.614	rs4820066	chr22:32409269	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.01	0.48	8.39e-21	Electroencephalogram traits;
LUSC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg13560548	chr3:10150139	C3orf24	0.49	6.89	0.35	2.82e-11	Alzheimer's disease;
LUSC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06634786	chr22:41940651	POLR3H	0.51	6.15	0.32	2.18e-9	Vitiligo;
LUSC	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg08601574	chr20:25228251	PYGB	0.55	8.83	0.43	6.23e-17	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.74	-0.35	6.85e-11	Crohn's disease;
LUSC	cis	rs7795096	0.743	rs9648726	chr7:151537433	C/T	cg17008978	chr7:151542804	PRKAG2	0.34	6.53	0.34	2.4e-10	Bipolar disorder (age of onset and psychotic symptoms);
LUSC	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg22906224	chr7:99728672	NA	0.46	6.4	0.33	5.29e-10	Coronary artery disease;
LUSC	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg08345082	chr10:99160200	RRP12	-0.35	-7.11	-0.36	7.29e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg00310523	chr12:86230176	RASSF9	0.37	6.67	0.34	1.08e-10	Major depressive disorder;
LUSC	cis	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs2262909	0.924	rs4290587	chr19:22164646	A/G	cg11619707	chr19:22235551	ZNF257	-0.39	-5.73	-0.3	2.28e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg06552810	chr11:31128660	NA	0.42	7.32	0.37	1.89e-12	Red blood cell count;
LUSC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg10018233	chr7:150070692	REPIN1	0.34	5.99	0.31	5.44e-9	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs1325195	0.920	rs2493124	chr1:179099021	T/C	cg11624085	chr17:8464688	MYH10	0.44	7.36	0.37	1.45e-12	IgE grass sensitization;
LUSC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.18	27.54	0.83	6.15e-88	Chronic sinus infection;
LUSC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	9.09	0.45	8.68e-18	Total body bone mineral density;
LUSC	trans	rs656319	0.625	rs34427895	chr8:9875221	G/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.2	-0.37	3.94e-12	Myopia (pathological);
LUSC	trans	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	7.56	0.38	3.82e-13	Menarche (age at onset);
LUSC	cis	rs6977660	0.660	rs10224938	chr7:19816227	A/G	cg07541023	chr7:19748670	TWISTNB	0.65	7.0	0.36	1.43e-11	Thyroid stimulating hormone;
LUSC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg04414720	chr1:150670196	GOLPH3L	0.55	9.02	0.44	1.56e-17	Tonsillectomy;
LUSC	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg25019033	chr10:957182	NA	-0.43	-5.7	-0.3	2.61e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs2070433	0.756	rs9637220	chr21:47887436	T/C	cg12379764	chr21:47803548	PCNT	0.7	9.35	0.46	1.27e-18	Lymphocyte counts;
LUSC	cis	rs7851660	0.809	rs7034249	chr9:100653821	C/T	cg13688889	chr9:100608707	NA	-0.53	-8.06	-0.4	1.36e-14	Strep throat;
LUSC	cis	rs6901250	0.655	rs1117046	chr6:117136978	G/C	cg12892004	chr6:117198278	RFX6	0.4	7.61	0.38	2.75e-13	C-reactive protein levels;
LUSC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg06784218	chr1:46089804	CCDC17	0.48	9.37	0.46	1.11e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2078087	0.568	rs609648	chr1:183234329	C/T	cg13843938	chr1:183241246	NMNAT2	-0.43	-6.99	-0.36	1.47e-11	Obesity-related traits;
LUSC	cis	rs4746818	0.901	rs10740317	chr10:70937566	G/A	cg11621586	chr10:70884670	VPS26A	1.13	10.72	0.51	3.08e-23	Left atrial antero-posterior diameter;
LUSC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg08470875	chr2:26401718	FAM59B	-0.64	-8.37	-0.42	1.55e-15	Gut microbiome composition (summer);
LUSC	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg20744362	chr22:50050164	C22orf34	0.38	7.85	0.39	5.69e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg11887960	chr12:57824829	NA	0.54	6.67	0.34	1.07e-10	Obesity-related traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09700855	chr17:78194207	SLC26A11;SGSH	-0.41	-6.52	-0.34	2.64e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg24687543	chr11:63912206	MACROD1	0.47	5.82	0.3	1.4e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.59e-25	Corneal astigmatism;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg05660315	chr16:30543920	ZNF747	-0.4	-6.07	-0.32	3.5e-9	N-glycan levels;
LUSC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg03060546	chr3:49711283	APEH	0.71	12.09	0.55	3.6e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.78	-12.93	-0.58	2.79e-31	Aortic root size;
LUSC	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg17294928	chr15:75287854	SCAMP5	-0.92	-13.07	-0.58	8.12e-32	Blood trace element (Zn levels);
LUSC	cis	rs6736093	0.966	rs4848899	chr2:112710111	G/A	cg12686935	chr2:112915763	FBLN7	-0.36	-5.81	-0.3	1.45e-8	Coronary artery disease;
LUSC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg11752832	chr7:134001865	SLC35B4	0.56	8.78	0.43	8.84e-17	Mean platelet volume;
LUSC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02034447	chr16:89574710	SPG7	0.43	6.44	0.33	4.16e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg19628046	chr18:33552617	C18orf21	0.51	6.13	0.32	2.48e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg14552801	chr7:65878734	NA	0.47	6.69	0.34	9.59e-11	Aortic root size;
LUSC	cis	rs12478296	0.748	rs10185596	chr2:243001029	C/A	cg06360820	chr2:242988706	NA	-0.75	-9.11	-0.45	7.66e-18	Obesity-related traits;
LUSC	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	8.0	0.4	2.02e-14	Retinal vascular caliber;
LUSC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.75	-0.35	6.52e-11	Lung cancer;
LUSC	cis	rs354225	0.544	rs28581481	chr2:54812372	T/G	cg01766943	chr2:54829624	SPTBN1	0.48	7.95	0.4	2.81e-14	Schizophrenia;
LUSC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg07741184	chr6:167504864	NA	-0.35	-6.39	-0.33	5.46e-10	Crohn's disease;
LUSC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg20891283	chr12:69753455	YEATS4	0.63	9.62	0.47	1.67e-19	Blood protein levels;
LUSC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-7.19	-0.37	4.24e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg05861140	chr6:150128134	PCMT1	0.39	6.09	0.32	3.09e-9	Lung cancer;
LUSC	trans	rs17189298	0.904	rs12998633	chr2:119841720	A/C	cg00109356	chr13:26625307	SHISA2	0.31	5.98	0.31	5.88e-9	Cerebrospinal T-tau levels;
LUSC	cis	rs9300255	0.664	rs28636834	chr12:123871070	A/C	cg00376283	chr12:123451042	ABCB9	-0.66	-7.58	-0.38	3.47e-13	Neutrophil percentage of white cells;
LUSC	cis	rs4363385	0.667	rs73014331	chr1:152964533	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.51	-0.38	5.59e-13	Inflammatory skin disease;
LUSC	cis	rs4654899	0.604	rs12031023	chr1:21148839	A/G	cg01072550	chr1:21505969	NA	0.47	6.99	0.36	1.47e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg13073564	chr4:8508604	NA	0.52	9.57	0.46	2.44e-19	Response to antineoplastic agents;
LUSC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs13089785	0.965	rs67028142	chr3:123635213	A/G	cg01860459	chr3:123419554	MYLK	0.35	5.94	0.31	7.31e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg06212747	chr3:49208901	KLHDC8B	0.46	6.31	0.33	8.62e-10	Parkinson's disease;
LUSC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg20908204	chr19:46285434	DMPK	0.41	8.19	0.41	5.76e-15	Coronary artery disease;
LUSC	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	1.17	18.26	0.71	3.72e-52	Corneal structure;
LUSC	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.84	12.36	0.56	3.88e-29	Cognitive ability;
LUSC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-5.83	-0.3	1.3e-8	Lung cancer;
LUSC	cis	rs4474465	0.688	rs4275650	chr11:78284822	T/A	cg27205649	chr11:78285834	NARS2	0.56	6.89	0.35	2.79e-11	Alzheimer's disease (survival time);
LUSC	cis	rs983392	0.868	rs7933202	chr11:59936926	A/C	cg24026212	chr11:59952134	MS4A6A	-0.34	-5.65	-0.3	3.36e-8	Alzheimer's disease (late onset);
LUSC	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.86	15.1	0.64	1.19e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg27165867	chr14:105738592	BRF1	-0.53	-7.67	-0.39	1.94e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg09655341	chr17:79618100	PDE6G	-0.29	-6.59	-0.34	1.67e-10	Eye color traits;
LUSC	cis	rs2742417	1.000	rs2742431	chr3:45737121	C/G	cg09608765	chr3:45636137	LIMD1	0.35	6.95	0.36	1.95e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04665974	chr16:30103391	TBX6	0.73	6.13	0.32	2.51e-9	Cognitive performance;
LUSC	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg04989706	chr14:50066350	PPIL5	-0.46	-5.97	-0.31	5.99e-9	Carotid intima media thickness;
LUSC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.84	-14.24	-0.61	2.68e-36	Height;
LUSC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.14	17.29	0.69	2.79e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9487051	0.735	rs419106	chr6:109520067	C/G	cg01475377	chr6:109611718	NA	-0.36	-6.23	-0.32	1.37e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg00383909	chr3:49044727	WDR6	-0.62	-7.61	-0.38	2.73e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs6500395	1.000	rs9936467	chr16:48677983	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.8	0.35	4.86e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg03522245	chr20:25566470	NINL	0.35	5.7	0.3	2.66e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg05234568	chr11:5960015	NA	-0.6	-8.66	-0.43	2.01e-16	DNA methylation (variation);
LUSC	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	1.05	17.93	0.7	8.17e-51	Testicular germ cell tumor;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26161045	chr2:55277080	RTN4	-0.54	-6.58	-0.34	1.86e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs742132	0.527	rs17252870	chr6:25494666	A/C	cg03517284	chr6:25882590	NA	-0.44	-6.18	-0.32	1.86e-9	Uric acid levels;
LUSC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg03948781	chr1:205179583	DSTYK	0.32	6.17	0.32	1.95e-9	Red blood cell count;
LUSC	cis	rs111547017	1	rs111547017	chr6:43341689	A/G	cg26312998	chr6:43337775	ZNF318	0.57	6.62	0.34	1.4e-10	Schizophrenia;
LUSC	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14442939	chr10:27389572	ANKRD26	0.53	6.07	0.32	3.4e-9	Breast cancer;
LUSC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-5.97	-0.31	6.02e-9	Schizophrenia;
LUSC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg00310523	chr12:86230176	RASSF9	-0.44	-8.28	-0.41	3.05e-15	Major depressive disorder;
LUSC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.54	-8.21	-0.41	4.94e-15	Gut microbiome composition (summer);
LUSC	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	11.72	0.54	8.14e-27	Coffee consumption (cups per day);
LUSC	cis	rs12928939	0.723	rs71403864	chr16:71695030	C/T	cg08717414	chr16:71523259	ZNF19	-0.41	-5.76	-0.3	1.87e-8	Post bronchodilator FEV1;
LUSC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14893161	chr1:205819251	PM20D1	0.54	8.94	0.44	2.67e-17	Menarche (age at onset);
LUSC	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.45	-6.73	-0.35	7.22e-11	Rheumatoid arthritis;
LUSC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.91	0.31	8.46e-9	Tonsillectomy;
LUSC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.58	-9.03	-0.44	1.37e-17	Menopause (age at onset);
LUSC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg22963979	chr7:1858916	MAD1L1	-0.73	-12.18	-0.55	1.69e-28	Bipolar disorder and schizophrenia;
LUSC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg21918786	chr6:109611834	NA	-0.38	-6.47	-0.33	3.45e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21724239	chr8:58056113	NA	0.8	9.0	0.44	1.69e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	1.15	13.83	0.6	1.01e-34	Arsenic metabolism;
LUSC	cis	rs55986470	0.646	rs79795396	chr2:239419181	T/C	cg18131467	chr2:239335373	ASB1	-0.78	-6.16	-0.32	2.14e-9	Chronotype;
LUSC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06481639	chr22:41940642	POLR3H	-0.5	-5.78	-0.3	1.73e-8	Vitiligo;
LUSC	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg20701182	chr2:24300061	SF3B14	0.71	7.14	0.36	5.77e-12	Lymphocyte counts;
LUSC	cis	rs11779988	0.545	rs208764	chr8:17806270	G/A	cg01800426	chr8:17659068	MTUS1	-0.47	-5.91	-0.31	8.27e-9	Breast cancer;
LUSC	cis	rs61931739	0.635	rs3937819	chr12:33942715	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.71	-0.34	8.31e-11	Morning vs. evening chronotype;
LUSC	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg08847533	chr14:75593920	NEK9	-0.81	-13.81	-0.6	1.21e-34	Height;
LUSC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg14829360	chr17:73884958	NA	-0.35	-5.89	-0.31	9.41e-9	White matter hyperintensity burden;
LUSC	cis	rs4888262	0.526	rs4404098	chr16:74570050	G/A	cg01733217	chr16:74700730	RFWD3	0.7	11.22	0.52	5.39e-25	Testicular germ cell tumor;
LUSC	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg05855489	chr10:104503620	C10orf26	-0.56	-8.75	-0.43	1.09e-16	Arsenic metabolism;
LUSC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg08847533	chr14:75593920	NEK9	0.83	14.38	0.62	7.83e-37	Height;
LUSC	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg05043794	chr9:111880884	C9orf5	-0.36	-7.94	-0.4	3.01e-14	Menarche (age at onset);
LUSC	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08645402	chr16:4508243	NA	0.49	7.83	0.39	6.43e-14	Schizophrenia;
LUSC	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg11502198	chr6:26597334	ABT1	0.59	9.08	0.44	9.97e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06022373	chr22:39101656	GTPBP1	0.75	11.75	0.54	6.67e-27	Menopause (age at onset);
LUSC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06022373	chr22:39101656	GTPBP1	0.77	12.39	0.56	2.9e-29	Menopause (age at onset);
LUSC	cis	rs4845459	0.967	rs4085613	chr1:152550018	T/G	cg08895932	chr1:152778580	LCE1C	-0.36	-6.1	-0.32	2.91e-9	Psoriasis;
LUSC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06112835	chr11:68658793	MRPL21	0.51	7.82	0.39	7.13e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12286929	0.839	rs12803174	chr11:115023159	T/C	cg04055981	chr11:115044050	NA	0.33	5.77	0.3	1.83e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs354225	0.584	rs9677089	chr2:54794927	A/C	cg01766943	chr2:54829624	SPTBN1	0.44	7.08	0.36	8.74e-12	Schizophrenia;
LUSC	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg05784532	chr1:230284198	GALNT2	-0.64	-8.77	-0.43	9.56e-17	Coronary artery disease;
LUSC	trans	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg11887960	chr12:57824829	NA	0.47	6.38	0.33	5.9e-10	Ulcerative colitis;
LUSC	trans	rs853679	0.567	rs3799499	chr6:28354250	G/T	cg01620082	chr3:125678407	NA	-0.44	-6.46	-0.33	3.68e-10	Depression;
LUSC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16386425	chr10:429943	DIP2C	-0.44	-7.03	-0.36	1.14e-11	Psychosis in Alzheimer's disease;
LUSC	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	6.6	0.34	1.57e-10	Resting heart rate;
LUSC	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.69	-11.0	-0.52	3.12e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg12963246	chr6:28129442	ZNF389	0.49	7.19	0.37	4.21e-12	Parkinson's disease;
LUSC	trans	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.72	0.35	7.86e-11	Morning vs. evening chronotype;
LUSC	cis	rs965513	1.000	rs10759927	chr9:100542176	A/G	cg13688889	chr9:100608707	NA	-0.57	-8.52	-0.42	5.73e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg18323236	chr1:24743029	NIPAL3	0.39	6.66	0.34	1.1e-10	Response to interferon beta in multiple sclerosis;
LUSC	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.7	-0.34	8.85e-11	Triglycerides;
LUSC	cis	rs11958404	0.860	rs72818116	chr5:157440616	G/T	cg05962755	chr5:157440814	NA	0.53	6.3	0.33	9.34e-10	IgG glycosylation;
LUSC	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg21640587	chr11:117668038	DSCAML1	0.7	10.53	0.5	1.42e-22	Myopia;
LUSC	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg18825076	chr15:78729989	IREB2	-0.45	-6.24	-0.32	1.3e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg05623727	chr3:50126028	RBM5	0.34	6.52	0.34	2.64e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg23711669	chr6:146136114	FBXO30	-0.89	-17.19	-0.69	7.03e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.33	-0.37	1.74e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg17691542	chr6:26056736	HIST1H1C	0.78	9.66	0.47	1.24e-19	Iron status biomarkers;
LUSC	cis	rs1018836	0.632	rs6995399	chr8:91481629	T/C	cg16814680	chr8:91681699	NA	-0.64	-9.65	-0.47	1.38e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7582720	1.000	rs72932554	chr2:203845828	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.35	0.42	1.88e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.45	-0.33	3.95e-10	Uric acid levels;
LUSC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg00990874	chr7:1149470	C7orf50	-0.5	-6.32	-0.33	8.61e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg05791153	chr7:19748676	TWISTNB	0.78	8.3	0.41	2.53e-15	Thyroid stimulating hormone;
LUSC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg14019146	chr3:50243930	SLC38A3	-0.36	-8.25	-0.41	3.68e-15	Body mass index;
LUSC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg16325326	chr1:53192061	ZYG11B	0.74	13.07	0.58	7.92e-32	Monocyte count;
LUSC	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-0.79	-14.15	-0.61	6.28e-36	Brugada syndrome;
LUSC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg12560992	chr17:57184187	TRIM37	0.9	17.84	0.7	1.78e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs9837602	0.882	rs9875664	chr3:99729130	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	6.14	0.32	2.35e-9	Breast cancer;
LUSC	trans	rs1941687	0.505	rs12605642	chr18:31313965	G/T	cg27147174	chr7:100797783	AP1S1	-0.56	-8.85	-0.44	5.33e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs11650494	0.908	rs78208413	chr17:47398282	G/A	cg08112188	chr17:47440006	ZNF652	1.26	10.98	0.52	3.67e-24	Prostate cancer;
LUSC	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg03929089	chr4:120376271	NA	-0.58	-7.52	-0.38	5.07e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg19187155	chr2:232395269	NMUR1	0.8	13.86	0.6	7.91e-35	Height;
LUSC	cis	rs1577917	0.920	rs1337842	chr6:86675097	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-6.18	-0.32	1.87e-9	Response to antipsychotic treatment;
LUSC	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-9.53	-0.46	3.37e-19	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg18225595	chr11:63971243	STIP1	0.5	6.2	0.32	1.63e-9	Mean platelet volume;
LUSC	cis	rs9653442	0.564	rs7565895	chr2:100774773	G/A	cg22139774	chr2:100720529	AFF3	-0.42	-7.23	-0.37	3.33e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg02018176	chr4:1364513	KIAA1530	0.53	9.24	0.45	2.99e-18	Obesity-related traits;
LUSC	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	9.0	0.44	1.76e-17	Lung cancer in ever smokers;
LUSC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg03790207	chr6:42947109	PEX6	-0.45	-6.87	-0.35	3.1e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg08867150	chr8:28259493	NA	0.81	6.67	0.34	1.03e-10	Cognitive performance;
LUSC	cis	rs11779988	0.545	rs208058	chr8:17820433	G/A	cg01800426	chr8:17659068	MTUS1	-0.48	-6.04	-0.31	4.03e-9	Breast cancer;
LUSC	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg23840854	chr1:161414152	NA	-0.91	-11.11	-0.52	1.34e-24	Rheumatoid arthritis;
LUSC	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.25	-0.32	1.23e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs75804782	0.691	rs55886641	chr2:239319185	T/C	cg18131467	chr2:239335373	ASB1	-0.74	-6.64	-0.34	1.28e-10	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07970400	chr15:40650285	DISP2	-0.51	-6.7	-0.34	8.64e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01591470	chr14:39736043	CTAGE5	-0.51	-6.54	-0.34	2.32e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg14895029	chr7:2775587	GNA12	-0.37	-5.88	-0.31	9.96e-9	Height;
LUSC	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg24642439	chr20:33292090	TP53INP2	-0.51	-7.63	-0.39	2.49e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.89	-0.44	3.82e-17	Metabolite levels;
LUSC	cis	rs3741151	0.686	rs7114376	chr11:73227361	T/C	cg17517138	chr11:73019481	ARHGEF17	0.8	7.43	0.38	9.37e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs71435601	0.628	rs574461	chr2:21400013	A/G	cg20757404	chr19:378427	NA	0.37	5.96	0.31	6.28e-9	Cholesterol, total;
LUSC	cis	rs760794	0.729	rs6921786	chr6:19794016	C/T	cg02404759	chr6:19790362	NA	0.38	6.15	0.32	2.25e-9	Endometriosis;
LUSC	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg23791538	chr6:167370224	RNASET2	0.5	8.44	0.42	1e-15	Crohn's disease;
LUSC	cis	rs3789045	0.560	rs1002779	chr1:204405098	T/A	cg17419461	chr1:204415978	PIK3C2B	-0.5	-5.67	-0.3	3.1e-8	Educational attainment (college completion);
LUSC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	0.92	18.27	0.71	3.46e-52	Gestational age at birth (maternal effect);
LUSC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg07703079	chr11:430292	ANO9	0.69	6.94	0.36	2e-11	Body mass index;
LUSC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg18240062	chr17:79603768	NPLOC4	-0.69	-12.86	-0.58	4.98e-31	Eye color traits;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10641809	chr6:34664703	C6orf106	0.4	6.21	0.32	1.58e-9	Asthma;
LUSC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg02018176	chr4:1364513	KIAA1530	0.52	8.86	0.44	5e-17	Obesity-related traits;
LUSC	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.57	-9.51	-0.46	3.99e-19	Breast cancer;
LUSC	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.89	-0.31	9.19e-9	Birth weight;
LUSC	cis	rs10463316	0.894	rs4099169	chr5:150766526	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.32	-0.37	1.9e-12	Metabolite levels (Pyroglutamine);
LUSC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.29e-12	Tonsillectomy;
LUSC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg04518342	chr5:131593106	PDLIM4	0.39	7.19	0.37	4.21e-12	Breast cancer;
LUSC	trans	rs7980799	0.649	rs2084391	chr12:33655419	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-6.01	-0.31	4.83e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg14092571	chr14:90743983	NA	-0.36	-5.9	-0.31	8.86e-9	Mortality in heart failure;
LUSC	cis	rs7119	0.717	rs12916642	chr15:77818426	G/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.61	-0.34	1.53e-10	Type 2 diabetes;
LUSC	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.7	10.6	0.5	8.3e-23	Corneal astigmatism;
LUSC	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg24110177	chr3:50126178	RBM5	0.4	6.46	0.33	3.73e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs62432291	0.764	rs436743	chr6:159655102	A/G	cg14500486	chr6:159655392	FNDC1	-0.52	-5.84	-0.3	1.22e-8	Joint mobility (Beighton score);
LUSC	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg03676636	chr4:99064102	C4orf37	-0.36	-7.93	-0.4	3.26e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24110177	chr3:50126178	RBM5	0.61	10.55	0.5	1.22e-22	Body mass index;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg15025769	chr15:72410003	MYO9A;SENP8	0.45	5.96	0.31	6.33e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg26876637	chr1:152193138	HRNR	-0.46	-6.7	-0.34	8.68e-11	Atopic dermatitis;
LUSC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg23985595	chr17:80112537	CCDC57	-0.34	-6.51	-0.34	2.8e-10	Life satisfaction;
LUSC	cis	rs4443100	0.670	rs9608071	chr22:23408118	G/T	cg21100191	chr22:23484243	RTDR1	0.52	6.49	0.33	3.02e-10	Serum parathyroid hormone levels;
LUSC	cis	rs2798269	1.000	rs11618032	chr13:22134891	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.13	-0.32	2.42e-9	PR segment;
LUSC	cis	rs240764	0.817	rs239204	chr6:101135580	T/C	cg09795085	chr6:101329169	ASCC3	0.42	6.17	0.32	2.01e-9	Neuroticism;
LUSC	cis	rs4654899	0.931	rs10799679	chr1:21341776	A/G	cg01072550	chr1:21505969	NA	-0.53	-8.1	-0.41	1.02e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg17143192	chr8:8559678	CLDN23	0.59	8.53	0.42	5.04e-16	Obesity-related traits;
LUSC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg13798780	chr7:105162888	PUS7	0.56	6.12	0.32	2.55e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4845570	0.764	rs12122917	chr1:151716712	C/A	cg07092448	chr1:151763213	TDRKH	-1.05	-10.9	-0.51	6.96e-24	Coronary artery disease;
LUSC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.67	8.58	0.43	3.55e-16	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs8114671	0.967	rs34515766	chr20:33785221	C/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.93	-0.31	7.41e-9	Height;
LUSC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg00522288	chr12:125625016	AACS	0.33	6.34	0.33	7.53e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00684032	chr4:1343700	KIAA1530	0.37	6.51	0.34	2.82e-10	Obesity-related traits;
LUSC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	8.09e-13	Motion sickness;
LUSC	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14240646	chr10:27532245	ACBD5	-0.74	-8.16	-0.41	6.91e-15	Breast cancer;
LUSC	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg05347473	chr6:146136440	FBXO30	0.48	8.2	0.41	5.16e-15	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2018683	0.835	rs7782264	chr7:28978986	A/G	cg19402173	chr7:128379420	CALU	0.52	8.12	0.41	9.25e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg04851639	chr8:1020857	NA	-0.38	-8.15	-0.41	7.25e-15	Schizophrenia;
LUSC	cis	rs1190552	0.846	rs1044503	chr14:102965996	A/G	cg18135206	chr14:102964638	TECPR2	0.48	5.89	0.31	9.54e-9	Blood protein levels;
LUSC	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23158103	chr7:148848205	ZNF398	-0.48	-8.04	-0.4	1.6e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg21770322	chr7:97807741	LMTK2	0.41	7.21	0.37	3.79e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21171335	chr12:122356390	WDR66	0.65	9.79	0.47	4.74e-20	Mean corpuscular volume;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg19235966	chr1:16173721	SPEN;FLJ37453	-0.5	-6.51	-0.34	2.68e-10	Cognitive function;Information processing speed;
LUSC	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg11984989	chr7:158649758	WDR60	1.08	22.15	0.77	1.57e-67	Height;
LUSC	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg17691542	chr6:26056736	HIST1H1C	0.4	5.92	0.31	8.02e-9	Schizophrenia;
LUSC	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-16.42	-0.67	8.09e-45	Primary sclerosing cholangitis;
LUSC	cis	rs6840360	1.000	rs2007445	chr4:152600370	C/T	cg22705602	chr4:152727874	NA	-0.27	-5.7	-0.3	2.6e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.54	-10.56	-0.5	1.11e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg25456477	chr12:86230367	RASSF9	-0.42	-7.44	-0.38	8.41e-13	Major depressive disorder;
LUSC	trans	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.96	19.57	0.73	2.38e-57	Colorectal cancer;
LUSC	cis	rs17253792	0.915	rs77252471	chr14:56178075	C/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.86	-0.35	3.35e-11	Putamen volume;
LUSC	cis	rs9314323	0.767	rs13271042	chr8:26190212	T/G	cg13160058	chr8:26243215	BNIP3L	-0.39	-6.77	-0.35	5.71e-11	Red cell distribution width;
LUSC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg14668632	chr7:2872130	GNA12	-0.44	-6.31	-0.33	8.79e-10	Height;
LUSC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg24399712	chr22:39784796	NA	-0.61	-10.26	-0.49	1.2e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg24375607	chr4:120327624	NA	0.75	11.26	0.52	3.74e-25	Corneal astigmatism;
LUSC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg26338869	chr17:61819248	STRADA	0.4	5.67	0.3	3.13e-8	Prudent dietary pattern;
LUSC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg12564285	chr5:131593104	PDLIM4	-0.54	-9.59	-0.46	2.1e-19	Acylcarnitine levels;
LUSC	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg15571903	chr15:79123663	NA	0.33	6.12	0.32	2.61e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg18196295	chr10:418757	DIP2C	0.37	5.92	0.31	7.86e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.12	-0.32	2.55e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6920965	0.602	rs10872302	chr6:126180631	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.42	-6.34	-0.33	7.41e-10	High light scatter reticulocyte count;
LUSC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg23788917	chr6:8435910	SLC35B3	0.51	7.48	0.38	6.83e-13	Motion sickness;
LUSC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs57994353	0.578	rs10448340	chr9:139320069	A/C	cg14019695	chr9:139328340	INPP5E	0.42	7.25	0.37	2.99e-12	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.56	-9.35	-0.46	1.35e-18	Lymphocyte counts;
LUSC	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg08017756	chr2:100939284	LONRF2	-0.46	-8.63	-0.43	2.59e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9311676	0.656	rs12497250	chr3:58399399	T/C	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	7.12	0.36	6.53e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26314531	chr2:26401878	FAM59B	-0.66	-9.12	-0.45	7.39e-18	Gut microbiome composition (summer);
LUSC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg13877915	chr19:58951672	ZNF132	0.47	7.47	0.38	7.19e-13	Uric acid clearance;
LUSC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17509989	chr5:176798049	RGS14	0.68	11.0	0.52	3.29e-24	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.46	0.75	6.72e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg13010199	chr12:38710504	ALG10B	0.7	11.96	0.55	1.08e-27	Heart rate;
LUSC	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg12002119	chr2:101014098	CHST10	0.35	5.97	0.31	6.02e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08219700	chr8:58056026	NA	0.65	7.94	0.4	3.02e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.74	0.39	1.19e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg27661571	chr11:113659931	NA	-0.61	-6.92	-0.35	2.35e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg24631222	chr15:78858424	CHRNA5	0.64	8.37	0.42	1.56e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg03806693	chr22:41940476	POLR3H	0.99	13.85	0.6	9.09e-35	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.38	0.42	1.49e-15	Coffee consumption (cups per day);
LUSC	trans	rs10221833	0.602	rs355878	chr2:165633029	T/C	cg26993132	chr16:89239499	CDH15	0.31	5.97	0.31	6.09e-9	Response to statin therapy;
LUSC	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg04989706	chr14:50066350	PPIL5	-0.47	-6.33	-0.33	7.78e-10	Carotid intima media thickness;
LUSC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.67e-12	Motion sickness;
LUSC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	0.83	16.62	0.67	1.21e-45	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg01657329	chr11:68192670	LRP5	0.44	6.57	0.34	1.9e-10	Total body bone mineral density;
LUSC	cis	rs9326248	0.530	rs7112513	chr11:117037361	A/G	cg26566898	chr11:117069891	TAGLN	0.43	5.69	0.3	2.72e-8	Blood protein levels;
LUSC	cis	rs2710642	0.886	rs10153716	chr2:63007059	A/G	cg17519650	chr2:63277830	OTX1	-0.47	-6.62	-0.34	1.41e-10	LDL cholesterol levels;LDL cholesterol;
LUSC	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.49	16.86	0.68	1.38e-46	Opioid sensitivity;
LUSC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg19812747	chr11:111475976	SIK2	-0.55	-7.96	-0.4	2.75e-14	Primary sclerosing cholangitis;
LUSC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg06784218	chr1:46089804	CCDC17	0.53	10.97	0.51	3.94e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.38	-6.0	-0.31	5.17e-9	Testicular germ cell tumor;
LUSC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg25039879	chr17:56429692	SUPT4H1	0.66	8.88	0.44	4.12e-17	Cognitive test performance;
LUSC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg26528668	chr16:1614120	IFT140	0.41	6.79	0.35	5.11e-11	Coronary artery disease;
LUSC	cis	rs977987	0.750	rs4888414	chr16:75447233	A/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.62	-0.34	1.4e-10	Dupuytren's disease;
LUSC	cis	rs12681287	0.640	rs7461413	chr8:87470978	C/G	cg27223183	chr8:87520930	FAM82B	-0.54	-7.45	-0.38	7.92e-13	Caudate activity during reward;
LUSC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg04013166	chr16:89971882	TCF25	0.59	5.87	0.31	1.04e-8	Skin colour saturation;
LUSC	cis	rs4812048	1.000	rs4812048	chr20:57587771	C/T	cg14073986	chr20:57617431	SLMO2	0.6	6.56	0.34	2.08e-10	Mean platelet volume;
LUSC	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg27284194	chr4:1044797	NA	0.63	9.21	0.45	3.82e-18	Recombination rate (females);
LUSC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg23625390	chr15:77176239	SCAPER	0.46	7.0	0.36	1.44e-11	Blood metabolite levels;
LUSC	trans	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.09	-0.32	3.15e-9	Mood instability;
LUSC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg04944784	chr2:26401820	FAM59B	0.74	10.59	0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg08888203	chr3:10149979	C3orf24	0.66	9.08	0.45	9.57e-18	Alzheimer's disease;
LUSC	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-39.3	-0.91	2.68e-127	Myeloid white cell count;
LUSC	trans	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.18	-0.37	4.68e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg04989706	chr14:50066350	PPIL5	-0.48	-6.36	-0.33	6.83e-10	Carotid intima media thickness;
LUSC	trans	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg01620082	chr3:125678407	NA	-0.83	-7.18	-0.37	4.64e-12	Depression;
LUSC	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg15309053	chr8:964076	NA	0.34	7.04	0.36	1.09e-11	Schizophrenia;
LUSC	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg20991723	chr1:152506922	NA	0.47	8.46	0.42	8.41e-16	Hair morphology;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.69	10.62	0.5	7.09e-23	Lymphocyte counts;
LUSC	cis	rs1577917	0.958	rs4707229	chr6:86546237	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.99	-0.44	1.88e-17	Response to antipsychotic treatment;
LUSC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.0	-0.36	1.44e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.44	0.33	4.2e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06634786	chr22:41940651	POLR3H	-0.5	-6.26	-0.32	1.17e-9	Vitiligo;
LUSC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg08219700	chr8:58056026	NA	0.46	6.04	0.31	4.12e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs62432291	0.681	rs3003174	chr6:159655326	T/C	cg14500486	chr6:159655392	FNDC1	-0.52	-5.84	-0.3	1.22e-8	Joint mobility (Beighton score);
LUSC	trans	rs3857536	0.813	rs1891599	chr6:66941699	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-5.99	-0.31	5.53e-9	Blood trace element (Cu levels);
LUSC	cis	rs2273669	0.667	rs12210444	chr6:109305743	T/C	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11940773	chr11:63606512	MARK2	0.41	6.05	0.31	3.82e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs73206853	0.563	rs73194043	chr12:111188782	G/A	cg12870014	chr12:110450643	ANKRD13A	0.66	6.91	0.35	2.49e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg18187862	chr3:45730750	SACM1L	0.57	7.2	0.37	4.05e-12	Primary sclerosing cholangitis;
LUSC	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg09904177	chr6:26538194	HMGN4	-0.54	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg09044154	chr16:88155775	NA	-0.56	-7.56	-0.38	3.96e-13	Menopause (age at onset);
LUSC	cis	rs11112613	0.653	rs2374533	chr12:106047891	A/G	cg03607813	chr12:105948248	NA	0.62	7.69	0.39	1.7e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-1.14	-17.9	-0.7	1.07e-50	Exhaled nitric oxide output;
LUSC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg18357645	chr12:58087776	OS9	-0.5	-6.66	-0.34	1.12e-10	Multiple sclerosis;
LUSC	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg05340658	chr4:99064831	C4orf37	0.65	8.88	0.44	4.04e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg01733217	chr16:74700730	RFWD3	0.79	13.26	0.59	1.56e-32	Testicular germ cell tumor;
LUSC	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg05738196	chr6:26577821	NA	0.79	14.93	0.63	5.67e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.71	-0.47	8.8e-20	Hemoglobin concentration;
LUSC	cis	rs7605827	0.836	rs2052436	chr2:15697518	T/C	cg19274914	chr2:15703543	NA	0.45	8.43	0.42	1.02e-15	Educational attainment (years of education);
LUSC	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg22709100	chr7:91322751	NA	0.39	5.74	0.3	2.13e-8	Breast cancer;
LUSC	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg08079166	chr15:68083412	MAP2K5	-0.44	-7.3	-0.37	2.08e-12	Restless legs syndrome;
LUSC	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.71	11.54	0.53	3.88e-26	Eye color traits;
LUSC	trans	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.69	-0.39	1.71e-13	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.78	-0.57	1.02e-30	Platelet count;
LUSC	cis	rs62400317	0.762	rs12208605	chr6:44963735	A/C	cg18551225	chr6:44695536	NA	0.44	6.94	0.36	1.99e-11	Total body bone mineral density;
LUSC	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg05340658	chr4:99064831	C4orf37	0.57	8.81	0.43	7.13e-17	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25654301	chr17:73511699	TSEN54;CASKIN2	0.4	6.63	0.34	1.36e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7168353	0.519	rs725458	chr15:93634933	A/G	cg12595281	chr15:93633172	RGMA	-0.31	-5.68	-0.3	2.92e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg23815491	chr16:72088622	HP	0.38	6.6	0.34	1.59e-10	Fibrinogen levels;
LUSC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg17264618	chr3:40429014	ENTPD3	0.36	7.48	0.38	6.7e-13	Renal cell carcinoma;
LUSC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02475777	chr4:1388615	CRIPAK	-0.58	-8.56	-0.42	4.23e-16	Obesity-related traits;
LUSC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg20295408	chr7:1910781	MAD1L1	-0.55	-8.09	-0.4	1.15e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.93	0.35	2.11e-11	Height;
LUSC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-7.56	-0.38	3.83e-13	Mood instability;
LUSC	cis	rs500891	0.574	rs3798887	chr6:84121713	C/G	cg08257003	chr6:84140564	ME1	0.35	8.49	0.42	6.79e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	10.68	0.5	4.34e-23	Lymphocyte counts;
LUSC	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg09307838	chr4:120376055	NA	0.76	11.04	0.52	2.31e-24	Corneal astigmatism;
LUSC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-0.8	-13.38	-0.59	5.7e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6543140	0.964	rs6734203	chr2:103080066	G/C	cg09003973	chr2:102972529	NA	0.54	6.87	0.35	3.16e-11	Blood protein levels;
LUSC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00166722	chr3:10149974	C3orf24	0.56	7.54	0.38	4.61e-13	Alzheimer's disease;
LUSC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg10729496	chr3:10149963	C3orf24	0.55	7.57	0.38	3.79e-13	Alzheimer's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23097686	chr12:98910128	TMPO;LOC100128191	0.38	5.97	0.31	6.21e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6961069	0.503	rs3211816	chr7:80277990	G/A	cg04458919	chr7:80252533	CD36	-0.4	-6.79	-0.35	5.28e-11	Platelet count;
LUSC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg05855489	chr10:104503620	C10orf26	-0.62	-8.31	-0.41	2.49e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01341218	chr17:43662625	NA	0.77	11.23	0.52	5.03e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs12210905	0.841	rs28410967	chr6:27265235	T/C	cg11837749	chr1:55047332	ACOT11	0.66	6.3	0.33	9.13e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	9.12	0.45	7.04e-18	Bipolar disorder;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg04858616	chr1:40255010	BMP8B	0.42	5.96	0.31	6.37e-9	Mosquito bite size;
LUSC	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg03599575	chr15:90893182	GABARAPL3	0.33	5.81	0.3	1.47e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg20891558	chr2:74357851	NA	0.78	13.07	0.58	8.17e-32	Gestational age at birth (maternal effect);
LUSC	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg06223162	chr1:101003688	GPR88	-0.49	-9.35	-0.46	1.34e-18	Monocyte count;
LUSC	cis	rs4493873	0.731	rs34250051	chr8:92047462	G/A	cg16814680	chr8:91681699	NA	0.41	5.67	0.3	3.08e-8	Migraine - clinic-based;
LUSC	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg02023728	chr11:77925099	USP35	0.47	7.09	0.36	7.86e-12	Testicular germ cell tumor;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg15450734	chr14:103541957	NA	0.43	6.25	0.32	1.26e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg24851651	chr11:66362959	CCS	0.55	8.0	0.4	2.14e-14	Airway imaging phenotypes;
LUSC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg05896524	chr21:47604654	C21orf56	0.4	5.86	0.31	1.09e-8	Testicular germ cell tumor;
LUSC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg26441486	chr22:50317300	CRELD2	0.48	7.24	0.37	3.09e-12	Schizophrenia;
LUSC	cis	rs11997175	0.653	rs7817167	chr8:33633088	A/C	ch.8.33884649F	chr8:33765107	NA	0.48	7.78	0.39	9.25e-14	Body mass index;
LUSC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg27094323	chr7:1216898	NA	-0.36	-6.27	-0.32	1.09e-9	Longevity;Endometriosis;
LUSC	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.57	0.34	1.9e-10	Corneal astigmatism;
LUSC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg18225595	chr11:63971243	STIP1	0.63	10.94	0.51	4.98e-24	Platelet count;
LUSC	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14240646	chr10:27532245	ACBD5	0.71	8.21	0.41	4.81e-15	Breast cancer;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg01441114	chr19:12900873	JUNB	0.34	6.04	0.31	4.03e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs4680	0.737	rs2239393	chr22:19950428	A/G	cg06346307	chr22:19949965	COMT	-0.34	-7.03	-0.36	1.18e-11	Blood metabolite levels;
LUSC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg05084668	chr3:125655381	ALG1L	-0.5	-7.06	-0.36	1e-11	Blood pressure (smoking interaction);
LUSC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg21644426	chr2:191273491	MFSD6	0.63	9.79	0.47	4.47e-20	Pulse pressure;
LUSC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg12560992	chr17:57184187	TRIM37	-0.86	-16.48	-0.67	4.69e-45	Intelligence (multi-trait analysis);
LUSC	trans	rs7939886	0.920	rs11227372	chr11:55919682	C/A	cg15704280	chr7:45808275	SEPT13	0.83	6.68	0.34	9.95e-11	Myopia (pathological);
LUSC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg22601191	chr20:60968625	CABLES2	0.55	9.59	0.46	2.16e-19	Colorectal cancer;
LUSC	cis	rs12464559	0.522	rs13016166	chr2:152624144	G/A	cg01189475	chr2:152685088	ARL5A	0.67	7.42	0.38	9.53e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg01966878	chr4:90757139	SNCA	-0.35	-6.12	-0.32	2.56e-9	Dementia with Lewy bodies;
LUSC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg20848291	chr7:100343083	ZAN	-0.51	-6.25	-0.32	1.26e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg15445000	chr17:37608096	MED1	0.4	6.77	0.35	5.76e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14159672	chr1:205819179	PM20D1	0.73	12.1	0.55	3.42e-28	Menarche (age at onset);
LUSC	cis	rs7833986	1.000	rs34608229	chr8:57097017	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.63	9.35	0.46	1.28e-18	Height;
LUSC	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg23625390	chr15:77176239	SCAPER	0.48	7.44	0.38	8.73e-13	Blood metabolite levels;
LUSC	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg11901034	chr3:128598214	ACAD9	-0.41	-6.55	-0.34	2.19e-10	IgG glycosylation;
LUSC	cis	rs2247341	0.577	rs2236996	chr4:1703646	A/G	cg05874882	chr4:1763078	NA	-0.32	-5.99	-0.31	5.53e-9	Hip circumference adjusted for BMI;Height;
LUSC	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg23173402	chr1:227635558	NA	0.54	6.34	0.33	7.55e-10	Major depressive disorder;
LUSC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg14949292	chr17:78079608	GAA	-0.31	-5.89	-0.31	9.53e-9	Yeast infection;
LUSC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg02117656	chr17:79614917	TSPAN10	0.3	5.67	0.3	3.17e-8	Eye color traits;
LUSC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg10729496	chr3:10149963	C3orf24	0.52	6.88	0.35	2.9100000000000002e-11	Alzheimer's disease;
LUSC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.49	0.46	4.39e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg09479241	chr17:27052676	TLCD1	0.43	5.93	0.31	7.57e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg18932078	chr1:2524107	MMEL1	0.32	7.12	0.36	6.57e-12	Ulcerative colitis;
LUSC	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg08523384	chr5:141488047	NDFIP1	-0.48	-6.88	-0.35	3.03e-11	Crohn's disease;
LUSC	cis	rs12681287	0.640	rs13282351	chr8:87484669	C/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.36	6.24e-12	Caudate activity during reward;
LUSC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg05313129	chr8:58192883	C8orf71	-0.51	-6.61	-0.34	1.52e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7553864	0.667	rs10873820	chr1:87605973	C/G	cg17420885	chr1:87600446	LOC339524	0.46	6.44	0.33	4.16e-10	Smoking behavior;
LUSC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg18904891	chr8:8559673	CLDN23	-0.62	-8.58	-0.43	3.55e-16	Obesity-related traits;
LUSC	cis	rs10788972	0.903	rs7537946	chr1:54538700	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.27	-6.03	-0.31	4.39e-9	Parkinson disease and lewy body pathology;
LUSC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg23711669	chr6:146136114	FBXO30	0.76	13.72	0.6	2.76e-34	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07981364	chr11:47448113	PSMC3	-0.46	-6.77	-0.35	5.69e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.41	0.33	4.97e-10	Menopause (age at onset);
LUSC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg12292205	chr6:26970375	C6orf41	-0.7	-12.22	-0.56	1.23e-28	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.83	-0.54	3.32e-27	Chronic sinus infection;
LUSC	cis	rs6084875	0.840	rs1999664	chr20:4721148	C/T	cg07258627	chr20:4721683	PRNT	-0.35	-6.21	-0.32	1.6e-9	Systemic lupus erythematosus;
LUSC	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	5.97	0.31	6.22e-9	Schizophrenia;
LUSC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	7.04	0.36	1.07e-11	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.49e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-7.68	-0.39	1.81e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg21775007	chr8:11205619	TDH	-0.4	-5.94	-0.31	7.09e-9	Triglycerides;
LUSC	cis	rs17604090	0.938	rs10276157	chr7:29665016	A/G	cg19413766	chr7:29689036	LOC646762	-0.58	-6.65	-0.34	1.17e-10	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg08200582	chr11:442649	ANO9	-0.52	-5.95	-0.31	6.84e-9	Body mass index;
LUSC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg03785755	chr6:26196794	NA	0.54	5.7	0.3	2.62e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg17420585	chr12:42539391	GXYLT1	0.35	6.57	0.34	1.88e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2625529	0.667	rs16956381	chr15:72193237	A/C	cg16672083	chr15:72433130	SENP8	-0.51	-7.4	-0.38	1.13e-12	Red blood cell count;
LUSC	cis	rs722599	0.651	rs12887044	chr14:75255659	C/T	cg08847533	chr14:75593920	NEK9	0.43	6.02	0.31	4.55e-9	IgG glycosylation;
LUSC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	12.72	0.57	1.68e-30	Cognitive test performance;
LUSC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg26380479	chr7:97908229	NA	-0.27	-6.08	-0.32	3.21e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08219700	chr8:58056026	NA	0.56	7.5	0.38	6e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg05110241	chr16:68378359	PRMT7	-0.49	-6.31	-0.33	9.09e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.4	-0.42	1.29e-15	Lung cancer;
LUSC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg23711669	chr6:146136114	FBXO30	-0.9	-17.4	-0.69	9.72e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg25173405	chr17:45401733	C17orf57	-0.4	-5.84	-0.3	1.24e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4601821	1.000	rs6589375	chr11:113255111	C/A	cg14159747	chr11:113255604	NA	0.25	6.01	0.31	4.95e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-9.63	-0.47	1.51e-19	Mood instability;
LUSC	cis	rs611744	0.870	rs650925	chr8:109196725	T/C	cg18478394	chr8:109455254	TTC35	0.4	5.95	0.31	6.61e-9	Dupuytren's disease;
LUSC	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg26384229	chr12:38710491	ALG10B	0.56	7.83	0.39	6.44e-14	Morning vs. evening chronotype;
LUSC	cis	rs6426558	0.537	rs2492630	chr1:227286931	A/G	cg10327440	chr1:227177885	CDC42BPA	0.54	7.34	0.37	1.62e-12	Neutrophil percentage of white cells;
LUSC	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg01119278	chr6:110721349	DDO	-0.48	-8.71	-0.43	1.45e-16	Platelet distribution width;
LUSC	cis	rs10779751	1.000	rs11121711	chr1:11317661	A/T	cg08854313	chr1:11322531	MTOR	0.89	15.01	0.63	2.78e-39	Body mass index;
LUSC	trans	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.38e-9	Bladder cancer;
LUSC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg16362232	chr11:430036	ANO9	0.62	7.91	0.4	3.86e-14	Body mass index;
LUSC	cis	rs4654899	0.931	rs7520481	chr1:21140385	T/G	cg01072550	chr1:21505969	NA	0.49	7.38	0.37	1.3e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg27489772	chr12:121021490	NA	0.58	7.78	0.39	9.08e-14	Type 1 diabetes nephropathy;
LUSC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.69	-8.59	-0.43	3.31e-16	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs12541635	0.653	rs7014265	chr8:107026412	G/A	cg10147462	chr8:107024639	NA	0.66	13.63	0.6	6.35e-34	Age of smoking initiation;
LUSC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg08200582	chr11:442649	ANO9	-0.52	-5.67	-0.3	3.03e-8	Body mass index;
LUSC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg13395646	chr4:1353034	KIAA1530	0.54	7.65	0.39	2.21e-13	Longevity;
LUSC	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg22709100	chr7:91322751	NA	0.41	5.91	0.31	8.64e-9	Breast cancer;
LUSC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.58	-10.33	-0.49	6.63e-22	Extrinsic epigenetic age acceleration;
LUSC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg26441486	chr22:50317300	CRELD2	0.52	7.98	0.4	2.42e-14	Schizophrenia;
LUSC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08859206	chr1:53392774	SCP2	-0.55	-9.61	-0.47	1.81e-19	Monocyte count;
LUSC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.89	15.49	0.65	3.73e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06634786	chr22:41940651	POLR3H	0.49	6.17	0.32	1.99e-9	Vitiligo;
LUSC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.54	0.34	2.29e-10	Lung cancer;
LUSC	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.07	0.48	5.33e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.36e-13	Type 2 diabetes;
LUSC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg07507251	chr3:52567010	NT5DC2	0.36	6.55	0.34	2.21e-10	Bipolar disorder;
LUSC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg16586182	chr3:47516702	SCAP	-0.5	-7.88	-0.4	4.76e-14	Colorectal cancer;
LUSC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg12463550	chr7:65579703	CRCP	-0.63	-5.68	-0.3	2.92e-8	Diabetic kidney disease;
LUSC	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg12179176	chr11:130786555	SNX19	0.6	9.01	0.44	1.63e-17	Schizophrenia;
LUSC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00149659	chr3:10157352	C3orf10	0.91	12.92	0.58	3.1e-31	Alzheimer's disease;
LUSC	trans	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.85	0.39	5.9e-14	Morning vs. evening chronotype;
LUSC	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg11473876	chr11:109292803	C11orf87	0.42	6.96	0.36	1.8e-11	Schizophrenia;
LUSC	cis	rs7771547	0.519	rs12663882	chr6:36362441	G/T	cg07856975	chr6:36356162	ETV7	-0.44	-6.79	-0.35	5.22e-11	Platelet distribution width;
LUSC	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg06627628	chr2:24431161	ITSN2	0.52	7.34	0.37	1.66e-12	Asthma;
LUSC	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg26354017	chr1:205819088	PM20D1	-0.41	-5.96	-0.31	6.43e-9	Menarche (age at onset);
LUSC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.38	-0.37	1.24e-12	Electroencephalogram traits;
LUSC	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg26647111	chr11:31128758	NA	-0.41	-5.95	-0.31	6.95e-9	Red blood cell count;
LUSC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg14552801	chr7:65878734	NA	0.44	6.21	0.32	1.53e-9	Aortic root size;
LUSC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.66	11.79	0.54	4.63e-27	Height;
LUSC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg11812906	chr14:75593930	NEK9	0.65	10.7	0.51	3.58e-23	Height;
LUSC	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.48	-0.33	3.29e-10	Total cholesterol levels;
LUSC	trans	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.68	0.39	1.77e-13	Ulcerative colitis;
LUSC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg04733989	chr22:42467013	NAGA	-0.64	-9.85	-0.47	2.88e-20	Schizophrenia;
LUSC	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.21	-0.37	3.84e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9860340	0.730	rs4858965	chr3:87640363	C/T	cg03644585	chr7:884825	UNC84A	0.42	6.03	0.31	4.35e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.31	-5.82	-0.3	1.36e-8	IgG glycosylation;
LUSC	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	trans	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg16405210	chr4:1374714	KIAA1530	-0.86	-14.13	-0.61	7.37e-36	Longevity;
LUSC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs7241530	0.560	rs8094722	chr18:75904415	C/A	cg14642773	chr18:75888474	NA	0.39	6.02	0.31	4.59e-9	Educational attainment (years of education);
LUSC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg02487422	chr3:49467188	NICN1	0.48	7.59	0.38	3.32e-13	Resting heart rate;
LUSC	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg09462578	chr12:12878428	APOLD1	-0.53	-6.49	-0.33	3.01e-10	Systemic lupus erythematosus;
LUSC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	1.02	17.66	0.69	9.6e-50	Parkinson's disease;
LUSC	trans	rs3824660	0.591	rs3781094	chr10:8101427	G/T	cg15569512	chr14:104029667	BAG5;C14orf153	0.51	6.47	0.33	3.59e-10	Rheumatoid arthritis;
LUSC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.69	-0.3	2.78e-8	Depression;
LUSC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08109568	chr15:31115862	NA	-0.58	-8.19	-0.41	5.47e-15	Huntington's disease progression;
LUSC	cis	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.42	-6.04	-0.31	4.05e-9	Resting heart rate;
LUSC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg24562669	chr7:97807699	LMTK2	0.34	6.06	0.31	3.74e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03517284	chr6:25882590	NA	0.42	7.54	0.38	4.49e-13	Blood metabolite levels;
LUSC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg15448220	chr1:150897856	SETDB1	0.41	5.96	0.31	6.29e-9	Melanoma;
LUSC	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg05340658	chr4:99064831	C4orf37	0.44	6.92	0.35	2.25e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9650315	0.866	rs4623388	chr8:57190484	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.88	0.35	3.01e-11	Height;
LUSC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg11941060	chr3:133502564	NA	-0.52	-8.07	-0.4	1.25e-14	Iron status biomarkers;
LUSC	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.63	-0.34	1.35e-10	Reticulocyte count;
LUSC	cis	rs11208691	0.513	rs1938484	chr1:66081282	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.35	0.33	7.09e-10	Lymphocyte percentage of white cells;
LUSC	cis	rs559928	0.947	rs10792430	chr11:64147114	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.64	6.58	0.34	1.83e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	trans	rs9380880	0.826	rs12175102	chr6:39554898	C/T	cg12580580	chr10:74544059	CCDC109A	-0.53	-6.24	-0.32	1.3e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg23625390	chr15:77176239	SCAPER	0.46	7.01	0.36	1.31e-11	Blood metabolite levels;
LUSC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg09035930	chr12:129282057	SLC15A4	0.64	12.74	0.57	1.37e-30	Systemic lupus erythematosus;
LUSC	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.68	-11.29	-0.53	2.93e-25	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7572644	0.739	rs6547815	chr2:28155195	T/A	cg27432699	chr2:27873401	GPN1	-0.52	-6.81	-0.35	4.48e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs295140	1.000	rs4516413	chr2:201163920	T/C	cg04283868	chr2:201171347	SPATS2L	0.43	6.52	0.34	2.67e-10	QT interval;
LUSC	trans	rs3857536	0.813	rs6455084	chr6:66935658	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19622078	chr1:28157351	PPP1R8	-0.4	-6.07	-0.32	3.4e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg16230307	chr14:35515116	FAM177A1	0.79	10.01	0.48	8.4e-21	Psoriasis;
LUSC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-9.24	-0.45	2.91e-18	Longevity;
LUSC	cis	rs8030485	0.716	rs12899109	chr15:79410970	T/C	cg17916960	chr15:79447300	NA	0.34	6.13	0.32	2.51e-9	Left ventricle wall thickness;
LUSC	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.8	-15.11	-0.64	1.12e-39	Endometriosis;
LUSC	cis	rs17604090	0.793	rs73687726	chr7:29688773	T/C	cg19413766	chr7:29689036	LOC646762	-0.56	-7.01	-0.36	1.36e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs17433780	0.836	rs17434342	chr1:89505742	C/G	cg09516651	chr1:89888402	LOC400759	-0.55	-10.52	-0.5	1.53e-22	Carotid intima media thickness;
LUSC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg16362232	chr11:430036	ANO9	0.67	8.57	0.42	3.91e-16	Body mass index;
LUSC	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.77	12.74	0.57	1.43e-30	Metabolic syndrome;
LUSC	cis	rs3087591	1.000	rs1800845	chr17:29703438	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.59	-8.33	-0.41	2.05e-15	Hip circumference;
LUSC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	ch.11.42038R	chr11:967971	AP2A2	0.54	8.09	0.4	1.1e-14	Alzheimer's disease (late onset);
LUSC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg09754948	chr16:28834200	ATXN2L	0.41	6.12	0.32	2.63e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs67981189	0.634	rs221900	chr14:71604354	C/T	cg07012739	chr14:71606506	NA	0.33	5.84	0.3	1.24e-8	Schizophrenia;
LUSC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.43	-7.7	-0.39	1.51e-13	Longevity;Endometriosis;
LUSC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg01879757	chr17:41196368	BRCA1	-0.48	-7.44	-0.38	8.51e-13	Menopause (age at onset);
LUSC	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg19812747	chr11:111475976	SIK2	-0.47	-6.35	-0.33	7.16e-10	Primary sclerosing cholangitis;
LUSC	cis	rs68170813	0.559	rs75672288	chr7:107031549	G/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.27	-0.45	2.34e-18	Coronary artery disease;
LUSC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg12560992	chr17:57184187	TRIM37	-0.85	-15.3	-0.64	2.01e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg16586182	chr3:47516702	SCAP	-0.52	-8.11	-0.41	1e-14	Colorectal cancer;
LUSC	cis	rs2637266	1.000	rs7475686	chr10:78358761	T/C	cg18941641	chr10:78392320	NA	0.38	7.01	0.36	1.35e-11	Pulmonary function;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26546685	chr4:100870642	LOC256880;H2AFZ	-0.4	-6.04	-0.31	4.04e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg18512352	chr11:47633146	NA	-0.46	-9.02	-0.44	1.51e-17	Subjective well-being;
LUSC	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg02153584	chr22:29168773	CCDC117	0.67	10.12	0.48	3.44e-21	Lymphocyte counts;
LUSC	cis	rs7799006	0.527	rs6967286	chr7:2212758	C/A	cg21782813	chr7:2030301	MAD1L1	0.38	6.31	0.33	8.87e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7589342	0.566	rs11890447	chr2:106389691	T/C	cg14210321	chr2:106509881	NCK2	-0.41	-5.89	-0.31	9.28e-9	Addiction;
LUSC	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg04374321	chr14:90722782	PSMC1	0.7	11.18	0.52	7.29e-25	Mortality in heart failure;
LUSC	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg16797656	chr11:68205561	LRP5	0.34	5.85	0.31	1.14e-8	Bone mineral density (spine);
LUSC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg23719950	chr11:63933701	MACROD1	-0.62	-8.07	-0.4	1.26e-14	Mean platelet volume;
LUSC	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.52	7.5	0.38	5.9e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg16362232	chr11:430036	ANO9	0.61	7.98	0.4	2.43e-14	Body mass index;
LUSC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg09877947	chr5:131593287	PDLIM4	0.47	7.33	0.37	1.72e-12	Breast cancer;
LUSC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg17971929	chr21:40555470	PSMG1	-0.65	-10.62	-0.5	6.76e-23	Cognitive function;
LUSC	trans	rs4942242	0.663	rs1390371	chr13:44211727	A/G	cg19169023	chr15:41853346	TYRO3	0.57	8.65	0.43	2.16e-16	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.77	17.79	0.7	2.91e-50	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2637266	0.935	rs2583053	chr10:78402416	A/G	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.94e-13	Pulmonary function;
LUSC	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg15997130	chr1:24165203	NA	0.37	5.7	0.3	2.58e-8	Immature fraction of reticulocytes;
LUSC	cis	rs7808935	1.000	rs7808935	chr7:27977363	T/C	cg22168087	chr7:27702803	HIBADH	0.52	6.54	0.34	2.29e-10	Prostate cancer;
LUSC	cis	rs3126085	0.935	rs991231	chr1:152211898	T/G	cg26876637	chr1:152193138	HRNR	-0.46	-6.37	-0.33	6.38e-10	Atopic dermatitis;
LUSC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08280861	chr8:58055591	NA	0.56	5.98	0.31	5.87e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	13.42	0.59	3.8e-33	Primary sclerosing cholangitis;
LUSC	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg10523679	chr1:76189770	ACADM	-0.46	-6.67	-0.34	1.09e-10	Daytime sleep phenotypes;
LUSC	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.52e-8	Breast cancer;
LUSC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.52	7.16	0.36	5.17e-12	Tuberculosis;
LUSC	trans	rs67539049	1.000	rs67932868	chr8:11303445	G/A	cg26241650	chr22:40417538	FAM83F	0.43	5.99	0.31	5.54e-9	Itch intensity from mosquito bite;
LUSC	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg16482183	chr6:26056742	HIST1H1C	0.61	8.25	0.41	3.75e-15	Height;
LUSC	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg24631222	chr15:78858424	CHRNA5	0.83	11.47	0.53	6.47e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg26335602	chr6:28129616	ZNF389	0.49	6.69	0.34	9.67e-11	Parkinson's disease;
LUSC	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg19773385	chr1:10388646	KIF1B	-0.53	-8.33	-0.41	2.07e-15	Hepatocellular carcinoma;
LUSC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.93	0.44	2.82e-17	Motion sickness;
LUSC	cis	rs6692729	0.901	rs1295638	chr1:227069267	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.51	-7.32	-0.37	1.91e-12	Electrodermal activity;
LUSC	cis	rs2282300	0.739	rs34234618	chr11:30241701	T/C	cg25418670	chr11:30344373	C11orf46	-0.66	-9.53	-0.46	3.4e-19	Morning vs. evening chronotype;
LUSC	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg27068330	chr11:65405492	SIPA1	0.61	9.26	0.45	2.6e-18	Acne (severe);
LUSC	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.55	-9.37	-0.46	1.11e-18	Menopause (age at onset);
LUSC	trans	rs11935423	0.778	rs1800591	chr4:100495488	G/T	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.1	-0.32	3e-9	Gut microbiome composition (summer);
LUSC	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg01557791	chr16:72042693	DHODH	0.57	9.13	0.45	6.88e-18	Prostate cancer;
LUSC	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg16339924	chr4:17578868	LAP3	0.49	7.54	0.38	4.54e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08677398	chr8:58056175	NA	0.54	7.01	0.36	1.34e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9815354	0.812	rs73077358	chr3:41850005	C/T	cg03022575	chr3:42003672	ULK4	0.86	8.66	0.43	2.07e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg06609049	chr19:2785107	THOP1	1.12	22.02	0.77	4.98e-67	Total cholesterol levels;
LUSC	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg03585969	chr10:35415529	CREM	0.6	8.73	0.43	1.23e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.03e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg08017756	chr2:100939284	LONRF2	-0.45	-8.46	-0.42	8.2e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg24690094	chr11:67383802	NA	0.43	8.47	0.42	7.8e-16	Mean corpuscular volume;
LUSC	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg24375607	chr4:120327624	NA	0.79	11.63	0.54	1.73e-26	Corneal astigmatism;
LUSC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg06494592	chr3:125709126	NA	-0.52	-6.01	-0.31	4.85e-9	Blood pressure (smoking interaction);
LUSC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.22	0.37	3.45e-12	Motion sickness;
LUSC	cis	rs2835872	0.965	rs73222309	chr21:39013686	C/T	cg20424643	chr21:39039972	KCNJ6	0.42	6.42	0.33	4.57e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.05	-0.36	1.02e-11	Colorectal cancer;
LUSC	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg06627628	chr2:24431161	ITSN2	-0.87	-13.07	-0.58	7.95e-32	Asthma;
LUSC	trans	rs7395662	0.864	rs10839201	chr11:48989417	A/G	cg03929089	chr4:120376271	NA	0.43	5.95	0.31	6.85e-9	HDL cholesterol;
LUSC	cis	rs7582720	1.000	rs115396314	chr2:203721314	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	8.17	0.41	6.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.22	16.64	0.67	1.02e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg21545522	chr1:205238299	TMCC2	0.46	8.63	0.43	2.61e-16	Red blood cell count;
LUSC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg18240062	chr17:79603768	NPLOC4	0.58	10.12	0.48	3.47e-21	Eye color traits;
LUSC	cis	rs6539267	1.000	rs6539267	chr12:106785554	T/C	cg00173435	chr12:106696525	TCP11L2	0.41	6.04	0.31	4.04e-9	Tourette syndrome;
LUSC	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg12002119	chr2:101014098	CHST10	0.35	5.66	0.3	3.26e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs62458065	0.513	rs7788809	chr7:32552622	T/A	cg00845942	chr12:64062724	DPY19L2	-0.59	-7.41	-0.38	1.02e-12	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7615316	0.934	rs9855919	chr3:142234589	C/A	cg16271453	chr3:142027066	XRN1	-0.4	-6.88	-0.35	3.04e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs1532331	0.833	rs10058350	chr5:43141644	T/C	cg02477305	chr13:23993013	SACS	0.37	6.2	0.32	1.66e-9	Menarche (age at onset);
LUSC	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-13.7	-0.6	3.26e-34	Lymphocyte percentage of white cells;
LUSC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00149659	chr3:10157352	C3orf10	1.0	14.8	0.63	1.89e-38	Alzheimer's disease;
LUSC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg22638593	chr5:131593259	PDLIM4	-0.41	-5.84	-0.3	1.25e-8	Blood metabolite levels;
LUSC	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg18806716	chr10:30721971	MAP3K8	-0.48	-7.83	-0.39	6.36e-14	Inflammatory bowel disease;
LUSC	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg08601574	chr20:25228251	PYGB	-0.45	-6.89	-0.35	2.83e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg05283184	chr6:79620031	NA	-0.54	-10.73	-0.51	2.83e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs877282	0.853	rs11595507	chr10:756703	C/T	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs3784262	1.000	rs4646640	chr15:58247563	C/G	cg12031962	chr15:58353849	ALDH1A2	0.32	5.92	0.31	7.98e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg07741184	chr6:167504864	NA	0.43	7.57	0.38	3.58e-13	Primary biliary cholangitis;
LUSC	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg19622623	chr12:86230825	RASSF9	0.4	5.81	0.3	1.46e-8	Major depressive disorder;
LUSC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.34	-6.56	-0.34	2.09e-10	Total body bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05162137	chr1:146644430	PRKAB2	-0.41	-6.22	-0.32	1.52e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4631830	0.900	rs11006274	chr10:51540291	C/T	cg20129853	chr10:51489980	NA	0.32	6.47	0.33	3.53e-10	Prostate-specific antigen levels;
LUSC	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg12379764	chr21:47803548	PCNT	0.67	10.27	0.49	1.14e-21	Testicular germ cell tumor;
LUSC	cis	rs12519773	1.000	rs12519773	chr5:92464416	A/G	cg18783429	chr5:92414398	NA	0.27	5.96	0.31	6.5e-9	Migraine;
LUSC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.83	-0.54	3.32e-27	Chronic sinus infection;
LUSC	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg02176678	chr2:219576539	TTLL4	-0.58	-10.42	-0.5	3.41e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg23625390	chr15:77176239	SCAPER	-0.56	-8.86	-0.44	4.81e-17	Blood metabolite levels;
LUSC	cis	rs11587682	0.760	rs36020363	chr1:150448666	C/G	cg11822372	chr1:151115635	SEMA6C	-0.43	-5.74	-0.3	2.12e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg18305652	chr10:134549665	INPP5A	0.44	6.68	0.34	9.79e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg06238570	chr21:40685208	BRWD1	-0.63	-10.81	-0.51	1.54e-23	Cognitive function;
LUSC	cis	rs57590327	0.503	rs13062741	chr3:81887124	C/T	cg07356753	chr3:81810745	GBE1	-0.65	-10.2	-0.49	1.9e-21	Extraversion;
LUSC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg11764359	chr7:65958608	NA	-0.53	-6.87	-0.35	3.07e-11	Aortic root size;
LUSC	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg22482690	chr17:47019901	SNF8	0.34	6.13	0.32	2.49e-9	Type 2 diabetes;
LUSC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg26597838	chr10:835615	NA	0.96	12.5	0.56	1.13e-29	Eosinophil percentage of granulocytes;
LUSC	cis	rs7617773	0.832	rs6775114	chr3:48182620	G/C	cg11946769	chr3:48343235	NME6	-0.62	-9.45	-0.46	6.24e-19	Coronary artery disease;
LUSC	cis	rs2901656	1.000	rs6699095	chr1:172429245	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.29	5.9	0.31	9.11e-9	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.94	-0.4	3.06e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg14844989	chr11:31128820	NA	-0.39	-6.03	-0.31	4.39e-9	Red blood cell count;
LUSC	cis	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg09904177	chr6:26538194	HMGN4	-0.72	-6.17	-0.32	1.98e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg26338869	chr17:61819248	STRADA	0.41	6.02	0.31	4.68e-9	Prudent dietary pattern;
LUSC	cis	rs225245	0.782	rs321617	chr17:33915246	A/G	cg05299278	chr17:33885742	SLFN14	0.31	6.82	0.35	4.37e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs981844	0.796	rs13140722	chr4:154712203	T/A	cg14289246	chr4:154710475	SFRP2	-0.46	-5.92	-0.31	8.06e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg24505687	chr6:33548425	BAK1	0.45	6.52	0.34	2.6200000000000003e-10	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
LUSC	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg19610905	chr11:61596333	FADS2	-0.53	-8.0	-0.4	2.03e-14	Trans fatty acid levels;
LUSC	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg13126279	chr21:47581558	C21orf56	-0.39	-5.88	-0.31	9.83e-9	Testicular germ cell tumor;
LUSC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.79	0.39	8.73e-14	Prudent dietary pattern;
LUSC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.1	-0.36	7.5e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4654899	0.571	rs1888759	chr1:21065167	G/A	cg01072550	chr1:21505969	NA	-0.45	-6.76	-0.35	6.2e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs8179	0.553	rs42377	chr7:92243672	G/A	cg15732164	chr7:92237376	CDK6	-0.42	-6.49	-0.33	3.06e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg13722127	chr7:150037890	RARRES2	0.38	5.72	0.3	2.39e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg11062466	chr8:58055876	NA	0.51	6.58	0.34	1.85e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg21251018	chr6:28226885	NKAPL	0.31	5.79	0.3	1.62e-8	Pubertal anthropometrics;
LUSC	cis	rs11958404	0.932	rs7706111	chr5:157416053	C/T	cg05962755	chr5:157440814	NA	0.48	6.19	0.32	1.72e-9	IgG glycosylation;
LUSC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg07741184	chr6:167504864	NA	-0.39	-7.1	-0.36	7.35e-12	Crohn's disease;
LUSC	trans	rs731565	1.000	rs731565	chr7:147406262	C/T	cg12847240	chr6:10382088	NA	-0.55	-6.1	-0.32	2.97e-9	Diabetic kidney disease;
LUSC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.06	-0.55	4.59e-28	Type 2 diabetes;
LUSC	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg05373962	chr22:49881684	NA	-0.39	-8.25	-0.41	3.62e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg20701182	chr2:24300061	SF3B14	0.88	11.35	0.53	1.86e-25	Lymphocyte counts;
LUSC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.11	0.45	7.5e-18	Motion sickness;
LUSC	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-6.92	-0.35	2.38e-11	Blood metabolite levels;
LUSC	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg20307385	chr11:47447363	PSMC3	0.45	6.52	0.34	2.68e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.59	9.72	0.47	8.16e-20	Aortic root size;
LUSC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.4	0.33	5.34e-10	Bipolar disorder;
LUSC	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg11502198	chr6:26597334	ABT1	0.59	9.25	0.45	2.85e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs1163251	0.837	rs517533	chr1:120229170	T/G	cg19096424	chr1:120255104	PHGDH	0.45	6.18	0.32	1.85e-9	Blood metabolite levels;
LUSC	cis	rs7089973	0.523	rs7090904	chr10:116775885	G/T	cg23260525	chr10:116636907	FAM160B1	0.3	5.97	0.31	6.12e-9	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	6.5	0.34	2.88e-10	Height;
LUSC	cis	rs2430307	0.518	rs67763033	chr7:76517677	A/G	cg15770687	chr7:76625569	PMS2L11	0.85	8.87	0.44	4.64e-17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs909341	0.818	rs67468102	chr20:62344883	G/C	cg09650180	chr20:62225654	GMEB2	-0.44	-5.79	-0.3	1.62e-8	Atopic dermatitis;
LUSC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg09365446	chr1:150670422	GOLPH3L	0.51	7.83	0.39	6.48e-14	Melanoma;
LUSC	cis	rs6087990	0.735	rs2424907	chr20:31359819	C/T	cg13636640	chr20:31349939	DNMT3B	0.9	18.29	0.71	2.9e-52	Ulcerative colitis;
LUSC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg02951883	chr7:2050386	MAD1L1	-0.46	-7.85	-0.39	5.67e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg06002616	chr8:101225028	SPAG1	-0.4	-6.7	-0.34	8.89e-11	Atrioventricular conduction;
LUSC	cis	rs55665837	1.000	rs7121171	chr11:14446420	A/G	cg05501817	chr11:14380813	RRAS2	-0.4	-6.53	-0.34	2.46e-10	Vitamin D levels;
LUSC	cis	rs2798269	0.966	rs2040059	chr13:22143100	C/G	cg18095732	chr13:22033692	ZDHHC20	0.39	5.9	0.31	8.89e-9	PR segment;
LUSC	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg05855489	chr10:104503620	C10orf26	0.49	7.52	0.38	4.99e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7582720	1.000	rs72926794	chr2:203827432	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg04995722	chr7:26192034	NFE2L3	0.37	6.15	0.32	2.24e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-0.97	-8.32	-0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg02153584	chr22:29168773	CCDC117	-0.49	-7.69	-0.39	1.64e-13	Red cell distribution width;
LUSC	cis	rs9311676	0.656	rs6445977	chr3:58379560	T/C	cg13750441	chr3:58318267	PXK	0.36	7.06	0.36	9.88e-12	Systemic lupus erythematosus;
LUSC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg26924012	chr15:45694286	SPATA5L1	1.13	19.82	0.74	2.46e-58	Homoarginine levels;
LUSC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.4	-6.28	-0.33	1.04e-9	Total body bone mineral density;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10093594	chr1:206858754	MAPKAPK2	0.43	6.75	0.35	6.63e-11	Triglycerides;
LUSC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	0.95	18.99	0.72	4.85e-55	Cognitive function;
LUSC	cis	rs7712401	0.601	rs35479600	chr5:122324470	G/T	cg19077854	chr5:122220652	SNX24	-0.42	-9.14	-0.45	6.24e-18	Mean platelet volume;
LUSC	trans	rs12210905	0.925	rs115182402	chr6:26980110	G/T	cg11837749	chr1:55047332	ACOT11	0.55	5.96	0.31	6.41e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg06740227	chr12:86229804	RASSF9	0.45	7.18	0.37	4.43e-12	Major depressive disorder;
LUSC	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg02569458	chr12:86230093	RASSF9	0.48	7.7	0.39	1.6e-13	Major depressive disorder;
LUSC	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	11.08	0.52	1.67e-24	Colorectal cancer;
LUSC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.09	0.48	4.38e-21	Electroencephalogram traits;
LUSC	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg05973401	chr12:123451056	ABCB9	0.51	6.44	0.33	4.24e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg26408565	chr15:76604113	ETFA	-0.48	-7.64	-0.39	2.38e-13	Blood metabolite levels;
LUSC	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.69	12.47	0.56	1.49e-29	White blood cell count;
LUSC	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.18	0.37	4.48e-12	Blood metabolite levels;
LUSC	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.79	0.65	2.33e-42	Bladder cancer;
LUSC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.08	0.32	3.26e-9	Renal cell carcinoma;
LUSC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg15212455	chr7:39170539	POU6F2	0.66	11.19	0.52	6.55e-25	IgG glycosylation;
LUSC	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12545109	0.879	rs1975285	chr8:57358682	G/C	cg09654669	chr8:57350985	NA	-0.56	-7.48	-0.38	6.83e-13	Obesity-related traits;
LUSC	cis	rs1113500	0.933	rs745795	chr1:108629345	C/T	cg11967332	chr1:108735228	SLC25A24	0.38	5.76	0.3	1.92e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg13010199	chr12:38710504	ALG10B	0.47	7.09	0.36	8.21e-12	Heart rate;
LUSC	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	8.3	0.41	2.55e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg25174290	chr11:3078921	CARS	-0.41	-6.05	-0.31	3.94e-9	Calcium levels;
LUSC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg19592336	chr6:28129416	ZNF389	0.49	6.46	0.33	3.7e-10	Depression;
LUSC	cis	rs56399783	0.901	rs17132624	chr7:2778496	G/A	cg19731401	chr7:2775893	GNA12	0.72	8.67	0.43	1.95e-16	Childhood ear infection;
LUSC	cis	rs12681287	0.604	rs13279589	chr8:87477723	C/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.36	6.34e-12	Caudate activity during reward;
LUSC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.48	7.33	0.37	1.8e-12	Renal function-related traits (BUN);
LUSC	cis	rs7927771	0.524	rs10838775	chr11:47856382	C/G	cg20307385	chr11:47447363	PSMC3	0.45	6.55	0.34	2.17e-10	Subjective well-being;
LUSC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	0.94	17.96	0.7	5.88e-51	Heart rate;
LUSC	cis	rs7180079	0.620	rs7162324	chr15:64736287	A/G	cg08069370	chr15:64387884	SNX1	0.56	6.25	0.32	1.25e-9	Monocyte count;
LUSC	cis	rs2820315	0.867	rs2820321	chr1:201880296	G/C	cg10061532	chr1:201886748	LMOD1	0.27	6.19	0.32	1.73e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg11578532	chr1:161008127	TSTD1	0.35	7.29	0.37	2.28e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg05855489	chr10:104503620	C10orf26	0.51	7.73	0.39	1.29e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22590775	chr19:49891494	CCDC155	0.57	7.55	0.38	4.1e-13	Multiple sclerosis;
LUSC	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg20744362	chr22:50050164	C22orf34	0.39	7.18	0.37	4.45e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-14.97	-0.63	3.88e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21171335	chr12:122356390	WDR66	0.64	9.4	0.46	9.22e-19	Mean corpuscular volume;
LUSC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.37	-0.49	4.88e-22	Hemoglobin concentration;
LUSC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg20573242	chr4:122745356	CCNA2	0.45	6.88	0.35	2.97e-11	Type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26591144	chr17:1532201	SLC43A2	-0.4	-5.98	-0.31	5.63e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg17845761	chr1:175162550	KIAA0040	0.32	6.02	0.31	4.5e-9	Alcohol dependence;
LUSC	cis	rs56283067	0.887	rs12200892	chr6:44768925	T/C	cg18551225	chr6:44695536	NA	-0.48	-7.65	-0.39	2.22e-13	Total body bone mineral density;
LUSC	cis	rs13385	0.769	rs7737342	chr5:139611011	A/T	cg26211634	chr5:139558579	C5orf32	0.45	6.99	0.36	1.47e-11	Atrial fibrillation;
LUSC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.22	-14.04	-0.61	1.61e-35	Diabetic kidney disease;
LUSC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg04450456	chr4:17643702	FAM184B	0.35	5.81	0.3	1.47e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg14092988	chr3:52407081	DNAH1	0.3	5.93	0.31	7.54e-9	Bipolar disorder;
LUSC	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg09307838	chr4:120376055	NA	-0.74	-10.38	-0.49	4.63e-22	Corneal astigmatism;
LUSC	cis	rs17828380	1.000	rs8043419	chr15:63539622	C/T	cg05507819	chr15:63340323	TPM1	-0.71	-6.13	-0.32	2.54e-9	Social communication problems;
LUSC	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.29	0.33	1.01e-9	Lung cancer;
LUSC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.5	0.59	1.96e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg14895029	chr7:2775587	GNA12	-0.4	-5.95	-0.31	6.94e-9	Height;
LUSC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg21782813	chr7:2030301	MAD1L1	0.52	8.66	0.43	2.07e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs17253792	0.822	rs113692713	chr14:56087424	C/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg17411546	chr10:75410026	SYNPO2L	-0.51	-7.59	-0.38	3.16e-13	Inflammatory bowel disease;
LUSC	cis	rs12493885	0.818	rs62276828	chr3:153775941	C/T	cg17054900	chr3:154042577	DHX36	-0.72	-7.09	-0.36	8.25e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg23719950	chr11:63933701	MACROD1	-0.61	-7.94	-0.4	3.13e-14	Mean platelet volume;
LUSC	cis	rs3106136	0.934	rs35995707	chr4:95167150	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.02	-0.31	4.68e-9	Capecitabine sensitivity;
LUSC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22618164	chr12:122356400	WDR66	0.65	9.54	0.46	3.04e-19	Mean corpuscular volume;
LUSC	cis	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg05084668	chr3:125655381	ALG1L	-0.83	-11.86	-0.54	2.53e-27	Blood pressure (smoking interaction);
LUSC	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.43	-0.33	4.51e-10	Type 2 diabetes;
LUSC	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg20991723	chr1:152506922	NA	0.49	9.19	0.45	4.2e-18	Hair morphology;
LUSC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg27432699	chr2:27873401	GPN1	-0.65	-9.83	-0.47	3.32e-20	Total body bone mineral density;
LUSC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg13683864	chr3:40499215	RPL14	-1.13	-20.96	-0.75	7.35e-63	Renal cell carcinoma;
LUSC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-14.08	-0.61	1.14e-35	Bladder cancer;
LUSC	cis	rs9463078	0.753	rs636845	chr6:44935341	C/T	cg25276700	chr6:44698697	NA	-0.29	-6.04	-0.31	4.17e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg21672276	chr3:44754072	ZNF502	-0.38	-6.05	-0.31	3.8e-9	Depressive symptoms;
LUSC	cis	rs672059	1.000	rs638781	chr1:183157358	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.99	0.4	2.15e-14	Hypertriglyceridemia;
LUSC	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	12.42	0.56	2.19e-29	Ileal carcinoids;
LUSC	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.84	-0.44	5.62e-17	Metabolite levels;
LUSC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18876405	chr7:65276391	NA	-0.55	-8.76	-0.43	9.78e-17	Aortic root size;
LUSC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	8.83	0.43	6.23e-17	Monocyte percentage of white cells;
LUSC	cis	rs2346177	0.846	rs62138876	chr2:46650672	C/A	cg02822958	chr2:46747628	ATP6V1E2	0.39	6.73	0.35	7.31e-11	HDL cholesterol;
LUSC	cis	rs12519773	0.526	rs4285204	chr5:92528272	C/T	cg18783429	chr5:92414398	NA	0.34	7.19	0.37	4.38e-12	Migraine;
LUSC	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.41	-0.49	3.71e-22	Eye color traits;
LUSC	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg01629716	chr15:45996671	NA	0.39	5.96	0.31	6.31e-9	Waist circumference;Weight;
LUSC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg23262073	chr20:60523788	NA	-0.64	-9.21	-0.45	3.59e-18	Obesity-related traits;
LUSC	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg00277334	chr10:82204260	NA	-0.58	-8.71	-0.43	1.47e-16	Post bronchodilator FEV1;
LUSC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.47	6.23	0.32	1.38e-9	Renal function-related traits (BUN);
LUSC	cis	rs12210905	0.925	rs115182402	chr6:26980110	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.98	-0.31	5.84e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg04539111	chr16:67997858	SLC12A4	-0.42	-5.86	-0.31	1.09e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.43	5.96	0.31	6.27e-9	Blood trace element (Cu levels);
LUSC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.58	9.02	0.44	1.52e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7119	0.700	rs7497168	chr15:77886231	A/C	cg27398640	chr15:77910606	LINGO1	0.37	8.53	0.42	5.04e-16	Type 2 diabetes;
LUSC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06656553	chr16:89960601	TCF25	-0.65	-5.7	-0.3	2.63e-8	Skin colour saturation;
LUSC	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.68	-0.34	9.94e-11	Resting heart rate;
LUSC	cis	rs17001868	0.568	rs9611329	chr22:40792038	G/T	cg07138101	chr22:40742427	ADSL	0.61	7.5	0.38	5.72e-13	Mammographic density (dense area);
LUSC	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg21141812	chr3:48556323	PFKFB4	0.33	5.7	0.3	2.64e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs4363385	0.720	rs1611755	chr1:152956420	T/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.47e-13	Inflammatory skin disease;
LUSC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg18765753	chr7:1198926	ZFAND2A	-0.4	-7.42	-0.38	1e-12	Longevity;Endometriosis;
LUSC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	10.41	0.5	3.59e-22	Hip circumference adjusted for BMI;
LUSC	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg00310523	chr12:86230176	RASSF9	0.47	8.62	0.43	2.74e-16	Major depressive disorder;
LUSC	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg19610905	chr11:61596333	FADS2	-0.55	-8.26	-0.41	3.54e-15	Trans fatty acid levels;
LUSC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg08847533	chr14:75593920	NEK9	0.86	16.21	0.66	5.26e-44	Height;
LUSC	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	6.34	0.33	7.44e-10	Lymphocyte counts;
LUSC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.85	-13.84	-0.6	9.62e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg27094323	chr7:1216898	NA	-0.44	-7.51	-0.38	5.38e-13	Longevity;Endometriosis;
LUSC	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg03975922	chr5:140080575	ZMAT2	0.32	5.64	0.3	3.55e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00864171	chr11:67383662	NA	0.35	6.28	0.32	1.05e-9	Mean corpuscular volume;
LUSC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.92	0.35	2.31e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg24642439	chr20:33292090	TP53INP2	0.49	7.34	0.37	1.62e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg27170947	chr2:26402098	FAM59B	0.72	10.79	0.51	1.8e-23	Gut microbiome composition (summer);
LUSC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-17.35	-0.69	1.61e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2976388	0.669	rs1836633	chr8:143774592	G/A	cg17252645	chr8:143867129	LY6D	0.39	6.74	0.35	6.97e-11	Urinary tract infection frequency;
LUSC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg04369109	chr6:150039330	LATS1	-0.57	-8.31	-0.41	2.46e-15	Lung cancer;
LUSC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.54	-8.49	-0.42	6.84e-16	Longevity;Endometriosis;
LUSC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	10.4	0.49	4.09e-22	Cognitive test performance;
LUSC	cis	rs6977660	1.000	rs57916046	chr7:19800542	T/C	cg07541023	chr7:19748670	TWISTNB	0.57	6.22	0.32	1.5e-9	Thyroid stimulating hormone;
LUSC	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg11789530	chr4:8429930	ACOX3	-0.4	-5.86	-0.31	1.13e-8	Response to antineoplastic agents;
LUSC	cis	rs4144743	1.000	rs4144746	chr17:45323355	C/G	cg18085866	chr17:45331354	ITGB3	-0.7	-7.62	-0.38	2.61e-13	Body mass index;
LUSC	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg12863693	chr15:85201151	NMB	0.34	7.52	0.38	5.14e-13	Schizophrenia;
LUSC	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg22676075	chr6:135203613	NA	0.47	7.33	0.37	1.72e-12	Red blood cell count;
LUSC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg13319975	chr6:146136371	FBXO30	0.51	7.7	0.39	1.51e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg01503450	chr10:980765	NA	-0.4	-5.81	-0.3	1.45e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs7674212	0.507	rs223413	chr4:103732866	A/G	cg16532752	chr4:104119610	CENPE	0.41	5.88	0.31	9.87e-9	Type 2 diabetes;
LUSC	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-9.96	-0.48	1.27e-20	Morning vs. evening chronotype;
LUSC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg00701064	chr4:6280414	WFS1	0.58	14.61	0.62	9.98e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.7	12.15	0.55	2.24e-28	Prudent dietary pattern;
LUSC	cis	rs965513	1.000	rs10983761	chr9:100553957	A/C	cg13688889	chr9:100608707	NA	-0.54	-8.16	-0.41	6.68e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs7712401	0.580	rs10066632	chr5:122364683	C/A	cg19077854	chr5:122220652	SNX24	0.38	7.95	0.4	2.97e-14	Mean platelet volume;
LUSC	cis	rs71403859	0.614	rs12447033	chr16:71583655	G/T	cg08717414	chr16:71523259	ZNF19	-0.75	-8.91	-0.44	3.28e-17	Post bronchodilator FEV1;
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14893161	chr1:205819251	PM20D1	0.93	18.32	0.71	2.21e-52	Menarche (age at onset);
LUSC	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg17644776	chr2:200775616	C2orf69	0.37	6.06	0.31	3.68e-9	Osteoporosis;
LUSC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg15448220	chr1:150897856	SETDB1	0.41	5.89	0.31	9.46e-9	Melanoma;
LUSC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	9.88	0.48	2.23e-20	Personality dimensions;
LUSC	cis	rs62458065	0.850	rs6462362	chr7:32464733	C/T	cg20159608	chr7:32802032	NA	-0.61	-7.27	-0.37	2.54e-12	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg04455712	chr21:45112962	RRP1B	0.46	8.81	0.43	6.9e-17	Mean corpuscular volume;
LUSC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.8	-0.35	4.82e-11	Alzheimer's disease (late onset);
LUSC	cis	rs6545883	0.894	rs12997538	chr2:61564249	A/C	cg15711740	chr2:61764176	XPO1	0.48	7.4	0.38	1.09e-12	Tuberculosis;
LUSC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg01579765	chr21:45077557	HSF2BP	-0.56	-11.85	-0.54	2.82e-27	Mean corpuscular volume;
LUSC	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg08601574	chr20:25228251	PYGB	0.45	6.81	0.35	4.56e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.71	-11.03	-0.52	2.55e-24	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.66	-10.3	-0.49	8.65e-22	Menarche (age at onset);
LUSC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg07777115	chr5:623756	CEP72	-0.47	-5.88	-0.31	1.02e-8	Obesity-related traits;
LUSC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14893161	chr1:205819251	PM20D1	-0.8	-16.05	-0.66	2.34e-43	Monocyte percentage of white cells;
LUSC	cis	rs981844	0.857	rs62325142	chr4:154717790	A/G	cg14289246	chr4:154710475	SFRP2	0.49	6.21	0.32	1.6e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg25072359	chr17:41440525	NA	0.58	8.24	0.41	3.85e-15	Menopause (age at onset);
LUSC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11645453	chr3:52864694	ITIH4	0.31	7.25	0.37	2.85e-12	Bipolar disorder;
LUSC	trans	rs629535	0.734	rs659430	chr8:70009988	A/G	cg21567404	chr3:27674614	NA	0.79	13.04	0.58	1.04e-31	Dupuytren's disease;
LUSC	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.84	14.7	0.63	4.55e-38	Metabolic syndrome;
LUSC	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs10740039	0.883	rs10994455	chr10:62405347	G/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.86	-0.35	3.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6558174	1.000	rs6558174	chr8:22492129	A/G	cg03733263	chr8:22462867	KIAA1967	0.47	6.15	0.32	2.21e-9	Breast cancer;
LUSC	cis	rs9462027	0.675	rs13206387	chr6:34696792	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.31	-5.65	-0.3	3.46e-8	Systemic lupus erythematosus;
LUSC	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg11189052	chr15:85197271	WDR73	0.53	5.97	0.31	6.13e-9	Schizophrenia;
LUSC	cis	rs73206853	0.640	rs35026231	chr12:110832125	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.58	-0.5	9.6e-23	Chronic sinus infection;
LUSC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg13939156	chr17:80058883	NA	0.33	6.42	0.33	4.59e-10	Life satisfaction;
LUSC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.73	0.54	7.69e-27	Alzheimer's disease;
LUSC	trans	rs961253	0.556	rs6076983	chr20:6331376	C/T	cg21095983	chr6:86352623	SYNCRIP	0.45	6.81	0.35	4.68e-11	Colorectal cancer;
LUSC	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg13010199	chr12:38710504	ALG10B	0.58	9.23	0.45	3.24e-18	Morning vs. evening chronotype;
LUSC	cis	rs8038465	0.592	rs899981	chr15:73935329	G/A	cg15420318	chr15:73925796	NPTN	0.57	9.73	0.47	7.53e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs74181299	0.890	rs2540950	chr2:65279223	C/T	cg05010058	chr2:65284262	CEP68	0.31	6.11	0.32	2.75e-9	Pulse pressure;
LUSC	cis	rs62027291	0.561	rs2469196	chr15:77266688	A/G	cg26408565	chr15:76604113	ETFA	-0.45	-6.12	-0.32	2.69e-9	Plateletcrit;
LUSC	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.35	-0.42	1.87e-15	Total cholesterol levels;
LUSC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.36	0.42	1.73e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg08219700	chr8:58056026	NA	0.49	6.04	0.31	4.12e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg16342193	chr10:102329863	NA	-0.36	-6.56	-0.34	2.08e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11051970	0.879	rs2651362	chr12:32587851	G/C	cg02745156	chr12:32552066	NA	0.43	7.29	0.37	2.29e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg13798780	chr7:105162888	PUS7	0.56	6.04	0.31	4.04e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6736175	1.000	rs12463658	chr2:191965344	A/C	cg11255154	chr2:191879104	STAT1	0.35	5.68	0.3	2.9e-8	Systemic lupus erythematosus;
LUSC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.89	13.88	0.6	6.58e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-9.4	-0.46	8.62e-19	Platelet distribution width;
LUSC	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg00504896	chr12:9437009	LOC642846	-0.4	-6.02	-0.31	4.69e-9	Breast size;
LUSC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg18240062	chr17:79603768	NPLOC4	0.58	10.1	0.48	4.09e-21	Eye color traits;
LUSC	trans	rs3960554	0.569	rs10464565	chr7:75869526	T/G	cg19862616	chr7:65841803	NCRNA00174	0.64	7.88	0.4	4.65e-14	Eotaxin levels;
LUSC	trans	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg13010199	chr12:38710504	ALG10B	0.47	7.17	0.37	4.89e-12	Morning vs. evening chronotype;
LUSC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg14820908	chr5:178986412	RUFY1	0.68	13.01	0.58	1.36e-31	Lung cancer;
LUSC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg18681998	chr4:17616180	MED28	0.89	17.39	0.69	1.05e-48	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11822910	0.737	rs2729389	chr11:57211646	A/G	cg00522883	chr11:57194120	SLC43A3	-0.4	-6.62	-0.34	1.4e-10	Platelet distribution width;
LUSC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg17376030	chr22:41985996	PMM1	-0.47	-5.84	-0.3	1.25e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg09537434	chr19:41945824	ATP5SL	0.54	7.37	0.37	1.39e-12	Colorectal cancer;
LUSC	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg19875535	chr5:140030758	IK	-0.53	-8.75	-0.43	1.07e-16	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs72674100	1.000	rs28835944	chr4:97962356	A/G	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg12483005	chr1:23474871	LUZP1	0.45	6.92	0.35	2.28e-11	Height;
LUSC	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg15819921	chr19:927150	ARID3A	-0.46	-6.74	-0.35	7.14e-11	Life satisfaction;
LUSC	cis	rs13242816	1.000	rs4292624	chr7:116102724	A/C	cg16553024	chr7:116138462	CAV2	-0.53	-5.81	-0.3	1.46e-8	P wave duration;
LUSC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg04166393	chr7:2884313	GNA12	0.46	5.98	0.31	5.84e-9	Height;
LUSC	cis	rs9427116	0.677	rs9426831	chr1:154609657	A/T	cg17218026	chr1:154582156	ADAR	-0.55	-9.77	-0.47	5.39e-20	Blood protein levels;
LUSC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg09455208	chr3:40491958	NA	0.59	10.2	0.49	1.87e-21	Renal cell carcinoma;
LUSC	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg04362960	chr10:104952993	NT5C2	0.6	9.53	0.46	3.28e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg00631329	chr6:26305371	NA	0.33	5.71	0.3	2.52e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg08601574	chr20:25228251	PYGB	-0.54	-8.61	-0.43	2.95e-16	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.58	0.5	9.15e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg13531842	chr10:38383804	ZNF37A	-0.46	-7.19	-0.37	4.37e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg24154853	chr7:158122151	PTPRN2	-0.42	-8.15	-0.41	7.64e-15	Calcium levels;
LUSC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2481665	0.904	rs2481677	chr1:62632571	G/A	cg18591186	chr1:62594603	INADL	-0.46	-7.29	-0.37	2.24e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17467752	chr17:38218738	THRA	-0.53	-7.54	-0.38	4.42e-13	White blood cell count;
LUSC	cis	rs12618769	0.625	rs72819984	chr2:99044762	G/C	cg10123293	chr2:99228465	UNC50	0.45	7.64	0.39	2.31e-13	Bipolar disorder;
LUSC	cis	rs9324022	0.858	rs1004573	chr14:101178235	G/C	cg18089426	chr14:101175970	NA	0.46	5.65	0.3	3.45e-8	Plateletcrit;
LUSC	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg02018176	chr4:1364513	KIAA1530	0.41	5.87	0.31	1.03e-8	Recombination rate (females);
LUSC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.22	0.32	1.45e-9	Schizophrenia;
LUSC	trans	rs6030	1.000	rs2157581	chr1:169499190	A/G	cg16792071	chr10:134842795	NA	0.28	6.04	0.31	4.17e-9	Uric acid levels;
LUSC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.3	0.41	2.67e-15	Prudent dietary pattern;
LUSC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg23791538	chr6:167370224	RNASET2	-0.41	-6.73	-0.35	7.32e-11	Crohn's disease;
LUSC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg09365446	chr1:150670422	GOLPH3L	0.47	6.83	0.35	3.96e-11	Melanoma;
LUSC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.81	-11.1	-0.52	1.44e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs9401746	0.564	rs578658	chr6:124785562	A/G	cg16857858	chr7:27213984	HOXA10	0.51	6.29	0.33	9.92e-10	Bone mineral density (Ward's triangle area);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg26967579	chr5:65893440	MAST4	0.41	5.95	0.31	6.9e-9	Mosquito bite size;
LUSC	cis	rs4713675	0.565	rs3818524	chr6:33660695	G/C	cg14003231	chr6:33640908	ITPR3	0.31	5.94	0.31	7.14e-9	Plateletcrit;
LUSC	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.68	11.63	0.54	1.78e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12760731	0.623	rs3791026	chr1:178343890	G/A	cg00404053	chr1:178313656	RASAL2	0.48	5.82	0.3	1.38e-8	Obesity-related traits;
LUSC	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.6	-9.69	-0.47	9.72e-20	Body mass index;
LUSC	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-7.24	-0.37	3.19e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg07596845	chr6:82957841	IBTK	0.48	6.52	0.34	2.67e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg09654669	chr8:57350985	NA	-0.58	-7.84	-0.39	5.98e-14	Obesity-related traits;
LUSC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg11645453	chr3:52864694	ITIH4	0.33	7.24	0.37	3.11e-12	Bipolar disorder;
LUSC	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg10909506	chr17:38081995	ORMDL3	0.34	6.03	0.31	4.44e-9	Self-reported allergy;
LUSC	cis	rs9309473	0.554	rs4330127	chr2:73581320	A/T	cg20560298	chr2:73613845	ALMS1	-0.55	-8.1	-0.41	1.05e-14	Metabolite levels;
LUSC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg03351412	chr1:154909251	PMVK	0.52	8.06	0.4	1.33e-14	Prostate cancer;
LUSC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg06096015	chr1:231504339	EGLN1	-0.53	-9.18	-0.45	4.66e-18	Hemoglobin concentration;
LUSC	cis	rs77741769	0.571	rs11065283	chr12:121266453	A/G	cg02419362	chr12:121203948	SPPL3	0.46	8.41	0.42	1.24e-15	Mean corpuscular volume;
LUSC	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg24130564	chr14:104152367	KLC1	-0.45	-6.21	-0.32	1.54e-9	Body mass index;
LUSC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	0.96	15.12	0.64	1.05e-39	Body mass index;
LUSC	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg09655341	chr17:79618100	PDE6G	-0.29	-6.77	-0.35	5.94e-11	Eye color traits;
LUSC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06634786	chr22:41940651	POLR3H	0.53	6.18	0.32	1.82e-9	Vitiligo;
LUSC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg17211192	chr8:82754475	SNX16	-0.64	-9.11	-0.45	7.56e-18	Diastolic blood pressure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13626842	chr6:3157721	TUBB2A	-0.41	-6.01	-0.31	4.77e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.58	-6.83	-0.35	4.06e-11	Yeast infection;
LUSC	cis	rs7119	0.604	rs2271398	chr15:77907784	G/A	cg27398640	chr15:77910606	LINGO1	0.38	8.89	0.44	3.98e-17	Type 2 diabetes;
LUSC	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg12823233	chr7:2316876	SNX8	-0.38	-6.38	-0.33	5.87e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.24	-0.52	4.6e-25	Mean corpuscular volume;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg26151531	chr22:19842652	GNB1L;C22orf29	0.44	6.68	0.34	1.01e-10	Triglycerides;
LUSC	cis	rs2274273	0.686	rs57033289	chr14:55623317	C/A	cg04306507	chr14:55594613	LGALS3	0.48	9.7	0.47	9.24e-20	Protein biomarker;
LUSC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg05729581	chr11:3078854	CARS	0.53	8.0	0.4	2.11e-14	Longevity;
LUSC	cis	rs9392556	0.829	rs619873	chr6:4107455	A/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.39	-6.74	-0.35	6.76e-11	Blood metabolite levels;
LUSC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	12.36	0.56	3.77e-29	Colorectal cancer;
LUSC	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.64	0.43	2.33e-16	Migraine;Coronary artery disease;
LUSC	cis	rs1044826	0.692	rs184155	chr3:139229772	G/A	cg00490450	chr3:139108681	COPB2	-0.46	-7.08	-0.36	8.77e-12	Obesity-related traits;
LUSC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg17264618	chr3:40429014	ENTPD3	0.34	7.28	0.37	2.36e-12	Renal cell carcinoma;
LUSC	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg15556689	chr8:8085844	FLJ10661	0.63	9.08	0.44	9.83e-18	Neuroticism;
LUSC	cis	rs2637266	0.626	rs2583069	chr10:78546775	T/C	cg18941641	chr10:78392320	NA	0.37	6.84	0.35	3.77e-11	Pulmonary function;
LUSC	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg23283495	chr1:209979779	IRF6	0.63	7.76	0.39	1.04e-13	Cleft lip with or without cleft palate;
LUSC	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg23093090	chr10:104574429	C10orf26	-0.39	-7.35	-0.37	1.51e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg02574844	chr11:5959923	NA	-0.4	-6.06	-0.31	3.73e-9	DNA methylation (variation);
LUSC	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg05283184	chr6:79620031	NA	-0.57	-12.03	-0.55	6.25e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg09796270	chr17:17721594	SREBF1	0.4	7.12	0.36	6.49e-12	Total body bone mineral density;
LUSC	cis	rs6967385	0.560	rs55794302	chr7:12351495	C/A	cg10578991	chr7:12443926	VWDE	0.39	5.73	0.3	2.23e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg24296786	chr1:45957014	TESK2	0.41	5.73	0.3	2.2e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg02018176	chr4:1364513	KIAA1530	0.46	6.44	0.33	4.26e-10	Recombination rate (females);
LUSC	cis	rs1322512	1.000	rs2800626	chr6:153006340	T/A	cg27316956	chr6:152958899	SYNE1	0.34	5.98	0.31	5.72e-9	Tonometry;
LUSC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-7.91	-0.4	3.79e-14	Chronic sinus infection;
LUSC	cis	rs7180079	1.000	rs62024572	chr15:64499045	C/G	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg04691961	chr3:161091175	C3orf57	-0.35	-5.95	-0.31	6.76e-9	Morning vs. evening chronotype;
LUSC	cis	rs7011049	0.908	rs11986701	chr8:53833480	G/T	cg26025543	chr8:53854495	NA	0.51	6.28	0.32	1.05e-9	Systolic blood pressure;
LUSC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg01689657	chr7:91764605	CYP51A1	0.34	6.19	0.32	1.79e-9	Breast cancer;
LUSC	cis	rs983392	0.680	rs56357056	chr11:59986817	A/G	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.11	-0.32	2.75e-9	Alzheimer's disease (late onset);
LUSC	trans	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg01620082	chr3:125678407	NA	-0.82	-7.72	-0.39	1.35e-13	Depression;
LUSC	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-6.09	-0.32	3.1e-9	Joint mobility (Beighton score);
LUSC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg06454157	chr6:167490870	NA	-0.26	-5.88	-0.31	9.83e-9	Crohn's disease;
LUSC	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg07148914	chr20:33460835	GGT7	0.46	6.84	0.35	3.87e-11	Height;
LUSC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21545522	chr1:205238299	TMCC2	0.49	9.2	0.45	3.93e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg06637938	chr14:75390232	RPS6KL1	0.65	11.0	0.52	3.23e-24	Caffeine consumption;
LUSC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg15704280	chr7:45808275	SEPT13	0.96	14.47	0.62	3.47e-37	Height;
LUSC	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg07148914	chr20:33460835	GGT7	0.56	8.51	0.42	5.93e-16	Height;
LUSC	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	6.79	0.35	5.13e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs9341835	0.518	rs9350929	chr6:64175668	A/G	cg03326410	chr6:64151739	NA	-0.37	-5.95	-0.31	6.9e-9	Schizophrenia;
LUSC	trans	rs2048656	0.535	rs2014514	chr8:9647196	A/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.59	0.34	1.75e-10	Schizophrenia;
LUSC	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	cis	rs12220238	1.000	rs10824075	chr10:75880254	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.64	7.69	0.39	1.65e-13	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs7246657	0.509	rs10426093	chr19:37615629	G/A	cg23950597	chr19:37808831	NA	-0.54	-5.86	-0.31	1.11e-8	Coronary artery calcification;
LUSC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg27532560	chr4:187881888	NA	0.39	6.38	0.33	5.76e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg16006841	chr5:176797999	RGS14	-0.67	-9.66	-0.47	1.26e-19	Urate levels in lean individuals;
LUSC	cis	rs6733011	0.628	rs6713991	chr2:99464384	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-6.38	-0.33	5.77e-10	Bipolar disorder;
LUSC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg17507749	chr15:85114479	UBE2QP1	0.71	9.44	0.46	6.7e-19	Schizophrenia;
LUSC	cis	rs1560104	0.675	rs9927256	chr16:12705015	A/G	cg02946846	chr16:12632861	SNX29	0.32	5.9	0.31	8.75e-9	Obesity-related traits;
LUSC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg02569458	chr12:86230093	RASSF9	0.58	9.54	0.46	3.13e-19	Major depressive disorder;
LUSC	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg05805236	chr11:65401703	PCNXL3	0.66	10.81	0.51	1.47e-23	Acne (severe);
LUSC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg16325326	chr1:53192061	ZYG11B	0.81	13.96	0.61	3.24e-35	Monocyte count;
LUSC	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.7	-10.83	-0.51	1.31e-23	Hypertriglyceridemia;
LUSC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	0.96	16.31	0.67	2.17e-44	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14240098	chr7:50518052	FIGNL1	-0.4	-6.15	-0.32	2.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6543140	0.964	rs4851010	chr2:103056127	A/T	cg09003973	chr2:102972529	NA	-0.54	-6.93	-0.35	2.13e-11	Blood protein levels;
LUSC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	1.03	18.02	0.7	3.34e-51	Parkinson's disease;
LUSC	cis	rs9581857	0.547	rs75085794	chr13:28095944	A/C	cg22138327	chr13:27999177	GTF3A	0.7	7.18	0.37	4.58e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.53	0.38	4.65e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.76	-0.47	5.93e-20	Hemoglobin concentration;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.29	-7.43	-0.38	8.95e-13	Lymphocyte counts;
LUSC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg26335602	chr6:28129616	ZNF389	0.45	6.03	0.31	4.24e-9	Parkinson's disease;
LUSC	cis	rs4792901	0.759	rs3179927	chr17:41601911	A/G	cg22562494	chr17:41607896	ETV4	-0.31	-5.95	-0.31	6.72e-9	Dupuytren's disease;
LUSC	cis	rs4845459	0.967	rs6701307	chr1:152590444	G/A	cg08895932	chr1:152778580	LCE1C	-0.36	-6.26	-0.32	1.17e-9	Psoriasis;
LUSC	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg12002119	chr2:101014098	CHST10	0.35	5.8	0.3	1.53e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.45	-0.42	9.25e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg17173187	chr15:85201210	NMB	0.49	9.31	0.45	1.74e-18	Schizophrenia;
LUSC	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg23711669	chr6:146136114	FBXO30	0.85	15.19	0.64	5.67e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11971779	0.941	rs1127424	chr7:139107660	A/G	cg07862535	chr7:139043722	LUC7L2	0.74	8.31	0.41	2.47e-15	Diisocyanate-induced asthma;
LUSC	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg09904177	chr6:26538194	HMGN4	0.65	11.61	0.54	2.14e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg13395646	chr4:1353034	KIAA1530	0.55	8.42	0.42	1.13e-15	Longevity;
LUSC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.72	-0.35	7.97e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg18721089	chr20:30220636	NA	-0.41	-6.57	-0.34	1.93e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs7973719	0.868	rs2053887	chr12:7346530	G/A	cg07052231	chr12:7363540	PEX5	0.52	9.04	0.44	1.33e-17	IgG glycosylation;
LUSC	trans	rs12524093	0.541	rs12525094	chr6:143042815	G/T	cg22454011	chr18:13611439	C18orf1	0.68	5.96	0.31	6.53e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs593982	0.920	rs72922791	chr11:65567395	G/A	cg08755490	chr11:65554678	OVOL1	-1.42	-14.72	-0.63	3.63e-38	Atopic dermatitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16053281	chr3:196387058	LRRC33	0.41	6.18	0.32	1.85e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1124376	1.000	rs9857135	chr3:20147790	G/A	cg05072819	chr3:20081367	KAT2B	0.66	7.53	0.38	4.7e-13	Bipolar disorder and schizophrenia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05741182	chr16:72127884	DHX38;TXNL4B	-0.47	-6.06	-0.31	3.58e-9	Hepatitis;
LUSC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.23	0.41	4.29e-15	Prudent dietary pattern;
LUSC	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg21293242	chr8:11204541	TDH	0.34	6.47	0.33	3.56e-10	Retinal vascular caliber;
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	0.93	17.97	0.7	5.5e-51	Menarche (age at onset);
LUSC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg06618935	chr21:46677482	NA	-0.37	-7.4	-0.38	1.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7246967	0.611	rs62120304	chr19:22872268	G/T	cg23217946	chr19:22817039	ZNF492	0.45	6.01	0.31	4.91e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs4400599	0.901	rs2494670	chr1:154101057	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.37	6.01	0.31	4.87e-9	Platelet distribution width;
LUSC	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg05805236	chr11:65401703	PCNXL3	-0.37	-5.74	-0.3	2.08e-8	Breast cancer;
LUSC	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg03676636	chr4:99064102	C4orf37	0.37	7.91	0.4	3.7e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg20849893	chr7:64541193	NA	0.46	6.59	0.34	1.67e-10	Calcium levels;
LUSC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg27494647	chr7:150038898	RARRES2	0.42	6.54	0.34	2.27e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9361491	0.605	rs1185343	chr6:79436190	G/C	cg05283184	chr6:79620031	NA	-0.34	-6.2	-0.32	1.66e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10892866	chr1:154934115	PYGO2	-0.42	-6.26	-0.32	1.19e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg14154082	chr13:112174009	NA	0.37	7.7	0.39	1.54e-13	Menarche (age at onset);
LUSC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	0.65	13.92	0.61	4.91e-35	Prudent dietary pattern;
LUSC	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	6.38	0.33	5.82e-10	Schizophrenia;
LUSC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg17143192	chr8:8559678	CLDN23	-0.39	-6.02	-0.31	4.59e-9	Mood instability;
LUSC	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	10.05	0.48	6.11e-21	Coffee consumption (cups per day);
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.3	6.46	0.33	3.62e-10	Electroencephalogram traits;
LUSC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg06494592	chr3:125709126	NA	-0.52	-5.97	-0.31	6.04e-9	Blood pressure (smoking interaction);
LUSC	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg23791538	chr6:167370224	RNASET2	0.55	9.21	0.45	3.58e-18	Graves' disease;
LUSC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg08270630	chr22:50330655	NA	-0.42	-6.29	-0.33	1e-9	Schizophrenia;
LUSC	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg09455208	chr3:40491958	NA	-0.41	-7.96	-0.4	2.64e-14	Renal cell carcinoma;
LUSC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.92	0.31	8e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg18225595	chr11:63971243	STIP1	0.49	5.94	0.31	7.24e-9	Mean platelet volume;
LUSC	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg24675056	chr1:15929824	NA	0.45	7.76	0.39	1.03e-13	Systolic blood pressure;
LUSC	cis	rs12286929	0.898	rs11215384	chr11:115023851	C/G	cg04055981	chr11:115044050	NA	0.32	5.69	0.3	2.82e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6982240	0.514	rs28681435	chr8:142286573	C/A	cg27411547	chr8:142287226	NA	-0.47	-7.61	-0.38	2.91e-13	Tonsillectomy;
LUSC	cis	rs780094	0.500	rs7577311	chr2:27793921	G/T	cg27432699	chr2:27873401	GPN1	0.41	5.71	0.3	2.49e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	trans	rs2324999	0.632	rs12494510	chr3:86189861	A/G	cg20214535	chr21:43619310	ABCG1	0.36	6.18	0.32	1.91e-9	Subcutaneous adipose tissue;
LUSC	trans	rs2268344	0.515	rs1009325	chr10:124263877	A/G	cg11199862	chr13:46108984	COG3	-0.67	-5.99	-0.31	5.3300000000000004e-09	Coronary artery disease;
LUSC	cis	rs2224391	0.628	rs2753234	chr6:5251050	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.48	-6.59	-0.34	1.75e-10	Height;
LUSC	cis	rs7512552	1.000	rs7512552	chr1:150265704	T/C	cg15654264	chr1:150340011	RPRD2	-0.6	-10.0	-0.48	9.04e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs57590327	0.555	rs2053805	chr3:81738414	T/C	cg07356753	chr3:81810745	GBE1	-0.68	-10.37	-0.49	5.11e-22	Extraversion;
LUSC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg11965913	chr1:205819406	PM20D1	-0.79	-16.27	-0.66	3.17e-44	Monocyte percentage of white cells;
LUSC	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.46	-5.89	-0.31	9.34e-9	Bronchopulmonary dysplasia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23850707	chr15:55582494	RAB27A	-0.51	-5.99	-0.31	5.38e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg21880101	chr17:80066754	CCDC57	-0.31	-5.93	-0.31	7.37e-9	Life satisfaction;
LUSC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg11812906	chr14:75593930	NEK9	-0.62	-10.71	-0.51	3.29e-23	Height;
LUSC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.01	0.52	2.99e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	0.94	12.55	0.57	7.17e-30	Primary sclerosing cholangitis;
LUSC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg03188948	chr7:1209495	NA	0.47	6.29	0.33	9.82e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg21854759	chr1:92012499	NA	-0.41	-6.56	-0.34	2.02e-10	Breast cancer;
LUSC	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.12	0.45	7.1e-18	Motion sickness;
LUSC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg15848620	chr12:58087721	OS9	-0.55	-7.92	-0.4	3.5e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg22431228	chr1:16359049	CLCNKA	-0.38	-8.09	-0.4	1.1e-14	Systolic blood pressure;
LUSC	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg19610905	chr11:61596333	FADS2	-0.5	-7.58	-0.38	3.52e-13	Trans fatty acid levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25613101	chr22:38577875	PLA2G6	-0.46	-6.98	-0.36	1.62e-11	Hepatitis;
LUSC	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg20976159	chr1:228193529	WNT3A	0.29	5.86	0.31	1.11e-8	Diastolic blood pressure;
LUSC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg26335602	chr6:28129616	ZNF389	0.43	5.71	0.3	2.44e-8	Depression;
LUSC	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg25482853	chr8:67687455	SGK3	1.19	19.24	0.73	4.65e-56	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1267303	0.716	rs942255	chr1:46989792	C/T	cg25110126	chr1:46999211	NA	0.64	8.67	0.43	1.85e-16	Monobrow;
LUSC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg22903471	chr2:27725779	GCKR	-0.39	-6.62	-0.34	1.47e-10	Total body bone mineral density;
LUSC	cis	rs3820928	0.874	rs67513858	chr2:227804819	A/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.75	-0.39	1.14e-13	Pulmonary function;
LUSC	cis	rs9341808	0.667	rs7745301	chr6:80922561	G/T	cg08355045	chr6:80787529	NA	0.46	7.77	0.39	9.79e-14	Sitting height ratio;
LUSC	trans	rs17278117	0.614	rs73010755	chr4:182595798	A/T	cg11957848	chr6:169575326	NA	0.64	6.08	0.32	3.31e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg23711669	chr6:146136114	FBXO30	-0.82	-14.69	-0.63	5.14e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg23711669	chr6:146136114	FBXO30	-0.84	-15.75	-0.65	3.43e-42	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg17712092	chr4:129076599	LARP1B	-0.71	-10.28	-0.49	1.02e-21	Eosinophil percentage of white cells;
LUSC	cis	rs7712401	0.601	rs385547	chr5:122321833	C/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.54	-0.46	3.21e-19	Mean platelet volume;
LUSC	cis	rs2200578	0.732	rs56143125	chr2:99565143	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.61	6.99	0.36	1.55e-11	IgG glycosylation;
LUSC	cis	rs17621444	0.505	rs10886562	chr10:121760594	G/A	cg02041677	chr10:121771263	NA	-0.35	-6.62	-0.34	1.46e-10	IgG glycosylation;
LUSC	cis	rs1014246	0.826	rs4752004	chr10:118473209	A/G	cg14919929	chr10:118506882	NA	0.42	6.63	0.34	1.36e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs55871839	0.684	rs7829715	chr8:59803836	C/T	cg07426533	chr8:59803705	TOX	0.37	6.08	0.32	3.35e-9	Pneumonia;
LUSC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg06008330	chr7:65541103	ASL	0.4	6.19	0.32	1.77e-9	Aortic root size;
LUSC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg02487422	chr3:49467188	NICN1	-0.45	-7.12	-0.36	6.5e-12	Resting heart rate;
LUSC	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-0.93	-15.56	-0.65	1.99e-41	Dilated cardiomyopathy;
LUSC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg07701084	chr6:150067640	NUP43	0.49	7.38	0.37	1.31e-12	Lung cancer;
LUSC	cis	rs7712401	0.791	rs3822367	chr5:122146272	A/G	cg19077854	chr5:122220652	SNX24	-0.34	-7.87	-0.4	4.84e-14	Mean platelet volume;
LUSC	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg21775007	chr8:11205619	TDH	0.46	6.4	0.33	5.17e-10	Mood instability;
LUSC	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg11789530	chr4:8429930	ACOX3	-0.51	-7.79	-0.39	8.59e-14	Response to antineoplastic agents;
LUSC	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg15485101	chr11:133734466	NA	0.38	7.17	0.37	4.98e-12	Childhood ear infection;
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg09033563	chr22:24373618	LOC391322	-0.6	-9.36	-0.46	1.22e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.47	0.5	2.18e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11971779	0.774	rs7785906	chr7:139122652	T/C	cg07862535	chr7:139043722	LUC7L2	0.7	8.49	0.42	6.64e-16	Diisocyanate-induced asthma;
LUSC	cis	rs7953249	0.791	rs10774579	chr12:121405210	T/C	cg02403541	chr12:121454288	C12orf43	-0.5	-7.44	-0.38	8.81e-13	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	trans	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg26647312	chr5:1645268	NA	0.6	6.07	0.32	3.38e-9	Initial pursuit acceleration;
LUSC	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg16339924	chr4:17578868	LAP3	-0.53	-7.93	-0.4	3.27e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6714710	0.603	rs1470483	chr2:98393894	C/T	cg26665480	chr2:98280029	ACTR1B	0.62	9.06	0.44	1.16e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg06618935	chr21:46677482	NA	-0.39	-7.89	-0.4	4.43e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.67	-10.34	-0.49	6.58e-22	Morning vs. evening chronotype;
LUSC	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg22431228	chr1:16359049	CLCNKA	-0.4	-8.39	-0.42	1.42e-15	Systolic blood pressure;
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.46	7.77	0.39	1e-13	Lymphocyte counts;
LUSC	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.29	-0.33	9.8e-10	Bipolar disorder;
LUSC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00166722	chr3:10149974	C3orf24	0.62	8.47	0.42	8.07e-16	Alzheimer's disease;
LUSC	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.86	-0.44	4.94e-17	Metabolite levels;
LUSC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg13770153	chr20:60521292	NA	-0.61	-8.39	-0.42	1.43e-15	Body mass index;
LUSC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg19774624	chr17:42201019	HDAC5	0.79	12.34	0.56	4.59e-29	Total body bone mineral density;
LUSC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg00701064	chr4:6280414	WFS1	0.59	14.2	0.61	3.93e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs3916	0.794	rs3021337	chr12:121163261	C/T	cg27246729	chr12:121163418	ACADS	0.46	7.01	0.36	1.36e-11	Urinary metabolites (H-NMR features);
LUSC	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.55	-8.31	-0.41	2.35e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg25243455	chr2:114033360	PAX8;LOC440839	-0.34	-7.68	-0.39	1.73e-13	Lymphocyte counts;
LUSC	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-0.76	-10.72	-0.51	3.12e-23	Platelet distribution width;
LUSC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg25456477	chr12:86230367	RASSF9	0.43	7.71	0.39	1.41e-13	Major depressive disorder;
LUSC	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg10596483	chr8:143751796	JRK	0.52	7.33	0.37	1.73e-12	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.24e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg07701084	chr6:150067640	NUP43	0.51	7.5	0.38	5.74e-13	Lung cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17040068	chr7:102715209	ARMC10;FBXL13	0.43	6.14	0.32	2.33e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4499344	0.921	rs2277927	chr19:33088366	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.59	7.76	0.39	1.04e-13	Mean platelet volume;
LUSC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg22823121	chr1:150693482	HORMAD1	0.54	7.74	0.39	1.17e-13	Melanoma;
LUSC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg06713675	chr4:122721982	EXOSC9	-0.47	-8.18	-0.41	6.02e-15	Type 2 diabetes;
LUSC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	0.93	12.69	0.57	2.24e-30	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg24060327	chr5:131705240	SLC22A5	0.67	11.13	0.52	1.13e-24	Breast cancer;
LUSC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg27284194	chr4:1044797	NA	0.37	6.03	0.31	4.46e-9	Longevity;
LUSC	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg25174290	chr11:3078921	CARS	-0.41	-6.15	-0.32	2.19e-9	Calcium levels;
LUSC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	0.91	17.47	0.69	5.52e-49	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs17030434	0.911	rs17030490	chr4:154738340	C/T	cg14289246	chr4:154710475	SFRP2	-0.56	-7.49	-0.38	6.18e-13	Electrocardiographic conduction measures;
LUSC	cis	rs16867335	0.947	rs16867341	chr2:181488938	C/G	cg23363182	chr2:181467187	NA	-0.48	-6.06	-0.31	3.59e-9	Survival in rectal cancer;
LUSC	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-11.21	-0.52	5.51e-25	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg19812747	chr11:111475976	SIK2	0.49	6.67	0.34	1.05e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.51	-10.33	-0.49	7e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg22598563	chr5:131563921	P4HA2	-0.27	-5.72	-0.3	2.43e-8	Blood metabolite levels;
LUSC	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.83	0.3	1.32e-8	Breast cancer;
LUSC	cis	rs877282	0.898	rs10904547	chr10:766283	C/T	cg17470449	chr10:769945	NA	0.54	7.27	0.37	2.63e-12	Uric acid levels;
LUSC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg22532475	chr10:104410764	TRIM8	-0.32	-7.17	-0.37	4.83e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9815354	0.812	rs113300894	chr3:41984243	G/C	cg03022575	chr3:42003672	ULK4	0.85	8.85	0.44	5.2e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg10523679	chr1:76189770	ACADM	0.84	11.14	0.52	1e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg16049864	chr8:95962084	TP53INP1	-0.57	-10.41	-0.5	3.53e-22	Type 2 diabetes;
LUSC	cis	rs9359856	0.564	rs17292768	chr6:90379311	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.86	-0.44	4.69e-17	Bipolar disorder;
LUSC	cis	rs7923837	0.634	rs1544210	chr10:94487801	G/A	cg25093409	chr10:94429542	NA	-0.35	-5.95	-0.31	6.82e-9	Body mass index;Multiple sclerosis;
LUSC	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.86	-0.35	3.41e-11	Inflammatory bowel disease;
LUSC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg21862992	chr11:68658383	NA	0.51	8.11	0.41	9.65e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg24449463	chr1:168025552	DCAF6	0.62	9.33	0.45	1.52e-18	Schizophrenia;
LUSC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg04450456	chr4:17643702	FAM184B	0.41	7.04	0.36	1.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg18681998	chr4:17616180	MED28	0.84	15.32	0.64	1.65e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7520050	0.966	rs11589562	chr1:46466721	C/T	cg27013360	chr6:41040518	NFYA;C6orf130	-0.43	-6.18	-0.32	1.86e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-0.85	-13.41	-0.59	4.32e-33	Refractive error;
LUSC	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg21045802	chr8:109455806	TTC35	0.43	6.67	0.34	1.06e-10	Dupuytren's disease;
LUSC	cis	rs4903604	0.581	rs41347855	chr14:78037909	C/T	cg18872420	chr14:78023429	SPTLC2	0.39	6.02	0.31	4.65e-9	Gut microbiome composition (winter);
LUSC	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg15423357	chr2:25149977	NA	0.4	7.99	0.4	2.14e-14	Body mass index;
LUSC	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg11657440	chr19:46296263	DMWD	-0.72	-11.15	-0.52	9.34e-25	Coronary artery disease;
LUSC	cis	rs6060717	0.529	rs6060535	chr20:34235522	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.23	-0.32	1.41e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs4714291	0.832	rs1923462	chr6:39976100	T/C	cg02267698	chr19:7991119	CTXN1	-0.52	-7.64	-0.39	2.27e-13	Strep throat;
LUSC	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.69	12.27	0.56	8.27e-29	White blood cell count (basophil);White blood cell count;
LUSC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18404041	chr3:52824283	ITIH1	0.54	10.27	0.49	1.09e-21	Bipolar disorder;
LUSC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08048268	chr3:133502702	NA	-0.47	-9.26	-0.45	2.58e-18	Iron status biomarkers;
LUSC	cis	rs62408225	1.000	rs55881869	chr6:90968025	C/A	cg06866423	chr6:90926672	BACH2	0.4	5.75	0.3	2.02e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs400736	0.602	rs11121090	chr1:8168634	A/G	cg25007680	chr1:8021821	PARK7	0.45	6.8	0.35	4.78e-11	Response to antidepressants and depression;
LUSC	cis	rs9420	0.961	rs12146541	chr11:57508678	G/C	cg02958346	chr11:57425731	CLP1	-0.44	-6.35	-0.33	6.86e-10	Schizophrenia;
LUSC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg08355456	chr11:67383691	NA	-0.43	-8.14	-0.41	7.73e-15	Mean corpuscular volume;
LUSC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06221963	chr1:154839813	KCNN3	-0.61	-13.87	-0.6	7.21e-35	Prostate cancer;
LUSC	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg06609049	chr19:2785107	THOP1	0.72	11.34	0.53	1.88e-25	Total cholesterol levels;
LUSC	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg02997394	chr19:33096574	ANKRD27	0.79	8.95	0.44	2.44e-17	Eosinophilic esophagitis;
LUSC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.65	11.16	0.52	8.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg24562669	chr7:97807699	LMTK2	0.36	6.23	0.32	1.4e-9	Breast cancer;
LUSC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	0.65	13.92	0.61	4.91e-35	Prudent dietary pattern;
LUSC	trans	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg26043149	chr18:55253948	FECH	-0.51	-7.47	-0.38	7.17e-13	Bone mineral density;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08941173	chr11:125034971	PKNOX2	-0.45	-6.06	-0.31	3.68e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg10117171	chr1:25599238	RHD	-0.4	-6.22	-0.32	1.45e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19717773	chr7:2847554	GNA12	-0.39	-6.41	-0.33	5.08e-10	Height;
LUSC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg00431813	chr7:1051703	C7orf50	-0.43	-6.76	-0.35	6.12e-11	Longevity;Endometriosis;
LUSC	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg17724175	chr1:150552817	MCL1	-0.34	-5.84	-0.3	1.24e-8	Tonsillectomy;
LUSC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.89	-0.31	9.56e-9	Tonsillectomy;
LUSC	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg15557168	chr22:42548783	NA	-0.43	-7.23	-0.37	3.25e-12	Cognitive function;
LUSC	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	9.65	0.47	1.31e-19	Joint mobility (Beighton score);
LUSC	cis	rs1858037	0.867	rs1039765	chr2:65614362	A/T	cg08085232	chr2:65598271	SPRED2	0.41	6.19	0.32	1.78e-9	Rheumatoid arthritis;
LUSC	cis	rs1034435	0.692	rs6008739	chr22:48892542	T/C	cg05992904	chr22:48892994	FAM19A5	-0.41	-8.26	-0.41	3.44e-15	Late-onset Alzheimer's disease;
LUSC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg12560992	chr17:57184187	TRIM37	-0.84	-15.48	-0.65	3.83e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.84	-15.97	-0.66	4.85e-43	Heart rate;
LUSC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.56	-8.68	-0.43	1.83e-16	Ulcerative colitis;
LUSC	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.24	0.37	3.07e-12	Morning vs. evening chronotype;
LUSC	cis	rs977987	0.843	rs10431974	chr16:75435461	A/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.58	-0.34	1.85e-10	Dupuytren's disease;
LUSC	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg12292205	chr6:26970375	C6orf41	-0.63	-7.39	-0.37	1.23e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg18230493	chr5:56204884	C5orf35	-0.93	-13.72	-0.6	2.66e-34	Initial pursuit acceleration;
LUSC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.38	-5.75	-0.3	2.07e-8	Tonsillectomy;
LUSC	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-1.15	-18.01	-0.7	3.78e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg03036452	chr22:46663545	TTC38	0.52	5.7	0.3	2.69e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg04287289	chr16:89883240	FANCA	0.51	7.84	0.39	6.27e-14	Vitiligo;
LUSC	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.19	-0.41	5.74e-15	Retinal vascular caliber;
LUSC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08018356	chr19:36706053	ZNF146;ZNF565	-0.42	-7.15	-0.36	5.47e-12	Electrocardiographic conduction measures;
LUSC	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg24558204	chr6:135376177	HBS1L	0.59	9.12	0.45	7.4e-18	Red blood cell count;
LUSC	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg10840412	chr1:235813424	GNG4	0.59	7.54	0.38	4.39e-13	Bipolar disorder;
LUSC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.71	10.04	0.48	6.69e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg23601095	chr6:26197514	HIST1H3D	0.75	7.59	0.38	3.21e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg02931644	chr1:25747376	RHCE	0.38	7.09	0.36	7.98e-12	Plateletcrit;Mean corpuscular volume;
LUSC	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	6.96	0.36	1.79e-11	Neuroticism;
LUSC	cis	rs829883	0.659	rs12366950	chr12:98947900	T/C	cg25150519	chr12:98850993	NA	-0.64	-8.77	-0.43	9.6e-17	Colorectal adenoma (advanced);
LUSC	cis	rs80282103	0.764	rs12268949	chr10:1104257	A/G	cg08668510	chr10:1095578	IDI1	0.73	6.41	0.33	4.88e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg24006582	chr15:45444508	DUOX1	-0.62	-9.14	-0.45	6.18e-18	Uric acid levels;
LUSC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.87	-0.31	1.07e-8	Platelet count;
LUSC	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg01881094	chr2:180872142	CWC22	-0.82	-10.69	-0.5	3.83e-23	Schizophrenia;
LUSC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06112835	chr11:68658793	MRPL21	0.52	7.61	0.38	2.87e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9796	0.558	rs6492993	chr15:41526104	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.54	-0.42	4.71e-16	Menopause (age at onset);
LUSC	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg13010199	chr12:38710504	ALG10B	0.66	10.13	0.48	3.22e-21	Bladder cancer;
LUSC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.55	5.81	0.3	1.43e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7202877	0.610	rs4536500	chr16:75343197	C/G	cg03315344	chr16:75512273	CHST6	-0.4	-5.82	-0.3	1.36e-8	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9837602	1.000	rs4075038	chr3:99680086	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-6.48	-0.33	3.27e-10	Breast cancer;
LUSC	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg20129853	chr10:51489980	NA	-0.34	-6.84	-0.35	3.8e-11	Prostate-specific antigen levels;
LUSC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs10743315	0.778	rs9805106	chr12:19372357	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.53	-6.68	-0.34	1.01e-10	Gut microbiota (bacterial taxa);
LUSC	cis	rs1784581	0.588	rs1784583	chr6:162410132	C/T	cg17173639	chr6:162384350	PARK2	-0.55	-9.5	-0.46	4.06e-19	Itch intensity from mosquito bite;
LUSC	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg02997394	chr19:33096574	ANKRD27	0.82	8.98	0.44	1.96e-17	Eosinophilic esophagitis;
LUSC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg03354898	chr7:1950403	MAD1L1	-0.42	-8.41	-0.42	1.23e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs919433	0.679	rs10931788	chr2:198531084	A/G	cg00792783	chr2:198669748	PLCL1	0.42	5.68	0.3	3e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg27661571	chr11:113659931	NA	-0.71	-7.88	-0.4	4.61e-14	Hip circumference adjusted for BMI;
LUSC	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg03929089	chr4:120376271	NA	-0.55	-6.81	-0.35	4.54e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg24154853	chr7:158122151	PTPRN2	-0.42	-8.27	-0.41	3.16e-15	Calcium levels;
LUSC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg16606324	chr3:10149918	C3orf24	0.58	8.47	0.42	8.16e-16	Alzheimer's disease;
LUSC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.89	17.08	0.68	1.8e-47	Colorectal cancer;
LUSC	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg04455712	chr21:45112962	RRP1B	0.44	8.58	0.43	3.54e-16	Mean corpuscular volume;
LUSC	cis	rs7605827	0.930	rs1035247	chr2:15617846	T/A	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.37e-17	Educational attainment (years of education);
LUSC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.25	0.32	1.28e-9	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	20.77	0.75	4.03e-62	Prudent dietary pattern;
LUSC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.82	-0.3	1.41e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg17279839	chr7:150038598	RARRES2	0.45	6.93	0.35	2.24e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg22681709	chr2:178499509	PDE11A	-0.51	-9.02	-0.44	1.5e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.76	0.84	8.98e-89	Chronic sinus infection;
LUSC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg15147215	chr3:52552868	STAB1	-0.29	-5.76	-0.3	1.93e-8	Electroencephalogram traits;
LUSC	cis	rs9837602	1.000	rs923470	chr3:99757792	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.18	0.32	1.82e-9	Breast cancer;
LUSC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.88	-14.16	-0.61	5.75e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg05283184	chr6:79620031	NA	-0.46	-8.78	-0.43	8.59e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7113850	0.541	rs80336897	chr11:24224545	G/T	ch.11.24196551F	chr11:24239977	NA	1.0	8.93	0.44	2.94e-17	Bone fracture in osteoporosis;
LUSC	trans	rs2018683	0.677	rs55718000	chr7:28975625	T/C	cg19402173	chr7:128379420	CALU	-0.47	-7.22	-0.37	3.47e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.97	-11.76	-0.54	5.73e-27	Lung cancer in ever smokers;
LUSC	cis	rs240764	0.817	rs12207086	chr6:101150463	G/A	cg09795085	chr6:101329169	ASCC3	-0.41	-6.02	-0.31	4.68e-9	Neuroticism;
LUSC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.28	-0.37	2.36e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg02475777	chr4:1388615	CRIPAK	-0.47	-7.03	-0.36	1.14e-11	Obesity-related traits;
LUSC	cis	rs10189230	0.967	rs12993766	chr2:222350321	C/T	cg14652038	chr2:222343519	EPHA4	0.33	5.93	0.31	7.56e-9	Urate levels in lean individuals;
LUSC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08219700	chr8:58056026	NA	0.66	7.76	0.39	1.04e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.7	10.66	0.5	5e-23	Aortic root size;
LUSC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00166722	chr3:10149974	C3orf24	0.54	7.0	0.36	1.43e-11	Alzheimer's disease;
LUSC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg04414720	chr1:150670196	GOLPH3L	0.53	8.39	0.42	1.43e-15	Melanoma;
LUSC	cis	rs11997175	1.000	rs11997175	chr8:33770070	A/G	ch.8.33884649F	chr8:33765107	NA	-0.53	-8.63	-0.43	2.53e-16	Body mass index;
LUSC	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg08213375	chr14:104286397	PPP1R13B	0.41	7.98	0.4	2.37e-14	Schizophrenia;
LUSC	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.47	-0.38	7.29e-13	Retinal vascular caliber;
LUSC	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg12560992	chr17:57184187	TRIM37	-0.64	-10.66	-0.5	5.06e-23	Testicular germ cell tumor;
LUSC	cis	rs67072384	1.000	rs72964198	chr11:72446464	C/T	cg04827223	chr11:72435913	ARAP1	-0.8	-7.17	-0.37	4.78e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg00857998	chr1:205179979	DSTYK	0.62	9.55	0.46	2.88e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg24642844	chr7:1081250	C7orf50	-0.79	-10.59	-0.5	8.72e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9341808	0.690	rs2322634	chr6:80874014	A/C	cg08355045	chr6:80787529	NA	0.57	9.9	0.48	1.96e-20	Sitting height ratio;
LUSC	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg04586622	chr2:25135609	ADCY3	0.41	8.52	0.42	5.67e-16	Body mass index in non-asthmatics;
LUSC	cis	rs12519773	0.526	rs4242241	chr5:92518370	C/T	cg18783429	chr5:92414398	NA	0.33	7.18	0.37	4.67e-12	Migraine;
LUSC	cis	rs11677416	1.000	rs3783555	chr2:113531093	T/C	cg27083787	chr2:113543245	IL1A	0.46	7.27	0.37	2.57e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg04414720	chr1:150670196	GOLPH3L	0.56	9.07	0.44	1.03e-17	Tonsillectomy;
LUSC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03517284	chr6:25882590	NA	-0.71	-11.67	-0.54	1.26e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg05084668	chr3:125655381	ALG1L	-0.92	-13.12	-0.58	5.09e-32	Blood pressure (smoking interaction);
LUSC	cis	rs9506514	0.509	rs9509279	chr13:21133719	C/G	cg11940495	chr13:21141764	IFT88	-0.31	-5.88	-0.31	9.94e-9	Coronary artery calcification;
LUSC	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg20283391	chr11:68216788	NA	-0.52	-7.24	-0.37	3.01e-12	Total body bone mineral density;
LUSC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg24562669	chr7:97807699	LMTK2	0.33	5.8	0.3	1.54e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4908769	0.624	rs1763839	chr1:8473336	G/A	cg00546117	chr1:8445545	RERE	-0.3	-6.07	-0.31	3.57e-9	Allergy;
LUSC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.33	0.53	2.12e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs1728785	0.681	rs4783649	chr16:68558467	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.57	-6.85	-0.35	3.63e-11	Ulcerative colitis;
LUSC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg02423579	chr7:2872169	GNA12	-0.44	-6.02	-0.31	4.66e-9	Height;
LUSC	cis	rs11756438	0.572	rs2638544	chr6:119001978	G/A	cg21191810	chr6:118973309	C6orf204	0.34	5.81	0.3	1.46e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7527798	0.592	rs11118359	chr1:207858546	T/C	cg09232269	chr1:207846808	CR1L	-0.3	-6.31	-0.33	9.11e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg12419862	chr22:24373484	LOC391322	-0.88	-14.3	-0.62	1.55e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	6.67	0.34	1.04e-10	Personality dimensions;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg05205152	chr19:15529855	AKAP8L	0.38	6.37	0.33	6.42e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.67	-10.3	-0.49	8.58e-22	Monocyte percentage of white cells;
LUSC	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.87	0.4	4.86e-14	Coffee consumption (cups per day);
LUSC	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22980127	chr19:33182716	NUDT19	0.9	12.92	0.58	3.03e-31	Red blood cell traits;
LUSC	cis	rs11997175	0.625	rs7018213	chr8:33625770	T/C	ch.8.33884649F	chr8:33765107	NA	0.45	7.18	0.37	4.54e-12	Body mass index;
LUSC	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07636037	chr3:49044803	WDR6	0.67	8.77	0.43	9.04e-17	Menarche (age at onset);
LUSC	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg23625390	chr15:77176239	SCAPER	-0.54	-8.48	-0.42	7.13e-16	Blood metabolite levels;
LUSC	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.83	-20.1	-0.74	1.83e-59	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs12575480	0.637	rs74048176	chr11:2096908	C/T	cg15541987	chr11:2077307	NA	-0.43	-6.32	-0.33	8.23e-10	Pursuit maintenance gain;
LUSC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.68	0.34	9.71e-11	Menopause (age at onset);
LUSC	cis	rs2075165	1.000	rs2075165	chr1:156215899	G/A	cg20302342	chr1:156215951	PAQR6	0.32	6.13	0.32	2.49e-9	Tonsillectomy;
LUSC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg18681998	chr4:17616180	MED28	0.83	14.91	0.63	6.86e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg11859384	chr17:80120422	CCDC57	0.37	5.74	0.3	2.09e-8	Life satisfaction;
LUSC	trans	rs539514	0.690	rs480929	chr13:76312773	G/A	cg05302441	chr11:125157402	PKNOX2	0.26	6.04	0.31	4.13e-9	Type 1 diabetes;
LUSC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg12311346	chr5:56204834	C5orf35	-0.58	-8.93	-0.44	2.89e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg11645453	chr3:52864694	ITIH4	0.34	7.97	0.4	2.52e-14	Bipolar disorder;
LUSC	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg27502298	chr12:9555721	NA	0.75	12.66	0.57	2.8e-30	IgG glycosylation;
LUSC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg16624210	chr5:671434	TPPP	0.5	6.47	0.33	3.58e-10	Obesity-related traits;
LUSC	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg16006841	chr5:176797999	RGS14	-0.67	-9.33	-0.45	1.46e-18	Urate levels in lean individuals;
LUSC	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg03342759	chr3:160939853	NMD3	-0.36	-5.7	-0.3	2.58e-8	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg03806693	chr22:41940476	POLR3H	1.0	14.38	0.62	7.59e-37	Vitiligo;
LUSC	cis	rs1124376	1.000	rs17006610	chr3:20152563	G/A	cg05072819	chr3:20081367	KAT2B	0.68	8.16	0.41	7.07e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.87	13.15	0.58	4.16e-32	Multiple sclerosis;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02257048	chr17:78880031	RPTOR	-0.39	-6.0	-0.31	5.01e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-9.85	-0.47	2.85e-20	Response to antipsychotic treatment;
LUSC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg26335602	chr6:28129616	ZNF389	0.44	5.88	0.31	9.91e-9	Parkinson's disease;
LUSC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg11812906	chr14:75593930	NEK9	-0.64	-10.48	-0.5	2.01e-22	Height;
LUSC	cis	rs1403694	0.695	rs5029975	chr3:186436918	A/G	cg12454167	chr3:186435060	KNG1	-0.29	-7.43	-0.38	9.26e-13	Blood protein levels;
LUSC	trans	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg21775007	chr8:11205619	TDH	0.46	6.64	0.34	1.3e-10	Mood instability;
LUSC	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.75	-10.22	-0.49	1.66e-21	HIV-1 control;
LUSC	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.87	0.48	2.51e-20	Migraine;Coronary artery disease;
LUSC	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg05738196	chr6:26577821	NA	0.49	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.84	15.14	0.64	8.94e-40	Menarche (age at onset);
LUSC	cis	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg18131467	chr2:239335373	ASB1	-0.72	-6.54	-0.34	2.25e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7712401	0.755	rs965821	chr5:122137708	A/G	cg19077854	chr5:122220652	SNX24	0.32	7.07	0.36	9.18e-12	Mean platelet volume;
LUSC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-7.05	-0.36	1.01e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06634786	chr22:41940651	POLR3H	-0.58	-6.52	-0.34	2.61e-10	Vitiligo;
LUSC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg02018176	chr4:1364513	KIAA1530	0.48	7.89	0.4	4.27e-14	Obesity-related traits;
LUSC	trans	rs1941687	0.669	rs56171873	chr18:31400635	G/C	cg27147174	chr7:100797783	AP1S1	-0.43	-6.56	-0.34	2.11e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs6516091	0.850	rs11699483	chr20:6048460	G/A	cg25325723	chr20:6104886	FERMT1	-0.69	-7.2	-0.37	4.01e-12	Abdominal aortic aneurysm;
LUSC	cis	rs3018712	0.532	rs948863	chr11:68420974	G/A	cg22747802	chr11:68417633	NA	-0.43	-5.94	-0.31	7.02e-9	Total body bone mineral density;
LUSC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg17971929	chr21:40555470	PSMG1	-0.67	-10.92	-0.51	6.01e-24	Cognitive function;
LUSC	cis	rs9815354	1.000	rs9818169	chr3:41860599	A/G	cg03022575	chr3:42003672	ULK4	0.58	6.52	0.34	2.55e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7192380	1.000	rs8061052	chr16:69656532	G/A	cg26679644	chr16:69762563	NA	0.34	6.14	0.32	2.41e-9	Sjögren's syndrome;
LUSC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.74	-14.3	-0.62	1.59e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg04586622	chr2:25135609	ADCY3	0.32	6.22	0.32	1.51e-9	Body mass index;
LUSC	cis	rs12541635	0.966	rs4416800	chr8:106996677	T/C	cg10147462	chr8:107024639	NA	0.55	9.97	0.48	1.14e-20	Age of smoking initiation;
LUSC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.02	0.31	4.66e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7615952	0.605	rs34865555	chr3:125304134	C/T	cg07211511	chr3:129823064	LOC729375	-0.64	-6.33	-0.33	8.06e-10	Blood pressure (smoking interaction);
LUSC	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.86	-12.35	-0.56	4.17e-29	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs7633770	0.786	rs1520489	chr3:46677519	A/G	cg11219411	chr3:46661640	NA	-0.37	-7.56	-0.38	3.92e-13	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25890275	chr11:60929200	VPS37C	0.44	6.18	0.32	1.82e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1881797	0.527	rs79724455	chr1:247646957	T/C	cg14830002	chr1:247616686	OR2B11	0.65	7.43	0.38	9.39e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-1.13	-17.64	-0.69	1.06e-49	Exhaled nitric oxide output;
LUSC	cis	rs2625529	0.591	rs7172158	chr15:72405313	T/C	cg16672083	chr15:72433130	SENP8	0.48	7.88	0.4	4.69e-14	Red blood cell count;
LUSC	cis	rs8113142	0.614	rs55647098	chr19:29148429	T/G	cg04546413	chr19:29218101	NA	0.45	6.09	0.32	3.11e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.65	-0.34	1.18e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs62400317	0.762	rs12212190	chr6:44926271	T/C	cg18551225	chr6:44695536	NA	-0.45	-7.26	-0.37	2.75e-12	Total body bone mineral density;
LUSC	cis	rs7809950	0.817	rs2712224	chr7:107181235	C/A	cg23024343	chr7:107201750	COG5	-0.69	-9.89	-0.48	2.08e-20	Coronary artery disease;
LUSC	trans	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg06521331	chr12:34319734	NA	-0.39	-5.96	-0.31	6.46e-9	Bladder cancer;
LUSC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg07741184	chr6:167504864	NA	0.37	6.72	0.35	7.82e-11	Crohn's disease;
LUSC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.13	0.36	6.11e-12	Cognitive ability;
LUSC	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-8.06	-0.4	1.36e-14	Parkinson's disease;
LUSC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	0.76	14.56	0.62	1.53e-37	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22897130	chr10:89419623	PAPSS2	-0.47	-5.99	-0.31	5.55e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg03146154	chr1:46216737	IPP	-0.51	-7.57	-0.38	3.61e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4792901	0.802	rs79934399	chr17:41571961	C/T	cg22562494	chr17:41607896	ETV4	-0.33	-6.07	-0.32	3.52e-9	Dupuytren's disease;
LUSC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.43	-0.33	4.53e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg25344623	chr2:136566232	LCT	0.37	5.71	0.3	2.51e-8	Cholesterol, total;
LUSC	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg05564266	chr6:118973597	C6orf204	0.24	5.74	0.3	2.11e-8	Electrocardiographic conduction measures;
LUSC	cis	rs7264396	1.000	rs224430	chr20:34153341	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.39	-0.37	1.17e-12	Total cholesterol levels;
LUSC	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.47	-6.44	-0.33	4.08e-10	Reticulocyte count;
LUSC	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.7	10.65	0.5	5.42e-23	Corneal astigmatism;
LUSC	cis	rs6480314	0.831	rs7904069	chr10:69980193	T/C	cg06988349	chr10:69991859	ATOH7	0.36	5.92	0.31	7.94e-9	Optic nerve measurement (disc area);
LUSC	trans	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg20129853	chr10:51489980	NA	-0.36	-7.58	-0.38	3.46e-13	Prostate-specific antigen levels;
LUSC	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg26875233	chr11:93583750	C11orf90	0.3	5.75	0.3	1.97e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg13010199	chr12:38710504	ALG10B	0.56	8.62	0.43	2.81e-16	Morning vs. evening chronotype;
LUSC	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg19875535	chr5:140030758	IK	0.37	5.67	0.3	3.1e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7833986	1.000	rs4263734	chr8:57099931	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	9.18	0.45	4.7e-18	Height;
LUSC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg00376283	chr12:123451042	ABCB9	0.65	8.33	0.41	2.18e-15	Neutrophil percentage of white cells;
LUSC	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-8.37	-0.42	1.65e-15	Body mass index;
LUSC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-7.78	-0.39	9.01e-14	Lymphocyte counts;
LUSC	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg15123519	chr2:136567270	LCT	0.4	6.12	0.32	2.64e-9	Mosquito bite size;
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg00024416	chr22:24240387	NA	-0.34	-6.22	-0.32	1.48e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg20607287	chr7:12443886	VWDE	-0.65	-6.44	-0.33	4.17e-10	Coronary artery disease;
LUSC	trans	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.4	0.42	1.29e-15	Ulcerative colitis;
LUSC	cis	rs2901656	0.677	rs10752957	chr1:172408271	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.38	7.96	0.4	2.79e-14	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs9362426	0.887	rs1209113	chr6:88079456	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	6.06	0.31	3.67e-9	Depressive episodes in bipolar disorder;
LUSC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.18	0.88	4.53e-111	Chronic sinus infection;
LUSC	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	0.99	23.49	0.79	9.94e-73	Urate levels in lean individuals;
LUSC	trans	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.5	-7.19	-0.37	4.23e-12	Monocyte count;
LUSC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg00343986	chr7:65444356	GUSB	0.47	7.07	0.36	9.07e-12	Calcium levels;
LUSC	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.57	-0.42	3.85e-16	Response to antipsychotic treatment;
LUSC	trans	rs2251301	0.882	rs55690252	chr8:11117335	A/G	cg03839776	chr17:7750866	KDM6B	0.62	5.96	0.31	6.38e-9	Response to antipsychotic therapy (extrapyramidal side effects);
LUSC	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg14530993	chr4:882597	GAK	0.73	7.54	0.38	4.37e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6464929	0.955	rs6464930	chr7:148720906	C/T	cg23583168	chr7:148888333	NA	0.46	5.8	0.3	1.54e-8	Pediatric bone mineral content (hip);
LUSC	cis	rs10504229	0.516	rs58244172	chr8:57987805	G/A	cg11062466	chr8:58055876	NA	0.38	5.68	0.3	2.98e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-0.99	-17.63	-0.69	1.24e-49	Coronary artery disease;
LUSC	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg03732007	chr1:2071316	PRKCZ	0.36	6.05	0.31	3.82e-9	Coronary artery disease;
LUSC	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg08917208	chr2:24149416	ATAD2B	0.88	9.59	0.46	2.06e-19	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg03351412	chr1:154909251	PMVK	0.53	8.19	0.41	5.74e-15	Prostate cancer;
LUSC	cis	rs74544699	1.000	rs11574452	chr4:74846661	A/C	cg06834998	chr4:74847824	PF4	-0.82	-6.26	-0.32	1.2e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	0.91	15.18	0.64	5.84e-40	Breast cancer;
LUSC	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21984481	chr17:79567631	NPLOC4	-0.72	-15.48	-0.65	3.94e-41	Eye color traits;
LUSC	cis	rs4443100	0.917	rs725984	chr22:23387642	A/G	cg21100191	chr22:23484243	RTDR1	0.47	5.69	0.3	2.8e-8	Serum parathyroid hormone levels;
LUSC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-8.1	-0.41	1.06e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg26068271	chr17:76253126	NA	0.64	11.8	0.54	4.15e-27	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-13.38	-0.59	5.59e-33	Total body bone mineral density;
LUSC	cis	rs2116941	0.523	rs17000211	chr19:10369086	C/T	cg01850179	chr19:10340795	S1PR2	0.61	10.16	0.49	2.71e-21	Pulse pressure;
LUSC	trans	rs6601327	0.571	rs7820675	chr8:9647748	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	7.53	0.38	4.67e-13	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-0.88	-15.5	-0.65	3.41e-41	Height;
LUSC	cis	rs11677416	1.000	rs1878319	chr2:113544826	G/A	cg27083787	chr2:113543245	IL1A	0.45	7.13	0.36	6.29e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs12472274	0.618	rs12477307	chr2:239110514	G/T	cg17459225	chr2:239074497	NA	0.52	8.66	0.43	2.08e-16	Phospholipid levels (plasma);
LUSC	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg27284194	chr4:1044797	NA	0.59	8.8	0.43	7.59e-17	Recombination rate (females);
LUSC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg04181038	chr4:183730758	NA	0.84	12.95	0.58	2.29e-31	Pediatric autoimmune diseases;
LUSC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg08499158	chr17:42289980	UBTF	-0.5	-8.4	-0.42	1.33e-15	Total body bone mineral density;
LUSC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg16606324	chr3:10149918	C3orf24	0.59	8.55	0.42	4.49e-16	Alzheimer's disease;
LUSC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.34	-0.46	1.36e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg22800045	chr5:56110881	MAP3K1	0.78	9.7	0.47	9.52e-20	Initial pursuit acceleration;
LUSC	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg10326726	chr10:51549505	MSMB	0.34	5.87	0.31	1.03e-8	Prostate-specific antigen levels;
LUSC	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg03342759	chr3:160939853	NMD3	-0.57	-9.84	-0.47	3.07e-20	Morning vs. evening chronotype;
LUSC	trans	rs587847	0.507	rs10518956	chr15:37808780	A/G	cg18296784	chr11:116147929	NA	0.34	6.04	0.31	4.22e-9	Intraocular pressure;
LUSC	trans	rs11165623	0.564	rs9887887	chr1:96996930	A/G	cg10631902	chr5:14652156	NA	-0.41	-6.08	-0.32	3.24e-9	Hip circumference;Waist circumference;
LUSC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg15448220	chr1:150897856	SETDB1	0.38	5.77	0.3	1.77e-8	Tonsillectomy;
LUSC	cis	rs11809207	1.000	rs11247867	chr1:26517891	C/T	cg00300879	chr1:26503847	CNKSR1	0.29	5.67	0.3	3.14e-8	Height;
LUSC	cis	rs6460942	0.915	rs17324858	chr7:12305792	G/T	cg06484146	chr7:12443880	VWDE	-0.5	-6.16	-0.32	2.04e-9	Coronary artery disease;
LUSC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg24060327	chr5:131705240	SLC22A5	-0.63	-10.78	-0.51	1.96e-23	Breast cancer;
LUSC	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg01528321	chr10:82214614	TSPAN14	0.89	13.59	0.6	8.81e-34	Post bronchodilator FEV1;
LUSC	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.86	-14.07	-0.61	1.2e-35	Schizophrenia;
LUSC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.48	7.85	0.39	5.59e-14	IgG glycosylation;
LUSC	cis	rs12295403	0.691	rs11607934	chr11:18689168	C/T	cg09887367	chr11:18690185	NA	-0.37	-7.35	-0.37	1.55e-12	Ovarian reserve;
LUSC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg12564285	chr5:131593104	PDLIM4	0.33	5.83	0.3	1.3e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs2290159	0.800	rs5746187	chr3:12659419	A/G	cg23032965	chr3:12705835	RAF1	0.74	8.94	0.44	2.75e-17	Cholesterol, total;
LUSC	cis	rs73206853	0.534	rs7131996	chr12:111073276	C/A	cg12870014	chr12:110450643	ANKRD13A	0.7	7.69	0.39	1.67e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs27434	0.561	rs35134	chr5:96159523	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-7.53	-0.38	4.91e-13	Ankylosing spondylitis;
LUSC	cis	rs78545713	0.536	rs80202565	chr6:26233882	C/G	cg23601095	chr6:26197514	HIST1H3D	0.7	6.1	0.32	2.96e-9	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs8102476	0.905	rs7250689	chr19:38753625	C/T	cg14131526	chr19:38747285	PPP1R14A	0.34	5.99	0.31	5.32e-9	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg22823121	chr1:150693482	HORMAD1	0.5	7.21	0.37	3.67e-12	Melanoma;
LUSC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg17294928	chr15:75287854	SCAMP5	-0.93	-13.63	-0.6	6.13e-34	Blood trace element (Zn levels);
LUSC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21248554	chr2:27665150	KRTCAP3	0.3	6.01	0.31	4.81e-9	Total body bone mineral density;
LUSC	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg04374321	chr14:90722782	PSMC1	0.75	12.11	0.55	3.01e-28	Mortality in heart failure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23132254	chr6:18264719	DEK	-0.46	-6.91	-0.35	2.45e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg05347473	chr6:146136440	FBXO30	-0.66	-11.3	-0.53	2.81e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg15309053	chr8:964076	NA	0.31	6.3	0.33	9.42e-10	Schizophrenia;
LUSC	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg02153584	chr22:29168773	CCDC117	0.65	9.73	0.47	7.44e-20	Lymphocyte counts;
LUSC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.86	0.6	7.98e-35	Breast cancer;
LUSC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.13	-0.48	3.41e-21	Monocyte count;
LUSC	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.59	-0.43	3.42e-16	Body mass index;
LUSC	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.38e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-7.02	-0.36	1.24e-11	Aortic root size;
LUSC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.93	0.4	3.34e-14	Parkinson's disease;
LUSC	trans	rs1949829	0.826	rs6592923	chr7:51528494	C/T	cg20941110	chr15:83953819	BNC1	0.55	6.01	0.31	4.98e-9	Wegener's granulomatosis;
LUSC	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg02175503	chr12:58329896	NA	0.57	8.76	0.43	9.8e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs10927875	0.632	rs2013745	chr1:16126676	G/A	cg21385522	chr1:16154831	NA	-0.98	-18.12	-0.7	1.33e-51	Dilated cardiomyopathy;
LUSC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.74	14.28	0.62	1.91e-36	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg10253484	chr15:75165896	SCAMP2	-0.47	-6.61	-0.34	1.52e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs10489202	0.608	rs4657733	chr1:168086434	G/A	cg24449463	chr1:168025552	DCAF6	-0.66	-10.16	-0.49	2.67e-21	Schizophrenia;
LUSC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg04800585	chr6:26043546	HIST1H2BB	0.43	6.13	0.32	2.47e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1662342	1.000	rs12606445	chr18:3255700	C/T	cg00760847	chr18:3262519	MYL12B	-0.59	-5.81	-0.3	1.44e-8	QRS duration;
LUSC	cis	rs9807989	0.507	rs2160201	chr2:103033961	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.72e-12	Asthma;
LUSC	cis	rs7084921	0.608	rs12779818	chr10:101866118	G/A	cg11888571	chr10:102027403	CWF19L1	-0.42	-5.84	-0.3	1.27e-8	Bone mineral density;
LUSC	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg03859395	chr2:55845619	SMEK2	-0.86	-16.21	-0.66	5.08e-44	Metabolic syndrome;
LUSC	trans	rs13113376	0.912	rs1493224	chr4:131147580	A/G	cg20030024	chr7:157442494	PTPRN2	0.39	6.05	0.31	3.81e-9	Intelligence;
LUSC	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.75	-0.3	1.99e-8	IgG glycosylation;
LUSC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-1.18	-12.98	-0.58	1.75e-31	Diabetic kidney disease;
LUSC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg18240062	chr17:79603768	NPLOC4	-0.69	-12.85	-0.58	5.34e-31	Eye color traits;
LUSC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	0.95	12.51	0.56	1.06e-29	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg27471124	chr11:109292789	C11orf87	0.36	6.45	0.33	3.83e-10	Schizophrenia;
LUSC	cis	rs4704187	0.687	rs13359143	chr5:74433360	T/C	cg03227963	chr5:74354835	NA	0.3	6.45	0.33	3.94e-10	Response to amphetamines;
LUSC	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg17507749	chr15:85114479	UBE2QP1	0.65	8.15	0.41	7.64e-15	Schizophrenia;
LUSC	cis	rs9921338	0.923	rs6498181	chr16:11427193	C/T	cg00044050	chr16:11439710	C16orf75	-0.49	-6.56	-0.34	2.03e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.83	-0.3	1.33e-8	Breast cancer;
LUSC	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	6.55	0.34	2.24e-10	Fibroblast growth factor basic levels;
LUSC	trans	rs2018683	0.707	rs1021690	chr7:28974488	A/G	cg19402173	chr7:128379420	CALU	-0.47	-7.23	-0.37	3.36e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs4654899	0.802	rs10916906	chr1:21255675	C/A	cg01072550	chr1:21505969	NA	-0.53	-7.73	-0.39	1.32e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg20891283	chr12:69753455	YEATS4	0.62	9.13	0.45	6.58e-18	Response to diuretic therapy;
LUSC	cis	rs7590368	0.961	rs13432104	chr2:10960661	T/C	cg15705551	chr2:10952987	PDIA6	0.58	8.0	0.4	2.11e-14	Educational attainment (years of education);
LUSC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg08470875	chr2:26401718	FAM59B	-0.65	-8.44	-0.42	9.82e-16	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.72	0.78	9.87e-70	Prudent dietary pattern;
LUSC	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.87	-0.31	1.05e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg13699009	chr12:122356056	WDR66	0.48	7.56	0.38	3.87e-13	Mean corpuscular volume;
LUSC	cis	rs17102423	0.651	rs2296316	chr14:65520246	A/G	cg11161011	chr14:65562177	MAX	-0.47	-7.15	-0.36	5.46e-12	Obesity-related traits;
LUSC	cis	rs2797685	0.898	rs697693	chr1:7886424	C/T	cg04725166	chr1:7887271	PER3	-0.46	-6.56	-0.34	1.99e-10	Crohn's disease;
LUSC	cis	rs4363385	0.867	rs310103	chr1:153042554	C/A	cg00922841	chr1:152955080	SPRR1A	-0.46	-7.74	-0.39	1.21e-13	Inflammatory skin disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20548564	chr13:28240073	POLR1D	-0.78	-6.18	-0.32	1.9e-9	Cognitive performance;
LUSC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg18681998	chr4:17616180	MED28	0.79	14.71	0.63	4.12e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg13647721	chr17:30228624	UTP6	0.59	6.0	0.31	5.22e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-8.17	-0.41	6.34e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11997175	0.546	rs10808337	chr8:33583850	T/C	ch.8.33884649F	chr8:33765107	NA	0.47	7.43	0.38	8.95e-13	Body mass index;
LUSC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg06212747	chr3:49208901	KLHDC8B	0.58	8.67	0.43	1.87e-16	Menarche (age at onset);
LUSC	cis	rs6942756	0.774	rs891545	chr7:128866616	A/C	cg02491457	chr7:128862824	NA	0.55	8.31	0.41	2.49e-15	White matter hyperintensity burden;
LUSC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.74	-12.38	-0.56	3.08e-29	Motion sickness;
LUSC	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21545522	chr1:205238299	TMCC2	0.51	9.59	0.46	2.16e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg11502198	chr6:26597334	ABT1	0.72	12.12	0.55	2.76e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21016266	chr12:122356598	WDR66	0.59	9.0	0.44	1.71e-17	Mean corpuscular volume;
LUSC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg22166914	chr1:53195759	ZYG11B	0.61	10.06	0.48	5.73e-21	Monocyte count;
LUSC	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg17470449	chr10:769945	NA	0.52	7.08	0.36	8.38e-12	Uric acid levels;
LUSC	cis	rs11168618	0.567	rs7314569	chr12:48816981	G/T	cg24011408	chr12:48396354	COL2A1	0.41	6.45	0.33	3.88e-10	Adiponectin levels;
LUSC	trans	rs208520	0.742	rs208454	chr6:66907783	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-12.9	-0.58	3.55e-31	Exhaled nitric oxide output;
LUSC	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-1.08	-24.55	-0.8	8.68e-77	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs77216612	0.840	rs11055030	chr12:12878349	G/C	cg09462578	chr12:12878428	APOLD1	-1.0	-17.14	-0.68	1.1e-47	Lymphocyte counts;
LUSC	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.45	0.33	4.01e-10	Corneal astigmatism;
LUSC	cis	rs7569084	0.522	rs906577	chr2:65596657	A/G	cg08085232	chr2:65598271	SPRED2	-0.43	-6.76	-0.35	6.04e-11	Sum eosinophil basophil counts;
LUSC	cis	rs7512552	0.839	rs3820544	chr1:150457876	A/T	cg15654264	chr1:150340011	RPRD2	0.62	10.31	0.49	8.23e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7091068	0.522	rs10882323	chr10:95483280	T/C	cg20715218	chr10:95462985	C10orf4	0.6	7.32	0.37	1.86e-12	Urinary tract infection frequency;
LUSC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08219700	chr8:58056026	NA	0.69	8.02	0.4	1.79e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg20476274	chr7:133979776	SLC35B4	0.82	14.95	0.63	4.64e-39	Mean platelet volume;
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.48	7.19	0.37	4.25e-12	Longevity;Endometriosis;
LUSC	cis	rs11039100	0.850	rs34037040	chr11:5834673	G/A	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12210905	0.841	rs116485609	chr6:26864205	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.64	-5.66	-0.3	3.25e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg25173405	chr17:45401733	C17orf57	0.37	5.92	0.31	7.98e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06112835	chr11:68658793	MRPL21	0.49	7.4	0.38	1.14e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg26102564	chr10:131424627	MGMT	-0.46	-7.17	-0.37	4.97e-12	Response to temozolomide;
LUSC	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00631329	chr6:26305371	NA	0.45	8.78	0.43	8.68e-17	Educational attainment;
LUSC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-0.88	-10.92	-0.51	5.92e-24	Vitiligo;
LUSC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.37	-5.79	-0.3	1.6e-8	Primary tooth development (time to first tooth eruption);
LUSC	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg08807101	chr21:30365312	RNF160	-0.54	-8.2	-0.41	5.09e-15	Dental caries;
LUSC	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.63	0.57	3.83e-30	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs12681287	0.640	rs13253261	chr8:87458500	T/C	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs483180	0.511	rs496198	chr1:120207177	A/G	cg19096424	chr1:120255104	PHGDH	-0.48	-6.7	-0.34	8.67e-11	Macular telangiectasia type 2;
LUSC	cis	rs77633900	0.772	rs2956873	chr15:76695305	G/A	cg21673338	chr15:77095150	SCAPER	-0.72	-6.16	-0.32	2.14e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs727505	1.000	rs10241173	chr7:124453258	A/G	cg23710748	chr7:124431027	NA	-0.41	-7.32	-0.37	1.88e-12	Lewy body disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg24094374	chr14:81685932	GTF2A1	0.76	6.34	0.33	7.27e-10	Cognitive performance;
LUSC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg13206674	chr6:150067644	NUP43	0.6	9.37	0.46	1.12e-18	Lung cancer;
LUSC	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg13256891	chr4:100009986	ADH5	0.43	6.03	0.31	4.38e-9	Alcohol dependence;
LUSC	cis	rs11031096	0.678	rs2044135	chr11:4187233	G/A	cg18678763	chr11:4115507	RRM1	-0.43	-6.04	-0.31	4.15e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	8.84	0.44	5.4e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg15017067	chr4:17643749	FAM184B	0.34	5.72	0.3	2.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.09e-18	Menopause (age at onset);
LUSC	cis	rs7707921	0.958	rs6452447	chr5:81482522	A/G	cg15871215	chr5:81402204	ATG10	0.44	6.32	0.33	8.43e-10	Breast cancer;
LUSC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	5.89	0.31	9.6e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7539542	0.556	rs4950889	chr1:202874786	T/C	cg19681188	chr1:202830198	LOC148709	0.39	5.77	0.3	1.86e-8	Mean platelet volume;
LUSC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg22907277	chr7:1156413	C7orf50	0.64	6.68	0.34	1.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg06917634	chr15:78832804	PSMA4	0.48	6.02	0.31	4.61e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.09	25.55	0.81	1.45e-80	Schizophrenia;
LUSC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg11965913	chr1:205819406	PM20D1	0.83	15.46	0.65	4.81e-41	Menarche (age at onset);
LUSC	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs476633	0.691	rs11858115	chr15:41542591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.72	-0.43	1.35e-16	Glomerular filtration rate (creatinine);
LUSC	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22980127	chr19:33182716	NUDT19	0.93	12.44	0.56	1.88e-29	Red blood cell traits;
LUSC	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg15839431	chr19:19639596	YJEFN3	-0.67	-7.34	-0.37	1.62e-12	Bipolar disorder;
LUSC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg13397359	chr6:42928475	GNMT	0.65	10.85	0.51	1.04e-23	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs13067593	1.000	rs35300952	chr3:188572797	A/G	cg17809494	chr3:188572244	LPP	0.42	5.73	0.3	2.22e-8	Immune reponse to smallpox (secreted IFN-alpha);
LUSC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	0.77	11.41	0.53	1.12e-25	Gut microbiome composition (summer);
LUSC	cis	rs7043114	0.525	rs10739927	chr9:95052081	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.46	-0.33	3.63e-10	Height;
LUSC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg09796270	chr17:17721594	SREBF1	0.42	7.51	0.38	5.43e-13	Total body bone mineral density;
LUSC	cis	rs6681460	1.000	rs6656550	chr1:67122552	C/T	cg02459107	chr1:67143332	SGIP1	0.48	9.0	0.44	1.73e-17	Presence of antiphospholipid antibodies;
LUSC	trans	rs62055045	0.528	rs62056195	chr16:71549485	A/G	cg21834679	chr15:96891026	NA	-0.43	-6.67	-0.34	1.04e-10	Schizophrenia;
LUSC	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg05163923	chr11:71159392	DHCR7	0.75	11.19	0.52	6.83e-25	Vitamin D levels;
LUSC	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.23	-0.45	3.16e-18	Morning vs. evening chronotype;
LUSC	cis	rs7119	0.717	rs12912386	chr15:77817640	T/C	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs4654899	0.680	rs4654879	chr1:21186378	G/A	cg01072550	chr1:21505969	NA	0.48	7.39	0.37	1.21e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03713592	chr11:72463424	ARAP1	0.86	10.13	0.48	3.27e-21	Type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg17366294	chr4:99064904	C4orf37	0.61	10.78	0.51	1.87e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg23791538	chr6:167370224	RNASET2	0.52	8.74	0.43	1.15e-16	Crohn's disease;
LUSC	cis	rs9318086	0.712	rs12875437	chr13:24453956	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.42	6.39	0.33	5.54e-10	Myopia (pathological);
LUSC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15506890	chr2:3487001	NA	-0.58	-9.66	-0.47	1.27e-19	Neurofibrillary tangles;
LUSC	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg09526685	chr4:187126073	CYP4V2	0.62	6.09	0.32	3.13e-9	Activated partial thromboplastin time;
LUSC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg15147215	chr3:52552868	STAB1	-0.3	-5.82	-0.3	1.36e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12826209	chr6:26865740	GUSBL1	0.67	9.27	0.45	2.35e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs983392	0.678	rs4938933	chr11:60034429	C/T	cg20284999	chr11:59952153	MS4A6A	0.38	6.48	0.33	3.19e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-1.01	-15.25	-0.64	3.13e-40	Corneal structure;
LUSC	cis	rs2303282	0.933	rs7198524	chr16:56510601	C/T	cg00500540	chr16:56394104	NA	-0.44	-7.04	-0.36	1.09e-11	Breast cancer;
LUSC	cis	rs3126085	0.935	rs1390488	chr1:152199500	T/C	cg26876637	chr1:152193138	HRNR	0.45	6.22	0.32	1.47e-9	Atopic dermatitis;
LUSC	cis	rs4363385	0.693	rs490553	chr1:153033277	A/G	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.28	-0.37	2.39e-12	Inflammatory skin disease;
LUSC	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg05985134	chr18:33552581	C18orf21	0.52	7.21	0.37	3.66e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs62458065	0.513	rs7788809	chr7:32552622	T/A	cg20159608	chr7:32802032	NA	-0.68	-8.68	-0.43	1.77e-16	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-7.22	-0.37	3.55e-12	Response to antipsychotic treatment;
LUSC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.11	0.52	1.27e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg04998671	chr14:104000505	TRMT61A	-0.42	-6.22	-0.32	1.51e-9	Reticulocyte count;
LUSC	cis	rs1775715	0.870	rs7912121	chr10:32228995	T/G	cg26784012	chr10:32216390	ARHGAP12	0.41	6.9	0.35	2.59e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3755132	1.000	rs3755132	chr2:15729820	T/G	cg12888861	chr2:15731646	DDX1	0.51	7.32	0.37	1.81e-12	Wilms tumor;
LUSC	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg02569458	chr12:86230093	RASSF9	0.49	8.22	0.41	4.69e-15	Major depressive disorder;
LUSC	cis	rs858239	0.601	rs4440529	chr7:23168751	G/C	cg23682824	chr7:23144976	KLHL7	0.41	5.86	0.31	1.13e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-7.55	-0.38	4.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg22437258	chr11:111473054	SIK2	0.5	6.94	0.36	2.04e-11	Primary sclerosing cholangitis;
LUSC	trans	rs10492201	0.529	rs4913390	chr12:68387476	C/T	cg21566642	chr2:233284661	NA	-0.39	-6.03	-0.31	4.28e-9	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs28647808	0.881	rs41316982	chr9:136259117	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-0.98	-13.17	-0.58	3.39e-32	Vitiligo;
LUSC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg18230493	chr5:56204884	C5orf35	0.58	8.88	0.44	4.15e-17	Type 2 diabetes;
LUSC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg00546932	chr16:1947055	NA	-0.38	-5.67	-0.3	3.17e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs2286885	1.000	rs10733679	chr9:129242416	C/T	cg15282417	chr9:129245246	FAM125B	0.35	5.93	0.31	7.38e-9	Intraocular pressure;
LUSC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.09	0.52	1.58e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.72	-11.11	-0.52	1.34e-24	Cocaine dependence;
LUSC	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg17757837	chr7:157058334	UBE3C	0.82	13.03	0.58	1.18e-31	Body mass index;
LUSC	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg12179176	chr11:130786555	SNX19	-0.64	-10.08	-0.48	4.94e-21	Schizophrenia;
LUSC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg04414720	chr1:150670196	GOLPH3L	0.48	7.76	0.39	1.02e-13	Melanoma;
LUSC	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.53	-10.52	-0.5	1.51e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	1.11	13.8	0.6	1.37e-34	Nonalcoholic fatty liver disease;
LUSC	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg27129171	chr3:47204927	SETD2	-0.68	-10.95	-0.51	4.63e-24	Colorectal cancer;
LUSC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg26566898	chr11:117069891	TAGLN	0.49	8.07	0.4	1.3e-14	Blood protein levels;
LUSC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg18681998	chr4:17616180	MED28	0.86	15.73	0.65	4.21e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-11.8	-0.54	4.28e-27	Colorectal cancer;
LUSC	cis	rs870825	0.550	rs28525282	chr4:185631468	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.12	0.58	5.24e-32	Blood protein levels;
LUSC	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.63	-0.47	1.55e-19	Multiple sclerosis;
LUSC	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg21775007	chr8:11205619	TDH	0.45	6.34	0.33	7.5e-10	Myopia (pathological);
LUSC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.65	0.5	5.24e-23	Heart rate;
LUSC	cis	rs4343996	0.905	rs10233166	chr7:3343382	A/G	cg21248987	chr7:3385318	SDK1	0.41	6.93	0.35	2.21e-11	Motion sickness;
LUSC	cis	rs922692	0.773	rs2904220	chr15:79076704	G/T	cg00540400	chr15:79124168	NA	-0.41	-7.06	-0.36	9.95e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-6.1	-0.32	2.9e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9372253	0.843	rs9386895	chr6:110719632	T/A	cg00083206	chr6:110721305	DDO	-0.46	-8.42	-0.42	1.1e-15	Platelet distribution width;
LUSC	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.86	-0.35	3.42e-11	Morning vs. evening chronotype;
LUSC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	9.62	0.47	1.65e-19	Height;
LUSC	cis	rs516243	0.806	rs7545228	chr1:10740303	G/C	cg02903756	chr1:10750680	CASZ1	-0.5	-8.78	-0.43	8.63e-17	Migraine - clinic-based;
LUSC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg14343924	chr8:8086146	FLJ10661	0.45	6.3	0.33	9.64e-10	Mood instability;
LUSC	cis	rs17336368	1.000	rs17336368	chr6:44751668	G/A	cg18551225	chr6:44695536	NA	-0.49	-8.42	-0.42	1.14e-15	Chin dimples;
LUSC	trans	rs1994135	0.617	rs10743824	chr12:33733764	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.19	0.37	4.27e-12	Resting heart rate;
LUSC	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg18232548	chr7:50535776	DDC	-0.7	-11.03	-0.52	2.54e-24	Response to zileuton treatment in asthma (FEV1 change interaction);
LUSC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg26513180	chr16:89883248	FANCA	-0.58	-8.92	-0.44	3.14e-17	Vitiligo;
LUSC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12292205	chr6:26970375	C6orf41	-0.59	-7.58	-0.38	3.39e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg13256891	chr4:100009986	ADH5	-0.44	-6.07	-0.32	3.55e-9	Alcohol dependence;
LUSC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03060546	chr3:49711283	APEH	0.67	7.79	0.39	8.37e-14	Menarche (age at onset);
LUSC	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-7.94	-0.4	3.02e-14	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg22709100	chr7:91322751	NA	0.39	5.86	0.31	1.08e-8	Breast cancer;
LUSC	trans	rs12571093	0.803	rs17297418	chr10:70031651	A/G	cg04882175	chr6:131122610	NA	0.56	6.51	0.34	2.75e-10	Optic nerve measurement (disc area);
LUSC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg26695010	chr11:65641043	EFEMP2	0.54	8.03	0.4	1.64e-14	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-10.33	-0.49	6.89e-22	Body mass index;
LUSC	cis	rs6750047	0.719	rs100489	chr2:38266478	T/C	cg07380506	chr2:38303506	CYP1B1	-0.44	-5.98	-0.31	5.79e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs7215564	0.908	rs36077104	chr17:78661757	T/A	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	trans	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg02800362	chr5:177631904	HNRNPAB	0.88	13.12	0.58	5.45e-32	Obesity-related traits;
LUSC	cis	rs2625529	0.526	rs1035744	chr15:72566615	C/T	cg16672083	chr15:72433130	SENP8	0.46	7.48	0.38	6.56e-13	Red blood cell count;
LUSC	cis	rs10979	0.597	rs9496684	chr6:143908687	C/A	cg25407410	chr6:143891975	LOC285740	-0.65	-8.17	-0.41	6.6e-15	Hypospadias;
LUSC	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg11584989	chr19:19387371	SF4	0.59	7.01	0.36	1.33e-11	Bipolar disorder;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg20913137	chr8:145691627	CYHR1;KIFC2	0.37	6.26	0.32	1.16e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg02018176	chr4:1364513	KIAA1530	-0.57	-9.85	-0.47	2.92e-20	Obesity-related traits;
LUSC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg25039879	chr17:56429692	SUPT4H1	0.69	9.17	0.45	5.1e-18	Cognitive test performance;
LUSC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.66	0.34	1.11e-10	Lung cancer;
LUSC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	9.43	0.46	7.11e-19	Hip circumference adjusted for BMI;
LUSC	trans	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	7.83	0.39	6.49e-14	Retinal vascular caliber;
LUSC	cis	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg06521331	chr12:34319734	NA	-0.46	-7.33	-0.37	1.72e-12	Morning vs. evening chronotype;
LUSC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-18.08	-0.7	2.04e-51	Coronary artery disease;
LUSC	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-6.98	-0.36	1.58e-11	Monocyte percentage of white cells;
LUSC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.46e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.69	11.13	0.52	1.13e-24	Coronary artery disease;
LUSC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg12002119	chr2:101014098	CHST10	0.36	5.94	0.31	7.26e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4851254	0.961	rs13022707	chr2:100734946	C/A	cg07810366	chr2:100720526	AFF3	-0.38	-5.97	-0.31	6.21e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs77633900	0.772	rs2957611	chr15:76704878	C/T	cg21673338	chr15:77095150	SCAPER	-0.7	-5.99	-0.31	5.4e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg06521331	chr12:34319734	NA	-0.4	-6.27	-0.32	1.11e-9	Morning vs. evening chronotype;
LUSC	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	8.86e-24	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg26384229	chr12:38710491	ALG10B	0.55	8.81	0.43	7.02e-17	Morning vs. evening chronotype;
LUSC	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	6.48	0.33	3.38e-10	Height;
LUSC	cis	rs2282032	0.883	rs10143036	chr14:90774914	T/G	cg14092571	chr14:90743983	NA	0.48	6.23	0.32	1.43e-9	Longevity;
LUSC	cis	rs793571	0.522	rs11071398	chr15:59120077	A/G	cg05156742	chr15:59063176	FAM63B	0.55	8.51	0.42	6.11e-16	Schizophrenia;
LUSC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg00166722	chr3:10149974	C3orf24	-0.38	-5.66	-0.3	3.3e-8	Alzheimer's disease;
LUSC	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06002616	chr8:101225028	SPAG1	-0.43	-7.09	-0.36	8.24e-12	Atrioventricular conduction;
LUSC	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	10.29	0.49	9.47e-22	Hemoglobin concentration;
LUSC	trans	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg25214090	chr10:38739885	LOC399744	-0.42	-6.18	-0.32	1.92e-9	Corneal astigmatism;
LUSC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.51	-6.77	-0.35	5.75e-11	Tonsillectomy;
LUSC	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg15133208	chr4:90757351	SNCA	-0.53	-8.16	-0.41	6.98e-15	Neuroticism;
LUSC	cis	rs9815354	0.812	rs73069208	chr3:41939198	C/T	cg03022575	chr3:42003672	ULK4	0.83	8.64	0.43	2.32e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs360798	0.512	rs7562149	chr2:63008414	A/G	cg17519650	chr2:63277830	OTX1	-0.48	-6.85	-0.35	3.63e-11	Coronary artery disease;
LUSC	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg21775007	chr8:11205619	TDH	0.46	6.68	0.34	9.8e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7804356	0.906	rs3801828	chr7:26855284	C/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.39	-0.46	9.83e-19	Schizophrenia;
LUSC	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg05347473	chr6:146136440	FBXO30	0.48	7.85	0.39	5.78e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6693567	0.565	rs1694379	chr1:150292417	C/A	cg15654264	chr1:150340011	RPRD2	0.45	7.25	0.37	2.89e-12	Migraine;
LUSC	cis	rs10992471	0.639	rs10125587	chr9:95499882	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-6.84	-0.35	3.73e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg20848291	chr7:100343083	ZAN	-0.59	-7.99	-0.4	2.26e-14	Other erythrocyte phenotypes;
LUSC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg13560548	chr3:10150139	C3orf24	0.5	7.05	0.36	1.01e-11	Alzheimer's disease;
LUSC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg02454025	chr1:11042201	C1orf127	0.91	16.95	0.68	6.13e-47	Ewing sarcoma;
LUSC	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg02958346	chr11:57425731	CLP1	-0.43	-6.28	-0.32	1.06e-9	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg25124228	chr12:125621409	AACS	-0.41	-5.68	-0.3	2.97e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.74	-0.35	6.76e-11	Triglycerides;
LUSC	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.93	12.09	0.55	3.65e-28	Exhaled nitric oxide output;
LUSC	trans	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.43	5.99	0.31	5.48e-9	Corneal astigmatism;
LUSC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-8.46	-0.42	8.68e-16	Longevity;Endometriosis;
LUSC	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.44	-6.89	-0.35	2.85e-11	Tonsillectomy;
LUSC	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg08213375	chr14:104286397	PPP1R13B	0.45	8.68	0.43	1.8e-16	Schizophrenia;
LUSC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg02772935	chr3:125709198	NA	-0.48	-5.78	-0.3	1.67e-8	Blood pressure (smoking interaction);
LUSC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg20607798	chr8:58055168	NA	0.5	5.96	0.31	6.57e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7246967	0.673	rs4933026	chr19:22874492	A/T	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.34	-0.42	2.02e-15	Mood instability;
LUSC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.78	12.29	0.56	6.96e-29	Menopause (age at onset);
LUSC	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22590775	chr19:49891494	CCDC155	-0.48	-6.67	-0.34	1.05e-10	Multiple sclerosis;
LUSC	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg22709100	chr7:91322751	NA	-0.39	-5.76	-0.3	1.89e-8	Breast cancer;
LUSC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg00033643	chr7:134001901	SLC35B4	0.44	6.64	0.34	1.27e-10	Mean platelet volume;
LUSC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.49	7.35	0.37	1.51e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	6.71	0.34	8.33e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs877282	0.629	rs78997110	chr10:764388	A/G	cg17470449	chr10:769945	NA	0.52	6.81	0.35	4.47e-11	Uric acid levels;
LUSC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg11843238	chr5:131593191	PDLIM4	0.39	6.54	0.34	2.28e-10	Breast cancer;
LUSC	cis	rs7605827	0.634	rs13416086	chr2:15688107	T/C	cg19274914	chr2:15703543	NA	-0.45	-8.05	-0.4	1.43e-14	Educational attainment (years of education);
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	11.08	0.52	1.64e-24	Lymphocyte counts;
LUSC	cis	rs4704187	0.687	rs4340901	chr5:74404905	C/T	cg03227963	chr5:74354835	NA	0.33	7.1	0.36	7.73e-12	Response to amphetamines;
LUSC	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg00262122	chr8:11665843	FDFT1	-0.44	-6.66	-0.34	1.13e-10	Morning vs. evening chronotype;
LUSC	trans	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg18187862	chr3:45730750	SACM1L	0.58	7.55	0.38	4.07e-13	Primary sclerosing cholangitis;
LUSC	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg01097406	chr16:89675127	NA	0.35	6.96	0.36	1.77e-11	Hemoglobin concentration;
LUSC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.19	-13.56	-0.6	1.16e-33	Diabetic kidney disease;
LUSC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.53	0.6	1.46e-33	Platelet count;
LUSC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg13395646	chr4:1353034	KIAA1530	-0.58	-9.16	-0.45	5.38e-18	Longevity;
LUSC	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.81	0.51	1.45e-23	Colorectal cancer;
LUSC	cis	rs113835537	0.529	rs57207756	chr11:66270360	C/T	cg24851651	chr11:66362959	CCS	0.53	7.71	0.39	1.47e-13	Airway imaging phenotypes;
LUSC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg12751644	chr20:60527061	NA	-0.33	-5.89	-0.31	9.2e-9	Body mass index;
LUSC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg05861140	chr6:150128134	PCMT1	-0.39	-6.22	-0.32	1.52e-9	Lung cancer;
LUSC	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg03651054	chr13:50194643	NA	0.36	6.23	0.32	1.38e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26314531	chr2:26401878	FAM59B	0.74	10.06	0.48	5.92e-21	Gut microbiome composition (summer);
LUSC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg03036452	chr22:46663545	TTC38	0.57	5.79	0.3	1.63e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.37	0.53	1.47e-25	Prudent dietary pattern;
LUSC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg13628971	chr7:2884303	GNA12	0.48	6.69	0.34	9.15e-11	Height;
LUSC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.67	0.43	1.92e-16	Cognitive test performance;
LUSC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg08999081	chr20:33150536	PIGU	0.43	8.01	0.4	1.92e-14	Coronary artery disease;
LUSC	cis	rs6960043	0.818	rs10228796	chr7:15064190	C/G	cg19272540	chr7:15055459	NA	-0.32	-7.79	-0.39	8.77e-14	Type 2 diabetes;
LUSC	cis	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg06521331	chr12:34319734	NA	-0.35	-5.7	-0.3	2.61e-8	Morning vs. evening chronotype;
LUSC	cis	rs1971762	0.563	rs10219725	chr12:54080865	T/G	cg23533419	chr12:54090519	NA	-0.38	-6.2	-0.32	1.64e-9	Height;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12679980	chr5:43557583	PAIP1	-0.47	-6.09	-0.32	3.05e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs6601327	0.585	rs11249934	chr8:9510830	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	6.49	0.33	3.04e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.58e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4853525	0.522	rs62179717	chr2:191590813	T/G	cg11845111	chr2:191398756	TMEM194B	-0.43	-5.78	-0.3	1.75e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg27284194	chr4:1044797	NA	0.6	9.01	0.44	1.61e-17	Recombination rate (females);
LUSC	cis	rs7512552	0.966	rs1122967	chr1:150258838	C/G	cg15654264	chr1:150340011	RPRD2	-0.61	-10.05	-0.48	6e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24549020	chr5:56110836	MAP3K1	-0.44	-5.87	-0.31	1.04e-8	Initial pursuit acceleration;
LUSC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg06454157	chr6:167490870	NA	-0.3	-7.03	-0.36	1.19e-11	Crohn's disease;
LUSC	cis	rs9837602	1.000	rs6790535	chr3:99807735	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.31	0.33	8.83e-10	Breast cancer;
LUSC	trans	rs11039798	1.000	rs7942042	chr11:48520270	A/G	cg03929089	chr4:120376271	NA	0.65	6.07	0.32	3.39e-9	Axial length;
LUSC	cis	rs72781680	0.716	rs6731314	chr2:24048338	C/T	cg08917208	chr2:24149416	ATAD2B	-0.6	-6.89	-0.35	2.84e-11	Lymphocyte counts;
LUSC	cis	rs1832871	0.630	rs11754501	chr6:158710451	A/G	cg07165851	chr6:158734300	TULP4	0.45	6.9	0.35	2.66e-11	Height;
LUSC	cis	rs113835537	0.529	rs7928882	chr11:66234765	C/T	cg24851651	chr11:66362959	CCS	0.54	8.27	0.41	3.33e-15	Airway imaging phenotypes;
LUSC	cis	rs7000551	0.689	rs6997299	chr8:22324268	T/C	cg12081754	chr8:22256438	SLC39A14	0.46	6.91	0.35	2.48e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg02428538	chr16:24856791	SLC5A11	-0.6	-6.75	-0.35	6.4e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21016266	chr12:122356598	WDR66	0.63	9.43	0.46	7.11e-19	Mean corpuscular volume;
LUSC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.74	0.3	2.13e-8	Personality dimensions;
LUSC	cis	rs829883	0.621	rs11109516	chr12:98921035	G/A	cg25150519	chr12:98850993	NA	-0.63	-8.64	-0.43	2.36e-16	Colorectal adenoma (advanced);
LUSC	cis	rs6496667	0.510	rs7495784	chr15:91068882	T/C	cg10434728	chr15:90938212	IQGAP1	-0.35	-6.44	-0.33	4.15e-10	Rheumatoid arthritis;
LUSC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	8.63	0.43	2.59e-16	Menarche (age at onset);
LUSC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg08859206	chr1:53392774	SCP2	0.46	7.68	0.39	1.78e-13	Monocyte count;
LUSC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg13047869	chr3:10149882	C3orf24	0.59	8.52	0.42	5.61e-16	Alzheimer's disease;
LUSC	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg03676636	chr4:99064102	C4orf37	0.3	6.11	0.32	2.75e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.94	0.48	1.4e-20	Bipolar disorder;
LUSC	trans	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg07211511	chr3:129823064	LOC729375	-1.22	-20.76	-0.75	4.52e-62	Blood pressure (smoking interaction);
LUSC	cis	rs1891275	0.515	rs10786010	chr10:93443773	G/A	cg07889827	chr10:93443413	NA	-0.38	-8.55	-0.42	4.34e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.71	0.51	3.33e-23	Monocyte percentage of white cells;
LUSC	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.61	0.5	7.28e-23	Colorectal cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16584020	chr19:3573832	HMG20B	-0.46	-5.98	-0.31	5.8e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg10018233	chr7:150070692	REPIN1	-0.4	-6.67	-0.34	1.05e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg09904177	chr6:26538194	HMGN4	-0.7	-6.4	-0.33	5.27e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12893597	0.821	rs12896434	chr14:76816746	C/T	cg20290672	chr14:76816747	NA	-0.32	-5.64	-0.3	3.57e-8	Maximal oxygen uptake response;
LUSC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg26513180	chr16:89883248	FANCA	0.91	17.76	0.7	3.84e-50	Vitiligo;
LUSC	cis	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05901451	chr6:126070800	HEY2	-0.57	-8.56	-0.42	4.29e-16	Endometrial cancer;
LUSC	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-7.05	-0.36	1.04e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06634786	chr22:41940651	POLR3H	-0.55	-6.44	-0.33	4.06e-10	Vitiligo;
LUSC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg14582100	chr15:45693742	SPATA5L1	0.55	9.61	0.47	1.85e-19	Homoarginine levels;
LUSC	cis	rs977987	0.778	rs4888413	chr16:75443223	C/A	cg04384234	chr16:75411784	CFDP1	-0.41	-6.61	-0.34	1.52e-10	Dupuytren's disease;
LUSC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18404041	chr3:52824283	ITIH1	-0.59	-11.67	-0.54	1.26e-26	Bipolar disorder;
LUSC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg24562669	chr7:97807699	LMTK2	0.34	6.06	0.31	3.74e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg11062466	chr8:58055876	NA	0.5	6.06	0.31	3.61e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1018697	0.518	rs2482506	chr10:104563743	C/G	cg04362960	chr10:104952993	NT5C2	-0.68	-8.51	-0.42	6.09e-16	Colorectal adenoma (advanced);
LUSC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-0.97	-14.26	-0.62	2.33e-36	Vitiligo;
LUSC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.43	-5.83	-0.3	1.33e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs71435601	0.657	rs67599264	chr2:21418083	G/A	cg20757404	chr19:378427	NA	-0.42	-6.33	-0.33	7.97e-10	Cholesterol, total;
LUSC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg03115019	chr17:80708279	FN3K	-0.44	-7.02	-0.36	1.22e-11	Glycated hemoglobin levels;
LUSC	cis	rs2067615	0.599	rs3759310	chr12:107166122	C/G	cg15890332	chr12:107067104	RFX4	0.34	6.35	0.33	7.22e-10	Heart rate;
LUSC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg12257692	chr3:49977190	RBM6	-0.26	-7.32	-0.37	1.82e-12	Body mass index;
LUSC	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.63	-8.13	-0.41	8.49e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg17173187	chr15:85201210	NMB	-0.31	-6.35	-0.33	6.85e-10	P wave terminal force;
LUSC	trans	rs28735056	1.000	rs28865701	chr18:77620911	A/G	cg03973167	chr4:185394988	IRF2	0.44	6.17	0.32	1.96e-9	Schizophrenia;
LUSC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg11812906	chr14:75593930	NEK9	-0.67	-10.97	-0.51	4.01e-24	Height;
LUSC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg13319975	chr6:146136371	FBXO30	0.5	7.44	0.38	8.58e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg03161606	chr19:29218774	NA	0.57	6.89	0.35	2.76e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	trans	rs2786098	0.656	rs10922256	chr1:197545307	C/T	cg16005942	chr6:160526640	IGF2R	0.51	6.05	0.31	3.93e-9	Asthma;
LUSC	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg24375607	chr4:120327624	NA	0.76	12.15	0.55	2.15e-28	Corneal astigmatism;
LUSC	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.26	-27.65	-0.83	2.31e-88	Exhaled nitric oxide output;
LUSC	cis	rs12369635	0.929	rs3851667	chr12:129550552	G/T	cg01909103	chr12:129572610	TMEM132D	0.63	6.4	0.33	5.31e-10	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.67	11.22	0.52	5.24e-25	Bone mineral density;
LUSC	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg26597838	chr10:835615	NA	-0.69	-10.87	-0.51	9.11e-24	Eosinophil percentage of granulocytes;
LUSC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg05425664	chr17:57184151	TRIM37	-0.53	-8.35	-0.42	1.9e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.17e-10	Life satisfaction;
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg14004847	chr7:1930337	MAD1L1	-0.58	-9.04	-0.44	1.34e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs865483	0.860	rs860468	chr17:35793286	G/C	cg06716730	chr17:35851459	DUSP14	0.27	5.92	0.31	7.89e-9	Monocyte count;
LUSC	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-7.11	-0.36	6.95e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2348418	0.864	rs2137071	chr12:28716730	T/C	cg13890972	chr12:28721907	NA	-0.33	-5.75	-0.3	2.06e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg17376030	chr22:41985996	PMM1	0.51	6.03	0.31	4.44e-9	Vitiligo;
LUSC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.36	-0.37	1.45e-12	Height;
LUSC	cis	rs738321	0.725	rs9622738	chr22:38542346	G/A	cg25457927	chr22:38595422	NA	-0.42	-8.1	-0.41	1.01e-14	Breast cancer;
LUSC	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.3	-0.37	2.11e-12	Triglycerides;
LUSC	cis	rs9296092	0.538	rs9461882	chr6:33520221	A/C	cg13560919	chr6:33536144	NA	-0.82	-15.68	-0.65	6.77e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26314531	chr2:26401878	FAM59B	-0.67	-9.09	-0.45	8.85e-18	Gut microbiome composition (summer);
LUSC	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg11645453	chr3:52864694	ITIH4	0.47	10.77	0.51	2.03e-23	Schizophrenia;
LUSC	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg12002119	chr2:101014098	CHST10	0.35	5.74	0.3	2.07e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg07930552	chr6:133119739	C6orf192	0.83	7.74	0.39	1.16e-13	Type 2 diabetes nephropathy;
LUSC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18252515	chr7:66147081	NA	-0.4	-5.75	-0.3	2e-8	Aortic root size;
LUSC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.69	10.74	0.51	2.57e-23	Obesity-related traits;
LUSC	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg08330031	chr10:104623503	C10orf32	0.32	5.69	0.3	2.76e-8	Arsenic metabolism;
LUSC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.68	0.63	5.52e-38	Menopause (age at onset);
LUSC	cis	rs4631830	0.863	rs2926494	chr10:51517356	T/C	cg16070123	chr10:51489643	NA	-0.51	-7.91	-0.4	3.78e-14	Prostate-specific antigen levels;
LUSC	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.84	-0.35	3.74e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.23	0.56	1.14e-28	Prudent dietary pattern;
LUSC	cis	rs9650657	0.769	rs2116093	chr8:10613299	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.09	-0.32	3.17e-9	Neuroticism;
LUSC	cis	rs6599077	0.616	rs9883358	chr3:40175631	A/G	cg13683864	chr3:40499215	RPL14	-0.54	-6.78	-0.35	5.54e-11	Sleep-related phenotypes;
LUSC	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg13390004	chr1:15929781	NA	0.42	7.0	0.36	1.43e-11	Systolic blood pressure;
LUSC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.2	-0.32	1.68e-9	Menopause (age at onset);
LUSC	cis	rs10733682	0.659	rs13292976	chr9:129467340	C/T	cg00232160	chr9:129468157	NA	0.43	8.09	0.4	1.13e-14	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg24788636	chr1:40562667	PPT1	0.33	6.26	0.32	1.16e-9	Tuberculosis;
LUSC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg13939156	chr17:80058883	NA	-0.33	-6.39	-0.33	5.53e-10	Life satisfaction;
LUSC	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.68	-0.67	7.09e-46	Exhaled nitric oxide output;
LUSC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.37	0.33	6.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.52	-0.5	1.54e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs67072384	0.818	rs1872127	chr11:72465085	G/A	cg04827223	chr11:72435913	ARAP1	-0.73	-6.35	-0.33	7.13e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.62e-9	Aortic root size;
LUSC	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg09953122	chr20:23471693	CST8	-0.67	-5.72	-0.3	2.37e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs72634258	0.796	rs10746475	chr1:8168261	T/A	cg00042356	chr1:8021962	PARK7	-0.54	-6.65	-0.34	1.19e-10	Inflammatory bowel disease;
LUSC	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.31e-41	Bladder cancer;
LUSC	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2.04e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs4253772	0.530	rs11090875	chr22:46785301	C/T	cg24881330	chr22:46731750	TRMU	0.84	6.38	0.33	5.92e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg12463550	chr7:65579703	CRCP	-0.43	-6.36	-0.33	6.61e-10	Aortic root size;
LUSC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg02487422	chr3:49467188	NICN1	0.43	6.82	0.35	4.23e-11	Resting heart rate;
LUSC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg03929089	chr4:120376271	NA	0.82	11.67	0.54	1.27e-26	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.58	9.54	0.46	3.02e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.17	-0.32	1.95e-9	Electroencephalogram traits;
LUSC	trans	rs11039798	1.000	rs11039798	chr11:48540223	G/A	cg15704280	chr7:45808275	SEPT13	0.75	6.44	0.33	4.2e-10	Axial length;
LUSC	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg13813247	chr22:41461852	NA	-0.37	-6.56	-0.34	2.04e-10	Neuroticism;
LUSC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg18240062	chr17:79603768	NPLOC4	0.58	10.19	0.49	2.01e-21	Eye color traits;
LUSC	cis	rs7589342	0.839	rs1465641	chr2:106438936	C/T	cg14210321	chr2:106509881	NCK2	-0.53	-7.98	-0.4	2.44e-14	Addiction;
LUSC	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-12.49	-0.56	1.23e-29	Total body bone mineral density;
LUSC	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06481639	chr22:41940642	POLR3H	-0.47	-5.78	-0.3	1.71e-8	Vitiligo;
LUSC	cis	rs62400317	0.826	rs12205642	chr6:45331765	T/C	cg18551225	chr6:44695536	NA	-0.44	-7.32	-0.37	1.92e-12	Total body bone mineral density;
LUSC	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.55	8.28	0.41	2.98e-15	Colorectal cancer;
LUSC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.43	0.53	9.29e-26	Prudent dietary pattern;
LUSC	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.55	-0.34	2.12e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7903847	0.656	rs61861861	chr10:99143619	C/T	cg20016023	chr10:99160130	RRP12	-0.28	-6.15	-0.32	2.17e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6723226	0.572	rs176404	chr2:32638846	T/C	cg02381751	chr2:32503542	YIPF4	-0.51	-7.95	-0.4	2.95e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08677398	chr8:58056175	NA	0.54	7.01	0.36	1.34e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg08085267	chr17:45401833	C17orf57	0.6	10.0	0.48	9.4e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg23649088	chr2:200775458	C2orf69	-0.43	-6.42	-0.33	4.55e-10	QT interval;
LUSC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg16393715	chr7:1948819	MAD1L1	0.39	6.72	0.34	8.09e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.53	0.34	2.52e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9473147	0.543	rs9296558	chr6:47451883	C/T	cg02130027	chr6:47444894	CD2AP	0.36	5.85	0.3	1.2e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs3820928	0.874	rs4234064	chr2:227857497	G/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.63	-0.39	2.47e-13	Pulmonary function;
LUSC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg17724175	chr1:150552817	MCL1	0.36	6.61	0.34	1.56e-10	Tonsillectomy;
LUSC	trans	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg07393940	chr7:158741817	NA	0.38	6.91	0.35	2.53e-11	Life satisfaction;
LUSC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg02466173	chr16:30829666	NA	-0.68	-16.48	-0.67	4.71e-45	Dementia with Lewy bodies;
LUSC	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg14092571	chr14:90743983	NA	-0.35	-5.74	-0.3	2.1e-8	Mortality in heart failure;
LUSC	cis	rs7180079	1.000	rs8032196	chr15:64515822	A/C	cg08069370	chr15:64387884	SNX1	-0.54	-5.79	-0.3	1.63e-8	Monocyte count;
LUSC	cis	rs68170813	0.652	rs17482543	chr7:107169174	C/G	cg24556660	chr7:106842632	COG5;HBP1	-0.45	-5.65	-0.3	3.52e-8	Coronary artery disease;
LUSC	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg20307385	chr11:47447363	PSMC3	-0.43	-6.3	-0.33	9.64e-10	Subjective well-being;
LUSC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-6.7	-0.34	8.72e-11	Tonsillectomy;
LUSC	cis	rs1639906	1.000	rs1639906	chr7:2219966	T/C	cg18044113	chr7:2236405	MAD1L1	-0.33	-6.2	-0.32	1.66e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg13010344	chr12:123464640	ARL6IP4	0.45	6.76	0.35	6.04e-11	Neutrophil percentage of white cells;
LUSC	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg11189052	chr15:85197271	WDR73	0.53	5.98	0.31	5.81e-9	Schizophrenia;
LUSC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg18758796	chr5:131593413	PDLIM4	0.43	7.28	0.37	2.4e-12	Breast cancer;
LUSC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg05623727	chr3:50126028	RBM5	0.34	6.39	0.33	5.71e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg01689657	chr7:91764605	CYP51A1	0.34	6.12	0.32	2.69e-9	Breast cancer;
LUSC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg03676636	chr4:99064102	C4orf37	0.34	7.42	0.38	9.87e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7923609	0.967	rs10761766	chr10:65190327	G/A	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.01e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.9	-0.31	8.73e-9	Platelet count;
LUSC	cis	rs6066835	1.000	rs56343427	chr20:47355273	C/T	cg18078177	chr20:47281410	PREX1	0.72	6.23	0.32	1.42e-9	Multiple myeloma;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg14948946	chr7:45151503	TBRG4	0.39	6.01	0.31	4.92e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg20406979	chr6:167373233	NA	0.25	5.81	0.3	1.49e-8	Crohn's disease;
LUSC	cis	rs7106204	0.514	rs12293105	chr11:24256048	T/C	ch.11.24196551F	chr11:24239977	NA	0.94	10.41	0.49	3.63e-22	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08677398	chr8:58056175	NA	0.49	6.14	0.32	2.38e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg20302342	chr1:156215951	PAQR6	0.33	6.29	0.33	9.91e-10	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUSC	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg17173187	chr15:85201210	NMB	0.4	6.53	0.34	2.43e-10	Schizophrenia;
LUSC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.13	0.55	2.61e-28	Motion sickness;
LUSC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg16545954	chr1:2118288	C1orf86	0.32	6.22	0.32	1.45e-9	Height;
LUSC	trans	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg02800362	chr5:177631904	HNRNPAB	0.88	13.11	0.58	5.56e-32	Obesity-related traits;
LUSC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.71	0.6	3.09e-34	Cognitive test performance;
LUSC	cis	rs3916	0.641	rs7964786	chr12:121132100	C/T	cg27246729	chr12:121163418	ACADS	0.4	6.2	0.32	1.7e-9	Urinary metabolites (H-NMR features);
LUSC	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.26e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11645898	0.688	rs398580	chr16:72095453	A/G	cg14768367	chr16:72042858	DHODH	-0.73	-7.93	-0.4	3.22e-14	Blood protein levels;
LUSC	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg19812747	chr11:111475976	SIK2	0.49	6.76	0.35	6.2e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg27284194	chr4:1044797	NA	0.61	8.78	0.43	8.66e-17	Recombination rate (females);
LUSC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg21770322	chr7:97807741	LMTK2	0.41	7.08	0.36	8.48e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2227930	0.506	rs9814159	chr3:142125922	C/G	cg16271453	chr3:142027066	XRN1	-0.55	-9.76	-0.47	5.83e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg26647111	chr11:31128758	NA	-0.41	-5.98	-0.31	5.7e-9	Red blood cell count;
LUSC	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg26384229	chr12:38710491	ALG10B	0.79	13.58	0.6	9.51e-34	Morning vs. evening chronotype;
LUSC	cis	rs860295	0.756	rs7546258	chr1:155698645	T/A	cg08949192	chr1:155289623	RUSC1;FDPS	-0.35	-5.78	-0.3	1.68e-8	Body mass index;
LUSC	cis	rs7216064	1.000	rs7210027	chr17:65977053	C/T	cg12091567	chr17:66097778	LOC651250	0.69	9.34	0.46	1.42e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs17029056	0.527	rs17029053	chr2:42158297	C/G	cg25815440	chr2:42134162	NA	0.34	6.85	0.35	3.61e-11	Breast cancer;
LUSC	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg00631329	chr6:26305371	NA	-0.32	-5.73	-0.3	2.25e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs9309473	0.950	rs6546853	chr2:73833739	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.63	-0.34	1.37e-10	Metabolite levels;
LUSC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg03806693	chr22:41940476	POLR3H	-1.02	-13.77	-0.6	1.74e-34	Vitiligo;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg12229632	chr17:2607906	KIAA0664	-0.38	-6.01	-0.31	4.95e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.97	-18.7	-0.72	6.85e-54	Schizophrenia;
LUSC	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg10560079	chr2:191398806	TMEM194B	-0.66	-8.29	-0.41	2.85e-15	Diastolic blood pressure;
LUSC	cis	rs6060960	0.502	rs6089110	chr20:30486907	A/T	cg13852791	chr20:30311386	BCL2L1	0.64	6.79	0.35	5.17e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.65	11.6	0.54	2.18e-26	Aortic root size;
LUSC	cis	rs7215564	0.730	rs7212125	chr17:78628863	C/T	cg23238734	chr17:78661607	RPTOR	-0.44	-5.94	-0.31	7.15e-9	Myopia (pathological);
LUSC	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg22437258	chr11:111473054	SIK2	0.49	6.67	0.34	1.06e-10	Primary sclerosing cholangitis;
LUSC	cis	rs11650494	0.908	rs73324323	chr17:47420054	G/T	cg08112188	chr17:47440006	ZNF652	1.19	9.8	0.47	4.43e-20	Prostate cancer;
LUSC	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg24675056	chr1:15929824	NA	0.49	8.47	0.42	7.99e-16	Systolic blood pressure;
LUSC	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg00982548	chr2:198649783	BOLL	-0.56	-6.94	-0.35	2.06e-11	Ulcerative colitis;
LUSC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg12463550	chr7:65579703	CRCP	0.42	6.04	0.31	4.13e-9	Aortic root size;
LUSC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.94	-0.44	2.64e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.9	-0.4	4.1e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg05347473	chr6:146136440	FBXO30	0.51	8.76	0.43	9.89e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-1.11	-17.3	-0.69	2.55e-48	Exhaled nitric oxide output;
LUSC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg19622623	chr12:86230825	RASSF9	0.4	5.75	0.3	2.02e-8	Major depressive disorder;
LUSC	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg19773385	chr1:10388646	KIF1B	-0.56	-8.75	-0.43	1.07e-16	Hepatocellular carcinoma;
LUSC	cis	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg02508848	chr16:68573721	ZFP90	-0.43	-5.75	-0.3	2e-8	Ulcerative colitis;
LUSC	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.28	6.2	0.32	1.69e-9	Coronary artery disease;
LUSC	cis	rs897984	0.721	rs4889525	chr16:30989858	T/C	cg02466173	chr16:30829666	NA	0.55	11.21	0.52	5.56e-25	Dementia with Lewy bodies;
LUSC	cis	rs6967385	0.560	rs4301352	chr7:12356481	T/G	cg06484146	chr7:12443880	VWDE	0.51	7.65	0.39	2.21e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg15083037	chr5:83017644	HAPLN1	-0.48	-7.0	-0.36	1.45e-11	Prostate cancer;
LUSC	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg26384229	chr12:38710491	ALG10B	0.73	11.37	0.53	1.55e-25	Morning vs. evening chronotype;
LUSC	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg01420254	chr6:26195488	NA	0.66	7.31	0.37	2.05e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs4730250	0.707	rs78472146	chr7:106967491	C/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.76	-0.47	5.95e-20	Osteoarthritis;
LUSC	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06002616	chr8:101225028	SPAG1	-0.44	-7.3	-0.37	2.18e-12	Atrioventricular conduction;
LUSC	cis	rs1335645	0.570	rs10494127	chr1:111671783	A/C	cg00321911	chr1:111669324	DRAM2	-0.61	-6.43	-0.33	4.29e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg01097406	chr16:89675127	NA	-0.34	-6.79	-0.35	5.06e-11	Vitiligo;
LUSC	cis	rs6489882	0.902	rs7966314	chr12:113372539	C/T	cg20102336	chr12:113376681	OAS3	0.41	6.03	0.31	4.29e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg20368463	chr18:77673604	PQLC1	0.7	6.96	0.36	1.83e-11	Opioid sensitivity;
LUSC	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg02018176	chr4:1364513	KIAA1530	0.46	6.44	0.33	4.26e-10	Recombination rate (females);
LUSC	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg00898013	chr13:113819073	PROZ	-0.48	-7.19	-0.37	4.38e-12	Platelet distribution width;
LUSC	cis	rs2742417	1.000	rs2742390	chr3:45756722	A/G	cg04837898	chr3:45731254	SACM1L	0.35	5.88	0.31	9.89e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21211367	chr2:162094118	NA	0.44	7.13	0.36	6.38e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg24130564	chr14:104152367	KLC1	-0.5	-7.18	-0.37	4.57e-12	Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22619719	chr1:1891578	KIAA1751	0.41	6.23	0.32	1.41e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.26	0.32	1.15e-9	Mean platelet volume;
LUSC	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg23601095	chr6:26197514	HIST1H3D	0.73	7.46	0.38	7.42e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg05973401	chr12:123451056	ABCB9	0.52	6.45	0.33	3.85e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.41	-0.33	5.05e-10	Vitiligo;
LUSC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.76	-0.3	1.96e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.43	5.84	0.3	1.23e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg03289416	chr15:75166202	SCAMP2	0.4	6.08	0.32	3.2e-9	Breast cancer;
LUSC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.78	11.51	0.53	4.68e-26	Cognitive test performance;
LUSC	cis	rs6496667	0.532	rs2601207	chr15:90963542	C/G	cg22089800	chr15:90895588	ZNF774	-0.51	-7.49	-0.38	6.16e-13	Rheumatoid arthritis;
LUSC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg23205692	chr1:25664452	TMEM50A	-0.4	-5.98	-0.31	5.7e-9	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg09003973	chr2:102972529	NA	1.22	12.92	0.58	3e-31	Gut microbiota (bacterial taxa);
LUSC	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg26395211	chr5:140044315	WDR55	-0.38	-5.74	-0.3	2.14e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg19774624	chr17:42201019	HDAC5	0.8	12.82	0.57	7.44e-31	Total body bone mineral density;
LUSC	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg16342193	chr10:102329863	NA	-0.33	-6.1	-0.32	2.97e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg17173187	chr15:85201210	NMB	-0.28	-5.65	-0.3	3.53e-8	P wave terminal force;
LUSC	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg00310523	chr12:86230176	RASSF9	0.39	7.06	0.36	9.83e-12	Major depressive disorder;
LUSC	cis	rs708547	0.647	rs1718830	chr4:57888510	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	7.64	0.39	2.25e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs3772130	0.961	rs11716984	chr3:121362407	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	9.67	0.47	1.13e-19	Cognitive performance;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00797030	chr17:8151304	PFAS;C17orf68	0.75	6.02	0.31	4.47e-9	Cognitive performance;
LUSC	cis	rs2481665	0.772	rs6668421	chr1:62536619	C/G	cg18591186	chr1:62594603	INADL	-0.48	-7.5	-0.38	5.68e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs612683	0.536	rs1335753	chr1:101027157	G/T	cg09408571	chr1:101003634	GPR88	0.32	6.07	0.32	3.52e-9	Breast cancer;
LUSC	cis	rs1113500	0.933	rs61797345	chr1:108623728	G/A	cg11967332	chr1:108735228	SLC25A24	0.38	5.78	0.3	1.74e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-0.98	-16.38	-0.67	1.11e-44	Body mass index;
LUSC	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	1.12	15.24	0.64	3.58e-40	Nonalcoholic fatty liver disease;
LUSC	cis	rs17255340	0.520	rs1145911	chr6:84002954	T/C	cg08257003	chr6:84140564	ME1	0.31	7.62	0.38	2.6e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg12560992	chr17:57184187	TRIM37	0.64	10.99	0.52	3.38e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg21609526	chr1:3105151	PRDM16	-0.31	-6.17	-0.32	1.93e-9	Migraine;
LUSC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg22800045	chr5:56110881	MAP3K1	0.76	9.84	0.47	3.24e-20	Initial pursuit acceleration;
LUSC	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg17168535	chr8:21777572	XPO7	0.68	10.65	0.5	5.19e-23	Mean corpuscular volume;
LUSC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg15921436	chr17:44337874	NA	0.72	10.99	0.52	3.35e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.58	9.51	0.46	3.99e-19	Aortic root size;
LUSC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg26335602	chr6:28129616	ZNF389	0.44	5.97	0.31	6.22e-9	Depression;
LUSC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg03161606	chr19:29218774	NA	0.56	6.85	0.35	3.64e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg15557168	chr22:42548783	NA	0.47	7.16	0.36	5.26e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4478858	0.775	rs6685868	chr1:31706956	C/T	cg00250761	chr1:31883323	NA	-0.36	-9.32	-0.45	1.59e-18	Alcohol dependence;
LUSC	cis	rs9472414	0.680	rs9463020	chr6:44713432	G/A	cg20913747	chr6:44695427	NA	0.39	5.67	0.3	3.16e-8	Height;
LUSC	cis	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg06521331	chr12:34319734	NA	-0.4	-5.69	-0.3	2.76e-8	Resting heart rate;
LUSC	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg01966878	chr4:90757139	SNCA	-0.4	-5.72	-0.3	2.38e-8	Neuroticism;
LUSC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg26380479	chr7:97908229	NA	-0.26	-5.77	-0.3	1.78e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs56399783	0.901	rs11764225	chr7:2775607	G/A	cg19731401	chr7:2775893	GNA12	0.74	9.17	0.45	4.93e-18	Childhood ear infection;
LUSC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg09436375	chr6:42928200	GNMT	-0.29	-6.85	-0.35	3.63e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg09184832	chr6:79620586	NA	-0.44	-7.01	-0.36	1.34e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg06784218	chr1:46089804	CCDC17	0.54	11.06	0.52	1.96e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7193541	0.859	rs12598791	chr16:74500745	A/C	cg01733217	chr16:74700730	RFWD3	0.78	13.67	0.6	4.2e-34	Multiple myeloma;
LUSC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg08219700	chr8:58056026	NA	0.57	6.81	0.35	4.53e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs12530845	1.000	rs4291212	chr7:135335465	C/T	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.96e-9	Prostate cancer;
LUSC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg12016809	chr21:47604291	C21orf56	0.38	5.66	0.3	3.25e-8	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg00933542	chr6:150070202	PCMT1	0.33	6.82	0.35	4.38e-11	Lung cancer;
LUSC	cis	rs7189233	0.955	rs60420081	chr16:53520804	A/G	cg09728985	chr16:53543985	NA	-0.33	-6.02	-0.31	4.58e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg25767906	chr1:53392781	SCP2	0.48	8.47	0.42	8.04e-16	Monocyte count;
LUSC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.65	-0.39	2.1e-13	Bipolar disorder and schizophrenia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18794664	chr1:42922694	ZMYND12;PPCS	-0.45	-6.07	-0.32	3.48e-9	Hepatitis;
LUSC	cis	rs909341	0.818	rs6122154	chr20:62359345	C/T	cg09650180	chr20:62225654	GMEB2	-0.45	-5.81	-0.3	1.48e-8	Atopic dermatitis;
LUSC	cis	rs2398893	1.000	rs1411861	chr9:96763614	A/G	cg14459158	chr9:96720562	NA	0.33	6.27	0.32	1.11e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg05861140	chr6:150128134	PCMT1	-0.38	-5.87	-0.31	1.04e-8	Lung cancer;
LUSC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg00339695	chr16:24857497	SLC5A11	-0.5	-8.24	-0.41	3.91e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.47	-0.56	1.48e-29	Chronic sinus infection;
LUSC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg12564285	chr5:131593104	PDLIM4	0.46	8.12	0.41	9.17e-15	Breast cancer;
LUSC	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg25575065	chr22:51066394	ARSA	0.42	5.89	0.31	9.53e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06002616	chr8:101225028	SPAG1	0.42	7.11	0.36	6.91e-12	Atrioventricular conduction;
LUSC	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg22852734	chr6:133119734	C6orf192	-1.17	-14.37	-0.62	8.34e-37	Type 2 diabetes nephropathy;
LUSC	cis	rs7588746	0.621	rs11691757	chr2:201148951	C/T	cg23649088	chr2:200775458	C2orf69	-0.42	-5.91	-0.31	8.36e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.68	-0.34	9.79e-11	Longevity;Endometriosis;
LUSC	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg09184832	chr6:79620586	NA	-0.43	-6.94	-0.36	1.99e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	0.92	19.57	0.73	2.3e-57	Longevity;
LUSC	cis	rs3784262	0.528	rs11071364	chr15:58334113	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.3	-5.64	-0.3	3.57e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs7927771	0.524	rs10838760	chr11:47786414	A/G	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.18e-10	Subjective well-being;
LUSC	cis	rs7215564	0.908	rs4243240	chr17:78660342	T/C	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg09365446	chr1:150670422	GOLPH3L	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-13.71	-0.6	3.02e-34	Intelligence (multi-trait analysis);
LUSC	trans	rs12885454	1.000	rs35625199	chr14:29740239	A/C	cg13430755	chr9:110310795	NA	-0.31	-5.96	-0.31	6.42e-9	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index;
LUSC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg10556349	chr10:835070	NA	0.57	6.44	0.33	4.19e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs1160297	0.609	rs1597653	chr2:53100420	A/G	cg07782112	chr2:53107842	NA	-0.42	-6.92	-0.35	2.31e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg26395211	chr5:140044315	WDR55	-0.37	-5.77	-0.3	1.78e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.81	-0.35	4.49e-11	Menopause (age at onset);
LUSC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg16797656	chr11:68205561	LRP5	0.35	5.94	0.31	7.22e-9	Total body bone mineral density;
LUSC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21963583	chr11:68658836	MRPL21	0.56	8.42	0.42	1.15e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg25801113	chr15:45476975	SHF	0.33	6.87	0.35	3.14e-11	Uric acid levels;
LUSC	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg21963583	chr11:68658836	MRPL21	0.41	6.86	0.35	3.33e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg22532475	chr10:104410764	TRIM8	0.32	6.41	0.33	4.88e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg17178900	chr1:205818956	PM20D1	0.67	10.61	0.5	7.38e-23	Menarche (age at onset);
LUSC	cis	rs72634258	0.945	rs225120	chr1:8046378	C/T	cg00042356	chr1:8021962	PARK7	0.64	8.37	0.42	1.55e-15	Inflammatory bowel disease;
LUSC	cis	rs1018836	0.608	rs6998106	chr8:91479755	G/T	cg16814680	chr8:91681699	NA	-0.56	-8.24	-0.41	4.06e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	8.78	0.43	8.9e-17	Menopause (age at onset);
LUSC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-11.73	-0.54	7.89e-27	Chronic sinus infection;
LUSC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	0.64	13.57	0.6	1e-33	Prudent dietary pattern;
LUSC	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg21918786	chr6:109611834	NA	0.41	6.97	0.36	1.71e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg26395211	chr5:140044315	WDR55	0.45	6.99	0.36	1.5e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg24503407	chr1:205819492	PM20D1	-0.48	-6.38	-0.33	6.01e-10	Menarche (age at onset);
LUSC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg23711669	chr6:146136114	FBXO30	0.88	16.26	0.66	3.33e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1775715	0.707	rs1541261	chr10:32179523	G/A	cg18675610	chr10:32216311	ARHGAP12	0.31	6.67	0.34	1.07e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg11608241	chr8:8085544	FLJ10661	0.44	6.51	0.34	2.82e-10	Neuroticism;
LUSC	cis	rs2637266	0.783	rs2395436	chr10:78488513	G/T	cg18941641	chr10:78392320	NA	0.38	6.9	0.35	2.59e-11	Pulmonary function;
LUSC	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.65	-0.3	3.48e-8	Coronary artery disease;
LUSC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg25019033	chr10:957182	NA	-0.51	-6.49	-0.33	3.03e-10	Eosinophil percentage of granulocytes;
LUSC	trans	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg14791747	chr16:20752902	THUMPD1	-0.41	-6.41	-0.33	4.94e-10	Dental caries;
LUSC	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg16346588	chr10:242978	ZMYND11	-0.41	-5.67	-0.3	3.12e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg15103426	chr22:29168792	CCDC117	0.6	8.35	0.42	1.87e-15	Lymphocyte counts;
LUSC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg14583973	chr4:3374767	RGS12	0.37	7.82	0.39	6.99e-14	Serum sulfate level;
LUSC	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg04310649	chr10:35416472	CREM	-0.42	-6.46	-0.33	3.63e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9447004	0.584	rs56093139	chr6:74432923	C/T	cg03006477	chr6:74432658	CD109	0.28	5.84	0.3	1.27e-8	Blood protein levels;Calcium levels;
LUSC	cis	rs12464559	0.522	rs10200512	chr2:152626147	T/C	cg01189475	chr2:152685088	ARL5A	0.63	6.94	0.35	2.08e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg00431813	chr7:1051703	C7orf50	-0.44	-7.11	-0.36	7.04e-12	Longevity;Endometriosis;
LUSC	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-0.75	-9.1	-0.45	8.37e-18	Refractive error;
LUSC	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.77	-12.62	-0.57	4.01e-30	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs500891	0.553	rs2095447	chr6:84112756	C/G	cg08257003	chr6:84140564	ME1	-0.37	-8.79	-0.43	8.04e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs713477	1.000	rs8010013	chr14:55884828	A/C	cg13175173	chr14:55914753	NA	-0.29	-6.06	-0.31	3.63e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.61	-6.29	-0.33	1.02e-9	Yeast infection;
LUSC	cis	rs72802342	0.541	rs185052	chr16:75467063	C/T	cg04384234	chr16:75411784	CFDP1	0.7	9.66	0.47	1.23e-19	Advanced age-related macular degeneration;
LUSC	trans	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.53e-10	Corneal astigmatism;
LUSC	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg17623882	chr6:41773611	USP49	-0.65	-11.06	-0.52	1.94e-24	Menarche (age at onset);
LUSC	trans	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.42	0.5	3.29e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6754311	0.593	rs4954280	chr2:136420690	C/T	cg07169764	chr2:136633963	MCM6	-0.54	-7.13	-0.36	6.1e-12	Mosquito bite size;
LUSC	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.87	-0.44	4.51e-17	Neuroticism;
LUSC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg18402987	chr7:1209562	NA	0.73	7.85	0.39	5.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg02018176	chr4:1364513	KIAA1530	0.48	8.4	0.42	1.26e-15	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2667011	0.512	rs61094689	chr2:160797597	A/C	cg06573604	chr2:160760825	LY75	0.43	6.15	0.32	2.22e-9	Bilirubin levels;
LUSC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg15921436	chr17:44337874	NA	-0.71	-10.86	-0.51	9.89e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg15445000	chr17:37608096	MED1	0.38	6.5	0.34	2.95e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.64	6.24	0.32	1.34e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs57466243	1	rs57466243	chr17:27059666	T/A	cg21795637	chr17:26881880	PIGS	0.35	5.68	0.3	2.87e-8	Reticulocyte count;
LUSC	cis	rs16976116	0.851	rs28699327	chr15:55500335	A/G	cg11288833	chr15:55489084	RSL24D1	0.49	5.85	0.3	1.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	0.93	17.58	0.69	1.94e-49	Headache;
LUSC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg12257692	chr3:49977190	RBM6	0.21	5.8	0.3	1.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg06609049	chr19:2785107	THOP1	0.74	11.5	0.53	5.24e-26	Total cholesterol levels;
LUSC	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.41	6.6	0.34	1.64e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg10523860	chr14:103875565	MARK3	-0.36	-5.66	-0.3	3.26e-8	Body mass index;
LUSC	cis	rs1178968	1.000	rs4273741	chr7:72773966	C/A	cg25889504	chr7:72793014	NA	0.6	7.8	0.39	7.86e-14	Triglyceride levels;
LUSC	cis	rs68170813	0.559	rs7779062	chr7:106880195	T/A	cg02696742	chr7:106810147	HBP1	-0.63	-9.66	-0.47	1.24e-19	Coronary artery disease;
LUSC	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg06064525	chr11:970664	AP2A2	-0.34	-6.72	-0.35	7.69e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg22782873	chr19:19639568	YJEFN3	-0.49	-6.15	-0.32	2.23e-9	Bipolar disorder;
LUSC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg16414030	chr3:133502952	NA	-0.5	-7.93	-0.4	3.32e-14	Iron status biomarkers;
LUSC	trans	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg24313572	chr1:56050060	NA	-0.31	-6.44	-0.33	4.12e-10	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.635	rs1352208	chr12:33932543	T/C	cg13010199	chr12:38710504	ALG10B	0.4	6.03	0.31	4.29e-9	Morning vs. evening chronotype;
LUSC	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	1.27	11.48	0.53	5.96e-26	Cognitive function;
LUSC	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-0.8	-10.98	-0.52	3.7e-24	Response to hepatitis C treatment;
LUSC	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.15	-0.45	5.6e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08439880	chr3:133502540	NA	-0.38	-6.77	-0.35	5.84e-11	Iron status biomarkers;
LUSC	cis	rs7224314	1.000	rs57672368	chr17:65358688	G/C	cg01507342	chr17:65387096	PITPNC1	-0.39	-6.86	-0.35	3.36e-11	Diisocyanate-induced asthma;
LUSC	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg24881330	chr22:46731750	TRMU	0.83	7.26	0.37	2.71e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg06008330	chr7:65541103	ASL	-0.39	-6.03	-0.31	4.35e-9	Aortic root size;
LUSC	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.21	0.45	3.72e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg05347473	chr6:146136440	FBXO30	0.49	8.32	0.41	2.32e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg08270630	chr22:50330655	NA	-0.48	-6.78	-0.35	5.4e-11	Schizophrenia;
LUSC	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg12935359	chr14:103987150	CKB	-0.63	-10.38	-0.49	4.61e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg06784218	chr1:46089804	CCDC17	0.5	9.61	0.47	1.79e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg06784218	chr1:46089804	CCDC17	-0.58	-11.56	-0.53	3.15e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg21433313	chr16:3507492	NAT15	0.46	6.36	0.33	6.73e-10	Body mass index (adult);
LUSC	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.92	15.81	0.65	1.92e-42	Bladder cancer;
LUSC	cis	rs2303282	0.933	rs4784670	chr16:56498511	G/T	cg00500540	chr16:56394104	NA	-0.46	-7.32	-0.37	1.89e-12	Breast cancer;
LUSC	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg15556689	chr8:8085844	FLJ10661	0.54	8.26	0.41	3.34e-15	Retinal vascular caliber;
LUSC	cis	rs1997103	0.822	rs940878	chr7:55419663	A/G	cg17469321	chr7:55412551	NA	0.68	10.12	0.48	3.45e-21	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg21231944	chr12:82153410	PPFIA2	0.4	6.19	0.32	1.74e-9	Resting heart rate;
LUSC	cis	rs11039100	0.765	rs35863959	chr11:5834622	T/A	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg23172400	chr8:95962367	TP53INP1	-0.37	-7.5	-0.38	5.92e-13	Type 2 diabetes;
LUSC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03576123	chr11:487126	PTDSS2	-1.01	-10.64	-0.5	5.99e-23	Body mass index;
LUSC	cis	rs1355223	0.573	rs1097403	chr11:34730083	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.43	6.12	0.32	2.61e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	7.33	0.37	1.8e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	0.87	13.93	0.61	4.35e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs7615316	0.902	rs3922730	chr3:142202857	A/T	cg16271453	chr3:142027066	XRN1	-0.4	-6.86	-0.35	3.43e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs12210905	0.688	rs12194842	chr6:27367978	A/C	cg08851530	chr6:28072375	NA	0.97	6.41	0.33	4.91e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs73200209	0.789	rs74420242	chr12:116551289	A/T	cg01776926	chr12:116560359	MED13L	-0.5	-5.99	-0.31	5.44e-9	Total body bone mineral density;
LUSC	cis	rs10489202	1.000	rs4657727	chr1:167965241	T/C	cg24449463	chr1:168025552	DCAF6	-0.58	-7.37	-0.37	1.32e-12	Schizophrenia;
LUSC	trans	rs6828577	0.687	rs56203850	chr4:119454437	C/T	cg26518628	chr1:97050305	NA	-0.54	-7.85	-0.39	5.73e-14	Perioperative myocardial infarction in coronary artery bypass surgery;
LUSC	cis	rs6012953	1.000	rs6020563	chr20:49120395	T/G	cg13958625	chr20:49123093	NA	0.31	6.57	0.34	1.92e-10	Vitiligo;
LUSC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.22	0.32	1.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg20887711	chr4:1340912	KIAA1530	-0.49	-7.35	-0.37	1.5e-12	Obesity-related traits;
LUSC	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-8.36	-0.42	1.67e-15	Body mass index;
LUSC	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.07	14.26	0.62	2.27e-36	Uric acid levels;
LUSC	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg23625390	chr15:77176239	SCAPER	-0.67	-10.28	-0.49	9.91e-22	Blood metabolite levels;
LUSC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg24690094	chr11:67383802	NA	0.41	7.98	0.4	2.39e-14	Mean corpuscular volume;
LUSC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg00431813	chr7:1051703	C7orf50	-0.46	-7.82	-0.39	7.17e-14	Longevity;Endometriosis;
LUSC	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg12924262	chr12:102091054	CHPT1	0.43	6.07	0.32	3.47e-9	Blood protein levels;
LUSC	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg15103426	chr22:29168792	CCDC117	0.56	7.44	0.38	8.64e-13	Lymphocyte counts;
LUSC	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg22676075	chr6:135203613	NA	0.46	7.19	0.37	4.41e-12	Red blood cell count;
LUSC	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.9	-0.35	2.6e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg18180107	chr4:99064573	C4orf37	0.42	5.81	0.3	1.45e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.43	5.65	0.3	3.41e-8	Schizophrenia;
LUSC	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg00064840	chr7:4784485	FOXK1	0.33	6.2	0.32	1.69e-9	Mosquito bite size;
LUSC	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg27411982	chr8:10470053	RP1L1	-0.36	-5.8	-0.3	1.56e-8	Neuroticism;
LUSC	cis	rs870825	0.872	rs12507711	chr4:185571776	C/T	cg04058563	chr4:185651563	MLF1IP	0.71	10.0	0.48	9.13e-21	Blood protein levels;
LUSC	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12292205	chr6:26970375	C6orf41	-0.58	-7.39	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg23505145	chr19:12996616	KLF1	0.65	11.01	0.52	2.96e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1775715	0.677	rs2491272	chr10:32186783	A/G	cg04359828	chr10:32216031	ARHGAP12	0.39	6.65	0.34	1.17e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2279817	0.735	rs12067869	chr1:17989765	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.49	-6.32	-0.33	8.32e-10	Neuroticism;
LUSC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.44e-12	Motion sickness;
LUSC	cis	rs2425143	1.000	rs6060578	chr20:34305445	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.97	-0.31	6.1e-9	Blood protein levels;
LUSC	cis	rs7683537	0.554	rs55830081	chr4:185666477	A/C	cg07424746	chr4:185654737	MLF1IP	-0.49	-5.69	-0.3	2.75e-8	Systemic lupus erythematosus;
LUSC	cis	rs1595825	0.786	rs79490184	chr2:198894219	T/A	cg00982548	chr2:198649783	BOLL	-0.54	-6.89	-0.35	2.72e-11	Ulcerative colitis;
LUSC	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg13160058	chr8:26243215	BNIP3L	-0.39	-6.94	-0.35	2.1e-11	Red cell distribution width;
LUSC	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs7123876	0.587	rs11602616	chr11:72364077	T/C	cg03713592	chr11:72463424	ARAP1	0.71	7.55	0.38	4.2e-13	Body mass index;
LUSC	cis	rs600626	0.636	rs10793125	chr11:75452364	C/T	cg24262691	chr11:75473276	NA	-0.43	-6.36	-0.33	6.73e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18099408	chr3:52552593	STAB1	-0.4	-7.19	-0.37	4.15e-12	Electroencephalogram traits;
LUSC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg24733560	chr20:60626293	TAF4	0.43	7.82	0.39	6.95e-14	Body mass index;
LUSC	cis	rs2274273	0.870	rs17741831	chr14:55816715	T/A	cg04306507	chr14:55594613	LGALS3	0.53	11.62	0.54	1.95e-26	Protein biomarker;
LUSC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03264133	chr6:25882463	NA	-0.52	-9.51	-0.46	3.88e-19	Blood metabolite levels;
LUSC	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg18755752	chr8:142205143	DENND3	0.41	6.01	0.31	4.78e-9	Immature fraction of reticulocytes;
LUSC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg04944784	chr2:26401820	FAM59B	-0.75	-10.71	-0.51	3.38e-23	Gut microbiome composition (summer);
LUSC	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg11244672	chr19:19639970	YJEFN3	-0.5	-6.66	-0.34	1.14e-10	Bipolar disorder;
LUSC	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg03060546	chr3:49711283	APEH	0.64	6.96	0.36	1.76e-11	Menarche (age at onset);
LUSC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg08270630	chr22:50330655	NA	0.41	6.05	0.31	3.98e-9	Schizophrenia;
LUSC	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg03806693	chr22:41940476	POLR3H	-0.91	-12.72	-0.57	1.7e-30	Vitiligo;
LUSC	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg01528321	chr10:82214614	TSPAN14	0.88	13.62	0.6	6.45e-34	Post bronchodilator FEV1;
LUSC	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg05330977	chr17:18154724	FLII	-0.39	-6.13	-0.32	2.53e-9	N-glycan levels;
LUSC	trans	rs6600671	1.000	rs1856572	chr1:121169579	A/C	cg00646200	chr1:148855367	NA	0.43	6.73	0.35	7.59e-11	Hip geometry;
LUSC	trans	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg06606381	chr12:133084897	FBRSL1	0.59	6.99	0.36	1.54e-11	Depression;
LUSC	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-7.75	-0.39	1.12e-13	Schizophrenia;
LUSC	trans	rs11039798	0.841	rs11039760	chr11:48479009	C/T	cg15704280	chr7:45808275	SEPT13	0.73	6.2	0.32	1.66e-9	Axial length;
LUSC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.79	-12.88	-0.58	4.24e-31	Aortic root size;
LUSC	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg11019008	chr10:131425282	MGMT	0.41	6.25	0.32	1.26e-9	Response to temozolomide;
LUSC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14159672	chr1:205819179	PM20D1	0.42	5.72	0.3	2.4e-8	Parkinson's disease;
LUSC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.72	11.35	0.53	1.79e-25	Coronary artery disease;
LUSC	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg00290607	chr11:67383545	NA	0.37	6.88	0.35	3.04e-11	Mean corpuscular volume;
LUSC	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.49	-0.38	6.39e-13	Mood instability;
LUSC	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.68	-0.3	2.9e-8	Testicular germ cell tumor;
LUSC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13012494	chr21:47604986	C21orf56	-0.51	-7.81	-0.39	7.43e-14	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg17366294	chr4:99064904	C4orf37	0.61	10.84	0.51	1.2e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg19875535	chr5:140030758	IK	-0.55	-8.95	-0.44	2.45e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-14.27	-0.62	2.14e-36	Height;
LUSC	cis	rs13242816	1.000	rs55977427	chr7:116110768	C/T	cg16553024	chr7:116138462	CAV2	-0.52	-5.71	-0.3	2.44e-8	P wave duration;
LUSC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg07701084	chr6:150067640	NUP43	0.52	7.78	0.39	8.84e-14	Lung cancer;
LUSC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.5	-6.3	-0.33	9.21e-10	Mean platelet volume;
LUSC	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg01294253	chr9:136912663	BRD3	0.33	5.93	0.31	7.74e-9	Platelet distribution width;
LUSC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.61	-0.43	2.98e-16	Lung cancer;
LUSC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg26061582	chr7:22766209	IL6	0.48	6.98	0.36	1.63e-11	Lung cancer;
LUSC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-1.0	-17.6	-0.69	1.65e-49	Coronary artery disease;
LUSC	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-8.2	-0.41	5.07e-15	Retinal vascular caliber;
LUSC	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	5.87	0.31	1.04e-8	Breast cancer;
LUSC	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg24397884	chr7:158709396	WDR60	0.61	9.37	0.46	1.11e-18	Height;
LUSC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg07395648	chr5:131743802	NA	0.45	7.34	0.37	1.66e-12	Breast cancer;Mosquito bite size;
LUSC	cis	rs7659604	0.540	rs10001092	chr4:122677177	C/T	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.91	-0.31	8.47e-9	Type 2 diabetes;
LUSC	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg00484396	chr16:3507460	NAT15	0.47	7.0	0.36	1.44e-11	Body mass index (adult);
LUSC	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg00033643	chr7:134001901	SLC35B4	0.42	6.2	0.32	1.65e-9	Mean platelet volume;
LUSC	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg01528321	chr10:82214614	TSPAN14	0.97	14.78	0.63	2.22e-38	Post bronchodilator FEV1;
LUSC	cis	rs68170813	0.559	rs74774133	chr7:106941449	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.88	-0.48	2.31e-20	Coronary artery disease;
LUSC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	6.51	0.34	2.82e-10	Obesity-related traits;
LUSC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg27535305	chr1:53392650	SCP2	0.34	6.3	0.33	9.24e-10	Monocyte count;
LUSC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.74	11.31	0.53	2.42e-25	Type 2 diabetes;
LUSC	trans	rs6601327	0.602	rs7820917	chr8:9647868	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	7.13	0.36	6.32e-12	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs11676348	0.873	rs10210012	chr2:219013334	G/A	cg06547715	chr2:218990976	CXCR2	0.3	5.68	0.3	2.97e-8	Ulcerative colitis;
LUSC	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	0.9	16.12	0.66	1.15e-43	Bone mineral density;
LUSC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg00102166	chr1:43425337	SLC2A1	-0.32	-5.68	-0.3	2.98e-8	Red cell distribution width;
LUSC	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.59	-0.34	1.71e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.62	-0.47	1.71e-19	Coronary artery disease;
LUSC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg16606324	chr3:10149918	C3orf24	0.58	8.47	0.42	8.16e-16	Alzheimer's disease;
LUSC	cis	rs3087591	1.000	rs2854331	chr17:29711728	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.65	-9.46	-0.46	5.51e-19	Hip circumference;
LUSC	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg11861562	chr11:117069780	TAGLN	0.43	7.18	0.37	4.52e-12	Blood protein levels;
LUSC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.82	0.43	6.37e-17	Lung cancer;
LUSC	trans	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg06606381	chr12:133084897	FBRSL1	-1.05	-9.08	-0.44	9.63e-18	Depression;
LUSC	cis	rs9517320	1.000	rs9517320	chr13:99126303	G/T	cg20487152	chr13:99095054	FARP1	-0.37	-6.97	-0.36	1.7e-11	Longevity;
LUSC	trans	rs12677056	0.739	rs62514391	chr8:113298974	T/C	cg12159992	chr12:102059490	MYBPC1	0.36	6.03	0.31	4.3e-9	Peripheral artery disease;
LUSC	cis	rs6543140	0.693	rs7579737	chr2:102987361	A/G	cg09003973	chr2:102972529	NA	0.45	5.71	0.3	2.53e-8	Blood protein levels;
LUSC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg14664628	chr15:75095509	CSK	-0.57	-8.58	-0.42	3.72e-16	Breast cancer;
LUSC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	0.65	13.71	0.6	2.93e-34	Prudent dietary pattern;
LUSC	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg04511125	chr2:88470314	THNSL2	0.69	6.57	0.34	1.96e-10	Plasma clusterin levels;
LUSC	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg17385448	chr1:15911702	AGMAT	0.37	5.81	0.3	1.45e-8	Systolic blood pressure;
LUSC	cis	rs34638657	0.872	rs2911423	chr16:82188801	C/T	cg09439754	chr16:82129088	HSD17B2	-0.41	-6.56	-0.34	2.01e-10	Lung adenocarcinoma;
LUSC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg03732007	chr1:2071316	PRKCZ	-0.53	-9.47	-0.46	5.18e-19	Height;
LUSC	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	7.53	0.38	4.66e-13	Iron status biomarkers;
LUSC	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	0.97	15.59	0.65	1.44e-41	Dupuytren's disease;
LUSC	cis	rs9486719	0.741	rs2499799	chr6:96851676	T/C	cg06623918	chr6:96969491	KIAA0776	0.74	8.64	0.43	2.34e-16	Migraine;Coronary artery disease;
LUSC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	1.05	17.35	0.69	1.61e-48	Parkinson's disease;
LUSC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg05623727	chr3:50126028	RBM5	-0.35	-6.53	-0.34	2.4e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6433857	0.627	rs6741769	chr2:181500545	G/A	cg23363182	chr2:181467187	NA	-0.52	-8.4	-0.42	1.28e-15	Body mass index;
LUSC	cis	rs4971059	0.629	rs9297	chr1:155106550	A/G	cg22049894	chr1:155113146	DPM3	0.39	6.2	0.32	1.66e-9	Breast cancer;
LUSC	cis	rs9341808	0.519	rs7771593	chr6:81036127	T/C	cg08355045	chr6:80787529	NA	-0.44	-7.5	-0.38	5.77e-13	Sitting height ratio;
LUSC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	22.14	0.77	1.81e-67	Height;
LUSC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg03804128	chr16:635623	NA	0.33	6.57	0.34	1.98e-10	Height;
LUSC	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg04374321	chr14:90722782	PSMC1	0.73	11.59	0.54	2.57e-26	Mortality in heart failure;
LUSC	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.33	-0.53	2.16e-25	Alzheimer's disease;
LUSC	cis	rs3771570	1.000	rs1056801	chr2:242292307	T/C	cg21155796	chr2:242212141	HDLBP	0.63	6.76	0.35	6.25e-11	Prostate cancer;
LUSC	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg15556689	chr8:8085844	FLJ10661	0.56	8.47	0.42	7.67e-16	Neuroticism;
LUSC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg22709100	chr7:91322751	NA	0.38	5.65	0.3	3.48e-8	Breast cancer;
LUSC	trans	rs72674100	1.000	rs28483048	chr4:97990804	C/A	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg05368731	chr17:41323189	NBR1	0.85	14.27	0.62	2.14e-36	Menopause (age at onset);
LUSC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.85	-0.47	2.85e-20	Platelet count;
LUSC	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	0.96	13.62	0.6	6.83e-34	Primary sclerosing cholangitis;
LUSC	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.07	0.48	5.24e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg02176678	chr2:219576539	TTLL4	0.61	10.95	0.51	4.76e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg24596788	chr1:163392923	NA	-0.45	-7.63	-0.39	2.48e-13	Motion sickness;
LUSC	cis	rs2282032	0.527	rs3742666	chr14:90767860	T/C	cg14092571	chr14:90743983	NA	0.48	8.01	0.4	1.95e-14	Longevity;
LUSC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg05347473	chr6:146136440	FBXO30	-0.59	-10.32	-0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7523050	0.643	rs35860016	chr1:109404639	C/T	cg08274380	chr1:109419600	GPSM2	1.07	10.65	0.5	5.34e-23	Fat distribution (HIV);
LUSC	cis	rs2835872	0.965	rs702860	chr21:39008629	C/T	cg20424643	chr21:39039972	KCNJ6	-0.39	-5.98	-0.31	5.89e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7945718	0.967	rs7927470	chr11:12748899	A/T	cg25843174	chr11:12811716	TEAD1	0.32	7.05	0.36	1.04e-11	Educational attainment (years of education);
LUSC	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg18806716	chr10:30721971	MAP3K8	-0.64	-9.61	-0.47	1.86e-19	Inflammatory bowel disease;
LUSC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.54	-0.46	3.12e-19	Bipolar disorder;
LUSC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-7.27	-0.37	2.6e-12	Renal function-related traits (BUN);
LUSC	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-5.92	-0.31	7.88e-9	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08677398	chr8:58056175	NA	-0.55	-6.65	-0.34	1.22e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg02176678	chr2:219576539	TTLL4	0.6	10.98	0.52	3.7e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs56283067	0.887	rs7765371	chr6:44777204	G/A	cg20913747	chr6:44695427	NA	-0.47	-7.08	-0.36	8.8e-12	Total body bone mineral density;
LUSC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00166722	chr3:10149974	C3orf24	0.59	7.73	0.39	1.25e-13	Alzheimer's disease;
LUSC	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg17366294	chr4:99064904	C4orf37	-0.6	-10.52	-0.5	1.53e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.76	-12.82	-0.57	7.37e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg11584989	chr19:19387371	SF4	0.57	6.92	0.35	2.31e-11	Bipolar disorder;
LUSC	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg25456477	chr12:86230367	RASSF9	0.37	6.43	0.33	4.34e-10	Major depressive disorder;
LUSC	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg13535736	chr9:111863775	C9orf5	-0.38	-6.1	-0.32	2.91e-9	Menarche (age at onset);
LUSC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg02569458	chr12:86230093	RASSF9	0.61	10.27	0.49	1.07e-21	Major depressive disorder;
LUSC	cis	rs10779751	0.734	rs2261217	chr1:11127764	C/A	cg04508216	chr1:11107452	MASP2	0.33	5.87	0.31	1.03e-8	Body mass index;
LUSC	cis	rs56399783	0.901	rs56356906	chr7:2774383	G/A	cg19731401	chr7:2775893	GNA12	0.74	8.97	0.44	2.17e-17	Childhood ear infection;
LUSC	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg01689657	chr7:91764605	CYP51A1	0.34	6.1	0.32	2.9e-9	Breast cancer;
LUSC	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-14.04	-0.61	1.65e-35	Exhaled nitric oxide levels;
LUSC	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.14	-0.41	7.68e-15	Retinal vascular caliber;
LUSC	cis	rs2455601	1.000	rs7104661	chr11:8902501	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.56	-0.34	2e-10	Schizophrenia;
LUSC	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.55e-10	Corneal astigmatism;
LUSC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12379764	chr21:47803548	PCNT	-0.42	-5.96	-0.31	6.38e-9	Testicular germ cell tumor;
LUSC	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg04733989	chr22:42467013	NAGA	0.36	5.92	0.31	7.85e-9	Cognitive function;
LUSC	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg08000102	chr2:233561755	GIGYF2	-0.72	-11.93	-0.55	1.45e-27	Coronary artery disease;
LUSC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.39	5.66	0.3	3.21e-8	Tonsillectomy;
LUSC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg03804128	chr16:635623	NA	0.31	6.22	0.32	1.51e-9	Height;
LUSC	cis	rs4843185	0.769	rs709805	chr16:85706564	A/G	cg05245094	chr16:85669572	KIAA0182	-0.44	-6.36	-0.33	6.57e-10	Platelet distribution width;
LUSC	cis	rs9311676	0.656	rs11917529	chr3:58382158	C/T	cg26110898	chr3:58419937	PDHB	0.39	6.41	0.33	5.09e-10	Systemic lupus erythematosus;
LUSC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg22166914	chr1:53195759	ZYG11B	0.57	8.92	0.44	3.14e-17	Monocyte count;
LUSC	cis	rs4851254	0.961	rs13000759	chr2:100753903	A/T	cg07810366	chr2:100720526	AFF3	0.37	5.74	0.3	2.11e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg08088566	chr11:430123	ANO9	0.6	7.04	0.36	1.09e-11	Body mass index;
LUSC	trans	rs4252134	0.959	rs4252072	chr6:161128264	A/T	cg00639886	chr12:54943102	PDE1B	-0.43	-6.33	-0.33	7.68e-10	Giant cell arteritis;
LUSC	cis	rs67539049	1.000	rs73207496	chr8:11288485	T/G	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.42	-5.97	-0.31	6.18e-9	Itch intensity from mosquito bite;
LUSC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg16606324	chr3:10149918	C3orf24	0.59	8.6	0.43	3.15e-16	Alzheimer's disease;
LUSC	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg08000102	chr2:233561755	GIGYF2	-0.75	-11.84	-0.54	3.06e-27	Coronary artery disease;
LUSC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg15790184	chr11:494944	RNH1	0.52	5.98	0.31	5.62e-9	Body mass index;
LUSC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.46	-0.42	8.21e-16	Bipolar disorder;
LUSC	cis	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg06521331	chr12:34319734	NA	-0.5	-8.33	-0.41	2.06e-15	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg05347473	chr6:146136440	FBXO30	0.5	8.45	0.42	9.38e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.55	-0.38	4.24e-13	Educational attainment;
LUSC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.68	12.56	0.57	6.6e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg18225595	chr11:63971243	STIP1	0.51	6.33	0.33	7.83e-10	Mean platelet volume;
LUSC	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg20701182	chr2:24300061	SF3B14	0.55	6.02	0.31	4.59e-9	Lymphocyte counts;
LUSC	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.02e-14	Corneal astigmatism;
LUSC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.35	-0.53	1.84e-25	Mean corpuscular volume;
LUSC	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg00852783	chr1:26633632	UBXN11	0.6	9.59	0.46	2.2e-19	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14159672	chr1:205819179	PM20D1	0.78	14.67	0.63	5.9e-38	Monocyte percentage of white cells;
LUSC	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg17691542	chr6:26056736	HIST1H1C	0.56	7.84	0.39	6.09e-14	Iron status biomarkers;
LUSC	cis	rs1904096	0.506	rs12511433	chr4:95162425	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.23	-0.41	4.39e-15	Type 2 diabetes;
LUSC	cis	rs9473147	0.516	rs9367284	chr6:47516369	A/G	cg02130027	chr6:47444894	CD2AP	0.36	5.74	0.3	2.09e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg27535305	chr1:53392650	SCP2	0.36	6.66	0.34	1.13e-10	Monocyte count;
LUSC	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg13755796	chr4:20253514	NA	-0.43	-6.62	-0.34	1.43e-10	Life satisfaction;
LUSC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-1.01	-17.17	-0.68	8.19e-48	Body mass index;
LUSC	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg14092571	chr14:90743983	NA	-0.36	-5.9	-0.31	8.93e-9	Mortality in heart failure;
LUSC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg12463550	chr7:65579703	CRCP	-0.63	-5.69	-0.3	2.82e-8	Diabetic kidney disease;
LUSC	cis	rs3733418	0.929	rs13149738	chr4:165905697	T/C	cg11630554	chr4:165878136	TRIM61;C4orf39	-0.51	-5.83	-0.3	1.34e-8	Obesity-related traits;
LUSC	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg22676075	chr6:135203613	NA	0.47	7.41	0.38	1.03e-12	Red blood cell count;
LUSC	cis	rs12677618	1.000	rs12677618	chr8:142302024	C/T	cg27411547	chr8:142287226	NA	-0.4	-6.37	-0.33	6.18e-10	Plateletcrit;
LUSC	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg24579218	chr15:68104479	NA	-0.37	-6.58	-0.34	1.79e-10	Restless legs syndrome;
LUSC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.92	-0.35	2.29e-11	Total body bone mineral density;
LUSC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.16	0.32	2.14e-9	Menopause (age at onset);
LUSC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg14541582	chr5:601475	NA	-0.37	-5.71	-0.3	2.48e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7923609	0.749	rs12247907	chr10:65317045	G/C	cg01631684	chr10:65280961	REEP3	0.41	6.05	0.31	3.84e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.69	-10.88	-0.51	8.71e-24	Menarche (age at onset);
LUSC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg06740227	chr12:86229804	RASSF9	0.45	7.31	0.37	1.98e-12	Major depressive disorder;
LUSC	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg12590608	chr7:158785262	NA	0.31	5.92	0.31	8.17e-9	Facial morphology (factor 20);
LUSC	cis	rs12949688	0.967	rs9905938	chr17:55824351	G/A	cg12582317	chr17:55822272	NA	0.31	5.69	0.3	2.83e-8	Schizophrenia;
LUSC	cis	rs8018808	0.935	rs17824316	chr14:77930407	G/A	cg20045696	chr14:77926864	AHSA1	0.34	5.76	0.3	1.95e-8	Myeloid white cell count;
LUSC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg20135002	chr11:47629003	NA	-0.5	-7.82	-0.39	7.16e-14	Subjective well-being;
LUSC	cis	rs9650657	0.711	rs35091929	chr8:10693492	T/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.34	-0.33	7.62e-10	Neuroticism;
LUSC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-6.7	-0.34	9.07e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7224314	1.000	rs62084082	chr17:65388046	A/G	cg01507342	chr17:65387096	PITPNC1	-0.44	-7.72	-0.39	1.37e-13	Diisocyanate-induced asthma;
LUSC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.65	10.16	0.49	2.71e-21	Blood protein levels;
LUSC	cis	rs6692729	0.966	rs1150900	chr1:227045029	A/G	cg10327440	chr1:227177885	CDC42BPA	0.5	7.23	0.37	3.26e-12	Electrodermal activity;
LUSC	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg05729581	chr11:3078854	CARS	0.4	5.93	0.31	7.76e-9	Calcium levels;
LUSC	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg25427524	chr10:38739819	LOC399744	-0.5	-6.88	-0.35	3e-11	Obesity (extreme);
LUSC	trans	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg25214090	chr10:38739885	LOC399744	0.39	6.11	0.32	2.83e-9	Diastolic blood pressure;
LUSC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08280861	chr8:58055591	NA	0.58	7.09	0.36	8.24e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.64	-0.34	1.25e-10	Reticulocyte count;
LUSC	cis	rs4280164	0.945	rs2281472	chr14:24775846	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.58	7.48	0.38	6.5e-13	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs427941	0.703	rs201449	chr7:101739054	A/G	cg06246474	chr7:101738831	CUX1	0.38	6.33	0.33	7.73e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg07423050	chr13:99094983	FARP1	-0.56	-10.86	-0.51	1.02e-23	Longevity;
LUSC	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	9.06	0.44	1.13e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg27432699	chr2:27873401	GPN1	0.8	15.0	0.63	2.94e-39	Oral cavity cancer;
LUSC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg00933542	chr6:150070202	PCMT1	0.32	6.49	0.33	3.09e-10	Lung cancer;
LUSC	cis	rs3820928	0.874	rs7576081	chr2:227843634	C/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.41	-0.38	1.02e-12	Pulmonary function;
LUSC	cis	rs6542838	0.597	rs35107109	chr2:99386210	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-6.32	-0.33	8.16e-10	Fear of minor pain;
LUSC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg21017887	chr14:105400489	NA	0.69	13.21	0.59	2.42e-32	Rheumatoid arthritis;
LUSC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.6	0.38	2.95e-13	Prudent dietary pattern;
LUSC	trans	rs77372450	0.551	rs10866685	chr5:157104711	G/A	cg10450108	chr5:140208893	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.97	-0.31	6.18e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg14895029	chr7:2775587	GNA12	-0.37	-5.99	-0.31	5.5e-9	Height;
LUSC	cis	rs6460942	0.591	rs4721079	chr7:12337742	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.2	-0.32	1.67e-9	Coronary artery disease;
LUSC	cis	rs6546537	0.513	rs34878028	chr2:69891422	A/G	cg10773587	chr2:69614142	GFPT1	-0.35	-5.73	-0.3	2.23e-8	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-9.15	-0.45	5.94e-18	Obesity-related traits;
LUSC	cis	rs17255340	0.520	rs1170504	chr6:83993569	A/C	cg08257003	chr6:84140564	ME1	0.32	7.89	0.4	4.39e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.79	11.36	0.53	1.63e-25	Corneal astigmatism;
LUSC	trans	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg04995722	chr7:26192034	NFE2L3	0.38	6.28	0.32	1.07e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1775715	0.705	rs2778651	chr10:32106575	C/T	cg03015672	chr10:32216066	ARHGAP12	0.35	6.15	0.32	2.23e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.24	-0.37	3.09e-12	Bipolar disorder;
LUSC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.7	12.66	0.57	2.96e-30	Prudent dietary pattern;
LUSC	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs6599077	0.950	rs9867011	chr3:40105468	T/A	cg13683864	chr3:40499215	RPL14	-0.61	-7.6	-0.38	2.94e-13	Sleep-related phenotypes;
LUSC	cis	rs2236918	0.710	rs1776130	chr1:242023362	A/G	cg17736920	chr1:242011382	EXO1	0.43	6.84	0.35	3.85e-11	Menopause (age at onset);
LUSC	cis	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg20368463	chr18:77673604	PQLC1	-0.73	-11.47	-0.53	6.41e-26	Schizophrenia;
LUSC	cis	rs4363385	0.588	rs11586559	chr1:153025714	G/A	cg25856811	chr1:152973957	SPRR3	-0.37	-6.04	-0.31	4.08e-9	Inflammatory skin disease;
LUSC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.07	-0.48	5.45e-21	Hemoglobin concentration;
LUSC	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21545522	chr1:205238299	TMCC2	0.51	9.63	0.47	1.6e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10140922	0.966	rs4982260	chr14:35822105	T/A	cg07166546	chr14:35805898	NA	-0.24	-5.89	-0.31	9.53e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7215564	0.908	rs2340770	chr17:78754770	T/C	cg23238734	chr17:78661607	RPTOR	-0.44	-5.65	-0.3	3.4e-8	Myopia (pathological);
LUSC	cis	rs2176263	0.900	rs6756419	chr2:24126904	A/G	cg08063864	chr2:24346004	PFN4;LOC375190	-0.42	-5.71	-0.3	2.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg23711669	chr6:146136114	FBXO30	0.86	16.03	0.66	2.84e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg25716786	chr12:498630	KDM5A;CCDC77	0.41	6.2	0.32	1.65e-9	Triglycerides;
LUSC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg23283495	chr1:209979779	IRF6	0.59	8.36	0.42	1.66e-15	Cleft lip with or without cleft palate;
LUSC	cis	rs9503598	0.610	rs1328687	chr6:3468377	A/C	cg00476032	chr6:3446245	SLC22A23	0.31	6.07	0.32	3.52e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.747	rs946097	chr1:152974732	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.71	-0.39	1.44e-13	Inflammatory skin disease;
LUSC	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg14675211	chr2:100938903	LONRF2	0.37	5.76	0.3	1.94e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg26501027	chr6:150326334	RAET1K	0.43	6.32	0.33	8.48e-10	Triglycerides;
LUSC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg16606324	chr3:10149918	C3orf24	0.64	9.55	0.46	2.89e-19	Alzheimer's disease;
LUSC	cis	rs12549902	0.800	rs7825337	chr8:41507237	C/T	cg21772509	chr8:41503840	NKX6-3	0.69	11.4	0.53	1.19e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs80130819	0.591	rs17122651	chr12:48496660	C/T	cg24011408	chr12:48396354	COL2A1	-0.46	-6.13	-0.32	2.42e-9	Prostate cancer;
LUSC	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg00191853	chr8:101177733	SPAG1	-0.36	-6.03	-0.31	4.39e-9	Atrioventricular conduction;
LUSC	cis	rs6681460	0.932	rs659291	chr1:67180746	A/C	cg02459107	chr1:67143332	SGIP1	0.48	8.97	0.44	2.24e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.04e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs62055045	0.528	rs62053065	chr16:71557806	G/A	cg15281710	chr15:96890452	NA	-0.46	-6.39	-0.33	5.69e-10	Schizophrenia;
LUSC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg05043794	chr9:111880884	C9orf5	0.34	7.63	0.39	2.45e-13	Menarche (age at onset);
LUSC	cis	rs1904096	0.506	rs2865350	chr4:95212813	A/T	cg11021082	chr4:95130006	SMARCAD1	0.37	6.31	0.33	8.96e-10	Type 2 diabetes;
LUSC	cis	rs4400599	0.642	rs4364874	chr1:154167788	C/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.76	-0.3	1.87e-8	Platelet distribution width;
LUSC	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg13010344	chr12:123464640	ARL6IP4	-0.46	-6.21	-0.32	1.62e-9	Neutrophil percentage of white cells;
LUSC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-6.08	-0.32	3.35e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg09455208	chr3:40491958	NA	0.57	10.26	0.49	1.2e-21	Renal cell carcinoma;
LUSC	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg25174290	chr11:3078921	CARS	0.59	9.29	0.45	2.09e-18	Longevity;
LUSC	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg13939156	chr17:80058883	NA	-0.34	-6.76	-0.35	6.08e-11	Life satisfaction;
LUSC	cis	rs3857536	0.813	rs1029399	chr6:66952476	G/C	cg07460842	chr6:66804631	NA	-0.46	-6.36	-0.33	6.75e-10	Blood trace element (Cu levels);
LUSC	cis	rs4363385	0.818	rs409986	chr1:153014741	A/C	cg00922841	chr1:152955080	SPRR1A	0.45	7.96	0.4	2.72e-14	Inflammatory skin disease;
LUSC	cis	rs4285028	0.948	rs34181646	chr3:121705373	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-9.12	-0.45	6.98e-18	Multiple sclerosis;
LUSC	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg08085267	chr17:45401833	C17orf57	0.59	9.76	0.47	5.98e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg09375892	chr17:708413	NXN	-0.38	-6.33	-0.33	7.91e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg04989706	chr14:50066350	PPIL5	-0.45	-5.81	-0.3	1.43e-8	Carotid intima media thickness;
LUSC	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1692580	0.870	rs263533	chr1:2163568	C/T	cg03732007	chr1:2071316	PRKCZ	0.36	5.87	0.31	1.05e-8	Coronary artery disease;
LUSC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg09238746	chr17:78121135	EIF4A3	0.98	15.7	0.65	5.46e-42	Yeast infection;
LUSC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.64	0.34	1.3100000000000001e-10	Lung cancer;
LUSC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	6.97	0.36	1.74e-11	Multiple sclerosis;
LUSC	cis	rs9341808	0.718	rs9294171	chr6:80839815	C/T	cg08355045	chr6:80787529	NA	0.55	9.7	0.47	9.18e-20	Sitting height ratio;
LUSC	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.89	15.04	0.64	2.16e-39	Bladder cancer;
LUSC	cis	rs2273669	0.667	rs12198182	chr6:109318704	T/G	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg05738196	chr6:26577821	NA	0.78	14.95	0.63	4.82e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs2230307	0.536	rs580611	chr1:100622925	G/A	cg24955406	chr1:100503596	HIAT1	-0.6	-6.43	-0.33	4.34e-10	Carotid intima media thickness;
LUSC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg02807482	chr3:125708958	NA	-0.51	-6.37	-0.33	6.45e-10	Blood pressure (smoking interaction);
LUSC	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg03806693	chr22:41940476	POLR3H	0.91	12.83	0.57	6.85e-31	Vitiligo;
LUSC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg15445000	chr17:37608096	MED1	0.37	6.53	0.34	2.48e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs3741151	0.773	rs73544716	chr11:73170061	C/T	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg25258033	chr6:167368657	RNASET2	0.37	5.83	0.3	1.28e-8	Primary biliary cholangitis;
LUSC	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg13607699	chr17:42295918	UBTF	0.66	9.95	0.48	1.33e-20	Total body bone mineral density;
LUSC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08219700	chr8:58056026	NA	0.69	7.91	0.4	3.7e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-9.17	-0.45	4.86e-18	Brugada syndrome;
LUSC	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-0.87	-14.53	-0.62	2.02e-37	Headache;
LUSC	cis	rs7527798	0.592	rs960088	chr1:207827067	A/C	cg09232269	chr1:207846808	CR1L	-0.3	-6.39	-0.33	5.46e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs7560272	0.723	rs12995433	chr2:73641326	C/T	cg20560298	chr2:73613845	ALMS1	0.46	7.19	0.37	4.3e-12	Schizophrenia;
LUSC	cis	rs12995849	0.714	rs6543342	chr2:106462256	T/C	cg14210321	chr2:106509881	NCK2	-0.42	-5.96	-0.31	6.3e-9	Addiction;
LUSC	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-9.2	-0.45	3.85e-18	Response to antipsychotic treatment;
LUSC	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg12940439	chr1:67600707	NA	0.38	6.16	0.32	2.11e-9	Psoriasis;
LUSC	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg14403583	chr14:105418241	AHNAK2	-0.6	-9.9	-0.48	1.93e-20	Rheumatoid arthritis;
LUSC	cis	rs7712401	0.755	rs3213794	chr5:122161638	A/C	cg19077854	chr5:122220652	SNX24	0.36	8.13	0.41	8.68e-15	Mean platelet volume;
LUSC	trans	rs9467603	0.925	rs4712969	chr6:25764192	A/G	cg06606381	chr12:133084897	FBRSL1	0.58	6.07	0.32	3.57e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg12927641	chr6:109611667	NA	-0.37	-6.2	-0.32	1.66e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg00129232	chr17:37814104	STARD3	-0.49	-7.32	-0.37	1.91e-12	Asthma;
LUSC	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg25664220	chr3:72788482	NA	-0.67	-11.85	-0.54	2.77e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg21775007	chr8:11205619	TDH	-0.47	-6.87	-0.35	3.17e-11	Neuroticism;
LUSC	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.7	-10.92	-0.51	6.26e-24	Corneal astigmatism;
LUSC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.91	-0.51	6.58e-24	Schizophrenia;
LUSC	cis	rs2086824	0.702	rs3114891	chr16:89399455	A/G	cg00750074	chr16:89608354	SPG7	-0.4	-6.72	-0.35	7.68e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs11603020	0.904	rs11606677	chr11:57383377	G/A	cg23127183	chr11:57508653	C11orf31	-0.47	-6.57	-0.34	1.95e-10	Blood protein levels;
LUSC	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.08	0.55	4.06e-28	Ileal carcinoids;
LUSC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.46	0.42	8.48e-16	Prudent dietary pattern;
LUSC	trans	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-8.14	-0.41	8.17e-15	Obesity-related traits;
LUSC	cis	rs2540226	0.935	rs917963	chr2:39966537	C/A	cg23576258	chr2:39999331	THUMPD2	0.35	5.92	0.31	8.12e-9	Personality dimensions;
LUSC	cis	rs17255340	0.539	rs1145896	chr6:84041599	G/T	cg08257003	chr6:84140564	ME1	0.34	8.23	0.41	4.19e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg16342193	chr10:102329863	NA	-0.39	-6.93	-0.35	2.14e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs6681460	0.932	rs2146904	chr1:67160336	C/T	cg02459107	chr1:67143332	SGIP1	-0.44	-8.12	-0.41	8.89e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg22823121	chr1:150693482	HORMAD1	0.49	6.97	0.36	1.7e-11	Melanoma;
LUSC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24110177	chr3:50126178	RBM5	0.65	11.68	0.54	1.14e-26	Body mass index;
LUSC	cis	rs2573652	1.000	rs2573652	chr15:100514614	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.38	-6.93	-0.35	2.12e-11	Height;
LUSC	trans	rs11088226	0.758	rs2833864	chr21:33888393	A/C	cg09050820	chr6:167586206	TCP10L2	0.48	6.52	0.34	2.65e-10	Gastritis;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg14282440	chr2:27593116	EIF2B4;SNX17	0.38	5.99	0.31	5.44e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	trans	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.64e-15	Diabetic kidney disease;
LUSC	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg25554036	chr4:6271136	WFS1	0.58	11.43	0.53	9.34e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg27170947	chr2:26402098	FAM59B	-0.69	-10.55	-0.5	1.2e-22	Gut microbiome composition (summer);
LUSC	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg25110126	chr1:46999211	NA	0.77	11.11	0.52	1.28e-24	Monobrow;
LUSC	cis	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg05084668	chr3:125655381	ALG1L	-0.92	-13.12	-0.58	5.09e-32	Blood pressure (smoking interaction);
LUSC	trans	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.4	0.42	1.29e-15	Ulcerative colitis;
LUSC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.71	-0.3	2.55e-8	Life satisfaction;
LUSC	cis	rs4845570	0.920	rs3811414	chr1:151763246	A/G	cg07092448	chr1:151763213	TDRKH	-1.22	-16.88	-0.68	1.2e-46	Coronary artery disease;
LUSC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-0.92	-19.39	-0.73	1.26e-56	Dental caries;
LUSC	cis	rs3849570	0.555	rs6548783	chr3:81993621	G/A	cg07356753	chr3:81810745	GBE1	-0.42	-5.92	-0.31	7.89e-9	Waist circumference;Body mass index;
LUSC	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.73	-0.35	7.56e-11	Response to antipsychotic treatment;
LUSC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg17971929	chr21:40555470	PSMG1	-0.5	-7.48	-0.38	6.59e-13	Menarche (age at onset);
LUSC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg06238570	chr21:40685208	BRWD1	0.48	7.54	0.38	4.59e-13	Cognitive function;
LUSC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg11843238	chr5:131593191	PDLIM4	0.38	6.55	0.34	2.16e-10	Breast cancer;
LUSC	cis	rs1775715	0.737	rs2799015	chr10:32107712	C/T	cg03015672	chr10:32216066	ARHGAP12	0.35	6.15	0.32	2.23e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.87	14.84	0.63	1.29e-38	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.03	0.31	4.34e-9	Corneal astigmatism;
LUSC	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg26597838	chr10:835615	NA	0.92	12.43	0.56	2.03e-29	Eosinophil percentage of granulocytes;
LUSC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.52	-0.34	2.55e-10	Life satisfaction;
LUSC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.91	-0.35	2.41e-11	Lung cancer;
LUSC	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg11861562	chr11:117069780	TAGLN	0.32	6.22	0.32	1.45e-9	Blood protein levels;
LUSC	cis	rs11809207	1.000	rs11809207	chr1:26521140	G/A	cg00147160	chr1:26503991	CNKSR1	0.42	7.02	0.36	1.28e-11	Height;
LUSC	cis	rs11030122	0.673	rs10835474	chr11:4020819	G/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.9	-0.31	9.07e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.28	0.41	2.99e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg14530993	chr4:882597	GAK	0.72	7.45	0.38	7.91e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg18402987	chr7:1209562	NA	0.63	6.91	0.35	2.41e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.37	-7.91	-0.4	3.84e-14	Dupuytren's disease;
LUSC	cis	rs7577851	0.715	rs6729268	chr2:69623932	C/T	cg10773587	chr2:69614142	GFPT1	0.56	6.3	0.33	9.29e-10	Parkinson's disease (age of onset);
LUSC	cis	rs4964805	1.000	rs1866295	chr12:104186946	G/T	cg02344784	chr12:104178138	NT5DC3	0.45	7.14	0.36	5.88e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs2742417	1.000	rs2742432	chr3:45737467	G/T	cg09608765	chr3:45636137	LIMD1	-0.37	-7.2	-0.37	4.14e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.65	-10.95	-0.51	4.75e-24	Diastolic blood pressure;
LUSC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	9.71	0.47	8.69e-20	Cognitive test performance;
LUSC	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg05347473	chr6:146136440	FBXO30	0.49	8.13	0.41	8.58e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.92	-0.31	8e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12900413	0.645	rs28507224	chr15:90305393	T/C	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.4e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs4363385	0.574	rs61813182	chr1:152943868	T/A	cg00922841	chr1:152955080	SPRR1A	-0.36	-6.05	-0.31	3.88e-9	Inflammatory skin disease;
LUSC	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg24397884	chr7:158709396	WDR60	0.64	9.86	0.47	2.7e-20	Height;
LUSC	cis	rs11229555	0.874	rs7102852	chr11:58358348	G/A	cg15696309	chr11:58395628	NA	-0.71	-9.15	-0.45	5.57e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg06521331	chr12:34319734	NA	-0.36	-6.03	-0.31	4.41e-9	Morning vs. evening chronotype;
LUSC	cis	rs7095944	0.614	rs10901816	chr10:126440395	G/A	cg08799069	chr10:126477246	METTL10	-0.41	-6.31	-0.33	9.12e-10	Asthma;
LUSC	cis	rs7131987	0.650	rs7311912	chr12:29475703	G/C	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.77	-0.35	5.69e-11	QT interval;
LUSC	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.6	13.93	0.61	4.18e-35	Height;
LUSC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg24634471	chr8:143751801	JRK	0.59	9.01	0.44	1.66e-17	Schizophrenia;
LUSC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg00343986	chr7:65444356	GUSB	-0.43	-6.63	-0.34	1.32e-10	Aortic root size;
LUSC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg22823121	chr1:150693482	HORMAD1	-0.53	-7.54	-0.38	4.36e-13	Urate levels;
LUSC	cis	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.69	-0.34	9.21e-11	Morning vs. evening chronotype;
LUSC	cis	rs7589728	0.844	rs2363010	chr2:88496399	G/C	cg04511125	chr2:88470314	THNSL2	0.68	6.33	0.33	7.78e-10	Plasma clusterin levels;
LUSC	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.48	0.42	7.37e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12118280	0.612	rs591141	chr1:108694894	A/G	cg11967332	chr1:108735228	SLC25A24	0.54	7.27	0.37	2.49e-12	Myeloid white cell count;
LUSC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg20821713	chr7:1055600	C7orf50	-0.52	-6.9	-0.35	2.64e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg15997130	chr1:24165203	NA	-0.47	-7.0	-0.36	1.38e-11	Immature fraction of reticulocytes;
LUSC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07362569	chr17:61921086	SMARCD2	0.37	7.6	0.38	2.92e-13	Prudent dietary pattern;
LUSC	cis	rs4853525	0.522	rs6434412	chr2:191585275	A/G	cg11845111	chr2:191398756	TMEM194B	-0.42	-5.72	-0.3	2.32e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg25036284	chr2:26402008	FAM59B	-0.69	-9.58	-0.46	2.38e-19	Gut microbiome composition (summer);
LUSC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.47	-7.1	-0.36	7.72e-12	Neutrophil percentage of white cells;
LUSC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.88	0.44	4.2e-17	Schizophrenia;
LUSC	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg13010199	chr12:38710504	ALG10B	0.69	10.56	0.5	1.13e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7000551	0.715	rs2443502	chr8:22340499	G/A	cg12081754	chr8:22256438	SLC39A14	0.47	7.22	0.37	3.53e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.68	-10.69	-0.5	3.91e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2692947	0.711	rs34639392	chr2:96508976	T/C	cg22654517	chr2:96458247	NA	0.37	7.45	0.38	7.96e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21862992	chr11:68658383	NA	0.51	8.19	0.41	5.71e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs979233	0.502	rs276268	chr5:42072852	A/G	cg07010552	chr17:7358735	CHRNB1	-0.41	-5.98	-0.31	5.65e-9	Systemic lupus erythematosus;
LUSC	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg26727032	chr16:67993705	SLC12A4	-0.4	-5.98	-0.31	5.79e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg21856205	chr7:94953877	PON1	-0.36	-5.82	-0.3	1.37e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg05926928	chr17:57297772	GDPD1	-0.48	-6.71	-0.34	8.57e-11	Schizophrenia;
LUSC	cis	rs6445967	1.000	rs6777105	chr3:58307644	A/G	cg23715586	chr3:58305044	RPP14	0.5	10.02	0.48	7.67e-21	Platelet count;
LUSC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08109568	chr15:31115862	NA	-0.59	-8.24	-0.41	3.89e-15	Huntington's disease progression;
LUSC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg08847533	chr14:75593920	NEK9	0.86	16.21	0.66	5.23e-44	Height;
LUSC	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg03676636	chr4:99064102	C4orf37	0.36	7.99	0.4	2.18e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3736594	0.607	rs7584462	chr2:28176056	A/T	cg27432699	chr2:27873401	GPN1	-0.51	-6.95	-0.36	1.89e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.2e-13	Corneal astigmatism;
LUSC	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg05926928	chr17:57297772	GDPD1	1.56	18.18	0.71	8.12e-52	Opioid sensitivity;
LUSC	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg18209359	chr17:80159595	CCDC57	-0.36	-6.13	-0.32	2.41e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	14.41	0.62	6.29e-37	Total body bone mineral density;
LUSC	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.01	-0.4	1.89e-14	Glomerular filtration rate;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06888415	chr1:150336129	RPRD2	-0.42	-6.13	-0.32	2.47e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6480314	0.542	rs17231630	chr10:70028717	G/A	cg04882175	chr6:131122610	NA	-0.54	-6.32	-0.33	8.24e-10	Optic nerve measurement (disc area);
LUSC	cis	rs75804782	0.641	rs41264155	chr2:239342096	G/A	cg18131467	chr2:239335373	ASB1	-0.77	-6.63	-0.34	1.3100000000000001e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs9400467	0.528	rs110732	chr6:111679869	G/T	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-0.59	-9.29	-0.45	1.98e-18	Breast cancer;
LUSC	cis	rs17030434	1.000	rs952211	chr4:154717816	A/G	cg14289246	chr4:154710475	SFRP2	-0.46	-5.7	-0.3	2.68e-8	Electrocardiographic conduction measures;
LUSC	cis	rs12618769	0.597	rs3769727	chr2:99103318	C/T	cg10123293	chr2:99228465	UNC50	0.45	7.48	0.38	6.81e-13	Bipolar disorder;
LUSC	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg21427119	chr20:30132790	HM13	-0.43	-6.1	-0.32	3.01e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg13073564	chr4:8508604	NA	0.34	6.22	0.32	1.49e-9	Response to antineoplastic agents;
LUSC	cis	rs10761482	0.500	rs10821790	chr10:62288767	T/C	cg18175470	chr10:62150864	ANK3	-0.51	-7.38	-0.37	1.25e-12	Schizophrenia;
LUSC	cis	rs11955175	0.717	rs41271053	chr5:40835393	A/C	cg04002187	chr5:40835754	RPL37	0.71	5.89	0.31	9.66e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg08847533	chr14:75593920	NEK9	-0.82	-14.77	-0.63	2.41e-38	Height;
LUSC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.55	8.3	0.41	2.54e-15	Lymphocyte counts;
LUSC	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg08601574	chr20:25228251	PYGB	0.42	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.83	-0.57	6.66e-31	Chronic sinus infection;
LUSC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg16928487	chr17:17741425	SREBF1	0.46	9.23	0.45	3.28e-18	Total body bone mineral density;
LUSC	cis	rs11039100	0.573	rs11038951	chr11:5780343	G/C	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs890100	0.673	rs13424976	chr2:56658363	A/G	cg01657744	chr10:88471748	LDB3	0.43	5.95	0.31	6.75e-9	Gut microbiome composition (summer);
LUSC	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.6	10.05	0.48	6.31e-21	Birth weight;
LUSC	cis	rs9463078	0.585	rs718112	chr6:44859451	T/G	cg25276700	chr6:44698697	NA	0.29	5.88	0.31	1.01e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7896691	0.925	rs6602023	chr10:3155217	A/G	cg15228268	chr10:3146741	PFKP	-0.57	-5.67	-0.3	3.15e-8	Disc degeneration (lumbar);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05515713	chr2:10262434	RRM2	-0.41	-5.97	-0.31	6.22e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-8.28	-0.41	3.05e-15	Coronary artery disease;
LUSC	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6541297	0.699	rs4846916	chr1:230296492	G/A	cg20703242	chr1:230279135	GALNT2	0.5	5.72	0.3	2.33e-8	Coronary artery disease;
LUSC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg07936489	chr17:37558343	FBXL20	0.71	9.91	0.48	1.88e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs231513	0.954	rs231501	chr17:41972303	C/T	cg26893861	chr17:41843967	DUSP3	-0.5	-6.07	-0.32	3.42e-9	Cognitive function;
LUSC	cis	rs9905704	0.633	rs2531731	chr17:56546524	A/C	cg19466818	chr17:56409534	MIR142	0.37	6.65	0.34	1.23e-10	Testicular germ cell tumor;
LUSC	trans	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-6.8	-0.35	4.81e-11	Menarche (age at onset);
LUSC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	trans	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg19694781	chr19:47549865	TMEM160	0.58	9.39	0.46	9.66e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg05182265	chr7:156933206	UBE3C	0.44	6.66	0.34	1.15e-10	Body mass index;
LUSC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	19.53	0.73	3.44e-57	Prudent dietary pattern;
LUSC	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	0.93	8.07	0.4	1.27e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg13607699	chr17:42295918	UBTF	0.77	14.39	0.62	7.01e-37	Total body bone mineral density;
LUSC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg22823121	chr1:150693482	HORMAD1	0.6	9.28	0.45	2.21e-18	Tonsillectomy;
LUSC	trans	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg26043149	chr18:55253948	FECH	-0.46	-7.06	-0.36	9.83e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg08213375	chr14:104286397	PPP1R13B	0.52	10.33	0.49	6.97e-22	Schizophrenia;
LUSC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.69	0.54	1.04e-26	Prudent dietary pattern;
LUSC	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	cis	rs6500395	0.651	rs28432694	chr16:48666310	A/T	cg04672837	chr16:48644449	N4BP1	0.45	6.48	0.33	3.38e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-12.98	-0.58	1.87e-31	Chronic sinus infection;
LUSC	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.53	8.16	0.41	7e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.88	0.48	2.27e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3099143	1.000	rs2046415	chr15:77085253	A/G	cg21673338	chr15:77095150	SCAPER	-0.73	-7.47	-0.38	6.9e-13	Recalcitrant atopic dermatitis;
LUSC	trans	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg14227996	chr4:17616232	MED28	-0.58	-6.47	-0.33	3.42e-10	Opioid sensitivity;
LUSC	trans	rs9929218	0.954	rs10163398	chr16:68823124	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.09	-0.52	1.52e-24	Colorectal cancer;
LUSC	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-1.12	-24.64	-0.8	4.12e-77	Triglycerides;
LUSC	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.14	-0.45	6.2e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg09654669	chr8:57350985	NA	-0.58	-7.84	-0.39	5.98e-14	Obesity-related traits;
LUSC	cis	rs1775715	0.870	rs1251400	chr10:32235145	A/G	cg18675610	chr10:32216311	ARHGAP12	0.3	6.46	0.33	3.65e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4786125	0.636	rs9932626	chr16:6917014	C/G	cg03623568	chr16:6915990	A2BP1	-0.41	-6.97	-0.36	1.73e-11	Heart rate variability traits (SDNN);
LUSC	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg01557791	chr16:72042693	DHODH	-0.46	-5.85	-0.3	1.17e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12493885	0.505	rs357489	chr3:153884517	A/T	cg10247383	chr3:153839028	SGEF	-0.57	-7.52	-0.38	5.04e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs977987	0.843	rs4888427	chr16:75478447	A/G	cg04384234	chr16:75411784	CFDP1	-0.44	-7.36	-0.37	1.41e-12	Dupuytren's disease;
LUSC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.68	0.34	9.72e-11	Schizophrenia;
LUSC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-7.22	-0.37	3.57e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg05163923	chr11:71159392	DHCR7	0.74	11.0	0.52	3.15e-24	Vitamin D levels;
LUSC	trans	rs4811340	0.600	rs6068248	chr20:51179089	C/T	cg15736553	chr3:11610338	VGLL4	-0.33	-5.95	-0.31	6.7e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg14675211	chr2:100938903	LONRF2	0.37	5.77	0.3	1.81e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.77	-0.8	1.22e-77	Height;
LUSC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg01657329	chr11:68192670	LRP5	-0.44	-6.55	-0.34	2.19e-10	Total body bone mineral density;
LUSC	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.07	0.48	5.24e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg11887960	chr12:57824829	NA	0.56	6.84	0.35	3.75e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1018836	0.608	rs6986165	chr8:91477062	C/G	cg16814680	chr8:91681699	NA	-0.56	-8.26	-0.41	3.37e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs988712	0.705	rs4074134	chr11:27647285	C/T	cg10635145	chr11:27742435	BDNF	-0.45	-5.89	-0.31	9.21e-9	Obesity;
LUSC	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	0.8	11.29	0.53	3.04e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.31	0.49	8.3e-22	Bladder cancer;
LUSC	cis	rs17539620	0.702	rs6937366	chr6:154878832	T/A	cg20019720	chr6:154832845	CNKSR3	0.47	6.94	0.35	2.07e-11	Lipoprotein (a) levels;
LUSC	trans	rs72674100	1.000	rs112113294	chr4:97967853	G/T	cg16405019	chr1:18959625	PAX7	-0.61	-6.0	-0.31	5.27e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs78572108	0.858	rs72613885	chr2:42265011	A/G	cg00607755	chr2:42274082	PKDCC	0.37	6.56	0.34	2.03e-10	Total body bone mineral density;
LUSC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24549020	chr5:56110836	MAP3K1	0.49	5.96	0.31	6.45e-9	Initial pursuit acceleration;
LUSC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.46	-7.16	-0.36	5.28e-12	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg19116668	chr7:99932089	PMS2L1	0.33	5.72	0.3	2.34e-8	Coronary artery disease;
LUSC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.82	-13.78	-0.6	1.69e-34	Aortic root size;
LUSC	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg20503657	chr10:835505	NA	-0.49	-6.86	-0.35	3.31e-11	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs62400317	0.826	rs11968637	chr6:45348633	G/A	cg20913747	chr6:44695427	NA	-0.47	-7.76	-0.39	1.07e-13	Total body bone mineral density;
LUSC	cis	rs955333	0.685	rs1022404	chr6:154899702	G/T	cg20019720	chr6:154832845	CNKSR3	-0.43	-6.09	-0.32	3.07e-9	Diabetic kidney disease;
LUSC	cis	rs2012796	0.956	rs7147254	chr14:81820503	G/A	cg02996355	chr14:81879375	NA	0.49	7.1	0.36	7.5e-12	Night sleep phenotypes;
LUSC	cis	rs8135665	0.625	rs34385006	chr22:38450291	C/T	cg13116946	chr22:38479732	SLC16A8	0.4	5.91	0.31	8.46e-9	Advanced age-related macular degeneration;Age-related macular degeneration;
LUSC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.95	-0.4	2.95e-14	Obesity-related traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06825153	chr1:90287453	LRRC8D	-0.42	-6.85	-0.35	3.52e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-6.59	-0.34	1.74e-10	Type 2 diabetes;
LUSC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg14440974	chr22:39074834	NA	-0.34	-5.75	-0.3	1.97e-8	Menopause (age at onset);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg03904586	chr7:559740	PDGFA	0.39	6.38	0.33	5.85e-10	Mosquito bite size;
LUSC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.44	-7.09	-0.36	8.02e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-8.47	-0.42	8.19e-16	Lymphocyte counts;
LUSC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg07806771	chr7:64541737	NA	-0.44	-6.37	-0.33	6.24e-10	Calcium levels;
LUSC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg07701084	chr6:150067640	NUP43	0.54	8.02	0.4	1.82e-14	Lung cancer;
LUSC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.92	0.44	3.19e-17	Prudent dietary pattern;
LUSC	trans	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg02030672	chr11:45687055	CHST1	-0.44	-6.81	-0.35	4.65e-11	Obesity-related traits;
LUSC	cis	rs4363385	0.755	rs516198	chr1:153026196	T/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.41	-0.38	1.07e-12	Inflammatory skin disease;
LUSC	trans	rs1864729	1.000	rs2439700	chr8:98277168	G/A	cg08679828	chr8:102218111	ZNF706	-0.87	-7.83	-0.39	6.43e-14	Estradiol plasma levels (breast cancer);
LUSC	cis	rs983392	0.651	rs718376	chr11:60002935	C/T	cg20284999	chr11:59952153	MS4A6A	-0.35	-5.74	-0.3	2.18e-8	Alzheimer's disease (late onset);
LUSC	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.8	0.35	4.87e-11	Cognitive test performance;
LUSC	cis	rs16912285	0.748	rs7104694	chr11:24280281	A/C	ch.11.24196551F	chr11:24239977	NA	0.85	9.04	0.44	1.34e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7615952	0.546	rs16836896	chr3:125311262	A/T	cg05084668	chr3:125655381	ALG1L	-0.44	-5.82	-0.3	1.35e-8	Blood pressure (smoking interaction);
LUSC	trans	rs9860340	0.730	rs4859089	chr3:87648553	C/G	cg03644585	chr7:884825	UNC84A	-0.42	-6.03	-0.31	4.34e-9	Electroencephalographic traits in alcoholism;
LUSC	trans	rs4942242	0.663	rs9525816	chr13:44223898	A/G	cg19169023	chr15:41853346	TYRO3	-0.57	-8.6	-0.43	3.05e-16	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg05973401	chr12:123451056	ABCB9	-0.52	-7.65	-0.39	2.18e-13	Neutrophil percentage of white cells;
LUSC	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg23188684	chr11:67383651	NA	0.34	6.02	0.31	4.67e-9	Mean corpuscular volume;
LUSC	cis	rs9811920	0.809	rs4928153	chr3:99808445	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.34	5.77	0.3	1.78e-8	Axial length;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23587005	chr12:9600941	DDX12	0.36	5.96	0.31	6.56e-9	Triglycerides;
LUSC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.17	0.37	4.7e-12	Platelet count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09326880	chr3:43147587	C3orf39	-0.43	-6.59	-0.34	1.7e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.11e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7605827	0.930	rs10929366	chr2:15531754	C/T	cg19274914	chr2:15703543	NA	0.48	9.34	0.46	1.39e-18	Educational attainment (years of education);
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg23034840	chr1:205782522	SLC41A1	0.62	8.8	0.43	7.43e-17	Menarche (age at onset);
LUSC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs920590	0.643	rs3855754	chr8:19659499	C/G	cg03894339	chr8:19674705	INTS10	0.41	5.85	0.3	1.19e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg18904891	chr8:8559673	CLDN23	0.6	8.08	0.4	1.16e-14	Obesity-related traits;
LUSC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg15445000	chr17:37608096	MED1	0.38	6.61	0.34	1.53e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.82	-0.39	6.88e-14	Chronic sinus infection;
LUSC	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg04851639	chr8:1020857	NA	-0.37	-7.78	-0.39	8.96e-14	Schizophrenia;
LUSC	cis	rs860295	0.812	rs12081192	chr1:155738044	A/G	cg08949192	chr1:155289623	RUSC1;FDPS	-0.34	-5.76	-0.3	1.93e-8	Body mass index;
LUSC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg20090143	chr19:45452003	APOC2	0.47	8.77	0.43	9.29e-17	Blood protein levels;
LUSC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06112835	chr11:68658793	MRPL21	0.48	7.36	0.37	1.45e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg22166914	chr1:53195759	ZYG11B	-0.62	-10.46	-0.5	2.37e-22	Monocyte count;
LUSC	trans	rs9831754	1.000	rs9822043	chr3:78352113	T/C	cg06695833	chr19:18220682	MAST3	0.48	6.08	0.32	3.2e-9	Calcium levels;
LUSC	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg25797454	chr6:150327115	RAET1K	0.35	7.98	0.4	2.34e-14	Alopecia areata;
LUSC	cis	rs6714710	0.580	rs35564270	chr2:98602165	A/G	cg26665480	chr2:98280029	ACTR1B	0.59	8.41	0.42	1.24e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.79	-0.3	1.64e-8	Breast cancer;
LUSC	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.58	9.96	0.48	1.27e-20	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.62	9.59	0.46	2.06e-19	Schizophrenia;
LUSC	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.33e-21	Lymphocyte counts;
LUSC	trans	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg23029597	chr12:123009494	RSRC2	-0.74	-9.23	-0.45	3.1e-18	Body mass index;
LUSC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg21733973	chr7:65235735	NA	0.44	6.21	0.32	1.58e-9	Calcium levels;
LUSC	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.99	-0.36	1.5e-11	Monocyte percentage of white cells;
LUSC	cis	rs11030122	0.702	rs10835406	chr11:3992954	G/T	cg08557956	chr11:4115526	RRM1	0.45	5.67	0.3	3.13e-8	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg15556689	chr8:8085844	FLJ10661	0.54	8.12	0.41	9.32e-15	Neuroticism;
LUSC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.67	-11.71	-0.54	8.76e-27	Lung cancer;
LUSC	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg12257692	chr3:49977190	RBM6	-0.21	-5.72	-0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg16339924	chr4:17578868	LAP3	0.54	8.11	0.41	1e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10203711	0.966	rs4293520	chr2:239567184	A/C	cg14580085	chr2:239553406	NA	0.41	6.99	0.36	1.53e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg24642844	chr7:1081250	C7orf50	-0.79	-10.39	-0.49	4.39e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.71	-9.89	-0.48	2.06e-20	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.67	11.44	0.53	8.25e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg16447950	chr5:562315	NA	-0.52	-6.88	-0.35	3e-11	Obesity-related traits;
LUSC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg22535103	chr8:58192502	C8orf71	-0.58	-7.03	-0.36	1.2e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg07936489	chr17:37558343	FBXL20	0.72	10.11	0.48	3.74e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs7726558	0.642	rs3797371	chr5:118869764	C/T	cg14402224	chr7:50570049	DDC	0.48	6.45	0.33	3.9e-10	QT interval (sulfonylurea treatment interaction);
LUSC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-9.69	-0.47	9.62e-20	Gut microbiome composition (summer);
LUSC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.7	-0.47	9.39e-20	Platelet count;
LUSC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	6.43	0.33	4.39e-10	Obesity-related traits;
LUSC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.82	14.21	0.61	3.48e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10779751	0.734	rs7533211	chr1:11132965	G/C	cg04508216	chr1:11107452	MASP2	0.31	5.72	0.3	2.4e-8	Body mass index;
LUSC	cis	rs9925964	0.804	rs4889606	chr16:31011183	C/T	cg02466173	chr16:30829666	NA	-0.32	-5.74	-0.3	2.08e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs12692738	0.526	rs355852	chr2:165626304	C/A	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg11345693	chr17:79170810	AZI1	-0.34	-6.93	-0.35	2.22e-11	Frontotemporal dementia;
LUSC	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	13.38	0.59	5.28e-33	Blood protein levels;
LUSC	cis	rs11112613	0.609	rs4388999	chr12:106047758	G/T	cg03607813	chr12:105948248	NA	0.62	7.7	0.39	1.51e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs9650315	0.929	rs66592895	chr8:57167361	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.12	0.36	6.82e-12	Height;
LUSC	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg22709100	chr7:91322751	NA	0.42	6.19	0.32	1.75e-9	Breast cancer;
LUSC	cis	rs3087591	1.000	rs2012988	chr17:29547296	T/C	cg24425628	chr17:29625626	OMG;NF1	0.56	8.25	0.41	3.59e-15	Hip circumference;
LUSC	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.89	-0.31	9.23e-9	Height;
LUSC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg06238570	chr21:40685208	BRWD1	-0.57	-8.95	-0.44	2.49e-17	Menarche (age at onset);
LUSC	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg09654669	chr8:57350985	NA	-0.56	-7.78	-0.39	9.24e-14	Obesity-related traits;
LUSC	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg08501292	chr6:25962987	TRIM38	0.64	5.85	0.3	1.17e-8	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg23359048	chr12:2921757	ITFG2	0.53	6.44	0.33	4.28e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg03894339	chr8:19674705	INTS10	0.52	6.96	0.36	1.84e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg20701182	chr2:24300061	SF3B14	0.77	7.73	0.39	1.25e-13	Lymphocyte counts;
LUSC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg14154082	chr13:112174009	NA	0.38	7.88	0.4	4.53e-14	Menarche (age at onset);
LUSC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg00049323	chr5:472564	LOC25845	0.49	7.75	0.39	1.08e-13	Cystic fibrosis severity;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11064558	chr21:43430383	ZNF295	-0.45	-5.96	-0.31	6.52e-9	Hepatitis;
LUSC	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg04990556	chr1:26633338	UBXN11	-0.5	-6.91	-0.35	2.4e-11	Obesity-related traits;
LUSC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.76	13.54	0.6	1.38e-33	Aortic root size;
LUSC	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg17652424	chr22:38574118	PLA2G6	-0.28	-5.83	-0.3	1.34e-8	Breast cancer;
LUSC	trans	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.51	0.38	5.28e-13	Ulcerative colitis;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg13307023	chr16:1359278	UBE2I	0.45	6.85	0.35	3.54e-11	Metabolite levels (Pyroglutamine);
LUSC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-1.01	-14.26	-0.62	2.21e-36	Platelet count;
LUSC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg06212747	chr3:49208901	KLHDC8B	0.45	6.09	0.32	3.07e-9	Parkinson's disease;
LUSC	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg00310523	chr12:86230176	RASSF9	0.36	6.44	0.33	4.07e-10	Major depressive disorder;
LUSC	cis	rs239198	0.568	rs979122	chr6:101332215	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-6.3	-0.33	9.29e-10	Menarche (age at onset);
LUSC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg25767906	chr1:53392781	SCP2	0.48	8.69	0.43	1.67e-16	Monocyte count;
LUSC	cis	rs59698941	0.943	rs12515752	chr5:132312960	C/G	cg02081065	chr5:132209139	LEAP2	-0.64	-6.4	-0.33	5.16e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg01802117	chr1:53393560	SCP2	0.38	6.03	0.31	4.32e-9	Monocyte count;
LUSC	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg18721089	chr20:30220636	NA	-0.35	-5.98	-0.31	5.83e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.05	21.16	0.76	1.22e-63	Cognitive function;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01881136	chr16:89438758	ANKRD11	-0.72	-6.27	-0.32	1.13e-9	Cognitive performance;
LUSC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg21724239	chr8:58056113	NA	0.59	6.75	0.35	6.42e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg16989719	chr2:238392110	NA	-0.49	-6.32	-0.33	8.19e-10	Prostate cancer;
LUSC	trans	rs12458462	0.851	rs2169249	chr18:77489649	G/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-6.33	-0.33	7.73e-10	Monocyte count;
LUSC	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg13647721	chr17:30228624	UTP6	0.59	6.1	0.32	2.98e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10964577	chr17:15160725	PMP22	0.42	6.2	0.32	1.67e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs877282	0.898	rs12359731	chr10:759497	A/G	cg17470449	chr10:769945	NA	0.5	7.66	0.39	2.06e-13	Uric acid levels;
LUSC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Parkinson's disease;
LUSC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.3	0.37	2.14e-12	Prudent dietary pattern;
LUSC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.32	-0.37	1.87e-12	Bipolar disorder;
LUSC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg11812906	chr14:75593930	NEK9	-0.65	-10.63	-0.5	6.39e-23	Height;
LUSC	cis	rs9925964	0.748	rs4889603	chr16:30982225	C/T	cg02466173	chr16:30829666	NA	-0.38	-7.23	-0.37	3.37e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.72	-13.51	-0.59	1.8e-33	Extrinsic epigenetic age acceleration;
LUSC	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg01302019	chr3:143689584	C3orf58	-0.43	-7.52	-0.38	5.22e-13	Economic and political preferences (feminism/equality);
LUSC	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg10167463	chr7:75959203	YWHAG	-0.66	-10.07	-0.48	5.33e-21	Multiple sclerosis;
LUSC	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg05283184	chr6:79620031	NA	-0.57	-11.99	-0.55	8.43e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-9.39	-0.46	9.91e-19	Bipolar disorder;
LUSC	cis	rs4072705	1.000	rs13283284	chr9:127516177	T/C	cg13476313	chr9:127244764	NR5A1	0.29	5.65	0.3	3.52e-8	Menarche (age at onset);
LUSC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-1.03	-18.64	-0.71	1.17e-53	Height;
LUSC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.12	0.36	6.77e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06636551	chr8:101224915	SPAG1	-0.44	-8.03	-0.4	1.63e-14	Atrioventricular conduction;
LUSC	cis	rs9420	0.961	rs11602109	chr11:57435296	G/A	cg23127183	chr11:57508653	C11orf31	-0.59	-9.09	-0.45	8.86e-18	Schizophrenia;
LUSC	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg05340658	chr4:99064831	C4orf37	0.57	8.61	0.43	2.84e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4664308	0.935	rs6744567	chr2:160933781	C/G	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.62	-0.54	1.97e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-14.5	-0.62	2.59e-37	Vitiligo;
LUSC	cis	rs7605827	0.930	rs59135666	chr2:15592448	G/A	cg19274914	chr2:15703543	NA	0.48	9.21	0.45	3.77e-18	Educational attainment (years of education);
LUSC	cis	rs2387326	0.717	rs10829340	chr10:129943941	G/T	cg16087940	chr10:129947807	NA	-0.39	-6.0	-0.31	5.27e-9	Select biomarker traits;
LUSC	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.23	-39.3	-0.91	2.68e-127	Myeloid white cell count;
LUSC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg12560992	chr17:57184187	TRIM37	0.62	9.96	0.48	1.29e-20	Testicular germ cell tumor;
LUSC	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg00792783	chr2:198669748	PLCL1	0.43	5.87	0.31	1.04e-8	Dermatomyositis;
LUSC	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg04362960	chr10:104952993	NT5C2	-0.6	-9.35	-0.46	1.33e-18	Arsenic metabolism;
LUSC	cis	rs2273669	0.667	rs12195848	chr6:109279105	A/C	cg05315195	chr6:109294784	ARMC2	-0.6	-6.6	-0.34	1.66e-10	Prostate cancer;
LUSC	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg08345082	chr10:99160200	RRP12	-0.36	-7.31	-0.37	2.02e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.13	0.36	6.31e-12	Morning vs. evening chronotype;
LUSC	cis	rs13266463	0.830	rs7014552	chr8:143410423	A/G	cg16886403	chr8:143471632	TSNARE1	0.61	9.07	0.44	1.02e-17	Schizophrenia;
LUSC	cis	rs9399401	0.961	rs7741741	chr6:142655801	T/A	cg03128060	chr6:142623767	GPR126	0.31	5.68	0.3	3e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg17425144	chr1:10567563	PEX14	-0.58	-11.8	-0.54	4.15e-27	Prostate cancer;
LUSC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg07701084	chr6:150067640	NUP43	0.57	8.74	0.43	1.14e-16	Lung cancer;
LUSC	cis	rs7605827	0.897	rs11684844	chr2:15640552	T/A	cg19274914	chr2:15703543	NA	0.46	8.84	0.44	5.74e-17	Educational attainment (years of education);
LUSC	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-9.47	-0.46	5.4e-19	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg12560992	chr17:57184187	TRIM37	0.41	6.22	0.32	1.48e-9	Cognitive test performance;
LUSC	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg20991723	chr1:152506922	NA	0.51	9.74	0.47	6.76e-20	Hair morphology;
LUSC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg10729496	chr3:10149963	C3orf24	0.53	7.21	0.37	3.79e-12	Alzheimer's disease;
LUSC	cis	rs7560272	0.538	rs4241257	chr2:73938607	T/C	cg20560298	chr2:73613845	ALMS1	0.42	6.47	0.33	3.44e-10	Schizophrenia;
LUSC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.62	-10.56	-0.5	1.13e-22	Blood metabolite levels;
LUSC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg05872129	chr22:39784769	NA	-0.58	-10.59	-0.5	8.65e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs6961069	0.585	rs6968407	chr7:80238117	C/A	cg04458919	chr7:80252533	CD36	-0.4	-7.07	-0.36	9.39e-12	Platelet count;
LUSC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-7.07	-0.36	8.99e-12	Alzheimer's disease (late onset);
LUSC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.54	-7.6	-0.38	3.02e-13	Alzheimer's disease (late onset);
LUSC	cis	rs7246657	0.653	rs10401525	chr19:37658979	C/G	cg23950597	chr19:37808831	NA	-0.58	-5.84	-0.3	1.24e-8	Coronary artery calcification;
LUSC	cis	rs6977660	0.943	rs9638765	chr7:19840616	G/A	cg07541023	chr7:19748670	TWISTNB	0.53	6.13	0.32	2.51e-9	Thyroid stimulating hormone;
LUSC	trans	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg24247370	chr13:99142703	STK24	-0.33	-6.09	-0.32	3.09e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.83	0.75	2.5e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4132509	0.744	rs320305	chr1:243859909	G/T	cg21452805	chr1:244014465	NA	0.64	6.92	0.35	2.31e-11	RR interval (heart rate);
LUSC	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg14582100	chr15:45693742	SPATA5L1	-0.54	-9.13	-0.45	6.62e-18	Homoarginine levels;
LUSC	cis	rs72781680	0.821	rs11894756	chr2:24170214	A/G	cg08917208	chr2:24149416	ATAD2B	-0.64	-7.01	-0.36	1.34e-11	Lymphocyte counts;
LUSC	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg07395648	chr5:131743802	NA	-0.46	-7.37	-0.37	1.31e-12	Breast cancer;Mosquito bite size;
LUSC	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg19743168	chr1:23544995	NA	0.4	7.89	0.4	4.25e-14	Height;
LUSC	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg17507749	chr15:85114479	UBE2QP1	0.54	6.49	0.33	3.11e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg25281562	chr12:121454272	C12orf43	0.45	5.84	0.3	1.22e-8	N-glycan levels;
LUSC	cis	rs7119	0.651	rs12904208	chr15:77845911	C/T	cg27398640	chr15:77910606	LINGO1	-0.32	-6.92	-0.35	2.32e-11	Type 2 diabetes;
LUSC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg27266027	chr21:40555129	PSMG1	-0.39	-5.72	-0.3	2.43e-8	Cognitive function;
LUSC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	0.94	19.04	0.72	2.9e-55	Cognitive function;
LUSC	cis	rs7202877	0.706	rs2059257	chr16:75396376	G/A	cg04384234	chr16:75411784	CFDP1	-0.66	-9.47	-0.46	5.22e-19	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.43	0.5	3.19e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg13334819	chr7:99746414	C7orf59	-0.5	-6.67	-0.34	1.05e-10	Coronary artery disease;
LUSC	cis	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg07988820	chr12:82153109	PPFIA2	-0.4	-5.66	-0.3	3.31e-8	Resting heart rate;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15556090	chr7:149195153	ZNF746	-0.42	-6.07	-0.32	3.52e-9	Electrocardiographic conduction measures;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08830225	chr13:34116653	NA	-0.44	-6.62	-0.34	1.4e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-6.02	-0.31	4.47e-9	Huntington's disease progression;
LUSC	cis	rs3126085	0.877	rs3126045	chr1:152256794	A/G	cg26876637	chr1:152193138	HRNR	0.45	6.08	0.32	3.31e-9	Atopic dermatitis;
LUSC	cis	rs2652834	1.000	rs2729833	chr15:63397044	G/A	cg05507819	chr15:63340323	TPM1	0.66	8.01	0.4	1.95e-14	HDL cholesterol;
LUSC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg11366901	chr6:160182831	ACAT2	0.81	11.23	0.52	4.73e-25	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg22800045	chr5:56110881	MAP3K1	0.44	6.2	0.32	1.69e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg03975922	chr5:140080575	ZMAT2	0.31	5.65	0.3	3.46e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08958952	chr8:142262761	NA	0.48	6.15	0.32	2.23e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg13852791	chr20:30311386	BCL2L1	0.95	14.9	0.63	7.51e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.03	20.73	0.75	5.92e-62	Cognitive function;
LUSC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg05973401	chr12:123451056	ABCB9	0.52	6.48	0.33	3.34e-10	Neutrophil percentage of white cells;
LUSC	cis	rs834603	0.575	rs1799376	chr7:47479583	C/T	cg09696706	chr7:47479511	TNS3	0.35	6.33	0.33	8.01e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	1.08	25.53	0.81	1.77e-80	Testicular germ cell tumor;
LUSC	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg20243544	chr17:37824526	PNMT	0.39	5.85	0.3	1.19e-8	Self-reported allergy;
LUSC	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg08085267	chr17:45401833	C17orf57	-0.63	-10.82	-0.51	1.39e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12292205	chr6:26970375	C6orf41	-0.58	-7.16	-0.36	5.14e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg10857441	chr5:6722123	POLS	-0.44	-8.67	-0.43	1.88e-16	Menopause (age at onset);
LUSC	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg23173402	chr1:227635558	NA	0.57	6.23	0.32	1.38e-9	Major depressive disorder;
LUSC	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.47	-0.46	5.35e-19	Total cholesterol levels;
LUSC	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg18404041	chr3:52824283	ITIH1	0.42	7.32	0.37	1.83e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg01206211	chr2:36825736	FEZ2	-0.52	-11.96	-0.55	1.12e-27	Height;
LUSC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	7.02	0.36	1.28e-11	Melanoma;
LUSC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg12560992	chr17:57184187	TRIM37	0.83	15.25	0.64	3.25e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs2115536	0.720	rs12916091	chr15:80222572	T/G	cg00225070	chr15:80189496	MTHFS	0.6	8.88	0.44	4.31e-17	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.85	0.35	3.51e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg26441486	chr22:50317300	CRELD2	0.53	8.07	0.4	1.27e-14	Schizophrenia;
LUSC	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg23505145	chr19:12996616	KLF1	0.64	10.29	0.49	9.57e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg24829409	chr8:58192753	C8orf71	-0.59	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg19592336	chr6:28129416	ZNF389	0.49	6.58	0.34	1.87e-10	Depression;
LUSC	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.22	0.37	3.52e-12	Morning vs. evening chronotype;
LUSC	trans	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg18187862	chr3:45730750	SACM1L	0.53	6.9	0.35	2.6e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.27	-5.71	-0.3	2.44e-8	Crohn's disease;
LUSC	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg17507749	chr15:85114479	UBE2QP1	0.72	9.42	0.46	7.56e-19	Schizophrenia;
LUSC	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg03732007	chr1:2071316	PRKCZ	0.45	7.16	0.36	5.03e-12	Height;
LUSC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.92	-0.81	3.6e-78	Height;
LUSC	cis	rs4343996	0.967	rs4295560	chr7:3356072	G/A	cg21248987	chr7:3385318	SDK1	-0.36	-6.15	-0.32	2.16e-9	Motion sickness;
LUSC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg23711669	chr6:146136114	FBXO30	0.78	12.55	0.57	7.04e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.83	0.47	3.35e-20	Arsenic metabolism;
LUSC	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg05044414	chr3:183734942	ABCC5	0.2	6.78	0.35	5.41e-11	Anterior chamber depth;
LUSC	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg07936489	chr17:37558343	FBXL20	0.78	9.96	0.48	1.27e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg20243544	chr17:37824526	PNMT	0.48	6.88	0.35	2.89e-11	Asthma;
LUSC	cis	rs17030434	0.906	rs57446135	chr4:154679331	A/G	cg14289246	chr4:154710475	SFRP2	-0.49	-6.49	-0.33	3.12e-10	Electrocardiographic conduction measures;
LUSC	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg23750338	chr8:142222470	SLC45A4	0.58	11.15	0.52	9.23e-25	Immature fraction of reticulocytes;
LUSC	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg17462356	chr17:80056334	FASN	0.45	6.05	0.31	3.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9359856	0.564	rs72915933	chr6:90441464	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.59	-0.43	3.45e-16	Bipolar disorder;
LUSC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.61	0.38	2.89e-13	Schizophrenia;
LUSC	cis	rs2086824	0.702	rs3114896	chr16:89393562	C/T	cg00750074	chr16:89608354	SPG7	0.42	7.18	0.37	4.61e-12	Multiple myeloma (IgH translocation);
LUSC	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	trans	rs3857536	0.674	rs9345798	chr6:66951331	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-5.99	-0.31	5.34e-9	Blood trace element (Cu levels);
LUSC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.53	-0.34	2.42e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-0.92	-13.68	-0.6	4.06e-34	Vitiligo;
LUSC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-1.15	-16.9	-0.68	9.53e-47	Breast cancer;
LUSC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg08132940	chr7:1081526	C7orf50	-0.46	-6.14	-0.32	2.3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.79	0.39	8.71e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs77633900	0.892	rs874223	chr15:76631571	T/C	cg21673338	chr15:77095150	SCAPER	0.62	5.74	0.3	2.12e-8	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg07061783	chr6:25882402	NA	-0.37	-5.87	-0.31	1.07e-8	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.94	-0.31	7.19e-9	Reticulocyte count;
LUSC	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg04362960	chr10:104952993	NT5C2	0.57	8.97	0.44	2.18e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.64	-0.34	1.27e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg14440974	chr22:39074834	NA	0.34	5.77	0.3	1.85e-8	Menopause (age at onset);
LUSC	cis	rs3820928	0.874	rs10167086	chr2:227792729	A/T	cg11843606	chr2:227700838	RHBDD1	0.5	7.21	0.37	3.75e-12	Pulmonary function;
LUSC	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg22618164	chr12:122356400	WDR66	0.57	8.09	0.4	1.1e-14	Mean corpuscular volume;
LUSC	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-7.63	-0.39	2.42e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08109568	chr15:31115862	NA	-0.59	-8.22	-0.41	4.55e-15	Huntington's disease progression;
LUSC	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg25281562	chr12:121454272	C12orf43	-0.43	-5.65	-0.3	3.48e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs41271473	1.000	rs4993975	chr1:228878669	A/C	cg16512390	chr1:228756714	NA	0.5	6.04	0.31	4.05e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg01017244	chr2:74357527	NA	0.67	11.85	0.54	2.7e-27	Gestational age at birth (maternal effect);
LUSC	cis	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.53	8.16	0.41	7.08e-15	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg08742575	chr21:47604166	C21orf56	0.48	7.38	0.37	1.3e-12	Testicular germ cell tumor;
LUSC	cis	rs6542838	0.641	rs6704682	chr2:99499602	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.08	-0.32	3.32e-9	Fear of minor pain;
LUSC	cis	rs6939532	0.761	rs3799378	chr6:26404374	C/T	cg09904177	chr6:26538194	HMGN4	0.43	6.22	0.32	1.52e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14829155	chr15:31115871	NA	-0.72	-10.66	-0.5	5.02e-23	Huntington's disease progression;
LUSC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.47	0.38	7.12e-13	Bipolar disorder;
LUSC	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.11	-0.36	7.15e-12	Bipolar disorder;
LUSC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg01851573	chr8:8652454	MFHAS1	-0.37	-6.35	-0.33	7.06e-10	Mood instability;
LUSC	trans	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg07393940	chr7:158741817	NA	0.37	6.68	0.34	1.02e-10	Life satisfaction;
LUSC	cis	rs78707713	0.512	rs35793747	chr10:71182165	A/G	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.64	-0.47	1.42e-19	Venous thromboembolism;
LUSC	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.41	-0.46	8.46e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4144743	1.000	rs2015049	chr17:45332231	G/A	cg18085866	chr17:45331354	ITGB3	-0.75	-7.81	-0.39	7.38e-14	Body mass index;
LUSC	cis	rs7605827	0.930	rs1015837	chr2:15665847	C/T	cg19274914	chr2:15703543	NA	0.45	8.66	0.43	2.09e-16	Educational attainment (years of education);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03864326	chr16:67927170	PSKH1	0.38	5.98	0.31	5.61e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3812762	0.879	rs10769952	chr11:8776700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.38	6.58	0.34	1.85e-10	Hypospadias;
LUSC	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	10.3	0.49	8.57e-22	Psoriasis;
LUSC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg27165867	chr14:105738592	BRF1	-0.54	-7.88	-0.4	4.8e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg26876637	chr1:152193138	HRNR	-0.44	-6.12	-0.32	2.68e-9	Atopic dermatitis;
LUSC	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-10.17	-0.49	2.37e-21	HDL cholesterol;
LUSC	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg05283184	chr6:79620031	NA	-0.56	-11.8	-0.54	4.4e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg26647111	chr11:31128758	NA	-0.41	-6.0	-0.31	5.27e-9	Bone mineral density (spine);
LUSC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18876405	chr7:65276391	NA	-0.54	-8.68	-0.43	1.78e-16	Aortic root size;
LUSC	cis	rs9473147	0.516	rs10948367	chr6:47585615	A/G	cg12968598	chr6:47444699	CD2AP	0.52	7.94	0.4	3.05e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7727544	0.548	rs35696821	chr5:131508017	C/T	cg14196790	chr5:131705035	SLC22A5	0.47	8.01	0.4	1.89e-14	Blood metabolite levels;
LUSC	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.76	-11.92	-0.55	1.6e-27	Dilated cardiomyopathy;
LUSC	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	0.82	14.19	0.61	4.36e-36	Adiposity;
LUSC	cis	rs981844	0.712	rs1037652	chr4:154746565	C/T	cg14289246	chr4:154710475	SFRP2	0.46	6.23	0.32	1.37e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg26677194	chr12:130822605	PIWIL1	0.56	8.41	0.42	1.21e-15	Menopause (age at onset);
LUSC	cis	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.58	0.34	1.84e-10	Corneal astigmatism;
LUSC	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.65	0.34	1.22e-10	IgG glycosylation;
LUSC	cis	rs2742417	0.603	rs2064062	chr3:45761115	G/C	cg10512202	chr3:45649293	LIMD1	0.36	6.04	0.31	4.18e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.34	-6.53	-0.34	2.46e-10	Total body bone mineral density;
LUSC	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg22920501	chr2:26401640	FAM59B	-0.63	-8.69	-0.43	1.61e-16	Gut microbiome composition (summer);
LUSC	cis	rs8179	0.645	rs2282979	chr7:92264993	T/C	cg15732164	chr7:92237376	CDK6	-0.4	-5.71	-0.3	2.44e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs4409675	0.576	rs3766396	chr1:28221554	C/T	cg23691781	chr1:28212827	C1orf38	-0.31	-7.57	-0.38	3.7e-13	Corneal astigmatism;
LUSC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg14552801	chr7:65878734	NA	-0.41	-6.4	-0.33	5.13e-10	Aortic root size;
LUSC	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg11502198	chr6:26597334	ABT1	-0.59	-9.25	-0.45	2.77e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg19774624	chr17:42201019	HDAC5	-0.82	-13.9	-0.61	5.65e-35	Total body bone mineral density;
LUSC	cis	rs59072704	0.843	rs12028532	chr1:244498605	T/C	cg16908123	chr1:244486252	NA	-0.34	-6.77	-0.35	5.93e-11	Monocyte count;
LUSC	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg11965913	chr1:205819406	PM20D1	-0.49	-6.74	-0.35	6.9e-11	Menarche (age at onset);
LUSC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.73	13.05	0.58	9.68e-32	Dental caries;
LUSC	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg12935359	chr14:103987150	CKB	-0.56	-8.67	-0.43	1.92e-16	Body mass index;
LUSC	cis	rs829883	0.966	rs249818	chr12:98896994	A/C	cg25150519	chr12:98850993	NA	0.64	9.79	0.47	4.44e-20	Colorectal adenoma (advanced);
LUSC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18404041	chr3:52824283	ITIH1	-0.62	-12.3	-0.56	6.21e-29	Bipolar disorder;
LUSC	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg10253484	chr15:75165896	SCAMP2	-0.42	-5.7	-0.3	2.69e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg22532475	chr10:104410764	TRIM8	-0.34	-6.52	-0.34	2.61e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.89	18.14	0.7	1.17e-51	Intelligence (multi-trait analysis);
LUSC	cis	rs354225	0.584	rs7591231	chr2:54829596	C/G	cg01766943	chr2:54829624	SPTBN1	0.46	7.3	0.37	2.1e-12	Schizophrenia;
LUSC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.66	-9.9	-0.48	1.97e-20	IgG glycosylation;
LUSC	cis	rs6733011	0.628	rs4263159	chr2:99456151	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-5.67	-0.3	3.08e-8	Bipolar disorder;
LUSC	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	8.79	0.43	8.3e-17	Migraine;Coronary artery disease;
LUSC	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.72	-0.39	1.37e-13	Joint mobility (Beighton score);
LUSC	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg11019008	chr10:131425282	MGMT	0.42	6.43	0.33	4.42e-10	Response to temozolomide;
LUSC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.02	-15.41	-0.64	7.4e-41	Primary sclerosing cholangitis;
LUSC	cis	rs11214589	0.774	rs7116782	chr11:113250938	A/G	cg14159747	chr11:113255604	NA	0.31	7.93	0.4	3.28e-14	Neuroticism;
LUSC	cis	rs2227631	0.505	rs4729662	chr7:100765559	C/T	cg04735437	chr7:100647879	MUC12	0.44	5.94	0.31	7.26e-9	Plasminogen activator inhibitor type 1 levels (PAI-1);
LUSC	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg13010199	chr12:38710504	ALG10B	0.56	8.27	0.41	3.18e-15	Morning vs. evening chronotype;
LUSC	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg24642439	chr20:33292090	TP53INP2	0.5	7.43	0.38	8.94e-13	Height;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20317738	chr1:9749717	PIK3CD	0.46	7.26	0.37	2.72e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	0.92	13.97	0.61	3.03e-35	Breast cancer;
LUSC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg19622623	chr12:86230825	RASSF9	-0.43	-6.19	-0.32	1.8e-9	Major depressive disorder;
LUSC	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg24375607	chr4:120327624	NA	-0.72	-10.76	-0.51	2.23e-23	Corneal astigmatism;
LUSC	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.73	-12.85	-0.58	5.33e-31	White blood cell count (basophil);
LUSC	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg13334819	chr7:99746414	C7orf59	0.44	5.86	0.31	1.08e-8	Coronary artery disease;
LUSC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg04518342	chr5:131593106	PDLIM4	-0.43	-7.29	-0.37	2.32e-12	Breast cancer;
LUSC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg22920501	chr2:26401640	FAM59B	-0.79	-11.61	-0.54	2.05e-26	Gut microbiome composition (summer);
LUSC	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.87	14.76	0.63	2.57e-38	Bladder cancer;
LUSC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	12.13	0.55	2.54e-28	Colorectal cancer;
LUSC	cis	rs59104589	0.617	rs73002170	chr2:242325980	G/A	cg14842376	chr2:242211374	HDLBP	0.56	6.53	0.34	2.48e-10	Fibrinogen levels;
LUSC	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg24006582	chr15:45444508	DUOX1	-0.6	-8.75	-0.43	1.04e-16	Uric acid levels;
LUSC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg08847533	chr14:75593920	NEK9	-0.8	-13.77	-0.6	1.71e-34	Height;
LUSC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	8.48	0.42	7.38e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2652834	1.000	rs2652834	chr15:63396867	A/G	cg05507819	chr15:63340323	TPM1	0.68	8.27	0.41	3.21e-15	HDL cholesterol;
LUSC	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.41	-0.46	8.46e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs193541	0.632	rs7735618	chr5:122176245	C/G	cg19077854	chr5:122220652	SNX24	0.38	8.06	0.4	1.35e-14	Glucose homeostasis traits;
LUSC	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg12927641	chr6:109611667	NA	0.35	5.74	0.3	2.09e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs55665837	0.539	rs12794714	chr11:14913575	G/A	cg05501817	chr11:14380813	RRAS2	-0.39	-5.72	-0.3	2.41e-8	Vitamin D levels;
LUSC	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg04546413	chr19:29218101	NA	0.6	7.47	0.38	6.95e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	13.14	0.58	4.52e-32	Lymphocyte percentage of white cells;
LUSC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	1.05	20.45	0.75	7.54e-61	Menopause (age at onset);
LUSC	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg07211511	chr3:129823064	LOC729375	-1.2	-19.1	-0.72	1.74e-55	Blood pressure (smoking interaction);
LUSC	cis	rs6599077	0.950	rs10510706	chr3:40100257	T/A	cg13683864	chr3:40499215	RPL14	-0.59	-7.4	-0.38	1.11e-12	Sleep-related phenotypes;
LUSC	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06636551	chr8:101224915	SPAG1	-0.44	-7.98	-0.4	2.33e-14	Atrioventricular conduction;
LUSC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	7.82e-13	Motion sickness;
LUSC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.88	0.31	1.02e-8	Tonsillectomy;
LUSC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.39	0.53	1.26e-25	Menopause (age at onset);
LUSC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg01475377	chr6:109611718	NA	-0.46	-8.49	-0.42	6.94e-16	Reticulocyte fraction of red cells;
LUSC	cis	rs9921338	0.961	rs57579443	chr16:11442997	G/C	cg00044050	chr16:11439710	C16orf75	-0.5	-6.68	-0.34	1e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs6580649	0.883	rs1793955	chr12:48393106	G/T	cg05342945	chr12:48394962	COL2A1	-0.44	-5.83	-0.3	1.27e-8	Lung cancer;
LUSC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	5.99	0.31	5.53e-9	Breast cancer;
LUSC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2273669	0.504	rs77373614	chr6:109418075	T/C	cg05315195	chr6:109294784	ARMC2	-0.55	-5.92	-0.31	8e-9	Prostate cancer;
LUSC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg02018176	chr4:1364513	KIAA1530	0.52	8.87	0.44	4.63e-17	Obesity-related traits;
LUSC	cis	rs6840360	0.967	rs7684350	chr4:152672882	T/G	cg22705602	chr4:152727874	NA	-0.26	-5.7	-0.3	2.62e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg16545954	chr1:2118288	C1orf86	0.36	6.92	0.35	2.32e-11	Height;
LUSC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg11062466	chr8:58055876	NA	0.52	7.11	0.36	7.07e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6906287	0.647	rs35730412	chr6:118707343	T/C	cg21191810	chr6:118973309	C6orf204	0.33	5.9	0.31	9.13e-9	Electrocardiographic conduction measures;
LUSC	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg09307838	chr4:120376055	NA	0.63	9.38	0.46	1.03e-18	Corneal astigmatism;
LUSC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	6.19	0.32	1.8e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg27129171	chr3:47204927	SETD2	0.56	8.01	0.4	1.93e-14	Birth weight;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg18538332	chr22:24372958	LOC391322	-0.43	-7.73	-0.39	1.32e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6545883	0.894	rs7566035	chr2:61520815	C/T	cg15711740	chr2:61764176	XPO1	0.45	6.93	0.35	2.15e-11	Tuberculosis;
LUSC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg13397359	chr6:42928475	GNMT	0.57	9.43	0.46	7.22e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg23630131	chr7:65973040	NA	-0.21	-5.93	-0.31	7.77e-9	Aortic root size;
LUSC	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg05182265	chr7:156933206	UBE3C	-0.59	-9.69	-0.47	9.71e-20	Body mass index;
LUSC	cis	rs9398803	0.830	rs9401885	chr6:126825837	C/G	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	1.97e-9	Male-pattern baldness;
LUSC	cis	rs778371	0.723	rs34707169	chr2:233699459	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-12.4	-0.56	2.56e-29	Schizophrenia;
LUSC	cis	rs909002	0.800	rs6703093	chr1:32093561	C/T	cg01639898	chr1:32083012	HCRTR1	0.3	7.35	0.37	1.49e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08280861	chr8:58055591	NA	0.53	5.81	0.3	1.5e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2274273	1.000	rs3825613	chr14:55593172	A/C	cg04306507	chr14:55594613	LGALS3	0.53	11.51	0.53	4.72e-26	Protein biomarker;
LUSC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg19592336	chr6:28129416	ZNF389	0.48	6.29	0.33	1.02e-9	Depression;
LUSC	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg01620082	chr3:125678407	NA	-0.78	-7.6	-0.38	3.04e-13	Depression;
LUSC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.26	0.32	1.19e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg09323728	chr8:95962352	TP53INP1	-0.38	-7.73	-0.39	1.24e-13	Type 2 diabetes;
LUSC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg12403142	chr1:92012408	NA	0.36	5.86	0.31	1.13e-8	Breast cancer;
LUSC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.65	-0.3	3.53e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg18904891	chr8:8559673	CLDN23	0.59	8.1	0.41	1.03e-14	Obesity-related traits;
LUSC	cis	rs2273669	0.667	rs7765732	chr6:109347057	A/C	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	13.38	0.59	5.28e-33	Blood protein levels;
LUSC	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg17757837	chr7:157058334	UBE3C	0.82	13.03	0.58	1.16e-31	Body mass index;
LUSC	cis	rs7043114	0.507	rs7856204	chr9:95173814	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.86	-0.35	3.33e-11	Height;
LUSC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg05872129	chr22:39784769	NA	-0.53	-9.57	-0.46	2.44e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-11.61	-0.54	2.17e-26	Schizophrenia;
LUSC	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-8.12	-0.41	9.4e-15	Glomerular filtration rate (creatinine);
LUSC	trans	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg07211511	chr3:129823064	LOC729375	-0.78	-10.16	-0.49	2.55e-21	Blood pressure (smoking interaction);
LUSC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-6.16	-0.32	2.14e-9	Mood instability;
LUSC	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg08975724	chr8:8085496	FLJ10661	0.47	6.66	0.34	1.14e-10	Neuroticism;
LUSC	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg25801113	chr15:45476975	SHF	-0.34	-6.7	-0.34	9.1e-11	Uric acid levels;
LUSC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.41	-6.78	-0.35	5.32e-11	Electroencephalogram traits;
LUSC	trans	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg19894588	chr14:64061835	NA	0.49	7.13	0.36	6.25e-12	Glioblastoma;Glioma;
LUSC	cis	rs73200209	0.744	rs61939697	chr12:116555491	T/C	cg01776926	chr12:116560359	MED13L	-0.5	-5.99	-0.31	5.44e-9	Total body bone mineral density;
LUSC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg11344533	chr11:111475393	SIK2	-0.49	-6.61	-0.34	1.48e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6429082	0.755	rs291367	chr1:235690800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.64	8.97	0.44	2.25e-17	Adiposity;
LUSC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16405210	chr4:1374714	KIAA1530	-0.58	-9.36	-0.46	1.22e-18	Obesity-related traits;
LUSC	cis	rs6009527	1.000	rs6009527	chr22:49570587	C/T	cg12746016	chr22:49560550	NA	0.39	6.71	0.34	8.37e-11	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs9807841	0.592	rs10419865	chr19:10772685	C/G	cg17710535	chr19:10819994	QTRT1	0.42	6.94	0.36	1.99e-11	Inflammatory skin disease;
LUSC	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14442939	chr10:27389572	ANKRD26	0.85	9.93	0.48	1.62e-20	Breast cancer;
LUSC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06634786	chr22:41940651	POLR3H	-0.54	-6.22	-0.32	1.51e-9	Vitiligo;
LUSC	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07080220	chr10:102295463	HIF1AN	0.7	9.4	0.46	8.73e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg25456477	chr12:86230367	RASSF9	0.33	5.78	0.3	1.68e-8	Major depressive disorder;
LUSC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs2115536	0.730	rs4238512	chr15:80183898	A/C	cg00225070	chr15:80189496	MTHFS	-0.42	-6.09	-0.32	3.03e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7200543	0.961	rs1741	chr16:15130351	G/C	cg03427771	chr16:15082598	PDXDC1	-0.42	-5.85	-0.3	1.19e-8	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06028605	chr16:24865363	SLC5A11	0.67	9.78	0.47	5.08e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs71403859	0.554	rs12373065	chr16:71870032	T/A	cg03805757	chr16:71968109	PKD1L3	-0.6	-6.36	-0.33	6.45e-10	Post bronchodilator FEV1;
LUSC	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg03585969	chr10:35415529	CREM	0.63	9.32	0.45	1.68e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6967385	0.580	rs10258717	chr7:12331651	A/G	cg06484146	chr7:12443880	VWDE	0.4	6.44	0.33	4.13e-10	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg02772935	chr3:125709198	NA	-0.47	-5.64	-0.3	3.55e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.42	-0.38	1.01e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg15133208	chr4:90757351	SNCA	-0.32	-5.65	-0.3	3.38e-8	Dementia with Lewy bodies;
LUSC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg12463550	chr7:65579703	CRCP	-0.43	-6.36	-0.33	6.61e-10	Aortic root size;
LUSC	cis	rs7605827	0.930	rs13035283	chr2:15500939	G/C	cg19274914	chr2:15703543	NA	0.45	8.46	0.42	8.55e-16	Educational attainment (years of education);
LUSC	cis	rs7169223	0.653	rs1976007	chr15:79085023	T/C	cg21242079	chr15:79101063	ADAMTS7	0.42	6.4	0.33	5.2400000000000005e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.48e-12	Motion sickness;
LUSC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02018176	chr4:1364513	KIAA1530	-0.71	-13.67	-0.6	4.39e-34	Longevity;
LUSC	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	0.86	15.73	0.65	4.15e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg27661571	chr11:113659931	NA	-0.62	-7.41	-0.38	1.02e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18932078	chr1:2524107	MMEL1	-0.31	-6.93	-0.35	2.21e-11	Ulcerative colitis;
LUSC	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg18755752	chr8:142205143	DENND3	-0.76	-13.61	-0.6	7.1e-34	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg22903657	chr4:1355424	KIAA1530	-0.5	-8.41	-0.42	1.23e-15	Obesity-related traits;
LUSC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.02	19.57	0.73	2.39e-57	Cognitive function;
LUSC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg08888203	chr3:10149979	C3orf24	0.59	8.17	0.41	6.42e-15	Alzheimer's disease;
LUSC	cis	rs6489785	0.735	rs12825746	chr12:121268033	A/C	cg02403541	chr12:121454288	C12orf43	0.38	5.68	0.3	2.89e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6700896	0.864	rs11208718	chr1:66158995	G/A	cg04111102	chr1:66153794	NA	0.34	7.42	0.38	1e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg13866156	chr1:1669148	SLC35E2	0.5	8.3	0.41	2.69e-15	Body mass index;
LUSC	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.8	-13.14	-0.58	4.48e-32	Lymphocyte percentage of white cells;
LUSC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg07212818	chr11:638076	DRD4	-0.42	-7.15	-0.36	5.65e-12	Systemic lupus erythematosus;
LUSC	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg23029597	chr12:123009494	RSRC2	-0.74	-9.29	-0.45	1.98e-18	Body mass index;
LUSC	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.41	-0.33	5e-10	Cutaneous nevi;
LUSC	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg14530993	chr4:882597	GAK	0.64	6.73	0.35	7.19e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg26441486	chr22:50317300	CRELD2	0.49	7.45	0.38	7.81e-13	Schizophrenia;
LUSC	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.75	-12.2	-0.56	1.45e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25517151	chr20:30467953	TTLL9	-0.42	-6.12	-0.32	2.57e-9	Hepatitis;
LUSC	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg03522245	chr20:25566470	NINL	0.36	5.84	0.3	1.24e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg24579218	chr15:68104479	NA	-0.34	-5.67	-0.3	3.08e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg15848620	chr12:58087721	OS9	-0.56	-7.94	-0.4	3.09e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.35e-12	Asthma (childhood onset);
LUSC	cis	rs12286929	0.898	rs117569901	chr11:115018509	T/G	cg04055981	chr11:115044050	NA	0.35	5.93	0.31	7.44e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg06636001	chr8:8085503	FLJ10661	0.6	9.29	0.45	2e-18	Neuroticism;
LUSC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-10.13	-0.48	3.26e-21	Electroencephalogram traits;
LUSC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg05941027	chr17:61774174	LIMD2	0.22	5.83	0.3	1.29e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-0.96	-10.25	-0.49	1.29e-21	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7267979	0.816	rs390123	chr20:25480105	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.77	15.74	0.65	3.66e-42	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.89	-0.31	9.61e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3087591	0.708	rs8067440	chr17:29708155	A/T	cg24425628	chr17:29625626	OMG;NF1	0.54	8.29	0.41	2.88e-15	Hip circumference;
LUSC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg23490090	chr17:78081364	GAA	0.36	5.83	0.3	1.27e-8	Yeast infection;
LUSC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg07537917	chr2:241836409	C2orf54	0.26	5.94	0.31	7.33e-9	Urinary metabolites;
LUSC	cis	rs2230307	0.536	rs57637634	chr1:100447467	G/A	cg24955406	chr1:100503596	HIAT1	0.56	6.08	0.32	3.31e-9	Carotid intima media thickness;
LUSC	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg04450456	chr4:17643702	FAM184B	0.35	5.77	0.3	1.81e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg18825076	chr15:78729989	IREB2	0.46	6.44	0.33	4.18e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg17366294	chr4:99064904	C4orf37	0.5	8.81	0.43	6.78e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.5	7.79	0.39	8.3e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7582720	1.000	rs77931721	chr2:203763076	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.66	0.43	2.06e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs4901869	1.000	rs4901869	chr14:59334128	A/G	cg02291164	chr14:59296302	NA	0.57	10.93	0.51	5.74e-24	Panic disorder;
LUSC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg12863693	chr15:85201151	NMB	-0.25	-5.75	-0.3	2.07e-8	Schizophrenia;
LUSC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg22920501	chr2:26401640	FAM59B	0.76	9.87	0.48	2.47e-20	Gut microbiome composition (summer);
LUSC	cis	rs9581857	0.547	rs9579096	chr13:28084069	T/C	cg22138327	chr13:27999177	GTF3A	0.69	7.15	0.36	5.44e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs34638657	0.500	rs12446210	chr16:82185762	G/A	cg09439754	chr16:82129088	HSD17B2	-0.36	-6.52	-0.34	2.52e-10	Lung adenocarcinoma;
LUSC	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg06636551	chr8:101224915	SPAG1	0.36	6.68	0.34	9.77e-11	Atrioventricular conduction;
LUSC	trans	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg15556689	chr8:8085844	FLJ10661	0.54	7.79	0.39	8.77e-14	Systemic lupus erythematosus;
LUSC	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg03585969	chr10:35415529	CREM	0.66	9.47	0.46	5.19e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg20406979	chr6:167373233	NA	-0.26	-6.07	-0.32	3.4e-9	Crohn's disease;
LUSC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.47	-8.63	-0.43	2.6e-16	Total body bone mineral density;
LUSC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg14092988	chr3:52407081	DNAH1	0.32	6.25	0.32	1.27e-9	Bipolar disorder;
LUSC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg06640241	chr16:89574553	SPG7	0.72	11.3	0.53	2.63e-25	Multiple myeloma (IgH translocation);
LUSC	cis	rs11051970	1.000	rs6488051	chr12:32532733	G/C	cg24626660	chr12:32551988	NA	0.37	6.12	0.32	2.64e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs806215	1.000	rs806215	chr7:127237312	T/C	cg25922125	chr7:127225783	GCC1	-0.57	-7.18	-0.37	4.7e-12	Type 2 diabetes;
LUSC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06481639	chr22:41940642	POLR3H	-0.53	-6.08	-0.32	3.24e-9	Vitiligo;
LUSC	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg05855489	chr10:104503620	C10orf26	0.54	8.09	0.4	1.14e-14	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05901451	chr6:126070800	HEY2	-0.58	-8.59	-0.43	3.43e-16	Endometrial cancer;
LUSC	cis	rs4964805	0.612	rs11111758	chr12:104161084	A/G	cg02344784	chr12:104178138	NT5DC3	0.37	5.94	0.31	7.35e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg14196790	chr5:131705035	SLC22A5	-0.52	-9.13	-0.45	6.49e-18	Blood metabolite levels;
LUSC	cis	rs3784262	1.000	rs3204689	chr15:58246802	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-6.22	-0.32	1.52e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg17644776	chr2:200775616	C2orf69	0.5	8.62	0.43	2.71e-16	Osteoporosis;
LUSC	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg16950941	chr11:66035639	RAB1B	0.51	7.46	0.38	7.47e-13	Gout;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11905131	chr22:24372483	LOC391322	-0.51	-8.39	-0.42	1.37e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12980942	0.935	rs1865051	chr19:41824885	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.05	0.31	3.87e-9	Coronary artery disease;
LUSC	trans	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.4	-0.33	5.41e-10	Neuroticism;
LUSC	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg00012203	chr2:219082015	ARPC2	-0.57	-9.16	-0.45	5.27e-18	Ulcerative colitis;
LUSC	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg26102564	chr10:131424627	MGMT	0.42	6.69	0.34	9.38e-11	Response to temozolomide;
LUSC	cis	rs7127129	0.503	rs7105001	chr11:70051949	T/C	cg06159181	chr11:70072977	NA	-0.27	-6.75	-0.35	6.44e-11	Aortic root size;
LUSC	cis	rs894344	0.650	rs55675081	chr8:135582032	C/A	cg17885191	chr8:135476712	NA	0.4	5.65	0.3	3.45e-8	Systolic blood pressure;
LUSC	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg22676075	chr6:135203613	NA	0.48	7.48	0.38	6.5e-13	Red blood cell count;
LUSC	cis	rs2274273	0.837	rs7142857	chr14:55704128	C/T	cg04306507	chr14:55594613	LGALS3	0.58	13.66	0.6	4.84e-34	Protein biomarker;
LUSC	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg05283184	chr6:79620031	NA	-0.46	-8.63	-0.43	2.52e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs6076960	0.622	rs6054063	chr20:6262992	C/A	cg17788362	chr6:86352627	SYNCRIP	0.47	7.14	0.36	5.94e-12	Smooth-surface caries;
LUSC	trans	rs1223397	0.938	rs17767967	chr6:13282067	C/T	cg13974761	chr1:152670598	LCE2A	0.36	5.95	0.31	6.67e-9	Blood pressure;
LUSC	cis	rs8133932	0.608	rs373267	chr21:47343320	G/T	cg14185626	chr21:47401492	COL6A1	-0.44	-5.78	-0.3	1.74e-8	Schizophrenia;
LUSC	cis	rs1568889	1.000	rs34667360	chr11:28055650	T/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	8.94	0.44	2.63e-17	Bipolar disorder;
LUSC	trans	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.12	-0.32	2.67e-9	Bone mineral density;
LUSC	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg01733217	chr16:74700730	RFWD3	0.97	22.18	0.77	1.26e-67	Multiple myeloma;
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.43	7.22	0.37	3.58e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.95	12.31	0.56	5.59e-29	Exhaled nitric oxide output;
LUSC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	0.81	11.47	0.53	6.7e-26	Response to hepatitis C treatment;
LUSC	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.65	10.3	0.49	8.73e-22	Response to antipsychotic treatment;
LUSC	cis	rs7923609	0.812	rs10761753	chr10:65161903	G/A	cg01631684	chr10:65280961	REEP3	-0.42	-6.47	-0.33	3.48e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6500395	0.775	rs4277341	chr16:48664387	T/G	cg04672837	chr16:48644449	N4BP1	0.47	7.01	0.36	1.36e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08219700	chr8:58056026	NA	0.64	7.88	0.4	4.52e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg09904177	chr6:26538194	HMGN4	-0.75	-5.74	-0.3	2.14e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs1568889	0.548	rs34906813	chr11:28508819	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.5	5.86	0.31	1.13e-8	Bipolar disorder;
LUSC	cis	rs12681287	0.752	rs4472493	chr8:87251914	C/T	cg27223183	chr8:87520930	FAM82B	-0.45	-5.76	-0.3	1.87e-8	Caudate activity during reward;
LUSC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14298792	chr15:30685198	CHRFAM7A	0.64	8.34	0.42	1.96e-15	Huntington's disease progression;
LUSC	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg15556689	chr8:8085844	FLJ10661	0.65	10.48	0.5	2.05e-22	Mood instability;
LUSC	cis	rs11955175	0.717	rs41271053	chr5:40835393	A/C	cg05478818	chr5:40835740	RPL37	0.76	5.86	0.31	1.08e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs12210905	0.688	rs114157955	chr6:27329878	C/T	cg08851530	chr6:28072375	NA	0.9	5.78	0.3	1.75e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.76	-0.3	1.96e-8	Testicular germ cell tumor;
LUSC	cis	rs4722404	0.570	rs1968924	chr7:3137677	G/T	cg19214707	chr7:3157722	NA	-0.36	-6.92	-0.35	2.28e-11	Atopic dermatitis;
LUSC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg07148914	chr20:33460835	GGT7	0.39	5.77	0.3	1.82e-8	Coronary artery disease;
LUSC	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg15448220	chr1:150897856	SETDB1	0.43	6.23	0.32	1.43e-9	Melanoma;
LUSC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2274273	0.870	rs10144345	chr14:55847737	T/C	cg04306507	chr14:55594613	LGALS3	0.56	12.97	0.58	2.02e-31	Protein biomarker;
LUSC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg11189052	chr15:85197271	WDR73	0.47	5.66	0.3	3.24e-8	Schizophrenia;
LUSC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg08392591	chr16:89556376	ANKRD11	0.52	8.13	0.41	8.62e-15	Multiple myeloma (IgH translocation);
LUSC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg04414720	chr1:150670196	GOLPH3L	0.5	7.86	0.4	5.27e-14	Melanoma;
LUSC	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.12	-0.36	6.7e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.52e-8	Breast cancer;
LUSC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg06096015	chr1:231504339	EGLN1	0.57	9.97	0.48	1.16e-20	Hemoglobin concentration;
LUSC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg12310025	chr6:25882481	NA	-0.51	-9.34	-0.45	1.44e-18	Blood metabolite levels;
LUSC	cis	rs12190007	0.547	rs3006178	chr6:169823936	G/A	cg15038512	chr6:170123185	PHF10	-0.39	-6.26	-0.32	1.16e-9	Obesity-related traits;
LUSC	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	13.74	0.6	2.33e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.84	-13.98	-0.61	2.84e-35	Height;
LUSC	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg05985134	chr18:33552581	C18orf21	-0.52	-7.31	-0.37	2e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg23630131	chr7:65973040	NA	0.2	5.72	0.3	2.4e-8	Aortic root size;
LUSC	trans	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg18187862	chr3:45730750	SACM1L	0.54	7.05	0.36	1.02e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2425143	0.908	rs11697087	chr20:34427583	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-6.3	-0.33	9.6e-10	Blood protein levels;
LUSC	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg03929089	chr4:120376271	NA	-0.45	-6.12	-0.32	2.58e-9	HDL cholesterol;
LUSC	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg12935359	chr14:103987150	CKB	-0.65	-10.61	-0.5	7.5e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg00033643	chr7:134001901	SLC35B4	0.44	6.75	0.35	6.5500000000000006e-11	Mean platelet volume;
LUSC	trans	rs11935423	0.778	rs11933250	chr4:100491509	T/C	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.1	-0.32	3e-9	Gut microbiome composition (summer);
LUSC	cis	rs7827545	0.545	rs16905172	chr8:135556373	A/G	cg17885191	chr8:135476712	NA	0.61	7.83	0.39	6.53e-14	Hypertension (SNP x SNP interaction);
LUSC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-8.68	-0.43	1.83e-16	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17467752	chr17:38218738	THRA	-0.53	-8.03	-0.4	1.68e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs936229	0.813	rs72730503	chr15:75086386	G/A	cg10253484	chr15:75165896	SCAMP2	-0.51	-6.65	-0.34	1.19e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg12463550	chr7:65579703	CRCP	-0.55	-8.23	-0.41	4.27e-15	Aortic root size;
LUSC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg16362232	chr11:430036	ANO9	0.63	8.24	0.41	3.85e-15	Body mass index;
LUSC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg18681998	chr4:17616180	MED28	0.85	15.67	0.65	6.85e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	0.7	15.04	0.64	2.08e-39	Prudent dietary pattern;
LUSC	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg13010199	chr12:38710504	ALG10B	0.68	10.59	0.5	8.44e-23	Bladder cancer;
LUSC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg07061783	chr6:25882402	NA	-0.49	-6.49	-0.33	3.13e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-5.7	-0.3	2.67e-8	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg18904891	chr8:8559673	CLDN23	0.58	8.07	0.4	1.25e-14	Obesity-related traits;
LUSC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg00409905	chr10:38381863	ZNF37A	0.36	6.23	0.32	1.4e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg17385448	chr1:15911702	AGMAT	0.35	5.92	0.31	7.87e-9	Systolic blood pressure;
LUSC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg25767906	chr1:53392781	SCP2	0.53	9.76	0.47	5.75e-20	Monocyte count;
LUSC	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-0.57	-8.76	-0.43	9.79e-17	Breast cancer;
LUSC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg16928487	chr17:17741425	SREBF1	0.37	7.13	0.36	6.28e-12	Total body bone mineral density;
LUSC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg19318889	chr4:1322082	MAEA	-0.71	-12.08	-0.55	3.97e-28	Obesity-related traits;
LUSC	cis	rs9807989	0.839	rs13392100	chr2:102982094	C/A	cg09003973	chr2:102972529	NA	0.44	6.04	0.31	4.11e-9	Asthma;
LUSC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11764359	chr7:65958608	NA	0.61	9.2	0.45	3.91e-18	Calcium levels;
LUSC	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.79	0.51	1.7e-23	Coffee consumption (cups per day);
LUSC	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg03709012	chr19:19516395	GATAD2A	1.06	10.79	0.51	1.69e-23	LDL cholesterol;
LUSC	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg03983476	chr2:10830698	NOL10	-0.37	-5.71	-0.3	2.56e-8	Prostate cancer;
LUSC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.51	-0.42	6.04e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.25	0.52	4.11e-25	Eye color traits;
LUSC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08645402	chr16:4508243	NA	0.49	7.73	0.39	1.25e-13	Schizophrenia;
LUSC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.68	12.09	0.55	3.69e-28	Aortic root size;
LUSC	cis	rs4409675	0.597	rs1000431	chr1:28225114	C/T	cg23691781	chr1:28212827	C1orf38	0.31	7.43	0.38	9.31e-13	Corneal astigmatism;
LUSC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.89	-0.31	9.55e-9	Platelet count;
LUSC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg13206674	chr6:150067644	NUP43	0.6	9.55	0.46	2.91e-19	Lung cancer;
LUSC	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg02958346	chr11:57425731	CLP1	-0.43	-6.28	-0.32	1.06e-9	Schizophrenia;
LUSC	cis	rs4852324	0.541	rs7568898	chr2:74271577	C/T	cg19729930	chr2:74357872	NA	0.54	6.14	0.32	2.32e-9	Systemic lupus erythematosus;
LUSC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg17376030	chr22:41985996	PMM1	-0.48	-6.02	-0.31	4.57e-9	Vitiligo;
LUSC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.13	0.48	3.24e-21	Bipolar disorder;
LUSC	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg22709100	chr7:91322751	NA	0.39	5.79	0.3	1.64e-8	Breast cancer;
LUSC	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg07810366	chr2:100720526	AFF3	-0.42	-7.11	-0.36	7.19e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.44	0.33	4.21e-10	Alzheimer's disease (late onset);
LUSC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-7.73	-0.39	1.25e-13	Obesity-related traits;
LUSC	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg00784671	chr22:46762841	CELSR1	-0.6	-6.92	-0.35	2.34e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6554196	0.508	rs10488849	chr4:55510862	C/T	cg18836493	chr4:55524333	KIT	-0.41	-7.1	-0.36	7.66e-12	Monocyte count;
LUSC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg16262614	chr3:133464971	TF	0.43	7.54	0.38	4.61e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg11812906	chr14:75593930	NEK9	-0.65	-10.73	-0.51	2.9e-23	Height;
LUSC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-7.39	-0.38	1.15e-12	Alzheimer's disease (late onset);
LUSC	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.44	0.33	4.14e-10	Height;
LUSC	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg27284194	chr4:1044797	NA	0.55	7.97	0.4	2.57e-14	Recombination rate (females);
LUSC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg08968635	chr6:28129556	ZNF389	0.44	5.92	0.31	8.12e-9	Parkinson's disease;
LUSC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg13114125	chr14:105738426	BRF1	-0.87	-14.38	-0.62	8.24e-37	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg17252645	chr8:143867129	LY6D	0.45	8.13	0.41	8.71e-15	Urinary tract infection frequency;
LUSC	cis	rs1045714	0.895	rs4719602	chr7:2647800	G/A	cg24848437	chr7:2645542	IQCE	0.6	6.81	0.35	4.66e-11	Urate levels in lean individuals;
LUSC	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.06	24.19	0.8	2.16e-75	Schizophrenia;
LUSC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg22638593	chr5:131593259	PDLIM4	0.4	6.37	0.33	6.11e-10	Blood metabolite levels;
LUSC	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	7.08	0.36	8.68e-12	Retinal vascular caliber;
LUSC	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-8.84	-0.44	5.44e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs11809207	0.857	rs11247866	chr1:26517794	A/G	cg00147160	chr1:26503991	CNKSR1	0.41	6.77	0.35	5.87e-11	Height;
LUSC	cis	rs4619890	0.528	rs62289339	chr4:7878981	C/G	cg24250820	chr4:7887609	AFAP1	0.36	6.1	0.32	2.86e-9	Glaucoma (primary open-angle);
LUSC	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.38e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg09789173	chr7:4769017	FOXK1	0.66	12.3	0.56	6.2e-29	Mosquito bite size;
LUSC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21963583	chr11:68658836	MRPL21	0.55	8.28	0.41	3.08e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.77	12.58	0.57	5.68e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg12940439	chr1:67600707	NA	0.37	6.25	0.32	1.22e-9	Psoriasis;
LUSC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg15448220	chr1:150897856	SETDB1	-0.42	-5.93	-0.31	7.71e-9	Melanoma;
LUSC	cis	rs62400317	0.859	rs10456549	chr6:45225761	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.79	-0.39	8.69e-14	Total body bone mineral density;
LUSC	cis	rs354225	0.544	rs4641979	chr2:54811917	G/A	cg26097391	chr2:54893211	SPTBN1	0.42	6.35	0.33	6.88e-10	Schizophrenia;
LUSC	cis	rs1832871	0.683	rs9459852	chr6:158687250	T/G	cg07165851	chr6:158734300	TULP4	0.5	7.72	0.39	1.41e-13	Height;
LUSC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.16	0.77	1.43e-67	Prudent dietary pattern;
LUSC	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg26384229	chr12:38710491	ALG10B	0.67	9.39	0.46	9.49e-19	Resting heart rate;
LUSC	cis	rs12760731	0.565	rs10913516	chr1:178169493	G/A	cg00404053	chr1:178313656	RASAL2	0.68	6.86	0.35	3.3e-11	Obesity-related traits;
LUSC	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.51	8.87	0.44	4.42e-17	HDL cholesterol;
LUSC	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg00012203	chr2:219082015	ARPC2	-0.58	-9.35	-0.46	1.33e-18	Ulcerative colitis;
LUSC	cis	rs7799006	1.000	rs7810970	chr7:2276385	A/G	cg08027265	chr7:2291960	NA	-0.42	-7.33	-0.37	1.77e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	1.04	27.09	0.83	2.57e-86	Menarche (age at onset);
LUSC	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.98	-0.31	5.73e-9	IgG glycosylation;
LUSC	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	10.61	0.5	7.62e-23	Response to antipsychotic treatment;
LUSC	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg10434728	chr15:90938212	IQGAP1	0.33	6.24	0.32	1.32e-9	Rheumatoid arthritis;
LUSC	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-0.78	-11.88	-0.54	2.25e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	0.64	13.37	0.59	5.97e-33	Prudent dietary pattern;
LUSC	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg01420254	chr6:26195488	NA	0.65	7.28	0.37	2.44e-12	Gout;Renal underexcretion gout;
LUSC	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.81	-0.35	4.45e-11	Triglycerides;
LUSC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg24060327	chr5:131705240	SLC22A5	-0.48	-7.07	-0.36	8.85e-12	Breast cancer;
LUSC	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg26061582	chr7:22766209	IL6	0.48	6.9	0.35	2.61e-11	Lung cancer;
LUSC	trans	rs2905347	0.726	rs2961294	chr7:22695031	T/C	cg09038599	chr8:57233391	SDR16C5	-0.28	-6.11	-0.32	2.84e-9	Major depression and alcohol dependence;
LUSC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg04317338	chr11:64019027	PLCB3	0.68	7.7	0.39	1.52e-13	Mean platelet volume;
LUSC	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.46	-6.84	-0.35	3.81e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs7712401	0.623	rs7723798	chr5:122369717	C/G	cg19077854	chr5:122220652	SNX24	0.33	6.84	0.35	3.76e-11	Mean platelet volume;
LUSC	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg06636551	chr8:101224915	SPAG1	0.38	7.02	0.36	1.23e-11	Atrioventricular conduction;
LUSC	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg09877947	chr5:131593287	PDLIM4	0.38	6.15	0.32	2.27e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs478304	0.718	rs1144789	chr11:65389631	A/G	cg27068330	chr11:65405492	SIPA1	0.67	9.61	0.47	1.79e-19	Acne (severe);
LUSC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.1	0.52	1.4e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6969780	0.778	rs61384251	chr7:27146202	A/G	cg26364809	chr7:27145159	NA	-0.61	-6.12	-0.32	2.68e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg16325326	chr1:53192061	ZYG11B	0.96	18.57	0.71	2.3e-53	Monocyte count;
LUSC	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.81	10.69	0.51	3.78e-23	Triglycerides;
LUSC	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg15556689	chr8:8085844	FLJ10661	0.67	10.64	0.5	6.05e-23	Mood instability;
LUSC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg00129232	chr17:37814104	STARD3	-0.5	-7.43	-0.38	9.42e-13	Asthma;
LUSC	cis	rs259282	0.524	rs11878322	chr19:33122886	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.79	12.62	0.57	4.15e-30	Schizophrenia;
LUSC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg16989086	chr20:62203971	PRIC285	0.47	6.66	0.34	1.11e-10	Glioblastoma;
LUSC	cis	rs62408225	0.722	rs3734660	chr6:90916345	A/G	cg06866423	chr6:90926672	BACH2	0.41	6.45	0.33	3.95e-10	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.69	13.39	0.59	5.1e-33	Gestational age at birth (maternal effect);
LUSC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.88	0.63	8.88e-39	Platelet count;
LUSC	cis	rs6484504	0.600	rs942272	chr11:31364368	C/T	cg06552810	chr11:31128660	NA	0.39	6.74	0.35	7.04e-11	Red blood cell count;
LUSC	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.16	0.55	1.98e-28	Height;
LUSC	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18252515	chr7:66147081	NA	-0.58	-7.99	-0.4	2.16e-14	Corneal structure;
LUSC	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-7.03	-0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.56	-0.38	3.82e-13	Body mass index;
LUSC	cis	rs2637266	1.000	rs1907314	chr10:78337948	G/A	cg18941641	chr10:78392320	NA	0.36	6.52	0.34	2.66e-10	Pulmonary function;
LUSC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg05347473	chr6:146136440	FBXO30	-0.39	-6.57	-0.34	1.97e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11209002	0.738	rs10789222	chr1:67566651	C/T	cg02640540	chr1:67518911	SLC35D1	0.65	6.48	0.33	3.32e-10	Crohn's disease;
LUSC	trans	rs1325195	0.840	rs2793816	chr1:179244723	C/T	cg11624085	chr17:8464688	MYH10	0.38	6.14	0.32	2.29e-9	IgE grass sensitization;
LUSC	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.96	13.89	0.61	6.2e-35	Exhaled nitric oxide output;
LUSC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.77	-0.35	5.92e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg09436375	chr6:42928200	GNMT	-0.3	-6.8	-0.35	4.73e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	7.41	0.38	1.05e-12	Neuroticism;
LUSC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2055729	0.645	rs12543996	chr8:9742666	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.72	-0.35	8.04e-11	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.47	7.12	0.36	6.71e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg10840412	chr1:235813424	GNG4	0.45	5.96	0.31	6.57e-9	Bipolar disorder;
LUSC	cis	rs16937	0.711	rs6682229	chr1:205152932	T/C	cg00857998	chr1:205179979	DSTYK	0.46	6.47	0.33	3.46e-10	Schizophrenia;
LUSC	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg27539214	chr16:67997921	SLC12A4	-0.47	-6.24	-0.32	1.3e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08859206	chr1:53392774	SCP2	0.5	8.67	0.43	1.9e-16	Monocyte count;
LUSC	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg06552810	chr11:31128660	NA	0.42	7.32	0.37	1.89e-12	Bone mineral density (spine);
LUSC	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg04607235	chr12:12878440	APOLD1	-0.56	-6.38	-0.33	5.81e-10	Systemic lupus erythematosus;
LUSC	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg21427119	chr20:30132790	HM13	-0.46	-6.65	-0.34	1.2e-10	Mean corpuscular hemoglobin;
LUSC	trans	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.53e-9	Bladder cancer;
LUSC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg26769984	chr7:1090371	C7orf50	0.54	7.3	0.37	2.06e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.38	-0.37	1.27e-12	Bipolar disorder;
LUSC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.59	-0.38	3.19e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs73206853	0.841	rs59698293	chr12:111054455	C/G	cg12870014	chr12:110450643	ANKRD13A	0.69	6.51	0.34	2.76e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg10578777	chr12:7781093	NA	-0.6	-6.58	-0.34	1.82e-10	HDL cholesterol levels;
LUSC	cis	rs34779708	0.733	rs4298846	chr10:35547380	A/G	cg03585969	chr10:35415529	CREM	0.53	7.38	0.37	1.3e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.33	-0.41	2.17e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs28785552	0.769	rs28796114	chr19:53234319	T/C	cg10871876	chr19:53194124	ZNF83	0.55	8.31	0.41	2.36e-15	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg00012203	chr2:219082015	ARPC2	0.81	14.2	0.61	3.83e-36	Colorectal cancer;
LUSC	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg06671706	chr8:8559999	CLDN23	0.49	6.61	0.34	1.48e-10	Obesity-related traits;
LUSC	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg15896084	chr13:114927664	NA	0.38	6.85	0.35	3.54e-11	Schizophrenia;
LUSC	cis	rs3960554	0.610	rs10265696	chr7:75766712	G/A	cg17325771	chr7:75508891	RHBDD2	-0.42	-5.86	-0.31	1.11e-8	Eotaxin levels;
LUSC	cis	rs11158026	0.662	rs28481699	chr14:55406549	A/T	cg04306507	chr14:55594613	LGALS3	0.35	6.67	0.34	1.07e-10	Parkinson's disease;
LUSC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.09	0.61	1.02e-35	Platelet count;
LUSC	cis	rs7216064	1.000	rs1976054	chr17:65833224	T/G	cg12091567	chr17:66097778	LOC651250	-0.74	-9.39	-0.46	9.68e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg02751453	chr18:77725136	HSBP1L1	-0.48	-6.31	-0.33	8.81e-10	Opioid sensitivity;
LUSC	cis	rs7215564	0.908	rs9908112	chr17:78753455	A/G	cg06153925	chr17:78755379	RPTOR	-0.38	-5.75	-0.3	2e-8	Myopia (pathological);
LUSC	trans	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.74	0.54	6.94e-27	Mean corpuscular volume;
LUSC	cis	rs17102423	0.533	rs3783715	chr14:65490018	C/G	cg11161011	chr14:65562177	MAX	-0.73	-9.89	-0.48	2.06e-20	Obesity-related traits;
LUSC	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg06462663	chr19:18546047	ISYNA1	0.49	8.24	0.41	3.89e-15	Breast cancer;
LUSC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	1.04	18.76	0.72	4.04e-54	Parkinson's disease;
LUSC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg23630131	chr7:65973040	NA	0.2	5.66	0.3	3.3e-8	Aortic root size;
LUSC	trans	rs1459104	0.789	rs12802739	chr11:54899892	A/G	cg15704280	chr7:45808275	SEPT13	0.69	5.97	0.31	6.07e-9	Body mass index;
LUSC	cis	rs2742234	0.955	rs2503865	chr10:43659536	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.36	-6.63	-0.34	1.38e-10	Hirschsprung disease;
LUSC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-7.53	-0.38	4.66e-13	Mood instability;
LUSC	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.55	-8.94	-0.44	2.71e-17	Post bronchodilator FEV1;
LUSC	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg22681709	chr2:178499509	PDE11A	-0.4	-6.11	-0.32	2.72e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.21	-0.37	3.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg04518342	chr5:131593106	PDLIM4	0.33	5.96	0.31	6.57e-9	Blood metabolite levels;
LUSC	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg23625390	chr15:77176239	SCAPER	-0.67	-10.17	-0.49	2.38e-21	Blood metabolite levels;
LUSC	cis	rs16854884	0.657	rs1979910	chr3:143710268	A/C	cg06585982	chr3:143692056	C3orf58	0.49	7.6	0.38	3.11e-13	Economic and political preferences (feminism/equality);
LUSC	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.14	0.45	6.29e-18	Reticulocyte count;High light scatter reticulocyte count;
LUSC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.13	0.48	3.24e-21	Bipolar disorder;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.5	-7.08	-0.36	8.31e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg17469321	chr7:55412551	NA	0.68	10.8	0.51	1.59e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.88	14.27	0.62	2.16e-36	Coronary artery disease;
LUSC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14893161	chr1:205819251	PM20D1	-0.56	-8.92	-0.44	3.17e-17	Menarche (age at onset);
LUSC	cis	rs2540226	0.844	rs727376	chr2:40000487	T/G	cg23576258	chr2:39999331	THUMPD2	0.33	5.7	0.3	2.68e-8	Personality dimensions;
LUSC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg14004847	chr7:1930337	MAD1L1	-0.56	-8.44	-0.42	9.92e-16	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs7605827	0.836	rs4396685	chr2:15634407	C/T	cg19274914	chr2:15703543	NA	0.46	8.84	0.44	5.74e-17	Educational attainment (years of education);
LUSC	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg17168535	chr8:21777572	XPO7	0.86	15.91	0.66	8.28e-43	Mean corpuscular volume;
LUSC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.51	7.32	0.37	1.89e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.5	-6.8	-0.35	4.9e-11	Renal function-related traits (BUN);
LUSC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26314531	chr2:26401878	FAM59B	-0.7	-9.75	-0.47	6.29e-20	Gut microbiome composition (summer);
LUSC	cis	rs4776059	0.798	rs4774634	chr15:52872488	G/C	cg25063058	chr15:52860530	ARPP19	0.48	6.46	0.33	3.6e-10	Schizophrenia;
LUSC	cis	rs6714710	0.663	rs71429376	chr2:98534412	T/C	cg26665480	chr2:98280029	ACTR1B	0.57	8.31	0.41	2.48e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg20283391	chr11:68216788	NA	0.57	8.08	0.4	1.17e-14	Total body bone mineral density;
LUSC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg04871131	chr7:94954202	PON1	-0.37	-5.98	-0.31	5.79e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-10.45	-0.5	2.68e-22	Morning vs. evening chronotype;
LUSC	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg12310025	chr6:25882481	NA	-0.34	-5.68	-0.3	2.91e-8	Height;
LUSC	trans	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-8.69	-0.43	1.6e-16	Obesity-related traits;
LUSC	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg22709100	chr7:91322751	NA	0.41	5.94	0.31	7.08e-9	Breast cancer;
LUSC	cis	rs11158026	0.757	rs8013521	chr14:55413725	G/C	cg04306507	chr14:55594613	LGALS3	0.34	6.34	0.33	7.42e-10	Parkinson's disease;
LUSC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg24675658	chr1:53192096	ZYG11B	0.72	11.94	0.55	1.36e-27	Monocyte count;
LUSC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg04414720	chr1:150670196	GOLPH3L	0.53	8.33	0.41	2.16e-15	Melanoma;
LUSC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg03146154	chr1:46216737	IPP	0.55	8.21	0.41	5.01e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4363385	0.818	rs11205166	chr1:152988627	C/G	cg00922841	chr1:152955080	SPRR1A	-0.4	-6.77	-0.35	5.66e-11	Inflammatory skin disease;
LUSC	cis	rs68170813	0.559	rs75723759	chr7:106962407	A/G	cg02696742	chr7:106810147	HBP1	-0.64	-9.46	-0.46	5.6e-19	Coronary artery disease;
LUSC	trans	rs1325195	0.920	rs2793799	chr1:179202209	A/G	cg11624085	chr17:8464688	MYH10	-0.41	-6.52	-0.34	2.53e-10	IgE grass sensitization;
LUSC	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg11317459	chr13:21872234	NA	-1.13	-15.8	-0.65	2.23e-42	White matter hyperintensity burden;
LUSC	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg00750074	chr16:89608354	SPG7	-0.45	-7.75	-0.39	1.11e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.23	-0.37	3.4e-12	Alzheimer's disease (late onset);
LUSC	cis	rs7674212	0.510	rs2720468	chr4:104085153	A/G	cg16532752	chr4:104119610	CENPE	-0.48	-6.78	-0.35	5.31e-11	Type 2 diabetes;
LUSC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.82	13.96	0.61	3.32e-35	Monocyte count;
LUSC	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg09904177	chr6:26538194	HMGN4	-0.73	-6.68	-0.34	1e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.07	-0.32	3.51e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-6.28	-0.33	1.04e-9	Neuroticism;
LUSC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg07741184	chr6:167504864	NA	0.37	6.65	0.34	1.17e-10	Crohn's disease;
LUSC	cis	rs11958404	0.932	rs60504573	chr5:157436786	T/A	cg05962755	chr5:157440814	NA	0.53	6.3	0.33	9.34e-10	IgG glycosylation;
LUSC	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	0.7	11.13	0.52	1.1e-24	Blood metabolite ratios;
LUSC	cis	rs6942756	1.000	rs13235749	chr7:128879678	C/G	cg02491457	chr7:128862824	NA	-0.53	-7.66	-0.39	2.01e-13	White matter hyperintensity burden;
LUSC	cis	rs2274273	0.745	rs56262555	chr14:55561962	C/T	cg04306507	chr14:55594613	LGALS3	0.48	10.45	0.5	2.55e-22	Protein biomarker;
LUSC	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.56	-9.23	-0.45	3.27e-18	Breast cancer;
LUSC	cis	rs10754283	0.967	rs1320563	chr1:90121032	G/A	cg21401794	chr1:90099060	LRRC8C	0.63	8.98	0.44	2.08e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs4654899	0.812	rs7539512	chr1:21410791	A/G	cg01072550	chr1:21505969	NA	-0.51	-7.8	-0.39	8.21e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11764359	chr7:65958608	NA	-0.63	-9.64	-0.47	1.45e-19	Aortic root size;
LUSC	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.37	1.18e-12	Glomerular filtration rate (creatinine);
LUSC	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg15704280	chr7:45808275	SEPT13	0.75	8.36	0.42	1.74e-15	Axial length;
LUSC	cis	rs7084921	0.579	rs11596253	chr10:101849411	C/A	cg02250046	chr10:101825185	CPN1	-0.35	-6.2	-0.32	1.63e-9	Bone mineral density;
LUSC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg22437258	chr11:111473054	SIK2	0.46	6.05	0.31	3.93e-9	Primary sclerosing cholangitis;
LUSC	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg24579218	chr15:68104479	NA	-0.34	-6.0	-0.31	5.14e-9	Restless legs syndrome;
LUSC	trans	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg06606381	chr12:133084897	FBRSL1	-0.6	-7.09	-0.36	7.99e-12	Depression;
LUSC	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.47	-0.38	7.04e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg01802117	chr1:53393560	SCP2	0.36	5.88	0.31	9.95e-9	Monocyte count;
LUSC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.73	13.13	0.58	4.77e-32	Prudent dietary pattern;
LUSC	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg02023728	chr11:77925099	USP35	0.52	7.12	0.36	6.68e-12	Testicular germ cell tumor;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13615036	chr15:91475826	UNC45A;HDDC3	0.76	6.07	0.32	3.44e-9	Cognitive performance;
LUSC	cis	rs7131987	0.650	rs4331146	chr12:29440083	G/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.63	-0.34	1.37e-10	QT interval;
LUSC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.67	-10.77	-0.51	2.04e-23	Height;
LUSC	trans	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.61	-0.43	2.97e-16	Total cholesterol levels;
LUSC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.3	-0.37	2.08e-12	Bipolar disorder;
LUSC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg14500267	chr11:67383377	NA	0.31	5.99	0.31	5.3e-9	Mean corpuscular volume;
LUSC	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg09904177	chr6:26538194	HMGN4	0.73	13.27	0.59	1.45e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-8.29	-0.41	2.8e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg14552801	chr7:65878734	NA	-0.46	-6.53	-0.34	2.45e-10	Aortic root size;
LUSC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	7.25	0.37	2.98e-12	Schizophrenia;
LUSC	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg24154853	chr7:158122151	PTPRN2	0.45	8.8	0.43	7.55e-17	Calcium levels;
LUSC	cis	rs3741151	0.773	rs73544710	chr11:73162273	A/G	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg09367891	chr1:107599246	PRMT6	-0.56	-8.82	-0.43	6.58e-17	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg21724239	chr8:58056113	NA	0.79	8.36	0.42	1.73e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs12541635	0.966	rs1496182	chr8:107024505	C/T	cg10147462	chr8:107024639	NA	0.56	10.17	0.49	2.33e-21	Age of smoking initiation;
LUSC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg09455208	chr3:40491958	NA	0.59	10.39	0.49	4.25e-22	Renal cell carcinoma;
LUSC	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-25.28	-0.81	1.53e-79	Exhaled nitric oxide output;
LUSC	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg03433033	chr1:76189801	ACADM	-0.47	-7.06	-0.36	9.68e-12	Daytime sleep phenotypes;
LUSC	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg19640130	chr10:64028056	RTKN2	-0.41	-7.47	-0.38	7.09e-13	Rheumatoid arthritis;
LUSC	cis	rs6700896	0.931	rs59508186	chr1:66107881	C/A	cg04111102	chr1:66153794	NA	0.3	6.48	0.33	3.2e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg13042288	chr15:90349979	ANPEP	-0.48	-6.91	-0.35	2.46e-11	Uric acid levels;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02927485	chr7:97601469	MGC72080	0.45	5.97	0.31	6.03e-9	Neuroticism;
LUSC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg01283332	chr5:1856932	NA	-0.33	-6.15	-0.32	2.21e-9	Cardiovascular disease risk factors;
LUSC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26314531	chr2:26401878	FAM59B	-0.67	-9.3	-0.45	1.92e-18	Gut microbiome composition (summer);
LUSC	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg17031739	chr1:67600172	NA	0.49	7.59	0.38	3.33e-13	Psoriasis;
LUSC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-0.99	-17.59	-0.69	1.74e-49	Coronary artery disease;
LUSC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06637938	chr14:75390232	RPS6KL1	0.86	16.13	0.66	1.06e-43	Caffeine consumption;
LUSC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	0.63	13.44	0.59	3.14e-33	Prudent dietary pattern;
LUSC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03934478	chr11:495069	RNH1	0.85	9.72	0.47	7.65e-20	Body mass index;
LUSC	cis	rs9682041	0.569	rs11914970	chr3:170112307	T/G	cg11886554	chr3:170076028	SKIL	0.72	9.85	0.47	3.02e-20	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LUSC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4268898	0.760	rs55863105	chr2:24570695	C/T	cg06627628	chr2:24431161	ITSN2	0.57	8.07	0.4	1.24e-14	Asthma;
LUSC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs9942416	0.533	rs12109685	chr5:75024066	A/G	cg19683494	chr5:74908142	NA	0.5	6.88	0.35	2.94e-11	Age-related disease endophenotypes;
LUSC	cis	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg01733217	chr16:74700730	RFWD3	1.0	21.85	0.77	2.39e-66	Multiple myeloma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25235159	chr11:47600280	KBTBD4;NDUFS3	-0.45	-6.73	-0.35	7.61e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1595825	1.000	rs73058832	chr2:198873214	G/T	cg00982548	chr2:198649783	BOLL	-0.5	-6.23	-0.32	1.38e-9	Ulcerative colitis;
LUSC	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.7	-0.39	1.58e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg26384229	chr12:38710491	ALG10B	-0.6	-9.3	-0.45	1.91e-18	Morning vs. evening chronotype;
LUSC	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg04492858	chr10:133558786	NA	0.36	6.33	0.33	8.01e-10	Survival in rectal cancer;
LUSC	trans	rs4800353	0.929	rs7238695	chr18:19609624	G/T	cg01841828	chr16:69166849	CHTF8;CIRH1A	-0.58	-6.04	-0.31	4.02e-9	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg13535736	chr9:111863775	C9orf5	-0.4	-6.6	-0.34	1.59e-10	Menarche (age at onset);
LUSC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg09365446	chr1:150670422	GOLPH3L	0.51	7.5	0.38	5.68e-13	Melanoma;
LUSC	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg23029597	chr12:123009494	RSRC2	-0.73	-9.14	-0.45	6.05e-18	Body mass index;
LUSC	cis	rs2637266	1.000	rs35991266	chr10:78378733	A/G	cg18941641	chr10:78392320	NA	0.38	6.94	0.36	2.04e-11	Pulmonary function;
LUSC	cis	rs13242816	1.000	rs7809755	chr7:116110732	C/T	cg16553024	chr7:116138462	CAV2	-0.52	-5.71	-0.3	2.44e-8	P wave duration;
LUSC	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg12002119	chr2:101014098	CHST10	0.36	6.09	0.32	3.15e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg27068330	chr11:65405492	SIPA1	-0.76	-10.72	-0.51	3.02e-23	Acne (severe);
LUSC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg23283495	chr1:209979779	IRF6	0.64	9.36	0.46	1.21e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg13114125	chr14:105738426	BRF1	-0.91	-15.96	-0.66	5.17e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg15448220	chr1:150897856	SETDB1	0.42	6.12	0.32	2.6e-9	Melanoma;
LUSC	cis	rs2274273	0.624	rs10132453	chr14:55840851	C/T	cg04306507	chr14:55594613	LGALS3	0.49	9.94	0.48	1.47e-20	Protein biomarker;
LUSC	cis	rs11997175	0.716	rs7460818	chr8:33816362	A/G	ch.8.33884649F	chr8:33765107	NA	0.53	8.17	0.41	6.33e-15	Body mass index;
LUSC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05890377	chr2:74357713	NA	0.72	13.65	0.6	4.97e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-10.62	-0.5	7.08e-23	Bipolar disorder;
LUSC	cis	rs2262909	0.962	rs73019844	chr19:22249925	T/C	cg11619707	chr19:22235551	ZNF257	0.39	5.83	0.3	1.29e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9311676	0.632	rs56281646	chr3:58424917	G/A	cg13750441	chr3:58318267	PXK	0.35	6.73	0.35	7.53e-11	Systemic lupus erythematosus;
LUSC	cis	rs9311676	0.656	rs6445973	chr3:58336595	G/T	cg26110898	chr3:58419937	PDHB	-0.39	-6.11	-0.32	2.73e-9	Systemic lupus erythematosus;
LUSC	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.94	-0.35	2.06e-11	Response to antipsychotic treatment;
LUSC	trans	rs12043259	0.730	rs7539437	chr1:204795888	G/T	cg05134015	chr14:36973365	SFTA3	-0.5	-6.04	-0.31	4.05e-9	Addiction;
LUSC	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.92	15.65	0.65	8.39e-42	Bladder cancer;
LUSC	trans	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg06521331	chr12:34319734	NA	0.4	6.42	0.33	4.59e-10	Bladder cancer;
LUSC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.69	0.43	1.65e-16	Prudent dietary pattern;
LUSC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.72	0.51	3.04e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg17173187	chr15:85201210	NMB	0.49	9.48	0.46	4.73e-19	Schizophrenia;
LUSC	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-10.25	-0.49	1.28e-21	Mood instability;
LUSC	cis	rs16912285	0.688	rs7128680	chr11:24338796	C/T	ch.11.24196551F	chr11:24239977	NA	0.85	8.18	0.41	6.17e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs11603020	0.950	rs28362948	chr11:57369013	A/C	cg23127183	chr11:57508653	C11orf31	-0.46	-6.36	-0.33	6.65e-10	Blood protein levels;
LUSC	trans	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.35	-0.33	7.23e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg08508325	chr11:3079039	CARS	0.36	8.15	0.41	7.41e-15	Calcium levels;
LUSC	cis	rs6577655	0.547	rs7841171	chr8:135591699	G/A	cg17885191	chr8:135476712	NA	0.58	7.55	0.38	4.15e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs367943	0.712	rs13359330	chr5:112708529	T/C	cg12552261	chr5:112820674	MCC	0.35	5.73	0.3	2.23e-8	Type 2 diabetes;
LUSC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18595196	chr3:52726726	GNL3;SNORD69	-0.29	-5.65	-0.3	3.46e-8	Bipolar disorder;
LUSC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00684032	chr4:1343700	KIAA1530	-0.36	-6.32	-0.33	8.46e-10	Obesity-related traits;
LUSC	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg07423050	chr13:99094983	FARP1	-0.53	-9.76	-0.47	5.98e-20	Longevity;
LUSC	cis	rs10979	0.597	rs9403516	chr6:143908139	A/T	cg25407410	chr6:143891975	LOC285740	0.61	7.72	0.39	1.34e-13	Hypospadias;
LUSC	cis	rs11166629	0.637	rs1899432	chr8:135576255	C/T	cg27224718	chr8:135614730	ZFAT	0.54	7.84	0.39	5.92e-14	Smoking quantity;
LUSC	cis	rs1524927	0.933	rs12704874	chr7:96340744	A/G	cg03808172	chr7:96339361	SHFM1	0.43	6.66	0.34	1.12e-10	Total body bone mineral density;
LUSC	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg14227996	chr4:17616232	MED28	-0.6	-6.67	-0.34	1.06e-10	Opioid sensitivity;
LUSC	cis	rs7598759	0.712	rs997400	chr2:232332847	C/T	cg19187155	chr2:232395269	NMUR1	0.49	7.2	0.37	3.96e-12	Noise-induced hearing loss;
LUSC	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-9.07	-0.44	1.08e-17	Coffee consumption (cups per day);
LUSC	cis	rs7615316	1.000	rs9824893	chr3:142341152	A/T	cg16271453	chr3:142027066	XRN1	-0.36	-6.2	-0.32	1.64e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs71403859	0.730	rs35390364	chr16:71740049	A/G	cg08717414	chr16:71523259	ZNF19	-0.65	-7.11	-0.36	7.27e-12	Post bronchodilator FEV1;
LUSC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg06494592	chr3:125709126	NA	-0.5	-5.79	-0.3	1.64e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6546886	0.957	rs11886928	chr2:74258529	T/G	cg14702570	chr2:74259524	NA	-0.31	-5.91	-0.31	8.36e-9	Dialysis-related mortality;
LUSC	cis	rs654950	0.875	rs881719	chr1:41991427	C/T	cg06885757	chr1:42089581	HIVEP3	-0.38	-7.41	-0.38	1.04e-12	Airway imaging phenotypes;
LUSC	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg05738196	chr6:26577821	NA	0.81	15.2	0.64	4.92e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs4499344	0.730	rs259285	chr19:33164697	T/C	cg22980127	chr19:33182716	NUDT19	-0.42	-6.3	-0.33	9.55e-10	Mean platelet volume;
LUSC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08280861	chr8:58055591	NA	0.58	7.29	0.37	2.22e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg06784218	chr1:46089804	CCDC17	-0.57	-11.34	-0.53	1.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs4776059	1.000	rs17614559	chr15:52878719	G/A	cg22715398	chr15:52968154	KIAA1370	-0.66	-9.41	-0.46	8.34e-19	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs12410462	0.581	rs111356515	chr1:227537236	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.66	-6.52	-0.34	2.61e-10	Major depressive disorder;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.47	7.58	0.38	3.55e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-9.99	-0.48	1.02e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg16928487	chr17:17741425	SREBF1	-0.43	-8.55	-0.42	4.5e-16	Total body bone mineral density;
LUSC	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.65	0.39	2.21e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg11645453	chr3:52864694	ITIH4	0.29	6.84	0.35	3.86e-11	Electroencephalogram traits;
LUSC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	8.96	0.44	2.3e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.6	-9.67	-0.47	1.18e-19	Prudent dietary pattern;
LUSC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.16	0.68	9.42e-48	Chronic sinus infection;
LUSC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.72	11.55	0.53	3.46e-26	Prudent dietary pattern;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02938130	chr5:150460100	TNIP1	0.46	6.14	0.32	2.35e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.09	0.48	4.41e-21	Bladder cancer;
LUSC	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg15644404	chr18:77186268	NFATC1	-0.68	-7.62	-0.38	2.63e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7712401	0.601	rs374403	chr5:122341713	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.25	-0.45	2.68e-18	Mean platelet volume;
LUSC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	ch.11.42038R	chr11:967971	AP2A2	0.44	6.6	0.34	1.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg24006582	chr15:45444508	DUOX1	-0.6	-8.75	-0.43	1.04e-16	Uric acid levels;
LUSC	cis	rs72781680	0.716	rs72788206	chr2:24084989	T/C	cg08917208	chr2:24149416	ATAD2B	0.6	7.04	0.36	1.08e-11	Lymphocyte counts;
LUSC	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg06636001	chr8:8085503	FLJ10661	0.49	7.09	0.36	7.95e-12	Retinal vascular caliber;
LUSC	cis	rs3820928	0.874	rs3752896	chr2:227886925	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.69	-0.39	1.66e-13	Pulmonary function;
LUSC	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	0.99	14.7	0.63	4.58e-38	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg08392591	chr16:89556376	ANKRD11	0.44	6.82	0.35	4.38e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg05084668	chr3:125655381	ALG1L	-0.79	-11.93	-0.55	1.47e-27	Blood pressure (smoking interaction);
LUSC	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.56	-10.8	-0.51	1.57e-23	Educational attainment;
LUSC	cis	rs36093844	0.848	rs2084079	chr11:85590436	C/A	cg25872744	chr11:85566296	CCDC83	-0.42	-6.2	-0.32	1.64e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.42	-0.33	4.69e-10	Resting heart rate;
LUSC	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg12823233	chr7:2316876	SNX8	-0.45	-7.71	-0.39	1.43e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg03929089	chr4:120376271	NA	0.69	7.78	0.39	9.14e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2354432	0.505	rs4424556	chr1:146863973	G/C	cg25205988	chr1:146714368	CHD1L	0.86	7.57	0.38	3.78e-13	Mitochondrial DNA levels;
LUSC	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	13.96	0.61	3.41e-35	Lymphocyte percentage of white cells;
LUSC	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.74	-0.3	2.08e-8	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.18	0.52	7.07e-25	Menopause (age at onset);
LUSC	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-12.52	-0.57	9.36e-30	Primary sclerosing cholangitis;
LUSC	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg22852734	chr6:133119734	C6orf192	1.17	14.05	0.61	1.48e-35	Type 2 diabetes nephropathy;
LUSC	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg24006582	chr15:45444508	DUOX1	-0.62	-9.1	-0.45	8.07e-18	Uric acid levels;
LUSC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg13628971	chr7:2884303	GNA12	0.46	6.57	0.34	1.91e-10	Height;
LUSC	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg21918786	chr6:109611834	NA	-0.4	-6.9	-0.35	2.61e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg22089800	chr15:90895588	ZNF774	-0.64	-9.68	-0.47	1.06e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg14584255	chr6:163149320	PACRG;PARK2	-0.34	-6.52	-0.34	2.66e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg18131467	chr2:239335373	ASB1	-0.72	-6.6	-0.34	1.63e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg01238044	chr22:24384105	GSTT1	-0.71	-11.3	-0.53	2.61e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg08477640	chr19:41863820	B9D2	-0.53	-8.11	-0.41	9.52e-15	Colorectal cancer;
LUSC	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg20607287	chr7:12443886	VWDE	-0.57	-6.03	-0.31	4.43e-9	Coronary artery disease;
LUSC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg19230755	chr7:65878503	NA	-0.43	-5.96	-0.31	6.34e-9	Aortic root size;
LUSC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg05234568	chr11:5960015	NA	-0.55	-8.71	-0.43	1.43e-16	DNA methylation (variation);
LUSC	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg05738196	chr6:26577821	NA	0.81	15.2	0.64	4.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg20573242	chr4:122745356	CCNA2	0.45	6.89	0.35	2.72e-11	Type 2 diabetes;
LUSC	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg06885757	chr1:42089581	HIVEP3	0.49	10.05	0.48	6.05e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21862992	chr11:68658383	NA	0.51	7.94	0.4	3.06e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg12432903	chr7:1882776	MAD1L1	-0.39	-6.23	-0.32	1.42e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg13939156	chr17:80058883	NA	-0.33	-6.6	-0.34	1.65e-10	Life satisfaction;
LUSC	cis	rs7072216	0.587	rs3814141	chr10:100171028	G/A	cg26618903	chr10:100175079	PYROXD2	-0.43	-7.15	-0.36	5.46e-12	Metabolite levels;
LUSC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.52	7.81	0.39	7.58e-14	Lymphocyte counts;
LUSC	cis	rs243505	0.660	rs3807451	chr7:148538622	T/C	cg09806900	chr7:148480153	CUL1	0.49	6.46	0.33	3.78e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg17173187	chr15:85201210	NMB	0.49	9.48	0.46	4.73e-19	Schizophrenia;
LUSC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg17376030	chr22:41985996	PMM1	-0.46	-5.79	-0.3	1.65e-8	Vitiligo;
LUSC	cis	rs7712401	0.562	rs30062	chr5:122296376	C/G	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.84	-0.35	3.89e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.06e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	8.87	0.44	4.5e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs1178127	0.580	rs1178173	chr7:18795959	A/C	cg02370815	chr7:18831390	HDAC9	-0.39	-5.82	-0.3	1.34e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
LUSC	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.84	0.44	5.75e-17	Lung cancer;
LUSC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg09034736	chr1:150693464	HORMAD1	0.47	6.48	0.33	3.35e-10	Urate levels;
LUSC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg09365446	chr1:150670422	GOLPH3L	0.45	6.61	0.34	1.52e-10	Melanoma;
LUSC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10802521	chr3:52805072	NEK4	-0.53	-8.05	-0.4	1.48e-14	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.59e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg03351412	chr1:154909251	PMVK	0.56	8.9	0.44	3.73e-17	Prostate cancer;
LUSC	trans	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.51	-8.19	-0.41	5.53e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7428496	0.528	rs4256152	chr3:142219542	A/G	cg16271453	chr3:142027066	XRN1	0.5	8.96	0.44	2.34e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-0.53	-8.77	-0.43	9.16e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.26	0.45	2.6e-18	Prudent dietary pattern;
LUSC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg17178900	chr1:205818956	PM20D1	-0.41	-5.69	-0.3	2.72e-8	Parkinson's disease;
LUSC	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg02158880	chr13:53174818	NA	0.57	9.69	0.47	1.02e-19	Lewy body disease;
LUSC	cis	rs1784581	0.588	rs1789988	chr6:162408472	C/T	cg17173639	chr6:162384350	PARK2	-0.58	-9.94	-0.48	1.42e-20	Itch intensity from mosquito bite;
LUSC	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	7.27	0.37	2.49e-12	Neuroticism;
LUSC	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg04310649	chr10:35416472	CREM	-0.4	-6.04	-0.31	4.2e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	1.05	27.58	0.83	4.35e-88	Menarche (age at onset);
LUSC	trans	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg06636001	chr8:8085503	FLJ10661	0.42	6.13	0.32	2.43e-9	Retinal vascular caliber;
LUSC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg22117172	chr7:91764530	CYP51A1	0.32	5.68	0.3	2.9e-8	Breast cancer;
LUSC	cis	rs17253792	0.822	rs78323463	chr14:56045451	T/G	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	8.91e-12	Putamen volume;
LUSC	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg15556689	chr8:8085844	FLJ10661	0.55	8.28	0.41	3.03e-15	Neuroticism;
LUSC	cis	rs1322512	0.917	rs2758803	chr6:152955858	G/A	cg27316956	chr6:152958899	SYNE1	-0.36	-6.07	-0.32	3.55e-9	Tonometry;
LUSC	cis	rs7759001	0.857	rs9468111	chr6:27355083	T/A	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	1.97e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs12620999	0.941	rs62183342	chr2:237979140	C/A	cg23555395	chr2:238036564	NA	0.45	7.87	0.4	5.05e-14	Systemic lupus erythematosus;
LUSC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-0.93	-13.27	-0.59	1.43e-32	Vitiligo;
LUSC	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg18753928	chr3:113234510	CCDC52	-0.52	-8.01	-0.4	1.99e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg03146154	chr1:46216737	IPP	-0.57	-8.28	-0.41	2.94e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg19773385	chr1:10388646	KIF1B	0.57	9.95	0.48	1.35e-20	Hepatocellular carcinoma;
LUSC	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.42	-0.38	1.01e-12	Morning vs. evening chronotype;
LUSC	cis	rs12190007	0.517	rs3006210	chr6:169828915	C/T	ch.6.169577133F	chr6:169835210	NA	-0.4	-5.96	-0.31	6.54e-9	Obesity-related traits;
LUSC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs12541635	0.677	rs1496183	chr8:107024445	C/T	cg10147462	chr8:107024639	NA	0.68	14.15	0.61	5.93e-36	Age of smoking initiation;
LUSC	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg21775007	chr8:11205619	TDH	-0.49	-7.01	-0.36	1.3e-11	Neuroticism;
LUSC	cis	rs4746822	0.954	rs10998647	chr10:70977308	T/G	cg14418922	chr10:70824840	NA	-0.38	-6.1	-0.32	2.85e-9	Glycemic traits (pregnancy);
LUSC	cis	rs73206853	0.686	rs56339227	chr12:111164963	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.52	0.38	5.1e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08219700	chr8:58056026	NA	0.68	7.92	0.4	3.63e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg26384229	chr12:38710491	ALG10B	0.79	13.51	0.59	1.72e-33	Morning vs. evening chronotype;
LUSC	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg00540400	chr15:79124168	NA	-0.47	-8.17	-0.41	6.66e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg26513180	chr16:89883248	FANCA	-0.53	-7.89	-0.4	4.28e-14	Vitiligo;
LUSC	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg22681709	chr2:178499509	PDE11A	0.48	8.7	0.43	1.58e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9581857	0.615	rs3759435	chr13:27996813	T/G	cg22138327	chr13:27999177	GTF3A	0.85	10.8	0.51	1.61e-23	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19608455	chr18:48086580	MAPK4	-0.39	-5.97	-0.31	6.16e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg18190219	chr22:46762943	CELSR1	-0.48	-6.02	-0.31	4.53e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.11	-0.36	7.15e-12	Bipolar disorder;
LUSC	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg24130564	chr14:104152367	KLC1	-0.41	-5.83	-0.3	1.29e-8	Body mass index;
LUSC	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg22732515	chr19:44031385	ETHE1	-0.62	-10.44	-0.5	2.86e-22	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-8.71	-0.43	1.43e-16	Bipolar disorder;
LUSC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg11062466	chr8:58055876	NA	0.71	8.5	0.42	6.29e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2387326	0.717	rs11016102	chr10:129945154	A/G	cg16087940	chr10:129947807	NA	-0.4	-6.09	-0.32	3.03e-9	Select biomarker traits;
LUSC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg04025307	chr7:1156635	C7orf50	0.44	6.06	0.31	3.75e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7202877	0.706	rs4993971	chr16:75411634	C/G	cg04384234	chr16:75411784	CFDP1	0.62	8.84	0.44	5.73e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.1	-0.36	7.53e-12	Bipolar disorder;
LUSC	cis	rs7267979	0.586	rs1007707	chr20:25190598	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	12.73	0.57	1.59e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4953318	0.619	rs35744969	chr2:46353140	C/A	cg12428440	chr2:46370979	PRKCE	0.49	8.16	0.41	6.98e-15	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.78	-12.26	-0.56	8.46e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg06784218	chr1:46089804	CCDC17	-0.58	-11.64	-0.54	1.62e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg04998671	chr14:104000505	TRMT61A	0.46	7.09	0.36	8.13e-12	Coronary artery disease;
LUSC	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg18196295	chr10:418757	DIP2C	0.49	8.05	0.4	1.47e-14	Psychosis in Alzheimer's disease;
LUSC	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg02951883	chr7:2050386	MAD1L1	-0.38	-6.27	-0.32	1.15e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.21	0.56	1.29e-28	Motion sickness;
LUSC	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg05340658	chr4:99064831	C4orf37	0.43	6.87	0.35	3.23e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg21827317	chr3:136751795	NA	0.38	6.9	0.35	2.61e-11	Neuroticism;
LUSC	cis	rs4343996	0.558	rs7794534	chr7:3416396	T/C	cg21248987	chr7:3385318	SDK1	0.36	6.15	0.32	2.18e-9	Motion sickness;
LUSC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg00339695	chr16:24857497	SLC5A11	-0.41	-7.06	-0.36	9.49e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg25072359	chr17:41440525	NA	0.64	9.29	0.45	1.99e-18	Menopause (age at onset);
LUSC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18758796	chr5:131593413	PDLIM4	0.53	9.16	0.45	5.21e-18	Acylcarnitine levels;
LUSC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.74	10.27	0.49	1.07e-21	Gut microbiome composition (summer);
LUSC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg25258033	chr6:167368657	RNASET2	0.38	5.82	0.3	1.38e-8	Primary biliary cholangitis;
LUSC	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg06714761	chr1:201096289	NA	-0.43	-7.71	-0.39	1.42e-13	Permanent tooth development;
LUSC	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	11.78	0.54	4.88e-27	Coronary artery disease;
LUSC	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg15654264	chr1:150340011	RPRD2	0.61	10.09	0.48	4.38e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.96	-20.14	-0.74	1.32e-59	Ulcerative colitis;
LUSC	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg27068330	chr11:65405492	SIPA1	0.62	9.33	0.45	1.54e-18	Acne (severe);
LUSC	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg03806693	chr22:41940476	POLR3H	-0.5	-6.88	-0.35	2.9100000000000002e-11	Neuroticism;
LUSC	trans	rs8073060	0.544	rs17550716	chr17:33893208	A/G	cg19694781	chr19:47549865	TMEM160	1.13	18.22	0.71	5.4e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg15790184	chr11:494944	RNH1	0.49	7.53	0.38	4.71e-13	Systemic lupus erythematosus;
LUSC	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg12564285	chr5:131593104	PDLIM4	0.35	6.28	0.33	1.05e-9	Blood metabolite levels;
LUSC	cis	rs35094601	0.731	rs62161708	chr2:139230824	A/G	cg10095539	chr2:139258744	SPOPL	0.26	6.03	0.31	4.37e-9	Schizophrenia;
LUSC	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg18721089	chr20:30220636	NA	-0.41	-6.57	-0.34	1.93e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs11168618	0.567	rs12372687	chr12:48811799	G/T	cg24011408	chr12:48396354	COL2A1	0.42	6.64	0.34	1.3e-10	Adiponectin levels;
LUSC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg21782813	chr7:2030301	MAD1L1	-0.36	-5.94	-0.31	7.13e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs983392	0.709	rs7939882	chr11:59973929	A/C	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.21	-0.32	1.6e-9	Alzheimer's disease (late onset);
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg03395511	chr6:291903	DUSP22	0.71	11.96	0.55	1.12e-27	Menopause (age at onset);
LUSC	cis	rs9487051	0.768	rs351729	chr6:109511668	T/C	cg01475377	chr6:109611718	NA	0.36	6.1	0.32	2.88e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs4363385	0.747	rs4255332	chr1:152958745	G/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.78	-0.39	9.33e-14	Inflammatory skin disease;
LUSC	cis	rs10740039	0.842	rs10761539	chr10:62409491	C/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.85	-0.35	3.61e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs34421088	0.532	rs1545073	chr8:11167700	C/T	cg27411982	chr8:10470053	RP1L1	0.38	6.04	0.31	4.13e-9	Neuroticism;
LUSC	cis	rs1790761	0.802	rs2276118	chr11:67288594	A/G	cg24690094	chr11:67383802	NA	-0.31	-5.99	-0.31	5.55e-9	Mean corpuscular volume;
LUSC	cis	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg00495681	chr13:53174319	NA	-0.39	-6.07	-0.32	3.4e-9	Lewy body disease;
LUSC	cis	rs1355223	0.573	rs286865	chr11:34719916	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.41	5.75	0.3	2.02e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg13206674	chr6:150067644	NUP43	0.61	9.65	0.47	1.39e-19	Lung cancer;
LUSC	cis	rs12534701	1.000	rs13232266	chr7:154681363	A/T	cg24255201	chr7:154684926	DPP6	0.37	5.72	0.3	2.31e-8	Colorectal cancer (diet interaction);
LUSC	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.74	-0.43	1.15e-16	Mood instability;
LUSC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg24110177	chr3:50126178	RBM5	0.51	7.98	0.4	2.44e-14	Menarche (age at onset);
LUSC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-20.73	-0.75	6.03e-62	Coronary artery disease;
LUSC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18404041	chr3:52824283	ITIH1	-0.49	-9.01	-0.44	1.57e-17	Bipolar disorder;
LUSC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg04166393	chr7:2884313	GNA12	0.44	5.74	0.3	2.09e-8	Height;
LUSC	cis	rs12594515	1.000	rs35182335	chr15:45995184	C/G	cg19682013	chr15:45996608	NA	0.39	5.8	0.3	1.51e-8	Waist circumference;Weight;
LUSC	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.72	-0.35	7.71e-11	QT interval;
LUSC	cis	rs2857891	0.909	rs56261447	chr11:6939382	A/C	cg04053776	chr11:6947353	ZNF215	0.55	7.89	0.4	4.23e-14	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg16586182	chr3:47516702	SCAP	0.56	8.76	0.43	1.02e-16	Colorectal cancer;
LUSC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24531977	chr5:56204891	C5orf35	-0.86	-14.25	-0.61	2.6e-36	Initial pursuit acceleration;
LUSC	cis	rs701145	0.585	rs357477	chr3:153892717	A/G	cg10247383	chr3:153839028	SGEF	-0.65	-5.86	-0.31	1.11e-8	Coronary artery disease;
LUSC	cis	rs7527798	0.592	rs12119104	chr1:207861207	A/G	cg09232269	chr1:207846808	CR1L	-0.31	-6.46	-0.33	3.73e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg17469321	chr7:55412551	NA	0.65	10.58	0.5	9.39e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs11039100	0.850	rs34037040	chr11:5834673	G/A	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg16049864	chr8:95962084	TP53INP1	-0.49	-8.12	-0.41	8.97e-15	Type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19889152	chr6:33588278	ITPR3	-0.46	-6.92	-0.35	2.28e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg05347473	chr6:146136440	FBXO30	-0.39	-6.65	-0.34	1.2e-10	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.95	0.36	1.88e-11	Endometrial cancer;
LUSC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg02269571	chr22:50332266	NA	0.54	8.11	0.41	9.49e-15	Schizophrenia;
LUSC	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg05784532	chr1:230284198	GALNT2	0.49	7.39	0.38	1.16e-12	Coronary artery disease;
LUSC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg22166914	chr1:53195759	ZYG11B	0.51	8.19	0.41	5.63e-15	Monocyte count;
LUSC	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg13575925	chr12:9217583	LOC144571	0.35	6.66	0.34	1.13e-10	Sjögren's syndrome;
LUSC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg08200582	chr11:442649	ANO9	-0.5	-5.71	-0.3	2.55e-8	Body mass index;
LUSC	cis	rs2425143	1.000	rs7273668	chr20:34442731	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.09	-0.32	3.08e-9	Blood protein levels;
LUSC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-16.09	-0.66	1.58e-43	Height;
LUSC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg19812747	chr11:111475976	SIK2	-0.55	-8.24	-0.41	4.08e-15	Primary sclerosing cholangitis;
LUSC	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.28	0.32	1.04e-9	Corneal astigmatism;
LUSC	trans	rs9944715	0.954	rs11082514	chr18:43770207	C/T	cg01718231	chr17:29326311	RNF135	-0.51	-7.25	-0.37	2.91e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs1784581	0.761	rs7741581	chr6:162435250	C/T	cg17173639	chr6:162384350	PARK2	0.65	11.46	0.53	7.1e-26	Itch intensity from mosquito bite;
LUSC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.6	7.69	0.39	1.71e-13	Schizophrenia;
LUSC	cis	rs2835872	0.828	rs857980	chr21:38995142	G/A	cg20424643	chr21:39039972	KCNJ6	-0.38	-5.94	-0.31	7.07e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.55	8.55	0.42	4.62e-16	Schizophrenia;
LUSC	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.88	0.4	4.72e-14	Corneal astigmatism;
LUSC	cis	rs3771570	1.000	rs3771570	chr2:242382864	C/T	cg21155796	chr2:242212141	HDLBP	0.6	6.54	0.34	2.28e-10	Prostate cancer;
LUSC	cis	rs3774830	0.748	rs58854245	chr4:5466134	G/A	cg26943120	chr4:5472116	STK32B	0.29	5.76	0.3	1.93e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.31	-0.45	1.8e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.13	0.55	2.55e-28	Ileal carcinoids;
LUSC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs2953174	0.938	rs2975767	chr2:241538229	A/G	cg07929629	chr2:241523174	NA	0.44	5.94	0.31	7.14e-9	Bipolar disorder;
LUSC	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg27411982	chr8:10470053	RP1L1	0.38	5.91	0.31	8.47e-9	Retinal vascular caliber;
LUSC	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg17644776	chr2:200775616	C2orf69	-0.35	-5.66	-0.3	3.25e-8	Osteoporosis;
LUSC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-8.43	-0.42	1.05e-15	Gut microbiome composition (summer);
LUSC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	5.79	0.3	1.6e-8	Personality dimensions;
LUSC	cis	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg06521331	chr12:34319734	NA	0.4	6.57	0.34	1.97e-10	Morning vs. evening chronotype;
LUSC	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg25801113	chr15:45476975	SHF	0.34	7.0	0.36	1.37e-11	Uric acid levels;
LUSC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.87	14.29	0.62	1.68e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.9	17.03	0.68	2.99e-47	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6030	0.957	rs4656687	chr1:169505158	T/C	cg16792071	chr10:134842795	NA	0.28	6.07	0.32	3.45e-9	Uric acid levels;
LUSC	cis	rs36093844	0.904	rs7101889	chr11:85595579	C/G	cg25872744	chr11:85566296	CCDC83	0.43	7.06	0.36	9.73e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs8113142	0.581	rs4804849	chr19:29164489	A/C	cg04546413	chr19:29218101	NA	0.43	5.84	0.3	1.24e-8	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs4356932	1.000	rs4417995	chr4:76945999	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24503407	chr1:205819492	PM20D1	0.82	15.89	0.66	9.8e-43	Monocyte percentage of white cells;
LUSC	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.71	-12.38	-0.56	3.28e-29	White blood cell count (basophil);
LUSC	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg00530320	chr1:46809349	NSUN4	0.57	8.9	0.44	3.72e-17	Menopause (age at onset);
LUSC	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.47	-0.33	3.41e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg05347473	chr6:146136440	FBXO30	-0.59	-10.32	-0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.76	-12.44	-0.56	1.88e-29	Colorectal cancer;
LUSC	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg15309053	chr8:964076	NA	0.41	8.09	0.4	1.1e-14	Schizophrenia;
LUSC	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	7.8	0.39	7.91e-14	Lung cancer in ever smokers;
LUSC	trans	rs17683430	0.702	rs117983733	chr22:32387606	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5.04e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg13565492	chr6:43139072	SRF	-0.63	-6.63	-0.34	1.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg27284194	chr4:1044797	NA	0.57	8.71	0.43	1.47e-16	Recombination rate (females);
LUSC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.06	0.36	9.75e-12	Bipolar disorder;
LUSC	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg16482183	chr6:26056742	HIST1H1C	0.57	7.8	0.39	8.07e-14	Iron status biomarkers;
LUSC	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg13072238	chr3:49761600	GMPPB	0.68	8.8	0.43	7.27e-17	Menarche (age at onset);
LUSC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.63	13.71	0.6	3.01e-34	Hemoglobin concentration;
LUSC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.31	0.49	8.09e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.85	-14.36	-0.62	9.06e-37	Menarche (age at onset);
LUSC	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg01528321	chr10:82214614	TSPAN14	1.09	17.35	0.69	1.61e-48	Post bronchodilator FEV1;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg27427234	chr20:13201662	ISM1	0.69	5.95	0.31	6.82e-9	Cognitive performance;
LUSC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg14196790	chr5:131705035	SLC22A5	-0.36	-5.78	-0.3	1.75e-8	Breast cancer;
LUSC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg11812906	chr14:75593930	NEK9	-0.62	-10.16	-0.49	2.68e-21	Height;
LUSC	cis	rs2637266	0.749	rs4979831	chr10:78457588	G/T	cg18941641	chr10:78392320	NA	0.34	6.12	0.32	2.59e-9	Pulmonary function;
LUSC	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-10.81	-0.51	1.48e-23	Colorectal cancer;
LUSC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.62	0.38	2.59e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs739496	1.000	rs7296313	chr12:111878526	T/C	cg10833066	chr12:111807467	FAM109A	0.3	5.66	0.3	3.34e-8	Platelet count;
LUSC	cis	rs2191566	1.000	rs369106	chr19:44506930	C/T	cg03039196	chr19:44506973	ZNF230	-0.38	-6.18	-0.32	1.86e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg20891283	chr12:69753455	YEATS4	-0.45	-6.18	-0.32	1.85e-9	Response to diuretic therapy;
LUSC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg20891558	chr2:74357851	NA	0.83	14.86	0.63	1.04e-38	Gestational age at birth (maternal effect);
LUSC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.51	7.24	0.37	3.2e-12	Gut microbiome composition (summer);
LUSC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-1.03	-16.75	-0.68	3.86e-46	Systemic lupus erythematosus;
LUSC	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg26924012	chr15:45694286	SPATA5L1	1.14	20.47	0.75	6.21e-61	Homoarginine levels;
LUSC	cis	rs2273669	0.667	rs113477421	chr6:109310268	C/T	cg05315195	chr6:109294784	ARMC2	-0.53	-5.96	-0.31	6.33e-9	Prostate cancer;
LUSC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.63	8.34	0.42	1.94e-15	High light scatter reticulocyte count;
LUSC	cis	rs754466	0.914	rs12219971	chr10:79701526	T/C	cg17075019	chr10:79541650	NA	-0.61	-7.96	-0.4	2.75e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05901451	chr6:126070800	HEY2	0.57	8.64	0.43	2.36e-16	Endometrial cancer;
LUSC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg02569458	chr12:86230093	RASSF9	0.55	9.38	0.46	1.01e-18	Major depressive disorder;
LUSC	cis	rs6669919	0.540	rs11579048	chr1:211681919	C/G	cg10512769	chr1:211675356	NA	-0.3	-7.0	-0.36	1.41e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09407429	chr3:4534383	ITPR1	0.42	6.35	0.33	7.09e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs72674100	1.000	rs17026382	chr4:97995366	A/G	cg16405019	chr1:18959625	PAX7	-0.62	-6.83	-0.35	3.93e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg05729581	chr11:3078854	CARS	0.41	6.11	0.32	2.73e-9	Calcium levels;
LUSC	cis	rs4478858	0.684	rs4949202	chr1:31736800	T/C	cg00250761	chr1:31883323	NA	-0.33	-7.99	-0.4	2.22e-14	Alcohol dependence;
LUSC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08677398	chr8:58056175	NA	0.53	7.12	0.36	6.86e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs983392	0.776	rs2278867	chr11:59943109	A/T	cg24026212	chr11:59952134	MS4A6A	-0.37	-6.22	-0.32	1.49e-9	Alzheimer's disease (late onset);
LUSC	cis	rs17102423	0.755	rs11158572	chr14:65577411	C/T	cg11161011	chr14:65562177	MAX	-0.81	-12.25	-0.56	9.27e-29	Obesity-related traits;
LUSC	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.48	6.53	0.34	2.39e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs67366981	0.844	rs2287385	chr14:77715916	C/A	cg22824376	chr14:77648248	TMEM63C	0.7	6.4	0.33	5.12e-10	Obsessive-compulsive symptoms;
LUSC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-9.92	-0.48	1.64e-20	Chronic sinus infection;
LUSC	cis	rs2137920	1.000	rs2175918	chr10:50231840	C/T	cg27141751	chr10:50231850	C10orf72	0.38	5.76	0.3	1.89e-8	Migraine with aura;
LUSC	cis	rs7616330	0.887	rs2100142	chr3:71112560	A/G	cg01511742	chr3:71112437	FOXP1	-0.36	-5.83	-0.3	1.31e-8	QT interval;
LUSC	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg05855489	chr10:104503620	C10orf26	0.54	6.39	0.33	5.67e-10	Arsenic metabolism;
LUSC	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg13010199	chr12:38710504	ALG10B	0.53	8.25	0.41	3.81e-15	Morning vs. evening chronotype;
LUSC	cis	rs4789693	1.000	rs4789693	chr17:80421870	A/C	cg04308225	chr17:80449738	NA	0.47	7.67	0.39	1.93e-13	Glucocorticoid-induced osteonecrosis;
LUSC	cis	rs12681287	0.608	rs1135451	chr8:87483608	T/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.36	6.24e-12	Caudate activity during reward;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg16031515	chr1:205743344	RAB7L1	-0.28	-6.06	-0.31	3.76e-9	Menarche (age at onset);
LUSC	cis	rs12681287	0.752	rs1080170	chr8:87310108	C/T	cg27223183	chr8:87520930	FAM82B	-0.46	-5.67	-0.3	3.13e-8	Caudate activity during reward;
LUSC	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg19628046	chr18:33552617	C18orf21	0.51	6.1	0.32	2.94e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg03354898	chr7:1950403	MAD1L1	0.33	6.49	0.33	3.12e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs17095355	1.000	rs12247564	chr10:111721400	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.49	-0.38	6.22e-13	Biliary atresia;
LUSC	cis	rs727505	1.000	rs2286175	chr7:124431032	G/A	cg23710748	chr7:124431027	NA	-0.43	-7.63	-0.39	2.48e-13	Lewy body disease;
LUSC	trans	rs9847048	0.715	rs6778912	chr3:116368195	T/G	cg11621464	chr19:41120268	LTBP4	-0.62	-6.03	-0.31	4.34e-9	Gut microbiome composition (summer);
LUSC	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg04362960	chr10:104952993	NT5C2	1.11	12.91	0.58	3.29e-31	Arsenic metabolism;
LUSC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg08888203	chr3:10149979	C3orf24	0.68	9.46	0.46	5.8e-19	Alzheimer's disease;
LUSC	trans	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg01620082	chr3:125678407	NA	-0.82	-7.32	-0.37	1.84e-12	Depression;
LUSC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg26338869	chr17:61819248	STRADA	0.4	5.77	0.3	1.81e-8	Prudent dietary pattern;
LUSC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg26373071	chr5:1325741	CLPTM1L	0.41	7.55	0.38	4.06e-13	Lung cancer;
LUSC	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg22709100	chr7:91322751	NA	0.4	5.85	0.3	1.17e-8	Breast cancer;
LUSC	cis	rs1783925	1.000	rs640364	chr11:125300766	G/A	cg03464685	chr11:125439445	EI24	-0.47	-6.19	-0.32	1.72e-9	Formal thought disorder in schizophrenia;
LUSC	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-6.92	-0.35	2.37e-11	Fear of minor pain;
LUSC	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg08975724	chr8:8085496	FLJ10661	0.49	7.14	0.36	5.73e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22857025	chr5:266934	NA	-1.19	-13.86	-0.6	7.97e-35	Breast cancer;
LUSC	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	1.18	14.04	0.61	1.62e-35	Arsenic metabolism;
LUSC	cis	rs4363385	0.574	rs4845503	chr1:152959939	A/G	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.41	-0.33	4.87e-10	Inflammatory skin disease;
LUSC	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg18681998	chr4:17616180	MED28	0.77	13.57	0.6	1e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1325195	0.881	rs3813643	chr1:179070334	C/G	cg11624085	chr17:8464688	MYH10	0.43	7.07	0.36	8.87e-12	IgE grass sensitization;
LUSC	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg23283495	chr1:209979779	IRF6	0.46	7.53	0.38	4.7e-13	Monobrow;
LUSC	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg23942311	chr14:51606299	NA	0.49	11.51	0.53	4.73e-26	Cancer;
LUSC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	0.67	8.92	0.44	3.11e-17	Gut microbiome composition (summer);
LUSC	cis	rs807669	0.869	rs1061325	chr22:19184095	T/C	cg02655711	chr22:19163373	SLC25A1	0.59	10.82	0.51	1.37e-23	Metabolite levels;
LUSC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	0.58	9.19	0.45	4.45e-18	Breast cancer;
LUSC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg26043149	chr18:55253948	FECH	-0.44	-6.8	-0.35	4.9e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg24701985	chr7:149535383	ZNF862	0.44	6.03	0.31	4.46e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2882667	0.690	rs9327829	chr5:138261671	A/G	cg04439458	chr5:138467593	SIL1	0.4	7.62	0.39	2.56e-13	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18110333	chr6:292329	DUSP22	-0.73	-11.92	-0.55	1.57e-27	Menopause (age at onset);
LUSC	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	1.14	18.23	0.71	4.9e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg18402987	chr7:1209562	NA	0.71	7.85	0.39	5.89e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-7.01	-0.36	1.29e-11	Homocysteine levels;
LUSC	cis	rs6484504	0.625	rs7940420	chr11:31366700	T/A	cg06552810	chr11:31128660	NA	0.4	7.08	0.36	8.6e-12	Red blood cell count;
LUSC	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg04989706	chr14:50066350	PPIL5	-0.45	-6.05	-0.31	3.96e-9	Carotid intima media thickness;
LUSC	trans	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg16660971	chr17:78860029	RPTOR	0.37	6.01	0.31	4.78e-9	Major depressive disorder;
LUSC	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg08017756	chr2:100939284	LONRF2	-0.47	-8.66	-0.43	2.03e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26314531	chr2:26401878	FAM59B	0.74	10.04	0.48	6.81e-21	Gut microbiome composition (summer);
LUSC	cis	rs11997175	0.902	rs7462140	chr8:33717880	A/G	ch.8.33884649F	chr8:33765107	NA	0.42	6.49	0.33	3.18e-10	Body mass index;
LUSC	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07080220	chr10:102295463	HIF1AN	0.6	8.0	0.4	2.07e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9399401	0.890	rs3817929	chr6:142751062	G/C	cg03128060	chr6:142623767	GPR126	0.33	6.1	0.32	2.97e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg02569458	chr12:86230093	RASSF9	0.42	6.85	0.35	3.49e-11	Major depressive disorder;
LUSC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg18306943	chr3:40428807	ENTPD3	0.4	6.11	0.32	2.77e-9	Renal cell carcinoma;
LUSC	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.97	21.74	0.77	6.65e-66	Longevity;
LUSC	cis	rs79911532	0.515	rs887579	chr7:75701640	G/A	cg03592824	chr7:75666768	STYXL1	0.67	6.42	0.33	4.79e-10	Mononucleosis;
LUSC	cis	rs4363385	0.818	rs1591736	chr1:152987497	A/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.53e-13	Inflammatory skin disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16581840	chr6:137114203	MAP3K5	-0.43	-6.47	-0.33	3.52e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg25174290	chr11:3078921	CARS	-0.58	-9.51	-0.46	3.99e-19	Longevity;
LUSC	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg05738196	chr6:26577821	NA	0.79	14.9	0.63	7.47e-39	Intelligence (multi-trait analysis);
LUSC	trans	rs10792665	0.575	rs4625493	chr11:82540975	C/T	cg05254078	chr15:34502482	C15orf29	-0.35	-6.04	-0.31	4.06e-9	Obesity-related traits;
LUSC	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg27411982	chr8:10470053	RP1L1	0.41	6.21	0.32	1.56e-9	Neuroticism;
LUSC	cis	rs13006833	0.635	rs291460	chr2:191181585	G/A	cg21644426	chr2:191273491	MFSD6	0.43	6.16	0.32	2.13e-9	Urinary metabolites;
LUSC	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.55	-0.34	2.21e-10	Neuroticism;
LUSC	trans	rs7916697	0.520	rs10762201	chr10:70040111	A/G	cg04882175	chr6:131122610	NA	0.47	6.23	0.32	1.42e-9	Optic disc area;
LUSC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg13114125	chr14:105738426	BRF1	-0.9	-14.73	-0.63	3.46e-38	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6785206	0.892	rs6439143	chr3:128425132	C/T	cg16766828	chr3:128327626	NA	-0.65	-6.91	-0.35	2.48e-11	Lymphocyte percentage of white cells;
LUSC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg24829409	chr8:58192753	C8orf71	-0.59	-6.13	-0.32	2.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg02038168	chr22:39784481	NA	-0.47	-7.87	-0.4	5.1e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9549260	0.755	rs8001443	chr13:41216646	C/T	cg21288729	chr13:41239152	FOXO1	-0.62	-9.85	-0.47	2.8e-20	Red blood cell count;
LUSC	cis	rs6987853	0.865	rs2923445	chr8:42400743	C/A	cg09913449	chr8:42400586	C8orf40	0.49	8.24	0.41	4.06e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg11764359	chr7:65958608	NA	0.49	6.26	0.32	1.21e-9	Aortic root size;
LUSC	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg24631222	chr15:78858424	CHRNA5	0.84	11.49	0.53	5.46e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg11812906	chr14:75593930	NEK9	-0.67	-11.34	-0.53	1.91e-25	Height;
LUSC	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg03676636	chr4:99064102	C4orf37	0.36	7.72	0.39	1.35e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg22777020	chr22:31556080	RNF185	-0.46	-5.86	-0.31	1.13e-8	Colorectal cancer;
LUSC	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg04733989	chr22:42467013	NAGA	-0.38	-6.51	-0.34	2.74e-10	Cognitive function;
LUSC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.21	0.37	3.85e-12	Platelet count;
LUSC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg07701084	chr6:150067640	NUP43	0.54	8.02	0.4	1.82e-14	Lung cancer;
LUSC	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg05805236	chr11:65401703	PCNXL3	0.4	6.82	0.35	4.28e-11	Acne (severe);
LUSC	cis	rs7188861	0.768	rs9939877	chr16:11396779	G/A	cg00044050	chr16:11439710	C16orf75	0.55	6.21	0.32	1.55e-9	HDL cholesterol;
LUSC	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg09044154	chr16:88155775	NA	-0.53	-7.1	-0.36	7.69e-12	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04723886	chr5:1468204	LPCAT1	0.42	6.15	0.32	2.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4601821	0.895	rs2282511	chr11:113244177	A/C	cg14159747	chr11:113255604	NA	0.25	5.83	0.3	1.28e-8	Alcoholic chronic pancreatitis;
LUSC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-1.05	-15.08	-0.64	1.51e-39	Vitiligo;
LUSC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg27121462	chr16:89883253	FANCA	-0.48	-6.83	-0.35	4.13e-11	Vitiligo;
LUSC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg00106254	chr7:1943704	MAD1L1	-0.42	-6.07	-0.32	3.41e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs62238980	0.614	rs79397654	chr22:32468027	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs7575217	0.961	rs1192789	chr2:101782754	C/T	cg23907051	chr2:101730305	TBC1D8	-0.27	-6.61	-0.34	1.5e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg00311307	chr1:24829359	RCAN3	0.52	6.22	0.32	1.51e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6782228	0.675	rs9813845	chr3:128399623	G/C	cg16766828	chr3:128327626	NA	-0.31	-5.7	-0.3	2.68e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg21100191	chr22:23484243	RTDR1	0.92	15.99	0.66	4.03e-43	Bone mineral density;
LUSC	cis	rs58950470	0.521	rs7950197	chr11:65446126	T/C	cg05805236	chr11:65401703	PCNXL3	-0.33	-5.75	-0.3	1.98e-8	Schizophrenia;
LUSC	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg23791538	chr6:167370224	RNASET2	0.5	8.33	0.41	2.08e-15	Crohn's disease;
LUSC	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg08807101	chr21:30365312	RNF160	-0.53	-7.9	-0.4	4.17e-14	Dental caries;
LUSC	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg08917208	chr2:24149416	ATAD2B	0.99	10.33	0.49	6.73e-22	Lymphocyte counts;
LUSC	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.51	-6.92	-0.35	2.35e-11	Response to bleomycin (chromatid breaks);
LUSC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg25456477	chr12:86230367	RASSF9	-0.32	-5.69	-0.3	2.83e-8	Major depressive disorder;
LUSC	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.95	-0.31	6.77e-9	IgG glycosylation;
LUSC	cis	rs12681287	0.927	rs2976177	chr8:87332332	A/T	cg27223183	chr8:87520930	FAM82B	-0.47	-6.25	-0.32	1.23e-9	Caudate activity during reward;
LUSC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg17143192	chr8:8559678	CLDN23	0.59	8.53	0.42	5.18e-16	Obesity-related traits;
LUSC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg18827107	chr12:86230957	RASSF9	0.46	6.96	0.36	1.86e-11	Major depressive disorder;
LUSC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.98	-14.45	-0.62	4.11e-37	Gut microbiome composition (summer);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22583711	chr7:154795321	PAXIP1;LOC202781	-0.53	-6.76	-0.35	6.03e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-9.4	-0.46	9.08e-19	Bladder cancer;
LUSC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg02782426	chr3:40428986	ENTPD3	0.32	6.18	0.32	1.87e-9	Renal cell carcinoma;
LUSC	cis	rs28595532	0.800	rs67686161	chr4:119336720	C/T	cg21605333	chr4:119757512	SEC24D	0.95	7.97	0.4	2.59e-14	Cannabis dependence symptom count;
LUSC	trans	rs3114020	0.739	rs2622626	chr4:89066715	A/C	cg12667048	chr11:70644526	SHANK2	0.34	5.95	0.31	6.76e-9	Gout;
LUSC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg05973401	chr12:123451056	ABCB9	0.55	8.11	0.41	9.83e-15	Platelet count;
LUSC	cis	rs1969253	0.712	rs843344	chr3:183907032	C/G	cg21665078	chr3:183852786	EIF2B5	0.36	5.96	0.31	6.25e-9	Major depressive disorder;
LUSC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg06618935	chr21:46677482	NA	-0.32	-6.28	-0.33	1.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg22705602	chr4:152727874	NA	-0.3	-6.11	-0.32	2.83e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs4720118	0.875	rs71532576	chr7:33479160	G/T	cg23247845	chr10:3679085	NA	-0.33	-5.96	-0.31	6.54e-9	Leprosy;
LUSC	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg16482183	chr6:26056742	HIST1H1C	0.44	6.52	0.34	2.67e-10	Height;
LUSC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg06784218	chr1:46089804	CCDC17	-0.47	-8.92	-0.44	3.06e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7572644	0.640	rs4583413	chr2:28074824	C/T	cg27432699	chr2:27873401	GPN1	0.51	6.96	0.36	1.78e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs12681287	0.673	rs4464946	chr8:87326259	G/A	cg27223183	chr8:87520930	FAM82B	-0.51	-6.61	-0.34	1.55e-10	Caudate activity during reward;
LUSC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	6.48	0.33	3.22e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.84	-9.99	-0.48	9.88e-21	Body mass index;
LUSC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03264133	chr6:25882463	NA	0.42	7.23	0.37	3.36e-12	Blood metabolite levels;
LUSC	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg13010199	chr12:38710504	ALG10B	-0.6	-9.75	-0.47	6.26e-20	Heart rate;
LUSC	cis	rs3820928	0.874	rs7562776	chr2:227806550	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.75	-0.39	1.14e-13	Pulmonary function;
LUSC	cis	rs6690583	0.623	rs1371140	chr1:85455362	A/C	cg11262906	chr1:85462892	MCOLN2	0.67	6.53	0.34	2.51e-10	Serum sulfate level;
LUSC	cis	rs981844	0.775	rs17371545	chr4:154763980	A/G	cg14289246	chr4:154710475	SFRP2	-0.48	-6.38	-0.33	5.87e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs5770917	1.000	rs2073605	chr22:51008850	A/G	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.6	-5.74	-0.3	2.18e-8	Narcolepsy;
LUSC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg04727924	chr7:799746	HEATR2	-0.55	-5.87	-0.31	1.05e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg17470449	chr10:769945	NA	0.56	7.79	0.39	8.26e-14	Uric acid levels;
LUSC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.46	0.46	5.6e-19	Prudent dietary pattern;
LUSC	cis	rs1847202	0.787	rs13071878	chr3:72951084	G/A	cg25664220	chr3:72788482	NA	-0.42	-7.62	-0.38	2.6e-13	Motion sickness;
LUSC	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	6.96	0.36	1.79e-11	Neuroticism;
LUSC	cis	rs11696845	0.787	rs6031771	chr20:43363590	C/T	cg25301532	chr20:43378953	KCNK15	0.34	6.28	0.32	1.08e-9	Obesity-related traits;
LUSC	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.74	0.51	2.66e-23	Schizophrenia;
LUSC	cis	rs1160297	0.609	rs10168840	chr2:53084498	A/G	cg07782112	chr2:53107842	NA	0.35	5.96	0.31	6.58e-9	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg10835172	chr15:77224357	RCN2	0.36	5.98	0.31	5.79e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	0.59	9.17	0.45	4.88e-18	Breast cancer;
LUSC	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	1.18	17.76	0.7	3.84e-50	Corneal structure;
LUSC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.03e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs1790761	1.000	rs1790761	chr11:67221854	T/C	cg24690094	chr11:67383802	NA	-0.32	-5.77	-0.3	1.84e-8	Mean corpuscular volume;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17808901	chr3:39093368	WDR48	0.46	6.82	0.35	4.4e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg08917208	chr2:24149416	ATAD2B	0.55	6.25	0.32	1.24e-9	Lymphocyte counts;
LUSC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg14196790	chr5:131705035	SLC22A5	0.45	7.38	0.37	1.27e-12	Breast cancer;Mosquito bite size;
LUSC	cis	rs1355223	0.872	rs12802798	chr11:34747434	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.39	-5.67	-0.3	3.13e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.99	-0.36	1.47e-11	Blood metabolite levels;
LUSC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg01528321	chr10:82214614	TSPAN14	0.58	8.59	0.43	3.41e-16	Post bronchodilator FEV1;
LUSC	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg20991723	chr1:152506922	NA	0.5	9.26	0.45	2.52e-18	Hair morphology;
LUSC	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-8.4	-0.42	1.29e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg20243544	chr17:37824526	PNMT	0.4	6.08	0.32	3.3e-9	Self-reported allergy;
LUSC	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg17749961	chr2:30669863	LCLAT1	0.66	8.45	0.42	9.08e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	trans	rs6480314	0.542	rs7078967	chr10:70026321	G/T	cg20382233	chr11:66045718	CNIH2	0.5	7.1	0.36	7.52e-12	Optic nerve measurement (disc area);
LUSC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs12912251	0.894	rs7183893	chr15:38996981	A/C	cg01338139	chr15:38987640	C15orf53	-0.51	-7.14	-0.36	5.95e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs12464559	0.522	rs4300824	chr2:152581866	T/C	cg01189475	chr2:152685088	ARL5A	0.67	7.37	0.37	1.32e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	0.57	9.16	0.45	5.54e-18	Breast cancer;
LUSC	trans	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10886558	0.662	rs4752364	chr10:121761821	G/A	cg02041677	chr10:121771263	NA	-0.34	-5.72	-0.3	2.31e-8	Shingles;
LUSC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.94	0.31	7.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8099014	1.000	rs8092072	chr18:56129804	C/T	cg12907477	chr18:56117327	MIR122	0.43	6.89	0.35	2.86e-11	Platelet count;
LUSC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg12310025	chr6:25882481	NA	0.43	7.36	0.37	1.49e-12	Blood metabolite levels;
LUSC	cis	rs7851660	0.809	rs7866436	chr9:100650096	G/A	cg13688889	chr9:100608707	NA	-0.56	-8.55	-0.42	4.47e-16	Strep throat;
LUSC	cis	rs13315871	1.000	rs36037390	chr3:58321954	C/T	cg12435725	chr3:58293450	RPP14	-0.72	-7.18	-0.37	4.66e-12	Cholesterol, total;
LUSC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.53	-8.22	-0.41	4.42e-15	Acylcarnitine levels;
LUSC	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.56	-0.34	2.08e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.15	15.99	0.66	4.08e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.86	-11.31	-0.53	2.58e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs12474201	0.889	rs2346878	chr2:46922870	C/T	cg06386533	chr2:46925753	SOCS5	0.8	12.2	0.56	1.42e-28	Height;
LUSC	trans	rs961253	0.522	rs2225115	chr20:6360465	C/T	cg17788362	chr6:86352627	SYNCRIP	0.43	6.05	0.31	3.93e-9	Colorectal cancer;
LUSC	cis	rs10492096	1.000	rs11064218	chr12:6586261	C/T	cg13857086	chr12:6580257	VAMP1	0.77	8.43	0.42	1.02e-15	Hip geometry;
LUSC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-7.34	-0.37	1.66e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs2540226	0.844	rs10169390	chr2:40004249	C/T	cg23576258	chr2:39999331	THUMPD2	0.35	6.03	0.31	4.28e-9	Personality dimensions;
LUSC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg02079420	chr8:82753780	SNX16	-0.41	-7.1	-0.36	7.56e-12	Diastolic blood pressure;
LUSC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.85	13.7	0.6	3.32e-34	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg07393940	chr7:158741817	NA	-0.38	-6.8	-0.35	4.71e-11	Life satisfaction;
LUSC	cis	rs713477	0.967	rs10150617	chr14:55916225	A/C	cg13175173	chr14:55914753	NA	0.3	6.36	0.33	6.7e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.74	-0.35	6.77e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg08200582	chr11:442649	ANO9	-0.51	-5.98	-0.31	5.73e-9	Body mass index;
LUSC	cis	rs11018904	0.906	rs11603498	chr11:89928783	C/A	cg26834418	chr11:89957033	CHORDC1	-0.51	-6.02	-0.31	4.67e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9815354	0.812	rs73069390	chr3:41785513	C/T	cg03022575	chr3:42003672	ULK4	0.82	8.32	0.41	2.34e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4780355	0.843	rs243325	chr16:11354497	A/G	cg00044050	chr16:11439710	C16orf75	0.59	9.25	0.45	2.69e-18	Crohn's disease and psoriasis;
LUSC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg15147215	chr3:52552868	STAB1	-0.31	-6.0	-0.31	5.02e-9	Bipolar disorder;
LUSC	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg02696742	chr7:106810147	HBP1	-0.63	-9.69	-0.47	9.96e-20	Coronary artery disease;
LUSC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.7	11.58	0.54	2.59e-26	Heart rate;
LUSC	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg03929089	chr4:120376271	NA	-0.43	-5.98	-0.31	5.76e-9	Height;
LUSC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg02487422	chr3:49467188	NICN1	0.43	6.03	0.31	4.37e-9	Parkinson's disease;
LUSC	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg00791764	chr4:53727839	RASL11B	0.57	7.35	0.37	1.53e-12	Optic nerve measurement (cup area);
LUSC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg11812906	chr14:75593930	NEK9	0.65	11.12	0.52	1.21e-24	Height;
LUSC	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg06671706	chr8:8559999	CLDN23	0.45	6.3	0.33	9.35e-10	Obesity-related traits;
LUSC	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg04586622	chr2:25135609	ADCY3	0.34	6.8	0.35	4.75e-11	Body mass index in non-asthmatics;
LUSC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg15445000	chr17:37608096	MED1	0.38	6.67	0.34	1.04e-10	Glomerular filtration rate (creatinine);
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg05064044	chr6:292385	DUSP22	-0.73	-11.67	-0.54	1.24e-26	Menopause (age at onset);
LUSC	cis	rs6076065	0.707	rs2024746	chr20:23356862	G/A	cg11657817	chr20:23433608	CST11	0.54	11.2	0.52	6.21e-25	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg04287289	chr16:89883240	FANCA	0.78	6.24	0.32	1.3e-9	Skin colour saturation;
LUSC	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg02175503	chr12:58329896	NA	0.58	8.87	0.44	4.52e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg16586182	chr3:47516702	SCAP	0.42	5.9	0.31	8.71e-9	Birth weight;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg03790207	chr6:42947109	PEX6	-0.42	-6.17	-0.32	2.02e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7072216	0.763	rs942805	chr10:100168372	G/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	cis	rs3099143	1.000	rs3102712	chr15:77058926	G/A	cg21673338	chr15:77095150	SCAPER	-0.82	-8.05	-0.4	1.47e-14	Recalcitrant atopic dermatitis;
LUSC	cis	rs708547	0.647	rs1713982	chr4:57881715	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	7.59	0.38	3.31e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs10875595	0.509	rs115819920	chr5:140663745	A/C	cg24830062	chr5:140700576	TAF7	-0.52	-6.29	-0.33	1e-9	Pulmonary function decline;
LUSC	cis	rs9677476	0.863	rs12465477	chr2:232073282	G/A	cg07929768	chr2:232055508	NA	0.37	7.04	0.36	1.1e-11	Food antigen IgG levels;
LUSC	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg14196790	chr5:131705035	SLC22A5	0.45	7.57	0.38	3.68e-13	Blood metabolite levels;
LUSC	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg00376283	chr12:123451042	ABCB9	0.68	8.6	0.43	3.1e-16	Neutrophil percentage of white cells;
LUSC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg16797656	chr11:68205561	LRP5	-0.42	-7.81	-0.39	7.31e-14	Total body bone mineral density;
LUSC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg15556689	chr8:8085844	FLJ10661	0.62	9.74	0.47	6.6e-20	Parkinson's disease;
LUSC	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-9.75	-0.47	6.07e-20	Joint mobility (Beighton score);
LUSC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.16	-0.32	2.06e-9	Total body bone mineral density;
LUSC	trans	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg21051086	chr3:73046214	PPP4R2	-0.52	-8.0	-0.4	2.13e-14	Pancreatic cancer;
LUSC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg06618935	chr21:46677482	NA	0.32	6.16	0.32	2.12e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg12432903	chr7:1882776	MAD1L1	-0.4	-6.53	-0.34	2.41e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9815354	0.812	rs10510732	chr3:42007339	C/T	cg03022575	chr3:42003672	ULK4	0.87	8.49	0.42	6.68e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs8038465	0.662	rs57771618	chr15:73967578	T/C	cg15420318	chr15:73925796	NPTN	0.56	9.32	0.45	1.6e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg07777115	chr5:623756	CEP72	-0.45	-5.7	-0.3	2.62e-8	Obesity-related traits;
LUSC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg02023728	chr11:77925099	USP35	0.45	6.83	0.35	4.15e-11	Testicular germ cell tumor;
LUSC	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg24006582	chr15:45444508	DUOX1	-0.61	-8.75	-0.43	1.07e-16	Uric acid levels;
LUSC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-1.07	-20.13	-0.74	1.45e-59	Coronary artery disease;
LUSC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.08	0.36	8.48e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg27532560	chr4:187881888	NA	-0.37	-6.08	-0.32	3.33e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.28	0.53	3.14e-25	Menopause (age at onset);
LUSC	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg04455712	chr21:45112962	RRP1B	0.46	8.69	0.43	1.64e-16	Mean corpuscular volume;
LUSC	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg14664628	chr15:75095509	CSK	-0.69	-10.61	-0.5	7.22e-23	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg03929089	chr4:120376271	NA	-0.86	-11.79	-0.54	4.74e-27	Height;
LUSC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.73	-0.51	2.85e-23	Alzheimer's disease (late onset);
LUSC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg13575925	chr12:9217583	LOC144571	0.35	6.47	0.33	3.48e-10	Sjögren's syndrome;
LUSC	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg03929089	chr4:120376271	NA	0.65	6.08	0.32	3.36e-9	Axial length;
LUSC	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg18477163	chr1:228402036	OBSCN	0.57	9.49	0.46	4.62e-19	Diastolic blood pressure;
LUSC	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg13256891	chr4:100009986	ADH5	-0.42	-6.07	-0.32	3.43e-9	Alcohol dependence;
LUSC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg09699651	chr6:150184138	LRP11	0.37	5.87	0.31	1.04e-8	Lung cancer;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg14424210	chr9:101832044	COL15A1	-0.32	-5.96	-0.31	6.35e-9	Schizophrenia;
LUSC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg00701064	chr4:6280414	WFS1	0.59	14.51	0.62	2.4e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg19997662	chr15:101784653	CHSY1	-0.42	-6.19	-0.32	1.78e-9	Corneal structure;
LUSC	cis	rs4853525	0.522	rs10490538	chr2:191590066	C/T	cg11845111	chr2:191398756	TMEM194B	0.43	5.86	0.31	1.13e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.63	-8.73	-0.43	1.26e-16	Body mass index (adult);
LUSC	trans	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	6.04	0.31	4.19e-9	Cystic fibrosis severity;
LUSC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	7.45	0.38	8.23e-13	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs909002	0.962	rs10798883	chr1:32140305	C/T	cg13919466	chr1:32135498	COL16A1	-0.36	-6.81	-0.35	4.5e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6469656	0.892	rs10112604	chr8:117756518	C/G	cg24004040	chr8:117650383	NA	-0.4	-5.97	-0.31	5.95e-9	Colorectal cancer;
LUSC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-0.88	-16.85	-0.68	1.6e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg23630131	chr7:65973040	NA	0.21	5.78	0.3	1.74e-8	Aortic root size;
LUSC	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.77	11.08	0.52	1.71e-24	Corneal astigmatism;
LUSC	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.41	-0.33	4.93e-10	Response to antipsychotic treatment;
LUSC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs72674100	1.000	rs28612505	chr4:97992338	G/T	cg16405019	chr1:18959625	PAX7	-0.62	-6.57	-0.34	1.9e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1018836	0.608	rs1015994	chr8:91465011	T/C	cg16814680	chr8:91681699	NA	-0.54	-7.81	-0.39	7.41e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg09307838	chr4:120376055	NA	0.47	7.0	0.36	1.37e-11	Diastolic blood pressure;
LUSC	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg07148914	chr20:33460835	GGT7	0.47	6.95	0.36	1.92e-11	Height;
LUSC	trans	rs12699921	0.599	rs6973480	chr7:17978129	C/T	cg01137537	chr1:162039502	NOS1AP	0.4	5.99	0.31	5.39e-9	Fibrinogen levels;
LUSC	cis	rs72949976	0.584	rs4673729	chr2:214023810	A/G	cg08319019	chr2:214017104	IKZF2	0.67	11.55	0.53	3.4e-26	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg20243544	chr17:37824526	PNMT	0.53	7.52	0.38	4.95e-13	Asthma;
LUSC	trans	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.48	-0.33	3.37e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs1524927	1.000	rs13310130	chr7:96346088	T/G	cg03808172	chr7:96339361	SHFM1	0.43	6.65	0.34	1.19e-10	Total body bone mineral density;
LUSC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg17264618	chr3:40429014	ENTPD3	0.35	7.22	0.37	3.48e-12	Renal cell carcinoma;
LUSC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03576123	chr11:487126	PTDSS2	-0.95	-10.54	-0.5	1.29e-22	Body mass index;
LUSC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.52	8.78	0.43	8.41e-17	Blood metabolite levels;
LUSC	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg05925327	chr15:68127851	NA	-0.41	-6.26	-0.32	1.15e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs877282	0.898	rs11253349	chr10:765897	C/G	cg17470449	chr10:769945	NA	0.53	7.09	0.36	8.21e-12	Uric acid levels;
LUSC	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.95	-0.36	1.9e-11	Neuroticism;
LUSC	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg12863693	chr15:85201151	NMB	-0.35	-7.14	-0.36	5.73e-12	Schizophrenia;
LUSC	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg16989719	chr2:238392110	NA	0.36	6.02	0.31	4.51e-9	Prostate cancer;
LUSC	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-17.57	-0.69	2.11e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg25482853	chr8:67687455	SGK3	1.2	17.16	0.68	9.11e-48	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7532866	1.000	rs7532866	chr1:26741544	A/G	cg17456097	chr1:26900765	RPS6KA1	-0.43	-6.62	-0.34	1.44e-10	Height;
LUSC	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg05729581	chr11:3078854	CARS	0.45	6.36	0.33	6.62e-10	Calcium levels;
LUSC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.48	9.06	0.44	1.1e-17	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	trans	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	12.24	0.56	1.06e-28	Mean corpuscular volume;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg16316507	chr7:144533041	TPK1	0.4	6.18	0.32	1.84e-9	Schizophrenia;
LUSC	cis	rs4595586	0.655	rs11831499	chr12:39310114	A/T	cg26384229	chr12:38710491	ALG10B	0.45	6.16	0.32	2.09e-9	Morning vs. evening chronotype;
LUSC	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg17385448	chr1:15911702	AGMAT	0.34	6.0	0.31	5.18e-9	Systolic blood pressure;
LUSC	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg02569458	chr12:86230093	RASSF9	-0.47	-7.97	-0.4	2.6e-14	Major depressive disorder;
LUSC	cis	rs2573652	0.722	rs12914189	chr15:100544429	A/T	cg00587665	chr15:100533223	ADAMTS17	0.38	6.78	0.35	5.58e-11	Height;
LUSC	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.27	0.32	1.1e-9	Corneal astigmatism;
LUSC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.19e-30	Aortic root size;
LUSC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	1.03	20.56	0.75	2.75e-61	Menopause (age at onset);
LUSC	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	11.02	0.52	2.66e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg08847533	chr14:75593920	NEK9	-0.83	-15.44	-0.65	5.91e-41	Height;
LUSC	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	1.05	13.86	0.6	8.33e-35	Nonalcoholic fatty liver disease;
LUSC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.97	-0.4	2.52e-14	Height;
LUSC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-7.49	-0.38	6.31e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4363385	0.588	rs7540609	chr1:153024589	C/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.78	-0.3	1.67e-8	Inflammatory skin disease;
LUSC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg25039879	chr17:56429692	SUPT4H1	0.66	8.93	0.44	2.93e-17	Cognitive test performance;
LUSC	cis	rs3087591	1.000	rs9902893	chr17:29625638	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.55	-7.92	-0.4	3.51e-14	Hip circumference;
LUSC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg05802129	chr4:122689817	NA	-0.47	-7.82	-0.39	7.15e-14	Type 2 diabetes;
LUSC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg18827107	chr12:86230957	RASSF9	-0.48	-7.15	-0.36	5.49e-12	Major depressive disorder;
LUSC	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg05283184	chr6:79620031	NA	-0.58	-11.98	-0.55	9.08e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.747	rs4845509	chr1:152981900	T/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.33e-13	Inflammatory skin disease;
LUSC	cis	rs34734847	0.871	rs2239760	chr12:121163518	C/A	cg27246729	chr12:121163418	ACADS	0.46	7.36	0.37	1.48e-12	Mean corpuscular volume;
LUSC	cis	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg13319975	chr6:146136371	FBXO30	0.5	7.48	0.38	6.47e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg03563238	chr19:33554763	RHPN2	-0.41	-6.45	-0.33	3.91e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs4305317	0.546	rs6544484	chr2:42079411	A/C	cg20967028	chr12:14996272	ART4	0.37	6.02	0.31	4.48e-9	Rheumatoid arthritis;
LUSC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg18758796	chr5:131593413	PDLIM4	0.34	5.8	0.3	1.54e-8	Blood metabolite levels;
LUSC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg16325326	chr1:53192061	ZYG11B	0.96	18.47	0.71	5.49e-53	Monocyte count;
LUSC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.68	-13.01	-0.58	1.33e-31	Monocyte count;
LUSC	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.75e-12	Blood metabolite levels;
LUSC	cis	rs134594	1.000	rs134619	chr22:29478374	C/T	cg03665785	chr22:29458676	C22orf31	0.28	5.69	0.3	2.78e-8	Birth weight;
LUSC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-11.57	-0.53	2.87e-26	Chronic sinus infection;
LUSC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	1.05	19.08	0.72	1.98e-55	Parkinson's disease;
LUSC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.83	-0.35	4.1e-11	Schizophrenia;
LUSC	cis	rs28830936	0.966	rs890498	chr15:42111298	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.93	-0.31	7.61e-9	Diastolic blood pressure;
LUSC	cis	rs78707713	0.512	rs12772559	chr10:71184356	C/G	cg14388049	chr10:71211838	TSPAN15	-0.31	-5.7	-0.3	2.6e-8	Venous thromboembolism;
LUSC	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg26924012	chr15:45694286	SPATA5L1	0.74	10.78	0.51	1.93e-23	Glomerular filtration rate;
LUSC	cis	rs11264213	0.591	rs408986	chr1:36551895	C/T	cg27506609	chr1:36549197	TEKT2	0.8	10.51	0.5	1.69e-22	Schizophrenia;
LUSC	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg09469691	chr10:81107165	PPIF	0.63	9.3	0.45	1.96e-18	Height;
LUSC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs2108225	0.934	rs2301989	chr7:107443871	G/A	cg18560240	chr7:107437656	SLC26A3	-0.38	-5.79	-0.3	1.66e-8	Ulcerative colitis;
LUSC	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg25457927	chr22:38595422	NA	0.52	11.5	0.53	5.21e-26	Cutaneous nevi;
LUSC	cis	rs9372498	0.536	rs62422189	chr6:118907053	C/T	cg18833306	chr6:118973337	C6orf204	-0.45	-5.8	-0.3	1.53e-8	Diastolic blood pressure;
LUSC	cis	rs10193935	0.901	rs3088290	chr2:42578143	A/G	cg27598129	chr2:42591480	NA	-0.63	-8.37	-0.42	1.64e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg21854759	chr1:92012499	NA	0.42	5.74	0.3	2.17e-8	Eosinophil percentage of white cells;
LUSC	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg14458575	chr2:238380390	NA	0.64	11.2	0.52	6.32e-25	Prostate cancer;
LUSC	cis	rs1044826	1.000	rs9848241	chr3:139129631	C/G	cg00490450	chr3:139108681	COPB2	0.56	7.39	0.38	1.15e-12	Obesity-related traits;
LUSC	trans	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg05926928	chr17:57297772	GDPD1	0.87	9.19	0.45	4.35e-18	Opioid sensitivity;
LUSC	trans	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg26043149	chr18:55253948	FECH	-0.46	-7.1	-0.36	7.56e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7011192	0.793	rs13269921	chr8:10520913	A/G	cg17329886	chr8:10513629	RP1L1	0.64	7.28	0.37	2.44e-12	Suicide;
LUSC	cis	rs11585357	0.843	rs113593167	chr1:17613355	G/A	cg08277548	chr1:17600880	PADI3	-0.64	-6.62	-0.34	1.42e-10	Hair shape;
LUSC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.62	-0.34	1.39e-10	Schizophrenia;
LUSC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.57	9.06	0.44	1.11e-17	Vitiligo;
LUSC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.93	-0.35	2.17e-11	Aortic root size;
LUSC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg07952391	chr2:88470173	THNSL2	-0.58	-7.79	-0.39	8.51e-14	Response to metformin (IC50);
LUSC	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg24375607	chr4:120327624	NA	-0.69	-10.96	-0.51	4.56e-24	Corneal astigmatism;
LUSC	cis	rs68092024	0.704	rs793487	chr3:99495422	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-6.21	-0.32	1.55e-9	Cleft lip with or without cleft palate;
LUSC	trans	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg18187862	chr3:45730750	SACM1L	0.55	7.02	0.36	1.27e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs1256061	0.603	rs1256038	chr14:64740739	T/C	cg21174375	chr14:64681225	SYNE2	0.35	6.26	0.32	1.19e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-6.5	-0.34	2.89e-10	Response to antipsychotic treatment;
LUSC	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg22709100	chr7:91322751	NA	0.39	5.75	0.3	1.98e-8	Breast cancer;
LUSC	cis	rs963731	0.649	rs4670901	chr2:39199271	T/C	cg04010122	chr2:39346883	SOS1	-0.78	-5.7	-0.3	2.71e-8	Corticobasal degeneration;
LUSC	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg26647111	chr11:31128758	NA	0.41	5.92	0.31	7.88e-9	Red blood cell count;
LUSC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-9.98	-0.48	1.07e-20	Gut microbiome composition (summer);
LUSC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21984481	chr17:79567631	NPLOC4	-0.57	-10.91	-0.51	6.82e-24	Eye color traits;
LUSC	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg14227996	chr4:17616232	MED28	0.82	7.8	0.39	7.87e-14	Opioid sensitivity;
LUSC	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg22709100	chr7:91322751	NA	0.39	5.66	0.3	3.28e-8	Breast cancer;
LUSC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg03146154	chr1:46216737	IPP	0.55	8.25	0.41	3.82e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs17086172	0.841	rs76001318	chr18:70271977	G/A	cg00123055	chr8:55370951	SOX17	-0.68	-6.06	-0.31	3.61e-9	Airflow obstruction;
LUSC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.57	-0.38	3.58e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.46	-7.18	-0.37	4.64e-12	IgG glycosylation;
LUSC	cis	rs9549260	0.753	rs9549246	chr13:41220755	G/A	cg21288729	chr13:41239152	FOXO1	0.58	6.43	0.33	4.37e-10	Red blood cell count;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg15854934	chr14:55518152	MAPK1IP1L	0.5	6.08	0.32	3.21e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7927592	0.830	rs11228240	chr11:68218290	C/T	cg01657329	chr11:68192670	LRP5	-0.44	-6.3	-0.33	9.5e-10	Total body bone mineral density;
LUSC	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.99	-0.36	1.55e-11	Triglycerides;
LUSC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6460942	0.915	rs7803002	chr7:12306738	C/T	cg06484146	chr7:12443880	VWDE	-0.48	-5.71	-0.3	2.56e-8	Coronary artery disease;
LUSC	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg22508957	chr16:3507546	NAT15	0.44	6.32	0.33	8.24e-10	Body mass index (adult);
LUSC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg22907277	chr7:1156413	C7orf50	0.7	8.19	0.41	5.56e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg09021430	chr5:549028	NA	-0.57	-8.71	-0.43	1.45e-16	Obesity-related traits;
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.45	6.25	0.32	1.27e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3947	0.789	rs9009	chr8:11702006	A/T	cg00262122	chr8:11665843	FDFT1	0.51	6.85	0.35	3.65e-11	Blood protein levels;
LUSC	cis	rs12541635	0.677	rs2163124	chr8:107058862	G/T	cg10147462	chr8:107024639	NA	0.66	13.82	0.6	1.11e-34	Age of smoking initiation;
LUSC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg08493051	chr2:3487164	NA	-0.57	-8.84	-0.44	5.51e-17	Neurofibrillary tangles;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24003225	chr3:184870891	C3orf70	-0.35	-6.07	-0.32	3.41e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.74	-0.35	7.03e-11	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LUSC	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg23544223	chr18:12777786	NA	0.58	6.15	0.32	2.18e-9	Inflammatory skin disease;
LUSC	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg24692254	chr21:30365293	RNF160	0.71	11.42	0.53	1.01e-25	Pancreatic cancer;
LUSC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.38	5.89	0.31	9.43e-9	Multiple sclerosis;
LUSC	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg18721089	chr20:30220636	NA	-0.4	-6.68	-0.34	1.02e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs7188873	1	rs7188873	chr16:24727064	A/G	cg06028605	chr16:24865363	SLC5A11	-0.35	-6.36	-0.33	6.82e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs36093844	0.898	rs12361645	chr11:85595106	C/G	cg25872744	chr11:85566296	CCDC83	-0.46	-6.98	-0.36	1.63e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs3736594	0.513	rs1881396	chr2:27844601	G/T	cg27432699	chr2:27873401	GPN1	-0.63	-8.53	-0.42	5.28e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.71	0.51	3.24e-23	Menopause (age at onset);
LUSC	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg24690094	chr11:67383802	NA	0.44	8.5	0.42	6.36e-16	Mean corpuscular volume;
LUSC	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg23752985	chr2:85803571	VAMP8	0.33	6.34	0.33	7.49e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg15145296	chr3:125709740	NA	-0.56	-6.31	-0.33	9e-10	Blood pressure (smoking interaction);
LUSC	cis	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg01251360	chr16:68772225	CDH1	0.27	6.46	0.33	3.61e-10	Colorectal cancer;
LUSC	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.36	-0.33	6.77e-10	Response to antipsychotic treatment;
LUSC	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg20991723	chr1:152506922	NA	0.5	9.35	0.46	1.32e-18	Hair morphology;
LUSC	cis	rs28595532	0.623	rs34531766	chr4:119230339	T/C	cg21605333	chr4:119757512	SEC24D	0.73	6.2	0.32	1.67e-9	Cannabis dependence symptom count;
LUSC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg13607699	chr17:42295918	UBTF	0.53	8.25	0.41	3.6e-15	Total body bone mineral density;
LUSC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	cis	rs10746514	0.833	rs2356925	chr1:232261769	G/A	cg09506761	chr1:232265262	NA	-0.56	-9.56	-0.46	2.57e-19	Response to statin therapy;
LUSC	cis	rs727505	1.000	rs10464529	chr7:124520308	G/A	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs7580658	0.891	rs55998967	chr2:128048674	A/C	cg09760422	chr2:128146352	NA	-0.33	-7.24	-0.37	3.06e-12	Protein C levels;
LUSC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.86	0.39	5.51e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-13.69	-0.6	3.44e-34	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.88	-0.31	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg18232548	chr7:50535776	DDC	-0.53	-7.39	-0.37	1.17e-12	Malaria;
LUSC	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg24375607	chr4:120327624	NA	0.71	11.35	0.53	1.83e-25	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17502984	chr6:80714315	TTK	-0.41	-6.0	-0.31	5.16e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1564892	0.615	rs1843371	chr12:104454042	C/G	cg14987745	chr12:104360022	TDG	0.52	5.77	0.3	1.81e-8	Corneal structure;
LUSC	cis	rs9581857	0.685	rs11839899	chr13:28041780	G/A	cg22138327	chr13:27999177	GTF3A	0.74	8.04	0.4	1.53e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg00339695	chr16:24857497	SLC5A11	-0.38	-6.71	-0.34	8.22e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6076065	0.707	rs2424555	chr20:23417705	A/G	cg11657817	chr20:23433608	CST11	0.51	10.11	0.48	3.9e-21	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	1.05	18.3	0.71	2.53e-52	Testicular germ cell tumor;
LUSC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg21951975	chr1:209979733	IRF6	0.58	8.53	0.42	5.09e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg00933542	chr6:150070202	PCMT1	0.32	6.62	0.34	1.45e-10	Lung cancer;
LUSC	cis	rs41271473	1.000	rs4391638	chr1:228878481	A/C	cg10167378	chr1:228756711	NA	0.54	6.59	0.34	1.72e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	trans	rs787274	1.000	rs787272	chr9:115549547	C/T	cg12584355	chr7:100773851	SERPINE1	0.57	6.1	0.32	2.95e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg11752832	chr7:134001865	SLC35B4	0.59	9.3	0.45	1.94e-18	Mean platelet volume;
LUSC	cis	rs427941	0.655	rs2734782	chr7:101749667	T/C	cg06246474	chr7:101738831	CUX1	0.39	6.33	0.33	8.12e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	6.99	0.36	1.5e-11	Multiple sclerosis;
LUSC	cis	rs10779751	1.000	rs11121702	chr1:11293147	C/T	cg08854313	chr1:11322531	MTOR	0.87	14.52	0.62	2.22e-37	Body mass index;
LUSC	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg09915433	chr19:53449742	NA	-0.64	-10.55	-0.5	1.18e-22	Psoriasis;
LUSC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg02018176	chr4:1364513	KIAA1530	0.53	9.15	0.45	5.63e-18	Obesity-related traits;
LUSC	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.46	5.86	0.31	1.09e-8	Schizophrenia;
LUSC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg16447950	chr5:562315	NA	-0.57	-6.75	-0.35	6.5500000000000006e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg17127132	chr2:85788382	GGCX	0.49	8.03	0.4	1.64e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18404041	chr3:52824283	ITIH1	-0.52	-9.82	-0.47	3.77e-20	Electroencephalogram traits;
LUSC	cis	rs4474465	0.915	rs12273367	chr11:78173835	A/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.71	-0.3	2.51e-8	Alzheimer's disease (survival time);
LUSC	cis	rs2235649	0.798	rs9922462	chr16:1848011	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.06	-0.31	3.7e-9	Blood metabolite levels;
LUSC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg25456477	chr12:86230367	RASSF9	0.33	5.77	0.3	1.84e-8	Major depressive disorder;
LUSC	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.27	-0.32	1.1e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg15485101	chr11:133734466	NA	0.42	7.79	0.39	8.3e-14	Childhood ear infection;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	ch.20.661824R	chr20:32868459	AHCY	-0.5	-6.9	-0.35	2.68e-11	Hepatitis;
LUSC	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg26677194	chr12:130822605	PIWIL1	0.56	8.39	0.42	1.4e-15	Menopause (age at onset);
LUSC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg23887609	chr12:130822674	PIWIL1	0.49	7.27	0.37	2.65e-12	Menopause (age at onset);
LUSC	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg03676636	chr4:99064102	C4orf37	0.31	6.74	0.35	6.93e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.49e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7560272	0.682	rs2421546	chr2:73641077	A/C	cg20560298	chr2:73613845	ALMS1	0.48	7.45	0.38	8.26e-13	Schizophrenia;
LUSC	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.53	-8.92	-0.44	3.2e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs983392	0.679	rs6591559	chr11:60025565	C/T	cg20284999	chr11:59952153	MS4A6A	-0.39	-6.38	-0.33	5.85e-10	Alzheimer's disease (late onset);
LUSC	cis	rs75920871	0.528	rs12274388	chr11:116946238	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.48	-0.33	3.25e-10	Subjective well-being;
LUSC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg23978390	chr7:1156363	C7orf50	0.48	5.67	0.3	3.06e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg00579200	chr11:133705235	NA	-0.39	-5.9	-0.31	9.02e-9	Childhood ear infection;
LUSC	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-8.21	-0.41	4.82e-15	Axial length;
LUSC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg02487422	chr3:49467188	NICN1	0.45	7.07	0.36	9.28e-12	Resting heart rate;
LUSC	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg08330031	chr10:104623503	C10orf32	0.32	5.69	0.3	2.76e-8	Arsenic metabolism;
LUSC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.57	0.57	6.1e-30	Motion sickness;
LUSC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg17764715	chr19:33622953	WDR88	0.54	8.09	0.4	1.15e-14	Colorectal cancer;
LUSC	cis	rs13315871	1.000	rs9862969	chr3:58341917	A/G	cg20936604	chr3:58311152	NA	-0.72	-7.09	-0.36	8.14e-12	Cholesterol, total;
LUSC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg18240062	chr17:79603768	NPLOC4	0.69	12.86	0.58	4.98e-31	Eye color traits;
LUSC	cis	rs28595532	0.668	rs56410164	chr4:119331625	A/G	cg02775129	chr4:119771670	NA	-0.76	-6.31	-0.33	8.88e-10	Cannabis dependence symptom count;
LUSC	cis	rs472402	0.623	rs7707877	chr5:6635946	C/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.48	-7.17	-0.37	4.75e-12	Response to amphetamines;
LUSC	cis	rs7851660	0.809	rs7031386	chr9:100665669	G/T	cg13688889	chr9:100608707	NA	-0.54	-8.43	-0.42	1.05e-15	Strep throat;
LUSC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.68	-0.34	9.77e-11	Lung cancer;
LUSC	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg05340658	chr4:99064831	C4orf37	0.45	7.08	0.36	8.69e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	9.53	0.46	3.4e-19	IgG glycosylation;
LUSC	trans	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.08	-0.32	3.22e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg11812906	chr14:75593930	NEK9	0.66	11.51	0.53	4.73e-26	Height;
LUSC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg17279839	chr7:150038598	RARRES2	0.4	6.23	0.32	1.44e-9	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg05787951	chr6:166100605	NA	0.56	6.04	0.31	4.1e-9	Type 2 diabetes nephropathy;
LUSC	trans	rs9951602	0.920	rs3859334	chr18:76684193	G/A	cg02800362	chr5:177631904	HNRNPAB	0.67	7.29	0.37	2.27e-12	Obesity-related traits;
LUSC	cis	rs4654899	0.733	rs6698440	chr1:21258712	C/T	cg01072550	chr1:21505969	NA	-0.54	-8.17	-0.41	6.33e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.92	15.75	0.65	3.5e-42	Bladder cancer;
LUSC	cis	rs73200209	0.744	rs17498543	chr12:116581796	T/C	cg01776926	chr12:116560359	MED13L	-0.51	-6.13	-0.32	2.45e-9	Total body bone mineral density;
LUSC	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg05973401	chr12:123451056	ABCB9	0.53	6.59	0.34	1.73e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg08601574	chr20:25228251	PYGB	0.42	6.36	0.33	6.79e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg19230755	chr7:65878503	NA	-0.4	-5.65	-0.3	3.35e-8	Aortic root size;
LUSC	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg12935359	chr14:103987150	CKB	-0.57	-8.71	-0.43	1.45e-16	Body mass index;
LUSC	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.74	9.99	0.48	9.68e-21	Platelet count;
LUSC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.62	9.81	0.47	4.06e-20	Response to diuretic therapy;
LUSC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg12560992	chr17:57184187	TRIM37	-0.84	-15.34	-0.64	1.38e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11645453	chr3:52864694	ITIH4	0.43	9.04	0.44	1.27e-17	Schizophrenia;
LUSC	trans	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg25482853	chr8:67687455	SGK3	1.09	15.45	0.65	5.28e-41	Obesity-related traits;
LUSC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg05025164	chr4:1340916	KIAA1530	-0.48	-7.35	-0.37	1.55e-12	Obesity-related traits;
LUSC	cis	rs4851254	0.618	rs13033732	chr2:100644797	A/G	cg22139774	chr2:100720529	AFF3	-0.44	-5.79	-0.3	1.65e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg08684580	chr7:98029266	BAIAP2L1	0.38	7.0	0.36	1.4e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg25204440	chr1:209979598	IRF6	0.52	6.94	0.35	2.1e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.42	6.4	0.33	5.12e-10	Colorectal cancer;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg21303682	chr7:7606373	MIOS	0.41	6.23	0.32	1.38e-9	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg23241863	chr10:102295624	HIF1AN	0.5	6.16	0.32	2.15e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.19	-0.41	5.54e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg11993925	chr19:44307056	LYPD5	0.35	7.57	0.38	3.59e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg04850211	chr1:228464232	OBSCN	-0.37	-6.2	-0.32	1.62e-9	Diastolic blood pressure;
LUSC	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.47	6.3	0.33	9.12e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-9.68	-0.47	1.11e-19	Migraine;Coronary artery disease;
LUSC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.83	-13.29	-0.59	1.19e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11645453	chr3:52864694	ITIH4	0.33	7.72	0.39	1.4e-13	Bipolar disorder;
LUSC	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	7.58	0.38	3.42e-13	Glomerular filtration rate;
LUSC	cis	rs10193935	0.892	rs6744964	chr2:42441088	A/G	cg27598129	chr2:42591480	NA	-0.62	-8.47	-0.42	7.98e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg12560992	chr17:57184187	TRIM37	0.64	10.99	0.52	3.38e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg03678062	chr6:149772716	ZC3H12D	-0.3	-6.2	-0.32	1.7e-9	Dupuytren's disease;
LUSC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.8	14.71	0.63	4.16e-38	Cognitive function;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09350387	chr2:170430441	FASTKD1	-0.39	-5.95	-0.31	6.92e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.6	0.38	3.08e-13	Ulcerative colitis;
LUSC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg04025307	chr7:1156635	C7orf50	0.38	5.87	0.31	1.06e-8	Longevity;Endometriosis;
LUSC	cis	rs17253792	0.822	rs112308750	chr14:56080073	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg26380479	chr7:97908229	NA	-0.28	-6.3	-0.33	9.42e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg06028605	chr16:24865363	SLC5A11	0.47	8.55	0.42	4.35e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg17376030	chr22:41985996	PMM1	-0.47	-6.0	-0.31	5.08e-9	Vitiligo;
LUSC	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.87	-0.4	4.86e-14	Neuroticism;
LUSC	cis	rs1712517	1.000	rs3123794	chr10:105033742	A/G	cg05636881	chr10:105038444	INA	0.39	6.72	0.35	7.82e-11	Migraine;
LUSC	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.88	-0.35	2.92e-11	Response to antipsychotic treatment;
LUSC	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6545883	0.894	rs1186703	chr2:61672965	A/C	cg15711740	chr2:61764176	XPO1	-0.46	-7.1	-0.36	7.37e-12	Tuberculosis;
LUSC	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	7.24	0.37	3.08e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs500891	0.525	rs6926600	chr6:84109322	A/G	cg08257003	chr6:84140564	ME1	0.34	7.31	0.37	1.93e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14442939	chr10:27389572	ANKRD26	0.79	8.68	0.43	1.73e-16	Breast cancer;
LUSC	cis	rs8063160	0.799	rs1805007	chr16:89986117	A/G	cg07984980	chr16:89898383	SPIRE2	-0.82	-7.19	-0.37	4.22e-12	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LUSC	trans	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg07211511	chr3:129823064	LOC729375	-0.77	-9.84	-0.47	3.18e-20	Blood pressure (smoking interaction);
LUSC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg08219700	chr8:58056026	NA	0.56	6.75	0.35	6.65e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg00852783	chr1:26633632	UBXN11	0.49	8.71	0.43	1.45e-16	Obesity-related traits;
LUSC	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg17845761	chr1:175162550	KIAA0040	0.3	5.8	0.3	1.56e-8	Alcohol dependence;
LUSC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21984481	chr17:79567631	NPLOC4	0.58	11.22	0.52	5.07e-25	Eye color traits;
LUSC	trans	rs8030485	0.571	rs7174337	chr15:79441373	C/A	cg16586880	chr8:140854244	TRAPPC9	-0.38	-6.16	-0.32	2.11e-9	Left ventricle wall thickness;
LUSC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg04166393	chr7:2884313	GNA12	0.44	5.69	0.3	2.71e-8	Height;
LUSC	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg26898376	chr11:64110657	CCDC88B	0.31	5.81	0.3	1.45e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs738321	0.701	rs2413506	chr22:38593128	T/C	cg25457927	chr22:38595422	NA	-0.45	-8.44	-0.42	9.95e-16	Breast cancer;
LUSC	cis	rs472402	0.540	rs2288445	chr5:6620092	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.52	-7.49	-0.38	6.3e-13	Response to amphetamines;
LUSC	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg07828024	chr6:149772892	ZC3H12D	0.33	7.2	0.37	4.06e-12	Dupuytren's disease;
LUSC	trans	rs9467603	1.000	rs6902211	chr6:25767437	G/A	cg06606381	chr12:133084897	FBRSL1	0.58	6.16	0.32	2.12e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg00792783	chr2:198669748	PLCL1	0.43	5.7	0.3	2.66e-8	Dermatomyositis;
LUSC	trans	rs72674100	1.000	rs10005324	chr4:97989202	G/C	cg16405019	chr1:18959625	PAX7	-0.61	-6.44	-0.33	4.04e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12493885	0.729	rs10513452	chr3:153640429	A/C	cg17054900	chr3:154042577	DHX36	-0.58	-6.03	-0.31	4.32e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.96	-19.28	-0.73	3.47e-56	Brugada syndrome;
LUSC	cis	rs6906287	0.669	rs2356491	chr6:118806564	A/G	cg21191810	chr6:118973309	C6orf204	0.33	5.84	0.3	1.21e-8	Electrocardiographic conduction measures;
LUSC	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg09754948	chr16:28834200	ATXN2L	0.43	6.21	0.32	1.54e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg25456477	chr12:86230367	RASSF9	0.4	6.87	0.35	3.16e-11	Major depressive disorder;
LUSC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18876405	chr7:65276391	NA	-0.55	-8.77	-0.43	9.25e-17	Aortic root size;
LUSC	cis	rs8099014	0.861	rs6566969	chr18:56118999	A/G	cg12907477	chr18:56117327	MIR122	0.44	6.95	0.36	1.92e-11	Platelet count;
LUSC	cis	rs870825	0.616	rs6552809	chr4:185643984	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	13.04	0.58	1.05e-31	Blood protein levels;
LUSC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg00049323	chr5:472564	LOC25845	-0.44	-6.8	-0.35	4.79e-11	Cystic fibrosis severity;
LUSC	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	1.12	19.19	0.72	7.34e-56	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.43	-0.42	1.03e-15	Systolic blood pressure;
LUSC	cis	rs60695258	0.550	rs388401	chr4:87974415	C/G	cg10685359	chr4:87814065	C4orf36	0.35	6.24	0.32	1.32e-9	Hematocrit;
LUSC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.51	7.22	0.37	3.51e-12	Gut microbiome composition (summer);
LUSC	cis	rs7267979	0.844	rs6115188	chr20:25432170	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	16.49	0.67	4.05e-45	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg21951975	chr1:209979733	IRF6	0.59	6.97	0.36	1.75e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg16325326	chr1:53192061	ZYG11B	0.7	11.26	0.52	3.77e-25	Monocyte count;
LUSC	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg18755752	chr8:142205143	DENND3	-0.52	-8.33	-0.41	2.15e-15	Immature fraction of reticulocytes;
LUSC	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg23601095	chr6:26197514	HIST1H3D	0.67	7.15	0.36	5.37e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg21573476	chr21:45109991	RRP1B	-0.36	-5.77	-0.3	1.8e-8	Mean corpuscular volume;
LUSC	cis	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg06521331	chr12:34319734	NA	-0.37	-6.07	-0.32	3.55e-9	Morning vs. evening chronotype;
LUSC	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg26850624	chr5:429559	AHRR	-0.43	-8.21	-0.41	4.89e-15	Cystic fibrosis severity;
LUSC	cis	rs4654899	0.865	rs10493006	chr1:21375904	G/A	cg01072550	chr1:21505969	NA	-0.54	-7.91	-0.4	3.73e-14	Superior frontal gyrus grey matter volume;
LUSC	trans	rs225245	0.782	rs321601	chr17:33892087	A/C	cg19694781	chr19:47549865	TMEM160	0.41	6.5	0.34	2.94e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs17433780	0.897	rs12120863	chr1:89501522	T/C	cg09516651	chr1:89888402	LOC400759	0.57	9.93	0.48	1.53e-20	Carotid intima media thickness;
LUSC	cis	rs11958404	0.932	rs72816583	chr5:157432647	T/C	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg24675056	chr1:15929824	NA	0.44	7.56	0.38	3.98e-13	Systolic blood pressure;
LUSC	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.44	-0.42	9.75e-16	Retinal vascular caliber;
LUSC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.68	12.22	0.56	1.26e-28	Aortic root size;
LUSC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg07701084	chr6:150067640	NUP43	0.54	8.25	0.41	3.73e-15	Lung cancer;
LUSC	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.27e-8	Breast cancer;
LUSC	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg00310523	chr12:86230176	RASSF9	0.44	8.25	0.41	3.7e-15	Major depressive disorder;
LUSC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg09365446	chr1:150670422	GOLPH3L	0.54	7.75	0.39	1.11e-13	Urate levels;
LUSC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg12463550	chr7:65579703	CRCP	-0.56	-8.41	-0.42	1.19e-15	Aortic root size;
LUSC	cis	rs9788721	0.836	rs17483929	chr15:78742376	C/T	cg18825076	chr15:78729989	IREB2	-0.57	-9.11	-0.45	7.66e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.07	-0.32	3.42e-9	Total body bone mineral density;
LUSC	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg16342193	chr10:102329863	NA	-0.38	-6.67	-0.34	1.09e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.82	13.94	0.61	3.87e-35	Blood protein levels;
LUSC	cis	rs7903847	0.642	rs11189163	chr10:99121361	C/T	cg20016023	chr10:99160130	RRP12	-0.29	-6.2	-0.32	1.7e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg05347473	chr6:146136440	FBXO30	0.44	7.52	0.38	5.13e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4561483	0.583	rs17236573	chr16:11994655	G/C	cg08843971	chr16:11963173	GSPT1	0.41	6.23	0.32	1.41e-9	Testicular germ cell tumor;
LUSC	cis	rs2625529	0.762	rs1384007	chr15:72229534	T/C	cg16672083	chr15:72433130	SENP8	-0.5	-7.35	-0.37	1.56e-12	Red blood cell count;
LUSC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.72	13.69	0.6	3.73e-34	Alcohol dependence;
LUSC	cis	rs617219	0.746	rs56246109	chr5:78515198	T/G	cg24856658	chr5:78533917	JMY	-0.31	-6.01	-0.31	4.89e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs2282802	0.660	rs6873248	chr5:139683762	A/G	cg26211634	chr5:139558579	C5orf32	-0.39	-7.32	-0.37	1.81e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.67	-0.43	1.93e-16	Response to antipsychotic treatment;
LUSC	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg05855489	chr10:104503620	C10orf26	0.49	7.4	0.38	1.1e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg05890377	chr2:74357713	NA	0.72	13.39	0.59	5.1e-33	Gestational age at birth (maternal effect);
LUSC	cis	rs6961069	0.585	rs1984112	chr7:80242920	A/G	cg04458919	chr7:80252533	CD36	-0.4	-6.94	-0.36	2e-11	Platelet count;
LUSC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg27170947	chr2:26402098	FAM59B	0.63	9.8	0.47	4.21e-20	Gut microbiome composition (summer);
LUSC	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg22089800	chr15:90895588	ZNF774	0.6	9.35	0.46	1.28e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26580134	chr2:60777051	BCL11A	-0.43	-6.36	-0.33	6.46e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg20016023	chr10:99160130	RRP12	-0.33	-8.04	-0.4	1.57e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06481639	chr22:41940642	POLR3H	-0.54	-6.38	-0.33	5.76e-10	Vitiligo;
LUSC	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg27432699	chr2:27873401	GPN1	-0.88	-17.24	-0.69	4.35e-48	Oral cavity cancer;
LUSC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg02475777	chr4:1388615	CRIPAK	0.37	5.65	0.3	3.46e-8	Obesity-related traits;
LUSC	cis	rs58804349	0.685	rs9422671	chr10:43288626	T/G	cg08461752	chr10:43522343	NA	-0.6	-6.1	-0.32	2.94e-9	Pediatric bone mineral content (radius);
LUSC	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.9	0.61	5.49e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg14456004	chr13:21872349	NA	1.27	19.46	0.73	6.49e-57	White matter hyperintensity burden;
LUSC	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	12.06	0.55	4.66e-28	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.37	-0.37	1.34e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg05342945	chr12:48394962	COL2A1	0.4	5.67	0.3	3.1e-8	Lung cancer;
LUSC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg09455208	chr3:40491958	NA	0.52	9.45	0.46	6.03e-19	Renal cell carcinoma;
LUSC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14298792	chr15:30685198	CHRFAM7A	0.63	8.17	0.41	6.3e-15	Huntington's disease progression;
LUSC	cis	rs708547	1.000	rs10003229	chr4:57809598	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	0.46	5.69	0.3	2.84e-8	Response to bleomycin (chromatid breaks);
LUSC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.85	-0.35	3.58e-11	Lung cancer;
LUSC	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.32	0.56	5.39e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs2219968	0.962	rs7817567	chr8:78937473	A/T	cg00738934	chr8:78996279	NA	0.4	7.18	0.37	4.66e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg25173405	chr17:45401733	C17orf57	-0.38	-6.17	-0.32	1.93e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg07080220	chr10:102295463	HIF1AN	0.61	8.14	0.41	8.11e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs13315871	0.929	rs9871725	chr3:58292525	T/G	cg20936604	chr3:58311152	NA	-0.71	-6.68	-0.34	9.96e-11	Cholesterol, total;
LUSC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg12463550	chr7:65579703	CRCP	0.54	8.11	0.41	9.64e-15	Aortic root size;
LUSC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg12463550	chr7:65579703	CRCP	0.42	5.97	0.31	6.11e-9	Aortic root size;
LUSC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	1.04	19.77	0.73	3.88e-58	Menopause (age at onset);
LUSC	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg02023728	chr11:77925099	USP35	0.46	6.9	0.35	2.56e-11	Testicular germ cell tumor;
LUSC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg12463550	chr7:65579703	CRCP	0.42	6.07	0.32	3.49e-9	Aortic root size;
LUSC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg12560992	chr17:57184187	TRIM37	0.84	15.24	0.64	3.63e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg16482183	chr6:26056742	HIST1H1C	0.45	6.58	0.34	1.79e-10	Height;
LUSC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg07936489	chr17:37558343	FBXL20	-0.7	-9.74	-0.47	6.83e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.79	0.43	7.84e-17	Lung cancer;
LUSC	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.52	-0.38	5.25e-13	Total cholesterol levels;
LUSC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg09509183	chr1:209979624	IRF6	0.4	6.1	0.32	3e-9	Monobrow;
LUSC	cis	rs17253792	0.822	rs12100753	chr14:56042870	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.29	-0.37	2.25e-12	Putamen volume;
LUSC	cis	rs7575217	0.552	rs13006193	chr2:101665915	G/A	cg23907051	chr2:101730305	TBC1D8	0.27	6.69	0.34	9.46e-11	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.19	0.41	5.6e-15	Prudent dietary pattern;
LUSC	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg07169764	chr2:136633963	MCM6	-0.76	-10.14	-0.49	3.07e-21	Mosquito bite size;
LUSC	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg15704280	chr7:45808275	SEPT13	0.77	7.3	0.37	2.07e-12	Axial length;
LUSC	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg18132916	chr6:79620363	NA	-0.37	-5.65	-0.3	3.41e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.46	-7.33	-0.37	1.72e-12	Systemic lupus erythematosus;
LUSC	cis	rs9902453	0.730	rs2020939	chr17:28550732	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.51	-7.49	-0.38	6.11e-13	Coffee consumption (cups per day);
LUSC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-0.87	-18.4	-0.71	1.1e-52	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01516881	chr6:292596	DUSP22	-0.53	-7.85	-0.39	5.63e-14	Menopause (age at onset);
LUSC	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg02527881	chr3:46936655	PTH1R	0.39	6.85	0.35	3.66e-11	Colorectal cancer;
LUSC	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg19539972	chr4:7069911	GRPEL1	-0.7	-7.63	-0.39	2.46e-13	Monocyte percentage of white cells;
LUSC	cis	rs7582720	0.943	rs72934551	chr2:203984117	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.61	0.43	2.86e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	13.02	0.58	1.28e-31	Cognitive test performance;
LUSC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg02972257	chr16:68554789	NA	-0.53	-6.6	-0.34	1.64e-10	Ulcerative colitis;
LUSC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.88	-0.31	1.02e-8	Alzheimer's disease (late onset);
LUSC	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg18190219	chr22:46762943	CELSR1	-0.62	-6.3	-0.33	9.22e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg10018233	chr7:150070692	REPIN1	0.38	6.73	0.35	7.52e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg09307838	chr4:120376055	NA	-0.76	-10.57	-0.5	1e-22	Corneal astigmatism;
LUSC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	0.66	9.48	0.46	4.78e-19	Gestational age at birth (maternal effect);
LUSC	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg02527881	chr3:46936655	PTH1R	-0.38	-6.77	-0.35	5.92e-11	Colorectal cancer;
LUSC	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	6.17	0.32	1.96e-9	Schizophrenia;
LUSC	cis	rs4737010	0.501	rs7000282	chr8:41647493	A/C	cg17182837	chr8:41585554	ANK1	-0.39	-6.72	-0.35	7.87e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg17385448	chr1:15911702	AGMAT	0.37	6.23	0.32	1.41e-9	Systolic blood pressure;
LUSC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.76	-13.4	-0.59	4.63e-33	Height;
LUSC	trans	rs1493916	0.905	rs10460051	chr18:31413679	C/T	cg27147174	chr7:100797783	AP1S1	-0.65	-10.37	-0.49	5.19e-22	Life satisfaction;
LUSC	cis	rs7582720	1.000	rs114527590	chr2:203787405	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00908189	chr16:619842	PIGQ	0.68	10.79	0.51	1.79e-23	Height;
LUSC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-12.34	-0.56	4.25e-29	Chronic sinus infection;
LUSC	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.79	11.97	0.55	1.05e-27	Morning vs. evening chronotype;
LUSC	cis	rs1775715	0.705	rs2778651	chr10:32106575	C/T	cg26784012	chr10:32216390	ARHGAP12	0.46	7.67	0.39	1.89e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg07741184	chr6:167504864	NA	0.4	7.09	0.36	8.08e-12	Crohn's disease;
LUSC	trans	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg07923666	chr12:49932857	KCNH3	-0.49	-6.18	-0.32	1.88e-9	Resting heart rate;
LUSC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg13685833	chr1:53393034	SCP2	0.4	5.98	0.31	5.78e-9	Monocyte count;
LUSC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs3755132	0.929	rs4668949	chr2:15771615	C/T	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	cis	rs9309473	0.950	rs13408433	chr2:73883072	G/A	cg20560298	chr2:73613845	ALMS1	-0.42	-5.95	-0.31	6.72e-9	Metabolite levels;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.35	-5.8	-0.3	1.56e-8	Longevity;Endometriosis;
LUSC	cis	rs12541635	0.966	rs55729609	chr8:107056034	A/C	cg10147462	chr8:107024639	NA	0.55	9.92	0.48	1.69e-20	Age of smoking initiation;
LUSC	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg08999081	chr20:33150536	PIGU	-0.41	-7.56	-0.38	3.88e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg00024416	chr22:24240387	NA	-0.32	-5.75	-0.3	2.01e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg20243544	chr17:37824526	PNMT	0.39	5.92	0.31	7.93e-9	Self-reported allergy;
LUSC	cis	rs9487051	0.768	rs12176068	chr6:109521629	C/T	cg00509249	chr6:109615579	CCDC162	-0.33	-5.79	-0.3	1.66e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg03213289	chr20:61660250	NA	0.67	13.26	0.59	1.53e-32	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg07148914	chr20:33460835	GGT7	0.54	8.25	0.41	3.73e-15	Height;
LUSC	cis	rs6012953	0.845	rs2904270	chr20:49185272	G/A	cg13958625	chr20:49123093	NA	-0.26	-5.72	-0.3	2.37e-8	Vitiligo;
LUSC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg03188948	chr7:1209495	NA	0.61	7.02	0.36	1.25e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg24562669	chr7:97807699	LMTK2	-0.39	-6.4	-0.33	5.13e-10	Breast cancer;
LUSC	cis	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg05084668	chr3:125655381	ALG1L	-0.78	-11.57	-0.53	2.84e-26	Blood pressure (smoking interaction);
LUSC	cis	rs62458065	1.000	rs10275978	chr7:32466719	G/T	cg20159608	chr7:32802032	NA	-0.57	-7.01	-0.36	1.34e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12495069	chr2:1652362	PXDN	0.4	6.17	0.32	1.95e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg08917208	chr2:24149416	ATAD2B	0.99	10.48	0.5	2.04e-22	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs672059	0.513	rs627064	chr1:183165716	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	6.11	0.32	2.78e-9	Hypertriglyceridemia;
LUSC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg18402987	chr7:1209562	NA	0.71	7.55	0.38	4.11e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4959270	0.901	rs2316794	chr6:456344	C/T	cg09757644	chr6:447497	NA	0.29	6.08	0.32	3.26e-9	Limited cutaneous systemic scleroderma;
LUSC	cis	rs3106136	0.903	rs67552174	chr4:95203097	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.18	-0.32	1.89e-9	Capecitabine sensitivity;
LUSC	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg00083206	chr6:110721305	DDO	-0.45	-8.28	-0.41	2.95e-15	Platelet distribution width;
LUSC	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	5.77	0.3	1.82e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs17039065	1.000	rs59671813	chr4:109393618	A/C	cg07444054	chr2:108107501	NA	0.41	6.11	0.32	2.74e-9	Gut microbiome composition (summer);
LUSC	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.84	-0.39	6.25e-14	Body mass index;
LUSC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.1	-0.32	2.92e-9	Monocyte count;
LUSC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg17971929	chr21:40555470	PSMG1	0.78	13.72	0.6	2.7e-34	Cognitive function;
LUSC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg04414720	chr1:150670196	GOLPH3L	0.5	7.87	0.4	4.84e-14	Melanoma;
LUSC	cis	rs12318506	0.793	rs11180432	chr12:75661314	C/T	cg04728562	chr12:75699417	CAPS2	-0.77	-5.93	-0.31	7.49e-9	Coronary artery calcification;
LUSC	cis	rs9394152	0.845	rs9394153	chr6:33471630	A/C	cg13560919	chr6:33536144	NA	0.6	10.63	0.5	6.18e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.71	-0.39	1.46e-13	Lymphocyte counts;
LUSC	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg14346243	chr4:90757452	SNCA	-0.4	-5.78	-0.3	1.72e-8	Neuroticism;
LUSC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg23625390	chr15:77176239	SCAPER	0.46	6.94	0.36	2e-11	Blood metabolite levels;
LUSC	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg06108461	chr20:60628389	TAF4	-0.98	-16.75	-0.68	3.88e-46	Body mass index;
LUSC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg25036284	chr2:26402008	FAM59B	-0.74	-10.79	-0.51	1.73e-23	Gut microbiome composition (summer);
LUSC	cis	rs4285028	0.948	rs2877560	chr3:121699238	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-9.06	-0.44	1.11e-17	Multiple sclerosis;
LUSC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.04	-23.84	-0.79	4.49e-74	IgG glycosylation;
LUSC	cis	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-5.95	-0.31	6.73e-9	Systemic lupus erythematosus;
LUSC	cis	rs2425143	1.000	rs6058304	chr20:34299851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.35	-0.33	6.97e-10	Blood protein levels;
LUSC	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg03342759	chr3:160939853	NMD3	-0.56	-9.52	-0.46	3.56e-19	Morning vs. evening chronotype;
LUSC	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.87	-0.31	1.04e-8	Breast cancer;
LUSC	cis	rs9463078	0.605	rs10948188	chr6:44926212	G/A	cg25276700	chr6:44698697	NA	0.28	5.92	0.31	8.11e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs10789640	0.892	rs11212644	chr11:96574762	G/T	cg00988056	chr14:106374554	NA	0.55	5.97	0.31	6.07e-9	Immunoglobulin A vasculitis;
LUSC	cis	rs12210905	0.688	rs9368509	chr6:27379422	A/G	cg08851530	chr6:28072375	NA	-0.9	-6.37	-0.33	6.1e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg06671706	chr8:8559999	CLDN23	0.51	6.68	0.34	9.75e-11	Obesity-related traits;
LUSC	cis	rs73206853	0.841	rs3026486	chr12:110782532	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	6.43	0.33	4.37e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg09307838	chr4:120376055	NA	-0.6	-8.85	-0.44	5.24e-17	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10144964	chr16:31191008	FUS	-0.42	-6.36	-0.33	6.48e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.86	-0.44	4.97e-17	Response to antipsychotic treatment;
LUSC	cis	rs2230307	0.536	rs11166384	chr1:100439890	C/T	cg24955406	chr1:100503596	HIAT1	0.56	6.04	0.31	4.01e-9	Carotid intima media thickness;
LUSC	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg07701084	chr6:150067640	NUP43	0.43	6.44	0.33	4.08e-10	Testicular germ cell tumor;
LUSC	cis	rs394563	0.602	rs409099	chr6:149766863	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.33	-7.37	-0.37	1.34e-12	Dupuytren's disease;
LUSC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg18350739	chr11:68623251	NA	-0.33	-5.88	-0.31	9.72e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.28	6.13	0.32	2.49e-9	Electroencephalogram traits;
LUSC	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12826209	chr6:26865740	GUSBL1	0.67	8.65	0.43	2.22e-16	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg03929089	chr4:120376271	NA	-1.01	-17.41	-0.69	9.43e-49	Coronary artery disease;
LUSC	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg20019720	chr6:154832845	CNKSR3	0.62	8.69	0.43	1.63e-16	Lipoprotein (a) levels;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg02732134	chr10:101732382	DNMBP	-0.36	-6.01	-0.31	4.94e-9	Calcium levels;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg02259775	chr5:98104877	RGMB	0.49	6.54	0.34	2.36e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg15423357	chr2:25149977	NA	0.44	8.98	0.44	1.96e-17	Body mass index;
LUSC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg23711669	chr6:146136114	FBXO30	0.86	16.1	0.66	1.47e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.42	-6.81	-0.35	4.53e-11	Longevity;Endometriosis;
LUSC	cis	rs138918	1.000	rs113515	chr22:43556922	C/G	cg08909806	chr22:43548696	TSPO	0.37	6.94	0.36	2.04e-11	Monocyte count;
LUSC	cis	rs793571	0.590	rs347115	chr15:59082959	C/T	cg05156742	chr15:59063176	FAM63B	0.56	8.59	0.43	3.47e-16	Schizophrenia;
LUSC	trans	rs11039798	0.920	rs7478904	chr11:48630323	C/T	cg15704280	chr7:45808275	SEPT13	0.75	6.45	0.33	4.04e-10	Axial length;
LUSC	cis	rs6574644	1.000	rs1957544	chr14:81773268	A/T	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-14.55	-0.62	1.65e-37	Headache;
LUSC	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.59	0.5	8.82e-23	Colorectal cancer;
LUSC	cis	rs10159302	0.636	rs267644	chr1:57790529	C/G	cg23691223	chr1:57785036	DAB1	-0.37	-5.91	-0.31	8.41e-9	HIV-1 control;
LUSC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg04450456	chr4:17643702	FAM184B	0.38	6.48	0.33	3.27e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.79	14.57	0.62	1.45e-37	Obesity-related traits;
LUSC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg15147215	chr3:52552868	STAB1	-0.31	-6.2	-0.32	1.65e-9	Bipolar disorder;
LUSC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg01125463	chr6:42946178	PEX6	-0.37	-6.03	-0.31	4.27e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg11244672	chr19:19639970	YJEFN3	-0.54	-6.59	-0.34	1.76e-10	Bipolar disorder;
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.33	-0.41	2.17e-15	Lymphocyte counts;
LUSC	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg23277830	chr1:3704460	LRRC47	0.35	6.48	0.33	3.3e-10	Red cell distribution width;
LUSC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg08847533	chr14:75593920	NEK9	0.84	15.61	0.65	1.25e-41	Height;
LUSC	cis	rs10097731	0.901	rs10464890	chr8:82042727	A/G	cg25230327	chr8:82042993	NA	-0.48	-6.78	-0.35	5.55e-11	Serum total protein level;
LUSC	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg13072238	chr3:49761600	GMPPB	-0.73	-8.34	-0.42	1.94e-15	Menarche (age at onset);
LUSC	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02176678	chr2:219576539	TTLL4	-0.72	-13.52	-0.59	1.57e-33	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18301423	chr5:131593218	PDLIM4	0.47	7.03	0.36	1.15e-11	Acylcarnitine levels;
LUSC	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg18478394	chr8:109455254	TTC35	0.44	6.68	0.34	9.86e-11	Dupuytren's disease;
LUSC	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.27	0.71	3.52e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11168618	1.000	rs11168618	chr12:48933233	C/T	cg24011408	chr12:48396354	COL2A1	0.41	6.66	0.34	1.11e-10	Adiponectin levels;
LUSC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg20203395	chr5:56204925	C5orf35	-0.77	-10.47	-0.5	2.31e-22	Initial pursuit acceleration;
LUSC	cis	rs7818345	0.935	rs7016592	chr8:19277735	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	7.42	0.38	9.75e-13	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs11997175	0.846	rs7388664	chr8:33768773	T/G	ch.8.33884649F	chr8:33765107	NA	0.58	9.37	0.46	1.1e-18	Body mass index;
LUSC	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.79	11.44	0.53	8.35e-26	Corneal astigmatism;
LUSC	cis	rs477692	0.967	rs496692	chr10:131429100	C/T	cg05714579	chr10:131428358	MGMT	0.51	7.57	0.38	3.65e-13	Response to temozolomide;
LUSC	cis	rs7178572	1.000	rs8034133	chr15:77763712	C/G	cg22256960	chr15:77711686	NA	-0.55	-9.2	-0.45	4.07e-18	Type 2 diabetes;
LUSC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-0.97	-16.65	-0.67	9.23e-46	Body mass index;
LUSC	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg04362960	chr10:104952993	NT5C2	0.62	9.77	0.47	5.41e-20	Arsenic metabolism;
LUSC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11645453	chr3:52864694	ITIH4	0.34	8.08	0.4	1.23e-14	Electroencephalogram traits;
LUSC	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg04374321	chr14:90722782	PSMC1	-0.7	-10.62	-0.5	6.64e-23	Mortality in heart failure;
LUSC	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg26597838	chr10:835615	NA	0.59	7.71	0.39	1.44e-13	Eosinophil percentage of granulocytes;
LUSC	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.57	9.63	0.47	1.59e-19	Bone mineral density;
LUSC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg09877947	chr5:131593287	PDLIM4	0.34	5.77	0.3	1.77e-8	Blood metabolite levels;
LUSC	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.8	-0.3	1.57e-8	Recombination rate (females);
LUSC	cis	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg17187183	chr4:55093834	PDGFRA	0.38	5.83	0.3	1.3e-8	Corneal astigmatism;
LUSC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg12386194	chr3:101231763	SENP7	0.64	8.96	0.44	2.36e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg09537434	chr19:41945824	ATP5SL	-0.87	-15.12	-0.64	1.01e-39	Height;
LUSC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg21433313	chr16:3507492	NAT15	-0.81	-9.04	-0.44	1.28e-17	Tuberculosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24501027	chr1:92764777	RPAP2;GLMN	-0.43	-6.6	-0.34	1.62e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.55	-0.34	2.11e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg00522288	chr12:125625016	AACS	-0.3	-5.77	-0.3	1.79e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6545883	0.929	rs10200055	chr2:61628017	T/A	cg15711740	chr2:61764176	XPO1	0.43	6.54	0.34	2.25e-10	Tuberculosis;
LUSC	cis	rs16854884	0.586	rs7642551	chr3:143732167	C/T	cg06585982	chr3:143692056	C3orf58	0.52	8.34	0.42	1.91e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.33	-0.37	1.78e-12	Bipolar disorder;
LUSC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6084875	0.812	rs2093386	chr20:4724313	A/G	cg26097573	chr20:4721490	PRNT	-0.31	-5.78	-0.3	1.76e-8	Systemic lupus erythematosus;
LUSC	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg08999081	chr20:33150536	PIGU	0.55	10.97	0.51	4.18e-24	Coronary artery disease;
LUSC	trans	rs4714291	0.792	rs9471241	chr6:40080211	C/T	cg02267698	chr19:7991119	CTXN1	-0.57	-8.66	-0.43	2.01e-16	Strep throat;
LUSC	cis	rs11209002	0.567	rs983110	chr1:67539215	A/T	cg02640540	chr1:67518911	SLC35D1	0.62	8.53	0.42	5.27e-16	Crohn's disease;
LUSC	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg01528321	chr10:82214614	TSPAN14	0.82	12.33	0.56	4.69e-29	Post bronchodilator FEV1;
LUSC	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg20503657	chr10:835505	NA	-0.51	-6.94	-0.36	2.03e-11	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs1322512	0.917	rs1727050	chr6:152944716	C/G	cg27316956	chr6:152958899	SYNE1	-0.36	-6.03	-0.31	4.46e-9	Tonometry;
LUSC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.01e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11051970	0.659	rs950081	chr12:32588488	T/G	cg02745156	chr12:32552066	NA	0.37	5.82	0.3	1.37e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg03388025	chr16:89894329	SPIRE2	0.33	6.84	0.35	3.79e-11	Vitiligo;
LUSC	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg08027265	chr7:2291960	NA	-0.63	-11.23	-0.52	4.8e-25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.97	0.31	5.99e-9	Tonsillectomy;
LUSC	cis	rs7223966	1.000	rs8075273	chr17:61728881	G/T	cg11494091	chr17:61959527	GH2	0.46	6.93	0.35	2.22e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	0.7	11.06	0.52	1.95e-24	Blood metabolite ratios;
LUSC	cis	rs3820068	0.544	rs7551750	chr1:16035008	T/C	cg24675056	chr1:15929824	NA	0.4	6.58	0.34	1.87e-10	Systolic blood pressure;
LUSC	trans	rs2679649	1.000	rs2684263	chr6:122366184	T/C	cg10483660	chr13:112241077	NA	0.69	6.14	0.32	2.31e-9	Subcutaneous adipose tissue;
LUSC	cis	rs754466	0.958	rs58916802	chr10:79695870	G/A	cg17075019	chr10:79541650	NA	-0.63	-8.01	-0.4	1.92e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg26528668	chr16:1614120	IFT140	0.43	7.22	0.37	3.51e-12	Coronary artery disease;
LUSC	cis	rs909341	0.710	rs6011016	chr20:62302650	C/G	cg09650180	chr20:62225654	GMEB2	0.45	5.8	0.3	1.57e-8	Atopic dermatitis;
LUSC	cis	rs472402	0.560	rs10065299	chr5:6654489	T/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.45	-6.54	-0.34	2.24e-10	Response to amphetamines;
LUSC	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-6.96	-0.36	1.78e-11	Height;
LUSC	cis	rs3126085	0.935	rs11204939	chr1:152200942	G/C	cg26876637	chr1:152193138	HRNR	0.45	6.41	0.33	4.93e-10	Atopic dermatitis;
LUSC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg24634471	chr8:143751801	JRK	0.59	9.01	0.44	1.66e-17	Schizophrenia;
LUSC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg03233332	chr7:66118400	NA	-0.42	-6.18	-0.32	1.91e-9	Aortic root size;
LUSC	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg07741184	chr6:167504864	NA	0.51	8.73	0.43	1.2e-16	Crohn's disease;
LUSC	cis	rs11677416	1.000	rs72825514	chr2:113527706	G/T	cg27083787	chr2:113543245	IL1A	0.47	7.27	0.37	2.64e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-12.71	-0.57	1.82e-30	Total body bone mineral density;
LUSC	cis	rs6977660	1.000	rs13230910	chr7:19806003	A/G	cg05791153	chr7:19748676	TWISTNB	-0.55	-6.1	-0.32	3.02e-9	Thyroid stimulating hormone;
LUSC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg21972741	chr5:435613	AHRR	0.37	6.99	0.36	1.47e-11	Cystic fibrosis severity;
LUSC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.29	-0.33	9.82e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3771570	1.000	rs59496049	chr2:242260756	G/C	cg21155796	chr2:242212141	HDLBP	0.58	6.51	0.34	2.69e-10	Prostate cancer;
LUSC	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08645402	chr16:4508243	NA	0.5	8.55	0.42	4.56e-16	Schizophrenia;
LUSC	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg24006582	chr15:45444508	DUOX1	-0.61	-9.03	-0.44	1.43e-17	Uric acid levels;
LUSC	cis	rs11676348	0.904	rs10804264	chr2:218955809	T/C	cg06547715	chr2:218990976	CXCR2	0.3	5.72	0.3	2.34e-8	Ulcerative colitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03637614	chr7:129691233	ZC3HC1	0.48	7.43	0.38	9.24e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg14092571	chr14:90743983	NA	-0.88	-18.24	-0.71	4.54e-52	Gut microbiota (bacterial taxa);
LUSC	cis	rs68170813	0.605	rs74632724	chr7:107136759	A/G	cg24556660	chr7:106842632	COG5;HBP1	-0.44	-5.92	-0.31	7.91e-9	Coronary artery disease;
LUSC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg00800038	chr16:89945340	TCF25	-0.63	-6.68	-0.34	1.02e-10	Skin colour saturation;
LUSC	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg21100191	chr22:23484243	RTDR1	0.92	16.15	0.66	8.97e-44	Bone mineral density;
LUSC	cis	rs7640424	0.826	rs7635063	chr3:107818777	C/T	cg09227934	chr3:107805635	CD47	-0.55	-9.0	-0.44	1.77e-17	Body mass index;
LUSC	cis	rs760805	0.900	rs1005733	chr1:25261960	T/A	cg22509179	chr1:25234806	RUNX3	-0.61	-10.02	-0.48	7.98e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg12365402	chr11:9010492	NRIP3	0.45	8.26	0.41	3.33e-15	Hemoglobin concentration;
LUSC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.54	0.38	4.62e-13	Obesity-related traits;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24739457	chr1:205821442	NA	-0.34	-5.87	-0.31	1.04e-8	Menarche (age at onset);
LUSC	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg00898013	chr13:113819073	PROZ	-0.56	-7.91	-0.4	3.93e-14	Platelet distribution width;
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg27094323	chr7:1216898	NA	-0.46	-8.02	-0.4	1.85e-14	Longevity;Endometriosis;
LUSC	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg18132916	chr6:79620363	NA	-0.38	-5.8	-0.3	1.56e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9612	1.000	rs12669	chr19:44235535	G/A	cg08581076	chr19:44259116	C19orf61	0.52	6.36	0.33	6.53e-10	Exhaled nitric oxide output;
LUSC	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg00677455	chr12:58241039	CTDSP2	0.49	7.35	0.37	1.54e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.4	-0.38	1.1e-12	Breast cancer;
LUSC	cis	rs6066835	1.000	rs6122720	chr20:47351095	G/A	cg18078177	chr20:47281410	PREX1	0.71	6.21	0.32	1.61e-9	Multiple myeloma;
LUSC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs11779988	0.629	rs7465361	chr8:17854155	T/C	cg01800426	chr8:17659068	MTUS1	-0.51	-6.62	-0.34	1.47e-10	Breast cancer;
LUSC	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg13852791	chr20:30311386	BCL2L1	0.77	8.73	0.43	1.25e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg04455712	chr21:45112962	RRP1B	0.44	8.5	0.42	6.39e-16	Mean corpuscular volume;
LUSC	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg16342193	chr10:102329863	NA	-0.35	-6.24	-0.32	1.32e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7809950	1.000	rs10258385	chr7:107243350	T/C	cg23024343	chr7:107201750	COG5	0.57	8.97	0.44	2.14e-17	Coronary artery disease;
LUSC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18876405	chr7:65276391	NA	0.54	8.27	0.41	3.22e-15	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09225691	chr3:98312547	CPOX	-0.43	-6.45	-0.33	3.85e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg06784218	chr1:46089804	CCDC17	0.48	9.39	0.46	9.53e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg17366294	chr4:99064904	C4orf37	0.52	8.48	0.42	7.21e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg22823121	chr1:150693482	HORMAD1	0.47	7.01	0.36	1.3e-11	Melanoma;
LUSC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.85	0.47	3e-20	Personality dimensions;
LUSC	cis	rs79387448	0.505	rs17027327	chr2:103122513	C/A	cg09003973	chr2:102972529	NA	0.87	8.56	0.42	4.28e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg08888203	chr3:10149979	C3orf24	0.64	8.61	0.43	2.97e-16	Alzheimer's disease;
LUSC	cis	rs7180079	1.000	rs7177457	chr15:64530839	C/T	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg05347473	chr6:146136440	FBXO30	0.48	7.89	0.4	4.3e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg21770322	chr7:97807741	LMTK2	0.56	9.94	0.48	1.4e-20	Breast cancer;
LUSC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg16325326	chr1:53192061	ZYG11B	0.81	14.4	0.62	6.33e-37	Monocyte count;
LUSC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	0.79	13.58	0.6	9.75e-34	Cognitive function;
LUSC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg12560992	chr17:57184187	TRIM37	0.84	15.14	0.64	8.69e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-10.15	-0.49	2.82e-21	Longevity;Endometriosis;
LUSC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.92	17.02	0.68	3.35e-47	Cognitive function;
LUSC	cis	rs11229555	0.645	rs12295551	chr11:58188983	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.92	17.86	0.7	1.54e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4144027	0.869	rs55924227	chr14:104361350	G/C	cg12183467	chr14:104352244	NA	0.29	5.71	0.3	2.47e-8	Blood metabolite levels;
LUSC	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.87	0.51	9.49e-24	Fuchs's corneal dystrophy;
LUSC	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.58	0.6	9.87e-34	Morning vs. evening chronotype;
LUSC	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	9.85	0.47	2.98e-20	Lymphocyte percentage of white cells;
LUSC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg10018233	chr7:150070692	REPIN1	0.41	6.79	0.35	5.24e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg25036284	chr2:26402008	FAM59B	-0.72	-10.45	-0.5	2.69e-22	Gut microbiome composition (summer);
LUSC	cis	rs1113500	0.933	rs2077259	chr1:108629551	T/C	cg06207961	chr1:108661230	NA	0.4	7.45	0.38	8.2e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs35995292	0.534	rs7793692	chr7:38940580	G/C	cg19327137	chr7:38886074	VPS41	0.54	10.18	0.49	2.18e-21	Subjective well-being (multi-trait analysis);
LUSC	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg06917634	chr15:78832804	PSMA4	0.53	6.71	0.34	8.11e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6987853	0.761	rs2974321	chr8:42424727	A/G	cg09913449	chr8:42400586	C8orf40	0.53	9.16	0.45	5.49e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg08000102	chr2:233561755	GIGYF2	0.81	13.92	0.61	4.9e-35	Schizophrenia;
LUSC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg03354898	chr7:1950403	MAD1L1	-0.42	-8.43	-0.42	1.05e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg20283391	chr11:68216788	NA	-0.59	-8.31	-0.41	2.46e-15	Total body bone mineral density;
LUSC	cis	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg10665199	chr7:133106180	EXOC4	0.58	8.16	0.41	6.67e-15	Intelligence;Intelligence (multi-trait analysis);
LUSC	cis	rs7572644	0.766	rs13029008	chr2:28212890	A/G	cg27432699	chr2:27873401	GPN1	0.52	6.33	0.33	7.86e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-0.66	-9.53	-0.46	3.35e-19	Platelet distribution width;
LUSC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.77	-12.69	-0.57	2.21e-30	Hip circumference adjusted for BMI;
LUSC	trans	rs11700980	0.551	rs909329	chr21:30108262	G/A	cg14791747	chr16:20752902	THUMPD1	0.56	6.16	0.32	2.1e-9	QRS complex (12-leadsum);
LUSC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs4363385	0.693	rs6690549	chr1:152930426	C/T	cg07796016	chr1:152779584	LCE1C	-0.46	-6.54	-0.34	2.3e-10	Inflammatory skin disease;
LUSC	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg15704280	chr7:45808275	SEPT13	0.73	8.39	0.42	1.38e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg17986701	chr20:44574422	PCIF1	-0.4	-7.1	-0.36	7.6e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-14.55	-0.62	1.65e-37	Headache;
LUSC	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg21175976	chr8:11421337	BLK	-0.35	-5.7	-0.3	2.68e-8	Neuroticism;
LUSC	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-12.01	-0.55	7.22e-28	Hemoglobin concentration;
LUSC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg12963246	chr6:28129442	ZNF389	0.4	6.37	0.33	6.29e-10	Parkinson's disease;
LUSC	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.03e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.74	-13.35	-0.59	7.01e-33	Aortic root size;
LUSC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg04518342	chr5:131593106	PDLIM4	0.37	7.03	0.36	1.2e-11	Blood metabolite levels;
LUSC	cis	rs9815354	0.680	rs73073280	chr3:42025772	T/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs483180	0.512	rs677277	chr1:120202298	C/T	cg19096424	chr1:120255104	PHGDH	-0.49	-6.59	-0.34	1.72e-10	Macular telangiectasia type 2;
LUSC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg22166914	chr1:53195759	ZYG11B	0.48	7.61	0.38	2.74e-13	Monocyte count;
LUSC	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg20607287	chr7:12443886	VWDE	-0.59	-6.2	-0.32	1.71e-9	Coronary artery disease;
LUSC	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg23601095	chr6:26197514	HIST1H3D	0.72	7.7	0.39	1.51e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg22875332	chr1:76189707	ACADM	-0.42	-6.45	-0.33	3.83e-10	Daytime sleep phenotypes;
LUSC	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg06627628	chr2:24431161	ITSN2	-0.62	-9.29	-0.45	1.97e-18	Asthma;
LUSC	cis	rs2303282	0.716	rs1382359	chr16:56399514	G/A	cg00500540	chr16:56394104	NA	-0.44	-7.59	-0.38	3.27e-13	Breast cancer;
LUSC	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.95	18.85	0.72	1.65e-54	Brugada syndrome;
LUSC	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg18404041	chr3:52824283	ITIH1	-0.57	-9.65	-0.47	1.31e-19	Schizophrenia;
LUSC	trans	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg25482853	chr8:67687455	SGK3	1.12	15.79	0.65	2.41e-42	Obesity-related traits;
LUSC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg12863693	chr15:85201151	NMB	0.34	6.78	0.35	5.49e-11	Schizophrenia;
LUSC	trans	rs1459104	0.866	rs28873990	chr11:54812748	G/A	cg15704280	chr7:45808275	SEPT13	0.75	6.55	0.34	2.23e-10	Body mass index;
LUSC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.81	-12.44	-0.56	1.91e-29	Cognitive test performance;
LUSC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg03522245	chr20:25566470	NINL	0.35	5.67	0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg08213375	chr14:104286397	PPP1R13B	-0.53	-10.13	-0.48	3.33e-21	Schizophrenia;
LUSC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg08270630	chr22:50330655	NA	0.41	6.05	0.31	3.98e-9	Schizophrenia;
LUSC	trans	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg24459738	chr19:57751996	ZNF805	-0.5	-7.51	-0.38	5.32e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg12311346	chr5:56204834	C5orf35	0.5	7.57	0.38	3.64e-13	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg22907277	chr7:1156413	C7orf50	0.72	7.67	0.39	1.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg23791538	chr6:167370224	RNASET2	0.41	6.7	0.34	8.84e-11	Crohn's disease;
LUSC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg18827107	chr12:86230957	RASSF9	0.45	6.86	0.35	3.4e-11	Major depressive disorder;
LUSC	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.69	-10.12	-0.48	3.6e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs6961069	0.901	rs819436	chr7:80224314	C/T	cg04458919	chr7:80252533	CD36	-0.32	-5.9	-0.31	8.95e-9	Platelet count;
LUSC	trans	rs9944275	0.799	rs12916235	chr15:97192412	G/A	cg18834029	chr10:103349097	POLL;RP11-529I10.4	-0.6	-5.97	-0.31	6.23e-9	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LUSC	trans	rs10221833	0.602	rs355893	chr2:165635147	A/G	cg26993132	chr16:89239499	CDH15	0.31	5.99	0.31	5.47e-9	Response to statin therapy;
LUSC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg03146154	chr1:46216737	IPP	0.52	7.67	0.39	1.9e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4500972	1	rs4500972	chr2:73767897	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.57	-0.34	1.94e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7508679	1.000	rs10401485	chr19:7222234	T/C	cg09779027	chr19:7224513	INSR	0.44	9.55	0.46	2.98e-19	Hypothyroidism;
LUSC	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg17848003	chr1:3704513	LRRC47	0.33	6.2	0.32	1.65e-9	Red cell distribution width;
LUSC	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.08	23.5	0.79	9.18e-73	Schizophrenia;
LUSC	cis	rs9640161	0.830	rs11972067	chr7:150071605	G/A	cg21361702	chr7:150065534	REPIN1	0.59	9.18	0.45	4.49e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08219700	chr8:58056026	NA	0.69	7.85	0.39	5.69e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.65	-0.34	1.18e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg16235748	chr6:149772707	ZC3H12D	-0.28	-5.66	-0.3	3.26e-8	Dupuytren's disease;
LUSC	cis	rs4919687	0.550	rs12783444	chr10:104480659	G/A	cg04362960	chr10:104952993	NT5C2	0.45	6.47	0.33	3.56e-10	Colorectal cancer;
LUSC	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg21775007	chr8:11205619	TDH	-0.67	-10.73	-0.51	2.83e-23	Retinal vascular caliber;
LUSC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12379764	chr21:47803548	PCNT	-0.42	-5.91	-0.31	8.39e-9	Testicular germ cell tumor;
LUSC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	10.11	0.48	3.82e-21	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.26	0.45	2.6e-18	Prudent dietary pattern;
LUSC	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg15744005	chr10:104629667	AS3MT	-0.28	-5.9	-0.31	8.88e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg01629716	chr15:45996671	NA	0.4	5.87	0.31	1.05e-8	Waist circumference;Weight;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg12237616	chr13:21678564	NA	-0.42	-6.68	-0.34	9.96e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs7220711	0.902	rs4793019	chr17:41781160	A/C	cg26893861	chr17:41843967	DUSP3	-0.44	-6.13	-0.32	2.54e-9	Bone mineral density (spine);Bone mineral density (hip);
LUSC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	10.91	0.51	6.61e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs28595532	0.748	rs113336496	chr4:119336957	C/T	cg21605333	chr4:119757512	SEC24D	0.95	7.97	0.4	2.46e-14	Cannabis dependence symptom count;
LUSC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08677398	chr8:58056175	NA	0.53	6.36	0.33	6.53e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg24296786	chr1:45957014	TESK2	0.42	5.89	0.31	9.46e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.21	-0.37	3.87e-12	Bipolar disorder;
LUSC	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg18129178	chr5:148520854	ABLIM3	-0.67	-10.81	-0.51	1.49e-23	Breast cancer;
LUSC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg21535247	chr6:8435926	SLC35B3	0.6	9.27	0.45	2.37e-18	Motion sickness;
LUSC	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg12573674	chr2:1569213	NA	-0.55	-7.76	-0.39	1.08e-13	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.08	0.36	8.3e-12	Major depressive disorder;
LUSC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07256732	chr16:621771	PIGQ	-0.36	-6.54	-0.34	2.31e-10	Height;
LUSC	cis	rs2070997	0.607	rs3808821	chr9:133712801	G/T	cg11464064	chr9:133710261	ABL1	-0.46	-5.84	-0.3	1.21e-8	Response to amphetamines;
LUSC	cis	rs3931020	0.688	rs405445	chr1:75221150	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	-0.46	-5.92	-0.31	8.06e-9	Resistin levels;
LUSC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.83	-0.81	7.74e-78	Height;
LUSC	cis	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg05299278	chr17:33885742	SLFN14	0.3	6.23	0.32	1.38e-9	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs4954585	0.683	rs13024450	chr2:137014611	C/T	cg05194412	chr2:137003533	NA	0.41	7.57	0.38	3.79e-13	Colorectal cancer;
LUSC	cis	rs8032315	0.895	rs4932370	chr15:91404705	A/G	cg04510874	chr15:91427884	FES	-0.32	-6.65	-0.34	1.21e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13012494	chr21:47604986	C21orf56	-0.47	-7.01	-0.36	1.35e-11	Testicular germ cell tumor;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	ch.9.2051689R	chr9:128344852	MAPKAP1	-0.46	-6.07	-0.32	3.42e-9	Hepatitis;
LUSC	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg11965913	chr1:205819406	PM20D1	-0.49	-6.73	-0.35	7.57e-11	Menarche (age at onset);
LUSC	cis	rs17092148	0.887	rs6059916	chr20:33148861	T/G	cg16810054	chr20:33298113	TP53INP2	-0.35	-5.66	-0.3	3.26e-8	Neuroticism;
LUSC	cis	rs4964805	0.594	rs3812805	chr12:104170872	C/T	cg02344784	chr12:104178138	NT5DC3	0.36	5.83	0.3	1.31e-8	Attention deficit hyperactivity disorder;
LUSC	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.21	-0.49	1.74e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs1015291	0.748	rs941233	chr12:19993676	C/T	cg01501474	chr7:55323552	NA	0.46	6.03	0.31	4.36e-9	Diastolic blood pressure;
LUSC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11764359	chr7:65958608	NA	-0.67	-10.74	-0.51	2.67e-23	Aortic root size;
LUSC	cis	rs7113850	0.541	rs80243979	chr11:24231811	A/C	ch.11.24196551F	chr11:24239977	NA	1.0	9.14	0.45	6e-18	Bone fracture in osteoporosis;
LUSC	cis	rs929596	0.563	rs1105879	chr2:234602202	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.22	-0.37	3.62e-12	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs240768	0.826	rs240779	chr6:100963633	T/A	cg12253828	chr6:101329408	ASCC3	0.78	5.69	0.3	2.72e-8	Economic and political preferences (immigration/crime);
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18538332	chr22:24372958	LOC391322	-0.49	-8.87	-0.44	4.48e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg05527609	chr1:210001259	C1orf107	0.67	9.75	0.47	6.24e-20	Orofacial clefts;
LUSC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg16928487	chr17:17741425	SREBF1	0.47	9.32	0.45	1.66e-18	Total body bone mineral density;
LUSC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.84	0.3	1.27e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3733418	0.929	rs12512234	chr4:165908865	C/T	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-5.92	-0.31	8.03e-9	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg13047869	chr3:10149882	C3orf24	0.6	8.52	0.42	5.73e-16	Alzheimer's disease;
LUSC	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.44	-6.91	-0.35	2.43e-11	Tonsillectomy;
LUSC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.48	7.17	0.37	4.92e-12	Prudent dietary pattern;
LUSC	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg08079166	chr15:68083412	MAP2K5	0.4	8.28	0.41	3.04e-15	Restless legs syndrome;
LUSC	cis	rs2235649	0.703	rs2076428	chr16:1817768	T/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.47	5.92	0.31	8.04e-9	Blood metabolite levels;
LUSC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg01802117	chr1:53393560	SCP2	-0.36	-5.81	-0.3	1.47e-8	Monocyte count;
LUSC	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08045932	chr20:61659980	NA	0.43	6.34	0.33	7.56e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1950626	0.750	rs34144313	chr14:101431216	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.75	0.39	1.08e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg15997130	chr1:24165203	NA	-0.46	-6.6	-0.34	1.57e-10	Immature fraction of reticulocytes;
LUSC	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg00074818	chr8:8560427	CLDN23	0.59	9.59	0.46	2.12e-19	Obesity-related traits;
LUSC	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg26587870	chr6:27730563	NA	-0.61	-5.79	-0.3	1.62e-8	Breast cancer;
LUSC	trans	rs890100	0.867	rs11900485	chr2:56740189	C/A	cg08299783	chr2:48920986	GTF2A1L;LHCGR	-0.31	-6.07	-0.32	3.42e-9	Gut microbiome composition (summer);
LUSC	cis	rs7605827	0.893	rs7589238	chr2:15606409	C/A	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.03	-0.31	4.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10904908	0.862	rs359281	chr10:17320144	A/G	cg01003015	chr10:17271136	VIM	0.43	6.32	0.33	8.43e-10	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.75	12.41	0.56	2.45e-29	Coronary artery disease;
LUSC	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.19e-33	Morning vs. evening chronotype;
LUSC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg21665744	chr7:39171113	POU6F2	0.46	7.44	0.38	8.61e-13	IgG glycosylation;
LUSC	trans	rs1973993	0.708	rs6593605	chr1:96956775	A/G	cg10631902	chr5:14652156	NA	-0.46	-6.82	-0.35	4.18e-11	Weight;
LUSC	trans	rs724744	0.772	rs1772082	chr6:22354566	T/C	cg13807341	chr11:118445984	ARCN1	-0.36	-6.1	-0.32	2.86e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.03	0.52	2.51e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs72949976	1.000	rs62186569	chr2:214034151	C/T	cg08319019	chr2:214017104	IKZF2	-0.62	-9.61	-0.47	1.87e-19	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg03233332	chr7:66118400	NA	-0.42	-6.09	-0.32	3.02e-9	Aortic root size;
LUSC	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.58	7.81	0.39	7.43e-14	Primary sclerosing cholangitis;
LUSC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg08888203	chr3:10149979	C3orf24	-0.56	-8.11	-0.41	9.84e-15	Alzheimer's disease;
LUSC	trans	rs72674100	1.000	rs17026382	chr4:97995366	A/G	cg00855990	chr1:18959354	PAX7	-0.58	-6.2	-0.32	1.63e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	12.43	0.56	2.14e-29	Electrocardiographic conduction measures;
LUSC	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.73	12.13	0.55	2.69e-28	Alcohol dependence;
LUSC	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.56	-0.46	2.71e-19	Neuroticism;
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg09033563	chr22:24373618	LOC391322	0.48	6.71	0.34	8.15e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.09	-0.48	4.66e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg18187862	chr3:45730750	SACM1L	-0.51	-6.18	-0.32	1.83e-9	Primary sclerosing cholangitis;
LUSC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg27535305	chr1:53392650	SCP2	-0.39	-7.32	-0.37	1.85e-12	Monocyte count;
LUSC	cis	rs9326248	0.768	rs4936366	chr11:117026885	G/A	cg11861562	chr11:117069780	TAGLN	0.35	5.65	0.3	3.4e-8	Blood protein levels;
LUSC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg19812747	chr11:111475976	SIK2	-0.57	-8.23	-0.41	4.18e-15	Primary sclerosing cholangitis;
LUSC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg17143192	chr8:8559678	CLDN23	0.66	9.15	0.45	5.77e-18	Obesity-related traits;
LUSC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg20203395	chr5:56204925	C5orf35	-0.47	-6.85	-0.35	3.49e-11	Coronary artery disease;
LUSC	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg27661571	chr11:113659931	NA	0.6	6.25	0.32	1.26e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.59	-0.38	3.15e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg13047869	chr3:10149882	C3orf24	0.56	7.88	0.4	4.76e-14	Alzheimer's disease;
LUSC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18876405	chr7:65276391	NA	-0.56	-8.88	-0.44	4.07e-17	Aortic root size;
LUSC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg15649852	chr7:65879115	NA	-0.41	-5.81	-0.3	1.49e-8	Aortic root size;
LUSC	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.53	7.81	0.39	7.36e-14	Breast cancer;
LUSC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.6	0.46	2.01e-19	Mean platelet volume;
LUSC	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg00898013	chr13:113819073	PROZ	-0.57	-8.23	-0.41	4.12e-15	Platelet distribution width;
LUSC	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg00857998	chr1:205179979	DSTYK	0.55	8.34	0.42	1.99e-15	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs12210905	1.000	rs1062834	chr6:27222539	A/G	cg11837749	chr1:55047332	ACOT11	0.58	5.98	0.31	5.64e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24110177	chr3:50126178	RBM5	0.65	11.48	0.53	6.07e-26	Body mass index;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10150615	chr22:24372951	LOC391322	-0.41	-6.85	-0.35	3.52e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg09307838	chr4:120376055	NA	-0.59	-8.8	-0.43	7.49e-17	Corneal astigmatism;
LUSC	cis	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.43	-0.42	1.05e-15	Morning vs. evening chronotype;
LUSC	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg20713898	chr8:124780851	FAM91A1	-0.54	-7.67	-0.39	1.87e-13	Pancreatic cancer;
LUSC	cis	rs28655083	1.000	rs11863397	chr16:77060388	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-6.26	-0.32	1.16e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.24	-0.37	3.08e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg11498726	chr8:26250323	BNIP3L	-0.46	-6.8	-0.35	4.69e-11	Red cell distribution width;
LUSC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	11.34	0.53	1.95e-25	Colorectal cancer;
LUSC	cis	rs62400317	0.859	rs28583363	chr6:45231336	T/A	cg20913747	chr6:44695427	NA	-0.47	-7.65	-0.39	2.2e-13	Total body bone mineral density;
LUSC	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg25809561	chr17:30822961	MYO1D	0.55	9.72	0.47	7.91e-20	Schizophrenia;
LUSC	trans	rs12571093	0.803	rs61854825	chr10:70031292	G/A	cg04882175	chr6:131122610	NA	-0.55	-6.27	-0.32	1.09e-9	Optic nerve measurement (disc area);
LUSC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg18904891	chr8:8559673	CLDN23	0.38	5.89	0.31	9.52e-9	Mood instability;
LUSC	cis	rs1595825	0.891	rs77029420	chr2:198651492	G/A	cg00982548	chr2:198649783	BOLL	-0.56	-6.58	-0.34	1.78e-10	Ulcerative colitis;
LUSC	cis	rs4356932	0.811	rs68156651	chr4:76972468	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.86	0.31	1.11e-8	Blood protein levels;
LUSC	cis	rs10792830	0.707	rs613222	chr11:85769105	T/G	cg07180834	chr11:85838833	NA	-0.32	-6.04	-0.31	4.07e-9	Psychosis and Alzheimer's disease;
LUSC	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-6.28	-0.33	1.04e-9	Daytime sleep phenotypes;
LUSC	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.2	-35.46	-0.89	2.79e-115	Myeloid white cell count;
LUSC	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg15848620	chr12:58087721	OS9	-0.53	-7.63	-0.39	2.45e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.48	7.04	0.36	1.1e-11	Schizophrenia;
LUSC	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg08085267	chr17:45401833	C17orf57	-0.51	-7.18	-0.37	4.58e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.66	-0.3	3.31e-8	Life satisfaction;
LUSC	cis	rs4363385	0.747	rs6704105	chr1:152964397	C/G	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.76	-0.39	1.08e-13	Inflammatory skin disease;
LUSC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg14552801	chr7:65878734	NA	0.38	5.84	0.3	1.27e-8	Aortic root size;
LUSC	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs4776059	1.000	rs12902679	chr15:52881317	C/T	cg22715398	chr15:52968154	KIAA1370	0.73	10.25	0.49	1.27e-21	Schizophrenia;
LUSC	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg18827107	chr12:86230957	RASSF9	-0.4	-5.67	-0.3	3.01e-8	Major depressive disorder;
LUSC	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg01503450	chr10:980765	NA	-0.4	-5.81	-0.3	1.45e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs17102423	0.685	rs7156617	chr14:65541381	G/A	cg11161011	chr14:65562177	MAX	-0.76	-11.16	-0.52	8.75e-25	Obesity-related traits;
LUSC	cis	rs4343996	0.720	rs10250421	chr7:3458288	A/T	cg21248987	chr7:3385318	SDK1	0.34	5.65	0.3	3.37e-8	Motion sickness;
LUSC	cis	rs3018712	0.532	rs2510398	chr11:68421416	G/A	cg22747802	chr11:68417633	NA	-0.45	-6.26	-0.32	1.16e-9	Total body bone mineral density;
LUSC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.51	-7.82	-0.39	7.19e-14	Personality dimensions;
LUSC	cis	rs9937943	0.721	rs8059315	chr16:74506447	C/G	cg01733217	chr16:74700730	RFWD3	0.65	7.67	0.39	1.86e-13	Neutrophil percentage of white cells;
LUSC	cis	rs11645898	0.515	rs61747473	chr16:72258743	C/T	cg14768367	chr16:72042858	DHODH	-0.58	-5.92	-0.31	7.96e-9	Blood protein levels;
LUSC	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg25427524	chr10:38739819	LOC399744	-0.52	-6.38	-0.33	5.9e-10	Obesity (extreme);
LUSC	cis	rs9560113	0.960	rs1163862	chr13:112174319	C/T	cg14154082	chr13:112174009	NA	0.37	8.07	0.4	1.27e-14	Menarche (age at onset);
LUSC	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.62	-0.34	1.44e-10	Breast cancer;
LUSC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg22907277	chr7:1156413	C7orf50	0.48	7.26	0.37	2.77e-12	Longevity;Endometriosis;
LUSC	cis	rs2236918	0.932	rs1635517	chr1:242012033	A/G	cg17736920	chr1:242011382	EXO1	-0.47	-7.51	-0.38	5.58e-13	Menopause (age at onset);
LUSC	cis	rs9311676	0.656	rs59643048	chr3:58390248	A/G	cg13750441	chr3:58318267	PXK	0.35	6.75	0.35	6.64e-11	Systemic lupus erythematosus;
LUSC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	12.22	0.56	1.2e-28	Menopause (age at onset);
LUSC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg23262073	chr20:60523788	NA	-0.39	-6.09	-0.32	3.19e-9	Body mass index;
LUSC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg20887711	chr4:1340912	KIAA1530	0.44	6.57	0.34	1.97e-10	Obesity-related traits;
LUSC	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-21.66	-0.76	1.33e-65	Ulcerative colitis;
LUSC	trans	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg02113368	chr10:135107346	TUBGCP2	-0.34	-5.95	-0.31	6.76e-9	Dementia with Lewy bodies;
LUSC	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg08079166	chr15:68083412	MAP2K5	0.49	8.49	0.42	6.75e-16	Restless legs syndrome;
LUSC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg03146154	chr1:46216737	IPP	-0.55	-8.08	-0.4	1.22e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-0.83	-14.08	-0.61	1.14e-35	Menopause (age at onset);
LUSC	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg10356904	chr22:49881777	NA	-0.28	-5.76	-0.3	1.87e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04193083	chr17:41323562	NBR1	-0.51	-6.08	-0.32	3.3e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg16624210	chr5:671434	TPPP	0.5	6.31	0.33	8.97e-10	Obesity-related traits;
LUSC	cis	rs7582720	0.943	rs72932575	chr2:203866857	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	8.37	0.42	1.63e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.75	-13.12	-0.58	5.27e-32	Cognitive function;
LUSC	cis	rs955333	0.565	rs7770413	chr6:154904487	A/G	cg20019720	chr6:154832845	CNKSR3	0.46	6.86	0.35	3.36e-11	Diabetic kidney disease;
LUSC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg24399712	chr22:39784796	NA	-0.62	-11.09	-0.52	1.53e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg17845761	chr1:175162550	KIAA0040	-0.34	-6.51	-0.34	2.81e-10	Alcohol dependence;
LUSC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.45	6.39	0.33	5.54e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg15654264	chr1:150340011	RPRD2	0.62	10.29	0.49	9.57e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg02782426	chr3:40428986	ENTPD3	0.4	7.66	0.39	1.97e-13	Renal cell carcinoma;
LUSC	cis	rs16949788	1.000	rs7169463	chr15:66745929	G/C	cg08120210	chr15:66682733	MAP2K1	-0.61	-6.17	-0.32	2.03e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	0.59	9.55	0.46	2.8e-19	Breast cancer;
LUSC	cis	rs12368653	0.789	rs17852479	chr12:58126234	C/A	cg12615879	chr12:58013172	SLC26A10	0.39	9.25	0.45	2.81e-18	Multiple sclerosis;
LUSC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg14664628	chr15:75095509	CSK	-0.49	-7.01	-0.36	1.32e-11	Breast cancer;
LUSC	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	7.03	0.36	1.2e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg20744362	chr22:50050164	C22orf34	0.36	6.74	0.35	6.84e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14341449	chr11:18034693	SERGEF	-0.43	-6.39	-0.33	5.58e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7572733	0.576	rs6734781	chr2:198759973	G/A	cg00792783	chr2:198669748	PLCL1	0.46	6.25	0.32	1.28e-9	Dermatomyositis;
LUSC	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.47	0.56	1.41e-29	White blood cell count;
LUSC	cis	rs4499344	0.633	rs259260	chr19:33153261	G/A	cg22980127	chr19:33182716	NUDT19	-0.44	-6.45	-0.33	3.88e-10	Mean platelet volume;
LUSC	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg01119278	chr6:110721349	DDO	-0.45	-8.09	-0.4	1.16e-14	Platelet distribution width;
LUSC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.9	17.15	0.68	9.98e-48	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.41	-0.33	4.96e-10	Blood trace element (Cu levels);
LUSC	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.19	-0.32	1.72e-9	Triglycerides;
LUSC	trans	rs617791	0.508	rs747526	chr11:65776071	C/A	cg17712092	chr4:129076599	LARP1B	-0.69	-9.81	-0.47	4.03e-20	Breast cancer;
LUSC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06873352	chr17:61820015	STRADA	0.57	8.78	0.43	8.9e-17	Height;
LUSC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00149659	chr3:10157352	C3orf10	0.9	12.53	0.57	8.81e-30	Alzheimer's disease;
LUSC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg04155289	chr7:94953770	PON1	-0.35	-6.02	-0.31	4.7e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7539409	0.651	rs10747407	chr1:84314754	G/A	cg10977910	chr1:84465055	TTLL7	0.74	7.85	0.39	5.82e-14	Alzheimer's disease;
LUSC	trans	rs72674100	1.000	rs28656993	chr4:97965682	C/T	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg12610070	chr10:71211762	TSPAN15	-0.48	-9.34	-0.46	1.42e-18	Venous thromboembolism;
LUSC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.56	-8.87	-0.44	4.62e-17	Alzheimer's disease (late onset);
LUSC	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg00310523	chr12:86230176	RASSF9	-0.43	-8.06	-0.4	1.42e-14	Major depressive disorder;
LUSC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg04455712	chr21:45112962	RRP1B	0.46	8.81	0.43	6.9e-17	Mean corpuscular volume;
LUSC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg04155289	chr7:94953770	PON1	-0.34	-5.68	-0.3	2.96e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg27411982	chr8:10470053	RP1L1	0.44	6.39	0.33	5.72e-10	Neuroticism;
LUSC	cis	rs548181	0.611	rs2849225	chr11:125415936	A/G	cg03464685	chr11:125439445	EI24	1.36	14.72	0.63	3.83e-38	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg04362960	chr10:104952993	NT5C2	0.61	9.57	0.46	2.39e-19	Arsenic metabolism;
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.52	-8.89	-0.44	3.8e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg27129171	chr3:47204927	SETD2	0.56	8.01	0.4	1.88e-14	Birth weight;
LUSC	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.41	-6.06	-0.31	3.76e-9	Schizophrenia;
LUSC	cis	rs7809950	0.723	rs2237662	chr7:106874065	C/G	cg23024343	chr7:107201750	COG5	-0.66	-9.49	-0.46	4.46e-19	Coronary artery disease;
LUSC	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-5.79	-0.3	1.63e-8	Retinal vascular caliber;
LUSC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9815354	1.000	rs56776628	chr3:41866856	A/G	cg03022575	chr3:42003672	ULK4	0.58	6.52	0.34	2.6e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11608355	0.545	rs12822891	chr12:109896002	A/G	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg04398451	chr17:18023971	MYO15A	-0.48	-7.65	-0.39	2.12e-13	Total body bone mineral density;
LUSC	cis	rs367943	0.666	rs10041899	chr5:112724742	A/T	cg12552261	chr5:112820674	MCC	0.37	6.11	0.32	2.7e-9	Type 2 diabetes;
LUSC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg02428538	chr16:24856791	SLC5A11	0.54	6.06	0.31	3.7e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.13	-0.41	8.48e-15	Coronary artery disease;
LUSC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11645453	chr3:52864694	ITIH4	0.31	7.32	0.37	1.84e-12	Bipolar disorder;
LUSC	cis	rs7809950	1.000	rs10273733	chr7:107258121	A/G	cg23024343	chr7:107201750	COG5	0.49	7.16	0.36	5.17e-12	Coronary artery disease;
LUSC	cis	rs9341808	0.617	rs9294170	chr6:80814080	A/G	cg08355045	chr6:80787529	NA	0.62	11.46	0.53	7.23e-26	Sitting height ratio;
LUSC	cis	rs61990749	0.571	rs2364841	chr14:78284036	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.7	6.65	0.34	1.23e-10	Fibroblast growth factor basic levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14221825	chr19:46271408	SIX5	0.47	6.82	0.35	4.22e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs11039798	0.920	rs12279378	chr11:48571030	A/C	cg15704280	chr7:45808275	SEPT13	0.69	6.51	0.34	2.81e-10	Axial length;
LUSC	trans	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.34e-10	Life satisfaction;
LUSC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.37	-6.41	-0.33	5.04e-10	High light scatter reticulocyte count;
LUSC	cis	rs713477	0.505	rs4901561	chr14:55888578	T/C	cg13175173	chr14:55914753	NA	-0.31	-5.87	-0.31	1.07e-8	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg03289416	chr15:75166202	SCAMP2	0.45	7.06	0.36	9.73e-12	Breast cancer;
LUSC	cis	rs2303282	0.716	rs6499834	chr16:56442734	C/T	cg00500540	chr16:56394104	NA	-0.43	-7.32	-0.37	1.88e-12	Breast cancer;
LUSC	trans	rs12210905	1.000	rs3999221	chr6:26959322	C/G	cg11837749	chr1:55047332	ACOT11	0.55	5.98	0.31	5.64e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs62169186	0.826	rs62169174	chr2:145046987	T/C	cg02721902	chr17:46825371	NA	-0.55	-5.99	-0.31	5.56e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6545883	0.929	rs778154	chr2:61646631	T/C	cg15711740	chr2:61764176	XPO1	0.44	6.65	0.34	1.18e-10	Tuberculosis;
LUSC	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg00945038	chr17:61921165	SMARCD2	0.38	5.69	0.3	2.74e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	0.93	12.69	0.57	2.24e-30	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg10172584	chr19:19639581	YJEFN3	-0.46	-5.68	-0.3	3.01e-8	Bipolar disorder;
LUSC	cis	rs10979	1.000	rs9386038	chr6:143896358	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.78	-0.39	8.84e-14	Myopia (pathological);
LUSC	cis	rs7202877	0.656	rs8048677	chr16:75392028	C/G	cg04384234	chr16:75411784	CFDP1	-0.64	-9.07	-0.44	1.08e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg21775007	chr8:11205619	TDH	-0.5	-7.01	-0.36	1.36e-11	Triglycerides;
LUSC	cis	rs259282	0.605	rs55687317	chr19:33109191	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.66	9.87	0.48	2.45e-20	Schizophrenia;
LUSC	cis	rs1728785	0.901	rs7194664	chr16:68643313	T/C	cg02972257	chr16:68554789	NA	-0.51	-6.22	-0.32	1.51e-9	Ulcerative colitis;
LUSC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06481639	chr22:41940642	POLR3H	-0.52	-5.89	-0.31	9.37e-9	Vitiligo;
LUSC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg04155289	chr7:94953770	PON1	-0.36	-6.12	-0.32	2.56e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg05585544	chr11:47624801	NA	-0.42	-7.26	-0.37	2.71e-12	Subjective well-being;
LUSC	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg19784903	chr17:45786737	TBKBP1	-0.42	-6.04	-0.31	4.05e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs11088226	0.750	rs2833885	chr21:33923161	A/G	cg09050820	chr6:167586206	TCP10L2	0.64	9.17	0.45	4.94e-18	Gastritis;
LUSC	cis	rs1847202	0.563	rs13095184	chr3:72951008	A/G	cg25664220	chr3:72788482	NA	-0.42	-7.62	-0.38	2.6e-13	Motion sickness;
LUSC	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg21427119	chr20:30132790	HM13	-0.46	-6.65	-0.34	1.2e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg16339924	chr4:17578868	LAP3	0.57	8.79	0.43	8.02e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.23e-8	Breast cancer;
LUSC	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.6	-0.34	1.57e-10	Mood instability;
LUSC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-7.03	-0.36	1.19e-11	Aortic root size;
LUSC	trans	rs6104690	1.000	rs6131143	chr20:10988150	A/G	cg07172334	chr21:31655261	KRTAP24-1	-0.33	-5.94	-0.31	6.99e-9	Bladder cancer;
LUSC	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg09491104	chr22:46646882	C22orf40	-0.71	-7.14	-0.36	5.97e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg05925327	chr15:68127851	NA	-0.48	-7.01	-0.36	1.35e-11	Restless legs syndrome;
LUSC	cis	rs965469	1.000	rs2281494	chr20:3235494	A/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.84	-0.3	1.22e-8	IFN-related cytopenia;
LUSC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg05738196	chr6:26577821	NA	-0.61	-7.05	-0.36	1.06e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6066835	1.000	rs4568007	chr20:47316575	C/G	cg18078177	chr20:47281410	PREX1	0.72	6.13	0.32	2.51e-9	Multiple myeloma;
LUSC	cis	rs12912251	1.000	rs35102843	chr15:38988107	C/A	cg01338139	chr15:38987640	C15orf53	-0.5	-6.79	-0.35	5.12e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	trans	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg13565492	chr6:43139072	SRF	-0.61	-6.49	-0.33	3.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.83	-14.33	-0.62	1.25e-36	Breast cancer;
LUSC	trans	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg07211511	chr3:129823064	LOC729375	-0.81	-10.63	-0.5	6.5e-23	Blood pressure (smoking interaction);
LUSC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02018176	chr4:1364513	KIAA1530	-0.66	-11.82	-0.54	3.52e-27	Obesity-related traits;
LUSC	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg00806126	chr19:22604979	ZNF98	0.37	5.71	0.3	2.43e-8	Pain;
LUSC	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg27433088	chr4:174089019	GALNT7	-0.41	-5.83	-0.3	1.33e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg12419862	chr22:24373484	LOC391322	-0.87	-14.22	-0.61	3.27e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg13395646	chr4:1353034	KIAA1530	0.54	7.65	0.39	2.21e-13	Longevity;
LUSC	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	11.96	0.55	1.12e-27	Electrocardiographic conduction measures;
LUSC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg13560548	chr3:10150139	C3orf24	0.51	7.35	0.37	1.56e-12	Alzheimer's disease;
LUSC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25072359	chr17:41440525	NA	0.66	9.52	0.46	3.7e-19	Menopause (age at onset);
LUSC	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.43	-6.42	-0.33	4.67e-10	Neuroticism;
LUSC	cis	rs73206853	0.841	rs56117211	chr12:111123485	T/G	cg12870014	chr12:110450643	ANKRD13A	0.67	6.42	0.33	4.58e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6543140	0.964	rs2141781	chr2:103082906	G/A	cg09003973	chr2:102972529	NA	0.53	6.75	0.35	6.5500000000000006e-11	Blood protein levels;
LUSC	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg08085267	chr17:45401833	C17orf57	-0.56	-8.88	-0.44	4.29e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7095944	0.584	rs10901814	chr10:126431281	G/C	cg08799069	chr10:126477246	METTL10	-0.39	-5.96	-0.31	6.28e-9	Asthma;
LUSC	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.76	-0.51	2.15e-23	Glomerular filtration rate;
LUSC	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg05072774	chr3:49840536	C3orf54	-0.42	-5.68	-0.3	2.94e-8	Resting heart rate;
LUSC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.58	-8.47	-0.42	7.76e-16	Colorectal cancer;
LUSC	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg27494647	chr7:150038898	RARRES2	0.44	6.57	0.34	1.95e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6543140	0.964	rs13383602	chr2:103085962	C/T	cg09003973	chr2:102972529	NA	0.53	6.75	0.35	6.5500000000000006e-11	Blood protein levels;
LUSC	cis	rs6599077	1.000	rs6808524	chr3:40097129	A/G	cg13683864	chr3:40499215	RPL14	-0.59	-7.56	-0.38	3.95e-13	Sleep-related phenotypes;
LUSC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.59	7.88	0.4	4.72e-14	Alzheimer's disease;
LUSC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg07701084	chr6:150067640	NUP43	0.57	8.73	0.43	1.28e-16	Lung cancer;
LUSC	cis	rs7586879	0.789	rs13398155	chr2:25128550	C/T	cg01884057	chr2:25150051	NA	0.42	8.82	0.43	6.24e-17	Body mass index;
LUSC	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg14582100	chr15:45693742	SPATA5L1	0.56	10.09	0.48	4.35e-21	Homoarginine levels;
LUSC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg13047869	chr3:10149882	C3orf24	0.56	7.72	0.39	1.37e-13	Alzheimer's disease;
LUSC	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg13042288	chr15:90349979	ANPEP	-0.48	-6.75	-0.35	6.37e-11	Uric acid levels;
LUSC	cis	rs6847149	1.000	rs7669266	chr4:110804131	C/T	cg07850274	chr4:110748770	RRH	0.59	7.96	0.4	2.74e-14	Exercise treadmill test traits;
LUSC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg18681998	chr4:17616180	MED28	0.85	15.66	0.65	7.79e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.4	-0.38	1.15e-12	Psoriasis;
LUSC	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg13010199	chr12:38710504	ALG10B	0.59	9.46	0.46	5.59e-19	Morning vs. evening chronotype;
LUSC	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg02527881	chr3:46936655	PTH1R	0.38	6.38	0.33	5.8e-10	Colorectal cancer;
LUSC	trans	rs6445525	1.000	rs4688259	chr3:65995266	T/C	cg12639933	chr12:57626296	SHMT2	0.34	6.18	0.32	1.82e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg01629716	chr15:45996671	NA	-0.4	-6.18	-0.32	1.91e-9	Waist circumference;Weight;
LUSC	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.35	-0.46	1.25e-18	Extrinsic epigenetic age acceleration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15643885	chr8:17434749	PDGFRL	0.53	8.06	0.4	1.4e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12541635	0.677	rs55639043	chr8:107055993	C/T	cg10147462	chr8:107024639	NA	0.66	13.82	0.6	1.17e-34	Age of smoking initiation;
LUSC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.51	0.34	2.68e-10	Lung cancer;
LUSC	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-6.01	-0.31	4.78e-9	Fear of minor pain;
LUSC	cis	rs6489882	0.703	rs10774673	chr12:113361158	C/T	cg20102336	chr12:113376681	OAS3	-0.4	-5.71	-0.3	2.46e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs2742234	0.541	rs10793427	chr10:43747443	G/A	cg15436174	chr10:43711423	RASGEF1A	0.43	6.85	0.35	3.63e-11	Hirschsprung disease;
LUSC	cis	rs672059	0.934	rs641057	chr1:183156859	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.99	0.4	2.15e-14	Hypertriglyceridemia;
LUSC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg23985595	chr17:80112537	CCDC57	0.31	6.0	0.31	5.22e-9	Life satisfaction;
LUSC	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg12435725	chr3:58293450	RPP14	-0.71	-7.18	-0.37	4.5e-12	Cholesterol, total;
LUSC	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg09307838	chr4:120376055	NA	0.54	8.33	0.41	2.09e-15	Corneal astigmatism;
LUSC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg23188684	chr11:67383651	NA	0.42	7.79	0.39	8.52e-14	Mean corpuscular volume;
LUSC	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg13206674	chr6:150067644	NUP43	0.43	6.56	0.34	2.01e-10	Testicular germ cell tumor;
LUSC	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.47	-6.99	-0.36	1.5e-11	Neutrophil percentage of white cells;
LUSC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg13683864	chr3:40499215	RPL14	0.84	13.81	0.6	1.21e-34	Renal cell carcinoma;
LUSC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-6.05	-0.31	3.92e-9	Huntington's disease progression;
LUSC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	8.56	0.42	4.06e-16	Motion sickness;
LUSC	cis	rs4285028	0.747	rs7623901	chr3:121529011	A/G	cg11130432	chr3:121712080	ILDR1	0.64	9.58	0.46	2.33e-19	Multiple sclerosis;
LUSC	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg00376283	chr12:123451042	ABCB9	0.66	8.32	0.41	2.27e-15	Neutrophil percentage of white cells;
LUSC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg13319975	chr6:146136371	FBXO30	0.49	7.34	0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7212590	0.618	rs7217337	chr17:58023417	C/T	cg10252138	chr17:58120427	NA	-0.82	-7.64	-0.39	2.33e-13	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg08085267	chr17:45401833	C17orf57	-0.5	-7.24	-0.37	3.11e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.08	-0.91	1.14e-129	Myeloid white cell count;
LUSC	cis	rs4478037	1.000	rs4076086	chr3:33161898	C/T	cg19404215	chr3:33155277	CRTAP	0.96	10.11	0.48	4.01e-21	Major depressive disorder;
LUSC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg07741184	chr6:167504864	NA	-0.35	-6.42	-0.33	4.78e-10	Crohn's disease;
LUSC	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg13010199	chr12:38710504	ALG10B	0.61	10.34	0.49	6.57e-22	Heart rate;
LUSC	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg19875535	chr5:140030758	IK	0.5	8.28	0.41	3.06e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21028142	chr17:79581711	NPLOC4	0.34	8.17	0.41	6.66e-15	Eye color traits;
LUSC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.12	17.29	0.69	2.67e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs654351	0.543	rs622388	chr6:10387117	T/G	cg17959970	chr6:10383164	NA	-0.36	-6.72	-0.35	7.67e-11	Squamous cell lung carcinoma;
LUSC	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg17788362	chr6:86352627	SYNCRIP	0.49	7.39	0.37	1.17e-12	Smooth-surface caries;
LUSC	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs899997	0.862	rs4887074	chr15:78952110	G/C	cg04896959	chr15:78267971	NA	0.44	8.64	0.43	2.44e-16	Coronary artery disease or large artery stroke;
LUSC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg02428538	chr16:24856791	SLC5A11	-0.52	-6.05	-0.31	3.82e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs796825	0.530	rs13091848	chr3:119986024	T/G	cg21790991	chr3:120137480	FSTL1	-0.34	-6.1	-0.32	2.93e-9	HIV-1 susceptibility;
LUSC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18404041	chr3:52824283	ITIH1	-0.51	-9.86	-0.47	2.66e-20	Bipolar disorder;
LUSC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.58	-0.54	2.64e-26	Mean corpuscular volume;
LUSC	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg23241863	chr10:102295624	HIF1AN	0.49	5.98	0.31	5.84e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs45535039	1.000	rs7104210	chr11:119073886	T/G	cg16724696	chr11:118992527	HINFP	0.45	5.68	0.3	2.94e-8	Plateletcrit;
LUSC	cis	rs6987853	0.787	rs2923436	chr8:42425298	G/A	cg09913449	chr8:42400586	C8orf40	0.5	8.45	0.42	9.37e-16	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg00810483	chr4:3375144	RGS12	0.32	6.02	0.31	4.62e-9	Serum sulfate level;
LUSC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg24562669	chr7:97807699	LMTK2	0.34	5.91	0.31	8.4e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03168497	chr17:48586147	MYCBPAP	-0.58	-8.67	-0.43	1.87e-16	Visceral fat;
LUSC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.47	0.33	3.59e-10	Lung cancer;
LUSC	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg24375607	chr4:120327624	NA	0.77	11.31	0.53	2.57e-25	Corneal astigmatism;
LUSC	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg15556689	chr8:8085844	FLJ10661	0.65	9.08	0.44	9.67e-18	Neuroticism;
LUSC	cis	rs12313068	0.709	rs11064912	chr12:110505699	A/T	cg12870014	chr12:110450643	ANKRD13A	-0.66	-9.96	-0.48	1.28e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg23435118	chr5:141488016	NDFIP1	-0.56	-7.95	-0.4	2.93e-14	Crohn's disease;
LUSC	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg04586622	chr2:25135609	ADCY3	0.37	7.53	0.38	4.93e-13	Body mass index in non-asthmatics;
LUSC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg05347473	chr6:146136440	FBXO30	0.41	7.05	0.36	1.06e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg00603274	chr11:61596626	FADS2	-0.57	-7.66	-0.39	2.02e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs13253111	0.624	rs13277389	chr8:28100234	G/T	cg26534493	chr8:28060551	NA	0.38	6.92	0.35	2.28e-11	Childhood body mass index;
LUSC	trans	rs6945197	1.000	rs2349748	chr7:136130536	C/T	cg25184248	chr3:123813393	KALRN	0.77	5.97	0.31	5.92e-9	Late-onset Alzheimer's disease;
LUSC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.5	7.67	0.39	1.85e-13	Eosinophil percentage of white cells;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg09906747	chr21:34914446	SON;GART	0.45	6.21	0.32	1.56e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs4363385	0.818	rs382653	chr1:153006761	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.43e-12	Inflammatory skin disease;
LUSC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg00898013	chr13:113819073	PROZ	0.62	8.84	0.44	5.64e-17	Platelet distribution width;
LUSC	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.06	0.4	1.35e-14	Axial length;
LUSC	cis	rs1775715	0.737	rs12256714	chr10:32216262	A/G	cg26784012	chr10:32216390	ARHGAP12	-0.41	-6.92	-0.35	2.28e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6740322	0.901	rs2163228	chr2:43549246	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.8	-0.3	1.53e-8	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg18402987	chr7:1209562	NA	0.72	7.69	0.39	1.67e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg07923666	chr12:49932857	KCNH3	-0.49	-6.1	-0.32	3e-9	Resting heart rate;
LUSC	trans	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.19	-0.32	1.74e-9	Bladder cancer;
LUSC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg18230493	chr5:56204884	C5orf35	-0.87	-13.0	-0.58	1.52e-31	Initial pursuit acceleration;
LUSC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg10636054	chr15:40330586	SRP14	0.88	8.33	0.41	2.17e-15	Corneal curvature;
LUSC	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg22709100	chr7:91322751	NA	0.39	5.71	0.3	2.56e-8	Breast cancer;
LUSC	trans	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	9.24	0.45	2.9e-18	Exhaled nitric oxide output;
LUSC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-0.88	-16.83	-0.68	1.92e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6005807	0.719	rs73430118	chr22:28913950	C/T	cg12565055	chr22:29076175	TTC28	0.55	5.74	0.3	2.14e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs2769264	0.546	rs12047617	chr1:151392597	G/A	cg18801370	chr1:151430492	POGZ	0.68	8.29	0.41	2.88e-15	Blood trace element (Cu levels);
LUSC	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.81	-0.35	4.56e-11	Neuroticism;
LUSC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8099014	0.906	rs4940688	chr18:56089044	G/A	cg12907477	chr18:56117327	MIR122	0.43	6.72	0.35	7.66e-11	Platelet count;
LUSC	cis	rs4494114	0.967	rs9438978	chr1:39355058	G/T	cg25970120	chr1:39325951	RRAGC	-0.4	-6.33	-0.33	7.99e-10	Blood protein levels;
LUSC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg07741184	chr6:167504864	NA	0.44	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	trans	rs9393777	0.844	rs28360634	chr6:27332891	T/C	cg01620082	chr3:125678407	NA	-0.78	-6.94	-0.36	1.98e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2795502	0.564	rs72777186	chr10:43430464	C/T	cg08461752	chr10:43522343	NA	-0.55	-6.67	-0.34	1.06e-10	Blood protein levels;
LUSC	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg03585969	chr10:35415529	CREM	0.6	8.8	0.43	7.66e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6960043	0.875	rs6976381	chr7:15048814	T/C	cg19272540	chr7:15055459	NA	-0.3	-7.23	-0.37	3.26e-12	Type 2 diabetes;
LUSC	cis	rs12681287	0.547	rs66808088	chr8:87521212	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.27	-0.37	2.53e-12	Caudate activity during reward;
LUSC	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg13798780	chr7:105162888	PUS7	0.58	6.32	0.33	8.2e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	18.1	0.7	1.66e-51	Chronic sinus infection;
LUSC	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg05555928	chr11:63887634	MACROD1	-0.48	-6.19	-0.32	1.74e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs12999616	0.817	rs55933640	chr2:98328721	C/T	cg26665480	chr2:98280029	ACTR1B	0.52	5.94	0.31	7.15e-9	Colorectal cancer;
LUSC	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-6.64	-0.34	1.28e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg13628971	chr7:2884303	GNA12	0.49	6.82	0.35	4.33e-11	Height;
LUSC	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	10.95	0.51	4.92e-24	Lung cancer in ever smokers;
LUSC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg11663144	chr21:46675770	NA	-0.43	-7.67	-0.39	1.92e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg06808227	chr14:105710500	BRF1	-0.7	-11.24	-0.52	4.32e-25	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.68	12.13	0.55	2.6e-28	Aortic root size;
LUSC	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.37	-0.42	1.64e-15	Mood instability;
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-8.12	-0.41	9.16e-15	Lymphocyte counts;
LUSC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.34	-5.71	-0.3	2.52e-8	Bone mineral density (spine);Bone mineral density;
LUSC	trans	rs76248362	1.000	rs7998585	chr13:24435195	C/T	cg26511321	chr7:27196790	HOXA7	0.54	6.24	0.32	1.35e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg02508848	chr16:68573721	ZFP90	-0.42	-5.75	-0.3	2.07e-8	Ulcerative colitis;
LUSC	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.1	26.61	0.82	1.59e-84	Colorectal cancer;
LUSC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.95	0.36	1.9e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12220238	1.000	rs10824076	chr10:75886956	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.63	7.7	0.39	1.54e-13	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg18240062	chr17:79603768	NPLOC4	0.8	15.58	0.65	1.64e-41	Eye color traits;
LUSC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06221963	chr1:154839813	KCNN3	0.64	14.23	0.61	3.03e-36	Prostate cancer;
LUSC	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.02e-14	Corneal astigmatism;
LUSC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg25428297	chr7:1022841	CYP2W1	0.3	6.48	0.33	3.26e-10	Longevity;Endometriosis;
LUSC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg05295671	chr13:79234353	RNF219	0.46	6.41	0.33	5.06e-10	Large artery stroke;
LUSC	cis	rs1595825	0.945	rs59553483	chr2:198855201	T/C	cg00982548	chr2:198649783	BOLL	-0.54	-6.83	-0.35	4.14e-11	Ulcerative colitis;
LUSC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05776053	chr2:74358815	NA	0.45	6.44	0.33	4.18e-10	Gestational age at birth (maternal effect);
LUSC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg25456477	chr12:86230367	RASSF9	0.33	5.78	0.3	1.68e-8	Major depressive disorder;
LUSC	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.56	0.5	1.13e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg02423579	chr7:2872169	GNA12	-0.42	-6.39	-0.33	5.53e-10	Height;
LUSC	cis	rs7577696	0.554	rs3769605	chr2:32322456	A/G	cg02381751	chr2:32503542	YIPF4	-0.52	-7.05	-0.36	1.01e-11	Inflammatory biomarkers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26346718	chr17:79482045	NA	-0.5	-6.09	-0.32	3.17e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg22532475	chr10:104410764	TRIM8	0.25	5.87	0.31	1.03e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs2249625	0.584	rs2496506	chr6:72891324	A/C	cg18830697	chr6:72922368	RIMS1	-0.37	-7.43	-0.38	9.01e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.75	14.64	0.63	7.48e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-11.75	-0.54	6.7399999999999993e-27	Chronic sinus infection;
LUSC	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.52	-0.34	2.56e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg14668632	chr7:2872130	GNA12	-0.44	-6.26	-0.32	1.21e-9	Height;
LUSC	cis	rs9395066	0.545	rs35813980	chr6:44956008	C/T	cg25276700	chr6:44698697	NA	0.29	5.8	0.3	1.53e-8	Height;
LUSC	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.67	0.47	1.16e-19	Coffee consumption (cups per day);
LUSC	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg27205649	chr11:78285834	NARS2	0.5	6.1	0.32	2.94e-9	Alzheimer's disease (survival time);
LUSC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg19046167	chr17:80928561	B3GNTL1	-0.45	-6.56	-0.34	2.07e-10	Breast cancer;
LUSC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.45	-8.18	-0.41	5.9e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13089785	0.965	rs12493045	chr3:123620718	C/A	cg02558132	chr3:123411198	MYLK	0.36	6.21	0.32	1.59e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2692947	0.864	rs2579518	chr2:96675259	G/A	cg22654517	chr2:96458247	NA	0.35	7.0	0.36	1.38e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg02772935	chr3:125709198	NA	-0.49	-5.89	-0.31	9.62e-9	Blood pressure (smoking interaction);
LUSC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.57	-0.46	2.53e-19	Type 2 diabetes;
LUSC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg13397359	chr6:42928475	GNMT	-0.65	-11.15	-0.52	9.07e-25	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg23649088	chr2:200775458	C2orf69	0.49	6.77	0.35	5.85e-11	Schizophrenia;
LUSC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.72	-9.91	-0.48	1.9e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg00745463	chr17:30367425	LRRC37B	-0.67	-7.89	-0.4	4.47e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg11502198	chr6:26597334	ABT1	0.73	12.25	0.56	9.63e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg05585544	chr11:47624801	NA	0.41	7.25	0.37	2.92e-12	Subjective well-being;
LUSC	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19717773	chr7:2847554	GNA12	-0.39	-6.33	-0.33	7.72e-10	Height;
LUSC	cis	rs62027291	0.605	rs62030413	chr15:76878201	A/G	cg26408565	chr15:76604113	ETFA	0.75	6.95	0.36	1.98e-11	Plateletcrit;
LUSC	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg23260525	chr10:116636907	FAM160B1	0.4	8.1	0.41	1.02e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg26441486	chr22:50317300	CRELD2	0.49	7.18	0.37	4.63e-12	Schizophrenia;
LUSC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg18827107	chr12:86230957	RASSF9	-0.43	-6.37	-0.33	6.35e-10	Major depressive disorder;
LUSC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg01879757	chr17:41196368	BRCA1	-0.47	-7.2	-0.37	3.93e-12	Menopause (age at onset);
LUSC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.79	12.54	0.57	8.31e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg08079166	chr15:68083412	MAP2K5	0.36	6.23	0.32	1.39e-9	Obesity;
LUSC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg26335602	chr6:28129616	ZNF389	0.5	6.66	0.34	1.12e-10	Parkinson's disease;
LUSC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	6.84	0.35	3.79e-11	Schizophrenia;
LUSC	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.97	-0.61	3.08e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21293242	chr8:11204541	TDH	0.34	6.38	0.33	6.04e-10	Retinal vascular caliber;
LUSC	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.59	-9.97	-0.48	1.19e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg17264618	chr3:40429014	ENTPD3	0.33	7.02	0.36	1.28e-11	Renal cell carcinoma;
LUSC	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg26384229	chr12:38710491	ALG10B	0.7	10.84	0.51	1.21e-23	Morning vs. evening chronotype;
LUSC	cis	rs9807841	0.670	rs2010492	chr19:10803395	A/G	cg17710535	chr19:10819994	QTRT1	0.42	6.79	0.35	5.11e-11	Inflammatory skin disease;
LUSC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg08888203	chr3:10149979	C3orf24	0.48	7.21	0.37	3.81e-12	Alzheimer's disease;
LUSC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	0.93	16.01	0.66	3.23e-43	Menopause (age at onset);
LUSC	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg25456477	chr12:86230367	RASSF9	0.38	6.66	0.34	1.11e-10	Major depressive disorder;
LUSC	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.97	-0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg19682013	chr15:45996608	NA	0.38	5.88	0.31	1.02e-8	Waist circumference;Weight;
LUSC	cis	rs6942756	0.688	rs2718089	chr7:128927022	G/T	cg02491457	chr7:128862824	NA	0.49	7.3	0.37	2.13e-12	White matter hyperintensity burden;
LUSC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07677032	chr17:61819896	STRADA	0.49	8.34	0.42	1.94e-15	Prudent dietary pattern;
LUSC	cis	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.03	-0.31	4.33e-9	Morning vs. evening chronotype;
LUSC	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg04362960	chr10:104952993	NT5C2	0.61	9.64	0.47	1.45e-19	Arsenic metabolism;
LUSC	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg26395211	chr5:140044315	WDR55	-0.39	-6.0	-0.31	5.16e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.34	-0.53	1.89e-25	Mean corpuscular volume;
LUSC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.57	10.18	0.49	2.18e-21	Bone mineral density;
LUSC	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-6.2	-0.32	1.64e-9	IgG glycosylation;
LUSC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs9318086	0.648	rs9510927	chr13:24467641	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.45	6.62	0.34	1.4e-10	Myopia (pathological);
LUSC	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg10483660	chr13:112241077	NA	0.34	5.73	0.3	2.19e-8	Menarche (age at onset);
LUSC	cis	rs4664308	1.000	rs925410	chr2:160912652	C/T	cg03641300	chr2:160917029	PLA2R1	0.66	11.29	0.53	3.02e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs11608355	0.573	rs7970666	chr12:109793495	T/G	cg19025524	chr12:109796872	NA	-0.49	-9.24	-0.45	2.91e-18	Neuroticism;
LUSC	cis	rs7250872	0.647	rs12976128	chr19:1817113	A/C	cg10370574	chr19:1840461	REXO1	-0.56	-7.95	-0.4	2.98e-14	Bipolar disorder;
LUSC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08704250	chr15:31115839	NA	-0.47	-7.03	-0.36	1.14e-11	Huntington's disease progression;
LUSC	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.57	-0.34	1.92e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6087990	0.735	rs4911261	chr20:31391360	A/G	cg13636640	chr20:31349939	DNMT3B	0.93	18.92	0.72	9.01e-55	Ulcerative colitis;
LUSC	cis	rs7178572	0.633	rs11857860	chr15:77839761	T/C	cg22256960	chr15:77711686	NA	-0.47	-7.03	-0.36	1.19e-11	Type 2 diabetes;
LUSC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.67	0.5	4.47e-23	Monocyte percentage of white cells;
LUSC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	7.82e-13	Motion sickness;
LUSC	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.64	-9.63	-0.47	1.5700000000000001e-19	Glaucoma (primary open-angle);
LUSC	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.67	0.34	1.06e-10	IgG glycosylation;
LUSC	cis	rs13315871	1.000	rs13076951	chr3:58436703	C/T	cg20936604	chr3:58311152	NA	-0.72	-6.77	-0.35	5.83e-11	Cholesterol, total;
LUSC	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.61	0.34	1.48e-10	Corneal astigmatism;
LUSC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.47	8.11	0.41	9.61e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg24110177	chr3:50126178	RBM5	0.43	6.83	0.35	4.05e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg24331049	chr13:111365604	ING1	-0.57	-7.73	-0.39	1.26e-13	Coronary artery disease;
LUSC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	0.99	13.72	0.6	2.7200000000000002e-34	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.38	-0.33	5.91e-10	Mood instability;
LUSC	cis	rs72627509	1.000	rs72627509	chr4:57839051	C/G	cg26694713	chr4:57773883	REST	0.51	5.98	0.31	5.76e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg18350739	chr11:68623251	NA	-0.38	-6.91	-0.35	2.52e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg26898376	chr11:64110657	CCDC88B	0.37	7.09	0.36	7.97e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg15445000	chr17:37608096	MED1	0.41	6.84	0.35	3.85e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	trans	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	6.12	0.32	2.65e-9	Cystic fibrosis severity;
LUSC	cis	rs4682868	0.581	rs6774801	chr3:42923776	A/C	cg21365077	chr3:42922735	NA	-0.41	-5.85	-0.3	1.18e-8	Monocyte percentage of white cells;
LUSC	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-1.01	-19.97	-0.74	6.28e-59	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2361718	0.527	rs11150847	chr17:78153130	G/A	cg09238746	chr17:78121135	EIF4A3	-0.47	-6.7	-0.34	8.79e-11	Yeast infection;
LUSC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg16339924	chr4:17578868	LAP3	0.59	9.2	0.45	3.85e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg24375607	chr4:120327624	NA	0.79	12.05	0.55	5.41e-28	Corneal astigmatism;
LUSC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-9.36	-0.46	1.24e-18	Gut microbiome composition (summer);
LUSC	cis	rs662064	0.962	rs2506902	chr1:10563681	C/T	cg20482658	chr1:10539492	PEX14	0.33	6.64	0.34	1.25e-10	Asthma;
LUSC	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg08213375	chr14:104286397	PPP1R13B	0.52	9.99	0.48	1e-20	Schizophrenia;
LUSC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.71	0.39	1.41e-13	Parkinson's disease;
LUSC	cis	rs7215564	0.908	rs35071767	chr17:78652575	A/G	cg23238734	chr17:78661607	RPTOR	0.49	6.28	0.32	1.08e-9	Myopia (pathological);
LUSC	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg03676636	chr4:99064102	C4orf37	0.36	7.84	0.39	6.23e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg20283391	chr11:68216788	NA	-0.61	-8.46	-0.42	8.4e-16	Total body bone mineral density;
LUSC	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21659725	chr3:3221576	CRBN	0.62	8.53	0.42	5.06e-16	Resting heart rate;
LUSC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08280861	chr8:58055591	NA	0.48	6.05	0.31	3.82e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2857891	0.650	rs2857928	chr11:6989721	C/G	cg14883916	chr11:6947541	ZNF215	-0.42	-5.65	-0.3	3.45e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg23711669	chr6:146136114	FBXO30	0.72	12.82	0.57	7.47e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2932538	0.885	rs3762335	chr1:113100548	C/T	cg22162597	chr1:113214053	CAPZA1	0.69	9.93	0.48	1.6e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg24250549	chr1:154909240	PMVK	0.44	6.76	0.35	6.35e-11	Prostate cancer;
LUSC	trans	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.51	8.0	0.4	2.12e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg07157834	chr1:205819609	PM20D1	0.47	6.72	0.35	7.93e-11	Prostate-specific antigen levels;
LUSC	trans	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.21	-0.37	3.86e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg21880101	chr17:80066754	CCDC57	-0.31	-5.8	-0.3	1.54e-8	Life satisfaction;
LUSC	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg03732007	chr1:2071316	PRKCZ	0.47	7.53	0.38	4.67e-13	Height;
LUSC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg18351406	chr4:77819688	ANKRD56	0.57	8.3	0.41	2.58e-15	Emphysema distribution in smoking;
LUSC	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg06217071	chr17:408420	NA	-0.34	-6.03	-0.31	4.37e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	29.65	0.85	1.46e-95	Chronic sinus infection;
LUSC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-6.5	-0.33	2.99e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg25258033	chr6:167368657	RNASET2	0.37	5.76	0.3	1.91e-8	Primary biliary cholangitis;
LUSC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg22800045	chr5:56110881	MAP3K1	0.71	9.47	0.46	5.45e-19	Initial pursuit acceleration;
LUSC	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg20243544	chr17:37824526	PNMT	0.47	6.52	0.34	2.6200000000000003e-10	Asthma;
LUSC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.2	0.37	4.12e-12	Mean platelet volume;
LUSC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.8	-0.3	1.51e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs13089785	1.000	rs13089785	chr3:123653909	A/C	cg01860459	chr3:123419554	MYLK	0.35	5.99	0.31	5.29e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg25036284	chr2:26402008	FAM59B	0.77	10.97	0.51	3.94e-24	Gut microbiome composition (summer);
LUSC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg17971929	chr21:40555470	PSMG1	-0.5	-7.4	-0.38	1.09e-12	Menarche (age at onset);
LUSC	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-9.35	-0.46	1.3e-18	Neuroticism;
LUSC	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg07700843	chr1:2391317	NA	-0.47	-7.11	-0.36	7.05e-12	Non-obstructive azoospermia;
LUSC	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.82	0.78	4.1e-70	Prudent dietary pattern;
LUSC	cis	rs7091068	0.706	rs4919398	chr10:95429162	C/T	cg20715218	chr10:95462985	C10orf4	0.61	6.41	0.33	5.01e-10	Urinary tract infection frequency;
LUSC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg15147215	chr3:52552868	STAB1	-0.34	-6.75	-0.35	6.49e-11	Bipolar disorder;
LUSC	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg08847533	chr14:75593920	NEK9	-0.76	-13.11	-0.58	5.7e-32	Height;
LUSC	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg20026190	chr17:76395443	PGS1	0.45	8.06	0.4	1.35e-14	HDL cholesterol levels;
LUSC	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg26566898	chr11:117069891	TAGLN	0.35	6.6	0.34	1.63e-10	Blood protein levels;
LUSC	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	9.53	0.46	3.4e-19	IgG glycosylation;
LUSC	cis	rs10504229	0.516	rs58244172	chr8:57987805	G/A	cg21724239	chr8:58056113	NA	0.42	5.64	0.3	3.55e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17467752	chr17:38218738	THRA	-0.56	-7.9	-0.4	4.13e-14	Myeloid white cell count;
LUSC	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.49	0.42	6.73e-16	Response to antipsychotic treatment;
LUSC	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg09654669	chr8:57350985	NA	-0.56	-7.78	-0.39	9.24e-14	Obesity-related traits;
LUSC	trans	rs800082	0.668	rs6805395	chr3:144292116	T/C	cg24215973	chr2:240111563	HDAC4	-0.61	-9.81	-0.47	3.99e-20	Smoking behavior;
LUSC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg21782813	chr7:2030301	MAD1L1	0.36	5.84	0.3	1.27e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	7.32	0.37	1.83e-12	HDL cholesterol;
LUSC	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg06637938	chr14:75390232	RPS6KL1	0.66	10.94	0.51	5.23e-24	Caffeine consumption;
LUSC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg06784218	chr1:46089804	CCDC17	0.53	10.47	0.5	2.31e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.35	-0.42	1.88e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg05528280	chr10:464225	DIP2C	0.39	6.0	0.31	5.14e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg09904177	chr6:26538194	HMGN4	0.57	8.91	0.44	3.43e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs72627509	0.904	rs12645070	chr4:57770106	G/A	cg26694713	chr4:57773883	REST	0.52	6.38	0.33	6.01e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg05283184	chr6:79620031	NA	-0.58	-12.2	-0.56	1.43e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	9.03	0.44	1.36e-17	Menopause (age at onset);
LUSC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-1.02	-19.42	-0.73	9.06e-57	Height;
LUSC	cis	rs7605827	0.930	rs11687986	chr2:15591308	G/T	cg19274914	chr2:15703543	NA	0.46	8.91	0.44	3.37e-17	Educational attainment (years of education);
LUSC	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg03433033	chr1:76189801	ACADM	-0.4	-6.01	-0.31	4.82e-9	Daytime sleep phenotypes;
LUSC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.85	-0.44	5.17e-17	Aortic root size;
LUSC	cis	rs2191566	1.000	rs2356549	chr19:44511202	A/T	cg03039196	chr19:44506973	ZNF230	0.36	5.89	0.31	9.44e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6563842	0.528	rs56340348	chr13:41296371	C/T	cg21288729	chr13:41239152	FOXO1	0.53	7.97	0.4	2.47e-14	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUSC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg07414643	chr4:187882934	NA	-0.54	-10.22	-0.49	1.58e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	13.72	0.6	2.69e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg09826364	chr7:158789723	NA	0.37	5.83	0.3	1.28e-8	Facial morphology (factor 20);
LUSC	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg05472934	chr7:22766657	IL6	0.53	8.37	0.42	1.61e-15	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
LUSC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg20744362	chr22:50050164	C22orf34	0.39	8.09	0.4	1.13e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg21775007	chr8:11205619	TDH	-0.55	-8.18	-0.41	5.84e-15	Neuroticism;
LUSC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg13319975	chr6:146136371	FBXO30	0.68	9.65	0.47	1.36e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg18850127	chr7:39170497	POU6F2	0.62	9.39	0.46	9.69e-19	IgG glycosylation;
LUSC	cis	rs4363385	0.510	rs10888528	chr1:153050516	A/G	cg00922841	chr1:152955080	SPRR1A	0.38	6.41	0.33	5.08e-10	Inflammatory skin disease;
LUSC	cis	rs240764	0.621	rs6925840	chr6:101209386	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-6.39	-0.33	5.5e-10	Neuroticism;
LUSC	cis	rs72634258	0.786	rs7514098	chr1:8177632	G/A	cg00042356	chr1:8021962	PARK7	0.57	6.89	0.35	2.81e-11	Inflammatory bowel disease;
LUSC	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg27494647	chr7:150038898	RARRES2	0.44	6.55	0.34	2.15e-10	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.2	0.41	5.35e-15	Corneal astigmatism;
LUSC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg14004847	chr7:1930337	MAD1L1	-0.56	-8.83	-0.44	5.88e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg21775007	chr8:11205619	TDH	-0.48	-6.84	-0.35	3.84e-11	Neuroticism;
LUSC	cis	rs7696796	0.761	rs17236871	chr4:183162999	A/G	cg04638710	chr4:183167912	NA	0.32	5.83	0.3	1.33e-8	Neuroticism;
LUSC	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg20203395	chr5:56204925	C5orf35	-0.53	-7.97	-0.4	2.6e-14	Coronary artery disease;
LUSC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2479724	0.935	rs62396748	chr6:41782007	A/G	cg17623882	chr6:41773611	USP49	0.64	10.45	0.5	2.55e-22	Menarche (age at onset);
LUSC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.59	8.17	0.41	6.56e-15	Homoarginine levels;
LUSC	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg13385521	chr17:29058706	SUZ12P	0.68	6.74	0.35	7.03e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs28830936	0.934	rs28401754	chr15:42116903	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.91	-0.31	8.38e-9	Diastolic blood pressure;
LUSC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg13535736	chr9:111863775	C9orf5	-0.36	-5.86	-0.31	1.1e-8	Menarche (age at onset);
LUSC	cis	rs10186029	0.509	rs6726540	chr2:213943754	A/G	cg08319019	chr2:214017104	IKZF2	-0.42	-6.07	-0.32	3.5e-9	Systemic sclerosis;
LUSC	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg17168535	chr8:21777572	XPO7	0.68	10.43	0.5	3.22e-22	Mean corpuscular volume;
LUSC	cis	rs7945718	0.810	rs10831910	chr11:12830974	A/G	cg25843174	chr11:12811716	TEAD1	-0.31	-7.17	-0.37	4.89e-12	Educational attainment (years of education);
LUSC	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	7.66	0.39	2.01e-13	Neuroticism;
LUSC	cis	rs10193935	0.901	rs10170082	chr2:42623452	T/C	cg27598129	chr2:42591480	NA	-0.61	-8.21	-0.41	4.96e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.7	-0.6	3.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.49e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18402987	chr7:1209562	NA	0.43	5.66	0.3	3.2e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs16910800	0.731	rs56067480	chr11:23190184	C/T	cg20040320	chr11:23191996	NA	-0.59	-7.63	-0.39	2.4e-13	Cancer;
LUSC	trans	rs73228161	1.000	rs17022333	chr12:94662928	C/G	cg27125177	chr10:85956635	PCDH21	0.5	6.16	0.32	2.12e-9	Major depressive disorder;
LUSC	trans	rs2018683	0.745	rs917217	chr7:28975025	G/T	cg19402173	chr7:128379420	CALU	0.49	7.68	0.39	1.75e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs6545883	0.965	rs6545872	chr2:61724568	G/A	cg15711740	chr2:61764176	XPO1	-0.5	-7.85	-0.39	5.89e-14	Tuberculosis;
LUSC	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg08213375	chr14:104286397	PPP1R13B	0.44	8.51	0.42	5.83e-16	Schizophrenia;
LUSC	cis	rs8014204	0.816	rs10083386	chr14:75347585	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.55	-8.78	-0.43	8.82e-17	Caffeine consumption;
LUSC	cis	rs963731	0.649	rs3765058	chr2:39189636	A/G	cg04010122	chr2:39346883	SOS1	0.77	5.71	0.3	2.51e-8	Corticobasal degeneration;
LUSC	cis	rs7781370	1.000	rs6465508	chr7:96127355	A/G	cg00604640	chr7:96133485	NA	0.33	5.7	0.3	2.65e-8	Bone mineral density (hip);
LUSC	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg00071950	chr4:10020882	SLC2A9	-0.58	-9.55	-0.46	2.92e-19	Bone mineral density;
LUSC	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	1.09	25.33	0.81	9.94e-80	Platelet distribution width;
LUSC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg08847533	chr14:75593920	NEK9	-0.8	-13.67	-0.6	4.14e-34	Height;
LUSC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.76	-10.62	-0.5	7.07e-23	Gut microbiome composition (summer);
LUSC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg24562669	chr7:97807699	LMTK2	0.35	6.22	0.32	1.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.64	10.05	0.48	6.19e-21	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	0.64	13.57	0.6	1e-33	Prudent dietary pattern;
LUSC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	5.71	0.3	2.47e-8	Calcium levels;
LUSC	cis	rs7577696	0.924	rs7605242	chr2:32324135	G/A	cg02381751	chr2:32503542	YIPF4	-0.4	-5.76	-0.3	1.87e-8	Inflammatory biomarkers;
LUSC	cis	rs61990749	0.597	rs176946	chr14:78178439	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	6.66	0.34	1.11e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs1152591	0.562	rs872227	chr14:64656165	T/C	cg21174375	chr14:64681225	SYNE2	0.34	6.25	0.32	1.25e-9	Atrial fibrillation;
LUSC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg19318889	chr4:1322082	MAEA	0.47	7.67	0.39	1.93e-13	Obesity-related traits;
LUSC	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.35	-0.42	1.81e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs3820068	0.608	rs12734937	chr1:16047726	T/C	cg17385448	chr1:15911702	AGMAT	0.36	5.86	0.31	1.1e-8	Systolic blood pressure;
LUSC	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg09184832	chr6:79620586	NA	-0.45	-7.3	-0.37	2.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg18806716	chr10:30721971	MAP3K8	-0.7	-11.53	-0.53	4.04e-26	Inflammatory bowel disease;
LUSC	trans	rs11165623	0.792	rs6671371	chr1:96977039	A/G	cg10631902	chr5:14652156	NA	-0.44	-6.7	-0.34	8.83e-11	Hip circumference;Waist circumference;
LUSC	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg03929089	chr4:120376271	NA	0.68	7.63	0.39	2.56e-13	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03992926	chr1:186344761	TPR;C1orf27;MIR548F1	-0.54	-7.19	-0.37	4.3e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs10489202	1.000	rs11587594	chr1:167989180	A/T	cg24449463	chr1:168025552	DCAF6	-0.61	-7.78	-0.39	9.31e-14	Schizophrenia;
LUSC	cis	rs6977660	0.714	rs6954046	chr7:19820388	G/A	cg05791153	chr7:19748676	TWISTNB	0.64	6.81	0.35	4.49e-11	Thyroid stimulating hormone;
LUSC	cis	rs6028335	0.674	rs16987712	chr20:37601243	A/G	cg27552599	chr20:37590471	DHX35	0.45	5.7	0.3	2.59e-8	Alcohol and nicotine co-dependence;
LUSC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.56	-8.4	-0.42	1.26e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg10018233	chr7:150070692	REPIN1	0.4	7.2	0.37	4.08e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg22089800	chr15:90895588	ZNF774	-0.64	-9.62	-0.47	1.67e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg06096015	chr1:231504339	EGLN1	0.56	9.99	0.48	9.69e-21	Hemoglobin concentration;
LUSC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg18512352	chr11:47633146	NA	-0.46	-9.21	-0.45	3.73e-18	Subjective well-being;
LUSC	cis	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.4e-10	Ulcerative colitis;
LUSC	cis	rs6580649	1.000	rs7132668	chr12:48405860	C/T	cg24011408	chr12:48396354	COL2A1	0.52	7.05	0.36	1.02e-11	Lung cancer;
LUSC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.62e-9	Aortic root size;
LUSC	cis	rs3740540	0.507	rs2362500	chr10:126290431	T/C	cg04949429	chr10:126290192	LHPP	0.36	7.65	0.39	2.17e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg23625390	chr15:77176239	SCAPER	0.5	7.68	0.39	1.77e-13	Blood metabolite levels;
LUSC	cis	rs554111	0.634	rs34740989	chr1:21316782	C/T	cg01072550	chr1:21505969	NA	0.41	6.28	0.32	1.05e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg06917634	chr15:78832804	PSMA4	0.49	5.99	0.31	5.35e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03517284	chr6:25882590	NA	-0.44	-7.59	-0.38	3.12e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7605827	0.930	rs2111456	chr2:15560118	A/G	cg19274914	chr2:15703543	NA	0.47	9.17	0.45	5.11e-18	Educational attainment (years of education);
LUSC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg18209359	chr17:80159595	CCDC57	-0.41	-6.9	-0.35	2.61e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg06600287	chr1:53387719	ECHDC2	-0.28	-5.74	-0.3	2.11e-8	Monocyte count;
LUSC	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.06	-15.0	-0.63	3.03e-39	Lung cancer in ever smokers;
LUSC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-0.77	-11.41	-0.53	1.12e-25	Gut microbiome composition (summer);
LUSC	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.11	15.31	0.64	1.94e-40	Uric acid levels;
LUSC	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg06636551	chr8:101224915	SPAG1	-0.39	-7.27	-0.37	2.64e-12	Atrioventricular conduction;
LUSC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg25036284	chr2:26402008	FAM59B	-0.73	-10.66	-0.5	4.85e-23	Gut microbiome composition (summer);
LUSC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.51	-0.38	5.38e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs73001065	0.901	rs10401969	chr19:19407718	A/G	cg03709012	chr19:19516395	GATAD2A	0.79	6.48	0.33	3.33e-10	LDL cholesterol;
LUSC	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	7.72	0.39	1.34e-13	Iron status biomarkers;
LUSC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg04369109	chr6:150039330	LATS1	-0.56	-8.24	-0.41	3.94e-15	Lung cancer;
LUSC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	7.78	0.39	9.34e-14	Prudent dietary pattern;
LUSC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg08847533	chr14:75593920	NEK9	0.5	7.25	0.37	2.87e-12	Caffeine consumption;
LUSC	cis	rs10392	0.571	rs6015982	chr20:37534369	C/T	cg27552599	chr20:37590471	DHX35	0.44	6.98	0.36	1.63e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs4285028	0.848	rs4118376	chr3:121636450	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.74	-0.47	7.02e-20	Multiple sclerosis;
LUSC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg11812906	chr14:75593930	NEK9	-0.64	-10.93	-0.51	5.65e-24	Height;
LUSC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg07061783	chr6:25882402	NA	0.43	6.06	0.31	3.6e-9	Blood metabolite levels;
LUSC	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.43	6.23	0.32	1.37e-9	Insulin-like growth factors;
LUSC	cis	rs2050392	0.965	rs2480279	chr10:30700032	C/T	cg18806716	chr10:30721971	MAP3K8	-0.48	-7.94	-0.4	3.05e-14	Inflammatory bowel disease;
LUSC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.74	-11.34	-0.53	1.9e-25	Menopause (age at onset);
LUSC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg04727924	chr7:799746	HEATR2	-0.55	-6.67	-0.34	1.07e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	12.15	0.55	2.23e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.67	10.3	0.49	8.84e-22	Urinary electrolytes (magnesium/calcium ratio);
LUSC	cis	rs13089785	0.965	rs12493045	chr3:123620718	C/A	cg19611163	chr3:123411211	MYLK	0.34	5.81	0.3	1.45e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg15571903	chr15:79123663	NA	0.32	5.9	0.31	9.02e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg25801113	chr15:45476975	SHF	-0.34	-6.7	-0.34	8.69e-11	Uric acid levels;
LUSC	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg20243544	chr17:37824526	PNMT	0.41	6.13	0.32	2.49e-9	Self-reported allergy;
LUSC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.13	15.81	0.65	1.94e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg00757033	chr12:89920650	WDR51B	0.6	10.53	0.5	1.42e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19988671	chr7:155589783	NA	0.44	6.88	0.35	2.9e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg00191853	chr8:101177733	SPAG1	-0.41	-6.56	-0.34	2.08e-10	Atrioventricular conduction;
LUSC	trans	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg21051086	chr3:73046214	PPP4R2	-0.52	-7.79	-0.39	8.38e-14	Pancreatic cancer;
LUSC	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg00982548	chr2:198649783	BOLL	-0.56	-7.07	-0.36	9.23e-12	Ulcerative colitis;
LUSC	cis	rs13266463	0.898	rs13267784	chr8:143394915	C/T	cg16886403	chr8:143471632	TSNARE1	0.62	8.95	0.44	2.55e-17	Schizophrenia;
LUSC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg06096015	chr1:231504339	EGLN1	0.57	10.12	0.48	3.69e-21	Hemoglobin concentration;
LUSC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11645453	chr3:52864694	ITIH4	-0.49	-11.02	-0.52	2.62e-24	Schizophrenia;
LUSC	cis	rs73206853	0.841	rs56887341	chr12:110947185	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.5	0.38	5.91e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg02569458	chr12:86230093	RASSF9	0.54	9.21	0.45	3.78e-18	Major depressive disorder;
LUSC	trans	rs71435601	0.628	rs478442	chr2:21399216	A/C	cg20757404	chr19:378427	NA	-0.38	-6.09	-0.32	3.09e-9	Cholesterol, total;
LUSC	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23544223	chr18:12777786	NA	0.6	6.07	0.32	3.55e-9	Inflammatory skin disease;
LUSC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg13798780	chr7:105162888	PUS7	0.55	6.08	0.32	3.27e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg07393940	chr7:158741817	NA	-0.37	-6.7	-0.34	8.85e-11	Life satisfaction;
LUSC	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.32	-5.96	-0.31	6.26e-9	Coronary artery disease;
LUSC	cis	rs4851254	0.961	rs11677607	chr2:100751150	C/T	cg07810366	chr2:100720526	AFF3	-0.38	-5.91	-0.31	8.42e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-0.85	-13.98	-0.61	2.67e-35	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.6	-12.13	-0.55	2.69e-28	Paraoxonase activity;
LUSC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.03	20.82	0.75	2.6e-62	Cognitive function;
LUSC	cis	rs672059	0.934	rs6703054	chr1:183155778	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	8.49	0.42	6.74e-16	Hypertriglyceridemia;
LUSC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.82	0.39	7.02e-14	Prudent dietary pattern;
LUSC	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.22	-0.32	1.45e-9	Retinal vascular caliber;
LUSC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg16797656	chr11:68205561	LRP5	-0.42	-7.81	-0.39	7.39e-14	Total body bone mineral density;
LUSC	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg02023728	chr11:77925099	USP35	0.45	6.71	0.34	8.46e-11	Testicular germ cell tumor;
LUSC	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg21361702	chr7:150065534	REPIN1	0.45	6.26	0.32	1.16e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg22117172	chr7:91764530	CYP51A1	0.31	5.7	0.3	2.7e-8	Breast cancer;
LUSC	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	12.51	0.56	1.04e-29	Blood protein levels;
LUSC	cis	rs4141404	0.851	rs5997893	chr22:31556103	A/G	cg13145458	chr22:31556086	RNF185	0.45	5.91	0.31	8.37e-9	Paclitaxel-induced neuropathy;
LUSC	cis	rs10769945	0.679	rs7105710	chr11:1918083	T/C	cg26856596	chr11:1961893	NA	0.32	6.18	0.32	1.88e-9	DNA methylation (variation);
LUSC	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.37	-0.46	1.09e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08067268	chr2:26466485	HADHB;HADHA	0.58	8.69	0.43	1.67e-16	Gut microbiome composition (summer);
LUSC	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.25	0.52	4.16e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs10465746	0.967	rs942849	chr1:84427499	G/A	cg10977910	chr1:84465055	TTLL7	0.43	6.29	0.33	1.01e-9	Obesity-related traits;
LUSC	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg17845761	chr1:175162550	KIAA0040	-0.31	-6.0	-0.31	5.07e-9	Alcohol dependence;
LUSC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10802521	chr3:52805072	NEK4	-0.53	-8.55	-0.42	4.44e-16	Bipolar disorder;
LUSC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.54	-8.46	-0.42	8.5e-16	Personality dimensions;
LUSC	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg07148914	chr20:33460835	GGT7	0.45	6.68	0.34	9.92e-11	Height;
LUSC	trans	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg01620082	chr3:125678407	NA	-0.51	-6.04	-0.31	4.06e-9	Depression;
LUSC	cis	rs897080	0.515	rs1067336	chr2:44625876	G/A	cg00619915	chr2:44497795	NA	-0.4	-5.66	-0.3	3.29e-8	Height;
LUSC	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-7.52	-0.38	5.05e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs2262909	0.889	rs61268244	chr19:22310130	C/T	cg05197062	chr11:11642011	GALNTL4	0.55	7.77	0.39	1.01e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg02012338	chr4:187126139	CYP4V2	-0.63	-5.83	-0.3	1.32e-8	Blood protein levels;
LUSC	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg18477163	chr1:228402036	OBSCN	0.57	9.57	0.46	2.54e-19	Diastolic blood pressure;
LUSC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-1.05	-15.45	-0.65	5.46e-41	Initial pursuit acceleration;
LUSC	cis	rs62400317	0.762	rs12208332	chr6:44903221	C/T	cg18551225	chr6:44695536	NA	-0.48	-7.71	-0.39	1.51e-13	Total body bone mineral density;
LUSC	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg21775007	chr8:11205619	TDH	-0.67	-10.66	-0.5	5.14e-23	Retinal vascular caliber;
LUSC	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.22	0.32	1.49e-9	Corneal astigmatism;
LUSC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17261708	chr5:176794207	RGS14	0.34	5.94	0.31	7.05e-9	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	0.93	16.12	0.66	1.16e-43	Menopause (age at onset);
LUSC	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.88	14.84	0.63	1.28e-38	Bladder cancer;
LUSC	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.61	9.23	0.45	3.17e-18	Response to antineoplastic agents;
LUSC	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg20701182	chr2:24300061	SF3B14	0.77	7.73	0.39	1.25e-13	Lymphocyte counts;
LUSC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	11.22	0.52	5.3e-25	Bone mineral density;
LUSC	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	6.96	0.36	1.85e-11	Height;
LUSC	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-1.14	-18.17	-0.71	8.4e-52	Exhaled nitric oxide output;
LUSC	trans	rs4942242	0.740	rs6561137	chr13:44231965	A/T	cg19169023	chr15:41853346	TYRO3	-0.37	-6.22	-0.32	1.47e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg13560548	chr3:10150139	C3orf24	0.52	7.18	0.37	4.45e-12	Alzheimer's disease;
LUSC	cis	rs6546550	0.901	rs7598283	chr2:70128717	A/G	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.29	-0.37	2.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs7739264	0.564	rs760796	chr6:19790387	C/T	cg02404759	chr6:19790362	NA	-0.44	-6.9	-0.35	2.63e-11	Endometriosis;
LUSC	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg17031739	chr1:67600172	NA	0.46	7.11	0.36	7e-12	Psoriasis;
LUSC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg22903471	chr2:27725779	GCKR	-0.4	-6.83	-0.35	3.97e-11	Total body bone mineral density;
LUSC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.66	7.96	0.4	2.73e-14	Gut microbiome composition (summer);
LUSC	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg01689657	chr7:91764605	CYP51A1	0.31	5.65	0.3	3.48e-8	Breast cancer;
LUSC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	1e-64	Prudent dietary pattern;
LUSC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-1.01	-19.18	-0.72	8.42e-56	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16715692	chr19:1104863	GPX4	-0.41	-6.04	-0.31	4.14e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2637266	0.935	rs2579771	chr10:78407544	A/G	cg18941641	chr10:78392320	NA	0.41	7.37	0.37	1.34e-12	Pulmonary function;
LUSC	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04479987	chr5:180649488	TRIM41	0.39	6.03	0.31	4.24e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg09021430	chr5:549028	NA	-0.42	-7.49	-0.38	6.29e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs1403694	0.695	rs3821815	chr3:186434262	A/G	cg12454167	chr3:186435060	KNG1	0.32	7.82	0.39	7.04e-14	Blood protein levels;
LUSC	cis	rs9311676	0.656	rs10866016	chr3:58390844	C/T	cg13750441	chr3:58318267	PXK	0.35	6.84	0.35	3.85e-11	Systemic lupus erythematosus;
LUSC	cis	rs2227564	0.645	rs2633309	chr10:75654086	G/A	cg23231163	chr10:75533350	FUT11	-0.43	-6.16	-0.32	2.13e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.86	-0.47	2.61e-20	Bipolar disorder;
LUSC	cis	rs77633900	0.614	rs2439984	chr15:76923917	T/C	cg21673338	chr15:77095150	SCAPER	-0.74	-7.31	-0.37	1.99e-12	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg11871910	chr12:69753446	YEATS4	0.65	9.94	0.48	1.49e-20	Blood protein levels;
LUSC	trans	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg10756647	chr7:56101905	PSPH	-0.85	-8.45	-0.42	8.99e-16	Gout;
LUSC	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg03894339	chr8:19674705	INTS10	0.58	7.9	0.4	4.05e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg02782426	chr3:40428986	ENTPD3	0.32	6.03	0.31	4.42e-9	Renal cell carcinoma;
LUSC	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg26528668	chr16:1614120	IFT140	-0.41	-7.01	-0.36	1.29e-11	Coronary artery disease;
LUSC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg13683864	chr3:40499215	RPL14	0.93	16.26	0.66	3.44e-44	Renal cell carcinoma;
LUSC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg23791538	chr6:167370224	RNASET2	-0.36	-5.72	-0.3	2.36e-8	Crohn's disease;
LUSC	cis	rs12681287	0.640	rs6471314	chr8:87400459	G/A	cg27223183	chr8:87520930	FAM82B	0.55	7.43	0.38	9.34e-13	Caudate activity during reward;
LUSC	cis	rs1011108	1.000	rs1011108	chr2:26782621	A/G	cg18742855	chr2:26800399	C2orf70	-0.37	-6.71	-0.34	8.38e-11	Periodontal microbiota;
LUSC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg04871131	chr7:94954202	PON1	-0.38	-6.06	-0.31	3.74e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.58	9.75	0.47	6.46e-20	Breast cancer;
LUSC	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg17462356	chr17:80056334	FASN	-0.45	-6.17	-0.32	1.97e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6977660	0.714	rs13225018	chr7:19816567	C/T	cg05791153	chr7:19748676	TWISTNB	0.69	7.28	0.37	2.35e-12	Thyroid stimulating hormone;
LUSC	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg27284194	chr4:1044797	NA	0.59	8.61	0.43	3.01e-16	Recombination rate (females);
LUSC	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg22875332	chr1:76189707	ACADM	-0.39	-5.85	-0.3	1.19e-8	Daytime sleep phenotypes;
LUSC	cis	rs1595825	1.000	rs56765024	chr2:198876286	G/T	cg00982548	chr2:198649783	BOLL	-0.49	-6.15	-0.32	2.15e-9	Ulcerative colitis;
LUSC	cis	rs13427251	0.692	rs17765112	chr2:100149336	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.69	-0.34	9.49e-11	Chronic sinus infection;
LUSC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg11062466	chr8:58055876	NA	0.7	7.99	0.4	2.19e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg13385521	chr17:29058706	SUZ12P	0.61	6.31	0.33	9.06e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	cis	rs9908158	1	rs9908158	chr17:33890083	T/C	cg05299278	chr17:33885742	SLFN14	-0.32	-6.78	-0.35	5.32e-11	Platelet count;Platelet distribution width;
LUSC	cis	rs644148	0.676	rs2571114	chr19:44997579	A/G	cg15540054	chr19:45004280	ZNF180	-0.51	-7.25	-0.37	2.97e-12	Personality dimensions;
LUSC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg22655196	chr4:3374909	RGS12	0.31	5.96	0.31	6.35e-9	Serum sulfate level;
LUSC	cis	rs7113850	0.541	rs78652241	chr11:24234956	A/T	ch.11.24196551F	chr11:24239977	NA	0.99	9.07	0.44	1.01e-17	Bone fracture in osteoporosis;
LUSC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg04450456	chr4:17643702	FAM184B	0.39	6.78	0.35	5.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11608355	0.515	rs7310945	chr12:109946012	G/A	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.31	-0.37	1.95e-12	Joint mobility (Beighton score);
LUSC	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg05343316	chr1:45956843	TESK2	-0.62	-8.41	-0.42	1.2e-15	Platelet count;
LUSC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg25039879	chr17:56429692	SUPT4H1	0.67	9.01	0.44	1.6e-17	Cognitive test performance;
LUSC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg06219351	chr7:158114137	PTPRN2	0.51	9.16	0.45	5.28e-18	Calcium levels;
LUSC	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg24130564	chr14:104152367	KLC1	-0.52	-7.7	-0.39	1.53e-13	Body mass index;
LUSC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.62	0.5	6.81e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg03806693	chr22:41940476	POLR3H	-0.82	-10.73	-0.51	2.93e-23	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg06134567	chr22:46658398	PKDREJ	-0.54	-6.27	-0.32	1.14e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg01879757	chr17:41196368	BRCA1	-0.45	-6.99	-0.36	1.54e-11	Menopause (age at onset);
LUSC	cis	rs6076065	0.925	rs6083106	chr20:23368809	A/C	cg11657817	chr20:23433608	CST11	0.43	8.68	0.43	1.77e-16	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg00945038	chr17:61921165	SMARCD2	0.4	6.03	0.31	4.3e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs11608355	0.521	rs1119271	chr12:109819727	A/T	cg19025524	chr12:109796872	NA	-0.41	-7.71	-0.39	1.5e-13	Neuroticism;
LUSC	cis	rs8170	0.603	rs8110408	chr19:17440542	C/G	cg04749549	chr19:17459798	NA	-0.34	-6.11	-0.32	2.75e-9	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUSC	cis	rs1775715	0.870	rs1775731	chr10:32253512	A/G	cg04359828	chr10:32216031	ARHGAP12	0.38	6.29	0.33	9.91e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg23306229	chr2:178417860	TTC30B	0.56	6.38	0.33	5.74e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15369054	chr17:80825471	TBCD	-0.36	-5.9	-0.31	8.93e-9	Breast cancer;
LUSC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.65	-11.68	-0.54	1.15e-26	Extrinsic epigenetic age acceleration;
LUSC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	12.17	0.55	1.96e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg16624210	chr5:671434	TPPP	0.49	6.12	0.32	2.58e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6961069	0.745	rs11770358	chr7:80271330	A/T	cg04458919	chr7:80252533	CD36	0.35	6.15	0.32	2.22e-9	Platelet count;
LUSC	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg22681709	chr2:178499509	PDE11A	0.47	8.42	0.42	1.16e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1113500	0.548	rs3853497	chr1:108657184	C/T	cg11967332	chr1:108735228	SLC25A24	0.43	5.98	0.31	5.63e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.38	-6.23	-0.32	1.37e-9	Self-reported allergy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04999148	chr11:65188955	NEAT1	0.44	6.25	0.32	1.28e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9644630	0.897	rs6984644	chr8:19363425	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.35	6.64	0.34	1.28e-10	Oropharynx cancer;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04060830	chr9:132816023	GPR107	-0.52	-6.89	-0.35	2.82e-11	Hepatitis;
LUSC	cis	rs7215564	0.908	rs2873060	chr17:78663497	A/C	cg09596252	chr17:78655493	RPTOR	0.53	5.85	0.31	1.15e-8	Myopia (pathological);
LUSC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg09021430	chr5:549028	NA	-0.53	-7.49	-0.38	6.08e-13	Lung disease severity in cystic fibrosis;
LUSC	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg08975724	chr8:8085496	FLJ10661	0.48	7.06	0.36	9.61e-12	Neuroticism;
LUSC	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg22862634	chr11:62369728	EML3;MTA2	-0.49	-7.39	-0.37	1.19e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16684811	chr5:77944851	LHFPL2	-0.51	-7.09	-0.36	8.26e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.58	-9.36	-0.46	1.22e-18	Aortic root size;
LUSC	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg16989086	chr20:62203971	PRIC285	0.47	6.64	0.34	1.26e-10	Glioblastoma;
LUSC	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.57	9.46	0.46	5.48e-19	Bone mineral density;
LUSC	cis	rs16867321	0.950	rs1919152	chr2:181507765	C/T	cg23363182	chr2:181467187	NA	-0.45	-5.87	-0.31	1.03e-8	Obesity;
LUSC	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.44	-5.96	-0.31	6.45e-9	Corneal astigmatism;
LUSC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg15017067	chr4:17643749	FAM184B	0.36	5.9	0.31	8.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.95	0.31	6.78e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.85	0.3	1.2e-8	Lung cancer;
LUSC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg07341129	chr10:126685689	CTBP2	0.41	6.31	0.33	8.98e-10	Cognitive function;Information processing speed;
LUSC	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg01629716	chr15:45996671	NA	0.4	6.07	0.32	3.53e-9	Waist circumference;Weight;
LUSC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg23711669	chr6:146136114	FBXO30	0.82	14.71	0.63	4.15e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg22166914	chr1:53195759	ZYG11B	-0.41	-6.06	-0.31	3.72e-9	Monocyte count;
LUSC	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg07148914	chr20:33460835	GGT7	-0.43	-6.4	-0.33	5.34e-10	Height;
LUSC	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg09904177	chr6:26538194	HMGN4	0.66	11.93	0.55	1.38e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08704250	chr15:31115839	NA	-0.48	-7.05	-0.36	1.03e-11	Huntington's disease progression;
LUSC	trans	rs236907	0.859	rs34320898	chr1:171759139	G/C	cg13482142	chr2:234261155	NA	0.51	6.13	0.32	2.46e-9	Mean platelet volume;
LUSC	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg13010199	chr12:38710504	ALG10B	0.62	9.55	0.46	2.99e-19	Bladder cancer;
LUSC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg21643547	chr1:205240462	TMCC2	-0.41	-7.61	-0.38	2.85e-13	Red blood cell count;
LUSC	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg00898013	chr13:113819073	PROZ	0.54	8.04	0.4	1.59e-14	Platelet distribution width;
LUSC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	11.69	0.54	1.09e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg15556689	chr8:8085844	FLJ10661	0.51	7.18	0.37	4.55e-12	Neuroticism;
LUSC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-7.02	-0.36	1.27e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg12559939	chr2:27858050	GPN1	0.41	6.44	0.33	4.23e-10	Oral cavity cancer;
LUSC	cis	rs1113500	0.933	rs61797344	chr1:108622580	C/T	cg11967332	chr1:108735228	SLC25A24	0.39	5.84	0.3	1.22e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg13010344	chr12:123464640	ARL6IP4	0.44	7.15	0.36	5.6e-12	Platelet count;
LUSC	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg09904177	chr6:26538194	HMGN4	0.57	8.91	0.44	3.43e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs10221833	0.602	rs355886	chr2:165634156	G/A	cg26993132	chr16:89239499	CDH15	0.32	6.27	0.32	1.15e-9	Response to statin therapy;
LUSC	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.58	-0.43	3.6e-16	Body mass index;
LUSC	cis	rs10484885	0.793	rs9359862	chr6:90474508	A/G	cg13799429	chr6:90582589	CASP8AP2	0.92	11.07	0.52	1.86e-24	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7000551	0.751	rs2469770	chr8:22379856	G/A	cg12081754	chr8:22256438	SLC39A14	0.46	6.79	0.35	5.12e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg06697600	chr4:7070879	GRPEL1	0.4	5.89	0.31	9.34e-9	Monocyte percentage of white cells;
LUSC	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.9	18.57	0.71	2.26e-53	Monocyte count;
LUSC	trans	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg26384229	chr12:38710491	ALG10B	0.56	8.65	0.43	2.19e-16	Morning vs. evening chronotype;
LUSC	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-5.93	-0.31	7.5e-9	Retinal vascular caliber;
LUSC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg20821713	chr7:1055600	C7orf50	-0.5	-6.62	-0.34	1.42e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg08917208	chr2:24149416	ATAD2B	0.88	9.72	0.47	7.6e-20	Lymphocyte counts;
LUSC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg11494091	chr17:61959527	GH2	0.39	6.61	0.34	1.48e-10	Height;
LUSC	cis	rs10761482	0.861	rs7096426	chr10:62106545	C/T	cg18175470	chr10:62150864	ANK3	0.52	7.46	0.38	7.77e-13	Schizophrenia;
LUSC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg26850624	chr5:429559	AHRR	-0.4	-7.85	-0.39	5.68e-14	Cystic fibrosis severity;
LUSC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	1.05	19.36	0.73	1.59e-56	Parkinson's disease;
LUSC	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.53	7.81	0.39	7.23e-14	Gut microbiome composition (winter);
LUSC	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg06207120	chr15:45996521	NA	-0.4	-6.16	-0.32	2.04e-9	Waist circumference;Weight;
LUSC	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.71	-11.17	-0.52	7.69e-25	Alcohol dependence;
LUSC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.85	-0.51	1.12e-23	Alzheimer's disease;
LUSC	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg23649088	chr2:200775458	C2orf69	-0.6	-8.62	-0.43	2.7e-16	Schizophrenia;
LUSC	cis	rs13089785	0.725	rs2222822	chr3:123604788	T/A	cg01860459	chr3:123419554	MYLK	0.39	6.47	0.33	3.49e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg25214090	chr10:38739885	LOC399744	0.5	7.45	0.38	8.19e-13	Corneal astigmatism;
LUSC	cis	rs9800506	0.835	rs6923449	chr6:35527714	T/C	cg03566752	chr6:35512600	NA	0.24	5.81	0.3	1.45e-8	Neutrophil percentage of granulocytes;
LUSC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg12365402	chr11:9010492	NRIP3	-0.49	-9.42	-0.46	7.83e-19	Hemoglobin concentration;
LUSC	cis	rs3771570	1.000	rs12619369	chr2:242282957	A/T	cg21155796	chr2:242212141	HDLBP	0.58	6.7	0.34	8.91e-11	Prostate cancer;
LUSC	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg09699651	chr6:150184138	LRP11	0.45	7.15	0.36	5.64e-12	Testicular germ cell tumor;
LUSC	trans	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-9.28	-0.45	2.17e-18	Brugada syndrome;
LUSC	cis	rs6881634	0.508	rs10053035	chr5:77652346	C/T	cg11547950	chr5:77652471	NA	-0.34	-6.39	-0.33	5.51e-10	Hippocampal atrophy;
LUSC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	0.87	15.36	0.64	1.18e-40	Cognitive function;
LUSC	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg09988129	chr7:74988866	PMS2L2;STAG3L1	-0.38	-5.73	-0.3	2.26e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	6.64	0.34	1.3e-10	Lung cancer in ever smokers;
LUSC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg24562669	chr7:97807699	LMTK2	0.34	6.01	0.31	4.91e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7254114	0.578	rs12980863	chr19:11309871	C/T	cg02815516	chr19:11306319	KANK2	-0.41	-8.42	-0.42	1.09e-15	Immature fraction of reticulocytes;
LUSC	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19653624	chr11:20408972	PRMT3	-0.67	-8.55	-0.42	4.38e-16	Pursuit maintenance gain;
LUSC	cis	rs524023	1.000	rs12786214	chr11:64364203	G/A	cg19131476	chr11:64387923	NRXN2	-0.38	-10.24	-0.49	1.38e-21	Urate levels in obese individuals;
LUSC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg26380479	chr7:97908229	NA	0.26	5.89	0.31	9.58e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg27535305	chr1:53392650	SCP2	-0.44	-8.91	-0.44	3.44e-17	Monocyte count;
LUSC	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.51	1.26e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs75804782	0.691	rs55886641	chr2:239319185	T/C	cg01134436	chr17:81009848	B3GNTL1	0.64	6.08	0.32	3.37e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg25456477	chr12:86230367	RASSF9	0.43	7.65	0.39	2.18e-13	Major depressive disorder;
LUSC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg27529037	chr20:44575021	PCIF1	0.4	7.06	0.36	9.45e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs61931739	0.635	rs7979207	chr12:33910566	C/T	cg06521331	chr12:34319734	NA	0.42	6.97	0.36	1.7e-11	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.51	0.42	6.06e-16	Prudent dietary pattern;
LUSC	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg06627628	chr2:24431161	ITSN2	0.7	9.46	0.46	5.61e-19	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg06096015	chr1:231504339	EGLN1	-0.56	-9.93	-0.48	1.61e-20	Hemoglobin concentration;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05904194	chr2:85132663	TMSB10	-0.41	-6.23	-0.32	1.4e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.63	0.85	1.69e-95	Chronic sinus infection;
LUSC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg06713675	chr4:122721982	EXOSC9	-0.46	-8.14	-0.41	8e-15	Type 2 diabetes;
LUSC	trans	rs9944715	1.000	rs718514	chr18:43856354	A/C	cg01718231	chr17:29326311	RNF135	-0.52	-7.29	-0.37	2.32e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg02527881	chr3:46936655	PTH1R	0.4	7.0	0.36	1.41e-11	Colorectal cancer;
LUSC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg08847533	chr14:75593920	NEK9	-0.82	-14.82	-0.63	1.58e-38	Height;
LUSC	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg21238619	chr17:78079768	GAA	-0.29	-5.95	-0.31	6.59e-9	Yeast infection;
LUSC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg03909863	chr11:638404	DRD4	-0.43	-6.14	-0.32	2.4e-9	Systemic lupus erythematosus;
LUSC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg12560992	chr17:57184187	TRIM37	-0.84	-15.23	-0.64	3.72e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.778	rs7206541	chr16:75436713	A/T	cg03315344	chr16:75512273	CHST6	0.48	8.94	0.44	2.8e-17	Dupuytren's disease;
LUSC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg22823121	chr1:150693482	HORMAD1	0.51	7.49	0.38	6.11e-13	Melanoma;
LUSC	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.87	-0.31	1.05e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg23260525	chr10:116636907	FAM160B1	0.49	10.57	0.5	1.05e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg11189052	chr15:85197271	WDR73	0.53	8.14	0.41	8.09e-15	P wave terminal force;
LUSC	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg04369109	chr6:150039330	LATS1	-0.54	-7.82	-0.39	7.05e-14	Lung cancer;
LUSC	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg01966878	chr4:90757139	SNCA	-0.4	-5.72	-0.3	2.38e-8	Neuroticism;
LUSC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	11.36	0.53	1.73e-25	Prudent dietary pattern;
LUSC	cis	rs7929679	0.551	rs10466455	chr11:34780936	C/T	cg06937548	chr11:34938143	PDHX;APIP	-0.41	-6.03	-0.31	4.31e-9	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	cis	rs6542838	0.641	rs11123756	chr2:99508012	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.45	5.94	0.31	7.2e-9	Fear of minor pain;
LUSC	trans	rs931812	0.825	rs13271753	chr8:101895491	T/C	cg20993868	chr7:22813445	NA	0.59	10.34	0.49	6.19e-22	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg08645402	chr16:4508243	NA	0.51	8.12	0.41	9.29e-15	Schizophrenia;
LUSC	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.31	-0.37	2.01e-12	Bipolar disorder;
LUSC	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	trans	rs1998174	0.509	rs10798695	chr1:171812059	A/G	cg13482142	chr2:234261155	NA	0.42	6.02	0.31	4.51e-9	Platelet distribution width;
LUSC	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg00310523	chr12:86230176	RASSF9	0.42	7.56	0.38	4.01e-13	Major depressive disorder;
LUSC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg18190219	chr22:46762943	CELSR1	-0.48	-5.95	-0.31	6.67e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg25767906	chr1:53392781	SCP2	-0.5	-9.21	-0.45	3.66e-18	Monocyte count;
LUSC	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg17385448	chr1:15911702	AGMAT	0.38	5.91	0.31	8.64e-9	Systolic blood pressure;
LUSC	cis	rs4704187	0.687	rs115403098	chr5:74397384	A/G	cg03227963	chr5:74354835	NA	0.32	6.89	0.35	2.74e-11	Response to amphetamines;
LUSC	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg12062639	chr20:23401060	NAPB	0.97	7.93	0.4	3.23e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg21361702	chr7:150065534	REPIN1	0.48	6.79	0.35	5.1e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.92	15.65	0.65	8.39e-42	Bladder cancer;
LUSC	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg22676075	chr6:135203613	NA	0.47	7.38	0.37	1.25e-12	Red blood cell count;
LUSC	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg18132916	chr6:79620363	NA	-0.37	-5.74	-0.3	2.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg18512352	chr11:47633146	NA	-0.48	-9.73	-0.47	7.1e-20	Subjective well-being;
LUSC	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.56	-9.23	-0.45	3.27e-18	Breast cancer;
LUSC	cis	rs4474465	0.607	rs4945303	chr11:78283803	A/G	cg27205649	chr11:78285834	NARS2	0.59	7.31	0.37	2e-12	Alzheimer's disease (survival time);
LUSC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg08270630	chr22:50330655	NA	-0.48	-6.92	-0.35	2.34e-11	Schizophrenia;
LUSC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg20135002	chr11:47629003	NA	-0.51	-8.11	-0.41	9.83e-15	Subjective well-being;
LUSC	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg02018176	chr4:1364513	KIAA1530	-0.44	-6.18	-0.32	1.89e-9	Recombination rate (females);
LUSC	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg00105475	chr2:10696890	NA	0.36	6.08	0.32	3.35e-9	Prostate cancer;
LUSC	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	6.91	0.35	2.39e-11	Lung cancer in ever smokers;
LUSC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.58	10.6	0.5	8.09e-23	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg08888203	chr3:10149979	C3orf24	0.66	9.07	0.44	1.06e-17	Alzheimer's disease;
LUSC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.56	8.56	0.42	4.26e-16	Menopause (age at onset);
LUSC	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.92	-0.51	5.98e-24	Alcohol dependence;
LUSC	trans	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg10756647	chr7:56101905	PSPH	0.88	8.91	0.44	3.39e-17	Diabetic kidney disease;
LUSC	cis	rs721399	0.539	rs10089958	chr8:18269343	A/G	cg18736775	chr8:18248649	NAT2	-0.57	-6.72	-0.34	8.06e-11	Blood metabolite levels;
LUSC	cis	rs5753618	0.583	rs5753639	chr22:31870400	A/G	cg02404636	chr22:31891804	SFI1	-0.39	-5.83	-0.3	1.29e-8	Colorectal cancer;
LUSC	trans	rs62238980	0.614	rs75142210	chr22:32398992	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg02551604	chr5:131831745	NA	0.45	6.96	0.36	1.85e-11	Asthma (sex interaction);
LUSC	cis	rs12760731	0.623	rs2862378	chr1:178296566	A/G	cg00404053	chr1:178313656	RASAL2	0.47	5.81	0.3	1.48e-8	Obesity-related traits;
LUSC	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg10167463	chr7:75959203	YWHAG	-0.66	-10.1	-0.48	4.04e-21	Multiple sclerosis;
LUSC	cis	rs708547	0.957	rs2458552	chr4:57773442	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.54	6.57	0.34	1.88e-10	Response to bleomycin (chromatid breaks);
LUSC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg17724175	chr1:150552817	MCL1	0.35	6.38	0.33	5.96e-10	Tonsillectomy;
LUSC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg04944784	chr2:26401820	FAM59B	0.74	10.59	0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	trans	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.08	-0.32	3.31e-9	Depression;
LUSC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.63	-0.34	1.32e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	0.94	17.96	0.7	5.88e-51	Heart rate;
LUSC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.65	10.86	0.51	1.02e-23	Facial morphology (factor 20);
LUSC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13732083	chr21:47605072	C21orf56	0.42	6.27	0.32	1.14e-9	Testicular germ cell tumor;
LUSC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg06454157	chr6:167490870	NA	-0.28	-6.71	-0.34	8.57e-11	Primary biliary cholangitis;
LUSC	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-8.51	-0.42	5.85e-16	Coronary artery disease;
LUSC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg03948781	chr1:205179583	DSTYK	0.3	5.68	0.3	2.98e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6005807	0.719	rs60693420	chr22:29045930	T/C	cg12565055	chr22:29076175	TTC28	0.54	5.86	0.31	1.12e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg10483660	chr13:112241077	NA	0.37	6.4	0.33	5.12e-10	Menarche (age at onset);
LUSC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg03676636	chr4:99064102	C4orf37	0.32	6.9	0.35	2.61e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg10117171	chr1:25599238	RHD	-0.38	-5.79	-0.3	1.63e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg05084668	chr3:125655381	ALG1L	-0.79	-11.62	-0.54	1.88e-26	Blood pressure (smoking interaction);
LUSC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06481639	chr22:41940642	POLR3H	0.5	5.69	0.3	2.8e-8	Vitiligo;
LUSC	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg00982548	chr2:198649783	BOLL	-0.59	-7.43	-0.38	9.41e-13	Ulcerative colitis;
LUSC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg09034736	chr1:150693464	HORMAD1	0.42	5.8	0.3	1.55e-8	Melanoma;
LUSC	cis	rs6987853	0.761	rs2974322	chr8:42424724	T/C	cg09913449	chr8:42400586	C8orf40	0.52	9.1	0.45	8.55e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs11971779	0.616	rs6949963	chr7:139054325	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.4	0.56	2.59e-29	Prudent dietary pattern;
LUSC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg17340268	chr14:105411764	AHNAK2	-0.38	-6.07	-0.32	3.41e-9	Rheumatoid arthritis;
LUSC	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg21770322	chr7:97807741	LMTK2	-0.45	-7.21	-0.37	3.67e-12	Breast cancer;
LUSC	cis	rs12286929	0.702	rs11215419	chr11:115081810	A/T	cg04055981	chr11:115044050	NA	0.4	7.04	0.36	1.11e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg18904891	chr8:8559673	CLDN23	0.53	7.22	0.37	3.57e-12	Obesity-related traits;
LUSC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg21918786	chr6:109611834	NA	-0.42	-7.29	-0.37	2.33e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.42	-0.62	5.29e-37	Schizophrenia;
LUSC	cis	rs6840360	1.000	rs1864300	chr4:152663326	T/C	cg22705602	chr4:152727874	NA	-0.28	-6.02	-0.31	4.68e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs62408225	0.962	rs905671	chr6:90983850	A/T	cg06866423	chr6:90926672	BACH2	0.41	5.91	0.31	8.67e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg22431228	chr1:16359049	CLCNKA	0.42	8.44	0.42	9.8e-16	Systolic blood pressure;
LUSC	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg05501817	chr11:14380813	RRAS2	-0.47	-7.41	-0.38	1.05e-12	Sense of smell;
LUSC	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg21775007	chr8:11205619	TDH	0.82	13.79	0.6	1.53e-34	Retinal vascular caliber;
LUSC	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-17.27	-0.69	3.44e-48	Exhaled nitric oxide output;
LUSC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.61	-0.6	7.34e-34	Chronic sinus infection;
LUSC	cis	rs7809950	0.773	rs9791733	chr7:107041730	T/C	cg23024343	chr7:107201750	COG5	-0.7	-10.08	-0.48	4.82e-21	Coronary artery disease;
LUSC	cis	rs7202877	0.656	rs4887812	chr16:75310052	G/A	cg03315344	chr16:75512273	CHST6	0.49	7.0	0.36	1.41e-11	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	8.86	0.44	4.85e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.65	-8.73	-0.43	1.22e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg15423357	chr2:25149977	NA	0.46	9.45	0.46	5.97e-19	Body mass index in non-asthmatics;
LUSC	cis	rs11711311	0.869	rs12493635	chr3:113373019	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.29	0.33	9.66e-10	IgG glycosylation;
LUSC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.69	-0.57	2.24e-30	Platelet count;
LUSC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg07701084	chr6:150067640	NUP43	0.56	8.51	0.42	6.09e-16	Lung cancer;
LUSC	cis	rs34638657	0.872	rs8051436	chr16:82171979	G/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.04	-0.31	4.17e-9	Lung adenocarcinoma;
LUSC	trans	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg19894588	chr14:64061835	NA	-0.57	-7.44	-0.38	8.61e-13	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.83	12.19	0.55	1.6e-28	Cognitive ability;
LUSC	cis	rs4363385	0.747	rs1129655	chr1:152958267	T/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.5	-0.38	5.99e-13	Inflammatory skin disease;
LUSC	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg16989719	chr2:238392110	NA	-0.37	-6.6	-0.34	1.6e-10	Prostate cancer;
LUSC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	ch.11.42038R	chr11:967971	AP2A2	0.44	6.6	0.34	1.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg24531977	chr5:56204891	C5orf35	-0.61	-8.84	-0.44	5.54e-17	Coronary artery disease;
LUSC	cis	rs76793172	0.920	rs77588767	chr19:46326472	G/C	cg27118825	chr19:46318748	RSPH6A;SYMPK	0.46	5.69	0.3	2.75e-8	Eosinophil counts;
LUSC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg12463550	chr7:65579703	CRCP	-0.55	-8.09	-0.4	1.11e-14	Aortic root size;
LUSC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-12.3	-0.56	5.96e-29	Hemoglobin concentration;
LUSC	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg02403541	chr12:121454288	C12orf43	-0.72	-11.05	-0.52	2.08e-24	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg24375607	chr4:120327624	NA	0.76	11.45	0.53	7.76e-26	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17907730	chr7:35077704	DPY19L1	-0.42	-6.22	-0.32	1.52e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2637266	0.777	rs2637253	chr10:78311287	A/C	cg18941641	chr10:78392320	NA	-0.36	-6.29	-0.33	9.77e-10	Pulmonary function;
LUSC	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.45	-0.42	8.92e-16	Schizophrenia;
LUSC	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg25206134	chr2:45395956	NA	0.59	6.91	0.35	2.4e-11	Bipolar disorder;
LUSC	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg08017756	chr2:100939284	LONRF2	-0.44	-8.33	-0.41	2.05e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg07393940	chr7:158741817	NA	0.51	8.0	0.4	2.07e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg03948781	chr1:205179583	DSTYK	0.29	5.65	0.3	3.53e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs4729127	1.000	rs9641132	chr7:94011381	G/T	cg14660007	chr13:78271894	SLAIN1	0.51	6.61	0.34	1.5e-10	Intelligence;
LUSC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.61	-0.38	2.79e-13	Aortic root size;
LUSC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg23719950	chr11:63933701	MACROD1	-0.62	-8.08	-0.4	1.22e-14	Mean platelet volume;
LUSC	trans	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg02800362	chr5:177631904	HNRNPAB	0.98	11.15	0.52	9.51e-25	Obesity-related traits;
LUSC	cis	rs2219968	0.962	rs2368508	chr8:78951278	T/C	cg00738934	chr8:78996279	NA	0.38	6.73	0.35	7.25e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg03599575	chr15:90893182	GABARAPL3	0.33	5.81	0.3	1.47e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg03676636	chr4:99064102	C4orf37	0.35	7.56	0.38	3.82e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07862889	chr17:21156915	C17orf103	0.44	6.6	0.34	1.61e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs17540621	0.744	rs116777406	chr2:47196252	A/C	cg23978866	chr2:47230407	TTC7A	-0.92	-6.91	-0.35	2.44e-11	Response to statin therapy;
LUSC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18876405	chr7:65276391	NA	-0.54	-8.54	-0.42	4.87e-16	Aortic root size;
LUSC	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg24060327	chr5:131705240	SLC22A5	0.48	6.32	0.33	8.29e-10	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg07395648	chr5:131743802	NA	-0.38	-5.76	-0.3	1.88e-8	Breast cancer;
LUSC	cis	rs1891275	0.515	rs7093728	chr10:93443617	C/T	cg07889827	chr10:93443413	NA	-0.38	-8.55	-0.42	4.34e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg13798780	chr7:105162888	PUS7	0.53	5.93	0.31	7.72e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg05132306	chr1:1846340	CALML6	-0.34	-8.61	-0.43	2.93e-16	Body mass index;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10292851	chr8:101572103	ANKRD46	-0.47	-6.02	-0.31	4.55e-9	Hepatitis;
LUSC	cis	rs4664304	1.000	rs3806603	chr2:160761808	T/C	cg03641300	chr2:160917029	PLA2R1	-0.42	-6.79	-0.35	5.22e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg25555424	chr11:2950735	PHLDA2	0.41	6.17	0.32	1.98e-9	Schizophrenia (age at onset);
LUSC	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg12002119	chr2:101014098	CHST10	0.36	6.16	0.32	2.1e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12210905	0.858	rs72838249	chr6:26998489	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.95	-0.31	6.94e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg16325326	chr1:53192061	ZYG11B	0.94	17.26	0.69	3.71e-48	Monocyte count;
LUSC	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg11161011	chr14:65562177	MAX	-0.81	-12.51	-0.56	1.01e-29	Obesity-related traits;
LUSC	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.71	-0.91	1.49e-128	Myeloid white cell count;
LUSC	trans	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.61	-10.46	-0.5	2.54e-22	Mean corpuscular volume;
LUSC	cis	rs6500395	1.000	rs11644518	chr16:48616789	A/G	cg04672837	chr16:48644449	N4BP1	0.5	7.48	0.38	6.46e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg10909506	chr17:38081995	ORMDL3	0.35	6.16	0.32	2.11e-9	Self-reported allergy;
LUSC	cis	rs34734847	0.842	rs7308648	chr12:121144144	C/G	cg21892295	chr12:121157589	UNC119B	-0.37	-6.51	-0.34	2.8e-10	Mean corpuscular volume;
LUSC	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg05425664	chr17:57184151	TRIM37	0.49	7.32	0.37	1.84e-12	Testicular germ cell tumor;
LUSC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg06074448	chr4:187884817	NA	-0.41	-6.89	-0.35	2.85e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg12483005	chr1:23474871	LUZP1	0.42	6.17	0.32	1.99e-9	Height;
LUSC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg22800045	chr5:56110881	MAP3K1	0.76	10.05	0.48	6.05e-21	Initial pursuit acceleration;
LUSC	cis	rs9815354	0.767	rs73071238	chr3:41992243	A/G	cg03022575	chr3:42003672	ULK4	0.85	8.86	0.44	4.72e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg17691542	chr6:26056736	HIST1H1C	0.49	6.89	0.35	2.86e-11	Iron status biomarkers;
LUSC	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.94	0.7	7.29e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.31	-5.8	-0.3	1.55e-8	Lymphocyte counts;
LUSC	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg05234568	chr11:5960015	NA	-0.54	-7.58	-0.38	3.37e-13	DNA methylation (variation);
LUSC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg21471580	chr8:22132874	PIWIL2	0.35	6.06	0.31	3.75e-9	Hypertriglyceridemia;
LUSC	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg21775007	chr8:11205619	TDH	0.45	6.46	0.33	3.63e-10	Mood instability;
LUSC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg00814883	chr7:100076585	TSC22D4	-0.66	-8.53	-0.42	5.25e-16	Platelet count;
LUSC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	ch.11.42038R	chr11:967971	AP2A2	0.44	6.65	0.34	1.22e-10	Alzheimer's disease (late onset);
LUSC	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg24375607	chr4:120327624	NA	0.75	11.72	0.54	8.65e-27	Corneal astigmatism;
LUSC	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg08508325	chr11:3079039	CARS	0.38	8.51	0.42	6.01e-16	Calcium levels;
LUSC	trans	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.41	-0.33	4.96e-10	Blood trace element (Cu levels);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg00569385	chr1:151032336	MLLT11;CDC42SE1	0.55	6.61	0.34	1.48e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg26677194	chr12:130822605	PIWIL1	0.59	8.77	0.43	9.52e-17	Menopause (age at onset);
LUSC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14159672	chr1:205819179	PM20D1	-0.49	-7.51	-0.38	5.32e-13	Menarche (age at onset);
LUSC	cis	rs597583	0.951	rs599411	chr11:117422262	T/G	cg27161313	chr11:117392002	DSCAML1	-0.39	-7.0	-0.36	1.39e-11	Putamen volume;
LUSC	cis	rs80282103	0.764	rs10047383	chr10:1103095	A/G	cg18964960	chr10:1102726	WDR37	0.73	6.71	0.34	8.45e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg06462663	chr19:18546047	ISYNA1	0.47	8.05	0.4	1.49e-14	Breast cancer;
LUSC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.44	-0.33	4.14e-10	Life satisfaction;
LUSC	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg18200150	chr17:30822561	MYO1D	-0.29	-5.72	-0.3	2.31e-8	Schizophrenia;
LUSC	cis	rs9828933	0.752	rs13434089	chr3:63948566	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.64	6.3	0.33	9.21e-10	Type 2 diabetes;
LUSC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg05729581	chr11:3078854	CARS	-0.54	-8.25	-0.41	3.8e-15	Longevity;
LUSC	cis	rs12681288	0.676	rs6559208	chr8:1018833	A/G	cg04851639	chr8:1020857	NA	-0.38	-7.77	-0.39	1e-13	Schizophrenia;
LUSC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg15839431	chr19:19639596	YJEFN3	-0.5	-6.81	-0.35	4.59e-11	Tonsillectomy;
LUSC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg02269571	chr22:50332266	NA	-0.57	-8.45	-0.42	9.4e-16	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.04	-0.4	1.62e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg06636001	chr8:8085503	FLJ10661	0.52	7.87	0.4	5.14e-14	Retinal vascular caliber;
LUSC	cis	rs4954585	0.683	rs4452212	chr2:137015991	G/A	cg05194412	chr2:137003533	NA	0.41	7.57	0.38	3.79e-13	Colorectal cancer;
LUSC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00149659	chr3:10157352	C3orf10	1.01	14.42	0.62	5.3e-37	Alzheimer's disease;
LUSC	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-6.06	-0.31	3.77e-9	Fear of minor pain;
LUSC	cis	rs17030434	0.906	rs11099901	chr4:154671468	T/A	cg14289246	chr4:154710475	SFRP2	-0.49	-6.47	-0.33	3.43e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.73	-8.81	-0.43	7.03e-17	Menarche (age at onset);
LUSC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg01483505	chr11:975446	AP2A2	0.4	5.74	0.3	2.17e-8	Alzheimer's disease (late onset);
LUSC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.58	-0.34	1.78e-10	Lung cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19641644	chr7:44365627	CAMK2B	0.4	6.08	0.32	3.29e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1499972	0.941	rs62264766	chr3:117641227	A/G	cg07612923	chr3:117604196	NA	0.64	5.76	0.3	1.93e-8	Schizophrenia;
LUSC	cis	rs73206853	0.563	rs881961	chr12:111201646	C/T	cg12870014	chr12:110450643	ANKRD13A	0.64	6.42	0.33	4.55e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.91	11.6	0.54	2.31e-26	Menarche (age at onset);
LUSC	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg03733263	chr8:22462867	KIAA1967	0.99	18.13	0.7	1.23e-51	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg26597838	chr10:835615	NA	0.8	11.39	0.53	1.29e-25	Eosinophil percentage of granulocytes;
LUSC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg25039879	chr17:56429692	SUPT4H1	0.58	7.54	0.38	4.53e-13	Cognitive test performance;
LUSC	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg27411982	chr8:10470053	RP1L1	0.41	6.43	0.33	4.53e-10	Mood instability;
LUSC	cis	rs9473147	0.516	rs7754282	chr6:47502024	C/G	cg12968598	chr6:47444699	CD2AP	-0.52	-7.86	-0.4	5.26e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg12935359	chr14:103987150	CKB	0.65	10.45	0.5	2.68e-22	Intelligence (multi-trait analysis);
LUSC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.67	-10.5	-0.5	1.8e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.9	0.35	2.67e-11	Height;
LUSC	cis	rs10979	1.000	rs6570566	chr6:143899534	G/A	cg25407410	chr6:143891975	LOC285740	-0.68	-10.53	-0.5	1.42e-22	Hypospadias;
LUSC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg24977027	chr2:88469347	THNSL2	0.56	5.93	0.31	7.76e-9	Plasma clusterin levels;
LUSC	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-18.45	-0.71	6.86e-53	Primary sclerosing cholangitis;
LUSC	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.59	-0.6	8.31e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg15383120	chr6:291909	DUSP22	-0.65	-10.98	-0.51	3.88e-24	Menopause (age at onset);
LUSC	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg03678062	chr6:149772716	ZC3H12D	-0.3	-6.15	-0.32	2.24e-9	Dupuytren's disease;
LUSC	trans	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs295140	0.837	rs12474914	chr2:201130210	A/G	cg04283868	chr2:201171347	SPATS2L	0.41	5.95	0.31	6.78e-9	QT interval;
LUSC	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.3	-6.41	-0.33	5.09e-10	Dupuytren's disease;
LUSC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg11843238	chr5:131593191	PDLIM4	0.4	6.72	0.35	7.67e-11	Breast cancer;
LUSC	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.44	7.67	0.39	1.88e-13	HDL cholesterol;
LUSC	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	8.11	0.41	1.01e-14	Total body bone mineral density;
LUSC	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg19554555	chr3:13937349	NA	-0.38	-5.75	-0.3	2e-8	Ovarian reserve;
LUSC	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg17425144	chr1:10567563	PEX14	0.65	13.45	0.59	2.93e-33	Breast size;
LUSC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg21453287	chr8:37963019	ASH2L	0.47	6.74	0.35	7.08e-11	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg13010199	chr12:38710504	ALG10B	0.68	10.65	0.5	5.27e-23	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.7	11.5	0.53	5.12e-26	Heart rate;
LUSC	cis	rs1577917	0.883	rs9450375	chr6:86756629	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.43	6.22	0.32	1.51e-9	Response to antipsychotic treatment;
LUSC	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg08601574	chr20:25228251	PYGB	-0.44	-6.74	-0.35	6.84e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.16	16.01	0.66	3.2e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07685180	chr8:600429	NA	0.57	5.89	0.31	9.32e-9	IgG glycosylation;
LUSC	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg07828340	chr4:882639	GAK	1.03	10.95	0.51	4.79e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs80282103	0.618	rs7100114	chr10:1110231	A/G	cg08668510	chr10:1095578	IDI1	0.74	6.11	0.32	2.77e-9	Glomerular filtration rate (creatinine);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13411583	chr12:122064640	ORAI1	-0.44	-6.84	-0.35	3.84e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6700896	0.500	rs11208687	chr1:66076358	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.35	0.33	7.09e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.23	-0.49	1.57e-21	Monocyte count;
LUSC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg11663144	chr21:46675770	NA	0.44	7.9	0.4	4.2e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-12.36	-0.56	3.62e-29	Platelet count;
LUSC	cis	rs2692947	0.666	rs10183151	chr2:96774786	T/G	cg22654517	chr2:96458247	NA	-0.32	-5.82	-0.3	1.39e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.95	17.72	0.7	5.54e-50	Bone mineral density;
LUSC	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg25214090	chr10:38739885	LOC399744	0.56	8.21	0.41	4.83e-15	Corneal astigmatism;
LUSC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg25258033	chr6:167368657	RNASET2	0.39	6.3	0.33	9.49e-10	Crohn's disease;
LUSC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg17971929	chr21:40555470	PSMG1	0.79	13.91	0.61	4.96e-35	Cognitive function;
LUSC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg02269571	chr22:50332266	NA	-0.59	-8.72	-0.43	1.37e-16	Schizophrenia;
LUSC	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg13010199	chr12:38710504	ALG10B	0.55	7.56	0.38	3.86e-13	Resting heart rate;
LUSC	cis	rs6961069	0.671	rs10268340	chr7:80224798	T/G	cg04458919	chr7:80252533	CD36	-0.41	-7.25	-0.37	2.98e-12	Platelet count;
LUSC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.5	-9.68	-0.47	1.05e-19	Monocyte percentage of white cells;
LUSC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg08244238	chr11:790193	CEND1	0.33	5.67	0.3	3.03e-8	Breast cancer;
LUSC	cis	rs7771547	0.519	rs6923337	chr6:36369260	C/T	cg07856975	chr6:36356162	ETV7	0.45	6.63	0.34	1.35e-10	Platelet distribution width;
LUSC	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg05283184	chr6:79620031	NA	-0.57	-12.13	-0.55	2.55e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg01528321	chr10:82214614	TSPAN14	0.9	13.42	0.59	3.9e-33	Post bronchodilator FEV1;
LUSC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg05973401	chr12:123451056	ABCB9	0.55	8.05	0.4	1.5e-14	Platelet count;
LUSC	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg24375607	chr4:120327624	NA	0.77	12.56	0.57	6.5e-30	Corneal astigmatism;
LUSC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	12.14	0.55	2.36e-28	Colorectal cancer;
LUSC	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg02023728	chr11:77925099	USP35	0.46	6.74	0.35	7.17e-11	Testicular germ cell tumor;
LUSC	trans	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg26811252	chr16:29126840	RRN3P2	0.58	9.21	0.45	3.72e-18	Menopause (age at onset);
LUSC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg13393036	chr8:95962371	TP53INP1	-0.47	-9.69	-0.47	9.8e-20	Type 2 diabetes;
LUSC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.19	-0.45	4.25e-18	Monocyte percentage of white cells;
LUSC	trans	rs12439619	0.846	rs62012003	chr15:82475577	T/A	cg04831495	chr15:85060580	GOLGA6L5	-0.47	-6.38	-0.33	5.95e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg02569458	chr12:86230093	RASSF9	0.42	6.86	0.35	3.31e-11	Major depressive disorder;
LUSC	cis	rs11630290	1.000	rs72750986	chr15:63996338	C/A	cg12036633	chr15:63758958	NA	-0.73	-8.09	-0.4	1.12e-14	Iris characteristics;
LUSC	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg00191853	chr8:101177733	SPAG1	-0.37	-6.2	-0.32	1.69e-9	Atrioventricular conduction;
LUSC	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg24562669	chr7:97807699	LMTK2	0.44	7.88	0.4	4.65e-14	Breast cancer;
LUSC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg08847533	chr14:75593920	NEK9	-0.82	-14.83	-0.63	1.42e-38	Height;
LUSC	cis	rs3733631	1.000	rs10010631	chr4:104644543	A/G	cg24090629	chr4:104641072	TACR3	-0.48	-5.94	-0.31	7.32e-9	Menarche (age at onset);
LUSC	cis	rs3812762	0.871	rs3862352	chr11:8818020	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-6.36	-0.33	6.53e-10	Hypospadias;
LUSC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs17632159	0.619	rs7379816	chr5:72428831	A/G	cg01170694	chr5:72431891	NA	-0.3	-6.16	-0.32	2.06e-9	Urate levels;
LUSC	trans	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.55	-8.5	-0.42	6.19e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2282032	1.000	rs115667214	chr14:90733890	A/G	cg14092571	chr14:90743983	NA	0.56	7.04	0.36	1.11e-11	Longevity;
LUSC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.82	0.78	4.1e-70	Prudent dietary pattern;
LUSC	cis	rs7215564	0.908	rs4969411	chr17:78747982	T/C	cg23238734	chr17:78661607	RPTOR	-0.45	-5.71	-0.3	2.48e-8	Myopia (pathological);
LUSC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg06096015	chr1:231504339	EGLN1	0.56	10.03	0.48	7.06e-21	Hemoglobin concentration;
LUSC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07677032	chr17:61819896	STRADA	0.54	9.08	0.44	9.89e-18	Prudent dietary pattern;
LUSC	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23158103	chr7:148848205	ZNF398	-0.48	-7.73	-0.39	1.32e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9581857	0.685	rs9319369	chr13:28042323	A/T	cg22138327	chr13:27999177	GTF3A	0.72	7.8	0.39	7.89e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs11971779	0.625	rs2355784	chr7:139072493	G/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	cis	rs12594515	1.000	rs8029209	chr15:45993489	A/G	cg19682013	chr15:45996608	NA	0.38	5.68	0.3	2.89e-8	Waist circumference;Weight;
LUSC	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg03585969	chr10:35415529	CREM	0.62	9.13	0.45	6.91e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg24011408	chr12:48396354	COL2A1	-0.38	-5.66	-0.3	3.24e-8	Glycated hemoglobin levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16169373	chr8:67976534	CSPP1	-0.45	-6.79	-0.35	4.99e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4363385	0.818	rs10888524	chr1:153000125	A/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.11	-0.36	7.29e-12	Inflammatory skin disease;
LUSC	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg18129178	chr5:148520854	ABLIM3	-0.68	-10.92	-0.51	6.06e-24	Breast cancer;
LUSC	cis	rs4664304	0.595	rs2667004	chr2:160862094	G/A	cg03641300	chr2:160917029	PLA2R1	-0.37	-6.03	-0.31	4.42e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg14440974	chr22:39074834	NA	-0.37	-5.98	-0.31	5.75e-9	Menopause (age at onset);
LUSC	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg24558204	chr6:135376177	HBS1L	0.68	10.65	0.5	5.53e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg17042849	chr6:26104293	HIST1H4C	-0.5	-5.87	-0.31	1.06e-8	Iron status biomarkers;
LUSC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10802521	chr3:52805072	NEK4	-0.51	-8.52	-0.42	5.37e-16	Bipolar disorder;
LUSC	cis	rs3736594	0.513	rs59876138	chr2:27792323	A/C	cg27432699	chr2:27873401	GPN1	0.66	8.89	0.44	3.99e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg08917208	chr2:24149416	ATAD2B	1.01	10.6	0.5	8.3300000000000006e-23	Lymphocyte counts;
LUSC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.97	-21.38	-0.76	1.61e-64	Prudent dietary pattern;
LUSC	cis	rs4845570	0.831	rs11588634	chr1:151780686	T/A	cg07092448	chr1:151763213	TDRKH	-1.18	-12.3	-0.56	6.06e-29	Coronary artery disease;
LUSC	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg12311346	chr5:56204834	C5orf35	-0.57	-8.78	-0.43	8.57e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs2742234	0.541	rs871763	chr10:43734188	C/T	cg15436174	chr10:43711423	RASGEF1A	0.43	7.05	0.36	1.03e-11	Hirschsprung disease;
LUSC	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg22674798	chr1:3096360	PRDM16	-0.31	-7.03	-0.36	1.18e-11	Migraine;
LUSC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.75	-9.51	-0.46	3.93e-19	Gut microbiome composition (summer);
LUSC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.69	10.07	0.48	5.12e-21	IgG glycosylation;
LUSC	cis	rs2708377	0.656	rs73066852	chr12:11276541	A/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.81	7.9	0.4	4.08e-14	Bitter taste perception;
LUSC	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.91	-14.34	-0.62	1.12e-36	Prostate cancer;
LUSC	cis	rs1775715	0.966	rs1755067	chr10:32296195	C/T	cg04359828	chr10:32216031	ARHGAP12	-0.36	-6.09	-0.32	3.14e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7572644	0.679	rs4447576	chr2:28076248	T/C	cg27432699	chr2:27873401	GPN1	0.51	6.96	0.36	1.78e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg19230755	chr7:65878503	NA	0.43	6.1	0.32	3.01e-9	Aortic root size;
LUSC	trans	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20504077	chr8:27472321	CLU	0.8	6.31	0.33	9e-10	Cognitive performance;
LUSC	cis	rs939658	0.683	rs1434459	chr15:79465210	T/C	cg17916960	chr15:79447300	NA	-0.43	-7.98	-0.4	2.39e-14	Refractive error;
LUSC	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg02403541	chr12:121454288	C12orf43	0.61	8.7	0.43	1.53e-16	N-glycan levels;
LUSC	trans	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.28	-0.32	1.04e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs17095355	1.000	rs12570607	chr10:111696704	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.57	-7.06	-0.36	9.89e-12	Biliary atresia;
LUSC	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg12573674	chr2:1569213	NA	0.56	6.19	0.32	1.81e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.31	6.05	0.31	3.86e-9	Lymphocyte counts;
LUSC	cis	rs716595	0.867	rs3793885	chr10:111988578	T/G	cg13996003	chr10:112034540	MXI1	-0.7	-5.81	-0.3	1.42e-8	Normalized brain volume;
LUSC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg13397359	chr6:42928475	GNMT	0.57	9.53	0.46	3.32e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.89	-0.31	9.61e-9	Ulcerative colitis;
LUSC	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg25554036	chr4:6271136	WFS1	0.59	11.89	0.55	1.97e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg16797656	chr11:68205561	LRP5	0.38	6.22	0.32	1.48e-9	Total body bone mineral density;
LUSC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08859206	chr1:53392774	SCP2	-0.55	-9.55	-0.46	2.86e-19	Monocyte count;
LUSC	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg13010199	chr12:38710504	ALG10B	0.56	8.32	0.41	2.26e-15	Morning vs. evening chronotype;
LUSC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg14500267	chr11:67383377	NA	0.35	6.61	0.34	1.54e-10	Mean corpuscular volume;
LUSC	cis	rs713477	1.000	rs2185036	chr14:55907710	A/G	cg13175173	chr14:55914753	NA	-0.32	-6.67	-0.34	1.07e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg13560548	chr3:10150139	C3orf24	0.53	7.37	0.37	1.39e-12	Alzheimer's disease;
LUSC	cis	rs6740322	0.793	rs13414908	chr2:43546658	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-7.51	-0.38	5.33e-13	Coronary artery disease;
LUSC	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg20587970	chr11:113659929	NA	-1.18	-11.79	-0.54	4.77e-27	Height;
LUSC	cis	rs9473147	0.516	rs9395283	chr6:47551444	T/C	cg12968598	chr6:47444699	CD2AP	0.52	8.04	0.4	1.6e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg05110241	chr16:68378359	PRMT7	-0.58	-6.62	-0.34	1.41e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.54	-9.73	-0.47	7.17e-20	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg02807482	chr3:125708958	NA	-0.49	-6.65	-0.34	1.18e-10	Blood pressure (smoking interaction);
LUSC	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.25	-0.37	2.97e-12	Menopause (age at onset);
LUSC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg13866156	chr1:1669148	SLC35E2	-0.51	-8.31	-0.41	2.4e-15	Body mass index;
LUSC	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg20026190	chr17:76395443	PGS1	0.42	7.64	0.39	2.35e-13	HDL cholesterol levels;
LUSC	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg21466736	chr12:48725269	NA	-0.31	-5.71	-0.3	2.52e-8	Glycated hemoglobin levels;
LUSC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg06784218	chr1:46089804	CCDC17	0.54	10.7	0.51	3.57e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg23711669	chr6:146136114	FBXO30	0.77	13.3	0.59	1.09e-32	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.6	-0.38	2.96e-13	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LUSC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg13319975	chr6:146136371	FBXO30	0.53	8.01	0.4	1.87e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2200578	0.786	rs62154639	chr2:99646954	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.56	6.53	0.34	2.42e-10	IgG glycosylation;
LUSC	cis	rs9811920	0.695	rs1287284	chr3:99516962	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-7.29	-0.37	2.28e-12	Axial length;
LUSC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg12935359	chr14:103987150	CKB	-0.52	-8.0	-0.4	2.04e-14	Body mass index;
LUSC	cis	rs4948275	0.550	rs10994742	chr10:63132240	A/T	cg02461363	chr10:63212496	TMEM26	-0.37	-6.0	-0.31	5.27e-9	Night sleep phenotypes;
LUSC	cis	rs1775715	0.870	rs1251407	chr10:32238325	A/G	cg04359828	chr10:32216031	ARHGAP12	0.39	6.64	0.34	1.26e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg18755752	chr8:142205143	DENND3	0.38	5.67	0.3	3.11e-8	Immature fraction of reticulocytes;
LUSC	cis	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg06521331	chr12:34319734	NA	-0.41	-6.74	-0.35	6.92e-11	Morning vs. evening chronotype;
LUSC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg09877947	chr5:131593287	PDLIM4	0.47	7.72	0.39	1.39e-13	Breast cancer;
LUSC	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	5.86	0.31	1.09e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg13246856	chr1:44399776	ARTN	0.32	6.9	0.35	2.68e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs3755132	0.929	rs6431721	chr2:15791937	C/T	cg12888861	chr2:15731646	DDX1	0.49	7.12	0.36	6.47e-12	Wilms tumor;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07853084	chr13:73632891	KLF5	-0.46	-5.97	-0.31	6.08e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg21775007	chr8:11205619	TDH	-0.49	-6.82	-0.35	4.16e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LUSC	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg23277830	chr1:3704460	LRRC47	0.35	6.55	0.34	2.14e-10	Red cell distribution width;
LUSC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg13560548	chr3:10150139	C3orf24	0.49	6.85	0.35	3.53e-11	Alzheimer's disease;
LUSC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.5	-0.34	2.94e-10	Alzheimer's disease (late onset);
LUSC	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	1.14	19.67	0.73	9.55e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs870825	0.929	rs72689269	chr4:185592085	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	11.74	0.54	6.98e-27	Blood protein levels;
LUSC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03352830	chr11:487213	PTDSS2	0.69	8.64	0.43	2.43e-16	Body mass index;
LUSC	cis	rs71403859	0.614	rs12149533	chr16:71801946	C/T	cg08717414	chr16:71523259	ZNF19	-0.66	-6.96	-0.36	1.77e-11	Post bronchodilator FEV1;
LUSC	trans	rs75804782	0.641	rs72983834	chr2:239319895	G/A	cg01134436	chr17:81009848	B3GNTL1	0.64	6.08	0.32	3.37e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg14582100	chr15:45693742	SPATA5L1	0.45	8.5	0.42	6.48e-16	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs7980799	0.653	rs11052722	chr12:33626530	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-8.0	-0.4	2.11e-14	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05025164	chr4:1340916	KIAA1530	0.41	6.41	0.33	5.01e-10	Obesity-related traits;
LUSC	cis	rs7428496	0.510	rs12638158	chr3:142306165	A/G	cg16271453	chr3:142027066	XRN1	-0.48	-8.1	-0.41	1.07e-14	Mean corpuscular hemoglobin;
LUSC	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg06197492	chr11:2016605	H19	0.42	6.83	0.35	4.03e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs3105593	0.635	rs3131567	chr15:50757930	A/T	cg08437265	chr15:50716283	USP8	0.38	5.73	0.3	2.3e-8	QT interval;
LUSC	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg05754148	chr16:3507555	NAT15	-0.55	-7.92	-0.4	3.63e-14	Tuberculosis;
LUSC	cis	rs9311171	0.689	rs6790217	chr3:37949176	G/T	cg12605080	chr3:37966887	CTDSPL	-0.35	-6.81	-0.35	4.62e-11	Prostate cancer;
LUSC	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.82	0.43	6.31e-17	Menopause (age at onset);
LUSC	trans	rs6600671	1.000	rs10903161	chr1:121178741	A/T	cg00646200	chr1:148855367	NA	0.47	7.54	0.38	4.61e-13	Hip geometry;
LUSC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	0.93	15.69	0.65	5.75e-42	Menopause (age at onset);
LUSC	cis	rs7202877	0.610	rs3844219	chr16:75370230	G/T	cg04384234	chr16:75411784	CFDP1	-0.64	-8.94	-0.44	2.73e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs4356932	1.000	rs13130018	chr4:76955519	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs7681440	0.647	rs1442133	chr4:90819195	C/T	cg01966878	chr4:90757139	SNCA	-0.35	-5.67	-0.3	3.04e-8	Dementia with Lewy bodies;
LUSC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg01620082	chr3:125678407	NA	-0.75	-7.45	-0.38	8.11e-13	Depression;
LUSC	cis	rs7903847	0.642	rs7918948	chr10:99124975	G/A	cg20016023	chr10:99160130	RRP12	-0.28	-6.18	-0.32	1.85e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg11752832	chr7:134001865	SLC35B4	0.56	8.65	0.43	2.2e-16	Mean platelet volume;
LUSC	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.09	-0.36	7.93e-12	Morning vs. evening chronotype;
LUSC	cis	rs701145	0.585	rs1727948	chr3:153876929	G/T	cg17054900	chr3:154042577	DHX36	0.72	7.32	0.37	1.9e-12	Coronary artery disease;
LUSC	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.12	-19.37	-0.73	1.41e-56	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.79	-0.47	4.53e-20	Hemoglobin concentration;
LUSC	trans	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg18335740	chr13:41363409	SLC25A15	0.76	13.66	0.6	4.82e-34	Lewy body disease;
LUSC	cis	rs6489882	0.867	rs4766672	chr12:113365148	A/G	cg20102336	chr12:113376681	OAS3	-0.42	-6.05	-0.31	3.78e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg08742575	chr21:47604166	C21orf56	0.43	6.4	0.33	5.33e-10	Testicular germ cell tumor;
LUSC	cis	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg06521331	chr12:34319734	NA	-0.47	-7.63	-0.39	2.42e-13	Morning vs. evening chronotype;
LUSC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-0.81	-15.8	-0.65	2.26e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg18904891	chr8:8559673	CLDN23	-0.37	-5.9	-0.31	8.68e-9	Mood instability;
LUSC	trans	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg10756647	chr7:56101905	PSPH	0.85	8.47	0.42	7.94e-16	Gout;
LUSC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	7.85	0.39	5.61e-14	Prudent dietary pattern;
LUSC	cis	rs11997175	0.580	rs34398087	chr8:33813800	A/G	ch.8.33884649F	chr8:33765107	NA	-0.41	-6.14	-0.32	2.4e-9	Body mass index;
LUSC	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	5.85	0.3	1.16e-8	Neuroticism;
LUSC	cis	rs17095355	1.000	rs752584	chr10:111682934	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.64	-7.24	-0.37	3.03e-12	Biliary atresia;
LUSC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-0.93	-10.31	-0.49	7.79e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs71403859	0.803	rs7203606	chr16:71590511	A/C	cg08717414	chr16:71523259	ZNF19	-0.74	-8.19	-0.41	5.46e-15	Post bronchodilator FEV1;
LUSC	cis	rs7789940	0.809	rs12533836	chr7:75935622	G/T	cg10167463	chr7:75959203	YWHAG	-0.61	-8.96	-0.44	2.4e-17	Multiple sclerosis;
LUSC	cis	rs939658	0.626	rs11631406	chr15:79445789	C/T	cg17916960	chr15:79447300	NA	-0.46	-9.06	-0.44	1.11e-17	Refractive error;
LUSC	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg03342759	chr3:160939853	NMD3	-0.51	-8.49	-0.42	6.66e-16	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	14.99	0.63	3.42e-39	Platelet count;
LUSC	trans	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg07393940	chr7:158741817	NA	0.53	8.22	0.41	4.42e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.74	0.35	6.9e-11	Endometrial cancer;
LUSC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10802521	chr3:52805072	NEK4	-0.57	-8.94	-0.44	2.78e-17	Bipolar disorder;
LUSC	cis	rs3820068	0.608	rs12091750	chr1:16042766	T/C	cg13390004	chr1:15929781	NA	0.42	6.82	0.35	4.38e-11	Systolic blood pressure;
LUSC	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg09953122	chr20:23471693	CST8	-0.9	-7.18	-0.37	4.55e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg02503808	chr4:7069936	GRPEL1	1.05	14.94	0.63	5.16e-39	Monocyte percentage of white cells;
LUSC	cis	rs4631830	0.863	rs4554834	chr10:51530146	A/C	cg20129853	chr10:51489980	NA	-0.34	-6.86	-0.35	3.36e-11	Prostate-specific antigen levels;
LUSC	cis	rs548181	0.545	rs1054997	chr11:125618813	G/A	cg03464685	chr11:125439445	EI24	-0.93	-10.96	-0.51	4.55e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.31	0.53	2.59e-25	Morning vs. evening chronotype;
LUSC	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg03453431	chr7:157225567	NA	-0.58	-10.43	-0.5	3e-22	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg08017756	chr2:100939284	LONRF2	-0.44	-8.36	-0.42	1.7e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.92	0.35	2.38e-11	Height;
LUSC	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-9.32	-0.45	1.67e-18	Coffee consumption (cups per day);
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.64	-12.45	-0.56	1.76e-29	Longevity;Endometriosis;
LUSC	cis	rs1005224	0.927	rs8007792	chr14:76175666	C/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.59	-8.1	-0.41	1.07e-14	Large artery stroke;
LUSC	cis	rs1712517	0.744	rs11191641	chr10:105052940	C/T	cg05636881	chr10:105038444	INA	0.39	6.32	0.33	8.31e-10	Migraine;
LUSC	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.71e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1007190	0.881	rs9900293	chr17:42936003	G/C	cg15406952	chr17:42872593	NA	0.56	5.69	0.3	2.75e-8	DNA methylation (variation);
LUSC	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg11584989	chr19:19387371	SF4	0.61	7.17	0.37	5e-12	Bipolar disorder;
LUSC	cis	rs4654899	0.785	rs12070677	chr1:21337322	A/G	cg01072550	chr1:21505969	NA	-0.53	-8.16	-0.41	7.06e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.84	0.39	6.27e-14	Bipolar disorder;
LUSC	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg22508957	chr16:3507546	NAT15	-0.39	-6.05	-0.31	3.95e-9	Body mass index (adult);
LUSC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.84	-0.35	3.84e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14442939	chr10:27389572	ANKRD26	0.91	9.5	0.46	4.2e-19	Breast cancer;
LUSC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs4356932	1.000	rs4359937	chr4:76972155	G/A	cg00809888	chr4:76862425	NAAA	0.36	5.98	0.31	5.81e-9	Blood protein levels;
LUSC	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.01	0.52	2.93e-24	Hypertriglyceridemia;
LUSC	cis	rs8067287	0.762	rs11649835	chr17:16823541	C/G	cg26910001	chr17:16838321	NA	-0.48	-6.27	-0.32	1.11e-9	Diabetic kidney disease;
LUSC	cis	rs7923609	0.841	rs2163188	chr10:65314711	G/C	cg01631684	chr10:65280961	REEP3	0.41	6.05	0.31	3.84e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4290604	0.596	rs7566199	chr2:238053391	A/G	cg23555395	chr2:238036564	NA	-0.52	-6.94	-0.35	2.07e-11	Asthma;
LUSC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg25767906	chr1:53392781	SCP2	0.44	7.76	0.39	1.08e-13	Monocyte count;
LUSC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg04727924	chr7:799746	HEATR2	-0.55	-6.7	-0.34	8.94e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.81	10.54	0.5	1.31e-22	Alzheimer's disease;
LUSC	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg17764715	chr19:33622953	WDR88	0.6	8.29	0.41	2.72e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg13319975	chr6:146136371	FBXO30	0.49	7.36	0.37	1.42e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg21659725	chr3:3221576	CRBN	0.69	8.05	0.4	1.42e-14	Menarche (age at onset);
LUSC	cis	rs34421088	0.506	rs2409755	chr8:11169983	G/A	cg21775007	chr8:11205619	TDH	0.47	6.93	0.35	2.22e-11	Neuroticism;
LUSC	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg23950597	chr19:37808831	NA	0.63	7.73	0.39	1.27e-13	Coronary artery calcification;
LUSC	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg10560079	chr2:191398806	TMEM194B	-0.66	-8.08	-0.4	1.18e-14	Diastolic blood pressure;
LUSC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.86	0.6	7.98e-35	Breast cancer;
LUSC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg13607699	chr17:42295918	UBTF	0.52	8.23	0.41	4.32e-15	Total body bone mineral density;
LUSC	cis	rs8017423	0.626	rs8003363	chr14:90826840	T/C	cg04374321	chr14:90722782	PSMC1	-0.42	-6.23	-0.32	1.42e-9	Mortality in heart failure;
LUSC	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg03948781	chr1:205179583	DSTYK	0.29	5.74	0.3	2.08e-8	Red blood cell count;
LUSC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06634786	chr22:41940651	POLR3H	-0.55	-6.2	-0.32	1.66e-9	Vitiligo;
LUSC	cis	rs2046867	0.818	rs11929144	chr3:72868234	T/C	cg04365224	chr3:72788183	NA	-0.45	-6.05	-0.31	3.93e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2324229	0.861	rs983087	chr6:83954264	T/C	cg08257003	chr6:84140564	ME1	0.26	5.95	0.31	6.59e-9	Platelet-derived growth factor BB levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14031059	chr19:19626956	NDUFA13;TSSK6	-0.47	-6.26	-0.32	1.16e-9	Hepatitis;
LUSC	cis	rs62400317	0.556	rs10948196	chr6:44959384	A/T	cg20913747	chr6:44695427	NA	-0.35	-5.72	-0.3	2.4e-8	Total body bone mineral density;
LUSC	cis	rs2963155	0.518	rs862489	chr5:142634355	T/C	cg17617527	chr5:142782415	NR3C1	0.7	8.24	0.41	3.96e-15	Breast cancer;
LUSC	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg10255544	chr17:80519551	FOXK2	-0.39	-6.43	-0.33	4.54e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg06784218	chr1:46089804	CCDC17	0.54	10.88	0.51	8.41e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg00945038	chr17:61921165	SMARCD2	0.54	9.39	0.46	9.68e-19	Prudent dietary pattern;
LUSC	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg05283184	chr6:79620031	NA	-0.45	-8.44	-0.42	9.95e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg08888203	chr3:10149979	C3orf24	0.65	8.86	0.44	4.67e-17	Alzheimer's disease;
LUSC	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.77	0.51	2.06e-23	Morning vs. evening chronotype;
LUSC	cis	rs6076065	0.748	rs1016628	chr20:23398738	C/G	cg11657817	chr20:23433608	CST11	-0.51	-10.4	-0.49	3.83e-22	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7000551	0.689	rs2449339	chr8:22387981	G/A	cg12081754	chr8:22256438	SLC39A14	0.44	6.7	0.34	8.86e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg09796270	chr17:17721594	SREBF1	-0.42	-7.41	-0.38	1.01e-12	Total body bone mineral density;
LUSC	cis	rs7178572	0.633	rs12901130	chr15:77848806	C/T	cg22256960	chr15:77711686	NA	-0.51	-7.41	-0.38	1.02e-12	Type 2 diabetes;
LUSC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg04398451	chr17:18023971	MYO15A	-0.48	-7.63	-0.39	2.43e-13	Total body bone mineral density;
LUSC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg08847533	chr14:75593920	NEK9	0.81	14.12	0.61	8.1e-36	Height;
LUSC	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.75	0.51	2.4e-23	Bladder cancer;
LUSC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg02782426	chr3:40428986	ENTPD3	-0.39	-7.6	-0.38	3.05e-13	Renal cell carcinoma;
LUSC	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg26384229	chr12:38710491	ALG10B	0.73	11.95	0.55	1.17e-27	Morning vs. evening chronotype;
LUSC	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg15654264	chr1:150340011	RPRD2	0.67	10.69	0.51	3.79e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg00033643	chr7:134001901	SLC35B4	-0.4	-5.84	-0.3	1.26e-8	Mean platelet volume;
LUSC	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg07549590	chr16:15018862	NA	-0.57	-9.67	-0.47	1.13e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg09165964	chr15:75287851	SCAMP5	0.52	7.59	0.38	3.32e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs28647808	0.618	rs7025970	chr9:136267173	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg10434728	chr15:90938212	IQGAP1	-0.44	-8.87	-0.44	4.44e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg04995722	chr7:26192034	NFE2L3	0.36	6.01	0.31	4.92e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11039100	0.920	rs12792905	chr11:5821544	G/C	cg13902645	chr11:5959945	NA	-0.53	-5.94	-0.31	7.09e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs2048656	0.535	rs2014514	chr8:9647196	A/T	cg06636001	chr8:8085503	FLJ10661	0.51	7.59	0.38	3.1400000000000003e-13	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg06238570	chr21:40685208	BRWD1	0.46	7.08	0.36	8.78e-12	Cognitive function;
LUSC	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg25801113	chr15:45476975	SHF	0.34	7.0	0.36	1.37e-11	Uric acid levels;
LUSC	cis	rs7917772	0.715	rs7077678	chr10:104438565	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.46	6.34	0.33	7.61e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs28655083	0.529	rs645878	chr16:77099974	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.38	6.15	0.32	2.24e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.93	-19.27	-0.73	3.69e-56	Monocyte count;
LUSC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06850241	chr22:41845214	NA	-0.32	-5.81	-0.3	1.46e-8	Vitiligo;
LUSC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg21132104	chr15:45694354	SPATA5L1	0.57	7.96	0.4	2.63e-14	Homoarginine levels;
LUSC	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg13010199	chr12:38710504	ALG10B	0.63	9.67	0.47	1.14e-19	Bladder cancer;
LUSC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg09365446	chr1:150670422	GOLPH3L	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.76	-0.43	9.87e-17	Response to antipsychotic treatment;
LUSC	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg20026190	chr17:76395443	PGS1	0.45	8.17	0.41	6.52e-15	HDL cholesterol levels;
LUSC	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg09835421	chr16:68378352	PRMT7	-0.75	-8.42	-0.42	1.13e-15	Schizophrenia;
LUSC	cis	rs7590720	1.000	rs4674048	chr2:216900023	G/A	cg12620499	chr2:216877984	MREG	0.93	14.19	0.61	4.21e-36	Alcohol dependence;
LUSC	trans	rs62238980	0.614	rs2006867	chr22:32384307	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.89	-13.77	-0.6	1.79e-34	Prostate cancer;
LUSC	cis	rs12900413	0.959	rs11632886	chr15:90322945	A/G	cg24249390	chr15:90295951	MESP1	-0.43	-6.33	-0.33	7.69e-10	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg22815214	chr1:201083145	CACNA1S	-0.49	-8.61	-0.43	3.03e-16	Permanent tooth development;
LUSC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.89	0.35	2.81e-11	Tonsillectomy;
LUSC	cis	rs2658782	0.789	rs3020057	chr11:93118515	C/T	cg15737290	chr11:93063684	CCDC67	0.63	7.86	0.39	5.48e-14	Pulmonary function decline;
LUSC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg07332563	chr6:291687	DUSP22	-0.51	-7.88	-0.4	4.82e-14	Menopause (age at onset);
LUSC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	14.05	0.61	1.44e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg09904177	chr6:26538194	HMGN4	-0.48	-6.91	-0.35	2.53e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	7.64	0.39	2.25e-13	Iron status biomarkers;
LUSC	cis	rs939658	0.805	rs11631590	chr15:79446199	C/T	cg17916960	chr15:79447300	NA	-0.54	-10.99	-0.52	3.33e-24	Refractive error;
LUSC	cis	rs887829	0.694	rs6749496	chr2:234624286	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.12	-0.41	8.83e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs1044826	0.642	rs176983	chr3:139213755	G/A	cg00490450	chr3:139108681	COPB2	0.46	6.99	0.36	1.51e-11	Obesity-related traits;
LUSC	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg13256891	chr4:100009986	ADH5	-0.49	-6.37	-0.33	6.11e-10	Alcohol dependence;
LUSC	cis	rs7043114	0.525	rs10761161	chr9:95262342	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.66	-0.34	1.12e-10	Height;
LUSC	cis	rs2463822	0.844	rs7104149	chr11:62171627	A/G	cg06239285	chr11:62104954	ASRGL1	-0.98	-10.33	-0.49	6.59e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04720380	chr1:93297552	RPL5	-0.45	-6.68	-0.34	9.84e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg07395648	chr5:131743802	NA	0.37	5.8	0.3	1.52e-8	Asthma (sex interaction);
LUSC	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg16576597	chr16:28551801	NUPR1	0.28	5.72	0.3	2.37e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.78	11.21	0.52	5.56e-25	Corneal astigmatism;
LUSC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg15556689	chr8:8085844	FLJ10661	0.58	8.76	0.43	9.73e-17	Mood instability;
LUSC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.88	0.48	2.37e-20	Bipolar disorder;
LUSC	cis	rs6580649	0.941	rs3742074	chr12:48457385	C/T	cg24011408	chr12:48396354	COL2A1	-0.45	-6.07	-0.32	3.47e-9	Lung cancer;
LUSC	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg17385448	chr1:15911702	AGMAT	0.36	5.97	0.31	5.92e-9	Systolic blood pressure;
LUSC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg15448220	chr1:150897856	SETDB1	0.41	6.06	0.31	3.75e-9	Melanoma;
LUSC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg05941027	chr17:61774174	LIMD2	0.22	5.87	0.31	1.04e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.94	0.35	2.07e-11	Iron status biomarkers;
LUSC	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg13010199	chr12:38710504	ALG10B	0.58	9.23	0.45	3.24e-18	Morning vs. evening chronotype;
LUSC	cis	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg26384229	chr12:38710491	ALG10B	-0.6	-8.96	-0.44	2.41e-17	Bladder cancer;
LUSC	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.96	-0.36	1.8e-11	Response to antipsychotic treatment;
LUSC	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg17757837	chr7:157058334	UBE3C	-0.82	-13.31	-0.59	1.01e-32	Body mass index;
LUSC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg23205692	chr1:25664452	TMEM50A	0.42	6.26	0.32	1.21e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs17102423	0.826	rs12887607	chr14:65596887	G/A	cg11161011	chr14:65562177	MAX	-0.73	-11.0	-0.52	3.18e-24	Obesity-related traits;
LUSC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg02951883	chr7:2050386	MAD1L1	-0.38	-6.72	-0.35	7.97e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg08999081	chr20:33150536	PIGU	0.54	10.57	0.5	1.03e-22	Coronary artery disease;
LUSC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg08847533	chr14:75593920	NEK9	0.84	15.4	0.64	8.01e-41	Height;
LUSC	cis	rs983392	0.709	rs7928895	chr11:59975165	G/A	cg02771260	chr11:59836817	MS4A3	-0.37	-6.01	-0.31	4.95e-9	Alzheimer's disease (late onset);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21036854	chr14:77506705	NA	-0.4	-6.07	-0.32	3.5e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs3770081	1.000	rs58898686	chr2:86216909	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.98	-6.43	-0.33	4.34e-10	Facial emotion recognition (sad faces);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02184338	chr7:101331866	NA	-0.52	-6.5	-0.34	2.91e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg16482183	chr6:26056742	HIST1H1C	1.06	13.53	0.6	1.45e-33	Iron status biomarkers;
LUSC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg22535103	chr8:58192502	C8orf71	-0.7	-7.45	-0.38	8.32e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg03146154	chr1:46216737	IPP	0.57	8.51	0.42	6.03e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4588572	0.644	rs1428864	chr5:77780263	C/T	cg11547950	chr5:77652471	NA	-0.4	-5.81	-0.3	1.48e-8	Triglycerides;
LUSC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.56	0.38	3.81e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7172677	1.000	rs2029520	chr15:75415768	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.82	-0.3	1.35e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg22676075	chr6:135203613	NA	-0.64	-10.15	-0.49	2.93e-21	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg06808227	chr14:105710500	BRF1	-0.7	-11.07	-0.52	1.8e-24	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg15147215	chr3:52552868	STAB1	-0.32	-6.36	-0.33	6.45e-10	Bipolar disorder;
LUSC	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.82	0.3	1.34e-8	Rheumatoid arthritis;
LUSC	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg01620082	chr3:125678407	NA	-0.75	-7.26	-0.37	2.81e-12	Depression;
LUSC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24549020	chr5:56110836	MAP3K1	0.49	5.96	0.31	6.33e-9	Initial pursuit acceleration;
LUSC	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21659725	chr3:3221576	CRBN	0.63	10.36	0.49	5.2e-22	Intelligence (multi-trait analysis);
LUSC	trans	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg08949735	chr16:89699720	DPEP1	-0.23	-5.81	-0.3	1.46e-8	Vitiligo;
LUSC	cis	rs977987	0.806	rs4888390	chr16:75400320	G/A	cg04384234	chr16:75411784	CFDP1	-0.42	-6.94	-0.36	2e-11	Dupuytren's disease;
LUSC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg03690763	chr11:133734501	NA	0.37	6.71	0.34	8.52e-11	Childhood ear infection;
LUSC	cis	rs7119038	0.865	rs7117261	chr11:118741157	T/C	cg19308663	chr11:118741387	NA	-0.35	-5.93	-0.31	7.59e-9	Sjögren's syndrome;
LUSC	cis	rs7216064	0.953	rs1966410	chr17:65837215	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-9.44	-0.46	6.6e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs4280164	0.551	rs8008406	chr14:24811159	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.53	6.87	0.35	3.25e-11	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.69	0.75	8.37e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg11645453	chr3:52864694	ITIH4	0.35	7.99	0.4	2.28e-14	Bipolar disorder;
LUSC	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.43	0.46	7.11e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg07701084	chr6:150067640	NUP43	0.56	8.39	0.42	1.36e-15	Lung cancer;
LUSC	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg17848003	chr1:3704513	LRRC47	0.34	6.5	0.34	2.9e-10	Red cell distribution width;
LUSC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20307385	chr11:47447363	PSMC3	-0.44	-5.8	-0.3	1.5e-8	Subjective well-being;
LUSC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg08088566	chr11:430123	ANO9	0.6	7.04	0.36	1.09e-11	Body mass index;
LUSC	cis	rs3820928	0.904	rs60906902	chr2:227760034	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.72	-0.39	1.36e-13	Pulmonary function;
LUSC	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg22681709	chr2:178499509	PDE11A	0.38	5.84	0.3	1.26e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs79387448	0.745	rs7582378	chr2:103162263	C/A	cg09003973	chr2:102972529	NA	0.88	8.56	0.42	4.18e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	0.84	11.81	0.54	3.83e-27	Eosinophil percentage of granulocytes;
LUSC	trans	rs12692738	0.526	rs355850	chr2:165626043	C/T	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs67696533	0.600	rs879829	chr20:31114479	G/A	cg13636640	chr20:31349939	DNMT3B	0.46	6.11	0.32	2.71e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.72	-9.91	-0.48	1.76e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs10979	1.000	rs9403505	chr6:143885841	A/G	cg25407410	chr6:143891975	LOC285740	-0.73	-11.85	-0.54	2.87e-27	Hypospadias;
LUSC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07256732	chr16:621771	PIGQ	-0.35	-6.18	-0.32	1.9e-9	Height;
LUSC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg15181151	chr6:150070149	PCMT1	0.26	5.81	0.3	1.43e-8	Lung cancer;
LUSC	cis	rs6445797	0.589	rs11715395	chr3:56681949	G/A	cg13792233	chr3:56591045	CCDC66	0.41	5.68	0.3	2.89e-8	Gastritis;
LUSC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg19257562	chr1:2043853	PRKCZ	0.31	6.19	0.32	1.77e-9	Height;
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.73	-0.39	1.31e-13	Lymphocyte counts;
LUSC	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg14703610	chr5:56206110	C5orf35	0.4	5.73	0.3	2.23e-8	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21724239	chr8:58056113	NA	0.83	10.01	0.48	8.33e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg05360949	chr19:41903737	BCKDHA;EXOSC5	-0.4	-5.67	-0.3	3.15e-8	Height;
LUSC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg21132104	chr15:45694354	SPATA5L1	0.57	7.96	0.4	2.63e-14	Homoarginine levels;
LUSC	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.33	-5.66	-0.3	3.21e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7712401	0.562	rs2407403	chr5:122174031	C/T	cg19077854	chr5:122220652	SNX24	0.41	9.33	0.45	1.47e-18	Mean platelet volume;
LUSC	cis	rs3820928	1.000	rs7592387	chr2:227777095	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.96	-0.4	2.8e-14	Pulmonary function;
LUSC	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg16989719	chr2:238392110	NA	-0.42	-7.23	-0.37	3.41e-12	Prostate cancer;
LUSC	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg08847533	chr14:75593920	NEK9	0.82	15.25	0.64	3.1e-40	Height;
LUSC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.32	0.33	8.29e-10	Height;
LUSC	cis	rs1775715	0.737	rs2799000	chr10:32124894	C/T	cg18675610	chr10:32216311	ARHGAP12	0.29	6.34	0.33	7.56e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg08017756	chr2:100939284	LONRF2	-0.44	-8.27	-0.41	3.33e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg20203395	chr5:56204925	C5orf35	0.52	7.24	0.37	3.2e-12	Coronary artery disease;
LUSC	cis	rs6681460	1.000	rs964574	chr1:67062885	T/C	cg02459107	chr1:67143332	SGIP1	0.47	8.83	0.44	5.8e-17	Presence of antiphospholipid antibodies;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02004021	chr12:95868393	METAP2	0.47	6.47	0.33	3.41e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4713118	0.869	rs9295743	chr6:27715102	G/C	cg20933634	chr6:27740509	NA	0.41	5.88	0.31	9.8e-9	Parkinson's disease;
LUSC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.79	0.39	8.73e-14	Prudent dietary pattern;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.39	6.25	0.32	1.22e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-5.78	-0.3	1.67e-8	Subjective well-being;
LUSC	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg19682013	chr15:45996608	NA	0.39	5.84	0.3	1.24e-8	Waist circumference;Weight;
LUSC	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg18129178	chr5:148520854	ABLIM3	-0.66	-10.32	-0.49	7.39e-22	Breast cancer;
LUSC	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg18132916	chr6:79620363	NA	-0.4	-6.14	-0.32	2.4e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs611744	0.658	rs2443774	chr8:109064957	T/C	cg18478394	chr8:109455254	TTC35	0.41	6.01	0.31	4.98e-9	Dupuytren's disease;
LUSC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg18402987	chr7:1209562	NA	0.65	7.38	0.37	1.23e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.77	-0.39	9.69e-14	Morning vs. evening chronotype;
LUSC	cis	rs35995292	0.534	rs28460817	chr7:38921917	T/C	cg19327137	chr7:38886074	VPS41	0.55	10.38	0.49	4.61e-22	Subjective well-being (multi-trait analysis);
LUSC	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg01191920	chr7:158217561	PTPRN2	0.42	8.35	0.42	1.81e-15	Obesity-related traits;
LUSC	cis	rs2273669	0.667	rs75942063	chr6:109352545	G/A	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	9.1e-9	Prostate cancer;
LUSC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg27165867	chr14:105738592	BRF1	-0.5	-7.46	-0.38	7.35e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07677032	chr17:61819896	STRADA	0.53	8.94	0.44	2.77e-17	Prudent dietary pattern;
LUSC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.05	0.64	1.96e-39	Platelet count;
LUSC	trans	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	6.9	0.35	2.67e-11	Menarche (age at onset);
LUSC	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg15744005	chr10:104629667	AS3MT	-0.34	-6.89	-0.35	2.84e-11	Arsenic metabolism;
LUSC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.88	-0.51	8.12e-24	Schizophrenia;
LUSC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.71	0.51	3.24e-23	Menopause (age at onset);
LUSC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg10621924	chr7:39171070	POU6F2	0.47	7.46	0.38	7.6e-13	IgG glycosylation;
LUSC	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	cis	rs6489882	0.703	rs10774672	chr12:113360737	G/T	cg20102336	chr12:113376681	OAS3	-0.4	-5.67	-0.3	3.1e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs7953249	1.000	rs7953249	chr12:121403724	A/G	cg02403541	chr12:121454288	C12orf43	0.62	9.53	0.46	3.44e-19	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs116988415	1.000	rs1012376	chr14:65294790	C/T	cg00114569	chr14:65239327	SPTB	0.53	5.71	0.3	2.53e-8	Daytime sleep phenotypes;
LUSC	trans	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg16660971	chr17:78860029	RPTOR	0.37	6.01	0.31	4.78e-9	Major depressive disorder;
LUSC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.91	0.51	6.64e-24	Monocyte percentage of white cells;
LUSC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.55	0.42	4.4e-16	Prudent dietary pattern;
LUSC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27286337	chr10:134555280	INPP5A	0.92	11.97	0.55	1.05e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.4	5.82	0.3	1.37e-8	Tonsillectomy;
LUSC	cis	rs6489882	0.867	rs6489876	chr12:113368055	G/A	cg20102336	chr12:113376681	OAS3	-0.4	-5.74	-0.3	2.17e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.93	-0.51	5.64e-24	Alzheimer's disease (late onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01435196	chr19:46009946	VASP	0.47	7.21	0.37	3.67e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs554111	0.656	rs6685914	chr1:21362378	G/A	cg01072550	chr1:21505969	NA	0.4	6.14	0.32	2.29e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-8.13	-0.41	8.66e-15	Response to antipsychotic treatment;
LUSC	cis	rs6546550	0.901	rs11893500	chr2:70154187	T/C	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.31	-0.37	2.02e-12	Prevalent atrial fibrillation;
LUSC	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg01733217	chr16:74700730	RFWD3	0.74	11.89	0.55	1.99e-27	Testicular germ cell tumor;
LUSC	cis	rs10992471	0.627	rs4744138	chr9:95291909	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.44	-0.33	4.18e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.4	5.75	0.3	2.04e-8	Lung cancer;
LUSC	trans	rs6968419	1.000	rs10245914	chr7:115817585	A/G	cg05268155	chr13:24844880	SPATA13	0.35	6.01	0.31	4.81e-9	Intraocular pressure;
LUSC	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg02569458	chr12:86230093	RASSF9	0.36	5.83	0.3	1.34e-8	Major depressive disorder;
LUSC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg13770153	chr20:60521292	NA	-0.48	-6.91	-0.35	2.47e-11	Body mass index;
LUSC	cis	rs9361491	0.510	rs1507151	chr6:79483246	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.06	-0.31	3.62e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3829109	0.564	rs11145910	chr9:139300494	A/G	cg14019695	chr9:139328340	INPP5E	0.38	5.89	0.31	9.48e-9	Peak insulin response;Acute insulin response;
LUSC	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg09654669	chr8:57350985	NA	-0.58	-7.79	-0.39	8.28e-14	Obesity-related traits;
LUSC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg24558204	chr6:135376177	HBS1L	0.59	9.05	0.44	1.18e-17	Red blood cell count;
LUSC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg18230493	chr5:56204884	C5orf35	-0.91	-13.91	-0.61	4.93e-35	Initial pursuit acceleration;
LUSC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg02018176	chr4:1364513	KIAA1530	0.48	8.47	0.42	8.06e-16	Obesity-related traits;
LUSC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.41	5.8	0.3	1.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2625529	0.712	rs2054601	chr15:72184968	T/C	cg16672083	chr15:72433130	SENP8	-0.5	-7.37	-0.37	1.33e-12	Red blood cell count;
LUSC	cis	rs4285028	0.699	rs6771068	chr3:121478745	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.92	12.51	0.56	1.02e-29	Multiple sclerosis;
LUSC	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg05925327	chr15:68127851	NA	-0.38	-5.9	-0.31	8.84e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs699371	0.507	rs10149538	chr14:74925397	A/G	cg16374328	chr14:74960395	NPC2;ISCA2	0.37	6.01	0.31	4.8e-9	Height;
LUSC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.54	0.57	8.15e-30	Prudent dietary pattern;
LUSC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg05347473	chr6:146136440	FBXO30	0.56	9.62	0.47	1.66e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg14019146	chr3:50243930	SLC38A3	0.36	8.29	0.41	2.81e-15	Body mass index;
LUSC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-7.32	-0.37	1.91e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg26668828	chr6:292823	DUSP22	-0.73	-12.11	-0.55	3.02e-28	Menopause (age at onset);
LUSC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg13072238	chr3:49761600	GMPPB	0.68	8.74	0.43	1.11e-16	Menarche (age at onset);
LUSC	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.09	-0.36	8.12e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg14895029	chr7:2775587	GNA12	0.42	6.59	0.34	1.68e-10	Height;
LUSC	cis	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.67	-0.3	3.05e-8	Ulcerative colitis;
LUSC	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.71	-12.99	-0.58	1.63e-31	Ulcerative colitis;
LUSC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg06640241	chr16:89574553	SPG7	0.7	11.09	0.52	1.49e-24	Multiple myeloma (IgH translocation);
LUSC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.46	0.33	3.71e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6700896	0.931	rs7546242	chr1:66093030	C/T	cg04111102	chr1:66153794	NA	0.31	6.84	0.35	3.68e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	11.76	0.54	5.94e-27	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1044826	1.000	rs2349059	chr3:139176932	C/T	cg00490450	chr3:139108681	COPB2	0.5	6.61	0.34	1.5e-10	Obesity-related traits;
LUSC	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg05110241	chr16:68378359	PRMT7	-0.77	-8.51	-0.42	5.76e-16	Schizophrenia;
LUSC	cis	rs9309711	0.813	rs11690865	chr2:3471950	C/T	cg10845886	chr2:3471009	TTC15	-0.6	-7.83	-0.39	6.63e-14	Neurofibrillary tangles;
LUSC	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	12.56	0.57	6.54e-30	Ileal carcinoids;
LUSC	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg09201001	chr11:18656081	SPTY2D1	0.91	14.82	0.63	1.53e-38	Breast cancer;
LUSC	cis	rs9888739	0.920	rs12920597	chr16:31304382	C/T	cg15817542	chr16:31343056	ITGAM	-0.54	-6.08	-0.32	3.28e-9	Systemic lupus erythematosus;
LUSC	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg11247378	chr22:39784982	NA	-0.67	-13.66	-0.6	4.72e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg14552801	chr7:65878734	NA	-0.43	-6.14	-0.32	2.38e-9	Aortic root size;
LUSC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.12	-0.32	2.62e-9	Initial pursuit acceleration;
LUSC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.87	0.63	9.38e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg03342759	chr3:160939853	NMD3	-0.47	-7.72	-0.39	1.4e-13	Morning vs. evening chronotype;
LUSC	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg08601574	chr20:25228251	PYGB	0.42	6.37	0.33	6.26e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg03522245	chr20:25566470	NINL	-0.35	-5.74	-0.3	2.18e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.81	0.43	6.77e-17	Axial length;
LUSC	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.27	-0.32	1.13e-9	Morning vs. evening chronotype;
LUSC	cis	rs354225	0.544	rs10183867	chr2:54812722	C/G	cg26097391	chr2:54893211	SPTBN1	0.43	6.47	0.33	3.5e-10	Schizophrenia;
LUSC	cis	rs662064	0.962	rs6540933	chr1:10547263	C/T	cg20482658	chr1:10539492	PEX14	-0.33	-6.65	-0.34	1.23e-10	Asthma;
LUSC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg02117656	chr17:79614917	TSPAN10	0.3	5.67	0.3	3.16e-8	Eye color traits;
LUSC	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg01858014	chr14:56050164	KTN1	-0.86	-7.18	-0.37	4.47e-12	Putamen volume;
LUSC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg17143192	chr8:8559678	CLDN23	0.59	8.49	0.42	6.84e-16	Obesity-related traits;
LUSC	cis	rs4843185	0.733	rs1049868	chr16:85706633	A/G	cg05245094	chr16:85669572	KIAA0182	0.39	5.79	0.3	1.63e-8	Platelet distribution width;
LUSC	cis	rs12210905	0.925	rs11966939	chr6:27003749	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-6.01	-0.31	4.99e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9831754	0.906	rs4680929	chr3:78387591	T/A	cg06138941	chr3:78371609	NA	-0.7	-9.49	-0.46	4.42e-19	Calcium levels;
LUSC	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg14689365	chr7:158441557	NCAPG2	0.5	7.15	0.36	5.43e-12	Height;
LUSC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	1.04	18.83	0.72	2.12e-54	Parkinson's disease;
LUSC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	0.7	12.27	0.56	8.09e-29	Gestational age at birth (maternal effect);
LUSC	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg25801113	chr15:45476975	SHF	0.35	7.09	0.36	8.23e-12	Uric acid levels;
LUSC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-6.25	-0.32	1.23e-9	IgG glycosylation;
LUSC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg14004847	chr7:1930337	MAD1L1	-0.66	-10.61	-0.5	7.67e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg26893861	chr17:41843967	DUSP3	0.94	14.48	0.62	3.22e-37	Triglycerides;
LUSC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.8	0.43	7.45e-17	Lung cancer;
LUSC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg14634687	chr17:47094252	IGF2BP1	0.31	6.54	0.34	2.26e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg23188684	chr11:67383651	NA	0.33	5.8	0.3	1.56e-8	Mean corpuscular volume;
LUSC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg15556689	chr8:8085844	FLJ10661	0.65	10.59	0.5	8.58e-23	Mood instability;
LUSC	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg07274523	chr3:49395745	GPX1	0.67	10.28	0.49	9.91e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs3774830	0.714	rs7657964	chr4:5466327	C/G	cg26943120	chr4:5472116	STK32B	-0.29	-5.76	-0.3	1.89e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-5.9	-0.31	8.86e-9	Schizophrenia;
LUSC	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-7.23	-0.37	3.22e-12	Menopause (age at onset);
LUSC	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.27	-0.37	2.57e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9341808	0.935	rs9343974	chr6:80924645	A/G	cg08355045	chr6:80787529	NA	0.54	9.48	0.46	4.94e-19	Sitting height ratio;
LUSC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg22868518	chr11:507468	RNH1	-0.58	-5.76	-0.3	1.95e-8	Body mass index;
LUSC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg23985595	chr17:80112537	CCDC57	0.31	5.88	0.31	9.71e-9	Life satisfaction;
LUSC	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg13852791	chr20:30311386	BCL2L1	0.96	14.98	0.63	3.73e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg19748678	chr4:122722346	EXOSC9	0.48	7.47	0.38	7.05e-13	Type 2 diabetes;
LUSC	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg22508957	chr16:3507546	NAT15	0.45	6.44	0.33	4.28e-10	Body mass index (adult);
LUSC	trans	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg18335740	chr13:41363409	SLC25A15	0.6	10.11	0.48	3.71e-21	Lewy body disease;
LUSC	cis	rs12220238	0.915	rs75467340	chr10:75907318	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.9	0.35	2.58e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg20744362	chr22:50050164	C22orf34	0.4	8.3	0.41	2.56e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs12410462	0.581	rs113827839	chr1:227547180	C/T	cg23173402	chr1:227635558	NA	0.55	6.39	0.33	5.42e-10	Major depressive disorder;
LUSC	cis	rs17604090	0.701	rs60930239	chr7:29688544	A/G	cg19413766	chr7:29689036	LOC646762	-0.54	-6.77	-0.35	5.88e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg09699651	chr6:150184138	LRP11	0.44	6.98	0.36	1.61e-11	Testicular germ cell tumor;
LUSC	trans	rs11006747	0.539	rs6481485	chr10:28123364	A/G	cg26606327	chr7:98972104	ARPC1B	0.43	5.99	0.31	5.45e-9	Obesity-related traits;
LUSC	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.33	-0.33	8.06e-10	Response to antipsychotic treatment;
LUSC	cis	rs7246967	0.611	rs3951785	chr19:22851928	G/A	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	trans	rs62238980	0.614	rs117067740	chr22:32407944	C/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg04036182	chr15:45458818	NA	-0.36	-5.7	-0.3	2.69e-8	Glomerular filtration rate;
LUSC	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-5.87	-0.31	1.07e-8	Neuroticism;
LUSC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg02931644	chr1:25747376	RHCE	-0.34	-6.14	-0.32	2.38e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs17540621	1.000	rs114977142	chr2:47196104	C/T	cg23978866	chr2:47230407	TTC7A	-0.92	-6.91	-0.35	2.44e-11	Response to statin therapy;
LUSC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.82	-0.51	1.38e-23	Alzheimer's disease (late onset);
LUSC	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.56	-9.2	-0.45	4.02e-18	Schizophrenia;
LUSC	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg05110241	chr16:68378359	PRMT7	-0.51	-6.12	-0.32	2.69e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.96	0.51	4.51e-24	Menopause (age at onset);
LUSC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg27121462	chr16:89883253	FANCA	0.39	5.91	0.31	8.6e-9	Vitiligo;
LUSC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg06238570	chr21:40685208	BRWD1	0.49	7.54	0.38	4.4e-13	Cognitive function;
LUSC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg18681998	chr4:17616180	MED28	0.84	15.35	0.64	1.29e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg20135002	chr11:47629003	NA	-0.5	-7.94	-0.4	3.16e-14	Subjective well-being;
LUSC	trans	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg20935933	chr6:143382018	AIG1	0.5	7.27	0.37	2.61e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-22.54	-0.78	4.9e-69	Ulcerative colitis;
LUSC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg01416388	chr22:39784598	NA	-0.39	-5.78	-0.3	1.73e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg11965913	chr1:205819406	PM20D1	-0.47	-6.7	-0.34	9.06e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-1.0	-16.83	-0.68	1.77e-46	Systemic lupus erythematosus;
LUSC	cis	rs17001868	0.568	rs9611315	chr22:40736900	A/T	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	trans	rs1422110	0.572	rs6884343	chr5:85444051	G/T	cg01787110	chr1:109008453	NBPF6	0.52	8.82	0.43	6.53e-17	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg12935359	chr14:103987150	CKB	-0.51	-8.2	-0.41	5.2e-15	Body mass index;
LUSC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.09	20.67	0.75	1.06e-61	Cognitive ability;
LUSC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg16325326	chr1:53192061	ZYG11B	1.03	21.43	0.76	1.1e-64	Monocyte count;
LUSC	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.61	10.59	0.5	8.51e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-10.77	-0.51	2.13e-23	Alcohol dependence;
LUSC	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg18827107	chr12:86230957	RASSF9	0.43	6.67	0.34	1.07e-10	Major depressive disorder;
LUSC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.99	-0.31	5.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	16.51	0.67	3.51e-45	Gut microbiome composition (summer);
LUSC	cis	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg26958806	chr6:27640298	NA	0.83	6.57	0.34	1.94e-10	Depression;
LUSC	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg24375607	chr4:120327624	NA	0.76	12.17	0.55	1.85e-28	Corneal astigmatism;
LUSC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.12e-12	Motion sickness;
LUSC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg13047869	chr3:10149882	C3orf24	0.63	9.1	0.45	8.57e-18	Alzheimer's disease;
LUSC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg23711669	chr6:146136114	FBXO30	-0.9	-17.37	-0.69	1.38e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10754283	0.870	rs2390764	chr1:90112827	T/G	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg02777633	chr3:64009154	PSMD6	0.38	6.1	0.32	2.96e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs9462027	0.628	rs2764211	chr6:34704613	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.33	5.83	0.3	1.34e-8	Systemic lupus erythematosus;
LUSC	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg01620082	chr3:125678407	NA	-0.77	-7.12	-0.36	6.8e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg05625103	chr10:2543513	NA	0.37	5.73	0.3	2.21e-8	Age-related hearing impairment;
LUSC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg12310025	chr6:25882481	NA	-0.53	-9.71	-0.47	8.67e-20	Blood metabolite levels;
LUSC	cis	rs2455601	0.573	rs2653573	chr11:8989874	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.55	-0.34	2.12e-10	Schizophrenia;
LUSC	cis	rs10203711	0.933	rs4994754	chr2:239567218	A/G	cg14580085	chr2:239553406	NA	0.41	6.99	0.36	1.53e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14159672	chr1:205819179	PM20D1	-0.45	-6.12	-0.32	2.63e-9	Parkinson's disease;
LUSC	cis	rs6714710	0.603	rs35255677	chr2:98567820	G/A	cg26665480	chr2:98280029	ACTR1B	0.6	8.76	0.43	9.72e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg18002602	chr11:66138449	SLC29A2	0.45	7.98	0.4	2.43e-14	Educational attainment (years of education);
LUSC	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-6.03	-0.31	4.43e-9	Eosinophil percentage of white cells;
LUSC	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg25566285	chr7:158114605	PTPRN2	0.35	6.53	0.34	2.52e-10	Calcium levels;
LUSC	cis	rs2637266	0.935	rs2583057	chr10:78396019	C/T	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.95e-13	Pulmonary function;
LUSC	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.89	-0.35	2.77e-11	Response to antipsychotic treatment;
LUSC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg16606324	chr3:10149918	C3orf24	0.62	9.08	0.44	9.81e-18	Alzheimer's disease;
LUSC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.7	10.83	0.51	1.22e-23	Aortic root size;
LUSC	cis	rs11690935	0.921	rs3770445	chr2:172708919	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.6	-0.62	1.11e-37	Schizophrenia;
LUSC	cis	rs367943	0.712	rs1607159	chr5:112681044	C/A	cg12552261	chr5:112820674	MCC	0.37	6.12	0.32	2.62e-9	Type 2 diabetes;
LUSC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	10.2	0.49	1.95e-21	Bipolar disorder;
LUSC	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg12483005	chr1:23474871	LUZP1	0.45	6.92	0.35	2.28e-11	Height;
LUSC	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07636037	chr3:49044803	WDR6	0.71	9.31	0.45	1.79e-18	Menarche (age at onset);
LUSC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.79	0.6	1.47e-34	Alzheimer's disease;
LUSC	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.53	-8.39	-0.42	1.35e-15	Melanoma;
LUSC	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg21132104	chr15:45694354	SPATA5L1	-0.52	-6.91	-0.35	2.54e-11	Homoarginine levels;
LUSC	cis	rs67696533	0.600	rs733852	chr20:31111094	G/T	cg13636640	chr20:31349939	DNMT3B	0.47	6.21	0.32	1.55e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg10483660	chr13:112241077	NA	-0.4	-7.26	-0.37	2.81e-12	Menarche (age at onset);
LUSC	cis	rs6076065	0.723	rs6137940	chr20:23397491	G/C	cg11657817	chr20:23433608	CST11	0.44	8.22	0.41	4.64e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.54	-0.34	2.31e-10	Life satisfaction;
LUSC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-8.17	-0.41	6.29e-15	Obesity-related traits;
LUSC	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.08	-0.36	8.81e-12	Response to antipsychotic treatment;
LUSC	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.45	-0.46	6.15e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.18	0.45	4.79e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg04450456	chr4:17643702	FAM184B	0.35	5.77	0.3	1.81e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24531977	chr5:56204891	C5orf35	-0.89	-13.8	-0.6	1.31e-34	Initial pursuit acceleration;
LUSC	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg23625390	chr15:77176239	SCAPER	-0.66	-9.94	-0.48	1.47e-20	Blood metabolite levels;
LUSC	cis	rs28830936	1.000	rs11637341	chr15:41955825	G/T	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.36	-0.33	6.8e-10	Diastolic blood pressure;
LUSC	cis	rs983392	0.667	rs662196	chr11:59942757	C/T	cg24026212	chr11:59952134	MS4A6A	0.34	6.03	0.31	4.27e-9	Alzheimer's disease (late onset);
LUSC	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg21775007	chr8:11205619	TDH	-0.53	-8.05	-0.4	1.52e-14	Neuroticism;
LUSC	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg21293242	chr8:11204541	TDH	0.31	5.66	0.3	3.34e-8	Retinal vascular caliber;
LUSC	cis	rs10761482	0.861	rs1814117	chr10:62099897	C/T	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg11102782	chr19:18549136	ISYNA1	-0.36	-6.79	-0.35	5.04e-11	Breast cancer;
LUSC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg04025307	chr7:1156635	C7orf50	-0.4	-6.37	-0.33	6.26e-10	Longevity;Endometriosis;
LUSC	cis	rs8133932	0.654	rs410902	chr21:47341794	G/A	cg14185626	chr21:47401492	COL6A1	-0.45	-5.85	-0.3	1.16e-8	Schizophrenia;
LUSC	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg13319975	chr6:146136371	FBXO30	0.47	6.75	0.35	6.41e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs701145	0.938	rs701135	chr3:154065455	C/G	cg17054900	chr3:154042577	DHX36	0.79	8.25	0.41	3.74e-15	Coronary artery disease;
LUSC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06634786	chr22:41940651	POLR3H	-0.56	-6.54	-0.34	2.29e-10	Vitiligo;
LUSC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.06	-0.36	9.55e-12	Bipolar disorder;
LUSC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs6445797	0.632	rs4681951	chr3:56633402	A/G	cg13792233	chr3:56591045	CCDC66	0.4	5.7	0.3	2.67e-8	Gastritis;
LUSC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	7.77e-16	Aortic root size;
LUSC	cis	rs7119	0.604	rs939488	chr15:77867780	T/C	cg27398640	chr15:77910606	LINGO1	0.35	7.78	0.39	9.23e-14	Type 2 diabetes;
LUSC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg11608241	chr8:8085544	FLJ10661	-0.45	-6.19	-0.32	1.81e-9	Schizophrenia;
LUSC	cis	rs6977660	0.714	rs2390157	chr7:19786177	G/A	cg05791153	chr7:19748676	TWISTNB	0.75	7.42	0.38	1.01e-12	Thyroid stimulating hormone;
LUSC	cis	rs859767	0.812	rs842360	chr2:135347885	T/C	cg12500956	chr2:135428796	TMEM163	0.25	5.75	0.3	2.02e-8	Neuroticism;
LUSC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg24209194	chr3:40518798	ZNF619	0.56	6.75	0.35	6.72e-11	Renal cell carcinoma;
LUSC	trans	rs7094131	0.542	rs7071306	chr10:22867339	A/G	cg06317507	chr6:134159179	MGC34034	0.42	6.27	0.32	1.11e-9	Obesity-related traits;
LUSC	cis	rs12135894	0.648	rs4648423	chr1:3765678	C/T	cg13057898	chr1:3703894	LRRC47	-0.35	-6.51	-0.34	2.72e-10	Mean corpuscular volume;
LUSC	trans	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.94	0.4	3.18e-14	Ulcerative colitis;
LUSC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.61	0.34	1.56e-10	Personality dimensions;
LUSC	cis	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg07460842	chr6:66804631	NA	0.88	8.93	0.44	2.87e-17	Exhaled nitric oxide output;
LUSC	cis	rs478607	0.831	rs61884374	chr11:64388929	A/G	cg19131476	chr11:64387923	NRXN2	0.34	5.92	0.31	7.81e-9	Urate levels;
LUSC	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.87	0.4	4.86e-14	Coffee consumption (cups per day);
LUSC	cis	rs3820068	0.608	rs2057304	chr1:16017710	A/G	cg13390004	chr1:15929781	NA	0.42	6.82	0.35	4.38e-11	Systolic blood pressure;
LUSC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg04369109	chr6:150039330	LATS1	-0.52	-7.53	-0.38	4.91e-13	Lung cancer;
LUSC	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg15848620	chr12:58087721	OS9	-0.5	-7.04	-0.36	1.08e-11	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg01294253	chr9:136912663	BRD3	0.34	5.92	0.31	8.12e-9	Platelet distribution width;
LUSC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg00745463	chr17:30367425	LRRC37B	-0.76	-8.58	-0.42	3.68e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	9.16	0.45	5.22e-18	Lung cancer in ever smokers;
LUSC	cis	rs6546537	0.503	rs7576953	chr2:69911916	C/T	cg10773587	chr2:69614142	GFPT1	0.41	6.17	0.32	1.96e-9	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs68170813	0.523	rs3757713	chr7:107042750	A/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.28	-0.45	2.28e-18	Coronary artery disease;
LUSC	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg12002119	chr2:101014098	CHST10	0.38	6.38	0.33	6e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4654899	0.965	rs7512116	chr1:21501095	C/A	cg01072550	chr1:21505969	NA	-0.55	-8.49	-0.42	7e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.74	-0.3	2.1e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs5167	0.566	rs2075618	chr19:45495668	G/C	cg25746394	chr19:45450501	APOC2	0.32	6.07	0.32	3.55e-9	Blood protein levels;
LUSC	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg04374321	chr14:90722782	PSMC1	0.7	11.12	0.52	1.19e-24	Mortality in heart failure;
LUSC	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.81	-0.39	7.23e-14	Body mass index;
LUSC	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.41	6.51	0.34	2.76e-10	Homocysteine levels;
LUSC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.76	13.64	0.6	5.69e-34	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01813026	chr11:809279	RPLP2	-0.41	-6.1	-0.32	2.92e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg10523860	chr14:103875565	MARK3	-0.37	-5.92	-0.31	8.18e-9	Bone mineral density;
LUSC	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg05187965	chr10:45406764	TMEM72	-0.37	-8.7	-0.43	1.55e-16	Mean corpuscular volume;
LUSC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg06453172	chr10:134556979	INPP5A	-0.49	-6.11	-0.32	2.78e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg01256987	chr12:42539512	GXYLT1	0.35	6.44	0.33	4.18e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg13010199	chr12:38710504	ALG10B	0.52	7.86	0.4	5.4e-14	Morning vs. evening chronotype;
LUSC	cis	rs189798	0.807	rs330909	chr8:8995387	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	6.79	0.35	5.13e-11	Myopia (pathological);
LUSC	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg22117172	chr7:91764530	CYP51A1	-0.32	-5.82	-0.3	1.41e-8	Breast cancer;
LUSC	cis	rs9796	0.870	rs3986311	chr15:41264339	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.92	-0.35	2.33e-11	Menopause (age at onset);
LUSC	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg05110241	chr16:68378359	PRMT7	-0.64	-6.94	-0.36	1.99e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs701145	0.585	rs1713813	chr3:153873643	T/G	cg17054900	chr3:154042577	DHX36	0.69	6.76	0.35	6.15e-11	Coronary artery disease;
LUSC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	7.7	0.39	1.59e-13	Personality dimensions;
LUSC	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg01528321	chr10:82214614	TSPAN14	1.08	12.1	0.55	3.35e-28	Post bronchodilator FEV1;
LUSC	cis	rs12210905	0.925	rs4541737	chr6:27002821	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-6.01	-0.31	4.99e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg26587870	chr6:27730563	NA	-0.62	-5.79	-0.3	1.61e-8	Depression;
LUSC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg02423579	chr7:2872169	GNA12	-0.37	-5.64	-0.3	3.55e-8	Height;
LUSC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg25025879	chr12:53359317	NA	-0.44	-6.81	-0.35	4.62e-11	Prostate cancer;
LUSC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg11752832	chr7:134001865	SLC35B4	0.56	8.8	0.43	7.57e-17	Mean platelet volume;
LUSC	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg26395211	chr5:140044315	WDR55	-0.37	-5.72	-0.3	2.37e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs925255	0.774	rs7562	chr2:28635740	T/C	cg01273330	chr2:28605224	NA	0.4	6.32	0.33	8.25e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1322512	0.917	rs73009163	chr6:153002192	G/A	cg27316956	chr6:152958899	SYNE1	0.37	6.23	0.32	1.4e-9	Tonometry;
LUSC	cis	rs7809950	1.000	rs2520269	chr7:107191327	T/C	cg23024343	chr7:107201750	COG5	-0.57	-9.01	-0.44	1.62e-17	Coronary artery disease;
LUSC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.74	0.35	6.99e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs243505	0.595	rs10233740	chr7:148567263	C/T	cg09806900	chr7:148480153	CUL1	0.43	5.67	0.3	3.08e-8	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9309473	0.528	rs11126395	chr2:73564964	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-6.96	-0.36	1.79e-11	Metabolite levels;
LUSC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg18758796	chr5:131593413	PDLIM4	0.41	6.75	0.35	6.69e-11	Breast cancer;
LUSC	cis	rs9400467	0.528	rs11153280	chr6:111589293	A/C	cg22127309	chr6:111907043	TRAF3IP2	-0.35	-6.39	-0.33	5.72e-10	Blood metabolite levels;Amino acid levels;
LUSC	trans	rs7951105	1.000	rs11035155	chr11:39248248	C/T	cg24085930	chr3:21832523	NA	0.49	6.06	0.31	3.58e-9	Free thyroxine concentration;
LUSC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg06713675	chr4:122721982	EXOSC9	-0.47	-8.23	-0.41	4.19e-15	Type 2 diabetes;
LUSC	cis	rs62408225	0.925	rs6925032	chr6:91008027	C/A	cg06866423	chr6:90926672	BACH2	0.43	6.17	0.32	1.98e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.86	-0.44	4.83e-17	Monocyte percentage of white cells;
LUSC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg15557168	chr22:42548783	NA	-0.47	-7.33	-0.37	1.76e-12	Schizophrenia;
LUSC	cis	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg21775007	chr8:11205619	TDH	0.43	5.94	0.31	7.31e-9	Systemic lupus erythematosus;
LUSC	cis	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg20368463	chr18:77673604	PQLC1	0.76	12.74	0.57	1.46e-30	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUSC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.79	0.35	5.21e-11	Tonsillectomy;
LUSC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg07741184	chr6:167504864	NA	0.49	8.55	0.42	4.6e-16	Crohn's disease;
LUSC	cis	rs8092503	0.951	rs1833281	chr18:52498801	C/G	cg12377874	chr18:52495404	RAB27B	0.34	5.94	0.31	7.14e-9	Childhood body mass index;
LUSC	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg12483005	chr1:23474871	LUZP1	0.41	6.5	0.33	2.98e-10	Height;
LUSC	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	0.96	14.36	0.62	9.24e-37	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-0.76	-13.48	-0.59	2.21e-33	Gut microbiome composition (winter);
LUSC	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg11342453	chr6:26196699	NA	0.55	5.78	0.3	1.7e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03264133	chr6:25882463	NA	0.38	6.26	0.32	1.15e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10959786	chr13:74708124	KLF12	0.41	5.98	0.31	5.75e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs2055729	0.677	rs59880252	chr8:9741032	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.04	0.31	4.17e-9	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.96	-0.31	6.49e-9	Dementia with Lewy bodies;
LUSC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg24642844	chr7:1081250	C7orf50	-0.7	-9.7	-0.47	9.03e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg26043149	chr18:55253948	FECH	-0.47	-7.23	-0.37	3.28e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.38	-0.37	1.23e-12	Psoriasis;
LUSC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs931127	0.658	rs12787843	chr11:65477306	A/C	cg05805236	chr11:65401703	PCNXL3	-0.45	-7.61	-0.38	2.89e-13	Systemic lupus erythematosus;
LUSC	cis	rs354225	0.584	rs10206143	chr2:54817453	A/T	cg26097391	chr2:54893211	SPTBN1	0.43	6.5	0.33	2.96e-10	Schizophrenia;
LUSC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06481639	chr22:41940642	POLR3H	0.5	5.77	0.3	1.81e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg04352962	chr1:209979756	IRF6	0.54	6.28	0.33	1.03e-9	Cleft lip with or without cleft palate;
LUSC	trans	rs1941687	0.797	rs6507070	chr18:31393244	C/A	cg27147174	chr7:100797783	AP1S1	-0.44	-6.45	-0.33	3.83e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-8.15	-0.41	7.26e-15	Cystic fibrosis severity;
LUSC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.83	14.07	0.61	1.27e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.95	0.31	6.7e-9	Menopause (age at onset);
LUSC	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg19052272	chr2:3704530	ALLC	-0.35	-6.97	-0.36	1.68e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg02423579	chr7:2872169	GNA12	-0.48	-6.73	-0.35	7.45e-11	Height;
LUSC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs4499344	0.504	rs259248	chr19:33148041	T/C	cg22980127	chr19:33182716	NUDT19	-0.43	-6.39	-0.33	5.7e-10	Mean platelet volume;
LUSC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg26516362	chr5:178986906	RUFY1	0.55	10.09	0.48	4.57e-21	Lung cancer;
LUSC	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	trans	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.79	-0.43	8.32e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg23283495	chr1:209979779	IRF6	0.67	7.56	0.38	4e-13	Coronary artery disease;
LUSC	cis	rs9595066	0.941	rs9533777	chr13:44708720	C/T	cg04068111	chr13:44716778	NA	0.53	7.42	0.38	9.89e-13	Schizophrenia;
LUSC	cis	rs7106204	0.534	rs75335266	chr11:24256395	G/T	ch.11.24196551F	chr11:24239977	NA	0.75	6.39	0.33	5.58e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg04287289	chr16:89883240	FANCA	0.76	6.26	0.32	1.19e-9	Skin colour saturation;
LUSC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg09491104	chr22:46646882	C22orf40	-0.63	-7.19	-0.37	4.35e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg18755752	chr8:142205143	DENND3	-0.71	-12.52	-0.57	9.79e-30	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg18352616	chr4:3374830	RGS12	0.32	6.31	0.33	8.72e-10	Serum sulfate level;
LUSC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg00677455	chr12:58241039	CTDSP2	0.59	8.48	0.42	7.35e-16	Multiple sclerosis;
LUSC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg18302933	chr2:88491318	NA	-0.38	-7.47	-0.38	7.04e-13	Response to metformin (IC50);
LUSC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	13.96	0.61	3.25e-35	Platelet count;
LUSC	cis	rs9420	0.961	rs79260745	chr11:57612960	T/C	cg23127183	chr11:57508653	C11orf31	-0.56	-8.45	-0.42	9.27e-16	Schizophrenia;
LUSC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	8.37	0.42	1.63e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08645402	chr16:4508243	NA	0.52	8.75	0.43	1.1e-16	Schizophrenia;
LUSC	cis	rs12681288	0.640	rs6985741	chr8:962858	C/T	cg15309053	chr8:964076	NA	0.36	6.82	0.35	4.35e-11	Schizophrenia;
LUSC	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	7.18	0.37	4.46e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg08917208	chr2:24149416	ATAD2B	0.96	9.92	0.48	1.69e-20	Lymphocyte counts;
LUSC	cis	rs16854884	0.526	rs7643341	chr3:143726980	C/T	cg06585982	chr3:143692056	C3orf58	0.41	6.54	0.34	2.31e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.4	-6.04	-0.31	4.13e-9	Longevity;Endometriosis;
LUSC	cis	rs2607426	0.681	rs2607418	chr19:41257396	A/G	cg05508168	chr19:41255947	C19orf54;SNRPA	-0.88	-6.86	-0.35	3.38e-11	Blood protein levels;
LUSC	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg08601574	chr20:25228251	PYGB	0.55	8.84	0.44	5.66e-17	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg06017677	chr12:123236875	DENR	-0.6	-6.42	-0.33	4.79e-10	Schizophrenia;
LUSC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg26587870	chr6:27730563	NA	-0.46	-5.8	-0.3	1.54e-8	Breast cancer;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg02478158	chr15:67073907	SMAD6	-0.44	-6.8	-0.35	4.94e-11	N-glycan levels;
LUSC	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21659725	chr3:3221576	CRBN	0.54	8.76	0.43	9.82e-17	Body mass index;
LUSC	trans	rs877282	0.947	rs12358875	chr10:757531	T/C	cg13042288	chr15:90349979	ANPEP	-0.47	-6.51	-0.34	2.71e-10	Uric acid levels;
LUSC	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.63	10.58	0.5	9.35e-23	Blood metabolite ratios;
LUSC	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg23649088	chr2:200775458	C2orf69	-0.56	-6.69	-0.34	9.43e-11	Schizophrenia;
LUSC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg06671660	chr6:41068741	NFYA;LOC221442	-0.39	-5.67	-0.3	3.07e-8	Alzheimer's disease (late onset);
LUSC	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg10840412	chr1:235813424	GNG4	-0.65	-8.72	-0.43	1.29e-16	Bipolar disorder;
LUSC	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.37	-0.42	1.59e-15	Response to antipsychotic treatment;
LUSC	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.57	-11.18	-0.52	7.02e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg08079166	chr15:68083412	MAP2K5	0.37	6.18	0.32	1.82e-9	Obesity;
LUSC	trans	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg21659725	chr3:3221576	CRBN	-0.68	-7.95	-0.4	2.97e-14	Menarche (age at onset);
LUSC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg22823121	chr1:150693482	HORMAD1	0.51	7.39	0.38	1.15e-12	Melanoma;
LUSC	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg24562669	chr7:97807699	LMTK2	-0.4	-7.1	-0.36	7.6e-12	Breast cancer;
LUSC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg12292205	chr6:26970375	C6orf41	-0.7	-12.21	-0.56	1.3e-28	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg08017756	chr2:100939284	LONRF2	-0.44	-8.26	-0.41	3.39e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg06671706	chr8:8559999	CLDN23	0.48	6.58	0.34	1.86e-10	Obesity-related traits;
LUSC	cis	rs10761482	0.906	rs10740023	chr10:62088266	T/C	cg18175470	chr10:62150864	ANK3	-0.49	-6.72	-0.34	8.1e-11	Schizophrenia;
LUSC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.62e-9	Aortic root size;
LUSC	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg09184832	chr6:79620586	NA	-0.43	-6.96	-0.36	1.76e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.79	14.92	0.63	6.3e-39	Dental caries;
LUSC	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg04374321	chr14:90722782	PSMC1	-0.69	-10.43	-0.5	3.01e-22	Mortality in heart failure;
LUSC	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.99	0.31	5.5e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.16	0.32	2.1e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg04369109	chr6:150039330	LATS1	-0.52	-7.34	-0.37	1.65e-12	Lung cancer;
LUSC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg09021430	chr5:549028	NA	-0.57	-7.7	-0.39	1.61e-13	Obesity-related traits;
LUSC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg08847533	chr14:75593920	NEK9	-0.81	-13.91	-0.61	5.04e-35	Height;
LUSC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg16680214	chr1:154839983	KCNN3	-0.51	-9.28	-0.45	2.25e-18	Prostate cancer;
LUSC	cis	rs9341808	0.718	rs9359408	chr6:80820132	T/G	cg08355045	chr6:80787529	NA	0.56	9.59	0.46	2.06e-19	Sitting height ratio;
LUSC	cis	rs672059	1.000	rs660602	chr1:183162774	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.1	0.41	1.02e-14	Hypertriglyceridemia;
LUSC	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg13010199	chr12:38710504	ALG10B	-0.52	-7.91	-0.4	3.93e-14	Bladder cancer;
LUSC	cis	rs7903847	0.667	rs10882931	chr10:99165794	C/A	cg20016023	chr10:99160130	RRP12	-0.3	-7.44	-0.38	8.68e-13	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.91	-0.35	2.51e-11	Morning vs. evening chronotype;
LUSC	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg18825076	chr15:78729989	IREB2	-0.52	-8.21	-0.41	4.99e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg26587870	chr6:27730563	NA	-0.61	-5.67	-0.3	3.14e-8	Depression;
LUSC	cis	rs2742234	0.541	rs10899779	chr10:43723976	C/T	cg02780029	chr10:43622663	RET	0.35	5.76	0.3	1.94e-8	Hirschsprung disease;
LUSC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.87	0.35	3.09e-11	Parkinson's disease;
LUSC	trans	rs7156960	1.000	rs7156960	chr14:76703351	C/G	cg22433775	chr8:67976671	CSPP1	0.38	6.02	0.31	4.57e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06028605	chr16:24865363	SLC5A11	-0.68	-10.86	-0.51	9.61e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.33	-0.33	7.98e-10	Neutrophil percentage of white cells;
LUSC	cis	rs701145	0.878	rs355760	chr3:154009933	T/C	cg17054900	chr3:154042577	DHX36	0.84	8.56	0.42	4.29e-16	Coronary artery disease;
LUSC	cis	rs6690583	0.623	rs1371142	chr1:85455373	A/T	cg11262906	chr1:85462892	MCOLN2	0.67	6.53	0.34	2.51e-10	Serum sulfate level;
LUSC	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg17652424	chr22:38574118	PLA2G6	0.28	5.97	0.31	5.93e-9	Cutaneous nevi;
LUSC	cis	rs9322817	0.691	rs4591886	chr6:105249970	G/C	cg02098413	chr6:105308735	HACE1	-0.28	-5.8	-0.3	1.55e-8	Thyroid stimulating hormone;
LUSC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.13	-0.48	3.34e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg24675056	chr1:15929824	NA	0.42	7.15	0.36	5.37e-12	Systolic blood pressure;
LUSC	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-16.82	-0.68	2.1e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.71	0.34	8.14e-11	Lung cancer;
LUSC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24110177	chr3:50126178	RBM5	0.58	9.72	0.47	8.04e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg26677194	chr12:130822605	PIWIL1	-0.59	-8.79	-0.43	7.9e-17	Menopause (age at onset);
LUSC	cis	rs4731207	0.967	rs2299902	chr7:124397814	G/T	cg14311320	chr7:124405732	GPR37	0.31	6.01	0.31	4.96e-9	Cutaneous malignant melanoma;
LUSC	cis	rs2274273	0.588	rs17128145	chr14:55536406	G/T	cg04306507	chr14:55594613	LGALS3	-0.43	-8.79	-0.43	7.91e-17	Protein biomarker;
LUSC	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.84	-0.35	3.78e-11	Uric acid levels;
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	6.46	0.33	3.73e-10	Electroencephalogram traits;
LUSC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.05	0.55	5e-28	Prudent dietary pattern;
LUSC	cis	rs9888739	0.844	rs41476751	chr16:31335906	T/C	cg15817542	chr16:31343056	ITGAM	-0.44	-6.08	-0.32	3.27e-9	Systemic lupus erythematosus;
LUSC	cis	rs926938	0.527	rs1391484	chr1:115522366	A/G	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.41	-0.33	5.05e-10	Autism;
LUSC	cis	rs859767	0.741	rs2176341	chr2:135371421	A/G	cg12500956	chr2:135428796	TMEM163	-0.28	-6.23	-0.32	1.42e-9	Neuroticism;
LUSC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	8.4	0.42	1.31e-15	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02032696	chr14:67982198	TMEM229B	-0.41	-6.01	-0.31	4.77e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg11861562	chr11:117069780	TAGLN	0.45	7.57	0.38	3.7e-13	Blood protein levels;
LUSC	cis	rs500891	0.645	rs13196054	chr6:84174943	C/T	cg08257003	chr6:84140564	ME1	-0.31	-7.09	-0.36	8.24e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs6546537	0.550	rs4852272	chr2:69776730	C/T	cg10773587	chr2:69614142	GFPT1	-0.43	-6.83	-0.35	3.98e-11	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs2200578	1.000	rs2200578	chr2:99876244	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.53	6.19	0.32	1.72e-9	IgG glycosylation;
LUSC	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	8.12	0.41	8.87e-15	Iron status biomarkers;
LUSC	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.67	0.34	1.03e-10	Corneal astigmatism;
LUSC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg23205692	chr1:25664452	TMEM50A	0.46	7.06	0.36	9.74e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.82	0.51	1.4e-23	Menopause (age at onset);
LUSC	trans	rs2018683	0.523	rs4513881	chr7:29025410	C/T	cg19402173	chr7:128379420	CALU	0.47	7.04	0.36	1.08e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18876405	chr7:65276391	NA	0.55	8.59	0.43	3.48e-16	Aortic root size;
LUSC	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.54	-9.61	-0.47	1.83e-19	Osteoporosis;
LUSC	cis	rs10761482	0.861	rs7097138	chr10:62106755	G/T	cg18175470	chr10:62150864	ANK3	-0.51	-7.24	-0.37	3.06e-12	Schizophrenia;
LUSC	trans	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.78	-0.39	8.95e-14	Morning vs. evening chronotype;
LUSC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	9.61	0.47	1.77e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs35771425	0.536	rs6656860	chr1:211620805	A/G	cg25617285	chr1:211431773	RCOR3	-0.36	-5.87	-0.31	1.06e-8	Educational attainment (years of education);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13535478	chr19:15490918	AKAP8;AKAP8L	-0.4	-6.24	-0.32	1.32e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg07460842	chr6:66804631	NA	0.88	8.93	0.44	2.87e-17	Exhaled nitric oxide output;
LUSC	cis	rs9807989	0.801	rs7558339	chr2:102970243	T/G	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.67e-9	Asthma;
LUSC	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg20283391	chr11:68216788	NA	-0.61	-8.56	-0.42	4.03e-16	Total body bone mineral density;
LUSC	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg11861562	chr11:117069780	TAGLN	0.39	6.69	0.34	9.33e-11	Blood protein levels;
LUSC	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg14092571	chr14:90743983	NA	-0.89	-18.83	-0.72	2.03e-54	Gut microbiota (bacterial taxa);
LUSC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg12963246	chr6:28129442	ZNF389	0.53	7.3	0.37	2.16e-12	Depression;
LUSC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg21285383	chr16:89894308	SPIRE2	0.33	7.05	0.36	1.05e-11	Vitiligo;
LUSC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg05872129	chr22:39784769	NA	-0.61	-11.61	-0.54	2.16e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21984481	chr17:79567631	NPLOC4	-0.57	-10.89	-0.51	7.97e-24	Eye color traits;
LUSC	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.57	10.0	0.48	8.88e-21	Birth weight;
LUSC	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.3	0.56	5.99e-29	Lymphocyte percentage of white cells;
LUSC	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-10.55	-0.5	1.17e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs1775715	0.870	rs11008702	chr10:32244818	T/G	cg26784012	chr10:32216390	ARHGAP12	0.36	5.83	0.3	1.28e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-0.87	-12.7	-0.57	2.07e-30	Asthma;
LUSC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	0.92	15.33	0.64	1.58e-40	Breast cancer;
LUSC	trans	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.27	0.62	2.12e-36	Exhaled nitric oxide levels;
LUSC	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg16579770	chr16:72058938	DHODH	-0.36	-5.98	-0.31	5.75e-9	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.65	0.86	4.24e-99	Chronic sinus infection;
LUSC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg05738196	chr6:26577821	NA	0.53	8.33	0.41	2.14e-15	Schizophrenia;
LUSC	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.41	-0.42	1.23e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg08499158	chr17:42289980	UBTF	-0.56	-9.1	-0.45	8.62e-18	Total body bone mineral density;
LUSC	cis	rs4561483	0.583	rs11647580	chr16:11957609	G/C	cg08843971	chr16:11963173	GSPT1	0.42	6.4	0.33	5.29e-10	Testicular germ cell tumor;
LUSC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.71	11.55	0.53	3.34e-26	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	19.77	0.73	3.92e-58	Prudent dietary pattern;
LUSC	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg15704280	chr7:45808275	SEPT13	0.65	7.19	0.37	4.24e-12	Axial length;
LUSC	cis	rs17401966	0.838	rs8019	chr1:10366487	T/G	cg19773385	chr1:10388646	KIF1B	-0.5	-8.63	-0.43	2.52e-16	Hepatocellular carcinoma;
LUSC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg20203395	chr5:56204925	C5orf35	0.58	8.6	0.43	3.13e-16	Initial pursuit acceleration;
LUSC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg17294928	chr15:75287854	SCAMP5	-0.93	-13.47	-0.59	2.47e-33	Blood trace element (Zn levels);
LUSC	trans	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.2	-0.32	1.71e-9	Bladder cancer;
LUSC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22433210	chr17:43662623	NA	0.76	10.84	0.51	1.17e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg01028140	chr2:1542097	TPO	-0.49	-6.94	-0.36	2e-11	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs72792276	1.000	rs3805603	chr5:127451581	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.89	7.51	0.38	5.36e-13	Red cell distribution width;
LUSC	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs11971779	0.941	rs7800795	chr7:139080348	A/G	cg07862535	chr7:139043722	LUC7L2	0.73	8.23	0.41	4.24e-15	Diisocyanate-induced asthma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14826516	chr22:50639351	SELO	-0.39	-6.06	-0.31	3.76e-9	Electrocardiographic conduction measures;
LUSC	cis	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.26	-0.32	1.2e-9	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg13319975	chr6:146136371	FBXO30	0.68	10.55	0.5	1.19e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg18240062	chr17:79603768	NPLOC4	-0.58	-10.12	-0.48	3.59e-21	Eye color traits;
LUSC	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg02574844	chr11:5959923	NA	-0.41	-5.94	-0.31	7.25e-9	DNA methylation (variation);
LUSC	cis	rs11997175	0.646	rs4733180	chr8:33700520	C/T	ch.8.33884649F	chr8:33765107	NA	0.45	6.7	0.34	8.67e-11	Body mass index;
LUSC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg18230493	chr5:56204884	C5orf35	0.73	12.05	0.55	5.09e-28	Initial pursuit acceleration;
LUSC	cis	rs7215564	0.908	rs34785514	chr17:78661166	A/G	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs1865721	1.000	rs17284077	chr18:73204128	C/T	cg26385618	chr18:73139727	C18orf62	-0.48	-8.1	-0.41	1.08e-14	Intelligence;
LUSC	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-0.56	-9.0	-0.44	1.74e-17	Breast cancer;
LUSC	cis	rs7577696	0.785	rs7592239	chr2:32370258	C/A	cg02381751	chr2:32503542	YIPF4	-0.42	-5.72	-0.3	2.36e-8	Inflammatory biomarkers;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19509891	chr9:130662046	ST6GALNAC6	-0.5	-6.77	-0.35	5.92e-11	Hepatitis;
LUSC	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg22676075	chr6:135203613	NA	0.57	9.04	0.44	1.26e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs34734847	0.787	rs7976497	chr12:121135467	T/C	cg21892295	chr12:121157589	UNC119B	-0.36	-6.29	-0.33	1.01e-9	Mean corpuscular volume;
LUSC	cis	rs17102423	0.731	rs942629	chr14:65539318	A/G	cg11161011	chr14:65562177	MAX	-0.64	-9.91	-0.48	1.84e-20	Obesity-related traits;
LUSC	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg16606324	chr3:10149918	C3orf24	0.43	6.82	0.35	4.22e-11	Alzheimer's disease;
LUSC	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg09085632	chr11:111637200	PPP2R1B	1.14	17.27	0.69	3.35e-48	Primary sclerosing cholangitis;
LUSC	cis	rs9283706	0.852	rs73103937	chr5:66280577	T/C	cg11590213	chr5:66331682	MAST4	0.4	5.7	0.3	2.68e-8	Coronary artery disease;
LUSC	cis	rs6076065	0.748	rs2236023	chr20:23373043	A/C	cg11657817	chr20:23433608	CST11	0.53	11.03	0.52	2.42e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg13010199	chr12:38710504	ALG10B	-0.4	-6.01	-0.31	4.99e-9	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.5	0.42	6.19e-16	Prudent dietary pattern;
LUSC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg22875332	chr1:76189707	ACADM	0.76	10.17	0.49	2.4e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.13	-25.31	-0.81	1.16e-79	Triglycerides;
LUSC	cis	rs16912285	0.535	rs7936178	chr11:24252515	G/T	ch.11.24196551F	chr11:24239977	NA	0.92	10.2	0.49	1.98e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg04691961	chr3:161091175	C3orf57	-0.35	-6.14	-0.32	2.31e-9	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg17425144	chr1:10567563	PEX14	0.55	10.36	0.49	5.25e-22	Prostate cancer;
LUSC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg04518342	chr5:131593106	PDLIM4	-0.34	-6.23	-0.32	1.37e-9	Blood metabolite levels;
LUSC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.83	11.31	0.53	2.44e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1322512	0.917	rs1527367	chr6:152942517	A/T	cg27316956	chr6:152958899	SYNE1	-0.35	-5.77	-0.3	1.77e-8	Tonometry;
LUSC	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.24	-0.32	1.35e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg17366294	chr4:99064904	C4orf37	0.35	5.79	0.3	1.67e-8	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg27661571	chr11:113659931	NA	-0.72	-7.76	-0.39	1.04e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs500891	0.525	rs1145895	chr6:84042326	C/A	cg08257003	chr6:84140564	ME1	0.34	8.09	0.4	1.08e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.69	11.65	0.54	1.5e-26	Heart rate;
LUSC	cis	rs9788721	0.835	rs17487223	chr15:78923987	A/G	cg06917634	chr15:78832804	PSMA4	0.44	6.13	0.32	2.54e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs16867321	0.950	rs2887180	chr2:181449305	C/A	cg23363182	chr2:181467187	NA	-0.44	-5.95	-0.31	6.78e-9	Obesity;
LUSC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.69	0.54	1.11e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg06238570	chr21:40685208	BRWD1	0.47	7.25	0.37	2.84e-12	Cognitive function;
LUSC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.31	0.49	8.09e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.53	-7.53	-0.38	4.85e-13	Renal function-related traits (BUN);
LUSC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12756686	chr19:29218302	NA	0.58	6.81	0.35	4.47e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.0	0.44	1.75e-17	Motion sickness;
LUSC	cis	rs3741151	0.881	rs79623427	chr11:73094896	C/T	cg17517138	chr11:73019481	ARHGEF17	1.07	8.84	0.44	5.58e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1957429	0.520	rs72625642	chr14:65338884	G/T	cg23373153	chr14:65346875	NA	-0.87	-7.56	-0.38	4.04e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.77	0.35	5.93e-11	Body mass index;
LUSC	cis	rs72960926	0.744	rs55962148	chr6:74962021	G/T	cg03266952	chr6:74778945	NA	-0.85	-7.14	-0.36	5.86e-12	Metabolite levels (MHPG);
LUSC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg23590916	chr17:43697445	MGC57346	-0.48	-6.5	-0.34	2.93e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.92	0.31	8.02e-9	Schizophrenia;
LUSC	cis	rs62408225	1.000	rs62408235	chr6:90978383	T/C	cg06866423	chr6:90926672	BACH2	0.42	5.99	0.31	5.36e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21171335	chr12:122356390	WDR66	0.58	8.8	0.43	7.35e-17	Mean corpuscular volume;
LUSC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg25767906	chr1:53392781	SCP2	-0.51	-9.21	-0.45	3.7e-18	Monocyte count;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04824390	chr6:13710980	RANBP9	0.4	6.01	0.31	4.79e-9	Triglycerides;
LUSC	trans	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg25214090	chr10:38739885	LOC399744	0.46	6.72	0.35	7.96e-11	Corneal astigmatism;
LUSC	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg08854313	chr1:11322531	MTOR	0.8	12.45	0.56	1.6800000000000001e-29	Body mass index;
LUSC	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg08558340	chr7:100472263	SRRT	0.5	6.23	0.32	1.37e-9	Resting heart rate;
LUSC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.98	-16.38	-0.67	1.14e-44	Coronary artery disease;
LUSC	cis	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg07988820	chr12:82153109	PPFIA2	-0.4	-5.66	-0.3	3.26e-8	Resting heart rate;
LUSC	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-6.24	-0.32	1.31e-9	Self-reported allergy;
LUSC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg13939156	chr17:80058883	NA	-0.33	-6.46	-0.33	3.6e-10	Life satisfaction;
LUSC	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-9.34	-0.46	1.4e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10416265	0.528	rs17884930	chr19:33595390	A/G	cg17764715	chr19:33622953	WDR88	0.57	6.16	0.32	2.1e-9	Bone properties (heel);
LUSC	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg04362960	chr10:104952993	NT5C2	0.62	9.63	0.47	1.54e-19	Arsenic metabolism;
LUSC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg24375607	chr4:120327624	NA	0.77	11.8	0.54	4.1e-27	Corneal astigmatism;
LUSC	cis	rs8179	0.553	rs42038	chr7:92243719	A/G	cg15732164	chr7:92237376	CDK6	0.41	6.33	0.33	7.97e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.68	-10.99	-0.52	3.42e-24	Sudden cardiac arrest;
LUSC	cis	rs2286503	0.780	rs929464	chr7:22874770	T/C	cg11367502	chr7:22862612	TOMM7	0.49	6.33	0.33	7.92e-10	Fibrinogen;
LUSC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-6.04	-0.31	4.17e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg08975724	chr8:8085496	FLJ10661	0.49	7.26	0.37	2.71e-12	Myopia (pathological);
LUSC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.71	11.64	0.54	1.59e-26	Age at first birth;
LUSC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg15103426	chr22:29168792	CCDC117	0.6	8.35	0.42	1.89e-15	Lymphocyte counts;
LUSC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg08999081	chr20:33150536	PIGU	0.44	8.03	0.4	1.73e-14	Coronary artery disease;
LUSC	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg12091567	chr17:66097778	LOC651250	-0.71	-9.12	-0.45	7.15e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	trans	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg26811252	chr16:29126840	RRN3P2	0.64	10.32	0.49	7.6e-22	Menopause (age at onset);
LUSC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06022373	chr22:39101656	GTPBP1	0.75	11.92	0.55	1.55e-27	Menopause (age at onset);
LUSC	cis	rs6674970	1.000	rs7546304	chr1:151114484	C/G	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.45	-6.14	-0.32	2.39e-9	Childhood ear infection;
LUSC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.86	0.31	1.13e-8	Tonsillectomy;
LUSC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.88	-11.25	-0.52	4.16e-25	Chronic sinus infection;
LUSC	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg08807101	chr21:30365312	RNF160	0.53	7.11	0.36	7.24e-12	Cognitive test performance;
LUSC	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg16230307	chr14:35515116	FAM177A1	0.78	9.88	0.48	2.39e-20	Psoriasis;
LUSC	cis	rs73001065	0.901	rs73002956	chr19:19578743	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	7.2	0.37	4.02e-12	LDL cholesterol;
LUSC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.18	0.37	4.69e-12	Platelet count;
LUSC	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg03342759	chr3:160939853	NMD3	-0.48	-7.94	-0.4	3.05e-14	Morning vs. evening chronotype;
LUSC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg18135555	chr8:22132992	PIWIL2	0.39	7.71	0.39	1.5e-13	Hypertriglyceridemia;
LUSC	cis	rs2742234	0.541	rs1059484	chr10:43679800	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.03	-0.36	1.17e-11	Hirschsprung disease;
LUSC	cis	rs7188861	0.768	rs1794025	chr16:11380945	C/T	cg00044050	chr16:11439710	C16orf75	0.56	6.31	0.33	8.71e-10	HDL cholesterol;
LUSC	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.51	-8.09	-0.4	1.09e-14	Multiple sclerosis;
LUSC	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg15423357	chr2:25149977	NA	0.46	9.1	0.45	8.34e-18	Body mass index;
LUSC	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg05163923	chr11:71159392	DHCR7	-0.72	-10.52	-0.5	1.49e-22	Vitamin D levels;
LUSC	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg10645314	chr2:3704589	ALLC	-0.38	-6.66	-0.34	1.11e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg01879757	chr17:41196368	BRCA1	-0.48	-7.4	-0.38	1.12e-12	Menopause (age at onset);
LUSC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg18876405	chr7:65276391	NA	0.6	9.72	0.47	7.63e-20	Aortic root size;
LUSC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14159672	chr1:205819179	PM20D1	0.54	8.81	0.43	6.8e-17	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.23	0.52	4.91e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs662064	0.962	rs1188525	chr1:10550877	A/G	cg20482658	chr1:10539492	PEX14	-0.34	-6.9	-0.35	2.69e-11	Asthma;
LUSC	cis	rs7147624	1.000	rs2411821	chr14:65896914	G/T	cg03016385	chr14:66212404	NA	-0.78	-9.08	-0.44	9.59e-18	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg00792783	chr2:198669748	PLCL1	0.43	5.86	0.31	1.12e-8	Dermatomyositis;
LUSC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg09491104	chr22:46646882	C22orf40	-0.69	-8.91	-0.44	3.46e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	7.18	0.37	4.48e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.63	-0.43	2.49e-16	Total cholesterol levels;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg27233612	chr3:25824257	NGLY1	0.44	6.29	0.33	9.88e-10	Cognitive function;Information processing speed;
LUSC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg11502198	chr6:26597334	ABT1	0.64	10.07	0.48	5.3e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg22681709	chr2:178499509	PDE11A	-0.56	-10.49	-0.5	2e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg05340658	chr4:99064831	C4orf37	-0.43	-6.84	-0.35	3.9e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13170934	chr1:156722147	HDGF	-0.4	-5.94	-0.31	7.06e-9	Hepatitis;
LUSC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg23093090	chr10:104574429	C10orf26	0.46	8.63	0.43	2.46e-16	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs7582720	0.943	rs72932583	chr2:203869847	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	8.22	0.41	4.56e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg00376283	chr12:123451042	ABCB9	0.66	7.48	0.38	6.76e-13	Neutrophil percentage of white cells;
LUSC	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.66	-0.34	1.12e-10	QT interval;
LUSC	cis	rs6681460	0.649	rs1415984	chr1:67002117	A/G	cg02459107	chr1:67143332	SGIP1	0.38	6.07	0.32	3.48e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg04287289	chr16:89883240	FANCA	0.78	6.24	0.32	1.29e-9	Skin colour saturation;
LUSC	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg00310523	chr12:86230176	RASSF9	0.44	8.25	0.41	3.7e-15	Major depressive disorder;
LUSC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg05084668	chr3:125655381	ALG1L	-0.48	-6.79	-0.35	5.06e-11	Blood pressure (smoking interaction);
LUSC	cis	rs921665	1.000	rs7581068	chr2:3178831	T/C	cg02624386	chr2:3182749	NA	0.52	6.06	0.31	3.72e-9	World class endurance athleticism;
LUSC	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg08680598	chr22:49984980	NA	-0.34	-6.36	-0.33	6.69e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7106204	0.609	rs12804374	chr11:24338016	A/G	ch.11.24196551F	chr11:24239977	NA	0.71	5.92	0.31	7.99e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.77	-12.46	-0.56	1.54e-29	Chronic sinus infection;
LUSC	cis	rs67981189	0.634	rs221898	chr14:71605516	A/G	cg15816911	chr14:71606274	NA	0.35	6.28	0.32	1.05e-9	Schizophrenia;
LUSC	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg25457927	chr22:38595422	NA	-0.42	-8.93	-0.44	2.9e-17	Cutaneous nevi;
LUSC	cis	rs67366981	0.844	rs8004209	chr14:77716474	T/C	cg22824376	chr14:77648248	TMEM63C	0.62	5.88	0.31	1e-8	Obsessive-compulsive symptoms;
LUSC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.75	10.56	0.5	1.12e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg17054900	chr3:154042577	DHX36	0.44	5.77	0.3	1.78e-8	Coronary artery disease;
LUSC	cis	rs4917300	0.586	rs1352949	chr8:143096253	G/C	cg25363559	chr8:143086065	NA	-0.31	-7.01	-0.36	1.35e-11	Amyotrophic lateral sclerosis;
LUSC	cis	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05901451	chr6:126070800	HEY2	0.57	8.58	0.43	3.59e-16	Endometrial cancer;
LUSC	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.35	-0.42	1.84e-15	Bone mineral density;
LUSC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg19318889	chr4:1322082	MAEA	0.48	7.69	0.39	1.68e-13	Obesity-related traits;
LUSC	trans	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg08975724	chr8:8085496	FLJ10661	0.44	6.33	0.33	8.12e-10	Triglycerides;
LUSC	cis	rs73195822	0.614	rs73194061	chr12:111221941	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.14	0.36	5.98e-12	Itch intensity from mosquito bite;
LUSC	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg11161011	chr14:65562177	MAX	-0.81	-12.4	-0.56	2.58e-29	Obesity-related traits;
LUSC	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg00376283	chr12:123451042	ABCB9	0.65	8.22	0.41	4.63e-15	Neutrophil percentage of white cells;
LUSC	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg02493740	chr2:85810744	VAMP5	-0.32	-5.69	-0.3	2.77e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg11752832	chr7:134001865	SLC35B4	0.5	7.09	0.36	7.81e-12	Mean platelet volume;
LUSC	cis	rs12210905	0.688	rs12215353	chr6:27407022	C/T	cg08851530	chr6:28072375	NA	0.93	5.77	0.3	1.77e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg25124228	chr12:125621409	AACS	-0.48	-7.14	-0.36	6e-12	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg17652424	chr22:38574118	PLA2G6	-0.28	-5.9	-0.31	8.76e-9	Cutaneous nevi;
LUSC	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg16850897	chr7:100343110	ZAN	-0.53	-7.23	-0.37	3.38e-12	Other erythrocyte phenotypes;
LUSC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg15445000	chr17:37608096	MED1	0.4	6.76	0.35	6.29e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	8.71	0.43	1.41e-16	Lung cancer in ever smokers;
LUSC	cis	rs4285028	0.851	rs1986368	chr3:121710969	A/T	cg11130432	chr3:121712080	ILDR1	-0.66	-10.04	-0.48	6.43e-21	Multiple sclerosis;
LUSC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.69	-0.43	1.6e-16	Bipolar disorder;
LUSC	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg17173187	chr15:85201210	NMB	0.36	5.77	0.3	1.85e-8	Schizophrenia;
LUSC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg03785755	chr6:26196794	NA	0.53	5.66	0.3	3.24e-8	Gout;Renal underexcretion gout;
LUSC	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	8.32	0.41	2.26e-15	Monocyte count;
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg18538332	chr22:24372958	LOC391322	-0.51	-8.83	-0.44	5.83e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6546550	0.901	rs13028508	chr2:70118427	A/T	cg02498382	chr2:70120550	SNRNP27	0.28	7.09	0.36	7.8e-12	Prevalent atrial fibrillation;
LUSC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg10523860	chr14:103875565	MARK3	-0.4	-6.29	-0.33	9.91e-10	Body mass index;
LUSC	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg24375607	chr4:120327624	NA	0.72	11.69	0.54	1.04e-26	Corneal astigmatism;
LUSC	cis	rs1832871	0.711	rs9459954	chr6:158709345	G/T	cg07165851	chr6:158734300	TULP4	0.5	7.67	0.39	1.9e-13	Height;
LUSC	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg07148914	chr20:33460835	GGT7	0.53	8.17	0.41	6.57e-15	Height;
LUSC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.47	-0.38	7.17e-13	Aortic root size;
LUSC	cis	rs225245	0.817	rs225255	chr17:33955243	A/G	cg05299278	chr17:33885742	SLFN14	-0.31	-6.82	-0.35	4.39e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08470875	chr2:26401718	FAM59B	-0.67	-9.13	-0.45	6.46e-18	Gut microbiome composition (summer);
LUSC	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg14438399	chr17:27053147	TLCD1	0.53	5.86	0.31	1.13e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1866706	0.896	rs4757062	chr11:12876491	C/T	cg25843174	chr11:12811716	TEAD1	-0.28	-5.72	-0.3	2.36e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs72674100	1.000	rs4624660	chr4:97962814	T/A	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg03929089	chr4:120376271	NA	0.68	7.58	0.38	3.49e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.81	13.52	0.59	1.62e-33	Aortic root size;
LUSC	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-7.66	-0.39	2.01e-13	Schizophrenia;
LUSC	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	5.85	0.3	1.19e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg04310649	chr10:35416472	CREM	-0.41	-6.45	-0.33	3.96e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg18279467	chr3:5020901	BHLHE40	0.37	6.18	0.32	1.89e-9	Asthma;
LUSC	cis	rs9309473	0.519	rs2421584	chr2:73898852	G/A	cg20560298	chr2:73613845	ALMS1	0.47	7.01	0.36	1.3e-11	Metabolite levels;
LUSC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.78	-14.48	-0.62	3.38e-37	Osteoporosis;
LUSC	cis	rs4629180	0.630	rs10188189	chr2:102127926	A/G	cg04415270	chr2:102091202	RFX8	-0.44	-7.61	-0.38	2.83e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs16854884	0.770	rs13091882	chr3:143818661	C/T	cg06585982	chr3:143692056	C3orf58	0.45	6.74	0.35	6.88e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs500891	0.525	rs1170341	chr6:84033239	A/C	cg08257003	chr6:84140564	ME1	0.34	7.81	0.39	7.41e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs7264396	0.666	rs1536147	chr20:34173046	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.45	6.61	0.34	1.49e-10	Total cholesterol levels;
LUSC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20887711	chr4:1340912	KIAA1530	-0.7	-11.0	-0.52	3.11e-24	Longevity;
LUSC	cis	rs12545109	0.800	rs1437278	chr8:57357024	T/C	cg09654669	chr8:57350985	NA	-0.56	-7.48	-0.38	6.83e-13	Obesity-related traits;
LUSC	cis	rs8141797	0.818	rs1985047	chr22:24580381	G/C	cg00411358	chr22:24577142	SUSD2	-0.53	-5.92	-0.31	8.03e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg22615462	chr19:17416451	MRPL34	0.75	6.05	0.31	3.91e-9	Cognitive performance;
LUSC	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg21545522	chr1:205238299	TMCC2	0.48	9.1	0.45	8.33e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg05805236	chr11:65401703	PCNXL3	0.4	6.79	0.35	5.06e-11	Acne (severe);
LUSC	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.57	-0.34	1.89e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg05347473	chr6:146136440	FBXO30	0.66	11.55	0.53	3.35e-26	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9630182	0.540	rs10832029	chr11:13399080	C/T	cg00234616	chr2:74740572	TLX2	0.3	5.96	0.31	6.48e-9	Bone mineral density;
LUSC	cis	rs4704187	0.532	rs75392670	chr5:74394968	A/G	cg03227963	chr5:74354835	NA	0.31	6.65	0.34	1.19e-10	Response to amphetamines;
LUSC	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg24692254	chr21:30365293	RNF160	-0.58	-7.22	-0.37	3.57e-12	Cognitive test performance;
LUSC	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg08999081	chr20:33150536	PIGU	0.45	8.09	0.4	1.11e-14	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg17366294	chr4:99064904	C4orf37	0.56	9.93	0.48	1.54e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg11584989	chr19:19387371	SF4	0.57	6.97	0.36	1.66e-11	Bipolar disorder;
LUSC	trans	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg25206134	chr2:45395956	NA	0.56	6.58	0.34	1.8e-10	Bipolar disorder;
LUSC	trans	rs9944715	0.651	rs7228024	chr18:43782791	A/C	cg01718231	chr17:29326311	RNF135	-0.51	-7.28	-0.37	2.48e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg03790207	chr6:42947109	PEX6	-0.46	-7.06	-0.36	9.53e-12	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-10.45	-0.5	2.57e-22	Schizophrenia;
LUSC	cis	rs17155006	0.746	rs985152	chr7:107750357	G/A	cg05962710	chr7:107745446	LAMB4	-0.36	-6.36	-0.33	6.54e-10	Pneumococcal bacteremia;
LUSC	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg23649088	chr2:200775458	C2orf69	-0.5	-6.86	-0.35	3.41e-11	Schizophrenia;
LUSC	trans	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.61	0.38	2.92e-13	Ulcerative colitis;
LUSC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.43	-0.33	4.53e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs2975734	0.709	rs4841298	chr8:10111637	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.48	-0.33	3.2e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.74	-14.08	-0.61	1.14e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg23711669	chr6:146136114	FBXO30	0.76	13.58	0.6	9.4e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-9.23	-0.45	3.29e-18	Longevity;Endometriosis;
LUSC	cis	rs12618769	0.597	rs3769734	chr2:99096149	A/T	cg10123293	chr2:99228465	UNC50	0.47	7.67	0.39	1.89e-13	Bipolar disorder;
LUSC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.91	0.61	5.12e-35	Cognitive test performance;
LUSC	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg04317338	chr11:64019027	PLCB3	-0.63	-7.17	-0.37	4.93e-12	Mean platelet volume;
LUSC	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.07	-0.44	1.07e-17	Neuroticism;
LUSC	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.22	-0.32	1.52e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7131987	0.801	rs962866	chr12:29434147	A/G	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.31	-0.33	9.06e-10	QT interval;
LUSC	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg13010199	chr12:38710504	ALG10B	0.55	8.48	0.42	7.46e-16	Morning vs. evening chronotype;
LUSC	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22980127	chr19:33182716	NUDT19	0.94	12.79	0.57	9.57e-31	Red blood cell traits;
LUSC	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.81	-0.39	7.26e-14	Total cholesterol levels;
LUSC	cis	rs2979489	0.891	rs4537262	chr8:30306757	T/A	cg26383811	chr8:30366931	RBPMS	0.48	7.6	0.38	3.05e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs782590	0.574	rs12991445	chr2:55675939	C/T	cg18811423	chr2:55921094	PNPT1	0.61	8.74	0.43	1.15e-16	Metabolic syndrome;
LUSC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg05347473	chr6:146136440	FBXO30	0.46	7.97	0.4	2.55e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg21251018	chr6:28226885	NKAPL	0.31	5.88	0.31	9.71e-9	Pubertal anthropometrics;
LUSC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg13206674	chr6:150067644	NUP43	0.62	10.05	0.48	6.38e-21	Lung cancer;
LUSC	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.74	11.82	0.54	3.64e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2742417	0.624	rs2673029	chr3:45758867	A/G	cg10512202	chr3:45649293	LIMD1	0.36	6.13	0.32	2.53e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg01753270	chr2:239240285	TRAF3IP1	-0.42	-5.65	-0.3	3.48e-8	Multiple system atrophy;
LUSC	cis	rs2190422	0.677	rs2906639	chr7:103074580	T/C	cg04218035	chr7:103086829	SLC26A5	0.32	6.21	0.32	1.55e-9	Morning vs. evening chronotype;
LUSC	trans	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg20587970	chr11:113659929	NA	0.81	9.68	0.47	1.06e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg12062639	chr20:23401060	NAPB	0.97	7.93	0.4	3.23e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs2997457	0.818	rs298446	chr1:26305933	A/T	cg26343958	chr12:5539662	NA	-0.48	-6.01	-0.31	4.83e-9	Facial morphology (factor 16);
LUSC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18876405	chr7:65276391	NA	0.56	8.92	0.44	3.23e-17	Aortic root size;
LUSC	trans	rs7980799	0.649	rs2389215	chr12:33649457	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.95	-0.31	6.71e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg08854313	chr1:11322531	MTOR	0.8	12.45	0.56	1.6800000000000001e-29	Body mass index;
LUSC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.65	0.57	3.22e-30	Prudent dietary pattern;
LUSC	cis	rs9311676	0.656	rs11915190	chr3:58409700	G/A	cg13750441	chr3:58318267	PXK	0.34	6.71	0.34	8.2e-11	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg26043149	chr18:55253948	FECH	0.49	7.27	0.37	2.55e-12	Bone mineral density;
LUSC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg13683864	chr3:40499215	RPL14	1.0	17.13	0.68	1.15e-47	Renal cell carcinoma;
LUSC	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.93	0.31	7.38e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2729354	0.903	rs1846568	chr11:57357714	A/C	cg24343310	chr11:57249947	NA	0.36	6.53	0.34	2.47e-10	Blood protein levels;
LUSC	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg12483005	chr1:23474871	LUZP1	-0.43	-6.32	-0.33	8.51e-10	Height;
LUSC	cis	rs1843834	0.624	rs2396110	chr2:225560219	A/G	cg22455342	chr2:225449267	CUL3	0.44	5.78	0.3	1.72e-8	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.65	-8.84	-0.44	5.57e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.99	0.48	1.01e-20	Resting heart rate;
LUSC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.4	-0.33	5.27e-10	Schizophrenia;
LUSC	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg08345082	chr10:99160200	RRP12	-0.34	-6.97	-0.36	1.71e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2975734	0.709	rs4841298	chr8:10111637	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-5.65	-0.3	3.39e-8	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs1322512	1.000	rs2250514	chr6:153010920	C/T	cg27316956	chr6:152958899	SYNE1	0.35	6.04	0.31	4.22e-9	Tonometry;
LUSC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.82	12.93	0.58	2.84e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg24558204	chr6:135376177	HBS1L	0.58	8.87	0.44	4.49e-17	Red blood cell count;
LUSC	trans	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg26384229	chr12:38710491	ALG10B	0.61	8.46	0.42	8.24e-16	Resting heart rate;
LUSC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.07	15.66	0.65	7.58e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg13114125	chr14:105738426	BRF1	-0.91	-15.8	-0.65	2.25e-42	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.45	-5.7	-0.3	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs1493916	0.837	rs2172626	chr18:31410478	C/T	cg27147174	chr7:100797783	AP1S1	-0.55	-8.73	-0.43	1.21e-16	Life satisfaction;
LUSC	trans	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg03886242	chr7:26192032	NFE2L3	-0.42	-6.66	-0.34	1.11e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg07148914	chr20:33460835	GGT7	-0.46	-6.74	-0.35	7.17e-11	Height;
LUSC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.93	-0.35	2.13e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.94	20.34	0.74	2.08e-60	Longevity;
LUSC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	1.21	16.15	0.66	9.48e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg20573242	chr4:122745356	CCNA2	-0.42	-6.07	-0.32	3.44e-9	Type 2 diabetes;
LUSC	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg00520135	chr15:63333846	TPM1	-0.34	-6.63	-0.34	1.36e-10	Platelet count;
LUSC	cis	rs2282032	0.766	rs17799268	chr14:90788934	G/T	cg14092571	chr14:90743983	NA	0.48	5.88	0.31	9.97e-9	Longevity;
LUSC	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg13798780	chr7:105162888	PUS7	0.56	6.12	0.32	2.55e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg00852783	chr1:26633632	UBXN11	0.61	9.63	0.47	1.58e-19	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg27535305	chr1:53392650	SCP2	0.39	7.27	0.37	2.52e-12	Monocyte count;
LUSC	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.59	-0.43	3.45e-16	Neuroticism;
LUSC	cis	rs16949788	1.000	rs41315964	chr15:66779698	C/T	cg08120210	chr15:66682733	MAP2K1	-0.6	-6.3	-0.33	9.41e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13670615	chr19:49140625	SEC1;DBP	0.42	5.99	0.31	5.38e-9	Neuroticism;
LUSC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg13866156	chr1:1669148	SLC35E2	-0.51	-8.19	-0.41	5.68e-15	Body mass index;
LUSC	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg25801113	chr15:45476975	SHF	0.35	7.37	0.37	1.39e-12	Uric acid levels;
LUSC	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-20.02	-0.74	4.03e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17467752	chr17:38218738	THRA	0.77	12.45	0.56	1.7e-29	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs56283067	0.578	rs2894641	chr6:45393174	A/G	cg18551225	chr6:44695536	NA	-0.4	-5.82	-0.3	1.41e-8	Total body bone mineral density;
LUSC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.36	0.53	1.66e-25	Menopause (age at onset);
LUSC	cis	rs10740039	0.516	rs7072017	chr10:62344326	A/G	cg18175470	chr10:62150864	ANK3	-0.45	-6.81	-0.35	4.6e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03074984	chr11:64126431	RPS6KA4	-0.46	-6.65	-0.34	1.22e-10	Hepatitis;
LUSC	trans	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg15556689	chr8:8085844	FLJ10661	0.47	6.96	0.36	1.84e-11	Retinal vascular caliber;
LUSC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg05347473	chr6:146136440	FBXO30	0.46	7.99	0.4	2.16e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg25019033	chr10:957182	NA	-0.53	-6.1	-0.32	2.91e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg06521331	chr12:34319734	NA	0.36	5.91	0.31	8.25e-9	Morning vs. evening chronotype;
LUSC	cis	rs6500395	1.000	rs9933314	chr16:48676608	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.8	0.35	4.86e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg08975724	chr8:8085496	FLJ10661	0.45	6.67	0.34	1.09e-10	Retinal vascular caliber;
LUSC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg04398451	chr17:18023971	MYO15A	0.44	6.91	0.35	2.5e-11	Total body bone mineral density;
LUSC	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg06627628	chr2:24431161	ITSN2	-0.61	-7.4	-0.38	1.09e-12	Lymphocyte counts;
LUSC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg15147215	chr3:52552868	STAB1	-0.32	-5.8	-0.3	1.55e-8	Bipolar disorder;
LUSC	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	0.55	8.73	0.43	1.2e-16	Breast cancer;
LUSC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg06671706	chr8:8559999	CLDN23	0.49	6.47	0.33	3.55e-10	Obesity-related traits;
LUSC	cis	rs7615316	1.000	rs7615316	chr3:142355926	G/A	cg16271453	chr3:142027066	XRN1	-0.34	-5.74	-0.3	2.09e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg10253484	chr15:75165896	SCAMP2	0.6	8.34	0.42	1.91e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14476756	chr9:136243436	C9orf96;SURF4	0.41	6.14	0.32	2.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg15145296	chr3:125709740	NA	0.55	6.17	0.32	1.93e-9	Blood pressure (smoking interaction);
LUSC	cis	rs472402	0.580	rs8192186	chr5:6652009	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.53	-7.68	-0.39	1.74e-13	Response to amphetamines;
LUSC	cis	rs16854884	0.657	rs16854816	chr3:143734147	A/G	cg06585982	chr3:143692056	C3orf58	0.5	8.13	0.41	8.55e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24110177	chr3:50126178	RBM5	-0.57	-9.36	-0.46	1.25e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs8038465	0.615	rs11072430	chr15:73981701	A/G	cg15420318	chr15:73925796	NPTN	-0.55	-9.22	-0.45	3.45e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3018712	0.532	rs10791988	chr11:68416051	A/T	cg22747802	chr11:68417633	NA	-0.41	-5.65	-0.3	3.5e-8	Total body bone mineral density;
LUSC	cis	rs73198271	0.628	rs74433718	chr8:8591546	A/C	cg01851573	chr8:8652454	MFHAS1	0.46	5.77	0.3	1.83e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs734999	0.549	rs867436	chr1:2523723	C/T	cg18854424	chr1:2615690	NA	0.48	9.49	0.46	4.53e-19	Ulcerative colitis;
LUSC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg26380479	chr7:97908229	NA	-0.27	-6.02	-0.31	4.57e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9807989	0.839	rs10182710	chr2:102981306	A/G	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.5e-9	Asthma;
LUSC	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg04374321	chr14:90722782	PSMC1	0.75	12.12	0.55	2.92e-28	Mortality in heart failure;
LUSC	cis	rs909341	0.909	rs1151624	chr20:62369895	A/G	cg09650180	chr20:62225654	GMEB2	0.44	5.67	0.3	3.13e-8	Atopic dermatitis;
LUSC	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.9	15.63	0.65	1.05e-41	Morning vs. evening chronotype;
LUSC	trans	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.53	0.42	5.33e-16	Diabetic kidney disease;
LUSC	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg12823233	chr7:2316876	SNX8	-0.47	-8.03	-0.4	1.72e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg06221963	chr1:154839813	KCNN3	0.45	9.09	0.45	9.29e-18	Schizophrenia;
LUSC	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg08085267	chr17:45401833	C17orf57	-0.51	-7.3	-0.37	2.07e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg23791538	chr6:167370224	RNASET2	-0.41	-6.45	-0.33	3.87e-10	Crohn's disease;
LUSC	cis	rs250677	0.524	rs417413	chr5:148452726	T/C	cg12140854	chr5:148520817	ABLIM3	-0.34	-6.06	-0.31	3.68e-9	Breast cancer;
LUSC	trans	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg25214090	chr10:38739885	LOC399744	0.38	6.04	0.31	4.1e-9	Diastolic blood pressure;
LUSC	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.41	0.38	1.05e-12	Lung cancer in ever smokers;
LUSC	cis	rs9650657	0.769	rs1968400	chr8:10615431	G/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.05	-0.31	3.8e-9	Neuroticism;
LUSC	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	12.13	0.55	2.66e-28	Height;
LUSC	trans	rs9929218	1.000	rs4783681	chr16:68806508	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-11.75	-0.54	6.51e-27	Colorectal cancer;
LUSC	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg17143192	chr8:8559678	CLDN23	0.63	8.9	0.44	3.56e-17	Obesity-related traits;
LUSC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18876405	chr7:65276391	NA	-0.54	-8.5	-0.42	6.26e-16	Aortic root size;
LUSC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg21535247	chr6:8435926	SLC35B3	0.6	9.46	0.46	5.68e-19	Motion sickness;
LUSC	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg02153584	chr22:29168773	CCDC117	-0.56	-8.47	-0.42	7.91e-16	Lymphocyte counts;
LUSC	cis	rs9815354	0.680	rs73073291	chr3:42028004	G/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg09307838	chr4:120376055	NA	0.72	10.44	0.5	2.81e-22	Corneal astigmatism;
LUSC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg00933542	chr6:150070202	PCMT1	-0.32	-6.85	-0.35	3.64e-11	Lung cancer;
LUSC	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg10756475	chr4:1757242	NA	-0.36	-5.82	-0.3	1.41e-8	Bladder cancer;Urinary bladder cancer;
LUSC	cis	rs3772130	0.962	rs4311252	chr3:121514161	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.07	0.48	5.45e-21	Cognitive performance;
LUSC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.62	0.34	1.47e-10	Menopause (age at onset);
LUSC	cis	rs911119	0.908	rs8114619	chr20:23601813	G/T	cg16589663	chr20:23618590	CST3	0.58	6.91	0.35	2.48e-11	Chronic kidney disease;
LUSC	cis	rs4654899	0.865	rs6693020	chr1:21378057	A/G	cg01072550	chr1:21505969	NA	-0.54	-7.9	-0.4	4.21e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2073300	1.000	rs2073300	chr20:23471681	T/G	cg09953122	chr20:23471693	CST8	-0.87	-7.06	-0.36	9.78e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg00484396	chr16:3507460	NAT15	-0.84	-10.54	-0.5	1.26e-22	Tuberculosis;
LUSC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg03929089	chr4:120376271	NA	-0.94	-16.46	-0.67	5.66e-45	Height;
LUSC	cis	rs427941	0.703	rs201458	chr7:101741439	T/C	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs9326248	0.569	rs10892082	chr11:117039325	A/C	cg26566898	chr11:117069891	TAGLN	0.43	5.77	0.3	1.82e-8	Blood protein levels;
LUSC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	0.65	13.75	0.6	2.1e-34	Prudent dietary pattern;
LUSC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg25258033	chr6:167368657	RNASET2	-0.47	-7.95	-0.4	2.87e-14	Crohn's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19987288	chr12:56122958	CD63	-0.48	-6.43	-0.33	4.49e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3815700	1.000	rs8100168	chr19:33093084	G/A	cg02997394	chr19:33096574	ANKRD27	0.71	7.18	0.37	4.43e-12	Eosinophilic esophagitis;
LUSC	cis	rs9359856	0.510	rs17294495	chr6:90445753	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.92	-10.79	-0.51	1.8e-23	Bipolar disorder;
LUSC	trans	rs9944715	0.954	rs62096525	chr18:43743820	G/A	cg01718231	chr17:29326311	RNF135	0.48	6.79	0.35	5.09e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg00579484	chr14:23475993	C14orf93	0.39	5.78	0.3	1.72e-8	Cognitive ability (multi-trait analysis);
LUSC	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg13010199	chr12:38710504	ALG10B	-0.51	-7.79	-0.39	8.66e-14	Morning vs. evening chronotype;
LUSC	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.85	-11.77	-0.54	5.46e-27	Ileal carcinoids;
LUSC	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg17691542	chr6:26056736	HIST1H1C	0.46	6.56	0.34	2.02e-10	Iron status biomarkers;
LUSC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg18681998	chr4:17616180	MED28	0.85	15.66	0.65	8.11e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg09033563	chr22:24373618	LOC391322	-0.66	-10.42	-0.5	3.36e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg23625390	chr15:77176239	SCAPER	-0.66	-10.08	-0.48	4.95e-21	Blood metabolite levels;
LUSC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	0.65	9.21	0.45	3.57e-18	Methadone dose in opioid dependence;
LUSC	cis	rs10791097	0.506	rs10750446	chr11:130706918	T/C	cg12179176	chr11:130786555	SNX19	-0.55	-8.13	-0.41	8.32e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.86	0.54	2.63e-27	Cognitive ability;
LUSC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg11062466	chr8:58055876	NA	0.64	8.3	0.41	2.57e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06558623	chr16:89946397	TCF25	0.95	10.21	0.49	1.82e-21	Skin colour saturation;
LUSC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-12.64	-0.57	3.31e-30	Platelet count;
LUSC	cis	rs929596	0.564	rs2741027	chr2:234518011	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-6.37	-0.33	6.31e-10	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg04865166	chr7:105162814	PUS7	0.51	5.7	0.3	2.65e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1044826	1.000	rs34742758	chr3:139218378	C/G	cg00490450	chr3:139108681	COPB2	0.51	6.8	0.35	4.8e-11	Obesity-related traits;
LUSC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg03351412	chr1:154909251	PMVK	0.49	7.76	0.39	1.05e-13	Prostate cancer;
LUSC	cis	rs10992471	0.603	rs7033979	chr9:95223980	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.75	-0.39	1.15e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs4729127	1.000	rs7799378	chr7:94007546	C/G	cg20086523	chr13:52378287	DHRS12	-0.51	-6.02	-0.31	4.6e-9	Intelligence;
LUSC	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.75	12.71	0.57	1.78e-30	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.6	0.57	4.77e-30	Motion sickness;
LUSC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg10621924	chr7:39171070	POU6F2	0.45	7.17	0.37	4.91e-12	IgG glycosylation;
LUSC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg12463550	chr7:65579703	CRCP	0.43	6.17	0.32	2.01e-9	Calcium levels;
LUSC	trans	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg06606381	chr12:133084897	FBRSL1	-0.61	-5.95	-0.31	6.75e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg24812749	chr6:127587940	RNF146	0.71	10.21	0.49	1.76e-21	Breast cancer;
LUSC	cis	rs9311676	0.609	rs11925862	chr3:58417927	A/C	cg26110898	chr3:58419937	PDHB	0.4	6.4	0.33	5.22e-10	Systemic lupus erythematosus;
LUSC	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.59e-25	Corneal astigmatism;
LUSC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg20573242	chr4:122745356	CCNA2	0.66	10.43	0.5	3.07e-22	Type 2 diabetes;
LUSC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg05872129	chr22:39784769	NA	-0.55	-8.9	-0.44	3.59e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs11048434	0.736	rs11048338	chr12:9121362	C/G	cg13575925	chr12:9217583	LOC144571	0.33	6.03	0.31	4.23e-9	Sjögren's syndrome;
LUSC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2067615	0.524	rs4964186	chr12:107080235	C/T	cg15890332	chr12:107067104	RFX4	0.36	6.24	0.32	1.35e-9	Heart rate;
LUSC	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg03676636	chr4:99064102	C4orf37	0.36	7.89	0.4	4.25e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg13560548	chr3:10150139	C3orf24	0.48	6.9	0.35	2.69e-11	Alzheimer's disease;
LUSC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.74	10.31	0.49	7.84e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs16917546	1.000	rs10995258	chr10:64408787	C/T	cg03961010	chr10:64397487	ZNF365	-0.42	-6.7	-0.34	8.95e-11	Basal cell carcinoma;
LUSC	cis	rs6426558	0.537	rs6692080	chr1:227390162	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.53	-7.19	-0.37	4.2e-12	Neutrophil percentage of white cells;
LUSC	cis	rs3829251	0.786	rs7103591	chr11:71237619	T/C	cg05163923	chr11:71159392	DHCR7	-0.67	-7.05	-0.36	1.02e-11	Vitamin D levels;
LUSC	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-10.5	-0.5	1.72e-22	Migraine;Coronary artery disease;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg07791671	chr2:242255336	SEPT2;HDLBP	0.47	6.29	0.33	9.94e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg26850624	chr5:429559	AHRR	-0.43	-8.43	-0.42	1.08e-15	Cystic fibrosis severity;
LUSC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg05313129	chr8:58192883	C8orf71	-0.58	-6.29	-0.33	9.86e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg00792783	chr2:198669748	PLCL1	0.43	5.69	0.3	2.79e-8	Dermatomyositis;
LUSC	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14240646	chr10:27532245	ACBD5	0.71	8.19	0.41	5.71e-15	Breast cancer;
LUSC	cis	rs9648716	0.515	rs38732	chr7:140705162	A/T	cg23214464	chr7:140373596	ADCK2	0.72	6.24	0.32	1.34e-9	Type 2 diabetes;
LUSC	cis	rs3741151	0.773	rs57354084	chr11:73139376	A/T	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17916960	chr15:79447300	NA	-0.52	-10.39	-0.49	4.32e-22	Refractive error;
LUSC	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.11	0.32	2.83e-9	Rheumatoid arthritis;
LUSC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg23711669	chr6:146136114	FBXO30	0.87	16.53	0.67	2.75e-45	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg08999081	chr20:33150536	PIGU	0.37	6.82	0.35	4.34e-11	Height;
LUSC	trans	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.64	-0.34	1.24e-10	Life satisfaction;
LUSC	trans	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg24247370	chr13:99142703	STK24	-0.35	-6.38	-0.33	5.82e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg17376030	chr22:41985996	PMM1	-0.46	-5.72	-0.3	2.42e-8	Vitiligo;
LUSC	cis	rs7759001	0.857	rs10807022	chr6:27362598	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs2179367	0.600	rs9498352	chr6:149760244	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.35	-5.87	-0.31	1.03e-8	Dupuytren's disease;
LUSC	cis	rs500891	0.525	rs7758989	chr6:84061319	T/C	cg08257003	chr6:84140564	ME1	0.34	8.34	0.42	1.98e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-9.63	-0.47	1.53e-19	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-7.26	-0.37	2.73e-12	Colorectal cancer;
LUSC	cis	rs2274273	0.686	rs66842809	chr14:55630571	T/C	cg04306507	chr14:55594613	LGALS3	0.48	9.76	0.47	5.79e-20	Protein biomarker;
LUSC	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg24375607	chr4:120327624	NA	0.77	11.32	0.53	2.32e-25	Corneal astigmatism;
LUSC	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	15.15	0.64	7.69e-40	Lung cancer in ever smokers;
LUSC	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.87	14.78	0.63	2.2e-38	Bladder cancer;
LUSC	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg23795048	chr12:9217529	LOC144571	0.34	6.01	0.31	4.82e-9	Sjögren's syndrome;
LUSC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg03146154	chr1:46216737	IPP	0.55	8.25	0.41	3.82e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs73198271	1.000	rs11784958	chr8:8607781	C/A	cg01851573	chr8:8652454	MFHAS1	0.58	8.04	0.4	1.55e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22509189	chr2:225307070	NA	0.46	6.02	0.31	4.64e-9	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs12286929	0.661	rs7947402	chr11:115088420	T/C	cg04055981	chr11:115044050	NA	0.4	6.9	0.35	2.57e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg10326726	chr10:51549505	MSMB	-0.35	-5.94	-0.31	7.02e-9	Prostate-specific antigen levels;
LUSC	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg11645453	chr3:52864694	ITIH4	-0.4	-9.24	-0.45	2.94e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.61	8.09	0.4	1.1e-14	High light scatter reticulocyte count;
LUSC	cis	rs8064299	0.597	rs2166703	chr17:72781812	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.93	19.06	0.72	2.39e-55	Monocyte count;
LUSC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.33	0.45	1.55e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg04539111	chr16:67997858	SLC12A4	-0.47	-6.42	-0.33	4.7e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg13565492	chr6:43139072	SRF	-0.63	-6.59	-0.34	1.71e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg09509183	chr1:209979624	IRF6	0.53	6.29	0.33	9.68e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs11214589	0.905	rs12804573	chr11:113241726	G/A	cg14159747	chr11:113255604	NA	0.29	7.01	0.36	1.33e-11	Neuroticism;
LUSC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.7	12.77	0.57	1.14e-30	Prudent dietary pattern;
LUSC	cis	rs6942756	0.955	rs55638303	chr7:128885770	C/T	cg02491457	chr7:128862824	NA	-0.52	-7.42	-0.38	9.94e-13	White matter hyperintensity burden;
LUSC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg14552801	chr7:65878734	NA	-0.43	-5.95	-0.31	6.61e-9	Aortic root size;
LUSC	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg09408571	chr1:101003634	GPR88	-0.33	-6.68	-0.34	9.99e-11	Breast cancer;
LUSC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg26384229	chr12:38710491	ALG10B	0.71	10.93	0.51	5.75e-24	Morning vs. evening chronotype;
LUSC	cis	rs4780355	0.918	rs243323	chr16:11361202	A/G	cg00044050	chr16:11439710	C16orf75	0.56	8.39	0.42	1.35e-15	Crohn's disease and psoriasis;
LUSC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg20243544	chr17:37824526	PNMT	0.48	6.21	0.32	1.59e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	7.58	0.38	3.39e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7589342	0.536	rs10201738	chr2:106386294	C/T	cg09152813	chr2:106391379	NCK2	-0.37	-6.07	-0.32	3.43e-9	Addiction;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00671161	chr13:52586367	ALG11;ATP7B	0.52	7.22	0.37	3.56e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg13010199	chr12:38710504	ALG10B	0.41	5.9	0.31	8.95e-9	Morning vs. evening chronotype;
LUSC	cis	rs9506514	0.722	rs10400670	chr13:21253489	G/A	cg04906043	chr13:21280425	IL17D	-0.3	-5.66	-0.3	3.31e-8	Coronary artery calcification;
LUSC	cis	rs7113850	0.541	rs7944769	chr11:24224823	G/C	ch.11.24196551F	chr11:24239977	NA	0.99	9.0	0.44	1.76e-17	Bone fracture in osteoporosis;
LUSC	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9349203	1	rs9349203	chr6:41893323	G/A	cg17623882	chr6:41773611	USP49	-0.62	-10.19	-0.49	2.11e-21	Menarche (age at onset);
LUSC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg06028605	chr16:24865363	SLC5A11	0.48	8.33	0.41	2.16e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6545883	0.826	rs777593	chr2:61419103	C/A	cg15711740	chr2:61764176	XPO1	-0.43	-6.55	-0.34	2.22e-10	Tuberculosis;
LUSC	cis	rs11209002	0.545	rs2093332	chr1:67531974	G/A	cg02640540	chr1:67518911	SLC35D1	0.6	8.17	0.41	6.36e-15	Crohn's disease;
LUSC	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg17691542	chr6:26056736	HIST1H1C	0.45	6.76	0.35	6.12e-11	Height;
LUSC	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg18132916	chr6:79620363	NA	-0.4	-6.14	-0.32	2.4e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg03732007	chr1:2071316	PRKCZ	0.45	7.21	0.37	3.81e-12	Height;
LUSC	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg24006582	chr15:45444508	DUOX1	0.65	9.5	0.46	4.16e-19	Uric acid levels;
LUSC	trans	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg25482853	chr8:67687455	SGK3	1.02	16.28	0.67	2.82e-44	Obesity-related traits;
LUSC	cis	rs9815354	0.812	rs73073323	chr3:41834051	C/T	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.22	-0.37	3.45e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg05425664	chr17:57184151	TRIM37	-0.54	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs12210905	1.000	rs7759955	chr6:26709424	G/A	cg11837749	chr1:55047332	ACOT11	0.56	5.99	0.31	5.28e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg16339924	chr4:17578868	LAP3	0.55	8.42	0.42	1.11e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.67	0.43	1.87e-16	Menarche (age at onset);
LUSC	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg26384229	chr12:38710491	ALG10B	0.71	11.24	0.52	4.36e-25	Morning vs. evening chronotype;
LUSC	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg11130432	chr3:121712080	ILDR1	-0.63	-9.59	-0.46	2.19e-19	Multiple sclerosis;
LUSC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg21017887	chr14:105400489	NA	0.68	13.32	0.59	8.93e-33	Rheumatoid arthritis;
LUSC	cis	rs9309473	0.519	rs13017182	chr2:73891004	G/T	cg20560298	chr2:73613845	ALMS1	0.44	6.92	0.35	2.33e-11	Metabolite levels;
LUSC	trans	rs12431204	0.874	rs1538145	chr13:38445304	A/T	cg25252598	chr12:6641602	NA	0.37	6.31	0.33	8.77e-10	Schizophrenia;
LUSC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg06494592	chr3:125709126	NA	-0.51	-5.91	-0.31	8.67e-9	Blood pressure (smoking interaction);
LUSC	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg00310523	chr12:86230176	RASSF9	0.36	6.51	0.34	2.72e-10	Major depressive disorder;
LUSC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg15117754	chr3:10150083	C3orf24	0.43	5.7	0.3	2.59e-8	Alzheimer's disease;
LUSC	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.85	15.03	0.64	2.24e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg13114125	chr14:105738426	BRF1	0.89	15.74	0.65	3.64e-42	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.1e-12	Motion sickness;
LUSC	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg08085267	chr17:45401833	C17orf57	-0.53	-7.65	-0.39	2.13e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg05110241	chr16:68378359	PRMT7	-0.74	-8.43	-0.42	1.03e-15	Schizophrenia;
LUSC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg05425664	chr17:57184151	TRIM37	0.54	7.98	0.4	2.31e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08859206	chr1:53392774	SCP2	0.5	8.66	0.43	2e-16	Monocyte count;
LUSC	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.57	8.76	0.43	9.65e-17	Blood protein levels;
LUSC	cis	rs9532580	0.710	rs9577090	chr13:41225228	G/T	cg21288729	chr13:41239152	FOXO1	0.63	9.68	0.47	1.06e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg13535736	chr9:111863775	C9orf5	-0.39	-6.39	-0.33	5.53e-10	Menarche (age at onset);
LUSC	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg12365402	chr11:9010492	NRIP3	0.36	6.2	0.32	1.63e-9	Hemoglobin concentration;
LUSC	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg20503657	chr10:835505	NA	0.62	7.9	0.4	4.14e-14	Eosinophil percentage of granulocytes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09854653	chr6:163834903	QKI	-0.4	-6.16	-0.32	2.04e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.7	-0.3	2.69e-8	Depression;
LUSC	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg19743168	chr1:23544995	NA	0.56	10.84	0.51	1.16e-23	Height;
LUSC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-6.18	-0.32	1.82e-9	Total body bone mineral density;
LUSC	trans	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-9.68	-0.47	1.1e-19	Blood pressure (smoking interaction);
LUSC	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg13160058	chr8:26243215	BNIP3L	-0.4	-7.16	-0.36	5.32e-12	Red cell distribution width;
LUSC	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg10518543	chr12:38710700	ALG10B	0.41	5.79	0.3	1.66e-8	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2467099	0.732	rs2168855	chr17:73943350	C/T	cg19302996	chr17:73780495	UNK	-0.5	-5.76	-0.3	1.96e-8	Systolic blood pressure;
LUSC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg20503657	chr10:835505	NA	1.05	13.48	0.59	2.19e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	0.46	7.77	0.39	9.93e-14	Lymphocyte counts;
LUSC	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg17052675	chr2:3827356	NA	-0.57	-11.28	-0.53	3.32e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg18758796	chr5:131593413	PDLIM4	-0.42	-6.51	-0.34	2.77e-10	Breast cancer;
LUSC	cis	rs4363385	0.818	rs435633	chr1:153011811	A/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs10761482	0.861	rs10761486	chr10:62104303	C/T	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs6087990	0.701	rs1997797	chr20:31387954	C/G	cg13636640	chr20:31349939	DNMT3B	0.91	18.56	0.71	2.37e-53	Ulcerative colitis;
LUSC	trans	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg21659725	chr3:3221576	CRBN	0.48	7.18	0.37	4.67e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg08132940	chr7:1081526	C7orf50	-0.52	-6.27	-0.32	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7084921	0.521	rs12772820	chr10:101873824	A/G	cg02250046	chr10:101825185	CPN1	-0.31	-5.78	-0.3	1.73e-8	Bone mineral density;
LUSC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg17554472	chr22:41940697	POLR3H	0.48	5.95	0.31	6.68e-9	Vitiligo;
LUSC	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.42	0.53	9.82e-26	Eye color traits;
LUSC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg27094323	chr7:1216898	NA	-0.34	-5.71	-0.3	2.55e-8	Longevity;Endometriosis;
LUSC	cis	rs7560272	0.538	rs17434634	chr2:73922926	T/A	cg20560298	chr2:73613845	ALMS1	0.4	6.12	0.32	2.55e-9	Schizophrenia;
LUSC	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg21132104	chr15:45694354	SPATA5L1	0.4	5.92	0.31	8.03e-9	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg18187862	chr3:45730750	SACM1L	0.53	7.03	0.36	1.16e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg17469321	chr7:55412551	NA	0.65	10.58	0.5	9.39e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.56	-9.25	-0.45	2.75e-18	Breast cancer;
LUSC	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg16850897	chr7:100343110	ZAN	0.36	5.75	0.3	1.99e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21923990	chr19:8408412	KANK3	0.41	5.99	0.31	5.39e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg19920283	chr7:105172520	RINT1	0.57	5.97	0.31	5.98e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.7	10.58	0.5	9.21e-23	Corneal astigmatism;
LUSC	cis	rs73206853	0.563	rs1050587	chr12:111158161	T/C	cg12870014	chr12:110450643	ANKRD13A	0.67	7.4	0.38	1.13e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs17253792	0.822	rs79873916	chr14:56172631	G/C	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	8.91e-12	Putamen volume;
LUSC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg18306943	chr3:40428807	ENTPD3	0.38	5.72	0.3	2.34e-8	Renal cell carcinoma;
LUSC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8040855	0.599	rs4643289	chr15:85726714	C/T	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.85	0.35	3.67e-11	Bulimia nervosa;
LUSC	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.64	-0.3	3.56e-8	Coronary artery disease;
LUSC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg26587870	chr6:27730563	NA	-0.64	-6.07	-0.32	3.42e-9	Depression;
LUSC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.15	15.28	0.64	2.48e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25072359	chr17:41440525	NA	0.66	9.45	0.46	6.13e-19	Menopause (age at onset);
LUSC	cis	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg00745463	chr17:30367425	LRRC37B	-0.69	-8.78	-0.43	8.94e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg09904177	chr6:26538194	HMGN4	0.75	14.04	0.61	1.66e-35	Intelligence (multi-trait analysis);
LUSC	trans	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg10756647	chr7:56101905	PSPH	-0.87	-8.66	-0.43	2.02e-16	Diabetic kidney disease;
LUSC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.19e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	15.63	0.65	9.98e-42	Platelet count;
LUSC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.37	-0.46	1.12e-18	Mood instability;
LUSC	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg18105134	chr13:113819100	PROZ	-0.76	-10.64	-0.5	5.78e-23	Platelet distribution width;
LUSC	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.48	7.8	0.39	8.05e-14	Lung cancer;
LUSC	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.46	-6.37	-0.33	6.33e-10	Neutrophil percentage of white cells;
LUSC	cis	rs12367572	0.796	rs7979141	chr12:45282630	A/T	cg04608330	chr12:45269318	NELL2	-0.58	-9.4	-0.46	9.25e-19	Gut microbiome composition (summer);
LUSC	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.4	0.64	8.6e-41	Morning vs. evening chronotype;
LUSC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg19729930	chr2:74357872	NA	0.89	16.74	0.68	4.36e-46	Gestational age at birth (maternal effect);
LUSC	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg05776053	chr2:74358815	NA	0.39	5.88	0.31	1.02e-8	Gestational age at birth (maternal effect);
LUSC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg20276088	chr3:133502917	NA	-0.43	-6.47	-0.33	3.51e-10	Iron status biomarkers;
LUSC	cis	rs7759001	0.857	rs10946913	chr6:27369873	C/T	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-1.03	-20.48	-0.75	5.94e-61	Height;
LUSC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.97	-13.98	-0.61	2.89e-35	Initial pursuit acceleration;
LUSC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7614311	0.636	rs66490742	chr3:63913653	G/A	cg22134162	chr3:63841271	THOC7	-0.5	-6.02	-0.31	4.47e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.38e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs72634258	0.796	rs4369247	chr1:8168993	C/T	cg00042356	chr1:8021962	PARK7	-0.54	-6.66	-0.34	1.15e-10	Inflammatory bowel disease;
LUSC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg21573476	chr21:45109991	RRP1B	-0.4	-6.42	-0.33	4.74e-10	Mean corpuscular volume;
LUSC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg03351412	chr1:154909251	PMVK	0.55	8.7	0.43	1.52e-16	Prostate cancer;
LUSC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-10.87	-0.51	9.44e-24	Mean corpuscular volume;
LUSC	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg23711669	chr6:146136114	FBXO30	0.87	16.0	0.66	3.47e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg05347473	chr6:146136440	FBXO30	0.53	9.17	0.45	4.95e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6845621	0.745	rs6449426	chr4:18865678	A/C	cg12196642	chr4:18937545	NA	-0.32	-5.86	-0.31	1.1e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg18302933	chr2:88491318	NA	-0.34	-6.53	-0.34	2.39e-10	Response to metformin (IC50);
LUSC	cis	rs7523050	0.730	rs41279678	chr1:109440215	G/A	cg08274380	chr1:109419600	GPSM2	1.13	11.51	0.53	4.76e-26	Fat distribution (HIV);
LUSC	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg13010199	chr12:38710504	ALG10B	0.67	10.38	0.49	4.53e-22	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs6600671	1.000	rs1832558	chr1:121177380	A/G	cg08727972	chr1:148025634	NBPF14	0.46	6.3	0.33	9.5e-10	Hip geometry;
LUSC	cis	rs2227930	0.506	rs9836038	chr3:142130492	C/A	cg16271453	chr3:142027066	XRN1	-0.55	-9.75	-0.47	6.18e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs4363385	0.747	rs2879488	chr1:152975241	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.76	-0.39	1.05e-13	Inflammatory skin disease;
LUSC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.09	-0.4	1.14e-14	Type 2 diabetes;
LUSC	cis	rs6484504	0.576	rs208083	chr11:31196880	C/T	cg06552810	chr11:31128660	NA	-0.41	-7.14	-0.36	5.8e-12	Red blood cell count;
LUSC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.91	-0.35	2.41e-11	Lung cancer;
LUSC	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	1.15	17.85	0.7	1.57e-50	Corneal structure;
LUSC	cis	rs17401966	0.964	rs2027331	chr1:10276718	C/T	cg19773385	chr1:10388646	KIF1B	-0.53	-8.23	-0.41	4.11e-15	Hepatocellular carcinoma;
LUSC	cis	rs738322	0.511	rs5756947	chr22:38573230	G/A	cg17652424	chr22:38574118	PLA2G6	-0.3	-5.93	-0.31	7.56e-9	Cutaneous nevi;
LUSC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg05347473	chr6:146136440	FBXO30	0.46	7.89	0.4	4.48e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs870825	0.929	rs870822	chr4:185588200	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	11.07	0.52	1.81e-24	Blood protein levels;
LUSC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg03289416	chr15:75166202	SCAMP2	0.44	6.93	0.35	2.21e-11	Breast cancer;
LUSC	cis	rs1775715	0.707	rs2799024	chr10:32166922	A/G	cg18675610	chr10:32216311	ARHGAP12	0.31	6.67	0.34	1.06e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.94	0.35	2.09e-11	IgG glycosylation;
LUSC	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg17948913	chr5:572064	NA	0.33	5.68	0.3	2.97e-8	Obesity-related traits;
LUSC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg10351095	chr21:47802916	PCNT	0.43	6.12	0.32	2.64e-9	Testicular germ cell tumor;
LUSC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg24675658	chr1:53192096	ZYG11B	-0.6	-9.02	-0.44	1.52e-17	Monocyte count;
LUSC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-10.09	-0.48	4.53e-21	Joint mobility (Beighton score);
LUSC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.46e-35	Breast cancer;
LUSC	cis	rs668210	0.739	rs543952	chr11:65744275	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.58	7.55	0.38	4.17e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg26893861	chr17:41843967	DUSP3	0.96	14.79	0.63	1.94e-38	Triglycerides;
LUSC	cis	rs7808935	0.914	rs10807843	chr7:27992390	T/C	cg22168087	chr7:27702803	HIBADH	0.54	6.45	0.33	3.91e-10	Prostate cancer;
LUSC	cis	rs4363385	0.818	rs546666	chr1:153015385	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-5.79	-0.3	1.62e-8	Inflammatory skin disease;
LUSC	cis	rs1014246	1.000	rs2240705	chr10:118467334	C/T	cg14919929	chr10:118506882	NA	0.38	5.88	0.31	9.98e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.7	-10.34	-0.49	6.39e-22	Bronchopulmonary dysplasia;
LUSC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg26924012	chr15:45694286	SPATA5L1	1.13	20.65	0.75	1.23e-61	Homoarginine levels;
LUSC	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.89	14.82	0.63	1.52e-38	Bladder cancer;
LUSC	cis	rs7904985	0.813	rs1077092	chr10:88101391	G/A	cg07322936	chr10:88137208	NA	-0.56	-7.29	-0.37	2.32e-12	Barrett's esophagus;
LUSC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg00310523	chr12:86230176	RASSF9	0.45	8.31	0.41	2.43e-15	Major depressive disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19357178	chr21:45527350	PWP2	0.45	6.45	0.33	4.02e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6788232	0.822	rs9884065	chr3:138736641	T/C	cg05026658	chr7:102918083	DPY19L2P2	-0.54	-5.97	-0.31	6.14e-9	Male-pattern baldness;
LUSC	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.09	0.74	2.07e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.38	-6.27	-0.32	1.12e-9	Breast cancer;
LUSC	cis	rs6681460	1.000	rs2872078	chr1:67127367	C/A	cg02459107	chr1:67143332	SGIP1	0.48	8.97	0.44	2.14e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg05855489	chr10:104503620	C10orf26	0.63	8.2	0.41	5.12e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-1.02	-15.17	-0.64	6.53e-40	Initial pursuit acceleration;
LUSC	cis	rs11971779	0.618	rs10085814	chr7:139064089	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs11885103	0.746	rs2685242	chr2:595125	A/C	cg21195176	chr2:593345	NA	0.3	5.74	0.3	2.1e-8	Heschl's gyrus morphology;
LUSC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.5	0.56	1.12e-29	Motion sickness;
LUSC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.93	0.4	3.25e-14	Prudent dietary pattern;
LUSC	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg03806693	chr22:41940476	POLR3H	-0.63	-9.25	-0.45	2.67e-18	Vitiligo;
LUSC	cis	rs4704187	0.687	rs1477934	chr5:74423243	A/T	cg03227963	chr5:74354835	NA	0.32	6.77	0.35	5.68e-11	Response to amphetamines;
LUSC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg21433313	chr16:3507492	NAT15	0.68	11.32	0.53	2.34e-25	Tuberculosis;
LUSC	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg02696742	chr7:106810147	HBP1	0.62	9.5	0.46	4.31e-19	Coronary artery disease;
LUSC	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg20307385	chr11:47447363	PSMC3	-0.44	-6.61	-0.34	1.51e-10	Subjective well-being;
LUSC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg18225595	chr11:63971243	STIP1	0.42	6.84	0.35	3.71e-11	Platelet count;
LUSC	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-9.59	-0.46	2.14e-19	Body mass index;
LUSC	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-6.85	-0.35	3.54e-11	Blood metabolite levels;
LUSC	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg13575925	chr12:9217583	LOC144571	0.34	6.31	0.33	8.69e-10	Sjögren's syndrome;
LUSC	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg08000102	chr2:233561755	GIGYF2	-0.64	-10.28	-0.49	1.04e-21	Coronary artery disease;
LUSC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.61	0.6	7.09e-34	Cognitive test performance;
LUSC	cis	rs2273669	0.588	rs12201102	chr6:109317388	A/G	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs6442522	1.000	rs6442522	chr3:15440556	C/T	cg16303742	chr3:15540471	COLQ	0.28	5.67	0.3	3.07e-8	Uric acid levels;
LUSC	trans	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg19402173	chr7:128379420	CALU	-0.46	-6.92	-0.35	2.35e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9815354	0.951	rs73830511	chr3:41864643	G/T	cg03022575	chr3:42003672	ULK4	0.58	6.52	0.34	2.6e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1160297	0.576	rs1376570	chr2:53087099	G/A	cg07782112	chr2:53107842	NA	0.37	6.13	0.32	2.51e-9	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-10.13	-0.48	3.24e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.6	-0.43	3.16e-16	Total cholesterol levels;
LUSC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	0.65	9.14	0.45	6.14e-18	Methadone dose in opioid dependence;
LUSC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg27165867	chr14:105738592	BRF1	-0.5	-6.98	-0.36	1.6e-11	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg03233332	chr7:66118400	NA	-0.4	-5.92	-0.31	8.15e-9	Aortic root size;
LUSC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg07701084	chr6:150067640	NUP43	0.53	7.99	0.4	2.25e-14	Lung cancer;
LUSC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg10253484	chr15:75165896	SCAMP2	-0.46	-6.5	-0.34	2.96e-10	Breast cancer;
LUSC	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg07173049	chr1:7289937	CAMTA1	0.3	6.11	0.32	2.85e-9	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs56804039	1.000	rs67180327	chr8:8380754	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.27	-0.32	1.12e-9	Cervical cancer;
LUSC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg25019033	chr10:957182	NA	-0.51	-6.43	-0.33	4.5e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg24558204	chr6:135376177	HBS1L	0.68	10.82	0.51	1.32e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs10740039	0.842	rs10761537	chr10:62409021	C/G	cg18175470	chr10:62150864	ANK3	-0.47	-6.96	-0.36	1.77e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg11342453	chr6:26196699	NA	0.54	5.71	0.3	2.52e-8	Gout;Renal underexcretion gout;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26832062	chr1:54303852	TMEM48	0.47	6.57	0.34	1.93e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6489882	0.867	rs4766673	chr12:113365161	C/T	cg20102336	chr12:113376681	OAS3	0.4	5.84	0.3	1.22e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.84	-0.39	6.14e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg11812906	chr14:75593930	NEK9	0.63	10.55	0.5	1.22e-22	Height;
LUSC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7674212	0.541	rs2720471	chr4:104023840	A/G	cg16532752	chr4:104119610	CENPE	-0.51	-7.38	-0.37	1.23e-12	Type 2 diabetes;
LUSC	cis	rs3820068	0.562	rs10927841	chr1:16045261	T/C	cg13390004	chr1:15929781	NA	0.42	6.64	0.34	1.25e-10	Systolic blood pressure;
LUSC	cis	rs6684514	1.000	rs10494304	chr1:156285764	C/G	cg16558208	chr1:156270281	VHLL	-0.35	-5.85	-0.31	1.14e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUSC	cis	rs2580764	0.541	rs2968786	chr2:55264859	C/G	cg20993754	chr2:55226987	RTN4	-0.39	-6.47	-0.33	3.48e-10	Mean platelet volume;
LUSC	cis	rs6076065	0.723	rs2253925	chr20:23388021	C/G	cg11657817	chr20:23433608	CST11	0.42	7.98	0.4	2.32e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs4076764	0.522	rs4265409	chr1:163414559	C/T	cg24596788	chr1:163392923	NA	-0.37	-6.66	-0.34	1.16e-10	Motion sickness;
LUSC	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg07423050	chr13:99094983	FARP1	-0.56	-10.55	-0.5	1.17e-22	Longevity;
LUSC	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	0.85	14.78	0.63	2.29e-38	Height;
LUSC	cis	rs9303280	0.870	rs6503524	chr17:38069809	C/T	cg10909506	chr17:38081995	ORMDL3	-0.35	-6.28	-0.33	1.04e-9	Self-reported allergy;
LUSC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.58	-5.65	-0.3	3.42e-8	Narcolepsy;
LUSC	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg13660082	chr14:53194042	PSMC6	-0.75	-6.77	-0.35	5.9e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg04155289	chr7:94953770	PON1	-0.33	-5.69	-0.3	2.78e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg08000102	chr2:233561755	GIGYF2	0.68	11.39	0.53	1.31e-25	Coronary artery disease;
LUSC	cis	rs12541635	1.000	rs7817197	chr8:107089633	T/G	cg10147462	chr8:107024639	NA	-0.48	-8.76	-0.43	1.03e-16	Age of smoking initiation;
LUSC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.19	0.37	4.19e-12	Motion sickness;
LUSC	cis	rs6489785	0.710	rs2393717	chr12:121220375	G/C	cg02403541	chr12:121454288	C12orf43	0.39	5.75	0.3	1.99e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-8.9	-0.44	3.5e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg11247378	chr22:39784982	NA	-0.63	-11.43	-0.53	9.26e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.6	0.38	2.94e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7180079	0.502	rs6494466	chr15:64508763	A/G	cg08069370	chr15:64387884	SNX1	0.44	6.52	0.34	2.6e-10	Monocyte count;
LUSC	cis	rs240764	0.781	rs239227	chr6:101107089	C/G	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.69e-9	Neuroticism;
LUSC	cis	rs1461503	0.932	rs7944492	chr11:122838745	G/T	cg27398637	chr11:122830231	C11orf63	-0.42	-6.71	-0.34	8.41e-11	Menarche (age at onset);
LUSC	cis	rs467650	0.509	rs2591443	chr5:97997489	C/T	cg03885343	chr5:98108198	RGMB	0.32	5.79	0.3	1.64e-8	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg14668632	chr7:2872130	GNA12	-0.45	-6.83	-0.35	4.03e-11	Height;
LUSC	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg09876464	chr15:85330779	ZNF592	0.37	6.76	0.35	6.14e-11	P wave terminal force;
LUSC	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	9.3	0.45	1.88e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg15649852	chr7:65879115	NA	-0.4	-5.7	-0.3	2.65e-8	Aortic root size;
LUSC	trans	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg14227996	chr4:17616232	MED28	0.53	5.97	0.31	6.16e-9	Opioid sensitivity;
LUSC	cis	rs6942756	0.659	rs624118	chr7:129096653	C/T	cg02491457	chr7:128862824	NA	-0.41	-5.67	-0.3	3.05e-8	White matter hyperintensity burden;
LUSC	cis	rs6565180	0.962	rs35480350	chr16:30366039	G/A	cg17640201	chr16:30407289	ZNF48	-0.86	-14.11	-0.61	9.08e-36	Tonsillectomy;
LUSC	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg26102564	chr10:131424627	MGMT	-0.38	-5.92	-0.31	8.19e-9	Response to temozolomide;
LUSC	cis	rs12986413	0.651	rs2238612	chr19:2149694	C/T	cg09261902	chr19:2140048	AP3D1	-0.34	-6.04	-0.31	4.08e-9	Height;
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg00431813	chr7:1051703	C7orf50	-0.38	-5.87	-0.31	1.08e-8	Longevity;Endometriosis;
LUSC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg26850624	chr5:429559	AHRR	-0.41	-8.0	-0.4	2.1e-14	Cystic fibrosis severity;
LUSC	trans	rs62238980	0.614	rs76010922	chr22:32471678	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg26335602	chr6:28129616	ZNF389	0.46	6.34	0.33	7.57e-10	Parkinson's disease;
LUSC	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.66	-12.29	-0.56	6.83e-29	Survival in pancreatic cancer;
LUSC	cis	rs11123610	0.679	rs34705357	chr2:3716032	C/T	cg19052272	chr2:3704530	ALLC	-0.38	-6.72	-0.34	8.09e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg04998671	chr14:104000505	TRMT61A	-0.42	-6.12	-0.32	2.63e-9	Reticulocyte count;
LUSC	cis	rs9463078	0.547	rs4714819	chr6:44735285	G/C	cg25276700	chr6:44698697	NA	0.3	6.18	0.32	1.88e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.6	0.34	1.66e-10	Lung cancer;
LUSC	cis	rs111706465	1	rs111706465	chr2:239452382	A/C	cg18131467	chr2:239335373	ASB1	-0.61	-5.66	-0.3	3.28e-8	Morning vs. evening chronotype;
LUSC	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg21643547	chr1:205240462	TMCC2	-0.37	-7.0	-0.36	1.38e-11	Red blood cell count;
LUSC	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg03676636	chr4:99064102	C4orf37	0.3	6.12	0.32	2.57e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg20573242	chr4:122745356	CCNA2	0.65	9.55	0.46	2.9e-19	Type 2 diabetes;
LUSC	cis	rs72634258	0.786	rs7539807	chr1:8183789	C/T	cg26816564	chr1:7831052	VAMP3	0.46	5.88	0.31	9.82e-9	Inflammatory bowel disease;
LUSC	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg24579218	chr15:68104479	NA	-0.36	-6.45	-0.33	4.01e-10	Restless legs syndrome;
LUSC	cis	rs35883536	0.669	rs1932352	chr1:101161251	G/A	cg06223162	chr1:101003688	GPR88	-0.44	-7.68	-0.39	1.73e-13	Monocyte count;
LUSC	cis	rs6460942	0.908	rs78780802	chr7:12233216	T/C	cg06484146	chr7:12443880	VWDE	-0.56	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	cis	rs58749629	1.000	rs73128528	chr20:44582187	A/T	cg10662479	chr20:44420225	WFDC3;DNTTIP1	-0.63	-5.96	-0.31	6.28e-9	Abdominal aortic aneurysm;
LUSC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg15147215	chr3:52552868	STAB1	-0.29	-5.74	-0.3	2.08e-8	Electroencephalogram traits;
LUSC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg17971929	chr21:40555470	PSMG1	-0.51	-7.54	-0.38	4.47e-13	Menarche (age at onset);
LUSC	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg13852791	chr20:30311386	BCL2L1	0.74	8.32	0.41	2.2e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs977987	0.933	rs4888431	chr16:75500699	G/T	cg03315344	chr16:75512273	CHST6	0.55	10.7	0.51	3.58e-23	Dupuytren's disease;
LUSC	cis	rs16867321	1.000	rs1358521	chr2:181444628	T/C	cg23363182	chr2:181467187	NA	-0.43	-5.91	-0.31	8.31e-9	Obesity;
LUSC	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg21153622	chr11:89784906	NA	-0.39	-5.98	-0.31	5.61e-9	Height;
LUSC	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-1.07	-12.55	-0.57	7.17e-30	Schizophrenia;
LUSC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg14584255	chr6:163149320	PACRG;PARK2	-0.39	-7.63	-0.39	2.46e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.19e-14	Retinal vascular caliber;
LUSC	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg14092571	chr14:90743983	NA	-0.36	-5.9	-0.31	8.93e-9	Mortality in heart failure;
LUSC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.27	0.56	7.85e-29	Motion sickness;
LUSC	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-8.07	-0.4	1.29e-14	Systolic blood pressure;
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg24813613	chr7:1882135	MAD1L1	-0.36	-5.8	-0.3	1.56e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg22709100	chr7:91322751	NA	-0.4	-5.76	-0.3	1.9e-8	Breast cancer;
LUSC	cis	rs354225	0.512	rs9917248	chr2:54924463	C/T	cg26097391	chr2:54893211	SPTBN1	0.44	5.89	0.31	9.53e-9	Schizophrenia;
LUSC	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg26874229	chr2:105853672	NA	-0.32	-5.7	-0.3	2.57e-8	Type 2 diabetes;
LUSC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.11	0.61	8.77e-36	Platelet count;
LUSC	cis	rs7267979	0.528	rs2387976	chr20:25599560	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-12.64	-0.57	3.25e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.25	0.41	3.79e-15	Melanoma;
LUSC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg06484146	chr7:12443880	VWDE	0.64	7.85	0.39	5.75e-14	Coronary artery disease;
LUSC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	9.51	0.46	3.94e-19	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs4589502	1.000	rs7170743	chr15:67126339	T/G	cg09911534	chr15:67153556	NA	-0.66	-6.66	-0.34	1.14e-10	Lung cancer (smoking interaction);
LUSC	cis	rs6977660	0.652	rs10275246	chr7:19851059	G/A	cg05791153	chr7:19748676	TWISTNB	0.59	5.79	0.3	1.6e-8	Thyroid stimulating hormone;
LUSC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg04944784	chr2:26401820	FAM59B	-0.7	-9.96	-0.48	1.27e-20	Gut microbiome composition (summer);
LUSC	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.66	11.84	0.54	3.02e-27	Itch intensity from mosquito bite;
LUSC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg20283391	chr11:68216788	NA	0.55	8.39	0.42	1.39e-15	Total body bone mineral density;
LUSC	cis	rs16917546	0.935	rs10822050	chr10:64438771	T/C	cg03961010	chr10:64397487	ZNF365	-0.39	-6.12	-0.32	2.65e-9	Basal cell carcinoma;
LUSC	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg07828340	chr4:882639	GAK	0.84	9.57	0.46	2.52e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.31	-0.41	2.42e-15	Gut microbiome composition (summer);
LUSC	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-0.99	-13.72	-0.6	2.82e-34	Blood pressure (smoking interaction);
LUSC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg18451016	chr1:38461880	NA	-0.58	-10.25	-0.49	1.32e-21	Coronary artery disease;
LUSC	cis	rs3007168	1.000	rs3007075	chr14:51604860	A/G	cg23942311	chr14:51606299	NA	0.36	6.07	0.32	3.5e-9	Cancer;
LUSC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg14668632	chr7:2872130	GNA12	-0.41	-6.05	-0.31	3.93e-9	Height;
LUSC	cis	rs4704187	0.553	rs116188801	chr5:74398141	A/G	cg03227963	chr5:74354835	NA	0.32	6.87	0.35	3.09e-11	Response to amphetamines;
LUSC	cis	rs6456156	0.774	rs6456158	chr6:167528032	A/C	cg07741184	chr6:167504864	NA	0.36	6.31	0.33	8.7e-10	Primary biliary cholangitis;
LUSC	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg09754948	chr16:28834200	ATXN2L	0.44	6.47	0.33	3.56e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg03676636	chr4:99064102	C4orf37	0.35	7.91	0.4	3.88e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs977987	0.806	rs12444589	chr16:75454404	A/T	cg04384234	chr16:75411784	CFDP1	0.43	7.01	0.36	1.35e-11	Dupuytren's disease;
LUSC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg03351412	chr1:154909251	PMVK	0.55	8.85	0.44	5.3e-17	Prostate cancer;
LUSC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg22903471	chr2:27725779	GCKR	-0.41	-7.06	-0.36	9.43e-12	Total body bone mineral density;
LUSC	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg03647239	chr10:116582469	FAM160B1	0.47	7.51	0.38	5.45e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg01884057	chr2:25150051	NA	0.48	11.39	0.53	1.29e-25	Body mass index;
LUSC	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.15	-0.45	5.74e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs372883	0.935	rs1153294	chr21:30701096	A/G	cg08807101	chr21:30365312	RNF160	-0.44	-6.35	-0.33	7.04e-10	Pancreatic cancer;
LUSC	cis	rs3772130	0.962	rs9878086	chr3:121488353	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.17	0.49	2.48e-21	Cognitive performance;
LUSC	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg01966878	chr4:90757139	SNCA	-0.34	-5.85	-0.3	1.18e-8	Dementia with Lewy bodies;
LUSC	cis	rs9640161	0.830	rs11972067	chr7:150071605	G/A	cg27494647	chr7:150038898	RARRES2	0.36	5.8	0.3	1.52e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg15744005	chr10:104629667	AS3MT	0.35	6.75	0.35	6.64e-11	Arsenic metabolism;
LUSC	cis	rs2742417	1.000	rs2742435	chr3:45740863	C/T	cg09608765	chr3:45636137	LIMD1	-0.35	-6.44	-0.33	4.11e-10	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6546550	0.935	rs1531025	chr2:70055505	G/T	cg02498382	chr2:70120550	SNRNP27	-0.26	-5.94	-0.31	7.16e-9	Prevalent atrial fibrillation;
LUSC	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg18105134	chr13:113819100	PROZ	0.66	9.91	0.48	1.79e-20	Platelet distribution width;
LUSC	trans	rs1459104	0.866	rs12787024	chr11:54883667	C/T	cg15704280	chr7:45808275	SEPT13	0.71	6.34	0.33	7.62e-10	Body mass index;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg07920855	chr1:185286635	IVNS1ABP	-0.5	-7.38	-0.37	1.3e-12	Cognitive function;Information processing speed;
LUSC	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.81	12.47	0.56	1.4e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg25258033	chr6:167368657	RNASET2	0.36	5.66	0.3	3.2e-8	Primary biliary cholangitis;
LUSC	cis	rs262147	1.000	rs262147	chr7:158745142	A/G	cg11984989	chr7:158649758	WDR60	0.64	5.89	0.31	9.3e-9	Hippocampal volume;
LUSC	cis	rs12541635	0.677	rs1603357	chr8:107000565	G/C	cg10147462	chr8:107024639	NA	0.67	14.03	0.61	1.7000000000000001e-35	Age of smoking initiation;
LUSC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg20887711	chr4:1340912	KIAA1530	0.44	6.57	0.34	1.97e-10	Obesity-related traits;
LUSC	cis	rs11809207	0.857	rs11247866	chr1:26517794	A/G	cg00300879	chr1:26503847	CNKSR1	0.29	5.67	0.3	3.14e-8	Height;
LUSC	cis	rs62027291	0.950	rs55747356	chr15:77284813	C/T	cg26408565	chr15:76604113	ETFA	0.49	6.09	0.32	3.13e-9	Plateletcrit;
LUSC	cis	rs6845621	0.870	rs6449437	chr4:18918825	C/G	cg12196642	chr4:18937545	NA	-0.34	-6.38	-0.33	5.8e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs977987	0.806	rs4638613	chr16:75425553	C/T	cg03315344	chr16:75512273	CHST6	0.52	10.03	0.48	7.24e-21	Dupuytren's disease;
LUSC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg22823121	chr1:150693482	HORMAD1	0.6	9.28	0.45	2.21e-18	Tonsillectomy;
LUSC	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg23711669	chr6:146136114	FBXO30	0.77	13.29	0.59	1.17e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg21573476	chr21:45109991	RRP1B	-0.43	-6.81	-0.35	4.63e-11	Mean corpuscular volume;
LUSC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg21770322	chr7:97807741	LMTK2	0.41	7.03	0.36	1.14e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg16414030	chr3:133502952	NA	-0.52	-8.33	-0.41	2.1e-15	Iron status biomarkers;
LUSC	cis	rs1805008	0.535	rs7196459	chr16:90141477	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.86	-6.59	-0.34	1.68e-10	Skin colour saturation;
LUSC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg16339924	chr4:17578868	LAP3	0.64	10.11	0.48	3.72e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.5	7.85	0.39	5.67e-14	Cognitive test performance;
LUSC	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg05555928	chr11:63887634	MACROD1	-0.49	-6.05	-0.31	3.95e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg21466736	chr12:48725269	NA	-0.33	-5.74	-0.3	2.16e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg04995722	chr7:26192034	NFE2L3	-0.42	-6.46	-0.33	3.79e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg12927641	chr6:109611667	NA	-0.34	-5.8	-0.3	1.52e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg21963583	chr11:68658836	MRPL21	0.57	8.8	0.43	7.33e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg11845111	chr2:191398756	TMEM194B	-0.55	-9.49	-0.46	4.63e-19	Pulse pressure;
LUSC	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	10.61	0.5	7.15e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-1.2	-13.78	-0.6	1.67e-34	Diabetic kidney disease;
LUSC	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg06671706	chr8:8559999	CLDN23	0.49	6.33	0.33	8.06e-10	Obesity-related traits;
LUSC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg08270630	chr22:50330655	NA	-0.43	-6.58	-0.34	1.8e-10	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08280861	chr8:58055591	NA	0.52	5.73	0.3	2.21e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.74	-12.58	-0.57	5.54e-30	Iron status biomarkers;
LUSC	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs9296092	0.521	rs6929165	chr6:33515958	T/G	cg13560919	chr6:33536144	NA	-0.72	-13.4	-0.59	4.63e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs10207060	0.500	rs10177457	chr2:240708067	G/A	cg07506560	chr2:240697449	NA	0.44	6.86	0.35	3.26e-11	Obesity-related traits;
LUSC	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg04725166	chr1:7887271	PER3	-0.46	-6.45	-0.33	3.86e-10	Crohn's disease;
LUSC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg13319975	chr6:146136371	FBXO30	-0.53	-7.96	-0.4	2.78e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs939658	1.000	rs8027411	chr15:79461029	G/T	cg17916960	chr15:79447300	NA	0.5	9.95	0.48	1.33e-20	Refractive error;
LUSC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg27572855	chr1:25598939	RHD	-0.41	-7.1	-0.36	7.61e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.75	0.3	2.05e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.71e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.7	8.78	0.43	8.43e-17	Type 2 diabetes;
LUSC	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg25427524	chr10:38739819	LOC399744	-0.49	-6.54	-0.34	2.28e-10	Obesity (extreme);
LUSC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-11.87	-0.54	2.4200000000000002e-27	Platelet count;
LUSC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14240646	chr10:27532245	ACBD5	-0.74	-8.14	-0.41	8.13e-15	Breast cancer;
LUSC	cis	rs10761482	0.500	rs1892547	chr10:62292958	G/A	cg18175470	chr10:62150864	ANK3	-0.47	-6.84	-0.35	3.86e-11	Schizophrenia;
LUSC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg12311346	chr5:56204834	C5orf35	0.64	9.28	0.45	2.23e-18	Coronary artery disease;
LUSC	cis	rs9311676	0.656	rs11130635	chr3:58379143	A/G	cg13750441	chr3:58318267	PXK	0.36	7.06	0.36	9.88e-12	Systemic lupus erythematosus;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19352682	chr22:24059718	LOC91316	-0.46	-6.12	-0.32	2.66e-9	Hepatitis;
LUSC	cis	rs739496	0.947	rs10849949	chr12:111893537	C/T	cg10833066	chr12:111807467	FAM109A	-0.31	-5.7	-0.3	2.62e-8	Platelet count;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg17607973	chr7:100027408	MEPCE;ZCWPW1	0.43	7.0	0.36	1.45e-11	Triglycerides;
LUSC	cis	rs3771570	1.000	rs17386695	chr2:242379751	A/G	cg21155796	chr2:242212141	HDLBP	-0.62	-6.74	-0.35	6.8e-11	Prostate cancer;
LUSC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg22920501	chr2:26401640	FAM59B	0.83	11.99	0.55	8.76e-28	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg06008330	chr7:65541103	ASL	-0.4	-6.3	-0.33	9.14e-10	Aortic root size;
LUSC	cis	rs8040855	0.644	rs7495437	chr15:85726290	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.4	6.45	0.33	3.86e-10	Bulimia nervosa;
LUSC	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg12559939	chr2:27858050	GPN1	0.41	6.45	0.33	3.94e-10	Oral cavity cancer;
LUSC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg17294928	chr15:75287854	SCAMP5	-0.82	-10.91	-0.51	6.64e-24	Blood trace element (Zn levels);
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.15	0.41	7.37e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg16230307	chr14:35515116	FAM177A1	0.49	6.18	0.32	1.84e-9	Psoriasis;
LUSC	trans	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	10.3	0.49	8.81e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg04369109	chr6:150039330	LATS1	-0.56	-8.25	-0.41	3.74e-15	Lung cancer;
LUSC	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.51e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9487051	0.737	rs1260593	chr6:109521400	C/T	cg00509249	chr6:109615579	CCDC162	-0.33	-5.79	-0.3	1.66e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.62	-8.05	-0.4	1.47e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.68	-0.34	9.94e-11	Resting heart rate;
LUSC	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg11845111	chr2:191398756	TMEM194B	0.87	11.31	0.53	2.42e-25	Diastolic blood pressure;
LUSC	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg25767906	chr1:53392781	SCP2	-0.52	-9.58	-0.46	2.27e-19	Monocyte count;
LUSC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg23630131	chr7:65973040	NA	0.2	5.71	0.3	2.54e-8	Aortic root size;
LUSC	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.77	0.3	1.84e-8	Rheumatoid arthritis;
LUSC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.96	-0.36	1.78e-11	Menopause (age at onset);
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07167872	chr1:205819463	PM20D1	-0.84	-16.1	-0.66	1.39e-43	Menarche (age at onset);
LUSC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg00074818	chr8:8560427	CLDN23	-0.46	-7.5	-0.38	5.65e-13	Obesity-related traits;
LUSC	trans	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg25214090	chr10:38739885	LOC399744	-0.56	-8.35	-0.42	1.85e-15	Corneal astigmatism;
LUSC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg16447950	chr5:562315	NA	-0.55	-6.71	-0.34	8.15e-11	Obesity-related traits;
LUSC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg23625390	chr15:77176239	SCAPER	0.46	7.0	0.36	1.44e-11	Blood metabolite levels;
LUSC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg06028605	chr16:24865363	SLC5A11	0.48	8.42	0.42	1.13e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg18904891	chr8:8559673	CLDN23	-0.38	-5.74	-0.3	2.17e-8	Mood instability;
LUSC	cis	rs10463316	0.817	rs1810083	chr5:150776807	A/G	cg03212797	chr5:150827313	SLC36A1	0.44	6.74	0.35	6.98e-11	Metabolite levels (Pyroglutamine);
LUSC	cis	rs4631830	0.863	rs2926494	chr10:51517356	T/C	cg20129853	chr10:51489980	NA	-0.32	-6.35	-0.33	6.97e-10	Prostate-specific antigen levels;
LUSC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg05313129	chr8:58192883	C8orf71	-0.53	-5.96	-0.31	6.55e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.39	-0.37	1.19e-12	Neuroticism;
LUSC	cis	rs365132	0.875	rs2454952	chr5:176376493	C/T	cg25401027	chr5:176370377	UIMC1	0.35	5.76	0.3	1.94e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18404041	chr3:52824283	ITIH1	-0.61	-12.03	-0.55	6.09e-28	Bipolar disorder;
LUSC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg08499158	chr17:42289980	UBTF	0.41	6.3	0.33	9.56e-10	Total body bone mineral density;
LUSC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7524258	0.868	rs4243825	chr1:7308264	T/C	cg07173049	chr1:7289937	CAMTA1	0.34	6.92	0.35	2.37e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg02023728	chr11:77925099	USP35	0.42	6.4	0.33	5.32e-10	Testicular germ cell tumor;
LUSC	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg00277334	chr10:82204260	NA	-0.5	-7.28	-0.37	2.44e-12	Post bronchodilator FEV1;
LUSC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg23283495	chr1:209979779	IRF6	0.73	9.34	0.46	1.37e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg12257692	chr3:49977190	RBM6	-0.24	-6.42	-0.33	4.77e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg13010199	chr12:38710504	ALG10B	0.66	10.0	0.48	9.42e-21	Bladder cancer;
LUSC	cis	rs1413885	0.516	rs6659883	chr1:65838618	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	7.04	0.36	1.1e-11	Anticoagulant levels;
LUSC	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg24006582	chr15:45444508	DUOX1	-0.66	-9.64	-0.47	1.48e-19	Uric acid levels;
LUSC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg22638593	chr5:131593259	PDLIM4	-0.41	-5.87	-0.31	1.07e-8	Breast cancer;
LUSC	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.42	-0.38	9.56e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7106204	0.748	rs7946633	chr11:24237411	C/T	ch.11.24196551F	chr11:24239977	NA	1.17	14.66	0.63	6.73e-38	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg02574844	chr11:5959923	NA	-0.39	-6.06	-0.31	3.64e-9	DNA methylation (variation);
LUSC	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg03948781	chr1:205179583	DSTYK	0.3	5.72	0.3	2.31e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	10.74	0.51	2.53e-23	Response to antipsychotic treatment;
LUSC	trans	rs10411161	0.702	rs16983196	chr19:52384779	C/A	cg22319618	chr22:45562946	NUP50	-0.49	-5.94	-0.31	6.97e-9	Breast cancer;
LUSC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.57	-8.43	-0.42	1.06e-15	Alzheimer's disease;
LUSC	cis	rs727505	0.865	rs17325193	chr7:124648385	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.58	-0.34	1.79e-10	Lewy body disease;
LUSC	cis	rs73198271	0.960	rs11778970	chr8:8609334	G/C	cg01851573	chr8:8652454	MFHAS1	0.6	8.37	0.42	1.6e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg09307838	chr4:120376055	NA	0.64	9.56	0.46	2.59e-19	Corneal astigmatism;
LUSC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.23	-0.41	4.36e-15	Obesity-related traits;
LUSC	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg21951975	chr1:209979733	IRF6	0.54	7.04	0.36	1.12e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg15103426	chr22:29168792	CCDC117	-0.41	-5.7	-0.3	2.65e-8	Red cell distribution width;
LUSC	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg19812747	chr11:111475976	SIK2	-0.45	-6.23	-0.32	1.38e-9	Primary sclerosing cholangitis;
LUSC	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg09904177	chr6:26538194	HMGN4	-0.77	-6.04	-0.31	4.1e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg16545954	chr1:2118288	C1orf86	0.39	7.43	0.38	9.22e-13	Height;
LUSC	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.28	-0.37	2.35e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg24692254	chr21:30365293	RNF160	0.6	7.95	0.4	2.86e-14	Cognitive test performance;
LUSC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25373794	chr1:162760220	HSD17B7	-0.47	-6.73	-0.35	7.32e-11	Breast cancer;
LUSC	cis	rs11630290	0.736	rs72752925	chr15:64146100	C/G	cg12036633	chr15:63758958	NA	-0.67	-6.94	-0.35	2.06e-11	Iris characteristics;
LUSC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.71	12.72	0.57	1.68e-30	Prudent dietary pattern;
LUSC	cis	rs10986311	0.814	rs7861040	chr9:127044135	G/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.38	-5.96	-0.31	6.51e-9	Vitiligo;
LUSC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21171335	chr12:122356390	WDR66	0.63	9.42	0.46	7.83e-19	Mean corpuscular volume;
LUSC	cis	rs1034435	0.547	rs743846	chr22:48900819	C/T	cg05992904	chr22:48892994	FAM19A5	-0.39	-6.73	-0.35	7.45e-11	Late-onset Alzheimer's disease;
LUSC	cis	rs59698941	0.891	rs59707248	chr5:132267535	C/T	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg07424592	chr7:64974309	NA	-0.63	-5.68	-0.3	2.9e-8	Diabetic kidney disease;
LUSC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg11189052	chr15:85197271	WDR73	-0.66	-10.36	-0.49	5.55e-22	P wave terminal force;
LUSC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-7.4	-0.38	1.08e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg04851639	chr8:1020857	NA	-0.36	-7.51	-0.38	5.3e-13	Schizophrenia;
LUSC	cis	rs17818399	0.749	rs4142759	chr2:46783890	A/G	cg21681030	chr2:46777652	RHOQ	0.48	6.89	0.35	2.77e-11	Height;
LUSC	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-1.14	-18.05	-0.7	2.59e-51	Exhaled nitric oxide output;
LUSC	trans	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	9.12	0.45	7.01e-18	Exhaled nitric oxide output;
LUSC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.32	0.37	1.91e-12	Motion sickness;
LUSC	cis	rs4363385	0.818	rs419721	chr1:153006902	C/T	cg00922841	chr1:152955080	SPRR1A	-0.4	-7.07	-0.36	9.08e-12	Inflammatory skin disease;
LUSC	cis	rs3772130	0.962	rs28660600	chr3:121482637	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.14	0.49	3.04e-21	Cognitive performance;
LUSC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg14440974	chr22:39074834	NA	-0.37	-6.15	-0.32	2.22e-9	Menopause (age at onset);
LUSC	cis	rs10761482	0.859	rs972404	chr10:62095851	G/C	cg18175470	chr10:62150864	ANK3	-0.47	-6.88	-0.35	3e-11	Schizophrenia;
LUSC	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg06636001	chr8:8085503	FLJ10661	0.5	7.39	0.37	1.18e-12	Neuroticism;
LUSC	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-6.8	-0.35	4.87e-11	Blood metabolite levels;
LUSC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg12560992	chr17:57184187	TRIM37	-0.86	-16.74	-0.68	4.12e-46	Intelligence (multi-trait analysis);
LUSC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg12310025	chr6:25882481	NA	-0.5	-9.06	-0.44	1.09e-17	Blood metabolite levels;
LUSC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.59	7.92	0.4	3.54e-14	Lung function (FEV1/FVC);
LUSC	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	0.7	9.7	0.47	8.94e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	trans	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg26043149	chr18:55253948	FECH	-0.46	-7.05	-0.36	1.01e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg07148914	chr20:33460835	GGT7	0.55	8.63	0.43	2.54e-16	Height;
LUSC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg24642844	chr7:1081250	C7orf50	-0.46	-7.42	-0.38	9.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs923109	0.573	rs1060286	chr1:207250300	G/A	cg24040043	chr1:207224982	YOD1	-0.38	-7.52	-0.38	5.22e-13	Left atrial antero-posterior diameter;
LUSC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg07636037	chr3:49044803	WDR6	0.43	6.23	0.32	1.43e-9	Resting heart rate;
LUSC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg16325326	chr1:53192061	ZYG11B	-0.7	-10.72	-0.51	3.06e-23	Monocyte count;
LUSC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.48	7.82	0.39	6.91e-14	Vitiligo;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.59	9.98	0.48	1.09e-20	Lymphocyte counts;
LUSC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.15	-0.36	5.65e-12	Bipolar disorder;
LUSC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.8	-0.35	4.73e-11	Lung cancer;
LUSC	cis	rs7178572	0.688	rs12591335	chr15:77774894	A/G	cg22256960	chr15:77711686	NA	0.56	8.08	0.4	1.2e-14	Type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.89	0.55	2.01e-27	Prudent dietary pattern;
LUSC	cis	rs11971779	0.680	rs6954531	chr7:139054706	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	trans	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.81	0.35	4.46e-11	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs368755101	1	rs368755101	chr2:100762215	AG/A	cg22139774	chr2:100720529	AFF3	-0.43	-7.33	-0.37	1.71e-12	Plateletcrit;Red blood cell count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08701551	chr17:66287507	ARSG;SLC16A6	0.39	6.54	0.34	2.31e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4474465	0.850	rs11237537	chr11:78248397	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-5.98	-0.31	5.76e-9	Alzheimer's disease (survival time);
LUSC	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg27489772	chr12:121021490	NA	-0.52	-6.69	-0.34	9.54e-11	Type 1 diabetes nephropathy;
LUSC	cis	rs2286503	0.752	rs59538378	chr7:22877097	G/A	cg11367502	chr7:22862612	TOMM7	0.46	6.0	0.31	5.02e-9	Fibrinogen;
LUSC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.6	8.06	0.4	1.41e-14	High light scatter reticulocyte count;
LUSC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.26	0.52	3.72e-25	Alzheimer's disease;
LUSC	cis	rs6076065	0.676	rs6076059	chr20:23336261	C/T	cg11657817	chr20:23433608	CST11	0.44	8.35	0.42	1.86e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1568889	1.000	rs12803716	chr11:28055111	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.51	0.46	3.95e-19	Bipolar disorder;
LUSC	cis	rs6693567	0.545	rs1566225	chr1:150415990	G/C	cg15654264	chr1:150340011	RPRD2	0.44	7.11	0.36	7.28e-12	Migraine;
LUSC	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg11584989	chr19:19387371	SF4	0.61	7.27	0.37	2.54e-12	Bipolar disorder;
LUSC	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg06454157	chr6:167490870	NA	-0.25	-5.68	-0.3	2.97e-8	Crohn's disease;
LUSC	trans	rs979233	0.502	rs276237	chr5:42058597	A/G	cg07010552	chr17:7358735	CHRNB1	-0.41	-6.03	-0.31	4.43e-9	Systemic lupus erythematosus;
LUSC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg27532560	chr4:187881888	NA	-0.37	-6.09	-0.32	3.16e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.9	0.35	2.56e-11	Rheumatoid arthritis;
LUSC	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	0.82	11.44	0.53	8.71e-26	Coronary artery disease;
LUSC	cis	rs11673344	0.503	rs1667370	chr19:37490220	A/T	cg27390819	chr19:37464633	NA	-0.34	-5.68	-0.3	2.95e-8	Obesity-related traits;
LUSC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg12432903	chr7:1882776	MAD1L1	-0.38	-6.01	-0.31	4.88e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.07	0.32	3.47e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	trans	rs13390641	0.614	rs72932426	chr2:104094304	T/A	cg03260781	chr1:16346299	HSPB7	-0.46	-6.09	-0.32	3.14e-9	Blood pressure;Blood pressure (anthropometric measures interaction);
LUSC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg20887711	chr4:1340912	KIAA1530	0.49	7.72	0.39	1.38e-13	Longevity;
LUSC	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg17052675	chr2:3827356	NA	-0.63	-10.27	-0.49	1.12e-21	Type 2 diabetes;
LUSC	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg24006582	chr15:45444508	DUOX1	-0.61	-9.28	-0.45	2.14e-18	Uric acid levels;
LUSC	cis	rs7119	0.717	rs12901338	chr15:77804900	T/A	cg27398640	chr15:77910606	LINGO1	-0.29	-6.18	-0.32	1.89e-9	Type 2 diabetes;
LUSC	trans	rs7556950	0.572	rs60921002	chr2:41929675	C/T	cg13792581	chr20:43590115	TOMM34	0.75	6.36	0.33	6.74e-10	Major depression and alcohol dependence;
LUSC	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.74	-0.39	1.2e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4474465	0.915	rs4944204	chr11:78222013	G/T	cg27205649	chr11:78285834	NARS2	0.49	5.69	0.3	2.74e-8	Alzheimer's disease (survival time);
LUSC	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.85	13.4	0.59	4.79e-33	Bladder cancer;
LUSC	trans	rs2262909	0.925	rs73019900	chr19:22286680	G/A	cg17074339	chr11:11642133	GALNTL4	0.44	6.8	0.35	4.77e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg15819921	chr19:927150	ARID3A	-0.43	-6.46	-0.33	3.73e-10	Life satisfaction;
LUSC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00149659	chr3:10157352	C3orf10	0.96	13.92	0.61	4.8e-35	Alzheimer's disease;
LUSC	cis	rs12549902	0.800	rs7825494	chr8:41507350	C/T	cg21772509	chr8:41503840	NKX6-3	0.67	11.09	0.52	1.5e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg13010199	chr12:38710504	ALG10B	0.4	5.67	0.3	3.14e-8	Morning vs. evening chronotype;
LUSC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg08754478	chr10:133766260	PPP2R2D	0.6	8.15	0.41	7.14e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs4786125	0.512	rs55818804	chr16:6930199	T/C	cg03623568	chr16:6915990	A2BP1	-0.48	-7.8	-0.39	7.99e-14	Heart rate variability traits (SDNN);
LUSC	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg01733217	chr16:74700730	RFWD3	0.75	12.29	0.56	6.92e-29	Testicular germ cell tumor;
LUSC	cis	rs281408	0.559	rs281386	chr19:49217305	A/G	cg13540341	chr19:49222985	MAMSTR	0.37	6.15	0.32	2.16e-9	Urinary metabolites (H-NMR features);
LUSC	cis	rs7707921	1.000	rs4703879	chr5:81553815	C/T	cg15871215	chr5:81402204	ATG10	-0.43	-6.19	-0.32	1.81e-9	Breast cancer;
LUSC	cis	rs2953145	0.617	rs7557192	chr2:241541274	T/C	cg07929629	chr2:241523174	NA	0.61	11.07	0.52	1.73e-24	Bipolar disorder;
LUSC	cis	rs4285028	0.747	rs3772126	chr3:121354583	G/A	cg11130432	chr3:121712080	ILDR1	-0.58	-8.39	-0.42	1.42e-15	Multiple sclerosis;
LUSC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.61	0.43	2.91e-16	Prudent dietary pattern;
LUSC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg19622623	chr12:86230825	RASSF9	0.44	6.38	0.33	5.95e-10	Major depressive disorder;
LUSC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24110177	chr3:50126178	RBM5	-0.55	-8.92	-0.44	3.16e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	1.02	15.35	0.64	1.35e-40	Corneal structure;
LUSC	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg18512352	chr11:47633146	NA	-0.44	-9.33	-0.45	1.55e-18	Subjective well-being;
LUSC	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg17470449	chr10:769945	NA	0.49	6.44	0.33	4.26e-10	Uric acid levels;
LUSC	trans	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.64	-11.16	-0.52	8.6e-25	Mean corpuscular volume;
LUSC	trans	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg03886242	chr7:26192032	NFE2L3	-0.41	-6.57	-0.34	1.99e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.44	6.76	0.35	6.23e-11	Menarche (age at onset);
LUSC	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg03983476	chr2:10830698	NOL10	-0.38	-5.77	-0.3	1.79e-8	Prostate cancer;
LUSC	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg03929089	chr4:120376271	NA	0.64	6.17	0.32	1.96e-9	Intraocular pressure;
LUSC	cis	rs7084921	0.578	rs7474935	chr10:101875936	G/C	cg02250046	chr10:101825185	CPN1	-0.35	-6.27	-0.32	1.09e-9	Bone mineral density;
LUSC	cis	rs79911532	0.515	rs80171070	chr7:75636868	T/C	cg03592824	chr7:75666768	STYXL1	0.72	7.12	0.36	6.54e-12	Mononucleosis;
LUSC	trans	rs853679	0.546	rs200953	chr6:27837267	T/C	cg06606381	chr12:133084897	FBRSL1	-0.75	-7.46	-0.38	7.39e-13	Depression;
LUSC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.52	10.25	0.49	1.28e-21	Coronary artery disease;
LUSC	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-7.47	-0.38	7.11e-13	Atrioventricular conduction;
LUSC	cis	rs7605827	0.930	rs11687702	chr2:15682857	T/C	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.77e-16	Educational attainment (years of education);
LUSC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.44	-6.34	-0.33	7.42e-10	Corneal astigmatism;
LUSC	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg03585969	chr10:35415529	CREM	0.54	8.21	0.41	4.87e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg15445000	chr17:37608096	MED1	-0.41	-6.98	-0.36	1.59e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg24324837	chr19:49891574	CCDC155	0.44	5.98	0.31	5.59e-9	Multiple sclerosis;
LUSC	cis	rs10193935	0.901	rs222468	chr2:42642531	C/T	cg27598129	chr2:42591480	NA	-0.6	-8.22	-0.41	4.67e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11644478	chr21:40555479	PSMG1	0.63	10.2	0.49	1.94e-21	Cognitive function;
LUSC	cis	rs907612	0.638	rs11041476	chr11:1875067	C/T	cg26158194	chr11:1874320	LSP1	0.36	6.62	0.34	1.47e-10	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg13390004	chr1:15929781	NA	0.4	6.65	0.34	1.19e-10	Systolic blood pressure;
LUSC	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg22705602	chr4:152727874	NA	-0.33	-6.67	-0.34	1.08e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg17644776	chr2:200775616	C2orf69	0.39	6.16	0.32	2.1e-9	Schizophrenia;
LUSC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00149659	chr3:10157352	C3orf10	0.92	12.88	0.58	4.25e-31	Alzheimer's disease;
LUSC	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.87	-0.35	3.17e-11	Monocyte percentage of white cells;
LUSC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg21226059	chr5:178986404	RUFY1	0.56	9.77	0.47	5.56e-20	Lung cancer;
LUSC	trans	rs800082	0.690	rs800081	chr3:144339980	C/T	cg24215973	chr2:240111563	HDAC4	0.62	9.87	0.48	2.54e-20	Smoking behavior;
LUSC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg21724239	chr8:58056113	NA	0.63	7.4	0.38	1.08e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg07777115	chr5:623756	CEP72	-0.46	-5.89	-0.31	9.3e-9	Obesity-related traits;
LUSC	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.4	0.56	2.68e-29	Ileal carcinoids;
LUSC	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg21211680	chr2:198530	NA	-0.67	-7.17	-0.37	4.82e-12	Blood protein levels;
LUSC	cis	rs4700695	0.841	rs251294	chr5:65261848	A/G	cg21114390	chr5:65439923	SFRS12	0.49	5.64	0.3	3.56e-8	Facial morphology (factor 19);
LUSC	cis	rs1461503	0.932	rs10892934	chr11:122837950	C/T	cg27398637	chr11:122830231	C11orf63	-0.42	-6.71	-0.34	8.41e-11	Menarche (age at onset);
LUSC	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg17173187	chr15:85201210	NMB	0.49	9.27	0.45	2.34e-18	Schizophrenia;
LUSC	trans	rs62238980	0.614	rs117826138	chr22:32398149	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-9.11	-0.45	8.04e-18	Systolic blood pressure;
LUSC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg14416269	chr4:6271139	WFS1	0.5	10.62	0.5	6.83e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs11077773	1.000	rs11077773	chr17:73060073	C/T	cg27626185	chr17:73056755	KCTD2	0.85	9.48	0.46	5.07e-19	Information processing speed;
LUSC	cis	rs9865818	0.702	rs2030519	chr3:188119901	G/A	cg23651889	chr3:188115336	LPP	-0.39	-6.06	-0.31	3.64e-9	Allergic sensitization;
LUSC	cis	rs713477	0.692	rs56280202	chr14:55911201	C/T	cg13175173	chr14:55914753	NA	-0.3	-6.12	-0.32	2.66e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg05855489	chr10:104503620	C10orf26	0.49	7.4	0.38	1.1e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg02023728	chr11:77925099	USP35	0.49	7.33	0.37	1.79e-12	Testicular germ cell tumor;
LUSC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg03060546	chr3:49711283	APEH	0.72	12.18	0.55	1.79e-28	Resting heart rate;
LUSC	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg19743168	chr1:23544995	NA	0.43	8.21	0.41	4.9e-15	Height;
LUSC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg05623727	chr3:50126028	RBM5	0.33	6.02	0.31	4.62e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg03474202	chr17:45855739	NA	-0.29	-6.62	-0.34	1.44e-10	IgG glycosylation;
LUSC	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg18404041	chr3:52824283	ITIH1	0.42	7.22	0.37	3.57e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08286799	chr16:89989483	TUBB3	0.44	6.37	0.33	6.44e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg24375607	chr4:120327624	NA	0.78	11.49	0.53	5.51e-26	Corneal astigmatism;
LUSC	cis	rs6681460	0.546	rs4143025	chr1:67167548	A/G	cg02459107	chr1:67143332	SGIP1	-0.33	-5.8	-0.3	1.5e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg18478394	chr8:109455254	TTC35	0.41	6.31	0.33	8.86e-10	Dupuytren's disease;
LUSC	cis	rs9311676	0.656	rs66793022	chr3:58391565	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.44	0.33	4.09e-10	Systemic lupus erythematosus;
LUSC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.44	0.33	4.27e-10	Platelet count;
LUSC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26314531	chr2:26401878	FAM59B	0.74	10.09	0.48	4.67e-21	Gut microbiome composition (summer);
LUSC	trans	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg01620082	chr3:125678407	NA	-0.68	-6.72	-0.35	7.9e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2639990	1.000	rs609303	chr18:72895242	C/T	cg02750262	chr18:72916776	ZADH2	0.6	7.33	0.37	1.76e-12	Vascular endothelial growth factor levels;
LUSC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.3	0.41	2.67e-15	Prudent dietary pattern;
LUSC	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg22906224	chr7:99728672	NA	0.43	5.8	0.3	1.56e-8	Coronary artery disease;
LUSC	cis	rs1775715	0.835	rs1419169	chr10:32257204	C/G	cg04359828	chr10:32216031	ARHGAP12	0.38	6.25	0.32	1.27e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg06238570	chr21:40685208	BRWD1	-0.64	-10.7	-0.51	3.63e-23	Cognitive function;
LUSC	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg18478394	chr8:109455254	TTC35	0.41	6.28	0.32	1.05e-9	Dupuytren's disease;
LUSC	cis	rs9341808	0.718	rs2322630	chr6:80841033	A/G	cg08355045	chr6:80787529	NA	0.58	10.05	0.48	6.07e-21	Sitting height ratio;
LUSC	cis	rs59072704	0.843	rs12031783	chr1:244498748	A/G	cg16908123	chr1:244486252	NA	0.33	6.48	0.33	3.29e-10	Monocyte count;
LUSC	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg23202291	chr11:1979235	NA	0.49	7.83	0.39	6.49e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg13319975	chr6:146136371	FBXO30	0.46	6.93	0.35	2.19e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs59104589	0.569	rs4254498	chr2:242363611	G/C	cg14842376	chr2:242211374	HDLBP	0.54	6.25	0.32	1.22e-9	Fibrinogen levels;
LUSC	cis	rs2273669	0.667	rs12195372	chr6:109284223	A/G	cg05315195	chr6:109294784	ARMC2	-0.58	-6.47	-0.33	3.44e-10	Prostate cancer;
LUSC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-13.92	-0.61	4.61e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.44	7.04	0.36	1.11e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1971762	0.563	rs11170645	chr12:54079080	G/T	cg23533419	chr12:54090519	NA	-0.37	-6.05	-0.31	3.94e-9	Height;
LUSC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg00933542	chr6:150070202	PCMT1	0.31	6.48	0.33	3.27e-10	Lung cancer;
LUSC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03264133	chr6:25882463	NA	0.39	6.73	0.35	7.47e-11	Blood metabolite levels;
LUSC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	9.31	0.45	1.75e-18	Total body bone mineral density;
LUSC	cis	rs13082711	0.689	rs34946790	chr3:27345170	G/A	cg02860705	chr3:27208620	NA	0.78	12.55	0.57	7.54e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg02018176	chr4:1364513	KIAA1530	-0.4	-5.92	-0.31	7.94e-9	Recombination rate (females);
LUSC	cis	rs28595532	0.623	rs10016452	chr4:119277490	A/G	cg21605333	chr4:119757512	SEC24D	0.94	7.7	0.39	1.56e-13	Cannabis dependence symptom count;
LUSC	cis	rs72634258	0.554	rs4908705	chr1:7926401	C/T	cg26816564	chr1:7831052	VAMP3	0.69	9.59	0.46	2.08e-19	Inflammatory bowel disease;
LUSC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg13206674	chr6:150067644	NUP43	0.59	9.28	0.45	2.26e-18	Lung cancer;
LUSC	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs925255	0.591	rs7559046	chr2:28644670	G/C	cg01273330	chr2:28605224	NA	-0.4	-6.44	-0.33	4.23e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.99	0.31	5.57e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg21827317	chr3:136751795	NA	0.38	6.95	0.36	1.87e-11	Neuroticism;
LUSC	cis	rs7614311	0.731	rs73130544	chr3:63868596	G/A	cg22134162	chr3:63841271	THOC7	-0.49	-6.07	-0.32	3.43e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs6743030	0.521	rs1254901	chr2:85811229	G/A	cg17127132	chr2:85788382	GGCX	-0.43	-5.88	-0.31	9.75e-9	Coronary artery disease;
LUSC	cis	rs2346177	0.844	rs34712412	chr2:46652428	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.63	-0.39	2.5e-13	HDL cholesterol;
LUSC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg18402987	chr7:1209562	NA	0.72	7.69	0.39	1.67e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20307385	chr11:47447363	PSMC3	-0.45	-5.95	-0.31	6.71e-9	Subjective well-being;
LUSC	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.72	10.84	0.51	1.12e-23	Eosinophil percentage of white cells;
LUSC	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg23711669	chr6:146136114	FBXO30	-0.56	-7.55	-0.38	4.28e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg05234568	chr11:5960015	NA	-0.63	-8.97	-0.44	2.1e-17	DNA methylation (variation);
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18538332	chr22:24372958	LOC391322	-0.47	-8.47	-0.42	8.05e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg18512352	chr11:47633146	NA	0.47	9.53	0.46	3.24e-19	Subjective well-being;
LUSC	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	5.84	0.3	1.25e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7719624	0.756	rs6880837	chr5:135396669	A/G	cg12897067	chr5:135418308	NA	0.4	5.8	0.3	1.51e-8	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.81e-10	Bipolar disorder;
LUSC	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.98	-0.44	2.08e-17	Coffee consumption (cups per day);
LUSC	cis	rs62400317	0.762	rs10456120	chr6:44900107	C/T	cg20913747	chr6:44695427	NA	-0.48	-7.47	-0.38	7.22e-13	Total body bone mineral density;
LUSC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18404041	chr3:52824283	ITIH1	-0.62	-12.25	-0.56	9.44e-29	Bipolar disorder;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg25365783	chr7:108166722	PNPLA8	0.37	6.34	0.33	7.59e-10	Triglycerides;
LUSC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg11344533	chr11:111475393	SIK2	-0.5	-6.95	-0.36	1.88e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg21951975	chr1:209979733	IRF6	0.56	8.5	0.42	6.6e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs59104589	0.617	rs3771566	chr2:242358299	G/T	cg14842376	chr2:242211374	HDLBP	0.55	6.33	0.33	7.87e-10	Fibrinogen levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04849129	chr2:191513396	NAB1	-0.48	-6.25	-0.32	1.27e-9	Hepatitis;
LUSC	cis	rs1595825	0.735	rs1866665	chr2:198925980	A/G	cg00982548	chr2:198649783	BOLL	-0.54	-6.56	-0.34	2.11e-10	Ulcerative colitis;
LUSC	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-9.43	-0.46	7.39e-19	Hemoglobin concentration;
LUSC	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.76	8.37	0.42	1.62e-15	Yeast infection;
LUSC	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.55	0.34	2.17e-10	Corneal astigmatism;
LUSC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg06238570	chr21:40685208	BRWD1	-0.59	-9.14	-0.45	6e-18	Menarche (age at onset);
LUSC	cis	rs56399783	0.708	rs56208415	chr7:2813806	G/A	cg19731401	chr7:2775893	GNA12	0.6	8.06	0.4	1.37e-14	Childhood ear infection;
LUSC	cis	rs7216064	0.906	rs7223643	chr17:65830282	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-8.53	-0.42	5.28e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg10518543	chr12:38710700	ALG10B	-0.41	-5.67	-0.3	3.1e-8	Morning vs. evening chronotype;
LUSC	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg17652424	chr22:38574118	PLA2G6	-0.27	-5.81	-0.3	1.48e-8	Cutaneous nevi;
LUSC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.72	12.43	0.56	1.96e-29	Motion sickness;
LUSC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg15790184	chr11:494944	RNH1	0.5	7.46	0.38	7.36e-13	Systemic lupus erythematosus;
LUSC	cis	rs55665837	0.961	rs60622588	chr11:14456998	T/C	cg19336497	chr11:14380999	RRAS2	-0.37	-7.47	-0.38	7.25e-13	Vitamin D levels;
LUSC	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.74	15.5	0.65	3.38e-41	Systemic lupus erythematosus;
LUSC	cis	rs983392	0.709	rs2162254	chr11:60039917	T/A	cg02771260	chr11:59836817	MS4A3	0.37	6.11	0.32	2.75e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg09307838	chr4:120376055	NA	0.69	10.01	0.48	8.32e-21	Corneal astigmatism;
LUSC	cis	rs7119	0.651	rs12915057	chr15:77847745	C/A	cg27398640	chr15:77910606	LINGO1	-0.33	-7.04	-0.36	1.12e-11	Type 2 diabetes;
LUSC	cis	rs983392	0.805	rs11230183	chr11:59965725	C/T	cg02771260	chr11:59836817	MS4A3	-0.36	-5.77	-0.3	1.79e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg03060546	chr3:49711283	APEH	0.64	6.96	0.36	1.76e-11	Menarche (age at onset);
LUSC	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg08470875	chr2:26401718	FAM59B	-0.68	-8.95	-0.44	2.53e-17	Gut microbiome composition (summer);
LUSC	cis	rs10392	0.543	rs6028197	chr20:37534193	C/T	cg27552599	chr20:37590471	DHX35	0.44	6.98	0.36	1.6e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs4494114	0.967	rs11211566	chr1:39354700	G/C	cg25970120	chr1:39325951	RRAGC	-0.4	-6.19	-0.32	1.8e-9	Blood protein levels;
LUSC	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg16339924	chr4:17578868	LAP3	0.51	7.58	0.38	3.42e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg09044154	chr16:88155775	NA	-0.55	-7.27	-0.37	2.52e-12	Menopause (age at onset);
LUSC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.83	0.3	1.3e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2573652	1.000	rs2581343	chr15:100514418	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.46	-8.59	-0.43	3.38e-16	Height;
LUSC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg06027949	chr8:82754900	SNX16	-0.43	-5.81	-0.3	1.48e-8	Diastolic blood pressure;
LUSC	trans	rs890100	0.673	rs4141567	chr2:56658057	A/G	cg01657744	chr10:88471748	LDB3	0.43	5.95	0.31	6.75e-9	Gut microbiome composition (summer);
LUSC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.74	11.2	0.52	5.99e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4363385	0.643	rs12734348	chr1:152924650	A/G	cg07796016	chr1:152779584	LCE1C	-0.49	-7.27	-0.37	2.63e-12	Inflammatory skin disease;
LUSC	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg21849932	chr20:62369462	LIME1	-0.42	-6.1	-0.32	2.94e-9	Prostate cancer;
LUSC	cis	rs7011049	1.000	rs79169015	chr8:53843908	C/T	cg26025543	chr8:53854495	NA	0.53	6.35	0.33	7.13e-10	Systolic blood pressure;
LUSC	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.85	-0.35	3.67e-11	Retinal vascular caliber;
LUSC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg03538708	chr1:25844672	NA	-0.37	-6.11	-0.32	2.71e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg10792982	chr14:105748885	BRF1	0.47	8.39	0.42	1.36e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	7.27	0.37	2.5e-12	Prudent dietary pattern;
LUSC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg22166914	chr1:53195759	ZYG11B	0.49	7.84	0.39	6.05e-14	Monocyte count;
LUSC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg14440974	chr22:39074834	NA	-0.35	-5.86	-0.31	1.11e-8	Menopause (age at onset);
LUSC	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg04362960	chr10:104952993	NT5C2	0.58	9.07	0.44	1.03e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg12288994	chr5:1860383	NA	0.3	6.57	0.34	1.95e-10	Cardiovascular disease risk factors;
LUSC	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg27219399	chr15:67835830	MAP2K5	0.38	6.07	0.32	3.48e-9	Obesity;
LUSC	cis	rs6570726	0.559	rs11754523	chr6:145727951	A/G	cg23711669	chr6:146136114	FBXO30	-0.49	-6.99	-0.36	1.49e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg06740227	chr12:86229804	RASSF9	0.38	6.06	0.31	3.64e-9	Major depressive disorder;
LUSC	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.81	-0.65	2.07e-42	Height;
LUSC	cis	rs1957429	0.520	rs72625645	chr14:65343431	G/C	cg23373153	chr14:65346875	NA	-0.88	-8.03	-0.4	1.74e-14	Pediatric areal bone mineral density (radius);
LUSC	cis	rs12681287	0.605	rs2976181	chr8:87344470	C/T	cg27223183	chr8:87520930	FAM82B	-0.43	-5.92	-0.31	8.11e-9	Caudate activity during reward;
LUSC	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg13852791	chr20:30311386	BCL2L1	0.93	14.18	0.61	4.78e-36	Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08677398	chr8:58056175	NA	0.54	6.37	0.33	6.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg00579200	chr11:133705235	NA	-0.4	-6.05	-0.31	3.86e-9	Childhood ear infection;
LUSC	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg24375607	chr4:120327624	NA	0.72	11.69	0.54	1.05e-26	Corneal astigmatism;
LUSC	cis	rs72827839	0.516	rs111630961	chr17:45938097	T/G	cg23391107	chr17:45924227	SP6	0.42	7.42	0.38	9.86e-13	Ease of getting up in the morning;
LUSC	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.34	0.33	7.29e-10	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg17366294	chr4:99064904	C4orf37	0.61	10.91	0.51	6.76e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15664640	chr17:80829946	TBCD	0.47	8.5	0.42	6.41e-16	Breast cancer;
LUSC	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg02493740	chr2:85810744	VAMP5	-0.37	-6.59	-0.34	1.76e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg08000102	chr2:233561755	GIGYF2	0.71	11.84	0.54	3.11e-27	Coronary artery disease;
LUSC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.54	-8.75	-0.43	1.1e-16	Longevity;Endometriosis;
LUSC	cis	rs9815354	0.951	rs9831404	chr3:41871825	T/G	cg03022575	chr3:42003672	ULK4	0.58	6.56	0.34	2e-10	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg14791747	chr16:20752902	THUMPD1	0.71	9.62	0.47	1.72e-19	Cognitive test performance;
LUSC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.01	0.77	5.62e-67	Prudent dietary pattern;
LUSC	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg24579218	chr15:68104479	NA	-0.38	-6.43	-0.33	4.3e-10	Obesity;
LUSC	cis	rs7122539	0.839	rs6591223	chr11:66609289	C/T	cg24851651	chr11:66362959	CCS	0.47	7.53	0.38	4.93e-13	HIV-1 susceptibility;
LUSC	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-8.27	-0.41	3.32e-15	Body mass index;
LUSC	cis	rs72960926	0.744	rs72950543	chr6:74907232	G/A	cg03266952	chr6:74778945	NA	-0.78	-6.27	-0.32	1.12e-9	Metabolite levels (MHPG);
LUSC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-1.08	-19.9	-0.74	1.14e-58	Coronary artery disease;
LUSC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.1	-0.52	1.41e-24	Bipolar disorder;
LUSC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg21724239	chr8:58056113	NA	0.74	7.98	0.4	2.4e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.01	0.36	1.32e-11	Educational attainment;
LUSC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg25036284	chr2:26402008	FAM59B	-0.7	-9.88	-0.48	2.22e-20	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg14552801	chr7:65878734	NA	0.37	5.72	0.3	2.4e-8	Aortic root size;
LUSC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.75	13.54	0.6	1.3e-33	Aortic root size;
LUSC	cis	rs6901250	0.851	rs9374624	chr6:117145837	A/C	cg12892004	chr6:117198278	RFX6	0.44	8.35	0.42	1.83e-15	C-reactive protein levels;
LUSC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs500891	0.533	rs9969045	chr6:84185399	T/G	cg08257003	chr6:84140564	ME1	0.33	7.97	0.4	2.58e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs8113142	0.550	rs66459748	chr19:29131294	T/G	cg04546413	chr19:29218101	NA	0.4	5.79	0.3	1.62e-8	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs7903847	0.620	rs10882904	chr10:99115683	A/G	cg20016023	chr10:99160130	RRP12	-0.33	-7.96	-0.4	2.77e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg20607287	chr7:12443886	VWDE	-0.59	-6.14	-0.32	2.35e-9	Coronary artery disease;
LUSC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg06637938	chr14:75390232	RPS6KL1	0.52	8.35	0.42	1.87e-15	Height;
LUSC	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg20991723	chr1:152506922	NA	0.5	9.28	0.45	2.18e-18	Hair morphology;
LUSC	trans	rs2236293	0.724	rs11791889	chr9:35860942	G/A	cg11239633	chr3:37903682	CTDSPL	-0.33	-5.99	-0.31	5.38e-9	Blood protein levels;
LUSC	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg11473876	chr11:109292803	C11orf87	0.38	6.04	0.31	4e-9	Schizophrenia;
LUSC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg00431813	chr7:1051703	C7orf50	0.47	7.95	0.4	2.94e-14	Longevity;Endometriosis;
LUSC	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.5	7.97	0.4	2.57e-14	Uric acid clearance;
LUSC	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg09904177	chr6:26538194	HMGN4	0.65	11.7	0.54	9.83e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16275883	chr3:69129409	UBA3	0.48	6.46	0.33	3.66e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.95	15.15	0.64	7.72e-40	Coronary artery disease;
LUSC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.58	-9.5	-0.46	4.35e-19	Aortic root size;
LUSC	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg21951975	chr1:209979733	IRF6	0.55	6.99	0.36	1.53e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.76	0.47	5.92e-20	Bipolar disorder;
LUSC	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-20.56	-0.75	2.74e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg13560548	chr3:10150139	C3orf24	0.48	6.75	0.35	6.62e-11	Alzheimer's disease;
LUSC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg22185043	chr18:12947723	SEH1L	0.62	6.03	0.31	4.33e-9	Myocardial infarction;
LUSC	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg13119609	chr19:45449297	APOC2	0.33	5.74	0.3	2.09e-8	Blood protein levels;
LUSC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg07167872	chr1:205819463	PM20D1	0.47	6.93	0.35	2.19e-11	Menarche (age at onset);
LUSC	cis	rs983392	0.709	rs11603507	chr11:59982470	T/A	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.09	-0.32	3.18e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.01	-0.48	8.51e-21	Platelet count;
LUSC	cis	rs9653442	1.000	rs6712515	chr2:100806514	T/C	cg07810366	chr2:100720526	AFF3	-0.44	-7.72	-0.39	1.33e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21984481	chr17:79567631	NPLOC4	-0.69	-14.08	-0.61	1.09e-35	Eye color traits;
LUSC	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg00310523	chr12:86230176	RASSF9	-0.42	-8.0	-0.4	2e-14	Major depressive disorder;
LUSC	cis	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg09904177	chr6:26538194	HMGN4	-0.8	-6.0	-0.31	5.04e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg08330031	chr10:104623503	C10orf32	0.32	5.69	0.3	2.76e-8	Arsenic metabolism;
LUSC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.85	0.3	1.17e-8	Personality dimensions;
LUSC	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg03929089	chr4:120376271	NA	-0.44	-6.11	-0.32	2.7e-9	HDL cholesterol;
LUSC	trans	rs28588043	0.593	rs9427209	chr1:170942402	A/G	cg07135042	chr19:56905152	ZNF582	-0.61	-6.09	-0.32	3.02e-9	Number of children (6+ vs. 0 or 1);
LUSC	cis	rs6967385	0.560	rs4301352	chr7:12356481	T/G	cg10578991	chr7:12443926	VWDE	0.4	5.94	0.31	7.15e-9	Response to taxane treatment (placlitaxel);
LUSC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.93	15.0	0.63	2.95e-39	Coronary artery disease;
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.86	15.58	0.65	1.6e-41	Menarche (age at onset);
LUSC	cis	rs4792901	0.694	rs9907819	chr17:41602865	T/C	cg22562494	chr17:41607896	ETV4	-0.33	-6.05	-0.31	3.8e-9	Dupuytren's disease;
LUSC	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	1.1	17.28	0.69	3.11e-48	Exhaled nitric oxide output;
LUSC	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg08079166	chr15:68083412	MAP2K5	0.41	7.34	0.37	1.68e-12	Restless legs syndrome;
LUSC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs250677	0.522	rs2895837	chr5:148357535	C/T	cg18129178	chr5:148520854	ABLIM3	0.53	7.41	0.38	1.02e-12	Breast cancer;
LUSC	cis	rs17255340	0.539	rs1013318	chr6:83979447	A/G	cg08257003	chr6:84140564	ME1	-0.3	-7.12	-0.36	6.65e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg21724239	chr8:58056113	NA	0.55	6.65	0.34	1.23e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs11782517	0.883	rs12544801	chr8:10107382	C/G	cg06636001	chr8:8085503	FLJ10661	0.48	6.24	0.32	1.3e-9	Nose size;
LUSC	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.91	15.38	0.64	9.57e-41	Bladder cancer;
LUSC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	trans	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.06	-0.31	3.66e-9	Monocyte count;
LUSC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12310025	chr6:25882481	NA	-0.47	-8.08	-0.4	1.16e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg17407411	chr12:1800083	ADIPOR2	0.69	5.99	0.31	5.5e-9	Cognitive performance;
LUSC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg00152838	chr16:24741724	TNRC6A	0.45	5.65	0.3	3.45e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg19812747	chr11:111475976	SIK2	-0.55	-7.98	-0.4	2.29e-14	Primary sclerosing cholangitis;
LUSC	cis	rs72960926	0.744	rs7776273	chr6:74967693	T/C	cg03266952	chr6:74778945	NA	-0.78	-6.91	-0.35	2.47e-11	Metabolite levels (MHPG);
LUSC	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.79	11.74	0.54	7.16e-27	Corneal astigmatism;
LUSC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg17333051	chr19:2783644	SGTA	-0.49	-7.38	-0.37	1.24e-12	Total cholesterol levels;
LUSC	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-15.96	-0.66	4.93e-43	Height;
LUSC	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg22089800	chr15:90895588	ZNF774	-0.64	-9.65	-0.47	1.3e-19	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs381815	0.924	rs7926335	chr11:16917869	C/T	cg05701403	chr11:16947551	PLEKHA7	0.39	5.92	0.31	7.97e-9	Diastolic blood pressure;Systolic blood pressure;Blood pressure;
LUSC	cis	rs4478037	0.822	rs9827863	chr3:33118951	C/T	cg19404215	chr3:33155277	CRTAP	-0.96	-9.67	-0.47	1.18e-19	Major depressive disorder;
LUSC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-10.29	-0.49	9.32e-22	Menarche (age at onset);
LUSC	cis	rs11031096	0.617	rs12288918	chr11:4191466	G/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.76	-0.3	1.96e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg15556689	chr8:8085844	FLJ10661	-0.63	-9.54	-0.46	3.09e-19	Neuroticism;
LUSC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg14092988	chr3:52407081	DNAH1	-0.32	-6.27	-0.32	1.1e-9	Bipolar disorder;
LUSC	cis	rs2742417	0.603	rs2742458	chr3:45767602	C/T	cg10512202	chr3:45649293	LIMD1	0.36	5.93	0.31	7.48e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs509477	0.718	rs273344	chr18:32603927	C/T	cg23791764	chr18:32556832	MAPRE2	0.4	5.79	0.3	1.65e-8	Cerebrospinal fluid AB1-42 levels;
LUSC	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg00982548	chr2:198649783	BOLL	-0.56	-7.04	-0.36	1.12e-11	Ulcerative colitis;
LUSC	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.92	0.51	6.12e-24	Hypertriglyceridemia;
LUSC	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22590775	chr19:49891494	CCDC155	0.53	6.99	0.36	1.52e-11	Multiple sclerosis;
LUSC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg00033643	chr7:134001901	SLC35B4	0.47	7.19	0.37	4.22e-12	Mean platelet volume;
LUSC	cis	rs11997175	0.624	rs4733179	chr8:33692223	T/G	ch.8.33884649F	chr8:33765107	NA	0.44	6.57	0.34	1.93e-10	Body mass index;
LUSC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg02931644	chr1:25747376	RHCE	0.36	6.45	0.33	3.85e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02443732	chr16:88804373	FAM38A	0.4	6.41	0.33	5.04e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.26	-0.41	3.42e-15	Neuroticism;
LUSC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs7408868	0.563	rs10404382	chr19:15301389	C/A	cg14696996	chr19:15285081	NOTCH3	0.77	7.83	0.39	6.51e-14	Pulse pressure;
LUSC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg03477792	chr4:77819574	ANKRD56	0.62	8.86	0.44	4.88e-17	Emphysema distribution in smoking;
LUSC	cis	rs9487051	0.799	rs351725	chr6:109547939	G/A	cg01475377	chr6:109611718	NA	-0.35	-5.83	-0.3	1.28e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg24578937	chr1:2090814	PRKCZ	0.58	13.16	0.58	3.73e-32	Height;
LUSC	cis	rs6998277	0.830	rs965661	chr8:103597586	C/T	cg10187029	chr8:103597600	NA	0.77	11.83	0.54	3.41e-27	Migraine;
LUSC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.03	0.66	2.64e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg14689365	chr7:158441557	NCAPG2	0.51	7.33	0.37	1.72e-12	Height;
LUSC	cis	rs4343996	0.935	rs10276190	chr7:3348663	C/T	cg21248987	chr7:3385318	SDK1	0.4	6.74	0.35	6.99e-11	Motion sickness;
LUSC	trans	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg07393940	chr7:158741817	NA	-0.37	-6.59	-0.34	1.73e-10	Life satisfaction;
LUSC	cis	rs10207628	0.698	rs10182292	chr2:127869462	G/A	cg06223080	chr2:127868745	NA	0.38	6.56	0.34	2.06e-10	Psychosis and Alzheimer's disease;
LUSC	cis	rs9650657	0.740	rs34653170	chr8:10676542	G/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.1	-0.32	2.85e-9	Neuroticism;
LUSC	cis	rs17604090	0.823	rs28415620	chr7:29701104	T/C	cg19413766	chr7:29689036	LOC646762	-0.64	-7.7	-0.39	1.5700000000000001e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs13385	0.769	rs13175751	chr5:139601097	C/G	cg26211634	chr5:139558579	C5orf32	0.45	6.81	0.35	4.63e-11	Atrial fibrillation;
LUSC	trans	rs75804782	0.641	rs3769125	chr2:239349562	A/G	cg01134436	chr17:81009848	B3GNTL1	0.66	6.4	0.33	5.11e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs10193935	0.901	rs222471	chr2:42638057	C/T	cg27598129	chr2:42591480	NA	0.59	8.17	0.41	6.48e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg10523679	chr1:76189770	ACADM	-0.53	-7.75	-0.39	1.11e-13	Daytime sleep phenotypes;
LUSC	cis	rs3018712	0.532	rs7116363	chr11:68412798	G/A	cg20283391	chr11:68216788	NA	0.56	5.71	0.3	2.48e-8	Total body bone mineral density;
LUSC	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.15	0.52	9.13e-25	Hypertriglyceridemia;
LUSC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg26677194	chr12:130822605	PIWIL1	0.59	8.77	0.43	9.52e-17	Menopause (age at onset);
LUSC	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg20302533	chr7:39170763	POU6F2	0.51	7.94	0.4	3.08e-14	IgG glycosylation;
LUSC	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.22	-0.41	4.5e-15	Retinal vascular caliber;
LUSC	cis	rs9807989	0.839	rs4988956	chr2:102968007	G/A	cg09003973	chr2:102972529	NA	0.44	6.01	0.31	4.83e-9	Asthma;
LUSC	cis	rs2540226	0.844	rs12712656	chr2:39993952	C/G	cg23576258	chr2:39999331	THUMPD2	0.34	5.84	0.3	1.22e-8	Personality dimensions;
LUSC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg18301423	chr5:131593218	PDLIM4	0.42	6.67	0.34	1.07e-10	Blood metabolite levels;
LUSC	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg02466173	chr16:30829666	NA	-0.54	-10.66	-0.5	4.9e-23	Dementia with Lewy bodies;
LUSC	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg10434728	chr15:90938212	IQGAP1	0.31	6.07	0.32	3.53e-9	Rheumatoid arthritis;
LUSC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg08888203	chr3:10149979	C3orf24	-0.65	-8.66	-0.43	2.02e-16	Alzheimer's disease;
LUSC	cis	rs17604090	0.529	rs10239226	chr7:29716312	C/G	cg19413766	chr7:29689036	LOC646762	-0.55	-7.46	-0.38	7.46e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg18681998	chr4:17616180	MED28	0.81	14.1	0.61	9.26e-36	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.64	11.22	0.52	5.14e-25	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.62	-8.9	-0.44	3.53e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.03	0.44	1.37e-17	Motion sickness;
LUSC	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg00750074	chr16:89608354	SPG7	-0.57	-10.21	-0.49	1.71e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg18478394	chr8:109455254	TTC35	0.44	6.93	0.35	2.21e-11	Dupuytren's disease;
LUSC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg03579872	chr1:53393473	SCP2	-0.39	-5.79	-0.3	1.63e-8	Monocyte count;
LUSC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21984481	chr17:79567631	NPLOC4	-0.58	-11.03	-0.52	2.43e-24	Eye color traits;
LUSC	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg12473912	chr3:136751656	NA	0.37	6.45	0.33	3.83e-10	Neuroticism;
LUSC	cis	rs7215564	0.822	rs10871488	chr17:78739079	T/C	cg23238734	chr17:78661607	RPTOR	-0.45	-5.71	-0.3	2.48e-8	Myopia (pathological);
LUSC	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg03676636	chr4:99064102	C4orf37	0.27	5.84	0.3	1.24e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg24459738	chr19:57751996	ZNF805	-0.52	-7.69	-0.39	1.66e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs2219968	1.000	rs11777219	chr8:78959566	A/T	cg00738934	chr8:78996279	NA	0.34	6.19	0.32	1.81e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg10755058	chr3:40428713	ENTPD3	0.35	5.9	0.31	9.01e-9	Renal cell carcinoma;
LUSC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.73	0.43	1.24e-16	Schizophrenia;
LUSC	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg23283495	chr1:209979779	IRF6	0.71	9.01	0.44	1.67e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-9.19	-0.45	4.14e-18	Gut microbiome composition (summer);
LUSC	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg11584989	chr19:19387371	SF4	0.59	6.71	0.34	8.21e-11	Bipolar disorder;
LUSC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs4474465	1.000	rs6592780	chr11:78199888	C/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.91	-0.31	8.55e-9	Alzheimer's disease (survival time);
LUSC	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.92e-20	Coronary artery disease;
LUSC	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg11965913	chr1:205819406	PM20D1	-0.48	-6.71	-0.34	8.28e-11	Menarche (age at onset);
LUSC	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg21775007	chr8:11205619	TDH	-0.65	-10.3	-0.49	9.02e-22	Retinal vascular caliber;
LUSC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.39	-0.37	1.2e-12	Extrinsic epigenetic age acceleration;
LUSC	trans	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-9.34	-0.46	1.38e-18	Brugada syndrome;
LUSC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22590775	chr19:49891494	CCDC155	0.62	8.77	0.43	9.56e-17	Multiple sclerosis;
LUSC	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg06784218	chr1:46089804	CCDC17	0.29	5.83	0.3	1.31e-8	Red blood cell count;Reticulocyte count;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg20854551	chr18:61603789	NA	0.39	6.26	0.32	1.19e-9	Mosquito bite size;
LUSC	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg25214090	chr10:38739885	LOC399744	0.55	8.13	0.41	8.28e-15	Corneal astigmatism;
LUSC	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg01629716	chr15:45996671	NA	0.39	5.96	0.31	6.31e-9	Waist circumference;Weight;
LUSC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg16339924	chr4:17578868	LAP3	-0.61	-8.97	-0.44	2.13e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg23711669	chr6:146136114	FBXO30	-0.83	-14.81	-0.63	1.67e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.66	-11.34	-0.53	1.95e-25	Diastolic blood pressure;
LUSC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg18225595	chr11:63971243	STIP1	0.62	10.41	0.5	3.59e-22	Platelet count;
LUSC	trans	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg26043149	chr18:55253948	FECH	-0.45	-6.85	-0.35	3.67e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.806	rs12599361	chr16:75434973	A/T	cg03315344	chr16:75512273	CHST6	0.48	8.95	0.44	2.56e-17	Dupuytren's disease;
LUSC	cis	rs909685	1.000	rs909685	chr22:39747671	T/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.5	7.05	0.36	1.02e-11	Rheumatoid arthritis;
LUSC	cis	rs6690583	0.562	rs11588919	chr1:85442813	A/T	cg22153463	chr1:85462885	MCOLN2	0.63	6.01	0.31	4.85e-9	Serum sulfate level;
LUSC	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg15556689	chr8:8085844	FLJ10661	0.59	9.11	0.45	7.8e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg26898376	chr11:64110657	CCDC88B	0.37	7.01	0.36	1.36e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	9.54	0.46	3.2e-19	IgG glycosylation;
LUSC	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg24631222	chr15:78858424	CHRNA5	0.65	8.65	0.43	2.2e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg10978503	chr1:24200527	CNR2	-0.54	-12.93	-0.58	2.76e-31	Immature fraction of reticulocytes;
LUSC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg16606324	chr3:10149918	C3orf24	0.6	8.69	0.43	1.63e-16	Alzheimer's disease;
LUSC	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg02997394	chr19:33096574	ANKRD27	0.79	8.95	0.44	2.44e-17	Eosinophilic esophagitis;
LUSC	cis	rs4631830	1.000	rs4631830	chr10:51543344	C/T	cg16070123	chr10:51489643	NA	-0.48	-7.3	-0.37	2.1e-12	Prostate-specific antigen levels;
LUSC	cis	rs11955175	1.000	rs78855960	chr5:40657221	C/G	cg04002187	chr5:40835754	RPL37	0.65	5.67	0.3	3.07e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg12288994	chr5:1860383	NA	0.3	6.6	0.34	1.63e-10	Cardiovascular disease risk factors;
LUSC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg17524265	chr8:144659883	NAPRT1	-0.78	-9.01	-0.44	1.64e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs7524258	0.900	rs6670323	chr1:7301947	C/A	cg07173049	chr1:7289937	CAMTA1	0.32	6.6	0.34	1.58e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs62400317	0.826	rs12194628	chr6:45329376	G/C	cg20913747	chr6:44695427	NA	-0.48	-7.85	-0.39	5.56e-14	Total body bone mineral density;
LUSC	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18932078	chr1:2524107	MMEL1	0.32	7.02	0.36	1.23e-11	Ulcerative colitis;
LUSC	cis	rs7106204	0.668	rs7119198	chr11:24218267	A/G	ch.11.24196551F	chr11:24239977	NA	1.13	14.35	0.62	9.89e-37	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg06521331	chr12:34319734	NA	-0.43	-6.7	-0.34	9.01e-11	Morning vs. evening chronotype;
LUSC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.61	12.65	0.57	3.12e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	11.48	0.53	6.12e-26	Menarche (age at onset);
LUSC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.56	0.38	3.81e-13	Cognitive ability;
LUSC	cis	rs68170813	0.605	rs75659533	chr7:107134987	A/G	cg24556660	chr7:106842632	COG5;HBP1	-0.46	-5.96	-0.31	6.37e-9	Coronary artery disease;
LUSC	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-20.09	-0.74	2.1e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.87	-0.4	5.15e-14	Height;
LUSC	trans	rs2562456	0.833	rs516519	chr19:21481532	C/G	cg00806126	chr19:22604979	ZNF98	0.4	6.2	0.32	1.67e-9	Pain;
LUSC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.35	0.56	3.96e-29	Prudent dietary pattern;
LUSC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg08088566	chr11:430123	ANO9	0.6	7.04	0.36	1.09e-11	Body mass index;
LUSC	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg00105475	chr2:10696890	NA	0.39	6.51	0.34	2.75e-10	Prostate cancer;
LUSC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.25	-0.52	4.08e-25	Alzheimer's disease;
LUSC	cis	rs7589342	0.536	rs1367404	chr2:106386865	G/T	cg09152813	chr2:106391379	NCK2	-0.37	-6.12	-0.32	2.69e-9	Addiction;
LUSC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg08392591	chr16:89556376	ANKRD11	0.43	6.64	0.34	1.26e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.59	-7.53	-0.38	4.68e-13	Body mass index (adult);
LUSC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.0	-0.4	2.12e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7177699	0.526	rs7165042	chr15:79123338	C/G	cg15571903	chr15:79123663	NA	0.34	6.34	0.33	7.41e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9677476	0.863	rs3731775	chr2:232063578	G/A	cg07929768	chr2:232055508	NA	0.37	6.86	0.35	3.44e-11	Food antigen IgG levels;
LUSC	cis	rs6987853	0.787	rs2923442	chr8:42435493	T/C	cg09913449	chr8:42400586	C8orf40	0.53	9.23	0.45	3.26e-18	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12509004	chr7:129691220	ZC3HC1	0.39	6.02	0.31	4.65e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg05347473	chr6:146136440	FBXO30	0.5	8.43	0.42	1.07e-15	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg18187862	chr3:45730750	SACM1L	0.52	6.79	0.35	5.18e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg03972071	chr18:72917163	ZADH2	0.51	5.91	0.31	8.52e-9	Vascular endothelial growth factor levels;
LUSC	cis	rs472402	0.580	rs3733773	chr5:6652252	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.45	-6.54	-0.34	2.24e-10	Response to amphetamines;
LUSC	cis	rs9427116	0.702	rs884618	chr1:154601157	A/G	cg17218026	chr1:154582156	ADAR	0.56	9.84	0.47	3.08e-20	Blood protein levels;
LUSC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	12.17	0.55	1.93e-28	Platelet count;
LUSC	cis	rs981844	0.816	rs62325145	chr4:154725687	G/C	cg14289246	chr4:154710475	SFRP2	0.48	6.09	0.32	3.15e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg11062466	chr8:58055876	NA	0.42	5.66	0.3	3.32e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9816226	1.000	rs61587156	chr3:185831583	T/G	cg00760338	chr3:185826511	ETV5	-0.66	-8.18	-0.41	6.13e-15	Obesity;Body mass index;
LUSC	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.79	11.8	0.54	4.37e-27	Corneal astigmatism;
LUSC	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.36e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg25258033	chr6:167368657	RNASET2	0.36	5.66	0.3	3.2e-8	Primary biliary cholangitis;
LUSC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	0.84	14.91	0.63	6.63e-39	Cognitive function;
LUSC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg05729581	chr11:3078854	CARS	-0.58	-8.77	-0.43	9.5e-17	Longevity;
LUSC	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.83	-0.3	1.32e-8	Coronary artery disease;
LUSC	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg05855489	chr10:104503620	C10orf26	0.53	8.12	0.41	9.19e-15	Arsenic metabolism;
LUSC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg04398451	chr17:18023971	MYO15A	0.57	9.5	0.46	4.25e-19	Total body bone mineral density;
LUSC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg02820958	chr19:7099040	NA	-0.58	-6.2	-0.32	1.66e-9	Schizophrenia;
LUSC	cis	rs981844	0.890	rs56184506	chr4:154685889	G/T	cg14289246	chr4:154710475	SFRP2	0.55	7.13	0.36	6.34e-12	Response to statins (LDL cholesterol change);
LUSC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.59	9.44	0.46	6.42e-19	Pulse pressure;
LUSC	cis	rs6840360	0.901	rs4696293	chr4:152707380	C/T	cg22705602	chr4:152727874	NA	0.27	5.73	0.3	2.28e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2398893	0.774	rs10993047	chr9:96846500	C/T	cg14459158	chr9:96720562	NA	-0.32	-6.02	-0.31	4.68e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg24642844	chr7:1081250	C7orf50	-0.63	-9.18	-0.45	4.46e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs4720118	1.000	rs11972278	chr7:33431364	C/T	cg23247845	chr10:3679085	NA	-0.33	-5.95	-0.31	6.91e-9	Leprosy;
LUSC	trans	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.39	-0.33	5.66e-10	Mood instability;
LUSC	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	0.79	11.96	0.55	1.13e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	trans	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg07393940	chr7:158741817	NA	0.54	8.75	0.43	1.06e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7677751	0.806	rs17084051	chr4:55087581	C/A	cg17187183	chr4:55093834	PDGFRA	0.38	5.83	0.3	1.3e-8	Corneal astigmatism;
LUSC	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg01966878	chr4:90757139	SNCA	-0.36	-6.22	-0.32	1.52e-9	Dementia with Lewy bodies;
LUSC	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.55	11.06	0.52	1.88e-24	Coronary artery disease;
LUSC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg24977027	chr2:88469347	THNSL2	0.56	5.9	0.31	8.7e-9	Plasma clusterin levels;
LUSC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg17264618	chr3:40429014	ENTPD3	-0.32	-7.07	-0.36	8.91e-12	Renal cell carcinoma;
LUSC	cis	rs9815354	0.680	rs73073266	chr3:42021116	A/G	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7215564	0.908	rs35725122	chr17:78663275	A/T	cg23238734	chr17:78661607	RPTOR	0.47	6.1	0.32	2.98e-9	Myopia (pathological);
LUSC	cis	rs75920871	0.528	rs1531707	chr11:116944712	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.48	-0.33	3.25e-10	Subjective well-being;
LUSC	cis	rs7106204	0.748	rs28552633	chr11:24207518	A/C	ch.11.24196551F	chr11:24239977	NA	1.1	13.55	0.6	1.19e-33	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg05340658	chr4:99064831	C4orf37	0.43	6.89	0.35	2.75e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg14092988	chr3:52407081	DNAH1	0.31	6.12	0.32	2.62e-9	Bipolar disorder;
LUSC	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.89	-0.35	2.81e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg06640241	chr16:89574553	SPG7	0.68	10.74	0.51	2.57e-23	Multiple myeloma (IgH translocation);
LUSC	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg01884057	chr2:25150051	NA	0.44	10.17	0.49	2.41e-21	Body mass index;
LUSC	cis	rs1788820	0.957	rs1652375	chr18:21109269	T/C	cg14672496	chr18:21087552	C18orf8	0.43	6.8	0.35	4.81e-11	Body mass index;
LUSC	cis	rs2274273	0.638	rs17672364	chr14:55705904	G/T	cg04306507	chr14:55594613	LGALS3	0.48	9.48	0.46	4.9e-19	Protein biomarker;
LUSC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg18225595	chr11:63971243	STIP1	0.51	6.33	0.33	7.83e-10	Mean platelet volume;
LUSC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.69	-11.24	-0.52	4.6e-25	Intelligence (multi-trait analysis);
LUSC	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.63	-0.69	1.27e-49	Exhaled nitric oxide output;
LUSC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.88	0.35	3.02e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg20587970	chr11:113659929	NA	-1.12	-15.21	-0.64	4.59e-40	Hip circumference adjusted for BMI;
LUSC	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg15848620	chr12:58087721	OS9	-0.56	-8.06	-0.4	1.34e-14	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02123667	chr8:127570702	FAM84B	-0.39	-6.5	-0.34	2.99e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg08975724	chr8:8085496	FLJ10661	0.5	7.16	0.36	5.12e-12	Myopia (pathological);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10551016	chr22:41252963	ST13;XPNPEP3	-0.52	-6.59	-0.34	1.68e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08564027	chr20:61660810	NA	0.9	17.01	0.68	3.71e-47	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg09904177	chr6:26538194	HMGN4	0.76	14.14	0.61	6.79e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs9811920	0.535	rs792833	chr3:99475268	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.3	5.92	0.31	7.82e-9	Axial length;
LUSC	cis	rs8099014	0.861	rs4245270	chr18:56112854	A/G	cg12907477	chr18:56117327	MIR122	0.43	6.59	0.34	1.74e-10	Platelet count;
LUSC	cis	rs3849570	0.925	rs6798680	chr3:81905441	C/A	cg07356753	chr3:81810745	GBE1	-0.68	-11.34	-0.53	2.02e-25	Waist circumference;Body mass index;
LUSC	cis	rs10754283	0.967	rs2185195	chr1:90106697	T/C	cg21401794	chr1:90099060	LRRC8C	0.65	9.74	0.47	6.91e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.77	-0.43	9.01e-17	Neuroticism;
LUSC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14829155	chr15:31115871	NA	-0.56	-7.81	-0.39	7.42e-14	Huntington's disease progression;
LUSC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.69	11.59	0.54	2.49e-26	Heart rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10433104	chr11:18417767	LDHA	0.54	7.73	0.39	1.29e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-14.27	-0.62	2.06e-36	Height;
LUSC	cis	rs11078917	1	rs11078917	chr17:37746359	A/C	cg07936489	chr17:37558343	FBXL20	-0.55	-7.34	-0.37	1.61e-12	Mean corpuscular volume;
LUSC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg12365402	chr11:9010492	NRIP3	0.43	7.88	0.4	4.55e-14	Hemoglobin concentration;
LUSC	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.82	-0.35	4.27e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12122100	0.774	rs12124149	chr1:146523897	G/T	cg03526459	chr1:146549940	NA	-0.34	-5.77	-0.3	1.83e-8	HIV-1 control;
LUSC	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg11984989	chr7:158649758	WDR60	1.08	22.66	0.78	1.61e-69	Height;
LUSC	cis	rs16854884	0.632	rs35362423	chr3:143687441	C/A	cg06585982	chr3:143692056	C3orf58	0.45	6.83	0.35	4.09e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg09904177	chr6:26538194	HMGN4	-0.71	-6.76	-0.35	6.06e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	0.96	21.23	0.76	6.16e-64	Menarche (age at onset);
LUSC	cis	rs921665	0.680	rs4854132	chr2:3199378	T/A	cg16434511	chr2:3151078	NA	-0.62	-6.6	-0.34	1.63e-10	World class endurance athleticism;
LUSC	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg12850546	chr22:42539477	CYP2D7P1	-0.54	-6.34	-0.33	7.27e-10	Birth weight;
LUSC	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.02e-21	Bladder cancer;
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg02978959	chr19:57791520	ZNF460	0.4	6.01	0.31	4.75e-9	Eotaxin levels;
LUSC	cis	rs6772849	0.930	rs1962040	chr3:128324161	G/A	cg16766828	chr3:128327626	NA	-0.31	-5.77	-0.3	1.8e-8	Monocyte percentage of white cells;Monocyte count;
LUSC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.63	-0.47	1.55e-19	Subjective well-being;
LUSC	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg23029597	chr12:123009494	RSRC2	-0.59	-8.5	-0.42	6.41e-16	Body mass index;
LUSC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg09904177	chr6:26538194	HMGN4	0.47	7.48	0.38	6.76e-13	Schizophrenia;
LUSC	cis	rs72634258	0.740	rs6665452	chr1:8172492	A/T	cg00042356	chr1:8021962	PARK7	-0.54	-6.55	-0.34	2.13e-10	Inflammatory bowel disease;
LUSC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg07395648	chr5:131743802	NA	0.37	5.8	0.3	1.52e-8	Asthma (sex interaction);
LUSC	cis	rs354225	0.544	rs10208225	chr2:54806049	G/A	cg01766943	chr2:54829624	SPTBN1	0.48	7.61	0.38	2.89e-13	Schizophrenia;
LUSC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg18225595	chr11:63971243	STIP1	0.5	6.19	0.32	1.8e-9	Mean platelet volume;
LUSC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.69	10.69	0.5	3.99e-23	Aortic root size;
LUSC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg08888203	chr3:10149979	C3orf24	0.48	7.21	0.37	3.81e-12	Alzheimer's disease;
LUSC	cis	rs4654899	0.865	rs61779073	chr1:21398740	C/A	cg01072550	chr1:21505969	NA	-0.52	-7.71	-0.39	1.42e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg27411982	chr8:10470053	RP1L1	0.45	7.26	0.37	2.7e-12	Neuroticism;
LUSC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.78	11.07	0.52	1.86e-24	Corneal astigmatism;
LUSC	trans	rs629535	0.773	rs630235	chr8:70033529	T/G	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg08975724	chr8:8085496	FLJ10661	0.38	5.64	0.3	3.54e-8	Mood instability;
LUSC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	9.62	0.47	1.65e-19	Height;
LUSC	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	0.93	12.34	0.56	4.58e-29	Primary sclerosing cholangitis;
LUSC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11764359	chr7:65958608	NA	-0.6	-8.92	-0.44	3.1e-17	Aortic root size;
LUSC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg23711669	chr6:146136114	FBXO30	-0.78	-14.2	-0.61	4.07e-36	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.91	-0.44	3.34e-17	Retinal vascular caliber;
LUSC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg12935359	chr14:103987150	CKB	-0.47	-7.59	-0.38	3.33e-13	Body mass index;
LUSC	trans	rs724744	0.712	rs1737223	chr6:22355948	C/T	cg13807341	chr11:118445984	ARCN1	-0.36	-6.07	-0.32	3.43e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.51	0.38	5.61e-13	Prudent dietary pattern;
LUSC	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.77	0.39	9.81e-14	Iron status biomarkers;
LUSC	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-7.45	-0.38	7.85e-13	Parkinson's disease;
LUSC	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-6.92	-0.35	2.37e-11	Fear of minor pain;
LUSC	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg24449463	chr1:168025552	DCAF6	-0.76	-12.38	-0.56	3.09e-29	Schizophrenia;
LUSC	cis	rs9346649	0.630	rs4235913	chr6:168491697	T/C	cg02770688	chr6:168491649	NA	0.48	9.05	0.44	1.23e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs4901869	0.966	rs9972208	chr14:59336116	C/T	cg02291164	chr14:59296302	NA	0.57	10.88	0.51	8.53e-24	Panic disorder;
LUSC	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg04455712	chr21:45112962	RRP1B	0.47	9.03	0.44	1.42e-17	Mean corpuscular volume;
LUSC	cis	rs4363385	0.719	rs6664411	chr1:152932857	T/C	cg07796016	chr1:152779584	LCE1C	-0.47	-6.7	-0.34	8.81e-11	Inflammatory skin disease;
LUSC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.12	-0.41	8.84e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.73	-0.3	2.26e-8	Height;
LUSC	cis	rs568617	0.626	rs78028320	chr11:65582015	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.58	6.51	0.34	2.75e-10	Crohn's disease;
LUSC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-11.47	-0.53	6.58e-26	Mood instability;
LUSC	cis	rs7605827	0.930	rs7568874	chr2:15546361	T/C	cg19274914	chr2:15703543	NA	0.46	8.81	0.43	6.85e-17	Educational attainment (years of education);
LUSC	cis	rs11039100	1.000	rs12362071	chr11:5828450	T/C	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg05340658	chr4:99064831	C4orf37	0.43	6.83	0.35	4.08e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2742234	0.541	rs10899779	chr10:43723976	C/T	cg15436174	chr10:43711423	RASGEF1A	0.43	7.01	0.36	1.3e-11	Hirschsprung disease;
LUSC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08470875	chr2:26401718	FAM59B	0.71	9.7	0.47	9.2e-20	Gut microbiome composition (summer);
LUSC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg24562669	chr7:97807699	LMTK2	0.33	5.81	0.3	1.42e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-15.53	-0.65	2.62e-41	Heart rate;
LUSC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg14092988	chr3:52407081	DNAH1	0.33	6.39	0.33	5.69e-10	Bipolar disorder;
LUSC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg21251018	chr6:28226885	NKAPL	0.33	6.46	0.33	3.62e-10	Pubertal anthropometrics;
LUSC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg13072238	chr3:49761600	GMPPB	-0.66	-8.05	-0.4	1.51e-14	Menarche (age at onset);
LUSC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1865721	0.656	rs727894	chr18:73137117	C/T	cg26385618	chr18:73139727	C18orf62	-0.48	-8.94	-0.44	2.65e-17	Intelligence;
LUSC	cis	rs2425143	1.000	rs12480408	chr20:34234800	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.24	-0.32	1.33e-9	Blood protein levels;
LUSC	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg18190219	chr22:46762943	CELSR1	-0.71	-6.87	-0.35	3.12e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7843479	1.000	rs10503715	chr8:21850687	G/A	cg17168535	chr8:21777572	XPO7	0.64	9.54	0.46	3.04e-19	Mean corpuscular volume;
LUSC	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	7.44	0.38	8.62e-13	Axial length;
LUSC	cis	rs3087591	0.614	rs3785955	chr17:29647802	C/T	cg24425628	chr17:29625626	OMG;NF1	0.46	6.85	0.35	3.48e-11	Hip circumference;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.65	9.88	0.48	2.39e-20	Lymphocyte counts;
LUSC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg22963979	chr7:1858916	MAD1L1	0.73	12.58	0.57	5.76e-30	Bipolar disorder and schizophrenia;
LUSC	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg00277334	chr10:82204260	NA	-0.49	-7.22	-0.37	3.48e-12	Post bronchodilator FEV1;
LUSC	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg25214090	chr10:38739885	LOC399744	0.55	8.2	0.41	5.35e-15	Corneal astigmatism;
LUSC	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg25767906	chr1:53392781	SCP2	0.39	6.78	0.35	5.63e-11	Monocyte count;
LUSC	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg23950597	chr19:37808831	NA	-0.63	-7.68	-0.39	1.82e-13	Coronary artery calcification;
LUSC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	1.04	19.58	0.73	2.23e-57	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24389389	chr4:141075404	MAML3	-0.45	-6.81	-0.35	4.41e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.66	-0.39	2.02e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg20406979	chr6:167373233	NA	0.26	6.15	0.32	2.25e-9	Crohn's disease;
LUSC	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg02569458	chr12:86230093	RASSF9	-0.48	-8.03	-0.4	1.63e-14	Major depressive disorder;
LUSC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.39	0.67	1.04e-44	Platelet count;
LUSC	cis	rs9807989	0.839	rs10204137	chr2:102968212	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.91	0.31	8.63e-9	Asthma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06452642	chr19:13875641	MRI1	-0.49	-6.0	-0.31	4.99e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.5	-0.42	6.21e-16	Aortic root size;
LUSC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg17724175	chr1:150552817	MCL1	0.37	6.75	0.35	6.71e-11	Tonsillectomy;
LUSC	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-5.9	-0.31	8.72e-9	Retinal vascular caliber;
LUSC	cis	rs9653442	0.545	rs12987212	chr2:100761156	C/T	cg07810366	chr2:100720526	AFF3	-0.45	-7.75	-0.39	1.13e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	9.09	0.45	9.22e-18	Response to antipsychotic treatment;
LUSC	cis	rs4293296	0.525	rs1955458	chr14:54827524	A/C	cg02257953	chr14:54816093	NA	0.46	6.64	0.34	1.29e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.34	6.19	0.32	1.76e-9	Obesity-related traits;
LUSC	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg14835575	chr10:16859367	RSU1	0.64	8.54	0.42	4.67e-16	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08280861	chr8:58055591	NA	0.55	6.51	0.34	2.79e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2820315	0.867	rs2819346	chr1:201882087	A/C	cg10061532	chr1:201886748	LMOD1	0.29	6.9	0.35	2.67e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17691542	chr6:26056736	HIST1H1C	0.83	11.19	0.52	6.72e-25	Iron status biomarkers;
LUSC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg19318889	chr4:1322082	MAEA	0.48	7.69	0.39	1.68e-13	Obesity-related traits;
LUSC	cis	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05901451	chr6:126070800	HEY2	0.57	8.66	0.43	2.04e-16	Endometrial cancer;
LUSC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.06e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-18.18	-0.71	7.93e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg13072238	chr3:49761600	GMPPB	0.41	6.66	0.34	1.14e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.83	20.03	0.74	3.54e-59	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.85	0.39	5.56e-14	Colorectal cancer;
LUSC	cis	rs7759001	0.857	rs4713094	chr6:27373078	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	2e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.7	-0.43	1.49e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg25258033	chr6:167368657	RNASET2	0.37	5.83	0.3	1.28e-8	Primary biliary cholangitis;
LUSC	cis	rs6489785	0.710	rs3213566	chr12:121222578	T/C	cg02419362	chr12:121203948	SPPL3	0.41	7.34	0.37	1.6e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.42	-6.44	-0.33	4.13e-10	Prudent dietary pattern;
LUSC	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg25566285	chr7:158114605	PTPRN2	0.35	6.53	0.34	2.52e-10	Calcium levels;
LUSC	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg22815214	chr1:201083145	CACNA1S	0.46	6.54	0.34	2.33e-10	Permanent tooth development;
LUSC	cis	rs4654899	0.643	rs1408409	chr1:21089781	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.05	-0.36	1.03e-11	Superior frontal gyrus grey matter volume;
LUSC	trans	rs11165623	0.543	rs60982887	chr1:96989155	T/G	cg10631902	chr5:14652156	NA	-0.43	-6.18	-0.32	1.88e-9	Hip circumference;Waist circumference;
LUSC	trans	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg17675199	chr6:35436792	RPL10A	-0.43	-6.42	-0.33	4.61e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg08525481	chr20:61436809	OGFR	0.39	5.95	0.31	6.87e-9	Schizophrenia;
LUSC	trans	rs62238980	0.614	rs79061246	chr22:32468866	G/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs9311676	0.656	rs11130638	chr3:58405947	A/G	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.1e-10	Systemic lupus erythematosus;
LUSC	trans	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.4	-0.38	1.1e-12	Breast cancer;
LUSC	cis	rs2282300	0.702	rs2211018	chr11:30330079	C/T	cg25418670	chr11:30344373	C11orf46	0.64	9.23	0.45	3.29e-18	Morning vs. evening chronotype;
LUSC	cis	rs12530845	1.000	rs12537555	chr7:135334061	G/A	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg05738196	chr6:26577821	NA	0.83	16.17	0.66	7.47e-44	Intelligence (multi-trait analysis);
LUSC	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.59	-8.5	-0.42	6.35e-16	Superior crus of antihelix expression;
LUSC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg04155289	chr7:94953770	PON1	-0.35	-6.05	-0.31	3.82e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7804356	1.000	rs10486483	chr7:26892440	A/G	cg03456212	chr7:26904342	SKAP2	0.53	6.32	0.33	8.36e-10	Type 1 diabetes;
LUSC	cis	rs6840360	1.000	rs4696109	chr4:152668785	A/C	cg22705602	chr4:152727874	NA	-0.28	-6.07	-0.32	3.49e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6484504	0.532	rs7121949	chr11:31288160	G/T	cg06552810	chr11:31128660	NA	-0.39	-6.86	-0.35	3.38e-11	Red blood cell count;
LUSC	cis	rs2835872	0.965	rs2154553	chr21:39004501	G/A	cg20424643	chr21:39039972	KCNJ6	-0.4	-6.09	-0.32	3.15e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs8113142	0.651	rs61150903	chr19:29093321	A/G	cg04546413	chr19:29218101	NA	0.41	5.74	0.3	2.15e-8	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs73206853	0.660	rs12313068	chr12:110597304	C/T	cg12870014	chr12:110450643	ANKRD13A	0.51	6.92	0.35	2.38e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg08888203	chr3:10149979	C3orf24	0.59	8.1	0.41	1.08e-14	Alzheimer's disease;
LUSC	cis	rs6700896	0.500	rs11208692	chr1:66107946	A/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	6.36	0.33	6.62e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg20026190	chr17:76395443	PGS1	0.44	7.81	0.39	7.25e-14	HDL cholesterol levels;
LUSC	cis	rs7572644	0.581	rs35463245	chr2:28000724	C/G	cg27432699	chr2:27873401	GPN1	0.55	7.05	0.36	1.01e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs12317459	0.591	rs11609468	chr12:83206927	T/C	cg10237817	chr1:154519846	TDRD10	0.3	6.35	0.33	6.89e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg11663144	chr21:46675770	NA	-0.42	-7.25	-0.37	3.01e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-10.35	-0.49	5.96e-22	Gut microbiome composition (summer);
LUSC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg17279839	chr7:150038598	RARRES2	-0.43	-6.57	-0.34	1.92e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6163	0.540	rs11191385	chr10:104513049	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-6.57	-0.34	1.94e-10	Waist circumference;Hip circumference;
LUSC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.62	11.01	0.52	2.9e-24	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.14	0.36	5.87e-12	IgG glycosylation;
LUSC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg18402987	chr7:1209562	NA	0.67	7.08	0.36	8.56e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	trans	rs17641971	0.862	rs341817	chr8:50023600	A/C	cg15678142	chr1:167411538	CD247	0.4	6.12	0.32	2.64e-9	Blood metabolite levels;
LUSC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg17971929	chr21:40555470	PSMG1	0.75	11.77	0.54	5.39e-27	Cognitive function;
LUSC	cis	rs6845621	0.901	rs10489055	chr4:18933156	A/G	cg12196642	chr4:18937545	NA	-0.37	-6.88	-0.35	2.92e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	0.95	10.4	0.49	3.96e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg06618935	chr21:46677482	NA	0.37	7.63	0.39	2.51e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.67	-0.39	1.93e-13	Height;
LUSC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg00310523	chr12:86230176	RASSF9	0.52	9.86	0.47	2.61e-20	Major depressive disorder;
LUSC	cis	rs983392	0.776	rs2278867	chr11:59943109	A/T	cg02771260	chr11:59836817	MS4A3	-0.37	-5.88	-0.31	1.01e-8	Alzheimer's disease (late onset);
LUSC	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06634786	chr22:41940651	POLR3H	-0.5	-5.98	-0.31	5.72e-9	Vitiligo;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12216983	chr12:122751217	VPS33A	-0.41	-5.96	-0.31	6.44e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7586879	0.675	rs7600421	chr2:25075876	T/G	cg01884057	chr2:25150051	NA	0.35	7.01	0.36	1.36e-11	Body mass index;
LUSC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg00599273	chr12:58146742	CDK4	0.31	5.92	0.31	8.04e-9	Multiple sclerosis;
LUSC	cis	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg07460842	chr6:66804631	NA	-0.52	-7.4	-0.38	1.13e-12	Blood trace element (Cu levels);
LUSC	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg04518342	chr5:131593106	PDLIM4	-0.36	-6.56	-0.34	2.01e-10	Blood metabolite levels;
LUSC	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg23950597	chr19:37808831	NA	-0.61	-6.99	-0.36	1.53e-11	Coronary artery calcification;
LUSC	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg20307385	chr11:47447363	PSMC3	0.75	10.13	0.48	3.4e-21	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs1483890	0.723	rs1843046	chr3:69410614	C/A	cg22125112	chr3:69402811	FRMD4B	0.4	5.67	0.3	3.06e-8	Resting heart rate;
LUSC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg11645453	chr3:52864694	ITIH4	0.36	8.21	0.41	4.91e-15	Bipolar disorder;
LUSC	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg17294928	chr15:75287854	SCAMP5	-0.68	-5.83	-0.3	1.34e-8	Lung cancer;
LUSC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	1e-64	Prudent dietary pattern;
LUSC	cis	rs67539049	1.000	rs67539049	chr8:11307311	G/A	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.4	-6.08	-0.32	3.33e-9	Itch intensity from mosquito bite;
LUSC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.62	-8.05	-0.4	1.49e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg17845761	chr1:175162550	KIAA0040	0.31	5.93	0.31	7.53e-9	Alcohol dependence;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg06887542	chr12:48357506	TMEM106C	-0.48	-6.04	-0.31	4.16e-9	Neuroticism;
LUSC	cis	rs1559088	0.501	rs35492529	chr19:33597495	C/G	cg17764715	chr19:33622953	WDR88	0.57	6.16	0.32	2.1e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.43	16.18	0.66	6.92e-44	Opioid sensitivity;
LUSC	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.58	-0.43	3.56e-16	Rheumatoid arthritis;
LUSC	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg20307385	chr11:47447363	PSMC3	-0.44	-6.61	-0.34	1.51e-10	Subjective well-being;
LUSC	cis	rs77741769	0.571	rs34009825	chr12:121326183	A/G	cg02419362	chr12:121203948	SPPL3	0.45	8.24	0.41	3.89e-15	Mean corpuscular volume;
LUSC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg19748678	chr4:122722346	EXOSC9	0.5	7.67	0.39	1.86e-13	Type 2 diabetes;
LUSC	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.53	0.5	1.4e-22	Colorectal cancer;
LUSC	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.36	-0.46	1.18e-18	Total cholesterol levels;
LUSC	cis	rs950881	0.932	rs10189154	chr2:102937544	C/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.37	0.33	6.4e-10	Allergy;
LUSC	cis	rs3744061	0.530	rs8182300	chr17:74650608	T/C	cg27546012	chr17:74684504	MXRA7	-0.39	-6.74	-0.35	7.04e-11	Retinal arteriolar caliber;
LUSC	trans	rs72674100	1.000	rs7681234	chr4:97964425	T/A	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg12463550	chr7:65579703	CRCP	-0.47	-7.07	-0.36	9.33e-12	Aortic root size;
LUSC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.16	-0.45	5.27e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg17971929	chr21:40555470	PSMG1	0.8	13.37	0.59	6.01e-33	Cognitive function;
LUSC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-7.33	-0.37	1.73e-12	Alzheimer's disease (late onset);
LUSC	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg20701182	chr2:24300061	SF3B14	0.73	7.33	0.37	1.74e-12	Lymphocyte counts;
LUSC	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg06623918	chr6:96969491	KIAA0776	0.92	16.83	0.68	1.89e-46	Headache;
LUSC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg06096015	chr1:231504339	EGLN1	0.56	9.84	0.47	3.07e-20	Hemoglobin concentration;
LUSC	cis	rs11039100	1.000	rs12366070	chr11:5828394	C/T	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg08079166	chr15:68083412	MAP2K5	0.4	8.42	0.42	1.13e-15	Restless legs syndrome;
LUSC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07362569	chr17:61921086	SMARCD2	0.37	7.31	0.37	1.98e-12	Prudent dietary pattern;
LUSC	cis	rs6733011	0.622	rs12712036	chr2:99462711	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-5.66	-0.3	3.23e-8	Bipolar disorder;
LUSC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg06640241	chr16:89574553	SPG7	0.98	20.4	0.74	1.16e-60	Multiple myeloma (IgH translocation);
LUSC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg13256891	chr4:100009986	ADH5	0.44	6.69	0.34	9.19e-11	Alcohol dependence;
LUSC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	6.34	0.33	7.4e-10	Monocyte count;
LUSC	cis	rs7615316	0.816	rs13065075	chr3:142265166	T/C	cg16271453	chr3:142027066	XRN1	-0.38	-6.59	-0.34	1.7e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg13047869	chr3:10149882	C3orf24	0.44	6.71	0.34	8.55e-11	Alzheimer's disease;
LUSC	cis	rs9462027	0.628	rs9357181	chr6:34673833	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.36	6.34	0.33	7.36e-10	Systemic lupus erythematosus;
LUSC	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.17	-0.37	4.99e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.592	rs708140	chr12:33719563	G/A	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg12863693	chr15:85201151	NMB	0.39	8.16	0.41	6.9e-15	Schizophrenia;
LUSC	cis	rs4285028	0.747	rs12634032	chr3:121524575	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-12.33	-0.56	4.69e-29	Multiple sclerosis;
LUSC	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.64	-0.43	2.34e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg23752985	chr2:85803571	VAMP8	0.34	6.51	0.34	2.73e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs17253792	0.822	rs7150841	chr14:56088986	T/C	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-7.67	-0.39	1.95e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg11502198	chr6:26597334	ABT1	0.59	9.24	0.45	2.86e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.66	0.47	1.25e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg11632617	chr15:75315747	PPCDC	-0.54	-7.01	-0.36	1.29e-11	Blood trace element (Zn levels);
LUSC	cis	rs983392	0.719	rs610932	chr11:59939307	T/G	cg02771260	chr11:59836817	MS4A3	0.36	6.05	0.31	3.86e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg27532560	chr4:187881888	NA	-0.37	-6.08	-0.32	3.33e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	6.91	0.35	2.39e-11	Lung cancer in ever smokers;
LUSC	cis	rs501916	0.634	rs1561480	chr15:48070050	C/G	cg16110827	chr15:48056943	SEMA6D	-0.38	-5.91	-0.31	8.52e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	trans	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg25482853	chr8:67687455	SGK3	1.12	15.85	0.66	1.36e-42	Lung disease severity in cystic fibrosis;
LUSC	cis	rs238295	0.805	rs6053525	chr20:5577000	C/T	cg15842884	chr20:5591925	RP5-1022P6.2	-0.44	-5.94	-0.31	7.34e-9	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs10992471	0.528	rs3780347	chr9:95266812	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.2	-0.32	1.69e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4443100	0.670	rs3788338	chr22:23412058	G/A	cg21100191	chr22:23484243	RTDR1	0.57	7.2	0.37	4.1e-12	Serum parathyroid hormone levels;
LUSC	cis	rs13315871	0.929	rs9854438	chr3:58277327	G/A	cg12435725	chr3:58293450	RPP14	-0.73	-7.51	-0.38	5.33e-13	Cholesterol, total;
LUSC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.68	-12.2	-0.56	1.43e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg19812747	chr11:111475976	SIK2	-0.54	-7.6	-0.38	2.97e-13	Primary sclerosing cholangitis;
LUSC	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg18850127	chr7:39170497	POU6F2	0.64	9.64	0.47	1.41e-19	IgG glycosylation;
LUSC	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.0	0.52	3.3e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg18357526	chr6:26021779	HIST1H4A	0.38	6.07	0.32	3.39e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg02569458	chr12:86230093	RASSF9	0.51	8.47	0.42	7.84e-16	Major depressive disorder;
LUSC	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg08085267	chr17:45401833	C17orf57	-0.48	-7.6	-0.38	2.98e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg22852734	chr6:133119734	C6orf192	0.9	9.27	0.45	2.45e-18	Type 2 diabetes nephropathy;
LUSC	cis	rs137603	0.644	rs94852	chr22:39712334	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.5	-8.0	-0.4	2.02e-14	Primary biliary cholangitis;
LUSC	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg05805236	chr11:65401703	PCNXL3	-0.65	-10.68	-0.5	4.36e-23	Acne (severe);
LUSC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.77	-0.43	9.4e-17	Bipolar disorder;
LUSC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg08975724	chr8:8085496	FLJ10661	0.55	8.43	0.42	1.03e-15	Systolic blood pressure;
LUSC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg21724239	chr8:58056113	NA	0.57	6.46	0.33	3.62e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg09184832	chr6:79620586	NA	-0.44	-7.06	-0.36	9.88e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.26	0.45	2.56e-18	Bipolar disorder;
LUSC	cis	rs10979	1.000	rs9390104	chr6:143890978	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg00277334	chr10:82204260	NA	-0.57	-8.92	-0.44	3.14e-17	Post bronchodilator FEV1;
LUSC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg16743903	chr16:89593216	SPG7	-0.37	-5.85	-0.31	1.15e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.51	-7.82	-0.39	6.83e-14	Lymphocyte counts;
LUSC	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg02569458	chr12:86230093	RASSF9	0.48	7.63	0.39	2.49e-13	Major depressive disorder;
LUSC	cis	rs11673344	0.504	rs1667378	chr19:37492073	C/A	cg27390819	chr19:37464633	NA	-0.35	-5.66	-0.3	3.3e-8	Obesity-related traits;
LUSC	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg17063962	chr7:91808500	NA	0.56	8.54	0.42	4.84e-16	Breast cancer;
LUSC	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg26528668	chr16:1614120	IFT140	0.43	7.06	0.36	9.54e-12	Coronary artery disease;
LUSC	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-6.97	-0.36	1.73e-11	Blood metabolite levels;
LUSC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.38	-0.33	5.76e-10	Neuroticism;
LUSC	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.48	-6.48	-0.33	3.22e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg27284194	chr4:1044797	NA	0.59	9.01	0.44	1.64e-17	Recombination rate (females);
LUSC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00149659	chr3:10157352	C3orf10	0.98	14.52	0.62	2.16e-37	Alzheimer's disease;
LUSC	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	1.11	19.25	0.73	4.55e-56	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	7.56	0.38	3.86e-13	Lung cancer in ever smokers;
LUSC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg21361702	chr7:150065534	REPIN1	0.51	6.53	0.34	2.5e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06634786	chr22:41940651	POLR3H	-0.55	-6.46	-0.33	3.75e-10	Vitiligo;
LUSC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg21782813	chr7:2030301	MAD1L1	0.41	6.79	0.35	5.2e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.38	-0.33	5.86e-10	Extrinsic epigenetic age acceleration;
LUSC	trans	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.96	-0.36	1.86e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs11229555	0.574	rs12272310	chr11:58186462	A/C	cg15696309	chr11:58395628	NA	-0.64	-7.78	-0.39	9.19e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12421382	0.778	rs11213128	chr11:109489575	G/A	cg27471124	chr11:109292789	C11orf87	0.43	7.42	0.38	9.62e-13	Schizophrenia;
LUSC	cis	rs10779751	0.887	rs6686835	chr1:11305316	G/A	cg08854313	chr1:11322531	MTOR	0.88	14.96	0.63	4.48e-39	Body mass index;
LUSC	cis	rs8179	1.000	rs8179	chr7:92236164	T/C	cg15732164	chr7:92237376	CDK6	0.54	7.25	0.37	2.97e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22949040	chr2:204399512	RAPH1	0.5	6.65	0.34	1.19e-10	Neuroticism;
LUSC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.81	-0.35	4.42e-11	Menopause (age at onset);
LUSC	cis	rs1790761	0.967	rs869736	chr11:67205462	C/A	cg24690094	chr11:67383802	NA	-0.32	-5.84	-0.3	1.26e-8	Mean corpuscular volume;
LUSC	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.99	-0.31	5.32e-9	Breast cancer;
LUSC	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06022373	chr22:39101656	GTPBP1	0.79	13.08	0.58	7.2e-32	Menopause (age at onset);
LUSC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.12	-0.41	9.4e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg12560992	chr17:57184187	TRIM37	-0.89	-17.5	-0.69	3.97e-49	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18228282	chr17:46703908	HOXB9	-0.5	-5.97	-0.31	6.08e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-1.19	-12.84	-0.57	5.85e-31	Diabetic kidney disease;
LUSC	cis	rs17604090	0.878	rs10262227	chr7:29704073	G/A	cg19413766	chr7:29689036	LOC646762	-0.64	-7.7	-0.39	1.56e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg07211511	chr3:129823064	LOC729375	-1.04	-15.52	-0.65	2.79e-41	Blood pressure (smoking interaction);
LUSC	trans	rs10511400	0.541	rs923727	chr3:119918124	G/A	cg02809009	chr19:50354510	PTOV1	-0.68	-6.18	-0.32	1.82e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs62400317	0.859	rs12201555	chr6:45294400	T/A	cg18551225	chr6:44695536	NA	-0.45	-7.46	-0.38	7.62e-13	Total body bone mineral density;
LUSC	cis	rs7589342	0.628	rs11893695	chr2:106401300	C/G	cg14210321	chr2:106509881	NCK2	0.46	5.83	0.3	1.3e-8	Addiction;
LUSC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-10.26	-0.49	1.18e-21	Bladder cancer;
LUSC	cis	rs9644630	1.000	rs9644631	chr8:19370830	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.32	5.92	0.31	8.21e-9	Oropharynx cancer;
LUSC	cis	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg20159608	chr7:32802032	NA	0.71	9.34	0.46	1.36e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs1595825	0.627	rs76341431	chr2:198379118	G/A	cg00982548	chr2:198649783	BOLL	-0.52	-6.16	-0.32	2.13e-9	Ulcerative colitis;
LUSC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19723775	chr5:179050963	HNRNPH1	0.37	5.67	0.3	3.09e-8	Lung cancer;
LUSC	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg25173405	chr17:45401733	C17orf57	-0.41	-6.52	-0.34	2.63e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg04733989	chr22:42467013	NAGA	0.39	6.54	0.34	2.33e-10	Cognitive function;
LUSC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.2	0.37	4.12e-12	Mean platelet volume;
LUSC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.49	7.82	0.39	7e-14	Resistin levels;
LUSC	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg17691542	chr6:26056736	HIST1H1C	0.4	5.94	0.31	7.21e-9	Schizophrenia;
LUSC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg18301423	chr5:131593218	PDLIM4	0.46	7.03	0.36	1.16e-11	Acylcarnitine levels;
LUSC	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg21770322	chr7:97807741	LMTK2	-0.55	-9.86	-0.47	2.79e-20	Breast cancer;
LUSC	cis	rs2282300	0.702	rs4379811	chr11:30294760	C/T	cg25418670	chr11:30344373	C11orf46	0.64	9.09	0.45	9.01e-18	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg24642844	chr7:1081250	C7orf50	-0.69	-9.98	-0.48	1.06e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg24634471	chr8:143751801	JRK	0.59	8.98	0.44	1.97e-17	Schizophrenia;
LUSC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg23711669	chr6:146136114	FBXO30	-0.9	-17.81	-0.7	2.44e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10465746	0.933	rs2224990	chr1:84436275	C/A	cg10977910	chr1:84465055	TTLL7	0.41	6.05	0.31	3.81e-9	Obesity-related traits;
LUSC	cis	rs2898681	0.581	rs730247	chr4:53680696	T/G	cg00338735	chr4:53728038	RASL11B	0.43	5.81	0.3	1.46e-8	Optic nerve measurement (cup area);
LUSC	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg22089800	chr15:90895588	ZNF774	0.64	10.26	0.49	1.23e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg19640130	chr10:64028056	RTKN2	0.39	7.01	0.36	1.34e-11	Rheumatoid arthritis;
LUSC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg18479299	chr3:125709523	NA	-0.48	-5.89	-0.31	9.37e-9	Blood pressure (smoking interaction);
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg04025307	chr7:1156635	C7orf50	0.41	6.31	0.33	8.73e-10	Longevity;Endometriosis;
LUSC	cis	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.06	-0.31	3.58e-9	Neuroticism;
LUSC	cis	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg11879182	chr18:77439856	CTDP1	0.7	10.42	0.5	3.47e-22	Monocyte count;
LUSC	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg03929089	chr4:120376271	NA	-0.55	-6.77	-0.35	5.75e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg25258033	chr6:167368657	RNASET2	0.38	5.82	0.3	1.38e-8	Primary biliary cholangitis;
LUSC	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg12219531	chr12:120966889	COQ5	0.59	7.71	0.39	1.41e-13	High light scatter reticulocyte count;
LUSC	cis	rs13315871	0.929	rs11130628	chr3:58315835	T/C	cg12435725	chr3:58293450	RPP14	-0.69	-7.02	-0.36	1.21e-11	Cholesterol, total;
LUSC	cis	rs10208940	0.920	rs11893513	chr2:68760647	C/T	cg12452813	chr2:68675892	NA	0.57	5.95	0.31	6.95e-9	Urate levels in lean individuals;
LUSC	cis	rs7429990	0.965	rs1550914	chr3:47995168	A/C	cg11946769	chr3:48343235	NME6	0.48	6.6	0.34	1.59e-10	Educational attainment (years of education);
LUSC	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg02023728	chr11:77925099	USP35	0.46	6.7	0.34	8.82e-11	Testicular germ cell tumor;
LUSC	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.77	-0.43	9.38e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg00012203	chr2:219082015	ARPC2	-0.69	-11.35	-0.53	1.78e-25	Colorectal cancer;
LUSC	trans	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07923666	chr12:49932857	KCNH3	-0.53	-6.86	-0.35	3.39e-11	Resting heart rate;
LUSC	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.53	-0.42	5.24e-16	Menopause (age at onset);
LUSC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg05896524	chr21:47604654	C21orf56	0.47	6.92	0.35	2.31e-11	Testicular germ cell tumor;
LUSC	cis	rs9487051	0.768	rs351742	chr6:109527325	C/T	cg00509249	chr6:109615579	CCDC162	0.34	5.87	0.31	1.05e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg15485101	chr11:133734466	NA	0.42	7.65	0.39	2.13e-13	Childhood ear infection;
LUSC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg24562669	chr7:97807699	LMTK2	0.35	6.16	0.32	2.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg20243544	chr17:37824526	PNMT	0.5	6.95	0.36	1.96e-11	Asthma;
LUSC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	0.8	13.95	0.61	3.66e-35	Cognitive function;
LUSC	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs11676348	0.772	rs11676275	chr2:218944808	G/A	cg00012203	chr2:219082015	ARPC2	-0.48	-7.37	-0.37	1.34e-12	Ulcerative colitis;
LUSC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg22907277	chr7:1156413	C7orf50	0.57	6.31	0.33	9.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.26	-0.41	3.33e-15	Body mass index;
LUSC	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07636037	chr3:49044803	WDR6	0.7	9.29	0.45	2.11e-18	Menarche (age at onset);
LUSC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06634786	chr22:41940651	POLR3H	-0.49	-5.75	-0.3	2e-8	Vitiligo;
LUSC	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.23	-0.69	4.77e-48	Exhaled nitric oxide output;
LUSC	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-9.19	-0.45	4.25e-18	Myeloid white cell count;
LUSC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	10.02	0.48	7.68e-21	Bipolar disorder;
LUSC	trans	rs7980799	0.935	rs4931717	chr12:33521151	A/G	cg26384229	chr12:38710491	ALG10B	0.43	6.12	0.32	2.65e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg25174290	chr11:3078921	CARS	0.59	9.17	0.45	4.93e-18	Longevity;
LUSC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg23601095	chr6:26197514	HIST1H3D	0.66	7.06	0.36	9.54e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.71e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22819488	chr3:28390286	AZI2	-0.51	-6.6	-0.34	1.63e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg09699651	chr6:150184138	LRP11	0.37	5.76	0.3	1.92e-8	Lung cancer;
LUSC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-0.98	-18.12	-0.7	1.34e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs16937	0.521	rs78176224	chr1:205178609	G/A	cg00857998	chr1:205179979	DSTYK	0.47	6.66	0.34	1.1e-10	Schizophrenia;
LUSC	cis	rs10072221	0.836	rs7731240	chr5:75707576	T/C	cg03132911	chr5:75698732	IQGAP2	0.36	6.07	0.32	3.46e-9	Mean platelet volume;
LUSC	trans	rs1422110	0.513	rs987280	chr5:85448604	C/T	cg01787110	chr1:109008453	NBPF6	-0.43	-7.86	-0.4	5.47e-14	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg07701084	chr6:150067640	NUP43	0.53	8.01	0.4	1.97e-14	Lung cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01727434	chr2:152118530	RBM43	0.46	6.54	0.34	2.29e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3862260	1.000	rs3862260	chr1:120160789	G/A	cg16322792	chr1:120165303	ZNF697	0.5	9.59	0.46	2.2e-19	Systemic lupus erythematosus;
LUSC	cis	rs16976116	0.901	rs28541469	chr15:55500788	G/A	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs865483	0.895	rs4795203	chr17:35828972	T/C	cg06716730	chr17:35851459	DUSP14	0.28	6.18	0.32	1.91e-9	Monocyte count;
LUSC	trans	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17712092	chr4:129076599	LARP1B	-0.76	-11.19	-0.52	6.99e-25	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.54	0.57	8.02e-30	Motion sickness;
LUSC	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.84	-0.39	6.1e-14	Blood metabolite levels;
LUSC	cis	rs2652834	0.808	rs4775614	chr15:63351687	A/G	cg05507819	chr15:63340323	TPM1	0.69	8.66	0.43	2.05e-16	HDL cholesterol;
LUSC	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg24375607	chr4:120327624	NA	0.69	10.58	0.5	9.19e-23	Corneal astigmatism;
LUSC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.71	-10.02	-0.48	7.57e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs1403694	0.515	rs1656925	chr3:186449123	T/C	cg12454167	chr3:186435060	KNG1	0.28	7.6	0.38	2.98e-13	Blood protein levels;
LUSC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg15448220	chr1:150897856	SETDB1	0.4	5.89	0.31	9.28e-9	Melanoma;
LUSC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg20887711	chr4:1340912	KIAA1530	0.4	5.98	0.31	5.86e-9	Obesity-related traits;
LUSC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg05872129	chr22:39784769	NA	-0.58	-10.59	-0.5	8.65e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02018176	chr4:1364513	KIAA1530	-0.68	-12.62	-0.57	3.9e-30	Longevity;
LUSC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3741151	1.000	rs76887714	chr11:73045500	C/T	cg17517138	chr11:73019481	ARHGEF17	0.97	8.93	0.44	2.96e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs17092148	0.945	rs6060034	chr20:33351864	T/C	cg16810054	chr20:33298113	TP53INP2	-0.43	-6.81	-0.35	4.68e-11	Neuroticism;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg25732426	chr21:46294058	PTTG1IP	-0.48	-6.48	-0.33	3.28e-10	Cognitive function;Information processing speed;
LUSC	cis	rs2932538	0.922	rs6663922	chr1:113095948	T/C	cg22162597	chr1:113214053	CAPZA1	0.55	7.89	0.4	4.48e-14	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	1.14	14.77	0.63	2.43e-38	Nonalcoholic fatty liver disease;
LUSC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg03894339	chr8:19674705	INTS10	0.56	7.6	0.38	2.96e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3741151	0.686	rs12285885	chr11:73294478	A/G	cg17517138	chr11:73019481	ARHGEF17	0.86	8.29	0.41	2.84e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7827545	1.000	rs2119879	chr8:135549042	T/C	cg17885191	chr8:135476712	NA	0.56	8.2	0.41	5.4e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg10253484	chr15:75165896	SCAMP2	-0.41	-5.84	-0.3	1.27e-8	Breast cancer;
LUSC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg16524733	chr11:117070046	TAGLN	-0.44	-7.73	-0.39	1.3e-13	Blood protein levels;
LUSC	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg03806693	chr22:41940476	POLR3H	-0.86	-12.16	-0.55	2.1e-28	Vitiligo;
LUSC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.69	12.57	0.57	6.08e-30	Prudent dietary pattern;
LUSC	cis	rs6545883	0.540	rs11687956	chr2:61851342	T/C	cg15711740	chr2:61764176	XPO1	0.36	5.69	0.3	2.74e-8	Tuberculosis;
LUSC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg01416388	chr22:39784598	NA	-0.44	-7.34	-0.37	1.65e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs11630290	0.589	rs1396711	chr15:64168368	G/A	cg12036633	chr15:63758958	NA	0.48	6.03	0.31	4.41e-9	Iris characteristics;
LUSC	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg06917634	chr15:78832804	PSMA4	-0.52	-6.71	-0.34	8.12e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7267979	0.668	rs4815398	chr20:25237338	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.63	-11.17	-0.52	8.01e-25	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg02753203	chr1:228287806	NA	1.0	19.97	0.74	6.03e-59	Diastolic blood pressure;
LUSC	cis	rs9902453	0.868	rs12944395	chr17:28323499	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-10.29	-0.49	9.22e-22	Coffee consumption (cups per day);
LUSC	cis	rs13385	0.769	rs6878006	chr5:139595751	T/C	cg26211634	chr5:139558579	C5orf32	0.45	6.73	0.35	7.44e-11	Atrial fibrillation;
LUSC	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.29	0.53	3.03e-25	Eye color traits;
LUSC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg10596483	chr8:143751796	JRK	0.56	7.97	0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs12210905	0.925	rs11961181	chr6:26994163	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.95	-0.31	6.94e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09015484	chr9:96929106	NA	0.45	7.06	0.36	9.53e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2742417	0.967	rs6800556	chr3:45752229	G/T	cg09608765	chr3:45636137	LIMD1	-0.38	-7.53	-0.38	4.87e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg04989706	chr14:50066350	PPIL5	-0.43	-5.68	-0.3	2.87e-8	Carotid intima media thickness;
LUSC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg26380479	chr7:97908229	NA	-0.28	-6.26	-0.32	1.19e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg19812747	chr11:111475976	SIK2	-0.48	-6.92	-0.35	2.33e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.27e-28	Corneal astigmatism;
LUSC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.25	0.32	1.25e-9	Platelet count;
LUSC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg23281280	chr6:28129359	ZNF389	0.45	5.86	0.31	1.14e-8	Parkinson's disease;
LUSC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg04369109	chr6:150039330	LATS1	-0.58	-8.45	-0.42	9.34e-16	Lung cancer;
LUSC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	5.75	0.3	1.98e-8	Personality dimensions;
LUSC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg06238570	chr21:40685208	BRWD1	0.49	7.63	0.39	2.56e-13	Cognitive function;
LUSC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg18512352	chr11:47633146	NA	-0.46	-9.21	-0.45	3.73e-18	Subjective well-being;
LUSC	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.78	11.26	0.52	3.88e-25	Corneal astigmatism;
LUSC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.05	21.0	0.75	5.11e-63	Cognitive function;
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg06675538	chr2:114033490	PAX8;LOC440839	-0.31	-5.65	-0.3	3.46e-8	Lymphocyte counts;
LUSC	cis	rs11166629	1.000	rs966659	chr8:135639045	C/T	cg21672855	chr8:135614777	ZFAT	-0.37	-5.98	-0.31	5.65e-9	Smoking quantity;
LUSC	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg03983476	chr2:10830698	NOL10	-0.37	-5.66	-0.3	3.31e-8	Prostate cancer;
LUSC	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg24375607	chr4:120327624	NA	0.49	7.34	0.37	1.65e-12	Diastolic blood pressure;
LUSC	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.02	-0.31	4.56e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg03605463	chr16:89740564	NA	0.6	9.48	0.46	4.9e-19	Vitiligo;
LUSC	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg17168535	chr8:21777572	XPO7	-0.66	-10.23	-0.49	1.56e-21	Mean corpuscular volume;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg26396475	chr15:41186434	VPS18	-0.48	-6.13	-0.32	2.49e-9	Neuroticism;
LUSC	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg16342193	chr10:102329863	NA	-0.34	-6.03	-0.31	4.35e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg25036284	chr2:26402008	FAM59B	-0.69	-9.6	-0.46	1.99e-19	Gut microbiome composition (summer);
LUSC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg00431813	chr7:1051703	C7orf50	-0.46	-7.55	-0.38	4.26e-13	Longevity;Endometriosis;
LUSC	trans	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg27600084	chr12:12264075	NA	0.45	6.64	0.34	1.26e-10	Breast size;
LUSC	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg14092571	chr14:90743983	NA	-0.36	-5.92	-0.31	8.1e-9	Mortality in heart failure;
LUSC	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg18099408	chr3:52552593	STAB1	0.35	5.9	0.31	8.87e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg16327482	chr19:10226339	EIF3G	-0.39	-7.32	-0.37	1.82e-12	Narcolepsy;
LUSC	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg26618903	chr10:100175079	PYROXD2	-0.45	-8.49	-0.42	7.03e-16	Metabolite levels;
LUSC	trans	rs2587949	0.615	rs2587950	chr3:4225251	A/G	cg15139668	chr4:4577005	NA	-0.42	-6.18	-0.32	1.91e-9	Periodontitis (DPAL);
LUSC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	8.71	0.43	1.41e-16	Mean platelet volume;
LUSC	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg09835421	chr16:68378352	PRMT7	-0.54	-6.22	-0.32	1.5e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg05043794	chr9:111880884	C9orf5	-0.35	-7.46	-0.38	7.48e-13	Menarche (age at onset);
LUSC	cis	rs3099143	1.000	rs3110378	chr15:77127983	G/A	cg21673338	chr15:77095150	SCAPER	-0.81	-7.62	-0.38	2.59e-13	Recalcitrant atopic dermatitis;
LUSC	trans	rs12458462	0.859	rs34242155	chr18:77425192	G/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.49	-6.92	-0.35	2.29e-11	Monocyte count;
LUSC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg04450456	chr4:17643702	FAM184B	0.43	7.21	0.37	3.8e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg04166393	chr7:2884313	GNA12	0.41	5.68	0.3	2.93e-8	Height;
LUSC	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg03733263	chr8:22462867	KIAA1967	0.76	12.36	0.56	3.61e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg00898013	chr13:113819073	PROZ	-0.64	-9.1	-0.45	8.6e-18	Platelet distribution width;
LUSC	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg13010199	chr12:38710504	ALG10B	0.42	6.1	0.32	2.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	0.57	8.74	0.43	1.12e-16	Breast cancer;
LUSC	trans	rs1864585	0.520	rs12155811	chr8:10673513	C/T	cg26278703	chr11:58910052	FAM111A	0.54	6.01	0.31	4.92e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUSC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg01097406	chr16:89675127	NA	-0.33	-6.45	-0.33	3.94e-10	Vitiligo;
LUSC	cis	rs12928939	0.774	rs7205340	chr16:71645670	A/T	cg03805757	chr16:71968109	PKD1L3	0.39	5.73	0.3	2.2e-8	Post bronchodilator FEV1;
LUSC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg03233332	chr7:66118400	NA	0.41	6.05	0.31	3.95e-9	Aortic root size;
LUSC	cis	rs12545109	0.643	rs1119707	chr8:57411548	T/C	cg09654669	chr8:57350985	NA	-0.52	-6.66	-0.34	1.11e-10	Obesity-related traits;
LUSC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg13206674	chr6:150067644	NUP43	0.59	9.28	0.45	2.26e-18	Lung cancer;
LUSC	trans	rs4839604	0.568	rs62279673	chr3:142947027	A/C	cg27067618	chr19:15751949	CYP4F3	0.36	6.0	0.31	5.19e-9	N-glycan levels;
LUSC	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg18721089	chr20:30220636	NA	-0.39	-6.12	-0.32	2.66e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg11657440	chr19:46296263	DMWD	0.87	16.47	0.67	4.98e-45	Coronary artery disease;
LUSC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg06784218	chr1:46089804	CCDC17	-0.47	-8.88	-0.44	4.2e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg24375607	chr4:120327624	NA	-0.67	-10.87	-0.51	9.07e-24	Corneal astigmatism;
LUSC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg00049323	chr5:472564	LOC25845	0.49	7.77	0.39	1.01e-13	Cystic fibrosis severity;
LUSC	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2932538	0.922	rs6673930	chr1:113104887	A/G	cg22162597	chr1:113214053	CAPZA1	0.7	10.0	0.48	9.16e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs2979489	0.945	rs11993146	chr8:30319537	G/A	cg26383811	chr8:30366931	RBPMS	-0.49	-7.8	-0.39	7.78e-14	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg24642844	chr7:1081250	C7orf50	-0.46	-7.34	-0.37	1.64e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.32	-0.56	5.23e-29	Rheumatoid arthritis;
LUSC	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.17	-0.41	6.28e-15	Response to antipsychotic treatment;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17832277	chr13:103249000	TPP2	0.47	6.68	0.34	9.77e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.54	7.94	0.4	3.03e-14	Gut microbiome composition (summer);
LUSC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.5	7.97	0.4	2.57e-14	Uric acid clearance;
LUSC	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg24558204	chr6:135376177	HBS1L	0.68	10.64	0.5	6.01e-23	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs2227930	0.506	rs13087972	chr3:142047637	G/T	cg16271453	chr3:142027066	XRN1	-0.55	-9.96	-0.48	1.27e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs2200578	1.000	rs7566277	chr2:99916242	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	6.31	0.33	9.03e-10	IgG glycosylation;
LUSC	cis	rs12681287	0.517	rs68008113	chr8:87520894	C/A	cg00550725	chr8:87521180	FAM82B	0.44	5.75	0.3	1.99e-8	Caudate activity during reward;
LUSC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	0.63	11.01	0.52	2.81e-24	Blood metabolite levels;
LUSC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	1.0	13.8	0.6	1.32e-34	Vitiligo;
LUSC	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg23029597	chr12:123009494	RSRC2	-0.73	-9.05	-0.44	1.21e-17	Body mass index;
LUSC	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.74	-13.97	-0.61	3.16e-35	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg21770322	chr7:97807741	LMTK2	0.41	7.27	0.37	2.51e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3087591	0.920	rs7225014	chr17:29572973	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.55	-7.91	-0.4	3.72e-14	Hip circumference;
LUSC	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg13575925	chr12:9217583	LOC144571	0.35	6.43	0.33	4.51e-10	Sjögren's syndrome;
LUSC	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg24006582	chr15:45444508	DUOX1	0.67	9.61	0.47	1.77e-19	Uric acid levels;
LUSC	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg24692254	chr21:30365293	RNF160	0.68	10.46	0.5	2.49e-22	Pancreatic cancer;
LUSC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg23281280	chr6:28129359	ZNF389	0.44	5.82	0.3	1.36e-8	Parkinson's disease;
LUSC	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.74	-0.6	2.34e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.51	-6.93	-0.35	2.14e-11	Tuberculosis;
LUSC	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg13010199	chr12:38710504	ALG10B	0.65	10.04	0.48	6.91e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg06740227	chr12:86229804	RASSF9	0.39	6.23	0.32	1.44e-9	Major depressive disorder;
LUSC	cis	rs6977660	0.714	rs6976972	chr7:19818315	C/A	cg07541023	chr7:19748670	TWISTNB	0.6	6.51	0.34	2.7e-10	Thyroid stimulating hormone;
LUSC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg06618935	chr21:46677482	NA	-0.39	-8.03	-0.4	1.63e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07677032	chr17:61819896	STRADA	0.55	9.09	0.45	9.21e-18	Prudent dietary pattern;
LUSC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg06600287	chr1:53387719	ECHDC2	0.31	6.18	0.32	1.85e-9	Monocyte count;
LUSC	cis	rs16912285	0.591	rs12794505	chr11:24364195	A/G	ch.11.24196551F	chr11:24239977	NA	-0.8	-8.86	-0.44	4.72e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg21132104	chr15:45694354	SPATA5L1	-0.4	-6.0	-0.31	5.21e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-16.89	-0.68	1.03e-46	Gut microbiome composition (summer);
LUSC	cis	rs7189233	0.955	rs7189726	chr16:53497774	C/T	cg09728985	chr16:53543985	NA	-0.34	-6.13	-0.32	2.5e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg02972257	chr16:68554789	NA	0.46	6.02	0.31	4.5e-9	Colorectal cancer;
LUSC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg02931644	chr1:25747376	RHCE	0.34	6.11	0.32	2.77e-9	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.86	14.36	0.62	9.18e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg21782813	chr7:2030301	MAD1L1	0.49	8.28	0.41	2.94e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg19729930	chr2:74357872	NA	0.94	18.09	0.7	1.76e-51	Gestational age at birth (maternal effect);
LUSC	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg27219399	chr15:67835830	MAP2K5	0.37	5.93	0.31	7.37e-9	Obesity;
LUSC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.93	-0.4	3.36e-14	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.46	-6.4	-0.33	5.11e-10	Corneal astigmatism;
LUSC	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg13010199	chr12:38710504	ALG10B	0.67	10.34	0.49	6.17e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg08470875	chr2:26401718	FAM59B	-0.66	-8.86	-0.44	4.75e-17	Gut microbiome composition (summer);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15604682	chr7:102105781	ALKBH4;LRWD1	-0.35	-5.98	-0.31	5.74e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs4363385	0.510	rs6689066	chr1:153045154	T/C	cg25856811	chr1:152973957	SPRR3	-0.37	-6.11	-0.32	2.78e-9	Inflammatory skin disease;
LUSC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-9.76	-0.47	5.78e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.57	-0.42	3.86e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.06	0.44	1.09e-17	Motion sickness;
LUSC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-8.29	-0.41	2.82e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg27426351	chr10:43362370	NA	0.43	5.76	0.3	1.94e-8	Blood protein levels;
LUSC	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg17127132	chr2:85788382	GGCX	-0.47	-7.5	-0.38	5.68e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs926392	0.533	rs6129162	chr20:37683195	G/A	cg16355469	chr20:37678765	NA	0.53	7.04	0.36	1.08e-11	Dialysis-related mortality;
LUSC	cis	rs754466	0.874	rs55910200	chr10:79665173	T/C	cg17075019	chr10:79541650	NA	-0.64	-8.35	-0.42	1.84e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg15017067	chr4:17643749	FAM184B	0.35	5.7	0.3	2.58e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2742234	0.955	rs1272142	chr10:43695484	G/T	cg02780029	chr10:43622663	RET	-0.34	-6.44	-0.33	4.07e-10	Hirschsprung disease;
LUSC	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.37	6.52	0.34	2.57e-10	Depressive symptoms;
LUSC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-1.04	-20.24	-0.74	5.37e-60	Height;
LUSC	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-10.62	-0.5	6.96e-23	Body mass index;
LUSC	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	13.78	0.6	1.66e-34	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs35264875	0.808	rs921675	chr11:68869034	A/G	cg02660097	chr11:68866761	NA	-0.37	-5.94	-0.31	7.11e-9	Blond vs. brown hair color;
LUSC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.41	0.53	1.14e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9677476	0.863	rs2006780	chr2:232066704	T/G	cg07929768	chr2:232055508	NA	0.36	6.92	0.35	2.36e-11	Food antigen IgG levels;
LUSC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.46	-0.38	7.54e-13	Height;
LUSC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg08847533	chr14:75593920	NEK9	-0.79	-13.38	-0.59	5.35e-33	Height;
LUSC	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.54	-0.6	1.34e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg18512352	chr11:47633146	NA	-0.46	-9.27	-0.45	2.36e-18	Subjective well-being;
LUSC	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	1.13	17.36	0.69	1.42e-48	Corneal structure;
LUSC	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg12573674	chr2:1569213	NA	-0.54	-5.98	-0.31	5.59e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs977987	0.778	rs35214308	chr16:75476088	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.16	-0.36	5.2e-12	Dupuytren's disease;
LUSC	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-7.88	-0.4	4.69e-14	Parkinson's disease;
LUSC	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg02004499	chr7:4244250	SDK1	-0.48	-7.75	-0.39	1.12e-13	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LUSC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg26752657	chr1:75199075	CRYZ;TYW3	0.4	6.14	0.32	2.41e-9	Resistin levels;
LUSC	cis	rs7923609	0.776	rs10761785	chr10:65318766	G/T	cg01631684	chr10:65280961	REEP3	-0.4	-5.88	-0.31	9.82e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9311676	0.656	rs11917567	chr3:58382254	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.45	0.33	4.01e-10	Systemic lupus erythematosus;
LUSC	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg08601574	chr20:25228251	PYGB	0.44	6.76	0.35	6.18e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6942756	0.806	rs2718093	chr7:128939582	G/A	cg02491457	chr7:128862824	NA	-0.48	-7.33	-0.37	1.69e-12	White matter hyperintensity burden;
LUSC	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	0.78	11.55	0.53	3.48e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs7091068	0.671	rs517785	chr10:95403973	G/A	cg20715218	chr10:95462985	C10orf4	-0.59	-6.78	-0.35	5.32e-11	Urinary tract infection frequency;
LUSC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg11812906	chr14:75593930	NEK9	-0.65	-11.1	-0.52	1.41e-24	Height;
LUSC	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg05347473	chr6:146136440	FBXO30	0.54	9.24	0.45	3.03e-18	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03130627	chr6:159240554	EZR	-0.44	-6.65	-0.34	1.17e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7113850	0.541	rs78363992	chr11:24232126	C/T	ch.11.24196551F	chr11:24239977	NA	1.0	9.14	0.45	6e-18	Bone fracture in osteoporosis;
LUSC	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg14227996	chr4:17616232	MED28	0.79	8.14	0.41	7.78e-15	Opioid sensitivity;
LUSC	cis	rs2274273	0.624	rs1972221	chr14:55785381	C/A	cg04306507	chr14:55594613	LGALS3	0.48	9.7	0.47	9.23e-20	Protein biomarker;
LUSC	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.3	-0.33	9.46e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg13939156	chr17:80058883	NA	-0.34	-6.64	-0.34	1.28e-10	Life satisfaction;
LUSC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-7.07	-0.36	9.25e-12	Lung cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18147735	chr4:39460314	LIAS;RPL9	0.45	6.83	0.35	4.08e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	1.09	26.46	0.82	5.76e-84	Testicular germ cell tumor;
LUSC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs9910292	0.591	rs6505325	chr17:31354124	C/T	cg03789507	chr8:136667083	NA	0.48	6.13	0.32	2.44e-9	Mosquito bite size;
LUSC	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg24375607	chr4:120327624	NA	0.79	12.03	0.55	6.08e-28	Corneal astigmatism;
LUSC	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.06	0.36	9.49e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg05926928	chr17:57297772	GDPD1	1.49	19.18	0.72	8.55e-56	Opioid sensitivity;
LUSC	cis	rs9815354	0.812	rs17284313	chr3:41986787	G/T	cg03022575	chr3:42003672	ULK4	-0.83	-8.85	-0.44	5.12e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg08601574	chr20:25228251	PYGB	0.42	6.29	0.33	9.95e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.43	5.7	0.3	2.68e-8	Cognitive ability;
LUSC	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg03209541	chr12:89919758	WDR51B;GALNT4	0.4	5.97	0.31	6.09e-9	Bladder cancer;
LUSC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg15448220	chr1:150897856	SETDB1	0.41	5.96	0.31	6.27e-9	Melanoma;
LUSC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	0.92	15.35	0.64	1.35e-40	Breast cancer;
LUSC	cis	rs4704187	0.617	rs7356697	chr5:74354542	A/G	cg03227963	chr5:74354835	NA	0.32	6.94	0.36	2.03e-11	Response to amphetamines;
LUSC	cis	rs9650315	0.810	rs34747243	chr8:57202187	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.31	0.37	1.93e-12	Height;
LUSC	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg04036182	chr15:45458818	NA	0.34	5.74	0.3	2.13e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg06212747	chr3:49208901	KLHDC8B	0.48	6.13	0.32	2.54e-9	Parkinson's disease;
LUSC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg16386425	chr10:429943	DIP2C	-0.37	-5.76	-0.3	1.87e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg11344533	chr11:111475393	SIK2	-0.49	-6.79	-0.35	5.28e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6088813	0.961	rs745931	chr20:33956004	A/T	cg14752227	chr20:34000481	UQCC	-0.36	-5.66	-0.3	3.25e-8	Height;
LUSC	cis	rs7605827	0.930	rs2380653	chr2:15635011	C/A	cg19274914	chr2:15703543	NA	0.46	8.77	0.43	9.47e-17	Educational attainment (years of education);
LUSC	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg18721089	chr20:30220636	NA	-0.34	-5.82	-0.3	1.35e-8	Subcortical brain region volumes;Putamen volume;
LUSC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.94	15.1	0.64	1.29e-39	Coronary artery disease;
LUSC	cis	rs2573652	0.698	rs12916269	chr15:100530216	A/T	cg00587665	chr15:100533223	ADAMTS17	0.45	8.14	0.41	7.89e-15	Height;
LUSC	cis	rs7809950	1.000	rs4727684	chr7:107226470	C/T	cg23024343	chr7:107201750	COG5	-0.56	-8.81	-0.43	7.11e-17	Coronary artery disease;
LUSC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg27165867	chr14:105738592	BRF1	-0.51	-7.45	-0.38	8.03e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg02807482	chr3:125708958	NA	-0.54	-6.74	-0.35	6.88e-11	Blood pressure (smoking interaction);
LUSC	trans	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg05926928	chr17:57297772	GDPD1	0.6	9.25	0.45	2.77e-18	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUSC	cis	rs2073300	1.000	rs6137975	chr20:23461778	A/G	cg09953122	chr20:23471693	CST8	0.72	6.96	0.36	1.86e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.81	13.98	0.61	2.69e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs4285028	0.747	rs4048703	chr3:121374361	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-12.8	-0.57	8.41e-31	Multiple sclerosis;
LUSC	cis	rs7119	0.717	rs12901471	chr15:77818992	A/G	cg27398640	chr15:77910606	LINGO1	-0.31	-6.48	-0.33	3.24e-10	Type 2 diabetes;
LUSC	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg25457927	chr22:38595422	NA	0.48	10.26	0.49	1.18e-21	Cutaneous nevi;
LUSC	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg17462356	chr17:80056334	FASN	0.43	5.9	0.31	8.77e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg11473876	chr11:109292803	C11orf87	0.41	6.73	0.35	7.35e-11	Schizophrenia;
LUSC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.99	-17.7	-0.7	6.18e-50	Coronary artery disease;
LUSC	cis	rs9549260	0.755	rs3900833	chr13:41188292	A/G	cg21288729	chr13:41239152	FOXO1	0.6	9.05	0.44	1.17e-17	Red blood cell count;
LUSC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg18240062	chr17:79603768	NPLOC4	-0.59	-10.11	-0.48	3.92e-21	Eye color traits;
LUSC	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg07578070	chr6:150326732	RAET1K	0.41	6.37	0.33	6.21e-10	Alopecia areata;
LUSC	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg17252645	chr8:143867129	LY6D	-0.36	-6.31	-0.33	9.04e-10	Urinary tract infection frequency;
LUSC	cis	rs662064	0.962	rs596537	chr1:10554709	G/T	cg20482658	chr1:10539492	PEX14	-0.32	-6.66	-0.34	1.14e-10	Asthma;
LUSC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.57	-7.99	-0.4	2.23e-14	Alzheimer's disease;
LUSC	cis	rs41271951	0.512	rs114222784	chr1:151084781	C/T	cg11822372	chr1:151115635	SEMA6C	-0.76	-6.95	-0.36	1.98e-11	Blood protein levels;
LUSC	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	7.62	0.39	2.57e-13	Response to antipsychotic treatment;
LUSC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.02	0.55	6.46e-28	Prudent dietary pattern;
LUSC	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg02023728	chr11:77925099	USP35	0.43	6.59	0.34	1.68e-10	Testicular germ cell tumor;
LUSC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.21	0.59	2.51e-32	Cognitive test performance;
LUSC	cis	rs1461503	0.966	rs1461502	chr11:122844927	C/G	cg27398637	chr11:122830231	C11orf63	-0.41	-6.54	-0.34	2.29e-10	Menarche (age at onset);
LUSC	cis	rs11642862	0.892	rs11646082	chr16:30911950	T/G	cg02466173	chr16:30829666	NA	-0.62	-5.92	-0.31	8.19e-9	Tonsillectomy;
LUSC	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.77	-13.6	-0.6	7.94e-34	Brugada syndrome;
LUSC	cis	rs60154123	0.772	rs701942	chr1:210429392	C/G	cg22029157	chr1:209979665	IRF6	0.58	5.93	0.31	7.41e-9	Coronary artery disease;
LUSC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.75	-10.55	-0.5	1.18e-22	Gut microbiome composition (summer);
LUSC	cis	rs4363385	0.588	rs6661059	chr1:153027257	A/T	cg25856811	chr1:152973957	SPRR3	-0.36	-5.97	-0.31	5.93e-9	Inflammatory skin disease;
LUSC	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg02023728	chr11:77925099	USP35	0.52	6.99	0.36	1.54e-11	Testicular germ cell tumor;
LUSC	cis	rs68170813	0.559	rs76534758	chr7:106963262	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.69	-0.47	9.77e-20	Coronary artery disease;
LUSC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg16606324	chr3:10149918	C3orf24	0.44	7.01	0.36	1.36e-11	Alzheimer's disease;
LUSC	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg17420585	chr12:42539391	GXYLT1	-0.39	-7.85	-0.39	5.79e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg27411982	chr8:10470053	RP1L1	0.42	6.14	0.32	2.28e-9	Neuroticism;
LUSC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg09359103	chr1:154839909	KCNN3	-0.71	-16.34	-0.67	1.59e-44	Prostate cancer;
LUSC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.57	-8.86	-0.44	4.71e-17	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19052272	chr2:3704530	ALLC	-0.65	-11.19	-0.52	6.48e-25	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.72	13.42	0.59	3.71e-33	Height;
LUSC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg22875332	chr1:76189707	ACADM	-0.68	-9.23	-0.45	3.21e-18	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs16937	0.618	rs6659069	chr1:205182031	A/G	cg00857998	chr1:205179979	DSTYK	0.4	5.73	0.3	2.29e-8	Schizophrenia;
LUSC	trans	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg15556689	chr8:8085844	FLJ10661	0.5	7.26	0.37	2.7e-12	Schizophrenia;
LUSC	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg22681709	chr2:178499509	PDE11A	-0.49	-8.86	-0.44	4.87e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg08807101	chr21:30365312	RNF160	-0.5	-7.27	-0.37	2.62e-12	Pancreatic cancer;
LUSC	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	5.94	0.31	7.31e-9	Schizophrenia;
LUSC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg01579765	chr21:45077557	HSF2BP	-0.47	-9.77	-0.47	5.43e-20	Mean corpuscular volume;
LUSC	cis	rs7945718	0.875	rs6486057	chr11:12810338	T/A	cg25843174	chr11:12811716	TEAD1	0.32	7.31	0.37	1.98e-12	Educational attainment (years of education);
LUSC	cis	rs385076	0.502	rs13013695	chr2:32391231	G/A	cg02381751	chr2:32503542	YIPF4	-0.54	-7.22	-0.37	3.64e-12	Interleukin-18 levels;
LUSC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg14019146	chr3:50243930	SLC38A3	0.35	7.9	0.4	3.98e-14	Body mass index;
LUSC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg07703079	chr11:430292	ANO9	0.6	6.52	0.34	2.66e-10	Body mass index;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg11338389	chr11:63742044	COX8A	0.39	6.28	0.32	1.05e-9	Triglycerides;
LUSC	cis	rs3815700	1.000	rs8108840	chr19:33094452	A/C	cg02997394	chr19:33096574	ANKRD27	0.82	9.97	0.48	1.14e-20	Eosinophilic esophagitis;
LUSC	cis	rs6429082	0.689	rs10802803	chr1:235709610	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.45	-5.99	-0.31	5.54e-9	Adiposity;
LUSC	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.82	0.7	2.19e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9359856	0.510	rs4053618	chr6:90459454	G/A	cg13799429	chr6:90582589	CASP8AP2	0.91	10.68	0.5	4.36e-23	Bipolar disorder;
LUSC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg02782426	chr3:40428986	ENTPD3	0.41	7.32	0.37	1.82e-12	Renal cell carcinoma;
LUSC	trans	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg26647312	chr5:1645268	NA	0.61	5.97	0.31	6.06e-9	Initial pursuit acceleration;
LUSC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	13.05	0.58	9.94e-32	Platelet count;
LUSC	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg13699009	chr12:122356056	WDR66	0.49	7.38	0.37	1.23e-12	Mean corpuscular volume;
LUSC	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg02423579	chr7:2872169	GNA12	-0.37	-5.73	-0.3	2.24e-8	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00723019	chr19:48867290	TMEM143;SYNGR4	-0.43	-6.49	-0.33	3.08e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7131987	0.934	rs7316004	chr12:29411698	C/T	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.25	-0.32	1.28e-9	QT interval;
LUSC	cis	rs4889855	0.578	rs7216808	chr17:78484187	A/G	cg16591659	chr17:78472290	NA	-0.48	-7.83	-0.39	6.57e-14	Fractional excretion of uric acid;
LUSC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg07741184	chr6:167504864	NA	-0.36	-6.49	-0.33	3.11e-10	Crohn's disease;
LUSC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg20203395	chr5:56204925	C5orf35	-0.78	-10.35	-0.49	5.89e-22	Initial pursuit acceleration;
LUSC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg09904177	chr6:26538194	HMGN4	-0.5	-5.82	-0.3	1.38e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9398803	0.865	rs9375446	chr6:126835015	G/A	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	1.97e-9	Male-pattern baldness;
LUSC	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-5.79	-0.3	1.66e-8	Lung cancer;
LUSC	cis	rs2625529	0.652	rs2957724	chr15:72248474	A/C	cg16672083	chr15:72433130	SENP8	0.48	8.09	0.4	1.08e-14	Red blood cell count;
LUSC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08280861	chr8:58055591	NA	0.57	7.2	0.37	3.94e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.94	0.44	2.75e-17	Prudent dietary pattern;
LUSC	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg17385448	chr1:15911702	AGMAT	0.38	6.54	0.34	2.26e-10	Systolic blood pressure;
LUSC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg17948913	chr5:572064	NA	0.37	5.8	0.3	1.51e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg12564285	chr5:131593104	PDLIM4	0.36	6.78	0.35	5.43e-11	Blood metabolite levels;
LUSC	trans	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	11.97	0.55	1.05e-27	Exhaled nitric oxide output;
LUSC	cis	rs9837602	1.000	rs9833888	chr3:99723580	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.88	-0.31	1.02e-8	Breast cancer;
LUSC	cis	rs1832871	0.672	rs1342211	chr6:158759496	G/T	cg07165851	chr6:158734300	TULP4	0.46	6.97	0.36	1.66e-11	Height;
LUSC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.39	0.33	5.59e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg24881330	chr22:46731750	TRMU	0.92	10.35	0.49	5.7e-22	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.49	-6.34	-0.33	7.46e-10	Renal function-related traits (BUN);
LUSC	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg15997130	chr1:24165203	NA	0.37	5.7	0.3	2.58e-8	Immature fraction of reticulocytes;
LUSC	trans	rs12677056	0.651	rs7011864	chr8:113286963	T/A	cg12159992	chr12:102059490	MYBPC1	0.37	6.17	0.32	1.93e-9	Peripheral artery disease;
LUSC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg18758796	chr5:131593413	PDLIM4	-0.34	-5.87	-0.31	1.06e-8	Blood metabolite levels;
LUSC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18932078	chr1:2524107	MMEL1	0.31	6.93	0.35	2.21e-11	Ulcerative colitis;
LUSC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg08917208	chr2:24149416	ATAD2B	-0.52	-5.89	-0.31	9.48e-9	Lymphocyte counts;
LUSC	cis	rs1595825	0.735	rs16827267	chr2:198924967	G/A	cg00982548	chr2:198649783	BOLL	-0.55	-6.68	-0.34	1.03e-10	Ulcerative colitis;
LUSC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs8017423	0.935	rs59444150	chr14:90767175	T/C	cg04374321	chr14:90722782	PSMC1	0.68	10.58	0.5	9.21e-23	Mortality in heart failure;
LUSC	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	7.15	0.36	5.44e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05450995	chr12:122460105	BCL7A	0.47	6.39	0.33	5.65e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg24006582	chr15:45444508	DUOX1	-0.6	-8.82	-0.43	6.55e-17	Uric acid levels;
LUSC	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg15309053	chr8:964076	NA	0.36	7.22	0.37	3.64e-12	Schizophrenia;
LUSC	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg23625390	chr15:77176239	SCAPER	-0.62	-9.21	-0.45	3.72e-18	Blood metabolite levels;
LUSC	cis	rs4631830	0.900	rs11006274	chr10:51540291	C/T	cg16070123	chr10:51489643	NA	0.47	7.48	0.38	6.56e-13	Prostate-specific antigen levels;
LUSC	cis	rs9359856	0.564	rs56084221	chr6:90365349	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.88	-8.96	-0.44	2.37e-17	Bipolar disorder;
LUSC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg04117972	chr1:227635322	NA	0.79	7.9	0.4	3.94e-14	Major depressive disorder;
LUSC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg04450456	chr4:17643702	FAM184B	0.43	7.21	0.37	3.8e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg21770322	chr7:97807741	LMTK2	0.4	7.07	0.36	9.2e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs8073060	0.859	rs17550268	chr17:33874678	T/C	cg19694781	chr19:47549865	TMEM160	0.84	12.49	0.56	1.22e-29	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs6012953	0.845	rs718053	chr20:49196602	G/A	cg13958625	chr20:49123093	NA	-0.27	-6.09	-0.32	3.19e-9	Vitiligo;
LUSC	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg18132916	chr6:79620363	NA	-0.38	-5.81	-0.3	1.44e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	16.92	0.68	7.94e-47	Exhaled nitric oxide output;
LUSC	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	6.22	0.32	1.5e-9	Recombination rate (females);
LUSC	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg25173405	chr17:45401733	C17orf57	-0.4	-6.3	-0.33	9.36e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.64	0.57	3.36e-30	Motion sickness;
LUSC	cis	rs3087591	0.919	rs11080148	chr17:29609922	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.63	-9.03	-0.44	1.43e-17	Hip circumference;
LUSC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg19592336	chr6:28129416	ZNF389	0.47	6.19	0.32	1.75e-9	Depression;
LUSC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg27170947	chr2:26402098	FAM59B	0.64	9.15	0.45	5.72e-18	Gut microbiome composition (summer);
LUSC	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg00852783	chr1:26633632	UBXN11	0.59	9.45	0.46	6.26e-19	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-10.45	-0.5	2.7e-22	Menarche (age at onset);
LUSC	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg21293242	chr8:11204541	TDH	0.32	5.97	0.31	6.04e-9	Retinal vascular caliber;
LUSC	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.55	8.55	0.42	4.55e-16	Response to antipsychotic treatment;
LUSC	cis	rs2124969	0.506	rs10497209	chr2:160985586	A/C	cg03641300	chr2:160917029	PLA2R1	-0.47	-5.66	-0.3	3.21e-8	Waist circumference adjusted for body mass index;
LUSC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Depression;
LUSC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-9.0	-0.44	1.71e-17	Schizophrenia;
LUSC	cis	rs735860	0.712	rs6909592	chr6:53163090	C/G	cg10236188	chr6:53219634	NA	0.38	5.95	0.31	6.95e-9	Glaucoma;
LUSC	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg26893861	chr17:41843967	DUSP3	1.09	23.27	0.79	7.1e-72	Triglycerides;
LUSC	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg11632617	chr15:75315747	PPCDC	-0.5	-6.45	-0.33	4.03e-10	Blood trace element (Zn levels);
LUSC	cis	rs7605827	0.729	rs35131126	chr2:15537730	A/G	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg16230307	chr14:35515116	FAM177A1	0.81	10.38	0.49	4.58e-22	Psoriasis;
LUSC	cis	rs4964805	0.581	rs7312825	chr12:104188388	G/C	cg02344784	chr12:104178138	NT5DC3	0.46	8.86	0.44	4.8e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg24675056	chr1:15929824	NA	0.47	8.07	0.4	1.32e-14	Systolic blood pressure;
LUSC	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg22705602	chr4:152727874	NA	-0.34	-6.86	-0.35	3.29e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs8016982	0.662	rs7148100	chr14:81678096	A/G	cg01989461	chr14:81687754	GTF2A1	0.52	6.85	0.35	3.49e-11	Schizophrenia;
LUSC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.74	12.51	0.56	1.02e-29	Menarche (age at onset);
LUSC	cis	rs983392	0.792	rs1303621	chr11:59890674	A/G	cg24026212	chr11:59952134	MS4A6A	-0.31	-5.79	-0.3	1.61e-8	Alzheimer's disease (late onset);
LUSC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.25	0.45	2.66e-18	Prudent dietary pattern;
LUSC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg21573476	chr21:45109991	RRP1B	-0.42	-6.56	-0.34	2.09e-10	Mean corpuscular volume;
LUSC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.8	-0.47	4.39e-20	Platelet count;
LUSC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg14440974	chr22:39074834	NA	-0.35	-5.86	-0.31	1.11e-8	Menopause (age at onset);
LUSC	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg15934090	chr1:100435551	SLC35A3	0.48	8.3	0.41	2.61e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	0.93	17.54	0.69	2.66e-49	Heart rate;
LUSC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg27541892	chr1:1571801	CDK11B	-0.51	-8.19	-0.41	5.45e-15	Body mass index;
LUSC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg12463550	chr7:65579703	CRCP	0.52	7.54	0.38	4.45e-13	Aortic root size;
LUSC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg02423579	chr7:2872169	GNA12	-0.44	-6.37	-0.33	6.2e-10	Height;
LUSC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.64	-0.39	2.27e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg09509183	chr1:209979624	IRF6	0.37	5.69	0.3	2.84e-8	Monobrow;
LUSC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.6	-0.38	3.09e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4561483	0.583	rs11075032	chr16:12004450	C/T	cg08843971	chr16:11963173	GSPT1	0.42	6.35	0.33	7e-10	Testicular germ cell tumor;
LUSC	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00338735	chr4:53728038	RASL11B	0.48	5.67	0.3	3.03e-8	Optic nerve measurement (cup area);
LUSC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg27170947	chr2:26402098	FAM59B	0.72	10.77	0.51	2.12e-23	Gut microbiome composition (summer);
LUSC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.54	-0.42	4.74e-16	Personality dimensions;
LUSC	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg26384229	chr12:38710491	ALG10B	0.59	9.42	0.46	7.54e-19	Morning vs. evening chronotype;
LUSC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg21770322	chr7:97807741	LMTK2	0.42	7.29	0.37	2.27e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2548003	0.565	rs2554894	chr5:28762951	A/G	cg22863700	chr5:28928346	NA	0.45	6.38	0.33	6.04e-10	Hip geometry;
LUSC	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg02527881	chr3:46936655	PTH1R	0.39	6.73	0.35	7.27e-11	Colorectal cancer;
LUSC	cis	rs6500395	0.962	rs9937568	chr16:48612361	C/T	cg04672837	chr16:48644449	N4BP1	-0.5	-7.4	-0.38	1.13e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg02574844	chr11:5959923	NA	-0.43	-6.14	-0.32	2.37e-9	DNA methylation (variation);
LUSC	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg24675056	chr1:15929824	NA	0.46	7.91	0.4	3.85e-14	Systolic blood pressure;
LUSC	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg23711669	chr6:146136114	FBXO30	0.73	12.89	0.58	3.92e-31	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22433398	chr13:27825486	RPL21;RPL21P28	0.43	6.64	0.34	1.25e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09067793	chr2:73461223	CCT7;C2orf7	-0.48	-7.06	-0.36	9.53e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg05805236	chr11:65401703	PCNXL3	-0.64	-10.53	-0.5	1.41e-22	Acne (severe);
LUSC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg01416388	chr22:39784598	NA	-0.44	-7.32	-0.37	1.83e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	ch.21.33444458F	chr21:34522588	NA	0.38	6.5	0.34	2.96e-10	Triglycerides;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01355476	chr16:85722306	GINS2	0.75	5.95	0.31	6.89e-9	Cognitive performance;
LUSC	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg02176678	chr2:219576539	TTLL4	0.59	10.58	0.5	9.38e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg13206674	chr6:150067644	NUP43	0.59	9.28	0.45	2.26e-18	Lung cancer;
LUSC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.63	9.75	0.47	6.15e-20	Urinary electrolytes (magnesium/calcium ratio);
LUSC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.03	21.08	0.76	2.6e-63	Cognitive function;
LUSC	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.78	-0.3	1.74e-8	Retinal vascular caliber;
LUSC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg00106254	chr7:1943704	MAD1L1	-0.41	-5.89	-0.31	9.36e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg17294928	chr15:75287854	SCAMP5	-0.75	-8.75	-0.43	1.07e-16	Blood trace element (Zn levels);
LUSC	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	7.34	0.37	1.62e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.82	15.09	0.64	1.34e-39	Blood protein levels;
LUSC	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.27	-0.32	1.1e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs56399783	0.901	rs73051415	chr7:2850643	C/T	cg14895029	chr7:2775587	GNA12	0.51	6.35	0.33	6.94e-10	Childhood ear infection;
LUSC	cis	rs10203711	1.000	rs1810140	chr2:239568163	T/C	cg14580085	chr2:239553406	NA	0.42	7.1	0.36	7.48e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg13206674	chr6:150067644	NUP43	0.44	6.64	0.34	1.3100000000000001e-10	Lung cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07843956	chr16:692375	FAM195A	0.8	6.31	0.33	8.91e-10	Cognitive performance;
LUSC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg06145435	chr7:1022769	CYP2W1	-0.29	-6.01	-0.31	4.97e-9	Longevity;Endometriosis;
LUSC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg17470723	chr8:74884337	TCEB1	0.52	8.16	0.41	6.79e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg22777020	chr22:31556080	RNF185	-0.51	-6.81	-0.35	4.49e-11	Paclitaxel-induced neuropathy;
LUSC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg13939156	chr17:80058883	NA	-0.34	-6.75	-0.35	6.59e-11	Life satisfaction;
LUSC	cis	rs12410462	0.581	rs12402691	chr1:227543693	G/A	cg04117972	chr1:227635322	NA	0.61	6.74	0.35	7.09e-11	Major depressive disorder;
LUSC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	9.88	0.48	2.25e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg03676636	chr4:99064102	C4orf37	0.34	7.33	0.37	1.7e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17253792	0.915	rs76957332	chr14:56195370	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.79	-0.35	5.15e-11	Putamen volume;
LUSC	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg12311346	chr5:56204834	C5orf35	-0.62	-9.46	-0.46	5.79e-19	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg20476274	chr7:133979776	SLC35B4	0.82	14.95	0.63	4.92e-39	Mean platelet volume;
LUSC	cis	rs56283067	0.887	rs12197593	chr6:44740895	C/T	cg20913747	chr6:44695427	NA	-0.48	-8.07	-0.4	1.32e-14	Total body bone mineral density;
LUSC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	7.33	0.37	1.75e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs2983496	1.000	rs2983534	chr6:166015625	G/A	cg20192747	chr18:44774846	NA	-0.49	-6.39	-0.33	5.64e-10	Cortisol levels (saliva);
LUSC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.47	0.42	7.99e-16	Prudent dietary pattern;
LUSC	trans	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs939658	1.000	rs8033963	chr15:79455350	C/T	cg17916960	chr15:79447300	NA	0.47	9.51	0.46	3.94e-19	Refractive error;
LUSC	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.51e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg24069376	chr3:38537580	EXOG	0.35	6.22	0.32	1.47e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	0.92	15.33	0.64	1.58e-40	Breast cancer;
LUSC	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.5	0.46	4.34e-19	Bipolar disorder;
LUSC	cis	rs10761482	0.861	rs10761488	chr10:62105992	C/T	cg18175470	chr10:62150864	ANK3	-0.47	-6.78	-0.35	5.36e-11	Schizophrenia;
LUSC	cis	rs7512552	0.839	rs696616	chr1:150336173	G/A	cg15654264	chr1:150340011	RPRD2	0.67	11.18	0.52	7.2e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9937943	0.720	rs112685216	chr16:74609517	G/A	cg01733217	chr16:74700730	RFWD3	0.61	6.62	0.34	1.39e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6740322	0.748	rs13402621	chr2:43458611	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-6.97	-0.36	1.67e-11	Coronary artery disease;
LUSC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg24209194	chr3:40518798	ZNF619	0.47	6.37	0.33	6.32e-10	Renal cell carcinoma;
LUSC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06634786	chr22:41940651	POLR3H	0.53	6.19	0.32	1.81e-9	Vitiligo;
LUSC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.27	-0.32	1.12e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.59	6.52	0.34	2.63e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.62	10.3	0.49	8.92e-22	Lymphocyte counts;
LUSC	cis	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg21775007	chr8:11205619	TDH	0.4	5.91	0.31	8.48e-9	Neuroticism;
LUSC	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg12856521	chr11:46389249	DGKZ	-0.41	-6.4	-0.33	5.11e-10	Leprosy;
LUSC	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg08085267	chr17:45401833	C17orf57	-0.49	-7.45	-0.38	8.02e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-7.22	-0.37	3.6e-12	Homocysteine levels;
LUSC	cis	rs35883536	0.609	rs1855631	chr1:101040010	C/T	cg06223162	chr1:101003688	GPR88	-0.47	-8.89	-0.44	3.92e-17	Monocyte count;
LUSC	cis	rs2235544	0.579	rs1537322	chr1:54482306	G/T	cg25741118	chr1:54482237	LDLRAD1	-0.33	-7.61	-0.38	2.91e-13	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-6.29	-0.33	9.7e-10	Eosinophil percentage of white cells;
LUSC	cis	rs10193935	0.901	rs72800020	chr2:42655615	A/G	cg27598129	chr2:42591480	NA	-0.67	-8.74	-0.43	1.12e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg15448220	chr1:150897856	SETDB1	0.42	5.99	0.31	5.28e-9	Melanoma;
LUSC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg10253484	chr15:75165896	SCAMP2	-0.45	-6.43	-0.33	4.29e-10	Breast cancer;
LUSC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg05347473	chr6:146136440	FBXO30	-0.51	-8.74	-0.43	1.19e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg07395648	chr5:131743802	NA	0.47	7.49	0.38	6.24e-13	Breast cancer;Mosquito bite size;
LUSC	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg05805236	chr11:65401703	PCNXL3	0.49	7.96	0.4	2.65e-14	Acne (severe);
LUSC	cis	rs7191700	0.511	rs243330	chr16:11350991	C/T	cg00044050	chr16:11439710	C16orf75	0.67	11.51	0.53	4.67e-26	Multiple sclerosis;
LUSC	cis	rs2806561	0.704	rs6426779	chr1:23310485	T/C	cg19743168	chr1:23544995	NA	-0.38	-7.74	-0.39	1.21e-13	Height;
LUSC	cis	rs9837602	1.000	rs13323143	chr3:99811553	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.07	-0.32	3.4e-9	Breast cancer;
LUSC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg02187348	chr16:89574699	SPG7	0.47	7.13	0.36	6.16e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg07777115	chr5:623756	CEP72	-0.45	-5.7	-0.3	2.62e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs62400317	0.793	rs12210230	chr6:45344854	T/A	cg20913747	chr6:44695427	NA	-0.48	-7.81	-0.39	7.39e-14	Total body bone mineral density;
LUSC	cis	rs13315871	1.000	rs13315871	chr3:58381287	G/A	cg12435725	chr3:58293450	RPP14	-0.73	-7.27	-0.37	2.64e-12	Cholesterol, total;
LUSC	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg06917634	chr15:78832804	PSMA4	-0.48	-5.94	-0.31	7.15e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg13256891	chr4:100009986	ADH5	0.5	6.87	0.35	3.08e-11	Smoking initiation;
LUSC	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	0.62	9.91	0.48	1.81e-20	Breast cancer;
LUSC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg18099408	chr3:52552593	STAB1	-0.35	-5.88	-0.31	9.83e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-9.26	-0.45	2.46e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07677032	chr17:61819896	STRADA	0.53	8.86	0.44	4.89e-17	Prudent dietary pattern;
LUSC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg13395646	chr4:1353034	KIAA1530	0.56	8.12	0.41	9.3e-15	Longevity;
LUSC	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg03433033	chr1:76189801	ACADM	-0.42	-6.19	-0.32	1.81e-9	Daytime sleep phenotypes;
LUSC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.66	0.39	2.05e-13	Prudent dietary pattern;
LUSC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg09365446	chr1:150670422	GOLPH3L	0.47	7.01	0.36	1.33e-11	Tonsillectomy;
LUSC	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg24069376	chr3:38537580	EXOG	-0.41	-8.11	-0.41	1e-14	Electrocardiographic conduction measures;
LUSC	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.73	12.97	0.58	1.99e-31	White blood cell count (basophil);
LUSC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg09044154	chr16:88155775	NA	-0.55	-7.27	-0.37	2.59e-12	Menopause (age at onset);
LUSC	cis	rs1953600	0.805	rs2819947	chr10:81947757	T/C	cg00277334	chr10:82204260	NA	0.45	7.12	0.36	6.72e-12	Sarcoidosis;
LUSC	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg04586622	chr2:25135609	ADCY3	0.39	8.21	0.41	4.94e-15	Body mass index;
LUSC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.44	0.53	8.42e-26	Menopause (age at onset);
LUSC	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg23601095	chr6:26197514	HIST1H3D	0.75	7.59	0.38	3.21e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs9341808	0.628	rs9294172	chr6:80918561	G/A	cg08355045	chr6:80787529	NA	0.49	8.32	0.41	2.25e-15	Sitting height ratio;
LUSC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg03233332	chr7:66118400	NA	0.42	6.09	0.32	3.02e-9	Aortic root size;
LUSC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.77	-0.35	5.69e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06022373	chr22:39101656	GTPBP1	0.7	11.3	0.53	2.81e-25	Menopause (age at onset);
LUSC	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg11530693	chr1:120165357	ZNF697	-0.63	-9.75	-0.47	6.12e-20	Systemic lupus erythematosus;
LUSC	cis	rs7523050	0.643	rs17621922	chr1:109404454	C/T	cg08274380	chr1:109419600	GPSM2	1.0	10.54	0.5	1.3e-22	Fat distribution (HIV);
LUSC	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.4	-6.41	-0.33	4.92e-10	Systemic lupus erythematosus;
LUSC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-7.35	-0.37	1.51e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg13393036	chr8:95962371	TP53INP1	-0.47	-9.69	-0.47	9.74e-20	Type 2 diabetes;
LUSC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg04414720	chr1:150670196	GOLPH3L	0.55	9.04	0.44	1.28e-17	Tonsillectomy;
LUSC	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg04374321	chr14:90722782	PSMC1	0.46	6.57	0.34	1.97e-10	Mortality in heart failure;
LUSC	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg10547527	chr2:198650123	BOLL	-0.5	-5.91	-0.31	8.37e-9	Ulcerative colitis;
LUSC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-14.42	-0.62	5.61e-37	Dental caries;
LUSC	cis	rs9341808	0.667	rs2490244	chr6:80891112	A/T	cg08355045	chr6:80787529	NA	0.47	8.02	0.4	1.86e-14	Sitting height ratio;
LUSC	cis	rs2629540	0.847	rs10901811	chr10:126417914	G/A	cg08799069	chr10:126477246	METTL10	0.64	9.04	0.44	1.32e-17	Cocaine dependence;
LUSC	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg19156104	chr2:198669113	PLCL1	-0.46	-5.71	-0.3	2.44e-8	Ulcerative colitis;
LUSC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-0.81	-10.9	-0.51	7.43e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg23093090	chr10:104574429	C10orf26	-0.44	-7.85	-0.39	5.76e-14	Arsenic metabolism;
LUSC	cis	rs17433780	0.964	rs12121223	chr1:89481583	C/T	cg09516651	chr1:89888402	LOC400759	0.54	8.98	0.44	1.96e-17	Carotid intima media thickness;
LUSC	trans	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg10756647	chr7:56101905	PSPH	0.85	8.47	0.42	7.94e-16	Gout;
LUSC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08470875	chr2:26401718	FAM59B	-0.72	-9.9	-0.48	1.91e-20	Gut microbiome composition (summer);
LUSC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg01516881	chr6:292596	DUSP22	-0.52	-7.68	-0.39	1.79e-13	Menopause (age at onset);
LUSC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg16624210	chr5:671434	TPPP	0.5	6.54	0.34	2.35e-10	Obesity-related traits;
LUSC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.47	-6.27	-0.32	1.1e-9	Longevity;Endometriosis;
LUSC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.61e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg27165867	chr14:105738592	BRF1	-0.51	-7.44	-0.38	8.77e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10203711	0.966	rs10184252	chr2:239598164	A/G	cg14580085	chr2:239553406	NA	0.43	7.17	0.37	4.81e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1459104	0.704	rs12806568	chr11:54892378	G/A	cg03929089	chr4:120376271	NA	0.74	6.38	0.33	5.96e-10	Body mass index;
LUSC	trans	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.4	0.49	3.83e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs1941687	0.831	rs62091190	chr18:31387700	C/T	cg27147174	chr7:100797783	AP1S1	-0.46	-6.88	-0.35	2.97e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs13315871	0.790	rs28502788	chr3:58296208	A/T	cg12435725	chr3:58293450	RPP14	-0.69	-7.16	-0.36	5.24e-12	Cholesterol, total;
LUSC	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg03859395	chr2:55845619	SMEK2	0.86	15.72	0.65	4.52e-42	Metabolic syndrome;
LUSC	cis	rs4343996	0.676	rs4358698	chr7:3378616	A/T	cg21248987	chr7:3385318	SDK1	-0.37	-6.22	-0.32	1.49e-9	Motion sickness;
LUSC	cis	rs4720118	0.875	rs9784973	chr7:33389689	A/G	cg22798885	chr7:33102694	NT5C3	0.45	6.2	0.32	1.64e-9	Leprosy;
LUSC	cis	rs1957429	0.901	rs8008745	chr14:65351593	C/G	cg23373153	chr14:65346875	NA	1.03	12.37	0.56	3.41e-29	Pediatric areal bone mineral density (radius);
LUSC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg03233332	chr7:66118400	NA	-0.4	-5.81	-0.3	1.47e-8	Aortic root size;
LUSC	cis	rs739496	0.542	rs7399113	chr12:111792848	G/A	cg10833066	chr12:111807467	FAM109A	0.61	11.97	0.55	1.05e-27	Platelet count;
LUSC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg06238570	chr21:40685208	BRWD1	0.45	6.94	0.36	2.04e-11	Cognitive function;
LUSC	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg13334819	chr7:99746414	C7orf59	-0.5	-6.73	-0.35	7.41e-11	Coronary artery disease;
LUSC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-10.09	-0.48	4.6e-21	Monocyte percentage of white cells;
LUSC	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg00484396	chr16:3507460	NAT15	0.49	7.27	0.37	2.55e-12	Body mass index (adult);
LUSC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	16.76	0.68	3.58e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9463078	0.753	rs10948186	chr6:44903248	C/T	cg25276700	chr6:44698697	NA	-0.3	-5.94	-0.31	7.12e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg17376030	chr22:41985996	PMM1	-0.46	-5.7	-0.3	2.67e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	6.7	0.34	8.86e-11	Iron status biomarkers;
LUSC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg20135002	chr11:47629003	NA	-0.51	-7.72	-0.39	1.37e-13	Subjective well-being;
LUSC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg16743903	chr16:89593216	SPG7	-0.38	-5.98	-0.31	5.71e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg01966878	chr4:90757139	SNCA	-0.43	-6.0	-0.31	5.14e-9	Neuroticism;
LUSC	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.33	-21.45	-0.76	8.9e-65	Type 1 diabetes nephropathy;
LUSC	cis	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg21775007	chr8:11205619	TDH	-0.43	-5.79	-0.3	1.65e-8	Neuroticism;
LUSC	cis	rs7527798	0.592	rs11118345	chr1:207854827	A/T	cg09232269	chr1:207846808	CR1L	-0.3	-6.24	-0.32	1.3e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.84	-0.3	1.22e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg17127132	chr2:85788382	GGCX	0.46	7.55	0.38	4.3e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22228677	chr17:17495359	PEMT	-0.43	-6.43	-0.33	4.52e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg16393715	chr7:1948819	MAD1L1	0.33	5.9	0.31	8.87e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs73206853	0.841	rs74728497	chr12:111020179	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	6.54	0.34	2.3e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg17385448	chr1:15911702	AGMAT	0.38	5.73	0.3	2.22e-8	Systolic blood pressure;
LUSC	cis	rs6494488	0.500	rs72744749	chr15:65062819	G/C	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	cis	rs9361491	0.508	rs9343786	chr6:79414728	A/C	cg23262351	chr6:79576851	IRAK1BP1	0.38	5.67	0.3	3.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg04369109	chr6:150039330	LATS1	-0.58	-8.44	-0.42	9.96e-16	Lung cancer;
LUSC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	7.16	0.36	5.32e-12	Platelet count;
LUSC	cis	rs735860	0.712	rs9395855	chr6:53176765	G/T	cg10236188	chr6:53219634	NA	-0.4	-6.41	-0.33	4.94e-10	Glaucoma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03635536	chr5:96271340	LNPEP	-0.48	-6.18	-0.32	1.87e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.65	-10.16	-0.49	2.59e-21	Menarche (age at onset);
LUSC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	10.41	0.5	3.53e-22	Eosinophil percentage of white cells;
LUSC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	9.54	0.46	3.05e-19	Mean platelet volume;
LUSC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-10.47	-0.5	2.22e-22	Gut microbiome composition (summer);
LUSC	cis	rs2580764	0.598	rs7340476	chr2:55227346	G/C	cg09592903	chr2:55203963	RTN4	-0.49	-10.11	-0.48	4e-21	Mean platelet volume;
LUSC	cis	rs7605827	0.930	rs4668900	chr2:15511740	T/C	cg19274914	chr2:15703543	NA	0.46	8.95	0.44	2.45e-17	Educational attainment (years of education);
LUSC	cis	rs1997103	0.954	rs9649854	chr7:55410213	G/A	cg17469321	chr7:55412551	NA	0.64	10.38	0.49	4.6e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs76878669	0.561	rs7940980	chr11:66172910	C/T	cg18002602	chr11:66138449	SLC29A2	-0.49	-8.53	-0.42	5e-16	Educational attainment (years of education);
LUSC	cis	rs2625529	0.617	rs6494973	chr15:72145728	A/T	cg16672083	chr15:72433130	SENP8	0.49	7.91	0.4	3.79e-14	Red blood cell count;
LUSC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.34	-0.42	1.93e-15	Height;
LUSC	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg16586182	chr3:47516702	SCAP	-0.52	-8.13	-0.41	8.41e-15	Colorectal cancer;
LUSC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg23791538	chr6:167370224	RNASET2	0.41	6.73	0.35	7.6e-11	Crohn's disease;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg17567317	chr22:38349719	POLR2F;C22orf23	0.48	6.42	0.33	4.81e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6840360	1.000	rs9998462	chr4:152646548	T/A	cg22705602	chr4:152727874	NA	-0.28	-6.09	-0.32	3.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg12826209	chr6:26865740	GUSBL1	0.68	5.9	0.31	8.88e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.24	14.24	0.61	2.72e-36	Diabetic kidney disease;
LUSC	cis	rs9463078	0.605	rs9472411	chr6:44943183	T/C	cg25276700	chr6:44698697	NA	0.29	6.01	0.31	4.8e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	14.3	0.62	1.64e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.71	8.87	0.44	4.36e-17	Type 2 diabetes;
LUSC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg16339924	chr4:17578868	LAP3	0.59	9.12	0.45	7.3e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg02980000	chr4:1222292	CTBP1	-0.59	-7.42	-0.38	9.88e-13	Systolic blood pressure;
LUSC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg02951883	chr7:2050386	MAD1L1	-0.46	-7.89	-0.4	4.32e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg17127132	chr2:85788382	GGCX	0.49	7.89	0.4	4.47e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg10909506	chr17:38081995	ORMDL3	0.34	6.15	0.32	2.26e-9	Self-reported allergy;
LUSC	cis	rs9302690	0.557	rs223869	chr16:57494992	C/A	cg16753122	chr16:57506917	DOK4	0.58	7.21	0.37	3.87e-12	Blood protein levels;
LUSC	cis	rs2840044	1.000	rs225277	chr17:33973311	G/A	cg05299278	chr17:33885742	SLFN14	0.29	5.92	0.31	7.9e-9	Response to radiotherapy in cancer (late toxicity);
LUSC	trans	rs17158675	1.000	rs73380837	chr7:83783721	C/T	cg08326515	chr4:111564605	NA	0.82	6.06	0.31	3.76e-9	Obesity-related traits;
LUSC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	1.06	20.29	0.74	3.2e-60	Menopause (age at onset);
LUSC	cis	rs243505	0.691	rs243483	chr7:148449163	A/G	cg09806900	chr7:148480153	CUL1	-0.54	-7.21	-0.37	3.75e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg09796270	chr17:17721594	SREBF1	-0.43	-7.61	-0.38	2.91e-13	Total body bone mineral density;
LUSC	cis	rs62027291	0.654	rs11634136	chr15:77063039	A/G	cg26408565	chr15:76604113	ETFA	0.78	7.02	0.36	1.25e-11	Plateletcrit;
LUSC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg11812906	chr14:75593930	NEK9	0.66	11.23	0.52	4.9e-25	Height;
LUSC	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg15704280	chr7:45808275	SEPT13	-0.6	-7.36	-0.37	1.42e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg12963246	chr6:28129442	ZNF389	-0.5	-6.91	-0.35	2.4e-11	Depression;
LUSC	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg27411982	chr8:10470053	RP1L1	-0.38	-5.73	-0.3	2.29e-8	Triglycerides;
LUSC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.4	-0.38	1.12e-12	Blood metabolite levels;
LUSC	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.51	-8.92	-0.44	3.03e-17	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-0.85	-13.08	-0.58	7.57e-32	Blood protein levels;
LUSC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	6.83e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg20935933	chr6:143382018	AIG1	0.52	7.33	0.37	1.8e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs16976116	0.851	rs11855907	chr15:55494634	A/C	cg11288833	chr15:55489084	RSL24D1	0.49	5.8	0.3	1.53e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg17469321	chr7:55412551	NA	0.64	10.19	0.49	2.02e-21	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2200578	1.000	rs116648076	chr2:99882347	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.53	6.22	0.32	1.53e-9	IgG glycosylation;
LUSC	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg16230307	chr14:35515116	FAM177A1	0.81	10.13	0.48	3.28e-21	Psoriasis;
LUSC	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.82	14.03	0.61	1.8e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.26	-14.54	-0.62	1.94e-37	Gout;
LUSC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.7	0.39	1.54e-13	Vitiligo;
LUSC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg06808227	chr14:105710500	BRF1	-0.66	-10.28	-0.49	1.03e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24110177	chr3:50126178	RBM5	-0.67	-11.48	-0.53	5.97e-26	Body mass index;
LUSC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.78	11.32	0.53	2.25e-25	Corneal astigmatism;
LUSC	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg22532475	chr10:104410764	TRIM8	0.25	5.82	0.3	1.38e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03264133	chr6:25882463	NA	-0.5	-9.11	-0.45	7.57e-18	Blood metabolite levels;
LUSC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18876405	chr7:65276391	NA	0.53	8.35	0.42	1.81e-15	Aortic root size;
LUSC	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg11584989	chr19:19387371	SF4	0.6	7.33	0.37	1.78e-12	Bipolar disorder;
LUSC	cis	rs9420	0.884	rs644883	chr11:57663522	C/G	cg23127183	chr11:57508653	C11orf31	0.51	7.23	0.37	3.27e-12	Schizophrenia;
LUSC	cis	rs11264799	0.520	rs2777965	chr1:157550417	A/C	cg18268488	chr1:157545234	FCRL4	0.39	7.63	0.39	2.42e-13	IgA nephropathy;
LUSC	cis	rs472402	0.580	rs3822430	chr5:6651970	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.45	-6.54	-0.34	2.24e-10	Response to amphetamines;
LUSC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg16447950	chr5:562315	NA	-0.56	-7.67	-0.39	1.86e-13	Ulcerative colitis;
LUSC	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs7809950	0.954	rs2520247	chr7:107143946	A/T	cg23024343	chr7:107201750	COG5	-0.55	-8.81	-0.43	6.77e-17	Coronary artery disease;
LUSC	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg24642439	chr20:33292090	TP53INP2	-0.5	-7.59	-0.38	3.27e-13	Glomerular filtration rate (creatinine);
LUSC	trans	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg24644049	chr4:85504048	CDS1	0.88	7.56	0.38	3.94e-13	Skin colour saturation;
LUSC	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg05738196	chr6:26577821	NA	0.74	12.18	0.55	1.72e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.71	-0.43	1.47e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.47	6.67	0.34	1.09e-10	Lung function (FEV1/FVC);
LUSC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg03233332	chr7:66118400	NA	-0.42	-6.09	-0.32	3.02e-9	Aortic root size;
LUSC	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg21064579	chr19:49206444	FUT2	0.44	8.41	0.42	1.22e-15	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
LUSC	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg00376283	chr12:123451042	ABCB9	0.73	9.45	0.46	5.92e-19	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.63	-9.56	-0.46	2.63e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11264799	0.520	rs849814	chr1:157542216	G/A	cg18268488	chr1:157545234	FCRL4	0.38	7.36	0.37	1.4e-12	IgA nephropathy;
LUSC	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg17470723	chr8:74884337	TCEB1	0.53	8.28	0.41	3.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.52	6.98	0.36	1.63e-11	Gut microbiome composition (summer);
LUSC	cis	rs9462027	0.628	rs1125341	chr6:34786305	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.74	-0.3	2.13e-8	Systemic lupus erythematosus;
LUSC	cis	rs6690583	0.512	rs7547224	chr1:85456902	T/C	cg11262906	chr1:85462892	MCOLN2	0.7	6.47	0.33	3.56e-10	Serum sulfate level;
LUSC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg16414030	chr3:133502952	NA	0.41	6.4	0.33	5.14e-10	Iron status biomarkers;
LUSC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.49	-7.53	-0.38	4.74e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg15744005	chr10:104629667	AS3MT	-0.27	-5.72	-0.3	2.34e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs5758659	0.652	rs133335	chr22:42416056	C/T	cg04733989	chr22:42467013	NAGA	-0.45	-7.2	-0.37	4.03e-12	Cognitive function;
LUSC	trans	rs890100	0.673	rs35017848	chr2:56664100	A/T	cg01657744	chr10:88471748	LDB3	0.43	5.96	0.31	6.28e-9	Gut microbiome composition (summer);
LUSC	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg20503657	chr10:835505	NA	0.45	6.28	0.32	1.07e-9	Response to angiotensin II receptor blocker therapy;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg24868830	chr4:140374821	RAB33B	0.39	6.36	0.33	6.71e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.0	-0.48	9.03e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.97	-0.4	2.53e-14	Mood instability;
LUSC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg06454157	chr6:167490870	NA	-0.25	-6.02	-0.31	4.6e-9	Crohn's disease;
LUSC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.45	-7.12	-0.36	6.52e-12	Alzheimer's disease (late onset);
LUSC	trans	rs3857536	0.813	rs7743965	chr6:66941346	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs7833986	0.501	rs17812659	chr8:56889862	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	10.23	0.49	1.54e-21	Height;
LUSC	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg22139774	chr2:100720529	AFF3	-0.46	-7.82	-0.39	7.1e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	10.81	0.51	1.54e-23	Eye color traits;
LUSC	cis	rs11958404	0.932	rs72816556	chr5:157424412	C/G	cg05962755	chr5:157440814	NA	0.49	6.04	0.31	4.04e-9	IgG glycosylation;
LUSC	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	0.98	20.64	0.75	1.33e-61	Platelet distribution width;
LUSC	cis	rs12155623	0.803	rs6987879	chr8:49808062	T/C	cg22283653	chr8:49824208	NA	-0.37	-7.16	-0.36	5.09e-12	Sudden cardiac arrest;
LUSC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg23711669	chr6:146136114	FBXO30	0.73	11.36	0.53	1.63e-25	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg03929089	chr4:120376271	NA	0.59	6.53	0.34	2.38e-10	Axial length;
LUSC	cis	rs72634258	0.945	rs36016881	chr1:8051241	A/G	cg00042356	chr1:8021962	PARK7	0.77	9.81	0.47	3.97e-20	Inflammatory bowel disease;
LUSC	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.13	0.7	1.27e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.07	-0.36	9.22e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.77	11.74	0.54	7.18e-27	Itch intensity from mosquito bite;
LUSC	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.27	-17.78	-0.7	3.03e-50	Hip circumference adjusted for BMI;
LUSC	cis	rs68092024	0.731	rs793479	chr3:99488232	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	6.34	0.33	7.66e-10	Cleft lip with or without cleft palate;
LUSC	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	19.83	0.74	2.22e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg17211192	chr8:82754475	SNX16	-0.64	-9.11	-0.45	7.56e-18	Diastolic blood pressure;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24028381	chr8:145133668	EXOSC4	-0.54	-7.34	-0.37	1.65e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06636551	chr8:101224915	SPAG1	-0.45	-8.26	-0.41	3.54e-15	Atrioventricular conduction;
LUSC	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.69	10.5	0.5	1.74e-22	Corneal astigmatism;
LUSC	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg17168535	chr8:21777572	XPO7	0.67	10.29	0.49	9.63e-22	Mean corpuscular volume;
LUSC	trans	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg25214090	chr10:38739885	LOC399744	0.43	6.56	0.34	2.08e-10	Corneal astigmatism;
LUSC	cis	rs17490626	0.568	rs12413523	chr10:71211664	C/G	cg14388049	chr10:71211838	TSPAN15	-0.32	-5.81	-0.3	1.47e-8	Thrombosis;
LUSC	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg01528321	chr10:82214614	TSPAN14	0.86	13.08	0.58	7.25e-32	Post bronchodilator FEV1;
LUSC	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg19792802	chr11:65647270	CTSW	0.39	5.86	0.31	1.08e-8	Crohn's disease;
LUSC	cis	rs12472274	0.646	rs2305171	chr2:239097140	G/A	cg17459225	chr2:239074497	NA	0.58	7.89	0.4	4.27e-14	Phospholipid levels (plasma);
LUSC	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg04989706	chr14:50066350	PPIL5	-0.44	-5.77	-0.3	1.79e-8	Carotid intima media thickness;
LUSC	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs6977660	0.943	rs9638765	chr7:19840616	G/A	cg05791153	chr7:19748676	TWISTNB	0.56	6.24	0.32	1.34e-9	Thyroid stimulating hormone;
LUSC	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg02466173	chr16:30829666	NA	-0.57	-10.48	-0.5	2.02e-22	Multiple myeloma;
LUSC	cis	rs11158026	0.859	rs8019824	chr14:55365331	T/A	cg04306507	chr14:55594613	LGALS3	0.31	5.84	0.3	1.24e-8	Parkinson's disease;
LUSC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg14581129	chr12:53358946	NA	-0.69	-9.31	-0.45	1.75e-18	Cancer (pleiotropy);
LUSC	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg17366294	chr4:99064904	C4orf37	0.5	8.65	0.43	2.22e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.87	14.76	0.63	2.57e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2235649	0.663	rs6600167	chr16:1848912	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-5.96	-0.31	6.24e-9	Blood metabolite levels;
LUSC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-6.47	-0.33	3.44e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg12463550	chr7:65579703	CRCP	-0.49	-7.38	-0.37	1.29e-12	Aortic root size;
LUSC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	11.8	0.54	4.37e-27	Colorectal cancer;
LUSC	cis	rs3755132	0.929	rs6431717	chr2:15740570	C/T	cg12888861	chr2:15731646	DDX1	0.5	7.34	0.37	1.68e-12	Wilms tumor;
LUSC	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04607442	chr13:21872219	NA	-0.49	-6.28	-0.32	1.05e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg22920501	chr2:26401640	FAM59B	0.83	11.99	0.55	8.76e-28	Gut microbiome composition (summer);
LUSC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg11663144	chr21:46675770	NA	-0.41	-7.03	-0.36	1.15e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg02023728	chr11:77925099	USP35	0.54	7.23	0.37	3.24e-12	Testicular germ cell tumor;
LUSC	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg26384229	chr12:38710491	ALG10B	0.51	7.15	0.36	5.66e-12	Morning vs. evening chronotype;
LUSC	trans	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.76	-0.35	6.17e-11	Endometrial cancer;
LUSC	trans	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg19584341	chr11:506908	RNH1	0.47	6.45	0.33	4.03e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg26513180	chr16:89883248	FANCA	0.64	10.21	0.49	1.71e-21	Vitiligo;
LUSC	trans	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.59	-0.34	1.71e-10	Endometrial cancer;
LUSC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.63	-8.22	-0.41	4.61e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg02569458	chr12:86230093	RASSF9	0.53	8.65	0.43	2.17e-16	Major depressive disorder;
LUSC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.16	-0.41	6.68e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg00310523	chr12:86230176	RASSF9	0.4	7.31	0.37	1.94e-12	Major depressive disorder;
LUSC	cis	rs12618769	0.652	rs13402379	chr2:99209314	G/A	cg10123293	chr2:99228465	UNC50	0.42	6.57	0.34	1.95e-10	Bipolar disorder;
LUSC	cis	rs9815354	0.812	rs57809229	chr3:41840162	G/A	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7072216	0.763	rs942804	chr10:100168499	C/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.25e-17	Metabolite levels;
LUSC	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg17168535	chr8:21777572	XPO7	0.85	15.71	0.65	4.94e-42	Mean corpuscular volume;
LUSC	trans	rs4650994	0.524	rs2811299	chr1:178586377	A/G	cg05059571	chr16:84539110	KIAA1609	0.46	8.65	0.43	2.16e-16	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.59	7.39	0.37	1.18e-12	Schizophrenia;
LUSC	cis	rs240764	0.555	rs6919283	chr6:101235769	C/T	cg09795085	chr6:101329169	ASCC3	0.44	6.27	0.32	1.13e-9	Neuroticism;
LUSC	cis	rs10865541	0.902	rs13399186	chr2:3423201	G/T	cg15807143	chr2:3452624	TTC15	0.32	5.69	0.3	2.72e-8	Obesity-related traits;
LUSC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg11859384	chr17:80120422	CCDC57	0.36	5.69	0.3	2.71e-8	Life satisfaction;
LUSC	cis	rs73198271	0.515	rs17629935	chr8:8619381	A/T	cg01851573	chr8:8652454	MFHAS1	0.65	7.86	0.4	5.38e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2692947	0.673	rs584811	chr2:97069879	A/G	cg23100626	chr2:96804247	ASTL	-0.25	-6.08	-0.32	3.24e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs11214589	0.651	rs11214594	chr11:113259332	G/A	cg14159747	chr11:113255604	NA	0.29	7.69	0.39	1.69e-13	Neuroticism;
LUSC	trans	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg18187862	chr3:45730750	SACM1L	0.54	6.82	0.35	4.3e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11676855	1.000	rs729866	chr2:235899359	G/A	cg14917874	chr2:235941519	SH3BP4	0.49	8.07	0.4	1.24e-14	Dialysis-related mortality;
LUSC	cis	rs593982	0.925	rs3953806	chr11:65505153	C/T	cg08755490	chr11:65554678	OVOL1	-1.46	-15.35	-0.64	1.35e-40	Atopic dermatitis;
LUSC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg09877947	chr5:131593287	PDLIM4	0.4	6.26	0.32	1.2e-9	Breast cancer;Mosquito bite size;
LUSC	trans	rs62458065	0.640	rs10271491	chr7:32530665	C/A	cg00845942	chr12:64062724	DPY19L2	-0.59	-7.16	-0.36	5.04e-12	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg16968115	chr1:27560829	WDTC1	0.43	6.43	0.33	4.43e-10	Triglycerides;
LUSC	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg24397884	chr7:158709396	WDR60	0.61	9.37	0.46	1.11e-18	Height;
LUSC	cis	rs11051970	0.879	rs2728680	chr12:32583512	T/C	cg24626660	chr12:32551988	NA	0.33	5.66	0.3	3.2e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3770081	1.000	rs57398459	chr2:86291326	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.84	-0.35	3.84e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.16	-0.36	5.32e-12	Type 2 diabetes;
LUSC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-9.82	-0.47	3.77e-20	Bipolar disorder;
LUSC	cis	rs7246967	0.611	rs12973264	chr19:22867749	C/T	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg13206674	chr6:150067644	NUP43	0.6	9.54	0.46	3.08e-19	Lung cancer;
LUSC	cis	rs714027	0.605	rs41176	chr22:30432403	G/T	cg11564601	chr22:30592435	NA	-0.35	-6.01	-0.31	4.91e-9	Lymphocyte counts;
LUSC	cis	rs57590327	0.555	rs6795133	chr3:81756267	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-10.51	-0.5	1.66e-22	Extraversion;
LUSC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg14092988	chr3:52407081	DNAH1	0.31	5.96	0.31	6.35e-9	Bipolar disorder;
LUSC	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08564027	chr20:61660810	NA	0.93	17.11	0.68	1.47e-47	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs644799	0.511	rs11021302	chr11:95485768	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	10.21	0.49	1.81e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-10.85	-0.51	1.04e-23	Longevity;
LUSC	cis	rs10392	0.500	rs8118646	chr20:37600887	A/G	cg27552599	chr20:37590471	DHX35	0.46	7.43	0.38	9.03e-13	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.49	6.86	0.35	3.36e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg23601095	chr6:26197514	HIST1H3D	0.7	7.47	0.38	7.17e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg05855489	chr10:104503620	C10orf26	0.63	8.31	0.41	2.49e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg21427119	chr20:30132790	HM13	-0.37	-5.79	-0.3	1.62e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg02423579	chr7:2872169	GNA12	-0.38	-5.67	-0.3	3.12e-8	Height;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03161075	chr14:51298083	NIN	0.45	6.25	0.32	1.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.77	-0.35	5.69e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg04362960	chr10:104952993	NT5C2	0.6	9.11	0.45	7.51e-18	Arsenic metabolism;
LUSC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	0.92	13.9	0.61	5.47e-35	Breast cancer;
LUSC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg08677398	chr8:58056175	NA	0.43	5.99	0.31	5.47e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6750047	0.932	rs11124631	chr2:38274908	A/G	cg07380506	chr2:38303506	CYP1B1	-0.45	-6.47	-0.33	3.42e-10	Cutaneous malignant melanoma;Melanoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02038173	chr21:34852701	TMEM50B	0.5	7.35	0.37	1.49e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg09165964	chr15:75287851	SCAMP5	0.54	7.98	0.4	2.43e-14	Breast cancer;
LUSC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg11843238	chr5:131593191	PDLIM4	0.38	5.67	0.3	3.02e-8	Breast cancer;
LUSC	trans	rs62238980	0.614	rs76463308	chr22:32387270	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5.04e-9	Childhood ear infection;
LUSC	cis	rs9653442	0.545	rs2009095	chr2:100765081	C/T	cg07810366	chr2:100720526	AFF3	-0.43	-7.44	-0.38	8.49e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg16482183	chr6:26056742	HIST1H1C	0.58	8.02	0.4	1.86e-14	Iron status biomarkers;
LUSC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.7	0.3	2.59e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg02466173	chr16:30829666	NA	-0.59	-10.83	-0.51	1.28e-23	Multiple myeloma;
LUSC	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg07945448	chr16:4304224	NA	0.43	6.2	0.32	1.66e-9	Prostate-specific antigen levels;
LUSC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg07936489	chr17:37558343	FBXL20	0.72	9.97	0.48	1.12e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg05347473	chr6:146136440	FBXO30	0.55	9.37	0.46	1.09e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg17333051	chr19:2783644	SGTA	0.51	7.68	0.39	1.75e-13	Total cholesterol levels;
LUSC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg25214090	chr10:38739885	LOC399744	0.57	8.41	0.42	1.17e-15	Corneal astigmatism;
LUSC	cis	rs7582720	0.943	rs72928610	chr2:203838961	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.35	0.42	1.88e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-7.76	-0.39	1.02e-13	Response to antipsychotic treatment;
LUSC	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.67	-0.34	1.07e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg12863693	chr15:85201151	NMB	-0.35	-7.24	-0.37	3.1e-12	Schizophrenia;
LUSC	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.6	0.34	1.6e-10	IgG glycosylation;
LUSC	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.7	10.91	0.51	6.34e-24	Breast cancer;
LUSC	cis	rs963731	0.649	rs6752850	chr2:39220655	C/T	cg04010122	chr2:39346883	SOS1	-0.77	-5.68	-0.3	2.92e-8	Corticobasal degeneration;
LUSC	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg20701182	chr2:24300061	SF3B14	0.77	7.73	0.39	1.25e-13	Lymphocyte counts;
LUSC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.13	15.81	0.65	1.94e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.64	0.57	3.36e-30	Motion sickness;
LUSC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.47	7.81	0.39	7.35e-14	Vitiligo;
LUSC	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-9.83	-0.47	3.47e-20	Platelet distribution width;
LUSC	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-22.94	-0.78	1.3e-70	Exhaled nitric oxide output;
LUSC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg01097406	chr16:89675127	NA	-0.34	-6.73	-0.35	7.18e-11	Vitiligo;
LUSC	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg24690094	chr11:67383802	NA	0.42	8.18	0.41	5.89e-15	Mean corpuscular volume;
LUSC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg06784218	chr1:46089804	CCDC17	0.55	10.98	0.52	3.61e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg06671706	chr8:8559999	CLDN23	0.51	6.96	0.36	1.78e-11	Obesity-related traits;
LUSC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.7	11.93	0.55	1.4e-27	Mood instability;
LUSC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22590775	chr19:49891494	CCDC155	0.56	7.32	0.37	1.92e-12	Multiple sclerosis;
LUSC	cis	rs5756931	0.503	rs2076112	chr22:38538822	A/G	cg25457927	chr22:38595422	NA	-0.35	-6.96	-0.36	1.84e-11	Triglycerides;
LUSC	cis	rs2953174	0.786	rs2953177	chr2:241516616	A/G	cg07929629	chr2:241523174	NA	0.53	7.99	0.4	2.21e-14	Bipolar disorder;
LUSC	cis	rs3820928	1.000	rs12615988	chr2:227769000	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.86	-0.4	5.24e-14	Pulmonary function;
LUSC	cis	rs4654899	1.000	rs72865329	chr1:21517567	G/A	cg01072550	chr1:21505969	NA	-0.56	-8.61	-0.43	2.83e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1595825	0.891	rs58409972	chr2:198897061	A/T	cg00982548	chr2:198649783	BOLL	-0.56	-6.95	-0.36	1.93e-11	Ulcerative colitis;
LUSC	trans	rs62055045	0.528	rs62056191	chr16:71533831	C/T	cg21834679	chr15:96891026	NA	-0.42	-6.58	-0.34	1.85e-10	Schizophrenia;
LUSC	cis	rs4654899	0.865	rs12406144	chr1:21347228	A/C	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.42	-0.33	4.59e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg16482183	chr6:26056742	HIST1H1C	0.63	8.98	0.44	2.04e-17	Iron status biomarkers;
LUSC	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-8.2	-0.41	5.36e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg05343316	chr1:45956843	TESK2	0.68	9.4	0.46	9.28e-19	Platelet count;
LUSC	cis	rs2730260	0.537	rs3793222	chr7:158863536	A/C	cg02254261	chr7:158964346	NA	0.47	5.73	0.3	2.28e-8	Myopia (pathological);
LUSC	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-9.13	-0.45	6.86e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg04111992	chr7:158790115	NA	-0.43	-6.78	-0.35	5.31e-11	Facial morphology (factor 20);
LUSC	cis	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg02775129	chr4:119771670	NA	-0.79	-6.58	-0.34	1.81e-10	Cannabis dependence symptom count;
LUSC	cis	rs11158026	0.567	rs61224609	chr14:55403208	A/G	cg04306507	chr14:55594613	LGALS3	0.35	6.27	0.32	1.13e-9	Parkinson's disease;
LUSC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10802521	chr3:52805072	NEK4	-0.56	-8.78	-0.43	8.37e-17	Bipolar disorder;
LUSC	cis	rs2274273	0.967	rs2340931	chr14:55616937	T/G	cg04306507	chr14:55594613	LGALS3	0.58	13.72	0.6	2.84e-34	Protein biomarker;
LUSC	cis	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg21175976	chr8:11421337	BLK	0.4	6.63	0.34	1.35e-10	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg21724239	chr8:58056113	NA	0.8	8.6	0.43	3.04e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-8.27	-0.41	3.31e-15	Axial length;
LUSC	cis	rs1858037	0.867	rs67817304	chr2:65574116	C/T	cg08085232	chr2:65598271	SPRED2	-0.4	-5.92	-0.31	7.88e-9	Rheumatoid arthritis;
LUSC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg06877462	chr1:205807181	PM20D1	0.5	8.99	0.44	1.94e-17	Menarche (age at onset);
LUSC	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.73	-12.19	-0.55	1.6e-28	Schizophrenia;
LUSC	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg13852791	chr20:30311386	BCL2L1	0.86	12.03	0.55	6.28e-28	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-9.12	-0.45	7.26e-18	Blood protein levels;
LUSC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg06494592	chr3:125709126	NA	-0.52	-5.91	-0.31	8.54e-9	Blood pressure (smoking interaction);
LUSC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg09650180	chr20:62225654	GMEB2	-0.66	-9.69	-0.47	1.03e-19	Glioblastoma;
LUSC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg13206674	chr6:150067644	NUP43	0.5	7.53	0.38	4.76e-13	Lung cancer;
LUSC	cis	rs6977660	1.000	rs34367208	chr7:19818811	T/G	cg05791153	chr7:19748676	TWISTNB	0.54	5.94	0.31	7.08e-9	Thyroid stimulating hormone;
LUSC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg02896835	chr1:92012615	NA	-0.64	-11.56	-0.53	3.22e-26	Breast cancer;
LUSC	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg06627628	chr2:24431161	ITSN2	-0.59	-7.24	-0.37	3.06e-12	Lymphocyte counts;
LUSC	trans	rs2262909	0.962	rs1526884	chr19:22303651	A/G	cg17074339	chr11:11642133	GALNTL4	0.43	6.6	0.34	1.61e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg12386194	chr3:101231763	SENP7	0.54	7.71	0.39	1.48e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.56	-0.34	2.1e-10	Life satisfaction;
LUSC	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg13789015	chr9:136890014	NCRNA00094	0.7	12.67	0.57	2.67e-30	Platelet distribution width;
LUSC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.21	0.37	3.79e-12	Red cell distribution width;
LUSC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg07716408	chr11:68623521	NA	-0.32	-6.13	-0.32	2.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11039100	0.607	rs34841036	chr11:5782464	A/G	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg06238570	chr21:40685208	BRWD1	-0.62	-10.39	-0.49	4.41e-22	Cognitive function;
LUSC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	5.86	0.31	1.09e-8	Tonsillectomy;
LUSC	cis	rs7589728	1.000	rs6720809	chr2:88528943	T/C	cg04511125	chr2:88470314	THNSL2	0.65	6.15	0.32	2.2e-9	Plasma clusterin levels;
LUSC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg11645453	chr3:52864694	ITIH4	0.35	8.38	0.42	1.53e-15	Bipolar disorder;
LUSC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.4	5.7	0.3	2.61e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg06740227	chr12:86229804	RASSF9	0.42	6.61	0.34	1.53e-10	Major depressive disorder;
LUSC	cis	rs4363385	0.588	rs6698361	chr1:153023184	T/G	cg00922841	chr1:152955080	SPRR1A	-0.36	-5.94	-0.31	7.13e-9	Inflammatory skin disease;
LUSC	cis	rs983392	0.679	rs611418	chr11:60011013	C/T	cg02771260	chr11:59836817	MS4A3	0.37	6.16	0.32	2.12e-9	Alzheimer's disease (late onset);
LUSC	cis	rs238295	0.805	rs6116855	chr20:5555317	A/G	cg15842884	chr20:5591925	RP5-1022P6.2	-0.44	-5.95	-0.31	6.84e-9	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs7084921	0.608	rs11596211	chr10:101840119	T/A	cg11888571	chr10:102027403	CWF19L1	-0.43	-5.84	-0.3	1.23e-8	Bone mineral density;
LUSC	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.51	-0.38	5.61e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.38	0.37	1.23e-12	Bipolar disorder;
LUSC	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.38	0.67	1.16e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg21892295	chr12:121157589	UNC119B	-0.48	-8.59	-0.43	3.49e-16	Mean corpuscular volume;
LUSC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg17628894	chr11:804452	LRDD	0.48	11.21	0.52	5.55e-25	Breast cancer;
LUSC	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg15704280	chr7:45808275	SEPT13	0.73	8.22	0.41	4.64e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4805834	0.719	rs12151363	chr19:33309030	A/T	cg00891608	chr19:33463040	C19orf40;CCDC123	-0.56	-5.68	-0.3	2.87e-8	Creatinine levels;
LUSC	cis	rs672059	1.000	rs575474	chr1:183158599	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.98	0.4	2.42e-14	Hypertriglyceridemia;
LUSC	cis	rs7202877	0.611	rs4888395	chr16:75413715	T/G	cg04384234	chr16:75411784	CFDP1	-0.66	-9.59	-0.46	2.2e-19	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg14004847	chr7:1930337	MAD1L1	-0.56	-8.75	-0.43	1.09e-16	Bipolar disorder and schizophrenia;
LUSC	trans	rs1325195	0.920	rs2636276	chr1:179111060	A/G	cg11624085	chr17:8464688	MYH10	-0.42	-6.78	-0.35	5.57e-11	IgE grass sensitization;
LUSC	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg13072238	chr3:49761600	GMPPB	0.4	6.63	0.34	1.36e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4629710	0.592	rs4424112	chr6:131563788	C/T	cg12606694	chr6:131520996	AKAP7	0.63	9.57	0.46	2.46e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg25456477	chr12:86230367	RASSF9	0.43	7.75	0.39	1.15e-13	Major depressive disorder;
LUSC	trans	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.08	-0.32	3.31e-9	Depression;
LUSC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg06238570	chr21:40685208	BRWD1	-0.61	-10.05	-0.48	6.19e-21	Cognitive function;
LUSC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg04756594	chr16:24857601	SLC5A11	-0.37	-6.14	-0.32	2.36e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg05373962	chr22:49881684	NA	-0.45	-10.68	-0.5	4.3e-23	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg24375607	chr4:120327624	NA	0.76	11.3	0.53	2.72e-25	Corneal astigmatism;
LUSC	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg04310649	chr10:35416472	CREM	-0.41	-6.31	-0.33	8.91e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg05343316	chr1:45956843	TESK2	0.44	5.65	0.3	3.44e-8	Platelet count;
LUSC	cis	rs672059	1.000	rs563026	chr1:183161037	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.55	-8.21	-0.41	4.94e-15	Hypertriglyceridemia;
LUSC	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.02	0.4	1.81e-14	Parkinson's disease;
LUSC	cis	rs11997175	0.546	rs4545051	chr8:33608863	T/C	ch.8.33884649F	chr8:33765107	NA	0.49	7.78	0.39	8.96e-14	Body mass index;
LUSC	trans	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.0	-15.22	-0.64	4.31e-40	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg03128945	chr5:622914	CEP72	-0.44	-6.51	-0.34	2.77e-10	Obesity-related traits;
LUSC	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg22117172	chr7:91764530	CYP51A1	0.32	5.73	0.3	2.25e-8	Breast cancer;
LUSC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19717773	chr7:2847554	GNA12	-0.39	-6.14	-0.32	2.28e-9	Height;
LUSC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg07936489	chr17:37558343	FBXL20	-0.71	-9.99	-0.48	9.76e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.86	-14.99	-0.63	3.39e-39	Cognitive function;
LUSC	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg19773385	chr1:10388646	KIF1B	-0.54	-8.31	-0.41	2.44e-15	Hepatocellular carcinoma;
LUSC	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.66	-10.55	-0.5	1.22e-22	Colorectal cancer;
LUSC	cis	rs7180079	1.000	rs1388216	chr15:64500148	A/G	cg08069370	chr15:64387884	SNX1	-0.54	-5.85	-0.3	1.17e-8	Monocyte count;
LUSC	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg06885757	chr1:42089581	HIVEP3	0.46	9.49	0.46	4.56e-19	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06002616	chr8:101225028	SPAG1	-0.48	-7.81	-0.39	7.6e-14	Atrioventricular conduction;
LUSC	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg25801113	chr15:45476975	SHF	0.33	6.9	0.35	2.62e-11	Uric acid levels;
LUSC	trans	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg22153745	chr1:153894579	GATAD2B	-0.5	-6.97	-0.36	1.73e-11	Total cholesterol levels;
LUSC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.96	0.61	3.35e-35	Platelet count;
LUSC	cis	rs2729354	0.817	rs2250673	chr11:57268170	T/C	cg24343310	chr11:57249947	NA	0.44	8.5	0.42	6.52e-16	Blood protein levels;
LUSC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-17.63	-0.69	1.23e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg25258033	chr6:167368657	RNASET2	0.45	6.87	0.35	3.17e-11	Rheumatoid arthritis;
LUSC	cis	rs796364	0.616	rs769955	chr2:200692595	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	5.97	0.31	5.91e-9	Schizophrenia;
LUSC	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg01191920	chr7:158217561	PTPRN2	-0.41	-7.96	-0.4	2.75e-14	Obesity-related traits;
LUSC	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.95	-0.44	2.42e-17	Response to antipsychotic treatment;
LUSC	cis	rs4253772	0.575	rs9615364	chr22:46797503	G/A	cg00784671	chr22:46762841	CELSR1	-0.5	-5.74	-0.3	2.15e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg25039879	chr17:56429692	SUPT4H1	0.68	9.14	0.45	6.1e-18	Cognitive test performance;
LUSC	cis	rs9837602	0.938	rs28503408	chr3:99794842	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.32	0.33	8.6e-10	Breast cancer;
LUSC	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.32	0.37	1.81e-12	Iron status biomarkers;
LUSC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg09658497	chr7:2847517	GNA12	-0.32	-5.74	-0.3	2.13e-8	Height;
LUSC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg20684491	chr1:25596433	NA	0.37	5.92	0.31	8.2e-9	Erythrocyte sedimentation rate;
LUSC	trans	rs2514895	0.660	rs7109796	chr11:127111252	T/C	cg22738642	chr12:43137977	NA	0.5	6.26	0.32	1.18e-9	IgG glycosylation;
LUSC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg13206674	chr6:150067644	NUP43	0.59	9.45	0.46	5.92e-19	Lung cancer;
LUSC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg01528321	chr10:82214614	TSPAN14	0.62	9.08	0.45	9.41e-18	Post bronchodilator FEV1;
LUSC	trans	rs7939886	0.920	rs1905069	chr11:55887135	T/C	cg03929089	chr4:120376271	NA	0.75	6.11	0.32	2.77e-9	Myopia (pathological);
LUSC	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	6.51	0.34	2.68e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs12618769	0.652	rs3203856	chr2:99226021	C/T	cg10123293	chr2:99228465	UNC50	0.47	7.71	0.39	1.48e-13	Bipolar disorder;
LUSC	trans	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg14227996	chr4:17616232	MED28	-0.55	-6.15	-0.32	2.26e-9	Opioid sensitivity;
LUSC	cis	rs240764	0.817	rs12193960	chr6:101150326	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-6.15	-0.32	2.16e-9	Neuroticism;
LUSC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg08088566	chr11:430123	ANO9	0.67	7.42	0.38	1e-12	Body mass index;
LUSC	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.52	7.48	0.38	6.46e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg24687543	chr11:63912206	MACROD1	0.47	5.82	0.3	1.4e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-16.16	-0.66	8.05e-44	Exhaled nitric oxide output;
LUSC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	0.97	16.93	0.68	7.27e-47	Cognitive function;
LUSC	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg27205649	chr11:78285834	NARS2	0.53	6.45	0.33	4.02e-10	Alzheimer's disease (survival time);
LUSC	trans	rs17266958	0.892	rs118057986	chr9:83278885	G/C	cg01905489	chr1:26616534	UBXN11	-0.61	-6.27	-0.32	1.15e-9	Preschool internalizing problems;
LUSC	cis	rs62400317	0.859	rs10456549	chr6:45225761	C/T	cg18551225	chr6:44695536	NA	-0.44	-7.35	-0.37	1.55e-12	Total body bone mineral density;
LUSC	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg24579218	chr15:68104479	NA	-0.39	-6.28	-0.33	1.04e-9	Restless legs syndrome;
LUSC	cis	rs10887741	0.690	rs12781358	chr10:89444367	C/T	cg24243914	chr10:89418206	PAPSS2	0.31	6.09	0.32	3.09e-9	Exercise (leisure time);
LUSC	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg27284194	chr4:1044797	NA	0.59	8.87	0.44	4.34e-17	Recombination rate (females);
LUSC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg15445000	chr17:37608096	MED1	0.36	6.48	0.33	3.2e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg17691542	chr6:26056736	HIST1H1C	0.54	8.08	0.4	1.23e-14	Height;
LUSC	cis	rs354225	0.544	rs12713267	chr2:54805607	T/C	cg26097391	chr2:54893211	SPTBN1	0.46	6.95	0.36	1.88e-11	Schizophrenia;
LUSC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs243505	0.767	rs243518	chr7:148425028	A/G	cg09806900	chr7:148480153	CUL1	-0.52	-6.86	-0.35	3.42e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7584330	0.554	rs6705908	chr2:238433965	A/G	cg16989719	chr2:238392110	NA	-0.36	-5.68	-0.3	3e-8	Prostate cancer;
LUSC	cis	rs6464929	0.955	rs7781312	chr7:148724236	A/T	cg23583168	chr7:148888333	NA	0.46	5.77	0.3	1.83e-8	Pediatric bone mineral content (hip);
LUSC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.82	-0.35	4.31e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg13560548	chr3:10150139	C3orf24	-0.53	-7.84	-0.39	6.21e-14	Alzheimer's disease;
LUSC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.43	-0.38	9.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.91	-16.16	-0.66	8.34e-44	Cognitive function;
LUSC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg20891558	chr2:74357851	NA	0.79	14.27	0.62	2.04e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg23422044	chr7:1970798	MAD1L1	-0.67	-7.59	-0.38	3.19e-13	Bipolar disorder;
LUSC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.98	-0.31	5.81e-9	Platelet count;
LUSC	trans	rs2729385	1.000	rs2729385	chr11:57262993	C/T	cg10193671	chr17:79846205	THOC4	-0.43	-5.95	-0.31	6.68e-9	Interleukin-18 levels;
LUSC	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg04539111	chr16:67997858	SLC12A4	-0.43	-5.68	-0.3	2.96e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.8	-14.83	-0.63	1.4e-38	Obesity-related traits;
LUSC	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.95	0.51	4.95e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs2843152	0.524	rs1496555	chr1:2234251	A/G	cg07425568	chr1:2236650	SKI	0.51	6.47	0.33	3.48e-10	Coronary artery disease;
LUSC	cis	rs3740393	0.562	rs2297450	chr10:104503174	T/C	cg05855489	chr10:104503620	C10orf26	0.56	5.74	0.3	2.07e-8	Microalbuminuria;
LUSC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg01802117	chr1:53393560	SCP2	-0.38	-6.17	-0.32	1.93e-9	Monocyte count;
LUSC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.23	0.52	4.66e-25	Menopause (age at onset);
LUSC	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg09163369	chr1:210001066	C1orf107	0.51	5.88	0.31	9.74e-9	Orofacial clefts;
LUSC	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.66	-0.3	3.24e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs79911532	0.551	rs41301427	chr7:75614557	G/A	cg03592824	chr7:75666768	STYXL1	0.69	6.79	0.35	5.09e-11	Mononucleosis;
LUSC	trans	rs57046232	0.552	rs6133306	chr20:6333294	T/G	cg21095983	chr6:86352623	SYNCRIP	0.47	7.02	0.36	1.26e-11	Colorectal cancer;
LUSC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg22166914	chr1:53195759	ZYG11B	0.5	7.98	0.4	2.38e-14	Monocyte count;
LUSC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg22437258	chr11:111473054	SIK2	0.53	7.53	0.38	4.93e-13	Primary sclerosing cholangitis;
LUSC	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg00484396	chr16:3507460	NAT15	-0.36	-5.91	-0.31	8.22e-9	Body mass index (adult);
LUSC	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg10811474	chr19:8428787	ANGPTL4	-0.39	-5.97	-0.31	6.03e-9	HDL cholesterol;
LUSC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-10.7	-0.51	3.53e-23	Mood instability;
LUSC	cis	rs4622329	0.593	rs7960780	chr12:102309768	C/T	cg23541617	chr12:102225335	GNPTAB	0.26	5.82	0.3	1.36e-8	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg05340658	chr4:99064831	C4orf37	0.68	11.61	0.54	2.11e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	0.68	6.84	0.35	3.85e-11	Prostate cancer;
LUSC	trans	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg13010199	chr12:38710504	ALG10B	0.39	6.2	0.32	1.64e-9	Morning vs. evening chronotype;
LUSC	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg12573674	chr2:1569213	NA	-0.55	-6.16	-0.32	2.15e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-7.43	-0.38	9.36e-13	Hemoglobin concentration;
LUSC	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg27219399	chr15:67835830	MAP2K5	-0.36	-5.78	-0.3	1.68e-8	Motion sickness;
LUSC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg06145435	chr7:1022769	CYP2W1	0.31	6.34	0.33	7.57e-10	Longevity;Endometriosis;
LUSC	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg15556689	chr8:8085844	FLJ10661	0.56	8.43	0.42	1.05e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg05347473	chr6:146136440	FBXO30	-0.57	-9.83	-0.47	3.27e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg24558204	chr6:135376177	HBS1L	-0.64	-9.25	-0.45	2.7e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs17095355	0.605	rs2274978	chr10:111631665	C/G	cg00817464	chr10:111662876	XPNPEP1	0.55	6.47	0.33	3.53e-10	Biliary atresia;
LUSC	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2.04e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg10523679	chr1:76189770	ACADM	-0.49	-7.07	-0.36	9.34e-12	Daytime sleep phenotypes;
LUSC	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.55	-0.34	2.12e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-5.66	-0.3	3.34e-8	Coronary artery disease;
LUSC	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg12311346	chr5:56204834	C5orf35	0.61	9.29	0.45	2.09e-18	Coronary artery disease;
LUSC	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.59	-0.6	8.31e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg24881330	chr22:46731750	TRMU	0.78	6.56	0.34	2.07e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg23711669	chr6:146136114	FBXO30	0.84	15.12	0.64	9.9e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06481639	chr22:41940642	POLR3H	0.49	5.67	0.3	3.04e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9650315	0.610	rs11988740	chr8:57205976	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	7.24	0.37	3.02e-12	Height;
LUSC	cis	rs62408225	1.000	rs11757155	chr6:90941240	C/T	cg06866423	chr6:90926672	BACH2	0.4	5.78	0.3	1.74e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg03676636	chr4:99064102	C4orf37	0.36	8.01	0.4	1.97e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg03465714	chr1:152285911	FLG	0.42	6.2	0.32	1.7e-9	Atopic dermatitis;
LUSC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg16482183	chr6:26056742	HIST1H1C	0.51	7.48	0.38	6.48e-13	Height;
LUSC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg18230493	chr5:56204884	C5orf35	-0.92	-13.68	-0.6	3.94e-34	Initial pursuit acceleration;
LUSC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg02428538	chr16:24856791	SLC5A11	-0.52	-5.82	-0.3	1.38e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg11189052	chr15:85197271	WDR73	0.48	5.93	0.31	7.56e-9	Schizophrenia;
LUSC	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.41	5.91	0.31	8.56e-9	Monocyte percentage of white cells;
LUSC	cis	rs3772130	0.962	rs11706783	chr3:121534322	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.22	0.49	1.66e-21	Cognitive performance;
LUSC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg18477163	chr1:228402036	OBSCN	0.51	8.59	0.43	3.44e-16	Diastolic blood pressure;
LUSC	trans	rs11241130	0.669	rs255891	chr5:111003610	T/A	cg24626752	chr13:88328274	SLITRK5	0.73	6.31	0.33	8.65e-10	Obesity-related traits;
LUSC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg23978390	chr7:1156363	C7orf50	0.42	6.06	0.31	3.74e-9	Longevity;Endometriosis;
LUSC	cis	rs11031096	0.502	rs4910598	chr11:4101368	C/T	cg08557956	chr11:4115526	RRM1	-0.47	-5.96	-0.31	6.47e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4499344	0.730	rs369859	chr19:33104305	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	trans	rs6084875	0.840	rs6052833	chr20:4731142	C/G	cg26257163	chr5:25190441	NA	-0.36	-6.13	-0.32	2.44e-9	Systemic lupus erythematosus;
LUSC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.3	-0.49	8.89e-22	Hemoglobin concentration;
LUSC	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg01990225	chr2:97406019	LMAN2L	-1.08	-7.25	-0.37	3.01e-12	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg23034840	chr1:205782522	SLC41A1	0.68	9.88	0.48	2.39e-20	Menarche (age at onset);
LUSC	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.58	-0.5	9.73e-23	Glomerular filtration rate;
LUSC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.91	0.61	5.12e-35	Cognitive test performance;
LUSC	trans	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.87	0.35	3.16e-11	Endometrial cancer;
LUSC	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-7.14	-0.36	5.87e-12	Blood metabolite levels;
LUSC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08280861	chr8:58055591	NA	0.58	6.31	0.33	8.78e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.36	0.62	9.07e-37	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs2455799	0.533	rs2470550	chr3:15743721	C/T	cg09340198	chr3:15902540	ANKRD28	-0.33	-5.98	-0.31	5.71e-9	Mean platelet volume;
LUSC	cis	rs7927771	0.524	rs11039392	chr11:47798753	A/G	cg20307385	chr11:47447363	PSMC3	0.44	6.47	0.33	3.54e-10	Subjective well-being;
LUSC	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.45	-0.42	9.25e-16	Response to antipsychotic treatment;
LUSC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06481639	chr22:41940642	POLR3H	-0.53	-6.08	-0.32	3.19e-9	Vitiligo;
LUSC	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg23260525	chr10:116636907	FAM160B1	0.44	9.33	0.45	1.49e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg09998033	chr7:158218633	PTPRN2	0.54	8.68	0.43	1.82e-16	Obesity-related traits;
LUSC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg25039879	chr17:56429692	SUPT4H1	0.65	8.19	0.41	5.71e-15	Cognitive test performance;
LUSC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.32	0.77	3.6e-68	Prudent dietary pattern;
LUSC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg05717871	chr11:638507	DRD4	-0.35	-5.96	-0.31	6.35e-9	Systemic lupus erythematosus;
LUSC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg15839431	chr19:19639596	YJEFN3	0.44	5.99	0.31	5.56e-9	Tonsillectomy;
LUSC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.68	12.14	0.55	2.35e-28	Aortic root size;
LUSC	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	trans	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.41	-0.33	5.07e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg13636640	chr20:31349939	DNMT3B	-0.93	-19.79	-0.73	3.14e-58	Ulcerative colitis;
LUSC	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg15997130	chr1:24165203	NA	0.52	8.58	0.43	3.6e-16	Immature fraction of reticulocytes;
LUSC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg11247378	chr22:39784982	NA	-0.63	-12.41	-0.56	2.37e-29	Intelligence (multi-trait analysis);
LUSC	trans	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.32	0.41	2.28e-15	Resting heart rate;
LUSC	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.78	-0.43	8.55e-17	Response to antipsychotic treatment;
LUSC	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg18721089	chr20:30220636	NA	-0.34	-5.94	-0.31	7.26e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs28785552	0.589	rs7257371	chr19:53243910	A/G	cg10871876	chr19:53194124	ZNF83	0.54	7.81	0.39	7.48e-14	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg02269571	chr22:50332266	NA	-0.59	-8.94	-0.44	2.7e-17	Schizophrenia;
LUSC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.84	-12.32	-0.56	5.17e-29	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg06145435	chr7:1022769	CYP2W1	0.31	6.64	0.34	1.28e-10	Longevity;Endometriosis;
LUSC	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	13.51	0.59	1.78e-33	Lung cancer in ever smokers;
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.57	-8.97	-0.44	2.21e-17	Longevity;Endometriosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23743186	chr22:39152048	UNC84B	-0.4	-6.06	-0.31	3.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.57	9.24	0.45	2.86e-18	Aortic root size;
LUSC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.04	-16.58	-0.67	1.75e-45	Primary sclerosing cholangitis;
LUSC	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg09699651	chr6:150184138	LRP11	0.45	6.94	0.36	2.05e-11	Testicular germ cell tumor;
LUSC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg19678392	chr7:94953810	PON1	-0.36	-5.68	-0.3	2.9e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg11812906	chr14:75593930	NEK9	0.66	11.33	0.53	2.04e-25	Height;
LUSC	cis	rs8032315	0.862	rs7166599	chr15:91403674	A/G	cg04510874	chr15:91427884	FES	0.33	6.5	0.34	2.84e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-8.31	-0.41	2.44e-15	Obesity-related traits;
LUSC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.1	-0.41	1.03e-14	Neuroticism;
LUSC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg05973401	chr12:123451056	ABCB9	0.52	7.01	0.36	1.32e-11	Neutrophil percentage of white cells;
LUSC	cis	rs4409675	0.619	rs12070173	chr1:28231955	G/C	cg23691781	chr1:28212827	C1orf38	0.31	7.48	0.38	6.53e-13	Corneal astigmatism;
LUSC	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.51e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.54e-10	Menopause (age at onset);
LUSC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg16405210	chr4:1374714	KIAA1530	-0.51	-7.64	-0.39	2.32e-13	Obesity-related traits;
LUSC	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg03465714	chr1:152285911	FLG	-0.4	-5.67	-0.3	3.07e-8	Atopic dermatitis;
LUSC	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg27432699	chr2:27873401	GPN1	0.83	15.77	0.65	2.86e-42	Oral cavity cancer;
LUSC	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg12564285	chr5:131593104	PDLIM4	-0.42	-7.64	-0.39	2.33e-13	Breast cancer;
LUSC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	10.07	0.48	5.09e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4654899	0.931	rs6661116	chr1:21337155	C/G	cg01072550	chr1:21505969	NA	-0.55	-8.41	-0.42	1.23e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7605827	0.930	rs10179754	chr2:15541214	C/T	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg08470875	chr2:26401718	FAM59B	-0.69	-9.43	-0.46	7.31e-19	Gut microbiome composition (summer);
LUSC	cis	rs1507153	0.548	rs236853	chr6:79339466	T/C	cg05283184	chr6:79620031	NA	0.39	7.08	0.36	8.51e-12	Sjögren's syndrome;
LUSC	cis	rs4660306	0.677	rs781061	chr1:45932887	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.41	5.66	0.3	3.22e-8	Homocysteine levels;
LUSC	cis	rs7520050	0.807	rs3013594	chr1:46138000	T/C	cg06784218	chr1:46089804	CCDC17	0.29	5.81	0.3	1.43e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.26	-0.37	2.65e-12	Bipolar disorder;
LUSC	cis	rs10761482	0.566	rs10159663	chr10:62208417	A/G	cg18175470	chr10:62150864	ANK3	0.48	6.68	0.34	9.79e-11	Schizophrenia;
LUSC	trans	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.66	-0.34	1.16e-10	Endometrial cancer;
LUSC	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg00071950	chr4:10020882	SLC2A9	-0.62	-10.31	-0.49	8.26e-22	Bone mineral density;
LUSC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg00982548	chr2:198649783	BOLL	-0.56	-7.0	-0.36	1.41e-11	Ulcerative colitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08619651	chr7:127807832	NA	-0.38	-5.95	-0.31	6.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2262909	0.962	rs2017521	chr19:22126138	T/C	cg17074339	chr11:11642133	GALNTL4	-0.41	-6.19	-0.32	1.8e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg13852791	chr20:30311386	BCL2L1	0.93	14.15	0.61	6.1e-36	Mean corpuscular hemoglobin;
LUSC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-9.65	-0.47	1.37e-19	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17370395	chr8:135725535	ZFAT	0.45	5.96	0.31	6.29e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11672220	chr5:177302789	LOC728554	0.73	6.57	0.34	1.92e-10	Cognitive performance;
LUSC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg21665744	chr7:39171113	POU6F2	0.44	6.64	0.34	1.3e-10	IgG glycosylation;
LUSC	cis	rs1007190	0.881	rs9915066	chr17:42962166	C/T	cg15406952	chr17:42872593	NA	0.55	5.68	0.3	2.97e-8	DNA methylation (variation);
LUSC	cis	rs7712401	0.601	rs154500	chr5:122211991	T/G	cg19077854	chr5:122220652	SNX24	0.41	9.22	0.45	3.48e-18	Mean platelet volume;
LUSC	trans	rs750134	0.901	rs17040894	chr12:109092717	C/T	cg23338993	chr2:234600423	UGT1A10;UGT1A6;UGT1A9;UGT1A7;UGT1A8	0.48	6.13	0.32	2.51e-9	Low high density lipoprotein cholesterol levels;
LUSC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg12463550	chr7:65579703	CRCP	-0.55	-8.31	-0.41	2.49e-15	Aortic root size;
LUSC	trans	rs7567288	0.636	rs12989658	chr2:134462988	C/T	cg12381416	chr3:14359266	NA	0.56	6.26	0.32	1.17e-9	Height;
LUSC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg04546413	chr19:29218101	NA	0.71	11.42	0.53	1.03e-25	Methadone dose in opioid dependence;
LUSC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.68	6.93	0.35	2.14e-11	Initial pursuit acceleration;
LUSC	cis	rs6500395	0.962	rs55782524	chr16:48557493	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.11	0.32	2.77e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg27535305	chr1:53392650	SCP2	0.37	6.77	0.35	5.83e-11	Monocyte count;
LUSC	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg05754148	chr16:3507555	NAT15	-0.53	-7.82	-0.39	6.81e-14	Tuberculosis;
LUSC	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg15309053	chr8:964076	NA	-0.38	-7.76	-0.39	1.01e-13	Schizophrenia;
LUSC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.43	0.38	9.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs7084921	0.608	rs12780514	chr10:101865884	T/C	cg02250046	chr10:101825185	CPN1	-0.34	-6.28	-0.33	1.03e-9	Bone mineral density;
LUSC	cis	rs6733011	0.500	rs2280142	chr2:99434872	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-6.26	-0.32	1.16e-9	Bipolar disorder;
LUSC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg20476274	chr7:133979776	SLC35B4	0.8	13.85	0.6	8.46e-35	Mean platelet volume;
LUSC	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg20744362	chr22:50050164	C22orf34	0.39	7.38	0.37	1.29e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6961069	0.585	rs6969989	chr7:80254410	A/G	cg04458919	chr7:80252533	CD36	-0.38	-6.68	-0.34	9.79e-11	Platelet count;
LUSC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08439880	chr3:133502540	NA	0.31	5.71	0.3	2.44e-8	Iron status biomarkers;
LUSC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg16339924	chr4:17578868	LAP3	0.58	9.05	0.44	1.18e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg08888203	chr3:10149979	C3orf24	0.63	9.06	0.44	1.09e-17	Alzheimer's disease;
LUSC	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-10.52	-0.5	1.56e-22	Monocyte percentage of white cells;
LUSC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg03790207	chr6:42947109	PEX6	-0.43	-6.43	-0.33	4.4e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.77	-9.13	-0.45	6.74e-18	HIV-1 control;
LUSC	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.73	10.54	0.5	1.3e-22	Corneal astigmatism;
LUSC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.42	-6.33	-0.33	7.9e-10	Tonsillectomy;
LUSC	cis	rs2625529	0.652	rs11634608	chr15:72255718	A/G	cg16672083	chr15:72433130	SENP8	0.48	8.01	0.4	1.87e-14	Red blood cell count;
LUSC	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg12483005	chr1:23474871	LUZP1	0.45	6.92	0.35	2.28e-11	Height;
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg09704166	chr2:114031854	PAX8;LOC440839	0.46	7.79	0.39	8.3e-14	Lymphocyte counts;
LUSC	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-6.43	-0.33	4.3e-10	Electroencephalogram traits;
LUSC	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg08917208	chr2:24149416	ATAD2B	0.53	5.97	0.31	6e-9	Lymphocyte counts;
LUSC	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg03522245	chr20:25566470	NINL	0.35	5.66	0.3	3.26e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.32	-0.41	2.2e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.63	-0.47	1.55e-19	Multiple sclerosis;
LUSC	cis	rs9311676	0.656	rs55913214	chr3:58388026	A/G	cg26110898	chr3:58419937	PDHB	0.4	6.49	0.33	3.05e-10	Systemic lupus erythematosus;
LUSC	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg17470449	chr10:769945	NA	0.5	7.12	0.36	6.5e-12	Uric acid levels;
LUSC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg21361702	chr7:150065534	REPIN1	0.47	6.34	0.33	7.6e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg05340658	chr4:99064831	C4orf37	0.58	8.63	0.43	2.47e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.65	-0.3	3.38e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs12618769	0.597	rs17504774	chr2:99135627	A/G	cg10123293	chr2:99228465	UNC50	-0.46	-7.55	-0.38	4.08e-13	Bipolar disorder;
LUSC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg17971929	chr21:40555470	PSMG1	0.79	13.68	0.6	3.87e-34	Cognitive function;
LUSC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.18	0.61	4.74e-36	Platelet count;
LUSC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg20573242	chr4:122745356	CCNA2	0.64	9.03	0.44	1.36e-17	Type 2 diabetes;
LUSC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.94	-0.4	3.13e-14	Mean platelet volume;
LUSC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg05872129	chr22:39784769	NA	-0.6	-10.76	-0.51	2.21e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg19875535	chr5:140030758	IK	0.49	8.04	0.4	1.57e-14	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9318086	0.578	rs2077709	chr13:24476073	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.43	-6.46	-0.33	3.76e-10	Myopia (pathological);
LUSC	trans	rs4729127	1.000	rs74856107	chr7:94017640	C/T	cg20086523	chr13:52378287	DHRS12	0.62	6.65	0.34	1.23e-10	Intelligence;
LUSC	cis	rs4919087	0.926	rs2861875	chr10:98990139	C/G	cg25902810	chr10:99078978	FRAT1	-0.45	-6.67	-0.34	1.08e-10	Monocyte count;
LUSC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.46	0.53	7.26e-26	Menopause (age at onset);
LUSC	cis	rs11166629	1.000	rs4909331	chr8:135644540	T/C	cg27224718	chr8:135614730	ZFAT	0.64	10.62	0.5	7.01e-23	Smoking quantity;
LUSC	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg11693508	chr17:37793320	STARD3	0.65	7.95	0.4	2.97e-14	Bipolar disorder;
LUSC	cis	rs911119	0.913	rs13043266	chr20:23588127	C/T	cg16589663	chr20:23618590	CST3	0.61	7.23	0.37	3.41e-12	Chronic kidney disease;
LUSC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.01	0.44	1.56e-17	Height;
LUSC	cis	rs1322512	0.874	rs2038618	chr6:152971286	C/G	cg27316956	chr6:152958899	SYNE1	-0.37	-6.32	-0.33	8.18e-10	Tonometry;
LUSC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg24399712	chr22:39784796	NA	-0.64	-11.84	-0.54	2.99e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs7336332	0.598	rs74183666	chr13:28007765	A/T	cg22138327	chr13:27999177	GTF3A	0.82	9.95	0.48	1.34e-20	Weight;
LUSC	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg15556689	chr8:8085844	FLJ10661	0.58	8.71	0.43	1.44e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg02423579	chr7:2872169	GNA12	-0.4	-6.0	-0.31	5.22e-9	Height;
LUSC	trans	rs7939886	0.841	rs11231800	chr11:55770930	A/G	cg15704280	chr7:45808275	SEPT13	0.83	6.64	0.34	1.27e-10	Myopia (pathological);
LUSC	cis	rs73129298	0.551	rs6095728	chr20:48599960	C/T	cg25655593	chr20:48599521	SNAI1	0.6	6.48	0.33	3.34e-10	Inflammatory skin disease;
LUSC	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg08601574	chr20:25228251	PYGB	0.38	5.81	0.3	1.47e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg03563238	chr19:33554763	RHPN2	-0.41	-6.56	-0.34	2.09e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg22676075	chr6:135203613	NA	0.56	8.75	0.43	1.06e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.69	11.23	0.52	4.65e-25	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs7255	0.538	rs2289081	chr2:20881840	G/C	cg09074113	chr2:20870087	GDF7	-0.31	-5.81	-0.3	1.45e-8	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
LUSC	cis	rs7681440	0.647	rs4522832	chr4:90819391	A/C	cg01966878	chr4:90757139	SNCA	-0.35	-5.68	-0.3	2.89e-8	Dementia with Lewy bodies;
LUSC	trans	rs4940203	0.625	rs17682262	chr18:50227374	C/T	cg14465628	chr9:98125437	NA	0.3	6.09	0.32	3.12e-9	Obesity-related traits;
LUSC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg21285383	chr16:89894308	SPIRE2	0.33	7.09	0.36	8.26e-12	Vitiligo;
LUSC	cis	rs55665837	1.000	rs11023216	chr11:14437153	G/A	cg05501817	chr11:14380813	RRAS2	-0.41	-6.71	-0.34	8.1e-11	Vitamin D levels;
LUSC	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg13010199	chr12:38710504	ALG10B	-0.6	-9.31	-0.45	1.8e-18	Morning vs. evening chronotype;
LUSC	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg00745463	chr17:30367425	LRRC37B	0.63	7.58	0.38	3.37e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.85	-0.3	1.18e-8	Testicular germ cell tumor;
LUSC	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg24558204	chr6:135376177	HBS1L	0.59	9.2	0.45	3.94e-18	Red blood cell count;
LUSC	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.92	12.09	0.55	3.84e-28	Exhaled nitric oxide output;
LUSC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg13939156	chr17:80058883	NA	0.33	6.46	0.33	3.79e-10	Life satisfaction;
LUSC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg15147215	chr3:52552868	STAB1	0.31	6.02	0.31	4.52e-9	Bipolar disorder;
LUSC	cis	rs4499344	0.730	rs34270210	chr19:33103945	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg00484396	chr16:3507460	NAT15	0.49	7.28	0.37	2.34e-12	Body mass index (adult);
LUSC	cis	rs17125944	0.686	rs77650471	chr14:53364307	C/T	cg00686598	chr14:53173677	PSMC6	0.87	7.49	0.38	6.02e-13	Alzheimer's disease (late onset);
LUSC	cis	rs701145	0.938	rs701133	chr3:154070312	A/G	cg17054900	chr3:154042577	DHX36	0.79	8.03	0.4	1.73e-14	Coronary artery disease;
LUSC	cis	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.06e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4474465	1.000	rs10899525	chr11:78201454	T/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.91	-0.31	8.55e-9	Alzheimer's disease (survival time);
LUSC	cis	rs4776059	1.000	rs2288271	chr15:52886466	A/G	cg25063058	chr15:52860530	ARPP19	0.47	6.35	0.33	7.21e-10	Schizophrenia;
LUSC	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg06740227	chr12:86229804	RASSF9	0.39	6.02	0.31	4.51e-9	Major depressive disorder;
LUSC	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg19628046	chr18:33552617	C18orf21	0.52	6.26	0.32	1.15e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg26050004	chr1:235667680	B3GALNT2	0.57	8.12	0.41	8.82e-15	Adiposity;
LUSC	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg00277334	chr10:82204260	NA	-0.52	-6.92	-0.35	2.27e-11	Post bronchodilator FEV1;
LUSC	cis	rs4948102	0.595	rs10255049	chr7:56121304	G/A	cg17215666	chr7:56131930	SUMF2	0.44	5.96	0.31	6.26e-9	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs9369695	0.883	rs9473128	chr6:47505010	C/T	cg20196966	chr6:47445060	CD2AP	0.41	5.64	0.3	3.58e-8	Reticulocyte count;
LUSC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.54	-8.36	-0.42	1.69e-15	Height;
LUSC	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Body mass index;
LUSC	trans	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.28e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs41271473	0.607	rs10916361	chr1:228859971	A/T	cg16512390	chr1:228756714	NA	0.51	7.28	0.37	2.4e-12	Chronic lymphocytic leukemia;
LUSC	cis	rs11039131	0.629	rs67871383	chr11:47335838	T/C	cg20307385	chr11:47447363	PSMC3	-0.54	-6.87	-0.35	3.12e-11	Schizophrenia;
LUSC	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg05855489	chr10:104503620	C10orf26	0.93	18.91	0.72	1.02e-54	Waist circumference;Hip circumference;
LUSC	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg25237894	chr2:233734115	C2orf82	0.35	6.5	0.34	2.87e-10	Coronary artery disease;
LUSC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.85	11.06	0.52	1.91e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9650315	0.866	rs34205064	chr8:57199171	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	7.13	0.36	6.25e-12	Height;
LUSC	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg19812747	chr11:111475976	SIK2	-0.57	-8.44	-0.42	9.47e-16	Primary sclerosing cholangitis;
LUSC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg00031303	chr3:195681400	NA	0.7	10.09	0.48	4.37e-21	Pancreatic cancer;
LUSC	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg22618164	chr12:122356400	WDR66	0.62	9.35	0.46	1.27e-18	Mean corpuscular volume;
LUSC	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg21385522	chr1:16154831	NA	0.52	7.75	0.39	1.15e-13	Systolic blood pressure;
LUSC	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.83	0.68	1.9e-46	Exhaled nitric oxide output;
LUSC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	6.47	0.33	3.48e-10	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg27170947	chr2:26402098	FAM59B	0.6	8.1	0.41	1.03e-14	Gut microbiome composition (summer);
LUSC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg03146154	chr1:46216737	IPP	-0.5	-7.23	-0.37	3.3e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg22875332	chr1:76189707	ACADM	-0.43	-6.46	-0.33	3.8e-10	Daytime sleep phenotypes;
LUSC	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg13010199	chr12:38710504	ALG10B	0.64	9.86	0.47	2.64e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.37	-0.37	1.36e-12	Morning vs. evening chronotype;
LUSC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg01416388	chr22:39784598	NA	-0.49	-7.94	-0.4	3.14e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.52	0.69	3.21e-49	Chronic sinus infection;
LUSC	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg13010199	chr12:38710504	ALG10B	0.68	10.62	0.5	6.57e-23	Bladder cancer;
LUSC	trans	rs4729127	0.908	rs55746023	chr7:94006138	G/A	cg14660007	chr13:78271894	SLAIN1	0.51	6.54	0.34	2.35e-10	Intelligence;
LUSC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18876405	chr7:65276391	NA	0.55	8.59	0.43	3.48e-16	Aortic root size;
LUSC	cis	rs3087591	0.960	rs2953012	chr17:29496486	A/G	cg24425628	chr17:29625626	OMG;NF1	0.54	7.98	0.4	2.34e-14	Hip circumference;
LUSC	cis	rs2273669	0.504	rs74991574	chr6:109482270	A/G	cg05315195	chr6:109294784	ARMC2	-0.55	-5.85	-0.3	1.18e-8	Prostate cancer;
LUSC	cis	rs1775715	0.737	rs2151047	chr10:32102110	G/A	cg04359828	chr10:32216031	ARHGAP12	0.41	6.95	0.36	1.95e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs62408225	0.722	rs10944481	chr6:90917314	A/G	cg06866423	chr6:90926672	BACH2	-0.39	-6.22	-0.32	1.45e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg20587970	chr11:113659929	NA	1.1	13.16	0.58	3.68e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg07274523	chr3:49395745	GPX1	0.64	9.89	0.48	2.19e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg23978390	chr7:1156363	C7orf50	0.44	6.29	0.33	1.02e-9	Longevity;Endometriosis;
LUSC	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg22029157	chr1:209979665	IRF6	0.71	8.84	0.44	5.78e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs2742417	0.603	rs2742453	chr3:45765858	G/A	cg10512202	chr3:45649293	LIMD1	0.36	5.89	0.31	9.25e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg21775007	chr8:11205619	TDH	0.43	6.04	0.31	4.1e-9	Neuroticism;
LUSC	cis	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.5	-5.83	-0.3	1.34e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg27494647	chr7:150038898	RARRES2	0.52	7.88	0.4	4.61e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6987853	0.933	rs2923434	chr8:42422307	A/G	cg09913449	chr8:42400586	C8orf40	0.48	8.14	0.41	7.92e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg11062466	chr8:58055876	NA	0.66	8.49	0.42	7.08e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06022373	chr22:39101656	GTPBP1	0.78	12.08	0.55	3.89e-28	Menopause (age at onset);
LUSC	cis	rs13315871	1.000	rs11710058	chr3:58383048	G/A	cg20936604	chr3:58311152	NA	-0.65	-6.04	-0.31	4.06e-9	Cholesterol, total;
LUSC	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21293242	chr8:11204541	TDH	0.31	5.88	0.31	9.79e-9	Retinal vascular caliber;
LUSC	trans	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg25815440	chr2:42134162	NA	-0.26	-6.02	-0.31	4.51e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10207628	0.698	rs7566991	chr2:127880933	T/A	cg06223080	chr2:127868745	NA	0.38	6.58	0.34	1.79e-10	Psychosis and Alzheimer's disease;
LUSC	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg01420254	chr6:26195488	NA	0.62	7.06	0.36	9.63e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg04851639	chr8:1020857	NA	-0.35	-7.0	-0.36	1.4e-11	Schizophrenia;
LUSC	cis	rs12681287	0.608	rs13273338	chr8:87453361	T/G	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-6.84	-0.35	3.83e-11	Fear of minor pain;
LUSC	cis	rs898097	0.690	rs3785520	chr17:80895745	T/C	cg15664640	chr17:80829946	TBCD	0.64	9.79	0.47	4.55e-20	Breast cancer;
LUSC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.6	-10.03	-0.48	7.27e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs909002	0.772	rs12740754	chr1:32083273	G/C	cg01639898	chr1:32083012	HCRTR1	0.31	7.59	0.38	3.33e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg17340268	chr14:105411764	AHNAK2	-0.38	-6.29	-0.33	9.99e-10	Rheumatoid arthritis;
LUSC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg25025879	chr12:53359317	NA	-0.58	-9.04	-0.44	1.29e-17	Cancer (pleiotropy);
LUSC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.68	-9.47	-0.46	5.35e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs7567288	0.636	rs10496707	chr2:134458931	A/G	cg12381416	chr3:14359266	NA	0.57	6.29	0.33	1.01e-9	Height;
LUSC	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.09	-0.4	1.15e-14	Retinal vascular caliber;
LUSC	trans	rs8030485	0.571	rs10775219	chr15:79443894	G/A	cg16586880	chr8:140854244	TRAPPC9	-0.37	-6.0	-0.31	5.24e-9	Left ventricle wall thickness;
LUSC	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.79	-0.6	1.45e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.45e-17	Motion sickness;
LUSC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08048268	chr3:133502702	NA	-0.46	-8.83	-0.43	6.15e-17	Iron status biomarkers;
LUSC	cis	rs1018836	0.923	rs7812970	chr8:91541229	G/A	cg16814680	chr8:91681699	NA	-0.74	-12.34	-0.56	4.47e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg08558340	chr7:100472263	SRRT	0.51	6.27	0.32	1.11e-9	Resting heart rate;
LUSC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg03289416	chr15:75166202	SCAMP2	0.38	5.77	0.3	1.85e-8	Caffeine consumption;
LUSC	cis	rs9549260	0.753	rs9532578	chr13:41236407	G/A	cg21288729	chr13:41239152	FOXO1	0.56	6.2	0.32	1.69e-9	Red blood cell count;
LUSC	cis	rs6722750	0.716	rs2422115	chr2:64414815	A/G	cg22352474	chr2:64371530	PELI1	-0.5	-7.39	-0.37	1.17e-12	Neuroticism;
LUSC	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg08085267	chr17:45401833	C17orf57	-0.5	-7.25	-0.37	2.97e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg15744005	chr10:104629667	AS3MT	-0.33	-6.76	-0.35	6.2e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-0.7	-11.21	-0.52	5.52e-25	Blood metabolite ratios;
LUSC	cis	rs7523273	0.586	rs2724359	chr1:207935706	A/G	cg22525895	chr1:207977042	MIR29B2	0.41	6.61	0.34	1.5e-10	Schizophrenia;
LUSC	cis	rs4363385	0.747	rs1338180	chr1:152981404	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.71	-0.39	1.48e-13	Inflammatory skin disease;
LUSC	cis	rs6426558	0.537	rs2102634	chr1:227324308	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.55	-7.41	-0.38	1.02e-12	Neutrophil percentage of white cells;
LUSC	cis	rs10875746	0.951	rs10875747	chr12:48525861	A/G	cg13454099	chr12:49076203	C12orf41	-0.52	-6.16	-0.32	2.11e-9	Longevity (90 years and older);
LUSC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24531977	chr5:56204891	C5orf35	-0.93	-14.52	-0.62	2.24e-37	Initial pursuit acceleration;
LUSC	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.44	-9.51	-0.46	3.82e-19	Urate levels in overweight individuals;
LUSC	cis	rs9487051	0.834	rs436880	chr6:109553069	C/T	cg01475377	chr6:109611718	NA	-0.35	-5.76	-0.3	1.87e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs2692947	0.832	rs2579550	chr2:96741944	G/A	cg22654517	chr2:96458247	NA	0.33	6.15	0.32	2.27e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg11764359	chr7:65958608	NA	0.56	7.11	0.36	6.93e-12	Aortic root size;
LUSC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg20243544	chr17:37824526	PNMT	0.39	6.02	0.31	4.54e-9	Self-reported allergy;
LUSC	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg00071950	chr4:10020882	SLC2A9	0.53	8.65	0.43	2.22e-16	Bone mineral density;
LUSC	cis	rs11893307	0.507	rs1465305	chr2:191585392	C/G	cg11845111	chr2:191398756	TMEM194B	-0.42	-5.7	-0.3	2.6e-8	Mean platelet volume;
LUSC	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs2274273	0.805	rs11628437	chr14:55775468	G/A	cg04306507	chr14:55594613	LGALS3	0.54	12.05	0.55	5.23e-28	Protein biomarker;
LUSC	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	0.99	20.61	0.75	1.82e-61	Diastolic blood pressure;
LUSC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.29	0.56	6.76e-29	Prudent dietary pattern;
LUSC	trans	rs236907	0.859	rs6681322	chr1:171773871	A/G	cg13482142	chr2:234261155	NA	-0.5	-6.12	-0.32	2.56e-9	Mean platelet volume;
LUSC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg14773178	chr5:1868261	NA	0.31	5.65	0.3	3.4e-8	Cardiovascular disease risk factors;
LUSC	cis	rs9326248	0.530	rs562179	chr11:116805204	T/C	cg26566898	chr11:117069891	TAGLN	0.44	6.01	0.31	4.9e-9	Blood protein levels;
LUSC	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg07169764	chr2:136633963	MCM6	-0.59	-7.91	-0.4	3.86e-14	Corneal structure;
LUSC	trans	rs853679	0.607	rs200489	chr6:27798257	T/C	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.75	-0.39	1.13e-13	Depression;
LUSC	cis	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg21293242	chr8:11204541	TDH	0.31	5.82	0.3	1.37e-8	Retinal vascular caliber;
LUSC	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg24558204	chr6:135376177	HBS1L	0.59	9.24	0.45	2.88e-18	Red blood cell count;
LUSC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-1.23	-13.29	-0.59	1.17e-32	Diabetic kidney disease;
LUSC	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.21	-0.41	4.98e-15	Body mass index;
LUSC	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg05187965	chr10:45406764	TMEM72	-0.36	-8.47	-0.42	7.95e-16	Mean corpuscular volume;
LUSC	cis	rs4776059	0.550	rs55895733	chr15:52952159	T/G	cg22715398	chr15:52968154	KIAA1370	0.68	7.61	0.38	2.82e-13	Schizophrenia;
LUSC	cis	rs7246657	0.524	rs10411251	chr19:37428755	C/T	cg23950597	chr19:37808831	NA	-0.51	-5.7	-0.3	2.65e-8	Coronary artery calcification;
LUSC	cis	rs10203711	1.000	rs11682137	chr2:239588939	G/A	cg14580085	chr2:239553406	NA	0.42	7.02	0.36	1.21e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg02421172	chr7:1938701	MAD1L1	-0.44	-6.04	-0.31	4.22e-9	Bipolar disorder;
LUSC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03576123	chr11:487126	PTDSS2	-1.04	-10.97	-0.51	4.14e-24	Body mass index;
LUSC	cis	rs9473147	0.516	rs7749271	chr6:47485002	T/C	cg12968598	chr6:47444699	CD2AP	0.53	7.97	0.4	2.49e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17467752	chr17:38218738	THRA	0.52	7.71	0.39	1.44e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	trans	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg14343924	chr8:8086146	FLJ10661	-0.46	-6.31	-0.33	8.7e-10	Monocyte count;
LUSC	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	0.56	8.57	0.42	3.87e-16	Breast cancer;
LUSC	cis	rs981844	1.000	rs55702511	chr4:154665978	A/C	cg14289246	chr4:154710475	SFRP2	0.47	5.74	0.3	2.15e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.7	12.71	0.57	1.91e-30	Prudent dietary pattern;
LUSC	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.07	-0.36	9.28e-12	Systolic blood pressure;
LUSC	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg26597838	chr10:835615	NA	0.76	9.03	0.44	1.37e-17	Eosinophil percentage of granulocytes;
LUSC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.47	-7.22	-0.37	3.59e-12	Systemic lupus erythematosus;
LUSC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg16060761	chr17:80687452	NA	0.47	7.61	0.38	2.9e-13	Breast cancer;
LUSC	cis	rs1113500	0.933	rs1419003	chr1:108616955	A/C	cg06207961	chr1:108661230	NA	0.42	7.8	0.39	8.21e-14	Growth-regulated protein alpha levels;
LUSC	cis	rs864537	0.646	rs1773542	chr1:167432949	T/C	cg22356347	chr1:167427500	CD247	-0.34	-8.19	-0.41	5.49e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	trans	rs11123259	0.794	rs35894488	chr2:115696981	C/A	cg00844339	chr9:138873417	NA	0.3	6.01	0.31	4.79e-9	Gut microbiome composition (winter);
LUSC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.73	0.54	7.69e-27	Alzheimer's disease;
LUSC	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.43	0.42	1.04e-15	Coffee consumption (cups per day);
LUSC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	18.1	0.7	1.66e-51	Chronic sinus infection;
LUSC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.21	0.32	1.54e-9	Menopause (age at onset);
LUSC	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg02269571	chr22:50332266	NA	-0.84	-9.8	-0.47	4.29e-20	Acne (severe);
LUSC	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.5	-0.46	4.36e-19	Schizophrenia;
LUSC	cis	rs1712517	0.873	rs7913461	chr10:105001325	A/G	cg05636881	chr10:105038444	INA	0.4	6.55	0.34	2.18e-10	Migraine;
LUSC	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg00530320	chr1:46809349	NSUN4	0.56	8.7	0.43	1.57e-16	Menopause (age at onset);
LUSC	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg24558204	chr6:135376177	HBS1L	0.67	10.32	0.49	7.41e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs12620999	0.941	rs2875690	chr2:237977737	G/A	cg23555395	chr2:238036564	NA	0.45	7.62	0.38	2.59e-13	Systemic lupus erythematosus;
LUSC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg21573476	chr21:45109991	RRP1B	-0.41	-6.77	-0.35	5.75e-11	Mean corpuscular volume;
LUSC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.12	-0.41	8.88e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs10805346	0.558	rs12506562	chr4:10106954	G/T	cg26043149	chr18:55253948	FECH	0.45	7.12	0.36	6.72e-12	Urate levels in overweight individuals;Urate levels in obese individuals;
LUSC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.89	0.44	3.75e-17	Schizophrenia;
LUSC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg04111992	chr7:158790115	NA	0.45	7.15	0.36	5.51e-12	Facial morphology (factor 20);
LUSC	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg07936489	chr17:37558343	FBXL20	0.78	9.51	0.46	3.94e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg22437258	chr11:111473054	SIK2	0.54	7.65	0.39	2.16e-13	Primary sclerosing cholangitis;
LUSC	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.28	0.53	3.23e-25	Morning vs. evening chronotype;
LUSC	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg05340658	chr4:99064831	C4orf37	-0.47	-7.45	-0.38	8.22e-13	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg25456477	chr12:86230367	RASSF9	0.33	5.8	0.3	1.55e-8	Major depressive disorder;
LUSC	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg05855489	chr10:104503620	C10orf26	0.46	7.07	0.36	9.11e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.74	-13.13	-0.58	4.71e-32	Cognitive function;
LUSC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.01	0.31	4.91e-9	Menopause (age at onset);
LUSC	cis	rs983392	0.678	rs1562990	chr11:60023087	C/A	cg24026212	chr11:59952134	MS4A6A	0.37	6.39	0.33	5.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg17764715	chr19:33622953	WDR88	0.6	8.29	0.41	2.72e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.68	-14.84	-0.63	1.28e-38	Bone mineral density;
LUSC	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	1.07	17.26	0.69	3.57e-48	Testicular germ cell tumor;
LUSC	cis	rs17661538	0.504	rs11591227	chr10:18436307	A/G	cg03634479	chr10:18430412	CACNB2	0.69	6.61	0.34	1.53e-10	Response to antipsychotic treatment;
LUSC	cis	rs500891	0.574	rs34783351	chr6:84139030	G/T	cg08257003	chr6:84140564	ME1	0.37	9.1	0.45	8.48e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg22482690	chr17:47019901	SNF8	0.4	7.47	0.38	7.15e-13	Type 2 diabetes;
LUSC	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg05347473	chr6:146136440	FBXO30	0.51	8.64	0.43	2.35e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.71	10.64	0.5	5.59e-23	Monocyte percentage of white cells;
LUSC	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-7.99	-0.4	2.25e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg24296786	chr1:45957014	TESK2	-0.4	-5.66	-0.3	3.25e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg20701182	chr2:24300061	SF3B14	0.55	5.85	0.3	1.2e-8	Lymphocyte counts;
LUSC	cis	rs508618	0.731	rs576462	chr1:231544607	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-6.8	-0.35	4.72e-11	Red blood cell count;
LUSC	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.88	14.29	0.62	1.69e-36	Coronary artery disease;
LUSC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg18405360	chr17:1531863	SLC43A2	0.47	6.01	0.31	4.98e-9	Thyroid stimulating hormone;
LUSC	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.56e-22	Hypertriglyceridemia;
LUSC	cis	rs1395	1.000	rs1275528	chr2:27430781	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.39	-6.47	-0.33	3.47e-10	Blood metabolite levels;
LUSC	cis	rs2307022	0.566	rs2035869	chr16:68386754	A/G	cg02226672	chr16:68398533	SMPD3	0.32	6.09	0.32	3.06e-9	Body mass index;
LUSC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.62	-10.62	-0.5	7.04e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg11244672	chr19:19639970	YJEFN3	-0.55	-6.85	-0.35	3.47e-11	Bipolar disorder;
LUSC	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg18512352	chr11:47633146	NA	-0.43	-9.06	-0.44	1.09e-17	Subjective well-being;
LUSC	trans	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg03886242	chr7:26192032	NFE2L3	-0.41	-6.47	-0.33	3.47e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs57046232	0.552	rs6054184	chr20:6354592	A/G	cg21095983	chr6:86352623	SYNCRIP	0.49	7.25	0.37	2.95e-12	Colorectal cancer;
LUSC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg26338869	chr17:61819248	STRADA	0.42	6.07	0.32	3.43e-9	Prudent dietary pattern;
LUSC	cis	rs1983891	0.955	rs4714487	chr6:41547312	T/C	cg15051332	chr6:41514432	FOXP4	0.41	5.97	0.31	5.95e-9	Prostate cancer;
LUSC	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg13755796	chr4:20253514	NA	-0.43	-6.67	-0.34	1.07e-10	Life satisfaction;
LUSC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg12963246	chr6:28129442	ZNF389	0.39	6.22	0.32	1.5e-9	Parkinson's disease;
LUSC	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg24558204	chr6:135376177	HBS1L	0.59	9.14	0.45	6.29e-18	Red blood cell count;
LUSC	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg23942311	chr14:51606299	NA	0.48	10.75	0.51	2.41e-23	Cancer;
LUSC	cis	rs983392	0.679	rs1026254	chr11:60030457	A/G	cg24026212	chr11:59952134	MS4A6A	0.35	5.97	0.31	6.09e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7605827	0.930	rs3828465	chr2:15535497	A/T	cg19274914	chr2:15703543	NA	0.46	9.16	0.45	5.5e-18	Educational attainment (years of education);
LUSC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.07	0.77	3.19e-67	Prudent dietary pattern;
LUSC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg17691542	chr6:26056736	HIST1H1C	0.54	8.11	0.41	9.42e-15	Height;
LUSC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg25554036	chr4:6271136	WFS1	0.6	12.13	0.55	2.59e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs929596	0.564	rs2741030	chr2:234536152	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-6.31	-0.33	8.94e-10	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg11247378	chr22:39784982	NA	-0.64	-13.09	-0.58	6.72e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg11766577	chr21:47581405	C21orf56	-0.56	-8.64	-0.43	2.29e-16	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.67	0.34	1.06e-10	Lung cancer;
LUSC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.45	6.04	0.31	4.13e-9	Renal function-related traits (BUN);
LUSC	cis	rs9394438	0.628	rs4714079	chr6:37544439	C/T	cg00985040	chr6:37553208	NA	-0.4	-8.95	-0.44	2.42e-17	IgG glycosylation;
LUSC	cis	rs7582720	1.000	rs72936323	chr2:204050474	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.38	0.42	1.54e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs977987	0.806	rs12917651	chr16:75466696	G/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.4e-11	Dupuytren's disease;
LUSC	cis	rs7123876	0.541	rs61895574	chr11:72347988	A/T	cg03878208	chr11:72483293	STARD10	0.53	5.97	0.31	6.13e-9	Body mass index;
LUSC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg15017067	chr4:17643749	FAM184B	0.36	6.03	0.31	4.27e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs870825	1.000	rs870821	chr4:185587377	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	11.2	0.52	6.13e-25	Blood protein levels;
LUSC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.69	-0.39	1.63e-13	Aortic root size;
LUSC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.69e-20	Gut microbiome composition (summer);
LUSC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.77	7.65	0.39	2.1e-13	Initial pursuit acceleration;
LUSC	cis	rs35883536	0.609	rs10783142	chr1:101043902	C/G	cg06223162	chr1:101003688	GPR88	-0.48	-9.12	-0.45	7.32e-18	Monocyte count;
LUSC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg27588902	chr6:42928151	GNMT	-0.3	-6.55	-0.34	2.12e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg27398817	chr8:82754497	SNX16	-0.65	-8.11	-0.41	9.85e-15	Diastolic blood pressure;
LUSC	cis	rs1506636	1.000	rs1911145	chr7:123363658	A/G	cg03229431	chr7:123269106	ASB15	-0.65	-10.57	-0.5	9.99e-23	Plateletcrit;Platelet count;
LUSC	cis	rs3106136	0.527	rs10030586	chr4:95150805	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.41	-0.42	1.25e-15	Capecitabine sensitivity;
LUSC	cis	rs4654899	0.627	rs667071	chr1:21045726	T/C	cg01072550	chr1:21505969	NA	-0.41	-6.28	-0.32	1.06e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg03676636	chr4:99064102	C4orf37	0.36	7.89	0.4	4.25e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg08085267	chr17:45401833	C17orf57	-0.54	-8.6	-0.43	3.07e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg27535305	chr1:53392650	SCP2	-0.49	-9.75	-0.47	6.23e-20	Monocyte count;
LUSC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg03233332	chr7:66118400	NA	-0.41	-6.01	-0.31	4.84e-9	Aortic root size;
LUSC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00149659	chr3:10157352	C3orf10	0.91	11.55	0.53	3.41e-26	Alzheimer's disease;
LUSC	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg03433033	chr1:76189801	ACADM	-0.47	-7.29	-0.37	2.28e-12	Daytime sleep phenotypes;
LUSC	cis	rs3740713	0.669	rs2896526	chr11:18419806	A/G	cg07915343	chr11:18477680	LDHAL6A	-0.47	-5.88	-0.31	9.74e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs1018836	0.608	rs6982329	chr8:91467488	A/G	cg16814680	chr8:91681699	NA	-0.54	-7.89	-0.4	4.47e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3105593	0.901	rs3098200	chr15:50821945	G/A	cg08437265	chr15:50716283	USP8	0.42	6.26	0.32	1.16e-9	QT interval;
LUSC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.58	-9.59	-0.46	2.13e-19	Aortic root size;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg07700962	chr1:174968950	CACYBP	0.54	6.81	0.35	4.5e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.84	-14.24	-0.61	2.78e-36	Menarche (age at onset);
LUSC	cis	rs9472414	0.771	rs4714825	chr6:44761546	C/T	cg20913747	chr6:44695427	NA	0.41	5.92	0.31	7.92e-9	Height;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03134551	chr8:681291	ERICH1	0.37	6.11	0.32	2.74e-9	Asthma;
LUSC	cis	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg06521331	chr12:34319734	NA	0.38	6.51	0.34	2.69e-10	Morning vs. evening chronotype;
LUSC	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg00105475	chr2:10696890	NA	0.38	6.25	0.32	1.27e-9	Prostate cancer;
LUSC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg08200582	chr11:442649	ANO9	-0.53	-5.74	-0.3	2.07e-8	Body mass index;
LUSC	cis	rs7072216	0.763	rs12763044	chr10:100167451	C/G	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg05347473	chr6:146136440	FBXO30	-0.48	-7.99	-0.4	2.25e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9427116	1.000	rs9427117	chr1:154632231	C/G	cg17218026	chr1:154582156	ADAR	0.38	6.43	0.33	4.42e-10	Blood protein levels;
LUSC	cis	rs2963155	0.518	rs56150733	chr5:142765099	T/C	cg17617527	chr5:142782415	NR3C1	0.72	8.29	0.41	2.88e-15	Breast cancer;
LUSC	cis	rs2425143	1.000	rs17093026	chr20:34318911	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	6.15	0.32	2.26e-9	Blood protein levels;
LUSC	cis	rs4959270	0.967	rs4959914	chr6:453825	C/A	cg09757644	chr6:447497	NA	0.28	5.76	0.3	1.88e-8	Limited cutaneous systemic scleroderma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03437924	chr16:25123326	LCMT1	-0.47	-6.58	-0.34	1.85e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg27432699	chr2:27873401	GPN1	-0.58	-8.66	-0.43	2e-16	Total body bone mineral density;
LUSC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.12	-0.32	2.62e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08470875	chr2:26401718	FAM59B	0.74	9.89	0.48	2.15e-20	Gut microbiome composition (summer);
LUSC	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg22705602	chr4:152727874	NA	-0.33	-6.7	-0.34	9.13e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17720231	chr1:159915374	IGSF9	0.4	6.42	0.33	4.68e-10	Calcium levels;
LUSC	cis	rs6977940	0.558	rs11768054	chr7:2888015	T/G	cg19731401	chr7:2775893	GNA12	0.71	7.84	0.39	5.97e-14	White matter integrity;
LUSC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg10729496	chr3:10149963	C3orf24	-0.53	-6.06	-0.31	3.64e-9	Alzheimer's disease;
LUSC	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-10.56	-0.5	1.07e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg17810781	chr1:201082982	CACNA1S	0.33	6.32	0.33	8.58e-10	Permanent tooth development;
LUSC	cis	rs858239	0.601	rs11984129	chr7:23152677	A/G	cg23682824	chr7:23144976	KLHL7	0.4	5.79	0.3	1.62e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	9.29	0.45	2.08e-18	Mean platelet volume;
LUSC	cis	rs4132509	0.739	rs79367267	chr1:243689543	C/A	cg21452805	chr1:244014465	NA	0.61	6.22	0.32	1.45e-9	RR interval (heart rate);
LUSC	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.48	0.46	4.77e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11748023	0.605	rs185123	chr5:139517197	T/C	cg26211634	chr5:139558579	C5orf32	0.35	6.19	0.32	1.75e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6138458	0.620	rs914314	chr20:24897355	C/T	cg26195577	chr20:24973756	C20orf3	-1.1	-11.33	-0.53	2.2e-25	Blood protein levels;
LUSC	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-8.18	-0.41	6.14e-15	Axial length;
LUSC	cis	rs806215	1.000	rs712697	chr7:127247132	T/A	cg25922125	chr7:127225783	GCC1	0.57	7.17	0.37	4.96e-12	Type 2 diabetes;
LUSC	cis	rs6012953	1.000	rs3787334	chr20:49128020	T/C	cg13958625	chr20:49123093	NA	0.31	6.58	0.34	1.87e-10	Vitiligo;
LUSC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06634786	chr22:41940651	POLR3H	0.49	5.87	0.31	1.04e-8	Vitiligo;
LUSC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	8.16	0.41	6.96e-15	Total body bone mineral density;
LUSC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	11.35	0.53	1.75e-25	Personality dimensions;
LUSC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs10050311	0.800	rs17420966	chr4:87692129	T/G	cg10685359	chr4:87814065	C4orf36	-0.46	-5.77	-0.3	1.79e-8	Insulin-related traits;
LUSC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.93	0.4	3.25e-14	Prudent dietary pattern;
LUSC	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg24130564	chr14:104152367	KLC1	-0.47	-6.82	-0.35	4.31e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7178572	0.568	rs1125617	chr15:77532711	A/G	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	trans	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg21775007	chr8:11205619	TDH	0.54	7.79	0.39	8.59e-14	Mood instability;
LUSC	trans	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg17675199	chr6:35436792	RPL10A	-0.45	-6.51	-0.34	2.77e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10992471	0.528	rs7022562	chr9:95216340	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.27	-0.32	1.14e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9815354	0.680	rs73075204	chr3:42030392	G/A	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg12863693	chr15:85201151	NMB	0.37	7.72	0.39	1.34e-13	Schizophrenia;
LUSC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08048268	chr3:133502702	NA	-0.47	-8.96	-0.44	2.29e-17	Iron status biomarkers;
LUSC	cis	rs2901656	1.000	rs2901656	chr1:172434812	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.3	6.13	0.32	2.46e-9	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg11344533	chr11:111475393	SIK2	-0.49	-6.83	-0.35	4.02e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg23625390	chr15:77176239	SCAPER	0.61	9.1	0.45	8.34e-18	Blood metabolite levels;
LUSC	cis	rs977987	0.835	rs7200616	chr16:75366089	G/A	cg03315344	chr16:75512273	CHST6	0.54	10.48	0.5	2.15e-22	Dupuytren's disease;
LUSC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.85	13.88	0.6	6.99e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs3741151	0.686	rs60860405	chr11:73248673	A/C	cg17517138	chr11:73019481	ARHGEF17	0.82	7.61	0.38	2.82e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg05738196	chr6:26577821	NA	0.81	15.7	0.65	5.64e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-7.77	-0.39	9.65e-14	Lung cancer;
LUSC	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg20587970	chr11:113659929	NA	1.23	13.46	0.59	2.82e-33	Hip circumference adjusted for BMI;
LUSC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg20639618	chr4:183729073	NA	0.64	8.32	0.41	2.23e-15	Pediatric autoimmune diseases;
LUSC	cis	rs2445762	0.659	rs72729227	chr15:51670611	T/A	cg07517944	chr15:51633816	GLDN	0.37	6.45	0.33	4.01e-10	Hormone measurements;
LUSC	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.24	0.49	1.36e-21	Bladder cancer;
LUSC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg24399712	chr22:39784796	NA	-0.64	-11.52	-0.53	4.49e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs911119	0.657	rs13039144	chr20:23633755	A/G	cg16589663	chr20:23618590	CST3	0.55	6.06	0.31	3.75e-9	Chronic kidney disease;
LUSC	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg01884057	chr2:25150051	NA	0.45	10.25	0.49	1.3e-21	Body mass index in non-asthmatics;
LUSC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.72	-17.09	-0.68	1.64e-47	Prostate cancer;
LUSC	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.47	7.33	0.37	1.72e-12	Resistin levels;
LUSC	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg00540400	chr15:79124168	NA	0.48	8.48	0.42	7.16e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg09877947	chr5:131593287	PDLIM4	-0.4	-6.69	-0.34	9.14e-11	Blood metabolite levels;
LUSC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg21535247	chr6:8435926	SLC35B3	0.6	9.36	0.46	1.23e-18	Motion sickness;
LUSC	cis	rs9653442	0.900	rs6754937	chr2:100827720	T/G	cg07810366	chr2:100720526	AFF3	-0.47	-7.9	-0.4	4.04e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2625529	0.775	rs62023342	chr15:72161305	A/C	cg16672083	chr15:72433130	SENP8	-0.5	-7.32	-0.37	1.88e-12	Red blood cell count;
LUSC	cis	rs3740713	1.000	rs76599129	chr11:18471627	T/A	cg23797887	chr11:18477753	LDHAL6A	-0.56	-6.75	-0.35	6.38e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs1335645	0.570	rs61804560	chr1:111644247	G/A	cg00321911	chr1:111669324	DRAM2	-0.56	-6.0	-0.31	5.01e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2969070	1.000	rs2895171	chr7:2514209	G/A	cg03277898	chr7:2518824	NA	-0.26	-5.68	-0.3	2.99e-8	Diastolic blood pressure;
LUSC	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg10018233	chr7:150070692	REPIN1	0.35	5.94	0.31	7.05e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs965469	1.000	rs6037535	chr20:3270621	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-5.65	-0.3	3.51e-8	IFN-related cytopenia;
LUSC	trans	rs12510870	0.511	rs16849366	chr4:74293387	C/T	cg01940055	chr4:146018582	ANAPC10;ABCE1	0.39	6.39	0.33	5.68e-10	Iris color (b* coordinate);
LUSC	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22980127	chr19:33182716	NUDT19	-0.92	-12.61	-0.57	4.27e-30	Red blood cell traits;
LUSC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.12e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12122100	0.651	rs12127461	chr1:146551888	C/G	cg03526459	chr1:146549940	NA	-0.4	-6.69	-0.34	9.53e-11	HIV-1 control;
LUSC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg08048268	chr3:133502702	NA	-0.39	-7.08	-0.36	8.63e-12	Iron status biomarkers;
LUSC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.88	12.55	0.57	7.36e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs17155006	0.746	rs435522	chr7:107748701	A/G	cg05962710	chr7:107745446	LAMB4	-0.36	-6.52	-0.34	2.57e-10	Pneumococcal bacteremia;
LUSC	trans	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-6.14	-0.32	2.3e-9	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LUSC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	0.92	19.4	0.73	1.15e-56	Dental caries;
LUSC	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg13010199	chr12:38710504	ALG10B	0.65	10.25	0.49	1.32e-21	Bladder cancer;
LUSC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg25019033	chr10:957182	NA	-0.48	-5.75	-0.3	1.97e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs73206853	0.764	rs12311093	chr12:110978032	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.72	-9.54	-0.46	3.17e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-7.94	-0.4	3.11e-14	Bladder cancer;
LUSC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg20887711	chr4:1340912	KIAA1530	0.47	7.15	0.36	5.57e-12	Obesity-related traits;
LUSC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.29	-0.33	9.97e-10	Lung cancer;
LUSC	cis	rs4776059	0.798	rs1080731	chr15:52920658	C/T	cg22715398	chr15:52968154	KIAA1370	-0.54	-7.21	-0.37	3.65e-12	Schizophrenia;
LUSC	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.37	-0.42	1.63e-15	Schizophrenia;
LUSC	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.54	0.42	4.94e-16	Lung cancer in ever smokers;
LUSC	cis	rs4356932	0.967	rs7436646	chr4:76955229	T/G	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs6939532	0.522	rs6933583	chr6:26355283	A/C	cg09904177	chr6:26538194	HMGN4	-0.41	-5.79	-0.3	1.66e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg11645453	chr3:52864694	ITIH4	0.29	6.73	0.35	7.46e-11	Electroencephalogram traits;
LUSC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg00012203	chr2:219082015	ARPC2	0.76	13.51	0.59	1.81e-33	Colorectal cancer;
LUSC	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Educational attainment;
LUSC	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg10518572	chr11:65560635	OVOL1	-0.25	-5.82	-0.3	1.4e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs977987	0.806	rs11641587	chr16:75464419	G/T	cg03315344	chr16:75512273	CHST6	0.5	9.55	0.46	2.98e-19	Dupuytren's disease;
LUSC	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg13535736	chr9:111863775	C9orf5	-0.42	-6.88	-0.35	2.95e-11	Menarche (age at onset);
LUSC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg12257692	chr3:49977190	RBM6	-0.26	-7.22	-0.37	3.63e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg27572855	chr1:25598939	RHD	0.43	7.68	0.39	1.78e-13	Erythrocyte sedimentation rate;
LUSC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg12386194	chr3:101231763	SENP7	0.54	7.54	0.38	4.59e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.5	-8.12	-0.41	9.24e-15	Neutrophil percentage of white cells;
LUSC	cis	rs2729354	1.000	rs2649662	chr11:57352562	G/T	cg24343310	chr11:57249947	NA	-0.36	-6.51	-0.34	2.82e-10	Blood protein levels;
LUSC	cis	rs4842666	0.915	rs111478946	chr12:90058842	G/A	cg00757033	chr12:89920650	WDR51B	0.49	6.97	0.36	1.7e-11	Blood pressure;
LUSC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg27535305	chr1:53392650	SCP2	-0.37	-6.73	-0.35	7.44e-11	Monocyte count;
LUSC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg13175981	chr1:150552382	MCL1	-0.41	-5.7	-0.3	2.69e-8	Melanoma;
LUSC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-9.49	-0.46	4.41e-19	Type 2 diabetes;
LUSC	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.91	0.51	6.56e-24	Hypertriglyceridemia;
LUSC	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.0	-0.4	2.03e-14	Body mass index;
LUSC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg23743428	chr13:21893420	NA	-0.45	-8.97	-0.44	2.15e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.28	5.66	0.3	3.33e-8	Cognitive function;
LUSC	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.72	14.12	0.61	7.95e-36	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.75	-0.39	1.15e-13	Retinal vascular caliber;
LUSC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.92	-0.35	2.35e-11	Obesity-related traits;
LUSC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.39	0.59	4.96e-33	Platelet count;
LUSC	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg06917634	chr15:78832804	PSMA4	0.55	6.44	0.33	4.05e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.59	0.6	8.31e-34	Platelet count;
LUSC	cis	rs367615	0.506	rs1428932	chr5:108792479	A/G	cg17395555	chr5:108820864	NA	-0.54	-9.95	-0.48	1.32e-20	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.51	9.26	0.45	2.5e-18	Bone mineral density;
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.59	-10.96	-0.51	4.28e-24	Longevity;Endometriosis;
LUSC	cis	rs9341835	0.510	rs2622284	chr6:64193572	T/C	cg03326410	chr6:64151739	NA	0.36	5.77	0.3	1.83e-8	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-9.7	-0.47	9.37e-20	Gut microbiome composition (summer);
LUSC	cis	rs8022179	0.580	rs58153827	chr14:103844630	G/A	cg12935359	chr14:103987150	CKB	0.66	8.66	0.43	1.98e-16	Monocyte count;
LUSC	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Bladder cancer;
LUSC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.56	0.5	1.12e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg19318889	chr4:1322082	MAEA	0.46	7.45	0.38	8e-13	Obesity-related traits;
LUSC	cis	rs8014204	0.762	rs10138360	chr14:75293386	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-8.09	-0.4	1.14e-14	Caffeine consumption;
LUSC	cis	rs6690583	0.512	rs7547224	chr1:85456902	T/C	cg22153463	chr1:85462885	MCOLN2	0.62	5.7	0.3	2.68e-8	Serum sulfate level;
LUSC	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg27661571	chr11:113659931	NA	-0.59	-6.93	-0.35	2.15e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg06096015	chr1:231504339	EGLN1	0.56	9.83	0.47	3.27e-20	Hemoglobin concentration;
LUSC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg14895029	chr7:2775587	GNA12	-0.41	-6.13	-0.32	2.47e-9	Height;
LUSC	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg03060546	chr3:49711283	APEH	0.61	8.41	0.42	1.22e-15	Resting heart rate;
LUSC	cis	rs17621444	0.522	rs10788022	chr10:121812113	A/C	cg02041677	chr10:121771263	NA	-0.32	-6.02	-0.31	4.59e-9	IgG glycosylation;
LUSC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.9	13.0	0.58	1.5e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs860295	0.702	rs12041534	chr1:155407096	A/G	cg02153340	chr1:155202674	NA	0.37	5.72	0.3	2.39e-8	Body mass index;
LUSC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg20203395	chr5:56204925	C5orf35	0.51	7.43	0.38	9e-13	Type 2 diabetes;
LUSC	cis	rs600231	0.542	rs10896008	chr11:65245904	C/G	cg17120908	chr11:65337727	SSSCA1	-0.63	-9.04	-0.44	1.25e-17	Bone mineral density;
LUSC	cis	rs9807989	0.839	rs4988955	chr2:102967928	A/G	cg09003973	chr2:102972529	NA	0.44	6.14	0.32	2.39e-9	Asthma;
LUSC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.38	0.69	1.15e-48	Chronic sinus infection;
LUSC	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg24110177	chr3:50126178	RBM5	-0.41	-6.68	-0.34	1.01e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs354225	0.544	rs13423873	chr2:54786677	A/G	cg01766943	chr2:54829624	SPTBN1	0.49	7.54	0.38	4.57e-13	Schizophrenia;
LUSC	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg07578070	chr6:150326732	RAET1K	0.4	6.29	0.33	9.97e-10	Alopecia areata;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg19478983	chr7:120590592	ING3	0.4	6.96	0.36	1.83e-11	Triglycerides;
LUSC	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.1e-40	Bladder cancer;
LUSC	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs4588572	0.643	rs7716529	chr5:77738637	A/T	cg11547950	chr5:77652471	NA	-0.54	-7.88	-0.4	4.8e-14	Triglycerides;
LUSC	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg08601574	chr20:25228251	PYGB	-0.44	-6.72	-0.35	7.65e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg15485101	chr11:133734466	NA	0.38	7.17	0.37	4.98e-12	Childhood ear infection;
LUSC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.47	0.38	7.01e-13	Motion sickness;
LUSC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.22	-0.49	1.58e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs13385	0.723	rs36078551	chr5:139532339	C/T	cg26211634	chr5:139558579	C5orf32	0.41	5.97	0.31	6.08e-9	Atrial fibrillation;
LUSC	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg20991723	chr1:152506922	NA	0.53	9.87	0.48	2.41e-20	Hair morphology;
LUSC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg15704280	chr7:45808275	SEPT13	-1.01	-18.93	-0.72	8.57e-55	Height;
LUSC	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg00074818	chr8:8560427	CLDN23	0.59	9.8	0.47	4.21e-20	Obesity-related traits;
LUSC	cis	rs7597155	0.935	rs7577493	chr2:69980174	T/G	cg02498382	chr2:70120550	SNRNP27	-0.25	-5.87	-0.31	1.03e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6847149	0.929	rs11937583	chr4:110808173	A/G	cg07850274	chr4:110748770	RRH	0.52	7.07	0.36	9.07e-12	Exercise treadmill test traits;
LUSC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.63	-0.34	1.35e-10	Tonsillectomy;
LUSC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-12.22	-0.56	1.24e-28	Platelet count;
LUSC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg05623727	chr3:50126028	RBM5	-0.33	-6.22	-0.32	1.51e-9	Body mass index;
LUSC	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg24130564	chr14:104152367	KLC1	0.43	6.1	0.32	2.86e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg17252645	chr8:143867129	LY6D	-0.34	-5.64	-0.3	3.54e-8	Urinary tract infection frequency;
LUSC	cis	rs2273669	0.667	rs12196143	chr6:109302372	C/T	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg05665937	chr4:1216051	CTBP1	0.35	5.73	0.3	2.2e-8	Obesity-related traits;
LUSC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg13175981	chr1:150552382	MCL1	0.47	6.78	0.35	5.34e-11	Tonsillectomy;
LUSC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.88	13.32	0.59	9.28e-33	Menarche (age at onset);
LUSC	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.33	0.41	2.18e-15	Lung cancer;
LUSC	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg09307838	chr4:120376055	NA	0.71	10.32	0.49	7.35e-22	Corneal astigmatism;
LUSC	cis	rs13272568	0.502	rs10957882	chr8:78995713	C/A	cg00738934	chr8:78996279	NA	0.37	6.16	0.32	2.08e-9	Bone mineral density;
LUSC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	7.04	0.36	1.07e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg07806771	chr7:64541737	NA	-0.43	-6.32	-0.33	8.47e-10	Calcium levels;
LUSC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-7.87	-0.4	4.95e-14	Bipolar disorder and schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25992645	chr11:65244888	NA	-0.48	-6.12	-0.32	2.68e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	0.96	9.39	0.46	9.75e-19	Plasma clusterin levels;
LUSC	cis	rs68170813	0.652	rs6958969	chr7:107197755	A/T	cg02696742	chr7:106810147	HBP1	-0.64	-8.57	-0.42	3.82e-16	Coronary artery disease;
LUSC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg22535103	chr8:58192502	C8orf71	-0.7	-7.31	-0.37	1.97e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.6	-9.69	-0.47	9.72e-20	Body mass index;
LUSC	cis	rs62400317	0.859	rs72869127	chr6:45071712	T/C	cg20913747	chr6:44695427	NA	-0.46	-7.43	-0.38	9.41e-13	Total body bone mineral density;
LUSC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg02376097	chr19:46275166	DMPK	0.39	6.93	0.35	2.22e-11	Coronary artery disease;
LUSC	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg06191203	chr2:152266755	RIF1	-0.54	-7.28	-0.37	2.41e-12	Lung cancer;
LUSC	cis	rs17604090	0.938	rs28664977	chr7:29685369	C/T	cg19413766	chr7:29689036	LOC646762	-0.58	-6.93	-0.35	2.12e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	9.65	0.47	1.38e-19	Personality dimensions;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02621907	chr5:93954419	ANKRD32;C5orf36	0.45	6.44	0.33	4.06e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.65	-8.92	-0.44	3.2e-17	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg22676075	chr6:135203613	NA	0.48	7.48	0.38	6.5e-13	Red blood cell count;
LUSC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs1832871	0.672	rs9456289	chr6:158740347	G/A	cg07165851	chr6:158734300	TULP4	0.45	6.8	0.35	4.96e-11	Height;
LUSC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg09877947	chr5:131593287	PDLIM4	-0.34	-5.72	-0.3	2.39e-8	Blood metabolite levels;
LUSC	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg21643547	chr1:205240462	TMCC2	-0.43	-7.81	-0.39	7.28e-14	Red blood cell count;
LUSC	cis	rs981844	1.000	rs62325093	chr4:154669733	G/A	cg14289246	chr4:154710475	SFRP2	0.48	5.97	0.31	5.94e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.64	-0.34	1.3e-10	Fear of minor pain;
LUSC	cis	rs7215564	0.908	rs9972968	chr17:78652569	T/C	cg23238734	chr17:78661607	RPTOR	0.51	6.55	0.34	2.2e-10	Myopia (pathological);
LUSC	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg03647239	chr10:116582469	FAM160B1	0.44	7.15	0.36	5.58e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg16482183	chr6:26056742	HIST1H1C	0.44	6.49	0.33	3.11e-10	Height;
LUSC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg15744005	chr10:104629667	AS3MT	-0.28	-5.88	-0.31	9.93e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07677032	chr17:61819896	STRADA	0.55	9.09	0.45	9.21e-18	Prudent dietary pattern;
LUSC	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg04586622	chr2:25135609	ADCY3	0.43	9.23	0.45	3.12e-18	Body mass index;
LUSC	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-10.53	-0.5	1.36e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs10511400	0.618	rs4676809	chr3:119907244	C/T	cg02809009	chr19:50354510	PTOV1	0.68	6.34	0.33	7.27e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.53	7.31	0.37	1.99e-12	IgG glycosylation;
LUSC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-0.85	-14.77	-0.63	2.33e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-6.04	-0.31	4.04e-9	Morning vs. evening chronotype;
LUSC	cis	rs75920871	0.588	rs7118591	chr11:116908457	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.51	6.49	0.33	3.17e-10	Subjective well-being;
LUSC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.49	9.23	0.45	3.15e-18	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs243505	0.660	rs243487	chr7:148448211	G/A	cg09806900	chr7:148480153	CUL1	-0.54	-7.05	-0.36	1.04e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.97	0.77	8.13e-67	Prudent dietary pattern;
LUSC	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg18002602	chr11:66138449	SLC29A2	0.45	8.14	0.41	8.11e-15	Educational attainment (years of education);
LUSC	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg13010199	chr12:38710504	ALG10B	0.65	9.82	0.47	3.81e-20	Bladder cancer;
LUSC	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	1.53	13.65	0.6	5.31e-34	Atopic dermatitis;
LUSC	cis	rs6700896	0.931	rs2154384	chr1:66108517	C/T	cg04111102	chr1:66153794	NA	0.32	7.1	0.36	7.54e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.11	-0.32	2.85e-9	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20174699	chr12:50222232	LOC100286844;NCKAP5L	-0.41	-6.29	-0.33	9.87e-10	Hepatitis;
LUSC	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg05187965	chr10:45406764	TMEM72	0.31	6.77	0.35	5.72e-11	Mean corpuscular volume;
LUSC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg23711669	chr6:146136114	FBXO30	0.71	12.46	0.56	1.54e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg15445000	chr17:37608096	MED1	0.4	6.81	0.35	4.65e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20307385	chr11:47447363	PSMC3	-0.47	-5.98	-0.31	5.64e-9	Subjective well-being;
LUSC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg26441486	chr22:50317300	CRELD2	0.5	7.66	0.39	2.08e-13	Schizophrenia;
LUSC	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-1.23	-39.64	-0.91	2.47e-128	Myeloid white cell count;
LUSC	cis	rs6901250	0.632	rs688961	chr6:117089080	A/T	cg12892004	chr6:117198278	RFX6	0.36	6.63	0.34	1.35e-10	C-reactive protein levels;
LUSC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.62	0.34	1.45e-10	Platelet count;
LUSC	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg13010199	chr12:38710504	ALG10B	0.55	8.48	0.42	7.46e-16	Morning vs. evening chronotype;
LUSC	cis	rs6138458	0.626	rs6132789	chr20:25012809	C/T	cg26195577	chr20:24973756	C20orf3	-0.68	-10.48	-0.5	2.14e-22	Blood protein levels;
LUSC	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.62	-5.74	-0.3	2.07e-8	Narcolepsy;
LUSC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.63	-7.99	-0.4	2.27e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs7760949	0.963	rs1330118	chr6:13921016	C/T	cg27413430	chr6:13925136	RNF182	-0.41	-5.79	-0.3	1.59e-8	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.76	0.39	1.01e-13	Major depressive disorder;
LUSC	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.36	0.53	1.69e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.55e-13	Putamen volume;
LUSC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.39e-22	Alzheimer's disease (late onset);
LUSC	trans	rs1973993	0.934	rs588660	chr1:96886604	G/A	cg10631902	chr5:14652156	NA	0.56	9.46	0.46	5.6e-19	Weight;
LUSC	cis	rs9341808	0.754	rs9341811	chr6:80982701	G/A	cg08355045	chr6:80787529	NA	0.56	9.8	0.47	4.14e-20	Sitting height ratio;
LUSC	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.95	0.48	1.38e-20	Coffee consumption (cups per day);
LUSC	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg07148914	chr20:33460835	GGT7	-0.54	-8.31	-0.41	2.39e-15	Height;
LUSC	cis	rs7215564	0.730	rs2316066	chr17:78659785	A/G	cg09596252	chr17:78655493	RPTOR	0.55	6.05	0.31	3.92e-9	Myopia (pathological);
LUSC	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg14530993	chr4:882597	GAK	-0.71	-7.49	-0.38	6.12e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg12549451	chr6:135224345	NA	-0.35	-5.8	-0.3	1.57e-8	Red blood cell count;
LUSC	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg16989086	chr20:62203971	PRIC285	0.44	6.14	0.32	2.3e-9	Glioblastoma;
LUSC	cis	rs752010	0.695	rs10789408	chr1:42106579	T/C	cg06885757	chr1:42089581	HIVEP3	0.44	8.59	0.43	3.36e-16	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg27398640	chr15:77910606	LINGO1	-0.29	-5.93	-0.31	7.41e-9	Type 2 diabetes;
LUSC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	0.92	15.84	0.66	1.49e-42	Menopause (age at onset);
LUSC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.79	-12.47	-0.56	1.41e-29	Pancreatic cancer;
LUSC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg13319975	chr6:146136371	FBXO30	-0.39	-5.94	-0.31	7.19e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-10.17	-0.49	2.38e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-15.22	-0.64	4.25e-40	Heart rate;
LUSC	cis	rs9584850	0.834	rs7985565	chr13:99113471	C/G	cg07423050	chr13:99094983	FARP1	0.37	6.04	0.31	4.17e-9	Neuroticism;
LUSC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg15445000	chr17:37608096	MED1	-0.4	-6.81	-0.35	4.56e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs12122100	0.689	rs12129419	chr1:146546703	A/G	cg03526459	chr1:146549940	NA	-0.41	-6.73	-0.35	7.59e-11	HIV-1 control;
LUSC	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.57	-5.66	-0.3	3.24e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.36e-13	Type 2 diabetes;
LUSC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg04850211	chr1:228464232	OBSCN	0.35	6.28	0.32	1.07e-9	Diastolic blood pressure;
LUSC	cis	rs4939490	0.639	rs2905517	chr11:60768044	G/A	cg16817237	chr11:60793675	NA	-0.4	-7.75	-0.39	1.13e-13	Multiple sclerosis;
LUSC	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.15	0.45	5.56e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg09904177	chr6:26538194	HMGN4	-0.79	-6.14	-0.32	2.29e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7589342	0.831	rs6714861	chr2:106518893	C/T	cg14210321	chr2:106509881	NCK2	0.56	8.66	0.43	2.03e-16	Addiction;
LUSC	cis	rs2073300	1.000	rs6114144	chr20:23462022	A/T	cg09953122	chr20:23471693	CST8	-0.73	-7.41	-0.38	1.03e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7202877	0.656	rs6564245	chr16:75308899	A/G	cg04384234	chr16:75411784	CFDP1	0.64	8.63	0.43	2.55e-16	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.36	5.89	0.31	9.33e-9	Menopause (age at onset);
LUSC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg07870213	chr5:140052090	DND1	-0.75	-11.13	-0.52	1.11e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg19773385	chr1:10388646	KIF1B	-0.5	-8.68	-0.43	1.82e-16	Hepatocellular carcinoma;
LUSC	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg23992470	chr4:843637	GAK	0.6	6.4	0.33	5.14e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg01884057	chr2:25150051	NA	0.42	9.13	0.45	6.57e-18	Body mass index;
LUSC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg16447950	chr5:562315	NA	-0.58	-7.03	-0.36	1.15e-11	Lung disease severity in cystic fibrosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00366471	chr15:71184982	LRRC49;THAP10	0.46	6.66	0.34	1.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.64	0.57	3.29e-30	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg17366294	chr4:99064904	C4orf37	0.5	8.29	0.41	2.84e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.49	6.14	0.32	2.31e-9	Schizophrenia;
LUSC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg25204440	chr1:209979598	IRF6	0.53	7.08	0.36	8.6e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg04352962	chr1:209979756	IRF6	0.56	6.1	0.32	2.89e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs17095355	1.000	rs11194940	chr10:111742223	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.57	-7.36	-0.37	1.43e-12	Biliary atresia;
LUSC	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.9	-0.35	2.55e-11	Alcohol dependence;
LUSC	cis	rs1018836	0.700	rs12678527	chr8:91527411	T/C	cg16814680	chr8:91681699	NA	-0.73	-11.29	-0.53	2.89e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg17120908	chr11:65337727	SSSCA1	-0.54	-9.3	-0.45	1.9e-18	Bone mineral density;
LUSC	cis	rs9811920	0.809	rs793464	chr3:99626028	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	7.54	0.38	4.55e-13	Axial length;
LUSC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg17333051	chr19:2783644	SGTA	0.49	7.36	0.37	1.46e-12	Total cholesterol levels;
LUSC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.22	-29.5	-0.85	4.95e-95	Chronic sinus infection;
LUSC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.95	15.15	0.64	7.72e-40	Coronary artery disease;
LUSC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	6.99	0.36	1.46e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	trans	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg10756647	chr7:56101905	PSPH	0.85	8.47	0.42	7.94e-16	Gout;
LUSC	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg03929089	chr4:120376271	NA	0.74	6.91	0.35	2.4e-11	Axial length;
LUSC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.29	-0.41	2.71e-15	Obesity-related traits;
LUSC	cis	rs7582720	1.000	rs72926767	chr2:203796814	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.34	0.42	1.98e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.0	0.44	1.77e-17	Motion sickness;
LUSC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg10018233	chr7:150070692	REPIN1	0.36	6.19	0.32	1.77e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6426558	0.537	rs498020	chr1:227304180	G/A	cg10327440	chr1:227177885	CDC42BPA	0.54	7.39	0.37	1.18e-12	Neutrophil percentage of white cells;
LUSC	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.44	6.67	0.34	1.05e-10	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13763308	chr10:75910788	AP3M1;ADK	-0.5	-7.03	-0.36	1.16e-11	Electrocardiographic conduction measures;
LUSC	trans	rs7849782	1.000	rs7849782	chr9:104427264	C/G	cg22914338	chr19:14376960	NA	-0.25	-6.11	-0.32	2.82e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	1.04	19.29	0.73	2.97e-56	Menopause (age at onset);
LUSC	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg05966235	chr16:28915196	ATP2A1	0.32	5.71	0.3	2.51e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-11.11	-0.52	1.32e-24	Heart rate;
LUSC	cis	rs7106204	0.764	rs79362440	chr11:24212972	G/A	ch.11.24196551F	chr11:24239977	NA	0.89	7.48	0.38	6.45e-13	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-0.68	-6.84	-0.35	3.85e-11	Prostate cancer;
LUSC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg22907277	chr7:1156413	C7orf50	0.47	7.22	0.37	3.47e-12	Longevity;Endometriosis;
LUSC	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg09998033	chr7:158218633	PTPRN2	-0.6	-9.67	-0.47	1.16e-19	Obesity-related traits;
LUSC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg15147215	chr3:52552868	STAB1	-0.32	-6.39	-0.33	5.65e-10	Bipolar disorder;
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	0.89	16.3	0.67	2.43e-44	Menarche (age at onset);
LUSC	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg24110177	chr3:50126178	RBM5	-0.51	-7.83	-0.39	6.58e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg17173187	chr15:85201210	NMB	0.38	6.65	0.34	1.21e-10	Schizophrenia;
LUSC	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg11057378	chr10:81107060	PPIF	0.38	6.43	0.33	4.48e-10	Height;
LUSC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.61	-5.96	-0.31	6.44e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.59	-0.46	2.18e-19	Chronic sinus infection;
LUSC	cis	rs7527798	0.571	rs4844611	chr1:207827538	G/C	cg09232269	chr1:207846808	CR1L	-0.3	-6.36	-0.33	6.48e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs140244541	1	rs140244541	chr2:203808532	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.65	6.91	0.35	2.42e-11	LDL cholesterol;
LUSC	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg03929089	chr4:120376271	NA	0.61	6.6	0.34	1.65e-10	Axial length;
LUSC	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg22676075	chr6:135203613	NA	-0.65	-10.24	-0.49	1.41e-21	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9549260	0.632	rs7323267	chr13:41204015	A/G	cg21288729	chr13:41239152	FOXO1	0.58	6.66	0.34	1.15e-10	Red blood cell count;
LUSC	cis	rs9928842	0.722	rs1035540	chr16:75278795	A/G	cg09066997	chr16:75300724	BCAR1	0.51	6.54	0.34	2.31e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg21699342	chr2:239360505	ASB1	0.56	10.54	0.5	1.28e-22	Multiple system atrophy;
LUSC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg08847533	chr14:75593920	NEK9	-0.82	-15.13	-0.64	9.25e-40	Height;
LUSC	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg05925327	chr15:68127851	NA	0.39	6.08	0.32	3.35e-9	Restless legs syndrome;
LUSC	trans	rs2708977	0.665	rs772173	chr2:97000396	C/T	cg10782065	chr14:60823282	NA	0.37	6.17	0.32	1.94e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.69	11.38	0.53	1.46e-25	Cognitive function;
LUSC	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.57	-0.38	3.6e-13	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs2018683	0.523	rs886834	chr7:29021336	G/A	cg19402173	chr7:128379420	CALU	-0.46	-6.86	-0.35	3.31e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.46	6.92	0.35	2.35e-11	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	1.03	19.13	0.72	1.36e-55	Menopause (age at onset);
LUSC	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg20703242	chr1:230279135	GALNT2	-0.63	-8.76	-0.43	1.03e-16	Coronary artery disease;
LUSC	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg09184832	chr6:79620586	NA	-0.44	-7.24	-0.37	3.16e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg26924012	chr15:45694286	SPATA5L1	1.13	20.62	0.75	1.62e-61	Homoarginine levels;
LUSC	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg25482853	chr8:67687455	SGK3	1.19	19.12	0.72	1.43e-55	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg05855489	chr10:104503620	C10orf26	-0.69	-10.18	-0.49	2.31e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg15445000	chr17:37608096	MED1	0.4	6.89	0.35	2.83e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg05313129	chr8:58192883	C8orf71	-0.49	-6.72	-0.35	7.96e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7178572	0.633	rs4886877	chr15:77838535	C/G	cg22256960	chr15:77711686	NA	-0.47	-7.04	-0.36	1.11e-11	Type 2 diabetes;
LUSC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg19230755	chr7:65878503	NA	-0.43	-6.02	-0.31	4.48e-9	Aortic root size;
LUSC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg06363034	chr20:62225388	GMEB2	-0.46	-7.73	-0.39	1.32e-13	Glioblastoma;
LUSC	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg13010199	chr12:38710504	ALG10B	-0.49	-7.55	-0.38	4.18e-13	Morning vs. evening chronotype;
LUSC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20307385	chr11:47447363	PSMC3	-0.45	-5.97	-0.31	6.18e-9	Subjective well-being;
LUSC	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg25258033	chr6:167368657	RNASET2	0.39	5.76	0.3	1.94e-8	Primary biliary cholangitis;
LUSC	trans	rs2926702	0.810	rs2958370	chr8:71082718	A/G	cg16517358	chr11:46164796	NA	-0.4	-6.04	-0.31	4.09e-9	Non-small cell lung cancer;
LUSC	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg20701182	chr2:24300061	SF3B14	0.78	7.8	0.39	7.8500000000000006e-14	Lymphocyte counts;
LUSC	cis	rs7180079	0.620	rs500641	chr15:64851132	C/T	cg08069370	chr15:64387884	SNX1	0.51	5.74	0.3	2.13e-8	Monocyte count;
LUSC	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.34	-0.46	1.42e-18	Extrinsic epigenetic age acceleration;
LUSC	trans	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.69	-0.39	1.71e-13	Morning vs. evening chronotype;
LUSC	cis	rs7927771	0.507	rs11039432	chr11:47873327	G/A	cg20307385	chr11:47447363	PSMC3	0.46	6.76	0.35	6.07e-11	Subjective well-being;
LUSC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg26659404	chr1:25747437	RHCE	0.28	5.82	0.3	1.37e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs2617583	0.509	rs2937650	chr5:1458018	C/T	cg13982541	chr5:1466431	LPCAT1	-0.44	-6.46	-0.33	3.77e-10	Breast cancer;
LUSC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg23711669	chr6:146136114	FBXO30	0.8	14.41	0.62	6.03e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.56	7.42	0.38	9.68e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.61	-0.6	7.34e-34	Chronic sinus infection;
LUSC	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.83	-0.3	1.33e-8	Ileal carcinoids;
LUSC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg12564285	chr5:131593104	PDLIM4	0.45	8.72	0.43	1.31e-16	Blood metabolite levels;
LUSC	cis	rs2637266	0.935	rs2583058	chr10:78396018	T/A	cg18941641	chr10:78392320	NA	0.42	7.51	0.38	5.51e-13	Pulmonary function;
LUSC	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg18755752	chr8:142205143	DENND3	-0.52	-6.93	-0.35	2.22e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg06819704	chr5:159707559	CCNJL	0.54	6.22	0.32	1.45e-9	Schizophrenia;
LUSC	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-6.48	-0.33	3.26e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg11502198	chr6:26597334	ABT1	0.69	11.4	0.53	1.22e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.52	10.43	0.5	3.07e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs9928842	0.824	rs889515	chr16:75251299	T/C	cg09066997	chr16:75300724	BCAR1	0.54	6.4	0.33	5.34e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg15423357	chr2:25149977	NA	0.45	9.03	0.44	1.37e-17	Body mass index;
LUSC	cis	rs4704187	0.617	rs6898134	chr5:74456731	T/C	cg03227963	chr5:74354835	NA	0.31	6.86	0.35	3.34e-11	Response to amphetamines;
LUSC	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.71	-0.34	8.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-7.71	-0.39	1.43e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2224391	1.000	rs9784870	chr6:5261359	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.51	-7.33	-0.37	1.7e-12	Height;
LUSC	cis	rs6977660	0.714	rs13230381	chr7:19833896	T/C	cg07541023	chr7:19748670	TWISTNB	0.59	6.16	0.32	2.05e-9	Thyroid stimulating hormone;
LUSC	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg05110241	chr16:68378359	PRMT7	-0.83	-8.92	-0.44	3.09e-17	Magnesium levels;
LUSC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg11752832	chr7:134001865	SLC35B4	0.51	7.75	0.39	1.09e-13	Mean platelet volume;
LUSC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.69	0.39	1.71e-13	Electroencephalogram traits;
LUSC	cis	rs79387448	0.701	rs3752659	chr2:103001598	A/G	cg09003973	chr2:102972529	NA	0.98	10.07	0.48	5.28e-21	Gut microbiota (bacterial taxa);
LUSC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-12.0	-0.55	8.12e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07157834	chr1:205819609	PM20D1	-0.73	-13.65	-0.6	5.16e-34	Monocyte percentage of white cells;
LUSC	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.07	-0.36	8.87e-12	Schizophrenia;
LUSC	cis	rs7569084	1.000	rs7569084	chr2:65656969	C/T	cg08085232	chr2:65598271	SPRED2	0.38	5.8	0.3	1.52e-8	Sum eosinophil basophil counts;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg16031515	chr1:205743344	RAB7L1	-0.28	-6.11	-0.32	2.76e-9	Menarche (age at onset);
LUSC	trans	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg03886242	chr7:26192032	NFE2L3	0.37	6.25	0.32	1.22e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg22709100	chr7:91322751	NA	-0.4	-5.84	-0.3	1.21e-8	Breast cancer;
LUSC	cis	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.35	-0.33	6.93e-10	Morning vs. evening chronotype;
LUSC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg21285383	chr16:89894308	SPIRE2	0.36	7.85	0.39	5.77e-14	Vitiligo;
LUSC	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.08	0.52	1.71e-24	Hypertriglyceridemia;
LUSC	cis	rs136211	0.640	rs9306310	chr22:36758258	G/A	cg10790723	chr22:36903033	FOXRED2	0.4	5.86	0.31	1.1e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg17971929	chr21:40555470	PSMG1	-0.63	-10.39	-0.49	4.14e-22	Cognitive function;
LUSC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03060546	chr3:49711283	APEH	0.67	7.7	0.39	1.51e-13	Menarche (age at onset);
LUSC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.88	0.35	2.95e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.08	-0.4	1.18e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7980799	0.967	rs7971226	chr12:33586881	C/T	cg26384229	chr12:38710491	ALG10B	0.45	6.6	0.34	1.65e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg11645453	chr3:52864694	ITIH4	0.59	14.12	0.61	8.31e-36	Schizophrenia;
LUSC	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg09163369	chr1:210001066	C1orf107	0.59	6.86	0.35	3.28e-11	Orofacial clefts;
LUSC	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.92	12.01	0.55	7.51e-28	Menarche (age at onset);
LUSC	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.47	8.42	0.42	1.16e-15	Obesity-related traits;
LUSC	cis	rs701145	0.938	rs242117	chr3:154026467	T/C	cg17054900	chr3:154042577	DHX36	0.84	8.6	0.43	3.25e-16	Coronary artery disease;
LUSC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.48	6.48	0.33	3.21e-10	Renal function-related traits (BUN);
LUSC	trans	rs1998174	0.527	rs6685974	chr1:171837604	C/G	cg13482142	chr2:234261155	NA	0.42	6.13	0.32	2.44e-9	Platelet distribution width;
LUSC	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-7.63	-0.39	2.54e-13	Schizophrenia;
LUSC	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-8.15	-0.41	7.24e-15	Breast cancer;
LUSC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg20203395	chr5:56204925	C5orf35	-0.46	-6.87	-0.35	3.14e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg02569458	chr12:86230093	RASSF9	0.52	8.66	0.43	2.05e-16	Major depressive disorder;
LUSC	cis	rs9815354	0.767	rs115702638	chr3:42058594	C/T	cg03022575	chr3:42003672	ULK4	0.59	6.33	0.33	8.03e-10	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.51	-0.34	2.8e-10	Neuroticism;
LUSC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg25258033	chr6:167368657	RNASET2	0.45	6.87	0.35	3.17e-11	Rheumatoid arthritis;
LUSC	cis	rs12928939	0.815	rs11648483	chr16:71707398	T/C	cg03805757	chr16:71968109	PKD1L3	-0.39	-5.7	-0.3	2.68e-8	Post bronchodilator FEV1;
LUSC	trans	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.6	0.38	3.08e-13	Ulcerative colitis;
LUSC	cis	rs7582720	0.943	rs72932556	chr2:203845996	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.35	0.42	1.88e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg08132940	chr7:1081526	C7orf50	-0.51	-5.93	-0.31	7.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6785206	0.667	rs6439139	chr3:128410285	T/C	cg16766828	chr3:128327626	NA	-0.69	-7.62	-0.38	2.58e-13	Lymphocyte percentage of white cells;
LUSC	cis	rs2637266	0.935	rs1978927	chr10:78399786	A/T	cg18941641	chr10:78392320	NA	0.42	7.75	0.39	1.1e-13	Pulmonary function;
LUSC	cis	rs6460942	0.591	rs4721078	chr7:12334657	T/A	cg06484146	chr7:12443880	VWDE	-0.56	-5.89	-0.31	9.39e-9	Coronary artery disease;
LUSC	cis	rs3740713	1.000	rs73440615	chr11:18467283	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.57	-6.8	-0.35	4.8e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg27165867	chr14:105738592	BRF1	-0.54	-7.62	-0.39	2.57e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg03585969	chr10:35415529	CREM	0.6	8.76	0.43	9.64e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11039100	0.850	rs12363853	chr11:5830163	G/A	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.67	0.43	1.92e-16	Cognitive test performance;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12767885	chr10:134350658	INPP5A	0.64	6.02	0.31	4.57e-9	Cognitive performance;
LUSC	cis	rs10986311	0.775	rs10986324	chr9:127121825	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.43	6.82	0.35	4.41e-11	Vitiligo;
LUSC	cis	rs897984	0.574	rs11647284	chr16:31077335	G/A	cg02466173	chr16:30829666	NA	-0.48	-8.94	-0.44	2.8e-17	Dementia with Lewy bodies;
LUSC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	11.49	0.53	5.77e-26	Tonsillectomy;
LUSC	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	0.87	17.44	0.69	7.17e-49	Ulcerative colitis;
LUSC	cis	rs9650315	0.733	rs11988714	chr8:57205891	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	-0.52	-6.76	-0.35	6.01e-11	Height;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21561596	chr19:36239797	LIN37	0.41	5.96	0.31	6.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13089785	1.000	rs2271969	chr3:123650432	A/G	cg19611163	chr3:123411211	MYLK	0.34	5.89	0.31	9.17e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	8.49	0.42	7.03e-16	Type 2 diabetes;
LUSC	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	6.66	0.34	1.13e-10	Lung cancer in ever smokers;
LUSC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg06263672	chr7:65235340	NA	0.41	5.93	0.31	7.57e-9	Calcium levels;
LUSC	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.11	0.32	2.77e-9	Neuroticism;
LUSC	cis	rs1538970	0.962	rs2153607	chr1:45813820	G/A	cg05343316	chr1:45956843	TESK2	0.59	8.23	0.41	4.24e-15	Platelet count;
LUSC	trans	rs236907	0.859	rs2223602	chr1:171781735	C/T	cg13482142	chr2:234261155	NA	0.51	6.21	0.32	1.61e-9	Mean platelet volume;
LUSC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23521916	chr3:48754752	IP6K2	0.55	6.18	0.32	1.9e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg10326726	chr10:51549505	MSMB	0.35	6.09	0.32	3.14e-9	Prostate-specific antigen levels;
LUSC	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	6.65	0.34	1.22e-10	Resting heart rate;
LUSC	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg18477163	chr1:228402036	OBSCN	-0.52	-9.15	-0.45	5.8e-18	Diastolic blood pressure;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg21936775	chr1:153607143	C1orf77;S100A13	0.44	6.73	0.35	7.46e-11	Triglycerides;
LUSC	cis	rs1440410	0.835	rs7684847	chr4:144054567	C/T	cg01719995	chr4:144104893	USP38	0.33	5.82	0.3	1.36e-8	Ischemic stroke;
LUSC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.68	11.58	0.54	2.7e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg03684893	chr10:554711	DIP2C	-0.45	-8.36	-0.42	1.77e-15	Psychosis in Alzheimer's disease;
LUSC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.44	-6.08	-0.32	3.38e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.36	-0.33	6.81e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg10645314	chr2:3704589	ALLC	0.33	5.74	0.3	2.11e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg18350739	chr11:68623251	NA	-0.39	-6.78	-0.35	5.47e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.69	-0.43	1.66e-16	Body mass index;
LUSC	cis	rs3833788	1	rs3833788	chr12:121151062	CTCTCTTG/C	cg27246729	chr12:121163418	ACADS	0.47	7.53	0.38	4.89e-13	Mean corpuscular hemoglobin;
LUSC	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-1.14	-18.24	-0.71	4.67e-52	Exhaled nitric oxide output;
LUSC	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg19052272	chr2:3704530	ALLC	-0.46	-7.56	-0.38	4.04e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg17507749	chr15:85114479	UBE2QP1	0.59	7.51	0.38	5.37e-13	Schizophrenia;
LUSC	cis	rs314370	1.000	rs10278546	chr7:100516003	G/T	cg10426581	chr7:100472382	SRRT	-0.7	-9.64	-0.47	1.41e-19	Resting heart rate;
LUSC	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg13575925	chr12:9217583	LOC144571	0.34	6.22	0.32	1.46e-9	Sjögren's syndrome;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21904595	chr2:61991516	NA	0.44	6.27	0.32	1.09e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg18758796	chr5:131593413	PDLIM4	0.43	7.31	0.37	2.05e-12	Blood metabolite levels;
LUSC	cis	rs2455601	1.000	rs56336128	chr11:8908299	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.6	-0.34	1.58e-10	Schizophrenia;
LUSC	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.74	14.58	0.62	1.34e-37	Metabolite levels;
LUSC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg25767906	chr1:53392781	SCP2	-0.36	-6.1	-0.32	2.89e-9	Monocyte count;
LUSC	cis	rs2249625	0.508	rs60020363	chr6:72844706	C/T	cg18830697	chr6:72922368	RIMS1	0.38	7.59	0.38	3.18e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg02972257	chr16:68554789	NA	0.45	5.94	0.31	7.05e-9	Colorectal cancer;
LUSC	cis	rs9311676	0.656	rs4339119	chr3:58389462	A/G	cg26110898	chr3:58419937	PDHB	0.4	6.49	0.33	3.05e-10	Systemic lupus erythematosus;
LUSC	cis	rs76878669	0.561	rs10896112	chr11:66116836	G/C	cg18002602	chr11:66138449	SLC29A2	-0.48	-8.43	-0.42	1.07e-15	Educational attainment (years of education);
LUSC	cis	rs9311676	0.632	rs11130642	chr3:58420042	C/T	cg13750441	chr3:58318267	PXK	0.35	6.83	0.35	4.14e-11	Systemic lupus erythematosus;
LUSC	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg08645402	chr16:4508243	NA	0.54	9.26	0.45	2.61e-18	Schizophrenia;
LUSC	cis	rs7122539	0.734	rs4930391	chr11:66645254	A/G	cg18002602	chr11:66138449	SLC29A2	0.33	5.88	0.31	9.72e-9	HIV-1 susceptibility;
LUSC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg18240062	chr17:79603768	NPLOC4	0.58	10.02	0.48	7.82e-21	Eye color traits;
LUSC	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	0.69	11.06	0.52	1.87e-24	Blood metabolite ratios;
LUSC	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg24069376	chr3:38537580	EXOG	-0.38	-7.46	-0.38	7.49e-13	Electrocardiographic conduction measures;
LUSC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg13206674	chr6:150067644	NUP43	0.54	8.33	0.41	2.15e-15	Lung cancer;
LUSC	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-10.61	-0.5	7.21e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg23630131	chr7:65973040	NA	0.2	5.71	0.3	2.54e-8	Aortic root size;
LUSC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg08847533	chr14:75593920	NEK9	-0.82	-14.74	-0.63	3.15e-38	Height;
LUSC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg17366294	chr4:99064904	C4orf37	-0.57	-10.1	-0.48	4.21e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg18904891	chr8:8559673	CLDN23	0.6	8.13	0.41	8.6e-15	Obesity-related traits;
LUSC	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg15412446	chr2:106886593	NA	-0.5	-6.22	-0.32	1.47e-9	Facial morphology (factor 23);
LUSC	cis	rs3791556	1.000	rs3791556	chr2:240112972	G/A	cg03281426	chr2:240109471	HDAC4	0.49	5.93	0.31	7.53e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs859767	0.501	rs1568121	chr2:135406606	G/A	cg12500956	chr2:135428796	TMEM163	-0.27	-6.29	-0.33	9.76e-10	Neuroticism;
LUSC	cis	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg17469321	chr7:55412551	NA	0.66	10.63	0.5	6.09e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg21095983	chr6:86352623	SYNCRIP	0.53	8.46	0.42	8.29e-16	Smooth-surface caries;
LUSC	cis	rs10986311	0.775	rs6478658	chr9:127127810	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.44	-7.21	-0.37	3.7e-12	Vitiligo;
LUSC	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg11657440	chr19:46296263	DMWD	0.87	16.29	0.67	2.48e-44	Coronary artery disease;
LUSC	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg23241863	chr10:102295624	HIF1AN	0.46	5.76	0.3	1.92e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.46	0.38	7.73e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7106204	0.514	rs1596280	chr11:24250853	T/C	ch.11.24196551F	chr11:24239977	NA	0.91	10.09	0.48	4.56e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs4947962	0.617	rs729969	chr7:55128207	C/T	cg23757825	chr7:55092271	EGFR	-0.51	-6.35	-0.33	6.97e-10	Subjective response to lithium treatment;
LUSC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg16339924	chr4:17578868	LAP3	0.64	10.13	0.48	3.35e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.69	-0.43	1.66e-16	Response to antipsychotic treatment;
LUSC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.24	0.52	4.48e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg10623288	chr13:32421051	EEF1DP3	0.48	6.23	0.32	1.4e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	11.75	0.54	6.26e-27	Alzheimer's disease;
LUSC	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg19773385	chr1:10388646	KIF1B	0.53	9.08	0.44	9.77e-18	Hepatocellular carcinoma;
LUSC	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg06740227	chr12:86229804	RASSF9	0.36	5.75	0.3	2.04e-8	Major depressive disorder;
LUSC	cis	rs4285028	0.747	rs3772126	chr3:121354583	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-12.78	-0.57	1.0500000000000001e-30	Multiple sclerosis;
LUSC	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.26	-0.41	3.35e-15	Total cholesterol levels;
LUSC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.88	18.29	0.71	2.92e-52	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.7	0.3	2.64e-8	Menopause (age at onset);
LUSC	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg13813247	chr22:41461852	NA	-0.34	-6.35	-0.33	7.09e-10	Neuroticism;
LUSC	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg24375607	chr4:120327624	NA	0.75	12.08	0.55	4.2e-28	Corneal astigmatism;
LUSC	trans	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.3	-0.33	9.17e-10	Bladder cancer;
LUSC	cis	rs467650	0.509	rs2545678	chr5:98000368	T/A	cg03885343	chr5:98108198	RGMB	0.31	5.84	0.3	1.27e-8	Venous thromboembolism (SNP x SNP interaction);
LUSC	trans	rs4729127	1.000	rs17166206	chr7:94004197	C/T	cg20086523	chr13:52378287	DHRS12	0.56	6.38	0.33	6.03e-10	Intelligence;
LUSC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg03161606	chr19:29218774	NA	0.61	9.03	0.44	1.38e-17	Methadone dose in opioid dependence;
LUSC	cis	rs4654899	0.833	rs3816454	chr1:21191416	T/G	cg01072550	chr1:21505969	NA	0.45	6.61	0.34	1.57e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6700896	0.966	rs1938485	chr1:66082084	A/G	cg04111102	chr1:66153794	NA	0.31	6.92	0.35	2.3e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg12002119	chr2:101014098	CHST10	0.35	5.8	0.3	1.53e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg09307838	chr4:120376055	NA	0.48	7.2	0.37	4.07e-12	Diastolic blood pressure;
LUSC	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg17054900	chr3:154042577	DHX36	0.44	5.76	0.3	1.95e-8	Coronary artery disease;
LUSC	cis	rs7804356	1.000	rs13438514	chr7:26860688	C/T	cg03456212	chr7:26904342	SKAP2	-0.52	-6.1	-0.32	2.92e-9	Type 1 diabetes;
LUSC	cis	rs1375194	0.509	rs62150473	chr2:33822320	G/A	cg04131969	chr2:33951647	MYADML	-0.63	-8.81	-0.43	6.8e-17	Response to antidepressants in depression;
LUSC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg05973401	chr12:123451056	ABCB9	0.62	9.24	0.45	2.85e-18	Platelet count;
LUSC	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-10.84	-0.51	1.16e-23	Coffee consumption (cups per day);
LUSC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.7	0.51	3.46e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs394563	0.601	rs439495	chr6:149793224	A/G	cg07828024	chr6:149772892	ZC3H12D	0.4	7.99	0.4	2.24e-14	Dupuytren's disease;
LUSC	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg11342453	chr6:26196699	NA	0.55	5.78	0.3	1.7e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg11905131	chr22:24372483	LOC391322	-0.58	-9.66	-0.47	1.27e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg19023700	chr7:131012349	MKLN1	0.41	6.35	0.33	6.88e-10	Triglycerides;
LUSC	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	trans	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg10756647	chr7:56101905	PSPH	0.87	8.84	0.44	5.54e-17	Diabetic kidney disease;
LUSC	trans	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.94	0.55	1.29e-27	Exhaled nitric oxide output;
LUSC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.76	-10.62	-0.5	7.07e-23	Gut microbiome composition (summer);
LUSC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21862992	chr11:68658383	NA	0.51	7.94	0.4	3.06e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6669919	0.553	rs12568639	chr1:211675300	G/A	cg10512769	chr1:211675356	NA	-0.29	-6.88	-0.35	3e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg24558204	chr6:135376177	HBS1L	0.57	8.77	0.43	9.11e-17	Red blood cell count;
LUSC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg08132940	chr7:1081526	C7orf50	-0.52	-6.25	-0.32	1.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg06223162	chr1:101003688	GPR88	0.49	9.44	0.46	6.6e-19	Monocyte count;
LUSC	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-8.3	-0.41	2.54e-15	Crohn's disease;
LUSC	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg08000102	chr2:233561755	GIGYF2	0.69	11.52	0.53	4.47e-26	Coronary artery disease;
LUSC	cis	rs7119	0.717	rs62009070	chr15:77817884	G/C	cg27398640	chr15:77910606	LINGO1	-0.31	-6.48	-0.33	3.3e-10	Type 2 diabetes;
LUSC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg18825076	chr15:78729989	IREB2	-0.6	-9.81	-0.47	3.86e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.45	5.73	0.3	2.23e-8	Schizophrenia;
LUSC	cis	rs9462027	0.628	rs7771778	chr6:34660324	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.35	6.26	0.32	1.19e-9	Systemic lupus erythematosus;
LUSC	cis	rs500891	0.525	rs750386	chr6:84030692	G/A	cg08257003	chr6:84140564	ME1	0.31	6.88	0.35	2.88e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs7149337	0.805	rs4350491	chr14:51675798	A/G	cg23942311	chr14:51606299	NA	0.48	10.63	0.5	6.41e-23	Cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02841941	chr3:152552615	P2RY1	0.46	6.41	0.33	4.86e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1461503	0.966	rs1461501	chr11:122844416	A/G	cg27398637	chr11:122830231	C11orf63	-0.41	-6.54	-0.34	2.29e-10	Menarche (age at onset);
LUSC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg02951883	chr7:2050386	MAD1L1	-0.52	-9.07	-0.44	1e-17	Bipolar disorder and schizophrenia;
LUSC	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg15704280	chr7:45808275	SEPT13	-0.43	-5.98	-0.31	5.63e-9	HDL cholesterol;
LUSC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg06618935	chr21:46677482	NA	-0.39	-7.79	-0.39	8.32e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.72	-10.3	-0.49	8.47e-22	Cognitive test performance;
LUSC	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	1.18	13.92	0.61	4.83e-35	Arsenic metabolism;
LUSC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-0.59	-12.38	-0.56	3.2e-29	Obesity-related traits;
LUSC	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg21775007	chr8:11205619	TDH	0.83	13.73	0.6	2.58e-34	Retinal vascular caliber;
LUSC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.69	0.39	1.63e-13	Prudent dietary pattern;
LUSC	cis	rs9925964	0.967	rs1978487	chr16:31129942	C/T	cg03418659	chr16:31128414	MYST1	-0.39	-6.17	-0.32	2e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg21132104	chr15:45694354	SPATA5L1	0.57	7.97	0.4	2.54e-14	Homoarginine levels;
LUSC	trans	rs1325195	0.520	rs2783389	chr1:179228396	G/A	cg11624085	chr17:8464688	MYH10	0.45	6.89	0.35	2.77e-11	IgE grass sensitization;
LUSC	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	6.9	0.35	2.56e-11	Rheumatoid arthritis;
LUSC	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg24692254	chr21:30365293	RNF160	-0.54	-7.87	-0.4	5.06e-14	Dental caries;
LUSC	cis	rs2548003	0.518	rs1833823	chr5:28741723	A/G	cg22863700	chr5:28928346	NA	0.47	6.49	0.33	3.1e-10	Hip geometry;
LUSC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg06462663	chr19:18546047	ISYNA1	0.46	7.85	0.39	5.53e-14	Breast cancer;
LUSC	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg17376030	chr22:41985996	PMM1	-0.43	-5.67	-0.3	3.01e-8	Vitiligo;
LUSC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.83	11.47	0.53	6.46e-26	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7131987	0.650	rs7954871	chr12:29459732	G/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.72	-0.34	7.98e-11	QT interval;
LUSC	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.57e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6599077	1.000	rs9822101	chr3:40095554	C/A	cg13683864	chr3:40499215	RPL14	-0.6	-7.66	-0.39	2.06e-13	Sleep-related phenotypes;
LUSC	trans	rs12439619	0.530	rs7162177	chr15:82474069	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.49	-7.86	-0.4	5.19e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs8099014	1.000	rs1806761	chr18:56132499	A/C	cg12907477	chr18:56117327	MIR122	0.42	6.38	0.33	5.83e-10	Platelet count;
LUSC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07918776	chr15:49170303	SHC4;EID1	-0.39	-6.26	-0.32	1.21e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	15.01	0.63	2.83e-39	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg11984989	chr7:158649758	WDR60	0.96	19.64	0.73	1.2e-57	Height;
LUSC	cis	rs9815354	0.597	rs59432762	chr3:41812294	G/C	cg03022575	chr3:42003672	ULK4	0.85	8.67	0.43	1.87e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs888194	0.544	rs2196612	chr12:109849535	A/G	cg19025524	chr12:109796872	NA	-0.34	-5.85	-0.3	1.2e-8	Neuroticism;
LUSC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.71	12.23	0.56	1.14e-28	Heart rate;
LUSC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10862848	chr6:42927986	GNMT	-0.28	-6.9	-0.35	2.69e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg00631329	chr6:26305371	NA	0.34	5.92	0.31	7.93e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg15711740	chr2:61764176	XPO1	-0.5	-7.94	-0.4	3.11e-14	Tuberculosis;
LUSC	cis	rs9807841	0.592	rs10407349	chr19:10758453	G/A	cg17710535	chr19:10819994	QTRT1	0.42	6.8	0.35	4.91e-11	Inflammatory skin disease;
LUSC	cis	rs16854884	0.586	rs4613453	chr3:143735600	C/G	cg06585982	chr3:143692056	C3orf58	0.51	8.17	0.41	6.38e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06481639	chr22:41940642	POLR3H	0.48	5.87	0.31	1.05e-8	Vitiligo;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24113505	chr7:92861286	CCDC132	0.37	6.18	0.32	1.83e-9	Triglycerides;
LUSC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg05313129	chr8:58192883	C8orf71	-0.51	-6.64	-0.34	1.26e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg21545522	chr1:205238299	TMCC2	0.47	8.6	0.43	3.09e-16	Red blood cell count;
LUSC	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.34	6.14	0.32	2.31e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg26384229	chr12:38710491	ALG10B	0.73	11.93	0.55	1.42e-27	Morning vs. evening chronotype;
LUSC	cis	rs2230307	0.536	rs6677998	chr1:100461046	G/A	cg24955406	chr1:100503596	HIAT1	0.56	6.04	0.31	4.01e-9	Carotid intima media thickness;
LUSC	cis	rs2729354	0.729	rs2581923	chr11:57249991	C/T	cg24343310	chr11:57249947	NA	0.44	8.5	0.42	6.55e-16	Blood protein levels;
LUSC	cis	rs6469656	0.772	rs2118108	chr8:117654773	G/T	cg24004040	chr8:117650383	NA	-0.43	-6.33	-0.33	8.11e-10	Colorectal cancer;
LUSC	cis	rs2274273	0.840	rs10467798	chr14:55724927	C/T	cg04306507	chr14:55594613	LGALS3	0.56	13.15	0.58	3.92e-32	Protein biomarker;
LUSC	cis	rs713477	0.967	rs10483642	chr14:55920460	A/G	cg13175173	chr14:55914753	NA	0.29	6.11	0.32	2.7e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.3	-0.49	8.95e-22	Eye color traits;
LUSC	cis	rs2108225	0.872	rs6980029	chr7:107446127	T/C	cg18560240	chr7:107437656	SLC26A3	-0.44	-6.53	-0.34	2.42e-10	Ulcerative colitis;
LUSC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg23625390	chr15:77176239	SCAPER	0.51	7.77	0.39	9.83e-14	Blood metabolite levels;
LUSC	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.31	-0.33	8.83e-10	Alcohol dependence;
LUSC	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg27284194	chr4:1044797	NA	0.6	9.01	0.44	1.61e-17	Recombination rate (females);
LUSC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.17	-0.52	7.89e-25	Mean corpuscular volume;
LUSC	cis	rs62408225	1.000	rs62408222	chr6:90948476	A/G	cg06866423	chr6:90926672	BACH2	0.4	5.75	0.3	2.01e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs870825	0.698	rs72703549	chr4:185623963	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs7833986	1.000	rs34404111	chr8:57099190	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.63	9.35	0.46	1.28e-18	Height;
LUSC	cis	rs6736093	0.932	rs17174697	chr2:112662914	A/G	cg12686935	chr2:112915763	FBLN7	-0.37	-5.83	-0.3	1.34e-8	Coronary artery disease;
LUSC	cis	rs7215564	0.818	rs112155856	chr17:78594573	A/T	cg23238734	chr17:78661607	RPTOR	0.49	6.34	0.33	7.35e-10	Myopia (pathological);
LUSC	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.57	0.34	1.97e-10	Sudden cardiac arrest;
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg12419862	chr22:24373484	LOC391322	-0.95	-17.32	-0.69	1.99e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4751006	0.649	rs76125285	chr10:128779647	C/T	cg05702161	chr10:128779687	DOCK1	-0.79	-6.68	-0.34	9.75e-11	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg26912877	chr1:6305344	HES3	0.43	6.66	0.34	1.14e-10	N-glycan levels;
LUSC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08219700	chr8:58056026	NA	-0.66	-7.87	-0.4	5.15e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7220711	0.967	rs4793022	chr17:41798855	C/G	cg26893861	chr17:41843967	DUSP3	0.43	6.01	0.31	4.8e-9	Bone mineral density (spine);Bone mineral density (hip);
LUSC	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg17366294	chr4:99064904	C4orf37	0.58	10.38	0.49	4.47e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2708377	0.860	rs2600347	chr12:11267880	G/A	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg13206674	chr6:150067644	NUP43	0.62	10.17	0.49	2.43e-21	Lung cancer;
LUSC	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg23711669	chr6:146136114	FBXO30	0.86	15.52	0.65	2.69e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.59	7.83	0.39	6.5e-14	High light scatter reticulocyte count;
LUSC	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg23093090	chr10:104574429	C10orf26	-0.36	-6.85	-0.35	3.49e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-0.99	-14.45	-0.62	4.26e-37	Initial pursuit acceleration;
LUSC	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg04851639	chr8:1020857	NA	-0.38	-7.97	-0.4	2.57e-14	Schizophrenia;
LUSC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg15848620	chr12:58087721	OS9	0.45	5.74	0.3	2.18e-8	Multiple sclerosis;
LUSC	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.56	9.25	0.45	2.81e-18	Myeloid white cell count;
LUSC	cis	rs2857891	0.817	rs2857902	chr11:6980256	C/G	cg04053776	chr11:6947353	ZNF215	0.41	5.69	0.3	2.73e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg23093090	chr10:104574429	C10orf26	-0.35	-6.54	-0.34	2.34e-10	Waist circumference;Hip circumference;
LUSC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06544989	chr22:39130855	UNC84B	0.33	5.67	0.3	3.02e-8	Menopause (age at onset);
LUSC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg00745463	chr17:30367425	LRRC37B	-0.79	-9.22	-0.45	3.42e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.43	6.31	0.33	8.8e-10	Systemic lupus erythematosus;
LUSC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08439880	chr3:133502540	NA	-0.34	-6.04	-0.31	4.09e-9	Iron status biomarkers;
LUSC	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14442939	chr10:27389572	ANKRD26	0.84	9.84	0.47	3.2e-20	Breast cancer;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg18844144	chr14:23528430	ACIN1	-0.38	-6.25	-0.32	1.24e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs3803170	0.513	rs10774623	chr12:111833589	C/T	cg10833066	chr12:111807467	FAM109A	-0.39	-7.32	-0.37	1.9e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs7188861	0.681	rs34947566	chr16:11412926	C/A	cg00044050	chr16:11439710	C16orf75	0.59	6.08	0.32	3.22e-9	HDL cholesterol;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.3	-5.69	-0.3	2.85e-8	Lymphocyte counts;
LUSC	trans	rs12043259	0.730	rs12044625	chr1:204794737	T/G	cg05134015	chr14:36973365	SFTA3	-0.5	-6.04	-0.31	4.05e-9	Addiction;
LUSC	cis	rs41271473	1.000	rs11583565	chr1:228880135	C/T	cg10167378	chr1:228756711	NA	0.54	6.59	0.34	1.72e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg17279839	chr7:150038598	RARRES2	0.39	5.86	0.31	1.12e-8	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs4729127	1.000	rs12665908	chr7:94010770	T/C	cg20086523	chr13:52378287	DHRS12	0.54	6.31	0.33	9.11e-10	Intelligence;
LUSC	cis	rs3784262	0.904	rs12901462	chr15:58316487	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-5.93	-0.31	7.5e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08038078	chr1:160002094	PIGM	0.44	6.36	0.33	6.62e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.15	0.41	7.55e-15	Myopia (pathological);
LUSC	trans	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg24562669	chr7:97807699	LMTK2	0.36	6.29	0.33	9.85e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg12292205	chr6:26970375	C6orf41	0.41	6.18	0.32	1.88e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg26647111	chr11:31128758	NA	-0.4	-5.75	-0.3	1.99e-8	Red blood cell count;
LUSC	trans	rs75804782	0.641	rs72985397	chr2:239341354	A/G	cg01134436	chr17:81009848	B3GNTL1	0.63	6.13	0.32	2.55e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg06784218	chr1:46089804	CCDC17	0.48	9.63	0.47	1.62e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6840360	0.837	rs13137669	chr4:152710943	A/G	cg22705602	chr4:152727874	NA	-0.27	-5.9	-0.31	8.98e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg04414720	chr1:150670196	GOLPH3L	0.51	8.11	0.41	9.78e-15	Melanoma;
LUSC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.21	-0.32	1.57e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9398803	0.865	rs1538171	chr6:126752884	C/G	cg19875578	chr6:126661172	C6orf173	0.41	5.96	0.31	6.26e-9	Male-pattern baldness;
LUSC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.54	-8.93	-0.44	3.01e-17	Longevity;Endometriosis;
LUSC	trans	rs984440	0.524	rs6577869	chr8:139083777	C/A	cg03334052	chr1:168888044	NA	0.39	6.47	0.33	3.52e-10	Obesity-related traits;
LUSC	cis	rs7598759	0.712	rs6727510	chr2:232332016	T/C	cg19187155	chr2:232395269	NMUR1	0.49	7.2	0.37	3.96e-12	Noise-induced hearing loss;
LUSC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.39	0.42	1.36e-15	Lung cancer;
LUSC	cis	rs1009647	0.529	rs56098354	chr14:55668170	G/T	cg04306507	chr14:55594613	LGALS3	0.45	6.12	0.32	2.67e-9	Testicular germ cell tumor;
LUSC	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg23649088	chr2:200775458	C2orf69	0.51	6.94	0.35	2.05e-11	Schizophrenia;
LUSC	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg09307838	chr4:120376055	NA	0.64	9.64	0.47	1.4e-19	Corneal astigmatism;
LUSC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	12.66	0.57	2.91e-30	Menopause (age at onset);
LUSC	cis	rs7712401	0.791	rs1870559	chr5:122116706	G/C	cg19077854	chr5:122220652	SNX24	0.35	7.87	0.4	5.01e-14	Mean platelet volume;
LUSC	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg13010199	chr12:38710504	ALG10B	0.62	9.14	0.45	6.27e-18	Heart rate;
LUSC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.84	-12.91	-0.58	3.37e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg25643088	chr3:52874325	TMEM110	0.39	5.78	0.3	1.71e-8	Schizophrenia;
LUSC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.11	0.41	9.88e-15	Cognitive test performance;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10150615	chr22:24372951	LOC391322	-0.34	-5.88	-0.31	9.96e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg03465714	chr1:152285911	FLG	0.4	5.72	0.3	2.34e-8	Atopic dermatitis;
LUSC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.6	-0.6	7.64e-34	Initial pursuit acceleration;
LUSC	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg17031739	chr1:67600172	NA	0.38	5.84	0.3	1.23e-8	Psoriasis;
LUSC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.22	0.32	1.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6500395	1.000	rs1004909	chr16:48725580	C/G	cg04672837	chr16:48644449	N4BP1	-0.46	-6.88	-0.35	3e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg21849932	chr20:62369462	LIME1	-0.41	-6.1	-0.32	2.94e-9	Prostate cancer;
LUSC	cis	rs6882046	0.533	rs599402	chr5:88043656	G/C	cg22951263	chr5:87985283	NA	-0.47	-7.81	-0.39	7.54e-14	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LUSC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg25456477	chr12:86230367	RASSF9	0.43	7.8	0.39	8.24e-14	Major depressive disorder;
LUSC	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.55	10.47	0.5	2.33e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	1.1	14.57	0.62	1.44e-37	Nonalcoholic fatty liver disease;
LUSC	cis	rs1595825	0.891	rs59617443	chr2:198653204	C/A	cg00982548	chr2:198649783	BOLL	-0.58	-7.21	-0.37	3.87e-12	Ulcerative colitis;
LUSC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg07741184	chr6:167504864	NA	0.37	6.64	0.34	1.25e-10	Crohn's disease;
LUSC	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	9.46	0.46	5.69e-19	Response to antipsychotic treatment;
LUSC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg16545954	chr1:2118288	C1orf86	0.31	5.9	0.31	8.83e-9	Height;
LUSC	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg21643547	chr1:205240462	TMCC2	-0.38	-7.02	-0.36	1.24e-11	Red blood cell count;
LUSC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg21724239	chr8:58056113	NA	0.57	6.53	0.34	2.39e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.13	10.29	0.49	9.55e-22	Alzheimer's disease (late onset);
LUSC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-1.11	-23.51	-0.79	8.21e-73	Height;
LUSC	cis	rs4889911	0.544	rs1285273	chr17:77830885	A/G	cg00646381	chr17:77835854	NA	0.6	9.75	0.47	6.38e-20	Electroencephalogram traits;
LUSC	cis	rs7539409	0.833	rs2057083	chr1:84269942	T/G	cg10977910	chr1:84465055	TTLL7	0.64	6.08	0.32	3.33e-9	Alzheimer's disease;
LUSC	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg23435118	chr5:141488016	NDFIP1	-0.56	-7.77	-0.39	9.49e-14	Crohn's disease;
LUSC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg09034736	chr1:150693464	HORMAD1	0.44	5.93	0.31	7.74e-9	Urate levels;
LUSC	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.5	-0.5	1.72e-22	Glomerular filtration rate;
LUSC	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg21361702	chr7:150065534	REPIN1	0.59	8.25	0.41	3.77e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg07701084	chr6:150067640	NUP43	0.54	8.08	0.4	1.17e-14	Lung cancer;
LUSC	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg27068330	chr11:65405492	SIPA1	-0.74	-10.3	-0.49	8.46e-22	Acne (severe);
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.58	7.38	0.37	1.24e-12	Renal function-related traits (BUN);
LUSC	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-16.25	-0.66	3.52e-44	Exhaled nitric oxide output;
LUSC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg16405210	chr4:1374714	KIAA1530	-0.85	-13.94	-0.61	3.89e-35	Longevity;
LUSC	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg15997130	chr1:24165203	NA	-0.51	-8.24	-0.41	4.03e-15	Immature fraction of reticulocytes;
LUSC	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.72	-0.43	1.34e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg00405596	chr8:11794950	NA	0.35	5.83	0.3	1.3e-8	Neuroticism;
LUSC	cis	rs500891	0.533	rs6454328	chr6:84171230	A/G	cg08257003	chr6:84140564	ME1	0.35	8.67	0.43	1.87e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg00484396	chr16:3507460	NAT15	-0.45	-7.51	-0.38	5.39e-13	Body mass index (adult);
LUSC	cis	rs12681287	0.640	rs7460342	chr8:87475137	C/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.44	-0.38	8.39e-13	Caudate activity during reward;
LUSC	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg08601574	chr20:25228251	PYGB	0.42	6.41	0.33	4.9e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.9	-0.31	8.91e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg07211511	chr3:129823064	LOC729375	-0.83	-11.9	-0.55	1.86e-27	Blood pressure (smoking interaction);
LUSC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg04414720	chr1:150670196	GOLPH3L	0.5	7.76	0.39	1.03e-13	Melanoma;
LUSC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.46	-7.86	-0.39	5.47e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs939574	1.000	rs7574937	chr2:220099331	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.07	8.71	0.43	1.42e-16	Platelet distribution width;
LUSC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg23205692	chr1:25664452	TMEM50A	0.43	6.42	0.33	4.78e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-8.92	-0.44	3.02e-17	Response to antipsychotic treatment;
LUSC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg01765077	chr12:122356316	WDR66	0.54	7.69	0.39	1.66e-13	Mean corpuscular volume;
LUSC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg17173187	chr15:85201210	NMB	0.37	6.52	0.34	2.64e-10	Schizophrenia;
LUSC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg26513180	chr16:89883248	FANCA	0.61	5.84	0.3	1.22e-8	Skin colour saturation;
LUSC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg01765077	chr12:122356316	WDR66	0.49	6.73	0.35	7.54e-11	Mean corpuscular volume;
LUSC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg12963246	chr6:28129442	ZNF389	0.56	7.89	0.4	4.28e-14	Parkinson's disease;
LUSC	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.94	-0.31	7.31e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.07e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg09033563	chr22:24373618	LOC391322	-0.48	-6.77	-0.35	5.86e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-6.46	-0.33	3.74e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg02569458	chr12:86230093	RASSF9	-0.49	-8.25	-0.41	3.64e-15	Major depressive disorder;
LUSC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg18301423	chr5:131593218	PDLIM4	0.48	7.44	0.38	8.77e-13	Acylcarnitine levels;
LUSC	cis	rs12449964	0.524	rs4925094	chr17:17569012	C/T	cg09796270	chr17:17721594	SREBF1	-0.41	-7.24	-0.37	3.15e-12	Coronary artery disease or ischemic stroke;
LUSC	cis	rs11051970	0.879	rs2171373	chr12:32575777	C/T	cg02745156	chr12:32552066	NA	0.43	7.33	0.37	1.73e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6469656	0.892	rs12547058	chr8:117663147	C/G	cg24004040	chr8:117650383	NA	-0.42	-6.26	-0.32	1.16e-9	Colorectal cancer;
LUSC	trans	rs502716	1.000	rs518281	chr20:926325	T/C	cg25252482	chr7:119893751	NA	-0.33	-6.01	-0.31	4.96e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg09877947	chr5:131593287	PDLIM4	0.41	6.83	0.35	4.08e-11	Blood metabolite levels;
LUSC	trans	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg07393940	chr7:158741817	NA	0.37	6.78	0.35	5.58e-11	Blood metabolite levels;
LUSC	cis	rs1865721	1.000	rs8096298	chr18:73187608	C/T	cg26385618	chr18:73139727	C18orf62	-0.48	-7.93	-0.4	3.27e-14	Intelligence;
LUSC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg20476274	chr7:133979776	SLC35B4	0.88	16.9	0.68	1.01e-46	Mean platelet volume;
LUSC	trans	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.58e-15	Diabetic kidney disease;
LUSC	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.78	-0.43	8.34e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	7.47	0.38	7.23e-13	Breast cancer;
LUSC	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg10523860	chr14:103875565	MARK3	-0.38	-6.03	-0.31	4.39e-9	Body mass index;
LUSC	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg26695010	chr11:65641043	EFEMP2	0.46	6.68	0.34	1.02e-10	Eosinophil percentage of white cells;
LUSC	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg20744362	chr22:50050164	C22orf34	0.38	7.32	0.37	1.87e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2625529	0.713	rs12903980	chr15:72165549	C/T	cg16672083	chr15:72433130	SENP8	-0.5	-7.27	-0.37	2.57e-12	Red blood cell count;
LUSC	cis	rs7799006	0.527	rs6967286	chr7:2212758	C/A	cg04267008	chr7:1944627	MAD1L1	-0.42	-6.13	-0.32	2.55e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.96	12.45	0.56	1.77e-29	Exhaled nitric oxide output;
LUSC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.02	0.52	2.69e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6942756	1.000	rs2141075	chr7:128877305	C/T	cg02491457	chr7:128862824	NA	0.54	7.78	0.39	8.96e-14	White matter hyperintensity burden;
LUSC	trans	rs2926702	0.810	rs11993276	chr8:71095359	A/G	cg13462967	chr19:40396032	FCGBP	-0.47	-6.03	-0.31	4.37e-9	Non-small cell lung cancer;
LUSC	trans	rs2786098	0.656	rs12025476	chr1:197525439	A/C	cg16005942	chr6:160526640	IGF2R	0.51	6.03	0.31	4.34e-9	Asthma;
LUSC	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-9.71	-0.47	8.5e-20	Bladder cancer;
LUSC	cis	rs7712401	0.715	rs385996	chr5:122355228	T/G	cg19077854	chr5:122220652	SNX24	-0.41	-8.71	-0.43	1.45e-16	Mean platelet volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01932091	chr1:29213675	EPB41	0.45	6.28	0.32	1.04e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.85	16.26	0.66	3.22e-44	Mean platelet volume;
LUSC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg16405210	chr4:1374714	KIAA1530	-0.5	-7.3	-0.37	2.13e-12	Obesity-related traits;
LUSC	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg13010199	chr12:38710504	ALG10B	-0.58	-9.17	-0.45	5.12e-18	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6545883	0.860	rs6545848	chr2:61461183	G/T	cg15711740	chr2:61764176	XPO1	0.43	6.77	0.35	5.88e-11	Tuberculosis;
LUSC	cis	rs13315871	1.000	rs9844128	chr3:58391127	C/T	cg20936604	chr3:58311152	NA	-0.67	-6.29	-0.33	9.73e-10	Cholesterol, total;
LUSC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.53	-10.07	-0.48	5.2e-21	Prostate cancer;
LUSC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg03676636	chr4:99064102	C4orf37	0.33	7.16	0.36	5.04e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg02951883	chr7:2050386	MAD1L1	-0.44	-7.7	-0.39	1.52e-13	Bipolar disorder and schizophrenia;
LUSC	trans	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.5	0.34	2.87e-10	Corneal astigmatism;
LUSC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-0.85	-14.83	-0.63	1.36e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6084875	0.840	rs2065704	chr20:4719344	A/T	cg07258627	chr20:4721683	PRNT	-0.34	-6.06	-0.31	3.75e-9	Systemic lupus erythematosus;
LUSC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg11494091	chr17:61959527	GH2	-0.38	-6.69	-0.34	9.69e-11	Height;
LUSC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg14019146	chr3:50243930	SLC38A3	-0.36	-8.2	-0.41	5.14e-15	Body mass index;
LUSC	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg22676075	chr6:135203613	NA	0.58	9.12	0.45	7.32e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg27535305	chr1:53392650	SCP2	0.32	5.85	0.3	1.19e-8	Monocyte count;
LUSC	cis	rs10871290	0.650	rs12600126	chr16:74489732	A/T	cg01733217	chr16:74700730	RFWD3	-0.64	-9.78	-0.47	5.03e-20	Breast cancer;
LUSC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.93	0.31	7.75e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04004882	chr2:215674386	BARD1	0.48	6.38	0.33	5.89e-10	Neuroblastoma;
LUSC	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.9	0.48	2e-20	Migraine;Coronary artery disease;
LUSC	cis	rs4363385	0.747	rs9919276	chr1:152968654	A/T	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.5	-0.38	5.93e-13	Inflammatory skin disease;
LUSC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.6	-0.34	1.66e-10	Calcium levels;
LUSC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11764359	chr7:65958608	NA	-0.63	-9.73	-0.47	7.23e-20	Aortic root size;
LUSC	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.66	10.14	0.49	3.14e-21	Metabolic syndrome;
LUSC	trans	rs9886428	1.000	rs1427024	chr8:14119015	G/A	cg11959399	chr20:741723	C20orf54	-0.4	-6.28	-0.32	1.05e-9	IgG glycosylation;
LUSC	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg01411142	chr8:19674711	INTS10	0.5	5.66	0.3	3.31e-8	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg16660971	chr17:78860029	RPTOR	0.37	6.01	0.31	4.78e-9	Major depressive disorder;
LUSC	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.51	-7.83	-0.39	6.75e-14	Cognitive test performance;
LUSC	cis	rs244293	0.760	rs8069447	chr17:53008873	A/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.42	-6.31	-0.33	8.9e-10	Menarche (age at onset);
LUSC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	4.03e-10	Life satisfaction;
LUSC	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.25	0.32	1.25e-9	Diisocyanate-induced asthma;
LUSC	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	11.78	0.54	4.8400000000000004e-27	Electrocardiographic conduction measures;
LUSC	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.77	0.35	5.78e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg05714579	chr10:131428358	MGMT	-0.81	-13.06	-0.58	9e-32	Response to temozolomide;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03008165	chr11:77024667	NA	0.54	6.76	0.35	6.08e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg00898013	chr13:113819073	PROZ	-0.55	-7.87	-0.4	5.12e-14	Platelet distribution width;
LUSC	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg09998033	chr7:158218633	PTPRN2	-0.5	-8.12	-0.41	9.2e-15	Obesity-related traits;
LUSC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg22868518	chr11:507468	RNH1	-0.59	-5.8	-0.3	1.56e-8	Body mass index;
LUSC	cis	rs2294693	0.853	rs9296350	chr6:40977623	G/A	cg14769373	chr6:40998127	UNC5CL	-0.45	-6.53	-0.34	2.51e-10	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs7178572	1.000	rs2055901	chr15:77759295	G/A	cg22256960	chr15:77711686	NA	-0.54	-9.05	-0.44	1.22e-17	Type 2 diabetes;
LUSC	trans	rs2950393	0.804	rs2958132	chr12:57144533	C/G	cg14367344	chr1:146644336	PRKAB2	-0.42	-6.02	-0.31	4.61e-9	Platelet distribution width;
LUSC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg06640241	chr16:89574553	SPG7	0.72	11.64	0.54	1.66e-26	Multiple myeloma (IgH translocation);
LUSC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg18225595	chr11:63971243	STIP1	0.48	5.79	0.3	1.66e-8	Mean platelet volume;
LUSC	cis	rs58235267	0.553	rs11890276	chr2:63366191	C/T	cg17519650	chr2:63277830	OTX1	0.72	10.51	0.5	1.71e-22	Prostate-specific antigen levels (conditioned on lead SNPs);
LUSC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg12257692	chr3:49977190	RBM6	-0.25	-7.14	-0.36	5.84e-12	Body mass index;
LUSC	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-6.56	-0.34	2.09e-10	Response to antipsychotic treatment;
LUSC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg06238570	chr21:40685208	BRWD1	-0.53	-8.16	-0.41	6.76e-15	Menarche (age at onset);
LUSC	cis	rs12519773	1.000	rs6880789	chr5:92451777	A/G	cg18783429	chr5:92414398	NA	0.29	6.38	0.33	6.07e-10	Migraine;
LUSC	cis	rs965604	1.000	rs8043227	chr15:78768871	C/G	cg18825076	chr15:78729989	IREB2	-0.44	-7.14	-0.36	5.9e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg17264618	chr3:40429014	ENTPD3	0.34	6.91	0.35	2.52e-11	Renal cell carcinoma;
LUSC	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.23e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg12751644	chr20:60527061	NA	-0.33	-5.89	-0.31	9.2e-9	Body mass index;
LUSC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg03690763	chr11:133734501	NA	-0.32	-5.93	-0.31	7.64e-9	Childhood ear infection;
LUSC	cis	rs7605827	0.930	rs7595512	chr2:15678368	C/T	cg19274914	chr2:15703543	NA	0.47	9.03	0.44	1.43e-17	Educational attainment (years of education);
LUSC	cis	rs117623576	0.618	rs211413	chr10:32396902	C/A	cg03047570	chr10:32398778	NA	0.5	5.68	0.3	2.98e-8	Anti-saccade response;
LUSC	cis	rs1775715	1.000	rs1775715	chr10:32309005	A/G	cg18675610	chr10:32216311	ARHGAP12	-0.27	-5.71	-0.3	2.5e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.81	-0.43	6.81e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7264396	1.000	rs224424	chr20:34147998	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.38	-0.37	1.28e-12	Total cholesterol levels;
LUSC	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg15704280	chr7:45808275	SEPT13	0.81	7.73	0.39	1.27e-13	Axial length;
LUSC	cis	rs6704644	0.719	rs3768801	chr2:234373702	G/A	cg05711037	chr2:234359783	DGKD	0.66	6.42	0.33	4.75e-10	Bilirubin levels;
LUSC	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg18833306	chr6:118973337	C6orf204	-0.46	-5.83	-0.3	1.34e-8	Diastolic blood pressure;
LUSC	cis	rs10761482	0.861	rs1380458	chr10:62107690	A/T	cg18175470	chr10:62150864	ANK3	-0.51	-7.24	-0.37	3.06e-12	Schizophrenia;
LUSC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04267008	chr7:1944627	MAD1L1	0.5	7.51	0.38	5.34e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs4700695	0.719	rs27588	chr5:65459360	C/A	cg21114390	chr5:65439923	SFRS12	-0.63	-8.98	-0.44	2.07e-17	Facial morphology (factor 19);
LUSC	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg00484396	chr16:3507460	NAT15	0.5	7.42	0.38	9.71e-13	Body mass index (adult);
LUSC	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg24375607	chr4:120327624	NA	0.77	12.49	0.56	1.24e-29	Corneal astigmatism;
LUSC	cis	rs920590	0.796	rs10788700	chr8:19635098	T/C	cg03894339	chr8:19674705	INTS10	0.42	5.66	0.3	3.21e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	14.45	0.62	4.3e-37	Menopause (age at onset);
LUSC	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg05347473	chr6:146136440	FBXO30	0.52	8.89	0.44	3.99e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg11812906	chr14:75593930	NEK9	-0.64	-10.54	-0.5	1.25e-22	Height;
LUSC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg14061069	chr19:46274453	DMPK	0.68	13.89	0.61	6.07e-35	Coronary artery disease;
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg06877462	chr1:205807181	PM20D1	0.52	9.33	0.45	1.5e-18	Menarche (age at onset);
LUSC	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg15309053	chr8:964076	NA	0.4	8.23	0.41	4.34e-15	Schizophrenia;
LUSC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg20283391	chr11:68216788	NA	-0.58	-8.24	-0.41	3.96e-15	Total body bone mineral density;
LUSC	trans	rs62055045	0.528	rs7194638	chr16:71573818	A/G	cg21834679	chr15:96891026	NA	-0.37	-6.05	-0.31	3.97e-9	Schizophrenia;
LUSC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.44	-0.46	6.75e-19	Electroencephalogram traits;
LUSC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.86	0.31	1.09e-8	Menopause (age at onset);
LUSC	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-6.17	-0.32	1.93e-9	Fear of minor pain;
LUSC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg05805236	chr11:65401703	PCNXL3	-0.38	-5.83	-0.3	1.27e-8	Breast cancer;
LUSC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg22535103	chr8:58192502	C8orf71	-0.63	-7.06	-0.36	9.52e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10761482	0.813	rs10509130	chr10:62121112	C/T	cg18175470	chr10:62150864	ANK3	-0.53	-7.44	-0.38	8.57e-13	Schizophrenia;
LUSC	cis	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg26958806	chr6:27640298	NA	0.83	6.57	0.34	1.94e-10	Depression;
LUSC	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg11901034	chr3:128598214	ACAD9	-0.4	-6.17	-0.32	1.95e-9	IgG glycosylation;
LUSC	cis	rs12618769	0.597	rs3754893	chr2:99063149	T/A	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.14e-13	Bipolar disorder;
LUSC	cis	rs12493885	0.725	rs4680113	chr3:153727337	C/T	cg17054900	chr3:154042577	DHX36	-0.58	-6.17	-0.32	1.93e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21659725	chr3:3221576	CRBN	0.56	9.21	0.45	3.66e-18	Body mass index;
LUSC	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg21775007	chr8:11205619	TDH	0.48	6.93	0.35	2.18e-11	Neuroticism;
LUSC	cis	rs1775715	0.651	rs2808033	chr10:32194127	A/T	cg03015672	chr10:32216066	ARHGAP12	0.34	6.22	0.32	1.49e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg24069376	chr3:38537580	EXOG	0.4	7.85	0.39	5.55e-14	Electrocardiographic conduction measures;
LUSC	cis	rs870825	0.860	rs2705886	chr4:185608591	T/C	cg04058563	chr4:185651563	MLF1IP	-0.75	-10.22	-0.49	1.67e-21	Blood protein levels;
LUSC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg16545954	chr1:2118288	C1orf86	0.33	6.22	0.32	1.5e-9	Height;
LUSC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg13206674	chr6:150067644	NUP43	0.52	7.93	0.4	3.42e-14	Lung cancer;
LUSC	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg05621596	chr22:47072043	GRAMD4	-0.54	-8.62	-0.43	2.75e-16	Urate levels in obese individuals;
LUSC	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	11.92	0.55	1.57e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7561273	0.586	rs116650625	chr2:24353212	C/G	cg06627628	chr2:24431161	ITSN2	-0.51	-6.8	-0.35	4.71e-11	Quantitative traits;
LUSC	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg18806716	chr10:30721971	MAP3K8	0.62	9.9	0.48	2.02e-20	Inflammatory bowel disease;
LUSC	cis	rs2398893	0.924	rs7047684	chr9:96792790	C/T	cg14459158	chr9:96720562	NA	0.29	5.68	0.3	2.92e-8	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.28	-0.32	1.06e-9	Neuroticism;
LUSC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-8.36	-0.42	1.7e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg23815491	chr16:72088622	HP	0.35	6.14	0.32	2.34e-9	Fibrinogen levels;
LUSC	cis	rs6469656	1.000	rs4289846	chr8:117651368	A/C	cg24004040	chr8:117650383	NA	-0.43	-6.22	-0.32	1.46e-9	Colorectal cancer;
LUSC	cis	rs9534288	0.830	rs940	chr13:46627480	C/G	cg15192986	chr13:46630673	CPB2	-0.79	-13.02	-0.58	1.22e-31	Blood protein levels;
LUSC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25072359	chr17:41440525	NA	0.59	8.52	0.42	5.62e-16	Menopause (age at onset);
LUSC	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.09	15.58	0.65	1.59e-41	Lung cancer in ever smokers;
LUSC	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.46	-8.94	-0.44	2.7e-17	Menopause (age at onset);
LUSC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg16405210	chr4:1374714	KIAA1530	-0.56	-8.61	-0.43	3.02e-16	Obesity-related traits;
LUSC	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg09184832	chr6:79620586	NA	-0.44	-7.18	-0.37	4.66e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.18	0.77	1.27e-67	Prudent dietary pattern;
LUSC	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.18	-0.37	4.56e-12	Bipolar disorder;
LUSC	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.73	-0.35	7.59e-11	Colorectal cancer;
LUSC	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg12002119	chr2:101014098	CHST10	0.35	5.76	0.3	1.89e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10992471	0.603	rs7872610	chr9:95299137	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-6.97	-0.36	1.7e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg18404041	chr3:52824283	ITIH1	-0.56	-9.51	-0.46	3.92e-19	Schizophrenia;
LUSC	cis	rs2580764	0.598	rs6726158	chr2:55239202	G/T	cg20993754	chr2:55226987	RTN4	0.36	6.06	0.31	3.59e-9	Mean platelet volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17308661	chr14:57857235	NAA30	0.44	6.4	0.33	5.23e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg18230493	chr5:56204884	C5orf35	-0.86	-12.98	-0.58	1.85e-31	Initial pursuit acceleration;
LUSC	cis	rs4343996	0.558	rs1554498	chr7:3415568	A/G	cg21248987	chr7:3385318	SDK1	0.36	6.12	0.32	2.59e-9	Motion sickness;
LUSC	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	0.96	13.3	0.59	1.14e-32	Primary sclerosing cholangitis;
LUSC	cis	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg20368463	chr18:77673604	PQLC1	0.69	6.75	0.35	6.41e-11	Opioid sensitivity;
LUSC	cis	rs9283706	0.595	rs1115252	chr5:66322741	A/G	cg11590213	chr5:66331682	MAST4	0.45	6.96	0.36	1.81e-11	Coronary artery disease;
LUSC	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.75	-0.35	6.64e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.74	-0.35	7e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg04455712	chr21:45112962	RRP1B	0.44	8.19	0.41	5.68e-15	Mean corpuscular volume;
LUSC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.83	-0.51	1.31e-23	Aortic root size;
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.69	10.43	0.5	2.99e-22	Lymphocyte counts;
LUSC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg12751644	chr20:60527061	NA	-0.34	-6.16	-0.32	2.07e-9	Body mass index;
LUSC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.72	-0.39	1.4e-13	Aortic root size;
LUSC	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg04155231	chr12:9217510	LOC144571	0.3	5.7	0.3	2.67e-8	Sjögren's syndrome;
LUSC	cis	rs1483890	1.000	rs1483890	chr3:69410725	A/G	cg22125112	chr3:69402811	FRMD4B	0.38	5.65	0.3	3.46e-8	Resting heart rate;
LUSC	trans	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg10756647	chr7:56101905	PSPH	0.86	8.36	0.42	1.7e-15	Diabetic kidney disease;
LUSC	cis	rs10193935	0.901	rs6724626	chr2:42689757	C/G	cg27598129	chr2:42591480	NA	0.62	7.95	0.4	2.94e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg08916839	chr5:415575	AHRR	0.73	7.0	0.36	1.4e-11	Fat distribution (HIV);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg05310920	chr2:150186634	LYPD6	0.47	6.05	0.31	3.8e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg14631576	chr9:95140430	CENPP	-0.31	-5.68	-0.3	2.97e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs8014204	0.747	rs2070598	chr14:75360906	C/T	cg08847533	chr14:75593920	NEK9	-0.42	-6.09	-0.32	3.19e-9	Caffeine consumption;
LUSC	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg02640540	chr1:67518911	SLC35D1	-0.53	-7.82	-0.39	6.85e-14	Lymphocyte percentage of white cells;
LUSC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	0.85	14.47	0.62	3.69e-37	Tonsillectomy;
LUSC	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg00071950	chr4:10020882	SLC2A9	-0.58	-9.55	-0.46	2.92e-19	Bone mineral density;
LUSC	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg20243544	chr17:37824526	PNMT	0.39	5.96	0.31	6.59e-9	Self-reported allergy;
LUSC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg10117171	chr1:25599238	RHD	-0.37	-5.7	-0.3	2.68e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg22431228	chr1:16359049	CLCNKA	-0.51	-10.18	-0.49	2.27e-21	Dilated cardiomyopathy;
LUSC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg11502198	chr6:26597334	ABT1	0.59	9.3	0.45	1.85e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg26441486	chr22:50317300	CRELD2	0.46	6.67	0.34	1.05e-10	Schizophrenia;
LUSC	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg24631222	chr15:78858424	CHRNA5	0.68	9.11	0.45	7.54e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1113500	0.524	rs11185270	chr1:108654362	G/A	cg06207961	chr1:108661230	NA	0.34	5.82	0.3	1.4e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.85	-16.07	-0.66	1.93e-43	Longevity;
LUSC	trans	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-6.28	-0.32	1.07e-9	Mood instability;
LUSC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	1.11	27.31	0.83	4.24e-87	Testicular germ cell tumor;
LUSC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.88	-17.9	-0.7	1.02e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg05738196	chr6:26577821	NA	0.82	15.82	0.65	1.9e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg04287289	chr16:89883240	FANCA	0.79	14.0	0.61	2.4e-35	Vitiligo;
LUSC	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg01420254	chr6:26195488	NA	0.72	7.48	0.38	6.52e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg00042356	chr1:8021962	PARK7	0.64	8.47	0.42	7.79e-16	Inflammatory bowel disease;
LUSC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg00933542	chr6:150070202	PCMT1	0.32	6.67	0.34	1.08e-10	Lung cancer;
LUSC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg16339924	chr4:17578868	LAP3	0.63	9.87	0.48	2.51e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg25206134	chr2:45395956	NA	0.61	6.98	0.36	1.55e-11	Bipolar disorder;
LUSC	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg20701182	chr2:24300061	SF3B14	0.77	7.74	0.39	1.17e-13	Lymphocyte counts;
LUSC	cis	rs6669072	0.739	rs712026	chr1:91251381	T/C	cg08895590	chr1:91227319	NA	0.28	5.86	0.31	1.09e-8	Cognitive function;
LUSC	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg24110177	chr3:50126178	RBM5	-0.43	-6.79	-0.35	5.18e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg17252645	chr8:143867129	LY6D	-0.34	-5.7	-0.3	2.61e-8	Urinary tract infection frequency;
LUSC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg01879757	chr17:41196368	BRCA1	-0.46	-7.1	-0.36	7.39e-12	Menopause (age at onset);
LUSC	cis	rs2742417	1.000	rs2742438	chr3:45743390	G/T	cg09608765	chr3:45636137	LIMD1	-0.38	-7.5	-0.38	5.91e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg00409905	chr10:38381863	ZNF37A	0.34	5.81	0.3	1.44e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.85	14.78	0.63	2.22e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7264396	0.832	rs224361	chr20:34061578	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-5.96	-0.31	6.35e-9	Total cholesterol levels;
LUSC	cis	rs3740540	0.530	rs2362503	chr10:126290538	T/C	cg04949429	chr10:126290192	LHPP	0.37	7.77	0.39	9.52e-14	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg16524733	chr11:117070046	TAGLN	0.42	7.5	0.38	5.92e-13	Blood protein levels;
LUSC	cis	rs540254	0.551	rs12143580	chr1:160790918	G/C	cg20255094	chr1:160771763	LY9	0.57	6.92	0.35	2.31e-11	Blood protein levels;
LUSC	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.84	-10.09	-0.48	4.69e-21	Body mass index;
LUSC	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.59	0.5	8.78e-23	Lung cancer in ever smokers;
LUSC	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.81	-13.42	-0.59	4.02e-33	Bladder cancer;
LUSC	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.15	-0.36	5.46e-12	Coronary artery disease;
LUSC	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg08975724	chr8:8085496	FLJ10661	0.51	7.24	0.37	3.09e-12	Monocyte count;
LUSC	cis	rs35771425	0.626	rs55761812	chr1:211653935	C/T	cg10512769	chr1:211675356	NA	-0.27	-5.93	-0.31	7.77e-9	Educational attainment (years of education);
LUSC	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg14541582	chr5:601475	NA	-0.37	-5.87	-0.31	1.08e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg11211951	chr8:145729740	GPT	-0.55	-10.71	-0.51	3.29e-23	Age at first birth;
LUSC	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg07169764	chr2:136633963	MCM6	1.02	15.22	0.64	4.28e-40	Corneal structure;
LUSC	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg04352962	chr1:209979756	IRF6	0.55	6.35	0.33	6.97e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg18825076	chr15:78729989	IREB2	-0.47	-6.45	-0.33	3.93e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs11610422	1.000	rs12823902	chr12:31414290	A/G	cg02734259	chr12:9559402	NA	-0.59	-6.35	-0.33	7.09e-10	Coronary artery disease;
LUSC	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg09479241	chr17:27052676	TLCD1	-0.4	-5.69	-0.3	2.85e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.5	-0.34	2.93e-10	Retinal vascular caliber;
LUSC	trans	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.94	0.48	1.4e-20	Mean corpuscular volume;
LUSC	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.77	0.47	5.22e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-8.77	-0.43	9.05e-17	Bipolar disorder;
LUSC	cis	rs6426558	0.537	rs2813950	chr1:227426072	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.53	-7.32	-0.37	1.88e-12	Neutrophil percentage of white cells;
LUSC	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg10518572	chr11:65560635	OVOL1	-0.25	-5.75	-0.3	1.97e-8	Acne (severe);
LUSC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg15147215	chr3:52552868	STAB1	-0.29	-5.83	-0.3	1.28e-8	Bipolar disorder;
LUSC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-1.05	-15.45	-0.65	5.46e-41	Initial pursuit acceleration;
LUSC	cis	rs13242816	1.000	rs56250718	chr7:116103303	A/G	cg16553024	chr7:116138462	CAV2	-0.53	-5.81	-0.3	1.46e-8	P wave duration;
LUSC	cis	rs372883	0.967	rs2832292	chr21:30738760	C/A	cg08807101	chr21:30365312	RNF160	0.43	6.24	0.32	1.35e-9	Pancreatic cancer;
LUSC	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg04362960	chr10:104952993	NT5C2	0.61	9.51	0.46	3.99e-19	Arsenic metabolism;
LUSC	cis	rs7759001	0.817	rs10080814	chr6:27362874	T/G	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg19508488	chr2:152266495	RIF1	0.51	6.89	0.35	2.82e-11	Lung cancer;
LUSC	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg22676075	chr6:135203613	NA	0.48	7.61	0.38	2.8e-13	Red blood cell count;
LUSC	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.6	-8.54	-0.42	4.92e-16	Macular telangiectasia type 2;
LUSC	cis	rs2898681	0.521	rs6833350	chr4:53740868	A/G	cg00791764	chr4:53727839	RASL11B	0.48	6.39	0.33	5.59e-10	Optic nerve measurement (cup area);
LUSC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg21573476	chr21:45109991	RRP1B	-0.41	-6.82	-0.35	4.2e-11	Mean corpuscular volume;
LUSC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg21963583	chr11:68658836	MRPL21	0.55	7.95	0.4	2.98e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg23630131	chr7:65973040	NA	0.21	5.78	0.3	1.74e-8	Aortic root size;
LUSC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.48	6.92	0.35	2.26e-11	Renal function-related traits (BUN);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02706205	chr15:49447933	GALK2;COPS2	0.39	5.99	0.31	5.39e-9	Triglycerides;
LUSC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.79	7.73	0.39	1.29e-13	Initial pursuit acceleration;
LUSC	cis	rs5758511	0.731	rs58302269	chr22:42351309	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.49	-6.02	-0.31	4.5e-9	Birth weight;
LUSC	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-9.93	-0.48	1.52e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg00431813	chr7:1051703	C7orf50	-0.42	-6.65	-0.34	1.23e-10	Longevity;Endometriosis;
LUSC	cis	rs1577917	0.839	rs12664634	chr6:86579414	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.69e-9	Response to antipsychotic treatment;
LUSC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg19046167	chr17:80928561	B3GNTL1	0.46	7.57	0.38	3.75e-13	Breast cancer;
LUSC	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.58e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg00990874	chr7:1149470	C7orf50	-0.44	-5.76	-0.3	1.86e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg24375607	chr4:120327624	NA	0.5	7.73	0.39	1.31e-13	Diastolic blood pressure;
LUSC	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.37	-6.69	-0.34	9.6e-11	Height;
LUSC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.74	-12.79	-0.57	9.25e-31	Cognitive function;
LUSC	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.76	11.22	0.52	5.12e-25	Corneal astigmatism;
LUSC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg06877462	chr1:205807181	PM20D1	0.5	8.93	0.44	2.8e-17	Menarche (age at onset);
LUSC	cis	rs4363385	0.719	rs6587714	chr1:152933023	T/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-6.98	-0.36	1.56e-11	Inflammatory skin disease;
LUSC	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg01616529	chr11:638424	DRD4	-0.35	-6.02	-0.31	4.64e-9	Systemic lupus erythematosus;
LUSC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg16339924	chr4:17578868	LAP3	-0.58	-9.01	-0.44	1.63e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08219700	chr8:58056026	NA	0.66	8.16	0.41	6.98e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.11	-0.61	8.76e-36	Exhaled nitric oxide output;
LUSC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg27588902	chr6:42928151	GNMT	-0.29	-6.54	-0.34	2.34e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs68170813	0.523	rs3757713	chr7:107042750	A/C	cg24556660	chr7:106842632	COG5;HBP1	-0.43	-5.65	-0.3	3.4e-8	Coronary artery disease;
LUSC	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg22815214	chr1:201083145	CACNA1S	0.58	9.9	0.48	1.94e-20	Permanent tooth development;
LUSC	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg23093090	chr10:104574429	C10orf26	-0.38	-6.93	-0.35	2.14e-11	Arsenic metabolism;
LUSC	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg22491629	chr6:157744540	C6orf35	-0.79	-9.9	-0.48	1.98e-20	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs394563	0.601	rs431978	chr6:149793000	C/T	cg11245181	chr6:149772854	ZC3H12D	0.3	5.86	0.31	1.11e-8	Dupuytren's disease;
LUSC	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg27494647	chr7:150038898	RARRES2	0.46	7.09	0.36	8.27e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs56283067	0.578	rs12211510	chr6:45361189	A/G	cg18551225	chr6:44695536	NA	-0.42	-6.35	-0.33	6.91e-10	Total body bone mineral density;
LUSC	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.6	0.65	1.31e-41	Bladder cancer;
LUSC	cis	rs73206853	0.841	rs7297096	chr12:110798322	G/C	cg12870014	chr12:110450643	ANKRD13A	0.68	6.43	0.33	4.37e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9473147	0.543	rs4711878	chr6:47456118	A/G	cg12968598	chr6:47444699	CD2AP	0.53	7.99	0.4	2.22e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg06494592	chr3:125709126	NA	-0.5	-6.14	-0.32	2.36e-9	Blood pressure (smoking interaction);
LUSC	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.85	0.54	2.71e-27	Cognitive ability;
LUSC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg06740227	chr12:86229804	RASSF9	0.44	7.05	0.36	1.03e-11	Major depressive disorder;
LUSC	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg24112000	chr20:60950667	NA	-0.34	-6.5	-0.34	2.91e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg20503657	chr10:835505	NA	0.52	6.27	0.32	1.12e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs934734	0.563	rs11673987	chr2:65597671	A/G	cg08085232	chr2:65598271	SPRED2	-0.45	-6.9	-0.35	2.62e-11	Rheumatoid arthritis;
LUSC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07343612	chr16:622815	PIGQ	-0.71	-11.97	-0.55	1.01e-27	Height;
LUSC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg27284194	chr4:1044797	NA	0.38	6.51	0.34	2.73e-10	Obesity-related traits;
LUSC	cis	rs12044355	0.827	rs11586191	chr1:231831781	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	5.84	0.3	1.26e-8	Alzheimer's disease;
LUSC	cis	rs3774830	0.534	rs7687596	chr4:5472092	C/T	cg26943120	chr4:5472116	STK32B	-0.4	-8.64	-0.43	2.31e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4594175	1.000	rs4594175	chr14:51606541	C/A	cg23942311	chr14:51606299	NA	0.31	5.9	0.31	8.82e-9	Cancer;
LUSC	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg15997130	chr1:24165203	NA	0.52	8.54	0.42	4.67e-16	Immature fraction of reticulocytes;
LUSC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	1.04	20.84	0.75	2.29e-62	Cognitive function;
LUSC	cis	rs75557865	1	rs75557865	chr3:121652141	G/A	cg11130432	chr3:121712080	ILDR1	0.41	6.97	0.36	1.72e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg22437258	chr11:111473054	SIK2	-0.48	-6.21	-0.32	1.56e-9	Primary sclerosing cholangitis;
LUSC	cis	rs6546550	0.835	rs13002091	chr2:70118388	C/T	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.46	-0.38	7.68e-13	Prevalent atrial fibrillation;
LUSC	trans	rs72674100	1.000	rs7671134	chr4:97990088	A/G	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs71435601	0.515	rs486246	chr2:21406751	G/A	cg20757404	chr19:378427	NA	0.37	5.98	0.31	5.75e-9	Cholesterol, total;
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg07806771	chr7:64541737	NA	-0.47	-6.69	-0.34	9.65e-11	Calcium levels;
LUSC	cis	rs12980942	1.000	rs3826714	chr19:41825776	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.15	0.32	2.17e-9	Coronary artery disease;
LUSC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg24642844	chr7:1081250	C7orf50	-0.68	-9.44	-0.46	6.82e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02711726	chr17:80685570	FN3KRP	-0.41	-6.26	-0.32	1.18e-9	Glycated hemoglobin levels;
LUSC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.25	0.45	2.83e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11645453	chr3:52864694	ITIH4	0.35	8.2	0.41	5.41e-15	Bipolar disorder;
LUSC	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg04455712	chr21:45112962	RRP1B	-0.48	-8.98	-0.44	2.06e-17	Mean corpuscular volume;
LUSC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg07703079	chr11:430292	ANO9	0.6	6.52	0.34	2.66e-10	Body mass index;
LUSC	cis	rs12912251	1.000	rs12916379	chr15:38991520	A/G	cg01338139	chr15:38987640	C15orf53	-0.49	-6.8	-0.35	4.75e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs2262909	1.000	rs2175366	chr19:22128279	C/T	cg11619707	chr19:22235551	ZNF257	-0.39	-5.72	-0.3	2.32e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11958404	0.929	rs79656592	chr5:157430291	G/A	cg05962755	chr5:157440814	NA	0.55	6.27	0.32	1.11e-9	IgG glycosylation;
LUSC	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.56e-22	Colorectal cancer;
LUSC	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg16339924	chr4:17578868	LAP3	0.51	7.6	0.38	3.05e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	7.1	0.36	7.55e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg03289416	chr15:75166202	SCAMP2	0.43	6.61	0.34	1.56e-10	Breast cancer;
LUSC	cis	rs367615	0.537	rs17161729	chr5:108660528	C/G	cg17395555	chr5:108820864	NA	-0.52	-9.28	-0.45	2.24e-18	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	0.57	9.09	0.45	8.73e-18	Breast cancer;
LUSC	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.44	6.57	0.34	1.89e-10	Axial length;
LUSC	cis	rs62400317	0.826	rs12194682	chr6:45320520	T/A	cg20913747	chr6:44695427	NA	-0.47	-7.74	-0.39	1.18e-13	Total body bone mineral density;
LUSC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg24690094	chr11:67383802	NA	0.43	8.31	0.41	2.36e-15	Mean corpuscular volume;
LUSC	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.37	0.49	5.04e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.12	-0.36	6.79e-12	Colorectal cancer;
LUSC	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-7.69	-0.39	1.7e-13	Total cholesterol levels;
LUSC	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg08085267	chr17:45401833	C17orf57	-0.6	-9.97	-0.48	1.12e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg04234412	chr22:24373322	LOC391322	-0.86	-14.01	-0.61	2.2e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs73206853	0.764	rs55991901	chr12:110962702	C/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	7.83e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs259282	0.602	rs194589	chr19:33144621	T/C	cg22980127	chr19:33182716	NUDT19	-0.42	-5.69	-0.3	2.77e-8	Schizophrenia;
LUSC	cis	rs9811920	0.665	rs1872609	chr3:99906579	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.33	-6.39	-0.33	5.63e-10	Axial length;
LUSC	cis	rs1030268	0.546	rs12707100	chr7:133274376	T/C	cg10665199	chr7:133106180	EXOC4	0.61	6.83	0.35	4.12e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6580649	0.941	rs4760615	chr12:48428150	A/G	cg24011408	chr12:48396354	COL2A1	0.51	6.83	0.35	4.11e-11	Lung cancer;
LUSC	cis	rs897984	0.647	rs8060857	chr16:31002720	G/A	cg02466173	chr16:30829666	NA	0.57	10.91	0.51	6.45e-24	Dementia with Lewy bodies;
LUSC	cis	rs6060717	0.536	rs11696912	chr20:34497660	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.56	5.8	0.3	1.55e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	0.96	18.57	0.71	2.27e-53	Heart rate;
LUSC	cis	rs7561273	0.586	rs7589717	chr2:24357463	G/A	cg06627628	chr2:24431161	ITSN2	-0.51	-6.8	-0.35	4.71e-11	Quantitative traits;
LUSC	cis	rs2050392	1.000	rs2253585	chr10:30696503	C/T	cg18806716	chr10:30721971	MAP3K8	-0.46	-7.44	-0.38	8.6e-13	Inflammatory bowel disease;
LUSC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg20203395	chr5:56204925	C5orf35	-0.81	-10.73	-0.51	2.93e-23	Initial pursuit acceleration;
LUSC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg20243544	chr17:37824526	PNMT	0.52	7.41	0.38	1.06e-12	Asthma;
LUSC	cis	rs9535307	0.769	rs9535306	chr13:50290817	A/G	cg04663916	chr13:50265991	EBPL	0.49	6.31	0.33	8.8e-10	Obesity-related traits;
LUSC	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg04218760	chr10:45406644	TMEM72	-0.3	-7.41	-0.38	1.03e-12	Mean corpuscular volume;
LUSC	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.69	-10.82	-0.51	1.35e-23	Alcohol dependence;
LUSC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg11812906	chr14:75593930	NEK9	0.63	10.04	0.48	6.8e-21	Height;
LUSC	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg11632617	chr15:75315747	PPCDC	-0.5	-6.45	-0.33	4.03e-10	Blood trace element (Zn levels);
LUSC	cis	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg17187183	chr4:55093834	PDGFRA	0.4	6.11	0.32	2.83e-9	Corneal astigmatism;
LUSC	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg04827223	chr11:72435913	ARAP1	-0.67	-8.4	-0.42	1.28e-15	Type 2 diabetes;
LUSC	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg12940439	chr1:67600707	NA	0.36	6.08	0.32	3.3e-9	Psoriasis;
LUSC	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg21775007	chr8:11205619	TDH	0.46	6.56	0.34	2.06e-10	Mood instability;
LUSC	trans	rs2262909	0.962	rs425781	chr19:22229306	A/G	cg17074339	chr11:11642133	GALNTL4	-0.46	-7.07	-0.36	9.1e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg04871131	chr7:94954202	PON1	-0.38	-6.06	-0.31	3.74e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs877282	0.583	rs12358255	chr10:828626	C/T	cg13775593	chr10:823151	NA	0.3	5.99	0.31	5.52e-9	Uric acid levels;
LUSC	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.56	-0.46	2.64e-19	Retinal vascular caliber;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03010907	chr6:131384623	EPB41L2	-0.49	-6.31	-0.33	9.11e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg13010199	chr12:38710504	ALG10B	0.5	7.81	0.39	7.56e-14	Morning vs. evening chronotype;
LUSC	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg01294253	chr9:136912663	BRD3	0.36	6.35	0.33	6.86e-10	Platelet distribution width;
LUSC	cis	rs983392	0.709	rs2015475	chr11:59998963	A/C	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.1	-0.32	2.9e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6484504	0.625	rs796341	chr11:31414151	G/A	cg06552810	chr11:31128660	NA	0.35	6.01	0.31	4.86e-9	Red blood cell count;
LUSC	trans	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg11693508	chr17:37793320	STARD3	0.59	7.66	0.39	2.04e-13	Bipolar disorder;
LUSC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06112835	chr11:68658793	MRPL21	0.52	7.78	0.39	8.9e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9815354	0.857	rs6798152	chr3:42023558	A/T	cg03022575	chr3:42003672	ULK4	0.57	6.0	0.31	5.24e-9	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs3764021	0.870	rs2401393	chr12:9879084	C/T	cg20894963	chr12:9885564	CLECL1	0.34	7.0	0.36	1.44e-11	Type 1 diabetes;
LUSC	cis	rs78545713	0.649	rs79308455	chr6:26224377	A/G	cg23601095	chr6:26197514	HIST1H3D	0.66	5.79	0.3	1.64e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.67	9.83	0.47	3.49e-20	Huntington's disease progression;
LUSC	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg21905437	chr5:178450457	ZNF879	0.43	5.71	0.3	2.54e-8	Pubertal anthropometrics;
LUSC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg06238570	chr21:40685208	BRWD1	0.48	7.28	0.37	2.45e-12	Cognitive function;
LUSC	cis	rs7605827	0.866	rs6717492	chr2:15538171	A/G	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg03526776	chr6:41159608	TREML2	0.34	6.53	0.34	2.51e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6693567	0.516	rs519126	chr1:150288859	T/G	cg15654264	chr1:150340011	RPRD2	-0.44	-7.31	-0.37	1.98e-12	Migraine;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07805730	chr1:85156430	SSX2IP	0.45	6.09	0.32	3.16e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.56	0.34	2.09e-10	Menopause (age at onset);
LUSC	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg26597838	chr10:835615	NA	0.81	11.31	0.53	2.58e-25	Eosinophil percentage of granulocytes;
LUSC	trans	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	cis	rs240768	1.000	rs171257	chr6:101048197	T/A	cg12253828	chr6:101329408	ASCC3	0.83	5.71	0.3	2.5e-8	Economic and political preferences (immigration/crime);
LUSC	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.0	-0.44	1.7e-17	Total cholesterol levels;
LUSC	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.75	-12.17	-0.55	1.84e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg26566898	chr11:117069891	TAGLN	0.33	6.39	0.33	5.73e-10	Blood protein levels;
LUSC	cis	rs11608355	0.545	rs36094325	chr12:109911542	A/T	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg05805236	chr11:65401703	PCNXL3	-0.53	-8.93	-0.44	2.85e-17	Non-alcoholic fatty liver disease histology (lobular);
LUSC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg12863693	chr15:85201151	NMB	0.36	7.01	0.36	1.34e-11	Schizophrenia;
LUSC	cis	rs7809950	0.593	rs62482503	chr7:106987988	A/G	cg23024343	chr7:107201750	COG5	-0.66	-9.92	-0.48	1.76e-20	Coronary artery disease;
LUSC	cis	rs7712401	0.601	rs30035	chr5:122278545	A/G	cg19077854	chr5:122220652	SNX24	0.41	9.16	0.45	5.23e-18	Mean platelet volume;
LUSC	trans	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.15	0.45	5.56e-18	Mean corpuscular volume;
LUSC	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg10356904	chr22:49881777	NA	-0.32	-7.2	-0.37	4.03e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9905704	0.560	rs2632507	chr17:56530597	C/A	cg19466818	chr17:56409534	MIR142	-0.36	-6.74	-0.35	7.06e-11	Testicular germ cell tumor;
LUSC	cis	rs4988958	0.584	rs12712149	chr2:103045193	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.06	0.36	9.92e-12	Asthma (childhood onset);
LUSC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	0.58	9.25	0.45	2.71e-18	Breast cancer;
LUSC	cis	rs2742234	0.504	rs7093409	chr10:43740067	A/G	cg02780029	chr10:43622663	RET	0.32	5.85	0.3	1.19e-8	Hirschsprung disease;
LUSC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.61e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.88	-0.4	4.75e-14	Morning vs. evening chronotype;
LUSC	cis	rs6977660	0.660	rs12531296	chr7:19816450	A/C	cg05791153	chr7:19748676	TWISTNB	0.68	7.22	0.37	3.49e-12	Thyroid stimulating hormone;
LUSC	cis	rs17253792	0.822	rs76267907	chr14:56066969	C/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg18681998	chr4:17616180	MED28	0.81	14.55	0.62	1.76e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg10909506	chr17:38081995	ORMDL3	0.34	6.07	0.32	3.53e-9	Self-reported allergy;
LUSC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg05340658	chr4:99064831	C4orf37	0.62	9.77	0.47	5.28e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg21770322	chr7:97807741	LMTK2	0.56	10.24	0.49	1.34e-21	Breast cancer;
LUSC	cis	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg26958806	chr6:27640298	NA	-0.74	-6.1	-0.32	2.94e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg00750074	chr16:89608354	SPG7	-0.54	-9.79	-0.47	4.57e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg17623882	chr6:41773611	USP49	-0.59	-10.1	-0.48	4.22e-21	Menarche (age at onset);
LUSC	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg09307838	chr4:120376055	NA	0.51	7.71	0.39	1.48e-13	Diastolic blood pressure;
LUSC	cis	rs2219968	0.676	rs11781543	chr8:78836409	C/T	cg00738934	chr8:78996279	NA	-0.35	-6.0	-0.31	5.12e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg11584989	chr19:19387371	SF4	0.6	7.08	0.36	8.81e-12	Bipolar disorder;
LUSC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg03732007	chr1:2071316	PRKCZ	-0.53	-9.49	-0.46	4.59e-19	Height;
LUSC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg15105969	chr2:36825350	FEZ2	-0.51	-7.47	-0.38	7.07e-13	Height;
LUSC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.19	0.37	4.33e-12	Mean platelet volume;
LUSC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06544989	chr22:39130855	UNC84B	0.37	6.41	0.33	5.04e-10	Menopause (age at onset);
LUSC	trans	rs12200782	1.000	rs12208390	chr6:26437106	C/T	cg11837749	chr1:55047332	ACOT11	0.58	6.23	0.32	1.41e-9	Small cell lung carcinoma;
LUSC	cis	rs7818345	1.000	rs13278459	chr8:19297583	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.37	7.12	0.36	6.78e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	trans	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg19402173	chr7:128379420	CALU	-0.46	-7.11	-0.36	6.93e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22857025	chr5:266934	NA	-1.16	-14.35	-0.62	1.06e-36	Breast cancer;
LUSC	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.43	5.83	0.3	1.27e-8	IgG glycosylation;
LUSC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22307029	chr19:49891270	CCDC155	0.63	8.09	0.4	1.13e-14	Multiple sclerosis;
LUSC	trans	rs208520	1.000	rs208537	chr6:66963544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-12.34	-0.56	4.42e-29	Exhaled nitric oxide output;
LUSC	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.77	-0.47	5.47e-20	Hemoglobin concentration;
LUSC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.41	0.46	8.32e-19	Monocyte percentage of white cells;
LUSC	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg05855489	chr10:104503620	C10orf26	0.53	8.11	0.41	9.87e-15	Arsenic metabolism;
LUSC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg17420585	chr12:42539391	GXYLT1	-0.4	-7.97	-0.4	2.61e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg05283184	chr6:79620031	NA	-0.47	-8.97	-0.44	2.13e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg24296786	chr1:45957014	TESK2	0.47	6.86	0.35	3.33e-11	High light scatter reticulocyte count;
LUSC	cis	rs7771547	0.589	rs6941918	chr6:36514721	T/G	cg07856975	chr6:36356162	ETV7	0.41	6.01	0.31	4.76e-9	Platelet distribution width;
LUSC	trans	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg25214090	chr10:38739885	LOC399744	0.39	5.96	0.31	6.43e-9	Corneal astigmatism;
LUSC	trans	rs2262909	0.849	rs2666447	chr19:22132868	T/A	cg05197062	chr11:11642011	GALNTL4	-0.5	-6.96	-0.36	1.78e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg21798802	chr22:38057573	PDXP	0.48	10.64	0.5	6.02e-23	Fat distribution (HIV);
LUSC	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg03342759	chr3:160939853	NMD3	-0.57	-9.81	-0.47	3.88e-20	Morning vs. evening chronotype;
LUSC	cis	rs2455601	0.638	rs2568092	chr11:8987438	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.4	6.29	0.33	9.73e-10	Schizophrenia;
LUSC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg18681998	chr4:17616180	MED28	0.83	15.21	0.64	4.52e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg04362960	chr10:104952993	NT5C2	0.61	9.4	0.46	8.7e-19	Arsenic metabolism;
LUSC	trans	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg19894588	chr14:64061835	NA	-0.56	-7.34	-0.37	1.68e-12	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs10992471	0.528	rs10117627	chr9:95203953	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.25	-0.32	1.23e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.56	-9.23	-0.45	3.27e-18	Breast cancer;
LUSC	trans	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg25214090	chr10:38739885	LOC399744	0.42	6.3	0.33	9.58e-10	Corneal astigmatism;
LUSC	cis	rs9653442	1.000	rs1160542	chr2:100832155	A/G	cg22139774	chr2:100720529	AFF3	0.44	7.77	0.39	9.6e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs911119	0.954	rs35966482	chr20:23620716	G/T	cg16589663	chr20:23618590	CST3	0.59	6.95	0.36	1.9e-11	Chronic kidney disease;
LUSC	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg25208724	chr1:156163844	SLC25A44	0.78	6.37	0.33	6.32e-10	Paclitaxel disposition in epithelial ovarian cancer;
LUSC	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg16472389	chr18:74514291	NA	0.63	9.64	0.47	1.49e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LUSC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	0.96	19.16	0.72	1.04e-55	Cognitive function;
LUSC	cis	rs2235544	0.565	rs635509	chr1:54469227	A/G	cg25741118	chr1:54482237	LDLRAD1	0.28	5.98	0.31	5.61e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	trans	rs9472138	0.756	rs2396084	chr6:43804825	A/G	cg19073447	chr10:134024191	STK32C	0.38	6.0	0.31	5.21e-9	Type 2 diabetes;Thyroid hormone levels;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24001477	chr11:31531492	ELP4;IMMP1L	0.4	6.44	0.33	4.2e-10	Asthma;
LUSC	trans	rs75804782	0.641	rs55740938	chr2:239332647	G/A	cg01134436	chr17:81009848	B3GNTL1	0.67	6.04	0.31	4.2e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs2274273	0.840	rs72715769	chr14:55762429	C/G	cg04306507	chr14:55594613	LGALS3	0.54	12.08	0.55	3.86e-28	Protein biomarker;
LUSC	cis	rs3820928	0.839	rs13413292	chr2:227893747	G/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.57	-0.38	3.59e-13	Pulmonary function;
LUSC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	11.12	0.52	1.21e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-13.05	-0.58	1.02e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.38	7.39e-13	Bipolar disorder;
LUSC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.6e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs847577	0.540	rs3847055	chr7:97680645	A/G	cg21770322	chr7:97807741	LMTK2	-0.39	-5.8	-0.3	1.53e-8	Breast cancer;
LUSC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg22920501	chr2:26401640	FAM59B	0.76	10.9	0.51	7.4e-24	Gut microbiome composition (summer);
LUSC	cis	rs10865397	0.506	rs6546810	chr2:73389716	A/G	cg24220031	chr2:73402428	NA	-0.26	-6.17	-0.32	1.96e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.91	-13.58	-0.6	9.61e-34	Alzheimer's disease;
LUSC	cis	rs10792830	1.000	rs10792830	chr11:85838808	G/A	cg07180834	chr11:85838833	NA	-0.3	-5.84	-0.3	1.25e-8	Psychosis and Alzheimer's disease;
LUSC	cis	rs4664308	0.692	rs10497213	chr2:160963603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.62	-10.2	-0.49	1.94e-21	Idiopathic membranous nephropathy;
LUSC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03264133	chr6:25882463	NA	-0.5	-9.11	-0.45	7.57e-18	Blood metabolite levels;
LUSC	cis	rs4363385	0.782	rs10788857	chr1:153024941	T/G	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.41	-0.38	1.07e-12	Inflammatory skin disease;
LUSC	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.64	11.5	0.53	5.31e-26	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06022373	chr22:39101656	GTPBP1	0.66	9.43	0.46	7.12e-19	Menopause (age at onset);
LUSC	cis	rs9905704	0.918	rs302862	chr17:56697444	G/T	cg12560992	chr17:57184187	TRIM37	0.55	7.74	0.39	1.19e-13	Testicular germ cell tumor;
LUSC	trans	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-8.86	-0.44	4.74e-17	Obesity-related traits;
LUSC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg12963246	chr6:28129442	ZNF389	0.38	5.66	0.3	3.28e-8	Cardiac Troponin-T levels;
LUSC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	10.02	0.48	7.97e-21	Personality dimensions;
LUSC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.39	-6.05	-0.31	3.89e-9	Platelet count;
LUSC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg05025164	chr4:1340916	KIAA1530	0.54	8.45	0.42	9.43e-16	Longevity;
LUSC	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg10845886	chr2:3471009	TTC15	-0.61	-7.75	-0.39	1.09e-13	Neurofibrillary tangles;
LUSC	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.11	0.41	9.98e-15	Axial length;
LUSC	cis	rs6087990	0.863	rs1569686	chr20:31367079	G/T	cg13636640	chr20:31349939	DNMT3B	0.99	21.29	0.76	3.66e-64	Ulcerative colitis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05743054	chr3:158288903	MLF1	0.53	7.45	0.38	7.99e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7781370	0.961	rs4383904	chr7:96121636	T/C	cg00604640	chr7:96133485	NA	-0.33	-5.82	-0.3	1.36e-8	Bone mineral density (hip);
LUSC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg14664628	chr15:75095509	CSK	-0.55	-8.59	-0.43	3.37e-16	Breast cancer;
LUSC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg15445000	chr17:37608096	MED1	-0.39	-6.71	-0.34	8.49e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.07e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.56	-0.34	2.04e-10	Neuroticism;
LUSC	trans	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg05267876	chr1:229644265	NUP133	-0.56	-6.08	-0.32	3.25e-9	Lung cancer in ever smokers;
LUSC	trans	rs72674100	1.000	rs72882340	chr4:97993584	A/C	cg09670535	chr1:18959427	PAX7	-0.61	-6.23	-0.32	1.41e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.88	0.31	1.02e-8	Lung cancer;
LUSC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg18240062	chr17:79603768	NPLOC4	-0.68	-12.43	-0.56	2.05e-29	Eye color traits;
LUSC	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg06552810	chr11:31128660	NA	0.4	7.17	0.37	4.83e-12	Red blood cell count;
LUSC	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.54	-10.61	-0.5	7.47e-23	Educational attainment;
LUSC	trans	rs11696501	0.789	rs1487319	chr20:44295943	A/G	cg03272292	chr12:48577362	C12orf68	0.49	5.95	0.31	6.79e-9	Brain structure;
LUSC	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.6	6.13	0.32	2.52e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg13531842	chr10:38383804	ZNF37A	-0.46	-7.23	-0.37	3.4e-12	Extrinsic epigenetic age acceleration;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg13679077	chr7:22862647	TOMM7	0.38	6.01	0.31	4.92e-9	Schizophrenia;
LUSC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg03732007	chr1:2071316	PRKCZ	-0.55	-9.89	-0.48	2.07e-20	Height;
LUSC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.93	-0.48	1.59e-20	Hemoglobin concentration;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25814383	chr19:19336240	NCAN	0.74	6.85	0.35	3.65e-11	Cognitive performance;
LUSC	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-7.03	-0.36	1.17e-11	Monocyte count;
LUSC	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg13010199	chr12:38710504	ALG10B	0.56	8.38	0.42	1.49e-15	Morning vs. evening chronotype;
LUSC	cis	rs1729407	0.786	rs5100	chr11:116692694	G/A	cg08985259	chr11:116699649	APOC3	-0.25	-5.78	-0.3	1.76e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg24250549	chr1:154909240	PMVK	0.65	10.87	0.51	9.05e-24	Prostate cancer;
LUSC	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg07382826	chr16:28625726	SULT1A1	0.27	5.78	0.3	1.68e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg26876637	chr1:152193138	HRNR	-0.42	-5.92	-0.31	7.86e-9	Atopic dermatitis;
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.71	10.92	0.51	6.12e-24	Lymphocyte counts;
LUSC	cis	rs67072384	1.000	rs7124056	chr11:72444747	C/T	cg04827223	chr11:72435913	ARAP1	0.73	7.12	0.36	6.54e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.64	0.63	8.06e-38	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs3771570	1.000	rs7557535	chr2:242206555	T/C	cg21155796	chr2:242212141	HDLBP	0.68	7.52	0.38	5.12e-13	Prostate cancer;
LUSC	cis	rs472402	0.623	rs8192131	chr5:6636465	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.51	-7.69	-0.39	1.66e-13	Response to amphetamines;
LUSC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.64	-11.0	-0.52	3.06e-24	Lung cancer;
LUSC	cis	rs35123781	0.955	rs34530707	chr5:139059016	G/A	cg10513866	chr5:139070639	NA	0.46	8.96	0.44	2.35e-17	Schizophrenia;
LUSC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg21733973	chr7:65235735	NA	0.41	5.74	0.3	2.09e-8	Calcium levels;
LUSC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	16.73	0.68	4.74e-46	Gut microbiome composition (summer);
LUSC	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg03929089	chr4:120376271	NA	-0.58	-7.46	-0.38	7.43e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2692947	0.702	rs6717101	chr2:96505552	C/T	cg22654517	chr2:96458247	NA	0.38	7.5	0.38	5.99e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg17366294	chr4:99064904	C4orf37	0.59	10.46	0.5	2.54e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg14541582	chr5:601475	NA	-0.37	-5.65	-0.3	3.43e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg04518342	chr5:131593106	PDLIM4	0.45	8.29	0.41	2.72e-15	Breast cancer;
LUSC	cis	rs7000551	0.689	rs4872000	chr8:22337323	G/T	cg12081754	chr8:22256438	SLC39A14	0.44	6.78	0.35	5.58e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs79387448	0.745	rs75644281	chr2:103151316	A/T	cg09003973	chr2:102972529	NA	0.86	8.44	0.42	9.66e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg13660082	chr14:53194042	PSMC6	-0.78	-6.81	-0.35	4.55e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg16339924	chr4:17578868	LAP3	0.63	9.45	0.46	6.16e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg14895029	chr7:2775587	GNA12	-0.44	-6.89	-0.35	2.81e-11	Height;
LUSC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.56	11.17	0.52	7.79e-25	Asthma (sex interaction);
LUSC	cis	rs7202877	0.610	rs3851735	chr16:75372092	A/G	cg04384234	chr16:75411784	CFDP1	-0.59	-7.85	-0.39	5.82e-14	Type 2 diabetes;Type 1 diabetes;
LUSC	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.0	-0.31	5.01e-9	HDL cholesterol;
LUSC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	0.95	18.49	0.71	4.54e-53	Cognitive function;
LUSC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.33	2.98e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg02527881	chr3:46936655	PTH1R	0.38	6.53	0.34	2.42e-10	Colorectal cancer;
LUSC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg22823121	chr1:150693482	HORMAD1	0.57	8.78	0.43	8.67e-17	Melanoma;
LUSC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg23352942	chr3:46931381	PTH1R	0.39	7.67	0.39	1.93e-13	Birth weight;
LUSC	cis	rs9653442	0.564	rs10175599	chr2:100787635	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-7.04	-0.36	1.09e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg08200582	chr11:442649	ANO9	-0.57	-6.4	-0.33	5.31e-10	Body mass index;
LUSC	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg05340658	chr4:99064831	C4orf37	0.45	7.08	0.36	8.69e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg01879757	chr17:41196368	BRCA1	-0.5	-7.94	-0.4	3.06e-14	Menopause (age at onset);
LUSC	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg23277830	chr1:3704460	LRRC47	0.35	6.68	0.34	9.77e-11	Red cell distribution width;
LUSC	trans	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.37	-5.98	-0.31	5.67e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12210905	0.925	rs115507154	chr6:26970811	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg23711669	chr6:146136114	FBXO30	0.76	13.58	0.6	9.51e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.83e-30	Motion sickness;
LUSC	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg14634687	chr17:47094252	IGF2BP1	0.32	6.96	0.36	1.79e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-15.53	-0.65	2.62e-41	Heart rate;
LUSC	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-1.1	-22.13	-0.77	1.93e-67	Coronary artery disease;
LUSC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.11	-0.48	3.92e-21	Monocyte count;
LUSC	cis	rs6142102	0.961	rs4911392	chr20:32570518	G/C	cg08999081	chr20:33150536	PIGU	0.34	5.9	0.31	9.15e-9	Skin pigmentation;
LUSC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.5	0.42	6.51e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	7.34	0.37	1.6e-12	Personality dimensions;
LUSC	cis	rs17253792	0.822	rs17683614	chr14:56041058	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.04	-0.36	1.1e-11	Putamen volume;
LUSC	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-10.82	-0.51	1.38e-23	Bladder cancer;
LUSC	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg03605463	chr16:89740564	NA	-0.55	-8.7	-0.43	1.55e-16	Hemoglobin concentration;
LUSC	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-17.14	-0.68	1.09e-47	Exhaled nitric oxide output;
LUSC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg04315214	chr1:2043799	PRKCZ	-0.37	-7.27	-0.37	2.61e-12	Height;
LUSC	cis	rs9311676	0.656	rs11721168	chr3:58408679	G/A	cg13750441	chr3:58318267	PXK	0.35	6.77	0.35	5.86e-11	Systemic lupus erythematosus;
LUSC	cis	rs6750047	0.932	rs2116232	chr2:38268718	C/A	cg07380506	chr2:38303506	CYP1B1	0.47	6.5	0.34	2.85e-10	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	8.6	0.43	3.14e-16	Lung cancer in ever smokers;
LUSC	cis	rs554111	0.634	rs10799673	chr1:21274671	T/G	cg01072550	chr1:21505969	NA	0.39	6.0	0.31	5.01e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg17470449	chr10:769945	NA	0.49	6.44	0.33	4.26e-10	Uric acid levels;
LUSC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.29	0.45	2.01e-18	Prudent dietary pattern;
LUSC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg16524733	chr11:117070046	TAGLN	0.44	7.73	0.39	1.29e-13	Blood protein levels;
LUSC	cis	rs9359856	0.564	rs36040566	chr6:90372574	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.89	-8.73	-0.43	1.25e-16	Bipolar disorder;
LUSC	cis	rs68170813	0.599	rs77878465	chr7:106890996	G/A	cg02696742	chr7:106810147	HBP1	-0.62	-9.43	-0.46	7.17e-19	Coronary artery disease;
LUSC	trans	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.51	8.66	0.43	2.06e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12472274	0.646	rs11688732	chr2:239096622	G/T	cg17459225	chr2:239074497	NA	0.58	7.94	0.4	3.18e-14	Phospholipid levels (plasma);
LUSC	cis	rs7615316	0.934	rs6791816	chr3:142233990	T/C	cg16271453	chr3:142027066	XRN1	-0.4	-6.88	-0.35	3.04e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg07828340	chr4:882639	GAK	1.0	11.54	0.53	3.69e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs73206853	0.841	rs73191816	chr12:110918564	G/A	cg12870014	chr12:110450643	ANKRD13A	0.67	6.47	0.33	3.57e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-9.47	-0.46	5.26e-19	Platelet distribution width;
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.25	-0.37	2.99e-12	Electroencephalogram traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22346429	chr12:132504721	EP400	0.46	6.27	0.32	1.13e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg13206674	chr6:150067644	NUP43	0.62	10.12	0.48	3.53e-21	Lung cancer;
LUSC	cis	rs262150	0.566	rs262159	chr7:158772172	C/T	cg12590608	chr7:158785262	NA	-0.35	-6.05	-0.31	3.84e-9	Facial morphology (factor 20);
LUSC	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.91	18.72	0.72	5.65e-54	Ulcerative colitis;
LUSC	cis	rs9653442	1.000	rs11676922	chr2:100806940	T/A	cg22139774	chr2:100720529	AFF3	-0.44	-8.01	-0.4	1.95e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg15790184	chr11:494944	RNH1	0.53	6.01	0.31	4.84e-9	Body mass index;
LUSC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-1.01	-15.27	-0.64	2.58e-40	Initial pursuit acceleration;
LUSC	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.43	-6.66	-0.34	1.1e-10	Tonsillectomy;
LUSC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg16989086	chr20:62203971	PRIC285	0.46	6.41	0.33	5.09e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUSC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg13206674	chr6:150067644	NUP43	0.62	9.96	0.48	1.24e-20	Lung cancer;
LUSC	cis	rs7177699	0.557	rs7176187	chr15:79121373	A/G	cg15571903	chr15:79123663	NA	0.33	6.02	0.31	4.49e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs11018904	0.906	rs10501713	chr11:89953013	G/A	cg26834418	chr11:89957033	CHORDC1	-0.51	-6.28	-0.32	1.06e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg12908607	chr1:44402522	ARTN	0.48	6.92	0.35	2.36e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.66	-8.39	-0.42	1.36e-15	Menarche (age at onset);
LUSC	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg23711669	chr6:146136114	FBXO30	0.74	12.45	0.56	1.76e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg12002119	chr2:101014098	CHST10	-0.38	-6.31	-0.33	9.01e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.78	-13.77	-0.6	1.8e-34	Cognitive function;
LUSC	cis	rs11158026	0.757	rs9285583	chr14:55431435	T/C	cg04306507	chr14:55594613	LGALS3	0.34	6.48	0.33	3.27e-10	Parkinson's disease;
LUSC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-7.96	-0.4	2.62e-14	Type 2 diabetes;
LUSC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs12464559	0.522	rs7583148	chr2:152620986	C/T	cg01189475	chr2:152685088	ARL5A	0.64	6.99	0.36	1.49e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg01528321	chr10:82214614	TSPAN14	0.61	9.07	0.44	1.06e-17	Post bronchodilator FEV1;
LUSC	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg15654264	chr1:150340011	RPRD2	0.66	10.96	0.51	4.44e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg13010199	chr12:38710504	ALG10B	-0.52	-7.93	-0.4	3.26e-14	Morning vs. evening chronotype;
LUSC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg13902645	chr11:5959945	NA	-0.53	-8.33	-0.41	2.08e-15	DNA methylation (variation);
LUSC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-7.55	-0.38	4.13e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21028142	chr17:79581711	NPLOC4	-0.32	-7.49	-0.38	6.23e-13	Eye color traits;
LUSC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-6.87	-0.35	3.18e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs8014204	0.762	rs10148293	chr14:75296831	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-8.11	-0.41	9.81e-15	Caffeine consumption;
LUSC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-9.91	-0.48	1.88e-20	Personality dimensions;
LUSC	cis	rs2479724	0.613	rs9367113	chr6:41809801	T/G	cg17623882	chr6:41773611	USP49	-0.53	-7.35	-0.37	1.51e-12	Menarche (age at onset);
LUSC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg05861140	chr6:150128134	PCMT1	-0.39	-5.89	-0.31	9.35e-9	Lung cancer;
LUSC	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg13175981	chr1:150552382	MCL1	0.46	6.43	0.33	4.43e-10	Monocyte chemoattractant protein-1 levels;
LUSC	cis	rs13401104	0.740	rs12465430	chr2:237113578	C/T	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.35e-8	Educational attainment;
LUSC	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg03859395	chr2:55845619	SMEK2	-0.84	-15.21	-0.64	4.68e-40	Metabolic syndrome;
LUSC	cis	rs11690935	0.550	rs7584187	chr2:172866105	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.53	-8.18	-0.41	6.15e-15	Schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23260799	chr11:451101	PTDSS2	0.41	6.37	0.33	6.13e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7178572	1.000	rs7178572	chr15:77747190	A/G	cg22256960	chr15:77711686	NA	-0.53	-8.99	-0.44	1.84e-17	Type 2 diabetes;
LUSC	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg24558204	chr6:135376177	HBS1L	-0.58	-8.9	-0.44	3.69e-17	Red blood cell count;
LUSC	cis	rs17433780	0.808	rs1074541	chr1:89509499	A/G	cg09516651	chr1:89888402	LOC400759	0.61	11.67	0.54	1.25e-26	Carotid intima media thickness;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14210236	chr1:145208980	NOTCH2NL	-0.44	-6.37	-0.33	6.43e-10	Electrocardiographic conduction measures;
LUSC	cis	rs12220238	1.000	rs10824084	chr10:75911415	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.27	0.37	2.65e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg09092052	chr15:45571596	NA	0.42	5.77	0.3	1.85e-8	Glomerular filtration rate;
LUSC	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.63	0.47	1.53e-19	Lymphocyte counts;
LUSC	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg08477640	chr19:41863820	B9D2	0.53	7.68	0.39	1.75e-13	Colorectal cancer;
LUSC	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21659725	chr3:3221576	CRBN	0.62	8.77	0.43	9.55e-17	Resting heart rate;
LUSC	cis	rs2274273	0.661	rs2147964	chr14:55564395	T/G	cg04306507	chr14:55594613	LGALS3	0.5	10.87	0.51	9.15e-24	Protein biomarker;
LUSC	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg22431228	chr1:16359049	CLCNKA	-0.56	-12.39	-0.56	2.84e-29	Systolic blood pressure;
LUSC	cis	rs3772130	1.000	rs17691170	chr3:121357626	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	9.57	0.46	2.47e-19	Cognitive performance;
LUSC	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.34	-7.51	-0.38	5.51e-13	Dupuytren's disease;
LUSC	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.64	-0.5	5.77e-23	Coffee consumption (cups per day);
LUSC	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.53	0.38	4.83e-13	Morning vs. evening chronotype;
LUSC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg07741184	chr6:167504864	NA	-0.35	-6.39	-0.33	5.46e-10	Crohn's disease;
LUSC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-8.63	-0.43	2.58e-16	Hemoglobin concentration;
LUSC	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.32	0.37	1.81e-12	Iron status biomarkers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08679808	chr17:79886116	LOC92659;MAFG	-0.49	-6.5	-0.34	2.91e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg08601574	chr20:25228251	PYGB	-0.44	-6.76	-0.35	6.17e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg18351406	chr4:77819688	ANKRD56	0.55	8.19	0.41	5.55e-15	Emphysema distribution in smoking;
LUSC	cis	rs2224391	0.628	rs9392666	chr6:5249888	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.49	-6.75	-0.35	6.5500000000000006e-11	Height;
LUSC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	8.12	0.41	9.21e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs61931739	0.635	rs10743836	chr12:33961680	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.72	-0.35	7.9e-11	Morning vs. evening chronotype;
LUSC	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg04450456	chr4:17643702	FAM184B	-0.4	-6.43	-0.33	4.33e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.67	-0.3	3.01e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg05340658	chr4:99064831	C4orf37	0.58	9.44	0.46	6.74e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg14092988	chr3:52407081	DNAH1	0.31	5.96	0.31	6.37e-9	Bipolar disorder;
LUSC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg23630131	chr7:65973040	NA	0.21	5.83	0.3	1.33e-8	Aortic root size;
LUSC	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg03948781	chr1:205179583	DSTYK	0.32	6.21	0.32	1.61e-9	Red blood cell count;
LUSC	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg27588902	chr6:42928151	GNMT	0.28	5.91	0.31	8.42e-9	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
LUSC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg18305652	chr10:134549665	INPP5A	0.46	6.73	0.35	7.44e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg11062466	chr8:58055876	NA	0.66	8.52	0.42	5.58e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1775715	0.737	rs2799012	chr10:32103077	C/T	cg26784012	chr10:32216390	ARHGAP12	0.44	7.39	0.37	1.21e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg17143192	chr8:8559678	CLDN23	0.38	5.98	0.31	5.62e-9	Mood instability;
LUSC	cis	rs6942756	0.955	rs68187585	chr7:129002211	T/C	cg02491457	chr7:128862824	NA	-0.53	-7.07	-0.36	8.91e-12	White matter hyperintensity burden;
LUSC	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg04691961	chr3:161091175	C3orf57	-0.35	-6.06	-0.31	3.63e-9	Morning vs. evening chronotype;
LUSC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	9.46	0.46	5.81e-19	Personality dimensions;
LUSC	cis	rs11871801	0.517	rs35635959	chr17:40772288	T/C	cg16308533	chr17:40838983	CNTNAP1	0.39	5.8	0.3	1.55e-8	Crohn's disease;
LUSC	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.07	0.48	5.08e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg10909506	chr17:38081995	ORMDL3	0.34	5.91	0.31	8.59e-9	Self-reported allergy;
LUSC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg27494647	chr7:150038898	RARRES2	0.35	5.69	0.3	2.77e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg09877947	chr5:131593287	PDLIM4	-0.44	-6.62	-0.34	1.44e-10	Breast cancer;
LUSC	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg22906224	chr7:99728672	NA	-0.5	-6.99	-0.36	1.49e-11	Coronary artery disease;
LUSC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-1.01	-16.99	-0.68	4.2e-47	Body mass index;
LUSC	cis	rs1595825	0.891	rs16867018	chr2:198521490	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.63	-0.34	1.34e-10	Ulcerative colitis;
LUSC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	0.92	15.38	0.64	1.02e-40	Breast cancer;
LUSC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.33	-5.87	-0.31	1.06e-8	Longevity;Endometriosis;
LUSC	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.36	-0.33	6.75e-10	Bipolar disorder;
LUSC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.56	-9.09	-0.45	9.24e-18	Tonsillectomy;
LUSC	cis	rs2274273	0.905	rs4652	chr14:55605036	A/C	cg04306507	chr14:55594613	LGALS3	0.58	13.39	0.59	4.93e-33	Protein biomarker;
LUSC	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg03859395	chr2:55845619	SMEK2	0.74	12.1	0.55	3.49e-28	Metabolic syndrome;
LUSC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg06600287	chr1:53387719	ECHDC2	-0.28	-5.72	-0.3	2.34e-8	Monocyte count;
LUSC	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg20701182	chr2:24300061	SF3B14	0.88	11.42	0.53	1.05e-25	Lymphocyte counts;
LUSC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg06008330	chr7:65541103	ASL	-0.4	-6.37	-0.33	6.37e-10	Aortic root size;
LUSC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg02423579	chr7:2872169	GNA12	-0.42	-6.32	-0.33	8.35e-10	Height;
LUSC	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	9.43	0.46	7.39e-19	Bipolar disorder;
LUSC	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg07148914	chr20:33460835	GGT7	0.54	8.42	0.42	1.11e-15	Height;
LUSC	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg23229984	chr5:148520753	ABLIM3	0.41	6.47	0.33	3.4e-10	Breast cancer;
LUSC	cis	rs9341808	0.727	rs4706834	chr6:81012605	G/T	cg08355045	chr6:80787529	NA	0.56	9.8	0.47	4.15e-20	Sitting height ratio;
LUSC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg08859206	chr1:53392774	SCP2	0.55	9.48	0.46	5.03e-19	Monocyte count;
LUSC	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg05714579	chr10:131428358	MGMT	0.52	7.9	0.4	4e-14	Response to temozolomide;
LUSC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg25767906	chr1:53392781	SCP2	-0.57	-11.35	-0.53	1.82e-25	Monocyte count;
LUSC	cis	rs6688613	0.685	rs11579987	chr1:166889364	C/G	cg07049167	chr1:166818506	POGK	-0.42	-5.95	-0.31	6.72e-9	Refractive astigmatism;
LUSC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22307029	chr19:49891270	CCDC155	0.58	7.61	0.38	2.9e-13	Multiple sclerosis;
LUSC	cis	rs1832871	0.672	rs9457343	chr6:158740567	A/G	cg07165851	chr6:158734300	TULP4	0.46	6.89	0.35	2.81e-11	Height;
LUSC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	5.95	0.31	6.6e-9	Cystic fibrosis severity;
LUSC	cis	rs240764	0.604	rs9404016	chr6:101177728	G/A	cg09795085	chr6:101329169	ASCC3	0.43	6.18	0.32	1.86e-9	Neuroticism;
LUSC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.46	-6.09	-0.32	3.12e-9	Renal function-related traits (BUN);
LUSC	cis	rs9463078	0.838	rs2396373	chr6:44983134	G/A	cg25276700	chr6:44698697	NA	-0.29	-5.72	-0.3	2.31e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-6.37	-0.33	6.33e-10	Neutrophil percentage of white cells;
LUSC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg01620082	chr3:125678407	NA	-0.7	-6.96	-0.36	1.81e-11	Depression;
LUSC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg08683831	chr4:1404607	NA	0.35	5.94	0.31	7.27e-9	Obesity-related traits;
LUSC	cis	rs4356932	0.790	rs6848620	chr4:76973549	G/C	cg00809888	chr4:76862425	NAAA	0.35	5.82	0.3	1.37e-8	Blood protein levels;
LUSC	cis	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.59	-0.34	1.76e-10	Morning vs. evening chronotype;
LUSC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg20684491	chr1:25596433	NA	-0.36	-5.69	-0.3	2.73e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs8179	1.000	rs4272	chr7:92236829	C/T	cg15732164	chr7:92237376	CDK6	0.49	6.98	0.36	1.62e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-0.75	-9.1	-0.45	8.37e-18	Refractive error;
LUSC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg01097406	chr16:89675127	NA	-0.35	-7.04	-0.36	1.07e-11	Vitiligo;
LUSC	cis	rs72772090	0.539	rs3334	chr5:96115085	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-6.56	-0.34	2.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-8.33	-0.41	2.14e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.68	-8.58	-0.43	3.52e-16	Menarche (age at onset);
LUSC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	6.57	0.34	1.94e-10	Tonsillectomy;
LUSC	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg08017756	chr2:100939284	LONRF2	-0.43	-7.99	-0.4	2.18e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg02475777	chr4:1388615	CRIPAK	0.39	6.16	0.32	2.14e-9	Longevity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21489753	chr5:137667158	CDC25C	0.4	6.12	0.32	2.62e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg19318889	chr4:1322082	MAEA	0.43	5.7	0.3	2.66e-8	Recombination rate (females);
LUSC	cis	rs9815354	0.537	rs73073272	chr3:42022446	G/A	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg06784218	chr1:46089804	CCDC17	0.54	10.59	0.5	8.43e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg18225595	chr11:63971243	STIP1	0.63	10.62	0.5	6.96e-23	Platelet count;
LUSC	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg22681709	chr2:178499509	PDE11A	-0.51	-9.18	-0.45	4.62e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg11608241	chr8:8085544	FLJ10661	0.41	6.19	0.32	1.76e-9	Mood instability;
LUSC	trans	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.53	-0.38	4.72e-13	Triglycerides;
LUSC	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg23029597	chr12:123009494	RSRC2	-0.68	-9.15	-0.45	5.6e-18	Body mass index;
LUSC	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23598886	chr18:12777645	NA	0.65	6.6	0.34	1.61e-10	Inflammatory skin disease;
LUSC	cis	rs2073300	1.000	rs6137967	chr20:23447108	A/T	cg09953122	chr20:23471693	CST8	0.69	5.85	0.3	1.17e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg16624210	chr5:671434	TPPP	0.49	6.12	0.32	2.58e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg16482183	chr6:26056742	HIST1H1C	0.44	6.59	0.34	1.72e-10	Height;
LUSC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg18512352	chr11:47633146	NA	-0.46	-9.21	-0.45	3.73e-18	Subjective well-being;
LUSC	cis	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg24631222	chr15:78858424	CHRNA5	0.52	5.87	0.31	1.05e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg26850624	chr5:429559	AHRR	0.34	6.07	0.32	3.55e-9	Cystic fibrosis severity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22870899	chr14:65347138	NA	0.45	6.16	0.32	2.08e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-9.27	-0.45	2.34e-18	Joint mobility (Beighton score);
LUSC	cis	rs9653442	0.564	rs13013594	chr2:100784190	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-7.12	-0.36	6.51e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2820315	0.867	rs2820319	chr1:201878650	G/A	cg10061532	chr1:201886748	LMOD1	0.27	6.19	0.32	1.73e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.49	-8.47	-0.42	8.14e-16	Lymphocyte counts;
LUSC	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg00277334	chr10:82204260	NA	-0.58	-8.65	-0.43	2.21e-16	Post bronchodilator FEV1;
LUSC	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg09173681	chr1:183549694	NCF2	0.63	11.18	0.52	7.23e-25	Systemic lupus erythematosus;
LUSC	cis	rs2227930	0.528	rs6786320	chr3:142111273	G/C	cg16271453	chr3:142027066	XRN1	-0.55	-9.78	-0.47	5.09e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs10979	1.000	rs1054752	chr6:143890097	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg02569458	chr12:86230093	RASSF9	0.58	9.82	0.47	3.54e-20	Major depressive disorder;
LUSC	cis	rs59104589	0.617	rs16842449	chr2:242354979	C/T	cg14842376	chr2:242211374	HDLBP	0.57	6.6	0.34	1.61e-10	Fibrinogen levels;
LUSC	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.39	-6.91	-0.35	2.42e-11	Eosinophil percentage of white cells;
LUSC	trans	rs11723530	0.538	rs10025523	chr4:170813307	T/C	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.16	-0.32	2.13e-9	Myopia (pathological);
LUSC	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg26441486	chr22:50317300	CRELD2	0.42	6.58	0.34	1.8e-10	Schizophrenia;
LUSC	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg15571903	chr15:79123663	NA	0.31	5.86	0.31	1.1e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg06008330	chr7:65541103	ASL	0.41	6.55	0.34	2.22e-10	Aortic root size;
LUSC	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	10.16	0.49	2.68e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1499972	0.941	rs62263116	chr3:117622719	T/G	cg07612923	chr3:117604196	NA	0.61	5.67	0.3	3.1e-8	Schizophrenia;
LUSC	cis	rs6554196	0.525	rs2192158	chr4:55505360	C/T	cg18836493	chr4:55524333	KIT	0.39	6.52	0.34	2.54e-10	Monocyte count;
LUSC	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg20016023	chr10:99160130	RRP12	-0.31	-7.82	-0.39	6.85e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg17143192	chr8:8559678	CLDN23	0.56	7.83	0.39	6.51e-14	Obesity-related traits;
LUSC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg07701084	chr6:150067640	NUP43	0.54	8.15	0.41	7.58e-15	Lung cancer;
LUSC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.54	-0.42	4.86e-16	Lung cancer;
LUSC	trans	rs62055045	0.528	rs9935288	chr16:71552741	T/C	cg15281710	chr15:96890452	NA	-0.42	-6.3	-0.33	9.27e-10	Schizophrenia;
LUSC	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg13385521	chr17:29058706	SUZ12P	-0.67	-6.26	-0.32	1.16e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg16898833	chr6:26189333	HIST1H4D	0.68	6.34	0.33	7.25e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg12615879	chr12:58013172	SLC26A10	0.29	6.74	0.35	7.01e-11	Multiple sclerosis;
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg17541715	chr7:1216824	NA	-0.39	-6.18	-0.32	1.92e-9	Longevity;Endometriosis;
LUSC	cis	rs909002	0.830	rs7542583	chr1:32110813	A/G	cg01639898	chr1:32083012	HCRTR1	0.32	7.79	0.39	8.8e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg22029157	chr1:209979665	IRF6	0.74	9.54	0.46	3.12e-19	Cleft lip with or without cleft palate;
LUSC	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg10172584	chr19:19639581	YJEFN3	-0.5	-5.84	-0.3	1.23e-8	Bipolar disorder;
LUSC	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg21775007	chr8:11205619	TDH	-0.67	-10.67	-0.5	4.64e-23	Retinal vascular caliber;
LUSC	cis	rs4843185	0.637	rs4143866	chr16:85716366	A/G	cg00168118	chr16:85669675	KIAA0182	0.38	5.79	0.3	1.66e-8	Platelet distribution width;
LUSC	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg02023728	chr11:77925099	USP35	0.45	6.87	0.35	3.09e-11	Testicular germ cell tumor;
LUSC	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg09904177	chr6:26538194	HMGN4	-0.79	-6.17	-0.32	1.95e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.18	-24.54	-0.8	9.75e-77	Exhaled nitric oxide output;
LUSC	cis	rs9532580	0.778	rs34373380	chr13:41244217	T/A	cg21288729	chr13:41239152	FOXO1	0.62	9.52	0.46	3.52e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	8.69	0.43	1.62e-16	Motion sickness;
LUSC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg21775007	chr8:11205619	TDH	-0.67	-10.64	-0.5	6.04e-23	Retinal vascular caliber;
LUSC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg06637938	chr14:75390232	RPS6KL1	0.53	8.44	0.42	1.01e-15	Height;
LUSC	cis	rs28647808	0.881	rs57394597	chr9:136261030	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg11189052	chr15:85197271	WDR73	0.46	5.72	0.3	2.35e-8	Schizophrenia;
LUSC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-9.73	-0.47	7.44e-20	Bipolar disorder;
LUSC	cis	rs35123781	0.502	rs261532	chr5:138949362	A/C	cg26929925	chr5:138714136	SLC23A1	0.47	7.38	0.37	1.27e-12	Schizophrenia;
LUSC	cis	rs6580649	0.825	rs4760611	chr12:48421449	A/G	cg24011408	chr12:48396354	COL2A1	0.45	6.05	0.31	3.86e-9	Lung cancer;
LUSC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg13206674	chr6:150067644	NUP43	0.5	7.46	0.38	7.55e-13	Lung cancer;
LUSC	cis	rs4622329	0.636	rs7975403	chr12:102288527	G/C	cg23541617	chr12:102225335	GNPTAB	0.26	6.07	0.32	3.51e-9	Systemic lupus erythematosus;
LUSC	cis	rs7165170	0.808	rs12915979	chr15:91199025	C/T	cg05609160	chr15:91208370	NA	-0.4	-5.89	-0.31	9.64e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	0.99	18.67	0.71	8.81e-54	Cognitive function;
LUSC	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg24375607	chr4:120327624	NA	0.71	11.31	0.53	2.45e-25	Corneal astigmatism;
LUSC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg08888203	chr3:10149979	C3orf24	0.66	8.79	0.43	8.06e-17	Alzheimer's disease;
LUSC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg07716408	chr11:68623521	NA	-0.31	-5.82	-0.3	1.38e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs1864729	0.748	rs2635138	chr8:98301418	A/G	cg08679828	chr8:102218111	ZNF706	0.78	6.53	0.34	2.44e-10	Estradiol plasma levels (breast cancer);
LUSC	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	9.46	0.46	5.76e-19	Response to antipsychotic treatment;
LUSC	cis	rs6977660	0.714	rs10155949	chr7:19834747	T/C	cg05791153	chr7:19748676	TWISTNB	0.65	6.68	0.34	1e-10	Thyroid stimulating hormone;
LUSC	cis	rs71403859	0.730	rs17347255	chr16:71587225	C/T	cg08717414	chr16:71523259	ZNF19	-0.76	-8.38	-0.42	1.5e-15	Post bronchodilator FEV1;
LUSC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.58	-0.42	3.74e-16	Obesity-related traits;
LUSC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-7.29	-0.37	2.26e-12	Colorectal cancer;
LUSC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23158103	chr7:148848205	ZNF398	-0.41	-6.53	-0.34	2.45e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg03146154	chr1:46216737	IPP	0.55	8.21	0.41	5.01e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg21775007	chr8:11205619	TDH	-0.41	-5.82	-0.3	1.39e-8	Neuroticism;
LUSC	cis	rs77633900	0.772	rs78181637	chr15:76672569	A/C	cg21673338	chr15:77095150	SCAPER	-0.7	-6.1	-0.32	2.99e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs17253792	0.822	rs8013714	chr14:56172286	T/C	cg01858014	chr14:56050164	KTN1	-0.71	-6.35	-0.33	6.97e-10	Putamen volume;
LUSC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg12751644	chr20:60527061	NA	-0.34	-6.0	-0.31	5.25e-9	Body mass index;
LUSC	cis	rs9324022	0.929	rs9635184	chr14:101173056	C/T	cg18089426	chr14:101175970	NA	0.48	5.76	0.3	1.93e-8	Plateletcrit;
LUSC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	7.33	0.37	1.75e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg25173405	chr17:45401733	C17orf57	0.38	6.05	0.31	3.96e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs2055729	0.601	rs12546952	chr8:9744002	G/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.1	-0.32	2.99e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg05283184	chr6:79620031	NA	-0.57	-11.79	-0.54	4.8e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg15117754	chr3:10150083	C3orf24	0.44	5.79	0.3	1.59e-8	Alzheimer's disease;
LUSC	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg04414720	chr1:150670196	GOLPH3L	-0.46	-7.0	-0.36	1.44e-11	Tonsillectomy;
LUSC	cis	rs12891047	1.000	rs2235962	chr14:68248281	A/G	cg20999565	chr14:68265668	ZFYVE26	0.37	5.67	0.3	3.09e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg03929089	chr4:120376271	NA	0.72	6.86	0.35	3.37e-11	Axial length;
LUSC	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	0.93	17.77	0.7	3.49e-50	Headache;
LUSC	cis	rs10203711	0.966	rs4998692	chr2:239564772	T/G	cg14580085	chr2:239553406	NA	0.41	6.96	0.36	1.76e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg06092702	chr1:163392909	NA	-0.43	-7.18	-0.37	4.62e-12	Motion sickness;
LUSC	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg20129853	chr10:51489980	NA	-0.36	-7.56	-0.38	3.84e-13	Prostate-specific antigen levels;
LUSC	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg10518543	chr12:38710700	ALG10B	0.41	5.78	0.3	1.74e-8	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2120243	0.591	rs9871290	chr3:157099591	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.36	5.69	0.3	2.78e-8	Hepatocellular carcinoma in hepatitis B infection;
LUSC	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg11984989	chr7:158649758	WDR60	1.04	20.72	0.75	6.58e-62	Height;
LUSC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg20243544	chr17:37824526	PNMT	0.41	6.25	0.32	1.23e-9	Asthma;
LUSC	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg15557168	chr22:42548783	NA	-0.39	-5.85	-0.3	1.17e-8	Schizophrenia;
LUSC	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.4	-5.98	-0.31	5.58e-9	Schizophrenia;
LUSC	trans	rs853679	0.599	rs149943	chr6:28002388	G/A	cg01620082	chr3:125678407	NA	-0.61	-6.92	-0.35	2.35e-11	Depression;
LUSC	cis	rs11031096	0.628	rs10835735	chr11:4211865	G/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.72	-0.3	2.31e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs72674100	1.000	rs72880546	chr4:97973701	T/C	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg14210321	chr2:106509881	NCK2	-0.55	-8.36	-0.42	1.71e-15	Addiction;
LUSC	cis	rs977987	0.836	rs4888376	chr16:75322573	T/C	cg03315344	chr16:75512273	CHST6	0.47	8.59	0.43	3.39e-16	Dupuytren's disease;
LUSC	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg05347473	chr6:146136440	FBXO30	-0.47	-7.87	-0.4	5.09e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9650657	0.769	rs1968400	chr8:10615431	G/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.01	-0.31	4.77e-9	Neuroticism;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20141549	chr3:51534298	VPRBP	0.39	6.08	0.32	3.3e-9	Triglycerides;
LUSC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg18190219	chr22:46762943	CELSR1	-0.54	-6.02	-0.31	4.61e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg20821713	chr7:1055600	C7orf50	-0.46	-7.52	-0.38	5.06e-13	Longevity;Endometriosis;
LUSC	trans	rs4596713	0.508	rs35490502	chr9:71747895	T/A	cg25283916	chr1:242222868	NA	-0.32	-6.71	-0.34	8.55e-11	Headache;
LUSC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-0.87	-16.33	-0.67	1.78e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg13047869	chr3:10149882	C3orf24	-0.52	-7.71	-0.39	1.47e-13	Alzheimer's disease;
LUSC	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg14582100	chr15:45693742	SPATA5L1	0.56	10.09	0.48	4.35e-21	Homoarginine levels;
LUSC	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg23625390	chr15:77176239	SCAPER	-0.65	-9.78	-0.47	4.88e-20	Blood metabolite levels;
LUSC	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg23229984	chr5:148520753	ABLIM3	0.38	5.73	0.3	2.22e-8	Breast cancer;
LUSC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg20713898	chr8:124780851	FAM91A1	-0.54	-7.52	-0.38	5.13e-13	Pancreatic cancer;
LUSC	cis	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg06521331	chr12:34319734	NA	-0.45	-7.2	-0.37	3.95e-12	Morning vs. evening chronotype;
LUSC	cis	rs2073300	1.000	rs6114126	chr20:23452127	A/T	cg09953122	chr20:23471693	CST8	-0.72	-6.61	-0.34	1.54e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg06454157	chr6:167490870	NA	-0.28	-6.71	-0.34	8.57e-11	Primary biliary cholangitis;
LUSC	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg04362960	chr10:104952993	NT5C2	0.68	9.95	0.48	1.35e-20	Arsenic metabolism;
LUSC	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg15896084	chr13:114927664	NA	0.4	7.34	0.37	1.66e-12	Schizophrenia;
LUSC	cis	rs1865721	0.656	rs724765	chr18:73139794	A/G	cg26385618	chr18:73139727	C18orf62	-0.46	-8.52	-0.42	5.69e-16	Intelligence;
LUSC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg11812906	chr14:75593930	NEK9	0.65	11.13	0.52	1.09e-24	Height;
LUSC	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg17764715	chr19:33622953	WDR88	0.59	7.95	0.4	2.96e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg21211680	chr2:198530	NA	0.68	7.31	0.37	1.98e-12	Blood protein levels;
LUSC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg15110403	chr19:17392923	ANKLE1	0.51	7.25	0.37	2.99e-12	Systemic lupus erythematosus;
LUSC	trans	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.44	-0.33	4.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.54	-8.46	-0.42	8.63e-16	Longevity;Endometriosis;
LUSC	cis	rs9837602	1.000	rs9851645	chr3:99767409	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.01	-0.31	4.82e-9	Breast cancer;
LUSC	trans	rs8030485	0.571	rs4778904	chr15:79418856	A/C	cg16586880	chr8:140854244	TRAPPC9	-0.37	-6.15	-0.32	2.26e-9	Left ventricle wall thickness;
LUSC	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.43	6.57	0.34	1.92e-10	Dupuytren's disease;
LUSC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.47	6.12	0.32	2.58e-9	Blood protein levels;
LUSC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.86	-13.91	-0.61	5.25e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7939886	0.920	rs11227158	chr11:55843795	A/G	cg15704280	chr7:45808275	SEPT13	0.79	6.65	0.34	1.23e-10	Myopia (pathological);
LUSC	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg15997130	chr1:24165203	NA	0.53	8.73	0.43	1.25e-16	Immature fraction of reticulocytes;
LUSC	cis	rs193541	0.501	rs3943379	chr5:122056137	A/G	cg19077854	chr5:122220652	SNX24	0.33	6.58	0.34	1.77e-10	Glucose homeostasis traits;
LUSC	cis	rs9322817	0.669	rs4079063	chr6:105266118	A/G	cg02098413	chr6:105308735	HACE1	-0.27	-5.65	-0.3	3.5e-8	Thyroid stimulating hormone;
LUSC	cis	rs11608355	1.000	rs9669684	chr12:109860644	C/T	cg05360138	chr12:110035743	NA	0.47	6.35	0.33	6.87e-10	Neuroticism;
LUSC	trans	rs9784649	0.891	rs57762467	chr5:25025700	C/T	cg08600765	chr20:34638493	LOC647979	-0.6	-6.89	-0.35	2.84e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs17095355	1.000	rs2122517	chr10:111754787	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-7.99	-0.4	2.23e-14	Biliary atresia;
LUSC	cis	rs10498514	1.000	rs117727667	chr14:65028278	T/A	cg25134081	chr14:64931936	AKAP5	0.95	6.82	0.35	4.4e-11	Cognitive performance;
LUSC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg00745463	chr17:30367425	LRRC37B	-0.79	-9.15	-0.45	5.71e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg22906224	chr7:99728672	NA	0.44	5.73	0.3	2.22e-8	Coronary artery disease;
LUSC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs10170846	0.530	rs56353541	chr2:223421187	G/C	cg25565276	chr2:223520875	FARSB	0.68	9.69	0.47	9.64e-20	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg10018233	chr7:150070692	REPIN1	0.39	6.44	0.33	4.13e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	0.76	11.29	0.53	2.89e-25	Gut microbiome composition (summer);
LUSC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg16624210	chr5:671434	TPPP	0.5	6.25	0.32	1.27e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg18681998	chr4:17616180	MED28	0.86	16.05	0.66	2.21e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg09307838	chr4:120376055	NA	0.73	10.42	0.5	3.39e-22	Corneal astigmatism;
LUSC	trans	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.62	-0.43	2.67e-16	Obesity-related traits;
LUSC	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.6	9.47	0.46	5.28e-19	Morning vs. evening chronotype;
LUSC	cis	rs7095944	0.614	rs10901818	chr10:126449428	G/A	cg08799069	chr10:126477246	METTL10	-0.42	-6.56	-0.34	2.04e-10	Asthma;
LUSC	cis	rs601339	1.000	rs601339	chr12:123174743	A/G	cg11919336	chr12:123188078	GPR109A	0.44	6.58	0.34	1.78e-10	Adiponectin levels;
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18110333	chr6:292329	DUSP22	-0.72	-11.76	-0.54	5.81e-27	Menopause (age at onset);
LUSC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg21770322	chr7:97807741	LMTK2	0.4	6.85	0.35	3.48e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1549118	0.595	rs7160485	chr14:78332734	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.43	-5.74	-0.3	2.12e-8	Resting heart rate;
LUSC	trans	rs459571	1.000	rs459571	chr9:136912626	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.43	-6.21	-0.32	1.61e-9	Platelet distribution width;
LUSC	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg15557168	chr22:42548783	NA	-0.4	-6.13	-0.32	2.49e-9	Schizophrenia;
LUSC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg24578937	chr1:2090814	PRKCZ	0.46	10.44	0.5	2.8e-22	Height;
LUSC	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.87	15.08	0.64	1.52e-39	Bladder cancer;
LUSC	cis	rs11676348	0.772	rs11687200	chr2:218944615	A/G	cg06547715	chr2:218990976	CXCR2	0.3	5.69	0.3	2.75e-8	Ulcerative colitis;
LUSC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.39	0.42	1.43e-15	Parkinson's disease;
LUSC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	1.03	19.58	0.73	2.08e-57	Menopause (age at onset);
LUSC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg27165867	chr14:105738592	BRF1	-0.51	-7.49	-0.38	6.18e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs2692947	0.794	rs2692893	chr2:96756547	C/T	cg22654517	chr2:96458247	NA	0.33	6.13	0.32	2.54e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9303542	0.625	rs9904760	chr17:46575031	C/T	cg09704116	chr17:46666958	LOC404266	-0.3	-5.84	-0.3	1.25e-8	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs9487051	0.735	rs455839	chr6:109524221	G/A	cg00509249	chr6:109615579	CCDC162	-0.33	-5.76	-0.3	1.92e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.01	0.44	1.59e-17	Motion sickness;
LUSC	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07012702	chr16:25118409	NA	-0.48	-6.34	-0.33	7.49e-10	Hepatitis;
LUSC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg08888203	chr3:10149979	C3orf24	0.6	8.3	0.41	2.68e-15	Alzheimer's disease;
LUSC	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-0.99	-16.84	-0.68	1.61e-46	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7633857	0.512	rs13098529	chr3:160657053	A/G	cg03342759	chr3:160939853	NMD3	-0.43	-6.35	-0.33	7.13e-10	Educational attainment (years of education);
LUSC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-0.84	-13.8	-0.6	1.35e-34	Longevity;
LUSC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05535760	chr7:792225	HEATR2	0.94	9.79	0.47	4.7e-20	Cerebrospinal P-tau181p levels;
LUSC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg07212818	chr11:638076	DRD4	-0.33	-5.74	-0.3	2.13e-8	Systemic lupus erythematosus;
LUSC	cis	rs77741769	0.571	rs12580949	chr12:121298164	A/G	cg02419362	chr12:121203948	SPPL3	0.46	8.5	0.42	6.39e-16	Mean corpuscular volume;
LUSC	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg25427524	chr10:38739819	LOC399744	0.43	5.75	0.3	2e-8	Obesity (extreme);
LUSC	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03713592	chr11:72463424	ARAP1	0.84	9.87	0.48	2.41e-20	Type 2 diabetes;
LUSC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg06640241	chr16:89574553	SPG7	0.65	9.72	0.47	7.97e-20	Multiple myeloma (IgH translocation);
LUSC	trans	rs7538876	0.787	rs57142672	chr1:17744536	A/G	cg13009662	chr5:127419527	SLC12A2;FLJ33630	0.41	5.99	0.31	5.49e-9	Basal cell carcinoma;
LUSC	trans	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg25214090	chr10:38739885	LOC399744	0.44	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.06	0.36	9.57e-12	Morning vs. evening chronotype;
LUSC	cis	rs4845570	0.920	rs11810571	chr1:151762308	C/G	cg07092448	chr1:151763213	TDRKH	1.26	16.59	0.67	1.69e-45	Coronary artery disease;
LUSC	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg24631222	chr15:78858424	CHRNA5	-0.66	-8.64	-0.43	2.3e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg04450456	chr4:17643702	FAM184B	0.4	6.85	0.35	3.65e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07988820	chr12:82153109	PPFIA2	-0.41	-5.74	-0.3	2.13e-8	Resting heart rate;
LUSC	cis	rs4077515	0.901	rs11791262	chr9:139271919	C/T	cg14169450	chr9:139327907	INPP5E	0.42	7.53	0.38	4.81e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg24642439	chr20:33292090	TP53INP2	0.53	8.1	0.41	1.02e-14	Coronary artery disease;
LUSC	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg27433088	chr4:174089019	GALNT7	-0.39	-5.75	-0.3	2.04e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs7264396	0.887	rs2236159	chr20:34102189	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.58	-0.34	1.82e-10	Total cholesterol levels;
LUSC	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.17	-0.41	6.57e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg13010199	chr12:38710504	ALG10B	-0.65	-10.3	-0.49	8.48e-22	Morning vs. evening chronotype;
LUSC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.89	13.9	0.61	5.5e-35	Menarche (age at onset);
LUSC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.58	0.38	3.4e-13	Bipolar disorder;
LUSC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00149659	chr3:10157352	C3orf10	0.96	14.74	0.63	3.24e-38	Alzheimer's disease;
LUSC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.75	-11.67	-0.54	1.3e-26	Menarche (age at onset);
LUSC	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.72	-0.47	7.67e-20	Total cholesterol levels;
LUSC	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.87	-0.48	2.41e-20	Hemoglobin concentration;
LUSC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	6.13	0.32	2.46e-9	Schizophrenia;
LUSC	cis	rs10144321	0.729	rs724392	chr14:100832252	C/T	cg14882082	chr14:100845427	WDR25	-0.42	-7.98	-0.4	2.37e-14	Menarche (age at onset);
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10150615	chr22:24372951	LOC391322	-0.43	-7.13	-0.36	6.06e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9420	0.961	rs576859	chr11:57480623	A/C	cg23127183	chr11:57508653	C11orf31	0.48	7.29	0.37	2.3e-12	Schizophrenia;
LUSC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.71	-0.34	8.22e-11	Total body bone mineral density;
LUSC	cis	rs4474465	0.850	rs10899536	chr11:78216992	C/A	cg27205649	chr11:78285834	NARS2	0.52	6.0	0.31	5.01e-9	Alzheimer's disease (survival time);
LUSC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00152838	chr16:24741724	TNRC6A	-0.48	-6.01	-0.31	4.82e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.806	rs11640674	chr16:75394944	A/G	cg03315344	chr16:75512273	CHST6	0.48	9.26	0.45	2.6e-18	Dupuytren's disease;
LUSC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg08680598	chr22:49984980	NA	-0.32	-5.91	-0.31	8.61e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs35883536	0.566	rs4908086	chr1:101088124	C/T	cg06223162	chr1:101003688	GPR88	0.39	6.79	0.35	5.02e-11	Monocyte count;
LUSC	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	10.19	0.49	2.14e-21	Coffee consumption (cups per day);
LUSC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg23172400	chr8:95962367	TP53INP1	-0.37	-7.46	-0.38	7.71e-13	Type 2 diabetes;
LUSC	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.74	-10.99	-0.52	3.32e-24	Glomerular filtration rate;
LUSC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.25	-0.41	3.75e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9309473	0.950	rs13431529	chr2:73876041	G/C	cg20560298	chr2:73613845	ALMS1	-0.43	-6.15	-0.32	2.22e-9	Metabolite levels;
LUSC	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg23625390	chr15:77176239	SCAPER	-0.44	-6.84	-0.35	3.79e-11	Blood metabolite levels;
LUSC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.19	-13.56	-0.6	1.16e-33	Diabetic kidney disease;
LUSC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.59	-0.6	8.89e-34	Chronic sinus infection;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25581932	chr17:7892150	NA	-0.49	-6.52	-0.34	2.54e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg23093090	chr10:104574429	C10orf26	-0.39	-7.35	-0.37	1.51e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs240768	1.000	rs240166	chr6:101037678	T/C	cg12253828	chr6:101329408	ASCC3	0.83	5.7	0.3	2.7e-8	Economic and political preferences (immigration/crime);
LUSC	trans	rs1171606	0.731	rs1171652	chr10:61449512	A/G	cg14119616	chr11:17099403	RPS13	-0.4	-6.08	-0.32	3.24e-9	Acylcarnitine levels;
LUSC	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg14458575	chr2:238380390	NA	0.68	8.28	0.41	2.94e-15	Prostate cancer;
LUSC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg00933542	chr6:150070202	PCMT1	0.3	6.01	0.31	4.73e-9	Lung cancer;
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23978390	chr7:1156363	C7orf50	0.54	7.67	0.39	1.91e-13	Longevity;Endometriosis;
LUSC	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.79	-0.51	1.71e-23	Alcohol dependence;
LUSC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.78	0.6	1.67e-34	Chronic sinus infection;
LUSC	cis	rs13082711	0.911	rs35532045	chr3:27515870	A/G	cg02860705	chr3:27208620	NA	0.47	7.91	0.4	3.88e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs12545109	0.879	rs893234	chr8:57363885	G/A	cg09654669	chr8:57350985	NA	-0.56	-7.43	-0.38	8.93e-13	Obesity-related traits;
LUSC	cis	rs11997175	0.624	rs17778980	chr8:33700926	T/C	ch.8.33884649F	chr8:33765107	NA	0.45	6.65	0.34	1.2e-10	Body mass index;
LUSC	cis	rs9948	0.655	rs6576981	chr2:97394406	G/C	cg01990225	chr2:97406019	LMAN2L	-1.09	-8.15	-0.41	7.59e-15	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.93	13.5	0.59	1.95e-33	Initial pursuit acceleration;
LUSC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg04733989	chr22:42467013	NAGA	0.61	9.48	0.46	4.84e-19	Schizophrenia;
LUSC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg02269571	chr22:50332266	NA	-0.55	-8.47	-0.42	7.91e-16	Schizophrenia;
LUSC	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg20703242	chr1:230279135	GALNT2	0.54	8.41	0.42	1.17e-15	Coronary artery disease;
LUSC	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.78	-0.7	2.97e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.63	8.48	0.42	7.34e-16	Chronic sinus infection;
LUSC	cis	rs7113850	0.541	rs56679749	chr11:24235649	G/A	ch.11.24196551F	chr11:24239977	NA	1.0	9.09	0.45	9.2e-18	Bone fracture in osteoporosis;
LUSC	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg13010199	chr12:38710504	ALG10B	0.44	6.34	0.33	7.66e-10	Morning vs. evening chronotype;
LUSC	cis	rs3106136	0.967	rs72665658	chr4:95144761	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.12	-0.32	2.68e-9	Capecitabine sensitivity;
LUSC	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.52	-0.34	2.66e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.54	-14.59	-0.62	1.18e-37	Urate levels in overweight individuals;
LUSC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg23788917	chr6:8435910	SLC35B3	0.48	7.23	0.37	3.21e-12	Motion sickness;
LUSC	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.66	0.67	8.34e-46	Exhaled nitric oxide output;
LUSC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg25767906	chr1:53392781	SCP2	0.48	8.69	0.43	1.67e-16	Monocyte count;
LUSC	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.0	-0.36	1.38e-11	Type 2 diabetes;
LUSC	cis	rs7119	0.651	rs12909292	chr15:77837982	G/T	cg27398640	chr15:77910606	LINGO1	-0.28	-5.66	-0.3	3.28e-8	Type 2 diabetes;
LUSC	cis	rs9314323	0.767	rs10866848	chr8:26208209	G/C	cg11498726	chr8:26250323	BNIP3L	-0.43	-6.05	-0.31	3.96e-9	Red cell distribution width;
LUSC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg25258033	chr6:167368657	RNASET2	0.46	7.67	0.39	1.91e-13	Crohn's disease;
LUSC	cis	rs2301888	1.000	rs2240335	chr1:17674537	G/T	cg01790353	chr1:17674483	PADI4	0.36	6.99	0.36	1.51e-11	Rheumatoid arthritis;
LUSC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg21770322	chr7:97807741	LMTK2	0.41	7.03	0.36	1.18e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs16854884	0.710	rs1530479	chr3:143819653	C/T	cg01302019	chr3:143689584	C3orf58	-0.35	-5.96	-0.31	6.5e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs6138458	0.743	rs3746330	chr20:24999795	A/G	cg26195577	chr20:24973756	C20orf3	0.76	11.68	0.54	1.16e-26	Blood protein levels;
LUSC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00684032	chr4:1343700	KIAA1530	0.37	6.5	0.34	2.89e-10	Obesity-related traits;
LUSC	cis	rs708547	0.647	rs1718878	chr4:57876955	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	7.59	0.38	3.31e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs4363385	0.714	rs4845329	chr1:152974454	G/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.76	-0.39	1.05e-13	Inflammatory skin disease;
LUSC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg03388025	chr16:89894329	SPIRE2	0.35	7.28	0.37	2.47e-12	Vitiligo;
LUSC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg07741184	chr6:167504864	NA	-0.36	-6.59	-0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg16049864	chr8:95962084	TP53INP1	-0.56	-10.61	-0.5	7.67e-23	Type 2 diabetes;
LUSC	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-0.9	-17.6	-0.69	1.57e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg27094323	chr7:1216898	NA	-0.45	-7.75	-0.39	1.11e-13	Longevity;Endometriosis;
LUSC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.75	-0.8	1.56e-77	Height;
LUSC	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-9.81	-0.47	3.99e-20	Lymphocyte percentage of white cells;
LUSC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg07741184	chr6:167504864	NA	0.36	6.43	0.33	4.32e-10	Crohn's disease;
LUSC	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg06636001	chr8:8085503	FLJ10661	0.52	7.79	0.39	8.75e-14	Retinal vascular caliber;
LUSC	cis	rs2834081	0.536	rs11702285	chr21:34474294	G/A	cg10915739	chr21:34405733	NA	0.37	6.38	0.33	5.96e-10	Sum eosinophil basophil counts;
LUSC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg13560548	chr3:10150139	C3orf24	0.54	7.52	0.38	5.24e-13	Alzheimer's disease;
LUSC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg00033643	chr7:134001901	SLC35B4	0.42	6.17	0.32	2e-9	Mean platelet volume;
LUSC	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg11161011	chr14:65562177	MAX	-0.72	-11.05	-0.52	2.16e-24	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.01e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	10.79	0.51	1.81e-23	Homoarginine levels;
LUSC	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.37	-6.88	-0.35	2.95e-11	Axial length;
LUSC	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg12002119	chr2:101014098	CHST10	0.35	5.75	0.3	1.98e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3733418	0.929	rs4690797	chr4:165908505	G/C	cg11630554	chr4:165878136	TRIM61;C4orf39	-0.51	-5.83	-0.3	1.34e-8	Obesity-related traits;
LUSC	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-9.46	-0.46	5.53e-19	Bladder cancer;
LUSC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg04450456	chr4:17643702	FAM184B	0.36	6.01	0.31	4.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.58	-10.01	-0.48	8.56e-21	Bone mineral density;
LUSC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg10909506	chr17:38081995	ORMDL3	0.34	5.98	0.31	5.87e-9	Self-reported allergy;
LUSC	cis	rs12474201	0.832	rs6738426	chr2:46986416	A/G	cg06386533	chr2:46925753	SOCS5	0.65	9.58	0.46	2.24e-19	Height;
LUSC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.75	-10.68	-0.5	4.33e-23	Gut microbiome composition (summer);
LUSC	trans	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg23791538	chr6:167370224	RNASET2	0.41	6.6	0.34	1.64e-10	Crohn's disease;
LUSC	trans	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg12856521	chr11:46389249	DGKZ	0.4	6.24	0.32	1.35e-9	Leprosy;
LUSC	cis	rs12286929	0.639	rs10891802	chr11:115043888	C/A	cg04055981	chr11:115044050	NA	0.43	7.84	0.39	6.21e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg05729581	chr11:3078854	CARS	0.4	5.79	0.3	1.65e-8	Calcium levels;
LUSC	trans	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg04995722	chr7:26192034	NFE2L3	0.37	6.09	0.32	3.03e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs71636778	0.543	rs11810321	chr1:27220521	T/G	cg12203394	chr1:27248618	NUDC	0.54	5.68	0.3	2.98e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg11645453	chr3:52864694	ITIH4	-0.35	-8.01	-0.4	1.88e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7291412	0.540	rs9627391	chr22:46447097	C/T	cg09693106	chr22:46449821	C22orf26;LOC150381	0.4	6.96	0.36	1.8e-11	Dupuytren's disease;Subjective well-being;
LUSC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg05585544	chr11:47624801	NA	-0.42	-7.34	-0.37	1.67e-12	Subjective well-being;
LUSC	cis	rs6138458	0.626	rs6050261	chr20:25014206	C/T	cg26195577	chr20:24973756	C20orf3	0.69	10.48	0.5	2.06e-22	Blood protein levels;
LUSC	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.45	0.33	3.83e-10	Corneal astigmatism;
LUSC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.59	-8.19	-0.41	5.54e-15	Longevity;Endometriosis;
LUSC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08677398	chr8:58056175	NA	0.45	6.41	0.33	4.84e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs236907	0.859	rs10913683	chr1:171758699	T/C	cg13482142	chr2:234261155	NA	0.48	6.05	0.31	3.8e-9	Mean platelet volume;
LUSC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg01802117	chr1:53393560	SCP2	-0.37	-6.01	-0.31	4.95e-9	Monocyte count;
LUSC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.7	-10.85	-0.51	1.07e-23	Aortic root size;
LUSC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg22535103	chr8:58192502	C8orf71	-0.84	-9.29	-0.45	2.11e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs61931739	0.635	rs1852224	chr12:33963080	A/C	cg06521331	chr12:34319734	NA	-0.41	-6.73	-0.35	7.34e-11	Morning vs. evening chronotype;
LUSC	cis	rs17155006	0.746	rs435125	chr7:107748934	A/G	cg05962710	chr7:107745446	LAMB4	-0.36	-6.52	-0.34	2.57e-10	Pneumococcal bacteremia;
LUSC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.51	-11.17	-0.52	8.18e-25	Type 2 diabetes;
LUSC	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg23649088	chr2:200775458	C2orf69	-0.54	-6.32	-0.33	8.48e-10	Schizophrenia;
LUSC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.86	0.31	1.11e-8	Hip circumference adjusted for BMI;
LUSC	trans	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg06606381	chr12:133084897	FBRSL1	-0.97	-8.2	-0.41	5.16e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.28	0.56	7.3e-29	Motion sickness;
LUSC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg07741184	chr6:167504864	NA	-0.36	-6.62	-0.34	1.47e-10	Crohn's disease;
LUSC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg17376030	chr22:41985996	PMM1	-0.46	-5.87	-0.31	1.03e-8	Vitiligo;
LUSC	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	10.58	0.5	9.54e-23	Colorectal cancer;
LUSC	cis	rs3770081	1.000	rs12612513	chr2:86301225	G/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.08	-6.95	-0.36	1.88e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs9928842	0.882	rs8048956	chr16:75254966	C/G	cg09066997	chr16:75300724	BCAR1	-0.48	-6.09	-0.32	3.07e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg06917634	chr15:78832804	PSMA4	-0.48	-6.95	-0.36	1.94e-11	Sudden cardiac arrest;
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg23034840	chr1:205782522	SLC41A1	0.59	8.38	0.42	1.52e-15	Menarche (age at onset);
LUSC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg06637938	chr14:75390232	RPS6KL1	0.53	8.46	0.42	8.74e-16	Height;
LUSC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg00933542	chr6:150070202	PCMT1	0.32	6.47	0.33	3.51e-10	Lung cancer;
LUSC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg21827317	chr3:136751795	NA	0.38	6.9	0.35	2.63e-11	Neuroticism;
LUSC	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg00484396	chr16:3507460	NAT15	0.51	7.16	0.36	5.32e-12	Body mass index (adult);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21957174	chr11:64511624	RASGRP2	0.41	6.35	0.33	7.06e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2274273	0.588	rs9919923	chr14:55813899	A/G	cg04306507	chr14:55594613	LGALS3	0.48	9.46	0.46	5.53e-19	Protein biomarker;
LUSC	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.39	-0.42	1.41e-15	Schizophrenia;
LUSC	trans	rs72674100	1.000	rs28655295	chr4:97990984	T/G	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg07080220	chr10:102295463	HIF1AN	0.6	7.64	0.39	2.38e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6977660	0.941	rs6953957	chr7:19820560	A/G	cg05791153	chr7:19748676	TWISTNB	0.53	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LUSC	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg03929089	chr4:120376271	NA	0.54	6.23	0.32	1.37e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg27432699	chr2:27873401	GPN1	-0.9	-18.17	-0.7	9.02e-52	Oral cavity cancer;
LUSC	trans	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg11887960	chr12:57824829	NA	0.51	6.69	0.34	9.16e-11	Obesity-related traits;
LUSC	cis	rs7615316	0.934	rs9869842	chr3:142272314	C/T	cg16271453	chr3:142027066	XRN1	-0.35	-6.23	-0.32	1.41e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13353245	chr8:146127515	ZNF250	-0.42	-6.31	-0.33	8.64e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg08677398	chr8:58056175	NA	0.41	5.74	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg05425664	chr17:57184151	TRIM37	0.51	7.62	0.38	2.63e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs11955175	1.000	rs11951044	chr5:40671189	G/A	cg05478818	chr5:40835740	RPL37	0.72	5.95	0.31	6.65e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10465746	0.967	rs7531537	chr1:84414924	C/T	cg10977910	chr1:84465055	TTLL7	0.43	6.38	0.33	5.92e-10	Obesity-related traits;
LUSC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.95	-0.31	6.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg18681998	chr4:17616180	MED28	0.85	15.94	0.66	6.13e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2708977	0.901	rs3731938	chr2:97166204	A/G	cg01950434	chr2:97203154	ARID5A	-0.54	-8.01	-0.4	1.97e-14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-6.11	-0.32	2.7e-9	Waist circumference;Hip circumference;
LUSC	trans	rs9929218	1.000	rs12443730	chr16:68804342	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.54	-0.53	3.64e-26	Colorectal cancer;
LUSC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	0.91	17.45	0.69	6.11e-49	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs73416724	0.925	rs2651201	chr6:43293366	G/A	cg26312998	chr6:43337775	ZNF318	-0.54	-6.27	-0.32	1.11e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17095355	1.000	rs12570612	chr10:111717685	C/T	cg00817464	chr10:111662876	XPNPEP1	0.49	6.52	0.34	2.59e-10	Biliary atresia;
LUSC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.97	-0.31	6.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8038465	0.967	rs3935942	chr15:73971361	C/A	cg15420318	chr15:73925796	NPTN	0.42	6.83	0.35	4.07e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg08854313	chr1:11322531	MTOR	0.86	14.48	0.62	3.19e-37	Body mass index;
LUSC	cis	rs9300255	0.722	rs67624109	chr12:123824635	C/T	cg00376283	chr12:123451042	ABCB9	-0.64	-7.35	-0.37	1.5e-12	Neutrophil percentage of white cells;
LUSC	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.91	0.51	6.74e-24	Bladder cancer;
LUSC	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg09754948	chr16:28834200	ATXN2L	0.41	6.12	0.32	2.63e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg10840412	chr1:235813424	GNG4	0.68	9.13	0.45	6.54e-18	Bipolar disorder;
LUSC	cis	rs10788264	0.504	rs4751885	chr10:124020305	G/T	cg09507567	chr10:124027408	NA	0.56	9.88	0.48	2.26e-20	Total body bone mineral density;
LUSC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.59	-0.43	3.41e-16	Bipolar disorder;
LUSC	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg04990556	chr1:26633338	UBXN11	-0.46	-6.26	-0.32	1.18e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2274273	0.905	rs8007944	chr14:55576816	A/C	cg04306507	chr14:55594613	LGALS3	0.55	12.56	0.57	6.75e-30	Protein biomarker;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09475815	chr1:246670754	SMYD3	-0.43	-6.34	-0.33	7.27e-10	Electrocardiographic conduction measures;
LUSC	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg24687543	chr11:63912206	MACROD1	0.48	5.84	0.3	1.26e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs3820928	0.874	rs4675133	chr2:227843010	A/G	cg11843606	chr2:227700838	RHBDD1	0.5	7.24	0.37	3.04e-12	Pulmonary function;
LUSC	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.15	-0.49	2.75e-21	Hemoglobin concentration;
LUSC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.07	0.55	4.22e-28	Prudent dietary pattern;
LUSC	cis	rs6142102	0.961	rs2284386	chr20:32644396	G/A	cg08999081	chr20:33150536	PIGU	0.36	6.22	0.32	1.49e-9	Skin pigmentation;
LUSC	cis	rs9399401	0.710	rs7765770	chr6:142687305	C/T	cg03128060	chr6:142623767	GPR126	0.62	10.11	0.48	3.99e-21	Chronic obstructive pulmonary disease;
LUSC	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg01579765	chr21:45077557	HSF2BP	-0.46	-8.7	-0.43	1.57e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg11861562	chr11:117069780	TAGLN	0.34	6.58	0.34	1.84e-10	Blood protein levels;
LUSC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.3	-0.45	1.91e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg03342759	chr3:160939853	NMD3	-0.51	-8.47	-0.42	7.93e-16	Morning vs. evening chronotype;
LUSC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg26879891	chr1:152191343	HRNR	-0.38	-6.78	-0.35	5.36e-11	Inflammatory skin disease;
LUSC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	13.19	0.59	2.8099999999999997e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs61990749	0.597	rs176971	chr14:78191599	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	6.46	0.33	3.59e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs7681440	0.647	rs4522832	chr4:90819391	A/C	cg15133208	chr4:90757351	SNCA	-0.35	-5.98	-0.31	5.81e-9	Dementia with Lewy bodies;
LUSC	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07080220	chr10:102295463	HIF1AN	0.69	9.38	0.46	1.06e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg17279839	chr7:150038598	RARRES2	0.49	7.49	0.38	6.24e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg21724239	chr8:58056113	NA	0.79	9.39	0.46	9.94e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.74	0.39	1.19e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg26395211	chr5:140044315	WDR55	-0.37	-5.72	-0.3	2.43e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg06784218	chr1:46089804	CCDC17	0.32	5.87	0.31	1.03e-8	Platelet count;
LUSC	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg15485101	chr11:133734466	NA	0.38	7.4	0.38	1.11e-12	Childhood ear infection;
LUSC	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg02569458	chr12:86230093	RASSF9	0.48	7.72	0.39	1.41e-13	Major depressive disorder;
LUSC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18932078	chr1:2524107	MMEL1	-0.27	-6.05	-0.31	3.81e-9	Ulcerative colitis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09085823	chr20:30795283	POFUT1;PLAGL2	-0.46	-6.04	-0.31	4.05e-9	Hepatitis;
LUSC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.84	-11.33	-0.53	2.04e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg20019720	chr6:154832845	CNKSR3	0.63	8.53	0.42	5.29e-16	Lipoprotein (a) levels;
LUSC	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg02117656	chr17:79614917	TSPAN10	0.32	5.86	0.31	1.11e-8	Eye color traits;
LUSC	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg05340658	chr4:99064831	C4orf37	0.44	6.91	0.35	2.46e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg02800362	chr5:177631904	HNRNPAB	0.83	12.4	0.56	2.55e-29	Obesity-related traits;
LUSC	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg19628046	chr18:33552617	C18orf21	0.51	6.17	0.32	1.96e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs68170813	0.559	rs4730229	chr7:106925353	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.79	-0.47	4.7e-20	Coronary artery disease;
LUSC	cis	rs6480314	0.831	rs7080267	chr10:69980750	T/C	cg06988349	chr10:69991859	ATOH7	0.36	5.91	0.31	8.42e-9	Optic nerve measurement (disc area);
LUSC	cis	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-8.23	-0.41	4.13e-15	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg26513180	chr16:89883248	FANCA	0.78	6.39	0.33	5.68e-10	Skin colour saturation;
LUSC	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg13010199	chr12:38710504	ALG10B	0.7	11.97	0.55	1.04e-27	Heart rate;
LUSC	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg03929089	chr4:120376271	NA	0.68	7.63	0.39	2.56e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg26116260	chr4:7069785	GRPEL1	1.17	17.89	0.7	1.16e-50	Monocyte percentage of white cells;
LUSC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg10729496	chr3:10149963	C3orf24	0.55	7.41	0.38	1.04e-12	Alzheimer's disease;
LUSC	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07080220	chr10:102295463	HIF1AN	0.65	8.72	0.43	1.34e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg10609677	chr17:41278573	BRCA1;NBR2	0.35	5.71	0.3	2.54e-8	Menopause (age at onset);
LUSC	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg20026190	chr17:76395443	PGS1	0.34	5.85	0.31	1.15e-8	HDL cholesterol;
LUSC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg25036284	chr2:26402008	FAM59B	-0.68	-9.47	-0.46	5.29e-19	Gut microbiome composition (summer);
LUSC	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg13010199	chr12:38710504	ALG10B	0.68	10.74	0.51	2.68e-23	Morning vs. evening chronotype;
LUSC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.41	-6.43	-0.33	4.36e-10	Mean platelet volume;
LUSC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg19318889	chr4:1322082	MAEA	0.53	8.71	0.43	1.46e-16	Obesity-related traits;
LUSC	cis	rs2637266	0.935	rs7918777	chr10:78394375	A/G	cg18941641	chr10:78392320	NA	0.42	7.62	0.38	2.59e-13	Pulmonary function;
LUSC	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg04362960	chr10:104952993	NT5C2	0.59	8.47	0.42	7.78e-16	Immature fraction of reticulocytes;Schizophrenia;
LUSC	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg26384229	chr12:38710491	ALG10B	0.73	11.91	0.55	1.64e-27	Morning vs. evening chronotype;
LUSC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	15.29	0.64	2.21e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.71	-12.52	-0.57	9.7e-30	White blood cell count (basophil);
LUSC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	11.88	0.55	2.17e-27	Colorectal cancer;
LUSC	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg22532475	chr10:104410764	TRIM8	-0.32	-7.26	-0.37	2.67e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.59	9.72	0.47	8.16e-20	Aortic root size;
LUSC	trans	rs877282	0.520	rs12360072	chr10:813082	C/T	cg22713356	chr15:30763199	NA	0.48	7.16	0.36	5.32e-12	Uric acid levels;
LUSC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg05973401	chr12:123451056	ABCB9	-0.5	-6.81	-0.35	4.57e-11	Neutrophil percentage of white cells;
LUSC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg03146154	chr1:46216737	IPP	0.57	8.31	0.41	2.38e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg17757837	chr7:157058334	UBE3C	0.86	13.85	0.6	9e-35	Body mass index;
LUSC	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg02951883	chr7:2050386	MAD1L1	-0.37	-6.08	-0.32	3.37e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg09835421	chr16:68378352	PRMT7	-0.67	-7.02	-0.36	1.28e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.43	6.78	0.35	5.31e-11	Height;
LUSC	trans	rs3808502	0.527	rs2736389	chr8:11161310	C/A	cg06636001	chr8:8085503	FLJ10661	0.47	6.81	0.35	4.63e-11	Neuroticism;
LUSC	cis	rs10193935	0.901	rs3755304	chr2:42589921	A/G	cg27598129	chr2:42591480	NA	0.6	8.36	0.42	1.67e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg06002616	chr8:101225028	SPAG1	-0.41	-6.93	-0.35	2.21e-11	Atrioventricular conduction;
LUSC	cis	rs4478858	0.735	rs6687819	chr1:31801112	G/A	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs6076065	0.723	rs1936013	chr20:23363989	A/G	cg11657817	chr20:23433608	CST11	0.42	7.9	0.4	4.11e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg20307385	chr11:47447363	PSMC3	0.71	9.98	0.48	1.06e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg12963246	chr6:28129442	ZNF389	0.41	5.69	0.3	2.84e-8	Parkinson's disease;
LUSC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg19774624	chr17:42201019	HDAC5	-0.81	-13.61	-0.6	7.03e-34	Total body bone mineral density;
LUSC	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg22681709	chr2:178499509	PDE11A	-0.55	-10.98	-0.52	3.63e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6062509	0.895	rs6062497	chr20:62336258	C/T	cg21849932	chr20:62369462	LIME1	-0.42	-6.03	-0.31	4.4e-9	Prostate cancer;
LUSC	trans	rs28647808	0.881	rs41297211	chr9:136260721	G/A	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	trans	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.94	0.55	1.29e-27	Exhaled nitric oxide output;
LUSC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg12463550	chr7:65579703	CRCP	0.56	8.35	0.42	1.79e-15	Aortic root size;
LUSC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	0.7	14.86	0.63	1.09e-38	Prudent dietary pattern;
LUSC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	7.56	0.38	4.03e-13	Obesity-related traits;
LUSC	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg03465714	chr1:152285911	FLG	0.41	5.66	0.3	3.22e-8	Atopic dermatitis;
LUSC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.1	-0.36	7.5e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg25237894	chr2:233734115	C2orf82	0.35	6.59	0.34	1.69e-10	Coronary artery disease;
LUSC	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg18904891	chr8:8559673	CLDN23	0.4	5.8	0.3	1.55e-8	Neuroticism;
LUSC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06656553	chr16:89960601	TCF25	-0.63	-5.7	-0.3	2.68e-8	Skin colour saturation;
LUSC	cis	rs4474465	0.688	rs7929656	chr11:78276416	T/C	cg27205649	chr11:78285834	NARS2	0.55	6.75	0.35	6.54e-11	Alzheimer's disease (survival time);
LUSC	cis	rs28785552	0.796	rs8112908	chr19:53248041	C/T	cg22067481	chr19:53234126	ZNF611	-0.43	-5.82	-0.3	1.39e-8	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.23e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2562456	0.755	rs2562421	chr19:21631304	T/G	cg00806126	chr19:22604979	ZNF98	0.37	5.85	0.3	1.19e-8	Pain;
LUSC	cis	rs6690583	0.623	rs2083284	chr1:85440023	C/T	cg22153463	chr1:85462885	MCOLN2	0.62	5.78	0.3	1.7e-8	Serum sulfate level;
LUSC	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg09092052	chr15:45571596	NA	0.47	6.62	0.34	1.4e-10	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg20368463	chr18:77673604	PQLC1	-0.54	-7.75	-0.39	1.15e-13	Schizophrenia;
LUSC	cis	rs6546550	0.933	rs6546554	chr2:70135706	G/A	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg03340356	chr1:67600835	NA	0.4	6.46	0.33	3.74e-10	Psoriasis;
LUSC	cis	rs4730250	0.707	rs3729877	chr7:106787065	T/G	cg02696742	chr7:106810147	HBP1	0.64	9.04	0.44	1.32e-17	Osteoarthritis;
LUSC	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg03894339	chr8:19674705	INTS10	0.53	7.28	0.37	2.4e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.18	0.55	1.76e-28	Prudent dietary pattern;
LUSC	cis	rs72772090	0.539	rs11750671	chr5:96188482	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.88	-0.35	2.88e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg17385448	chr1:15911702	AGMAT	0.37	6.23	0.32	1.41e-9	Systolic blood pressure;
LUSC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg05347473	chr6:146136440	FBXO30	0.54	9.12	0.45	7.22e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg26727032	chr16:67993705	SLC12A4	-0.39	-6.01	-0.31	4.8e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg25039879	chr17:56429692	SUPT4H1	0.67	8.95	0.44	2.48e-17	Cognitive test performance;
LUSC	cis	rs9318086	0.648	rs78881146	chr13:24468704	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.45	6.64	0.34	1.27e-10	Myopia (pathological);
LUSC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg02428538	chr16:24856791	SLC5A11	-0.56	-6.27	-0.32	1.12e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-6.67	-0.34	1.03e-10	Homocysteine levels;
LUSC	cis	rs9462027	0.628	rs7776219	chr6:34784667	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.74	-0.3	2.13e-8	Systemic lupus erythematosus;
LUSC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg22823121	chr1:150693482	HORMAD1	0.59	9.07	0.44	1.03e-17	Tonsillectomy;
LUSC	cis	rs9807989	0.811	rs67088699	chr2:102968751	C/T	cg09003973	chr2:102972529	NA	0.44	6.01	0.31	4.83e-9	Asthma;
LUSC	cis	rs66731853	0.769	rs477679	chr1:20894618	A/G	cg04087271	chr1:20915334	CDA	0.54	8.96	0.44	2.27e-17	Mean corpuscular volume;
LUSC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg25767906	chr1:53392781	SCP2	0.39	6.68	0.34	9.86e-11	Monocyte count;
LUSC	cis	rs4594175	0.677	rs7149846	chr14:51739654	A/C	cg23942311	chr14:51606299	NA	0.31	6.08	0.32	3.28e-9	Cancer;
LUSC	trans	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg01620082	chr3:125678407	NA	-0.82	-7.24	-0.37	3.06e-12	Depression;
LUSC	trans	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-8.71	-0.43	1.45e-16	Obesity-related traits;
LUSC	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg21775007	chr8:11205619	TDH	0.54	7.6	0.38	3.06e-13	Neuroticism;
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.54	-9.69	-0.47	9.97e-20	Longevity;Endometriosis;
LUSC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.14	-0.36	6e-12	Bipolar disorder;
LUSC	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg06740227	chr12:86229804	RASSF9	0.36	5.75	0.3	2.04e-8	Major depressive disorder;
LUSC	cis	rs713477	0.967	rs8020152	chr14:55907025	T/A	cg13175173	chr14:55914753	NA	-0.32	-6.67	-0.34	1.07e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs6542838	0.641	rs11123756	chr2:99508012	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.47	6.1	0.32	2.99e-9	Fear of minor pain;
LUSC	cis	rs601339	1.000	rs507525	chr12:123181581	T/C	cg11919336	chr12:123188078	GPR109A	0.41	6.03	0.31	4.25e-9	Adiponectin levels;
LUSC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg02269571	chr22:50332266	NA	-0.57	-8.54	-0.42	4.87e-16	Schizophrenia;
LUSC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26314531	chr2:26401878	FAM59B	0.74	8.8	0.43	7.3e-17	Gut microbiome composition (summer);
LUSC	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg08017756	chr2:100939284	LONRF2	-0.44	-8.33	-0.41	2.09e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg27411982	chr8:10470053	RP1L1	0.42	6.59	0.34	1.71e-10	Mood instability;
LUSC	cis	rs9560113	0.960	rs950891	chr13:112173992	G/A	cg14154082	chr13:112174009	NA	-0.36	-7.77	-0.39	9.73e-14	Menarche (age at onset);
LUSC	cis	rs10746514	1.000	rs10746514	chr1:232246027	G/A	cg09506761	chr1:232265262	NA	0.47	7.64	0.39	2.37e-13	Response to statin therapy;
LUSC	cis	rs2230307	0.536	rs561119	chr1:100603891	G/A	cg24955406	chr1:100503596	HIAT1	-0.64	-6.9	-0.35	2.63e-11	Carotid intima media thickness;
LUSC	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	trans	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg20935933	chr6:143382018	AIG1	0.5	7.36	0.37	1.45e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg08847533	chr14:75593920	NEK9	-0.85	-15.37	-0.64	1.08e-40	Height;
LUSC	cis	rs6546886	0.957	rs12713806	chr2:74258136	T/G	cg14702570	chr2:74259524	NA	-0.31	-5.96	-0.31	6.42e-9	Dialysis-related mortality;
LUSC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00339695	chr16:24857497	SLC5A11	0.38	6.64	0.34	1.27e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.91	-0.35	2.41e-11	Lung cancer;
LUSC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02711726	chr17:80685570	FN3KRP	-0.42	-6.56	-0.34	2.1e-10	Glycated hemoglobin levels;
LUSC	trans	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	14.41	0.62	5.8e-37	Exhaled nitric oxide levels;
LUSC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg05754148	chr16:3507555	NAT15	0.58	8.55	0.42	4.5e-16	Tuberculosis;
LUSC	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg18357645	chr12:58087776	OS9	0.49	7.3	0.37	2.17e-12	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg12011299	chr4:100065546	ADH4	0.64	10.09	0.48	4.42e-21	Alcohol dependence;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00177390	chr1:185126125	C1orf25;C1orf26	-0.43	-6.3	-0.33	9.25e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.93	0.48	1.54e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9815354	0.857	rs73073252	chr3:42016891	C/T	cg03022575	chr3:42003672	ULK4	0.56	5.92	0.31	7.96e-9	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs12618769	0.597	rs7585939	chr2:99219206	T/A	cg10123293	chr2:99228465	UNC50	0.47	7.6	0.38	2.98e-13	Bipolar disorder;
LUSC	cis	rs73206853	0.764	rs17682012	chr12:111094454	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.73	-7.27	-0.37	2.52e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg27124370	chr19:33622961	WDR88	0.57	7.42	0.38	1.01e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Bladder cancer;
LUSC	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg27411982	chr8:10470053	RP1L1	0.39	6.02	0.31	4.7e-9	Neuroticism;
LUSC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00149659	chr3:10157352	C3orf10	-0.93	-13.58	-0.6	9.68e-34	Alzheimer's disease;
LUSC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg07741184	chr6:167504864	NA	0.33	5.96	0.31	6.54e-9	Crohn's disease;
LUSC	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg16482183	chr6:26056742	HIST1H1C	0.58	8.0	0.4	2.04e-14	Iron status biomarkers;
LUSC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg00599273	chr12:58146742	CDK4	0.31	5.96	0.31	6.5e-9	Multiple sclerosis;
LUSC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg01879757	chr17:41196368	BRCA1	-0.5	-8.0	-0.4	2.03e-14	Menopause (age at onset);
LUSC	cis	rs9361491	0.508	rs9352611	chr6:79396968	T/C	cg05283184	chr6:79620031	NA	-0.39	-6.93	-0.35	2.16e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2835872	0.584	rs1709816	chr21:39077259	A/C	cg20424643	chr21:39039972	KCNJ6	-0.42	-6.57	-0.34	1.97e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg05855489	chr10:104503620	C10orf26	0.57	9.18	0.45	4.79e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg18721089	chr20:30220636	NA	-0.41	-6.78	-0.35	5.38e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs62400317	0.859	rs11964844	chr6:45258823	T/A	cg20913747	chr6:44695427	NA	-0.45	-7.42	-0.38	9.65e-13	Total body bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23889236	chr11:706100	EPS8L2	-0.39	-6.02	-0.31	4.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11971779	0.680	rs6467837	chr7:139023575	A/G	cg07862535	chr7:139043722	LUC7L2	0.53	6.6	0.34	1.66e-10	Diisocyanate-induced asthma;
LUSC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.42	5.87	0.31	1.05e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7712401	0.715	rs13164161	chr5:122346897	G/A	cg19077854	chr5:122220652	SNX24	-0.41	-8.85	-0.44	5.29e-17	Mean platelet volume;
LUSC	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.82	-0.3	1.39e-8	Birth weight;
LUSC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg02038168	chr22:39784481	NA	-0.48	-8.01	-0.4	1.92e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg21573476	chr21:45109991	RRP1B	-0.38	-6.19	-0.32	1.72e-9	Mean corpuscular volume;
LUSC	trans	rs6030	1.000	rs10800454	chr1:169509163	A/G	cg16792071	chr10:134842795	NA	0.28	6.18	0.32	1.83e-9	Uric acid levels;
LUSC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg23711669	chr6:146136114	FBXO30	0.9	17.11	0.68	1.48e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg03678062	chr6:149772716	ZC3H12D	0.31	6.33	0.33	8.1e-10	Dupuytren's disease;
LUSC	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.45	0.53	7.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.69	10.37	0.49	5.1e-22	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg02176678	chr2:219576539	TTLL4	-0.66	-12.89	-0.58	4.08e-31	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs12980942	0.872	rs10421990	chr19:41797099	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.58	6.31	0.33	8.86e-10	Coronary artery disease;
LUSC	cis	rs2273669	0.588	rs79465564	chr6:109350290	C/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	9.1e-9	Prostate cancer;
LUSC	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg26102564	chr10:131424627	MGMT	0.39	6.04	0.31	4.07e-9	Response to temozolomide;
LUSC	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg26536354	chr8:144654954	C8orf73	0.58	6.79	0.35	5.15e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.3	-0.45	1.91e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs2652834	0.851	rs16946416	chr15:63356721	A/T	cg05507819	chr15:63340323	TPM1	-0.69	-8.66	-0.43	2.05e-16	HDL cholesterol;
LUSC	trans	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg21775007	chr8:11205619	TDH	0.44	6.08	0.32	3.37e-9	Neuroticism;
LUSC	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg05425664	chr17:57184151	TRIM37	-0.5	-7.44	-0.38	8.48e-13	Testicular germ cell tumor;
LUSC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.52	7.37	0.37	1.37e-12	Tonsillectomy;
LUSC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg16586182	chr3:47516702	SCAP	-0.52	-8.03	-0.4	1.65e-14	Colorectal cancer;
LUSC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg00343986	chr7:65444356	GUSB	-0.41	-6.07	-0.32	3.52e-9	Aortic root size;
LUSC	cis	rs17621444	0.522	rs10886580	chr10:121803633	A/G	cg02041677	chr10:121771263	NA	0.32	6.14	0.32	2.4e-9	IgG glycosylation;
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11905131	chr22:24372483	LOC391322	-0.54	-8.9	-0.44	3.64e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg05738196	chr6:26577821	NA	-0.59	-6.93	-0.35	2.12e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg25206134	chr2:45395956	NA	0.59	6.38	0.33	5.8e-10	Neuroticism;
LUSC	cis	rs7766436	0.885	rs765782	chr6:22592216	A/G	cg13666174	chr6:22585274	NA	-0.43	-6.31	-0.33	8.81e-10	Coronary artery disease;
LUSC	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg13010199	chr12:38710504	ALG10B	0.59	9.34	0.46	1.38e-18	Morning vs. evening chronotype;
LUSC	cis	rs12681287	0.547	rs9942823	chr8:87509177	A/G	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	cis	rs7712401	0.601	rs246303	chr5:122251717	C/G	cg19077854	chr5:122220652	SNX24	0.41	8.97	0.44	2.22e-17	Mean platelet volume;
LUSC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-10.95	-0.51	4.68e-24	Bipolar disorder and schizophrenia;
LUSC	cis	rs965469	1.000	rs6037560	chr20:3323055	T/C	cg25506879	chr20:3388711	C20orf194	-0.51	-5.7	-0.3	2.57e-8	IFN-related cytopenia;
LUSC	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg14343924	chr8:8086146	FLJ10661	0.42	5.75	0.3	1.97e-8	Mood instability;
LUSC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg24829409	chr8:58192753	C8orf71	0.55	5.84	0.3	1.26e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs77633900	0.614	rs2469241	chr15:76873908	A/G	cg21673338	chr15:77095150	SCAPER	-0.65	-6.68	-0.34	1.02e-10	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs791888	0.929	rs2755431	chr10:89415104	C/T	cg13926569	chr10:89418898	PAPSS2	-0.34	-6.52	-0.34	2.57e-10	Magnesium levels;
LUSC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg22963979	chr7:1858916	MAD1L1	-0.7	-11.81	-0.54	4.04e-27	Bipolar disorder and schizophrenia;
LUSC	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.1	-0.36	7.45e-12	Total cholesterol levels;
LUSC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg00049323	chr5:472564	LOC25845	-0.44	-6.8	-0.35	4.87e-11	Cystic fibrosis severity;
LUSC	cis	rs10779751	1.000	rs4845987	chr1:11306279	G/C	cg08854313	chr1:11322531	MTOR	0.92	16.17	0.66	7.91e-44	Body mass index;
LUSC	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg15997130	chr1:24165203	NA	0.52	8.62	0.43	2.63e-16	Immature fraction of reticulocytes;
LUSC	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	0.99	18.35	0.71	1.7e-52	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs17661538	0.504	rs34537345	chr10:18458587	A/G	cg03634479	chr10:18430412	CACNB2	0.63	5.92	0.31	8.07e-9	Response to antipsychotic treatment;
LUSC	cis	rs1692580	0.870	rs263532	chr1:2164116	T/C	cg04315214	chr1:2043799	PRKCZ	-0.3	-5.75	-0.3	1.98e-8	Coronary artery disease;
LUSC	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.46	-6.59	-0.34	1.66e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg23505145	chr19:12996616	KLF1	0.64	10.74	0.51	2.69e-23	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.1	-17.42	-0.69	8.65e-49	Primary sclerosing cholangitis;
LUSC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg22823121	chr1:150693482	HORMAD1	0.6	9.28	0.45	2.21e-18	Tonsillectomy;
LUSC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg08432527	chr16:48278242	LONP2	0.76	6.09	0.32	3.17e-9	Cognitive performance;
LUSC	cis	rs9462027	0.606	rs205258	chr6:34564243	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.17	-0.32	1.94e-9	Systemic lupus erythematosus;
LUSC	cis	rs8179	1.000	rs42033	chr7:92237533	A/T	cg15732164	chr7:92237376	CDK6	-0.54	-7.2	-0.37	4.02e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg02569458	chr12:86230093	RASSF9	-0.47	-7.95	-0.4	2.95e-14	Major depressive disorder;
LUSC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg25838465	chr1:92012736	NA	-0.77	-16.45	-0.67	5.71e-45	Breast cancer;
LUSC	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg13010199	chr12:38710504	ALG10B	0.67	10.54	0.5	1.25e-22	Morning vs. evening chronotype;
LUSC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg08392591	chr16:89556376	ANKRD11	-0.4	-6.02	-0.31	4.68e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs6736093	0.763	rs4848973	chr2:112790562	G/A	cg12686935	chr2:112915763	FBLN7	-0.39	-6.22	-0.32	1.45e-9	Coronary artery disease;
LUSC	cis	rs4494114	0.967	rs3814342	chr1:39325983	A/G	cg25970120	chr1:39325951	RRAGC	-0.42	-6.46	-0.33	3.77e-10	Blood protein levels;
LUSC	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.6	-9.73	-0.47	7.32e-20	Body mass index;
LUSC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg04850211	chr1:228464232	OBSCN	0.31	5.68	0.3	2.95e-8	Diastolic blood pressure;
LUSC	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-9.66	-0.47	1.24e-19	Body mass index;
LUSC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	8.59	0.43	3.3e-16	Coronary artery disease;
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg10150615	chr22:24372951	LOC391322	-0.42	-6.82	-0.35	4.24e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14442939	chr10:27389572	ANKRD26	0.84	9.84	0.47	3.2e-20	Breast cancer;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg25729922	chr1:20834612	MUL1	0.67	5.96	0.31	6.32e-9	Body mass index;
LUSC	cis	rs4839421	0.646	rs4839026	chr1:111018505	A/G	cg06880108	chr1:111021908	CYMP	0.35	5.74	0.3	2.16e-8	Response to bupropion in depression;
LUSC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg09455208	chr3:40491958	NA	0.57	10.09	0.48	4.35e-21	Renal cell carcinoma;
LUSC	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06636551	chr8:101224915	SPAG1	0.42	7.53	0.38	4.78e-13	Atrioventricular conduction;
LUSC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.72	-9.95	-0.48	1.35e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9399401	0.601	rs262120	chr6:142842360	C/A	cg03128060	chr6:142623767	GPR126	0.5	8.29	0.41	2.82e-15	Chronic obstructive pulmonary disease;
LUSC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14893161	chr1:205819251	PM20D1	0.45	6.41	0.33	4.84e-10	Parkinson's disease;
LUSC	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	8.44	0.42	9.62e-16	Retinal vascular caliber;
LUSC	trans	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg04995722	chr7:26192034	NFE2L3	-0.39	-6.28	-0.32	1.06e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg09904177	chr6:26538194	HMGN4	0.43	6.29	0.33	1.02e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7674212	0.556	rs223401	chr4:103738972	T/C	cg16532752	chr4:104119610	CENPE	-0.42	-5.96	-0.31	6.27e-9	Type 2 diabetes;
LUSC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.78	8.11	0.41	9.99e-15	Initial pursuit acceleration;
LUSC	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.11	-28.41	-0.84	3.92e-91	Myeloid white cell count;
LUSC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.39	0.46	9.85e-19	Prudent dietary pattern;
LUSC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.73	-0.47	7.5e-20	Bipolar disorder;
LUSC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.83	-0.81	7.74e-78	Height;
LUSC	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg01065977	chr19:18549689	ISYNA1	-0.23	-6.06	-0.31	3.73e-9	Breast cancer;
LUSC	cis	rs454953	0.533	rs211436	chr6:133612992	A/G	cg07327468	chr6:133561765	EYA4	-0.41	-5.98	-0.31	5.79e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.25	0.52	4.11e-25	Eye color traits;
LUSC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-0.98	-18.94	-0.72	7.15e-55	Menopause (age at onset);
LUSC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.9	-0.44	3.6e-17	Acne (severe);
LUSC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19717773	chr7:2847554	GNA12	-0.38	-6.2	-0.32	1.67e-9	Height;
LUSC	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg16049864	chr8:95962084	TP53INP1	0.41	6.75	0.35	6.4e-11	Type 2 diabetes;
LUSC	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16386425	chr10:429943	DIP2C	-0.45	-7.19	-0.37	4.24e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.99	0.36	1.52e-11	Rheumatoid arthritis;
LUSC	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg15556689	chr8:8085844	FLJ10661	0.56	8.64	0.43	2.4e-16	Retinal vascular caliber;
LUSC	cis	rs1983170	0.799	rs2063055	chr1:92020835	G/T	cg25838465	chr1:92012736	NA	0.43	5.92	0.31	7.8e-9	Eosinophil percentage of white cells;
LUSC	cis	rs2413583	0.591	rs115371106	chr22:39726809	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.64	5.77	0.3	1.79e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs752010	0.523	rs10890160	chr1:42120011	A/G	cg06885757	chr1:42089581	HIVEP3	0.46	9.89	0.48	2.12e-20	Lupus nephritis in systemic lupus erythematosus;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14943953	chr10:64564468	ADO	-0.44	-6.6	-0.34	1.6e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg20887711	chr4:1340912	KIAA1530	0.48	7.51	0.38	5.43e-13	Longevity;
LUSC	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.36	-6.85	-0.35	3.53e-11	Schizophrenia;
LUSC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06221963	chr1:154839813	KCNN3	-0.61	-13.72	-0.6	2.81e-34	Prostate cancer;
LUSC	cis	rs7605827	0.930	rs1852751	chr2:15557320	C/T	cg19274914	chr2:15703543	NA	0.46	8.88	0.44	4.23e-17	Educational attainment (years of education);
LUSC	cis	rs12519773	0.549	rs11738974	chr5:92537336	G/A	cg18783429	chr5:92414398	NA	0.33	6.91	0.35	2.53e-11	Migraine;
LUSC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg21665744	chr7:39171113	POU6F2	0.47	7.56	0.38	4e-13	IgG glycosylation;
LUSC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg07701084	chr6:150067640	NUP43	0.51	7.64	0.39	2.37e-13	Lung cancer;
LUSC	cis	rs2274273	0.600	rs10134317	chr14:55793448	C/T	cg04306507	chr14:55594613	LGALS3	0.47	9.23	0.45	3.27e-18	Protein biomarker;
LUSC	cis	rs7043114	0.525	rs10761153	chr9:95130769	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.58	-0.34	1.85e-10	Height;
LUSC	trans	rs61931739	0.635	rs1525895	chr12:33966496	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.48	0.38	6.72e-13	Morning vs. evening chronotype;
LUSC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	1.04	20.08	0.74	2.21e-59	Menopause (age at onset);
LUSC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg15145296	chr3:125709740	NA	-0.58	-6.44	-0.33	4.06e-10	Blood pressure (smoking interaction);
LUSC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	8.73	0.43	1.22e-16	Height;
LUSC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg16339924	chr4:17578868	LAP3	0.54	8.12	0.41	9.14e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg00310523	chr12:86230176	RASSF9	-0.43	-7.91	-0.4	3.85e-14	Major depressive disorder;
LUSC	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg08755490	chr11:65554678	OVOL1	0.41	5.87	0.31	1.05e-8	Acne (severe);
LUSC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1499972	0.941	rs62264774	chr3:117647906	C/G	cg07612923	chr3:117604196	NA	0.65	5.87	0.31	1.03e-8	Schizophrenia;
LUSC	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg02176678	chr2:219576539	TTLL4	-0.58	-10.17	-0.49	2.38e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4363385	0.747	rs4314835	chr1:152984901	C/T	cg25856811	chr1:152973957	SPRR3	-0.35	-5.88	-0.31	9.76e-9	Inflammatory skin disease;
LUSC	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.0	0.44	1.76e-17	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2018683	1.000	rs2018683	chr7:29014195	G/T	cg19402173	chr7:128379420	CALU	-0.56	-9.69	-0.47	9.76e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg22496339	chr2:162101262	NA	0.52	7.52	0.38	5.26e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.7	-0.47	9.19e-20	Hemoglobin concentration;
LUSC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg08999081	chr20:33150536	PIGU	0.43	7.86	0.4	5.2e-14	Coronary artery disease;
LUSC	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg00933542	chr6:150070202	PCMT1	0.33	6.78	0.35	5.49e-11	Lung cancer;
LUSC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.88	15.5	0.65	3.43e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.12	0.48	3.65e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-7.06	-0.36	9.65e-12	Alzheimer's disease (late onset);
LUSC	cis	rs6977660	0.941	rs10273208	chr7:19816371	T/C	cg07541023	chr7:19748670	TWISTNB	0.56	6.38	0.33	5.97e-10	Thyroid stimulating hormone;
LUSC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg05347473	chr6:146136440	FBXO30	0.58	10.1	0.48	4.16e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg20302533	chr7:39170763	POU6F2	0.51	7.94	0.4	3.08e-14	IgG glycosylation;
LUSC	cis	rs12519773	1.000	rs7711868	chr5:92461247	T/A	cg18783429	chr5:92414398	NA	0.29	6.48	0.33	3.2e-10	Migraine;
LUSC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg21724239	chr8:58056113	NA	0.78	9.42	0.46	7.46e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg09238746	chr17:78121135	EIF4A3	-0.6	-8.96	-0.44	2.34e-17	Yeast infection;
LUSC	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.98	-0.31	5.63e-9	IgG glycosylation;
LUSC	cis	rs7851660	0.967	rs7860598	chr9:100600702	G/A	cg13688889	chr9:100608707	NA	-0.61	-10.38	-0.49	4.54e-22	Strep throat;
LUSC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg23985595	chr17:80112537	CCDC57	-0.31	-6.05	-0.31	3.88e-9	Life satisfaction;
LUSC	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.67	0.34	1.04e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	2.03e-12	Bone mineral density;
LUSC	cis	rs9469578	1.000	rs9469582	chr6:33715939	A/G	cg18708504	chr6:33715942	IP6K3	0.7	8.84	0.44	5.53e-17	Phosphorus levels;
LUSC	cis	rs6500395	1.000	rs11641458	chr16:48670845	C/T	cg04672837	chr16:48644449	N4BP1	0.46	6.91	0.35	2.41e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg24375607	chr4:120327624	NA	0.74	11.31	0.53	2.41e-25	Corneal astigmatism;
LUSC	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.87	-0.44	4.36e-17	Response to antipsychotic treatment;
LUSC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.38	-0.42	1.52e-15	Joint mobility (Beighton score);
LUSC	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.71	13.42	0.59	3.9e-33	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg26874229	chr2:105853672	NA	-0.32	-5.68	-0.3	2.87e-8	Type 2 diabetes;
LUSC	trans	rs12495832	0.822	rs4405877	chr3:147829462	A/C	cg05062820	chr16:1098546	NA	-0.41	-6.18	-0.32	1.86e-9	Chin dimples;
LUSC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg02269571	chr22:50332266	NA	-0.55	-8.22	-0.41	4.65e-15	Schizophrenia;
LUSC	cis	rs981844	0.775	rs17371274	chr4:154738713	A/G	cg14289246	chr4:154710475	SFRP2	0.46	6.22	0.32	1.5e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg03647239	chr10:116582469	FAM160B1	0.44	7.15	0.36	5.46e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg11494091	chr17:61959527	GH2	-0.71	-16.54	-0.67	2.7e-45	Prudent dietary pattern;
LUSC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.75	-0.35	6.54e-11	Blood protein levels;
LUSC	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg24375607	chr4:120327624	NA	0.71	10.36	0.49	5.29e-22	Corneal astigmatism;
LUSC	cis	rs250677	0.522	rs7702695	chr5:148402550	T/A	cg18129178	chr5:148520854	ABLIM3	-0.56	-8.14	-0.41	7.77e-15	Breast cancer;
LUSC	cis	rs36096196	0.891	rs12081179	chr1:2251119	A/G	cg06784691	chr1:2245988	NA	-0.33	-6.04	-0.31	4.04e-9	Coronary artery disease;
LUSC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	13.1	0.58	6.35e-32	Platelet count;
LUSC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.41	-0.38	1.01e-12	Blood metabolite levels;
LUSC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg11752832	chr7:134001865	SLC35B4	0.56	8.8	0.43	7.24e-17	Mean platelet volume;
LUSC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg10729496	chr3:10149963	C3orf24	0.57	7.54	0.38	4.62e-13	Alzheimer's disease;
LUSC	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg24642439	chr20:33292090	TP53INP2	-0.52	-7.92	-0.4	3.6e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg07424592	chr7:64974309	NA	0.69	6.19	0.32	1.81e-9	Diabetic kidney disease;
LUSC	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg03676636	chr4:99064102	C4orf37	0.36	7.95	0.4	2.98e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01341218	chr17:43662625	NA	1.0	14.83	0.63	1.43e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg06640241	chr16:89574553	SPG7	0.7	11.41	0.53	1.11e-25	Multiple myeloma (IgH translocation);
LUSC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg18306943	chr3:40428807	ENTPD3	0.39	5.99	0.31	5.41e-9	Renal cell carcinoma;
LUSC	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg10857441	chr5:6722123	POLS	-0.47	-9.23	-0.45	3.28e-18	Menopause (age at onset);
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg13453750	chr1:205783389	SLC41A1	-0.34	-6.67	-0.34	1.04e-10	Menarche (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03562264	chr6:36646551	CDKN1A	0.43	6.58	0.34	1.77e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg25174290	chr11:3078921	CARS	0.61	9.79	0.47	4.75e-20	Longevity;
LUSC	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg23625390	chr15:77176239	SCAPER	0.46	7.11	0.36	6.91e-12	Blood metabolite levels;
LUSC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg26335602	chr6:28129616	ZNF389	0.43	5.77	0.3	1.79e-8	Depression;
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg01238044	chr22:24384105	GSTT1	0.52	7.7	0.39	1.5700000000000001e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg21775007	chr8:11205619	TDH	0.44	6.11	0.32	2.72e-9	Mood instability;
LUSC	cis	rs11828289	0.660	rs76458473	chr11:23237355	T/G	cg20040320	chr11:23191996	NA	-0.63	-6.19	-0.32	1.79e-9	Cancer;
LUSC	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg17385448	chr1:15911702	AGMAT	0.35	5.97	0.31	6.18e-9	Systolic blood pressure;
LUSC	cis	rs7833986	1.000	rs34480844	chr8:57092973	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	8.87	0.44	4.64e-17	Height;
LUSC	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg07578070	chr6:150326732	RAET1K	0.39	5.96	0.31	6.59e-9	Alopecia areata;
LUSC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.67	0.39	1.92e-13	Bipolar disorder;
LUSC	cis	rs367615	0.537	rs10463600	chr5:108663636	G/A	cg17395555	chr5:108820864	NA	0.55	9.62	0.47	1.72e-19	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15664640	chr17:80829946	TBCD	0.66	11.64	0.54	1.63e-26	Breast cancer;
LUSC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg22166914	chr1:53195759	ZYG11B	0.49	7.61	0.38	2.77e-13	Monocyte count;
LUSC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	1.09	26.49	0.82	4.57e-84	Testicular germ cell tumor;
LUSC	cis	rs7123876	0.587	rs11600831	chr11:72360220	C/T	cg04827223	chr11:72435913	ARAP1	-0.59	-6.69	-0.34	9.45e-11	Body mass index;
LUSC	cis	rs8099014	0.954	rs28393850	chr18:56129141	T/C	cg12907477	chr18:56117327	MIR122	0.43	6.69	0.34	9.48e-11	Platelet count;
LUSC	cis	rs10746514	0.804	rs1854822	chr1:232262270	G/C	cg09506761	chr1:232265262	NA	-0.56	-9.58	-0.46	2.36e-19	Response to statin therapy;
LUSC	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg08975724	chr8:8085496	FLJ10661	0.5	7.51	0.38	5.42e-13	Neuroticism;
LUSC	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg06096015	chr1:231504339	EGLN1	0.56	10.02	0.48	7.84e-21	Hemoglobin concentration;
LUSC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.05	-0.36	1.02e-11	Colorectal cancer;
LUSC	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	7.84	0.39	6.1e-14	Iron status biomarkers;
LUSC	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	6.88	0.35	3.02e-11	Educational attainment;
LUSC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg08999081	chr20:33150536	PIGU	0.44	8.08	0.4	1.19e-14	Coronary artery disease;
LUSC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-14.71	-0.63	4.3e-38	Vitiligo;
LUSC	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	1.14	12.68	0.57	2.42e-30	Arsenic metabolism;
LUSC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.86	0.31	1.13e-8	Tonsillectomy;
LUSC	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg05966235	chr16:28915196	ATP2A1	0.34	5.87	0.31	1.07e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06022373	chr22:39101656	GTPBP1	-0.76	-12.24	-0.56	1.08e-28	Menopause (age at onset);
LUSC	cis	rs1775715	0.737	rs12256714	chr10:32216262	A/G	cg04359828	chr10:32216031	ARHGAP12	-0.38	-6.55	-0.34	2.19e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg22117172	chr7:91764530	CYP51A1	0.31	5.7	0.3	2.7e-8	Breast cancer;
LUSC	cis	rs6429082	0.967	rs704710	chr1:235621026	A/G	cg26050004	chr1:235667680	B3GALNT2	0.43	6.1	0.32	2.92e-9	Adiposity;
LUSC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg14092988	chr3:52407081	DNAH1	0.32	6.24	0.32	1.3e-9	Bipolar disorder;
LUSC	cis	rs7193541	0.510	rs79473128	chr16:74589192	G/A	cg01733217	chr16:74700730	RFWD3	0.73	11.18	0.52	7.36e-25	Multiple myeloma;
LUSC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg18512352	chr11:47633146	NA	0.46	9.23	0.45	3.18e-18	Subjective well-being;
LUSC	cis	rs13315871	0.929	rs79813245	chr3:58318475	G/A	cg20936604	chr3:58311152	NA	-0.76	-6.95	-0.36	1.9e-11	Cholesterol, total;
LUSC	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg08975724	chr8:8085496	FLJ10661	0.46	6.85	0.35	3.61e-11	Retinal vascular caliber;
LUSC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg03060546	chr3:49711283	APEH	0.57	7.02	0.36	1.22e-11	Menarche (age at onset);
LUSC	trans	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg14227996	chr4:17616232	MED28	-0.51	-6.17	-0.32	1.99e-9	Opioid sensitivity;
LUSC	cis	rs12042938	0.507	rs1655301	chr1:231731730	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-11.61	-0.54	2.08e-26	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs4561483	0.549	rs33657	chr16:11969724	G/C	cg08843971	chr16:11963173	GSPT1	-0.45	-6.9	-0.35	2.68e-11	Testicular germ cell tumor;
LUSC	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg11584989	chr19:19387371	SF4	-0.62	-7.26	-0.37	2.72e-12	Bipolar disorder;
LUSC	cis	rs6714710	0.603	rs58546246	chr2:98521823	C/A	cg26665480	chr2:98280029	ACTR1B	0.58	8.56	0.42	4.18e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.55	-0.34	2.13e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs10100465	0.805	rs10955823	chr8:118676625	A/G	cg09430518	chr8:118662568	NA	-0.3	-5.76	-0.3	1.95e-8	Leprosy;
LUSC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.62	-8.04	-0.4	1.62e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs1982963	1.000	rs1982963	chr14:52509101	C/T	cg10843707	chr14:52510701	NID2	-0.41	-7.26	-0.37	2.79e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6460942	0.818	rs116613169	chr7:12234669	T/C	cg06484146	chr7:12443880	VWDE	-0.58	-5.65	-0.3	3.39e-8	Coronary artery disease;
LUSC	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg23241863	chr10:102295624	HIF1AN	0.48	5.72	0.3	2.38e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg24556660	chr7:106842632	COG5;HBP1	0.44	5.88	0.31	9.9e-9	Coronary artery disease;
LUSC	trans	rs2262909	0.962	rs436662	chr19:22232107	C/T	cg17074339	chr11:11642133	GALNTL4	-0.46	-7.07	-0.36	9.1e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg04511125	chr2:88470314	THNSL2	0.67	6.33	0.33	7.76e-10	Plasma clusterin levels;
LUSC	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.25	-0.45	2.76e-18	Morning vs. evening chronotype;
LUSC	cis	rs1160297	0.576	rs1451460	chr2:53088148	C/T	cg07782112	chr2:53107842	NA	0.4	6.45	0.33	3.84e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg06008330	chr7:65541103	ASL	-0.4	-6.22	-0.32	1.52e-9	Aortic root size;
LUSC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	0.98	13.57	0.6	1.07e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.44	-0.33	4.25e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4654899	0.758	rs10218584	chr1:21474480	C/G	cg01072550	chr1:21505969	NA	0.48	7.42	0.38	9.68e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg03146154	chr1:46216737	IPP	0.55	8.31	0.41	2.44e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7927771	0.800	rs11039200	chr11:47379646	A/C	cg05585544	chr11:47624801	NA	-0.42	-7.03	-0.36	1.14e-11	Subjective well-being;
LUSC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.39	6.0	0.31	5.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11166629	1.000	rs11166629	chr8:135636964	C/T	cg21672855	chr8:135614777	ZFAT	0.35	5.71	0.3	2.47e-8	Smoking quantity;
LUSC	cis	rs7940866	0.903	rs7940465	chr11:130861339	C/T	cg12179176	chr11:130786555	SNX19	0.61	9.47	0.46	5.37e-19	Schizophrenia;
LUSC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg09021430	chr5:549028	NA	0.44	7.8	0.39	8.2e-14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg04310649	chr10:35416472	CREM	-0.4	-6.13	-0.32	2.5e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg15017067	chr4:17643749	FAM184B	0.35	5.7	0.3	2.69e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg26811252	chr16:29126840	RRN3P2	0.65	10.55	0.5	1.15e-22	Menopause (age at onset);
LUSC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg18240062	chr17:79603768	NPLOC4	0.58	10.12	0.48	3.7e-21	Eye color traits;
LUSC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg24375607	chr4:120327624	NA	0.77	11.46	0.53	7.47e-26	Corneal astigmatism;
LUSC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg26335602	chr6:28129616	ZNF389	0.46	6.17	0.32	1.97e-9	Parkinson's disease;
LUSC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg21433313	chr16:3507492	NAT15	0.67	11.16	0.52	8.44e-25	Tuberculosis;
LUSC	trans	rs1495965	0.524	rs7546245	chr1:67750474	C/T	cg16262963	chr14:104851903	NA	0.24	6.03	0.31	4.3e-9	Behcet's disease;
LUSC	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg12863693	chr15:85201151	NMB	0.39	8.09	0.4	1.14e-14	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg15790184	chr11:494944	RNH1	0.42	6.4	0.33	5.37e-10	Systemic lupus erythematosus;
LUSC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg12257692	chr3:49977190	RBM6	0.24	6.61	0.34	1.53e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg05855489	chr10:104503620	C10orf26	0.67	9.76	0.47	5.8e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs3733418	0.929	rs4691138	chr4:165908641	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-5.92	-0.31	8.03e-9	Obesity-related traits;
LUSC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.71	0.34	8.5e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	1.16	10.36	0.49	5.26e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg18350739	chr11:68623251	NA	-0.38	-6.86	-0.35	3.35e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs524023	0.914	rs11606370	chr11:64378452	C/A	cg19131476	chr11:64387923	NRXN2	-0.38	-10.46	-0.5	2.47e-22	Urate levels in obese individuals;
LUSC	cis	rs4964805	0.594	rs9132	chr12:104166243	C/T	cg02344784	chr12:104178138	NT5DC3	0.38	6.05	0.31	3.94e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg02569458	chr12:86230093	RASSF9	0.52	8.57	0.42	3.81e-16	Major depressive disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02591199	chr4:113066609	C4orf32	-0.39	-6.24	-0.32	1.29e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.47e-11	Morning vs. evening chronotype;
LUSC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.64	-10.78	-0.51	1.84e-23	Blood metabolite levels;
LUSC	trans	rs7671266	0.611	rs10939833	chr4:10309537	A/G	cg26043149	chr18:55253948	FECH	-0.5	-6.14	-0.32	2.37e-9	Cardiovascular disease risk factors;
LUSC	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	11.4	0.53	1.22e-25	Lung cancer in ever smokers;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg06789412	chr3:101405552	RPL24	0.33	6.35	0.33	6.99e-10	Tuberculosis;
LUSC	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	0.81	11.21	0.52	5.76e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg11941060	chr3:133502564	NA	-0.45	-6.5	-0.33	3e-10	Iron status biomarkers;
LUSC	trans	rs7605827	0.675	rs2111449	chr2:15616215	C/T	cg21544402	chr1:151129160	TNFAIP8L2	-0.41	-6.07	-0.32	3.52e-9	Educational attainment (years of education);
LUSC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg19046167	chr17:80928561	B3GNTL1	-0.52	-6.44	-0.33	4.07e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUSC	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg11344533	chr11:111475393	SIK2	-0.49	-6.89	-0.35	2.86e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg27102117	chr16:15229624	NA	0.58	9.69	0.47	9.63e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg23719950	chr11:63933701	MACROD1	-0.61	-7.99	-0.4	2.22e-14	Mean platelet volume;
LUSC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.13	-0.36	6.2e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.29	-0.33	9.81e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs800082	0.675	rs2117004	chr3:144180576	G/A	cg24215973	chr2:240111563	HDAC4	0.45	6.74	0.35	6.79e-11	Smoking behavior;
LUSC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	0.7	15.04	0.64	2.08e-39	Prudent dietary pattern;
LUSC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg06454157	chr6:167490870	NA	-0.28	-6.87	-0.35	3.1e-11	Primary biliary cholangitis;
LUSC	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.61	10.22	0.49	1.61e-21	Blood metabolite ratios;
LUSC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg20307385	chr11:47447363	PSMC3	-0.46	-6.08	-0.32	3.35e-9	Subjective well-being;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11342277	chr1:116915598	ATP1A1	-0.49	-6.54	-0.34	2.26e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg25214090	chr10:38739885	LOC399744	0.57	8.39	0.42	1.44e-15	Corneal astigmatism;
LUSC	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-11.19	-0.52	6.55e-25	Eye color traits;
LUSC	cis	rs2011503	0.739	rs4808973	chr19:19725456	A/G	cg11244672	chr19:19639970	YJEFN3	0.48	6.15	0.32	2.16e-9	Bipolar disorder;
LUSC	cis	rs9462027	0.628	rs2744949	chr6:34633862	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.08	-0.32	3.24e-9	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg03676636	chr4:99064102	C4orf37	0.33	6.79	0.35	5.21e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg12863693	chr15:85201151	NMB	0.34	6.78	0.35	5.6e-11	Schizophrenia;
LUSC	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.65	0.39	2.21e-13	Iron status biomarkers;
LUSC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg21972741	chr5:435613	AHRR	0.36	6.8	0.35	4.8e-11	Cystic fibrosis severity;
LUSC	cis	rs7560272	0.538	rs12233115	chr2:73931891	G/A	cg20560298	chr2:73613845	ALMS1	0.38	5.74	0.3	2.14e-8	Schizophrenia;
LUSC	cis	rs977987	0.806	rs8057203	chr16:75404974	T/C	cg03315344	chr16:75512273	CHST6	0.48	9.25	0.45	2.73e-18	Dupuytren's disease;
LUSC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg25039879	chr17:56429692	SUPT4H1	0.67	9.01	0.44	1.65e-17	Cognitive test performance;
LUSC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg03146154	chr1:46216737	IPP	-0.51	-7.44	-0.38	8.45e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02034447	chr16:89574710	SPG7	0.44	6.49	0.33	3.09e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg19592336	chr6:28129416	ZNF389	0.46	5.92	0.31	8.12e-9	Depression;
LUSC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg21435336	chr19:17392852	ANKLE1	-0.43	-5.87	-0.31	1.07e-8	Systemic lupus erythematosus;
LUSC	cis	rs7224314	1.000	rs11079691	chr17:65362552	T/A	cg01507342	chr17:65387096	PITPNC1	-0.4	-6.85	-0.35	3.55e-11	Diisocyanate-induced asthma;
LUSC	trans	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg05926928	chr17:57297772	GDPD1	-0.71	-8.41	-0.42	1.17e-15	Opioid sensitivity;
LUSC	trans	rs62055045	0.528	rs9935288	chr16:71552741	T/C	cg09088153	chr15:96890598	NA	-0.42	-6.09	-0.32	3.13e-9	Schizophrenia;
LUSC	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg23093090	chr10:104574429	C10orf26	-0.38	-7.06	-0.36	9.93e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg06547715	chr2:218990976	CXCR2	0.33	6.35	0.33	7e-10	Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg20607798	chr8:58055168	NA	0.54	6.22	0.32	1.5e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11997175	0.545	rs59563980	chr8:33665377	C/T	ch.8.33884649F	chr8:33765107	NA	0.51	7.44	0.38	8.81e-13	Body mass index;
LUSC	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg06028605	chr16:24865363	SLC5A11	0.46	8.1	0.41	1.03e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg13393036	chr8:95962371	TP53INP1	0.31	6.09	0.32	3.06e-9	Type 2 diabetes;
LUSC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.66	0.34	1.16e-10	Lung cancer;
LUSC	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg10547527	chr2:198650123	BOLL	-0.5	-5.85	-0.3	1.16e-8	Ulcerative colitis;
LUSC	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg24110177	chr3:50126178	RBM5	-0.43	-6.84	-0.35	3.77e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	9.3	0.45	1.88e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	-0.41	-6.42	-0.33	4.57e-10	Menopause (age at onset);
LUSC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg12963246	chr6:28129442	ZNF389	0.54	7.45	0.38	8.25e-13	Depression;
LUSC	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg04989706	chr14:50066350	PPIL5	-0.47	-6.34	-0.33	7.28e-10	Carotid intima media thickness;
LUSC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	5.79	0.3	1.58e-8	Breast cancer;
LUSC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg14092988	chr3:52407081	DNAH1	0.33	6.32	0.33	8.52e-10	Bipolar disorder;
LUSC	cis	rs4834770	1.000	rs10034579	chr4:120244029	A/C	cg24375607	chr4:120327624	NA	0.41	5.84	0.3	1.21e-8	Blood protein levels;
LUSC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg24920358	chr1:40204285	PPIE	0.6	10.8	0.51	1.64e-23	Blood protein levels;
LUSC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg20203395	chr5:56204925	C5orf35	-0.74	-10.28	-0.49	9.79e-22	Initial pursuit acceleration;
LUSC	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg00857998	chr1:205179979	DSTYK	0.65	10.16	0.49	2.63e-21	Red blood cell count;
LUSC	cis	rs11112613	0.775	rs7959699	chr12:105959848	C/A	cg03607813	chr12:105948248	NA	0.83	11.96	0.55	1.1e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs72960926	0.744	rs6926606	chr6:75034904	T/C	cg03266952	chr6:74778945	NA	-0.6	-6.01	-0.31	4.84e-9	Metabolite levels (MHPG);
LUSC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs11958404	0.860	rs56090852	chr5:157431120	A/G	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.43	-6.58	-0.34	1.87e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.39	0.33	5.59e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg00982548	chr2:198649783	BOLL	-0.56	-7.04	-0.36	1.12e-11	Ulcerative colitis;
LUSC	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg05163923	chr11:71159392	DHCR7	-0.77	-10.02	-0.48	7.56e-21	Vitamin D levels;
LUSC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.85	-13.69	-0.6	3.66e-34	Menarche (age at onset);
LUSC	trans	rs7581030	0.517	rs7590738	chr2:71525698	G/A	cg06465196	chr4:154387603	KIAA0922	0.43	6.1	0.32	2.92e-9	Testicular germ cell tumor;
LUSC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	0.65	13.88	0.6	6.8000000000000005e-35	Prudent dietary pattern;
LUSC	cis	rs11997175	0.520	rs4733449	chr8:33628652	G/T	ch.8.33884649F	chr8:33765107	NA	0.51	8.19	0.41	5.69e-15	Body mass index;
LUSC	cis	rs10504073	0.647	rs341807	chr8:50032676	C/T	cg00325661	chr8:49890786	NA	0.6	9.75	0.47	6.18e-20	Blood metabolite ratios;
LUSC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg07936489	chr17:37558343	FBXL20	-0.72	-10.14	-0.49	3.08e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg06885757	chr1:42089581	HIVEP3	0.43	8.7	0.43	1.53e-16	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs6062509	0.630	rs6011058	chr20:62356627	C/T	cg01176363	chr20:62369445	LIME1	-0.46	-6.83	-0.35	4.11e-11	Prostate cancer;
LUSC	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg17366294	chr4:99064904	C4orf37	0.5	8.7	0.43	1.54e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg19592336	chr6:28129416	ZNF389	0.52	6.96	0.36	1.86e-11	Parkinson's disease;
LUSC	trans	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg18187862	chr3:45730750	SACM1L	-0.51	-6.26	-0.32	1.21e-9	Primary sclerosing cholangitis;
LUSC	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg00757033	chr12:89920650	WDR51B	0.59	10.15	0.49	2.74e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	10.65	0.5	5.23e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg22532475	chr10:104410764	TRIM8	-0.35	-6.42	-0.33	4.7e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg03522245	chr20:25566470	NINL	-0.35	-5.72	-0.3	2.34e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06170053	chr6:21596959	SOX4	0.8	6.25	0.32	1.23e-9	Cognitive performance;
LUSC	cis	rs1572438	0.811	rs9379179	chr6:879853	A/C	cg13447295	chr6:887704	NA	0.46	7.18	0.37	4.47e-12	Aging;
LUSC	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.3	-0.41	2.52e-15	Obesity-related traits;
LUSC	cis	rs12973672	0.812	rs35250673	chr19:35762548	G/A	cg12095397	chr19:35769544	USF2	0.44	6.67	0.34	1.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg12002119	chr2:101014098	CHST10	0.36	5.93	0.31	7.6e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11997175	0.646	rs6468195	chr8:33724817	A/G	ch.8.33884649F	chr8:33765107	NA	0.47	6.99	0.36	1.48e-11	Body mass index;
LUSC	cis	rs8048589	0.515	rs4780412	chr16:12232409	A/G	cg02910054	chr16:12241554	SNX29	0.48	6.63	0.34	1.37e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs7188861	0.813	rs7189989	chr16:11442710	G/A	cg00044050	chr16:11439710	C16orf75	-0.55	-6.22	-0.32	1.45e-9	HDL cholesterol;
LUSC	trans	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	8.57	0.42	3.98e-16	Mean corpuscular volume;
LUSC	cis	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg06521331	chr12:34319734	NA	-0.51	-8.37	-0.42	1.55e-15	Morning vs. evening chronotype;
LUSC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg00074818	chr8:8560427	CLDN23	0.57	9.71	0.47	8.22e-20	Obesity-related traits;
LUSC	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg27661571	chr11:113659931	NA	-0.66	-7.58	-0.38	3.54e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21028142	chr17:79581711	NPLOC4	0.34	8.31	0.41	2.36e-15	Eye color traits;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg13860548	chr1:15853252	DNAJC16	0.47	6.05	0.31	3.8e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs979233	0.502	rs3851450	chr5:42126067	C/T	cg07010552	chr17:7358735	CHRNB1	-0.42	-6.08	-0.32	3.36e-9	Systemic lupus erythematosus;
LUSC	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg14343924	chr8:8086146	FLJ10661	0.42	5.69	0.3	2.72e-8	Mood instability;
LUSC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04267008	chr7:1944627	MAD1L1	0.45	6.65	0.34	1.2e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	12.92	0.58	3.03e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.87	14.03	0.61	1.77e-35	Bladder cancer;
LUSC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.83	12.28	0.56	7.58e-29	Breast cancer;
LUSC	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg22431228	chr1:16359049	CLCNKA	0.4	8.31	0.41	2.49e-15	Systolic blood pressure;
LUSC	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg13334819	chr7:99746414	C7orf59	0.49	6.44	0.33	4.16e-10	Coronary artery disease;
LUSC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06544989	chr22:39130855	UNC84B	0.37	6.28	0.32	1.08e-9	Menopause (age at onset);
LUSC	trans	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg03785828	chr5:81573306	RPS23	-0.37	-5.98	-0.31	5.74e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.57	0.6	1.03e-33	Cognitive test performance;
LUSC	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-10.42	-0.5	3.2800000000000002e-22	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.2e-13	Corneal astigmatism;
LUSC	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.13	-0.41	8.5e-15	Triglycerides;
LUSC	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg17425144	chr1:10567563	PEX14	0.63	13.24	0.59	1.92e-32	Breast cancer;
LUSC	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	0.58	9.24	0.45	2.94e-18	Breast cancer;
LUSC	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-10.38	-0.49	4.57e-22	Schizophrenia;
LUSC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg09904177	chr6:26538194	HMGN4	-0.53	-6.21	-0.32	1.57e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03868159	chr6:42532252	UBR2	0.42	6.26	0.32	1.16e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg13685833	chr1:53393034	SCP2	0.41	6.17	0.32	1.97e-9	Monocyte count;
LUSC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg17554472	chr22:41940697	POLR3H	0.47	5.84	0.3	1.27e-8	Vitiligo;
LUSC	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg18209359	chr17:80159595	CCDC57	0.39	6.66	0.34	1.15e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs793571	0.500	rs2555356	chr15:59016431	T/G	cg05156742	chr15:59063176	FAM63B	0.51	7.53	0.38	4.72e-13	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.66	0.76	1.38e-65	Prudent dietary pattern;
LUSC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.69	13.11	0.58	6.01e-32	Gestational age at birth (maternal effect);
LUSC	cis	rs34779708	0.766	rs35308730	chr10:35549796	C/T	cg03585969	chr10:35415529	CREM	0.52	7.09	0.36	8.09e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg23711669	chr6:146136114	FBXO30	0.88	16.41	0.67	8.41e-45	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.73	0.39	1.29e-13	Iron status biomarkers;
LUSC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg06238570	chr21:40685208	BRWD1	0.46	7.08	0.36	8.78e-12	Cognitive function;
LUSC	trans	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.72	-0.35	7.85e-11	Monocyte count;
LUSC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.67e-12	Motion sickness;
LUSC	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg05855489	chr10:104503620	C10orf26	-0.49	-7.47	-0.38	7.25e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1981331	1.000	rs1981331	chr21:47995443	A/C	cg23283320	chr21:48055893	PRMT2	1.12	8.14	0.41	7.72e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-1.03	-20.48	-0.75	5.94e-61	Height;
LUSC	cis	rs6700896	0.932	rs6678033	chr1:66077624	G/A	cg04111102	chr1:66153794	NA	0.31	6.94	0.35	2.07e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Bladder cancer;
LUSC	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg06784218	chr1:46089804	CCDC17	0.34	5.67	0.3	3.15e-8	Platelet count;
LUSC	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg12863693	chr15:85201151	NMB	0.37	7.72	0.39	1.34e-13	Schizophrenia;
LUSC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg24060327	chr5:131705240	SLC22A5	-0.43	-6.86	-0.35	3.43e-11	Blood metabolite levels;
LUSC	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg08601574	chr20:25228251	PYGB	0.41	6.12	0.32	2.63e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.51	0.46	3.9e-19	Bipolar disorder;
LUSC	cis	rs7674212	0.556	rs34475639	chr4:103954851	C/T	cg16532752	chr4:104119610	CENPE	-0.45	-6.08	-0.32	3.35e-9	Type 2 diabetes;
LUSC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg26384229	chr12:38710491	ALG10B	0.74	11.93	0.55	1.42e-27	Morning vs. evening chronotype;
LUSC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.39	0.37	1.21e-12	Schizophrenia;
LUSC	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.34	-0.33	7.38e-10	Bipolar disorder;
LUSC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg23788917	chr6:8435910	SLC35B3	0.51	7.58	0.38	3.38e-13	Motion sickness;
LUSC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.07e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11031096	0.678	rs11031220	chr11:4197638	G/A	cg18678763	chr11:4115507	RRM1	-0.4	-5.69	-0.3	2.75e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg09455208	chr3:40491958	NA	0.59	10.09	0.48	4.42e-21	Renal cell carcinoma;
LUSC	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.08	0.44	9.68e-18	Menarche (age at onset);
LUSC	trans	rs7939886	0.920	rs10792448	chr11:55804542	C/G	cg15704280	chr7:45808275	SEPT13	0.8	6.88	0.35	3.04e-11	Myopia (pathological);
LUSC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg15557168	chr22:42548783	NA	-0.47	-7.54	-0.38	4.43e-13	Schizophrenia;
LUSC	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg24375607	chr4:120327624	NA	0.77	12.51	0.56	1.08e-29	Educational attainment;
LUSC	cis	rs243505	0.528	rs1558419	chr7:148480233	C/T	cg09806900	chr7:148480153	CUL1	0.61	9.31	0.45	1.76e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.24	-0.41	4.06e-15	Total body bone mineral density;
LUSC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg09953122	chr20:23471693	CST8	0.63	5.76	0.3	1.91e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg10172584	chr19:19639581	YJEFN3	-0.47	-5.89	-0.31	9.64e-9	Bipolar disorder;
LUSC	cis	rs1775715	0.870	rs1755072	chr10:32266642	A/G	cg04359828	chr10:32216031	ARHGAP12	-0.39	-6.49	-0.33	3.14e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg23283495	chr1:209979779	IRF6	0.64	9.29	0.45	2.04e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg24578937	chr1:2090814	PRKCZ	-0.44	-9.71	-0.47	8.31e-20	Height;
LUSC	trans	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg03929089	chr4:120376271	NA	-0.55	-6.3	-0.33	9.37e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	13.19	0.59	2.77e-32	Lung cancer in ever smokers;
LUSC	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg14893161	chr1:205819251	PM20D1	-0.47	-6.36	-0.33	6.61e-10	Menarche (age at onset);
LUSC	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg24130564	chr14:104152367	KLC1	-0.48	-7.01	-0.36	1.29e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.49	-6.72	-0.35	7.64e-11	Fear of minor pain;
LUSC	cis	rs12738007	0.717	rs4654328	chr1:29230345	C/T	cg01925633	chr1:29338769	EPB41	0.38	5.66	0.3	3.25e-8	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.52e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg10253484	chr15:75165896	SCAMP2	-0.42	-5.98	-0.31	5.8e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08280861	chr8:58055591	NA	0.54	6.39	0.33	5.53e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.4	5.71	0.3	2.45e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg08132940	chr7:1081526	C7orf50	-0.46	-5.93	-0.31	7.64e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4704187	0.663	rs6897274	chr5:74426103	T/A	cg03227963	chr5:74354835	NA	0.32	6.77	0.35	5.68e-11	Response to amphetamines;
LUSC	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg26924012	chr15:45694286	SPATA5L1	0.78	12.41	0.56	2.5e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs6692729	0.966	rs6697001	chr1:227014835	C/T	cg10327440	chr1:227177885	CDC42BPA	0.48	6.96	0.36	1.81e-11	Electrodermal activity;
LUSC	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	9.69	0.47	9.79e-20	Lung cancer in ever smokers;
LUSC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg11062466	chr8:58055876	NA	0.5	6.57	0.34	1.89e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg17178900	chr1:205818956	PM20D1	0.44	5.94	0.31	7.3e-9	Parkinson's disease;
LUSC	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.15	0.41	7.55e-15	Myopia (pathological);
LUSC	cis	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.55	-5.94	-0.31	7.2e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs3857536	0.776	rs1002764	chr6:66945760	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg14019146	chr3:50243930	SLC38A3	0.32	7.11	0.36	7e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs11031096	0.655	rs10835734	chr11:4211832	A/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.72	-0.3	2.32e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.25	0.52	4.11e-25	Eye color traits;
LUSC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-13.83	-0.6	1.02e-34	Total body bone mineral density;
LUSC	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg00277334	chr10:82204260	NA	0.43	6.11	0.32	2.82e-9	Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg12119029	chr16:89752879	CDK10	0.29	5.67	0.3	3.11e-8	Vitiligo;
LUSC	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21659725	chr3:3221576	CRBN	-0.62	-10.29	-0.49	9.7e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs3767633	0.528	rs4417044	chr1:161888955	T/C	cg27519958	chr1:161735129	ATF6	-0.43	-7.09	-0.36	8.08e-12	IgG glycosylation;
LUSC	cis	rs7180079	0.925	rs56101352	chr15:64534299	C/T	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.57	0.38	3.73e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11608355	0.618	rs2075435	chr12:109796832	C/T	cg19025524	chr12:109796872	NA	-0.5	-9.16	-0.45	5.34e-18	Neuroticism;
LUSC	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.75	-0.3	1.97e-8	IgG glycosylation;
LUSC	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.46	0.38	7.32e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg18705301	chr15:41695430	NDUFAF1	0.48	8.54	0.42	4.83e-16	Menopause (age at onset);
LUSC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg14552801	chr7:65878734	NA	0.37	5.65	0.3	3.47e-8	Aortic root size;
LUSC	cis	rs6681460	0.549	rs6680968	chr1:67034661	C/T	cg02459107	chr1:67143332	SGIP1	0.32	5.67	0.3	3.05e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21963583	chr11:68658836	MRPL21	0.54	8.18	0.41	5.88e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.57	-11.79	-0.54	4.75e-27	Sense of smell;
LUSC	cis	rs11785693	0.862	rs11784262	chr8:4996942	G/A	cg26367366	chr8:4980734	NA	0.71	8.39	0.42	1.35e-15	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg21775007	chr8:11205619	TDH	0.51	7.91	0.4	3.78e-14	Systolic blood pressure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14544983	chr19:47248940	FKRP;STRN4	-0.41	-6.2	-0.32	1.71e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12545109	0.800	rs1996105	chr8:57413123	A/G	cg09654669	chr8:57350985	NA	-0.52	-6.66	-0.34	1.11e-10	Obesity-related traits;
LUSC	cis	rs80130819	0.688	rs10783233	chr12:48590899	C/G	cg24011408	chr12:48396354	COL2A1	0.44	5.67	0.3	3.1e-8	Prostate cancer;
LUSC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg16405210	chr4:1374714	KIAA1530	-0.52	-7.98	-0.4	2.43e-14	Obesity-related traits;
LUSC	cis	rs7568498	0.564	rs10490563	chr2:161914168	G/A	cg22496339	chr2:162101262	NA	-0.57	-7.41	-0.38	1.03e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LUSC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19346786	chr7:2764209	NA	-0.44	-7.54	-0.38	4.55e-13	Height;
LUSC	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.73	10.91	0.51	6.83e-24	Colorectal cancer;
LUSC	cis	rs72781680	0.716	rs72788284	chr2:24097539	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	6.81	0.35	4.57e-11	Lymphocyte counts;
LUSC	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg08085267	chr17:45401833	C17orf57	-0.64	-10.75	-0.51	2.41e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.19	-0.32	1.78e-9	Neuroticism;
LUSC	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg18404041	chr3:52824283	ITIH1	-0.58	-9.62	-0.47	1.75e-19	Schizophrenia;
LUSC	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg12826209	chr6:26865740	GUSBL1	0.53	7.57	0.38	3.73e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02176678	chr2:219576539	TTLL4	0.64	11.85	0.54	2.83e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs400736	0.562	rs10864331	chr1:8172178	A/G	cg25007680	chr1:8021821	PARK7	-0.4	-6.06	-0.31	3.78e-9	Response to antidepressants and depression;
LUSC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg03146154	chr1:46216737	IPP	0.5	7.51	0.38	5.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs3114020	0.739	rs2622627	chr4:89065353	C/A	cg19815589	chr11:70709062	SHANK2	-0.34	-6.12	-0.32	2.56e-9	Gout;
LUSC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg12963246	chr6:28129442	ZNF389	0.52	7.33	0.37	1.8e-12	Parkinson's disease;
LUSC	cis	rs4474465	0.790	rs4945290	chr11:78252249	C/T	cg27205649	chr11:78285834	NARS2	0.52	6.28	0.33	1.02e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-0.77	-13.63	-0.6	6.11e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.38	-0.37	1.29e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	9.32	0.45	1.61e-18	Bone mineral density;
LUSC	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg23992470	chr4:843637	GAK	0.55	5.84	0.3	1.25e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.67	-0.39	1.96e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7561273	0.609	rs2160943	chr2:24288775	G/A	cg20701182	chr2:24300061	SF3B14	0.45	5.77	0.3	1.76e-8	Quantitative traits;
LUSC	cis	rs7615316	1.000	rs9866958	chr3:142338441	T/C	cg16271453	chr3:142027066	XRN1	-0.35	-5.87	-0.31	1.02e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs73416724	0.925	rs112053368	chr6:43382960	C/A	cg26312998	chr6:43337775	ZNF318	0.53	6.15	0.32	2.23e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg05147244	chr20:61493195	TCFL5	0.93	7.49	0.38	6.04e-13	Obesity-related traits;
LUSC	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg05340658	chr4:99064831	C4orf37	0.47	7.55	0.38	4.08e-13	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08280861	chr8:58055591	NA	0.54	6.39	0.33	5.53e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10761482	0.861	rs4456215	chr10:62103249	G/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg27539214	chr16:67997921	SLC12A4	-0.5	-6.72	-0.35	7.83e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg01802117	chr1:53393560	SCP2	-0.4	-6.63	-0.34	1.32e-10	Monocyte count;
LUSC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-12.85	-0.58	5.44e-31	Alzheimer's disease;
LUSC	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	0.99	18.01	0.7	3.63e-51	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg24503407	chr1:205819492	PM20D1	0.89	16.53	0.67	2.94e-45	Menarche (age at onset);
LUSC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg18230493	chr5:56204884	C5orf35	-0.97	-14.41	-0.62	6.28e-37	Initial pursuit acceleration;
LUSC	trans	rs2055729	0.645	rs62489486	chr8:9741925	G/A	cg15556689	chr8:8085844	FLJ10661	0.51	6.14	0.32	2.35e-9	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg15556689	chr8:8085844	FLJ10661	0.55	8.04	0.4	1.56e-14	Morning vs. evening chronotype;
LUSC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg13560548	chr3:10150139	C3orf24	0.47	6.65	0.34	1.18e-10	Alzheimer's disease;
LUSC	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg03788504	chr6:150331562	NA	-0.27	-6.03	-0.31	4.29e-9	Alopecia areata;
LUSC	cis	rs7119038	0.818	rs6421571	chr11:118743772	T/C	cg19308663	chr11:118741387	NA	-0.33	-5.78	-0.3	1.75e-8	Sjögren's syndrome;
LUSC	cis	rs36093844	0.800	rs17744711	chr11:85600724	T/C	cg25872744	chr11:85566296	CCDC83	-0.44	-5.65	-0.3	3.43e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg00191853	chr8:101177733	SPAG1	-0.41	-6.59	-0.34	1.68e-10	Atrioventricular conduction;
LUSC	cis	rs7084921	0.579	rs11596253	chr10:101849411	C/A	cg11888571	chr10:102027403	CWF19L1	-0.47	-6.36	-0.33	6.53e-10	Bone mineral density;
LUSC	cis	rs3784262	0.967	rs12910752	chr15:58314679	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.67	-0.3	3.02e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23158103	chr7:148848205	ZNF398	-0.41	-6.01	-0.31	4.95e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg25243455	chr2:114033360	PAX8;LOC440839	-0.34	-7.66	-0.39	1.97e-13	Lymphocyte counts;
LUSC	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg17691542	chr6:26056736	HIST1H1C	0.55	8.18	0.41	5.91e-15	Height;
LUSC	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.69	10.48	0.5	2.11e-22	Corneal astigmatism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01198024	chr21:33672713	MRAP	-0.41	-6.9	-0.35	2.7e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg20991723	chr1:152506922	NA	0.49	9.08	0.44	9.93e-18	Hair morphology;
LUSC	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg04117972	chr1:227635322	NA	0.77	7.74	0.39	1.17e-13	Major depressive disorder;
LUSC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg12463550	chr7:65579703	CRCP	0.5	7.02	0.36	1.22e-11	Aortic root size;
LUSC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg13206674	chr6:150067644	NUP43	0.56	8.86	0.44	4.74e-17	Lung cancer;
LUSC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.74	-10.11	-0.48	3.83e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12667521	chr19:29218732	NA	0.56	7.24	0.37	3.12e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.68	-12.23	-0.56	1.11e-28	Aortic root size;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06888554	chr19:42580220	ZNF574	0.7	6.06	0.31	3.71e-9	Cognitive performance;
LUSC	cis	rs6845621	0.870	rs13114606	chr4:18930791	A/C	cg12196642	chr4:18937545	NA	-0.36	-6.69	-0.34	9.3e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	trans	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg22153745	chr1:153894579	GATAD2B	-0.49	-6.85	-0.35	3.54e-11	Total cholesterol levels;
LUSC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	8.04	0.4	1.59e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.78	-13.04	-0.58	1.05e-31	Aortic root size;
LUSC	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.79	-0.65	2.36e-42	Height;
LUSC	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs9420	0.961	rs708228	chr11:57585662	C/T	cg23127183	chr11:57508653	C11orf31	-0.57	-8.69	-0.43	1.7e-16	Schizophrenia;
LUSC	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.74	-0.39	1.2e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg00129232	chr17:37814104	STARD3	-0.5	-7.49	-0.38	6.21e-13	Asthma;
LUSC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.09	-0.32	3.17e-9	Neuroticism;
LUSC	trans	rs7939886	0.920	rs17150102	chr11:55904382	A/C	cg03929089	chr4:120376271	NA	0.77	6.09	0.32	3.03e-9	Myopia (pathological);
LUSC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg01097406	chr16:89675127	NA	-0.36	-7.11	-0.36	7.29e-12	Vitiligo;
LUSC	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg11608241	chr8:8085544	FLJ10661	-0.42	-6.14	-0.32	2.35e-9	Systolic blood pressure;
LUSC	trans	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.09	0.52	1.58e-24	Mean corpuscular volume;
LUSC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.65	-0.43	2.17e-16	Aortic root size;
LUSC	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.49	-7.31	-0.37	1.96e-12	Menarche (age at onset);
LUSC	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.36	0.53	1.66e-25	Morning vs. evening chronotype;
LUSC	cis	rs7508	0.511	rs208026	chr8:17878155	A/G	cg01800426	chr8:17659068	MTUS1	-0.52	-6.26	-0.32	1.17e-9	Atrial fibrillation;
LUSC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg22920501	chr2:26401640	FAM59B	0.7	9.1	0.45	8.43e-18	Gut microbiome composition (summer);
LUSC	cis	rs7169223	0.653	rs1994017	chr15:79080306	T/C	cg21242079	chr15:79101063	ADAMTS7	0.38	5.76	0.3	1.91e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	0.8	14.27	0.62	2.18e-36	Cognitive function;
LUSC	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-15.64	-0.65	9.62e-42	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.13	0.32	2.46e-9	Menopause (age at onset);
LUSC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.6	-8.61	-0.43	2.99e-16	Mean platelet volume;
LUSC	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg00745463	chr17:30367425	LRRC37B	0.79	8.4	0.42	1.28e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs6489882	0.836	rs2384071	chr12:113367343	A/G	cg20102336	chr12:113376681	OAS3	-0.42	-5.96	-0.31	6.39e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg22681709	chr2:178499509	PDE11A	-0.51	-9.13	-0.45	6.86e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4363385	0.588	rs11586559	chr1:153025714	G/A	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.28	-0.32	1.06e-9	Inflammatory skin disease;
LUSC	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg10978503	chr1:24200527	CNR2	-0.53	-12.52	-0.57	9.21e-30	Immature fraction of reticulocytes;
LUSC	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg00071950	chr4:10020882	SLC2A9	0.49	7.89	0.4	4.26e-14	Bone mineral density;
LUSC	cis	rs7267979	0.789	rs6083820	chr20:25354178	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.76	-15.5	-0.65	3.44e-41	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21211367	chr2:162094118	NA	0.44	7.04	0.36	1.12e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs4588572	0.643	rs6861678	chr5:77764613	G/C	cg11547950	chr5:77652471	NA	-0.56	-7.9	-0.4	4.03e-14	Triglycerides;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17404403	chr4:110737017	GAR1	-0.53	-6.87	-0.35	3.13e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.85	-0.51	1.03e-23	Alzheimer's disease (late onset);
LUSC	cis	rs1823874	0.720	rs1993296	chr15:100363588	T/A	cg16400843	chr15:100339927	C15orf51	0.36	6.99	0.36	1.53e-11	IgG glycosylation;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02310562	chr12:117348663	FBXW8	0.38	6.12	0.32	2.66e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg14703610	chr5:56206110	C5orf35	-0.41	-6.13	-0.32	2.51e-9	Coronary artery disease;
LUSC	cis	rs394563	0.601	rs432582	chr6:149794143	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.35	-7.08	-0.36	8.58e-12	Dupuytren's disease;
LUSC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.54	0.34	2.26e-10	Lung cancer;
LUSC	cis	rs8017423	1.000	rs59052550	chr14:90665098	C/T	cg04374321	chr14:90722782	PSMC1	0.67	10.43	0.5	3.08e-22	Mortality in heart failure;
LUSC	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.46	-0.42	8.45e-16	Bladder cancer;
LUSC	trans	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg10756647	chr7:56101905	PSPH	0.84	8.5	0.42	6.25e-16	Diabetic kidney disease;
LUSC	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg13073564	chr4:8508604	NA	0.34	6.29	0.33	1e-9	Response to antineoplastic agents;
LUSC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg03579872	chr1:53393473	SCP2	0.39	5.67	0.3	3.16e-8	Monocyte count;
LUSC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg19257562	chr1:2043853	PRKCZ	0.33	6.7	0.34	8.87e-11	Height;
LUSC	cis	rs3018712	0.590	rs4930236	chr11:68414000	C/A	cg22747802	chr11:68417633	NA	-0.4	-5.64	-0.3	3.57e-8	Total body bone mineral density;
LUSC	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg00049323	chr5:472564	LOC25845	-0.43	-6.78	-0.35	5.41e-11	Cystic fibrosis severity;
LUSC	cis	rs716595	1.000	rs72830450	chr10:111989086	G/T	cg13996003	chr10:112034540	MXI1	-0.7	-5.81	-0.3	1.42e-8	Normalized brain volume;
LUSC	cis	rs1957429	0.614	rs78603758	chr14:65396648	C/G	cg23373153	chr14:65346875	NA	-0.98	-7.73	-0.39	1.3e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	trans	rs984440	0.535	rs1325057	chr8:139076027	G/A	cg03334052	chr1:168888044	NA	0.41	6.48	0.33	3.22e-10	Obesity-related traits;
LUSC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg24733560	chr20:60626293	TAF4	0.41	6.69	0.34	9.26e-11	Body mass index;
LUSC	cis	rs11676348	0.772	rs10932745	chr2:218942976	T/C	cg00012203	chr2:219082015	ARPC2	-0.47	-7.08	-0.36	8.41e-12	Ulcerative colitis;
LUSC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.71	13.43	0.59	3.66e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg18721089	chr20:30220636	NA	-0.35	-5.94	-0.31	7.09e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg22903471	chr2:27725779	GCKR	-0.39	-6.58	-0.34	1.86e-10	Total body bone mineral density;
LUSC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg05084668	chr3:125655381	ALG1L	-0.53	-8.03	-0.4	1.71e-14	Blood pressure (smoking interaction);
LUSC	cis	rs34779708	0.931	rs12268745	chr10:35305989	C/G	cg04310649	chr10:35416472	CREM	-0.4	-6.1	-0.32	2.95e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg04607235	chr12:12878440	APOLD1	0.61	10.11	0.48	4e-21	Birth weight;
LUSC	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg17462356	chr17:80056334	FASN	0.46	5.95	0.31	6.81e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6539288	0.500	rs11113116	chr12:107195929	C/A	cg15890332	chr12:107067104	RFX4	0.36	6.57	0.34	1.89e-10	Total body bone mineral density;
LUSC	cis	rs7512552	0.966	rs2274127	chr1:150252984	T/G	cg15654264	chr1:150340011	RPRD2	-0.62	-9.95	-0.48	1.36e-20	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11971779	0.680	rs1862879	chr7:139019951	A/G	cg07862535	chr7:139043722	LUC7L2	0.55	6.83	0.35	4.09e-11	Diisocyanate-induced asthma;
LUSC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg04450456	chr4:17643702	FAM184B	0.42	7.09	0.36	8.02e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	11.53	0.53	3.97e-26	Lung cancer in ever smokers;
LUSC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg24154853	chr7:158122151	PTPRN2	0.44	8.28	0.41	2.91e-15	Calcium levels;
LUSC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.98	0.4	2.33e-14	Prudent dietary pattern;
LUSC	cis	rs977987	0.778	rs11858992	chr16:75411445	A/C	cg04384234	chr16:75411784	CFDP1	-0.44	-7.28	-0.37	2.4e-12	Dupuytren's disease;
LUSC	cis	rs9648716	0.515	rs246739	chr7:140687173	A/T	cg23214464	chr7:140373596	ADCK2	0.7	5.92	0.31	7.78e-9	Type 2 diabetes;
LUSC	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg13660082	chr14:53194042	PSMC6	-0.78	-6.43	-0.33	4.36e-10	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18876405	chr7:65276391	NA	0.54	8.47	0.42	8.18e-16	Aortic root size;
LUSC	cis	rs1783925	1.000	rs2845845	chr11:125303663	A/G	cg03464685	chr11:125439445	EI24	-0.48	-6.49	-0.33	3.09e-10	Formal thought disorder in schizophrenia;
LUSC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg20090143	chr19:45452003	APOC2	0.47	9.37	0.46	1.11e-18	Blood protein levels;
LUSC	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-6.14	-0.32	2.39e-9	Crohn's disease;
LUSC	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg08916839	chr5:415575	AHRR	0.76	7.1	0.36	7.48e-12	Fat distribution (HIV);
LUSC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg22907277	chr7:1156413	C7orf50	0.71	7.44	0.38	8.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2688608	0.934	rs2675679	chr10:75658581	C/T	cg23231163	chr10:75533350	FUT11	-0.39	-6.5	-0.34	2.91e-10	Inflammatory bowel disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00576402	chr7:77167212	PTPN12	-0.41	-6.2	-0.32	1.69e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	0.6	9.34	0.45	1.43e-18	Breast cancer;
LUSC	trans	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg25214090	chr10:38739885	LOC399744	0.42	6.42	0.33	4.62e-10	Corneal astigmatism;
LUSC	cis	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.82	-0.3	1.35e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs853679	0.567	rs6905380	chr6:28374902	A/G	cg06606381	chr12:133084897	FBRSL1	-0.41	-5.98	-0.31	5.67e-9	Depression;
LUSC	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.92	12.13	0.55	2.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg08859206	chr1:53392774	SCP2	-0.55	-9.79	-0.47	4.76e-20	Monocyte count;
LUSC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.67	8.69	0.43	1.71e-16	Schizophrenia;
LUSC	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.72	-0.43	1.29e-16	Coffee consumption (cups per day);
LUSC	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg07169764	chr2:136633963	MCM6	0.87	11.91	0.55	1.67e-27	Corneal structure;
LUSC	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.81e-12	Blood metabolite levels;
LUSC	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.73	10.36	0.49	5.62e-22	Corneal astigmatism;
LUSC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-1.03	-19.86	-0.74	1.61e-58	Height;
LUSC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg15790184	chr11:494944	RNH1	0.59	6.22	0.32	1.49e-9	Body mass index;
LUSC	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg24558204	chr6:135376177	HBS1L	0.67	10.12	0.48	3.55e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	0.93	16.12	0.66	1.16e-43	Menopause (age at onset);
LUSC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg13047869	chr3:10149882	C3orf24	0.63	8.72	0.43	1.31e-16	Alzheimer's disease;
LUSC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg19622623	chr12:86230825	RASSF9	0.4	5.8	0.3	1.56e-8	Major depressive disorder;
LUSC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg26380479	chr7:97908229	NA	0.29	6.68	0.34	1.03e-10	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.42	-0.33	4.57e-10	Mood instability;
LUSC	cis	rs154659	0.887	rs154660	chr16:89667637	C/G	cg01710450	chr16:89662404	CPNE7	-0.41	-6.2	-0.32	1.67e-9	Tanning;
LUSC	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.73	-12.85	-0.58	5.33e-31	White blood cell count (basophil);
LUSC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg27427491	chr17:78079615	GAA	0.45	7.76	0.39	1.06e-13	Yeast infection;
LUSC	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg13010199	chr12:38710504	ALG10B	0.42	6.16	0.32	2.05e-9	Morning vs. evening chronotype;
LUSC	cis	rs7577696	0.597	rs13006495	chr2:32355490	C/T	cg02381751	chr2:32503542	YIPF4	-0.53	-7.07	-0.36	8.97e-12	Inflammatory biomarkers;
LUSC	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg27661571	chr11:113659931	NA	0.59	6.42	0.33	4.67e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs2679649	1.000	rs2679688	chr6:122362802	A/G	cg00167820	chr8:131663355	NA	0.53	6.2	0.32	1.68e-9	Subcutaneous adipose tissue;
LUSC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.4	-6.28	-0.32	1.08e-9	Total body bone mineral density;
LUSC	trans	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg06636001	chr8:8085503	FLJ10661	0.55	7.5	0.38	5.78e-13	Neuroticism;
LUSC	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.4	0.42	1.3e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg02016764	chr4:38805732	TLR1	-0.53	-5.74	-0.3	2.16e-8	Breast cancer;
LUSC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg13047869	chr3:10149882	C3orf24	0.56	7.73	0.39	1.24e-13	Alzheimer's disease;
LUSC	cis	rs4740619	0.905	rs4146291	chr9:15783266	C/T	cg14451791	chr9:16040625	NA	-0.3	-5.65	-0.3	3.48e-8	Body mass index;
LUSC	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.84	12.82	0.57	6.91e-31	Body mass index;
LUSC	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg03676636	chr4:99064102	C4orf37	0.36	7.86	0.4	5.37e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg23601095	chr6:26197514	HIST1H3D	0.73	7.49	0.38	6.15e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg21017887	chr14:105400489	NA	0.69	13.26	0.59	1.5e-32	Rheumatoid arthritis;
LUSC	cis	rs4631830	0.863	rs10826125	chr10:51530505	G/A	cg16070123	chr10:51489643	NA	-0.5	-7.96	-0.4	2.78e-14	Prostate-specific antigen levels;
LUSC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg05347473	chr6:146136440	FBXO30	0.65	11.21	0.52	5.68e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4400599	0.618	rs9804045	chr1:154191691	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.37	6.18	0.32	1.86e-9	Platelet distribution width;
LUSC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg16405210	chr4:1374714	KIAA1530	0.71	10.97	0.51	4.05e-24	Obesity-related traits;
LUSC	cis	rs394563	0.663	rs415434	chr6:149772645	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.31	-6.7	-0.34	9.06e-11	Dupuytren's disease;
LUSC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg13114125	chr14:105738426	BRF1	-0.87	-14.49	-0.62	3.07e-37	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.97	-0.44	2.18e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs117623576	0.941	rs7070675	chr10:32407269	G/T	cg03047570	chr10:32398778	NA	-0.63	-6.05	-0.31	3.83e-9	Anti-saccade response;
LUSC	cis	rs11031096	0.655	rs56172516	chr11:4182004	G/T	cg18678763	chr11:4115507	RRM1	-0.4	-5.67	-0.3	3.07e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg17252645	chr8:143867129	LY6D	0.37	6.61	0.34	1.54e-10	Urinary tract infection frequency;
LUSC	cis	rs7119	0.651	rs12905044	chr15:77846215	G/A	cg27398640	chr15:77910606	LINGO1	-0.32	-6.92	-0.35	2.32e-11	Type 2 diabetes;
LUSC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26314531	chr2:26401878	FAM59B	0.71	9.78	0.47	4.98e-20	Gut microbiome composition (summer);
LUSC	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.93	15.96	0.66	5.05e-43	Bladder cancer;
LUSC	cis	rs12618769	0.597	rs72821924	chr2:99114924	C/T	cg10123293	chr2:99228465	UNC50	0.45	7.48	0.38	6.81e-13	Bipolar disorder;
LUSC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.79	-12.47	-0.56	1.41e-29	Pancreatic cancer;
LUSC	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg00290607	chr11:67383545	NA	0.36	6.7	0.34	9.12e-11	Mean corpuscular volume;
LUSC	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.8	16.84	0.68	1.75e-46	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg11871910	chr12:69753446	YEATS4	0.61	9.08	0.44	9.9e-18	Response to diuretic therapy;
LUSC	cis	rs11688816	0.569	rs7591708	chr2:63022050	T/C	cg17519650	chr2:63277830	OTX1	-0.6	-8.02	-0.4	1.82e-14	Body mass index;
LUSC	cis	rs36093844	0.904	rs1445502	chr11:85589298	T/A	cg25872744	chr11:85566296	CCDC83	-0.42	-6.84	-0.35	3.7e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs6681460	0.634	rs12143964	chr1:67010266	T/G	cg02459107	chr1:67143332	SGIP1	0.38	6.35	0.33	7.19e-10	Presence of antiphospholipid antibodies;
LUSC	trans	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.15	-0.36	5.58e-12	Myopia (pathological);
LUSC	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg21053147	chr12:120880522	NA	0.49	5.99	0.31	5.52e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	trans	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg06636001	chr8:8085503	FLJ10661	0.45	6.42	0.33	4.57e-10	Retinal vascular caliber;
LUSC	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg07138452	chr17:17141020	FLCN	0.37	6.1	0.32	2.89e-9	Bladder cancer;
LUSC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg05025164	chr4:1340916	KIAA1530	0.54	8.61	0.43	3.03e-16	Longevity;
LUSC	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg12292205	chr6:26970375	C6orf41	-0.63	-7.57	-0.38	3.72e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6084875	0.840	rs2249483	chr20:4719176	C/T	cg07258627	chr20:4721683	PRNT	-0.34	-6.06	-0.31	3.75e-9	Systemic lupus erythematosus;
LUSC	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg11502198	chr6:26597334	ABT1	0.71	12.06	0.55	4.63e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg00033643	chr7:134001901	SLC35B4	0.46	7.09	0.36	7.8e-12	Mean platelet volume;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg03461704	chr1:205818484	PM20D1	0.36	5.78	0.3	1.69e-8	Menarche (age at onset);
LUSC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg14784868	chr12:69753453	YEATS4	0.58	7.37	0.37	1.33e-12	Response to diuretic therapy;
LUSC	cis	rs2820315	0.867	rs2644121	chr1:201881284	A/G	cg10061532	chr1:201886748	LMOD1	0.28	6.42	0.33	4.65e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg17971929	chr21:40555470	PSMG1	0.77	12.79	0.57	8.89e-31	Cognitive function;
LUSC	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg07930552	chr6:133119739	C6orf192	0.97	9.55	0.46	2.92e-19	Type 2 diabetes nephropathy;
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.38	-0.42	1.45e-15	Lymphocyte counts;
LUSC	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg15556689	chr8:8085844	FLJ10661	0.47	7.03	0.36	1.19e-11	Morning vs. evening chronotype;
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg15112475	chr7:1198522	ZFAND2A	-0.34	-7.27	-0.37	2.63e-12	Longevity;Endometriosis;
LUSC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg05872129	chr22:39784769	NA	-0.62	-11.84	-0.54	3e-27	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.02	-0.4	1.85e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-17.68	-0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg22963979	chr7:1858916	MAD1L1	-0.6	-9.47	-0.46	5.33e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg13560548	chr3:10150139	C3orf24	0.5	7.09	0.36	8.1e-12	Alzheimer's disease;
LUSC	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg14092571	chr14:90743983	NA	-0.35	-5.81	-0.3	1.47e-8	Mortality in heart failure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23868899	chr8:124553478	FBXO32	-0.42	-6.26	-0.32	1.15e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10193935	1.000	rs12612527	chr2:42392099	T/C	cg27598129	chr2:42591480	NA	-0.65	-8.29	-0.41	2.73e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72781680	0.821	rs72796378	chr2:24167385	G/A	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg03522245	chr20:25566470	NINL	-0.36	-5.75	-0.3	2.02e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.16	-0.32	2.13e-9	Life satisfaction;
LUSC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-1.1	-23.72	-0.79	1.27e-73	Height;
LUSC	cis	rs9815354	0.812	rs11129932	chr3:41838767	C/A	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs3737883	1.000	rs3737883	chr1:203034906	C/T	cg00805880	chr1:203045044	PPFIA4	0.29	5.93	0.31	7.36e-9	Early onset atrial fibrillation;
LUSC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg07424592	chr7:64974309	NA	0.69	6.08	0.32	3.31e-9	Diabetic kidney disease;
LUSC	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg18825076	chr15:78729989	IREB2	-0.62	-10.03	-0.48	7.25e-21	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12220238	1.000	rs7909915	chr10:75960942	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.3	0.37	2.12e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg15309053	chr8:964076	NA	-0.4	-8.17	-0.41	6.57e-15	Schizophrenia;
LUSC	cis	rs6977660	0.619	rs4721823	chr7:19785888	G/C	cg07541023	chr7:19748670	TWISTNB	0.57	5.92	0.31	7.83e-9	Thyroid stimulating hormone;
LUSC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg23590916	chr17:43697445	MGC57346	-0.46	-6.14	-0.32	2.33e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.74	12.88	0.58	4.16e-31	Colorectal cancer;
LUSC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg11663144	chr21:46675770	NA	-0.4	-6.55	-0.34	2.12e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1376359	0.537	rs2244031	chr1:103257185	C/G	cg17154563	chr19:40477487	PSMC4	0.48	6.05	0.31	3.79e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg05585544	chr11:47624801	NA	0.41	7.39	0.37	1.22e-12	Subjective well-being;
LUSC	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg15445000	chr17:37608096	MED1	0.37	6.46	0.33	3.76e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7568458	0.704	rs10176176	chr2:85762048	A/T	cg23752985	chr2:85803571	VAMP8	0.28	5.78	0.3	1.68e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	0.46	7.79	0.39	8.3e-14	Lymphocyte counts;
LUSC	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg24375607	chr4:120327624	NA	0.8	12.39	0.56	2.79e-29	Corneal astigmatism;
LUSC	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg23711669	chr6:146136114	FBXO30	0.74	13.07	0.58	7.88e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.6	8.66	0.43	2.06e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9837602	1.000	rs793499	chr3:99565576	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.37	-5.74	-0.3	2.15e-8	Breast cancer;
LUSC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg24881330	chr22:46731750	TRMU	0.84	7.39	0.37	1.22e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.2	-0.49	1.9e-21	Eye color traits;
LUSC	cis	rs8027181	1.000	rs4777542	chr15:73082366	C/T	cg25632853	chr15:73088954	NA	-0.34	-6.61	-0.34	1.56e-10	Triglyceride levels;
LUSC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg12963246	chr6:28129442	ZNF389	0.52	7.16	0.36	5.3e-12	Depression;
LUSC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg00343986	chr7:65444356	GUSB	-0.44	-6.74	-0.35	6.83e-11	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08189659	chr19:17622568	PGLS	-0.41	-6.1	-0.32	2.9e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg25767906	chr1:53392781	SCP2	0.49	8.71	0.43	1.4e-16	Monocyte count;
LUSC	cis	rs12208915	0.945	rs12190108	chr6:79562655	T/C	cg05283184	chr6:79620031	NA	0.46	5.97	0.31	5.97e-9	Left atrial antero-posterior diameter;
LUSC	cis	rs11828289	0.660	rs79067807	chr11:23228262	T/C	cg20040320	chr11:23191996	NA	-0.61	-6.2	-0.32	1.69e-9	Cancer;
LUSC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg04369109	chr6:150039330	LATS1	-0.55	-8.18	-0.41	5.94e-15	Lung cancer;
LUSC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-11.86	-0.54	2.57e-27	Alzheimer's disease;
LUSC	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg09165964	chr15:75287851	SCAMP5	-0.48	-6.94	-0.36	2e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21724239	chr8:58056113	NA	0.88	9.73	0.47	7.33e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21984481	chr17:79567631	NPLOC4	0.68	14.41	0.62	5.81e-37	Eye color traits;
LUSC	trans	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	11.04	0.52	2.31e-24	Exhaled nitric oxide levels;
LUSC	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.25	0.37	2.93e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7815909	0.610	rs11987972	chr8:57205975	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	7.24	0.37	3.02e-12	Height;
LUSC	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg14458575	chr2:238380390	NA	0.63	10.49	0.5	1.91e-22	Prostate cancer;
LUSC	trans	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg06636001	chr8:8085503	FLJ10661	0.46	6.66	0.34	1.14e-10	Retinal vascular caliber;
LUSC	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	1.05	14.32	0.62	1.33e-36	Exhaled nitric oxide levels;
LUSC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg10434728	chr15:90938212	IQGAP1	0.34	6.55	0.34	2.19e-10	Rheumatoid arthritis;
LUSC	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	9.09	0.45	8.92e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18099408	chr3:52552593	STAB1	-0.34	-5.85	-0.3	1.19e-8	Bipolar disorder;
LUSC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.46	-0.42	8.46e-16	Bipolar disorder;
LUSC	cis	rs9311676	0.632	rs11924677	chr3:58420542	T/C	cg26110898	chr3:58419937	PDHB	0.4	6.4	0.33	5.22e-10	Systemic lupus erythematosus;
LUSC	cis	rs10887741	0.624	rs6586092	chr10:89428994	A/T	cg13926569	chr10:89418898	PAPSS2	0.33	7.21	0.37	3.88e-12	Exercise (leisure time);
LUSC	trans	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-6.87	-0.35	3.11e-11	Menarche (age at onset);
LUSC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg15445000	chr17:37608096	MED1	-0.4	-6.79	-0.35	5.14e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg22117172	chr7:91764530	CYP51A1	0.32	5.74	0.3	2.15e-8	Breast cancer;
LUSC	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg05340658	chr4:99064831	C4orf37	0.46	7.29	0.37	2.23e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg02423579	chr7:2872169	GNA12	-0.5	-7.14	-0.36	5.96e-12	Height;
LUSC	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.16	0.55	1.98e-28	Height;
LUSC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.44	7.38	0.37	1.24e-12	Pulse pressure;
LUSC	cis	rs654950	0.840	rs2810551	chr1:41995402	G/A	cg06885757	chr1:42089581	HIVEP3	-0.34	-6.55	-0.34	2.24e-10	Airway imaging phenotypes;
LUSC	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg27129171	chr3:47204927	SETD2	0.55	6.77	0.35	5.9e-11	Birth weight;
LUSC	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg23093090	chr10:104574429	C10orf26	-0.34	-6.26	-0.32	1.19e-9	Arsenic metabolism;
LUSC	cis	rs7818345	0.967	rs4391454	chr8:19275653	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.94	0.35	2.08e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	trans	rs77372450	0.551	rs11134891	chr5:157103373	G/A	cg10450108	chr5:140208893	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.53	-5.97	-0.31	6.01e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs76935404	1.000	rs76935404	chr19:41419294	C/T	cg04176888	chr19:41596066	CYP2A13	0.39	6.15	0.32	2.17e-9	nicotine metabolite ratio in current smokers;
LUSC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg19230755	chr7:65878503	NA	0.42	5.83	0.3	1.29e-8	Aortic root size;
LUSC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02353165	chr6:42928485	GNMT	0.67	11.53	0.53	4.18e-26	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	5.71	0.3	2.47e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05025164	chr4:1340916	KIAA1530	0.44	6.87	0.35	3.13e-11	Obesity-related traits;
LUSC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg14019146	chr3:50243930	SLC38A3	0.32	7.11	0.36	7.17e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg04703951	chr17:43578652	NA	0.43	6.81	0.35	4.68e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg08219700	chr8:58056026	NA	0.47	5.94	0.31	7.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.95	-0.31	6.92e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg02951883	chr7:2050386	MAD1L1	-0.56	-10.4	-0.49	3.82e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg08508325	chr11:3079039	CARS	-0.53	-13.35	-0.59	7.16e-33	Longevity;
LUSC	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg12311346	chr5:56204834	C5orf35	-0.6	-9.27	-0.45	2.4e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg20487152	chr13:99095054	FARP1	-0.48	-9.29	-0.45	2.02e-18	Neuroticism;
LUSC	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	8.26	0.41	3.4e-15	Triglycerides;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05061208	chr7:2281363	NUDT1;FTSJ2	-0.47	-6.11	-0.32	2.76e-9	Hepatitis;
LUSC	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18932078	chr1:2524107	MMEL1	-0.29	-6.44	-0.33	4.14e-10	Ulcerative colitis;
LUSC	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	0.8	9.85	0.47	2.9e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.64	0.5	5.85e-23	Bladder cancer;
LUSC	cis	rs77633900	0.772	rs494268	chr15:76815713	T/C	cg21673338	chr15:77095150	SCAPER	-0.67	-5.71	-0.3	2.53e-8	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg13206674	chr6:150067644	NUP43	0.59	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.78	11.3	0.53	2.71e-25	Corneal astigmatism;
LUSC	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg00982548	chr2:198649783	BOLL	-0.58	-7.29	-0.37	2.32e-12	Ulcerative colitis;
LUSC	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg16342193	chr10:102329863	NA	-0.39	-6.81	-0.35	4.54e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2235649	0.789	rs9929803	chr16:1852748	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-6.13	-0.32	2.55e-9	Blood metabolite levels;
LUSC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-17.16	-0.68	8.97e-48	Primary sclerosing cholangitis;
LUSC	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.81	-0.3	1.48e-8	IgG glycosylation;
LUSC	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg20587970	chr11:113659929	NA	1.14	13.53	0.6	1.47e-33	Hip circumference adjusted for BMI;
LUSC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg26897989	chr16:1907736	C16orf73	0.42	6.7	0.34	8.94e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.76	0.57	1.21e-30	Bipolar disorder;
LUSC	trans	rs6725041	0.805	rs6745249	chr2:213130571	A/G	cg13707768	chr11:65081977	CDC42EP2	-0.41	-6.38	-0.33	6.02e-10	QT interval (ambient particulate matter interaction);
LUSC	cis	rs11867934	0.861	rs7217091	chr17:17060805	A/G	cg26176665	chr17:16994978	MPRIP	0.42	6.06	0.31	3.74e-9	Diabetic retinopathy;
LUSC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg20821713	chr7:1055600	C7orf50	-0.5	-6.29	-0.33	1.01e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.77	-0.35	5.93e-11	Menopause (age at onset);
LUSC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.07	0.52	1.76e-24	Alzheimer's disease;
LUSC	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg25237894	chr2:233734115	C2orf82	-0.37	-6.92	-0.35	2.34e-11	Coronary artery disease;
LUSC	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg02175503	chr12:58329896	NA	0.4	5.69	0.3	2.71e-8	Multiple sclerosis;
LUSC	cis	rs7582720	1.000	rs72936353	chr2:204070956	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.38	0.42	1.54e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.5	7.61	0.38	2.87e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg18232548	chr7:50535776	DDC	0.55	7.44	0.38	8.74e-13	Malaria;
LUSC	cis	rs7828089	0.935	rs2293144	chr8:22262418	A/G	cg12081754	chr8:22256438	SLC39A14	0.54	8.47	0.42	8.05e-16	Verbal declarative memory;
LUSC	cis	rs847649	0.699	rs7794668	chr7:102510416	C/T	cg18108683	chr7:102477205	FBXL13	0.34	5.74	0.3	2.15e-8	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-6.07	-0.32	3.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7178572	0.962	rs1022172	chr15:77793359	A/G	cg22256960	chr15:77711686	NA	-0.55	-9.25	-0.45	2.69e-18	Type 2 diabetes;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg24352938	chr1:200008808	NR5A2	0.72	6.31	0.33	8.78e-10	Cognitive performance;
LUSC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2237234	0.542	rs7755997	chr6:26483048	G/A	cg12292205	chr6:26970375	C6orf41	0.43	6.86	0.35	3.29e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg16586182	chr3:47516702	SCAP	0.52	7.99	0.4	2.23e-14	Colorectal cancer;
LUSC	cis	rs6060717	0.536	rs6060683	chr20:34507921	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.74	-0.3	2.13e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg04450456	chr4:17643702	FAM184B	0.34	5.68	0.3	2.89e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6977660	0.714	rs7357319	chr7:19817525	A/G	cg07541023	chr7:19748670	TWISTNB	0.61	6.57	0.34	1.91e-10	Thyroid stimulating hormone;
LUSC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-6.12	-0.32	2.61e-9	IgG glycosylation;
LUSC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg11494091	chr17:61959527	GH2	0.38	6.24	0.32	1.31e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg19567339	chr10:100142640	NA	0.38	5.66	0.3	3.2e-8	Metabolite levels;
LUSC	cis	rs7503807	0.935	rs7215534	chr17:78612119	C/T	cg09596252	chr17:78655493	RPTOR	0.45	7.75	0.39	1.15e-13	Obesity;
LUSC	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg22676075	chr6:135203613	NA	0.47	7.4	0.38	1.12e-12	Red blood cell count;
LUSC	trans	rs11681884	0.681	rs11883847	chr2:113792171	A/G	cg19632953	chr13:113635898	MCF2L	-0.69	-6.47	-0.33	3.52e-10	Stroke;
LUSC	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg05714579	chr10:131428358	MGMT	0.45	6.3	0.33	9.35e-10	Response to temozolomide;
LUSC	cis	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg06521331	chr12:34319734	NA	-0.4	-6.3	-0.33	9.13e-10	Morning vs. evening chronotype;
LUSC	cis	rs7712401	0.601	rs34126945	chr5:122329729	A/G	cg19077854	chr5:122220652	SNX24	-0.41	-8.93	-0.44	2.82e-17	Mean platelet volume;
LUSC	cis	rs9517320	1.000	rs7994160	chr13:99132749	C/A	cg07423050	chr13:99094983	FARP1	0.34	6.43	0.33	4.48e-10	Longevity;
LUSC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg11062466	chr8:58055876	NA	0.65	8.39	0.42	1.41e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	7.17	0.37	4.89e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs113352275	1	rs113352275	chr15:78840567	C/T	cg06917634	chr15:78832804	PSMA4	-0.57	-6.79	-0.35	5.2e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2108225	0.837	rs6958729	chr7:107451211	A/G	cg18560240	chr7:107437656	SLC26A3	0.44	6.78	0.35	5.49e-11	Ulcerative colitis;
LUSC	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg08085267	chr17:45401833	C17orf57	0.45	6.62	0.34	1.44e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs4942242	1.000	rs9562501	chr13:44205683	C/T	cg19169023	chr15:41853346	TYRO3	-0.45	-7.71	-0.39	1.48e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg05623727	chr3:50126028	RBM5	0.33	6.04	0.31	4e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg24375607	chr4:120327624	NA	0.79	11.67	0.54	1.27e-26	Corneal astigmatism;
LUSC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.13	0.45	6.62e-18	Height;
LUSC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02034447	chr16:89574710	SPG7	0.43	6.44	0.33	4.25e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-7.46	-0.38	7.67e-13	Response to antipsychotic treatment;
LUSC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08109568	chr15:31115862	NA	-0.75	-10.86	-0.51	1.02e-23	Huntington's disease progression;
LUSC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg20607798	chr8:58055168	NA	0.49	5.9	0.31	8.7e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg26202797	chr2:240005956	HDAC4	-0.4	-6.0	-0.31	5.22e-9	Thyroid stimulating hormone;
LUSC	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg17328964	chr8:145687451	CYHR1	0.67	11.49	0.53	5.85e-26	Age at first birth;
LUSC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg00149659	chr3:10157352	C3orf10	0.61	8.75	0.43	1.07e-16	Alzheimer's disease;
LUSC	cis	rs2625529	0.938	rs8747	chr15:72115541	C/A	cg16672083	chr15:72433130	SENP8	-0.49	-6.91	-0.35	2.39e-11	Red blood cell count;
LUSC	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.99	-0.36	1.5e-11	Monocyte percentage of white cells;
LUSC	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.82	-13.77	-0.6	1.83e-34	Morning vs. evening chronotype;
LUSC	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.36e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs80282103	0.764	rs7093915	chr10:1107341	A/G	cg08668510	chr10:1095578	IDI1	-0.7	-6.39	-0.33	5.68e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs308403	0.568	rs309344	chr4:123644812	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	10.85	0.51	1.06e-23	Blood protein levels;
LUSC	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg04691961	chr3:161091175	C3orf57	-0.36	-6.22	-0.32	1.51e-9	Morning vs. evening chronotype;
LUSC	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg25182066	chr10:30743637	MAP3K8	-0.47	-6.65	-0.34	1.22e-10	Inflammatory bowel disease;
LUSC	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg03342759	chr3:160939853	NMD3	-0.41	-6.76	-0.35	6.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg03213289	chr20:61660250	NA	0.67	13.61	0.6	7.23e-34	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg19875535	chr5:140030758	IK	-0.5	-8.41	-0.42	1.23e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06544989	chr22:39130855	UNC84B	0.37	6.74	0.35	6.93e-11	Menopause (age at onset);
LUSC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg07395648	chr5:131743802	NA	0.44	7.04	0.36	1.07e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs56399783	0.901	rs73049341	chr7:2812255	G/C	cg19731401	chr7:2775893	GNA12	0.6	8.06	0.4	1.37e-14	Childhood ear infection;
LUSC	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg12863693	chr15:85201151	NMB	0.38	7.66	0.39	2.08e-13	Schizophrenia;
LUSC	cis	rs1507153	0.551	rs236859	chr6:79333116	G/A	cg05283184	chr6:79620031	NA	0.38	6.97	0.36	1.7e-11	Sjögren's syndrome;
LUSC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	6.86	0.35	3.28e-11	Bipolar disorder;
LUSC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.7	-10.72	-0.51	2.99e-23	Platelet count;
LUSC	cis	rs11608355	0.545	rs918107	chr12:109904198	C/T	cg05360138	chr12:110035743	NA	-0.86	-11.03	-0.52	2.5e-24	Neuroticism;
LUSC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-6.49	-0.33	3.05e-10	Height;
LUSC	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg21827317	chr3:136751795	NA	0.39	6.91	0.35	2.41e-11	Neuroticism;
LUSC	trans	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.15	-0.49	2.79e-21	Obesity-related traits;
LUSC	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg12826209	chr6:26865740	GUSBL1	0.52	7.52	0.38	5.08e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg23281280	chr6:28129359	ZNF389	0.45	5.86	0.31	1.14e-8	Parkinson's disease;
LUSC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg21862992	chr11:68658383	NA	0.5	7.9	0.4	3.94e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-13.91	-0.61	5.22e-35	Exhaled nitric oxide output;
LUSC	trans	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg18187862	chr3:45730750	SACM1L	-0.52	-6.37	-0.33	6.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	1.0	18.51	0.71	3.77e-53	Cognitive function;
LUSC	cis	rs7264396	0.887	rs11698935	chr20:34075015	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.57	-0.34	1.89e-10	Total cholesterol levels;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg06145435	chr7:1022769	CYP2W1	0.27	5.68	0.3	3.01e-8	Longevity;Endometriosis;
LUSC	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs4596713	0.538	rs7048094	chr9:71745660	G/C	cg25283916	chr1:242222868	NA	-0.29	-6.04	-0.31	4.19e-9	Headache;
LUSC	cis	rs7582720	1.000	rs114393235	chr2:203795987	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg23131131	chr22:24373011	LOC391322	-0.43	-6.12	-0.32	2.56e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1018836	0.608	rs2142146	chr8:91464808	T/C	cg16814680	chr8:91681699	NA	-0.54	-7.95	-0.4	2.97e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26094983	chr17:65242096	HELZ	-0.41	-6.18	-0.32	1.84e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs72960926	0.744	rs11757177	chr6:74871785	C/A	cg03266952	chr6:74778945	NA	-0.79	-6.39	-0.33	5.64e-10	Metabolite levels (MHPG);
LUSC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.69	11.42	0.53	1.02e-25	Heart rate;
LUSC	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg08330031	chr10:104623503	C10orf32	-0.33	-5.88	-0.31	9.79e-9	Arsenic metabolism;
LUSC	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.8	-0.39	8.21e-14	Pulmonary function;
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg18538332	chr22:24372958	LOC391322	0.46	8.24	0.41	3.84e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg12935359	chr14:103987150	CKB	0.66	10.71	0.51	3.27e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg11502198	chr6:26597334	ABT1	0.7	11.83	0.54	3.39e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg27446573	chr6:127587934	RNF146	0.48	7.5	0.38	5.76e-13	Breast cancer;
LUSC	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg04450456	chr4:17643702	FAM184B	0.37	6.34	0.33	7.37e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	0.57	9.07	0.44	1.02e-17	Breast cancer;
LUSC	cis	rs6942756	0.806	rs1880854	chr7:128949748	G/T	cg02491457	chr7:128862824	NA	0.51	7.69	0.39	1.63e-13	White matter hyperintensity burden;
LUSC	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg22676075	chr6:135203613	NA	-0.56	-9.08	-0.45	9.35e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs1832871	0.672	rs12529235	chr6:158766950	A/G	cg07165851	chr6:158734300	TULP4	0.46	6.95	0.36	1.94e-11	Height;
LUSC	cis	rs4853525	0.859	rs1882397	chr2:191720132	A/C	cg11845111	chr2:191398756	TMEM194B	-0.42	-6.18	-0.32	1.91e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	11.78	0.54	4.92e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg24675056	chr1:15929824	NA	0.45	7.85	0.39	5.81e-14	Systolic blood pressure;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15891644	chr15:40751006	BAHD1	-0.42	-6.23	-0.32	1.42e-9	Asthma;
LUSC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg20891283	chr12:69753455	YEATS4	0.66	10.48	0.5	2.16e-22	Blood protein levels;
LUSC	cis	rs7927771	0.507	rs10838754	chr11:47758532	A/C	cg20307385	chr11:47447363	PSMC3	0.44	6.35	0.33	7.06e-10	Subjective well-being;
LUSC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg04315214	chr1:2043799	PRKCZ	-0.4	-8.01	-0.4	1.89e-14	Height;
LUSC	cis	rs7799006	0.757	rs2398668	chr7:2298227	A/G	cg12823233	chr7:2316876	SNX8	0.43	7.48	0.38	6.8e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs1300170	0.685	rs1733504	chr3:71372797	C/T	cg06537372	chr1:244923979	NA	0.52	6.74	0.35	7.05e-11	Myringotomy;
LUSC	cis	rs6500395	0.926	rs9929569	chr16:48677584	C/T	cg04672837	chr16:48644449	N4BP1	0.44	6.4	0.33	5.11e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	8.76	0.43	9.74e-17	Exhaled nitric oxide output;
LUSC	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg09876464	chr15:85330779	ZNF592	0.35	6.42	0.33	4.81e-10	P wave terminal force;
LUSC	trans	rs9929218	1.000	rs9282650	chr16:68809640	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.72	-0.54	8.62e-27	Colorectal cancer;
LUSC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg20476274	chr7:133979776	SLC35B4	0.83	15.07	0.64	1.56e-39	Mean platelet volume;
LUSC	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg05110241	chr16:68378359	PRMT7	-0.57	-6.61	-0.34	1.52e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1975974	1.000	rs4889732	chr17:21721443	T/C	cg18423549	chr17:21743878	NA	-0.5	-7.62	-0.38	2.6e-13	Psoriasis;
LUSC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.43	-6.42	-0.33	4.69e-10	Tonsillectomy;
LUSC	cis	rs12101261	0.560	rs1035144	chr14:81445121	C/T	cg06600135	chr14:81408086	NA	0.47	7.23	0.37	3.22e-12	Graves' disease;
LUSC	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg23093090	chr10:104574429	C10orf26	-0.37	-6.71	-0.34	8.2e-11	Arsenic metabolism;
LUSC	cis	rs911119	1.000	rs34897231	chr20:23620268	A/G	cg16589663	chr20:23618590	CST3	0.6	7.08	0.36	8.36e-12	Chronic kidney disease;
LUSC	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.77	15.37	0.64	1.03e-40	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.49	-0.33	3.05e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg20302533	chr7:39170763	POU6F2	0.55	9.24	0.45	2.87e-18	IgG glycosylation;
LUSC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg16797656	chr11:68205561	LRP5	0.39	7.12	0.36	6.6e-12	Total body bone mineral density;
LUSC	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg02016764	chr4:38805732	TLR1	-0.54	-5.74	-0.3	2.17e-8	Breast cancer;
LUSC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	cis	rs983392	0.679	rs1026252	chr11:60030559	C/T	cg24026212	chr11:59952134	MS4A6A	0.36	6.15	0.32	2.27e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg18721089	chr20:30220636	NA	-0.35	-5.94	-0.31	7.09e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg14582100	chr15:45693742	SPATA5L1	-0.43	-8.15	-0.41	7.45e-15	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg20587970	chr11:113659929	NA	-1.1	-13.4	-0.59	4.63e-33	Hip circumference adjusted for BMI;
LUSC	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.83	-15.55	-0.65	2.11e-41	Heart rate;
LUSC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg01947301	chr1:205718900	NUCKS1	-0.46	-6.53	-0.34	2.46e-10	Cognitive function;Information processing speed;
LUSC	cis	rs9815354	0.812	rs17280952	chr3:41810834	T/C	cg03022575	chr3:42003672	ULK4	0.85	8.65	0.43	2.23e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg20684491	chr1:25596433	NA	0.38	5.88	0.31	9.87e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs11018904	0.861	rs12786959	chr11:89943676	A/T	cg26834418	chr11:89957033	CHORDC1	-0.52	-6.21	-0.32	1.61e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-19.59	-0.73	1.96e-57	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg09699651	chr6:150184138	LRP11	0.37	5.65	0.3	3.47e-8	Lung cancer;
LUSC	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg24634471	chr8:143751801	JRK	0.51	7.18	0.37	4.47e-12	Schizophrenia;
LUSC	trans	rs11039798	0.764	rs12418936	chr11:48986418	T/C	cg03929089	chr4:120376271	NA	0.73	6.23	0.32	1.39e-9	Axial length;
LUSC	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg10523860	chr14:103875565	MARK3	-0.39	-6.03	-0.31	4.31e-9	Body mass index;
LUSC	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg15073853	chr19:18549131	ISYNA1	-0.33	-6.06	-0.31	3.76e-9	Breast cancer;
LUSC	cis	rs62400317	0.826	rs11970412	chr6:45037516	C/T	cg18551225	chr6:44695536	NA	-0.42	-6.89	-0.35	2.72e-11	Total body bone mineral density;
LUSC	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg05855489	chr10:104503620	C10orf26	-0.53	-8.18	-0.41	6.09e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg03579872	chr1:53393473	SCP2	-0.39	-5.74	-0.3	2.09e-8	Monocyte count;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11829371	chr17:981724	ABR	-0.37	-6.13	-0.32	2.51e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1322512	0.876	rs1727051	chr6:152944891	A/C	cg27316956	chr6:152958899	SYNE1	-0.34	-5.74	-0.3	2.17e-8	Tonometry;
LUSC	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg26395211	chr5:140044315	WDR55	-0.37	-5.7	-0.3	2.62e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9309473	0.847	rs4547554	chr2:73867862	G/C	cg20560298	chr2:73613845	ALMS1	-0.42	-5.97	-0.31	6.21e-9	Metabolite levels;
LUSC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-12.94	-0.58	2.6e-31	Platelet count;
LUSC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg15103426	chr22:29168792	CCDC117	0.6	8.35	0.42	1.89e-15	Lymphocyte counts;
LUSC	cis	rs9811920	0.965	rs6767441	chr3:99863183	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	6.77	0.35	5.79e-11	Axial length;
LUSC	cis	rs11649653	0.502	rs4889490	chr16:30823047	A/C	cg02466173	chr16:30829666	NA	-0.47	-9.2	-0.45	4.1e-18	Triglycerides;
LUSC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg21782813	chr7:2030301	MAD1L1	0.45	7.49	0.38	6.06e-13	Schizophrenia;
LUSC	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg14530993	chr4:882597	GAK	-0.65	-7.16	-0.36	5.04e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg26338869	chr17:61819248	STRADA	0.4	5.77	0.3	1.81e-8	Prudent dietary pattern;
LUSC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg04455712	chr21:45112962	RRP1B	0.43	8.14	0.41	7.98e-15	Mean corpuscular volume;
LUSC	cis	rs7712401	0.715	rs407392	chr5:122360994	C/T	cg19077854	chr5:122220652	SNX24	-0.42	-9.04	-0.44	1.35e-17	Mean platelet volume;
LUSC	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.76	-14.69	-0.63	5.06e-38	Ulcerative colitis;
LUSC	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg01689657	chr7:91764605	CYP51A1	-0.32	-5.69	-0.3	2.77e-8	Breast cancer;
LUSC	cis	rs9420	0.922	rs35808061	chr11:57547000	T/C	cg02958346	chr11:57425731	CLP1	-0.44	-6.44	-0.33	4.22e-10	Schizophrenia;
LUSC	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg01620082	chr3:125678407	NA	-0.81	-7.34	-0.37	1.6e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.4	-6.14	-0.32	2.34e-9	IgG glycosylation;
LUSC	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.57	-0.46	2.56e-19	Schizophrenia;
LUSC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg05535760	chr7:792225	HEATR2	-0.77	-8.28	-0.41	2.95e-15	Cerebrospinal P-tau181p levels;
LUSC	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg12615879	chr12:58013172	SLC26A10	0.36	8.16	0.41	7.09e-15	Multiple sclerosis;
LUSC	cis	rs1506636	1.000	rs689341	chr7:123403974	C/A	cg03229431	chr7:123269106	ASB15	0.65	10.7	0.51	3.69e-23	Plateletcrit;Platelet count;
LUSC	trans	rs3857536	0.813	rs7766786	chr6:66932889	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.44e-9	Blood trace element (Cu levels);
LUSC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.37	0.37	1.38e-12	Bipolar disorder;
LUSC	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg00792783	chr2:198669748	PLCL1	0.44	5.83	0.3	1.28e-8	Dermatomyositis;
LUSC	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-15.1	-0.64	1.28e-39	Exhaled nitric oxide output;
LUSC	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg13010199	chr12:38710504	ALG10B	0.56	8.42	0.42	1.12e-15	Morning vs. evening chronotype;
LUSC	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg17517138	chr11:73019481	ARHGEF17	1.14	9.69	0.47	9.65e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg14416269	chr4:6271139	WFS1	0.54	11.41	0.53	1.08e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg13319975	chr6:146136371	FBXO30	0.48	7.25	0.37	2.96e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg11645453	chr3:52864694	ITIH4	0.35	8.0	0.4	2.1e-14	Bipolar disorder;
LUSC	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg26384229	chr12:38710491	ALG10B	0.73	11.91	0.55	1.75e-27	Morning vs. evening chronotype;
LUSC	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg00852783	chr1:26633632	UBXN11	0.49	8.71	0.43	1.45e-16	Obesity-related traits;
LUSC	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg22676075	chr6:135203613	NA	0.56	8.89	0.44	3.95e-17	Red blood cell count;
LUSC	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg05360949	chr19:41903737	BCKDHA;EXOSC5	0.41	5.66	0.3	3.22e-8	Height;
LUSC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.01	0.48	8.39e-21	Electroencephalogram traits;
LUSC	trans	rs12210905	0.925	rs12212317	chr6:26986553	G/A	cg11837749	chr1:55047332	ACOT11	0.55	5.96	0.31	6.41e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg11247378	chr22:39784982	NA	-0.65	-12.86	-0.58	4.87e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs12545109	0.837	rs1437277	chr8:57356734	T/C	cg09654669	chr8:57350985	NA	-0.56	-7.48	-0.38	6.83e-13	Obesity-related traits;
LUSC	cis	rs713587	0.571	rs546217	chr2:25311537	A/C	cg01884057	chr2:25150051	NA	-0.27	-5.84	-0.3	1.25e-8	Body mass index in non-asthmatics;
LUSC	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	9.27	0.45	2.37e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs13006833	0.739	rs291470	chr2:191189558	T/A	cg21644426	chr2:191273491	MFSD6	0.44	6.36	0.33	6.81e-10	Urinary metabolites;
LUSC	cis	rs2637266	0.783	rs846633	chr10:78535744	A/C	cg18941641	chr10:78392320	NA	-0.39	-7.0	-0.36	1.37e-11	Pulmonary function;
LUSC	cis	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.43	-0.42	1.09e-15	Morning vs. evening chronotype;
LUSC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	0.96	9.39	0.46	9.75e-19	Plasma clusterin levels;
LUSC	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.0	14.25	0.61	2.51e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00166722	chr3:10149974	C3orf24	0.6	7.97	0.4	2.62e-14	Alzheimer's disease;
LUSC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11764359	chr7:65958608	NA	0.63	9.45	0.46	6.08e-19	Calcium levels;
LUSC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg02487422	chr3:49467188	NICN1	0.45	7.08	0.36	8.74e-12	Resting heart rate;
LUSC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-8.78	-0.43	8.49e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg08847533	chr14:75593920	NEK9	-0.79	-14.28	-0.62	1.99e-36	Height;
LUSC	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg22782873	chr19:19639568	YJEFN3	-0.49	-6.12	-0.32	2.56e-9	Bipolar disorder;
LUSC	cis	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.37e-9	Ulcerative colitis;
LUSC	trans	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg03886242	chr7:26192032	NFE2L3	-0.4	-6.21	-0.32	1.58e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.2	-0.32	1.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7582180	0.903	rs2309818	chr2:100898634	G/T	cg08017756	chr2:100939284	LONRF2	-0.37	-6.23	-0.32	1.41e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.5	-7.06	-0.36	9.62e-12	Tuberculosis;
LUSC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg13206674	chr6:150067644	NUP43	0.6	9.55	0.46	2.91e-19	Lung cancer;
LUSC	cis	rs2625529	0.652	rs2034879	chr15:72429989	A/G	cg16672083	chr15:72433130	SENP8	-0.5	-8.15	-0.41	7.52e-15	Red blood cell count;
LUSC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05535760	chr7:792225	HEATR2	0.82	9.72	0.47	7.74e-20	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg02569458	chr12:86230093	RASSF9	0.52	8.4	0.42	1.31e-15	Major depressive disorder;
LUSC	cis	rs6732160	0.691	rs1960233	chr2:73421378	A/G	cg24220031	chr2:73402428	NA	-0.23	-5.76	-0.3	1.9e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.720	rs6704498	chr1:152964740	C/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.64	-0.39	2.34e-13	Inflammatory skin disease;
LUSC	cis	rs9549260	0.755	rs7993233	chr13:41219434	T/A	cg21288729	chr13:41239152	FOXO1	0.65	10.06	0.48	5.76e-21	Red blood cell count;
LUSC	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg06713675	chr4:122721982	EXOSC9	0.38	6.02	0.31	4.56e-9	Type 2 diabetes;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg08721076	chr2:172967670	DLX2	0.43	6.35	0.33	7.08e-10	Asthma;
LUSC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06481639	chr22:41940642	POLR3H	0.48	5.8	0.3	1.57e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	16.08	0.66	1.78e-43	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg23649088	chr2:200775458	C2orf69	0.51	6.94	0.35	2.05e-11	Schizophrenia;
LUSC	trans	rs2370759	0.891	rs11592754	chr10:32619572	A/C	cg07829597	chr10:77161705	C10orf41;ZNF503	0.67	6.38	0.33	6.05e-10	Sexual dysfunction (female);
LUSC	cis	rs4363385	0.747	rs4845332	chr1:152982632	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.33e-13	Inflammatory skin disease;
LUSC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22433210	chr17:43662623	NA	-0.73	-10.61	-0.5	7.63e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg10360139	chr7:1886902	MAD1L1	-0.46	-7.07	-0.36	9.23e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.93	-0.35	2.23e-11	Lung cancer;
LUSC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg26924012	chr15:45694286	SPATA5L1	1.14	20.94	0.75	9e-63	Homoarginine levels;
LUSC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00908189	chr16:619842	PIGQ	0.67	10.37	0.49	4.85e-22	Height;
LUSC	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg24642439	chr20:33292090	TP53INP2	0.48	7.23	0.37	3.41e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs2227564	0.620	rs12783161	chr10:75572201	G/C	cg23231163	chr10:75533350	FUT11	-0.45	-6.59	-0.34	1.69e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg21775007	chr8:11205619	TDH	-0.46	-6.3	-0.33	9.18e-10	Neuroticism;
LUSC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.95	-12.54	-0.57	7.84e-30	Platelet count;
LUSC	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.86	-0.47	2.63e-20	Migraine;Coronary artery disease;
LUSC	cis	rs1348850	0.597	rs13014512	chr2:178470851	T/A	cg27490568	chr2:178487706	NA	0.42	5.87	0.31	1.07e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.45	7.13	0.36	6.09e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg16558253	chr16:72132732	DHX38	-0.41	-6.32	-0.33	8.5e-10	Fibrinogen levels;
LUSC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.9	-0.35	2.69e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.69	-10.59	-0.5	8.56e-23	Aortic root size;
LUSC	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg20734569	chr3:48348370	SPINK8	-0.46	-7.81	-0.39	7.43e-14	Coronary artery disease;
LUSC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg08677398	chr8:58056175	NA	0.58	5.8	0.3	1.52e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.7	-9.8	-0.47	4.26e-20	Gut microbiome composition (summer);
LUSC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10802521	chr3:52805072	NEK4	-0.57	-9.23	-0.45	3.23e-18	Bipolar disorder;
LUSC	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg24675056	chr1:15929824	NA	0.46	8.03	0.4	1.69e-14	Systolic blood pressure;
LUSC	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg09754948	chr16:28834200	ATXN2L	0.43	6.07	0.32	3.5e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg15654264	chr1:150340011	RPRD2	0.65	10.8	0.51	1.56e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg01802117	chr1:53393560	SCP2	-0.37	-6.13	-0.32	2.52e-9	Monocyte count;
LUSC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg16624210	chr5:671434	TPPP	0.44	5.7	0.3	2.64e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4629180	0.917	rs7560926	chr2:102125098	C/A	cg04415270	chr2:102091202	RFX8	0.56	8.93	0.44	2.81e-17	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg00944433	chr1:107599041	PRMT6	0.38	6.96	0.36	1.79e-11	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	13.57	0.6	1.05e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs240764	0.645	rs239208	chr6:101139285	G/A	cg09795085	chr6:101329169	ASCC3	0.41	5.93	0.31	7.56e-9	Neuroticism;
LUSC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg13319975	chr6:146136371	FBXO30	0.5	7.6	0.38	3.04e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg23791538	chr6:167370224	RNASET2	-0.37	-5.85	-0.3	1.17e-8	Crohn's disease;
LUSC	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg23029597	chr12:123009494	RSRC2	-0.7	-9.79	-0.47	4.7e-20	Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13093793	chr14:35099518	SNX6	0.41	6.21	0.32	1.59e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3760982	1.000	rs12460161	chr19:44293986	C/A	cg11993925	chr19:44307056	LYPD5	0.28	6.04	0.31	4.16e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs7123876	0.587	rs184654	chr11:72364405	C/G	cg04827223	chr11:72435913	ARAP1	-0.49	-6.08	-0.32	3.23e-9	Body mass index;
LUSC	cis	rs2652834	0.851	rs4551986	chr15:63424400	T/G	cg05507819	chr15:63340323	TPM1	0.47	6.03	0.31	4.35e-9	HDL cholesterol;
LUSC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg27170947	chr2:26402098	FAM59B	0.59	8.15	0.41	7.43e-15	Gut microbiome composition (summer);
LUSC	cis	rs13385	0.769	rs6872766	chr5:139595614	A/C	cg26211634	chr5:139558579	C5orf32	0.45	6.73	0.35	7.44e-11	Atrial fibrillation;
LUSC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.58	0.34	1.79e-10	Aortic root size;
LUSC	cis	rs4654899	0.802	rs115818417	chr1:21200411	C/T	cg02927042	chr1:21476669	EIF4G3	-0.38	-5.91	-0.31	8.49e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.74	11.18	0.52	7.35e-25	Type 2 diabetes;
LUSC	cis	rs4730250	0.595	rs7789500	chr7:106915723	A/C	cg02696742	chr7:106810147	HBP1	-0.54	-7.33	-0.37	1.8e-12	Osteoarthritis;
LUSC	trans	rs2229238	0.911	rs77184252	chr1:154492533	A/G	cg25273160	chr11:56955011	LRRC55	0.31	5.96	0.31	6.37e-9	Coronary heart disease;
LUSC	cis	rs2011503	0.782	rs35545554	chr19:19715613	A/G	cg11244672	chr19:19639970	YJEFN3	0.47	6.08	0.32	3.23e-9	Bipolar disorder;
LUSC	cis	rs3007168	1.000	rs2999363	chr14:51605141	A/G	cg23942311	chr14:51606299	NA	0.37	6.02	0.31	4.5e-9	Cancer;
LUSC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg01802117	chr1:53393560	SCP2	-0.38	-6.0	-0.31	5.06e-9	Monocyte count;
LUSC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.33	0.37	1.8e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.84	-0.3	1.27e-8	Alzheimer's disease (late onset);
LUSC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.89	18.14	0.7	1.17e-51	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg18512352	chr11:47633146	NA	-0.47	-9.32	-0.45	1.62e-18	Subjective well-being;
LUSC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06481639	chr22:41940642	POLR3H	-0.51	-5.76	-0.3	1.86e-8	Vitiligo;
LUSC	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg05925327	chr15:68127851	NA	-0.39	-6.01	-0.31	4.97e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg27266060	chr8:22091797	NA	0.42	7.7	0.39	1.61e-13	Hypertriglyceridemia;
LUSC	cis	rs977987	0.843	rs10871312	chr16:75486202	C/T	cg04384234	chr16:75411784	CFDP1	-0.42	-6.96	-0.36	1.79e-11	Dupuytren's disease;
LUSC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00166722	chr3:10149974	C3orf24	0.61	8.38	0.42	1.46e-15	Alzheimer's disease;
LUSC	cis	rs4654899	0.733	rs10916907	chr1:21261088	A/C	cg01072550	chr1:21505969	NA	-0.53	-7.99	-0.4	2.25e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.6	-9.47	-0.46	5.4e-19	HDL cholesterol;
LUSC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg05717871	chr11:638507	DRD4	-0.34	-5.9	-0.31	8.74e-9	Systemic lupus erythematosus;
LUSC	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.12	0.36	6.81e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.07	-0.4	1.31e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg00898013	chr13:113819073	PROZ	-0.57	-8.22	-0.41	4.55e-15	Platelet distribution width;
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg22530072	chr19:1546320	NA	0.44	6.18	0.32	1.91e-9	Eotaxin levels;
LUSC	cis	rs4363385	0.530	rs11205181	chr1:153045728	C/T	cg25856811	chr1:152973957	SPRR3	-0.39	-6.5	-0.34	2.96e-10	Inflammatory skin disease;
LUSC	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg03354898	chr7:1950403	MAD1L1	0.33	6.33	0.33	7.74e-10	Schizophrenia;
LUSC	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg23029597	chr12:123009494	RSRC2	-0.62	-8.2	-0.41	5.16e-15	Body mass index;
LUSC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg14416269	chr4:6271139	WFS1	-0.52	-11.07	-0.52	1.75e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg09699651	chr6:150184138	LRP11	0.45	7.19	0.37	4.17e-12	Testicular germ cell tumor;
LUSC	cis	rs6545883	0.929	rs6707830	chr2:61749472	G/A	cg15711740	chr2:61764176	XPO1	-0.48	-7.59	-0.38	3.23e-13	Tuberculosis;
LUSC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg08470875	chr2:26401718	FAM59B	0.72	9.46	0.46	5.58e-19	Gut microbiome composition (summer);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00628130	chr8:95908808	CCNE2	-0.35	-6.03	-0.31	4.41e-9	Electrocardiographic conduction measures;
LUSC	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg05805236	chr11:65401703	PCNXL3	-0.65	-10.64	-0.5	5.92e-23	Acne (severe);
LUSC	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg24375607	chr4:120327624	NA	0.71	10.36	0.49	5.29e-22	Corneal astigmatism;
LUSC	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.35	-0.33	7.19e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1355223	0.573	rs1361646	chr11:34746360	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.86	-0.31	1.14e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	0.63	13.38	0.59	5.41e-33	Prudent dietary pattern;
LUSC	cis	rs6542838	0.673	rs13005148	chr2:99467538	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.21	-0.32	1.53e-9	Fear of minor pain;
LUSC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs34779708	0.931	rs17582416	chr10:35287650	A/C	cg03585969	chr10:35415529	CREM	0.54	7.89	0.4	4.28e-14	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg01851573	chr8:8652454	MFHAS1	-0.35	-6.11	-0.32	2.85e-9	Mood instability;
LUSC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg25767906	chr1:53392781	SCP2	-0.51	-9.28	-0.45	2.23e-18	Monocyte count;
LUSC	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-10.54	-0.5	1.26e-22	Heart rate;
LUSC	cis	rs1957429	0.808	rs1951492	chr14:65346895	G/A	cg23373153	chr14:65346875	NA	1.11	13.01	0.58	1.35e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.71	-0.43	1.43e-16	Type 2 diabetes;
LUSC	cis	rs727505	1.000	rs6943653	chr7:124512249	G/A	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.93	-12.73	-0.57	1.55e-30	Initial pursuit acceleration;
LUSC	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg25801113	chr15:45476975	SHF	-0.33	-6.7	-0.34	8.9e-11	Uric acid levels;
LUSC	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg22676075	chr6:135203613	NA	0.58	9.18	0.45	4.49e-18	Red blood cell count;
LUSC	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg25110126	chr1:46999211	NA	-0.76	-10.42	-0.5	3.48e-22	Monobrow;
LUSC	cis	rs4917300	0.967	rs2201177	chr8:143119176	T/C	cg25363559	chr8:143086065	NA	-0.28	-5.98	-0.31	5.64e-9	Amyotrophic lateral sclerosis;
LUSC	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.73	10.34	0.49	6.36e-22	Corneal astigmatism;
LUSC	cis	rs9394152	0.810	rs9380364	chr6:33471721	T/C	cg13560919	chr6:33536144	NA	0.6	10.63	0.5	6.18e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.62	10.4	0.49	3.99e-22	Blood metabolite ratios;
LUSC	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg07828340	chr4:882639	GAK	1.11	10.81	0.51	1.44e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs6960043	0.875	rs10249299	chr7:15054391	C/T	cg19272540	chr7:15055459	NA	0.35	8.89	0.44	3.97e-17	Type 2 diabetes;
LUSC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02034447	chr16:89574710	SPG7	0.4	5.96	0.31	6.4e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg01119278	chr6:110721349	DDO	-0.49	-8.79	-0.43	8.09e-17	Platelet distribution width;
LUSC	cis	rs11871801	0.517	rs645692	chr17:40701073	C/T	cg16308533	chr17:40838983	CNTNAP1	0.41	5.97	0.31	6.11e-9	Crohn's disease;
LUSC	cis	rs983392	0.679	rs1530914	chr11:60028940	C/T	cg02771260	chr11:59836817	MS4A3	0.37	6.11	0.32	2.83e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg12310025	chr6:25882481	NA	0.4	6.65	0.34	1.22e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs28595532	0.623	rs34958556	chr4:119222074	C/T	cg21605333	chr4:119757512	SEC24D	0.8	6.67	0.34	1.04e-10	Cannabis dependence symptom count;
LUSC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.87	16.03	0.66	2.64e-43	Colorectal cancer;
LUSC	cis	rs1107366	0.722	rs9862438	chr3:125910381	C/T	cg01346077	chr3:125931526	NA	0.36	6.95	0.36	1.98e-11	Metabolite levels;
LUSC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg22920501	chr2:26401640	FAM59B	0.83	12.02	0.55	6.49e-28	Gut microbiome composition (summer);
LUSC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg13395646	chr4:1353034	KIAA1530	0.59	9.02	0.44	1.51e-17	Obesity-related traits;
LUSC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.93	-0.4	3.29e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.93	13.08	0.58	7.68e-32	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	0.9	16.3	0.67	2.25e-44	Cognitive function;
LUSC	cis	rs2294693	0.945	rs9381023	chr6:40983281	C/T	cg14769373	chr6:40998127	UNC5CL	0.54	7.71	0.39	1.44e-13	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.84	-0.35	3.74e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg23600533	chr11:64885249	ZNHIT2	0.7	6.0	0.31	5.04e-9	Cognitive performance;
LUSC	cis	rs7582720	1.000	rs72936847	chr2:203774748	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.38	0.42	1.49e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg17764715	chr19:33622953	WDR88	-0.53	-7.8	-0.39	7.84e-14	Bone properties (heel);
LUSC	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.22	0.32	1.49e-9	Corneal astigmatism;
LUSC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg14895029	chr7:2775587	GNA12	-0.41	-6.07	-0.32	3.46e-9	Height;
LUSC	cis	rs6500395	0.788	rs12446280	chr16:48651171	G/T	cg04672837	chr16:48644449	N4BP1	0.47	6.73	0.35	7.28e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg05343316	chr1:45956843	TESK2	0.59	8.0	0.4	2e-14	Platelet count;
LUSC	cis	rs10754283	0.967	rs7546410	chr1:90109815	C/T	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9311676	0.632	rs6445978	chr3:58379586	T/A	cg13750441	chr3:58318267	PXK	0.36	7.06	0.36	9.88e-12	Systemic lupus erythematosus;
LUSC	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg26769984	chr7:1090371	C7orf50	0.57	7.16	0.36	5.3e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg04450456	chr4:17643702	FAM184B	0.38	6.28	0.33	1.03e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.84	0.51	1.21e-23	Heart rate;
LUSC	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg08085267	chr17:45401833	C17orf57	-0.51	-7.3	-0.37	2.07e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg02487422	chr3:49467188	NICN1	-0.44	-7.16	-0.36	5.15e-12	Resting heart rate;
LUSC	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg07930552	chr6:133119739	C6orf192	0.94	8.39	0.42	1.41e-15	Type 2 diabetes nephropathy;
LUSC	cis	rs10484885	0.757	rs72912535	chr6:90159762	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.61	-5.67	-0.3	3.04e-8	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs2786098	0.616	rs10922251	chr1:197521810	C/G	cg16005942	chr6:160526640	IGF2R	0.53	6.28	0.32	1.04e-9	Asthma;
LUSC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg03146154	chr1:46216737	IPP	0.54	7.73	0.39	1.27e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs2282032	1.000	rs75816060	chr14:90759470	C/T	cg11965331	chr8:7651924	NA	0.42	5.96	0.31	6.31e-9	Longevity;
LUSC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.19	0.56	1.52e-28	Motion sickness;
LUSC	cis	rs4240897	0.935	rs4846082	chr1:12042443	C/T	cg13216073	chr1:12042593	MFN2	0.38	6.66	0.34	1.11e-10	Tuberculosis;
LUSC	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg13798780	chr7:105162888	PUS7	0.56	6.08	0.32	3.26e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg13770153	chr20:60521292	NA	-0.63	-8.76	-0.43	9.88e-17	Body mass index;
LUSC	cis	rs4776059	0.550	rs17651941	chr15:52948626	C/G	cg22715398	chr15:52968154	KIAA1370	0.7	7.81	0.39	7.24e-14	Schizophrenia;
LUSC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12756686	chr19:29218302	NA	0.47	5.79	0.3	1.61e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg01475377	chr6:109611718	NA	-0.4	-7.15	-0.36	5.47e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs6460942	0.915	rs7803051	chr7:12306904	A/T	cg06484146	chr7:12443880	VWDE	-0.49	-5.9	-0.31	8.72e-9	Coronary artery disease;
LUSC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg23711669	chr6:146136114	FBXO30	-0.82	-14.69	-0.63	5.14e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg25767906	chr1:53392781	SCP2	0.48	8.69	0.43	1.67e-16	Monocyte count;
LUSC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg07741184	chr6:167504864	NA	0.39	6.88	0.35	2.9e-11	Primary biliary cholangitis;
LUSC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23158103	chr7:148848205	ZNF398	-0.5	-8.39	-0.42	1.34e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg00933542	chr6:150070202	PCMT1	0.27	5.65	0.3	3.43e-8	Lung cancer;
LUSC	cis	rs4776059	0.761	rs12594964	chr15:52900208	G/A	cg24008177	chr15:52972085	KIAA1370	-0.34	-5.93	-0.31	7.39e-9	Schizophrenia;
LUSC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg20476274	chr7:133979776	SLC35B4	0.87	17.01	0.68	3.4e-47	Mean platelet volume;
LUSC	cis	rs2438150	1	rs2438150	chr5:122199196	C/T	cg19077854	chr5:122220652	SNX24	0.36	8.34	0.42	2e-15	Plateletcrit;
LUSC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.54	-0.38	4.54e-13	Height;
LUSC	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-6.33	-0.33	7.88e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11603020	0.950	rs28362947	chr11:57369008	C/G	cg23127183	chr11:57508653	C11orf31	-0.46	-6.36	-0.33	6.65e-10	Blood protein levels;
LUSC	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg09307838	chr4:120376055	NA	0.7	10.37	0.49	4.84e-22	Corneal astigmatism;
LUSC	cis	rs7424096	0.582	rs12105781	chr2:37221567	T/C	cg14987922	chr2:37194071	STRN	0.6	8.09	0.4	1.11e-14	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.89	0.61	5.99e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7804356	1.000	rs6956088	chr7:26835727	T/A	cg03456212	chr7:26904342	SKAP2	-0.55	-6.47	-0.33	3.53e-10	Type 1 diabetes;
LUSC	cis	rs600231	0.542	rs11227196	chr11:65234922	G/A	cg17120908	chr11:65337727	SSSCA1	-0.62	-9.01	-0.44	1.61e-17	Bone mineral density;
LUSC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg14983838	chr19:29218262	NA	0.49	5.97	0.31	5.93e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13012494	chr21:47604986	C21orf56	0.39	5.75	0.3	2.01e-8	Testicular germ cell tumor;
LUSC	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg21427119	chr20:30132790	HM13	0.37	5.65	0.3	3.5e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg06008330	chr7:65541103	ASL	-0.4	-6.28	-0.32	1.05e-9	Aortic root size;
LUSC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg12292205	chr6:26970375	C6orf41	0.51	8.56	0.42	4.13e-16	Schizophrenia;
LUSC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg12365402	chr11:9010492	NRIP3	0.45	8.32	0.41	2.21e-15	Hemoglobin concentration;
LUSC	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg16049864	chr8:95962084	TP53INP1	-0.55	-10.06	-0.48	5.75e-21	Hemoglobin concentration;
LUSC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	6.2	0.32	1.7e-9	Menopause (age at onset);
LUSC	cis	rs4588572	0.688	rs2362829	chr5:77724036	T/A	cg11547950	chr5:77652471	NA	-0.47	-7.15	-0.36	5.67e-12	Triglycerides;
LUSC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg20573242	chr4:122745356	CCNA2	0.45	6.89	0.35	2.87e-11	Type 2 diabetes;
LUSC	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg19610905	chr11:61596333	FADS2	-0.51	-7.99	-0.4	2.29e-14	Trans fatty acid levels;
LUSC	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg22431228	chr1:16359049	CLCNKA	0.41	8.37	0.42	1.55e-15	Systolic blood pressure;
LUSC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.37e-9	Life satisfaction;
LUSC	cis	rs2835872	0.965	rs717859	chr21:39012802	A/G	cg20424643	chr21:39039972	KCNJ6	-0.37	-5.73	-0.3	2.19e-8	Electroencephalographic traits in alcoholism;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg19013620	chr14:90756653	C14orf102	-0.38	-6.01	-0.31	4.88e-9	N-glycan levels;
LUSC	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.03	0.31	4.23e-9	Recombination rate (females);
LUSC	trans	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.44	6.58	0.34	1.85e-10	Endometrial cancer;
LUSC	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg26395211	chr5:140044315	WDR55	-0.38	-5.74	-0.3	2.14e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg16339924	chr4:17578868	LAP3	0.51	7.6	0.38	3.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg14675211	chr2:100938903	LONRF2	0.37	5.76	0.3	1.89e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs67366981	1.000	rs56357623	chr14:77697393	C/A	cg22824376	chr14:77648248	TMEM63C	0.83	7.63	0.39	2.5e-13	Obsessive-compulsive symptoms;
LUSC	cis	rs12575480	0.779	rs11602585	chr11:2101345	C/T	cg15541987	chr11:2077307	NA	-0.46	-6.6	-0.34	1.63e-10	Pursuit maintenance gain;
LUSC	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg00191853	chr8:101177733	SPAG1	-0.37	-5.95	-0.31	6.76e-9	Atrioventricular conduction;
LUSC	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg20019720	chr6:154832845	CNKSR3	0.62	8.69	0.43	1.63e-16	Lipoprotein (a) levels;
LUSC	trans	rs76248362	0.737	rs6490836	chr13:24434585	A/G	cg26511321	chr7:27196790	HOXA7	0.54	6.24	0.32	1.35e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg11984989	chr7:158649758	WDR60	1.13	13.36	0.59	6.28e-33	Height;
LUSC	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg10523679	chr1:76189770	ACADM	-0.49	-7.06	-0.36	9.81e-12	Daytime sleep phenotypes;
LUSC	cis	rs6424115	0.867	rs4649119	chr1:24171543	C/G	cg15997130	chr1:24165203	NA	-0.52	-8.37	-0.42	1.57e-15	Immature fraction of reticulocytes;
LUSC	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg18209359	chr17:80159595	CCDC57	-0.35	-5.74	-0.3	2.17e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.83	13.25	0.59	1.78e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg05738196	chr6:26577821	NA	0.74	12.18	0.55	1.72e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs13253111	0.967	rs7821358	chr8:28060690	A/G	cg26534493	chr8:28060551	NA	0.46	8.74	0.43	1.12e-16	Childhood body mass index;
LUSC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.93	-15.12	-0.64	1.05e-39	Systemic lupus erythematosus;
LUSC	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg22529645	chr1:3704559	LRRC47	0.37	6.22	0.32	1.46e-9	Red cell distribution width;
LUSC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.51e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7180079	1.000	rs12903745	chr15:64632840	G/A	cg02848875	chr15:64387786	SNX1	0.4	5.76	0.3	1.92e-8	Monocyte count;
LUSC	cis	rs11583043	0.708	rs1060481	chr1:101546699	A/G	cg11406453	chr1:101602562	NA	-0.41	-6.84	-0.35	3.76e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	0.57	8.69	0.43	1.66e-16	Breast cancer;
LUSC	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-1.16	-16.05	-0.66	2.24e-43	Hip circumference adjusted for BMI;
LUSC	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	0.93	12.91	0.58	3.25e-31	Uric acid levels;
LUSC	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs16937	0.640	rs6664706	chr1:205182563	T/C	cg21643547	chr1:205240462	TMCC2	-0.36	-6.42	-0.33	4.72e-10	Schizophrenia;
LUSC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	0.79	13.73	0.6	2.61e-34	Cognitive function;
LUSC	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg19743168	chr1:23544995	NA	-0.46	-10.03	-0.48	7.03e-21	Height;
LUSC	cis	rs9905704	0.918	rs694720	chr17:56708019	T/C	cg12560992	chr17:57184187	TRIM37	0.54	7.72	0.39	1.36e-13	Testicular germ cell tumor;
LUSC	cis	rs7113850	0.541	rs11826483	chr11:24237730	C/T	ch.11.24196551F	chr11:24239977	NA	1.0	9.1	0.45	8.45e-18	Bone fracture in osteoporosis;
LUSC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.75	-0.35	6.64e-11	Blood protein levels;
LUSC	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.84	-0.51	1.2e-23	Glomerular filtration rate;
LUSC	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg08807101	chr21:30365312	RNF160	-0.53	-6.68	-0.34	9.85e-11	Cognitive test performance;
LUSC	cis	rs752010	0.574	rs6671999	chr1:42120416	G/A	cg06885757	chr1:42089581	HIVEP3	0.44	9.33	0.45	1.49e-18	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.79	-0.47	4.54e-20	Total cholesterol levels;
LUSC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg20135002	chr11:47629003	NA	-0.51	-8.11	-0.41	9.83e-15	Subjective well-being;
LUSC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg22791324	chr7:157949174	PTPRN2	0.29	5.84	0.3	1.21e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg16325326	chr1:53192061	ZYG11B	0.97	19.12	0.72	1.4e-55	Monocyte count;
LUSC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg20302533	chr7:39170763	POU6F2	0.57	9.32	0.45	1.63e-18	IgG glycosylation;
LUSC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg17340268	chr14:105411764	AHNAK2	-0.37	-5.93	-0.31	7.4e-9	Rheumatoid arthritis;
LUSC	trans	rs3960554	0.529	rs7800970	chr7:75880198	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.61	-7.63	-0.39	2.47e-13	Eotaxin levels;
LUSC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg07777115	chr5:623756	CEP72	-0.46	-5.93	-0.31	7.72e-9	Obesity-related traits;
LUSC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg27529037	chr20:44575021	PCIF1	0.43	7.56	0.38	3.81e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-9.78	-0.47	4.88e-20	Morning vs. evening chronotype;
LUSC	cis	rs7575217	0.588	rs11675224	chr2:101670955	C/T	cg23907051	chr2:101730305	TBC1D8	0.27	6.62	0.34	1.44e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg24375607	chr4:120327624	NA	0.76	11.1	0.52	1.42e-24	Corneal astigmatism;
LUSC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg15468180	chr1:107600409	PRMT6	0.38	5.83	0.3	1.32e-8	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs4964805	0.802	rs11111778	chr12:104185431	G/A	cg02344784	chr12:104178138	NT5DC3	0.41	6.47	0.33	3.45e-10	Attention deficit hyperactivity disorder;
LUSC	trans	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs6906287	0.625	rs9320648	chr6:118690014	A/C	cg21191810	chr6:118973309	C6orf204	0.38	6.88	0.35	3.01e-11	Electrocardiographic conduction measures;
LUSC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg09323728	chr8:95962352	TP53INP1	0.38	7.7	0.39	1.58e-13	Type 2 diabetes;
LUSC	cis	rs12210905	0.800	rs12201890	chr6:26662626	A/C	cg11502198	chr6:26597334	ABT1	-0.74	-5.77	-0.3	1.8e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.5	7.69	0.39	1.64e-13	Testicular germ cell tumor;
LUSC	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg19748678	chr4:122722346	EXOSC9	0.65	9.81	0.47	3.98e-20	Type 2 diabetes;
LUSC	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg07169764	chr2:136633963	MCM6	-0.59	-7.76	-0.39	1.02e-13	Mosquito bite size;
LUSC	cis	rs13082711	0.911	rs11719386	chr3:27505636	G/C	cg02860705	chr3:27208620	NA	0.49	8.2	0.41	5.36e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs6546886	0.912	rs13006407	chr2:74280275	G/A	cg14702570	chr2:74259524	NA	-0.31	-5.74	-0.3	2.07e-8	Dialysis-related mortality;
LUSC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4253772	0.938	rs77378083	chr22:46639386	G/A	cg18190219	chr22:46762943	CELSR1	-0.52	-6.01	-0.31	4.77e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs600231	0.542	rs11227198	chr11:65237974	G/A	cg17120908	chr11:65337727	SSSCA1	-0.62	-8.95	-0.44	2.47e-17	Bone mineral density;
LUSC	cis	rs12210905	0.748	rs6901225	chr6:26670491	A/G	cg11502198	chr6:26597334	ABT1	-0.71	-6.38	-0.33	6.05e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs12220238	1.000	rs6480723	chr10:75966366	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.22	0.37	3.42e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg03146154	chr1:46216737	IPP	0.5	7.49	0.38	6.02e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs73200209	0.744	rs7314858	chr12:116565050	T/C	cg01776926	chr12:116560359	MED13L	-0.5	-6.06	-0.31	3.58e-9	Total body bone mineral density;
LUSC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg16797656	chr11:68205561	LRP5	0.4	7.26	0.37	2.67e-12	Total body bone mineral density;
LUSC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.64	-11.27	-0.52	3.43e-25	Menopause (age at onset);
LUSC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.5	-0.34	2.93e-10	Breast cancer;
LUSC	cis	rs10208940	0.920	rs13400463	chr2:68723912	G/A	cg12452813	chr2:68675892	NA	0.58	5.95	0.31	6.61e-9	Urate levels in lean individuals;
LUSC	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.51	-6.59	-0.34	1.69e-10	Response to bleomycin (chromatid breaks);
LUSC	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg23093090	chr10:104574429	C10orf26	-0.37	-6.67	-0.34	1.04e-10	Arsenic metabolism;
LUSC	cis	rs6142102	0.961	rs1055857	chr20:32613873	A/G	cg08999081	chr20:33150536	PIGU	0.35	5.99	0.31	5.29e-9	Skin pigmentation;
LUSC	cis	rs7605827	0.930	rs4133515	chr2:15696655	A/G	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.32e-17	Educational attainment (years of education);
LUSC	cis	rs73206853	0.841	rs28480627	chr12:110834659	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg05347473	chr6:146136440	FBXO30	0.57	10.06	0.48	5.51e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7246967	0.611	rs3931771	chr19:22896820	A/G	cg23217946	chr19:22817039	ZNF492	0.41	5.68	0.3	2.93e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.48	0.46	5e-19	Mean platelet volume;
LUSC	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg09699651	chr6:150184138	LRP11	0.47	7.47	0.38	7.12e-13	Testicular germ cell tumor;
LUSC	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg15704280	chr7:45808275	SEPT13	0.78	7.46	0.38	7.71e-13	Axial length;
LUSC	cis	rs12618769	0.656	rs56091613	chr2:99103761	A/G	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	7.21	0.37	3.81e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg24060327	chr5:131705240	SLC22A5	0.42	6.57	0.34	1.95e-10	Blood metabolite levels;
LUSC	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.54	9.05	0.44	1.2e-17	IgG glycosylation;
LUSC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg08470875	chr2:26401718	FAM59B	-0.68	-9.08	-0.45	9.33e-18	Gut microbiome composition (summer);
LUSC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	14.48	0.62	3.16e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs8042849	1	rs8042849	chr15:78817929	C/T	cg18825076	chr15:78729989	IREB2	0.49	7.86	0.4	5.37e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Parental lifespan;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg06238570	chr21:40685208	BRWD1	0.61	10.13	0.48	3.34e-21	Cognitive function;
LUSC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-10.05	-0.48	6.14e-21	Gut microbiome composition (summer);
LUSC	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg08132940	chr7:1081526	C7orf50	0.35	6.34	0.33	7.56e-10	Longevity;Endometriosis;
LUSC	cis	rs2625529	0.824	rs11072346	chr15:72400434	G/A	cg16672083	chr15:72433130	SENP8	-0.52	-7.64	-0.39	2.26e-13	Red blood cell count;
LUSC	cis	rs2078087	0.522	rs649954	chr1:183216448	G/A	cg13843938	chr1:183241246	NMNAT2	0.41	6.77	0.35	5.85e-11	Obesity-related traits;
LUSC	cis	rs981844	1.000	rs62325083	chr4:154661775	T/C	cg14289246	chr4:154710475	SFRP2	0.5	6.44	0.33	4.05e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs6546550	0.935	rs13392884	chr2:70036711	A/G	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.15	-0.36	5.44e-12	Prevalent atrial fibrillation;
LUSC	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg02454025	chr1:11042201	C1orf127	1.04	19.33	0.73	2.07e-56	Ewing sarcoma;
LUSC	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	9.06	0.44	1.15e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11644478	chr21:40555479	PSMG1	-0.57	-8.25	-0.41	3.74e-15	Menarche (age at onset);
LUSC	cis	rs9875589	1.000	rs9875589	chr3:13961157	A/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.33	-5.74	-0.3	2.11e-8	Ovarian reserve;
LUSC	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg15485101	chr11:133734466	NA	0.36	6.74	0.35	7.07e-11	Childhood ear infection;
LUSC	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg05887092	chr17:76393375	PGS1	0.65	12.8	0.57	8.8e-31	HDL cholesterol levels;
LUSC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg21251018	chr6:28226885	NKAPL	0.31	5.9	0.31	9.02e-9	Pubertal anthropometrics;
LUSC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	12.23	0.56	1.16e-28	Cognitive test performance;
LUSC	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg23690444	chr14:81902736	NA	0.42	5.88	0.31	9.87e-9	Prudent dietary pattern;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01626569	chr16:20911881	LYRM1;DCUN1D3	-0.51	-6.78	-0.35	5.55e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs155346	1.000	rs6891658	chr5:139403517	A/G	cg01090482	chr5:139365336	NRG2	-0.37	-5.88	-0.31	1.01e-8	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.95	-16.06	-0.66	2.15e-43	Coronary artery disease;
LUSC	trans	rs6600671	1.000	rs12145080	chr1:121185531	C/T	cg00646200	chr1:148855367	NA	-0.48	-7.71	-0.39	1.45e-13	Hip geometry;
LUSC	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg17691542	chr6:26056736	HIST1H1C	0.47	7.04	0.36	1.08e-11	Height;
LUSC	cis	rs6967385	0.538	rs10275154	chr7:12355002	T/C	cg10578991	chr7:12443926	VWDE	0.39	5.85	0.3	1.18e-8	Response to taxane treatment (placlitaxel);
LUSC	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg26384229	chr12:38710491	ALG10B	0.74	11.95	0.55	1.17e-27	Morning vs. evening chronotype;
LUSC	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	1.17	13.66	0.6	4.72e-34	Arsenic metabolism;
LUSC	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg08000102	chr2:233561755	GIGYF2	-0.69	-11.41	-0.53	1.08e-25	Coronary artery disease;
LUSC	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.36	0.53	1.62e-25	Coffee consumption (cups per day);
LUSC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-6.9	-0.35	2.59e-11	Alzheimer's disease (late onset);
LUSC	cis	rs6942756	1.000	rs11979476	chr7:128993756	G/T	cg02491457	chr7:128862824	NA	0.54	7.19	0.37	4.4e-12	White matter hyperintensity burden;
LUSC	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg04733989	chr22:42467013	NAGA	0.39	6.55	0.34	2.2e-10	Cognitive function;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11311579	chr10:102106754	SCD	-0.41	-6.13	-0.32	2.42e-9	Electrocardiographic conduction measures;
LUSC	cis	rs17125944	0.615	rs12589020	chr14:53312002	C/T	cg00686598	chr14:53173677	PSMC6	0.83	7.21	0.37	3.65e-12	Alzheimer's disease (late onset);
LUSC	trans	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.45	6.63	0.34	1.36e-10	Endometrial cancer;
LUSC	cis	rs1506636	0.886	rs6945841	chr7:123266094	G/A	cg03229431	chr7:123269106	ASB15	-0.69	-11.48	-0.53	6.28e-26	Plateletcrit;Platelet count;
LUSC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	0.55	6.0	0.31	5.16e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg13246856	chr1:44399776	ARTN	0.26	5.79	0.3	1.63e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg22535103	chr8:58192502	C8orf71	-0.56	-6.74	-0.35	7.17e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.1	-0.41	1.05e-14	Lung cancer;
LUSC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg08859206	chr1:53392774	SCP2	-0.4	-6.47	-0.33	3.41e-10	Monocyte count;
LUSC	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg05985134	chr18:33552581	C18orf21	0.5	7.07	0.36	9.21e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg26043149	chr18:55253948	FECH	0.47	7.32	0.37	1.84e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03352830	chr11:487213	PTDSS2	0.68	8.61	0.43	2.91e-16	Body mass index;
LUSC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg18230493	chr5:56204884	C5orf35	-0.76	-12.81	-0.57	7.56e-31	Initial pursuit acceleration;
LUSC	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.06	0.4	1.41e-14	Corneal astigmatism;
LUSC	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-7.08	-0.36	8.5e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4356932	1.000	rs7655350	chr4:76977073	A/C	cg00809888	chr4:76862425	NAAA	0.34	5.7	0.3	2.6e-8	Blood protein levels;
LUSC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg23711669	chr6:146136114	FBXO30	0.7	10.69	0.5	3.89e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg10360139	chr7:1886902	MAD1L1	-0.42	-6.34	-0.33	7.66e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.57	8.11	0.41	9.56e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg03233332	chr7:66118400	NA	-0.41	-5.96	-0.31	6.35e-9	Aortic root size;
LUSC	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18252515	chr7:66147081	NA	-0.58	-7.89	-0.4	4.31e-14	Corneal structure;
LUSC	cis	rs12042938	0.935	rs823159	chr1:231777168	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.42	6.21	0.32	1.6e-9	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-6.77	-0.35	5.7e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg20283391	chr11:68216788	NA	-0.61	-8.42	-0.42	1.15e-15	Total body bone mineral density;
LUSC	cis	rs59698941	0.943	rs59484796	chr5:132293543	C/T	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.34	-0.42	2.01e-15	Response to antipsychotic treatment;
LUSC	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg03647239	chr10:116582469	FAM160B1	0.43	6.56	0.34	2.09e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg05043794	chr9:111880884	C9orf5	-0.35	-7.34	-0.37	1.6e-12	Menarche (age at onset);
LUSC	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg23173402	chr1:227635558	NA	0.59	7.08	0.36	8.53e-12	Major depressive disorder;
LUSC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg12639453	chr1:2035780	PRKCZ	0.3	6.31	0.33	8.91e-10	Height;
LUSC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.47	-0.33	3.58e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.42	-5.96	-0.31	6.54e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs2237234	0.580	rs7763910	chr6:26472655	C/T	cg12292205	chr6:26970375	C6orf41	-0.42	-6.78	-0.35	5.5e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7267979	0.816	rs404775	chr20:25481117	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.25	0.66	3.75e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12545109	0.800	rs2576591	chr8:57423606	A/G	cg09654669	chr8:57350985	NA	-0.47	-6.42	-0.33	4.71e-10	Obesity-related traits;
LUSC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg16325326	chr1:53192061	ZYG11B	0.87	16.07	0.66	1.89e-43	Monocyte count;
LUSC	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg00784671	chr22:46762841	CELSR1	-0.61	-6.64	-0.34	1.27e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs12891047	0.934	rs10483805	chr14:68255651	T/C	cg20999565	chr14:68265668	ZFYVE26	-0.37	-5.82	-0.3	1.41e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg06623918	chr6:96969491	KIAA0776	-0.92	-17.08	-0.68	1.83e-47	Headache;
LUSC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg14004847	chr7:1930337	MAD1L1	0.5	7.68	0.39	1.73e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs7246967	0.673	rs12978964	chr19:22819244	G/A	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs75920871	0.528	rs7950093	chr11:116963519	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-5.98	-0.31	5.87e-9	Subjective well-being;
LUSC	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg25407064	chr15:40226267	EIF2AK4	0.52	6.14	0.32	2.29e-9	Response to haloperidol in psychosis;
LUSC	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg18129178	chr5:148520854	ABLIM3	-0.7	-10.7	-0.51	3.48e-23	Breast cancer;
LUSC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg14993813	chr1:46806288	NSUN4	-0.53	-7.35	-0.37	1.55e-12	Menopause (age at onset);
LUSC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg25036284	chr2:26402008	FAM59B	-0.7	-9.62	-0.47	1.69e-19	Gut microbiome composition (summer);
LUSC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	4.73e-15	Homoarginine levels;
LUSC	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg08085267	chr17:45401833	C17orf57	0.54	8.8	0.43	7.28e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.75	9.82	0.47	3.7799999999999997e-20	Migraine;Coronary artery disease;
LUSC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.15	-0.49	2.88e-21	Obesity-related traits;
LUSC	cis	rs7597155	0.905	rs6710136	chr2:69986256	T/C	cg02498382	chr2:70120550	SNRNP27	-0.24	-5.75	-0.3	1.99e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg05738196	chr6:26577821	NA	-0.52	-5.64	-0.3	3.56e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg03585969	chr10:35415529	CREM	0.62	9.12	0.45	6.97e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	8.89	0.44	3.85e-17	Multiple sclerosis;
LUSC	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg16230307	chr14:35515116	FAM177A1	0.74	8.83	0.43	6.15e-17	Psoriasis;
LUSC	trans	rs4460079	0.531	rs7658266	chr4:114863706	C/T	cg23278040	chr19:266712	NA	0.46	6.1	0.32	3.01e-9	Blood pressure measurement (high sodium and potassium intervention);
LUSC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.47	-0.38	6.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	8.99	0.44	1.91e-17	Motion sickness;
LUSC	cis	rs3770081	1.000	rs2289237	chr2:86266274	C/G	cg23655155	chr2:86332777	POLR1A;PTCD3	1.03	6.96	0.36	1.81e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.76	12.5	0.56	1.15e-29	Cognitive function;
LUSC	cis	rs4792901	0.759	rs1382685	chr17:41563151	G/A	cg22562494	chr17:41607896	ETV4	-0.34	-6.53	-0.34	2.45e-10	Dupuytren's disease;
LUSC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg26338869	chr17:61819248	STRADA	0.4	5.77	0.3	1.81e-8	Prudent dietary pattern;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg23159081	chr2:198364596	HSPD1;HSPE1	0.42	6.29	0.33	1.01e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg08917208	chr2:24149416	ATAD2B	0.98	9.81	0.47	4.02e-20	Lymphocyte counts;
LUSC	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.69	-10.09	-0.48	4.37e-21	Systemic lupus erythematosus;
LUSC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg17420585	chr12:42539391	GXYLT1	-0.36	-7.04	-0.36	1.11e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs34421088	0.506	rs4841519	chr8:11146228	A/T	cg21775007	chr8:11205619	TDH	0.46	7.13	0.36	6.09e-12	Neuroticism;
LUSC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg24977027	chr2:88469347	THNSL2	0.56	5.86	0.31	1.11e-8	Plasma clusterin levels;
LUSC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg09796270	chr17:17721594	SREBF1	0.4	7.07	0.36	9.07e-12	Total body bone mineral density;
LUSC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.83	15.14	0.64	8.94e-40	Mean platelet volume;
LUSC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08859206	chr1:53392774	SCP2	0.56	9.77	0.47	5.43e-20	Monocyte count;
LUSC	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07080220	chr10:102295463	HIF1AN	0.65	8.72	0.43	1.34e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2692947	0.599	rs7561198	chr2:96774981	C/G	cg23100626	chr2:96804247	ASTL	-0.31	-7.32	-0.37	1.83e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg25019033	chr10:957182	NA	0.52	5.86	0.31	1.11e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	0.93	17.13	0.68	1.22e-47	Bone mineral density;
LUSC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg13939156	chr17:80058883	NA	0.34	6.77	0.35	5.94e-11	Life satisfaction;
LUSC	cis	rs7113850	0.541	rs79932281	chr11:24231839	T/G	ch.11.24196551F	chr11:24239977	NA	1.0	9.14	0.45	6e-18	Bone fracture in osteoporosis;
LUSC	cis	rs4072705	0.614	rs1570581	chr9:127234059	A/G	cg13476313	chr9:127244764	NR5A1	0.34	6.54	0.34	2.34e-10	Menarche (age at onset);
LUSC	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg05340658	chr4:99064831	C4orf37	0.59	9.04	0.44	1.31e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10740039	0.883	rs7089720	chr10:62393821	G/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9472414	0.771	rs2139863	chr6:44796139	A/G	cg20913747	chr6:44695427	NA	0.4	5.69	0.3	2.83e-8	Height;
LUSC	cis	rs11583043	0.708	rs915405	chr1:101574145	T/C	cg11406453	chr1:101602562	NA	-0.4	-6.9	-0.35	2.6e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg18187862	chr3:45730750	SACM1L	0.53	7.03	0.36	1.16e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	12.39	0.56	2.78e-29	Height;
LUSC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg16743903	chr16:89593216	SPG7	-0.4	-6.18	-0.32	1.84e-9	Multiple myeloma (IgH translocation);
LUSC	trans	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg24247370	chr13:99142703	STK24	-0.34	-6.15	-0.32	2.21e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.54	0.5	1.27e-22	Colorectal cancer;
LUSC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.77	7.65	0.39	2.1e-13	Initial pursuit acceleration;
LUSC	cis	rs12989701	1.000	rs12989701	chr2:127887985	C/A	cg08168897	chr2:127865431	BIN1	0.71	8.27	0.41	3.25e-15	Alzheimer's disease (late onset);
LUSC	cis	rs2425143	1.000	rs1970357	chr20:34339200	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.59	6.29	0.33	1.02e-9	Blood protein levels;
LUSC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-1.03	-20.21	-0.74	7.12e-60	Height;
LUSC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.99	0.36	1.46e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.05	-14.65	-0.63	7.2700000000000005e-38	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg18132916	chr6:79620363	NA	0.39	5.64	0.3	3.57e-8	Left atrial antero-posterior diameter;
LUSC	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg13852791	chr20:30311386	BCL2L1	0.92	14.19	0.61	4.35e-36	Mean corpuscular hemoglobin;
LUSC	cis	rs7577696	0.597	rs6756085	chr2:32336522	A/G	cg02381751	chr2:32503542	YIPF4	-0.51	-6.88	-0.35	2.93e-11	Inflammatory biomarkers;
LUSC	cis	rs9905704	0.645	rs17175543	chr17:56803598	G/T	cg12560992	chr17:57184187	TRIM37	0.5	5.84	0.3	1.22e-8	Testicular germ cell tumor;
LUSC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.6	9.67	0.47	1.14e-19	Aortic root size;
LUSC	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21643547	chr1:205240462	TMCC2	-0.5	-9.46	-0.46	5.79e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6688613	0.685	rs61815130	chr1:166910465	T/C	cg07049167	chr1:166818506	POGK	0.45	6.5	0.34	2.95e-10	Refractive astigmatism;
LUSC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg06637938	chr14:75390232	RPS6KL1	0.54	8.65	0.43	2.16e-16	Height;
LUSC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.26	-0.41	3.38e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg23625390	chr15:77176239	SCAPER	-0.56	-7.96	-0.4	2.63e-14	Blood metabolite levels;
LUSC	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.25	0.37	2.94e-12	Blood metabolite levels;
LUSC	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg12826209	chr6:26865740	GUSBL1	0.68	7.67	0.39	1.85e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg00750074	chr16:89608354	SPG7	-0.54	-9.82	-0.47	3.67e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs4566357	0.595	rs10201538	chr2:227914449	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.2	-0.41	5.4e-15	Coronary artery disease;
LUSC	cis	rs6906287	0.647	rs973944	chr6:118850956	T/G	cg21191810	chr6:118973309	C6orf204	0.32	5.83	0.3	1.27e-8	Electrocardiographic conduction measures;
LUSC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.43	6.4	0.33	5.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9398803	0.830	rs1159619	chr6:126801144	C/A	cg19875578	chr6:126661172	C6orf173	0.42	6.18	0.32	1.9e-9	Male-pattern baldness;
LUSC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.99	0.55	8.55e-28	Chronic sinus infection;
LUSC	trans	rs1133146	1.000	rs1133146	chr19:53666660	A/G	cg23709988	chr14:23772096	PPP1R3E	-0.4	-6.31	-0.33	8.62e-10	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg24399712	chr22:39784796	NA	-0.61	-10.86	-0.51	1.01e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg03983476	chr2:10830698	NOL10	-0.37	-5.66	-0.3	3.31e-8	Prostate cancer;
LUSC	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg17385448	chr1:15911702	AGMAT	0.35	5.97	0.31	6.18e-9	Systolic blood pressure;
LUSC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg05347473	chr6:146136440	FBXO30	0.56	9.56	0.46	2.7e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs116988415	0.584	rs2269306	chr14:65245417	A/G	cg25083366	chr14:65239357	SPTB	-0.57	-6.04	-0.31	4e-9	Daytime sleep phenotypes;
LUSC	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg01966878	chr4:90757139	SNCA	-0.35	-6.12	-0.32	2.56e-9	Dementia with Lewy bodies;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24997989	chr18:21977798	OSBPL1A	-0.41	-6.37	-0.33	6.29e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.37	-0.33	6.25e-10	Monocyte count;
LUSC	cis	rs73206853	0.702	rs7960516	chr12:110529238	T/A	cg12870014	chr12:110450643	ANKRD13A	0.48	6.3	0.33	9.17e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.8	12.63	0.57	3.72e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg00339695	chr16:24857497	SLC5A11	0.35	6.09	0.32	3.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg07507251	chr3:52567010	NT5DC2	0.29	5.68	0.3	2.96e-8	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08219700	chr8:58056026	NA	0.64	8.51	0.42	5.97e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs3771570	1.000	rs62193171	chr2:242276523	C/A	cg21155796	chr2:242212141	HDLBP	0.63	6.86	0.35	3.32e-11	Prostate cancer;
LUSC	cis	rs2979489	0.699	rs17554116	chr8:30419334	C/T	cg26383811	chr8:30366931	RBPMS	-0.44	-6.65	-0.34	1.17e-10	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs858239	0.601	rs1034963	chr7:23148473	T/C	cg23682824	chr7:23144976	KLHL7	0.39	5.81	0.3	1.48e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs11166629	0.637	rs721000	chr8:135574196	T/C	cg27224718	chr8:135614730	ZFAT	0.57	8.1	0.41	1.05e-14	Smoking quantity;
LUSC	cis	rs4285028	0.580	rs12496036	chr3:121640362	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.48	-6.68	-0.34	9.9e-11	Multiple sclerosis;
LUSC	cis	rs6138458	0.585	rs1007881	chr20:25014385	A/G	cg26195577	chr20:24973756	C20orf3	0.71	10.78	0.51	1.83e-23	Blood protein levels;
LUSC	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.24e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9399401	0.845	rs263187	chr6:142860789	G/A	cg03128060	chr6:142623767	GPR126	0.32	5.96	0.31	6.54e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-1.07	-15.83	-0.65	1.64e-42	Initial pursuit acceleration;
LUSC	cis	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg09904177	chr6:26538194	HMGN4	-0.75	-5.79	-0.3	1.61e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs231513	0.954	rs231512	chr17:41965831	G/A	cg26893861	chr17:41843967	DUSP3	-0.55	-6.12	-0.32	2.65e-9	Cognitive function;
LUSC	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg04865166	chr7:105162814	PUS7	0.51	5.67	0.3	3.06e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7582720	1.000	rs7605484	chr2:203724495	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	8.06	0.4	1.37e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg12463550	chr7:65579703	CRCP	0.56	8.35	0.42	1.79e-15	Aortic root size;
LUSC	cis	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg05084668	chr3:125655381	ALG1L	-0.84	-11.99	-0.55	8.7300000000000009e-28	Blood pressure (smoking interaction);
LUSC	cis	rs12928939	0.815	rs1345868	chr16:71669624	G/T	cg08717414	chr16:71523259	ZNF19	-0.42	-5.99	-0.31	5.3e-9	Post bronchodilator FEV1;
LUSC	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg25643088	chr3:52874325	TMEM110	0.39	5.82	0.3	1.4e-8	Schizophrenia;
LUSC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	0.84	13.95	0.61	3.6e-35	Menopause (age at onset);
LUSC	cis	rs965469	0.947	rs7274193	chr20:3329750	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-5.65	-0.3	3.48e-8	IFN-related cytopenia;
LUSC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg11812906	chr14:75593930	NEK9	-0.65	-11.1	-0.52	1.41e-24	Height;
LUSC	trans	rs6828577	0.626	rs17642633	chr4:119412100	A/G	cg26518628	chr1:97050305	NA	-0.53	-7.41	-0.38	1.03e-12	Perioperative myocardial infarction in coronary artery bypass surgery;
LUSC	cis	rs9311676	0.656	rs34579268	chr3:58410554	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.55	0.34	2.17e-10	Systemic lupus erythematosus;
LUSC	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg04539111	chr16:67997858	SLC12A4	-0.43	-5.68	-0.3	2.96e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg27539214	chr16:67997921	SLC12A4	-0.54	-7.46	-0.38	7.75e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.88	0.31	9.87e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg26384229	chr12:38710491	ALG10B	-0.53	-8.5	-0.42	6.58e-16	Morning vs. evening chronotype;
LUSC	cis	rs2797685	1.000	rs707472	chr1:7906008	A/C	cg04725166	chr1:7887271	PER3	0.45	6.13	0.32	2.47e-9	Crohn's disease;
LUSC	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	8.71	0.43	1.42e-16	Menarche (age at onset);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25436822	chr8:124054773	DERL1	-0.41	-5.96	-0.31	6.55e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg02493740	chr2:85810744	VAMP5	-0.36	-6.44	-0.33	4.13e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.54	-7.79	-0.39	8.82e-14	Gut microbiome composition (summer);
LUSC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg14416269	chr4:6271139	WFS1	0.52	10.98	0.52	3.62e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg11764359	chr7:65958608	NA	0.51	6.55	0.34	2.19e-10	Aortic root size;
LUSC	cis	rs7119	0.717	rs12910513	chr15:77817258	C/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg12483005	chr1:23474871	LUZP1	0.41	6.5	0.34	2.89e-10	Height;
LUSC	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.66	-10.16	-0.49	2.56e-21	Morning vs. evening chronotype;
LUSC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg09035930	chr12:129282057	SLC15A4	-0.7	-15.0	-0.63	3.08e-39	Systemic lupus erythematosus;
LUSC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg13560548	chr3:10150139	C3orf24	-0.52	-7.73	-0.39	1.27e-13	Alzheimer's disease;
LUSC	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg04398451	chr17:18023971	MYO15A	-0.44	-6.93	-0.35	2.19e-11	Total body bone mineral density;
LUSC	cis	rs12464559	0.579	rs6433590	chr2:152588120	A/C	cg01189475	chr2:152685088	ARL5A	0.63	5.65	0.3	3.52e-8	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg21770322	chr7:97807741	LMTK2	0.56	10.08	0.48	4.99e-21	Breast cancer;
LUSC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-1.09	-21.84	-0.77	2.65e-66	Height;
LUSC	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-6.88	-0.35	3.02e-11	Axial length;
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg06877462	chr1:205807181	PM20D1	0.5	9.03	0.44	1.43e-17	Menarche (age at onset);
LUSC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg11843238	chr5:131593191	PDLIM4	0.37	6.46	0.33	3.77e-10	Breast cancer;
LUSC	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.44	0.46	6.85e-19	Coffee consumption (cups per day);
LUSC	cis	rs12712073	0.845	rs6729966	chr2:100781566	A/G	cg07810366	chr2:100720526	AFF3	-0.42	-7.17	-0.37	5e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg09021430	chr5:549028	NA	0.42	7.55	0.38	4.28e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg27535305	chr1:53392650	SCP2	-0.4	-7.49	-0.38	6.15e-13	Monocyte count;
LUSC	cis	rs2078087	0.831	rs10911294	chr1:183238100	C/T	cg13843938	chr1:183241246	NMNAT2	0.44	5.89	0.31	9.45e-9	Obesity-related traits;
LUSC	trans	rs1998174	0.509	rs7514627	chr1:171812466	A/G	cg13482142	chr2:234261155	NA	0.42	6.02	0.31	4.51e-9	Platelet distribution width;
LUSC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.87	0.4	4.97e-14	Bipolar disorder;
LUSC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg05425664	chr17:57184151	TRIM37	0.54	7.98	0.4	2.31e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg04310649	chr10:35416472	CREM	-0.43	-6.55	-0.34	2.18e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg14019146	chr3:50243930	SLC38A3	0.36	8.42	0.42	1.12e-15	Body mass index;
LUSC	trans	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07923666	chr12:49932857	KCNH3	-0.53	-6.6	-0.34	1.66e-10	Resting heart rate;
LUSC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.41	-0.42	1.23e-15	Height;
LUSC	cis	rs36093844	0.898	rs11234462	chr11:85596924	C/T	cg25872744	chr11:85566296	CCDC83	-0.45	-6.81	-0.35	4.61e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg02079420	chr8:82753780	SNX16	0.4	5.97	0.31	6.09e-9	Diastolic blood pressure;
LUSC	cis	rs7560272	0.723	rs1083923	chr2:73703374	A/G	cg20560298	chr2:73613845	ALMS1	0.46	7.19	0.37	4.24e-12	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.58	0.38	3.4e-13	Bipolar disorder;
LUSC	cis	rs2274273	1.000	rs2147972	chr14:55598030	T/C	cg04306507	chr14:55594613	LGALS3	0.54	11.49	0.53	5.85e-26	Protein biomarker;
LUSC	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	6.87	0.35	3.17e-11	Height;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.87	16.92	0.68	7.97e-47	Menarche (age at onset);
LUSC	cis	rs2708377	0.658	rs2708347	chr12:11281492	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.22	-13.8	-0.6	1.31e-34	Diabetic kidney disease;
LUSC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.33	0.45	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg15448220	chr1:150897856	SETDB1	0.38	5.69	0.3	2.84e-8	Tonsillectomy;
LUSC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs554111	0.613	rs6699704	chr1:21241432	G/C	cg01072550	chr1:21505969	NA	0.41	6.21	0.32	1.56e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs8032315	1.000	rs8032315	chr15:91418297	A/T	cg05469396	chr15:91419421	FURIN	-0.42	-6.76	-0.35	6.09e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg24130564	chr14:104152367	KLC1	0.47	6.74	0.35	6.91e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg07636037	chr3:49044803	WDR6	0.44	6.51	0.34	2.69e-10	Resting heart rate;
LUSC	trans	rs13314892	1.000	rs13314892	chr3:69795052	A/G	cg24703757	chr4:183838736	DCTD	0.51	6.91	0.35	2.49e-11	QRS complex (12-leadsum);
LUSC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.55	10.06	0.48	5.64e-21	Bone mineral density;
LUSC	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg05234568	chr11:5960015	NA	-0.64	-9.41	-0.46	8.5e-19	DNA methylation (variation);
LUSC	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg13647721	chr17:30228624	UTP6	-0.69	-7.5	-0.38	5.71e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg02487422	chr3:49467188	NICN1	0.44	7.13	0.36	6.21e-12	Resting heart rate;
LUSC	cis	rs7000551	0.560	rs4872483	chr8:22255684	C/T	cg12081754	chr8:22256438	SLC39A14	0.87	13.85	0.6	8.99e-35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg11584989	chr19:19387371	SF4	-0.58	-6.85	-0.35	3.46e-11	Bipolar disorder;
LUSC	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.58	-0.34	1.87e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs225245	0.765	rs226428	chr17:34049950	C/T	cg19694781	chr19:47549865	TMEM160	0.38	6.01	0.31	4.74e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9788682	0.706	rs2656055	chr15:78720194	C/A	cg24631222	chr15:78858424	CHRNA5	-0.66	-8.51	-0.42	6.06e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs73206853	0.609	rs55833146	chr12:110872335	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	7.16	0.36	5.29e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.73	10.83	0.51	1.3e-23	Type 2 diabetes;
LUSC	cis	rs354225	0.544	rs4455200	chr2:54801591	T/A	cg01766943	chr2:54829624	SPTBN1	0.47	7.57	0.38	3.72e-13	Schizophrenia;
LUSC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg02038168	chr22:39784481	NA	-0.45	-6.69	-0.34	9.39e-11	Post bronchodilator FEV1;
LUSC	trans	rs683250	1.000	rs683125	chr11:83276245	A/G	cg26617787	chr11:123396133	GRAMD1B	-0.32	-6.09	-0.32	3.14e-9	Subcortical brain region volumes;
LUSC	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17467752	chr17:38218738	THRA	0.53	7.9	0.4	3.96e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	1.03	18.0	0.7	3.96e-51	Parkinson's disease;
LUSC	cis	rs72960926	0.744	rs56365866	chr6:74910810	T/C	cg03266952	chr6:74778945	NA	-0.78	-6.22	-0.32	1.5e-9	Metabolite levels (MHPG);
LUSC	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-0.97	-10.27	-0.49	1.14e-21	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs55665837	0.539	rs10500804	chr11:14910273	A/C	cg05501817	chr11:14380813	RRAS2	-0.4	-5.86	-0.31	1.13e-8	Vitamin D levels;
LUSC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	19.6	0.73	1.74e-57	Prudent dietary pattern;
LUSC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg09165964	chr15:75287851	SCAMP5	0.45	6.45	0.33	3.92e-10	Caffeine consumption;
LUSC	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg15490075	chr13:100150979	NA	0.66	7.99	0.4	2.18e-14	Obesity-related traits;
LUSC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.31	-6.09	-0.32	3.15e-9	Total body bone mineral density;
LUSC	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	cis	rs13082711	0.595	rs6778612	chr3:27370789	T/C	cg02860705	chr3:27208620	NA	-0.68	-11.49	-0.53	5.63e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	trans	rs61931739	0.649	rs860088	chr12:33721807	T/C	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.06	0.44	1.1e-17	Height;
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg22907277	chr7:1156413	C7orf50	0.57	8.76	0.43	1e-16	Longevity;Endometriosis;
LUSC	cis	rs8017423	0.967	rs2151748	chr14:90694897	G/C	cg14092571	chr14:90743983	NA	-0.38	-6.24	-0.32	1.31e-9	Mortality in heart failure;
LUSC	cis	rs67072384	0.901	rs58076660	chr11:72441495	G/A	cg04827223	chr11:72435913	ARAP1	-0.79	-7.42	-0.38	9.6e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg18478394	chr8:109455254	TTC35	-0.45	-7.02	-0.36	1.28e-11	Dupuytren's disease;
LUSC	cis	rs7084921	0.578	rs11592631	chr10:101878219	G/A	cg02250046	chr10:101825185	CPN1	-0.34	-5.99	-0.31	5.55e-9	Bone mineral density;
LUSC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.44	0.33	4.12e-10	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.57	0.78	3.62e-69	Prudent dietary pattern;
LUSC	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg07382826	chr16:28625726	SULT1A1	0.28	5.92	0.31	8.01e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.53	10.46	0.5	2.53e-22	Coronary artery disease;
LUSC	cis	rs2219968	0.701	rs7015968	chr8:78995994	A/G	cg00738934	chr8:78996279	NA	0.42	7.65	0.39	2.24e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6845621	0.901	rs6449433	chr4:18906202	C/T	cg12196642	chr4:18937545	NA	0.34	6.45	0.33	3.88e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2115536	0.606	rs8024713	chr15:80206958	C/G	cg02196730	chr15:80188777	MTHFS	0.4	6.29	0.33	9.83e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs11039100	0.607	rs968992	chr11:5783889	G/A	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg10556349	chr10:835070	NA	0.59	6.55	0.34	2.24e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.81	-0.51	1.53e-23	Aortic root size;
LUSC	cis	rs12681287	0.640	rs7833049	chr8:87445898	T/C	cg27223183	chr8:87520930	FAM82B	0.54	7.47	0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg24631222	chr15:78858424	CHRNA5	0.64	8.45	0.42	9e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2067615	0.507	rs11113083	chr12:107073316	C/A	cg15890332	chr12:107067104	RFX4	0.36	6.33	0.33	7.72e-10	Heart rate;
LUSC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21643547	chr1:205240462	TMCC2	-0.53	-10.21	-0.49	1.82e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg00033643	chr7:134001901	SLC35B4	0.43	6.68	0.34	9.73e-11	Mean platelet volume;
LUSC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg04317338	chr11:64019027	PLCB3	0.66	7.54	0.38	4.47e-13	Mean platelet volume;
LUSC	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-7.0	-0.36	1.37e-11	Total cholesterol levels;
LUSC	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg11693508	chr17:37793320	STARD3	0.52	6.14	0.32	2.28e-9	Neuroticism;
LUSC	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-7.1	-0.36	7.73e-12	Axial length;
LUSC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08736216	chr1:53307985	ZYG11A	-0.27	-5.7	-0.3	2.68e-8	Monocyte count;
LUSC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.3	0.37	2.12e-12	Platelet count;
LUSC	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg24692254	chr21:30365293	RNF160	-0.53	-7.08	-0.36	8.56e-12	Cognitive test performance;
LUSC	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.88	0.44	4.07e-17	Lung cancer in ever smokers;
LUSC	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg09408571	chr1:101003634	GPR88	0.32	5.94	0.31	6.99e-9	Breast cancer;
LUSC	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.16	-0.32	2.06e-9	Response to antipsychotic treatment;
LUSC	trans	rs2262909	0.962	rs12609368	chr19:22263996	T/C	cg05197062	chr11:11642011	GALNTL4	0.57	7.91	0.4	3.71e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17102423	0.964	rs11627859	chr14:65602384	G/A	cg11161011	chr14:65562177	MAX	-0.64	-9.91	-0.48	1.85e-20	Obesity-related traits;
LUSC	cis	rs11229555	0.645	rs34350060	chr11:58184902	T/C	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg04990556	chr1:26633338	UBXN11	-0.48	-6.18	-0.32	1.87e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6543140	0.964	rs13393175	chr2:103078849	T/G	cg09003973	chr2:102972529	NA	0.54	6.87	0.35	3.16e-11	Blood protein levels;
LUSC	cis	rs9473147	0.516	rs9381564	chr6:47443806	A/G	cg12968598	chr6:47444699	CD2AP	0.54	8.14	0.41	7.83e-15	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg17143192	chr8:8559678	CLDN23	0.63	8.9	0.44	3.56e-17	Obesity-related traits;
LUSC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg27165867	chr14:105738592	BRF1	-0.51	-7.21	-0.37	3.83e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg24675658	chr1:53192096	ZYG11B	0.73	12.29	0.56	6.6e-29	Monocyte count;
LUSC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06850241	chr22:41845214	NA	0.3	5.75	0.3	2.05e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs10992471	0.676	rs13286566	chr9:95473178	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.54	-0.34	2.38e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs16854884	0.657	rs35788195	chr3:143739311	C/T	cg06585982	chr3:143692056	C3orf58	0.46	7.01	0.36	1.33e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs61931739	0.635	rs10772123	chr12:33975557	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.94	-0.36	2.04e-11	Morning vs. evening chronotype;
LUSC	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg05738196	chr6:26577821	NA	-0.55	-8.64	-0.43	2.32e-16	Schizophrenia;
LUSC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3741151	0.773	rs73542960	chr11:73115946	T/C	cg17517138	chr11:73019481	ARHGEF17	0.98	8.39	0.42	1.34e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs897984	0.609	rs732173	chr16:31050023	C/A	cg02466173	chr16:30829666	NA	-0.54	-10.37	-0.49	5.05e-22	Dementia with Lewy bodies;
LUSC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.7	-12.56	-0.57	6.54e-30	Aortic root size;
LUSC	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg05110241	chr16:68378359	PRMT7	-0.47	-6.04	-0.31	4.18e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1941023	0.584	rs2197236	chr11:60168859	T/C	cg08716584	chr11:60157161	MS4A7	-0.62	-11.34	-0.53	1.9e-25	Congenital heart disease (maternal effect);
LUSC	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg05043794	chr9:111880884	C9orf5	-0.37	-7.62	-0.38	2.65e-13	Menarche (age at onset);
LUSC	trans	rs28647808	0.881	rs7040821	chr9:136263584	C/A	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs11608355	0.545	rs6606721	chr12:109891999	G/A	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.1e-26	Neuroticism;
LUSC	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg03938978	chr2:103052716	IL18RAP	0.38	7.16	0.36	5.06e-12	Asthma;
LUSC	cis	rs13089785	1.000	rs2271969	chr3:123650432	A/G	cg02558132	chr3:123411198	MYLK	0.36	6.21	0.32	1.61e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.45	10.11	0.48	3.93e-21	Schizophrenia;
LUSC	cis	rs9300255	0.739	rs1879380	chr12:123739111	G/A	cg00376283	chr12:123451042	ABCB9	-0.68	-7.57	-0.38	3.59e-13	Neutrophil percentage of white cells;
LUSC	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg17691542	chr6:26056736	HIST1H1C	0.47	7.04	0.36	1.09e-11	Height;
LUSC	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg21681030	chr2:46777652	RHOQ	0.43	6.0	0.31	5e-9	Height;
LUSC	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg25344623	chr2:136566232	LCT	0.37	5.69	0.3	2.82e-8	Mosquito bite size;
LUSC	cis	rs3772130	0.624	rs56382357	chr3:121452339	T/C	cg20356878	chr3:121714668	ILDR1	0.51	8.26	0.41	3.43e-15	Cognitive performance;
LUSC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg00074818	chr8:8560427	CLDN23	0.57	9.87	0.48	2.47e-20	Obesity-related traits;
LUSC	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.89	-18.8	-0.72	2.6e-54	Gut microbiota (bacterial taxa);
LUSC	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg24881330	chr22:46731750	TRMU	0.84	7.39	0.37	1.22e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4776059	1.000	rs11857150	chr15:52922216	G/A	cg25063058	chr15:52860530	ARPP19	0.42	5.93	0.31	7.42e-9	Schizophrenia;
LUSC	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-5.65	-0.3	3.48e-8	IgG glycosylation;
LUSC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg00750074	chr16:89608354	SPG7	-0.46	-7.98	-0.4	2.37e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs4363385	0.818	rs3806222	chr1:153002606	C/T	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.9	-0.4	4e-14	Inflammatory skin disease;
LUSC	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg05283184	chr6:79620031	NA	-0.57	-11.83	-0.54	3.38e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg15649852	chr7:65879115	NA	-0.41	-5.78	-0.3	1.74e-8	Aortic root size;
LUSC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	12.32	0.56	5.39e-29	Chronic sinus infection;
LUSC	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg15556689	chr8:8085844	FLJ10661	0.63	9.49	0.46	4.63e-19	Neuroticism;
LUSC	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg13256891	chr4:100009986	ADH5	-0.43	-5.95	-0.31	6.78e-9	Alcohol dependence;
LUSC	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.56	0.5	1.1e-22	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg25206134	chr2:45395956	NA	0.56	6.82	0.35	4.15e-11	Bipolar disorder;
LUSC	trans	rs9886428	1.000	rs11203588	chr8:14116631	T/A	cg11959399	chr20:741723	C20orf54	-0.4	-6.42	-0.33	4.67e-10	IgG glycosylation;
LUSC	cis	rs941764	1.000	rs941764	chr14:91841069	C/T	cg10511902	chr14:91842949	CCDC88C	-0.37	-6.21	-0.32	1.6e-9	Breast cancer;
LUSC	cis	rs4363385	0.747	rs1611753	chr1:152956381	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.63	-0.39	2.41e-13	Inflammatory skin disease;
LUSC	cis	rs7605827	0.930	rs1015835	chr2:15625768	T/C	cg19274914	chr2:15703543	NA	0.46	8.87	0.44	4.51e-17	Educational attainment (years of education);
LUSC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21984481	chr17:79567631	NPLOC4	0.68	14.27	0.62	2.03e-36	Eye color traits;
LUSC	cis	rs524023	0.957	rs561193	chr11:64353029	A/G	cg19131476	chr11:64387923	NRXN2	0.37	10.0	0.48	8.79e-21	Urate levels in obese individuals;
LUSC	cis	rs10979	0.679	rs9403510	chr6:143892174	C/T	cg25407410	chr6:143891975	LOC285740	-0.65	-9.2	-0.45	3.88e-18	Hypospadias;
LUSC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.67	0.34	1.05e-10	Tonsillectomy;
LUSC	cis	rs2540226	0.515	rs2540248	chr2:39909117	G/T	cg23576258	chr2:39999331	THUMPD2	0.34	5.65	0.3	3.36e-8	Personality dimensions;
LUSC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11644478	chr21:40555479	PSMG1	0.64	10.51	0.5	1.61e-22	Cognitive function;
LUSC	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg01444801	chr10:135216882	MTG1	-0.49	-6.35	-0.33	7e-10	Systemic lupus erythematosus;
LUSC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg27284194	chr4:1044797	NA	0.37	5.75	0.3	2.06e-8	Longevity;
LUSC	cis	rs7523273	0.526	rs2745975	chr1:208013620	C/T	cg22525895	chr1:207977042	MIR29B2	-0.4	-6.7	-0.34	9.08e-11	Schizophrenia;
LUSC	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg11693508	chr17:37793320	STARD3	0.56	6.7	0.34	8.87e-11	Bipolar disorder;
LUSC	cis	rs4285028	0.747	rs9820511	chr3:121361345	G/A	cg11130432	chr3:121712080	ILDR1	-0.58	-8.44	-0.42	9.92e-16	Multiple sclerosis;
LUSC	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-17.52	-0.69	3.23e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg18827107	chr12:86230957	RASSF9	-0.4	-5.95	-0.31	6.77e-9	Major depressive disorder;
LUSC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg09021430	chr5:549028	NA	-0.57	-7.7	-0.39	1.61e-13	Obesity-related traits;
LUSC	cis	rs988712	0.705	rs35051342	chr11:27634373	G/C	cg10635145	chr11:27742435	BDNF	-0.5	-6.58	-0.34	1.86e-10	Obesity;
LUSC	cis	rs892961	0.932	rs12453822	chr17:75416792	G/A	cg05865280	chr17:75406074	SEPT9	0.45	9.37	0.46	1.15e-18	Airflow obstruction;
LUSC	cis	rs2835872	0.733	rs1787393	chr21:39035934	G/A	cg20424643	chr21:39039972	KCNJ6	-0.44	-7.43	-0.38	8.98e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7799006	0.929	rs7781856	chr7:2257199	C/T	cg12823233	chr7:2316876	SNX8	-0.36	-6.06	-0.31	3.6e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs983392	0.709	rs11601689	chr11:59996266	G/C	cg02771260	chr11:59836817	MS4A3	-0.36	-5.89	-0.31	9.34e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.64	-0.34	1.24e-10	Life satisfaction;
LUSC	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.79	0.6	1.44e-34	Platelet count;
LUSC	cis	rs6430549	0.518	rs41521049	chr2:135693069	G/A	cg15893373	chr2:135677154	CCNT2	-0.47	-6.43	-0.33	4.45e-10	Hematocrit;
LUSC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08439880	chr3:133502540	NA	0.36	6.34	0.33	7.33e-10	Iron status biomarkers;
LUSC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-14.28	-0.62	1.95e-36	Chronic sinus infection;
LUSC	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.52	0.38	4.98e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2273669	0.667	rs112319185	chr6:109305318	T/C	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	trans	rs953492	0.644	rs10926976	chr1:243402721	G/A	cg25284624	chr1:224180302	NA	-0.44	-6.73	-0.35	7.56e-11	Diastolic blood pressure;
LUSC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.73	-12.95	-0.58	2.37e-31	Personality dimensions;
LUSC	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	1.08	16.95	0.68	6.24e-47	Exhaled nitric oxide output;
LUSC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg19266014	chr7:2183958	MAD1L1	-0.34	-5.66	-0.3	3.27e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.68	8.85	0.44	5.27e-17	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs1728785	0.892	rs4783648	chr16:68558334	C/T	cg02508848	chr16:68573721	ZFP90	0.46	5.79	0.3	1.65e-8	Ulcerative colitis;
LUSC	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg05082376	chr22:42548792	NA	-0.37	-6.27	-0.32	1.11e-9	Cognitive function;
LUSC	cis	rs3770081	1.000	rs2012798	chr2:86182756	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.03	-6.59	-0.34	1.67e-10	Facial emotion recognition (sad faces);
LUSC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg22800045	chr5:56110881	MAP3K1	-0.74	-9.68	-0.47	1.11e-19	Initial pursuit acceleration;
LUSC	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.8	12.26	0.56	8.59e-29	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs6076065	0.723	rs2236022	chr20:23373534	G/A	cg11657817	chr20:23433608	CST11	0.43	8.07	0.4	1.25e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg27170947	chr2:26402098	FAM59B	-0.69	-10.55	-0.5	1.2e-22	Gut microbiome composition (summer);
LUSC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg08888203	chr3:10149979	C3orf24	0.59	8.23	0.41	4.19e-15	Alzheimer's disease;
LUSC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg03929089	chr4:120376271	NA	-0.52	-7.25	-0.37	2.92e-12	Coronary artery disease;
LUSC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg18512352	chr11:47633146	NA	0.48	10.02	0.48	7.95e-21	Subjective well-being;
LUSC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.72	-13.51	-0.59	1.8e-33	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.64	11.0	0.52	3.11e-24	Bone mineral density;
LUSC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	1.05	18.89	0.72	1.18e-54	Parkinson's disease;
LUSC	cis	rs968451	0.865	rs2007418	chr22:39712394	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.69	9.14	0.45	6.21e-18	Primary biliary cholangitis;
LUSC	cis	rs7590368	0.961	rs2357815	chr2:10959769	C/T	cg15705551	chr2:10952987	PDIA6	0.58	8.0	0.4	2.11e-14	Educational attainment (years of education);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02708722	chr12:124118329	EIF2B1;GTF2H3	-0.4	-6.0	-0.31	5.23e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2229238	0.911	rs12405637	chr1:154501285	C/T	cg25273160	chr11:56955011	LRRC55	0.32	6.11	0.32	2.82e-9	Coronary heart disease;
LUSC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-9.85	-0.47	2.91e-20	Gut microbiome composition (summer);
LUSC	cis	rs11958404	0.932	rs6884954	chr5:157436772	C/T	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs6489882	0.902	rs3759376	chr12:113373563	A/G	cg20102336	chr12:113376681	OAS3	-0.42	-6.03	-0.31	4.29e-9	Chronic lymphocytic leukemia;
LUSC	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg27661571	chr11:113659931	NA	-0.66	-7.8	-0.39	7.72e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.54	6.72	0.35	7.95e-11	Renal function-related traits (BUN);
LUSC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg21724239	chr8:58056113	NA	0.79	9.74	0.47	6.95e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg23387468	chr7:139079360	LUC7L2	0.42	6.31	0.33	9.09e-10	Diisocyanate-induced asthma;
LUSC	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg00376283	chr12:123451042	ABCB9	0.75	8.33	0.41	2.04e-15	Neutrophil percentage of white cells;
LUSC	trans	rs710987	0.967	rs710991	chr5:3518510	G/T	cg27629735	chr1:3556483	WDR8	-0.35	-6.01	-0.31	4.9e-9	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
LUSC	cis	rs243505	0.691	rs243486	chr7:148448221	A/C	cg09806900	chr7:148480153	CUL1	-0.54	-7.1	-0.36	7.78e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3768617	1.000	rs2027077	chr1:183073453	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.49	0.42	6.65e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.43	0.5	2.99e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.72	-9.65	-0.47	1.31e-19	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg10911889	chr6:126070802	HEY2	0.39	5.78	0.3	1.73e-8	High light scatter reticulocyte count;
LUSC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03517284	chr6:25882590	NA	0.45	7.83	0.39	6.42e-14	Blood metabolite levels;
LUSC	trans	rs72674100	1.000	rs28496290	chr4:97969761	G/T	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7605827	0.897	rs13004112	chr2:15604048	C/T	cg19274914	chr2:15703543	NA	0.46	8.74	0.43	1.16e-16	Educational attainment (years of education);
LUSC	cis	rs4919687	0.550	rs10437480	chr10:104453024	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-5.94	-0.31	7.19e-9	Colorectal cancer;
LUSC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg04546413	chr19:29218101	NA	0.57	7.82	0.39	6.88e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg14343924	chr8:8086146	FLJ10661	-0.41	-5.65	-0.3	3.51e-8	Mood instability;
LUSC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.23	-0.41	4.36e-15	Obesity-related traits;
LUSC	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17916960	chr15:79447300	NA	-0.53	-10.55	-0.5	1.24e-22	Refractive error;
LUSC	cis	rs6977940	0.512	rs11765726	chr7:2850878	A/G	cg19731401	chr7:2775893	GNA12	0.69	9.8	0.47	4.31e-20	White matter integrity;
LUSC	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg05283184	chr6:79620031	NA	-0.57	-11.95	-0.55	1.16e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.85	-16.5	-0.67	3.91e-45	Ulcerative colitis;
LUSC	cis	rs7727544	0.508	rs10900804	chr5:131401845	C/T	cg14196790	chr5:131705035	SLC22A5	0.48	7.81	0.39	7.39e-14	Blood metabolite levels;
LUSC	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg11843606	chr2:227700838	RHBDD1	-0.65	-10.17	-0.49	2.38e-21	Pulmonary function;
LUSC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.71	0.51	3.24e-23	Menopause (age at onset);
LUSC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg20701182	chr2:24300061	SF3B14	0.57	6.17	0.32	1.99e-9	Lymphocyte counts;
LUSC	cis	rs17641971	0.599	rs818555	chr8:49999211	A/G	cg00325661	chr8:49890786	NA	-0.56	-9.37	-0.46	1.1e-18	Blood metabolite levels;
LUSC	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg14500267	chr11:67383377	NA	-0.3	-5.68	-0.3	2.96e-8	Mean corpuscular volume;
LUSC	cis	rs3784262	1.000	rs12910113	chr15:58248373	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.09	-0.32	3.1e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg06484146	chr7:12443880	VWDE	-0.69	-7.35	-0.37	1.53e-12	Coronary artery disease;
LUSC	trans	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg26043149	chr18:55253948	FECH	-0.43	-6.6	-0.34	1.64e-10	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg03576123	chr11:487126	PTDSS2	-0.45	-5.81	-0.3	1.45e-8	Systemic lupus erythematosus;
LUSC	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg01579765	chr21:45077557	HSF2BP	-0.48	-9.94	-0.48	1.48e-20	Mean corpuscular volume;
LUSC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	0.94	13.2	0.59	2.58e-32	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs1864585	0.520	rs17776404	chr8:10672829	A/G	cg26278703	chr11:58910052	FAM111A	0.56	6.29	0.33	9.69e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUSC	cis	rs4792901	0.802	rs72833136	chr17:41599690	G/A	cg22562494	chr17:41607896	ETV4	-0.32	-5.95	-0.31	6.89e-9	Dupuytren's disease;
LUSC	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg16850897	chr7:100343110	ZAN	-0.47	-5.77	-0.3	1.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg20406979	chr6:167373233	NA	-0.26	-6.22	-0.32	1.45e-9	Crohn's disease;
LUSC	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.86	15.14	0.64	8.3e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06692871	chr8:101964133	YWHAZ	-0.41	-6.27	-0.32	1.09e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9487051	0.768	rs463503	chr6:109525757	T/C	cg01475377	chr6:109611718	NA	-0.34	-5.8	-0.3	1.5e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg13256891	chr4:100009986	ADH5	0.51	6.96	0.36	1.79e-11	Smoking initiation;
LUSC	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.3	0.67	2.26e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1568889	1.000	rs7949704	chr11:28373543	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	8.94	0.44	2.73e-17	Bipolar disorder;
LUSC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg04369109	chr6:150039330	LATS1	0.53	7.79	0.39	8.34e-14	Lung cancer;
LUSC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg02079420	chr8:82753780	SNX16	-0.43	-7.26	-0.37	2.67e-12	Diastolic blood pressure;
LUSC	cis	rs9837602	1.000	rs6790877	chr3:99779658	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.17	0.32	2e-9	Breast cancer;
LUSC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.63	-9.61	-0.47	1.89e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7833986	0.501	rs72653921	chr8:56897157	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	11.02	0.52	2.62e-24	Height;
LUSC	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg05343316	chr1:45956843	TESK2	0.72	9.67	0.47	1.18e-19	Platelet count;
LUSC	cis	rs2067615	0.599	rs3759310	chr12:107166122	C/G	cg19260189	chr12:106995001	RFX4	0.22	5.65	0.3	3.43e-8	Heart rate;
LUSC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg12564285	chr5:131593104	PDLIM4	0.44	7.88	0.4	4.67e-14	Breast cancer;
LUSC	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg15423357	chr2:25149977	NA	0.45	9.12	0.45	7.07e-18	Body mass index in non-asthmatics;
LUSC	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.53	-0.42	5.32e-16	Body mass index;
LUSC	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.31	-18.22	-0.71	5.26e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg23630131	chr7:65973040	NA	-0.21	-5.82	-0.3	1.38e-8	Aortic root size;
LUSC	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg26752888	chr8:11627280	NEIL2	-0.43	-5.9	-0.31	8.7e-9	Myopia (pathological);
LUSC	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.69	10.35	0.49	5.71e-22	Corneal astigmatism;
LUSC	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg23173402	chr1:227635558	NA	0.56	6.39	0.33	5.47e-10	Major depressive disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01399255	chr7:100271274	GNB2	-0.48	-6.03	-0.31	4.27e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg01629716	chr15:45996671	NA	0.4	6.01	0.31	4.9e-9	Waist circumference;Weight;
LUSC	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg25174290	chr11:3078921	CARS	-0.41	-6.15	-0.32	2.22e-9	Calcium levels;
LUSC	cis	rs7903847	0.642	rs9888117	chr10:99159963	C/G	cg20016023	chr10:99160130	RRP12	-0.29	-7.34	-0.37	1.6e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg12292205	chr6:26970375	C6orf41	0.5	8.2	0.41	5.09e-15	Schizophrenia;
LUSC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	9.67	0.47	1.2e-19	Height;
LUSC	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg22676075	chr6:135203613	NA	0.48	7.48	0.38	6.5e-13	Red blood cell count;
LUSC	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg06636551	chr8:101224915	SPAG1	-0.4	-7.47	-0.38	7.09e-13	Atrioventricular conduction;
LUSC	cis	rs2720460	0.502	rs223374	chr4:103758301	T/C	cg16532752	chr4:104119610	CENPE	-0.42	-5.81	-0.3	1.46e-8	Testicular germ cell tumor;
LUSC	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.73	14.19	0.61	4.47e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg16928487	chr17:17741425	SREBF1	-0.42	-8.26	-0.41	3.35e-15	Total body bone mineral density;
LUSC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg06740227	chr12:86229804	RASSF9	0.44	7.07	0.36	9.33e-12	Major depressive disorder;
LUSC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.97	-0.36	1.74e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg04539111	chr16:67997858	SLC12A4	-0.42	-5.86	-0.31	1.09e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6977660	0.943	rs10254261	chr7:19846001	A/G	cg07541023	chr7:19748670	TWISTNB	-0.51	-5.91	-0.31	8.58e-9	Thyroid stimulating hormone;
LUSC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg00810483	chr4:3375144	RGS12	0.31	5.94	0.31	7.34e-9	Serum sulfate level;
LUSC	cis	rs7605827	0.897	rs6729018	chr2:15540676	A/G	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs7705502	0.962	rs55946741	chr5:173345023	A/G	cg18693985	chr5:173351052	CPEB4	-0.36	-5.7	-0.3	2.66e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg07507251	chr3:52567010	NT5DC2	0.43	9.21	0.45	3.62e-18	Electroencephalogram traits;
LUSC	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg05784532	chr1:230284198	GALNT2	0.49	7.39	0.38	1.16e-12	Coronary artery disease;
LUSC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg15556689	chr8:8085844	FLJ10661	0.68	11.4	0.53	1.22e-25	Mood instability;
LUSC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-0.92	-17.33	-0.69	1.88e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	10.76	0.51	2.28e-23	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg05714579	chr10:131428358	MGMT	-0.65	-10.51	-0.5	1.68e-22	Response to temozolomide;
LUSC	trans	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	6.48	0.33	3.25e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg21775007	chr8:11205619	TDH	-0.49	-6.67	-0.34	1.06e-10	Morning vs. evening chronotype;
LUSC	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg17385448	chr1:15911702	AGMAT	0.35	5.94	0.31	7.3e-9	Systolic blood pressure;
LUSC	cis	rs679087	1.000	rs672107	chr12:29917266	T/A	cg14258853	chr12:29935411	TMTC1	-0.98	-16.21	-0.66	5.08e-44	Schizophrenia;
LUSC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg07061783	chr6:25882402	NA	-0.38	-6.1	-0.32	2.94e-9	Blood metabolite levels;
LUSC	cis	rs2249625	0.526	rs17725666	chr6:72889711	G/A	cg18830697	chr6:72922368	RIMS1	0.37	7.33	0.37	1.79e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25204440	chr1:209979598	IRF6	0.68	11.75	0.54	6.28e-27	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg04586622	chr2:25135609	ADCY3	-0.42	-9.12	-0.45	7.16e-18	Body mass index;
LUSC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	15.11	0.64	1.15e-39	Platelet count;
LUSC	cis	rs77972916	0.505	rs6753197	chr2:43527962	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.47	-5.74	-0.3	2.12e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.7	12.62	0.57	4.03e-30	Prudent dietary pattern;
LUSC	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.51	-7.13	-0.36	6.11e-12	Tuberculosis;
LUSC	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg24558204	chr6:135376177	HBS1L	0.59	9.09	0.45	8.72e-18	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg13206674	chr6:150067644	NUP43	0.55	7.93	0.4	3.25e-14	Lung cancer;
LUSC	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg16482183	chr6:26056742	HIST1H1C	0.56	7.79	0.39	8.37e-14	Iron status biomarkers;
LUSC	cis	rs6693567	0.565	rs578353	chr1:150287884	C/G	cg15654264	chr1:150340011	RPRD2	0.44	7.34	0.37	1.66e-12	Migraine;
LUSC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg04369109	chr6:150039330	LATS1	-0.58	-8.44	-0.42	9.96e-16	Lung cancer;
LUSC	cis	rs4588572	0.643	rs1019739	chr5:77770241	G/C	cg11547950	chr5:77652471	NA	-0.55	-7.69	-0.39	1.62e-13	Triglycerides;
LUSC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-1.22	-16.54	-0.67	2.67e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs7843479	0.562	rs2127206	chr8:21786989	C/T	cg17168535	chr8:21777572	XPO7	0.82	14.81	0.63	1.64e-38	Mean corpuscular volume;
LUSC	cis	rs11608355	0.545	rs2302706	chr12:109894028	A/G	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.1e-26	Neuroticism;
LUSC	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	6.7	0.34	8.82e-11	Recombination measurement;
LUSC	cis	rs67072384	1.000	rs7120605	chr11:72444615	A/G	cg04827223	chr11:72435913	ARAP1	-0.82	-7.76	-0.39	1.04e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	1.23	16.47	0.67	4.98e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05776053	chr2:74358815	NA	0.45	7.22	0.37	3.62e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs2708977	0.965	rs12717781	chr2:97249142	G/A	cg01950434	chr2:97203154	ARID5A	0.57	8.7	0.43	1.57e-16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg20503657	chr10:835505	NA	0.78	9.56	0.46	2.76e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.6	8.02	0.4	1.85e-14	High light scatter reticulocyte count;
LUSC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	0.79	13.75	0.6	2.1e-34	Cognitive function;
LUSC	cis	rs7172677	0.691	rs12901092	chr15:75374145	C/A	cg14664628	chr15:75095509	CSK	0.43	6.06	0.31	3.62e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	0.95	13.78	0.6	1.67e-34	Initial pursuit acceleration;
LUSC	cis	rs4959270	0.967	rs4246068	chr6:457987	G/A	cg09757644	chr6:447497	NA	0.29	5.9	0.31	8.86e-9	Limited cutaneous systemic scleroderma;
LUSC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg24503407	chr1:205819492	PM20D1	0.56	9.32	0.45	1.63e-18	Menarche (age at onset);
LUSC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00166722	chr3:10149974	C3orf24	0.59	8.16	0.41	6.95e-15	Alzheimer's disease;
LUSC	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg22345647	chr11:68609526	CPT1A	-0.38	-5.98	-0.31	5.66e-9	Emphysema imaging phenotypes;
LUSC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.94	-0.31	7.06e-9	Personality dimensions;
LUSC	trans	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg02800362	chr5:177631904	HNRNPAB	0.83	12.44	0.56	1.95e-29	Obesity-related traits;
LUSC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg11366901	chr6:160182831	ACAT2	0.93	13.07	0.58	8.42e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg15423357	chr2:25149977	NA	0.44	8.98	0.44	1.96e-17	Body mass index;
LUSC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-1.04	-20.32	-0.74	2.6e-60	Height;
LUSC	cis	rs17604090	1.000	rs17661896	chr7:29692708	G/A	cg19413766	chr7:29689036	LOC646762	-0.62	-7.46	-0.38	7.31e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg06808227	chr14:105710500	BRF1	-0.63	-9.69	-0.47	9.62e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-8.49	-0.42	7.07e-16	Lymphocyte counts;
LUSC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	0.96	17.13	0.68	1.23e-47	Heart rate;
LUSC	trans	rs1949829	0.826	rs57295596	chr7:51543037	G/T	cg20941110	chr15:83953819	BNC1	0.56	6.06	0.31	3.58e-9	Wegener's granulomatosis;
LUSC	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.97	-0.44	2.18e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	trans	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg05059571	chr16:84539110	KIAA1609	0.48	9.16	0.45	5.47e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg16584290	chr5:462447	EXOC3	-0.37	-6.43	-0.33	4.39e-10	Cystic fibrosis severity;
LUSC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg11062466	chr8:58055876	NA	0.64	8.49	0.42	7.06e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg01620082	chr3:125678407	NA	-0.69	-7.05	-0.36	1.06e-11	Breast cancer;
LUSC	cis	rs13385	0.769	rs7726349	chr5:139537771	C/T	cg26211634	chr5:139558579	C5orf32	0.41	5.98	0.31	5.76e-9	Atrial fibrillation;
LUSC	cis	rs7945705	0.846	rs4929912	chr11:8816695	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-10.49	-0.5	1.88e-22	Hemoglobin concentration;
LUSC	cis	rs6087990	0.836	rs2424909	chr20:31361861	T/C	cg13636640	chr20:31349939	DNMT3B	0.99	21.69	0.76	9.62e-66	Ulcerative colitis;
LUSC	cis	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg21775007	chr8:11205619	TDH	-0.47	-6.47	-0.33	3.45e-10	Triglycerides;
LUSC	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.45	-0.5	2.56e-22	Eye color traits;
LUSC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg18477163	chr1:228402036	OBSCN	0.62	12.2	0.56	1.49e-28	Diastolic blood pressure;
LUSC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg05973401	chr12:123451056	ABCB9	0.59	8.6	0.43	3.17e-16	Platelet count;
LUSC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg20887711	chr4:1340912	KIAA1530	0.44	6.67	0.34	1.09e-10	Obesity-related traits;
LUSC	trans	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg01620082	chr3:125678407	NA	-0.53	-6.35	-0.33	7.07e-10	Depression;
LUSC	cis	rs9837602	1.000	rs7620228	chr3:99790332	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-5.99	-0.31	5.48e-9	Breast cancer;
LUSC	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg04117972	chr1:227635322	NA	0.61	6.54	0.34	2.3e-10	Major depressive disorder;
LUSC	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg21775007	chr8:11205619	TDH	-0.53	-7.86	-0.39	5.44e-14	Neuroticism;
LUSC	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg06484146	chr7:12443880	VWDE	-0.74	-7.32	-0.37	1.86e-12	Coronary artery disease;
LUSC	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg06462663	chr19:18546047	ISYNA1	0.49	8.25	0.41	3.58e-15	Breast cancer;
LUSC	cis	rs936229	0.749	rs8042694	chr15:75225415	G/A	cg14664628	chr15:75095509	CSK	-0.79	-11.67	-0.54	1.3e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg05110241	chr16:68378359	PRMT7	-0.64	-6.74	-0.35	6.99e-11	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg15704280	chr7:45808275	SEPT13	-0.63	-7.62	-0.38	2.63e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7124681	0.584	rs11039448	chr11:47918416	G/T	cg20307385	chr11:47447363	PSMC3	-0.52	-7.71	-0.39	1.41e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	1.04	21.8	0.77	3.7e-66	Ulcerative colitis;
LUSC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-0.72	-12.2	-0.56	1.47e-28	Height;
LUSC	cis	rs6961069	0.749	rs1537477	chr7:80251202	A/C	cg04458919	chr7:80252533	CD36	0.36	6.47	0.33	3.43e-10	Platelet count;
LUSC	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg04218760	chr10:45406644	TMEM72	-0.3	-7.24	-0.37	3.14e-12	Mean corpuscular volume;
LUSC	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg19468946	chr17:37922297	IKZF3	-0.36	-5.65	-0.3	3.38e-8	Self-reported allergy;
LUSC	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.78e-15	Bladder cancer;
LUSC	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.59	-0.46	2.1e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs939574	1.000	rs2071385	chr2:220118782	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.09	8.89	0.44	3.98e-17	Platelet distribution width;
LUSC	cis	rs9311676	0.656	rs7647184	chr3:58370046	C/T	cg13750441	chr3:58318267	PXK	0.35	6.7	0.34	8.72e-11	Systemic lupus erythematosus;
LUSC	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg13755796	chr4:20253514	NA	0.41	6.22	0.32	1.47e-9	Life satisfaction;
LUSC	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22455342	chr2:225449267	CUL3	0.44	6.05	0.31	3.88e-9	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs2969070	0.965	rs9691234	chr7:2508415	A/G	cg03277898	chr7:2518824	NA	-0.27	-5.74	-0.3	2.18e-8	Diastolic blood pressure;
LUSC	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.77	0.35	5.64e-11	Rheumatoid arthritis;
LUSC	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	6.54	0.34	2.33e-10	Lung cancer in ever smokers;
LUSC	trans	rs12043259	1.000	rs12043259	chr1:204828041	C/G	cg23865240	chr7:27134109	HOXA1	0.53	6.04	0.31	4.09e-9	Addiction;
LUSC	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07636037	chr3:49044803	WDR6	0.69	9.2	0.45	4.05e-18	Menarche (age at onset);
LUSC	cis	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg03522245	chr20:25566470	NINL	-0.36	-5.88	-0.31	1.01e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.75	-10.68	-0.5	4.33e-23	Gut microbiome composition (summer);
LUSC	cis	rs6495367	1.000	rs1007365	chr15:79379492	T/G	cg17916960	chr15:79447300	NA	0.37	6.96	0.36	1.79e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg12560992	chr17:57184187	TRIM37	0.52	7.91	0.4	3.86e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.83	10.18	0.49	2.15e-21	Exhaled nitric oxide output;
LUSC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	0.99	14.14	0.61	6.88e-36	Vitiligo;
LUSC	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg18827107	chr12:86230957	RASSF9	-0.44	-6.61	-0.34	1.55e-10	Major depressive disorder;
LUSC	trans	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg25214090	chr10:38739885	LOC399744	-0.43	-6.43	-0.33	4.31e-10	Corneal astigmatism;
LUSC	cis	rs2290159	0.898	rs2290160	chr3:12633083	A/G	cg23032965	chr3:12705835	RAF1	0.56	7.2	0.37	3.96e-12	Cholesterol, total;
LUSC	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.63	-5.86	-0.31	1.08e-8	Major depressive disorder;
LUSC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg07148914	chr20:33460835	GGT7	-0.46	-6.74	-0.35	7.17e-11	Height;
LUSC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.41	-5.65	-0.3	3.46e-8	Longevity;Endometriosis;
LUSC	trans	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg18187862	chr3:45730750	SACM1L	0.58	7.3	0.37	2.12e-12	Primary sclerosing cholangitis;
LUSC	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg05234568	chr11:5960015	NA	-0.63	-8.96	-0.44	2.27e-17	DNA methylation (variation);
LUSC	cis	rs9420	0.816	rs674094	chr11:57665336	A/C	cg23127183	chr11:57508653	C11orf31	0.5	6.73	0.35	7.41e-11	Schizophrenia;
LUSC	cis	rs6669008	1.000	rs6669008	chr1:114166561	A/G	cg26035817	chr1:114414802	PTPN22	0.44	6.94	0.35	2.08e-11	Bacteremia;
LUSC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg23034840	chr1:205782522	SLC41A1	-0.75	-12.84	-0.57	6.23e-31	Monocyte percentage of white cells;
LUSC	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg21427119	chr20:30132790	HM13	-0.42	-6.13	-0.32	2.5e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs1322512	0.917	rs1830642	chr6:152963826	A/G	cg27316956	chr6:152958899	SYNE1	-0.37	-6.32	-0.33	8.6e-10	Tonometry;
LUSC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg05973401	chr12:123451056	ABCB9	0.55	6.82	0.35	4.37e-11	Neutrophil percentage of white cells;
LUSC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg14895029	chr7:2775587	GNA12	-0.39	-6.02	-0.31	4.64e-9	Height;
LUSC	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg13010199	chr12:38710504	ALG10B	0.52	7.89	0.4	4.44e-14	Morning vs. evening chronotype;
LUSC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg00376283	chr12:123451042	ABCB9	0.67	8.42	0.42	1.1e-15	Neutrophil percentage of white cells;
LUSC	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg12140854	chr5:148520817	ABLIM3	-0.39	-5.89	-0.31	9.55e-9	Breast cancer;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08803129	chr18:33708920	SLC39A6;ELP2	-0.51	-6.64	-0.34	1.3e-10	Hepatitis;
LUSC	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg13798780	chr7:105162888	PUS7	0.6	6.46	0.33	3.61e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.83	0.35	4.07e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg14541582	chr5:601475	NA	-0.37	-5.65	-0.3	3.43e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg13453750	chr1:205783389	SLC41A1	-0.3	-5.86	-0.31	1.11e-8	Menarche (age at onset);
LUSC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.38	7.03	0.36	1.2e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg04944784	chr2:26401820	FAM59B	-0.72	-9.88	-0.48	2.35e-20	Gut microbiome composition (summer);
LUSC	cis	rs3770081	1.000	rs6750765	chr2:86300308	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.9	-6.46	-0.33	3.63e-10	Facial emotion recognition (sad faces);
LUSC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18099408	chr3:52552593	STAB1	-0.38	-6.17	-0.32	1.92e-9	Bipolar disorder;
LUSC	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19346786	chr7:2764209	NA	-0.45	-7.83	-0.39	6.53e-14	Height;
LUSC	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg24642439	chr20:33292090	TP53INP2	0.5	7.5	0.38	5.67e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs354225	0.554	rs10166844	chr2:54798272	T/C	cg26097391	chr2:54893211	SPTBN1	0.47	7.06	0.36	9.87e-12	Schizophrenia;
LUSC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg01879757	chr17:41196368	BRCA1	-0.49	-7.8	-0.39	8.11e-14	Menopause (age at onset);
LUSC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg11812906	chr14:75593930	NEK9	-0.63	-10.52	-0.5	1.56e-22	Height;
LUSC	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Fuchs's corneal dystrophy;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05225062	chr19:13227642	TRMT1;NACC1	-0.41	-6.05	-0.31	3.99e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7122539	0.506	rs11227625	chr11:66684151	T/G	cg24851651	chr11:66362959	CCS	0.45	7.73	0.39	1.24e-13	HIV-1 susceptibility;
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.57	-9.6	-0.47	1.97e-19	Lymphocyte counts;
LUSC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg00074818	chr8:8560427	CLDN23	0.57	9.71	0.47	8.22e-20	Obesity-related traits;
LUSC	cis	rs7075426	0.669	rs10887608	chr10:88191938	A/G	cg07322936	chr10:88137208	NA	-0.44	-6.2	-0.32	1.69e-9	Migraine without aura;
LUSC	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.56	10.39	0.49	4.42e-22	Bone mineral density;
LUSC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.15	-0.58	4.15e-32	Platelet count;
LUSC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	7.61	0.38	2.77e-13	Tonsillectomy;
LUSC	cis	rs243505	0.660	rs10274535	chr7:148543525	A/G	cg09806900	chr7:148480153	CUL1	0.48	6.4	0.33	5.15e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs593982	0.843	rs565267	chr11:65473597	T/C	cg08755490	chr11:65554678	OVOL1	1.52	12.84	0.57	6.01e-31	Atopic dermatitis;
LUSC	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	7.8	0.39	8.15e-14	Breast cancer;
LUSC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg22105103	chr4:187893119	NA	0.71	13.88	0.6	6.72e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9815354	1.000	rs9815354	chr3:41912651	G/A	cg03022575	chr3:42003672	ULK4	0.58	6.24	0.32	1.33e-9	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg22166914	chr1:53195759	ZYG11B	-0.55	-8.77	-0.43	9.2e-17	Monocyte count;
LUSC	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg01448562	chr3:133502909	NA	-0.51	-8.0	-0.4	2.09e-14	Iron status biomarkers (transferrin levels);
LUSC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	5.96e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg21724239	chr8:58056113	NA	0.78	9.03	0.44	1.43e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs12286929	0.515	rs6589486	chr11:115084297	T/C	cg04055981	chr11:115044050	NA	0.36	6.4	0.33	5.12e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs117623576	0.941	rs211424	chr10:32398895	A/G	cg03047570	chr10:32398778	NA	0.68	7.53	0.38	4.72e-13	Anti-saccade response;
LUSC	cis	rs68170813	0.617	rs76923959	chr7:107182915	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-8.63	-0.43	2.46e-16	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.67	0.39	1.88e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12410462	0.681	rs113316536	chr1:227547033	T/G	cg04117972	chr1:227635322	NA	0.6	6.68	0.34	1e-10	Major depressive disorder;
LUSC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg03161606	chr19:29218774	NA	0.6	8.89	0.44	4.03e-17	Methadone dose in opioid dependence;
LUSC	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg00520135	chr15:63333846	TPM1	0.35	5.89	0.31	9.56e-9	Platelet count;
LUSC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.53	8.5	0.42	6.2e-16	Calcium levels;
LUSC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg13560548	chr3:10150139	C3orf24	0.5	6.66	0.34	1.1e-10	Alzheimer's disease;
LUSC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.79	-10.17	-0.49	2.34e-21	Ankle injury;
LUSC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg13722127	chr7:150037890	RARRES2	0.38	5.68	0.3	3e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	5.85	0.3	1.15e-8	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35079168	0.809	rs11103483	chr9:137287874	G/A	cg13941235	chr9:137270186	RXRA	-0.32	-5.7	-0.3	2.66e-8	Intelligence;
LUSC	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg25801113	chr15:45476975	SHF	0.34	7.04	0.36	1.13e-11	Uric acid levels;
LUSC	trans	rs11700980	0.551	rs2832027	chr21:30114365	C/T	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg23711669	chr6:146136114	FBXO30	0.82	14.02	0.61	2e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05535760	chr7:792225	HEATR2	0.8	9.37	0.46	1.14e-18	Cerebrospinal P-tau181p levels;
LUSC	trans	rs629535	0.954	rs559245	chr8:70009238	T/A	cg21567404	chr3:27674614	NA	-0.86	-13.02	-0.58	1.24e-31	Dupuytren's disease;
LUSC	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg09537434	chr19:41945824	ATP5SL	-0.59	-7.82	-0.39	7.13e-14	Colorectal cancer;
LUSC	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg15309053	chr8:964076	NA	0.3	6.19	0.32	1.75e-9	Schizophrenia;
LUSC	cis	rs4474465	0.646	rs10751297	chr11:78278567	C/T	cg27205649	chr11:78285834	NARS2	0.54	6.7	0.34	8.92e-11	Alzheimer's disease (survival time);
LUSC	cis	rs965469	0.947	rs1854834	chr20:3376619	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-5.8	-0.3	1.53e-8	IFN-related cytopenia;
LUSC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.39e-12	Motion sickness;
LUSC	cis	rs7929679	0.551	rs11032840	chr11:34779464	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.83	0.3	1.32e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	6.2	0.32	1.63e-9	Calcium levels;
LUSC	cis	rs9517320	1.000	rs9584857	chr13:99128572	T/C	cg07423050	chr13:99094983	FARP1	0.34	6.32	0.33	8.56e-10	Longevity;
LUSC	cis	rs1981331	0.867	rs76188425	chr21:48002207	C/T	cg17243659	chr21:48055224	PRMT2	0.86	6.24	0.32	1.31e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	cis	rs9473147	0.516	rs9296561	chr6:47488938	G/A	cg12968598	chr6:47444699	CD2AP	0.53	7.97	0.4	2.49e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg08085267	chr17:45401833	C17orf57	0.53	8.54	0.42	4.97e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08645402	chr16:4508243	NA	0.48	8.09	0.4	1.11e-14	Schizophrenia;
LUSC	cis	rs66731853	0.557	rs576968	chr1:20901246	A/G	cg04087271	chr1:20915334	CDA	-0.5	-8.86	-0.44	4.77e-17	Mean corpuscular volume;
LUSC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.9	-0.35	2.62e-11	Total body bone mineral density;
LUSC	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg13798780	chr7:105162888	PUS7	0.58	6.26	0.32	1.21e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.7	-0.34	8.91e-11	Longevity;Endometriosis;
LUSC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg04025307	chr7:1156635	C7orf50	0.47	6.25	0.32	1.26e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg22823121	chr1:150693482	HORMAD1	0.57	8.85	0.44	5.08e-17	Tonsillectomy;
LUSC	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg04362960	chr10:104952993	NT5C2	-0.59	-9.38	-0.46	1.05e-18	Arsenic metabolism;
LUSC	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg13010199	chr12:38710504	ALG10B	0.44	6.59	0.34	1.7e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs62432291	0.614	rs452112	chr6:159658028	A/G	cg14500486	chr6:159655392	FNDC1	-0.52	-5.7	-0.3	2.67e-8	Joint mobility (Beighton score);
LUSC	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.23	-0.69	4.77e-48	Exhaled nitric oxide output;
LUSC	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg13010199	chr12:38710504	ALG10B	0.57	9.09	0.45	9.21e-18	Morning vs. evening chronotype;
LUSC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg23743428	chr13:21893420	NA	-0.44	-8.83	-0.44	5.93e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs11997175	1.000	rs6468201	chr8:33746854	G/C	ch.8.33884649F	chr8:33765107	NA	0.52	8.24	0.41	3.91e-15	Body mass index;
LUSC	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-9.59	-0.46	2.17e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg17650050	chr22:19419470	HIRA;MRPL40	0.74	6.02	0.31	4.6e-9	Cognitive performance;
LUSC	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg13010199	chr12:38710504	ALG10B	0.54	8.05	0.4	1.48e-14	Morning vs. evening chronotype;
LUSC	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg11057378	chr10:81107060	PPIF	0.35	5.96	0.31	6.33e-9	Height;
LUSC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Depression;
LUSC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg16339924	chr4:17578868	LAP3	0.55	8.38	0.42	1.46e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	trans	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg17675199	chr6:35436792	RPL10A	-0.42	-6.22	-0.32	1.5e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg08847533	chr14:75593920	NEK9	0.84	15.33	0.64	1.54e-40	Height;
LUSC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg16898833	chr6:26189333	HIST1H4D	0.62	5.84	0.3	1.24e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11971779	0.616	rs1862878	chr7:139019914	C/G	cg07862535	chr7:139043722	LUC7L2	0.55	6.81	0.35	4.45e-11	Diisocyanate-induced asthma;
LUSC	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg17691542	chr6:26056736	HIST1H1C	0.4	5.87	0.31	1.03e-8	Schizophrenia;
LUSC	cis	rs4363385	0.818	rs10888526	chr1:153000311	G/T	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.91	-0.4	3.94e-14	Inflammatory skin disease;
LUSC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.71	-16.49	-0.67	4.11e-45	Prostate cancer;
LUSC	trans	rs16848425	1.000	rs28631242	chr4:73526282	T/A	cg15289899	chr11:2397255	CD81	0.68	5.96	0.31	6.35e-9	Height;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.63	-12.91	-0.58	3.21e-31	Longevity;Endometriosis;
LUSC	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg16342193	chr10:102329863	NA	-0.33	-6.13	-0.32	2.54e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg24324837	chr19:49891574	CCDC155	0.5	6.41	0.33	5.07e-10	Multiple sclerosis;
LUSC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27286337	chr10:134555280	INPP5A	0.93	12.01	0.55	6.99e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.72	0.54	8.34e-27	Ileal carcinoids;
LUSC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg15605315	chr1:45957053	TESK2	-0.43	-6.81	-0.35	4.6e-11	High light scatter reticulocyte count;
LUSC	cis	rs3771570	1.000	rs62193256	chr2:242362168	C/T	cg21155796	chr2:242212141	HDLBP	0.62	6.69	0.34	9.6e-11	Prostate cancer;
LUSC	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg08999081	chr20:33150536	PIGU	0.55	10.8	0.51	1.66e-23	Coronary artery disease;
LUSC	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg06917634	chr15:78832804	PSMA4	0.47	5.78	0.3	1.68e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg25237894	chr2:233734115	C2orf82	-0.37	-6.92	-0.35	2.37e-11	Coronary artery disease;
LUSC	cis	rs1950500	0.585	rs8003339	chr14:24817817	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	0.56	8.9	0.44	3.58e-17	Height;
LUSC	cis	rs524023	0.957	rs552307	chr11:64357539	G/A	cg07220939	chr11:64358617	SLC22A12	0.23	6.0	0.31	5.01e-9	Urate levels in obese individuals;
LUSC	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	12.46	0.56	1.61e-29	Height;
LUSC	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.86	0.47	2.66e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.6	-9.47	-0.46	5.33e-19	Iron status biomarkers;
LUSC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg07741184	chr6:167504864	NA	0.49	8.55	0.42	4.42e-16	Rheumatoid arthritis;
LUSC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg25258033	chr6:167368657	RNASET2	0.36	5.66	0.3	3.2e-8	Primary biliary cholangitis;
LUSC	cis	rs752010	0.645	rs1109254	chr1:42091770	T/C	cg06885757	chr1:42089581	HIVEP3	0.62	12.79	0.57	9.53e-31	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.39	6.16	0.32	2.09e-9	Total body bone mineral density;
LUSC	cis	rs3820928	0.874	rs10199655	chr2:227892428	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.55	-0.38	4.32e-13	Pulmonary function;
LUSC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg02551604	chr5:131831745	NA	-0.4	-6.27	-0.32	1.1e-9	Asthma (sex interaction);
LUSC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg06145435	chr7:1022769	CYP2W1	0.35	5.77	0.3	1.82e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.79	0.72	2.92e-54	Chronic sinus infection;
LUSC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg11608241	chr8:8085544	FLJ10661	-0.4	-5.81	-0.3	1.44e-8	Mood instability;
LUSC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.74	-0.51	2.59e-23	Alzheimer's disease (late onset);
LUSC	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.67	-8.67	-0.43	1.96e-16	Schizophrenia;
LUSC	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.48	6.68	0.34	9.84e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs12618769	0.625	rs72819982	chr2:99043337	A/G	cg10123293	chr2:99228465	UNC50	0.46	7.64	0.39	2.27e-13	Bipolar disorder;
LUSC	cis	rs16937	0.711	rs11240382	chr1:205168569	A/G	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.36e-10	Schizophrenia;
LUSC	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.49	-0.33	3.02e-10	Dupuytren's disease;
LUSC	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg13010199	chr12:38710504	ALG10B	0.4	5.88	0.31	1.01e-8	Morning vs. evening chronotype;
LUSC	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg24375607	chr4:120327624	NA	0.78	11.52	0.53	4.39e-26	Corneal astigmatism;
LUSC	trans	rs1325195	0.537	rs2793808	chr1:179170249	T/C	cg11624085	chr17:8464688	MYH10	0.43	6.38	0.33	5.94e-10	IgE grass sensitization;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg16530077	chr14:50319734	SDCCAG1	0.46	6.51	0.34	2.84e-10	Triglycerides;
LUSC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.46	-7.13	-0.36	6.11e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg21724239	chr8:58056113	NA	0.57	6.55	0.34	2.18e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-8.33	-0.41	2.07e-15	Coronary artery disease;
LUSC	trans	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.13	-0.32	2.49e-9	Bladder cancer;
LUSC	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg09654669	chr8:57350985	NA	-0.58	-7.84	-0.39	5.98e-14	Obesity-related traits;
LUSC	cis	rs7103648	0.567	rs12287076	chr11:47606865	G/C	cg20307385	chr11:47447363	PSMC3	-0.81	-12.45	-0.56	1.71e-29	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs7605827	0.930	rs13004154	chr2:15664325	A/G	cg19274914	chr2:15703543	NA	0.47	8.76	0.43	9.81e-17	Educational attainment (years of education);
LUSC	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg21770322	chr7:97807741	LMTK2	0.55	9.73	0.47	7.22e-20	Breast cancer;
LUSC	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg26647111	chr11:31128758	NA	-0.41	-5.98	-0.31	5.75e-9	Red blood cell count;
LUSC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg10862848	chr6:42927986	GNMT	0.24	5.69	0.3	2.75e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.44	6.16	0.32	2.08e-9	Renal function-related traits (BUN);
LUSC	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg08975724	chr8:8085496	FLJ10661	0.52	7.36	0.37	1.48e-12	Retinal vascular caliber;
LUSC	cis	rs13088318	0.521	rs7374860	chr3:101223721	A/G	cg12386194	chr3:101231763	SENP7	0.38	5.77	0.3	1.82e-8	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg11247378	chr22:39784982	NA	-0.64	-11.76	-0.54	5.75e-27	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg25703541	chr22:24373054	LOC391322	-0.86	-13.14	-0.58	4.56e-32	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg15212455	chr7:39170539	POU6F2	0.68	11.64	0.54	1.63e-26	IgG glycosylation;
LUSC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg22907277	chr7:1156413	C7orf50	0.38	5.91	0.31	8.67e-9	Longevity;Endometriosis;
LUSC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg20243544	chr17:37824526	PNMT	0.39	6.02	0.31	4.54e-9	Self-reported allergy;
LUSC	cis	rs9393777	0.778	rs13212921	chr6:27205422	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.81	-0.3	1.49e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg04287289	chr16:89883240	FANCA	-0.5	-5.89	-0.31	9.66e-9	Skin aging (microtopography measurement);
LUSC	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg05340658	chr4:99064831	C4orf37	0.64	10.17	0.49	2.45e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg27494647	chr7:150038898	RARRES2	0.42	6.27	0.32	1.13e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.49	6.95	0.36	1.97e-11	Iron status biomarkers;
LUSC	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg08999081	chr20:33150536	PIGU	0.41	7.81	0.39	7.29e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs2303282	0.716	rs2587871	chr16:56412526	C/T	cg00500540	chr16:56394104	NA	0.45	7.88	0.4	4.68e-14	Breast cancer;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg09033563	chr22:24373618	LOC391322	-0.47	-6.59	-0.34	1.75e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-0.8	-9.73	-0.47	7.14e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg16342193	chr10:102329863	NA	-0.35	-6.32	-0.33	8.52e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg22852734	chr6:133119734	C6orf192	1.22	14.16	0.61	5.52e-36	Type 2 diabetes nephropathy;
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.34	-0.42	1.94e-15	Lymphocyte counts;
LUSC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg20406979	chr6:167373233	NA	0.25	5.96	0.31	6.39e-9	Crohn's disease;
LUSC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg12863693	chr15:85201151	NMB	0.34	6.82	0.35	4.26e-11	Schizophrenia;
LUSC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg26441486	chr22:50317300	CRELD2	0.48	7.1	0.36	7.5e-12	Schizophrenia;
LUSC	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg04733989	chr22:42467013	NAGA	0.63	9.82	0.47	3.7799999999999997e-20	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21953508	chr4:38690502	KLF3	0.41	6.08	0.32	3.25e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.09	-0.32	3.1e-9	Neuroticism;
LUSC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg24209194	chr3:40518798	ZNF619	0.47	6.51	0.34	2.72e-10	Renal cell carcinoma;
LUSC	trans	rs9693857	0.553	rs10100760	chr8:9370559	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.42	-0.33	4.71e-10	Systolic blood pressure;
LUSC	cis	rs2290405	0.527	rs935965	chr4:928684	T/C	cg04824913	chr4:887549	GAK	0.72	9.66	0.47	1.25e-19	Systemic sclerosis;
LUSC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg17739936	chr11:789930	CEND1	0.38	6.45	0.33	3.86e-10	Breast cancer;
LUSC	cis	rs617219	0.819	rs4704552	chr5:78580368	C/T	cg24856658	chr5:78533917	JMY	0.31	6.14	0.32	2.36e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.55	-10.81	-0.51	1.5e-23	Educational attainment;
LUSC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-7.54	-0.38	4.33e-13	Blood metabolite levels;
LUSC	trans	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg07923666	chr12:49932857	KCNH3	0.48	6.09	0.32	3.03e-9	Resting heart rate;
LUSC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg12501923	chr17:73937416	FBF1	0.46	8.17	0.41	6.58e-15	Triglycerides;
LUSC	cis	rs6942756	0.747	rs692432	chr7:129113287	G/A	cg02491457	chr7:128862824	NA	-0.4	-5.65	-0.3	3.4e-8	White matter hyperintensity burden;
LUSC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg16339924	chr4:17578868	LAP3	0.56	8.5	0.42	6.45e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.34	0.56	4.55e-29	Prudent dietary pattern;
LUSC	cis	rs10072221	0.966	rs11743541	chr5:75738858	A/G	cg03132911	chr5:75698732	IQGAP2	-0.35	-5.71	-0.3	2.55e-8	Mean platelet volume;
LUSC	cis	rs10189230	0.967	rs13012429	chr2:222350788	C/T	cg14652038	chr2:222343519	EPHA4	0.33	5.93	0.31	7.56e-9	Urate levels in lean individuals;
LUSC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg23649088	chr2:200775458	C2orf69	-0.58	-7.13	-0.36	6.36e-12	Schizophrenia;
LUSC	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-1.15	-18.16	-0.7	9.3e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.78	-13.29	-0.59	1.15e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4343996	0.692	rs1546742	chr7:3456210	C/A	cg21248987	chr7:3385318	SDK1	0.35	5.75	0.3	2.03e-8	Motion sickness;
LUSC	cis	rs4631830	0.869	rs7896437	chr10:51529593	A/C	cg20129853	chr10:51489980	NA	-0.33	-6.61	-0.34	1.55e-10	Prostate-specific antigen levels;
LUSC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg27432699	chr2:27873401	GPN1	0.62	9.39	0.46	9.98e-19	Total body bone mineral density;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg24476096	chr1:43855459	MED8;C1orf84	0.37	5.97	0.31	5.98e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs7202877	0.610	rs3784936	chr16:75337583	C/G	cg04384234	chr16:75411784	CFDP1	-0.6	-7.64	-0.39	2.37e-13	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg19230755	chr7:65878503	NA	-0.42	-5.93	-0.31	7.69e-9	Aortic root size;
LUSC	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-0.91	-16.24	-0.66	4.18e-44	Height;
LUSC	cis	rs4917300	0.626	rs1388796	chr8:143096437	A/G	cg25363559	chr8:143086065	NA	-0.31	-7.01	-0.36	1.35e-11	Amyotrophic lateral sclerosis;
LUSC	cis	rs6752107	0.500	rs11893210	chr2:234204672	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	8.12	0.41	9.29e-15	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs742614	0.576	rs2747537	chr20:32405217	A/G	cg06304546	chr20:32448765	NA	-0.38	-5.8	-0.3	1.51e-8	Stearic acid (18:0) levels;
LUSC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.7	-10.62	-0.5	7.05e-23	Aortic root size;
LUSC	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg04450456	chr4:17643702	FAM184B	0.37	6.39	0.33	5.7e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.62	-0.34	1.47e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.43	-0.38	9.21e-13	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-6.96	-0.36	1.84e-11	Bipolar disorder;
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.9	16.95	0.68	6.11e-47	Menarche (age at onset);
LUSC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.47	0.42	7.84e-16	Tonsillectomy;
LUSC	cis	rs7903847	0.620	rs61863815	chr10:99124389	A/G	cg20016023	chr10:99160130	RRP12	-0.34	-8.18	-0.41	5.86e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2279817	0.675	rs1416853	chr1:18024880	G/C	cg21791023	chr1:18019539	ARHGEF10L	0.5	7.27	0.37	2.55e-12	Neuroticism;
LUSC	cis	rs6754311	0.593	rs656326	chr2:136428460	A/C	cg07169764	chr2:136633963	MCM6	0.54	7.2	0.37	3.91e-12	Mosquito bite size;
LUSC	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.58	-7.84	-0.39	6.09e-14	Adiposity;
LUSC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.17	-0.32	2.01e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg06627628	chr2:24431161	ITSN2	-0.78	-10.77	-0.51	2.03e-23	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg05347473	chr6:146136440	FBXO30	0.41	6.84	0.35	3.78e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9807989	0.839	rs1362348	chr2:102984624	C/G	cg09003973	chr2:102972529	NA	0.42	5.7	0.3	2.65e-8	Asthma;
LUSC	cis	rs6500395	1.000	rs9922734	chr16:48603192	A/G	cg04672837	chr16:48644449	N4BP1	-0.43	-6.38	-0.33	5.94e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9815354	1.000	rs9873207	chr3:41884750	C/T	cg03022575	chr3:42003672	ULK4	0.64	7.02	0.36	1.21e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg26338869	chr17:61819248	STRADA	0.4	5.77	0.3	1.81e-8	Prudent dietary pattern;
LUSC	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg11502198	chr6:26597334	ABT1	0.57	8.43	0.42	1.07e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10463316	0.817	rs6897109	chr5:150777738	T/C	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.2	-0.37	3.95e-12	Metabolite levels (Pyroglutamine);
LUSC	trans	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.74	-0.35	7.03e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	0.92	18.09	0.7	1.86e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7809950	0.598	rs2283038	chr7:106835410	C/T	cg23024343	chr7:107201750	COG5	-0.62	-8.95	-0.44	2.5e-17	Coronary artery disease;
LUSC	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg05585544	chr11:47624801	NA	-0.33	-5.99	-0.31	5.29e-9	Subjective well-being;
LUSC	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	1.17	13.82	0.6	1.12e-34	Arsenic metabolism;
LUSC	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg04310649	chr10:35416472	CREM	-0.41	-6.22	-0.32	1.5e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7523050	0.730	rs7519107	chr1:109399367	A/C	cg08274380	chr1:109419600	GPSM2	1.1	10.62	0.5	6.89e-23	Fat distribution (HIV);
LUSC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg18827107	chr12:86230957	RASSF9	0.46	6.96	0.36	1.86e-11	Major depressive disorder;
LUSC	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg06360820	chr2:242988706	NA	-0.85	-10.14	-0.49	3.06e-21	Obesity-related traits;
LUSC	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg24088639	chr11:34937564	PDHX;APIP	0.46	6.75	0.35	6.47e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	trans	rs2468186	0.903	rs2468184	chr8:120197863	A/G	cg15910414	chr5:137879246	ETF1	-0.42	-5.96	-0.31	6.28e-9	Osteoprotegerin levels;
LUSC	cis	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg01251360	chr16:68772225	CDH1	-0.27	-6.24	-0.32	1.34e-9	Colorectal cancer;
LUSC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg22437258	chr11:111473054	SIK2	0.52	7.44	0.38	8.76e-13	Primary sclerosing cholangitis;
LUSC	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg09491104	chr22:46646882	C22orf40	-0.61	-8.62	-0.43	2.7e-16	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg00599273	chr12:58146742	CDK4	0.3	5.71	0.3	2.48e-8	Multiple sclerosis;
LUSC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.64	11.09	0.52	1.51e-24	Aortic root size;
LUSC	cis	rs12681287	0.547	rs60982560	chr8:87515046	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.35	-0.37	1.52e-12	Caudate activity during reward;
LUSC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-1.24	-13.99	-0.61	2.59e-35	Diabetic kidney disease;
LUSC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.21	-0.37	3.87e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg12002119	chr2:101014098	CHST10	0.36	5.94	0.31	7.24e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03878208	chr11:72483293	STARD10	0.5	5.76	0.3	1.94e-8	Type 2 diabetes;
LUSC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.35	-5.81	-0.3	1.49e-8	Total body bone mineral density;
LUSC	trans	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg06606381	chr12:133084897	FBRSL1	-0.97	-9.13	-0.45	6.87e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4363385	0.818	rs6661791	chr1:152994113	G/A	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.5	-0.38	5.84e-13	Inflammatory skin disease;
LUSC	cis	rs10876993	0.622	rs7978394	chr12:58091695	C/A	cg15848620	chr12:58087721	OS9	-0.57	-8.16	-0.41	6.96e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.43	6.63	0.34	1.38e-10	Dupuytren's disease;
LUSC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.94	-19.32	-0.73	2.36e-56	Post bronchodilator FEV1;
LUSC	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg06636001	chr8:8085503	FLJ10661	0.52	7.28	0.37	2.45e-12	Neuroticism;
LUSC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg05347473	chr6:146136440	FBXO30	0.56	9.62	0.47	1.66e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg06521331	chr12:34319734	NA	-0.41	-6.52	-0.34	2.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.69	10.13	0.48	3.34e-21	IgG glycosylation;
LUSC	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.5	6.98	0.36	1.64e-11	Corneal astigmatism;
LUSC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-9.47	-0.46	5.1e-19	Longevity;Endometriosis;
LUSC	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg12292205	chr6:26970375	C6orf41	-0.5	-8.19	-0.41	5.49e-15	Schizophrenia;
LUSC	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg18825076	chr15:78729989	IREB2	-0.5	-7.86	-0.4	5.24e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs7264396	1.000	rs224429	chr20:34152018	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.51	-0.38	5.32e-13	Total cholesterol levels;
LUSC	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.54	-0.34	2.27e-10	Retinal vascular caliber;
LUSC	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	7.05	0.36	1.05e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	cis	rs17255340	0.539	rs1170514	chr6:84009042	T/C	cg08257003	chr6:84140564	ME1	0.32	7.8	0.39	7.87e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg06637938	chr14:75390232	RPS6KL1	0.65	10.91	0.51	6.45e-24	Caffeine consumption;
LUSC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg26677194	chr12:130822605	PIWIL1	0.56	8.41	0.42	1.21e-15	Menopause (age at onset);
LUSC	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg04398451	chr17:18023971	MYO15A	-0.44	-6.92	-0.35	2.29e-11	Total body bone mineral density;
LUSC	cis	rs7809950	0.862	rs58391518	chr7:107030787	T/C	cg23024343	chr7:107201750	COG5	-0.54	-8.39	-0.42	1.38e-15	Coronary artery disease;
LUSC	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg14582100	chr15:45693742	SPATA5L1	0.46	8.66	0.43	2.11e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.9	0.48	2e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7809950	0.906	rs2253269	chr7:107201114	C/T	cg23024343	chr7:107201750	COG5	-0.56	-8.76	-0.43	9.82e-17	Coronary artery disease;
LUSC	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.14	-0.32	2.35e-9	Coronary artery disease;
LUSC	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg05738196	chr6:26577821	NA	-0.49	-6.94	-0.36	2.01e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.93	14.88	0.63	9.31e-39	Multiple sclerosis;
LUSC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg12463550	chr7:65579703	CRCP	0.42	5.96	0.31	6.27e-9	Aortic root size;
LUSC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg02951883	chr7:2050386	MAD1L1	-0.45	-7.89	-0.4	4.47e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	8.64	0.43	2.34e-16	Bipolar disorder;
LUSC	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.12	0.32	2.58e-9	Rheumatoid arthritis;
LUSC	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg25173405	chr17:45401733	C17orf57	-0.41	-6.58	-0.34	1.82e-10	Multiple sclerosis;Ankylosing spondylitis;
LUSC	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg12935359	chr14:103987150	CKB	-0.57	-8.56	-0.42	4.26e-16	Body mass index;
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.53	-8.11	-0.41	9.51e-15	Lymphocyte counts;
LUSC	trans	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg06521331	chr12:34319734	NA	-0.39	-6.26	-0.32	1.18e-9	Bladder cancer;
LUSC	trans	rs2834485	1.000	rs5010906	chr21:35818590	G/C	cg07474852	chr4:123073612	NA	0.45	6.63	0.34	1.38e-10	Cancer;
LUSC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	7.27	0.37	2.61e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg03209412	chr4:183728196	NA	0.47	7.81	0.39	7.26e-14	Pediatric autoimmune diseases;
LUSC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg02428538	chr16:24856791	SLC5A11	-0.55	-6.31	-0.33	8.98e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg09904177	chr6:26538194	HMGN4	0.47	7.48	0.38	6.8e-13	Schizophrenia;
LUSC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg19774624	chr17:42201019	HDAC5	0.71	10.39	0.49	4.28e-22	Total body bone mineral density;
LUSC	trans	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.99	-0.31	5.47e-9	Dementia with Lewy bodies;
LUSC	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg05738196	chr6:26577821	NA	0.78	14.95	0.63	4.82e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg21466736	chr12:48725269	NA	-0.33	-5.75	-0.3	2.06e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-7.78	-0.39	9.39e-14	Menarche (age at onset);
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg21522636	chr3:50374980	RASSF1	0.44	6.23	0.32	1.39e-9	Calcium levels;
LUSC	cis	rs6445967	0.530	rs62258104	chr3:58379984	G/C	cg23715586	chr3:58305044	RPP14	0.46	7.78	0.39	9.39e-14	Platelet count;
LUSC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg00431813	chr7:1051703	C7orf50	-0.48	-8.19	-0.41	5.51e-15	Longevity;Endometriosis;
LUSC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg11247378	chr22:39784982	NA	0.66	13.49	0.59	2.09e-33	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg26597838	chr10:835615	NA	0.83	11.57	0.54	2.8e-26	Eosinophil percentage of granulocytes;
LUSC	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg20991723	chr1:152506922	NA	0.53	9.87	0.48	2.55e-20	Plantar warts;
LUSC	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg04586622	chr2:25135609	ADCY3	0.39	8.09	0.4	1.11e-14	Body mass index in non-asthmatics;
LUSC	cis	rs7904985	1.000	rs12777097	chr10:88115638	G/A	cg07322936	chr10:88137208	NA	-0.58	-7.41	-0.38	1.02e-12	Barrett's esophagus;
LUSC	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.46	-6.37	-0.33	6.33e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.94e-12	Blood metabolite levels;
LUSC	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	14.92	0.63	6.44e-39	Exhaled nitric oxide output;
LUSC	cis	rs7903847	0.642	rs4635018	chr10:99137839	C/G	cg08345082	chr10:99160200	RRP12	0.37	7.09	0.36	7.82e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg06092702	chr1:163392909	NA	-0.35	-5.94	-0.31	7e-9	Motion sickness;
LUSC	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg19743168	chr1:23544995	NA	0.47	10.3	0.49	8.8e-22	Height;
LUSC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg13393036	chr8:95962371	TP53INP1	-0.41	-8.51	-0.42	6.15e-16	Type 2 diabetes;
LUSC	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg09835421	chr16:68378352	PRMT7	-0.54	-6.12	-0.32	2.56e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7580658	0.724	rs7568261	chr2:128117324	C/T	cg09760422	chr2:128146352	NA	-0.27	-5.86	-0.31	1.08e-8	Protein C levels;
LUSC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	1.03	21.0	0.75	5.38e-63	Cognitive function;
LUSC	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg18209359	chr17:80159595	CCDC57	0.38	6.36	0.33	6.61e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg22705602	chr4:152727874	NA	0.36	7.69	0.39	1.63e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs240764	0.669	rs846800	chr6:101270498	C/G	cg09795085	chr6:101329169	ASCC3	0.43	6.32	0.33	8.46e-10	Neuroticism;
LUSC	cis	rs868036	0.681	rs28376010	chr15:68063739	G/T	cg05925327	chr15:68127851	NA	-0.43	-6.71	-0.34	8.36e-11	Restless legs syndrome;
LUSC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18404041	chr3:52824283	ITIH1	-0.64	-12.53	-0.57	8.86e-30	Bipolar disorder;
LUSC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg08499158	chr17:42289980	UBTF	-0.38	-6.12	-0.32	2.69e-9	Total body bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14950855	chr12:49740781	DNAJC22	-0.42	-6.2	-0.32	1.69e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17125944	0.686	rs73304351	chr14:53375140	G/A	cg00686598	chr14:53173677	PSMC6	0.82	7.14	0.36	6.05e-12	Alzheimer's disease (late onset);
LUSC	cis	rs12101261	0.580	rs8003515	chr14:81446242	G/C	cg06600135	chr14:81408086	NA	0.46	7.11	0.36	6.96e-12	Graves' disease;
LUSC	cis	rs7408868	1.000	rs10418305	chr19:15278808	C/G	cg14696996	chr19:15285081	NOTCH3	0.97	9.33	0.45	1.56e-18	Pulse pressure;
LUSC	cis	rs62400317	0.859	rs10948220	chr6:45236654	A/G	cg18551225	chr6:44695536	NA	-0.44	-7.28	-0.37	2.46e-12	Total body bone mineral density;
LUSC	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg21951975	chr1:209979733	IRF6	-0.58	-7.07	-0.36	9.28e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs9479482	0.686	rs2010259	chr6:150385475	C/T	cg25797454	chr6:150327115	RAET1K	0.33	7.19	0.37	4.22e-12	Alopecia areata;
LUSC	cis	rs6740322	0.895	rs6744746	chr2:43555805	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.53	7.62	0.38	2.67e-13	Coronary artery disease;
LUSC	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg17120908	chr11:65337727	SSSCA1	-0.54	-9.25	-0.45	2.82e-18	Bone mineral density;
LUSC	cis	rs6700896	0.500	rs66728245	chr1:66127710	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.93	0.31	7.6e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg20608306	chr11:116969690	SIK3	0.36	6.78	0.35	5.58e-11	Blood protein levels;
LUSC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg03060546	chr3:49711283	APEH	0.71	12.08	0.55	4.16e-28	Resting heart rate;
LUSC	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg16482183	chr6:26056742	HIST1H1C	0.65	9.13	0.45	6.68e-18	Iron status biomarkers;
LUSC	cis	rs3784262	1.000	rs4646593	chr15:58302467	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.04	-0.31	4.18e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs7113850	0.541	rs2896686	chr11:24213156	G/A	ch.11.24196551F	chr11:24239977	NA	0.92	7.82	0.39	6.77e-14	Bone fracture in osteoporosis;
LUSC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg09796270	chr17:17721594	SREBF1	0.33	5.66	0.3	3.25e-8	Total body bone mineral density;
LUSC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.65	-0.47	1.32e-19	Bipolar disorder;
LUSC	cis	rs12367572	1.000	rs12822444	chr12:45276677	G/A	cg04608330	chr12:45269318	NELL2	-0.58	-9.24	-0.45	2.85e-18	Gut microbiome composition (summer);
LUSC	cis	rs12986413	1.000	rs4807208	chr19:2170205	A/C	cg09261902	chr19:2140048	AP3D1	0.31	5.99	0.31	5.38e-9	Height;
LUSC	trans	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg07393940	chr7:158741817	NA	-0.37	-6.68	-0.34	1.02e-10	Life satisfaction;
LUSC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg04455712	chr21:45112962	RRP1B	0.43	8.14	0.41	8.09e-15	Mean corpuscular volume;
LUSC	cis	rs7539542	0.600	rs9943282	chr1:202895140	C/T	cg19681188	chr1:202830198	LOC148709	0.4	5.91	0.31	8.37e-9	Mean platelet volume;
LUSC	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg23625390	chr15:77176239	SCAPER	0.51	7.85	0.39	5.7e-14	Blood metabolite levels;
LUSC	trans	rs8073060	0.586	rs17638867	chr17:34052513	C/T	cg19694781	chr19:47549865	TMEM160	1.13	18.01	0.7	3.64e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs61931739	0.570	rs7315655	chr12:33912869	G/A	cg13010199	chr12:38710504	ALG10B	0.41	6.12	0.32	2.65e-9	Morning vs. evening chronotype;
LUSC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg11752832	chr7:134001865	SLC35B4	0.56	8.68	0.43	1.72e-16	Mean platelet volume;
LUSC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg09365446	chr1:150670422	GOLPH3L	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.51	7.73	0.39	1.27e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2625529	0.818	rs16956241	chr15:72111688	G/T	cg16672083	chr15:72433130	SENP8	-0.52	-7.36	-0.37	1.48e-12	Red blood cell count;
LUSC	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg21344124	chr8:22857393	RHOBTB2	0.39	5.99	0.31	5.38e-9	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.98	-16.19	-0.66	6.36e-44	Coronary artery disease;
LUSC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg26338869	chr17:61819248	STRADA	0.41	5.94	0.31	7.15e-9	Prudent dietary pattern;
LUSC	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.07	-22.54	-0.78	4.9e-69	Ulcerative colitis;
LUSC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg07741184	chr6:167504864	NA	0.36	6.65	0.34	1.22e-10	Crohn's disease;
LUSC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg15445000	chr17:37608096	MED1	-0.38	-6.46	-0.33	3.79e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs75804782	0.521	rs72993074	chr2:239413582	T/G	cg18131467	chr2:239335373	ASB1	-0.68	-6.29	-0.33	9.76e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7586879	0.789	rs13428763	chr2:25132855	T/G	cg01884057	chr2:25150051	NA	0.42	8.58	0.43	3.58e-16	Body mass index;
LUSC	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg01028140	chr2:1542097	TPO	-0.37	-6.08	-0.32	3.19e-9	IgG glycosylation;
LUSC	cis	rs9815354	0.812	rs17217746	chr3:41926021	A/G	cg03022575	chr3:42003672	ULK4	0.83	8.88	0.44	4.32e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	0.98	13.46	0.59	2.8e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs13401104	0.796	rs60159414	chr2:237119178	T/C	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.59	0.34	1.69e-10	Height;
LUSC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg04455712	chr21:45112962	RRP1B	0.47	8.96	0.44	2.42e-17	Mean corpuscular volume;
LUSC	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg05973401	chr12:123451056	ABCB9	0.52	6.45	0.33	4.04e-10	Neutrophil percentage of white cells;
LUSC	cis	rs28655083	0.529	rs662101	chr16:77105405	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.43	-7.02	-0.36	1.25e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.86	0.51	9.54e-24	Monocyte percentage of white cells;
LUSC	cis	rs7267979	0.565	rs3752273	chr20:25594783	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-12.99	-0.58	1.65e-31	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10035607	chr16:30366449	CD2BP2	0.41	6.86	0.35	3.39e-11	Triglycerides;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25367318	chr6:138725211	HEBP2	0.43	6.23	0.32	1.4e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2742234	0.590	rs1254960	chr10:43699657	C/T	cg15436174	chr10:43711423	RASGEF1A	0.43	6.99	0.36	1.53e-11	Hirschsprung disease;
LUSC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.71	-10.02	-0.48	7.57e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg04455712	chr21:45112962	RRP1B	0.5	9.47	0.46	5.26e-19	Mean corpuscular volume;
LUSC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg17143192	chr8:8559678	CLDN23	0.59	8.48	0.42	7.54e-16	Obesity-related traits;
LUSC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-8.26	-0.41	3.41e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.93	15.97	0.66	4.9e-43	Morning vs. evening chronotype;
LUSC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg09796270	chr17:17721594	SREBF1	0.43	7.6	0.38	2.97e-13	Total body bone mineral density;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02351056	chr10:126480372	METTL10	-0.45	-6.76	-0.35	6.27e-11	Electrocardiographic conduction measures;
LUSC	cis	rs548987	0.529	rs651578	chr6:25873883	T/C	cg03517284	chr6:25882590	NA	-0.39	-5.84	-0.3	1.21e-8	Homocysteine levels;
LUSC	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg12091567	chr17:66097778	LOC651250	-0.75	-9.35	-0.46	1.27e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs6961069	0.806	rs4728183	chr7:80256003	A/G	cg04458919	chr7:80252533	CD36	0.37	6.67	0.34	1.08e-10	Platelet count;
LUSC	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	18.97	0.72	5.86e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg17691542	chr6:26056736	HIST1H1C	0.47	7.04	0.36	1.11e-11	Height;
LUSC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21545522	chr1:205238299	TMCC2	0.52	9.92	0.48	1.63e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg12463550	chr7:65579703	CRCP	0.57	8.52	0.42	5.51e-16	Aortic root size;
LUSC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06850241	chr22:41845214	NA	-0.31	-5.7	-0.3	2.7e-8	Vitiligo;
LUSC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg03676636	chr4:99064102	C4orf37	0.36	7.82	0.39	6.87e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7833986	1.000	rs13273123	chr8:57100791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	-0.58	-8.67	-0.43	1.87e-16	Height;
LUSC	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	10.02	0.48	7.9e-21	Lymphocyte counts;
LUSC	cis	rs7129556	0.520	rs7943742	chr11:77268856	C/T	cg12586386	chr11:77299805	AQP11	0.23	5.71	0.3	2.49e-8	Weight loss (gastric bypass surgery);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04215179	chr7:23719682	C7orf46	-0.45	-5.99	-0.31	5.3300000000000004e-09	Bipolar disorder and schizophrenia;
LUSC	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg21231944	chr12:82153410	PPFIA2	-0.41	-6.2	-0.32	1.68e-9	Resting heart rate;
LUSC	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.67	-0.47	1.16e-19	Morning vs. evening chronotype;
LUSC	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	9.54	0.46	3.12e-19	Response to antipsychotic treatment;
LUSC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg07930552	chr6:133119739	C6orf192	0.77	9.86	0.47	2.67e-20	Type 2 diabetes nephropathy;
LUSC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg16624210	chr5:671434	TPPP	0.5	6.52	0.34	2.56e-10	Obesity-related traits;
LUSC	cis	rs6541297	0.555	rs910502	chr1:230294185	A/T	cg20703242	chr1:230279135	GALNT2	0.51	5.66	0.3	3.34e-8	Coronary artery disease;
LUSC	cis	rs977987	0.806	rs4993970	chr16:75411619	G/A	cg04384234	chr16:75411784	CFDP1	-0.44	-7.28	-0.37	2.4e-12	Dupuytren's disease;
LUSC	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg00484396	chr16:3507460	NAT15	0.46	6.58	0.34	1.86e-10	Body mass index (adult);
LUSC	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg23202291	chr11:1979235	NA	0.4	6.14	0.32	2.31e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg06552810	chr11:31128660	NA	-0.41	-7.14	-0.36	5.86e-12	Red blood cell count;
LUSC	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.67	-0.34	1.06e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	1.53	13.68	0.6	3.88e-34	Atopic dermatitis;
LUSC	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg17252645	chr8:143867129	LY6D	0.38	6.67	0.34	1.06e-10	Urinary tract infection frequency;
LUSC	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg02569458	chr12:86230093	RASSF9	0.42	6.71	0.34	8.27e-11	Major depressive disorder;
LUSC	cis	rs7705502	1.000	rs17694791	chr5:173326891	C/T	cg18693985	chr5:173351052	CPEB4	-0.37	-5.85	-0.3	1.19e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.66	11.26	0.52	3.78e-25	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2816062	0.786	rs742486	chr1:18900829	G/A	cg18795169	chr1:18902165	NA	-1.0	-23.38	-0.79	2.57e-72	Urate levels in lean individuals;
LUSC	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	10.16	0.49	2.64e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs12210905	0.925	rs17345718	chr6:26964258	A/G	cg11837749	chr1:55047332	ACOT11	0.57	6.09	0.32	3.07e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs6692729	0.965	rs1289395	chr1:227042462	T/C	cg10327440	chr1:227177885	CDC42BPA	0.48	6.77	0.35	5.84e-11	Electrodermal activity;
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.37	5.75	0.3	1.99e-8	Lymphocyte counts;
LUSC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05165339	chr4:1420672	NA	-0.3	-6.74	-0.35	7.03e-11	Longevity;
LUSC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-1.08	-19.9	-0.74	1.14e-58	Coronary artery disease;
LUSC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg00599273	chr12:58146742	CDK4	0.31	5.81	0.3	1.48e-8	Multiple sclerosis;
LUSC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	27.97	0.84	1.54e-89	Chronic sinus infection;
LUSC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg05347473	chr6:146136440	FBXO30	0.38	6.37	0.33	6.3e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10761482	0.861	rs10821728	chr10:62099135	T/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.11	-0.36	7.07e-12	Schizophrenia;
LUSC	cis	rs11958404	0.932	rs56204919	chr5:157431084	C/T	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	9.91e-22	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9951602	0.920	rs28639710	chr18:76679847	G/A	cg02800362	chr5:177631904	HNRNPAB	0.79	8.72	0.43	1.37e-16	Obesity-related traits;
LUSC	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg22618164	chr12:122356400	WDR66	0.62	9.01	0.44	1.63e-17	Mean corpuscular volume;
LUSC	trans	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg26043149	chr18:55253948	FECH	0.48	7.38	0.37	1.3e-12	Bone mineral density;
LUSC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg00800038	chr16:89945340	TCF25	-0.75	-6.58	-0.34	1.83e-10	Skin colour saturation;
LUSC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg05738196	chr6:26577821	NA	0.82	15.84	0.66	1.48e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg07701084	chr6:150067640	NUP43	0.58	9.09	0.45	9.32e-18	Lung cancer;
LUSC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-7.77	-0.39	9.65e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg23601095	chr6:26197514	HIST1H3D	0.51	6.02	0.31	4.55e-9	Gout;Renal underexcretion gout;
LUSC	cis	rs1107366	0.722	rs1992855	chr3:125909669	C/T	cg01346077	chr3:125931526	NA	-0.33	-6.37	-0.33	6.17e-10	Metabolite levels;
LUSC	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs9929218	0.954	rs12596834	chr16:68823199	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.09	-0.52	1.52e-24	Colorectal cancer;
LUSC	trans	rs1973993	0.544	rs2800427	chr1:97002766	A/C	cg10631902	chr5:14652156	NA	0.47	7.53	0.38	4.85e-13	Weight;
LUSC	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.9	-0.4	4.1e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg26162295	chr17:38119207	GSDMA	-0.24	-5.68	-0.3	2.95e-8	Self-reported allergy;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg18595293	chr21:44527201	U2AF1	0.5	6.1	0.32	2.86e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg24642439	chr20:33292090	TP53INP2	-0.48	-7.11	-0.36	7.2e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs6426558	0.537	rs4500279	chr1:227484482	G/A	cg10327440	chr1:227177885	CDC42BPA	0.55	7.59	0.38	3.1400000000000003e-13	Neutrophil percentage of white cells;
LUSC	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg00495681	chr13:53174319	NA	-0.54	-8.67	-0.43	1.89e-16	Lewy body disease;
LUSC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.16	0.36	5.14e-12	Hip circumference adjusted for BMI;
LUSC	trans	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg18230493	chr5:56204884	C5orf35	-0.58	-9.07	-0.44	1.06e-17	Breast cancer;Breast cancer (early onset);
LUSC	trans	rs10817971	0.503	rs10817967	chr9:119712401	C/T	cg20710266	chr15:96877855	NR2F2	0.35	5.99	0.31	5.32e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg13010199	chr12:38710504	ALG10B	0.42	6.12	0.32	2.66e-9	Morning vs. evening chronotype;
LUSC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14969806	chr1:5919854	NA	0.44	6.88	0.35	2.93e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7939886	0.920	rs74707325	chr11:56005562	T/A	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg09033563	chr22:24373618	LOC391322	-0.48	-6.47	-0.33	3.45e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	5.9	0.31	8.85e-9	Neutrophil percentage of white cells;
LUSC	cis	rs6906287	0.647	rs2356183	chr6:118770264	A/G	cg21191810	chr6:118973309	C6orf204	0.33	6.0	0.31	5.17e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2273669	0.667	rs12214567	chr6:109317330	C/T	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg13647721	chr17:30228624	UTP6	0.64	6.9	0.35	2.68e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs12144044	0.701	rs2999159	chr1:113230758	A/G	cg22162597	chr1:113214053	CAPZA1	-0.67	-7.77	-0.39	9.86e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	12.01	0.55	7.35e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	1.11	19.03	0.72	3.14e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg11941060	chr3:133502564	NA	-0.43	-6.19	-0.32	1.75e-9	Iron status biomarkers;
LUSC	cis	rs116988415	0.584	rs17767466	chr14:65252095	G/T	cg25083366	chr14:65239357	SPTB	0.66	6.82	0.35	4.17e-11	Daytime sleep phenotypes;
LUSC	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg26395211	chr5:140044315	WDR55	-0.37	-5.72	-0.3	2.37e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg21427119	chr20:30132790	HM13	-0.43	-6.15	-0.32	2.26e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.56	-0.6	1.12e-33	Chronic sinus infection;
LUSC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.61	-0.57	4.37e-30	Chronic sinus infection;
LUSC	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.67	-9.75	-0.47	6.1e-20	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg01802117	chr1:53393560	SCP2	-0.37	-6.02	-0.31	4.52e-9	Monocyte count;
LUSC	cis	rs4460629	0.521	rs7367897	chr1:155083289	A/T	cg23973274	chr1:155060172	NA	-0.31	-6.24	-0.32	1.36e-9	Serum magnesium levels;
LUSC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg08975724	chr8:8085496	FLJ10661	0.41	6.11	0.32	2.8e-9	Joint mobility (Beighton score);
LUSC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18932078	chr1:2524107	MMEL1	-0.33	-7.21	-0.37	3.83e-12	Ulcerative colitis;
LUSC	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg20587970	chr11:113659929	NA	-0.75	-9.69	-0.47	9.73e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	10.3	0.49	8.56e-22	Ileal carcinoids;
LUSC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg14004847	chr7:1930337	MAD1L1	-0.47	-6.95	-0.36	1.93e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg19694781	chr19:47549865	TMEM160	-0.4	-6.41	-0.33	5e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg03886242	chr7:26192032	NFE2L3	-0.36	-5.98	-0.31	5.69e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	8.0	0.4	2.01e-14	Bipolar disorder;
LUSC	cis	rs2742234	0.541	rs1254959	chr10:43700979	C/G	cg15436174	chr10:43711423	RASGEF1A	0.43	6.99	0.36	1.53e-11	Hirschsprung disease;
LUSC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.23e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg12463550	chr7:65579703	CRCP	0.43	6.39	0.33	5.64e-10	Aortic root size;
LUSC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg19230755	chr7:65878503	NA	0.41	5.8	0.3	1.58e-8	Aortic root size;
LUSC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg10117171	chr1:25599238	RHD	-0.41	-6.27	-0.32	1.14e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs9810089	1.000	rs1279831	chr3:135933264	A/G	cg12473912	chr3:136751656	NA	0.33	5.65	0.3	3.45e-8	Gestational age at birth (child effect);
LUSC	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg15839431	chr19:19639596	YJEFN3	0.6	6.75	0.35	6.71e-11	Bipolar disorder;
LUSC	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg16576597	chr16:28551801	NUPR1	0.32	6.53	0.34	2.49e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7106204	0.609	rs12788438	chr11:24284068	G/T	ch.11.24196551F	chr11:24239977	NA	0.72	6.04	0.31	4.08e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24110177	chr3:50126178	RBM5	0.66	11.39	0.53	1.28e-25	Body mass index;
LUSC	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.48	10.12	0.48	3.59e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06634786	chr22:41940651	POLR3H	0.47	5.69	0.3	2.71e-8	Vitiligo;
LUSC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.36	-0.33	6.51e-10	Total body bone mineral density;
LUSC	trans	rs62344088	1.000	rs10037843	chr5:120078	G/C	cg11454300	chr2:2256402	MYT1L	0.75	6.03	0.31	4.27e-9	Asthma (childhood onset);
LUSC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.78	-0.43	8.66e-17	Monocyte count;
LUSC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg06238570	chr21:40685208	BRWD1	0.5	7.62	0.38	2.65e-13	Cognitive function;
LUSC	cis	rs4704187	0.687	rs4703657	chr5:74461850	T/G	cg03227963	chr5:74354835	NA	0.32	6.93	0.35	2.21e-11	Response to amphetamines;
LUSC	trans	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	8.49	0.42	7.03e-16	Type 2 diabetes;
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	1.01	22.07	0.77	3.27e-67	Menarche (age at onset);
LUSC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg03233332	chr7:66118400	NA	0.42	6.09	0.32	3.02e-9	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13826709	chr21:46708041	POFUT2;LOC642852	-0.45	-6.74	-0.35	6.82e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2018683	0.700	rs13227954	chr7:29017188	A/C	cg19402173	chr7:128379420	CALU	0.48	7.68	0.39	1.78e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.55	-7.72	-0.39	1.4e-13	Iron status biomarkers;
LUSC	cis	rs3740713	1.000	rs73440636	chr11:18473556	C/T	cg07915343	chr11:18477680	LDHAL6A	-0.56	-7.08	-0.36	8.47e-12	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg05110241	chr16:68378359	PRMT7	-0.58	-6.62	-0.34	1.41e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg01097406	chr16:89675127	NA	-0.32	-5.96	-0.31	6.24e-9	Vitiligo;
LUSC	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg13072238	chr3:49761600	GMPPB	0.68	8.82	0.43	6.64e-17	Menarche (age at onset);
LUSC	cis	rs7607369	0.536	rs12623740	chr2:219665715	T/A	cg02176678	chr2:219576539	TTLL4	-0.51	-8.91	-0.44	3.38e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs4589502	0.925	rs57729347	chr15:67136438	G/A	cg09911534	chr15:67153556	NA	-0.5	-6.37	-0.33	6.3e-10	Lung cancer (smoking interaction);
LUSC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.64	8.85	0.44	5.22e-17	High light scatter reticulocyte count;
LUSC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg07061783	chr6:25882402	NA	-0.37	-5.78	-0.3	1.69e-8	Blood metabolite levels;
LUSC	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg11247378	chr22:39784982	NA	-0.52	-7.61	-0.38	2.78e-13	IgG glycosylation;
LUSC	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg17366294	chr4:99064904	C4orf37	0.51	8.78	0.43	8.8e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11644478	chr21:40555479	PSMG1	-0.59	-9.3	-0.45	1.91e-18	Menarche (age at onset);
LUSC	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.34	0.67	1.6e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12681287	0.640	rs13269259	chr8:87470453	G/A	cg27223183	chr8:87520930	FAM82B	-0.54	-7.45	-0.38	7.92e-13	Caudate activity during reward;
LUSC	cis	rs3099143	1.000	rs2011635	chr15:77134891	T/A	cg21673338	chr15:77095150	SCAPER	-0.78	-7.26	-0.37	2.77e-12	Recalcitrant atopic dermatitis;
LUSC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	1.05	18.84	0.72	1.88e-54	Parkinson's disease;
LUSC	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg24558204	chr6:135376177	HBS1L	0.57	8.56	0.42	4.24e-16	Red blood cell count;
LUSC	trans	rs17112190	1.000	rs112476011	chr10:98558276	C/A	cg05472874	chr22:44258179	SULT4A1	0.71	6.29	0.33	9.79e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.1	-0.32	2.98e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7809950	1.000	rs2712200	chr7:107142435	G/T	cg23024343	chr7:107201750	COG5	-0.55	-8.73	-0.43	1.27e-16	Coronary artery disease;
LUSC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.13	0.36	6.07e-12	Bipolar disorder;
LUSC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg05802129	chr4:122689817	NA	-0.52	-8.67	-0.43	1.96e-16	Type 2 diabetes;
LUSC	cis	rs9807841	0.568	rs3859514	chr19:10748820	T/C	cg09936142	chr19:10668400	KRI1	-0.4	-6.34	-0.33	7.33e-10	Inflammatory skin disease;
LUSC	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg23029597	chr12:123009494	RSRC2	-0.74	-9.33	-0.45	1.52e-18	Body mass index;
LUSC	cis	rs977987	0.835	rs8046109	chr16:75360096	A/G	cg04384234	chr16:75411784	CFDP1	-0.39	-6.42	-0.33	4.57e-10	Dupuytren's disease;
LUSC	cis	rs9811920	0.809	rs793443	chr3:99573547	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-5.92	-0.31	7.83e-9	Axial length;
LUSC	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg07382826	chr16:28625726	SULT1A1	0.27	5.8	0.3	1.56e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs17014483	0.749	rs3017900	chr4:89639466	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.69	6.08	0.32	3.28e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4474465	0.646	rs6592794	chr11:78275743	A/G	cg27205649	chr11:78285834	NARS2	0.53	6.56	0.34	2.1e-10	Alzheimer's disease (survival time);
LUSC	cis	rs2579500	0.660	rs6711452	chr2:97139307	G/A	cg23100626	chr2:96804247	ASTL	0.25	5.72	0.3	2.35e-8	Eosinophil counts;Eosinophil percentage of white cells;
LUSC	trans	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg01620082	chr3:125678407	NA	-0.6	-6.11	-0.32	2.74e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-1.09	-21.42	-0.76	1.17e-64	Height;
LUSC	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg19773385	chr1:10388646	KIF1B	-0.51	-8.81	-0.43	6.93e-17	Hepatocellular carcinoma;
LUSC	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-6.21	-0.32	1.54e-9	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-11.96	-0.55	1.07e-27	Colorectal cancer;
LUSC	cis	rs9297145	0.678	rs62473051	chr7:98781955	C/T	cg05967295	chr7:98741636	SMURF1	0.92	12.77	0.57	1.11e-30	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs10838798	0.504	rs7121133	chr11:48156131	G/A	cg18512352	chr11:47633146	NA	-0.28	-5.73	-0.3	2.28e-8	Height;
LUSC	trans	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg18187862	chr3:45730750	SACM1L	-0.59	-7.4	-0.38	1.09e-12	Primary sclerosing cholangitis;
LUSC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg21724239	chr8:58056113	NA	0.59	6.17	0.32	1.97e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg01557791	chr16:72042693	DHODH	-0.51	-7.43	-0.38	8.96e-13	Fibrinogen levels;
LUSC	cis	rs17155006	0.664	rs405869	chr7:107742609	T/C	cg05962710	chr7:107745446	LAMB4	-0.35	-6.17	-0.32	1.97e-9	Pneumococcal bacteremia;
LUSC	cis	rs10875746	0.951	rs7485355	chr12:48548342	G/A	cg13454099	chr12:49076203	C12orf41	-0.52	-6.03	-0.31	4.46e-9	Longevity (90 years and older);
LUSC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.88	0.66	1.09e-42	Platelet count;
LUSC	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg21827317	chr3:136751795	NA	0.38	6.95	0.36	1.88e-11	Neuroticism;
LUSC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06221963	chr1:154839813	KCNN3	-0.62	-13.89	-0.61	6.1e-35	Prostate cancer;
LUSC	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.52e-8	Breast cancer;
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-0.43	-7.14	-0.36	5.99e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.1	0.32	2.92e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg22681709	chr2:178499509	PDE11A	-0.45	-6.65	-0.34	1.19e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs2335704	1.000	rs2335704	chr2:205864832	G/T	cg17022038	chr19:18260479	MAST3	-0.52	-5.98	-0.31	5.87e-9	Tuberculosis;
LUSC	cis	rs9653442	0.628	rs12474386	chr2:100857017	G/A	cg07810366	chr2:100720526	AFF3	-0.36	-5.93	-0.31	7.56e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg06951627	chr6:26196580	NA	0.53	5.72	0.3	2.39e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.28	0.41	2.91e-15	Tonsillectomy;
LUSC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	7.12	0.36	6.6e-12	Platelet count;
LUSC	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.82	-12.64	-0.57	3.28e-30	Tonsillectomy;
LUSC	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg18478394	chr8:109455254	TTC35	0.41	6.33	0.33	7.89e-10	Dupuytren's disease;
LUSC	cis	rs12681287	0.752	rs4641037	chr8:87268379	A/G	cg27223183	chr8:87520930	FAM82B	-0.43	-5.66	-0.3	3.34e-8	Caudate activity during reward;
LUSC	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg06363034	chr20:62225388	GMEB2	-0.46	-7.62	-0.38	2.6e-13	Glioblastoma;
LUSC	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21659725	chr3:3221576	CRBN	0.64	9.2	0.45	3.96e-18	Resting heart rate;
LUSC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg15412446	chr2:106886593	NA	-0.48	-6.95	-0.36	1.94e-11	Facial morphology (factor 23);
LUSC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg14552801	chr7:65878734	NA	-0.46	-6.54	-0.34	2.31e-10	Aortic root size;
LUSC	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	0.97	18.01	0.7	3.81e-51	Bone mineral density;
LUSC	trans	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	7.01	0.36	1.32e-11	Triglycerides;
LUSC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.05	0.55	5.3e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10050311	0.586	rs2054592	chr4:87673445	G/A	cg10685359	chr4:87814065	C4orf36	-0.43	-5.66	-0.3	3.19e-8	Insulin-related traits;
LUSC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg00810483	chr4:3375144	RGS12	0.3	5.7	0.3	2.7e-8	Serum sulfate level;
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg04775059	chr7:64541387	NA	-0.54	-8.08	-0.4	1.18e-14	Calcium levels;
LUSC	cis	rs72781680	0.559	rs72796103	chr2:23900382	G/A	cg08917208	chr2:24149416	ATAD2B	0.97	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.19	0.45	4.16e-18	Prudent dietary pattern;
LUSC	cis	rs754466	0.874	rs10430531	chr10:79660125	T/C	cg17075019	chr10:79541650	NA	-0.64	-8.3	-0.41	2.54e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg14552801	chr7:65878734	NA	-0.45	-6.48	-0.33	3.36e-10	Aortic root size;
LUSC	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg12002119	chr2:101014098	CHST10	0.35	5.85	0.3	1.19e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg18209359	chr17:80159595	CCDC57	-0.36	-5.82	-0.3	1.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.87	0.51	9.12e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg12963246	chr6:28129442	ZNF389	0.51	7.06	0.36	9.81e-12	Parkinson's disease;
LUSC	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg26566898	chr11:117069891	TAGLN	0.34	6.46	0.33	3.77e-10	Blood protein levels;
LUSC	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg04733989	chr22:42467013	NAGA	-0.41	-6.97	-0.36	1.67e-11	Cognitive function;
LUSC	cis	rs1448094	0.617	rs1393612	chr12:86474576	T/C	cg00310523	chr12:86230176	RASSF9	-0.33	-5.97	-0.31	5.98e-9	Major depressive disorder;
LUSC	cis	rs11608355	0.538	rs12228876	chr12:109796799	C/A	cg19025524	chr12:109796872	NA	-0.41	-7.6	-0.38	2.99e-13	Neuroticism;
LUSC	cis	rs11229555	0.645	rs7945992	chr11:58187755	T/A	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.59	9.14	0.45	6.22e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg05926928	chr17:57297772	GDPD1	0.9	10.48	0.5	2.15e-22	Opioid sensitivity;
LUSC	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.47e-8	Breast cancer;
LUSC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	11.65	0.54	1.5e-26	Menopause (age at onset);
LUSC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg08680598	chr22:49984980	NA	-0.34	-6.4	-0.33	5.37e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg08508325	chr11:3079039	CARS	0.39	8.77	0.43	8.95e-17	Calcium levels;
LUSC	cis	rs4363385	0.679	rs6686285	chr1:152984561	T/G	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.22	-0.37	3.51e-12	Inflammatory skin disease;
LUSC	cis	rs1751492	0.518	rs11208685	chr1:66070031	A/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	6.51	0.34	2.68e-10	Soluble leptin receptor levels;
LUSC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	0.65	9.18	0.45	4.46e-18	Methadone dose in opioid dependence;
LUSC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg17294928	chr15:75287854	SCAMP5	0.44	6.45	0.33	3.83e-10	Breast cancer;
LUSC	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-8.22	-0.41	4.45e-15	Lymphocyte counts;
LUSC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.88	0.54	2.22e-27	Prudent dietary pattern;
LUSC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg16482183	chr6:26056742	HIST1H1C	-0.55	-7.51	-0.38	5.3e-13	Iron status biomarkers;
LUSC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03517284	chr6:25882590	NA	-0.38	-6.5	-0.34	2.9e-10	Blood metabolite levels;
LUSC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg13647721	chr17:30228624	UTP6	0.59	5.89	0.31	9.59e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs60154123	0.881	rs1774107	chr1:210453923	C/T	cg22029157	chr1:209979665	IRF6	0.49	5.79	0.3	1.6e-8	Coronary artery disease;
LUSC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.79	13.27	0.59	1.47e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19346786	chr7:2764209	NA	-0.43	-7.31	-0.37	2.05e-12	Height;
LUSC	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg07148914	chr20:33460835	GGT7	0.55	8.35	0.42	1.79e-15	Height;
LUSC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg05754148	chr16:3507555	NAT15	0.56	8.57	0.42	3.88e-16	Tuberculosis;
LUSC	cis	rs926392	1.000	rs926391	chr20:37690485	A/G	cg27552599	chr20:37590471	DHX35	0.35	6.21	0.32	1.54e-9	Dialysis-related mortality;
LUSC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21545522	chr1:205238299	TMCC2	0.52	9.99	0.48	9.6e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs61990749	0.597	rs1048147	chr14:78139988	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.6	-6.43	-0.33	4.5e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg19789473	chr17:27170043	C17orf63	-0.29	-5.65	-0.3	3.41e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.48	7.27	0.37	2.5e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.82	13.29	0.59	1.2e-32	Cognitive test performance;
LUSC	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-1.17	-16.31	-0.67	2.14e-44	Hip circumference adjusted for BMI;
LUSC	cis	rs2806974	0.665	rs7984963	chr13:53812390	C/T	cg14823544	chr13:53775958	NA	-0.36	-6.08	-0.32	3.35e-9	Trans fatty acid levels;
LUSC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.54	0.46	3.12e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs3857536	0.741	rs2097679	chr6:66937994	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-15.74	-0.65	3.8e-42	Lymphocyte percentage of white cells;
LUSC	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.48	-0.42	7.16e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg16339924	chr4:17578868	LAP3	-0.56	-8.28	-0.41	2.95e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.87	0.4	4.86e-14	Coffee consumption (cups per day);
LUSC	cis	rs2455601	0.638	rs2742484	chr11:8988083	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-6.35	-0.33	7.11e-10	Schizophrenia;
LUSC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08859206	chr1:53392774	SCP2	0.5	8.58	0.43	3.56e-16	Monocyte count;
LUSC	cis	rs56399783	0.901	rs73051444	chr7:2866529	G/A	cg14895029	chr7:2775587	GNA12	0.46	5.82	0.3	1.38e-8	Childhood ear infection;
LUSC	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg13514129	chr1:39547527	MACF1	0.73	12.07	0.55	4.23e-28	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg09408571	chr1:101003634	GPR88	0.29	5.84	0.3	1.25e-8	Monocyte count;
LUSC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24549020	chr5:56110836	MAP3K1	0.49	5.92	0.31	7.79e-9	Initial pursuit acceleration;
LUSC	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg25011763	chr5:6727354	POLS	-0.36	-6.18	-0.32	1.83e-9	Menopause (age at onset);
LUSC	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg00376283	chr12:123451042	ABCB9	0.65	8.31	0.41	2.45e-15	Neutrophil percentage of white cells;
LUSC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg07507251	chr3:52567010	NT5DC2	-0.34	-6.88	-0.35	2.99e-11	Bipolar disorder;
LUSC	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg05555928	chr11:63887634	MACROD1	-0.49	-6.05	-0.31	3.95e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg26384229	chr12:38710491	ALG10B	0.53	7.42	0.38	1.01e-12	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.77	9.25	0.45	2.66e-18	Gut microbiome composition (summer);
LUSC	trans	rs1486139	0.967	rs1903672	chr7:46282452	C/T	cg17534202	chr9:96721102	NA	-0.37	-6.56	-0.34	2.01e-10	Select biomarker traits;
LUSC	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.7	11.35	0.53	1.75e-25	Monocyte count;
LUSC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg12016809	chr21:47604291	C21orf56	0.46	6.95	0.36	1.87e-11	Testicular germ cell tumor;
LUSC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg01483505	chr11:975446	AP2A2	0.41	5.9	0.31	9.14e-9	Alzheimer's disease (late onset);
LUSC	trans	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-12.63	-0.57	3.82e-30	Colorectal cancer;
LUSC	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.43	0.46	7.29e-19	Arsenic metabolism;
LUSC	cis	rs11039100	0.573	rs11038950	chr11:5780334	C/T	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.98	-16.38	-0.67	1.14e-44	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg23262073	chr20:60523788	NA	0.48	6.79	0.35	5.27e-11	Body mass index;
LUSC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg14196790	chr5:131705035	SLC22A5	0.41	7.0	0.36	1.45e-11	Blood metabolite levels;
LUSC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg04369109	chr6:150039330	LATS1	-0.52	-7.54	-0.38	4.62e-13	Lung cancer;
LUSC	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg03563238	chr19:33554763	RHPN2	-0.4	-6.26	-0.32	1.16e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/A	cg13736514	chr6:26305472	NA	-0.44	-6.34	-0.33	7.63e-10	Educational attainment;
LUSC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg04017836	chr7:65315216	NA	-0.37	-5.95	-0.31	6.75e-9	Height;
LUSC	cis	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg15556689	chr8:8085844	FLJ10661	0.46	6.92	0.35	2.35e-11	Myopia (pathological);
LUSC	cis	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg21775007	chr8:11205619	TDH	-0.5	-6.79	-0.35	5.17e-11	Neuroticism;
LUSC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg26513180	chr16:89883248	FANCA	0.72	11.21	0.52	5.76e-25	Vitiligo;
LUSC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.74	12.18	0.55	1.74e-28	Cognitive function;
LUSC	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg16850897	chr7:100343110	ZAN	0.37	5.89	0.31	9.66e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs7923609	0.967	rs7920058	chr10:65293924	T/G	cg01631684	chr10:65280961	REEP3	-0.42	-6.46	-0.33	3.74e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs34779708	0.931	rs7079205	chr10:35324619	C/T	cg03585969	chr10:35415529	CREM	0.65	9.28	0.45	2.24e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg01879757	chr17:41196368	BRCA1	-0.47	-7.31	-0.37	2.04e-12	Menopause (age at onset);
LUSC	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg12573674	chr2:1569213	NA	-0.55	-6.13	-0.32	2.44e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg12639453	chr1:2035780	PRKCZ	-0.3	-6.54	-0.34	2.36e-10	Height;
LUSC	trans	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg25815440	chr2:42134162	NA	-0.25	-5.96	-0.31	6.49e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg02569458	chr12:86230093	RASSF9	0.38	6.07	0.32	3.39e-9	Major depressive disorder;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12129209	chr14:102276033	PPP2R5C	0.36	6.13	0.32	2.53e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08645402	chr16:4508243	NA	0.47	7.22	0.37	3.59e-12	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg26050004	chr1:235667680	B3GALNT2	0.59	8.44	0.42	9.99e-16	Adiposity;
LUSC	cis	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg18131467	chr2:239335373	ASB1	-0.77	-6.63	-0.34	1.3100000000000001e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-7.01	-0.36	1.35e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.06	-0.36	9.57e-12	Longevity;Endometriosis;
LUSC	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg13010199	chr12:38710504	ALG10B	0.65	10.17	0.49	2.37e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg13395646	chr4:1353034	KIAA1530	0.49	6.91	0.35	2.47e-11	Obesity-related traits;
LUSC	cis	rs7927771	0.524	rs7939420	chr11:47723938	A/G	cg20307385	chr11:47447363	PSMC3	-0.42	-6.22	-0.32	1.53e-9	Subjective well-being;
LUSC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg03146154	chr1:46216737	IPP	-0.57	-8.23	-0.41	4.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg11984989	chr7:158649758	WDR60	1.13	13.48	0.59	2.25e-33	Height;
LUSC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.06	-0.58	8.6e-32	Alzheimer's disease;
LUSC	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg00857998	chr1:205179979	DSTYK	0.65	10.17	0.49	2.45e-21	Red blood cell count;
LUSC	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.42	-0.33	4.69e-10	Resting heart rate;
LUSC	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg06612196	chr6:6737390	NA	0.64	13.55	0.6	1.19e-33	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs7168353	0.948	rs10520720	chr15:93634724	A/G	cg02918577	chr15:93633145	RGMA	-0.48	-7.63	-0.39	2.54e-13	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg00310523	chr12:86230176	RASSF9	0.44	7.86	0.4	5.31e-14	Major depressive disorder;
LUSC	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg18806716	chr10:30721971	MAP3K8	-0.48	-7.92	-0.4	3.49e-14	Inflammatory bowel disease;
LUSC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg19318889	chr4:1322082	MAEA	0.45	7.41	0.38	1.05e-12	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08280861	chr8:58055591	NA	0.54	6.39	0.33	5.53e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg23711669	chr6:146136114	FBXO30	0.9	17.34	0.69	1.79e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg27398817	chr8:82754497	SNX16	-0.51	-6.79	-0.35	5.01e-11	Diastolic blood pressure;
LUSC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg23711669	chr6:146136114	FBXO30	-0.68	-11.46	-0.53	7.01e-26	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg11645453	chr3:52864694	ITIH4	0.29	6.6	0.34	1.62e-10	Electroencephalogram traits;
LUSC	cis	rs722599	0.683	rs2302834	chr14:75279395	T/A	cg06637938	chr14:75390232	RPS6KL1	0.39	5.68	0.3	2.93e-8	IgG glycosylation;
LUSC	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg26162295	chr17:38119207	GSDMA	0.24	5.76	0.3	1.91e-8	Self-reported allergy;
LUSC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg26335602	chr6:28129616	ZNF389	0.42	5.71	0.3	2.52e-8	Depression;
LUSC	cis	rs9296092	0.560	rs9469505	chr6:33527348	A/G	cg13560919	chr6:33536144	NA	-0.85	-16.44	-0.67	6.54e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg24006582	chr15:45444508	DUOX1	0.67	9.67	0.47	1.16e-19	Uric acid levels;
LUSC	trans	rs1998174	0.509	rs12405583	chr1:171812292	A/G	cg13482142	chr2:234261155	NA	0.42	6.02	0.31	4.51e-9	Platelet distribution width;
LUSC	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.61e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	6.83	0.35	4.13e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg12927641	chr6:109611667	NA	-0.35	-5.87	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs6580649	0.882	rs2286022	chr12:48436647	G/A	cg24011408	chr12:48396354	COL2A1	-0.51	-6.75	-0.35	6.42e-11	Lung cancer;
LUSC	cis	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg01251360	chr16:68772225	CDH1	-0.27	-6.38	-0.33	5.89e-10	Colorectal cancer;
LUSC	cis	rs9309473	0.898	rs10201159	chr2:73858965	T/C	cg20560298	chr2:73613845	ALMS1	-0.42	-5.94	-0.31	7e-9	Metabolite levels;
LUSC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06656553	chr16:89960601	TCF25	-0.65	-5.7	-0.3	2.65e-8	Skin colour saturation;
LUSC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg14820908	chr5:178986412	RUFY1	0.55	9.78	0.47	4.94e-20	Lung cancer;
LUSC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg00376283	chr12:123451042	ABCB9	0.76	11.54	0.53	3.65e-26	Platelet count;
LUSC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg26958806	chr6:27640298	NA	0.62	5.65	0.3	3.47e-8	Depression;
LUSC	cis	rs1185460	1.000	rs1784305	chr11:118942048	G/A	cg01677386	chr11:118938358	VPS11	-0.44	-6.08	-0.32	3.33e-9	Coronary artery disease;
LUSC	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.87	-11.93	-0.55	1.43e-27	Ileal carcinoids;
LUSC	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.79	-0.91	8.51e-129	Myeloid white cell count;
LUSC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg00409905	chr10:38381863	ZNF37A	-0.39	-6.73	-0.35	7.48e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs983392	0.642	rs636147	chr11:59957092	C/T	cg24026212	chr11:59952134	MS4A6A	0.34	6.15	0.32	2.22e-9	Alzheimer's disease (late onset);
LUSC	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	8.91	0.44	3.37e-17	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg02423579	chr7:2872169	GNA12	-0.46	-6.5	-0.33	2.96e-10	Height;
LUSC	trans	rs11165623	0.564	rs12752866	chr1:97000181	T/C	cg10631902	chr5:14652156	NA	-0.41	-6.06	-0.31	3.69e-9	Hip circumference;Waist circumference;
LUSC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg02475777	chr4:1388615	CRIPAK	-0.41	-6.08	-0.32	3.37e-9	Obesity-related traits;
LUSC	cis	rs4308124	0.708	rs7585313	chr2:111975203	A/G	cg04571233	chr2:111982156	NA	-0.53	-6.9	-0.35	2.6e-11	Vitiligo;
LUSC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg15557168	chr22:42548783	NA	-0.46	-7.15	-0.36	5.58e-12	Schizophrenia;
LUSC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg15445000	chr17:37608096	MED1	-0.41	-6.95	-0.36	1.95e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22618164	chr12:122356400	WDR66	0.61	9.2	0.45	4.07e-18	Mean corpuscular volume;
LUSC	cis	rs1865721	1.000	rs17283454	chr18:73186619	G/A	cg26385618	chr18:73139727	C18orf62	-0.48	-8.02	-0.4	1.86e-14	Intelligence;
LUSC	cis	rs1005224	0.853	rs2360035	chr14:76297093	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	0.63	8.8	0.43	7.64e-17	Large artery stroke;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06224551	chr11:124670268	C11orf61	-0.53	-6.4	-0.33	5.2400000000000005e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg10755058	chr3:40428713	ENTPD3	0.35	5.85	0.3	1.17e-8	Renal cell carcinoma;
LUSC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg23034840	chr1:205782522	SLC41A1	0.78	13.13	0.58	4.86e-32	Monocyte percentage of white cells;
LUSC	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg18477163	chr1:228402036	OBSCN	-0.55	-9.75	-0.47	6.18e-20	Diastolic blood pressure;
LUSC	cis	rs7805747	0.961	rs55779150	chr7:151406449	A/T	cg17611936	chr7:151411526	PRKAG2	0.43	5.9	0.31	9.13e-9	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUSC	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg14664628	chr15:75095509	CSK	0.43	6.07	0.32	3.43e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs243505	0.559	rs7802887	chr7:148494758	C/T	cg09806900	chr7:148480153	CUL1	0.64	9.5	0.46	4.32e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg14343924	chr8:8086146	FLJ10661	0.43	6.04	0.31	4.07e-9	Mood instability;
LUSC	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg05340658	chr4:99064831	C4orf37	0.58	8.82	0.43	6.37e-17	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs3857536	0.707	rs9345793	chr6:66929807	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.12	-0.32	2.7e-9	Blood trace element (Cu levels);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg26039424	chr1:46154040	TMEM69	0.44	6.21	0.32	1.59e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.17	0.37	4.71e-12	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.58	0.34	1.86e-10	Lung cancer;
LUSC	cis	rs738322	0.646	rs132972	chr22:38562056	T/C	cg25457927	chr22:38595422	NA	-0.34	-6.92	-0.35	2.38e-11	Cutaneous nevi;
LUSC	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg23029597	chr12:123009494	RSRC2	-0.6	-8.51	-0.42	5.83e-16	Body mass index;
LUSC	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg13206674	chr6:150067644	NUP43	-0.42	-6.39	-0.33	5.62e-10	Testicular germ cell tumor;
LUSC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg05043794	chr9:111880884	C9orf5	-0.35	-7.46	-0.38	7.48e-13	Menarche (age at onset);
LUSC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.39	-0.37	1.22e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg13072238	chr3:49761600	GMPPB	-0.71	-8.92	-0.44	3.03e-17	Menarche (age at onset);
LUSC	cis	rs7119	0.634	rs11635634	chr15:77863412	T/C	cg27398640	chr15:77910606	LINGO1	0.35	7.7	0.39	1.55e-13	Type 2 diabetes;
LUSC	trans	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg06521331	chr12:34319734	NA	0.4	6.32	0.33	8.45e-10	Morning vs. evening chronotype;
LUSC	cis	rs4851254	0.660	rs13430705	chr2:100690616	G/A	cg07810366	chr2:100720526	AFF3	-0.45	-6.06	-0.31	3.7e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6005807	0.668	rs60065194	chr22:28993756	A/G	cg12565055	chr22:29076175	TTC28	0.56	5.97	0.31	6.06e-9	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs2425143	0.822	rs6060677	chr20:34499368	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.58	5.9	0.31	8.9e-9	Blood protein levels;
LUSC	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-6.85	-0.35	3.53e-11	Cystic fibrosis severity;
LUSC	cis	rs3824867	0.920	rs7126210	chr11:47460306	A/G	cg20307385	chr11:47447363	PSMC3	0.65	9.66	0.47	1.27e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs6500395	0.890	rs9936445	chr16:48617754	T/G	cg04672837	chr16:48644449	N4BP1	0.49	7.09	0.36	7.99e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-9.52	-0.46	3.58e-19	Response to antipsychotic treatment;
LUSC	cis	rs4566357	1.000	rs2177597	chr2:227922546	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.76	-0.3	1.87e-8	Coronary artery disease;
LUSC	cis	rs3931020	0.688	rs1051122	chr1:75190452	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.46	5.81	0.3	1.48e-8	Resistin levels;
LUSC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg14541582	chr5:601475	NA	-0.37	-5.71	-0.3	2.48e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg18512352	chr11:47633146	NA	-0.44	-9.55	-0.46	2.81e-19	Subjective well-being;
LUSC	trans	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg09904177	chr6:26538194	HMGN4	-0.82	-5.95	-0.31	6.72e-9	Depression;
LUSC	cis	rs7789940	0.904	rs6953281	chr7:75946943	C/T	cg15798862	chr7:76129360	DTX2	-0.47	-7.67	-0.39	1.92e-13	Multiple sclerosis;
LUSC	cis	rs314370	0.570	rs314314	chr7:100423841	C/T	cg10426581	chr7:100472382	SRRT	0.52	8.14	0.41	8.04e-15	Resting heart rate;
LUSC	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg08079166	chr15:68083412	MAP2K5	0.41	7.5	0.38	5.85e-13	Restless legs syndrome;
LUSC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.86	11.24	0.52	4.32e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-8.05	-0.4	1.5e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	10.48	0.5	2.15e-22	Coronary artery disease;
LUSC	cis	rs6076065	0.748	rs6137933	chr20:23383103	A/T	cg11657817	chr20:23433608	CST11	0.53	11.03	0.52	2.42e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.39	-0.33	5.72e-10	Platelet count;
LUSC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.63	0.34	1.37e-10	Tonsillectomy;
LUSC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg04727924	chr7:799746	HEATR2	-0.56	-6.65	-0.34	1.23e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9549260	0.753	rs9549243	chr13:41217205	G/A	cg21288729	chr13:41239152	FOXO1	0.57	6.32	0.33	8.37e-10	Red blood cell count;
LUSC	cis	rs7605827	0.930	rs6761904	chr2:15599658	A/G	cg19274914	chr2:15703543	NA	0.46	8.8	0.43	7.47e-17	Educational attainment (years of education);
LUSC	cis	rs757278	0.552	rs6943317	chr7:117313645	C/T	cg10524701	chr7:117356490	CTTNBP2	0.4	5.75	0.3	1.99e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs10986311	0.814	rs12379417	chr9:127029736	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.36	5.68	0.3	2.91e-8	Vitiligo;
LUSC	trans	rs970548	0.688	rs10900228	chr10:46082128	A/G	cg14222797	chr10:16859974	RSU1	-0.57	-6.04	-0.31	4.07e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg09323728	chr8:95962352	TP53INP1	-0.3	-5.69	-0.3	2.78e-8	Type 2 diabetes;
LUSC	cis	rs7799006	0.929	rs35791351	chr7:2269248	C/T	cg02951883	chr7:2050386	MAD1L1	-0.36	-6.26	-0.32	1.17e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-5.84	-0.3	1.22e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.08	-0.36	8.53e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.62	-0.43	2.67e-16	Aortic root size;
LUSC	cis	rs4594175	0.926	rs10873044	chr14:51615856	T/C	cg23942311	chr14:51606299	NA	0.31	6.07	0.32	3.39e-9	Cancer;
LUSC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.21	-13.88	-0.6	6.79e-35	Diabetic kidney disease;
LUSC	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg24296786	chr1:45957014	TESK2	0.5	6.9	0.35	2.61e-11	Red blood cell count;Reticulocyte count;
LUSC	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	0.9	17.93	0.7	7.5400000000000006e-51	Metabolite levels;
LUSC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg16584290	chr5:462447	EXOC3	-0.37	-6.43	-0.33	4.39e-10	Cystic fibrosis severity;
LUSC	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.84	-10.24	-0.49	1.35e-21	Body mass index;
LUSC	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-0.82	-9.82	-0.47	3.65e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs6489882	0.836	rs7967461	chr12:113369759	G/C	cg20102336	chr12:113376681	OAS3	-0.42	-6.13	-0.32	2.44e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg20019720	chr6:154832845	CNKSR3	0.62	8.69	0.43	1.63e-16	Lipoprotein (a) levels;
LUSC	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.39	-0.33	5.47e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg16545954	chr1:2118288	C1orf86	-0.41	-7.83	-0.39	6.64e-14	Height;
LUSC	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg22681709	chr2:178499509	PDE11A	-0.58	-11.82	-0.54	3.66e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg16624210	chr5:671434	TPPP	0.48	6.35	0.33	7.13e-10	Obesity-related traits;
LUSC	trans	rs9329221	0.509	rs3088186	chr8:10226355	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.81	0.35	4.68e-11	Neuroticism;
LUSC	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	0.58	9.34	0.46	1.35e-18	Breast cancer;
LUSC	cis	rs10992471	0.528	rs1535754	chr9:95201917	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.37	-6.42	-0.33	4.58e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7903847	0.620	rs11189168	chr10:99125769	T/C	cg08345082	chr10:99160200	RRP12	-0.37	-7.31	-0.37	1.97e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg22681709	chr2:178499509	PDE11A	-0.59	-11.89	-0.55	2.07e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg25214090	chr10:38739885	LOC399744	0.56	8.09	0.4	1.08e-14	Corneal astigmatism;
LUSC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg25036284	chr2:26402008	FAM59B	0.68	9.07	0.44	1.01e-17	Gut microbiome composition (summer);
LUSC	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.6	10.73	0.51	2.8e-23	Weight;
LUSC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03264133	chr6:25882463	NA	-0.44	-7.73	-0.39	1.28e-13	Blood metabolite levels;
LUSC	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.51	8.04	0.4	1.53e-14	Birth weight;
LUSC	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg09975044	chr14:104007538	NA	-0.36	-5.68	-0.3	2.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg03060546	chr3:49711283	APEH	-0.61	-7.18	-0.37	4.46e-12	Menarche (age at onset);
LUSC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg13560548	chr3:10150139	C3orf24	0.53	7.43	0.38	9.1e-13	Alzheimer's disease;
LUSC	cis	rs1403694	0.515	rs1648700	chr3:186449916	C/T	cg12454167	chr3:186435060	KNG1	-0.28	-7.47	-0.38	6.92e-13	Blood protein levels;
LUSC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.87	-14.34	-0.62	1.11e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7903847	0.642	rs7092350	chr10:99140218	A/T	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.51e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg09904177	chr6:26538194	HMGN4	-0.68	-6.55	-0.34	2.18e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4906332	0.834	rs12882130	chr14:103878774	C/G	cg04998671	chr14:104000505	TRMT61A	-0.41	-6.29	-0.33	9.69e-10	Coronary artery disease;
LUSC	cis	rs10193935	0.792	rs222472	chr2:42662911	C/T	cg27598129	chr2:42591480	NA	-0.58	-7.98	-0.4	2.4e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs727505	0.826	rs11532793	chr7:124747952	A/G	cg23710748	chr7:124431027	NA	-0.4	-7.01	-0.36	1.34e-11	Lewy body disease;
LUSC	cis	rs17030434	0.953	rs10010787	chr4:154692059	G/A	cg14289246	chr4:154710475	SFRP2	-0.48	-6.39	-0.33	5.42e-10	Electrocardiographic conduction measures;
LUSC	trans	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg06606381	chr12:133084897	FBRSL1	-0.56	-6.55	-0.34	2.16e-10	Depression;
LUSC	cis	rs9399401	0.925	rs2294764	chr6:142737504	G/A	cg03128060	chr6:142623767	GPR126	0.33	6.15	0.32	2.22e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6906287	0.631	rs9320665	chr6:118986309	G/A	cg21191810	chr6:118973309	C6orf204	0.32	6.05	0.31	3.83e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10886558	0.662	rs10886556	chr10:121757792	A/T	cg02041677	chr10:121771263	NA	-0.34	-5.8	-0.3	1.56e-8	Shingles;
LUSC	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg01516881	chr6:292596	DUSP22	0.51	7.74	0.39	1.21e-13	Menopause (age at onset);
LUSC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03951724	chr22:30723125	TBC1D10A	-0.48	-6.52	-0.34	2.57e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.65	-0.47	1.39e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs72634258	0.554	rs4908699	chr1:7905274	G/A	cg26816564	chr1:7831052	VAMP3	0.94	13.17	0.58	3.49e-32	Inflammatory bowel disease;
LUSC	cis	rs9394152	0.845	rs7743060	chr6:33470519	C/T	cg13560919	chr6:33536144	NA	0.61	10.72	0.51	3.04e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs12989701	0.877	rs34745987	chr2:127875384	C/T	cg08168897	chr2:127865431	BIN1	0.73	9.38	0.46	1e-18	Alzheimer's disease (late onset);
LUSC	cis	rs6142102	0.961	rs6120487	chr20:32622608	A/G	cg08999081	chr20:33150536	PIGU	0.34	5.86	0.31	1.08e-8	Skin pigmentation;
LUSC	cis	rs11971779	0.616	rs6467836	chr7:139023517	C/G	cg07862535	chr7:139043722	LUC7L2	0.54	6.7	0.34	9.08e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg02023728	chr11:77925099	USP35	0.44	6.41	0.33	5.01e-10	Testicular germ cell tumor;
LUSC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.55	11.42	0.53	9.75e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs4356932	0.790	rs6532130	chr4:76969190	A/G	cg00809888	chr4:76862425	NAAA	0.34	5.68	0.3	2.94e-8	Blood protein levels;
LUSC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.1e-30	Aortic root size;
LUSC	cis	rs4666002	0.636	rs13023194	chr2:27967260	G/C	cg27432699	chr2:27873401	GPN1	0.49	5.72	0.3	2.37e-8	Phospholipid levels (plasma);
LUSC	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.79	12.94	0.58	2.49e-31	Bladder cancer;
LUSC	cis	rs7173743	0.756	rs4551997	chr15:79130433	G/A	cg00540400	chr15:79124168	NA	0.36	6.2	0.32	1.7e-9	Coronary artery disease;
LUSC	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg07541023	chr7:19748670	TWISTNB	-0.66	-7.09	-0.36	7.8e-12	Thyroid stimulating hormone;
LUSC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg13939156	chr17:80058883	NA	0.33	6.42	0.33	4.73e-10	Life satisfaction;
LUSC	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	trans	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg03886242	chr7:26192032	NFE2L3	-0.42	-6.48	-0.33	3.25e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg19875535	chr5:140030758	IK	0.49	7.91	0.4	3.76e-14	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4132509	0.793	rs74379351	chr1:243779604	T/C	cg21452805	chr1:244014465	NA	0.64	6.15	0.32	2.19e-9	RR interval (heart rate);
LUSC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	cis	rs10465746	0.775	rs4907186	chr1:84340753	G/T	cg10977910	chr1:84465055	TTLL7	0.53	7.57	0.38	3.76e-13	Obesity-related traits;
LUSC	cis	rs738321	0.790	rs4820317	chr22:38543287	T/C	cg25457927	chr22:38595422	NA	-0.36	-7.01	-0.36	1.37e-11	Breast cancer;
LUSC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08048268	chr3:133502702	NA	-0.47	-9.09	-0.45	8.77e-18	Iron status biomarkers;
LUSC	cis	rs17253792	0.822	rs117050012	chr14:56038729	G/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.04	-0.36	1.1e-11	Putamen volume;
LUSC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg25456477	chr12:86230367	RASSF9	0.44	7.87	0.4	4.98e-14	Major depressive disorder;
LUSC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg12463550	chr7:65579703	CRCP	-0.44	-6.56	-0.34	2.01e-10	Aortic root size;
LUSC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg26039829	chr8:22132926	PIWIL2	0.44	8.13	0.41	8.7e-15	Hypertriglyceridemia;
LUSC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg04906043	chr13:21280425	IL17D	0.45	8.68	0.43	1.74e-16	Dental caries;
LUSC	cis	rs7523050	0.643	rs36047249	chr1:109401499	T/C	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	cis	rs8032315	0.965	rs1894400	chr15:91428955	C/T	cg04510874	chr15:91427884	FES	0.31	6.13	0.32	2.49e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg07716408	chr11:68623521	NA	0.31	6.05	0.31	3.95e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs78663649	0.614	rs76626935	chr19:16581375	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.94	-6.45	-0.33	3.95e-10	White blood cell count;
LUSC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	0.93	16.21	0.66	5.46e-44	Menopause (age at onset);
LUSC	cis	rs1595825	1.000	rs74935794	chr2:198871195	T/G	cg00982548	chr2:198649783	BOLL	-0.49	-6.15	-0.32	2.15e-9	Ulcerative colitis;
LUSC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg13560548	chr3:10150139	C3orf24	0.49	6.93	0.35	2.13e-11	Alzheimer's disease;
LUSC	cis	rs7131987	0.650	rs7301398	chr12:29455390	G/T	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.51	-0.34	2.71e-10	QT interval;
LUSC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg00784671	chr22:46762841	CELSR1	-0.48	-6.53	-0.34	2.42e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.79	11.16	0.52	8.65e-25	Corneal astigmatism;
LUSC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.44e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg02158880	chr13:53174818	NA	0.56	9.83	0.47	3.44e-20	Lewy body disease;
LUSC	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-8.57	-0.42	3.88e-16	Body mass index;
LUSC	cis	rs12474201	0.928	rs1109380	chr2:46924490	G/T	cg06386533	chr2:46925753	SOCS5	0.8	12.37	0.56	3.42e-29	Height;
LUSC	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	8.3	0.41	2.67e-15	Retinal vascular caliber;
LUSC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00149659	chr3:10157352	C3orf10	0.93	11.87	0.54	2.29e-27	Alzheimer's disease;
LUSC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.2	-13.79	-0.6	1.55e-34	Diabetic kidney disease;
LUSC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.78	12.01	0.55	7.22e-28	Tonsillectomy;
LUSC	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.66	9.51	0.46	3.86e-19	IgG glycosylation;
LUSC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg03161606	chr19:29218774	NA	0.6	8.81	0.43	7.07e-17	Methadone dose in opioid dependence;
LUSC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg09796270	chr17:17721594	SREBF1	-0.41	-7.03	-0.36	1.16e-11	Total body bone mineral density;
LUSC	cis	rs4144743	1.000	rs3809862	chr17:45330428	C/T	cg18085866	chr17:45331354	ITGB3	-0.74	-7.72	-0.39	1.38e-13	Body mass index;
LUSC	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg22676075	chr6:135203613	NA	0.47	7.33	0.37	1.72e-12	Red blood cell count;
LUSC	cis	rs791888	0.723	rs1980648	chr10:89422369	T/C	cg13926569	chr10:89418898	PAPSS2	0.36	7.1	0.36	7.63e-12	Magnesium levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26016210	chr1:156426331	NA	0.46	6.47	0.33	3.57e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4692589	0.540	rs1904823	chr4:170956772	C/T	cg19918862	chr4:170955249	NA	0.35	6.3	0.33	9.43e-10	Anxiety disorder;
LUSC	cis	rs73206853	0.563	rs16940992	chr12:111207515	C/T	cg12870014	chr12:110450643	ANKRD13A	-0.59	-7.78	-0.39	9.38e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg19418458	chr7:158789849	NA	-0.64	-10.5	-0.5	1.83e-22	Facial morphology (factor 20);
LUSC	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg03678062	chr6:149772716	ZC3H12D	0.3	6.13	0.32	2.45e-9	Dupuytren's disease;
LUSC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1891275	0.508	rs7099557	chr10:93445364	C/G	cg07889827	chr10:93443413	NA	-0.38	-8.48	-0.42	7.42e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs12530134	0.523	rs7762088	chr6:170794570	T/C	cg16453901	chr6:170730693	NA	-0.95	-6.14	-0.32	2.35e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs3736594	0.513	rs6704596	chr2:27796927	A/G	cg27432699	chr2:27873401	GPN1	0.66	8.89	0.44	3.99e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	7.43	0.38	9.31e-13	Initial pursuit acceleration;
LUSC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg00071950	chr4:10020882	SLC2A9	0.51	8.44	0.42	9.98e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6489882	0.867	rs4767036	chr12:113369177	T/G	cg20102336	chr12:113376681	OAS3	-0.42	-6.13	-0.32	2.44e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg00074818	chr8:8560427	CLDN23	0.6	9.86	0.47	2.72e-20	Obesity-related traits;
LUSC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.74	-12.56	-0.57	6.48e-30	Iron status biomarkers;
LUSC	trans	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg07817883	chr1:32538562	TMEM39B	0.61	6.31	0.33	8.99e-10	Monocyte percentage of white cells;
LUSC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.8	0.35	4.84e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs56307353	0.753	rs62129495	chr19:1962789	T/C	cg11709110	chr19:1989583	BTBD2	-0.33	-5.68	-0.3	2.98e-8	Coronary artery disease;
LUSC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	13.48	0.59	2.22e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2692947	0.770	rs6719831	chr2:96502590	A/C	cg23100626	chr2:96804247	ASTL	0.26	6.47	0.33	3.52e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9517320	1.000	rs9645890	chr13:99126637	C/T	cg20487152	chr13:99095054	FARP1	0.34	6.38	0.33	5.98e-10	Longevity;
LUSC	cis	rs400736	0.930	rs442862	chr1:8079494	T/C	cg25007680	chr1:8021821	PARK7	0.57	9.11	0.45	7.79e-18	Response to antidepressants and depression;
LUSC	cis	rs7180079	1.000	rs8029682	chr15:64628534	C/T	cg02848875	chr15:64387786	SNX1	0.41	5.84	0.3	1.27e-8	Monocyte count;
LUSC	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg15556689	chr8:8085844	FLJ10661	0.46	6.77	0.35	5.67e-11	Retinal vascular caliber;
LUSC	trans	rs1015291	0.708	rs2638435	chr12:19999520	C/T	cg01501474	chr7:55323552	NA	-0.44	-5.94	-0.31	7e-9	Diastolic blood pressure;
LUSC	cis	rs11229555	0.834	rs7925560	chr11:58263036	G/A	cg15696309	chr11:58395628	NA	-0.71	-9.05	-0.44	1.17e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg16989719	chr2:238392110	NA	-0.44	-6.14	-0.32	2.33e-9	Prostate cancer;
LUSC	cis	rs6500395	1.000	rs904819	chr16:48622583	C/A	cg04672837	chr16:48644449	N4BP1	0.5	7.42	0.38	9.53e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05025164	chr4:1340916	KIAA1530	0.44	6.87	0.35	3.13e-11	Obesity-related traits;
LUSC	trans	rs12200782	1.000	rs6456742	chr6:26617075	T/C	cg11837749	chr1:55047332	ACOT11	0.57	5.98	0.31	5.64e-9	Small cell lung carcinoma;
LUSC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg11764359	chr7:65958608	NA	0.51	6.6	0.34	1.58e-10	Aortic root size;
LUSC	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg11789530	chr4:8429930	ACOX3	-0.44	-6.55	-0.34	2.12e-10	Response to antineoplastic agents;
LUSC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.49	-0.73	4.84e-57	Height;
LUSC	cis	rs4722404	0.592	rs13221367	chr7:3119823	C/T	cg19214707	chr7:3157722	NA	-0.4	-6.78	-0.35	5.33e-11	Atopic dermatitis;
LUSC	cis	rs6845621	0.899	rs6812302	chr4:18893038	G/A	cg12196642	chr4:18937545	NA	-0.31	-5.85	-0.3	1.19e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.15	-0.36	5.57e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7582720	1.000	rs72936862	chr2:203786812	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08045932	chr20:61659980	NA	0.57	9.88	0.48	2.38e-20	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7106204	0.609	rs11825384	chr11:24285137	G/T	ch.11.24196551F	chr11:24239977	NA	0.72	6.07	0.31	3.57e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg02782426	chr3:40428986	ENTPD3	0.43	7.98	0.4	2.31e-14	Renal cell carcinoma;
LUSC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg04450456	chr4:17643702	FAM184B	0.39	6.49	0.33	3.05e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-8.49	-0.42	7.07e-16	Lymphocyte counts;
LUSC	trans	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	7.22	0.37	3.64e-12	Retinal vascular caliber;
LUSC	cis	rs7552167	0.925	rs11249021	chr1:24512881	G/T	cg01960748	chr1:24522592	NA	-0.69	-10.8	-0.51	1.56e-23	Psoriasis vulgaris;
LUSC	cis	rs1322512	0.834	rs2623984	chr6:152948615	A/C	cg27316956	chr6:152958899	SYNE1	-0.36	-5.97	-0.31	5.91e-9	Tonometry;
LUSC	trans	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.44	6.2	0.32	1.71e-9	Blood trace element (Cu levels);
LUSC	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg01294253	chr9:136912663	BRD3	0.33	5.66	0.3	3.3e-8	Platelet distribution width;
LUSC	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg08000102	chr2:233561755	GIGYF2	-0.47	-7.06	-0.36	9.41e-12	Coronary artery disease;
LUSC	cis	rs701145	0.585	rs1713853	chr3:153795595	A/G	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg04036182	chr15:45458818	NA	0.34	5.7	0.3	2.6e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.6	8.27	0.41	3.31e-15	High light scatter reticulocyte count;
LUSC	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6570726	0.516	rs9322025	chr6:145729196	C/T	cg23711669	chr6:146136114	FBXO30	0.45	7.01	0.36	1.29e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg21427119	chr20:30132790	HM13	-0.46	-6.65	-0.34	1.2e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs2562456	0.876	rs7252585	chr19:21657943	C/T	cg00806126	chr19:22604979	ZNF98	0.41	6.57	0.34	1.96e-10	Pain;
LUSC	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg08873628	chr1:175162347	KIAA0040	0.39	5.66	0.3	3.23e-8	Alcohol dependence;
LUSC	cis	rs7246967	0.673	rs6511383	chr19:22956900	C/T	cg23217946	chr19:22817039	ZNF492	0.43	5.85	0.3	1.16e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg27170947	chr2:26402098	FAM59B	-0.72	-10.98	-0.51	3.76e-24	Gut microbiome composition (summer);
LUSC	trans	rs9951602	0.850	rs56367211	chr18:76677563	G/T	cg02800362	chr5:177631904	HNRNPAB	-0.59	-6.77	-0.35	5.76e-11	Obesity-related traits;
LUSC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg21665744	chr7:39171113	POU6F2	0.48	7.68	0.39	1.73e-13	IgG glycosylation;
LUSC	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg27411982	chr8:10470053	RP1L1	-0.37	-5.88	-0.31	9.81e-9	Neuroticism;
LUSC	cis	rs7605827	0.930	rs3815597	chr2:15625404	T/C	cg19274914	chr2:15703543	NA	0.47	8.99	0.44	1.94e-17	Educational attainment (years of education);
LUSC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.6	7.5	0.38	5.87e-13	Schizophrenia;
LUSC	trans	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg07393940	chr7:158741817	NA	0.38	6.88	0.35	2.93e-11	Life satisfaction;
LUSC	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-1.42	-17.26	-0.69	3.56e-48	Plateletcrit;
LUSC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg02269571	chr22:50332266	NA	0.59	8.71	0.43	1.44e-16	Schizophrenia;
LUSC	trans	rs11700980	1.000	rs59580249	chr21:30129226	A/C	cg05609335	chr17:75789393	NA	0.4	6.13	0.32	2.44e-9	QRS complex (12-leadsum);
LUSC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.49	0.33	3.07e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg07169764	chr2:136633963	MCM6	1.15	17.44	0.69	6.87e-49	Corneal structure;
LUSC	cis	rs4700695	0.719	rs27084	chr5:65435286	G/A	cg21114390	chr5:65439923	SFRS12	-0.62	-8.74	-0.43	1.12e-16	Facial morphology (factor 19);
LUSC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg20203395	chr5:56204925	C5orf35	-0.74	-10.1	-0.48	4.21e-21	Initial pursuit acceleration;
LUSC	cis	rs7589728	0.748	rs3791357	chr2:88478664	C/T	cg04511125	chr2:88470314	THNSL2	0.74	6.87	0.35	3.06e-11	Plasma clusterin levels;
LUSC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7119	0.717	rs12909645	chr15:77816819	A/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs1034435	0.755	rs5768681	chr22:48894501	C/T	cg05992904	chr22:48892994	FAM19A5	-0.4	-8.03	-0.4	1.63e-14	Late-onset Alzheimer's disease;
LUSC	cis	rs6543140	0.964	rs6761350	chr2:103030776	A/G	cg09003973	chr2:102972529	NA	0.57	7.44	0.38	8.7e-13	Blood protein levels;
LUSC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00166722	chr3:10149974	C3orf24	0.55	7.51	0.38	5.38e-13	Alzheimer's disease;
LUSC	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg10596483	chr8:143751796	JRK	0.61	9.26	0.45	2.64e-18	Schizophrenia;
LUSC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Depression;
LUSC	trans	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg26043149	chr18:55253948	FECH	-0.46	-7.03	-0.36	1.14e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg22117172	chr7:91764530	CYP51A1	0.31	5.7	0.3	2.7e-8	Breast cancer;
LUSC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg15468180	chr1:107600409	PRMT6	0.37	5.7	0.3	2.67e-8	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg06484146	chr7:12443880	VWDE	-0.63	-7.41	-0.38	1.07e-12	Coronary artery disease;
LUSC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.47	-0.33	3.53e-10	Platelet count;
LUSC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	11.48	0.53	6.11e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.84	-0.44	5.44e-17	Monocyte count;
LUSC	trans	rs453301	0.506	rs686189	chr8:8623637	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.02	-0.31	4.54e-9	Joint mobility (Beighton score);
LUSC	cis	rs12956009	0.583	rs12965907	chr18:44888455	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.14	0.32	2.36e-9	Educational attainment (years of education);
LUSC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.7	-11.62	-0.54	1.93e-26	Colorectal cancer;
LUSC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.23	-0.41	4.16e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs4566357	0.930	rs12621916	chr2:227923564	T/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.75	-0.3	1.97e-8	Coronary artery disease;
LUSC	cis	rs9487051	0.768	rs398944	chr6:109523444	T/G	cg00509249	chr6:109615579	CCDC162	-0.33	-5.79	-0.3	1.66e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs13315871	0.929	rs7628038	chr3:58313813	T/C	cg12435725	chr3:58293450	RPP14	-0.71	-7.27	-0.37	2.62e-12	Cholesterol, total;
LUSC	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.67	-8.67	-0.43	1.96e-16	Schizophrenia;
LUSC	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg26677194	chr12:130822605	PIWIL1	0.56	8.39	0.42	1.4e-15	Menopause (age at onset);
LUSC	cis	rs7705502	1.000	rs72812805	chr5:173344153	T/C	cg18693985	chr5:173351052	CPEB4	-0.36	-5.7	-0.3	2.66e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs4786125	0.636	rs8062299	chr16:6902722	T/C	cg03623568	chr16:6915990	A2BP1	-0.46	-7.62	-0.38	2.71e-13	Heart rate variability traits (SDNN);
LUSC	cis	rs1775715	1.000	rs1775715	chr10:32309005	A/G	cg04359828	chr10:32216031	ARHGAP12	-0.35	-5.84	-0.3	1.21e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg04166393	chr7:2884313	GNA12	-0.44	-5.99	-0.31	5.35e-9	Height;
LUSC	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	6.24	0.32	1.31e-9	Response to antipsychotic treatment;
LUSC	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg09165964	chr15:75287851	SCAMP5	0.85	8.21	0.41	4.84e-15	Lung cancer;
LUSC	cis	rs4903214	0.895	rs1860716	chr14:74713273	T/A	cg08255017	chr14:74727001	VSX2	-0.5	-6.82	-0.35	4.33e-11	Inflammatory bowel disease;
LUSC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg10207240	chr12:122356781	WDR66	-0.41	-5.98	-0.31	5.69e-9	Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.4	-6.32	-0.33	8.6e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs713477	0.967	rs10483642	chr14:55920460	A/G	cg04306507	chr14:55594613	LGALS3	0.3	6.03	0.31	4.46e-9	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18539474	chr1:113933413	MAGI3	-0.44	-6.48	-0.33	3.28e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg26001750	chr1:26324559	PAFAH2	0.42	6.03	0.31	4.4e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.59	-11.93	-0.55	1.37e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.18	0.52	7.01e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg24631222	chr15:78858424	CHRNA5	0.62	8.36	0.42	1.68e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg26441486	chr22:50317300	CRELD2	0.5	7.34	0.37	1.69e-12	Schizophrenia;
LUSC	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg02187348	chr16:89574699	SPG7	0.49	7.55	0.38	4.1e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs1403694	0.695	rs5029970	chr3:186434491	T/C	cg12454167	chr3:186435060	KNG1	0.34	8.44	0.42	9.55e-16	Blood protein levels;
LUSC	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg20701182	chr2:24300061	SF3B14	0.88	11.42	0.53	1.05e-25	Lymphocyte counts;
LUSC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg00784671	chr22:46762841	CELSR1	-0.48	-6.62	-0.34	1.41e-10	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg10573190	chr2:85843190	USP39	-0.43	-6.11	-0.32	2.83e-9	Mean corpuscular volume;
LUSC	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg10840412	chr1:235813424	GNG4	0.45	5.95	0.31	6.8e-9	Bipolar disorder;
LUSC	cis	rs2073300	1.000	rs6137982	chr20:23468892	T/A	cg09953122	chr20:23471693	CST8	-0.87	-6.99	-0.36	1.54e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg02475777	chr4:1388615	CRIPAK	-0.47	-7.1	-0.36	7.71e-12	Obesity-related traits;
LUSC	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg13175981	chr1:150552382	MCL1	0.44	6.21	0.32	1.55e-9	Tonsillectomy;
LUSC	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	1.1	17.23	0.69	4.59e-48	Exhaled nitric oxide output;
LUSC	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-0.89	-16.8	-0.68	2.42e-46	Tonsillectomy;
LUSC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg16743903	chr16:89593216	SPG7	0.38	5.88	0.31	9.86e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.24	0.52	4.63e-25	Prudent dietary pattern;
LUSC	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg10820045	chr2:198174542	NA	-0.32	-5.85	-0.3	1.17e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg18758796	chr5:131593413	PDLIM4	-0.41	-6.47	-0.33	3.56e-10	Breast cancer;
LUSC	cis	rs2348418	0.864	rs2137072	chr12:28716805	G/A	cg13890972	chr12:28721907	NA	-0.34	-5.81	-0.3	1.49e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg07169764	chr2:136633963	MCM6	-0.6	-8.05	-0.4	1.47e-14	Mosquito bite size;
LUSC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg12564285	chr5:131593104	PDLIM4	0.56	10.76	0.51	2.22e-23	Acylcarnitine levels;
LUSC	cis	rs977987	0.806	rs4888391	chr16:75400746	C/T	cg04384234	chr16:75411784	CFDP1	-0.42	-6.94	-0.36	2e-11	Dupuytren's disease;
LUSC	cis	rs9473147	0.516	rs7749167	chr6:47493940	G/A	cg20196966	chr6:47445060	CD2AP	0.42	5.83	0.3	1.31e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg07741184	chr6:167504864	NA	0.39	6.95	0.36	1.96e-11	Primary biliary cholangitis;
LUSC	cis	rs5758511	0.541	rs6002494	chr22:42199860	C/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-7.47	-0.38	7.22e-13	Birth weight;
LUSC	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	11.29	0.53	2.97e-25	Coronary artery disease;
LUSC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg00343986	chr7:65444356	GUSB	-0.4	-6.19	-0.32	1.79e-9	Cotinine glucuronidation;
LUSC	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg01236616	chr12:121019343	POP5	1.31	21.4	0.76	1.34e-64	Type 1 diabetes nephropathy;
LUSC	trans	rs149866169	1	rs149866169	chr6:27441723	T/A	cg01620082	chr3:125678407	NA	-0.69	-6.76	-0.35	6.15e-11	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg24631222	chr15:78858424	CHRNA5	-0.64	-8.55	-0.42	4.48e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg04455712	chr21:45112962	RRP1B	0.46	8.54	0.42	4.85e-16	Mean corpuscular volume;
LUSC	cis	rs2067615	0.579	rs10507214	chr12:107194461	G/A	cg15890332	chr12:107067104	RFX4	0.34	6.18	0.32	1.91e-9	Heart rate;
LUSC	trans	rs1459104	0.570	rs56152290	chr11:54858073	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.08	0.32	3.28e-9	Body mass index;
LUSC	cis	rs9650315	0.733	rs13270845	chr8:57204188	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.33	0.37	1.73e-12	Height;
LUSC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg06238570	chr21:40685208	BRWD1	-0.59	-9.16	-0.45	5.51e-18	Menarche (age at onset);
LUSC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.69	-0.34	9.59e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2281558	0.754	rs73597824	chr20:25591477	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.59	8.8	0.43	7.29e-17	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg25643088	chr3:52874325	TMEM110	0.4	6.06	0.31	3.7e-9	Schizophrenia;
LUSC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.63	-0.39	2.42e-13	Aortic root size;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22278056	chr19:44439434	NA	0.46	5.96	0.31	6.55e-9	Neuroticism;
LUSC	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	9.88	0.48	2.28e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	12.78	0.57	9.81e-31	Cognitive test performance;
LUSC	cis	rs1971762	0.583	rs10876485	chr12:54087648	C/T	cg23533419	chr12:54090519	NA	0.37	6.21	0.32	1.56e-9	Height;
LUSC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg13114125	chr14:105738426	BRF1	-0.93	-16.05	-0.66	2.36e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9467773	0.587	rs3208733	chr6:26414425	C/T	cg05738196	chr6:26577821	NA	-0.5	-7.4	-0.38	1.11e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg01251360	chr16:68772225	CDH1	-0.25	-5.84	-0.3	1.24e-8	Colorectal cancer;
LUSC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.65	-0.34	1.21e-10	Total body bone mineral density;
LUSC	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.4	5.98	0.31	5.77e-9	Height;
LUSC	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-7.23	-0.37	3.32e-12	Response to antipsychotic treatment;
LUSC	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg21775007	chr8:11205619	TDH	-0.73	-11.15	-0.52	9.56e-25	Retinal vascular caliber;
LUSC	trans	rs34421088	0.576	rs2736369	chr8:11101398	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.67	-0.34	1.04e-10	Neuroticism;
LUSC	cis	rs12980942	0.591	rs4591267	chr19:41765407	A/C	cg25627403	chr19:41769009	HNRNPUL1	0.69	7.27	0.37	2.61e-12	Coronary artery disease;
LUSC	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg25801113	chr15:45476975	SHF	0.34	7.08	0.36	8.49e-12	Uric acid levels;
LUSC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg22800045	chr5:56110881	MAP3K1	0.8	10.45	0.5	2.68e-22	Initial pursuit acceleration;
LUSC	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg16339924	chr4:17578868	LAP3	-0.52	-7.67	-0.39	1.94e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs7712401	0.562	rs364723	chr5:122326464	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.48	-0.46	4.83e-19	Mean platelet volume;
LUSC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg15412446	chr2:106886593	NA	-0.52	-6.03	-0.31	4.26e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUSC	trans	rs11700980	0.551	rs2832032	chr21:30114790	G/A	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	trans	rs4596713	0.568	rs6560584	chr9:71747172	A/G	cg25283916	chr1:242222868	NA	-0.3	-6.14	-0.32	2.36e-9	Headache;
LUSC	cis	rs6700896	0.500	rs4655564	chr1:66083537	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.35	0.33	7.09e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs2274273	0.870	rs10149420	chr14:55854257	T/C	cg04306507	chr14:55594613	LGALS3	0.55	12.81	0.57	7.95e-31	Protein biomarker;
LUSC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg07507251	chr3:52567010	NT5DC2	0.34	6.68	0.34	1e-10	Bipolar disorder;
LUSC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24110177	chr3:50126178	RBM5	0.55	9.12	0.45	7.31e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs3764021	0.837	rs7306557	chr12:9877356	G/A	cg20894963	chr12:9885564	CLECL1	0.35	7.1	0.36	7.47e-12	Type 1 diabetes;
LUSC	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.88	15.31	0.64	1.87e-40	Metabolic syndrome;
LUSC	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.74	-10.9	-0.51	7.23e-24	Glomerular filtration rate;
LUSC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.26	-0.32	1.16e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6489785	0.547	rs625228	chr12:121278266	G/A	cg02419362	chr12:121203948	SPPL3	-0.39	-6.96	-0.36	1.85e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4363385	0.719	rs12748969	chr1:152932654	T/C	cg07796016	chr1:152779584	LCE1C	-0.46	-6.5	-0.34	2.85e-10	Inflammatory skin disease;
LUSC	cis	rs7119	0.604	rs2682924	chr15:77863720	C/T	cg27398640	chr15:77910606	LINGO1	-0.35	-7.75	-0.39	1.1e-13	Type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18001866	chr11:33061388	TCP11L1	-0.41	-6.16	-0.32	2.09e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs56399783	0.901	rs73051469	chr7:2877811	A/G	cg19731401	chr7:2775893	GNA12	0.7	9.38	0.46	1.03e-18	Childhood ear infection;
LUSC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.82	-14.66	-0.63	6.74e-38	Cognitive function;
LUSC	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg18681998	chr4:17616180	MED28	0.78	13.81	0.6	1.26e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs929596	0.556	rs10202865	chr2:234587707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-7.82	-0.39	6.82e-14	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-16.46	-0.67	5.61e-45	Cognitive function;
LUSC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg24060327	chr5:131705240	SLC22A5	0.66	10.98	0.51	3.75e-24	Breast cancer;
LUSC	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.59	-0.69	1.73e-49	Exhaled nitric oxide output;
LUSC	cis	rs3803170	0.513	rs7299142	chr12:111829513	G/A	cg10833066	chr12:111807467	FAM109A	0.39	7.24	0.37	3.19e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs710865	1.000	rs710866	chr1:19568722	G/C	cg13387374	chr1:19411106	UBR4	0.43	6.24	0.32	1.34e-9	Brain structure;
LUSC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-7.85	-0.39	5.86e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg03146154	chr1:46216737	IPP	-0.52	-7.45	-0.38	8.15e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg21970626	chr13:21893289	NA	-0.52	-9.55	-0.46	2.91e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg11984989	chr7:158649758	WDR60	1.12	13.43	0.59	3.46e-33	Height;
LUSC	cis	rs3820928	0.874	rs55748731	chr2:227818629	C/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.65	-0.39	2.11e-13	Pulmonary function;
LUSC	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg15556689	chr8:8085844	FLJ10661	0.56	8.25	0.41	3.59e-15	Monocyte count;
LUSC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg18230493	chr5:56204884	C5orf35	-0.92	-13.64	-0.6	5.77e-34	Initial pursuit acceleration;
LUSC	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg19792802	chr11:65647270	CTSW	0.41	6.21	0.32	1.57e-9	Crohn's disease;
LUSC	cis	rs9650657	0.737	rs2116095	chr8:10635297	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-6.64	-0.34	1.29e-10	Neuroticism;
LUSC	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg27494647	chr7:150038898	RARRES2	0.46	6.91	0.35	2.52e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11018904	0.861	rs4589254	chr11:89963355	A/C	cg26834418	chr11:89957033	CHORDC1	0.47	6.04	0.31	4.16e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs16895831	0.519	rs61298049	chr6:42540394	T/G	cg10605015	chr6:42532144	UBR2	-0.49	-5.94	-0.31	7.02e-9	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs1506636	0.962	rs1472808	chr7:123354536	A/G	cg03229431	chr7:123269106	ASB15	-0.64	-10.57	-0.5	1.05e-22	Plateletcrit;Platelet count;
LUSC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.6	-0.43	3.2e-16	Personality dimensions;
LUSC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-1.06	-20.13	-0.74	1.46e-59	Coronary artery disease;
LUSC	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg16482183	chr6:26056742	HIST1H1C	0.53	7.53	0.38	4.66e-13	Iron status biomarkers;
LUSC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg03388025	chr16:89894329	SPIRE2	0.31	6.47	0.33	3.52e-10	Vitiligo;
LUSC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.82	0.78	4.03e-70	Prudent dietary pattern;
LUSC	cis	rs7119	0.635	rs907374	chr15:77884026	C/T	cg27398640	chr15:77910606	LINGO1	0.36	8.41	0.42	1.2e-15	Type 2 diabetes;
LUSC	cis	rs2274273	0.840	rs3742569	chr14:55818706	T/C	cg04306507	chr14:55594613	LGALS3	0.53	11.56	0.53	3.15e-26	Protein biomarker;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22456132	chr7:66309881	LOC729156	-0.4	-5.99	-0.31	5.53e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9815354	0.767	rs111708447	chr3:41809583	G/A	cg03022575	chr3:42003672	ULK4	0.83	8.34	0.41	2.04e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg09201001	chr11:18656081	SPTY2D1	0.91	14.87	0.63	1e-38	Breast cancer;
LUSC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg02807482	chr3:125708958	NA	-0.53	-6.62	-0.34	1.46e-10	Blood pressure (smoking interaction);
LUSC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.67	-11.68	-0.54	1.17e-26	Lung cancer;
LUSC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg02153584	chr22:29168773	CCDC117	0.59	8.84	0.44	5.54e-17	Lymphocyte counts;
LUSC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg06494592	chr3:125709126	NA	-0.53	-6.03	-0.31	4.35e-9	Blood pressure (smoking interaction);
LUSC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg10018233	chr7:150070692	REPIN1	0.33	6.02	0.31	4.53e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg00074818	chr8:8560427	CLDN23	0.57	9.88	0.48	2.27e-20	Obesity-related traits;
LUSC	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.61	8.33	0.41	2.06e-15	Adiposity;
LUSC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg21141812	chr3:48556323	PFKFB4	0.35	6.24	0.32	1.32e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg00999904	chr2:3704751	ALLC	0.46	7.09	0.36	8.04e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	12.62	0.57	3.95e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs320035	0.605	rs319957	chr1:49112458	G/A	cg02479497	chr16:85548895	NA	0.28	6.05	0.31	3.94e-9	Liver injury in anti-tuberculosis drug treatment;
LUSC	cis	rs6066835	1.000	rs6066835	chr20:47355009	A/G	cg15609812	chr20:47281632	PREX1	0.56	5.73	0.3	2.27e-8	Multiple myeloma;
LUSC	cis	rs713477	1.000	rs10782426	chr14:55890702	G/A	cg04306507	chr14:55594613	LGALS3	-0.32	-6.33	-0.33	7.83e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs7605827	0.930	rs10201925	chr2:15528742	G/A	cg19274914	chr2:15703543	NA	0.45	8.76	0.43	1.02e-16	Educational attainment (years of education);
LUSC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27297192	chr10:134578999	INPP5A	-0.37	-5.96	-0.31	6.48e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs34638657	0.872	rs7192444	chr16:82180338	C/G	cg09439754	chr16:82129088	HSD17B2	0.37	5.91	0.31	8.22e-9	Lung adenocarcinoma;
LUSC	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.85	-0.3	1.18e-8	Testicular germ cell tumor;
LUSC	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	10.75	0.51	2.46e-23	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs8133932	0.654	rs369245	chr21:47337821	G/A	cg14185626	chr21:47401492	COL6A1	-0.44	-5.68	-0.3	2.93e-8	Schizophrenia;
LUSC	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.79	11.5	0.53	5.34e-26	Corneal astigmatism;
LUSC	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg15103426	chr22:29168792	CCDC117	0.57	7.52	0.38	5.05e-13	Lymphocyte counts;
LUSC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.68	9.59	0.46	2.11e-19	Methadone dose in opioid dependence;
LUSC	cis	rs859767	0.501	rs1123184	chr2:135431057	C/G	cg12500956	chr2:135428796	TMEM163	-0.29	-6.89	-0.35	2.74e-11	Neuroticism;
LUSC	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-6.01	-0.31	4.75e-9	Recombination measurement;
LUSC	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg23711669	chr6:146136114	FBXO30	0.74	13.2	0.59	2.66e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg00310523	chr12:86230176	RASSF9	-0.5	-9.56	-0.46	2.69e-19	Major depressive disorder;
LUSC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg05623727	chr3:50126028	RBM5	0.33	6.08	0.32	3.22e-9	Body mass index;
LUSC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg20243544	chr17:37824526	PNMT	-0.46	-5.75	-0.3	2.06e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18644618	chr3:101280570	RG9MTD1	-0.48	-6.11	-0.32	2.75e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.44	-0.33	4.15e-10	Arsenic metabolism;
LUSC	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	0.93	17.54	0.69	2.88e-49	Headache;
LUSC	cis	rs7572644	0.581	rs10205313	chr2:28176527	A/C	cg27432699	chr2:27873401	GPN1	-0.52	-6.51	-0.34	2.83e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg20821713	chr7:1055600	C7orf50	-0.52	-6.78	-0.35	5.42e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg15147215	chr3:52552868	STAB1	-0.31	-6.2	-0.32	1.65e-9	Bipolar disorder;
LUSC	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg06636001	chr8:8085503	FLJ10661	0.54	7.96	0.4	2.77e-14	Myopia (pathological);
LUSC	cis	rs10225163	0.590	rs10266923	chr7:27918229	C/T	cg22168087	chr7:27702803	HIBADH	-0.47	-7.17	-0.37	4.83e-12	Gout;
LUSC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg13393036	chr8:95962371	TP53INP1	0.44	8.42	0.42	1.13e-15	Type 2 diabetes;
LUSC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08109568	chr15:31115862	NA	-0.72	-10.65	-0.5	5.34e-23	Huntington's disease progression;
LUSC	cis	rs701145	0.938	rs789380	chr3:154081424	G/A	cg17054900	chr3:154042577	DHX36	0.8	8.0	0.4	2.13e-14	Coronary artery disease;
LUSC	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg05868516	chr6:26286170	HIST1H4H	-0.37	-6.24	-0.32	1.32e-9	Educational attainment;
LUSC	cis	rs10203711	0.966	rs9287635	chr2:239582267	C/T	cg14580085	chr2:239553406	NA	0.42	7.11	0.36	7.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2932538	0.961	rs3795820	chr1:113163042	C/A	cg22162597	chr1:113214053	CAPZA1	-0.69	-9.82	-0.47	3.65e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg05872129	chr22:39784769	NA	-0.59	-10.03	-0.48	7.18e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2281845	0.859	rs58364051	chr1:201077667	A/G	cg22815214	chr1:201083145	CACNA1S	0.53	9.22	0.45	3.55e-18	Permanent tooth development;
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg13453750	chr1:205783389	SLC41A1	-0.33	-6.45	-0.33	3.96e-10	Menarche (age at onset);
LUSC	trans	rs961253	0.556	rs1571217	chr20:6316526	A/C	cg21095983	chr6:86352623	SYNCRIP	-0.44	-6.66	-0.34	1.12e-10	Colorectal cancer;
LUSC	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg17127132	chr2:85788382	GGCX	-0.44	-7.12	-0.36	6.55e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg13057898	chr1:3703894	LRRC47	0.48	8.4	0.42	1.34e-15	Red cell distribution width;
LUSC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs3125734	0.633	rs10740068	chr10:63982254	A/C	cg09941381	chr10:64027924	RTKN2	-0.39	-7.38	-0.37	1.25e-12	Rheumatoid arthritis;
LUSC	cis	rs11958404	0.932	rs72816550	chr5:157418457	A/T	cg05962755	chr5:157440814	NA	0.5	6.14	0.32	2.34e-9	IgG glycosylation;
LUSC	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg25922239	chr6:33757077	LEMD2	0.54	7.98	0.4	2.44e-14	Crohn's disease;
LUSC	cis	rs10789491	1.000	rs618505	chr1:47144532	T/C	cg15501359	chr1:47185051	KIAA0494	0.8	11.29	0.53	2.98e-25	Response to hepatitis C treatment;
LUSC	cis	rs3755132	0.929	rs57670756	chr2:15753821	G/A	cg12888861	chr2:15731646	DDX1	0.52	7.48	0.38	6.45e-13	Wilms tumor;
LUSC	cis	rs668210	0.793	rs619701	chr11:65772080	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.59	-7.52	-0.38	4.99e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg10729496	chr3:10149963	C3orf24	0.54	7.17	0.37	4.98e-12	Alzheimer's disease;
LUSC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	9.51	0.46	3.94e-19	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00166722	chr3:10149974	C3orf24	0.62	8.79	0.43	8.13e-17	Alzheimer's disease;
LUSC	cis	rs1570989	0.571	rs6916066	chr6:12016009	G/C	cg17804551	chr6:12015979	HIVEP1	0.39	6.88	0.35	2.89e-11	Alcohol and nicotine co-dependence;
LUSC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.72	0.43	1.3e-16	Motion sickness;
LUSC	cis	rs6494488	0.500	rs72744766	chr15:65079091	T/C	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	cis	rs56346965	0.967	rs11900804	chr2:191533767	T/C	cg11845111	chr2:191398756	TMEM194B	-0.43	-6.3	-0.33	9.4e-10	Bone mineral density (Ward's triangle area);
LUSC	trans	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg07211511	chr3:129823064	LOC729375	-0.81	-10.63	-0.5	6.5e-23	Blood pressure (smoking interaction);
LUSC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg05025164	chr4:1340916	KIAA1530	0.39	5.74	0.3	2.18e-8	Obesity-related traits;
LUSC	cis	rs722599	0.599	rs8003660	chr14:75227098	T/C	cg08847533	chr14:75593920	NEK9	0.42	5.88	0.31	9.78e-9	IgG glycosylation;
LUSC	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg09654669	chr8:57350985	NA	-0.59	-7.9	-0.4	4.15e-14	Obesity-related traits;
LUSC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	28.99	0.85	3.21e-93	Chronic sinus infection;
LUSC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.72	0.3	2.4e-8	Life satisfaction;
LUSC	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg19773385	chr1:10388646	KIF1B	-0.57	-9.79	-0.47	4.78e-20	Hepatocellular carcinoma;
LUSC	cis	rs11779988	0.545	rs427168	chr8:17784829	G/A	cg01800426	chr8:17659068	MTUS1	-0.5	-6.13	-0.32	2.54e-9	Breast cancer;
LUSC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg03732007	chr1:2071316	PRKCZ	-0.51	-9.13	-0.45	6.94e-18	Height;
LUSC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-9.16	-0.45	5.46e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs67517081	1	rs67517081	chr16:30987380	GT/G	cg02466173	chr16:30829666	NA	0.55	10.76	0.51	2.3e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.52	10.25	0.49	1.3e-21	Monocyte percentage of white cells;
LUSC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.72	-0.43	1.31e-16	Lung cancer;
LUSC	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-10.15	-0.49	2.89e-21	Migraine;Coronary artery disease;
LUSC	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg02903104	chr8:1507517	DLGAP2	-0.36	-6.7	-0.34	9.04e-11	Lung cancer;
LUSC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg19622623	chr12:86230825	RASSF9	-0.45	-6.48	-0.33	3.26e-10	Major depressive disorder;
LUSC	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg14689365	chr7:158441557	NCAPG2	0.54	7.87	0.4	5.12e-14	Height;
LUSC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg09455208	chr3:40491958	NA	0.52	9.37	0.46	1.13e-18	Renal cell carcinoma;
LUSC	cis	rs2302729	0.790	rs10505724	chr12:2782070	C/T	cg19945202	chr12:2788847	CACNA1C	-0.46	-6.3	-0.33	9.57e-10	Sleep quality;
LUSC	cis	rs72634258	0.842	rs7545677	chr1:8165619	C/T	cg00042356	chr1:8021962	PARK7	0.56	7.17	0.37	4.79e-12	Inflammatory bowel disease;
LUSC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	1.08	23.54	0.79	6.31e-73	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3790645	0.645	rs17162190	chr1:26872832	G/A	cg17456097	chr1:26900765	RPS6KA1	0.5	6.55	0.34	2.12e-10	Glucose homeostasis traits;
LUSC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.22	-0.45	3.34e-18	Bipolar disorder;
LUSC	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg11395062	chr17:14139857	CDRT15	0.4	5.99	0.31	5.29e-9	Temperament;
LUSC	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.29	-0.41	2.71e-15	Coffee consumption (cups per day);
LUSC	cis	rs7818345	0.967	rs11784873	chr8:19281113	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.32	0.37	1.87e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg10729496	chr3:10149963	C3orf24	0.54	7.17	0.37	4.98e-12	Alzheimer's disease;
LUSC	cis	rs4766566	0.609	rs933305	chr12:111738287	G/A	cg10833066	chr12:111807467	FAM109A	0.51	8.9	0.44	3.57e-17	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUSC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg13535736	chr9:111863775	C9orf5	-0.42	-6.69	-0.34	9.51e-11	Menarche (age at onset);
LUSC	cis	rs61935443	0.832	rs10859778	chr12:95268010	C/G	cg21533806	chr12:95267307	NA	0.52	6.68	0.34	9.95e-11	Schizophrenia;
LUSC	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg19610905	chr11:61596333	FADS2	-0.47	-6.82	-0.35	4.25e-11	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
LUSC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.77	-13.54	-0.6	1.31e-33	Cognitive function;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26871885	chr11:207525	RIC8A;BET1L	-0.53	-7.24	-0.37	3.06e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg19592336	chr6:28129416	ZNF389	0.48	6.27	0.32	1.11e-9	Depression;
LUSC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg03146154	chr1:46216737	IPP	0.52	7.79	0.39	8.3e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg19539972	chr4:7069911	GRPEL1	0.7	8.83	0.43	6.23e-17	Monocyte percentage of white cells;
LUSC	cis	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg21775007	chr8:11205619	TDH	0.49	6.76	0.35	6.35e-11	Triglycerides;
LUSC	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg12311346	chr5:56204834	C5orf35	-0.61	-9.35	-0.46	1.32e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.62	8.15	0.41	7.43e-15	Response to diuretic therapy;
LUSC	trans	rs621942	0.635	rs12786057	chr11:85858417	C/T	cg24608144	chr20:62398219	ZBTB46	0.4	6.06	0.31	3.75e-9	Tourette syndrome;
LUSC	cis	rs8051431	0.876	rs4788589	chr16:72019948	A/T	cg27261665	chr16:71265020	HYDIN	0.35	5.69	0.3	2.72e-8	LDL cholesterol levels;
LUSC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg04315214	chr1:2043799	PRKCZ	0.47	9.53	0.46	3.39e-19	Height;
LUSC	cis	rs6834538	0.597	rs6822451	chr4:113463265	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.36	5.82	0.3	1.37e-8	Free thyroxine concentration;
LUSC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg06627628	chr2:24431161	ITSN2	-0.6	-7.21	-0.37	3.78e-12	Lymphocyte counts;
LUSC	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.84	13.92	0.61	4.87e-35	Bladder cancer;
LUSC	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg00509249	chr6:109615579	CCDC162	-0.34	-6.09	-0.32	3.07e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-9.83	-0.47	3.33e-20	Hemoglobin concentration;
LUSC	cis	rs11955175	1.000	rs79132719	chr5:40668525	T/C	cg05478818	chr5:40835740	RPL37	0.7	5.7	0.3	2.65e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.51	0.65	3.1e-41	Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21423973	chr7:72298667	TYW1B;SBDSP	0.42	6.06	0.31	3.67e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg02493740	chr2:85810744	VAMP5	-0.33	-5.86	-0.31	1.12e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.14	-0.36	6e-12	Bipolar disorder;
LUSC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg05347473	chr6:146136440	FBXO30	0.59	9.69	0.47	9.73e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg05110241	chr16:68378359	PRMT7	-0.64	-6.94	-0.36	1.99e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg27068330	chr11:65405492	SIPA1	-0.44	-5.8	-0.3	1.52e-8	Breast cancer;
LUSC	cis	rs7771547	0.519	rs12206445	chr6:36379628	G/A	cg07856975	chr6:36356162	ETV7	0.42	6.19	0.32	1.79e-9	Platelet distribution width;
LUSC	cis	rs9815354	0.812	rs73073352	chr3:41842184	T/C	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg01802117	chr1:53393560	SCP2	-0.37	-5.95	-0.31	6.66e-9	Monocyte count;
LUSC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	trans	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg06521331	chr12:34319734	NA	-0.39	-6.0	-0.31	5.25e-9	Bladder cancer;
LUSC	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg21605333	chr4:119757512	SEC24D	-1.04	-10.29	-0.49	9.12e-22	Cannabis dependence symptom count;
LUSC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07234876	chr8:600039	NA	0.86	8.85	0.44	5.13e-17	IgG glycosylation;
LUSC	cis	rs7524258	0.867	rs35399313	chr1:7277293	T/C	cg07173049	chr1:7289937	CAMTA1	0.33	6.82	0.35	4.41e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-1.03	-20.48	-0.75	5.94e-61	Height;
LUSC	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg02569458	chr12:86230093	RASSF9	0.48	7.63	0.39	2.55e-13	Major depressive disorder;
LUSC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg03538708	chr1:25844672	NA	-0.35	-5.82	-0.3	1.38e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg24881330	chr22:46731750	TRMU	0.83	7.46	0.38	7.31e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs78545713	0.541	rs111465843	chr6:26222823	G/A	cg23601095	chr6:26197514	HIST1H3D	0.67	5.68	0.3	2.87e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg07828340	chr4:882639	GAK	1.07	11.42	0.53	1.01e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg11244672	chr19:19639970	YJEFN3	-0.63	-7.46	-0.38	7.66e-13	Bipolar disorder;
LUSC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15369054	chr17:80825471	TBCD	-0.36	-5.91	-0.31	8.3e-9	Breast cancer;
LUSC	cis	rs748404	0.723	rs11853991	chr15:43557549	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	7.96	0.4	2.72e-14	Lung cancer;
LUSC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg15790184	chr11:494944	RNH1	0.54	6.04	0.31	4.08e-9	Body mass index;
LUSC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.85	-14.8	-0.63	1.9e-38	Cognitive function;
LUSC	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	7.02	0.36	1.22e-11	Rheumatoid arthritis;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg03246824	chr11:118966313	H2AFX	0.46	5.96	0.31	6.42e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06634786	chr22:41940651	POLR3H	-0.6	-7.1	-0.36	7.43e-12	Vitiligo;
LUSC	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg03859395	chr2:55845619	SMEK2	0.88	16.62	0.67	1.23e-45	Metabolic syndrome;
LUSC	cis	rs7428	0.924	rs12714140	chr2:85557591	A/T	cg24342717	chr2:85555507	TGOLN2	-0.6	-8.66	-0.43	2.05e-16	Ear protrusion;
LUSC	trans	rs198712	0.505	rs198312	chr7:24191306	A/C	cg06529468	chr19:10676722	KRI1	0.38	6.11	0.32	2.83e-9	Aggressive periodontitis (sex interaction);
LUSC	cis	rs57590327	0.508	rs9820349	chr3:81958587	A/G	cg07356753	chr3:81810745	GBE1	-0.57	-8.04	-0.4	1.59e-14	Extraversion;
LUSC	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg06636551	chr8:101224915	SPAG1	-0.38	-7.13	-0.36	6.31e-12	Atrioventricular conduction;
LUSC	cis	rs79387448	0.745	rs1403549	chr2:103110745	G/C	cg09003973	chr2:102972529	NA	0.87	8.56	0.42	4.21e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg27170947	chr2:26402098	FAM59B	0.72	11.04	0.52	2.26e-24	Gut microbiome composition (summer);
LUSC	cis	rs62400317	0.859	rs12199256	chr6:45303493	T/G	cg20913747	chr6:44695427	NA	-0.47	-7.72	-0.39	1.35e-13	Total body bone mineral density;
LUSC	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg17764715	chr19:33622953	WDR88	0.59	7.95	0.4	2.96e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20152424	chr11:576455	PHRF1;LOC143666	0.43	6.43	0.33	4.32e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs72781680	0.821	rs72781644	chr2:24209348	T/C	cg08917208	chr2:24149416	ATAD2B	0.6	6.9	0.35	2.66e-11	Lymphocyte counts;
LUSC	cis	rs193541	0.626	rs4426910	chr5:122088838	A/T	cg19077854	chr5:122220652	SNX24	0.28	6.26	0.32	1.18e-9	Glucose homeostasis traits;
LUSC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18404041	chr3:52824283	ITIH1	-0.52	-9.82	-0.47	3.77e-20	Bipolar disorder;
LUSC	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.71	-12.44	-0.56	1.88e-29	White blood cell count (basophil);
LUSC	cis	rs4654899	0.865	rs7541923	chr1:21403582	G/C	cg01072550	chr1:21505969	NA	-0.49	-7.15	-0.36	5.6e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2580764	0.541	rs2968786	chr2:55264859	C/G	cg09592903	chr2:55203963	RTN4	0.49	9.83	0.47	3.51e-20	Mean platelet volume;
LUSC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.6	-0.6	7.64e-34	Initial pursuit acceleration;
LUSC	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.72	11.36	0.53	1.64e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg03885332	chr11:832357	CD151	-0.34	-5.84	-0.3	1.26e-8	Mean platelet volume;
LUSC	cis	rs10979	1.000	rs9386033	chr6:143888520	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg16591659	chr17:78472290	NA	0.48	8.15	0.41	7.21e-15	Fractional excretion of uric acid;
LUSC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg13047869	chr3:10149882	C3orf24	0.63	9.07	0.44	1.01e-17	Alzheimer's disease;
LUSC	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg22676075	chr6:135203613	NA	0.49	7.62	0.39	2.56e-13	Red blood cell count;
LUSC	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-10.07	-0.48	5.09e-21	Migraine;Coronary artery disease;
LUSC	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg14196676	chr1:1911069	KIAA1751	-0.6	-9.66	-0.47	1.27e-19	Severe influenza A (H1N1) infection;
LUSC	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg03684893	chr10:554711	DIP2C	-0.4	-7.21	-0.37	3.82e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-7.36	-0.37	1.42e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7119	0.651	rs12902449	chr15:77850926	A/G	cg27398640	chr15:77910606	LINGO1	-0.33	-6.82	-0.35	4.32e-11	Type 2 diabetes;
LUSC	cis	rs3849570	0.695	rs6792696	chr3:81874009	G/A	cg07356753	chr3:81810745	GBE1	-0.59	-8.78	-0.43	8.46e-17	Waist circumference;Body mass index;
LUSC	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg18357645	chr12:58087776	OS9	0.44	6.11	0.32	2.74e-9	Multiple sclerosis;
LUSC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg10523679	chr1:76189770	ACADM	0.85	11.3	0.53	2.74e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.14	0.32	2.31e-9	Corneal astigmatism;
LUSC	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.41	-0.33	4.97e-10	Uric acid levels;
LUSC	cis	rs2346177	0.875	rs2166745	chr2:46646879	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-8.77	-0.43	9.27e-17	HDL cholesterol;
LUSC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.7	-0.3	2.59e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00149659	chr3:10157352	C3orf10	0.88	12.31	0.56	5.95e-29	Alzheimer's disease;
LUSC	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.15	0.52	9.34e-25	Coffee consumption (cups per day);
LUSC	cis	rs8077577	0.895	rs62072464	chr17:18108314	T/C	cg16794390	chr17:18148240	FLII	0.41	5.73	0.3	2.28e-8	Obesity-related traits;
LUSC	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg26395211	chr5:140044315	WDR55	-0.39	-6.0	-0.31	5.16e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.78	11.68	0.54	1.15e-26	Corneal astigmatism;
LUSC	cis	rs7759001	0.857	rs12195788	chr6:27356406	C/T	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	1.97e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.44	0.46	6.85e-19	Coffee consumption (cups per day);
LUSC	cis	rs7106204	0.748	rs7101572	chr11:24213982	A/G	ch.11.24196551F	chr11:24239977	NA	1.12	12.64	0.57	3.29e-30	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg07382826	chr16:28625726	SULT1A1	0.27	5.82	0.3	1.39e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.17	-0.32	2.02e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg18209359	chr17:80159595	CCDC57	0.39	6.5	0.34	2.94e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg13535736	chr9:111863775	C9orf5	-0.43	-7.1	-0.36	7.64e-12	Menarche (age at onset);
LUSC	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06636551	chr8:101224915	SPAG1	-0.45	-8.29	-0.41	2.89e-15	Atrioventricular conduction;
LUSC	cis	rs2717559	0.568	rs35093407	chr8:143885501	G/A	cg17252645	chr8:143867129	LY6D	-0.32	-5.67	-0.3	3.11e-8	Urinary tract infection frequency;
LUSC	cis	rs2479724	0.591	rs2243605	chr6:41828070	T/A	cg17623882	chr6:41773611	USP49	-0.52	-6.79	-0.35	5.25e-11	Menarche (age at onset);
LUSC	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg04058563	chr4:185651563	MLF1IP	-0.79	-11.92	-0.55	1.5e-27	Blood protein levels;
LUSC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg19747945	chr6:42946146	PEX6	-0.34	-5.73	-0.3	2.27e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.84	15.34	0.64	1.48e-40	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg22508957	chr16:3507546	NAT15	-0.35	-5.69	-0.3	2.82e-8	Body mass index (adult);
LUSC	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg17279839	chr7:150038598	RARRES2	0.43	6.58	0.34	1.81e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7005380	0.531	rs9649948	chr8:120913535	A/G	cg21744203	chr8:120868354	DSCC1	-0.48	-5.79	-0.3	1.63e-8	Interstitial lung disease;
LUSC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.46	6.95	0.36	1.94e-11	Platelet count;
LUSC	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07741184	chr6:167504864	NA	-0.49	-8.7	-0.43	1.53e-16	Rheumatoid arthritis;
LUSC	cis	rs965469	1.000	rs6037553	chr20:3313884	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-5.65	-0.3	3.37e-8	IFN-related cytopenia;
LUSC	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg21096502	chr7:56174374	CHCHD2	-0.58	-6.3	-0.33	9.24e-10	PR interval in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.93	-0.48	1.53e-20	Hemoglobin concentration;
LUSC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	14.39	0.62	7.35e-37	Platelet count;
LUSC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg20302533	chr7:39170763	POU6F2	0.57	9.48	0.46	4.86e-19	IgG glycosylation;
LUSC	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.27	0.32	1.14e-9	Corneal astigmatism;
LUSC	trans	rs7939886	0.844	rs17150088	chr11:55894862	T/G	cg15704280	chr7:45808275	SEPT13	0.81	6.78	0.35	5.49e-11	Myopia (pathological);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19783675	chr5:132362235	ZCCHC10	-0.5	-5.97	-0.31	6.1e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs28830936	1.000	rs17677991	chr15:42032383	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.03	-0.31	4.33e-9	Diastolic blood pressure;
LUSC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg13042288	chr15:90349979	ANPEP	-0.48	-6.99	-0.36	1.47e-11	Uric acid levels;
LUSC	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg26395211	chr5:140044315	WDR55	-0.47	-7.39	-0.37	1.21e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg13047869	chr3:10149882	C3orf24	0.65	9.51	0.46	3.98e-19	Alzheimer's disease;
LUSC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22590775	chr19:49891494	CCDC155	0.61	8.79	0.43	8.23e-17	Multiple sclerosis;
LUSC	cis	rs6692729	1.000	rs6692729	chr1:227018919	C/T	cg10327440	chr1:227177885	CDC42BPA	0.48	6.96	0.36	1.85e-11	Electrodermal activity;
LUSC	cis	rs965469	1.000	rs6051736	chr20:3296898	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-5.66	-0.3	3.18e-8	IFN-related cytopenia;
LUSC	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.42	-7.51	-0.38	5.46e-13	Eosinophil percentage of white cells;
LUSC	cis	rs17597773	0.527	rs1537806	chr1:221084222	G/A	cg16008148	chr1:221062819	NA	0.41	7.77	0.39	1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11924390	0.800	rs5030059	chr3:186452455	C/G	cg12454167	chr3:186435060	KNG1	0.29	7.45	0.38	7.85e-13	Adiponectin levels;
LUSC	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg01528321	chr10:82214614	TSPAN14	0.61	9.41	0.46	8.6e-19	Post bronchodilator FEV1;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08638395	chr1:180601032	XPR1	0.51	7.25	0.37	2.85e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs137603	0.502	rs137627	chr22:39716341	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.52	-8.28	-0.41	2.92e-15	Primary biliary cholangitis;
LUSC	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08564027	chr20:61660810	NA	0.92	17.17	0.68	8.42e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg20849893	chr7:64541193	NA	0.44	6.39	0.33	5.51e-10	Calcium levels;
LUSC	trans	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	7.86	0.4	5.32e-14	Bipolar disorder;
LUSC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	10.3	0.49	8.64e-22	Alzheimer's disease;
LUSC	cis	rs506338	0.517	rs490192	chr11:64471369	C/T	cg19395706	chr11:64412079	NRXN2	0.29	5.93	0.31	7.43e-9	Body mass index;Urate levels;
LUSC	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg16346588	chr10:242978	ZMYND11	-0.42	-6.03	-0.31	4.28e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.96	-18.12	-0.7	1.37e-51	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs394563	0.625	rs394526	chr6:149796975	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.34	-6.99	-0.36	1.54e-11	Dupuytren's disease;
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.3	6.01	0.31	4.83e-9	Lymphocyte counts;
LUSC	cis	rs6690583	0.524	rs12045710	chr1:85451765	T/C	cg11262906	chr1:85462892	MCOLN2	0.68	6.56	0.34	2.02e-10	Serum sulfate level;
LUSC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21984481	chr17:79567631	NPLOC4	0.68	14.27	0.62	2.03e-36	Eye color traits;
LUSC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg10729496	chr3:10149963	C3orf24	0.52	6.93	0.35	2.21e-11	Alzheimer's disease;
LUSC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-7.45	-0.38	7.92e-13	Aortic root size;
LUSC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg14773178	chr5:1868261	NA	0.32	5.92	0.31	8.16e-9	Cardiovascular disease risk factors;
LUSC	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg13175981	chr1:150552382	MCL1	0.45	6.23	0.32	1.4e-9	Tonsillectomy;
LUSC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg21285383	chr16:89894308	SPIRE2	0.33	7.03	0.36	1.19e-11	Vitiligo;
LUSC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg24209194	chr3:40518798	ZNF619	0.48	6.41	0.33	4.93e-10	Renal cell carcinoma;
LUSC	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg26395211	chr5:140044315	WDR55	0.46	7.33	0.37	1.72e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg05347473	chr6:146136440	FBXO30	0.51	8.61	0.43	2.96e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.87	15.06	0.64	1.73e-39	Cognitive function;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16488304	chr1:151119217	SEMA6C	0.46	6.39	0.33	5.61e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg16414030	chr3:133502952	NA	-0.51	-8.05	-0.4	1.45e-14	Iron status biomarkers;
LUSC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.95	0.7	6.41e-51	Chronic sinus infection;
LUSC	cis	rs8077577	1.000	rs2015336	chr17:18073610	A/G	cg16794390	chr17:18148240	FLII	0.43	6.12	0.32	2.63e-9	Obesity-related traits;
LUSC	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.36	-19.2	-0.72	6.89e-56	Hip circumference adjusted for BMI;
LUSC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg05347473	chr6:146136440	FBXO30	0.48	8.11	0.41	9.98e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg15556689	chr8:8085844	FLJ10661	0.57	8.98	0.44	2.08e-17	Joint mobility (Beighton score);
LUSC	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.12	0.64	1.04e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg23711669	chr6:146136114	FBXO30	0.82	14.37	0.62	8.27e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg15423357	chr2:25149977	NA	0.45	9.03	0.44	1.37e-17	Body mass index;
LUSC	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg13256891	chr4:100009986	ADH5	0.43	5.99	0.31	5.48e-9	Alcohol dependence;
LUSC	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg21231944	chr12:82153410	PPFIA2	0.39	5.97	0.31	6.07e-9	Resting heart rate;
LUSC	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg16342193	chr10:102329863	NA	-0.36	-6.5	-0.34	2.87e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.51	6.68	0.34	9.92e-11	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.56	0.5	1.07e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-1.17	-16.86	-0.68	1.46e-46	Breast cancer;
LUSC	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg11189052	chr15:85197271	WDR73	0.49	5.98	0.31	5.78e-9	Schizophrenia;
LUSC	trans	rs6854783	0.715	rs6812389	chr4:145626096	C/G	cg07161172	chr15:71184870	LRRC49;THAP10	0.4	6.17	0.32	2.02e-9	Height;
LUSC	cis	rs3771570	0.901	rs4675963	chr2:242324763	G/A	cg21155796	chr2:242212141	HDLBP	0.51	6.25	0.32	1.28e-9	Prostate cancer;
LUSC	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg25124228	chr12:125621409	AACS	-0.4	-5.67	-0.3	3.09e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10489202	1.000	rs7520232	chr1:168011995	T/C	cg24449463	chr1:168025552	DCAF6	-0.58	-7.32	-0.37	1.88e-12	Schizophrenia;
LUSC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg17971929	chr21:40555470	PSMG1	-0.64	-10.52	-0.5	1.52e-22	Cognitive function;
LUSC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs113835537	0.808	rs10896128	chr11:66324529	G/A	cg24851651	chr11:66362959	CCS	0.47	5.82	0.3	1.37e-8	Airway imaging phenotypes;
LUSC	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg11057378	chr10:81107060	PPIF	0.36	6.05	0.31	3.97e-9	Height;
LUSC	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg01557791	chr16:72042693	DHODH	-0.5	-6.44	-0.33	4.22e-10	Blood protein levels;
LUSC	cis	rs12493885	0.585	rs787811	chr3:153622907	G/T	cg17054900	chr3:154042577	DHX36	-0.59	-6.08	-0.32	3.33e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1506636	1.000	rs10225428	chr7:123357646	A/G	cg03229431	chr7:123269106	ASB15	-0.64	-10.57	-0.5	1.05e-22	Plateletcrit;Platelet count;
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-8.13	-0.41	8.56e-15	Lymphocyte counts;
LUSC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.59	10.75	0.51	2.45e-23	Bone mineral density;
LUSC	cis	rs6574644	0.959	rs28622938	chr14:81772635	G/T	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs7589342	0.507	rs6543338	chr2:106403911	C/G	cg14210321	chr2:106509881	NCK2	-0.41	-5.87	-0.31	1.06e-8	Addiction;
LUSC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg21951975	chr1:209979733	IRF6	0.58	8.64	0.43	2.31e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg15445000	chr17:37608096	MED1	-0.4	-6.81	-0.35	4.56e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22998610	chr11:62538411	TAF6L	-0.39	-6.0	-0.31	5.17e-9	Hepatitis;
LUSC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg09455208	chr3:40491958	NA	0.6	10.16	0.49	2.59e-21	Renal cell carcinoma;
LUSC	cis	rs7572644	0.723	rs13023003	chr2:28032137	G/C	cg27432699	chr2:27873401	GPN1	0.57	7.39	0.37	1.17e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2273669	0.510	rs78596296	chr6:109374465	T/C	cg05315195	chr6:109294784	ARMC2	-0.55	-5.83	-0.3	1.28e-8	Prostate cancer;
LUSC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg04450456	chr4:17643702	FAM184B	0.39	6.57	0.34	1.9e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8114671	0.967	rs4911476	chr20:33780768	A/C	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.9	-0.31	9.15e-9	Height;
LUSC	cis	rs9921338	0.961	rs72773825	chr16:11412448	A/G	cg00044050	chr16:11439710	C16orf75	-0.5	-6.83	-0.35	3.91e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	trans	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-8.0	-0.4	2.09e-14	Obesity-related traits;
LUSC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.63	-7.99	-0.4	2.27e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs7818345	1.000	rs6981898	chr8:19305705	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.47	0.33	3.39e-10	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs1790761	0.806	rs1638557	chr11:67215988	C/G	cg24690094	chr11:67383802	NA	-0.31	-5.67	-0.3	3.12e-8	Mean corpuscular volume;
LUSC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg12641515	chr19:46296257	DMWD	0.5	7.43	0.38	8.93e-13	Coronary artery disease;
LUSC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.63	-0.5	6.39e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg06212747	chr3:49208901	KLHDC8B	0.66	9.37	0.46	1.11e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs3754214	0.836	rs12023277	chr1:150466737	A/G	cg15654264	chr1:150340011	RPRD2	0.45	7.24	0.37	3.13e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.63	-8.6	-0.43	3.06e-16	Lymphocyte counts;Red cell distribution width;
LUSC	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.86	-0.35	3.4e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	0.524	rs61895760	chr11:47794538	G/C	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.18e-10	Subjective well-being;
LUSC	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.05	0.4	1.49e-14	Homoarginine levels;
LUSC	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.89	-0.4	4.34e-14	Glomerular filtration rate;
LUSC	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	11.91	0.55	1.64e-27	Height;
LUSC	cis	rs10761482	0.500	rs10994411	chr10:62304808	C/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.55e-12	Schizophrenia;
LUSC	cis	rs4654899	0.802	rs10493004	chr1:21442736	T/C	cg02927042	chr1:21476669	EIF4G3	-0.37	-5.88	-0.31	9.98e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs394563	0.602	rs409099	chr6:149766863	T/G	cg16235748	chr6:149772707	ZC3H12D	-0.29	-5.95	-0.31	6.74e-9	Dupuytren's disease;
LUSC	cis	rs28595532	0.702	rs56217716	chr4:119338490	T/G	cg02775129	chr4:119771670	NA	-0.76	-6.33	-0.33	7.79e-10	Cannabis dependence symptom count;
LUSC	cis	rs2742234	0.910	rs2503866	chr10:43646261	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.37	-6.76	-0.35	6.22e-11	Hirschsprung disease;
LUSC	trans	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg02800362	chr5:177631904	HNRNPAB	0.88	13.11	0.58	5.56e-32	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.39	0.42	1.37e-15	Prudent dietary pattern;
LUSC	cis	rs2710642	0.962	rs7557501	chr2:63086639	C/T	cg17519650	chr2:63277830	OTX1	0.48	6.8	0.35	4.96e-11	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs9815354	0.812	rs73081321	chr3:41890231	G/A	cg03022575	chr3:42003672	ULK4	0.84	8.74	0.43	1.14e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1003719	0.591	rs1053966	chr21:38568009	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.52	-7.65	-0.39	2.18e-13	Eye color traits;
LUSC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg07395648	chr5:131743802	NA	0.39	5.74	0.3	2.09e-8	Blood metabolite levels;
LUSC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg15839431	chr19:19639596	YJEFN3	0.57	6.26	0.32	1.18e-9	Bipolar disorder;
LUSC	cis	rs4588572	0.643	rs10474555	chr5:77799193	A/G	cg11547950	chr5:77652471	NA	0.57	8.63	0.43	2.62e-16	Triglycerides;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg08385486	chr2:74874383	C2orf65	-0.7	-6.5	-0.34	2.94e-10	Cognitive performance;
LUSC	cis	rs4631830	0.896	rs7088225	chr10:51522120	T/C	cg16070123	chr10:51489643	NA	0.49	7.93	0.4	3.29e-14	Prostate-specific antigen levels;
LUSC	cis	rs2798269	1.000	rs2761912	chr13:22134037	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.13	-0.32	2.42e-9	PR segment;
LUSC	cis	rs11112613	0.609	rs6539218	chr12:105934875	C/T	cg03607813	chr12:105948248	NA	0.64	8.19	0.41	5.68e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs7106204	0.748	rs7947388	chr11:24224903	A/G	ch.11.24196551F	chr11:24239977	NA	1.13	14.81	0.63	1.67e-38	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	9.39	0.46	9.37e-19	Bipolar disorder;
LUSC	cis	rs2050392	0.792	rs684395	chr10:30719112	C/G	cg18806716	chr10:30721971	MAP3K8	-0.49	-7.99	-0.4	2.28e-14	Inflammatory bowel disease;
LUSC	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg20607287	chr7:12443886	VWDE	-0.6	-6.2	-0.32	1.65e-9	Coronary artery disease;
LUSC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg22655196	chr4:3374909	RGS12	0.31	5.97	0.31	5.9e-9	Serum sulfate level;
LUSC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	6.8	0.35	4.77e-11	Cognitive function;
LUSC	trans	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg09060275	chr22:27053596	MIAT	-0.4	-6.03	-0.31	4.45e-9	Height;
LUSC	cis	rs8141797	1.000	rs8138799	chr22:24556902	G/A	cg00411358	chr22:24577142	SUSD2	-0.58	-6.05	-0.31	3.84e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg22777020	chr22:31556080	RNF185	-0.47	-5.94	-0.31	7.04e-9	Colorectal cancer;
LUSC	cis	rs67981189	0.593	rs2877708	chr14:71484126	C/G	cg15816911	chr14:71606274	NA	0.32	5.73	0.3	2.26e-8	Schizophrenia;
LUSC	cis	rs698813	0.763	rs1067335	chr2:44625958	T/C	cg00619915	chr2:44497795	NA	-0.42	-6.04	-0.31	4.06e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs6500395	0.962	rs989070	chr16:48602243	G/A	cg04672837	chr16:48644449	N4BP1	0.43	6.29	0.33	1e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs34844492	0.744	rs17072704	chr3:65271885	C/T	cg25341313	chr1:235069288	NA	0.59	6.01	0.31	4.92e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	0.84	10.46	0.5	2.36e-22	Menopause (age at onset);
LUSC	cis	rs7572644	0.679	rs9679543	chr2:28050951	C/T	cg27432699	chr2:27873401	GPN1	0.52	7.14	0.36	5.69e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9311676	0.656	rs55913214	chr3:58388026	A/G	cg13750441	chr3:58318267	PXK	0.35	6.72	0.35	7.86e-11	Systemic lupus erythematosus;
LUSC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg06697600	chr4:7070879	GRPEL1	0.41	6.14	0.32	2.34e-9	Monocyte percentage of white cells;
LUSC	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg10523679	chr1:76189770	ACADM	-0.49	-7.16	-0.36	5.33e-12	Daytime sleep phenotypes;
LUSC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg05025164	chr4:1340916	KIAA1530	0.42	6.28	0.32	1.07e-9	Obesity-related traits;
LUSC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-1.07	-24.0	-0.8	1.07e-74	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg05347473	chr6:146136440	FBXO30	0.66	11.35	0.53	1.75e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg19622623	chr12:86230825	RASSF9	-0.45	-6.52	-0.34	2.59e-10	Major depressive disorder;
LUSC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11644478	chr21:40555479	PSMG1	-0.57	-8.72	-0.43	1.31e-16	Menarche (age at onset);
LUSC	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.62	8.55	0.42	4.53e-16	Adiposity;
LUSC	cis	rs346785	0.610	rs347674	chr17:74278548	C/G	cg09812376	chr17:74270190	QRICH2	-0.38	-7.11	-0.36	7.27e-12	White matter hyperintensities in ischemic stroke;
LUSC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.31	-0.37	1.95e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07636037	chr3:49044803	WDR6	-0.69	-9.0	-0.44	1.76e-17	Menarche (age at onset);
LUSC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.13	0.48	3.24e-21	Bipolar disorder;
LUSC	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg05163923	chr11:71159392	DHCR7	-0.77	-10.02	-0.48	7.56e-21	Vitamin D levels;
LUSC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg26513180	chr16:89883248	FANCA	0.79	6.38	0.33	5.97e-10	Skin colour saturation;
LUSC	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg00262122	chr8:11665843	FDFT1	0.51	7.72	0.39	1.35e-13	Morning vs. evening chronotype;
LUSC	cis	rs721399	0.553	rs59416053	chr8:18240800	G/C	cg18736775	chr8:18248649	NAT2	-0.58	-6.88	-0.35	2.98e-11	Blood metabolite levels;
LUSC	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg26875233	chr11:93583750	C11orf90	-0.3	-5.89	-0.31	9.44e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs11587682	0.578	rs12121421	chr1:150404666	A/G	cg11822372	chr1:151115635	SEMA6C	-0.47	-6.11	-0.32	2.73e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.44	6.17	0.32	2.03e-9	Osteoporosis;
LUSC	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg23752985	chr2:85803571	VAMP8	0.3	5.79	0.3	1.62e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	7.95	0.4	2.83e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs931812	0.757	rs4734014	chr8:101908844	A/G	cg20993868	chr7:22813445	NA	0.53	9.99	0.48	9.99e-21	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.89	-0.44	3.84e-17	Bipolar disorder;
LUSC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26314531	chr2:26401878	FAM59B	-0.69	-9.67	-0.47	1.13e-19	Gut microbiome composition (summer);
LUSC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.12	-0.36	6.49e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00339695	chr16:24857497	SLC5A11	0.62	9.47	0.46	5.47e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.43	6.63	0.34	1.38e-10	Dupuytren's disease;
LUSC	cis	rs1358748	0.555	rs2815388	chr1:67538853	C/T	cg02640540	chr1:67518911	SLC35D1	0.66	6.69	0.34	9.24e-11	Tuberculosis;
LUSC	cis	rs73416724	1.000	rs1214762	chr6:43355151	C/T	cg26312998	chr6:43337775	ZNF318	-0.52	-6.35	-0.33	6.93e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.57	-0.46	2.49e-19	Type 2 diabetes;
LUSC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg23205692	chr1:25664452	TMEM50A	0.44	6.65	0.34	1.19e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7119	0.717	rs62009071	chr15:77817886	C/G	cg27398640	chr15:77910606	LINGO1	-0.31	-6.48	-0.33	3.3e-10	Type 2 diabetes;
LUSC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg05623727	chr3:50126028	RBM5	-0.35	-6.66	-0.34	1.11e-10	Body mass index;
LUSC	cis	rs1535500	1.000	rs3734618	chr6:39284184	A/G	cg06347083	chr6:39282316	KCNK17	-0.27	-5.98	-0.31	5.68e-9	Type 2 diabetes;
LUSC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg25036284	chr2:26402008	FAM59B	-0.68	-9.64	-0.47	1.49e-19	Gut microbiome composition (summer);
LUSC	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17467752	chr17:38218738	THRA	-0.49	-6.87	-0.35	3.12e-11	White blood cell count;
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg12143784	chr7:64541923	NA	-0.44	-6.89	-0.35	2.81e-11	Calcium levels;
LUSC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.79	-12.39	-0.56	2.84e-29	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2274459	0.841	rs12661400	chr6:33696477	C/T	cg06253072	chr6:33679850	C6orf125	0.5	6.0	0.31	5.28e-9	Obesity (extreme);
LUSC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg11861562	chr11:117069780	TAGLN	0.45	8.16	0.41	6.97e-15	Blood protein levels;
LUSC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg07716408	chr11:68623521	NA	-0.34	-6.76	-0.35	6.28e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg01475377	chr6:109611718	NA	0.46	8.4	0.42	1.28e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs7122539	0.646	rs682842	chr11:66568943	A/G	cg18002602	chr11:66138449	SLC29A2	0.33	5.99	0.31	5.37e-9	HIV-1 susceptibility;
LUSC	cis	rs6537837	0.762	rs6691984	chr1:110144024	G/T	cg05049280	chr1:110155535	GNAT2	0.43	6.21	0.32	1.53e-9	Major depressive disorder;
LUSC	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.38	-0.49	4.5e-22	Coffee consumption (cups per day);
LUSC	cis	rs62380364	0.557	rs663046	chr5:88036486	C/T	cg22951263	chr5:87985283	NA	-0.45	-7.25	-0.37	2.85e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.74	10.7	0.51	3.6e-23	Corneal astigmatism;
LUSC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00166722	chr3:10149974	C3orf24	0.57	7.65	0.39	2.14e-13	Alzheimer's disease;
LUSC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.48	-0.33	3.25e-10	Menopause (age at onset);
LUSC	cis	rs7178375	0.607	rs7171212	chr15:31207711	C/T	cg03767031	chr15:31195708	MTMR15	0.79	6.41	0.33	4.95e-10	Hypertriglyceridemia;
LUSC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg11062466	chr8:58055876	NA	0.67	7.65	0.39	2.2e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7615316	0.779	rs6769786	chr3:142097777	A/G	cg16271453	chr3:142027066	XRN1	-0.41	-7.18	-0.37	4.48e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.35	-5.84	-0.3	1.21e-8	Longevity;Endometriosis;
LUSC	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg09941381	chr10:64027924	RTKN2	-0.37	-6.94	-0.36	2.03e-11	Rheumatoid arthritis;
LUSC	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg26597838	chr10:835615	NA	0.85	11.75	0.54	6.37e-27	Eosinophil percentage of granulocytes;
LUSC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg08493051	chr2:3487164	NA	-0.56	-8.81	-0.43	6.76e-17	Neurofibrillary tangles;
LUSC	cis	rs9469578	1.000	rs73743336	chr6:33715391	G/A	cg18708504	chr6:33715942	IP6K3	0.72	8.8	0.43	7.52e-17	Phosphorus levels;
LUSC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.27	-0.45	2.34e-18	Gut microbiome composition (summer);
LUSC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg22638593	chr5:131593259	PDLIM4	0.44	6.48	0.33	3.29e-10	Acylcarnitine levels;
LUSC	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.86	14.35	0.62	1.04e-36	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg18105134	chr13:113819100	PROZ	0.65	9.62	0.47	1.67e-19	Platelet distribution width;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.51	-8.78	-0.43	8.92e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9314323	0.557	rs3779916	chr8:26250906	C/A	cg13160058	chr8:26243215	BNIP3L	-0.33	-6.05	-0.31	3.8e-9	Red cell distribution width;
LUSC	cis	rs12190007	0.517	rs3006210	chr6:169828915	C/T	cg15038512	chr6:170123185	PHF10	-0.39	-6.31	-0.33	9.05e-10	Obesity-related traits;
LUSC	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg16230307	chr14:35515116	FAM177A1	0.79	10.05	0.48	6.13e-21	Psoriasis;
LUSC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	0.92	15.84	0.66	1.49e-42	Menopause (age at onset);
LUSC	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.13	-0.36	6.22e-12	Major depressive disorder;
LUSC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08048268	chr3:133502702	NA	-0.41	-8.06	-0.4	1.42e-14	Iron status biomarkers;
LUSC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.96	-0.4	2.7e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg24642439	chr20:33292090	TP53INP2	0.52	7.91	0.4	3.72e-14	Coronary artery disease;
LUSC	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg11645453	chr3:52864694	ITIH4	0.48	10.32	0.49	7.62e-22	Bipolar disorder;
LUSC	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg00982548	chr2:198649783	BOLL	-0.58	-7.24	-0.37	3.14e-12	Ulcerative colitis;
LUSC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11764359	chr7:65958608	NA	0.62	9.11	0.45	7.59e-18	Aortic root size;
LUSC	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg04310649	chr10:35416472	CREM	-0.4	-6.13	-0.32	2.5e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.77	11.16	0.52	8.86e-25	Corneal astigmatism;
LUSC	cis	rs1403694	0.695	rs3806689	chr3:186435077	A/G	cg12454167	chr3:186435060	KNG1	0.34	8.47	0.42	8.11e-16	Blood protein levels;
LUSC	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22307029	chr19:49891270	CCDC155	0.62	7.87	0.4	5.04e-14	Multiple sclerosis;
LUSC	cis	rs11997175	0.935	rs6990082	chr8:33708034	C/A	ch.8.33884649F	chr8:33765107	NA	0.42	6.49	0.33	3.18e-10	Body mass index;
LUSC	trans	rs7637701	0.713	rs9818780	chr3:156492758	T/C	cg11006288	chr14:69012387	RAD51L1	0.39	6.23	0.32	1.41e-9	Breast cancer;
LUSC	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00631329	chr6:26305371	NA	-0.45	-8.9	-0.44	3.69e-17	Educational attainment;
LUSC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg15448220	chr1:150897856	SETDB1	0.38	5.66	0.3	3.19e-8	Tonsillectomy;
LUSC	cis	rs1009647	0.677	rs11851870	chr14:55815982	A/C	cg04306507	chr14:55594613	LGALS3	0.46	6.37	0.33	6.15e-10	Testicular germ cell tumor;
LUSC	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg21640587	chr11:117668038	DSCAML1	0.7	10.53	0.5	1.42e-22	Myopia;
LUSC	cis	rs12291225	0.883	rs1864658	chr11:14256444	C/T	cg19336497	chr11:14380999	RRAS2	0.44	8.17	0.41	6.23e-15	Sense of smell;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01056350	chr1:210502156	HHAT	-0.41	-6.06	-0.31	3.77e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.43	7.73	0.39	1.25e-13	Obesity-related traits;
LUSC	cis	rs4253772	0.530	rs9615989	chr22:46803774	A/T	cg24881330	chr22:46731750	TRMU	0.78	5.75	0.3	2.02e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg07716408	chr11:68623521	NA	-0.31	-6.24	-0.32	1.33e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg19920283	chr7:105172520	RINT1	0.58	6.11	0.32	2.71e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg03804128	chr16:635623	NA	0.3	5.86	0.31	1.13e-8	Height;
LUSC	cis	rs6066835	1.000	rs6066835	chr20:47355009	A/G	cg18078177	chr20:47281410	PREX1	0.71	6.7	0.34	8.84e-11	Multiple myeloma;
LUSC	cis	rs7192380	0.965	rs7187634	chr16:69663371	T/C	cg26679644	chr16:69762563	NA	0.35	6.15	0.32	2.17e-9	Sjögren's syndrome;
LUSC	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg24690094	chr11:67383802	NA	-0.45	-8.09	-0.4	1.11e-14	Mean corpuscular volume;
LUSC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-8.53	-0.42	5.29e-16	Personality dimensions;
LUSC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.54	0.76	3.92e-65	Prudent dietary pattern;
LUSC	cis	rs12318506	0.793	rs71460129	chr12:75699427	C/T	cg04728562	chr12:75699417	CAPS2	-0.82	-6.03	-0.31	4.29e-9	Coronary artery calcification;
LUSC	cis	rs1595825	0.735	rs113834557	chr2:198611624	A/G	cg19156104	chr2:198669113	PLCL1	-0.47	-5.66	-0.3	3.26e-8	Ulcerative colitis;
LUSC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg06740227	chr12:86229804	RASSF9	0.44	7.15	0.36	5.5e-12	Major depressive disorder;
LUSC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	0.65	13.92	0.61	4.91e-35	Prudent dietary pattern;
LUSC	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg13057898	chr1:3703894	LRRC47	0.49	8.66	0.43	2.02e-16	Red cell distribution width;
LUSC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg15557168	chr22:42548783	NA	0.46	7.39	0.37	1.18e-12	Schizophrenia;
LUSC	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	8.43	0.42	1.04e-15	Lung cancer in ever smokers;
LUSC	cis	rs34524635	1	rs34524635	chr10:65261176	CT/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.44	-0.33	4.07e-10	Vascular endothelial growth factor levels;
LUSC	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg26513180	chr16:89883248	FANCA	0.92	17.98	0.7	5.01e-51	Vitiligo;
LUSC	cis	rs672059	0.806	rs3754524	chr1:183153267	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.52	7.76	0.39	1.03e-13	Hypertriglyceridemia;
LUSC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg17340268	chr14:105411764	AHNAK2	-0.38	-6.06	-0.31	3.75e-9	Rheumatoid arthritis;
LUSC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg23711669	chr6:146136114	FBXO30	0.73	12.77	0.57	1.14e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7953249	0.807	rs2393791	chr12:121423956	A/G	cg02403541	chr12:121454288	C12orf43	0.6	8.8	0.43	7.22e-17	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	trans	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg26384229	chr12:38710491	ALG10B	0.67	10.48	0.5	2.08e-22	Morning vs. evening chronotype;
LUSC	trans	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg03886242	chr7:26192032	NFE2L3	-0.4	-6.08	-0.32	3.29e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-7.23	-0.37	3.33e-12	Menarche (age at onset);
LUSC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg27588902	chr6:42928151	GNMT	-0.29	-6.46	-0.33	3.78e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs10979	1.000	rs9399448	chr6:143896315	G/T	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg01557791	chr16:72042693	DHODH	-0.51	-7.36	-0.37	1.48e-12	Fibrinogen levels;
LUSC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg14092988	chr3:52407081	DNAH1	-0.31	-6.06	-0.31	3.61e-9	Bipolar disorder;
LUSC	cis	rs9469578	1.000	rs73743328	chr6:33713550	G/A	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17106222	chr13:33590343	KL	0.44	6.45	0.33	3.97e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg25124228	chr12:125621409	AACS	-0.4	-5.7	-0.3	2.65e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6977660	0.714	rs9969381	chr7:19827454	C/T	cg05791153	chr7:19748676	TWISTNB	0.65	6.55	0.34	2.17e-10	Thyroid stimulating hormone;
LUSC	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.37	3.79e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs1577917	0.917	rs1579886	chr6:86557191	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs6960043	0.875	rs17168594	chr7:15048776	T/C	cg19272540	chr7:15055459	NA	-0.31	-7.31	-0.37	1.93e-12	Type 2 diabetes;
LUSC	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg07150166	chr2:30669952	LCLAT1	-0.53	-6.26	-0.32	1.16e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg06917634	chr15:78832804	PSMA4	0.48	6.02	0.31	4.61e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg13206674	chr6:150067644	NUP43	0.44	6.7	0.34	8.89e-11	Testicular germ cell tumor;
LUSC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg14092988	chr3:52407081	DNAH1	0.32	6.15	0.32	2.19e-9	Bipolar disorder;
LUSC	trans	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg10756647	chr7:56101905	PSPH	-0.78	-7.82	-0.39	6.82e-14	Diabetic kidney disease;
LUSC	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg23711669	chr6:146136114	FBXO30	0.84	15.05	0.64	1.97e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg14092988	chr3:52407081	DNAH1	0.31	5.94	0.31	7.06e-9	Bipolar disorder;
LUSC	cis	rs11785693	0.862	rs11780705	chr8:4988221	G/A	cg26367366	chr8:4980734	NA	0.83	9.78	0.47	4.92e-20	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-25.77	-0.82	2.2e-81	Exhaled nitric oxide output;
LUSC	trans	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg17675199	chr6:35436792	RPL10A	-0.43	-6.25	-0.32	1.29e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7202877	0.706	rs37602	chr16:75505046	C/T	cg04384234	chr16:75411784	CFDP1	0.63	8.99	0.44	1.87e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	9.49	0.46	4.6e-19	Hemoglobin concentration;
LUSC	cis	rs7582720	0.943	rs72934734	chr2:203739970	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.56	0.42	4.25e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg00012203	chr2:219082015	ARPC2	-0.57	-9.06	-0.44	1.11e-17	Ulcerative colitis;
LUSC	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg09904177	chr6:26538194	HMGN4	0.73	13.27	0.59	1.45e-32	Intelligence (multi-trait analysis);
LUSC	trans	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg19676328	chr12:49525230	TUBA1B	0.51	7.34	0.37	1.6e-12	Total cholesterol levels;
LUSC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg16479474	chr6:28041457	NA	0.34	5.89	0.31	9.45e-9	Parkinson's disease;
LUSC	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg09904177	chr6:26538194	HMGN4	0.69	11.95	0.55	1.22e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg14791747	chr16:20752902	THUMPD1	-0.42	-6.41	-0.33	4.97e-10	Dental caries;
LUSC	cis	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg21775007	chr8:11205619	TDH	-0.57	-7.64	-0.39	2.33e-13	Neuroticism;
LUSC	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg03060546	chr3:49711283	APEH	0.56	7.77	0.39	1.01e-13	Resting heart rate;
LUSC	cis	rs2286885	1.000	rs10760439	chr9:129250830	A/C	cg15282417	chr9:129245246	FAM125B	0.4	6.61	0.34	1.54e-10	Intraocular pressure;
LUSC	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.37	-5.7	-0.3	2.63e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6460942	0.630	rs17670901	chr7:12386622	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.14	-0.32	2.38e-9	Coronary artery disease;
LUSC	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.45	-8.37	-0.42	1.55e-15	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs3770081	1.000	rs12614260	chr2:86303079	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.08	-6.95	-0.36	1.88e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs3741151	0.773	rs73542990	chr11:73134398	C/T	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg05425664	chr17:57184151	TRIM37	0.57	8.04	0.4	1.57e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs17095355	1.000	rs11194924	chr10:111695773	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.96	-0.36	1.81e-11	Biliary atresia;
LUSC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg27535305	chr1:53392650	SCP2	-0.37	-6.83	-0.35	3.99e-11	Monocyte count;
LUSC	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg07959070	chr22:50026188	C22orf34	-0.33	-6.23	-0.32	1.4e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.52	-0.59	1.59e-33	Chronic sinus infection;
LUSC	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg22676075	chr6:135203613	NA	0.47	7.37	0.37	1.32e-12	Red blood cell count;
LUSC	cis	rs3820928	0.874	rs11685983	chr2:227799853	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.65	-0.39	2.11e-13	Pulmonary function;
LUSC	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-9.82	-0.47	3.71e-20	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs714027	1.000	rs757024	chr22:30471679	G/C	cg11564601	chr22:30592435	NA	-0.37	-6.89	-0.35	2.76e-11	Lymphocyte counts;
LUSC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg05347473	chr6:146136440	FBXO30	-0.49	-8.27	-0.41	3.29e-15	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6982636	1.000	rs2954019	chr8:126477759	G/A	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.35	-6.68	-0.34	1e-10	Lipid metabolism phenotypes;
LUSC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22433210	chr17:43662623	NA	-0.72	-10.45	-0.5	2.62e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg24692254	chr21:30365293	RNF160	-0.58	-7.22	-0.37	3.57e-12	Cognitive test performance;
LUSC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg14895029	chr7:2775587	GNA12	-0.37	-6.06	-0.31	3.77e-9	Height;
LUSC	cis	rs4363385	0.617	rs5010885	chr1:152973141	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.88	-0.4	4.72e-14	Inflammatory skin disease;
LUSC	cis	rs354225	0.544	rs1137645	chr2:54807592	C/G	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs3820928	0.874	rs10439363	chr2:227815065	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.91	-0.4	3.79e-14	Pulmonary function;
LUSC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg04414720	chr1:150670196	GOLPH3L	0.53	8.47	0.42	8.01e-16	Melanoma;
LUSC	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg14582100	chr15:45693742	SPATA5L1	0.57	10.06	0.48	5.61e-21	Homoarginine levels;
LUSC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.63	0.6	6.32e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg08499158	chr17:42289980	UBTF	0.51	8.55	0.42	4.61e-16	Total body bone mineral density;
LUSC	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg08213375	chr14:104286397	PPP1R13B	0.34	5.68	0.3	2.87e-8	Reticulocyte count;
LUSC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.86	0.4	5.38e-14	Bipolar disorder;
LUSC	cis	rs11997175	0.583	rs66622174	chr8:33812542	T/G	ch.8.33884649F	chr8:33765107	NA	0.45	6.65	0.34	1.17e-10	Body mass index;
LUSC	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg18132916	chr6:79620363	NA	-0.37	-5.73	-0.3	2.28e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs17604090	0.775	rs76480599	chr7:29689180	A/G	cg19413766	chr7:29689036	LOC646762	-0.54	-6.71	-0.34	8.45e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.63	-0.43	2.52e-16	Lung cancer;
LUSC	cis	rs2573652	1.000	rs2573625	chr15:100513158	A/G	cg09918751	chr15:100517450	ADAMTS17	0.37	6.79	0.35	5.16e-11	Height;
LUSC	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg20701182	chr2:24300061	SF3B14	0.75	7.63	0.39	2.55e-13	Lymphocyte counts;
LUSC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg12257692	chr3:49977190	RBM6	-0.26	-7.41	-0.38	1.02e-12	Body mass index;
LUSC	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg12310025	chr6:25882481	NA	-0.35	-5.78	-0.3	1.74e-8	Height;
LUSC	cis	rs4499344	0.531	rs259247	chr19:33147657	T/C	cg22980127	chr19:33182716	NUDT19	-0.43	-6.24	-0.32	1.34e-9	Mean platelet volume;
LUSC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg09365446	chr1:150670422	GOLPH3L	0.52	7.47	0.38	6.89e-13	Melanoma;
LUSC	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg09324608	chr17:30823087	MYO1D	0.34	5.77	0.3	1.83e-8	Schizophrenia;
LUSC	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.07	0.44	1.02e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	0.84	14.22	0.61	3.22e-36	Menopause (age at onset);
LUSC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20307385	chr11:47447363	PSMC3	0.44	5.8	0.3	1.58e-8	Subjective well-being;
LUSC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	13.62	0.6	6.8e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.32	0.33	8.32e-10	Lung cancer;
LUSC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.46	-6.73	-0.35	7.2e-11	Menarche (age at onset);
LUSC	cis	rs4654899	0.865	rs72988025	chr1:21351441	A/G	cg01072550	chr1:21505969	NA	-0.51	-7.52	-0.38	5.13e-13	Superior frontal gyrus grey matter volume;
LUSC	trans	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04565464	chr8:145669602	NFKBIL2	0.39	6.41	0.33	4.9e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg19774624	chr17:42201019	HDAC5	-0.8	-13.17	-0.58	3.49e-32	Total body bone mineral density;
LUSC	cis	rs6580649	1.000	rs7305954	chr12:48403530	C/T	cg24011408	chr12:48396354	COL2A1	0.54	7.57	0.38	3.76e-13	Lung cancer;
LUSC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14829155	chr15:31115871	NA	-0.69	-10.23	-0.49	1.56e-21	Huntington's disease progression;
LUSC	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.96	0.36	1.77e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg02549819	chr16:58548995	SETD6	0.96	9.16	0.45	5.54e-18	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.25	0.37	3e-12	Platelet count;
LUSC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg04851639	chr8:1020857	NA	-0.39	-7.98	-0.4	2.3e-14	Schizophrenia;
LUSC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg12963246	chr6:28129442	ZNF389	0.52	7.5	0.38	5.81e-13	Parkinson's disease;
LUSC	trans	rs9650657	0.665	rs7002117	chr8:10616169	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	6.29	0.33	9.75e-10	Neuroticism;
LUSC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.6	0.57	4.77e-30	Motion sickness;
LUSC	cis	rs7777754	1.000	rs7777754	chr7:50666033	A/C	cg18232548	chr7:50535776	DDC	-0.47	-6.35	-0.33	6.93e-10	Response to zileuton treatment in asthma (FEV1 change interaction);
LUSC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg00750074	chr16:89608354	SPG7	-0.44	-7.56	-0.38	3.99e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs7719624	0.870	rs58759191	chr5:135395827	C/G	cg12897067	chr5:135418308	NA	0.4	5.77	0.3	1.79e-8	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs1577917	0.655	rs1059307	chr6:86387888	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.44	7.03	0.36	1.17e-11	Response to antipsychotic treatment;
LUSC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-10.28	-0.49	9.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs354225	0.626	rs7608414	chr2:54844995	G/A	cg01766943	chr2:54829624	SPTBN1	0.47	7.55	0.38	4.28e-13	Schizophrenia;
LUSC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg27535305	chr1:53392650	SCP2	-0.35	-6.59	-0.34	1.68e-10	Monocyte count;
LUSC	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg27124370	chr19:33622961	WDR88	0.57	7.37	0.37	1.37e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs73200209	0.662	rs17426872	chr12:116636915	T/C	cg01776926	chr12:116560359	MED13L	-0.48	-5.98	-0.31	5.75e-9	Total body bone mineral density;
LUSC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg24349631	chr22:46449752	C22orf26;LOC150381	0.38	6.25	0.32	1.23e-9	Dupuytren's disease;Subjective well-being;
LUSC	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg05855489	chr10:104503620	C10orf26	0.52	7.98	0.4	2.38e-14	Arsenic metabolism;
LUSC	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-0.9	-16.82	-0.68	2.1e-46	Headache;
LUSC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.81	13.83	0.6	1.03e-34	Blood protein levels;
LUSC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.68	0.3	2.88e-8	Menopause (age at onset);
LUSC	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	6.01	0.31	4.96e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg05347473	chr6:146136440	FBXO30	0.47	7.68	0.39	1.75e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg19468946	chr17:37922297	IKZF3	-0.43	-6.85	-0.35	3.54e-11	Self-reported allergy;
LUSC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.48	6.49	0.33	3.16e-10	Renal function-related traits (BUN);
LUSC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg12560992	chr17:57184187	TRIM37	0.64	10.49	0.5	1.97e-22	Testicular germ cell tumor;
LUSC	trans	rs9860340	0.730	rs57368400	chr3:87639755	G/A	cg03644585	chr7:884825	UNC84A	0.42	6.03	0.31	4.35e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.8	0.47	4.11e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2607426	0.681	rs2254338	chr19:41255603	G/A	cg05508168	chr19:41255947	C19orf54;SNRPA	0.84	5.85	0.3	1.18e-8	Blood protein levels;
LUSC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.98	0.36	1.57e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg04310649	chr10:35416472	CREM	-0.41	-6.34	-0.33	7.54e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.4e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg02466173	chr16:30829666	NA	0.56	10.92	0.51	6.12e-24	Dementia with Lewy bodies;
LUSC	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg18825076	chr15:78729989	IREB2	-0.6	-9.81	-0.47	3.86e-20	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg22705602	chr4:152727874	NA	-0.34	-6.82	-0.35	4.21e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-12.61	-0.57	4.54e-30	Chronic sinus infection;
LUSC	cis	rs1957429	0.901	rs1467569	chr14:65347986	T/C	cg23373153	chr14:65346875	NA	1.07	12.89	0.58	3.85e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg08470875	chr2:26401718	FAM59B	-0.68	-9.08	-0.45	9.33e-18	Gut microbiome composition (summer);
LUSC	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg25251562	chr2:3704773	ALLC	-0.43	-7.26	-0.37	2.74e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-7.15	-0.36	5.54e-12	Colorectal cancer;
LUSC	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg17173187	chr15:85201210	NMB	0.35	6.37	0.33	6.25e-10	Schizophrenia;
LUSC	cis	rs7953508	0.659	rs1316739	chr12:93968256	G/A	cg18151635	chr12:93972918	NA	-0.63	-9.63	-0.47	1.5700000000000001e-19	Pubertal anthropometrics;
LUSC	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg22532475	chr10:104410764	TRIM8	-0.25	-6.01	-0.31	4.97e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg01620082	chr3:125678407	NA	-0.69	-7.05	-0.36	1.06e-11	Breast cancer;
LUSC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs10465746	0.725	rs4907185	chr1:84336047	T/C	cg10977910	chr1:84465055	TTLL7	0.53	7.57	0.38	3.76e-13	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.67e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2820315	0.867	rs2820317	chr1:201878537	G/C	cg10061532	chr1:201886748	LMOD1	0.28	6.44	0.33	4.04e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13732083	chr21:47605072	C21orf56	-0.43	-6.48	-0.33	3.39e-10	Testicular germ cell tumor;
LUSC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg00080972	chr5:178986291	RUFY1	-0.64	-12.35	-0.56	3.95e-29	Lung cancer;
LUSC	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg17376030	chr22:41985996	PMM1	-0.42	-5.7	-0.3	2.6e-8	Vitiligo;
LUSC	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg00376283	chr12:123451042	ABCB9	0.68	8.46	0.42	8.47e-16	Neutrophil percentage of white cells;
LUSC	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.82	-0.35	4.33e-11	Monocyte percentage of white cells;
LUSC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg19539972	chr4:7069911	GRPEL1	0.6	7.0	0.36	1.44e-11	Monocyte percentage of white cells;
LUSC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg13319975	chr6:146136371	FBXO30	0.49	7.43	0.38	9.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9815354	1.000	rs6768542	chr3:41865474	G/A	cg03022575	chr3:42003672	ULK4	0.59	6.55	0.34	2.2e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.52	-0.62	2.36e-37	Schizophrenia;
LUSC	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg22705602	chr4:152727874	NA	-0.31	-6.17	-0.32	1.98e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.45	7.38	0.37	1.23e-12	Vitiligo;
LUSC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg21918786	chr6:109611834	NA	0.42	7.31	0.37	1.97e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.64	-0.47	1.5e-19	Type 2 diabetes;
LUSC	cis	rs909002	0.830	rs10914460	chr1:32113216	T/C	cg01639898	chr1:32083012	HCRTR1	0.32	7.83	0.39	6.71e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	12.06	0.55	4.65e-28	Mean corpuscular volume;
LUSC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23158103	chr7:148848205	ZNF398	-0.5	-8.06	-0.4	1.38e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs9650657	0.615	rs11986935	chr8:10691549	T/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.18	-0.32	1.85e-9	Neuroticism;
LUSC	cis	rs7674212	0.507	rs223317	chr4:103802824	T/C	cg16532752	chr4:104119610	CENPE	-0.41	-5.67	-0.3	3.14e-8	Type 2 diabetes;
LUSC	cis	rs12760731	0.565	rs12732507	chr1:178098296	A/G	cg00404053	chr1:178313656	RASAL2	0.68	6.9	0.35	2.55e-11	Obesity-related traits;
LUSC	cis	rs6906287	0.647	rs10456917	chr6:118779419	A/C	cg21191810	chr6:118973309	C6orf204	0.33	6.0	0.31	5.17e-9	Electrocardiographic conduction measures;
LUSC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg06640241	chr16:89574553	SPG7	0.92	17.08	0.68	1.88e-47	Multiple myeloma (IgH translocation);
LUSC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg00990874	chr7:1149470	C7orf50	-0.61	-8.15	-0.41	7.3e-15	Bronchopulmonary dysplasia;
LUSC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-6.1	-0.32	2.9e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg01557791	chr16:72042693	DHODH	-0.51	-6.59	-0.34	1.74e-10	Blood protein levels;
LUSC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.18	-0.41	6.04e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4356932	1.000	rs4456983	chr4:76958688	A/G	cg00809888	chr4:76862425	NAAA	0.34	5.75	0.3	1.98e-8	Blood protein levels;
LUSC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg00049323	chr5:472564	LOC25845	0.5	7.94	0.4	3.13e-14	Cystic fibrosis severity;
LUSC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.0	-23.08	-0.78	3.95e-71	Prudent dietary pattern;
LUSC	cis	rs57590327	0.503	rs898763	chr3:81513408	T/C	cg07356753	chr3:81810745	GBE1	0.46	6.1	0.32	3.01e-9	Extraversion;
LUSC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	16.98	0.68	4.78e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.84	-20.23	-0.74	5.51e-60	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg01448562	chr3:133502909	NA	0.59	9.15	0.45	5.78e-18	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02711726	chr17:80685570	FN3KRP	-0.42	-6.43	-0.33	4.31e-10	Glycated hemoglobin levels;
LUSC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg27535305	chr1:53392650	SCP2	-0.49	-9.66	-0.47	1.22e-19	Monocyte count;
LUSC	cis	rs3136441	1.000	rs2306028	chr11:46900659	G/T	cg01183595	chr11:46746236	F2	0.38	5.67	0.3	3.12e-8	HDL cholesterol;
LUSC	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	1.12	18.11	0.7	1.48e-51	Corneal structure;
LUSC	cis	rs4654899	0.865	rs1472831	chr1:21435940	C/T	cg01072550	chr1:21505969	NA	-0.5	-7.4	-0.38	1.13e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.14	-0.45	6.37e-18	Monocyte percentage of white cells;
LUSC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg11645453	chr3:52864694	ITIH4	0.3	7.06	0.36	9.72e-12	Electroencephalogram traits;
LUSC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26818010	chr10:134567672	INPP5A	-0.82	-10.72	-0.51	2.99e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2688608	0.647	rs2633319	chr10:75691247	A/T	cg17411546	chr10:75410026	SYNPO2L	-0.39	-5.7	-0.3	2.7e-8	Inflammatory bowel disease;
LUSC	trans	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg07817883	chr1:32538562	TMEM39B	-0.58	-7.23	-0.37	3.26e-12	Monocyte percentage of white cells;
LUSC	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	13.88	0.6	6.44e-35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg22532475	chr10:104410764	TRIM8	0.35	7.95	0.4	2.82e-14	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg11766577	chr21:47581405	C21orf56	0.41	5.84	0.3	1.25e-8	Testicular germ cell tumor;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11468462	chr12:57610686	NXPH4	-0.53	-6.28	-0.32	1.04e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.59	-13.83	-0.6	1.04e-34	Height;
LUSC	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg27129171	chr3:47204927	SETD2	0.69	11.58	0.54	2.66e-26	Colorectal cancer;
LUSC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.15	0.32	2.17e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg05294307	chr14:35346193	BAZ1A	-0.58	-6.75	-0.35	6.68e-11	Psoriasis;
LUSC	cis	rs3736594	0.513	rs62138966	chr2:27819172	G/A	cg27432699	chr2:27873401	GPN1	0.65	8.63	0.43	2.6e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.57	-8.22	-0.41	4.67e-15	Homoarginine levels;
LUSC	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg16339924	chr4:17578868	LAP3	0.61	9.08	0.44	9.76e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7760535	0.757	rs10456875	chr6:111749725	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.73	-0.35	7.4e-11	Metabolic traits;
LUSC	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg11621586	chr10:70884670	VPS26A	-0.97	-11.31	-0.53	2.54e-25	Left atrial antero-posterior diameter;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22517552	chr7:30518520	NOD1	-0.51	-6.06	-0.31	3.62e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg13010199	chr12:38710504	ALG10B	0.66	9.93	0.48	1.57e-20	Bladder cancer;
LUSC	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.81	-0.3	1.48e-8	IgG glycosylation;
LUSC	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg00310523	chr12:86230176	RASSF9	0.43	7.95	0.4	2.96e-14	Major depressive disorder;
LUSC	cis	rs4594175	0.926	rs9323207	chr14:51621908	A/G	cg23942311	chr14:51606299	NA	-0.32	-6.02	-0.31	4.71e-9	Cancer;
LUSC	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg05580060	chr16:74700937	RFWD3	0.41	5.68	0.3	2.88e-8	Testicular germ cell tumor;
LUSC	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg05234568	chr11:5960015	NA	-0.62	-8.81	-0.43	7.2e-17	DNA methylation (variation);
LUSC	cis	rs7605827	0.897	rs10166702	chr2:15528454	T/C	cg19274914	chr2:15703543	NA	0.45	8.78	0.43	8.59e-17	Educational attainment (years of education);
LUSC	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg03806693	chr22:41940476	POLR3H	-0.46	-6.39	-0.33	5.62e-10	Neuroticism;
LUSC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-10.59	-0.5	8.37e-23	Gut microbiome composition (summer);
LUSC	cis	rs7561273	0.609	rs10197527	chr2:24352398	A/C	cg20701182	chr2:24300061	SF3B14	0.46	5.98	0.31	5.75e-9	Quantitative traits;
LUSC	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.52	7.93	0.4	3.28e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.19e-10	Alzheimer's disease (late onset);
LUSC	cis	rs965469	1.000	rs6051827	chr20:3372007	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-5.76	-0.3	1.9e-8	IFN-related cytopenia;
LUSC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3803170	0.513	rs10774622	chr12:111833348	C/T	cg10833066	chr12:111807467	FAM109A	0.38	7.19	0.37	4.31e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg05347473	chr6:146136440	FBXO30	0.52	8.79	0.43	7.96e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.78	0.43	8.69e-17	Axial length;
LUSC	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.4	-0.42	1.28e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs911119	0.866	rs6048920	chr20:23576844	A/G	cg16589663	chr20:23618590	CST3	0.57	6.79	0.35	5.14e-11	Chronic kidney disease;
LUSC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg22963979	chr7:1858916	MAD1L1	-0.65	-10.71	-0.51	3.4e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs7851660	0.809	rs12004762	chr9:100652755	A/G	cg13688889	chr9:100608707	NA	-0.53	-8.06	-0.4	1.36e-14	Strep throat;
LUSC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg05941027	chr17:61774174	LIMD2	0.21	5.68	0.3	2.95e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg14092571	chr14:90743983	NA	-0.36	-5.94	-0.31	7.24e-9	Mortality in heart failure;
LUSC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg14552801	chr7:65878734	NA	0.37	5.86	0.31	1.12e-8	Aortic root size;
LUSC	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg11608241	chr8:8085544	FLJ10661	0.4	5.72	0.3	2.35e-8	Mood instability;
LUSC	cis	rs9811920	0.809	rs793476	chr3:99541747	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-7.25	-0.37	2.94e-12	Axial length;
LUSC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg00944433	chr1:107599041	PRMT6	0.38	7.0	0.36	1.4e-11	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg06740227	chr12:86229804	RASSF9	0.46	7.49	0.38	6.14e-13	Major depressive disorder;
LUSC	cis	rs30380	0.632	rs149189	chr5:96137804	A/G	cg16492584	chr5:96139282	ERAP1	-0.57	-7.71	-0.39	1.5e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg10909506	chr17:38081995	ORMDL3	0.35	6.22	0.32	1.45e-9	Self-reported allergy;
LUSC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg07741184	chr6:167504864	NA	0.49	8.55	0.42	4.6e-16	Crohn's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19518383	chr11:64577818	MEN1	0.43	6.45	0.33	3.87e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs55871839	0.684	rs4738729	chr8:59808617	T/C	cg07426533	chr8:59803705	TOX	-0.37	-6.01	-0.31	4.76e-9	Pneumonia;
LUSC	cis	rs9646944	0.501	rs11687768	chr2:103025738	A/G	cg20060108	chr2:102954350	IL1RL1	0.5	6.99	0.36	1.54e-11	Blood protein levels;
LUSC	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg13010199	chr12:38710504	ALG10B	0.54	8.3	0.41	2.53e-15	Morning vs. evening chronotype;
LUSC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg07716408	chr11:68623521	NA	-0.33	-6.32	-0.33	8.44e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg01346077	chr3:125931526	NA	0.36	6.98	0.36	1.63e-11	Metabolite levels;
LUSC	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg22681709	chr2:178499509	PDE11A	-0.47	-8.53	-0.42	5.28e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg03806693	chr22:41940476	POLR3H	-0.51	-6.96	-0.36	1.86e-11	Neuroticism;
LUSC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg18876405	chr7:65276391	NA	0.53	8.33	0.41	2.15e-15	Calcium levels;
LUSC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.92	0.61	4.72e-35	Alzheimer's disease;
LUSC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.58	9.57	0.46	2.55e-19	Aortic root size;
LUSC	cis	rs9815354	0.812	rs17283677	chr3:41926148	C/T	cg03022575	chr3:42003672	ULK4	-0.76	-8.16	-0.41	7.1e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-0.81	-9.95	-0.48	1.35e-20	Refractive error;
LUSC	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg09904177	chr6:26538194	HMGN4	-0.74	-6.97	-0.36	1.7e-11	Urinary tract infection frequency;
LUSC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg02551604	chr5:131831745	NA	-0.42	-6.62	-0.34	1.39e-10	Asthma (sex interaction);
LUSC	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg02023728	chr11:77925099	USP35	0.52	7.2	0.37	4.11e-12	Testicular germ cell tumor;
LUSC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg18230493	chr5:56204884	C5orf35	-0.93	-13.72	-0.6	2.66e-34	Initial pursuit acceleration;
LUSC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.18	-0.37	4.42e-12	Schizophrenia;
LUSC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg05425664	chr17:57184151	TRIM37	-0.55	-8.11	-0.41	9.42e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg23505145	chr19:12996616	KLF1	0.52	7.28	0.37	2.41e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg13010199	chr12:38710504	ALG10B	0.66	10.17	0.49	2.5e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg05714579	chr10:131428358	MGMT	0.51	7.8	0.39	8.26e-14	Response to temozolomide;
LUSC	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg06640241	chr16:89574553	SPG7	0.41	6.02	0.31	4.58e-9	Hemoglobin concentration;
LUSC	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg19628046	chr18:33552617	C18orf21	0.48	5.8	0.3	1.56e-8	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg17173187	chr15:85201210	NMB	0.37	6.37	0.33	6.23e-10	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08677398	chr8:58056175	NA	0.52	6.34	0.33	7.28e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.74	-0.51	2.58e-23	Alzheimer's disease (late onset);
LUSC	trans	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	9.0	0.44	1.77e-17	Type 2 diabetes;
LUSC	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg20744362	chr22:50050164	C22orf34	0.39	7.35	0.37	1.54e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11645453	chr3:52864694	ITIH4	0.33	7.81	0.39	7.22e-14	Bipolar disorder;
LUSC	cis	rs6693567	0.565	rs698917	chr1:150319884	G/A	cg15654264	chr1:150340011	RPRD2	0.46	7.36	0.37	1.46e-12	Migraine;
LUSC	cis	rs28647808	0.881	rs7852803	chr9:136245903	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.98	-0.31	5.67e-9	Blood protein levels;
LUSC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg17764715	chr19:33622953	WDR88	-0.61	-8.43	-0.42	1.08e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg19318889	chr4:1322082	MAEA	0.51	8.79	0.43	8.32e-17	Obesity-related traits;
LUSC	cis	rs1979679	0.573	rs6487693	chr12:28727091	T/G	cg13890972	chr12:28721907	NA	-0.4	-5.86	-0.31	1.09e-8	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs7267979	0.714	rs1555329	chr20:25231858	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	12.14	0.55	2.38e-28	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg27284194	chr4:1044797	NA	0.57	8.45	0.42	8.91e-16	Recombination rate (females);
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg11965913	chr1:205819406	PM20D1	0.94	19.33	0.73	2.12e-56	Menarche (age at onset);
LUSC	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg03585969	chr10:35415529	CREM	0.63	9.24	0.45	2.97e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg21770322	chr7:97807741	LMTK2	0.56	10.12	0.48	3.51e-21	Breast cancer;
LUSC	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.98	-0.36	1.64e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg17168535	chr8:21777572	XPO7	0.66	10.09	0.48	4.62e-21	Mean corpuscular volume;
LUSC	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.62	6.57	0.34	1.96e-10	Schizophrenia;
LUSC	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.79	-0.43	8.23e-17	Coffee consumption (cups per day);
LUSC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg22143856	chr6:28129313	ZNF389	0.41	5.97	0.31	6.03e-9	Parkinson's disease;
LUSC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-1.04	-20.3	-0.74	2.97e-60	Height;
LUSC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.25	-0.49	1.28e-21	Hemoglobin concentration;
LUSC	cis	rs981844	0.816	rs62325148	chr4:154727993	A/G	cg14289246	chr4:154710475	SFRP2	0.48	6.3	0.33	9.33e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs2233152	0.572	rs10411008	chr19:41297241	T/C	cg21869046	chr19:41225005	ITPKC	0.44	6.53	0.34	2.4e-10	Kawasaki disease;
LUSC	trans	rs72674100	0.867	rs28673828	chr4:97991632	T/C	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg22782873	chr19:19639568	YJEFN3	-0.53	-6.17	-0.32	1.99e-9	Bipolar disorder;
LUSC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-11.11	-0.52	1.25e-24	Chronic sinus infection;
LUSC	cis	rs7241530	0.662	rs56261404	chr18:75905961	G/A	cg14642773	chr18:75888474	NA	0.39	5.99	0.31	5.45e-9	Educational attainment (years of education);
LUSC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg27490568	chr2:178487706	NA	-0.42	-5.92	-0.31	7.98e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7215564	0.908	rs7501659	chr17:78662061	C/T	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.51	-7.27	-0.37	2.59e-12	Iron status biomarkers;
LUSC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	13.2	0.59	2.71e-32	Alzheimer's disease;
LUSC	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg16049864	chr8:95962084	TP53INP1	-0.49	-7.86	-0.4	5.36e-14	Type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	0.65	13.71	0.6	2.93e-34	Prudent dietary pattern;
LUSC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs7582720	1.000	rs72934510	chr2:203925360	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.65	0.43	2.2e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.61	8.61	0.43	2.99e-16	Obesity-related traits;
LUSC	cis	rs858239	0.601	rs6461693	chr7:23160133	A/G	cg23682824	chr7:23144976	KLHL7	-0.41	-5.98	-0.31	5.87e-9	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08219700	chr8:58056026	NA	0.72	8.29	0.41	2.9e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg05340658	chr4:99064831	C4orf37	0.6	8.9	0.44	3.64e-17	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.72	-0.72	5.79e-54	Height;
LUSC	cis	rs9359856	0.510	rs2748298	chr6:90436877	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.93	-11.18	-0.52	7.07e-25	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	1.04	19.29	0.73	2.97e-56	Menopause (age at onset);
LUSC	cis	rs2298450	0.593	rs2835326	chr21:37615731	C/G	cg02919814	chr21:37666008	DOPEY2	-0.41	-6.13	-0.32	2.42e-9	Schizophrenia;
LUSC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15664640	chr17:80829946	TBCD	0.62	9.93	0.48	1.51e-20	Breast cancer;
LUSC	cis	rs6686643	0.762	rs9333432	chr1:165611159	A/G	cg16553119	chr1:165599451	MGST3	-0.46	-6.48	-0.33	3.32e-10	Total ventricular volume;
LUSC	cis	rs4720118	0.875	rs3779239	chr7:33430271	G/A	cg22798885	chr7:33102694	NT5C3	-0.47	-6.56	-0.34	2.07e-10	Leprosy;
LUSC	cis	rs62400317	0.859	rs10456548	chr6:45219699	T/C	cg20913747	chr6:44695427	NA	-0.48	-7.62	-0.38	2.66e-13	Total body bone mineral density;
LUSC	cis	rs716595	1.000	rs17127170	chr10:111992222	T/C	cg13996003	chr10:112034540	MXI1	-0.7	-5.79	-0.3	1.63e-8	Normalized brain volume;
LUSC	cis	rs6942756	1.000	rs1473236	chr7:128880831	G/T	cg02491457	chr7:128862824	NA	-0.53	-7.6	-0.38	3.09e-13	White matter hyperintensity burden;
LUSC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.87	-0.35	3.2e-11	Lung cancer;
LUSC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg01448562	chr3:133502909	NA	-0.67	-10.98	-0.51	3.83e-24	Iron status biomarkers;
LUSC	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.34	5.65	0.3	3.46e-8	Electroencephalogram traits;
LUSC	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg26597838	chr10:835615	NA	0.71	8.68	0.43	1.72e-16	Eosinophil percentage of granulocytes;
LUSC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.86	-0.81	6.04e-78	Height;
LUSC	trans	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.65	10.34	0.49	6.1e-22	Endometrial cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg19857457	chr18:47018947	RPL17;SNORD58A;SNORD58B	0.44	7.78	0.39	9.12e-14	Triglycerides;
LUSC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.65	10.99	0.52	3.31e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg08601574	chr20:25228251	PYGB	0.47	7.38	0.37	1.27e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg01483505	chr11:975446	AP2A2	0.41	5.79	0.3	1.67e-8	Alzheimer's disease (late onset);
LUSC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg21138405	chr5:131827807	IRF1	-0.33	-6.0	-0.31	5.11e-9	Asthma;
LUSC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg06784218	chr1:46089804	CCDC17	-0.56	-11.73	-0.54	7.97e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.62e-12	Motion sickness;
LUSC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.49	6.06	0.31	3.77e-9	Renal function-related traits (BUN);
LUSC	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.4	-0.42	1.3e-15	Schizophrenia;
LUSC	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs427941	0.632	rs201509	chr7:101765002	C/T	cg06246474	chr7:101738831	CUX1	0.39	6.4	0.33	5.38e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.09	16.64	0.67	1.09e-45	Gut microbiome composition (summer);
LUSC	cis	rs2979489	0.945	rs11992441	chr8:30313649	A/G	cg26383811	chr8:30366931	RBPMS	0.5	8.08	0.4	1.2e-14	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs10875746	0.903	rs12306451	chr12:48483241	T/C	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg21361702	chr7:150065534	REPIN1	0.5	6.81	0.35	4.65e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg03605463	chr16:89740564	NA	-0.57	-8.94	-0.44	2.77e-17	Vitiligo;
LUSC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-6.02	-0.31	4.5e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.46	7.05	0.36	1.05e-11	Longevity;Endometriosis;
LUSC	cis	rs2742417	0.603	rs6807438	chr3:45778623	G/A	cg04837898	chr3:45731254	SACM1L	-0.45	-7.39	-0.37	1.22e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.43	-0.42	1.02e-15	Morning vs. evening chronotype;
LUSC	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg16342193	chr10:102329863	NA	-0.35	-6.2	-0.32	1.65e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg26446133	chr18:72167187	CNDP2	-0.78	-8.8	-0.43	7.49e-17	Refractive error;
LUSC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg04369109	chr6:150039330	LATS1	-0.56	-8.21	-0.41	4.77e-15	Lung cancer;
LUSC	cis	rs10465746	0.809	rs2389617	chr1:84437652	A/T	cg10977910	chr1:84465055	TTLL7	0.43	6.29	0.33	1.02e-9	Obesity-related traits;
LUSC	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.38	-6.24	-0.32	1.31e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg23711669	chr6:146136114	FBXO30	0.84	15.31	0.64	1.92e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7000551	0.715	rs1530874	chr8:22347777	G/C	cg12081754	chr8:22256438	SLC39A14	0.45	6.95	0.36	1.89e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg23630131	chr7:65973040	NA	0.2	5.66	0.3	3.25e-8	Aortic root size;
LUSC	cis	rs7084921	0.608	rs12779818	chr10:101866118	G/A	cg02250046	chr10:101825185	CPN1	-0.34	-6.28	-0.33	1.03e-9	Bone mineral density;
LUSC	cis	rs1790761	0.967	rs1638556	chr11:67213518	A/G	cg24690094	chr11:67383802	NA	-0.31	-5.71	-0.3	2.46e-8	Mean corpuscular volume;
LUSC	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	0.89	14.74	0.63	3.23e-38	Schizophrenia;
LUSC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg19318889	chr4:1322082	MAEA	0.43	6.99	0.36	1.47e-11	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg00129232	chr17:37814104	STARD3	-0.47	-7.0	-0.36	1.39e-11	Asthma;
LUSC	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg12292205	chr6:26970375	C6orf41	-0.4	-5.9	-0.31	8.77e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12368055	chr3:15469185	METTL6;EAF1	-0.41	-6.17	-0.32	1.96e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.47	7.42	0.38	9.95e-13	Menarche (age at onset);
LUSC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.76	-0.35	6.26e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg13334819	chr7:99746414	C7orf59	0.49	6.5	0.34	2.96e-10	Coronary artery disease;
LUSC	cis	rs9398803	0.965	rs6919397	chr6:126659043	A/C	cg19875578	chr6:126661172	C6orf173	0.37	5.66	0.3	3.22e-8	Male-pattern baldness;
LUSC	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg07828340	chr4:882639	GAK	1.09	10.99	0.52	3.44e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.48	-8.37	-0.42	1.59e-15	Longevity;Endometriosis;
LUSC	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg22681709	chr2:178499509	PDE11A	-0.48	-8.48	-0.42	7.37e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.62	-0.43	2.69e-16	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg01879757	chr17:41196368	BRCA1	-0.46	-6.92	-0.35	2.26e-11	Menopause (age at onset);
LUSC	cis	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-6.74	-0.35	6.91e-11	Morning vs. evening chronotype;
LUSC	cis	rs6005807	0.719	rs9625522	chr22:29045212	C/A	cg12565055	chr22:29076175	TTC28	0.54	5.86	0.31	1.12e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs2970818	0.764	rs11063161	chr12:4569117	C/T	cg11146114	chr12:4671731	NA	-0.62	-5.87	-0.31	1.03e-8	Phosphorus levels;
LUSC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg02269571	chr22:50332266	NA	0.5	7.45	0.38	8.12e-13	Schizophrenia;
LUSC	cis	rs11640533	1.000	rs11640533	chr16:53412862	A/G	cg10144400	chr16:53407678	NA	-0.41	-6.19	-0.32	1.77e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.77	-0.35	5.69e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7903847	0.642	rs7092499	chr10:99140313	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.47	-0.38	7.17e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg00225070	chr15:80189496	MTHFS	0.42	6.15	0.32	2.27e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.48e-24	Aortic root size;
LUSC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg24562669	chr7:97807699	LMTK2	0.35	6.03	0.31	4.42e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg23719950	chr11:63933701	MACROD1	-0.62	-8.12	-0.41	9.04e-15	Mean platelet volume;
LUSC	cis	rs977987	0.843	rs12927562	chr16:75482860	G/A	cg03315344	chr16:75512273	CHST6	0.49	9.36	0.46	1.17e-18	Dupuytren's disease;
LUSC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.15	-0.32	2.26e-9	Neutrophil percentage of white cells;
LUSC	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg16482183	chr6:26056742	HIST1H1C	0.66	9.13	0.45	6.79e-18	Iron status biomarkers;
LUSC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg18230493	chr5:56204884	C5orf35	0.58	9.14	0.45	6.19e-18	Coronary artery disease;
LUSC	cis	rs8099014	0.861	rs4940706	chr18:56121803	C/T	cg12907477	chr18:56117327	MIR122	-0.5	-7.11	-0.36	7.15e-12	Platelet count;
LUSC	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg00898013	chr13:113819073	PROZ	-0.52	-7.74	-0.39	1.19e-13	Platelet distribution width;
LUSC	cis	rs10484885	0.793	rs1465954	chr6:90475013	G/A	cg13799429	chr6:90582589	CASP8AP2	0.92	11.07	0.52	1.86e-24	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg18827107	chr12:86230957	RASSF9	0.46	6.96	0.36	1.86e-11	Major depressive disorder;
LUSC	cis	rs2286885	1.000	rs741025	chr9:129251792	C/T	cg15282417	chr9:129245246	FAM125B	0.39	6.72	0.35	7.65e-11	Intraocular pressure;
LUSC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg09165964	chr15:75287851	SCAMP5	0.46	6.83	0.35	4.14e-11	Breast cancer;
LUSC	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg05855489	chr10:104503620	C10orf26	0.92	18.54	0.71	3.01e-53	Waist circumference;Hip circumference;
LUSC	cis	rs72634258	0.519	rs744001	chr1:7934557	G/A	cg00042356	chr1:8021962	PARK7	0.63	7.17	0.37	4.86e-12	Inflammatory bowel disease;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg10982358	chr1:51435615	CDKN2C	0.44	6.53	0.34	2.49e-10	Schizophrenia;
LUSC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	9.13	0.45	6.63e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs55728055	0.661	rs62239172	chr22:32047941	G/A	cg01338084	chr22:32026380	PISD	0.94	6.72	0.35	7.7e-11	Age-related hearing impairment;
LUSC	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg14689365	chr7:158441557	NCAPG2	-0.46	-6.19	-0.32	1.76e-9	Height;
LUSC	cis	rs9807989	0.839	rs10206753	chr2:102968362	T/C	cg09003973	chr2:102972529	NA	0.44	6.01	0.31	4.83e-9	Asthma;
LUSC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.39e-8	Aortic root size;
LUSC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg00049323	chr5:472564	LOC25845	-0.44	-6.8	-0.35	4.79e-11	Cystic fibrosis severity;
LUSC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg09365446	chr1:150670422	GOLPH3L	-0.43	-6.45	-0.33	3.93e-10	Tonsillectomy;
LUSC	cis	rs7818345	0.967	rs4546679	chr8:19283335	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	7.48	0.38	6.81e-13	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg07741184	chr6:167504864	NA	0.45	7.62	0.38	2.64e-13	Primary biliary cholangitis;
LUSC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg05896524	chr21:47604654	C21orf56	-0.49	-7.54	-0.38	4.44e-13	Testicular germ cell tumor;
LUSC	trans	rs6982636	1.000	rs2980868	chr8:126488235	C/T	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.33	-6.32	-0.33	8.36e-10	Lipid metabolism phenotypes;
LUSC	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg06885757	chr1:42089581	HIVEP3	-0.46	-9.52	-0.46	3.6e-19	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	1.02	17.93	0.7	8.01e-51	Parkinson's disease;
LUSC	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg22705602	chr4:152727874	NA	-0.32	-6.49	-0.33	3.05e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-12.68	-0.57	2.3e-30	Hemoglobin concentration;
LUSC	cis	rs1775715	0.737	rs2799017	chr10:32203460	A/G	cg03015672	chr10:32216066	ARHGAP12	0.34	6.22	0.32	1.49e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.39e-22	Alzheimer's disease (late onset);
LUSC	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg17757837	chr7:157058334	UBE3C	-0.82	-13.31	-0.59	1.01e-32	Body mass index;
LUSC	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg17757837	chr7:157058334	UBE3C	0.83	13.33	0.59	8.46e-33	Body mass index;
LUSC	cis	rs41271473	1.000	rs55956922	chr1:228872549	T/A	cg10167378	chr1:228756711	NA	0.54	6.58	0.34	1.87e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg11244672	chr19:19639970	YJEFN3	-0.48	-6.39	-0.33	5.44e-10	Tonsillectomy;
LUSC	cis	rs7809950	0.817	rs11535285	chr7:107143866	A/G	cg23024343	chr7:107201750	COG5	-0.69	-10.12	-0.48	3.48e-21	Coronary artery disease;
LUSC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.55	9.02	0.44	1.54e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7572644	0.766	rs12165240	chr2:28172125	A/T	cg27432699	chr2:27873401	GPN1	-0.52	-6.52	-0.34	2.64e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6977660	0.943	rs12668201	chr7:19831610	A/C	cg07541023	chr7:19748670	TWISTNB	-0.56	-6.52	-0.34	2.54e-10	Thyroid stimulating hormone;
LUSC	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg16989719	chr2:238392110	NA	-0.42	-6.73	-0.35	7.45e-11	Prostate cancer;
LUSC	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg16359550	chr11:109292809	C11orf87	0.32	5.78	0.3	1.74e-8	Schizophrenia;
LUSC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.92	-0.81	3.6e-78	Height;
LUSC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg26513180	chr16:89883248	FANCA	0.66	6.64	0.34	1.24e-10	Skin colour saturation;
LUSC	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.81	0.7	2.41e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg09796270	chr17:17721594	SREBF1	0.42	7.36	0.37	1.44e-12	Total body bone mineral density;
LUSC	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg08000102	chr2:233561755	GIGYF2	-0.8	-13.87	-0.6	7.07e-35	Schizophrenia;
LUSC	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.68	-0.39	1.78e-13	Morning vs. evening chronotype;
LUSC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	12.42	0.56	2.25e-29	Personality dimensions;
LUSC	cis	rs472402	0.560	rs2303705	chr5:6622017	A/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.51	-7.54	-0.38	4.39e-13	Response to amphetamines;
LUSC	cis	rs12190007	0.547	rs3006184	chr6:169805128	C/T	cg15038512	chr6:170123185	PHF10	-0.38	-6.14	-0.32	2.34e-9	Obesity-related traits;
LUSC	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-8.2	-0.41	5.21e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23544223	chr18:12777786	NA	-0.56	-5.8	-0.3	1.51e-8	Inflammatory skin disease;
LUSC	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg03161606	chr19:29218774	NA	0.49	6.06	0.31	3.67e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06481639	chr22:41940642	POLR3H	0.5	5.72	0.3	2.42e-8	Vitiligo;
LUSC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.55	0.34	2.2e-10	Menopause (age at onset);
LUSC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg13206674	chr6:150067644	NUP43	0.63	10.08	0.48	4.97e-21	Lung cancer;
LUSC	cis	rs9473147	0.543	rs9473119	chr6:47450618	G/A	cg20196966	chr6:47445060	CD2AP	0.42	5.92	0.31	7.99e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs922692	0.715	rs11072803	chr15:79077878	G/A	cg00540400	chr15:79124168	NA	-0.41	-7.06	-0.36	9.95e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg27471124	chr11:109292789	C11orf87	0.41	7.09	0.36	8.05e-12	Schizophrenia;
LUSC	cis	rs2446066	0.659	rs34109204	chr12:53872283	C/A	cg20730629	chr12:53886622	MAP3K12	-0.47	-5.98	-0.31	5.66e-9	Red blood cell count;
LUSC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg26513180	chr16:89883248	FANCA	0.91	17.66	0.69	9.25e-50	Vitiligo;
LUSC	trans	rs12145833	0.596	rs12043646	chr1:243281992	G/A	cg01826367	chr1:224180288	NA	0.67	6.26	0.32	1.21e-9	Obesity (early onset extreme);
LUSC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-6.65	-0.34	1.21e-10	Mean corpuscular volume;
LUSC	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg13010199	chr12:38710504	ALG10B	0.64	9.78	0.47	4.83e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg26727032	chr16:67993705	SLC12A4	-0.43	-6.84	-0.35	3.69e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1784581	0.588	rs6415086	chr6:162418147	C/T	cg17173639	chr6:162384350	PARK2	0.57	9.98	0.48	1.09e-20	Itch intensity from mosquito bite;
LUSC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-10.64	-0.5	6.05e-23	Bipolar disorder;
LUSC	cis	rs7106204	0.668	rs7951530	chr11:24246904	T/C	ch.11.24196551F	chr11:24239977	NA	1.14	14.03	0.61	1.83e-35	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg00277334	chr10:82204260	NA	-0.45	-6.28	-0.32	1.07e-9	Post bronchodilator FEV1;
LUSC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07677032	chr17:61819896	STRADA	0.54	8.94	0.44	2.71e-17	Prudent dietary pattern;
LUSC	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg16230307	chr14:35515116	FAM177A1	0.78	9.88	0.48	2.39e-20	Psoriasis;
LUSC	cis	rs62400317	0.859	rs4498350	chr6:45268438	C/T	cg18551225	chr6:44695536	NA	-0.43	-7.12	-0.36	6.86e-12	Total body bone mineral density;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18404039	chr20:3184938	DDRGK1	0.46	7.05	0.36	1.01e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9581857	0.615	rs79553479	chr13:28007862	G/A	cg22138327	chr13:27999177	GTF3A	0.89	9.45	0.46	6.21e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs6987853	0.787	rs2974351	chr8:42407047	A/T	cg09913449	chr8:42400586	C8orf40	0.53	9.22	0.45	3.48e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4780401	0.539	rs62040604	chr16:11803641	G/A	cg01061890	chr16:11836724	TXNDC11	-0.57	-8.54	-0.42	4.96e-16	Rheumatoid arthritis;
LUSC	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.66	-10.71	-0.51	3.21e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg16447950	chr5:562315	NA	0.53	6.6	0.34	1.58e-10	Obesity-related traits;
LUSC	cis	rs8114671	0.647	rs1415771	chr20:33734493	G/A	cg24642439	chr20:33292090	TP53INP2	0.4	5.74	0.3	2.08e-8	Height;
LUSC	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.73	11.15	0.52	9.17e-25	Eosinophil percentage of white cells;
LUSC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg23625390	chr15:77176239	SCAPER	0.46	7.0	0.36	1.44e-11	Blood metabolite levels;
LUSC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.6	8.84	0.44	5.69e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2455601	0.573	rs2653573	chr11:8989874	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-5.97	-0.31	6.03e-9	Schizophrenia;
LUSC	cis	rs735860	0.687	rs2294852	chr6:53157214	C/G	cg10236188	chr6:53219634	NA	-0.38	-6.04	-0.31	4.05e-9	Glaucoma;
LUSC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19346786	chr7:2764209	NA	-0.43	-7.14	-0.36	5.9e-12	Height;
LUSC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.66	0.57	2.79e-30	Prudent dietary pattern;
LUSC	trans	rs62238980	0.614	rs75584049	chr22:32468790	C/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs12956009	0.518	rs1560902	chr18:44898765	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.44	0.33	4.13e-10	Educational attainment (years of education);
LUSC	cis	rs9462027	0.628	rs2744957	chr6:34618516	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.91	-0.31	8.54e-9	Systemic lupus erythematosus;
LUSC	cis	rs968451	0.906	rs12628367	chr22:39717104	A/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	8.51	0.42	6.07e-16	Primary biliary cholangitis;
LUSC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg11645453	chr3:52864694	ITIH4	0.37	8.58	0.43	3.5e-16	Bipolar disorder;
LUSC	cis	rs6845621	0.901	rs10030946	chr4:18927120	T/C	cg12196642	chr4:18937545	NA	-0.35	-6.46	-0.33	3.74e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	trans	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg18335740	chr13:41363409	SLC25A15	-0.56	-8.45	-0.42	9.1e-16	Lewy body disease;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg27280034	chr8:59465622	SDCBP	-0.51	-6.56	-0.34	2.04e-10	Neuroticism;
LUSC	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg08085267	chr17:45401833	C17orf57	-0.51	-7.29	-0.37	2.22e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg26384229	chr12:38710491	ALG10B	0.7	10.84	0.51	1.12e-23	Morning vs. evening chronotype;
LUSC	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	0.92	8.03	0.4	1.65e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7589342	0.831	rs6714861	chr2:106518893	C/T	cg16077055	chr2:106428750	NCK2	-0.32	-6.14	-0.32	2.3e-9	Addiction;
LUSC	cis	rs6546550	0.935	rs3771541	chr2:70031797	C/G	cg02498382	chr2:70120550	SNRNP27	-0.29	-6.9	-0.35	2.68e-11	Prevalent atrial fibrillation;
LUSC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.5	0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs983392	0.805	rs7926344	chr11:59962166	G/A	cg20284999	chr11:59952153	MS4A6A	-0.39	-6.44	-0.33	4.21e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7264396	0.836	rs41293080	chr20:34187697	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.73	-0.39	1.26e-13	Total cholesterol levels;
LUSC	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.71	0.34	8.46e-11	IgG glycosylation;
LUSC	cis	rs240764	0.817	rs239229	chr6:101105975	T/C	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.69e-9	Neuroticism;
LUSC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.07	-17.76	-0.7	3.74e-50	Primary sclerosing cholangitis;
LUSC	trans	rs1998174	0.509	rs2235696	chr1:171811469	A/T	cg13482142	chr2:234261155	NA	0.42	6.02	0.31	4.51e-9	Platelet distribution width;
LUSC	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg05738196	chr6:26577821	NA	-0.6	-7.21	-0.37	3.78e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg18187862	chr3:45730750	SACM1L	0.57	7.08	0.36	8.31e-12	Primary sclerosing cholangitis;
LUSC	cis	rs9815354	0.680	rs73073296	chr3:42028074	G/A	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg24675658	chr1:53192096	ZYG11B	-0.58	-9.11	-0.45	7.64e-18	Monocyte count;
LUSC	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.83	-0.44	6.04e-17	Total cholesterol levels;
LUSC	cis	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg07988820	chr12:82153109	PPFIA2	-0.41	-5.9	-0.31	9.13e-9	Resting heart rate;
LUSC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.59	10.66	0.5	4.93e-23	Bone mineral density;
LUSC	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07636037	chr3:49044803	WDR6	0.71	9.64	0.47	1.48e-19	Menarche (age at onset);
LUSC	trans	rs8060598	0.866	rs3135499	chr16:50766127	G/T	cg06583108	chr12:85430029	TSPAN19;LRRIQ1	-0.4	-6.07	-0.32	3.5e-9	Leprosy;
LUSC	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg16579770	chr16:72058938	DHODH	0.35	5.86	0.31	1.08e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26623224	chr19:49661080	TRPM4	-0.49	-5.97	-0.31	5.94e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.21	0.74	6.52e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4974559	0.948	rs3856982	chr4:1328863	C/T	cg02980000	chr4:1222292	CTBP1	-0.65	-7.49	-0.38	6.32e-13	Systolic blood pressure;
LUSC	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.21	0.37	3.73e-12	Mean platelet volume;
LUSC	cis	rs7945718	1.000	rs7945718	chr11:12748819	A/G	cg25843174	chr11:12811716	TEAD1	0.32	7.04	0.36	1.09e-11	Educational attainment (years of education);
LUSC	cis	rs4629180	0.593	rs6707517	chr2:102089878	C/T	cg01388757	chr2:102091195	RFX8	-0.44	-7.09	-0.36	7.79e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg20701182	chr2:24300061	SF3B14	0.73	7.42	0.38	9.58e-13	Lymphocyte counts;
LUSC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg02696742	chr7:106810147	HBP1	-0.63	-9.56	-0.46	2.67e-19	Coronary artery disease;
LUSC	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg21775007	chr8:11205619	TDH	-0.52	-7.56	-0.38	3.9e-13	Triglycerides;
LUSC	trans	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.05	-0.31	3.9e-9	Triglycerides;
LUSC	cis	rs3925075	1.000	rs9674009	chr16:31347541	C/A	cg02846316	chr16:31340340	ITGAM	0.36	6.66	0.34	1.11e-10	IgA nephropathy;
LUSC	cis	rs524023	0.914	rs11607663	chr11:64368670	G/C	cg19131476	chr11:64387923	NRXN2	-0.39	-10.47	-0.5	2.21e-22	Urate levels in obese individuals;
LUSC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg18904891	chr8:8559673	CLDN23	0.42	6.56	0.34	2.05e-10	Mood instability;
LUSC	cis	rs11690935	0.843	rs9784123	chr2:172785005	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.8	-12.19	-0.55	1.61e-28	Schizophrenia;
LUSC	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg26752003	chr8:145688521	CYHR1	0.69	11.86	0.54	2.51e-27	Age at first birth;
LUSC	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg04586622	chr2:25135609	ADCY3	0.42	8.99	0.44	1.88e-17	Body mass index;
LUSC	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg04218760	chr10:45406644	TMEM72	-0.29	-7.14	-0.36	5.82e-12	Mean corpuscular volume;
LUSC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08219700	chr8:58056026	NA	0.64	7.4	0.38	1.14e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg15485101	chr11:133734466	NA	0.39	7.36	0.37	1.46e-12	Childhood ear infection;
LUSC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.1	14.83	0.63	1.35e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg17691542	chr6:26056736	HIST1H1C	0.52	7.77	0.39	9.47e-14	Height;
LUSC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-7.23	-0.37	3.4e-12	Colorectal cancer;
LUSC	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg03676636	chr4:99064102	C4orf37	0.36	8.01	0.4	1.97e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1943345	0.642	rs642669	chr11:82892454	A/T	cg07047830	chr11:82868014	PCF11	0.65	9.61	0.47	1.78e-19	Obesity-related traits;
LUSC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg21251018	chr6:28226885	NKAPL	-0.34	-6.57	-0.34	1.94e-10	Pubertal anthropometrics;
LUSC	cis	rs7524258	1.000	rs7524258	chr1:7292229	T/C	cg07173049	chr1:7289937	CAMTA1	0.34	7.07	0.36	8.94e-12	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs12493885	0.769	rs61791504	chr3:153745537	C/G	cg17054900	chr3:154042577	DHX36	-0.63	-6.79	-0.35	5.28e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1499972	0.941	rs62263119	chr3:117630175	T/G	cg07612923	chr3:117604196	NA	0.64	5.76	0.3	1.95e-8	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.08	-0.4	1.19e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg06521331	chr12:34319734	NA	-0.48	-7.7	-0.39	1.56e-13	Morning vs. evening chronotype;
LUSC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg20887711	chr4:1340912	KIAA1530	0.44	6.57	0.34	1.97e-10	Obesity-related traits;
LUSC	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.85	14.71	0.63	4.19e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg03806693	chr22:41940476	POLR3H	-0.51	-6.96	-0.36	1.86e-11	Neuroticism;
LUSC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg00316803	chr15:76480434	C15orf27	-0.4	-7.02	-0.36	1.26e-11	Blood metabolite levels;
LUSC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.72	-0.57	1.64e-30	Alzheimer's disease;
LUSC	cis	rs3820928	0.874	rs12614648	chr2:227785535	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.01	-0.4	1.99e-14	Pulmonary function;
LUSC	cis	rs7771547	0.573	rs546272	chr6:36398562	G/A	cg07856975	chr6:36356162	ETV7	0.35	6.26	0.32	1.21e-9	Platelet distribution width;
LUSC	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17507749	chr15:85114479	UBE2QP1	0.56	7.19	0.37	4.23e-12	Schizophrenia;
LUSC	cis	rs7903847	0.642	rs7078004	chr10:99140511	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.33	-0.37	1.78e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg06618935	chr21:46677482	NA	0.39	8.1	0.41	1.02e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg22800045	chr5:56110881	MAP3K1	0.8	10.65	0.5	5.23e-23	Initial pursuit acceleration;
LUSC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg27266027	chr21:40555129	PSMG1	0.4	5.88	0.31	1e-8	Cognitive function;
LUSC	cis	rs7188861	0.768	rs1646026	chr16:11382695	C/T	cg00044050	chr16:11439710	C16orf75	0.56	6.31	0.33	8.71e-10	HDL cholesterol;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg24101359	chr6:42928495	GNMT	0.38	6.43	0.33	4.49e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg05527609	chr1:210001259	C1orf107	0.67	9.63	0.47	1.5700000000000001e-19	Orofacial clefts;
LUSC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.75	-10.46	-0.5	2.53e-22	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg21643547	chr1:205240462	TMCC2	-0.41	-7.54	-0.38	4.37e-13	Red blood cell count;
LUSC	cis	rs6681460	0.901	rs1373911	chr1:67041065	T/C	cg02459107	chr1:67143332	SGIP1	0.44	7.8	0.39	7.81e-14	Presence of antiphospholipid antibodies;
LUSC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg09877947	chr5:131593287	PDLIM4	0.58	9.82	0.47	3.56e-20	Acylcarnitine levels;
LUSC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg17986701	chr20:44574422	PCIF1	0.41	7.18	0.37	4.44e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs6600671	1.000	rs4844607	chr1:121184059	C/T	cg09829573	chr1:144692074	NBPF9	0.33	6.32	0.33	8.2e-10	Hip geometry;
LUSC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg05754148	chr16:3507555	NAT15	0.83	8.66	0.43	1.98e-16	Tuberculosis;
LUSC	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg07382826	chr16:28625726	SULT1A1	0.28	5.86	0.31	1.14e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.6	9.88	0.48	2.28e-20	Bone mineral density;
LUSC	cis	rs7264396	0.832	rs224378	chr20:34088764	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.23	-0.32	1.44e-9	Total cholesterol levels;
LUSC	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg23855989	chr12:50355821	AQP5	0.72	11.72	0.54	8.32e-27	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-18.01	-0.7	3.71e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg16329197	chr12:53359506	NA	-0.67	-9.42	-0.46	7.57e-19	Cancer (pleiotropy);
LUSC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg03036452	chr22:46663545	TTC38	0.52	5.7	0.3	2.69e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7577696	0.962	rs2235134	chr2:32332543	G/A	cg02381751	chr2:32503542	YIPF4	-0.4	-5.68	-0.3	2.93e-8	Inflammatory biomarkers;
LUSC	cis	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg04896959	chr15:78267971	NA	-0.42	-6.66	-0.34	1.12e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7665147	1	rs7665147	chr4:57767327	T/A	cg26694713	chr4:57773883	REST	0.52	6.37	0.33	6.11e-10	Platelet count;
LUSC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.72	-0.43	1.28e-16	Electroencephalogram traits;
LUSC	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg22709100	chr7:91322751	NA	0.39	5.78	0.3	1.68e-8	Breast cancer;
LUSC	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08109568	chr15:31115862	NA	-0.67	-9.13	-0.45	6.55e-18	Huntington's disease progression;
LUSC	cis	rs3820928	0.709	rs2894627	chr2:227910171	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-6.92	-0.35	2.39e-11	Pulmonary function;
LUSC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.75	-0.35	6.5e-11	Menopause (age at onset);
LUSC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg09034736	chr1:150693464	HORMAD1	0.49	7.13	0.36	6.06e-12	Tonsillectomy;
LUSC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg11062466	chr8:58055876	NA	0.52	7.02	0.36	1.27e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg23978390	chr7:1156363	C7orf50	0.48	5.75	0.3	2.04e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg13535736	chr9:111863775	C9orf5	-0.4	-6.6	-0.34	1.59e-10	Menarche (age at onset);
LUSC	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	9.49	0.46	4.43e-19	Lung cancer in ever smokers;
LUSC	cis	rs2281558	1.000	rs2281558	chr20:25240189	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.55	8.16	0.41	7.03e-15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg17948913	chr5:572064	NA	0.36	6.08	0.32	3.32e-9	Obesity-related traits;
LUSC	cis	rs4474465	1.000	rs7927722	chr11:78210893	T/C	cg27205649	chr11:78285834	NARS2	0.54	6.13	0.32	2.46e-9	Alzheimer's disease (survival time);
LUSC	cis	rs11997175	0.624	rs4621768	chr8:33677452	T/C	ch.8.33884649F	chr8:33765107	NA	0.47	7.1	0.36	7.41e-12	Body mass index;
LUSC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg05896524	chr21:47604654	C21orf56	0.54	8.18	0.41	6.04e-15	Testicular germ cell tumor;
LUSC	cis	rs6728861	1	rs6728861	chr2:203873743	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	8.22	0.41	4.56e-15	Coronary artery disease;
LUSC	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg11621586	chr10:70884670	VPS26A	1.17	14.83	0.63	1.45e-38	Left atrial antero-posterior diameter;
LUSC	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg22437258	chr11:111473054	SIK2	0.51	6.93	0.35	2.15e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg09509183	chr1:209979624	IRF6	0.52	6.21	0.32	1.61e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg16586182	chr3:47516702	SCAP	0.54	8.58	0.43	3.6e-16	Colorectal cancer;
LUSC	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.71	10.27	0.49	1.07e-21	Corneal astigmatism;
LUSC	cis	rs859767	0.540	rs6739706	chr2:135407409	A/C	cg12500956	chr2:135428796	TMEM163	-0.27	-6.29	-0.33	9.76e-10	Neuroticism;
LUSC	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg00745463	chr17:30367425	LRRC37B	-0.85	-10.0	-0.48	8.86e-21	Hip circumference adjusted for BMI;
LUSC	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	1.04	17.84	0.7	1.71e-50	Testicular germ cell tumor;
LUSC	cis	rs7043114	0.525	rs7864630	chr9:95267560	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.7	-0.34	9.03e-11	Height;
LUSC	cis	rs9341808	0.667	rs1575541	chr6:80917485	T/A	cg08355045	chr6:80787529	NA	0.46	7.95	0.4	2.94e-14	Sitting height ratio;
LUSC	cis	rs3850699	0.683	rs67481356	chr10:104317811	C/A	cg04362960	chr10:104952993	NT5C2	0.52	6.95	0.36	1.88e-11	Prostate cancer;
LUSC	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg10326726	chr10:51549505	MSMB	-0.36	-6.3	-0.33	9.62e-10	Prostate-specific antigen levels;
LUSC	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs427394	1.000	rs182135	chr5:6747453	G/A	cg10857441	chr5:6722123	POLS	-0.41	-7.72	-0.39	1.38e-13	Menopause (age at onset);
LUSC	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg08997352	chr12:9597637	DDX12	-0.71	-11.07	-0.52	1.83e-24	Breast size;
LUSC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg18305652	chr10:134549665	INPP5A	0.45	6.85	0.35	3.46e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.2	-0.32	1.66e-9	Life satisfaction;
LUSC	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14240646	chr10:27532245	ACBD5	-0.5	-6.98	-0.36	1.56e-11	Breast cancer;
LUSC	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.56	0.38	3.98e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18876405	chr7:65276391	NA	0.48	6.42	0.33	4.57e-10	Corneal structure;
LUSC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-10.68	-0.5	4.36e-23	Monocyte count;
LUSC	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg05855489	chr10:104503620	C10orf26	0.55	6.42	0.33	4.69e-10	Arsenic metabolism;
LUSC	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg10523860	chr14:103875565	MARK3	-0.39	-6.11	-0.32	2.79e-9	Body mass index;
LUSC	cis	rs6546537	0.869	rs13035491	chr2:69827456	G/A	cg10773587	chr2:69614142	GFPT1	-0.54	-8.29	-0.41	2.87e-15	Serum thyroid-stimulating hormone levels;
LUSC	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg17830980	chr10:43048298	ZNF37B	-0.42	-6.51	-0.34	2.72e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg06145435	chr7:1022769	CYP2W1	0.3	6.43	0.33	4.37e-10	Longevity;Endometriosis;
LUSC	cis	rs6693567	0.565	rs3125808	chr1:150314272	T/C	cg15654264	chr1:150340011	RPRD2	0.44	7.02	0.36	1.22e-11	Migraine;
LUSC	cis	rs3736594	0.546	rs7571558	chr2:27839832	C/G	cg27432699	chr2:27873401	GPN1	0.62	8.48	0.42	7.18e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-6.7	-0.34	8.95e-11	Mean corpuscular volume;
LUSC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.31	-0.41	2.42e-15	Gut microbiome composition (summer);
LUSC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.89	-0.4	4.46e-14	Gut microbiome composition (summer);
LUSC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.4	6.73	0.35	7.57e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg04155289	chr7:94953770	PON1	-0.35	-5.87	-0.31	1.03e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7241530	0.662	rs1566903	chr18:75901684	T/C	cg14642773	chr18:75888474	NA	0.41	6.29	0.33	1.02e-9	Educational attainment (years of education);
LUSC	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.64	0.43	2.33e-16	Migraine;Coronary artery disease;
LUSC	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg05887092	chr17:76393375	PGS1	0.66	12.99	0.58	1.59e-31	HDL cholesterol levels;
LUSC	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg11502198	chr6:26597334	ABT1	0.59	9.08	0.44	9.97e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg25173405	chr17:45401733	C17orf57	-0.39	-5.92	-0.31	7.86e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg12386194	chr3:101231763	SENP7	0.45	6.35	0.33	7.23e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg03146154	chr1:46216737	IPP	0.51	7.66	0.39	2.08e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3733418	0.929	rs72697952	chr4:165900928	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.44	-5.65	-0.3	3.4e-8	Obesity-related traits;
LUSC	trans	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg06521331	chr12:34319734	NA	-0.4	-6.46	-0.33	3.72e-10	Morning vs. evening chronotype;
LUSC	cis	rs11625487	0.609	rs78371022	chr14:77971029	G/A	cg16049707	chr14:77965284	ISM2	-0.64	-6.58	-0.34	1.85e-10	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs983392	0.678	rs4938933	chr11:60034429	C/T	cg02771260	chr11:59836817	MS4A3	0.37	6.17	0.32	1.96e-9	Alzheimer's disease (late onset);
LUSC	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg17425144	chr1:10567563	PEX14	-0.62	-12.74	-0.57	1.48e-30	Prostate cancer;
LUSC	trans	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg04995722	chr7:26192034	NFE2L3	-0.37	-6.06	-0.31	3.67e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.62	9.46	0.46	5.51e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg23711669	chr6:146136114	FBXO30	0.87	16.1	0.66	1.44e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg06657462	chr10:94608040	EXOC6	0.4	6.01	0.31	4.73e-9	Schizophrenia;
LUSC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg05082376	chr22:42548792	NA	-0.4	-6.03	-0.31	4.41e-9	Schizophrenia;
LUSC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18404041	chr3:52824283	ITIH1	-0.63	-12.44	-0.56	1.91e-29	Bipolar disorder;
LUSC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.01	0.44	1.65e-17	Motion sickness;
LUSC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg10729496	chr3:10149963	C3orf24	0.57	7.48	0.38	6.62e-13	Alzheimer's disease;
LUSC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00149659	chr3:10157352	C3orf10	1.01	14.57	0.62	1.42e-37	Alzheimer's disease;
LUSC	cis	rs9296092	0.522	rs62405955	chr6:33527176	T/C	cg13560919	chr6:33536144	NA	-0.85	-16.44	-0.67	6.54e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg00191853	chr8:101177733	SPAG1	-0.39	-6.47	-0.33	3.49e-10	Atrioventricular conduction;
LUSC	cis	rs9309473	0.519	rs2421667	chr2:73832459	T/C	cg20560298	chr2:73613845	ALMS1	0.51	7.82	0.39	7e-14	Metabolite levels;
LUSC	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg23173402	chr1:227635558	NA	0.57	7.22	0.37	3.53e-12	Major depressive disorder;
LUSC	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.66e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	1.0	17.23	0.69	4.97e-48	Systemic lupus erythematosus;
LUSC	cis	rs7539409	0.651	rs910182	chr1:84297117	A/G	cg10977910	chr1:84465055	TTLL7	0.68	7.19	0.37	4.25e-12	Alzheimer's disease;
LUSC	cis	rs1044826	0.957	rs4683799	chr3:139210258	G/C	cg00490450	chr3:139108681	COPB2	0.51	7.12	0.36	6.45e-12	Obesity-related traits;
LUSC	cis	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.23	0.52	4.78e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1595825	0.678	rs57265854	chr2:198917263	C/A	cg00982548	chr2:198649783	BOLL	-0.56	-6.87	-0.35	3.09e-11	Ulcerative colitis;
LUSC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg25039879	chr17:56429692	SUPT4H1	0.7	9.21	0.45	3.73e-18	Cognitive test performance;
LUSC	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg16482183	chr6:26056742	HIST1H1C	0.65	9.13	0.45	6.68e-18	Iron status biomarkers;
LUSC	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg27539214	chr16:67997921	SLC12A4	-0.52	-6.77	-0.35	5.69e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.46	-0.5	2.48e-22	Alzheimer's disease;
LUSC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg04553112	chr3:125709451	NA	-0.48	-5.76	-0.3	1.92e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg01879757	chr17:41196368	BRCA1	-0.46	-7.1	-0.36	7.39e-12	Menopause (age at onset);
LUSC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg25319279	chr11:5960081	NA	-0.37	-5.83	-0.3	1.3e-8	DNA methylation (variation);
LUSC	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg04733989	chr22:42467013	NAGA	0.63	9.9	0.48	1.95e-20	Schizophrenia;
LUSC	cis	rs981844	0.714	rs2405204	chr4:154705248	A/G	cg14289246	chr4:154710475	SFRP2	-0.5	-7.04	-0.36	1.12e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg09034736	chr1:150693464	HORMAD1	0.41	5.72	0.3	2.38e-8	Melanoma;
LUSC	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.86e-12	Blood metabolite levels;
LUSC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg14895029	chr7:2775587	GNA12	-0.4	-6.14	-0.32	2.36e-9	Height;
LUSC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg16989086	chr20:62203971	PRIC285	0.45	6.34	0.33	7.32e-10	Glioblastoma;
LUSC	trans	rs6600671	0.902	rs2222371	chr1:121289118	T/C	cg00646200	chr1:148855367	NA	-0.51	-7.88	-0.4	4.75e-14	Hip geometry;
LUSC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg18350739	chr11:68623251	NA	-0.38	-6.61	-0.34	1.56e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg17366294	chr4:99064904	C4orf37	0.56	8.94	0.44	2.61e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7074356	0.915	rs17617970	chr10:82206892	A/G	cg00277334	chr10:82204260	NA	-0.66	-6.19	-0.32	1.8e-9	Borderline personality disorder;
LUSC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.78	-13.85	-0.6	8.68e-35	Cognitive function;
LUSC	cis	rs11018904	0.768	rs56160356	chr11:89987280	G/C	cg26138821	chr11:89956704	CHORDC1	-0.59	-6.72	-0.35	7.83e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6690583	0.524	rs12029690	chr1:85452867	C/G	cg11262906	chr1:85462892	MCOLN2	0.68	6.56	0.34	2.02e-10	Serum sulfate level;
LUSC	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg12473912	chr3:136751656	NA	0.39	6.82	0.35	4.29e-11	Neuroticism;
LUSC	cis	rs7843479	0.526	rs34802507	chr8:21773853	C/T	cg17168535	chr8:21777572	XPO7	0.72	12.24	0.56	1.06e-28	Mean corpuscular volume;
LUSC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg06808227	chr14:105710500	BRF1	-0.66	-10.31	-0.49	8.06e-22	Platelet count;
LUSC	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg05738196	chr6:26577821	NA	0.78	14.95	0.63	4.82e-39	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.8	-0.35	4.79e-11	Triglycerides;
LUSC	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-6.53	-0.34	2.48e-10	Homocysteine levels;
LUSC	trans	rs4674124	1.000	rs35304811	chr2:217759271	C/G	cg18563886	chr10:135203102	PAOX	-0.47	-6.53	-0.34	2.5e-10	Breast cancer;
LUSC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg03146154	chr1:46216737	IPP	-0.5	-7.26	-0.37	2.69e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.79	0.7	2.73e-50	Chronic sinus infection;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg04814837	chr3:133380720	TOPBP1	0.66	6.04	0.31	4.22e-9	Body mass index;
LUSC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.02	0.31	4.49e-9	Menopause (age at onset);
LUSC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg02773041	chr1:40204384	PPIE	0.54	8.26	0.41	3.35e-15	Blood protein levels;
LUSC	cis	rs16854884	1.000	rs17668478	chr3:143794370	G/A	cg06585982	chr3:143692056	C3orf58	0.45	6.1	0.32	2.86e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs41271473	1.000	rs11580020	chr1:228880466	A/G	cg16512390	chr1:228756714	NA	-0.5	-6.1	-0.32	2.93e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs6845621	0.901	rs1377151	chr4:18922884	A/C	cg12196642	chr4:18937545	NA	-0.38	-7.23	-0.37	3.39e-12	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.91	15.83	0.65	1.68e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.6	0.65	1.31e-41	Bladder cancer;
LUSC	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg18538332	chr22:24372958	LOC391322	-0.46	-8.24	-0.41	3.91e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs72781680	0.651	rs13019016	chr2:23894773	C/G	cg08917208	chr2:24149416	ATAD2B	0.86	9.19	0.45	4.2e-18	Lymphocyte counts;
LUSC	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg20307385	chr11:47447363	PSMC3	0.45	6.59	0.34	1.7e-10	Subjective well-being;
LUSC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg25258033	chr6:167368657	RNASET2	-0.5	-8.24	-0.41	3.98e-15	Crohn's disease;
LUSC	cis	rs2067615	0.560	rs1882542	chr12:107070049	A/C	cg15890332	chr12:107067104	RFX4	0.33	5.92	0.31	7.86e-9	Heart rate;
LUSC	cis	rs240764	0.658	rs4840147	chr6:101182323	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-6.32	-0.33	8.54e-10	Neuroticism;
LUSC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	21.31	0.76	3.25e-64	Prudent dietary pattern;
LUSC	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.7	-10.69	-0.51	3.76e-23	Alcohol dependence;
LUSC	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg13010344	chr12:123464640	ARL6IP4	-0.44	-5.92	-0.31	7.93e-9	Neutrophil percentage of white cells;
LUSC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10802521	chr3:52805072	NEK4	-0.47	-6.84	-0.35	3.7e-11	Bipolar disorder;
LUSC	cis	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg06521331	chr12:34319734	NA	-0.48	-7.71	-0.39	1.43e-13	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.72	-0.35	7.68e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.8	-14.93	-0.63	5.85e-39	Obesity-related traits;
LUSC	cis	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.4e-10	Ulcerative colitis;
LUSC	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.69	-12.52	-0.57	9.13e-30	Platelet distribution width;
LUSC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg20744362	chr22:50050164	C22orf34	0.39	8.01	0.4	1.96e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg08270630	chr22:50330655	NA	0.41	6.06	0.31	3.64e-9	Schizophrenia;
LUSC	cis	rs6669919	0.553	rs12733443	chr1:211667751	C/T	cg10512769	chr1:211675356	NA	-0.29	-6.94	-0.36	1.99e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15947940	chr1:39957129	BMP8A	0.68	6.06	0.31	3.67e-9	Cognitive performance;
LUSC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg04369109	chr6:150039330	LATS1	-0.55	-8.22	-0.41	4.54e-15	Lung cancer;
LUSC	cis	rs7799006	0.606	rs4721527	chr7:2306655	G/A	cg02951883	chr7:2050386	MAD1L1	-0.35	-5.64	-0.3	3.54e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg07169764	chr2:136633963	MCM6	-0.57	-7.67	-0.39	1.95e-13	Mosquito bite size;
LUSC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg20307385	chr11:47447363	PSMC3	0.44	5.68	0.3	2.95e-8	Subjective well-being;
LUSC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06022373	chr22:39101656	GTPBP1	0.84	14.01	0.61	2.17e-35	Menopause (age at onset);
LUSC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	11.96	0.55	1.1e-27	Menopause (age at onset);
LUSC	cis	rs8040855	0.559	rs6496801	chr15:85728399	G/A	cg04831495	chr15:85060580	GOLGA6L5	0.49	7.86	0.39	5.5e-14	Bulimia nervosa;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08979737	chr8:97505843	SDC2	-0.48	-6.47	-0.33	3.49e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06850241	chr22:41845214	NA	0.34	6.22	0.32	1.49e-9	Vitiligo;
LUSC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25072359	chr17:41440525	NA	0.64	8.98	0.44	1.97e-17	Menopause (age at onset);
LUSC	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2.04e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.78	11.76	0.54	5.79e-27	Corneal astigmatism;
LUSC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	6.93	0.35	2.23e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg07856975	chr6:36356162	ETV7	0.34	6.17	0.32	1.93e-9	Platelet distribution width;
LUSC	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.57	0.38	3.75e-13	Blood metabolite levels;
LUSC	cis	rs8051149	0.688	rs16943320	chr16:87870379	A/G	cg01412419	chr16:87856264	NA	0.47	7.43	0.38	9.11e-13	Blood metabolite levels;
LUSC	cis	rs4713675	0.584	rs6917140	chr6:33678394	C/G	cg14003231	chr6:33640908	ITPR3	0.29	5.69	0.3	2.82e-8	Plateletcrit;
LUSC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-6.47	-0.33	3.47e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.65	-0.54	1.53e-26	Schizophrenia;
LUSC	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg10167378	chr1:228756711	NA	0.76	9.78	0.47	5.16e-20	Chronic lymphocytic leukemia;
LUSC	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.74	-14.69	-0.63	5.13e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1505368	0.837	rs10167244	chr2:213281310	A/G	cg16329650	chr2:213403929	ERBB4	0.57	9.7	0.47	9.17e-20	Symmetrical dimethylarginine levels;
LUSC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08859206	chr1:53392774	SCP2	0.5	8.58	0.43	3.56e-16	Monocyte count;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18815006	chr10:71906516	TYSND1	0.77	6.03	0.31	4.25e-9	Cognitive performance;
LUSC	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs9463078	0.528	rs12196818	chr6:44911414	G/A	cg25276700	chr6:44698697	NA	0.28	5.8	0.3	1.55e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg09034736	chr1:150693464	HORMAD1	0.42	5.82	0.3	1.42e-8	Melanoma;
LUSC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg12310025	chr6:25882481	NA	0.43	7.36	0.37	1.49e-12	Blood metabolite levels;
LUSC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg05025164	chr4:1340916	KIAA1530	0.41	6.35	0.33	6.97e-10	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg08888203	chr3:10149979	C3orf24	0.65	8.96	0.44	2.4e-17	Alzheimer's disease;
LUSC	cis	rs1355223	0.867	rs3818514	chr11:34680053	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.86	-0.31	1.13e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22442454	chr1:209979470	IRF6	0.43	5.88	0.31	9.86e-9	Cleft lip with or without cleft palate;
LUSC	trans	rs72674100	1.000	rs17026369	chr4:97989437	C/G	cg09670535	chr1:18959427	PAX7	-0.62	-6.34	-0.33	7.58e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg08392591	chr16:89556376	ANKRD11	0.52	8.19	0.41	5.69e-15	Multiple myeloma (IgH translocation);
LUSC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.74	-12.13	-0.55	2.7e-28	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.87	-0.4	5.04e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg21890820	chr11:65308645	LTBP3	0.51	7.65	0.39	2.21e-13	Bone mineral density;
LUSC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.05	-0.31	3.97e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03264133	chr6:25882463	NA	-0.5	-9.15	-0.45	5.96e-18	Blood metabolite levels;
LUSC	cis	rs6489882	0.867	rs4766663	chr12:113362974	C/T	cg20102336	chr12:113376681	OAS3	0.43	6.05	0.31	3.79e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg25174290	chr11:3078921	CARS	0.6	9.47	0.46	5.17e-19	Longevity;
LUSC	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.47	0.38	7.1e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg05163923	chr11:71159392	DHCR7	0.75	11.16	0.52	8.43e-25	Vitamin D levels;
LUSC	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.67	-0.34	1.06e-10	Bladder cancer;
LUSC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg25258033	chr6:167368657	RNASET2	-0.47	-7.82	-0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg09915433	chr19:53449742	NA	0.61	9.77	0.47	5.55e-20	Psoriasis;
LUSC	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-10.13	-0.48	3.2e-21	Schizophrenia;
LUSC	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg27471124	chr11:109292789	C11orf87	0.38	6.94	0.35	2.08e-11	Schizophrenia;
LUSC	cis	rs9309473	0.519	rs13022145	chr2:73863473	G/A	cg20560298	chr2:73613845	ALMS1	0.43	6.51	0.34	2.7e-10	Metabolite levels;
LUSC	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg18132916	chr6:79620363	NA	-0.37	-5.73	-0.3	2.28e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs79149102	0.579	rs7172065	chr15:75321910	C/T	cg09165964	chr15:75287851	SCAMP5	-0.93	-7.92	-0.4	3.52e-14	Lung cancer;
LUSC	cis	rs977987	0.832	rs37597	chr16:75500275	T/G	cg04384234	chr16:75411784	CFDP1	0.5	8.1	0.41	1.02e-14	Dupuytren's disease;
LUSC	cis	rs2040771	0.745	rs2283646	chr22:19273902	A/G	cg02655711	chr22:19163373	SLC25A1	-0.43	-7.69	-0.39	1.61e-13	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg15468180	chr1:107600409	PRMT6	0.42	6.66	0.34	1.1e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	1e-64	Prudent dietary pattern;
LUSC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg18230493	chr5:56204884	C5orf35	-0.58	-9.05	-0.44	1.21e-17	Coronary artery disease;
LUSC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg08219700	chr8:58056026	NA	0.56	6.75	0.35	6.65e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg24112000	chr20:60950667	NA	0.36	5.75	0.3	2.05e-8	Colorectal cancer;
LUSC	cis	rs2274273	0.774	rs17128440	chr14:55861912	C/T	cg04306507	chr14:55594613	LGALS3	0.56	12.61	0.57	4.38e-30	Protein biomarker;
LUSC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.94	0.44	2.75e-17	Lung cancer;
LUSC	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg23992470	chr4:843637	GAK	0.53	5.66	0.3	3.33e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs17102423	1.000	rs4902365	chr14:65602064	T/C	cg11161011	chr14:65562177	MAX	-0.63	-9.73	-0.47	7.53e-20	Obesity-related traits;
LUSC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-6.56	-0.34	2.04e-10	Electroencephalogram traits;
LUSC	cis	rs75229567	0.717	rs17107156	chr12:70234066	A/G	cg10114359	chr12:70132523	RAB3IP	-1.03	-9.55	-0.46	2.89e-19	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg11244672	chr19:19639970	YJEFN3	-0.56	-7.19	-0.37	4.18e-12	Bipolar disorder;
LUSC	cis	rs3784262	1.000	rs12915901	chr15:58279432	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.68	-0.3	2.94e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs4356932	1.000	rs4309862	chr4:76945981	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg13683864	chr3:40499215	RPL14	-0.97	-16.18	-0.66	7.23e-44	Renal cell carcinoma;
LUSC	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg12365402	chr11:9010492	NRIP3	0.4	7.02	0.36	1.28e-11	Hemoglobin concentration;
LUSC	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.5	0.56	1.09e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg03233332	chr7:66118400	NA	0.43	6.16	0.32	2.06e-9	Aortic root size;
LUSC	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	0.6	9.41	0.46	8.58e-19	Breast cancer;
LUSC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11764359	chr7:65958608	NA	-0.68	-10.76	-0.51	2.17e-23	Aortic root size;
LUSC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg00933542	chr6:150070202	PCMT1	0.28	5.87	0.31	1.08e-8	Lung cancer;
LUSC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg06494592	chr3:125709126	NA	-0.52	-5.93	-0.31	7.44e-9	Blood pressure (smoking interaction);
LUSC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12016809	chr21:47604291	C21orf56	-0.45	-6.71	-0.34	8.23e-11	Testicular germ cell tumor;
LUSC	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg00540400	chr15:79124168	NA	-0.47	-8.15	-0.41	7.33e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7589342	0.831	rs34554853	chr2:106448931	G/A	cg16077055	chr2:106428750	NCK2	0.37	7.05	0.36	1.01e-11	Addiction;
LUSC	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg19508488	chr2:152266495	RIF1	0.4	5.87	0.31	1.02e-8	Lung cancer;
LUSC	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg27489772	chr12:121021490	NA	0.59	7.72	0.39	1.4e-13	Type 1 diabetes nephropathy;
LUSC	cis	rs77741769	0.700	rs61946385	chr12:121362330	G/A	cg02403541	chr12:121454288	C12orf43	0.49	7.33	0.37	1.71e-12	Mean corpuscular volume;
LUSC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg11861562	chr11:117069780	TAGLN	0.35	6.87	0.35	3.18e-11	Blood protein levels;
LUSC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.71	11.14	0.52	9.82e-25	Monocyte percentage of white cells;
LUSC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.64	10.05	0.48	6.01e-21	Hemoglobin concentration;
LUSC	cis	rs11166629	0.637	rs4909475	chr8:135557622	A/G	cg27224718	chr8:135614730	ZFAT	0.52	7.46	0.38	7.47e-13	Smoking quantity;
LUSC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.31	-7.86	-0.4	5.18e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg09835421	chr16:68378352	PRMT7	-0.54	-6.09	-0.32	3.03e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg24375607	chr4:120327624	NA	-0.47	-7.23	-0.37	3.29e-12	Diastolic blood pressure;
LUSC	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg27284194	chr4:1044797	NA	0.59	8.61	0.43	3.01e-16	Recombination rate (females);
LUSC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.49	-0.33	3.04e-10	Blood metabolite levels;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg24153548	chr3:100119764	LNP1;TOMM70A	0.39	5.97	0.31	6.03e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs722599	0.683	rs17102847	chr14:75324780	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.4	-5.8	-0.3	1.58e-8	IgG glycosylation;
LUSC	cis	rs2692947	0.644	rs3821051	chr2:96912787	A/G	cg23100626	chr2:96804247	ASTL	-0.27	-6.69	-0.34	9.6e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs3820928	0.874	rs10195072	chr2:227794452	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.57	-0.38	3.71e-13	Pulmonary function;
LUSC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24838063	chr12:130822603	PIWIL1	0.71	11.02	0.52	2.72e-24	Menopause (age at onset);
LUSC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg05802129	chr4:122689817	NA	-0.52	-8.78	-0.43	8.4e-17	Type 2 diabetes;
LUSC	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg22875332	chr1:76189707	ACADM	-0.42	-6.15	-0.32	2.24e-9	Daytime sleep phenotypes;
LUSC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg16325326	chr1:53192061	ZYG11B	0.73	12.8	0.57	8.52e-31	Monocyte count;
LUSC	cis	rs10761482	1.000	rs1340652	chr10:62078203	C/T	cg18175470	chr10:62150864	ANK3	0.46	6.51	0.34	2.74e-10	Schizophrenia;
LUSC	cis	rs754466	0.958	rs11002341	chr10:79701363	A/C	cg17075019	chr10:79541650	NA	-0.61	-7.96	-0.4	2.75e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1941687	0.527	rs6507059	chr18:31303643	A/G	cg27147174	chr7:100797783	AP1S1	-0.46	-7.08	-0.36	8.37e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg04450456	chr4:17643702	FAM184B	0.39	6.54	0.34	2.34e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.91	0.35	2.53e-11	Morning vs. evening chronotype;
LUSC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-17.01	-0.68	3.62e-47	Primary sclerosing cholangitis;
LUSC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg14019146	chr3:50243930	SLC38A3	0.32	7.03	0.36	1.19e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg17031739	chr1:67600172	NA	0.45	7.1	0.36	7.53e-12	Psoriasis;
LUSC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg06219351	chr7:158114137	PTPRN2	-0.61	-11.27	-0.52	3.4e-25	Calcium levels;
LUSC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06634786	chr22:41940651	POLR3H	0.51	5.87	0.31	1.04e-8	Cannabis dependence symptom count;
LUSC	cis	rs2274273	0.837	rs10141483	chr14:55786871	T/C	cg04306507	chr14:55594613	LGALS3	0.56	12.99	0.58	1.58e-31	Protein biomarker;
LUSC	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg09904177	chr6:26538194	HMGN4	-0.77	-6.04	-0.31	4.1e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs314370	0.570	rs314313	chr7:100423365	C/T	cg10426581	chr7:100472382	SRRT	-0.5	-7.95	-0.4	2.88e-14	Resting heart rate;
LUSC	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	0.57	9.07	0.44	1.02e-17	Breast cancer;
LUSC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.56	8.71	0.43	1.42e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4144743	1.000	rs7224990	chr17:45326878	C/T	cg18085866	chr17:45331354	ITGB3	-0.75	-7.79	-0.39	8.26e-14	Body mass index;
LUSC	cis	rs9807989	0.839	rs3771166	chr2:102986222	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.68	0.3	2.87e-8	Asthma;
LUSC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg11843238	chr5:131593191	PDLIM4	0.37	6.31	0.33	8.89e-10	Breast cancer;
LUSC	trans	rs9944715	0.906	rs4453596	chr18:43749826	T/C	cg01718231	chr17:29326311	RNF135	0.48	6.76	0.35	6.1e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg08999081	chr20:33150536	PIGU	0.37	6.81	0.35	4.61e-11	Height;
LUSC	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	6.38	0.33	5.95e-10	Schizophrenia;
LUSC	trans	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.43	0.42	1.06e-15	Diabetic kidney disease;
LUSC	cis	rs78572108	0.858	rs4952581	chr2:42268444	T/C	cg00607755	chr2:42274082	PKDCC	0.35	5.98	0.31	5.72e-9	Total body bone mineral density;
LUSC	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg18240062	chr17:79603768	NPLOC4	0.79	15.38	0.64	9.93e-41	Eye color traits;
LUSC	trans	rs11696501	0.739	rs6073822	chr20:44251880	A/G	cg03272292	chr12:48577362	C12orf68	0.49	5.99	0.31	5.29e-9	Brain structure;
LUSC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg21782813	chr7:2030301	MAD1L1	0.57	10.0	0.48	9.04e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg16339924	chr4:17578868	LAP3	0.5	7.63	0.39	2.45e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg24110177	chr3:50126178	RBM5	0.42	6.73	0.35	7.18e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.48	6.12	0.32	2.56e-9	Multiple sclerosis;
LUSC	trans	rs3960554	1.000	rs3960554	chr7:75845597	G/T	cg19862616	chr7:65841803	NCRNA00174	0.84	9.06	0.44	1.14e-17	Eotaxin levels;
LUSC	cis	rs2219968	1.000	rs6982916	chr8:78972362	A/G	cg00738934	chr8:78996279	NA	-0.33	-5.83	-0.3	1.31e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-6.66	-0.34	1.11e-10	Hematocrit;
LUSC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.53	0.38	4.68e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg13010199	chr12:38710504	ALG10B	0.49	7.38	0.37	1.28e-12	Morning vs. evening chronotype;
LUSC	cis	rs12541635	0.966	rs4734895	chr8:107002604	A/G	cg10147462	chr8:107024639	NA	0.55	9.76	0.47	5.68e-20	Age of smoking initiation;
LUSC	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg09165964	chr15:75287851	SCAMP5	-1.07	-17.68	-0.7	7.92e-50	Blood trace element (Zn levels);
LUSC	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg15485101	chr11:133734466	NA	-0.42	-7.77	-0.39	9.49e-14	Childhood ear infection;
LUSC	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg11965913	chr1:205819406	PM20D1	0.49	6.75	0.35	6.52e-11	Parkinson's disease;
LUSC	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg22467129	chr15:76604101	ETFA	-0.43	-6.8	-0.35	4.84e-11	Blood metabolite levels;
LUSC	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.08	0.64	1.48e-39	Lymphocyte percentage of white cells;
LUSC	trans	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.46	0.42	8.65e-16	Ulcerative colitis;
LUSC	cis	rs7575217	1.000	rs7575217	chr2:101776932	A/G	cg23907051	chr2:101730305	TBC1D8	-0.27	-6.94	-0.36	2.04e-11	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg06740227	chr12:86229804	RASSF9	-0.4	-6.57	-0.34	1.88e-10	Major depressive disorder;
LUSC	cis	rs10992471	0.651	rs2296669	chr9:95373790	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.42	7.07	0.36	9.08e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg11235426	chr6:292522	DUSP22	-0.45	-6.77	-0.35	5.86e-11	Menopause (age at onset);
LUSC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg14582100	chr15:45693742	SPATA5L1	0.6	10.95	0.51	4.7e-24	Homoarginine levels;
LUSC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg06494592	chr3:125709126	NA	-0.51	-6.36	-0.33	6.53e-10	Blood pressure (smoking interaction);
LUSC	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg20333904	chr2:240724165	NA	-0.41	-7.27	-0.37	2.58e-12	Obesity-related traits;
LUSC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.76	17.17	0.68	8.03e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08392591	chr16:89556376	ANKRD11	0.52	8.06	0.4	1.35e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg22903471	chr2:27725779	GCKR	-0.42	-7.2	-0.37	3.91e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08645402	chr16:4508243	NA	0.53	8.74	0.43	1.16e-16	Schizophrenia;
LUSC	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-6.67	-0.34	1.06e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	8.48	0.42	7.5e-16	Lung cancer in ever smokers;
LUSC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg16606324	chr3:10149918	C3orf24	0.6	8.0	0.4	2.03e-14	Alzheimer's disease;
LUSC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13012494	chr21:47604986	C21orf56	-0.51	-7.81	-0.39	7.43e-14	Testicular germ cell tumor;
LUSC	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg22482690	chr17:47019901	SNF8	0.39	7.38	0.37	1.3e-12	Type 2 diabetes;
LUSC	cis	rs12313068	0.600	rs7136207	chr12:110491487	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	9.83	0.47	3.52e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg05347473	chr6:146136440	FBXO30	0.57	10.06	0.48	5.62e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18876405	chr7:65276391	NA	-0.56	-8.96	-0.44	2.27e-17	Aortic root size;
LUSC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg03146154	chr1:46216737	IPP	0.51	7.55	0.38	4.21e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18047607	chr2:15701435	NBAS	-0.44	-6.64	-0.34	1.3e-10	Hepatitis;
LUSC	cis	rs965469	1.000	rs6037583	chr20:3360632	G/A	cg25506879	chr20:3388711	C20orf194	-0.52	-5.68	-0.3	2.97e-8	IFN-related cytopenia;
LUSC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg13560548	chr3:10150139	C3orf24	0.48	6.6	0.34	1.6e-10	Alzheimer's disease;
LUSC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg10968187	chr4:17616003	MED28	-0.4	-5.77	-0.3	1.86e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.64	8.67	0.43	1.86e-16	Reticulocyte fraction of red cells;
LUSC	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg16049864	chr8:95962084	TP53INP1	-0.51	-8.96	-0.44	2.35e-17	Type 2 diabetes;
LUSC	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg12386194	chr3:101231763	SENP7	0.63	8.57	0.42	3.76e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg18230493	chr5:56204884	C5orf35	-0.77	-12.11	-0.55	3.02e-28	Coronary artery disease;
LUSC	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg27147174	chr7:100797783	AP1S1	-0.64	-10.28	-0.49	1.02e-21	Life satisfaction;
LUSC	cis	rs2377585	0.524	rs35146959	chr12:8847546	C/T	cg03761649	chr12:8850719	RIMKLB	0.48	6.42	0.33	4.77e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.69	-10.67	-0.5	4.58e-23	Platelet count;
LUSC	cis	rs4654899	0.865	rs12131353	chr1:21321163	C/G	cg01072550	chr1:21505969	NA	-0.5	-7.4	-0.38	1.14e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg19592336	chr6:28129416	ZNF389	0.45	5.81	0.3	1.46e-8	Depression;
LUSC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg14829155	chr15:31115871	NA	-0.56	-7.84	-0.39	6.22e-14	Huntington's disease progression;
LUSC	cis	rs11997175	0.574	rs12541661	chr8:33649856	T/G	ch.8.33884649F	chr8:33765107	NA	0.51	8.34	0.42	1.94e-15	Body mass index;
LUSC	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg03342759	chr3:160939853	NMD3	-0.52	-8.77	-0.43	9.03e-17	Morning vs. evening chronotype;
LUSC	cis	rs1113500	0.614	rs1343192	chr1:108613888	C/T	cg06207961	chr1:108661230	NA	0.35	5.67	0.3	3.09e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	10.74	0.51	2.64e-23	Homoarginine levels;
LUSC	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.68	0.3	3.01e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg25174290	chr11:3078921	CARS	-0.4	-5.99	-0.31	5.57e-9	Calcium levels;
LUSC	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg03585969	chr10:35415529	CREM	0.62	9.05	0.44	1.16e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs17607347	0.542	rs17677890	chr16:72557243	T/A	cg12945194	chr11:64703312	GPHA2	0.38	6.06	0.31	3.74e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg00945038	chr17:61921165	SMARCD2	-0.38	-5.72	-0.3	2.35e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9581857	0.547	rs9581881	chr13:28106637	A/G	cg22138327	chr13:27999177	GTF3A	0.64	7.15	0.36	5.37e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg21775007	chr8:11205619	TDH	0.47	6.67	0.34	1.09e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14993530	chr1:245027115	HNRNPU	-0.41	-6.12	-0.32	2.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3771570	0.892	rs55751610	chr2:242346057	C/T	cg21155796	chr2:242212141	HDLBP	0.61	6.76	0.35	6.18e-11	Prostate cancer;
LUSC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.82	0.68	1.93e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.85	0.66	1.36e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9888739	0.841	rs11864503	chr16:31331137	T/C	cg15817542	chr16:31343056	ITGAM	-0.51	-6.18	-0.32	1.82e-9	Systemic lupus erythematosus;
LUSC	cis	rs381815	0.821	rs416258	chr11:16911636	G/C	cg05701403	chr11:16947551	PLEKHA7	0.36	5.65	0.3	3.42e-8	Diastolic blood pressure;Systolic blood pressure;Blood pressure;
LUSC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.37	-6.4	-0.33	5.39e-10	High light scatter reticulocyte count;
LUSC	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	1.01	15.33	0.64	1.5e-40	Corneal structure;
LUSC	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg02175503	chr12:58329896	NA	0.61	9.99	0.48	9.8e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg22638593	chr5:131593259	PDLIM4	0.42	6.18	0.32	1.89e-9	Acylcarnitine levels;
LUSC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg24130564	chr14:104152367	KLC1	-0.44	-6.22	-0.32	1.49e-9	Body mass index;
LUSC	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg05714579	chr10:131428358	MGMT	0.52	7.98	0.4	2.44e-14	Response to temozolomide;
LUSC	cis	rs1045714	0.895	rs4721866	chr7:2643341	G/A	cg24848437	chr7:2645542	IQCE	0.62	6.93	0.35	2.13e-11	Urate levels in lean individuals;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07138452	chr17:17141020	FLCN	0.45	7.21	0.37	3.82e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs11165623	0.564	rs6669908	chr1:96998261	G/A	cg10631902	chr5:14652156	NA	-0.41	-6.06	-0.31	3.69e-9	Hip circumference;Waist circumference;
LUSC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-1.03	-20.12	-0.74	1.48e-59	Height;
LUSC	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18252515	chr7:66147081	NA	0.53	7.17	0.37	4.9e-12	Corneal structure;
LUSC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg06784218	chr1:46089804	CCDC17	0.48	9.63	0.47	1.62e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08677398	chr8:58056175	NA	0.52	6.98	0.36	1.59e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.95	0.36	1.96e-11	Rheumatoid arthritis;
LUSC	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg14582100	chr15:45693742	SPATA5L1	0.57	10.18	0.49	2.21e-21	Homoarginine levels;
LUSC	cis	rs73206853	0.764	rs61117387	chr12:110867725	C/A	cg12870014	chr12:110450643	ANKRD13A	0.67	7.16	0.36	5.29e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.27	0.59	1.5e-32	Total body bone mineral density;
LUSC	trans	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg25482853	chr8:67687455	SGK3	1.15	16.64	0.67	1.03e-45	Obesity-related traits;
LUSC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.54	-0.34	2.34e-10	Schizophrenia;
LUSC	trans	rs4693167	0.927	rs6837088	chr4:88400924	A/C	cg20462512	chr12:5543155	NTF3	0.33	6.22	0.32	1.46e-9	Blood protein levels;
LUSC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.51	-0.46	4.02e-19	Chronic sinus infection;
LUSC	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.51	6.31	0.33	9.02e-10	Multiple sclerosis;
LUSC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg12560992	chr17:57184187	TRIM37	-0.9	-17.69	-0.7	6.85e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs12973672	0.812	rs28365133	chr19:35761519	A/G	cg12095397	chr19:35769544	USF2	0.44	6.67	0.34	1.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1668873	0.562	rs10157145	chr1:205261963	T/C	cg21643547	chr1:205240462	TMCC2	0.31	5.89	0.31	9.34e-9	Mean platelet volume;
LUSC	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07080220	chr10:102295463	HIF1AN	0.59	7.86	0.4	5.23e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg06521331	chr12:34319734	NA	-0.41	-6.43	-0.33	4.4e-10	Morning vs. evening chronotype;
LUSC	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.67	-10.35	-0.49	5.75e-22	Colorectal cancer;
LUSC	cis	rs7255045	0.788	rs8111370	chr19:12948864	G/T	cg21491176	chr19:12958399	MAST1	-0.33	-5.8	-0.3	1.55e-8	Mean corpuscular volume;
LUSC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg02569458	chr12:86230093	RASSF9	0.58	9.78	0.47	4.91e-20	Major depressive disorder;
LUSC	cis	rs12493885	0.725	rs11718646	chr3:153741996	C/T	cg17054900	chr3:154042577	DHX36	-0.7	-7.37	-0.37	1.33e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg13565492	chr6:43139072	SRF	-0.41	-6.04	-0.31	4.04e-9	Longevity;Endometriosis;
LUSC	trans	rs62056376	0.646	rs2857657	chr17:32583132	G/C	cg19986872	chr5:131347773	ACSL6	-0.38	-5.98	-0.31	5.72e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg16339924	chr4:17578868	LAP3	0.53	8.07	0.4	1.31e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg05868516	chr6:26286170	HIST1H4H	0.36	6.0	0.31	5.18e-9	Educational attainment;
LUSC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.64	-0.34	1.26e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg00864171	chr11:67383662	NA	0.34	5.91	0.31	8.43e-9	Mean corpuscular volume;
LUSC	cis	rs73206853	0.563	rs9706438	chr12:111195158	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	6.91	0.35	2.49e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg09034736	chr1:150693464	HORMAD1	0.45	6.13	0.32	2.53e-9	Melanoma;
LUSC	cis	rs7589342	0.628	rs12996286	chr2:106399667	A/G	cg14210321	chr2:106509881	NCK2	-0.45	-5.66	-0.3	3.24e-8	Addiction;
LUSC	cis	rs11906854	0.501	rs7265718	chr20:34635441	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.1	-0.32	2.87e-9	Migraine - clinic-based;
LUSC	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-20.57	-0.75	2.54e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.61	12.27	0.56	7.88e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg27068330	chr11:65405492	SIPA1	0.56	6.53	0.34	2.51e-10	Blood pressure (age interaction);
LUSC	cis	rs2544523	0.511	rs10929387	chr2:15912926	A/G	cg26669897	chr2:15909070	NA	0.3	6.21	0.32	1.58e-9	Asthma or chronic obstructive pulmonary disease;
LUSC	cis	rs17604090	0.818	rs73090342	chr7:29687540	T/C	cg19413766	chr7:29689036	LOC646762	-0.63	-7.43	-0.38	8.91e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg04064380	chr11:117688259	NA	-0.44	-5.69	-0.3	2.82e-8	Myopia;
LUSC	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-17.57	-0.69	2.11e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.38	7.47	0.38	7.28e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04565464	chr8:145669602	NFKBIL2	0.38	6.15	0.32	2.23e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg10253484	chr15:75165896	SCAMP2	-0.46	-6.55	-0.34	2.11e-10	Breast cancer;
LUSC	cis	rs10072221	0.836	rs7707426	chr5:75707371	C/G	cg03132911	chr5:75698732	IQGAP2	0.36	6.07	0.32	3.44e-9	Mean platelet volume;
LUSC	cis	rs73001065	0.901	rs73004926	chr19:19671266	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	6.92	0.35	2.27e-11	LDL cholesterol;
LUSC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg26338869	chr17:61819248	STRADA	0.41	5.94	0.31	7.17e-9	Prudent dietary pattern;
LUSC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg06096015	chr1:231504339	EGLN1	0.54	9.51	0.46	3.95e-19	Hemoglobin concentration;
LUSC	trans	rs11949289	1.000	rs12188000	chr5:28349377	A/G	cg18220921	chr1:242687527	PLD5	0.35	5.96	0.31	6.56e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg18681998	chr4:17616180	MED28	0.86	15.49	0.65	3.49e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10053473	chr17:62856997	LRRC37A3	0.65	10.33	0.49	6.89e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.82	-15.1	-0.64	1.19e-39	Dental caries;
LUSC	cis	rs4664304	0.903	rs72957576	chr2:160754132	A/C	cg23995753	chr2:160760732	LY75	-0.31	-5.75	-0.3	2.05e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.04e-11	Body mass index;
LUSC	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg03676636	chr4:99064102	C4orf37	0.36	8.04	0.4	1.59e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.89	16.49	0.67	4.19e-45	Menarche (age at onset);
LUSC	trans	rs11949289	0.935	rs1035886	chr5:28336609	T/C	cg18220921	chr1:242687527	PLD5	0.35	5.96	0.31	6.44e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg13683864	chr3:40499215	RPL14	-0.97	-17.11	-0.68	1.49e-47	Renal cell carcinoma;
LUSC	cis	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg07460842	chr6:66804631	NA	-0.46	-6.47	-0.33	3.5e-10	Blood trace element (Cu levels);
LUSC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11671005	0.616	rs12980907	chr19:58956326	C/T	cg13877915	chr19:58951672	ZNF132	0.45	5.78	0.3	1.71e-8	Mean platelet volume;
LUSC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs6942756	0.806	rs10257620	chr7:128901429	C/A	cg02491457	chr7:128862824	NA	0.51	7.74	0.39	1.18e-13	White matter hyperintensity burden;
LUSC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.7	-10.8	-0.51	1.57e-23	Aortic root size;
LUSC	cis	rs713587	0.571	rs2918630	chr2:25314186	A/G	cg01884057	chr2:25150051	NA	-0.27	-5.78	-0.3	1.74e-8	Body mass index in non-asthmatics;
LUSC	cis	rs35995292	0.500	rs2392606	chr7:38926955	C/A	cg19327137	chr7:38886074	VPS41	0.55	10.25	0.49	1.33e-21	Subjective well-being (multi-trait analysis);
LUSC	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	0.93	12.47	0.56	1.45e-29	Primary sclerosing cholangitis;
LUSC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg23262073	chr20:60523788	NA	-0.43	-6.16	-0.32	2.09e-9	Body mass index;
LUSC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg12863693	chr15:85201151	NMB	0.36	7.38	0.37	1.25e-12	Schizophrenia;
LUSC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.86	0.31	1.11e-8	Menopause (age at onset);
LUSC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg11494091	chr17:61959527	GH2	0.39	6.77	0.35	5.68e-11	Height;
LUSC	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg05925327	chr15:68127851	NA	-0.37	-5.9	-0.31	8.83e-9	Restless legs syndrome;
LUSC	cis	rs3755132	0.929	rs3770463	chr2:15749658	T/C	cg12888861	chr2:15731646	DDX1	0.5	7.34	0.37	1.61e-12	Wilms tumor;
LUSC	cis	rs9865818	0.791	rs56046601	chr3:188108642	G/C	cg23651889	chr3:188115336	LPP	0.39	5.91	0.31	8.33e-9	Allergic sensitization;
LUSC	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg19773385	chr1:10388646	KIF1B	-0.55	-8.49	-0.42	6.95e-16	Hepatocellular carcinoma;
LUSC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.96	0.51	4.51e-24	Menopause (age at onset);
LUSC	cis	rs7560272	0.695	rs780394	chr2:73700930	A/G	cg20560298	chr2:73613845	ALMS1	0.46	7.19	0.37	4.24e-12	Schizophrenia;
LUSC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.36	0.33	6.81e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs2742417	1.000	rs2742373	chr3:45784046	C/G	cg09608765	chr3:45636137	LIMD1	-0.36	-7.17	-0.37	4.98e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg09307838	chr4:120376055	NA	0.75	10.89	0.51	7.5e-24	Corneal astigmatism;
LUSC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.6	-9.54	-0.46	3.16e-19	Pulse pressure;
LUSC	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg17376030	chr22:41985996	PMM1	-0.47	-6.03	-0.31	4.35e-9	Vitiligo;
LUSC	trans	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg04995722	chr7:26192034	NFE2L3	0.42	6.59	0.34	1.67e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9837602	1.000	rs10212525	chr3:99713377	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.17	0.32	1.96e-9	Breast cancer;
LUSC	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg06636551	chr8:101224915	SPAG1	-0.38	-7.13	-0.36	6.31e-12	Atrioventricular conduction;
LUSC	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg08079166	chr15:68083412	MAP2K5	0.4	8.28	0.41	3.04e-15	Restless legs syndrome;
LUSC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg00701064	chr4:6280414	WFS1	0.61	15.96	0.66	4.98e-43	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg05347473	chr6:146136440	FBXO30	-0.6	-10.6	-0.5	7.93e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	10.02	0.48	8.1e-21	Bipolar disorder;
LUSC	cis	rs9311676	0.656	rs11918201	chr3:58387777	C/T	cg13750441	chr3:58318267	PXK	0.35	6.72	0.35	7.86e-11	Systemic lupus erythematosus;
LUSC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg16680214	chr1:154839983	KCNN3	-0.52	-9.76	-0.47	5.77e-20	Prostate cancer;
LUSC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-5.9	-0.31	8.99e-9	Vitiligo;
LUSC	cis	rs7582720	1.000	rs72934765	chr2:203758551	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.67	0.43	1.95e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9649465	0.561	rs2429621	chr7:123430316	A/G	cg03229431	chr7:123269106	ASB15	0.48	7.68	0.39	1.76e-13	Migraine;
LUSC	cis	rs12973672	0.812	rs35497966	chr19:35764965	A/C	cg12095397	chr19:35769544	USF2	0.45	6.83	0.35	3.93e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg05623727	chr3:50126028	RBM5	-0.31	-5.83	-0.3	1.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24838063	chr12:130822603	PIWIL1	0.69	10.71	0.51	3.44e-23	Menopause (age at onset);
LUSC	cis	rs9796	0.621	rs7170049	chr15:41484287	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-9.07	-0.44	1.05e-17	Menopause (age at onset);
LUSC	cis	rs68170813	0.617	rs7797791	chr7:107197222	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-8.34	-0.42	1.92e-15	Coronary artery disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11328403	chr17:16120890	PIGL	-0.48	-6.15	-0.32	2.27e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs724744	0.680	rs1318601	chr6:22357345	G/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.06	-0.31	3.61e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg07701084	chr6:150067640	NUP43	0.57	8.74	0.43	1.18e-16	Lung cancer;
LUSC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg05347473	chr6:146136440	FBXO30	0.53	8.91	0.44	3.27e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg12463550	chr7:65579703	CRCP	0.52	7.61	0.38	2.87e-13	Aortic root size;
LUSC	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg00579200	chr11:133705235	NA	-0.43	-6.4	-0.33	5.35e-10	Childhood ear infection;
LUSC	cis	rs9677476	1.000	rs7584535	chr2:232106857	C/T	cg07929768	chr2:232055508	NA	0.31	5.9	0.31	8.8e-9	Food antigen IgG levels;
LUSC	cis	rs2290159	0.948	rs73130305	chr3:12621075	C/T	cg23032965	chr3:12705835	RAF1	0.57	7.08	0.36	8.42e-12	Cholesterol, total;
LUSC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.42	-0.33	4.68e-10	Blood metabolite levels;
LUSC	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg13393036	chr8:95962371	TP53INP1	0.32	6.38	0.33	5.94e-10	Type 2 diabetes;
LUSC	trans	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.08	-0.44	9.93e-18	Depression;
LUSC	cis	rs9807989	0.501	rs11903946	chr2:103005330	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.29e-12	Asthma;
LUSC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.71	-16.54	-0.67	2.59e-45	Prostate cancer;
LUSC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg09359103	chr1:154839909	KCNN3	-0.69	-15.95	-0.66	5.7e-43	Prostate cancer;
LUSC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.6	0.46	2.01e-19	Mean platelet volume;
LUSC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg03806693	chr22:41940476	POLR3H	0.99	13.72	0.6	2.7200000000000002e-34	Cannabis dependence symptom count;
LUSC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg02038168	chr22:39784481	NA	-0.48	-7.72	-0.39	1.35e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg11473876	chr11:109292803	C11orf87	0.34	5.74	0.3	2.15e-8	Schizophrenia;
LUSC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23978390	chr7:1156363	C7orf50	0.52	7.41	0.38	1.01e-12	Longevity;Endometriosis;
LUSC	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg10518572	chr11:65560635	OVOL1	-0.26	-6.01	-0.31	4.88e-9	Acne (severe);
LUSC	cis	rs12956009	0.518	rs71352652	chr18:44869536	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.41	0.33	5.01e-10	Educational attainment (years of education);
LUSC	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg01092361	chr6:42185687	MRPS10	0.79	8.17	0.41	6.55e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs968451	0.789	rs1569501	chr22:39683534	A/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.7	10.16	0.49	2.58e-21	Primary biliary cholangitis;
LUSC	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg00310523	chr12:86230176	RASSF9	0.38	6.99	0.36	1.49e-11	Major depressive disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11141497	chr11:6633666	TAF10	-0.43	-6.33	-0.33	8.01e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17095355	1.000	rs17126886	chr10:111695257	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.96	-0.36	1.81e-11	Biliary atresia;
LUSC	cis	rs9463078	0.764	rs3846896	chr6:44834094	G/A	cg25276700	chr6:44698697	NA	-0.28	-5.67	-0.3	3.09e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.31	0.33	8.63e-10	Personality dimensions;
LUSC	trans	rs4714291	0.963	rs1923466	chr6:39965946	A/C	cg02267698	chr19:7991119	CTXN1	0.49	6.84	0.35	3.9e-11	Strep throat;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07545948	chr6:12012569	HIVEP1	0.4	6.36	0.33	6.76e-10	Asthma;
LUSC	cis	rs3772130	0.962	rs35679661	chr3:121484763	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	9.77	0.47	5.21e-20	Cognitive performance;
LUSC	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg22906224	chr7:99728672	NA	0.47	6.54	0.34	2.36e-10	Coronary artery disease;
LUSC	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg00310523	chr12:86230176	RASSF9	0.44	8.25	0.41	3.7e-15	Major depressive disorder;
LUSC	cis	rs12190007	0.512	rs2984464	chr6:169837242	T/C	cg15038512	chr6:170123185	PHF10	-0.38	-6.24	-0.32	1.33e-9	Obesity-related traits;
LUSC	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg05855489	chr10:104503620	C10orf26	-0.68	-9.85	-0.47	2.9e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg00074818	chr8:8560427	CLDN23	0.57	9.76	0.47	5.63e-20	Obesity-related traits;
LUSC	trans	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg07393940	chr7:158741817	NA	0.53	8.22	0.41	4.42e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg18806716	chr10:30721971	MAP3K8	-0.47	-7.7	-0.39	1.54e-13	Inflammatory bowel disease;
LUSC	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg00631329	chr6:26305371	NA	-0.34	-5.98	-0.31	5.89e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-1.13	-17.76	-0.7	3.58e-50	Exhaled nitric oxide output;
LUSC	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg21775007	chr8:11205619	TDH	0.44	6.57	0.34	1.95e-10	Mood instability;
LUSC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs754133	0.964	rs4759318	chr12:54420098	C/T	cg10005224	chr12:54424964	HOXC4;HOXC5	0.42	8.39	0.42	1.4e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
LUSC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg03146154	chr1:46216737	IPP	0.51	7.48	0.38	6.55e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg05528280	chr10:464225	DIP2C	-0.4	-6.17	-0.32	1.99e-9	Psychosis in Alzheimer's disease;
LUSC	trans	rs57046232	0.552	rs6085497	chr20:6315937	A/G	cg21095983	chr6:86352623	SYNCRIP	0.52	7.78	0.39	9.2e-14	Colorectal cancer;
LUSC	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg17366294	chr4:99064904	C4orf37	0.56	9.77	0.47	5.22e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg12615879	chr12:58013172	SLC26A10	0.41	9.61	0.47	1.82e-19	Multiple sclerosis;
LUSC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg24562669	chr7:97807699	LMTK2	0.33	5.81	0.3	1.42e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg26195577	chr20:24973756	C20orf3	1.12	18.1	0.7	1.58e-51	Blood protein levels;
LUSC	cis	rs7188861	0.592	rs1794022	chr16:11376446	A/G	cg00044050	chr16:11439710	C16orf75	0.47	5.71	0.3	2.46e-8	HDL cholesterol;
LUSC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg16339924	chr4:17578868	LAP3	-0.59	-8.71	-0.43	1.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.79	-12.83	-0.57	6.65e-31	Height;
LUSC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg27165867	chr14:105738592	BRF1	-0.53	-7.71	-0.39	1.45e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg14036092	chr11:66035641	RAB1B	0.41	5.94	0.31	7.3e-9	Gout;
LUSC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.43	-0.33	4.31e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg13319975	chr6:146136371	FBXO30	-0.72	-11.46	-0.53	7.1e-26	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs701145	0.585	rs1612933	chr3:153786119	G/A	cg17054900	chr3:154042577	DHX36	-0.55	-5.92	-0.31	8.07e-9	Coronary artery disease;
LUSC	cis	rs2303282	0.664	rs2587867	chr16:56404011	C/T	cg00500540	chr16:56394104	NA	-0.4	-6.86	-0.35	3.34e-11	Breast cancer;
LUSC	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	0.58	9.24	0.45	2.94e-18	Breast cancer;
LUSC	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg12179176	chr11:130786555	SNX19	-0.64	-9.89	-0.48	2.07e-20	Schizophrenia;
LUSC	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg02269571	chr22:50332266	NA	0.59	8.76	0.43	9.92e-17	Schizophrenia;
LUSC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg05313129	chr8:58192883	C8orf71	-0.5	-6.76	-0.35	6.15e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs35883536	0.647	rs17402630	chr1:101046587	C/T	cg06223162	chr1:101003688	GPR88	-0.47	-8.81	-0.43	6.81e-17	Monocyte count;
LUSC	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg01657329	chr11:68192670	LRP5	0.51	7.98	0.4	2.34e-14	Total body bone mineral density;
LUSC	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg26618903	chr10:100175079	PYROXD2	-0.45	-8.57	-0.42	3.77e-16	Metabolite levels;
LUSC	cis	rs17621444	0.522	rs4536126	chr10:121809519	T/C	cg02041677	chr10:121771263	NA	-0.34	-6.31	-0.33	8.87e-10	IgG glycosylation;
LUSC	cis	rs7508679	1.000	rs7508679	chr19:7222832	A/G	cg09779027	chr19:7224513	INSR	0.43	9.45	0.46	6.06e-19	Hypothyroidism;
LUSC	cis	rs467650	0.549	rs720859	chr5:97995417	A/G	cg03885343	chr5:98108198	RGMB	0.32	5.77	0.3	1.83e-8	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg15556689	chr8:8085844	FLJ10661	0.54	8.0	0.4	2.11e-14	Retinal vascular caliber;
LUSC	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg12927641	chr6:109611667	NA	-0.37	-6.35	-0.33	6.85e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.3	-0.41	2.63e-15	Obesity-related traits;
LUSC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	0.95	19.19	0.72	7.57e-56	Cognitive function;
LUSC	cis	rs6076065	0.723	rs6076073	chr20:23414489	G/A	cg11657817	chr20:23433608	CST11	0.41	7.29	0.37	2.24e-12	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs8018808	0.935	rs11627385	chr14:77936343	T/C	cg20045696	chr14:77926864	AHSA1	0.34	5.8	0.3	1.56e-8	Myeloid white cell count;
LUSC	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg27284194	chr4:1044797	NA	0.6	8.96	0.44	2.34e-17	Recombination rate (females);
LUSC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.18	0.64	6.19e-40	Platelet count;
LUSC	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg11584989	chr19:19387371	SF4	0.51	6.49	0.33	3.1e-10	Bipolar disorder;
LUSC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17246714	chr3:55519186	WNT5A	0.42	6.24	0.32	1.3e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20110633	chr19:44302906	LYPD5	-0.5	-6.81	-0.35	4.43e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9549260	0.755	rs7988604	chr13:41215802	G/T	cg21288729	chr13:41239152	FOXO1	0.64	9.9	0.48	2.01e-20	Red blood cell count;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17510133	chr11:17298268	NUCB2	-0.43	-6.32	-0.33	8.38e-10	Electrocardiographic conduction measures;
LUSC	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-0.61	-9.58	-0.46	2.24e-19	Breast cancer;
LUSC	cis	rs7149337	0.836	rs34953083	chr14:51672432	A/G	cg23942311	chr14:51606299	NA	0.48	10.42	0.5	3.29e-22	Cancer;
LUSC	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg24881330	chr22:46731750	TRMU	0.91	7.03	0.36	1.15e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs113835537	0.529	rs3816492	chr11:66297363	C/T	cg24851651	chr11:66362959	CCS	0.53	7.56	0.38	3.95e-13	Airway imaging phenotypes;
LUSC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.74	0.3	2.13e-8	Schizophrenia;
LUSC	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-16.94	-0.68	6.71e-47	Exhaled nitric oxide output;
LUSC	cis	rs17253792	0.822	rs12323476	chr14:56172722	C/T	cg01858014	chr14:56050164	KTN1	0.68	6.27	0.32	1.13e-9	Putamen volume;
LUSC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs28785552	0.769	rs28796114	chr19:53234319	T/C	cg22067481	chr19:53234126	ZNF611	-0.47	-6.37	-0.33	6.13e-10	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs2273669	0.667	rs12205053	chr6:109338110	T/C	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	8.89e-9	Prostate cancer;
LUSC	cis	rs11585357	0.895	rs72633803	chr1:17616758	G/A	cg08277548	chr1:17600880	PADI3	-0.64	-6.62	-0.34	1.42e-10	Hair shape;
LUSC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg13662262	chr21:30364895	RNF160	-0.35	-6.2	-0.32	1.64e-9	Breast cancer;
LUSC	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg24562669	chr7:97807699	LMTK2	0.49	8.83	0.44	5.97e-17	Breast cancer;
LUSC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg03676636	chr4:99064102	C4orf37	0.36	8.12	0.41	9.4e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs939658	0.776	rs4778925	chr15:79443791	C/T	cg17916960	chr15:79447300	NA	-0.54	-10.78	-0.51	1.93e-23	Refractive error;
LUSC	cis	rs6580649	0.941	rs4760614	chr12:48427884	A/G	cg24011408	chr12:48396354	COL2A1	-0.46	-6.22	-0.32	1.53e-9	Lung cancer;
LUSC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg26335602	chr6:28129616	ZNF389	0.46	6.3	0.33	9.49e-10	Parkinson's disease;
LUSC	cis	rs7633770	0.664	rs7373994	chr3:46701114	C/G	cg11219411	chr3:46661640	NA	-0.35	-6.92	-0.35	2.39e-11	Coronary artery disease;
LUSC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.01	-0.36	1.35e-11	Major depressive disorder;
LUSC	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.5	6.58	0.34	1.87e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs13315871	0.929	rs11717783	chr3:58267642	A/T	cg20936604	chr3:58311152	NA	-0.75	-6.97	-0.36	1.7e-11	Cholesterol, total;
LUSC	cis	rs4363385	0.588	rs7540609	chr1:153024589	C/A	cg00922841	chr1:152955080	SPRR1A	-0.36	-5.97	-0.31	6.18e-9	Inflammatory skin disease;
LUSC	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg11584989	chr19:19387371	SF4	0.58	7.02	0.36	1.22e-11	Bipolar disorder;
LUSC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.78	-12.97	-0.58	1.91e-31	Platelet count;
LUSC	cis	rs9815354	0.812	rs7629767	chr3:42043509	T/G	cg03022575	chr3:42003672	ULK4	0.6	6.43	0.33	4.44e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00149659	chr3:10157352	C3orf10	0.98	14.25	0.61	2.48e-36	Alzheimer's disease;
LUSC	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg21095983	chr6:86352623	SYNCRIP	0.53	8.31	0.41	2.42e-15	Smooth-surface caries;
LUSC	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg03806693	chr22:41940476	POLR3H	0.85	12.22	0.56	1.25e-28	Vitiligo;
LUSC	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-10.28	-0.49	1.02e-21	Morning vs. evening chronotype;
LUSC	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-0.89	-13.67	-0.6	4.14e-34	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg15556689	chr8:8085844	FLJ10661	0.71	12.21	0.56	1.36e-28	Mood instability;
LUSC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Smoking initiation;
LUSC	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg00857998	chr1:205179979	DSTYK	0.64	10.03	0.48	7.3e-21	Red blood cell count;
LUSC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg24399712	chr22:39784796	NA	-0.61	-10.22	-0.49	1.59e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9788682	0.747	rs938682	chr15:78896547	A/G	cg24631222	chr15:78858424	CHRNA5	0.68	9.53	0.46	3.45e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-7.29	-0.37	2.2e-12	Menopause (age at onset);
LUSC	trans	rs57046232	0.511	rs6054143	chr20:6334697	C/T	cg17788362	chr6:86352627	SYNCRIP	0.42	5.96	0.31	6.34e-9	Colorectal cancer;
LUSC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg07936489	chr17:37558343	FBXL20	-0.7	-9.55	-0.46	2.85e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg17507749	chr15:85114479	UBE2QP1	0.52	6.41	0.33	5.1e-10	Schizophrenia;
LUSC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg11843238	chr5:131593191	PDLIM4	0.33	6.0	0.31	5.02e-9	Blood metabolite levels;
LUSC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg03609598	chr5:56110824	MAP3K1	-0.43	-6.3	-0.33	9.31e-10	Initial pursuit acceleration;
LUSC	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.61	9.64	0.47	1.49e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.18	0.41	5.87e-15	Menarche (age at onset);
LUSC	cis	rs7255	0.545	rs9306895	chr2:20878153	T/C	cg05481257	chr2:20870211	GDF7	-0.33	-5.77	-0.3	1.85e-8	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
LUSC	cis	rs17661538	0.504	rs71491145	chr10:18460336	G/A	cg03634479	chr10:18430412	CACNB2	0.65	5.95	0.31	6.89e-9	Response to antipsychotic treatment;
LUSC	cis	rs3106136	0.527	rs2632410	chr4:95149507	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.41	-0.42	1.2e-15	Capecitabine sensitivity;
LUSC	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg07148914	chr20:33460835	GGT7	0.54	8.4	0.42	1.33e-15	Height;
LUSC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.26e-25	Gut microbiome composition (summer);
LUSC	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg27147174	chr7:100797783	AP1S1	-0.63	-10.12	-0.48	3.7e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg17469321	chr7:55412551	NA	0.66	10.62	0.5	6.87e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05115182	chr10:99496889	ZFYVE27	-0.51	-6.23	-0.32	1.38e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.71	-0.3	2.44e-8	Recombination rate (females);
LUSC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg03585969	chr10:35415529	CREM	0.6	8.74	0.43	1.15e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9788682	0.624	rs518425	chr15:78883813	A/G	cg24631222	chr15:78858424	CHRNA5	0.62	9.39	0.46	9.38e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg08847533	chr14:75593920	NEK9	0.83	14.19	0.61	4.34e-36	Height;
LUSC	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg17279839	chr7:150038598	RARRES2	0.43	6.58	0.34	1.81e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg06641503	chr3:48959341	ARIH2	-0.39	-5.97	-0.31	6.03e-9	Parkinson's disease;
LUSC	cis	rs68170813	0.559	rs12537785	chr7:107050221	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.14	-0.45	6.29e-18	Coronary artery disease;
LUSC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg08270630	chr22:50330655	NA	-0.46	-6.92	-0.35	2.31e-11	Schizophrenia;
LUSC	cis	rs10755723	1	rs10755723	chr6:42593718	T/A	cg10605015	chr6:42532144	UBR2	0.48	5.65	0.3	3.41e-8	Lung cancer in never smokers;
LUSC	cis	rs7177699	0.557	rs12898292	chr15:79112603	A/G	cg00540400	chr15:79124168	NA	0.45	7.57	0.38	3.63e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg24209194	chr3:40518798	ZNF619	-0.52	-7.4	-0.38	1.08e-12	Renal cell carcinoma;
LUSC	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	11.87	0.54	2.28e-27	Height;
LUSC	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg07701084	chr6:150067640	NUP43	0.45	6.6	0.34	1.62e-10	Testicular germ cell tumor;
LUSC	cis	rs2708377	0.929	rs4763634	chr12:11307615	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg21385522	chr1:16154831	NA	-0.98	-18.46	-0.71	6.21e-53	Dilated cardiomyopathy;
LUSC	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg17420585	chr12:42539391	GXYLT1	-0.38	-7.58	-0.38	3.46e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg26769984	chr7:1090371	C7orf50	0.56	8.79	0.43	7.82e-17	Bronchopulmonary dysplasia;
LUSC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00166722	chr3:10149974	C3orf24	0.54	7.5	0.38	5.85e-13	Alzheimer's disease;
LUSC	cis	rs72634258	0.503	rs697674	chr1:7837878	C/G	cg26816564	chr1:7831052	VAMP3	0.97	13.99	0.61	2.47e-35	Inflammatory bowel disease;
LUSC	cis	rs7119	0.717	rs12902912	chr15:77809170	A/G	cg27398640	chr15:77910606	LINGO1	-0.3	-6.39	-0.33	5.43e-10	Type 2 diabetes;
LUSC	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.8	-0.51	1.62e-23	Glomerular filtration rate;
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg13453750	chr1:205783389	SLC41A1	-0.32	-6.26	-0.32	1.18e-9	Menarche (age at onset);
LUSC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg14416269	chr4:6271139	WFS1	0.53	11.32	0.53	2.23e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.33	-0.41	2.09e-15	Neuroticism;
LUSC	cis	rs3126085	0.877	rs57597406	chr1:152246619	C/G	cg26876637	chr1:152193138	HRNR	0.45	6.04	0.31	4.13e-9	Atopic dermatitis;
LUSC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg23788917	chr6:8435910	SLC35B3	-0.5	-7.42	-0.38	9.8e-13	Motion sickness;
LUSC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.81	-13.41	-0.59	4.05e-33	Bladder cancer;
LUSC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg00074818	chr8:8560427	CLDN23	0.43	7.07	0.36	9.09e-12	Obesity-related traits;
LUSC	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.35	0.64	1.31e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg03233332	chr7:66118400	NA	0.42	6.06	0.31	3.61e-9	Aortic root size;
LUSC	cis	rs41271951	0.558	rs79671334	chr1:151115887	C/G	cg11822372	chr1:151115635	SEMA6C	-0.86	-6.67	-0.34	1.07e-10	Blood protein levels;
LUSC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.6	-0.38	3.06e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6496044	0.568	rs6496049	chr15:86069205	C/G	cg13263323	chr15:86062960	AKAP13	-0.37	-6.04	-0.31	4.14e-9	Interstitial lung disease;
LUSC	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg02018176	chr4:1364513	KIAA1530	0.43	6.15	0.32	2.24e-9	Recombination rate (females);
LUSC	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg12863693	chr15:85201151	NMB	0.38	7.97	0.4	2.47e-14	Schizophrenia;
LUSC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg07741184	chr6:167504864	NA	0.36	6.53	0.34	2.52e-10	Crohn's disease;
LUSC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.64	9.24	0.45	2.88e-18	Menarche (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18950002	chr17:79673969	MRPL12	0.45	6.4	0.33	5.26e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg12856521	chr11:46389249	DGKZ	0.43	6.44	0.33	4.28e-10	Leprosy;
LUSC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg23630131	chr7:65973040	NA	0.21	5.81	0.3	1.45e-8	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26586300	chr17:80416415	NARF	-0.4	-6.04	-0.31	4.12e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg18190219	chr22:46762943	CELSR1	-0.62	-6.21	-0.32	1.62e-9	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg26384229	chr12:38710491	ALG10B	0.62	10.08	0.48	4.78e-21	Morning vs. evening chronotype;
LUSC	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.88	17.03	0.68	2.95e-47	Body mass index (adult);
LUSC	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg06092702	chr1:163392909	NA	-0.44	-7.41	-0.38	1.02e-12	Motion sickness;
LUSC	cis	rs7258465	1.000	rs271624	chr19:18627953	A/G	cg25828334	chr19:18545568	ISYNA1	-0.35	-6.0	-0.31	5.13e-9	Breast cancer;
LUSC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg01097406	chr16:89675127	NA	-0.36	-7.11	-0.36	7.15e-12	Vitiligo;
LUSC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	6.99	0.36	1.46e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	trans	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg07393940	chr7:158741817	NA	0.36	6.52	0.34	2.61e-10	Life satisfaction;
LUSC	cis	rs6430585	0.527	rs2278731	chr2:136396300	T/C	cg07169764	chr2:136633963	MCM6	1.06	13.9	0.61	5.76e-35	Corneal structure;
LUSC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg01657329	chr11:68192670	LRP5	-0.44	-6.62	-0.34	1.46e-10	Total body bone mineral density;
LUSC	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg04374321	chr14:90722782	PSMC1	0.77	12.46	0.56	1.64e-29	Mortality in heart failure;
LUSC	cis	rs859767	0.741	rs35599954	chr2:135392481	T/C	cg12500956	chr2:135428796	TMEM163	-0.27	-6.11	-0.32	2.8e-9	Neuroticism;
LUSC	cis	rs11971779	0.680	rs10273527	chr7:139036598	A/C	cg07862535	chr7:139043722	LUC7L2	-0.56	-7.25	-0.37	2.97e-12	Diisocyanate-induced asthma;
LUSC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg06917634	chr15:78832804	PSMA4	-0.58	-7.24	-0.37	3.03e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg04586622	chr2:25135609	ADCY3	0.43	9.06	0.44	1.11e-17	Body mass index;
LUSC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg00944433	chr1:107599041	PRMT6	0.36	6.66	0.34	1.14e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.63	-10.2	-0.49	1.86e-21	Schizophrenia;
LUSC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg16506815	chr2:162101123	NA	0.42	6.33	0.33	7.81e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg25767906	chr1:53392781	SCP2	0.48	8.71	0.43	1.47e-16	Monocyte count;
LUSC	cis	rs524023	1.000	rs537246	chr11:64360630	G/A	cg19131476	chr11:64387923	NRXN2	0.37	10.03	0.48	7.09e-21	Urate levels in obese individuals;
LUSC	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg06197492	chr11:2016605	H19	0.41	6.78	0.35	5.53e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00166722	chr3:10149974	C3orf24	0.55	7.51	0.38	5.38e-13	Alzheimer's disease;
LUSC	cis	rs9549260	0.683	rs4941988	chr13:41196006	T/G	cg21288729	chr13:41239152	FOXO1	0.6	9.19	0.45	4.44e-18	Red blood cell count;
LUSC	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg23260525	chr10:116636907	FAM160B1	0.45	9.83	0.47	3.37e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg09626299	chr10:82213104	TSPAN14	-0.2	-5.92	-0.31	8.16e-9	Post bronchodilator FEV1;
LUSC	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg05347473	chr6:146136440	FBXO30	0.51	8.58	0.42	3.62e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg19539972	chr4:7069911	GRPEL1	0.4	6.07	0.32	3.52e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26314531	chr2:26401878	FAM59B	-0.69	-9.27	-0.45	2.34e-18	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7107174	1.000	rs2510036	chr11:77966788	G/T	cg02023728	chr11:77925099	USP35	0.5	7.1	0.36	7.74e-12	Testicular germ cell tumor;
LUSC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	8.36	0.42	1.71e-15	Colorectal cancer;
LUSC	cis	rs2137920	0.836	rs2254617	chr10:50236892	T/G	cg27141751	chr10:50231850	C10orf72	0.38	5.73	0.3	2.28e-8	Migraine with aura;
LUSC	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg16230307	chr14:35515116	FAM177A1	0.78	10.03	0.48	7.34e-21	Psoriasis;
LUSC	cis	rs2249625	0.584	rs2463744	chr6:72875936	C/T	cg18830697	chr6:72922368	RIMS1	-0.36	-7.26	-0.37	2.69e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs7809950	1.000	rs2712201	chr7:107145564	T/C	cg23024343	chr7:107201750	COG5	-0.55	-8.69	-0.43	1.62e-16	Coronary artery disease;
LUSC	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	11.45	0.53	8.11e-26	Mean platelet volume;
LUSC	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg00784671	chr22:46762841	CELSR1	-0.54	-6.94	-0.35	2.07e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.63	-7.99	-0.4	2.27e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.39e-22	Alzheimer's disease (late onset);
LUSC	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg21045802	chr8:109455806	TTC35	0.42	6.58	0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.49	-8.92	-0.44	3.06e-17	Urinary metabolites;
LUSC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.55	11.62	0.54	1.98e-26	Height;
LUSC	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg11161846	chr1:160990452	F11R	-0.35	-6.38	-0.33	5.79e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg23711669	chr6:146136114	FBXO30	0.72	10.99	0.52	3.5e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg21775007	chr8:11205619	TDH	0.47	6.63	0.34	1.38e-10	Morning vs. evening chronotype;
LUSC	cis	rs3820928	0.874	rs13430941	chr2:227904447	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.81	-0.39	7.71e-14	Pulmonary function;
LUSC	cis	rs1881396	0.588	rs1881394	chr2:27949052	G/A	cg27432699	chr2:27873401	GPN1	0.6	7.29	0.37	2.23e-12	Nonalcoholic fatty liver disease;
LUSC	cis	rs7267979	0.932	rs13040655	chr20:25582197	C/T	cg03522245	chr20:25566470	NINL	0.36	5.8	0.3	1.5e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.34	5.83	0.3	1.27e-8	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg16434002	chr17:42200994	HDAC5	0.44	5.86	0.31	1.12e-8	Total body bone mineral density;
LUSC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-9.46	-0.46	5.81e-19	Chronic sinus infection;
LUSC	cis	rs7577851	0.762	rs2312205	chr2:69704941	A/G	cg10773587	chr2:69614142	GFPT1	0.5	6.1	0.32	2.98e-9	Parkinson's disease (age of onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27507545	chr10:103880405	LDB1	0.43	6.34	0.33	7.39e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs672059	1.000	rs659307	chr1:183163078	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.11	0.41	9.74e-15	Hypertriglyceridemia;
LUSC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg06671706	chr8:8559999	CLDN23	0.47	6.4	0.33	5.13e-10	Obesity-related traits;
LUSC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06022373	chr22:39101656	GTPBP1	0.83	13.91	0.61	5.22e-35	Menopause (age at onset);
LUSC	cis	rs1997103	0.822	rs10273426	chr7:55417857	G/A	cg17469321	chr7:55412551	NA	0.68	10.14	0.49	3.03e-21	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17932484	chr13:24463526	MIPEP;PCOTH	-0.45	-6.62	-0.34	1.4e-10	Electrocardiographic conduction measures;
LUSC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg09877947	chr5:131593287	PDLIM4	0.56	9.17	0.45	4.89e-18	Acylcarnitine levels;
LUSC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg08847533	chr14:75593920	NEK9	0.85	15.9	0.66	8.51e-43	Height;
LUSC	cis	rs778371	0.647	rs974321	chr2:233638351	G/A	cg08000102	chr2:233561755	GIGYF2	0.78	12.28	0.56	7.42e-29	Schizophrenia;
LUSC	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.77	-0.35	5.75e-11	Monocyte percentage of white cells;
LUSC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg12463550	chr7:65579703	CRCP	-0.56	-8.45	-0.42	8.83e-16	Aortic root size;
LUSC	cis	rs8081395	0.801	rs2665404	chr17:57875396	A/G	cg18434674	chr17:58106139	NA	0.27	6.13	0.32	2.54e-9	White blood cell count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18045461	chr22:29601862	EMID1	-0.42	-6.01	-0.31	4.88e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg11663144	chr21:46675770	NA	-0.44	-7.64	-0.39	2.28e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg19875535	chr5:140030758	IK	0.37	5.77	0.3	1.8e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9905704	0.918	rs304293	chr17:56823298	T/G	cg12560992	chr17:57184187	TRIM37	0.55	7.84	0.39	6.19e-14	Testicular germ cell tumor;
LUSC	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg21775007	chr8:11205619	TDH	0.46	6.46	0.33	3.75e-10	Neuroticism;
LUSC	cis	rs2274273	0.624	rs7154796	chr14:55771458	T/C	cg04306507	chr14:55594613	LGALS3	0.49	10.03	0.48	7.04e-21	Protein biomarker;
LUSC	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg23029597	chr12:123009494	RSRC2	-0.74	-9.13	-0.45	6.67e-18	Body mass index;
LUSC	cis	rs3764563	1.000	rs2283603	chr19:15731128	T/C	cg20725493	chr19:15740067	CYP4F8	-0.6	-6.59	-0.34	1.67e-10	Inflammatory biomarkers;
LUSC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg15445000	chr17:37608096	MED1	-0.41	-6.87	-0.35	3.18e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-11.03	-0.52	2.41e-24	Response to antipsychotic treatment;
LUSC	cis	rs7215564	0.908	rs7501659	chr17:78662061	C/T	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg20368463	chr18:77673604	PQLC1	-0.6	-6.4	-0.33	5.33e-10	Opioid sensitivity;
LUSC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.78	0.3	1.7e-8	Menopause (age at onset);
LUSC	trans	rs11039798	1.000	rs6485848	chr11:48541517	G/T	cg15704280	chr7:45808275	SEPT13	0.69	6.56	0.34	2.06e-10	Axial length;
LUSC	cis	rs1775715	0.835	rs113450267	chr10:32223728	G/A	cg04359828	chr10:32216031	ARHGAP12	0.38	6.43	0.33	4.43e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg19894588	chr14:64061835	NA	0.54	7.7	0.39	1.5700000000000001e-13	Glioblastoma;Glioma;
LUSC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1712517	0.525	rs11191667	chr10:105128898	G/A	cg04362960	chr10:104952993	NT5C2	-0.5	-6.65	-0.34	1.21e-10	Migraine;
LUSC	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg06671706	chr8:8559999	CLDN23	0.51	6.96	0.36	1.8e-11	Obesity-related traits;
LUSC	cis	rs4903214	0.848	rs62006811	chr14:74717699	C/A	cg08255017	chr14:74727001	VSX2	-0.49	-6.76	-0.35	6.13e-11	Inflammatory bowel disease;
LUSC	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg11663144	chr21:46675770	NA	-0.37	-5.96	-0.31	6.35e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg08499158	chr17:42289980	UBTF	0.5	8.66	0.43	2.06e-16	Total body bone mineral density;
LUSC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.72	9.56	0.46	2.58e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7727544	0.582	rs10075459	chr5:131541363	C/G	cg14196790	chr5:131705035	SLC22A5	0.45	7.38	0.37	1.28e-12	Blood metabolite levels;
LUSC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03352830	chr11:487213	PTDSS2	0.7	8.49	0.42	6.86e-16	Body mass index;
LUSC	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.45	-0.42	8.92e-16	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg22903471	chr2:27725779	GCKR	-0.41	-6.95	-0.36	1.96e-11	Total body bone mineral density;
LUSC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	8.86	0.44	4.9e-17	Alzheimer's disease;
LUSC	cis	rs1035144	0.510	rs12432357	chr14:81299468	A/G	cg06600135	chr14:81408086	NA	-0.56	-8.28	-0.41	2.96e-15	Male sexual orientation;
LUSC	cis	rs10266483	0.774	rs10949901	chr7:63812774	G/A	cg24201672	chr7:64023550	ZNF680	0.45	5.86	0.31	1.11e-8	Response to statin therapy;
LUSC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	0.59	9.36	0.46	1.22e-18	Breast cancer;
LUSC	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg19468946	chr17:37922297	IKZF3	-0.43	-6.83	-0.35	3.97e-11	Self-reported allergy;
LUSC	cis	rs6543140	0.964	rs11886793	chr2:103072220	T/G	cg09003973	chr2:102972529	NA	0.54	7.02	0.36	1.25e-11	Blood protein levels;
LUSC	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg06917634	chr15:78832804	PSMA4	0.48	5.85	0.3	1.18e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg05025164	chr4:1340916	KIAA1530	0.45	6.87	0.35	3.19e-11	Obesity-related traits;
LUSC	cis	rs68170813	0.652	rs6957186	chr7:107200592	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-8.6	-0.43	3.11e-16	Coronary artery disease;
LUSC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg22800045	chr5:56110881	MAP3K1	0.47	6.29	0.33	9.99e-10	Coronary artery disease;
LUSC	cis	rs394563	0.559	rs7753269	chr6:149671360	G/A	cg11245181	chr6:149772854	ZC3H12D	0.29	6.24	0.32	1.36e-9	Dupuytren's disease;
LUSC	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg03676636	chr4:99064102	C4orf37	0.36	7.88	0.4	4.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2692947	0.770	rs4527246	chr2:96560303	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.23	0.32	1.42e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs55728055	0.661	rs73162112	chr22:32045449	G/A	cg01338084	chr22:32026380	PISD	0.94	6.72	0.35	7.7e-11	Age-related hearing impairment;
LUSC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-1.19	-12.7	-0.57	1.98e-30	Diabetic kidney disease;
LUSC	cis	rs9400467	0.528	rs9689727	chr6:111796563	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.35	-6.57	-0.34	1.98e-10	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs7605827	0.930	rs1997305	chr2:15512383	T/C	cg19274914	chr2:15703543	NA	0.46	8.89	0.44	3.98e-17	Educational attainment (years of education);
LUSC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	cis	rs4478858	0.735	rs11583123	chr1:31751772	T/C	cg00250761	chr1:31883323	NA	-0.34	-8.15	-0.41	7.26e-15	Alcohol dependence;
LUSC	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg22681709	chr2:178499509	PDE11A	0.43	6.3	0.33	9.19e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.4	0.74	1.26e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg27165867	chr14:105738592	BRF1	-0.5	-7.29	-0.37	2.19e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg11502198	chr6:26597334	ABT1	0.75	11.72	0.54	8.53e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg12963246	chr6:28129442	ZNF389	0.52	7.17	0.37	4.94e-12	Depression;
LUSC	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg01689657	chr7:91764605	CYP51A1	0.31	5.71	0.3	2.51e-8	Breast cancer;
LUSC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08045932	chr20:61659980	NA	0.59	10.39	0.49	4.41e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.71	-11.1	-0.52	1.44e-24	Menarche (age at onset);
LUSC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.21	0.59	2.34e-32	Total body bone mineral density;
LUSC	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg03627880	chr6:151815985	C6orf97	0.55	6.0	0.31	5.24e-9	Menarche (age at onset);
LUSC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03934478	chr11:495069	RNH1	0.85	10.24	0.49	1.37e-21	Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24095222	chr5:161178787	NA	-0.4	-6.53	-0.34	2.47e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg09904177	chr6:26538194	HMGN4	0.74	13.74	0.6	2.27e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	8.87	0.44	4.46e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg06552810	chr11:31128660	NA	-0.4	-7.12	-0.36	6.5e-12	Red blood cell count;
LUSC	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.59	0.5	8.39e-23	Colorectal cancer;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg23978390	chr7:1156363	C7orf50	0.45	6.44	0.33	4.21e-10	Longevity;Endometriosis;
LUSC	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg07148914	chr20:33460835	GGT7	0.56	8.53	0.42	5.25e-16	Height;
LUSC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg22166914	chr1:53195759	ZYG11B	0.67	11.34	0.53	1.93e-25	Monocyte count;
LUSC	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.42	-9.32	-0.45	1.62e-18	Urate levels in overweight individuals;
LUSC	cis	rs7674212	0.539	rs6821617	chr4:104128410	G/A	cg16532752	chr4:104119610	CENPE	-0.46	-6.66	-0.34	1.14e-10	Type 2 diabetes;
LUSC	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg26384229	chr12:38710491	ALG10B	0.7	10.74	0.51	2.52e-23	Morning vs. evening chronotype;
LUSC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.54	-7.22	-0.37	3.62e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs701145	0.529	rs355746	chr3:153961627	C/G	cg17054900	chr3:154042577	DHX36	0.46	6.06	0.31	3.63e-9	Coronary artery disease;
LUSC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.81	13.64	0.6	5.83e-34	Aortic root size;
LUSC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg16606324	chr3:10149918	C3orf24	0.58	8.43	0.42	1.07e-15	Alzheimer's disease;
LUSC	cis	rs983392	0.805	rs10897011	chr11:59961427	G/A	cg20284999	chr11:59952153	MS4A6A	-0.39	-6.49	-0.33	3.14e-10	Alzheimer's disease (late onset);
LUSC	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg02696742	chr7:106810147	HBP1	-0.64	-9.58	-0.46	2.35e-19	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg11062466	chr8:58055876	NA	0.66	9.08	0.44	9.89e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg25801113	chr15:45476975	SHF	-0.36	-7.04	-0.36	1.11e-11	Uric acid levels;
LUSC	trans	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg24687543	chr11:63912206	MACROD1	0.45	5.76	0.3	1.9e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg04374321	chr14:90722782	PSMC1	-0.7	-10.71	-0.51	3.25e-23	Mortality in heart failure;
LUSC	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-6.79	-0.35	5.04e-11	Colorectal cancer;
LUSC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	8.96	0.44	2.31e-17	Monocyte percentage of white cells;
LUSC	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg13072238	chr3:49761600	GMPPB	-0.73	-8.94	-0.44	2.68e-17	Menarche (age at onset);
LUSC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.13	-0.48	3.34e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.53e-26	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.46	0.33	3.71e-10	Alzheimer's disease (late onset);
LUSC	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.13	0.64	9.65e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	6.68	0.34	9.98e-11	Lung cancer in ever smokers;
LUSC	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg05855489	chr10:104503620	C10orf26	0.6	9.61	0.47	1.88e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	8.97	0.44	2.23e-17	Lung cancer in ever smokers;
LUSC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg23711669	chr6:146136114	FBXO30	-0.89	-16.79	-0.68	2.69e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg18827107	chr12:86230957	RASSF9	-0.41	-5.99	-0.31	5.42e-9	Major depressive disorder;
LUSC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg23791538	chr6:167370224	RNASET2	0.42	6.79	0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs4132509	0.793	rs10803152	chr1:243846167	C/A	cg21452805	chr1:244014465	NA	0.65	6.93	0.35	2.15e-11	RR interval (heart rate);
LUSC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg00990874	chr7:1149470	C7orf50	-0.46	-6.08	-0.32	3.31e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg04518342	chr5:131593106	PDLIM4	0.36	6.64	0.34	1.29e-10	Blood metabolite levels;
LUSC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg16339924	chr4:17578868	LAP3	0.55	8.27	0.41	3.16e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg24642844	chr7:1081250	C7orf50	-0.74	-6.88	-0.35	3e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.12	-0.45	6.98e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.05	0.31	3.97e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg25801113	chr15:45476975	SHF	0.34	7.04	0.36	1.13e-11	Uric acid levels;
LUSC	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg11584989	chr19:19387371	SF4	0.6	7.33	0.37	1.78e-12	Bipolar disorder;
LUSC	cis	rs3770081	1.000	rs12617717	chr2:86342303	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.07	-7.21	-0.37	3.85e-12	Facial emotion recognition (sad faces);
LUSC	cis	rs3820928	0.874	rs10183633	chr2:227887828	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.69	-0.39	1.66e-13	Pulmonary function;
LUSC	cis	rs7605827	0.930	rs4668927	chr2:15706683	C/T	cg19274914	chr2:15703543	NA	0.46	8.84	0.44	5.64e-17	Educational attainment (years of education);
LUSC	cis	rs16912285	0.585	rs7950920	chr11:24356464	G/A	ch.11.24196551F	chr11:24239977	NA	0.85	8.17	0.41	6.45e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7815909	0.605	rs77831403	chr8:57202791	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	6.86	0.35	3.39e-11	Height;
LUSC	cis	rs4604732	0.536	rs12037221	chr1:247631212	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.45	6.87	0.35	3.13e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg23093090	chr10:104574429	C10orf26	-0.38	-7.1	-0.36	7.78e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20385508	chr2:128180829	PROC	-0.42	-6.48	-0.33	3.22e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6138458	0.828	rs6138466	chr20:24997137	A/G	cg06937882	chr20:24974362	C20orf3	-0.33	-5.97	-0.31	5.91e-9	Blood protein levels;
LUSC	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg00310523	chr12:86230176	RASSF9	-0.43	-8.1	-0.41	1.07e-14	Major depressive disorder;
LUSC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg09455208	chr3:40491958	NA	0.5	9.12	0.45	7e-18	Renal cell carcinoma;
LUSC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21643547	chr1:205240462	TMCC2	-0.53	-10.22	-0.49	1.63e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.64	0.6	5.58e-34	Cognitive test performance;
LUSC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg07936489	chr17:37558343	FBXL20	-0.7	-9.71	-0.47	8.41e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2637266	0.935	rs1866891	chr10:78396941	C/A	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.95e-13	Pulmonary function;
LUSC	cis	rs80130819	0.688	rs2634672	chr12:48649640	G/A	cg24011408	chr12:48396354	COL2A1	0.46	5.84	0.3	1.22e-8	Prostate cancer;
LUSC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg20203395	chr5:56204925	C5orf35	-0.57	-8.02	-0.4	1.75e-14	Coronary artery disease;
LUSC	cis	rs7605827	0.704	rs2160695	chr2:15673478	T/A	cg19274914	chr2:15703543	NA	0.45	8.67	0.43	1.97e-16	Educational attainment (years of education);
LUSC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg13560548	chr3:10150139	C3orf24	0.48	6.6	0.34	1.6e-10	Alzheimer's disease;
LUSC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg25767906	chr1:53392781	SCP2	0.47	8.41	0.42	1.22e-15	Monocyte count;
LUSC	cis	rs2040771	0.740	rs9605960	chr22:19214636	G/C	cg02655711	chr22:19163373	SLC25A1	0.47	8.4	0.42	1.28e-15	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-9.47	-0.46	5.48e-19	Platelet distribution width;
LUSC	cis	rs4851254	0.961	rs13011181	chr2:100732446	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-5.99	-0.31	5.34e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15560632	chr7:100183617	LRCH4;FBXO24	-0.4	-5.95	-0.31	6.86e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg05234568	chr11:5960015	NA	-0.54	-8.24	-0.41	4.05e-15	DNA methylation (variation);
LUSC	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.47	-0.42	7.93e-16	Joint mobility (Beighton score);
LUSC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg15103426	chr22:29168792	CCDC117	0.46	5.97	0.31	6.04e-9	Lymphocyte counts;
LUSC	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.73	0.35	7.39e-11	Corneal astigmatism;
LUSC	cis	rs16854884	0.657	rs35309714	chr3:143735011	T/A	cg06585982	chr3:143692056	C3orf58	0.5	8.13	0.41	8.55e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg08079166	chr15:68083412	MAP2K5	0.4	7.11	0.36	7.05e-12	Restless legs syndrome;
LUSC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg18512352	chr11:47633146	NA	-0.46	-9.25	-0.45	2.73e-18	Subjective well-being;
LUSC	cis	rs6556937	0.562	rs31248	chr5:96014683	A/G	cg07690455	chr5:95997198	CAST	0.49	6.76	0.35	6.3e-11	Blood protein levels;
LUSC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg13685833	chr1:53393034	SCP2	0.38	5.74	0.3	2.17e-8	Monocyte count;
LUSC	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.33	-0.41	2.13e-15	Body mass index;
LUSC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.98	-0.48	1.03e-20	Type 2 diabetes;
LUSC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg20295408	chr7:1910781	MAD1L1	-0.4	-5.79	-0.3	1.61e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-5.72	-0.3	2.35e-8	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg02825527	chr7:2087843	MAD1L1	-0.5	-5.73	-0.3	2.29e-8	Bipolar disorder;
LUSC	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg14664628	chr15:75095509	CSK	0.43	6.18	0.32	1.91e-9	Systemic lupus erythematosus;
LUSC	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg05855489	chr10:104503620	C10orf26	0.52	7.98	0.4	2.38e-14	Arsenic metabolism;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27006547	chr11:62606509	WDR74	0.53	8.05	0.4	1.42e-14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.37	-5.8	-0.3	1.56e-8	Homocysteine levels;
LUSC	cis	rs9462027	0.628	rs7756405	chr6:34722659	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.93	-0.31	7.62e-9	Systemic lupus erythematosus;
LUSC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.98	0.4	2.38e-14	Parkinson's disease;
LUSC	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg26893861	chr17:41843967	DUSP3	1.01	14.98	0.63	3.74e-39	Triglycerides;
LUSC	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.37	-5.91	-0.31	8.62e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.26	-0.37	2.68e-12	Neuroticism;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25683204	chr20:34129839	ERGIC3	-0.45	-6.25	-0.32	1.26e-9	Hepatitis;
LUSC	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.95	0.51	4.59e-24	Colorectal cancer;
LUSC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg13395646	chr4:1353034	KIAA1530	0.58	8.78	0.43	8.89e-17	Obesity-related traits;
LUSC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00166722	chr3:10149974	C3orf24	0.58	7.81	0.39	7.42e-14	Alzheimer's disease;
LUSC	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg18681998	chr4:17616180	MED28	0.75	11.18	0.52	7.08e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.81	-12.51	-0.56	1.03e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg13072238	chr3:49761600	GMPPB	-0.71	-8.92	-0.44	3.03e-17	Menarche (age at onset);
LUSC	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg18196295	chr10:418757	DIP2C	-0.41	-6.18	-0.32	1.89e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	12.59	0.57	5.03e-30	Menopause (age at onset);
LUSC	cis	rs7178572	0.524	rs1473922	chr15:77656798	G/T	cg22256960	chr15:77711686	NA	-0.51	-8.09	-0.4	1.11e-14	Type 2 diabetes;
LUSC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.7	10.74	0.51	2.63e-23	Aortic root size;
LUSC	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg00105475	chr2:10696890	NA	0.43	7.16	0.36	5.22e-12	Prostate cancer;
LUSC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.33	0.37	1.78e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs12310956	0.510	rs10129020	chr12:33858936	T/G	cg13010199	chr12:38710504	ALG10B	0.43	6.43	0.33	4.51e-10	Morning vs. evening chronotype;
LUSC	cis	rs4474465	1.000	rs11237510	chr11:78173584	G/A	cg27205649	chr11:78285834	NARS2	-0.48	-5.71	-0.3	2.51e-8	Alzheimer's disease (survival time);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00140813	chr16:28857836	TUFM	-0.48	-6.08	-0.32	3.37e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.17	0.52	7.95e-25	Menopause (age at onset);
LUSC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg20135002	chr11:47629003	NA	-0.51	-8.0	-0.4	2.13e-14	Subjective well-being;
LUSC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.5	-6.47	-0.33	3.5e-10	Multiple sclerosis;
LUSC	trans	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg25206134	chr2:45395956	NA	0.56	6.12	0.32	2.6e-9	Neuroticism;
LUSC	trans	rs7939886	0.920	rs17145425	chr11:55950030	A/G	cg15704280	chr7:45808275	SEPT13	0.9	6.94	0.36	2.07e-11	Myopia (pathological);
LUSC	trans	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	6.84	0.35	3.81e-11	Menarche (age at onset);
LUSC	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.68	9.91	0.48	1.78e-20	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg05347473	chr6:146136440	FBXO30	-0.49	-8.24	-0.41	3.87e-15	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04100724	chr12:92539208	BTG1	0.44	6.8	0.35	4.79e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7709377	0.595	rs1644268	chr5:115640808	G/T	cg23108291	chr5:115420582	COMMD10	-0.4	-5.66	-0.3	3.26e-8	Metabolite levels  (X-11787);
LUSC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg16434002	chr17:42200994	HDAC5	-0.43	-5.99	-0.31	5.34e-9	Total body bone mineral density;
LUSC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg22834771	chr12:69754056	YEATS4	-0.44	-6.63	-0.34	1.39e-10	Blood protein levels;
LUSC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg09021430	chr5:549028	NA	-0.56	-7.67	-0.39	1.96e-13	Obesity-related traits;
LUSC	cis	rs7659604	0.540	rs9998385	chr4:122676673	C/T	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.91	-0.31	8.47e-9	Type 2 diabetes;
LUSC	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg00645731	chr22:42541494	CYP2D7P1	-0.5	-7.7	-0.39	1.6e-13	Birth weight;
LUSC	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-9.03	-0.44	1.42e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg15485101	chr11:133734466	NA	0.38	7.17	0.37	4.84e-12	Childhood ear infection;
LUSC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg11663144	chr21:46675770	NA	-0.42	-7.25	-0.37	3.01e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg23719950	chr11:63933701	MACROD1	-0.58	-7.42	-0.38	9.69e-13	Mean platelet volume;
LUSC	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.83	-0.7	1.98e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs977987	0.843	rs11149824	chr16:75431830	C/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.77	-0.35	5.88e-11	Dupuytren's disease;
LUSC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.21	0.45	3.79e-18	Lung cancer in ever smokers;
LUSC	cis	rs1784581	0.722	rs1789993	chr6:162398976	T/C	cg17173639	chr6:162384350	PARK2	-0.66	-11.54	-0.53	3.67e-26	Itch intensity from mosquito bite;
LUSC	trans	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg10756647	chr7:56101905	PSPH	0.86	8.4	0.42	1.27e-15	Diabetic kidney disease;
LUSC	cis	rs7715806	0.500	rs17649266	chr5:75001252	C/T	cg19683494	chr5:74908142	NA	-0.54	-7.55	-0.38	4.21e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg06145435	chr7:1022769	CYP2W1	0.3	6.32	0.33	8.27e-10	Longevity;Endometriosis;
LUSC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	9.25	0.45	2.72e-18	Height;
LUSC	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	8.26	0.41	3.51e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg08601574	chr20:25228251	PYGB	0.43	6.64	0.34	1.28e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2629540	0.924	rs1545910	chr10:126428145	G/C	cg08799069	chr10:126477246	METTL10	-0.7	-10.22	-0.49	1.66e-21	Cocaine dependence;
LUSC	cis	rs7584330	0.554	rs9646713	chr2:238443542	T/C	cg14458575	chr2:238380390	NA	0.43	5.71	0.3	2.47e-8	Prostate cancer;
LUSC	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg17757837	chr7:157058334	UBE3C	-0.82	-13.32	-0.59	9.02e-33	Body mass index;
LUSC	cis	rs2692947	0.673	rs2229169	chr2:96780716	T/G	cg22654517	chr2:96458247	NA	-0.31	-5.87	-0.31	1.05e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7539409	0.764	rs4001465	chr1:84285304	T/C	cg10977910	chr1:84465055	TTLL7	0.64	5.89	0.31	9.36e-9	Alzheimer's disease;
LUSC	cis	rs76793172	1.000	rs7249022	chr19:46354558	G/A	cg00442267	chr19:46317840	RSPH6A	-0.5	-5.69	-0.3	2.77e-8	Eosinophil counts;
LUSC	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg04310649	chr10:35416472	CREM	0.44	6.89	0.35	2.73e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03934478	chr11:495069	RNH1	-0.83	-9.95	-0.48	1.36e-20	Body mass index;
LUSC	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg23795048	chr12:9217529	LOC144571	0.34	5.88	0.31	1.02e-8	Sjögren's syndrome;
LUSC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.8	13.3	0.59	1.14e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01708711	chr7:75959031	YWHAG	0.45	6.69	0.34	9.5e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg06784218	chr1:46089804	CCDC17	-0.32	-6.31	-0.33	8.9e-10	Red blood cell count;Reticulocyte count;
LUSC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.81	15.55	0.65	2.11e-41	Dental caries;
LUSC	cis	rs4959270	0.836	rs10900950	chr6:462968	C/T	cg09757644	chr6:447497	NA	0.29	5.79	0.3	1.61e-8	Limited cutaneous systemic scleroderma;
LUSC	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.48	10.28	0.49	1.02e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg24977027	chr2:88469347	THNSL2	0.56	5.84	0.3	1.21e-8	Plasma clusterin levels;
LUSC	cis	rs1322512	0.917	rs1727049	chr6:152942962	A/G	cg27316956	chr6:152958899	SYNE1	-0.35	-5.77	-0.3	1.77e-8	Tonometry;
LUSC	trans	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.38	0.62	7.6e-37	Exhaled nitric oxide levels;
LUSC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.78	-12.48	-0.56	1.39e-29	Hip circumference adjusted for BMI;
LUSC	trans	rs6788232	0.908	rs9866149	chr3:138731753	G/A	cg05026658	chr7:102918083	DPY19L2P2	-0.55	-6.14	-0.32	2.32e-9	Male-pattern baldness;
LUSC	cis	rs9811920	0.715	rs6810262	chr3:99906342	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.32	6.11	0.32	2.76e-9	Axial length;
LUSC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg07701084	chr6:150067640	NUP43	0.58	8.92	0.44	3.05e-17	Lung cancer;
LUSC	cis	rs4474465	1.000	rs7934678	chr11:78192968	G/A	cg27205649	chr11:78285834	NARS2	-0.52	-6.02	-0.31	4.59e-9	Alzheimer's disease (survival time);
LUSC	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg14530993	chr4:882597	GAK	0.72	7.42	0.38	1e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg09034736	chr1:150693464	HORMAD1	0.41	5.65	0.3	3.51e-8	Melanoma;
LUSC	cis	rs524023	0.881	rs544838	chr11:64429059	T/C	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.7	-0.3	2.69e-8	Urate levels in obese individuals;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02123667	chr8:127570702	FAM84B	-0.48	-6.38	-0.33	6.04e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-6.87	-0.35	3.11e-11	Menarche (age at onset);
LUSC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.51	0.69	3.59e-49	Chronic sinus infection;
LUSC	cis	rs2274273	1.000	rs72718804	chr14:55630610	G/A	cg04306507	chr14:55594613	LGALS3	0.55	12.02	0.55	6.51e-28	Protein biomarker;
LUSC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	8.92	0.44	3.03e-17	Prudent dietary pattern;
LUSC	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg12463550	chr7:65579703	CRCP	0.54	7.68	0.39	1.75e-13	Aortic root size;
LUSC	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.68	-0.47	1.07e-19	Multiple sclerosis;
LUSC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	10.77	0.51	2e-23	Bone mineral density;
LUSC	cis	rs7580658	0.864	rs10928761	chr2:128003247	C/T	cg09760422	chr2:128146352	NA	-0.28	-6.11	-0.32	2.79e-9	Protein C levels;
LUSC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg00343986	chr7:65444356	GUSB	-0.39	-5.98	-0.31	5.79e-9	Aortic root size;
LUSC	trans	rs800082	0.646	rs2717394	chr3:144280612	A/T	cg24215973	chr2:240111563	HDAC4	0.6	9.56	0.46	2.65e-19	Smoking behavior;
LUSC	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21028142	chr17:79581711	NPLOC4	0.34	8.17	0.41	6.45e-15	Eye color traits;
LUSC	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg05714579	chr10:131428358	MGMT	-0.52	-7.9	-0.4	4e-14	Response to temozolomide;
LUSC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg07636037	chr3:49044803	WDR6	0.56	5.73	0.3	2.24e-8	Menarche (age at onset);
LUSC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg12257692	chr3:49977190	RBM6	0.23	6.3	0.33	9.34e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg17366294	chr4:99064904	C4orf37	0.5	8.54	0.42	4.84e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4974559	0.594	rs59544360	chr4:1313575	G/T	cg02980000	chr4:1222292	CTBP1	0.83	8.93	0.44	2.99e-17	Systolic blood pressure;
LUSC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05165339	chr4:1420672	NA	-0.29	-6.56	-0.34	2.07e-10	Longevity;
LUSC	cis	rs13223928	0.565	rs10951053	chr7:3155579	C/T	cg19214707	chr7:3157722	NA	-0.49	-9.52	-0.46	3.6e-19	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs7771547	0.519	rs4713973	chr6:36382044	A/G	cg07856975	chr6:36356162	ETV7	0.42	6.22	0.32	1.51e-9	Platelet distribution width;
LUSC	cis	rs554111	0.656	rs4654900	chr1:21422021	G/C	cg01072550	chr1:21505969	NA	0.39	6.01	0.31	4.82e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs16917546	0.933	rs10995238	chr10:64387108	A/G	cg03961010	chr10:64397487	ZNF365	0.43	6.79	0.35	4.99e-11	Basal cell carcinoma;
LUSC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg27432699	chr2:27873401	GPN1	-0.59	-8.94	-0.44	2.7e-17	Total body bone mineral density;
LUSC	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	7.68	0.39	1.78e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg22160112	chr17:46696077	NA	0.45	6.19	0.32	1.8e-9	Mosquito bite size;
LUSC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg05347473	chr6:146136440	FBXO30	0.55	9.73	0.47	7.59e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg00343986	chr7:65444356	GUSB	0.47	7.09	0.36	7.84e-12	Aortic root size;
LUSC	cis	rs2051773	0.567	rs11024113	chr11:17042444	G/A	cg15084286	chr11:17036142	PLEKHA7	0.44	5.64	0.3	3.57e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUSC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg12311346	chr5:56204834	C5orf35	-0.81	-13.01	-0.58	1.39e-31	Coronary artery disease;
LUSC	cis	rs2688608	0.836	rs2675668	chr10:75636148	G/A	cg17411546	chr10:75410026	SYNPO2L	-0.41	-5.84	-0.3	1.23e-8	Inflammatory bowel disease;
LUSC	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	6.66	0.34	1.09e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs113835537	0.597	rs2305534	chr11:66313203	T/C	cg24851651	chr11:66362959	CCS	0.53	7.86	0.4	5.33e-14	Airway imaging phenotypes;
LUSC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg12564285	chr5:131593104	PDLIM4	-0.34	-6.15	-0.32	2.2e-9	Blood metabolite levels;
LUSC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg01802117	chr1:53393560	SCP2	-0.39	-6.36	-0.33	6.81e-10	Monocyte count;
LUSC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg04733989	chr22:42467013	NAGA	0.55	8.55	0.42	4.57e-16	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg22907277	chr7:1156413	C7orf50	0.68	7.3	0.37	2.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.14	0.32	2.33e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06221963	chr1:154839813	KCNN3	-0.61	-13.83	-0.6	1.03e-34	Prostate cancer;
LUSC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg12927641	chr6:109611667	NA	-0.42	-7.5	-0.38	5.9e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs5756931	0.503	rs5750542	chr22:38534507	T/C	cg25457927	chr22:38595422	NA	-0.35	-7.01	-0.36	1.29e-11	Triglycerides;
LUSC	cis	rs10465746	0.846	rs9700285	chr1:84336685	G/A	cg10977910	chr1:84465055	TTLL7	0.44	6.21	0.32	1.54e-9	Obesity-related traits;
LUSC	cis	rs4851254	0.550	rs13402289	chr2:100659389	C/T	cg22139774	chr2:100720529	AFF3	-0.44	-5.75	-0.3	2.06e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	12.62	0.57	3.86e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.07e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg00745463	chr17:30367425	LRRC37B	-0.83	-9.23	-0.45	3.07e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs9534288	0.664	rs1926447	chr13:46629944	C/T	cg15192986	chr13:46630673	CPB2	0.66	10.37	0.49	5.03e-22	Blood protein levels;
LUSC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg22166914	chr1:53195759	ZYG11B	-0.62	-10.34	-0.49	6.45e-22	Monocyte count;
LUSC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg04800585	chr6:26043546	HIST1H2BB	0.39	5.92	0.31	8.07e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg26897989	chr16:1907736	C16orf73	0.46	7.36	0.37	1.45e-12	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg26695010	chr11:65641043	EFEMP2	-0.47	-7.14	-0.36	5.95e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs72960926	0.744	rs72950570	chr6:74913740	T/C	cg03266952	chr6:74778945	NA	-0.78	-6.22	-0.32	1.5e-9	Metabolite levels (MHPG);
LUSC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.35	-0.37	1.49e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7607369	0.559	rs4674339	chr2:219659787	C/G	cg02176678	chr2:219576539	TTLL4	-0.53	-9.51	-0.46	4.03e-19	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs240764	0.658	rs9485410	chr6:101261007	A/G	cg09795085	chr6:101329169	ASCC3	0.46	6.66	0.34	1.13e-10	Neuroticism;
LUSC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-1.22	-13.44	-0.59	3.3e-33	Diabetic kidney disease;
LUSC	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-1.02	-24.9	-0.81	4.01e-78	Urate levels in lean individuals;
LUSC	cis	rs13315871	0.929	rs13080508	chr3:58300116	G/A	cg12435725	chr3:58293450	RPP14	-0.68	-7.18	-0.37	4.62e-12	Cholesterol, total;
LUSC	cis	rs17125944	0.686	rs7158645	chr14:53332152	C/T	cg00686598	chr14:53173677	PSMC6	-0.64	-5.98	-0.31	5.6e-9	Alzheimer's disease (late onset);
LUSC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg17507749	chr15:85114479	UBE2QP1	0.69	8.78	0.43	8.54e-17	Schizophrenia;
LUSC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.29	0.37	2.29e-12	Platelet count;
LUSC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg03804128	chr16:635623	NA	0.31	5.99	0.31	5.53e-9	Height;
LUSC	cis	rs17253792	0.822	rs78395034	chr14:56069783	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-6.96	-0.36	1.81e-11	Putamen volume;
LUSC	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	8.49	0.42	6.87e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.67	11.84	0.54	3.15e-27	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-12.67	-0.57	2.7e-30	Platelet count;
LUSC	cis	rs7200543	1.000	rs6498541	chr16:15140657	A/G	cg03427771	chr16:15082598	PDXDC1	-0.4	-5.78	-0.3	1.69e-8	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-7.1	-0.36	7.7e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg03241323	chr2:187454863	ITGAV	0.39	6.14	0.32	2.28e-9	Mosquito bite size;
LUSC	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg09408571	chr1:101003634	GPR88	0.37	7.51	0.38	5.55e-13	Breast cancer;
LUSC	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg26384229	chr12:38710491	ALG10B	0.72	11.22	0.52	5.39e-25	Morning vs. evening chronotype;
LUSC	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg09184832	chr6:79620586	NA	-0.41	-6.34	-0.33	7.41e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	9.76	0.47	5.99e-20	Eosinophil percentage of white cells;
LUSC	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg02527881	chr3:46936655	PTH1R	-0.38	-6.62	-0.34	1.47e-10	Colorectal cancer;
LUSC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.43e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg05861140	chr6:150128134	PCMT1	-0.38	-5.87	-0.31	1.04e-8	Lung cancer;
LUSC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg18352616	chr4:3374830	RGS12	0.33	6.61	0.34	1.51e-10	Serum sulfate level;
LUSC	trans	rs12200782	0.932	rs12189841	chr6:26544798	A/T	cg18180407	chr1:55047736	ACOT11	0.48	5.97	0.31	6.12e-9	Small cell lung carcinoma;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg07904447	chr11:94823506	ENDOD1	-0.5	-6.22	-0.32	1.48e-9	Neuroticism;
LUSC	cis	rs10740039	0.516	rs7088259	chr10:62318852	T/C	cg18175470	chr10:62150864	ANK3	-0.45	-6.89	-0.35	2.87e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg26897989	chr16:1907736	C16orf73	-0.42	-6.63	-0.34	1.37e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.43	6.57	0.34	1.92e-10	Dupuytren's disease;
LUSC	cis	rs6546550	0.901	rs10167142	chr2:70062360	T/C	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.17	-0.37	4.87e-12	Prevalent atrial fibrillation;
LUSC	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.76	-11.11	-0.52	1.32e-24	Glomerular filtration rate;
LUSC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg08847533	chr14:75593920	NEK9	0.85	15.82	0.65	1.82e-42	Height;
LUSC	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.39	16.09	0.66	1.62e-43	Opioid sensitivity;
LUSC	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg01733217	chr16:74700730	RFWD3	0.75	12.49	0.56	1.25e-29	Testicular germ cell tumor;
LUSC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	9.09	0.45	8.89e-18	Total body bone mineral density;
LUSC	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg04310649	chr10:35416472	CREM	-0.41	-6.32	-0.33	8.17e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg24130564	chr14:104152367	KLC1	0.45	6.54	0.34	2.3e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg16414030	chr3:133502952	NA	-0.54	-8.74	-0.43	1.14e-16	Iron status biomarkers;
LUSC	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg03522245	chr20:25566470	NINL	0.37	5.96	0.31	6.4e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg08345082	chr10:99160200	RRP12	0.31	6.37	0.33	6.44e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg16928487	chr17:17741425	SREBF1	-0.43	-8.43	-0.42	1.03e-15	Total body bone mineral density;
LUSC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	10.01	0.48	8.74e-21	Eosinophil percentage of white cells;
LUSC	cis	rs3931020	0.657	rs277368	chr1:75230606	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.64	-8.41	-0.42	1.17e-15	Resistin levels;
LUSC	cis	rs6736093	0.796	rs13006228	chr2:112806738	G/A	cg12686935	chr2:112915763	FBLN7	-0.4	-6.35	-0.33	7.04e-10	Coronary artery disease;
LUSC	cis	rs6599077	0.950	rs4676562	chr3:40105039	A/G	cg13683864	chr3:40499215	RPL14	-0.61	-7.6	-0.38	3.09e-13	Sleep-related phenotypes;
LUSC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg24060327	chr5:131705240	SLC22A5	0.67	11.03	0.52	2.42e-24	Breast cancer;
LUSC	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg13010199	chr12:38710504	ALG10B	0.56	8.27	0.41	3.18e-15	Morning vs. evening chronotype;
LUSC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg10169327	chr19:45448959	APOC2	0.31	6.66	0.34	1.15e-10	Blood protein levels;
LUSC	cis	rs253664	0.846	rs166195	chr3:138093164	T/C	cg25188949	chr3:137893707	DBR1	-0.49	-5.72	-0.3	2.37e-8	Body mass index;
LUSC	trans	rs11088226	0.581	rs2833856	chr21:33877691	A/G	cg09050820	chr6:167586206	TCP10L2	-0.49	-7.69	-0.39	1.69e-13	Gastritis;
LUSC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.47	0.33	3.59e-10	Lung cancer;
LUSC	cis	rs921665	0.831	rs2242084	chr2:3196040	A/G	cg02624386	chr2:3182749	NA	0.59	6.61	0.34	1.56e-10	World class endurance athleticism;
LUSC	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-1.15	-18.23	-0.71	5.05e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg26335602	chr6:28129616	ZNF389	0.49	6.56	0.34	2e-10	Parkinson's disease;
LUSC	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.07	0.44	1.02e-17	Coffee consumption (cups per day);
LUSC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	10.83	0.51	1.25e-23	Homoarginine levels;
LUSC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.72	9.97	0.48	1.17e-20	Gut microbiome composition (summer);
LUSC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg02018176	chr4:1364513	KIAA1530	0.52	8.87	0.44	4.63e-17	Obesity-related traits;
LUSC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg16606324	chr3:10149918	C3orf24	0.59	8.55	0.42	4.49e-16	Alzheimer's disease;
LUSC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.56	10.96	0.51	4.23e-24	Asthma (sex interaction);
LUSC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.23	-0.45	3.31e-18	Acne (severe);
LUSC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02475777	chr4:1388615	CRIPAK	-0.61	-9.05	-0.44	1.22e-17	Longevity;
LUSC	cis	rs7707921	0.881	rs73134739	chr5:81370760	T/C	cg15871215	chr5:81402204	ATG10	-0.44	-6.44	-0.33	4.13e-10	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19977408	chr4:129209103	PGRMC2	0.45	6.95	0.36	1.91e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	11.87	0.54	2.28e-27	Height;
LUSC	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.25	0.37	3e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1506636	1.000	rs641491	chr7:123399726	C/A	cg03229431	chr7:123269106	ASB15	0.65	10.7	0.51	3.66e-23	Plateletcrit;Platelet count;
LUSC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg07701084	chr6:150067640	NUP43	0.57	8.6	0.43	3.13e-16	Lung cancer;
LUSC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg05347473	chr6:146136440	FBXO30	0.66	11.35	0.53	1.86e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg15147215	chr3:52552868	STAB1	-0.32	-6.4	-0.33	5.28e-10	Electroencephalogram traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25804072	chr2:10829725	NOL10	0.51	6.9	0.35	2.65e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg12639453	chr1:2035780	PRKCZ	-0.31	-6.56	-0.34	2e-10	Height;
LUSC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-6.49	-0.33	3.04e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg23102388	chr7:1867652	MAD1L1	-0.3	-5.68	-0.3	2.97e-8	Bipolar disorder and schizophrenia;
LUSC	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg15704280	chr7:45808275	SEPT13	0.68	6.43	0.33	4.36e-10	Axial length;
LUSC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg04141948	chr7:1023156	CYP2W1	0.27	5.85	0.3	1.18e-8	Longevity;Endometriosis;
LUSC	cis	rs10740039	0.732	rs10159808	chr10:62362190	C/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.73	-0.35	7.28e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg08017756	chr2:100939284	LONRF2	-0.45	-8.56	-0.42	4.11e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7582720	1.000	rs72932791	chr2:203700870	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.73	0.43	1.22e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.65	-10.18	-0.49	2.18e-21	Menarche (age at onset);
LUSC	trans	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg18187862	chr3:45730750	SACM1L	-0.63	-7.56	-0.38	3.92e-13	Primary sclerosing cholangitis;
LUSC	cis	rs9399401	0.961	rs9403383	chr6:142694049	G/A	cg03128060	chr6:142623767	GPR126	0.34	6.16	0.32	2.1e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg13206674	chr6:150067644	NUP43	0.6	9.5	0.46	4.09e-19	Lung cancer;
LUSC	cis	rs8018808	0.935	rs760257	chr14:77935145	G/A	cg20045696	chr14:77926864	AHSA1	0.34	5.76	0.3	1.95e-8	Myeloid white cell count;
LUSC	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.06	-0.31	3.71e-9	Bipolar disorder;
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg04234412	chr22:24373322	LOC391322	-0.85	-13.74	-0.6	2.21e-34	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs965469	0.762	rs6515783	chr20:3245006	T/C	cg25506879	chr20:3388711	C20orf194	-0.49	-5.67	-0.3	3.17e-8	IFN-related cytopenia;
LUSC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg23711669	chr6:146136114	FBXO30	0.72	12.67	0.57	2.53e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.9	0.61	5.49e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs3742264	0.656	rs9534263	chr13:46541450	C/T	cg15192986	chr13:46630673	CPB2	-0.38	-5.82	-0.3	1.4e-8	Blood protein levels;
LUSC	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg17168535	chr8:21777572	XPO7	0.68	10.52	0.5	1.46e-22	Mean corpuscular volume;
LUSC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08280861	chr8:58055591	NA	-0.53	-5.89	-0.31	9.29e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs59698941	0.943	rs66685494	chr5:132291056	A/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg00376283	chr12:123451042	ABCB9	0.67	8.42	0.42	1.1e-15	Neutrophil percentage of white cells;
LUSC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.57	0.78	3.62e-69	Prudent dietary pattern;
LUSC	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg04733989	chr22:42467013	NAGA	0.38	6.37	0.33	6.36e-10	Cognitive function;
LUSC	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg24130564	chr14:104152367	KLC1	0.41	5.64	0.3	3.54e-8	Bone mineral density;
LUSC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-6.92	-0.35	2.34e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg18402987	chr7:1209562	NA	0.74	7.99	0.4	2.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.82	0.39	7.09e-14	Retinal vascular caliber;
LUSC	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21028142	chr17:79581711	NPLOC4	0.34	7.98	0.4	2.39e-14	Eye color traits;
LUSC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg09165964	chr15:75287851	SCAMP5	0.45	6.83	0.35	3.93e-11	Breast cancer;
LUSC	cis	rs7582720	0.887	rs72934591	chr2:204019762	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.83	8.78	0.43	8.34e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg10556349	chr10:835070	NA	0.57	6.44	0.33	4.19e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs9378357	0.850	rs9391986	chr6:3290583	A/G	cg08754725	chr6:3293098	SLC22A23	0.82	8.11	0.41	9.59e-15	Obesity-related traits;
LUSC	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg25319279	chr11:5960081	NA	-0.45	-6.32	-0.33	8.2e-10	DNA methylation (variation);
LUSC	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg17366294	chr4:99064904	C4orf37	0.56	8.91	0.44	3.4e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.41	-6.49	-0.33	3.18e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg18681998	chr4:17616180	MED28	0.87	16.17	0.66	7.54e-44	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg24375607	chr4:120327624	NA	0.78	11.34	0.53	2e-25	Corneal astigmatism;
LUSC	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg20734569	chr3:48348370	SPINK8	-0.49	-7.82	-0.39	7.13e-14	Coronary artery disease;
LUSC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg27432699	chr2:27873401	GPN1	-0.56	-8.37	-0.42	1.62e-15	Total body bone mineral density;
LUSC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	trans	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg01620082	chr3:125678407	NA	-0.67	-6.9	-0.35	2.63e-11	Breast cancer;
LUSC	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg03522245	chr20:25566470	NINL	0.37	5.96	0.31	6.4e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg02403541	chr12:121454288	C12orf43	-0.73	-11.4	-0.53	1.15e-25	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg16342193	chr10:102329863	NA	-0.35	-6.62	-0.34	1.4e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg03161606	chr19:29218774	NA	0.6	8.89	0.44	4.03e-17	Methadone dose in opioid dependence;
LUSC	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg00857998	chr1:205179979	DSTYK	0.6	9.07	0.44	1.06e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg12863693	chr15:85201151	NMB	0.35	7.18	0.37	4.63e-12	Schizophrenia;
LUSC	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.63	-9.49	-0.46	4.38e-19	Platelet distribution width;
LUSC	cis	rs2230307	0.536	rs834278	chr1:100510882	T/C	cg24955406	chr1:100503596	HIAT1	0.57	6.15	0.32	2.23e-9	Carotid intima media thickness;
LUSC	cis	rs9323205	1.000	rs7149022	chr14:51613980	A/C	cg23942311	chr14:51606299	NA	-0.49	-10.25	-0.49	1.24e-21	Cancer;
LUSC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg19539972	chr4:7069911	GRPEL1	-0.72	-7.46	-0.38	7.61e-13	Monocyte percentage of white cells;
LUSC	cis	rs7258465	0.563	rs10854166	chr19:18652844	A/G	cg11102782	chr19:18549136	ISYNA1	0.31	5.78	0.3	1.71e-8	Breast cancer;
LUSC	cis	rs1044826	1.000	rs3772877	chr3:139187626	C/G	cg00490450	chr3:139108681	COPB2	0.52	6.68	0.34	1.03e-10	Obesity-related traits;
LUSC	cis	rs6504340	0.739	rs1062037	chr17:46638154	T/C	cg09704116	chr17:46666958	LOC404266	-0.36	-5.74	-0.3	2.15e-8	Primary tooth development (number of teeth);
LUSC	trans	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.4	0.42	1.29e-15	Ulcerative colitis;
LUSC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg08888203	chr3:10149979	C3orf24	0.59	8.21	0.41	4.83e-15	Alzheimer's disease;
LUSC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	6.29	0.33	1.01e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2692947	0.644	rs1030864	chr2:96822373	A/G	cg23100626	chr2:96804247	ASTL	0.3	7.07	0.36	9.11e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.86e-12	Blood metabolite levels;
LUSC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg16606324	chr3:10149918	C3orf24	0.6	8.13	0.41	8.64e-15	Alzheimer's disease;
LUSC	cis	rs10193935	1.000	rs10185742	chr2:42429666	A/G	cg27598129	chr2:42591480	NA	-0.64	-8.64	-0.43	2.28e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.49	-0.38	6.15e-13	Aortic root size;
LUSC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg21951975	chr1:209979733	IRF6	0.49	8.35	0.42	1.84e-15	Monobrow;
LUSC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg06671706	chr8:8559999	CLDN23	0.48	6.6	0.34	1.66e-10	Obesity-related traits;
LUSC	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg03806693	chr22:41940476	POLR3H	-0.56	-8.13	-0.41	8.4e-15	Neuroticism;
LUSC	cis	rs908922	0.742	rs499913	chr1:152476743	T/A	cg20991723	chr1:152506922	NA	0.52	8.79	0.43	8.08e-17	Hair morphology;
LUSC	trans	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg18239417	chr7:154684963	DPP6	0.29	5.96	0.31	6.5e-9	Blood metabolite levels;
LUSC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.67	-0.34	1.04e-10	Total body bone mineral density;
LUSC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg05535760	chr7:792225	HEATR2	-0.78	-7.77	-0.39	1e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg03806693	chr22:41940476	POLR3H	-0.83	-12.3	-0.56	5.96e-29	Vitiligo;
LUSC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs983392	0.836	rs7935829	chr11:59942815	A/G	cg20284999	chr11:59952153	MS4A6A	-0.38	-6.3	-0.33	9.48e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6087990	0.735	rs2424913	chr20:31374259	C/T	cg13636640	chr20:31349939	DNMT3B	0.85	16.33	0.67	1.75e-44	Ulcerative colitis;
LUSC	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg04283868	chr2:201171347	SPATS2L	-0.42	-6.16	-0.32	2.03e-9	QT interval;
LUSC	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg05110241	chr16:68378359	PRMT7	0.75	8.55	0.42	4.42e-16	Schizophrenia;
LUSC	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg22153463	chr1:85462885	MCOLN2	-0.62	-8.01	-0.4	1.89e-14	Serum sulfate level;
LUSC	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	6.39	0.33	5.53e-10	Rheumatoid arthritis;
LUSC	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.33	-0.45	1.56e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg21782813	chr7:2030301	MAD1L1	0.38	6.27	0.32	1.14e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06221963	chr1:154839813	KCNN3	-0.6	-13.52	-0.59	1.57e-33	Prostate cancer;
LUSC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg08470875	chr2:26401718	FAM59B	0.69	8.96	0.44	2.27e-17	Gut microbiome composition (summer);
LUSC	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg12292205	chr6:26970375	C6orf41	-0.41	-6.19	-0.32	1.78e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg11693508	chr17:37793320	STARD3	0.51	6.12	0.32	2.69e-9	Bipolar disorder;
LUSC	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg22782873	chr19:19639568	YJEFN3	-0.48	-5.75	-0.3	2.02e-8	Bipolar disorder;
LUSC	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg25182066	chr10:30743637	MAP3K8	-0.41	-5.82	-0.3	1.38e-8	Itch intensity from mosquito bite;
LUSC	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg22709100	chr7:91322751	NA	0.39	5.84	0.3	1.23e-8	Breast cancer;
LUSC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg15848620	chr12:58087721	OS9	-0.57	-8.18	-0.41	5.81e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.89	-0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	0.85	11.03	0.52	2.49e-24	Blood trace element (Zn levels);
LUSC	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg25919922	chr13:100150906	NA	0.76	9.27	0.45	2.44e-18	Obesity-related traits;
LUSC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-7.63	-0.39	2.48e-13	Menarche (age at onset);
LUSC	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg20991723	chr1:152506922	NA	0.47	8.71	0.43	1.42e-16	Hair morphology;
LUSC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.11	-0.41	9.99e-15	Lung cancer;
LUSC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg16928487	chr17:17741425	SREBF1	-0.35	-6.84	-0.35	3.81e-11	Total body bone mineral density;
LUSC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	6.86	0.35	3.43e-11	Lung cancer in ever smokers;
LUSC	cis	rs6580649	0.771	rs1635535	chr12:48386241	A/G	cg24011408	chr12:48396354	COL2A1	0.49	6.07	0.32	3.52e-9	Lung cancer;
LUSC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.71	0.6	3.09e-34	Cognitive test performance;
LUSC	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg20026190	chr17:76395443	PGS1	0.45	8.08	0.4	1.22e-14	HDL cholesterol levels;
LUSC	trans	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg26043149	chr18:55253948	FECH	-0.52	-7.7	-0.39	1.51e-13	Bone mineral density;
LUSC	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg19875535	chr5:140030758	IK	-0.54	-8.71	-0.43	1.43e-16	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7572644	0.766	rs13025314	chr2:28080214	G/A	cg27432699	chr2:27873401	GPN1	0.51	6.47	0.33	3.46e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7683537	0.692	rs12509936	chr4:185662203	G/A	cg04058563	chr4:185651563	MLF1IP	0.8	10.99	0.52	3.55e-24	Systemic lupus erythematosus;
LUSC	cis	rs367943	0.672	rs1517207	chr5:112717245	G/A	cg12552261	chr5:112820674	MCC	0.37	6.11	0.32	2.71e-9	Type 2 diabetes;
LUSC	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.62	10.33	0.49	6.65e-22	Blood metabolite ratios;
LUSC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs354225	0.544	rs12713269	chr2:54809154	C/G	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	cis	rs2013441	0.835	rs2526491	chr17:20097462	A/G	cg04132472	chr17:19861366	AKAP10	-0.35	-5.65	-0.3	3.49e-8	Obesity-related traits;
LUSC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg05802129	chr4:122689817	NA	-0.36	-6.46	-0.33	3.63e-10	Type 2 diabetes;
LUSC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	10.48	0.5	2.16e-22	Cognitive test performance;
LUSC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg09877947	chr5:131593287	PDLIM4	0.43	6.64	0.34	1.29e-10	Breast cancer;
LUSC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg10360139	chr7:1886902	MAD1L1	-0.45	-6.9	-0.35	2.7e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg07211511	chr3:129823064	LOC729375	-0.75	-9.74	-0.47	6.87e-20	Blood pressure (smoking interaction);
LUSC	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	0.89	14.91	0.63	6.85e-39	Schizophrenia;
LUSC	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.52	8.01	0.4	1.94e-14	Birth weight;
LUSC	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	12.0	0.55	8.08e-28	Height;
LUSC	cis	rs9902453	0.584	rs3809790	chr17:27955540	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.52	-7.68	-0.39	1.79e-13	Coffee consumption (cups per day);
LUSC	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg05527609	chr1:210001259	C1orf107	0.7	10.07	0.48	5.22e-21	Orofacial clefts;
LUSC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg03036452	chr22:46663545	TTC38	0.58	5.83	0.3	1.32e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs477692	1.000	rs522891	chr10:131430916	T/C	cg26102564	chr10:131424627	MGMT	-0.4	-6.19	-0.32	1.8e-9	Response to temozolomide;
LUSC	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg18806716	chr10:30721971	MAP3K8	0.6	9.54	0.46	3.15e-19	Inflammatory bowel disease;
LUSC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25072359	chr17:41440525	NA	0.65	9.39	0.46	9.33e-19	Menopause (age at onset);
LUSC	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg03342759	chr3:160939853	NMD3	-0.57	-9.78	-0.47	4.88e-20	Morning vs. evening chronotype;
LUSC	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg26384229	chr12:38710491	ALG10B	0.86	14.29	0.62	1.8e-36	Bladder cancer;
LUSC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.71	10.56	0.5	1.09e-22	Chronic sinus infection;
LUSC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg04455712	chr21:45112962	RRP1B	0.45	8.33	0.41	2.18e-15	Mean corpuscular volume;
LUSC	trans	rs61931739	0.564	rs7304271	chr12:33757011	G/T	cg26384229	chr12:38710491	ALG10B	0.43	6.24	0.32	1.3e-9	Morning vs. evening chronotype;
LUSC	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.85	-13.71	-0.6	2.94e-34	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg26102564	chr10:131424627	MGMT	0.42	6.54	0.34	2.25e-10	Response to temozolomide;
LUSC	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg21385522	chr1:16154831	NA	0.58	9.0	0.44	1.78e-17	Dilated cardiomyopathy;
LUSC	cis	rs2303282	0.716	rs4784667	chr16:56462000	G/A	cg00500540	chr16:56394104	NA	-0.43	-7.33	-0.37	1.75e-12	Breast cancer;
LUSC	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg12046867	chr14:103022105	NA	0.42	5.81	0.3	1.48e-8	Platelet count;
LUSC	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	6.44	0.33	4.26e-10	Recombination rate (females);
LUSC	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.33	0.41	2.18e-15	Lung cancer;
LUSC	cis	rs6580649	0.941	rs10492080	chr12:48501411	A/G	cg24011408	chr12:48396354	COL2A1	-0.45	-6.1	-0.32	2.9e-9	Lung cancer;
LUSC	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg27539214	chr16:67997921	SLC12A4	-0.45	-5.9	-0.31	8.9e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg03929089	chr4:120376271	NA	0.74	6.95	0.36	1.87e-11	Axial length;
LUSC	trans	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.29	0.49	9.55e-22	Mean corpuscular volume;
LUSC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.84	-11.24	-0.52	4.63e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg18105134	chr13:113819100	PROZ	-0.71	-10.47	-0.5	2.2e-22	Platelet distribution width;
LUSC	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	trans	rs1941687	0.769	rs1493911	chr18:31356019	A/G	cg27147174	chr7:100797783	AP1S1	-0.47	-6.97	-0.36	1.66e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs317689	0.959	rs317688	chr12:69726850	T/C	cg11871910	chr12:69753446	YEATS4	0.55	7.14	0.36	5.86e-12	Response to diuretic therapy;
LUSC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg26513180	chr16:89883248	FANCA	-0.65	-10.46	-0.5	2.54e-22	Vitiligo;
LUSC	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	7.39	0.37	1.21e-12	Iron status biomarkers;
LUSC	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	1.11	29.37	0.85	1.44e-94	Myeloid white cell count;
LUSC	cis	rs34638657	0.872	rs2967352	chr16:82196676	T/C	cg09439754	chr16:82129088	HSD17B2	-0.4	-6.1	-0.32	3.01e-9	Lung adenocarcinoma;
LUSC	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg05861140	chr6:150128134	PCMT1	-0.39	-5.89	-0.31	9.45e-9	Lung cancer;
LUSC	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg20019720	chr6:154832845	CNKSR3	0.62	8.69	0.43	1.63e-16	Lipoprotein (a) levels;
LUSC	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.84	0.51	1.15e-23	Fuchs's corneal dystrophy;
LUSC	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.91	-0.68	8.65e-47	Exhaled nitric oxide output;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg21304062	chr17:78075816	GAA	0.4	6.35	0.33	7.13e-10	Mosquito bite size;
LUSC	cis	rs117623576	0.941	rs11008775	chr10:32410307	T/C	cg03047570	chr10:32398778	NA	-0.61	-6.61	-0.34	1.49e-10	Anti-saccade response;
LUSC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg17948913	chr5:572064	NA	0.36	6.08	0.32	3.32e-9	Obesity-related traits;
LUSC	cis	rs2710642	0.925	rs72807578	chr2:63008044	G/A	cg17519650	chr2:63277830	OTX1	-0.51	-7.2	-0.37	3.97e-12	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg03128534	chr1:43423976	SLC2A1	0.51	6.6	0.34	1.61e-10	Red cell distribution width;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09315468	chr8:38089562	DDHD2	-0.44	-6.59	-0.34	1.73e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs17102423	0.559	rs4899160	chr14:65481212	C/T	cg11161011	chr14:65562177	MAX	-0.69	-9.37	-0.46	1.1e-18	Obesity-related traits;
LUSC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg06238570	chr21:40685208	BRWD1	0.49	7.51	0.38	5.59e-13	Cognitive function;
LUSC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg03929089	chr4:120376271	NA	-0.77	-12.25	-0.56	9.36e-29	Height;
LUSC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.39	0.37	1.2e-12	Schizophrenia;
LUSC	cis	rs2882667	0.690	rs160404	chr5:138084269	A/G	cg04439458	chr5:138467593	SIL1	-0.33	-6.16	-0.32	2.14e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.83	14.6	0.62	1.09e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg19592336	chr6:28129416	ZNF389	0.45	5.96	0.31	6.36e-9	Depression;
LUSC	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg06606381	chr12:133084897	FBRSL1	-0.85	-8.07	-0.4	1.28e-14	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-8.8	-0.43	7.66e-17	Triglycerides;
LUSC	trans	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07923666	chr12:49932857	KCNH3	-0.5	-6.11	-0.32	2.81e-9	Resting heart rate;
LUSC	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg05043794	chr9:111880884	C9orf5	0.31	6.84	0.35	3.78e-11	Menarche (age at onset);
LUSC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg22655196	chr4:3374909	RGS12	0.3	5.91	0.31	8.28e-9	Serum sulfate level;
LUSC	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.64	0.63	8.06e-38	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6733011	0.628	rs4851163	chr2:99466664	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-5.68	-0.3	2.92e-8	Bipolar disorder;
LUSC	trans	rs7507204	0.906	rs11671513	chr19:3429937	C/T	cg08382705	chr11:45687319	CHST1	-0.54	-7.57	-0.38	3.71e-13	Height;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09134682	chr17:17140493	FLCN	0.52	7.31	0.37	1.98e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7605827	0.930	rs6745731	chr2:15537915	C/T	cg19274914	chr2:15703543	NA	0.46	8.98	0.44	2e-17	Educational attainment (years of education);
LUSC	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07080220	chr10:102295463	HIF1AN	0.68	9.2	0.45	3.94e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16680214	chr1:154839983	KCNN3	-0.55	-10.58	-0.5	9.78e-23	Prostate cancer;
LUSC	cis	rs9322817	0.691	rs9499954	chr6:105205826	C/T	cg02098413	chr6:105308735	HACE1	-0.29	-5.91	-0.31	8.65e-9	Thyroid stimulating hormone;
LUSC	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg13042288	chr15:90349979	ANPEP	-0.41	-6.23	-0.32	1.43e-9	Uric acid levels;
LUSC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.77	-0.3	1.79e-8	Personality dimensions;
LUSC	cis	rs4730250	0.708	rs4730242	chr7:107057373	G/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.32	-0.45	1.62e-18	Osteoarthritis;
LUSC	cis	rs7264396	0.623	rs761827	chr20:34207897	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.15	-0.36	5.4e-12	Total cholesterol levels;
LUSC	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-9.47	-0.46	5.48e-19	Platelet distribution width;
LUSC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg04553112	chr3:125709451	NA	-0.51	-5.78	-0.3	1.76e-8	Blood pressure (smoking interaction);
LUSC	cis	rs12712135	0.706	rs6543114	chr2:102925994	A/C	cg20060108	chr2:102954350	IL1RL1	0.38	5.76	0.3	1.95e-8	Blood protein levels;
LUSC	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg24060327	chr5:131705240	SLC22A5	-0.46	-6.37	-0.33	6.36e-10	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg18827107	chr12:86230957	RASSF9	-0.44	-6.61	-0.34	1.48e-10	Major depressive disorder;
LUSC	cis	rs27434	0.583	rs151911	chr5:96157084	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-7.57	-0.38	3.61e-13	Ankylosing spondylitis;
LUSC	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	8.13	0.41	8.21e-15	Homoarginine levels;
LUSC	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.32	-0.41	2.25e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg17143192	chr8:8559678	CLDN23	-0.61	-8.98	-0.44	1.99e-17	Obesity-related traits;
LUSC	trans	rs12196849	0.668	rs1078326	chr6:98785243	C/T	cg04408923	chr7:5464875	NA	-0.36	-6.01	-0.31	4.73e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.806	rs12444589	chr16:75454404	A/T	cg03315344	chr16:75512273	CHST6	-0.49	-9.2	-0.45	4.13e-18	Dupuytren's disease;
LUSC	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg19773385	chr1:10388646	KIF1B	-0.59	-9.76	-0.47	5.95e-20	Hepatocellular carcinoma;
LUSC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg00033643	chr7:134001901	SLC35B4	0.44	6.83	0.35	4.02e-11	Mean platelet volume;
LUSC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg12365402	chr11:9010492	NRIP3	0.48	8.99	0.44	1.91e-17	Hemoglobin concentration;
LUSC	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg21770322	chr7:97807741	LMTK2	0.56	10.08	0.48	4.99e-21	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06577708	chr3:64008893	PSMD6	0.44	6.59	0.34	1.75e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	8.3	0.41	2.62e-15	Height;
LUSC	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg27471124	chr11:109292789	C11orf87	-0.55	-9.81	-0.47	4.02e-20	Schizophrenia;
LUSC	cis	rs36051895	0.588	rs12340895	chr9:5076691	C/G	cg02405213	chr9:5042618	JAK2	0.66	9.7	0.47	9.03e-20	Pediatric autoimmune diseases;
LUSC	trans	rs8073060	0.592	rs225306	chr17:33920036	A/C	cg19694781	chr19:47549865	TMEM160	0.74	11.82	0.54	3.67e-27	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	cis	rs10743315	0.557	rs16915323	chr12:19437529	A/G	cg02471346	chr12:19282374	PLEKHA5	0.79	6.08	0.32	3.29e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs35000415	0.938	rs34381587	chr7:128666825	A/G	cg19972273	chr7:128594194	NA	0.68	6.9	0.35	2.56e-11	Systemic lupus erythematosus;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg12419862	chr22:24373484	LOC391322	-0.84	-13.65	-0.6	5.34e-34	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg24675056	chr1:15929824	NA	0.48	8.33	0.41	2.17e-15	Systolic blood pressure;
LUSC	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg08085267	chr17:45401833	C17orf57	0.54	8.69	0.43	1.65e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg00191853	chr8:101177733	SPAG1	-0.39	-6.47	-0.33	3.49e-10	Atrioventricular conduction;
LUSC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	6.7	0.34	8.67e-11	Menarche (age at onset);
LUSC	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg15556689	chr8:8085844	FLJ10661	0.68	10.81	0.51	1.44e-23	Joint mobility (Beighton score);
LUSC	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg27471124	chr11:109292789	C11orf87	0.49	8.99	0.44	1.84e-17	Schizophrenia;
LUSC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.43	-0.33	4.31e-10	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg05925327	chr15:68127851	NA	-0.39	-6.36	-0.33	6.68e-10	Restless legs syndrome;
LUSC	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.68	-0.63	5.34e-38	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.79	-0.43	7.85e-17	Bipolar disorder;
LUSC	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.7	-9.99	-0.48	9.74e-21	Glomerular filtration rate;
LUSC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26314531	chr2:26401878	FAM59B	-0.68	-9.13	-0.45	6.62e-18	Gut microbiome composition (summer);
LUSC	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21984481	chr17:79567631	NPLOC4	-0.72	-15.22	-0.64	4.16e-40	Eye color traits;
LUSC	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg27529037	chr20:44575021	PCIF1	0.37	6.43	0.33	4.44e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg04310649	chr10:35416472	CREM	-0.43	-6.86	-0.35	3.34e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg02951883	chr7:2050386	MAD1L1	-0.57	-10.3	-0.49	8.78e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg13683864	chr3:40499215	RPL14	-0.95	-16.24	-0.66	3.94e-44	Renal cell carcinoma;
LUSC	cis	rs55675132	0.667	rs2798471	chr1:115634898	T/C	cg01522456	chr1:115632236	TSPAN2	0.47	6.52	0.34	2.53e-10	Schizophrenia;
LUSC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg10802521	chr3:52805072	NEK4	-0.46	-7.09	-0.36	7.94e-12	Electroencephalogram traits;
LUSC	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg09092052	chr15:45571596	NA	0.47	6.53	0.34	2.42e-10	Glomerular filtration rate;
LUSC	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg04827223	chr11:72435913	ARAP1	-0.73	-9.23	-0.45	3.17e-18	Type 2 diabetes;
LUSC	cis	rs2274273	0.662	rs4525413	chr14:55661138	A/T	cg04306507	chr14:55594613	LGALS3	0.47	9.48	0.46	5e-19	Protein biomarker;
LUSC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg15445000	chr17:37608096	MED1	0.4	6.76	0.35	6.04e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs17155006	0.664	rs401487	chr7:107743409	A/G	cg05962710	chr7:107745446	LAMB4	-0.33	-5.82	-0.3	1.4e-8	Pneumococcal bacteremia;
LUSC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.4	-5.8	-0.3	1.52e-8	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7202877	0.656	rs977986	chr16:75506696	T/G	cg03315344	chr16:75512273	CHST6	0.42	5.99	0.31	5.55e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25183470	chr7:39605805	C7orf36	-0.4	-6.08	-0.32	3.33e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-11.01	-0.52	2.95e-24	Response to antipsychotic treatment;
LUSC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.8	10.37	0.49	4.87e-22	Schizophrenia;
LUSC	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-6.87	-0.35	3.2e-11	Colorectal cancer;
LUSC	cis	rs6545883	0.929	rs1838978	chr2:61540923	T/C	cg15711740	chr2:61764176	XPO1	0.48	7.51	0.38	5.4e-13	Tuberculosis;
LUSC	cis	rs2464469	0.654	rs2067062	chr15:58341954	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.97	-0.31	6.04e-9	Barrett's esophagus  or Esophageal adenocarcinoma;
LUSC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg00376283	chr12:123451042	ABCB9	0.81	12.38	0.56	3.16e-29	Platelet count;
LUSC	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg22709100	chr7:91322751	NA	0.41	5.88	0.31	1.01e-8	Breast cancer;
LUSC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-7.58	-0.38	3.33e-13	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.43	0.46	7.01e-19	Prudent dietary pattern;
LUSC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	0.96	17.69	0.7	7.15e-50	Heart rate;
LUSC	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.8	-0.3	1.52e-8	Breast cancer;
LUSC	cis	rs12681287	0.640	rs4490816	chr8:87384938	T/C	cg00550725	chr8:87521180	FAM82B	-0.43	-5.71	-0.3	2.51e-8	Caudate activity during reward;
LUSC	cis	rs1505368	0.534	rs10185241	chr2:213244124	C/T	cg16329650	chr2:213403929	ERBB4	0.45	7.21	0.37	3.83e-12	Symmetrical dimethylarginine levels;
LUSC	cis	rs73200209	0.744	rs11615689	chr12:116699675	T/C	cg01776926	chr12:116560359	MED13L	-0.48	-5.8	-0.3	1.53e-8	Total body bone mineral density;
LUSC	cis	rs6681460	1.000	rs9662962	chr1:67121364	C/T	cg02459107	chr1:67143332	SGIP1	0.47	8.94	0.44	2.71e-17	Presence of antiphospholipid antibodies;
LUSC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	1.03	17.61	0.69	1.42e-49	Coronary artery disease;
LUSC	trans	rs6601327	0.641	rs9644704	chr8:9560169	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.52	-0.34	2.6e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs72772090	0.539	rs11746534	chr5:96124807	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-6.96	-0.36	1.82e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg22029157	chr1:209979665	IRF6	0.77	10.03	0.48	7.39e-21	Cleft lip with or without cleft palate;
LUSC	cis	rs870825	0.860	rs2696044	chr4:185595988	C/G	cg04058563	chr4:185651563	MLF1IP	0.79	11.48	0.53	5.96e-26	Blood protein levels;
LUSC	cis	rs6722750	0.840	rs6712700	chr2:64374041	A/G	cg22352474	chr2:64371530	PELI1	0.68	10.91	0.51	6.4e-24	Neuroticism;
LUSC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg14440974	chr22:39074834	NA	-0.34	-5.69	-0.3	2.76e-8	Menopause (age at onset);
LUSC	cis	rs7903847	0.642	rs10882908	chr10:99134970	T/C	cg06359132	chr10:99160096	RRP12	-0.24	-5.65	-0.3	3.39e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.74	-10.34	-0.49	6.33e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg12179176	chr11:130786555	SNX19	-0.76	-12.73	-0.57	1.5e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs1443512	0.773	rs2366149	chr12:54347698	T/G	cg17410650	chr12:54324560	NA	-0.47	-7.36	-0.37	1.41e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-0.96	-13.38	-0.59	5.37e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg16383222	chr8:145688536	CYHR1	0.34	5.83	0.3	1.31e-8	Age at first birth;
LUSC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg12310025	chr6:25882481	NA	-0.5	-9.09	-0.45	8.78e-18	Blood metabolite levels;
LUSC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	9.79	0.47	4.77e-20	Personality dimensions;
LUSC	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg22709100	chr7:91322751	NA	0.46	6.84	0.35	3.89e-11	Breast cancer;
LUSC	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg07423050	chr13:99094983	FARP1	-0.52	-9.5	-0.46	4.31e-19	Longevity;
LUSC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	12.56	0.57	7.01e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg14019146	chr3:50243930	SLC38A3	-0.36	-8.07	-0.4	1.31e-14	Body mass index;
LUSC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.52	-0.53	4.54e-26	Schizophrenia;
LUSC	cis	rs7572644	0.713	rs35841453	chr2:28072702	T/C	cg27432699	chr2:27873401	GPN1	0.52	6.62	0.34	1.45e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.08	13.45	0.59	2.87e-33	Sexual dysfunction (female);
LUSC	cis	rs11229555	0.574	rs11603800	chr11:58202085	A/G	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	8.88	0.44	4.09e-17	Monocyte percentage of white cells;
LUSC	cis	rs601339	1.000	rs2454722	chr12:123171218	A/G	cg11919336	chr12:123188078	GPR109A	0.4	5.94	0.31	7.13e-9	Adiponectin levels;
LUSC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg12639453	chr1:2035780	PRKCZ	-0.31	-6.6	-0.34	1.58e-10	Height;
LUSC	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.63	0.6	6.23e-34	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg00982548	chr2:198649783	BOLL	-0.58	-7.21	-0.37	3.87e-12	Ulcerative colitis;
LUSC	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08704250	chr15:31115839	NA	-0.56	-8.1	-0.41	1.03e-14	Huntington's disease progression;
LUSC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.56	0.57	6.99e-30	Prudent dietary pattern;
LUSC	cis	rs4704187	0.687	rs6453111	chr5:74379926	C/T	cg03227963	chr5:74354835	NA	0.31	6.73	0.35	7.4e-11	Response to amphetamines;
LUSC	cis	rs2315504	1.000	rs2524306	chr17:39035811	G/A	cg17985300	chr17:38952333	KRT28	-0.35	-7.12	-0.36	6.56e-12	Height;
LUSC	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg10621924	chr7:39171070	POU6F2	0.46	7.32	0.37	1.9e-12	IgG glycosylation;
LUSC	cis	rs9309473	0.848	rs17009159	chr2:73797762	A/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.53	-0.34	2.47e-10	Metabolite levels;
LUSC	cis	rs10740039	0.516	rs1938546	chr10:62315986	G/A	cg18175470	chr10:62150864	ANK3	-0.47	-6.94	-0.36	2.01e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.11	-0.36	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.05	-0.31	3.78e-9	Initial pursuit acceleration;
LUSC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg20203395	chr5:56204925	C5orf35	-0.46	-6.79	-0.35	5e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-6.42	-0.33	4.69e-10	Retinal vascular caliber;
LUSC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7923609	0.838	rs7909960	chr10:65239177	T/A	cg01631684	chr10:65280961	REEP3	-0.41	-6.26	-0.32	1.19e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.56	10.08	0.48	4.91e-21	Bone mineral density;
LUSC	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg02023728	chr11:77925099	USP35	0.46	7.01	0.36	1.34e-11	Testicular germ cell tumor;
LUSC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.83	14.64	0.63	7.86e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.45	-0.42	9.1e-16	Axial length;
LUSC	cis	rs4594175	0.962	rs8008182	chr14:51608357	C/T	cg23942311	chr14:51606299	NA	0.3	5.73	0.3	2.23e-8	Cancer;
LUSC	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg20307385	chr11:47447363	PSMC3	0.46	6.77	0.35	5.93e-11	Subjective well-being;
LUSC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.11	0.36	6.98e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs73206853	0.563	rs57488849	chr12:111181785	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	7.13	0.36	6.19e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs78366141	0.649	rs112818517	chr4:89653103	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.95	7.1	0.36	7.53e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.89	-0.31	9.18e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg00339695	chr16:24857497	SLC5A11	0.6	8.87	0.44	4.51e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg07212818	chr11:638076	DRD4	-0.38	-6.51	-0.34	2.79e-10	Systemic lupus erythematosus;
LUSC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg11632617	chr15:75315747	PPCDC	-0.52	-6.78	-0.35	5.39e-11	Blood trace element (Zn levels);
LUSC	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	7.11	0.36	7.16e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs1178968	0.688	rs6951676	chr7:72753243	C/T	cg25889504	chr7:72793014	NA	0.58	7.53	0.38	4.84e-13	Triglyceride levels;
LUSC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-12.92	-0.58	3.05e-31	Total body bone mineral density;
LUSC	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg00191853	chr8:101177733	SPAG1	0.34	5.78	0.3	1.74e-8	Atrioventricular conduction;
LUSC	cis	rs6714788	0.565	rs7558817	chr2:100654482	C/A	cg22139774	chr2:100720529	AFF3	-0.38	-6.04	-0.31	4.2e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg03433033	chr1:76189801	ACADM	-0.45	-6.74	-0.35	7.09e-11	Daytime sleep phenotypes;
LUSC	cis	rs3845702	0.736	rs56401468	chr2:180857757	C/T	cg01881094	chr2:180872142	CWC22	1.05	12.34	0.56	4.29e-29	Schizophrenia;
LUSC	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.99	0.31	5.5e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs41271473	0.898	rs55730631	chr1:228865663	C/A	cg16512390	chr1:228756714	NA	0.53	6.22	0.32	1.5e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg06917634	chr15:78832804	PSMA4	-0.47	-5.95	-0.31	6.63e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg23887609	chr12:130822674	PIWIL1	0.49	7.34	0.37	1.64e-12	Menopause (age at onset);
LUSC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	8.67	0.43	1.96e-16	Motion sickness;
LUSC	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.62	11.23	0.52	4.82e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs2731664	0.792	rs2544809	chr5:176885499	T/C	cg23176889	chr5:176863531	GRK6	-0.65	-13.03	-0.58	1.17e-31	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.19	-0.8	2.08e-75	Height;
LUSC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg12963246	chr6:28129442	ZNF389	0.58	8.07	0.4	1.24e-14	Parkinson's disease;
LUSC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.35	6.85	0.35	3.5e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg09367891	chr1:107599246	PRMT6	-0.54	-8.57	-0.42	3.84e-16	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7075426	0.669	rs11202042	chr10:88237104	T/C	cg07322936	chr10:88137208	NA	0.46	6.57	0.34	1.9e-10	Migraine without aura;
LUSC	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.55	10.66	0.5	4.93e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-1.04	-20.04	-0.74	3.08e-59	Height;
LUSC	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06002616	chr8:101225028	SPAG1	0.39	6.62	0.34	1.41e-10	Atrioventricular conduction;
LUSC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg12963246	chr6:28129442	ZNF389	0.51	7.06	0.36	9.81e-12	Depression;
LUSC	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.61	-0.43	2.97e-16	Total cholesterol levels;
LUSC	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-8.25	-0.41	3.72e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.89	0.66	9.59e-43	Bladder cancer;
LUSC	cis	rs73206853	0.841	rs56251637	chr12:110833869	T/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1775715	0.769	rs2799030	chr10:32172935	G/T	cg26784012	chr10:32216390	ARHGAP12	0.46	7.84	0.39	6.07e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg18232548	chr7:50535776	DDC	-0.7	-11.0	-0.52	3.07e-24	Response to zileuton treatment in asthma (FEV1 change interaction);
LUSC	trans	rs9987353	0.830	rs4841114	chr8:9129698	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.99	-0.31	5.44e-9	Recombination measurement;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02801482	chr2:159824941	TANC1	-0.5	-5.98	-0.31	5.72e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-1.1	-17.39	-0.69	1.1e-48	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg22676075	chr6:135203613	NA	0.48	7.41	0.38	1.02e-12	Red blood cell count;
LUSC	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg12863693	chr15:85201151	NMB	0.39	8.1	0.41	1.07e-14	Schizophrenia;
LUSC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg19257562	chr1:2043853	PRKCZ	0.31	6.15	0.32	2.19e-9	Height;
LUSC	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.71	-12.85	-0.58	5.32e-31	Ulcerative colitis;
LUSC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg22907277	chr7:1156413	C7orf50	0.45	6.82	0.35	4.19e-11	Longevity;Endometriosis;
LUSC	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.38	0.49	4.76e-22	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg03146154	chr1:46216737	IPP	0.51	7.74	0.39	1.21e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg04374321	chr14:90722782	PSMC1	0.72	11.32	0.53	2.26e-25	Mortality in heart failure;
LUSC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg22907277	chr7:1156413	C7orf50	-0.58	-9.15	-0.45	5.77e-18	Longevity;Endometriosis;
LUSC	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg03264133	chr6:25882463	NA	-0.34	-5.68	-0.3	2.9e-8	Height;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01430372	chr17:38976870	TMEM99;KRT10	0.41	6.1	0.32	3.01e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13315871	0.929	rs1554124	chr3:58268968	C/G	cg12435725	chr3:58293450	RPP14	-0.71	-7.53	-0.38	4.8e-13	Cholesterol, total;
LUSC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg00101154	chr16:420108	MRPL28	-0.38	-5.76	-0.3	1.91e-8	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.21	-0.32	1.59e-9	Daytime sleep phenotypes;
LUSC	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.62	-0.34	1.45e-10	Blood metabolite levels;
LUSC	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg22563815	chr15:78856949	CHRNA5	0.26	6.34	0.33	7.29e-10	Sudden cardiac arrest;
LUSC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg05861140	chr6:150128134	PCMT1	-0.38	-6.04	-0.31	4.07e-9	Lung cancer;
LUSC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19717773	chr7:2847554	GNA12	-0.39	-6.07	-0.32	3.47e-9	Height;
LUSC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.79	-0.57	9.28e-31	Platelet count;
LUSC	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg18721089	chr20:30220636	NA	-0.35	-6.01	-0.31	4.78e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.77	-10.41	-0.5	3.55e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg01416388	chr22:39784598	NA	0.45	7.55	0.38	4.23e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg04691961	chr3:161091175	C3orf57	-0.34	-5.9	-0.31	9.03e-9	Morning vs. evening chronotype;
LUSC	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.0	-0.36	1.43e-11	Blood metabolite levels;
LUSC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg22800045	chr5:56110881	MAP3K1	0.75	9.64	0.47	1.46e-19	Initial pursuit acceleration;
LUSC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.58	-10.36	-0.49	5.28e-22	Extrinsic epigenetic age acceleration;
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22442454	chr1:209979470	IRF6	0.7	13.06	0.58	9.15e-32	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg27411982	chr8:10470053	RP1L1	-0.48	-7.24	-0.37	3.06e-12	Neuroticism;
LUSC	cis	rs12545109	0.842	rs2582379	chr8:57395243	C/T	cg09654669	chr8:57350985	NA	0.46	5.8	0.3	1.56e-8	Obesity-related traits;
LUSC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg03388025	chr16:89894329	SPIRE2	-0.31	-5.88	-0.31	1.01e-8	Vitiligo;
LUSC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg24675658	chr1:53192096	ZYG11B	-0.65	-10.35	-0.49	5.78e-22	Monocyte count;
LUSC	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg19773385	chr1:10388646	KIF1B	-0.57	-9.61	-0.47	1.81e-19	Hepatocellular carcinoma;
LUSC	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg23643435	chr2:38893251	GALM	-0.66	-6.96	-0.36	1.76e-11	5-HTT brain serotonin transporter levels;
LUSC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.82	13.74	0.6	2.25e-34	Aortic root size;
LUSC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.91	0.44	3.31e-17	Motion sickness;
LUSC	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg11019008	chr10:131425282	MGMT	0.41	6.29	0.33	9.83e-10	Response to temozolomide;
LUSC	cis	rs3755132	0.929	rs6746074	chr2:15743816	G/A	cg12888861	chr2:15731646	DDX1	0.5	7.3	0.37	2.16e-12	Wilms tumor;
LUSC	trans	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.82	-0.43	6.37e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg03929089	chr4:120376271	NA	-0.58	-7.09	-0.36	7.87e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2439831	0.717	rs10518820	chr15:43888976	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.59	0.43	3.37e-16	Lung cancer in ever smokers;
LUSC	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7582720	1.000	rs72934514	chr2:203933339	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	8.72	0.43	1.37e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.9	16.45	0.67	5.98e-45	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg04374321	chr14:90722782	PSMC1	0.76	12.18	0.55	1.7e-28	Mortality in heart failure;
LUSC	cis	rs3820928	0.874	rs1320407	chr2:227867385	G/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-7.13	-0.36	6.22e-12	Pulmonary function;
LUSC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg12463550	chr7:65579703	CRCP	-0.55	-8.19	-0.41	5.77e-15	Aortic root size;
LUSC	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg04539111	chr16:67997858	SLC12A4	-0.48	-6.18	-0.32	1.91e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs796825	0.530	rs56103727	chr3:119986843	G/A	cg21790991	chr3:120137480	FSTL1	-0.34	-6.1	-0.32	2.93e-9	HIV-1 susceptibility;
LUSC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.58	-11.4	-0.53	1.24e-25	Monocyte percentage of white cells;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02222290	chr10:72575603	SGPL1	-0.43	-6.15	-0.32	2.16e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg01879757	chr17:41196368	BRCA1	-0.46	-6.92	-0.35	2.26e-11	Menopause (age at onset);
LUSC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg16434002	chr17:42200994	HDAC5	0.46	6.74	0.35	7.02e-11	Total body bone mineral density;
LUSC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg04287289	chr16:89883240	FANCA	-0.73	-6.12	-0.32	2.65e-9	Skin colour saturation;
LUSC	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg00310523	chr12:86230176	RASSF9	0.36	6.56	0.34	2.1e-10	Major depressive disorder;
LUSC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg14664628	chr15:75095509	CSK	-0.64	-10.01	-0.48	8.52e-21	Breast cancer;
LUSC	cis	rs1113500	0.933	rs4593854	chr1:108638519	A/G	cg11967332	chr1:108735228	SLC25A24	0.4	6.11	0.32	2.77e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg01943577	chr7:158741284	NA	-0.4	-5.72	-0.3	2.37e-8	Height;
LUSC	cis	rs4400599	0.594	rs7526644	chr1:154208753	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.35	-5.7	-0.3	2.61e-8	Platelet distribution width;
LUSC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06481639	chr22:41940642	POLR3H	-0.54	-5.97	-0.31	6.16e-9	Vitiligo;
LUSC	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg25801113	chr15:45476975	SHF	0.34	7.0	0.36	1.37e-11	Uric acid levels;
LUSC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs701145	0.730	rs2666192	chr3:154004009	T/C	cg17054900	chr3:154042577	DHX36	0.84	8.49	0.42	6.84e-16	Coronary artery disease;
LUSC	cis	rs738321	0.756	rs4821740	chr22:38514423	C/G	cg25457927	chr22:38595422	NA	-0.32	-6.01	-0.31	4.8e-9	Breast cancer;
LUSC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.92	0.4	3.59e-14	Colorectal cancer;
LUSC	cis	rs427941	0.632	rs201498	chr7:101756262	G/A	cg06246474	chr7:101738831	CUX1	0.39	6.32	0.33	8.36e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg08017756	chr2:100939284	LONRF2	-0.43	-8.14	-0.41	8.07e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs62458065	1.000	rs10231294	chr7:32465357	C/T	cg20159608	chr7:32802032	NA	-0.57	-7.01	-0.36	1.34e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg04455712	chr21:45112962	RRP1B	0.46	8.38	0.42	1.51e-15	Mean corpuscular volume;
LUSC	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg22491629	chr6:157744540	C6orf35	-0.89	-10.89	-0.51	7.48e-24	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9921338	0.961	rs7199821	chr16:11425011	T/G	cg00044050	chr16:11439710	C16orf75	-0.5	-6.64	-0.34	1.3e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg05472934	chr7:22766657	IL6	0.4	6.16	0.32	2.08e-9	Lung cancer;
LUSC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg19747945	chr6:42946146	PEX6	-0.34	-5.67	-0.3	3.11e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg14789911	chr21:47582049	C21orf56	-0.37	-5.65	-0.3	3.42e-8	Testicular germ cell tumor;
LUSC	cis	rs1577917	0.839	rs9450333	chr6:86519755	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-6.31	-0.33	8.61e-10	Response to antipsychotic treatment;
LUSC	trans	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg26043149	chr18:55253948	FECH	-0.46	-7.09	-0.36	7.93e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.7	12.65	0.57	3.11e-30	Prudent dietary pattern;
LUSC	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg15423357	chr2:25149977	NA	0.45	9.09	0.45	8.9e-18	Body mass index;
LUSC	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg18230493	chr5:56204884	C5orf35	-0.57	-8.95	-0.44	2.48e-17	Coronary artery disease;
LUSC	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg16989719	chr2:238392110	NA	-0.41	-6.77	-0.35	5.98e-11	Prostate cancer;
LUSC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08859206	chr1:53392774	SCP2	0.51	8.74	0.43	1.14e-16	Monocyte count;
LUSC	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.91	-0.35	2.44e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg17385448	chr1:15911702	AGMAT	0.37	6.06	0.31	3.7e-9	Systolic blood pressure;
LUSC	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.61	0.34	1.54e-10	Rheumatoid arthritis;
LUSC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg04944784	chr2:26401820	FAM59B	-0.74	-10.91	-0.51	6.48e-24	Gut microbiome composition (summer);
LUSC	cis	rs4363385	0.818	rs1334848	chr1:153004721	A/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.42e-12	Inflammatory skin disease;
LUSC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.82	-0.39	6.91e-14	Personality dimensions;
LUSC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg00509249	chr6:109615579	CCDC162	-0.32	-5.83	-0.3	1.31e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.09	14.43	0.62	5.1e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg22535103	chr8:58192502	C8orf71	0.66	7.28	0.37	2.48e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs35150201	0.517	rs10260691	chr7:135328110	C/T	cg23117316	chr7:135346802	PL-5283	0.34	6.94	0.35	2.05e-11	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
LUSC	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg03859395	chr2:55845619	SMEK2	0.81	14.82	0.63	1.47e-38	Metabolic syndrome;
LUSC	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	11.65	0.54	1.45e-26	Blood protein levels;
LUSC	cis	rs6693567	0.565	rs497128	chr1:150269952	A/G	cg15654264	chr1:150340011	RPRD2	-0.45	-7.4	-0.38	1.09e-12	Migraine;
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.4	-6.48	-0.33	3.31e-10	Longevity;Endometriosis;
LUSC	trans	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.61	-10.38	-0.49	4.44e-22	Mean corpuscular volume;
LUSC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.61	-8.44	-0.42	1.01e-15	Mean platelet volume;
LUSC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.46	-6.36	-0.33	6.57e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	6.29	0.33	1.01e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg11764359	chr7:65958608	NA	0.51	6.6	0.34	1.58e-10	Aortic root size;
LUSC	cis	rs9463078	0.625	rs679713	chr6:44899632	T/C	cg25276700	chr6:44698697	NA	-0.27	-5.71	-0.3	2.52e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg13047869	chr3:10149882	C3orf24	0.65	9.51	0.46	3.98e-19	Alzheimer's disease;
LUSC	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg23625390	chr15:77176239	SCAPER	0.46	7.12	0.36	6.71e-12	Blood metabolite levels;
LUSC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.74	10.58	0.5	9.68e-23	Type 2 diabetes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06943149	chr12:77157476	ZDHHC17	0.45	6.75	0.35	6.65e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs981844	0.890	rs55917677	chr4:154701051	C/T	cg14289246	chr4:154710475	SFRP2	0.53	6.67	0.34	1.06e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs2652834	0.808	rs966331	chr15:63411927	T/C	cg05507819	chr15:63340323	TPM1	0.44	5.69	0.3	2.79e-8	HDL cholesterol;
LUSC	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg13514129	chr1:39547527	MACF1	0.71	11.58	0.54	2.64e-26	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg04691961	chr3:161091175	C3orf57	-0.34	-5.8	-0.3	1.5e-8	Morning vs. evening chronotype;
LUSC	cis	rs9837602	1.000	rs6799379	chr3:99762840	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.13	-0.32	2.52e-9	Breast cancer;
LUSC	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg05501817	chr11:14380813	RRAS2	-0.57	-9.06	-0.44	1.08e-17	Sense of smell;
LUSC	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg16006841	chr5:176797999	RGS14	-0.66	-9.56	-0.46	2.58e-19	Urate levels in lean individuals;
LUSC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.92	13.52	0.59	1.54e-33	Chronic sinus infection;
LUSC	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg09307838	chr4:120376055	NA	0.78	11.23	0.52	4.93e-25	Corneal astigmatism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00722097	chr6:111195976	AMD1	-0.57	-7.01	-0.36	1.35e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9807989	0.507	rs1420094	chr2:103015687	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.19e-12	Asthma;
LUSC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.25	-0.37	3.01e-12	Subjective well-being;
LUSC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg12463550	chr7:65579703	CRCP	0.52	7.54	0.38	4.45e-13	Aortic root size;
LUSC	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg04518342	chr5:131593106	PDLIM4	-0.36	-5.97	-0.31	6.14e-9	Blood metabolite levels;
LUSC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg18827107	chr12:86230957	RASSF9	0.45	6.86	0.35	3.4e-11	Major depressive disorder;
LUSC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg09626299	chr10:82213104	TSPAN14	-0.21	-6.01	-0.31	4.85e-9	Post bronchodilator FEV1;
LUSC	cis	rs9311676	0.656	rs55692656	chr3:58383174	A/T	cg13750441	chr3:58318267	PXK	0.34	6.63	0.34	1.37e-10	Systemic lupus erythematosus;
LUSC	trans	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg25214090	chr10:38739885	LOC399744	0.5	7.07	0.36	9.33e-12	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11047049	chr3:195163937	ACAP2	-0.45	-6.77	-0.35	5.63e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg03433033	chr1:76189801	ACADM	-0.43	-6.4	-0.33	5.14e-10	Daytime sleep phenotypes;
LUSC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	0.65	13.71	0.6	3.1e-34	Prudent dietary pattern;
LUSC	cis	rs9815354	0.812	rs116393551	chr3:41865476	G/A	cg03022575	chr3:42003672	ULK4	0.85	8.9	0.44	3.75e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs8017423	1.000	rs10129210	chr14:90668379	G/T	cg14092571	chr14:90743983	NA	-0.36	-5.85	-0.31	1.14e-8	Mortality in heart failure;
LUSC	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg09307838	chr4:120376055	NA	0.68	9.75	0.47	6.31e-20	Corneal astigmatism;
LUSC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.85	-10.78	-0.51	1.87e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg12940439	chr1:67600707	NA	-0.39	-6.49	-0.33	3.02e-10	Psoriasis;
LUSC	cis	rs1572072	0.545	rs1572069	chr13:24124492	A/C	cg24350296	chr13:24144486	TNFRSF19	-0.31	-5.68	-0.3	2.93e-8	Nasopharyngeal carcinoma;
LUSC	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.55	-0.42	4.45e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-8.6	-0.43	3.07e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00339695	chr16:24857497	SLC5A11	0.59	8.98	0.44	2.04e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2425143	0.730	rs6060624	chr20:34413663	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-5.84	-0.3	1.27e-8	Blood protein levels;
LUSC	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.86	0.68	1.45e-46	Exhaled nitric oxide output;
LUSC	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg22117172	chr7:91764530	CYP51A1	0.32	5.71	0.3	2.49e-8	Breast cancer;
LUSC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19717773	chr7:2847554	GNA12	-0.41	-6.45	-0.33	3.94e-10	Height;
LUSC	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.73	-0.35	7.42e-11	Response to antipsychotic treatment;
LUSC	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg06885757	chr1:42089581	HIVEP3	0.52	11.17	0.52	8.18e-25	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7572644	0.640	rs4665392	chr2:28029649	A/G	cg27432699	chr2:27873401	GPN1	0.55	7.3	0.37	2.19e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs12824058	0.737	rs2398508	chr12:130816460	G/A	cg26677194	chr12:130822605	PIWIL1	0.59	8.31	0.41	2.52e-15	Menopause (age at onset);
LUSC	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg00376283	chr12:123451042	ABCB9	0.67	8.45	0.42	9.23e-16	Neutrophil percentage of white cells;
LUSC	cis	rs7605827	0.823	rs6431692	chr2:15478364	A/G	cg19274914	chr2:15703543	NA	0.42	8.11	0.41	9.59e-15	Educational attainment (years of education);
LUSC	cis	rs12220238	0.908	rs11000893	chr10:75905996	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.61	6.94	0.36	2.02e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs56161922	0.915	rs12563415	chr1:207856666	G/T	cg11752769	chr1:207818423	CR1L	-0.71	-6.0	-0.31	5.07e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.85	0.54	2.69e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg00857998	chr1:205179979	DSTYK	0.62	9.8	0.47	4.27e-20	Red blood cell count;
LUSC	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.39	-7.53	-0.38	4.66e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs35860234	0.806	rs6561054	chr13:43059882	C/T	cg17512187	chr2:85082845	C2orf89	-0.26	-6.1	-0.32	2.89e-9	Vitiligo;
LUSC	cis	rs12541635	0.934	rs1353450	chr8:107035120	A/G	cg10147462	chr8:107024639	NA	-0.54	-9.93	-0.48	1.53e-20	Age of smoking initiation;
LUSC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg11764359	chr7:65958608	NA	0.52	6.71	0.34	8.57e-11	Aortic root size;
LUSC	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.71	-0.3	2.47e-8	Obesity-related traits;
LUSC	cis	rs2625529	0.824	rs12899485	chr15:72143215	A/G	cg16672083	chr15:72433130	SENP8	0.48	7.17	0.37	4.95e-12	Red blood cell count;
LUSC	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg05110241	chr16:68378359	PRMT7	-0.64	-6.74	-0.35	6.99e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	7.08	0.36	8.38e-12	Platelet count;
LUSC	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg10857441	chr5:6722123	POLS	-0.48	-8.99	-0.44	1.85e-17	Menopause (age at onset);
LUSC	trans	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg01134436	chr17:81009848	B3GNTL1	0.63	6.13	0.32	2.54e-9	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs9886428	1.000	rs7839860	chr8:14113760	C/T	cg11959399	chr20:741723	C20orf54	0.39	6.35	0.33	7.19e-10	IgG glycosylation;
LUSC	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.68	10.0	0.48	8.88e-21	Corneal astigmatism;
LUSC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.55	0.34	2.22e-10	Aortic root size;
LUSC	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg08798685	chr6:27730294	NA	-0.64	-6.01	-0.31	4.93e-9	Breast cancer;
LUSC	cis	rs6693567	0.565	rs1776273	chr1:150270209	C/T	cg15654264	chr1:150340011	RPRD2	0.41	6.7	0.34	8.85e-11	Migraine;
LUSC	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg18850127	chr7:39170497	POU6F2	0.62	9.32	0.45	1.58e-18	IgG glycosylation;
LUSC	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.27	0.49	1.1e-21	Bladder cancer;
LUSC	cis	rs7712401	0.601	rs246269	chr5:122256741	T/C	cg19077854	chr5:122220652	SNX24	0.42	9.55	0.46	2.79e-19	Mean platelet volume;
LUSC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg12257692	chr3:49977190	RBM6	0.24	6.8	0.35	4.88e-11	Body mass index;
LUSC	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg00810483	chr4:3375144	RGS12	0.3	5.73	0.3	2.22e-8	Serum sulfate level;
LUSC	cis	rs354225	0.544	rs3287	chr2:54807657	T/C	cg01766943	chr2:54829624	SPTBN1	0.48	7.76	0.39	1.05e-13	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg04944784	chr2:26401820	FAM59B	-0.71	-10.06	-0.48	5.61e-21	Gut microbiome composition (summer);
LUSC	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg02153584	chr22:29168773	CCDC117	0.54	7.24	0.37	3.02e-12	Lymphocyte counts;
LUSC	cis	rs10979	1.000	rs9403504	chr6:143885430	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-12.02	-0.55	6.53e-28	Hypospadias;
LUSC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.6	-0.57	4.58e-30	Chronic sinus infection;
LUSC	cis	rs2637266	0.967	rs12246430	chr10:78352879	C/T	cg18941641	chr10:78392320	NA	0.39	7.22	0.37	3.53e-12	Pulmonary function;
LUSC	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg17333051	chr19:2783644	SGTA	0.49	7.42	0.38	9.84e-13	Total cholesterol levels;
LUSC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg09034736	chr1:150693464	HORMAD1	-0.46	-6.58	-0.34	1.86e-10	Melanoma;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg03379200	chr15:91537914	PRC1	0.44	6.18	0.32	1.92e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg14092571	chr14:90743983	NA	-0.36	-5.86	-0.31	1.11e-8	Mortality in heart failure;
LUSC	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.86	13.09	0.58	6.74e-32	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg06363034	chr20:62225388	GMEB2	-0.46	-7.68	-0.39	1.79e-13	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUSC	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg02476566	chr12:106696527	TCP11L2	0.53	6.63	0.34	1.38e-10	Tourette syndrome;
LUSC	trans	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg07817883	chr1:32538562	TMEM39B	1.47	12.2	0.56	1.43e-28	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.52	10.36	0.49	5.48e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.56	10.98	0.52	3.71e-24	Asthma (sex interaction);
LUSC	cis	rs75804782	0.521	rs60779166	chr2:239433943	G/A	cg18131467	chr2:239335373	ASB1	-0.7	-6.01	-0.31	4.98e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg11247378	chr22:39784982	NA	-0.64	-11.42	-0.53	1.03e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs966423	0.527	rs6723847	chr2:218256489	C/T	cg15335768	chr2:218268053	DIRC3	-0.3	-6.26	-0.32	1.16e-9	Thyroid cancer;
LUSC	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg26394196	chr10:1453818	ADARB2	-0.38	-6.52	-0.34	2.67e-10	Radiation response;
LUSC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg20283391	chr11:68216788	NA	-0.57	-8.11	-0.41	9.78e-15	Total body bone mineral density;
LUSC	cis	rs9361491	0.508	rs9359338	chr6:79396751	T/C	cg05283184	chr6:79620031	NA	-0.4	-7.05	-0.36	1.05e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg17724175	chr1:150552817	MCL1	0.37	6.7	0.34	8.92e-11	Tonsillectomy;
LUSC	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.09	15.45	0.65	5.42e-41	Uric acid levels;
LUSC	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg23601095	chr6:26197514	HIST1H3D	0.7	7.53	0.38	4.89e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.7	0.34	9.07e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg09409435	chr16:70099608	PDXDC2	0.84	11.75	0.54	6.22e-27	Menarche (age at onset);
LUSC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.34	0.59	8.12e-33	Cognitive test performance;
LUSC	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg10518572	chr11:65560635	OVOL1	0.26	5.83	0.3	1.28e-8	Acne (severe);
LUSC	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg18105134	chr13:113819100	PROZ	-0.65	-9.59	-0.46	2.1e-19	Platelet distribution width;
LUSC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06634786	chr22:41940651	POLR3H	0.5	6.01	0.31	4.81e-9	Vitiligo;
LUSC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-8.44	-0.42	9.51e-16	Total body bone mineral density;
LUSC	cis	rs4356932	1.000	rs6852075	chr4:76952280	T/G	cg00809888	chr4:76862425	NAAA	0.35	5.77	0.3	1.78e-8	Blood protein levels;
LUSC	cis	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg17187183	chr4:55093834	PDGFRA	0.39	5.89	0.31	9.61e-9	Corneal astigmatism;
LUSC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	trans	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg03929089	chr4:120376271	NA	0.67	6.32	0.33	8.22e-10	Axial length;
LUSC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.45	0.33	3.85e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg23933602	chr10:16859644	RSU1	0.62	7.71	0.39	1.45e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	8.21	0.41	4.76e-15	Coffee consumption (cups per day);
LUSC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.32	6.36	0.33	6.54e-10	Schizophrenia;
LUSC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg18758796	chr5:131593413	PDLIM4	-0.49	-7.89	-0.4	4.44e-14	Acylcarnitine levels;
LUSC	cis	rs79149102	0.737	rs74450883	chr15:75193432	A/G	cg09165964	chr15:75287851	SCAMP5	-0.91	-6.84	-0.35	3.82e-11	Lung cancer;
LUSC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	8.1	0.41	1.01e-14	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg07169764	chr2:136633963	MCM6	1.05	16.81	0.68	2.14e-46	Corneal structure;
LUSC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg03684893	chr10:554711	DIP2C	-0.37	-6.68	-0.34	9.82e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg09365446	chr1:150670422	GOLPH3L	0.53	8.09	0.4	1.15e-14	Tonsillectomy;
LUSC	trans	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg01620082	chr3:125678407	NA	-0.76	-6.88	-0.35	3.05e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.16	0.55	2.03e-28	Motion sickness;
LUSC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.42	0.33	4.71e-10	Menopause (age at onset);
LUSC	cis	rs1443512	0.773	rs2366146	chr12:54331002	G/A	cg25024717	chr12:54324583	NA	-0.39	-6.81	-0.35	4.42e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	1.24	16.83	0.68	1.79e-46	Eosinophil percentage of granulocytes;
LUSC	cis	rs981844	0.712	rs2405208	chr4:154755774	T/C	cg14289246	chr4:154710475	SFRP2	-0.46	-6.41	-0.33	4.85e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	0.93	16.05	0.66	2.27e-43	Menopause (age at onset);
LUSC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.38	0.33	5.94e-10	Personality dimensions;
LUSC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg01802117	chr1:53393560	SCP2	-0.37	-6.17	-0.32	1.97e-9	Monocyte count;
LUSC	cis	rs11051970	0.918	rs12229856	chr12:32531220	C/T	cg02745156	chr12:32552066	NA	0.43	6.99	0.36	1.46e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12980942	0.591	rs2304231	chr19:41762670	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.69	7.28	0.37	2.47e-12	Coronary artery disease;
LUSC	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.71	-0.34	8.15e-11	QT interval;
LUSC	cis	rs4494114	0.967	rs1925677	chr1:39346905	T/G	cg25970120	chr1:39325951	RRAGC	-0.39	-6.08	-0.32	3.27e-9	Blood protein levels;
LUSC	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg12081754	chr8:22256438	SLC39A14	-0.54	-8.54	-0.42	4.75e-16	Verbal declarative memory;
LUSC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.08	0.52	1.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12891047	1.000	rs11158693	chr14:68241261	A/G	cg20999565	chr14:68265668	ZFYVE26	0.38	5.82	0.3	1.38e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.45e-9	Menopause (age at onset);
LUSC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03934478	chr11:495069	RNH1	0.82	9.84	0.47	3.08e-20	Body mass index;
LUSC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.65	-9.5	-0.46	4.28e-19	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs7527798	0.592	rs2025372	chr1:207829653	T/G	cg09232269	chr1:207846808	CR1L	-0.3	-6.4	-0.33	5.18e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs71335811	1	rs71335811	chr19:49130070	TC/T	cg06677660	chr19:49140777	SEC1;DBP	-0.44	-5.66	-0.3	3.31e-8	Myeloid white cell count;
LUSC	cis	rs10484885	0.757	rs12201016	chr6:90149275	C/T	cg13799429	chr6:90582589	CASP8AP2	0.6	5.87	0.31	1.03e-8	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg01125463	chr6:42946178	PEX6	-0.36	-5.97	-0.31	6.19e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.79	-0.3	1.63e-8	Retinal vascular caliber;
LUSC	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.32	0.33	8.24e-10	IgG glycosylation;
LUSC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.67	11.93	0.55	1.38e-27	Aortic root size;
LUSC	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg02493740	chr2:85810744	VAMP5	-0.54	-9.48	-0.46	4.82e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.38	6.61	0.34	1.54e-10	Total body bone mineral density;
LUSC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg27121462	chr16:89883253	FANCA	0.42	6.45	0.33	3.83e-10	Vitiligo;
LUSC	cis	rs4478858	0.775	rs6701861	chr1:31708125	A/C	cg00250761	chr1:31883323	NA	-0.36	-9.53	-0.46	3.29e-19	Alcohol dependence;
LUSC	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.54	-0.5	1.26e-22	Eye color traits;
LUSC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg00990874	chr7:1149470	C7orf50	-0.6	-7.8	-0.39	8.03e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg07936489	chr17:37558343	FBXL20	0.71	9.91	0.48	1.88e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg05738196	chr6:26577821	NA	0.81	15.74	0.65	3.89e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg17623882	chr6:41773611	USP49	-0.63	-10.69	-0.5	3.9e-23	Menarche (age at onset);
LUSC	trans	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg25482853	chr8:67687455	SGK3	1.11	15.36	0.64	1.21e-40	Obesity-related traits;
LUSC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05890377	chr2:74357713	NA	0.72	13.81	0.6	1.25e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg01879757	chr17:41196368	BRCA1	-0.45	-6.9	-0.35	2.62e-11	Menopause (age at onset);
LUSC	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	1.17	13.65	0.6	5.27e-34	Arsenic metabolism;
LUSC	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.88	-11.25	-0.52	4.06e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg11406453	chr1:101602562	NA	-0.32	-5.66	-0.3	3.3e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg14092988	chr3:52407081	DNAH1	0.31	6.05	0.31	3.96e-9	Bipolar disorder;
LUSC	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg05855489	chr10:104503620	C10orf26	0.57	9.18	0.45	4.51e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12519773	0.517	rs17360811	chr5:92492349	G/A	cg18783429	chr5:92414398	NA	0.32	6.76	0.35	6.04e-11	Migraine;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16204370	chr22:41682343	RANGAP1	0.53	7.41	0.38	1.01e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg08847533	chr14:75593920	NEK9	0.4	5.75	0.3	2.04e-8	Caffeine consumption;
LUSC	cis	rs116988415	0.584	rs77490765	chr14:65278537	T/G	cg25083366	chr14:65239357	SPTB	0.68	6.82	0.35	4.31e-11	Daytime sleep phenotypes;
LUSC	trans	rs6601327	0.606	rs13268319	chr8:9579249	C/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.57	-0.34	1.97e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg12257692	chr3:49977190	RBM6	0.25	7.03	0.36	1.2e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.16	-0.52	8.95e-25	Coffee consumption (cups per day);
LUSC	cis	rs7177699	0.557	rs34372090	chr15:79110735	C/T	cg15571903	chr15:79123663	NA	-0.33	-5.99	-0.31	5.49e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	6.71	0.34	8.55e-11	Retinal vascular caliber;
LUSC	trans	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg07211511	chr3:129823064	LOC729375	-0.77	-9.74	-0.47	6.53e-20	Blood pressure (smoking interaction);
LUSC	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.88	14.69	0.63	5.1e-38	Bladder cancer;
LUSC	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg26597838	chr10:835615	NA	0.79	9.73	0.47	7.58e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	8.48	0.42	7.28e-16	Total body bone mineral density;
LUSC	cis	rs1775715	0.675	rs2808085	chr10:32148599	C/T	cg26784012	chr10:32216390	ARHGAP12	0.45	7.7	0.39	1.54e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs698833	0.506	rs4952705	chr2:44499867	T/C	cg00619915	chr2:44497795	NA	-0.53	-7.2	-0.37	4.13e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.69	-0.3	2.72e-8	Testicular germ cell tumor;
LUSC	cis	rs4499344	0.577	rs259289	chr19:33164927	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	11.73	0.54	7.5e-27	Mean platelet volume;
LUSC	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.8	0.51	1.57e-23	Bladder cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27297724	chr4:48781911	FRYL	0.49	6.78	0.35	5.56e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg13170934	chr1:156722147	HDGF	0.49	6.05	0.31	3.82e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg09479241	chr17:27052676	TLCD1	0.44	5.94	0.31	7.01e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs59104589	0.550	rs73002181	chr2:242342379	C/G	cg14842376	chr2:242211374	HDLBP	0.6	6.28	0.33	1.04e-9	Fibrinogen levels;
LUSC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg02782426	chr3:40428986	ENTPD3	0.39	7.46	0.38	7.6e-13	Renal cell carcinoma;
LUSC	trans	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.46	0.42	8.32e-16	Diabetic kidney disease;
LUSC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg15448220	chr1:150897856	SETDB1	0.41	6.06	0.31	3.69e-9	Melanoma;
LUSC	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg16339924	chr4:17578868	LAP3	0.57	7.73	0.39	1.28e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.71	12.29	0.56	6.91e-29	Motion sickness;
LUSC	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.62	-9.4	-0.46	8.77e-19	Personality dimensions;
LUSC	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg10911889	chr6:126070802	HEY2	-0.42	-6.47	-0.33	3.45e-10	Brugada syndrome;
LUSC	cis	rs9323205	1.000	rs12589519	chr14:51596684	C/G	cg23942311	chr14:51606299	NA	-0.48	-9.67	-0.47	1.16e-19	Cancer;
LUSC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg22437258	chr11:111473054	SIK2	0.53	7.45	0.38	7.84e-13	Primary sclerosing cholangitis;
LUSC	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.04	-0.4	1.6e-14	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02788857	chr8:22132959	PIWIL2	0.39	7.65	0.39	2.11e-13	Hypertriglyceridemia;
LUSC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-6.86	-0.35	3.35e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg04450456	chr4:17643702	FAM184B	0.43	7.21	0.37	3.8e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9650315	0.866	rs13281759	chr8:57193582	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	7.12	0.36	6.75e-12	Height;
LUSC	cis	rs7000551	0.715	rs7828610	chr8:22307326	C/T	cg12081754	chr8:22256438	SLC39A14	0.48	7.58	0.38	3.44e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.57	-7.01	-0.36	1.33e-11	Lung function (FEV1/FVC);
LUSC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	16.98	0.68	4.78e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg23985595	chr17:80112537	CCDC57	0.31	5.84	0.3	1.23e-8	Life satisfaction;
LUSC	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg05791153	chr7:19748676	TWISTNB	0.76	8.48	0.42	7.52e-16	Thyroid stimulating hormone;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04654365	chr17:19281636	MAPK7	0.75	6.42	0.33	4.62e-10	Cognitive performance;
LUSC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	1.22	16.34	0.67	1.68e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg25809561	chr17:30822961	MYO1D	0.53	8.88	0.44	4.14e-17	Schizophrenia;
LUSC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg17143192	chr8:8559678	CLDN23	0.66	9.61	0.47	1.84e-19	Obesity-related traits;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03603505	chr12:122839920	CLIP1	0.52	6.92	0.35	2.26e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.49	-0.42	6.65e-16	Bone mineral density;
LUSC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	0.94	17.87	0.7	1.34e-50	Heart rate;
LUSC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg16989086	chr20:62203971	PRIC285	0.46	6.47	0.33	3.56e-10	Glioblastoma;
LUSC	cis	rs5009270	0.553	rs62476688	chr7:112232716	C/T	cg23628563	chr7:112262597	NA	0.43	5.92	0.31	8.16e-9	Osteoarthritis (hip);
LUSC	trans	rs9784649	1.000	rs55924805	chr5:24999756	C/T	cg08600765	chr20:34638493	LOC647979	-0.54	-6.42	-0.33	4.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.84	0.35	3.78e-11	Lung cancer in ever smokers;
LUSC	trans	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.14	0.32	2.31e-9	Corneal astigmatism;
LUSC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	0.89	11.5	0.53	5.3e-26	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	13.29	0.59	1.19e-32	Blood protein levels;
LUSC	trans	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg25214090	chr10:38739885	LOC399744	0.43	6.49	0.33	3.12e-10	Educational attainment;
LUSC	cis	rs9905704	0.918	rs12947196	chr17:56902444	G/A	cg12560992	chr17:57184187	TRIM37	0.57	8.05	0.4	1.47e-14	Testicular germ cell tumor;
LUSC	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg14092571	chr14:90743983	NA	0.36	5.78	0.3	1.69e-8	Mortality in heart failure;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24806732	chr17:7608859	EFNB3	0.4	6.05	0.31	3.83e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.76	-0.3	1.92e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2236918	0.710	rs1626057	chr1:242038136	G/C	cg17736920	chr1:242011382	EXO1	0.41	6.34	0.33	7.52e-10	Menopause (age at onset);
LUSC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg04756594	chr16:24857601	SLC5A11	0.35	5.83	0.3	1.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	0.93	17.21	0.69	5.86e-48	Heart rate;
LUSC	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg03465714	chr1:152285911	FLG	-0.4	-5.67	-0.3	3.07e-8	Atopic dermatitis;
LUSC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6722750	1.000	rs4671552	chr2:64393955	A/G	cg22352474	chr2:64371530	PELI1	0.57	8.63	0.43	2.62e-16	Neuroticism;
LUSC	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg03733263	chr8:22462867	KIAA1967	1.0	17.88	0.7	1.2e-50	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg22676075	chr6:135203613	NA	0.55	8.72	0.43	1.37e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg15704280	chr7:45808275	SEPT13	0.65	7.19	0.37	4.24e-12	Axial length;
LUSC	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13064411	0.660	rs3829889	chr3:113015464	G/A	cg18753928	chr3:113234510	CCDC52	-0.43	-6.24	-0.32	1.36e-9	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	trans	rs6600671	1.000	rs11249351	chr1:121171942	G/A	cg08727972	chr1:148025634	NBPF14	0.45	6.25	0.32	1.24e-9	Hip geometry;
LUSC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg25036284	chr2:26402008	FAM59B	0.68	9.15	0.45	5.62e-18	Gut microbiome composition (summer);
LUSC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg23711669	chr6:146136114	FBXO30	-0.78	-12.9	-0.58	3.58e-31	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg27661571	chr11:113659931	NA	-0.64	-6.68	-0.34	9.75e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.59	-10.47	-0.5	2.34e-22	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs2979489	0.891	rs2915591	chr8:30395948	C/G	cg26383811	chr8:30366931	RBPMS	-0.52	-8.16	-0.41	6.8e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs1577917	0.839	rs6454492	chr6:86483214	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-6.47	-0.33	3.53e-10	Response to antipsychotic treatment;
LUSC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.43	6.37	0.33	6.29e-10	Dupuytren's disease;
LUSC	cis	rs1832871	0.711	rs6920506	chr6:158695017	T/A	cg07165851	chr6:158734300	TULP4	0.5	7.8	0.39	7.87e-14	Height;
LUSC	cis	rs2282802	0.677	rs9686454	chr5:139627813	T/C	cg26211634	chr5:139558579	C5orf32	0.43	8.11	0.41	9.51e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	6.62	0.34	1.45e-10	Menarche (age at onset);
LUSC	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg01579765	chr21:45077557	HSF2BP	-0.47	-9.64	-0.47	1.5e-19	Mean corpuscular volume;
LUSC	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-0.89	-13.16	-0.58	3.82e-32	Obesity-related traits;
LUSC	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg05283184	chr6:79620031	NA	-0.57	-11.83	-0.54	3.38e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20972416	chr2:220025218	NHEJ1	0.48	6.65	0.34	1.2e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18861140	chr18:3449789	TGIF1	-0.49	-6.52	-0.34	2.6e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg18512352	chr11:47633146	NA	-0.48	-9.6	-0.47	1.94e-19	Subjective well-being;
LUSC	cis	rs2273669	0.667	rs2145765	chr6:109296362	C/G	cg05315195	chr6:109294784	ARMC2	-0.58	-6.45	-0.33	4.03e-10	Prostate cancer;
LUSC	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg08213375	chr14:104286397	PPP1R13B	0.53	10.51	0.5	1.69e-22	Schizophrenia;
LUSC	cis	rs10208940	0.920	rs7571506	chr2:68836317	C/A	cg12452813	chr2:68675892	NA	0.55	5.67	0.3	3.06e-8	Urate levels in lean individuals;
LUSC	cis	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg23950597	chr19:37808831	NA	-0.65	-7.67	-0.39	1.89e-13	Coronary artery calcification;
LUSC	cis	rs4654899	0.758	rs12137408	chr1:21282945	A/G	cg01072550	chr1:21505969	NA	-0.53	-8.03	-0.4	1.67e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.81	-0.43	6.7e-17	Monocyte count;
LUSC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	0.6	8.05	0.4	1.45e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg11752832	chr7:134001865	SLC35B4	0.6	9.54	0.46	3.17e-19	Mean platelet volume;
LUSC	cis	rs7124681	0.584	rs12226590	chr11:47571808	T/C	cg20307385	chr11:47447363	PSMC3	0.42	5.98	0.31	5.88e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs11971779	0.680	rs10229249	chr7:139052510	A/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg04013166	chr16:89971882	TCF25	0.54	5.92	0.31	7.93e-9	Skin colour saturation;
LUSC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg08499158	chr17:42289980	UBTF	0.4	6.12	0.32	2.6e-9	Total body bone mineral density;
LUSC	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	10.03	0.48	7.45e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs12940923	0.935	rs11079342	chr17:56367633	G/C	cg19466818	chr17:56409534	MIR142	-0.39	-6.87	-0.35	3.19e-11	Circulating myeloperoxidase levels (plasma);
LUSC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.77	-0.8	1.22e-77	Height;
LUSC	trans	rs1864729	1.000	rs2567773	chr8:98279182	G/A	cg08679828	chr8:102218111	ZNF706	-0.81	-7.38	-0.37	1.28e-12	Estradiol plasma levels (breast cancer);
LUSC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg00745463	chr17:30367425	LRRC37B	0.78	8.66	0.43	2.06e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs4566357	1.000	rs6705989	chr2:227923320	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.75	-0.3	1.97e-8	Coronary artery disease;
LUSC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.17	0.37	4.94e-12	Cognitive ability;
LUSC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg06792262	chr3:44622596	ZNF167	0.35	5.96	0.31	6.42e-9	Depressive symptoms;
LUSC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg02376097	chr19:46275166	DMPK	0.39	6.94	0.35	2.06e-11	Coronary artery disease;
LUSC	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17467752	chr17:38218738	THRA	0.77	12.42	0.56	2.3e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg23791538	chr6:167370224	RNASET2	-0.37	-5.74	-0.3	2.1e-8	Crohn's disease;
LUSC	cis	rs2677744	0.626	rs868547	chr15:91498760	G/A	cg23684204	chr15:91497937	RCCD1	0.55	7.74	0.39	1.18e-13	Attention deficit hyperactivity disorder;
LUSC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-14.21	-0.61	3.52e-36	Hemoglobin concentration;
LUSC	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg15654264	chr1:150340011	RPRD2	0.59	9.69	0.47	1.03e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.7	10.48	0.5	2.07e-22	IgG glycosylation;
LUSC	cis	rs7923609	0.811	rs3847326	chr10:65331859	A/G	cg01631684	chr10:65280961	REEP3	0.4	5.92	0.31	7.83e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg11247378	chr22:39784982	NA	0.65	12.88	0.58	4.13e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.37	6.03	0.31	4.32e-9	Self-reported allergy;
LUSC	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.56	8.67	0.43	1.93e-16	Menopause (age at onset);
LUSC	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg05343316	chr1:45956843	TESK2	-0.58	-8.27	-0.41	3.15e-15	Platelet count;
LUSC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg11766577	chr21:47581405	C21orf56	-0.55	-8.48	-0.42	7.46e-16	Testicular germ cell tumor;
LUSC	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg10596483	chr8:143751796	JRK	0.52	7.57	0.38	3.79e-13	Schizophrenia;
LUSC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.3	0.53	2.82e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg24829409	chr8:58192753	C8orf71	-0.6	-7.41	-0.38	1.03e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg12573674	chr2:1569213	NA	-0.63	-8.74	-0.43	1.15e-16	IgG glycosylation;
LUSC	cis	rs7953508	0.711	rs11107116	chr12:93978504	G/T	cg18151635	chr12:93972918	NA	-0.58	-8.03	-0.4	1.63e-14	Pubertal anthropometrics;
LUSC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg07716408	chr11:68623521	NA	-0.31	-5.94	-0.31	7.27e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg22903657	chr4:1355424	KIAA1530	-0.37	-6.14	-0.32	2.4e-9	Longevity;
LUSC	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg00579484	chr14:23475993	C14orf93	0.39	5.85	0.3	1.2e-8	Cognitive ability (multi-trait analysis);
LUSC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg20848291	chr7:100343083	ZAN	-0.58	-7.02	-0.36	1.21e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg17757837	chr7:157058334	UBE3C	0.82	13.25	0.59	1.76e-32	Body mass index;
LUSC	cis	rs5762813	0.524	rs5762835	chr22:29230754	A/G	cg02153584	chr22:29168773	CCDC117	0.54	6.36	0.33	6.54e-10	Hematocrit;Hemoglobin concentration;
LUSC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	11.98	0.55	9e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg08000102	chr2:233561755	GIGYF2	-0.69	-11.49	-0.53	5.48e-26	Coronary artery disease;
LUSC	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.88	14.29	0.62	1.69e-36	Coronary artery disease;
LUSC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg12463550	chr7:65579703	CRCP	0.52	7.61	0.38	2.85e-13	Aortic root size;
LUSC	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg22681709	chr2:178499509	PDE11A	-0.37	-5.66	-0.3	3.34e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.75	-0.3	2.06e-8	Height;
LUSC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-6.3	-0.33	9.26e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg04369109	chr6:150039330	LATS1	-0.58	-8.56	-0.42	4.25e-16	Lung cancer;
LUSC	cis	rs16949788	1.000	rs9806474	chr15:66646513	C/T	cg08120210	chr15:66682733	MAP2K1	-0.58	-5.88	-0.31	9.73e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg21211680	chr2:198530	NA	0.68	7.21	0.37	3.7e-12	Blood protein levels;
LUSC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02788857	chr8:22132959	PIWIL2	0.39	7.55	0.38	4.3e-13	Hypertriglyceridemia;
LUSC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00166722	chr3:10149974	C3orf24	0.59	7.73	0.39	1.25e-13	Alzheimer's disease;
LUSC	cis	rs11650494	0.908	rs77488129	chr17:47448970	G/A	cg08112188	chr17:47440006	ZNF652	1.4	11.42	0.53	1.02e-25	Prostate cancer;
LUSC	trans	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg24247370	chr13:99142703	STK24	-0.35	-6.2	-0.32	1.63e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg24829409	chr8:58192753	C8orf71	-0.57	-7.23	-0.37	3.27e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs17253792	0.731	rs74823888	chr14:56049800	T/C	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	8.91e-12	Putamen volume;
LUSC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.58	0.46	2.25e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg23649088	chr2:200775458	C2orf69	-0.54	-6.37	-0.33	6.23e-10	Schizophrenia;
LUSC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg27170947	chr2:26402098	FAM59B	-0.7	-10.69	-0.5	3.92e-23	Gut microbiome composition (summer);
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg09033563	chr22:24373618	LOC391322	-0.6	-9.42	-0.46	7.85e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4845570	1.000	rs4845570	chr1:151759104	C/T	cg07092448	chr1:151763213	TDRKH	1.23	14.14	0.61	6.53e-36	Coronary artery disease;
LUSC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06558623	chr16:89946397	TCF25	1.08	9.74	0.47	6.73e-20	Skin colour saturation;
LUSC	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg21643547	chr1:205240462	TMCC2	-0.42	-7.65	-0.39	2.15e-13	Red blood cell count;
LUSC	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg01475377	chr6:109611718	NA	-0.45	-8.27	-0.41	3.13e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	0.42	6.24	0.32	1.31e-9	Response to bleomycin (chromatid breaks);
LUSC	cis	rs2617583	0.509	rs4738	chr5:1461568	C/T	cg13982541	chr5:1466431	LPCAT1	0.41	5.76	0.3	1.93e-8	Breast cancer;
LUSC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg12516959	chr21:47718080	NA	-0.38	-6.15	-0.32	2.25e-9	Testicular germ cell tumor;
LUSC	cis	rs12476592	0.636	rs196123	chr2:63841712	T/C	cg10828910	chr2:63850056	LOC388955	0.54	6.29	0.33	9.71e-10	Childhood ear infection;
LUSC	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.07	14.15	0.61	6.32e-36	Uric acid levels;
LUSC	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-9.78	-0.47	4.92e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg23887609	chr12:130822674	PIWIL1	0.53	8.11	0.41	9.87e-15	Menopause (age at onset);
LUSC	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.34	0.64	1.46e-40	Lymphocyte percentage of white cells;
LUSC	trans	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg13309027	chr11:47870224	NUP160	-0.44	-6.77	-0.35	5.72e-11	Gait speed in old age;
LUSC	cis	rs7640424	0.502	rs326359	chr3:107820619	G/A	cg09227934	chr3:107805635	CD47	0.54	9.9	0.48	1.98e-20	Body mass index;
LUSC	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg09184832	chr6:79620586	NA	-0.43	-7.02	-0.36	1.27e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs12220238	1.000	rs7905536	chr10:75997209	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.58	6.65	0.34	1.22e-10	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs2274459	0.841	rs13214874	chr6:33686368	G/A	cg06253072	chr6:33679850	C6orf125	0.5	5.89	0.31	9.29e-9	Obesity (extreme);
LUSC	cis	rs3741151	1.000	rs57893472	chr11:73042826	C/T	cg17517138	chr11:73019481	ARHGEF17	1.0	9.24	0.45	2.95e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg01028140	chr2:1542097	TPO	-0.49	-6.9	-0.35	2.56e-11	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs2637266	1.000	rs7914880	chr10:78363693	A/G	cg18941641	chr10:78392320	NA	0.39	7.22	0.37	3.61e-12	Pulmonary function;
LUSC	trans	rs62238980	0.614	rs76363976	chr22:32383968	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg21053147	chr12:120880522	NA	0.5	5.97	0.31	5.92e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg04944784	chr2:26401820	FAM59B	-0.61	-7.86	-0.4	5.38e-14	Gut microbiome composition (summer);
LUSC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-0.92	-13.2	-0.59	2.68e-32	Vitiligo;
LUSC	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.67	-0.34	1.07e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg12560992	chr17:57184187	TRIM37	0.9	17.69	0.7	6.85e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs2637266	1.000	rs2579750	chr10:78340260	C/G	cg18941641	chr10:78392320	NA	-0.38	-7.02	-0.36	1.25e-11	Pulmonary function;
LUSC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg07424592	chr7:64974309	NA	0.68	6.14	0.32	2.29e-9	Diabetic kidney disease;
LUSC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.79	-11.02	-0.52	2.62e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs56146971	0.763	rs34854034	chr14:91870677	A/G	cg10511902	chr14:91842949	CCDC88C	0.43	5.69	0.3	2.8e-8	Alzheimer disease and age of onset;
LUSC	cis	rs6669919	0.553	rs7546343	chr1:211671801	C/T	cg10512769	chr1:211675356	NA	-0.3	-7.03	-0.36	1.14e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-7.79	-0.39	8.41e-14	Monocyte percentage of white cells;
LUSC	trans	rs6832769	0.621	rs10033028	chr4:56519876	C/G	cg25365783	chr7:108166722	PNPLA8	-0.36	-6.4	-0.33	5.12e-10	Personality dimensions;
LUSC	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg00191853	chr8:101177733	SPAG1	-0.41	-6.64	-0.34	1.24e-10	Atrioventricular conduction;
LUSC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg02079420	chr8:82753780	SNX16	0.39	6.03	0.31	4.24e-9	Diastolic blood pressure;
LUSC	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg05855489	chr10:104503620	C10orf26	0.52	8.03	0.4	1.63e-14	Arsenic metabolism;
LUSC	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.65	-0.39	2.24e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg13683864	chr3:40499215	RPL14	-1.11	-21.36	-0.76	2.03e-64	Renal cell carcinoma;
LUSC	cis	rs6987853	0.688	rs2923433	chr8:42418723	T/C	cg09913449	chr8:42400586	C8orf40	0.5	8.46	0.42	8.67e-16	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6700896	0.931	rs1805096	chr1:66102257	C/T	cg04111102	chr1:66153794	NA	0.31	6.85	0.35	3.57e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10170846	0.893	rs10932967	chr2:223544111	C/T	cg25565276	chr2:223520875	FARSB	0.6	8.91	0.44	3.28e-17	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg20607287	chr7:12443886	VWDE	-0.65	-6.32	-0.33	8.15e-10	Coronary artery disease;
LUSC	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg25237894	chr2:233734115	C2orf82	0.36	6.74	0.35	7.17e-11	Coronary artery disease;
LUSC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg10621924	chr7:39171070	POU6F2	0.43	6.56	0.34	2.01e-10	IgG glycosylation;
LUSC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg06238570	chr21:40685208	BRWD1	0.49	7.48	0.38	6.56e-13	Cognitive function;
LUSC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.52	-0.34	2.53e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs2386661	0.547	rs11259582	chr10:5646767	C/T	cg11398623	chr21:37499189	NA	0.27	6.17	0.32	2.01e-9	Breast cancer;
LUSC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg11871910	chr12:69753446	YEATS4	0.63	9.14	0.45	6.19e-18	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg07460842	chr6:66804631	NA	-0.48	-6.72	-0.35	7.74e-11	Blood trace element (Cu levels);
LUSC	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg20307385	chr11:47447363	PSMC3	0.52	6.44	0.33	4.26e-10	Subjective well-being;
LUSC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg16049864	chr8:95962084	TP53INP1	0.6	11.14	0.52	1.03e-24	Type 2 diabetes;
LUSC	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg19508488	chr2:152266495	RIF1	0.55	7.33	0.37	1.74e-12	Lung cancer;
LUSC	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-0.82	-14.25	-0.61	2.46e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2273669	0.667	rs78714994	chr6:109350351	G/C	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.37	-6.25	-0.32	1.23e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg14154082	chr13:112174009	NA	0.38	7.88	0.4	4.53e-14	Menarche (age at onset);
LUSC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg05347473	chr6:146136440	FBXO30	0.48	8.2	0.41	5.16e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg08999081	chr20:33150536	PIGU	-0.38	-6.86	-0.35	3.34e-11	Height;
LUSC	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg04455712	chr21:45112962	RRP1B	-0.48	-9.09	-0.45	8.99e-18	Mean corpuscular volume;
LUSC	cis	rs9394152	0.845	rs4713632	chr6:33472990	G/T	cg13560919	chr6:33536144	NA	0.6	10.63	0.5	6.18e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.95	0.31	6.59e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9815354	0.670	rs73073238	chr3:42014325	G/C	cg03022575	chr3:42003672	ULK4	0.82	8.44	0.42	1.01e-15	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs7495211	0.529	rs8040797	chr15:98624483	G/C	cg08901157	chr15:56033728	PRTG	0.36	6.34	0.33	7.34e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg16928487	chr17:17741425	SREBF1	0.47	9.21	0.45	3.57e-18	Total body bone mineral density;
LUSC	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg20744362	chr22:50050164	C22orf34	0.4	8.29	0.41	2.75e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4474465	1.000	rs7131199	chr11:78192148	T/G	cg27205649	chr11:78285834	NARS2	-0.55	-6.3	-0.33	9.57e-10	Alzheimer's disease (survival time);
LUSC	trans	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.44	6.02	0.31	4.65e-9	Corneal astigmatism;
LUSC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05776053	chr2:74358815	NA	0.45	7.12	0.36	6.54e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg22681709	chr2:178499509	PDE11A	-0.57	-11.33	-0.53	2.19e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.81	-11.86	-0.54	2.67e-27	Multiple sclerosis;
LUSC	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.51	10.3	0.49	8.71e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg11812906	chr14:75593930	NEK9	0.67	11.64	0.54	1.58e-26	Height;
LUSC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.82	14.29	0.62	1.77e-36	Blood protein levels;
LUSC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg05973401	chr12:123451056	ABCB9	0.54	6.68	0.34	1.01e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	9.83	0.47	3.32e-20	Lupus nephritis in systemic lupus erythematosus;
LUSC	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg26384229	chr12:38710491	ALG10B	0.7	10.82	0.51	1.41e-23	Morning vs. evening chronotype;
LUSC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg03146154	chr1:46216737	IPP	-0.58	-8.42	-0.42	1.11e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs2018683	0.677	rs12531456	chr7:28970611	A/C	cg19402173	chr7:128379420	CALU	-0.47	-7.08	-0.36	8.76e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg24910161	chr17:38119198	GSDMA	-0.29	-6.46	-0.33	3.76e-10	Asthma;
LUSC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg25767906	chr1:53392781	SCP2	0.48	8.63	0.43	2.55e-16	Monocyte count;
LUSC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg22166914	chr1:53195759	ZYG11B	-0.69	-12.08	-0.55	4.17e-28	Monocyte count;
LUSC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.49	7.09	0.36	8.23e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg08219700	chr8:58056026	NA	0.46	6.03	0.31	4.26e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg09092052	chr15:45571596	NA	0.45	6.18	0.32	1.85e-9	Glomerular filtration rate;
LUSC	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg04518342	chr5:131593106	PDLIM4	0.36	6.71	0.34	8.3e-11	Blood metabolite levels;
LUSC	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.62	9.95	0.48	1.3e-20	Blood metabolite ratios;
LUSC	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg25214090	chr10:38739885	LOC399744	0.56	8.16	0.41	7.08e-15	Corneal astigmatism;
LUSC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	9.48	0.46	4.79e-19	Total body bone mineral density;
LUSC	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg00677455	chr12:58241039	CTDSP2	0.7	10.53	0.5	1.45e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.84	-0.54	3.05e-27	Chronic sinus infection;
LUSC	cis	rs7582720	0.943	rs72936866	chr2:203787120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6577655	0.517	rs6996991	chr8:135589255	G/A	cg17885191	chr8:135476712	NA	0.61	7.97	0.4	2.61e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg06740227	chr12:86229804	RASSF9	0.45	7.23	0.37	3.37e-12	Major depressive disorder;
LUSC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	0.93	16.17	0.66	7.55e-44	Menopause (age at onset);
LUSC	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg27411982	chr8:10470053	RP1L1	-0.47	-7.2	-0.37	4.06e-12	Mood instability;
LUSC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg27535305	chr1:53392650	SCP2	0.36	6.78	0.35	5.47e-11	Monocyte count;
LUSC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg05665937	chr4:1216051	CTBP1	-0.37	-5.79	-0.3	1.65e-8	Obesity-related traits;
LUSC	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04004882	chr2:215674386	BARD1	0.48	6.37	0.33	6.34e-10	Neuroblastoma;
LUSC	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.67	-0.47	1.19e-19	Multiple sclerosis;
LUSC	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg03585969	chr10:35415529	CREM	0.65	9.25	0.45	2.78e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.39	-0.56	2.93e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.18	0.64	6e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs9296092	0.560	rs9469502	chr6:33526648	G/A	cg13560919	chr6:33536144	NA	-0.85	-16.44	-0.67	6.54e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.64	0.34	1.25e-10	Tonsillectomy;
LUSC	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg20026190	chr17:76395443	PGS1	0.45	8.06	0.4	1.4e-14	HDL cholesterol levels;
LUSC	trans	rs61931739	0.649	rs1068864	chr12:33733119	A/C	cg26384229	chr12:38710491	ALG10B	0.43	6.18	0.32	1.9e-9	Morning vs. evening chronotype;
LUSC	cis	rs4409675	0.576	rs7520860	chr1:28232952	C/A	cg23691781	chr1:28212827	C1orf38	0.32	7.65	0.39	2.21e-13	Corneal astigmatism;
LUSC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg26335602	chr6:28129616	ZNF389	0.46	6.3	0.33	9.49e-10	Parkinson's disease;
LUSC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	14.31	0.62	1.51e-36	Platelet count;
LUSC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21310689	chr19:55865288	COX6B2	0.71	6.09	0.32	3.19e-9	Cognitive performance;
LUSC	cis	rs2479724	0.636	rs1192238	chr6:41803836	C/T	cg17623882	chr6:41773611	USP49	0.53	7.29	0.37	2.26e-12	Menarche (age at onset);
LUSC	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg25258033	chr6:167368657	RNASET2	0.36	5.73	0.3	2.27e-8	Crohn's disease;
LUSC	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.58	-0.38	3.4e-13	Blood metabolite levels;
LUSC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg24250549	chr1:154909240	PMVK	0.59	9.69	0.47	9.63e-20	Prostate cancer;
LUSC	cis	rs6693567	0.565	rs543179	chr1:150274610	G/A	cg15654264	chr1:150340011	RPRD2	-0.45	-7.41	-0.38	1.06e-12	Migraine;
LUSC	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg05026186	chr5:148520876	ABLIM3	-0.39	-5.93	-0.31	7.76e-9	Breast cancer;
LUSC	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg23029597	chr12:123009494	RSRC2	-0.72	-9.33	-0.45	1.51e-18	Body mass index;
LUSC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg18402987	chr7:1209562	NA	0.73	7.84	0.39	5.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg26876637	chr1:152193138	HRNR	0.47	6.6	0.34	1.66e-10	Atopic dermatitis;
LUSC	cis	rs887829	0.570	rs6736508	chr2:234595747	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.41	-0.33	5.08e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19487718	chr4:185747708	ACSL1	0.42	6.02	0.31	4.54e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg16405210	chr4:1374714	KIAA1530	-0.49	-7.04	-0.36	1.11e-11	Obesity-related traits;
LUSC	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	23.49	0.79	1.05e-72	Colorectal cancer;
LUSC	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg21890820	chr11:65308645	LTBP3	1.41	9.74	0.47	7e-20	Height;
LUSC	cis	rs6681460	0.565	rs2147776	chr1:67107403	T/C	cg02459107	chr1:67143332	SGIP1	0.43	7.98	0.4	2.29e-14	Presence of antiphospholipid antibodies;
LUSC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg00933542	chr6:150070202	PCMT1	0.33	6.91	0.35	2.42e-11	Lung cancer;
LUSC	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17467752	chr17:38218738	THRA	-0.71	-11.3	-0.53	2.64e-25	Sum eosinophil basophil counts;
LUSC	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.58	9.57	0.46	2.5e-19	Bone mineral density;
LUSC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg08999081	chr20:33150536	PIGU	0.43	7.83	0.39	6.51e-14	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg13206674	chr6:150067644	NUP43	-0.61	-8.99	-0.44	1.82e-17	Lung cancer;
LUSC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg20887711	chr4:1340912	KIAA1530	0.43	6.56	0.34	2.05e-10	Obesity-related traits;
LUSC	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg07701084	chr6:150067640	NUP43	0.48	7.21	0.37	3.75e-12	Testicular germ cell tumor;
LUSC	cis	rs28655083	0.957	rs7185514	chr16:77070129	T/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.41	-6.46	-0.33	3.79e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs16937	0.711	rs10751429	chr1:205107478	C/T	cg00857998	chr1:205179979	DSTYK	0.47	6.59	0.34	1.71e-10	Schizophrenia;
LUSC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg17718321	chr1:152188247	HRNR	-0.38	-6.8	-0.35	4.71e-11	Inflammatory skin disease;
LUSC	cis	rs9399401	0.884	rs263179	chr6:142863888	T/C	cg03128060	chr6:142623767	GPR126	0.33	6.07	0.32	3.42e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	0.7	11.06	0.52	1.95e-24	Blood metabolite ratios;
LUSC	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg23029597	chr12:123009494	RSRC2	-0.61	-8.67	-0.43	1.9e-16	Body mass index;
LUSC	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.9	20.74	0.75	5.32e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg17385448	chr1:15911702	AGMAT	0.34	5.68	0.3	2.91e-8	Systolic blood pressure;
LUSC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.59	-9.57	-0.46	2.43e-19	Aortic root size;
LUSC	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg22508957	chr16:3507546	NAT15	0.84	10.68	0.5	4.13e-23	Tuberculosis;
LUSC	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.41	-0.38	1.06e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg08219700	chr8:58056026	NA	0.51	6.49	0.33	3.08e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9646944	0.578	rs13418548	chr2:102917239	C/T	cg20060108	chr2:102954350	IL1RL1	0.46	5.88	0.31	9.99e-9	Blood protein levels;
LUSC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg21132104	chr15:45694354	SPATA5L1	0.58	8.11	0.41	9.55e-15	Homoarginine levels;
LUSC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13347679	chr3:9774065	BRPF1	-0.41	-5.97	-0.31	5.9e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg16797656	chr11:68205561	LRP5	0.44	8.12	0.41	9.31e-15	Total body bone mineral density;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg25551287	chr1:205649424	SLC45A3	0.44	6.04	0.31	4.2e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg02475777	chr4:1388615	CRIPAK	-0.42	-6.17	-0.32	1.96e-9	Obesity-related traits;
LUSC	cis	rs73198271	0.740	rs1039910	chr8:8648066	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.28	-0.32	1.06e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg18105134	chr13:113819100	PROZ	0.65	9.62	0.47	1.67e-19	Platelet distribution width;
LUSC	trans	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.63	-0.34	1.39e-10	Monocyte count;
LUSC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg06238570	chr21:40685208	BRWD1	0.37	5.64	0.3	3.57e-8	Cognitive function;
LUSC	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg21053147	chr12:120880522	NA	0.52	6.39	0.33	5.53e-10	Type 1 diabetes nephropathy;
LUSC	cis	rs1775715	0.966	rs1755066	chr10:32309160	C/G	cg18675610	chr10:32216311	ARHGAP12	-0.27	-5.71	-0.3	2.5e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg02423579	chr7:2872169	GNA12	-0.39	-6.16	-0.32	2.06e-9	Height;
LUSC	cis	rs9612	0.950	rs346546	chr19:44256910	T/C	cg08581076	chr19:44259116	C19orf61	0.53	6.71	0.34	8.22e-11	Exhaled nitric oxide output;
LUSC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg24250549	chr1:154909240	PMVK	0.49	7.47	0.38	6.99e-13	Prostate cancer;
LUSC	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg17385448	chr1:15911702	AGMAT	0.37	5.81	0.3	1.45e-8	Systolic blood pressure;
LUSC	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.81	-13.2	-0.59	2.61e-32	Schizophrenia;
LUSC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg05347473	chr6:146136440	FBXO30	0.52	8.87	0.44	4.4e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7577851	0.715	rs7605572	chr2:69646504	G/A	cg10773587	chr2:69614142	GFPT1	0.58	7.06	0.36	9.94e-12	Parkinson's disease (age of onset);
LUSC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg24578937	chr1:2090814	PRKCZ	-0.43	-9.54	-0.46	3.18e-19	Height;
LUSC	cis	rs258324	0.720	rs154663	chr16:89726035	T/C	cg26513180	chr16:89883248	FANCA	-0.75	-6.64	-0.34	1.28e-10	Height;
LUSC	trans	rs587847	0.507	rs12593565	chr15:37807627	G/A	cg18296784	chr11:116147929	NA	-0.35	-6.37	-0.33	6.39e-10	Intraocular pressure;
LUSC	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg02569458	chr12:86230093	RASSF9	0.42	6.83	0.35	4.04e-11	Major depressive disorder;
LUSC	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg25930673	chr12:123319894	HIP1R	-0.72	-7.12	-0.36	6.69e-12	Schizophrenia;
LUSC	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.64	-0.34	1.28e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg06145435	chr7:1022769	CYP2W1	-0.32	-5.64	-0.3	3.56e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.81	13.41	0.59	4.23e-33	Aortic root size;
LUSC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.54	0.38	4.58e-13	Parkinson's disease;
LUSC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs4363385	0.510	rs6661063	chr1:153036048	C/A	cg00922841	chr1:152955080	SPRR1A	-0.36	-6.25	-0.32	1.22e-9	Inflammatory skin disease;
LUSC	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	7.36	0.37	1.46e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7712401	0.601	rs246274	chr5:122280803	A/C	cg19077854	chr5:122220652	SNX24	0.41	9.17	0.45	4.86e-18	Mean platelet volume;
LUSC	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg22532475	chr10:104410764	TRIM8	-0.32	-7.09	-0.36	8.12e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.7	0.34	8.68e-11	Menopause (age at onset);
LUSC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg23711669	chr6:146136114	FBXO30	0.81	14.78	0.63	2.11e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9807841	0.670	rs10405617	chr19:10752968	C/T	cg17710535	chr19:10819994	QTRT1	-0.41	-6.6	-0.34	1.63e-10	Inflammatory skin disease;
LUSC	cis	rs1670533	1.000	rs2290410	chr4:1052078	A/T	cg27284194	chr4:1044797	NA	0.56	8.07	0.4	1.3e-14	Recombination rate (females);
LUSC	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.34	-0.37	1.63e-12	Triglycerides;
LUSC	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg05707623	chr12:122985044	ZCCHC8	0.67	8.19	0.41	5.44e-15	Body mass index;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg24449302	chr15:66679100	MAP2K1	-0.42	-5.95	-0.31	6.73e-9	Height;
LUSC	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg22777020	chr22:31556080	RNF185	-0.47	-6.04	-0.31	4.07e-9	Colorectal cancer;
LUSC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg08392591	chr16:89556376	ANKRD11	0.5	7.59	0.38	3.27e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs427941	0.632	rs201508	chr7:101764199	T/G	cg06246474	chr7:101738831	CUX1	0.39	6.32	0.33	8.21e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.44	-0.38	8.85e-13	Psoriasis;
LUSC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg22800045	chr5:56110881	MAP3K1	0.79	10.33	0.49	6.92e-22	Initial pursuit acceleration;
LUSC	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg16586182	chr3:47516702	SCAP	0.52	7.93	0.4	3.31e-14	Colorectal cancer;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg09302904	chr17:62340561	TEX2	0.5	6.03	0.31	4.37e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg07701084	chr6:150067640	NUP43	0.58	8.69	0.43	1.68e-16	Lung cancer;
LUSC	cis	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg21775007	chr8:11205619	TDH	0.42	6.13	0.32	2.45e-9	Systolic blood pressure;
LUSC	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg05340658	chr4:99064831	C4orf37	0.41	6.24	0.32	1.31e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg24558204	chr6:135376177	HBS1L	0.57	8.77	0.43	9.11e-17	Red blood cell count;
LUSC	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg10560079	chr2:191398806	TMEM194B	-0.71	-8.42	-0.42	1.11e-15	Diastolic blood pressure;
LUSC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.2	0.45	4.07e-18	Prudent dietary pattern;
LUSC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg13206674	chr6:150067644	NUP43	-0.59	-9.37	-0.46	1.1e-18	Lung cancer;
LUSC	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.61	-0.69	1.49e-49	Exhaled nitric oxide output;
LUSC	cis	rs240764	0.604	rs1336242	chr6:101199634	C/T	cg09795085	chr6:101329169	ASCC3	0.43	6.2	0.32	1.71e-9	Neuroticism;
LUSC	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg08345082	chr10:99160200	RRP12	-0.41	-7.98	-0.4	2.34e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	11.82	0.54	3.71e-27	Chronic sinus infection;
LUSC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	13.55	0.6	1.23e-33	Platelet count;
LUSC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12050794	0.671	rs7179427	chr15:72516821	G/A	cg16672083	chr15:72433130	SENP8	0.47	7.75	0.39	1.09e-13	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg00012203	chr2:219082015	ARPC2	-0.76	-13.58	-0.6	9.19e-34	Colorectal cancer;
LUSC	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16557308	chr1:52082719	OSBPL9	-0.5	-6.36	-0.33	6.48e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs727505	1.000	rs28523990	chr7:124436139	C/T	cg23710748	chr7:124431027	NA	-0.44	-8.03	-0.4	1.65e-14	Lewy body disease;
LUSC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	0.91	13.51	0.59	1.7e-33	Breast cancer;
LUSC	cis	rs7799006	0.527	rs6967286	chr7:2212758	C/A	cg12823233	chr7:2316876	SNX8	-0.34	-5.79	-0.3	1.65e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11630290	0.592	rs1017531	chr15:64158650	G/A	cg12036633	chr15:63758958	NA	0.53	6.73	0.35	7.35e-11	Iris characteristics;
LUSC	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.86	-0.31	1.12e-8	Ileal carcinoids;
LUSC	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg12935359	chr14:103987150	CKB	0.5	7.82	0.39	6.84e-14	Body mass index;
LUSC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg17971929	chr21:40555470	PSMG1	-0.49	-7.09	-0.36	7.88e-12	Menarche (age at onset);
LUSC	cis	rs3007168	0.794	rs11850707	chr14:51627074	A/G	cg23942311	chr14:51606299	NA	0.36	6.85	0.35	3.64e-11	Cancer;
LUSC	trans	rs12902680	0.641	rs12440603	chr15:46585722	C/T	cg04321580	chr8:143696133	ARC	-0.4	-6.04	-0.31	4.18e-9	Neuroticism;
LUSC	cis	rs10072221	0.738	rs10065322	chr5:75709413	G/A	cg03132911	chr5:75698732	IQGAP2	0.36	6.06	0.31	3.74e-9	Mean platelet volume;
LUSC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.35	0.49	5.78e-22	Bone mineral density;
LUSC	cis	rs9303542	0.625	rs7225995	chr17:46596268	G/C	cg09704116	chr17:46666958	LOC404266	-0.38	-6.87	-0.35	3.12e-11	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg11062466	chr8:58055876	NA	0.68	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs13394619	0.936	rs9789414	chr2:11724684	A/G	cg07314298	chr2:11723111	GREB1	-0.59	-10.54	-0.5	1.28e-22	Endometriosis;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg09272869	chr15:68569991	FEM1B	0.41	6.33	0.33	8.04e-10	Schizophrenia;
LUSC	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-0.92	-16.08	-0.66	1.79e-43	Height;
LUSC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13012494	chr21:47604986	C21orf56	0.42	6.3	0.33	9.61e-10	Testicular germ cell tumor;
LUSC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	11.11	0.52	1.29e-24	Alzheimer's disease;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08436942	chr4:4249992	TMEM128	-0.41	-6.05	-0.31	3.94e-9	Hepatitis;
LUSC	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg25801113	chr15:45476975	SHF	0.35	7.22	0.37	3.5e-12	Uric acid levels;
LUSC	cis	rs2798269	0.668	rs1199938	chr13:22068225	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.38	-5.99	-0.31	5.55e-9	PR segment;
LUSC	trans	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.97	-0.31	6.23e-9	Dementia with Lewy bodies;
LUSC	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.54	10.96	0.51	4.22e-24	Coronary artery disease;
LUSC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg05863683	chr7:1912471	MAD1L1	0.31	5.97	0.31	6.08e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12900413	0.687	rs34284515	chr15:90308061	T/G	cg24249390	chr15:90295951	MESP1	-0.37	-5.87	-0.31	1.03e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.32	0.37	1.91e-12	Motion sickness;
LUSC	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg10978503	chr1:24200527	CNR2	0.54	13.21	0.59	2.32e-32	Immature fraction of reticulocytes;
LUSC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.21	0.56	1.29e-28	Prudent dietary pattern;
LUSC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.34	-0.41	2.04e-15	Height;
LUSC	cis	rs5771242	0.518	rs5771258	chr22:50675648	C/A	cg16473166	chr22:50639996	SELO	0.72	9.64	0.47	1.44e-19	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LUSC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg23711669	chr6:146136114	FBXO30	0.87	16.53	0.67	2.75e-45	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1692580	0.870	rs263533	chr1:2163568	C/T	cg04315214	chr1:2043799	PRKCZ	-0.31	-5.94	-0.31	7.32e-9	Coronary artery disease;
LUSC	cis	rs10979	0.651	rs9321921	chr6:143895053	C/T	cg25407410	chr6:143891975	LOC285740	-0.68	-9.47	-0.46	5.22e-19	Hypospadias;
LUSC	cis	rs6494488	0.500	rs72744741	chr15:65050514	T/C	cg08069370	chr15:64387884	SNX1	-0.65	-5.91	-0.31	8.23e-9	Coronary artery disease;
LUSC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg04414720	chr1:150670196	GOLPH3L	0.51	8.26	0.41	3.47e-15	Tonsillectomy;
LUSC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.99	0.58	1.65e-31	Chronic sinus infection;
LUSC	cis	rs12900413	0.603	rs12911871	chr15:90301429	T/C	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.56e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.85	-0.31	1.14e-8	Retinal vascular caliber;
LUSC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg17127132	chr2:85788382	GGCX	0.45	7.08	0.36	8.6e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg20307385	chr11:47447363	PSMC3	-0.45	-6.69	-0.34	9.64e-11	Subjective well-being;
LUSC	cis	rs6495367	1.000	rs28412916	chr15:79378167	A/C	cg17916960	chr15:79447300	NA	0.37	6.86	0.35	3.28e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18932078	chr1:2524107	MMEL1	0.32	7.08	0.36	8.45e-12	Ulcerative colitis;
LUSC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.49	6.13	0.32	2.44e-9	Schizophrenia;
LUSC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06112835	chr11:68658793	MRPL21	0.52	7.8	0.39	7.84e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg18904891	chr8:8559673	CLDN23	0.6	8.33	0.41	2.08e-15	Obesity-related traits;
LUSC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg14004847	chr7:1930337	MAD1L1	-0.57	-8.65	-0.43	2.26e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-1.23	-13.41	-0.59	4.23e-33	Diabetic kidney disease;
LUSC	cis	rs2692947	0.696	rs1724121	chr2:96808549	T/C	cg23100626	chr2:96804247	ASTL	0.27	6.59	0.34	1.72e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg04362960	chr10:104952993	NT5C2	-0.6	-9.33	-0.45	1.52e-18	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6445967	0.689	rs11714574	chr3:58380465	A/T	cg23715586	chr3:58305044	RPP14	0.44	8.56	0.42	4.11e-16	Platelet count;
LUSC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.65	11.1	0.52	1.44e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg26408565	chr15:76604113	ETFA	-0.5	-7.93	-0.4	3.26e-14	Blood metabolite levels;
LUSC	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg18232548	chr7:50535776	DDC	-0.52	-7.25	-0.37	2.91e-12	Malaria;
LUSC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.05	-0.31	3.92e-9	Platelet count;
LUSC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22590775	chr19:49891494	CCDC155	0.6	8.8	0.43	7.62e-17	Multiple sclerosis;
LUSC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg06784218	chr1:46089804	CCDC17	0.54	10.91	0.51	6.6e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6542838	0.780	rs981601	chr2:99463882	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-6.38	-0.33	5.77e-10	Fear of minor pain;
LUSC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-0.81	-11.99	-0.55	8.92e-28	Breast cancer;
LUSC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg22903471	chr2:27725779	GCKR	-0.41	-6.96	-0.36	1.83e-11	Total body bone mineral density;
LUSC	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-9.4	-0.46	8.77e-19	Response to antipsychotic treatment;
LUSC	cis	rs7809950	0.954	rs2189839	chr7:107230026	A/G	cg23024343	chr7:107201750	COG5	0.55	8.62	0.43	2.68e-16	Coronary artery disease;
LUSC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg27432699	chr2:27873401	GPN1	-0.57	-8.48	-0.42	7.29e-16	Total body bone mineral density;
LUSC	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg09184832	chr6:79620586	NA	-0.45	-7.34	-0.37	1.67e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.66	0.3	3.21e-8	Cerebrospinal P-tau181p levels;
LUSC	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.82	-0.35	4.26e-11	Uric acid levels;
LUSC	cis	rs7615316	0.779	rs9821271	chr3:142034522	A/C	cg16271453	chr3:142027066	XRN1	-0.41	-7.13	-0.36	6.32e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg19875535	chr5:140030758	IK	-0.37	-5.71	-0.3	2.5e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	1.05	20.45	0.75	7.54e-61	Menopause (age at onset);
LUSC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg17911788	chr17:44343683	NA	0.3	5.82	0.3	1.36e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1395	0.767	rs1821986	chr2:27405835	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.4	-6.68	-0.34	9.89e-11	Blood metabolite levels;
LUSC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.49	6.09	0.32	3.14e-9	Renal function-related traits (BUN);
LUSC	cis	rs17540621	1.000	rs17540621	chr2:47229839	G/C	cg23978866	chr2:47230407	TTC7A	-0.97	-6.63	-0.34	1.38e-10	Response to statin therapy;
LUSC	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg08999081	chr20:33150536	PIGU	0.53	10.3	0.49	8.6e-22	Coronary artery disease;
LUSC	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg08601574	chr20:25228251	PYGB	0.43	6.53	0.34	2.4e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9322817	0.691	rs4299867	chr6:105325383	G/C	cg02098413	chr6:105308735	HACE1	0.27	5.8	0.3	1.52e-8	Thyroid stimulating hormone;
LUSC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg05896524	chr21:47604654	C21orf56	-0.57	-8.9	-0.44	3.65e-17	Testicular germ cell tumor;
LUSC	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg20503657	chr10:835505	NA	0.9	12.36	0.56	3.66e-29	Eosinophil percentage of granulocytes;
LUSC	cis	rs870825	0.929	rs72689256	chr4:185590174	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	11.5	0.53	5.34e-26	Blood protein levels;
LUSC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22618164	chr12:122356400	WDR66	0.58	8.79	0.43	7.78e-17	Mean corpuscular volume;
LUSC	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg07701084	chr6:150067640	NUP43	0.52	7.65	0.39	2.12e-13	Lung cancer;
LUSC	cis	rs2625529	0.652	rs2957735	chr15:72265173	T/C	cg16672083	chr15:72433130	SENP8	0.48	7.95	0.4	2.86e-14	Red blood cell count;
LUSC	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.85	-14.39	-0.62	7.09e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	0.91	15.83	0.65	1.66e-42	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs1775715	0.678	rs2778649	chr10:32146803	C/G	cg04359828	chr10:32216031	ARHGAP12	0.42	7.3	0.37	2.15e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs11687659	0.515	rs6725611	chr2:191579025	G/A	cg11845111	chr2:191398756	TMEM194B	-0.44	-5.93	-0.31	7.41e-9	Immature fraction of reticulocytes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24848557	chr11:94227106	MRE11A;ANKRD49	-0.41	-6.04	-0.31	4.22e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4343996	0.521	rs10246895	chr7:3427874	A/G	cg21248987	chr7:3385318	SDK1	0.38	6.4	0.33	5.23e-10	Motion sickness;
LUSC	cis	rs4343996	1.000	rs12537549	chr7:3361023	T/G	cg21248987	chr7:3385318	SDK1	-0.39	-6.62	-0.34	1.39e-10	Motion sickness;
LUSC	cis	rs10203711	0.932	rs4502365	chr2:239597792	G/A	cg14580085	chr2:239553406	NA	0.42	7.15	0.36	5.56e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.51	-0.46	3.89e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg03340356	chr1:67600835	NA	0.43	6.65	0.34	1.2e-10	Psoriasis;
LUSC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg14895029	chr7:2775587	GNA12	-0.37	-5.76	-0.3	1.91e-8	Height;
LUSC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg24250549	chr1:154909240	PMVK	0.64	10.73	0.51	2.82e-23	Prostate cancer;
LUSC	cis	rs28655083	0.509	rs285020	chr16:77099517	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.39	6.25	0.32	1.28e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg04871131	chr7:94954202	PON1	-0.4	-6.16	-0.32	2.08e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6546886	0.917	rs11884748	chr2:74248451	A/C	cg14702570	chr2:74259524	NA	-0.3	-5.65	-0.3	3.37e-8	Dialysis-related mortality;
LUSC	cis	rs7605827	0.930	rs6723785	chr2:15688314	T/C	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.82e-16	Educational attainment (years of education);
LUSC	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.94	0.51	4.97e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg11608241	chr8:8085544	FLJ10661	0.39	5.65	0.3	3.53e-8	Joint mobility (Beighton score);
LUSC	cis	rs1865721	0.682	rs35282535	chr18:73141206	G/A	cg26385618	chr18:73139727	C18orf62	-0.48	-8.98	-0.44	2.07e-17	Intelligence;
LUSC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg09034736	chr1:150693464	HORMAD1	0.44	6.16	0.32	2.05e-9	Melanoma;
LUSC	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	1.01	20.87	0.75	1.73e-62	Diastolic blood pressure;
LUSC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg00074818	chr8:8560427	CLDN23	0.57	9.8	0.47	4.22e-20	Obesity-related traits;
LUSC	cis	rs2348418	0.715	rs7971717	chr12:28723020	T/C	cg13890972	chr12:28721907	NA	-0.39	-6.89	-0.35	2.81e-11	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg22467129	chr15:76604101	ETFA	-0.43	-6.85	-0.35	3.54e-11	Blood metabolite levels;
LUSC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.87	0.31	1.04e-8	Menopause (age at onset);
LUSC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg23625390	chr15:77176239	SCAPER	-0.66	-10.08	-0.48	4.87e-21	Blood metabolite levels;
LUSC	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg16898833	chr6:26189333	HIST1H4D	0.64	6.12	0.32	2.66e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-10.72	-0.51	3.17e-23	Alcohol dependence;
LUSC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg23283495	chr1:209979779	IRF6	0.65	9.55	0.46	2.85e-19	Cleft lip with or without cleft palate;
LUSC	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.86	14.72	0.63	3.93e-38	Bladder cancer;
LUSC	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.78	11.81	0.54	3.85e-27	Heart rate;
LUSC	trans	rs459571	0.920	rs433402	chr9:136898627	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-12.03	-0.55	6.18e-28	Platelet distribution width;
LUSC	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-10.62	-0.5	6.94e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs708547	1.000	rs2412770	chr4:57794660	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	6.81	0.35	4.47e-11	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	9.64	0.47	1.43e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg05373962	chr22:49881684	NA	-0.43	-10.42	-0.5	3.23e-22	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.91	0.7	9.06e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg07703079	chr11:430292	ANO9	0.6	6.54	0.34	2.28e-10	Body mass index;
LUSC	cis	rs34734847	0.898	rs696339	chr12:121169436	A/T	cg21892295	chr12:121157589	UNC119B	-0.34	-5.99	-0.31	5.41e-9	Mean corpuscular volume;
LUSC	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg27147174	chr7:100797783	AP1S1	0.55	8.57	0.42	3.84e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg04025307	chr7:1156635	C7orf50	0.45	7.07	0.36	9.06e-12	Longevity;Endometriosis;
LUSC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg12463550	chr7:65579703	CRCP	0.52	7.54	0.38	4.45e-13	Aortic root size;
LUSC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg12963246	chr6:28129442	ZNF389	0.4	5.99	0.31	5.44e-9	Cardiac Troponin-T levels;
LUSC	cis	rs6693567	0.565	rs1313569	chr1:150344171	G/A	cg15654264	chr1:150340011	RPRD2	0.46	7.35	0.37	1.5e-12	Migraine;
LUSC	cis	rs9303542	0.625	rs8066613	chr17:46583520	T/A	cg09704116	chr17:46666958	LOC404266	-0.36	-6.54	-0.34	2.26e-10	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg12615879	chr12:58013172	SLC26A10	-0.29	-6.1	-0.32	2.92e-9	Multiple sclerosis;
LUSC	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg00857998	chr1:205179979	DSTYK	-0.6	-9.12	-0.45	7.46e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10465746	0.746	rs6663949	chr1:84452853	T/C	cg10977910	chr1:84465055	TTLL7	0.44	6.43	0.33	4.32e-10	Obesity-related traits;
LUSC	cis	rs7091068	0.616	rs1890657	chr10:95506087	G/A	cg20715218	chr10:95462985	C10orf4	0.61	6.58	0.34	1.85e-10	Urinary tract infection frequency;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06748584	chr17:79520919	C17orf70	-0.45	-6.25	-0.32	1.24e-9	Hepatitis;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg18008202	chr2:131100479	IMP4;CCDC115	0.48	6.0	0.31	5.16e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1775715	0.737	rs2151047	chr10:32102110	G/A	cg03015672	chr10:32216066	ARHGAP12	0.35	6.15	0.32	2.23e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg15654264	chr1:150340011	RPRD2	-0.66	-11.25	-0.52	4.09e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.72	-0.3	2.37e-8	Depression;
LUSC	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg05084668	chr3:125655381	ALG1L	-0.79	-11.95	-0.55	1.26e-27	Blood pressure (smoking interaction);
LUSC	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg06636001	chr8:8085503	FLJ10661	0.54	8.21	0.41	4.82e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg11764359	chr7:65958608	NA	-0.51	-6.57	-0.34	1.94e-10	Aortic root size;
LUSC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg25039879	chr17:56429692	SUPT4H1	0.69	9.08	0.45	9.49e-18	Cognitive test performance;
LUSC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg22963979	chr7:1858916	MAD1L1	-0.53	-8.24	-0.41	3.94e-15	Schizophrenia;
LUSC	trans	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.35	0.49	5.71e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7589342	0.929	rs6725519	chr2:106445209	A/G	cg16077055	chr2:106428750	NCK2	-0.35	-6.7	-0.34	9.06e-11	Addiction;
LUSC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg04017836	chr7:65315216	NA	-0.37	-5.95	-0.31	6.75e-9	Height;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15132342	chr17:72978526	NA	0.71	5.95	0.31	6.67e-9	Cognitive performance;
LUSC	cis	rs11650494	0.710	rs11654557	chr17:47390136	A/G	cg08112188	chr17:47440006	ZNF652	1.22	10.72	0.51	2.99e-23	Prostate cancer;
LUSC	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg24562669	chr7:97807699	LMTK2	0.47	8.29	0.41	2.73e-15	Breast cancer;
LUSC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-1.02	-15.49	-0.65	3.7e-41	Initial pursuit acceleration;
LUSC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.34	-0.56	4.44e-29	Rheumatoid arthritis;
LUSC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	9.45	0.46	5.99e-19	Multiple sclerosis;
LUSC	cis	rs12493885	0.725	rs73158447	chr3:153729792	A/G	cg17054900	chr3:154042577	DHX36	-0.68	-7.03	-0.36	1.2e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg14416269	chr4:6271139	WFS1	0.54	11.38	0.53	1.35e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg22166914	chr1:53195759	ZYG11B	0.56	9.12	0.45	6.96e-18	Monocyte count;
LUSC	cis	rs506338	0.517	rs471618	chr11:64465403	T/C	cg19131476	chr11:64387923	NRXN2	0.35	7.64	0.39	2.39e-13	Body mass index;Urate levels;
LUSC	trans	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.58	0.34	1.82e-10	Resting heart rate;
LUSC	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg06937882	chr20:24974362	C20orf3	-0.43	-7.41	-0.38	1.04e-12	Blood protein levels;
LUSC	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-7.66	-0.39	2.01e-13	Schizophrenia;
LUSC	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.61	-0.34	1.48e-10	Retinal vascular caliber;
LUSC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg20295408	chr7:1910781	MAD1L1	-0.42	-5.78	-0.3	1.69e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-14.42	-0.62	5.61e-37	Dental caries;
LUSC	cis	rs9905704	0.918	rs385793	chr17:56730593	G/A	cg12560992	chr17:57184187	TRIM37	0.54	7.72	0.39	1.36e-13	Testicular germ cell tumor;
LUSC	cis	rs11785400	0.793	rs12546978	chr8:143750205	T/A	cg24634471	chr8:143751801	JRK	-0.49	-7.01	-0.36	1.32e-11	Schizophrenia;
LUSC	cis	rs10788264	0.504	rs4751883	chr10:124018027	A/C	cg09507567	chr10:124027408	NA	0.53	9.3	0.45	1.91e-18	Total body bone mineral density;
LUSC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.6	9.34	0.46	1.39e-18	Blood protein levels;
LUSC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.24	0.32	1.32e-9	Personality dimensions;
LUSC	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg15704280	chr7:45808275	SEPT13	0.81	7.73	0.39	1.27e-13	Axial length;
LUSC	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg20701182	chr2:24300061	SF3B14	0.55	5.99	0.31	5.31e-9	Lymphocyte counts;
LUSC	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	0.96	13.34	0.59	8.01e-33	Primary sclerosing cholangitis;
LUSC	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg20302533	chr7:39170763	POU6F2	0.49	8.19	0.41	5.77e-15	IgG glycosylation;
LUSC	cis	rs72792276	1.000	rs72792276	chr5:127364126	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.9	7.8	0.39	7.94e-14	Red cell distribution width;
LUSC	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg12559939	chr2:27858050	GPN1	0.39	6.01	0.31	4.83e-9	Oral cavity cancer;
LUSC	cis	rs926392	0.799	rs742274	chr20:37680944	T/C	cg27552599	chr20:37590471	DHX35	0.35	6.14	0.32	2.33e-9	Dialysis-related mortality;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25010622	chr20:32700257	EIF2S2	-0.5	-6.03	-0.31	4.39e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1775715	0.737	rs2778661	chr10:32159191	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.76	0.35	6.02e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	13.45	0.59	2.9e-33	Monocyte percentage of white cells;
LUSC	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.65	-0.3	3.39e-8	IgG glycosylation;
LUSC	cis	rs7189233	0.955	rs72801817	chr16:53474568	C/T	cg09728985	chr16:53543985	NA	-0.33	-6.05	-0.31	3.84e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg09796270	chr17:17721594	SREBF1	0.4	7.07	0.36	9.07e-12	Total body bone mineral density;
LUSC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg08088566	chr11:430123	ANO9	0.6	7.04	0.36	1.09e-11	Body mass index;
LUSC	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.15	0.52	9.05e-25	Colorectal cancer;
LUSC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.88	-18.04	-0.7	2.96e-51	Intelligence (multi-trait analysis);
LUSC	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.37	5.68	0.3	2.9e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26314531	chr2:26401878	FAM59B	0.7	9.08	0.44	9.65e-18	Gut microbiome composition (summer);
LUSC	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg26102564	chr10:131424627	MGMT	-0.38	-5.82	-0.3	1.36e-8	Response to temozolomide;
LUSC	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg15485101	chr11:133734466	NA	0.39	7.36	0.37	1.46e-12	Childhood ear infection;
LUSC	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg12473912	chr3:136751656	NA	0.39	6.89	0.35	2.86e-11	Neuroticism;
LUSC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11644478	chr21:40555479	PSMG1	-0.63	-10.21	-0.49	1.75e-21	Cognitive function;
LUSC	cis	rs3784262	0.528	rs6493979	chr15:58338052	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.01	-0.31	4.84e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-9.19	-0.45	4.43e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg22800045	chr5:56110881	MAP3K1	-0.49	-6.38	-0.33	5.82e-10	Coronary artery disease;
LUSC	cis	rs2742417	1.000	rs2742447	chr3:45763977	C/T	cg04837898	chr3:45731254	SACM1L	-0.34	-5.69	-0.3	2.85e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1784581	0.651	rs1784588	chr6:162390027	T/A	cg17173639	chr6:162384350	PARK2	-0.68	-12.36	-0.56	3.68e-29	Itch intensity from mosquito bite;
LUSC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg15790184	chr11:494944	RNH1	0.51	5.9	0.31	9.04e-9	Body mass index;
LUSC	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg01420254	chr6:26195488	NA	-0.69	-7.28	-0.37	2.38e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg03354898	chr7:1950403	MAD1L1	-0.36	-7.06	-0.36	9.84e-12	Bipolar disorder and schizophrenia;
LUSC	trans	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg01620082	chr3:125678407	NA	-0.69	-7.05	-0.36	1.06e-11	Breast cancer;
LUSC	trans	rs12310956	0.510	rs7301767	chr12:33886529	A/T	cg26384229	chr12:38710491	ALG10B	0.56	8.72	0.43	1.29e-16	Morning vs. evening chronotype;
LUSC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.79	12.88	0.58	4.22e-31	Aortic root size;
LUSC	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg24558204	chr6:135376177	HBS1L	-0.6	-9.36	-0.46	1.22e-18	Red blood cell count;
LUSC	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg18357645	chr12:58087776	OS9	0.5	7.51	0.38	5.45e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs62400317	0.762	rs857601	chr6:44805214	G/T	cg20913747	chr6:44695427	NA	0.44	6.95	0.36	1.94e-11	Total body bone mineral density;
LUSC	cis	rs1034435	0.755	rs5768679	chr22:48892847	T/G	cg05992904	chr22:48892994	FAM19A5	-0.41	-8.16	-0.41	6.85e-15	Late-onset Alzheimer's disease;
LUSC	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg12559939	chr2:27858050	GPN1	-0.39	-6.03	-0.31	4.25e-9	Oral cavity cancer;
LUSC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg20790798	chr5:1857306	NA	-0.45	-7.71	-0.39	1.43e-13	Cardiovascular disease risk factors;
LUSC	cis	rs500891	0.525	rs13209274	chr6:84052966	C/T	cg08257003	chr6:84140564	ME1	0.32	7.08	0.36	8.45e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg25767906	chr1:53392781	SCP2	0.55	9.64	0.47	1.47e-19	Monocyte count;
LUSC	cis	rs72781680	0.716	rs2675363	chr2:24080003	G/C	cg08917208	chr2:24149416	ATAD2B	0.6	6.91	0.35	2.51e-11	Lymphocyte counts;
LUSC	cis	rs6977660	1.000	rs6977660	chr7:19805480	C/T	cg05791153	chr7:19748676	TWISTNB	0.55	6.24	0.32	1.31e-9	Thyroid stimulating hormone;
LUSC	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg11568697	chr18:72916393	ZADH2	0.61	6.63	0.34	1.39e-10	Vascular endothelial growth factor levels;
LUSC	cis	rs11112613	0.648	rs11112635	chr12:106047112	A/G	cg03607813	chr12:105948248	NA	0.42	5.77	0.3	1.78e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg16447950	chr5:562315	NA	-0.6	-7.43	-0.38	9.17e-13	Obesity-related traits;
LUSC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg27432699	chr2:27873401	GPN1	-0.56	-8.34	-0.42	1.94e-15	Total body bone mineral density;
LUSC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg04450456	chr4:17643702	FAM184B	0.37	6.25	0.32	1.26e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.83	0.3	1.29e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg27494647	chr7:150038898	RARRES2	0.58	8.59	0.43	3.48e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg00852783	chr1:26633632	UBXN11	0.6	8.87	0.44	4.35e-17	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.5	-7.59	-0.38	3.2e-13	Menarche (age at onset);
LUSC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg10018233	chr7:150070692	REPIN1	0.39	6.76	0.35	6.1e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10189230	0.967	rs12613015	chr2:222356119	G/A	cg14652038	chr2:222343519	EPHA4	0.32	5.68	0.3	2.9e-8	Urate levels in lean individuals;
LUSC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg20742385	chr13:113633654	MCF2L	-0.31	-5.94	-0.31	7.21e-9	Systolic blood pressure;
LUSC	trans	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg09781936	chr22:19749961	TBX1	-0.34	-5.96	-0.31	6.46e-9	Inflammatory bowel disease;
LUSC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9815354	0.812	rs17284472	chr3:41996304	A/G	cg03022575	chr3:42003672	ULK4	-0.85	-8.81	-0.43	6.91e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2303282	0.716	rs2617848	chr16:56399835	T/C	cg00500540	chr16:56394104	NA	-0.44	-7.55	-0.38	4.1e-13	Breast cancer;
LUSC	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg11645453	chr3:52864694	ITIH4	-0.36	-8.46	-0.42	8.66e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg17971929	chr21:40555470	PSMG1	0.57	7.12	0.36	6.84e-12	Cognitive function;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13792025	chr7:66205470	RABGEF1	-0.4	-6.12	-0.32	2.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7560272	0.723	rs6744697	chr2:73765438	T/C	cg20560298	chr2:73613845	ALMS1	-0.49	-7.61	-0.38	2.86e-13	Schizophrenia;
LUSC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg13683864	chr3:40499215	RPL14	-0.99	-16.92	-0.68	7.92e-47	Renal cell carcinoma;
LUSC	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg24449463	chr1:168025552	DCAF6	-0.63	-9.51	-0.46	3.96e-19	Schizophrenia;
LUSC	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg18131467	chr2:239335373	ASB1	1.0	22.51	0.78	6.37e-69	Multiple system atrophy;
LUSC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg21724239	chr8:58056113	NA	0.8	8.55	0.42	4.58e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg25801113	chr15:45476975	SHF	-0.36	-7.18	-0.37	4.57e-12	Uric acid levels;
LUSC	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg15556689	chr8:8085844	FLJ10661	0.58	8.8	0.43	7.22e-17	Myopia (pathological);
LUSC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg04287289	chr16:89883240	FANCA	0.76	6.26	0.32	1.19e-9	Skin colour saturation;
LUSC	cis	rs2274273	0.710	rs67395212	chr14:55591939	T/A	cg04306507	chr14:55594613	LGALS3	0.48	9.43	0.46	6.89e-19	Protein biomarker;
LUSC	cis	rs4285028	0.898	rs73855476	chr3:121633412	A/G	cg11130432	chr3:121712080	ILDR1	-0.64	-9.81	-0.47	3.84e-20	Multiple sclerosis;
LUSC	cis	rs7215564	0.908	rs74000899	chr17:78653542	T/C	cg09596252	chr17:78655493	RPTOR	0.56	6.05	0.31	3.85e-9	Myopia (pathological);
LUSC	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg23625390	chr15:77176239	SCAPER	0.46	7.04	0.36	1.09e-11	Blood metabolite levels;
LUSC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg09034736	chr1:150693464	HORMAD1	0.51	7.51	0.38	5.57e-13	Tonsillectomy;
LUSC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.38	-0.33	5.93e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9811920	0.931	rs7629487	chr3:99860401	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.35	6.55	0.34	2.18e-10	Axial length;
LUSC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg05855489	chr10:104503620	C10orf26	-0.7	-10.18	-0.49	2.28e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9715521	0.677	rs11944208	chr4:59860652	G/A	cg11281224	chr4:60001000	NA	-0.51	-7.12	-0.36	6.72e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.76	-12.0	-0.55	8.09e-28	Menopause (age at onset);
LUSC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg20203395	chr5:56204925	C5orf35	-0.59	-8.41	-0.42	1.17e-15	Coronary artery disease;
LUSC	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg18753928	chr3:113234510	CCDC52	-0.54	-8.2	-0.41	5.19e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg24579218	chr15:68104479	NA	-0.39	-6.52	-0.34	2.61e-10	Obesity;
LUSC	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg24375607	chr4:120327624	NA	0.77	11.4	0.53	1.16e-25	Corneal astigmatism;
LUSC	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg26384229	chr12:38710491	ALG10B	0.46	6.74	0.35	6.95e-11	Morning vs. evening chronotype;
LUSC	cis	rs3812111	0.510	rs17077755	chr6:116592033	C/T	cg18828861	chr6:116576566	TSPYL4	0.39	6.8	0.35	4.8e-11	Age-related macular degeneration;
LUSC	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg08085267	chr17:45401833	C17orf57	-0.5	-7.25	-0.37	2.97e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs829883	0.867	rs1641640	chr12:98896017	A/G	cg25150519	chr12:98850993	NA	0.63	9.43	0.46	7.25e-19	Colorectal adenoma (advanced);
LUSC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-8.95	-0.44	2.51e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg04756594	chr16:24857601	SLC5A11	0.47	6.49	0.33	3.14e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg03146154	chr1:46216737	IPP	0.56	8.37	0.42	1.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-10.81	-0.51	1.44e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg03233332	chr7:66118400	NA	-0.4	-5.77	-0.3	1.83e-8	Aortic root size;
LUSC	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.44	-7.04	-0.36	1.09e-11	Height;
LUSC	cis	rs9398803	0.763	rs576049	chr6:126730543	T/G	cg19875578	chr6:126661172	C6orf173	0.43	6.27	0.32	1.11e-9	Male-pattern baldness;
LUSC	cis	rs4812048	0.602	rs59637156	chr20:57619618	T/C	cg14073986	chr20:57617431	SLMO2	0.88	9.56	0.46	2.65e-19	Mean platelet volume;
LUSC	cis	rs950881	0.601	rs11465705	chr2:103058810	T/G	cg20060108	chr2:102954350	IL1RL1	0.49	6.64	0.34	1.28e-10	Allergy;
LUSC	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.83	12.97	0.58	1.97e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08704250	chr15:31115839	NA	0.59	9.27	0.45	2.37e-18	Huntington's disease progression;
LUSC	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.57	10.5	0.5	1.84e-22	Bone mineral density;
LUSC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg06096015	chr1:231504339	EGLN1	0.56	10.06	0.48	5.82e-21	Hemoglobin concentration;
LUSC	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg15423357	chr2:25149977	NA	-0.37	-7.35	-0.37	1.55e-12	Body mass index in non-asthmatics;
LUSC	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg23649088	chr2:200775458	C2orf69	0.49	6.77	0.35	5.85e-11	Schizophrenia;
LUSC	trans	rs13011075	0.878	rs1542135	chr2:68620848	C/T	cg14221825	chr19:46271408	SIX5	0.43	6.21	0.32	1.57e-9	Mean corpuscular volume;
LUSC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg04450456	chr4:17643702	FAM184B	0.36	5.89	0.31	9.29e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg11887960	chr12:57824829	NA	0.55	6.62	0.34	1.48e-10	Lung disease severity in cystic fibrosis;
LUSC	trans	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.34	0.56	4.42e-29	Exhaled nitric oxide output;
LUSC	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.93	-0.48	1.58e-20	Total cholesterol levels;
LUSC	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg27284194	chr4:1044797	NA	0.52	8.59	0.43	3.38e-16	Recombination rate (males);
LUSC	cis	rs12545109	0.800	rs1837617	chr8:57417592	C/T	cg09654669	chr8:57350985	NA	-0.49	-6.5	-0.33	2.96e-10	Obesity-related traits;
LUSC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20135002	chr11:47629003	NA	0.49	7.8	0.39	8.06e-14	Subjective well-being;
LUSC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	0.59	9.36	0.46	1.22e-18	Breast cancer;
LUSC	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg25214090	chr10:38739885	LOC399744	0.54	8.05	0.4	1.44e-14	Corneal astigmatism;
LUSC	trans	rs11165623	0.792	rs9437609	chr1:96977961	A/C	cg10631902	chr5:14652156	NA	-0.46	-7.26	-0.37	2.74e-12	Hip circumference;Waist circumference;
LUSC	cis	rs4853525	0.859	rs6434424	chr2:191722126	A/C	cg11845111	chr2:191398756	TMEM194B	-0.4	-5.95	-0.31	6.95e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs2742417	0.967	rs2742426	chr3:45735901	A/G	cg09608765	chr3:45636137	LIMD1	-0.36	-7.05	-0.36	1.04e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.85	-15.75	-0.65	3.56e-42	Dental caries;
LUSC	cis	rs9840812	0.680	rs17252498	chr3:136014198	A/C	cg15507776	chr3:136538369	TMEM22	-0.45	-5.69	-0.3	2.77e-8	Fibrinogen levels;
LUSC	cis	rs9361491	0.657	rs7766318	chr6:79451515	A/C	cg05283184	chr6:79620031	NA	-0.32	-5.91	-0.31	8.65e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1322512	0.677	rs1744392	chr6:152936093	G/T	cg27316956	chr6:152958899	SYNE1	-0.35	-5.92	-0.31	7.84e-9	Tonometry;
LUSC	trans	rs979233	0.502	rs276253	chr5:42062844	T/G	cg07010552	chr17:7358735	CHRNB1	-0.42	-6.02	-0.31	4.47e-9	Systemic lupus erythematosus;
LUSC	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg04455712	chr21:45112962	RRP1B	0.44	8.19	0.41	5.71e-15	Mean corpuscular volume;
LUSC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg17376030	chr22:41985996	PMM1	0.51	6.35	0.33	7.03e-10	Vitiligo;
LUSC	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.81	0.54	3.97e-27	Cognitive ability;
LUSC	trans	rs2492906	0.556	rs2815499	chr10:28087006	C/T	cg06704170	chr2:85843078	USP39	-0.44	-6.04	-0.31	4.02e-9	Prostate-specific antigen levels (conditioned on lead SNPs);
LUSC	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.4	7.94	0.4	3.05e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg13939156	chr17:80058883	NA	-0.32	-6.38	-0.33	5.99e-10	Life satisfaction;
LUSC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg01416388	chr22:39784598	NA	-0.43	-7.17	-0.37	4.92e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-8.38	-0.42	1.5e-15	Morning vs. evening chronotype;
LUSC	cis	rs2180341	0.594	rs7738385	chr6:127777516	T/C	cg24812749	chr6:127587940	RNF146	0.54	7.45	0.38	8.1e-13	Breast cancer;
LUSC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.21	-13.94	-0.61	4.07e-35	Diabetic kidney disease;
LUSC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg04287289	chr16:89883240	FANCA	0.8	14.0	0.61	2.4e-35	Vitiligo;
LUSC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.52	-0.38	5.1e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11238505	chr8:145691776	CYHR1;KIFC2	-0.39	-6.16	-0.32	2.15e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	12.57	0.57	6.26e-30	Cognitive test performance;
LUSC	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg23422044	chr7:1970798	MAD1L1	0.62	6.93	0.35	2.17e-11	Bipolar disorder;
LUSC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19346786	chr7:2764209	NA	-0.48	-7.88	-0.4	4.61e-14	Height;
LUSC	cis	rs1982963	0.627	rs8020559	chr14:52490690	T/G	cg10843707	chr14:52510701	NID2	0.46	6.24	0.32	1.29e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg26528668	chr16:1614120	IFT140	0.44	7.19	0.37	4.24e-12	Coronary artery disease;
LUSC	cis	rs6087990	0.669	rs2424929	chr20:31389518	A/G	cg13636640	chr20:31349939	DNMT3B	0.92	18.94	0.72	7.43e-55	Ulcerative colitis;
LUSC	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg25566285	chr7:158114605	PTPRN2	-0.33	-6.23	-0.32	1.43e-9	Calcium levels;
LUSC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg11764359	chr7:65958608	NA	-0.78	-12.7	-0.57	2.07e-30	Aortic root size;
LUSC	cis	rs77741769	0.571	rs3809313	chr12:121329967	T/C	cg02419362	chr12:121203948	SPPL3	0.46	8.71	0.43	1.42e-16	Mean corpuscular volume;
LUSC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4343996	0.837	rs7802250	chr7:3475820	G/C	cg21248987	chr7:3385318	SDK1	0.36	5.91	0.31	8.33e-9	Motion sickness;
LUSC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg16339924	chr4:17578868	LAP3	0.56	8.4	0.42	1.32e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18932078	chr1:2524107	MMEL1	-0.32	-7.2	-0.37	4.05e-12	Ulcerative colitis;
LUSC	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.26	0.45	2.61e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg06219351	chr7:158114137	PTPRN2	-0.54	-9.82	-0.47	3.58e-20	Calcium levels;
LUSC	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	0.96	18.11	0.7	1.53e-51	Bone mineral density;
LUSC	cis	rs11645898	0.687	rs11075919	chr16:72106906	T/C	cg14768367	chr16:72042858	DHODH	-0.51	-5.99	-0.31	5.42e-9	Blood protein levels;
LUSC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.44	-0.33	4.2e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.27	0.52	3.49e-25	Menopause (age at onset);
LUSC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg16850897	chr7:100343110	ZAN	-0.6	-8.39	-0.42	1.38e-15	Other erythrocyte phenotypes;
LUSC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg13560548	chr3:10150139	C3orf24	-0.48	-6.83	-0.35	4.03e-11	Alzheimer's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10509185	chr10:134504666	INPP5A	0.52	7.03	0.36	1.19e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs72960926	0.744	rs11756283	chr6:74901380	T/C	cg03266952	chr6:74778945	NA	-0.76	-6.05	-0.31	3.85e-9	Metabolite levels (MHPG);
LUSC	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	trans	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg17830980	chr10:43048298	ZNF37B	-0.43	-6.84	-0.35	3.77e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.9e-20	Migraine;Coronary artery disease;
LUSC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.19	-13.56	-0.6	1.16e-33	Diabetic kidney disease;
LUSC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg08999081	chr20:33150536	PIGU	-0.42	-7.88	-0.4	4.68e-14	Coronary artery disease;
LUSC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12667521	chr19:29218732	NA	0.63	9.05	0.44	1.18e-17	Methadone dose in opioid dependence;
LUSC	cis	rs2324229	0.828	rs1180202	chr6:83957723	A/C	cg08257003	chr6:84140564	ME1	0.29	6.84	0.35	3.69e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.15	-0.36	5.48e-12	Bipolar disorder;
LUSC	cis	rs35883536	0.528	rs1542837	chr1:101029768	T/C	cg09408571	chr1:101003634	GPR88	0.31	6.12	0.32	2.63e-9	Monocyte count;
LUSC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg17554472	chr22:41940697	POLR3H	0.47	5.84	0.3	1.27e-8	Vitiligo;
LUSC	cis	rs2963155	0.518	rs72801029	chr5:142625806	T/C	cg17617527	chr5:142782415	NR3C1	0.8	8.79	0.43	8.12e-17	Breast cancer;
LUSC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg16325326	chr1:53192061	ZYG11B	0.83	15.05	0.64	1.91e-39	Monocyte count;
LUSC	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg18806716	chr10:30721971	MAP3K8	-0.61	-9.8	-0.47	4.27e-20	Inflammatory bowel disease;
LUSC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.76	-0.39	1.02e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs7923609	0.811	rs12245367	chr10:65321464	C/T	cg01631684	chr10:65280961	REEP3	0.4	5.84	0.3	1.22e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs629535	0.590	rs55988608	chr8:70133619	A/G	cg21567404	chr3:27674614	NA	-0.94	-13.6	-0.6	7.7e-34	Dupuytren's disease;
LUSC	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg24296786	chr1:45957014	TESK2	0.49	7.29	0.37	2.28e-12	High light scatter reticulocyte count;
LUSC	cis	rs2262909	0.849	rs10420483	chr19:22190378	A/G	cg11619707	chr19:22235551	ZNF257	-0.38	-5.65	-0.3	3.41e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg03886242	chr7:26192032	NFE2L3	0.39	6.28	0.32	1.06e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1847202	0.859	rs13068268	chr3:72938132	G/A	cg25664220	chr3:72788482	NA	-0.39	-7.05	-0.36	1.06e-11	Motion sickness;
LUSC	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg00484396	chr16:3507460	NAT15	-0.41	-6.78	-0.35	5.3e-11	Body mass index (adult);
LUSC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg05147244	chr20:61493195	TCFL5	-0.69	-6.09	-0.32	3.09e-9	Obesity-related traits;
LUSC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg14552801	chr7:65878734	NA	0.38	5.91	0.31	8.41e-9	Aortic root size;
LUSC	trans	rs853679	0.599	rs188015	chr6:27877446	T/A	cg01620082	chr3:125678407	NA	-0.68	-7.04	-0.36	1.1e-11	Depression;
LUSC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.69	-12.38	-0.56	3.03e-29	Aortic root size;
LUSC	cis	rs1483890	0.962	rs1483891	chr3:69410416	G/C	cg22125112	chr3:69402811	FRMD4B	0.39	5.8	0.3	1.5e-8	Resting heart rate;
LUSC	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-0.65	-8.23	-0.41	4.17e-15	Pulmonary function decline;
LUSC	cis	rs7605827	0.930	rs12995845	chr2:15520539	C/T	cg19274914	chr2:15703543	NA	0.45	8.75	0.43	1.07e-16	Educational attainment (years of education);
LUSC	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg12463550	chr7:65579703	CRCP	0.52	7.63	0.39	2.55e-13	Aortic root size;
LUSC	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg08601574	chr20:25228251	PYGB	0.41	6.4	0.33	5.31e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs35995292	0.500	rs6945239	chr7:38932208	C/T	cg19327137	chr7:38886074	VPS41	0.55	10.26	0.49	1.15e-21	Subjective well-being (multi-trait analysis);
LUSC	cis	rs6982240	0.569	rs6992286	chr8:142279412	G/A	cg00131261	chr8:142287264	NA	-0.39	-6.74	-0.35	7.11e-11	Tonsillectomy;
LUSC	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg24578937	chr1:2090814	PRKCZ	-0.6	-13.79	-0.6	1.44e-34	Height;
LUSC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	0.92	17.04	0.68	2.81e-47	Heart rate;
LUSC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg02079420	chr8:82753780	SNX16	0.37	5.67	0.3	3.03e-8	Diastolic blood pressure;
LUSC	cis	rs2742417	0.904	rs2251021	chr3:45796657	A/G	cg09608765	chr3:45636137	LIMD1	0.32	6.06	0.31	3.69e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.24	0.41	4.04e-15	Resting heart rate;
LUSC	cis	rs7481584	0.924	rs4758502	chr11:2998461	C/T	cg08508325	chr11:3079039	CARS	0.31	5.96	0.31	6.4e-9	Calcium levels;
LUSC	cis	rs1957429	0.901	rs3813423	chr14:65347475	C/A	cg23373153	chr14:65346875	NA	1.07	12.89	0.58	3.85e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.45	-0.42	9.23e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7575217	0.588	rs7572457	chr2:101675808	A/G	cg23907051	chr2:101730305	TBC1D8	0.26	6.61	0.34	1.53e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg18230493	chr5:56204884	C5orf35	-0.53	-8.5	-0.42	6.39e-16	Coronary artery disease;
LUSC	trans	rs72674100	1.000	rs2865759	chr4:97992416	C/T	cg00855990	chr1:18959354	PAX7	-0.6	-6.57	-0.34	1.94e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg25036284	chr2:26402008	FAM59B	-0.68	-9.38	-0.46	1.06e-18	Gut microbiome composition (summer);
LUSC	cis	rs1451375	0.669	rs59086818	chr7:50653830	G/A	cg18232548	chr7:50535776	DDC	0.51	7.61	0.38	2.85e-13	Malaria;
LUSC	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.35	0.33	7.03e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg05802129	chr4:122689817	NA	-0.52	-8.8	-0.43	7.4e-17	Type 2 diabetes;
LUSC	cis	rs1506636	1.000	rs646753	chr7:123401237	G/T	cg03229431	chr7:123269106	ASB15	0.65	10.7	0.51	3.66e-23	Plateletcrit;Platelet count;
LUSC	cis	rs4664308	0.618	rs3749117	chr2:160885442	T/C	cg03641300	chr2:160917029	PLA2R1	-0.47	-7.7	-0.39	1.51e-13	Idiopathic membranous nephropathy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08849938	chr19:57791810	ZNF460	-0.4	-6.04	-0.31	4.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg21724239	chr8:58056113	NA	0.54	6.6	0.34	1.63e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.59	0.6	8.62e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.74	-10.9	-0.51	7.23e-24	Glomerular filtration rate;
LUSC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14893161	chr1:205819251	PM20D1	0.59	10.03	0.48	7.08e-21	Menarche (age at onset);
LUSC	cis	rs7923609	0.967	rs4454603	chr10:65012750	C/T	cg01631684	chr10:65280961	REEP3	-0.42	-6.55	-0.34	2.14e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.72	9.27	0.45	2.28e-18	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg24558204	chr6:135376177	HBS1L	0.68	10.47	0.5	2.3e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18099408	chr3:52552593	STAB1	-0.4	-6.92	-0.35	2.26e-11	Bipolar disorder;
LUSC	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg24331049	chr13:111365604	ING1	0.58	7.4	0.38	1.12e-12	Coronary artery disease;
LUSC	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg22508957	chr16:3507546	NAT15	-0.4	-6.28	-0.32	1.06e-9	Body mass index (adult);
LUSC	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.75	-0.43	1.04e-16	Uric acid levels;
LUSC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19346786	chr7:2764209	NA	-0.39	-6.9	-0.35	2.63e-11	Height;
LUSC	cis	rs10465746	0.935	rs2389647	chr1:84403041	C/T	cg10977910	chr1:84465055	TTLL7	0.41	5.94	0.31	7.32e-9	Obesity-related traits;
LUSC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg14552801	chr7:65878734	NA	0.38	5.84	0.3	1.23e-8	Aortic root size;
LUSC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-11.79	-0.54	4.57e-27	Monocyte count;
LUSC	cis	rs2303282	0.700	rs35626903	chr16:56431613	A/G	cg00500540	chr16:56394104	NA	-0.39	-6.7	-0.34	8.91e-11	Breast cancer;
LUSC	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg05580060	chr16:74700937	RFWD3	0.41	5.71	0.3	2.51e-8	Testicular germ cell tumor;
LUSC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg12310025	chr6:25882481	NA	0.6	10.04	0.48	6.62e-21	Blood metabolite levels;
LUSC	cis	rs897080	0.552	rs1067377	chr2:44648239	T/G	cg00619915	chr2:44497795	NA	-0.42	-6.03	-0.31	4.46e-9	Height;
LUSC	cis	rs360798	0.532	rs13013218	chr2:63011671	C/T	cg17519650	chr2:63277830	OTX1	-0.51	-7.3	-0.37	2.15e-12	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.7	0.3	2.64e-8	Menopause (age at onset);
LUSC	cis	rs79911532	0.515	rs79131789	chr7:75756463	C/A	cg03592824	chr7:75666768	STYXL1	0.67	6.37	0.33	6.32e-10	Mononucleosis;
LUSC	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg22782873	chr19:19639568	YJEFN3	-0.53	-6.45	-0.33	3.94e-10	Bipolar disorder;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg19019804	chr17:72919384	OTOP2;USH1G	-0.48	-6.3	-0.33	9.16e-10	Cognitive function;Information processing speed;
LUSC	trans	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg04995722	chr7:26192034	NFE2L3	-0.43	-6.59	-0.34	1.68e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg07828340	chr4:882639	GAK	0.95	10.1	0.48	4.07e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg11247378	chr22:39784982	NA	0.63	11.75	0.54	6.53e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-9.65	-0.47	1.39e-19	Morning vs. evening chronotype;
LUSC	cis	rs113835537	0.529	rs57634456	chr11:66250838	A/C	cg24851651	chr11:66362959	CCS	0.54	8.1	0.41	1.06e-14	Airway imaging phenotypes;
LUSC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg03929089	chr4:120376271	NA	-0.94	-16.2	-0.66	5.86e-44	Height;
LUSC	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg00509249	chr6:109615579	CCDC162	0.32	5.73	0.3	2.28e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-0.93	-18.73	-0.72	5.09e-54	Dental caries;
LUSC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	9.05	0.44	1.21e-17	Mean platelet volume;
LUSC	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg09877947	chr5:131593287	PDLIM4	0.44	7.3	0.37	2.12e-12	Blood metabolite levels;
LUSC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg13683864	chr3:40499215	RPL14	1.07	21.28	0.76	4.17e-64	Renal cell carcinoma;
LUSC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg07167872	chr1:205819463	PM20D1	-0.46	-6.92	-0.35	2.37e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg08999081	chr20:33150536	PIGU	0.42	7.24	0.37	3.07e-12	Coronary artery disease;
LUSC	trans	rs11935423	0.778	rs11933937	chr4:100489238	A/G	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.01	-0.31	4.77e-9	Gut microbiome composition (summer);
LUSC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-1.03	-19.85	-0.74	1.79e-58	Height;
LUSC	cis	rs654950	0.806	rs1815257	chr1:42041479	A/C	cg06885757	chr1:42089581	HIVEP3	-0.43	-8.67	-0.43	1.85e-16	Airway imaging phenotypes;
LUSC	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg20503657	chr10:835505	NA	-0.47	-6.49	-0.33	3.01e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg25566285	chr7:158114605	PTPRN2	-0.32	-6.1	-0.32	2.92e-9	Calcium levels;
LUSC	cis	rs6500395	0.928	rs723807	chr16:48691443	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3925075	0.833	rs11641202	chr16:31330161	A/G	cg02846316	chr16:31340340	ITGAM	0.33	5.95	0.31	6.84e-9	IgA nephropathy;
LUSC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg26338869	chr17:61819248	STRADA	0.41	5.9	0.31	8.69e-9	Prudent dietary pattern;
LUSC	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg21100191	chr22:23484243	RTDR1	0.87	14.61	0.62	1.03e-37	Bone mineral density;
LUSC	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg26384229	chr12:38710491	ALG10B	0.5	7.2	0.37	3.91e-12	Morning vs. evening chronotype;
LUSC	cis	rs2637266	0.935	rs2579751	chr10:78339890	G/A	cg18941641	chr10:78392320	NA	0.36	6.51	0.34	2.69e-10	Pulmonary function;
LUSC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.97	-16.61	-0.67	1.39e-45	Body mass index;
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg24503407	chr1:205819492	PM20D1	0.91	17.03	0.68	2.96e-47	Menarche (age at onset);
LUSC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg22618164	chr12:122356400	WDR66	0.62	9.43	0.46	6.98e-19	Mean corpuscular volume;
LUSC	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.85	-0.35	3.57e-11	Monocyte percentage of white cells;
LUSC	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg03599575	chr15:90893182	GABARAPL3	-0.34	-5.69	-0.3	2.8e-8	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs4474465	0.920	rs4474466	chr11:78204406	C/T	cg27205649	chr11:78285834	NARS2	0.51	5.91	0.31	8.55e-9	Alzheimer's disease (survival time);
LUSC	cis	rs713477	1.000	rs12893964	chr14:55912268	T/C	cg13175173	chr14:55914753	NA	-0.3	-6.35	-0.33	6.91e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.03	-0.31	4.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.26	-0.37	2.65e-12	Bipolar disorder;
LUSC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-11.72	-0.54	8.03e-27	Systemic lupus erythematosus;
LUSC	cis	rs17092148	1.000	rs11699062	chr20:33400379	A/T	cg16810054	chr20:33298113	TP53INP2	0.45	6.77	0.35	5.85e-11	Neuroticism;
LUSC	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg13755796	chr4:20253514	NA	-0.42	-6.51	-0.34	2.77e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg17691542	chr6:26056736	HIST1H1C	0.51	7.63	0.39	2.51e-13	Height;
LUSC	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg24112000	chr20:60950667	NA	0.36	6.82	0.35	4.3e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs12760731	0.720	rs16852717	chr1:178309723	T/C	cg00404053	chr1:178313656	RASAL2	0.56	6.1	0.32	2.98e-9	Obesity-related traits;
LUSC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs738322	0.511	rs2267370	chr22:38576826	G/A	cg25457927	chr22:38595422	NA	-0.38	-7.23	-0.37	3.36e-12	Cutaneous nevi;
LUSC	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.03e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs96067	0.711	rs272811	chr1:36634414	G/A	cg24686825	chr1:36642396	MAP7D1	-0.72	-11.26	-0.52	3.66e-25	Corneal structure;
LUSC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg02269571	chr22:50332266	NA	-0.59	-8.72	-0.43	1.31e-16	Schizophrenia;
LUSC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg23625390	chr15:77176239	SCAPER	0.46	6.85	0.35	3.54e-11	Blood metabolite levels;
LUSC	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	6.82	0.35	4.36e-11	Height;
LUSC	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg01509843	chr8:143695822	ARC	0.39	5.91	0.31	8.32e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7937682	0.564	rs9633937	chr11:111372799	C/T	cg09085632	chr11:111637200	PPP2R1B	0.47	6.11	0.32	2.75e-9	Primary sclerosing cholangitis;
LUSC	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg04362960	chr10:104952993	NT5C2	0.59	9.34	0.46	1.42e-18	Arsenic metabolism;
LUSC	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-6.62	-0.34	1.47e-10	Blood protein levels;
LUSC	cis	rs2976388	1.000	rs2976392	chr8:143762932	G/A	cg17252645	chr8:143867129	LY6D	-0.36	-6.31	-0.33	9.04e-10	Urinary tract infection frequency;
LUSC	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg12179176	chr11:130786555	SNX19	0.77	12.07	0.55	4.21e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg07701084	chr6:150067640	NUP43	0.57	8.82	0.43	6.57e-17	Lung cancer;
LUSC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg00431813	chr7:1051703	C7orf50	-0.49	-8.17	-0.41	6.57e-15	Longevity;Endometriosis;
LUSC	cis	rs1005224	0.926	rs12892551	chr14:76159902	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.64	-8.69	-0.43	1.66e-16	Large artery stroke;
LUSC	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.71	-0.6	2.98e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg10018233	chr7:150070692	REPIN1	0.4	7.22	0.37	3.51e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1385374	0.858	rs12321643	chr12:129302867	A/T	cg09035930	chr12:129282057	SLC15A4	-0.61	-6.56	-0.34	2.11e-10	Systemic lupus erythematosus;
LUSC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg07701084	chr6:150067640	NUP43	0.57	8.87	0.44	4.47e-17	Lung cancer;
LUSC	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg05340658	chr4:99064831	C4orf37	0.6	8.9	0.44	3.74e-17	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04865715	chr14:92573100	ATXN3	0.45	6.16	0.32	2.04e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.99	0.36	1.51e-11	Morning vs. evening chronotype;
LUSC	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg01528321	chr10:82214614	TSPAN14	-1.22	-16.16	-0.66	8.1e-44	Post bronchodilator FEV1;
LUSC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg03894339	chr8:19674705	INTS10	0.58	7.79	0.39	8.28e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22590775	chr19:49891494	CCDC155	-0.56	-7.36	-0.37	1.46e-12	Multiple sclerosis;
LUSC	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.4	-0.38	1.12e-12	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04050850	chr2:219536800	STK36;RNF25	-0.49	-6.43	-0.33	4.49e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.31e-41	Bladder cancer;
LUSC	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg25237894	chr2:233734115	C2orf82	0.36	6.13	0.32	2.43e-9	Coronary artery disease;
LUSC	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.31e-11	Response to antipsychotic treatment;
LUSC	cis	rs977987	0.806	rs8050059	chr16:75388731	C/T	cg03315344	chr16:75512273	CHST6	0.51	9.54	0.46	3.04e-19	Dupuytren's disease;
LUSC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg09796270	chr17:17721594	SREBF1	-0.42	-7.32	-0.37	1.85e-12	Total body bone mineral density;
LUSC	cis	rs54211	1.000	rs54211	chr22:39687484	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.57	5.73	0.3	2.2e-8	Sudden cardiac arrest;
LUSC	cis	rs3768617	0.811	rs10911200	chr1:182998377	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.78	0.43	8.63e-17	Fuchs's corneal dystrophy;
LUSC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.73	-0.39	1.24e-13	Type 2 diabetes;
LUSC	cis	rs9831754	0.704	rs1512491	chr3:78470954	T/C	cg06138941	chr3:78371609	NA	0.48	6.43	0.33	4.37e-10	Calcium levels;
LUSC	cis	rs56161922	1.000	rs11118363	chr1:207859251	G/A	cg11752769	chr1:207818423	CR1L	0.7	5.91	0.31	8.43e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg07157834	chr1:205819609	PM20D1	-0.44	-5.87	-0.31	1.03e-8	Menarche (age at onset);
LUSC	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg21643547	chr1:205240462	TMCC2	0.4	7.35	0.37	1.57e-12	Red blood cell count;
LUSC	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.25	0.56	9.52e-29	Height;
LUSC	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg08213375	chr14:104286397	PPP1R13B	0.35	5.9	0.31	8.79e-9	Reticulocyte count;
LUSC	cis	rs4730250	0.554	rs17428504	chr7:106914944	T/C	cg02696742	chr7:106810147	HBP1	-0.54	-7.09	-0.36	8.03e-12	Osteoarthritis;
LUSC	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg19773385	chr1:10388646	KIF1B	-0.52	-8.79	-0.43	7.75e-17	Hepatocellular carcinoma;
LUSC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg02221750	chr19:17393354	ANKLE1	-0.91	-13.6	-0.6	8.08e-34	Systemic lupus erythematosus;
LUSC	trans	rs9860340	0.730	rs4643731	chr3:87651251	T/C	cg03644585	chr7:884825	UNC84A	0.43	6.07	0.32	3.52e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.77	0.3	1.77e-8	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.8	0.39	7.91e-14	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg17366294	chr4:99064904	C4orf37	0.61	10.74	0.51	2.7e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7072216	0.922	rs7097824	chr10:100151799	A/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-5.64	-0.3	3.57e-8	Metabolite levels;
LUSC	cis	rs6840360	0.967	rs10776524	chr4:152602585	G/A	cg22705602	chr4:152727874	NA	-0.27	-5.71	-0.3	2.48e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.07	0.52	1.76e-24	Alzheimer's disease;
LUSC	cis	rs55675132	0.833	rs76537915	chr1:115636496	C/T	cg01522456	chr1:115632236	TSPAN2	-0.45	-5.88	-0.31	1.02e-8	Schizophrenia;
LUSC	cis	rs4654899	1.000	rs885363	chr1:21325360	C/A	cg01072550	chr1:21505969	NA	-0.55	-8.46	-0.42	8.55e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg16362232	chr11:430036	ANO9	-0.62	-8.13	-0.41	8.63e-15	Body mass index;
LUSC	cis	rs12220238	1.000	rs11000925	chr10:75972601	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.22	0.37	3.42e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22307029	chr19:49891270	CCDC155	0.63	9.08	0.44	9.83e-18	Multiple sclerosis;
LUSC	cis	rs950776	0.642	rs34694149	chr15:78965917	C/T	cg06917634	chr15:78832804	PSMA4	0.49	6.81	0.35	4.58e-11	Sudden cardiac arrest;
LUSC	cis	rs75920871	0.528	rs7124872	chr11:116927951	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.51	6.38	0.33	5.87e-10	Subjective well-being;
LUSC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg16393715	chr7:1948819	MAD1L1	0.35	6.06	0.31	3.59e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg13319975	chr6:146136371	FBXO30	-0.53	-7.93	-0.4	3.44e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs926392	1.000	rs2867898	chr20:37690952	G/A	cg27552599	chr20:37590471	DHX35	0.33	5.75	0.3	2.06e-8	Dialysis-related mortality;
LUSC	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.36	-5.96	-0.31	6.34e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg08917208	chr2:24149416	ATAD2B	0.88	9.72	0.47	7.6e-20	Lymphocyte counts;
LUSC	cis	rs36093844	0.848	rs1564550	chr11:85535361	A/T	cg25872744	chr11:85566296	CCDC83	-0.44	-6.47	-0.33	3.4e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	trans	rs72674100	1.000	rs72874648	chr4:97964979	A/G	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg11812906	chr14:75593930	NEK9	0.65	10.58	0.5	9.14e-23	Height;
LUSC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.24	0.37	3.03e-12	Cognitive ability;
LUSC	cis	rs72634258	0.786	rs7537362	chr1:8177564	C/T	cg00042356	chr1:8021962	PARK7	0.58	7.12	0.36	6.71e-12	Inflammatory bowel disease;
LUSC	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg23795048	chr12:9217529	LOC144571	0.34	5.87	0.31	1.08e-8	Sjögren's syndrome;
LUSC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	1.03	18.74	0.72	4.56e-54	Menopause (age at onset);
LUSC	cis	rs55728055	0.661	rs55894054	chr22:31976299	T/C	cg01338084	chr22:32026380	PISD	0.93	6.78	0.35	5.4e-11	Age-related hearing impairment;
LUSC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.67	11.93	0.55	1.38e-27	Aortic root size;
LUSC	cis	rs10746514	0.931	rs11582890	chr1:232251218	C/T	cg09506761	chr1:232265262	NA	0.51	8.28	0.41	2.96e-15	Response to statin therapy;
LUSC	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs13089785	0.965	rs12488058	chr3:123599681	C/T	cg01860459	chr3:123419554	MYLK	0.34	5.66	0.3	3.27e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg00750074	chr16:89608354	SPG7	-0.54	-9.83	-0.47	3.38e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs939658	0.805	rs11635757	chr15:79432737	T/C	cg17916960	chr15:79447300	NA	-0.53	-10.55	-0.5	1.24e-22	Refractive error;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02374680	chr20:36322378	CTNNBL1	0.75	6.44	0.33	4.23e-10	Cognitive performance;
LUSC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08219700	chr8:58056026	NA	0.63	7.54	0.38	4.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.44	0.75	8.43e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg06521331	chr12:34319734	NA	-0.45	-7.39	-0.37	1.18e-12	Morning vs. evening chronotype;
LUSC	cis	rs12545109	0.837	rs4738500	chr8:57356193	G/A	cg09654669	chr8:57350985	NA	-0.56	-7.48	-0.38	6.83e-13	Obesity-related traits;
LUSC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg07936489	chr17:37558343	FBXL20	-0.44	-5.75	-0.3	1.98e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg16386425	chr10:429943	DIP2C	-0.41	-6.53	-0.34	2.48e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg16576597	chr16:28551801	NUPR1	0.34	6.88	0.35	2.97e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs61990749	0.597	rs176944	chr14:78176211	G/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.59	-6.44	-0.33	4.24e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs2742417	0.967	rs9825559	chr3:45740278	T/C	cg09608765	chr3:45636137	LIMD1	-0.38	-7.58	-0.38	3.39e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00149659	chr3:10157352	C3orf10	0.98	14.43	0.62	5.21e-37	Alzheimer's disease;
LUSC	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg08807101	chr21:30365312	RNF160	-0.66	-10.17	-0.49	2.33e-21	Pancreatic cancer;
LUSC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg16339924	chr4:17578868	LAP3	0.6	9.43	0.46	7.3e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	1.04	20.08	0.74	2.21e-59	Menopause (age at onset);
LUSC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.23	0.37	3.3e-12	Platelet count;
LUSC	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	1.17	13.83	0.6	1.04e-34	Arsenic metabolism;
LUSC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-8.66	-0.43	2.07e-16	Alzheimer's disease (late onset);
LUSC	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-9.13	-0.45	6.6e-18	Morning vs. evening chronotype;
LUSC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg04756594	chr16:24857601	SLC5A11	0.48	6.71	0.34	8.26e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs394563	0.601	rs431978	chr6:149793000	C/T	cg07828024	chr6:149772892	ZC3H12D	0.35	6.9	0.35	2.68e-11	Dupuytren's disease;
LUSC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg09626299	chr10:82213104	TSPAN14	-0.2	-6.17	-0.32	2.03e-9	Post bronchodilator FEV1;
LUSC	cis	rs4654899	0.772	rs10916892	chr1:21201325	A/G	cg01072550	chr1:21505969	NA	-0.5	-7.32	-0.37	1.88e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg19318889	chr4:1322082	MAEA	-0.55	-9.15	-0.45	5.8e-18	Obesity-related traits;
LUSC	cis	rs2658782	0.724	rs2605627	chr11:93259515	A/G	cg15737290	chr11:93063684	CCDC67	0.6	7.31	0.37	1.97e-12	Pulmonary function decline;
LUSC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs73206853	0.764	rs73206878	chr12:110835015	A/C	cg12870014	chr12:110450643	ANKRD13A	0.68	6.43	0.33	4.37e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg23188684	chr11:67383651	NA	0.34	6.01	0.31	4.94e-9	Mean corpuscular volume;
LUSC	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.12	-0.45	7.26e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7939886	0.920	rs59168428	chr11:55956018	G/A	cg03929089	chr4:120376271	NA	0.82	6.22	0.32	1.53e-9	Myopia (pathological);
LUSC	trans	rs12210905	0.920	rs858995	chr6:27181701	T/C	cg01357846	chr2:79252794	REG3G	-0.35	-5.97	-0.31	6.19e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.76	0.3	1.9e-8	Life satisfaction;
LUSC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.45	6.68	0.34	9.88e-11	Systemic lupus erythematosus;
LUSC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	8.13	0.41	8.43e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11650494	1.000	rs11650494	chr17:47345186	G/A	cg08112188	chr17:47440006	ZNF652	1.16	9.88	0.48	2.35e-20	Prostate cancer;
LUSC	cis	rs7833787	1.000	rs7007413	chr8:18705432	A/G	cg17701159	chr8:18705777	PSD3	0.38	6.38	0.33	5.95e-10	Obesity-related traits;
LUSC	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg13010199	chr12:38710504	ALG10B	0.52	7.89	0.4	4.32e-14	Morning vs. evening chronotype;
LUSC	cis	rs7605827	0.576	rs35785577	chr2:15659611	A/G	cg19274914	chr2:15703543	NA	0.48	9.37	0.46	1.1e-18	Educational attainment (years of education);
LUSC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.49	-0.38	6.2800000000000005e-13	Caffeine consumption;
LUSC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg15556689	chr8:8085844	FLJ10661	0.66	11.14	0.52	1.02e-24	Mood instability;
LUSC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07362569	chr17:61921086	SMARCD2	0.36	7.02	0.36	1.21e-11	Prudent dietary pattern;
LUSC	cis	rs921968	0.565	rs608047	chr2:219615910	A/C	cg02176678	chr2:219576539	TTLL4	0.56	9.99	0.48	1e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4654899	0.865	rs6671056	chr1:21488610	G/A	cg01072550	chr1:21505969	NA	-0.49	-7.36	-0.37	1.47e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg16743903	chr16:89593216	SPG7	-0.37	-5.74	-0.3	2.15e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg17052675	chr2:3827356	NA	-0.64	-10.2	-0.49	1.87e-21	Type 2 diabetes;
LUSC	trans	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg02800362	chr5:177631904	HNRNPAB	0.84	12.6	0.57	4.68e-30	Obesity-related traits;
LUSC	cis	rs12594515	1.000	rs8043291	chr15:45996247	T/A	cg01629716	chr15:45996671	NA	0.39	5.87	0.31	1.08e-8	Waist circumference;Weight;
LUSC	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg21171335	chr12:122356390	WDR66	0.6	8.84	0.44	5.75e-17	Mean corpuscular volume;
LUSC	cis	rs10754283	0.840	rs6428560	chr1:90102462	A/T	cg21401794	chr1:90099060	LRRC8C	0.64	9.64	0.47	1.49e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg09323728	chr8:95962352	TP53INP1	-0.34	-6.2	-0.32	1.66e-9	Type 2 diabetes;
LUSC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg02951883	chr7:2050386	MAD1L1	-0.52	-9.35	-0.46	1.34e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg12552261	chr5:112820674	MCC	-0.44	-7.06	-0.36	9.68e-12	Type 2 diabetes;
LUSC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg13114125	chr14:105738426	BRF1	-0.95	-16.27	-0.66	3.09e-44	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7582720	1.000	rs72936348	chr2:204064839	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.29	0.41	2.71e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9807989	0.811	rs7608638	chr2:102970289	A/G	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.67e-9	Asthma;
LUSC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg20406979	chr6:167373233	NA	0.25	5.76	0.3	1.92e-8	Crohn's disease;
LUSC	cis	rs3741151	0.764	rs73548680	chr11:73271335	T/C	cg17517138	chr11:73019481	ARHGEF17	0.98	8.16	0.41	6.87e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg24011408	chr12:48396354	COL2A1	0.4	5.8	0.3	1.56e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs10740039	0.883	rs10740037	chr10:62397505	C/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs394563	0.517	rs385303	chr6:149779064	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.41	-8.13	-0.41	8.34e-15	Dupuytren's disease;
LUSC	cis	rs4629180	0.586	rs7583526	chr2:102124665	G/A	cg01388757	chr2:102091195	RFX8	-0.35	-6.08	-0.32	3.33e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7189233	0.531	rs56126229	chr16:53510687	G/A	cg09728985	chr16:53543985	NA	-0.31	-5.82	-0.3	1.38e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.52	-0.34	2.56e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg24634471	chr8:143751801	JRK	0.59	8.89	0.44	3.97e-17	Schizophrenia;
LUSC	trans	rs9944715	0.954	rs13381529	chr18:43747827	A/T	cg01718231	chr17:29326311	RNF135	0.51	7.19	0.37	4.3e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg05527609	chr1:210001259	C1orf107	0.94	12.18	0.55	1.67e-28	Orofacial clefts;
LUSC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg09254001	chr12:99038219	IKBIP;APAF1	0.42	6.04	0.31	4.1e-9	Triglycerides;
LUSC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg23711669	chr6:146136114	FBXO30	-0.9	-17.65	-0.69	9.73e-50	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs17266958	1.000	rs1332042	chr9:83312270	T/A	cg01905489	chr1:26616534	UBXN11	-0.56	-6.09	-0.32	3.1e-9	Preschool internalizing problems;
LUSC	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg11344533	chr11:111475393	SIK2	-0.49	-6.89	-0.35	2.86e-11	Primary sclerosing cholangitis;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24532665	chr1:26146191	FAM54B	0.46	6.44	0.33	4.06e-10	Asthma;
LUSC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg05585544	chr11:47624801	NA	0.41	7.19	0.37	4.39e-12	Subjective well-being;
LUSC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.58	0.57	5.44e-30	Motion sickness;
LUSC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg12560992	chr17:57184187	TRIM37	0.82	15.12	0.64	1e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg07716408	chr11:68623521	NA	-0.34	-6.8	-0.35	4.9e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7818345	1.000	rs11780343	chr8:19290963	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.36	7.03	0.36	1.2e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg16362232	chr11:430036	ANO9	0.71	8.65	0.43	2.24e-16	Body mass index;
LUSC	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg04310649	chr10:35416472	CREM	-0.42	-6.47	-0.33	3.56e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg05064044	chr6:292385	DUSP22	0.75	12.5	0.56	1.14e-29	Menopause (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02362450	chr8:99129674	POP1;HRSP12	0.45	6.0	0.31	5.19e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.04	0.4	1.6e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg05585544	chr11:47624801	NA	0.41	7.21	0.37	3.88e-12	Subjective well-being;
LUSC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg05347473	chr6:146136440	FBXO30	0.45	7.69	0.39	1.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7561273	0.609	rs1056122	chr2:24342505	C/T	cg20701182	chr2:24300061	SF3B14	-0.45	-5.82	-0.3	1.38e-8	Quantitative traits;
LUSC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg22823121	chr1:150693482	HORMAD1	-0.46	-6.85	-0.35	3.47e-11	Tonsillectomy;
LUSC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg11584989	chr19:19387371	SF4	0.51	6.78	0.35	5.58e-11	Bipolar disorder;
LUSC	cis	rs9341808	0.754	rs3812126	chr6:80952701	A/G	cg08355045	chr6:80787529	NA	-0.55	-9.65	-0.47	1.33e-19	Sitting height ratio;
LUSC	cis	rs9462027	0.606	rs7341253	chr6:34726838	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.91	-0.31	8.62e-9	Systemic lupus erythematosus;
LUSC	cis	rs12681287	0.547	rs7465511	chr8:87521481	C/T	cg00550725	chr8:87521180	FAM82B	0.44	5.73	0.3	2.2e-8	Caudate activity during reward;
LUSC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg21643547	chr1:205240462	TMCC2	-0.42	-7.67	-0.39	1.93e-13	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs6011368	0.840	rs2427638	chr20:62900717	C/T	cg13869341	chr1:15865	WASH5P	0.43	6.87	0.35	3.17e-11	Clozapine-induced cytotoxicity;
LUSC	cis	rs4713675	0.584	rs4713667	chr6:33680016	G/C	cg14003231	chr6:33640908	ITPR3	0.3	5.77	0.3	1.84e-8	Plateletcrit;
LUSC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg23711669	chr6:146136114	FBXO30	0.78	12.97	0.58	2.01e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg13628971	chr7:2884303	GNA12	0.46	6.79	0.35	5.03e-11	Height;
LUSC	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.07	0.48	5.42e-21	Bladder cancer;
LUSC	trans	rs8060598	0.866	rs3135499	chr16:50766127	G/T	ch.3.541014R	chr3:25654052	TOP2B	-0.38	-6.0	-0.31	5.04e-9	Leprosy;
LUSC	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg16586182	chr3:47516702	SCAP	0.5	7.13	0.36	6.36e-12	Colorectal cancer;
LUSC	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg08854313	chr1:11322531	MTOR	-0.92	-15.7	-0.65	5.42e-42	Body mass index;
LUSC	cis	rs9309473	0.528	rs11898362	chr2:73565293	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-6.96	-0.36	1.79e-11	Metabolite levels;
LUSC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.16	0.32	2.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9323205	0.677	rs12589680	chr14:51723138	T/C	cg23942311	chr14:51606299	NA	-0.39	-7.25	-0.37	2.92e-12	Cancer;
LUSC	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg05714579	chr10:131428358	MGMT	0.5	7.43	0.38	9.36e-13	Response to temozolomide;
LUSC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.84e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs593982	0.920	rs645621	chr11:65490756	T/C	cg08755490	chr11:65554678	OVOL1	1.48	12.95	0.58	2.37e-31	Atopic dermatitis;
LUSC	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg15556689	chr8:8085844	FLJ10661	0.69	10.92	0.51	6.09e-24	Neuroticism;
LUSC	cis	rs9311676	0.632	rs11923181	chr3:58380569	A/C	cg13750441	chr3:58318267	PXK	0.36	7.03	0.36	1.18e-11	Systemic lupus erythematosus;
LUSC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg11663144	chr21:46675770	NA	-0.35	-5.65	-0.3	3.44e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.5	-0.46	4.34e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs9840812	0.610	rs34967300	chr3:136268818	A/G	cg15507776	chr3:136538369	TMEM22	-0.45	-5.93	-0.31	7.39e-9	Fibrinogen levels;
LUSC	trans	rs7178375	1.000	rs28693590	chr15:31195021	A/G	cg04373760	chr16:53404718	NA	0.67	8.9	0.44	3.68e-17	Hypertriglyceridemia;
LUSC	cis	rs6681460	1.000	rs6680944	chr1:67122565	A/T	cg02459107	chr1:67143332	SGIP1	0.48	9.02	0.44	1.47e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg09184832	chr6:79620586	NA	-0.42	-6.79	-0.35	5.28e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs887829	0.570	rs7563561	chr2:234598991	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.38	-6.17	-0.32	1.92e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg13072238	chr3:49761600	GMPPB	0.65	8.33	0.41	2.14e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10498514	0.793	rs116373409	chr14:65039437	T/C	cg25134081	chr14:64931936	AKAP5	0.95	6.53	0.34	2.45e-10	Cognitive performance;
LUSC	cis	rs2559856	0.967	rs2695297	chr12:102082218	T/C	cg12924262	chr12:102091054	CHPT1	0.42	5.84	0.3	1.24e-8	Blood protein levels;
LUSC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg12432903	chr7:1882776	MAD1L1	-0.49	-8.13	-0.41	8.74e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs11039100	0.681	rs11039170	chr11:5845187	T/G	cg13902645	chr11:5959945	NA	-0.54	-5.99	-0.31	5.41e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg10729496	chr3:10149963	C3orf24	0.53	6.38	0.33	5.92e-10	Alzheimer's disease;
LUSC	cis	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg21775007	chr8:11205619	TDH	0.5	7.21	0.37	3.75e-12	Neuroticism;
LUSC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg04518342	chr5:131593106	PDLIM4	0.46	8.56	0.42	4.27e-16	Breast cancer;
LUSC	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg23649088	chr2:200775458	C2orf69	0.56	6.49	0.33	3.17e-10	Schizophrenia;
LUSC	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.24	0.32	1.32e-9	Retinal vascular caliber;
LUSC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg04733989	chr22:42467013	NAGA	-0.41	-6.77	-0.35	5.96e-11	Cognitive function;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04875476	chr1:156720919	HDGF	-0.43	-6.21	-0.32	1.59e-9	Electrocardiographic conduction measures;
LUSC	cis	rs73206853	0.841	rs73206854	chr12:110731375	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	7.53	0.38	4.86e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg20283391	chr11:68216788	NA	-0.54	-8.04	-0.4	1.58e-14	Total body bone mineral density;
LUSC	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.67	0.39	1.9e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2302729	0.860	rs7138079	chr12:2781304	G/A	cg19945202	chr12:2788847	CACNA1C	-0.39	-5.87	-0.31	1.07e-8	Sleep quality;
LUSC	cis	rs877282	0.853	rs4579862	chr10:753298	A/C	cg17470449	chr10:769945	NA	0.49	6.69	0.34	9.39e-11	Uric acid levels;
LUSC	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg20701182	chr2:24300061	SF3B14	0.73	7.33	0.37	1.76e-12	Lymphocyte counts;
LUSC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg11764359	chr7:65958608	NA	-0.78	-12.69	-0.57	2.23e-30	Aortic root size;
LUSC	cis	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg06521331	chr12:34319734	NA	0.48	7.94	0.4	3.09e-14	Morning vs. evening chronotype;
LUSC	cis	rs2200578	0.626	rs72959128	chr2:99769602	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	6.44	0.33	4.24e-10	IgG glycosylation;
LUSC	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg24011408	chr12:48396354	COL2A1	-0.44	-6.53	-0.34	2.47e-10	Glycated hemoglobin levels;
LUSC	cis	rs1775715	0.870	rs1755080	chr10:32255195	G/A	cg26784012	chr10:32216390	ARHGAP12	0.4	6.45	0.33	3.85e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.69	-0.3	2.8e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg22681709	chr2:178499509	PDE11A	-0.46	-7.44	-0.38	8.46e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg03146154	chr1:46216737	IPP	0.55	8.33	0.41	2.13e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4851254	0.660	rs34714421	chr2:100692175	T/C	cg07810366	chr2:100720526	AFF3	-0.45	-6.06	-0.31	3.7e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9469578	1.000	rs16869466	chr6:33715265	A/G	cg18708504	chr6:33715942	IP6K3	0.72	8.8	0.43	7.52e-17	Phosphorus levels;
LUSC	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg21849932	chr20:62369462	LIME1	-0.4	-5.92	-0.31	8e-9	Prostate cancer;
LUSC	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg13798780	chr7:105162888	PUS7	0.56	6.15	0.32	2.23e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg02018176	chr4:1364513	KIAA1530	0.49	8.27	0.41	3.33e-15	Obesity-related traits;
LUSC	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17467752	chr17:38218738	THRA	-0.51	-7.15	-0.36	5.59e-12	White blood cell count (neutrophil);
LUSC	cis	rs7851660	0.809	rs12006522	chr9:100652711	G/C	cg13688889	chr9:100608707	NA	-0.53	-8.06	-0.4	1.36e-14	Strep throat;
LUSC	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	8.77	0.43	9.6e-17	Lung cancer in ever smokers;
LUSC	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	7.21	0.37	3.83e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.84e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	7.98	0.4	2.34e-14	Axial length;
LUSC	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg10523679	chr1:76189770	ACADM	-0.51	-7.56	-0.38	3.9e-13	Daytime sleep phenotypes;
LUSC	trans	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg26384229	chr12:38710491	ALG10B	0.6	8.41	0.42	1.2e-15	Resting heart rate;
LUSC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg19257562	chr1:2043853	PRKCZ	0.29	5.77	0.3	1.85e-8	Height;
LUSC	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.56	9.05	0.44	1.24e-17	Breast cancer;
LUSC	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg18806716	chr10:30721971	MAP3K8	0.7	11.23	0.52	5.01e-25	Inflammatory bowel disease;
LUSC	cis	rs9472414	0.680	rs9463040	chr6:44752286	C/T	cg20913747	chr6:44695427	NA	0.41	6.03	0.31	4.28e-9	Height;
LUSC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.66	-11.66	-0.54	1.34e-26	Aortic root size;
LUSC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg03146154	chr1:46216737	IPP	-0.51	-7.43	-0.38	9.2e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs36093844	0.752	rs56396016	chr11:85596390	C/A	cg25872744	chr11:85566296	CCDC83	-0.45	-5.86	-0.31	1.14e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg10518543	chr12:38710700	ALG10B	0.41	5.79	0.3	1.66e-8	Morning vs. evening chronotype;
LUSC	cis	rs9687065	1.000	rs7704297	chr5:148390295	A/G	cg23229984	chr5:148520753	ABLIM3	-0.39	-6.15	-0.32	2.26e-9	Diastolic blood pressure;
LUSC	trans	rs2834485	1.000	rs2834484	chr21:35816941	G/T	cg07474852	chr4:123073612	NA	-0.44	-6.5	-0.34	2.89e-10	Cancer;
LUSC	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.24	-0.37	3.14e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg24154853	chr7:158122151	PTPRN2	-0.42	-8.18	-0.41	6.1e-15	Calcium levels;
LUSC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg05347473	chr6:146136440	FBXO30	0.55	9.47	0.46	5.41e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1595825	0.786	rs116046984	chr2:198884413	G/A	cg00982548	chr2:198649783	BOLL	-0.54	-6.88	-0.35	2.9e-11	Ulcerative colitis;
LUSC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg01657329	chr11:68192670	LRP5	-0.45	-7.1	-0.36	7.74e-12	Total body bone mineral density;
LUSC	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg27633287	chr12:130766243	NA	-0.33	-6.25	-0.32	1.27e-9	Menopause (age at onset);
LUSC	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg21775007	chr8:11205619	TDH	0.77	12.86	0.58	5.27e-31	Retinal vascular caliber;
LUSC	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.76	-10.3	-0.49	8.69e-22	Coronary artery disease;
LUSC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg21535247	chr6:8435926	SLC35B3	-0.58	-8.97	-0.44	2.17e-17	Motion sickness;
LUSC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.87	0.35	3.2e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.39	6.0	0.31	5.15e-9	Total body bone mineral density;
LUSC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.89	-0.31	9.18e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg04450456	chr4:17643702	FAM184B	0.38	6.37	0.33	6.19e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg14552801	chr7:65878734	NA	0.38	5.9	0.31	8.97e-9	Aortic root size;
LUSC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg06877462	chr1:205807181	PM20D1	0.38	7.05	0.36	1.03e-11	Menarche (age at onset);
LUSC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.0	-0.4	2e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg06784218	chr1:46089804	CCDC17	0.47	9.22	0.45	3.52e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-6.71	-0.34	8.53e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg27411982	chr8:10470053	RP1L1	0.37	5.71	0.3	2.54e-8	Retinal vascular caliber;
LUSC	cis	rs5167	0.566	rs7253458	chr19:45482570	C/T	cg13119609	chr19:45449297	APOC2	0.34	5.67	0.3	3.01e-8	Blood protein levels;
LUSC	cis	rs7177699	0.550	rs7182716	chr15:79123753	T/C	cg15571903	chr15:79123663	NA	0.34	6.32	0.33	8.21e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	0.93	18.43	0.71	7.84e-53	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.36	6.2	0.32	1.69e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg01973587	chr1:228161476	NA	0.42	7.77	0.39	9.84e-14	Diastolic blood pressure;
LUSC	trans	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.29	-0.33	1.01e-9	Bladder cancer;
LUSC	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.24	-0.32	1.3e-9	Bipolar disorder;
LUSC	cis	rs28830936	1.000	rs112896623	chr15:42001845	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.0	-0.31	5.06e-9	Diastolic blood pressure;
LUSC	trans	rs6852435	1.000	rs62335849	chr4:175304179	A/G	cg23753247	chr11:8615842	STK33	-0.53	-5.97	-0.31	5.91e-9	Response to acetaminophen (hepatotoxicity);
LUSC	cis	rs10986311	0.862	rs2416924	chr9:127108146	A/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.38	5.87	0.31	1.06e-8	Vitiligo;
LUSC	trans	rs800082	0.501	rs10935507	chr3:144214631	A/T	cg24215973	chr2:240111563	HDAC4	0.49	7.36	0.37	1.48e-12	Smoking behavior;
LUSC	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg05343316	chr1:45956843	TESK2	0.66	9.01	0.44	1.62e-17	Platelet count;
LUSC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg13114125	chr14:105738426	BRF1	-0.95	-16.27	-0.66	3.09e-44	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	6.16	0.32	2.07e-9	Height;
LUSC	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg18678763	chr11:4115507	RRM1	-0.48	-6.91	-0.35	2.39e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.54	0.42	4.93e-16	Prudent dietary pattern;
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18099408	chr3:52552593	STAB1	-0.39	-6.95	-0.36	1.9e-11	Electroencephalogram traits;
LUSC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg11062466	chr8:58055876	NA	0.42	5.66	0.3	3.32e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9549260	1.000	rs9549260	chr13:41254104	G/T	cg21288729	chr13:41239152	FOXO1	0.46	6.09	0.32	3.07e-9	Red blood cell count;
LUSC	cis	rs6500395	0.962	rs9972682	chr16:48686644	T/G	cg04672837	chr16:48644449	N4BP1	0.44	6.29	0.33	1.01e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg13560548	chr3:10150139	C3orf24	0.51	7.32	0.37	1.92e-12	Alzheimer's disease;
LUSC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.77	-13.55	-0.6	1.24e-33	Cognitive function;
LUSC	trans	rs2319125	0.866	rs229859	chr17:64121580	A/T	cg06156093	chr1:184633273	NA	0.37	6.27	0.32	1.13e-9	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LUSC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	6.17	0.32	1.97e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7615316	0.934	rs13098343	chr3:142228486	T/C	cg16271453	chr3:142027066	XRN1	-0.4	-6.87	-0.35	3.22e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs11923600	0.793	rs62285822	chr3:175890900	T/C	cg02188190	chr13:112894616	NA	0.44	6.21	0.32	1.58e-9	Height;
LUSC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.36	-0.37	1.42e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg26441486	chr22:50317300	CRELD2	0.52	7.95	0.4	2.85e-14	Schizophrenia;
LUSC	cis	rs34891900	0.507	rs2587084	chr22:18140644	T/G	cg08824373	chr22:18117835	NA	-0.41	-6.35	-0.33	7.07e-10	Sum neutrophil eosinophil counts;
LUSC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg21782813	chr7:2030301	MAD1L1	0.49	8.37	0.42	1.59e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs983392	0.667	rs631853	chr11:59944898	T/G	cg02771260	chr11:59836817	MS4A3	0.36	6.21	0.32	1.54e-9	Alzheimer's disease (late onset);
LUSC	trans	rs1973993	0.672	rs17367240	chr1:96960057	G/A	cg10631902	chr5:14652156	NA	-0.46	-6.8	-0.35	4.72e-11	Weight;
LUSC	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	10.52	0.5	1.49e-22	Lung cancer in ever smokers;
LUSC	cis	rs9650315	0.866	rs13254111	chr8:57181776	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	6.34	0.33	7.34e-10	Height;
LUSC	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg04176472	chr15:90893244	GABARAPL3	0.35	5.99	0.31	5.41e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg04369109	chr6:150039330	LATS1	-0.56	-8.4	-0.42	1.3e-15	Lung cancer;
LUSC	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg26876637	chr1:152193138	HRNR	0.38	5.66	0.3	3.22e-8	Atopic dermatitis;
LUSC	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg05234568	chr11:5960015	NA	-0.55	-7.95	-0.4	2.92e-14	DNA methylation (variation);
LUSC	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg24642439	chr20:33292090	TP53INP2	0.51	7.65	0.39	2.14e-13	Height;
LUSC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg16586182	chr3:47516702	SCAP	-0.48	-7.58	-0.38	3.45e-13	Colorectal cancer;
LUSC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg18131467	chr2:239335373	ASB1	0.96	21.24	0.76	5.97e-64	Multiple system atrophy;
LUSC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg22834771	chr12:69754056	YEATS4	-0.49	-7.37	-0.37	1.31e-12	Blood protein levels;
LUSC	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg06718696	chr17:78121285	EIF4A3	0.43	6.24	0.32	1.33e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-9.08	-0.44	9.63e-18	Depression;
LUSC	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	1.03	11.06	0.52	1.92e-24	Type 2 diabetes;
LUSC	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg04450456	chr4:17643702	FAM184B	0.39	6.54	0.34	2.34e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.41	6.75	0.35	6.73e-11	Cystic fibrosis severity;
LUSC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg05347473	chr6:146136440	FBXO30	0.56	9.54	0.46	3.19e-19	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg13010199	chr12:38710504	ALG10B	0.55	8.37	0.42	1.63e-15	Morning vs. evening chronotype;
LUSC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg04398451	chr17:18023971	MYO15A	-0.48	-7.65	-0.39	2.12e-13	Total body bone mineral density;
LUSC	cis	rs60695258	0.529	rs340630	chr4:87958395	G/A	cg10685359	chr4:87814065	C4orf36	0.34	6.06	0.31	3.59e-9	Hematocrit;
LUSC	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.54	-8.52	-0.42	5.39e-16	Response to antineoplastic agents;
LUSC	cis	rs55986470	0.763	rs11888775	chr2:239424876	C/T	cg18131467	chr2:239335373	ASB1	0.52	5.99	0.31	5.31e-9	Chronotype;
LUSC	cis	rs6977660	0.714	rs7357319	chr7:19817525	A/G	cg05791153	chr7:19748676	TWISTNB	0.67	7.1	0.36	7.78e-12	Thyroid stimulating hormone;
LUSC	cis	rs1953600	1.000	rs2789679	chr10:81907884	A/T	cg00277334	chr10:82204260	NA	-0.51	-7.86	-0.4	5.27e-14	Sarcoidosis;
LUSC	cis	rs1858037	0.867	rs67453645	chr2:65586042	C/T	cg08085232	chr2:65598271	SPRED2	-0.4	-5.95	-0.31	6.88e-9	Rheumatoid arthritis;
LUSC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	9.54	0.46	3.12e-19	Height;
LUSC	cis	rs3106136	0.900	rs13142645	chr4:95208714	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.09	-0.32	3.14e-9	Capecitabine sensitivity;
LUSC	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg04310649	chr10:35416472	CREM	0.4	6.25	0.32	1.26e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.98	0.58	1.79e-31	Prudent dietary pattern;
LUSC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg23093090	chr10:104574429	C10orf26	-0.43	-7.47	-0.38	7.05e-13	Arsenic metabolism;
LUSC	cis	rs3820928	0.874	rs10177995	chr2:227781600	T/C	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.01	-0.4	1.99e-14	Pulmonary function;
LUSC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.13	0.45	6.72e-18	Motion sickness;
LUSC	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg25482853	chr8:67687455	SGK3	1.18	16.55	0.67	2.28e-45	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2667011	0.512	rs77743444	chr2:160804410	G/C	cg06573604	chr2:160760825	LY75	0.45	6.28	0.32	1.07e-9	Bilirubin levels;
LUSC	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg12091567	chr17:66097778	LOC651250	-0.75	-9.35	-0.46	1.27e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	trans	rs61931739	0.649	rs815049	chr12:33726757	G/C	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg00049323	chr5:472564	LOC25845	-0.43	-6.48	-0.33	3.34e-10	Cystic fibrosis severity;
LUSC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg13319975	chr6:146136371	FBXO30	0.51	7.75	0.39	1.15e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.13	0.41	8.64e-15	Type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-6.08	-0.32	3.37e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11158026	0.501	rs67620272	chr14:55351579	G/C	cg04306507	chr14:55594613	LGALS3	0.4	6.41	0.33	4.88e-10	Parkinson's disease;
LUSC	trans	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg04995722	chr7:26192034	NFE2L3	0.37	6.12	0.32	2.6e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.46	-0.42	8.72e-16	Response to antipsychotic treatment;
LUSC	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.07	-0.36	9.36e-12	Response to antipsychotic treatment;
LUSC	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg14664628	chr15:75095509	CSK	0.43	6.07	0.32	3.43e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg18825076	chr15:78729989	IREB2	0.44	6.13	0.32	2.46e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg27494647	chr7:150038898	RARRES2	0.57	8.51	0.42	5.88e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.23e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	16.24	0.66	3.92e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3784262	0.528	rs1994926	chr15:58334587	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.3	-5.77	-0.3	1.78e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg12310025	chr6:25882481	NA	0.39	6.86	0.35	3.43e-11	Blood metabolite levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23145915	chr12:58146234	CDK4	-0.46	-6.01	-0.31	4.8e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs72792276	1.000	rs72794386	chr5:127479278	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.91	8.4	0.42	1.31e-15	Red cell distribution width;
LUSC	cis	rs10823500	0.604	rs10740329	chr10:71941253	A/T	cg26699283	chr10:71892715	AIFM2	0.38	6.04	0.31	4.17e-9	Blood protein levels;
LUSC	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg17757837	chr7:157058334	UBE3C	0.83	13.17	0.58	3.51e-32	Body mass index;
LUSC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.49	0.38	6.07e-13	Motion sickness;
LUSC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg03526776	chr6:41159608	TREML2	-0.32	-6.23	-0.32	1.4e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg10360139	chr7:1886902	MAD1L1	-0.44	-6.69	-0.34	9.17e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13012494	chr21:47604986	C21orf56	-0.51	-7.81	-0.39	7.43e-14	Testicular germ cell tumor;
LUSC	cis	rs11055008	0.620	rs10845608	chr12:12836088	C/T	cg09462578	chr12:12878428	APOLD1	0.43	6.31	0.33	8.73e-10	Pulse pressure;
LUSC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg08200582	chr11:442649	ANO9	-0.52	-6.1	-0.32	3.02e-9	Body mass index;
LUSC	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg19812747	chr11:111475976	SIK2	0.52	7.18	0.37	4.63e-12	Primary sclerosing cholangitis;
LUSC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.14	0.36	5.83e-12	Major depressive disorder;
LUSC	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00631329	chr6:26305371	NA	-0.45	-8.84	-0.44	5.59e-17	Educational attainment;
LUSC	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg10578777	chr12:7781093	NA	-0.7	-6.77	-0.35	5.76e-11	HDL cholesterol levels;
LUSC	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	0.98	8.74	0.43	1.19e-16	Type 2 diabetes nephropathy;
LUSC	cis	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg02972257	chr16:68554789	NA	-0.5	-6.27	-0.32	1.12e-9	Ulcerative colitis;
LUSC	cis	rs727505	0.954	rs1014163	chr7:124443604	G/A	cg23710748	chr7:124431027	NA	-0.43	-7.83	-0.39	6.49e-14	Lewy body disease;
LUSC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg09365446	chr1:150670422	GOLPH3L	0.51	7.93	0.4	3.36e-14	Tonsillectomy;
LUSC	cis	rs500891	0.574	rs7757427	chr6:84131300	T/A	cg08257003	chr6:84140564	ME1	0.37	9.02	0.44	1.53e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.22	25.21	0.81	2.81e-79	Exhaled nitric oxide output;
LUSC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.62	12.64	0.57	3.5e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08439880	chr3:133502540	NA	-0.38	-6.81	-0.35	4.66e-11	Iron status biomarkers;
LUSC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg00049323	chr5:472564	LOC25845	-0.44	-6.8	-0.35	4.79e-11	Cystic fibrosis severity;
LUSC	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg10978503	chr1:24200527	CNR2	-0.46	-9.5	-0.46	4.32e-19	Immature fraction of reticulocytes;
LUSC	cis	rs17021463	0.966	rs7657789	chr4:95178589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.52	-0.42	5.42e-16	Testicular germ cell tumor;
LUSC	trans	rs931812	0.895	rs4734013	chr8:101908687	A/C	cg20993868	chr7:22813445	NA	0.65	11.78	0.54	5.1e-27	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs9811920	0.535	rs793483	chr3:99489825	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.3	-5.76	-0.3	1.87e-8	Axial length;
LUSC	cis	rs929596	0.639	rs2070959	chr2:234602191	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-7.76	-0.39	1.06e-13	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg17507749	chr15:85114479	UBE2QP1	0.65	8.1	0.41	1.04e-14	Schizophrenia;
LUSC	cis	rs1499972	0.941	rs62264783	chr3:117658033	G/A	cg07612923	chr3:117604196	NA	0.63	5.72	0.3	2.32e-8	Schizophrenia;
LUSC	cis	rs472402	0.560	rs10037161	chr5:6624294	C/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.53	-7.7	-0.39	1.55e-13	Response to amphetamines;
LUSC	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.67	-0.34	1.04e-10	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg07663200	chr17:42030104	NA	-0.39	-6.46	-0.33	3.6e-10	Post bronchodilator FEV1;
LUSC	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.03	-0.36	1.17e-11	Colorectal cancer;
LUSC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.68	-0.5	4.39e-23	Bipolar disorder;
LUSC	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg09408571	chr1:101003634	GPR88	0.35	6.93	0.35	2.23e-11	Monocyte count;
LUSC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg15557168	chr22:42548783	NA	-0.45	-6.87	-0.35	3.11e-11	Schizophrenia;
LUSC	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg18132916	chr6:79620363	NA	-0.38	-5.85	-0.3	1.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2742234	0.590	rs1254965	chr10:43689853	C/T	cg15436174	chr10:43711423	RASGEF1A	0.43	7.03	0.36	1.17e-11	Hirschsprung disease;
LUSC	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg08917208	chr2:24149416	ATAD2B	1.01	10.61	0.5	7.29e-23	Immature fraction of reticulocytes;
LUSC	cis	rs7851660	0.874	rs1955143	chr9:100634579	A/T	cg13688889	chr9:100608707	NA	-0.57	-9.02	-0.44	1.53e-17	Strep throat;
LUSC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.78	0.47	5.09e-20	Bipolar disorder;
LUSC	cis	rs2282300	0.739	rs7952339	chr11:30327344	C/T	cg25418670	chr11:30344373	C11orf46	0.6	8.67	0.43	1.86e-16	Morning vs. evening chronotype;
LUSC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg02951883	chr7:2050386	MAD1L1	-0.52	-9.17	-0.45	4.89e-18	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs9311676	0.632	rs7643057	chr3:58374015	C/T	cg13750441	chr3:58318267	PXK	0.36	6.93	0.35	2.12e-11	Systemic lupus erythematosus;
LUSC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.69	-0.39	1.68e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs16949788	1.000	rs11071885	chr15:66625161	A/G	cg08120210	chr15:66682733	MAP2K1	-0.58	-5.88	-0.31	1.01e-8	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs4771122	0.697	rs1475220	chr13:28037448	G/C	cg22138327	chr13:27999177	GTF3A	-0.66	-8.63	-0.43	2.62e-16	Body mass index;
LUSC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg06453172	chr10:134556979	INPP5A	-0.49	-6.25	-0.32	1.24e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.89	13.21	0.59	2.43e-32	Alzheimer's disease;
LUSC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg25174290	chr11:3078921	CARS	0.61	9.17	0.45	4.94e-18	Longevity;
LUSC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg06637938	chr14:75390232	RPS6KL1	0.53	8.44	0.42	1.01e-15	Height;
LUSC	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg09904177	chr6:26538194	HMGN4	-0.51	-8.08	-0.4	1.17e-14	Schizophrenia;
LUSC	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg21951975	chr1:209979733	IRF6	0.59	7.0	0.36	1.38e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs250677	0.522	rs4705302	chr5:148354962	G/C	cg18129178	chr5:148520854	ABLIM3	0.55	7.87	0.4	5.07e-14	Breast cancer;
LUSC	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg04450456	chr4:17643702	FAM184B	-0.37	-6.1	-0.32	3.02e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg18190219	chr22:46762943	CELSR1	-0.63	-6.76	-0.35	6.31e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.68	-11.36	-0.53	1.6e-25	Cognitive function;
LUSC	cis	rs4285028	0.699	rs1920297	chr3:121598000	T/C	cg11130432	chr3:121712080	ILDR1	-0.62	-9.4	-0.46	9.2e-19	Multiple sclerosis;
LUSC	cis	rs4604732	0.603	rs10802513	chr1:247633919	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.34	5.65	0.3	3.49e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs981844	0.740	rs7653960	chr4:154697430	T/G	cg10279832	chr4:154682576	RNF175	0.36	5.65	0.3	3.43e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs12410462	0.581	rs6675521	chr1:227544702	C/T	cg04117972	chr1:227635322	NA	0.6	6.68	0.34	1e-10	Major depressive disorder;
LUSC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03060546	chr3:49711283	APEH	0.67	7.7	0.39	1.51e-13	Menarche (age at onset);
LUSC	cis	rs6121246	0.559	rs6060915	chr20:30330306	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	13.36	0.59	6.74e-33	Mean corpuscular hemoglobin;
LUSC	cis	rs7681440	0.647	rs1442136	chr4:90819026	C/T	cg01966878	chr4:90757139	SNCA	0.36	5.87	0.31	1.06e-8	Dementia with Lewy bodies;
LUSC	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg27205649	chr11:78285834	NARS2	-0.5	-5.65	-0.3	3.35e-8	Testicular germ cell tumor;
LUSC	cis	rs12931792	0.782	rs6565176	chr16:30174926	T/C	cg17640201	chr16:30407289	ZNF48	0.62	10.17	0.49	2.46e-21	Tonsillectomy;
LUSC	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg22117172	chr7:91764530	CYP51A1	0.33	5.84	0.3	1.24e-8	Breast cancer;
LUSC	cis	rs9905704	0.918	rs72828707	chr17:56883236	A/G	cg12560992	chr17:57184187	TRIM37	0.56	8.02	0.4	1.81e-14	Testicular germ cell tumor;
LUSC	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg02403541	chr12:121454288	C12orf43	-0.56	-8.56	-0.42	4.17e-16	Subjective well-being;Cardiovascular disease risk factors;
LUSC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.0	-0.31	5.01e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg06784218	chr1:46089804	CCDC17	-0.55	-11.25	-0.52	4.03e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1403694	0.695	rs3774292	chr3:186433574	A/T	cg12454167	chr3:186435060	KNG1	0.34	8.38	0.42	1.49e-15	Blood protein levels;
LUSC	cis	rs2040771	0.804	rs2073754	chr22:19221406	G/T	cg02655711	chr22:19163373	SLC25A1	-0.47	-8.64	-0.43	2.42e-16	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	0.64	9.15	0.45	5.95e-18	Platelet distribution width;
LUSC	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg02466173	chr16:30829666	NA	0.55	11.21	0.52	5.56e-25	Dementia with Lewy bodies;
LUSC	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg25427524	chr10:38739819	LOC399744	0.43	5.75	0.3	2.01e-8	Obesity (extreme);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07105333	chr17:27277048	PHF12	-0.45	-5.98	-0.31	5.73e-9	Hepatitis;
LUSC	cis	rs9837602	1.000	rs10049383	chr3:99748548	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.21	-0.32	1.54e-9	Breast cancer;
LUSC	cis	rs3820928	0.933	rs1429267	chr2:227767593	G/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.73	-0.39	1.3e-13	Pulmonary function;
LUSC	cis	rs2997447	0.706	rs61776573	chr1:26429356	A/C	cg19633962	chr1:26362018	EXTL1	-0.48	-5.64	-0.3	3.56e-8	QRS complex (12-leadsum);
LUSC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg09367891	chr1:107599246	PRMT6	0.52	8.15	0.41	7.44e-15	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	10.56	0.5	1.11e-22	Homoarginine levels;
LUSC	trans	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg02800362	chr5:177631904	HNRNPAB	0.88	13.12	0.58	5.45e-32	Obesity-related traits;
LUSC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg18512352	chr11:47633146	NA	-0.46	-9.21	-0.45	3.67e-18	Subjective well-being;
LUSC	cis	rs790123	0.604	rs16834903	chr3:122379614	G/A	cg00926285	chr3:122398533	PARP14	-0.41	-6.09	-0.32	3.05e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.88	-0.68	1.16e-46	Primary sclerosing cholangitis;
LUSC	cis	rs12286929	0.644	rs12099024	chr11:115082142	A/G	cg04055981	chr11:115044050	NA	0.36	6.36	0.33	6.53e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7582720	1.000	rs72934704	chr2:203706433	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	8.16	0.41	7.08e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.69	0.34	9.34e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	11.08	0.52	1.67e-24	Bone mineral density;
LUSC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	9.96	0.48	1.22e-20	Personality dimensions;
LUSC	trans	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg06521331	chr12:34319734	NA	-0.39	-6.23	-0.32	1.44e-9	Bladder cancer;
LUSC	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg17848003	chr1:3704513	LRRC47	0.34	6.15	0.32	2.18e-9	Red cell distribution width;
LUSC	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg24675056	chr1:15929824	NA	0.43	7.39	0.37	1.22e-12	Systolic blood pressure;
LUSC	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg14196790	chr5:131705035	SLC22A5	-0.43	-6.86	-0.35	3.31e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg04317338	chr11:64019027	PLCB3	0.56	5.91	0.31	8.27e-9	Mean platelet volume;
LUSC	cis	rs2652834	0.851	rs9302231	chr15:63427394	G/A	cg05507819	chr15:63340323	TPM1	0.45	5.76	0.3	1.87e-8	HDL cholesterol;
LUSC	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg19789473	chr17:27170043	C17orf63	-0.31	-5.85	-0.31	1.15e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs730566	0.640	rs6442112	chr3:48316034	A/G	cg07636037	chr3:49044803	WDR6	0.46	5.9	0.31	8.79e-9	Prion diseases;
LUSC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	1.0	15.06	0.64	1.73e-39	Initial pursuit acceleration;
LUSC	cis	rs240764	0.658	rs10457849	chr6:101245591	A/G	cg09795085	chr6:101329169	ASCC3	0.44	6.46	0.33	3.7e-10	Neuroticism;
LUSC	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg20848291	chr7:100343083	ZAN	0.4	6.37	0.33	6.35e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs12928939	0.815	rs7185575	chr16:71672569	A/G	cg08717414	chr16:71523259	ZNF19	-0.42	-5.88	-0.31	9.86e-9	Post bronchodilator FEV1;
LUSC	cis	rs2324229	0.828	rs1180240	chr6:83937762	C/G	cg08257003	chr6:84140564	ME1	0.28	6.32	0.33	8.31e-10	Platelet-derived growth factor BB levels;
LUSC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg13206674	chr6:150067644	NUP43	0.64	10.48	0.5	2.17e-22	Lung cancer;
LUSC	trans	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg11887960	chr12:57824829	NA	0.47	6.14	0.32	2.35e-9	Obesity-related traits;
LUSC	cis	rs6460942	0.915	rs7803056	chr7:12306913	A/C	cg06484146	chr7:12443880	VWDE	-0.49	-5.9	-0.31	8.72e-9	Coronary artery disease;
LUSC	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg06462663	chr19:18546047	ISYNA1	0.47	8.11	0.41	9.74e-15	Breast cancer;
LUSC	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg00310523	chr12:86230176	RASSF9	0.47	8.47	0.42	7.74e-16	Major depressive disorder;
LUSC	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	1.14	18.04	0.7	2.84e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.62	9.33	0.45	1.47e-18	Response to antineoplastic agents;
LUSC	cis	rs6736093	1.000	rs1967530	chr2:112659512	A/T	cg12686935	chr2:112915763	FBLN7	-0.39	-5.99	-0.31	5.37e-9	Coronary artery disease;
LUSC	cis	rs7674212	0.510	rs55715738	chr4:104130189	A/G	cg16532752	chr4:104119610	CENPE	-0.44	-6.54	-0.34	2.31e-10	Type 2 diabetes;
LUSC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg27121462	chr16:89883253	FANCA	0.54	8.74	0.43	1.19e-16	Vitiligo;
LUSC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24110177	chr3:50126178	RBM5	0.61	10.23	0.49	1.54e-21	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07761912	chr1:179846929	TOR1AIP2	-0.39	-6.79	-0.35	5.04e-11	Electrocardiographic conduction measures;
LUSC	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg21427119	chr20:30132790	HM13	-0.39	-6.43	-0.33	4.4e-10	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs1018836	0.886	rs10283086	chr8:91616651	G/A	cg16814680	chr8:91681699	NA	-0.79	-13.33	-0.59	8.65e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-7.44	-0.38	8.71e-13	Chronic sinus infection;
LUSC	cis	rs62400317	0.826	rs4544895	chr6:45271917	A/T	cg20913747	chr6:44695427	NA	-0.46	-7.49	-0.38	6.15e-13	Total body bone mineral density;
LUSC	cis	rs6500395	0.926	rs11645193	chr16:48594229	C/T	cg04672837	chr16:48644449	N4BP1	0.43	6.17	0.32	1.94e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg26304593	chr6:42947056	PEX6	-0.54	-8.49	-0.42	6.8e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7212590	0.748	rs8073489	chr17:57861794	A/C	cg10252138	chr17:58120427	NA	-0.73	-6.91	-0.35	2.44e-11	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg09699651	chr6:150184138	LRP11	0.38	5.87	0.31	1.08e-8	Lung cancer;
LUSC	cis	rs34638657	0.673	rs67661146	chr16:82199669	G/A	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.47	-0.33	3.55e-10	Lung adenocarcinoma;
LUSC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg12463550	chr7:65579703	CRCP	-0.52	-7.45	-0.38	8.06e-13	Aortic root size;
LUSC	cis	rs728616	0.558	rs2880599	chr10:82164435	A/G	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.78	-0.3	1.71e-8	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9875589	1.000	rs9875589	chr3:13961157	A/C	cg19554555	chr3:13937349	NA	0.45	6.99	0.36	1.52e-11	Ovarian reserve;
LUSC	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg09491104	chr22:46646882	C22orf40	-0.67	-7.08	-0.36	8.7e-12	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg26043149	chr18:55253948	FECH	-0.46	-7.05	-0.36	1.01e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.82	14.89	0.63	8e-39	Blood protein levels;
LUSC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	8.68	0.43	1.73e-16	Mean platelet volume;
LUSC	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg05855489	chr10:104503620	C10orf26	-0.48	-7.35	-0.37	1.53e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg08601574	chr20:25228251	PYGB	-0.43	-6.59	-0.34	1.71e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.62	-5.98	-0.31	5.62e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs3862435	0.666	rs2905963	chr15:90964891	C/T	cg22089800	chr15:90895588	ZNF774	0.6	6.52	0.34	2.66e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs11039100	0.607	rs10838607	chr11:5778538	T/C	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs895636	1.000	rs895636	chr2:45188353	A/G	cg14014731	chr9:19378679	RPS6	-0.51	-6.43	-0.33	4.3e-10	Metabolite levels;Fasting plasma glucose;
LUSC	cis	rs1113500	0.897	rs4628530	chr1:108638708	T/G	cg11967332	chr1:108735228	SLC25A24	0.39	5.92	0.31	7.96e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs28655083	1.000	rs7197078	chr16:77072735	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.38	-5.65	-0.3	3.47e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	7.69	0.39	1.69e-13	Response to antipsychotic treatment;
LUSC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-7.2	-0.37	3.9e-12	Obesity-related traits;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg08100565	chr3:140660748	SLC25A36	0.39	6.29	0.33	9.83e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg06877462	chr1:205807181	PM20D1	0.54	10.18	0.49	2.2e-21	Menarche (age at onset);
LUSC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04398451	chr17:18023971	MYO15A	0.67	11.78	0.54	5.06e-27	Total body bone mineral density;
LUSC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.67	-9.32	-0.45	1.63e-18	Testicular germ cell tumor;
LUSC	cis	rs73195822	0.614	rs7975139	chr12:111221131	T/C	cg12870014	chr12:110450643	ANKRD13A	0.67	6.89	0.35	2.75e-11	Itch intensity from mosquito bite;
LUSC	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg25930673	chr12:123319894	HIP1R	-0.62	-6.1	-0.32	2.92e-9	Schizophrenia;
LUSC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.85e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2692947	0.550	rs4613327	chr2:96583823	G/A	cg22654517	chr2:96458247	NA	0.37	6.74	0.35	6.77e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs9860340	0.730	rs1509782	chr3:87641526	C/T	cg03644585	chr7:884825	UNC84A	0.42	6.03	0.31	4.35e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg05729581	chr11:3078854	CARS	-0.53	-7.97	-0.4	2.55e-14	Longevity;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09523086	chr21:33984856	C21orf59	-0.5	-6.59	-0.34	1.74e-10	Hepatitis;
LUSC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-1.02	-15.45	-0.65	5.12e-41	Initial pursuit acceleration;
LUSC	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg13072238	chr3:49761600	GMPPB	-0.37	-6.14	-0.32	2.3e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.11	-0.58	5.82e-32	Platelet count;
LUSC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg18681998	chr4:17616180	MED28	0.85	15.88	0.66	1.07e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg09904177	chr6:26538194	HMGN4	-0.73	-6.85	-0.35	3.67e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg19046167	chr17:80928561	B3GNTL1	0.49	7.1	0.36	7.62e-12	Glycated hemoglobin levels;
LUSC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg09365446	chr1:150670422	GOLPH3L	0.52	7.98	0.4	2.3e-14	Tonsillectomy;
LUSC	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.77	-10.36	-0.49	5.21e-22	Ileal carcinoids;
LUSC	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.33	-7.31	-0.37	2.05e-12	Dupuytren's disease;
LUSC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg22823121	chr1:150693482	HORMAD1	0.51	7.56	0.38	4.03e-13	Melanoma;
LUSC	cis	rs6545977	0.531	rs2539981	chr2:63104904	T/C	cg17519650	chr2:63277830	OTX1	0.74	10.94	0.51	5.14e-24	Prostate cancer;
LUSC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg05347473	chr6:146136440	FBXO30	0.41	7.0	0.36	1.4e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7911712	0.515	rs1771996	chr10:45258544	T/C	cg04948906	chr11:124413229	OR8B12	0.46	6.04	0.31	4.18e-9	Emphysema-related traits;
LUSC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg12257692	chr3:49977190	RBM6	-0.26	-7.24	-0.37	3.2e-12	Body mass index;
LUSC	trans	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg04995722	chr7:26192034	NFE2L3	-0.39	-6.38	-0.33	6.03e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.81e-10	Life satisfaction;
LUSC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.93	14.88	0.63	9.31e-39	Multiple sclerosis;
LUSC	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.34	-0.37	1.65e-12	Psoriasis;
LUSC	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	7.64	0.39	2.32e-13	Height;
LUSC	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.86	-0.31	1.13e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.54	6.97	0.36	1.69e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs6733011	0.500	rs2280142	chr2:99434872	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-5.78	-0.3	1.67e-8	Bipolar disorder;
LUSC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.63	0.86	5.12e-99	Chronic sinus infection;
LUSC	cis	rs12042938	1.000	rs823158	chr1:231782650	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	5.99	0.31	5.36e-9	Neuranatomic and neurocognitive phenotypes;
LUSC	trans	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg08975724	chr8:8085496	FLJ10661	0.43	6.12	0.32	2.56e-9	Retinal vascular caliber;
LUSC	cis	rs2286885	1.000	rs10819169	chr9:129249625	C/T	cg15282417	chr9:129245246	FAM125B	0.38	6.33	0.33	7.96e-10	Intraocular pressure;
LUSC	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.01e-14	Retinal vascular caliber;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06588483	chr12:42877540	PRICKLE1	0.77	5.98	0.31	5.67e-9	Cognitive performance;
LUSC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06873352	chr17:61820015	STRADA	0.56	8.57	0.42	3.99e-16	Height;
LUSC	trans	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.49	-0.33	3.1e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg23887609	chr12:130822674	PIWIL1	0.46	6.64	0.34	1.3100000000000001e-10	Menopause (age at onset);
LUSC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.75	13.71	0.6	3.03e-34	Calcium levels;
LUSC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg14440974	chr22:39074834	NA	-0.35	-5.87	-0.31	1.02e-8	Menopause (age at onset);
LUSC	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg26816564	chr1:7831052	VAMP3	0.7	9.63	0.47	1.54e-19	Inflammatory bowel disease;
LUSC	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	1.0	19.73	0.73	5.26e-58	Diastolic blood pressure;Systolic blood pressure;
LUSC	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.6	-0.34	1.66e-10	Retinal vascular caliber;
LUSC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.4	5.96	0.31	6.35e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg13072238	chr3:49761600	GMPPB	-0.36	-5.88	-0.31	9.99e-9	Body mass index;
LUSC	trans	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg07211511	chr3:129823064	LOC729375	-0.53	-6.08	-0.32	3.25e-9	Blood pressure (smoking interaction);
LUSC	cis	rs4363385	0.510	rs6689510	chr1:153048039	G/A	cg25856811	chr1:152973957	SPRR3	-0.38	-6.23	-0.32	1.43e-9	Inflammatory skin disease;
LUSC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg04450456	chr4:17643702	FAM184B	0.38	6.5	0.33	2.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg11901034	chr3:128598214	ACAD9	-0.42	-6.69	-0.34	9.27e-11	IgG glycosylation;
LUSC	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg01028140	chr2:1542097	TPO	-0.62	-7.98	-0.4	2.43e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg21724239	chr8:58056113	NA	0.55	6.55	0.34	2.17e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg10207240	chr12:122356781	WDR66	0.4	5.75	0.3	1.98e-8	Mean corpuscular volume;
LUSC	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.6	9.51	0.46	3.96e-19	Morning vs. evening chronotype;
LUSC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg26924012	chr15:45694286	SPATA5L1	1.14	20.41	0.75	1.08e-60	Homoarginine levels;
LUSC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg09877947	chr5:131593287	PDLIM4	0.45	7.04	0.36	1.07e-11	Acylcarnitine levels;
LUSC	cis	rs7147624	0.608	rs4902413	chr14:66187091	T/C	cg03016385	chr14:66212404	NA	-0.79	-8.56	-0.42	4.19e-16	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4714291	0.855	rs1743971	chr6:40095927	A/C	cg02267698	chr19:7991119	CTXN1	0.53	7.4	0.38	1.11e-12	Strep throat;
LUSC	cis	rs11039100	1.000	rs61875914	chr11:5828299	T/G	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7771547	0.607	rs9348997	chr6:36430560	A/G	cg07856975	chr6:36356162	ETV7	-0.37	-6.53	-0.34	2.5e-10	Platelet distribution width;
LUSC	cis	rs250677	0.522	rs6580590	chr5:148360374	C/T	cg18129178	chr5:148520854	ABLIM3	0.52	7.36	0.37	1.41e-12	Breast cancer;
LUSC	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg04362960	chr10:104952993	NT5C2	1.15	13.39	0.59	5.24e-33	Arsenic metabolism;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25875824	chr1:29063431	YTHDF2	-0.4	-6.0	-0.31	5.01e-9	Electrocardiographic conduction measures;
LUSC	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.55	-8.73	-0.43	1.28e-16	Schizophrenia;
LUSC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg00166722	chr3:10149974	C3orf24	0.4	5.91	0.31	8.24e-9	Alzheimer's disease;
LUSC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.66	0.6	4.84e-34	Platelet count;
LUSC	cis	rs68092024	0.704	rs704575	chr3:99486075	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	6.34	0.33	7.66e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.76	-0.47	5.98e-20	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.67	0.39	1.94e-13	Prudent dietary pattern;
LUSC	cis	rs10761482	0.861	rs7085259	chr10:62107418	T/G	cg18175470	chr10:62150864	ANK3	-0.51	-7.24	-0.37	3.06e-12	Schizophrenia;
LUSC	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg25237894	chr2:233734115	C2orf82	-0.34	-5.99	-0.31	5.31e-9	Coronary artery disease;
LUSC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs17661538	0.504	rs35667846	chr10:18464913	G/A	cg03634479	chr10:18430412	CACNB2	0.63	5.86	0.31	1.11e-8	Response to antipsychotic treatment;
LUSC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19717773	chr7:2847554	GNA12	-0.36	-5.91	-0.31	8.38e-9	Height;
LUSC	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg24375607	chr4:120327624	NA	0.7	11.14	0.52	1.03e-24	Corneal astigmatism;
LUSC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.52	7.4	0.38	1.13e-12	Tuberculosis;
LUSC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg23985595	chr17:80112537	CCDC57	0.31	5.93	0.31	7.45e-9	Life satisfaction;
LUSC	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg23625390	chr15:77176239	SCAPER	0.64	9.52	0.46	3.66e-19	Blood metabolite levels;
LUSC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg16060761	chr17:80687452	NA	0.42	6.5	0.34	2.87e-10	Breast cancer;
LUSC	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg15704280	chr7:45808275	SEPT13	0.66	7.32	0.37	1.82e-12	Axial length;
LUSC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-6.03	-0.31	4.35e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.4	6.04	0.31	4.15e-9	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs9325144	0.681	rs7957376	chr12:39096518	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.56	0.34	2.04e-10	Morning vs. evening chronotype;
LUSC	cis	rs62400317	0.723	rs755	chr6:44795790	C/T	cg18551225	chr6:44695536	NA	-0.47	-7.5	-0.38	5.8e-13	Total body bone mineral density;
LUSC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	12.18	0.55	1.71e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs62238980	0.614	rs77511414	chr22:32406941	A/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	7.23	0.37	3.22e-12	Iron status biomarkers;
LUSC	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg04545296	chr12:48745243	ZNF641	0.33	6.21	0.32	1.57e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs4081724	0.638	rs17602094	chr19:33848683	A/T	cg15602950	chr3:45731220	SACM1L	-0.52	-6.1	-0.32	3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg01657329	chr11:68192670	LRP5	-0.44	-7.1	-0.36	7.71e-12	Total body bone mineral density;
LUSC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-0.87	-16.03	-0.66	2.6900000000000002e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7771547	0.519	rs28371845	chr6:36377709	C/T	cg07856975	chr6:36356162	ETV7	0.44	6.38	0.33	5.9e-10	Platelet distribution width;
LUSC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.01	0.4	1.9e-14	Parkinson's disease;
LUSC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.06e-12	Motion sickness;
LUSC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.67	-0.57	2.7e-30	Type 2 diabetes;
LUSC	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg06096015	chr1:231504339	EGLN1	0.53	9.06	0.44	1.1e-17	Hemoglobin concentration;
LUSC	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg15654264	chr1:150340011	RPRD2	-0.64	-10.73	-0.51	2.85e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-0.69	-10.89	-0.51	7.74e-24	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs7374394	1.000	rs2301052	chr3:184953662	C/T	cg02182827	chr1:51808561	TTC39A	0.36	6.0	0.31	5.26e-9	Cognitive performance;
LUSC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg16743903	chr16:89593216	SPG7	-0.37	-5.88	-0.31	9.84e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.63	-0.43	2.54e-16	Rheumatoid arthritis;
LUSC	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg07828340	chr4:882639	GAK	0.97	9.61	0.47	1.8e-19	Parkinson's disease;
LUSC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.99	0.4	2.22e-14	Bipolar disorder;
LUSC	cis	rs2658782	0.789	rs2658773	chr11:93126914	A/G	cg15737290	chr11:93063684	CCDC67	0.64	7.92	0.4	3.59e-14	Pulmonary function decline;
LUSC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.16e-9	Diabetic kidney disease;
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.84	15.09	0.64	1.35e-39	Menarche (age at onset);
LUSC	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-0.86	-16.38	-0.67	1.17e-44	Urate levels;
LUSC	cis	rs117623576	0.941	rs211422	chr10:32398589	A/G	cg03047570	chr10:32398778	NA	0.73	7.86	0.4	5.39e-14	Anti-saccade response;
LUSC	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.5	-0.34	2.85e-10	Myopia (pathological);
LUSC	cis	rs13082711	0.911	rs35904501	chr3:27443317	T/C	cg02860705	chr3:27208620	NA	0.48	7.91	0.4	3.7e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	trans	rs2562456	0.833	rs55790393	chr19:21506184	A/T	cg00806126	chr19:22604979	ZNF98	-0.42	-5.99	-0.31	5.56e-9	Pain;
LUSC	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg07148914	chr20:33460835	GGT7	0.54	8.4	0.42	1.33e-15	Height;
LUSC	cis	rs73206853	0.764	rs55859138	chr12:110775610	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	6.44	0.33	4.21e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs12776158	0.901	rs35355528	chr10:71216268	A/G	cg12610070	chr10:71211762	TSPAN15	-0.46	-6.05	-0.31	3.9e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.58	0.38	3.37e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg03188948	chr7:1209495	NA	0.67	7.1	0.36	7.38e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg22963979	chr7:1858916	MAD1L1	-0.59	-8.98	-0.44	1.96e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.57	-0.42	4e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs2625529	0.652	rs2929518	chr15:72332748	A/C	cg16672083	chr15:72433130	SENP8	0.49	8.12	0.41	9.35e-15	Red blood cell count;
LUSC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.46	0.78	9.92e-69	Prudent dietary pattern;
LUSC	cis	rs36093844	0.752	rs74404559	chr11:85565669	G/A	cg25872744	chr11:85566296	CCDC83	-0.45	-5.78	-0.3	1.68e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs10992471	0.603	rs7865019	chr9:95325631	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.81	-0.35	4.47e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg09904177	chr6:26538194	HMGN4	0.75	14.27	0.62	2.07e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	0.94	12.53	0.57	8.85e-30	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg25206134	chr2:45395956	NA	0.59	6.79	0.35	5.26e-11	Bipolar disorder;
LUSC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg12564285	chr5:131593104	PDLIM4	0.49	8.68	0.43	1.72e-16	Acylcarnitine levels;
LUSC	trans	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-6.36	-0.33	6.69e-10	Neuroticism;
LUSC	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg10596483	chr8:143751796	JRK	0.52	7.57	0.38	3.79e-13	Schizophrenia;
LUSC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg03354898	chr7:1950403	MAD1L1	-0.36	-7.13	-0.36	6.41e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	12.4	0.56	2.72e-29	Prudent dietary pattern;
LUSC	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg07423050	chr13:99094983	FARP1	-0.45	-8.57	-0.42	3.77e-16	Longevity;
LUSC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg18758796	chr5:131593413	PDLIM4	0.4	7.07	0.36	9.38e-12	Blood metabolite levels;
LUSC	cis	rs9650315	0.929	rs11988517	chr8:57181143	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.8	0.35	4.85e-11	Height;
LUSC	trans	rs62238980	0.614	rs17744899	chr22:32406766	G/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.96	0.31	6.32e-9	Morning vs. evening chronotype;
LUSC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg05623727	chr3:50126028	RBM5	-0.34	-6.36	-0.33	6.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg13535736	chr9:111863775	C9orf5	-0.42	-6.9	-0.35	2.56e-11	Menarche (age at onset);
LUSC	cis	rs113835537	0.529	rs3819247	chr11:66293779	T/C	cg24851651	chr11:66362959	CCS	0.55	8.06	0.4	1.33e-14	Airway imaging phenotypes;
LUSC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg04450456	chr4:17643702	FAM184B	0.4	6.74	0.35	6.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21582582	chr3:182698605	DCUN1D1	0.46	8.19	0.41	5.64e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg22920501	chr2:26401640	FAM59B	-0.77	-11.45	-0.53	8.11e-26	Gut microbiome composition (summer);
LUSC	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-8.94	-0.44	2.61e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg04518342	chr5:131593106	PDLIM4	-0.45	-7.53	-0.38	4.66e-13	Blood metabolite levels;
LUSC	cis	rs9837602	1.000	rs7627991	chr3:99808338	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-5.71	-0.3	2.49e-8	Breast cancer;
LUSC	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg14844989	chr11:31128820	NA	-0.37	-5.76	-0.3	1.95e-8	Red blood cell count;
LUSC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.68	-10.47	-0.5	2.3e-22	Aortic root size;
LUSC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	0.7	14.63	0.62	8.79e-38	Prudent dietary pattern;
LUSC	cis	rs907683	0.584	rs12920	chr2:220285666	C/G	cg15015639	chr2:220282977	DES	0.3	6.96	0.36	1.86e-11	Resting heart rate;
LUSC	cis	rs7106204	0.514	rs12805363	chr11:24258357	T/G	ch.11.24196551F	chr11:24239977	NA	0.73	6.22	0.32	1.49e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg04414720	chr1:150670196	GOLPH3L	0.53	8.11	0.41	1e-14	Melanoma;
LUSC	trans	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg26043149	chr18:55253948	FECH	0.48	6.99	0.36	1.48e-11	Bone mineral density;
LUSC	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg24634471	chr8:143751801	JRK	0.59	9.01	0.44	1.66e-17	Schizophrenia;
LUSC	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg14346243	chr4:90757452	SNCA	-0.41	-5.97	-0.31	5.97e-9	Neuroticism;
LUSC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg24562669	chr7:97807699	LMTK2	0.35	6.22	0.32	1.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg22618164	chr12:122356400	WDR66	-0.51	-7.49	-0.38	6.2e-13	Mean corpuscular volume;
LUSC	cis	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05881034	chr3:42623675	SEC22C	-0.49	-6.39	-0.33	5.48e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.08	0.4	1.19e-14	Parkinson's disease;
LUSC	cis	rs9937943	0.564	rs74820302	chr16:74698252	A/T	cg01733217	chr16:74700730	RFWD3	0.66	7.81	0.39	7.44e-14	Neutrophil percentage of white cells;
LUSC	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg09491104	chr22:46646882	C22orf40	-0.7	-6.2	-0.32	1.67e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg16447950	chr5:562315	NA	-0.59	-7.06	-0.36	9.96e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg15494558	chr6:150152522	LRP11	0.33	5.72	0.3	2.4e-8	Lung cancer;
LUSC	cis	rs6740322	0.748	rs6727631	chr2:43470408	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-6.48	-0.33	3.23e-10	Coronary artery disease;
LUSC	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	1.12	16.95	0.68	6.26e-47	Corneal structure;
LUSC	trans	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.67	0.34	1.05e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg04414720	chr1:150670196	GOLPH3L	0.54	8.46	0.42	8.59e-16	Melanoma;
LUSC	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg00898013	chr13:113819073	PROZ	-0.58	-8.8	-0.43	7.44e-17	Platelet distribution width;
LUSC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08470875	chr2:26401718	FAM59B	-0.69	-9.35	-0.46	1.28e-18	Gut microbiome composition (summer);
LUSC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg17376030	chr22:41985996	PMM1	-0.48	-5.9	-0.31	8.9e-9	Vitiligo;
LUSC	cis	rs10140922	0.966	rs4982259	chr14:35821950	T/C	cg07166546	chr14:35805898	NA	-0.24	-5.89	-0.31	9.53e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03264133	chr6:25882463	NA	0.39	6.91	0.35	2.47e-11	Blood metabolite levels;
LUSC	cis	rs394563	0.601	rs382720	chr6:149795261	C/T	cg07828024	chr6:149772892	ZC3H12D	0.38	7.86	0.39	5.49e-14	Dupuytren's disease;
LUSC	trans	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg01973587	chr1:228161476	NA	0.44	7.98	0.4	2.35e-14	Diastolic blood pressure;
LUSC	cis	rs2219968	0.770	rs12545292	chr8:78886841	A/T	cg00738934	chr8:78996279	NA	-0.39	-6.95	-0.36	1.93e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg00383909	chr3:49044727	WDR6	1.08	9.51	0.46	3.95e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13763729	chr18:5294883	ZFP161	-0.47	-6.2	-0.32	1.67e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23281280	chr6:28129359	ZNF389	-0.44	-5.77	-0.3	1.8e-8	Depression;
LUSC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11645453	chr3:52864694	ITIH4	0.33	7.57	0.38	3.67e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg20608306	chr11:116969690	SIK3	-0.33	-6.14	-0.32	2.35e-9	Blood protein levels;
LUSC	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg14664628	chr15:75095509	CSK	0.42	6.02	0.31	4.6e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg16606324	chr3:10149918	C3orf24	0.58	8.23	0.41	4.27e-15	Alzheimer's disease;
LUSC	cis	rs9309473	1.000	rs7564890	chr2:73641853	T/C	cg20560298	chr2:73613845	ALMS1	-0.43	-6.18	-0.32	1.88e-9	Metabolite levels;
LUSC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	0.86	11.31	0.53	2.52e-25	Glomerular filtration rate (creatinine);
LUSC	trans	rs3889199	0.740	rs7412276	chr1:59667721	A/C	cg24327262	chr19:46929907	NA	-0.39	-6.09	-0.32	3.09e-9	Pulse pressure;
LUSC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.07	13.4	0.59	4.64e-33	Sexual dysfunction (female);
LUSC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15320075	chr8:145703422	NA	0.66	11.33	0.53	2.16e-25	Age at first birth;
LUSC	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg12756686	chr19:29218302	NA	0.53	6.19	0.32	1.74e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9309473	1.000	rs9309473	chr2:73743982	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.56	-0.34	2.06e-10	Metabolite levels;
LUSC	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-9.56	-0.46	2.6e-19	Schizophrenia;
LUSC	cis	rs7215564	0.818	rs78905718	chr17:78604278	G/A	cg23238734	chr17:78661607	RPTOR	0.44	5.79	0.3	1.65e-8	Myopia (pathological);
LUSC	trans	rs11681884	0.892	rs72950867	chr2:113858671	A/G	cg09636715	chr7:27217057	HOXA10	0.73	6.04	0.31	4.16e-9	Stroke;
LUSC	cis	rs3741151	0.686	rs7123985	chr11:73260463	A/C	cg17517138	chr11:73019481	ARHGEF17	0.82	7.67	0.39	1.9e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg03233332	chr7:66118400	NA	0.41	5.94	0.31	7.17e-9	Aortic root size;
LUSC	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg22532475	chr10:104410764	TRIM8	-0.35	-7.71	-0.39	1.43e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg03929089	chr4:120376271	NA	-0.45	-6.12	-0.32	2.58e-9	HDL cholesterol;
LUSC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.69	11.45	0.53	7.93e-26	Heart rate;
LUSC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.7	0.39	1.61e-13	Prudent dietary pattern;
LUSC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg03060546	chr3:49711283	APEH	0.72	12.22	0.56	1.2e-28	Resting heart rate;
LUSC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.83	11.31	0.53	2.5e-25	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4704187	0.617	rs1477936	chr5:74448502	T/A	cg03227963	chr5:74354835	NA	0.32	6.91	0.35	2.44e-11	Response to amphetamines;
LUSC	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	7.31	0.37	1.98e-12	Morning vs. evening chronotype;
LUSC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.87	0.4	5.07e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg22875332	chr1:76189707	ACADM	0.64	9.1	0.45	8.36e-18	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg22709100	chr7:91322751	NA	-0.39	-5.83	-0.3	1.33e-8	Breast cancer;
LUSC	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg00012203	chr2:219082015	ARPC2	0.59	9.89	0.48	2.19e-20	Ulcerative colitis;
LUSC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg05585544	chr11:47624801	NA	-0.4	-6.91	-0.35	2.44e-11	Subjective well-being;
LUSC	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg18209359	chr17:80159595	CCDC57	0.38	6.45	0.33	4e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs79911532	0.515	rs117690214	chr7:75718237	C/T	cg03592824	chr7:75666768	STYXL1	0.67	6.41	0.33	4.98e-10	Mononucleosis;
LUSC	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg25206134	chr2:45395956	NA	0.63	7.25	0.37	2.9e-12	Neuroticism;
LUSC	trans	rs225245	0.782	rs321617	chr17:33915246	A/G	cg19694781	chr19:47549865	TMEM160	-0.42	-6.65	-0.34	1.18e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg18904891	chr8:8559673	CLDN23	0.4	6.08	0.32	3.35e-9	Mood instability;
LUSC	trans	rs2392780	0.667	rs432470	chr8:128339044	C/T	cg10195415	chr17:73887371	TRIM65	0.42	6.65	0.34	1.19e-10	Breast cancer (early onset);
LUSC	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.85	10.76	0.51	2.21e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-5.86	-0.31	1.1e-8	Response to antipsychotic treatment;
LUSC	cis	rs367943	0.712	rs7734304	chr5:112730165	G/A	cg12552261	chr5:112820674	MCC	0.37	6.11	0.32	2.72e-9	Type 2 diabetes;
LUSC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg21132104	chr15:45694354	SPATA5L1	0.56	7.82	0.39	7.06e-14	Homoarginine levels;
LUSC	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.83	-0.35	4.03e-11	Triglycerides;
LUSC	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg15556689	chr8:8085844	FLJ10661	0.58	8.56	0.42	4.29e-16	Neuroticism;
LUSC	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg12615879	chr12:58013172	SLC26A10	0.42	10.38	0.49	4.68e-22	Multiple sclerosis;
LUSC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg22166914	chr1:53195759	ZYG11B	0.61	10.32	0.49	7.26e-22	Monocyte count;
LUSC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg08270630	chr22:50330655	NA	-0.44	-6.62	-0.34	1.43e-10	Schizophrenia;
LUSC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11644478	chr21:40555479	PSMG1	0.71	9.18	0.45	4.71e-18	Cognitive function;
LUSC	trans	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg13565492	chr6:43139072	SRF	-0.73	-10.59	-0.5	8.78e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18404041	chr3:52824283	ITIH1	-0.5	-9.57	-0.46	2.44e-19	Electroencephalogram traits;
LUSC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg10792982	chr14:105748885	BRF1	-0.47	-8.71	-0.43	1.44e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg23601095	chr6:26197514	HIST1H3D	0.69	7.36	0.37	1.45e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.4	-5.99	-0.31	5.42e-9	Menarche (age at onset);
LUSC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.62	-9.78	-0.47	4.96e-20	Height;
LUSC	cis	rs10392	0.543	rs2867240	chr20:37538354	C/T	cg27552599	chr20:37590471	DHX35	0.42	6.67	0.34	1.09e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18864164	chr10:115934049	MIR2110;C10orf118	0.45	6.38	0.33	6.04e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.73	-10.1	-0.48	4.22e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs12618769	0.570	rs17032866	chr2:99132415	A/G	cg10123293	chr2:99228465	UNC50	0.45	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00684032	chr4:1343700	KIAA1530	0.37	6.5	0.34	2.89e-10	Obesity-related traits;
LUSC	cis	rs1982963	0.627	rs3783632	chr14:52498111	C/A	cg10843707	chr14:52510701	NID2	0.47	6.3	0.33	9.23e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.81	-10.31	-0.49	8.18e-22	Exhaled nitric oxide output;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03586379	chr3:140660603	SLC25A36	-0.48	-6.08	-0.32	3.24e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.6	9.48	0.46	4.93e-19	Morning vs. evening chronotype;
LUSC	cis	rs76878669	0.606	rs2282531	chr11:66099494	C/T	cg18002602	chr11:66138449	SLC29A2	-0.47	-8.47	-0.42	8.19e-16	Educational attainment (years of education);
LUSC	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg17168535	chr8:21777572	XPO7	0.77	13.88	0.6	6.9e-35	Mean corpuscular volume;
LUSC	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	1.08	16.53	0.67	2.91e-45	Corneal structure;
LUSC	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg03929089	chr4:120376271	NA	-0.59	-6.29	-0.33	9.96e-10	Axial length;
LUSC	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.59	-9.56	-0.46	2.61e-19	Body mass index;
LUSC	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.7	0.34	8.72e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs73200209	0.626	rs56159711	chr12:116578050	T/C	cg01776926	chr12:116560359	MED13L	-0.51	-6.13	-0.32	2.45e-9	Total body bone mineral density;
LUSC	cis	rs9467711	0.720	rs7749823	chr6:26158079	A/C	cg16898833	chr6:26189333	HIST1H4D	0.71	7.15	0.36	5.5e-12	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg07898084	chr13:53029385	CKAP2	0.45	6.32	0.33	8.15e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7561273	0.586	rs9309225	chr2:24292863	T/C	cg20701182	chr2:24300061	SF3B14	0.45	5.77	0.3	1.76e-8	Quantitative traits;
LUSC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs983392	0.679	rs636341	chr11:60019161	A/C	cg02771260	chr11:59836817	MS4A3	0.37	6.1	0.32	3.02e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg08017756	chr2:100939284	LONRF2	-0.43	-8.03	-0.4	1.69e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.54	-10.61	-0.5	7.47e-23	Educational attainment;
LUSC	cis	rs9039	1.000	rs56193985	chr16:9207199	C/A	cg08831531	chr16:9218945	NA	-0.67	-10.39	-0.49	4.22e-22	Menopause (age at onset);
LUSC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg21960279	chr19:17905606	B3GNT3	0.38	6.0	0.31	5.2e-9	Tumor biomarkers;
LUSC	cis	rs2019216	0.542	rs1850564	chr17:21911794	T/C	cg22648282	chr17:21454238	C17orf51	-0.52	-7.8	-0.39	7.82e-14	Pelvic organ prolapse;
LUSC	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.8	-14.87	-0.63	9.73e-39	Obesity-related traits;
LUSC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg05507819	chr15:63340323	TPM1	0.62	8.39	0.42	1.42e-15	Platelet count;
LUSC	trans	rs62238980	0.614	rs117185558	chr22:32403523	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	trans	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.67	8.31	0.41	2.48e-15	Type 2 diabetes;
LUSC	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg09021430	chr5:549028	NA	-0.56	-7.36	-0.37	1.41e-12	Obesity-related traits;
LUSC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg10253484	chr15:75165896	SCAMP2	-0.47	-6.61	-0.34	1.52e-10	Breast cancer;
LUSC	trans	rs800082	0.507	rs2222701	chr3:144258813	C/T	cg24215973	chr2:240111563	HDAC4	0.48	7.48	0.38	6.75e-13	Smoking behavior;
LUSC	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg21045802	chr8:109455806	TTC35	0.42	6.65	0.34	1.17e-10	Dupuytren's disease;
LUSC	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-7.23	-0.37	3.28e-12	Morning vs. evening chronotype;
LUSC	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg22709100	chr7:91322751	NA	0.44	6.44	0.33	4.07e-10	Breast cancer;
LUSC	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg04518342	chr5:131593106	PDLIM4	0.37	6.87	0.35	3.15e-11	Blood metabolite levels;
LUSC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg16240275	chr20:61666158	NCRNA00029	0.42	9.39	0.46	9.76e-19	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	10.92	0.51	6.24e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg12863693	chr15:85201151	NMB	0.34	6.13	0.32	2.45e-9	Schizophrenia;
LUSC	cis	rs9314323	0.698	rs1064807	chr8:26236978	C/T	cg13160058	chr8:26243215	BNIP3L	-0.42	-7.63	-0.39	2.56e-13	Red cell distribution width;
LUSC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg12386194	chr3:101231763	SENP7	0.64	8.64	0.43	2.35e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.91	0.35	2.41e-11	Axial length;
LUSC	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg18753928	chr3:113234510	CCDC52	-0.51	-7.96	-0.4	2.8e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg24562669	chr7:97807699	LMTK2	-0.35	-6.2	-0.32	1.65e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg02175503	chr12:58329896	NA	0.48	6.92	0.35	2.33e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	10.48	0.5	2.03e-22	Hip circumference adjusted for BMI;
LUSC	cis	rs12681287	0.577	rs10481197	chr8:87546551	A/T	cg27223183	chr8:87520930	FAM82B	0.53	6.99	0.36	1.54e-11	Caudate activity during reward;
LUSC	cis	rs4704187	0.663	rs28448485	chr5:74425775	G/A	cg03227963	chr5:74354835	NA	0.32	6.86	0.35	3.34e-11	Response to amphetamines;
LUSC	cis	rs6998277	1.000	rs6998277	chr8:103639941	T/C	cg10187029	chr8:103597600	NA	0.67	8.42	0.42	1.09e-15	Migraine;
LUSC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg05738196	chr6:26577821	NA	0.53	8.32	0.41	2.23e-15	Schizophrenia;
LUSC	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg10840412	chr1:235813424	GNG4	0.54	7.09	0.36	8.24e-12	Bipolar disorder;
LUSC	trans	rs1941687	0.526	rs9959347	chr18:31316169	C/T	cg27147174	chr7:100797783	AP1S1	-0.52	-8.19	-0.41	5.46e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg10862848	chr6:42927986	GNMT	-0.27	-6.28	-0.33	1.04e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08677398	chr8:58056175	NA	0.51	6.68	0.34	9.95e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	7.18	0.37	4.69e-12	Electroencephalogram traits;
LUSC	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg11502198	chr6:26597334	ABT1	-0.56	-8.98	-0.44	1.95e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg02569458	chr12:86230093	RASSF9	0.58	9.78	0.47	4.91e-20	Major depressive disorder;
LUSC	cis	rs2580764	0.566	rs2920878	chr2:55296415	C/T	cg20993754	chr2:55226987	RTN4	-0.36	-5.99	-0.31	5.34e-9	Mean platelet volume;
LUSC	trans	rs10411161	0.702	rs10403189	chr19:52400673	A/G	cg22319618	chr22:45562946	NUP50	0.5	6.02	0.31	4.63e-9	Breast cancer;
LUSC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg06212747	chr3:49208901	KLHDC8B	0.54	7.13	0.36	6.21e-12	Parkinson's disease;
LUSC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-11.66	-0.54	1.34e-26	Coronary artery disease;
LUSC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	11.75	0.54	6.37e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg08601574	chr20:25228251	PYGB	0.43	6.57	0.34	1.94e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg09455208	chr3:40491958	NA	0.59	11.13	0.52	1.13e-24	Renal cell carcinoma;
LUSC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11764359	chr7:65958608	NA	-0.68	-11.03	-0.52	2.52e-24	Cotinine glucuronidation;
LUSC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	6.11	0.32	2.75e-9	Tonsillectomy;
LUSC	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.82	-12.54	-0.57	7.94e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.71	-0.34	8.45e-11	Monocyte percentage of white cells;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04499797	chr7:7222060	C1GALT1	-0.42	-6.75	-0.35	6.74e-11	Electrocardiographic conduction measures;
LUSC	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18876405	chr7:65276391	NA	0.55	8.45	0.42	8.98e-16	Aortic root size;
LUSC	cis	rs10740039	0.883	rs7920170	chr10:62407524	G/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.86	-0.35	3.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs17133449	0.718	rs7905751	chr10:4752837	A/T	cg17844448	chr7:27782764	TAX1BP1	-0.38	-6.15	-0.32	2.2e-9	Major depressive disorder;
LUSC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	8.79	0.43	8.24e-17	Height;
LUSC	trans	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg25214090	chr10:38739885	LOC399744	0.42	6.3	0.33	9.58e-10	Corneal astigmatism;
LUSC	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg05855489	chr10:104503620	C10orf26	-0.68	-10.0	-0.48	8.83e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9581857	0.685	rs17808758	chr13:28036412	C/T	cg22138327	chr13:27999177	GTF3A	0.74	7.71	0.39	1.46e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	trans	rs1908814	0.510	rs7819276	chr8:11755804	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-5.95	-0.31	6.72e-9	Neuroticism;
LUSC	cis	rs9486719	0.843	rs2499787	chr6:96841762	G/C	cg06623918	chr6:96969491	KIAA0776	0.76	8.63	0.43	2.51e-16	Migraine;Coronary artery disease;
LUSC	cis	rs225245	0.782	rs225272	chr17:33969911	T/C	cg05299278	chr17:33885742	SLFN14	0.31	6.77	0.35	5.81e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg01528321	chr10:82214614	TSPAN14	-0.59	-8.83	-0.44	5.82e-17	Post bronchodilator FEV1;
LUSC	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg02569458	chr12:86230093	RASSF9	-0.48	-7.59	-0.38	3.19e-13	Major depressive disorder;
LUSC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-0.86	-17.47	-0.69	5.36e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg25173405	chr17:45401733	C17orf57	-0.37	-5.73	-0.3	2.22e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.47	-0.33	3.41e-10	High light scatter reticulocyte count;
LUSC	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg06271696	chr7:157225062	NA	-0.43	-8.34	-0.42	1.99e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg22496339	chr2:162101262	NA	-0.52	-7.54	-0.38	4.4e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg22166914	chr1:53195759	ZYG11B	-0.7	-12.07	-0.55	4.3e-28	Monocyte count;
LUSC	cis	rs2425143	1.000	rs56904633	chr20:34400757	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.71	-0.3	2.56e-8	Blood protein levels;
LUSC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.24	0.52	4.63e-25	Prudent dietary pattern;
LUSC	cis	rs11785693	0.909	rs62489558	chr8:4968620	G/A	cg26367366	chr8:4980734	NA	0.83	8.58	0.43	3.53e-16	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	15.67	0.65	7.14e-42	Platelet count;
LUSC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.84	0.3	1.22e-8	Menopause (age at onset);
LUSC	cis	rs9399401	0.845	rs263184	chr6:142862022	A/G	cg03128060	chr6:142623767	GPR126	-0.3	-5.65	-0.3	3.42e-8	Chronic obstructive pulmonary disease;
LUSC	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg13042288	chr15:90349979	ANPEP	-0.48	-6.77	-0.35	5.86e-11	Uric acid levels;
LUSC	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.56	0.6	1.12e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6580649	0.941	rs1968071	chr12:48489357	A/G	cg24011408	chr12:48396354	COL2A1	-0.44	-6.07	-0.32	3.41e-9	Lung cancer;
LUSC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.45	-9.28	-0.45	2.24e-18	Paraoxonase activity;
LUSC	trans	rs62458065	0.850	rs7804998	chr7:32461197	T/C	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.25	-0.32	1.28e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg18681998	chr4:17616180	MED28	0.69	11.12	0.52	1.23e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.88	-0.35	2.96e-11	Lung cancer;
LUSC	trans	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg02800362	chr5:177631904	HNRNPAB	0.83	12.44	0.56	1.95e-29	Obesity-related traits;
LUSC	cis	rs12541635	0.902	rs59123253	chr8:107006365	C/T	cg10147462	chr8:107024639	NA	0.55	9.97	0.48	1.16e-20	Age of smoking initiation;
LUSC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs1568889	1.000	rs9783281	chr11:28033786	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.59	0.46	2.08e-19	Bipolar disorder;
LUSC	cis	rs117623576	0.941	rs67225815	chr10:32408946	C/T	cg03047570	chr10:32398778	NA	-0.64	-7.15	-0.36	5.37e-12	Anti-saccade response;
LUSC	cis	rs6754311	0.593	rs313528	chr2:136445869	G/A	cg07169764	chr2:136633963	MCM6	0.55	7.29	0.37	2.32e-12	Mosquito bite size;
LUSC	cis	rs12989701	0.877	rs34854727	chr2:127855392	C/T	cg08168897	chr2:127865431	BIN1	0.64	7.98	0.4	2.38e-14	Alzheimer's disease (late onset);
LUSC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	16.16	0.66	8.26e-44	Platelet count;
LUSC	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.51	-10.37	-0.49	5.03e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg09904177	chr6:26538194	HMGN4	-0.45	-6.63	-0.34	1.38e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg05855489	chr10:104503620	C10orf26	0.57	7.43	0.38	9.15e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6982240	0.514	rs2060357	chr8:142259829	G/A	cg27411547	chr8:142287226	NA	-0.47	-7.97	-0.4	2.51e-14	Tonsillectomy;
LUSC	cis	rs6977940	0.558	rs11770455	chr7:2888014	G/A	cg19731401	chr7:2775893	GNA12	0.71	7.84	0.39	5.97e-14	White matter integrity;
LUSC	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	1.48	13.19	0.59	2.78e-32	Atopic dermatitis;
LUSC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg15556689	chr8:8085844	FLJ10661	-0.62	-10.05	-0.48	6.23e-21	Mood instability;
LUSC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg05347473	chr6:146136440	FBXO30	0.52	8.92	0.44	3.16e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2455601	0.786	rs2568070	chr11:8976893	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.46	-8.06	-0.4	1.38e-14	Schizophrenia;
LUSC	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg15556689	chr8:8085844	FLJ10661	0.61	9.44	0.46	6.47e-19	Neuroticism;
LUSC	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg05555928	chr11:63887634	MACROD1	-0.49	-6.05	-0.31	3.95e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.96	0.4	2.7e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4363385	0.510	rs11812015	chr1:153045584	G/T	cg25856811	chr1:152973957	SPRR3	-0.38	-6.23	-0.32	1.43e-9	Inflammatory skin disease;
LUSC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.15	-0.36	5.65e-12	Body mass index;
LUSC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21984481	chr17:79567631	NPLOC4	-0.57	-10.79	-0.51	1.76e-23	Eye color traits;
LUSC	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg24596788	chr1:163392923	NA	0.41	6.94	0.36	2.03e-11	Motion sickness;
LUSC	cis	rs8103278	0.662	rs16980051	chr19:46345886	T/C	cg20908204	chr19:46285434	DMPK	-0.3	-5.68	-0.3	2.95e-8	Coronary artery disease;
LUSC	cis	rs13385	0.769	rs13188675	chr5:139606718	G/A	cg26211634	chr5:139558579	C5orf32	0.45	6.75	0.35	6.51e-11	Atrial fibrillation;
LUSC	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg17507749	chr15:85114479	UBE2QP1	0.57	7.32	0.37	1.88e-12	Schizophrenia;
LUSC	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-7.88	-0.4	4.54e-14	Menarche (age at onset);
LUSC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.89	-0.31	9.56e-9	Tonsillectomy;
LUSC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg18479299	chr3:125709523	NA	-0.5	-5.79	-0.3	1.66e-8	Blood pressure (smoking interaction);
LUSC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-1.12	-24.24	-0.8	1.33e-75	Height;
LUSC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17261708	chr5:176794207	RGS14	0.34	6.0	0.31	4.99e-9	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7605827	0.897	rs2178238	chr2:15533520	C/T	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg25110126	chr1:46999211	NA	-0.57	-7.4	-0.38	1.11e-12	Monobrow;
LUSC	trans	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg18187862	chr3:45730750	SACM1L	0.55	6.99	0.36	1.51e-11	Primary sclerosing cholangitis;
LUSC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg04362960	chr10:104952993	NT5C2	0.59	9.39	0.46	9.6e-19	Reticulocyte count;
LUSC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg11752832	chr7:134001865	SLC35B4	0.56	8.8	0.43	7.57e-17	Mean platelet volume;
LUSC	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg20203395	chr5:56204925	C5orf35	-0.46	-6.91	-0.35	2.42e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg12559939	chr2:27858050	GPN1	-0.41	-6.32	-0.33	8.49e-10	Oral cavity cancer;
LUSC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06481639	chr22:41940642	POLR3H	-0.56	-6.23	-0.32	1.4e-9	Vitiligo;
LUSC	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg01557791	chr16:72042693	DHODH	0.55	8.23	0.41	4.15e-15	Fibrinogen levels;
LUSC	cis	rs189798	0.807	rs12785	chr8:8994936	A/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.8	0.35	4.82e-11	Myopia (pathological);
LUSC	cis	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs9815354	0.812	rs74947509	chr3:42006323	T/C	cg03022575	chr3:42003672	ULK4	0.79	8.31	0.41	2.48e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10050311	0.746	rs72665791	chr4:87678787	C/T	cg10685359	chr4:87814065	C4orf36	-0.43	-5.66	-0.3	3.19e-8	Insulin-related traits;
LUSC	trans	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg24313572	chr1:56050060	NA	0.29	5.97	0.31	5.9e-9	Morning vs. evening chronotype;
LUSC	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg13902645	chr11:5959945	NA	-0.6	-8.26	-0.41	3.39e-15	DNA methylation (variation);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06074314	chr2:70475575	TIA1	0.47	7.02	0.36	1.28e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	6.87	0.35	3.08e-11	Multiple sclerosis;
LUSC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs250677	0.559	rs17109198	chr5:148369712	C/T	cg18129178	chr5:148520854	ABLIM3	-0.5	-7.25	-0.37	3e-12	Breast cancer;
LUSC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.07	-0.32	3.51e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg04691961	chr3:161091175	C3orf57	-0.34	-5.89	-0.31	9.47e-9	Morning vs. evening chronotype;
LUSC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg11608241	chr8:8085544	FLJ10661	0.4	5.87	0.31	1.04e-8	Mood instability;
LUSC	trans	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg01620082	chr3:125678407	NA	-0.51	-6.04	-0.31	4.06e-9	Depression;
LUSC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.63	-8.13	-0.41	8.49e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs2273669	0.667	rs12215344	chr6:109329641	A/C	cg05315195	chr6:109294784	ARMC2	-0.53	-5.9	-0.31	8.99e-9	Prostate cancer;
LUSC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg23205692	chr1:25664452	TMEM50A	0.43	6.54	0.34	2.25e-10	Plateletcrit;Mean corpuscular volume;
LUSC	trans	rs1973993	0.689	rs17131755	chr1:96886167	G/A	cg10631902	chr5:14652156	NA	-0.54	-8.07	-0.4	1.29e-14	Weight;
LUSC	cis	rs9815354	0.723	rs79741604	chr3:41947321	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.49	0.42	6.81e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg06618935	chr21:46677482	NA	-0.36	-6.89	-0.35	2.77e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-9.21	-0.45	3.59e-18	Personality dimensions;
LUSC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg05084668	chr3:125655381	ALG1L	-0.5	-6.93	-0.35	2.15e-11	Blood pressure (smoking interaction);
LUSC	cis	rs6545883	0.929	rs3732171	chr2:61749690	C/T	cg15711740	chr2:61764176	XPO1	-0.52	-8.24	-0.41	3.95e-15	Tuberculosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17818798	chr19:14228473	PRKACA	-0.51	-6.84	-0.35	3.83e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6681460	0.674	rs7543607	chr1:67012592	G/T	cg02459107	chr1:67143332	SGIP1	0.37	6.15	0.32	2.24e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.68	-0.54	1.16e-26	Coffee consumption (cups per day);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12044295	chr8:56686133	TMEM68;TGS1	0.73	6.1	0.32	2.91e-9	Cognitive performance;
LUSC	cis	rs7923609	1.000	rs1935	chr10:64927823	C/G	cg01631684	chr10:65280961	REEP3	-0.41	-6.47	-0.33	3.49e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.9	11.64	0.54	1.69e-26	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg27539214	chr16:67997921	SLC12A4	-0.51	-6.76	-0.35	6.3e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg26380479	chr7:97908229	NA	-0.29	-6.39	-0.33	5.55e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4450131	0.522	rs11245328	chr10:126358413	G/A	cg20435097	chr10:126320824	FAM53B	0.24	6.05	0.31	3.87e-9	White blood cell count (basophil);
LUSC	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	0.93	8.78	0.43	8.83e-17	Mitochondrial DNA levels;
LUSC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg07424592	chr7:64974309	NA	0.6	5.82	0.3	1.41e-8	Diabetic kidney disease;
LUSC	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg09184832	chr6:79620586	NA	-0.44	-7.2	-0.37	4.13e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg15691649	chr6:25882328	NA	-0.41	-5.95	-0.31	6.66e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.81	15.39	0.64	9.35e-41	Menarche (age at onset);
LUSC	cis	rs722599	0.748	rs741096	chr14:75351487	A/G	cg08847533	chr14:75593920	NEK9	-0.48	-6.88	-0.35	3e-11	IgG glycosylation;
LUSC	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21659725	chr3:3221576	CRBN	-0.58	-8.2	-0.41	5.33e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs12980942	0.935	rs1865052	chr19:41824467	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.15	0.32	2.17e-9	Coronary artery disease;
LUSC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg11861562	chr11:117069780	TAGLN	0.41	7.39	0.37	1.23e-12	Blood protein levels;
LUSC	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.95	0.31	6.89e-9	Breast cancer;
LUSC	cis	rs9815354	0.680	rs73073274	chr3:42022810	T/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.57	9.74	0.47	6.56e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg15448220	chr1:150897856	SETDB1	0.4	5.87	0.31	1.02e-8	Melanoma;
LUSC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.99	-0.44	1.85e-17	Electroencephalogram traits;
LUSC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22618164	chr12:122356400	WDR66	0.6	8.76	0.43	9.78e-17	Mean corpuscular volume;
LUSC	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg10523679	chr1:76189770	ACADM	-0.53	-7.87	-0.4	5.03e-14	Daytime sleep phenotypes;
LUSC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	5.99	0.31	5.3e-9	Platelet count;
LUSC	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-6.62	-0.34	1.4e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg20701182	chr2:24300061	SF3B14	0.75	7.54	0.38	4.62e-13	Lymphocyte counts;
LUSC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.5	0.53	5.42e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg07211511	chr3:129823064	LOC729375	-0.55	-6.07	-0.32	3.38e-9	Blood pressure (smoking interaction);
LUSC	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg05973401	chr12:123451056	ABCB9	0.54	6.73	0.35	7.52e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg12311346	chr5:56204834	C5orf35	-0.62	-9.52	-0.46	3.7e-19	Coronary artery disease;
LUSC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg10018233	chr7:150070692	REPIN1	0.34	6.01	0.31	4.93e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.4	-0.38	1.15e-12	Psoriasis;
LUSC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	1.08	21.02	0.75	4.3e-63	Cognitive ability;
LUSC	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg25817165	chr18:72167213	CNDP2	-0.72	-9.74	-0.47	6.57e-20	Refractive error;
LUSC	cis	rs12956009	0.583	rs11663646	chr18:44862895	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.41	-6.14	-0.32	2.29e-9	Educational attainment (years of education);
LUSC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg08270630	chr22:50330655	NA	-0.41	-5.92	-0.31	7.82e-9	Schizophrenia;
LUSC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg07701084	chr6:150067640	NUP43	0.58	8.86	0.44	4.78e-17	Lung cancer;
LUSC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06022373	chr22:39101656	GTPBP1	0.85	14.43	0.62	4.86e-37	Menopause (age at onset);
LUSC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	0.92	15.84	0.66	1.49e-42	Menopause (age at onset);
LUSC	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg20701182	chr2:24300061	SF3B14	0.58	6.2	0.32	1.71e-9	Lymphocyte counts;
LUSC	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg10978503	chr1:24200527	CNR2	-0.49	-11.45	-0.53	7.89e-26	Immature fraction of reticulocytes;
LUSC	cis	rs7830933	0.955	rs1550280	chr8:23601830	C/T	cg04349084	chr8:23602677	NA	0.38	6.06	0.31	3.72e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUSC	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg25214090	chr10:38739885	LOC399744	0.57	8.42	0.42	1.14e-15	Corneal astigmatism;
LUSC	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg25457927	chr22:38595422	NA	-0.4	-7.91	-0.4	3.84e-14	Cutaneous nevi;
LUSC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg13628971	chr7:2884303	GNA12	0.49	7.21	0.37	3.68e-12	Height;
LUSC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.23	-0.41	4.37e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs977987	0.806	rs12449170	chr16:75463012	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.39e-11	Dupuytren's disease;
LUSC	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg15423357	chr2:25149977	NA	0.35	6.43	0.33	4.46e-10	Body mass index;
LUSC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg13628971	chr7:2884303	GNA12	0.45	6.51	0.34	2.78e-10	Height;
LUSC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7084921	0.608	rs11592689	chr10:101865516	A/T	cg11888571	chr10:102027403	CWF19L1	-0.45	-6.23	-0.32	1.4e-9	Bone mineral density;
LUSC	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg09998033	chr7:158218633	PTPRN2	-0.52	-8.34	-0.42	1.98e-15	Obesity-related traits;
LUSC	cis	rs922692	0.710	rs1994016	chr15:79080234	C/T	cg00540400	chr15:79124168	NA	-0.35	-6.09	-0.32	3.02e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg13902645	chr11:5959945	NA	0.66	10.1	0.48	4.18e-21	DNA methylation (variation);
LUSC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12016809	chr21:47604291	C21orf56	0.41	6.24	0.32	1.36e-9	Testicular germ cell tumor;
LUSC	cis	rs72781680	0.821	rs111571980	chr2:24201695	C/G	cg08917208	chr2:24149416	ATAD2B	0.6	6.9	0.35	2.66e-11	Lymphocyte counts;
LUSC	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg09839279	chr12:125627357	AACS	-0.35	-6.64	-0.34	1.26e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6722750	0.933	rs12999721	chr2:64407710	C/T	cg22352474	chr2:64371530	PELI1	0.51	7.63	0.39	2.54e-13	Neuroticism;
LUSC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.84	-0.44	5.44e-17	Monocyte count;
LUSC	cis	rs738322	0.511	rs5756947	chr22:38573230	G/A	cg25457927	chr22:38595422	NA	-0.37	-6.93	-0.35	2.13e-11	Cutaneous nevi;
LUSC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.83	14.99	0.63	3.28e-39	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg08975724	chr8:8085496	FLJ10661	0.45	6.53	0.34	2.41e-10	Neuroticism;
LUSC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg09035930	chr12:129282057	SLC15A4	0.73	15.97	0.66	4.51e-43	Systemic lupus erythematosus;
LUSC	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.91	-0.31	8.25e-9	Neuroticism;
LUSC	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.74	12.2	0.56	1.45e-28	Alcohol dependence;
LUSC	cis	rs3770081	1.000	rs3770081	chr2:86280925	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.07	-6.9	-0.35	2.62e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.3	0.45	1.83e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22688104	chr4:47916759	NFXL1	-0.44	-6.53	-0.34	2.5e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg15744005	chr10:104629667	AS3MT	-0.28	-5.93	-0.31	7.59e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs2729385	1.000	rs2729385	chr11:57262993	C/T	cg02565297	chr12:133144810	FBRSL1	-0.42	-6.05	-0.31	3.9e-9	Interleukin-18 levels;
LUSC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-11.53	-0.53	3.91e-26	Monocyte count;
LUSC	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.84	-0.39	6.1e-14	Blood metabolite levels;
LUSC	cis	rs4363385	0.530	rs6663448	chr1:152894627	C/T	cg00922841	chr1:152955080	SPRR1A	-0.36	-5.99	-0.31	5.47e-9	Inflammatory skin disease;
LUSC	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg12639453	chr1:2035780	PRKCZ	-0.3	-6.3	-0.33	9.13e-10	Height;
LUSC	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg19554555	chr3:13937349	NA	-0.38	-5.71	-0.3	2.44e-8	Ovarian reserve;
LUSC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg18904891	chr8:8559673	CLDN23	0.38	5.73	0.3	2.27e-8	Joint mobility (Beighton score);
LUSC	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.61	-0.34	1.53e-10	Total cholesterol levels;
LUSC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg27535305	chr1:53392650	SCP2	-0.49	-9.55	-0.46	2.99e-19	Monocyte count;
LUSC	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.25	-0.45	2.79e-18	Acne (severe);
LUSC	cis	rs2859741	0.528	rs2359647	chr1:37483054	A/T	cg09363841	chr1:37513479	NA	-0.39	-7.47	-0.38	6.88e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg00509249	chr6:109615579	CCDC162	0.32	5.87	0.31	1.05e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.39	-0.42	1.42e-15	Coronary artery disease;
LUSC	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.36	0.37	1.41e-12	Lung cancer in ever smokers;
LUSC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg11062466	chr8:58055876	NA	0.51	6.9	0.35	2.67e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	10.64	0.5	5.61e-23	Homoarginine levels;
LUSC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg06096015	chr1:231504339	EGLN1	0.57	10.04	0.48	6.89e-21	Hemoglobin concentration;
LUSC	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg04455712	chr21:45112962	RRP1B	-0.44	-8.04	-0.4	1.61e-14	Mean corpuscular volume;
LUSC	cis	rs7119038	0.818	rs4936444	chr11:118743338	A/G	cg19308663	chr11:118741387	NA	-0.33	-5.8	-0.3	1.57e-8	Sjögren's syndrome;
LUSC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg15556689	chr8:8085844	FLJ10661	0.69	11.24	0.52	4.36e-25	Mood instability;
LUSC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg15691649	chr6:25882328	NA	-0.37	-6.14	-0.32	2.31e-9	Blood metabolite levels;
LUSC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.08	13.44	0.59	3.21e-33	Sexual dysfunction (female);
LUSC	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg23950597	chr19:37808831	NA	-0.64	-7.64	-0.39	2.31e-13	Coronary artery calcification;
LUSC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg03233332	chr7:66118400	NA	-0.42	-6.09	-0.32	3.05e-9	Aortic root size;
LUSC	cis	rs2932538	0.961	rs2932529	chr1:113193364	G/A	cg22162597	chr1:113214053	CAPZA1	-0.7	-9.88	-0.48	2.33e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg05082376	chr22:42548792	NA	-0.45	-7.19	-0.37	4.24e-12	Schizophrenia;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg11239145	chr4:26320844	RBPJ	0.52	6.61	0.34	1.5e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs791888	0.698	rs7893652	chr10:89431060	A/G	cg13926569	chr10:89418898	PAPSS2	-0.36	-7.26	-0.37	2.74e-12	Magnesium levels;
LUSC	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg25182066	chr10:30743637	MAP3K8	0.45	6.63	0.34	1.33e-10	Inflammatory bowel disease;
LUSC	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg27426351	chr10:43362370	NA	-0.43	-6.0	-0.31	5.26e-9	Blood protein levels;
LUSC	cis	rs7192380	0.965	rs9938213	chr16:69640590	T/C	cg26679644	chr16:69762563	NA	0.35	6.2	0.32	1.7e-9	Sjögren's syndrome;
LUSC	cis	rs11714574	0.557	rs6787467	chr3:58377888	G/A	cg23715586	chr3:58305044	RPP14	0.35	6.31	0.33	9.08e-10	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);
LUSC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg08048268	chr3:133502702	NA	0.29	5.66	0.3	3.35e-8	Iron status biomarkers;
LUSC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg12257692	chr3:49977190	RBM6	-0.26	-7.25	-0.37	2.87e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg18335740	chr13:41363409	SLC25A15	0.79	14.99	0.63	3.41e-39	Lewy body disease;
LUSC	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg19920283	chr7:105172520	RINT1	0.58	6.28	0.32	1.08e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg20283391	chr11:68216788	NA	-0.58	-8.24	-0.41	4.1e-15	Total body bone mineral density;
LUSC	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.89	-0.35	2.85e-11	QT interval;
LUSC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.83	0.43	6.17e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.68	12.94	0.58	2.53e-31	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg02038168	chr22:39784481	NA	-0.41	-6.11	-0.32	2.83e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs12464559	0.649	rs7557801	chr2:152586658	G/A	cg01189475	chr2:152685088	ARL5A	0.63	5.65	0.3	3.52e-8	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg14458575	chr2:238380390	NA	0.44	5.67	0.3	3.16e-8	Prostate cancer;
LUSC	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg13010199	chr12:38710504	ALG10B	0.7	10.92	0.51	5.92e-24	Bladder cancer;
LUSC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14893161	chr1:205819251	PM20D1	0.81	16.1	0.66	1.5e-43	Monocyte percentage of white cells;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04522604	chr5:111093927	C5orf13	0.53	7.69	0.39	1.7e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg00579484	chr14:23475993	C14orf93	0.39	5.74	0.3	2.12e-8	Cognitive ability (multi-trait analysis);
LUSC	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg21890820	chr11:65308645	LTBP3	0.5	7.36	0.37	1.47e-12	Bone mineral density;
LUSC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	9.26	0.45	2.49e-18	Motion sickness;
LUSC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg22823121	chr1:150693482	HORMAD1	-0.5	-7.04	-0.36	1.1e-11	Blood protein levels;
LUSC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg20135002	chr11:47629003	NA	-0.51	-8.11	-0.41	9.83e-15	Subjective well-being;
LUSC	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg19628046	chr18:33552617	C18orf21	0.49	5.91	0.31	8.33e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs2262909	0.962	rs390730	chr19:22233509	C/A	cg17074339	chr11:11642133	GALNTL4	-0.46	-7.07	-0.36	9.1e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg03929089	chr4:120376271	NA	-0.83	-11.43	-0.53	9e-26	Height;
LUSC	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg09165964	chr15:75287851	SCAMP5	-0.47	-6.85	-0.35	3.54e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06022373	chr22:39101656	GTPBP1	-0.76	-11.35	-0.53	1.84e-25	Menopause (age at onset);
LUSC	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg19773385	chr1:10388646	KIF1B	-0.54	-8.39	-0.42	1.42e-15	Hepatocellular carcinoma;
LUSC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg07157834	chr1:205819609	PM20D1	0.44	6.18	0.32	1.89e-9	Menarche (age at onset);
LUSC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg06713675	chr4:122721982	EXOSC9	-0.66	-11.43	-0.53	9.68e-26	Type 2 diabetes;
LUSC	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.34	0.49	6.17e-22	Bladder cancer;
LUSC	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.75	-13.04	-0.58	1.03e-31	Sudden cardiac arrest;
LUSC	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.61	0.5	7.28e-23	Colorectal cancer;
LUSC	cis	rs2346177	0.846	rs62138876	chr2:46650672	C/A	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-8.47	-0.42	7.93e-16	HDL cholesterol;
LUSC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	1.02	20.24	0.74	5.16e-60	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14140629	chr6:127587906	RNF146	-0.45	-6.66	-0.34	1.13e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs317865	0.737	rs73234642	chr4:16186730	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.62	6.0	0.31	5.04e-9	Kidney disease (early stage) in type 1 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17602823	chr1:28586543	SESN2	-0.49	-6.52	-0.34	2.56e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-9.83	-0.47	3.34e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg23188684	chr11:67383651	NA	0.35	6.27	0.32	1.1e-9	Mean corpuscular volume;
LUSC	cis	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg02972257	chr16:68554789	NA	0.45	5.79	0.3	1.6e-8	Colorectal cancer;
LUSC	cis	rs9462027	0.539	rs9469883	chr6:34758627	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.02	-0.31	4.55e-9	Systemic lupus erythematosus;
LUSC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg03806693	chr22:41940476	POLR3H	0.99	13.72	0.6	2.7200000000000002e-34	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.58	-0.42	3.72e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg27432699	chr2:27873401	GPN1	-0.55	-8.24	-0.41	3.98e-15	Total body bone mineral density;
LUSC	cis	rs7264396	0.563	rs17093093	chr20:34380925	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.4	-0.38	1.08e-12	Total cholesterol levels;
LUSC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg19592336	chr6:28129416	ZNF389	0.45	5.85	0.3	1.16e-8	Depression;
LUSC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.97	-0.36	1.67e-11	Blood metabolite levels;
LUSC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg23719950	chr11:63933701	MACROD1	-0.61	-8.07	-0.4	1.29e-14	Mean platelet volume;
LUSC	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg00509249	chr6:109615579	CCDC162	-0.35	-6.29	-0.33	1.01e-9	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
LUSC	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-5.78	-0.3	1.68e-8	IgG glycosylation;
LUSC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg09796270	chr17:17721594	SREBF1	0.4	6.93	0.35	2.23e-11	Total body bone mineral density;
LUSC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.28	-0.56	7.46e-29	Alzheimer's disease;
LUSC	cis	rs3733418	0.929	rs17623445	chr4:165894658	C/T	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.47	-5.75	-0.3	2.02e-8	Obesity-related traits;
LUSC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs13394619	0.775	rs10165819	chr2:11722102	A/T	cg07314298	chr2:11723111	GREB1	-0.54	-9.4	-0.46	8.73e-19	Endometriosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15487600	chr1:155113158	DPM3	-0.47	-6.2	-0.32	1.71e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.32	0.56	5.14e-29	Prudent dietary pattern;
LUSC	cis	rs1790761	0.505	rs7927657	chr11:67346988	T/C	cg24690094	chr11:67383802	NA	-0.3	-5.71	-0.3	2.46e-8	Mean corpuscular volume;
LUSC	cis	rs71403859	0.667	rs12149264	chr16:71720921	T/G	cg08717414	chr16:71523259	ZNF19	-0.64	-7.31	-0.37	2.02e-12	Post bronchodilator FEV1;
LUSC	trans	rs11935423	0.778	rs1800804	chr4:100495817	T/C	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.1	-0.32	3e-9	Gut microbiome composition (summer);
LUSC	trans	rs12439619	0.693	rs7165536	chr15:82566084	T/A	cg04831495	chr15:85060580	GOLGA6L5	-0.45	-6.12	-0.32	2.56e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg26043149	chr18:55253948	FECH	-0.45	-6.99	-0.36	1.49e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg10356904	chr22:49881777	NA	-0.29	-5.8	-0.3	1.55e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg11062466	chr8:58055876	NA	0.77	8.65	0.43	2.16e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg23840854	chr1:161414152	NA	-0.89	-11.0	-0.52	3.1e-24	Rheumatoid arthritis;
LUSC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22590775	chr19:49891494	CCDC155	0.56	7.32	0.37	1.92e-12	Multiple sclerosis;
LUSC	trans	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	8.86	0.44	4.84e-17	Type 2 diabetes;
LUSC	trans	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.75	-0.35	6.4e-11	Neuroticism;
LUSC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	15.68	0.65	6.64e-42	Platelet count;
LUSC	cis	rs4285028	0.747	rs12634032	chr3:121524575	G/A	cg11130432	chr3:121712080	ILDR1	-0.63	-9.29	-0.45	2e-18	Multiple sclerosis;
LUSC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.41	-0.33	5.08e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-8.15	-0.41	7.17e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.79	-0.57	9.23e-31	Platelet count;
LUSC	cis	rs6496044	0.568	rs12898783	chr15:86066100	G/C	cg13263323	chr15:86062960	AKAP13	-0.38	-6.27	-0.32	1.12e-9	Interstitial lung disease;
LUSC	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg06096015	chr1:231504339	EGLN1	-0.53	-9.26	-0.45	2.5e-18	Hemoglobin concentration;
LUSC	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg01689657	chr7:91764605	CYP51A1	0.31	5.65	0.3	3.48e-8	Breast cancer;
LUSC	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg05738196	chr6:26577821	NA	-0.48	-6.87	-0.35	3.21e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7809950	1.000	rs2520268	chr7:107191161	T/A	cg23024343	chr7:107201750	COG5	-0.58	-9.07	-0.44	1.01e-17	Coronary artery disease;
LUSC	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.88	0.31	1.02e-8	Lung cancer;
LUSC	cis	rs75229567	0.618	rs11495622	chr12:70161286	G/A	cg10114359	chr12:70132523	RAB3IP	1.34	12.39	0.56	3.01e-29	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg03733263	chr8:22462867	KIAA1967	0.98	17.34	0.69	1.72e-48	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00166722	chr3:10149974	C3orf24	0.6	8.36	0.42	1.72e-15	Alzheimer's disease;
LUSC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg15839431	chr19:19639596	YJEFN3	-0.43	-5.95	-0.31	6.64e-9	Tonsillectomy;
LUSC	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	0.86	13.86	0.6	8.21e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	trans	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.53	-0.53	4.11e-26	Colorectal cancer;
LUSC	cis	rs6723108	0.616	rs6752634	chr2:135407355	G/A	cg12500956	chr2:135428796	TMEM163	-0.27	-6.29	-0.33	9.76e-10	Type 2 diabetes;
LUSC	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg05855489	chr10:104503620	C10orf26	0.63	9.17	0.45	4.86e-18	Arsenic metabolism;
LUSC	cis	rs921665	0.831	rs7578217	chr2:3175376	A/G	cg02624386	chr2:3182749	NA	-0.58	-6.76	-0.35	6.19e-11	World class endurance athleticism;
LUSC	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg05855489	chr10:104503620	C10orf26	0.65	9.75	0.47	6.17e-20	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.8	0.35	4.94e-11	Rheumatoid arthritis;
LUSC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg23711669	chr6:146136114	FBXO30	0.87	16.1	0.66	1.46e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg18512352	chr11:47633146	NA	0.46	9.23	0.45	3.18e-18	Subjective well-being;
LUSC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg08219700	chr8:58056026	NA	0.51	5.9	0.31	8.96e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1595825	0.891	rs16866980	chr2:198513009	A/C	cg00982548	chr2:198649783	BOLL	-0.52	-6.61	-0.34	1.52e-10	Ulcerative colitis;
LUSC	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg00999904	chr2:3704751	ALLC	-0.47	-7.34	-0.37	1.67e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg02574844	chr11:5959923	NA	-0.42	-5.89	-0.31	9.19e-9	DNA methylation (variation);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24796471	chr19:6737389	GPR108	0.47	6.26	0.32	1.19e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg20701182	chr2:24300061	SF3B14	0.57	5.87	0.31	1.04e-8	Lymphocyte counts;
LUSC	cis	rs12760731	0.517	rs34437852	chr1:178228721	T/C	cg00404053	chr1:178313656	RASAL2	0.69	6.96	0.36	1.78e-11	Obesity-related traits;
LUSC	trans	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg16487237	chr3:137487248	NA	0.36	6.02	0.31	4.69e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg21433313	chr16:3507492	NAT15	0.45	5.94	0.31	7.02e-9	Body mass index (adult);
LUSC	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.72	7.98	0.4	2.36e-14	Yeast infection;
LUSC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.92	-0.31	7.84e-9	Platelet count;
LUSC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.41	6.14	0.32	2.35e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.7	-0.34	9.12e-11	Alzheimer's disease (late onset);
LUSC	trans	rs208520	1.000	rs208520	chr6:66952828	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-12.26	-0.56	8.59e-29	Exhaled nitric oxide output;
LUSC	cis	rs2742417	1.000	rs2245705	chr3:45749722	A/G	cg09608765	chr3:45636137	LIMD1	-0.35	-7.09	-0.36	7.95e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-0.69	-10.47	-0.5	2.25e-22	Platelet distribution width;
LUSC	cis	rs8099014	1.000	rs9946396	chr18:56107163	G/A	cg12907477	chr18:56117327	MIR122	0.39	6.18	0.32	1.84e-9	Platelet count;
LUSC	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg09877947	chr5:131593287	PDLIM4	-0.36	-5.78	-0.3	1.71e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24531977	chr5:56204891	C5orf35	0.84	13.55	0.6	1.27e-33	Initial pursuit acceleration;
LUSC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg20203395	chr5:56204925	C5orf35	0.46	6.82	0.35	4.38e-11	Coronary artery disease;
LUSC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg07636037	chr3:49044803	WDR6	0.46	6.64	0.34	1.28e-10	Resting heart rate;
LUSC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg23262073	chr20:60523788	NA	-0.43	-6.16	-0.32	2.08e-9	Body mass index;
LUSC	trans	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg26043149	chr18:55253948	FECH	0.49	7.3	0.37	2.09e-12	Bone mineral density;
LUSC	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	0.69	11.09	0.52	1.52e-24	Blood metabolite ratios;
LUSC	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	0.59	9.17	0.45	4.98e-18	Breast cancer;
LUSC	cis	rs7516138	1.000	rs4240896	chr1:9713500	A/G	cg26573321	chr1:9711663	PIK3CD	-0.63	-11.02	-0.52	2.66e-24	Monocyte count;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg05374718	chr1:112282133	C1orf183	0.44	6.31	0.33	8.91e-10	Mosquito bite size;
LUSC	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg17366294	chr4:99064904	C4orf37	0.57	8.73	0.43	1.22e-16	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs72792513	1.000	rs56113869	chr2:22909457	G/A	cg05844895	chr16:88969569	CBFA2T3	0.53	6.19	0.32	1.77e-9	Hepatitis B;
LUSC	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg24812749	chr6:127587940	RNF146	0.64	9.56	0.46	2.76e-19	Breast cancer;
LUSC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg00149659	chr3:10157352	C3orf10	0.64	9.07	0.44	1.04e-17	Alzheimer's disease;
LUSC	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg21798802	chr22:38057573	PDXP	0.48	10.53	0.5	1.4e-22	Fat distribution (HIV);
LUSC	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg22491629	chr6:157744540	C6orf35	-0.9	-10.83	-0.51	1.29e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg25173405	chr17:45401733	C17orf57	-0.39	-6.19	-0.32	1.74e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg18187862	chr3:45730750	SACM1L	0.53	6.9	0.35	2.6e-11	Primary sclerosing cholangitis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg24268822	chr3:49059985	NDUFAF3	0.46	6.16	0.32	2.04e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg06521331	chr12:34319734	NA	0.39	6.12	0.32	2.67e-9	Bladder cancer;
LUSC	cis	rs1256061	0.603	rs1256041	chr14:64738029	A/G	cg23250157	chr14:64679961	SYNE2	0.32	5.7	0.3	2.68e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs2147959	0.882	rs4653552	chr1:228628138	A/G	cg18477163	chr1:228402036	OBSCN	-0.42	-5.86	-0.31	1.08e-8	Adult asthma;
LUSC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.12	0.36	6.47e-12	Bipolar disorder;
LUSC	cis	rs6545883	0.929	rs2593625	chr2:61668769	C/T	cg15711740	chr2:61764176	XPO1	-0.46	-7.12	-0.36	6.47e-12	Tuberculosis;
LUSC	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg06636551	chr8:101224915	SPAG1	-0.38	-7.13	-0.36	6.31e-12	Atrioventricular conduction;
LUSC	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.61	9.64	0.47	1.49e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12620999	0.941	rs4663701	chr2:238036884	C/T	cg23555395	chr2:238036564	NA	-0.51	-8.73	-0.43	1.28e-16	Systemic lupus erythematosus;
LUSC	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg22681709	chr2:178499509	PDE11A	-0.48	-7.38	-0.37	1.26e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg06521331	chr12:34319734	NA	-0.46	-7.59	-0.38	3.27e-13	Morning vs. evening chronotype;
LUSC	trans	rs800082	0.934	rs6788831	chr3:144290498	G/T	cg24215973	chr2:240111563	HDAC4	-0.48	-7.36	-0.37	1.43e-12	Smoking behavior;
LUSC	cis	rs73200209	0.744	rs61937387	chr12:116707971	A/T	cg01776926	chr12:116560359	MED13L	-0.49	-5.83	-0.3	1.29e-8	Total body bone mineral density;
LUSC	cis	rs3764021	0.870	rs7956831	chr12:9889157	A/G	cg20894963	chr12:9885564	CLECL1	-0.33	-6.82	-0.35	4.39e-11	Type 1 diabetes;
LUSC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00864171	chr11:67383662	NA	0.42	7.8	0.39	7.89e-14	Mean corpuscular volume;
LUSC	trans	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg18335740	chr13:41363409	SLC25A15	0.77	13.82	0.6	1.12e-34	Lewy body disease;
LUSC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg00745463	chr17:30367425	LRRC37B	-0.66	-8.06	-0.4	1.41e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg21427119	chr20:30132790	HM13	-0.42	-6.23	-0.32	1.38e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg15485101	chr11:133734466	NA	0.43	7.65	0.39	2.17e-13	Childhood ear infection;
LUSC	cis	rs9677476	0.909	rs6437010	chr2:232113263	G/C	cg07929768	chr2:232055508	NA	0.31	5.89	0.31	9.42e-9	Food antigen IgG levels;
LUSC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg06238570	chr21:40685208	BRWD1	0.48	7.37	0.37	1.34e-12	Cognitive function;
LUSC	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg24130564	chr14:104152367	KLC1	-0.44	-6.14	-0.32	2.32e-9	Body mass index;
LUSC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg12463550	chr7:65579703	CRCP	0.56	8.54	0.42	4.88e-16	Aortic root size;
LUSC	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg04374321	chr14:90722782	PSMC1	-0.42	-6.39	-0.33	5.65e-10	Mortality in heart failure;
LUSC	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg19683494	chr5:74908142	NA	0.59	8.03	0.4	1.68e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06112835	chr11:68658793	MRPL21	-0.47	-7.31	-0.37	1.95e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg04920474	chr2:44395004	PPM1B	0.7	8.86	0.44	4.73e-17	Height;
LUSC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg22963979	chr7:1858916	MAD1L1	0.56	8.84	0.44	5.71e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	0.65	9.07	0.44	1.06e-17	Methadone dose in opioid dependence;
LUSC	cis	rs4766566	0.694	rs3843673	chr12:111746499	A/G	cg10833066	chr12:111807467	FAM109A	0.54	10.07	0.48	5.41e-21	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUSC	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg01884057	chr2:25150051	NA	0.38	8.5	0.42	6.49e-16	Body mass index in non-asthmatics;
LUSC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	8.0	0.4	2.01e-14	Bipolar disorder;
LUSC	cis	rs8064299	0.536	rs2290038	chr17:72786611	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.92	-17.51	-0.69	3.52e-49	Monocyte count;
LUSC	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.34	-5.67	-0.3	3.11e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs73129298	0.551	rs4647959	chr20:48600557	T/C	cg25655593	chr20:48599521	SNAI1	0.6	6.43	0.33	4.49e-10	Inflammatory skin disease;
LUSC	cis	rs12368653	0.651	rs2277326	chr12:58202419	A/C	cg12615879	chr12:58013172	SLC26A10	-0.37	-8.32	-0.41	2.35e-15	Multiple sclerosis;
LUSC	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.82	-13.33	-0.59	8.19e-33	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.77	11.37	0.53	1.57e-25	Corneal astigmatism;
LUSC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg02951883	chr7:2050386	MAD1L1	-0.64	-12.48	-0.56	1.34e-29	Bipolar disorder and schizophrenia;
LUSC	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg22532475	chr10:104410764	TRIM8	0.26	6.12	0.32	2.6e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-1.04	-16.0	-0.66	3.43e-43	Initial pursuit acceleration;
LUSC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg13206674	chr6:150067644	NUP43	0.62	9.96	0.48	1.26e-20	Lung cancer;
LUSC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg10621924	chr7:39171070	POU6F2	0.49	7.81	0.39	7.63e-14	IgG glycosylation;
LUSC	cis	rs7608623	0.644	rs2339940	chr2:24251787	G/T	cg08917208	chr2:24149416	ATAD2B	-0.44	-5.93	-0.31	7.71e-9	Obesity-related traits;
LUSC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22307029	chr19:49891270	CCDC155	0.68	9.57	0.46	2.55e-19	Multiple sclerosis;
LUSC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.92	-0.35	2.25e-11	Lung cancer;
LUSC	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg04733989	chr22:42467013	NAGA	0.39	6.55	0.34	2.18e-10	Cognitive function;
LUSC	cis	rs10887741	0.690	rs7908056	chr10:89444650	G/A	cg13926569	chr10:89418898	PAPSS2	0.33	6.84	0.35	3.81e-11	Exercise (leisure time);
LUSC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg10018233	chr7:150070692	REPIN1	0.38	6.67	0.34	1.06e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9879311	0.643	rs1473183	chr3:10411827	C/T	cg08489410	chr3:10329245	GHRL;GHRLOS	0.43	6.79	0.35	5.29e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.44	16.72	0.68	5.09e-46	Opioid sensitivity;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg23123362	chr5:157158174	THG1L	0.76	6.37	0.33	6.28e-10	Body mass index;
LUSC	cis	rs1124376	0.882	rs6791385	chr3:20136439	A/C	cg05072819	chr3:20081367	KAT2B	0.67	8.19	0.41	5.56e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs7119	0.717	rs12910512	chr15:77817253	C/A	cg27398640	chr15:77910606	LINGO1	-0.31	-6.66	-0.34	1.13e-10	Type 2 diabetes;
LUSC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-12.7	-0.57	2.08e-30	Alzheimer's disease;
LUSC	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-0.85	-13.41	-0.59	4.32e-33	Refractive error;
LUSC	cis	rs1461503	0.966	rs11218907	chr11:122841562	A/G	cg27398637	chr11:122830231	C11orf63	-0.41	-6.54	-0.34	2.29e-10	Menarche (age at onset);
LUSC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	19.1	0.72	1.79e-55	Chronic sinus infection;
LUSC	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20135002	chr11:47629003	NA	0.34	5.79	0.3	1.65e-8	Neuroticism;Neuroticism (multi-trait analysis);
LUSC	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg23711669	chr6:146136114	FBXO30	0.85	15.26	0.64	2.8e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg07148914	chr20:33460835	GGT7	-0.45	-6.66	-0.34	1.1e-10	Height;
LUSC	cis	rs7428496	0.528	rs13092593	chr3:142213824	G/A	cg16271453	chr3:142027066	XRN1	-0.51	-8.95	-0.44	2.6e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs73206853	0.764	rs73206857	chr12:110767721	T/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs11153147	0.655	rs117298489	chr6:109432996	T/G	cg05315195	chr6:109294784	ARMC2	-0.55	-5.85	-0.3	1.18e-8	Mean corpuscular volume;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26526036	chr4:183838753	DCTD	0.4	6.74	0.35	6.94e-11	Asthma;
LUSC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg19230755	chr7:65878503	NA	0.41	5.84	0.3	1.24e-8	Aortic root size;
LUSC	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg22800045	chr5:56110881	MAP3K1	0.43	5.99	0.31	5.46e-9	Coronary artery disease;
LUSC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg16325326	chr1:53192061	ZYG11B	0.88	16.0	0.66	3.49e-43	Monocyte count;
LUSC	cis	rs4363385	0.747	rs2339491	chr1:152985322	T/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.86	-0.39	5.44e-14	Inflammatory skin disease;
LUSC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg24397884	chr7:158709396	WDR60	0.76	8.35	0.42	1.88e-15	Height;
LUSC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg05855489	chr10:104503620	C10orf26	0.52	7.83	0.39	6.44e-14	Arsenic metabolism;
LUSC	trans	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-7.25	-0.37	2.89e-12	Menarche (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01674679	chr13:27998804	GTF3A	-0.47	-6.96	-0.36	1.84e-11	Electrocardiographic conduction measures;
LUSC	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg00509249	chr6:109615579	CCDC162	-0.34	-6.14	-0.32	2.4e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05535760	chr7:792225	HEATR2	0.76	9.1	0.45	8.65e-18	Cerebrospinal P-tau181p levels;
LUSC	cis	rs4629180	0.920	rs4851458	chr2:102108794	T/C	cg01388757	chr2:102091195	RFX8	-0.46	-7.42	-0.38	1.01e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg03188948	chr7:1209495	NA	0.64	6.88	0.35	2.88e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.41	-7.55	-0.38	4.27e-13	Glomerular filtration rate;
LUSC	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg05925327	chr15:68127851	NA	-0.41	-6.46	-0.33	3.79e-10	Restless legs syndrome;
LUSC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg22800045	chr5:56110881	MAP3K1	0.79	10.35	0.49	6.04e-22	Initial pursuit acceleration;
LUSC	cis	rs4595586	0.655	rs11831502	chr12:39310127	A/T	cg26384229	chr12:38710491	ALG10B	0.45	6.16	0.32	2.09e-9	Morning vs. evening chronotype;
LUSC	cis	rs4356932	1.000	rs4859414	chr4:76949997	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg17264618	chr3:40429014	ENTPD3	0.3	6.53	0.34	2.51e-10	Renal cell carcinoma;
LUSC	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg21466736	chr12:48725269	NA	-0.32	-5.71	-0.3	2.56e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs7605827	0.930	rs12989038	chr2:15549862	A/T	cg19274914	chr2:15703543	NA	0.45	8.62	0.43	2.78e-16	Educational attainment (years of education);
LUSC	cis	rs6688613	0.694	rs12062326	chr1:166820186	G/A	cg07049167	chr1:166818506	POGK	0.54	8.05	0.4	1.42e-14	Refractive astigmatism;
LUSC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.03	20.82	0.75	2.6e-62	Cognitive function;
LUSC	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg18964960	chr10:1102726	WDR37	-0.46	-6.16	-0.32	2.09e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg08481491	chr3:125900108	ALDH1L1	-0.32	-6.52	-0.34	2.67e-10	Metabolite levels;
LUSC	cis	rs9633740	0.578	rs11185951	chr10:82301536	G/C	cg01528321	chr10:82214614	TSPAN14	-0.82	-7.27	-0.37	2.55e-12	Post bronchodilator FEV1;
LUSC	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.18	-0.32	1.82e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7075426	0.789	rs7083506	chr10:88199668	A/G	cg07322936	chr10:88137208	NA	0.48	6.9	0.35	2.61e-11	Migraine without aura;
LUSC	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.81	-0.39	7.37e-14	Morning vs. evening chronotype;
LUSC	cis	rs7929679	0.521	rs11499809	chr11:34790743	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.91	0.31	8.29e-9	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	1.14	16.7	0.67	5.82e-46	Monocyte percentage of white cells;
LUSC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.58	-9.38	-0.46	1.08e-18	Aortic root size;
LUSC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg06096015	chr1:231504339	EGLN1	0.56	10.01	0.48	8.18e-21	Hemoglobin concentration;
LUSC	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg25801113	chr15:45476975	SHF	0.35	7.12	0.36	6.47e-12	Uric acid levels;
LUSC	cis	rs2414856	0.510	rs12102207	chr15:64607472	A/G	cg08069370	chr15:64387884	SNX1	-0.73	-6.43	-0.33	4.3e-10	Pulse pressure;Systolic blood pressure;
LUSC	trans	rs2392780	0.536	rs444318	chr8:128333513	A/G	cg10897648	chr18:56338258	MALT1	-0.41	-6.3	-0.33	9.46e-10	Breast cancer (early onset);
LUSC	trans	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.44	6.05	0.31	3.86e-9	Corneal astigmatism;
LUSC	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18876405	chr7:65276391	NA	-0.56	-8.93	-0.44	2.9e-17	Aortic root size;
LUSC	cis	rs7615316	0.934	rs9855140	chr3:142190101	T/C	cg16271453	chr3:142027066	XRN1	-0.4	-6.87	-0.35	3.22e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	0.56	8.91	0.44	3.45e-17	Breast cancer;
LUSC	cis	rs1863824	0.625	rs10887598	chr10:88166160	T/A	cg07322936	chr10:88137208	NA	-0.66	-9.68	-0.47	1.1e-19	Schizophrenia;
LUSC	trans	rs12439619	0.846	rs28697264	chr15:82557900	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.48	-6.48	-0.33	3.35e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03517284	chr6:25882590	NA	-0.48	-8.09	-0.4	1.15e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02259698	chr2:10953349	PDIA6	-0.51	-6.06	-0.31	3.69e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9398803	0.678	rs9388500	chr6:126876580	C/G	cg19875578	chr6:126661172	C6orf173	0.4	5.91	0.31	8.55e-9	Male-pattern baldness;
LUSC	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg05283184	chr6:79620031	NA	-0.45	-8.66	-0.43	1.98e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9788682	1.000	rs57064725	chr15:78833036	C/A	cg18825076	chr15:78729989	IREB2	0.45	6.24	0.32	1.36e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	0.93	12.47	0.56	1.45e-29	Primary sclerosing cholangitis;
LUSC	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg01620082	chr3:125678407	NA	-0.74	-7.08	-0.36	8.67e-12	Depression;
LUSC	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg00587665	chr15:100533223	ADAMTS17	-0.38	-6.13	-0.32	2.44e-9	Height;
LUSC	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg06740227	chr12:86229804	RASSF9	-0.38	-6.11	-0.32	2.79e-9	Major depressive disorder;
LUSC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg26898376	chr11:64110657	CCDC88B	0.33	6.17	0.32	1.92e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	7.34	0.37	1.64e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg06145435	chr7:1022769	CYP2W1	0.31	6.4	0.33	5.39e-10	Longevity;Endometriosis;
LUSC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg18753928	chr3:113234510	CCDC52	-0.5	-7.5	-0.38	5.89e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs467650	0.549	rs162676	chr5:97991503	C/T	cg03885343	chr5:98108198	RGMB	0.3	5.78	0.3	1.75e-8	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg10729496	chr3:10149963	C3orf24	-0.6	-8.44	-0.42	9.55e-16	Alzheimer's disease;
LUSC	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.7	10.41	0.5	3.52e-22	Corneal astigmatism;
LUSC	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	8.35	0.42	1.84e-15	Coronary artery disease;
LUSC	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg18478394	chr8:109455254	TTC35	0.45	6.91	0.35	2.51e-11	Dupuytren's disease;
LUSC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06544989	chr22:39130855	UNC84B	0.34	5.8	0.3	1.57e-8	Menopause (age at onset);
LUSC	trans	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.88	0.35	3.01e-11	Endometrial cancer;
LUSC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg09165964	chr15:75287851	SCAMP5	-1.01	-15.08	-0.64	1.44e-39	Blood trace element (Zn levels);
LUSC	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.05	-0.44	1.22e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg18352616	chr4:3374830	RGS12	0.31	6.0	0.31	5.26e-9	Serum sulfate level;
LUSC	cis	rs7903847	0.620	rs10882907	chr10:99125788	C/G	cg20016023	chr10:99160130	RRP12	0.29	7.1	0.36	7.74e-12	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.42	-0.46	7.55e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.47	-7.64	-0.39	2.32e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.19	0.45	4.15e-18	Motion sickness;
LUSC	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-0.88	-17.41	-0.69	9.46e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg09904177	chr6:26538194	HMGN4	-0.73	-14.17	-0.61	5.11e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs9469578	0.892	rs6929527	chr6:33707976	G/T	cg18708504	chr6:33715942	IP6K3	0.72	8.99	0.44	1.93e-17	Phosphorus levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25333056	chr10:135107159	TUBGCP2	-0.34	-6.09	-0.32	3.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg26061582	chr7:22766209	IL6	0.52	7.64	0.39	2.32e-13	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
LUSC	trans	rs12439619	0.693	rs8034801	chr15:82476337	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.44	-6.25	-0.32	1.27e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg07507251	chr3:52567010	NT5DC2	0.34	6.59	0.34	1.68e-10	Bipolar disorder;
LUSC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06112835	chr11:68658793	MRPL21	0.48	7.44	0.38	8.49e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7215564	0.908	rs4889783	chr17:78667160	C/T	cg09596252	chr17:78655493	RPTOR	0.52	5.67	0.3	3.1e-8	Myopia (pathological);
LUSC	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg14121845	chr20:25566513	NINL	0.44	7.21	0.37	3.76e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg10356904	chr22:49881777	NA	-0.3	-6.72	-0.35	7.74e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg02196730	chr15:80188777	MTHFS	0.4	6.02	0.31	4.5e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.04	21.37	0.76	1.82e-64	Cognitive function;
LUSC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg06238570	chr21:40685208	BRWD1	0.48	7.33	0.37	1.79e-12	Cognitive function;
LUSC	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg24634471	chr8:143751801	JRK	0.59	8.99	0.44	1.82e-17	Schizophrenia;
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg00431813	chr7:1051703	C7orf50	-0.38	-5.99	-0.31	5.42e-9	Longevity;Endometriosis;
LUSC	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.64	-6.22	-0.32	1.5e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.38	-0.42	1.45e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.53	0.34	2.5e-10	Menopause (age at onset);
LUSC	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg10818794	chr15:86012489	AKAP13	-0.42	-6.72	-0.35	7.82e-11	Coronary artery disease;
LUSC	cis	rs11630290	0.592	rs12324668	chr15:64161786	A/T	cg12036633	chr15:63758958	NA	0.56	7.17	0.37	4.94e-12	Iris characteristics;
LUSC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-0.98	-14.66	-0.63	6.33e-38	Initial pursuit acceleration;
LUSC	cis	rs9837602	0.938	rs9873709	chr3:99711687	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.15	0.32	2.17e-9	Breast cancer;
LUSC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg19418458	chr7:158789849	NA	0.49	8.16	0.41	6.96e-15	Facial morphology (factor 20);
LUSC	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.87	-0.35	3.1e-11	Bipolar disorder;
LUSC	cis	rs9648716	0.515	rs17695935	chr7:140507937	A/T	cg23214464	chr7:140373596	ADCK2	0.69	5.98	0.31	5.66e-9	Type 2 diabetes;
LUSC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.6	-0.38	3.1e-13	Aortic root size;
LUSC	cis	rs6681460	0.899	rs499263	chr1:67179937	T/C	cg02459107	chr1:67143332	SGIP1	0.47	8.71	0.43	1.38e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00166722	chr3:10149974	C3orf24	0.55	7.46	0.38	7.77e-13	Alzheimer's disease;
LUSC	trans	rs9503598	0.636	rs6596977	chr6:3466254	G/A	cg05722439	chr19:14072965	RFX1	-0.31	-6.04	-0.31	4.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs6546537	0.824	rs55864699	chr2:69803650	C/T	cg10773587	chr2:69614142	GFPT1	-0.56	-8.73	-0.43	1.25e-16	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs1113500	0.702	rs11185262	chr1:108639742	C/T	cg06207961	chr1:108661230	NA	0.42	7.68	0.39	1.82e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg12559939	chr2:27858050	GPN1	0.4	6.21	0.32	1.57e-9	Oral cavity cancer;
LUSC	trans	rs72674100	1.000	rs9995442	chr4:97963208	A/G	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.69	-0.39	1.71e-13	Morning vs. evening chronotype;
LUSC	cis	rs1847202	0.826	rs13063441	chr3:72952400	A/G	cg25664220	chr3:72788482	NA	-0.45	-7.98	-0.4	2.45e-14	Motion sickness;
LUSC	cis	rs500891	0.553	rs6454329	chr6:84171532	A/T	cg08257003	chr6:84140564	ME1	0.35	8.71	0.43	1.43e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg27124370	chr19:33622961	WDR88	0.53	6.69	0.34	9.21e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg01503450	chr10:980765	NA	-0.37	-5.74	-0.3	2.13e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03352830	chr11:487213	PTDSS2	0.73	8.44	0.42	9.94e-16	Body mass index;
LUSC	cis	rs7804356	1.000	rs1327988	chr7:26828965	C/G	cg03456212	chr7:26904342	SKAP2	0.54	6.27	0.32	1.13e-9	Type 1 diabetes;
LUSC	trans	rs3960554	0.610	rs10265696	chr7:75766712	G/A	cg19862616	chr7:65841803	NCRNA00174	0.88	9.81	0.47	3.89e-20	Eotaxin levels;
LUSC	cis	rs11030122	0.702	rs4910868	chr11:3980224	A/C	cg18678763	chr11:4115507	RRM1	-0.47	-6.0	-0.31	5.25e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-0.53	-8.81	-0.43	6.74e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.28e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg05234568	chr11:5960015	NA	-0.57	-8.35	-0.42	1.81e-15	DNA methylation (variation);
LUSC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06481639	chr22:41940642	POLR3H	-0.53	-6.02	-0.31	4.55e-9	Vitiligo;
LUSC	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7809950	1.000	rs2520260	chr7:107172794	A/G	cg23024343	chr7:107201750	COG5	-0.56	-8.81	-0.43	7.12e-17	Coronary artery disease;
LUSC	trans	rs6601327	1.000	rs6601327	chr8:9395532	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.79	-0.35	5.08e-11	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs16854884	1.000	rs13068298	chr3:143772247	T/C	cg06585982	chr3:143692056	C3orf58	0.48	6.93	0.35	2.23e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg18479299	chr3:125709523	NA	-0.5	-5.79	-0.3	1.66e-8	Blood pressure (smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03565782	chr1:181057814	IER5	-0.41	-6.13	-0.32	2.55e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9297145	0.678	rs62473007	chr7:98749598	G/C	cg05967295	chr7:98741636	SMURF1	0.94	13.86	0.6	7.82e-35	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg05855489	chr10:104503620	C10orf26	0.5	7.68	0.39	1.8e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-6.97	-0.36	1.71e-11	Blood metabolite levels;
LUSC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.06	-0.55	4.59e-28	Type 2 diabetes;
LUSC	cis	rs977987	0.843	rs35737321	chr16:75439185	A/T	cg03315344	chr16:75512273	CHST6	0.53	10.16	0.49	2.69e-21	Dupuytren's disease;
LUSC	cis	rs7705502	1.000	rs56184817	chr5:173367586	T/C	cg18693985	chr5:173351052	CPEB4	-0.37	-5.83	-0.3	1.3e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	12.39	0.56	2.97e-29	Personality dimensions;
LUSC	cis	rs12195417	0.563	rs499872	chr6:84217403	C/T	cg08257003	chr6:84140564	ME1	-0.28	-6.66	-0.34	1.15e-10	Schizophrenia;
LUSC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs12940923	1.000	rs11868285	chr17:56371181	C/T	cg19466818	chr17:56409534	MIR142	-0.38	-6.76	-0.35	6.25e-11	Circulating myeloperoxidase levels (plasma);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21678189	chr6:10838625	NA	-0.52	-6.36	-0.33	6.66e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.19	0.45	4.35e-18	Coffee consumption (cups per day);
LUSC	cis	rs1863824	0.625	rs2018507	chr10:88163251	A/G	cg07322936	chr10:88137208	NA	0.68	10.15	0.49	2.91e-21	Schizophrenia;
LUSC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg23630131	chr7:65973040	NA	-0.21	-5.8	-0.3	1.56e-8	Aortic root size;
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.97	-0.4	2.62e-14	Lymphocyte counts;
LUSC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	6.56	0.34	2.07e-10	Bipolar disorder;
LUSC	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.66	-0.39	2.09e-13	Neuroticism;
LUSC	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg16077055	chr2:106428750	NCK2	0.32	5.94	0.31	7.26e-9	Addiction;
LUSC	cis	rs2932538	0.961	rs4839257	chr1:113219388	A/T	cg22162597	chr1:113214053	CAPZA1	-0.55	-7.97	-0.4	2.49e-14	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs2688608	0.967	rs9971040	chr10:75661162	G/C	cg17411546	chr10:75410026	SYNPO2L	-0.42	-6.16	-0.32	2.05e-9	Inflammatory bowel disease;
LUSC	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-8.3	-0.41	2.64e-15	Schizophrenia;
LUSC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg11247378	chr22:39784982	NA	-0.6	-10.35	-0.49	5.76e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	6.74	0.35	6.82e-11	Response to antipsychotic treatment;
LUSC	cis	rs17253792	0.818	rs78393484	chr14:56065802	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.96	-0.36	1.81e-11	Putamen volume;
LUSC	cis	rs11051970	0.636	rs2733704	chr12:32567858	C/T	cg02745156	chr12:32552066	NA	0.38	7.01	0.36	1.34e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg00814883	chr7:100076585	TSC22D4	-0.66	-8.64	-0.43	2.36e-16	Platelet count;
LUSC	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.5	-0.38	5.85e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg00757033	chr12:89920650	WDR51B	0.61	10.77	0.51	2.12e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg10840412	chr1:235813424	GNG4	0.71	8.74	0.43	1.12e-16	Bipolar disorder;
LUSC	cis	rs36093844	0.706	rs116940726	chr11:85584052	A/C	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg13010199	chr12:38710504	ALG10B	-0.58	-9.11	-0.45	8.04e-18	Bladder cancer;
LUSC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg23711669	chr6:146136114	FBXO30	0.87	15.63	0.65	1.03e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg14675211	chr2:100938903	LONRF2	0.37	5.78	0.3	1.76e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg02269571	chr22:50332266	NA	-0.59	-8.58	-0.43	3.52e-16	Schizophrenia;
LUSC	cis	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg27411982	chr8:10470053	RP1L1	0.42	6.47	0.33	3.48e-10	Morning vs. evening chronotype;
LUSC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg07777115	chr5:623756	CEP72	-0.45	-5.7	-0.3	2.62e-8	Obesity-related traits;
LUSC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg21972741	chr5:435613	AHRR	0.37	6.99	0.36	1.47e-11	Cystic fibrosis severity;
LUSC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.61	0.34	1.52e-10	Corneal astigmatism;
LUSC	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg20703242	chr1:230279135	GALNT2	0.57	8.7	0.43	1.55e-16	Coronary artery disease;
LUSC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg19318889	chr4:1322082	MAEA	0.44	6.78	0.35	5.38e-11	Obesity-related traits;
LUSC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg11764359	chr7:65958608	NA	0.54	7.0	0.36	1.39e-11	Aortic root size;
LUSC	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	11.27	0.52	3.59e-25	Lung cancer in ever smokers;
LUSC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	0.97	13.28	0.59	1.3e-32	Eosinophil percentage of granulocytes;
LUSC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.35	-0.33	7.17e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9341835	0.772	rs9344090	chr6:64135830	G/A	cg00787780	chr6:64151745	NA	-0.34	-5.78	-0.3	1.72e-8	Schizophrenia;
LUSC	cis	rs7766436	0.848	rs2294828	chr6:22598018	G/A	cg13666174	chr6:22585274	NA	-0.42	-5.72	-0.3	2.38e-8	Coronary artery disease;
LUSC	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg08601574	chr20:25228251	PYGB	0.42	6.47	0.33	3.46e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs259282	0.605	rs28615461	chr19:33110149	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	9.5	0.46	4.33e-19	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg22963979	chr7:1858916	MAD1L1	-0.62	-9.8	-0.47	4.16e-20	Bipolar disorder and schizophrenia;
LUSC	cis	rs4400599	0.838	rs2494667	chr1:154109153	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.36	5.84	0.3	1.24e-8	Platelet distribution width;
LUSC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.61	9.95	0.48	1.38e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg04362960	chr10:104952993	NT5C2	-0.62	-9.85	-0.47	3e-20	Arsenic metabolism;
LUSC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	0.98	16.61	0.67	1.37e-45	Cognitive function;
LUSC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	7.06	0.36	9.81e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9309473	0.539	rs6732440	chr2:73827099	T/G	cg20560298	chr2:73613845	ALMS1	0.51	7.8	0.39	7.8500000000000006e-14	Metabolite levels;
LUSC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	8.32	0.41	2.25e-15	Colorectal cancer;
LUSC	cis	rs73200209	0.744	rs17498452	chr12:116538854	C/T	cg01776926	chr12:116560359	MED13L	0.48	5.81	0.3	1.42e-8	Total body bone mineral density;
LUSC	cis	rs778371	0.676	rs17164	chr2:233593499	C/T	cg08000102	chr2:233561755	GIGYF2	0.79	12.81	0.57	8.05e-31	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.79	-0.43	8e-17	Bipolar disorder;
LUSC	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.01	-0.31	4.97e-9	Retinal vascular caliber;
LUSC	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg20637307	chr2:213403960	ERBB4	0.44	7.51	0.38	5.38e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg07424592	chr7:64974309	NA	0.69	6.2	0.32	1.68e-9	Diabetic kidney disease;
LUSC	trans	rs10877945	0.702	rs12820630	chr12:63400179	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.39	-6.69	-0.34	9.41e-11	Obesity-related traits;
LUSC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	9.27	0.45	2.37e-18	Motion sickness;
LUSC	trans	rs12210905	0.925	rs6920115	chr6:26988417	T/C	cg11837749	chr1:55047332	ACOT11	0.55	5.96	0.31	6.41e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.79	0.43	7.84e-17	Lung cancer;
LUSC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg00343986	chr7:65444356	GUSB	0.47	7.02	0.36	1.26e-11	Aortic root size;
LUSC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.94	-0.31	7.19e-9	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg14830952	chr8:86089500	E2F5	0.39	5.94	0.31	6.97e-9	Calcium levels;
LUSC	trans	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg24644049	chr4:85504048	CDS1	0.73	7.36	0.37	1.41e-12	Skin colour saturation;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09372928	chr1:6845395	CAMTA1	-0.49	-6.61	-0.34	1.56e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg07741184	chr6:167504864	NA	-0.39	-7.09	-0.36	7.98e-12	Lung cancer;
LUSC	trans	rs800082	0.516	rs1178892	chr3:144238173	A/G	cg24215973	chr2:240111563	HDAC4	0.45	6.98	0.36	1.6e-11	Smoking behavior;
LUSC	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg15896084	chr13:114927664	NA	0.39	7.21	0.37	3.66e-12	Schizophrenia;
LUSC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	11.93	0.55	1.48e-27	Cognitive test performance;
LUSC	cis	rs11583043	0.668	rs6681915	chr1:101558521	G/A	cg11406453	chr1:101602562	NA	-0.41	-6.86	-0.35	3.39e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs9369695	0.842	rs2396825	chr6:47568696	A/G	cg02130027	chr6:47444894	CD2AP	0.35	5.76	0.3	1.92e-8	Reticulocyte count;
LUSC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg23791538	chr6:167370224	RNASET2	-0.43	-6.95	-0.36	1.93e-11	Crohn's disease;
LUSC	cis	rs6740322	0.857	rs11690012	chr2:43542480	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.46	-6.48	-0.33	3.24e-10	Coronary artery disease;
LUSC	cis	rs4692589	0.743	rs3806825	chr4:170948619	T/C	cg19918862	chr4:170955249	NA	0.33	6.45	0.33	3.94e-10	Anxiety disorder;
LUSC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg06697600	chr4:7070879	GRPEL1	0.45	6.42	0.33	4.8e-10	Monocyte percentage of white cells;
LUSC	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg02269571	chr22:50332266	NA	-0.5	-7.36	-0.37	1.4e-12	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08280861	chr8:58055591	NA	0.52	5.73	0.3	2.21e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg22800045	chr5:56110881	MAP3K1	-0.6	-8.49	-0.42	6.89e-16	Initial pursuit acceleration;
LUSC	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06002616	chr8:101225028	SPAG1	-0.46	-7.56	-0.38	3.93e-13	Atrioventricular conduction;
LUSC	cis	rs7072216	0.843	rs4400721	chr10:100147097	C/T	cg26618903	chr10:100175079	PYROXD2	-0.34	-6.45	-0.33	3.92e-10	Metabolite levels;
LUSC	cis	rs17881320	0.510	rs6503699	chr17:40554261	C/G	cg05878104	chr17:40932452	WNK4	0.7	7.94	0.4	3.02e-14	Atopic dermatitis;
LUSC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg10621924	chr7:39171070	POU6F2	0.49	7.69	0.39	1.62e-13	IgG glycosylation;
LUSC	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg23711669	chr6:146136114	FBXO30	0.77	13.57	0.6	1.08e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.45	-7.29	-0.37	2.25e-12	IgG glycosylation;
LUSC	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg08601574	chr20:25228251	PYGB	-0.44	-6.8	-0.35	4.83e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.33	0.45	1.52e-18	Prudent dietary pattern;
LUSC	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg15485101	chr11:133734466	NA	0.41	7.72	0.39	1.32e-13	Childhood ear infection;
LUSC	cis	rs1577917	0.560	rs9450288	chr6:86221586	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.4	6.18	0.32	1.88e-9	Response to antipsychotic treatment;
LUSC	cis	rs829883	0.902	rs829884	chr12:98879500	C/G	cg25150519	chr12:98850993	NA	0.64	10.02	0.48	7.74e-21	Colorectal adenoma (advanced);
LUSC	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.67	-10.32	-0.49	7.15e-22	Glaucoma (primary open-angle);
LUSC	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.49	6.87	0.35	3.16e-11	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05492810	chr11:78129288	GAB2	0.42	6.35	0.33	7.21e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg18932078	chr1:2524107	MMEL1	0.29	6.44	0.33	4.05e-10	Ulcerative colitis;
LUSC	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg05775895	chr3:12838266	CAND2	0.51	8.64	0.43	2.33e-16	P wave duration;
LUSC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg04369109	chr6:150039330	LATS1	-0.55	-8.18	-0.41	5.94e-15	Lung cancer;
LUSC	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg05393297	chr12:53359155	NA	-0.6	-9.64	-0.47	1.44e-19	Prostate cancer;
LUSC	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.69	-0.39	1.67e-13	Retinal vascular caliber;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17602776	chr5:178977377	RUFY1	0.44	6.02	0.31	4.67e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs1376359	0.576	rs2783561	chr1:103257429	C/A	cg17154563	chr19:40477487	PSMC4	0.48	6.06	0.31	3.61e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05256447	chr13:22245171	FGF9	-0.42	-6.02	-0.31	4.57e-9	Electrocardiographic conduction measures;
LUSC	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.94	0.51	4.97e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs367943	0.666	rs10074214	chr5:112702214	A/G	cg12552261	chr5:112820674	MCC	0.35	5.69	0.3	2.75e-8	Type 2 diabetes;
LUSC	cis	rs8099014	1.000	rs7241204	chr18:56130246	G/A	cg12907477	chr18:56117327	MIR122	0.44	7.04	0.36	1.11e-11	Platelet count;
LUSC	cis	rs4589502	0.841	rs55855162	chr15:67140523	C/A	cg09911534	chr15:67153556	NA	-0.64	-7.22	-0.37	3.52e-12	Lung cancer (smoking interaction);
LUSC	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg19610905	chr11:61596333	FADS2	-0.49	-7.55	-0.38	4.31e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUSC	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg27087555	chr16:88793112	FAM38A	-1.5	-12.57	-0.57	6.05e-30	Plateletcrit;
LUSC	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg11161011	chr14:65562177	MAX	-0.72	-10.92	-0.51	6.28e-24	Obesity-related traits;
LUSC	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg08085267	chr17:45401833	C17orf57	0.6	9.93	0.48	1.62e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.85	-15.04	-0.64	2.21e-39	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg22437258	chr11:111473054	SIK2	-0.51	-6.96	-0.36	1.86e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg04369109	chr6:150039330	LATS1	-0.54	-7.99	-0.4	2.21e-14	Lung cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04632724	chr15:102192393	TM2D3	-0.45	-6.26	-0.32	1.16e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg12564285	chr5:131593104	PDLIM4	0.44	8.14	0.41	8.12e-15	Breast cancer;
LUSC	cis	rs4363385	0.693	rs4845497	chr1:152904162	T/C	cg07796016	chr1:152779584	LCE1C	-0.46	-6.57	-0.34	1.98e-10	Inflammatory skin disease;
LUSC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18932078	chr1:2524107	MMEL1	-0.33	-7.17	-0.37	4.74e-12	Ulcerative colitis;
LUSC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg06784218	chr1:46089804	CCDC17	-0.52	-10.27	-0.49	1.11e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg17507749	chr15:85114479	UBE2QP1	0.7	8.87	0.44	4.59e-17	Schizophrenia;
LUSC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg19230755	chr7:65878503	NA	-0.42	-6.02	-0.31	4.6e-9	Aortic root size;
LUSC	trans	rs1997103	1.000	rs10224446	chr7:55413147	C/G	cg20935933	chr6:143382018	AIG1	0.51	7.38	0.37	1.26e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6847149	0.929	rs4698798	chr4:110792629	C/T	cg07850274	chr4:110748770	RRH	-0.57	-8.66	-0.43	2.1e-16	Exercise treadmill test traits;
LUSC	trans	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-10.32	-0.49	7.63e-22	Colorectal cancer;
LUSC	cis	rs12210905	0.764	rs72835248	chr6:26931817	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.84	-0.3	1.26e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	0.82	12.43	0.56	2.01e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.89	0.55	2.01e-27	Prudent dietary pattern;
LUSC	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg05347473	chr6:146136440	FBXO30	-0.66	-11.3	-0.53	2.81e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.05	-0.31	3.79e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9837602	0.882	rs6807176	chr3:99760864	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.36	0.33	6.81e-10	Breast cancer;
LUSC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.54	-0.34	2.29e-10	Lung cancer;
LUSC	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.55	-15.08	-0.64	1.42e-39	Urate levels in overweight individuals;
LUSC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg15110403	chr19:17392923	ANKLE1	-0.52	-7.17	-0.37	4.89e-12	Systemic lupus erythematosus;
LUSC	cis	rs974417	0.529	rs13196850	chr6:97318086	T/C	cg10979063	chr6:97285822	GPR63	0.45	7.47	0.38	7.26e-13	Body mass index;
LUSC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	0.95	19.43	0.73	8.13e-57	Cognitive function;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08530030	chr7:44530236	NUDCD3	-0.42	-6.12	-0.32	2.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.85	-0.35	3.57e-11	Daytime sleep phenotypes;
LUSC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg21782813	chr7:2030301	MAD1L1	0.35	5.8	0.3	1.55e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg05347473	chr6:146136440	FBXO30	0.44	7.53	0.38	4.7e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17227506	0.606	rs6985004	chr8:13440282	G/C	cg03566418	chr8:13424080	C8orf48	0.41	6.25	0.32	1.26e-9	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg11789530	chr4:8429930	ACOX3	0.56	8.46	0.42	8.25e-16	Response to antineoplastic agents;
LUSC	cis	rs16910800	0.689	rs7101825	chr11:23164951	C/G	cg20040320	chr11:23191996	NA	0.53	6.96	0.36	1.79e-11	Cancer;
LUSC	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.63	6.79	0.35	5e-11	Schizophrenia;
LUSC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg13628971	chr7:2884303	GNA12	0.46	6.53	0.34	2.47e-10	Height;
LUSC	cis	rs4851254	0.660	rs58683655	chr2:100686519	G/C	cg22139774	chr2:100720529	AFF3	-0.43	-5.75	-0.3	1.99e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2979489	0.891	rs4449748	chr8:30304402	A/G	cg26383811	chr8:30366931	RBPMS	0.48	7.35	0.37	1.55e-12	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs7590368	0.673	rs56264212	chr2:10931435	A/C	cg15705551	chr2:10952987	PDIA6	0.52	5.86	0.31	1.13e-8	Educational attainment (years of education);
LUSC	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg00083206	chr6:110721305	DDO	-0.46	-8.29	-0.41	2.81e-15	Platelet distribution width;
LUSC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.65	10.91	0.51	6.69e-24	Bone mineral density;
LUSC	cis	rs2274273	0.934	rs10140869	chr14:55795283	G/A	cg04306507	chr14:55594613	LGALS3	0.53	11.68	0.54	1.2e-26	Protein biomarker;
LUSC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg25039879	chr17:56429692	SUPT4H1	0.67	9.05	0.44	1.19e-17	Cognitive test performance;
LUSC	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg25258033	chr6:167368657	RNASET2	0.39	6.37	0.33	6.15e-10	Crohn's disease;
LUSC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg08999081	chr20:33150536	PIGU	0.45	8.12	0.41	9.36e-15	Coronary artery disease;
LUSC	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18252515	chr7:66147081	NA	-0.45	-6.54	-0.34	2.34e-10	Aortic root size;
LUSC	trans	rs4942242	0.640	rs17460861	chr13:44230078	C/G	cg19169023	chr15:41853346	TYRO3	0.6	8.94	0.44	2.68e-17	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11229555	1.000	rs11229545	chr11:58386650	A/G	cg15696309	chr11:58395628	NA	-0.69	-9.27	-0.45	2.43e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	9.49	0.46	4.38e-19	Eotaxin levels;
LUSC	cis	rs59698941	0.527	rs7719428	chr5:132180919	C/G	cg14825688	chr5:132208181	LEAP2	0.42	6.16	0.32	2.05e-9	Apolipoprotein A-IV levels;
LUSC	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg24558204	chr6:135376177	HBS1L	0.59	8.98	0.44	2.02e-17	Red blood cell count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21736309	chr19:19774664	ATP13A1	-0.41	-5.99	-0.31	5.55e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg16989719	chr2:238392110	NA	-0.41	-7.25	-0.37	3e-12	Prostate cancer;
LUSC	cis	rs3862435	0.706	rs12595061	chr15:90974057	A/T	cg22089800	chr15:90895588	ZNF774	0.58	6.33	0.33	8.01e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	8.31	0.41	2.37e-15	Fuchs's corneal dystrophy;
LUSC	cis	rs36405	0.500	rs11621704	chr14:72355193	G/A	cg23396177	chr14:72358413	NA	-0.38	-7.04	-0.36	1.11e-11	Yang-deficiency constitution;
LUSC	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg25039879	chr17:56429692	SUPT4H1	0.67	8.95	0.44	2.48e-17	Cognitive test performance;
LUSC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.62	0.43	2.64e-16	Menarche (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07750655	chr16:5121855	ALG1	-0.4	-6.02	-0.31	4.6e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg04545296	chr12:48745243	ZNF641	0.37	6.68	0.34	1.01e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.13	25.27	0.81	1.56e-79	Schizophrenia;
LUSC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	0.91	15.04	0.64	2.1e-39	Breast cancer;
LUSC	cis	rs9400467	0.528	rs10872066	chr6:111593611	C/G	cg22127309	chr6:111907043	TRAF3IP2	-0.35	-6.44	-0.33	4.07e-10	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg00509249	chr6:109615579	CCDC162	-0.33	-5.9	-0.31	9.08e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04626574	chr22:26879726	HPS4;SRRD	0.47	6.21	0.32	1.58e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg20935933	chr6:143382018	AIG1	0.51	7.43	0.38	8.96e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.2	0.32	1.69e-9	Retinal vascular caliber;
LUSC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg16797656	chr11:68205561	LRP5	0.36	5.94	0.31	7.09e-9	Total body bone mineral density;
LUSC	cis	rs36093844	0.799	rs7124956	chr11:85588819	A/G	cg25872744	chr11:85566296	CCDC83	-0.42	-6.89	-0.35	2.76e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs2710642	0.540	rs12993804	chr2:63494689	T/A	cg17519650	chr2:63277830	OTX1	-0.45	-6.13	-0.32	2.44e-9	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg20476274	chr7:133979776	SLC35B4	0.85	16.22	0.66	4.85e-44	Mean platelet volume;
LUSC	trans	rs1941687	0.702	rs10460050	chr18:31413671	G/T	cg27147174	chr7:100797783	AP1S1	-0.45	-6.76	-0.35	6.26e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg19539972	chr4:7069911	GRPEL1	0.67	8.68	0.43	1.76e-16	Monocyte percentage of white cells;
LUSC	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg04450456	chr4:17643702	FAM184B	-0.39	-6.38	-0.33	5.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg05855489	chr10:104503620	C10orf26	0.5	7.68	0.39	1.81e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg00409905	chr10:38381863	ZNF37A	0.37	6.24	0.32	1.33e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg09323728	chr8:95962352	TP53INP1	0.36	6.71	0.34	8.32e-11	Type 2 diabetes;
LUSC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg01879757	chr17:41196368	BRCA1	-0.39	-5.96	-0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs96067	0.805	rs7522400	chr1:36613380	A/G	cg24686825	chr1:36642396	MAP7D1	-0.65	-9.08	-0.44	1e-17	Corneal structure;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg00929878	chr9:95087334	NOL8;CENPP	0.34	6.02	0.31	4.68e-9	Tuberculosis;
LUSC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg14343924	chr8:8086146	FLJ10661	0.44	5.9	0.31	9.11e-9	Neuroticism;
LUSC	cis	rs7586879	0.719	rs7565468	chr2:25130092	C/T	cg01884057	chr2:25150051	NA	0.42	8.75	0.43	1.1e-16	Body mass index;
LUSC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg20476274	chr7:133979776	SLC35B4	0.82	14.99	0.63	3.23e-39	Mean platelet volume;
LUSC	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.62	-5.79	-0.3	1.59e-8	Major depressive disorder;
LUSC	cis	rs6733011	0.500	rs885115	chr2:99446445	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-6.65	-0.34	1.18e-10	Bipolar disorder;
LUSC	cis	rs7759001	0.857	rs4713088	chr6:27350626	C/T	cg18711553	chr6:27366782	ZNF391	0.41	5.98	0.31	5.84e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-9.62	-0.47	1.75e-19	Schizophrenia;
LUSC	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg09904177	chr6:26538194	HMGN4	-0.74	-6.83	-0.35	4.11e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg13451222	chr11:65405525	SIPA1	0.43	5.66	0.3	3.31e-8	Blood pressure (age interaction);
LUSC	cis	rs73200209	0.744	rs56187732	chr12:116688042	C/T	cg01776926	chr12:116560359	MED13L	-0.5	-6.07	-0.32	3.46e-9	Total body bone mineral density;
LUSC	cis	rs7914558	0.621	rs10786722	chr10:104660068	C/T	cg05855489	chr10:104503620	C10orf26	0.42	5.76	0.3	1.92e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg13319975	chr6:146136371	FBXO30	-0.38	-5.78	-0.3	1.71e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs73416724	1.000	rs79329802	chr6:43387332	G/A	cg26312998	chr6:43337775	ZNF318	0.53	6.15	0.32	2.23e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg25427524	chr10:38739819	LOC399744	0.43	5.75	0.3	2e-8	Obesity (extreme);
LUSC	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg19682013	chr15:45996608	NA	0.39	5.95	0.31	6.77e-9	Waist circumference;Weight;
LUSC	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.77e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg08917208	chr2:24149416	ATAD2B	0.56	6.35	0.33	7.14e-10	Lymphocyte counts;
LUSC	cis	rs16976116	0.901	rs28499113	chr15:55503621	T/C	cg11288833	chr15:55489084	RSL24D1	0.5	5.93	0.31	7.52e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15122365	chr12:51664392	SMAGP	0.81	6.47	0.33	3.55e-10	Cognitive performance;
LUSC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg14196790	chr5:131705035	SLC22A5	0.51	8.82	0.43	6.65e-17	Blood metabolite levels;
LUSC	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg05887092	chr17:76393375	PGS1	0.52	9.11	0.45	7.88e-18	HDL cholesterol levels;
LUSC	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07080220	chr10:102295463	HIF1AN	0.67	8.7	0.43	1.49e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg27432699	chr2:27873401	GPN1	-0.62	-9.74	-0.47	7e-20	Total body bone mineral density;
LUSC	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.52	-0.34	2.67e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg08499158	chr17:42289980	UBTF	-0.46	-7.65	-0.39	2.13e-13	Total body bone mineral density;
LUSC	trans	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg10756647	chr7:56101905	PSPH	-0.87	-8.67	-0.43	1.88e-16	Diabetic kidney disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01147013	chr3:45017855	ZDHHC3;EXOSC7	-0.42	-5.99	-0.31	5.52e-9	Electrocardiographic conduction measures;
LUSC	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	0.96	14.36	0.62	9.24e-37	Gout;Urate levels;Serum uric acid levels;
LUSC	trans	rs7739264	0.602	rs6925511	chr6:19773553	C/T	cg13431028	chr2:169073609	STK39	-0.35	-5.99	-0.31	5.47e-9	Endometriosis;
LUSC	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg17127132	chr2:85788382	GGCX	0.49	7.92	0.4	3.6e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg02772935	chr3:125709198	NA	-0.48	-5.84	-0.3	1.23e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.51	0.5	1.68e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg11993925	chr19:44307056	LYPD5	0.36	7.86	0.4	5.35e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.11	0.52	1.34e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg04545296	chr12:48745243	ZNF641	0.33	6.06	0.31	3.63e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-17.68	-0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg23791538	chr6:167370224	RNASET2	-0.37	-5.86	-0.31	1.12e-8	Crohn's disease;
LUSC	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.02	-0.44	1.54e-17	Total cholesterol levels;
LUSC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	0.88	12.77	0.57	1.06e-30	Vitiligo;
LUSC	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg17366294	chr4:99064904	C4orf37	0.55	8.77	0.43	9.47e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg21573476	chr21:45109991	RRP1B	-0.38	-6.32	-0.33	8.23e-10	Mean corpuscular volume;
LUSC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.4	0.56	2.59e-29	Prudent dietary pattern;
LUSC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.58	9.96	0.48	1.27e-20	Bone mineral density;
LUSC	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg08345082	chr10:99160200	RRP12	-0.35	-7.17	-0.37	4.75e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg27219399	chr15:67835830	MAP2K5	0.35	5.7	0.3	2.63e-8	Obesity;
LUSC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg16479474	chr6:28041457	NA	-0.33	-5.91	-0.31	8.31e-9	Depression;
LUSC	trans	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg07393940	chr7:158741817	NA	-0.51	-8.09	-0.4	1.12e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg16606324	chr3:10149918	C3orf24	0.6	8.55	0.42	4.59e-16	Alzheimer's disease;
LUSC	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg08975724	chr8:8085496	FLJ10661	0.41	6.0	0.31	5.2e-9	Neuroticism;
LUSC	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg11057378	chr10:81107060	PPIF	-0.38	-6.53	-0.34	2.51e-10	Height;
LUSC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	13.55	0.6	1.23e-33	Platelet count;
LUSC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg09323728	chr8:95962352	TP53INP1	0.38	7.83	0.39	6.56e-14	Type 2 diabetes;
LUSC	trans	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.45	6.88	0.35	2.92e-11	Endometrial cancer;
LUSC	cis	rs7674212	0.531	rs6816370	chr4:103939433	C/T	cg16532752	chr4:104119610	CENPE	-0.43	-6.02	-0.31	4.5e-9	Type 2 diabetes;
LUSC	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg15556689	chr8:8085844	FLJ10661	0.41	6.03	0.31	4.23e-9	Platelet distribution width;
LUSC	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	6.35	0.33	7.16e-10	Response to antipsychotic treatment;
LUSC	cis	rs6087990	0.735	rs1003522	chr20:31368560	T/C	cg13636640	chr20:31349939	DNMT3B	0.91	18.52	0.71	3.6e-53	Ulcerative colitis;
LUSC	cis	rs7615316	1.000	rs1983434	chr3:142347757	A/G	cg16271453	chr3:142027066	XRN1	-0.34	-5.82	-0.3	1.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg14664628	chr15:75095509	CSK	0.46	6.19	0.32	1.75e-9	Systemic lupus erythematosus;
LUSC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg00677455	chr12:58241039	CTDSP2	0.61	8.47	0.42	7.68e-16	Multiple sclerosis;
LUSC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg04025307	chr7:1156635	C7orf50	0.43	5.98	0.31	5.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1506636	1.000	rs2402669	chr7:123297460	C/G	cg03229431	chr7:123269106	ASB15	-0.65	-10.61	-0.5	7.56e-23	Plateletcrit;Platelet count;
LUSC	cis	rs4363385	0.747	rs2339494	chr1:152975143	G/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.67	-0.39	1.85e-13	Inflammatory skin disease;
LUSC	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.37	-0.46	1.15e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg27494647	chr7:150038898	RARRES2	0.52	7.97	0.4	2.5e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg08132940	chr7:1081526	C7orf50	-0.51	-5.93	-0.31	7.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg16989719	chr2:238392110	NA	-0.44	-6.14	-0.32	2.33e-9	Prostate cancer;
LUSC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25072359	chr17:41440525	NA	0.65	9.46	0.46	5.86e-19	Menopause (age at onset);
LUSC	cis	rs9612	0.718	rs346535	chr19:44251425	C/T	cg08581076	chr19:44259116	C19orf61	0.49	6.29	0.33	9.86e-10	Exhaled nitric oxide output;
LUSC	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg16230307	chr14:35515116	FAM177A1	0.77	10.03	0.48	7.02e-21	Psoriasis;
LUSC	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg25110126	chr1:46999211	NA	-0.6	-7.94	-0.4	3.1e-14	Monobrow;
LUSC	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.48	0.42	7.52e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4499344	0.696	rs10402929	chr19:33100245	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg05425664	chr17:57184151	TRIM37	-0.57	-8.42	-0.42	1.13e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg13685833	chr1:53393034	SCP2	-0.38	-5.74	-0.3	2.08e-8	Monocyte count;
LUSC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.45	6.66	0.34	1.12e-10	Systemic lupus erythematosus;
LUSC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg22800045	chr5:56110881	MAP3K1	0.77	9.85	0.47	2.96e-20	Initial pursuit acceleration;
LUSC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.91	0.31	8.46e-9	Menopause (age at onset);
LUSC	trans	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-6.61	-0.34	1.49e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	11.94	0.55	1.36e-27	Prudent dietary pattern;
LUSC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg24060327	chr5:131705240	SLC22A5	-0.42	-6.65	-0.34	1.18e-10	Blood metabolite levels;
LUSC	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg08079166	chr15:68083412	MAP2K5	0.36	6.23	0.32	1.39e-9	Obesity;
LUSC	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg17470723	chr8:74884337	TCEB1	0.52	8.21	0.41	4.83e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.46	-6.37	-0.33	6.15e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs12681287	0.752	rs9297861	chr8:87254730	G/C	cg27223183	chr8:87520930	FAM82B	-0.45	-5.72	-0.3	2.33e-8	Caudate activity during reward;
LUSC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.79	0.65	2.34e-42	Platelet count;
LUSC	cis	rs17621444	0.522	rs10886570	chr10:121786379	G/T	cg02041677	chr10:121771263	NA	-0.35	-6.39	-0.33	5.62e-10	IgG glycosylation;
LUSC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg18479299	chr3:125709523	NA	-0.5	-5.7	-0.3	2.68e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg10862848	chr6:42927986	GNMT	-0.28	-6.57	-0.34	1.91e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg14121845	chr20:25566513	NINL	0.31	5.66	0.3	3.21e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg09491104	chr22:46646882	C22orf40	0.7	9.07	0.44	1.03e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.31	0.41	2.42e-15	Melanoma;
LUSC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg12639453	chr1:2035780	PRKCZ	-0.3	-6.41	-0.33	4.91e-10	Height;
LUSC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg20821713	chr7:1055600	C7orf50	0.5	6.63	0.34	1.38e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs829883	0.714	rs249847	chr12:98867716	C/T	cg25150519	chr12:98850993	NA	0.8	14.01	0.61	2.21e-35	Colorectal adenoma (advanced);
LUSC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21963583	chr11:68658836	MRPL21	0.56	8.57	0.42	3.8e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg02782426	chr3:40428986	ENTPD3	0.33	6.22	0.32	1.47e-9	Renal cell carcinoma;
LUSC	trans	rs1864729	1.000	rs1835743	chr8:98282643	T/C	cg08679828	chr8:102218111	ZNF706	-0.87	-7.9	-0.4	3.95e-14	Estradiol plasma levels (breast cancer);
LUSC	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg00277334	chr10:82204260	NA	0.54	8.85	0.44	5.02e-17	Post bronchodilator FEV1;
LUSC	cis	rs6469656	1.000	rs13277714	chr8:117791528	A/G	cg24004040	chr8:117650383	NA	0.41	5.79	0.3	1.63e-8	Colorectal cancer;
LUSC	cis	rs13253111	0.967	rs11136036	chr8:28061310	C/T	cg26534493	chr8:28060551	NA	0.46	8.64	0.43	2.36e-16	Childhood body mass index;
LUSC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg21573476	chr21:45109991	RRP1B	-0.4	-6.47	-0.33	3.41e-10	Mean corpuscular volume;
LUSC	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg22437258	chr11:111473054	SIK2	0.5	6.82	0.35	4.3e-11	Primary sclerosing cholangitis;
LUSC	cis	rs983392	0.667	rs632185	chr11:59951433	A/G	cg24026212	chr11:59952134	MS4A6A	0.34	6.15	0.32	2.22e-9	Alzheimer's disease (late onset);
LUSC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg19257562	chr1:2043853	PRKCZ	0.33	6.65	0.34	1.21e-10	Height;
LUSC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg17279839	chr7:150038598	RARRES2	0.48	7.6	0.38	3.05e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs983392	0.709	rs11601689	chr11:59996266	G/C	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.05	-0.31	3.78e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg11494091	chr17:61959527	GH2	0.38	6.71	0.34	8.54e-11	Height;
LUSC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg05802129	chr4:122689817	NA	-0.37	-6.69	-0.34	9.68e-11	Type 2 diabetes;
LUSC	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg01028140	chr2:1542097	TPO	-0.6	-7.98	-0.4	2.45e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	0.92	18.14	0.7	1.15e-51	Dental caries;
LUSC	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	6.37	0.33	6.29e-10	Rheumatoid arthritis;
LUSC	cis	rs3849570	0.643	rs11705789	chr3:81969196	G/T	cg07356753	chr3:81810745	GBE1	-0.54	-8.0	-0.4	2.1e-14	Waist circumference;Body mass index;
LUSC	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg07828024	chr6:149772892	ZC3H12D	0.35	7.6	0.38	2.97e-13	Dupuytren's disease;
LUSC	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	8.96	0.44	2.34e-17	Iron status biomarkers;
LUSC	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg04906043	chr13:21280425	IL17D	0.45	8.6	0.43	3.04e-16	Dental caries;
LUSC	cis	rs13385	0.769	rs9042	chr5:139625347	A/C	cg26211634	chr5:139558579	C5orf32	0.45	6.59	0.34	1.75e-10	Atrial fibrillation;
LUSC	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.18	0.52	7.13e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg21545522	chr1:205238299	TMCC2	0.46	8.58	0.42	3.7e-16	Red blood cell count;
LUSC	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	8.3	0.41	2.56e-15	Axial length;
LUSC	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	6.82	0.35	4.38e-11	Height;
LUSC	cis	rs1784581	0.569	rs9364629	chr6:162416831	T/G	cg17173639	chr6:162384350	PARK2	0.57	9.94	0.48	1.44e-20	Itch intensity from mosquito bite;
LUSC	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg06636001	chr8:8085503	FLJ10661	0.54	7.79	0.39	8.64e-14	Myopia (pathological);
LUSC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg13647721	chr17:30228624	UTP6	0.58	5.66	0.3	3.23e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs3755132	0.929	rs3213793	chr2:15744123	T/G	cg12888861	chr2:15731646	DDX1	0.5	7.3	0.37	2.16e-12	Wilms tumor;
LUSC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1864400	0.645	rs2249005	chr10:43627280	A/G	cg02780029	chr10:43622663	RET	-0.34	-5.7	-0.3	2.68e-8	Hirschsprung disease;
LUSC	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06636551	chr8:101224915	SPAG1	0.54	10.65	0.5	5.55e-23	Atrioventricular conduction;
LUSC	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.64	-7.91	-0.4	3.91e-14	Yeast infection;
LUSC	trans	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg18335740	chr13:41363409	SLC25A15	-0.51	-7.32	-0.37	1.89e-12	Lewy body disease;
LUSC	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	1.13	19.69	0.73	7.88e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	8.02	0.4	1.8e-14	Axial length;
LUSC	cis	rs3733418	0.799	rs13151735	chr4:165932516	G/C	cg11630554	chr4:165878136	TRIM61;C4orf39	-0.48	-5.65	-0.3	3.46e-8	Obesity-related traits;
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.68	10.44	0.5	2.84e-22	Lymphocyte counts;
LUSC	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.56	0.6	1.12e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg05868516	chr6:26286170	HIST1H4H	0.36	5.99	0.31	5.35e-9	Educational attainment;
LUSC	cis	rs73206853	0.841	rs56130410	chr12:110824112	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	6.43	0.33	4.37e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg05347473	chr6:146136440	FBXO30	0.48	7.9	0.4	4.04e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.29	0.37	2.2e-12	Motion sickness;
LUSC	cis	rs7095944	0.614	rs1055256	chr10:126446592	A/G	cg08799069	chr10:126477246	METTL10	-0.42	-6.52	-0.34	2.53e-10	Asthma;
LUSC	cis	rs4363385	0.720	rs883810	chr1:152941345	T/C	cg07796016	chr1:152779584	LCE1C	-0.4	-5.69	-0.3	2.78e-8	Inflammatory skin disease;
LUSC	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg03599575	chr15:90893182	GABARAPL3	-0.34	-5.75	-0.3	1.97e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg17469321	chr7:55412551	NA	0.68	10.76	0.51	2.16e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg18132916	chr6:79620363	NA	-0.38	-5.69	-0.3	2.82e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg27539214	chr16:67997921	SLC12A4	0.58	7.02	0.36	1.24e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg24848339	chr3:12840334	CAND2	0.36	7.92	0.4	3.52e-14	P wave duration;
LUSC	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg04362960	chr10:104952993	NT5C2	0.6	9.53	0.46	3.28e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.86	-0.4	5.24e-14	Neuroticism;
LUSC	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06636551	chr8:101224915	SPAG1	-0.45	-8.17	-0.41	6.22e-15	Atrioventricular conduction;
LUSC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	7.5	0.38	5.77e-13	Multiple sclerosis;
LUSC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.61	0.43	2.91e-16	Prudent dietary pattern;
LUSC	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg21100191	chr22:23484243	RTDR1	-0.93	-16.16	-0.66	8.65e-44	Bone mineral density;
LUSC	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg04691961	chr3:161091175	C3orf57	-0.34	-5.81	-0.3	1.49e-8	Morning vs. evening chronotype;
LUSC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg03477792	chr4:77819574	ANKRD56	0.62	8.76	0.43	9.75e-17	Emphysema distribution in smoking;
LUSC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg14552801	chr7:65878734	NA	0.36	5.66	0.3	3.23e-8	Aortic root size;
LUSC	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg15133208	chr4:90757351	SNCA	-0.32	-5.66	-0.3	3.26e-8	Dementia with Lewy bodies;
LUSC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg00376283	chr12:123451042	ABCB9	0.72	11.05	0.52	2.03e-24	Platelet count;
LUSC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	0.94	18.71	0.72	5.98e-54	Cognitive function;
LUSC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-6.51	-0.34	2.69e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2481665	0.680	rs2481671	chr1:62611666	A/C	cg18591186	chr1:62594603	INADL	-0.45	-7.23	-0.37	3.27e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7674212	0.540	rs2711897	chr4:104023567	C/T	cg16532752	chr4:104119610	CENPE	-0.49	-6.92	-0.35	2.35e-11	Type 2 diabetes;
LUSC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.24	0.37	3.18e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg13047869	chr3:10149882	C3orf24	0.63	8.73	0.43	1.21e-16	Alzheimer's disease;
LUSC	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	trans	rs1422110	0.616	rs6452689	chr5:85445059	A/T	cg01787110	chr1:109008453	NBPF6	0.53	9.08	0.44	9.9e-18	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.8	-14.87	-0.63	9.73e-39	Obesity-related traits;
LUSC	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg09307838	chr4:120376055	NA	0.7	9.64	0.47	1.49e-19	Corneal astigmatism;
LUSC	cis	rs2200578	1.000	rs12053519	chr2:99875018	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.61	7.16	0.36	5.11e-12	IgG glycosylation;
LUSC	trans	rs17536732	0.688	rs1440602	chr4:162816315	C/G	cg25554740	chr10:135047333	NA	-0.41	-6.04	-0.31	4.08e-9	Risky sexual behaviors (alcohol dependence interaction);
LUSC	cis	rs2540226	0.569	rs6722306	chr2:40052970	A/G	cg23576258	chr2:39999331	THUMPD2	0.35	5.68	0.3	2.89e-8	Personality dimensions;
LUSC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04260516	chr14:24630327	IRF9	0.45	6.37	0.33	6.42e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg01097406	chr16:89675127	NA	-0.34	-6.65	-0.34	1.2e-10	Vitiligo;
LUSC	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.69	-11.33	-0.53	2.06e-25	Prostate cancer;
LUSC	cis	rs11608355	0.960	rs3742021	chr12:109883117	T/C	cg19025524	chr12:109796872	NA	-0.36	-5.71	-0.3	2.53e-8	Neuroticism;
LUSC	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.53	0.38	4.76e-13	Colorectal cancer;
LUSC	cis	rs9326248	0.861	rs4938353	chr11:117046197	G/A	cg16524733	chr11:117070046	TAGLN	0.36	5.87	0.31	1.04e-8	Blood protein levels;
LUSC	cis	rs5770917	1.000	rs2073604	chr22:51008925	G/A	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.64	-5.85	-0.3	1.18e-8	Narcolepsy;
LUSC	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg24812749	chr6:127587940	RNF146	0.51	7.56	0.38	3.92e-13	Breast cancer;
LUSC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.35	-5.92	-0.31	7.96e-9	Breast cancer;
LUSC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	8.86e-24	Morning vs. evening chronotype;
LUSC	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg20701182	chr2:24300061	SF3B14	0.88	11.49	0.53	5.5e-26	Lymphocyte counts;
LUSC	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg24375607	chr4:120327624	NA	0.75	11.04	0.52	2.24e-24	Corneal astigmatism;
LUSC	cis	rs11018904	0.636	rs61903695	chr11:89922417	A/G	cg26138821	chr11:89956704	CHORDC1	-0.58	-7.47	-0.38	7.11e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs17255340	0.581	rs1144187	chr6:83986196	T/C	cg08257003	chr6:84140564	ME1	0.31	7.54	0.38	4.4e-13	Platelet-derived growth factor BB levels;
LUSC	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg23505145	chr19:12996616	KLF1	0.64	10.29	0.49	9.57e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.07	20.86	0.75	1.91e-62	Cognitive ability;
LUSC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg11663144	chr21:46675770	NA	-0.36	-5.76	-0.3	1.89e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs17641971	1.000	rs73579339	chr8:49888184	G/A	cg15678142	chr1:167411538	CD247	0.42	5.97	0.31	6.09e-9	Blood metabolite levels;
LUSC	cis	rs3916	0.794	rs10431384	chr12:121127347	C/T	cg21892295	chr12:121157589	UNC119B	0.36	5.97	0.31	6.23e-9	Urinary metabolites (H-NMR features);
LUSC	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg22681709	chr2:178499509	PDE11A	-0.47	-6.88	-0.35	2.89e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg13560548	chr3:10150139	C3orf24	0.49	6.86	0.35	3.38e-11	Alzheimer's disease;
LUSC	cis	rs3812762	0.917	rs905289	chr11:8753552	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.38	6.43	0.33	4.44e-10	Hypospadias;
LUSC	cis	rs8040855	0.599	rs6496795	chr15:85725853	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.87	0.35	3.1e-11	Bulimia nervosa;
LUSC	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg01528321	chr10:82214614	TSPAN14	-0.92	-14.49	-0.62	2.87e-37	Post bronchodilator FEV1;
LUSC	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	1.06	16.42	0.67	7.52e-45	Primary sclerosing cholangitis;
LUSC	cis	rs4948275	0.550	rs10994742	chr10:63132240	A/T	cg03237606	chr10:63212265	TMEM26	-0.39	-5.94	-0.31	7.2e-9	Night sleep phenotypes;
LUSC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.66	15.01	0.63	2.89e-39	Hemoglobin concentration;
LUSC	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg08779649	chr13:50194554	NA	0.37	6.22	0.32	1.49e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.97	0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg06671706	chr8:8559999	CLDN23	0.48	6.57	0.34	1.97e-10	Obesity-related traits;
LUSC	cis	rs2361718	0.527	rs7211994	chr17:78152514	A/G	cg06718696	chr17:78121285	EIF4A3	-0.45	-6.5	-0.34	2.87e-10	Yeast infection;
LUSC	cis	rs13315871	1.000	rs11713214	chr3:58445991	C/T	cg20936604	chr3:58311152	NA	-0.72	-6.77	-0.35	5.83e-11	Cholesterol, total;
LUSC	cis	rs2290159	0.800	rs9849807	chr3:12675026	A/G	cg23032965	chr3:12705835	RAF1	0.74	9.13	0.45	6.87e-18	Cholesterol, total;
LUSC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg14019146	chr3:50243930	SLC38A3	0.32	7.11	0.36	7.17e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg23283495	chr1:209979779	IRF6	0.67	8.71	0.43	1.48e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.88	0.63	8.88e-39	Platelet count;
LUSC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg23630131	chr7:65973040	NA	-0.22	-6.03	-0.31	4.35e-9	Aortic root size;
LUSC	cis	rs738322	0.555	rs5756932	chr22:38546118	C/T	cg25457927	chr22:38595422	NA	-0.41	-8.25	-0.41	3.7e-15	Cutaneous nevi;
LUSC	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg07700843	chr1:2391317	NA	-0.46	-7.02	-0.36	1.28e-11	Non-obstructive azoospermia;
LUSC	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg17031739	chr1:67600172	NA	0.45	6.91	0.35	2.43e-11	Psoriasis;
LUSC	cis	rs9434723	0.844	rs2239561	chr1:9304205	C/T	cg04199779	chr1:9294473	H6PD	-0.5	-5.86	-0.31	1.08e-8	Height;
LUSC	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	17.13	0.68	1.22e-47	Body mass index (adult);
LUSC	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg16230307	chr14:35515116	FAM177A1	0.74	8.78	0.43	8.74e-17	Psoriasis;
LUSC	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg07169764	chr2:136633963	MCM6	-0.6	-7.95	-0.4	2.88e-14	Mosquito bite size;
LUSC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17818399	0.735	rs11894342	chr2:46836439	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.34	5.78	0.3	1.71e-8	Height;
LUSC	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg07169764	chr2:136633963	MCM6	0.87	11.94	0.55	1.28e-27	Mosquito bite size;
LUSC	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.82	-13.45	-0.59	2.9e-33	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg23172400	chr8:95962367	TP53INP1	-0.37	-7.6	-0.38	2.93e-13	Type 2 diabetes;
LUSC	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg03676636	chr4:99064102	C4orf37	0.32	6.89	0.35	2.77e-11	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.81	-0.43	6.71e-17	Retinal vascular caliber;
LUSC	cis	rs240764	0.658	rs35168784	chr6:101183499	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-6.65	-0.34	1.21e-10	Neuroticism;
LUSC	cis	rs17401966	0.624	rs6696978	chr1:10209557	C/T	cg19773385	chr1:10388646	KIF1B	0.42	6.21	0.32	1.54e-9	Hepatocellular carcinoma;
LUSC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg19812747	chr11:111475976	SIK2	-0.55	-8.18	-0.41	5.92e-15	Primary sclerosing cholangitis;
LUSC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.76	7.37	0.37	1.38e-12	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1113500	0.897	rs55980437	chr1:108639498	G/A	cg11967332	chr1:108735228	SLC25A24	0.39	5.94	0.31	7.31e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13126279	chr21:47581558	C21orf56	0.47	7.05	0.36	1e-11	Testicular germ cell tumor;
LUSC	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.82	0.43	6.31e-17	Menopause (age at onset);
LUSC	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg08684580	chr7:98029266	BAIAP2L1	0.39	5.98	0.31	5.66e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg10518572	chr11:65560635	OVOL1	-0.27	-6.0	-0.31	5.24e-9	Acne (severe);
LUSC	cis	rs4594175	0.926	rs10145287	chr14:51626808	G/T	cg23942311	chr14:51606299	NA	0.31	5.78	0.3	1.73e-8	Cancer;
LUSC	trans	rs72674100	1.000	rs72874654	chr4:97966415	A/G	cg16405019	chr1:18959625	PAX7	-0.64	-6.78	-0.35	5.33e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg00376283	chr12:123451042	ABCB9	0.69	7.76	0.39	1.07e-13	Neutrophil percentage of white cells;
LUSC	cis	rs6942756	0.806	rs7794622	chr7:128996268	T/C	cg02491457	chr7:128862824	NA	-0.5	-7.29	-0.37	2.2e-12	White matter hyperintensity burden;
LUSC	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg24851651	chr11:66362959	CCS	-0.39	-6.14	-0.32	2.37e-9	Educational attainment (years of education);
LUSC	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.02	-21.22	-0.76	7.29e-64	Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.2e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs74181299	1.000	rs74181299	chr2:65283972	T/C	cg05010058	chr2:65284262	CEP68	0.31	6.11	0.32	2.73e-9	Pulse pressure;
LUSC	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg11693508	chr17:37793320	STARD3	-0.52	-6.31	-0.33	9.01e-10	Bipolar disorder;
LUSC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg06008330	chr7:65541103	ASL	-0.4	-6.24	-0.32	1.36e-9	Aortic root size;
LUSC	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.88e-9	Prostate cancer;
LUSC	cis	rs2742234	0.666	rs715106	chr10:43616751	C/A	cg15436174	chr10:43711423	RASGEF1A	-0.45	-7.33	-0.37	1.71e-12	Hirschsprung disease;
LUSC	cis	rs926938	0.584	rs2798663	chr1:115363582	G/A	cg12756093	chr1:115239321	AMPD1	0.53	7.92	0.4	3.61e-14	Autism;
LUSC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.99	0.4	2.22e-14	Bipolar disorder;
LUSC	cis	rs354225	0.626	rs7591204	chr2:54829458	C/G	cg01766943	chr2:54829624	SPTBN1	-0.49	-7.63	-0.39	2.4e-13	Schizophrenia;
LUSC	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.82	-0.47	3.7e-20	Total cholesterol levels;
LUSC	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.15	-0.36	5.46e-12	Coronary artery disease;
LUSC	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg09307838	chr4:120376055	NA	0.75	10.89	0.51	7.5e-24	Corneal astigmatism;
LUSC	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg13010199	chr12:38710504	ALG10B	0.41	5.94	0.31	7.08e-9	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.0	0.52	3.28e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9650315	0.641	rs67781593	chr8:57187632	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	7.45	0.38	7.92e-13	Height;
LUSC	trans	rs12210905	0.688	rs12194842	chr6:27367978	A/C	cg14616345	chr9:133901267	LAMC3	-0.65	-5.95	-0.31	6.6e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg23202291	chr11:1979235	NA	0.39	6.07	0.32	3.52e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg17211192	chr8:82754475	SNX16	-0.82	-11.22	-0.52	5.21e-25	Diastolic blood pressure;
LUSC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.11	-0.48	3.92e-21	Monocyte count;
LUSC	cis	rs28830936	1.000	rs9672298	chr15:41912368	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.32	-0.33	8.25e-10	Diastolic blood pressure;
LUSC	cis	rs9648716	0.515	rs57725920	chr7:140428350	A/T	cg23214464	chr7:140373596	ADCK2	0.72	5.87	0.31	1.02e-8	Type 2 diabetes;
LUSC	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg13010199	chr12:38710504	ALG10B	0.7	10.75	0.51	2.33e-23	Bladder cancer;
LUSC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg13683864	chr3:40499215	RPL14	-1.13	-21.22	-0.76	6.9e-64	Renal cell carcinoma;
LUSC	cis	rs968451	1.000	rs57078777	chr22:39697458	A/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	9.0	0.44	1.8e-17	Primary biliary cholangitis;
LUSC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.48	-7.48	-0.38	6.47e-13	Height;
LUSC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.53	-8.86	-0.44	4.95e-17	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg14004847	chr7:1930337	MAD1L1	-0.48	-7.14	-0.36	6.03e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17807624	0.780	rs13277929	chr8:11453030	G/A	cg21175976	chr8:11421337	BLK	0.37	6.11	0.32	2.8e-9	Systemic lupus erythematosus;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg25971741	chr6:15343116	JARID2	-0.39	-6.28	-0.32	1.03e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.65	11.3	0.53	2.64e-25	Menopause (age at onset);
LUSC	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	5.65	0.3	3.39e-8	Schizophrenia;
LUSC	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg05425664	chr17:57184151	TRIM37	0.49	7.41	0.38	1.06e-12	Testicular germ cell tumor;
LUSC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.69	-10.89	-0.51	7.82e-24	Aortic root size;
LUSC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.2	31.07	0.86	1.56e-100	Testicular germ cell tumor;
LUSC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.12	-0.48	3.44e-21	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.23e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.24	0.45	2.91e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-9.17	-0.45	4.97e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg11812906	chr14:75593930	NEK9	-0.62	-10.7	-0.51	3.72e-23	Height;
LUSC	cis	rs908922	0.885	rs2181173	chr1:152474866	A/T	cg20991723	chr1:152506922	NA	-0.51	-9.3	-0.45	1.87e-18	Hair morphology;
LUSC	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg15704280	chr7:45808275	SEPT13	0.81	7.73	0.39	1.27e-13	Axial length;
LUSC	cis	rs977987	0.872	rs3743609	chr16:75467021	G/C	cg03315344	chr16:75512273	CHST6	0.54	10.28	0.49	9.87e-22	Dupuytren's disease;
LUSC	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg09307838	chr4:120376055	NA	0.69	10.03	0.48	7.01e-21	Corneal astigmatism;
LUSC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg16479474	chr6:28041457	NA	0.32	5.7	0.3	2.6e-8	Depression;
LUSC	cis	rs11158026	0.603	rs12147796	chr14:55408696	C/T	cg04306507	chr14:55594613	LGALS3	0.37	6.52	0.34	2.67e-10	Parkinson's disease;
LUSC	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg24110177	chr3:50126178	RBM5	0.42	6.73	0.35	7.18e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.69	-0.34	9.62e-11	QT interval;
LUSC	cis	rs2279817	0.820	rs11203440	chr1:18026352	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.43	5.91	0.31	8.27e-9	Neuroticism;
LUSC	cis	rs17828380	0.920	rs7177131	chr15:63443189	C/T	cg05507819	chr15:63340323	TPM1	-0.78	-5.91	-0.31	8.37e-9	Social communication problems;
LUSC	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.43	5.83	0.3	1.32e-8	IgG glycosylation;
LUSC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs67072384	0.892	rs67034709	chr11:72451004	T/C	cg04827223	chr11:72435913	ARAP1	-0.81	-7.3	-0.37	2.13e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs28647808	0.881	rs4246171	chr9:136264731	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.92	-0.35	2.29e-11	Lung cancer;
LUSC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.48	-0.33	3.3e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg02153584	chr22:29168773	CCDC117	-0.57	-8.48	-0.42	7.17e-16	Lymphocyte counts;
LUSC	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	1.12	18.97	0.72	5.86e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg13256891	chr4:100009986	ADH5	-0.5	-6.47	-0.33	3.53e-10	Alcohol dependence;
LUSC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	5.9e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg11062466	chr8:58055876	NA	0.44	5.79	0.3	1.61e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-1.0	-16.59	-0.67	1.63e-45	Body mass index;
LUSC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs853679	0.546	rs200953	chr6:27837267	T/C	cg01620082	chr3:125678407	NA	-0.69	-7.03	-0.36	1.19e-11	Depression;
LUSC	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.08	0.32	3.24e-9	Recombination rate (females);
LUSC	cis	rs9309473	1.000	rs7586463	chr2:73798476	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-6.53	-0.34	2.47e-10	Metabolite levels;
LUSC	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.67	10.84	0.51	1.18e-23	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg05340658	chr4:99064831	C4orf37	0.66	11.2	0.52	5.97e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10992471	0.603	rs7868013	chr9:95240173	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.68	-0.39	1.78e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1413885	0.548	rs6588136	chr1:65837119	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.49	7.18	0.37	4.41e-12	Anticoagulant levels;
LUSC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg04287289	chr16:89883240	FANCA	0.6	8.77	0.43	8.99e-17	Vitiligo;
LUSC	trans	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-9.13	-0.45	6.91e-18	Initial pursuit acceleration in psychotic disorders;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04571327	chr6:97345972	NDUFAF4	0.41	6.25	0.32	1.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9612	1.000	rs61002661	chr19:44269032	T/A	cg08581076	chr19:44259116	C19orf61	0.48	5.9	0.31	9.06e-9	Exhaled nitric oxide output;
LUSC	cis	rs8099014	0.906	rs4940696	chr18:56106596	C/T	cg12907477	chr18:56117327	MIR122	-0.42	-6.45	-0.33	3.86e-10	Platelet count;
LUSC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg22834771	chr12:69754056	YEATS4	-0.54	-8.08	-0.4	1.23e-14	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25022925	chr5:126112600	LMNB1	0.41	6.04	0.31	4.09e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06112835	chr11:68658793	MRPL21	0.52	8.1	0.41	1.06e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9625935	0.957	rs36607	chr22:30341260	G/T	cg11564601	chr22:30592435	NA	0.38	5.68	0.3	2.96e-8	Tonsillectomy;
LUSC	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.35	-5.83	-0.3	1.29e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.67	11.18	0.52	7.24e-25	Tuberculosis;
LUSC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg09034736	chr1:150693464	HORMAD1	0.42	5.91	0.31	8.51e-9	Melanoma;
LUSC	cis	rs4601821	0.635	rs11214579	chr11:113208186	A/C	cg14159747	chr11:113255604	NA	-0.24	-5.78	-0.3	1.69e-8	Alcoholic chronic pancreatitis;
LUSC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg14416269	chr4:6271139	WFS1	0.47	10.14	0.49	2.94e-21	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg05347473	chr6:146136440	FBXO30	0.4	6.78	0.35	5.5e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18854424	chr1:2615690	NA	0.52	10.79	0.51	1.71e-23	Ulcerative colitis;
LUSC	trans	rs1325195	0.920	rs2130576	chr1:179181102	T/C	cg11624085	chr17:8464688	MYH10	0.41	6.58	0.34	1.87e-10	IgE grass sensitization;
LUSC	trans	rs78547376	0.516	rs10445896	chr2:58390547	C/T	cg10600964	chr10:114492301	VTI1A	0.56	6.11	0.32	2.83e-9	Neuroticism;
LUSC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg18681998	chr4:17616180	MED28	0.85	15.42	0.64	7.01e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21440829	chr7:100808893	VGF	0.49	6.83	0.35	3.92e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4714291	0.832	rs3008839	chr6:40052660	G/A	cg02267698	chr19:7991119	CTXN1	-0.53	-7.84	-0.39	6.31e-14	Strep throat;
LUSC	cis	rs27434	0.583	rs149431	chr5:96157541	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-7.53	-0.38	4.91e-13	Ankylosing spondylitis;
LUSC	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg05714579	chr10:131428358	MGMT	-0.51	-7.73	-0.39	1.32e-13	Response to temozolomide;
LUSC	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg11584989	chr19:19387371	SF4	0.57	6.97	0.36	1.66e-11	Bipolar disorder;
LUSC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg22823121	chr1:150693482	HORMAD1	0.49	7.03	0.36	1.18e-11	Melanoma;
LUSC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.12	-0.32	2.63e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.84	-0.44	5.48e-17	Response to antipsychotic treatment;
LUSC	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.63	-8.11	-0.41	9.61e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs12410462	0.581	rs112572966	chr1:227553905	C/T	cg04117972	chr1:227635322	NA	0.58	6.46	0.33	3.76e-10	Major depressive disorder;
LUSC	cis	rs243505	0.762	rs3779036	chr7:148488507	C/T	cg09806900	chr7:148480153	CUL1	0.58	8.51	0.42	5.84e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1044826	0.642	rs295479	chr3:139223865	C/T	cg15131784	chr3:139108705	COPB2	0.39	6.34	0.33	7.33e-10	Obesity-related traits;
LUSC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	0.84	13.9	0.61	5.86e-35	Tonsillectomy;
LUSC	cis	rs62400317	0.859	rs10948221	chr6:45236707	T/G	cg18551225	chr6:44695536	NA	-0.44	-7.28	-0.37	2.46e-12	Total body bone mineral density;
LUSC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg16545954	chr1:2118288	C1orf86	-0.35	-6.76	-0.35	6.22e-11	Height;
LUSC	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg05110241	chr16:68378359	PRMT7	-0.55	-6.52	-0.34	2.6e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	4.99e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12464559	0.649	rs11896217	chr2:152591189	G/A	cg01189475	chr2:152685088	ARL5A	0.62	5.67	0.3	3.06e-8	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.43	-5.72	-0.3	2.42e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg16989719	chr2:238392110	NA	0.4	6.78	0.35	5.59e-11	Prostate cancer;
LUSC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2742234	0.590	rs2435377	chr10:43683600	A/G	cg15436174	chr10:43711423	RASGEF1A	0.43	7.16	0.36	5.27e-12	Hirschsprung disease;
LUSC	cis	rs73198271	1.000	rs11775476	chr8:8607869	T/C	cg01851573	chr8:8652454	MFHAS1	0.59	8.13	0.41	8.61e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg05347473	chr6:146136440	FBXO30	-0.61	-10.81	-0.51	1.45e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg03146154	chr1:46216737	IPP	0.5	7.41	0.38	1.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg21293242	chr8:11204541	TDH	0.32	5.98	0.31	5.69e-9	Retinal vascular caliber;
LUSC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.75	-0.51	2.45e-23	Chronic sinus infection;
LUSC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs17095355	1.000	rs17126883	chr10:111694696	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-7.39	-0.37	1.2e-12	Biliary atresia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08047886	chr11:57425128	CLP1	-0.41	-7.09	-0.36	8.28e-12	Electrocardiographic conduction measures;
LUSC	cis	rs8044995	0.563	rs8059585	chr16:68376811	G/A	cg05110241	chr16:68378359	PRMT7	-0.76	-8.7	-0.43	1.59e-16	Schizophrenia;
LUSC	cis	rs977987	0.806	rs4888404	chr16:75428097	G/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.41e-11	Dupuytren's disease;
LUSC	cis	rs354225	0.615	rs12713274	chr2:54848728	C/T	cg26097391	chr2:54893211	SPTBN1	-0.43	-6.8	-0.35	4.82e-11	Schizophrenia;
LUSC	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg14844989	chr11:31128820	NA	-0.39	-6.02	-0.31	4.6e-9	Red blood cell count;
LUSC	trans	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg03886242	chr7:26192032	NFE2L3	0.41	6.5	0.34	2.94e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg11764359	chr7:65958608	NA	0.52	6.58	0.34	1.84e-10	Aortic root size;
LUSC	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg20587970	chr11:113659929	NA	-1.06	-13.08	-0.58	7.3e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	8.12e-16	Aortic root size;
LUSC	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg06191203	chr2:152266755	RIF1	-0.61	-8.29	-0.41	2.89e-15	Lung cancer;
LUSC	cis	rs4343996	0.521	rs10499327	chr7:3407856	A/T	cg21248987	chr7:3385318	SDK1	0.37	6.33	0.33	7.85e-10	Motion sickness;
LUSC	cis	rs4319547	0.506	rs2062488	chr12:122804256	C/T	cg05707623	chr12:122985044	ZCCHC8	0.5	6.3	0.33	9.47e-10	Body mass index;
LUSC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg05973401	chr12:123451056	ABCB9	0.63	9.19	0.45	4.35e-18	Platelet count;
LUSC	cis	rs6429082	0.683	rs868815	chr1:235584543	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-7.57	-0.38	3.76e-13	Adiposity;
LUSC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	0.93	16.12	0.66	1.16e-43	Menopause (age at onset);
LUSC	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg02018176	chr4:1364513	KIAA1530	0.44	6.25	0.32	1.27e-9	Recombination rate (females);
LUSC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-15.75	-0.65	3.47e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg09021430	chr5:549028	NA	-0.54	-7.06	-0.36	9.57e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	16.98	0.68	4.78e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1034435	0.755	rs6007871	chr22:48894392	C/G	cg05992904	chr22:48892994	FAM19A5	-0.39	-7.85	-0.39	5.79e-14	Late-onset Alzheimer's disease;
LUSC	cis	rs10789491	1.000	rs2083485	chr1:47170091	G/C	cg15501359	chr1:47185051	KIAA0494	0.82	11.6	0.54	2.34e-26	Response to hepatitis C treatment;
LUSC	trans	rs12495832	0.778	rs1456669	chr3:147935635	A/C	cg05062820	chr16:1098546	NA	-0.41	-6.01	-0.31	4.91e-9	Chin dimples;
LUSC	cis	rs12681287	0.640	rs10095498	chr8:87425651	C/T	cg27223183	chr8:87520930	FAM82B	0.55	7.5	0.38	5.74e-13	Caudate activity during reward;
LUSC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg23719950	chr11:63933701	MACROD1	-0.62	-8.12	-0.41	9.04e-15	Mean platelet volume;
LUSC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg21918786	chr6:109611834	NA	-0.41	-7.2	-0.37	3.92e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg15798862	chr7:76129360	DTX2	-0.51	-8.54	-0.42	4.77e-16	Multiple sclerosis;
LUSC	cis	rs6700896	0.931	rs4420065	chr1:66161461	T/C	cg04111102	chr1:66153794	NA	-0.34	-7.39	-0.37	1.19e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6690583	0.623	rs74761855	chr1:85432947	A/C	cg22153463	chr1:85462885	MCOLN2	0.64	6.17	0.32	2.01e-9	Serum sulfate level;
LUSC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.29	0.33	9.99e-10	Menopause (age at onset);
LUSC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg15448220	chr1:150897856	SETDB1	0.42	6.16	0.32	2.12e-9	Melanoma;
LUSC	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg14092571	chr14:90743983	NA	0.37	5.95	0.31	6.92e-9	Mortality in heart failure;
LUSC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	8.34	0.42	2.02e-15	Height;
LUSC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg09165964	chr15:75287851	SCAMP5	-1.15	-19.33	-0.73	2.1e-56	Blood trace element (Zn levels);
LUSC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg05717871	chr11:638507	DRD4	-0.33	-5.84	-0.3	1.26e-8	Systemic lupus erythematosus;
LUSC	trans	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.14	-0.32	2.31e-9	Monocyte count;
LUSC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs6681460	0.649	rs967325	chr1:67003722	C/T	cg02459107	chr1:67143332	SGIP1	0.37	6.04	0.31	4.22e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg14416269	chr4:6271139	WFS1	0.54	11.38	0.53	1.35e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg22782873	chr19:19639568	YJEFN3	-0.52	-6.06	-0.31	3.71e-9	Bipolar disorder;
LUSC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg06494592	chr3:125709126	NA	-0.52	-5.95	-0.31	6.8e-9	Blood pressure (smoking interaction);
LUSC	cis	rs4654899	0.802	rs3767247	chr1:21227338	T/C	cg01072550	chr1:21505969	NA	-0.51	-7.55	-0.38	4.17e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg01238044	chr22:24384105	GSTT1	-0.52	-7.58	-0.38	3.51e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.69	-10.61	-0.5	7.19e-23	Aortic root size;
LUSC	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.85	14.85	0.63	1.22e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg05738196	chr6:26577821	NA	0.8	15.1	0.64	1.22e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.633	rs7770835	chr6:86608907	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.14	-0.32	2.32e-9	Response to antipsychotic treatment;
LUSC	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.52	-0.38	5.17e-13	Neuroticism;
LUSC	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06636551	chr8:101224915	SPAG1	-0.45	-8.12	-0.41	9.03e-15	Atrioventricular conduction;
LUSC	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg03342759	chr3:160939853	NMD3	-0.51	-7.26	-0.37	2.74e-12	Parkinson's disease;
LUSC	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg13736514	chr6:26305472	NA	-0.45	-8.94	-0.44	2.72e-17	Educational attainment;
LUSC	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-1.13	-17.75	-0.7	4.18e-50	Exhaled nitric oxide output;
LUSC	cis	rs6681460	0.966	rs10749763	chr1:67062126	G/A	cg02459107	chr1:67143332	SGIP1	0.46	8.64	0.43	2.4e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.84	-0.3	1.22e-8	Total body bone mineral density;
LUSC	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-9.85	-0.47	2.9e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg20283391	chr11:68216788	NA	-0.53	-7.27	-0.37	2.53e-12	Total body bone mineral density;
LUSC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.75	0.35	6.62e-11	Platelet count;
LUSC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21963583	chr11:68658836	MRPL21	0.56	8.28	0.41	3.09e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg00105475	chr2:10696890	NA	0.37	6.09	0.32	3.03e-9	Prostate cancer;
LUSC	cis	rs5009270	0.512	rs1024412	chr7:112247758	A/G	cg27282281	chr7:112262583	NA	0.45	6.03	0.31	4.32e-9	Osteoarthritis (hip);
LUSC	trans	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.66	-0.34	1.11e-10	Endometrial cancer;
LUSC	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.52	-7.27	-0.37	2.57e-12	Iron status biomarkers;
LUSC	cis	rs17401966	0.558	rs12128374	chr1:10426417	G/A	cg17425144	chr1:10567563	PEX14	-0.34	-6.08	-0.32	3.32e-9	Hepatocellular carcinoma;
LUSC	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.34	-0.46	1.42e-18	Morning vs. evening chronotype;
LUSC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg08270630	chr22:50330655	NA	-0.43	-6.43	-0.33	4.39e-10	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	9.22	0.45	3.53e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg00166722	chr3:10149974	C3orf24	0.39	5.81	0.3	1.43e-8	Alzheimer's disease;
LUSC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg15704280	chr7:45808275	SEPT13	-0.88	-12.2	-0.56	1.52e-28	Coronary artery disease;
LUSC	cis	rs3125734	0.633	rs7088891	chr10:64034019	G/T	cg19640130	chr10:64028056	RTKN2	-0.41	-7.06	-0.36	9.51e-12	Rheumatoid arthritis;
LUSC	trans	rs488628	1.000	rs513011	chr3:118130697	C/G	cg06621744	chr14:37052470	NKX2-8	-0.29	-6.47	-0.33	3.56e-10	White matter integrity (bipolar disorder risk interaction);
LUSC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg09626299	chr10:82213104	TSPAN14	-0.21	-5.97	-0.31	6.12e-9	Post bronchodilator FEV1;
LUSC	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	0.9	18.13	0.7	1.27e-51	Ulcerative colitis;
LUSC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg13114125	chr14:105738426	BRF1	-0.95	-15.95	-0.66	5.69e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg01579765	chr21:45077557	HSF2BP	0.55	11.55	0.53	3.57e-26	Mean corpuscular volume;
LUSC	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg15744005	chr10:104629667	AS3MT	-0.28	-5.89	-0.31	9.58e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1413885	0.549	rs4593866	chr1:65850968	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.49	7.21	0.37	3.66e-12	Anticoagulant levels;
LUSC	cis	rs2273669	0.667	rs2003315	chr6:109367169	C/T	cg05315195	chr6:109294784	ARMC2	-0.53	-5.79	-0.3	1.6e-8	Prostate cancer;
LUSC	cis	rs10072221	0.836	rs11738470	chr5:75693904	A/G	cg03132911	chr5:75698732	IQGAP2	-0.37	-6.33	-0.33	7.82e-10	Mean platelet volume;
LUSC	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg03806693	chr22:41940476	POLR3H	1.03	14.29	0.62	1.71e-36	Vitiligo;
LUSC	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg12002119	chr2:101014098	CHST10	0.36	5.92	0.31	8.07e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg23711669	chr6:146136114	FBXO30	0.77	13.37	0.59	5.92e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs2425143	1.000	rs78421482	chr20:34376486	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-5.7	-0.3	2.64e-8	Blood protein levels;
LUSC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.94	-0.4	3.13e-14	Mean platelet volume;
LUSC	cis	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg09307838	chr4:120376055	NA	0.53	7.85	0.39	5.52e-14	Diastolic blood pressure;
LUSC	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	8.3	0.41	2.56e-15	Axial length;
LUSC	cis	rs500891	0.645	rs1180192	chr6:83964709	C/T	cg08257003	chr6:84140564	ME1	0.29	6.53	0.34	2.38e-10	Platelet-derived growth factor BB levels;
LUSC	trans	rs6461503	0.644	rs916789	chr7:20572530	A/C	cg06798092	chr14:50328478	NA	0.38	5.97	0.31	6.14e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg08917208	chr2:24149416	ATAD2B	0.87	9.73	0.47	7.07e-20	Lymphocyte counts;
LUSC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.5	-0.33	2.99e-10	Lung cancer;
LUSC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.7	-11.58	-0.54	2.74e-26	Cognitive function;
LUSC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.66	-12.16	-0.55	2.02e-28	Birth weight;
LUSC	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg19622623	chr12:86230825	RASSF9	0.39	5.72	0.3	2.4e-8	Major depressive disorder;
LUSC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg03709012	chr19:19516395	GATAD2A	-0.82	-12.97	-0.58	1.9e-31	Tonsillectomy;
LUSC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.89	15.49	0.65	3.73e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11645898	0.872	rs4788459	chr16:72153125	C/G	cg14768367	chr16:72042858	DHODH	-0.63	-7.24	-0.37	3.03e-12	Blood protein levels;
LUSC	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg08017756	chr2:100939284	LONRF2	-0.45	-8.36	-0.42	1.72e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4919087	0.926	rs953097	chr10:98981914	T/C	cg25902810	chr10:99078978	FRAT1	0.5	7.1	0.36	7.66e-12	Monocyte count;
LUSC	cis	rs1506636	0.962	rs1019220	chr7:123365122	G/A	cg03229431	chr7:123269106	ASB15	-0.65	-10.57	-0.5	9.99e-23	Plateletcrit;Platelet count;
LUSC	cis	rs1451375	0.698	rs68143668	chr7:50638110	C/T	cg18232548	chr7:50535776	DDC	0.51	7.59	0.38	3.31e-13	Malaria;
LUSC	trans	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg02030672	chr11:45687055	CHST1	-0.43	-6.72	-0.35	7.63e-11	Obesity-related traits;
LUSC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg14391382	chr7:866102	UNC84A	0.42	6.35	0.33	6.88e-10	Subjective well-being;
LUSC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-6.95	-0.36	1.88e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3772130	0.775	rs6769102	chr3:121560722	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	9.91	0.48	1.88e-20	Cognitive performance;
LUSC	trans	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.45	0.5	2.57e-22	Mean corpuscular volume;
LUSC	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg27068330	chr11:65405492	SIPA1	-0.77	-10.79	-0.51	1.67e-23	Acne (severe);
LUSC	trans	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg18187862	chr3:45730750	SACM1L	0.55	7.09	0.36	8.01e-12	Primary sclerosing cholangitis;
LUSC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg08132940	chr7:1081526	C7orf50	-0.48	-6.21	-0.32	1.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg18758796	chr5:131593413	PDLIM4	-0.39	-6.18	-0.32	1.89e-9	Breast cancer;
LUSC	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg11693508	chr17:37793320	STARD3	0.65	7.91	0.4	3.9e-14	Bipolar disorder;
LUSC	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-17.56	-0.69	2.39e-49	Headache;
LUSC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg11645453	chr3:52864694	ITIH4	0.36	8.63	0.43	2.5e-16	Bipolar disorder;
LUSC	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.52	-7.35	-0.37	1.53e-12	Body mass index;
LUSC	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg16339924	chr4:17578868	LAP3	0.51	7.6	0.38	3.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg15704280	chr7:45808275	SEPT13	0.93	13.53	0.6	1.44e-33	Height;
LUSC	cis	rs6500395	0.963	rs2041921	chr16:48714002	T/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.73	-0.35	7.3e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4363385	0.510	rs11576797	chr1:153049417	T/C	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.31	-0.33	8.73e-10	Inflammatory skin disease;
LUSC	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.85	-0.3	1.15e-8	Resting heart rate;
LUSC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg18478394	chr8:109455254	TTC35	0.41	6.33	0.33	8.12e-10	Dupuytren's disease;
LUSC	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg08000102	chr2:233561755	GIGYF2	0.68	11.26	0.52	3.82e-25	Coronary artery disease;
LUSC	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg24642439	chr20:33292090	TP53INP2	0.53	8.16	0.41	6.81e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg21433313	chr16:3507492	NAT15	-0.81	-8.94	-0.44	2.63e-17	Tuberculosis;
LUSC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	1.02	19.93	0.74	8.56e-59	Cognitive function;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23974812	chr11:134123664	THYN1;ACAD8	-0.36	-6.13	-0.32	2.46e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.52	-7.24	-0.37	3.18e-12	Renal function-related traits (BUN);
LUSC	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.41	-6.14	-0.32	2.4e-9	Menarche (age at onset);
LUSC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg13319975	chr6:146136371	FBXO30	0.49	7.34	0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg20891283	chr12:69753455	YEATS4	0.66	10.49	0.5	1.89e-22	Blood protein levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11204671	chr14:24583351	DCAF11	-0.48	-6.39	-0.33	5.63e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.79	-0.39	8.36e-14	Morning vs. evening chronotype;
LUSC	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg13902645	chr11:5959945	NA	-0.63	-9.03	-0.44	1.43e-17	DNA methylation (variation);
LUSC	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg00579200	chr11:133705235	NA	-0.41	-6.26	-0.32	1.16e-9	Childhood ear infection;
LUSC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg13206674	chr6:150067644	NUP43	0.58	9.08	0.45	9.37e-18	Lung cancer;
LUSC	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg15934090	chr1:100435551	SLC35A3	0.49	8.49	0.42	7.11e-16	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-10.61	-0.5	7.3e-23	Chronic sinus infection;
LUSC	cis	rs4409675	0.576	rs2815707	chr1:28238880	T/C	cg23691781	chr1:28212827	C1orf38	0.32	7.87	0.4	5.06e-14	Corneal astigmatism;
LUSC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg18350739	chr11:68623251	NA	-0.39	-7.2	-0.37	4.06e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg27068330	chr11:65405492	SIPA1	0.73	10.18	0.49	2.16e-21	Acne (severe);
LUSC	trans	rs208520	0.909	rs9354410	chr6:67018584	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	8.52	0.42	5.37e-16	Exhaled nitric oxide output;
LUSC	cis	rs7180079	0.544	rs674745	chr15:64847554	A/G	cg08069370	chr15:64387884	SNX1	0.52	5.82	0.3	1.4e-8	Monocyte count;
LUSC	trans	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg00845942	chr12:64062724	DPY19L2	-0.62	-7.92	-0.4	3.6e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14893161	chr1:205819251	PM20D1	-0.43	-6.01	-0.31	4.93e-9	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg00850481	chr1:228891306	NA	-0.37	-5.79	-0.3	1.64e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg23590916	chr17:43697445	MGC57346	0.5	6.81	0.35	4.51e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg06532163	chr17:45867833	NA	-0.33	-6.49	-0.33	3.19e-10	IgG glycosylation;
LUSC	cis	rs72960926	0.744	rs1931273	chr6:74950660	A/T	cg03266952	chr6:74778945	NA	-0.81	-6.08	-0.32	3.25e-9	Metabolite levels (MHPG);
LUSC	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg11984989	chr7:158649758	WDR60	-1.05	-11.65	-0.54	1.52e-26	Height;
LUSC	trans	rs1729836	0.959	rs2698256	chr7:52763843	C/T	cg11852671	chr15:96960214	NA	-0.36	-5.96	-0.31	6.49e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs6066835	1.000	rs6066831	chr20:47354131	C/A	cg18078177	chr20:47281410	PREX1	0.71	6.21	0.32	1.61e-9	Multiple myeloma;
LUSC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg16606324	chr3:10149918	C3orf24	0.59	8.6	0.43	3.15e-16	Alzheimer's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08830818	chr3:122514143	HSPBAP1;DIRC2	-0.4	-6.22	-0.32	1.49e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg14541582	chr5:601475	NA	-0.37	-5.71	-0.3	2.48e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg19920283	chr7:105172520	RINT1	0.59	6.07	0.32	3.45e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg12386194	chr3:101231763	SENP7	-0.5	-7.1	-0.36	7.36e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6681460	0.966	rs10889643	chr1:67143368	G/C	cg02459107	chr1:67143332	SGIP1	0.48	8.8	0.43	7.38e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs243505	0.898	rs243535	chr7:148410123	A/C	cg09806900	chr7:148480153	CUL1	-0.47	-6.66	-0.34	1.12e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	6.12	0.32	2.59e-9	Height;
LUSC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg06600287	chr1:53387719	ECHDC2	-0.28	-5.74	-0.3	2.11e-8	Monocyte count;
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg06815965	chr1:205818668	PM20D1	0.39	5.9	0.31	8.76e-9	Menarche (age at onset);
LUSC	cis	rs4629180	1.000	rs13031791	chr2:102108790	T/C	cg01388757	chr2:102091195	RFX8	0.48	7.64	0.39	2.37e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs2273669	0.667	rs77002235	chr6:109321497	G/A	cg05315195	chr6:109294784	ARMC2	-0.56	-6.21	-0.32	1.54e-9	Prostate cancer;
LUSC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg26408565	chr15:76604113	ETFA	-0.51	-8.15	-0.41	7.45e-15	Blood metabolite levels;
LUSC	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg08601574	chr20:25228251	PYGB	0.39	5.96	0.31	6.48e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg05234568	chr11:5960015	NA	-0.59	-8.46	-0.42	8.25e-16	DNA methylation (variation);
LUSC	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.5	0.34	2.87e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	trans	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg18187862	chr3:45730750	SACM1L	-0.52	-6.3	-0.33	9.22e-10	Primary sclerosing cholangitis;
LUSC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.85	0.35	3.67e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.69e-10	Life satisfaction;
LUSC	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg08601574	chr20:25228251	PYGB	-0.45	-6.89	-0.35	2.83e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.74	15.5	0.65	3.38e-41	Systemic lupus erythematosus;
LUSC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg13047869	chr3:10149882	C3orf24	0.61	8.74	0.43	1.18e-16	Alzheimer's disease;
LUSC	cis	rs8114671	0.967	rs2093058	chr20:33791281	C/T	cg07148914	chr20:33460835	GGT7	-0.44	-6.54	-0.34	2.25e-10	Height;
LUSC	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg12002119	chr2:101014098	CHST10	0.35	5.81	0.3	1.49e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3772130	0.962	rs9839617	chr3:121516577	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.21	0.49	1.78e-21	Cognitive performance;
LUSC	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg24558204	chr6:135376177	HBS1L	-0.68	-11.06	-0.52	1.95e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.9	-0.51	6.89e-24	Hemoglobin concentration;
LUSC	cis	rs62400317	0.793	rs6924185	chr6:45017228	C/A	cg20913747	chr6:44695427	NA	-0.46	-7.46	-0.38	7.68e-13	Total body bone mineral density;
LUSC	cis	rs4478858	0.624	rs10914333	chr1:31701491	A/G	cg00250761	chr1:31883323	NA	-0.31	-7.74	-0.39	1.2e-13	Alcohol dependence;
LUSC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg22823121	chr1:150693482	HORMAD1	0.47	6.65	0.34	1.17e-10	Melanoma;
LUSC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03934478	chr11:495069	RNH1	0.9	10.16	0.49	2.55e-21	Body mass index;
LUSC	cis	rs934734	0.563	rs1858037	chr2:65598300	T/A	cg08085232	chr2:65598271	SPRED2	-0.44	-6.9	-0.35	2.56e-11	Rheumatoid arthritis;
LUSC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08048268	chr3:133502702	NA	0.46	8.81	0.43	7.09e-17	Iron status biomarkers;
LUSC	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg04545296	chr12:48745243	ZNF641	0.36	6.66	0.34	1.15e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs6484504	0.625	rs4922859	chr11:31382517	A/G	cg06552810	chr11:31128660	NA	0.38	6.62	0.34	1.45e-10	Red blood cell count;
LUSC	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg22681709	chr2:178499509	PDE11A	-0.59	-11.79	-0.54	4.57e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs780094	0.500	rs4665987	chr2:27755825	G/A	cg27432699	chr2:27873401	GPN1	0.4	5.67	0.3	3.16e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs6060717	0.536	rs11697851	chr20:34524494	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-5.8	-0.3	1.53e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.07	0.52	1.78e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg17971929	chr21:40555470	PSMG1	-0.48	-6.93	-0.35	2.18e-11	Menarche (age at onset);
LUSC	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg08755490	chr11:65554678	OVOL1	0.41	5.87	0.31	1.05e-8	Acne (severe);
LUSC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs10498514	0.793	rs74673631	chr14:65047841	A/T	cg25134081	chr14:64931936	AKAP5	0.97	6.73	0.35	7.22e-11	Cognitive performance;
LUSC	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg08000102	chr2:233561755	GIGYF2	-0.5	-7.73	-0.39	1.3e-13	Coronary artery disease;
LUSC	cis	rs814295	1.000	rs814295	chr2:27743215	A/G	cg27432699	chr2:27873401	GPN1	0.49	5.89	0.31	9.46e-9	Triglyceride levels;
LUSC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-0.91	-17.16	-0.68	9.16e-48	Heart rate;
LUSC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.66	9.11	0.45	7.8e-18	High light scatter reticulocyte count;
LUSC	cis	rs11051970	0.636	rs2651368	chr12:32561506	T/C	cg24626660	chr12:32551988	NA	0.31	5.66	0.3	3.25e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg26513180	chr16:89883248	FANCA	0.91	17.79	0.7	2.82e-50	Vitiligo;
LUSC	cis	rs2236918	1.000	rs1776137	chr1:242027045	A/G	cg17736920	chr1:242011382	EXO1	0.44	6.93	0.35	2.12e-11	Menopause (age at onset);
LUSC	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-1.0	-9.49	-0.46	4.59e-19	Mitochondrial DNA levels;
LUSC	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg22705602	chr4:152727874	NA	0.33	6.78	0.35	5.4e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.52e-8	Extrinsic epigenetic age acceleration;
LUSC	trans	rs57046232	0.552	rs6085506	chr20:6326507	T/C	cg21095983	chr6:86352623	SYNCRIP	0.5	7.35	0.37	1.49e-12	Colorectal cancer;
LUSC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg11663144	chr21:46675770	NA	-0.41	-7.19	-0.37	4.15e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg26924012	chr15:45694286	SPATA5L1	0.73	11.14	0.52	1.01e-24	Glomerular filtration rate;
LUSC	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg18357645	chr12:58087776	OS9	0.57	8.58	0.42	3.74e-16	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg15704280	chr7:45808275	SEPT13	0.66	7.2	0.37	4.14e-12	Axial length;
LUSC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6840360	1.000	rs749982	chr4:152601353	A/G	cg22705602	chr4:152727874	NA	-0.27	-5.7	-0.3	2.6e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg07741184	chr6:167504864	NA	0.49	8.61	0.43	3.03e-16	Crohn's disease;
LUSC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	10.09	0.48	4.6e-21	Bipolar disorder;
LUSC	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.82	-0.35	4.38e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	trans	rs7495211	0.529	rs12592382	chr15:98624268	A/C	cg08901157	chr15:56033728	PRTG	-0.34	-6.08	-0.32	3.23e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg08859206	chr1:53392774	SCP2	-0.58	-10.87	-0.51	9.47e-24	Monocyte count;
LUSC	cis	rs4654899	0.865	rs9426730	chr1:21452255	A/T	cg01072550	chr1:21505969	NA	-0.53	-8.2	-0.41	5.28e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg16482183	chr6:26056742	HIST1H1C	0.59	7.99	0.4	2.15e-14	Height;
LUSC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02187348	chr16:89574699	SPG7	0.58	9.31	0.45	1.79e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg17420585	chr12:42539391	GXYLT1	-0.56	-12.58	-0.57	5.7e-30	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2652834	1.000	rs2652816	chr15:63403368	C/T	cg05507819	chr15:63340323	TPM1	0.66	8.03	0.4	1.73e-14	HDL cholesterol;
LUSC	cis	rs6847149	0.929	rs11736783	chr4:110808321	A/G	cg07850274	chr4:110748770	RRH	-0.49	-7.07	-0.36	8.84e-12	Exercise treadmill test traits;
LUSC	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg05347473	chr6:146136440	FBXO30	0.51	8.55	0.42	4.64e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg14092571	chr14:90743983	NA	-0.35	-5.71	-0.3	2.45e-8	Mortality in heart failure;
LUSC	cis	rs67366981	0.720	rs4396457	chr14:77685379	G/A	cg22824376	chr14:77648248	TMEM63C	0.88	8.51	0.42	5.88e-16	Obsessive-compulsive symptoms;
LUSC	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg17376030	chr22:41985996	PMM1	-0.42	-5.66	-0.3	3.25e-8	Vitiligo;
LUSC	cis	rs2692947	0.696	rs2576437	chr2:96800417	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.44	0.33	4.09e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg02493740	chr2:85810744	VAMP5	-0.38	-6.73	-0.35	7.18e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg23649088	chr2:200775458	C2orf69	0.54	7.35	0.37	1.58e-12	Schizophrenia;
LUSC	cis	rs9831754	0.906	rs7621811	chr3:78388816	G/A	cg06138941	chr3:78371609	NA	-0.66	-8.99	-0.44	1.89e-17	Calcium levels;
LUSC	cis	rs7804356	0.906	rs12540388	chr7:26905731	A/T	cg03456212	chr7:26904342	SKAP2	-0.58	-6.65	-0.34	1.22e-10	Type 1 diabetes;
LUSC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg04414720	chr1:150670196	GOLPH3L	0.56	8.59	0.43	3.49e-16	Urate levels;
LUSC	cis	rs4144743	1.000	rs10438781	chr17:45323819	A/G	cg18085866	chr17:45331354	ITGB3	-0.7	-7.62	-0.38	2.61e-13	Body mass index;
LUSC	cis	rs7760535	0.763	rs10457241	chr6:111849034	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.38	-7.18	-0.37	4.41e-12	Metabolic traits;
LUSC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs9487051	0.768	rs463916	chr6:109520538	A/G	cg00509249	chr6:109615579	CCDC162	-0.34	-5.87	-0.31	1.06e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	6.29	0.33	9.74e-10	Mean platelet volume;
LUSC	cis	rs7727544	0.625	rs3091338	chr5:131402738	C/T	cg14196790	chr5:131705035	SLC22A5	0.44	6.57	0.34	1.96e-10	Blood metabolite levels;
LUSC	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg17470449	chr10:769945	NA	0.53	7.12	0.36	6.81e-12	Uric acid levels;
LUSC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg11502198	chr6:26597334	ABT1	0.64	10.06	0.48	5.52e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs6732160	0.691	rs10197935	chr2:73412362	A/T	cg24220031	chr2:73402428	NA	-0.23	-5.71	-0.3	2.45e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg06532163	chr17:45867833	NA	0.34	6.3	0.33	9.46e-10	IgG glycosylation;
LUSC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg18240062	chr17:79603768	NPLOC4	0.69	12.86	0.58	4.98e-31	Eye color traits;
LUSC	cis	rs13253111	0.687	rs7840565	chr8:28060783	C/T	cg26534493	chr8:28060551	NA	0.36	6.57	0.34	1.89e-10	Childhood body mass index;
LUSC	cis	rs865483	0.895	rs2522972	chr17:35839021	C/T	cg06716730	chr17:35851459	DUSP14	0.26	5.83	0.3	1.3e-8	Monocyte count;
LUSC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg14416269	chr4:6271139	WFS1	0.5	10.1	0.48	4.12e-21	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg01028140	chr2:1542097	TPO	-0.6	-7.98	-0.4	2.45e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.12	0.66	1.24e-43	Platelet count;
LUSC	cis	rs983392	0.679	rs654415	chr11:60013674	G/A	cg02771260	chr11:59836817	MS4A3	0.37	6.15	0.32	2.16e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3770081	1.000	rs76081054	chr2:86285037	T/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.94	-6.99	-0.36	1.51e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg15445000	chr17:37608096	MED1	0.4	6.81	0.35	4.65e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg01966878	chr4:90757139	SNCA	-0.34	-5.85	-0.3	1.17e-8	Dementia with Lewy bodies;
LUSC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg08132940	chr7:1081526	C7orf50	-0.48	-6.2	-0.32	1.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg11062466	chr8:58055876	NA	0.55	7.36	0.37	1.41e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs11166629	0.502	rs2439813	chr8:135669158	C/T	cg27224718	chr8:135614730	ZFAT	0.49	7.55	0.38	4.13e-13	Smoking quantity;
LUSC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	1.12	22.16	0.77	1.43e-67	Total cholesterol levels;
LUSC	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg10911889	chr6:126070802	HEY2	0.4	6.19	0.32	1.72e-9	Brugada syndrome;
LUSC	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.16	-0.36	5.18e-12	Bipolar disorder;
LUSC	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.5	-0.38	5.78e-13	Blood metabolite levels;
LUSC	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg00191853	chr8:101177733	SPAG1	0.36	5.77	0.3	1.84e-8	Atrioventricular conduction;
LUSC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg00310523	chr12:86230176	RASSF9	0.5	9.52	0.46	3.51e-19	Major depressive disorder;
LUSC	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.81	11.76	0.54	5.77e-27	Corneal astigmatism;
LUSC	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.58	-0.46	2.28e-19	Joint mobility (Beighton score);
LUSC	cis	rs9652601	0.959	rs7200940	chr16:11164567	G/C	cg04616529	chr16:11181986	CLEC16A	-0.34	-5.92	-0.31	8.13e-9	Systemic lupus erythematosus;
LUSC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06544989	chr22:39130855	UNC84B	-0.34	-5.99	-0.31	5.54e-9	Menopause (age at onset);
LUSC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06544989	chr22:39130855	UNC84B	0.34	5.8	0.3	1.53e-8	Menopause (age at onset);
LUSC	trans	rs62238980	0.614	rs117256264	chr22:32381750	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.63	11.42	0.53	9.71e-26	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs7605827	0.930	rs13035937	chr2:15698050	C/T	cg19274914	chr2:15703543	NA	-0.47	-9.02	-0.44	1.46e-17	Educational attainment (years of education);
LUSC	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.68	0.3	2.87e-8	Self-reported allergy;
LUSC	cis	rs11997175	0.603	rs4291230	chr8:33674570	A/C	ch.8.33884649F	chr8:33765107	NA	-0.45	-6.58	-0.34	1.87e-10	Body mass index;
LUSC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.01	-0.48	8.34e-21	Hemoglobin concentration;
LUSC	trans	rs17685	0.767	rs10954732	chr7:75611149	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.95	-15.4	-0.64	8.61e-41	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs600231	0.508	rs11227201	chr11:65242548	G/A	cg17120908	chr11:65337727	SSSCA1	-0.61	-8.8	-0.43	7.42e-17	Bone mineral density;
LUSC	cis	rs4954585	0.659	rs13018756	chr2:137008235	C/T	cg05194412	chr2:137003533	NA	0.41	7.51	0.38	5.32e-13	Colorectal cancer;
LUSC	cis	rs6469656	1.000	rs4601347	chr8:117687218	C/A	cg24004040	chr8:117650383	NA	-0.43	-6.23	-0.32	1.41e-9	Colorectal cancer;
LUSC	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg08975724	chr8:8085496	FLJ10661	0.45	6.09	0.32	3.06e-9	Neuroticism;
LUSC	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14442939	chr10:27389572	ANKRD26	-0.88	-9.91	-0.48	1.79e-20	Breast cancer;
LUSC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-8.61	-0.43	2.94e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg13503067	chr12:58176460	TSFM	0.42	6.05	0.31	3.83e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1018836	0.786	rs4734237	chr8:91533361	A/C	cg16814680	chr8:91681699	NA	0.6	9.21	0.45	3.64e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.5	0.56	1.14e-29	Motion sickness;
LUSC	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04850017	chr11:63683019	RCOR2	0.49	10.83	0.51	1.22e-23	Pulse pressure;
LUSC	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg06191203	chr2:152266755	RIF1	-0.54	-7.28	-0.37	2.37e-12	Lung cancer;
LUSC	cis	rs2667011	0.512	rs62176719	chr2:160817963	C/T	cg06573604	chr2:160760825	LY75	0.46	6.34	0.33	7.48e-10	Bilirubin levels;
LUSC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg22166914	chr1:53195759	ZYG11B	-0.56	-8.76	-0.43	9.77e-17	Monocyte count;
LUSC	cis	rs4363385	0.934	rs4240865	chr1:152954839	G/T	cg07796016	chr1:152779584	LCE1C	0.41	5.8	0.3	1.58e-8	Inflammatory skin disease;
LUSC	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.66	9.51	0.46	3.77e-19	Menarche (age at onset);
LUSC	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg02175503	chr12:58329896	NA	0.49	7.11	0.36	7.27e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12541635	0.934	rs2029882	chr8:107022894	G/A	cg10147462	chr8:107024639	NA	0.55	9.87	0.48	2.51e-20	Age of smoking initiation;
LUSC	cis	rs4356932	0.691	rs2242471	chr4:76878716	G/C	cg00809888	chr4:76862425	NAAA	-0.36	-5.72	-0.3	2.31e-8	Blood protein levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23657003	chr1:1014978	NA	0.42	6.28	0.32	1.05e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs7000551	0.556	rs6998780	chr8:22254639	C/T	cg12081754	chr8:22256438	SLC39A14	0.98	15.51	0.65	3e-41	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg06623918	chr6:96969491	KIAA0776	-0.83	-10.11	-0.48	3.96e-21	Migraine;Coronary artery disease;
LUSC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.45	-7.41	-0.38	1.04e-12	Pulse pressure;
LUSC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg04455712	chr21:45112962	RRP1B	-0.47	-8.94	-0.44	2.7e-17	Mean corpuscular volume;
LUSC	cis	rs9372253	0.843	rs9386895	chr6:110719632	T/A	cg01119278	chr6:110721349	DDO	-0.49	-8.85	-0.44	5.04e-17	Platelet distribution width;
LUSC	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg09173681	chr1:183549694	NCF2	0.66	12.0	0.55	7.9e-28	Systemic lupus erythematosus;
LUSC	trans	rs62458065	0.713	rs62463967	chr7:32498329	G/A	cg00845942	chr12:64062724	DPY19L2	-0.55	-6.58	-0.34	1.8e-10	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg24812749	chr6:127587940	RNF146	0.7	9.89	0.48	2.07e-20	Breast cancer;
LUSC	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.27	0.41	3.11e-15	Body mass index;
LUSC	cis	rs1878931	0.559	rs1968055	chr16:3392053	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.62	9.97	0.48	1.15e-20	Body mass index (adult);
LUSC	trans	rs1949829	0.826	rs4947596	chr7:51537143	T/C	cg20941110	chr15:83953819	BNC1	0.55	6.01	0.31	4.98e-9	Wegener's granulomatosis;
LUSC	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg00579200	chr11:133705235	NA	-0.39	-5.66	-0.3	3.22e-8	Childhood ear infection;
LUSC	cis	rs6494488	0.500	rs72742923	chr15:64855696	C/T	cg08069370	chr15:64387884	SNX1	-0.64	-5.73	-0.3	2.24e-8	Coronary artery disease;
LUSC	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg23625390	chr15:77176239	SCAPER	-0.62	-9.61	-0.47	1.83e-19	Blood metabolite levels;
LUSC	cis	rs1950626	0.743	rs12887333	chr14:101462612	C/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.36	5.87	0.31	1.06e-8	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg22655196	chr4:3374909	RGS12	0.3	5.71	0.3	2.53e-8	Serum sulfate level;
LUSC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg24060327	chr5:131705240	SLC22A5	-0.67	-11.47	-0.53	6.61e-26	Breast cancer;
LUSC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg06145435	chr7:1022769	CYP2W1	0.33	7.35	0.37	1.55e-12	Longevity;Endometriosis;
LUSC	cis	rs10779751	1.000	rs6679878	chr1:11306882	A/G	cg08854313	chr1:11322531	MTOR	0.87	15.01	0.63	2.81e-39	Body mass index;
LUSC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg00383909	chr3:49044727	WDR6	0.42	5.64	0.3	3.58e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg19230755	chr7:65878503	NA	-0.43	-6.01	-0.31	4.8e-9	Aortic root size;
LUSC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg21016266	chr12:122356598	WDR66	0.6	8.77	0.43	9.2e-17	Mean corpuscular volume;
LUSC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg03641300	chr2:160917029	PLA2R1	-0.4	-6.69	-0.34	9.18e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg04287289	chr16:89883240	FANCA	0.8	14.0	0.61	2.4e-35	Vitiligo;
LUSC	cis	rs11214589	0.747	rs11493880	chr11:113225144	C/T	cg14159747	chr11:113255604	NA	0.24	5.9	0.31	8.99e-9	Neuroticism;
LUSC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg07701084	chr6:150067640	NUP43	0.56	8.65	0.43	2.26e-16	Lung cancer;
LUSC	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.43	5.71	0.3	2.56e-8	Menarche (age at onset);
LUSC	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg12062639	chr20:23401060	NAPB	0.85	7.36	0.37	1.4e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.52	0.59	1.66e-33	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04565464	chr8:145669602	NFKBIL2	-0.4	-6.68	-0.34	9.82e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.98	0.52	3.62e-24	Colorectal cancer;
LUSC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg12963246	chr6:28129442	ZNF389	-0.41	-5.73	-0.3	2.29e-8	Parkinson's disease;
LUSC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12667521	chr19:29218732	NA	0.61	7.51	0.38	5.53e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14240646	chr10:27532245	ACBD5	-0.46	-5.66	-0.3	3.21e-8	Breast cancer;
LUSC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg12927641	chr6:109611667	NA	-0.43	-7.58	-0.38	3.46e-13	Reticulocyte fraction of red cells;
LUSC	trans	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	2.03e-12	Bone mineral density;
LUSC	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.71	10.75	0.51	2.33e-23	Alcohol dependence;
LUSC	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg24642439	chr20:33292090	TP53INP2	0.62	9.68	0.47	1.04e-19	Coronary artery disease;
LUSC	trans	rs72674100	1.000	rs17026369	chr4:97989437	C/G	cg16405019	chr1:18959625	PAX7	-0.61	-6.44	-0.33	4.04e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg05527609	chr1:210001259	C1orf107	-0.93	-12.05	-0.55	5.19e-28	Orofacial clefts;
LUSC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg19318889	chr4:1322082	MAEA	-0.48	-7.92	-0.4	3.67e-14	Obesity-related traits;
LUSC	cis	rs56399783	0.901	rs17132594	chr7:2775102	G/A	cg19731401	chr7:2775893	GNA12	0.7	8.45	0.42	9.01e-16	Childhood ear infection;
LUSC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.68	0.43	1.76e-16	Prudent dietary pattern;
LUSC	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg15395560	chr15:45543142	SLC28A2	0.33	5.71	0.3	2.54e-8	Uric acid levels;
LUSC	cis	rs9905704	0.918	rs302857	chr17:56692387	C/G	cg12560992	chr17:57184187	TRIM37	0.55	7.87	0.4	5.02e-14	Testicular germ cell tumor;
LUSC	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg04362960	chr10:104952993	NT5C2	0.63	9.67	0.47	1.13e-19	Arsenic metabolism;
LUSC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.51	-9.93	-0.48	1.57e-20	Longevity;Endometriosis;
LUSC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg21724239	chr8:58056113	NA	-0.79	-9.27	-0.45	2.32e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg20713898	chr8:124780851	FAM91A1	-0.55	-7.53	-0.38	4.81e-13	Pancreatic cancer;
LUSC	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg21366198	chr4:185655624	MLF1IP	0.41	5.83	0.3	1.29e-8	Kawasaki disease;
LUSC	cis	rs10992471	0.603	rs1535755	chr9:95202031	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-7.89	-0.4	4.36e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg11473876	chr11:109292803	C11orf87	0.35	5.9	0.31	8.93e-9	Schizophrenia;
LUSC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-1.1	-22.16	-0.77	1.46e-67	Coronary artery disease;
LUSC	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.38	0.42	1.52e-15	Hemoglobin concentration;
LUSC	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg05855489	chr10:104503620	C10orf26	0.5	7.65	0.39	2.19e-13	Arsenic metabolism;
LUSC	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg20129853	chr10:51489980	NA	-0.36	-7.58	-0.38	3.5e-13	Prostate-specific antigen levels;
LUSC	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg08975724	chr8:8085496	FLJ10661	0.49	7.05	0.36	1.02e-11	Joint mobility (Beighton score);
LUSC	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	0.71	11.05	0.52	2.08e-24	Blood metabolite ratios;
LUSC	cis	rs7659604	0.540	rs7699289	chr4:122671553	G/A	cg19748678	chr4:122722346	EXOSC9	-0.43	-6.37	-0.33	6.4e-10	Type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19709743	chr11:118230230	UBE4A	-0.41	-6.62	-0.34	1.44e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs675209	0.637	rs1285879	chr6:7137363	T/C	cg23726566	chr6:7051754	NA	-0.36	-5.67	-0.3	3.07e-8	Urate levels;
LUSC	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-7.75	-0.39	1.1e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg22638593	chr5:131593259	PDLIM4	0.42	6.32	0.33	8.15e-10	Blood metabolite levels;
LUSC	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-9.67	-0.47	1.13e-19	Neuroticism;
LUSC	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg08601574	chr20:25228251	PYGB	0.55	8.83	0.43	6.14e-17	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.65	-10.43	-0.5	3.22e-22	Type 2 diabetes;
LUSC	cis	rs2742417	0.624	rs2673068	chr3:45768981	G/A	cg04837898	chr3:45731254	SACM1L	-0.45	-7.26	-0.37	2.69e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg11584989	chr19:19387371	SF4	0.52	6.31	0.33	8.76e-10	Bipolar disorder;
LUSC	trans	rs12200782	1.000	rs12213722	chr6:26473083	A/G	cg18180407	chr1:55047736	ACOT11	0.49	6.02	0.31	4.48e-9	Small cell lung carcinoma;
LUSC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02034447	chr16:89574710	SPG7	0.44	6.54	0.34	2.37e-10	Multiple myeloma (IgH translocation);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15820809	chr22:43507369	BIK	0.72	5.97	0.31	6.14e-9	Cognitive performance;
LUSC	cis	rs970548	0.688	rs1059696	chr10:45934437	G/A	cg15590007	chr10:45870220	ALOX5	0.51	5.78	0.3	1.7e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg17385448	chr1:15911702	AGMAT	0.36	6.0	0.31	5.18e-9	Systolic blood pressure;
LUSC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg08645402	chr16:4508243	NA	0.54	8.97	0.44	2.17e-17	Schizophrenia;
LUSC	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08645402	chr16:4508243	NA	0.54	9.21	0.45	3.67e-18	Schizophrenia;
LUSC	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg26875233	chr11:93583750	C11orf90	-0.3	-5.75	-0.3	2.05e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	9.97	0.48	1.19e-20	Hemoglobin concentration;
LUSC	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.64	-9.44	-0.46	6.49e-19	Superior crus of antihelix expression;
LUSC	trans	rs2018683	0.624	rs1006521	chr7:28996220	G/A	cg19402173	chr7:128379420	CALU	-0.52	-7.75	-0.39	1.08e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs8179	0.514	rs11773884	chr7:92285123	A/G	cg15732164	chr7:92237376	CDK6	-0.43	-6.45	-0.33	3.92e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.67	-11.53	-0.53	3.96e-26	IgG glycosylation;
LUSC	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg25427524	chr10:38739819	LOC399744	-0.51	-7.21	-0.37	3.79e-12	Obesity (extreme);
LUSC	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.64	-0.39	2.39e-13	Retinal vascular caliber;
LUSC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	0.93	16.11	0.66	1.32e-43	Menopause (age at onset);
LUSC	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg13114125	chr14:105738426	BRF1	-0.86	-14.21	-0.61	3.63e-36	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg10207240	chr12:122356781	WDR66	0.44	6.19	0.32	1.72e-9	Mean corpuscular volume;
LUSC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg25554036	chr4:6271136	WFS1	0.51	9.15	0.45	5.87e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	8.15	0.41	7.49e-15	Coronary artery disease;
LUSC	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg11130432	chr3:121712080	ILDR1	-0.63	-9.54	-0.46	3.19e-19	Multiple sclerosis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20297566	chr3:99979976	TBC1D23	-0.43	-6.14	-0.32	2.31e-9	Hepatitis;
LUSC	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.12	0.32	2.63e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs4144743	0.528	rs16941802	chr17:45355353	C/G	cg18085866	chr17:45331354	ITGB3	0.7	6.06	0.31	3.65e-9	Body mass index;
LUSC	cis	rs12760731	0.777	rs6701080	chr1:178382261	A/C	cg00404053	chr1:178313656	RASAL2	0.64	6.52	0.34	2.59e-10	Obesity-related traits;
LUSC	cis	rs7561273	0.609	rs2339945	chr2:24348096	G/A	cg20701182	chr2:24300061	SF3B14	0.46	5.87	0.31	1.05e-8	Quantitative traits;
LUSC	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.94	-0.44	2.76e-17	Neuroticism;
LUSC	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-6.0	-0.31	5.14e-9	Mean corpuscular volume;
LUSC	cis	rs7903847	0.642	rs2297667	chr10:99145492	A/T	cg08345082	chr10:99160200	RRP12	-0.36	-7.3	-0.37	2.08e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7843479	0.828	rs4357289	chr8:21777476	G/A	cg17168535	chr8:21777572	XPO7	0.69	10.67	0.5	4.55e-23	Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg06096015	chr1:231504339	EGLN1	0.57	10.07	0.48	5.37e-21	Hemoglobin concentration;
LUSC	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.96	-0.31	6.31e-9	Aortic root size;
LUSC	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg20744362	chr22:50050164	C22orf34	0.4	8.33	0.41	2.15e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01511126	chr1:40506125	CAP1	0.48	7.27	0.37	2.56e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg17567195	chr5:167378696	ODZ2	0.37	6.03	0.31	4.4e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	cis	rs9359856	0.564	rs72913975	chr6:90387116	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.89	-0.44	3.8e-17	Bipolar disorder;
LUSC	cis	rs9790314	0.690	rs7651087	chr3:160821929	T/C	cg03342759	chr3:160939853	NMD3	-0.42	-6.78	-0.35	5.43e-11	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08859206	chr1:53392774	SCP2	-0.66	-12.58	-0.57	5.43e-30	Monocyte count;
LUSC	cis	rs9875589	0.509	rs7651599	chr3:14010974	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	6.26	0.32	1.19e-9	Ovarian reserve;
LUSC	trans	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg23093090	chr10:104574429	C10orf26	-0.38	-7.09	-0.36	8.04e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg04352962	chr1:209979756	IRF6	-0.52	-6.03	-0.31	4.24e-9	Cleft lip with or without cleft palate;
LUSC	trans	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg19894588	chr14:64061835	NA	0.49	7.05	0.36	1.05e-11	Glioblastoma;Glioma;
LUSC	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs4363385	0.791	rs372490	chr1:153008971	A/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg00852783	chr1:26633632	UBXN11	0.61	9.66	0.47	1.28e-19	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg03563238	chr19:33554763	RHPN2	-0.4	-6.45	-0.33	3.95e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg23791538	chr6:167370224	RNASET2	-0.41	-6.76	-0.35	6.24e-11	Crohn's disease;
LUSC	cis	rs2692947	0.759	rs2692937	chr2:96751871	G/A	cg23100626	chr2:96804247	ASTL	0.31	7.52	0.38	5.05e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg25173405	chr17:45401733	C17orf57	0.36	5.73	0.3	2.26e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs78707713	0.560	rs61848397	chr10:71225584	C/A	cg14388049	chr10:71211838	TSPAN15	-0.33	-5.84	-0.3	1.22e-8	Venous thromboembolism;
LUSC	cis	rs2387326	0.717	rs12252256	chr10:129944616	C/T	cg16087940	chr10:129947807	NA	-0.41	-6.22	-0.32	1.51e-9	Select biomarker traits;
LUSC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.18	-14.3	-0.62	1.62e-36	Breast cancer;
LUSC	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	0.95	13.67	0.6	4.25e-34	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg09307838	chr4:120376055	NA	0.53	7.97	0.4	2.62e-14	Diastolic blood pressure;
LUSC	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.71	11.64	0.54	1.58e-26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUSC	trans	rs800082	1.000	rs11718059	chr3:144305997	G/A	cg24215973	chr2:240111563	HDAC4	-0.46	-6.93	-0.35	2.24e-11	Smoking behavior;
LUSC	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.43	-0.62	5.22e-37	Schizophrenia;
LUSC	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg25754956	chr12:51612065	POU6F1	1.02	16.72	0.67	5.25e-46	Cisplatin-induced ototoxicity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17680823	chr2:240016541	HDAC4	0.45	6.6	0.34	1.66e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg25643088	chr3:52874325	TMEM110	-0.39	-5.84	-0.3	1.25e-8	Schizophrenia;
LUSC	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg04155231	chr12:9217510	LOC144571	0.3	5.66	0.3	3.26e-8	Sjögren's syndrome;
LUSC	cis	rs10392	0.543	rs59777567	chr20:37557548	A/G	cg27552599	chr20:37590471	DHX35	0.43	6.86	0.35	3.3e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg14440974	chr22:39074834	NA	-0.38	-6.26	-0.32	1.15e-9	Menopause (age at onset);
LUSC	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg23625390	chr15:77176239	SCAPER	-0.67	-10.28	-0.49	9.91e-22	Blood metabolite levels;
LUSC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg08859206	chr1:53392774	SCP2	-0.47	-7.8	-0.39	8e-14	Monocyte count;
LUSC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	14.03	0.61	1.79e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6690583	0.623	rs61768852	chr1:85454613	T/C	cg22153463	chr1:85462885	MCOLN2	0.62	6.0	0.31	5.12e-9	Serum sulfate level;
LUSC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg11871910	chr12:69753446	YEATS4	0.94	17.4	0.69	1.05e-48	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg21951975	chr1:209979733	IRF6	0.4	6.63	0.34	1.32e-10	Monobrow;
LUSC	cis	rs4285028	0.747	rs7610298	chr3:121419100	T/A	cg11130432	chr3:121712080	ILDR1	-0.53	-7.84	-0.39	6.07e-14	Multiple sclerosis;
LUSC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg23711669	chr6:146136114	FBXO30	0.82	14.87	0.63	9.54e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.7	0.3	2.59e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-0.89	-12.81	-0.57	7.52e-31	Initial pursuit acceleration;
LUSC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs10504073	0.584	rs56134839	chr8:49918899	C/T	cg00325661	chr8:49890786	NA	0.7	11.08	0.52	1.6e-24	Blood metabolite ratios;
LUSC	cis	rs9309473	0.519	rs1815027	chr2:73831840	T/C	cg20560298	chr2:73613845	ALMS1	0.48	7.38	0.37	1.31e-12	Metabolite levels;
LUSC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg05855489	chr10:104503620	C10orf26	-0.76	-13.08	-0.58	7.59e-32	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs3799378	0.579	rs9348715	chr6:26375642	C/G	cg09904177	chr6:26538194	HMGN4	-0.45	-6.4	-0.33	5.33e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg12564285	chr5:131593104	PDLIM4	-0.47	-7.65	-0.39	2.21e-13	Breast cancer;
LUSC	trans	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg10756647	chr7:56101905	PSPH	0.85	8.34	0.42	2.04e-15	Diabetic kidney disease;
LUSC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.64	-9.86	-0.47	2.78e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9303542	0.559	rs1042822	chr17:46620095	G/T	cg09704116	chr17:46666958	LOC404266	-0.38	-6.54	-0.34	2.34e-10	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg02269571	chr22:50332266	NA	-0.55	-8.22	-0.41	4.59e-15	Schizophrenia;
LUSC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg18357645	chr12:58087776	OS9	0.58	8.82	0.43	6.45e-17	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg16423285	chr20:60520624	NA	-0.63	-8.03	-0.4	1.69e-14	Body mass index;
LUSC	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.59	-0.34	1.75e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg05081339	chr9:140082886	ANAPC2;SSNA1	0.39	6.15	0.32	2.19e-9	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg02086790	chr16:375327	AXIN1	-0.38	-5.88	-0.31	1.01e-8	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg03233332	chr7:66118400	NA	0.38	5.81	0.3	1.43e-8	Aortic root size;
LUSC	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg13010344	chr12:123464640	ARL6IP4	-0.48	-5.9	-0.31	8.74e-9	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg03859395	chr2:55845619	SMEK2	0.82	14.08	0.61	1.15e-35	Metabolic syndrome;
LUSC	cis	rs16867321	0.950	rs1919148	chr2:181501758	G/A	cg23363182	chr2:181467187	NA	-0.45	-5.92	-0.31	7.98e-9	Obesity;
LUSC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg27170947	chr2:26402098	FAM59B	-0.69	-10.55	-0.5	1.2e-22	Gut microbiome composition (summer);
LUSC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg26659404	chr1:25747437	RHCE	-0.28	-5.73	-0.3	2.19e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg13206674	chr6:150067644	NUP43	0.62	10.17	0.49	2.43e-21	Lung cancer;
LUSC	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg11845111	chr2:191398756	TMEM194B	-0.87	-11.13	-0.52	1.11e-24	Diastolic blood pressure;
LUSC	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.46	-8.69	-0.43	1.64e-16	Monocyte percentage of white cells;
LUSC	cis	rs9309473	0.555	rs2901437	chr2:73597024	T/G	cg20560298	chr2:73613845	ALMS1	-0.53	-7.81	-0.39	7.72e-14	Metabolite levels;
LUSC	cis	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.9	-0.4	4e-14	Height;
LUSC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.49	-6.88	-0.35	3.04e-11	Mean platelet volume;
LUSC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg02773041	chr1:40204384	PPIE	0.51	7.47	0.38	7.16e-13	Blood protein levels;
LUSC	cis	rs2708377	0.872	rs2708323	chr12:11198433	A/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	trans	rs2926702	0.810	rs16936761	chr8:71051850	C/A	cg16517358	chr11:46164796	NA	0.39	6.18	0.32	1.9e-9	Non-small cell lung cancer;
LUSC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg07741184	chr6:167504864	NA	-0.35	-6.28	-0.33	1.04e-9	Crohn's disease;
LUSC	cis	rs983392	0.836	rs17602572	chr11:59948374	C/G	cg24026212	chr11:59952134	MS4A6A	-0.38	-6.63	-0.34	1.39e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg14196790	chr5:131705035	SLC22A5	0.48	8.13	0.41	8.53e-15	Blood metabolite levels;
LUSC	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.44	0.5	2.97e-22	Bladder cancer;
LUSC	cis	rs977987	0.645	rs34904236	chr16:75498253	G/T	cg04384234	chr16:75411784	CFDP1	-0.48	-7.9	-0.4	4.01e-14	Dupuytren's disease;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg06784260	chr12:69634187	CPSF6	0.42	6.27	0.32	1.1e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg26408565	chr15:76604113	ETFA	-0.51	-8.13	-0.41	8.37e-15	Blood metabolite levels;
LUSC	cis	rs62408225	1.000	rs1604831	chr6:90967197	G/A	cg06866423	chr6:90926672	BACH2	0.4	5.82	0.3	1.37e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1322512	0.958	rs74608294	chr6:152944818	T/C	cg27316956	chr6:152958899	SYNE1	-0.33	-5.66	-0.3	3.25e-8	Tonometry;
LUSC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00166722	chr3:10149974	C3orf24	0.56	7.54	0.38	4.61e-13	Alzheimer's disease;
LUSC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.04	21.0	0.75	5.16e-63	Cognitive function;
LUSC	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg04851639	chr8:1020857	NA	-0.35	-7.15	-0.36	5.6e-12	Schizophrenia;
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-8.04	-0.4	1.57e-14	Lymphocyte counts;
LUSC	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.85	-14.32	-0.62	1.3e-36	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg21293242	chr8:11204541	TDH	0.31	5.92	0.31	7.88e-9	Retinal vascular caliber;
LUSC	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg02023728	chr11:77925099	USP35	0.53	7.59	0.38	3.24e-13	Testicular germ cell tumor;
LUSC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15369054	chr17:80825471	TBCD	0.71	11.94	0.55	1.34e-27	Breast cancer;
LUSC	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg05340658	chr4:99064831	C4orf37	0.59	8.73	0.43	1.28e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12900413	0.959	rs12908026	chr15:90318884	C/T	cg24249390	chr15:90295951	MESP1	-0.46	-6.75	-0.35	6.64e-11	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs6987853	0.712	rs2974343	chr8:42400679	G/A	cg09913449	chr8:42400586	C8orf40	0.54	9.31	0.45	1.7e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg20090143	chr19:45452003	APOC2	0.35	5.9	0.31	9.14e-9	Blood protein levels;
LUSC	cis	rs3850699	0.683	rs67481356	chr10:104317811	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-5.77	-0.3	1.82e-8	Prostate cancer;
LUSC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	10.83	0.51	1.25e-23	Homoarginine levels;
LUSC	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06636551	chr8:101224915	SPAG1	0.43	7.89	0.4	4.24e-14	Atrioventricular conduction;
LUSC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg05340658	chr4:99064831	C4orf37	0.6	9.21	0.45	3.72e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg09904177	chr6:26538194	HMGN4	0.76	14.16	0.61	5.54e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-0.99	-15.1	-0.64	1.26e-39	Initial pursuit acceleration;
LUSC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg00012203	chr2:219082015	ARPC2	0.89	17.23	0.69	4.95e-48	Colorectal cancer;
LUSC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg15790184	chr11:494944	RNH1	0.54	6.08	0.32	3.37e-9	Body mass index;
LUSC	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg11584989	chr19:19387371	SF4	0.56	6.32	0.33	8.54e-10	Bipolar disorder;
LUSC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.67	6.42	0.33	4.63e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg24060327	chr5:131705240	SLC22A5	-0.53	-8.78	-0.43	8.48e-17	Acylcarnitine levels;
LUSC	cis	rs11209002	0.614	rs10732837	chr1:67573120	A/G	cg02640540	chr1:67518911	SLC35D1	0.61	8.53	0.42	5.03e-16	Crohn's disease;
LUSC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-1.01	-24.65	-0.8	3.53e-77	Urate levels in lean individuals;
LUSC	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg15654264	chr1:150340011	RPRD2	0.66	10.9	0.51	7.07e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.73	-0.35	7.2e-11	Monocyte percentage of white cells;
LUSC	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg06219351	chr7:158114137	PTPRN2	-0.54	-8.36	-0.42	1.71e-15	Response to amphetamines;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21577651	chr17:6939140	SLC16A13	0.47	6.44	0.33	4.19e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12122100	0.651	rs12737860	chr1:146546343	G/T	cg03526459	chr1:146549940	NA	-0.4	-6.49	-0.33	3.18e-10	HIV-1 control;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06513149	chr13:33002431	N4BP2L1	-0.42	-6.07	-0.32	3.54e-9	Hepatitis;
LUSC	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg22676075	chr6:135203613	NA	0.62	9.68	0.47	1.04e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg18478394	chr8:109455254	TTC35	0.41	6.32	0.33	8.55e-10	Dupuytren's disease;
LUSC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08736216	chr1:53307985	ZYG11A	-0.29	-6.0	-0.31	5.15e-9	Monocyte count;
LUSC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08859206	chr1:53392774	SCP2	-0.59	-11.0	-0.52	3.07e-24	Monocyte count;
LUSC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.08	0.4	1.17e-14	Prudent dietary pattern;
LUSC	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14442939	chr10:27389572	ANKRD26	0.9	9.49	0.46	4.38e-19	Breast cancer;
LUSC	cis	rs701145	0.586	rs355785	chr3:153990251	T/G	cg17054900	chr3:154042577	DHX36	0.82	8.52	0.42	5.56e-16	Coronary artery disease;
LUSC	cis	rs10754283	0.967	rs10922679	chr1:90100925	T/C	cg21401794	chr1:90099060	LRRC8C	0.65	9.9	0.48	1.98e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg26513180	chr16:89883248	FANCA	0.9	17.26	0.69	3.48e-48	Vitiligo;
LUSC	cis	rs2273669	0.667	rs4527738	chr6:109309150	T/C	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	0.93	8.06	0.4	1.33e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg19077165	chr18:44547161	KATNAL2	-0.37	-5.72	-0.3	2.33e-8	Personality dimensions;
LUSC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.89	0.31	9.24e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg03289416	chr15:75166202	SCAMP2	0.45	6.76	0.35	6.11e-11	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08063194	chr16:20817608	ERI2;LOC81691	-0.4	-6.01	-0.31	4.91e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.39	0.67	1.04e-44	Platelet count;
LUSC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	ch.11.42038R	chr11:967971	AP2A2	0.43	6.49	0.33	3.13e-10	Alzheimer's disease (late onset);
LUSC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg06238570	chr21:40685208	BRWD1	0.47	7.3	0.37	2.12e-12	Cognitive function;
LUSC	cis	rs4631830	0.900	rs10763576	chr10:51538813	A/T	cg16070123	chr10:51489643	NA	-0.47	-7.39	-0.37	1.23e-12	Prostate-specific antigen levels;
LUSC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg06636001	chr8:8085503	FLJ10661	0.86	14.65	0.63	7.19e-38	Neuroticism;
LUSC	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-7.56	-0.38	3.84e-13	Morning vs. evening chronotype;
LUSC	cis	rs4268898	0.735	rs12469585	chr2:24489054	A/T	cg06627628	chr2:24431161	ITSN2	0.59	8.47	0.42	7.65e-16	Asthma;
LUSC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg09034736	chr1:150693464	HORMAD1	0.46	6.76	0.35	6.02e-11	Tonsillectomy;
LUSC	cis	rs6442522	0.867	rs12637268	chr3:15500248	T/C	cg16303742	chr3:15540471	COLQ	0.3	5.94	0.31	7.09e-9	Uric acid levels;
LUSC	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg19418458	chr7:158789849	NA	0.52	6.9	0.35	2.61e-11	Facial morphology (factor 20);
LUSC	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07988820	chr12:82153109	PPFIA2	-0.41	-5.7	-0.3	2.68e-8	Resting heart rate;
LUSC	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg07148914	chr20:33460835	GGT7	0.47	6.93	0.35	2.22e-11	Height;
LUSC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.26	0.52	3.81e-25	Prudent dietary pattern;
LUSC	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg09904177	chr6:26538194	HMGN4	-0.78	-6.38	-0.33	5.92e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	6.56	0.34	2.02e-10	Iron status biomarkers;
LUSC	cis	rs9658691	0.607	rs12416581	chr10:90780440	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.55	-5.92	-0.31	8.12e-9	Mosquito bite size;
LUSC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.65	11.03	0.52	2.39e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg00012203	chr2:219082015	ARPC2	-0.56	-8.99	-0.44	1.83e-17	Ulcerative colitis;
LUSC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	7.43	0.38	9.18e-13	Menarche (age at onset);
LUSC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg02534363	chr3:47050950	NBEAL2	0.36	5.84	0.3	1.26e-8	Colorectal cancer;
LUSC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg08508325	chr11:3079039	CARS	-0.52	-12.66	-0.57	2.91e-30	Longevity;
LUSC	cis	rs28647808	0.881	rs57394597	chr9:136261030	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18854424	chr1:2615690	NA	0.52	10.79	0.51	1.71e-23	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg19418458	chr7:158789849	NA	-0.65	-10.41	-0.49	3.69e-22	Facial morphology (factor 20);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14671666	chr5:41904456	C5orf51	-0.39	-6.3	-0.33	9.18e-10	Electrocardiographic conduction measures;
LUSC	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg09462578	chr12:12878428	APOLD1	-0.99	-16.97	-0.68	5.06e-47	Lymphocyte counts;
LUSC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg23303369	chr20:44641161	MMP9	0.35	6.07	0.32	3.47e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs13011075	0.919	rs56188212	chr2:68611631	T/C	cg14221825	chr19:46271408	SIX5	0.42	6.06	0.31	3.74e-9	Mean corpuscular volume;
LUSC	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg19628046	chr18:33552617	C18orf21	0.51	6.1	0.32	2.94e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.09	-17.41	-0.69	9.58e-49	Primary sclerosing cholangitis;
LUSC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.76	0.39	1.03e-13	Electroencephalogram traits;
LUSC	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.94	0.4	3.18e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7043114	0.544	rs7852510	chr9:95316359	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.49	-0.33	3.02e-10	Height;
LUSC	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg05738196	chr6:26577821	NA	0.78	14.89	0.63	7.91e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.28	0.32	1.07e-9	Platelet count;
LUSC	cis	rs3862435	0.572	rs2601165	chr15:90908934	C/G	cg22089800	chr15:90895588	ZNF774	-0.57	-6.32	-0.33	8.61e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs780096	0.526	rs11682621	chr2:27749669	G/A	cg22903471	chr2:27725779	GCKR	-0.38	-6.34	-0.33	7.45e-10	Total body bone mineral density;
LUSC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg03605463	chr16:89740564	NA	0.6	9.43	0.46	6.96e-19	Vitiligo;
LUSC	cis	rs9650315	0.530	rs61334940	chr8:57072570	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	8.57	0.42	3.89e-16	Height;
LUSC	cis	rs1775715	0.737	rs2778650	chr10:32106851	A/G	cg03015672	chr10:32216066	ARHGAP12	0.33	5.84	0.3	1.22e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg12379764	chr21:47803548	PCNT	0.73	8.47	0.42	7.72e-16	Lymphocyte counts;
LUSC	cis	rs2274273	0.588	rs7154831	chr14:55823965	A/C	cg04306507	chr14:55594613	LGALS3	0.48	9.81	0.47	3.89e-20	Protein biomarker;
LUSC	trans	rs61931739	0.649	rs815037	chr12:33725193	C/T	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg14664628	chr15:75095509	CSK	-0.48	-6.93	-0.35	2.22e-11	Breast cancer;
LUSC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg25233709	chr10:116636983	FAM160B1	0.44	7.89	0.4	4.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg10729496	chr3:10149963	C3orf24	0.54	7.17	0.37	4.98e-12	Alzheimer's disease;
LUSC	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	9.66	0.47	1.25e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg06238570	chr21:40685208	BRWD1	-0.53	-8.19	-0.41	5.67e-15	Menarche (age at onset);
LUSC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.71	0.54	9.03e-27	Prudent dietary pattern;
LUSC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg09877947	chr5:131593287	PDLIM4	-0.46	-6.88	-0.35	3.01e-11	Blood metabolite levels;
LUSC	cis	rs4938330	0.629	rs12269901	chr11:116973929	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-6.15	-0.32	2.2e-9	Blood protein levels;
LUSC	cis	rs4629710	0.592	rs67399092	chr6:131582936	G/A	cg12606694	chr6:131520996	AKAP7	0.63	9.57	0.46	2.49e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.37	-6.5	-0.33	2.98e-10	Breast cancer;
LUSC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg04155289	chr7:94953770	PON1	-0.36	-5.91	-0.31	8.42e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs73206853	0.686	rs73194018	chr12:111127697	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	6.73	0.35	7.61e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg23978390	chr7:1156363	C7orf50	0.48	5.65	0.3	3.49e-8	Bronchopulmonary dysplasia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg07118243	chr12:94853994	CCDC41;LOC144486	0.42	6.26	0.32	1.16e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	7.89	0.4	4.31e-14	Chronic sinus infection;
LUSC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg21285383	chr16:89894308	SPIRE2	0.33	7.0	0.36	1.44e-11	Vitiligo;
LUSC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg13560548	chr3:10150139	C3orf24	0.54	7.2	0.37	4.05e-12	Alzheimer's disease;
LUSC	trans	rs4942242	0.663	rs1472330	chr13:44209628	A/G	cg19169023	chr15:41853346	TYRO3	0.58	8.96	0.44	2.39e-17	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10551759	chr7:121036528	FAM3C	-0.4	-6.04	-0.31	4.2e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.76	-12.82	-0.57	7.37e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	13.55	0.6	1.2e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg25237894	chr2:233734115	C2orf82	-0.37	-6.92	-0.35	2.31e-11	Coronary artery disease;
LUSC	trans	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg13565492	chr6:43139072	SRF	-0.41	-6.07	-0.32	3.43e-9	Longevity;Endometriosis;
LUSC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg20203395	chr5:56204925	C5orf35	-0.74	-9.97	-0.48	1.14e-20	Initial pursuit acceleration;
LUSC	cis	rs2285947	0.967	rs2285948	chr7:21584229	T/C	cg04471919	chr7:21584483	DNAH11	0.34	7.73	0.39	1.29e-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg17211192	chr8:82754475	SNX16	-0.59	-8.48	-0.42	7.62e-16	Diastolic blood pressure;
LUSC	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg24634471	chr8:143751801	JRK	0.52	7.23	0.37	3.26e-12	Schizophrenia;
LUSC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.29	-5.81	-0.3	1.49e-8	Total body bone mineral density;
LUSC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg06713675	chr4:122721982	EXOSC9	-0.7	-11.97	-0.55	1.02e-27	Type 2 diabetes;
LUSC	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	10.1	0.48	4.15e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg04025307	chr7:1156635	C7orf50	0.55	8.48	0.42	7.47e-16	Longevity;Endometriosis;
LUSC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg21724239	chr8:58056113	NA	0.56	6.92	0.35	2.35e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6565180	0.926	rs4788409	chr16:30393771	G/A	cg17640201	chr16:30407289	ZNF48	0.9	15.41	0.64	7.41e-41	Tonsillectomy;
LUSC	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg19920283	chr7:105172520	RINT1	0.58	6.22	0.32	1.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs806215	1.000	rs712698	chr7:127249098	C/T	cg25922125	chr7:127225783	GCC1	0.57	7.17	0.37	4.96e-12	Type 2 diabetes;
LUSC	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg24675056	chr1:15929824	NA	0.46	8.02	0.4	1.83e-14	Systolic blood pressure;
LUSC	trans	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg06521331	chr12:34319734	NA	-0.41	-6.35	-0.33	7.12e-10	Bladder cancer;
LUSC	cis	rs7191700	0.509	rs416603	chr16:11364079	A/T	cg00044050	chr16:11439710	C16orf75	-0.6	-10.18	-0.49	2.29e-21	Multiple sclerosis;
LUSC	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg06606381	chr12:133084897	FBRSL1	-0.97	-8.98	-0.44	1.96e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg18232548	chr7:50535776	DDC	-0.64	-9.7	-0.47	9.04e-20	Systemic sclerosis;
LUSC	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg02527881	chr3:46936655	PTH1R	0.39	6.95	0.36	1.9e-11	Colorectal cancer;
LUSC	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg22676075	chr6:135203613	NA	0.59	9.42	0.46	7.88e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg10909506	chr17:38081995	ORMDL3	0.34	5.89	0.31	9.49e-9	Self-reported allergy;
LUSC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.18	-0.32	1.84e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg12365402	chr11:9010492	NRIP3	-0.47	-8.82	-0.43	6.25e-17	Hemoglobin concentration;
LUSC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.8	-14.89	-0.63	8.42e-39	Obesity-related traits;
LUSC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.72	0.35	7.92e-11	Renal cell carcinoma;
LUSC	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg24642439	chr20:33292090	TP53INP2	-0.43	-6.14	-0.32	2.39e-9	Height;
LUSC	cis	rs2652834	0.851	rs7170462	chr15:63345622	A/G	cg05507819	chr15:63340323	TPM1	0.67	8.52	0.42	5.72e-16	HDL cholesterol;
LUSC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg13397359	chr6:42928475	GNMT	0.58	9.56	0.46	2.58e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.59	0.34	1.74e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.83	-0.54	3.32e-27	Chronic sinus infection;
LUSC	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg08000102	chr2:233561755	GIGYF2	-0.67	-10.88	-0.51	8.32e-24	Coronary artery disease;
LUSC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg23034840	chr1:205782522	SLC41A1	0.53	7.37	0.37	1.39e-12	Menarche (age at onset);
LUSC	cis	rs10504229	0.516	rs7821160	chr8:57986281	C/T	cg22535103	chr8:58192502	C8orf71	0.46	6.32	0.33	8.16e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg05340658	chr4:99064831	C4orf37	-0.47	-7.45	-0.38	7.97e-13	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg25214090	chr10:38739885	LOC399744	0.47	6.86	0.35	3.32e-11	Corneal astigmatism;
LUSC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.65	-10.13	-0.48	3.2e-21	Menarche (age at onset);
LUSC	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg21141812	chr3:48556323	PFKFB4	0.34	6.12	0.32	2.66e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg13010199	chr12:38710504	ALG10B	0.53	8.08	0.4	1.16e-14	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.37	-0.46	1.11e-18	Acne (severe);
LUSC	cis	rs6686643	0.762	rs9333433	chr1:165611455	G/C	cg16553119	chr1:165599451	MGST3	-0.46	-6.49	-0.33	3.07e-10	Total ventricular volume;
LUSC	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.51	-7.67	-0.39	1.9e-13	Menarche (age at onset);
LUSC	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg07930552	chr6:133119739	C6orf192	-0.8	-10.5	-0.5	1.78e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.44	0.33	4.17e-10	Rheumatoid arthritis;
LUSC	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg21153622	chr11:89784906	NA	-0.4	-6.25	-0.32	1.22e-9	HDL cholesterol;
LUSC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	ch.11.42038R	chr11:967971	AP2A2	-0.41	-6.08	-0.32	3.28e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4285028	0.747	rs7647351	chr3:121422109	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-12.97	-0.58	1.9e-31	Multiple sclerosis;
LUSC	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg26384229	chr12:38710491	ALG10B	0.73	11.89	0.55	2.05e-27	Morning vs. evening chronotype;
LUSC	cis	rs11997175	0.624	rs17700425	chr8:33691467	T/G	ch.8.33884649F	chr8:33765107	NA	0.47	6.98	0.36	1.6e-11	Body mass index;
LUSC	cis	rs240764	0.567	rs12528607	chr6:101260131	A/G	cg09795085	chr6:101329169	ASCC3	0.44	6.23	0.32	1.41e-9	Neuroticism;
LUSC	cis	rs75804782	0.641	rs77448526	chr2:239353487	A/C	cg18131467	chr2:239335373	ASB1	-0.73	-6.63	-0.34	1.37e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs4930561	0.714	rs7950452	chr11:67962407	C/A	cg16338278	chr11:67432957	ALDH3B2	0.4	6.73	0.35	7.35e-11	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg25237894	chr2:233734115	C2orf82	-0.33	-6.04	-0.31	4.03e-9	Coronary artery disease;
LUSC	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.31	-6.07	-0.31	3.57e-9	Schizophrenia;
LUSC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg25345767	chr1:226070210	TMEM63A	0.4	6.08	0.32	3.23e-9	Schizophrenia (age at onset);
LUSC	cis	rs9463078	0.764	rs10948190	chr6:44942300	C/T	cg25276700	chr6:44698697	NA	-0.29	-5.98	-0.31	5.83e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs921665	0.831	rs6836	chr2:3192798	A/G	cg16434511	chr2:3151078	NA	-0.55	-5.99	-0.31	5.45e-9	World class endurance athleticism;
LUSC	cis	rs56346965	0.967	rs2159819	chr2:191532737	C/G	cg11845111	chr2:191398756	TMEM194B	-0.43	-6.37	-0.33	6.23e-10	Bone mineral density (Ward's triangle area);
LUSC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	0.93	15.66	0.65	7.69e-42	Menopause (age at onset);
LUSC	cis	rs9818941	0.824	rs2686541	chr3:157788184	G/C	cg08654915	chr3:157813417	NA	-0.31	-7.33	-0.37	1.79e-12	Height;
LUSC	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg04310649	chr10:35416472	CREM	-0.43	-6.49	-0.33	3.03e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg25019033	chr10:957182	NA	-0.52	-6.59	-0.34	1.67e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs977987	0.750	rs4888406	chr16:75432334	G/T	cg04384234	chr16:75411784	CFDP1	-0.44	-7.2	-0.37	4.08e-12	Dupuytren's disease;
LUSC	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg25039879	chr17:56429692	SUPT4H1	-0.4	-6.1	-0.32	2.88e-9	Primary tooth development (time to first tooth eruption);
LUSC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	0.83	13.76	0.6	1.91e-34	Tonsillectomy;
LUSC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	trans	rs6601327	0.540	rs12542912	chr8:9585196	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.47	-0.33	3.46e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.08	0.32	3.32e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9506514	0.722	rs11147813	chr13:21258558	T/C	cg04906043	chr13:21280425	IL17D	-0.31	-5.8	-0.3	1.52e-8	Coronary artery calcification;
LUSC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg04450456	chr4:17643702	FAM184B	0.38	6.4	0.33	5.26e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg21665744	chr7:39171113	POU6F2	0.42	6.63	0.34	1.37e-10	IgG glycosylation;
LUSC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	14.09	0.61	1.09e-35	Platelet count;
LUSC	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.34	5.7	0.3	2.63e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg08798685	chr6:27730294	NA	-0.69	-6.14	-0.32	2.4e-9	Depression;
LUSC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.55	8.73	0.43	1.24e-16	Longevity;Endometriosis;
LUSC	trans	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg10756647	chr7:56101905	PSPH	0.88	8.43	0.42	1.02e-15	Diabetic kidney disease;
LUSC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	7.25	0.37	2.83e-12	Ovarian reserve;
LUSC	cis	rs2580764	0.566	rs2920900	chr2:55280083	T/C	cg20993754	chr2:55226987	RTN4	-0.36	-5.91	-0.31	8.45e-9	Mean platelet volume;
LUSC	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.7	-10.7	-0.51	3.54e-23	Alcohol dependence;
LUSC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.25	0.59	1.67e-32	Chronic sinus infection;
LUSC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.7	-0.43	1.58e-16	Platelet count;
LUSC	trans	rs1325195	0.920	rs4651013	chr1:179072966	C/T	cg11624085	chr17:8464688	MYH10	-0.42	-6.93	-0.35	2.2e-11	IgE grass sensitization;
LUSC	cis	rs859767	0.741	rs7571113	chr2:135427392	A/G	cg12500956	chr2:135428796	TMEM163	-0.27	-6.04	-0.31	4.1e-9	Neuroticism;
LUSC	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg27433088	chr4:174089019	GALNT7	-0.39	-5.72	-0.3	2.37e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs6998277	0.830	rs17186961	chr8:103630028	G/A	cg10187029	chr8:103597600	NA	0.76	10.59	0.5	9.03e-23	Migraine;
LUSC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.3	-0.53	2.78e-25	Mean corpuscular volume;
LUSC	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.7	0.34	8.87e-11	Height;
LUSC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	15.68	0.65	6.58e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg12165864	chr7:66369176	NA	-0.53	-7.15	-0.36	5.51e-12	Corneal structure;
LUSC	cis	rs7177699	0.557	rs62011002	chr15:79120578	C/T	cg15571903	chr15:79123663	NA	0.32	5.91	0.31	8.39e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg00431813	chr7:1051703	C7orf50	-0.48	-7.82	-0.39	6.98e-14	Longevity;Endometriosis;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg13464717	chr19:2269532	OAZ1	0.64	6.14	0.32	2.3e-9	Body mass index;
LUSC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg04944784	chr2:26401820	FAM59B	0.72	9.98	0.48	1.1e-20	Gut microbiome composition (summer);
LUSC	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg08085267	chr17:45401833	C17orf57	0.61	10.05	0.48	6e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6599222	0.500	rs4130467	chr3:38611704	C/T	cg26255052	chr1:23038321	EPHB2	-0.4	-6.22	-0.32	1.47e-9	PR interval;
LUSC	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg01966878	chr4:90757139	SNCA	-0.34	-5.85	-0.31	1.15e-8	Dementia with Lewy bodies;
LUSC	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg07169764	chr2:136633963	MCM6	0.61	7.94	0.4	3.08e-14	Mosquito bite size;
LUSC	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg18129178	chr5:148520854	ABLIM3	-0.77	-11.97	-0.55	1e-27	Breast cancer;
LUSC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4786125	0.542	rs2345826	chr16:6916235	G/T	cg03623568	chr16:6915990	A2BP1	-0.43	-7.39	-0.37	1.22e-12	Heart rate variability traits (SDNN);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13653482	chr9:103361209	NA	-0.41	-5.95	-0.31	6.91e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.83	0.44	5.96e-17	Lung cancer;
LUSC	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.83	11.23	0.52	4.97e-25	Mean corpuscular hemoglobin;
LUSC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-7.76	-0.39	1.04e-13	Homoarginine levels;
LUSC	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg20283391	chr11:68216788	NA	-0.61	-8.51	-0.42	5.91e-16	Total body bone mineral density;
LUSC	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.39	-5.72	-0.3	2.4e-8	Schizophrenia;
LUSC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.53	-0.34	2.45e-10	Schizophrenia;
LUSC	cis	rs3768617	1.000	rs12026314	chr1:183104527	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.62	9.26	0.45	2.63e-18	Fuchs's corneal dystrophy;
LUSC	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg08345082	chr10:99160200	RRP12	-0.38	-7.45	-0.38	7.85e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg06521331	chr12:34319734	NA	-0.35	-6.01	-0.31	4.82e-9	Morning vs. evening chronotype;
LUSC	trans	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg07393940	chr7:158741817	NA	-0.37	-6.54	-0.34	2.29e-10	Life satisfaction;
LUSC	cis	rs921665	0.831	rs4402798	chr2:3190969	G/A	cg16434511	chr2:3151078	NA	-0.61	-6.84	-0.35	3.73e-11	World class endurance athleticism;
LUSC	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.29	0.33	1.01e-9	Lung cancer;
LUSC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.7	-10.46	-0.5	2.45e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-6.89	-0.35	2.77e-11	Alzheimer's disease (late onset);
LUSC	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg16342193	chr10:102329863	NA	-0.38	-6.94	-0.35	2.06e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs27434	0.583	rs151954	chr5:96157689	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-7.53	-0.38	4.91e-13	Ankylosing spondylitis;
LUSC	cis	rs4474465	0.541	rs10736814	chr11:78286462	C/G	cg27205649	chr11:78285834	NARS2	0.58	7.01	0.36	1.33e-11	Alzheimer's disease (survival time);
LUSC	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg21573476	chr21:45109991	RRP1B	-0.4	-6.28	-0.33	1.05e-9	Mean corpuscular volume;
LUSC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg06238570	chr21:40685208	BRWD1	0.48	7.54	0.38	4.41e-13	Cognitive function;
LUSC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg00825309	chr19:58991885	ZNF446	-0.5	-7.16	-0.36	5.09e-12	Uric acid clearance;
LUSC	cis	rs116988415	0.539	rs11623956	chr14:65270391	G/A	cg25083366	chr14:65239357	SPTB	0.66	6.99	0.36	1.46e-11	Daytime sleep phenotypes;
LUSC	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.41	-0.42	1.25e-15	Neuroticism;
LUSC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg20887711	chr4:1340912	KIAA1530	0.44	6.57	0.34	1.97e-10	Obesity-related traits;
LUSC	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.13	-0.41	8.42e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg24690094	chr11:67383802	NA	0.44	8.5	0.42	6.36e-16	Mean corpuscular volume;
LUSC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07677032	chr17:61819896	STRADA	0.53	8.91	0.44	3.48e-17	Prudent dietary pattern;
LUSC	cis	rs9512730	0.527	rs11619784	chr13:27999643	A/G	cg04070771	chr13:27998621	GTF3A	0.49	6.43	0.33	4.46e-10	Schizophrenia;
LUSC	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.84	13.47	0.59	2.56e-33	Coronary artery disease;
LUSC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19782173	chr5:76383047	LOC728723;ZBED3	-0.41	-6.03	-0.31	4.4e-9	Electrocardiographic conduction measures;
LUSC	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg27411982	chr8:10470053	RP1L1	0.44	6.98	0.36	1.59e-11	Mood instability;
LUSC	cis	rs4474465	1.000	rs952605	chr11:78200427	A/T	cg27205649	chr11:78285834	NARS2	-0.51	-5.91	-0.31	8.55e-9	Alzheimer's disease (survival time);
LUSC	cis	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg05299278	chr17:33885742	SLFN14	0.29	6.31	0.33	8.76e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg15423357	chr2:25149977	NA	0.45	9.09	0.45	8.9e-18	Body mass index;
LUSC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.56e-24	Aortic root size;
LUSC	cis	rs9788682	0.948	rs905739	chr15:78845110	A/G	cg06917634	chr15:78832804	PSMA4	-0.58	-6.98	-0.36	1.64e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-12.04	-0.55	5.88e-28	Personality dimensions;
LUSC	cis	rs2467099	1.000	rs2467099	chr17:73949045	C/T	cg19302996	chr17:73780495	UNK	-0.51	-5.93	-0.31	7.62e-9	Systolic blood pressure;
LUSC	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg15848620	chr12:58087721	OS9	-0.53	-7.55	-0.38	4.14e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.5	-0.42	6.44e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg22117172	chr7:91764530	CYP51A1	0.33	5.83	0.3	1.34e-8	Breast cancer;
LUSC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg00945038	chr17:61921165	SMARCD2	0.4	6.09	0.32	3.17e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.6	9.73	0.47	7.5e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15369054	chr17:80825471	TBCD	0.36	6.01	0.31	4.92e-9	Breast cancer;
LUSC	cis	rs10992471	0.603	rs10114932	chr9:95307901	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.88	-0.35	2.92e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg21064579	chr19:49206444	FUT2	-0.42	-7.99	-0.4	2.23e-14	Dietary macronutrient intake;
LUSC	cis	rs1867631	0.585	rs11208940	chr1:67127242	A/G	cg02459107	chr1:67143332	SGIP1	-0.33	-5.74	-0.3	2.1e-8	Menopause (age at onset);
LUSC	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.41	-6.65	-0.34	1.19e-10	Alcohol dependence;
LUSC	cis	rs6960043	0.738	rs2358159	chr7:15054908	T/C	cg19272540	chr7:15055459	NA	0.35	9.03	0.44	1.39e-17	Type 2 diabetes;
LUSC	cis	rs377070	0.816	rs309400	chr4:123616189	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.4	5.67	0.3	3.06e-8	Mosquito bite size;
LUSC	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-10.84	-0.51	1.13e-23	Mean corpuscular volume;
LUSC	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg05283184	chr6:79620031	NA	-0.55	-10.99	-0.52	3.35e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs10761482	0.683	rs4488150	chr10:62104918	G/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.12	-0.36	6.69e-12	Schizophrenia;
LUSC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11644478	chr21:40555479	PSMG1	0.93	17.84	0.7	1.72e-50	Cognitive function;
LUSC	trans	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.51	0.38	5.28e-13	Ulcerative colitis;
LUSC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18854424	chr1:2615690	NA	0.51	10.16	0.49	2.58e-21	Ulcerative colitis;
LUSC	cis	rs708547	0.647	rs12621	chr4:57897570	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.52	7.56	0.38	3.92e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg12292205	chr6:26970375	C6orf41	0.51	8.56	0.42	4.13e-16	Schizophrenia;
LUSC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	7.49	0.38	6.31e-13	Initial pursuit acceleration;
LUSC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.26	0.64	2.87e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-8.23	-0.41	4.13e-15	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg01851573	chr8:8652454	MFHAS1	0.54	8.73	0.43	1.23e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-8.16	-0.41	6.89e-15	Schizophrenia;
LUSC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg17211192	chr8:82754475	SNX16	-0.81	-11.02	-0.52	2.72e-24	Diastolic blood pressure;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04203429	chr16:29822912	PRRT2	0.45	6.67	0.34	1.08e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21659725	chr3:3221576	CRBN	0.62	10.31	0.49	8.16e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs12367572	0.623	rs10880718	chr12:45362806	G/C	cg04608330	chr12:45269318	NELL2	-0.4	-6.14	-0.32	2.41e-9	Gut microbiome composition (summer);
LUSC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.99	0.31	5.3e-9	Lung cancer;
LUSC	cis	rs3812762	0.879	rs3763920	chr11:8808587	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-6.89	-0.35	2.86e-11	Hypospadias;
LUSC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03934478	chr11:495069	RNH1	0.84	10.03	0.48	7.31e-21	Body mass index;
LUSC	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg20129853	chr10:51489980	NA	-0.33	-6.77	-0.35	5.84e-11	Prostate-specific antigen levels;
LUSC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg02475777	chr4:1388615	CRIPAK	0.44	6.82	0.35	4.34e-11	Obesity-related traits;
LUSC	cis	rs713477	0.935	rs7147968	chr14:55909040	G/A	cg13175173	chr14:55914753	NA	-0.32	-6.74	-0.35	7.01e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg23985595	chr17:80112537	CCDC57	-0.31	-6.14	-0.32	2.31e-9	Life satisfaction;
LUSC	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg21699342	chr2:239360505	ASB1	0.51	8.9	0.44	3.6e-17	Multiple system atrophy;
LUSC	cis	rs9810089	0.967	rs10935177	chr3:135851077	G/T	cg12473912	chr3:136751656	NA	-0.32	-5.65	-0.3	3.48e-8	Gestational age at birth (child effect);
LUSC	cis	rs7760949	0.963	rs9396248	chr6:13906360	A/G	cg27413430	chr6:13925136	RNF182	0.52	7.85	0.39	5.84e-14	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6987853	0.966	rs2974359	chr8:42434194	T/C	cg09913449	chr8:42400586	C8orf40	0.49	8.29	0.41	2.9e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg03885332	chr11:832357	CD151	-0.35	-5.93	-0.31	7.55e-9	Mean platelet volume;
LUSC	cis	rs757081	0.667	rs12577388	chr11:17101155	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-6.04	-0.31	4e-9	Systolic blood pressure;
LUSC	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg13535736	chr9:111863775	C9orf5	0.37	6.25	0.32	1.26e-9	Menarche (age at onset);
LUSC	cis	rs17030434	0.906	rs12641631	chr4:154665279	A/G	cg14289246	chr4:154710475	SFRP2	-0.61	-8.17	-0.41	6.3e-15	Electrocardiographic conduction measures;
LUSC	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-17.31	-0.69	2.28e-48	Primary sclerosing cholangitis;
LUSC	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg05272587	chr13:111038400	COL4A2	-0.38	-6.11	-0.32	2.7e-9	White matter hyperintensity burden;
LUSC	cis	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg01251360	chr16:68772225	CDH1	-0.27	-6.23	-0.32	1.43e-9	Colorectal cancer;
LUSC	cis	rs3125734	0.572	rs3864794	chr10:64041956	A/C	cg19640130	chr10:64028056	RTKN2	-0.4	-6.93	-0.35	2.24e-11	Rheumatoid arthritis;
LUSC	cis	rs1595825	0.891	rs73058867	chr2:198891568	A/G	cg00982548	chr2:198649783	BOLL	-0.54	-6.93	-0.35	2.2e-11	Ulcerative colitis;
LUSC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg04017836	chr7:65315216	NA	0.39	5.98	0.31	5.59e-9	Coronary artery disease;
LUSC	cis	rs3812762	0.957	rs7120004	chr11:8769097	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.38	6.56	0.34	2.06e-10	Hypospadias;
LUSC	cis	rs4285028	0.747	rs7648340	chr3:121426188	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-12.97	-0.58	1.9e-31	Multiple sclerosis;
LUSC	cis	rs16854884	0.632	rs4446205	chr3:143682607	A/G	cg06585982	chr3:143692056	C3orf58	0.45	6.7	0.34	8.62e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg08975724	chr8:8085496	FLJ10661	0.53	8.24	0.41	3.97e-15	Mood instability;
LUSC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	6.89	0.35	2.76e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	trans	rs2319125	0.866	rs229859	chr17:64121580	A/T	cg18807011	chr1:184633572	NA	0.33	6.13	0.32	2.53e-9	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LUSC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg13319975	chr6:146136371	FBXO30	0.71	11.11	0.52	1.24e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg06552810	chr11:31128660	NA	-0.4	-7.13	-0.36	6.38e-12	Red blood cell count;
LUSC	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07636037	chr3:49044803	WDR6	0.66	8.82	0.43	6.69e-17	Menarche (age at onset);
LUSC	trans	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08859206	chr1:53392774	SCP2	-0.54	-9.26	-0.45	2.46e-18	Monocyte count;
LUSC	cis	rs6076065	0.723	rs6083104	chr20:23366038	C/T	cg11657817	chr20:23433608	CST11	0.42	8.03	0.4	1.64e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg06784218	chr1:46089804	CCDC17	0.57	11.63	0.54	1.79e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs68170813	0.559	rs17349904	chr7:106897237	A/C	cg02696742	chr7:106810147	HBP1	-0.62	-9.36	-0.46	1.25e-18	Coronary artery disease;
LUSC	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg19116668	chr7:99932089	PMS2L1	0.35	6.12	0.32	2.68e-9	Coronary artery disease;
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.39	-0.42	1.36e-15	Lymphocyte counts;
LUSC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.85	13.88	0.6	6.66e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs12122100	0.651	rs12126527	chr1:146551259	C/G	cg03526459	chr1:146549940	NA	-0.41	-6.62	-0.34	1.47e-10	HIV-1 control;
LUSC	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg25214090	chr10:38739885	LOC399744	0.52	7.59	0.38	3.33e-13	Corneal astigmatism;
LUSC	trans	rs2039659	0.752	rs1764954	chr13:86253251	G/A	cg22803222	chr6:76636725	IMPG1	0.37	5.99	0.31	5.56e-9	Blood osmolality (transformed sodium);
LUSC	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg19508488	chr2:152266495	RIF1	0.54	7.74	0.39	1.17e-13	Lung cancer;
LUSC	cis	rs7408868	0.706	rs7257550	chr19:15292088	C/G	cg14696996	chr19:15285081	NOTCH3	0.77	7.82	0.39	7.05e-14	Pulse pressure;
LUSC	cis	rs926938	0.527	rs360580	chr1:115462334	A/G	cg12756093	chr1:115239321	AMPD1	0.46	7.0	0.36	1.43e-11	Autism;
LUSC	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-14.05	-0.61	1.51e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14830952	chr8:86089500	E2F5	0.45	6.7	0.34	8.72e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs870825	0.929	rs10003354	chr4:185589782	G/A	cg04058563	chr4:185651563	MLF1IP	0.82	10.86	0.51	1.02e-23	Blood protein levels;
LUSC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg11861562	chr11:117069780	TAGLN	0.43	8.06	0.4	1.37e-14	Blood protein levels;
LUSC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg26587870	chr6:27730563	NA	-0.64	-5.87	-0.31	1.05e-8	Depression;
LUSC	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg06462663	chr19:18546047	ISYNA1	0.49	8.24	0.41	3.89e-15	Breast cancer;
LUSC	cis	rs17102423	0.654	rs8015921	chr14:65523015	G/A	cg11161011	chr14:65562177	MAX	-0.58	-8.87	-0.44	4.37e-17	Obesity-related traits;
LUSC	cis	rs6977660	1.000	rs714239	chr7:19803944	C/T	cg07541023	chr7:19748670	TWISTNB	0.53	6.14	0.32	2.37e-9	Thyroid stimulating hormone;
LUSC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	0.95	19.4	0.73	1.07e-56	Cognitive function;
LUSC	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	6.65	0.34	1.2e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7712401	0.715	rs424247	chr5:122347993	G/A	cg19077854	chr5:122220652	SNX24	-0.41	-8.85	-0.44	5.29e-17	Mean platelet volume;
LUSC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs3924048	0.559	rs4075303	chr1:12626593	C/G	cg00291366	chr1:12616550	NA	0.32	7.39	0.38	1.16e-12	Optic cup area;
LUSC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg20406979	chr6:167373233	NA	0.25	5.81	0.3	1.49e-8	Crohn's disease;
LUSC	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg18932078	chr1:2524107	MMEL1	0.34	7.34	0.37	1.63e-12	Ulcerative colitis;
LUSC	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg04398451	chr17:18023971	MYO15A	0.47	7.31	0.37	2e-12	Total body bone mineral density;
LUSC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	12.15	0.55	2.25e-28	Chronic sinus infection;
LUSC	cis	rs983392	0.709	rs2162254	chr11:60039917	T/A	cg24026212	chr11:59952134	MS4A6A	0.37	6.38	0.33	5.77e-10	Alzheimer's disease (late onset);
LUSC	cis	rs16976116	0.901	rs28589384	chr15:55494366	A/G	cg11288833	chr15:55489084	RSL24D1	0.49	5.85	0.3	1.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4343996	0.521	rs10237577	chr7:3424305	C/A	cg21248987	chr7:3385318	SDK1	0.37	6.3	0.33	9.65e-10	Motion sickness;
LUSC	cis	rs4595586	0.679	rs1878228	chr12:39355595	T/C	cg26384229	chr12:38710491	ALG10B	0.43	5.97	0.31	6.11e-9	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.46	-0.33	3.66e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg12463550	chr7:65579703	CRCP	0.41	5.85	0.31	1.15e-8	Aortic root size;
LUSC	cis	rs116139393	0.505	rs3801033	chr7:6734103	A/G	cg09896999	chr7:6746977	ZNF12	0.53	8.76	0.43	9.83e-17	Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.49	0.75	5.16e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.82	-0.51	1.35e-23	Glomerular filtration rate;
LUSC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg04518342	chr5:131593106	PDLIM4	0.32	5.72	0.3	2.33e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg08680598	chr22:49984980	NA	-0.35	-6.43	-0.33	4.37e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1572438	0.811	rs6916781	chr6:880493	G/A	cg13447295	chr6:887704	NA	0.41	6.45	0.33	3.98e-10	Aging;
LUSC	cis	rs259282	0.538	rs6510272	chr19:33117842	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	10.46	0.5	2.52e-22	Schizophrenia;
LUSC	trans	rs72674100	1.000	rs7694339	chr4:97968342	C/T	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg01283332	chr5:1856932	NA	-0.33	-6.29	-0.33	1e-9	Cardiovascular disease risk factors;
LUSC	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.47	-6.38	-0.33	6.03e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4417855	0.665	rs955305	chr3:187409112	A/C	cg19198148	chr3:187451818	BCL6	0.55	9.71	0.47	8.32e-20	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg09301410	chr7:157951964	PTPRN2	0.47	8.59	0.43	3.26e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12618769	0.597	rs3769716	chr2:99133305	G/A	cg10123293	chr2:99228465	UNC50	0.46	7.67	0.39	1.95e-13	Bipolar disorder;
LUSC	trans	rs7944735	0.507	rs7934659	chr11:48066374	C/T	cg03929089	chr4:120376271	NA	0.59	7.0	0.36	1.42e-11	Intraocular pressure;
LUSC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	8.96	0.44	2.29e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12618769	0.652	rs72823788	chr2:99213080	C/T	cg10123293	chr2:99228465	UNC50	0.47	7.7	0.39	1.59e-13	Bipolar disorder;
LUSC	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.69	0.47	9.71e-20	Coffee consumption (cups per day);
LUSC	cis	rs2019216	0.564	rs1518053	chr17:21924272	G/T	cg22648282	chr17:21454238	C17orf51	-0.49	-7.28	-0.37	2.48e-12	Pelvic organ prolapse;
LUSC	cis	rs10979	0.597	rs9403514	chr6:143907790	T/C	cg25407410	chr6:143891975	LOC285740	-0.65	-8.19	-0.41	5.6e-15	Hypospadias;
LUSC	cis	rs2795502	0.564	rs11239840	chr10:43439353	C/T	cg08461752	chr10:43522343	NA	-0.55	-6.45	-0.33	3.85e-10	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.65e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg19230755	chr7:65878503	NA	-0.42	-5.97	-0.31	5.91e-9	Aortic root size;
LUSC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg05729581	chr11:3078854	CARS	-0.54	-8.12	-0.41	8.88e-15	Longevity;
LUSC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg22535103	chr8:58192502	C8orf71	-0.6	-6.81	-0.35	4.55e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg17691542	chr6:26056736	HIST1H1C	0.53	7.32	0.37	1.83e-12	Iron status biomarkers;
LUSC	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg12002119	chr2:101014098	CHST10	0.37	6.29	0.33	1.02e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.56	5.78	0.3	1.73e-8	Menarche (age at onset);
LUSC	cis	rs240764	0.658	rs10872634	chr6:101199579	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-6.09	-0.32	3.04e-9	Neuroticism;
LUSC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg02117656	chr17:79614917	TSPAN10	0.32	5.86	0.31	1.12e-8	Eye color traits;
LUSC	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg05340658	chr4:99064831	C4orf37	0.61	9.35	0.46	1.3e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7188861	0.681	rs12922090	chr16:11415117	C/T	cg00044050	chr16:11439710	C16orf75	0.62	6.41	0.33	4.9e-10	HDL cholesterol;
LUSC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg02773041	chr1:40204384	PPIE	-0.53	-8.13	-0.41	8.59e-15	Blood protein levels;
LUSC	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	1.23	19.55	0.73	2.84e-57	Corneal structure;
LUSC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg23711669	chr6:146136114	FBXO30	0.77	12.61	0.57	4.46e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-0.98	-14.68	-0.63	5.64e-38	Initial pursuit acceleration;
LUSC	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg00898013	chr13:113819073	PROZ	-0.56	-8.08	-0.4	1.21e-14	Platelet distribution width;
LUSC	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.49	-11.79	-0.54	4.81e-27	Urate levels in overweight individuals;
LUSC	cis	rs6736093	0.966	rs13033393	chr2:112697632	C/G	cg12686935	chr2:112915763	FBLN7	-0.37	-5.9	-0.31	8.73e-9	Coronary artery disease;
LUSC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18876405	chr7:65276391	NA	-0.55	-8.66	-0.43	2.09e-16	Aortic root size;
LUSC	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg23711669	chr6:146136114	FBXO30	0.87	16.13	0.66	1.08e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3087591	0.683	rs2040792	chr17:29628549	G/T	cg24425628	chr17:29625626	OMG;NF1	0.46	6.9	0.35	2.69e-11	Hip circumference;
LUSC	trans	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg21775007	chr8:11205619	TDH	0.44	6.35	0.33	6.92e-10	Systolic blood pressure;
LUSC	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	1.1	24.61	0.8	5.03e-77	Triglycerides;
LUSC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg06134567	chr22:46658398	PKDREJ	-0.53	-5.93	-0.31	7.54e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg22823121	chr1:150693482	HORMAD1	0.46	6.6	0.34	1.64e-10	Melanoma;
LUSC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	7.1	0.36	7.56e-12	Colorectal cancer;
LUSC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.86	0.31	1.14e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9467773	0.572	rs2076029	chr6:26390830	T/C	cg05738196	chr6:26577821	NA	-0.45	-6.41	-0.33	4.95e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg05855489	chr10:104503620	C10orf26	0.59	9.47	0.46	5.44e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.15	-0.36	5.4e-12	Neuroticism;
LUSC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	12.09	0.55	3.69e-28	Personality dimensions;
LUSC	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg11057378	chr10:81107060	PPIF	0.37	6.26	0.32	1.2e-9	Height;
LUSC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.37	-6.4	-0.33	5.39e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg02023728	chr11:77925099	USP35	0.49	7.02	0.36	1.24e-11	Testicular germ cell tumor;
LUSC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.88	-0.31	1.01e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg17366294	chr4:99064904	C4orf37	0.61	10.91	0.51	6.76e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg00310523	chr12:86230176	RASSF9	0.4	7.18	0.37	4.67e-12	Major depressive disorder;
LUSC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08219700	chr8:58056026	NA	0.66	8.19	0.41	5.63e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs4474465	0.850	rs10899539	chr11:78243743	T/C	cg27205649	chr11:78285834	NARS2	0.48	5.84	0.3	1.24e-8	Alzheimer's disease (survival time);
LUSC	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg00791764	chr4:53727839	RASL11B	0.56	7.74	0.39	1.22e-13	Optic nerve measurement (cup area);
LUSC	cis	rs9811920	0.893	rs6798114	chr3:99892825	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.35	6.49	0.33	3.16e-10	Axial length;
LUSC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg26335602	chr6:28129616	ZNF389	-0.4	-5.7	-0.3	2.64e-8	Depression;
LUSC	cis	rs1775715	0.707	rs2778669	chr10:32161541	C/T	cg04359828	chr10:32216031	ARHGAP12	0.4	6.87	0.35	3.07e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs12900413	0.603	rs2118848	chr15:90302503	T/C	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.56e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg03146154	chr1:46216737	IPP	0.52	7.66	0.39	2.02e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9837602	1.000	rs4571265	chr3:99705111	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-6.17	-0.32	1.96e-9	Breast cancer;
LUSC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg04287289	chr16:89883240	FANCA	0.79	14.13	0.61	7.02e-36	Vitiligo;
LUSC	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.57	-0.46	2.51e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs59698941	0.943	rs12513758	chr5:132239939	C/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.31	-0.33	8.76e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg13206674	chr6:150067644	NUP43	0.43	6.52	0.34	2.67e-10	Testicular germ cell tumor;
LUSC	cis	rs2236918	1.000	rs1776133	chr1:242025098	C/T	cg17736920	chr1:242011382	EXO1	0.45	7.09	0.36	8.27e-12	Menopause (age at onset);
LUSC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.37	5.69	0.3	2.82e-8	Platelet count;
LUSC	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg12292205	chr6:26970375	C6orf41	0.38	5.91	0.31	8.31e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs4144743	1.000	rs11871447	chr17:45331618	C/G	cg18085866	chr17:45331354	ITGB3	-0.75	-7.81	-0.39	7.38e-14	Body mass index;
LUSC	cis	rs72960926	0.744	rs72957999	chr6:74973822	T/C	cg03266952	chr6:74778945	NA	-0.87	-7.19	-0.37	4.34e-12	Metabolite levels (MHPG);
LUSC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg17724175	chr1:150552817	MCL1	0.37	6.75	0.35	6.68e-11	Tonsillectomy;
LUSC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg13866156	chr1:1669148	SLC35E2	0.49	7.85	0.39	5.78e-14	Body mass index;
LUSC	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg04545296	chr12:48745243	ZNF641	0.33	6.14	0.32	2.4e-9	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-8.66	-0.43	1.98e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg26754761	chr2:177040938	NA	-0.39	-7.66	-0.39	2.09e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.68	-12.26	-0.56	9.02e-29	Cotinine glucuronidation;
LUSC	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg07423050	chr13:99094983	FARP1	-0.55	-10.01	-0.48	8.48e-21	Longevity;
LUSC	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg06636001	chr8:8085503	FLJ10661	0.55	8.38	0.42	1.48e-15	Neuroticism;
LUSC	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg11502198	chr6:26597334	ABT1	0.6	9.37	0.46	1.11e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg12935359	chr14:103987150	CKB	0.66	10.66	0.5	4.99e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg05768032	chr16:30646687	NA	0.4	5.96	0.31	6.32e-9	Multiple myeloma;
LUSC	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg24558204	chr6:135376177	HBS1L	-0.69	-10.92	-0.51	6.29e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg05084668	chr3:125655381	ALG1L	-0.5	-6.98	-0.36	1.58e-11	Blood pressure (smoking interaction);
LUSC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00339695	chr16:24857497	SLC5A11	-0.59	-9.3	-0.45	1.9e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg01596870	chr19:55963115	NA	-0.53	-7.32	-0.37	1.9e-12	Obesity-related traits;
LUSC	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg08975724	chr8:8085496	FLJ10661	-0.48	-7.16	-0.36	5.13e-12	Neuroticism;
LUSC	cis	rs7527798	0.592	rs11118281	chr1:207832102	C/T	cg09232269	chr1:207846808	CR1L	-0.29	-6.15	-0.32	2.17e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg23625390	chr15:77176239	SCAPER	-0.56	-8.47	-0.42	7.81e-16	Blood metabolite levels;
LUSC	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg22709100	chr7:91322751	NA	0.39	5.75	0.3	1.98e-8	Breast cancer;
LUSC	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg08213375	chr14:104286397	PPP1R13B	0.47	9.18	0.45	4.76e-18	Schizophrenia;
LUSC	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	11.24	0.52	4.6e-25	Blood protein levels;
LUSC	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg06612196	chr6:6737390	NA	0.56	11.11	0.52	1.31e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs6688613	0.694	rs11576455	chr1:166811970	G/A	cg07049167	chr1:166818506	POGK	0.52	7.67	0.39	1.93e-13	Refractive astigmatism;
LUSC	cis	rs2970818	0.831	rs11063193	chr12:4591100	T/C	cg11146114	chr12:4671731	NA	-0.63	-6.29	-0.33	1e-9	Phosphorus levels;
LUSC	cis	rs3099143	1.000	rs3102710	chr15:77061148	T/C	cg21673338	chr15:77095150	SCAPER	-0.84	-8.22	-0.41	4.7e-15	Recalcitrant atopic dermatitis;
LUSC	cis	rs9419702	0.538	rs4074772	chr10:133540006	A/T	cg04492858	chr10:133558786	NA	0.38	6.05	0.31	3.82e-9	Survival in rectal cancer;
LUSC	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg16797656	chr11:68205561	LRP5	-0.42	-7.4	-0.38	1.09e-12	Total body bone mineral density;
LUSC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg13535736	chr9:111863775	C9orf5	-0.4	-6.69	-0.34	9.51e-11	Menarche (age at onset);
LUSC	cis	rs7903847	0.620	rs11189165	chr10:99123457	A/G	cg20016023	chr10:99160130	RRP12	-0.34	-8.18	-0.41	5.86e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg16482183	chr6:26056742	HIST1H1C	0.63	8.96	0.44	2.34e-17	Iron status biomarkers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00298675	chr2:73612788	ALMS1	-0.39	-5.99	-0.31	5.46e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.84	14.54	0.62	1.97e-37	Menarche (age at onset);
LUSC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg11645453	chr3:52864694	ITIH4	0.31	7.24	0.37	3.16e-12	Electroencephalogram traits;
LUSC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08736216	chr1:53307985	ZYG11A	0.29	6.03	0.31	4.36e-9	Monocyte count;
LUSC	cis	rs3755132	0.929	rs4668458	chr2:15789441	G/A	cg12888861	chr2:15731646	DDX1	0.51	7.66	0.39	1.99e-13	Wilms tumor;
LUSC	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg17788362	chr6:86352627	SYNCRIP	-0.48	-7.24	-0.37	3.02e-12	Smooth-surface caries;
LUSC	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg13010199	chr12:38710504	ALG10B	-0.59	-8.66	-0.43	2.05e-16	Heart rate;
LUSC	cis	rs742132	0.527	rs12526321	chr6:25494503	A/G	cg12310025	chr6:25882481	NA	0.45	6.16	0.32	2.05e-9	Uric acid levels;
LUSC	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.27e-8	Breast cancer;
LUSC	cis	rs9369695	0.881	rs9349409	chr6:47463126	G/T	cg12968598	chr6:47444699	CD2AP	0.53	8.0	0.4	2.1e-14	Reticulocyte count;
LUSC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.8	14.66	0.63	6.31e-38	Gestational age at birth (maternal effect);
LUSC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.35	0.46	1.28e-18	Monocyte percentage of white cells;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05270290	chr15:29562120	NDNL2;FAM189A1	0.47	6.28	0.32	1.08e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.72	0.7	5.41e-50	Chronic sinus infection;
LUSC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	7.33	0.37	1.75e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg00814883	chr7:100076585	TSC22D4	-0.66	-8.6	-0.43	3.07e-16	Platelet count;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13150040	chr1:204381152	PPP1R15B	0.71	6.14	0.32	2.32e-9	Cognitive performance;
LUSC	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.37	-0.37	1.34e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06112835	chr11:68658793	MRPL21	0.49	7.42	0.38	9.55e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4692589	0.581	rs6821231	chr4:170959988	C/T	cg19918862	chr4:170955249	NA	0.36	6.75	0.35	6.47e-11	Anxiety disorder;
LUSC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg06096015	chr1:231504339	EGLN1	0.55	9.66	0.47	1.23e-19	Hemoglobin concentration;
LUSC	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg12365402	chr11:9010492	NRIP3	-0.36	-6.05	-0.31	3.95e-9	Hematocrit;
LUSC	cis	rs3931020	0.688	rs455032	chr1:75196488	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.63	-8.55	-0.42	4.6e-16	Resistin levels;
LUSC	trans	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg06636001	chr8:8085503	FLJ10661	0.45	6.33	0.33	7.77e-10	Monocyte count;
LUSC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21016266	chr12:122356598	WDR66	0.63	9.43	0.46	7.11e-19	Mean corpuscular volume;
LUSC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg24733560	chr20:60626293	TAF4	0.36	5.93	0.31	7.49e-9	Body mass index;
LUSC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.12	17.29	0.69	2.67e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.78	0.3	1.74e-8	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19895882	chr13:42534974	KIAA0564	-0.43	-6.48	-0.33	3.21e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.97	-0.36	1.69e-11	Total cholesterol levels;
LUSC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg04871131	chr7:94954202	PON1	-0.38	-6.06	-0.31	3.62e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg12419862	chr22:24373484	LOC391322	-0.58	-7.24	-0.37	3.06e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs4722404	0.800	rs7809262	chr7:3141137	A/G	cg19214707	chr7:3157722	NA	-0.32	-5.89	-0.31	9.37e-9	Atopic dermatitis;
LUSC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg03395651	chr16:88107091	BANP	-0.36	-5.68	-0.3	2.97e-8	Menopause (age at onset);
LUSC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg08999081	chr20:33150536	PIGU	-0.4	-7.49	-0.38	6.16e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs9650315	0.866	rs34108747	chr8:57197355	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	7.13	0.36	6.25e-12	Height;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25595571	chr14:104029029	BAG5;C14orf153	-0.56	-7.45	-0.38	8.05e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs28647808	0.881	rs7040821	chr9:136263584	C/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs3087591	1.000	rs7406983	chr17:29703374	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.56	-7.95	-0.4	2.85e-14	Hip circumference;
LUSC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg06784218	chr1:46089804	CCDC17	-0.57	-11.33	-0.53	2.14e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-6.86	-0.35	3.25e-11	Tonsillectomy;
LUSC	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg05775895	chr3:12838266	CAND2	-0.41	-5.94	-0.31	7.04e-9	P wave duration;
LUSC	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg03342759	chr3:160939853	NMD3	-0.44	-6.11	-0.32	2.7e-9	Parkinson's disease;
LUSC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg21770322	chr7:97807741	LMTK2	0.4	7.01	0.36	1.31e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.62	-9.54	-0.46	3.1400000000000002e-19	Morning vs. evening chronotype;
LUSC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-0.8	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg09658497	chr7:2847517	GNA12	-0.33	-5.74	-0.3	2.18e-8	Height;
LUSC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	trans	rs6496932	0.913	rs7403354	chr15:85820855	C/T	cg26334166	chr20:61950840	COL20A1	0.31	6.11	0.32	2.85e-9	Central corneal thickness;Corneal structure;
LUSC	cis	rs4786125	0.581	rs7193000	chr16:6918270	G/C	cg03623568	chr16:6915990	A2BP1	-0.43	-7.5	-0.38	5.74e-13	Heart rate variability traits (SDNN);
LUSC	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg09184832	chr6:79620586	NA	-0.42	-6.8	-0.35	4.71e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg12223502	chr10:5658492	NA	-0.37	-6.03	-0.31	4.34e-9	Breast cancer;
LUSC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg03342759	chr3:160939853	NMD3	-0.42	-5.81	-0.3	1.42e-8	Parkinson's disease;
LUSC	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg06937882	chr20:24974362	C20orf3	-0.44	-7.57	-0.38	3.67e-13	Blood protein levels;
LUSC	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.81	-0.47	4e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg15556689	chr8:8085844	FLJ10661	0.63	10.19	0.49	2.03e-21	Mood instability;
LUSC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg16339924	chr4:17578868	LAP3	0.66	10.37	0.49	4.83e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2239815	0.576	rs10427628	chr22:29239766	T/C	cg02153584	chr22:29168773	CCDC117	0.58	7.19	0.37	4.3e-12	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	cis	rs10887741	0.546	rs7903516	chr10:89441102	T/C	cg13926569	chr10:89418898	PAPSS2	0.32	6.94	0.36	2.05e-11	Exercise (leisure time);
LUSC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22029157	chr1:209979665	IRF6	0.75	11.18	0.52	7.25e-25	Cleft lip with or without cleft palate;
LUSC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg17366294	chr4:99064904	C4orf37	0.58	10.25	0.49	1.25e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.46	0.75	6.72e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10186029	0.582	rs12052695	chr2:214003559	G/T	cg08319019	chr2:214017104	IKZF2	0.49	7.55	0.38	4.22e-13	Systemic sclerosis;
LUSC	cis	rs10504073	0.584	rs56068225	chr8:49923988	A/G	cg00325661	chr8:49890786	NA	0.7	11.11	0.52	1.28e-24	Blood metabolite ratios;
LUSC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg03233332	chr7:66118400	NA	-0.41	-5.96	-0.31	6.35e-9	Aortic root size;
LUSC	trans	rs61931739	0.591	rs4931764	chr12:33979423	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.61	0.38	2.78e-13	Morning vs. evening chronotype;
LUSC	trans	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.66	-0.34	1.16e-10	Endometrial cancer;
LUSC	cis	rs4363385	0.747	rs11205149	chr1:152958840	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.64	-0.39	2.39e-13	Inflammatory skin disease;
LUSC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07157834	chr1:205819609	PM20D1	-0.52	-7.98	-0.4	2.37e-14	Menarche (age at onset);
LUSC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	0.92	16.06	0.66	2.14e-43	Menopause (age at onset);
LUSC	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg03030879	chr14:75389066	RPS6KL1	0.39	7.46	0.38	7.64e-13	Caffeine consumption;
LUSC	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg14835575	chr10:16859367	RSU1	0.75	9.41	0.46	8.36e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs4343996	0.566	rs55940354	chr7:3431534	C/T	cg21248987	chr7:3385318	SDK1	0.36	5.94	0.31	7.33e-9	Motion sickness;
LUSC	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg07959070	chr22:50026188	C22orf34	-0.36	-7.39	-0.37	1.22e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs500891	0.574	rs13193879	chr6:84123006	T/C	cg08257003	chr6:84140564	ME1	0.36	8.81	0.43	7e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs244293	1.000	rs244295	chr17:53242899	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.4	-5.78	-0.3	1.68e-8	Menarche (age at onset);
LUSC	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg12863693	chr15:85201151	NMB	0.41	8.48	0.42	7.34e-16	Schizophrenia;
LUSC	cis	rs894734	0.535	rs10783613	chr12:54321966	G/T	cg17410650	chr12:54324560	NA	-0.56	-10.22	-0.49	1.64e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07763516	chr16:71496321	ZNF23	0.43	6.62	0.34	1.43e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.91	0.7	9.06e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.49	-0.33	3.07e-10	Joint mobility (Beighton score);
LUSC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-16.23	-0.66	4.58e-44	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs2200578	0.841	rs116668293	chr2:99596991	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.55	6.61	0.34	1.48e-10	IgG glycosylation;
LUSC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-15.86	-0.66	1.22e-42	Blood trace element (Zn levels);
LUSC	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg18129178	chr5:148520854	ABLIM3	-0.73	-10.91	-0.51	6.51e-24	Breast cancer;
LUSC	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg09307838	chr4:120376055	NA	-0.6	-8.77	-0.43	8.98e-17	Corneal astigmatism;
LUSC	cis	rs10905065	0.965	rs10737019	chr10:5783733	G/A	cg11519256	chr10:5708881	ASB13	0.4	5.82	0.3	1.35e-8	Menopause (age at onset);
LUSC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg14552801	chr7:65878734	NA	0.37	5.74	0.3	2.14e-8	Aortic root size;
LUSC	cis	rs727505	0.866	rs66650870	chr7:124713194	T/C	cg23710748	chr7:124431027	NA	-0.4	-7.04	-0.36	1.11e-11	Lewy body disease;
LUSC	cis	rs113835537	0.529	rs75003264	chr11:66256099	G/A	cg24851651	chr11:66362959	CCS	0.53	7.72	0.39	1.37e-13	Airway imaging phenotypes;
LUSC	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg13660082	chr14:53194042	PSMC6	-0.79	-6.97	-0.36	1.69e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg12365402	chr11:9010492	NRIP3	0.48	8.48	0.42	7.46e-16	Hemoglobin concentration;
LUSC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-0.81	-10.9	-0.51	7.43e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg23711669	chr6:146136114	FBXO30	0.84	15.6	0.65	1.39e-41	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1325195	0.920	rs4651012	chr1:179071865	G/A	cg11624085	chr17:8464688	MYH10	-0.42	-6.84	-0.35	3.7e-11	IgE grass sensitization;
LUSC	cis	rs57590327	0.508	rs4622918	chr3:81965382	A/G	cg07356753	chr3:81810745	GBE1	-0.58	-8.28	-0.41	3.07e-15	Extraversion;
LUSC	cis	rs1107366	0.593	rs12635766	chr3:125930021	T/C	cg01346077	chr3:125931526	NA	0.51	9.83	0.47	3.31e-20	Metabolite levels;
LUSC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.45	10.17	0.49	2.37e-21	Schizophrenia;
LUSC	cis	rs2227631	1.000	rs2227631	chr7:100769538	A/G	cg08053846	chr7:100769605	SERPINE1	-0.37	-7.77	-0.39	9.82e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
LUSC	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg00432049	chr6:150390894	ULBP3	-0.29	-6.17	-0.32	1.95e-9	Alopecia areata;
LUSC	cis	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05901451	chr6:126070800	HEY2	-0.58	-8.67	-0.43	1.88e-16	Endometrial cancer;
LUSC	cis	rs11608355	0.810	rs2217971	chr12:109857666	G/C	cg05360138	chr12:110035743	NA	0.6	8.06	0.4	1.34e-14	Neuroticism;
LUSC	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.15	-0.36	5.64e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg21890820	chr11:65308645	LTBP3	-0.57	-8.37	-0.42	1.65e-15	Bone mineral density;
LUSC	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-6.41	-0.33	4.9e-10	Monocyte percentage of white cells;
LUSC	cis	rs7590368	0.640	rs56260452	chr2:10954843	C/G	cg15705551	chr2:10952987	PDIA6	0.52	5.71	0.3	2.5e-8	Educational attainment (years of education);
LUSC	cis	rs56283067	0.847	rs62435998	chr6:44695206	C/T	cg18551225	chr6:44695536	NA	-0.48	-8.07	-0.4	1.25e-14	Total body bone mineral density;
LUSC	cis	rs3784262	0.654	rs4646568	chr15:58344290	A/G	cg12031962	chr15:58353849	ALDH1A2	0.41	7.67	0.39	1.85e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg26380479	chr7:97908229	NA	-0.26	-5.77	-0.3	1.78e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	ch.11.42038R	chr11:967971	AP2A2	0.53	7.83	0.39	6.49e-14	Alzheimer's disease (late onset);
LUSC	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg15704280	chr7:45808275	SEPT13	-0.88	-11.66	-0.54	1.34e-26	Coronary artery disease;
LUSC	cis	rs6982240	0.514	rs892362	chr8:142269214	A/G	cg27411547	chr8:142287226	NA	0.47	7.93	0.4	3.38e-14	Tonsillectomy;
LUSC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24110177	chr3:50126178	RBM5	0.57	9.36	0.46	1.18e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	0.62	9.81	0.47	3.87e-20	Breast cancer;
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg15147215	chr3:52552868	STAB1	-0.32	-6.25	-0.32	1.24e-9	Electroencephalogram traits;
LUSC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg06740227	chr12:86229804	RASSF9	0.44	7.07	0.36	9.33e-12	Major depressive disorder;
LUSC	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg01193554	chr1:41846683	NA	-0.28	-5.9	-0.31	9.13e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs17490626	0.533	rs12771890	chr10:71189483	T/A	cg12610070	chr10:71211762	TSPAN15	-0.5	-9.63	-0.47	1.54e-19	Thrombosis;
LUSC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg16606324	chr3:10149918	C3orf24	0.62	9.15	0.45	5.73e-18	Alzheimer's disease;
LUSC	cis	rs1113500	0.966	rs11185249	chr1:108611646	C/A	cg06207961	chr1:108661230	NA	0.4	7.27	0.37	2.5e-12	Growth-regulated protein alpha levels;
LUSC	trans	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg18825076	chr15:78729989	IREB2	0.44	6.07	0.31	3.56e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1784581	0.631	rs3016544	chr6:162393065	T/C	cg17173639	chr6:162384350	PARK2	-0.68	-12.1	-0.55	3.28e-28	Itch intensity from mosquito bite;
LUSC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg21238619	chr17:78079768	GAA	-0.3	-6.05	-0.31	3.96e-9	Yeast infection;
LUSC	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg00277334	chr10:82204260	NA	-0.55	-8.74	-0.43	1.19e-16	Post bronchodilator FEV1;
LUSC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.52	8.67	0.43	1.9e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12516959	chr21:47718080	NA	-0.39	-6.3	-0.33	9.61e-10	Testicular germ cell tumor;
LUSC	cis	rs968451	1.000	rs12628705	chr22:39693518	C/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.69	9.02	0.44	1.47e-17	Primary biliary cholangitis;
LUSC	cis	rs9650315	0.929	rs7841006	chr8:57172068	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	6.58	0.34	1.84e-10	Height;
LUSC	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.61	-0.54	2.01e-26	Mean corpuscular volume;
LUSC	cis	rs13006833	0.739	rs291428	chr2:191197226	G/T	cg21644426	chr2:191273491	MFSD6	0.45	6.38	0.33	6.07e-10	Urinary metabolites;
LUSC	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg22681709	chr2:178499509	PDE11A	-0.34	-6.11	-0.32	2.81e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg20991723	chr1:152506922	NA	0.51	9.63	0.47	1.55e-19	Hair morphology;
LUSC	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg23422044	chr7:1970798	MAD1L1	-0.65	-7.32	-0.37	1.84e-12	Bipolar disorder;
LUSC	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg21466736	chr12:48725269	NA	-0.33	-5.8	-0.3	1.53e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg14416269	chr4:6271139	WFS1	0.51	10.73	0.51	2.89e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.2	-0.61	4e-36	Chronic sinus infection;
LUSC	cis	rs2303282	0.716	rs7187883	chr16:56445999	C/A	cg00500540	chr16:56394104	NA	-0.43	-7.35	-0.37	1.57e-12	Breast cancer;
LUSC	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg01884057	chr2:25150051	NA	0.49	11.37	0.53	1.49e-25	Body mass index;
LUSC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg21918786	chr6:109611834	NA	-0.41	-7.21	-0.37	3.87e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	13.17	0.58	3.47e-32	Menopause (age at onset);
LUSC	trans	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg21659725	chr3:3221576	CRBN	-0.72	-7.62	-0.38	2.66e-13	Menarche (age at onset);
LUSC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.45	6.18	0.32	1.83e-9	Renal function-related traits (BUN);
LUSC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg20976159	chr1:228193529	WNT3A	0.28	5.79	0.3	1.64e-8	Diastolic blood pressure;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20504077	chr8:27472321	CLU	-0.43	-6.42	-0.33	4.68e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1267303	0.675	rs1267309	chr1:46987342	G/A	cg25110126	chr1:46999211	NA	-0.56	-7.54	-0.38	4.58e-13	Monobrow;
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg16031515	chr1:205743344	RAB7L1	-0.27	-5.74	-0.3	2.13e-8	Menarche (age at onset);
LUSC	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg12927641	chr6:109611667	NA	-0.43	-7.47	-0.38	7.04e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg22823121	chr1:150693482	HORMAD1	0.5	7.57	0.38	3.78e-13	Tonsillectomy;
LUSC	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg00042356	chr1:8021962	PARK7	0.78	9.27	0.45	2.37e-18	Inflammatory bowel disease;
LUSC	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg02751453	chr18:77725136	HSBP1L1	0.46	6.3	0.33	9.58e-10	Opioid sensitivity;
LUSC	cis	rs12464559	0.522	rs1916301	chr2:152640498	G/A	cg01189475	chr2:152685088	ARL5A	0.61	6.61	0.34	1.5e-10	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs7575217	0.682	rs4851401	chr2:101700518	T/C	cg23907051	chr2:101730305	TBC1D8	0.29	7.72	0.39	1.34e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg25319279	chr11:5960081	NA	-0.38	-5.79	-0.3	1.65e-8	DNA methylation (variation);
LUSC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	1.1	26.78	0.83	3.78e-85	Testicular germ cell tumor;
LUSC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg13683864	chr3:40499215	RPL14	-1.14	-20.56	-0.75	2.88e-61	Renal cell carcinoma;
LUSC	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.72	-0.35	7.76e-11	Reticulocyte count;
LUSC	cis	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg21775007	chr8:11205619	TDH	0.46	7.02	0.36	1.21e-11	Retinal vascular caliber;
LUSC	cis	rs977987	0.866	rs12932606	chr16:75493944	C/T	cg03315344	chr16:75512273	CHST6	0.53	9.98	0.48	1.07e-20	Dupuytren's disease;
LUSC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03352830	chr11:487213	PTDSS2	0.7	8.47	0.42	8.12e-16	Body mass index;
LUSC	cis	rs11585357	1.000	rs11203346	chr1:17600822	A/G	cg08277548	chr1:17600880	PADI3	-0.66	-7.02	-0.36	1.26e-11	Hair shape;
LUSC	cis	rs6594499	0.872	rs10045255	chr5:110438357	C/T	cg04022379	chr5:110408740	TSLP	-0.42	-6.56	-0.34	2.04e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2742417	1.000	rs2742421	chr3:45732515	G/T	cg09608765	chr3:45636137	LIMD1	0.36	6.87	0.35	3.06e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21659725	chr3:3221576	CRBN	-0.59	-8.31	-0.41	2.47e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg24642439	chr20:33292090	TP53INP2	0.52	7.86	0.39	5.51e-14	Coronary artery disease;
LUSC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg12463550	chr7:65579703	CRCP	-0.47	-7.1	-0.36	7.36e-12	Aortic root size;
LUSC	trans	rs17266958	1.000	rs1591017	chr9:83300287	G/A	cg01905489	chr1:26616534	UBXN11	-0.58	-6.38	-0.33	6.04e-10	Preschool internalizing problems;
LUSC	trans	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg26043149	chr18:55253948	FECH	0.51	7.47	0.38	7.28e-13	Bone mineral density;
LUSC	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.87	0.35	3.15e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6845621	0.727	rs28799570	chr4:18912156	T/C	cg12196642	chr4:18937545	NA	-0.34	-6.34	-0.33	7.28e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg13206674	chr6:150067644	NUP43	0.43	6.52	0.34	2.67e-10	Testicular germ cell tumor;
LUSC	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.34	-0.42	1.98e-15	Schizophrenia;
LUSC	cis	rs1062746	0.520	rs17698303	chr16:87329543	C/G	cg02258303	chr16:87377426	FBXO31	-0.51	-7.75	-0.39	1.15e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	7.41	0.38	1.08e-12	Mood instability;
LUSC	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	5.65	0.3	3.48e-8	Systolic blood pressure;
LUSC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg13319975	chr6:146136371	FBXO30	0.52	7.73	0.39	1.32e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00339695	chr16:24857497	SLC5A11	-0.62	-9.66	-0.47	1.27e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6500395	0.775	rs7191225	chr16:48662675	C/G	cg04672837	chr16:48644449	N4BP1	0.51	7.86	0.39	5.43e-14	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs13082711	0.834	rs2172297	chr3:27428423	C/T	cg02860705	chr3:27208620	NA	0.45	7.5	0.38	5.65e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs34734847	0.842	rs7308648	chr12:121144144	C/G	cg27246729	chr12:121163418	ACADS	0.42	6.69	0.34	9.4e-11	Mean corpuscular volume;
LUSC	trans	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg11887960	chr12:57824829	NA	0.47	6.47	0.33	3.41e-10	Ulcerative colitis;
LUSC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06634786	chr22:41940651	POLR3H	-0.46	-5.83	-0.3	1.34e-8	Vitiligo;
LUSC	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.56	9.45	0.46	6.08e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6977660	0.619	rs10271639	chr7:19779604	G/A	cg07541023	chr7:19748670	TWISTNB	0.6	6.57	0.34	1.95e-10	Thyroid stimulating hormone;
LUSC	cis	rs2274273	0.624	rs8015211	chr14:55841447	A/G	cg04306507	chr14:55594613	LGALS3	0.46	9.01	0.44	1.68e-17	Protein biomarker;
LUSC	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.7	10.25	0.49	1.24e-21	Corneal astigmatism;
LUSC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg24642844	chr7:1081250	C7orf50	-0.79	-10.59	-0.5	8.72e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs62400317	0.826	rs62400335	chr6:45347782	G/A	cg20913747	chr6:44695427	NA	-0.48	-7.81	-0.39	7.39e-14	Total body bone mineral density;
LUSC	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg16386425	chr10:429943	DIP2C	0.46	7.31	0.37	1.94e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs2235649	0.663	rs113908028	chr16:1848915	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-5.92	-0.31	7.81e-9	Blood metabolite levels;
LUSC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.58	-0.34	1.86e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs5758511	0.773	rs8140869	chr22:42344297	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-6.66	-0.34	1.12e-10	Birth weight;
LUSC	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.71	10.08	0.48	4.93e-21	Corneal astigmatism;
LUSC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg18479299	chr3:125709523	NA	-0.48	-5.85	-0.3	1.18e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg22532475	chr10:104410764	TRIM8	-0.32	-7.26	-0.37	2.67e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1335645	0.502	rs618089	chr1:111625277	T/C	cg00321911	chr1:111669324	DRAM2	0.51	5.83	0.3	1.32e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.62	10.08	0.48	5.07e-21	Blood metabolite ratios;
LUSC	cis	rs9650657	0.771	rs4840516	chr8:10667335	C/G	cg27411982	chr8:10470053	RP1L1	0.36	5.86	0.31	1.09e-8	Neuroticism;
LUSC	cis	rs6736093	0.966	rs11674891	chr2:112713116	A/G	cg12686935	chr2:112915763	FBLN7	-0.36	-5.81	-0.3	1.45e-8	Coronary artery disease;
LUSC	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	1.14	19.67	0.73	9.55e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.84	0.3	1.21e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.17	-0.41	6.51e-15	Chronic sinus infection;
LUSC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg08975724	chr8:8085496	FLJ10661	0.52	7.75	0.39	1.11e-13	Mood instability;
LUSC	cis	rs1267303	0.642	rs11588450	chr1:47000996	C/T	cg25110126	chr1:46999211	NA	-0.71	-10.64	-0.5	5.7e-23	Monobrow;
LUSC	cis	rs1124376	1.000	rs73038113	chr3:20139025	T/A	cg05072819	chr3:20081367	KAT2B	0.66	7.38	0.37	1.25e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg04267008	chr7:1944627	MAD1L1	-0.51	-7.44	-0.38	8.38e-13	Schizophrenia;
LUSC	cis	rs710865	0.519	rs10753518	chr1:19483593	T/C	cg13387374	chr1:19411106	UBR4	0.52	8.15	0.41	7.55e-15	Brain structure;
LUSC	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg04310649	chr10:35416472	CREM	-0.44	-6.89	-0.35	2.74e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9297145	0.761	rs28545226	chr7:98732472	A/T	cg05967295	chr7:98741636	SMURF1	0.97	14.54	0.62	1.84e-37	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg18099408	chr3:52552593	STAB1	0.35	5.75	0.3	2.05e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg24250549	chr1:154909240	PMVK	0.5	7.77	0.39	9.54e-14	Prostate cancer;
LUSC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03352830	chr11:487213	PTDSS2	0.7	8.41	0.42	1.24e-15	Body mass index;
LUSC	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg23127183	chr11:57508653	C11orf31	-0.58	-8.91	-0.44	3.41e-17	Schizophrenia;
LUSC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08219700	chr8:58056026	NA	0.64	8.25	0.41	3.79e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg22709100	chr7:91322751	NA	-0.39	-5.78	-0.3	1.76e-8	Breast cancer;
LUSC	cis	rs2074585	0.517	rs11635361	chr15:91081791	G/T	cg22089800	chr15:90895588	ZNF774	-0.56	-7.97	-0.4	2.49e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs3818285	0.959	rs35420248	chr10:111643074	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-8.3	-0.41	2.56e-15	Superior crus of antihelix expression;
LUSC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.72	12.16	0.55	2.03e-28	Motion sickness;
LUSC	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg13010199	chr12:38710504	ALG10B	0.55	8.34	0.42	1.98e-15	Morning vs. evening chronotype;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg21235925	chr17:80678270	FN3KRP	-0.35	-6.21	-0.32	1.55e-9	N-glycan levels;
LUSC	cis	rs1403694	0.695	rs1836860	chr3:186436604	C/T	cg12454167	chr3:186435060	KNG1	-0.31	-7.85	-0.39	5.79e-14	Blood protein levels;
LUSC	cis	rs7582720	1.000	rs72928613	chr2:203839628	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.35	0.42	1.85e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs981844	0.922	rs75543972	chr4:154664792	G/C	cg10279832	chr4:154682576	RNF175	-0.4	-5.85	-0.3	1.19e-8	Response to statins (LDL cholesterol change);
LUSC	trans	rs11039798	0.841	rs11039783	chr11:48526828	G/C	cg15704280	chr7:45808275	SEPT13	0.71	6.68	0.34	9.87e-11	Axial length;
LUSC	cis	rs3770081	1.000	rs11899576	chr2:86256193	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.81	-5.86	-0.31	1.1e-8	Facial emotion recognition (sad faces);
LUSC	cis	rs372883	0.935	rs379592	chr21:30706470	A/G	cg08807101	chr21:30365312	RNF160	-0.41	-5.87	-0.31	1.07e-8	Pancreatic cancer;
LUSC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg23887609	chr12:130822674	PIWIL1	0.48	7.11	0.36	7.08e-12	Menopause (age at onset);
LUSC	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.49	-5.82	-0.3	1.39e-8	Birth weight;
LUSC	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg03647239	chr10:116582469	FAM160B1	0.45	7.27	0.37	2.55e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg04871131	chr7:94954202	PON1	-0.38	-6.09	-0.32	3.12e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs4499344	0.633	rs259271	chr19:33157100	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	11.42	0.53	1.02e-25	Mean platelet volume;
LUSC	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg03929089	chr4:120376271	NA	-0.58	-7.59	-0.38	3.19e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22980127	chr19:33182716	NUDT19	0.9	12.86	0.58	5.17e-31	Red blood cell traits;
LUSC	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg11189052	chr15:85197271	WDR73	0.48	5.93	0.31	7.56e-9	Schizophrenia;
LUSC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg23281280	chr6:28129359	ZNF389	0.45	5.88	0.31	1.02e-8	Depression;
LUSC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.75	-10.4	-0.49	3.92e-22	Body mass index;
LUSC	trans	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.09	-0.32	3.07e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03264133	chr6:25882463	NA	0.42	7.23	0.37	3.36e-12	Blood metabolite levels;
LUSC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg27121462	chr16:89883253	FANCA	0.55	8.86	0.44	4.78e-17	Vitiligo;
LUSC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg10253484	chr15:75165896	SCAMP2	-0.45	-6.52	-0.34	2.67e-10	Breast cancer;
LUSC	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.39	5.73	0.3	2.24e-8	Height;
LUSC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg25019033	chr10:957182	NA	-0.52	-6.56	-0.34	1.99e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.17	0.58	3.41e-32	Cognitive test performance;
LUSC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3733418	0.929	rs12510464	chr4:165919040	A/G	cg11630554	chr4:165878136	TRIM61;C4orf39	-0.52	-5.93	-0.31	7.69e-9	Obesity-related traits;
LUSC	cis	rs17255340	0.520	rs3798885	chr6:84131874	T/C	cg08257003	chr6:84140564	ME1	0.37	8.91	0.44	3.25e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs56283067	0.847	rs10948156	chr6:44689459	G/A	cg20913747	chr6:44695427	NA	-0.48	-7.78	-0.39	9.29e-14	Total body bone mineral density;
LUSC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.02	0.4	1.76e-14	Parkinson's disease;
LUSC	cis	rs9303280	0.870	rs1011082	chr17:38068514	T/C	cg10909506	chr17:38081995	ORMDL3	-0.35	-6.38	-0.33	5.86e-10	Self-reported allergy;
LUSC	cis	rs7771547	0.508	rs1570368	chr6:36437136	C/G	cg07856975	chr6:36356162	ETV7	0.4	6.66	0.34	1.15e-10	Platelet distribution width;
LUSC	trans	rs7657257	1.000	rs4321629	chr4:15732380	C/T	cg17675199	chr6:35436792	RPL10A	-0.83	-6.11	-0.32	2.84e-9	Blood protein levels;
LUSC	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.68	-0.3	2.95e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg22029157	chr1:209979665	IRF6	0.51	8.12	0.41	9e-15	Monobrow;
LUSC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg07701084	chr6:150067640	NUP43	0.53	7.85	0.39	5.88e-14	Lung cancer;
LUSC	cis	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg06521331	chr12:34319734	NA	-0.47	-7.56	-0.38	3.82e-13	Morning vs. evening chronotype;
LUSC	trans	rs9934935	1.000	rs9934935	chr16:82704528	G/A	cg06378491	chr11:64564012	MAP4K2	-0.38	-5.97	-0.31	6.06e-9	Trans fatty acid levels;
LUSC	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg23202291	chr11:1979235	NA	0.39	6.01	0.31	4.74e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs9925964	0.933	rs2303222	chr16:31085470	A/G	cg02466173	chr16:30829666	NA	0.34	6.12	0.32	2.69e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2262909	0.962	rs12609368	chr19:22263996	T/C	cg17074339	chr11:11642133	GALNTL4	0.47	7.2	0.37	3.93e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg05347473	chr6:146136440	FBXO30	0.51	8.78	0.43	8.73e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg06637938	chr14:75390232	RPS6KL1	0.53	8.41	0.42	1.23e-15	Height;
LUSC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.22e-30	Aortic root size;
LUSC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.04	-0.36	1.12e-11	Alzheimer's disease (late onset);
LUSC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg15782153	chr7:917662	C7orf20	-0.43	-6.65	-0.34	1.23e-10	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg24558204	chr6:135376177	HBS1L	0.58	8.83	0.44	5.98e-17	Red blood cell count;
LUSC	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-7.07	-0.36	9.36e-12	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs4853525	0.923	rs1882398	chr2:191724460	A/G	cg11845111	chr2:191398756	TMEM194B	-0.4	-5.87	-0.31	1.07e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg09877947	chr5:131593287	PDLIM4	0.39	6.61	0.34	1.52e-10	Blood metabolite levels;
LUSC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	7.82e-13	Motion sickness;
LUSC	trans	rs2665103	0.715	rs11639440	chr15:82571046	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.46	-7.01	-0.36	1.28e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.86	0.6	8.34e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg00343986	chr7:65444356	GUSB	0.48	7.12	0.36	6.59e-12	Calcium levels;
LUSC	trans	rs877282	0.583	rs11253424	chr10:813426	C/T	cg13042288	chr15:90349979	ANPEP	-0.38	-6.25	-0.32	1.25e-9	Uric acid levels;
LUSC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg18904891	chr8:8559673	CLDN23	0.61	8.47	0.42	7.74e-16	Obesity-related traits;
LUSC	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg03522245	chr20:25566470	NINL	-0.35	-5.73	-0.3	2.21e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs243505	1.000	rs243511	chr7:148430148	A/C	cg09806900	chr7:148480153	CUL1	-0.49	-6.92	-0.35	2.27e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.51	7.33	0.37	1.78e-12	Coronary heart disease;
LUSC	cis	rs877426	0.645	rs2297103	chr13:114775816	G/T	cg02745494	chr13:114771098	RASA3	0.38	5.82	0.3	1.41e-8	Facial morphology (factor 14, intercanthal width);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19596991	chr10:126432951	FAM53B	0.47	6.64	0.34	1.29e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11608355	0.557	rs759971	chr12:109826046	A/T	cg19025524	chr12:109796872	NA	-0.41	-7.6	-0.38	3.09e-13	Neuroticism;
LUSC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	8.36	0.42	1.66e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg12856521	chr11:46389249	DGKZ	-0.57	-7.52	-0.38	4.99e-13	Crohn's disease;
LUSC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg17264618	chr3:40429014	ENTPD3	0.33	6.93	0.35	2.23e-11	Renal cell carcinoma;
LUSC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg07148914	chr20:33460835	GGT7	0.54	8.36	0.42	1.72e-15	Height;
LUSC	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg26897989	chr16:1907736	C16orf73	-0.41	-6.58	-0.34	1.79e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18876405	chr7:65276391	NA	0.55	8.81	0.43	6.74e-17	Aortic root size;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11691170	chr11:130318691	ADAMTS15	-0.5	-6.69	-0.34	9.46e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.7	0.34	8.9e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg13010199	chr12:38710504	ALG10B	0.49	7.62	0.38	2.72e-13	Morning vs. evening chronotype;
LUSC	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.96	0.51	4.32e-24	Hypertriglyceridemia;
LUSC	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg02454025	chr1:11042201	C1orf127	1.03	18.67	0.71	8.68e-54	Male-pattern baldness;
LUSC	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.51	-0.34	2.82e-10	Menarche (age at onset);
LUSC	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.22	-15.5	-0.65	3.23e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs79911532	0.515	rs80351761	chr7:75698945	G/A	cg03592824	chr7:75666768	STYXL1	0.67	6.42	0.33	4.79e-10	Mononucleosis;
LUSC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.66	-0.39	2.09e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg22681709	chr2:178499509	PDE11A	-0.36	-6.68	-0.34	9.9e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08280861	chr8:58055591	NA	0.54	5.89	0.31	9.6e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-17.88	-0.7	1.27e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg25664220	chr3:72788482	NA	-0.66	-10.72	-0.51	3.15e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-6.78	-0.35	5.4e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4654899	0.965	rs4654907	chr1:21521094	C/T	cg01072550	chr1:21505969	NA	-0.57	-8.64	-0.43	2.34e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg05707623	chr12:122985044	ZCCHC8	0.66	8.18	0.41	5.92e-15	Body mass index;
LUSC	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg16434002	chr17:42200994	HDAC5	0.44	5.84	0.3	1.21e-8	Total body bone mineral density;
LUSC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.07e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9560113	0.960	rs4773378	chr13:112174154	G/A	cg14154082	chr13:112174009	NA	0.38	7.95	0.4	2.97e-14	Menarche (age at onset);
LUSC	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg15704280	chr7:45808275	SEPT13	0.64	7.26	0.37	2.71e-12	Axial length;
LUSC	cis	rs11051970	0.838	rs2651369	chr12:32552769	C/G	cg02745156	chr12:32552066	NA	0.41	7.08	0.36	8.33e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg13939156	chr17:80058883	NA	0.36	7.21	0.37	3.84e-12	Life satisfaction;
LUSC	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	5.97	0.31	6.09e-9	Blood metabolite levels;
LUSC	cis	rs2274273	0.901	rs112870553	chr14:55790062	T/G	cg04306507	chr14:55594613	LGALS3	0.56	12.99	0.58	1.58e-31	Protein biomarker;
LUSC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	0.94	16.46	0.67	5.38e-45	Menopause (age at onset);
LUSC	cis	rs1561296	0.529	rs10497860	chr2:201272705	A/G	cg23649088	chr2:200775458	C2orf69	0.39	6.05	0.31	3.95e-9	Schizophrenia;
LUSC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg09021430	chr5:549028	NA	-0.41	-7.34	-0.37	1.61e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	0.92	15.23	0.64	3.94e-40	Breast cancer;
LUSC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg21361702	chr7:150065534	REPIN1	0.59	8.61	0.43	3.02e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9314323	0.767	rs7012604	chr8:26204089	G/A	cg13160058	chr8:26243215	BNIP3L	-0.39	-6.69	-0.34	9.59e-11	Red cell distribution width;
LUSC	cis	rs2625529	0.652	rs2929532	chr15:72345110	C/T	cg16672083	chr15:72433130	SENP8	0.49	8.19	0.41	5.72e-15	Red blood cell count;
LUSC	cis	rs72960926	0.744	rs72964239	chr6:74874498	C/A	cg03266952	chr6:74778945	NA	-0.8	-6.4	-0.33	5.18e-10	Metabolite levels (MHPG);
LUSC	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg03433033	chr1:76189801	ACADM	-0.41	-6.1	-0.32	3.02e-9	Daytime sleep phenotypes;
LUSC	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg17764715	chr19:33622953	WDR88	0.59	8.87	0.44	4.66e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs35094601	0.731	rs4954929	chr2:139212829	T/C	cg10095539	chr2:139258744	SPOPL	0.25	5.86	0.31	1.13e-8	Schizophrenia;
LUSC	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg08508325	chr11:3079039	CARS	0.33	6.57	0.34	1.95e-10	Calcium levels;
LUSC	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg22655196	chr4:3374909	RGS12	0.31	5.97	0.31	6.14e-9	Serum sulfate level;
LUSC	cis	rs4722585	0.533	rs2237335	chr7:26200213	A/G	cg07876897	chr7:26191696	NFE2L3	0.46	6.87	0.35	3.15e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUSC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg07636037	chr3:49044803	WDR6	0.46	6.51	0.34	2.81e-10	Resting heart rate;
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.83	-13.55	-0.6	1.25e-33	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.7	-11.5	-0.53	5.21e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7180079	1.000	rs7165405	chr15:64662900	C/T	cg08069370	chr15:64387884	SNX1	-0.56	-6.06	-0.31	3.68e-9	Monocyte count;
LUSC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg12560992	chr17:57184187	TRIM37	0.84	15.48	0.65	3.82e-41	Intelligence (multi-trait analysis);
LUSC	trans	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg15704280	chr7:45808275	SEPT13	0.69	6.45	0.33	3.92e-10	Axial length;
LUSC	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.58	-9.33	-0.45	1.55e-18	Body mass index;
LUSC	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg11861562	chr11:117069780	TAGLN	0.33	6.38	0.33	5.8e-10	Blood protein levels;
LUSC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.23	0.37	3.39e-12	Mean platelet volume;
LUSC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg13393036	chr8:95962371	TP53INP1	-0.47	-9.69	-0.47	9.74e-20	Type 2 diabetes;
LUSC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg08470875	chr2:26401718	FAM59B	-0.68	-9.08	-0.45	9.33e-18	Gut microbiome composition (summer);
LUSC	cis	rs79247733	1.000	rs79247733	chr22:30757436	G/A	cg03868770	chr22:30783737	RNF215	-0.52	-5.93	-0.31	7.6e-9	Tonsillectomy;
LUSC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg26924012	chr15:45694286	SPATA5L1	1.13	20.89	0.75	1.35e-62	Homoarginine levels;
LUSC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg13047869	chr3:10149882	C3orf24	0.56	7.73	0.39	1.24e-13	Alzheimer's disease;
LUSC	cis	rs9905704	0.918	rs35934668	chr17:56894638	A/G	cg12560992	chr17:57184187	TRIM37	0.55	7.84	0.39	6.19e-14	Testicular germ cell tumor;
LUSC	cis	rs10779751	0.734	rs6701726	chr1:11126941	C/T	cg04508216	chr1:11107452	MASP2	0.33	5.87	0.31	1.03e-8	Body mass index;
LUSC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg16423285	chr20:60520624	NA	-0.47	-5.92	-0.31	8.15e-9	Body mass index;
LUSC	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-6.98	-0.36	1.63e-11	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs1325195	0.506	rs2636266	chr1:179199652	A/G	cg11624085	chr17:8464688	MYH10	0.43	6.38	0.33	5.94e-10	IgE grass sensitization;
LUSC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg07212818	chr11:638076	DRD4	-0.46	-7.61	-0.38	2.74e-13	Systemic lupus erythematosus;
LUSC	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-7.97	-0.4	2.56e-14	Schizophrenia;
LUSC	cis	rs295140	0.803	rs4233994	chr2:201129211	G/C	cg04283868	chr2:201171347	SPATS2L	0.41	5.95	0.31	6.78e-9	QT interval;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg21829265	chr6:56911139	KIAA1586	0.39	6.27	0.32	1.11e-9	Triglycerides;
LUSC	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-15.02	-0.63	2.6e-39	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs55871839	0.708	rs10093993	chr8:59811454	T/C	cg07426533	chr8:59803705	TOX	-0.36	-5.93	-0.31	7.66e-9	Pneumonia;
LUSC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.94	0.51	5.25e-24	Menopause (age at onset);
LUSC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9815354	0.767	rs60764195	chr3:41812522	G/C	cg03022575	chr3:42003672	ULK4	0.85	8.67	0.43	1.87e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg23625390	chr15:77176239	SCAPER	0.45	6.95	0.36	1.89e-11	Blood metabolite levels;
LUSC	cis	rs7255	0.545	rs9306894	chr2:20878105	A/G	cg05481257	chr2:20870211	GDF7	-0.34	-5.99	-0.31	5.4e-9	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
LUSC	trans	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg09904177	chr6:26538194	HMGN4	-0.8	-6.0	-0.31	5.13e-9	Depression;
LUSC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-1.02	-15.52	-0.65	2.71e-41	Initial pursuit acceleration;
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg18538332	chr22:24372958	LOC391322	-0.47	-8.25	-0.41	3.64e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg26924012	chr15:45694286	SPATA5L1	1.13	20.84	0.75	2.15e-62	Homoarginine levels;
LUSC	trans	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg10840412	chr1:235813424	GNG4	0.6	8.42	0.42	1.15e-15	Bipolar disorder;
LUSC	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg11502198	chr6:26597334	ABT1	0.6	9.37	0.46	1.09e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg05868516	chr6:26286170	HIST1H4H	0.36	5.89	0.31	9.34e-9	Educational attainment;
LUSC	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg26384229	chr12:38710491	ALG10B	0.72	10.12	0.48	3.66e-21	Resting heart rate;
LUSC	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.74	-10.02	-0.48	7.92e-21	Coronary artery disease;
LUSC	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg03585969	chr10:35415529	CREM	0.64	9.18	0.45	4.74e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7180079	1.000	rs4777181	chr15:64670566	T/C	cg08069370	chr15:64387884	SNX1	0.58	6.18	0.32	1.84e-9	Monocyte count;
LUSC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg18681998	chr4:17616180	MED28	0.86	15.66	0.65	7.88e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg03342759	chr3:160939853	NMD3	-0.4	-5.91	-0.31	8.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs4654899	0.802	rs10916903	chr1:21247944	T/C	cg01072550	chr1:21505969	NA	-0.52	-7.54	-0.38	4.52e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg06238570	chr21:40685208	BRWD1	0.48	7.46	0.38	7.44e-13	Cognitive function;
LUSC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-0.81	-16.0	-0.66	3.69e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs62400317	0.859	rs55964727	chr6:45259079	A/C	cg20913747	chr6:44695427	NA	-0.45	-7.42	-0.38	9.97e-13	Total body bone mineral density;
LUSC	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg26384229	chr12:38710491	ALG10B	0.73	11.48	0.53	5.99e-26	Morning vs. evening chronotype;
LUSC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-1.2	-13.16	-0.58	3.72e-32	Diabetic kidney disease;
LUSC	cis	rs4629710	0.592	rs9492865	chr6:131534403	T/A	cg12606694	chr6:131520996	AKAP7	0.6	8.99	0.44	1.94e-17	Multiple myeloma (IgH translocation);
LUSC	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg12432903	chr7:1882776	MAD1L1	0.53	6.63	0.34	1.33e-10	Bipolar disorder;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02396668	chr19:50528878	VRK3;ZNF473	0.45	6.74	0.35	7e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg11887960	chr12:57824829	NA	0.57	7.03	0.36	1.18e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2235649	0.828	rs9925354	chr16:1849866	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.44	-6.04	-0.31	4.12e-9	Blood metabolite levels;
LUSC	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg09479241	chr17:27052676	TLCD1	0.43	5.96	0.31	6.29e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs5839475	1	rs5839475	chr2:234188015	A/AG	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.58	8.12	0.41	9.05e-15	Strep throat;
LUSC	trans	rs10492201	0.529	rs11176998	chr12:68387554	T/G	cg21566642	chr2:233284661	NA	-0.39	-6.03	-0.31	4.28e-9	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-9.13	-0.45	6.6e-18	Morning vs. evening chronotype;
LUSC	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg00857998	chr1:205179979	DSTYK	0.62	9.52	0.46	3.48e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1595825	0.891	rs76637837	chr2:198529496	G/A	cg19156104	chr2:198669113	PLCL1	-0.45	-5.69	-0.3	2.74e-8	Ulcerative colitis;
LUSC	cis	rs67072384	0.892	rs72966136	chr11:72456710	G/C	cg04827223	chr11:72435913	ARAP1	-0.82	-6.71	-0.34	8.49e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs2652834	0.851	rs10851723	chr15:63416335	G/T	cg05507819	chr15:63340323	TPM1	0.45	5.8	0.3	1.58e-8	HDL cholesterol;
LUSC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.01	0.31	4.87e-9	Menopause (age at onset);
LUSC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.53	10.54	0.5	1.32e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg13010199	chr12:38710504	ALG10B	0.71	10.9	0.51	7.24e-24	Bladder cancer;
LUSC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	-0.37	-6.08	-0.32	3.26e-9	Menopause (age at onset);
LUSC	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg25801113	chr15:45476975	SHF	-0.32	-6.43	-0.33	4.34e-10	Uric acid levels;
LUSC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.89	14.89	0.63	8.25e-39	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg08499158	chr17:42289980	UBTF	0.42	6.34	0.33	7.29e-10	Total body bone mineral density;
LUSC	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg20701182	chr2:24300061	SF3B14	0.74	7.28	0.37	2.48e-12	Lymphocyte counts;
LUSC	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.97	-0.48	1.13e-20	Total cholesterol levels;
LUSC	cis	rs17095355	0.605	rs7075964	chr10:111631265	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.55	-6.5	-0.34	2.92e-10	Biliary atresia;
LUSC	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg22676075	chr6:135203613	NA	0.59	9.41	0.46	8.46e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg19862616	chr7:65841803	NCRNA00174	0.87	10.19	0.49	2.01e-21	Eotaxin levels;
LUSC	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg25930673	chr12:123319894	HIP1R	-0.63	-6.17	-0.32	2.01e-9	Schizophrenia;
LUSC	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.11	-0.36	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.42	6.33	0.33	7.87e-10	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.94	15.2	0.64	4.91e-40	Developmental language disorder (linguistic errors);
LUSC	cis	rs62400317	0.859	rs4479922	chr6:45248371	T/C	cg18551225	chr6:44695536	NA	-0.44	-7.21	-0.37	3.75e-12	Total body bone mineral density;
LUSC	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg08085267	chr17:45401833	C17orf57	-0.47	-6.66	-0.34	1.11e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12940923	1.000	rs12949848	chr17:56362067	A/G	cg19466818	chr17:56409534	MIR142	-0.39	-6.86	-0.35	3.35e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs1775715	0.870	rs1775731	chr10:32253512	A/G	cg26784012	chr10:32216390	ARHGAP12	0.41	6.56	0.34	2.02e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg13010199	chr12:38710504	ALG10B	0.56	8.41	0.42	1.19e-15	Morning vs. evening chronotype;
LUSC	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg06606381	chr12:133084897	FBRSL1	-0.92	-8.91	-0.44	3.3e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.71	-12.37	-0.56	3.47e-29	White blood cell count (basophil);
LUSC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg23630131	chr7:65973040	NA	0.22	6.2	0.32	1.7e-9	Aortic root size;
LUSC	cis	rs7843479	0.601	rs1031882	chr8:21788934	T/G	cg17168535	chr8:21777572	XPO7	0.85	15.76	0.65	3.13e-42	Mean corpuscular volume;
LUSC	trans	rs62458065	0.713	rs62463968	chr7:32501242	G/A	cg00845942	chr12:64062724	DPY19L2	-0.56	-6.75	-0.35	6.42e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	6.47	0.33	3.5e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27199889	chr11:58910235	FAM111A	-0.42	-6.03	-0.31	4.25e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.24e-19	Prudent dietary pattern;
LUSC	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-0.53	-8.1	-0.41	1.01e-14	Breast cancer;
LUSC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg09555818	chr19:45449301	APOC2	0.44	8.18	0.41	5.99e-15	Blood protein levels;
LUSC	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg08807101	chr21:30365312	RNF160	-0.53	-7.91	-0.4	3.87e-14	Dental caries;
LUSC	cis	rs7744392	0.557	rs12211943	chr6:35306857	G/A	cg06087101	chr6:35551932	FKBP5	0.47	5.77	0.3	1.82e-8	Cataracts in type 2 diabetes;
LUSC	cis	rs34779708	0.733	rs4391768	chr10:35547595	A/G	cg03585969	chr10:35415529	CREM	0.53	7.38	0.37	1.3e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	12.58	0.57	5.75e-30	Lung cancer in ever smokers;
LUSC	cis	rs243505	1.000	rs243502	chr7:148437205	C/T	cg09806900	chr7:148480153	CUL1	-0.5	-7.01	-0.36	1.35e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs41271473	1.000	rs41270187	chr1:228878871	T/C	cg10167378	chr1:228756711	NA	0.51	6.32	0.33	8.24e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg08997352	chr12:9597637	DDX12	-0.71	-11.07	-0.52	1.83e-24	Breast size;
LUSC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg15147215	chr3:52552868	STAB1	-0.29	-5.83	-0.3	1.28e-8	Bipolar disorder;
LUSC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-7.36	-0.37	1.42e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7267979	0.714	rs3787082	chr20:25235736	A/T	cg08601574	chr20:25228251	PYGB	0.48	7.45	0.38	8.3e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg05340658	chr4:99064831	C4orf37	0.63	9.85	0.47	2.88e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg10756647	chr7:56101905	PSPH	0.86	8.36	0.42	1.7e-15	Diabetic kidney disease;
LUSC	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	9.42	0.46	7.41e-19	Lung cancer;
LUSC	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg22782873	chr19:19639568	YJEFN3	-0.47	-6.12	-0.32	2.65e-9	Bipolar disorder;
LUSC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg23281280	chr6:28129359	ZNF389	0.45	5.86	0.31	1.14e-8	Parkinson's disease;
LUSC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.35	-0.42	1.88e-15	Coronary artery disease;
LUSC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08677398	chr8:58056175	NA	0.52	6.95	0.36	1.88e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.88	0.31	1.02e-8	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg21770322	chr7:97807741	LMTK2	0.4	7.03	0.36	1.19e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg20503657	chr10:835505	NA	0.89	12.37	0.56	3.37e-29	Eosinophil percentage of granulocytes;
LUSC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.92	0.35	2.33e-11	Platelet count;
LUSC	cis	rs11229555	0.645	rs12269928	chr11:58184358	T/C	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs16854884	1.000	rs2370171	chr3:143765177	C/T	cg06585982	chr3:143692056	C3orf58	0.49	7.0	0.36	1.44e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg22508957	chr16:3507546	NAT15	-0.42	-6.33	-0.33	7.95e-10	Body mass index (adult);
LUSC	cis	rs9462027	0.583	rs2814947	chr6:34653268	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.16	-0.32	2.13e-9	Systemic lupus erythematosus;
LUSC	cis	rs1461503	0.932	rs10892944	chr11:122843895	T/C	cg27398637	chr11:122830231	C11orf63	-0.42	-6.73	-0.35	7.37e-11	Menarche (age at onset);
LUSC	cis	rs7091068	0.706	rs1147645	chr10:95401241	C/G	cg20715218	chr10:95462985	C10orf4	-0.63	-6.31	-0.33	8.9e-10	Urinary tract infection frequency;
LUSC	cis	rs7712401	0.601	rs30039	chr5:122277179	A/C	cg19077854	chr5:122220652	SNX24	-0.42	-8.64	-0.43	2.35e-16	Mean platelet volume;
LUSC	cis	rs17253792	0.915	rs75296402	chr14:56182491	C/T	cg01858014	chr14:56050164	KTN1	-0.86	-6.91	-0.35	2.43e-11	Putamen volume;
LUSC	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.78	11.21	0.52	5.78e-25	Corneal astigmatism;
LUSC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.94	-14.97	-0.63	4.03e-39	Coronary artery disease;
LUSC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-11.83	-0.54	3.43e-27	Platelet count;
LUSC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06505273	chr16:24850292	NA	-0.41	-5.74	-0.3	2.16e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg18827107	chr12:86230957	RASSF9	-0.42	-6.08	-0.32	3.35e-9	Major depressive disorder;
LUSC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.49	-0.38	6.15e-13	Aortic root size;
LUSC	cis	rs9840812	0.773	rs61789601	chr3:135954979	C/T	cg15507776	chr3:136538369	TMEM22	-0.44	-5.77	-0.3	1.77e-8	Fibrinogen levels;
LUSC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg02034447	chr16:89574710	SPG7	0.42	6.14	0.32	2.33e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18758796	chr5:131593413	PDLIM4	0.53	9.16	0.45	5.21e-18	Acylcarnitine levels;
LUSC	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	0.86	11.39	0.53	1.35e-25	Coronary artery disease;
LUSC	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg02423579	chr7:2872169	GNA12	-0.37	-5.71	-0.3	2.52e-8	Height;
LUSC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg02807482	chr3:125708958	NA	-0.49	-6.1	-0.32	3.01e-9	Blood pressure (smoking interaction);
LUSC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6087990	0.735	rs6057647	chr20:31381690	A/T	cg13636640	chr20:31349939	DNMT3B	0.91	18.47	0.71	5.77e-53	Ulcerative colitis;
LUSC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00339695	chr16:24857497	SLC5A11	0.61	9.21	0.45	3.58e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.08	23.42	0.79	1.91e-72	Schizophrenia;
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24739457	chr1:205821442	NA	0.35	6.02	0.31	4.66e-9	Menarche (age at onset);
LUSC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg09365446	chr1:150670422	GOLPH3L	0.5	7.4	0.38	1.08e-12	Melanoma;
LUSC	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.88	-0.4	4.81e-14	Blood metabolite levels;
LUSC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	12.88	0.58	4.13e-31	Platelet count;
LUSC	cis	rs977987	0.735	rs11149831	chr16:75451461	G/A	cg03315344	chr16:75512273	CHST6	0.54	9.78	0.47	5.17e-20	Dupuytren's disease;
LUSC	cis	rs3768617	0.811	rs4396114	chr1:183007441	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.54	0.42	4.75e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg14500267	chr11:67383377	NA	-0.32	-5.81	-0.3	1.44e-8	Mean corpuscular volume;
LUSC	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.47	-5.83	-0.3	1.31e-8	Birth weight;
LUSC	cis	rs9649213	0.574	rs17436977	chr7:97883459	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.41	-7.26	-0.37	2.79e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.96	0.51	4.51e-24	Menopause (age at onset);
LUSC	cis	rs4478858	0.735	rs4494186	chr1:31857847	G/A	cg00250761	chr1:31883323	NA	0.33	7.78	0.39	9.16e-14	Alcohol dependence;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10729317	chr20:2821390	FAM113A;VPS16	-0.47	-6.39	-0.33	5.49e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.31	5.85	0.3	1.16e-8	Obesity-related traits;
LUSC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg13699009	chr12:122356056	WDR66	0.45	6.79	0.35	5e-11	Mean corpuscular volume;
LUSC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06481639	chr22:41940642	POLR3H	0.51	5.85	0.3	1.19e-8	Vitiligo;
LUSC	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg07080220	chr10:102295463	HIF1AN	0.6	7.75	0.39	1.1e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg01973587	chr1:228161476	NA	-0.4	-7.24	-0.37	3.09e-12	Diastolic blood pressure;
LUSC	trans	rs853679	0.546	rs200990	chr6:27815823	T/G	cg01620082	chr3:125678407	NA	-0.7	-7.18	-0.37	4.47e-12	Depression;
LUSC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.22	0.41	4.67e-15	Menarche (age at onset);
LUSC	cis	rs418053	0.648	rs204228	chr6:13680776	A/G	cg02206980	chr6:13574034	SIRT5	-0.29	-5.69	-0.3	2.75e-8	Breast cancer;
LUSC	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg08854313	chr1:11322531	MTOR	-0.82	-12.72	-0.57	1.73e-30	Body mass index;
LUSC	cis	rs7851660	0.844	rs10123699	chr9:100637859	A/G	cg13688889	chr9:100608707	NA	-0.55	-8.52	-0.42	5.57e-16	Strep throat;
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg16132339	chr22:24313637	DDTL;DDT	-0.4	-6.17	-0.32	1.94e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg03676636	chr4:99064102	C4orf37	0.38	7.92	0.4	3.55e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	8.82	0.43	6.29e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg03340356	chr1:67600835	NA	0.46	7.38	0.37	1.27e-12	Psoriasis;
LUSC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg22834771	chr12:69754056	YEATS4	0.43	6.66	0.34	1.1e-10	Blood protein levels;
LUSC	cis	rs4660306	0.614	rs781057	chr1:45936017	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.42	5.8	0.3	1.55e-8	Homocysteine levels;
LUSC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg12639453	chr1:2035780	PRKCZ	-0.33	-7.16	-0.36	5.3e-12	Height;
LUSC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg22029157	chr1:209979665	IRF6	0.8	10.25	0.49	1.27e-21	Cleft lip with or without cleft palate;
LUSC	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg26314531	chr2:26401878	FAM59B	-0.55	-7.23	-0.37	3.3e-12	Gut microbiome composition (summer);
LUSC	cis	rs12930096	1.000	rs12929430	chr16:11679467	C/T	cg07439791	chr16:11680400	LITAF	0.53	5.78	0.3	1.71e-8	QT interval;
LUSC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-0.68	-11.09	-0.52	1.5e-24	Blood metabolite ratios;
LUSC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg12564285	chr5:131593104	PDLIM4	-0.47	-8.21	-0.41	4.79e-15	Breast cancer;
LUSC	trans	rs2679649	1.000	rs2684272	chr6:122351593	G/A	cg00167820	chr8:131663355	NA	0.54	6.35	0.33	6.96e-10	Subcutaneous adipose tissue;
LUSC	cis	rs11229555	0.645	rs12290089	chr11:58176849	A/G	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg19862616	chr7:65841803	NCRNA00174	0.89	9.85	0.47	2.86e-20	Eotaxin levels;
LUSC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg07395648	chr5:131743802	NA	-0.44	-6.87	-0.35	3.12e-11	Breast cancer;Mosquito bite size;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg20814355	chr7:44646092	OGDH	0.5	6.34	0.33	7.26e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg25206134	chr2:45395956	NA	-0.53	-6.32	-0.33	8.23e-10	Bipolar disorder;
LUSC	cis	rs9309473	0.607	rs7567343	chr2:73596605	C/A	cg20560298	chr2:73613845	ALMS1	-0.57	-8.42	-0.42	1.15e-15	Metabolite levels;
LUSC	cis	rs926938	0.765	rs1884296	chr1:115235716	A/C	cg12756093	chr1:115239321	AMPD1	-0.53	-8.1	-0.41	1.02e-14	Autism;
LUSC	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-7.09	-0.36	7.98e-12	Homocysteine levels;
LUSC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.89	-0.4	4.32e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg07936489	chr17:37558343	FBXL20	0.72	9.94	0.48	1.45e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	8.09	0.4	1.12e-14	Height;
LUSC	cis	rs2463822	0.920	rs72923207	chr11:62117959	A/G	cg06239285	chr11:62104954	ASRGL1	-0.97	-10.27	-0.49	1.1e-21	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.12	-0.41	8.81e-15	Bone mineral density;
LUSC	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg08085267	chr17:45401833	C17orf57	0.54	8.86	0.44	4.76e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2279817	0.954	rs12143113	chr1:18018857	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.53	6.93	0.35	2.24e-11	Neuroticism;
LUSC	trans	rs1391576	1	rs1391576	chr11:51394932	C/T	cg15704280	chr7:45808275	SEPT13	0.72	6.37	0.33	6.35e-10	Body mass index;
LUSC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22590775	chr19:49891494	CCDC155	0.61	8.69	0.43	1.6e-16	Multiple sclerosis;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02473350	chr3:160939232	NMD3	0.75	5.97	0.31	6.07e-9	Cognitive performance;
LUSC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-1.25	-13.99	-0.61	2.56e-35	Diabetic kidney disease;
LUSC	cis	rs9837602	1.000	rs793496	chr3:99507254	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.37	-6.02	-0.31	4.66e-9	Breast cancer;
LUSC	trans	rs1697137	0.622	rs2545395	chr5:66380379	T/C	cg12187567	chr8:95907389	CCNE2	0.48	6.02	0.31	4.59e-9	Carotid atherosclerosis in HIV infection;
LUSC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg15445000	chr17:37608096	MED1	0.4	6.85	0.35	3.65e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg13010199	chr12:38710504	ALG10B	0.49	7.5	0.38	6e-13	Morning vs. evening chronotype;
LUSC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg17971929	chr21:40555470	PSMG1	-0.51	-7.65	-0.39	2.24e-13	Menarche (age at onset);
LUSC	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg02527881	chr3:46936655	PTH1R	-0.39	-6.94	-0.36	2.05e-11	Colorectal cancer;
LUSC	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.45	-6.98	-0.36	1.55e-11	Menarche (age at onset);
LUSC	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-6.23	-0.32	1.37e-9	Height;
LUSC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.88e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.4	8.41	0.42	1.19e-15	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs4704187	0.687	rs10214239	chr5:74357475	G/A	cg03227963	chr5:74354835	NA	0.33	7.03	0.36	1.17e-11	Response to amphetamines;
LUSC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs80282103	0.764	rs10047383	chr10:1103095	A/G	cg23359895	chr10:1095482	IDI1	0.64	5.76	0.3	1.88e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg21770322	chr7:97807741	LMTK2	0.55	9.86	0.47	2.74e-20	Breast cancer;
LUSC	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.54	10.96	0.51	4.22e-24	Coronary artery disease;
LUSC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg06453172	chr10:134556979	INPP5A	-0.51	-6.39	-0.33	5.41e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-6.03	-0.31	4.43e-9	Eosinophil percentage of white cells;
LUSC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg04369109	chr6:150039330	LATS1	-0.56	-8.29	-0.41	2.81e-15	Lung cancer;
LUSC	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg05084668	chr3:125655381	ALG1L	-0.92	-13.12	-0.58	5.09e-32	Blood pressure (smoking interaction);
LUSC	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg22676075	chr6:135203613	NA	0.48	7.5	0.38	5.74e-13	Red blood cell count;
LUSC	cis	rs2041895	0.509	rs12368448	chr12:107316796	A/C	cg13944111	chr12:107296891	NA	-0.38	-6.71	-0.34	8.42e-11	Glaucoma (low intraocular pressure);
LUSC	trans	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg13010199	chr12:38710504	ALG10B	0.54	7.84	0.39	6.24e-14	Resting heart rate;
LUSC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-7.32	-0.37	1.86e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10193935	0.792	rs10204778	chr2:42498121	G/T	cg27598129	chr2:42591480	NA	-0.6	-8.1	-0.41	1.03e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs926392	0.572	rs6129157	chr20:37672247	G/T	cg16355469	chr20:37678765	NA	0.52	6.95	0.36	1.9e-11	Dialysis-related mortality;
LUSC	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	0.57	8.43	0.42	1.06e-15	Breast cancer;
LUSC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg04414720	chr1:150670196	GOLPH3L	0.51	7.88	0.4	4.63e-14	Melanoma;
LUSC	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg17366294	chr4:99064904	C4orf37	0.57	10.0	0.48	9.03e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg25664220	chr3:72788482	NA	-0.69	-11.99	-0.55	8.28e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg11766577	chr21:47581405	C21orf56	-0.41	-5.97	-0.31	6.03e-9	Testicular germ cell tumor;
LUSC	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg04545296	chr12:48745243	ZNF641	0.37	6.72	0.35	7.87e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs11577318	0.579	rs11583205	chr1:26684141	C/A	cg00852783	chr1:26633632	UBXN11	-0.51	-7.1	-0.36	7.4e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.55	0.46	2.95e-19	Prudent dietary pattern;
LUSC	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.15	0.32	2.21e-9	Corneal astigmatism;
LUSC	cis	rs1712517	0.740	rs11191643	chr10:105057561	C/G	cg05636881	chr10:105038444	INA	0.39	6.33	0.33	7.69e-10	Migraine;
LUSC	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg26597838	chr10:835615	NA	0.89	12.27	0.56	8.26e-29	Eosinophil percentage of granulocytes;
LUSC	cis	rs2836633	0.895	rs991816	chr21:40042150	C/A	cg12884169	chr21:40033163	ERG	0.61	12.41	0.56	2.5e-29	Coronary artery disease;
LUSC	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg25251562	chr2:3704773	ALLC	0.54	8.17	0.41	6.53e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-11.87	-0.54	2.4200000000000002e-27	Platelet count;
LUSC	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	12.58	0.57	5.75e-30	Lung cancer in ever smokers;
LUSC	cis	rs7949030	0.964	rs2957122	chr11:62392100	G/C	cg13298116	chr11:62369859	EML3;MTA2	-0.52	-8.68	-0.43	1.75e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg23711669	chr6:146136114	FBXO30	0.85	15.28	0.64	2.33e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4713675	0.505	rs2395450	chr6:33654588	C/T	cg14003231	chr6:33640908	ITPR3	0.32	6.11	0.32	2.85e-9	Plateletcrit;
LUSC	cis	rs12220238	1.000	rs10824129	chr10:76008855	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.3	0.37	2.18e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-9.95	-0.48	1.33e-20	Monocyte count;
LUSC	trans	rs488628	0.848	rs1083825	chr3:118136831	A/T	cg06621744	chr14:37052470	NKX2-8	-0.25	-5.96	-0.31	6.42e-9	White matter integrity (bipolar disorder risk interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08115069	chr19:55866329	COX6B2;FAM71E2	-0.49	-6.21	-0.32	1.59e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07923666	chr12:49932857	KCNH3	-0.53	-6.57	-0.34	1.88e-10	Resting heart rate;
LUSC	cis	rs243505	0.898	rs243543	chr7:148402984	C/G	cg09806900	chr7:148480153	CUL1	-0.47	-6.76	-0.35	6.01e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs227833	1.000	rs227830	chr6:44680555	G/C	cg20913747	chr6:44695427	NA	0.38	5.77	0.3	1.82e-8	Monobrow;
LUSC	trans	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg18335740	chr13:41363409	SLC25A15	0.47	6.83	0.35	4.12e-11	Lewy body disease;
LUSC	cis	rs4961252	0.505	rs6990155	chr8:142098977	C/T	cg09914555	chr8:142094789	NA	0.49	7.47	0.38	6.88e-13	Isovolumetric relaxation time;Response to interferon beta therapy;
LUSC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg16414030	chr3:133502952	NA	-0.39	-5.71	-0.3	2.47e-8	Iron status biomarkers;
LUSC	cis	rs240764	0.658	rs1336251	chr6:101247698	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-6.65	-0.34	1.18e-10	Neuroticism;
LUSC	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg15133208	chr4:90757351	SNCA	-0.52	-7.75	-0.39	1.15e-13	Neuroticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16676300	chr1:155658576	YY1AP1;DAP3	0.45	6.06	0.31	3.62e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.41	5.76	0.3	1.9e-8	Insulin-like growth factors;
LUSC	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg13319975	chr6:146136371	FBXO30	0.49	7.32	0.37	1.88e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	trans	rs9871760	0.956	rs2002913	chr3:126994823	A/G	cg17872838	chr13:52607339	UTP14C	0.35	6.23	0.32	1.44e-9	Whole-brain volume;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25791773	chr11:129910324	NA	-0.4	-6.13	-0.32	2.43e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs12286929	0.600	rs4445669	chr11:115045237	C/T	cg04055981	chr11:115044050	NA	-0.45	-8.27	-0.41	3.18e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.69	11.24	0.52	4.33e-25	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs2742417	0.603	rs1468542	chr3:45779136	A/T	cg10512202	chr3:45649293	LIMD1	-0.36	-6.37	-0.33	6.35e-10	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg13010199	chr12:38710504	ALG10B	0.64	10.02	0.48	7.68e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs73001065	0.591	rs57009615	chr19:19613622	A/G	cg03709012	chr19:19516395	GATAD2A	1.04	10.4	0.49	3.93e-22	LDL cholesterol;
LUSC	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.08	-0.36	8.5e-12	Major depressive disorder;
LUSC	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg18827107	chr12:86230957	RASSF9	0.47	6.97	0.36	1.69e-11	Major depressive disorder;
LUSC	trans	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg26043149	chr18:55253948	FECH	-0.52	-7.6	-0.38	3e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg21573476	chr21:45109991	RRP1B	-0.38	-6.15	-0.32	2.25e-9	Mean corpuscular volume;
LUSC	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg02493740	chr2:85810744	VAMP5	-0.36	-6.47	-0.33	3.41e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.82	0.35	4.2e-11	IgG glycosylation;
LUSC	cis	rs12681287	0.547	rs13249177	chr8:87513034	A/G	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	cis	rs1065852	0.861	rs5758627	chr22:42572547	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.57	9.73	0.47	7.06e-20	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs7202877	0.706	rs8046184	chr16:75411725	T/C	cg04384234	chr16:75411784	CFDP1	-0.65	-9.05	-0.44	1.18e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg05064044	chr6:292385	DUSP22	-0.48	-6.7	-0.34	8.66e-11	Menopause (age at onset);
LUSC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.22	-0.32	1.49e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7681440	0.560	rs67876224	chr4:90808918	T/C	cg06632027	chr4:90757378	SNCA	-0.37	-5.73	-0.3	2.26e-8	Dementia with Lewy bodies;
LUSC	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg05738196	chr6:26577821	NA	0.77	14.74	0.63	3.02e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg21951975	chr1:209979733	IRF6	0.57	8.52	0.42	5.6e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg04036182	chr15:45458818	NA	-0.36	-5.78	-0.3	1.69e-8	Glomerular filtration rate;
LUSC	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg17052675	chr2:3827356	NA	-0.58	-11.38	-0.53	1.42e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	0.9	17.93	0.7	7.5400000000000006e-51	Metabolite levels;
LUSC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	9.41	0.46	8.26e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.34	-0.42	1.93e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9650315	0.733	rs55853952	chr8:57204930	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.33	0.37	1.73e-12	Height;
LUSC	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg05738196	chr6:26577821	NA	0.81	15.2	0.64	4.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg10978503	chr1:24200527	CNR2	0.48	11.15	0.52	9.46e-25	Immature fraction of reticulocytes;
LUSC	cis	rs9463078	0.764	rs3799968	chr6:44805377	C/T	cg25276700	chr6:44698697	NA	-0.3	-6.03	-0.31	4.36e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs9796	0.621	rs537244	chr15:41469313	G/T	cg18705301	chr15:41695430	NDUFAF1	0.48	8.53	0.42	5.24e-16	Menopause (age at onset);
LUSC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.74	-18.16	-0.7	9.16e-52	Prostate cancer;
LUSC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.28	6.17	0.32	1.94e-9	Electroencephalogram traits;
LUSC	cis	rs2637266	1.000	rs2579749	chr10:78332105	T/C	cg18941641	chr10:78392320	NA	0.37	6.58	0.34	1.83e-10	Pulmonary function;
LUSC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.86	-0.35	3.32e-11	Total body bone mineral density;
LUSC	cis	rs2853333	0.934	rs2519961	chr19:35751679	G/A	cg12287945	chr19:35758300	LSR	-0.37	-5.76	-0.3	1.96e-8	Red blood cell count;
LUSC	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.51	-0.34	2.72e-10	Uric acid levels;
LUSC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24110177	chr3:50126178	RBM5	-0.55	-9.05	-0.44	1.22e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg27398817	chr8:82754497	SNX16	-0.66	-8.42	-0.42	1.13e-15	Diastolic blood pressure;
LUSC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg06618935	chr21:46677482	NA	-0.39	-7.81	-0.39	7.65e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg01420254	chr6:26195488	NA	0.65	7.24	0.37	3.03e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs6541297	0.699	rs966333	chr1:230305477	T/C	cg05784532	chr1:230284198	GALNT2	0.59	6.78	0.35	5.46e-11	Coronary artery disease;
LUSC	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.64	-9.66	-0.47	1.29e-19	QT interval;
LUSC	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg12935359	chr14:103987150	CKB	-0.62	-9.96	-0.48	1.28e-20	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg26384229	chr12:38710491	ALG10B	0.68	10.67	0.5	4.61e-23	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06634786	chr22:41940651	POLR3H	-0.53	-6.12	-0.32	2.61e-9	Vitiligo;
LUSC	cis	rs7923609	0.811	rs7919685	chr10:65315800	G/T	cg01631684	chr10:65280961	REEP3	0.41	6.05	0.31	3.84e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg02773041	chr1:40204384	PPIE	0.54	8.26	0.41	3.35e-15	Blood protein levels;
LUSC	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	9.71	0.47	8.32e-20	Migraine;Coronary artery disease;
LUSC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg14552801	chr7:65878734	NA	0.38	5.85	0.3	1.18e-8	Aortic root size;
LUSC	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg22709100	chr7:91322751	NA	0.39	5.86	0.31	1.13e-8	Breast cancer;
LUSC	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.78	10.21	0.49	1.8e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs9487051	0.799	rs830553	chr6:109550017	T/G	cg01475377	chr6:109611718	NA	-0.36	-5.93	-0.31	7.69e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg23649088	chr2:200775458	C2orf69	-0.55	-6.98	-0.36	1.64e-11	Schizophrenia;
LUSC	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	6.73	0.35	7.2e-11	Neuroticism;
LUSC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg27124370	chr19:33622961	WDR88	0.51	7.38	0.37	1.24e-12	Colorectal cancer;
LUSC	trans	rs853679	1.000	rs853694	chr6:28279100	A/T	cg06606381	chr12:133084897	FBRSL1	-0.56	-6.45	-0.33	3.88e-10	Depression;
LUSC	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.06	-0.36	9.78e-12	Coronary artery disease;
LUSC	cis	rs10203711	1.000	rs907107	chr2:239565780	T/C	cg14580085	chr2:239553406	NA	0.41	6.93	0.35	2.24e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg02018176	chr4:1364513	KIAA1530	0.46	6.49	0.33	3.07e-10	Recombination rate (females);
LUSC	trans	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg09904177	chr6:26538194	HMGN4	-0.8	-6.0	-0.31	5.13e-9	Depression;
LUSC	cis	rs28595532	0.748	rs72670248	chr4:119335536	A/C	cg21605333	chr4:119757512	SEC24D	1.02	8.3	0.41	2.57e-15	Cannabis dependence symptom count;
LUSC	cis	rs752010	0.905	rs4525030	chr1:42091307	G/C	cg06885757	chr1:42089581	HIVEP3	0.45	8.98	0.44	2.09e-17	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg13575925	chr12:9217583	LOC144571	0.35	6.43	0.33	4.51e-10	Sjögren's syndrome;
LUSC	cis	rs7903847	0.620	rs11189165	chr10:99123457	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.22	-0.37	3.46e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.72	-0.47	7.83e-20	Platelet count;
LUSC	cis	rs68170813	0.559	rs6971774	chr7:106834139	A/G	cg02696742	chr7:106810147	HBP1	-0.63	-9.88	-0.48	2.3e-20	Coronary artery disease;
LUSC	trans	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21862992	chr11:68658383	NA	0.51	7.94	0.4	3.19e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg12432903	chr7:1882776	MAD1L1	0.53	6.79	0.35	5.03e-11	Bipolar disorder;
LUSC	cis	rs9905704	0.756	rs302860	chr17:56695008	C/A	cg12560992	chr17:57184187	TRIM37	0.58	8.38	0.42	1.49e-15	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg13206674	chr6:150067644	NUP43	0.6	9.5	0.46	4.2e-19	Lung cancer;
LUSC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg08888203	chr3:10149979	C3orf24	0.45	6.83	0.35	4.08e-11	Alzheimer's disease;
LUSC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.42	-7.8	-0.39	7.73e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg23283495	chr1:209979779	IRF6	0.67	7.92	0.4	3.5e-14	Coronary artery disease;
LUSC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.34	-0.33	7.59e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7572644	0.665	rs4665393	chr2:28040276	G/A	cg27432699	chr2:27873401	GPN1	0.57	7.28	0.37	2.47e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs11630290	0.592	rs1039818	chr15:64155296	A/G	cg12036633	chr15:63758958	NA	0.52	6.63	0.34	1.37e-10	Iris characteristics;
LUSC	cis	rs7582720	0.832	rs116426890	chr2:204196618	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	6.88	0.35	2.92e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg02389323	chr16:88786976	FAM38A	1.15	11.14	0.52	1.01e-24	Plateletcrit;
LUSC	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg25214090	chr10:38739885	LOC399744	0.54	8.05	0.4	1.44e-14	Corneal astigmatism;
LUSC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg22484793	chr3:52261325	TLR9	0.29	6.42	0.33	4.55e-10	Electroencephalogram traits;
LUSC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg19318889	chr4:1322082	MAEA	0.55	9.04	0.44	1.26e-17	Longevity;
LUSC	cis	rs3733631	1.000	rs1482582	chr4:104651553	A/C	cg24090629	chr4:104641072	TACR3	-0.46	-5.76	-0.3	1.89e-8	Menarche (age at onset);
LUSC	cis	rs12286929	0.637	rs34138164	chr11:115050127	A/G	cg04055981	chr11:115044050	NA	0.43	7.85	0.39	5.79e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08280861	chr8:58055591	NA	0.59	6.9	0.35	2.64e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg00599273	chr12:58146742	CDK4	0.31	5.96	0.31	6.44e-9	Multiple sclerosis;
LUSC	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	12.31	0.56	5.69e-29	Ileal carcinoids;
LUSC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg24675658	chr1:53192096	ZYG11B	0.75	12.9	0.58	3.69e-31	Monocyte count;
LUSC	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg16558253	chr16:72132732	DHX38	-0.38	-6.07	-0.32	3.45e-9	Fibrinogen levels;
LUSC	cis	rs1775715	0.737	rs2778661	chr10:32159191	C/T	cg03015672	chr10:32216066	ARHGAP12	0.34	6.07	0.31	3.57e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg05738196	chr6:26577821	NA	-0.52	-5.76	-0.3	1.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3807375	1.000	rs3807375	chr7:150667210	C/T	cg10636020	chr7:150656979	KCNH2	-0.3	-6.15	-0.32	2.17e-9	Electrocardiographic traits;QT interval;
LUSC	cis	rs76419734	0.510	rs2544402	chr4:106687733	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.57	-6.64	-0.34	1.3e-10	Post bronchodilator FEV1;
LUSC	cis	rs11585357	0.947	rs11584287	chr1:17607501	G/C	cg08277548	chr1:17600880	PADI3	-0.69	-6.94	-0.36	1.99e-11	Hair shape;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05228964	chr6:170597377	DLL1	-0.48	-8.2	-0.41	5.13e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2235649	0.833	rs9925460	chr16:1849943	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-5.88	-0.31	9.73e-9	Blood metabolite levels;
LUSC	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.33	-0.33	7.91e-10	Dupuytren's disease;
LUSC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg12463550	chr7:65579703	CRCP	0.65	5.92	0.31	7.98e-9	Diabetic kidney disease;
LUSC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.47	-8.63	-0.43	2.47e-16	Urinary metabolites;
LUSC	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.72	10.87	0.51	9.12e-24	Eosinophil percentage of white cells;
LUSC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg18352616	chr4:3374830	RGS12	0.34	6.92	0.35	2.34e-11	Serum sulfate level;
LUSC	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	0.85	13.38	0.59	5.28e-33	Blood protein levels;
LUSC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.25	0.32	1.24e-9	Bipolar disorder;
LUSC	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg20283391	chr11:68216788	NA	-0.61	-8.42	-0.42	1.15e-15	Total body bone mineral density;
LUSC	cis	rs71444571	1	rs71444571	chr12:123771015	G/A	cg13010344	chr12:123464640	ARL6IP4	0.55	6.69	0.34	9.37e-11	Lymphocyte percentage of white cells;
LUSC	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.4	0.59	4.63e-33	Morning vs. evening chronotype;
LUSC	trans	rs11700980	1.000	rs73898415	chr21:30125827	G/A	cg05609335	chr17:75789393	NA	0.41	6.21	0.32	1.59e-9	QRS complex (12-leadsum);
LUSC	cis	rs11676348	0.772	rs12694427	chr2:218945045	C/T	cg00012203	chr2:219082015	ARPC2	-0.46	-7.02	-0.36	1.23e-11	Ulcerative colitis;
LUSC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg25204440	chr1:209979598	IRF6	0.5	5.72	0.3	2.36e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02788857	chr8:22132959	PIWIL2	0.39	7.42	0.38	9.77e-13	Hypertriglyceridemia;
LUSC	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.35e-12	Asthma (childhood onset);
LUSC	cis	rs4776059	1.000	rs12914502	chr15:52911335	A/G	cg22715398	chr15:52968154	KIAA1370	-0.67	-9.95	-0.48	1.38e-20	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.58	0.54	2.74e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.63	7.72	0.39	1.39e-13	Lung function (FEV1/FVC);
LUSC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg19912559	chr1:40204330	PPIE	0.53	8.14	0.41	8.17e-15	Blood protein levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14597223	chr7:56119231	PSPH;CCT6A	-0.41	-5.99	-0.31	5.52e-9	Hepatitis;
LUSC	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg23093090	chr10:104574429	C10orf26	-0.4	-6.8	-0.35	4.88e-11	Arsenic metabolism;
LUSC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg19046167	chr17:80928561	B3GNTL1	0.5	7.08	0.36	8.79e-12	Glycated hemoglobin levels;
LUSC	cis	rs9323205	0.773	rs11625621	chr14:51713659	G/C	cg23942311	chr14:51606299	NA	-0.41	-7.84	-0.39	6.13e-14	Cancer;
LUSC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg25036284	chr2:26402008	FAM59B	-0.68	-9.66	-0.47	1.21e-19	Gut microbiome composition (summer);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg17218495	chr19:11071743	SMARCA4	0.48	7.57	0.38	3.65e-13	Triglycerides;
LUSC	trans	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg18187862	chr3:45730750	SACM1L	0.56	7.07	0.36	9.38e-12	Primary sclerosing cholangitis;
LUSC	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	0.94	17.57	0.69	2.21e-49	Headache;
LUSC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.51	-12.19	-0.55	1.65e-28	Longevity;
LUSC	cis	rs17824933	0.943	rs2074230	chr11:60783804	C/T	cg16817237	chr11:60793675	NA	0.4	6.44	0.33	4.04e-10	Multiple sclerosis;
LUSC	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	0.87	14.27	0.62	2.14e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	trans	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg07393940	chr7:158741817	NA	0.36	6.47	0.33	3.47e-10	Life satisfaction;
LUSC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg20684491	chr1:25596433	NA	0.38	6.03	0.31	4.28e-9	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.92	0.35	2.36e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg18811423	chr2:55921094	PNPT1	-0.65	-9.19	-0.45	4.3e-18	Metabolic syndrome;
LUSC	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg23093090	chr10:104574429	C10orf26	-0.37	-6.79	-0.35	5.23e-11	Arsenic metabolism;
LUSC	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg18964960	chr10:1102726	WDR37	-0.45	-6.13	-0.32	2.54e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg09835421	chr16:68378352	PRMT7	-0.45	-5.71	-0.3	2.45e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg08807101	chr21:30365312	RNF160	0.7	11.11	0.52	1.25e-24	Selective IgA deficiency;
LUSC	cis	rs7112043	0.868	rs10768093	chr11:34777559	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.75	0.3	2.03e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg20849893	chr7:64541193	NA	-0.65	-5.7	-0.3	2.68e-8	Diabetic kidney disease;
LUSC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg16447950	chr5:562315	NA	0.55	7.02	0.36	1.22e-11	Obesity-related traits;
LUSC	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg27284194	chr4:1044797	NA	-0.49	-8.16	-0.41	6.69e-15	Recombination rate (males);
LUSC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	0.88	12.29	0.56	7.03e-29	Vitiligo;
LUSC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.81	14.38	0.62	8.18e-37	Blood protein levels;
LUSC	cis	rs2742417	1.000	rs17328701	chr3:45734258	A/G	cg09608765	chr3:45636137	LIMD1	-0.37	-7.23	-0.37	3.35e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg06238570	chr21:40685208	BRWD1	-0.63	-10.57	-0.5	1.01e-22	Cognitive function;
LUSC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg12165864	chr7:66369176	NA	-0.53	-7.07	-0.36	8.93e-12	Corneal structure;
LUSC	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg05855489	chr10:104503620	C10orf26	0.53	8.09	0.4	1.11e-14	Arsenic metabolism;
LUSC	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg19682013	chr15:45996608	NA	0.38	5.74	0.3	2.12e-8	Waist circumference;Weight;
LUSC	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg03929089	chr4:120376271	NA	0.74	6.91	0.35	2.4e-11	Axial length;
LUSC	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.77	-0.35	5.87e-11	Response to antipsychotic treatment;
LUSC	cis	rs2219968	0.962	rs62508224	chr8:78941659	C/T	cg00738934	chr8:78996279	NA	0.39	6.97	0.36	1.66e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg22823121	chr1:150693482	HORMAD1	0.55	7.96	0.4	2.65e-14	Melanoma;
LUSC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg11812906	chr14:75593930	NEK9	0.67	11.39	0.53	1.31e-25	Height;
LUSC	trans	rs67133203	0.799	rs12828536	chr12:51426035	C/T	cg17484237	chr5:156536107	HAVCR2	0.44	5.97	0.31	6.2e-9	Urinary tract infection frequency;
LUSC	trans	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg02800362	chr5:177631904	HNRNPAB	0.88	13.12	0.58	5.29e-32	Obesity-related traits;
LUSC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23281280	chr6:28129359	ZNF389	0.44	5.73	0.3	2.27e-8	Depression;
LUSC	cis	rs17433780	0.897	rs12142922	chr1:89489915	A/G	cg09516651	chr1:89888402	LOC400759	0.58	9.97	0.48	1.15e-20	Carotid intima media thickness;
LUSC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-16.3	-0.67	2.29e-44	Blood trace element (Zn levels);
LUSC	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg19682013	chr15:45996608	NA	0.39	6.04	0.31	4.13e-9	Waist circumference;Weight;
LUSC	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg19628046	chr18:33552617	C18orf21	0.52	6.14	0.32	2.28e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs56399783	0.901	rs79932907	chr7:2827901	C/G	cg19731401	chr7:2775893	GNA12	0.68	9.34	0.46	1.39e-18	Childhood ear infection;
LUSC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg22800045	chr5:56110881	MAP3K1	-0.4	-5.66	-0.3	3.21e-8	Coronary artery disease;
LUSC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.45	0.38	8.3e-13	Bipolar disorder;
LUSC	cis	rs2273669	0.588	rs6568555	chr6:109331777	A/G	cg05315195	chr6:109294784	ARMC2	-0.53	-5.89	-0.31	9.28e-9	Prostate cancer;
LUSC	cis	rs56399783	0.901	rs17241904	chr7:2875574	C/T	cg19731401	chr7:2775893	GNA12	0.69	9.31	0.45	1.8e-18	Childhood ear infection;
LUSC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg21285383	chr16:89894308	SPIRE2	0.33	6.82	0.35	4.21e-11	Vitiligo;
LUSC	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg07606381	chr6:8435919	SLC35B3	-0.72	-11.75	-0.54	6.6e-27	Motion sickness;
LUSC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg03188948	chr7:1209495	NA	0.45	6.05	0.31	3.91e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-1.04	-23.21	-0.79	1.25e-71	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1595825	0.891	rs78198610	chr2:198522769	T/C	cg00982548	chr2:198649783	BOLL	-0.52	-6.63	-0.34	1.34e-10	Ulcerative colitis;
LUSC	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg03732007	chr1:2071316	PRKCZ	0.59	10.77	0.51	2.04e-23	Height;
LUSC	cis	rs2637266	0.935	rs2583048	chr10:78404507	C/G	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.93e-13	Pulmonary function;
LUSC	cis	rs738322	0.532	rs9622746	chr22:38564041	C/G	cg25457927	chr22:38595422	NA	-0.35	-6.67	-0.34	1.09e-10	Cutaneous nevi;
LUSC	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.77e-22	Eye color traits;
LUSC	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	6.07	0.32	3.52e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs7589342	0.839	rs1465639	chr2:106439181	T/C	cg16077055	chr2:106428750	NCK2	0.37	7.0	0.36	1.43e-11	Addiction;
LUSC	cis	rs7202877	0.610	rs11646418	chr16:75367585	G/C	cg03315344	chr16:75512273	CHST6	0.43	6.01	0.31	4.83e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg01629716	chr15:45996671	NA	-0.41	-6.1	-0.32	2.85e-9	Waist circumference;Weight;
LUSC	cis	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg20368463	chr18:77673604	PQLC1	0.48	6.74	0.35	7.01e-11	Schizophrenia;
LUSC	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg17385448	chr1:15911702	AGMAT	0.37	6.14	0.32	2.41e-9	Systolic blood pressure;
LUSC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs17767294	0.541	rs733743	chr6:28327371	C/G	cg08851530	chr6:28072375	NA	-0.93	-7.02	-0.36	1.23e-11	Parkinson's disease;
LUSC	cis	rs2348418	0.715	rs11049720	chr12:28720410	A/G	cg13890972	chr12:28721907	NA	-0.39	-6.87	-0.35	3.24e-11	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg13010199	chr12:38710504	ALG10B	0.7	10.77	0.51	1.97e-23	Bladder cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20481816	chr11:47448111	PSMC3	-0.47	-7.2	-0.37	4.06e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg05855489	chr10:104503620	C10orf26	0.58	9.34	0.46	1.41e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg22963979	chr7:1858916	MAD1L1	0.5	7.55	0.38	4.2e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg24217984	chr15:93633278	RGMA	0.35	5.94	0.31	6.97e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs6687430	0.526	rs12127400	chr1:10613660	C/T	cg17425144	chr1:10567563	PEX14	0.61	11.97	0.55	9.92e-28	Hand grip strength;
LUSC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23158103	chr7:148848205	ZNF398	-0.47	-7.71	-0.39	1.5e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg14552801	chr7:65878734	NA	-0.37	-5.87	-0.31	1.08e-8	Aortic root size;
LUSC	cis	rs9638182	0.666	rs14415	chr7:72984780	T/C	cg07452164	chr7:72993570	TBL2	0.46	6.5	0.34	2.95e-10	Triglycerides;
LUSC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg07952391	chr2:88470173	THNSL2	0.76	6.71	0.34	8.5e-11	Plasma clusterin levels;
LUSC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg20821713	chr7:1055600	C7orf50	-0.45	-6.22	-0.32	1.47e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg09526685	chr4:187126073	CYP4V2	0.66	6.53	0.34	2.44e-10	Blood protein levels;
LUSC	cis	rs7122539	0.506	rs10791896	chr11:66689240	G/T	cg24851651	chr11:66362959	CCS	0.45	7.76	0.39	1.03e-13	HIV-1 susceptibility;
LUSC	cis	rs367943	0.712	rs7731465	chr5:112687385	A/G	cg12552261	chr5:112820674	MCC	-0.38	-6.29	-0.33	9.9e-10	Type 2 diabetes;
LUSC	cis	rs3741151	1.000	rs76610873	chr11:73084387	C/T	cg17517138	chr11:73019481	ARHGEF17	1.0	8.46	0.42	8.69e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-1.0	-16.37	-0.67	1.21e-44	Alcohol dependence;Nicotine use;
LUSC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.75	0.51	2.47e-23	Hip circumference adjusted for BMI;
LUSC	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg13902645	chr11:5959945	NA	-0.57	-7.89	-0.4	4.46e-14	DNA methylation (variation);
LUSC	cis	rs13266463	0.830	rs6983790	chr8:143406575	A/G	cg16886403	chr8:143471632	TSNARE1	0.62	8.94	0.44	2.76e-17	Schizophrenia;
LUSC	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg20933634	chr6:27740509	NA	0.4	5.87	0.31	1.06e-8	Parkinson's disease;
LUSC	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05731713	chr7:157510257	PTPRN2	0.49	9.42	0.46	7.82e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg23241863	chr10:102295624	HIF1AN	0.48	5.73	0.3	2.29e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.36	0.42	1.69e-15	Tonsillectomy;
LUSC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg01879757	chr17:41196368	BRCA1	-0.47	-7.21	-0.37	3.83e-12	Menopause (age at onset);
LUSC	cis	rs1982963	0.585	rs61971558	chr14:52496024	G/A	cg10843707	chr14:52510701	NID2	0.46	6.29	0.33	1.01e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg23719950	chr11:63933701	MACROD1	-0.62	-7.41	-0.38	1.05e-12	Mean platelet volume;
LUSC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.32	0.56	5.39e-29	Prudent dietary pattern;
LUSC	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg27490568	chr2:178487706	NA	0.39	5.74	0.3	2.14e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18738857	chr19:3606974	TBXA2R	0.4	6.55	0.34	2.2e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg06600287	chr1:53387719	ECHDC2	-0.3	-5.9	-0.31	9.03e-9	Monocyte count;
LUSC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg13047869	chr3:10149882	C3orf24	0.58	8.28	0.41	3.07e-15	Alzheimer's disease;
LUSC	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg01884057	chr2:25150051	NA	-0.38	-8.63	-0.43	2.58e-16	Body mass index;
LUSC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.76	-14.02	-0.61	1.9e-35	Age at first birth;
LUSC	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg07541023	chr7:19748670	TWISTNB	0.7	7.92	0.4	3.55e-14	Thyroid stimulating hormone;
LUSC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-11.86	-0.54	2.59e-27	Extrinsic epigenetic age acceleration;
LUSC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-13.32	-0.59	9.22e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.5	-5.99	-0.31	5.45e-9	Crohn's disease;
LUSC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.59	0.34	1.74e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg25767906	chr1:53392781	SCP2	-0.5	-9.21	-0.45	3.66e-18	Monocyte count;
LUSC	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg04398451	chr17:18023971	MYO15A	0.47	7.48	0.38	6.71e-13	Total body bone mineral density;
LUSC	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg22705602	chr4:152727874	NA	-0.39	-8.52	-0.42	5.42e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.59	-0.38	3.29e-13	Mood instability;
LUSC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-25.08	-0.81	8.21e-79	Height;
LUSC	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg17764715	chr19:33622953	WDR88	0.59	7.9	0.4	4.06e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1847202	0.517	rs13062803	chr3:72951840	T/A	cg25664220	chr3:72788482	NA	-0.43	-7.76	-0.39	1.07e-13	Motion sickness;
LUSC	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-1.06	-12.75	-0.57	1.28e-30	Schizophrenia;
LUSC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg11608241	chr8:8085544	FLJ10661	0.44	6.68	0.34	1.01e-10	Systolic blood pressure;
LUSC	cis	rs9646944	0.501	rs12712144	chr2:102995600	C/G	cg20060108	chr2:102954350	IL1RL1	0.47	6.32	0.33	8.2e-10	Blood protein levels;
LUSC	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg14664628	chr15:75095509	CSK	-1.01	-17.86	-0.7	1.48e-50	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-6.05	-0.31	3.94e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-6.87	-0.35	3.16e-11	Renal function-related traits (BUN);
LUSC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg06637938	chr14:75390232	RPS6KL1	0.49	7.57	0.38	3.61e-13	Height;
LUSC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg18904891	chr8:8559673	CLDN23	0.38	5.77	0.3	1.8e-8	Mood instability;
LUSC	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg05373962	chr22:49881684	NA	-0.41	-8.5	-0.42	6.28e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.56	7.86	0.39	5.49e-14	Gut microbiome composition (summer);
LUSC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg17971929	chr21:40555470	PSMG1	-0.62	-10.27	-0.49	1.06e-21	Cognitive function;
LUSC	cis	rs228769	0.673	rs375677	chr17:42108974	A/C	cg19774624	chr17:42201019	HDAC5	0.62	7.76	0.39	1.02e-13	Bone mineral density (hip);Bone mineral density (spine);
LUSC	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg13010199	chr12:38710504	ALG10B	0.56	8.45	0.42	9.2e-16	Morning vs. evening chronotype;
LUSC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.63	8.37	0.42	1.61e-15	High light scatter reticulocyte count;
LUSC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.69	12.31	0.56	5.48e-29	Diastolic blood pressure;
LUSC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.95	0.31	6.72e-9	Menopause (age at onset);
LUSC	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.86	-0.31	1.14e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs12210905	0.925	rs11961179	chr6:26994157	C/G	cg11837749	chr1:55047332	ACOT11	0.57	6.13	0.32	2.51e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg04352962	chr1:209979756	IRF6	0.54	5.76	0.3	1.88e-8	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01614598	chr2:38152364	FAM82A1	0.42	6.12	0.32	2.6e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	8.62	0.43	2.68e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2286885	0.965	rs10987301	chr9:129250688	T/C	cg15282417	chr9:129245246	FAM125B	-0.37	-6.15	-0.32	2.25e-9	Intraocular pressure;
LUSC	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg06002616	chr8:101225028	SPAG1	0.42	6.99	0.36	1.48e-11	Atrioventricular conduction;
LUSC	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg09904177	chr6:26538194	HMGN4	0.66	11.93	0.55	1.38e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg05425664	chr17:57184151	TRIM37	0.52	7.68	0.39	1.75e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg10483660	chr13:112241077	NA	-0.38	-7.05	-0.36	1.04e-11	Menarche (age at onset);
LUSC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg22535103	chr8:58192502	C8orf71	-0.78	-7.97	-0.4	2.62e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg02018176	chr4:1364513	KIAA1530	0.54	9.18	0.45	4.49e-18	Obesity-related traits;
LUSC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg10523860	chr14:103875565	MARK3	-0.36	-5.73	-0.3	2.2e-8	Body mass index;
LUSC	trans	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.38	0.42	1.46e-15	Ulcerative colitis;
LUSC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.56	0.65	1.98e-41	Platelet count;
LUSC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg06363034	chr20:62225388	GMEB2	-0.45	-7.71	-0.39	1.47e-13	Glioblastoma;
LUSC	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg23093090	chr10:104574429	C10orf26	-0.39	-7.44	-0.38	8.66e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19048535	chr5:89770306	MBLAC2;POLR3G	-0.42	-6.2	-0.32	1.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg11766577	chr21:47581405	C21orf56	0.41	5.9	0.31	8.81e-9	Testicular germ cell tumor;
LUSC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	6.72	0.35	7.7e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg21775007	chr8:11205619	TDH	0.52	7.66	0.39	2e-13	Mood instability;
LUSC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg13683864	chr3:40499215	RPL14	0.9	15.13	0.64	9.27e-40	Renal cell carcinoma;
LUSC	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg10845886	chr2:3471009	TTC15	-0.61	-7.83	-0.39	6.35e-14	Neurofibrillary tangles;
LUSC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.01	0.31	4.93e-9	Personality dimensions;
LUSC	cis	rs10193935	0.901	rs12620021	chr2:42477034	T/C	cg27598129	chr2:42591480	NA	-0.62	-8.34	-0.42	1.98e-15	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.94	0.55	1.29e-27	Exhaled nitric oxide output;
LUSC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.56	-8.52	-0.42	5.47e-16	Total body bone mineral density;
LUSC	cis	rs1941023	0.584	rs4938941	chr11:60173360	C/T	cg08716584	chr11:60157161	MS4A7	0.62	11.57	0.53	2.84e-26	Congenital heart disease (maternal effect);
LUSC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	10.78	0.51	1.84e-23	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.38e-9	Bladder cancer;
LUSC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg03388025	chr16:89894329	SPIRE2	0.34	7.05	0.36	1.03e-11	Vitiligo;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14907986	chr6:24645932	KIAA0319	0.38	5.97	0.31	6.21e-9	Triglycerides;
LUSC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg21665744	chr7:39171113	POU6F2	0.45	7.33	0.37	1.79e-12	IgG glycosylation;
LUSC	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.34	-0.37	1.65e-12	Psoriasis;
LUSC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg06740227	chr12:86229804	RASSF9	0.45	7.15	0.36	5.35e-12	Major depressive disorder;
LUSC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg22823121	chr1:150693482	HORMAD1	0.6	9.37	0.46	1.11e-18	Tonsillectomy;
LUSC	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg05985134	chr18:33552581	C18orf21	0.51	6.87	0.35	3.19e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-6.99	-0.36	1.53e-11	Menarche (age at onset);
LUSC	cis	rs6500395	1.000	rs924476	chr16:48556847	C/T	cg04672837	chr16:48644449	N4BP1	0.46	6.73	0.35	7.23e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs611744	0.658	rs2443775	chr8:109062481	A/G	cg18478394	chr8:109455254	TTC35	-0.43	-6.26	-0.32	1.2e-9	Dupuytren's disease;
LUSC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg04166393	chr7:2884313	GNA12	-0.46	-6.36	-0.33	6.71e-10	Height;
LUSC	cis	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg21775007	chr8:11205619	TDH	0.44	5.95	0.31	6.71e-9	Monocyte count;
LUSC	cis	rs708547	1.000	rs2412770	chr4:57794660	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.48	-5.88	-0.31	9.93e-9	Response to bleomycin (chromatid breaks);
LUSC	cis	rs2219968	0.926	rs13258410	chr8:78924203	T/C	cg00738934	chr8:78996279	NA	0.39	6.98	0.36	1.58e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2985334	0.558	rs204063	chr1:29196466	T/G	cg05928980	chr1:29567425	PTPRU	0.3	5.67	0.3	3.16e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.71	-0.34	8.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg03522245	chr20:25566470	NINL	0.35	5.66	0.3	3.26e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs240764	0.621	rs4840154	chr6:101225723	A/C	cg09795085	chr6:101329169	ASCC3	-0.45	-6.34	-0.33	7.38e-10	Neuroticism;
LUSC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg02117656	chr17:79614917	TSPAN10	0.3	5.67	0.3	3.16e-8	Eye color traits;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26898955	chr1:84945537	RPF1	-0.43	-6.0	-0.31	5.27e-9	Hepatitis;
LUSC	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg11553311	chr5:66541588	NA	0.34	6.33	0.33	7.87e-10	Breast cancer;
LUSC	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg22491629	chr6:157744540	C6orf35	-0.61	-7.52	-0.38	5.14e-13	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.56	-10.24	-0.49	1.39e-21	Type 2 diabetes;
LUSC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	15.98	0.66	4.1e-43	Platelet count;
LUSC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	11.39	0.53	1.28e-25	Cognitive test performance;
LUSC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg16629158	chr2:122042988	TFCP2L1	0.37	5.97	0.31	5.99e-9	Mosquito bite size;
LUSC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs6977660	0.714	rs12333747	chr7:19814394	G/A	cg07541023	chr7:19748670	TWISTNB	0.66	7.21	0.37	3.71e-12	Thyroid stimulating hormone;
LUSC	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg05985134	chr18:33552581	C18orf21	0.53	7.18	0.37	4.43e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg10862848	chr6:42927986	GNMT	-0.28	-6.67	-0.34	1.08e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs983392	0.680	rs7929589	chr11:59975078	C/T	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.23	-0.32	1.4e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6690583	0.623	rs6672362	chr1:85454881	C/G	cg11262906	chr1:85462892	MCOLN2	0.68	6.56	0.34	2.02e-10	Serum sulfate level;
LUSC	trans	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg03973167	chr4:185394988	IRF2	0.44	6.14	0.32	2.28e-9	Schizophrenia;
LUSC	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg13042288	chr15:90349979	ANPEP	-0.46	-6.6	-0.34	1.63e-10	Uric acid levels;
LUSC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.8	-13.21	-0.59	2.42e-32	Aortic root size;
LUSC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	16.09	0.66	1.53e-43	Platelet count;
LUSC	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.72e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg13683864	chr3:40499215	RPL14	-1.11	-21.4	-0.76	1.4e-64	Renal cell carcinoma;
LUSC	cis	rs17604090	0.557	rs10279965	chr7:29717082	C/G	cg19413766	chr7:29689036	LOC646762	-0.55	-7.46	-0.38	7.46e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07208908	chr17:79818639	P4HB	-0.46	-6.04	-0.31	4.11e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.68	0.39	1.82e-13	Prudent dietary pattern;
LUSC	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg25930673	chr12:123319894	HIP1R	-0.6	-6.1	-0.32	2.93e-9	Schizophrenia;
LUSC	cis	rs6977660	1.000	rs6943114	chr7:19818354	G/T	cg07541023	chr7:19748670	TWISTNB	0.5	5.74	0.3	2.18e-8	Thyroid stimulating hormone;
LUSC	cis	rs1957429	0.520	rs72625646	chr14:65343809	C/A	cg23373153	chr14:65346875	NA	-0.9	-7.84	-0.39	5.92e-14	Pediatric areal bone mineral density (radius);
LUSC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg19747945	chr6:42946146	PEX6	-0.35	-5.88	-0.31	9.99e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9341808	0.754	rs6907729	chr6:81004922	A/T	cg08355045	chr6:80787529	NA	-0.55	-9.75	-0.47	6.35e-20	Sitting height ratio;
LUSC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	21.98	0.77	7.08e-67	Prudent dietary pattern;
LUSC	cis	rs250677	0.522	rs10477400	chr5:148359598	T/C	cg18129178	chr5:148520854	ABLIM3	0.52	7.36	0.37	1.48e-12	Breast cancer;
LUSC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg03351412	chr1:154909251	PMVK	0.47	7.21	0.37	3.74e-12	Prostate cancer;
LUSC	cis	rs193541	0.632	rs62377425	chr5:122332625	C/G	cg19077854	chr5:122220652	SNX24	-0.39	-8.07	-0.4	1.3e-14	Glucose homeostasis traits;
LUSC	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg15309053	chr8:964076	NA	0.4	7.97	0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg24631222	chr15:78858424	CHRNA5	-0.7	-9.51	-0.46	3.96e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg19318889	chr4:1322082	MAEA	-0.54	-8.76	-0.43	1.02e-16	Obesity-related traits;
LUSC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.64	9.71	0.47	8.77e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs897080	0.515	rs698795	chr2:44689326	C/A	cg00619915	chr2:44497795	NA	-0.44	-6.05	-0.31	3.98e-9	Height;
LUSC	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg07169764	chr2:136633963	MCM6	1.04	13.97	0.61	3.08e-35	Corneal structure;
LUSC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.61	-0.57	4.37e-30	Chronic sinus infection;
LUSC	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.6	10.06	0.48	5.85e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.75	10.76	0.51	2.17e-23	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg13042288	chr15:90349979	ANPEP	-0.49	-7.08	-0.36	8.35e-12	Uric acid levels;
LUSC	cis	rs4660531	1.000	rs4660531	chr1:41839822	G/T	cg08462924	chr1:41848221	NA	0.45	6.76	0.35	6.19e-11	Bipolar disorder;
LUSC	cis	rs9399401	0.626	rs9373347	chr6:142779885	C/T	cg03128060	chr6:142623767	GPR126	0.51	8.74	0.43	1.12e-16	Chronic obstructive pulmonary disease;
LUSC	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.55	10.47	0.5	2.33e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg16797656	chr11:68205561	LRP5	0.45	7.76	0.39	1.02e-13	Total body bone mineral density;
LUSC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg25566285	chr7:158114605	PTPRN2	0.31	5.69	0.3	2.84e-8	Calcium levels;
LUSC	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg14664628	chr15:75095509	CSK	-0.52	-7.8	-0.39	7.81e-14	Breast cancer;
LUSC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.53	-7.91	-0.4	3.94e-14	Colorectal cancer;
LUSC	cis	rs11247915	0.501	rs34209692	chr1:26608782	C/T	cg15628303	chr1:26608928	UBXN11	0.49	8.0	0.4	2.01e-14	Obesity-related traits;
LUSC	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg27284194	chr4:1044797	NA	0.48	7.84	0.39	6.24e-14	Recombination rate (males);
LUSC	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg27398640	chr15:77910606	LINGO1	-0.29	-5.85	-0.3	1.17e-8	Type 2 diabetes;
LUSC	cis	rs3820928	1.000	rs2396433	chr2:227772502	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.85	-0.39	5.89e-14	Pulmonary function;
LUSC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.89	-0.31	9.56e-9	Tonsillectomy;
LUSC	cis	rs2274273	0.516	rs10136972	chr14:55370285	A/G	cg04306507	chr14:55594613	LGALS3	0.32	6.0	0.31	5.19e-9	Protein biomarker;
LUSC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	trans	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg06521331	chr12:34319734	NA	-0.39	-6.0	-0.31	5.08e-9	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20564458	chr20:33999865	UQCC	-0.45	-6.68	-0.34	9.94e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs12153263	0.504	rs4866177	chr5:20274081	A/G	cg07262001	chr22:42734088	NA	0.32	5.95	0.31	6.64e-9	Obstetric antiphospholipid syndrome;
LUSC	cis	rs57590327	0.503	rs12497231	chr3:81519291	A/G	cg07356753	chr3:81810745	GBE1	0.45	6.02	0.31	4.68e-9	Extraversion;
LUSC	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg21366198	chr4:185655624	MLF1IP	-0.42	-5.87	-0.31	1.05e-8	Kawasaki disease;
LUSC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	5.74	0.3	2.13e-8	Aortic root size;
LUSC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg05926928	chr17:57297772	GDPD1	-0.46	-6.43	-0.33	4.49e-10	Schizophrenia;
LUSC	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.15	21.64	0.76	1.53e-65	Exhaled nitric oxide output;
LUSC	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg24851651	chr11:66362959	CCS	-0.37	-5.92	-0.31	8.01e-9	Educational attainment (years of education);
LUSC	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg27068330	chr11:65405492	SIPA1	0.54	7.6	0.38	2.95e-13	Urate levels;
LUSC	cis	rs908922	0.924	rs6669608	chr1:152475233	A/G	cg20991723	chr1:152506922	NA	0.5	8.1	0.41	1.07e-14	Hair morphology;
LUSC	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg16230307	chr14:35515116	FAM177A1	0.6	7.37	0.37	1.37e-12	Psoriasis;
LUSC	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg00792783	chr2:198669748	PLCL1	0.43	5.86	0.31	1.12e-8	Dermatomyositis;
LUSC	cis	rs6484504	0.817	rs67707190	chr11:31210500	A/G	cg14844989	chr11:31128820	NA	-0.47	-6.74	-0.35	7.15e-11	Red blood cell count;
LUSC	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg04362960	chr10:104952993	NT5C2	0.61	9.81	0.47	3.95e-20	Arsenic metabolism;
LUSC	cis	rs34638657	0.518	rs7196560	chr16:82168162	A/T	cg09439754	chr16:82129088	HSD17B2	-0.32	-5.88	-0.31	9.86e-9	Lung adenocarcinoma;
LUSC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg26566898	chr11:117069891	TAGLN	0.31	5.85	0.3	1.16e-8	Blood protein levels;
LUSC	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg18129178	chr5:148520854	ABLIM3	-0.7	-10.7	-0.51	3.48e-23	Breast cancer;
LUSC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.38	-0.33	5.89e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs981844	0.775	rs62323976	chr4:154739032	A/G	cg14289246	chr4:154710475	SFRP2	0.46	6.25	0.32	1.23e-9	Response to statins (LDL cholesterol change);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14913181	chr1:6845123	CAMTA1	0.44	6.57	0.34	1.88e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg18132916	chr6:79620363	NA	-0.38	-5.69	-0.3	2.82e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg04586622	chr2:25135609	ADCY3	0.42	8.99	0.44	1.88e-17	Body mass index;
LUSC	cis	rs4842666	0.915	rs11105376	chr12:90088768	G/A	cg00757033	chr12:89920650	WDR51B	0.46	6.44	0.33	4.26e-10	Blood pressure;
LUSC	cis	rs977987	0.806	rs35787595	chr16:75466847	G/C	cg03315344	chr16:75512273	CHST6	0.5	9.52	0.46	3.5e-19	Dupuytren's disease;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	0.94	18.91	0.72	1.02e-54	Menarche (age at onset);
LUSC	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg02023728	chr11:77925099	USP35	0.52	7.1	0.36	7.33e-12	Testicular germ cell tumor;
LUSC	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg12257692	chr3:49977190	RBM6	-0.21	-5.83	-0.3	1.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10416265	0.528	rs28654374	chr19:33613610	G/A	cg17764715	chr19:33622953	WDR88	0.6	6.37	0.33	6.44e-10	Bone properties (heel);
LUSC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg13560548	chr3:10150139	C3orf24	0.53	7.55	0.38	4.1e-13	Alzheimer's disease;
LUSC	cis	rs7267979	0.528	rs2387976	chr20:25599560	C/T	cg03522245	chr20:25566470	NINL	-0.4	-6.12	-0.32	2.59e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.73	0.63	3.45e-38	Platelet count;
LUSC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg13319975	chr6:146136371	FBXO30	0.5	7.44	0.38	8.58e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg06238570	chr21:40685208	BRWD1	-0.58	-8.82	-0.43	6.44e-17	Menarche (age at onset);
LUSC	cis	rs12210905	0.925	rs72838262	chr6:27008517	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-5.96	-0.31	6.58e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.2	-0.32	1.7e-9	Resting heart rate;
LUSC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-0.89	-11.39	-0.53	1.27e-25	Diabetic retinopathy;
LUSC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	11.03	0.52	2.5e-24	Hemoglobin concentration;
LUSC	cis	rs6076065	0.748	rs2180139	chr20:23405281	G/A	cg11657817	chr20:23433608	CST11	0.52	10.38	0.49	4.59e-22	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs72781680	0.678	rs2551341	chr2:24014778	G/T	cg08917208	chr2:24149416	ATAD2B	0.6	6.91	0.35	2.44e-11	Lymphocyte counts;
LUSC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	13.04	0.58	1.09e-31	Cognitive test performance;
LUSC	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.96	0.31	6.33e-9	Rheumatoid arthritis;
LUSC	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg24558204	chr6:135376177	HBS1L	0.59	9.2	0.45	3.94e-18	Red blood cell count;
LUSC	cis	rs1385374	0.858	rs10847692	chr12:129289679	A/T	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.78	-0.35	5.5e-11	Systemic lupus erythematosus;
LUSC	cis	rs2019216	0.524	rs1518049	chr17:21922055	C/T	cg22648282	chr17:21454238	C17orf51	-0.49	-7.28	-0.37	2.48e-12	Pelvic organ prolapse;
LUSC	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg17749961	chr2:30669863	LCLAT1	0.69	7.93	0.4	3.4e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg09877947	chr5:131593287	PDLIM4	0.48	7.93	0.4	3.33e-14	Breast cancer;
LUSC	cis	rs62400317	0.556	rs10948196	chr6:44959384	A/T	cg18551225	chr6:44695536	NA	-0.35	-6.01	-0.31	4.81e-9	Total body bone mineral density;
LUSC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.55	-8.0	-0.4	2.05e-14	Alzheimer's disease (late onset);
LUSC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.76	9.12	0.45	7.41e-18	Body mass index;
LUSC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg05802129	chr4:122689817	NA	0.36	6.52	0.34	2.6e-10	Type 2 diabetes;
LUSC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg04287289	chr16:89883240	FANCA	-0.77	-13.46	-0.59	2.72e-33	Vitiligo;
LUSC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg00409905	chr10:38381863	ZNF37A	0.35	5.81	0.3	1.42e-8	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03576123	chr11:487126	PTDSS2	0.94	10.37	0.49	4.88e-22	Body mass index;
LUSC	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg02997394	chr19:33096574	ANKRD27	0.81	8.46	0.42	8.62e-16	Eosinophilic esophagitis;
LUSC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg07741184	chr6:167504864	NA	0.41	7.26	0.37	2.72e-12	Crohn's disease;
LUSC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg14343924	chr8:8086146	FLJ10661	0.4	5.7	0.3	2.69e-8	Mood instability;
LUSC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg11247378	chr22:39784982	NA	0.62	10.92	0.51	6.12e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg15557168	chr22:42548783	NA	0.48	7.39	0.38	1.16e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg04450456	chr4:17643702	FAM184B	0.37	6.22	0.32	1.47e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.51	-10.3	-0.49	9.03e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg14159672	chr1:205819179	PM20D1	0.82	14.69	0.63	4.76e-38	Menarche (age at onset);
LUSC	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.71	11.67	0.54	1.31e-26	Eye color traits;
LUSC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.93	14.88	0.63	9.31e-39	Multiple sclerosis;
LUSC	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg20891558	chr2:74357851	NA	0.75	12.5	0.56	1.15e-29	Gestational age at birth (maternal effect);
LUSC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg05234568	chr11:5960015	NA	-0.6	-8.57	-0.42	3.84e-16	DNA methylation (variation);
LUSC	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg25482853	chr8:67687455	SGK3	1.18	16.97	0.68	5.1e-47	Lung disease severity in cystic fibrosis;
LUSC	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.71	8.87	0.44	4.61e-17	Type 2 diabetes;
LUSC	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg12935359	chr14:103987150	CKB	-0.54	-8.41	-0.42	1.18e-15	Body mass index;
LUSC	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.55	0.38	4.06e-13	Iron status biomarkers;
LUSC	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg08917208	chr2:24149416	ATAD2B	0.96	10.07	0.48	5.08e-21	Lymphocyte counts;
LUSC	trans	rs11165623	0.792	rs1125358	chr1:96971800	T/C	cg10631902	chr5:14652156	NA	-0.48	-7.37	-0.37	1.37e-12	Hip circumference;Waist circumference;
LUSC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.15	0.55	2.19e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00684032	chr4:1343700	KIAA1530	0.38	6.6	0.34	1.63e-10	Obesity-related traits;
LUSC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	1.05	14.65	0.63	7.17e-38	Breast cancer;
LUSC	cis	rs2410601	0.520	rs1426916	chr8:18882501	C/G	cg19414122	chr8:18896631	NA	0.29	5.81	0.3	1.48e-8	Urinary albumin excretion rate in type 1 diabetes;
LUSC	cis	rs9807989	0.801	rs10176664	chr2:102976172	G/A	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.5e-9	Asthma;
LUSC	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12760731	0.623	rs721289	chr1:178395682	A/G	cg00404053	chr1:178313656	RASAL2	0.47	5.67	0.3	3.15e-8	Obesity-related traits;
LUSC	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg18105134	chr13:113819100	PROZ	0.66	9.91	0.48	1.79e-20	Platelet distribution width;
LUSC	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.72	11.47	0.53	6.95e-26	Sudden cardiac arrest;
LUSC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg25767906	chr1:53392781	SCP2	-0.34	-5.96	-0.31	6.46e-9	Monocyte count;
LUSC	trans	rs72674100	1.000	rs112113294	chr4:97967853	G/T	cg09670535	chr1:18959427	PAX7	-0.64	-6.12	-0.32	2.68e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.45	-7.46	-0.38	7.37e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.81	-15.75	-0.65	3.4e-42	Inflammatory bowel disease;
LUSC	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg09085632	chr11:111637200	PPP2R1B	0.93	12.48	0.56	1.29e-29	Primary sclerosing cholangitis;
LUSC	cis	rs77633900	0.772	rs157788	chr15:76806011	T/C	cg21673338	chr15:77095150	SCAPER	-0.71	-6.12	-0.32	2.65e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg02403541	chr12:121454288	C12orf43	0.59	8.24	0.41	3.99e-15	N-glycan levels;
LUSC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.42	-6.14	-0.32	2.4e-9	IgG glycosylation;
LUSC	cis	rs2932538	0.614	rs6537741	chr1:113085175	A/C	cg22162597	chr1:113214053	CAPZA1	-0.63	-7.79	-0.39	8.4e-14	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg03948781	chr1:205179583	DSTYK	0.32	6.18	0.32	1.84e-9	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.08	0.52	1.71e-24	Colorectal cancer;
LUSC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg06219351	chr7:158114137	PTPRN2	-0.52	-9.51	-0.46	3.88e-19	Calcium levels;
LUSC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.13	-0.36	6.11e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	1.14	18.04	0.7	2.84e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs12249377	0.519	rs35987367	chr10:92591992	C/T	cg14313238	chr10:92632228	RPP30	0.42	5.79	0.3	1.62e-8	White matter microstructure (global fractional anisotropy);
LUSC	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-11.17	-0.52	8.13e-25	Schizophrenia;
LUSC	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg23711669	chr6:146136114	FBXO30	0.87	16.35	0.67	1.49e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg05985134	chr18:33552581	C18orf21	0.51	6.92	0.35	2.35e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs75804782	0.641	rs55844289	chr2:239323207	C/T	cg01134436	chr17:81009848	B3GNTL1	0.65	6.42	0.33	4.55e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10802521	chr3:52805072	NEK4	-0.53	-8.57	-0.42	3.89e-16	Bipolar disorder;
LUSC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg25036284	chr2:26402008	FAM59B	-0.7	-9.88	-0.48	2.22e-20	Gut microbiome composition (summer);
LUSC	cis	rs16958440	0.867	rs16948928	chr18:44675821	C/T	cg17192377	chr18:44677553	HDHD2	0.69	6.88	0.35	2.99e-11	Sitting height ratio;
LUSC	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg18795169	chr1:18902165	NA	-1.01	-24.29	-0.8	8.47e-76	Urate levels in lean individuals;
LUSC	cis	rs9463078	0.817	rs2145826	chr6:44763781	G/A	cg25276700	chr6:44698697	NA	0.3	5.84	0.3	1.26e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.63	-10.34	-0.49	6.53e-22	Prudent dietary pattern;
LUSC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.68	0.5	4.32e-23	Menopause (age at onset);
LUSC	cis	rs7000551	0.700	rs7431	chr8:22398462	G/A	cg12081754	chr8:22256438	SLC39A14	0.42	6.19	0.32	1.79e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg18240062	chr17:79603768	NPLOC4	0.71	12.97	0.58	1.96e-31	Eye color traits;
LUSC	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg11244672	chr19:19639970	YJEFN3	0.59	7.32	0.37	1.89e-12	Bipolar disorder;
LUSC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg04317338	chr11:64019027	PLCB3	0.68	7.75	0.39	1.12e-13	Mean platelet volume;
LUSC	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.77e-22	Eye color traits;
LUSC	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	11.24	0.52	4.61e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3741151	0.773	rs7945825	chr11:73287140	G/C	cg17517138	chr11:73019481	ARHGEF17	0.94	8.09	0.4	1.15e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	9.69	0.47	9.85e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21659725	chr3:3221576	CRBN	-0.58	-8.34	-0.42	1.92e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs6546550	0.935	rs1056482	chr2:70108256	A/T	cg02498382	chr2:70120550	SNRNP27	-0.28	-6.97	-0.36	1.74e-11	Prevalent atrial fibrillation;
LUSC	cis	rs2414856	0.510	rs72756996	chr15:64607787	A/G	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg05985134	chr18:33552581	C18orf21	0.51	7.05	0.36	1.01e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg22709100	chr7:91322751	NA	0.4	5.81	0.3	1.48e-8	Breast cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08301597	chr12:95397587	NDUFA12	-0.43	-6.11	-0.32	2.83e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08564027	chr20:61660810	NA	0.9	17.32	0.69	2.14e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17253792	0.822	rs76205307	chr14:56166038	C/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.09	-0.36	8.16e-12	Putamen volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27346088	chr10:61469843	SLC16A9	-0.56	-6.95	-0.36	1.91e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs354225	0.544	rs12713264	chr2:54805218	A/C	cg01766943	chr2:54829624	SPTBN1	-0.46	-7.46	-0.38	7.53e-13	Schizophrenia;
LUSC	cis	rs3772130	0.962	rs13065245	chr3:121566729	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	9.71	0.47	8.54e-20	Cognitive performance;
LUSC	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	0.52	7.33	0.37	1.79e-12	Breast cancer;
LUSC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg00255919	chr5:131827918	IRF1	0.43	8.28	0.41	3.11e-15	Asthma (sex interaction);
LUSC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.43e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs701145	0.537	rs1713847	chr3:153791107	C/A	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg09365446	chr1:150670422	GOLPH3L	0.52	7.99	0.4	2.17e-14	Blood protein levels;
LUSC	cis	rs10849689	1	rs10849689	chr12:110493222	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	9.67	0.47	1.14e-19	Schizophrenia;
LUSC	cis	rs11997175	0.646	rs61693382	chr8:33697255	A/C	ch.8.33884649F	chr8:33765107	NA	0.45	6.73	0.35	7.29e-11	Body mass index;
LUSC	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.8	-0.3	1.57e-8	Recombination rate (females);
LUSC	cis	rs899997	0.862	rs4887074	chr15:78952110	G/C	cg24631222	chr15:78858424	CHRNA5	-0.43	-5.76	-0.3	1.86e-8	Coronary artery disease or large artery stroke;
LUSC	trans	rs9392918	0.967	rs7769495	chr6:7712702	C/G	cg12631351	chr5:80256738	RASGRF2	-0.35	-6.0	-0.31	5.02e-9	Height;
LUSC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg16346588	chr10:242978	ZMYND11	-0.41	-6.02	-0.31	4.5e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18876405	chr7:65276391	NA	-0.55	-8.61	-0.43	2.92e-16	Aortic root size;
LUSC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg01294253	chr9:136912663	BRD3	0.35	6.02	0.31	4.59e-9	Platelet distribution width;
LUSC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.7e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2274273	0.662	rs2147970	chr14:55660217	C/T	cg04306507	chr14:55594613	LGALS3	0.48	9.67	0.47	1.2e-19	Protein biomarker;
LUSC	trans	rs34421088	0.532	rs2736258	chr8:11170449	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.95	0.36	1.93e-11	Neuroticism;
LUSC	trans	rs7951105	0.737	rs61886667	chr11:39255607	A/T	cg24085930	chr3:21832523	NA	0.55	6.53	0.34	2.44e-10	Free thyroxine concentration;
LUSC	cis	rs17401966	0.928	rs11121531	chr1:10277357	G/A	cg19773385	chr1:10388646	KIF1B	-0.54	-8.31	-0.41	2.52e-15	Hepatocellular carcinoma;
LUSC	trans	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg21659725	chr3:3221576	CRBN	-0.72	-8.2	-0.41	5.17e-15	Menarche (age at onset);
LUSC	cis	rs2806561	0.754	rs10917337	chr1:23300723	G/A	cg19743168	chr1:23544995	NA	-0.38	-7.87	-0.4	5.11e-14	Height;
LUSC	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg24069376	chr3:38537580	EXOG	-0.38	-7.38	-0.37	1.24e-12	Electrocardiographic conduction measures;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07423155	chr1:110527259	AHCYL1	-0.4	-6.06	-0.31	3.61e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg03585969	chr10:35415529	CREM	0.65	9.36	0.46	1.19e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6977660	0.619	rs10950752	chr7:19781531	A/G	cg05791153	chr7:19748676	TWISTNB	0.67	7.02	0.36	1.22e-11	Thyroid stimulating hormone;
LUSC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12379764	chr21:47803548	PCNT	-0.48	-6.98	-0.36	1.61e-11	Testicular germ cell tumor;
LUSC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.25	-14.44	-0.62	4.77e-37	Gout;
LUSC	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg01236616	chr12:121019343	POP5	1.19	17.5	0.69	4.19e-49	Type 1 diabetes nephropathy;
LUSC	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.33	-0.53	2.08e-25	Coffee consumption (cups per day);
LUSC	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg05738196	chr6:26577821	NA	0.81	15.89	0.66	9.79e-43	Intelligence (multi-trait analysis);
LUSC	cis	rs7828089	0.504	rs4872505	chr8:22337996	A/T	cg12081754	chr8:22256438	SLC39A14	0.46	6.89	0.35	2.77e-11	Verbal declarative memory;
LUSC	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	1.07	15.27	0.64	2.57e-40	Uric acid levels;
LUSC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22029157	chr1:209979665	IRF6	0.73	10.82	0.51	1.34e-23	Cleft lip with or without cleft palate;
LUSC	cis	rs7071206	0.853	rs66786803	chr10:79429941	A/G	cg07817648	chr10:79422355	NA	-0.45	-6.29	-0.33	1.01e-9	Bone mineral density;
LUSC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.48	0.53	6.19e-26	Prudent dietary pattern;
LUSC	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg24642439	chr20:33292090	TP53INP2	0.41	6.02	0.31	4.66e-9	Height;
LUSC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.47	7.11	0.36	7.25e-12	Colorectal cancer;
LUSC	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg18132916	chr6:79620363	NA	-0.39	-5.99	-0.31	5.41e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg11019008	chr10:131425282	MGMT	-0.4	-5.99	-0.31	5.3e-9	Response to temozolomide;
LUSC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg17279839	chr7:150038598	RARRES2	0.54	8.05	0.4	1.47e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.7	12.66	0.57	2.96e-30	Prudent dietary pattern;
LUSC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg27170947	chr2:26402098	FAM59B	-0.56	-7.5	-0.38	5.75e-13	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg23630131	chr7:65973040	NA	-0.21	-6.0	-0.31	5.16e-9	Aortic root size;
LUSC	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg15556689	chr8:8085844	FLJ10661	0.57	8.3	0.41	2.69e-15	Morning vs. evening chronotype;
LUSC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.74	-11.45	-0.53	7.72e-26	Menopause (age at onset);
LUSC	trans	rs11039798	1.000	rs7924372	chr11:48556319	T/A	cg15704280	chr7:45808275	SEPT13	0.75	6.44	0.33	4.2e-10	Axial length;
LUSC	cis	rs10733682	0.659	rs867560	chr9:129465233	C/G	cg00232160	chr9:129468157	NA	-0.38	-6.87	-0.35	3.11e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs11625487	0.957	rs7156032	chr14:77951364	G/A	cg16900964	chr18:77280354	NFATC1	-0.37	-5.95	-0.31	6.93e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg08601574	chr20:25228251	PYGB	0.47	7.3	0.37	2.14e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4950928	0.823	rs2486065	chr1:203167871	A/G	cg17014757	chr1:203156097	CHI3L1	-0.43	-7.8	-0.39	8.05e-14	YKL-40 levels;
LUSC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.71	-11.9	-0.55	1.87e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg18806716	chr10:30721971	MAP3K8	-0.49	-8.04	-0.4	1.61e-14	Inflammatory bowel disease;
LUSC	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg03929089	chr4:120376271	NA	0.72	6.79	0.35	5.2e-11	Axial length;
LUSC	cis	rs7804356	1.000	rs10244986	chr7:26849558	C/A	cg03456212	chr7:26904342	SKAP2	-0.54	-6.31	-0.33	8.74e-10	Type 1 diabetes;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg06877462	chr1:205807181	PM20D1	0.49	8.8	0.43	7.55e-17	Menarche (age at onset);
LUSC	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg17509989	chr5:176798049	RGS14	0.67	10.72	0.51	2.95e-23	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg12292205	chr6:26970375	C6orf41	0.68	11.53	0.53	4.12e-26	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg13072238	chr3:49761600	GMPPB	-0.39	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg01652190	chr22:50026171	C22orf34	-0.3	-6.37	-0.33	6.2e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg07274523	chr3:49395745	GPX1	-0.65	-10.02	-0.48	7.72e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-7.91	-0.4	3.74e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	13.12	0.58	5.26e-32	Alzheimer's disease;
LUSC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.29e-12	Tonsillectomy;
LUSC	cis	rs377070	0.934	rs309418	chr4:123623441	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.46	6.81	0.35	4.56e-11	Mosquito bite size;
LUSC	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	8.13	0.41	8.4e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7523050	0.643	rs12729998	chr1:109405505	T/C	cg08274380	chr1:109419600	GPSM2	1.09	10.73	0.51	2.88e-23	Fat distribution (HIV);
LUSC	cis	rs420259	0.681	rs26760	chr16:23680286	C/T	cg01460202	chr16:23706506	ERN2	-0.3	-5.84	-0.3	1.21e-8	Bipolar disorder;
LUSC	cis	rs1005224	0.929	rs11625260	chr14:76162293	G/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-5.86	-0.31	1.12e-8	Large artery stroke;
LUSC	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg08000102	chr2:233561755	GIGYF2	-0.66	-10.89	-0.51	7.54e-24	Coronary artery disease;
LUSC	cis	rs7851660	0.809	rs7044799	chr9:100665393	A/T	cg13688889	chr9:100608707	NA	-0.54	-8.43	-0.42	1.05e-15	Strep throat;
LUSC	cis	rs6940638	1.000	rs12215773	chr6:27039233	T/C	cg05738196	chr6:26577821	NA	-0.5	-5.74	-0.3	2.18e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9399401	0.601	rs9321870	chr6:142800758	A/T	cg03128060	chr6:142623767	GPR126	0.39	6.6	0.34	1.63e-10	Chronic obstructive pulmonary disease;
LUSC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.71	11.51	0.53	4.99e-26	Coronary artery disease;
LUSC	cis	rs9311676	0.656	rs6773193	chr3:58385960	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.49	0.33	3.05e-10	Systemic lupus erythematosus;
LUSC	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg15997130	chr1:24165203	NA	-0.53	-8.82	-0.43	6.68e-17	Immature fraction of reticulocytes;
LUSC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg06008330	chr7:65541103	ASL	-0.4	-6.38	-0.33	5.99e-10	Aortic root size;
LUSC	cis	rs500891	0.645	rs2186162	chr6:84163113	A/T	cg08257003	chr6:84140564	ME1	0.37	8.97	0.44	2.23e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg18357645	chr12:58087776	OS9	0.56	8.52	0.42	5.37e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.27e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-6.13	-0.32	2.45e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3106136	0.967	rs17310266	chr4:95177051	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.21	-0.32	1.61e-9	Capecitabine sensitivity;
LUSC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg15704280	chr7:45808275	SEPT13	0.94	13.51	0.59	1.74e-33	Coronary artery disease;
LUSC	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg05343316	chr1:45956843	TESK2	0.66	9.01	0.44	1.62e-17	Platelet count;
LUSC	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg00857998	chr1:205179979	DSTYK	0.59	8.89	0.44	3.85e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg08733960	chr6:52529248	LOC730101	0.42	6.23	0.32	1.43e-9	Triglycerides;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13645767	chr9:97766849	C9orf3	0.43	6.21	0.32	1.6e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12759997	chr1:54518742	TMEM59;C1orf83	-0.54	-6.95	-0.36	1.9e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6500395	0.926	rs11076571	chr16:48598064	A/G	cg04672837	chr16:48644449	N4BP1	0.43	6.17	0.32	1.94e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs72674100	1.000	rs10005324	chr4:97989202	G/C	cg09670535	chr1:18959427	PAX7	-0.62	-6.34	-0.33	7.58e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08677398	chr8:58056175	NA	0.52	6.36	0.33	6.6e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg16359550	chr11:109292809	C11orf87	0.36	6.07	0.32	3.55e-9	Schizophrenia;
LUSC	cis	rs4363385	0.818	rs382653	chr1:153006761	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.45e-8	Inflammatory skin disease;
LUSC	cis	rs2227930	0.506	rs2306699	chr3:142122451	T/A	cg16271453	chr3:142027066	XRN1	-0.55	-9.71	-0.47	8.4e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs5758511	0.513	rs7292782	chr22:42200324	A/C	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-7.58	-0.38	3.38e-13	Birth weight;
LUSC	cis	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05901451	chr6:126070800	HEY2	0.77	12.43	0.56	2.06e-29	Endometrial cancer;
LUSC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg20684491	chr1:25596433	NA	0.36	5.65	0.3	3.43e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs6987853	0.787	rs10958722	chr8:42425487	T/C	cg09913449	chr8:42400586	C8orf40	0.5	8.45	0.42	9.37e-16	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.67	0.65	7.43e-42	Bladder cancer;
LUSC	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg11901034	chr3:128598214	ACAD9	0.39	6.1	0.32	2.91e-9	IgG glycosylation;
LUSC	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg24375607	chr4:120327624	NA	0.77	11.39	0.53	1.32e-25	Corneal astigmatism;
LUSC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.99	0.36	1.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg01966878	chr4:90757139	SNCA	-0.34	-5.85	-0.3	1.2e-8	Dementia with Lewy bodies;
LUSC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg23202291	chr11:1979235	NA	0.49	7.64	0.39	2.33e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg23711669	chr6:146136114	FBXO30	0.85	15.09	0.64	1.32e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg17410650	chr12:54324560	NA	-0.58	-10.51	-0.5	1.66e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	trans	rs10511400	0.867	rs6777971	chr3:119936272	T/C	cg02809009	chr19:50354510	PTOV1	-0.69	-5.99	-0.31	5.46e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg04944784	chr2:26401820	FAM59B	-0.74	-10.91	-0.51	6.48e-24	Gut microbiome composition (summer);
LUSC	cis	rs9815354	0.812	rs58360908	chr3:41839837	A/G	cg03022575	chr3:42003672	ULK4	0.85	8.58	0.42	3.72e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg07424592	chr7:64974309	NA	0.67	5.89	0.31	9.55e-9	Diabetic kidney disease;
LUSC	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg21361702	chr7:150065534	REPIN1	0.57	8.02	0.4	1.85e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1832871	0.683	rs6908487	chr6:158713047	G/T	cg07165851	chr6:158734300	TULP4	0.5	7.66	0.39	2.05e-13	Height;
LUSC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.76	-13.53	-0.59	1.52e-33	Cognitive function;
LUSC	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg00757033	chr12:89920650	WDR51B	0.59	10.36	0.49	5.37e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg13010199	chr12:38710504	ALG10B	0.68	10.74	0.51	2.68e-23	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg10253484	chr15:75165896	SCAMP2	-0.5	-7.56	-0.38	3.97e-13	Airflow obstruction;
LUSC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4474465	0.915	rs12794810	chr11:78212743	T/C	cg27205649	chr11:78285834	NARS2	0.5	5.79	0.3	1.64e-8	Alzheimer's disease (survival time);
LUSC	trans	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.61	-0.43	3.01e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs6494488	0.500	rs72744729	chr15:65038484	G/A	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.09	0.36	7.93e-12	Diisocyanate-induced asthma;
LUSC	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.52	3.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.12	-0.32	2.69e-9	Resting heart rate;
LUSC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-5.82	-0.3	1.36e-8	Tonsillectomy;
LUSC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05025164	chr4:1340916	KIAA1530	-0.62	-9.52	-0.46	3.74e-19	Longevity;
LUSC	cis	rs6841333	0.539	rs4859592	chr4:76948664	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.78	0.3	1.67e-8	Monokine induced by gamma interferon levels;
LUSC	cis	rs12681287	0.511	rs4129535	chr8:87524094	G/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.15	-0.36	5.67e-12	Caudate activity during reward;
LUSC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg08677398	chr8:58056175	NA	0.41	5.73	0.3	2.19e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg26061582	chr7:22766209	IL6	0.48	6.64	0.34	1.28e-10	Lung cancer;
LUSC	trans	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg18187862	chr3:45730750	SACM1L	0.56	7.1	0.36	7.61e-12	Primary sclerosing cholangitis;
LUSC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.69	11.39	0.53	1.28e-25	Heart rate;
LUSC	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.75	-0.35	6.41e-11	Response to antipsychotic treatment;
LUSC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg23711669	chr6:146136114	FBXO30	0.93	18.36	0.71	1.46e-52	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-7.87	-0.4	5.09e-14	Body mass index;
LUSC	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-16.25	-0.66	3.52e-44	Exhaled nitric oxide output;
LUSC	trans	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.08	-0.36	8.44e-12	Neuroticism;
LUSC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.27	-0.32	1.09e-9	Total body bone mineral density;
LUSC	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg09788416	chr12:39539408	NA	0.38	5.67	0.3	3.04e-8	Morning vs. evening chronotype;
LUSC	trans	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg07393940	chr7:158741817	NA	0.36	6.45	0.33	3.84e-10	Life satisfaction;
LUSC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	0.78	13.41	0.59	4.32e-33	Cognitive function;
LUSC	cis	rs7577851	0.904	rs12475178	chr2:69730942	C/T	cg10773587	chr2:69614142	GFPT1	0.51	5.96	0.31	6.36e-9	Parkinson's disease (age of onset);
LUSC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.69	-10.85	-0.51	1.06e-23	Monocyte percentage of white cells;
LUSC	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-7.51	-0.38	5.49e-13	Morning vs. evening chronotype;
LUSC	cis	rs7681440	0.715	rs17016305	chr4:90791381	A/G	cg15133208	chr4:90757351	SNCA	-0.36	-6.05	-0.31	3.9e-9	Dementia with Lewy bodies;
LUSC	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg14092571	chr14:90743983	NA	-0.35	-5.65	-0.3	3.35e-8	Mortality in heart failure;
LUSC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg26441486	chr22:50317300	CRELD2	0.46	7.07	0.36	9.35e-12	Schizophrenia;
LUSC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg00310523	chr12:86230176	RASSF9	-0.42	-7.7	-0.39	1.52e-13	Major depressive disorder;
LUSC	cis	rs400736	0.860	rs371452	chr1:8084051	C/T	cg25007680	chr1:8021821	PARK7	0.57	9.07	0.44	1.01e-17	Response to antidepressants and depression;
LUSC	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg00864171	chr11:67383662	NA	0.35	6.14	0.32	2.31e-9	Mean corpuscular volume;
LUSC	cis	rs56399783	0.901	rs17132744	chr7:2874982	T/C	cg19731401	chr7:2775893	GNA12	0.68	9.29	0.45	2.05e-18	Childhood ear infection;
LUSC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	16.76	0.68	3.58e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg22800045	chr5:56110881	MAP3K1	0.77	10.03	0.48	7.09e-21	Initial pursuit acceleration;
LUSC	cis	rs9395066	0.545	rs10948192	chr6:44947321	G/A	cg25276700	chr6:44698697	NA	0.28	5.78	0.3	1.75e-8	Height;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.66	10.24	0.49	1.37e-21	Lymphocyte counts;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.42	6.19	0.32	1.75e-9	Longevity;Endometriosis;
LUSC	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	7.52	0.38	5.1e-13	Lung cancer in ever smokers;
LUSC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg12463550	chr7:65579703	CRCP	0.55	8.21	0.41	4.85e-15	Aortic root size;
LUSC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.65	-0.3	3.51e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs193541	0.530	rs1466371	chr5:122083788	T/C	cg19077854	chr5:122220652	SNX24	0.36	7.15	0.36	5.53e-12	Glucose homeostasis traits;
LUSC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg16624210	chr5:671434	TPPP	0.53	6.44	0.33	4.28e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.41	-0.42	1.18e-15	Coffee consumption (cups per day);
LUSC	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg15704280	chr7:45808275	SEPT13	0.73	8.39	0.42	1.38e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg21775007	chr8:11205619	TDH	0.52	7.4	0.38	1.13e-12	Monocyte count;
LUSC	cis	rs137699	0.695	rs137653	chr22:39732171	A/G	cg11247378	chr22:39784982	NA	0.35	6.11	0.32	2.85e-9	IgG glycosylation;
LUSC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg17366294	chr4:99064904	C4orf37	0.54	9.52	0.46	3.65e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13315871	1.000	rs71311873	chr3:58447106	C/A	cg12435725	chr3:58293450	RPP14	-0.7	-6.93	-0.35	2.21e-11	Cholesterol, total;
LUSC	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	6.42	0.33	4.76e-10	Recombination rate (females);
LUSC	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg24675056	chr1:15929824	NA	0.45	7.65	0.39	2.12e-13	Systolic blood pressure;
LUSC	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	1.16	17.8	0.7	2.5e-50	Corneal structure;
LUSC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg11871910	chr12:69753446	YEATS4	0.45	5.93	0.31	7.38e-9	Response to diuretic therapy;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12753518	chr1:28414763	EYA3	0.38	6.01	0.31	4.76e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg00750074	chr16:89608354	SPG7	0.45	6.8	0.35	4.96e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-10.27	-0.49	1.11e-21	Morning vs. evening chronotype;
LUSC	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg05855489	chr10:104503620	C10orf26	0.51	7.45	0.38	8.31e-13	Arsenic metabolism;
LUSC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg18904891	chr8:8559673	CLDN23	0.4	6.2	0.32	1.66e-9	Mood instability;
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.68	-11.25	-0.52	3.98e-25	Longevity;Endometriosis;
LUSC	trans	rs941408	0.515	rs878893	chr19:2781325	A/G	cg19676328	chr12:49525230	TUBA1B	-0.53	-7.53	-0.38	4.8e-13	Total cholesterol levels;
LUSC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.53	-0.38	4.87e-13	Personality dimensions;
LUSC	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg14395844	chr9:139980277	LOC100289341;MAN1B1	0.48	7.25	0.37	2.98e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.67	-0.54	1.26e-26	Coffee consumption (cups per day);
LUSC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	-0.39	-5.96	-0.31	6.32e-9	Menopause (age at onset);
LUSC	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg20019720	chr6:154832845	CNKSR3	0.62	9.57	0.46	2.54e-19	Lipoprotein (a) levels;
LUSC	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg24675056	chr1:15929824	NA	0.43	7.12	0.36	6.69e-12	Systolic blood pressure;
LUSC	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg18404041	chr3:52824283	ITIH1	0.44	7.85	0.39	5.66e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg16584290	chr5:462447	EXOC3	-0.34	-5.8	-0.3	1.52e-8	Cystic fibrosis severity;
LUSC	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.06	0.55	4.66e-28	Ileal carcinoids;
LUSC	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg11502198	chr6:26597334	ABT1	0.71	12.06	0.55	4.63e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9549260	0.755	rs7335520	chr13:41196407	C/T	cg21288729	chr13:41239152	FOXO1	0.6	9.14	0.45	6.27e-18	Red blood cell count;
LUSC	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14442939	chr10:27389572	ANKRD26	0.89	9.43	0.46	6.88e-19	Breast cancer;
LUSC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.58	-9.42	-0.46	7.8e-19	Personality dimensions;
LUSC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	0.92	17.77	0.7	3.32e-50	Heart rate;
LUSC	cis	rs7605827	0.930	rs10200346	chr2:15635728	A/C	cg19274914	chr2:15703543	NA	0.47	9.12	0.45	7.34e-18	Educational attainment (years of education);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24950336	chr3:113464879	ATP6V1A;NAA50	0.41	6.18	0.32	1.91e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg17173187	chr15:85201210	NMB	0.35	6.38	0.33	5.78e-10	Schizophrenia;
LUSC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg06740227	chr12:86229804	RASSF9	0.43	6.76	0.35	6.18e-11	Major depressive disorder;
LUSC	cis	rs968451	1.000	rs11703434	chr22:39698915	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	9.0	0.44	1.8e-17	Primary biliary cholangitis;
LUSC	cis	rs6489882	0.867	rs1859332	chr12:113371114	T/C	cg20102336	chr12:113376681	OAS3	-0.42	-6.17	-0.32	1.98e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs1034435	0.755	rs713923	chr22:48891519	C/T	cg05992904	chr22:48892994	FAM19A5	0.39	7.47	0.38	7.06e-13	Late-onset Alzheimer's disease;
LUSC	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg15896084	chr13:114927664	NA	0.4	7.26	0.37	2.74e-12	Schizophrenia;
LUSC	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg16950941	chr11:66035639	RAB1B	0.54	8.01	0.4	1.97e-14	Gout;
LUSC	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.81	7.47	0.38	7.11e-13	Body mass index;
LUSC	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.53	-0.42	5.12e-16	Response to antipsychotic treatment;
LUSC	cis	rs11051970	0.879	rs10844201	chr12:32575029	A/G	cg24626660	chr12:32551988	NA	0.33	5.69	0.3	2.82e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4363385	0.667	rs454245	chr1:153031979	A/C	cg00922841	chr1:152955080	SPRR1A	0.42	7.27	0.37	2.54e-12	Inflammatory skin disease;
LUSC	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg00509249	chr6:109615579	CCDC162	-0.34	-6.05	-0.31	3.83e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg10792982	chr14:105748885	BRF1	0.51	8.92	0.44	3.14e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.47	7.13	0.36	6.42e-12	Testicular germ cell tumor;
LUSC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg23791538	chr6:167370224	RNASET2	-0.37	-5.71	-0.3	2.52e-8	Crohn's disease;
LUSC	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.8	8.39	0.42	1.43e-15	Yeast infection;
LUSC	cis	rs11971779	0.680	rs2355786	chr7:139065622	A/C	cg07862535	chr7:139043722	LUC7L2	-0.56	-7.01	-0.36	1.3e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-1.25	-13.99	-0.61	2.56e-35	Diabetic kidney disease;
LUSC	cis	rs2302729	0.578	rs2302728	chr12:2774668	A/C	cg19945202	chr12:2788847	CACNA1C	0.35	6.22	0.32	1.48e-9	Sleep quality;
LUSC	cis	rs10761482	0.859	rs4948408	chr10:62110213	T/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.05	-0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg00857998	chr1:205179979	DSTYK	0.64	10.11	0.48	3.78e-21	Red blood cell count;
LUSC	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6599077	0.724	rs11129862	chr3:40113047	A/C	cg13683864	chr3:40499215	RPL14	0.56	7.67	0.39	1.96e-13	Sleep-related phenotypes;
LUSC	cis	rs977987	0.806	rs12051136	chr16:75435731	G/T	cg04384234	chr16:75411784	CFDP1	-0.41	-6.6	-0.34	1.6e-10	Dupuytren's disease;
LUSC	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg18477163	chr1:228402036	OBSCN	0.57	9.54	0.46	3.15e-19	Diastolic blood pressure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00560671	chr13:21635735	LATS2	-0.41	-6.01	-0.31	4.98e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg09941381	chr10:64027924	RTKN2	-0.38	-7.05	-0.36	1.02e-11	Rheumatoid arthritis;
LUSC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg14552801	chr7:65878734	NA	0.37	5.67	0.3	3.15e-8	Aortic root size;
LUSC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	1.01	18.98	0.72	5.41e-55	Cognitive function;
LUSC	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	0.85	13.38	0.59	5.28e-33	Blood protein levels;
LUSC	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg02980000	chr4:1222292	CTBP1	0.74	7.37	0.37	1.33e-12	Systolic blood pressure;
LUSC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg11608241	chr8:8085544	FLJ10661	0.4	5.84	0.3	1.21e-8	Mood instability;
LUSC	cis	rs6500395	1.000	rs1039340	chr16:48574637	A/C	cg04672837	chr16:48644449	N4BP1	0.46	6.82	0.35	4.17e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18758796	chr5:131593413	PDLIM4	0.52	8.87	0.44	4.49e-17	Acylcarnitine levels;
LUSC	cis	rs9650657	0.801	rs718741	chr8:10614384	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.09	-0.32	3.13e-9	Neuroticism;
LUSC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12756686	chr19:29218302	NA	0.47	5.79	0.3	1.64e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.88	-0.44	4.24e-17	Response to antipsychotic treatment;
LUSC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.72	-0.3	2.31e-8	Depression;
LUSC	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg27284194	chr4:1044797	NA	0.6	8.85	0.44	5.26e-17	Recombination rate (females);
LUSC	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg05925327	chr15:68127851	NA	0.33	5.85	0.3	1.19e-8	Restless legs syndrome;
LUSC	cis	rs9308433	0.505	rs867446	chr1:214502322	G/T	cg06198575	chr1:214491504	SMYD2	0.47	7.22	0.37	3.61e-12	IgG glycosylation;
LUSC	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg05855489	chr10:104503620	C10orf26	0.58	9.29	0.45	2.03e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6580649	0.941	rs4760618	chr12:48434767	G/A	cg24011408	chr12:48396354	COL2A1	-0.51	-6.81	-0.35	4.45e-11	Lung cancer;
LUSC	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-1.11	-16.94	-0.68	6.59e-47	Exhaled nitric oxide output;
LUSC	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg15557168	chr22:42548783	NA	-0.33	-5.67	-0.3	3.03e-8	Cognitive function;
LUSC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-10.1	-0.48	4.1e-21	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2797685	0.755	rs41402249	chr1:7822723	C/G	cg04725166	chr1:7887271	PER3	0.45	5.8	0.3	1.51e-8	Crohn's disease;
LUSC	cis	rs13401104	0.796	rs72620809	chr2:237116050	T/C	cg19324714	chr2:237145437	ASB18	0.43	5.65	0.3	3.43e-8	Educational attainment;
LUSC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg23788917	chr6:8435910	SLC35B3	0.51	7.58	0.38	3.38e-13	Motion sickness;
LUSC	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg04851639	chr8:1020857	NA	0.38	8.09	0.4	1.15e-14	Schizophrenia;
LUSC	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.98	-0.4	2.44e-14	Body mass index;
LUSC	cis	rs7712401	0.580	rs30041	chr5:122275353	G/C	cg19077854	chr5:122220652	SNX24	0.42	9.32	0.45	1.68e-18	Mean platelet volume;
LUSC	cis	rs4663866	1.000	rs4663300	chr2:239181491	T/C	cg16914508	chr2:239161102	PER2	0.69	7.39	0.37	1.17e-12	Irritable bowel syndrome;
LUSC	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-12.35	-0.56	4.11e-29	Platelet distribution width;
LUSC	trans	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07923666	chr12:49932857	KCNH3	-0.49	-6.27	-0.32	1.14e-9	Resting heart rate;
LUSC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg06219351	chr7:158114137	PTPRN2	-0.51	-9.32	-0.45	1.64e-18	Calcium levels;
LUSC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	1.03	20.14	0.74	1.26e-59	Menopause (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00243897	chr12:122326549	PSMD9	-0.49	-6.13	-0.32	2.49e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg22532475	chr10:104410764	TRIM8	-0.3	-5.92	-0.31	7.9e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	0.77	12.99	0.58	1.7e-31	Cognitive function;
LUSC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08859206	chr1:53392774	SCP2	-0.51	-8.53	-0.42	5.16e-16	Monocyte count;
LUSC	cis	rs4629710	0.592	rs9492868	chr6:131542238	A/C	cg12606694	chr6:131520996	AKAP7	0.61	9.38	0.46	1.06e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs2692947	0.770	rs2315417	chr2:96500289	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.46	0.33	3.8e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs7259376	0.936	rs8110854	chr19:22549453	C/T	cg08058610	chr19:52674483	ZNF836	0.38	5.95	0.31	6.93e-9	Menopause (age at onset);
LUSC	cis	rs740160	0.558	rs17161662	chr7:98907396	C/T	cg24650262	chr7:98904301	NA	0.6	6.62	0.34	1.47e-10	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs360798	0.532	rs360800	chr2:62954326	C/T	cg17519650	chr2:63277830	OTX1	-0.51	-7.13	-0.36	6.21e-12	Coronary artery disease;
LUSC	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg02023728	chr11:77925099	USP35	0.46	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg06671706	chr8:8559999	CLDN23	0.45	6.08	0.32	3.32e-9	Obesity-related traits;
LUSC	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg09904177	chr6:26538194	HMGN4	0.76	14.13	0.61	7.08e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs11587682	0.760	rs12141218	chr1:150448707	T/C	cg11822372	chr1:151115635	SEMA6C	-0.43	-5.74	-0.3	2.18e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg17724175	chr1:150552817	MCL1	0.37	6.67	0.34	1.05e-10	Tonsillectomy;
LUSC	cis	rs12210905	0.925	rs12200985	chr6:27004892	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-6.01	-0.31	4.74e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg06877462	chr1:205807181	PM20D1	-0.33	-6.04	-0.31	4.22e-9	Monocyte percentage of white cells;
LUSC	cis	rs225245	0.782	rs178649	chr17:33908197	C/G	cg05299278	chr17:33885742	SLFN14	0.31	6.82	0.35	4.37e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9905704	0.633	rs2632511	chr17:56490989	G/A	cg19466818	chr17:56409534	MIR142	-0.32	-6.06	-0.31	3.73e-9	Testicular germ cell tumor;
LUSC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg25894440	chr7:65020034	NA	0.39	6.1	0.32	2.99e-9	Calcium levels;
LUSC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg17279839	chr7:150038598	RARRES2	0.4	6.08	0.32	3.26e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7674212	0.570	rs2069274	chr4:104020781	C/G	cg16532752	chr4:104119610	CENPE	-0.51	-7.56	-0.38	3.94e-13	Type 2 diabetes;
LUSC	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.61	10.19	0.49	2e-21	Breast cancer;
LUSC	cis	rs9303542	0.559	rs12939811	chr17:46607958	A/T	cg09704116	chr17:46666958	LOC404266	-0.38	-6.74	-0.35	6.89e-11	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.35	-7.59	-0.38	3.17e-13	Cystic fibrosis severity;
LUSC	cis	rs7267979	0.586	rs6050445	chr20:25195394	C/T	cg08601574	chr20:25228251	PYGB	0.44	6.68	0.34	9.83e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg04850211	chr1:228464232	OBSCN	0.32	5.71	0.3	2.54e-8	Diastolic blood pressure;
LUSC	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.54	0.57	8.07e-30	White blood cell count;
LUSC	cis	rs9811920	0.965	rs9289981	chr3:99868104	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.34	-5.78	-0.3	1.67e-8	Axial length;
LUSC	cis	rs2073300	1.000	rs6048825	chr20:23457671	T/C	cg09953122	chr20:23471693	CST8	-0.69	-6.86	-0.35	3.28e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg25173405	chr17:45401733	C17orf57	0.42	6.85	0.35	3.49e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs1864729	1.000	rs2583506	chr8:98281847	G/A	cg08679828	chr8:102218111	ZNF706	-0.84	-7.77	-0.39	1e-13	Estradiol plasma levels (breast cancer);
LUSC	cis	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg18196295	chr10:418757	DIP2C	-0.48	-7.12	-0.36	6.5e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg01416388	chr22:39784598	NA	-0.41	-6.35	-0.33	7.17e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg12826209	chr6:26865740	GUSBL1	0.67	7.76	0.39	1.05e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg20587970	chr11:113659929	NA	-0.98	-12.21	-0.56	1.38e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21963583	chr11:68658836	MRPL21	0.56	8.08	0.4	1.19e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg18305652	chr10:134549665	INPP5A	0.44	6.64	0.34	1.3e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg12463550	chr7:65579703	CRCP	0.54	8.11	0.41	9.64e-15	Aortic root size;
LUSC	cis	rs7712401	0.692	rs6881135	chr5:122080371	A/T	cg19077854	chr5:122220652	SNX24	-0.33	-7.24	-0.37	3.02e-12	Mean platelet volume;
LUSC	cis	rs56283067	0.547	rs12192267	chr6:45393787	C/T	cg20913747	chr6:44695427	NA	-0.42	-6.07	-0.32	3.56e-9	Total body bone mineral density;
LUSC	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg03806693	chr22:41940476	POLR3H	-0.96	-13.04	-0.58	1.08e-31	Vitiligo;
LUSC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-1.18	-13.6	-0.6	8.06e-34	Diabetic kidney disease;
LUSC	cis	rs75920871	0.528	rs11216245	chr11:116913202	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-6.05	-0.31	3.92e-9	Subjective well-being;
LUSC	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg03342759	chr3:160939853	NMD3	-0.52	-7.42	-0.38	9.59e-13	Parkinson's disease;
LUSC	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.68	-0.43	1.76e-16	Response to antipsychotic treatment;
LUSC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.49	-6.59	-0.34	1.73e-10	Tonsillectomy;
LUSC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg05585544	chr11:47624801	NA	-0.42	-7.46	-0.38	7.56e-13	Subjective well-being;
LUSC	cis	rs4851254	0.517	rs13020141	chr2:100653842	G/A	cg07810366	chr2:100720526	AFF3	-0.47	-6.04	-0.31	4e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1335645	0.570	rs12403848	chr1:111627231	C/T	cg00321911	chr1:111669324	DRAM2	-0.57	-6.15	-0.32	2.24e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg02475777	chr4:1388615	CRIPAK	0.45	6.76	0.35	6.03e-11	Obesity-related traits;
LUSC	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg14584255	chr6:163149320	PACRG;PARK2	-0.4	-7.86	-0.4	5.25e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg15649852	chr7:65879115	NA	0.43	5.93	0.31	7.74e-9	Aortic root size;
LUSC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	0.93	13.24	0.59	1.93e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9517320	0.934	rs9517319	chr13:99125956	T/G	cg07423050	chr13:99094983	FARP1	0.33	6.33	0.33	7.74e-10	Longevity;
LUSC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	7.13	0.36	6.21e-12	Parkinson's disease;
LUSC	trans	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg07211511	chr3:129823064	LOC729375	-0.8	-10.6	-0.5	7.71e-23	Blood pressure (smoking interaction);
LUSC	cis	rs2219968	1.000	rs13263569	chr8:78954480	A/G	cg00738934	chr8:78996279	NA	0.34	6.17	0.32	1.94e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg00343986	chr7:65444356	GUSB	-0.38	-5.73	-0.3	2.29e-8	Aortic root size;
LUSC	cis	rs7799006	0.862	rs3757439	chr7:2272122	C/T	cg08027265	chr7:2291960	NA	-0.42	-7.37	-0.37	1.34e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg19318889	chr4:1322082	MAEA	0.45	7.28	0.37	2.42e-12	Obesity-related traits;
LUSC	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg01884057	chr2:25150051	NA	0.44	10.17	0.49	2.41e-21	Body mass index;
LUSC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg08499158	chr17:42289980	UBTF	-0.53	-8.79	-0.43	8.24e-17	Total body bone mineral density;
LUSC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg13535736	chr9:111863775	C9orf5	-0.4	-6.6	-0.34	1.6e-10	Menarche (age at onset);
LUSC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg15691649	chr6:25882328	NA	-0.38	-6.22	-0.32	1.49e-9	Blood metabolite levels;
LUSC	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg09998033	chr7:158218633	PTPRN2	0.41	6.42	0.33	4.63e-10	Obesity-related traits;
LUSC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg12560992	chr17:57184187	TRIM37	-0.72	-12.68	-0.57	2.45e-30	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07818646	chr13:51483769	RNASEH2B	0.45	6.37	0.33	6.24e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg17173187	chr15:85201210	NMB	0.49	9.49	0.46	4.65e-19	Schizophrenia;
LUSC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg19318889	chr4:1322082	MAEA	0.45	7.28	0.37	2.42e-12	Obesity-related traits;
LUSC	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg02018176	chr4:1364513	KIAA1530	0.55	7.05	0.36	1.02e-11	Recombination rate (females);
LUSC	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg01881094	chr2:180872142	CWC22	-0.82	-10.71	-0.51	3.19e-23	Schizophrenia;
LUSC	cis	rs17407555	0.697	rs56079809	chr4:10102736	C/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-5.99	-0.31	5.29e-9	Schizophrenia (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05021923	chr6:18387560	RNF144B	0.69	6.14	0.32	2.28e-9	Cognitive performance;
LUSC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-7.85	-0.39	5.67e-14	Hemoglobin concentration;
LUSC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg06238570	chr21:40685208	BRWD1	-0.65	-10.84	-0.51	1.12e-23	Cognitive function;
LUSC	cis	rs16910800	1.000	rs12420544	chr11:23200505	A/C	cg20040320	chr11:23191996	NA	-0.43	-6.34	-0.33	7.37e-10	Cancer;
LUSC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-7.03	-0.36	1.16e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.69	12.71	0.57	1.82e-30	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg25482853	chr8:67687455	SGK3	1.18	16.74	0.68	4.07e-46	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.41	-0.38	1.06e-12	Morning vs. evening chronotype;
LUSC	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg15605315	chr1:45957053	TESK2	0.46	7.33	0.37	1.78e-12	High light scatter reticulocyte count;
LUSC	cis	rs2235544	0.542	rs11206272	chr1:54470035	G/C	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs4144743	1.000	rs7223003	chr17:45324293	G/A	cg18085866	chr17:45331354	ITGB3	-0.7	-7.62	-0.38	2.61e-13	Body mass index;
LUSC	cis	rs238295	0.766	rs6139762	chr20:5546694	C/T	cg15842884	chr20:5591925	RP5-1022P6.2	0.44	5.91	0.31	8.43e-9	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg00310523	chr12:86230176	RASSF9	0.45	8.02	0.4	1.82e-14	Major depressive disorder;
LUSC	cis	rs6546886	0.912	rs7589915	chr2:74282130	G/C	cg14702570	chr2:74259524	NA	-0.3	-5.67	-0.3	3.08e-8	Dialysis-related mortality;
LUSC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg26695010	chr11:65641043	EFEMP2	0.41	5.74	0.3	2.14e-8	Breast cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02923393	chr16:1543003	TELO2	0.44	6.39	0.33	5.73e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg03146154	chr1:46216737	IPP	-0.51	-7.46	-0.38	7.41e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg15110403	chr19:17392923	ANKLE1	-0.54	-7.58	-0.38	3.54e-13	Systemic lupus erythematosus;
LUSC	trans	rs6601327	0.641	rs11785923	chr8:9587674	G/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.4	-0.33	5.21e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg26659404	chr1:25747437	RHCE	-0.27	-5.69	-0.3	2.74e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg07157834	chr1:205819609	PM20D1	-0.44	-5.85	-0.3	1.2e-8	Menarche (age at onset);
LUSC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.62	7.85	0.39	5.67e-14	Lung function (FEV1/FVC);
LUSC	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.22	-0.45	3.35e-18	Total cholesterol levels;
LUSC	cis	rs4704187	0.687	rs9293650	chr5:74497084	C/T	cg03227963	chr5:74354835	NA	0.31	6.79	0.35	5.25e-11	Response to amphetamines;
LUSC	cis	rs909002	0.925	rs4949455	chr1:32114793	C/T	cg01639898	chr1:32083012	HCRTR1	0.24	5.68	0.3	2.86e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-0.9	-16.74	-0.68	4.08e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00850453	chr7:12726919	ARL4A	-0.54	-6.71	-0.34	8.5e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg25456477	chr12:86230367	RASSF9	0.35	6.16	0.32	2.14e-9	Major depressive disorder;
LUSC	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg03676636	chr4:99064102	C4orf37	0.37	8.14	0.41	7.81e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4919087	0.892	rs10882881	chr10:99010067	T/A	cg25902810	chr10:99078978	FRAT1	0.44	6.48	0.33	3.27e-10	Monocyte count;
LUSC	trans	rs11700980	0.551	rs2832010	chr21:30110378	T/C	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.31e-9	QRS complex (12-leadsum);
LUSC	trans	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg07817883	chr1:32538562	TMEM39B	-0.58	-6.75	-0.35	6.74e-11	Monocyte percentage of white cells;
LUSC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.27	0.45	2.34e-18	Prudent dietary pattern;
LUSC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg25838465	chr1:92012736	NA	-0.74	-15.09	-0.64	1.31e-39	Breast cancer;
LUSC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg18758796	chr5:131593413	PDLIM4	0.4	5.8	0.3	1.52e-8	Breast cancer;
LUSC	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg04586622	chr2:25135609	ADCY3	0.3	6.24	0.32	1.36e-9	Breast cancer;
LUSC	cis	rs11030122	0.702	rs12286710	chr11:3967171	T/G	cg18678763	chr11:4115507	RRM1	-0.47	-6.13	-0.32	2.47e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg26958806	chr6:27640298	NA	0.61	5.73	0.3	2.3e-8	Breast cancer;
LUSC	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg05294307	chr14:35346193	BAZ1A	-0.49	-6.21	-0.32	1.61e-9	Psoriasis;
LUSC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18932078	chr1:2524107	MMEL1	-0.31	-6.89	-0.35	2.79e-11	Ulcerative colitis;
LUSC	cis	rs10208940	0.920	rs11894861	chr2:68706723	C/G	cg12452813	chr2:68675892	NA	0.55	5.79	0.3	1.66e-8	Urate levels in lean individuals;
LUSC	cis	rs80130819	0.748	rs2258342	chr12:48690363	T/C	cg24011408	chr12:48396354	COL2A1	0.46	5.88	0.31	9.77e-9	Prostate cancer;
LUSC	trans	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.22	-0.32	1.47e-9	Blood trace element (Cu levels);
LUSC	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05731713	chr7:157510257	PTPRN2	0.47	9.11	0.45	8.03e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs34375054	0.672	rs10400509	chr12:125592173	T/C	cg25124228	chr12:125621409	AACS	-0.48	-7.62	-0.38	2.62e-13	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg19812747	chr11:111475976	SIK2	0.5	6.89	0.35	2.87e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.28	-0.49	9.99e-22	Hemoglobin concentration;
LUSC	trans	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg07817883	chr1:32538562	TMEM39B	-0.55	-6.44	-0.33	4.21e-10	Monocyte percentage of white cells;
LUSC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18854424	chr1:2615690	NA	-0.49	-9.94	-0.48	1.48e-20	Ulcerative colitis;
LUSC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg18402987	chr7:1209562	NA	0.71	7.53	0.38	4.64e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg01256987	chr12:42539512	GXYLT1	-0.38	-6.92	-0.35	2.26e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg22834771	chr12:69754056	YEATS4	-0.55	-8.13	-0.41	8.34e-15	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs5747327	0.835	rs181396	chr22:18224155	A/G	cg13083436	chr11:24518414	LUZP2	-0.33	-6.63	-0.34	1.37e-10	Myeloid white cell count;Granulocyte count;
LUSC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg08975724	chr8:8085496	FLJ10661	0.49	7.57	0.38	3.56e-13	Mood instability;
LUSC	cis	rs2969070	0.831	rs886627	chr7:2498054	C/T	cg03277898	chr7:2518824	NA	-0.29	-6.11	-0.32	2.85e-9	Diastolic blood pressure;
LUSC	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg10253484	chr15:75165896	SCAMP2	0.42	5.96	0.31	6.25e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	1.03	22.6	0.78	2.7e-69	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.38	7.39e-13	Bipolar disorder;
LUSC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg14784868	chr12:69753453	YEATS4	0.63	9.39	0.46	9.5e-19	Blood protein levels;
LUSC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-9.9	-0.48	1.96e-20	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg22372815	chr12:71833833	LGR5	0.68	6.6	0.34	1.62e-10	Cognitive performance;
LUSC	cis	rs3818285	1.000	rs3818285	chr10:111635212	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.46	-0.38	7.45e-13	Superior crus of antihelix expression;
LUSC	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg06618935	chr21:46677482	NA	-0.36	-7.23	-0.37	3.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10875746	0.903	rs61918774	chr12:48448134	C/G	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs11051970	0.704	rs2733694	chr12:32555230	A/G	cg02745156	chr12:32552066	NA	0.37	6.81	0.35	4.48e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7043114	0.525	rs6479417	chr9:95064562	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.46	-0.33	3.63e-10	Height;
LUSC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06544989	chr22:39130855	UNC84B	0.37	6.41	0.33	5.04e-10	Menopause (age at onset);
LUSC	cis	rs4654899	0.865	rs4654891	chr1:21286391	T/C	cg01072550	chr1:21505969	NA	-0.49	-7.28	-0.37	2.44e-12	Superior frontal gyrus grey matter volume;
LUSC	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg01620082	chr3:125678407	NA	-0.85	-7.4	-0.38	1.09e-12	Depression;
LUSC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg12257692	chr3:49977190	RBM6	0.25	6.92	0.35	2.29e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs80130819	0.515	rs917055	chr12:48385576	A/G	cg24011408	chr12:48396354	COL2A1	0.54	6.76	0.35	6.01e-11	Prostate cancer;
LUSC	cis	rs59698941	0.943	rs4705873	chr5:132267167	G/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17891123	chr15:90931113	IQGAP1	-0.48	-6.34	-0.33	7.5e-10	Hepatitis;
LUSC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.01	-0.36	1.29e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.62	-13.16	-0.58	3.77e-32	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7589342	0.517	rs6736701	chr2:106390440	G/T	cg14210321	chr2:106509881	NCK2	-0.41	-5.83	-0.3	1.29e-8	Addiction;
LUSC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg27535305	chr1:53392650	SCP2	0.37	6.8	0.35	4.85e-11	Monocyte count;
LUSC	cis	rs56804039	0.895	rs11776995	chr8:8385547	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.5	-0.34	2.89e-10	Cervical cancer;
LUSC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg27532560	chr4:187881888	NA	-0.39	-6.39	-0.33	5.65e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg13813247	chr22:41461852	NA	-0.37	-6.68	-0.34	9.83e-11	Neuroticism;
LUSC	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg08213375	chr14:104286397	PPP1R13B	0.53	10.54	0.5	1.28e-22	Schizophrenia;
LUSC	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg02023728	chr11:77925099	USP35	0.45	6.75	0.35	6.37e-11	Testicular germ cell tumor;
LUSC	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg13334819	chr7:99746414	C7orf59	0.49	6.5	0.34	2.96e-10	Coronary artery disease;
LUSC	cis	rs2219968	0.828	rs12545997	chr8:78910679	C/A	cg00738934	chr8:78996279	NA	-0.4	-7.2	-0.37	3.91e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg02931644	chr1:25747376	RHCE	0.33	5.99	0.31	5.39e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg00255919	chr5:131827918	IRF1	0.44	8.6	0.43	3.04e-16	Asthma (sex interaction);
LUSC	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.03	-0.44	1.43e-17	Monocyte percentage of white cells;
LUSC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.31	-0.33	8.73e-10	Blood metabolite levels;
LUSC	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg12826209	chr6:26865740	GUSBL1	0.54	7.78	0.39	9e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg13010199	chr12:38710504	ALG10B	0.59	8.84	0.44	5.46e-17	Heart rate;
LUSC	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg15704280	chr7:45808275	SEPT13	0.77	8.48	0.42	7.41e-16	Axial length;
LUSC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	0.97	14.06	0.61	1.34e-35	Vitiligo;
LUSC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-13.85	-0.6	8.76e-35	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs34421088	0.532	rs2409754	chr8:11155613	A/G	cg15556689	chr8:8085844	FLJ10661	0.41	6.08	0.32	3.24e-9	Neuroticism;
LUSC	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg26587870	chr6:27730563	NA	-0.61	-5.79	-0.3	1.62e-8	Breast cancer;
LUSC	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.88	0.58	4.26e-31	Exhaled nitric oxide output;
LUSC	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg24642439	chr20:33292090	TP53INP2	0.47	7.08	0.36	8.53e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs72634258	0.842	rs7545677	chr1:8165619	C/T	cg26816564	chr1:7831052	VAMP3	0.43	5.88	0.31	9.7e-9	Inflammatory bowel disease;
LUSC	cis	rs12980942	1.000	rs7245398	chr19:41810644	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.18	0.32	1.91e-9	Coronary artery disease;
LUSC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.47	-5.99	-0.31	5.36e-9	Parkinson's disease;
LUSC	cis	rs524023	0.957	rs893006	chr11:64365796	C/A	cg19131476	chr11:64387923	NRXN2	-0.39	-10.58	-0.5	9.15e-23	Urate levels in obese individuals;
LUSC	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg23625390	chr15:77176239	SCAPER	-0.62	-9.58	-0.46	2.34e-19	Blood metabolite levels;
LUSC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.88	-0.31	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9905704	0.918	rs11657676	chr17:56842043	A/G	cg12560992	chr17:57184187	TRIM37	0.55	7.84	0.39	6.19e-14	Testicular germ cell tumor;
LUSC	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg23933602	chr10:16859644	RSU1	0.58	6.85	0.35	3.46e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs9644630	0.930	rs6586839	chr8:19365543	A/T	cg01280390	chr8:19363452	CSGALNACT1	-0.36	-6.76	-0.35	6.18e-11	Oropharynx cancer;
LUSC	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg19610905	chr11:61596333	FADS2	-0.54	-8.02	-0.4	1.82e-14	Trans fatty acid levels;
LUSC	cis	rs13315871	1.000	rs36037390	chr3:58321954	C/T	cg20936604	chr3:58311152	NA	-0.76	-7.26	-0.37	2.66e-12	Cholesterol, total;
LUSC	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-7.96	-0.4	2.71e-14	Schizophrenia;
LUSC	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg01420254	chr6:26195488	NA	0.65	7.28	0.37	2.44e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	7.84	0.39	6.23e-14	Iron status biomarkers;
LUSC	cis	rs4363385	0.747	rs3737867	chr1:152976474	A/C	cg00922841	chr1:152955080	SPRR1A	-0.35	-5.89	-0.31	9.18e-9	Inflammatory skin disease;
LUSC	trans	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg21775007	chr8:11205619	TDH	-0.41	-6.22	-0.32	1.49e-9	Mood instability;
LUSC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg15468180	chr1:107600409	PRMT6	0.38	6.14	0.32	2.34e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.21	-0.32	1.6e-9	Electroencephalogram traits;
LUSC	trans	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg15556689	chr8:8085844	FLJ10661	0.44	6.85	0.35	3.61e-11	Retinal vascular caliber;
LUSC	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg15848620	chr12:58087721	OS9	0.45	5.73	0.3	2.23e-8	Multiple sclerosis;
LUSC	cis	rs11214589	0.806	rs4551806	chr11:113250540	T/A	cg14159747	chr11:113255604	NA	0.3	7.56	0.38	3.93e-13	Neuroticism;
LUSC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.54	-8.33	-0.41	2.15e-15	Longevity;Endometriosis;
LUSC	cis	rs7607369	0.574	rs12990478	chr2:219667463	T/A	cg02176678	chr2:219576539	TTLL4	-0.52	-9.12	-0.45	7.46e-18	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.68	12.02	0.55	6.86e-28	Aortic root size;
LUSC	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.26	0.45	2.63e-18	Red blood cell count;
LUSC	trans	rs62238980	0.614	rs78078590	chr22:32370487	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17739459	chr12:53835901	PRR13	0.44	6.17	0.32	1.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	7.82e-13	Motion sickness;
LUSC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg01879757	chr17:41196368	BRCA1	-0.47	-7.21	-0.37	3.83e-12	Menopause (age at onset);
LUSC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.75	13.73	0.6	2.53e-34	Aortic root size;
LUSC	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg18806716	chr10:30721971	MAP3K8	-0.69	-10.73	-0.51	2.89e-23	Inflammatory bowel disease;
LUSC	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.41	-0.46	8.23e-19	Neuroticism;
LUSC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.53	-9.5	-0.46	4.14e-19	Menopause (age at onset);
LUSC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00149659	chr3:10157352	C3orf10	0.88	12.38	0.56	3.02e-29	Alzheimer's disease;
LUSC	trans	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	8.81	0.43	7.1e-17	Type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.24e-19	Prudent dietary pattern;
LUSC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg03929089	chr4:120376271	NA	-0.93	-16.14	-0.66	9.76e-44	Height;
LUSC	cis	rs11018904	0.906	rs17227345	chr11:89954685	A/T	cg26138821	chr11:89956704	CHORDC1	0.57	6.87	0.35	3.22e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6845621	0.901	rs11723047	chr4:18923910	C/T	cg12196642	chr4:18937545	NA	-0.36	-6.66	-0.34	1.12e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.72	0.57	1.74e-30	Motion sickness;
LUSC	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg10596483	chr8:143751796	JRK	0.52	7.54	0.38	4.41e-13	Schizophrenia;
LUSC	trans	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg03886242	chr7:26192032	NFE2L3	0.38	6.32	0.33	8.36e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg05064044	chr6:292385	DUSP22	-0.53	-7.79	-0.39	8.49e-14	Menopause (age at onset);
LUSC	cis	rs16854884	0.586	rs11914731	chr3:143725594	A/G	cg01302019	chr3:143689584	C3orf58	-0.34	-5.65	-0.3	3.46e-8	Economic and political preferences (feminism/equality);
LUSC	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg10523679	chr1:76189770	ACADM	-0.5	-7.29	-0.37	2.31e-12	Daytime sleep phenotypes;
LUSC	cis	rs500891	1.000	rs13201274	chr6:84176481	G/A	cg08257003	chr6:84140564	ME1	0.34	7.12	0.36	6.55e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg13256891	chr4:100009986	ADH5	-0.47	-6.63	-0.34	1.38e-10	Smoking initiation;
LUSC	trans	rs6480314	0.542	rs4592311	chr10:70028249	C/T	cg04882175	chr6:131122610	NA	-0.54	-6.32	-0.33	8.24e-10	Optic nerve measurement (disc area);
LUSC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg05347473	chr6:146136440	FBXO30	-0.64	-11.01	-0.52	2.85e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg21724239	chr8:58056113	NA	0.57	6.58	0.34	1.87e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg08219700	chr8:58056026	NA	0.5	6.2	0.32	1.67e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg01448562	chr3:133502909	NA	-0.54	-7.94	-0.4	3.16e-14	Iron status biomarkers;
LUSC	trans	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg13565492	chr6:43139072	SRF	-0.57	-6.11	-0.32	2.78e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg06521331	chr12:34319734	NA	-0.41	-6.43	-0.33	4.4e-10	Morning vs. evening chronotype;
LUSC	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg21138405	chr5:131827807	IRF1	0.35	6.22	0.32	1.45e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs477692	0.569	rs10764886	chr10:131310680	C/T	cg05714579	chr10:131428358	MGMT	0.42	5.96	0.31	6.43e-9	Response to temozolomide;
LUSC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.73	0.35	7.39e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs12476592	0.714	rs262491	chr2:63841113	A/G	cg10828910	chr2:63850056	LOC388955	0.51	5.95	0.31	6.95e-9	Childhood ear infection;
LUSC	trans	rs10822407	0.710	rs10996078	chr10:66640749	C/T	cg26654559	chr16:86492912	NA	0.34	6.06	0.31	3.63e-9	Diastolic blood pressure;
LUSC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg06453172	chr10:134556979	INPP5A	-0.51	-6.22	-0.32	1.5e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01763057	chr2:239112731	ILKAP	-0.39	-6.05	-0.31	3.92e-9	Hepatitis;
LUSC	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg05527609	chr1:210001259	C1orf107	0.93	11.98	0.55	9.53e-28	Orofacial clefts;
LUSC	cis	rs2282300	0.739	rs35883696	chr11:30246407	A/C	cg06241208	chr11:30344200	C11orf46	-0.44	-5.65	-0.3	3.52e-8	Morning vs. evening chronotype;
LUSC	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg03433033	chr1:76189801	ACADM	0.42	6.28	0.33	1.05e-9	Daytime sleep phenotypes;
LUSC	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.52	-0.34	2.61e-10	Breast cancer;
LUSC	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.53	-0.5	1.46e-22	Coffee consumption (cups per day);
LUSC	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg02023728	chr11:77925099	USP35	0.52	7.07	0.36	8.94e-12	Testicular germ cell tumor;
LUSC	cis	rs7508679	1.000	rs10410204	chr19:7224350	C/T	cg09779027	chr19:7224513	INSR	0.43	9.13	0.45	6.5e-18	Hypothyroidism;
LUSC	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg00376283	chr12:123451042	ABCB9	0.65	8.16	0.41	7.13e-15	Neutrophil percentage of white cells;
LUSC	cis	rs17095355	1.000	rs1376111	chr10:111707255	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.62	-0.38	2.6e-13	Biliary atresia;
LUSC	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg13010199	chr12:38710504	ALG10B	0.55	8.14	0.41	7.97e-15	Bladder cancer;
LUSC	cis	rs10186029	0.509	rs2371793	chr2:213945082	G/C	cg08319019	chr2:214017104	IKZF2	-0.44	-6.46	-0.33	3.67e-10	Systemic sclerosis;
LUSC	cis	rs10392	0.543	rs4810245	chr20:37549309	G/A	cg27552599	chr20:37590471	DHX35	0.43	6.84	0.35	3.77e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.5	-0.46	4.09e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.51	0.53	4.85e-26	Menopause (age at onset);
LUSC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.16	15.5	0.65	3.26e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6545883	0.894	rs778157	chr2:61554289	C/G	cg15711740	chr2:61764176	XPO1	-0.41	-6.43	-0.33	4.41e-10	Tuberculosis;
LUSC	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg04218760	chr10:45406644	TMEM72	-0.3	-7.24	-0.37	3.16e-12	Mean corpuscular volume;
LUSC	cis	rs6977660	1.000	rs13237667	chr7:19820288	G/C	cg07541023	chr7:19748670	TWISTNB	0.51	5.73	0.3	2.3e-8	Thyroid stimulating hormone;
LUSC	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg16989719	chr2:238392110	NA	-0.37	-6.31	-0.33	8.83e-10	Prostate cancer;
LUSC	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	1.09	25.68	0.81	4.5e-81	Platelet distribution width;
LUSC	cis	rs1227969	0.706	rs1665581	chr10:71262048	G/T	cg12610070	chr10:71211762	TSPAN15	-0.3	-6.74	-0.35	6.86e-11	Response to taxane treatment (placlitaxel);
LUSC	cis	rs354225	0.584	rs6706263	chr2:54815240	C/T	cg01766943	chr2:54829624	SPTBN1	0.5	8.16	0.41	7.07e-15	Schizophrenia;
LUSC	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.96	21.5	0.76	5.45e-65	Longevity;
LUSC	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	0.62	9.4	0.46	8.9e-19	Response to antineoplastic agents;
LUSC	cis	rs68170813	0.641	rs1978085	chr7:107095216	T/C	cg02696742	chr7:106810147	HBP1	-0.67	-9.69	-0.47	9.63e-20	Coronary artery disease;
LUSC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.66	-0.39	2.06e-13	Bipolar disorder and schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg22776125	chr6:167041314	RPS6KA2	0.45	6.64	0.34	1.24e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.43	0.46	7e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4253772	0.530	rs28362161	chr22:46807439	C/T	cg18190219	chr22:46762943	CELSR1	-0.6	-5.81	-0.3	1.46e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.71	-0.39	1.43e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs607541	0.850	rs2218309	chr15:45938661	A/G	cg26924012	chr15:45694286	SPATA5L1	0.84	6.81	0.35	4.59e-11	Obesity-related traits;
LUSC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18876405	chr7:65276391	NA	0.56	8.88	0.44	4.18e-17	Aortic root size;
LUSC	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg12935359	chr14:103987150	CKB	-0.64	-10.56	-0.5	1.14e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.83	0.3	1.29e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.61	-8.81	-0.43	7.04e-17	Facial morphology (factor 19);
LUSC	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg15704280	chr7:45808275	SEPT13	-0.57	-7.1	-0.36	7.41e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg22166914	chr1:53195759	ZYG11B	0.57	9.31	0.45	1.81e-18	Monocyte count;
LUSC	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-8.52	-0.42	5.74e-16	Hepatocellular carcinoma;
LUSC	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg27471124	chr11:109292789	C11orf87	0.41	7.22	0.37	3.44e-12	Schizophrenia;
LUSC	cis	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05901451	chr6:126070800	HEY2	0.57	8.65	0.43	2.22e-16	Endometrial cancer;
LUSC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.52	-0.34	2.6200000000000003e-10	Lung cancer;
LUSC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg13395646	chr4:1353034	KIAA1530	-0.79	-13.0	-0.58	1.57e-31	Obesity-related traits;
LUSC	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.03	0.31	4.33e-9	Corneal astigmatism;
LUSC	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.46	-0.42	8.33e-16	Response to antipsychotic treatment;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07605469	chr12:113573757	RASAL1	-0.51	-6.91	-0.35	2.44e-11	Hepatitis;
LUSC	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-9.32	-0.45	1.64e-18	Neuroticism;
LUSC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	6.12	0.32	2.58e-9	Schizophrenia;
LUSC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06481639	chr22:41940642	POLR3H	0.5	5.77	0.3	1.81e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.06	-0.36	9.88e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.58	-9.38	-0.46	1.08e-18	Aortic root size;
LUSC	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg05340658	chr4:99064831	C4orf37	0.57	8.81	0.43	7.13e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg04827223	chr11:72435913	ARAP1	0.67	11.17	0.52	8.2e-25	Body mass index;
LUSC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg05738196	chr6:26577821	NA	0.49	7.19	0.37	4.34e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.9	16.97	0.68	5.1e-47	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.88	-0.44	4.16e-17	Neuroticism;
LUSC	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.61	9.71	0.47	8.65e-20	Alcohol dependence;
LUSC	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg18232548	chr7:50535776	DDC	0.54	7.58	0.38	3.41e-13	Malaria;
LUSC	cis	rs13006833	0.703	rs291427	chr2:191194059	C/T	cg21644426	chr2:191273491	MFSD6	0.42	6.11	0.32	2.76e-9	Urinary metabolites;
LUSC	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	6.46	0.33	3.74e-10	Height;
LUSC	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.69e-11	Response to antipsychotic treatment;
LUSC	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.33	0.41	2.18e-15	Lung cancer;
LUSC	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.55	-7.88	-0.4	4.53e-14	Reticulocyte count;
LUSC	cis	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.82	-0.3	1.35e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11208691	0.513	rs11208698	chr1:66131238	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.93	0.31	7.6e-9	Lymphocyte percentage of white cells;
LUSC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg22764044	chr5:178986830	RUFY1	0.62	11.37	0.53	1.48e-25	Lung cancer;
LUSC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg09699651	chr6:150184138	LRP11	0.37	5.75	0.3	2.02e-8	Lung cancer;
LUSC	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.04	0.36	1.12e-11	Asthma;
LUSC	cis	rs78579285	0.584	rs9930994	chr16:88800693	C/T	cg01900006	chr16:88814613	FAM38A	0.61	6.83	0.35	4.14e-11	Joint mobility (Beighton score);
LUSC	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.9	0.48	2e-20	Migraine;Coronary artery disease;
LUSC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg16928487	chr17:17741425	SREBF1	0.45	8.88	0.44	4.18e-17	Total body bone mineral density;
LUSC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.02	22.69	0.78	1.3e-69	Prudent dietary pattern;
LUSC	trans	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg13010199	chr12:38710504	ALG10B	0.42	6.17	0.32	1.99e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs4363385	0.747	rs4845506	chr1:152968407	G/A	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.9	-0.4	3.97e-14	Inflammatory skin disease;
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg25428297	chr7:1022841	CYP2W1	0.28	5.77	0.3	1.85e-8	Longevity;Endometriosis;
LUSC	cis	rs427941	0.632	rs201469	chr7:101743932	C/G	cg06246474	chr7:101738831	CUX1	0.39	6.42	0.33	4.68e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg15605315	chr1:45957053	TESK2	0.46	7.54	0.38	4.34e-13	High light scatter reticulocyte count;
LUSC	cis	rs6845621	0.774	rs1452556	chr4:18936647	A/G	cg12196642	chr4:18937545	NA	-0.36	-6.76	-0.35	6.14e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg20476274	chr7:133979776	SLC35B4	0.81	14.71	0.63	4.3e-38	Mean platelet volume;
LUSC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg11062466	chr8:58055876	NA	0.67	7.63	0.39	2.4e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06949789	chr3:23958708	NKIRAS1;RPL15	-0.48	-6.32	-0.33	8.2e-10	Hepatitis;
LUSC	trans	rs7170930	0.618	rs1513932	chr15:66537899	G/A	cg06396762	chr16:3202609	NA	-0.72	-5.97	-0.31	5.91e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12346351	chr4:152330392	FAM160A1	0.42	6.01	0.31	4.96e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg02527881	chr3:46936655	PTH1R	-0.39	-6.87	-0.35	3.2e-11	Colorectal cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22728534	chr2:87034800	CD8A	-0.39	-5.95	-0.31	6.67e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg21775007	chr8:11205619	TDH	0.44	6.12	0.32	2.64e-9	Morning vs. evening chronotype;
LUSC	cis	rs7572644	0.712	rs1911128	chr2:28279649	T/G	cg27432699	chr2:27873401	GPN1	-0.54	-6.86	-0.35	3.44e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg23795048	chr12:9217529	LOC144571	0.34	6.01	0.31	4.82e-9	Sjögren's syndrome;
LUSC	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg13615516	chr5:77269221	NA	0.39	6.62	0.34	1.39e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg15147215	chr3:52552868	STAB1	-0.3	-5.87	-0.31	1.03e-8	Electroencephalogram traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16676734	chr14:93582668	ITPK1	0.43	6.26	0.32	1.18e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22590775	chr19:49891494	CCDC155	0.56	7.32	0.37	1.92e-12	Multiple sclerosis;
LUSC	cis	rs243505	1.000	rs243515	chr7:148426672	A/C	cg09806900	chr7:148480153	CUL1	-0.47	-6.61	-0.34	1.51e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24110177	chr3:50126178	RBM5	0.57	9.21	0.45	3.63e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg24296786	chr1:45957014	TESK2	0.48	7.36	0.37	1.45e-12	High light scatter reticulocyte count;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24235997	chr7:105264584	ATXN7L1	-0.4	-6.57	-0.34	1.91e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg12863693	chr15:85201151	NMB	0.36	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg20368463	chr18:77673604	PQLC1	-0.64	-7.03	-0.36	1.13e-11	Opioid sensitivity;
LUSC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-7.24	-0.37	3.2e-12	Aortic root size;
LUSC	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg12560992	chr17:57184187	TRIM37	-0.64	-10.71	-0.51	3.44e-23	Testicular germ cell tumor;
LUSC	cis	rs860295	0.627	rs11264410	chr1:155745349	G/A	cg08949192	chr1:155289623	RUSC1;FDPS	-0.34	-5.74	-0.3	2.07e-8	Body mass index;
LUSC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.79	-0.3	1.64e-8	Platelet count;
LUSC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg22029157	chr1:209979665	IRF6	0.78	10.26	0.49	1.17e-21	Cleft lip with or without cleft palate;
LUSC	cis	rs9943753	0.525	rs6606708	chr12:109833146	T/C	cg19025524	chr12:109796872	NA	-0.38	-6.98	-0.36	1.59e-11	HDL cholesterol;
LUSC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.76	12.55	0.57	7.15e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs56283067	0.886	rs2023311	chr6:44678306	A/T	cg18551225	chr6:44695536	NA	-0.45	-7.83	-0.39	6.63e-14	Total body bone mineral density;
LUSC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.29	-0.41	2.82e-15	Mean platelet volume;
LUSC	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg20587970	chr11:113659929	NA	1.14	13.52	0.59	1.65e-33	Hip circumference adjusted for BMI;
LUSC	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.9	0.48	2e-20	Migraine;Coronary artery disease;
LUSC	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.48	0.56	1.38e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg12011299	chr4:100065546	ADH4	-0.72	-10.43	-0.5	3.12e-22	Alcohol dependence;
LUSC	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg25801113	chr15:45476975	SHF	0.35	7.15	0.36	5.6e-12	Uric acid levels;
LUSC	trans	rs1376359	0.537	rs526349	chr1:103274737	A/G	cg17154563	chr19:40477487	PSMC4	0.47	5.97	0.31	5.95e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.67	0.39	1.87e-13	Bipolar disorder;
LUSC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.6	0.46	2.01e-19	Attention deficit hyperactivity disorder;
LUSC	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg02023728	chr11:77925099	USP35	0.46	7.0	0.36	1.43e-11	Testicular germ cell tumor;
LUSC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	7.57	0.38	3.58e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg18512352	chr11:47633146	NA	-0.47	-9.63	-0.47	1.58e-19	Subjective well-being;
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg03461704	chr1:205818484	PM20D1	0.36	5.82	0.3	1.39e-8	Menarche (age at onset);
LUSC	cis	rs62344088	1.000	rs6880143	chr5:137516	C/T	cg22857025	chr5:266934	NA	-1.03	-7.61	-0.38	2.76e-13	Asthma (childhood onset);
LUSC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg20203395	chr5:56204925	C5orf35	-0.8	-10.74	-0.51	2.61e-23	Initial pursuit acceleration;
LUSC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg00343986	chr7:65444356	GUSB	0.48	7.28	0.37	2.42e-12	Aortic root size;
LUSC	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.86	14.7	0.63	4.43e-38	Bladder cancer;
LUSC	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg19700328	chr14:106028568	NA	-0.41	-6.94	-0.36	1.99e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg24375607	chr4:120327624	NA	0.78	11.55	0.53	3.41e-26	Corneal astigmatism;
LUSC	cis	rs6545883	0.895	rs2421192	chr2:61643631	T/C	cg15711740	chr2:61764176	XPO1	0.44	6.66	0.34	1.13e-10	Tuberculosis;
LUSC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.71	0.54	9.35e-27	Alzheimer's disease;
LUSC	cis	rs4776059	0.798	rs4776063	chr15:52904046	C/A	cg24008177	chr15:52972085	KIAA1370	0.32	5.82	0.3	1.39e-8	Schizophrenia;
LUSC	cis	rs4664304	0.772	rs6737904	chr2:160872526	G/C	cg03641300	chr2:160917029	PLA2R1	-0.37	-5.99	-0.31	5.48e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7254114	0.686	rs3745681	chr19:11303943	A/G	cg02815516	chr19:11306319	KANK2	-0.43	-9.13	-0.45	6.64e-18	Immature fraction of reticulocytes;
LUSC	cis	rs11608355	0.538	rs7305165	chr12:109804222	G/A	cg19025524	chr12:109796872	NA	-0.42	-7.65	-0.39	2.11e-13	Neuroticism;
LUSC	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00631329	chr6:26305371	NA	-0.45	-8.86	-0.44	4.68e-17	Educational attainment;
LUSC	cis	rs977987	0.933	rs4888431	chr16:75500699	G/T	cg04384234	chr16:75411784	CFDP1	-0.49	-8.11	-0.41	9.52e-15	Dupuytren's disease;
LUSC	cis	rs12313068	0.709	rs73404675	chr12:110504102	G/A	cg12870014	chr12:110450643	ANKRD13A	0.66	9.66	0.47	1.25e-19	Intelligence (multi-trait analysis);
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg14752429	chr2:26569594	GPR113;SELI	0.41	5.99	0.31	5.34e-9	Eotaxin levels;
LUSC	cis	rs4746822	0.906	rs10762264	chr10:70976833	G/A	cg14418922	chr10:70824840	NA	-0.38	-6.29	-0.33	1.01e-9	Glycemic traits (pregnancy);
LUSC	trans	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg26043149	chr18:55253948	FECH	-0.45	-6.93	-0.35	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs8099014	0.911	rs8098308	chr18:56130661	A/G	cg12907477	chr18:56117327	MIR122	0.44	7.04	0.36	1.09e-11	Platelet count;
LUSC	cis	rs1775715	0.644	rs2799022	chr10:32137198	C/T	cg03015672	chr10:32216066	ARHGAP12	0.35	6.27	0.32	1.13e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs897080	0.515	rs1067368	chr2:44654889	C/T	cg00619915	chr2:44497795	NA	-0.43	-6.37	-0.33	6.39e-10	Height;
LUSC	cis	rs9304742	0.540	rs10416138	chr19:53465152	C/T	cg09915433	chr19:53449742	NA	-0.44	-6.86	-0.35	3.41e-11	Psoriasis;
LUSC	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg24675056	chr1:15929824	NA	0.49	8.52	0.42	5.69e-16	Systolic blood pressure;
LUSC	cis	rs870825	0.872	rs12506750	chr4:185571123	C/T	cg04058563	chr4:185651563	MLF1IP	0.89	11.13	0.52	1.11e-24	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25572309	chr10:134145729	LRRC27	-0.4	-6.11	-0.32	2.81e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.7	12.58	0.57	5.53e-30	Prudent dietary pattern;
LUSC	cis	rs240764	0.658	rs7768210	chr6:101261494	C/T	cg09795085	chr6:101329169	ASCC3	0.46	6.6	0.34	1.61e-10	Neuroticism;
LUSC	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg11802864	chr11:65308245	LTBP3	0.84	5.81	0.3	1.45e-8	Height;
LUSC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg21724239	chr8:58056113	NA	0.77	7.97	0.4	2.61e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg20991723	chr1:152506922	NA	0.49	9.23	0.45	3.09e-18	Hair morphology;
LUSC	cis	rs2073300	1.000	rs6114098	chr20:23444276	G/A	cg09953122	chr20:23471693	CST8	-0.77	-6.62	-0.34	1.46e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4363385	0.626	rs10888531	chr1:153063406	T/C	cg00922841	chr1:152955080	SPRR1A	-0.35	-6.04	-0.31	4.02e-9	Inflammatory skin disease;
LUSC	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg26384229	chr12:38710491	ALG10B	0.56	9.0	0.44	1.77e-17	Morning vs. evening chronotype;
LUSC	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg10356904	chr22:49881777	NA	-0.29	-5.78	-0.3	1.75e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4462272	0.503	rs11596076	chr10:101845434	A/G	cg02250046	chr10:101825185	CPN1	-0.31	-5.74	-0.3	2.09e-8	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23956071	chr17:4710044	PLD2	-0.47	-6.13	-0.32	2.46e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.2	0.49	1.94e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg26677194	chr12:130822605	PIWIL1	-0.59	-8.76	-0.43	9.77e-17	Menopause (age at onset);
LUSC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.63	-0.43	2.55e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.58	10.45	0.5	2.65e-22	Bone mineral density;
LUSC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg09365446	chr1:150670422	GOLPH3L	0.54	8.28	0.41	2.91e-15	Tonsillectomy;
LUSC	cis	rs10761482	0.769	rs10761483	chr10:62098398	T/A	cg18175470	chr10:62150864	ANK3	-0.51	-7.32	-0.37	1.89e-12	Schizophrenia;
LUSC	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg08601574	chr20:25228251	PYGB	0.41	6.29	0.33	1e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08645402	chr16:4508243	NA	0.51	8.74	0.43	1.15e-16	Schizophrenia;
LUSC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg21251018	chr6:28226885	NKAPL	0.32	6.12	0.32	2.65e-9	Cardiac Troponin-T levels;
LUSC	cis	rs354225	0.544	rs10182538	chr2:54808251	T/A	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg01528321	chr10:82214614	TSPAN14	0.87	13.17	0.58	3.37e-32	Post bronchodilator FEV1;
LUSC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	32.85	0.87	1.22e-106	Chronic sinus infection;
LUSC	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg03806693	chr22:41940476	POLR3H	-0.96	-13.04	-0.58	1.08e-31	Vitiligo;
LUSC	cis	rs9921338	0.886	rs3931015	chr16:11415639	G/A	cg00044050	chr16:11439710	C16orf75	0.48	6.47	0.33	3.47e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg08000102	chr2:233561755	GIGYF2	-0.64	-10.28	-0.49	1.03e-21	Coronary artery disease;
LUSC	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg25182066	chr10:30743637	MAP3K8	0.45	6.85	0.35	3.47e-11	Inflammatory bowel disease;
LUSC	cis	rs58235267	0.553	rs1025132	chr2:63360639	G/A	cg17519650	chr2:63277830	OTX1	0.67	9.67	0.47	1.13e-19	Prostate-specific antigen levels (conditioned on lead SNPs);
LUSC	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg08355456	chr11:67383691	NA	0.32	5.8	0.3	1.54e-8	Mean corpuscular volume;
LUSC	cis	rs710216	0.917	rs2297977	chr1:43415288	G/T	cg22176566	chr1:43424700	SLC2A1	0.43	5.69	0.3	2.8e-8	Red cell distribution width;
LUSC	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-9.61	-0.47	1.88e-19	Morning vs. evening chronotype;
LUSC	cis	rs1538970	0.884	rs781226	chr1:45872662	T/C	cg05343316	chr1:45956843	TESK2	-0.58	-8.04	-0.4	1.54e-14	Platelet count;
LUSC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.12	0.58	5.41e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg22681709	chr2:178499509	PDE11A	-0.47	-8.55	-0.42	4.39e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9399401	0.677	rs11155241	chr6:142664439	T/A	cg03128060	chr6:142623767	GPR126	0.57	9.3	0.45	1.86e-18	Chronic obstructive pulmonary disease;
LUSC	cis	rs11585357	0.947	rs6666990	chr1:17611520	G/A	cg08277548	chr1:17600880	PADI3	0.63	6.8	0.35	4.74e-11	Hair shape;
LUSC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11030122	0.702	rs12223176	chr11:3982537	T/G	cg08557956	chr11:4115526	RRM1	-0.46	-5.72	-0.3	2.39e-8	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg06521331	chr12:34319734	NA	-0.39	-6.12	-0.32	2.68e-9	Bladder cancer;
LUSC	cis	rs6580649	0.771	rs1034762	chr12:48389643	G/T	cg24011408	chr12:48396354	COL2A1	-0.5	-6.62	-0.34	1.4e-10	Lung cancer;
LUSC	cis	rs7267979	0.565	rs3752273	chr20:25594783	A/T	cg03522245	chr20:25566470	NINL	-0.39	-6.1	-0.32	2.93e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7605827	0.930	rs2052435	chr2:15687306	A/T	cg19274914	chr2:15703543	NA	0.45	8.43	0.42	1.02e-15	Educational attainment (years of education);
LUSC	cis	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg02972257	chr16:68554789	NA	0.43	5.71	0.3	2.48e-8	Colorectal cancer;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24006384	chr1:8021553	PARK7	0.39	6.11	0.32	2.85e-9	Asthma;
LUSC	cis	rs7528419	0.895	rs1277930	chr1:109822143	G/A	cg00908766	chr1:109817496	CELSR2	0.74	11.34	0.53	1.92e-25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUSC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.48	-6.98	-0.36	1.63e-11	Menarche (age at onset);
LUSC	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg23241863	chr10:102295624	HIF1AN	0.5	6.15	0.32	2.17e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg19077165	chr18:44547161	KATNAL2	0.39	5.96	0.31	6.51e-9	Personality dimensions;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25669900	chr5:133861733	PHF15	-0.45	-6.66	-0.34	1.16e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg26335602	chr6:28129616	ZNF389	0.46	6.06	0.31	3.64e-9	Depression;
LUSC	cis	rs7605827	0.930	rs2241236	chr2:15655480	A/G	cg19274914	chr2:15703543	NA	0.46	8.83	0.43	6.22e-17	Educational attainment (years of education);
LUSC	cis	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg10665199	chr7:133106180	EXOC4	-0.59	-8.31	-0.41	2.37e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2667011	0.818	rs2715918	chr2:160833188	A/G	cg06573604	chr2:160760825	LY75	-0.47	-6.04	-0.31	4.16e-9	Bilirubin levels;
LUSC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.14	0.32	2.31e-9	Schizophrenia;
LUSC	cis	rs11023332	0.832	rs10832289	chr11:14669496	A/T	cg05501817	chr11:14380813	RRAS2	0.39	6.13	0.32	2.48e-9	Adiponectin levels;Vitamin D levels;
LUSC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg13206674	chr6:150067644	NUP43	0.59	9.36	0.46	1.24e-18	Lung cancer;
LUSC	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	6.75	0.35	6.44e-11	Systolic blood pressure;
LUSC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg04362960	chr10:104952993	NT5C2	-0.6	-9.32	-0.45	1.65e-18	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg15691649	chr6:25882328	NA	-0.39	-6.36	-0.33	6.75e-10	Blood metabolite levels;
LUSC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg20302342	chr1:156215951	PAQR6	0.32	6.09	0.32	3.11e-9	Tonsillectomy;
LUSC	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg15423357	chr2:25149977	NA	0.35	6.42	0.33	4.79e-10	Body mass index;
LUSC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.42	-6.01	-0.31	4.82e-9	Platelet count;
LUSC	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-5.97	-0.31	6.06e-9	Retinal vascular caliber;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13875899	chr6:5004148	RPP40	-0.45	-6.03	-0.31	4.38e-9	Hepatitis;
LUSC	cis	rs11690935	0.550	rs62183801	chr2:172867475	G/A	cg13550731	chr2:172543902	DYNC1I2	0.53	7.96	0.4	2.7e-14	Schizophrenia;
LUSC	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.95	-0.36	1.91e-11	Height;
LUSC	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg07978099	chr16:83986941	OSGIN1	0.56	9.13	0.45	6.69e-18	Pursuit maintenance gain;
LUSC	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg14530993	chr4:882597	GAK	0.66	6.9	0.35	2.68e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-1.23	-13.28	-0.59	1.37e-32	Diabetic kidney disease;
LUSC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg13319975	chr6:146136371	FBXO30	0.47	7.09	0.36	8.06e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7250872	0.647	rs12976128	chr19:1817113	A/C	cg02747822	chr19:1826707	REXO1	0.37	5.71	0.3	2.46e-8	Bipolar disorder;
LUSC	cis	rs7177699	0.526	rs7182529	chr15:79123631	T/C	cg15571903	chr15:79123663	NA	0.34	6.34	0.33	7.41e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.64	0.34	1.26e-10	Menopause (age at onset);
LUSC	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg04362960	chr10:104952993	NT5C2	1.14	13.5	0.59	1.89e-33	Arsenic metabolism;
LUSC	cis	rs7940866	0.809	rs11222410	chr11:130833994	A/G	cg12179176	chr11:130786555	SNX19	0.63	9.68	0.47	1.05e-19	Schizophrenia;
LUSC	cis	rs981844	0.778	rs55895613	chr4:154638121	G/T	cg14289246	chr4:154710475	SFRP2	0.47	5.83	0.3	1.32e-8	Response to statins (LDL cholesterol change);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03768916	chr10:49813307	ARHGAP22	0.41	6.55	0.34	2.19e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs96067	0.772	rs6700737	chr1:36598214	A/G	cg24686825	chr1:36642396	MAP7D1	-0.7	-9.32	-0.45	1.63e-18	Corneal structure;
LUSC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	12.0	0.55	7.98e-28	Prudent dietary pattern;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13855674	chr2:32853033	TTC27	-0.46	-6.02	-0.31	4.53e-9	Hepatitis;
LUSC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg15557168	chr22:42548783	NA	-0.46	-7.01	-0.36	1.35e-11	Schizophrenia;
LUSC	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.4	-5.72	-0.3	2.32e-8	Bipolar disorder;
LUSC	cis	rs400736	0.671	rs863171	chr1:7992615	A/G	cg25007680	chr1:8021821	PARK7	0.49	7.32	0.37	1.89e-12	Response to antidepressants and depression;
LUSC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08677398	chr8:58056175	NA	-0.56	-6.92	-0.35	2.32e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs7980799	0.649	rs10772088	chr12:33663849	A/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.16	-0.32	2.04e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg24675056	chr1:15929824	NA	0.45	7.76	0.39	1.03e-13	Systolic blood pressure;
LUSC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	8.67	0.43	1.92e-16	Mean platelet volume;
LUSC	cis	rs10193935	0.901	rs7601905	chr2:42494144	A/G	cg27598129	chr2:42591480	NA	-0.54	-7.45	-0.38	8.22e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.88	-13.01	-0.58	1.4e-31	Coronary artery disease;
LUSC	cis	rs9311676	0.632	rs62259772	chr3:58417416	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.4	0.33	5.22e-10	Systemic lupus erythematosus;
LUSC	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg23260525	chr10:116636907	FAM160B1	0.48	10.32	0.49	7.38e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg06238570	chr21:40685208	BRWD1	0.58	9.74	0.47	7.02e-20	Cognitive function;
LUSC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg09455208	chr3:40491958	NA	0.58	9.98	0.48	1.06e-20	Renal cell carcinoma;
LUSC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg02038168	chr22:39784481	NA	-0.48	-7.78	-0.39	9.41e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg11502198	chr6:26597334	ABT1	0.93	11.29	0.53	2.9e-25	Small cell lung carcinoma;
LUSC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg11062466	chr8:58055876	NA	0.47	6.37	0.33	6.36e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg18230493	chr5:56204884	C5orf35	-0.76	-12.46	-0.56	1.53e-29	Initial pursuit acceleration;
LUSC	cis	rs77741769	0.569	rs10774572	chr12:121309561	A/G	cg02419362	chr12:121203948	SPPL3	0.46	8.51	0.42	5.87e-16	Mean corpuscular volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04716446	chr5:79703937	ZFYVE16	0.47	6.69	0.34	9.46e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13082711	0.522	rs653886	chr3:27343549	C/T	cg02860705	chr3:27208620	NA	0.47	8.47	0.42	8.01e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.53	0.62	2.14e-37	Platelet count;
LUSC	cis	rs7927592	0.830	rs11228240	chr11:68218290	C/T	cg20283391	chr11:68216788	NA	-0.62	-8.56	-0.42	4.04e-16	Total body bone mineral density;
LUSC	cis	rs7589342	0.801	rs13031068	chr2:106455021	A/G	cg14210321	chr2:106509881	NCK2	-0.54	-8.07	-0.4	1.25e-14	Addiction;
LUSC	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg03806693	chr22:41940476	POLR3H	-0.54	-7.3	-0.37	2.11e-12	Neuroticism;
LUSC	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg17366294	chr4:99064904	C4orf37	0.55	8.84	0.44	5.57e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg14440974	chr22:39074834	NA	-0.39	-6.46	-0.33	3.67e-10	Menopause (age at onset);
LUSC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg23711669	chr6:146136114	FBXO30	0.87	15.63	0.65	1.03e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg08601574	chr20:25228251	PYGB	0.42	6.41	0.33	4.9e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.37	5.91	0.31	8.34e-9	Response to antipsychotic treatment;
LUSC	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg18675610	chr10:32216311	ARHGAP12	0.3	6.59	0.34	1.72e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg24562669	chr7:97807699	LMTK2	0.34	6.02	0.31	4.55e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg02972257	chr16:68554789	NA	-0.49	-6.35	-0.33	7.09e-10	Ulcerative colitis;
LUSC	cis	rs727505	0.564	rs68107250	chr7:124870200	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.79	-0.35	5.07e-11	Lewy body disease;
LUSC	cis	rs6942756	1.000	rs9640854	chr7:128884057	A/T	cg02491457	chr7:128862824	NA	-0.52	-7.42	-0.38	9.94e-13	White matter hyperintensity burden;
LUSC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg15691649	chr6:25882328	NA	-0.39	-6.32	-0.33	8.37e-10	Blood metabolite levels;
LUSC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg12863693	chr15:85201151	NMB	0.34	6.78	0.35	5.49e-11	Schizophrenia;
LUSC	trans	rs57046232	0.552	rs6085506	chr20:6326507	T/C	cg17788362	chr6:86352627	SYNCRIP	0.45	6.23	0.32	1.38e-9	Colorectal cancer;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg27094323	chr7:1216898	NA	-0.46	-7.9	-0.4	4.06e-14	Longevity;Endometriosis;
LUSC	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg10978503	chr1:24200527	CNR2	-0.44	-9.94	-0.48	1.49e-20	Immature fraction of reticulocytes;
LUSC	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg11608241	chr8:8085544	FLJ10661	0.42	6.18	0.32	1.82e-9	Systolic blood pressure;
LUSC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg22907277	chr7:1156413	C7orf50	0.52	5.9	0.31	9.13e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.71	-0.43	1.42e-16	Total cholesterol levels;
LUSC	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4663866	0.901	rs35390666	chr2:239193578	C/T	cg16914508	chr2:239161102	PER2	0.7	7.47	0.38	7.07e-13	Irritable bowel syndrome;
LUSC	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-8.76	-0.43	9.71e-17	Response to antipsychotic treatment;
LUSC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg18512352	chr11:47633146	NA	-0.48	-9.8	-0.47	4.44e-20	Subjective well-being;
LUSC	cis	rs6500395	0.962	rs1564980	chr16:48651377	A/T	cg04672837	chr16:48644449	N4BP1	0.49	7.19	0.37	4.22e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg02951883	chr7:2050386	MAD1L1	-0.47	-7.94	-0.4	3.02e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs988712	0.705	rs11030099	chr11:27677583	C/A	cg10635145	chr11:27742435	BDNF	-0.46	-5.88	-0.31	9.87e-9	Obesity;
LUSC	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.19	-0.41	5.51e-15	Axial length;
LUSC	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg22709100	chr7:91322751	NA	0.41	5.92	0.31	8.03e-9	Breast cancer;
LUSC	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21545522	chr1:205238299	TMCC2	-0.46	-8.67	-0.43	1.88e-16	Platelet count;
LUSC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg13319975	chr6:146136371	FBXO30	0.38	5.7	0.3	2.66e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg08219700	chr8:58056026	NA	0.46	5.88	0.31	1e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg24130564	chr14:104152367	KLC1	-0.43	-6.0	-0.31	5.17e-9	Body mass index;
LUSC	cis	rs9419702	0.538	rs9322837	chr10:133539229	G/A	cg23460707	chr10:133558971	NA	0.36	6.17	0.32	2e-9	Survival in rectal cancer;
LUSC	cis	rs472402	0.580	rs3733773	chr5:6652252	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.54	-7.77	-0.39	1.01e-13	Response to amphetamines;
LUSC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.42	0.38	9.97e-13	Bipolar disorder;
LUSC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg00033643	chr7:134001901	SLC35B4	0.45	6.84	0.35	3.84e-11	Mean platelet volume;
LUSC	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg20608306	chr11:116969690	SIK3	0.37	6.8	0.35	4.86e-11	Blood protein levels;
LUSC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02353165	chr6:42928485	GNMT	0.68	11.84	0.54	3.07e-27	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs13040088	1.000	rs12480117	chr20:61558274	G/A	cg23096297	chr20:61557774	DIDO1	0.85	11.33	0.53	2.19e-25	Menopause (age at onset);
LUSC	cis	rs259282	0.605	rs34727912	chr19:33110058	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.63	9.38	0.46	1.05e-18	Schizophrenia;
LUSC	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg05347473	chr6:146136440	FBXO30	0.54	9.16	0.45	5.52e-18	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07770353	chr16:69782764	NOB1	-0.72	-6.2	-0.32	1.66e-9	Cognitive performance;
LUSC	cis	rs888194	0.544	rs7316486	chr12:109849540	A/G	cg19025524	chr12:109796872	NA	-0.34	-5.71	-0.3	2.49e-8	Neuroticism;
LUSC	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg27432699	chr2:27873401	GPN1	0.78	14.73	0.63	3.51e-38	Oral cavity cancer;
LUSC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg13531842	chr10:38383804	ZNF37A	-0.43	-6.71	-0.34	8.11e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-7.11	-0.36	7.13e-12	Aortic root size;
LUSC	cis	rs13089785	1.000	rs17310322	chr3:123670721	T/C	cg02558132	chr3:123411198	MYLK	0.34	5.8	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-13.31	-0.59	1.01e-32	Total body bone mineral density;
LUSC	cis	rs11031096	0.655	rs11031252	chr11:4211165	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-6.01	-0.31	4.94e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg05714579	chr10:131428358	MGMT	0.51	7.43	0.38	9.46e-13	Response to temozolomide;
LUSC	cis	rs2414856	0.510	rs72758937	chr15:64667930	T/C	cg08069370	chr15:64387884	SNX1	-0.78	-6.58	-0.34	1.84e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg03585969	chr10:35415529	CREM	0.6	8.79	0.43	8.31e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.56	10.31	0.49	8.27e-22	Metabolite levels;
LUSC	cis	rs698813	0.789	rs2592195	chr2:44607707	A/G	cg00619915	chr2:44497795	NA	-0.39	-5.66	-0.3	3.22e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.9	-0.44	3.51e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2898681	0.618	rs79471207	chr4:53738524	C/T	cg21521518	chr4:53727714	RASL11B	0.44	5.7	0.3	2.63e-8	Optic nerve measurement (cup area);
LUSC	cis	rs68170813	0.559	rs79026644	chr7:107031803	A/G	cg02696742	chr7:106810147	HBP1	-0.63	-9.11	-0.45	7.97e-18	Coronary artery disease;
LUSC	cis	rs7572644	0.680	rs12623170	chr2:28020157	C/T	cg27432699	chr2:27873401	GPN1	0.55	7.22	0.37	3.49e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6987853	0.787	rs1343874	chr8:42424746	C/T	cg09913449	chr8:42400586	C8orf40	0.49	8.34	0.42	1.91e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3824867	0.879	rs10742806	chr11:47456226	T/A	cg20307385	chr11:47447363	PSMC3	0.66	9.74	0.47	6.62e-20	Mean corpuscular hemoglobin;
LUSC	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-10.76	-0.51	2.19e-23	Monocyte percentage of white cells;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12040534	chr17:17942854	ATPAF2;C17orf39	0.44	6.11	0.32	2.77e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1044826	0.642	rs167187	chr3:139237008	C/T	cg00490450	chr3:139108681	COPB2	-0.47	-7.19	-0.37	4.28e-12	Obesity-related traits;
LUSC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg10909506	chr17:38081995	ORMDL3	0.33	5.85	0.3	1.17e-8	Self-reported allergy;
LUSC	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-10.04	-0.48	6.67e-21	Migraine;Coronary artery disease;
LUSC	cis	rs4443100	0.631	rs13054904	chr22:23410918	A/T	cg14186256	chr22:23484241	RTDR1	-0.55	-7.12	-0.36	6.53e-12	Serum parathyroid hormone levels;
LUSC	cis	rs7705502	0.962	rs17696407	chr5:173387335	C/A	cg18693985	chr5:173351052	CPEB4	-0.4	-6.26	-0.32	1.2e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs1535500	1.000	rs1535500	chr6:39284050	G/T	cg06347083	chr6:39282316	KCNK17	-0.28	-6.1	-0.32	2.99e-9	Type 2 diabetes;
LUSC	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.53	-8.04	-0.4	1.62e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06544989	chr22:39130855	UNC84B	0.33	5.65	0.3	3.51e-8	Menopause (age at onset);
LUSC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg09517075	chr8:22133004	PIWIL2	0.43	8.57	0.42	4e-16	Hypertriglyceridemia;
LUSC	cis	rs10489525	0.502	rs12026930	chr1:115597836	G/A	cg01522456	chr1:115632236	TSPAN2	0.47	6.88	0.35	2.92e-11	Autism;
LUSC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg01097406	chr16:89675127	NA	-0.35	-7.1	-0.36	7.44e-12	Vitiligo;
LUSC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.03	0.58	1.16e-31	Chronic sinus infection;
LUSC	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg24397884	chr7:158709396	WDR60	0.77	8.55	0.42	4.52e-16	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13898548	chr5:176924827	PDLIM7	-0.35	-5.95	-0.31	6.83e-9	Electrocardiographic conduction measures;
LUSC	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg08999081	chr20:33150536	PIGU	0.37	6.82	0.35	4.3e-11	Height;
LUSC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00149659	chr3:10157352	C3orf10	0.89	12.11	0.55	3.04e-28	Alzheimer's disease;
LUSC	cis	rs11168618	0.810	rs6580671	chr12:48841057	G/A	cg24011408	chr12:48396354	COL2A1	0.38	6.07	0.32	3.48e-9	Adiponectin levels;
LUSC	cis	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg05084668	chr3:125655381	ALG1L	-0.47	-5.92	-0.31	8.2e-9	Blood pressure (smoking interaction);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg02361781	chr15:52043731	TMOD2;LYSMD2	0.46	6.05	0.31	3.92e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg00504896	chr12:9437009	LOC642846	-0.47	-7.73	-0.39	1.25e-13	Breast size;
LUSC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.44	-0.38	8.58e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.54	0.38	4.59e-13	Bipolar disorder;
LUSC	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg15848620	chr12:58087721	OS9	-0.55	-7.84	-0.39	6.28e-14	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs28647808	0.881	rs28494844	chr9:136266188	T/C	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg27266060	chr8:22091797	NA	0.36	6.72	0.35	7.74e-11	Hypertriglyceridemia;
LUSC	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg02023728	chr11:77925099	USP35	0.45	6.62	0.34	1.42e-10	Testicular germ cell tumor;
LUSC	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg12615879	chr12:58013172	SLC26A10	0.27	6.43	0.33	4.48e-10	Multiple sclerosis;
LUSC	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg03690763	chr11:133734501	NA	-0.33	-5.66	-0.3	3.21e-8	Childhood ear infection;
LUSC	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.42	0.33	4.61e-10	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13633754	chr9:95858523	C9orf89	-0.38	-6.01	-0.31	4.76e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs10486158	0.843	rs1294621	chr7:7392688	C/T	cg01895333	chr3:109035405	DPPA2	-0.37	-6.09	-0.32	3.15e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	7.15	0.36	5.58e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs11671664	0.732	rs67775326	chr19:46160969	A/G	cg13320842	chr19:46175254	GIPR	0.5	6.58	0.34	1.77e-10	Type 2 diabetes;Body mass index;Body mass index (SNP x SNP interaction);
LUSC	cis	rs7131987	0.650	rs12366527	chr12:29474256	C/G	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.77	-0.35	5.69e-11	QT interval;
LUSC	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg06808227	chr14:105710500	BRF1	-0.63	-9.69	-0.47	9.62e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg12292205	chr6:26970375	C6orf41	0.68	11.53	0.53	4.12e-26	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs981844	0.813	rs72731678	chr4:154671476	T/C	cg14289246	chr4:154710475	SFRP2	0.51	6.57	0.34	1.98e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.77	-0.3	1.78e-8	IgG glycosylation;
LUSC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-6.3	-0.33	9.2e-10	Longevity;Endometriosis;
LUSC	cis	rs1535500	0.967	rs11756091	chr6:39282806	G/T	cg06347083	chr6:39282316	KCNK17	-0.29	-6.27	-0.32	1.14e-9	Type 2 diabetes;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg26618056	chr16:25043323	NA	0.38	6.52	0.34	2.54e-10	Mosquito bite size;
LUSC	cis	rs231513	0.911	rs124720	chr17:41960141	A/G	cg26893861	chr17:41843967	DUSP3	-0.53	-5.84	-0.3	1.26e-8	Cognitive function;
LUSC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.39	0.53	1.28e-25	Prudent dietary pattern;
LUSC	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs5758511	0.773	rs9623482	chr22:42360574	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.5	-6.12	-0.32	2.6e-9	Birth weight;
LUSC	cis	rs9653442	0.545	rs4851257	chr2:100775297	C/T	cg07810366	chr2:100720526	AFF3	-0.44	-7.51	-0.38	5.58e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg20219074	chr11:18656078	SPTY2D1	-0.71	-10.48	-0.5	2.05e-22	Breast cancer;
LUSC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg26162295	chr17:38119207	GSDMA	0.24	5.9	0.31	9.1e-9	Self-reported allergy;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12876261	chr7:56119223	PSPH;CCT6A	-0.54	-7.06	-0.36	9.97e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs8027181	0.804	rs7178130	chr15:72978202	A/G	cg25632853	chr15:73088954	NA	-0.32	-6.45	-0.33	3.93e-10	Triglyceride levels;
LUSC	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg07169764	chr2:136633963	MCM6	1.05	14.07	0.61	1.21e-35	Corneal structure;
LUSC	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg26384229	chr12:38710491	ALG10B	0.56	9.07	0.44	1.07e-17	Morning vs. evening chronotype;
LUSC	cis	rs72634258	0.945	rs67717282	chr1:8041290	C/T	cg00042356	chr1:8021962	PARK7	0.75	9.38	0.46	1.05e-18	Inflammatory bowel disease;
LUSC	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg23649088	chr2:200775458	C2orf69	-0.57	-7.01	-0.36	1.33e-11	Schizophrenia;
LUSC	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg23277830	chr1:3704460	LRRC47	0.35	6.66	0.34	1.11e-10	Red cell distribution width;
LUSC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06481639	chr22:41940642	POLR3H	-0.51	-5.76	-0.3	1.86e-8	Vitiligo;
LUSC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.07e-12	Motion sickness;
LUSC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7189233	0.531	rs4281707	chr16:53501946	G/A	cg09728985	chr16:53543985	NA	-0.32	-5.96	-0.31	6.3e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.08	-0.4	1.19e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.82	13.74	0.6	2.25e-34	Aortic root size;
LUSC	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg05340658	chr4:99064831	C4orf37	0.43	6.6	0.34	1.64e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg10621924	chr7:39171070	POU6F2	0.48	7.36	0.37	1.49e-12	IgG glycosylation;
LUSC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg12564285	chr5:131593104	PDLIM4	-0.47	-8.04	-0.4	1.6e-14	Breast cancer;
LUSC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.29e-12	Tonsillectomy;
LUSC	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.51	10.22	0.49	1.58e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.8	-14.41	-0.62	5.8e-37	Cognitive function;
LUSC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg04369109	chr6:150039330	LATS1	-0.56	-8.21	-0.41	4.77e-15	Lung cancer;
LUSC	cis	rs73206853	0.620	rs28720928	chr12:111126609	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	7.68	0.39	1.82e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9815354	0.812	rs73069213	chr3:41940590	G/A	cg03022575	chr3:42003672	ULK4	0.82	8.61	0.43	3.02e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12292205	chr6:26970375	C6orf41	-0.64	-9.14	-0.45	6.03e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs716595	0.581	rs12415370	chr10:112015221	C/T	cg13996003	chr10:112034540	MXI1	-0.61	-7.22	-0.37	3.62e-12	Normalized brain volume;
LUSC	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg24562669	chr7:97807699	LMTK2	0.47	8.39	0.42	1.38e-15	Breast cancer;
LUSC	cis	rs16854884	0.632	rs4563409	chr3:143682122	T/G	cg06585982	chr3:143692056	C3orf58	0.45	6.7	0.34	8.62e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.86	15.81	0.65	2e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg00908189	chr16:619842	PIGQ	0.67	10.41	0.5	3.54e-22	Height;
LUSC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg09904177	chr6:26538194	HMGN4	0.73	13.41	0.59	4.05e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs9309473	1.000	rs56672945	chr2:73622663	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-6.83	-0.35	3.95e-11	Metabolite levels;
LUSC	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.98	-0.31	5.65e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs11165623	0.792	rs9437607	chr1:96977788	G/A	cg10631902	chr5:14652156	NA	-0.45	-6.95	-0.36	1.96e-11	Hip circumference;Waist circumference;
LUSC	cis	rs1506636	1.000	rs652497	chr7:123423671	G/T	cg03229431	chr7:123269106	ASB15	0.65	10.68	0.5	4.29e-23	Plateletcrit;Platelet count;
LUSC	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg21672276	chr3:44754072	ZNF502	-0.38	-5.77	-0.3	1.85e-8	Depressive symptoms;
LUSC	cis	rs9467773	0.595	rs9366657	chr6:26434914	C/G	cg09904177	chr6:26538194	HMGN4	0.59	9.12	0.45	7.16e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.57	8.23	0.41	4.23e-15	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7561273	0.586	rs11896092	chr2:24317827	G/A	cg20701182	chr2:24300061	SF3B14	0.51	6.55	0.34	2.19e-10	Quantitative traits;
LUSC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg02487422	chr3:49467188	NICN1	0.44	7.03	0.36	1.17e-11	Resting heart rate;
LUSC	cis	rs540254	0.647	rs12405457	chr1:160759052	A/G	cg20255094	chr1:160771763	LY9	0.55	6.54	0.34	2.25e-10	Blood protein levels;
LUSC	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg18196295	chr10:418757	DIP2C	0.5	8.34	0.42	1.91e-15	Psychosis in Alzheimer's disease;
LUSC	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.52	0.34	2.68e-10	Subjective well-being;
LUSC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg24399712	chr22:39784796	NA	-0.62	-11.36	-0.53	1.66e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg06532163	chr17:45867833	NA	0.35	6.53	0.34	2.45e-10	IgG glycosylation;
LUSC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg17724175	chr1:150552817	MCL1	-0.44	-8.0	-0.4	2.13e-14	Urate levels;
LUSC	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg10857441	chr5:6722123	POLS	-0.36	-6.58	-0.34	1.81e-10	Menopause (age at onset);
LUSC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.43	-0.42	1.08e-15	Height;
LUSC	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg21366198	chr4:185655624	MLF1IP	0.42	6.0	0.31	5.19e-9	Kawasaki disease;
LUSC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-11.45	-0.53	8.21e-26	Heart rate;
LUSC	trans	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg01620082	chr3:125678407	NA	-0.69	-7.46	-0.38	7.76e-13	Depression;
LUSC	cis	rs4704187	0.640	rs1600073	chr5:74436737	C/T	cg03227963	chr5:74354835	NA	0.3	6.34	0.33	7.48e-10	Response to amphetamines;
LUSC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg21132104	chr15:45694354	SPATA5L1	0.57	8.14	0.41	7.67e-15	Homoarginine levels;
LUSC	trans	rs1973993	0.745	rs6686016	chr1:96948002	G/A	cg10631902	chr5:14652156	NA	-0.49	-7.37	-0.37	1.34e-12	Weight;
LUSC	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg05985134	chr18:33552581	C18orf21	0.51	7.01	0.36	1.33e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.32e-23	Alcohol dependence;
LUSC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24549020	chr5:56110836	MAP3K1	0.49	5.67	0.3	3.12e-8	Initial pursuit acceleration;
LUSC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.24	0.52	4.63e-25	Prudent dietary pattern;
LUSC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.51	0.34	2.77e-10	Menopause (age at onset);
LUSC	cis	rs2580764	0.678	rs2255112	chr2:55200800	T/G	cg09592903	chr2:55203963	RTN4	0.48	9.97	0.48	1.17e-20	Mean platelet volume;
LUSC	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg12940439	chr1:67600707	NA	0.37	6.01	0.31	4.96e-9	Psoriasis;
LUSC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg16329197	chr12:53359506	NA	-0.51	-7.23	-0.37	3.32e-12	Prostate cancer;
LUSC	cis	rs4947962	0.585	rs57682440	chr7:55156075	G/A	cg23757825	chr7:55092271	EGFR	-0.46	-5.67	-0.3	3.08e-8	Subjective response to lithium treatment;
LUSC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg03213289	chr20:61660250	NA	0.67	13.96	0.61	3.26e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04362095	chr11:63592001	C11orf84	-0.58	-8.9	-0.44	3.59e-17	Pulse pressure;
LUSC	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg05855489	chr10:104503620	C10orf26	0.52	8.02	0.4	1.81e-14	Arsenic metabolism;
LUSC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs929596	0.574	rs75444879	chr2:234587848	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-7.47	-0.38	7.23e-13	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs2115630	0.791	rs2008262	chr15:85305270	C/T	cg09876464	chr15:85330779	ZNF592	0.37	6.73	0.35	7.22e-11	P wave terminal force;
LUSC	cis	rs6693567	0.565	rs1260404	chr1:150304150	T/A	cg15654264	chr1:150340011	RPRD2	0.44	7.02	0.36	1.22e-11	Migraine;
LUSC	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg04545296	chr12:48745243	ZNF641	0.33	6.27	0.32	1.11e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs7428496	0.528	rs6440085	chr3:142232743	A/T	cg16271453	chr3:142027066	XRN1	-0.51	-8.95	-0.44	2.6e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	7.14	0.36	5.75e-12	Mean platelet volume;
LUSC	trans	rs6982636	0.934	rs2954022	chr8:126482621	C/A	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.33	-6.39	-0.33	5.59e-10	Lipid metabolism phenotypes;
LUSC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	1.13	17.44	0.69	6.81e-49	Corneal structure;
LUSC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.55	-0.42	4.48e-16	Personality dimensions;
LUSC	cis	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg12435725	chr3:58293450	RPP14	-0.68	-7.11	-0.36	6.88e-12	Cholesterol, total;
LUSC	trans	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	trans	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.41	-0.33	4.9e-10	Monocyte count;
LUSC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg20203395	chr5:56204925	C5orf35	-0.62	-7.99	-0.4	2.23e-14	Initial pursuit acceleration;
LUSC	cis	rs1577917	0.958	rs12209668	chr6:86566517	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg11189052	chr15:85197271	WDR73	0.49	6.3	0.33	9.15e-10	Schizophrenia;
LUSC	cis	rs11608355	0.545	rs11615949	chr12:109894347	G/A	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.1e-26	Neuroticism;
LUSC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg22823121	chr1:150693482	HORMAD1	-0.54	-7.82	-0.39	7.11e-14	Blood protein levels;
LUSC	trans	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.63	0.5	6.54e-23	Mean corpuscular volume;
LUSC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.55	10.06	0.48	5.64e-21	Bone mineral density;
LUSC	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg00784671	chr22:46762841	CELSR1	-0.63	-7.02	-0.36	1.27e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-7.01	-0.36	1.29e-11	Homocysteine levels;
LUSC	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.11	-0.32	2.82e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00339695	chr16:24857497	SLC5A11	0.6	8.76	0.43	9.9900000000000006e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05397629	chr11:3848986	RHOG	0.46	6.0	0.31	5.1e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg27170947	chr2:26402098	FAM59B	0.61	8.46	0.42	8.73e-16	Gut microbiome composition (summer);
LUSC	cis	rs1348850	0.757	rs4893954	chr2:178340520	T/G	cg22681709	chr2:178499509	PDE11A	-0.52	-9.52	-0.46	3.72e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.75	14.43	0.62	5.06e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.31	-5.77	-0.3	1.84e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	14.39	0.62	7.47e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11169552	0.510	rs10783376	chr12:50981249	C/G	cg12884762	chr12:50931848	DIP2B	-0.31	-5.65	-0.3	3.5e-8	Colorectal cancer;
LUSC	cis	rs11587400	0.656	rs6689415	chr1:115107469	G/T	cg12756093	chr1:115239321	AMPD1	0.4	5.89	0.31	9.27e-9	Autism;
LUSC	cis	rs710216	0.957	rs12041787	chr1:43432275	G/C	cg03128534	chr1:43423976	SLC2A1	0.47	5.86	0.31	1.09e-8	Red cell distribution width;
LUSC	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.73	-11.52	-0.53	4.47e-26	Schizophrenia;
LUSC	cis	rs977987	0.778	rs7206541	chr16:75436713	A/T	cg04384234	chr16:75411784	CFDP1	-0.41	-6.58	-0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs4629180	0.586	rs10206804	chr2:102132431	C/T	cg04415270	chr2:102091202	RFX8	0.44	7.68	0.39	1.82e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22307029	chr19:49891270	CCDC155	0.68	9.33	0.45	1.49e-18	Multiple sclerosis;
LUSC	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.81	-11.36	-0.53	1.66e-25	Ileal carcinoids;
LUSC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.44	7.48	0.38	6.6e-13	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs73001065	0.901	rs73004959	chr19:19711139	C/T	cg03709012	chr19:19516395	GATAD2A	0.91	7.2	0.37	4.06e-12	LDL cholesterol;
LUSC	cis	rs6500395	1.000	rs9939103	chr16:48592376	G/C	cg04672837	chr16:48644449	N4BP1	0.43	6.47	0.33	3.44e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg13010199	chr12:38710504	ALG10B	-0.44	-6.7	-0.34	8.94e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg21775007	chr8:11205619	TDH	0.44	5.8	0.3	1.55e-8	Neuroticism;
LUSC	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg13755796	chr4:20253514	NA	-0.43	-6.66	-0.34	1.12e-10	Life satisfaction;
LUSC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg11657440	chr19:46296263	DMWD	0.87	16.62	0.67	1.22e-45	Coronary artery disease;
LUSC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg04369109	chr6:150039330	LATS1	0.59	8.76	0.43	9.94e-17	Lung cancer;
LUSC	cis	rs9311676	0.656	rs4681679	chr3:58332068	A/G	cg13750441	chr3:58318267	PXK	-0.31	-5.88	-0.31	1.01e-8	Systemic lupus erythematosus;
LUSC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg17211192	chr8:82754475	SNX16	0.74	9.96	0.48	1.22e-20	Diastolic blood pressure;
LUSC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg20684491	chr1:25596433	NA	-0.36	-5.69	-0.3	2.73e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs1395	1.000	rs2014252	chr2:27462405	T/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.37	5.98	0.31	5.78e-9	Blood metabolite levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02257048	chr17:78880031	RPTOR	0.47	6.68	0.34	9.77e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7561273	0.609	rs2080727	chr2:24350907	A/G	cg06627628	chr2:24431161	ITSN2	-0.51	-6.8	-0.35	4.71e-11	Quantitative traits;
LUSC	cis	rs67072384	0.892	rs72964172	chr11:72436436	G/A	cg04827223	chr11:72435913	ARAP1	-0.87	-7.72	-0.39	1.34e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg21918786	chr6:109611834	NA	0.39	6.66	0.34	1.12e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg24692254	chr21:30365293	RNF160	-0.74	-11.36	-0.53	1.62e-25	Pancreatic cancer;
LUSC	cis	rs3018712	0.590	rs4930236	chr11:68414000	C/A	cg20283391	chr11:68216788	NA	0.57	5.72	0.3	2.42e-8	Total body bone mineral density;
LUSC	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg08824895	chr13:115047677	UPF3A	0.56	8.69	0.43	1.63e-16	Schizophrenia;
LUSC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg02487422	chr3:49467188	NICN1	0.46	7.2	0.37	4.02e-12	Resting heart rate;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23369371	chr2:220118598	TUBA4A;TUBA4B	-0.41	-5.98	-0.31	5.61e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.73	-12.68	-0.57	2.33e-30	Brugada syndrome;
LUSC	cis	rs4664308	1.000	rs16844715	chr2:160915106	A/G	cg03641300	chr2:160917029	PLA2R1	0.67	11.0	0.52	3.21e-24	Idiopathic membranous nephropathy;
LUSC	cis	rs2625529	0.824	rs12592364	chr15:72284647	C/A	cg16672083	chr15:72433130	SENP8	-0.51	-7.44	-0.38	8.7e-13	Red blood cell count;
LUSC	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg12863693	chr15:85201151	NMB	0.34	6.31	0.33	8.89e-10	Schizophrenia;
LUSC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-6.08	-0.32	3.26e-9	Obesity-related traits;
LUSC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg23788917	chr6:8435910	SLC35B3	-0.48	-7.18	-0.37	4.68e-12	Motion sickness;
LUSC	cis	rs889512	0.642	rs28439846	chr16:75280378	G/A	cg04987608	chr16:75300043	BCAR1	-0.5	-5.74	-0.3	2.18e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs17490626	0.568	rs12413529	chr10:71211644	G/T	cg14388049	chr10:71211838	TSPAN15	-0.32	-5.81	-0.3	1.47e-8	Thrombosis;
LUSC	trans	rs12439619	0.846	rs62012059	chr15:82544010	A/C	cg04831495	chr15:85060580	GOLGA6L5	-0.47	-6.27	-0.32	1.13e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg09997546	chr11:8931473	C11orf17;ST5	0.38	7.08	0.36	8.82e-12	Schizophrenia;
LUSC	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg01620082	chr3:125678407	NA	-0.78	-7.29	-0.37	2.28e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.2e-15	Neuroticism;
LUSC	cis	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg18209359	chr17:80159595	CCDC57	-0.36	-5.83	-0.3	1.31e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg05340658	chr4:99064831	C4orf37	-0.59	-9.39	-0.46	9.69e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs356992	0.830	rs356991	chr2:60744872	T/G	cg08426369	chr2:60753602	BCL11A	0.44	5.96	0.31	6.36e-9	Educational attainment (years of education);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02091366	chr17:16342131	NCRNA00188;SNORD49B;SNORD49A	0.4	6.23	0.32	1.44e-9	Triglycerides;
LUSC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.42	-6.82	-0.35	4.22e-11	Platelet count;
LUSC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.4	0.33	5.28e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24110177	chr3:50126178	RBM5	0.64	11.28	0.53	3.1e-25	Body mass index;
LUSC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg00815214	chr21:47717953	NA	-0.38	-6.16	-0.32	2.09e-9	Testicular germ cell tumor;
LUSC	cis	rs7843479	0.601	rs12056476	chr8:21854188	T/A	cg17168535	chr8:21777572	XPO7	0.81	14.64	0.63	7.42e-38	Mean corpuscular volume;
LUSC	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg15744005	chr10:104629667	AS3MT	-0.3	-5.73	-0.3	2.29e-8	Arsenic metabolism;
LUSC	cis	rs9462027	0.628	rs6899938	chr6:34749113	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.11e-8	Systemic lupus erythematosus;
LUSC	cis	rs56399783	0.901	rs56356906	chr7:2774383	G/A	cg14895029	chr7:2775587	GNA12	0.53	5.77	0.3	1.81e-8	Childhood ear infection;
LUSC	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-11.76	-0.54	5.79e-27	Systemic lupus erythematosus;
LUSC	cis	rs113835537	0.529	rs17496250	chr11:66270774	C/G	cg24851651	chr11:66362959	CCS	0.53	7.73	0.39	1.31e-13	Airway imaging phenotypes;
LUSC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.69	0.34	9.34e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg03929089	chr4:120376271	NA	-0.83	-12.09	-0.55	3.76e-28	Coronary artery disease;
LUSC	cis	rs17162190	0.698	rs4659443	chr1:26823631	C/T	cg17456097	chr1:26900765	RPS6KA1	0.4	5.88	0.31	1.02e-8	Mean corpuscular volume;
LUSC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	6.96	0.36	1.78e-11	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg25214090	chr10:38739885	LOC399744	0.53	7.78	0.39	9.04e-14	Corneal astigmatism;
LUSC	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg01236616	chr12:121019343	POP5	-1.34	-21.81	-0.77	3.35e-66	Type 1 diabetes nephropathy;
LUSC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg25319279	chr11:5960081	NA	-0.39	-5.87	-0.31	1.05e-8	DNA methylation (variation);
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg15242686	chr22:24348715	GSTTP1	0.41	6.13	0.32	2.42e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg23711669	chr6:146136114	FBXO30	-0.67	-11.61	-0.54	2.09e-26	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.14	0.41	8.16e-15	Axial length;
LUSC	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg16342193	chr10:102329863	NA	-0.35	-6.27	-0.32	1.12e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg24675658	chr1:53192096	ZYG11B	0.72	11.91	0.55	1.75e-27	Monocyte count;
LUSC	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg11502198	chr6:26597334	ABT1	0.7	11.83	0.54	3.39e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs62056376	0.646	rs1024610	chr17:32580231	A/T	cg19986872	chr5:131347773	ACSL6	0.38	6.29	0.33	9.68e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.4	6.96	0.36	1.8e-11	Axial length;
LUSC	cis	rs983392	0.679	rs72920867	chr11:60005424	T/C	cg20284999	chr11:59952153	MS4A6A	-0.36	-6.01	-0.31	4.74e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.52e-8	Breast cancer;
LUSC	cis	rs11650494	0.808	rs61286260	chr17:47433222	T/C	cg08112188	chr17:47440006	ZNF652	1.13	10.12	0.48	3.46e-21	Prostate cancer;
LUSC	trans	rs2562456	0.558	rs62108173	chr19:21427188	C/T	cg00806126	chr19:22604979	ZNF98	-0.42	-6.04	-0.31	4.05e-9	Pain;
LUSC	cis	rs9395066	0.545	rs10948193	chr6:44949176	G/A	cg25276700	chr6:44698697	NA	0.28	5.78	0.3	1.75e-8	Height;
LUSC	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg23093090	chr10:104574429	C10orf26	-0.39	-7.5	-0.38	5.84e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg27471124	chr11:109292789	C11orf87	0.38	6.94	0.35	2.08e-11	Schizophrenia;
LUSC	cis	rs11587400	0.514	rs222499	chr1:115146488	C/A	cg12756093	chr1:115239321	AMPD1	-0.43	-6.42	-0.33	4.67e-10	Autism;
LUSC	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	0.68	10.81	0.51	1.5e-23	Blood metabolite ratios;
LUSC	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg17764715	chr19:33622953	WDR88	0.55	7.57	0.38	3.75e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01171360	chr6:293285	DUSP22	-0.48	-7.01	-0.36	1.29e-11	Menopause (age at onset);
LUSC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.72	0.57	1.74e-30	Motion sickness;
LUSC	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.54	-0.34	2.36e-10	QT interval;
LUSC	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg04586622	chr2:25135609	ADCY3	0.4	8.37	0.42	1.58e-15	Body mass index;
LUSC	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg16070123	chr10:51489643	NA	-0.53	-7.89	-0.4	4.33e-14	Prostate-specific antigen levels;
LUSC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg26566898	chr11:117069891	TAGLN	0.33	6.28	0.32	1.08e-9	Blood protein levels;
LUSC	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg24675056	chr1:15929824	NA	0.44	7.36	0.37	1.46e-12	Systolic blood pressure;
LUSC	cis	rs13385	0.769	rs7727069	chr5:139573265	A/G	cg26211634	chr5:139558579	C5orf32	0.44	6.31	0.33	8.82e-10	Atrial fibrillation;
LUSC	cis	rs7113850	0.541	rs7102578	chr11:24244671	G/T	ch.11.24196551F	chr11:24239977	NA	1.0	9.14	0.45	6.23e-18	Bone fracture in osteoporosis;
LUSC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg20818283	chr2:191399100	TMEM194B	0.45	6.98	0.36	1.59e-11	Pulse pressure;
LUSC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.55	0.34	2.16e-10	Schizophrenia;
LUSC	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg13010199	chr12:38710504	ALG10B	0.7	10.92	0.51	5.92e-24	Bladder cancer;
LUSC	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	1.09	14.67	0.63	6.13e-38	Nonalcoholic fatty liver disease;
LUSC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg12615879	chr12:58013172	SLC26A10	0.28	5.76	0.3	1.92e-8	Multiple sclerosis;
LUSC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.37	0.33	6.28e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg20991723	chr1:152506922	NA	0.5	9.52	0.46	3.74e-19	Hair morphology;
LUSC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg22907277	chr7:1156413	C7orf50	0.49	7.43	0.38	9.12e-13	Longevity;Endometriosis;
LUSC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg08470875	chr2:26401718	FAM59B	-0.66	-8.86	-0.44	4.75e-17	Gut microbiome composition (summer);
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg06675538	chr2:114033490	PAX8;LOC440839	-0.32	-5.7	-0.3	2.68e-8	Lymphocyte counts;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04829863	chr8:116680636	TRPS1	0.47	6.17	0.32	1.92e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg20203395	chr5:56204925	C5orf35	-0.46	-6.74	-0.35	6.98e-11	Coronary artery disease;
LUSC	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg19628046	chr18:33552617	C18orf21	0.51	6.17	0.32	1.96e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg00343986	chr7:65444356	GUSB	-0.38	-5.71	-0.3	2.46e-8	Aortic root size;
LUSC	cis	rs1983891	1.000	rs9381082	chr6:41542214	T/C	cg15051332	chr6:41514432	FOXP4	0.41	5.91	0.31	8.43e-9	Prostate cancer;
LUSC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-12.11	-0.55	3.2e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg13114125	chr14:105738426	BRF1	-0.9	-15.6	-0.65	1.38e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg22800045	chr5:56110881	MAP3K1	0.75	9.61	0.47	1.89e-19	Initial pursuit acceleration;
LUSC	cis	rs6012953	0.730	rs6020562	chr20:49119606	G/C	cg13958625	chr20:49123093	NA	0.28	6.01	0.31	4.81e-9	Vitiligo;
LUSC	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.94	0.51	5.25e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.61	-11.02	-0.52	2.61e-24	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg24375607	chr4:120327624	NA	-0.62	-9.83	-0.47	3.3e-20	Corneal astigmatism;
LUSC	trans	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.32	-0.33	8.32e-10	Monocyte count;
LUSC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg04944784	chr2:26401820	FAM59B	0.78	11.14	0.52	1.04e-24	Gut microbiome composition (summer);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02522952	chr6:119671260	MAN1A1	-0.47	-6.1	-0.32	2.94e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	11.51	0.53	4.92e-26	Prudent dietary pattern;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27194164	chr19:17666205	GLT25D1	-0.49	-6.21	-0.32	1.56e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs4729127	1.000	rs17166212	chr7:94008385	A/G	cg14660007	chr13:78271894	SLAIN1	0.5	6.45	0.33	3.88e-10	Intelligence;
LUSC	cis	rs6460942	0.908	rs77034890	chr7:12244506	A/T	cg06484146	chr7:12443880	VWDE	-0.59	-5.88	-0.31	9.76e-9	Coronary artery disease;
LUSC	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg23649088	chr2:200775458	C2orf69	-0.57	-7.01	-0.36	1.33e-11	Schizophrenia;
LUSC	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg23840854	chr1:161414152	NA	-0.91	-11.11	-0.52	1.34e-24	Rheumatoid arthritis;
LUSC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg03351412	chr1:154909251	PMVK	0.56	8.87	0.44	4.52e-17	Prostate cancer;
LUSC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg27094323	chr7:1216898	NA	-0.43	-7.22	-0.37	3.62e-12	Longevity;Endometriosis;
LUSC	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg21665744	chr7:39171113	POU6F2	0.44	6.54	0.34	2.24e-10	IgG glycosylation;
LUSC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg02807482	chr3:125708958	NA	-0.5	-6.12	-0.32	2.67e-9	Blood pressure (smoking interaction);
LUSC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.42	0.38	9.97e-13	Bipolar disorder;
LUSC	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14169450	chr9:139327907	INPP5E	0.46	8.22	0.41	4.61e-15	Monocyte percentage of white cells;
LUSC	cis	rs6537837	0.887	rs17024195	chr1:110143755	G/T	cg05049280	chr1:110155535	GNAT2	0.45	6.73	0.35	7.22e-11	Major depressive disorder;
LUSC	trans	rs9929218	1.000	rs2113201	chr16:68815000	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.53	-0.53	3.92e-26	Colorectal cancer;
LUSC	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs1322512	1.000	rs2758782	chr6:153010341	C/T	cg27316956	chr6:152958899	SYNE1	0.35	6.06	0.31	3.59e-9	Tonometry;
LUSC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg00106254	chr7:1943704	MAD1L1	-0.41	-5.98	-0.31	5.6e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg11189052	chr15:85197271	WDR73	-0.42	-5.99	-0.31	5.43e-9	P wave terminal force;
LUSC	cis	rs1832871	0.521	rs878585	chr6:158815897	C/T	cg07165851	chr6:158734300	TULP4	0.4	6.39	0.33	5.42e-10	Height;
LUSC	cis	rs713477	1.000	rs12893964	chr14:55912268	T/C	cg04306507	chr14:55594613	LGALS3	-0.29	-5.68	-0.3	2.99e-8	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	7.47	0.38	6.86e-13	Menarche (age at onset);
LUSC	cis	rs983392	0.709	rs1426250	chr11:60001325	A/G	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.11	-0.32	2.73e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	0.93	15.66	0.65	7.69e-42	Menopause (age at onset);
LUSC	cis	rs28829049	0.570	rs12060125	chr1:19391108	A/G	cg13387374	chr1:19411106	UBR4	-0.43	-6.26	-0.32	1.16e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.01	-21.47	-0.76	7.5e-65	Height;
LUSC	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg12935359	chr14:103987150	CKB	-0.61	-9.89	-0.48	2.12e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	7.89	0.4	4.26e-14	Breast cancer;
LUSC	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg25237894	chr2:233734115	C2orf82	0.37	6.95	0.36	1.93e-11	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.76	-0.43	1.02e-16	Lung cancer;
LUSC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg00343986	chr7:65444356	GUSB	-0.43	-6.55	-0.34	2.17e-10	Aortic root size;
LUSC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.46e-35	Breast cancer;
LUSC	cis	rs7572644	0.640	rs11127125	chr2:28023120	T/C	cg27432699	chr2:27873401	GPN1	0.56	7.36	0.37	1.46e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg08499158	chr17:42289980	UBTF	-0.49	-8.28	-0.41	3.05e-15	Total body bone mineral density;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18159740	chr13:30881703	KATNAL1	0.43	6.29	0.33	1.02e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg25237894	chr2:233734115	C2orf82	0.35	6.59	0.34	1.69e-10	Coronary artery disease;
LUSC	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg15557168	chr22:42548783	NA	-0.33	-5.67	-0.3	3.11e-8	Cognitive function;
LUSC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg02269571	chr22:50332266	NA	-0.58	-8.67	-0.43	1.97e-16	Schizophrenia;
LUSC	cis	rs13385	0.769	rs2053058	chr5:139563483	T/C	cg26211634	chr5:139558579	C5orf32	0.45	6.54	0.34	2.25e-10	Atrial fibrillation;
LUSC	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.14	0.74	1.3e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-20.1	-0.74	1.91e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg04315214	chr1:2043799	PRKCZ	-0.37	-7.1	-0.36	7.39e-12	Height;
LUSC	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg26536354	chr8:144654954	C8orf73	0.61	6.85	0.35	3.61e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg01238044	chr22:24384105	GSTT1	0.52	7.59	0.38	3.23e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs603424	0.551	rs610745	chr10:102089436	G/A	cg10365880	chr10:102089681	PKD2L1	0.59	6.76	0.35	6.1e-11	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
LUSC	cis	rs3755132	0.929	rs976015	chr2:15772546	C/G	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.25	0.37	3.01e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	0.6	10.28	0.49	1.04e-21	Gut microbiome composition (winter);
LUSC	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.19	0.32	1.77e-9	Neuroticism;
LUSC	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg05283184	chr6:79620031	NA	-0.58	-12.41	-0.56	2.39e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg01028140	chr2:1542097	TPO	-0.49	-6.94	-0.36	2e-11	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.33	6.32	0.33	8.58e-10	Platelet count;
LUSC	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg17507749	chr15:85114479	UBE2QP1	0.56	6.91	0.35	2.45e-11	Schizophrenia;
LUSC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg15556689	chr8:8085844	FLJ10661	0.56	9.02	0.44	1.46e-17	Joint mobility (Beighton score);
LUSC	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg19052272	chr2:3704530	ALLC	-0.46	-7.58	-0.38	3.35e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24838063	chr12:130822603	PIWIL1	0.71	11.02	0.52	2.72e-24	Menopause (age at onset);
LUSC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg16447950	chr5:562315	NA	-0.54	-6.59	-0.34	1.77e-10	Obesity-related traits;
LUSC	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg05043794	chr9:111880884	C9orf5	-0.34	-7.15	-0.36	5.42e-12	Menarche (age at onset);
LUSC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg01475377	chr6:109611718	NA	-0.46	-8.37	-0.42	1.59e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg04362960	chr10:104952993	NT5C2	0.47	5.88	0.31	9.95e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs35767	0.841	rs860598	chr12:102898446	C/T	cg12923613	chr4:83812206	SEC31A	0.49	5.98	0.31	5.86e-9	Homeostasis model assessment of insulin resistance;Fasting blood insulin;
LUSC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	6.95	0.36	1.95e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg06454157	chr6:167490870	NA	-0.28	-6.77	-0.35	5.86e-11	Primary biliary cholangitis;
LUSC	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg12473912	chr3:136751656	NA	0.39	6.74	0.35	6.96e-11	Neuroticism;
LUSC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	0.6	9.39	0.46	9.48e-19	Breast cancer;
LUSC	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.3e-11	Uric acid levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00316777	chr8:86376489	CA2	-0.41	-6.29	-0.33	1.02e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7119	0.636	rs11635606	chr15:77819591	A/G	cg27398640	chr15:77910606	LINGO1	-0.31	-6.39	-0.33	5.48e-10	Type 2 diabetes;
LUSC	cis	rs9399401	0.710	rs10484733	chr6:142710988	C/G	cg04461802	chr6:142623433	GPR126	0.47	5.87	0.31	1.06e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg00945038	chr17:61921165	SMARCD2	0.51	8.47	0.42	7.97e-16	Prudent dietary pattern;
LUSC	cis	rs1160297	0.585	rs12713227	chr2:53090018	A/G	cg07782112	chr2:53107842	NA	0.37	6.24	0.32	1.3e-9	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7508679	1.000	rs10410204	chr19:7224350	C/T	cg00428638	chr19:7224713	INSR	0.37	7.8	0.39	8.1e-14	Hypothyroidism;
LUSC	trans	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg27600084	chr12:12264075	NA	0.45	6.64	0.34	1.26e-10	Breast size;
LUSC	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.27e-8	Breast cancer;
LUSC	cis	rs9314323	0.767	rs10866848	chr8:26208209	G/C	cg13160058	chr8:26243215	BNIP3L	-0.41	-7.12	-0.36	6.83e-12	Red cell distribution width;
LUSC	cis	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.45e-10	Ulcerative colitis;
LUSC	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg14416269	chr4:6271139	WFS1	0.52	10.7	0.51	3.6e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg22153745	chr1:153894579	GATAD2B	0.5	6.92	0.35	2.27e-11	Total cholesterol levels;
LUSC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs12286929	0.646	rs12805914	chr11:115019739	T/A	cg04055981	chr11:115044050	NA	0.35	5.96	0.31	6.34e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg21132104	chr15:45694354	SPATA5L1	0.57	8.14	0.41	7.67e-15	Homoarginine levels;
LUSC	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.75	-0.65	3.35e-42	Height;
LUSC	cis	rs9472414	0.510	rs609699	chr6:44705266	G/A	cg20913747	chr6:44695427	NA	0.38	5.77	0.3	1.81e-8	Height;
LUSC	trans	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg25214090	chr10:38739885	LOC399744	0.49	7.2	0.37	3.9e-12	Corneal astigmatism;
LUSC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	1.03	21.0	0.75	5.38e-63	Cognitive function;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg20060089	chr17:41561319	DHX8	0.36	6.17	0.32	2.02e-9	Tuberculosis;
LUSC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg04155289	chr7:94953770	PON1	-0.34	-5.72	-0.3	2.42e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg26384229	chr12:38710491	ALG10B	0.7	10.84	0.51	1.21e-23	Morning vs. evening chronotype;
LUSC	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg13575925	chr12:9217583	LOC144571	0.33	5.99	0.31	5.42e-9	Sjögren's syndrome;
LUSC	cis	rs17125944	0.615	rs7151474	chr14:53313680	C/T	cg00686598	chr14:53173677	PSMC6	-0.62	-5.82	-0.3	1.36e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7712401	0.601	rs193539	chr5:122257617	C/G	cg19077854	chr5:122220652	SNX24	0.41	9.19	0.45	4.27e-18	Mean platelet volume;
LUSC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	8.11	0.41	9.9e-15	Bipolar disorder;
LUSC	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg18681998	chr4:17616180	MED28	-0.71	-11.81	-0.54	3.83e-27	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11931598	0.702	rs10937780	chr4:7048842	A/G	cg26116260	chr4:7069785	GRPEL1	-0.44	-6.75	-0.35	6.59e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.66	-0.34	1.1e-10	Response to antipsychotic treatment;
LUSC	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg04989706	chr14:50066350	PPIL5	-0.45	-5.77	-0.3	1.85e-8	Carotid intima media thickness;
LUSC	cis	rs7707921	0.801	rs862243	chr5:81586829	C/G	cg15871215	chr5:81402204	ATG10	0.45	7.07	0.36	8.95e-12	Breast cancer;
LUSC	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg06627628	chr2:24431161	ITSN2	-0.6	-7.34	-0.37	1.66e-12	Lymphocyte counts;
LUSC	cis	rs909341	0.818	rs2259858	chr20:62346459	A/T	cg09650180	chr20:62225654	GMEB2	-0.45	-5.84	-0.3	1.27e-8	Atopic dermatitis;
LUSC	cis	rs2274273	0.682	rs1201378	chr14:55493408	A/G	cg04306507	chr14:55594613	LGALS3	-0.5	-10.93	-0.51	5.72e-24	Protein biomarker;
LUSC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg23711669	chr6:146136114	FBXO30	0.77	13.91	0.61	5.36e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg12463550	chr7:65579703	CRCP	-0.42	-6.05	-0.31	3.89e-9	Aortic root size;
LUSC	cis	rs9646944	0.540	rs12712148	chr2:103025547	G/A	cg20060108	chr2:102954350	IL1RL1	0.48	6.6	0.34	1.65e-10	Blood protein levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04802657	chr16:28565199	CCDC101	0.74	6.2	0.32	1.67e-9	Cognitive performance;
LUSC	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg00191853	chr8:101177733	SPAG1	-0.38	-6.34	-0.33	7.3e-10	Atrioventricular conduction;
LUSC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg27398817	chr8:82754497	SNX16	0.64	8.13	0.41	8.71e-15	Diastolic blood pressure;
LUSC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06544989	chr22:39130855	UNC84B	0.33	5.74	0.3	2.12e-8	Menopause (age at onset);
LUSC	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg05110241	chr16:68378359	PRMT7	-0.49	-6.1	-0.32	2.92e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg02016764	chr4:38805732	TLR1	-0.54	-5.92	-0.31	7.93e-9	Breast cancer;
LUSC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	0.85	14.43	0.62	4.84e-37	Tonsillectomy;
LUSC	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg15654264	chr1:150340011	RPRD2	0.62	10.29	0.49	9.57e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9311676	0.656	rs62258081	chr3:58367705	A/C	cg13750441	chr3:58318267	PXK	0.35	6.84	0.35	3.72e-11	Systemic lupus erythematosus;
LUSC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg05082376	chr22:42548792	NA	0.43	6.59	0.34	1.73e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.05	-0.36	1.01e-11	Blood metabolite levels;
LUSC	cis	rs17030434	0.654	rs10021447	chr4:154646459	A/C	cg14289246	chr4:154710475	SFRP2	-0.46	-6.05	-0.31	3.98e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg18105134	chr13:113819100	PROZ	0.67	9.83	0.47	3.31e-20	Platelet distribution width;
LUSC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg15445000	chr17:37608096	MED1	-0.41	-6.98	-0.36	1.59e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg13010199	chr12:38710504	ALG10B	-0.58	-9.15	-0.45	5.64e-18	Bladder cancer;
LUSC	cis	rs1413885	0.525	rs1334878	chr1:65846124	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	6.99	0.36	1.49e-11	Anticoagulant levels;
LUSC	trans	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg13010199	chr12:38710504	ALG10B	0.43	6.7	0.34	8.99e-11	Morning vs. evening chronotype;
LUSC	cis	rs868036	0.522	rs3784711	chr15:68072527	C/T	cg08079166	chr15:68083412	MAP2K5	-0.38	-8.24	-0.41	3.96e-15	Restless legs syndrome;
LUSC	cis	rs7119	0.717	rs12902896	chr15:77809150	G/T	cg27398640	chr15:77910606	LINGO1	0.3	6.47	0.33	3.51e-10	Type 2 diabetes;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17946375	chr10:126150274	LHPP	-0.43	-6.57	-0.34	1.88e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.51	0.34	2.8e-10	Schizophrenia;
LUSC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg06784218	chr1:46089804	CCDC17	0.54	11.06	0.52	1.88e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg27170947	chr2:26402098	FAM59B	-0.67	-10.14	-0.49	2.95e-21	Gut microbiome composition (summer);
LUSC	cis	rs6578985	1.000	rs868330	chr11:2136605	A/G	cg25742037	chr11:2171694	INS-IGF2;IGF2	0.32	5.91	0.31	8.31e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs308403	0.600	rs309361	chr4:123657978	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.83	11.53	0.53	3.9e-26	Blood protein levels;
LUSC	cis	rs6574644	1.000	rs4903979	chr14:81778158	T/C	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg03342759	chr3:160939853	NMD3	-0.48	-6.55	-0.34	2.24e-10	Parkinson's disease;
LUSC	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg05163923	chr11:71159392	DHCR7	-0.66	-8.52	-0.42	5.58e-16	Vitamin D levels;
LUSC	cis	rs742132	0.527	rs17252870	chr6:25494666	A/C	cg03264133	chr6:25882463	NA	-0.45	-6.26	-0.32	1.2e-9	Uric acid levels;
LUSC	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg08601574	chr20:25228251	PYGB	-0.42	-6.35	-0.33	7.19e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1595825	0.838	rs73058854	chr2:198885060	G/A	cg00982548	chr2:198649783	BOLL	-0.56	-7.06	-0.36	9.65e-12	Ulcerative colitis;
LUSC	cis	rs3106136	0.967	rs12643901	chr4:95145132	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.12	-0.32	2.68e-9	Capecitabine sensitivity;
LUSC	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg05729581	chr11:3078854	CARS	-0.58	-8.91	-0.44	3.36e-17	Longevity;
LUSC	cis	rs2629751	0.512	rs2722169	chr12:104415450	C/T	cg14987745	chr12:104360022	TDG	-0.7	-8.67	-0.43	1.92e-16	Hepatitis C induced liver fibrosis;
LUSC	cis	rs1044826	0.642	rs6799312	chr3:139211932	C/T	cg15131784	chr3:139108705	COPB2	0.4	6.38	0.33	6.03e-10	Obesity-related traits;
LUSC	cis	rs6700896	0.522	rs59258332	chr1:66143591	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	6.03	0.31	4.25e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg13010199	chr12:38710504	ALG10B	0.66	10.16	0.49	2.56e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg10857441	chr5:6722123	POLS	-0.47	-9.02	-0.44	1.56e-17	Menopause (age at onset);
LUSC	cis	rs13088645	0.532	rs9857134	chr3:134161607	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.46	6.02	0.31	4.72e-9	Coronary artery disease;
LUSC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.35	5.67	0.3	3.11e-8	Systemic lupus erythematosus;
LUSC	cis	rs6700896	0.931	rs1892534	chr1:66105944	C/T	cg04111102	chr1:66153794	NA	0.31	6.82	0.35	4.16e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg19875535	chr5:140030758	IK	-0.54	-8.88	-0.44	4.18e-17	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg18187862	chr3:45730750	SACM1L	0.53	7.03	0.36	1.16e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg15744005	chr10:104629667	AS3MT	-0.29	-6.24	-0.32	1.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.9	-0.4	4.02e-14	Glomerular filtration rate;
LUSC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-7.01	-0.36	1.35e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg23283495	chr1:209979779	IRF6	0.44	7.21	0.37	3.74e-12	Monobrow;
LUSC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg24060327	chr5:131705240	SLC22A5	-0.52	-8.78	-0.43	8.45e-17	Breast cancer;
LUSC	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.92	0.51	6.12e-24	Hypertriglyceridemia;
LUSC	cis	rs113835537	0.529	rs2305532	chr11:66298594	C/T	cg24851651	chr11:66362959	CCS	0.54	7.86	0.4	5.2e-14	Airway imaging phenotypes;
LUSC	cis	rs4888262	0.545	rs7193959	chr16:74664969	T/A	cg01733217	chr16:74700730	RFWD3	0.78	12.74	0.57	1.44e-30	Testicular germ cell tumor;
LUSC	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.0	-0.44	1.72e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-7.42	-0.38	9.48e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.51	6.2	0.32	1.69e-9	Multiple sclerosis;
LUSC	cis	rs55665837	1.000	rs7945167	chr11:14451820	T/G	cg05501817	chr11:14380813	RRAS2	-0.41	-6.53	-0.34	2.5e-10	Vitamin D levels;
LUSC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg15448220	chr1:150897856	SETDB1	0.42	6.25	0.32	1.24e-9	Melanoma;
LUSC	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.29	0.59	1.19e-32	Blood protein levels;
LUSC	cis	rs6693567	0.826	rs1260387	chr1:150371448	T/C	cg15654264	chr1:150340011	RPRD2	0.43	6.03	0.31	4.45e-9	Migraine;
LUSC	cis	rs35883536	0.626	rs80052576	chr1:101039229	A/G	cg09408571	chr1:101003634	GPR88	-0.29	-5.73	-0.3	2.24e-8	Monocyte count;
LUSC	cis	rs225245	0.765	rs226428	chr17:34049950	C/T	cg05299278	chr17:33885742	SLFN14	-0.29	-6.41	-0.33	4.96e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	0.56	8.67	0.43	1.93e-16	Breast cancer;
LUSC	trans	rs979233	0.502	rs276246	chr5:42062189	T/C	cg07010552	chr17:7358735	CHRNB1	-0.41	-6.02	-0.31	4.72e-9	Systemic lupus erythematosus;
LUSC	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.67	-10.59	-0.5	8.39e-23	Menarche (age at onset);
LUSC	trans	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg12856521	chr11:46389249	DGKZ	0.4	6.27	0.32	1.09e-9	Leprosy;
LUSC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-7.85	-0.39	5.65e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	11.0	0.52	3.11e-24	Bone mineral density;
LUSC	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg04691961	chr3:161091175	C3orf57	-0.36	-5.65	-0.3	3.51e-8	Morning vs. evening chronotype;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg05222119	chr17:80211999	CSNK1D	-0.45	-6.67	-0.34	1.04e-10	N-glycan levels;
LUSC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.09	0.32	3.11e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.87	-0.31	1.07e-8	Birth weight;
LUSC	cis	rs4919087	1.000	rs11189127	chr10:99079023	G/A	cg25902810	chr10:99078978	FRAT1	0.5	7.47	0.38	6.94e-13	Monocyte count;
LUSC	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg27411982	chr8:10470053	RP1L1	0.39	6.06	0.31	3.57e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.28	0.32	1.08e-9	Corneal astigmatism;
LUSC	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg01528321	chr10:82214614	TSPAN14	0.59	8.84	0.44	5.79e-17	Post bronchodilator FEV1;
LUSC	cis	rs2294693	0.680	rs4714423	chr6:41012483	C/A	cg14769373	chr6:40998127	UNC5CL	-0.44	-6.21	-0.32	1.59e-9	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg23711669	chr6:146136114	FBXO30	0.91	17.89	0.7	1.12e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7577696	0.512	rs9789593	chr2:32381110	T/G	cg02381751	chr2:32503542	YIPF4	-0.53	-6.93	-0.35	2.2e-11	Inflammatory biomarkers;
LUSC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg11845111	chr2:191398756	TMEM194B	0.55	9.44	0.46	6.49e-19	Pulse pressure;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06557630	chr16:49889701	NA	-0.44	-5.97	-0.31	6.23e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1775715	1.000	rs1251363	chr10:32328526	G/C	cg18675610	chr10:32216311	ARHGAP12	-0.3	-6.17	-0.32	2.03e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.84	0.3	1.23e-8	Breast cancer;
LUSC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg22549504	chr19:17448937	GTPBP3	0.53	6.64	0.34	1.29e-10	Systemic lupus erythematosus;
LUSC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-11.59	-0.54	2.42e-26	Schizophrenia;
LUSC	trans	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.46	-0.38	7.64e-13	Neuroticism;
LUSC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg22535103	chr8:58192502	C8orf71	-0.58	-7.03	-0.36	1.2e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg13683864	chr3:40499215	RPL14	-0.94	-16.01	-0.66	3.38e-43	Renal cell carcinoma;
LUSC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg26513180	chr16:89883248	FANCA	-0.88	-16.52	-0.67	3.12e-45	Vitiligo;
LUSC	trans	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.34	-0.53	1.92e-25	Colorectal cancer;
LUSC	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-1.09	-20.76	-0.75	4.76e-62	Coronary artery disease;
LUSC	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg12292205	chr6:26970375	C6orf41	-0.62	-7.38	-0.37	1.3e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg01557791	chr16:72042693	DHODH	-0.43	-6.53	-0.34	2.42e-10	Fibrinogen levels;
LUSC	cis	rs77216612	1.000	rs77216612	chr12:12877983	A/G	cg04607235	chr12:12878440	APOLD1	-0.95	-15.59	-0.65	1.52e-41	Lymphocyte counts;
LUSC	cis	rs6977660	0.619	rs10223937	chr7:19787697	C/T	cg07541023	chr7:19748670	TWISTNB	0.62	6.84	0.35	3.71e-11	Thyroid stimulating hormone;
LUSC	cis	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg27411982	chr8:10470053	RP1L1	-0.36	-5.79	-0.3	1.6e-8	Neuroticism;
LUSC	cis	rs644148	0.836	rs2686777	chr19:45000386	T/C	cg15540054	chr19:45004280	ZNF180	-0.62	-9.16	-0.45	5.44e-18	Personality dimensions;
LUSC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.26	-0.49	1.18e-21	Platelet count;
LUSC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg14895029	chr7:2775587	GNA12	-0.43	-6.8	-0.35	4.74e-11	Height;
LUSC	trans	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg10756647	chr7:56101905	PSPH	0.86	8.4	0.42	1.27e-15	Diabetic kidney disease;
LUSC	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg01557791	chr16:72042693	DHODH	-0.46	-6.84	-0.35	3.81e-11	Fibrinogen levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01861349	chr15:75198956	C15orf17	-0.51	-6.47	-0.33	3.45e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12410462	0.581	rs7543931	chr1:227550976	A/T	cg04117972	chr1:227635322	NA	0.63	6.9	0.35	2.59e-11	Major depressive disorder;
LUSC	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg04851639	chr8:1020857	NA	-0.39	-8.25	-0.41	3.8e-15	Schizophrenia;
LUSC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg18538332	chr22:24372958	LOC391322	0.31	5.67	0.3	3.09e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg01620082	chr3:125678407	NA	-0.68	-6.72	-0.35	7.9e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg11861562	chr11:117069780	TAGLN	0.32	6.21	0.32	1.61e-9	Blood protein levels;
LUSC	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.22	-0.37	3.45e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg05132306	chr1:1846340	CALML6	0.31	7.89	0.4	4.33e-14	Body mass index;
LUSC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg09035930	chr12:129282057	SLC15A4	0.66	13.28	0.59	1.37e-32	Systemic lupus erythematosus;
LUSC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg18477163	chr1:228402036	OBSCN	-0.56	-10.2	-0.49	1.97e-21	Diastolic blood pressure;
LUSC	cis	rs4423214	0.570	rs7118246	chr11:71231124	G/C	cg05163923	chr11:71159392	DHCR7	0.6	7.73	0.39	1.31e-13	Vitamin D levels;
LUSC	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg03676636	chr4:99064102	C4orf37	0.32	7.05	0.36	1.06e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7043114	0.563	rs10820986	chr9:95312961	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.35	-6.2	-0.32	1.65e-9	Height;
LUSC	cis	rs13315871	1.000	rs13066269	chr3:58449244	T/C	cg12435725	chr3:58293450	RPP14	-0.7	-6.93	-0.35	2.21e-11	Cholesterol, total;
LUSC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.25	-14.44	-0.62	4.77e-37	Gout;
LUSC	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg22681709	chr2:178499509	PDE11A	-0.45	-6.65	-0.34	1.19e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	0.86	14.08	0.61	1.14e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.93	-0.35	2.23e-11	Body mass index;
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg10774155	chr7:65338427	VKORC1L1	-0.39	-5.65	-0.3	3.52e-8	Calcium levels;
LUSC	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg01881094	chr2:180872142	CWC22	-0.82	-10.71	-0.51	3.19e-23	Schizophrenia;
LUSC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg18350739	chr11:68623251	NA	-0.37	-6.48	-0.33	3.28e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg15605315	chr1:45957053	TESK2	0.38	5.74	0.3	2.13e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.46	6.99	0.36	1.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg20203395	chr5:56204925	C5orf35	-0.74	-10.2	-0.49	1.89e-21	Initial pursuit acceleration;
LUSC	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.86	14.28	0.62	2e-36	Bladder cancer;
LUSC	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg21775007	chr8:11205619	TDH	-0.44	-6.41	-0.33	4.95e-10	Neuroticism;
LUSC	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg04851639	chr8:1020857	NA	-0.39	-8.12	-0.41	9.16e-15	Schizophrenia;
LUSC	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs977987	0.843	rs11860231	chr16:75385159	A/G	cg04384234	chr16:75411784	CFDP1	-0.39	-6.19	-0.32	1.79e-9	Dupuytren's disease;
LUSC	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.88	15.21	0.64	4.78e-40	Bladder cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18674212	chr6:149867144	PPIL4	-0.41	-6.06	-0.31	3.64e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.73	-0.3	2.21e-8	Ileal carcinoids;
LUSC	cis	rs117623576	0.941	rs7098334	chr10:32418501	G/T	cg03047570	chr10:32398778	NA	-0.6	-6.55	-0.34	2.22e-10	Anti-saccade response;
LUSC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg11235426	chr6:292522	DUSP22	-0.42	-6.03	-0.31	4.37e-9	Menopause (age at onset);
LUSC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg04944784	chr2:26401820	FAM59B	0.78	11.21	0.52	5.54e-25	Gut microbiome composition (summer);
LUSC	cis	rs4629180	0.675	rs6742474	chr2:102091075	G/A	cg01388757	chr2:102091195	RFX8	-0.36	-6.32	-0.33	8.42e-10	Chronic rhinosinusitis with nasal polyps;
LUSC	trans	rs6982636	0.967	rs2980875	chr8:126481747	A/G	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.31	-6.05	-0.31	3.82e-9	Lipid metabolism phenotypes;
LUSC	cis	rs2692947	0.711	rs56791141	chr2:96587496	C/T	cg23100626	chr2:96804247	ASTL	0.26	6.37	0.33	6.33e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg21427119	chr20:30132790	HM13	-0.38	-6.01	-0.31	4.83e-9	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs4842666	0.915	rs11105352	chr12:90026462	G/A	cg00757033	chr12:89920650	WDR51B	0.48	6.39	0.33	5.49e-10	Blood pressure;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02693249	chr1:205600567	ELK4	-0.38	-6.17	-0.32	1.94e-9	Electrocardiographic conduction measures;
LUSC	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg04374321	chr14:90722782	PSMC1	0.76	12.04	0.55	5.82e-28	Mortality in heart failure;
LUSC	cis	rs12618769	0.597	rs72821943	chr2:99141640	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	cis	rs10489202	1.000	rs1846416	chr1:167905411	G/A	cg24449463	chr1:168025552	DCAF6	-0.58	-7.16	-0.36	5.1e-12	Schizophrenia;
LUSC	cis	rs7215564	0.908	rs35844609	chr17:78664850	T/C	cg23238734	chr17:78661607	RPTOR	0.49	6.32	0.33	8.32e-10	Myopia (pathological);
LUSC	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg03709012	chr19:19516395	GATAD2A	-0.51	-7.21	-0.37	3.67e-12	Tonsillectomy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24350392	chr17:37026147	LASP1	-0.4	-6.03	-0.31	4.26e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6845621	0.700	rs6449431	chr4:18894940	C/T	cg12196642	chr4:18937545	NA	-0.32	-5.8	-0.3	1.52e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.16	-0.36	5.04e-12	Schizophrenia;
LUSC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	0.51	7.96	0.4	2.67e-14	Uric acid clearance;
LUSC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.8	0.3	1.51e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs354225	0.584	rs10188545	chr2:54831875	A/G	cg26097391	chr2:54893211	SPTBN1	0.45	6.57	0.34	1.89e-10	Schizophrenia;
LUSC	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	9.92	0.48	1.75e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7587476	0.531	rs35933323	chr2:215674090	T/G	cg04004882	chr2:215674386	BARD1	-0.53	-7.37	-0.37	1.34e-12	Neuroblastoma;
LUSC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.63	-9.91	-0.48	1.84e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25072359	chr17:41440525	NA	0.62	9.19	0.45	4.36e-18	Menopause (age at onset);
LUSC	cis	rs17253792	0.822	rs77761669	chr14:56034216	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-6.41	-0.33	4.87e-10	Putamen volume;
LUSC	cis	rs3772130	0.583	rs7618041	chr3:121566481	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.83	13.54	0.6	1.29e-33	Cognitive performance;
LUSC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg06453172	chr10:134556979	INPP5A	-0.49	-6.18	-0.32	1.91e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-8.58	-0.43	3.52e-16	Schizophrenia;
LUSC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7202877	0.656	rs4888370	chr16:75308230	T/C	cg03315344	chr16:75512273	CHST6	0.44	6.32	0.33	8.38e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs1983170	0.808	rs10782962	chr1:92016210	C/A	cg25838465	chr1:92012736	NA	0.43	6.05	0.31	3.82e-9	Eosinophil percentage of white cells;
LUSC	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.27	0.59	1.5e-32	Total body bone mineral density;
LUSC	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg01528321	chr10:82214614	TSPAN14	0.93	14.14	0.61	6.72e-36	Post bronchodilator FEV1;
LUSC	cis	rs2742234	0.614	rs3026750	chr10:43607756	G/A	cg02780029	chr10:43622663	RET	-0.33	-6.14	-0.32	2.37e-9	Hirschsprung disease;
LUSC	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg19812747	chr11:111475976	SIK2	-0.48	-6.84	-0.35	3.87e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg12927641	chr6:109611667	NA	-0.35	-5.87	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg26754761	chr2:177040938	NA	-0.39	-7.66	-0.39	2.09e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs7215564	0.908	rs35128297	chr17:78652909	A/C	cg09596252	chr17:78655493	RPTOR	0.55	5.92	0.31	7.92e-9	Myopia (pathological);
LUSC	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg08330031	chr10:104623503	C10orf32	0.31	5.64	0.3	3.54e-8	Arsenic metabolism;
LUSC	cis	rs12541635	0.966	rs1603363	chr8:107031319	A/G	cg10147462	chr8:107024639	NA	0.55	10.04	0.48	6.9e-21	Age of smoking initiation;
LUSC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.45	7.44	0.38	8.69e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg01528321	chr10:82214614	TSPAN14	1.03	16.05	0.66	2.21e-43	Post bronchodilator FEV1;
LUSC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.65	-0.5	5.34e-23	Hemoglobin concentration;
LUSC	cis	rs7582720	1.000	rs72936830	chr2:203769803	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.66	0.43	2.06e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7241530	0.662	rs6506751	chr18:75904506	T/C	cg14642773	chr18:75888474	NA	0.39	6.02	0.31	4.59e-9	Educational attainment (years of education);
LUSC	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-6.76	-0.35	6.17e-11	Homocysteine levels;
LUSC	cis	rs1178968	1.000	rs799304	chr7:72803321	C/T	cg25889504	chr7:72793014	NA	0.63	7.83	0.39	6.56e-14	Triglyceride levels;
LUSC	cis	rs11229555	0.645	rs12272911	chr11:58183839	G/C	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	0.96	16.31	0.67	2.17e-44	Menopause (age at onset);
LUSC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg02782426	chr3:40428986	ENTPD3	-0.36	-7.17	-0.37	4.88e-12	Renal cell carcinoma;
LUSC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg16928487	chr17:17741425	SREBF1	-0.43	-8.43	-0.42	1.03e-15	Total body bone mineral density;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02705895	chr4:6642252	MRFAP1	0.68	5.96	0.31	6.3e-9	Cognitive performance;
LUSC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-6.9	-0.35	2.59e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg01528321	chr10:82214614	TSPAN14	0.82	12.36	0.56	3.74e-29	Post bronchodilator FEV1;
LUSC	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg16342193	chr10:102329863	NA	-0.37	-6.74	-0.35	7.17e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4561483	0.771	rs7202234	chr16:11942322	A/G	cg08843971	chr16:11963173	GSPT1	0.44	6.55	0.34	2.12e-10	Testicular germ cell tumor;
LUSC	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg13010199	chr12:38710504	ALG10B	0.42	6.67	0.34	1.08e-10	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg21724239	chr8:58056113	NA	0.57	5.78	0.3	1.71e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7582180	0.903	rs13008568	chr2:100896242	A/G	cg08017756	chr2:100939284	LONRF2	-0.36	-6.01	-0.31	4.77e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg20243544	chr17:37824526	PNMT	0.5	7.11	0.36	6.96e-12	Asthma;
LUSC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg03060546	chr3:49711283	APEH	-0.6	-7.21	-0.37	3.74e-12	Menarche (age at onset);
LUSC	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg05805236	chr11:65401703	PCNXL3	0.4	6.76	0.35	6.32e-11	Acne (severe);
LUSC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.63	0.6	6.06e-34	Cognitive test performance;
LUSC	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	10.4	0.49	4.09e-22	Eye color traits;
LUSC	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg21545522	chr1:205238299	TMCC2	0.47	8.79	0.43	8.29e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-13.0	-0.58	1.54e-31	Platelet count;
LUSC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg02018176	chr4:1364513	KIAA1530	0.5	8.57	0.42	3.88e-16	Longevity;
LUSC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg08847533	chr14:75593920	NEK9	-0.79	-13.4	-0.59	4.55e-33	Height;
LUSC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23158103	chr7:148848205	ZNF398	-0.46	-7.4	-0.38	1.11e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7202877	0.611	rs56092808	chr16:75312716	A/T	cg03315344	chr16:75512273	CHST6	0.45	6.37	0.33	6.29e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs6546537	0.562	rs7565783	chr2:69750113	C/T	cg10773587	chr2:69614142	GFPT1	-0.58	-9.65	-0.47	1.36e-19	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg05855489	chr10:104503620	C10orf26	0.53	8.01	0.4	1.98e-14	Arsenic metabolism;
LUSC	trans	rs417096	1.000	rs417096	chr6:39727833	G/A	cg17457912	chr17:1617102	C17orf91	-0.31	-6.05	-0.31	3.89e-9	Hypospadias;
LUSC	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg10911889	chr6:126070802	HEY2	0.42	6.39	0.33	5.59e-10	Brugada syndrome;
LUSC	cis	rs3106136	0.967	rs2306803	chr4:95161996	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.06	-0.31	3.75e-9	Capecitabine sensitivity;
LUSC	cis	rs7147624	0.766	rs11158597	chr14:65913536	T/G	cg03016385	chr14:66212404	NA	-0.83	-9.44	-0.46	6.63e-19	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1865721	0.958	rs72977878	chr18:73193037	T/G	cg26385618	chr18:73139727	C18orf62	-0.48	-8.1	-0.41	1.04e-14	Intelligence;
LUSC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg22903657	chr4:1355424	KIAA1530	-0.35	-5.77	-0.3	1.78e-8	Obesity-related traits;
LUSC	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg09904177	chr6:26538194	HMGN4	0.65	11.67	0.54	1.3e-26	Intelligence (multi-trait analysis);
LUSC	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg27147174	chr7:100797783	AP1S1	-0.64	-10.48	-0.5	2.08e-22	Life satisfaction;
LUSC	cis	rs2273669	0.667	rs12202145	chr6:109357829	A/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.09	0.74	1.98e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs919433	0.679	rs6757632	chr2:198530266	C/T	cg00792783	chr2:198669748	PLCL1	0.42	5.66	0.3	3.23e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg13813247	chr22:41461852	NA	-0.36	-6.43	-0.33	4.54e-10	Neuroticism;
LUSC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg27170947	chr2:26402098	FAM59B	-0.72	-10.53	-0.5	1.43e-22	Gut microbiome composition (summer);
LUSC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg05347473	chr6:146136440	FBXO30	0.58	10.1	0.48	4.16e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg09307838	chr4:120376055	NA	0.73	10.22	0.49	1.58e-21	Corneal astigmatism;
LUSC	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	7.56	0.38	3.81e-13	Neuroticism;
LUSC	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.05	-0.44	1.17e-17	Schizophrenia;
LUSC	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.16	0.49	2.52e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	0.95	18.49	0.71	4.54e-53	Cognitive function;
LUSC	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg06223162	chr1:101003688	GPR88	-0.48	-9.09	-0.45	8.68e-18	Monocyte count;
LUSC	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg04362960	chr10:104952993	NT5C2	0.88	11.23	0.52	4.85e-25	Arsenic metabolism;
LUSC	cis	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05901451	chr6:126070800	HEY2	-0.58	-8.59	-0.43	3.43e-16	Endometrial cancer;
LUSC	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg24596788	chr1:163392923	NA	0.37	6.24	0.32	1.36e-9	Motion sickness;
LUSC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg03146154	chr1:46216737	IPP	0.55	8.24	0.41	3.92e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg08085267	chr17:45401833	C17orf57	0.59	9.62	0.47	1.69e-19	Multiple sclerosis or amyotrophic lateral sclerosis;
LUSC	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-7.06	-0.36	9.85e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.74	11.19	0.52	6.82e-25	Type 2 diabetes;
LUSC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.92	0.48	1.65e-20	Lung cancer;
LUSC	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg22491629	chr6:157744540	C6orf35	-0.85	-10.38	-0.49	4.48e-22	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg05738196	chr6:26577821	NA	0.51	5.97	0.31	6.01e-9	Small cell lung carcinoma;
LUSC	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg13609457	chr4:120235615	NA	0.37	5.84	0.3	1.24e-8	Diastolic blood pressure;
LUSC	cis	rs3960554	0.709	rs73138006	chr7:75769990	T/C	cg17325771	chr7:75508891	RHBDD2	-0.41	-5.73	-0.3	2.25e-8	Eotaxin levels;
LUSC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg19318889	chr4:1322082	MAEA	0.53	8.69	0.43	1.67e-16	Obesity-related traits;
LUSC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg27165867	chr14:105738592	BRF1	-0.52	-7.45	-0.38	7.91e-13	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs7313075	0.714	rs76127916	chr12:102740904	T/C	cg12813724	chr1:26690537	ZNF683	0.69	5.96	0.31	6.47e-9	Height;
LUSC	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg13010344	chr12:123464640	ARL6IP4	0.49	6.44	0.33	4.06e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg19812747	chr11:111475976	SIK2	-0.55	-8.15	-0.41	7.59e-15	Primary sclerosing cholangitis;
LUSC	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.88	15.78	0.65	2.66e-42	Metabolic syndrome;
LUSC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-9.29	-0.45	1.99e-18	Bipolar disorder;
LUSC	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg09307838	chr4:120376055	NA	-0.58	-8.86	-0.44	4.9e-17	Corneal astigmatism;
LUSC	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg01884057	chr2:25150051	NA	0.44	10.37	0.49	5.07e-22	Body mass index;
LUSC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg24399712	chr22:39784796	NA	-0.62	-11.46	-0.53	7.19e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs7712401	0.601	rs442911	chr5:122325551	T/C	cg19077854	chr5:122220652	SNX24	-0.43	-9.48	-0.46	4.83e-19	Mean platelet volume;
LUSC	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.78	-0.35	5.52e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.41	-6.28	-0.32	1.07e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2842992	0.747	rs4709379	chr6:160227530	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.15	16.42	0.67	7.64e-45	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7589342	0.839	rs1465639	chr2:106439181	T/C	cg14210321	chr2:106509881	NCK2	-0.53	-7.98	-0.4	2.44e-14	Addiction;
LUSC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.36	0.42	1.67e-15	Hemoglobin concentration;
LUSC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg14784868	chr12:69753453	YEATS4	0.5	7.74	0.39	1.17e-13	Blood protein levels;
LUSC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg26441486	chr22:50317300	CRELD2	0.51	7.78	0.39	9.05e-14	Schizophrenia;
LUSC	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg10792982	chr14:105748885	BRF1	0.46	7.83	0.39	6.35e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	0.9	12.43	0.56	2.06e-29	Vitiligo;
LUSC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg27532560	chr4:187881888	NA	-0.43	-6.97	-0.36	1.75e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.67	-11.43	-0.53	9.13e-26	Menarche (age at onset);
LUSC	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg08916839	chr5:415575	AHRR	0.76	7.1	0.36	7.48e-12	Fat distribution (HIV);
LUSC	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	0.89	14.76	0.63	2.73e-38	Schizophrenia;
LUSC	cis	rs554111	0.656	rs964466	chr1:21375163	T/G	cg01072550	chr1:21505969	NA	0.39	5.94	0.31	7.13e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs4954585	0.683	rs13004902	chr2:137027680	A/G	cg05194412	chr2:137003533	NA	0.41	7.57	0.38	3.65e-13	Colorectal cancer;
LUSC	cis	rs12618769	0.597	rs12622341	chr2:99074680	A/T	cg10123293	chr2:99228465	UNC50	0.45	7.45	0.38	8.3e-13	Bipolar disorder;
LUSC	cis	rs983392	0.709	rs7932740	chr11:59976111	G/A	cg02771260	chr11:59836817	MS4A3	-0.36	-5.92	-0.31	8.06e-9	Alzheimer's disease (late onset);
LUSC	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg15556689	chr8:8085844	FLJ10661	0.58	8.63	0.43	2.48e-16	Neuroticism;
LUSC	cis	rs73001065	0.711	rs58489806	chr19:19456917	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	6.79	0.35	5.19e-11	LDL cholesterol;
LUSC	cis	rs61935443	0.778	rs78522691	chr12:95267340	G/T	cg21533806	chr12:95267307	NA	0.52	6.6	0.34	1.59e-10	Schizophrenia;
LUSC	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	1.43	10.52	0.5	1.52e-22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs8032315	0.965	rs1894400	chr15:91428955	C/T	cg05469396	chr15:91419421	FURIN	-0.42	-6.66	-0.34	1.15e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06022373	chr22:39101656	GTPBP1	-0.63	-9.93	-0.48	1.57e-20	Menopause (age at onset);
LUSC	cis	rs11625487	0.645	rs8006951	chr14:77965304	G/A	cg20045696	chr14:77926864	AHSA1	0.44	6.06	0.31	3.73e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	trans	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-9.17	-0.45	5.07e-18	Brugada syndrome;
LUSC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.86	0.35	3.37e-11	Tonsillectomy;
LUSC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.72e-10	Bipolar disorder;
LUSC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	trans	rs1741464	0.555	rs229581	chr14:65271650	A/G	cg22491548	chr7:128000861	PRRT4	-0.28	-6.01	-0.31	4.92e-9	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs13006833	0.694	rs291444	chr2:191176223	T/C	cg21644426	chr2:191273491	MFSD6	0.43	6.16	0.32	2.13e-9	Urinary metabolites;
LUSC	cis	rs360798	0.512	rs1906198	chr2:62946658	C/T	cg17519650	chr2:63277830	OTX1	0.53	7.45	0.38	7.87e-13	Coronary artery disease;
LUSC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg09640425	chr7:158790006	NA	-0.52	-8.38	-0.42	1.45e-15	Facial morphology (factor 20);
LUSC	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg02023728	chr11:77925099	USP35	0.52	7.2	0.37	4.11e-12	Testicular germ cell tumor;
LUSC	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.04	-22.52	-0.78	5.53e-69	Ulcerative colitis;
LUSC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg16647868	chr5:131706066	SLC22A5	-0.38	-5.71	-0.3	2.53e-8	Breast cancer;
LUSC	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg21951975	chr1:209979733	IRF6	0.57	6.87	0.35	3.14e-11	Coronary artery disease;
LUSC	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg06547715	chr2:218990976	CXCR2	0.33	6.47	0.33	3.57e-10	Ulcerative colitis;
LUSC	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg08508325	chr11:3079039	CARS	0.36	8.18	0.41	5.9e-15	Calcium levels;
LUSC	cis	rs10193935	0.786	rs10178087	chr2:42409631	C/A	cg27598129	chr2:42591480	NA	-0.59	-7.88	-0.4	4.72e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg12615879	chr12:58013172	SLC26A10	-0.29	-5.94	-0.31	7.18e-9	Multiple sclerosis;
LUSC	cis	rs2932538	0.922	rs2273369	chr1:113072477	A/G	cg22162597	chr1:113214053	CAPZA1	0.73	10.43	0.5	3.18e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs2688608	0.901	rs2459446	chr10:75601596	C/T	cg17411546	chr10:75410026	SYNPO2L	0.4	5.67	0.3	3.1e-8	Inflammatory bowel disease;
LUSC	trans	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg17830980	chr10:43048298	ZNF37B	0.46	6.56	0.34	2.03e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4664304	0.652	rs2221808	chr2:160870944	T/C	cg23995753	chr2:160760732	LY75	-0.3	-5.67	-0.3	3.16e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	1.23	16.43	0.67	6.93e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg06917634	chr15:78832804	PSMA4	-0.59	-7.25	-0.37	2.85e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg16325326	chr1:53192061	ZYG11B	0.88	15.1	0.64	1.28e-39	Monocyte count;
LUSC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg10621924	chr7:39171070	POU6F2	0.45	6.61	0.34	1.48e-10	IgG glycosylation;
LUSC	cis	rs3126085	0.867	rs12748016	chr1:152197235	T/C	cg26876637	chr1:152193138	HRNR	-0.45	-6.29	-0.33	9.91e-10	Atopic dermatitis;
LUSC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg01097406	chr16:89675127	NA	0.37	7.18	0.37	4.42e-12	Vitiligo;
LUSC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06221963	chr1:154839813	KCNN3	-0.59	-13.47	-0.59	2.55e-33	Prostate cancer;
LUSC	cis	rs9296092	0.538	rs56205713	chr6:33517510	A/G	cg13560919	chr6:33536144	NA	-0.82	-15.73	-0.65	4.02e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg13319975	chr6:146136371	FBXO30	-0.54	-8.13	-0.41	8.34e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4363385	0.626	rs6667103	chr1:153064438	A/G	cg07796016	chr1:152779584	LCE1C	-0.41	-6.28	-0.32	1.06e-9	Inflammatory skin disease;
LUSC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15664640	chr17:80829946	TBCD	0.51	8.92	0.44	3.1e-17	Breast cancer;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg07242783	chr1:28052377	FAM76A	-0.48	-6.75	-0.35	6.42e-11	Cognitive function;Information processing speed;
LUSC	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.74	-13.39	-0.59	5.13e-33	Obesity-related traits;
LUSC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg03804128	chr16:635623	NA	0.32	6.26	0.32	1.19e-9	Height;
LUSC	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg09462578	chr12:12878428	APOLD1	-0.54	-6.54	-0.34	2.27e-10	Systemic lupus erythematosus;
LUSC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg00990874	chr7:1149470	C7orf50	-0.58	-7.73	-0.39	1.3e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs6087990	0.842	rs6119279	chr20:31330612	A/G	cg13636640	chr20:31349939	DNMT3B	0.98	21.42	0.76	1.15e-64	Ulcerative colitis;
LUSC	cis	rs6012953	1.000	rs6020586	chr20:49155663	T/C	cg13958625	chr20:49123093	NA	0.3	6.69	0.34	9.65e-11	Vitiligo;
LUSC	cis	rs791888	0.667	rs2762520	chr10:89414845	A/G	cg13926569	chr10:89418898	PAPSS2	-0.29	-5.67	-0.3	3.14e-8	Magnesium levels;
LUSC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg22963979	chr7:1858916	MAD1L1	-0.69	-11.68	-0.54	1.14e-26	Bipolar disorder and schizophrenia;
LUSC	cis	rs10875595	0.836	rs7703869	chr5:140666494	C/T	cg24830062	chr5:140700576	TAF7	-0.52	-6.29	-0.33	1e-9	Pulmonary function decline;
LUSC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg04833646	chr19:10679720	CDKN2D	-1.17	-17.35	-0.69	1.52e-48	Red cell distribution width;
LUSC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg02915803	chr1:1606292	LOC728661;CDK11B	0.38	5.96	0.31	6.24e-9	Body mass index;
LUSC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg13395646	chr4:1353034	KIAA1530	-0.6	-9.38	-0.46	1.05e-18	Longevity;
LUSC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg11062466	chr8:58055876	NA	0.49	6.45	0.33	3.88e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.96	-0.4	2.78e-14	Lymphocyte counts;
LUSC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.09	0.32	3.1e-9	Personality dimensions;
LUSC	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg20933634	chr6:27740509	NA	0.43	6.06	0.31	3.76e-9	Parkinson's disease;
LUSC	trans	rs72674100	1.000	rs4632666	chr4:97990707	A/T	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs3857536	0.813	rs9354403	chr6:66943426	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg15704280	chr7:45808275	SEPT13	-0.46	-6.34	-0.33	7.57e-10	HDL cholesterol;
LUSC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg02018176	chr4:1364513	KIAA1530	-0.57	-9.88	-0.48	2.25e-20	Obesity-related traits;
LUSC	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg14844989	chr11:31128820	NA	-0.37	-5.74	-0.3	2.1e-8	Bone mineral density (spine);
LUSC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg05896524	chr21:47604654	C21orf56	0.4	5.92	0.31	7.87e-9	Testicular germ cell tumor;
LUSC	trans	rs8060598	0.866	rs3135499	chr16:50766127	G/T	cg26110710	chr13:88323607	SLITRK5	-0.39	-6.23	-0.32	1.41e-9	Leprosy;
LUSC	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg27432699	chr2:27873401	GPN1	0.78	14.13	0.61	7.32e-36	Oral cavity cancer;
LUSC	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.69	-11.18	-0.52	7.14e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg05340658	chr4:99064831	C4orf37	0.57	8.61	0.43	2.84e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12995491	1.000	rs12995491	chr2:88527414	C/T	cg18302933	chr2:88491318	NA	0.35	6.89	0.35	2.86e-11	Response to metformin (IC50);
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg00106254	chr7:1943704	MAD1L1	-0.39	-5.68	-0.3	2.95e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	6.02	0.31	4.59e-9	Tonsillectomy;
LUSC	cis	rs7607369	0.536	rs4674345	chr2:219671598	A/G	cg02176678	chr2:219576539	TTLL4	-0.5	-8.8	-0.43	7.58e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg00750074	chr16:89608354	SPG7	-0.58	-10.2	-0.49	1.94e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	4.73e-15	Homoarginine levels;
LUSC	cis	rs56399783	0.614	rs73047368	chr7:2766396	G/T	cg14895029	chr7:2775587	GNA12	0.54	5.85	0.3	1.2e-8	Childhood ear infection;
LUSC	cis	rs7106204	0.514	rs34587986	chr11:24253053	T/C	ch.11.24196551F	chr11:24239977	NA	0.92	10.2	0.49	1.98e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.86	0.58	4.98e-31	Prudent dietary pattern;
LUSC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-8.53	-0.42	5.23e-16	Hemoglobin concentration;
LUSC	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg19773385	chr1:10388646	KIF1B	-0.54	-8.38	-0.42	1.5e-15	Hepatocellular carcinoma;
LUSC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg04155289	chr7:94953770	PON1	-0.34	-5.75	-0.3	2.02e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7572644	0.664	rs12620151	chr2:28102704	T/A	cg27432699	chr2:27873401	GPN1	0.53	6.5	0.33	3.01e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg02018176	chr4:1364513	KIAA1530	0.51	8.74	0.43	1.14e-16	Obesity-related traits;
LUSC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19346786	chr7:2764209	NA	-0.38	-6.58	-0.34	1.82e-10	Height;
LUSC	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg04310649	chr10:35416472	CREM	-0.44	-6.85	-0.35	3.54e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs35883536	0.605	rs2133118	chr1:101034337	C/T	cg09408571	chr1:101003634	GPR88	-0.29	-5.74	-0.3	2.13e-8	Monocyte count;
LUSC	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg23188684	chr11:67383651	NA	0.35	6.19	0.32	1.76e-9	Mean corpuscular volume;
LUSC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.86	-0.31	1.13e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg03676636	chr4:99064102	C4orf37	0.31	6.22	0.32	1.47e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4363385	0.818	rs3806222	chr1:153002606	C/T	cg25856811	chr1:152973957	SPRR3	-0.36	-5.94	-0.31	6.97e-9	Inflammatory skin disease;
LUSC	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg19743168	chr1:23544995	NA	0.39	7.68	0.39	1.83e-13	Height;
LUSC	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	0.81	11.21	0.52	5.69e-25	Vitiligo;
LUSC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	8.16	0.41	7.01e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg22907277	chr7:1156413	C7orf50	0.72	7.57	0.38	3.61e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10178409	1	rs10178409	chr2:73855507	G/T	cg20560298	chr2:73613845	ALMS1	-0.42	-5.93	-0.31	7.39e-9	Urinary metabolites;
LUSC	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg14154082	chr13:112174009	NA	0.39	7.89	0.4	4.29e-14	Menarche (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12041467	chr19:45873960	ERCC2	-0.44	-6.4	-0.33	5.15e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7678296	0.649	rs77896458	chr4:37237843	A/G	cg06805348	chr4:37245195	KIAA1239	0.57	5.88	0.31	9.88e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04371633	chr14:65381025	CHURC1	0.43	6.54	0.34	2.33e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	0.96	9.4	0.46	8.95e-19	Plasma clusterin levels;
LUSC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg20608306	chr11:116969690	SIK3	-0.38	-6.34	-0.33	7.55e-10	Blood protein levels;
LUSC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg20302533	chr7:39170763	POU6F2	0.51	8.15	0.41	7.56e-15	IgG glycosylation;
LUSC	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg26384229	chr12:38710491	ALG10B	0.54	7.65	0.39	2.2e-13	Morning vs. evening chronotype;
LUSC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg16586182	chr3:47516702	SCAP	-0.5	-7.83	-0.39	6.35e-14	Colorectal cancer;
LUSC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-0.82	-10.09	-0.48	4.5e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	6.83e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.68	-0.63	5.51e-38	Schizophrenia;
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.41	-6.74	-0.35	6.9e-11	Longevity;Endometriosis;
LUSC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg07148914	chr20:33460835	GGT7	-0.45	-6.67	-0.34	1.07e-10	Height;
LUSC	cis	rs791888	0.858	rs2180968	chr10:89418730	A/C	cg13926569	chr10:89418898	PAPSS2	0.35	6.87	0.35	3.08e-11	Magnesium levels;
LUSC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.67	-10.62	-0.5	6.81e-23	Menarche (age at onset);
LUSC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg11871910	chr12:69753446	YEATS4	0.86	14.9	0.63	7.81e-39	Blood protein levels;
LUSC	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-0.77	-12.25	-0.56	9.55e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12956009	0.583	rs4452038	chr18:44856529	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	6.1	0.32	2.87e-9	Educational attainment (years of education);
LUSC	trans	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg06606381	chr12:133084897	FBRSL1	-0.66	-7.14	-0.36	5.96e-12	Depression;
LUSC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg12615879	chr12:58013172	SLC26A10	-0.27	-5.74	-0.3	2.11e-8	Multiple sclerosis;
LUSC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	0.79	13.82	0.6	1.1e-34	Cognitive function;
LUSC	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.62	0.43	2.78e-16	Menopause (age at onset);
LUSC	cis	rs9811920	0.809	rs7649349	chr3:99725629	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.69	-0.34	9.47e-11	Axial length;
LUSC	cis	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg07460842	chr6:66804631	NA	0.89	9.06	0.44	1.1e-17	Exhaled nitric oxide output;
LUSC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg19592336	chr6:28129416	ZNF389	0.47	6.16	0.32	2.05e-9	Depression;
LUSC	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.9	0.61	5.49e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs72781680	0.611	rs74661620	chr2:24365260	C/A	cg06627628	chr2:24431161	ITSN2	-0.67	-7.97	-0.4	2.53e-14	Lymphocyte counts;
LUSC	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.5	6.83	0.35	3.91e-11	Corneal astigmatism;
LUSC	cis	rs4132509	0.744	rs10927068	chr1:243923452	C/T	cg21452805	chr1:244014465	NA	0.63	6.94	0.35	2.07e-11	RR interval (heart rate);
LUSC	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-7.2	-0.37	4.12e-12	Coronary artery disease;
LUSC	cis	rs698813	0.555	rs7605771	chr2:44479778	G/A	cg00619915	chr2:44497795	NA	-0.53	-7.52	-0.38	4.96e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs6580649	0.941	rs72644843	chr12:48465061	A/G	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05986781	chr7:127291658	SND1	0.45	6.2	0.32	1.67e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg07424592	chr7:64974309	NA	0.68	5.99	0.31	5.51e-9	Diabetic kidney disease;
LUSC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.05	0.64	1.96e-39	Platelet count;
LUSC	cis	rs2286503	0.839	rs4722189	chr7:22860474	G/A	cg11367502	chr7:22862612	TOMM7	0.44	6.01	0.31	4.92e-9	Fibrinogen;
LUSC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15369054	chr17:80825471	TBCD	-0.63	-9.74	-0.47	6.68e-20	Breast cancer;
LUSC	cis	rs2658782	0.724	rs2605629	chr11:93264037	C/G	cg15737290	chr11:93063684	CCDC67	-0.65	-8.14	-0.41	7.77e-15	Pulmonary function decline;
LUSC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg05347473	chr6:146136440	FBXO30	0.63	10.51	0.5	1.6e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6499755	1.000	rs6499755	chr16:55341135	T/C	cg02859129	chr16:55357253	IRX6	0.36	6.1	0.32	2.86e-9	Hypospadias;
LUSC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg06784218	chr1:46089804	CCDC17	0.48	9.53	0.46	3.45e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg18904891	chr8:8559673	CLDN23	-0.38	-5.66	-0.3	3.33e-8	Mood instability;
LUSC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg26039829	chr8:22132926	PIWIL2	0.45	8.29	0.41	2.81e-15	Hypertriglyceridemia;
LUSC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.3	-0.56	6.36e-29	Mean corpuscular volume;
LUSC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg24562669	chr7:97807699	LMTK2	0.35	6.27	0.32	1.15e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg20307385	chr11:47447363	PSMC3	0.51	5.98	0.31	5.72e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10186029	0.509	rs13417355	chr2:213943030	C/T	cg08319019	chr2:214017104	IKZF2	-0.41	-6.0	-0.31	5.17e-9	Systemic sclerosis;
LUSC	cis	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg27411982	chr8:10470053	RP1L1	-0.42	-6.86	-0.35	3.36e-11	Systolic blood pressure;
LUSC	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg25922239	chr6:33757077	LEMD2	0.55	8.26	0.41	3.56e-15	Crohn's disease;
LUSC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.37	0.46	1.15e-18	Bipolar disorder;
LUSC	trans	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg13628971	chr7:2884303	GNA12	0.5	6.93	0.35	2.21e-11	Height;
LUSC	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg25214090	chr10:38739885	LOC399744	0.55	7.93	0.4	3.28e-14	Corneal astigmatism;
LUSC	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg05347473	chr6:146136440	FBXO30	0.37	6.3	0.33	9.47e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18404041	chr3:52824283	ITIH1	-0.53	-10.22	-0.49	1.66e-21	Electroencephalogram traits;
LUSC	cis	rs6714710	0.603	rs35505530	chr2:98506910	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.56	0.42	4.18e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.64	14.3	0.62	1.54e-36	Hemoglobin concentration;
LUSC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg22903471	chr2:27725779	GCKR	-0.41	-6.96	-0.36	1.78e-11	Total body bone mineral density;
LUSC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg04546413	chr19:29218101	NA	0.71	11.0	0.52	3.19e-24	Methadone dose in opioid dependence;
LUSC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02187348	chr16:89574699	SPG7	0.61	10.03	0.48	7.29e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs11587400	0.572	rs2268699	chr1:115227896	G/T	cg12756093	chr1:115239321	AMPD1	0.45	6.95	0.36	1.98e-11	Autism;
LUSC	trans	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.41	-0.33	4.96e-10	Blood trace element (Cu levels);
LUSC	cis	rs7572733	0.534	rs6760891	chr2:198768166	T/G	cg00792783	chr2:198669748	PLCL1	0.46	6.2	0.32	1.68e-9	Dermatomyositis;
LUSC	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-5.99	-0.31	5.55e-9	Fear of minor pain;
LUSC	cis	rs9888739	0.800	rs11859300	chr16:31355895	G/T	cg15817542	chr16:31343056	ITGAM	-0.53	-7.27	-0.37	2.63e-12	Systemic lupus erythematosus;
LUSC	cis	rs6920965	0.561	rs9401851	chr6:126181956	T/C	cg05901451	chr6:126070800	HEY2	-0.49	-7.31	-0.37	1.93e-12	High light scatter reticulocyte count;
LUSC	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg00504896	chr12:9437009	LOC642846	-0.39	-5.8	-0.3	1.58e-8	Breast size;
LUSC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg13560548	chr3:10150139	C3orf24	0.49	6.89	0.35	2.82e-11	Alzheimer's disease;
LUSC	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg22875332	chr1:76189707	ACADM	-0.41	-6.2	-0.32	1.65e-9	Daytime sleep phenotypes;
LUSC	cis	rs1790761	0.933	rs1790752	chr11:67202044	G/A	cg24690094	chr11:67383802	NA	-0.33	-6.08	-0.32	3.35e-9	Mean corpuscular volume;
LUSC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg13531842	chr10:38383804	ZNF37A	-0.46	-7.23	-0.37	3.4e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg14458575	chr2:238380390	NA	0.68	11.41	0.53	1.06e-25	Prostate cancer;
LUSC	cis	rs2286885	1.000	rs741022	chr9:129252113	C/G	cg15282417	chr9:129245246	FAM125B	0.39	6.71	0.34	8.41e-11	Intraocular pressure;
LUSC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.39	0.56	2.99e-29	Motion sickness;
LUSC	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.16	0.49	2.55e-21	Lymphocyte counts;
LUSC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg19622623	chr12:86230825	RASSF9	-0.43	-6.11	-0.32	2.77e-9	Major depressive disorder;
LUSC	cis	rs6076065	0.723	rs2424541	chr20:23386776	T/C	cg11657817	chr20:23433608	CST11	0.42	8.01	0.4	1.94e-14	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24506149	chr1:39339048	MYCBP	-0.41	-6.14	-0.32	2.32e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg00677455	chr12:58241039	CTDSP2	0.7	10.75	0.51	2.41e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs12928939	0.517	rs12934512	chr16:71965230	C/G	cg03805757	chr16:71968109	PKD1L3	-0.64	-9.8	-0.47	4.31e-20	Post bronchodilator FEV1;
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg01238044	chr22:24384105	GSTT1	-0.72	-11.53	-0.53	4.15e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg25342872	chr17:79175132	AZI1	-0.47	-8.09	-0.4	1.15e-14	Frontotemporal dementia;
LUSC	cis	rs13385	0.769	rs10060203	chr5:139599319	T/G	cg26211634	chr5:139558579	C5orf32	0.45	6.81	0.35	4.63e-11	Atrial fibrillation;
LUSC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	0.79	13.73	0.6	2.61e-34	Cognitive function;
LUSC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg19318889	chr4:1322082	MAEA	0.44	7.27	0.37	2.49e-12	Obesity-related traits;
LUSC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.92	13.7	0.6	3.27e-34	Chronic sinus infection;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21755257	chr18:23806431	TAF4B	0.81	7.56	0.38	3.89e-13	Cognitive performance;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05968270	chr1:65533502	NA	0.44	6.63	0.34	1.35e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	7.66	0.39	1.98e-13	Response to antipsychotic treatment;
LUSC	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg02527881	chr3:46936655	PTH1R	0.42	7.5	0.38	5.92e-13	Colorectal cancer;
LUSC	cis	rs9921338	0.961	rs4315353	chr16:11414160	T/C	cg00044050	chr16:11439710	C16orf75	0.48	6.53	0.34	2.5e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs17604090	0.793	rs10226095	chr7:29690059	A/G	cg19413766	chr7:29689036	LOC646762	0.57	7.45	0.38	8e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs7614311	0.681	rs6796317	chr3:63927739	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-5.84	-0.3	1.25e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.02	0.31	4.49e-9	Menopause (age at onset);
LUSC	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.56	0.57	6.67e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23066280	chr7:158032496	PTPRN2	0.39	6.7	0.34	8.75e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs963731	0.571	rs4670270	chr2:39230351	G/A	cg04010122	chr2:39346883	SOS1	-0.79	-5.73	-0.3	2.2e-8	Corticobasal degeneration;
LUSC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg20701182	chr2:24300061	SF3B14	0.57	6.17	0.32	1.99e-9	Lymphocyte counts;
LUSC	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg10840412	chr1:235813424	GNG4	0.51	7.05	0.36	1.01e-11	Bipolar disorder;
LUSC	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg23289794	chr7:2394357	EIF3B	-0.7	-9.52	-0.46	3.74e-19	Multiple sclerosis;
LUSC	trans	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg20935933	chr6:143382018	AIG1	0.49	6.88	0.35	3.04e-11	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg24503407	chr1:205819492	PM20D1	0.84	14.7	0.63	4.36e-38	Menarche (age at onset);
LUSC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.72	-0.43	1.35e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2197308	0.549	rs10785517	chr12:38577992	G/T	cg26384229	chr12:38710491	ALG10B	0.57	8.41	0.42	1.22e-15	Morning vs. evening chronotype;
LUSC	cis	rs57590327	0.508	rs7621968	chr3:81951460	A/G	cg07356753	chr3:81810745	GBE1	-0.54	-7.63	-0.39	2.52e-13	Extraversion;
LUSC	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg08523384	chr5:141488047	NDFIP1	-0.51	-7.41	-0.38	1.04e-12	Crohn's disease;
LUSC	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.44	-0.33	4.21e-10	Resting heart rate;
LUSC	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.3	0.37	2.06e-12	Motion sickness;
LUSC	trans	rs1325195	0.920	rs2816199	chr1:179158932	G/A	cg11624085	chr17:8464688	MYH10	0.4	6.53	0.34	2.44e-10	IgE grass sensitization;
LUSC	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg21827317	chr3:136751795	NA	0.39	7.12	0.36	6.45e-12	Neuroticism;
LUSC	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg04374321	chr14:90722782	PSMC1	-0.67	-10.06	-0.48	5.63e-21	Mortality in heart failure;
LUSC	cis	rs10203711	0.933	rs10180937	chr2:239597184	A/G	cg14580085	chr2:239553406	NA	0.43	7.17	0.37	4.81e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg13736514	chr6:26305472	NA	-0.46	-9.26	-0.45	2.64e-18	Educational attainment;
LUSC	cis	rs240764	0.717	rs1039031	chr6:101161812	A/G	cg09795085	chr6:101329169	ASCC3	0.4	5.68	0.3	2.91e-8	Neuroticism;
LUSC	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.26e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.2	-0.32	1.67e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08280861	chr8:58055591	NA	0.53	5.73	0.3	2.22e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26943658	chr12:105501532	KIAA1033	-0.45	-6.41	-0.33	4.93e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg05347473	chr6:146136440	FBXO30	0.59	10.32	0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg16606324	chr3:10149918	C3orf24	0.44	7.01	0.36	1.36e-11	Alzheimer's disease;
LUSC	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg00757033	chr12:89920650	WDR51B	0.59	10.45	0.5	2.65e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6700896	0.500	rs1892535	chr1:66097181	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	6.07	0.32	3.56e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs701145	0.585	rs1713843	chr3:153786394	C/G	cg17054900	chr3:154042577	DHX36	-0.55	-5.92	-0.31	8.07e-9	Coronary artery disease;
LUSC	cis	rs11039100	1.000	rs12792952	chr11:5826813	C/G	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.05	0.55	5.3e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1953600	0.668	rs3122586	chr10:81950326	C/T	cg00277334	chr10:82204260	NA	0.5	7.95	0.4	2.97e-14	Sarcoidosis;
LUSC	trans	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg25206134	chr2:45395956	NA	0.59	6.06	0.31	3.59e-9	Neuroticism;
LUSC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.51	8.5	0.42	6.22e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-11.68	-0.54	1.2e-26	Monocyte count;
LUSC	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg08000102	chr2:233561755	GIGYF2	-0.64	-10.48	-0.5	2.17e-22	Coronary artery disease;
LUSC	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.35	-6.65	-0.34	1.22e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg15848620	chr12:58087721	OS9	-0.57	-8.12	-0.41	8.89e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg11473876	chr11:109292803	C11orf87	0.34	5.74	0.3	2.15e-8	Schizophrenia;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg10389385	chr7:77427730	TMEM60;PHTF2	0.39	6.0	0.31	5.14e-9	Schizophrenia;
LUSC	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.64	-9.64	-0.47	1.41e-19	Platelet distribution width;
LUSC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.56	-8.8	-0.43	7.66e-17	Total body bone mineral density;
LUSC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg12463550	chr7:65579703	CRCP	0.48	7.2	0.37	4.03e-12	Aortic root size;
LUSC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.97	-0.4	2.6e-14	Joint mobility (Beighton score);
LUSC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-1.22	-13.35	-0.59	7.04e-33	Diabetic kidney disease;
LUSC	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.68	-12.0	-0.55	7.95e-28	White blood cell count (basophil);
LUSC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg26677194	chr12:130822605	PIWIL1	-0.54	-8.39	-0.42	1.37e-15	Menopause (age at onset);
LUSC	trans	rs6030	0.957	rs916438	chr1:169499659	A/T	cg16792071	chr10:134842795	NA	-0.27	-5.97	-0.31	6.07e-9	Uric acid levels;
LUSC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg09041756	chr7:5570314	ACTB	0.64	6.04	0.31	4.14e-9	Myocardial infarction;
LUSC	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg17470449	chr10:769945	NA	-0.47	-6.62	-0.34	1.45e-10	Uric acid levels;
LUSC	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.58	9.96	0.48	1.27e-20	Bone mineral density;
LUSC	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.86	14.36	0.62	9.24e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.94	17.97	0.7	5.42e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.02	-0.44	1.46e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg03929089	chr4:120376271	NA	0.68	7.58	0.38	3.49e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.74	14.33	0.62	1.24e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25072359	chr17:41440525	NA	0.66	9.45	0.46	6.13e-19	Menopause (age at onset);
LUSC	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.8	-0.35	4.83e-11	Response to antipsychotic treatment;
LUSC	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-5.98	-0.31	5.64e-9	Ulcerative colitis;
LUSC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg01017244	chr2:74357527	NA	0.69	13.25	0.59	1.7e-32	Gestational age at birth (maternal effect);
LUSC	cis	rs9318086	0.648	rs4067969	chr13:24469120	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.43	6.43	0.33	4.3e-10	Myopia (pathological);
LUSC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg10596483	chr8:143751796	JRK	0.61	9.41	0.46	8.19e-19	Schizophrenia;
LUSC	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg22029157	chr1:209979665	IRF6	0.77	8.9	0.44	3.52e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg06238570	chr21:40685208	BRWD1	-0.6	-9.91	-0.48	1.81e-20	Cognitive function;
LUSC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg13770153	chr20:60521292	NA	-0.64	-8.89	-0.44	3.86e-17	Body mass index;
LUSC	cis	rs12997796	0.556	rs34353387	chr2:86974834	A/C	cg25203885	chr2:87302643	LOC285074	-0.8	-8.16	-0.41	6.99e-15	Schizophrenia;
LUSC	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg05347473	chr6:146136440	FBXO30	0.51	8.45	0.42	9.4e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11997175	0.670	rs34985841	chr8:33661889	C/A	ch.8.33884649F	chr8:33765107	NA	0.5	7.92	0.4	3.56e-14	Body mass index;
LUSC	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg27205649	chr11:78285834	NARS2	-0.49	-5.7	-0.3	2.61e-8	Testicular germ cell tumor;
LUSC	cis	rs12295403	0.691	rs9705036	chr11:18686916	A/G	cg09887367	chr11:18690185	NA	0.32	6.63	0.34	1.35e-10	Ovarian reserve;
LUSC	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg02660097	chr11:68866761	NA	0.42	5.78	0.3	1.68e-8	Blond vs. brown hair color;
LUSC	trans	rs2587949	0.615	rs1485249	chr3:4238075	G/A	cg15139668	chr4:4577005	NA	-0.4	-5.98	-0.31	5.86e-9	Periodontitis (DPAL);
LUSC	cis	rs7739264	0.602	rs2223362	chr6:19778171	C/A	cg02404759	chr6:19790362	NA	-0.43	-6.6	-0.34	1.59e-10	Endometriosis;
LUSC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg07424592	chr7:64974309	NA	-0.4	-5.74	-0.3	2.16e-8	Calcium levels;
LUSC	cis	rs10416265	0.528	rs3786932	chr19:33620488	T/A	cg17764715	chr19:33622953	WDR88	0.59	6.62	0.34	1.46e-10	Bone properties (heel);
LUSC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg06917634	chr15:78832804	PSMA4	0.83	15.05	0.64	1.89e-39	Sudden cardiac arrest;
LUSC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg21770322	chr7:97807741	LMTK2	0.41	7.0	0.36	1.45e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1568889	1.000	rs61889054	chr11:28333000	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.56	7.46	0.38	7.65e-13	Bipolar disorder;
LUSC	cis	rs6076065	0.723	rs6083087	chr20:23341529	C/T	cg11657817	chr20:23433608	CST11	0.43	8.15	0.41	7.44e-15	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg22438376	chr5:141348885	RNF14	0.39	5.94	0.31	6.98e-9	Triglycerides;
LUSC	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg16558253	chr16:72132732	DHX38	-0.36	-5.78	-0.3	1.75e-8	Fibrinogen levels;
LUSC	cis	rs4129585	0.665	rs10098073	chr8:143309504	A/C	cg16886403	chr8:143471632	TSNARE1	0.46	6.64	0.34	1.29e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs738321	0.690	rs11570750	chr22:38513138	G/A	cg25457927	chr22:38595422	NA	-0.32	-6.11	-0.32	2.8e-9	Breast cancer;
LUSC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.46	6.94	0.36	2.02e-11	Schizophrenia;
LUSC	trans	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg10756647	chr7:56101905	PSPH	0.86	8.63	0.43	2.62e-16	Diabetic kidney disease;
LUSC	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg01528321	chr10:82214614	TSPAN14	1.07	12.16	0.55	1.97e-28	Post bronchodilator FEV1;
LUSC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	cis	rs4073416	0.504	rs6573612	chr14:65912829	G/A	cg03016385	chr14:66212404	NA	-0.38	-5.68	-0.3	3e-8	N-glycan levels;
LUSC	cis	rs12681287	0.511	rs9297923	chr8:87548989	T/C	cg27223183	chr8:87520930	FAM82B	0.53	6.99	0.36	1.54e-11	Caudate activity during reward;
LUSC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg12463550	chr7:65579703	CRCP	0.5	7.18	0.37	4.47e-12	Aortic root size;
LUSC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs7814319	0.933	rs7002575	chr8:97242124	G/A	cg20787634	chr8:97240163	UQCRB	-0.34	-5.92	-0.31	7.94e-9	Lung function (FVC);
LUSC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg00800038	chr16:89945340	TCF25	-0.63	-6.68	-0.34	1.02e-10	Skin colour saturation;
LUSC	cis	rs12989701	0.778	rs7584040	chr2:127863224	C/T	cg08168897	chr2:127865431	BIN1	0.53	7.32	0.37	1.82e-12	Alzheimer's disease (late onset);
LUSC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg05844789	chr1:228464394	OBSCN	0.35	6.77	0.35	5.78e-11	Diastolic blood pressure;
LUSC	cis	rs9644630	0.897	rs28671342	chr8:19352420	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.39	-7.25	-0.37	2.85e-12	Oropharynx cancer;
LUSC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg12463550	chr7:65579703	CRCP	0.63	5.7	0.3	2.63e-8	Gout;
LUSC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-0.85	-17.32	-0.69	2.01e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.76	13.74	0.6	2.4e-34	Aortic root size;
LUSC	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg00432049	chr6:150390894	ULBP3	-0.27	-5.93	-0.31	7.75e-9	Alopecia areata;
LUSC	cis	rs2274273	0.870	rs1109170	chr14:55785788	A/C	cg04306507	chr14:55594613	LGALS3	0.56	12.99	0.58	1.58e-31	Protein biomarker;
LUSC	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg11789530	chr4:8429930	ACOX3	0.59	9.11	0.45	7.8e-18	Response to antineoplastic agents;
LUSC	cis	rs367943	0.712	rs13188946	chr5:112722855	C/T	cg12552261	chr5:112820674	MCC	0.37	6.11	0.32	2.78e-9	Type 2 diabetes;
LUSC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg08125733	chr17:73851984	WBP2	0.49	6.9	0.35	2.64e-11	White matter hyperintensity burden;
LUSC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.94	0.31	7.01e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg18209359	chr17:80159595	CCDC57	0.4	6.61	0.34	1.52e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg24130564	chr14:104152367	KLC1	-0.51	-7.24	-0.37	3.07e-12	Body mass index;
LUSC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.69	0.54	1.09e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9818941	0.740	rs11713363	chr3:157828322	A/G	cg08654915	chr3:157813417	NA	0.29	7.09	0.36	8.22e-12	Height;
LUSC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	-0.36	-5.95	-0.31	6.72e-9	Menopause (age at onset);
LUSC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg09509183	chr1:209979624	IRF6	0.52	6.21	0.32	1.61e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.89	12.55	0.57	7.43e-30	Ileal carcinoids;
LUSC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg06640241	chr16:89574553	SPG7	0.87	15.32	0.64	1.63e-40	Multiple myeloma (IgH translocation);
LUSC	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg05347473	chr6:146136440	FBXO30	0.39	6.19	0.32	1.75e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	13.13	0.58	4.92e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg26876637	chr1:152193138	HRNR	0.43	6.18	0.32	1.91e-9	Atopic dermatitis;
LUSC	cis	rs11785693	0.862	rs11778306	chr8:4988269	A/C	cg26367366	chr8:4980734	NA	0.73	8.62	0.43	2.72e-16	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg25258033	chr6:167368657	RNASET2	-0.46	-7.52	-0.38	5.24e-13	Crohn's disease;
LUSC	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.91	-0.31	8.46e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9921338	0.961	rs8043692	chr16:11426957	C/T	cg00044050	chr16:11439710	C16orf75	-0.49	-6.56	-0.34	2.03e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs926938	0.552	rs360613	chr1:115394864	C/G	cg12756093	chr1:115239321	AMPD1	0.47	7.23	0.37	3.33e-12	Autism;
LUSC	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg02023728	chr11:77925099	USP35	0.51	7.12	0.36	6.52e-12	Testicular germ cell tumor;
LUSC	cis	rs524023	0.914	rs11231845	chr11:64407419	G/A	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.73	-0.3	2.27e-8	Urate levels in obese individuals;
LUSC	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	8.94	0.44	2.72e-17	Lung cancer in ever smokers;
LUSC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.73	13.3	0.59	1.1e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg18683606	chr7:100471612	SRRT	0.45	5.96	0.31	6.4e-9	Resting heart rate;
LUSC	cis	rs7615316	0.763	rs10935465	chr3:142271797	A/C	cg16271453	chr3:142027066	XRN1	-0.37	-6.3	-0.33	9.46e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg23093090	chr10:104574429	C10orf26	-0.39	-7.34	-0.37	1.62e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09358240	chr1:185126285	C1orf25;C1orf26	-0.38	-5.95	-0.31	6.83e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg03678139	chr1:41832388	NA	0.41	5.99	0.31	5.42e-9	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs9860340	0.652	rs57087351	chr3:87637535	G/A	cg03644585	chr7:884825	UNC84A	0.42	6.03	0.31	4.35e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	0.75	10.77	0.51	2.12e-23	Platelet distribution width;
LUSC	trans	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.88	0.55	2.21e-27	Exhaled nitric oxide output;
LUSC	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg06917634	chr15:78832804	PSMA4	0.49	6.35	0.33	7.15e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg06808227	chr14:105710500	BRF1	-0.69	-10.72	-0.51	2.94e-23	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs72960926	0.744	rs72950524	chr6:74900108	G/A	cg03266952	chr6:74778945	NA	-0.76	-6.05	-0.31	3.85e-9	Metabolite levels (MHPG);
LUSC	trans	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg07817883	chr1:32538562	TMEM39B	1.09	10.08	0.48	4.88e-21	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg26061582	chr7:22766209	IL6	-0.47	-5.98	-0.31	5.58e-9	Lung cancer;
LUSC	cis	rs2625529	0.878	rs71395051	chr15:72239789	C/T	cg16672083	chr15:72433130	SENP8	-0.52	-7.51	-0.38	5.28e-13	Red blood cell count;
LUSC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	0.96	18.39	0.71	1.14e-52	Heart rate;
LUSC	cis	rs6977660	0.941	rs5017197	chr7:19819967	T/A	cg05791153	chr7:19748676	TWISTNB	0.53	5.86	0.31	1.08e-8	Thyroid stimulating hormone;
LUSC	cis	rs58785573	0.504	rs13151185	chr4:38609196	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.55	7.84	0.39	6.17e-14	Lymphocyte percentage of white cells;
LUSC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg17971929	chr21:40555470	PSMG1	-0.49	-7.24	-0.37	3.07e-12	Menarche (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26417871	chr18:18691918	ROCK1	-0.4	-6.04	-0.31	4.03e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10779751	1.000	rs1135172	chr1:11301714	C/T	cg08854313	chr1:11322531	MTOR	-0.85	-14.02	-0.61	2e-35	Body mass index;
LUSC	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg10513866	chr5:139070639	NA	0.53	9.41	0.46	8.2e-19	Schizophrenia;
LUSC	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	1.14	19.67	0.73	9.55e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7605827	0.930	rs10176967	chr2:15686086	G/T	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.82e-16	Educational attainment (years of education);
LUSC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg22655196	chr4:3374909	RGS12	0.33	6.36	0.33	6.75e-10	Serum sulfate level;
LUSC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg13319975	chr6:146136371	FBXO30	-0.39	-5.96	-0.31	6.3e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-8.34	-0.42	2.01e-15	Body mass index;
LUSC	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg13010199	chr12:38710504	ALG10B	0.47	7.33	0.37	1.75e-12	Morning vs. evening chronotype;
LUSC	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg17623882	chr6:41773611	USP49	-0.65	-11.06	-0.52	1.94e-24	Menarche (age at onset);
LUSC	cis	rs1775715	0.737	rs2778672	chr10:32122419	T/C	cg26784012	chr10:32216390	ARHGAP12	0.44	7.29	0.37	2.23e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1062746	0.545	rs3815947	chr16:87359648	C/T	cg02258303	chr16:87377426	FBXO31	-0.49	-7.62	-0.38	2.58e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg07424592	chr7:64974309	NA	0.42	5.92	0.31	7.97e-9	Calcium levels;
LUSC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg15445000	chr17:37608096	MED1	-0.39	-6.77	-0.35	5.69e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.74	-0.51	2.66e-23	Alzheimer's disease (late onset);
LUSC	cis	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg09307838	chr4:120376055	NA	0.48	7.2	0.37	4.07e-12	Diastolic blood pressure;
LUSC	cis	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05901451	chr6:126070800	HEY2	-0.58	-8.7	-0.43	1.5e-16	Endometrial cancer;
LUSC	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-8.01	-0.4	1.88e-14	Acne (severe);
LUSC	cis	rs8027181	0.839	rs10459647	chr15:73035241	T/C	cg25632853	chr15:73088954	NA	0.31	6.4	0.33	5.34e-10	Triglyceride levels;
LUSC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg04234412	chr22:24373322	LOC391322	-0.86	-14.01	-0.61	2.2e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg06714761	chr1:201096289	NA	0.43	7.73	0.39	1.25e-13	Permanent tooth development;
LUSC	cis	rs6599077	1.000	rs6766178	chr3:40098109	T/C	cg13683864	chr3:40499215	RPL14	-0.59	-7.38	-0.37	1.29e-12	Sleep-related phenotypes;
LUSC	trans	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.68	-0.34	9.77e-11	Depression;
LUSC	trans	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg10573190	chr2:85843190	USP39	-0.42	-6.05	-0.31	3.78e-9	Mean corpuscular volume;
LUSC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg25358565	chr5:93447407	FAM172A	-1.06	-12.04	-0.55	5.75e-28	Diabetic retinopathy;
LUSC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg12463550	chr7:65579703	CRCP	0.53	7.66	0.39	2.06e-13	Aortic root size;
LUSC	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg25214090	chr10:38739885	LOC399744	0.56	8.09	0.4	1.08e-14	Corneal astigmatism;
LUSC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg11502198	chr6:26597334	ABT1	0.6	9.33	0.45	1.56e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg11766577	chr21:47581405	C21orf56	-0.54	-8.46	-0.42	8.25e-16	Testicular germ cell tumor;
LUSC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg22166914	chr1:53195759	ZYG11B	0.5	7.93	0.4	3.23e-14	Monocyte count;
LUSC	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg23942311	chr14:51606299	NA	0.48	10.76	0.51	2.17e-23	Cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17841838	chr19:3626645	C19orf29	-0.52	-6.83	-0.35	3.98e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg16928487	chr17:17741425	SREBF1	0.44	8.61	0.43	2.91e-16	Total body bone mineral density;
LUSC	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.26	-0.62	2.3e-36	Schizophrenia;
LUSC	trans	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg13565492	chr6:43139072	SRF	-0.73	-10.85	-0.51	1.03e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.37	5.69	0.3	2.73e-8	Longevity;Endometriosis;
LUSC	cis	rs9403521	1.000	rs117303301	chr6:143999003	C/T	cg18240653	chr6:144019428	PHACTR2	-0.51	-6.16	-0.32	2.13e-9	Obesity-related traits;
LUSC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg16606324	chr3:10149918	C3orf24	0.65	9.65	0.47	1.38e-19	Alzheimer's disease;
LUSC	cis	rs8017423	0.904	rs2149647	chr14:90769539	C/T	cg14092571	chr14:90743983	NA	0.35	5.65	0.3	3.36e-8	Mortality in heart failure;
LUSC	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg24110177	chr3:50126178	RBM5	-0.41	-6.58	-0.34	1.79e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.72	-14.91	-0.63	6.88e-39	Longevity;Endometriosis;
LUSC	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg00012203	chr2:219082015	ARPC2	-0.55	-8.63	-0.43	2.49e-16	Ulcerative colitis;
LUSC	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.96	0.31	6.32e-9	Rheumatoid arthritis;
LUSC	cis	rs16910800	1.000	rs2449442	chr11:23197362	C/T	cg20040320	chr11:23191996	NA	0.44	6.58	0.34	1.81e-10	Cancer;
LUSC	cis	rs1983891	1.000	rs9296365	chr6:41535379	A/G	cg20194872	chr6:41519635	FOXP4	0.37	6.61	0.34	1.48e-10	Prostate cancer;
LUSC	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg01528321	chr10:82214614	TSPAN14	0.98	14.61	0.62	1.03e-37	Post bronchodilator FEV1;
LUSC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg18758796	chr5:131593413	PDLIM4	0.42	6.76	0.35	6.09e-11	Breast cancer;
LUSC	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg21890820	chr11:65308645	LTBP3	0.49	7.22	0.37	3.51e-12	Bone mineral density;
LUSC	cis	rs17030434	0.911	rs115948674	chr4:154742052	G/T	cg14289246	chr4:154710475	SFRP2	-0.55	-7.32	-0.37	1.85e-12	Electrocardiographic conduction measures;
LUSC	cis	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg21775007	chr8:11205619	TDH	0.47	6.66	0.34	1.11e-10	Neuroticism;
LUSC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.59	-0.34	1.68e-10	Menopause (age at onset);
LUSC	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg24110177	chr3:50126178	RBM5	0.43	6.7	0.34	8.65e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4664308	0.505	rs1037694	chr2:161028992	A/G	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.45	-0.38	7.91e-13	Idiopathic membranous nephropathy;
LUSC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs4704187	0.687	rs4447960	chr5:74361857	C/A	cg03227963	chr5:74354835	NA	0.33	7.02	0.36	1.23e-11	Response to amphetamines;
LUSC	cis	rs12681287	0.604	rs41469550	chr8:87406544	G/T	cg27223183	chr8:87520930	FAM82B	0.55	7.49	0.38	6.24e-13	Caudate activity during reward;
LUSC	cis	rs500891	1.000	rs1171134	chr6:84204477	G/A	cg08257003	chr6:84140564	ME1	-0.32	-6.55	-0.34	2.22e-10	Platelet-derived growth factor BB levels;
LUSC	cis	rs479844	0.617	rs12146493	chr11:65547333	G/A	cg27068330	chr11:65405492	SIPA1	0.48	6.53	0.34	2.45e-10	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
LUSC	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	17.09	0.68	1.66e-47	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg10556349	chr10:835070	NA	0.58	6.58	0.34	1.82e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg12463550	chr7:65579703	CRCP	0.53	7.71	0.39	1.48e-13	Aortic root size;
LUSC	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg27147174	chr7:100797783	AP1S1	-0.65	-10.41	-0.49	3.75e-22	Life satisfaction;
LUSC	cis	rs10871290	0.801	rs3851726	chr16:74471644	G/C	cg01733217	chr16:74700730	RFWD3	-0.54	-7.75	-0.39	1.12e-13	Breast cancer;
LUSC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg22906224	chr7:99728672	NA	0.56	8.05	0.4	1.52e-14	Coronary artery disease;
LUSC	cis	rs9650315	0.789	rs57887485	chr8:57201243	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.31	0.37	1.93e-12	Height;
LUSC	trans	rs9886428	0.967	rs10087038	chr8:14115672	A/G	cg19037007	chr20:741798	C20orf54	-0.39	-6.04	-0.31	4.02e-9	IgG glycosylation;
LUSC	trans	rs62238980	0.614	rs79221399	chr22:32368918	C/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.01	-0.31	4.85e-9	Childhood ear infection;
LUSC	cis	rs9943753	0.525	rs7957928	chr12:109835975	C/G	cg19025524	chr12:109796872	NA	-0.38	-6.81	-0.35	4.43e-11	HDL cholesterol;
LUSC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg20243544	chr17:37824526	PNMT	-0.46	-5.71	-0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg01528321	chr10:82214614	TSPAN14	0.97	14.68	0.63	5.28e-38	Post bronchodilator FEV1;
LUSC	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-1.11	-17.48	-0.69	4.68e-49	Exhaled nitric oxide output;
LUSC	cis	rs3741151	0.686	rs7938391	chr11:73221957	A/G	cg17517138	chr11:73019481	ARHGEF17	0.77	7.25	0.37	2.98e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs4253772	0.938	rs41378347	chr22:46636976	G/A	cg24881330	chr22:46731750	TRMU	0.62	5.84	0.3	1.26e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7586879	0.789	rs13035239	chr2:25134000	T/A	cg01884057	chr2:25150051	NA	0.42	8.53	0.42	5.01e-16	Body mass index;
LUSC	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg11502198	chr6:26597334	ABT1	0.59	9.08	0.44	9.97e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.85	-0.31	1.15e-8	Alzheimer's disease (late onset);
LUSC	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg14530993	chr4:882597	GAK	0.64	6.73	0.35	7.19e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7582720	1.000	rs72932789	chr2:203699379	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.73	0.43	1.22e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.49	7.07	0.36	8.98e-12	Coronary heart disease;
LUSC	cis	rs6076065	0.683	rs1419010	chr20:23365254	G/C	cg11657817	chr20:23433608	CST11	0.43	8.07	0.4	1.25e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg04553112	chr3:125709451	NA	-0.51	-5.83	-0.3	1.31e-8	Blood pressure (smoking interaction);
LUSC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg27532560	chr4:187881888	NA	-0.37	-6.09	-0.32	3.16e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.02	0.44	1.46e-17	Motion sickness;
LUSC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg04733989	chr22:42467013	NAGA	-0.63	-9.79	-0.47	4.63e-20	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg10756647	chr7:56101905	PSPH	0.84	8.53	0.42	5.19e-16	Gout;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg24575065	chr7:72972219	BCL7B	0.35	6.22	0.32	1.5e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg05729581	chr11:3078854	CARS	0.39	5.7	0.3	2.57e-8	Calcium levels;
LUSC	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg11189052	chr15:85197271	WDR73	-0.46	-6.66	-0.34	1.16e-10	P wave terminal force;
LUSC	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg08601574	chr20:25228251	PYGB	0.44	6.76	0.35	6.18e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21545522	chr1:205238299	TMCC2	0.49	9.0	0.44	1.68e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.82	13.98	0.61	2.89e-35	Blood protein levels;
LUSC	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg22705602	chr4:152727874	NA	-0.34	-6.82	-0.35	4.21e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs8092503	0.859	rs35509548	chr18:52472408	A/G	cg12377874	chr18:52495404	RAB27B	0.33	5.97	0.31	6.2e-9	Childhood body mass index;
LUSC	cis	rs911119	0.955	rs61035931	chr20:23595714	A/G	cg16589663	chr20:23618590	CST3	0.57	6.82	0.35	4.18e-11	Chronic kidney disease;
LUSC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg20503657	chr10:835505	NA	0.86	12.13	0.55	2.58e-28	Eosinophil percentage of granulocytes;
LUSC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg04414720	chr1:150670196	GOLPH3L	0.51	7.93	0.4	3.39e-14	Melanoma;
LUSC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg12403142	chr1:92012408	NA	-0.39	-6.27	-0.32	1.12e-9	Breast cancer;
LUSC	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-6.49	-0.33	3.08e-10	Type 2 diabetes;
LUSC	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg09184832	chr6:79620586	NA	-0.42	-6.87	-0.35	3.21e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg06740227	chr12:86229804	RASSF9	-0.43	-6.99	-0.36	1.47e-11	Major depressive disorder;
LUSC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg21361702	chr7:150065534	REPIN1	-0.59	-8.43	-0.42	1.06e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg10811474	chr19:8428787	ANGPTL4	-0.39	-5.97	-0.31	6.07e-9	HDL cholesterol;
LUSC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg07716408	chr11:68623521	NA	-0.33	-6.41	-0.33	4.99e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	6.78	0.35	5.41e-11	Height;
LUSC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg10018233	chr7:150070692	REPIN1	0.39	6.81	0.35	4.52e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.75	0.39	1.09e-13	Mean platelet volume;
LUSC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03934478	chr11:495069	RNH1	0.86	9.38	0.46	1.06e-18	Body mass index;
LUSC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg25258033	chr6:167368657	RNASET2	0.47	7.84	0.39	6.15e-14	Crohn's disease;
LUSC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg26335602	chr6:28129616	ZNF389	0.49	6.56	0.34	2e-10	Parkinson's disease;
LUSC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg05347473	chr6:146136440	FBXO30	0.42	7.22	0.37	3.47e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg23630131	chr7:65973040	NA	-0.21	-5.83	-0.3	1.33e-8	Aortic root size;
LUSC	cis	rs4363385	0.818	rs377768	chr1:153016594	T/C	cg25856811	chr1:152973957	SPRR3	-0.34	-5.79	-0.3	1.62e-8	Inflammatory skin disease;
LUSC	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg08213375	chr14:104286397	PPP1R13B	0.47	8.5	0.42	6.58e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10871290	0.507	rs3851731	chr16:74485788	C/T	cg01733217	chr16:74700730	RFWD3	0.57	8.15	0.41	7.27e-15	Breast cancer;
LUSC	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg05283184	chr6:79620031	NA	-0.55	-11.41	-0.53	1.05e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs12776158	0.901	rs60110374	chr10:71217090	C/T	cg12610070	chr10:71211762	TSPAN15	-0.46	-5.91	-0.31	8.46e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.25	0.52	4.16e-25	Fuchs's corneal dystrophy;
LUSC	trans	rs11933661	0.528	rs1022008	chr4:130966269	C/G	cg14421548	chr9:77111779	RORB	0.4	5.98	0.31	5.87e-9	Alcohol dependence;
LUSC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg22638593	chr5:131593259	PDLIM4	0.43	6.57	0.34	1.94e-10	Blood metabolite levels;
LUSC	cis	rs6076065	0.962	rs1003417	chr20:23348007	T/A	cg11657817	chr20:23433608	CST11	0.43	8.45	0.42	9.37e-16	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.79	11.4	0.53	1.23e-25	Corneal astigmatism;
LUSC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg26441486	chr22:50317300	CRELD2	0.46	6.73	0.35	7.54e-11	Schizophrenia;
LUSC	cis	rs926938	0.527	rs360679	chr1:115494121	G/T	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.42	-0.33	4.76e-10	Autism;
LUSC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg23985595	chr17:80112537	CCDC57	0.33	6.28	0.33	1.05e-9	Life satisfaction;
LUSC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg22800045	chr5:56110881	MAP3K1	0.76	9.84	0.47	3.24e-20	Initial pursuit acceleration;
LUSC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.48	-6.35	-0.33	6.9e-10	Longevity;Endometriosis;
LUSC	cis	rs1185460	0.967	rs2509121	chr11:118928253	C/T	cg23280166	chr11:118938394	VPS11	0.46	6.98	0.36	1.62e-11	Coronary artery disease;
LUSC	trans	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg21051086	chr3:73046214	PPP4R2	-0.53	-8.02	-0.4	1.85e-14	Pancreatic cancer;
LUSC	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg08088566	chr11:430123	ANO9	0.61	6.85	0.35	3.64e-11	Body mass index;
LUSC	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg10978503	chr1:24200527	CNR2	0.5	11.61	0.54	2.06e-26	Immature fraction of reticulocytes;
LUSC	cis	rs2625529	0.824	rs2415121	chr15:72134018	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-7.8	-0.39	7.83e-14	Red blood cell count;
LUSC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-7.5	-0.38	5.7e-13	Alzheimer's disease (late onset);
LUSC	cis	rs3857536	0.813	rs6903411	chr6:66938288	T/C	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.82	0.39	7.05e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11608355	0.521	rs11066503	chr12:109842434	A/G	cg19025524	chr12:109796872	NA	-0.4	-7.37	-0.37	1.39e-12	Neuroticism;
LUSC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg17366294	chr4:99064904	C4orf37	0.58	10.43	0.5	3.19e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15369054	chr17:80825471	TBCD	0.54	6.91	0.35	2.42e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUSC	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.03	-0.44	1.37e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05819172	chr1:33815750	PHC2	-0.4	-5.96	-0.31	6.41e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1712517	0.525	rs11191642	chr10:105055912	A/G	cg04362960	chr10:104952993	NT5C2	-0.5	-6.75	-0.35	6.74e-11	Migraine;
LUSC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg12463550	chr7:65579703	CRCP	0.42	5.94	0.31	7.2e-9	Aortic root size;
LUSC	cis	rs4144743	1.000	rs2037150	chr17:45328718	G/A	cg18085866	chr17:45331354	ITGB3	-0.75	-7.79	-0.39	8.26e-14	Body mass index;
LUSC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06221963	chr1:154839813	KCNN3	-0.6	-13.38	-0.59	5.65e-33	Prostate cancer;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17937102	chr1:165667565	ALDH9A1	-0.37	-6.43	-0.33	4.49e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1784581	0.775	rs7755404	chr6:162427731	T/C	cg17173639	chr6:162384350	PARK2	0.66	11.74	0.54	7.27e-27	Itch intensity from mosquito bite;
LUSC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.2	-0.41	5.35e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs17001868	0.614	rs5995849	chr22:40777072	C/G	cg07138101	chr22:40742427	ADSL	-0.56	-7.09	-0.36	8.27e-12	Mammographic density (dense area);
LUSC	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg09184832	chr6:79620586	NA	-0.44	-7.18	-0.37	4.66e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs10096351	0.528	rs74588857	chr8:128336741	C/T	cg10195415	chr17:73887371	TRIM65	0.4	6.37	0.33	6.34e-10	Breast cancer;
LUSC	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg16342193	chr10:102329863	NA	-0.36	-6.95	-0.36	1.87e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg01733217	chr16:74700730	RFWD3	0.75	12.17	0.55	1.88e-28	Testicular germ cell tumor;
LUSC	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg01884057	chr2:25150051	NA	0.44	10.11	0.48	3.94e-21	Body mass index in non-asthmatics;
LUSC	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.49	16.86	0.68	1.38e-46	Opioid sensitivity;
LUSC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.05	-0.36	1.04e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs17095355	1.000	rs9988702	chr10:111703389	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.7	-0.39	1.58e-13	Biliary atresia;
LUSC	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.39	0.37	1.21e-12	Body mass index;
LUSC	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg00495681	chr13:53174319	NA	0.55	8.56	0.42	4.1e-16	Lewy body disease;
LUSC	cis	rs2445762	0.659	rs55810637	chr15:51664903	G/A	cg07517944	chr15:51633816	GLDN	0.37	6.25	0.32	1.27e-9	Hormone measurements;
LUSC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg16060761	chr17:80687452	NA	0.39	5.83	0.3	1.33e-8	Breast cancer;
LUSC	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg25214090	chr10:38739885	LOC399744	0.53	7.97	0.4	2.55e-14	Corneal astigmatism;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg12633890	chr1:116382096	NHLH2	0.35	5.99	0.31	5.49e-9	Schizophrenia;
LUSC	cis	rs9359856	0.564	rs56224741	chr6:90475231	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.45	-0.42	9.19e-16	Bipolar disorder;
LUSC	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg09796270	chr17:17721594	SREBF1	0.43	7.6	0.38	2.97e-13	Total body bone mineral density;
LUSC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03517284	chr6:25882590	NA	-0.52	-9.74	-0.47	6.97e-20	Blood metabolite levels;
LUSC	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg07817648	chr10:79422355	NA	-0.55	-7.5	-0.38	5.96e-13	Bone mineral density;
LUSC	trans	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg06521331	chr12:34319734	NA	0.41	6.54	0.34	2.35e-10	Morning vs. evening chronotype;
LUSC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg02117656	chr17:79614917	TSPAN10	-0.3	-5.67	-0.3	3.16e-8	Eye color traits;
LUSC	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.97	0.36	1.73e-11	Menarche (age at onset);
LUSC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg23172400	chr8:95962367	TP53INP1	0.35	6.7	0.34	8.71e-11	Type 2 diabetes;
LUSC	cis	rs6942756	0.806	rs2694572	chr7:128911721	A/G	cg02491457	chr7:128862824	NA	0.48	7.27	0.37	2.64e-12	White matter hyperintensity burden;
LUSC	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg24812749	chr6:127587940	RNF146	0.65	9.78	0.47	4.88e-20	Breast cancer;
LUSC	cis	rs9399401	0.589	rs2294775	chr6:142766347	C/G	cg04461802	chr6:142623433	GPR126	0.41	5.95	0.31	6.61e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg01657329	chr11:68192670	LRP5	0.41	6.39	0.33	5.65e-10	Total body bone mineral density;
LUSC	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.13	-25.31	-0.81	1.16e-79	Triglycerides;
LUSC	cis	rs240764	0.578	rs6927598	chr6:101232729	T/C	cg09795085	chr6:101329169	ASCC3	0.44	6.27	0.32	1.13e-9	Neuroticism;
LUSC	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.15	-0.32	2.19e-9	Neutrophil percentage of white cells;
LUSC	cis	rs865483	0.826	rs853198	chr17:35849342	A/C	cg06716730	chr17:35851459	DUSP14	0.28	6.14	0.32	2.3e-9	Monocyte count;
LUSC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg13397359	chr6:42928475	GNMT	0.65	10.85	0.51	1.04e-23	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs62432291	0.681	rs7757530	chr6:159647929	G/A	cg14500486	chr6:159655392	FNDC1	0.52	5.84	0.3	1.22e-8	Joint mobility (Beighton score);
LUSC	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-7.58	-0.38	3.48e-13	Body mass index;
LUSC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg22868518	chr11:507468	RNH1	-0.59	-5.8	-0.3	1.56e-8	Body mass index;
LUSC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg21770322	chr7:97807741	LMTK2	0.43	7.38	0.37	1.26e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.08	-0.36	8.6e-12	Longevity;Endometriosis;
LUSC	cis	rs6669072	1.000	rs3856225	chr1:91242473	G/A	cg08895590	chr1:91227319	NA	-0.38	-8.61	-0.43	3.03e-16	Cognitive function;
LUSC	cis	rs6494488	0.500	rs7165925	chr15:64985604	A/G	cg08069370	chr15:64387884	SNX1	0.58	5.67	0.3	3.07e-8	Coronary artery disease;
LUSC	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg03522245	chr20:25566470	NINL	0.37	6.0	0.31	5.2e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9653442	0.564	rs7593261	chr2:100789907	A/G	cg07810366	chr2:100720526	AFF3	-0.41	-6.76	-0.35	6.22e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg17971929	chr21:40555470	PSMG1	-0.5	-7.25	-0.37	2.86e-12	Menarche (age at onset);
LUSC	trans	rs4561177	0.548	rs61901857	chr11:109944838	G/T	cg00999152	chr2:72369887	CYP26B1	-0.34	-5.98	-0.31	5.59e-9	Psoriasis vulgaris;
LUSC	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg26395211	chr5:140044315	WDR55	0.41	6.43	0.33	4.47e-10	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs11608355	0.515	rs7971160	chr12:109946751	T/A	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs11955175	0.850	rs111959286	chr5:40704141	A/T	cg05478818	chr5:40835740	RPL37	0.74	5.89	0.31	9.43e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs4698048	0.506	rs2080072	chr4:10235622	G/C	cg26043149	chr18:55253948	FECH	-0.53	-8.46	-0.42	8.44e-16	Skin aging (microtopography measurement);
LUSC	cis	rs9323205	0.953	rs61144314	chr14:51620556	G/A	cg23942311	chr14:51606299	NA	-0.5	-10.26	-0.49	1.15e-21	Cancer;
LUSC	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-13.76	-0.6	1.86e-34	Height;
LUSC	cis	rs2455601	1.000	rs12418190	chr11:8899818	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.46	-0.33	3.77e-10	Schizophrenia;
LUSC	trans	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg12966876	chr2:111873850	ACOXL	0.33	6.4	0.33	5.25e-10	Bipolar disorder;
LUSC	cis	rs12220238	1.000	rs12357530	chr10:75928654	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.88	0.35	2.97e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs11039100	0.607	rs34451835	chr11:5782456	C/G	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs2288327	0.545	rs2562834	chr2:179580583	T/C	cg14011486	chr1:26737247	LIN28	0.5	6.17	0.32	1.96e-9	Atrial fibrillation;
LUSC	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.11	0.74	1.73e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg17031739	chr1:67600172	NA	0.37	6.03	0.31	4.29e-9	Psoriasis;
LUSC	cis	rs9818941	0.826	rs2670286	chr3:157638213	C/G	cg08654915	chr3:157813417	NA	0.26	6.01	0.31	4.9e-9	Height;
LUSC	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.58	0.6	9.87e-34	Morning vs. evening chronotype;
LUSC	cis	rs2348418	0.864	rs7977817	chr12:28715482	G/T	cg13890972	chr12:28721907	NA	-0.34	-5.81	-0.3	1.49e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg02176678	chr2:219576539	TTLL4	-0.57	-10.09	-0.48	4.66e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1535500	0.935	rs11753141	chr6:39283083	G/A	cg06347083	chr6:39282316	KCNK17	-0.27	-5.97	-0.31	6.23e-9	Type 2 diabetes;
LUSC	cis	rs6499755	0.965	rs9932163	chr16:55350683	C/A	cg02859129	chr16:55357253	IRX6	0.35	5.85	0.3	1.18e-8	Hypospadias;
LUSC	cis	rs12195417	0.719	rs1170330	chr6:83996875	T/A	cg08257003	chr6:84140564	ME1	0.32	7.75	0.39	1.08e-13	Schizophrenia;
LUSC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-18.2	-0.71	6.59e-52	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.13	-26.27	-0.82	2.8e-83	Triglycerides;
LUSC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg09359103	chr1:154839909	KCNN3	-0.7	-16.24	-0.66	4.09e-44	Prostate cancer;
LUSC	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg09904177	chr6:26538194	HMGN4	-0.53	-8.23	-0.41	4.3e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg08975724	chr8:8085496	FLJ10661	0.48	6.94	0.36	2.09e-11	Myopia (pathological);
LUSC	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.23	0.32	1.38e-9	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08219700	chr8:58056026	NA	0.69	8.22	0.41	4.58e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg05347473	chr6:146136440	FBXO30	0.6	10.6	0.5	7.93e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9463078	0.753	rs1980265	chr6:44928868	C/A	cg25276700	chr6:44698697	NA	-0.29	-5.9	-0.31	9.09e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg00431813	chr7:1051703	C7orf50	-0.47	-7.9	-0.4	4.06e-14	Longevity;Endometriosis;
LUSC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.48	0.33	3.36e-10	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.52	0.38	4.98e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs760794	0.764	rs7764632	chr6:19795585	C/G	cg02404759	chr6:19790362	NA	-0.41	-6.24	-0.32	1.36e-9	Endometriosis;
LUSC	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.86	-0.35	3.3e-11	Menopause (age at onset);
LUSC	trans	rs7916697	0.520	rs12246624	chr10:70036562	C/T	cg04882175	chr6:131122610	NA	-0.56	-7.53	-0.38	4.79e-13	Optic disc area;
LUSC	cis	rs4654899	0.929	rs7552999	chr1:21314454	T/C	cg01072550	chr1:21505969	NA	-0.56	-8.5	-0.42	6.28e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4654899	0.802	rs17410008	chr1:21220701	G/C	cg01072550	chr1:21505969	NA	-0.51	-7.58	-0.38	3.37e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg20135002	chr11:47629003	NA	-0.51	-7.91	-0.4	3.88e-14	Subjective well-being;
LUSC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg20849893	chr7:64541193	NA	0.47	6.71	0.34	8.54e-11	Calcium levels;
LUSC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1712517	0.771	rs7921655	chr10:105113701	C/T	cg05636881	chr10:105038444	INA	0.41	6.75	0.35	6.73e-11	Migraine;
LUSC	cis	rs955333	1.000	rs62434207	chr6:154950419	A/G	cg20019720	chr6:154832845	CNKSR3	0.45	5.75	0.3	2.01e-8	Diabetic kidney disease;
LUSC	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.71	-13.26	-0.59	1.53e-32	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10208940	0.920	rs12713643	chr2:68724129	C/G	cg12452813	chr2:68675892	NA	0.58	5.95	0.31	6.61e-9	Urate levels in lean individuals;
LUSC	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.94	0.36	2.01e-11	Tonsillectomy;
LUSC	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg10621924	chr7:39171070	POU6F2	0.42	6.26	0.32	1.21e-9	IgG glycosylation;
LUSC	trans	rs629535	0.814	rs56326813	chr8:70107736	T/A	cg21567404	chr3:27674614	NA	-0.98	-15.88	-0.66	1.02e-42	Dupuytren's disease;
LUSC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.27	0.45	2.39e-18	Monocyte percentage of white cells;
LUSC	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22857025	chr5:266934	NA	-1.14	-8.39	-0.42	1.39e-15	Breast cancer;
LUSC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg18512352	chr11:47633146	NA	0.48	9.94	0.48	1.45e-20	Subjective well-being;
LUSC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg03188948	chr7:1209495	NA	0.47	6.04	0.31	4.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg00579200	chr11:133705235	NA	-0.41	-5.86	-0.31	1.1e-8	Childhood ear infection;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09239099	chr12:1100377	ERC1	-0.41	-6.35	-0.33	6.92e-10	Electrocardiographic conduction measures;
LUSC	cis	rs10779751	1.000	rs11121698	chr1:11267283	C/T	cg08854313	chr1:11322531	MTOR	0.91	16.32	0.67	1.93e-44	Body mass index;
LUSC	cis	rs7216064	0.953	rs4790905	chr17:65863350	C/A	cg12091567	chr17:66097778	LOC651250	-0.73	-9.37	-0.46	1.13e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-7.02	-0.36	1.24e-11	Aortic root size;
LUSC	cis	rs9807841	0.670	rs10948	chr19:10754905	G/T	cg17710535	chr19:10819994	QTRT1	0.43	6.93	0.35	2.14e-11	Inflammatory skin disease;
LUSC	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-0.79	-12.51	-0.56	1.08e-29	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.07	0.32	3.49e-9	Recombination rate (females);
LUSC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg03563238	chr19:33554763	RHPN2	0.34	5.84	0.3	1.24e-8	Bone properties (heel);
LUSC	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg19875535	chr5:140030758	IK	0.49	7.92	0.4	3.52e-14	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-8.59	-0.43	3.38e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg09796270	chr17:17721594	SREBF1	-0.42	-7.39	-0.38	1.16e-12	Total body bone mineral density;
LUSC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.3	-0.41	2.65e-15	Mean platelet volume;
LUSC	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-7.09	-0.36	8.23e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01401337	chr9:96339159	PHF2	-0.4	-6.01	-0.31	4.74e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4917300	0.626	rs902821	chr8:143100074	G/A	cg25363559	chr8:143086065	NA	-0.32	-7.17	-0.37	4.72e-12	Amyotrophic lateral sclerosis;
LUSC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg22782873	chr19:19639568	YJEFN3	-0.53	-6.45	-0.33	3.82e-10	Bipolar disorder;
LUSC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.9	0.35	2.69e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9399401	0.667	rs7757571	chr6:142702589	A/C	cg04461802	chr6:142623433	GPR126	0.47	5.87	0.31	1.06e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.54	-0.42	4.79e-16	Gut microbiome composition (summer);
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg23034840	chr1:205782522	SLC41A1	0.62	8.8	0.43	7.43e-17	Menarche (age at onset);
LUSC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.56	0.38	3.9e-13	Colorectal cancer;
LUSC	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg13010199	chr12:38710504	ALG10B	0.55	8.27	0.41	3.16e-15	Morning vs. evening chronotype;
LUSC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg18240062	chr17:79603768	NPLOC4	0.69	12.96	0.58	2.22e-31	Eye color traits;
LUSC	trans	rs11696501	0.688	rs2281211	chr20:44312858	C/T	cg03272292	chr12:48577362	C12orf68	0.5	6.03	0.31	4.22e-9	Brain structure;
LUSC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24110177	chr3:50126178	RBM5	0.58	9.76	0.47	5.63e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	1.01	10.69	0.51	3.78e-23	Skin colour saturation;
LUSC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13126279	chr21:47581558	C21orf56	-0.47	-6.94	-0.36	1.99e-11	Testicular germ cell tumor;
LUSC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.3	-6.19	-0.32	1.79e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg00033643	chr7:134001901	SLC35B4	0.46	7.24	0.37	3.05e-12	Mean platelet volume;
LUSC	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg22681709	chr2:178499509	PDE11A	-0.34	-6.39	-0.33	5.45e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg13206674	chr6:150067644	NUP43	0.58	9.11	0.45	7.88e-18	Lung cancer;
LUSC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg06600287	chr1:53387719	ECHDC2	0.31	6.22	0.32	1.46e-9	Monocyte count;
LUSC	cis	rs2109514	0.902	rs6980387	chr7:116126882	A/G	cg12739419	chr7:116140593	CAV2	-0.27	-5.77	-0.3	1.78e-8	Prevalent atrial fibrillation;
LUSC	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	6.46	0.33	3.74e-10	Height;
LUSC	cis	rs2235649	0.753	rs7200472	chr16:1849669	T/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-6.1	-0.32	2.92e-9	Blood metabolite levels;
LUSC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00166722	chr3:10149974	C3orf24	0.55	7.58	0.38	3.39e-13	Alzheimer's disease;
LUSC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg02167203	chr6:41068553	NFYA;LOC221442	-0.38	-5.79	-0.3	1.65e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-8.28	-0.41	3.07e-15	Total cholesterol levels;
LUSC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.56	0.42	4.21e-16	Motion sickness;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00841452	chr19:10535506	PDE4A	0.4	6.0	0.31	5.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg02527881	chr3:46936655	PTH1R	0.42	7.24	0.37	3.02e-12	Colorectal cancer;
LUSC	cis	rs73195822	0.506	rs61440260	chr12:111142855	G/T	cg12870014	chr12:110450643	ANKRD13A	0.67	7.4	0.38	1.13e-12	Itch intensity from mosquito bite;
LUSC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg07424592	chr7:64974309	NA	0.65	5.74	0.3	2.15e-8	Diabetic kidney disease;
LUSC	trans	rs9929218	1.000	rs12599517	chr16:68814590	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.44	-0.53	8.45e-26	Colorectal cancer;
LUSC	cis	rs11039100	0.850	rs11039117	chr11:5832464	G/A	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2247341	1.000	rs8051	chr4:1694809	C/T	cg07465881	chr4:1713556	SLBP	0.4	6.18	0.32	1.85e-9	Hip circumference adjusted for BMI;Height;
LUSC	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.68	0.3	2.91e-8	Rheumatoid arthritis;
LUSC	trans	rs12210905	0.925	rs11961181	chr6:26994163	C/G	cg11837749	chr1:55047332	ACOT11	0.57	6.13	0.32	2.51e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg04691961	chr3:161091175	C3orf57	-0.34	-5.78	-0.3	1.73e-8	Morning vs. evening chronotype;
LUSC	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg04362960	chr10:104952993	NT5C2	0.61	9.6	0.47	1.95e-19	Arsenic metabolism;
LUSC	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg14844989	chr11:31128820	NA	-0.39	-6.02	-0.31	4.62e-9	Red blood cell count;
LUSC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23158103	chr7:148848205	ZNF398	-0.47	-7.59	-0.38	3.21e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14019695	chr9:139328340	INPP5E	0.51	9.75	0.47	6.07e-20	Monocyte percentage of white cells;
LUSC	cis	rs7512552	0.809	rs696618	chr1:150376139	T/G	cg15654264	chr1:150340011	RPRD2	0.63	10.38	0.49	4.66e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs354225	0.584	rs6749802	chr2:54824146	A/G	cg01766943	chr2:54829624	SPTBN1	0.48	7.78	0.39	9.33e-14	Schizophrenia;
LUSC	cis	rs3087591	0.919	rs2953004	chr17:29502723	C/T	cg24425628	chr17:29625626	OMG;NF1	0.62	8.91	0.44	3.45e-17	Hip circumference;
LUSC	cis	rs27434	0.529	rs34757	chr5:96152588	T/C	cg16492584	chr5:96139282	ERAP1	-0.56	-7.71	-0.39	1.49e-13	Ankylosing spondylitis;
LUSC	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg23625390	chr15:77176239	SCAPER	0.46	7.02	0.36	1.22e-11	Blood metabolite levels;
LUSC	cis	rs3770081	1.000	rs111295372	chr2:86283357	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.94	-6.99	-0.36	1.51e-11	Facial emotion recognition (sad faces);
LUSC	trans	rs1864585	0.520	rs73208756	chr8:10657535	C/T	cg26278703	chr11:58910052	FAM111A	0.53	5.98	0.31	5.84e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUSC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.05	0.44	1.22e-17	Motion sickness;
LUSC	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg09904177	chr6:26538194	HMGN4	0.66	11.72	0.54	8.26e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2406342	0.920	rs4890784	chr18:74484655	C/T	cg16472389	chr18:74514291	NA	0.37	5.78	0.3	1.75e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg05666077	chr12:56652063	ANKRD52	0.35	5.97	0.31	6.23e-9	Educational attainment (years of education);
LUSC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg21672276	chr3:44754072	ZNF502	-0.41	-6.68	-0.34	1.03e-10	Depressive symptoms;
LUSC	cis	rs2625529	0.627	rs1037680	chr15:72514319	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-7.25	-0.37	2.97e-12	Red blood cell count;
LUSC	cis	rs8099014	0.834	rs4940699	chr18:56109007	A/C	cg12907477	chr18:56117327	MIR122	0.44	7.02	0.36	1.28e-11	Platelet count;
LUSC	cis	rs5769707	0.681	rs1107514	chr22:50042383	T/C	cg05373962	chr22:49881684	NA	-0.4	-8.29	-0.41	2.85e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2299587	0.560	rs3913555	chr8:17781810	A/C	cg01800426	chr8:17659068	MTUS1	-0.49	-6.45	-0.33	3.86e-10	Economic and political preferences;
LUSC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.95	0.31	6.91e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7582720	1.000	rs72932574	chr2:203866336	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	8.37	0.42	1.63e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg20703242	chr1:230279135	GALNT2	0.52	8.2	0.41	5.22e-15	Coronary artery disease;
LUSC	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg10523679	chr1:76189770	ACADM	-0.49	-7.25	-0.37	2.96e-12	Daytime sleep phenotypes;
LUSC	cis	rs2731664	0.792	rs465670	chr5:176877624	C/T	cg23176889	chr5:176863531	GRK6	-0.68	-14.07	-0.61	1.21e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg11130432	chr3:121712080	ILDR1	-0.63	-9.49	-0.46	4.55e-19	Multiple sclerosis;
LUSC	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.69	-11.59	-0.54	2.41e-26	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.68	0.47	1.06e-19	Bipolar disorder;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11539424	chr4:141348862	CLGN	-0.41	-5.96	-0.31	6.26e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg19729930	chr2:74357872	NA	0.86	14.94	0.63	5.33e-39	Gestational age at birth (maternal effect);
LUSC	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg00432049	chr6:150390894	ULBP3	-0.28	-6.0	-0.31	5.05e-9	Alopecia areata;
LUSC	cis	rs11997175	0.902	rs7462610	chr8:33693318	A/T	ch.8.33884649F	chr8:33765107	NA	0.42	6.53	0.34	2.51e-10	Body mass index;
LUSC	cis	rs9311676	0.594	rs55954186	chr3:58436476	G/A	cg13750441	chr3:58318267	PXK	0.36	6.93	0.35	2.21e-11	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-6.74	-0.35	6.9e-11	Endometrial cancer;
LUSC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.81	12.65	0.57	3.11e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg23359895	chr10:1095482	IDI1	0.68	6.26	0.32	1.16e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg13535736	chr9:111863775	C9orf5	-0.39	-6.58	-0.34	1.87e-10	Menarche (age at onset);
LUSC	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg15557168	chr22:42548783	NA	-0.33	-5.72	-0.3	2.43e-8	Cognitive function;
LUSC	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg06917634	chr15:78832804	PSMA4	-0.44	-5.97	-0.31	5.94e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	14.71	0.63	4.17e-38	Menopause (age at onset);
LUSC	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg01191920	chr7:158217561	PTPRN2	-0.52	-10.81	-0.51	1.5e-23	Obesity-related traits;
LUSC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg06600287	chr1:53387719	ECHDC2	-0.3	-6.37	-0.33	6.19e-10	Monocyte count;
LUSC	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.53	0.5	1.37e-22	Colorectal cancer;
LUSC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg06238570	chr21:40685208	BRWD1	-0.62	-10.51	-0.5	1.66e-22	Cognitive function;
LUSC	cis	rs17253792	0.822	rs75560658	chr14:56079896	C/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs2282300	0.956	rs654710	chr11:30394303	A/G	cg25418670	chr11:30344373	C11orf46	0.49	6.81	0.35	4.67e-11	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07866464	chr2:106810675	UXS1	-0.44	-6.74	-0.35	6.97e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.65	-0.43	2.25e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg06521331	chr12:34319734	NA	0.4	6.62	0.34	1.44e-10	Morning vs. evening chronotype;
LUSC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg13683864	chr3:40499215	RPL14	-1.15	-21.55	-0.76	3.67e-65	Renal cell carcinoma;
LUSC	cis	rs7246967	0.673	rs8104564	chr19:22867207	G/A	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00166722	chr3:10149974	C3orf24	0.63	8.77	0.43	9.36e-17	Alzheimer's disease;
LUSC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25072359	chr17:41440525	NA	0.64	9.02	0.44	1.51e-17	Menopause (age at onset);
LUSC	cis	rs950881	0.932	rs10173081	chr2:102957348	C/T	cg20060108	chr2:102954350	IL1RL1	0.46	6.01	0.31	4.77e-9	Allergy;
LUSC	cis	rs727505	0.564	rs57841320	chr7:124847732	T/A	cg23710748	chr7:124431027	NA	-0.4	-6.85	-0.35	3.6e-11	Lewy body disease;
LUSC	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg24675056	chr1:15929824	NA	0.46	8.03	0.4	1.69e-14	Systolic blood pressure;
LUSC	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg26102564	chr10:131424627	MGMT	0.44	6.81	0.35	4.51e-11	Response to temozolomide;
LUSC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg18230493	chr5:56204884	C5orf35	-0.88	-13.39	-0.59	4.99e-33	Initial pursuit acceleration;
LUSC	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg12215294	chr3:40350768	EIF1B	-0.34	-5.75	-0.3	2.04e-8	Renal cell carcinoma;
LUSC	cis	rs1957429	0.520	rs72625648	chr14:65344602	A/G	cg23373153	chr14:65346875	NA	-0.89	-8.08	-0.4	1.24e-14	Pediatric areal bone mineral density (radius);
LUSC	trans	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg24375607	chr4:120327624	NA	0.53	8.07	0.4	1.31e-14	Diastolic blood pressure;
LUSC	cis	rs4363385	0.776	rs1890284	chr1:152942190	G/A	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.27	-0.37	2.62e-12	Inflammatory skin disease;
LUSC	cis	rs1712517	0.566	rs1163073	chr10:105022934	C/T	cg04362960	chr10:104952993	NT5C2	0.48	6.32	0.33	8.47e-10	Migraine;
LUSC	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-1.13	-17.91	-0.7	9.52e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs1595825	1.000	rs1304164	chr2:198877234	C/A	cg00982548	chr2:198649783	BOLL	-0.49	-6.15	-0.32	2.15e-9	Ulcerative colitis;
LUSC	cis	rs427941	0.655	rs201468	chr7:101742673	C/T	cg06246474	chr7:101738831	CUX1	0.38	6.23	0.32	1.4e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs73129298	0.551	rs6020175	chr20:48602116	T/C	cg25655593	chr20:48599521	SNAI1	0.59	6.36	0.33	6.69e-10	Inflammatory skin disease;
LUSC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg18876405	chr7:65276391	NA	-0.56	-8.91	-0.44	3.45e-17	Aortic root size;
LUSC	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg12365402	chr11:9010492	NRIP3	-0.45	-8.17	-0.41	6.4e-15	Hemoglobin concentration;
LUSC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	10.66	0.5	4.78e-23	Homoarginine levels;
LUSC	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-6.49	-0.33	3.1e-10	Primary tooth development (time to first tooth eruption);
LUSC	cis	rs10761482	0.861	rs10821733	chr10:62103405	A/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg17764715	chr19:33622953	WDR88	0.6	8.23	0.41	4.37e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg24250549	chr1:154909240	PMVK	-0.66	-11.12	-0.52	1.16e-24	Prostate cancer;
LUSC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.77	13.17	0.58	3.54e-32	Monocyte count;
LUSC	cis	rs9653442	0.564	rs6707067	chr2:100767232	G/A	cg07810366	chr2:100720526	AFF3	-0.43	-7.31	-0.37	2.03e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	trans	rs11118883	0.567	rs11579212	chr1:222072819	A/C	cg10861897	chr8:49835988	NA	0.24	6.05	0.31	3.98e-9	Colorectal cancer;
LUSC	cis	rs6700896	0.500	rs12040007	chr1:66080160	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.35	0.33	7.09e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg13047869	chr3:10149882	C3orf24	0.56	7.88	0.4	4.57e-14	Alzheimer's disease;
LUSC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg11663144	chr21:46675770	NA	-0.41	-7.22	-0.37	3.46e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg13175981	chr1:150552382	MCL1	0.47	6.7	0.34	8.66e-11	Tonsillectomy;
LUSC	cis	rs61869271	0.799	rs35501899	chr10:116739109	T/G	cg23260525	chr10:116636907	FAM160B1	0.29	5.71	0.3	2.43e-8	Tonsillectomy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24068859	chr3:194392930	LSG1	-0.43	-6.44	-0.33	4.17e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	11.27	0.52	3.6e-25	Tonsillectomy;
LUSC	cis	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg17187183	chr4:55093834	PDGFRA	0.4	6.11	0.32	2.83e-9	Corneal astigmatism;
LUSC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg06238570	chr21:40685208	BRWD1	0.49	7.45	0.38	8.26e-13	Cognitive function;
LUSC	cis	rs7674212	0.581	rs13150953	chr4:103942498	A/G	cg16532752	chr4:104119610	CENPE	-0.43	-5.87	-0.31	1.04e-8	Type 2 diabetes;
LUSC	cis	rs977987	0.843	rs6564260	chr16:75447426	A/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.62	-0.34	1.4e-10	Dupuytren's disease;
LUSC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06481639	chr22:41940642	POLR3H	-0.5	-5.78	-0.3	1.68e-8	Vitiligo;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01338834	chr21:40720919	HMGN1	0.47	7.4	0.38	1.11e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg14895029	chr7:2775587	GNA12	-0.39	-6.03	-0.31	4.45e-9	Height;
LUSC	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg22571038	chr17:48585470	MYCBPAP	0.49	6.26	0.32	1.19e-9	Visceral fat;
LUSC	trans	rs9860340	0.730	rs73137449	chr3:87641049	C/G	cg03644585	chr7:884825	UNC84A	0.42	6.06	0.31	3.62e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg06271696	chr7:157225062	NA	-0.42	-8.21	-0.41	4.79e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg20476274	chr7:133979776	SLC35B4	0.78	12.95	0.58	2.41e-31	Mean platelet volume;
LUSC	cis	rs394563	0.517	rs385303	chr6:149779064	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.44	-0.33	4.15e-10	Dupuytren's disease;
LUSC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-6.45	-0.33	3.86e-10	Renal function-related traits (BUN);
LUSC	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.14	0.36	6.05e-12	Asthma;
LUSC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	11.08	0.52	1.69e-24	Prudent dietary pattern;
LUSC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-0.82	-12.46	-0.56	1.59e-29	Gut microbiome composition (summer);
LUSC	cis	rs4363385	0.530	rs61815714	chr1:152921380	C/T	cg25856811	chr1:152973957	SPRR3	-0.38	-6.21	-0.32	1.58e-9	Inflammatory skin disease;
LUSC	cis	rs1322512	0.713	rs2758794	chr6:152930965	T/C	cg27316956	chr6:152958899	SYNE1	-0.35	-5.85	-0.31	1.15e-8	Tonometry;
LUSC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg17764715	chr19:33622953	WDR88	0.58	8.4	0.42	1.3e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-6.84	-0.35	3.83e-11	Electroencephalogram traits;
LUSC	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg05347473	chr6:146136440	FBXO30	0.53	9.01	0.44	1.67e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg17330251	chr7:94953956	PON1	-0.38	-5.88	-0.31	9.77e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7833986	0.534	rs2667980	chr8:56896541	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	11.11	0.52	1.24e-24	Height;
LUSC	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg13010199	chr12:38710504	ALG10B	0.57	8.61	0.43	2.89e-16	Morning vs. evening chronotype;
LUSC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg06238570	chr21:40685208	BRWD1	-0.56	-9.03	-0.44	1.37e-17	Menarche (age at onset);
LUSC	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg03289416	chr15:75166202	SCAMP2	0.45	6.75	0.35	6.49e-11	Breast cancer;
LUSC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg22823121	chr1:150693482	HORMAD1	0.5	7.7	0.39	1.52e-13	Melanoma;
LUSC	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg18002602	chr11:66138449	SLC29A2	0.45	8.12	0.41	8.95e-15	Educational attainment (years of education);
LUSC	cis	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05901451	chr6:126070800	HEY2	0.57	8.66	0.43	2.04e-16	Endometrial cancer;
LUSC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg10664184	chr19:17420304	DDA1	0.47	6.13	0.32	2.46e-9	Systemic lupus erythematosus;
LUSC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.31	0.53	2.45e-25	Menopause (age at onset);
LUSC	cis	rs9403521	1.000	rs7766510	chr6:144002291	C/G	cg18240653	chr6:144019428	PHACTR2	-0.48	-5.93	-0.31	7.7e-9	Obesity-related traits;
LUSC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg19230755	chr7:65878503	NA	-0.4	-5.73	-0.3	2.18e-8	Aortic root size;
LUSC	cis	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg07460842	chr6:66804631	NA	-0.47	-6.54	-0.34	2.29e-10	Blood trace element (Cu levels);
LUSC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg16624210	chr5:671434	TPPP	0.49	6.12	0.32	2.58e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	9.4	0.46	9.2e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.33	-6.05	-0.31	3.97e-9	Coronary artery disease;
LUSC	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	7.71	0.39	1.46e-13	Response to antipsychotic treatment;
LUSC	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg15744005	chr10:104629667	AS3MT	-0.28	-5.93	-0.31	7.59e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg11845111	chr2:191398756	TMEM194B	0.54	9.3	0.45	1.83e-18	Pulse pressure;
LUSC	cis	rs12365397	0.526	rs11607331	chr11:43157244	T/C	cg03447554	chr11:43094025	NA	0.35	5.89	0.31	9.33e-9	Migraine;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15941057	chr17:27169869	C17orf63	-0.42	-6.33	-0.33	8.1e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg01238044	chr22:24384105	GSTT1	-0.5	-7.24	-0.37	3.03e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.06	-17.57	-0.69	2.14e-49	Primary sclerosing cholangitis;
LUSC	cis	rs62400317	0.762	rs10484625	chr6:44823449	G/A	cg18551225	chr6:44695536	NA	-0.46	-7.41	-0.38	1.02e-12	Total body bone mineral density;
LUSC	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg01528321	chr10:82214614	TSPAN14	-0.83	-12.83	-0.57	6.65e-31	Post bronchodilator FEV1;
LUSC	cis	rs9815354	0.812	rs73081392	chr3:41923009	G/A	cg03022575	chr3:42003672	ULK4	0.83	8.57	0.42	3.85e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-6.51	-0.34	2.8e-10	Neuroticism;
LUSC	cis	rs16912285	0.688	rs7124856	chr11:24324926	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	9.61	0.47	1.81e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg12292205	chr6:26970375	C6orf41	-0.63	-7.51	-0.38	5.42e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19429466	chr4:87515395	PTPN13	-0.38	-6.14	-0.32	2.31e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg05347473	chr6:146136440	FBXO30	0.56	9.49	0.46	4.47e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	0.83	14.07	0.61	1.24e-35	Tonsillectomy;
LUSC	cis	rs28829049	0.597	rs34219832	chr1:19502432	C/T	cg13387374	chr1:19411106	UBR4	0.44	6.23	0.32	1.39e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg05234568	chr11:5960015	NA	-0.65	-9.51	-0.46	3.76e-19	DNA methylation (variation);
LUSC	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-6.76	-0.35	6.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs35146811	0.700	rs866500	chr7:99840461	A/G	cg13334819	chr7:99746414	C7orf59	0.49	6.09	0.32	3.07e-9	Coronary artery disease;
LUSC	cis	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg21775007	chr8:11205619	TDH	0.44	5.96	0.31	6.52e-9	Monocyte count;
LUSC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg08470875	chr2:26401718	FAM59B	0.69	8.8	0.43	7.27e-17	Gut microbiome composition (summer);
LUSC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.09	14.43	0.62	5.1e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg06784218	chr1:46089804	CCDC17	-0.47	-8.97	-0.44	2.13e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg17480646	chr11:65405466	SIPA1	-0.45	-5.83	-0.3	1.31e-8	Acne (severe);
LUSC	cis	rs7903847	0.642	rs7088410	chr10:99135539	G/T	cg20016023	chr10:99160130	RRP12	-0.34	-8.38	-0.42	1.45e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg12927641	chr6:109611667	NA	-0.37	-6.38	-0.33	5.82e-10	Reticulocyte fraction of red cells;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg05064044	chr6:292385	DUSP22	-0.72	-11.82	-0.54	3.69e-27	Menopause (age at onset);
LUSC	cis	rs7640424	0.628	rs7628325	chr3:107816314	G/A	cg09227934	chr3:107805635	CD47	-0.55	-7.91	-0.4	3.84e-14	Body mass index;
LUSC	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Alcohol dependence;
LUSC	cis	rs965513	1.000	rs10739496	chr9:100552559	C/T	cg13688889	chr9:100608707	NA	-0.51	-7.75	-0.39	1.13e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.48	0.46	5e-19	Mean platelet volume;
LUSC	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg03929089	chr4:120376271	NA	0.68	6.39	0.33	5.54e-10	Intraocular pressure;
LUSC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg16339924	chr4:17578868	LAP3	0.59	9.17	0.45	4.96e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg03821727	chr12:1026369	RAD52	-0.4	-5.97	-0.31	5.93e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg22166914	chr1:53195759	ZYG11B	-0.54	-8.68	-0.43	1.73e-16	Monocyte count;
LUSC	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg19653624	chr11:20408972	PRMT3	-0.69	-8.84	-0.44	5.41e-17	Pursuit maintenance gain;
LUSC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg02423579	chr7:2872169	GNA12	-0.43	-6.25	-0.32	1.28e-9	Height;
LUSC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.14e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6977660	1.000	rs12531373	chr7:19816825	A/C	cg07541023	chr7:19748670	TWISTNB	0.52	6.01	0.31	4.83e-9	Thyroid stimulating hormone;
LUSC	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg00825309	chr19:58991885	ZNF446	-0.5	-7.23	-0.37	3.35e-12	Uric acid clearance;
LUSC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.3	-0.45	1.93e-18	Systolic blood pressure;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18247339	chr14:35183597	CFL2	0.4	6.33	0.33	8e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg01819863	chr10:32635814	EPC1	1.06	10.97	0.51	4.02e-24	Sexual dysfunction (female);
LUSC	trans	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg06565620	chr18:47792949	CCDC11	0.53	5.97	0.31	6.1e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.15	-0.45	5.74e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs67072384	1.000	rs11235579	chr11:72453095	A/G	cg04827223	chr11:72435913	ARAP1	-0.8	-7.39	-0.37	1.18e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	trans	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg20935933	chr6:143382018	AIG1	-0.51	-7.31	-0.37	1.98e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26159030	chr19:36214806	MLL4	0.42	6.43	0.33	4.35e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg12463550	chr7:65579703	CRCP	0.45	6.76	0.35	6.19e-11	Aortic root size;
LUSC	cis	rs12367572	0.663	rs1118481	chr12:45354469	C/G	cg04608330	chr12:45269318	NELL2	-0.38	-5.75	-0.3	2.06e-8	Gut microbiome composition (summer);
LUSC	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.77	-0.39	9.67e-14	Glomerular filtration rate;
LUSC	cis	rs62400317	0.762	rs62436375	chr6:44875818	T/C	cg18551225	chr6:44695536	NA	-0.46	-7.44	-0.38	8.7e-13	Total body bone mineral density;
LUSC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg24881330	chr22:46731750	TRMU	0.89	8.95	0.44	2.52e-17	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs6906287	0.647	rs7772214	chr6:118793703	A/T	cg21191810	chr6:118973309	C6orf204	0.32	5.84	0.3	1.21e-8	Electrocardiographic conduction measures;
LUSC	cis	rs7084921	0.578	rs11190393	chr10:101869988	C/T	cg02250046	chr10:101825185	CPN1	-0.33	-6.02	-0.31	4.5e-9	Bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10839663	chr1:113261613	NA	-0.42	-6.35	-0.33	7.08e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg17462356	chr17:80056334	FASN	0.43	5.87	0.31	1.03e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.16	-0.32	2.09e-9	Retinal vascular caliber;
LUSC	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.97	-0.61	2.98e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4474465	0.850	rs10793326	chr11:78255422	A/C	cg27205649	chr11:78285834	NARS2	0.55	6.45	0.33	3.87e-10	Alzheimer's disease (survival time);
LUSC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg04733989	chr22:42467013	NAGA	0.55	8.67	0.43	1.95e-16	Schizophrenia;
LUSC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18876405	chr7:65276391	NA	0.55	8.59	0.43	3.48e-16	Aortic root size;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg16371341	chr5:56469761	GPBP1	0.75	6.23	0.32	1.43e-9	Body mass index;
LUSC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.07	0.52	1.76e-24	Alzheimer's disease;
LUSC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.82	14.05	0.61	1.48e-35	Vitiligo;
LUSC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.51	-0.42	5.93e-16	Chronic sinus infection;
LUSC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg02018176	chr4:1364513	KIAA1530	0.45	7.38	0.37	1.25e-12	Obesity-related traits;
LUSC	cis	rs12760731	0.565	rs12036491	chr1:178163651	C/A	cg00404053	chr1:178313656	RASAL2	0.66	6.82	0.35	4.26e-11	Obesity-related traits;
LUSC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg04317338	chr11:64019027	PLCB3	0.63	6.98	0.36	1.57e-11	Mean platelet volume;
LUSC	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	0.81	11.42	0.53	1.05e-25	Response to hepatitis C treatment;
LUSC	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg09165964	chr15:75287851	SCAMP5	-1.15	-18.88	-0.72	1.33e-54	Blood trace element (Zn levels);
LUSC	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.74	0.3	2.18e-8	Rheumatoid arthritis;
LUSC	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg13010199	chr12:38710504	ALG10B	0.41	5.94	0.31	7.32e-9	Morning vs. evening chronotype;
LUSC	trans	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg14791747	chr16:20752902	THUMPD1	-0.4	-6.14	-0.32	2.33e-9	Dental caries;
LUSC	cis	rs2625529	0.668	rs34189331	chr15:72404573	A/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.89	-0.4	4.44e-14	Red blood cell count;
LUSC	cis	rs7503807	1.000	rs4889775	chr17:78592287	A/G	cg09596252	chr17:78655493	RPTOR	0.42	7.39	0.37	1.19e-12	Obesity;
LUSC	trans	rs11681884	0.892	rs17042888	chr2:113862173	C/T	cg02642549	chr5:77805886	LHFPL2	-0.58	-5.99	-0.31	5.52e-9	Stroke;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05896465	chr22:45560692	NUP50	0.47	6.77	0.35	5.92e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg24578937	chr1:2090814	PRKCZ	0.47	10.53	0.5	1.43e-22	Height;
LUSC	trans	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.88	0.35	2.9e-11	Endometrial cancer;
LUSC	cis	rs6500395	0.962	rs1477135	chr16:48726823	C/T	cg04672837	chr16:48644449	N4BP1	0.46	6.67	0.34	1.06e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.76	-11.13	-0.52	1.1e-24	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs12618769	0.625	rs3769709	chr2:99187433	A/T	cg10123293	chr2:99228465	UNC50	0.46	7.43	0.38	9.29e-13	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.44e-10	Menopause (age at onset);
LUSC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-0.99	-18.0	-0.7	4.19e-51	Height;
LUSC	trans	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg21659725	chr3:3221576	CRBN	-0.69	-8.04	-0.4	1.58e-14	Menarche (age at onset);
LUSC	cis	rs11690935	0.632	rs6723259	chr2:172622527	A/C	cg13550731	chr2:172543902	DYNC1I2	0.58	9.13	0.45	6.47e-18	Schizophrenia;
LUSC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.31	6.0	0.31	5.02e-9	Obesity-related traits;
LUSC	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg07148914	chr20:33460835	GGT7	0.57	8.66	0.43	1.99e-16	Height;
LUSC	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg00074818	chr8:8560427	CLDN23	0.58	9.42	0.46	7.61e-19	Obesity-related traits;
LUSC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg23630131	chr7:65973040	NA	-0.21	-5.93	-0.31	7.63e-9	Aortic root size;
LUSC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.74	13.09	0.58	6.95e-32	Colorectal cancer;
LUSC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	-0.52	-9.21	-0.45	3.68e-18	Menopause (age at onset);
LUSC	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg20991723	chr1:152506922	NA	0.49	9.13	0.45	6.46e-18	Hair morphology;
LUSC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.83	12.39	0.56	2.88e-29	Cognitive test performance;
LUSC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-0.74	-9.37	-0.46	1.15e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.67e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg17724175	chr1:150552817	MCL1	-0.35	-6.3	-0.33	9.36e-10	Tonsillectomy;
LUSC	cis	rs654351	0.541	rs533746	chr6:10388968	C/T	cg17959970	chr6:10383164	NA	0.36	6.68	0.34	1.01e-10	Squamous cell lung carcinoma;
LUSC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg14227996	chr4:17616232	MED28	0.67	7.1	0.36	7.65e-12	Opioid sensitivity;
LUSC	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.41	5.94	0.31	7.34e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-0.77	-10.74	-0.51	2.62e-23	Platelet distribution width;
LUSC	cis	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg20368463	chr18:77673604	PQLC1	0.54	7.82	0.39	7.17e-14	Schizophrenia;
LUSC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.4	-6.18	-0.32	1.88e-9	Tonsillectomy;
LUSC	cis	rs5770917	1.000	rs2073605	chr22:51008850	A/G	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.64	-5.82	-0.3	1.36e-8	Narcolepsy;
LUSC	cis	rs62432291	0.681	rs404435	chr6:159654487	G/T	cg14500486	chr6:159655392	FNDC1	-0.52	-5.84	-0.3	1.22e-8	Joint mobility (Beighton score);
LUSC	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg05855489	chr10:104503620	C10orf26	0.53	8.01	0.4	1.98e-14	Arsenic metabolism;
LUSC	cis	rs17030434	1.000	rs12646124	chr4:154718084	G/T	cg14289246	chr4:154710475	SFRP2	-0.53	-6.92	-0.35	2.32e-11	Electrocardiographic conduction measures;
LUSC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.86	-0.44	4.75e-17	Gut microbiome composition (summer);
LUSC	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg23711669	chr6:146136114	FBXO30	-0.82	-14.68	-0.63	5.24e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-10.4	-0.49	3.84e-22	Body mass index;
LUSC	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.96	-0.48	1.2e-20	Coronary artery disease;
LUSC	cis	rs1958560	0.867	rs2185454	chr14:65870594	G/T	cg03016385	chr14:66212404	NA	-0.39	-6.03	-0.31	4.32e-9	Menarche (age at onset);
LUSC	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.58	9.57	0.46	2.44e-19	Bone mineral density;
LUSC	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.38e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg25838465	chr1:92012736	NA	0.56	10.21	0.49	1.77e-21	Breast cancer;
LUSC	cis	rs34375054	0.641	rs34624329	chr12:125608028	T/G	cg06287003	chr12:125626642	AACS	-0.38	-6.67	-0.34	1.04e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg01283332	chr5:1856932	NA	-0.34	-6.49	-0.33	3.03e-10	Cardiovascular disease risk factors;
LUSC	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg26856596	chr11:1961893	NA	0.34	6.3	0.33	9.45e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg08079166	chr15:68083412	MAP2K5	-0.36	-6.34	-0.33	7.28e-10	Motion sickness;
LUSC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg25258033	chr6:167368657	RNASET2	-0.46	-7.82	-0.39	7.17e-14	Crohn's disease;
LUSC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg13206674	chr6:150067644	NUP43	0.59	9.25	0.45	2.68e-18	Lung cancer;
LUSC	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-7.41	-0.38	1.01e-12	Morning vs. evening chronotype;
LUSC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.35	-0.37	1.55e-12	Subjective well-being;
LUSC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.68	10.56	0.5	1.14e-22	Aortic root size;
LUSC	cis	rs3087591	0.708	rs2107359	chr17:29697223	A/T	cg24425628	chr17:29625626	OMG;NF1	0.49	7.28	0.37	2.48e-12	Hip circumference;
LUSC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg14893161	chr1:205819251	PM20D1	-0.43	-6.42	-0.33	4.73e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg01238044	chr22:24384105	GSTT1	-0.53	-7.64	-0.39	2.25e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg06096015	chr1:231504339	EGLN1	0.56	9.95	0.48	1.38e-20	Hemoglobin concentration;
LUSC	cis	rs4845459	0.967	rs4112788	chr1:152551276	A/G	cg08895932	chr1:152778580	LCE1C	-0.35	-5.73	-0.3	2.22e-8	Psoriasis;
LUSC	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-7.3	-0.37	2.06e-12	Daytime sleep phenotypes;
LUSC	cis	rs372883	0.967	rs2832290	chr21:30728863	C/T	cg24692254	chr21:30365293	RNF160	-0.44	-6.16	-0.32	2.14e-9	Pancreatic cancer;
LUSC	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02176678	chr2:219576539	TTLL4	0.66	13.07	0.58	8.21e-32	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg21856205	chr7:94953877	PON1	-0.36	-5.77	-0.3	1.77e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg12179176	chr11:130786555	SNX19	0.87	14.66	0.63	6.69e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg27129171	chr3:47204927	SETD2	0.72	12.42	0.56	2.16e-29	Colorectal cancer;
LUSC	cis	rs4654899	0.680	rs4654881	chr1:21209769	T/C	cg01072550	chr1:21505969	NA	0.53	7.88	0.4	4.63e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg04450456	chr4:17643702	FAM184B	-0.4	-6.77	-0.35	5.91e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2019216	0.521	rs6565386	chr17:21901755	A/G	cg22648282	chr17:21454238	C17orf51	0.45	6.74	0.35	6.87e-11	Pelvic organ prolapse;
LUSC	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg01629716	chr15:45996671	NA	0.4	5.96	0.31	6.25e-9	Waist circumference;Weight;
LUSC	cis	rs1866706	0.896	rs4757955	chr11:12876492	C/A	cg25843174	chr11:12811716	TEAD1	-0.28	-5.72	-0.3	2.36e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg05347473	chr6:146136440	FBXO30	-0.5	-8.41	-0.42	1.2e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.09	0.32	3.09e-9	Personality dimensions;
LUSC	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.61	-0.69	1.43e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg00509249	chr6:109615579	CCDC162	-0.34	-6.13	-0.32	2.46e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09104050	chr16:68563912	NA	-0.46	-6.16	-0.32	2.1e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg08508325	chr11:3079039	CARS	-0.52	-12.94	-0.58	2.49e-31	Longevity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27287882	chr3:48282590	ZNF589	0.45	6.39	0.33	5.51e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg02773041	chr1:40204384	PPIE	0.54	8.26	0.41	3.35e-15	Blood protein levels;
LUSC	cis	rs2227564	1	rs2227564	chr10:75673101	C/T	cg23231163	chr10:75533350	FUT11	0.42	5.75	0.3	1.97e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs6961069	0.585	rs10265457	chr7:80257373	G/A	cg04458919	chr7:80252533	CD36	-0.41	-7.28	-0.37	2.49e-12	Platelet count;
LUSC	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg23711669	chr6:146136114	FBXO30	0.71	12.34	0.56	4.27e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.42	-0.33	4.55e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08859206	chr1:53392774	SCP2	-0.64	-12.22	-0.56	1.26e-28	Monocyte count;
LUSC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg15691649	chr6:25882328	NA	-0.37	-5.85	-0.3	1.19e-8	Blood metabolite levels;
LUSC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg21573476	chr21:45109991	RRP1B	0.38	5.99	0.31	5.58e-9	Mean corpuscular volume;
LUSC	trans	rs72674100	1.000	rs28368345	chr4:97991439	T/C	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07362569	chr17:61921086	SMARCD2	0.37	7.62	0.38	2.61e-13	Prudent dietary pattern;
LUSC	cis	rs12042938	0.579	rs980394	chr1:231779507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.42	-6.24	-0.32	1.35e-9	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-1.01	-14.3	-0.62	1.55e-36	Exhaled nitric oxide output;
LUSC	cis	rs7246967	0.611	rs66620859	chr19:22837230	G/T	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs12594515	1.000	rs7162201	chr15:45992658	A/C	cg19682013	chr15:45996608	NA	0.39	5.86	0.31	1.14e-8	Waist circumference;Weight;
LUSC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg09034736	chr1:150693464	HORMAD1	0.45	6.48	0.33	3.36e-10	Melanoma;
LUSC	cis	rs9534288	0.797	rs992631	chr13:46591989	A/G	cg15192986	chr13:46630673	CPB2	0.65	10.76	0.51	2.29e-23	Blood protein levels;
LUSC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.66	0.47	1.29e-19	Eosinophil percentage of white cells;
LUSC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.6	9.89	0.48	2.14e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg13514129	chr1:39547527	MACF1	0.71	11.82	0.54	3.64e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs9616064	0.889	rs5767287	chr22:46996179	G/A	cg05621596	chr22:47072043	GRAMD4	-0.43	-6.43	-0.33	4.51e-10	Urate levels in obese individuals;
LUSC	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.36	-0.33	6.66e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg26384229	chr12:38710491	ALG10B	-0.55	-8.3	-0.41	2.53e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11748023	0.605	rs155948	chr5:139519181	A/G	cg26211634	chr5:139558579	C5orf32	-0.35	-6.38	-0.33	5.93e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg22823121	chr1:150693482	HORMAD1	0.51	7.47	0.38	7.01e-13	Melanoma;
LUSC	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-7.36	-0.37	1.46e-12	Axial length;
LUSC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg03929089	chr4:120376271	NA	-0.94	-16.27	-0.66	3.03e-44	Height;
LUSC	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg00999904	chr2:3704751	ALLC	-0.43	-5.97	-0.31	6.15e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9815354	0.638	rs111465678	chr3:41864405	C/A	cg03022575	chr3:42003672	ULK4	0.58	6.52	0.34	2.6e-10	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg13010199	chr12:38710504	ALG10B	0.55	8.2	0.41	5.23e-15	Morning vs. evening chronotype;
LUSC	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	13.14	0.58	4.43e-32	Alzheimer's disease;
LUSC	cis	rs7615316	0.872	rs7635146	chr3:142350079	A/G	cg16271453	chr3:142027066	XRN1	-0.34	-5.82	-0.3	1.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg06764241	chr13:99092976	FARP1	0.52	7.16	0.36	5.05e-12	Cognitive function;Information processing speed;
LUSC	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg09835421	chr16:68378352	PRMT7	-0.52	-5.79	-0.3	1.59e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.47	-6.52	-0.34	2.64e-10	Reticulocyte count;
LUSC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg16339924	chr4:17578868	LAP3	0.57	8.79	0.43	8.02e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg23649088	chr2:200775458	C2orf69	0.61	7.84	0.39	6.01e-14	Schizophrenia;
LUSC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg02782426	chr3:40428986	ENTPD3	0.31	6.02	0.31	4.57e-9	Renal cell carcinoma;
LUSC	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg09184832	chr6:79620586	NA	-0.42	-6.8	-0.35	4.71e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg14343924	chr8:8086146	FLJ10661	-0.45	-6.23	-0.32	1.43e-9	Monocyte count;
LUSC	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	8.52	0.42	5.65e-16	Lung cancer in ever smokers;
LUSC	cis	rs7169223	0.653	rs3743057	chr15:79089007	T/C	cg21242079	chr15:79101063	ADAMTS7	0.42	6.32	0.33	8.44e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-7.85	-0.39	5.64e-14	Schizophrenia;
LUSC	cis	rs1440410	0.798	rs10002867	chr4:144169650	G/T	cg01719995	chr4:144104893	USP38	0.33	5.79	0.3	1.6e-8	Ischemic stroke;
LUSC	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg22676075	chr6:135203613	NA	0.55	8.73	0.43	1.25e-16	Red blood cell count;
LUSC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg15556689	chr8:8085844	FLJ10661	0.54	8.06	0.4	1.37e-14	Neuroticism;
LUSC	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg09307838	chr4:120376055	NA	0.68	9.54	0.46	3.11e-19	Corneal astigmatism;
LUSC	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg00383909	chr3:49044727	WDR6	1.14	9.53	0.46	3.4e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs68170813	0.641	rs34084719	chr7:107095227	A/G	cg02696742	chr7:106810147	HBP1	-0.62	-8.76	-0.43	9.65e-17	Coronary artery disease;
LUSC	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.8	13.26	0.59	1.6e-32	Morning vs. evening chronotype;
LUSC	cis	rs8032315	0.965	rs12906125	chr15:91427612	G/A	cg04510874	chr15:91427884	FES	0.3	5.93	0.31	7.51e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9549260	0.755	rs4943800	chr13:41216831	A/G	cg21288729	chr13:41239152	FOXO1	0.66	10.17	0.49	2.4e-21	Red blood cell count;
LUSC	cis	rs1215050	0.846	rs783923	chr4:98968686	C/T	cg05340658	chr4:99064831	C4orf37	-0.43	-6.57	-0.34	1.88e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7254114	0.578	rs3745682	chr19:11313256	C/T	cg02815516	chr19:11306319	KANK2	-0.41	-8.41	-0.42	1.21e-15	Immature fraction of reticulocytes;
LUSC	cis	rs6684514	1.000	rs10908500	chr1:156280671	A/T	cg16558208	chr1:156270281	VHLL	0.36	5.75	0.3	2e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUSC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.02	0.31	4.49e-9	Menopause (age at onset);
LUSC	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg01966878	chr4:90757139	SNCA	-0.43	-6.22	-0.32	1.49e-9	Neuroticism;
LUSC	cis	rs13315871	0.615	rs6794695	chr3:58423498	A/C	cg12435725	chr3:58293450	RPP14	-0.4	-5.65	-0.3	3.52e-8	Cholesterol, total;
LUSC	cis	rs2282032	0.527	rs8020828	chr14:90768183	C/T	cg04374321	chr14:90722782	PSMC1	0.44	6.06	0.31	3.63e-9	Longevity;
LUSC	cis	rs12760731	0.720	rs10913557	chr1:178442190	C/T	cg00404053	chr1:178313656	RASAL2	0.6	6.3	0.33	9.21e-10	Obesity-related traits;
LUSC	cis	rs2806561	0.808	rs2294518	chr1:23372771	T/C	cg19743168	chr1:23544995	NA	-0.44	-9.02	-0.44	1.5e-17	Height;
LUSC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs62400317	1.000	rs62400317	chr6:45284923	C/T	cg18551225	chr6:44695536	NA	-0.42	-6.97	-0.36	1.69e-11	Total body bone mineral density;
LUSC	cis	rs12940923	0.872	rs11650865	chr17:56364741	G/T	cg19466818	chr17:56409534	MIR142	-0.39	-6.86	-0.35	3.35e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19346786	chr7:2764209	NA	-0.42	-7.07	-0.36	9.39e-12	Height;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg20592144	chr17:80049216	FASN	-0.39	-5.97	-0.31	6e-9	N-glycan levels;
LUSC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg21238619	chr17:78079768	GAA	-0.45	-8.16	-0.41	6.77e-15	Yeast infection;
LUSC	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.69	10.47	0.5	2.2e-22	Educational attainment;
LUSC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.45	-0.5	2.56e-22	Electroencephalogram traits;
LUSC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.53	0.57	8.85e-30	Motion sickness;
LUSC	trans	rs1997103	0.954	rs2177807	chr7:55391002	G/T	cg20935933	chr6:143382018	AIG1	-0.45	-6.78	-0.35	5.56e-11	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.45	7.4	0.38	1.12e-12	Alzheimer's disease (late onset);
LUSC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06112835	chr11:68658793	MRPL21	0.48	7.02	0.36	1.21e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs629535	0.547	rs62513420	chr8:70122597	G/A	cg21567404	chr3:27674614	NA	-0.9	-12.79	-0.57	8.93e-31	Dupuytren's disease;
LUSC	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	9.33	0.45	1.57e-18	Response to antipsychotic treatment;
LUSC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06634786	chr22:41940651	POLR3H	-0.53	-6.23	-0.32	1.37e-9	Vitiligo;
LUSC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg20684491	chr1:25596433	NA	-0.36	-5.72	-0.3	2.42e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg14092988	chr3:52407081	DNAH1	0.31	5.97	0.31	6.11e-9	Bipolar disorder;
LUSC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.64	0.57	3.36e-30	Motion sickness;
LUSC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17994379	chr17:43025264	KIF18B	0.55	7.83	0.39	6.69e-14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.58	7.72	0.39	1.39e-13	High light scatter reticulocyte count;
LUSC	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg14092571	chr14:90743983	NA	-0.36	-5.82	-0.3	1.37e-8	Mortality in heart failure;
LUSC	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.89	12.78	0.57	1.02e-30	Ileal carcinoids;
LUSC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg16586182	chr3:47516702	SCAP	-0.51	-8.03	-0.4	1.74e-14	Colorectal cancer;
LUSC	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg11502198	chr6:26597334	ABT1	0.52	7.67	0.39	1.91e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4903214	0.848	rs11627178	chr14:74718280	G/C	cg08255017	chr14:74727001	VSX2	-0.49	-6.72	-0.35	7.93e-11	Inflammatory bowel disease;
LUSC	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg02569458	chr12:86230093	RASSF9	-0.49	-8.08	-0.4	1.23e-14	Major depressive disorder;
LUSC	cis	rs7131987	0.650	rs10843377	chr12:29437053	C/G	cg09582351	chr12:29534625	ERGIC2	0.34	6.93	0.35	2.15e-11	QT interval;
LUSC	trans	rs1486139	0.967	rs4724464	chr7:46296433	A/G	cg17534202	chr9:96721102	NA	-0.36	-6.51	-0.34	2.82e-10	Select biomarker traits;
LUSC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg13628971	chr7:2884303	GNA12	0.49	6.83	0.35	4e-11	Height;
LUSC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg04944784	chr2:26401820	FAM59B	-0.67	-9.71	-0.47	8.72e-20	Gut microbiome composition (summer);
LUSC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg06784218	chr1:46089804	CCDC17	0.48	9.53	0.46	3.45e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1178968	0.901	rs4717753	chr7:72754354	C/T	cg25889504	chr7:72793014	NA	0.53	7.25	0.37	2.95e-12	Triglyceride levels;
LUSC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg03909863	chr11:638404	DRD4	-0.39	-5.74	-0.3	2.17e-8	Systemic lupus erythematosus;
LUSC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg02931644	chr1:25747376	RHCE	-0.32	-5.76	-0.3	1.89e-8	Erythrocyte sedimentation rate;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg11845071	chr6:35695859	FKBP5;LOC285847	0.4	6.11	0.32	2.79e-9	N-glycan levels;
LUSC	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.69	0.57	2.12e-30	White blood cell count;
LUSC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg16524733	chr11:117070046	TAGLN	0.31	5.92	0.31	8.15e-9	Blood protein levels;
LUSC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03352830	chr11:487213	PTDSS2	0.73	8.7	0.43	1.54e-16	Body mass index;
LUSC	cis	rs3106136	0.967	rs35670996	chr4:95199479	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.18	-0.32	1.91e-9	Capecitabine sensitivity;
LUSC	trans	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg10756647	chr7:56101905	PSPH	-0.82	-8.56	-0.42	4.12e-16	Diabetic kidney disease;
LUSC	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-10.88	-0.51	8.15e-24	Response to antipsychotic treatment;
LUSC	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg08917208	chr2:24149416	ATAD2B	0.91	10.18	0.49	2.2e-21	Lymphocyte counts;
LUSC	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.4	0.33	5.31e-10	Testicular germ cell tumor;
LUSC	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg13660082	chr14:53194042	PSMC6	-0.8	-6.65	-0.34	1.17e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7524258	0.900	rs6577425	chr1:7306338	G/T	cg07173049	chr1:7289937	CAMTA1	0.32	6.56	0.34	2.01e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs4629180	0.675	rs6742474	chr2:102091075	G/A	cg04415270	chr2:102091202	RFX8	-0.46	-8.08	-0.4	1.18e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.33	0.45	1.56e-18	Coffee consumption (cups per day);
LUSC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg00814883	chr7:100076585	TSC22D4	-0.68	-9.45	-0.46	6.18e-19	Platelet count;
LUSC	cis	rs4845459	1.000	rs4845459	chr1:152603842	C/A	cg08895932	chr1:152778580	LCE1C	-0.36	-5.8	-0.3	1.56e-8	Psoriasis;
LUSC	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg17173187	chr15:85201210	NMB	0.5	9.39	0.46	9.83e-19	Schizophrenia;
LUSC	cis	rs17433780	0.857	rs12144445	chr1:89465238	C/T	cg09516651	chr1:89888402	LOC400759	0.49	8.12	0.41	8.9e-15	Carotid intima media thickness;
LUSC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg21171335	chr12:122356390	WDR66	0.61	9.13	0.45	6.84e-18	Mean corpuscular volume;
LUSC	cis	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg01251360	chr16:68772225	CDH1	-0.26	-6.28	-0.32	1.06e-9	Colorectal cancer;
LUSC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-1.08	-25.56	-0.81	1.33e-80	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg10756647	chr7:56101905	PSPH	-0.88	-8.46	-0.42	8.54e-16	Diabetic kidney disease;
LUSC	cis	rs60154123	0.614	rs662424	chr1:210458472	T/C	cg22029157	chr1:209979665	IRF6	0.51	6.02	0.31	4.63e-9	Coronary artery disease;
LUSC	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-0.91	-15.71	-0.65	4.87e-42	Height;
LUSC	cis	rs757081	0.667	rs615424	chr11:17210481	G/A	cg15432903	chr11:17409602	KCNJ11	-0.38	-5.94	-0.31	7.29e-9	Systolic blood pressure;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13377803	chr19:5978247	RANBP3	0.7	6.29	0.33	9.94e-10	Cognitive performance;
LUSC	trans	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg18335740	chr13:41363409	SLC25A15	-0.73	-13.2	-0.59	2.6e-32	Lewy body disease;
LUSC	cis	rs17030434	0.953	rs74845915	chr4:154696778	G/T	cg14289246	chr4:154710475	SFRP2	-0.51	-6.65	-0.34	1.19e-10	Electrocardiographic conduction measures;
LUSC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg14895029	chr7:2775587	GNA12	-0.37	-5.81	-0.3	1.43e-8	Height;
LUSC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg11812906	chr14:75593930	NEK9	-0.63	-10.39	-0.49	4.36e-22	Height;
LUSC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.6	10.24	0.49	1.41e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.41	-6.11	-0.32	2.8e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12826209	chr6:26865740	GUSBL1	0.74	9.08	0.44	9.64e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg16339924	chr4:17578868	LAP3	0.52	7.93	0.4	3.3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs2562456	0.833	rs7260065	chr19:21516977	A/G	cg00806126	chr19:22604979	ZNF98	-0.42	-6.03	-0.31	4.3e-9	Pain;
LUSC	cis	rs13385	0.769	rs7705932	chr5:139533115	G/A	cg26211634	chr5:139558579	C5orf32	0.42	5.96	0.31	6.48e-9	Atrial fibrillation;
LUSC	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg08085267	chr17:45401833	C17orf57	0.53	8.53	0.42	5.04e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg18827107	chr12:86230957	RASSF9	-0.45	-6.77	-0.35	5.7e-11	Major depressive disorder;
LUSC	trans	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg05926928	chr17:57297772	GDPD1	1.09	13.61	0.6	7.39e-34	Opioid sensitivity;
LUSC	cis	rs13315871	0.929	rs9871725	chr3:58292525	T/G	cg12435725	chr3:58293450	RPP14	-0.76	-7.66	-0.39	2.07e-13	Cholesterol, total;
LUSC	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.89	15.03	0.64	2.37e-39	Bladder cancer;
LUSC	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg13073564	chr4:8508604	NA	0.35	6.45	0.33	3.9e-10	Response to antineoplastic agents;
LUSC	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg23029597	chr12:123009494	RSRC2	-0.74	-9.29	-0.45	1.98e-18	Body mass index;
LUSC	cis	rs9399401	0.961	rs9389985	chr6:142653898	A/G	cg03128060	chr6:142623767	GPR126	0.31	5.68	0.3	3e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg21064579	chr19:49206444	FUT2	0.44	8.56	0.42	4.29e-16	Dietary macronutrient intake;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.32	-5.85	-0.31	1.14e-8	Lymphocyte counts;
LUSC	trans	rs2278907	0.898	rs4531478	chr11:68482489	A/G	cg10806483	chr12:102459329	NA	-0.33	-6.22	-0.32	1.5e-9	Total body bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17156855	chr1:168195023	SFT2D2	-0.4	-6.0	-0.31	5.19e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg08601574	chr20:25228251	PYGB	0.46	7.07	0.36	8.84e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs9944715	0.906	rs7505861	chr18:43745406	A/G	cg01718231	chr17:29326311	RNF135	0.47	6.63	0.34	1.37e-10	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs10743315	0.557	rs16915108	chr12:19290406	T/C	cg02471346	chr12:19282374	PLEKHA5	0.96	6.92	0.35	2.29e-11	Gut microbiota (bacterial taxa);
LUSC	cis	rs2227564	0.678	rs2242257	chr10:75597605	A/G	cg23231163	chr10:75533350	FUT11	0.42	5.79	0.3	1.66e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9311676	0.656	rs6445973	chr3:58336595	G/T	cg13750441	chr3:58318267	PXK	-0.31	-5.67	-0.3	3.1e-8	Systemic lupus erythematosus;
LUSC	cis	rs9837602	1.000	rs28714363	chr3:99752068	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.09	-0.32	3.14e-9	Breast cancer;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg14331148	chr19:47551893	TMEM160	0.37	5.94	0.31	6.98e-9	Calcium levels;
LUSC	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg08999081	chr20:33150536	PIGU	-0.4	-7.35	-0.37	1.54e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg06145435	chr7:1022769	CYP2W1	0.34	5.75	0.3	1.98e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg16339924	chr4:17578868	LAP3	0.55	8.42	0.42	1.12e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs722599	0.683	rs10144845	chr14:75237770	C/T	cg08847533	chr14:75593920	NEK9	0.44	6.3	0.33	9.25e-10	IgG glycosylation;
LUSC	cis	rs6987853	0.933	rs2923401	chr8:42442208	T/C	cg09913449	chr8:42400586	C8orf40	0.47	7.67	0.39	1.86e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.63	11.59	0.54	2.47e-26	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs500891	0.574	rs4706994	chr6:84126824	G/A	cg08257003	chr6:84140564	ME1	0.37	8.9	0.44	3.73e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg04310649	chr10:35416472	CREM	-0.41	-6.47	-0.33	3.5e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg05925327	chr15:68127851	NA	-0.43	-6.82	-0.35	4.18e-11	Obesity;
LUSC	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg00784671	chr22:46762841	CELSR1	-0.54	-6.94	-0.35	2.07e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.25	-0.59	1.75e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg13073564	chr4:8508604	NA	0.46	8.74	0.43	1.17e-16	Response to antineoplastic agents;
LUSC	cis	rs7633770	0.710	rs34820891	chr3:46698059	A/G	cg11219411	chr3:46661640	NA	-0.34	-6.48	-0.33	3.39e-10	Coronary artery disease;
LUSC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg04317338	chr11:64019027	PLCB3	0.68	7.75	0.39	1.12e-13	Mean platelet volume;
LUSC	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg11812906	chr14:75593930	NEK9	-0.63	-10.35	-0.49	5.99e-22	Height;
LUSC	cis	rs7605827	0.930	rs10929376	chr2:15692856	A/T	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.82e-16	Educational attainment (years of education);
LUSC	cis	rs460214	0.539	rs55819392	chr21:40038207	G/A	cg05519781	chr21:40033154	ERG	-0.43	-5.7	-0.3	2.58e-8	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs240764	0.817	rs239221	chr6:101113085	G/A	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.69e-9	Neuroticism;
LUSC	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg03676636	chr4:99064102	C4orf37	0.27	5.8	0.3	1.58e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg04025307	chr7:1156635	C7orf50	0.4	6.53	0.34	2.49e-10	Longevity;Endometriosis;
LUSC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.12	0.66	1.24e-43	Platelet count;
LUSC	cis	rs7202877	0.610	rs7202284	chr16:75374346	A/T	cg03315344	chr16:75512273	CHST6	0.41	5.84	0.3	1.22e-8	Type 2 diabetes;Type 1 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04135372	chr2:99061383	INPP4A	-0.55	-6.69	-0.34	9.37e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg06917634	chr15:78832804	PSMA4	-0.58	-7.05	-0.36	1.04e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg05855489	chr10:104503620	C10orf26	0.52	7.96	0.4	2.72e-14	Arsenic metabolism;
LUSC	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg03342759	chr3:160939853	NMD3	-0.42	-6.83	-0.35	3.91e-11	Morning vs. evening chronotype;
LUSC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg15103426	chr22:29168792	CCDC117	-0.54	-7.25	-0.37	3e-12	Lymphocyte counts;
LUSC	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg05985134	chr18:33552581	C18orf21	0.5	6.77	0.35	5.96e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.46	0.42	8.27e-16	Diabetic kidney disease;
LUSC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg05025164	chr4:1340916	KIAA1530	0.49	7.78	0.39	9.33e-14	Obesity-related traits;
LUSC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg16325326	chr1:53192061	ZYG11B	0.81	14.3	0.62	1.62e-36	Monocyte count;
LUSC	cis	rs3772130	0.962	rs1920320	chr3:121547527	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.19	0.49	1.99e-21	Cognitive performance;
LUSC	cis	rs7577696	0.568	rs115985725	chr2:32335807	G/A	cg02381751	chr2:32503542	YIPF4	-0.4	-5.67	-0.3	3.06e-8	Inflammatory biomarkers;
LUSC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.15	0.45	5.97e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9815354	0.767	rs73081335	chr3:41895177	A/G	cg03022575	chr3:42003672	ULK4	0.84	8.74	0.43	1.14e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	13.93	0.61	4.46e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.7	-0.47	9.44e-20	Gut microbiome composition (summer);
LUSC	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg16070123	chr10:51489643	NA	-0.53	-8.4	-0.42	1.31e-15	Prostate-specific antigen levels;
LUSC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.6	8.98	0.44	1.96e-17	Eosinophil percentage of white cells;
LUSC	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg08499158	chr17:42289980	UBTF	-0.55	-8.46	-0.42	8.37e-16	Total body bone mineral density;
LUSC	cis	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg01251360	chr16:68772225	CDH1	0.27	6.72	0.35	7.71e-11	Colorectal cancer;
LUSC	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg13902645	chr11:5959945	NA	-0.53	-7.45	-0.38	8.17e-13	DNA methylation (variation);
LUSC	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg26597838	chr10:835615	NA	0.63	8.05	0.4	1.45e-14	Eosinophil percentage of granulocytes;
LUSC	cis	rs6005807	0.719	rs12169460	chr22:29042079	A/G	cg12565055	chr22:29076175	TTC28	0.54	5.86	0.31	1.12e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg12826209	chr6:26865740	GUSBL1	-0.55	-7.92	-0.4	3.48e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg24209194	chr3:40518798	ZNF619	-0.45	-5.82	-0.3	1.36e-8	Renal cell carcinoma;
LUSC	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg10560079	chr2:191398806	TMEM194B	0.74	9.19	0.45	4.15e-18	Diastolic blood pressure;
LUSC	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg12927641	chr6:109611667	NA	0.35	5.89	0.31	9.29e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg20935933	chr6:143382018	AIG1	0.5	7.32	0.37	1.92e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg24558204	chr6:135376177	HBS1L	-0.6	-8.74	-0.43	1.14e-16	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg06212747	chr3:49208901	KLHDC8B	0.45	6.17	0.32	1.94e-9	Parkinson's disease;
LUSC	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.43	6.56	0.34	2e-10	Dupuytren's disease;
LUSC	cis	rs877282	0.945	rs10904554	chr10:786768	T/C	cg17470449	chr10:769945	NA	0.49	6.71	0.34	8.1e-11	Uric acid levels;
LUSC	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg24006582	chr15:45444508	DUOX1	-0.61	-9.03	-0.44	1.43e-17	Uric acid levels;
LUSC	cis	rs12042938	0.600	rs4658880	chr1:231764621	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.42	5.95	0.31	6.63e-9	Neuranatomic and neurocognitive phenotypes;
LUSC	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.13	-14.31	-0.62	1.52e-36	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.7	8.29	0.41	2.81e-15	Lung function (FEV1/FVC);
LUSC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.79	-0.39	8.44e-14	Type 2 diabetes;
LUSC	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg16070123	chr10:51489643	NA	0.59	10.29	0.49	9.5e-22	Prostate-specific antigen levels;
LUSC	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.41	8.17	0.41	6.58e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2108225	0.900	rs2051956	chr7:107441358	G/C	cg18560240	chr7:107437656	SLC26A3	-0.38	-5.73	-0.3	2.27e-8	Ulcerative colitis;
LUSC	trans	rs6104690	0.967	rs6074225	chr20:10982994	A/G	cg07172334	chr21:31655261	KRTAP24-1	-0.34	-6.11	-0.32	2.85e-9	Bladder cancer;
LUSC	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg22437258	chr11:111473054	SIK2	0.5	6.82	0.35	4.3e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg12365402	chr11:9010492	NRIP3	0.45	8.26	0.41	3.33e-15	Hemoglobin concentration;
LUSC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.54	-0.34	2.34e-10	Schizophrenia;
LUSC	cis	rs231513	1.000	rs231518	chr17:41961451	C/T	cg26893861	chr17:41843967	DUSP3	0.59	6.67	0.34	1.05e-10	Cognitive function;
LUSC	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	8.76	0.43	9.72e-17	Schizophrenia;
LUSC	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.82	-14.41	-0.62	6.05e-37	Metabolic syndrome;
LUSC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg12963246	chr6:28129442	ZNF389	0.56	7.89	0.4	4.28e-14	Parkinson's disease;
LUSC	cis	rs9891119	0.631	rs963987	chr17:40561679	A/G	cg16308533	chr17:40838983	CNTNAP1	-0.38	-5.7	-0.3	2.67e-8	Multiple sclerosis;Crohn's disease;
LUSC	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.41	-0.42	1.18e-15	Total cholesterol levels;
LUSC	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.56	0.34	2.08e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs67539049	1.000	rs73546312	chr8:11302709	G/A	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.4	-6.2	-0.32	1.63e-9	Itch intensity from mosquito bite;
LUSC	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg03563238	chr19:33554763	RHPN2	-0.4	-6.43	-0.33	4.3e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03709012	chr19:19516395	GATAD2A	-0.51	-7.32	-0.37	1.84e-12	Tonsillectomy;
LUSC	cis	rs9513627	0.833	rs73556146	chr13:100116920	A/G	cg25919922	chr13:100150906	NA	-0.74	-6.22	-0.32	1.52e-9	Obesity-related traits;
LUSC	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg21132104	chr15:45694354	SPATA5L1	0.56	7.84	0.39	6.29e-14	Homoarginine levels;
LUSC	cis	rs55665837	1.000	rs10832269	chr11:14465069	C/A	cg19336497	chr11:14380999	RRAS2	-0.37	-7.54	-0.38	4.47e-13	Vitamin D levels;
LUSC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg03609598	chr5:56110824	MAP3K1	-0.43	-6.11	-0.32	2.83e-9	Type 2 diabetes;
LUSC	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg26384229	chr12:38710491	ALG10B	0.52	7.36	0.37	1.42e-12	Morning vs. evening chronotype;
LUSC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg16989086	chr20:62203971	PRIC285	0.45	6.34	0.33	7.32e-10	Glioblastoma;
LUSC	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg08917208	chr2:24149416	ATAD2B	0.88	9.72	0.47	7.6e-20	Lymphocyte counts;
LUSC	cis	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg00806126	chr19:22604979	ZNF98	0.38	5.9	0.31	9.06e-9	Pain;
LUSC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg22535103	chr8:58192502	C8orf71	-0.69	-7.61	-0.38	2.77e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg05147244	chr20:61493195	TCFL5	0.8	6.51	0.34	2.75e-10	Obesity-related traits;
LUSC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-15.79	-0.65	2.44e-42	Height;
LUSC	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	8.98	0.44	2.09e-17	Response to antipsychotic treatment;
LUSC	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	9.09	0.45	9.27e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6693567	0.565	rs12731296	chr1:150411787	A/G	cg15654264	chr1:150340011	RPRD2	0.44	7.11	0.36	7.28e-12	Migraine;
LUSC	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg23625390	chr15:77176239	SCAPER	-0.66	-10.06	-0.48	5.61e-21	Blood metabolite levels;
LUSC	cis	rs2348418	0.864	rs2203088	chr12:28709700	G/A	cg13890972	chr12:28721907	NA	-0.35	-6.18	-0.32	1.88e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.16	-0.32	2.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.88e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg05283184	chr6:79620031	NA	-0.54	-10.73	-0.51	2.83e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs6084875	0.840	rs743252	chr20:4720667	C/T	cg26097573	chr20:4721490	PRNT	-0.31	-5.75	-0.3	2.03e-8	Systemic lupus erythematosus;
LUSC	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg11984989	chr7:158649758	WDR60	1.08	22.23	0.77	7.93e-68	Height;
LUSC	cis	rs2835872	0.930	rs2835880	chr21:39032477	A/G	cg20424643	chr21:39039972	KCNJ6	0.49	7.39	0.37	1.19e-12	Electroencephalographic traits in alcoholism;
LUSC	cis	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	12.86	0.58	5.05e-31	Platelet count;
LUSC	cis	rs68170813	0.527	rs75382408	chr7:107010406	C/T	cg02696742	chr7:106810147	HBP1	-0.6	-9.1	-0.45	8.27e-18	Coronary artery disease;
LUSC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg05234568	chr11:5960015	NA	-0.54	-8.63	-0.43	2.63e-16	DNA methylation (variation);
LUSC	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg21433313	chr16:3507492	NAT15	-0.39	-6.15	-0.32	2.22e-9	Body mass index (adult);
LUSC	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-8.47	-0.42	8.04e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.75	0.51	2.31e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg22875332	chr1:76189707	ACADM	-0.72	-9.93	-0.48	1.57e-20	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg25174290	chr11:3078921	CARS	-0.41	-6.14	-0.32	2.29e-9	Calcium levels;
LUSC	cis	rs997295	0.554	rs4261477	chr15:68073968	G/T	cg08079166	chr15:68083412	MAP2K5	0.37	7.81	0.39	7.47e-14	Motion sickness;
LUSC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.89	14.21	0.61	3.54e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg15848620	chr12:58087721	OS9	-0.53	-7.55	-0.38	4.14e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-5.8	-0.3	1.5e-8	Response to antipsychotic treatment;
LUSC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	13.32	0.59	8.96e-33	Platelet count;
LUSC	trans	rs1027479	0.842	rs3019341	chr8:109721351	T/C	cg14904725	chr13:113777045	F10	-0.25	-6.11	-0.32	2.78e-9	Facial morphology (factor 6, height of vermillion lower lip);
LUSC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.58	-5.73	-0.3	2.21e-8	Narcolepsy;
LUSC	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg01509843	chr8:143695822	ARC	0.41	6.36	0.33	6.59e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01741397	chr15:89786926	FANCI	0.48	6.82	0.35	4.34e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06634786	chr22:41940651	POLR3H	0.53	6.19	0.32	1.79e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs3812762	0.871	rs3844100	chr11:8817808	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.37	6.06	0.31	3.71e-9	Hypospadias;
LUSC	cis	rs10779751	0.690	rs28729193	chr1:11180151	T/C	cg08854313	chr1:11322531	MTOR	-0.82	-12.92	-0.58	3.14e-31	Body mass index;
LUSC	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg15556689	chr8:8085844	FLJ10661	0.56	8.44	0.42	1.01e-15	Retinal vascular caliber;
LUSC	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg26384229	chr12:38710491	ALG10B	-0.55	-8.22	-0.41	4.49e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg04155289	chr7:94953770	PON1	-0.34	-5.69	-0.3	2.72e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.89	-0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg07701084	chr6:150067640	NUP43	0.56	8.64	0.43	2.28e-16	Lung cancer;
LUSC	cis	rs73058052	1.000	rs73057994	chr19:50091273	C/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.53	6.11	0.32	2.81e-9	Fibrinogen levels;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01012244	chr7:127344973	SND1	0.38	6.24	0.32	1.35e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07636037	chr3:49044803	WDR6	-0.69	-9.12	-0.45	6.98e-18	Menarche (age at onset);
LUSC	cis	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg07460842	chr6:66804631	NA	0.45	6.36	0.33	6.71e-10	Blood trace element (Cu levels);
LUSC	cis	rs3770081	1.000	rs73943920	chr2:86186195	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.0	-6.34	-0.33	7.31e-10	Facial emotion recognition (sad faces);
LUSC	cis	rs9346649	0.967	rs6907103	chr6:168490016	C/T	cg02770688	chr6:168491649	NA	-0.4	-7.61	-0.38	2.78e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg23840854	chr1:161414152	NA	-0.92	-11.22	-0.52	5.42e-25	Rheumatoid arthritis;
LUSC	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg15103426	chr22:29168792	CCDC117	0.58	7.68	0.39	1.77e-13	Lymphocyte counts;
LUSC	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.65	8.46	0.42	8.6e-16	Migraine;
LUSC	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs12928939	0.517	rs12445641	chr16:71967783	C/T	cg03805757	chr16:71968109	PKD1L3	-0.64	-9.8	-0.47	4.31e-20	Post bronchodilator FEV1;
LUSC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg21251018	chr6:28226885	NKAPL	0.31	5.79	0.3	1.59e-8	Pubertal anthropometrics;
LUSC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg11940773	chr11:63606512	MARK2	0.43	6.59	0.34	1.69e-10	Bladder cancer;
LUSC	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg01475377	chr6:109611718	NA	0.37	6.34	0.33	7.25e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21293242	chr8:11204541	TDH	0.32	5.95	0.31	6.93e-9	Retinal vascular caliber;
LUSC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18099408	chr3:52552593	STAB1	-0.39	-6.68	-0.34	1.03e-10	Bipolar disorder;
LUSC	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg09184832	chr6:79620586	NA	-0.44	-7.0	-0.36	1.41e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg08976749	chr12:49716792	TROAP	0.74	5.98	0.31	5.85e-9	Cognitive performance;
LUSC	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.54	0.57	8.04e-30	Lymphocyte percentage of white cells;
LUSC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg19257562	chr1:2043853	PRKCZ	0.33	6.72	0.35	7.85e-11	Height;
LUSC	cis	rs1823874	0.720	rs2003037	chr15:100361962	G/T	cg16400843	chr15:100339927	C15orf51	0.36	7.21	0.37	3.77e-12	IgG glycosylation;
LUSC	cis	rs711244	0.756	rs2372786	chr2:37159799	A/G	cg14987922	chr2:37194071	STRN	0.43	6.19	0.32	1.8e-9	Mean platelet volume;
LUSC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.6	8.43	0.42	1.05e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.29	0.37	2.24e-12	Platelet count;
LUSC	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg24558204	chr6:135376177	HBS1L	0.68	10.64	0.5	6.01e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.49	-7.76	-0.39	1.03e-13	Blood metabolite levels;
LUSC	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg17031739	chr1:67600172	NA	-0.44	-6.57	-0.34	1.98e-10	Psoriasis;
LUSC	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg24375607	chr4:120327624	NA	0.77	10.99	0.52	3.44e-24	Corneal astigmatism;
LUSC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.55	0.34	2.2e-10	Menopause (age at onset);
LUSC	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.85	14.75	0.63	2.97e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg13319975	chr6:146136371	FBXO30	0.49	7.43	0.38	9.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg14582100	chr15:45693742	SPATA5L1	0.57	10.28	0.49	1.04e-21	Homoarginine levels;
LUSC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg16325326	chr1:53192061	ZYG11B	0.91	16.87	0.68	1.3e-46	Monocyte count;
LUSC	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg16359550	chr11:109292809	C11orf87	0.37	6.31	0.33	8.71e-10	Schizophrenia;
LUSC	cis	rs4356932	1.000	rs4859587	chr4:76943296	A/C	cg00809888	chr4:76862425	NAAA	0.35	5.78	0.3	1.72e-8	Blood protein levels;
LUSC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg22823121	chr1:150693482	HORMAD1	0.53	8.05	0.4	1.49e-14	Melanoma;
LUSC	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07636037	chr3:49044803	WDR6	-0.69	-8.98	-0.44	2.07e-17	Menarche (age at onset);
LUSC	cis	rs5758511	0.773	rs12167978	chr22:42346475	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.39	0.37	1.17e-12	Birth weight;
LUSC	cis	rs73200209	0.744	rs17426970	chr12:116665099	T/C	cg01776926	chr12:116560359	MED13L	-0.49	-6.05	-0.31	3.97e-9	Total body bone mineral density;
LUSC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02463440	chr8:22132932	PIWIL2	0.42	7.61	0.38	2.85e-13	Hypertriglyceridemia;
LUSC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.13	-0.36	6.38e-12	Bipolar disorder;
LUSC	cis	rs7188861	0.724	rs443299	chr16:11372656	G/A	cg00044050	chr16:11439710	C16orf75	0.53	6.01	0.31	4.85e-9	HDL cholesterol;
LUSC	cis	rs11209185	0.503	rs4655573	chr1:68438778	C/T	cg22082780	chr1:68452167	NA	-0.43	-7.12	-0.36	6.55e-12	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs6782228	0.606	rs2712404	chr3:128332679	C/T	cg16766828	chr3:128327626	NA	0.32	5.77	0.3	1.83e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs10193935	0.901	rs1439231	chr2:42542884	G/A	cg27598129	chr2:42591480	NA	-0.59	-8.43	-0.42	1.07e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs751728	0.664	rs4711347	chr6:33735292	G/A	cg25922239	chr6:33757077	LEMD2	0.41	5.98	0.31	5.67e-9	Crohn's disease;
LUSC	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	7.05	0.36	1.02e-11	Schizophrenia;
LUSC	trans	rs7556950	0.572	rs79273885	chr2:41931372	C/T	cg13792581	chr20:43590115	TOMM34	0.74	6.27	0.32	1.12e-9	Major depression and alcohol dependence;
LUSC	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg13010199	chr12:38710504	ALG10B	0.65	10.13	0.48	3.32e-21	Bladder cancer;
LUSC	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg06606381	chr12:133084897	FBRSL1	-1.03	-8.88	-0.44	4.15e-17	Depression;
LUSC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	8.44	0.42	9.76e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2742417	1.000	rs1877934	chr3:45753295	G/A	cg09608765	chr3:45636137	LIMD1	-0.38	-7.53	-0.38	4.87e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg14664628	chr15:75095509	CSK	-0.57	-8.58	-0.42	3.72e-16	Breast cancer;
LUSC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	10.64	0.5	5.72e-23	Homoarginine levels;
LUSC	cis	rs4285028	0.603	rs79312528	chr3:121608997	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.81	-10.63	-0.5	6.17e-23	Multiple sclerosis;
LUSC	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg25730555	chr22:47059586	GRAMD4	0.45	7.07	0.36	9.04e-12	Urate levels in obese individuals;
LUSC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg10862848	chr6:42927986	GNMT	-0.28	-6.57	-0.34	1.91e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs67072384	0.901	rs11235580	chr11:72455645	G/A	cg04827223	chr11:72435913	ARAP1	-0.78	-6.8	-0.35	4.98e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.3	-0.49	8.6e-22	Monocyte count;
LUSC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg24209194	chr3:40518798	ZNF619	0.43	5.78	0.3	1.69e-8	Renal cell carcinoma;
LUSC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.82	-13.97	-0.61	2.9e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4629180	0.540	rs6747670	chr2:102130368	T/C	cg01388757	chr2:102091195	RFX8	-0.36	-6.25	-0.32	1.25e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.78	-0.39	9.4e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs55665837	0.922	rs12287212	chr11:14449861	C/A	cg05501817	chr11:14380813	RRAS2	-0.4	-6.48	-0.33	3.23e-10	Vitamin D levels;
LUSC	trans	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg18187862	chr3:45730750	SACM1L	0.56	7.06	0.36	9.52e-12	Primary sclerosing cholangitis;
LUSC	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-7.14	-0.36	5.93e-12	Daytime sleep phenotypes;
LUSC	cis	rs4730250	0.655	rs4727671	chr7:106876045	A/G	cg02696742	chr7:106810147	HBP1	-0.63	-9.48	-0.46	5.01e-19	Osteoarthritis;
LUSC	cis	rs7582720	1.000	rs72934706	chr2:203707752	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	8.14	0.41	8e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.11	0.32	2.79e-9	Schizophrenia;
LUSC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-5.79	-0.3	1.64e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	12.12	0.55	2.99e-28	Height;
LUSC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	0.92	15.42	0.64	7.18e-41	Breast cancer;
LUSC	cis	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg15737290	chr11:93063684	CCDC67	0.68	8.4	0.42	1.29e-15	Pulmonary function decline;
LUSC	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg13798780	chr7:105162888	PUS7	0.56	6.07	0.32	3.43e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2637266	0.935	rs2252661	chr10:78404793	A/G	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.94e-13	Pulmonary function;
LUSC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg09177884	chr7:1199841	ZFAND2A	0.45	6.19	0.32	1.73e-9	Longevity;Endometriosis;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11516594	chr18:3013156	LPIN2	-0.43	-6.4	-0.33	5.41e-10	Electrocardiographic conduction measures;
LUSC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg15649852	chr7:65879115	NA	0.41	5.76	0.3	1.93e-8	Aortic root size;
LUSC	cis	rs4494114	1.000	rs7539067	chr1:39359694	A/G	cg25970120	chr1:39325951	RRAGC	-0.37	-5.98	-0.31	5.59e-9	Blood protein levels;
LUSC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.86	-14.1	-0.61	9.4e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg14552801	chr7:65878734	NA	-0.44	-6.18	-0.32	1.85e-9	Aortic root size;
LUSC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18402987	chr7:1209562	NA	0.43	5.77	0.3	1.83e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs61931739	0.612	rs1906136	chr12:33905293	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.44	-0.33	4.16e-10	Morning vs. evening chronotype;
LUSC	cis	rs983392	0.805	rs7116190	chr11:59964992	G/A	cg20284999	chr11:59952153	MS4A6A	-0.39	-6.4	-0.33	5.12e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	0.58	8.92	0.44	3.2e-17	Breast cancer;
LUSC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg20607798	chr8:58055168	NA	0.54	6.22	0.32	1.5e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.4	0.49	3.9e-22	Morning vs. evening chronotype;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14576616	chr7:91763911	CYP51A1	0.48	6.3	0.33	9.45e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg02423579	chr7:2872169	GNA12	-0.47	-6.73	-0.35	7.52e-11	Height;
LUSC	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg07148914	chr20:33460835	GGT7	-0.45	-6.58	-0.34	1.86e-10	Height;
LUSC	cis	rs9309473	0.583	rs11126397	chr2:73588733	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-7.96	-0.4	2.79e-14	Metabolite levels;
LUSC	cis	rs1113500	0.965	rs10881495	chr1:108610986	C/A	cg06207961	chr1:108661230	NA	0.4	7.29	0.37	2.3e-12	Growth-regulated protein alpha levels;
LUSC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg18357645	chr12:58087776	OS9	0.58	8.67	0.43	1.94e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-0.53	-8.18	-0.41	6.03e-15	Breast cancer;
LUSC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.35	-0.8	4.97e-76	Height;
LUSC	trans	rs4148689	0.951	rs4148706	chr7:117190996	T/G	cg10450175	chr16:88689712	ZC3H18	0.46	5.99	0.31	5.37e-9	Gout;
LUSC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.3	0.45	1.84e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Body mass index;
LUSC	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.25	0.49	1.34e-21	Bladder cancer;
LUSC	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg24881330	chr22:46731750	TRMU	0.84	6.69	0.34	9.33e-11	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.28e-9	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.19e-14	Retinal vascular caliber;
LUSC	cis	rs1595825	0.891	rs74965164	chr2:198499162	C/T	cg19156104	chr2:198669113	PLCL1	-0.46	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg22709100	chr7:91322751	NA	0.43	6.33	0.33	8.02e-10	Breast cancer;
LUSC	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg24110177	chr3:50126178	RBM5	0.42	6.66	0.34	1.1e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs78572108	0.858	rs4952397	chr2:42266513	T/A	cg00607755	chr2:42274082	PKDCC	0.36	6.47	0.33	3.56e-10	Total body bone mineral density;
LUSC	cis	rs13082711	0.911	rs17682751	chr3:27497027	C/T	cg02860705	chr3:27208620	NA	-0.48	-8.38	-0.42	1.52e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	trans	rs1325195	0.879	rs2816187	chr1:179101606	C/G	cg11624085	chr17:8464688	MYH10	0.44	7.34	0.37	1.65e-12	IgE grass sensitization;
LUSC	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.37	-6.01	-0.31	4.88e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg00701064	chr4:6280414	WFS1	0.62	16.31	0.67	2.18e-44	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24425829	chr1:59250882	JUN	-0.46	-5.99	-0.31	5.31e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6684514	1.000	rs12041164	chr1:156279811	G/A	cg16558208	chr1:156270281	VHLL	0.35	5.67	0.3	3.1e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUSC	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg13010199	chr12:38710504	ALG10B	-0.64	-10.89	-0.51	7.99e-24	Heart rate;
LUSC	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.88	14.18	0.61	4.69e-36	Coronary artery disease;
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.34	-7.6	-0.38	2.98e-13	Lymphocyte counts;
LUSC	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs9905704	0.831	rs12949598	chr17:56707245	C/T	cg12560992	chr17:57184187	TRIM37	0.55	7.85	0.39	5.74e-14	Testicular germ cell tumor;
LUSC	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg26195577	chr20:24973756	C20orf3	1.11	18.48	0.71	5e-53	Blood protein levels;
LUSC	trans	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg27275811	chr11:74457193	NA	0.6	6.06	0.31	3.73e-9	Type 2 diabetes nephropathy;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03705947	chr1:68152081	GADD45A	0.41	6.19	0.32	1.79e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg08798685	chr6:27730294	NA	-0.7	-6.08	-0.32	3.22e-9	Depression;
LUSC	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.62	-10.36	-0.49	5.42e-22	Schizophrenia;
LUSC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg09877947	chr5:131593287	PDLIM4	-0.44	-6.63	-0.34	1.37e-10	Breast cancer;
LUSC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.7	11.76	0.54	5.86e-27	Heart rate;
LUSC	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.49	-5.77	-0.3	1.83e-8	Iron status biomarkers;
LUSC	cis	rs28829049	0.597	rs1009806	chr1:19500551	T/C	cg13387374	chr1:19411106	UBR4	0.44	6.23	0.32	1.39e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9462027	0.628	rs2296360	chr6:34803558	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.03	-0.31	4.26e-9	Systemic lupus erythematosus;
LUSC	cis	rs9650657	0.812	rs11250074	chr8:10632259	A/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.56	-0.34	1.99e-10	Neuroticism;
LUSC	cis	rs7095944	0.614	rs61872084	chr10:126439062	C/T	cg08799069	chr10:126477246	METTL10	-0.41	-6.34	-0.33	7.51e-10	Asthma;
LUSC	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg23093090	chr10:104574429	C10orf26	-0.43	-7.65	-0.39	2.21e-13	Arsenic metabolism;
LUSC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2625529	0.641	rs11852789	chr15:72265494	G/C	cg16672083	chr15:72433130	SENP8	-0.51	-7.39	-0.37	1.19e-12	Red blood cell count;
LUSC	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.44	6.73	0.35	7.27e-11	Dupuytren's disease;
LUSC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.47	-5.91	-0.31	8.29e-9	Neutrophil percentage of white cells;
LUSC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg11764359	chr7:65958608	NA	-0.5	-6.37	-0.33	6.12e-10	Aortic root size;
LUSC	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.56	-0.42	4.06e-16	Neuroticism;
LUSC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg06521331	chr12:34319734	NA	-0.34	-5.9	-0.31	8.73e-9	Morning vs. evening chronotype;
LUSC	cis	rs981844	0.712	rs1037646	chr4:154738015	C/T	cg14289246	chr4:154710475	SFRP2	-0.44	-6.13	-0.32	2.46e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	9.66	0.47	1.26e-19	Height;
LUSC	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg05340658	chr4:99064831	C4orf37	0.57	9.54	0.46	3.03e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12681288	0.576	rs6990403	chr8:963471	C/A	cg04851639	chr8:1020857	NA	-0.39	-7.72	-0.39	1.4e-13	Schizophrenia;
LUSC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg12365402	chr11:9010492	NRIP3	-0.51	-9.78	-0.47	4.9e-20	Hemoglobin concentration;
LUSC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg25456477	chr12:86230367	RASSF9	0.33	5.82	0.3	1.39e-8	Major depressive disorder;
LUSC	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg17507749	chr15:85114479	UBE2QP1	0.59	7.51	0.38	5.32e-13	Schizophrenia;
LUSC	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg09904177	chr6:26538194	HMGN4	0.76	14.42	0.62	5.75e-37	Intelligence (multi-trait analysis);
LUSC	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg11244672	chr19:19639970	YJEFN3	0.6	7.33	0.37	1.72e-12	Bipolar disorder;
LUSC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg06453172	chr10:134556979	INPP5A	-0.5	-6.35	-0.33	6.9e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18854424	chr1:2615690	NA	-0.47	-9.29	-0.45	2.02e-18	Ulcerative colitis;
LUSC	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.48	7.35	0.37	1.52e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs2230307	0.536	rs629340	chr1:100538621	A/T	cg24955406	chr1:100503596	HIAT1	0.59	6.44	0.33	4.23e-10	Carotid intima media thickness;
LUSC	cis	rs7582180	1.000	rs4851285	chr2:100907598	A/G	cg08017756	chr2:100939284	LONRF2	-0.36	-6.07	-0.32	3.49e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12973672	1.000	rs10414846	chr19:35772471	A/G	cg12095397	chr19:35769544	USF2	-0.46	-7.06	-0.36	9.77e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs28588043	0.652	rs11486179	chr1:170957028	C/A	cg07135042	chr19:56905152	ZNF582	-0.6	-6.33	-0.33	8.08e-10	Number of children (6+ vs. 0 or 1);
LUSC	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.76	-0.3	1.94e-8	Resting heart rate;
LUSC	cis	rs7212590	0.748	rs7220187	chr17:57897609	C/T	cg10252138	chr17:58120427	NA	-0.74	-7.0	-0.36	1.39e-11	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.05	-0.36	1.02e-11	Colorectal cancer;
LUSC	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.74	-0.39	1.2e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.4	-0.38	1.12e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg00982548	chr2:198649783	BOLL	-0.58	-7.22	-0.37	3.57e-12	Ulcerative colitis;
LUSC	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.73	-13.36	-0.59	6.47e-33	Ulcerative colitis;
LUSC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.55	-0.34	2.24e-10	Lung cancer;
LUSC	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.51	10.3	0.49	8.95e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg10434728	chr15:90938212	IQGAP1	0.4	8.36	0.42	1.7e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg26335602	chr6:28129616	ZNF389	-0.44	-5.97	-0.31	5.97e-9	Parkinson's disease;
LUSC	cis	rs7712401	0.601	rs246275	chr5:122231413	C/T	cg19077854	chr5:122220652	SNX24	0.4	8.65	0.43	2.2e-16	Mean platelet volume;
LUSC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.56	0.42	4.18e-16	Prudent dietary pattern;
LUSC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.91	0.4	3.77e-14	Prudent dietary pattern;
LUSC	trans	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.72	0.39	1.39e-13	Ulcerative colitis;
LUSC	cis	rs7246967	0.673	rs4933036	chr19:22963069	C/A	cg23217946	chr19:22817039	ZNF492	0.43	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg14664628	chr15:75095509	CSK	-0.56	-8.75	-0.43	1.04e-16	Breast cancer;
LUSC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.45	-0.42	8.92e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7200543	1.000	rs16966952	chr16:15135943	C/T	cg03427771	chr16:15082598	PDXDC1	-0.4	-5.68	-0.3	2.9e-8	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.37	-0.62	8.79e-37	Schizophrenia;
LUSC	cis	rs977987	0.902	rs34539062	chr16:75493279	C/A	cg04384234	chr16:75411784	CFDP1	-0.48	-7.87	-0.4	5.05e-14	Dupuytren's disease;
LUSC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	8.51	0.42	5.91e-16	Lymphocyte counts;
LUSC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg26587870	chr6:27730563	NA	-0.56	-5.69	-0.3	2.84e-8	Breast cancer;
LUSC	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg11584989	chr19:19387371	SF4	0.57	6.78	0.35	5.44e-11	Bipolar disorder;
LUSC	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.57	-0.42	3.81e-16	Hemoglobin concentration;
LUSC	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg09699651	chr6:150184138	LRP11	0.45	7.16	0.36	5.11e-12	Testicular germ cell tumor;
LUSC	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.54	7.16	0.36	5.1e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs11650494	0.908	rs77338752	chr17:47372328	A/C	cg08112188	chr17:47440006	ZNF652	1.21	10.4	0.49	4.01e-22	Prostate cancer;
LUSC	cis	rs17095355	1.000	rs55781439	chr10:111670220	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.57	-7.2	-0.37	3.93e-12	Biliary atresia;
LUSC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs9487051	0.768	rs445796	chr6:109520145	T/C	cg00509249	chr6:109615579	CCDC162	-0.34	-5.88	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	12.06	0.55	4.64e-28	Prudent dietary pattern;
LUSC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18876405	chr7:65276391	NA	0.54	8.22	0.41	4.42e-15	Aortic root size;
LUSC	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg21775007	chr8:11205619	TDH	0.45	6.73	0.35	7.52e-11	Mood instability;
LUSC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg21724239	chr8:58056113	NA	0.78	8.56	0.42	4.04e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg08345082	chr10:99160200	RRP12	-0.38	-7.45	-0.38	7.85e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg06627628	chr2:24431161	ITSN2	-0.61	-9.12	-0.45	7.02e-18	Asthma;
LUSC	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg05855489	chr10:104503620	C10orf26	-0.49	-7.4	-0.38	1.11e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs9311676	0.656	rs12495490	chr3:58373251	A/G	cg26110898	chr3:58419937	PDHB	0.41	6.69	0.34	9.67e-11	Systemic lupus erythematosus;
LUSC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07677032	chr17:61819896	STRADA	0.56	9.26	0.45	2.62e-18	Prudent dietary pattern;
LUSC	cis	rs34891900	0.507	rs9605364	chr22:18127437	G/A	cg08824373	chr22:18117835	NA	-0.44	-6.71	-0.34	8.56e-11	Sum neutrophil eosinophil counts;
LUSC	cis	rs4363385	0.818	rs10888526	chr1:153000311	G/T	cg25856811	chr1:152973957	SPRR3	-0.36	-6.02	-0.31	4.57e-9	Inflammatory skin disease;
LUSC	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg10434728	chr15:90938212	IQGAP1	-0.45	-8.94	-0.44	2.63e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg26441486	chr22:50317300	CRELD2	-0.55	-8.28	-0.41	2.94e-15	Schizophrenia;
LUSC	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	0.94	8.24	0.41	3.94e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00166722	chr3:10149974	C3orf24	0.54	7.0	0.36	1.43e-11	Alzheimer's disease;
LUSC	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg08601574	chr20:25228251	PYGB	0.44	6.75	0.35	6.5e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.66	-0.3	3.35e-8	Coronary artery disease;
LUSC	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg19682013	chr15:45996608	NA	0.4	6.05	0.31	3.83e-9	Waist circumference;Weight;
LUSC	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg24375607	chr4:120327624	NA	0.7	10.58	0.5	9.42e-23	Corneal astigmatism;
LUSC	cis	rs10504073	0.669	rs62507253	chr8:50028836	C/T	cg00325661	chr8:49890786	NA	0.61	9.5	0.46	4.27e-19	Blood metabolite ratios;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01357671	chr17:3626806	ITGAE;GSG2	0.47	6.82	0.35	4.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.69	-11.54	-0.53	3.77e-26	Systemic lupus erythematosus;
LUSC	cis	rs7119038	0.774	rs874621	chr11:118655645	G/A	cg19308663	chr11:118741387	NA	0.39	6.64	0.34	1.25e-10	Sjögren's syndrome;
LUSC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.94	0.4	3.04e-14	Parkinson's disease;
LUSC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.26e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg17911788	chr17:44343683	NA	-0.31	-5.99	-0.31	5.3300000000000004e-09	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.93	-0.35	2.15e-11	Bipolar disorder;
LUSC	cis	rs11971779	0.648	rs10230407	chr7:139103893	A/G	cg07862535	chr7:139043722	LUC7L2	0.55	6.76	0.35	6.16e-11	Diisocyanate-induced asthma;
LUSC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg26897989	chr16:1907736	C16orf73	-0.43	-6.28	-0.32	1.08e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg05855489	chr10:104503620	C10orf26	-0.49	-7.42	-0.38	9.5e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7011192	0.793	rs11774104	chr8:10526434	C/G	cg17329886	chr8:10513629	RP1L1	-0.72	-7.78	-0.39	8.94e-14	Suicide;
LUSC	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg27284194	chr4:1044797	NA	0.5	8.02	0.4	1.75e-14	Recombination rate (males);
LUSC	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg03647239	chr10:116582469	FAM160B1	0.45	7.27	0.37	2.55e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6087990	0.814	rs2424895	chr20:31335978	C/T	cg13636640	chr20:31349939	DNMT3B	-0.93	-19.76	-0.73	4.02e-58	Ulcerative colitis;
LUSC	cis	rs4601821	0.789	rs7123797	chr11:113262571	A/G	cg14159747	chr11:113255604	NA	0.25	6.06	0.31	3.75e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.44	-5.85	-0.31	1.15e-8	Height;
LUSC	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg03340356	chr1:67600835	NA	0.44	6.82	0.35	4.25e-11	Psoriasis;
LUSC	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.69	10.42	0.5	3.26e-22	Corneal astigmatism;
LUSC	cis	rs983392	0.679	rs1026255	chr11:60029949	A/G	cg02771260	chr11:59836817	MS4A3	-0.37	-6.13	-0.32	2.52e-9	Alzheimer's disease (late onset);
LUSC	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.73	-9.49	-0.46	4.39e-19	Iron status biomarkers;
LUSC	cis	rs4363385	0.720	rs1611764	chr1:152957887	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.69	-0.39	1.68e-13	Inflammatory skin disease;
LUSC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg26944245	chr16:421049	TMEM8A;MRPL28	0.41	6.18	0.32	1.87e-9	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg06552810	chr11:31128660	NA	-0.41	-7.25	-0.37	2.89e-12	Red blood cell count;
LUSC	cis	rs400736	0.562	rs12711516	chr1:8181227	G/C	cg25007680	chr1:8021821	PARK7	-0.42	-6.05	-0.31	3.87e-9	Response to antidepressants and depression;
LUSC	cis	rs7216064	1.000	rs56404791	chr17:65893019	T/G	cg12091567	chr17:66097778	LOC651250	-0.72	-9.62	-0.47	1.68e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg07424592	chr7:64974309	NA	0.66	5.83	0.3	1.32e-8	Diabetic kidney disease;
LUSC	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.32	-0.37	1.91e-12	Body mass index;
LUSC	cis	rs977987	0.931	rs1424013	chr16:75495986	T/C	cg04384234	chr16:75411784	CFDP1	-0.48	-7.83	-0.39	6.46e-14	Dupuytren's disease;
LUSC	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg16342193	chr10:102329863	NA	-0.34	-6.22	-0.32	1.47e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4974559	0.847	rs28477912	chr4:1331350	C/T	cg02980000	chr4:1222292	CTBP1	0.76	7.35	0.37	1.49e-12	Systolic blood pressure;
LUSC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg06637938	chr14:75390232	RPS6KL1	0.52	8.29	0.41	2.85e-15	Height;
LUSC	cis	rs3812111	0.510	rs1569824	chr6:116590802	T/A	cg18828861	chr6:116576566	TSPYL4	0.38	6.71	0.34	8.55e-11	Age-related macular degeneration;
LUSC	cis	rs10979	1.000	rs1416205	chr6:143889397	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg05738196	chr6:26577821	NA	0.81	15.7	0.65	5.64e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-7.83	-0.39	6.64e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg03060546	chr3:49711283	APEH	0.72	11.83	0.54	3.25e-27	Resting heart rate;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05554353	chr6:126277910	HINT3	-0.49	-5.97	-0.31	6.16e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg11645453	chr3:52864694	ITIH4	-0.36	-8.1	-0.41	1.03e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg06713675	chr4:122721982	EXOSC9	-0.55	-9.44	-0.46	6.48e-19	Type 2 diabetes;
LUSC	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg07169764	chr2:136633963	MCM6	-0.6	-7.86	-0.4	5.34e-14	Mosquito bite size;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17185823	chr8:11324806	FAM167A	-0.44	-6.09	-0.32	3.13e-9	Hepatitis;
LUSC	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.77	-0.3	1.82e-8	Type 2 diabetes;
LUSC	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg13010199	chr12:38710504	ALG10B	0.56	8.56	0.42	4.15e-16	Morning vs. evening chronotype;
LUSC	trans	rs9944715	1.000	rs7239351	chr18:43851338	A/T	cg01718231	chr17:29326311	RNF135	-0.49	-7.02	-0.36	1.24e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg01483505	chr11:975446	AP2A2	0.42	5.9	0.31	9.15e-9	Alzheimer's disease (late onset);
LUSC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	11.84	0.54	3e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs10838798	0.517	rs1967210	chr11:48096692	G/T	cg15704280	chr7:45808275	SEPT13	-0.65	-6.78	-0.35	5.58e-11	Height;
LUSC	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg18850127	chr7:39170497	POU6F2	0.59	9.48	0.46	4.96e-19	IgG glycosylation;
LUSC	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg05347473	chr6:146136440	FBXO30	0.5	8.43	0.42	1.07e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs877282	0.898	rs35743076	chr10:758991	C/T	cg17470449	chr10:769945	NA	0.52	7.47	0.38	6.99e-13	Uric acid levels;
LUSC	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg17366294	chr4:99064904	C4orf37	0.55	9.61	0.47	1.79e-19	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10511400	0.541	rs12152218	chr3:119878877	A/G	cg02809009	chr19:50354510	PTOV1	-0.67	-6.11	-0.32	2.71e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.36	5.65	0.3	3.49e-8	Lymphocyte counts;
LUSC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.89	0.31	9.64e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	cis	rs965469	1.000	rs6051732	chr20:3294182	G/A	cg25506879	chr20:3388711	C20orf194	-0.52	-5.67	-0.3	3.14e-8	IFN-related cytopenia;
LUSC	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.58	0.34	1.81e-10	Corneal astigmatism;
LUSC	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	cis	rs16937	0.574	rs10900455	chr1:205123534	T/C	cg00857998	chr1:205179979	DSTYK	0.47	6.79	0.35	5.19e-11	Schizophrenia;
LUSC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.65	13.51	0.59	1.7e-33	Monocyte percentage of white cells;
LUSC	cis	rs11039100	0.850	rs34930440	chr11:5834157	A/T	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg09699651	chr6:150184138	LRP11	0.45	6.99	0.36	1.46e-11	Testicular germ cell tumor;
LUSC	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg06885757	chr1:42089581	HIVEP3	0.49	10.16	0.49	2.51e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7904985	1.000	rs7904985	chr10:88116479	A/G	cg07322936	chr10:88137208	NA	0.56	7.06	0.36	9.87e-12	Barrett's esophagus;
LUSC	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg08017756	chr2:100939284	LONRF2	0.33	5.86	0.31	1.1e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg06521331	chr12:34319734	NA	-0.48	-7.77	-0.39	9.54e-14	Morning vs. evening chronotype;
LUSC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.31	-0.33	9.06e-10	Life satisfaction;
LUSC	cis	rs4642101	0.561	rs9831765	chr3:12805934	A/T	cg05775895	chr3:12838266	CAND2	0.48	7.5	0.38	5.95e-13	QRS complex (12-leadsum);
LUSC	trans	rs6982636	1.000	rs2980882	chr8:126480700	A/G	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.34	-6.54	-0.34	2.34e-10	Lipid metabolism phenotypes;
LUSC	cis	rs2797160	0.547	rs10872298	chr6:125956348	A/C	cg05901451	chr6:126070800	HEY2	-0.42	-5.91	-0.31	8.39e-9	Endometrial cancer;
LUSC	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg01802117	chr1:53393560	SCP2	-0.41	-6.83	-0.35	4.01e-11	Monocyte count;
LUSC	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.28	-0.41	3.1e-15	Systolic blood pressure;
LUSC	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.6	-0.34	1.66e-10	Retinal vascular caliber;
LUSC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg27572855	chr1:25598939	RHD	0.43	7.61	0.38	2.8e-13	Erythrocyte sedimentation rate;
LUSC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg00012203	chr2:219082015	ARPC2	0.7	11.64	0.54	1.61e-26	Colorectal cancer;
LUSC	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.37	-5.75	-0.3	1.98e-8	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03517284	chr6:25882590	NA	-0.52	-9.75	-0.47	6.07e-20	Blood metabolite levels;
LUSC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg05347473	chr6:146136440	FBXO30	0.46	7.97	0.4	2.55e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg02551604	chr5:131831745	NA	-0.42	-6.8	-0.35	4.69e-11	Asthma (sex interaction);
LUSC	cis	rs4400599	0.805	rs12063830	chr1:154150911	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.4	-6.48	-0.33	3.31e-10	Platelet distribution width;
LUSC	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg18825076	chr15:78729989	IREB2	0.46	6.45	0.33	4.04e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.38	-0.37	1.25e-12	Glomerular filtration rate (creatinine);
LUSC	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	19.75	0.73	4.46e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-0.86	-12.64	-0.57	3.35e-30	Vitiligo;
LUSC	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg16989719	chr2:238392110	NA	-0.38	-6.48	-0.33	3.25e-10	Prostate cancer;
LUSC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg27572855	chr1:25598939	RHD	0.41	7.35	0.37	1.58e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.8	0.39	8.08e-14	Major depressive disorder;
LUSC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.81	-13.56	-0.6	1.15e-33	Aortic root size;
LUSC	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg20744362	chr22:50050164	C22orf34	0.4	8.33	0.41	2.15e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9296092	0.538	rs62405948	chr6:33522753	A/C	cg13560919	chr6:33536144	NA	-0.82	-15.86	-0.66	1.26e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15157791	chr20:2854198	PTPRA	0.69	5.97	0.31	6.11e-9	Cognitive performance;
LUSC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	1.06	20.2	0.74	7.16e-60	Menopause (age at onset);
LUSC	cis	rs7923609	1.000	rs4400684	chr10:65012687	A/G	cg01631684	chr10:65280961	REEP3	-0.42	-6.55	-0.34	2.14e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18604133	chr13:27746144	USP12	-0.4	-6.75	-0.35	6.71e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg24579218	chr15:68104479	NA	-0.37	-6.13	-0.32	2.48e-9	Obesity;
LUSC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02034447	chr16:89574710	SPG7	0.44	6.48	0.33	3.2e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.72	9.69	0.47	1.01e-19	Platelet count;
LUSC	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	8.39	0.42	1.39e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg09455208	chr3:40491958	NA	-0.57	-10.52	-0.5	1.56e-22	Renal cell carcinoma;
LUSC	cis	rs4619890	0.528	rs17770213	chr4:7896866	C/T	cg24250820	chr4:7887609	AFAP1	-0.37	-6.35	-0.33	6.89e-10	Glaucoma (primary open-angle);
LUSC	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.82	0.68	2.11e-46	Exhaled nitric oxide output;
LUSC	trans	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-6.07	-0.32	3.52e-9	Morning vs. evening chronotype;
LUSC	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-7.09	-0.36	8.23e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg11861562	chr11:117069780	TAGLN	0.44	7.81	0.39	7.71e-14	Blood protein levels;
LUSC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg15445000	chr17:37608096	MED1	0.39	6.71	0.34	8.49e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.59	0.57	5.27e-30	White blood cell count;
LUSC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.69	9.75	0.47	6.11e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17467752	chr17:38218738	THRA	0.77	12.42	0.56	2.3e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs8044868	0.586	rs6499557	chr16:72082654	A/G	cg16579770	chr16:72058938	DHODH	0.34	5.76	0.3	1.95e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg18225595	chr11:63971243	STIP1	-0.41	-6.57	-0.34	1.97e-10	Platelet count;
LUSC	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg03806693	chr22:41940476	POLR3H	-0.84	-12.38	-0.56	3.13e-29	Vitiligo;
LUSC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg04450456	chr4:17643702	FAM184B	0.36	5.87	0.31	1.04e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs983392	0.651	rs718376	chr11:60002935	C/T	cg02771260	chr11:59836817	MS4A3	-0.35	-5.68	-0.3	2.86e-8	Alzheimer's disease (late onset);
LUSC	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06636551	chr8:101224915	SPAG1	-0.44	-8.03	-0.4	1.63e-14	Atrioventricular conduction;
LUSC	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg04414720	chr1:150670196	GOLPH3L	-0.45	-6.97	-0.36	1.75e-11	Tonsillectomy;
LUSC	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg17788362	chr6:86352627	SYNCRIP	0.46	7.02	0.36	1.22e-11	Smooth-surface caries;
LUSC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg17143192	chr8:8559678	CLDN23	0.36	5.8	0.3	1.56e-8	Mood instability;
LUSC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg13319975	chr6:146136371	FBXO30	0.49	7.47	0.38	6.96e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg13395646	chr4:1353034	KIAA1530	-0.58	-8.28	-0.41	2.95e-15	Longevity;
LUSC	cis	rs12824058	0.707	rs2398509	chr12:130816464	T/C	cg26677194	chr12:130822605	PIWIL1	0.59	8.31	0.41	2.52e-15	Menopause (age at onset);
LUSC	cis	rs4363385	0.620	rs4388644	chr1:152983674	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.69	-0.39	1.71e-13	Inflammatory skin disease;
LUSC	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg13010199	chr12:38710504	ALG10B	0.66	9.93	0.48	1.57e-20	Bladder cancer;
LUSC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.65	0.86	4.24e-99	Chronic sinus infection;
LUSC	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-10.2	-0.49	1.88e-21	Bladder cancer;
LUSC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg24733560	chr20:60626293	TAF4	-0.39	-6.24	-0.32	1.36e-9	Body mass index;
LUSC	trans	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	5.95	0.31	6.6e-9	Cystic fibrosis severity;
LUSC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg13175981	chr1:150552382	MCL1	0.43	5.98	0.31	5.82e-9	Tonsillectomy;
LUSC	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg01733217	chr16:74700730	RFWD3	-0.97	-21.94	-0.77	1.1e-66	Multiple myeloma;
LUSC	cis	rs1018836	0.668	rs9297857	chr8:91480964	A/C	cg16814680	chr8:91681699	NA	-0.65	-9.61	-0.47	1.79e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg18478394	chr8:109455254	TTC35	0.41	6.33	0.33	7.89e-10	Dupuytren's disease;
LUSC	cis	rs11031096	0.714	rs3794049	chr11:4145658	A/G	cg18678763	chr11:4115507	RRM1	0.38	5.77	0.3	1.79e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg21100191	chr22:23484243	RTDR1	0.93	16.53	0.67	2.82e-45	Bone mineral density;
LUSC	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.1	23.27	0.79	7.21e-72	Schizophrenia;
LUSC	cis	rs10186029	0.623	rs10497996	chr2:213997865	T/C	cg08319019	chr2:214017104	IKZF2	0.52	7.9	0.4	4.21e-14	Systemic sclerosis;
LUSC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs977987	0.836	rs35209155	chr16:75470496	G/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.11	-0.36	7.07e-12	Dupuytren's disease;
LUSC	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.49	0.38	6.3e-13	Rheumatoid arthritis;
LUSC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg18477163	chr1:228402036	OBSCN	-0.57	-10.45	-0.5	2.61e-22	Diastolic blood pressure;
LUSC	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg01346077	chr3:125931526	NA	0.35	6.7	0.34	8.75e-11	Metabolite levels;
LUSC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg17971929	chr21:40555470	PSMG1	-0.51	-7.63	-0.39	2.48e-13	Menarche (age at onset);
LUSC	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.1	15.11	0.64	1.09e-39	Uric acid levels;
LUSC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.57	0.34	1.88e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg04374321	chr14:90722782	PSMC1	-0.68	-10.24	-0.49	1.39e-21	Mortality in heart failure;
LUSC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03517284	chr6:25882590	NA	-0.52	-9.66	-0.47	1.25e-19	Blood metabolite levels;
LUSC	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg00376283	chr12:123451042	ABCB9	0.66	8.34	0.42	2e-15	Neutrophil percentage of white cells;
LUSC	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	11.02	0.52	2.65e-24	Lung cancer in ever smokers;
LUSC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06544989	chr22:39130855	UNC84B	0.34	5.91	0.31	8.33e-9	Menopause (age at onset);
LUSC	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg18705301	chr15:41695430	NDUFAF1	0.44	7.74	0.39	1.2e-13	Menopause (age at onset);
LUSC	trans	rs62344088	1.000	rs13436694	chr5:122882	A/T	cg11454300	chr2:2256402	MYT1L	0.75	6.03	0.31	4.27e-9	Asthma (childhood onset);
LUSC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.85	14.08	0.61	1.16e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs939658	0.728	rs12904323	chr15:79412583	A/C	cg17916960	chr15:79447300	NA	-0.49	-9.13	-0.45	6.73e-18	Refractive error;
LUSC	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg19773385	chr1:10388646	KIF1B	-0.5	-8.66	-0.43	2.11e-16	Hepatocellular carcinoma;
LUSC	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg15704280	chr7:45808275	SEPT13	-0.55	-6.28	-0.32	1.03e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg20608306	chr11:116969690	SIK3	0.37	6.8	0.35	4.86e-11	Blood protein levels;
LUSC	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg16342193	chr10:102329863	NA	-0.34	-6.03	-0.31	4.38e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05776053	chr2:74358815	NA	0.45	7.22	0.37	3.62e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs30380	0.506	rs469735	chr5:96130014	T/C	cg16492584	chr5:96139282	ERAP1	-0.53	-7.18	-0.37	4.44e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg22166914	chr1:53195759	ZYG11B	0.71	12.07	0.55	4.43e-28	Monocyte count;
LUSC	cis	rs28795989	0.795	rs4696778	chr4:7919308	C/G	cg00251875	chr4:7801337	AFAP1	-0.43	-6.42	-0.33	4.6e-10	Intraocular pressure;
LUSC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg19046167	chr17:80928561	B3GNTL1	0.45	6.81	0.35	4.52e-11	Breast cancer;
LUSC	cis	rs7119038	0.865	rs4938573	chr11:118741842	C/T	cg19308663	chr11:118741387	NA	-0.34	-5.75	-0.3	2.02e-8	Sjögren's syndrome;
LUSC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg06212747	chr3:49208901	KLHDC8B	0.45	5.84	0.3	1.25e-8	Parkinson's disease;
LUSC	cis	rs10170846	0.800	rs10180462	chr2:223526385	C/T	cg25565276	chr2:223520875	FARSB	0.64	9.7	0.47	9.46e-20	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs2742234	0.541	rs61268333	chr10:43721370	G/A	cg15436174	chr10:43711423	RASGEF1A	0.44	7.06	0.36	9.75e-12	Hirschsprung disease;
LUSC	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	6.73	0.35	7.44e-11	Total cholesterol levels;
LUSC	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.22	-15.44	-0.65	5.73e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.72	13.82	0.6	1.11e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg25039879	chr17:56429692	SUPT4H1	0.68	9.14	0.45	6.1e-18	Cognitive test performance;
LUSC	cis	rs9811920	0.809	rs13059754	chr3:99678490	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.44	-6.57	-0.34	1.9e-10	Axial length;
LUSC	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg24250549	chr1:154909240	PMVK	0.64	10.43	0.5	3.19e-22	Prostate cancer;
LUSC	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg20243544	chr17:37824526	PNMT	0.4	6.01	0.31	4.94e-9	Self-reported allergy;
LUSC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg11062466	chr8:58055876	NA	0.43	5.79	0.3	1.63e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.36	-6.36	-0.33	6.78e-10	Hematocrit;
LUSC	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	8.2	0.41	5.1e-15	Neuroticism;
LUSC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg26958806	chr6:27640298	NA	0.68	5.75	0.3	2.02e-8	Depression;
LUSC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg11502198	chr6:26597334	ABT1	0.64	10.07	0.48	5.3e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.82	-13.33	-0.59	8.19e-33	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	trans	rs74417235	0.610	rs13178134	chr5:154063032	A/T	cg13111374	chr4:17812581	NCAPG;DCAF16	-0.57	-5.96	-0.31	6.3e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg17075019	chr10:79541650	NA	-0.65	-10.15	-0.49	2.87e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	0.92	15.33	0.64	1.58e-40	Breast cancer;
LUSC	cis	rs9308433	0.733	rs11120300	chr1:214509499	A/T	cg06198575	chr1:214491504	SMYD2	-0.4	-6.44	-0.33	4.15e-10	IgG glycosylation;
LUSC	cis	rs10484885	0.878	rs72921959	chr6:90591326	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.88	-8.37	-0.42	1.58e-15	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.6	-0.38	2.92e-13	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg14416269	chr4:6271139	WFS1	-0.47	-9.13	-0.45	6.7e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg25554036	chr4:6271136	WFS1	0.51	9.11	0.45	7.51e-18	Cisplatin-induced ototoxicity;
LUSC	trans	rs72674100	0.737	rs28461925	chr4:97991609	G/T	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg27275811	chr11:74457193	NA	-0.64	-6.22	-0.32	1.51e-9	Type 2 diabetes nephropathy;
LUSC	cis	rs4713675	0.584	rs6916949	chr6:33678290	C/G	cg14003231	chr6:33640908	ITPR3	0.29	5.69	0.3	2.82e-8	Plateletcrit;
LUSC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	0.94	18.4	0.71	1.07e-52	Cognitive function;
LUSC	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg18904891	chr8:8559673	CLDN23	-0.38	-5.71	-0.3	2.5e-8	Mood instability;
LUSC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.16	15.87	0.66	1.16e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs35079168	0.923	rs10858276	chr9:137287913	C/T	cg13941235	chr9:137270186	RXRA	-0.33	-5.75	-0.3	2.03e-8	Intelligence;
LUSC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg19230755	chr7:65878503	NA	0.43	6.1	0.32	2.96e-9	Aortic root size;
LUSC	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg22681709	chr2:178499509	PDE11A	0.43	6.27	0.32	1.13e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg10523860	chr14:103875565	MARK3	-0.37	-5.9	-0.31	9.07e-9	Body mass index;
LUSC	cis	rs16976116	0.855	rs7172289	chr15:55501705	A/G	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2046867	0.862	rs6805234	chr3:72829869	A/G	cg25664220	chr3:72788482	NA	-0.67	-12.43	-0.56	2.05e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg22782873	chr19:19639568	YJEFN3	-0.48	-6.11	-0.32	2.7e-9	Bipolar disorder;
LUSC	cis	rs9837602	1.000	rs2291495	chr3:99782227	T/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.16	0.32	2.03e-9	Breast cancer;
LUSC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg12463550	chr7:65579703	CRCP	-0.43	-6.36	-0.33	6.61e-10	Aortic root size;
LUSC	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg18196295	chr10:418757	DIP2C	-0.48	-7.95	-0.4	2.81e-14	Psychosis in Alzheimer's disease;
LUSC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.82	12.4	0.56	2.57e-29	Cognitive test performance;
LUSC	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg24692254	chr21:30365293	RNF160	-0.54	-7.19	-0.37	4.39e-12	Cognitive test performance;
LUSC	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg20129853	chr10:51489980	NA	-0.37	-7.65	-0.39	2.13e-13	Prostate-specific antigen levels;
LUSC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg05973401	chr12:123451056	ABCB9	0.52	7.09	0.36	7.87e-12	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg23711669	chr6:146136114	FBXO30	-0.83	-14.9	-0.63	7.35e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9837602	1.000	rs9851645	chr3:99767409	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.17	0.32	1.98e-9	Breast cancer;
LUSC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-6.93	-0.35	2.11e-11	Blood metabolite levels;
LUSC	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.71	-0.43	1.43e-16	Depression;
LUSC	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg06287003	chr12:125626642	AACS	0.37	5.92	0.31	7.89e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.72	-0.35	7.72e-11	Crohn's disease;
LUSC	cis	rs4499344	0.657	rs259238	chr19:33140381	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.78	11.49	0.53	5.77e-26	Mean platelet volume;
LUSC	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.63	-0.43	2.59e-16	Hip circumference adjusted for BMI;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06211272	chr1:59012675	OMA1	-0.45	-6.62	-0.34	1.41e-10	Electrocardiographic conduction measures;
LUSC	trans	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg26043149	chr18:55253948	FECH	-0.54	-8.25	-0.41	3.75e-15	Bone mineral density;
LUSC	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.76	11.44	0.53	8.56e-26	Corneal astigmatism;
LUSC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	0.64	13.34	0.59	7.84e-33	Prudent dietary pattern;
LUSC	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg00530320	chr1:46809349	NSUN4	0.56	8.59	0.43	3.46e-16	Menopause (age at onset);
LUSC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg26354017	chr1:205819088	PM20D1	0.47	6.82	0.35	4.41e-11	Prostate-specific antigen levels;
LUSC	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg18827107	chr12:86230957	RASSF9	-0.41	-6.29	-0.33	1e-9	Major depressive disorder;
LUSC	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg18449964	chr18:72917101	ZADH2	0.48	5.72	0.3	2.31e-8	Vascular endothelial growth factor levels;
LUSC	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg24375607	chr4:120327624	NA	0.77	12.5	0.56	1.08e-29	Corneal astigmatism;
LUSC	cis	rs9487051	0.839	rs13196590	chr6:109561918	T/C	cg01475377	chr6:109611718	NA	-0.36	-5.83	-0.3	1.28e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg10360139	chr7:1886902	MAD1L1	-0.45	-6.95	-0.36	1.89e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs57244997	0.932	rs73026582	chr6:162406460	C/T	cg17173639	chr6:162384350	PARK2	-0.59	-6.02	-0.31	4.68e-9	Mosquito bite size;
LUSC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.55	7.16	0.36	5.03e-12	Multiple sclerosis;
LUSC	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.7	13.04	0.58	1.07e-31	Platelet distribution width;
LUSC	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg13010199	chr12:38710504	ALG10B	0.68	10.81	0.51	1.49e-23	Morning vs. evening chronotype;
LUSC	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg19773385	chr1:10388646	KIF1B	-0.57	-9.86	-0.47	2.77e-20	Hepatocellular carcinoma;
LUSC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	7.93	0.4	3.33e-14	Personality dimensions;
LUSC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.54	0.46	3.08e-19	Mean platelet volume;
LUSC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg17469321	chr7:55412551	NA	0.65	10.58	0.5	9.39e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.71	-0.6	2.98e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg23229984	chr5:148520753	ABLIM3	-0.36	-6.21	-0.32	1.54e-9	Breast cancer;
LUSC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg18876405	chr7:65276391	NA	0.51	7.93	0.4	3.3e-14	Aortic root size;
LUSC	cis	rs6599077	0.950	rs4676560	chr3:40097649	G/C	cg13683864	chr3:40499215	RPL14	-0.6	-7.36	-0.37	1.4e-12	Sleep-related phenotypes;
LUSC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg26566898	chr11:117069891	TAGLN	0.38	7.43	0.38	8.95e-13	Blood protein levels;
LUSC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg14004847	chr7:1930337	MAD1L1	-0.57	-8.49	-0.42	6.73e-16	Schizophrenia;
LUSC	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.05	0.52	2.14e-24	Colorectal cancer;
LUSC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg24250549	chr1:154909240	PMVK	0.66	11.05	0.52	2.07e-24	Prostate cancer;
LUSC	cis	rs7336332	0.598	rs74563672	chr13:28010660	A/G	cg22138327	chr13:27999177	GTF3A	0.8	10.02	0.48	7.6e-21	Weight;
LUSC	cis	rs2742417	0.967	rs1969625	chr3:45734975	A/G	cg09608765	chr3:45636137	LIMD1	-0.38	-7.38	-0.37	1.24e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.03e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.84	15.56	0.65	1.93e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08280861	chr8:58055591	NA	0.54	6.39	0.33	5.62e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg12403142	chr1:92012408	NA	-0.38	-6.03	-0.31	4.31e-9	Breast cancer;
LUSC	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg10523860	chr14:103875565	MARK3	-0.4	-6.44	-0.33	4.18e-10	Body mass index;
LUSC	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg09044154	chr16:88155775	NA	-0.56	-7.56	-0.38	3.96e-13	Menopause (age at onset);
LUSC	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg17691542	chr6:26056736	HIST1H1C	0.59	8.36	0.42	1.77e-15	Height;
LUSC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.6	0.46	2.01e-19	Mean platelet volume;
LUSC	trans	rs2797501	0.615	rs2797491	chr10:5788608	C/G	cg27513495	chr1:11714724	FBXO2;FBXO44	0.53	6.0	0.31	5.04e-9	Osteosarcoma;
LUSC	cis	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg02972257	chr16:68554789	NA	-0.53	-6.6	-0.34	1.64e-10	Ulcerative colitis;
LUSC	trans	rs2392780	0.536	rs34628978	chr8:128336744	G/A	cg10897648	chr18:56338258	MALT1	-0.42	-6.24	-0.32	1.33e-9	Breast cancer (early onset);
LUSC	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.9	20.65	0.75	1.23e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg14019146	chr3:50243930	SLC38A3	0.37	8.43	0.42	1.04e-15	Body mass index;
LUSC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg17178900	chr1:205818956	PM20D1	0.74	13.07	0.58	8.16e-32	Monocyte percentage of white cells;
LUSC	cis	rs7818345	0.935	rs4633071	chr8:19275852	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.92	0.35	2.31e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg00310523	chr12:86230176	RASSF9	0.45	7.99	0.4	2.18e-14	Major depressive disorder;
LUSC	cis	rs2594989	0.836	rs347607	chr3:11268021	A/C	cg00170343	chr3:11313890	ATG7	-0.52	-5.97	-0.31	6.05e-9	Circulating chemerin levels;
LUSC	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg11473876	chr11:109292803	C11orf87	0.35	5.97	0.31	5.95e-9	Schizophrenia;
LUSC	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg16482183	chr6:26056742	HIST1H1C	0.65	9.0	0.44	1.7e-17	Iron status biomarkers;
LUSC	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg24631222	chr15:78858424	CHRNA5	0.58	6.4	0.33	5.37e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2573652	0.722	rs12904962	chr15:100544113	A/G	cg00587665	chr15:100533223	ADAMTS17	0.38	6.92	0.35	2.3e-11	Height;
LUSC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.24	0.37	3.19e-12	Alzheimer's disease;
LUSC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19346786	chr7:2764209	NA	0.49	8.55	0.42	4.62e-16	Height;
LUSC	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.57	-11.78	-0.54	5.12e-27	Sense of smell;
LUSC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg24881330	chr22:46731750	TRMU	0.85	8.39	0.42	1.38e-15	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg13755796	chr4:20253514	NA	-0.42	-6.57	-0.34	1.95e-10	Life satisfaction;
LUSC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.51	0.62	2.44e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg08601574	chr20:25228251	PYGB	0.55	8.78	0.43	8.87e-17	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs656319	0.580	rs17690549	chr8:9998538	C/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.36	-0.33	6.74e-10	Myopia (pathological);
LUSC	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg05738196	chr6:26577821	NA	0.78	14.89	0.63	7.91e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.63	-0.34	1.37e-10	Response to antipsychotic treatment;
LUSC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg01802117	chr1:53393560	SCP2	0.38	6.2	0.32	1.67e-9	Monocyte count;
LUSC	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.68	9.14	0.45	6.02e-18	Menarche (age at onset);
LUSC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	0.91	16.26	0.66	3.41e-44	Menopause (age at onset);
LUSC	cis	rs3733631	1.000	rs10014175	chr4:104659515	T/A	cg24090629	chr4:104641072	TACR3	-0.49	-5.99	-0.31	5.58e-9	Menarche (age at onset);
LUSC	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.99	-0.36	1.5e-11	Monocyte percentage of white cells;
LUSC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg26536354	chr8:144654954	C8orf73	-0.46	-6.49	-0.33	3.16e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs17401966	1.000	rs12117765	chr1:10268170	A/G	cg19773385	chr1:10388646	KIF1B	-0.52	-8.26	-0.41	3.34e-15	Hepatocellular carcinoma;
LUSC	cis	rs6963495	0.745	rs73192150	chr7:105211610	A/C	cg13798780	chr7:105162888	PUS7	0.56	5.83	0.3	1.28e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.77	-0.39	9.83e-14	Blood metabolite levels;
LUSC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg22029157	chr1:209979665	IRF6	0.51	8.12	0.41	9e-15	Monobrow;
LUSC	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.85	-0.35	3.6e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.93	0.48	1.54e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	11.18	0.52	7.3e-25	Bone mineral density;
LUSC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	1.04	20.08	0.74	2.21e-59	Menopause (age at onset);
LUSC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-9.53	-0.46	3.3e-19	Coronary artery disease;
LUSC	cis	rs4494114	0.967	rs9438977	chr1:39354958	A/G	cg25970120	chr1:39325951	RRAGC	-0.39	-6.07	-0.32	3.44e-9	Blood protein levels;
LUSC	cis	rs11608355	0.545	rs2302709	chr12:109893697	A/G	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.1e-26	Neuroticism;
LUSC	cis	rs6460942	0.591	rs80311633	chr7:12339690	G/C	cg06484146	chr7:12443880	VWDE	-0.58	-6.15	-0.32	2.25e-9	Coronary artery disease;
LUSC	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs2274273	0.901	rs7147136	chr14:55826688	G/C	cg04306507	chr14:55594613	LGALS3	0.54	11.97	0.55	1.05e-27	Protein biomarker;
LUSC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg23982607	chr1:1823379	GNB1	-0.5	-8.98	-0.44	1.99e-17	Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17212720	chr6:160148002	WTAP	-0.45	-6.87	-0.35	3.1e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10761482	0.500	rs7072229	chr10:62284220	C/G	cg18175470	chr10:62150864	ANK3	-0.51	-7.45	-0.38	8.19e-13	Schizophrenia;
LUSC	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg09796270	chr17:17721594	SREBF1	-0.41	-7.14	-0.36	5.86e-12	Total body bone mineral density;
LUSC	trans	rs28647808	0.881	rs4246171	chr9:136264731	G/A	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg26102564	chr10:131424627	MGMT	-0.36	-5.69	-0.3	2.74e-8	Response to temozolomide;
LUSC	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.33	0.62	1.18e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11997175	0.625	rs11777333	chr8:33596470	C/A	ch.8.33884649F	chr8:33765107	NA	0.42	6.66	0.34	1.15e-10	Body mass index;
LUSC	cis	rs2625529	0.689	rs12898868	chr15:72112918	A/G	cg16672083	chr15:72433130	SENP8	0.46	7.54	0.38	4.53e-13	Red blood cell count;
LUSC	cis	rs427941	0.703	rs201454	chr7:101740056	A/G	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg24399712	chr22:39784796	NA	-0.58	-9.32	-0.45	1.61e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg25036284	chr2:26402008	FAM59B	0.78	11.3	0.53	2.64e-25	Gut microbiome composition (summer);
LUSC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.5	6.68	0.34	9.93e-11	Corneal astigmatism;
LUSC	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.79	0.3	1.64e-8	Rheumatoid arthritis;
LUSC	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg14809332	chr8:144654887	C8orf73	0.52	6.47	0.33	3.57e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	0.92	13.2	0.59	2.63e-32	Triglycerides;
LUSC	cis	rs259282	0.583	rs3760938	chr19:33106907	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	9.7	0.47	9.23e-20	Schizophrenia;
LUSC	cis	rs10979	1.000	rs7774497	chr6:143889033	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs6700896	0.500	rs11208688	chr1:66081355	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.35	0.33	7.09e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-12.35	-0.56	4.23e-29	Colorectal cancer;
LUSC	trans	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg19694781	chr19:47549865	TMEM160	0.59	9.52	0.46	3.59e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	trans	rs12210905	1.000	rs76889265	chr6:27008835	T/C	cg11837749	chr1:55047332	ACOT11	0.58	6.07	0.32	3.47e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg02153584	chr22:29168773	CCDC117	0.66	10.29	0.49	9.61e-22	Lymphocyte counts;
LUSC	cis	rs10266483	0.515	rs6948710	chr7:63866003	G/A	cg24201672	chr7:64023550	ZNF680	0.5	6.14	0.32	2.39e-9	Response to statin therapy;
LUSC	cis	rs7215564	0.818	rs1032130	chr17:78610636	A/G	cg09596252	chr17:78655493	RPTOR	-0.56	-6.27	-0.32	1.1e-9	Myopia (pathological);
LUSC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06481639	chr22:41940642	POLR3H	-0.54	-6.42	-0.33	4.64e-10	Vitiligo;
LUSC	cis	rs8038465	1.000	rs8041523	chr15:73982556	C/T	cg15420318	chr15:73925796	NPTN	0.39	6.14	0.32	2.34e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10465746	0.967	rs11163861	chr1:84354282	T/C	cg10977910	chr1:84465055	TTLL7	0.44	6.35	0.33	6.92e-10	Obesity-related traits;
LUSC	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg24692254	chr21:30365293	RNF160	-0.68	-10.51	-0.5	1.58e-22	Pancreatic cancer;
LUSC	cis	rs10489202	0.633	rs4657734	chr1:168086743	C/T	cg24449463	chr1:168025552	DCAF6	-0.65	-9.97	-0.48	1.12e-20	Schizophrenia;
LUSC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg03929089	chr4:120376271	NA	0.6	6.53	0.34	2.43e-10	Axial length;
LUSC	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg19875535	chr5:140030758	IK	0.47	7.54	0.38	4.59e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9311676	0.656	rs7647078	chr3:58369912	C/T	cg13750441	chr3:58318267	PXK	0.35	6.7	0.34	8.72e-11	Systemic lupus erythematosus;
LUSC	trans	rs9908158	1	rs9908158	chr17:33890083	T/C	cg19694781	chr19:47549865	TMEM160	0.58	9.28	0.45	2.14e-18	Platelet count;Platelet distribution width;
LUSC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-10.29	-0.49	9.15e-22	Bipolar disorder;
LUSC	cis	rs7129556	0.520	rs12290511	chr11:77266663	T/G	cg12586386	chr11:77299805	AQP11	0.23	5.79	0.3	1.66e-8	Weight loss (gastric bypass surgery);
LUSC	cis	rs2249625	0.545	rs2496505	chr6:72891063	C/G	cg18830697	chr6:72922368	RIMS1	-0.36	-7.37	-0.37	1.34e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg07212818	chr11:638076	DRD4	-0.42	-7.15	-0.36	5.65e-12	Systemic lupus erythematosus;
LUSC	cis	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.68	-0.3	2.88e-8	Resting heart rate;
LUSC	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg08000102	chr2:233561755	GIGYF2	-0.51	-7.96	-0.4	2.79e-14	Coronary artery disease;
LUSC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg23630131	chr7:65973040	NA	0.21	5.94	0.31	7.16e-9	Aortic root size;
LUSC	cis	rs7809950	1.000	rs10251808	chr7:107120453	G/A	cg23024343	chr7:107201750	COG5	-0.55	-8.83	-0.43	6.08e-17	Coronary artery disease;
LUSC	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg03585969	chr10:35415529	CREM	0.6	8.67	0.43	1.86e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg22834771	chr12:69754056	YEATS4	-0.5	-7.45	-0.38	8.09e-13	Blood protein levels;
LUSC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg15448220	chr1:150897856	SETDB1	0.41	5.92	0.31	8.13e-9	Melanoma;
LUSC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg19468946	chr17:37922297	IKZF3	-0.42	-6.57	-0.34	1.88e-10	Self-reported allergy;
LUSC	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg12165864	chr7:66369176	NA	-0.53	-7.07	-0.36	8.93e-12	Corneal structure;
LUSC	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg06552810	chr11:31128660	NA	-0.42	-7.41	-0.38	1.05e-12	Red blood cell count;
LUSC	cis	rs6987853	0.901	rs2974344	chr8:42400732	T/G	cg09913449	chr8:42400586	C8orf40	0.49	8.24	0.41	4.06e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.54	8.24	0.41	3.85e-15	Lymphocyte counts;
LUSC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg08888203	chr3:10149979	C3orf24	0.6	8.27	0.41	3.2e-15	Alzheimer's disease;
LUSC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.47	-7.94	-0.4	3.02e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg20887711	chr4:1340912	KIAA1530	0.39	5.77	0.3	1.78e-8	Obesity-related traits;
LUSC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.44	-0.33	4.08e-10	Alzheimer's disease (late onset);
LUSC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg04141948	chr7:1023156	CYP2W1	0.28	5.91	0.31	8.49e-9	Longevity;Endometriosis;
LUSC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg05347473	chr6:146136440	FBXO30	0.44	7.48	0.38	6.41e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1368882	0.814	rs1702020	chr1:55105728	C/T	cg01517571	chr1:55089959	ACOT11;FAM151A	0.51	8.12	0.41	9.23e-15	Non-substance related behavioral disinhibition;
LUSC	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg20283391	chr11:68216788	NA	-0.61	-8.55	-0.42	4.43e-16	Total body bone mineral density;
LUSC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg07389463	chr12:132296394	NA	0.39	7.24	0.37	3.13e-12	Migraine;
LUSC	cis	rs3733418	0.929	rs4690797	chr4:165908505	G/C	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-5.92	-0.31	8.03e-9	Obesity-related traits;
LUSC	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-7.15	-0.36	5.63e-12	Blood metabolite levels;
LUSC	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.86	-0.35	3.44e-11	Inflammatory bowel disease;
LUSC	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg06207120	chr15:45996521	NA	0.4	6.14	0.32	2.33e-9	Waist circumference;Weight;
LUSC	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg07080220	chr10:102295463	HIF1AN	0.69	8.35	0.42	1.82e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs78545713	0.649	rs11757549	chr6:26231608	G/A	cg23601095	chr6:26197514	HIST1H3D	0.64	5.76	0.3	1.87e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg08085267	chr17:45401833	C17orf57	-0.5	-7.83	-0.39	6.37e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg19249749	chr1:223853145	CAPN8	0.49	6.47	0.33	3.49e-10	Gut microbiome composition (summer);
LUSC	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-7.69	-0.39	1.67e-13	Blood metabolite levels;
LUSC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.75	-0.39	1.13e-13	Neuroticism;
LUSC	cis	rs12190007	0.573	rs13202383	chr6:169826544	A/G	cg15038512	chr6:170123185	PHF10	-0.39	-6.32	-0.33	8.58e-10	Obesity-related traits;
LUSC	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.2	-0.32	1.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg09877947	chr5:131593287	PDLIM4	0.45	7.06	0.36	9.41e-12	Breast cancer;
LUSC	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.43	-6.13	-0.32	2.47e-9	Platelet distribution width;
LUSC	cis	rs3925075	1.000	rs9673405	chr16:31347599	A/C	cg02846316	chr16:31340340	ITGAM	0.36	6.66	0.34	1.11e-10	IgA nephropathy;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11808854	chr20:60697627	LSM14B	-0.45	-6.29	-0.33	1e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03526776	chr6:41159608	TREML2	-0.48	-9.28	-0.45	2.27e-18	Alzheimer's disease (late onset);
LUSC	cis	rs6961069	0.527	rs997906	chr7:80279835	A/T	cg04458919	chr7:80252533	CD36	-0.39	-6.63	-0.34	1.36e-10	Platelet count;
LUSC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18404041	chr3:52824283	ITIH1	-0.54	-10.45	-0.5	2.62e-22	Bipolar disorder;
LUSC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	1.21	16.6	0.67	1.46e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg06718696	chr17:78121285	EIF4A3	0.44	6.23	0.32	1.37e-9	Yeast infection;
LUSC	cis	rs6977660	0.714	rs10249635	chr7:19787090	A/G	cg05791153	chr7:19748676	TWISTNB	0.76	7.46	0.38	7.38e-13	Thyroid stimulating hormone;
LUSC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4363385	0.818	rs407448	chr1:153007504	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.91	-0.4	3.76e-14	Inflammatory skin disease;
LUSC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	12.65	0.57	3.13e-30	Cognitive test performance;
LUSC	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg13798780	chr7:105162888	PUS7	0.58	6.32	0.33	8.2e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.84	0.44	5.5e-17	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10979	1.000	rs9403506	chr6:143887805	C/G	cg25407410	chr6:143891975	LOC285740	-0.73	-11.85	-0.54	2.71e-27	Hypospadias;
LUSC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg27432699	chr2:27873401	GPN1	-0.57	-8.4	-0.42	1.27e-15	Total body bone mineral density;
LUSC	trans	rs6982636	0.744	rs2954021	chr8:126482077	A/G	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.33	-6.35	-0.33	6.9e-10	Lipid metabolism phenotypes;
LUSC	cis	rs9309473	0.528	rs11126396	chr2:73565143	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-6.87	-0.35	3.12e-11	Metabolite levels;
LUSC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.42	-0.38	9.65e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	0.92	13.9	0.61	5.47e-35	Breast cancer;
LUSC	cis	rs7149337	0.837	rs4296182	chr14:51662167	A/C	cg23942311	chr14:51606299	NA	0.45	9.72	0.47	7.72e-20	Cancer;
LUSC	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.12	-0.36	6.84e-12	Response to antipsychotic treatment;
LUSC	trans	rs62238980	0.614	rs115866486	chr22:32510228	A/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.52	-6.12	-0.32	2.69e-9	Childhood ear infection;
LUSC	cis	rs1113500	1.000	rs1113500	chr1:108595442	G/T	cg11967332	chr1:108735228	SLC25A24	-0.38	-5.65	-0.3	3.42e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs2652834	0.808	rs2652789	chr15:63415223	A/C	cg05507819	chr15:63340323	TPM1	0.45	5.82	0.3	1.37e-8	HDL cholesterol;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg24419099	chr11:47270565	NR1H3;ACP2	0.43	6.49	0.33	3.17e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.33	-0.49	6.83e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs354225	0.544	rs10208219	chr2:54806047	G/A	cg01766943	chr2:54829624	SPTBN1	0.48	7.61	0.38	2.89e-13	Schizophrenia;
LUSC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg16228356	chr17:43848958	NA	-0.27	-6.1	-0.32	2.89e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9650657	0.707	rs7814757	chr8:10675188	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.24	-0.32	1.3e-9	Neuroticism;
LUSC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg21724239	chr8:58056113	NA	0.78	9.78	0.47	5.05e-20	Developmental language disorder (linguistic errors);
LUSC	trans	rs2587949	0.593	rs2600135	chr3:4209896	C/T	cg15139668	chr4:4577005	NA	-0.41	-6.03	-0.31	4.44e-9	Periodontitis (DPAL);
LUSC	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg25930673	chr12:123319894	HIP1R	-0.72	-7.2	-0.37	4.13e-12	Schizophrenia;
LUSC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg10411590	chr13:21900810	NA	0.29	5.75	0.3	2e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20143895	chr1:247095226	AHCTF1	0.48	6.55	0.34	2.16e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06221963	chr1:154839813	KCNN3	-0.59	-12.97	-0.58	2.03e-31	Prostate cancer;
LUSC	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg06002616	chr8:101225028	SPAG1	0.39	6.57	0.34	1.97e-10	Atrioventricular conduction;
LUSC	cis	rs4074961	0.669	rs6687545	chr1:38071195	C/T	cg02930200	chr1:38022384	DNALI1	0.28	5.78	0.3	1.68e-8	Axial length;
LUSC	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg23933602	chr10:16859644	RSU1	0.62	8.08	0.4	1.2e-14	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs4776059	1.000	rs4776065	chr15:52929716	A/G	cg22715398	chr15:52968154	KIAA1370	0.64	9.39	0.46	9.85e-19	Schizophrenia;
LUSC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg13047869	chr3:10149882	C3orf24	0.64	9.14	0.45	6.38e-18	Alzheimer's disease;
LUSC	cis	rs7789940	0.817	rs6946310	chr7:75936099	T/C	cg10167463	chr7:75959203	YWHAG	-0.51	-7.21	-0.37	3.83e-12	Multiple sclerosis;
LUSC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg10018233	chr7:150070692	REPIN1	0.38	6.19	0.32	1.73e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00149659	chr3:10157352	C3orf10	1.0	14.64	0.63	7.9e-38	Alzheimer's disease;
LUSC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg12935359	chr14:103987150	CKB	-0.56	-8.57	-0.42	3.85e-16	Body mass index;
LUSC	cis	rs4499344	0.535	rs7260509	chr19:33121595	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.71	11.15	0.52	9.6e-25	Mean platelet volume;
LUSC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg19592336	chr6:28129416	ZNF389	0.48	6.27	0.32	1.11e-9	Depression;
LUSC	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.83	0.75	2.5e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg00509249	chr6:109615579	CCDC162	-0.34	-6.03	-0.31	4.24e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	8.96	0.44	2.3e-17	Schizophrenia;
LUSC	cis	rs892085	0.681	rs3826803	chr19:10883126	C/G	cg17710535	chr19:10819994	QTRT1	-0.35	-5.74	-0.3	2.09e-8	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs10266483	1.000	rs10266483	chr7:63733331	A/G	cg24201672	chr7:64023550	ZNF680	-0.43	-5.97	-0.31	6.02e-9	Response to statin therapy;
LUSC	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg24375607	chr4:120327624	NA	0.78	11.63	0.54	1.83e-26	Corneal astigmatism;
LUSC	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-9.48	-0.46	4.83e-19	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.53	-0.34	2.47e-10	Neuroticism;
LUSC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02034447	chr16:89574710	SPG7	0.4	6.01	0.31	4.82e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg14552801	chr7:65878734	NA	-0.38	-5.95	-0.31	6.75e-9	Aortic root size;
LUSC	trans	rs12902680	0.706	rs28575923	chr15:46525609	G/A	cg04321580	chr8:143696133	ARC	-0.42	-6.0	-0.31	5e-9	Neuroticism;
LUSC	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg12218747	chr21:37451666	NA	-0.39	-5.73	-0.3	2.29e-8	Mitral valve prolapse;
LUSC	cis	rs2200578	0.836	rs72957179	chr2:99693578	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.55	6.63	0.34	1.36e-10	IgG glycosylation;
LUSC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg14061069	chr19:46274453	DMPK	0.67	13.89	0.61	6.14e-35	Coronary artery disease;
LUSC	trans	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	10.81	0.51	1.43e-23	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg22705602	chr4:152727874	NA	-0.34	-6.82	-0.35	4.21e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.6	-8.7	-0.43	1.58e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs71435601	0.527	rs544039	chr2:21398985	C/A	cg20757404	chr19:378427	NA	0.37	6.01	0.31	4.87e-9	Cholesterol, total;
LUSC	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-6.27	-0.32	1.11e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg24375607	chr4:120327624	NA	0.7	11.14	0.52	1.03e-24	Educational attainment;
LUSC	cis	rs7605827	0.930	rs11692377	chr2:15659848	C/T	cg19274914	chr2:15703543	NA	0.47	9.19	0.45	4.24e-18	Educational attainment (years of education);
LUSC	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg26395211	chr5:140044315	WDR55	-0.37	-5.74	-0.3	2.17e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6669008	1.000	rs6669008	chr1:114166561	A/G	cg13572289	chr1:114447746	DCLRE1B;AP4B1	-0.36	-5.77	-0.3	1.78e-8	Bacteremia;
LUSC	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg17411546	chr10:75410026	SYNPO2L	-0.43	-6.43	-0.33	4.5e-10	Inflammatory bowel disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14550653	chr6:52149695	MCM3	-0.44	-6.45	-0.33	3.88e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8056893	0.879	rs3961282	chr16:68365157	A/G	cg02226672	chr16:68398533	SMPD3	0.33	5.91	0.31	8.67e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs4132509	0.696	rs12023642	chr1:243767826	T/G	cg21452805	chr1:244014465	NA	0.64	6.31	0.33	8.91e-10	RR interval (heart rate);
LUSC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg16049864	chr8:95962084	TP53INP1	0.63	10.96	0.51	4.35e-24	Type 2 diabetes;
LUSC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg17507749	chr15:85114479	UBE2QP1	0.68	8.55	0.42	4.36e-16	Schizophrenia;
LUSC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.41	6.37	0.33	6.33e-10	Platelet count;
LUSC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg10792982	chr14:105748885	BRF1	0.48	8.68	0.43	1.75e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.69	10.51	0.5	1.65e-22	Corneal astigmatism;
LUSC	cis	rs9650315	0.810	rs67283156	chr8:57202814	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.33	0.37	1.76e-12	Height;
LUSC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg09323728	chr8:95962352	TP53INP1	0.33	6.07	0.32	3.42e-9	Type 2 diabetes;
LUSC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.77	-0.43	8.98e-17	Gut microbiome composition (summer);
LUSC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.39	6.0	0.31	5.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7181230	0.885	rs17723133	chr15:40365418	A/G	cg22705835	chr10:65332833	REEP3	0.39	6.34	0.33	7.67e-10	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.76	-0.3	1.87e-8	Depression;
LUSC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.43	-0.46	6.97e-19	Chronic sinus infection;
LUSC	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.25	0.52	4.16e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg10523679	chr1:76189770	ACADM	-0.51	-7.47	-0.38	6.99e-13	Daytime sleep phenotypes;
LUSC	cis	rs4285028	0.948	rs34478505	chr3:121694071	C/T	cg11130432	chr3:121712080	ILDR1	-0.64	-9.8	-0.47	4.37e-20	Multiple sclerosis;
LUSC	cis	rs9811920	0.809	rs4928153	chr3:99808445	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.35	-6.52	-0.34	2.55e-10	Axial length;
LUSC	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg17168535	chr8:21777572	XPO7	0.8	14.16	0.61	5.36e-36	Mean corpuscular volume;
LUSC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.86	14.01	0.61	2.16e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs877282	0.583	rs10904564	chr10:819459	C/G	cg13042288	chr15:90349979	ANPEP	-0.42	-6.34	-0.33	7.44e-10	Uric acid levels;
LUSC	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	22.61	0.78	2.48e-69	Colorectal cancer;
LUSC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-9.3	-0.45	1.82e-18	Gut microbiome composition (summer);
LUSC	cis	rs4664308	0.710	rs13001911	chr2:161020703	G/C	cg03641300	chr2:160917029	PLA2R1	-0.61	-10.34	-0.49	6.11e-22	Idiopathic membranous nephropathy;
LUSC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg14552801	chr7:65878734	NA	-0.38	-5.96	-0.31	6.31e-9	Aortic root size;
LUSC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg06784218	chr1:46089804	CCDC17	0.47	9.26	0.45	2.6e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2282300	0.956	rs594937	chr11:30390132	A/G	cg25418670	chr11:30344373	C11orf46	0.51	7.16	0.36	5.23e-12	Morning vs. evening chronotype;
LUSC	trans	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	6.06	0.31	3.71e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs870825	0.616	rs28500698	chr4:185627746	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.77e-32	Blood protein levels;
LUSC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.5	6.58	0.34	1.82e-10	Blood protein levels;
LUSC	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg09915433	chr19:53449742	NA	-0.57	-9.27	-0.45	2.38e-18	Psoriasis;
LUSC	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	16.23	0.66	4.45e-44	Exhaled nitric oxide output;
LUSC	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg11473876	chr11:109292803	C11orf87	0.41	6.57	0.34	1.94e-10	Schizophrenia;
LUSC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg26441486	chr22:50317300	CRELD2	-0.55	-8.28	-0.41	2.94e-15	Schizophrenia;
LUSC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg06454157	chr6:167490870	NA	-0.24	-6.04	-0.31	4.19e-9	Crohn's disease;
LUSC	cis	rs80130819	0.636	rs2634690	chr12:48712638	C/T	cg24011408	chr12:48396354	COL2A1	0.46	5.95	0.31	6.73e-9	Prostate cancer;
LUSC	cis	rs28655083	0.828	rs11640648	chr16:77122494	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.52	7.91	0.4	3.69e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2617583	0.967	rs2550948	chr5:1450444	C/T	cg07148919	chr5:1466943	LPCAT1	0.38	5.83	0.3	1.3e-8	Breast cancer;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg08224763	chr17:6917993	C17orf49	0.49	6.38	0.33	5.8e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	6.79	0.35	5.1e-11	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg07936489	chr17:37558343	FBXL20	0.72	10.04	0.48	6.43e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs7215564	0.908	rs35374347	chr17:78642244	C/T	cg23238734	chr17:78661607	RPTOR	0.5	6.2	0.32	1.69e-9	Myopia (pathological);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg18045831	chr1:19577885	MRTO4;KIAA0090	0.35	6.32	0.33	8.39e-10	Triglycerides;
LUSC	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.42	-0.38	9.65e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs59698941	0.943	rs66483023	chr5:132257748	A/T	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs2227930	0.506	rs9867210	chr3:142132749	T/C	cg16271453	chr3:142027066	XRN1	-0.54	-9.64	-0.47	1.51e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs12681287	0.547	rs71502658	chr8:87478785	T/A	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.36	6.24e-12	Caudate activity during reward;
LUSC	trans	rs3960554	0.740	rs10216079	chr7:75690988	A/C	cg19862616	chr7:65841803	NCRNA00174	0.85	9.54	0.46	3.1400000000000002e-19	Eotaxin levels;
LUSC	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg15412446	chr2:106886593	NA	-0.49	-5.86	-0.31	1.09e-8	Facial morphology (factor 23);
LUSC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-8.54	-0.42	4.78e-16	Bipolar disorder;
LUSC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.16	-0.36	5.12e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg03733263	chr8:22462867	KIAA1967	0.99	17.54	0.69	2.73e-49	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg00191853	chr8:101177733	SPAG1	0.36	5.9	0.31	8.98e-9	Atrioventricular conduction;
LUSC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg17376030	chr22:41985996	PMM1	-0.48	-5.9	-0.31	8.71e-9	Vitiligo;
LUSC	cis	rs727505	0.821	rs73225498	chr7:124704197	C/T	cg23710748	chr7:124431027	NA	-0.4	-6.98	-0.36	1.63e-11	Lewy body disease;
LUSC	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg02466173	chr16:30829666	NA	-0.6	-11.2	-0.52	6.15e-25	Multiple myeloma;
LUSC	cis	rs227833	1.000	rs227835	chr6:44682316	A/G	cg20913747	chr6:44695427	NA	0.38	5.76	0.3	1.87e-8	Monobrow;
LUSC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-17.88	-0.7	1.27e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2769264	0.505	rs4246526	chr1:151403916	G/T	cg18801370	chr1:151430492	POGZ	0.69	8.44	0.42	9.58e-16	Blood trace element (Cu levels);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27634258	chr15:51058042	SPPL2A	-0.47	-6.48	-0.33	3.39e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6599077	1.000	rs2371140	chr3:40098381	A/G	cg13683864	chr3:40499215	RPL14	-0.59	-7.4	-0.38	1.11e-12	Sleep-related phenotypes;
LUSC	cis	rs34779708	0.897	rs7900480	chr10:35338699	A/G	cg03585969	chr10:35415529	CREM	-0.57	-8.34	-0.42	1.97e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2011503	0.509	rs884480	chr19:19773923	G/A	cg11584989	chr19:19387371	SF4	0.51	5.82	0.3	1.41e-8	Bipolar disorder;
LUSC	trans	rs2048656	0.605	rs13249234	chr8:9650401	T/C	cg06636001	chr8:8085503	FLJ10661	0.46	6.43	0.33	4.4e-10	Schizophrenia;
LUSC	cis	rs977987	0.843	rs59155720	chr16:75483806	A/G	cg03315344	chr16:75512273	CHST6	0.49	9.56	0.46	2.74e-19	Dupuytren's disease;
LUSC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg18357645	chr12:58087776	OS9	0.58	8.8	0.43	7.25e-17	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs10203711	0.966	rs4998693	chr2:239564753	G/T	cg14580085	chr2:239553406	NA	0.41	6.96	0.36	1.76e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg18479299	chr3:125709523	NA	-0.52	-5.94	-0.31	7.16e-9	Blood pressure (smoking interaction);
LUSC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-7.5	-0.38	5.77e-13	Aortic root size;
LUSC	cis	rs2798269	1.000	rs2476638	chr13:22133729	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.13	-0.32	2.42e-9	PR segment;
LUSC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	0.97	14.15	0.61	6.21e-36	Vitiligo;
LUSC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg13628971	chr7:2884303	GNA12	0.42	6.27	0.32	1.11e-9	Height;
LUSC	cis	rs4908769	0.553	rs301792	chr1:8468278	A/G	cg00546117	chr1:8445545	RERE	-0.28	-5.65	-0.3	3.37e-8	Allergy;
LUSC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg19774624	chr17:42201019	HDAC5	0.7	10.29	0.49	9.36e-22	Total body bone mineral density;
LUSC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg21573476	chr21:45109991	RRP1B	0.4	6.69	0.34	9.26e-11	Mean corpuscular volume;
LUSC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg00898013	chr13:113819073	PROZ	-0.53	-7.85	-0.39	5.78e-14	Platelet distribution width;
LUSC	trans	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg10756647	chr7:56101905	PSPH	0.85	8.34	0.42	2.04e-15	Diabetic kidney disease;
LUSC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg05501817	chr11:14380813	RRAS2	-0.57	-8.9	-0.44	3.72e-17	Sense of smell;
LUSC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	7.57	0.38	3.58e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9847710	0.933	rs1529544	chr3:53039455	A/G	cg18404041	chr3:52824283	ITIH1	-0.37	-6.67	-0.34	1.05e-10	Ulcerative colitis;
LUSC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.31	0.64	1.89e-40	Platelet count;
LUSC	cis	rs7923609	0.967	rs7082470	chr10:65277026	G/A	cg01631684	chr10:65280961	REEP3	-0.41	-6.39	-0.33	5.65e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg19773385	chr1:10388646	KIF1B	-0.49	-8.37	-0.42	1.57e-15	Hepatocellular carcinoma;
LUSC	cis	rs1322512	0.917	rs2623944	chr6:152959314	C/T	cg27316956	chr6:152958899	SYNE1	-0.37	-6.2	-0.32	1.62e-9	Tonometry;
LUSC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg18225595	chr11:63971243	STIP1	0.52	6.54	0.34	2.38e-10	Mean platelet volume;
LUSC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.91	-0.35	2.44e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs73001065	0.591	rs11668386	chr19:19531910	A/G	cg03709012	chr19:19516395	GATAD2A	1.0	9.39	0.46	9.68e-19	LDL cholesterol;
LUSC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg12257692	chr3:49977190	RBM6	0.24	6.66	0.34	1.16e-10	Body mass index;
LUSC	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg17294928	chr15:75287854	SCAMP5	-0.92	-13.07	-0.58	8.12e-32	Blood trace element (Zn levels);
LUSC	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	9.54	0.46	3.03e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9649213	0.614	rs10953254	chr7:97914305	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.38	5.73	0.3	2.19e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg06191203	chr2:152266755	RIF1	-0.55	-7.27	-0.37	2.64e-12	Lung cancer;
LUSC	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg23649088	chr2:200775458	C2orf69	-0.5	-6.86	-0.35	3.41e-11	Schizophrenia;
LUSC	cis	rs865483	0.860	rs862490	chr17:35850275	T/C	cg06716730	chr17:35851459	DUSP14	0.29	6.61	0.34	1.51e-10	Monocyte count;
LUSC	cis	rs7241530	0.662	rs924890	chr18:75900657	C/T	cg14642773	chr18:75888474	NA	0.4	6.11	0.32	2.71e-9	Educational attainment (years of education);
LUSC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg26769984	chr7:1090371	C7orf50	0.57	7.86	0.4	5.34e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-6.01	-0.31	4.82e-9	Longevity;
LUSC	trans	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-6.62	-0.34	1.46e-10	Monocyte count;
LUSC	cis	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.8	13.45	0.59	3.01e-33	Aortic root size;
LUSC	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	0.59	8.03	0.4	1.74e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg12091567	chr17:66097778	LOC651250	-0.74	-9.32	-0.45	1.62e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.78	0.3	1.68e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg21545522	chr1:205238299	TMCC2	0.46	8.6	0.43	3.05e-16	Red blood cell count;
LUSC	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg00012203	chr2:219082015	ARPC2	-0.77	-13.72	-0.6	2.88e-34	Colorectal cancer;
LUSC	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg18005901	chr6:33739558	LEMD2	-0.39	-5.8	-0.3	1.53e-8	Schizophrenia;
LUSC	cis	rs1507153	0.523	rs236884	chr6:79319525	C/G	cg05283184	chr6:79620031	NA	0.38	6.95	0.36	1.94e-11	Sjögren's syndrome;
LUSC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg21433313	chr16:3507492	NAT15	0.81	8.76	0.43	1e-16	Tuberculosis;
LUSC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg24399712	chr22:39784796	NA	-0.63	-10.44	-0.5	2.8e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	0.69	14.72	0.63	3.91e-38	Prudent dietary pattern;
LUSC	cis	rs8141797	0.901	rs2330722	chr22:24491488	C/G	cg00411358	chr22:24577142	SUSD2	0.61	6.09	0.32	3.14e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	trans	rs11700980	0.551	rs2832035	chr21:30115032	C/T	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs2798269	0.902	rs1359190	chr13:22096611	T/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-5.79	-0.3	1.61e-8	PR segment;
LUSC	cis	rs727505	1.000	rs720614	chr7:124452790	T/C	cg23710748	chr7:124431027	NA	-0.43	-7.79	-0.39	8.52e-14	Lewy body disease;
LUSC	trans	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.05	0.48	6.24e-21	Mean corpuscular volume;
LUSC	trans	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.56	0.46	2.66e-19	Mean corpuscular volume;
LUSC	trans	rs7939886	0.920	rs10431119	chr11:55977069	C/T	cg15704280	chr7:45808275	SEPT13	0.91	6.86	0.35	3.36e-11	Myopia (pathological);
LUSC	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg24130564	chr14:104152367	KLC1	-0.41	-5.75	-0.3	1.98e-8	Body mass index;
LUSC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg02269571	chr22:50332266	NA	0.59	8.72	0.43	1.33e-16	Schizophrenia;
LUSC	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg02196730	chr15:80188777	MTHFS	0.39	5.92	0.31	7.97e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.89	-0.4	4.42e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg00083206	chr6:110721305	DDO	-0.46	-8.45	-0.42	8.94e-16	Platelet distribution width;
LUSC	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-6.81	-0.35	4.45e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs17095355	1.000	rs59804002	chr10:111692043	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.63	-7.35	-0.37	1.54e-12	Biliary atresia;
LUSC	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg07080220	chr10:102295463	HIF1AN	0.67	7.88	0.4	4.58e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3820068	0.705	rs4645992	chr1:15849742	G/T	cg17385448	chr1:15911702	AGMAT	0.39	6.03	0.31	4.23e-9	Systolic blood pressure;
LUSC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg10909506	chr17:38081995	ORMDL3	0.34	6.02	0.31	4.69e-9	Self-reported allergy;
LUSC	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg13902645	chr11:5959945	NA	-0.61	-8.34	-0.42	1.92e-15	DNA methylation (variation);
LUSC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.84	0.6	9.47e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg22532475	chr10:104410764	TRIM8	0.33	6.65	0.34	1.22e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.94	0.31	7.28e-9	Menopause (age at onset);
LUSC	cis	rs240764	0.782	rs151637	chr6:101104191	C/T	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.69e-9	Neuroticism;
LUSC	cis	rs11166629	0.502	rs6577717	chr8:135653832	G/T	cg27224718	chr8:135614730	ZFAT	0.51	7.88	0.4	4.65e-14	Smoking quantity;
LUSC	cis	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.37e-9	Ulcerative colitis;
LUSC	trans	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.63	0.39	2.44e-13	Ulcerative colitis;
LUSC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg27588902	chr6:42928151	GNMT	-0.3	-6.6	-0.34	1.65e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2235642	0.525	rs2667688	chr16:1561446	A/G	cg26528668	chr16:1614120	IFT140	0.4	5.81	0.3	1.42e-8	Coronary artery disease;
LUSC	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg21775007	chr8:11205619	TDH	-0.53	-8.02	-0.4	1.83e-14	Neuroticism;
LUSC	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg00376283	chr12:123451042	ABCB9	0.67	8.43	0.42	1.07e-15	Neutrophil percentage of white cells;
LUSC	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg23625390	chr15:77176239	SCAPER	0.46	6.97	0.36	1.66e-11	Blood metabolite levels;
LUSC	cis	rs10465746	0.780	rs1952065	chr1:84464205	T/C	cg10977910	chr1:84465055	TTLL7	0.43	6.08	0.32	3.28e-9	Obesity-related traits;
LUSC	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.67	0.6	4.14e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3820928	0.874	rs2396452	chr2:227838040	T/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.94	-0.4	3.16e-14	Pulmonary function;
LUSC	cis	rs11608355	0.515	rs34038572	chr12:109901657	A/G	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs72960926	0.744	rs55795936	chr6:75006841	A/G	cg03266952	chr6:74778945	NA	-0.75	-6.61	-0.34	1.49e-10	Metabolite levels (MHPG);
LUSC	cis	rs62432291	0.681	rs433786	chr6:159665946	T/A	cg14500486	chr6:159655392	FNDC1	-0.56	-5.99	-0.31	5.36e-9	Joint mobility (Beighton score);
LUSC	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.88	14.95	0.63	4.68e-39	Bladder cancer;
LUSC	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg04362960	chr10:104952993	NT5C2	0.57	8.31	0.41	2.36e-15	Arsenic metabolism;
LUSC	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg17127132	chr2:85788382	GGCX	0.49	7.92	0.4	3.6e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7814319	0.966	rs10955069	chr8:97253788	C/T	cg20787634	chr8:97240163	UQCRB	-0.35	-6.12	-0.32	2.68e-9	Lung function (FVC);
LUSC	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg02023728	chr11:77925099	USP35	0.41	6.24	0.32	1.34e-9	Testicular germ cell tumor;
LUSC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg15345415	chr5:151150903	G3BP1	0.34	5.99	0.31	5.53e-9	Educational attainment (years of education);
LUSC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.35	0.37	1.53e-12	Motion sickness;
LUSC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.89	14.21	0.61	3.55e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg10130564	chr11:117069849	TAGLN	0.38	6.49	0.33	3.07e-10	Blood protein levels;
LUSC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg05347473	chr6:146136440	FBXO30	0.59	10.57	0.5	1.04e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs440932	1.000	rs365309	chr8:9026940	C/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.94	-0.31	7.17e-9	High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg03387311	chr17:17106229	PLD6	-0.37	-6.07	-0.32	3.49e-9	N-glycan levels;
LUSC	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg01966878	chr4:90757139	SNCA	-0.43	-6.22	-0.32	1.49e-9	Neuroticism;
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.85	15.36	0.64	1.22e-40	Menarche (age at onset);
LUSC	cis	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg21775007	chr8:11205619	TDH	-0.41	-5.79	-0.3	1.62e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs4704187	0.687	rs1903839	chr5:74421397	A/G	cg03227963	chr5:74354835	NA	0.32	6.89	0.35	2.72e-11	Response to amphetamines;
LUSC	cis	rs1524927	0.966	rs7789402	chr7:96353085	A/G	cg03808172	chr7:96339361	SHFM1	0.42	6.52	0.34	2.53e-10	Total body bone mineral density;
LUSC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg05347473	chr6:146136440	FBXO30	0.41	6.91	0.35	2.54e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg09877947	chr5:131593287	PDLIM4	-0.42	-6.15	-0.32	2.17e-9	Blood metabolite levels;
LUSC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg22535103	chr8:58192502	C8orf71	-0.57	-6.72	-0.34	8.09e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg08917208	chr2:24149416	ATAD2B	0.56	6.36	0.33	6.82e-10	Lymphocyte counts;
LUSC	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg03605463	chr16:89740564	NA	-0.53	-8.37	-0.42	1.59e-15	Hemoglobin concentration;
LUSC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg04450456	chr4:17643702	FAM184B	0.41	6.93	0.35	2.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9677476	0.731	rs28690417	chr2:232064182	G/A	cg07929768	chr2:232055508	NA	0.4	6.87	0.35	3.15e-11	Food antigen IgG levels;
LUSC	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg22491629	chr6:157744540	C6orf35	-0.91	-10.85	-0.51	1.08e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs10905065	1.000	rs10737013	chr10:5746772	C/G	cg11519256	chr10:5708881	ASB13	0.39	5.84	0.3	1.25e-8	Menopause (age at onset);
LUSC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg08470875	chr2:26401718	FAM59B	-0.63	-8.71	-0.43	1.45e-16	Gut microbiome composition (summer);
LUSC	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg05855489	chr10:104503620	C10orf26	-0.66	-10.09	-0.48	4.54e-21	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs4363385	0.693	rs56347903	chr1:152932175	T/G	cg07796016	chr1:152779584	LCE1C	-0.45	-6.49	-0.33	3.04e-10	Inflammatory skin disease;
LUSC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	0.66	13.94	0.61	3.9e-35	Prudent dietary pattern;
LUSC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg06671706	chr8:8559999	CLDN23	0.49	6.43	0.33	4.36e-10	Obesity-related traits;
LUSC	cis	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg06521331	chr12:34319734	NA	-0.37	-6.46	-0.33	3.79e-10	Morning vs. evening chronotype;
LUSC	cis	rs9807989	0.839	rs4988958	chr2:102968285	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.91	0.31	8.63e-9	Asthma;
LUSC	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg22139774	chr2:100720529	AFF3	0.41	6.98	0.36	1.57e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg23711669	chr6:146136114	FBXO30	-0.78	-12.9	-0.58	3.58e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg22437258	chr11:111473054	SIK2	0.52	7.44	0.38	8.76e-13	Primary sclerosing cholangitis;
LUSC	cis	rs9487051	0.768	rs427960	chr6:109524939	C/T	cg00509249	chr6:109615579	CCDC162	-0.36	-6.05	-0.31	3.91e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg18002602	chr11:66138449	SLC29A2	0.45	8.04	0.4	1.55e-14	Educational attainment (years of education);
LUSC	cis	rs354225	0.544	rs10169975	chr2:54808159	C/T	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs11051970	0.614	rs2728684	chr12:32575665	C/A	cg02745156	chr12:32552066	NA	0.37	5.92	0.31	8.03e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11031096	0.502	rs7935824	chr11:4046900	C/G	cg18678763	chr11:4115507	RRM1	-0.49	-6.45	-0.33	3.94e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg22029157	chr1:209979665	IRF6	0.51	8.12	0.41	9e-15	Monobrow;
LUSC	cis	rs4478858	0.684	rs12135540	chr1:31764693	G/A	cg00250761	chr1:31883323	NA	-0.35	-8.37	-0.42	1.61e-15	Alcohol dependence;
LUSC	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.64	-0.43	2.38e-16	Total cholesterol levels;
LUSC	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg01884057	chr2:25150051	NA	0.46	10.6	0.5	8.23e-23	Body mass index in non-asthmatics;
LUSC	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg02176678	chr2:219576539	TTLL4	0.61	10.93	0.51	5.45e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs524023	1.000	rs3825018	chr11:64358809	G/A	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.67	-0.3	3.12e-8	Urate levels in obese individuals;
LUSC	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.85	-0.39	5.78e-14	Neuroticism;
LUSC	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	1.03	17.11	0.68	1.46e-47	Menopause (age at onset);
LUSC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg04398451	chr17:18023971	MYO15A	0.57	9.53	0.46	3.41e-19	Total body bone mineral density;
LUSC	trans	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg04998671	chr14:104000505	TRMT61A	-0.42	-6.17	-0.32	2.01e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg22868518	chr11:507468	RNH1	-0.59	-5.81	-0.3	1.47e-8	Body mass index;
LUSC	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-9.02	-0.44	1.54e-17	Schizophrenia;
LUSC	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg23625390	chr15:77176239	SCAPER	0.47	7.23	0.37	3.25e-12	Blood metabolite levels;
LUSC	cis	rs7945718	0.839	rs10831911	chr11:12834858	C/T	cg25843174	chr11:12811716	TEAD1	0.3	6.86	0.35	3.26e-11	Educational attainment (years of education);
LUSC	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	8.3	0.41	2.55e-15	Lung cancer in ever smokers;
LUSC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	12.99	0.58	1.61e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg10523679	chr1:76189770	ACADM	-0.49	-7.16	-0.36	5.33e-12	Daytime sleep phenotypes;
LUSC	cis	rs500891	0.553	rs12209499	chr6:84147303	A/G	cg08257003	chr6:84140564	ME1	0.37	9.29	0.45	2.06e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg03474202	chr17:45855739	NA	-0.28	-6.32	-0.33	8.55e-10	IgG glycosylation;
LUSC	cis	rs12519773	0.526	rs6897863	chr5:92512481	A/C	cg18783429	chr5:92414398	NA	0.33	7.02	0.36	1.21e-11	Migraine;
LUSC	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg00898013	chr13:113819073	PROZ	-0.59	-8.68	-0.43	1.72e-16	Platelet distribution width;
LUSC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg05347473	chr6:146136440	FBXO30	0.39	6.61	0.34	1.53e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg11244672	chr19:19639970	YJEFN3	-0.61	-7.59	-0.38	3.3e-13	Bipolar disorder;
LUSC	cis	rs6087990	0.871	rs2424905	chr20:31352927	T/C	cg13636640	chr20:31349939	DNMT3B	1.01	22.53	0.78	5.45e-69	Ulcerative colitis;
LUSC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.3	0.49	8.56e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg18357645	chr12:58087776	OS9	0.52	7.72	0.39	1.32e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg05340658	chr4:99064831	C4orf37	-0.44	-6.98	-0.36	1.65e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2798269	0.867	rs1539562	chr13:22117071	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.41	-6.34	-0.33	7.44e-10	PR segment;
LUSC	cis	rs67981189	0.593	rs8007425	chr14:71508200	A/G	cg15816911	chr14:71606274	NA	0.33	5.86	0.31	1.09e-8	Schizophrenia;
LUSC	cis	rs9653442	0.500	rs72819191	chr2:100826572	A/G	cg07810366	chr2:100720526	AFF3	0.5	7.92	0.4	3.57e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg25894440	chr7:65020034	NA	0.37	5.86	0.31	1.1e-8	Calcium levels;
LUSC	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg04450456	chr4:17643702	FAM184B	0.39	6.53	0.34	2.44e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs367943	0.712	rs26967	chr5:112741467	C/G	cg12552261	chr5:112820674	MCC	0.36	5.95	0.31	6.72e-9	Type 2 diabetes;
LUSC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05165339	chr4:1420672	NA	-0.28	-6.3	-0.33	9.57e-10	Longevity;
LUSC	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	10.41	0.5	3.54e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg06740227	chr12:86229804	RASSF9	0.37	5.84	0.3	1.27e-8	Major depressive disorder;
LUSC	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg13010199	chr12:38710504	ALG10B	0.55	8.5	0.42	6.53e-16	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs12692738	0.526	rs355854	chr2:165628693	T/C	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-7.61	-0.38	2.78e-13	Neuroticism;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg11193173	chr8:99837846	STK3	0.45	6.09	0.32	3.12e-9	Mosquito bite size;
LUSC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.26	11.09	0.52	1.56e-24	Alzheimer's disease (late onset);
LUSC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.69	0.83	1.71e-88	Chronic sinus infection;
LUSC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg16423285	chr20:60520624	NA	-0.47	-5.9	-0.31	8.91e-9	Body mass index;
LUSC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg22903657	chr4:1355424	KIAA1530	-0.49	-8.09	-0.4	1.11e-14	Obesity-related traits;
LUSC	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg21293242	chr8:11204541	TDH	0.32	5.91	0.31	8.27e-9	Retinal vascular caliber;
LUSC	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg18105134	chr13:113819100	PROZ	-0.74	-10.63	-0.5	6.44e-23	Platelet distribution width;
LUSC	cis	rs3930017	1.000	rs3930016	chr7:76720449	A/G	cg15770687	chr7:76625569	PMS2L11	0.42	5.92	0.31	7.83e-9	Body mass index;
LUSC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg12257692	chr3:49977190	RBM6	-0.26	-7.13	-0.36	6.45e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg05901451	chr6:126070800	HEY2	-0.65	-10.2	-0.49	1.88e-21	Brugada syndrome;
LUSC	cis	rs713477	1.000	rs28604440	chr14:55911324	C/T	cg13175173	chr14:55914753	NA	-0.3	-6.31	-0.33	8.72e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg01294253	chr9:136912663	BRD3	-0.36	-6.16	-0.32	2.15e-9	Platelet distribution width;
LUSC	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg04586622	chr2:25135609	ADCY3	0.43	9.16	0.45	5.26e-18	Body mass index;
LUSC	cis	rs28830936	1.000	rs11632424	chr15:42095351	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.77	-0.3	1.78e-8	Diastolic blood pressure;
LUSC	cis	rs6961069	0.645	rs1524596	chr7:80229313	G/C	cg04458919	chr7:80252533	CD36	-0.41	-7.2	-0.37	4.05e-12	Platelet count;
LUSC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.74	-0.3	2.14e-8	Depression;
LUSC	cis	rs9434723	1.000	rs9434723	chr1:9292282	C/T	cg04199779	chr1:9294473	H6PD	0.56	6.48	0.33	3.3e-10	Height;
LUSC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.4	-7.41	-0.38	1.04e-12	Longevity;Endometriosis;
LUSC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg26380479	chr7:97908229	NA	-0.27	-6.06	-0.31	3.66e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg22535103	chr8:58192502	C8orf71	-0.65	-7.32	-0.37	1.89e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg12863693	chr15:85201151	NMB	0.36	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg02569458	chr12:86230093	RASSF9	0.4	6.42	0.33	4.6e-10	Major depressive disorder;
LUSC	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg14631576	chr9:95140430	CENPP	-0.35	-6.15	-0.32	2.24e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg24375607	chr4:120327624	NA	0.78	11.04	0.52	2.38e-24	Corneal astigmatism;
LUSC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg18230493	chr5:56204884	C5orf35	-0.93	-13.72	-0.6	2.66e-34	Initial pursuit acceleration;
LUSC	cis	rs3087591	1.000	rs984125	chr17:29547254	A/G	cg24425628	chr17:29625626	OMG;NF1	0.6	8.94	0.44	2.78e-17	Hip circumference;
LUSC	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.59	-9.27	-0.45	2.29e-18	HDL cholesterol;
LUSC	cis	rs244293	1.000	rs244292	chr17:53230734	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-5.83	-0.3	1.34e-8	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.73	-12.48	-0.56	1.31e-29	Sudden cardiac arrest;
LUSC	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14240646	chr10:27532245	ACBD5	-0.68	-8.2	-0.41	5.35e-15	Breast cancer;
LUSC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.57	0.46	2.47e-19	Mean platelet volume;
LUSC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg03188948	chr7:1209495	NA	0.66	7.29	0.37	2.2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.93	0.35	2.24e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg21251018	chr6:28226885	NKAPL	-0.31	-5.88	-0.31	9.99e-9	Cardiac Troponin-T levels;
LUSC	cis	rs12893668	0.703	rs4906335	chr14:104021141	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.42	-5.79	-0.3	1.65e-8	Reticulocyte count;
LUSC	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-0.97	-15.59	-0.65	1.43e-41	Dupuytren's disease;
LUSC	cis	rs3755132	0.929	rs68147799	chr2:15754346	T/G	cg12888861	chr2:15731646	DDX1	0.52	7.48	0.38	6.45e-13	Wilms tumor;
LUSC	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg04539111	chr16:67997858	SLC12A4	-0.43	-5.68	-0.3	2.96e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs7980799	0.905	rs4244866	chr12:33511983	G/C	cg26384229	chr12:38710491	ALG10B	-0.42	-6.04	-0.31	4.17e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.55	7.56	0.38	3.96e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg11871910	chr12:69753446	YEATS4	0.64	9.73	0.47	7.23e-20	Blood protein levels;
LUSC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg01879757	chr17:41196368	BRCA1	-0.47	-7.18	-0.37	4.53e-12	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg17366294	chr4:99064904	C4orf37	0.59	10.54	0.5	1.24e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2073300	1.000	rs6048803	chr20:23438889	A/G	cg09953122	chr20:23471693	CST8	-0.73	-6.43	-0.33	4.33e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3755132	0.929	rs4668945	chr2:15764078	G/C	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	cis	rs10992471	0.630	rs10992322	chr9:95159196	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.89	-0.35	2.77e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg15605315	chr1:45957053	TESK2	0.39	5.67	0.3	3.12e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs17540621	0.793	rs114980657	chr2:47214280	G/A	cg23978866	chr2:47230407	TTC7A	-0.97	-6.65	-0.34	1.2e-10	Response to statin therapy;
LUSC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18402987	chr7:1209562	NA	0.44	5.92	0.31	8.13e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12101261	0.580	rs3783950	chr14:81448282	C/G	cg06600135	chr14:81408086	NA	-0.45	-7.06	-0.36	9.84e-12	Graves' disease;
LUSC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg16060761	chr17:80687452	NA	-0.53	-8.09	-0.4	1.13e-14	Glycated hemoglobin levels;
LUSC	cis	rs7131987	0.834	rs12228468	chr12:29453610	A/C	cg09582351	chr12:29534625	ERGIC2	0.34	7.05	0.36	1.05e-11	QT interval;
LUSC	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg15654264	chr1:150340011	RPRD2	0.62	10.24	0.49	1.44e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs12900413	0.603	rs2882678	chr15:90299542	A/G	cg24249390	chr15:90295951	MESP1	-0.37	-5.9	-0.31	8.76e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.03	0.58	1.16e-31	Chronic sinus infection;
LUSC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18099408	chr3:52552593	STAB1	-0.4	-6.84	-0.35	3.86e-11	Bipolar disorder;
LUSC	trans	rs3858145	0.588	rs76854765	chr10:70037456	C/T	cg04882175	chr6:131122610	NA	-0.65	-8.7	-0.43	1.51e-16	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUSC	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg16230307	chr14:35515116	FAM177A1	0.78	9.88	0.48	2.39e-20	Psoriasis;
LUSC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg11812906	chr14:75593930	NEK9	-0.65	-10.61	-0.5	7.65e-23	Height;
LUSC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg20302533	chr7:39170763	POU6F2	0.57	9.49	0.46	4.54e-19	IgG glycosylation;
LUSC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.54	0.69	2.89e-49	Chronic sinus infection;
LUSC	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg09835421	chr16:68378352	PRMT7	-0.56	-6.31	-0.33	8.67e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg00376283	chr12:123451042	ABCB9	-0.65	-7.67	-0.39	1.91e-13	Neutrophil percentage of white cells;
LUSC	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs73206853	0.841	rs61663407	chr12:111055128	A/G	cg12870014	chr12:110450643	ANKRD13A	0.69	6.51	0.34	2.76e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg20744362	chr22:50050164	C22orf34	0.4	8.14	0.41	7.66e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-8.37	-0.42	1.57e-15	Gut microbiome composition (summer);
LUSC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg00049323	chr5:472564	LOC25845	-0.44	-6.8	-0.35	4.79e-11	Cystic fibrosis severity;
LUSC	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg12002119	chr2:101014098	CHST10	0.34	5.74	0.3	2.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg04102894	chr7:1000210	NA	-0.27	-6.37	-0.33	6.27e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg05863683	chr7:1912471	MAD1L1	0.31	6.03	0.31	4.24e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg17173187	chr15:85201210	NMB	0.47	8.9	0.44	3.57e-17	Schizophrenia;
LUSC	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg00339695	chr16:24857497	SLC5A11	0.36	6.57	0.34	1.9e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg08508325	chr11:3079039	CARS	0.37	8.32	0.41	2.24e-15	Calcium levels;
LUSC	cis	rs62408225	0.722	rs17712288	chr6:90909157	G/A	cg06866423	chr6:90926672	BACH2	0.41	6.44	0.33	4.09e-10	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.44	-0.42	9.55e-16	Response to antipsychotic treatment;
LUSC	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	12.06	0.55	4.66e-28	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs10946292	0.706	rs6938545	chr6:170435570	T/C	cg17832364	chr10:94847294	NA	0.38	6.26	0.32	1.17e-9	Obesity-related traits;
LUSC	trans	rs11004008	1.000	rs7082950	chr10:55790727	C/T	cg07892413	chr2:129076032	HS6ST1	-0.34	-5.96	-0.31	6.51e-9	Schizophrenia;
LUSC	cis	rs1775715	0.707	rs2065443	chr10:32164236	C/G	cg04359828	chr10:32216031	ARHGAP12	0.39	6.66	0.34	1.14e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.69	-11.21	-0.52	5.76e-25	Sudden cardiac arrest;
LUSC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.32	-6.71	-0.34	8.19e-11	Dupuytren's disease;
LUSC	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg24531977	chr5:56204891	C5orf35	-0.54	-7.92	-0.4	3.5e-14	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg03474202	chr17:45855739	NA	-0.28	-6.43	-0.33	4.3e-10	IgG glycosylation;
LUSC	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.36	-0.42	1.77e-15	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.47	-8.29	-0.41	2.78e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg22491629	chr6:157744540	C6orf35	-0.85	-10.38	-0.49	4.48e-22	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg06521331	chr12:34319734	NA	0.4	6.24	0.32	1.36e-9	Morning vs. evening chronotype;
LUSC	cis	rs17021463	0.966	rs10856908	chr4:95222755	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.42	-0.42	1.15e-15	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.86	-0.35	3.41e-11	Lung cancer;
LUSC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg21535247	chr6:8435926	SLC35B3	0.56	8.81	0.43	7.17e-17	Motion sickness;
LUSC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg20821713	chr7:1055600	C7orf50	-0.49	-6.56	-0.34	2.01e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs10465746	0.780	rs11163862	chr1:84355418	A/T	cg10977910	chr1:84465055	TTLL7	-0.48	-6.88	-0.35	2.9100000000000002e-11	Obesity-related traits;
LUSC	cis	rs4072705	0.646	rs915032	chr9:127245682	G/C	cg13476313	chr9:127244764	NR5A1	0.33	6.36	0.33	6.81e-10	Menarche (age at onset);
LUSC	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.93	0.4	3.39e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.46	-8.13	-0.41	8.35e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg26043149	chr18:55253948	FECH	-0.45	-6.92	-0.35	2.27e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg17294928	chr15:75287854	SCAMP5	-0.71	-6.45	-0.33	3.89e-10	Lung cancer;
LUSC	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg20587970	chr11:113659929	NA	-1.19	-16.26	-0.66	3.23e-44	Hip circumference adjusted for BMI;
LUSC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg00012203	chr2:219082015	ARPC2	0.68	11.08	0.52	1.64e-24	Colorectal cancer;
LUSC	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg01884057	chr2:25150051	NA	0.42	9.71	0.47	8.31e-20	Body mass index;
LUSC	cis	rs6558174	0.863	rs17746902	chr8:22491980	A/C	cg03733263	chr8:22462867	KIAA1967	-0.46	-6.44	-0.33	4.08e-10	Breast cancer;
LUSC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.89	0.35	2.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7572644	0.656	rs4666018	chr2:28042059	C/T	cg27432699	chr2:27873401	GPN1	0.58	7.36	0.37	1.47e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.99	0.36	1.49e-11	Height;
LUSC	cis	rs3916	0.955	rs35771722	chr12:121154000	A/G	cg27246729	chr12:121163418	ACADS	0.5	7.25	0.37	2.99e-12	Urinary metabolites (H-NMR features);
LUSC	cis	rs2040771	0.770	rs9605962	chr22:19233615	C/T	cg02655711	chr22:19163373	SLC25A1	0.47	8.41	0.42	1.23e-15	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.54	8.7	0.43	1.49e-16	Breast cancer;
LUSC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg23711669	chr6:146136114	FBXO30	0.92	17.68	0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6681460	0.546	rs1359462	chr1:67169201	C/A	cg02459107	chr1:67143332	SGIP1	0.34	5.98	0.31	5.75e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg21064579	chr19:49206444	FUT2	0.44	8.44	0.42	9.61e-16	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
LUSC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-10.96	-0.51	4.35e-24	Gut microbiome composition (summer);
LUSC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg26441486	chr22:50317300	CRELD2	0.5	7.66	0.39	2.08e-13	Schizophrenia;
LUSC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg04733989	chr22:42467013	NAGA	-0.62	-9.72	-0.47	7.81e-20	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.38	0.62	8.18e-37	Platelet count;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg27275115	chr18:10526342	NAPG	0.46	6.74	0.35	7.09e-11	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7173743	0.935	rs12232282	chr15:79136525	T/C	cg00540400	chr15:79124168	NA	-0.33	-5.74	-0.3	2.12e-8	Coronary artery disease;
LUSC	cis	rs35063026	1.000	rs35063026	chr16:89736157	C/T	cg07984980	chr16:89898383	SPIRE2	0.92	7.63	0.39	2.46e-13	Facial pigmentation;Squamous cell carcinoma;
LUSC	cis	rs9303280	0.587	rs35123741	chr17:38092930	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.36	-5.91	-0.31	8.22e-9	Self-reported allergy;
LUSC	cis	rs1881396	0.783	rs10181342	chr2:27757343	A/G	cg27432699	chr2:27873401	GPN1	0.67	9.19	0.45	4.39e-18	Nonalcoholic fatty liver disease;
LUSC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg26380479	chr7:97908229	NA	-0.27	-6.14	-0.32	2.28e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs800082	0.516	rs1178895	chr3:144240563	G/T	cg24215973	chr2:240111563	HDAC4	0.44	6.81	0.35	4.59e-11	Smoking behavior;
LUSC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.91	-0.51	6.79e-24	Alzheimer's disease;
LUSC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.44	0.62	4.62e-37	Platelet count;
LUSC	cis	rs12912251	0.947	rs7165988	chr15:38988815	C/G	cg01338139	chr15:38987640	C15orf53	-0.5	-6.83	-0.35	3.95e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs12928939	0.769	rs1056303	chr16:71670066	C/T	cg08717414	chr16:71523259	ZNF19	-0.41	-5.8	-0.3	1.52e-8	Post bronchodilator FEV1;
LUSC	cis	rs354225	0.539	rs10175967	chr2:54931457	T/C	cg26097391	chr2:54893211	SPTBN1	0.46	6.1	0.32	2.95e-9	Schizophrenia;
LUSC	cis	rs7178572	1.000	rs1565756	chr15:77741640	G/A	cg22256960	chr15:77711686	NA	-0.54	-9.13	-0.45	6.77e-18	Type 2 diabetes;
LUSC	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24531977	chr5:56204891	C5orf35	-0.89	-13.72	-0.6	2.83e-34	Initial pursuit acceleration;
LUSC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08859206	chr1:53392774	SCP2	-0.52	-8.87	-0.44	4.52e-17	Monocyte count;
LUSC	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	17.46	0.69	5.73e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.77	-0.3	1.82e-8	Alzheimer's disease (survival time);
LUSC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg05425664	chr17:57184151	TRIM37	-0.56	-8.28	-0.41	2.93e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-9.42	-0.46	7.58e-19	Gut microbiome composition (summer);
LUSC	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg20368463	chr18:77673604	PQLC1	-0.63	-6.89	-0.35	2.76e-11	Opioid sensitivity;
LUSC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg18352616	chr4:3374830	RGS12	0.31	6.26	0.32	1.16e-9	Serum sulfate level;
LUSC	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg11789530	chr4:8429930	ACOX3	-0.41	-5.95	-0.31	6.71e-9	Response to antineoplastic agents;
LUSC	cis	rs240764	0.680	rs12209777	chr6:101156639	G/A	cg09795085	chr6:101329169	ASCC3	-0.41	-5.88	-0.31	1e-8	Neuroticism;
LUSC	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg10820045	chr2:198174542	NA	-0.33	-6.06	-0.31	3.73e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg13385521	chr17:29058706	SUZ12P	0.7	6.91	0.35	2.44e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.47	-7.27	-0.37	2.53e-12	Insulin-like growth factors;
LUSC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg03806693	chr22:41940476	POLR3H	0.99	14.24	0.61	2.63e-36	Vitiligo;
LUSC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.6	0.46	2.01e-19	Mean platelet volume;
LUSC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.58	-7.85	-0.39	5.86e-14	High light scatter reticulocyte count;
LUSC	cis	rs7000551	0.751	rs2449340	chr8:22389900	T/G	cg12081754	chr8:22256438	SLC39A14	0.47	7.04	0.36	1.11e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.76	0.3	1.89e-8	Breast cancer;
LUSC	trans	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.32	-0.37	1.9e-12	Triglycerides;
LUSC	cis	rs68170813	0.559	rs4730223	chr7:106814234	A/T	cg02696742	chr7:106810147	HBP1	0.65	9.89	0.48	2.08e-20	Coronary artery disease;
LUSC	cis	rs2820315	0.867	rs2819348	chr1:201884952	T/C	cg10061532	chr1:201886748	LMOD1	0.29	6.78	0.35	5.37e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.63	-0.43	2.52e-16	Rheumatoid arthritis;
LUSC	cis	rs977987	0.806	rs11642572	chr16:75452782	C/T	cg03315344	chr16:75512273	CHST6	0.49	9.1	0.45	8.63e-18	Dupuytren's disease;
LUSC	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg21770322	chr7:97807741	LMTK2	-0.48	-8.43	-0.42	1.03e-15	Breast cancer;
LUSC	cis	rs2070433	0.500	rs9306156	chr21:47960493	T/C	cg12379764	chr21:47803548	PCNT	0.72	10.93	0.51	5.73e-24	Lymphocyte counts;
LUSC	trans	rs61931739	0.591	rs4931764	chr12:33979423	A/G	cg13010199	chr12:38710504	ALG10B	0.39	5.98	0.31	5.79e-9	Morning vs. evening chronotype;
LUSC	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-1.24	-18.99	-0.72	4.75e-55	Blood pressure (smoking interaction);
LUSC	cis	rs78707713	0.535	rs3812705	chr10:71211146	A/G	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.46	-0.46	5.56e-19	Venous thromboembolism;
LUSC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg01802117	chr1:53393560	SCP2	0.38	6.32	0.33	8.48e-10	Monocyte count;
LUSC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.46e-12	Motion sickness;
LUSC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg05552183	chr6:42928497	GNMT	0.49	8.17	0.41	6.42e-15	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs6960043	1.000	rs6980437	chr7:15054916	T/G	cg19272540	chr7:15055459	NA	-0.33	-8.04	-0.4	1.63e-14	Type 2 diabetes;
LUSC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.51	0.65	3.1e-41	Platelet count;
LUSC	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.82	-0.47	3.7e-20	Total cholesterol levels;
LUSC	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg22117172	chr7:91764530	CYP51A1	0.32	5.8	0.3	1.51e-8	Breast cancer;
LUSC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	11.05	0.52	2.15e-24	Lung cancer in ever smokers;
LUSC	trans	rs13424581	1.000	rs7589474	chr2:225727431	C/T	cg12623045	chr10:135067449	NA	-0.47	-6.08	-0.32	3.25e-9	Platelet distribution width;
LUSC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-10.64	-0.5	5.73e-23	Bipolar disorder;
LUSC	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.51	-0.34	2.68e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg27411982	chr8:10470053	RP1L1	-0.36	-5.73	-0.3	2.25e-8	Retinal vascular caliber;
LUSC	cis	rs2835872	0.965	rs73222314	chr21:39014802	A/G	cg20424643	chr21:39039972	KCNJ6	0.43	6.52	0.34	2.67e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.81	-0.47	4e-20	Multiple sclerosis;
LUSC	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg00277334	chr10:82204260	NA	-0.52	-7.69	-0.39	1.65e-13	Post bronchodilator FEV1;
LUSC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	trans	rs7939886	0.764	rs11227350	chr11:55912289	T/C	cg03929089	chr4:120376271	NA	0.77	6.09	0.32	3.03e-9	Myopia (pathological);
LUSC	cis	rs677665	0.537	rs72641831	chr1:9335173	G/T	cg25755851	chr1:9335794	NA	0.8	12.78	0.57	1.02e-30	Eosinophil percentage of white cells;
LUSC	cis	rs4474465	0.850	rs7112872	chr11:78227396	C/A	cg27205649	chr11:78285834	NARS2	0.5	5.75	0.3	2.03e-8	Alzheimer's disease (survival time);
LUSC	trans	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg06521331	chr12:34319734	NA	0.41	6.5	0.34	2.93e-10	Morning vs. evening chronotype;
LUSC	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.7	10.51	0.5	1.6400000000000001e-22	Dilated cardiomyopathy;
LUSC	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.35	2.06e-11	Monocyte percentage of white cells;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg00417297	chr3:40518742	ZNF619	0.41	6.32	0.33	8.19e-10	Schizophrenia;
LUSC	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg00792783	chr2:198669748	PLCL1	0.43	5.86	0.31	1.12e-8	Dermatomyositis;
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.88	17.16	0.68	9.06e-48	Menarche (age at onset);
LUSC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	10.06	0.48	5.6e-21	Hip circumference adjusted for BMI;
LUSC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg16850897	chr7:100343110	ZAN	-0.61	-8.09	-0.4	1.12e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs11214589	0.905	rs10891539	chr11:113236492	G/C	cg14159747	chr11:113255604	NA	0.28	7.1	0.36	7.74e-12	Neuroticism;
LUSC	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.33e-21	Lymphocyte counts;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15065069	chr1:154974120	ZBTB7B	-0.46	-7.0	-0.36	1.39e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.74	11.3	0.53	2.7e-25	Tonsillectomy;
LUSC	cis	rs9650315	0.866	rs13275320	chr8:57193032	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	6.39	0.33	5.64e-10	Height;
LUSC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg03146154	chr1:46216737	IPP	-0.55	-8.08	-0.4	1.22e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs897984	0.609	rs732172	chr16:31050033	C/T	cg02466173	chr16:30829666	NA	-0.54	-10.37	-0.49	5.05e-22	Dementia with Lewy bodies;
LUSC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg15448220	chr1:150897856	SETDB1	0.42	6.02	0.31	4.48e-9	Melanoma;
LUSC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.29	0.33	1.02e-9	Menopause (age at onset);
LUSC	cis	rs922692	1.000	rs12901913	chr15:78981348	C/T	cg00540400	chr15:79124168	NA	-0.34	-5.67	-0.3	3.13e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.73	0.35	7.58e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg20573242	chr4:122745356	CCNA2	0.52	7.62	0.38	2.67e-13	Type 2 diabetes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01538984	chr7:140396422	LOC100134713;NDUFB2	0.46	6.55	0.34	2.14e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg18301423	chr5:131593218	PDLIM4	0.38	6.19	0.32	1.74e-9	Blood metabolite levels;
LUSC	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg23202291	chr11:1979235	NA	0.38	5.92	0.31	8.08e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.39	-0.33	5.44e-10	Type 2 diabetes;
LUSC	cis	rs6138458	0.626	rs6138473	chr20:25012155	A/G	cg26195577	chr20:24973756	C20orf3	-0.77	-11.84	-0.54	3.05e-27	Blood protein levels;
LUSC	cis	rs9815354	0.767	rs17280980	chr3:41810949	A/T	cg03022575	chr3:42003672	ULK4	0.85	8.65	0.43	2.23e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4380275	0.782	rs4335978	chr2:750078	A/G	cg21665850	chr2:731073	NA	0.34	5.66	0.3	3.3e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.54	-7.53	-0.38	4.79e-13	Gut microbiome composition (winter);
LUSC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg15445000	chr17:37608096	MED1	0.39	6.71	0.34	8.49e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs17253792	0.822	rs78826571	chr14:56048906	G/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	8.91e-12	Putamen volume;
LUSC	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.77	-0.43	9.17e-17	Response to antipsychotic treatment;
LUSC	cis	rs12137294	0.866	rs896320	chr1:205205347	T/C	cg21643547	chr1:205240462	TMCC2	-0.36	-6.46	-0.33	3.74e-10	Red cell distribution width;
LUSC	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg17385448	chr1:15911702	AGMAT	0.38	5.83	0.3	1.29e-8	Systolic blood pressure;
LUSC	cis	rs897984	0.520	rs4889614	chr16:30862135	G/A	cg02466173	chr16:30829666	NA	0.55	9.26	0.45	2.55e-18	Dementia with Lewy bodies;
LUSC	cis	rs6688613	0.685	rs10918599	chr1:166918786	T/C	cg07049167	chr1:166818506	POGK	0.41	5.85	0.3	1.18e-8	Refractive astigmatism;
LUSC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08677398	chr8:58056175	NA	0.53	7.1	0.36	7.61e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1028488	0.535	rs9460109	chr6:170618195	C/T	cg20370364	chr6:170703943	FAM120B	-0.51	-7.88	-0.4	4.54e-14	Interferon alpha levels in systemic lupus erythematosus;
LUSC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.96	0.36	1.81e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.7	10.91	0.51	6.34e-24	Breast cancer;
LUSC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg01528321	chr10:82214614	TSPAN14	0.62	8.94	0.44	2.67e-17	Post bronchodilator FEV1;
LUSC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg01125463	chr6:42946178	PEX6	-0.36	-5.96	-0.31	6.4e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19717773	chr7:2847554	GNA12	-0.41	-6.45	-0.33	3.87e-10	Height;
LUSC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.47	6.16	0.32	2.12e-9	Renal function-related traits (BUN);
LUSC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08677398	chr8:58056175	NA	0.52	6.33	0.33	7.78e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2109514	0.967	rs4730743	chr7:116145957	A/T	cg12739419	chr7:116140593	CAV2	-0.28	-6.3	-0.33	9.46e-10	Prevalent atrial fibrillation;
LUSC	cis	rs17094222	0.504	rs4917904	chr10:102447292	G/A	cg04918978	chr10:102441148	NA	-0.39	-5.65	-0.3	3.53e-8	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24110177	chr3:50126178	RBM5	0.65	11.68	0.54	1.14e-26	Body mass index;
LUSC	cis	rs1185460	0.565	rs1182922	chr11:118932859	G/A	cg01677386	chr11:118938358	VPS11	0.41	5.74	0.3	2.15e-8	Coronary artery disease;
LUSC	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.31	0.45	1.77e-18	Blood protein levels;
LUSC	cis	rs354225	0.544	rs3796019	chr2:54807279	G/A	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg12386194	chr3:101231763	SENP7	-0.52	-7.3	-0.37	2.08e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg11663144	chr21:46675770	NA	-0.38	-6.62	-0.34	1.43e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6960043	0.620	rs11760782	chr7:15064788	A/T	cg19272540	chr7:15055459	NA	0.34	7.9	0.4	4.17e-14	Type 2 diabetes;
LUSC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg06484146	chr7:12443880	VWDE	-0.69	-7.35	-0.37	1.53e-12	Coronary artery disease;
LUSC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg14895029	chr7:2775587	GNA12	-0.4	-6.07	-0.32	3.38e-9	Height;
LUSC	trans	rs11949289	0.935	rs61390992	chr5:28336243	T/C	cg18220921	chr1:242687527	PLD5	0.35	5.96	0.31	6.44e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6496044	1.000	rs6496044	chr15:86067306	G/A	cg13263323	chr15:86062960	AKAP13	-0.37	-5.88	-0.31	9.99e-9	Interstitial lung disease;
LUSC	cis	rs7598759	0.679	rs6437018	chr2:232327691	A/C	cg19187155	chr2:232395269	NMUR1	0.49	7.16	0.36	5.16e-12	Noise-induced hearing loss;
LUSC	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg00012203	chr2:219082015	ARPC2	0.81	14.41	0.62	6.1e-37	Colorectal cancer;
LUSC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.48	7.83	0.39	6.52e-14	Vitiligo;
LUSC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11645453	chr3:52864694	ITIH4	0.34	8.09	0.4	1.13e-14	Bipolar disorder;
LUSC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg16797656	chr11:68205561	LRP5	-0.4	-7.26	-0.37	2.7e-12	Total body bone mineral density;
LUSC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg19318889	chr4:1322082	MAEA	0.45	7.28	0.37	2.42e-12	Obesity-related traits;
LUSC	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg05110241	chr16:68378359	PRMT7	-0.6	-6.75	-0.35	6.37e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg04586622	chr2:25135609	ADCY3	0.32	6.17	0.32	1.94e-9	Body mass index;
LUSC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg09034736	chr1:150693464	HORMAD1	0.49	7.15	0.36	5.43e-12	Tonsillectomy;
LUSC	cis	rs9467773	0.595	rs3799379	chr6:26404694	C/T	cg05738196	chr6:26577821	NA	-0.49	-7.01	-0.36	1.34e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.68	10.76	0.51	2.15e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.37	0.33	6.34e-10	Corneal astigmatism;
LUSC	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg04607235	chr12:12878440	APOLD1	-0.95	-15.54	-0.65	2.25e-41	Lymphocyte counts;
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg27094323	chr7:1216898	NA	-0.44	-7.57	-0.38	3.79e-13	Longevity;Endometriosis;
LUSC	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg23625390	chr15:77176239	SCAPER	0.46	7.02	0.36	1.23e-11	Blood metabolite levels;
LUSC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg06713675	chr4:122721982	EXOSC9	-0.45	-8.02	-0.4	1.86e-14	Type 2 diabetes;
LUSC	cis	rs28785552	0.800	rs10853854	chr19:53232128	A/G	cg22067481	chr19:53234126	ZNF611	0.51	7.16	0.36	5.18e-12	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg05347473	chr6:146136440	FBXO30	0.53	9.07	0.44	1.08e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1178968	0.901	rs1178970	chr7:72750345	G/A	cg25889504	chr7:72793014	NA	0.59	7.91	0.4	3.86e-14	Triglyceride levels;
LUSC	cis	rs870825	0.860	rs62339895	chr4:185598681	A/G	cg04058563	chr4:185651563	MLF1IP	-0.82	-12.3	-0.56	6.24e-29	Blood protein levels;
LUSC	cis	rs17401966	0.798	rs12408435	chr1:10323342	T/A	cg19773385	chr1:10388646	KIF1B	-0.55	-8.72	-0.43	1.36e-16	Hepatocellular carcinoma;
LUSC	cis	rs983392	0.868	rs7926954	chr11:59932579	G/A	cg02771260	chr11:59836817	MS4A3	-0.36	-5.8	-0.3	1.55e-8	Alzheimer's disease (late onset);
LUSC	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.68	9.95	0.48	1.33e-20	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.51	7.79	0.39	8.28e-14	Testicular germ cell tumor;
LUSC	cis	rs3820928	0.839	rs58580037	chr2:227876274	G/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.93	-0.4	3.36e-14	Pulmonary function;
LUSC	cis	rs981844	0.712	rs11099915	chr4:154743624	A/G	cg14289246	chr4:154710475	SFRP2	-0.44	-6.11	-0.32	2.82e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg12432903	chr7:1882776	MAD1L1	0.51	6.25	0.32	1.23e-9	Bipolar disorder;
LUSC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.58	-9.46	-0.46	5.77e-19	Aortic root size;
LUSC	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.6	10.05	0.48	6.31e-21	Birth weight;
LUSC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg12463550	chr7:65579703	CRCP	0.44	6.5	0.33	3.01e-10	Aortic root size;
LUSC	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.47	-6.32	-0.33	8.59e-10	Schizophrenia;
LUSC	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.48	7.12	0.36	6.82e-12	Neuroticism;
LUSC	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.62	-6.43	-0.33	4.33e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06022373	chr22:39101656	GTPBP1	0.84	13.32	0.59	8.97e-33	Menopause (age at onset);
LUSC	cis	rs6700896	0.931	rs12034502	chr1:66099831	C/T	cg04111102	chr1:66153794	NA	0.32	7.08	0.36	8.57e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	0.62	7.25	0.37	2.94e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.58	9.91	0.48	1.8899999999999998e-20	DNA methylation (variation);
LUSC	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23158103	chr7:148848205	ZNF398	-0.46	-6.8	-0.35	4.82e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg04850211	chr1:228464232	OBSCN	-0.32	-5.81	-0.3	1.43e-8	Diastolic blood pressure;
LUSC	cis	rs9420	0.961	rs2847308	chr11:57498232	C/T	cg02958346	chr11:57425731	CLP1	0.42	6.12	0.32	2.64e-9	Schizophrenia;
LUSC	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.97	19.37	0.73	1.45e-56	Diastolic blood pressure;
LUSC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.45	7.08	0.36	8.72e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.6	-9.19	-0.45	4.36e-18	Morning vs. evening chronotype;
LUSC	cis	rs977987	0.806	rs1544810	chr16:75411163	A/T	cg04384234	chr16:75411784	CFDP1	-0.42	-7.0	-0.36	1.39e-11	Dupuytren's disease;
LUSC	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg22532475	chr10:104410764	TRIM8	-0.26	-6.12	-0.32	2.61e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg01657329	chr11:68192670	LRP5	-0.42	-6.3	-0.33	9.42e-10	Total body bone mineral density;
LUSC	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.17	0.32	1.95e-9	Recombination rate (females);
LUSC	cis	rs9807841	0.617	rs892087	chr19:10794793	C/T	cg17710535	chr19:10819994	QTRT1	0.42	6.91	0.35	2.51e-11	Inflammatory skin disease;
LUSC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	10.13	0.48	3.21e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg03526776	chr6:41159608	TREML2	0.33	6.19	0.32	1.74e-9	Alzheimer's disease (late onset);
LUSC	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg26384229	chr12:38710491	ALG10B	0.68	10.61	0.5	7.34e-23	Morning vs. evening chronotype;
LUSC	cis	rs2835872	0.828	rs702858	chr21:38995169	A/G	cg20424643	chr21:39039972	KCNJ6	-0.38	-5.94	-0.31	7.07e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs12618769	0.625	rs3769717	chr2:99124817	G/A	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg24642844	chr7:1081250	C7orf50	-0.71	-10.09	-0.48	4.57e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg08888203	chr3:10149979	C3orf24	-0.59	-8.33	-0.41	2.15e-15	Alzheimer's disease;
LUSC	cis	rs12681287	0.547	rs11992656	chr8:87534869	T/A	cg27223183	chr8:87520930	FAM82B	0.53	6.99	0.36	1.54e-11	Caudate activity during reward;
LUSC	cis	rs2274459	0.841	rs10456075	chr6:33681603	G/A	cg06253072	chr6:33679850	C6orf125	0.48	5.82	0.3	1.39e-8	Obesity (extreme);
LUSC	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.52	0.34	2.67e-10	Testicular germ cell tumor;
LUSC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.16	0.68	8.7e-48	Chronic sinus infection;
LUSC	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.08	0.52	1.68e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	13.9	0.61	5.42e-35	Platelet count;
LUSC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg21770322	chr7:97807741	LMTK2	0.41	7.13	0.36	6.18e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg05043794	chr9:111880884	C9orf5	-0.35	-7.32	-0.37	1.87e-12	Menarche (age at onset);
LUSC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg14019146	chr3:50243930	SLC38A3	-0.33	-7.37	-0.37	1.31e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22278056	chr19:44439434	NA	0.45	6.59	0.34	1.72e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.43	0.33	4.37e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs629535	0.814	rs571682	chr8:70062793	A/G	cg21567404	chr3:27674614	NA	0.96	15.28	0.64	2.49e-40	Dupuytren's disease;
LUSC	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg06207120	chr15:45996521	NA	0.4	6.22	0.32	1.5e-9	Waist circumference;Weight;
LUSC	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	7.36	0.37	1.49e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg17294928	chr15:75287854	SCAMP5	-0.76	-10.12	-0.48	3.67e-21	Blood trace element (Zn levels);
LUSC	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg06223162	chr1:101003688	GPR88	0.49	9.35	0.46	1.26e-18	Monocyte count;
LUSC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.76	-0.43	1.02e-16	Gut microbiome composition (summer);
LUSC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg20821713	chr7:1055600	C7orf50	-0.48	-6.53	-0.34	2.46e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg22906224	chr7:99728672	NA	-0.5	-6.95	-0.36	1.91e-11	Coronary artery disease;
LUSC	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg26384229	chr12:38710491	ALG10B	-0.79	-13.28	-0.59	1.33e-32	Morning vs. evening chronotype;
LUSC	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg03161606	chr19:29218774	NA	0.49	5.94	0.31	7.3e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.54	-6.85	-0.35	3.59e-11	Chronic sinus infection;
LUSC	cis	rs9650315	0.929	rs6987156	chr8:57169465	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.12	0.36	6.82e-12	Height;
LUSC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.02	0.58	1.31e-31	Cognitive test performance;
LUSC	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.84	-15.73	-0.65	4.07e-42	Heart rate;
LUSC	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg22709100	chr7:91322751	NA	0.41	5.91	0.31	8.64e-9	Breast cancer;
LUSC	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg10434728	chr15:90938212	IQGAP1	0.37	7.89	0.4	4.44e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs9837602	1.000	rs6802422	chr3:99778655	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	5.67	0.3	3.17e-8	Breast cancer;
LUSC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.88	15.23	0.64	3.86e-40	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17712092	chr4:129076599	LARP1B	0.81	12.19	0.55	1.59e-28	Eosinophil percentage of white cells;
LUSC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.82	11.57	0.53	3.03e-26	Chronic sinus infection;
LUSC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.8	0.35	4.92e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2235649	0.552	rs7203361	chr16:1963085	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-5.75	-0.3	2e-8	Blood metabolite levels;
LUSC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg22166914	chr1:53195759	ZYG11B	0.56	9.13	0.45	6.88e-18	Monocyte count;
LUSC	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.3	6.07	0.32	3.56e-9	Lymphocyte counts;
LUSC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg23711669	chr6:146136114	FBXO30	-0.9	-17.01	-0.68	3.67e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28647808	0.881	rs7029386	chr9:136263736	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg00012203	chr2:219082015	ARPC2	-0.54	-8.51	-0.42	5.99e-16	Ulcerative colitis;
LUSC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.32	-6.26	-0.32	1.16e-9	Total body bone mineral density;
LUSC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.26e-25	Gut microbiome composition (summer);
LUSC	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg04733989	chr22:42467013	NAGA	-0.38	-6.41	-0.33	5.02e-10	Cognitive function;
LUSC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.13	0.55	2.54e-28	Cognitive test performance;
LUSC	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	6.78	0.35	5.49e-11	Menarche (age at onset);
LUSC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg14789911	chr21:47582049	C21orf56	-0.37	-5.65	-0.3	3.38e-8	Testicular germ cell tumor;
LUSC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg01802117	chr1:53393560	SCP2	-0.39	-6.52	-0.34	2.55e-10	Monocyte count;
LUSC	cis	rs1506636	0.886	rs4731112	chr7:123269118	C/G	cg03229431	chr7:123269106	ASB15	-0.7	-11.73	-0.54	7.66e-27	Plateletcrit;Platelet count;
LUSC	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg14664628	chr15:75095509	CSK	-0.45	-6.49	-0.33	3.02e-10	Systemic lupus erythematosus;
LUSC	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.0	0.52	3.3e-24	Fuchs's corneal dystrophy;
LUSC	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.17	-0.41	6.28e-15	Neuroticism;
LUSC	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-1.24	-18.99	-0.72	4.75e-55	Blood pressure (smoking interaction);
LUSC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg18479299	chr3:125709523	NA	-0.51	-5.87	-0.31	1.05e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.56e-13	Motion sickness;
LUSC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.27	-0.45	2.34e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs3768617	0.811	rs61808068	chr1:182979377	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.42	0.42	1.12e-15	Fuchs's corneal dystrophy;
LUSC	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg26597838	chr10:835615	NA	0.64	8.08	0.4	1.21e-14	Eosinophil percentage of granulocytes;
LUSC	cis	rs10170846	0.893	rs12614976	chr2:223542896	A/T	cg25565276	chr2:223520875	FARSB	0.62	9.38	0.46	1.02e-18	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs75804782	0.521	rs72982598	chr2:239455052	G/A	cg18131467	chr2:239335373	ASB1	-0.63	-6.01	-0.31	4.74e-9	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-8.15	-0.41	7.42e-15	Blood pressure (smoking interaction);
LUSC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg20203395	chr5:56204925	C5orf35	-0.44	-6.45	-0.33	4e-10	Coronary artery disease;
LUSC	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg20608306	chr11:116969690	SIK3	0.37	6.92	0.35	2.32e-11	Blood protein levels;
LUSC	cis	rs57994353	0.566	rs10870160	chr9:139312996	C/T	cg14019695	chr9:139328340	INPP5E	0.36	5.67	0.3	3.1e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUSC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.5	-0.38	5.88e-13	Morning vs. evening chronotype;
LUSC	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg20476159	chr18:77451067	CTDP1	-0.32	-5.74	-0.3	2.15e-8	Monocyte count;
LUSC	trans	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg04995722	chr7:26192034	NFE2L3	-0.38	-6.35	-0.33	7.18e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12618769	1.000	rs72825719	chr2:99247465	C/T	cg10123293	chr2:99228465	UNC50	0.43	5.89	0.31	9.65e-9	Bipolar disorder;
LUSC	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg24562669	chr7:97807699	LMTK2	0.48	8.56	0.42	4.18e-16	Breast cancer;
LUSC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1493916	0.837	rs9945976	chr18:31409314	C/T	cg27147174	chr7:100797783	AP1S1	-0.55	-8.73	-0.43	1.21e-16	Life satisfaction;
LUSC	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	10.33	0.49	7.13e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.5	-6.84	-0.35	3.88e-11	Mean platelet volume;
LUSC	cis	rs6977660	1.000	rs12673970	chr7:19813018	T/C	cg05791153	chr7:19748676	TWISTNB	0.55	6.14	0.32	2.31e-9	Thyroid stimulating hormone;
LUSC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.67	-10.61	-0.5	7.68e-23	Menarche (age at onset);
LUSC	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg26354017	chr1:205819088	PM20D1	-0.39	-5.68	-0.3	2.98e-8	Prostate-specific antigen levels;
LUSC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.53	-0.34	2.45e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg01802117	chr1:53393560	SCP2	0.38	6.2	0.32	1.62e-9	Monocyte count;
LUSC	cis	rs3862435	0.518	rs2601170	chr15:90914209	C/T	cg22089800	chr15:90895588	ZNF774	0.59	6.3	0.33	9.65e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg02574844	chr11:5959923	NA	-0.47	-6.75	-0.35	6.74e-11	DNA methylation (variation);
LUSC	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg20587970	chr11:113659929	NA	-1.15	-15.81	-0.65	1.98e-42	Hip circumference adjusted for BMI;
LUSC	cis	rs6669072	0.528	rs3856226	chr1:91245109	C/T	cg08895590	chr1:91227319	NA	0.29	6.14	0.32	2.28e-9	Cognitive function;
LUSC	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg06713675	chr4:122721982	EXOSC9	0.38	6.11	0.32	2.78e-9	Type 2 diabetes;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	0.99	22.3	0.77	4.09e-68	Menarche (age at onset);
LUSC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13126279	chr21:47581558	C21orf56	-0.55	-8.49	-0.42	6.82e-16	Testicular germ cell tumor;
LUSC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg20891283	chr12:69753455	YEATS4	0.44	5.78	0.3	1.67e-8	Response to diuretic therapy;
LUSC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	0.77	13.25	0.59	1.65e-32	Cognitive function;
LUSC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg09365446	chr1:150670422	GOLPH3L	0.46	6.74	0.35	7.09e-11	Melanoma;
LUSC	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg05855489	chr10:104503620	C10orf26	0.52	7.96	0.4	2.64e-14	Arsenic metabolism;
LUSC	cis	rs35995292	0.534	rs13228087	chr7:38909204	A/C	cg19327137	chr7:38886074	VPS41	0.53	10.02	0.48	7.82e-21	Subjective well-being (multi-trait analysis);
LUSC	cis	rs7605827	0.893	rs1024871	chr2:15626162	C/T	cg19274914	chr2:15703543	NA	0.46	8.87	0.44	4.51e-17	Educational attainment (years of education);
LUSC	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg10857441	chr5:6722123	POLS	-0.44	-8.05	-0.4	1.45e-14	Menopause (age at onset);
LUSC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg19318889	chr4:1322082	MAEA	-0.54	-8.89	-0.44	3.92e-17	Obesity-related traits;
LUSC	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg21681030	chr2:46777652	RHOQ	0.49	6.77	0.35	5.74e-11	Height;
LUSC	cis	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg13636640	chr20:31349939	DNMT3B	-0.81	-15.5	-0.65	3.37e-41	Inflammatory bowel disease;
LUSC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg11502198	chr6:26597334	ABT1	0.64	10.06	0.48	5.52e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2639990	1.000	rs609303	chr18:72895242	C/T	cg03972071	chr18:72917163	ZADH2	0.46	5.79	0.3	1.63e-8	Vascular endothelial growth factor levels;
LUSC	cis	rs9815354	0.812	rs17214945	chr3:41808660	A/C	cg03022575	chr3:42003672	ULK4	0.8	8.84	0.44	5.75e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1941023	0.606	rs3825020	chr11:60184191	G/A	cg08716584	chr11:60157161	MS4A7	-0.56	-10.26	-0.49	1.16e-21	Congenital heart disease (maternal effect);
LUSC	cis	rs41271951	0.512	rs12058128	chr1:151106113	C/T	cg11822372	chr1:151115635	SEMA6C	-0.74	-6.74	-0.35	7.15e-11	Blood protein levels;
LUSC	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg01851573	chr8:8652454	MFHAS1	0.58	8.5	0.42	6.24e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6977660	0.619	rs10231972	chr7:19789354	C/G	cg07541023	chr7:19748670	TWISTNB	0.59	6.77	0.35	5.76e-11	Thyroid stimulating hormone;
LUSC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg06238570	chr21:40685208	BRWD1	-0.52	-8.04	-0.4	1.63e-14	Menarche (age at onset);
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg04000159	chr8:54755598	ATP6V1H	-0.49	-5.99	-0.31	5.39e-9	Height;
LUSC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg03563238	chr19:33554763	RHPN2	-0.37	-6.19	-0.32	1.74e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs3790645	1.000	rs657227	chr1:26892104	T/A	cg17456097	chr1:26900765	RPS6KA1	0.42	6.07	0.32	3.44e-9	Glucose homeostasis traits;
LUSC	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21545522	chr1:205238299	TMCC2	0.5	9.36	0.46	1.21e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs4596713	0.538	rs4421408	chr9:71760884	G/T	cg25283916	chr1:242222868	NA	-0.33	-6.76	-0.35	6.34e-11	Headache;
LUSC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg18230493	chr5:56204884	C5orf35	-0.64	-9.91	-0.48	1.88e-20	Coronary artery disease;
LUSC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.58	-0.38	3.5e-13	Blood metabolite levels;
LUSC	trans	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.47	7.04	0.36	1.1e-11	Endometrial cancer;
LUSC	trans	rs34421088	0.576	rs2572437	chr8:11098441	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.09	-0.36	8.16e-12	Neuroticism;
LUSC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.42	-0.46	7.9e-19	Chronic sinus infection;
LUSC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg15672331	chr15:85923765	AKAP13	-0.47	-6.12	-0.32	2.68e-9	Height;
LUSC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	7.4	0.38	1.11e-12	Obesity-related traits;
LUSC	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	10.18	0.49	2.21e-21	Total body bone mineral density;
LUSC	cis	rs7712401	0.692	rs9327273	chr5:122073550	T/G	cg19077854	chr5:122220652	SNX24	0.33	7.12	0.36	6.74e-12	Mean platelet volume;
LUSC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg13628971	chr7:2884303	GNA12	0.47	6.56	0.34	2.08e-10	Height;
LUSC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg20887711	chr4:1340912	KIAA1530	0.45	6.74	0.35	7.15e-11	Obesity-related traits;
LUSC	cis	rs9811920	0.809	rs6440967	chr3:99722396	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.34	-5.65	-0.3	3.39e-8	Axial length;
LUSC	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.19	0.32	1.72e-9	Lymphocyte counts;
LUSC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg09436375	chr6:42928200	GNMT	-0.3	-6.89	-0.35	2.75e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6596100	0.500	rs12514041	chr5:132164313	C/T	cg02081065	chr5:132209139	LEAP2	-0.64	-6.25	-0.32	1.26e-9	Breast cancer;
LUSC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg18225595	chr11:63971243	STIP1	-0.53	-8.82	-0.43	6.51e-17	Platelet count;
LUSC	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg07148914	chr20:33460835	GGT7	-0.53	-8.1	-0.41	1.05e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11764359	chr7:65958608	NA	-0.58	-8.99	-0.44	1.87e-17	Aortic root size;
LUSC	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg10596483	chr8:143751796	JRK	0.53	7.59	0.38	3.17e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs10992471	0.603	rs968040	chr9:95279985	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.9	-0.35	2.68e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.98	-0.55	9.08e-28	Alzheimer's disease;
LUSC	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg06532163	chr17:45867833	NA	0.34	6.34	0.33	7.6e-10	IgG glycosylation;
LUSC	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg05340658	chr4:99064831	C4orf37	0.44	7.0	0.36	1.41e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg18758796	chr5:131593413	PDLIM4	-0.43	-6.8	-0.35	4.9e-11	Blood metabolite levels;
LUSC	cis	rs1712517	0.773	rs1063461	chr10:105049105	C/G	cg05636881	chr10:105038444	INA	0.39	6.44	0.33	4.15e-10	Migraine;
LUSC	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg19773385	chr1:10388646	KIF1B	0.51	8.28	0.41	2.94e-15	Hepatocellular carcinoma;
LUSC	trans	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg20935933	chr6:143382018	AIG1	0.5	7.33	0.37	1.71e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6578985	1.000	rs868331	chr11:2136794	A/G	cg25742037	chr11:2171694	INS-IGF2;IGF2	0.32	5.91	0.31	8.31e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg08975724	chr8:8085496	FLJ10661	0.51	7.41	0.38	1.02e-12	Mood instability;
LUSC	cis	rs6933660	0.610	rs71549125	chr6:151770796	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-8.33	-0.41	2.09e-15	Menarche (age at onset);
LUSC	cis	rs13401104	0.796	rs10929165	chr2:237111187	C/G	cg19324714	chr2:237145437	ASB18	0.43	5.79	0.3	1.6e-8	Educational attainment;
LUSC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06634786	chr22:41940651	POLR3H	0.53	6.18	0.32	1.82e-9	Vitiligo;
LUSC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.93	0.31	7.45e-9	Lung cancer;
LUSC	cis	rs28595532	0.748	rs72670248	chr4:119335536	A/C	cg02775129	chr4:119771670	NA	-0.76	-6.32	-0.33	8.37e-10	Cannabis dependence symptom count;
LUSC	cis	rs1775715	0.707	rs2799019	chr10:32142850	C/T	cg18675610	chr10:32216311	ARHGAP12	0.31	6.75	0.35	6.46e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9378688	1.000	rs12661136	chr6:2227239	C/A	cg12303981	chr6:2244766	GMDS	-0.54	-6.34	-0.33	7.49e-10	Caudate nucleus volume;
LUSC	cis	rs17661538	0.504	rs17662228	chr10:18440398	A/G	cg03634479	chr10:18430412	CACNB2	0.66	6.43	0.33	4.49e-10	Response to antipsychotic treatment;
LUSC	cis	rs17604090	0.628	rs875263	chr7:29711066	T/C	cg19413766	chr7:29689036	LOC646762	-0.54	-7.33	-0.37	1.75e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg03146154	chr1:46216737	IPP	0.55	8.25	0.41	3.82e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg00945038	chr17:61921165	SMARCD2	0.39	5.99	0.31	5.57e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg17294928	chr15:75287854	SCAMP5	-0.83	-11.27	-0.52	3.6e-25	Blood trace element (Zn levels);
LUSC	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg24675056	chr1:15929824	NA	0.49	8.46	0.42	8.28e-16	Systolic blood pressure;
LUSC	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg05966235	chr16:28915196	ATP2A1	-0.33	-5.72	-0.3	2.39e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9549260	0.564	rs9577107	chr13:41271676	A/T	cg21288729	chr13:41239152	FOXO1	0.54	8.31	0.41	2.35e-15	Red blood cell count;
LUSC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg14895029	chr7:2775587	GNA12	-0.41	-6.12	-0.32	2.58e-9	Height;
LUSC	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Bladder cancer;
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.42	-0.42	1.13e-15	Lymphocyte counts;
LUSC	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg04362960	chr10:104952993	NT5C2	0.6	9.38	0.46	1.07e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg16049864	chr8:95962084	TP53INP1	-0.42	-6.91	-0.35	2.51e-11	Type 2 diabetes;
LUSC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg08027265	chr7:2291960	NA	-0.37	-6.01	-0.31	4.99e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9300255	0.679	rs4759420	chr12:123794871	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.5	-6.42	-0.33	4.76e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24110177	chr3:50126178	RBM5	0.56	9.26	0.45	2.62e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-8.33	-0.41	2.18e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg13939156	chr17:80058883	NA	0.33	6.37	0.33	6.12e-10	Life satisfaction;
LUSC	cis	rs10875746	0.904	rs10875750	chr12:48545630	C/T	cg13454099	chr12:49076203	C12orf41	-0.52	-6.15	-0.32	2.17e-9	Longevity (90 years and older);
LUSC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-9.48	-0.46	4.74e-19	Chronic sinus infection;
LUSC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.12	0.45	7.37e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg08807101	chr21:30365312	RNF160	-0.53	-6.68	-0.34	9.85e-11	Cognitive test performance;
LUSC	cis	rs6494488	0.500	rs111793398	chr15:65079354	C/T	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	cis	rs983392	0.679	rs6591559	chr11:60025565	C/T	cg02771260	chr11:59836817	MS4A3	-0.4	-6.53	-0.34	2.51e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg03676636	chr4:99064102	C4orf37	0.36	7.83	0.39	6.75e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg00745463	chr17:30367425	LRRC37B	-0.45	-6.23	-0.32	1.38e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg13319975	chr6:146136371	FBXO30	-0.71	-11.44	-0.53	8.48e-26	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg04989706	chr14:50066350	PPIL5	-0.48	-6.32	-0.33	8.2e-10	Carotid intima media thickness;
LUSC	cis	rs870825	0.616	rs7692104	chr4:185650895	T/G	cg04058563	chr4:185651563	MLF1IP	0.83	12.71	0.57	1.82e-30	Blood protein levels;
LUSC	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.92	12.01	0.55	7.39e-28	Exhaled nitric oxide output;
LUSC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg12863693	chr15:85201151	NMB	0.4	8.49	0.42	7e-16	Schizophrenia;
LUSC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg18190219	chr22:46762943	CELSR1	-0.51	-5.79	-0.3	1.64e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg22906224	chr7:99728672	NA	0.47	6.54	0.34	2.36e-10	Coronary artery disease;
LUSC	cis	rs1847202	0.859	rs4274693	chr3:72949375	A/G	cg25664220	chr3:72788482	NA	-0.42	-7.75	-0.39	1.13e-13	Motion sickness;
LUSC	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.8	-11.75	-0.54	6.33e-27	Blood pressure (smoking interaction);
LUSC	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.74	-0.47	6.99e-20	Migraine;Coronary artery disease;
LUSC	trans	rs72674100	1.000	rs72880559	chr4:97975513	A/G	cg09670535	chr1:18959427	PAX7	-0.64	-6.61	-0.34	1.53e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg06718696	chr17:78121285	EIF4A3	0.45	6.42	0.33	4.72e-10	Yeast infection;
LUSC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg22907277	chr7:1156413	C7orf50	0.72	10.41	0.5	3.54e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9653442	0.564	rs7590378	chr2:100789877	A/G	cg07810366	chr2:100720526	AFF3	-0.43	-7.28	-0.37	2.43e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.21	0.37	3.78e-12	Morning vs. evening chronotype;
LUSC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg26566898	chr11:117069891	TAGLN	-0.47	-8.28	-0.41	3.06e-15	Blood protein levels;
LUSC	cis	rs7043114	0.525	rs10992374	chr9:95336327	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.44	-0.33	4.1e-10	Height;
LUSC	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg13010199	chr12:38710504	ALG10B	0.44	6.23	0.32	1.4e-9	Morning vs. evening chronotype;
LUSC	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg03060546	chr3:49711283	APEH	-0.61	-7.08	-0.36	8.68e-12	Menarche (age at onset);
LUSC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26314531	chr2:26401878	FAM59B	0.66	8.76	0.43	9.76e-17	Gut microbiome composition (summer);
LUSC	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg16339924	chr4:17578868	LAP3	-0.58	-8.39	-0.42	1.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	11.57	0.53	3e-26	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg10756647	chr7:56101905	PSPH	0.86	8.4	0.42	1.27e-15	Diabetic kidney disease;
LUSC	cis	rs12519773	0.526	rs4469186	chr5:92520266	T/C	cg18783429	chr5:92414398	NA	0.34	7.16	0.36	5.13e-12	Migraine;
LUSC	cis	rs4363385	0.647	rs1995308	chr1:153014082	A/T	cg25856811	chr1:152973957	SPRR3	-0.4	-6.53	-0.34	2.42e-10	Inflammatory skin disease;
LUSC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00684032	chr4:1343700	KIAA1530	0.38	6.58	0.34	1.8e-10	Obesity-related traits;
LUSC	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.82	0.3	1.38e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg25214090	chr10:38739885	LOC399744	0.53	7.72	0.39	1.33e-13	Corneal astigmatism;
LUSC	trans	rs12210905	1.000	rs12192446	chr6:26995638	C/A	cg11837749	chr1:55047332	ACOT11	0.57	6.01	0.31	4.99e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg08917208	chr2:24149416	ATAD2B	0.98	10.41	0.49	3.64e-22	Lymphocyte counts;
LUSC	trans	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg25214090	chr10:38739885	LOC399744	-0.41	-6.22	-0.32	1.52e-9	Corneal astigmatism;
LUSC	cis	rs9815354	1.000	rs3934103	chr3:41977214	C/T	cg03022575	chr3:42003672	ULK4	-0.59	-6.52	-0.34	2.53e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7945705	0.875	rs10769955	chr11:8784647	G/C	cg12365402	chr11:9010492	NRIP3	0.46	8.12	0.41	8.85e-15	Hemoglobin concentration;
LUSC	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg26102564	chr10:131424627	MGMT	0.38	6.0	0.31	5.07e-9	Response to temozolomide;
LUSC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg03388025	chr16:89894329	SPIRE2	0.32	6.56	0.34	2.01e-10	Vitiligo;
LUSC	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg01733217	chr16:74700730	RFWD3	0.8	13.34	0.59	7.52e-33	Testicular germ cell tumor;
LUSC	cis	rs6429082	0.818	rs453315	chr1:235680585	C/T	cg26050004	chr1:235667680	B3GALNT2	0.63	8.4	0.42	1.34e-15	Adiposity;
LUSC	cis	rs6690583	0.562	rs76839162	chr1:85530021	A/G	cg22153463	chr1:85462885	MCOLN2	0.61	5.67	0.3	3.05e-8	Serum sulfate level;
LUSC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.31	0.33	8.94e-10	Menopause (age at onset);
LUSC	trans	rs7849782	0.967	rs1535632	chr9:104433973	A/T	cg22914338	chr19:14376960	NA	0.25	6.14	0.32	2.35e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.57	0.46	2.54e-19	Mean platelet volume;
LUSC	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg14092571	chr14:90743983	NA	0.35	5.71	0.3	2.5e-8	Mortality in heart failure;
LUSC	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-1.03	-21.67	-0.76	1.21e-65	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11677416	0.677	rs2856840	chr2:113538604	T/A	cg27083787	chr2:113543245	IL1A	0.45	7.11	0.36	6.89e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg22482690	chr17:47019901	SNF8	0.4	7.47	0.38	6.92e-13	Type 2 diabetes;
LUSC	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg26597838	chr10:835615	NA	-0.53	-7.05	-0.36	1.03e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg04733989	chr22:42467013	NAGA	-0.42	-6.88	-0.35	2.94e-11	Cognitive function;
LUSC	cis	rs308403	0.509	rs10016979	chr4:123673192	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.94	16.4	0.67	8.96e-45	Blood protein levels;
LUSC	cis	rs9359856	0.564	rs72915944	chr6:90447226	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.55	-0.42	4.52e-16	Bipolar disorder;
LUSC	trans	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg19894588	chr14:64061835	NA	0.54	7.7	0.39	1.56e-13	Glioblastoma;Glioma;
LUSC	cis	rs9372253	0.564	rs2057151	chr6:110716608	G/C	cg19196401	chr6:110721138	DDO	-0.36	-5.75	-0.3	2.06e-8	Platelet distribution width;
LUSC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	12.09	0.55	3.72e-28	Ileal carcinoids;
LUSC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg23601095	chr6:26197514	HIST1H3D	0.73	7.79	0.39	8.56e-14	Gout;Renal underexcretion gout;
LUSC	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.63	11.89	0.55	1.93e-27	Sitting height ratio;
LUSC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	0.99	13.72	0.6	2.8e-34	Eosinophil percentage of granulocytes;
LUSC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11645453	chr3:52864694	ITIH4	-0.42	-10.37	-0.49	5.15e-22	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03333052	chr10:5683763	ASB13	-0.38	-6.33	-0.33	7.84e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg08601574	chr20:25228251	PYGB	0.42	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-6.91	-0.35	2.4e-11	Psoriasis;
LUSC	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg01528321	chr10:82214614	TSPAN14	0.87	13.18	0.58	3.14e-32	Post bronchodilator FEV1;
LUSC	cis	rs4654899	0.865	rs72988025	chr1:21351441	A/G	cg02927042	chr1:21476669	EIF4G3	-0.36	-5.65	-0.3	3.38e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9612	0.718	rs346536	chr19:44251470	A/T	cg08581076	chr19:44259116	C19orf61	0.49	6.29	0.33	9.86e-10	Exhaled nitric oxide output;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10814338	chr17:41132463	AARSD1;RUNDC1	-0.5	-6.57	-0.34	1.96e-10	Hepatitis;
LUSC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg02269571	chr22:50332266	NA	0.59	8.74	0.43	1.17e-16	Schizophrenia;
LUSC	cis	rs1451375	1.000	rs2329342	chr7:50624971	A/G	cg18232548	chr7:50535776	DDC	-0.52	-7.99	-0.4	2.23e-14	Malaria;
LUSC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.58	0.38	3.4e-13	Bipolar disorder;
LUSC	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg05855489	chr10:104503620	C10orf26	0.53	7.78	0.39	9.07e-14	Arsenic metabolism;
LUSC	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg05709478	chr1:6581295	PLEKHG5	-0.53	-6.38	-0.33	5.96e-10	Body mass index;
LUSC	cis	rs12681287	0.640	rs7846090	chr8:87467724	A/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.6	-7.45	-0.38	7.81e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs1127311	1.000	rs1127313	chr1:154556425	A/G	cg17218026	chr1:154582156	ADAR	-0.56	-9.8	-0.47	4.35e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22601191	chr20:60968625	CABLES2	-0.41	-6.62	-0.34	1.42e-10	Colorectal cancer;
LUSC	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.5	7.74	0.39	1.19e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4132509	0.947	rs320339	chr1:243870910	G/T	cg21452805	chr1:244014465	NA	0.5	5.69	0.3	2.79e-8	RR interval (heart rate);
LUSC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.29	0.33	1.02e-9	Menopause (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg20824237	chr3:99979579	TBC1D23	0.44	6.11	0.32	2.79e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg23649088	chr2:200775458	C2orf69	-0.41	-6.2	-0.32	1.7e-9	QT interval;
LUSC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg18758796	chr5:131593413	PDLIM4	-0.39	-6.18	-0.32	1.85e-9	Breast cancer;
LUSC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.93	-17.79	-0.7	2.95e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.88	-11.85	-0.54	2.85e-27	Mean corpuscular hemoglobin;
LUSC	cis	rs34891900	0.507	rs2535707	chr22:18181869	C/T	cg19898043	chr22:18121309	BCL2L13	-0.39	-6.03	-0.31	4.41e-9	Sum neutrophil eosinophil counts;
LUSC	cis	rs7712401	0.601	rs35858098	chr5:122334365	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.27	-0.45	2.29e-18	Mean platelet volume;
LUSC	cis	rs9403521	0.898	rs3924969	chr6:143979399	C/G	cg18240653	chr6:144019428	PHACTR2	-0.51	-6.13	-0.32	2.51e-9	Obesity-related traits;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg02050903	chr11:44117243	EXT2	0.35	6.07	0.32	3.4e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08859206	chr1:53392774	SCP2	0.5	8.51	0.42	6.03e-16	Monocyte count;
LUSC	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg27068330	chr11:65405492	SIPA1	0.64	9.76	0.47	5.64e-20	Acne (severe);
LUSC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.51	7.98	0.4	2.37e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs865483	0.929	rs853225	chr17:35791505	A/C	cg06716730	chr17:35851459	DUSP14	0.26	5.84	0.3	1.21e-8	Monocyte count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10577284	chr10:81838377	LOC219347;C10orf57	-0.43	-6.53	-0.34	2.45e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7215564	0.908	rs35103651	chr17:78666732	T/C	cg23238734	chr17:78661607	RPTOR	0.48	6.28	0.32	1.05e-9	Myopia (pathological);
LUSC	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.6	0.57	4.95e-30	White blood cell count;
LUSC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg12292205	chr6:26970375	C6orf41	0.49	7.7	0.39	1.54e-13	Schizophrenia;
LUSC	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg09835421	chr16:68378352	PRMT7	-0.52	-6.34	-0.33	7.38e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.43	-6.94	-0.35	2.06e-11	Schizophrenia;
LUSC	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg03948781	chr1:205179583	DSTYK	0.33	6.34	0.33	7.42e-10	Red blood cell count;
LUSC	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg21972741	chr5:435613	AHRR	0.33	5.87	0.31	1.02e-8	Cystic fibrosis severity;
LUSC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.18	-0.32	1.91e-9	Platelet count;
LUSC	cis	rs2224391	0.628	rs2753232	chr6:5250765	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.47	-6.39	-0.33	5.72e-10	Height;
LUSC	cis	rs7719624	0.756	rs13168506	chr5:135396452	A/G	cg12897067	chr5:135418308	NA	0.4	5.82	0.3	1.36e-8	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg13010199	chr12:38710504	ALG10B	0.42	6.12	0.32	2.66e-9	Morning vs. evening chronotype;
LUSC	cis	rs12474201	0.928	rs34186074	chr2:46965010	T/C	cg06386533	chr2:46925753	SOCS5	0.75	11.16	0.52	8.46e-25	Height;
LUSC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg09517075	chr8:22133004	PIWIL2	0.41	8.07	0.4	1.28e-14	Hypertriglyceridemia;
LUSC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.32	0.53	2.37e-25	Colorectal cancer;
LUSC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg06618935	chr21:46677482	NA	-0.41	-8.29	-0.41	2.8e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg23172400	chr8:95962367	TP53INP1	-0.39	-8.19	-0.41	5.68e-15	Type 2 diabetes;
LUSC	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.26e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg18350739	chr11:68623251	NA	-0.37	-6.71	-0.34	8.55e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11764359	chr7:65958608	NA	-0.54	-7.11	-0.36	7.23e-12	Aortic root size;
LUSC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.57	-0.46	2.45e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg05855489	chr10:104503620	C10orf26	0.54	6.39	0.33	5.67e-10	Arsenic metabolism;
LUSC	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg11247378	chr22:39784982	NA	-0.66	-13.12	-0.58	5.14e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-7.8	-0.39	7.89e-14	Platelet count;
LUSC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	27.87	0.84	3.57e-89	Chronic sinus infection;
LUSC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg25767906	chr1:53392781	SCP2	0.49	8.87	0.44	4.4e-17	Monocyte count;
LUSC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.84e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg04362960	chr10:104952993	NT5C2	0.66	9.2	0.45	4.07e-18	Arsenic metabolism;
LUSC	cis	rs7173743	0.935	rs11857877	chr15:79140838	G/C	cg00540400	chr15:79124168	NA	-0.34	-5.77	-0.3	1.84e-8	Coronary artery disease;
LUSC	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg25024717	chr12:54324583	NA	-0.4	-6.32	-0.33	8.56e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-7.58	-0.38	3.51e-13	Personality dimensions;
LUSC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg01802117	chr1:53393560	SCP2	-0.37	-5.93	-0.31	7.62e-9	Monocyte count;
LUSC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.41	-6.2	-0.32	1.63e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.55	8.76	0.43	1e-16	Breast cancer;
LUSC	trans	rs72674100	0.737	rs72874649	chr4:97965312	T/C	cg09670535	chr1:18959427	PAX7	-0.64	-6.61	-0.34	1.53e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.69	10.56	0.5	1.14e-22	Aortic root size;
LUSC	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg17691542	chr6:26056736	HIST1H1C	0.81	10.97	0.51	3.9e-24	Iron status biomarkers;
LUSC	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg23752985	chr2:85803571	VAMP8	-0.3	-6.33	-0.33	7.83e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9311676	0.656	rs56097407	chr3:58378079	G/A	cg26110898	chr3:58419937	PDHB	0.42	6.83	0.35	4.07e-11	Systemic lupus erythematosus;
LUSC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.48	-8.0	-0.4	2.09e-14	Vitiligo;
LUSC	trans	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.58	-10.23	-0.49	1.49e-21	Mean corpuscular volume;
LUSC	cis	rs7191700	0.583	rs243314	chr16:11385104	G/C	cg00044050	chr16:11439710	C16orf75	0.76	14.67	0.63	6.08e-38	Multiple sclerosis;
LUSC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg23283495	chr1:209979779	IRF6	0.64	9.36	0.46	1.21e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg15711740	chr2:61764176	XPO1	0.45	6.74	0.35	6.91e-11	Tuberculosis;
LUSC	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg05340658	chr4:99064831	C4orf37	0.59	9.59	0.46	2.05e-19	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4942242	0.663	rs7332737	chr13:44215043	C/T	cg19169023	chr15:41853346	TYRO3	-0.56	-8.45	-0.42	9.13e-16	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs75920871	0.528	rs11216240	chr11:116899248	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.42	-0.33	4.68e-10	Subjective well-being;
LUSC	cis	rs4766646	0.542	rs4766489	chr12:110306345	G/A	cg10794374	chr12:110278745	NA	-0.28	-5.81	-0.3	1.44e-8	Metabolite levels (MHPG);
LUSC	cis	rs8092503	1.000	rs12959833	chr18:52492579	A/G	cg12377874	chr18:52495404	RAB27B	-0.34	-6.18	-0.32	1.91e-9	Childhood body mass index;
LUSC	cis	rs2425143	1.000	rs8124505	chr20:34307247	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.05	-0.31	3.95e-9	Blood protein levels;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg22225258	chr1:1447235	ATAD3A	0.37	5.98	0.31	5.76e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs4764124	0.646	rs11610238	chr12:14975721	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.38	5.87	0.31	1.06e-8	Pubertal anthropometrics;
LUSC	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.6	-6.83	-0.35	3.93e-11	Yeast infection;
LUSC	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg22709100	chr7:91322751	NA	0.39	5.71	0.3	2.49e-8	Breast cancer;
LUSC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19346786	chr7:2764209	NA	-0.49	-8.16	-0.41	7.09e-15	Height;
LUSC	cis	rs3820928	0.874	rs1917125	chr2:227798981	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.72	-0.39	1.38e-13	Pulmonary function;
LUSC	cis	rs6076065	0.755	rs6076071	chr20:23406380	A/C	cg11657817	chr20:23433608	CST11	0.4	7.13	0.36	6.42e-12	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs4954585	0.593	rs12691881	chr2:137029668	A/G	cg05194412	chr2:137003533	NA	0.41	7.57	0.38	3.68e-13	Colorectal cancer;
LUSC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.79	0.43	8.03e-17	Prudent dietary pattern;
LUSC	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg06552810	chr11:31128660	NA	0.42	7.24	0.37	3.07e-12	Red blood cell count;
LUSC	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06634786	chr22:41940651	POLR3H	-0.55	-6.46	-0.33	3.75e-10	Vitiligo;
LUSC	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg13798780	chr7:105162888	PUS7	0.56	6.04	0.31	4.04e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg11502198	chr6:26597334	ABT1	0.63	9.95	0.48	1.31e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg24250549	chr1:154909240	PMVK	0.57	9.16	0.45	5.55e-18	Prostate cancer;
LUSC	cis	rs73206853	0.563	rs1107652	chr12:111176213	A/G	cg12870014	chr12:110450643	ANKRD13A	0.65	7.4	0.38	1.08e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-8.68	-0.43	1.83e-16	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.52	3.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7786877	0.582	rs2075674	chr7:100225031	G/A	cg20848291	chr7:100343083	ZAN	-0.6	-7.22	-0.37	3.47e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg22166914	chr1:53195759	ZYG11B	0.69	12.45	0.56	1.67e-29	Monocyte count;
LUSC	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.88	-15.11	-0.64	1.1e-39	Bladder cancer;
LUSC	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg13514129	chr1:39547527	MACF1	0.71	11.79	0.54	4.48e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg11335335	chr11:637885	DRD4	-0.31	-5.95	-0.31	6.74e-9	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg08677398	chr8:58056175	NA	0.41	5.71	0.3	2.51e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg10792982	chr14:105748885	BRF1	0.48	8.66	0.43	2.11e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4363385	0.818	rs558363	chr1:153010431	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.87	0.44	4.4e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg02782426	chr3:40428986	ENTPD3	-0.37	-7.15	-0.36	5.66e-12	Renal cell carcinoma;
LUSC	cis	rs56307353	0.753	rs34318825	chr19:1961342	T/C	cg11709110	chr19:1989583	BTBD2	-0.33	-5.66	-0.3	3.24e-8	Coronary artery disease;
LUSC	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.61	10.19	0.49	2e-21	Breast cancer;
LUSC	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg11266682	chr4:10021025	SLC2A9	0.47	8.46	0.42	8.29e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs34293785	1.000	rs34293785	chr1:66137192	T/C	cg04111102	chr1:66153794	NA	0.34	7.38	0.37	1.29e-12	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
LUSC	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg02079420	chr8:82753780	SNX16	0.39	5.92	0.31	8.18e-9	Diastolic blood pressure;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06349981	chr2:10443745	HPCAL1	-0.47	-6.21	-0.32	1.62e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.54	11.56	0.53	3.14e-26	Height;
LUSC	cis	rs55665837	0.539	rs12794714	chr11:14913575	G/A	cg19336497	chr11:14380999	RRAS2	-0.33	-5.96	-0.31	6.43e-9	Vitamin D levels;
LUSC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg23711669	chr6:146136114	FBXO30	0.92	17.48	0.69	4.97e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs2406342	0.511	rs10469087	chr18:74575538	A/C	cg16472389	chr18:74514291	NA	0.43	6.59	0.34	1.75e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LUSC	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg16850897	chr7:100343110	ZAN	0.36	5.75	0.3	1.99e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs9653442	0.527	rs2118280	chr2:100746395	G/A	cg07810366	chr2:100720526	AFF3	-0.42	-7.12	-0.36	6.61e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.54	-0.34	2.34e-10	Breast cancer;
LUSC	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.5	7.37	0.37	1.39e-12	Schizophrenia;
LUSC	trans	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	9.54	0.46	3.1400000000000002e-19	Eotaxin levels;
LUSC	cis	rs10761482	0.500	rs10740030	chr10:62291812	C/G	cg18175470	chr10:62150864	ANK3	-0.51	-7.7	-0.39	1.58e-13	Schizophrenia;
LUSC	cis	rs977987	0.806	rs11862095	chr16:75385418	T/A	cg03315344	chr16:75512273	CHST6	0.54	10.31	0.49	8.01e-22	Dupuytren's disease;
LUSC	cis	rs1322512	0.917	rs2623941	chr6:152950973	A/C	cg27316956	chr6:152958899	SYNE1	-0.35	-5.88	-0.31	1e-8	Tonometry;
LUSC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg15445000	chr17:37608096	MED1	-0.39	-6.72	-0.35	7.97e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.94	0.4	3.06e-14	Bipolar disorder;
LUSC	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg08847533	chr14:75593920	NEK9	-0.8	-13.68	-0.6	3.91e-34	Height;
LUSC	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.71	10.85	0.51	1.08e-23	Smoking initiation;
LUSC	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg05973401	chr12:123451056	ABCB9	0.52	7.0	0.36	1.44e-11	Neutrophil percentage of white cells;
LUSC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg23649088	chr2:200775458	C2orf69	0.54	7.34	0.37	1.61e-12	Schizophrenia;
LUSC	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.69	-11.2	-0.52	6.3e-25	Sudden cardiac arrest;
LUSC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg15448220	chr1:150897856	SETDB1	0.39	5.87	0.31	1.04e-8	Tonsillectomy;
LUSC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg20790798	chr5:1857306	NA	-0.49	-8.54	-0.42	4.92e-16	Cardiovascular disease risk factors;
LUSC	cis	rs9807989	0.507	rs2058659	chr2:103054556	A/G	cg03938978	chr2:103052716	IL18RAP	-0.37	-7.12	-0.36	6.52e-12	Asthma;
LUSC	cis	rs9549260	0.755	rs7324319	chr13:41233505	G/C	cg21288729	chr13:41239152	FOXO1	0.65	9.98	0.48	1.06e-20	Red blood cell count;
LUSC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.71	-11.04	-0.52	2.31e-24	Aortic root size;
LUSC	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg01657329	chr11:68192670	LRP5	-0.48	-7.2	-0.37	4.07e-12	Total body bone mineral density;
LUSC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	1.0	14.14	0.61	6.49e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs193541	0.530	rs2125857	chr5:122083156	G/A	cg19077854	chr5:122220652	SNX24	0.36	7.15	0.36	5.53e-12	Glucose homeostasis traits;
LUSC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.66	9.11	0.45	7.8e-18	High light scatter reticulocyte count;
LUSC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.38	7.15	0.36	5.66e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg12463550	chr7:65579703	CRCP	0.64	5.83	0.3	1.3e-8	Diabetic kidney disease;
LUSC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.48	-7.53	-0.38	4.88e-13	Testicular germ cell tumor;
LUSC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg00129232	chr17:37814104	STARD3	-0.4	-5.72	-0.3	2.33e-8	Asthma;
LUSC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg17691542	chr6:26056736	HIST1H1C	0.55	8.18	0.41	5.91e-15	Height;
LUSC	cis	rs2857891	0.817	rs2857899	chr11:6981668	A/C	cg14883916	chr11:6947541	ZNF215	0.45	5.83	0.3	1.29e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12516959	chr21:47718080	NA	-0.47	-7.48	-0.38	6.84e-13	Testicular germ cell tumor;
LUSC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg06637938	chr14:75390232	RPS6KL1	0.44	6.55	0.34	2.23e-10	Height;
LUSC	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg13390004	chr1:15929781	NA	0.42	7.04	0.36	1.07e-11	Systolic blood pressure;
LUSC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg04944784	chr2:26401820	FAM59B	-0.74	-11.06	-0.52	1.87e-24	Gut microbiome composition (summer);
LUSC	cis	rs9534288	0.740	rs7989892	chr13:46630641	C/T	cg15192986	chr13:46630673	CPB2	-0.8	-12.6	-0.57	4.66e-30	Blood protein levels;
LUSC	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs829883	0.664	rs249833	chr12:98832189	T/C	cg25150519	chr12:98850993	NA	0.8	13.45	0.59	3.01e-33	Colorectal adenoma (advanced);
LUSC	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	11.37	0.53	1.5e-25	Lung cancer in ever smokers;
LUSC	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.8	-0.47	4.39e-20	Coronary artery disease;
LUSC	cis	rs17621444	0.522	rs4237515	chr10:121811588	T/A	cg02041677	chr10:121771263	NA	-0.33	-6.31	-0.33	9.11e-10	IgG glycosylation;
LUSC	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.79	11.5	0.53	5.34e-26	Corneal astigmatism;
LUSC	cis	rs2637266	0.967	rs12246605	chr10:78352994	G/A	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs3960554	0.599	rs56090527	chr7:75762125	A/C	cg17325771	chr7:75508891	RHBDD2	-0.41	-5.8	-0.3	1.57e-8	Eotaxin levels;
LUSC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg05552183	chr6:42928497	GNMT	0.46	7.5	0.38	5.63e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg12863693	chr15:85201151	NMB	0.42	8.65	0.43	2.14e-16	Schizophrenia;
LUSC	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg04310649	chr10:35416472	CREM	-0.4	-6.13	-0.32	2.5e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg09904177	chr6:26538194	HMGN4	-0.64	-6.41	-0.33	4.96e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.84	12.69	0.57	2.13e-30	Cognitive ability;
LUSC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.43	0.46	7e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25765569	chr12:117175636	C12orf49;RNFT2	-0.5	-6.46	-0.33	3.69e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg01448562	chr3:133502909	NA	-0.51	-7.61	-0.38	2.88e-13	Iron status biomarkers;
LUSC	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	0.98	10.97	0.51	4.05e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4481887	0.617	rs7511986	chr1:248527810	G/A	cg26353448	chr1:248524236	OR2T4	-0.31	-6.06	-0.31	3.63e-9	Common traits (Other);
LUSC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg15103426	chr22:29168792	CCDC117	0.46	5.91	0.31	8.34e-9	Lymphocyte counts;
LUSC	cis	rs3744061	0.557	rs2098092	chr17:74646757	T/C	cg27546012	chr17:74684504	MXRA7	-0.37	-6.37	-0.33	6.19e-10	Retinal arteriolar caliber;
LUSC	cis	rs16867321	0.588	rs2368175	chr2:181493763	G/C	cg23363182	chr2:181467187	NA	-0.58	-9.13	-0.45	6.87e-18	Obesity;
LUSC	cis	rs73206853	0.841	rs55951950	chr12:110800254	A/T	cg12870014	chr12:110450643	ANKRD13A	0.68	6.43	0.33	4.37e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg08017756	chr2:100939284	LONRF2	-0.47	-8.8	-0.43	7.7e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg22582392	chr4:160024851	NA	-0.45	-5.97	-0.31	6.14e-9	Longevity;Endometriosis;
LUSC	cis	rs2637266	0.967	rs10400134	chr10:78365158	G/C	cg18941641	chr10:78392320	NA	0.41	7.59	0.38	3.18e-13	Pulmonary function;
LUSC	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.63	9.59	0.46	2.07e-19	Corneal astigmatism;
LUSC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.21	0.41	4.9e-15	Prudent dietary pattern;
LUSC	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.88	14.59	0.62	1.18e-37	Bladder cancer;
LUSC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg13609457	chr4:120235615	NA	0.39	5.98	0.31	5.71e-9	Diastolic blood pressure;
LUSC	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	0.97	21.55	0.76	3.54e-65	Longevity;
LUSC	cis	rs1358748	0.522	rs1321155	chr1:67589479	G/C	cg02640540	chr1:67518911	SLC35D1	0.67	6.55	0.34	2.15e-10	Tuberculosis;
LUSC	cis	rs9309473	1.000	rs10207220	chr2:73785046	G/C	cg20560298	chr2:73613845	ALMS1	-0.45	-6.5	-0.33	2.97e-10	Metabolite levels;
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg18538332	chr22:24372958	LOC391322	-0.42	-7.67	-0.39	1.89e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14829155	chr15:31115871	NA	0.7	10.47	0.5	2.21e-22	Huntington's disease progression;
LUSC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg03538708	chr1:25844672	NA	-0.39	-6.48	-0.33	3.22e-10	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg20821713	chr7:1055600	C7orf50	0.47	7.66	0.39	2.01e-13	Longevity;Endometriosis;
LUSC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	0.89	16.17	0.66	7.73e-44	Cognitive function;
LUSC	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg09904177	chr6:26538194	HMGN4	-0.54	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg15436174	chr10:43711423	RASGEF1A	0.33	6.05	0.31	3.78e-9	Hirschsprung disease;
LUSC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg04450456	chr4:17643702	FAM184B	-0.38	-6.28	-0.33	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06634786	chr22:41940651	POLR3H	0.49	6.04	0.31	4.01e-9	Vitiligo;
LUSC	cis	rs13092825	1.000	rs7613948	chr3:113279698	T/G	cg18753928	chr3:113234510	CCDC52	-0.38	-5.65	-0.3	3.5e-8	Dental caries;
LUSC	cis	rs10979	1.000	rs1416208	chr6:143889241	T/A	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg11262906	chr1:85462892	MCOLN2	-0.68	-9.06	-0.44	1.09e-17	Serum sulfate level;
LUSC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg03060546	chr3:49711283	APEH	0.47	6.29	0.33	1.02e-9	Menarche (age at onset);
LUSC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.88	0.63	8.88e-39	Platelet count;
LUSC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.77	-0.35	5.91e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2286503	0.839	rs2270103	chr7:22862722	C/T	cg11367502	chr7:22862612	TOMM7	0.46	6.22	0.32	1.51e-9	Fibrinogen;
LUSC	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg13010199	chr12:38710504	ALG10B	0.53	8.24	0.41	4.01e-15	Morning vs. evening chronotype;
LUSC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg17724175	chr1:150552817	MCL1	0.32	5.74	0.3	2.08e-8	Tonsillectomy;
LUSC	cis	rs2274273	0.624	rs11848456	chr14:55755392	A/G	cg04306507	chr14:55594613	LGALS3	0.48	9.85	0.47	2.9e-20	Protein biomarker;
LUSC	cis	rs981844	0.816	rs62325151	chr4:154730595	A/G	cg14289246	chr4:154710475	SFRP2	0.48	6.35	0.33	7.08e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs11997175	0.550	rs10105616	chr8:33786830	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	7.05	0.36	1.03e-11	Body mass index;
LUSC	cis	rs9650315	0.852	rs7833122	chr8:57178720	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	6.82	0.35	4.17e-11	Height;
LUSC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.66	10.76	0.51	2.23e-23	Extrinsic epigenetic age acceleration;
LUSC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg18350739	chr11:68623251	NA	-0.37	-6.48	-0.33	3.28e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg03342759	chr3:160939853	NMD3	-0.5	-8.51	-0.42	5.77e-16	Morning vs. evening chronotype;
LUSC	trans	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg18187862	chr3:45730750	SACM1L	0.55	7.09	0.36	8.01e-12	Primary sclerosing cholangitis;
LUSC	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-1.13	-17.85	-0.7	1.6e-50	Exhaled nitric oxide output;
LUSC	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg00677455	chr12:58241039	CTDSP2	0.54	7.86	0.4	5.27e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs11264799	0.581	rs849815	chr1:157542162	A/G	cg18268488	chr1:157545234	FCRL4	0.37	6.91	0.35	2.46e-11	IgA nephropathy;
LUSC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg12463550	chr7:65579703	CRCP	-0.55	-8.03	-0.4	1.68e-14	Aortic root size;
LUSC	cis	rs56283067	0.847	rs62435999	chr6:44695273	T/G	cg18551225	chr6:44695536	NA	-0.48	-8.11	-0.41	9.47e-15	Total body bone mineral density;
LUSC	cis	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg06609049	chr19:2785107	THOP1	0.72	11.74	0.54	6.87e-27	Total cholesterol levels;
LUSC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg23982607	chr1:1823379	GNB1	-0.73	-15.07	-0.64	1.66e-39	Body mass index;
LUSC	trans	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg19862616	chr7:65841803	NCRNA00174	0.9	10.09	0.48	4.56e-21	Eotaxin levels;
LUSC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18357526	chr6:26021779	HIST1H4A	0.41	6.38	0.33	5.91e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.82	-0.3	1.41e-8	Bipolar disorder;
LUSC	cis	rs6500395	0.775	rs1968902	chr16:48663974	A/G	cg04672837	chr16:48644449	N4BP1	0.47	7.03	0.36	1.18e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg24562669	chr7:97807699	LMTK2	0.37	6.42	0.33	4.68e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg27284194	chr4:1044797	NA	0.58	8.54	0.42	4.73e-16	Recombination rate (females);
LUSC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05165339	chr4:1420672	NA	0.28	6.19	0.32	1.72e-9	Obesity-related traits;
LUSC	cis	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg06521331	chr12:34319734	NA	-0.46	-7.55	-0.38	4.16e-13	Morning vs. evening chronotype;
LUSC	cis	rs2932538	0.885	rs6693880	chr1:113110261	A/G	cg22162597	chr1:113214053	CAPZA1	0.7	10.0	0.48	9.16e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs62400317	0.762	rs10484626	chr6:44882271	A/G	cg18551225	chr6:44695536	NA	-0.47	-7.71	-0.39	1.46e-13	Total body bone mineral density;
LUSC	cis	rs7503807	0.837	rs9915667	chr17:78754340	A/G	cg09596252	chr17:78655493	RPTOR	-0.43	-7.41	-0.38	1.07e-12	Obesity;
LUSC	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg11901034	chr3:128598214	ACAD9	-0.42	-6.61	-0.34	1.5e-10	IgG glycosylation;
LUSC	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg03585969	chr10:35415529	CREM	-0.6	-8.82	-0.43	6.44e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.6	0.34	1.66e-10	Lung cancer;
LUSC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg24879335	chr3:133465180	TF	0.44	7.51	0.38	5.5e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs5753037	0.809	rs713657	chr22:30211876	A/G	cg11564601	chr22:30592435	NA	0.32	5.72	0.3	2.39e-8	Type 1 diabetes;
LUSC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.77	14.99	0.63	3.42e-39	Monocyte count;
LUSC	cis	rs9951602	0.703	rs2959407	chr18:76682915	A/G	cg00806245	chr18:76673096	NA	-0.42	-6.09	-0.32	3.15e-9	Obesity-related traits;
LUSC	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg22782873	chr19:19639568	YJEFN3	0.5	6.03	0.31	4.38e-9	Bipolar disorder;
LUSC	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-8.17	-0.41	6.4e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg11993925	chr19:44307056	LYPD5	0.35	7.61	0.38	2.79e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19748678	chr4:122722346	EXOSC9	-0.48	-6.92	-0.35	2.35e-11	Type 2 diabetes;
LUSC	trans	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg11887960	chr12:57824829	NA	0.52	6.49	0.33	3.12e-10	Obesity-related traits;
LUSC	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg26875233	chr11:93583750	C11orf90	-0.31	-6.04	-0.31	4.07e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07274998	chr10:126107781	OAT	-0.4	-6.1	-0.32	2.87e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12200782	0.932	rs72844476	chr6:26574150	C/T	cg11502198	chr6:26597334	ABT1	-0.74	-5.69	-0.3	2.8e-8	Small cell lung carcinoma;
LUSC	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg15556689	chr8:8085844	FLJ10661	0.81	13.28	0.59	1.29e-32	Neuroticism;
LUSC	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.53	-0.34	2.44e-10	Neuroticism;
LUSC	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12826209	chr6:26865740	GUSBL1	0.67	7.65	0.39	2.16e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg12002119	chr2:101014098	CHST10	0.34	5.68	0.3	2.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg05347473	chr6:146136440	FBXO30	0.45	7.69	0.39	1.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg01966878	chr4:90757139	SNCA	-0.42	-5.96	-0.31	6.24e-9	Neuroticism;
LUSC	cis	rs3820928	0.874	rs7421491	chr2:227839278	C/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.91	-0.4	3.86e-14	Pulmonary function;
LUSC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg00484396	chr16:3507460	NAT15	0.88	11.7	0.54	9.96e-27	Tuberculosis;
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg25703541	chr22:24373054	LOC391322	-1.0	-18.24	-0.71	4.62e-52	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs61990749	0.544	rs2544567	chr14:78181739	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.59	6.45	0.33	3.85e-10	Fibroblast growth factor basic levels;
LUSC	trans	rs710987	0.740	rs698144	chr5:3528233	A/G	cg27629735	chr1:3556483	WDR8	-0.36	-6.07	-0.32	3.45e-9	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
LUSC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg01879757	chr17:41196368	BRCA1	-0.39	-5.9	-0.31	8.83e-9	Menopause (age at onset);
LUSC	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.26e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4363385	0.818	rs679378	chr1:153011716	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.25	-0.37	2.85e-12	Inflammatory skin disease;
LUSC	cis	rs1256061	0.603	rs1256044	chr14:64734027	G/A	cg21174375	chr14:64681225	SYNE2	0.35	6.26	0.32	1.18e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg03929089	chr4:120376271	NA	0.65	6.08	0.32	3.36e-9	Intraocular pressure;
LUSC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.46	0.69	5.95e-49	Chronic sinus infection;
LUSC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26314531	chr2:26401878	FAM59B	0.73	10.01	0.48	8.34e-21	Gut microbiome composition (summer);
LUSC	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg10247383	chr3:153839028	SGEF	-0.47	-5.82	-0.3	1.38e-8	Coronary artery disease;
LUSC	cis	rs12208915	0.731	rs9361473	chr6:79657042	C/T	cg05283184	chr6:79620031	NA	0.48	7.25	0.37	2.86e-12	Left atrial antero-posterior diameter;
LUSC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg00634984	chr7:65235879	NA	0.43	6.16	0.32	2.11e-9	Calcium levels;
LUSC	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg01028140	chr2:1542097	TPO	-0.6	-8.02	-0.4	1.86e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.22	0.32	1.45e-9	Schizophrenia;
LUSC	cis	rs1595825	0.891	rs2164070	chr2:198881730	G/C	cg10547527	chr2:198650123	BOLL	-0.53	-6.36	-0.33	6.65e-10	Ulcerative colitis;
LUSC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-6.8	-0.35	4.8e-11	Alzheimer's disease (late onset);
LUSC	cis	rs977987	0.800	rs11645329	chr16:75336679	C/G	cg04384234	chr16:75411784	CFDP1	-0.36	-5.68	-0.3	2.97e-8	Dupuytren's disease;
LUSC	trans	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.08	-0.44	9.93e-18	Depression;
LUSC	trans	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg13565492	chr6:43139072	SRF	-0.61	-6.83	-0.35	3.92e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg26874164	chr19:58962979	ZNF324B	0.7	10.93	0.51	5.71e-24	Mean platelet volume;
LUSC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.13	-0.41	8.2e-15	Coronary artery disease;
LUSC	cis	rs10203711	1.000	rs907111	chr2:239566426	T/C	cg14580085	chr2:239553406	NA	0.41	6.93	0.35	2.24e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg02428538	chr16:24856791	SLC5A11	-0.52	-6.09	-0.32	3.18e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg17509989	chr5:176798049	RGS14	-0.66	-9.51	-0.46	3.85e-19	Urate levels in lean individuals;
LUSC	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Colorectal cancer;
LUSC	cis	rs1775715	0.678	rs7096139	chr10:32217404	A/C	cg26784012	chr10:32216390	ARHGAP12	0.41	6.88	0.35	2.99e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.69	-0.34	9.51e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg11812906	chr14:75593930	NEK9	-0.67	-11.56	-0.53	3.21e-26	Height;
LUSC	cis	rs4919087	1.000	rs4919091	chr10:99088682	A/T	cg25902810	chr10:99078978	FRAT1	-0.46	-6.72	-0.35	7.88e-11	Monocyte count;
LUSC	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg02176678	chr2:219576539	TTLL4	-0.59	-10.42	-0.5	3.24e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7127129	0.503	rs1131715	chr11:70053487	C/T	cg06159181	chr11:70072977	NA	-0.27	-6.74	-0.35	7.13e-11	Aortic root size;
LUSC	cis	rs6772849	0.896	rs61112519	chr3:128338176	T/A	cg16766828	chr3:128327626	NA	-0.31	-5.68	-0.3	2.9e-8	Monocyte percentage of white cells;Monocyte count;
LUSC	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg23625390	chr15:77176239	SCAPER	0.54	8.36	0.42	1.77e-15	Blood metabolite levels;
LUSC	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.71	-12.65	-0.57	3.03e-30	White blood cell count (basophil);
LUSC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.03	-0.31	4.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.18	0.32	1.91e-9	Bipolar disorder;
LUSC	cis	rs62400317	0.859	rs72858517	chr6:45223467	A/C	cg20913747	chr6:44695427	NA	-0.47	-7.72	-0.39	1.41e-13	Total body bone mineral density;
LUSC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg20243544	chr17:37824526	PNMT	0.49	7.01	0.36	1.36e-11	Asthma;
LUSC	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg03676636	chr4:99064102	C4orf37	0.37	8.14	0.41	7.81e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg09074113	chr2:20870087	GDF7	-0.37	-7.58	-0.38	3.38e-13	Abdominal aortic aneurysm;
LUSC	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg13010199	chr12:38710504	ALG10B	0.65	10.2	0.49	1.94e-21	Morning vs. evening chronotype;
LUSC	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg23752985	chr2:85803571	VAMP8	-0.33	-7.11	-0.36	6.93e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg24675658	chr1:53192096	ZYG11B	-0.64	-10.06	-0.48	5.86e-21	Monocyte count;
LUSC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg07741184	chr6:167504864	NA	0.49	8.62	0.43	2.75e-16	Crohn's disease;
LUSC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg12560992	chr17:57184187	TRIM37	0.8	14.01	0.61	2.12e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Parkinson's disease;
LUSC	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg08345082	chr10:99160200	RRP12	-0.36	-7.28	-0.37	2.45e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg04865166	chr7:105162814	PUS7	0.51	5.71	0.3	2.49e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg05855489	chr10:104503620	C10orf26	0.5	7.5	0.38	5.98e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs2289328	0.823	rs71472433	chr15:40649609	A/C	cg13931752	chr15:40660718	DISP2	0.48	6.49	0.33	3.04e-10	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.3	-0.37	2.1e-12	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs11608355	0.846	rs4766598	chr12:109853306	A/G	cg19025524	chr12:109796872	NA	-0.4	-5.89	-0.31	9.48e-9	Neuroticism;
LUSC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	0.94	16.43	0.67	6.94e-45	Menopause (age at onset);
LUSC	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg06606381	chr12:133084897	FBRSL1	0.8	7.91	0.4	3.74e-14	Depression;
LUSC	trans	rs9380880	0.826	rs9380882	chr6:39547428	A/T	cg09045552	chr2:169506620	LASS6	0.73	6.56	0.34	2.11e-10	Immune response to smallpox vaccine (IL-6);
LUSC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-1.03	-20.12	-0.74	1.48e-59	Height;
LUSC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg26979012	chr14:53174064	PSMC6	0.36	6.15	0.32	2.21e-9	Tuberculosis;
LUSC	cis	rs997295	0.675	rs12902804	chr15:67988658	G/A	cg08079166	chr15:68083412	MAP2K5	-0.33	-6.49	-0.33	3.14e-10	Motion sickness;
LUSC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.68	0.63	5.52e-38	Menopause (age at onset);
LUSC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg16393715	chr7:1948819	MAD1L1	0.39	6.72	0.34	8.09e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg12863693	chr15:85201151	NMB	0.4	8.22	0.41	4.47e-15	Schizophrenia;
LUSC	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg10326726	chr10:51549505	MSMB	0.34	5.88	0.31	9.99e-9	Prostate-specific antigen levels;
LUSC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg14552801	chr7:65878734	NA	-0.43	-6.14	-0.32	2.38e-9	Aortic root size;
LUSC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg01990225	chr2:97406019	LMAN2L	-1.04	-7.26	-0.37	2.8e-12	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.97	-0.31	6.07e-9	Resting heart rate;
LUSC	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg03060546	chr3:49711283	APEH	0.63	7.35	0.37	1.52e-12	Menarche (age at onset);
LUSC	trans	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg10756647	chr7:56101905	PSPH	0.9	9.03	0.44	1.4e-17	Diabetic kidney disease;
LUSC	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17467752	chr17:38218738	THRA	0.78	12.54	0.57	7.66e-30	Neutrophil count;
LUSC	cis	rs13401104	0.796	rs1466204	chr2:237121154	C/A	cg19324714	chr2:237145437	ASB18	0.44	5.66	0.3	3.34e-8	Educational attainment;
LUSC	cis	rs397969	0.596	rs35925051	chr17:19877369	G/A	cg13482628	chr17:19912719	NA	0.46	5.71	0.3	2.46e-8	Platelet count;
LUSC	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg16928487	chr17:17741425	SREBF1	0.46	9.03	0.44	1.4e-17	Total body bone mineral density;
LUSC	cis	rs757081	0.613	rs11024151	chr11:17105730	T/G	cg15432903	chr11:17409602	KCNJ11	-0.36	-5.73	-0.3	2.2e-8	Systolic blood pressure;
LUSC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg04455712	chr21:45112962	RRP1B	0.46	8.69	0.43	1.67e-16	Mean corpuscular volume;
LUSC	cis	rs10170846	0.800	rs10194743	chr2:223518151	A/G	cg25565276	chr2:223520875	FARSB	0.67	10.19	0.49	2.13e-21	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.5	-0.34	2.93e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10207060	0.500	rs62183161	chr2:240699856	C/T	cg07506560	chr2:240697449	NA	0.46	6.81	0.35	4.45e-11	Obesity-related traits;
LUSC	cis	rs9837602	1.000	rs4279135	chr3:99733096	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.18	0.32	1.82e-9	Breast cancer;
LUSC	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg15744005	chr10:104629667	AS3MT	0.29	5.99	0.31	5.29e-9	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-7.72	-0.39	1.39e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs3741151	0.773	rs79994237	chr11:73147974	T/C	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg21724239	chr8:58056113	NA	0.78	9.78	0.47	5.05e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg03585969	chr10:35415529	CREM	0.62	9.18	0.45	4.58e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg09184832	chr6:79620586	NA	-0.38	-5.83	-0.3	1.3e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	6.08	0.32	3.24e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7945718	0.967	rs10831906	chr11:12783042	C/T	cg25843174	chr11:12811716	TEAD1	0.32	7.33	0.37	1.76e-12	Educational attainment (years of education);
LUSC	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg05425664	chr17:57184151	TRIM37	0.62	8.49	0.42	7.11e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg20295408	chr7:1910781	MAD1L1	0.44	6.1	0.32	2.98e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs2221154	0.648	rs12632615	chr3:28941450	T/C	cg16413675	chr16:2520055	NTN3	0.29	6.14	0.32	2.35e-9	Alzheimer's disease;
LUSC	cis	rs500891	0.525	rs1170485	chr6:84038677	G/T	cg08257003	chr6:84140564	ME1	0.35	8.36	0.42	1.77e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.84	0.35	3.9e-11	IgG glycosylation;
LUSC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg13390004	chr1:15929781	NA	0.42	7.04	0.36	1.07e-11	Systolic blood pressure;
LUSC	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.91	0.31	8.45e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03576123	chr11:487126	PTDSS2	-0.96	-10.61	-0.5	7.48e-23	Body mass index;
LUSC	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg11161011	chr14:65562177	MAX	-0.72	-11.07	-0.52	1.85e-24	Obesity-related traits;
LUSC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg17968037	chr7:100024898	ZCWPW1	-0.42	-6.1	-0.32	2.9e-9	Platelet count;
LUSC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg19468946	chr17:37922297	IKZF3	-0.44	-6.93	-0.35	2.22e-11	Self-reported allergy;
LUSC	cis	rs7759001	0.857	rs2143061	chr6:27353705	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.78	0.3	1.73e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg24069376	chr3:38537580	EXOG	0.49	9.95	0.48	1.39e-20	Electrocardiographic conduction measures;
LUSC	cis	rs6084875	0.840	rs6084850	chr20:4725662	G/A	cg07258627	chr20:4721683	PRNT	-0.34	-6.16	-0.32	2.05e-9	Systemic lupus erythematosus;
LUSC	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg01579765	chr21:45077557	HSF2BP	-0.45	-9.4	-0.46	9.19e-19	Mean corpuscular volume;
LUSC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.59	-8.25	-0.41	3.76e-15	Diastolic blood pressure;
LUSC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13770153	chr20:60521292	NA	-0.59	-7.95	-0.4	2.98e-14	Body mass index;
LUSC	cis	rs41271951	0.512	rs11204765	chr1:151016757	G/A	cg11822372	chr1:151115635	SEMA6C	-0.78	-7.16	-0.36	5.14e-12	Blood protein levels;
LUSC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg11812906	chr14:75593930	NEK9	-0.68	-11.61	-0.54	2.04e-26	Height;
LUSC	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg05340658	chr4:99064831	C4orf37	0.45	7.16	0.36	5.31e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7804356	1.000	rs3801836	chr7:26851400	C/T	cg03456212	chr7:26904342	SKAP2	-0.54	-6.35	-0.33	7.23e-10	Type 1 diabetes;
LUSC	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg18753928	chr3:113234510	CCDC52	-0.52	-8.01	-0.4	1.99e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	11.75	0.54	6.26e-27	Alzheimer's disease;
LUSC	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg00359181	chr2:38893519	GALM	-0.53	-6.11	-0.32	2.84e-9	5-HTT brain serotonin transporter levels;
LUSC	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	8.26	0.41	3.52e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04691540	chr1:179198414	ABL2	0.43	6.19	0.32	1.76e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs3812762	0.868	rs7934519	chr11:8791981	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.34	5.81	0.3	1.45e-8	Hypospadias;
LUSC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9359856	0.564	rs17584290	chr6:90467114	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.2	-0.41	5.08e-15	Bipolar disorder;
LUSC	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.34	0.46	1.39e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9815354	0.855	rs73071261	chr3:42003369	C/A	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.21e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.04	-0.31	4.14e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg16850897	chr7:100343110	ZAN	0.39	6.14	0.32	2.39e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg23173402	chr1:227635558	NA	0.69	7.51	0.38	5.36e-13	Major depressive disorder;
LUSC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg04518342	chr5:131593106	PDLIM4	-0.42	-7.77	-0.39	9.64e-14	Breast cancer;
LUSC	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg18478394	chr8:109455254	TTC35	0.41	6.26	0.32	1.2e-9	Dupuytren's disease;
LUSC	cis	rs2153904	0.609	rs4951254	chr1:205642390	T/C	cg23034840	chr1:205782522	SLC41A1	0.56	6.37	0.33	6.33e-10	Prostate-specific antigen levels;
LUSC	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.8	-0.43	7.62e-17	Axial length;
LUSC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg02073558	chr3:44770973	ZNF501	0.57	9.29	0.45	1.97e-18	Depressive symptoms;
LUSC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	6.01	0.31	4.85e-9	Tonsillectomy;
LUSC	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg10523679	chr1:76189770	ACADM	-0.48	-6.79	-0.35	5.03e-11	Daytime sleep phenotypes;
LUSC	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg25233709	chr10:116636983	FAM160B1	0.37	6.59	0.34	1.69e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-7.44	-0.38	8.62e-13	Chronic sinus infection;
LUSC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg13072238	chr3:49761600	GMPPB	-0.69	-8.14	-0.41	8.15e-15	Menarche (age at onset);
LUSC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg24675658	chr1:53192096	ZYG11B	0.67	11.18	0.52	7.13e-25	Monocyte count;
LUSC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.34	-0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg19893071	chr8:145667764	NFKBIL2	-0.74	-6.02	-0.31	4.64e-9	Cognitive performance;
LUSC	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.68	5.66	0.3	3.25e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs440932	0.757	rs330943	chr8:9021026	G/A	cg15556689	chr8:8085844	FLJ10661	0.43	6.09	0.32	3.04e-9	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7809950	0.678	rs17154040	chr7:107005246	C/T	cg23024343	chr7:107201750	COG5	0.66	10.25	0.49	1.26e-21	Coronary artery disease;
LUSC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.4	-0.33	5.15e-10	Total body bone mineral density;
LUSC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg15445000	chr17:37608096	MED1	0.39	6.68	0.34	1.02e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg04374321	chr14:90722782	PSMC1	-0.44	-6.61	-0.34	1.54e-10	Mortality in heart failure;
LUSC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg11663144	chr21:46675770	NA	-0.42	-7.25	-0.37	2.93e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07404784	chr11:43665970	NA	0.45	6.65	0.34	1.17e-10	Calcium levels;
LUSC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg00945038	chr17:61921165	SMARCD2	0.39	5.99	0.31	5.57e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg25039879	chr17:56429692	SUPT4H1	0.66	9.12	0.45	7.09e-18	Cognitive test performance;
LUSC	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Bladder cancer;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg06877462	chr1:205807181	PM20D1	0.54	10.29	0.49	9.34e-22	Menarche (age at onset);
LUSC	trans	rs4809760	0.901	rs9789783	chr20:48490801	C/A	cg15578140	chr7:147718109	MIR548F3;CNTNAP2	-0.25	-6.01	-0.31	4.9e-9	Gut microbiota (beta diversity);
LUSC	cis	rs3736594	0.513	rs3811644	chr2:27802805	A/G	cg27432699	chr2:27873401	GPN1	0.67	8.95	0.44	2.57e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg08313168	chr12:7315531	NA	0.46	6.02	0.31	4.48e-9	Lung disease severity in cystic fibrosis;
LUSC	trans	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg26384229	chr12:38710491	ALG10B	0.56	8.9	0.44	3.72e-17	Morning vs. evening chronotype;
LUSC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg00999904	chr2:3704751	ALLC	-0.62	-9.89	-0.48	2.13e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg11502198	chr6:26597334	ABT1	0.64	10.07	0.48	5.3e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg14019146	chr3:50243930	SLC38A3	0.31	6.85	0.35	3.58e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg02493740	chr2:85810744	VAMP5	-0.54	-9.48	-0.46	4.82e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-0.96	-12.87	-0.58	4.54e-31	Exhaled nitric oxide output;
LUSC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg09365446	chr1:150670422	GOLPH3L	0.55	8.46	0.42	8.5e-16	Tonsillectomy;
LUSC	cis	rs7809950	0.954	rs2712229	chr7:107295326	T/A	cg23024343	chr7:107201750	COG5	0.47	7.09	0.36	8.23e-12	Coronary artery disease;
LUSC	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg18806716	chr10:30721971	MAP3K8	-0.65	-9.98	-0.48	1.04e-20	Inflammatory bowel disease;
LUSC	cis	rs12618769	0.652	rs1516085	chr2:99232312	G/A	cg10123293	chr2:99228465	UNC50	0.43	6.93	0.35	2.19e-11	Bipolar disorder;
LUSC	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg05784532	chr1:230284198	GALNT2	0.65	9.02	0.44	1.46e-17	Coronary artery disease;
LUSC	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.7	12.33	0.56	4.87e-29	White blood cell count;
LUSC	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.47	-6.98	-0.36	1.56e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg04455712	chr21:45112962	RRP1B	0.46	8.8	0.43	7.57e-17	Mean corpuscular volume;
LUSC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg03582285	chr17:40700314	NA	-0.37	-6.32	-0.33	8.58e-10	Colorectal or endometrial cancer;
LUSC	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg27124370	chr19:33622961	WDR88	0.52	6.65	0.34	1.22e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg17143192	chr8:8559678	CLDN23	-0.36	-5.7	-0.3	2.7e-8	Joint mobility (Beighton score);
LUSC	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg24851651	chr11:66362959	CCS	-0.38	-5.94	-0.31	6.99e-9	Educational attainment (years of education);
LUSC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.57	0.42	3.84e-16	Prudent dietary pattern;
LUSC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg14983838	chr19:29218262	NA	0.58	6.8	0.35	4.82e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg26695010	chr11:65641043	EFEMP2	0.42	6.0	0.31	5.07e-9	Breast cancer;
LUSC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg25173405	chr17:45401733	C17orf57	-0.4	-6.42	-0.33	4.61e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs208520	1.000	rs208535	chr6:66962286	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-12.34	-0.56	4.42e-29	Exhaled nitric oxide output;
LUSC	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg22508957	chr16:3507546	NAT15	0.84	10.75	0.51	2.4e-23	Tuberculosis;
LUSC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03576123	chr11:487126	PTDSS2	-0.95	-10.54	-0.5	1.29e-22	Body mass index;
LUSC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg24578937	chr1:2090814	PRKCZ	-0.46	-9.77	-0.47	5.34e-20	Height;
LUSC	cis	rs8099014	0.861	rs6566974	chr18:56131156	A/G	cg12907477	chr18:56117327	MIR122	0.46	7.02	0.36	1.28e-11	Platelet count;
LUSC	cis	rs4766566	0.694	rs3847952	chr12:111746678	T/G	cg10833066	chr12:111807467	FAM109A	0.54	10.02	0.48	7.67e-21	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUSC	trans	rs991639	0.860	rs1949341	chr3:86204	G/T	cg20516845	chr21:43823604	UBASH3A	0.38	6.34	0.33	7.3e-10	Problematic alcohol use in trauma-exposed individuals;
LUSC	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg09307838	chr4:120376055	NA	0.69	9.7	0.47	8.87e-20	Corneal astigmatism;
LUSC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg25258033	chr6:167368657	RNASET2	0.39	6.3	0.33	9.49e-10	Crohn's disease;
LUSC	cis	rs57244997	1.000	rs73026573	chr6:162405119	C/T	cg17173639	chr6:162384350	PARK2	-0.64	-6.42	-0.33	4.61e-10	Mosquito bite size;
LUSC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06481639	chr22:41940642	POLR3H	-0.51	-5.84	-0.3	1.26e-8	Vitiligo;
LUSC	cis	rs7615316	1.000	rs9882763	chr3:142341308	T/G	cg16271453	chr3:142027066	XRN1	-0.36	-6.14	-0.32	2.39e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.85	14.21	0.61	3.59e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg19717773	chr7:2847554	GNA12	0.33	5.88	0.31	1.02e-8	Height;
LUSC	trans	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg25214090	chr10:38739885	LOC399744	0.47	7.55	0.38	4.11e-13	Corneal astigmatism;
LUSC	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.67	-0.34	1.08e-10	Monocyte percentage of white cells;
LUSC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.81	-0.43	6.75e-17	Platelet count;
LUSC	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg06606381	chr12:133084897	FBRSL1	-1.03	-9.56	-0.46	2.63e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.59	-6.41	-0.33	4.99e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14829155	chr15:31115871	NA	0.72	10.69	0.51	3.75e-23	Huntington's disease progression;
LUSC	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg01620082	chr3:125678407	NA	-0.77	-7.12	-0.36	6.8e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg12432903	chr7:1882776	MAD1L1	-0.37	-6.09	-0.32	3.04e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg00320862	chr3:170588302	RPL22L1	0.4	5.99	0.31	5.45e-9	Schizophrenia (age at onset);
LUSC	cis	rs4400599	0.569	rs10797058	chr1:154200704	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-6.02	-0.31	4.47e-9	Platelet distribution width;
LUSC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.7	-12.63	-0.57	3.63e-30	Aortic root size;
LUSC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	1.01	14.09	0.61	1.02e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	0.82	13.56	0.6	1.13e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.88	-0.44	4.32e-17	Response to antipsychotic treatment;
LUSC	trans	rs1459104	0.789	rs28896554	chr11:54812637	C/T	cg03929089	chr4:120376271	NA	0.72	6.26	0.32	1.17e-9	Body mass index;
LUSC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg04369109	chr6:150039330	LATS1	-0.57	-8.3	-0.41	2.62e-15	Lung cancer;
LUSC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	14.51	0.62	2.45e-37	Platelet count;
LUSC	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg10326726	chr10:51549505	MSMB	-0.38	-6.55	-0.34	2.21e-10	Prostate-specific antigen levels;
LUSC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11764359	chr7:65958608	NA	-0.69	-11.1	-0.52	1.4e-24	Aortic root size;
LUSC	cis	rs7640424	0.929	rs327139	chr3:107822481	G/C	cg09227934	chr3:107805635	CD47	0.45	7.47	0.38	7.11e-13	Body mass index;
LUSC	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg11548914	chr2:179343871	FKBP7;PLEKHA3;MIR548N	0.53	6.54	0.34	2.35e-10	Atrial fibrillation;
LUSC	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg25797454	chr6:150327115	RAET1K	0.37	8.49	0.42	7.01e-16	Alopecia areata;
LUSC	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	0.78	11.63	0.54	1.74e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs12618769	0.597	rs2278213	chr2:99136059	A/G	cg10123293	chr2:99228465	UNC50	0.44	7.33	0.37	1.77e-12	Bipolar disorder;
LUSC	cis	rs73198271	0.531	rs11985640	chr8:8652504	C/T	cg01851573	chr8:8652454	MFHAS1	0.58	7.72	0.39	1.34e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs240993	0.627	rs174389	chr6:111916393	A/C	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.03	-0.31	4.36e-9	Inflammatory skin disease;Psoriasis;
LUSC	cis	rs8017423	0.935	rs2236403	chr14:90736325	C/T	cg04374321	chr14:90722782	PSMC1	-0.68	-10.37	-0.49	4.94e-22	Mortality in heart failure;
LUSC	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg13852791	chr20:30311386	BCL2L1	0.9	13.34	0.59	7.48e-33	Mean corpuscular hemoglobin;
LUSC	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg27661571	chr11:113659931	NA	-0.58	-6.45	-0.33	3.92e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.67	10.68	0.5	4.37e-23	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg19875535	chr5:140030758	IK	-0.53	-8.76	-0.43	1.02e-16	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1160297	0.609	rs1839770	chr2:53104091	G/A	cg07782112	chr2:53107842	NA	0.38	6.37	0.33	6.12e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7605827	0.930	rs4668912	chr2:15610882	C/T	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg10018233	chr7:150070692	REPIN1	0.39	6.74	0.35	6.82e-11	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg15956273	chr12:65153476	GNS	0.41	6.36	0.33	6.65e-10	Triglycerides;
LUSC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg01475377	chr6:109611718	NA	-0.45	-8.21	-0.41	4.87e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.82	11.2	0.52	6.42e-25	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg09034736	chr1:150693464	HORMAD1	0.48	7.0	0.36	1.45e-11	Tonsillectomy;
LUSC	cis	rs6495367	0.872	rs7183818	chr15:79372413	A/G	cg17916960	chr15:79447300	NA	0.34	6.05	0.31	3.8e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs7408868	0.611	rs11669982	chr19:15292366	C/T	cg14696996	chr19:15285081	NOTCH3	0.63	6.71	0.34	8.55e-11	Pulse pressure;
LUSC	cis	rs11676348	0.808	rs1008563	chr2:219026888	G/A	cg00012203	chr2:219082015	ARPC2	-0.57	-8.91	-0.44	3.4e-17	Ulcerative colitis;
LUSC	cis	rs12711979	0.513	rs11676551	chr2:3836782	A/G	cg17052675	chr2:3827356	NA	-0.35	-5.71	-0.3	2.5e-8	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs2070433	1.000	rs11701310	chr21:47962836	G/C	cg12379764	chr21:47803548	PCNT	0.81	10.5	0.5	1.71e-22	Lymphocyte counts;
LUSC	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg24642844	chr7:1081250	C7orf50	-0.45	-7.22	-0.37	3.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.69	9.75	0.47	6.11e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg13256891	chr4:100009986	ADH5	0.41	5.67	0.3	3.14e-8	Alcohol dependence;
LUSC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.28e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.67	11.5	0.53	5.33e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg03676636	chr4:99064102	C4orf37	0.36	8.01	0.4	1.97e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6987853	0.636	rs6988165	chr8:42351176	C/G	cg09913449	chr8:42400586	C8orf40	-0.45	-7.48	-0.38	6.6e-13	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg25214090	chr10:38739885	LOC399744	0.53	7.93	0.4	3.22e-14	Corneal astigmatism;
LUSC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg20203395	chr5:56204925	C5orf35	0.53	7.61	0.38	2.75e-13	Coronary artery disease;
LUSC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg21782813	chr7:2030301	MAD1L1	0.38	6.17	0.32	1.95e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08859206	chr1:53392774	SCP2	-0.54	-9.57	-0.46	2.45e-19	Monocyte count;
LUSC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg21984481	chr17:79567631	NPLOC4	0.52	9.73	0.47	7.15e-20	Eye color traits;
LUSC	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.56	-11.44	-0.53	8.47e-26	Sense of smell;
LUSC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.11	-0.41	9.77e-15	Chronic sinus infection;
LUSC	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.74	-0.6	2.34e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-8.71	-0.43	1.42e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg16928487	chr17:17741425	SREBF1	-0.42	-8.21	-0.41	4.86e-15	Total body bone mineral density;
LUSC	cis	rs897984	0.762	rs11150601	chr16:30977799	G/A	cg02466173	chr16:30829666	NA	0.56	11.22	0.52	5.11e-25	Dementia with Lewy bodies;
LUSC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.66	-0.39	2e-13	Hemoglobin concentration;
LUSC	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg17470449	chr10:769945	NA	0.5	7.0	0.36	1.41e-11	Uric acid levels;
LUSC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.67	-11.15	-0.52	9.33e-25	Heart rate;
LUSC	cis	rs6690583	0.623	rs74689037	chr1:85439268	C/T	cg11262906	chr1:85462892	MCOLN2	0.7	6.66	0.34	1.16e-10	Serum sulfate level;
LUSC	trans	rs11700980	0.551	rs4999007	chr21:30109259	C/T	cg14791747	chr16:20752902	THUMPD1	0.55	5.98	0.31	5.75e-9	QRS complex (12-leadsum);
LUSC	trans	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg14343924	chr8:8086146	FLJ10661	-0.45	-6.23	-0.32	1.43e-9	Monocyte count;
LUSC	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg20701182	chr2:24300061	SF3B14	0.74	7.48	0.38	6.68e-13	Lymphocyte counts;
LUSC	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg20891283	chr12:69753455	YEATS4	0.43	6.03	0.31	4.26e-9	Response to diuretic therapy;
LUSC	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg21153622	chr11:89784906	NA	-0.39	-6.16	-0.32	2.13e-9	HDL cholesterol;
LUSC	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg02175503	chr12:58329896	NA	0.61	9.99	0.48	9.8e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg15309053	chr8:964076	NA	0.42	8.94	0.44	2.79e-17	Schizophrenia;
LUSC	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg25801113	chr15:45476975	SHF	0.34	7.07	0.36	9.18e-12	Uric acid levels;
LUSC	cis	rs926938	0.557	rs6667218	chr1:115238982	G/A	cg12756093	chr1:115239321	AMPD1	-0.55	-7.76	-0.39	1.07e-13	Autism;
LUSC	trans	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	7.05	0.36	1.03e-11	Menarche (age at onset);
LUSC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg07148914	chr20:33460835	GGT7	-0.48	-7.18	-0.37	4.41e-12	Height;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	0.89	16.29	0.67	2.55e-44	Menarche (age at onset);
LUSC	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.57	8.9	0.44	3.72e-17	Menopause (age at onset);
LUSC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.66	0.6	4.84e-34	Platelet count;
LUSC	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.89	-0.35	2.79e-11	Blood metabolite levels;
LUSC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg24675658	chr1:53192096	ZYG11B	-0.59	-9.23	-0.45	3.2e-18	Monocyte count;
LUSC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	13.39	0.59	5.09e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4971059	0.654	rs4971073	chr1:155113104	G/T	cg22049894	chr1:155113146	DPM3	0.38	5.97	0.31	5.92e-9	Breast cancer;
LUSC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg25019033	chr10:957182	NA	0.52	6.98	0.36	1.56e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg08949735	chr16:89699720	DPEP1	-0.24	-5.88	-0.31	9.96e-9	Vitiligo;
LUSC	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.81	0.3	1.49e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg26395211	chr5:140044315	WDR55	0.45	7.01	0.36	1.33e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg08601574	chr20:25228251	PYGB	0.42	6.31	0.33	8.95e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1044826	0.642	rs6439860	chr3:139175797	A/G	cg15131784	chr3:139108705	COPB2	0.38	6.11	0.32	2.76e-9	Obesity-related traits;
LUSC	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg15704280	chr7:45808275	SEPT13	-0.58	-7.16	-0.36	5.02e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6076065	0.723	rs2424545	chr20:23390876	A/G	cg11657817	chr20:23433608	CST11	-0.42	-7.89	-0.4	4.24e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19346786	chr7:2764209	NA	-0.45	-7.55	-0.38	4.25e-13	Height;
LUSC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg15649852	chr7:65879115	NA	-0.41	-5.78	-0.3	1.74e-8	Aortic root size;
LUSC	cis	rs3087591	0.659	rs7218930	chr17:29640204	A/G	cg24425628	chr17:29625626	OMG;NF1	0.47	7.09	0.36	8.2e-12	Hip circumference;
LUSC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-1.04	-14.65	-0.63	7.01e-38	Vitiligo;
LUSC	cis	rs10186029	0.680	rs10179425	chr2:213978441	T/C	cg08319019	chr2:214017104	IKZF2	0.6	8.62	0.43	2.65e-16	Systemic sclerosis;
LUSC	cis	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg27411982	chr8:10470053	RP1L1	-0.51	-8.07	-0.4	1.31e-14	Neuroticism;
LUSC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-9.42	-0.46	7.79e-19	Type 2 diabetes;
LUSC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg08773314	chr2:239334832	ASB1	0.42	9.26	0.45	2.63e-18	Multiple system atrophy;
LUSC	cis	rs9463078	0.764	rs976699	chr6:44952852	G/T	cg25276700	chr6:44698697	NA	-0.29	-5.85	-0.3	1.16e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs10484885	0.775	rs55926724	chr6:90417450	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.93	-11.18	-0.52	7.07e-25	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg11062466	chr8:58055876	NA	0.68	7.85	0.39	5.73e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg08873628	chr1:175162347	KIAA0040	0.42	6.04	0.31	4.21e-9	Alcohol dependence;
LUSC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg12564285	chr5:131593104	PDLIM4	0.45	8.13	0.41	8.27e-15	Breast cancer;
LUSC	cis	rs9467160	0.871	rs9467168	chr6:24449036	A/G	cg20631270	chr6:24437470	GPLD1	0.44	5.76	0.3	1.94e-8	Liver enzyme levels;
LUSC	cis	rs10450586	1.000	rs10450586	chr11:27308483	G/C	cg08958251	chr11:27270390	NA	0.35	5.74	0.3	2.15e-8	Total body bone mineral density;
LUSC	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg16482183	chr6:26056742	HIST1H1C	0.44	6.52	0.34	2.67e-10	Height;
LUSC	cis	rs9473147	0.503	rs9473123	chr6:47475339	G/A	cg20196966	chr6:47445060	CD2AP	0.42	5.89	0.31	9.61e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.87	0.4	5.04e-14	Prudent dietary pattern;
LUSC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	1.01	14.35	0.62	1e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg11262906	chr1:85462892	MCOLN2	-0.57	-7.31	-0.37	2.01e-12	Serum sulfate level;
LUSC	cis	rs9473147	0.516	rs2171089	chr6:47515811	A/G	cg12968598	chr6:47444699	CD2AP	0.52	7.96	0.4	2.74e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg09655341	chr17:79618100	PDE6G	0.26	5.9	0.31	9.15e-9	Eye color traits;
LUSC	cis	rs7973719	0.833	rs3825405	chr12:7360143	G/T	cg07052231	chr12:7363540	PEX5	0.52	9.11	0.45	8.02e-18	IgG glycosylation;
LUSC	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg04450456	chr4:17643702	FAM184B	0.38	6.28	0.33	1.03e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg15848620	chr12:58087721	OS9	-0.55	-7.87	-0.4	4.88e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg09877947	chr5:131593287	PDLIM4	0.46	6.41	0.33	5.09e-10	Breast cancer;
LUSC	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg13939156	chr17:80058883	NA	0.37	7.4	0.38	1.13e-12	Life satisfaction;
LUSC	trans	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg18335740	chr13:41363409	SLC25A15	0.78	14.02	0.61	2.03e-35	Lewy body disease;
LUSC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.47	-8.91	-0.44	3.27e-17	Monocyte percentage of white cells;
LUSC	cis	rs1790761	0.777	rs917570	chr11:67196544	C/G	cg24690094	chr11:67383802	NA	-0.32	-5.65	-0.3	3.49e-8	Mean corpuscular volume;
LUSC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg10755058	chr3:40428713	ENTPD3	0.36	5.92	0.31	8.17e-9	Renal cell carcinoma;
LUSC	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg18825076	chr15:78729989	IREB2	0.44	6.06	0.31	3.73e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg03609598	chr5:56110824	MAP3K1	0.38	5.7	0.3	2.7e-8	Initial pursuit acceleration;
LUSC	cis	rs1506636	0.720	rs2456552	chr7:123441400	A/G	cg03229431	chr7:123269106	ASB15	0.45	7.34	0.37	1.67e-12	Plateletcrit;Platelet count;
LUSC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.5	0.38	5.7e-13	Bipolar disorder;
LUSC	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg17623882	chr6:41773611	USP49	0.63	10.75	0.51	2.42e-23	Menarche (age at onset);
LUSC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10802521	chr3:52805072	NEK4	-0.54	-8.46	-0.42	8.46e-16	Bipolar disorder;
LUSC	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg25233709	chr10:116636983	FAM160B1	0.44	7.96	0.4	2.77e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06481639	chr22:41940642	POLR3H	0.51	5.85	0.3	1.19e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg24375607	chr4:120327624	NA	0.79	12.03	0.55	6.08e-28	Corneal astigmatism;
LUSC	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg22709100	chr7:91322751	NA	0.42	6.11	0.32	2.82e-9	Breast cancer;
LUSC	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg11189052	chr15:85197271	WDR73	-0.49	-7.32	-0.37	1.91e-12	P wave terminal force;
LUSC	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg24642439	chr20:33292090	TP53INP2	-0.48	-7.36	-0.37	1.45e-12	Glomerular filtration rate (creatinine);
LUSC	trans	rs9296661	0.530	rs9349593	chr6:51586771	G/A	cg19476788	chr18:77172117	NFATC1	-0.36	-5.97	-0.31	5.99e-9	Weight loss (gastric bypass surgery);
LUSC	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg05738196	chr6:26577821	NA	0.81	15.2	0.64	5.18e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.66	10.97	0.51	4.07e-24	Bone mineral density;
LUSC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg07701084	chr6:150067640	NUP43	0.57	8.84	0.44	5.51e-17	Lung cancer;
LUSC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.15	-0.49	2.88e-21	Obesity-related traits;
LUSC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg05855489	chr10:104503620	C10orf26	0.61	8.06	0.4	1.34e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg25237894	chr2:233734115	C2orf82	-0.37	-6.97	-0.36	1.72e-11	Coronary artery disease;
LUSC	cis	rs62408225	1.000	rs56106243	chr6:90975990	C/T	cg06866423	chr6:90926672	BACH2	0.41	5.92	0.31	7.79e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	8.64	0.43	2.43e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg08807101	chr21:30365312	RNF160	-0.51	-6.28	-0.32	1.07e-9	Cognitive test performance;
LUSC	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	8.95	0.44	2.55e-17	Total cholesterol levels;
LUSC	cis	rs10779751	1.000	rs7524202	chr1:11297762	T/C	cg08854313	chr1:11322531	MTOR	0.87	15.22	0.64	4.09e-40	Body mass index;
LUSC	cis	rs3087591	0.922	rs2905799	chr17:29536901	G/A	cg24425628	chr17:29625626	OMG;NF1	0.55	8.2	0.41	5.32e-15	Hip circumference;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15905960	chr11:111473361	SIK2	-0.4	-6.02	-0.31	4.58e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7402982	0.647	rs34038360	chr15:99201573	A/C	cg03437748	chr15:99193247	IGF1R	0.42	6.03	0.31	4.45e-9	Birth weight;
LUSC	cis	rs6700896	0.931	rs4655743	chr1:66087301	G/C	cg04111102	chr1:66153794	NA	0.32	7.07	0.36	9.38e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg17168535	chr8:21777572	XPO7	0.85	16.05	0.66	2.34e-43	Mean corpuscular volume;
LUSC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.44	-0.33	4.27e-10	Life satisfaction;
LUSC	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg04362960	chr10:104952993	NT5C2	0.66	9.48	0.46	4.91e-19	Arsenic metabolism;
LUSC	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg06484146	chr7:12443880	VWDE	-0.73	-7.34	-0.37	1.64e-12	Coronary artery disease;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20554926	chr5:162887199	HMMR;NUDCD2	-0.44	-6.86	-0.35	3.38e-11	Triglycerides;
LUSC	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg18002602	chr11:66138449	SLC29A2	0.49	8.79	0.43	7.95e-17	Educational attainment (years of education);
LUSC	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg23000734	chr10:126850823	CTBP2	-0.43	-7.0	-0.36	1.44e-11	Menarche (age at onset);
LUSC	trans	rs7181230	0.813	rs4924417	chr15:40366939	G/C	cg22705835	chr10:65332833	REEP3	-0.4	-6.59	-0.34	1.73e-10	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg02807482	chr3:125708958	NA	-0.53	-6.68	-0.34	9.76e-11	Blood pressure (smoking interaction);
LUSC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg19774624	chr17:42201019	HDAC5	-0.79	-12.73	-0.57	1.57e-30	Total body bone mineral density;
LUSC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.07	0.52	1.77e-24	Prudent dietary pattern;
LUSC	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg24069376	chr3:38537580	EXOG	-0.4	-7.83	-0.39	6.62e-14	Electrocardiographic conduction measures;
LUSC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg26338869	chr17:61819248	STRADA	0.4	5.75	0.3	1.99e-8	Prudent dietary pattern;
LUSC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg06221963	chr1:154839813	KCNN3	-0.44	-8.88	-0.44	4.07e-17	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.66	0.3	3.26e-8	Menopause (age at onset);
LUSC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg02569458	chr12:86230093	RASSF9	0.62	10.47	0.5	2.18e-22	Major depressive disorder;
LUSC	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg18230493	chr5:56204884	C5orf35	-0.94	-14.17	-0.61	5.14e-36	Initial pursuit acceleration;
LUSC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	10.8	0.51	1.55e-23	Homoarginine levels;
LUSC	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg18827107	chr12:86230957	RASSF9	-0.45	-6.77	-0.35	5.7e-11	Major depressive disorder;
LUSC	cis	rs6543140	0.964	rs4851593	chr2:103089227	C/T	cg09003973	chr2:102972529	NA	-0.51	-6.1	-0.32	2.88e-9	Blood protein levels;
LUSC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg20307385	chr11:47447363	PSMC3	-0.44	-6.43	-0.33	4.36e-10	Subjective well-being;
LUSC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg12963246	chr6:28129442	ZNF389	0.4	5.99	0.31	5.44e-9	Cardiac Troponin-T levels;
LUSC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg11247378	chr22:39784982	NA	-0.59	-10.01	-0.48	8.48e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg24250549	chr1:154909240	PMVK	0.63	10.05	0.48	6.22e-21	Prostate cancer;
LUSC	cis	rs924840	0.634	rs2869030	chr15:78711803	A/C	cg24631222	chr15:78858424	CHRNA5	0.55	7.49	0.38	6.02e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs460214	0.528	rs6517474	chr21:40023133	G/A	cg05519781	chr21:40033154	ERG	-0.42	-5.67	-0.3	3.05e-8	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	0.97	10.96	0.51	4.58e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs394563	0.901	rs448874	chr6:149796967	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.44	-0.33	4.21e-10	Dupuytren's disease;
LUSC	cis	rs9400467	0.508	rs11153294	chr6:111730246	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.98	-0.36	1.56e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg16989719	chr2:238392110	NA	-0.36	-6.46	-0.33	3.66e-10	Prostate cancer;
LUSC	cis	rs16949788	0.826	rs74245473	chr15:66708775	C/A	cg08120210	chr15:66682733	MAP2K1	-0.6	-5.97	-0.31	6.22e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg11062466	chr8:58055876	NA	0.48	5.96	0.31	6.37e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs17621444	0.522	rs10886584	chr10:121817282	A/G	cg02041677	chr10:121771263	NA	-0.33	-6.22	-0.32	1.48e-9	IgG glycosylation;
LUSC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg15309053	chr8:964076	NA	0.31	6.13	0.32	2.47e-9	Schizophrenia;
LUSC	cis	rs6967385	0.560	rs12673036	chr7:12343463	A/G	cg06484146	chr7:12443880	VWDE	0.46	6.83	0.35	4e-11	Response to taxane treatment (placlitaxel);
LUSC	cis	rs6083	0.536	rs4528512	chr15:58852226	A/T	cg05156742	chr15:59063176	FAM63B	0.41	6.31	0.33	8.89e-10	Schizophrenia;
LUSC	cis	rs4290604	0.665	rs4432400	chr2:238058938	A/G	cg23555395	chr2:238036564	NA	-0.52	-6.86	-0.35	3.26e-11	Asthma;
LUSC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.82	-0.35	4.29e-11	Total body bone mineral density;
LUSC	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.23e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.62	-8.25	-0.41	3.65e-15	Systemic lupus erythematosus;
LUSC	trans	rs61931739	0.635	rs1405025	chr12:33908491	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.75	0.39	1.1e-13	Morning vs. evening chronotype;
LUSC	cis	rs1692120	0.669	rs61898510	chr11:61425464	T/C	cg19838087	chr11:61442541	NA	0.3	5.94	0.31	7.16e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg25726756	chr21:47582351	C21orf56	0.33	5.65	0.3	3.45e-8	Testicular germ cell tumor;
LUSC	cis	rs2235649	0.833	rs9922139	chr16:1848329	G/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.46	-6.17	-0.32	1.96e-9	Blood metabolite levels;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07360250	chr5:176830358	F12	0.38	6.37	0.33	6.2e-10	Calcium levels;
LUSC	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg09835421	chr16:68378352	PRMT7	-0.59	-6.31	-0.33	8.82e-10	Schizophrenia;
LUSC	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg19789473	chr17:27170043	C17orf63	-0.3	-5.69	-0.3	2.75e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.22	0.49	1.67e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg11752832	chr7:134001865	SLC35B4	0.6	9.54	0.46	3.19e-19	Mean platelet volume;
LUSC	cis	rs12980942	1.000	rs4456618	chr19:41813957	G/C	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.24	0.32	1.31e-9	Coronary artery disease;
LUSC	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg07169764	chr2:136633963	MCM6	-0.59	-7.81	-0.39	7.72e-14	Mosquito bite size;
LUSC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg24250549	chr1:154909240	PMVK	0.65	10.87	0.51	9.05e-24	Prostate cancer;
LUSC	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.54	8.71	0.43	1.47e-16	Breast cancer;
LUSC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.81	-13.1	-0.58	6.17e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4478858	0.735	rs6679360	chr1:31817936	G/T	cg00250761	chr1:31883323	NA	-0.37	-9.16	-0.45	5.22e-18	Alcohol dependence;
LUSC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00166722	chr3:10149974	C3orf24	-0.65	-9.5	-0.46	4.23e-19	Alzheimer's disease;
LUSC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg12963246	chr6:28129442	ZNF389	0.55	7.85	0.39	5.77e-14	Depression;
LUSC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg03388025	chr16:89894329	SPIRE2	0.33	6.85	0.35	3.48e-11	Vitiligo;
LUSC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg02951883	chr7:2050386	MAD1L1	-0.5	-8.93	-0.44	2.9e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg16230307	chr14:35515116	FAM177A1	0.77	10.17	0.49	2.41e-21	Psoriasis;
LUSC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg24829409	chr8:58192753	C8orf71	-0.59	-6.25	-0.32	1.22e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg22907277	chr7:1156413	C7orf50	0.7	10.26	0.49	1.21e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.07	-0.32	3.43e-9	Neutrophil percentage of white cells;
LUSC	cis	rs3106136	0.933	rs34383543	chr4:95163792	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.08	-0.32	3.26e-9	Capecitabine sensitivity;
LUSC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06112835	chr11:68658793	MRPL21	0.52	7.75	0.39	1.12e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14442939	chr10:27389572	ANKRD26	0.54	7.01	0.36	1.31e-11	Breast cancer;
LUSC	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.64	0.39	2.25e-13	Iron status biomarkers;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg23467222	chr17:79926018	NA	0.39	6.03	0.31	4.3e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.69e-9	Response to antipsychotic treatment;
LUSC	cis	rs745570	1.000	rs745571	chr17:77781387	T/C	cg04986373	chr17:77768687	CBX8	0.38	7.43	0.38	8.93e-13	Breast cancer;
LUSC	cis	rs7739264	0.563	rs9465516	chr6:19771998	A/C	cg02404759	chr6:19790362	NA	-0.42	-6.67	-0.34	1.07e-10	Endometriosis;
LUSC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4664308	1.000	rs10929965	chr2:160906931	C/T	cg03641300	chr2:160917029	PLA2R1	0.67	11.19	0.52	6.83e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg16989086	chr20:62203971	PRIC285	0.46	6.42	0.33	4.69e-10	Glioblastoma;
LUSC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.88	-0.35	2.94e-11	Platelet count;
LUSC	trans	rs62238980	0.614	rs117161237	chr22:32501630	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.52	-5.96	-0.31	6.37e-9	Childhood ear infection;
LUSC	cis	rs2412208	0.509	rs7546792	chr1:7124346	C/T	cg20434152	chr1:7120926	CAMTA1	-0.37	-7.71	-0.39	1.48e-13	Survival in sporadic amyotrophic lateral sclerosis;
LUSC	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg05621596	chr22:47072043	GRAMD4	-0.44	-6.89	-0.35	2.73e-11	Urate levels in obese individuals;
LUSC	cis	rs1881797	1.000	rs55852476	chr1:247696173	G/A	cg14830002	chr1:247616686	OR2B11	0.51	7.27	0.37	2.59e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6982240	0.569	rs6992286	chr8:142279412	G/A	cg27411547	chr8:142287226	NA	-0.48	-8.51	-0.42	6.05e-16	Tonsillectomy;
LUSC	trans	rs4718428	1.000	rs4718421	chr7:66350300	C/T	cg18876405	chr7:65276391	NA	0.48	7.39	0.37	1.2e-12	Corneal structure;
LUSC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	6.06	0.31	3.7e-9	Electroencephalogram traits;
LUSC	trans	rs9860340	0.730	rs4859087	chr3:87636245	C/T	cg03644585	chr7:884825	UNC84A	-0.42	-5.99	-0.31	5.32e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg24397884	chr7:158709396	WDR60	0.62	9.57	0.46	2.48e-19	Height;
LUSC	cis	rs2652834	0.687	rs35963767	chr15:63397601	G/A	cg05507819	chr15:63340323	TPM1	0.55	7.07	0.36	8.99e-12	HDL cholesterol;
LUSC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6908843	0.532	rs79555858	chr6:166666497	G/A	cg06878426	chr6:166666287	NA	0.45	6.38	0.33	5.91e-10	Macrophage inflammatory protein 1b levels;
LUSC	trans	rs72674100	0.867	rs75247520	chr4:97980121	C/T	cg09670535	chr1:18959427	PAX7	-0.64	-6.12	-0.32	2.68e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.46	-6.72	-0.35	7.72e-11	Rheumatoid arthritis;
LUSC	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg18827107	chr12:86230957	RASSF9	-0.48	-7.08	-0.36	8.5e-12	Major depressive disorder;
LUSC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs722599	0.683	rs17102847	chr14:75324780	A/G	cg08847533	chr14:75593920	NEK9	-0.46	-6.52	-0.34	2.67e-10	IgG glycosylation;
LUSC	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg10978503	chr1:24200527	CNR2	0.54	13.24	0.59	1.85e-32	Immature fraction of reticulocytes;
LUSC	cis	rs9311676	0.656	rs55668308	chr3:58388453	C/T	cg13750441	chr3:58318267	PXK	0.35	6.72	0.35	7.86e-11	Systemic lupus erythematosus;
LUSC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg00310523	chr12:86230176	RASSF9	-0.5	-9.44	-0.46	6.49e-19	Major depressive disorder;
LUSC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg26924012	chr15:45694286	SPATA5L1	1.13	20.81	0.75	2.85e-62	Homoarginine levels;
LUSC	cis	rs7075426	0.789	rs6586011	chr10:88213604	A/G	cg07322936	chr10:88137208	NA	-0.46	-6.65	-0.34	1.17e-10	Migraine without aura;
LUSC	cis	rs3790515	1.000	rs3790515	chr1:151786372	A/G	cg07092448	chr1:151763213	TDRKH	0.86	7.18	0.37	4.43e-12	Depressive symptoms (SSRI exposure interaction);
LUSC	cis	rs73206853	0.620	rs73194027	chr12:111144317	C/A	cg12870014	chr12:110450643	ANKRD13A	0.67	6.52	0.34	2.64e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg02655711	chr22:19163373	SLC25A1	0.66	12.03	0.55	6.18e-28	Metabolite levels;
LUSC	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg27661571	chr11:113659931	NA	-0.66	-7.44	-0.38	8.49e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs911119	0.913	rs6036463	chr20:23578940	A/T	cg16589663	chr20:23618590	CST3	-0.63	-7.66	-0.39	2.04e-13	Chronic kidney disease;
LUSC	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg09877947	chr5:131593287	PDLIM4	0.41	6.79	0.35	5.11e-11	Blood metabolite levels;
LUSC	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg21890820	chr11:65308645	LTBP3	0.5	7.41	0.38	1.02e-12	Bone mineral density;
LUSC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.37	-0.46	1.12e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg03605463	chr16:89740564	NA	0.59	9.43	0.46	6.97e-19	Vitiligo;
LUSC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.12	-0.32	2.6e-9	Extrinsic epigenetic age acceleration;
LUSC	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg25482853	chr8:67687455	SGK3	1.12	16.14	0.66	1.01e-43	Obesity-related traits;
LUSC	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg00074818	chr8:8560427	CLDN23	0.59	9.95	0.48	1.32e-20	Obesity-related traits;
LUSC	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg09307838	chr4:120376055	NA	0.75	10.74	0.51	2.58e-23	Corneal astigmatism;
LUSC	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg07636037	chr3:49044803	WDR6	0.66	8.08	0.4	1.17e-14	Menarche (age at onset);
LUSC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg16405210	chr4:1374714	KIAA1530	0.53	8.19	0.41	5.43e-15	Obesity-related traits;
LUSC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs35123781	0.502	rs261532	chr5:138949362	A/C	cg00976381	chr5:138713954	SLC23A1	0.43	6.27	0.32	1.12e-9	Schizophrenia;
LUSC	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg11019008	chr10:131425282	MGMT	0.43	6.19	0.32	1.79e-9	Response to temozolomide;
LUSC	cis	rs3760982	1.000	rs4802200	chr19:44289518	G/A	cg11993925	chr19:44307056	LYPD5	0.29	6.32	0.33	8.54e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs8077577	0.945	rs11653988	chr17:18088833	C/T	cg16794390	chr17:18148240	FLII	0.4	5.68	0.3	2.96e-8	Obesity-related traits;
LUSC	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.94	0.31	7.08e-9	Morning vs. evening chronotype;
LUSC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.87	0.31	1.07e-8	Personality dimensions;
LUSC	cis	rs9473147	0.543	rs9473119	chr6:47450618	G/A	cg02130027	chr6:47444894	CD2AP	0.35	5.67	0.3	3.01e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg16339924	chr4:17578868	LAP3	0.6	9.43	0.46	7.3e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9311676	0.632	rs11714389	chr3:58447299	C/T	cg26110898	chr3:58419937	PDHB	0.41	6.97	0.36	1.75e-11	Systemic lupus erythematosus;
LUSC	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	6.87	0.35	3.17e-11	Ovarian reserve;
LUSC	cis	rs7122539	0.646	rs543191	chr11:66583779	T/G	cg18002602	chr11:66138449	SLC29A2	-0.36	-6.44	-0.33	4.08e-10	HIV-1 susceptibility;
LUSC	cis	rs1971762	0.602	rs4759283	chr12:54079243	C/T	cg23533419	chr12:54090519	NA	-0.37	-6.01	-0.31	4.8e-9	Height;
LUSC	cis	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg06521331	chr12:34319734	NA	-0.47	-7.53	-0.38	4.93e-13	Morning vs. evening chronotype;
LUSC	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg23202291	chr11:1979235	NA	0.39	6.1	0.32	2.96e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg07395648	chr5:131743802	NA	-0.35	-5.77	-0.3	1.8e-8	Blood metabolite levels;
LUSC	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg24642439	chr20:33292090	TP53INP2	-0.47	-6.85	-0.35	3.67e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs41271473	0.948	rs12082771	chr1:228830777	C/T	cg16512390	chr1:228756714	NA	0.57	6.88	0.35	2.93e-11	Chronic lymphocytic leukemia;
LUSC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.17	-0.37	4.97e-12	Bipolar disorder;
LUSC	cis	rs9925964	0.933	rs2359612	chr16:31103796	A/G	cg02466173	chr16:30829666	NA	-0.36	-6.41	-0.33	4.94e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg01475377	chr6:109611718	NA	-0.43	-7.8	-0.39	7.74e-14	Reticulocyte fraction of red cells;
LUSC	cis	rs3771570	0.892	rs59715783	chr2:242366262	C/T	cg21155796	chr2:242212141	HDLBP	0.62	6.69	0.34	9.6e-11	Prostate cancer;
LUSC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	cis	rs9886651	0.935	rs28660151	chr8:128803578	A/T	cg07795030	chr8:128802207	NA	-0.33	-6.0	-0.31	5.2e-9	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LUSC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg09455208	chr3:40491958	NA	-0.56	-9.43	-0.46	6.94e-19	Renal cell carcinoma;
LUSC	cis	rs2859741	0.967	rs522481	chr1:37488337	C/T	cg09363841	chr1:37513479	NA	-0.39	-7.71	-0.39	1.43e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg01657329	chr11:68192670	LRP5	-0.45	-6.68	-0.34	1.03e-10	Total body bone mineral density;
LUSC	cis	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg13636640	chr20:31349939	DNMT3B	-0.81	-15.5	-0.65	3.33e-41	Inflammatory bowel disease;
LUSC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.5	7.67	0.39	1.9e-13	Breast cancer;
LUSC	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg14092571	chr14:90743983	NA	0.36	5.89	0.31	9.22e-9	Mortality in heart failure;
LUSC	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg13010199	chr12:38710504	ALG10B	0.7	10.92	0.51	5.92e-24	Bladder cancer;
LUSC	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg06637938	chr14:75390232	RPS6KL1	0.53	8.51	0.42	5.82e-16	Height;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03157738	chr19:11308118	KANK2	0.45	6.61	0.34	1.51e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg25456477	chr12:86230367	RASSF9	-0.32	-5.66	-0.3	3.29e-8	Major depressive disorder;
LUSC	trans	rs4596713	0.538	rs11145484	chr9:71769857	G/C	cg25283916	chr1:242222868	NA	-0.31	-6.36	-0.33	6.58e-10	Headache;
LUSC	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg06207120	chr15:45996521	NA	0.39	6.09	0.32	3.08e-9	Waist circumference;Weight;
LUSC	cis	rs28829049	0.597	rs2066002	chr1:19504300	G/A	cg13387374	chr1:19411106	UBR4	0.45	6.23	0.32	1.39e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg05084668	chr3:125655381	ALG1L	-0.65	-10.15	-0.49	2.84e-21	Blood pressure (smoking interaction);
LUSC	cis	rs858239	0.601	rs6948469	chr7:23174766	G/T	cg23682824	chr7:23144976	KLHL7	0.39	5.7	0.3	2.59e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg02475777	chr4:1388615	CRIPAK	0.43	6.39	0.33	5.68e-10	Obesity-related traits;
LUSC	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg12002119	chr2:101014098	CHST10	0.35	5.88	0.31	9.71e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg15073853	chr19:18549131	ISYNA1	-0.33	-5.92	-0.31	8.14e-9	Breast cancer;
LUSC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg05738196	chr6:26577821	NA	0.47	6.8	0.35	4.7e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.39	0.33	5.72e-10	Corneal astigmatism;
LUSC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.7	12.45	0.56	1.71e-29	Diastolic blood pressure;
LUSC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg25767906	chr1:53392781	SCP2	-0.53	-9.61	-0.47	1.84e-19	Monocyte count;
LUSC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg17366294	chr4:99064904	C4orf37	0.54	9.54	0.46	3.1400000000000002e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2282300	0.739	rs7926465	chr11:30333016	C/T	cg25418670	chr11:30344373	C11orf46	0.64	9.23	0.45	3.29e-18	Morning vs. evening chronotype;
LUSC	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg03433033	chr1:76189801	ACADM	-0.45	-6.7	-0.34	9.03e-11	Daytime sleep phenotypes;
LUSC	cis	rs4478858	0.735	rs11590120	chr1:31792324	A/G	cg00250761	chr1:31883323	NA	-0.37	-8.97	-0.44	2.17e-17	Alcohol dependence;
LUSC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg13628971	chr7:2884303	GNA12	0.44	6.44	0.33	4.09e-10	Height;
LUSC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg04450456	chr4:17643702	FAM184B	0.36	6.06	0.31	3.7e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1595825	1.000	rs2165237	chr2:198875003	C/T	cg00982548	chr2:198649783	BOLL	-0.49	-6.15	-0.32	2.15e-9	Ulcerative colitis;
LUSC	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.38	-0.37	1.27e-12	Bipolar disorder;
LUSC	cis	rs7804356	1.000	rs3823936	chr7:26853830	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.16	-0.32	2.1e-9	Type 1 diabetes;
LUSC	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg05507819	chr15:63340323	TPM1	0.64	8.83	0.43	6.06e-17	Platelet count;
LUSC	cis	rs6961069	0.806	rs10480808	chr7:80250122	A/T	cg04458919	chr7:80252533	CD36	-0.35	-6.29	-0.33	1e-9	Platelet count;
LUSC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg13114125	chr14:105738426	BRF1	-0.89	-15.46	-0.65	4.96e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg04369109	chr6:150039330	LATS1	-0.55	-8.07	-0.4	1.24e-14	Lung cancer;
LUSC	cis	rs2348418	0.864	rs11049716	chr12:28717646	A/G	cg13890972	chr12:28721907	NA	-0.34	-5.93	-0.31	7.72e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg21854759	chr1:92012499	NA	-0.43	-5.71	-0.3	2.53e-8	Eosinophil percentage of white cells;
LUSC	cis	rs4363385	0.510	rs11577384	chr1:152899728	C/T	cg00922841	chr1:152955080	SPRR1A	-0.37	-6.01	-0.31	4.92e-9	Inflammatory skin disease;
LUSC	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg12473912	chr3:136751656	NA	0.4	7.17	0.37	4.99e-12	Neuroticism;
LUSC	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.9	0.48	2e-20	Migraine;Coronary artery disease;
LUSC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.99	0.4	2.15e-14	Prudent dietary pattern;
LUSC	cis	rs3806933	0.500	rs10491423	chr5:110453977	C/A	cg04022379	chr5:110408740	TSLP	0.64	9.6	0.47	1.9e-19	Eosinophilic esophagitis;
LUSC	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.49	8.06	0.4	1.41e-14	IgG glycosylation;
LUSC	cis	rs11608355	0.545	rs12822974	chr12:109909154	G/T	cg05360138	chr12:110035743	NA	0.88	11.29	0.53	2.95e-25	Neuroticism;
LUSC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.68	-12.93	-0.58	2.71e-31	Type 2 diabetes;
LUSC	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.68	-0.43	1.81e-16	Body mass index;
LUSC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg14530993	chr4:882597	GAK	0.69	7.12	0.36	6.64e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg13902645	chr11:5959945	NA	-0.54	-7.52	-0.38	5.04e-13	DNA methylation (variation);
LUSC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg19230755	chr7:65878503	NA	-0.43	-6.04	-0.31	4.06e-9	Aortic root size;
LUSC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.47	0.33	3.45e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.61	0.34	1.48e-10	Corneal astigmatism;
LUSC	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.14	0.36	5.87e-12	IgG glycosylation;
LUSC	trans	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg24644049	chr4:85504048	CDS1	0.86	7.56	0.38	3.83e-13	Skin colour saturation;
LUSC	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg17757837	chr7:157058334	UBE3C	0.78	12.46	0.56	1.56e-29	Body mass index;
LUSC	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg25801113	chr15:45476975	SHF	0.34	6.92	0.35	2.36e-11	Uric acid levels;
LUSC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg25039879	chr17:56429692	SUPT4H1	0.5	7.04	0.36	1.08e-11	Cognitive test performance;
LUSC	cis	rs6484504	0.600	rs2616815	chr11:31327316	C/T	cg26647111	chr11:31128758	NA	0.4	5.7	0.3	2.69e-8	Red blood cell count;
LUSC	cis	rs977987	0.806	rs4146809	chr16:75415775	A/G	cg04384234	chr16:75411784	CFDP1	0.41	6.63	0.34	1.37e-10	Dupuytren's disease;
LUSC	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg26195577	chr20:24973756	C20orf3	1.12	18.25	0.71	4.21e-52	Blood protein levels;
LUSC	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg09307838	chr4:120376055	NA	0.69	10.01	0.48	8.32e-21	Corneal astigmatism;
LUSC	cis	rs9311676	0.632	rs6785572	chr3:58361517	A/G	cg26110898	chr3:58419937	PDHB	-0.4	-6.65	-0.34	1.19e-10	Systemic lupus erythematosus;
LUSC	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg00612595	chr21:47717864	NA	0.39	5.69	0.3	2.74e-8	Testicular germ cell tumor;
LUSC	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.23	41.16	0.91	7.42e-133	Myeloid white cell count;
LUSC	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.68	-12.13	-0.55	2.59e-28	Multiple sclerosis;
LUSC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg13607699	chr17:42295918	UBTF	0.49	7.64	0.39	2.39e-13	Total body bone mineral density;
LUSC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg09455208	chr3:40491958	NA	-0.5	-9.25	-0.45	2.78e-18	Renal cell carcinoma;
LUSC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg14583973	chr4:3374767	RGS12	0.37	8.17	0.41	6.56e-15	Serum sulfate level;
LUSC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.52	0.69	3.21e-49	Chronic sinus infection;
LUSC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg03732007	chr1:2071316	PRKCZ	0.55	9.97	0.48	1.12e-20	Height;
LUSC	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg19052272	chr2:3704530	ALLC	-0.49	-8.19	-0.41	5.6e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.37	0.37	1.35e-12	Bipolar disorder;
LUSC	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg22431228	chr1:16359049	CLCNKA	0.4	8.53	0.42	5.25e-16	Systolic blood pressure;
LUSC	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg17830980	chr10:43048298	ZNF37B	0.42	6.61	0.34	1.5e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.43	-0.46	7.25e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg03461704	chr1:205818484	PM20D1	0.36	5.82	0.3	1.39e-8	Menarche (age at onset);
LUSC	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg19610905	chr11:61596333	FADS2	-0.55	-8.26	-0.41	3.54e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg11057378	chr10:81107060	PPIF	0.37	6.32	0.33	8.36e-10	Height;
LUSC	cis	rs9341808	0.739	rs4706831	chr6:81007699	T/C	cg08355045	chr6:80787529	NA	0.56	9.89	0.48	2.07e-20	Sitting height ratio;
LUSC	cis	rs6906287	0.559	rs2798322	chr6:118991605	G/T	cg21191810	chr6:118973309	C6orf204	0.33	6.02	0.31	4.7e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.42	-5.94	-0.31	7.12e-9	Monocyte percentage of white cells;
LUSC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg21862992	chr11:68658383	NA	0.51	7.73	0.39	1.28e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04652621	chr7:150671807	KCNH2	-0.53	-6.82	-0.35	4.36e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.06e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7712401	0.511	rs30068	chr5:122293609	C/T	cg19077854	chr5:122220652	SNX24	0.39	8.65	0.43	2.17e-16	Mean platelet volume;
LUSC	cis	rs16867321	0.639	rs12466864	chr2:181441417	C/G	cg23363182	chr2:181467187	NA	0.57	9.14	0.45	6.28e-18	Obesity;
LUSC	trans	rs8105895	0.735	rs17554694	chr19:22317148	A/G	cg05197062	chr11:11642011	GALNTL4	0.5	6.46	0.33	3.8e-10	Body mass index (change over time);
LUSC	cis	rs6977660	1.000	rs6959591	chr7:19821824	A/G	cg05791153	chr7:19748676	TWISTNB	0.53	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LUSC	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg22875332	chr1:76189707	ACADM	-0.42	-6.24	-0.32	1.35e-9	Daytime sleep phenotypes;
LUSC	cis	rs12980942	0.872	rs12976536	chr19:41799886	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.62	6.62	0.34	1.41e-10	Coronary artery disease;
LUSC	cis	rs10484885	0.553	rs17707975	chr6:90622318	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.57	-5.7	-0.3	2.6e-8	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs308403	0.509	rs7690409	chr4:123666757	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.92	16.06	0.66	2.01e-43	Blood protein levels;
LUSC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2692947	0.655	rs60090597	chr2:96406266	G/A	cg22654517	chr2:96458247	NA	0.36	6.77	0.35	5.86e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.59	-5.7	-0.3	2.67e-8	Narcolepsy;
LUSC	trans	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg20744362	chr22:50050164	C22orf34	0.41	7.58	0.38	3.34e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.69	-10.24	-0.49	1.42e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg12403142	chr1:92012408	NA	-0.38	-6.15	-0.32	2.22e-9	Breast cancer;
LUSC	cis	rs1160297	0.576	rs6754423	chr2:53096730	G/A	cg07782112	chr2:53107842	NA	0.43	7.0	0.36	1.42e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.58	6.06	0.31	3.59e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg14343924	chr8:8086146	FLJ10661	0.43	5.97	0.31	6.15e-9	Mood instability;
LUSC	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.42	6.6	0.34	1.65e-10	Schizophrenia;
LUSC	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-8.1	-0.41	1.03e-14	Morning vs. evening chronotype;
LUSC	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg26395211	chr5:140044315	WDR55	-0.38	-5.74	-0.3	2.14e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs3784262	1.000	rs12907038	chr15:58244032	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.09	-0.32	3.08e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg03188948	chr7:1209495	NA	0.62	6.56	0.34	2.03e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg17366294	chr4:99064904	C4orf37	0.56	9.77	0.47	5.22e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg18288967	chr1:45987694	PRDX1	0.52	5.94	0.31	7e-9	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04902826	chr10:105677453	OBFC1	0.46	6.63	0.34	1.34e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg23711669	chr6:146136114	FBXO30	0.87	16.14	0.66	1e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg26384229	chr12:38710491	ALG10B	0.7	10.88	0.51	8.52e-24	Morning vs. evening chronotype;
LUSC	trans	rs11165623	0.792	rs12123543	chr1:96964549	T/C	cg10631902	chr5:14652156	NA	-0.48	-7.33	-0.37	1.77e-12	Hip circumference;Waist circumference;
LUSC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg06784218	chr1:46089804	CCDC17	0.53	10.68	0.5	4.27e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg07423050	chr13:99094983	FARP1	-0.52	-9.38	-0.46	1.03e-18	Neuroticism;
LUSC	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg04369109	chr6:150039330	LATS1	-0.57	-8.32	-0.41	2.32e-15	Lung cancer;
LUSC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21862992	chr11:68658383	NA	0.52	8.08	0.4	1.17e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.0	-15.22	-0.64	4.31e-40	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.89	-0.68	1.11e-46	Monocyte count;
LUSC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.14	0.45	6.03e-18	Prudent dietary pattern;
LUSC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg01802117	chr1:53393560	SCP2	0.38	6.2	0.32	1.62e-9	Monocyte count;
LUSC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg23262073	chr20:60523788	NA	-0.42	-5.84	-0.3	1.21e-8	Body mass index;
LUSC	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.63	0.65	9.84e-42	Morning vs. evening chronotype;
LUSC	cis	rs9534288	0.783	rs1126366	chr13:46633148	C/G	cg15192986	chr13:46630673	CPB2	-0.8	-12.69	-0.57	2.14e-30	Blood protein levels;
LUSC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg00750074	chr16:89608354	SPG7	-0.46	-7.97	-0.4	2.52e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.52	-7.55	-0.38	4.32e-13	Blood protein levels;
LUSC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg14895029	chr7:2775587	GNA12	-0.39	-6.06	-0.31	3.6e-9	Height;
LUSC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21782813	chr7:2030301	MAD1L1	-0.51	-9.08	-0.44	9.75e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.68	-8.39	-0.42	1.43e-15	Lung function (FEV1/FVC);
LUSC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-9.48	-0.46	4.74e-19	Chronic sinus infection;
LUSC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	6.53	0.34	2.38e-10	Obesity-related traits;
LUSC	cis	rs55665837	1.000	rs10832264	chr11:14459982	T/A	cg19336497	chr11:14380999	RRAS2	-0.37	-7.47	-0.38	6.93e-13	Vitamin D levels;
LUSC	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.93	-0.44	2.88e-17	Response to antipsychotic treatment;
LUSC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.88	0.48	2.3e-20	Bipolar disorder;
LUSC	trans	rs7939886	0.920	rs17150096	chr11:55902996	C/T	cg15704280	chr7:45808275	SEPT13	0.83	6.64	0.34	1.27e-10	Myopia (pathological);
LUSC	cis	rs6599077	0.853	rs9832553	chr3:40097408	C/T	cg13683864	chr3:40499215	RPL14	-0.58	-7.15	-0.36	5.65e-12	Sleep-related phenotypes;
LUSC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.07	-0.32	3.5e-9	Mood instability;
LUSC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-7.98	-0.4	2.36e-14	Personality dimensions;
LUSC	cis	rs4889911	0.544	rs1294081	chr17:77829864	T/C	cg00646381	chr17:77835854	NA	0.58	9.22	0.45	3.52e-18	Electroencephalogram traits;
LUSC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg02038168	chr22:39784481	NA	-0.5	-8.16	-0.41	6.77e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-13.72	-0.6	2.67e-34	Height;
LUSC	trans	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	7.37	0.37	1.34e-12	Retinal vascular caliber;
LUSC	cis	rs4917300	1.000	rs2220696	chr8:143118812	C/G	cg25363559	chr8:143086065	NA	0.29	6.19	0.32	1.75e-9	Amyotrophic lateral sclerosis;
LUSC	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.91	15.42	0.64	7e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg13010199	chr12:38710504	ALG10B	0.67	10.3	0.49	9.03e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg25072359	chr17:41440525	NA	0.59	8.41	0.42	1.23e-15	Menopause (age at onset);
LUSC	cis	rs12681287	0.604	rs28378899	chr8:87434500	G/C	cg27223183	chr8:87520930	FAM82B	0.54	7.47	0.38	6.96e-13	Caudate activity during reward;
LUSC	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-7.94	-0.4	3.03e-14	Morning vs. evening chronotype;
LUSC	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg11657440	chr19:46296263	DMWD	-0.52	-7.63	-0.39	2.49e-13	Coronary artery disease;
LUSC	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg22852734	chr6:133119734	C6orf192	1.33	10.41	0.49	3.74e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg13770153	chr20:60521292	NA	-0.44	-6.13	-0.32	2.43e-9	Body mass index;
LUSC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs3740713	0.592	rs73434674	chr11:18411497	C/A	cg23797887	chr11:18477753	LDHAL6A	-0.47	-5.7	-0.3	2.65e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg00945038	chr17:61921165	SMARCD2	0.4	6.09	0.32	3.17e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9612	0.718	rs173202	chr19:44253588	C/T	cg08581076	chr19:44259116	C19orf61	0.51	6.35	0.33	6.96e-10	Exhaled nitric oxide output;
LUSC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18932078	chr1:2524107	MMEL1	0.3	6.43	0.33	4.33e-10	Multiple sclerosis;
LUSC	cis	rs7605827	0.930	rs4140715	chr2:15515899	G/A	cg19274914	chr2:15703543	NA	0.46	8.86	0.44	4.71e-17	Educational attainment (years of education);
LUSC	cis	rs7605827	0.930	rs11687253	chr2:15655869	A/G	cg19274914	chr2:15703543	NA	-0.46	-8.63	-0.43	2.58e-16	Educational attainment (years of education);
LUSC	cis	rs9309473	0.607	rs1522927	chr2:73556155	T/G	cg20560298	chr2:73613845	ALMS1	-0.54	-8.3	-0.41	2.64e-15	Metabolite levels;
LUSC	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg15704280	chr7:45808275	SEPT13	0.73	8.22	0.41	4.64e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10108704	1.000	rs10108704	chr8:110362461	G/T	cg20147595	chr8:110349212	ENY2	-0.44	-5.82	-0.3	1.41e-8	Multiple system atrophy (pathologically confirmed);
LUSC	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg03676636	chr4:99064102	C4orf37	0.37	8.16	0.41	6.97e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg17462356	chr17:80056334	FASN	0.46	6.21	0.32	1.56e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10354764	chr16:3285464	ZNF200	0.42	6.23	0.32	1.37e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-5.99	-0.31	5.57e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9581857	0.615	rs79793528	chr13:28007823	G/A	cg22138327	chr13:27999177	GTF3A	0.89	9.45	0.46	6.21e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	trans	rs7939886	0.920	rs1552151	chr11:55780951	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-7.46	-0.38	7.32e-13	Myopia (pathological);
LUSC	cis	rs4363385	0.818	rs546666	chr1:153015385	A/G	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.89	-0.4	4.44e-14	Inflammatory skin disease;
LUSC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg12560992	chr17:57184187	TRIM37	-0.9	-17.73	-0.7	4.75e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs2414856	0.510	rs72756979	chr15:64572551	G/A	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs501916	0.634	rs603569	chr15:48058929	G/A	cg16110827	chr15:48056943	SEMA6D	-0.38	-5.93	-0.31	7.5e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg19774624	chr17:42201019	HDAC5	-0.79	-12.66	-0.57	2.93e-30	Total body bone mineral density;
LUSC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07256732	chr16:621771	PIGQ	-0.36	-6.54	-0.34	2.37e-10	Height;
LUSC	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg00540400	chr15:79124168	NA	-0.4	-6.99	-0.36	1.54e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16405210	chr4:1374714	KIAA1530	-0.6	-9.38	-0.46	1.08e-18	Longevity;
LUSC	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.58	9.66	0.47	1.25e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.93	0.44	2.83e-17	Lung cancer in ever smokers;
LUSC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	0.99	14.15	0.61	6.33e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs2798269	0.902	rs12861578	chr13:22092762	T/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-5.84	-0.3	1.25e-8	PR segment;
LUSC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg03146154	chr1:46216737	IPP	0.51	7.66	0.39	2.08e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg24631222	chr15:78858424	CHRNA5	0.81	11.05	0.52	2.19e-24	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10802521	chr3:52805072	NEK4	-0.52	-8.52	-0.42	5.41e-16	Bipolar disorder;
LUSC	cis	rs12534701	1.000	rs12534701	chr7:154680910	A/C	cg24255201	chr7:154684926	DPP6	-0.37	-5.7	-0.3	2.6e-8	Colorectal cancer (diet interaction);
LUSC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.81	0.39	7.4e-14	Prudent dietary pattern;
LUSC	cis	rs1775715	0.707	rs2808073	chr10:32179275	A/G	cg03015672	chr10:32216066	ARHGAP12	0.32	5.79	0.3	1.61e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg25258033	chr6:167368657	RNASET2	0.45	6.81	0.35	4.5e-11	Crohn's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07431429	chr13:21750645	MRP63;SKA3	-0.58	-6.88	-0.35	3.01e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg23093090	chr10:104574429	C10orf26	-0.37	-6.86	-0.35	3.32e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.25	0.52	4.06e-25	Colorectal cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18082014	chr19:46088293	OPA3	-0.46	-6.87	-0.35	3.17e-11	Electrocardiographic conduction measures;
LUSC	trans	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg04995722	chr7:26192034	NFE2L3	0.37	6.0	0.31	5.05e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08704250	chr15:31115839	NA	0.58	9.13	0.45	6.46e-18	Huntington's disease progression;
LUSC	cis	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg26958806	chr6:27640298	NA	0.79	5.96	0.31	6.38e-9	Depression;
LUSC	cis	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg17469321	chr7:55412551	NA	0.64	10.19	0.49	2.02e-21	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg02951883	chr7:2050386	MAD1L1	-0.6	-11.19	-0.52	6.77e-25	Bipolar disorder and schizophrenia;
LUSC	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg00784671	chr22:46762841	CELSR1	-0.54	-6.79	-0.35	5.18e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg14004847	chr7:1930337	MAD1L1	-0.59	-9.14	-0.45	6.29e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg09640425	chr7:158790006	NA	0.39	5.81	0.3	1.42e-8	Facial morphology (factor 20);
LUSC	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-7.49	-0.38	6.15e-13	Axial length;
LUSC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs7246967	0.551	rs75360744	chr19:22857956	G/T	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.72	11.09	0.52	1.56e-24	Menarche (age at onset);
LUSC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg15145296	chr3:125709740	NA	-0.57	-6.36	-0.33	6.67e-10	Blood pressure (smoking interaction);
LUSC	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06636551	chr8:101224915	SPAG1	-0.43	-7.92	-0.4	3.51e-14	Atrioventricular conduction;
LUSC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg16928487	chr17:17741425	SREBF1	-0.35	-6.84	-0.35	3.81e-11	Total body bone mineral density;
LUSC	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg16586182	chr3:47516702	SCAP	-0.5	-6.05	-0.31	3.83e-9	Birth weight;
LUSC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg01879757	chr17:41196368	BRCA1	-0.39	-5.96	-0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg04450456	chr4:17643702	FAM184B	0.4	6.71	0.34	8.28e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg22875332	chr1:76189707	ACADM	0.66	9.12	0.45	7.39e-18	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10761482	0.500	rs1938535	chr10:62273900	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.44	-0.33	4.08e-10	Schizophrenia;
LUSC	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg24558204	chr6:135376177	HBS1L	0.59	9.26	0.45	2.63e-18	Red blood cell count;
LUSC	cis	rs11958404	0.932	rs6865373	chr5:157436728	A/G	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.38	-0.42	1.49e-15	Total cholesterol levels;
LUSC	cis	rs79387448	0.745	rs72993722	chr2:103124916	A/G	cg09003973	chr2:102972529	NA	0.86	8.52	0.42	5.6e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg18681998	chr4:17616180	MED28	0.85	15.84	0.65	1.54e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.91	0.35	2.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg26924012	chr15:45694286	SPATA5L1	0.8	12.4	0.56	2.61e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.63	-0.39	2.44e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg01416388	chr22:39784598	NA	-0.45	-6.94	-0.36	2.02e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg06606381	chr12:133084897	FBRSL1	-1.09	-9.57	-0.46	2.43e-19	Depression;
LUSC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.54	0.34	2.24e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11585357	0.895	rs2501795	chr1:17633499	A/G	cg08277548	chr1:17600880	PADI3	-0.66	-7.24	-0.37	3.15e-12	Hair shape;
LUSC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.36e-10	Menopause (age at onset);
LUSC	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg20703242	chr1:230279135	GALNT2	0.52	8.2	0.41	5.22e-15	Coronary artery disease;
LUSC	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg22676075	chr6:135203613	NA	0.46	7.13	0.36	6.1e-12	Red blood cell count;
LUSC	cis	rs10779751	0.770	rs2015818	chr1:11170743	G/A	cg08854313	chr1:11322531	MTOR	0.82	13.5	0.59	1.92e-33	Body mass index;
LUSC	cis	rs6693567	0.545	rs6699093	chr1:150440451	A/G	cg15654264	chr1:150340011	RPRD2	-0.46	-7.46	-0.38	7.73e-13	Migraine;
LUSC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg23625390	chr15:77176239	SCAPER	-0.61	-9.69	-0.47	9.85e-20	Blood metabolite levels;
LUSC	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg14844989	chr11:31128820	NA	-0.37	-5.71	-0.3	2.49e-8	Red blood cell count;
LUSC	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.89	-0.35	2.7e-11	Platelet count;
LUSC	trans	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.22	-0.32	1.47e-9	Blood trace element (Cu levels);
LUSC	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg15705551	chr2:10952987	PDIA6	0.52	6.51	0.34	2.71e-10	Cardiac Troponin-T levels;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg22667436	chr7:134671749	AGBL3	0.43	6.65	0.34	1.2e-10	Schizophrenia;
LUSC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg06740227	chr12:86229804	RASSF9	0.45	7.15	0.36	5.35e-12	Major depressive disorder;
LUSC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg20203395	chr5:56204925	C5orf35	0.77	10.38	0.49	4.54e-22	Initial pursuit acceleration;
LUSC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg26380479	chr7:97908229	NA	-0.26	-5.86	-0.31	1.13e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03576123	chr11:487126	PTDSS2	-0.95	-10.15	-0.49	2.75e-21	Body mass index;
LUSC	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg18357645	chr12:58087776	OS9	0.6	9.02	0.44	1.51e-17	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs4363385	0.693	rs581447	chr1:153033269	A/G	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.28	-0.37	2.39e-12	Inflammatory skin disease;
LUSC	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg18825076	chr15:78729989	IREB2	-0.47	-6.61	-0.34	1.48e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg01475377	chr6:109611718	NA	-0.38	-6.75	-0.35	6.74e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs2200578	0.732	rs56143125	chr2:99565143	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.5	5.82	0.3	1.42e-8	IgG glycosylation;
LUSC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg04315214	chr1:2043799	PRKCZ	-0.4	-8.04	-0.4	1.6e-14	Height;
LUSC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.18	-0.32	1.87e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg16928487	chr17:17741425	SREBF1	0.37	7.11	0.36	7.28e-12	Total body bone mineral density;
LUSC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-8.39	-0.42	1.38e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.47	-5.7	-0.3	2.67e-8	Birth weight;
LUSC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg11494091	chr17:61959527	GH2	0.38	6.5	0.34	2.86e-10	Height;
LUSC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.51	0.34	2.78e-10	Lung cancer;
LUSC	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-1.06	-15.7	-0.65	5.45e-42	Exhaled nitric oxide output;
LUSC	trans	rs7181230	0.885	rs4497657	chr15:40359433	A/T	cg22705835	chr10:65332833	REEP3	-0.39	-6.34	-0.33	7.41e-10	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg17554472	chr22:41940697	POLR3H	-0.48	-5.94	-0.31	7.16e-9	Vitiligo;
LUSC	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.08	15.38	0.64	9.93e-41	Uric acid levels;
LUSC	cis	rs10208940	0.920	rs6724540	chr2:68779356	A/G	cg12452813	chr2:68675892	NA	0.57	5.84	0.3	1.23e-8	Urate levels in lean individuals;
LUSC	cis	rs3849570	0.925	rs9841087	chr3:81907949	A/G	cg07356753	chr3:81810745	GBE1	-0.7	-11.56	-0.53	3.25e-26	Waist circumference;Body mass index;
LUSC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.34	0.59	7.64e-33	Platelet count;
LUSC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05165339	chr4:1420672	NA	0.3	7.1	0.36	7.69e-12	Longevity;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg13453750	chr1:205783389	SLC41A1	-0.3	-5.9	-0.31	8.7e-9	Menarche (age at onset);
LUSC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg09165964	chr15:75287851	SCAMP5	0.46	6.82	0.35	4.23e-11	Breast cancer;
LUSC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg14552801	chr7:65878734	NA	-0.46	-6.54	-0.34	2.31e-10	Aortic root size;
LUSC	cis	rs7582720	1.000	rs72932553	chr2:203842661	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.35	0.42	1.88e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.68	0.47	1.04e-19	Personality dimensions;
LUSC	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.4	0.38	1.11e-12	Lung cancer in ever smokers;
LUSC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg27532560	chr4:187881888	NA	0.36	5.88	0.31	9.76e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg26441486	chr22:50317300	CRELD2	-0.49	-7.46	-0.38	7.33e-13	Schizophrenia;
LUSC	trans	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.89	0.35	2.77e-11	Triglycerides;
LUSC	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.28	-0.37	2.45e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-15.59	-0.65	1.42e-41	Primary sclerosing cholangitis;
LUSC	cis	rs2692947	0.770	rs12471925	chr2:96555522	C/A	cg22654517	chr2:96458247	NA	0.37	6.9	0.35	2.68e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	cis	rs7681440	0.583	rs2737019	chr4:90744903	G/T	cg06632027	chr4:90757378	SNCA	-0.36	-5.72	-0.3	2.43e-8	Dementia with Lewy bodies;
LUSC	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.45	0.33	4.01e-10	Corneal astigmatism;
LUSC	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg21775007	chr8:11205619	TDH	-0.45	-6.72	-0.35	7.75e-11	Neuroticism;
LUSC	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg17252645	chr8:143867129	LY6D	-0.36	-6.31	-0.33	9.04e-10	Urinary tract infection frequency;
LUSC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13126279	chr21:47581558	C21orf56	-0.54	-8.02	-0.4	1.85e-14	Testicular germ cell tumor;
LUSC	cis	rs113835537	0.529	rs17495838	chr11:66196265	T/C	cg24851651	chr11:66362959	CCS	0.54	7.57	0.38	3.59e-13	Airway imaging phenotypes;
LUSC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg22764044	chr5:178986830	RUFY1	0.53	9.04	0.44	1.27e-17	Lung cancer;
LUSC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg14061069	chr19:46274453	DMPK	0.69	14.13	0.61	7.6e-36	Coronary artery disease;
LUSC	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg26061582	chr7:22766209	IL6	0.49	7.02	0.36	1.25e-11	Lung cancer;
LUSC	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg09699651	chr6:150184138	LRP11	0.45	7.15	0.36	5.64e-12	Testicular germ cell tumor;
LUSC	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg05340658	chr4:99064831	C4orf37	0.44	6.85	0.35	3.47e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-17.41	-0.69	9.34e-49	Body mass index;
LUSC	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	6.71	0.34	8.4e-11	Lung cancer;
LUSC	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-5.71	-0.3	2.44e-8	Major depressive disorder;
LUSC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.75	-11.63	-0.54	1.7e-26	Menarche (age at onset);
LUSC	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg04586622	chr2:25135609	ADCY3	0.31	6.01	0.31	4.95e-9	Body mass index;
LUSC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.59	9.16	0.45	5.54e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg03359095	chr20:61002866	C20orf151	-0.28	-5.68	-0.3	2.93e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs4356932	1.000	rs6814817	chr4:76951170	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.59e-8	Blood protein levels;
LUSC	cis	rs2050392	0.861	rs303448	chr10:30727084	G/T	cg18806716	chr10:30721971	MAP3K8	-0.48	-8.01	-0.4	1.98e-14	Inflammatory bowel disease;
LUSC	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg08680598	chr22:49984980	NA	-0.34	-6.31	-0.33	8.88e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19168507	chr11:107436485	ALKBH8	-0.4	-5.95	-0.31	6.89e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg02023728	chr11:77925099	USP35	0.46	6.7	0.34	9.09e-11	Testicular germ cell tumor;
LUSC	cis	rs13082711	0.640	rs66941564	chr3:27259702	C/A	cg02860705	chr3:27208620	NA	0.67	11.81	0.54	3.78e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg11812906	chr14:75593930	NEK9	-0.65	-10.66	-0.5	5.04e-23	Height;
LUSC	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.87	-0.44	4.46e-17	Monocyte percentage of white cells;
LUSC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	0.45	7.6	0.38	2.96e-13	Lymphocyte counts;
LUSC	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg22852734	chr6:133119734	C6orf192	-1.1	-13.67	-0.6	4.13e-34	Type 2 diabetes nephropathy;
LUSC	cis	rs9921338	0.961	rs72773834	chr16:11413293	G/A	cg00044050	chr16:11439710	C16orf75	-0.5	-6.75	-0.35	6.64e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs227833	1.000	rs227832	chr6:44681257	T/C	cg20913747	chr6:44695427	NA	0.37	5.75	0.3	2e-8	Monobrow;
LUSC	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.58	-0.34	1.82e-10	Triglycerides;
LUSC	cis	rs3744061	0.557	rs4261576	chr17:74648486	G/T	cg27546012	chr17:74684504	MXRA7	0.37	6.6	0.34	1.66e-10	Retinal arteriolar caliber;
LUSC	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.84	-0.3	1.24e-8	Breast cancer;
LUSC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	0.75	12.25	0.56	9.28e-29	Cognitive function;
LUSC	trans	rs445114	0.509	rs386883	chr8:128336871	G/A	cg10195415	chr17:73887371	TRIM65	0.42	6.66	0.34	1.11e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06634786	chr22:41940651	POLR3H	0.53	6.3	0.33	9.27e-10	Vitiligo;
LUSC	cis	rs4072705	0.617	rs10283445	chr9:127243637	A/G	cg13476313	chr9:127244764	NR5A1	0.35	6.91	0.35	2.49e-11	Menarche (age at onset);
LUSC	trans	rs2840044	0.534	rs167691	chr17:33885826	G/A	cg19694781	chr19:47549865	TMEM160	-0.42	-6.76	-0.35	6.06e-11	Response to radiotherapy in cancer (late toxicity);
LUSC	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg13514129	chr1:39547527	MACF1	0.74	11.87	0.54	2.39e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg04865166	chr7:105162814	PUS7	0.52	5.92	0.31	7.79e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg27411982	chr8:10470053	RP1L1	-0.37	-5.92	-0.31	7.82e-9	Retinal vascular caliber;
LUSC	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg00225070	chr15:80189496	MTHFS	0.62	9.62	0.47	1.64e-19	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg00310523	chr12:86230176	RASSF9	0.51	9.68	0.47	1.07e-19	Major depressive disorder;
LUSC	cis	rs13082711	0.863	rs77135084	chr3:27423549	A/C	cg02860705	chr3:27208620	NA	0.5	8.64	0.43	2.34e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21016266	chr12:122356598	WDR66	0.42	6.04	0.31	4.17e-9	Mean corpuscular volume;
LUSC	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg18721089	chr20:30220636	NA	-0.33	-5.81	-0.3	1.44e-8	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs6076065	0.748	rs2281431	chr20:23399304	C/G	cg11657817	chr20:23433608	CST11	0.53	10.82	0.51	1.42e-23	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1865721	0.771	rs4410169	chr18:73138840	A/G	cg26385618	chr18:73139727	C18orf62	-0.55	-10.11	-0.48	3.98e-21	Intelligence;
LUSC	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg22508957	chr16:3507546	NAT15	-0.4	-6.25	-0.32	1.26e-9	Body mass index (adult);
LUSC	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg27068330	chr11:65405492	SIPA1	-0.75	-10.35	-0.49	5.91e-22	Acne (severe);
LUSC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs2637266	1.000	rs2395385	chr10:78341125	G/A	cg18941641	chr10:78392320	NA	0.4	7.41	0.38	1.04e-12	Pulmonary function;
LUSC	cis	rs7712401	0.601	rs30058	chr5:122297703	A/G	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg12257692	chr3:49977190	RBM6	-0.25	-6.98	-0.36	1.61e-11	Body mass index;
LUSC	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.84	-0.44	5.62e-17	Metabolite levels;
LUSC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg01416388	chr22:39784598	NA	-0.42	-6.94	-0.35	2.11e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs8099014	0.954	rs4559989	chr18:56131869	G/A	cg12907477	chr18:56117327	MIR122	0.42	6.4	0.33	5.34e-10	Platelet count;
LUSC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg05738196	chr6:26577821	NA	0.82	15.84	0.66	1.48e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs8114671	0.545	rs2378335	chr20:33756830	A/C	cg08999081	chr20:33150536	PIGU	0.35	5.88	0.31	1.02e-8	Height;
LUSC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg24209194	chr3:40518798	ZNF619	0.48	6.43	0.33	4.3e-10	Renal cell carcinoma;
LUSC	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.84	13.92	0.61	4.87e-35	Bladder cancer;
LUSC	cis	rs2692947	0.683	rs2315416	chr2:96558477	C/T	cg23100626	chr2:96804247	ASTL	0.26	6.36	0.33	6.62e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs2354432	0.556	rs7525622	chr1:146774116	G/A	cg25205988	chr1:146714368	CHD1L	-1.03	-9.57	-0.46	2.48e-19	Mitochondrial DNA levels;
LUSC	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	7.21	0.37	3.81e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.66	8.79	0.43	8.12e-17	High light scatter reticulocyte count;
LUSC	cis	rs4290604	0.748	rs10164697	chr2:238032560	G/A	cg23555395	chr2:238036564	NA	-0.52	-6.79	-0.35	5.08e-11	Asthma;
LUSC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.6	8.08	0.4	1.2e-14	High light scatter reticulocyte count;
LUSC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03934478	chr11:495069	RNH1	0.82	9.89	0.48	2.07e-20	Body mass index;
LUSC	cis	rs17095355	0.605	rs41291880	chr10:111635785	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.63	-0.34	1.3100000000000001e-10	Biliary atresia;
LUSC	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg13256891	chr4:100009986	ADH5	0.51	6.89	0.35	2.74e-11	Alcohol dependence;
LUSC	cis	rs9653442	0.593	rs7597861	chr2:100853187	G/A	cg22139774	chr2:100720529	AFF3	-0.39	-6.4	-0.33	5.38e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.19	-13.37	-0.59	5.95e-33	Diabetic kidney disease;
LUSC	cis	rs12928939	0.517	rs12149307	chr16:71968091	A/C	cg03805757	chr16:71968109	PKD1L3	-0.64	-9.8	-0.47	4.31e-20	Post bronchodilator FEV1;
LUSC	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg04310649	chr10:35416472	CREM	-0.39	-5.98	-0.31	5.78e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg13256891	chr4:100009986	ADH5	0.52	8.47	0.42	7.94e-16	HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs977987	0.778	rs7203157	chr16:75417920	T/C	cg03315344	chr16:75512273	CHST6	0.48	9.1	0.45	8.27e-18	Dupuytren's disease;
LUSC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	7.57	0.38	3.63e-13	Multiple sclerosis;
LUSC	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg15848620	chr12:58087721	OS9	-0.57	-8.08	-0.4	1.18e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6681460	0.834	rs1280310	chr1:67216823	T/A	cg02459107	chr1:67143332	SGIP1	-0.47	-8.35	-0.42	1.81e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg02117656	chr17:79614917	TSPAN10	0.32	5.86	0.31	1.1e-8	Eye color traits;
LUSC	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg19792802	chr11:65647270	CTSW	0.4	6.24	0.32	1.35e-9	Crohn's disease;
LUSC	cis	rs9807841	0.592	rs2043304	chr19:10772112	T/C	cg17710535	chr19:10819994	QTRT1	0.42	6.88	0.35	2.98e-11	Inflammatory skin disease;
LUSC	trans	rs7989336	0.501	rs7985691	chr13:97007163	G/C	cg03198741	chr6:1003969	LOC285768	-0.4	-6.07	-0.32	3.52e-9	Obesity;
LUSC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-10.87	-0.51	9.44e-24	Mean corpuscular volume;
LUSC	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg24558204	chr6:135376177	HBS1L	0.59	9.26	0.45	2.63e-18	Red blood cell count;
LUSC	cis	rs10754283	0.967	rs6428561	chr1:90102619	G/A	cg21401794	chr1:90099060	LRRC8C	0.65	9.79	0.47	4.51e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	18.1	0.7	1.66e-51	Chronic sinus infection;
LUSC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg19266014	chr7:2183958	MAD1L1	-0.33	-5.65	-0.3	3.41e-8	Schizophrenia;
LUSC	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg21016266	chr12:122356598	WDR66	0.44	6.26	0.32	1.16e-9	Mean corpuscular volume;
LUSC	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.02	-0.4	1.79e-14	Type 2 diabetes;
LUSC	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg21064579	chr19:49206444	FUT2	0.44	8.56	0.42	4.11e-16	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
LUSC	cis	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg07460842	chr6:66804631	NA	0.7	8.69	0.43	1.68e-16	Type 2 diabetes;
LUSC	trans	rs9556711	0.581	rs16954076	chr13:98054592	G/T	cg03186877	chr9:34628238	ARID3C	0.6	6.2	0.32	1.66e-9	Alcoholism (alcohol use disorder factor score);Alcoholism (alcohol dependence factor score);
LUSC	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg06808227	chr14:105710500	BRF1	-0.63	-9.69	-0.47	9.62e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg12826209	chr6:26865740	GUSBL1	0.69	7.99	0.4	2.14e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg12552261	chr5:112820674	MCC	0.44	7.11	0.36	7.19e-12	Type 2 diabetes;
LUSC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg05941027	chr17:61774174	LIMD2	0.22	5.69	0.3	2.84e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9039	1.000	rs11075212	chr16:9203899	G/A	cg08831531	chr16:9218945	NA	-0.67	-10.04	-0.48	6.5e-21	Menopause (age at onset);
LUSC	trans	rs4714291	0.963	rs2395543	chr6:39965020	A/G	cg02267698	chr19:7991119	CTXN1	0.52	7.39	0.37	1.21e-12	Strep throat;
LUSC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg14895029	chr7:2775587	GNA12	0.36	5.75	0.3	2.05e-8	Height;
LUSC	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.3	-0.33	9.14e-10	Morning vs. evening chronotype;
LUSC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg15557168	chr22:42548783	NA	0.48	7.39	0.38	1.16e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg26566898	chr11:117069891	TAGLN	0.35	6.69	0.34	9.68e-11	Blood protein levels;
LUSC	cis	rs6967385	0.560	rs12673036	chr7:12343463	A/G	cg20607287	chr7:12443886	VWDE	0.47	7.12	0.36	6.53e-12	Response to taxane treatment (placlitaxel);
LUSC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg11843238	chr5:131593191	PDLIM4	0.37	6.3	0.33	9.45e-10	Breast cancer;
LUSC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12667521	chr19:29218732	NA	0.63	9.05	0.44	1.18e-17	Methadone dose in opioid dependence;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg13470557	chr20:61431876	C20orf20	-0.4	-6.48	-0.33	3.24e-10	N-glycan levels;
LUSC	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg06671706	chr8:8559999	CLDN23	0.5	6.55	0.34	2.21e-10	Obesity-related traits;
LUSC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg11871910	chr12:69753446	YEATS4	0.67	10.27	0.49	1.12e-21	Blood protein levels;
LUSC	cis	rs6681460	1.000	rs4655636	chr1:67068537	A/G	cg02459107	chr1:67143332	SGIP1	0.48	8.93	0.44	2.91e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs7760535	0.826	rs10872068	chr6:111849860	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.39	7.49	0.38	6.1e-13	Metabolic traits;
LUSC	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.92	-0.31	7.92e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	12.03	0.55	6.37e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18876405	chr7:65276391	NA	0.55	8.8	0.43	7.72e-17	Aortic root size;
LUSC	cis	rs12620999	0.941	rs10803654	chr2:238036570	C/T	cg23555395	chr2:238036564	NA	-0.53	-8.94	-0.44	2.77e-17	Systemic lupus erythematosus;
LUSC	cis	rs12541635	0.966	rs12681183	chr8:107007156	T/A	cg10147462	chr8:107024639	NA	0.55	9.97	0.48	1.16e-20	Age of smoking initiation;
LUSC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg19318889	chr4:1322082	MAEA	0.43	6.98	0.36	1.58e-11	Obesity-related traits;
LUSC	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg23601095	chr6:26197514	HIST1H3D	0.73	7.47	0.38	7.08e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.83	-0.54	3.41e-27	Chronic sinus infection;
LUSC	cis	rs7106204	0.609	rs11824883	chr11:24284952	G/A	ch.11.24196551F	chr11:24239977	NA	0.72	6.05	0.31	3.93e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	9.51	0.46	4.03e-19	Lung cancer in ever smokers;
LUSC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.43	-0.38	9.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg05084668	chr3:125655381	ALG1L	-0.48	-6.87	-0.35	3.17e-11	Blood pressure (smoking interaction);
LUSC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg06096015	chr1:231504339	EGLN1	0.54	9.51	0.46	3.95e-19	Hemoglobin concentration;
LUSC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg26816564	chr1:7831052	VAMP3	0.98	13.2	0.59	2.63e-32	Inflammatory bowel disease;
LUSC	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.34	5.66	0.3	3.29e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.86	-0.31	1.11e-8	Ulcerative colitis;
LUSC	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg26384229	chr12:38710491	ALG10B	-0.6	-9.28	-0.45	2.15e-18	Morning vs. evening chronotype;
LUSC	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg04374321	chr14:90722782	PSMC1	0.75	12.12	0.55	2.92e-28	Mortality in heart failure;
LUSC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	8.73	0.43	1.28e-16	Total body bone mineral density;
LUSC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.84	-14.4	-0.62	6.39e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg02711726	chr17:80685570	FN3KRP	-0.42	-6.3	-0.33	9.48e-10	Glycated hemoglobin levels;
LUSC	trans	rs11700980	0.551	rs56000932	chr21:30116268	G/A	cg14791747	chr16:20752902	THUMPD1	0.55	5.98	0.31	5.63e-9	QRS complex (12-leadsum);
LUSC	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.84	13.62	0.6	6.77e-34	Bladder cancer;
LUSC	cis	rs2860975	0.936	rs1934973	chr10:96783601	A/C	cg09036531	chr10:96991505	NA	-0.41	-5.75	-0.3	2.06e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Smoking initiation;
LUSC	trans	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg07393940	chr7:158741817	NA	0.36	6.55	0.34	2.16e-10	Life satisfaction;
LUSC	cis	rs2190422	0.577	rs6465922	chr7:103094968	A/G	cg04218035	chr7:103086829	SLC26A5	0.3	5.89	0.31	9.51e-9	Morning vs. evening chronotype;
LUSC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg11843238	chr5:131593191	PDLIM4	0.51	9.04	0.44	1.32e-17	Acylcarnitine levels;
LUSC	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.12	-0.45	7.37e-18	Schizophrenia;
LUSC	cis	rs1808579	0.935	rs1805082	chr18:21120444	C/T	cg14672496	chr18:21087552	C18orf8	-0.34	-5.95	-0.31	6.91e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs4343996	0.530	rs10262783	chr7:3431165	T/C	cg21248987	chr7:3385318	SDK1	0.36	6.01	0.31	4.82e-9	Motion sickness;
LUSC	cis	rs8114671	0.967	rs6142324	chr20:33789043	C/T	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.92	-0.31	7.84e-9	Height;
LUSC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.29	0.37	2.24e-12	Platelet count;
LUSC	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg10978503	chr1:24200527	CNR2	-0.45	-9.38	-0.46	1.03e-18	Immature fraction of reticulocytes;
LUSC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.96	-15.5	-0.65	3.22e-41	Coronary artery disease;
LUSC	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg00757033	chr12:89920650	WDR51B	0.58	9.87	0.48	2.47e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg08975724	chr8:8085496	FLJ10661	0.39	5.72	0.3	2.39e-8	Mood instability;
LUSC	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.82	-0.3	1.42e-8	Platelet count;
LUSC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.9	16.95	0.68	6.11e-47	Menarche (age at onset);
LUSC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg23711669	chr6:146136114	FBXO30	0.88	15.95	0.66	5.59e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg18827107	chr12:86230957	RASSF9	0.44	6.77	0.35	5.96e-11	Major depressive disorder;
LUSC	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs9653442	0.527	rs4851258	chr2:100780830	T/C	cg07810366	chr2:100720526	AFF3	-0.44	-7.49	-0.38	6.12e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs11622475	0.651	rs34982025	chr14:104360431	G/A	cg12183467	chr14:104352244	NA	-0.5	-9.87	-0.48	2.56e-20	Bipolar disorder;
LUSC	cis	rs62027291	1.000	rs5021805	chr15:77290300	G/A	cg26408565	chr15:76604113	ETFA	0.55	6.7	0.34	8.9e-11	Plateletcrit;
LUSC	cis	rs4478858	0.654	rs113490486	chr1:31712863	C/G	cg00250761	chr1:31883323	NA	-0.34	-8.21	-0.41	4.93e-15	Alcohol dependence;
LUSC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-15.46	-0.65	4.66e-41	Heart rate;
LUSC	cis	rs79911532	0.515	rs17148983	chr7:75649821	C/G	cg03592824	chr7:75666768	STYXL1	0.71	6.92	0.35	2.26e-11	Mononucleosis;
LUSC	cis	rs73206853	0.841	rs4131852	chr12:110812657	C/G	cg12870014	chr12:110450643	ANKRD13A	0.67	6.63	0.34	1.32e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg25767906	chr1:53392781	SCP2	0.47	8.41	0.42	1.22e-15	Monocyte count;
LUSC	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg26384229	chr12:38710491	ALG10B	-0.66	-10.26	-0.49	1.18e-21	Bladder cancer;
LUSC	trans	rs800082	0.966	rs2575192	chr3:144281170	C/T	cg24215973	chr2:240111563	HDAC4	0.47	7.05	0.36	1.03e-11	Smoking behavior;
LUSC	cis	rs2274273	0.870	rs4366639	chr14:55790516	T/G	cg04306507	chr14:55594613	LGALS3	0.54	11.81	0.54	3.98e-27	Protein biomarker;
LUSC	cis	rs35000415	0.873	rs34748780	chr7:128700153	A/G	cg19972273	chr7:128594194	NA	0.63	5.72	0.3	2.34e-8	Systemic lupus erythematosus;
LUSC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg16545954	chr1:2118288	C1orf86	0.36	6.98	0.36	1.61e-11	Height;
LUSC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.42	-7.8	-0.39	7.89e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg17644776	chr2:200775616	C2orf69	-0.44	-6.56	-0.34	2.09e-10	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3740713	1.000	rs16935432	chr11:18470487	G/A	cg23797887	chr11:18477753	LDHAL6A	-0.56	-6.77	-0.35	5.8e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg04518342	chr5:131593106	PDLIM4	0.41	7.48	0.38	6.53e-13	Breast cancer;
LUSC	cis	rs11209002	0.876	rs7517744	chr1:67570879	T/C	cg02640540	chr1:67518911	SLC35D1	0.68	7.78	0.39	8.99e-14	Crohn's disease;
LUSC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg26380479	chr7:97908229	NA	-0.27	-6.13	-0.32	2.54e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg22852734	chr6:133119734	C6orf192	1.33	10.3	0.49	8.52e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs909341	0.808	rs2263805	chr20:62351150	T/C	cg09650180	chr20:62225654	GMEB2	-0.47	-6.11	-0.32	2.75e-9	Atopic dermatitis;
LUSC	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg06547715	chr2:218990976	CXCR2	0.33	6.47	0.33	3.57e-10	Ulcerative colitis;
LUSC	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg07148914	chr20:33460835	GGT7	-0.44	-6.47	-0.33	3.41e-10	Height;
LUSC	cis	rs75557865	1	rs75557865	chr3:121652141	G/A	cg20356878	chr3:121714668	ILDR1	0.68	12.0	0.55	7.97e-28	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.92	-0.35	2.34e-11	Response to antipsychotic treatment;
LUSC	cis	rs9322817	0.691	rs17680345	chr6:105337409	A/T	cg02098413	chr6:105308735	HACE1	0.28	5.96	0.31	6.53e-9	Thyroid stimulating hormone;
LUSC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21984481	chr17:79567631	NPLOC4	0.67	13.88	0.6	6.79e-35	Eye color traits;
LUSC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.53	-7.54	-0.38	4.47e-13	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg14983838	chr19:29218262	NA	-0.52	-6.04	-0.31	4.2e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg02423579	chr7:2872169	GNA12	-0.44	-6.63	-0.34	1.37e-10	Height;
LUSC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.44	0.46	6.63e-19	Bipolar disorder;
LUSC	trans	rs34421088	0.532	rs2736385	chr8:11148613	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	6.67	0.34	1.08e-10	Neuroticism;
LUSC	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg09092052	chr15:45571596	NA	0.45	6.26	0.32	1.18e-9	Glomerular filtration rate;
LUSC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg22963979	chr7:1858916	MAD1L1	0.55	8.62	0.43	2.8e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg11812906	chr14:75593930	NEK9	0.63	10.55	0.5	1.22e-22	Height;
LUSC	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg15704280	chr7:45808275	SEPT13	-0.53	-6.19	-0.32	1.71e-9	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs1493916	0.837	rs9952002	chr18:31414314	C/G	cg27147174	chr7:100797783	AP1S1	-0.57	-8.89	-0.44	3.89e-17	Life satisfaction;
LUSC	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg25342872	chr17:79175132	AZI1	-0.38	-6.18	-0.32	1.82e-9	Frontotemporal dementia;
LUSC	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg20487152	chr13:99095054	FARP1	-0.44	-7.75	-0.39	1.11e-13	Longevity;
LUSC	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg24558204	chr6:135376177	HBS1L	0.59	9.26	0.45	2.63e-18	Red blood cell count;
LUSC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg21361702	chr7:150065534	REPIN1	0.5	6.46	0.33	3.72e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.84	0.35	3.9e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs921665	0.680	rs7571242	chr2:3199025	A/G	cg16434511	chr2:3151078	NA	-0.63	-6.62	-0.34	1.41e-10	World class endurance athleticism;
LUSC	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg18683606	chr7:100471612	SRRT	0.45	5.96	0.31	6.4e-9	Resting heart rate;
LUSC	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg24642439	chr20:33292090	TP53INP2	0.49	7.4	0.38	1.09e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs7809950	0.773	rs2237668	chr7:107050209	A/G	cg23024343	chr7:107201750	COG5	-0.7	-10.08	-0.48	4.85e-21	Coronary artery disease;
LUSC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	9.3	0.45	1.95e-18	Mean platelet volume;
LUSC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg11941060	chr3:133502564	NA	-0.42	-6.13	-0.32	2.47e-9	Iron status biomarkers;
LUSC	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg20933634	chr6:27740509	NA	0.4	5.87	0.31	1.06e-8	Parkinson's disease;
LUSC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	7.04	0.36	1.08e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1595825	0.735	rs6752454	chr2:198938959	T/G	cg00982548	chr2:198649783	BOLL	-0.54	-6.48	-0.33	3.2e-10	Ulcerative colitis;
LUSC	trans	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg26043149	chr18:55253948	FECH	-0.46	-7.07	-0.36	8.95e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.59	-9.63	-0.47	1.6e-19	Schizophrenia;
LUSC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg22823121	chr1:150693482	HORMAD1	0.6	9.34	0.46	1.35e-18	Tonsillectomy;
LUSC	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg20283391	chr11:68216788	NA	-0.61	-8.56	-0.42	4.21e-16	Total body bone mineral density;
LUSC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg06008330	chr7:65541103	ASL	0.37	5.68	0.3	2.97e-8	Aortic root size;
LUSC	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.15	-0.36	5.48e-12	Bipolar disorder;
LUSC	trans	rs12637928	0.560	rs11923659	chr3:110295279	T/A	cg17371621	chr15:61264283	RORA	-0.37	-6.0	-0.31	5.25e-9	Neuroticism;
LUSC	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg10560079	chr2:191398806	TMEM194B	-0.63	-8.04	-0.4	1.55e-14	Diastolic blood pressure;
LUSC	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg09092052	chr15:45571596	NA	0.47	6.64	0.34	1.25e-10	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg24558204	chr6:135376177	HBS1L	0.59	9.14	0.45	6.29e-18	Red blood cell count;
LUSC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg16743903	chr16:89593216	SPG7	-0.37	-5.71	-0.3	2.52e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg02747822	chr19:1826707	REXO1	0.38	6.03	0.31	4.44e-9	Bipolar disorder;
LUSC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg17971929	chr21:40555470	PSMG1	-0.48	-7.2	-0.37	4.1e-12	Menarche (age at onset);
LUSC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs5167	0.566	rs7253458	chr19:45482570	C/T	cg25746394	chr19:45450501	APOC2	0.32	6.07	0.32	3.55e-9	Blood protein levels;
LUSC	cis	rs6714710	0.603	rs953320	chr2:98606770	T/C	cg26665480	chr2:98280029	ACTR1B	0.62	8.83	0.44	5.97e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06481639	chr22:41940642	POLR3H	-0.55	-6.12	-0.32	2.63e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs10207060	0.500	rs72992168	chr2:240712932	G/A	cg20333904	chr2:240724165	NA	-0.35	-6.15	-0.32	2.26e-9	Obesity-related traits;
LUSC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg17971929	chr21:40555470	PSMG1	0.71	11.05	0.52	2.1e-24	Cognitive function;
LUSC	trans	rs587847	0.507	rs1457248	chr15:37793115	G/A	cg18296784	chr11:116147929	NA	-0.36	-6.33	-0.33	7.71e-10	Intraocular pressure;
LUSC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg20573242	chr4:122745356	CCNA2	0.59	8.48	0.42	7.16e-16	Type 2 diabetes;
LUSC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg20399509	chr21:47717575	C21orf57	-0.43	-6.18	-0.32	1.88e-9	Testicular germ cell tumor;
LUSC	cis	rs6546537	1.000	rs4852868	chr2:69831636	C/T	cg10773587	chr2:69614142	GFPT1	-0.44	-7.2	-0.37	3.98e-12	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg16342193	chr10:102329863	NA	-0.38	-6.43	-0.33	4.33e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.82	12.4	0.56	2.57e-29	Cognitive test performance;
LUSC	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg06636001	chr8:8085503	FLJ10661	0.69	10.95	0.51	4.61e-24	Mood instability;
LUSC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.16	-0.36	5.24e-12	Major depressive disorder;
LUSC	cis	rs73206853	0.841	rs55634798	chr12:110833748	G/T	cg12870014	chr12:110450643	ANKRD13A	0.67	6.73	0.35	7.44e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg09555818	chr19:45449301	APOC2	0.47	8.83	0.44	5.84e-17	Blood protein levels;
LUSC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.72	-16.97	-0.68	4.99e-47	Prostate cancer;
LUSC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.97	-0.4	2.53e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg09491104	chr22:46646882	C22orf40	-0.67	-7.0	-0.36	1.42e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg16482183	chr6:26056742	HIST1H1C	0.58	8.02	0.4	1.86e-14	Iron status biomarkers;
LUSC	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg27489772	chr12:121021490	NA	0.58	7.75	0.39	1.11e-13	Type 1 diabetes nephropathy;
LUSC	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg17366294	chr4:99064904	C4orf37	0.6	10.73	0.51	2.82e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg03522245	chr20:25566470	NINL	-0.36	-5.8	-0.3	1.54e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-7.06	-0.36	9.79e-12	Lung cancer;
LUSC	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg25019033	chr10:957182	NA	-0.58	-7.61	-0.38	2.75e-13	Eosinophil percentage of granulocytes;
LUSC	cis	rs1376877	0.519	rs12466364	chr2:204226331	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.5	6.43	0.33	4.33e-10	Subclinical atherosclerosis traits (other);
LUSC	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg00579200	chr11:133705235	NA	-0.4	-6.14	-0.32	2.33e-9	Childhood ear infection;
LUSC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.08	-0.4	1.19e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg09365446	chr1:150670422	GOLPH3L	0.44	6.33	0.33	7.88e-10	Melanoma;
LUSC	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg00277334	chr10:82204260	NA	-0.59	-9.81	-0.47	4.05e-20	Post bronchodilator FEV1;
LUSC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg22834771	chr12:69754056	YEATS4	-0.55	-8.13	-0.41	8.34e-15	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg20295408	chr7:1910781	MAD1L1	0.4	5.67	0.3	3.15e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg20976159	chr1:228193529	WNT3A	0.29	5.71	0.3	2.54e-8	Diastolic blood pressure;
LUSC	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.07	0.52	1.74e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1982963	1.000	rs4901186	chr14:52509484	G/A	cg10843707	chr14:52510701	NID2	-0.39	-6.75	-0.35	6.38e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7681440	0.647	rs6824979	chr4:90819407	C/G	cg01966878	chr4:90757139	SNCA	0.35	5.65	0.3	3.44e-8	Dementia with Lewy bodies;
LUSC	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.6	10.79	0.51	1.8e-23	Weight;
LUSC	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg10523679	chr1:76189770	ACADM	0.75	10.12	0.48	3.56e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.45	0.33	3.83e-10	Corneal astigmatism;
LUSC	cis	rs12618769	0.597	rs55900716	chr2:99109132	G/A	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg14092988	chr3:52407081	DNAH1	0.31	6.18	0.32	1.82e-9	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09659514	chr21:33765299	URB1;C21orf119	-0.4	-5.98	-0.31	5.79e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs757278	0.591	rs34637736	chr7:117294301	C/T	cg10524701	chr7:117356490	CTTNBP2	0.41	5.82	0.3	1.38e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	trans	rs4662863	0.566	rs17049012	chr2:129767539	G/A	cg05506011	chr3:118864587	C3orf30;IGSF11	0.36	6.03	0.31	4.38e-9	Gut microbiome composition (winter);
LUSC	cis	rs4478858	0.684	rs1532861	chr1:31766491	T/C	cg00250761	chr1:31883323	NA	-0.34	-8.15	-0.41	7.19e-15	Alcohol dependence;
LUSC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-1.19	-12.97	-0.58	2.03e-31	Diabetic kidney disease;
LUSC	cis	rs79911532	0.515	rs76083953	chr7:75698576	G/C	cg03592824	chr7:75666768	STYXL1	0.67	6.41	0.33	4.98e-10	Mononucleosis;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09916155	chr16:1728187	HN1L	0.75	5.96	0.31	6.26e-9	Cognitive performance;
LUSC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg09165964	chr15:75287851	SCAMP5	-1.01	-15.3	-0.64	2.03e-40	Blood trace element (Zn levels);
LUSC	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg03060546	chr3:49711283	APEH	0.64	7.54	0.38	4.41e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg24642439	chr20:33292090	TP53INP2	-0.48	-7.33	-0.37	1.7e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs17401966	0.540	rs11121557	chr1:10448260	T/G	cg17425144	chr1:10567563	PEX14	-0.34	-6.03	-0.31	4.3e-9	Hepatocellular carcinoma;
LUSC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg14780466	chr2:20870812	GDF7	-0.39	-7.79	-0.39	8.53e-14	Abdominal aortic aneurysm;
LUSC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg08847533	chr14:75593920	NEK9	-0.82	-14.81	-0.63	1.74e-38	Height;
LUSC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg09359103	chr1:154839909	KCNN3	-0.7	-15.74	-0.65	3.72e-42	Prostate cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18642567	chr14:21755798	RPGRIP1	0.48	6.03	0.31	4.39e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg13395646	chr4:1353034	KIAA1530	-0.78	-13.02	-0.58	1.21e-31	Obesity-related traits;
LUSC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.35	0.37	1.57e-12	Bipolar disorder;
LUSC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.92	-0.35	2.29e-11	Lung cancer;
LUSC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg03213289	chr20:61660250	NA	0.68	14.05	0.61	1.46e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4974559	0.690	rs28515563	chr4:1315123	G/A	cg02980000	chr4:1222292	CTBP1	1.01	9.53	0.46	3.42e-19	Systolic blood pressure;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg10298173	chr3:14166327	CHCHD4;TMEM43	0.44	6.86	0.35	3.38e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs500891	0.525	rs13198062	chr6:84075281	C/T	cg08257003	chr6:84140564	ME1	0.34	8.32	0.41	2.2e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg06713675	chr4:122721982	EXOSC9	-0.45	-7.06	-0.36	9.99e-12	Type 2 diabetes;
LUSC	cis	rs61142792	0.590	rs747861	chr5:177037397	C/G	cg15051221	chr5:177434457	FAM153C	0.65	5.98	0.31	5.72e-9	Alzheimer disease and age of onset;
LUSC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg07936489	chr17:37558343	FBXL20	-0.71	-9.99	-0.48	9.76e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13126279	chr21:47581558	C21orf56	-0.56	-8.56	-0.42	4.05e-16	Testicular germ cell tumor;
LUSC	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg23422044	chr7:1970798	MAD1L1	-0.65	-7.31	-0.37	2.04e-12	Bipolar disorder;
LUSC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	0.96	19.47	0.73	5.67e-57	Cognitive function;
LUSC	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.2e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg00677455	chr12:58241039	CTDSP2	0.61	9.02	0.44	1.5e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08280861	chr8:58055591	NA	0.52	5.68	0.3	2.99e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg07393940	chr7:158741817	NA	0.37	6.7	0.34	8.88e-11	Life satisfaction;
LUSC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	9.61	0.47	1.76e-19	Personality dimensions;
LUSC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.67	-12.09	-0.55	3.73e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2072499	0.833	rs2842873	chr1:156204653	C/T	cg24450063	chr1:156163899	SLC25A44	1.11	24.5	0.8	1.4e-76	Testicular germ cell tumor;
LUSC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg08132940	chr7:1081526	C7orf50	-0.52	-6.15	-0.32	2.27e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg05163923	chr11:71159392	DHCR7	0.76	11.26	0.52	3.78e-25	Vitamin D levels;
LUSC	cis	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg06521331	chr12:34319734	NA	-0.4	-5.76	-0.3	1.94e-8	Resting heart rate;
LUSC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg07701084	chr6:150067640	NUP43	0.53	7.99	0.4	2.17e-14	Lung cancer;
LUSC	cis	rs911119	0.657	rs2104005	chr20:23630761	G/A	cg16589663	chr20:23618590	CST3	0.62	6.65	0.34	1.18e-10	Chronic kidney disease;
LUSC	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg26408565	chr15:76604113	ETFA	-0.44	-7.0	-0.36	1.43e-11	Blood metabolite levels;
LUSC	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.92	12.13	0.55	2.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-10.43	-0.5	3.01e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg02931644	chr1:25747376	RHCE	0.35	6.33	0.33	8.07e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs11264799	0.520	rs849826	chr1:157546346	A/T	cg18268488	chr1:157545234	FCRL4	0.41	8.21	0.41	4.88e-15	IgA nephropathy;
LUSC	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg24642439	chr20:33292090	TP53INP2	-0.54	-8.16	-0.41	7.03e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	5.85	0.3	1.18e-8	Menopause (age at onset);
LUSC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg10518572	chr11:65560635	OVOL1	-0.26	-5.93	-0.31	7.37e-9	Acne (severe);
LUSC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg02423579	chr7:2872169	GNA12	-0.47	-6.59	-0.34	1.76e-10	Height;
LUSC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.42	-7.67	-0.39	1.85e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs698813	0.637	rs7579841	chr2:44498887	T/A	cg00619915	chr2:44497795	NA	-0.52	-7.29	-0.37	2.26e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	trans	rs72674100	1.000	rs2865753	chr4:97992752	A/T	cg09670535	chr1:18959427	PAX7	-0.61	-6.23	-0.32	1.41e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26314531	chr2:26401878	FAM59B	-0.69	-9.3	-0.45	1.91e-18	Gut microbiome composition (summer);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10684905	chr12:2999782	TULP3	0.42	6.83	0.35	4.01e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg25174290	chr11:3078921	CARS	-0.56	-8.77	-0.43	9.35e-17	Longevity;
LUSC	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg25233709	chr10:116636983	FAM160B1	0.38	6.68	0.34	1.03e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg05082376	chr22:42548792	NA	-0.38	-5.8	-0.3	1.57e-8	Schizophrenia;
LUSC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg11062466	chr8:58055876	NA	0.5	6.72	0.35	7.7e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4356932	0.967	rs6856681	chr4:76975113	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.83	0.3	1.33e-8	Blood protein levels;
LUSC	cis	rs1881396	0.531	rs76586169	chr2:27897835	G/A	cg27432699	chr2:27873401	GPN1	0.63	7.51	0.38	5.33e-13	Nonalcoholic fatty liver disease;
LUSC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg22166914	chr1:53195759	ZYG11B	0.43	6.79	0.35	5.15e-11	Monocyte count;
LUSC	cis	rs17401966	0.540	rs1536262	chr1:10438687	C/T	cg19773385	chr1:10388646	KIF1B	-0.37	-6.29	-0.33	9.98e-10	Hepatocellular carcinoma;
LUSC	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.88	-11.25	-0.52	4.06e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18932078	chr1:2524107	MMEL1	0.32	7.2	0.37	4e-12	Ulcerative colitis;
LUSC	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg09408571	chr1:101003634	GPR88	0.29	5.67	0.3	3.12e-8	Monocyte count;
LUSC	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg17127132	chr2:85788382	GGCX	-0.42	-6.08	-0.32	3.3e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2302729	1.000	rs7974589	chr12:2785089	G/A	cg19945202	chr12:2788847	CACNA1C	-0.39	-5.99	-0.31	5.57e-9	Sleep quality;
LUSC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-7.09	-0.36	8.23e-12	Lung cancer;
LUSC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg03354898	chr7:1950403	MAD1L1	0.34	6.67	0.34	1.09e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg04450456	chr4:17643702	FAM184B	0.35	5.85	0.3	1.18e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg16393715	chr7:1948819	MAD1L1	-0.33	-5.71	-0.3	2.51e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.22	-0.37	3.45e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs67696533	0.600	rs910890	chr20:31108932	G/T	cg13636640	chr20:31349939	DNMT3B	0.49	6.68	0.34	1.03e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs9462027	0.606	rs7756009	chr6:34715395	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.9	-0.31	9.02e-9	Systemic lupus erythematosus;
LUSC	cis	rs12594515	1.000	rs12592190	chr15:45994028	G/A	cg06207120	chr15:45996521	NA	0.38	5.75	0.3	2.02e-8	Waist circumference;Weight;
LUSC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg17279839	chr7:150038598	RARRES2	0.45	6.92	0.35	2.34e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	1.24	16.51	0.67	3.35e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg03948781	chr1:205179583	DSTYK	0.32	6.1	0.32	2.98e-9	Red blood cell count;
LUSC	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg23950597	chr19:37808831	NA	-0.63	-7.8	-0.39	8.08e-14	Coronary artery calcification;
LUSC	cis	rs17095355	0.818	rs61881639	chr10:111863501	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.59	-6.83	-0.35	4.13e-11	Biliary atresia;
LUSC	cis	rs9677476	0.818	rs28678038	chr2:232063997	A/T	cg07929768	chr2:232055508	NA	0.37	6.85	0.35	3.49e-11	Food antigen IgG levels;
LUSC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.7	10.83	0.51	1.22e-23	Aortic root size;
LUSC	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.43	-0.33	4.39e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg09509183	chr1:209979624	IRF6	0.52	6.21	0.32	1.61e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs4474465	0.646	rs10899556	chr11:78278986	C/T	cg27205649	chr11:78285834	NARS2	0.56	6.82	0.35	4.31e-11	Alzheimer's disease (survival time);
LUSC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	0.66	9.24	0.45	3.02e-18	Methadone dose in opioid dependence;
LUSC	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg26395211	chr5:140044315	WDR55	0.4	6.24	0.32	1.3e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg09034736	chr1:150693464	HORMAD1	0.41	5.75	0.3	1.96e-8	Melanoma;
LUSC	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.14	-0.36	5.89e-12	Blood metabolite levels;
LUSC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg15448220	chr1:150897856	SETDB1	0.41	6.17	0.32	1.97e-9	Melanoma;
LUSC	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg15423357	chr2:25149977	NA	0.45	9.1	0.45	8.6e-18	Body mass index;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg13679077	chr7:22862647	TOMM7	0.41	6.64	0.34	1.28e-10	Tuberculosis;
LUSC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg00012203	chr2:219082015	ARPC2	-0.7	-11.43	-0.53	9.14e-26	Colorectal cancer;
LUSC	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.94	19.64	0.73	1.19e-57	Ulcerative colitis;
LUSC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg27612695	chr17:29059191	SUZ12P	0.39	5.96	0.31	6.39e-9	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs57549656	0.799	rs72980732	chr19:2711278	A/G	cg06609049	chr19:2785107	THOP1	0.49	6.43	0.33	4.51e-10	Schizophrenia;
LUSC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.51	6.72	0.35	7.83e-11	Blood protein levels;
LUSC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg04851639	chr8:1020857	NA	0.37	7.67	0.39	1.94e-13	Schizophrenia;
LUSC	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg23950597	chr19:37808831	NA	-0.63	-7.52	-0.38	5.22e-13	Coronary artery calcification;
LUSC	cis	rs11676348	0.774	rs13397673	chr2:219047782	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-5.89	-0.31	9.22e-9	Ulcerative colitis;
LUSC	cis	rs2108225	0.934	rs2301988	chr7:107443833	A/G	cg18560240	chr7:107437656	SLC26A3	0.39	5.83	0.3	1.28e-8	Ulcerative colitis;
LUSC	cis	rs4285028	0.747	rs1128163	chr3:121350573	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-12.41	-0.56	2.48e-29	Multiple sclerosis;
LUSC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg26338869	chr17:61819248	STRADA	0.41	5.95	0.31	6.66e-9	Prudent dietary pattern;
LUSC	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg13852791	chr20:30311386	BCL2L1	0.95	14.9	0.63	7.51e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-10.57	-0.5	1.01e-22	Gut microbiome composition (summer);
LUSC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.42	-0.42	1.16e-15	Obesity-related traits;
LUSC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.03	0.31	4.32e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg04450456	chr4:17643702	FAM184B	-0.36	-5.66	-0.3	3.33e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg07080220	chr10:102295463	HIF1AN	0.6	7.75	0.39	1.15e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs12677056	0.610	rs6992196	chr8:113287399	A/T	cg12159992	chr12:102059490	MYBPC1	0.37	6.17	0.32	1.93e-9	Peripheral artery disease;
LUSC	cis	rs11229555	0.645	rs11229442	chr11:58196790	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs16867321	0.950	rs1919155	chr2:181457053	T/C	cg23363182	chr2:181467187	NA	-0.44	-5.91	-0.31	8.46e-9	Obesity;
LUSC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs67072384	1.000	rs66628852	chr11:72454260	C/A	cg04827223	chr11:72435913	ARAP1	-0.78	-6.8	-0.35	4.98e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs7766436	0.885	rs13220769	chr6:22596464	T/A	cg13666174	chr6:22585274	NA	-0.41	-5.72	-0.3	2.4e-8	Coronary artery disease;
LUSC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg20849893	chr7:64541193	NA	-0.44	-6.31	-0.33	8.67e-10	Calcium levels;
LUSC	trans	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07923666	chr12:49932857	KCNH3	-0.52	-6.74	-0.35	6.79e-11	Resting heart rate;
LUSC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg22907277	chr7:1156413	C7orf50	0.4	5.94	0.31	7e-9	Longevity;Endometriosis;
LUSC	cis	rs2273669	0.667	rs1424479	chr6:109355790	G/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs4776059	0.724	rs11633933	chr15:52948357	T/C	cg22715398	chr15:52968154	KIAA1370	-0.74	-9.91	-0.48	1.8e-20	Schizophrenia;
LUSC	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2.04e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.0	0.44	1.74e-17	Motion sickness;
LUSC	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg04374321	chr14:90722782	PSMC1	-0.68	-10.26	-0.49	1.17e-21	Mortality in heart failure;
LUSC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg02574844	chr11:5959923	NA	0.4	6.64	0.34	1.28e-10	DNA methylation (variation);
LUSC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12620999	0.941	rs62183344	chr2:237979165	T/C	cg23555395	chr2:238036564	NA	0.45	7.87	0.4	5.05e-14	Systemic lupus erythematosus;
LUSC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.18	-0.45	4.76e-18	Type 2 diabetes;
LUSC	trans	rs6600671	1.000	rs12047116	chr1:121185770	G/A	cg00646200	chr1:148855367	NA	0.46	7.33	0.37	1.77e-12	Hip geometry;
LUSC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg07701084	chr6:150067640	NUP43	0.51	7.65	0.39	2.23e-13	Lung cancer;
LUSC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.97	-0.44	2.18e-17	Electroencephalogram traits;
LUSC	cis	rs2281558	0.583	rs7260957	chr20:25722462	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.23	0.32	1.42e-9	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs2637266	1.000	rs7101318	chr10:78379780	T/C	cg18941641	chr10:78392320	NA	0.38	6.94	0.35	2.08e-11	Pulmonary function;
LUSC	cis	rs365132	1.000	rs601923	chr5:176417386	C/G	cg25401027	chr5:176370377	UIMC1	0.37	6.29	0.33	9.95e-10	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	trans	rs984440	0.621	rs1028779	chr8:139076802	A/G	cg03334052	chr1:168888044	NA	-0.4	-6.29	-0.33	9.73e-10	Obesity-related traits;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg13272430	chr14:67708475	MPP5	0.43	6.52	0.34	2.67e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg18827107	chr12:86230957	RASSF9	-0.47	-7.06	-0.36	9.92e-12	Major depressive disorder;
LUSC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	7.92	0.4	3.58e-14	Colorectal cancer;
LUSC	cis	rs793571	0.543	rs4775087	chr15:58974904	T/C	cg05156742	chr15:59063176	FAM63B	0.52	7.62	0.38	2.61e-13	Schizophrenia;
LUSC	cis	rs887829	0.570	rs10171367	chr2:234597667	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.28	-0.33	1.04e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg04998671	chr14:104000505	TRMT61A	0.57	8.03	0.4	1.69e-14	Coronary artery disease;
LUSC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg08508325	chr11:3079039	CARS	-0.52	-12.45	-0.56	1.76e-29	Longevity;
LUSC	cis	rs9341808	0.667	rs2322632	chr6:80845608	G/A	cg08355045	chr6:80787529	NA	0.47	8.22	0.41	4.62e-15	Sitting height ratio;
LUSC	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.9	-0.35	2.68e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg25174290	chr11:3078921	CARS	0.61	9.6	0.46	2.04e-19	Longevity;
LUSC	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg03859395	chr2:55845619	SMEK2	0.88	16.19	0.66	6.22e-44	Metabolic syndrome;
LUSC	cis	rs9462027	0.628	rs2764207	chr6:34712998	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.87	-0.31	1.02e-8	Systemic lupus erythematosus;
LUSC	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.13	0.36	6.25e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs12594515	1.000	rs57299255	chr15:45996532	C/A	cg06207120	chr15:45996521	NA	0.39	5.9	0.31	8.78e-9	Waist circumference;Weight;
LUSC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.94	0.58	2.56e-31	Prudent dietary pattern;
LUSC	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg25482853	chr8:67687455	SGK3	1.03	15.45	0.65	5.41e-41	Obesity-related traits;
LUSC	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	7.73	0.39	1.27e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs9784649	0.882	rs2201296	chr5:24967119	G/A	cg08600765	chr20:34638493	LOC647979	-0.56	-6.25	-0.32	1.28e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-36.83	-0.9	1.24e-119	Myeloid white cell count;
LUSC	cis	rs7851660	0.874	rs925487	chr9:100636398	C/T	cg13688889	chr9:100608707	NA	-0.55	-8.68	-0.43	1.77e-16	Strep throat;
LUSC	cis	rs3847687	0.966	rs3847689	chr12:131525534	T/G	cg25772418	chr12:131519998	GPR133	-0.26	-5.81	-0.3	1.44e-8	Longevity;
LUSC	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg22815214	chr1:201083145	CACNA1S	0.57	10.05	0.48	6.06e-21	Permanent tooth development;
LUSC	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.68	12.75	0.57	1.35e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg13395646	chr4:1353034	KIAA1530	-0.78	-13.08	-0.58	7.57e-32	Obesity-related traits;
LUSC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.86	16.57	0.67	1.92e-45	Mean platelet volume;
LUSC	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.48	-0.33	3.27e-10	Resting heart rate;
LUSC	cis	rs9653442	0.545	rs12987209	chr2:100761148	C/T	cg22139774	chr2:100720529	AFF3	-0.42	-7.26	-0.37	2.8e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-7.26	-0.37	2.69e-12	Glaucoma (primary open-angle);
LUSC	trans	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-8.48	-0.42	7.55e-16	Obesity-related traits;
LUSC	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.84	-0.35	3.74e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6426558	0.559	rs7549520	chr1:227258858	G/C	cg10327440	chr1:227177885	CDC42BPA	0.55	7.43	0.38	9.1e-13	Neutrophil percentage of white cells;
LUSC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.65	-10.18	-0.49	2.21e-21	Menarche (age at onset);
LUSC	cis	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg09904177	chr6:26538194	HMGN4	-0.73	-5.73	-0.3	2.3e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10802521	chr3:52805072	NEK4	-0.55	-8.78	-0.43	8.36e-17	Bipolar disorder;
LUSC	cis	rs68170813	0.652	rs76742243	chr7:107144202	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.46	-5.69	-0.3	2.79e-8	Coronary artery disease;
LUSC	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.48	10.12	0.48	3.59e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs909341	0.909	rs6122159	chr20:62370732	G/T	cg09650180	chr20:62225654	GMEB2	-0.44	-5.67	-0.3	3.15e-8	Atopic dermatitis;
LUSC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05025164	chr4:1340916	KIAA1530	0.64	9.63	0.47	1.55e-19	Longevity;
LUSC	cis	rs3849570	1.000	rs9842330	chr3:81814688	G/A	cg07356753	chr3:81810745	GBE1	-0.68	-10.94	-0.51	5.14e-24	Waist circumference;Body mass index;
LUSC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg06784218	chr1:46089804	CCDC17	-0.5	-10.06	-0.48	5.91e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3018712	0.532	rs2513289	chr11:68419655	A/C	cg22747802	chr11:68417633	NA	-0.43	-5.95	-0.31	6.89e-9	Total body bone mineral density;
LUSC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.7	-12.59	-0.57	5.36e-30	Aortic root size;
LUSC	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg11584989	chr19:19387371	SF4	0.68	8.02	0.4	1.86e-14	Bipolar disorder;
LUSC	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.24	-0.37	3.09e-12	Bipolar disorder;
LUSC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg05457628	chr5:178986728	RUFY1	-0.65	-11.24	-0.52	4.34e-25	Lung cancer;
LUSC	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.62	10.04	0.48	6.47e-21	Blood metabolite ratios;
LUSC	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg22117172	chr7:91764530	CYP51A1	0.32	5.67	0.3	3.11e-8	Breast cancer;
LUSC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg16423285	chr20:60520624	NA	-0.91	-12.63	-0.57	3.6e-30	Obesity-related traits;
LUSC	cis	rs35995292	0.500	rs1019065	chr7:38939775	C/T	cg19327137	chr7:38886074	VPS41	0.56	10.4	0.49	3.92e-22	Subjective well-being (multi-trait analysis);
LUSC	cis	rs2455601	0.744	rs2163626	chr11:8983547	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.46	-7.96	-0.4	2.77e-14	Schizophrenia;
LUSC	cis	rs4499344	0.556	rs259219	chr19:33138067	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	11.41	0.53	1.09e-25	Mean platelet volume;
LUSC	cis	rs11235843	0.613	rs71464090	chr11:73596791	T/G	cg18195628	chr11:73498948	MRPL48	0.53	5.87	0.31	1.07e-8	Hand grip strength;
LUSC	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg05340658	chr4:99064831	C4orf37	0.44	6.92	0.35	2.25e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	5.84	0.3	1.24e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg03929089	chr4:120376271	NA	0.69	7.78	0.39	9.14e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-7.67	-0.39	1.9e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg23649088	chr2:200775458	C2orf69	0.55	7.38	0.37	1.26e-12	Schizophrenia;
LUSC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg06096015	chr1:231504339	EGLN1	0.57	10.02	0.48	7.85e-21	Hemoglobin concentration;
LUSC	cis	rs59698941	0.943	rs12516416	chr5:132248630	C/T	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	trans	rs953492	0.644	rs12124014	chr1:243376757	T/C	cg25284624	chr1:224180302	NA	-0.44	-6.8	-0.35	4.96e-11	Diastolic blood pressure;
LUSC	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg07810366	chr2:100720526	AFF3	-0.48	-8.06	-0.4	1.4e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg22681709	chr2:178499509	PDE11A	-0.45	-6.65	-0.34	1.19e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg13010199	chr12:38710504	ALG10B	-0.49	-7.4	-0.38	1.11e-12	Morning vs. evening chronotype;
LUSC	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg25797454	chr6:150327115	RAET1K	0.32	7.26	0.37	2.78e-12	Alopecia areata;
LUSC	cis	rs11039100	0.850	rs12792672	chr11:5833938	C/T	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg27124370	chr19:33622961	WDR88	0.57	7.35	0.37	1.51e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.58	-0.34	1.87e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8027181	1.000	rs7166595	chr15:73094204	A/G	cg25632853	chr15:73088954	NA	0.32	6.29	0.33	9.79e-10	Triglyceride levels;
LUSC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.09	0.48	4.68e-21	Electroencephalogram traits;
LUSC	cis	rs4903604	0.581	rs11159279	chr14:78036358	C/T	cg18872420	chr14:78023429	SPTLC2	0.39	5.95	0.31	6.78e-9	Gut microbiome composition (winter);
LUSC	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.8	-0.39	8.08e-14	Pulmonary function;
LUSC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.11	-0.48	3.97e-21	Obesity-related traits;
LUSC	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg08601574	chr20:25228251	PYGB	-0.44	-6.68	-0.34	1.02e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs757278	0.591	rs34927137	chr7:117294730	C/T	cg10524701	chr7:117356490	CTTNBP2	0.4	5.7	0.3	2.63e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs12458462	0.859	rs34242155	chr18:77425192	G/A	cg11879182	chr18:77439856	CTDP1	0.72	11.56	0.53	3.13e-26	Monocyte count;
LUSC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10802521	chr3:52805072	NEK4	-0.54	-8.89	-0.44	3.84e-17	Bipolar disorder;
LUSC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg02782426	chr3:40428986	ENTPD3	0.39	7.55	0.38	4.09e-13	Renal cell carcinoma;
LUSC	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg06532163	chr17:45867833	NA	0.34	6.2	0.32	1.64e-9	IgG glycosylation;
LUSC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22029157	chr1:209979665	IRF6	0.74	10.99	0.52	3.49e-24	Cleft lip with or without cleft palate;
LUSC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.67	10.75	0.51	2.36e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7633770	0.769	rs2385858	chr3:46660436	T/C	cg11219411	chr3:46661640	NA	0.48	10.12	0.48	3.62e-21	Coronary artery disease;
LUSC	cis	rs11630290	0.592	rs11071767	chr15:64154635	A/G	cg12036633	chr15:63758958	NA	-0.5	-6.38	-0.33	5.78e-10	Iris characteristics;
LUSC	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	8.73	0.43	1.25e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.07	-0.36	9.02e-12	Blood metabolite levels;
LUSC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg21191810	chr6:118973309	C6orf204	0.36	6.56	0.34	2.11e-10	Electrocardiographic conduction measures;
LUSC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.09	0.48	4.54e-21	Electroencephalogram traits;
LUSC	cis	rs2282300	0.696	rs1222214	chr11:30347695	C/G	cg25418670	chr11:30344373	C11orf46	-0.64	-9.18	-0.45	4.63e-18	Morning vs. evening chronotype;
LUSC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02475777	chr4:1388615	CRIPAK	0.39	5.81	0.3	1.44e-8	Longevity;
LUSC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg12615879	chr12:58013172	SLC26A10	-0.29	-5.94	-0.31	7.18e-9	Multiple sclerosis;
LUSC	cis	rs7674212	0.541	rs2615539	chr4:104081106	C/G	cg16532752	chr4:104119610	CENPE	-0.5	-7.31	-0.37	1.99e-12	Type 2 diabetes;
LUSC	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-5.77	-0.3	1.83e-8	Retinal vascular caliber;
LUSC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg18306943	chr3:40428807	ENTPD3	0.4	6.01	0.31	4.99e-9	Renal cell carcinoma;
LUSC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg13114125	chr14:105738426	BRF1	-0.93	-16.05	-0.66	2.2e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.09	-0.32	3.1e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg18129178	chr5:148520854	ABLIM3	0.54	8.57	0.42	3.91e-16	Breast cancer;
LUSC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs6500395	0.962	rs1872652	chr16:48642928	C/A	cg04672837	chr16:48644449	N4BP1	0.46	6.36	0.33	6.52e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6987853	0.830	rs4361746	chr8:42355041	C/T	cg09913449	chr8:42400586	C8orf40	-0.4	-6.65	-0.34	1.2e-10	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs77633900	0.772	rs8031378	chr15:76657874	A/G	cg21673338	chr15:77095150	SCAPER	-0.68	-6.0	-0.31	5.2e-9	Non-glioblastoma glioma;Glioma;
LUSC	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg15934090	chr1:100435551	SLC35A3	0.48	8.26	0.41	3.47e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs117352156	0.883	rs4587639	chr10:29213174	A/T	cg06394621	chr10:29236369	NA	-0.48	-6.49	-0.33	3.09e-10	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg02269571	chr22:50332266	NA	0.58	8.69	0.43	1.65e-16	Schizophrenia;
LUSC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg04414720	chr1:150670196	GOLPH3L	0.56	9.09	0.45	8.97e-18	Tonsillectomy;
LUSC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg05729581	chr11:3078854	CARS	-0.54	-8.21	-0.41	4.86e-15	Longevity;
LUSC	cis	rs7851660	0.839	rs10818213	chr9:100648631	T/C	cg13688889	chr9:100608707	NA	-0.56	-8.44	-0.42	9.94e-16	Strep throat;
LUSC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	8.94	0.44	2.77e-17	Height;
LUSC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg11861562	chr11:117069780	TAGLN	-0.45	-7.97	-0.4	2.5e-14	Blood protein levels;
LUSC	trans	rs800082	1.000	rs1405596	chr3:144314033	C/G	cg24215973	chr2:240111563	HDAC4	-0.45	-6.98	-0.36	1.63e-11	Smoking behavior;
LUSC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg14581129	chr12:53358946	NA	-0.72	-10.16	-0.49	2.66e-21	Cancer (pleiotropy);
LUSC	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.35	-0.46	1.26e-18	Acne (severe);
LUSC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg20607798	chr8:58055168	NA	-0.56	-5.97	-0.31	5.98e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg04847795	chr1:70820736	HHLA3;ANKRD13C	0.35	6.06	0.31	3.62e-9	Schizophrenia;
LUSC	cis	rs4285028	0.747	rs10049060	chr3:121358448	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.9	12.85	0.58	5.44e-31	Multiple sclerosis;
LUSC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.65	-10.05	-0.48	6.28e-21	Menarche (age at onset);
LUSC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg15556689	chr8:8085844	FLJ10661	0.66	10.99	0.52	3.57e-24	Mood instability;
LUSC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	10.78	0.51	1.84e-23	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg20608306	chr11:116969690	SIK3	0.37	6.92	0.35	2.32e-11	Blood protein levels;
LUSC	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.67	-0.3	3.12e-8	Breast cancer;
LUSC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg13531842	chr10:38383804	ZNF37A	0.45	7.0	0.36	1.39e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg11764359	chr7:65958608	NA	0.52	6.87	0.35	3.16e-11	Aortic root size;
LUSC	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg21521518	chr4:53727714	RASL11B	0.44	5.83	0.3	1.32e-8	Optic nerve measurement (cup area);
LUSC	cis	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg07460842	chr6:66804631	NA	1.08	14.62	0.62	9.38e-38	Exhaled nitric oxide levels;
LUSC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	6.22	0.32	1.48e-9	Multiple sclerosis;
LUSC	trans	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg11887960	chr12:57824829	NA	0.51	6.69	0.34	9.16e-11	Obesity-related traits;
LUSC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-1.0	-16.81	-0.68	2.25e-46	Body mass index;
LUSC	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg05784532	chr1:230284198	GALNT2	0.5	7.45	0.38	8.02e-13	Coronary artery disease;
LUSC	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg02269571	chr22:50332266	NA	-0.57	-8.69	-0.43	1.68e-16	Schizophrenia;
LUSC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg24829409	chr8:58192753	C8orf71	-0.56	-7.08	-0.36	8.49e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7106204	0.514	rs7123539	chr11:24272000	G/A	ch.11.24196551F	chr11:24239977	NA	-0.84	-8.13	-0.41	8.38e-15	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg00990874	chr7:1149470	C7orf50	0.53	6.87	0.35	3.24e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg25036284	chr2:26402008	FAM59B	-0.69	-9.34	-0.46	1.42e-18	Gut microbiome composition (summer);
LUSC	cis	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg21775007	chr8:11205619	TDH	-0.44	-6.02	-0.31	4.54e-9	Triglycerides;
LUSC	cis	rs7246657	0.551	rs10407224	chr19:37651470	G/T	cg23950597	chr19:37808831	NA	-0.59	-6.11	-0.32	2.72e-9	Coronary artery calcification;
LUSC	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg10978503	chr1:24200527	CNR2	0.49	11.53	0.53	4.2e-26	Immature fraction of reticulocytes;
LUSC	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg14835575	chr10:16859367	RSU1	0.76	9.42	0.46	7.86e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs2302729	0.625	rs12228313	chr12:2831297	C/T	cg19945202	chr12:2788847	CACNA1C	0.39	5.69	0.3	2.74e-8	Sleep quality;
LUSC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg01802117	chr1:53393560	SCP2	-0.36	-5.81	-0.3	1.47e-8	Monocyte count;
LUSC	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.31	0.33	8.78e-10	Corneal astigmatism;
LUSC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg05347473	chr6:146136440	FBXO30	0.47	7.89	0.4	4.25e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs977987	0.806	rs1544810	chr16:75411163	A/T	cg03315344	chr16:75512273	CHST6	0.48	9.2	0.45	4.05e-18	Dupuytren's disease;
LUSC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg06637938	chr14:75390232	RPS6KL1	0.49	7.57	0.38	3.61e-13	Height;
LUSC	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.46	9.67	0.47	1.13e-19	Airflow obstruction;
LUSC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.16	0.36	5.25e-12	Major depressive disorder;
LUSC	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg11019008	chr10:131425282	MGMT	0.46	6.94	0.36	2.03e-11	Response to temozolomide;
LUSC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg17264618	chr3:40429014	ENTPD3	-0.26	-5.74	-0.3	2.16e-8	Renal cell carcinoma;
LUSC	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg08917208	chr2:24149416	ATAD2B	0.53	5.97	0.31	6e-9	Lymphocyte counts;
LUSC	cis	rs2227930	0.506	rs7647329	chr3:142075505	G/A	cg16271453	chr3:142027066	XRN1	-0.55	-9.93	-0.48	1.57e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.8	12.26	0.56	9.03e-29	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.41	5.85	0.3	1.18e-8	Bipolar disorder;
LUSC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg12963246	chr6:28129442	ZNF389	0.38	5.76	0.3	1.9e-8	Cardiac Troponin-T levels;
LUSC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg11843238	chr5:131593191	PDLIM4	0.33	5.73	0.3	2.24e-8	Breast cancer;
LUSC	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg24375607	chr4:120327624	NA	0.79	11.69	0.54	1.03e-26	Corneal astigmatism;
LUSC	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg22676075	chr6:135203613	NA	0.47	7.37	0.37	1.32e-12	Red blood cell count;
LUSC	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg02415014	chr8:143852576	LYNX1	0.33	7.71	0.39	1.45e-13	Urinary tract infection frequency;
LUSC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg06784218	chr1:46089804	CCDC17	-0.58	-11.58	-0.54	2.66e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg06547715	chr2:218990976	CXCR2	-0.33	-6.36	-0.33	6.73e-10	Ulcerative colitis;
LUSC	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg26513180	chr16:89883248	FANCA	-0.54	-7.97	-0.4	2.5e-14	Vitiligo;
LUSC	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg06740227	chr12:86229804	RASSF9	0.36	5.75	0.3	2.04e-8	Major depressive disorder;
LUSC	cis	rs6012953	1.000	rs6020572	chr20:49128240	G/A	cg13958625	chr20:49123093	NA	0.31	6.63	0.34	1.33e-10	Vitiligo;
LUSC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg18827107	chr12:86230957	RASSF9	-0.49	-7.46	-0.38	7.58e-13	Major depressive disorder;
LUSC	cis	rs7107174	1.000	rs2510037	chr11:77966099	A/G	cg02023728	chr11:77925099	USP35	0.49	7.29	0.37	2.26e-12	Testicular germ cell tumor;
LUSC	trans	rs9322817	0.583	rs7770002	chr6:105173445	A/G	cg03900355	chr11:64521088	PYGM	-0.42	-6.07	-0.32	3.5e-9	Thyroid stimulating hormone;
LUSC	trans	rs9860340	0.730	rs67302043	chr3:87641033	T/C	cg03644585	chr7:884825	UNC84A	0.42	6.06	0.31	3.62e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02176678	chr2:219576539	TTLL4	-0.65	-12.62	-0.57	3.98e-30	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.54	-8.86	-0.44	4.85e-17	Breast cancer;
LUSC	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg11812906	chr14:75593930	NEK9	-0.65	-11.19	-0.52	6.48e-25	Height;
LUSC	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.35	0.53	1.8e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7590368	1.000	rs72779469	chr2:10963764	C/G	cg15705551	chr2:10952987	PDIA6	0.56	7.75	0.39	1.14e-13	Educational attainment (years of education);
LUSC	trans	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg18187862	chr3:45730750	SACM1L	-0.52	-6.32	-0.33	8.33e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-12.68	-0.57	2.3e-30	Hemoglobin concentration;
LUSC	cis	rs9549260	0.727	rs4603422	chr13:41148353	T/C	cg21288729	chr13:41239152	FOXO1	0.6	9.39	0.46	9.46e-19	Red blood cell count;
LUSC	trans	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg25214090	chr10:38739885	LOC399744	-0.4	-6.13	-0.32	2.46e-9	Corneal astigmatism;
LUSC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg04455712	chr21:45112962	RRP1B	0.46	8.78	0.43	8.92e-17	Mean corpuscular volume;
LUSC	cis	rs7707921	0.723	rs226197	chr5:81574925	G/A	cg21483461	chr5:81570383	RPS23	0.39	5.65	0.3	3.51e-8	Breast cancer;
LUSC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-7.97	-0.4	2.62e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg05552183	chr6:42928497	GNMT	0.5	8.33	0.41	2.13e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg13902645	chr11:5959945	NA	-0.54	-8.26	-0.41	3.48e-15	DNA methylation (variation);
LUSC	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-6.89	-0.35	2.85e-11	Blood metabolite levels;
LUSC	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg26384229	chr12:38710491	ALG10B	-0.56	-8.35	-0.42	1.85e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg02660097	chr11:68866761	NA	0.42	6.04	0.31	4.12e-9	Blond vs. brown hair color;
LUSC	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg08179530	chr6:36648295	CDKN1A	0.6	8.38	0.42	1.54e-15	QRS duration;
LUSC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10802521	chr3:52805072	NEK4	-0.54	-8.71	-0.43	1.43e-16	Bipolar disorder;
LUSC	cis	rs6681460	0.549	rs4655620	chr1:67037194	G/A	cg02459107	chr1:67143332	SGIP1	0.31	5.66	0.3	3.25e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs17154702	0.506	rs28583936	chr8:8647160	C/T	cg01851573	chr8:8652454	MFHAS1	0.61	6.47	0.33	3.42e-10	Neurocognitive impairment in HIV-1 infection (continuous);
LUSC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg21724239	chr8:58056113	NA	0.56	6.66	0.34	1.13e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.91	14.58	0.62	1.3e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs6500395	1.000	rs7198773	chr16:48606091	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.61	0.34	1.5e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12618769	0.597	rs3754884	chr2:99125376	C/T	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs2479724	0.870	rs7766817	chr6:41918104	T/A	cg17623882	chr6:41773611	USP49	-0.58	-9.45	-0.46	5.97e-19	Menarche (age at onset);
LUSC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.91	0.4	3.87e-14	Parkinson's disease;
LUSC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg11812906	chr14:75593930	NEK9	0.67	11.5	0.53	5.15e-26	Height;
LUSC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.92e-10	Life satisfaction;
LUSC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg22963979	chr7:1858916	MAD1L1	0.55	8.51	0.42	6.09e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.16	-0.52	8.55e-25	Mean corpuscular volume;
LUSC	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	6.12	0.32	2.66e-9	IgG glycosylation;
LUSC	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg13073564	chr4:8508604	NA	-0.44	-8.25	-0.41	3.59e-15	Response to antineoplastic agents;
LUSC	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg23231163	chr10:75533350	FUT11	-0.41	-6.68	-0.34	9.94e-11	Inflammatory bowel disease;
LUSC	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg11344533	chr11:111475393	SIK2	0.44	5.78	0.3	1.68e-8	Primary sclerosing cholangitis;
LUSC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg17279839	chr7:150038598	RARRES2	0.56	8.32	0.41	2.28e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1595825	0.891	rs1016883	chr2:198881668	A/G	cg00982548	chr2:198649783	BOLL	0.54	7.02	0.36	1.28e-11	Ulcerative colitis;
LUSC	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg19812747	chr11:111475976	SIK2	0.49	6.94	0.35	2.11e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg11244672	chr19:19639970	YJEFN3	-0.52	-6.49	-0.33	3.05e-10	Bipolar disorder;
LUSC	trans	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg07393940	chr7:158741817	NA	0.37	6.78	0.35	5.52e-11	Life satisfaction;
LUSC	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg20476159	chr18:77451067	CTDP1	-0.32	-5.8	-0.3	1.58e-8	Monocyte count;
LUSC	trans	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg19694781	chr19:47549865	TMEM160	-0.41	-6.42	-0.33	4.71e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-0.81	-8.54	-0.42	4.82e-16	Breast cancer;
LUSC	cis	rs10733682	0.659	rs13287548	chr9:129466456	C/T	cg00232160	chr9:129468157	NA	0.43	7.65	0.39	2.22e-13	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.02	20.66	0.75	1.09e-61	Cognitive function;
LUSC	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg15556689	chr8:8085844	FLJ10661	0.55	8.33	0.41	2.18e-15	Retinal vascular caliber;
LUSC	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg18753928	chr3:113234510	CCDC52	-0.45	-6.86	-0.35	3.43e-11	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg07148914	chr20:33460835	GGT7	-0.56	-8.62	-0.43	2.74e-16	Height;
LUSC	cis	rs72960926	0.744	rs67076726	chr6:74992577	A/G	cg03266952	chr6:74778945	NA	-0.63	-6.02	-0.31	4.7e-9	Metabolite levels (MHPG);
LUSC	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg00191853	chr8:101177733	SPAG1	-0.39	-6.51	-0.34	2.73e-10	Atrioventricular conduction;
LUSC	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg18683606	chr7:100471612	SRRT	0.45	5.96	0.31	6.4e-9	Resting heart rate;
LUSC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg05805236	chr11:65401703	PCNXL3	-0.37	-5.65	-0.3	3.5e-8	Breast cancer;
LUSC	cis	rs11997175	0.510	rs34465523	chr8:33796849	C/T	ch.8.33884649F	chr8:33765107	NA	0.47	6.92	0.35	2.34e-11	Body mass index;
LUSC	cis	rs80130819	0.686	rs78239819	chr12:48412550	C/T	cg24011408	chr12:48396354	COL2A1	-0.65	-5.93	-0.31	7.56e-9	Prostate cancer;
LUSC	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.53	0.62	2.03e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6542838	0.673	rs1949424	chr2:99468341	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.45	6.31	0.33	8.88e-10	Fear of minor pain;
LUSC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01171360	chr6:293285	DUSP22	-0.52	-7.9	-0.4	4.07e-14	Menopause (age at onset);
LUSC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.8	12.67	0.57	2.64e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg07701084	chr6:150067640	NUP43	0.57	8.73	0.43	1.28e-16	Lung cancer;
LUSC	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg24642439	chr20:33292090	TP53INP2	0.41	5.93	0.31	7.46e-9	Height;
LUSC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00166722	chr3:10149974	C3orf24	0.62	8.43	0.42	1.06e-15	Alzheimer's disease;
LUSC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg24209194	chr3:40518798	ZNF619	0.48	6.45	0.33	3.91e-10	Renal cell carcinoma;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg10143842	chr3:88198517	C3orf38	0.45	6.39	0.33	5.63e-10	Mosquito bite size;
LUSC	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg24375607	chr4:120327624	NA	0.78	11.51	0.53	4.8e-26	Corneal astigmatism;
LUSC	trans	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-9.53	-0.46	3.42e-19	Migraine;
LUSC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg04414720	chr1:150670196	GOLPH3L	0.53	8.5	0.42	6.19e-16	Tonsillectomy;
LUSC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg22800045	chr5:56110881	MAP3K1	0.79	10.51	0.5	1.59e-22	Initial pursuit acceleration;
LUSC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.68	9.86	0.47	2.69e-20	Aortic root size;
LUSC	trans	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.34	-0.33	7.6e-10	Neuroticism;
LUSC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.77	0.43	9.32e-17	Lung cancer;
LUSC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg11632617	chr15:75315747	PPCDC	0.55	7.07	0.36	9.21e-12	Blood trace element (Zn levels);
LUSC	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.49	5.82	0.3	1.41e-8	Crohn's disease;
LUSC	cis	rs11958404	0.932	rs72816564	chr5:157427484	T/C	cg05962755	chr5:157440814	NA	0.55	6.44	0.33	4.11e-10	IgG glycosylation;
LUSC	cis	rs983392	0.709	rs11603507	chr11:59982470	T/A	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.16	-0.32	2.1e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10492096	0.947	rs10774435	chr12:6616120	G/T	cg13857086	chr12:6580257	VAMP1	0.6	7.26	0.37	2.77e-12	Hip geometry;
LUSC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	19.1	0.72	1.79e-55	Chronic sinus infection;
LUSC	cis	rs1003719	0.679	rs2835674	chr21:38581522	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.2	-0.49	1.91e-21	Eye color traits;
LUSC	cis	rs2067615	0.524	rs10778498	chr12:107063340	C/A	cg15890332	chr12:107067104	RFX4	0.35	6.17	0.32	1.98e-9	Heart rate;
LUSC	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.86	-0.44	4.93e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs10193935	0.901	rs10169971	chr2:42602189	G/A	cg27598129	chr2:42591480	NA	-0.65	-8.37	-0.42	1.59e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9837602	1.000	rs9837602	chr3:99824685	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.24	0.32	1.32e-9	Breast cancer;
LUSC	cis	rs13067593	1.000	rs66506558	chr3:188580731	G/A	cg17809494	chr3:188572244	LPP	0.45	6.25	0.32	1.25e-9	Immune reponse to smallpox (secreted IFN-alpha);
LUSC	cis	rs12712073	0.512	rs6710355	chr2:100699994	T/C	cg07810366	chr2:100720526	AFF3	-0.4	-6.29	-0.33	1.02e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg18827107	chr12:86230957	RASSF9	-0.47	-7.1	-0.36	7.78e-12	Major depressive disorder;
LUSC	trans	rs1422110	0.681	rs35625401	chr5:85465408	G/A	cg07913362	chr3:180546450	NA	0.35	6.1	0.32	3.01e-9	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg03709012	chr19:19516395	GATAD2A	0.94	10.71	0.51	3.28e-23	Nonalcoholic fatty liver disease;
LUSC	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.06	-0.31	3.62e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-7.72	-0.39	1.38e-13	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.93	0.51	5.58e-24	Menopause (age at onset);
LUSC	cis	rs8040855	0.825	rs4843021	chr15:85694548	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.42	6.13	0.32	2.46e-9	Bulimia nervosa;
LUSC	cis	rs12541635	0.966	rs62525736	chr8:107000638	G/C	cg10147462	chr8:107024639	NA	0.55	9.62	0.47	1.75e-19	Age of smoking initiation;
LUSC	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg04455712	chr21:45112962	RRP1B	-0.46	-8.39	-0.42	1.41e-15	Mean corpuscular volume;
LUSC	cis	rs727505	1.000	rs67084428	chr7:124499388	G/T	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs2294693	0.786	rs12055704	chr6:40988504	C/T	cg14769373	chr6:40998127	UNC5CL	-0.58	-7.37	-0.37	1.36e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs501916	0.605	rs11070612	chr15:48073174	C/G	cg16110827	chr15:48056943	SEMA6D	-0.37	-5.85	-0.3	1.18e-8	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg06675538	chr2:114033490	PAX8;LOC440839	-0.33	-5.88	-0.31	9.98e-9	Lymphocyte counts;
LUSC	cis	rs72772090	0.539	rs114006288	chr5:96118004	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.58	-0.34	1.83e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	9.44	0.46	6.69e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg18252515	chr7:66147081	NA	0.57	7.86	0.4	5.29e-14	Corneal structure;
LUSC	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg02660097	chr11:68866761	NA	0.44	6.2	0.32	1.66e-9	Blond vs. brown hair color;
LUSC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.84	-12.28	-0.56	7.33e-29	Multiple sclerosis;
LUSC	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg01028140	chr2:1542097	TPO	-0.6	-8.23	-0.41	4.3e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs10489525	0.517	rs7526694	chr1:115617135	C/T	cg01522456	chr1:115632236	TSPAN2	0.41	5.85	0.3	1.17e-8	Autism;
LUSC	cis	rs1577917	0.958	rs12202188	chr6:86562700	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs3092073	0.617	rs56324610	chr20:44564030	G/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.36	-5.68	-0.3	2.91e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg05855489	chr10:104503620	C10orf26	0.57	8.83	0.44	5.91e-17	Arsenic metabolism;
LUSC	cis	rs11229555	0.609	rs4519113	chr11:58216825	T/C	cg15696309	chr11:58395628	NA	-0.65	-7.92	-0.4	3.67e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg21466736	chr12:48725269	NA	-0.33	-5.75	-0.3	2.06e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg25206134	chr2:45395956	NA	0.59	6.73	0.35	7.35e-11	Bipolar disorder;
LUSC	cis	rs12594515	1.000	rs11855509	chr15:45995474	C/T	cg19682013	chr15:45996608	NA	0.39	5.8	0.3	1.51e-8	Waist circumference;Weight;
LUSC	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs7267979	0.844	rs4423675	chr20:25402778	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.78	-16.35	-0.67	1.41e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs983392	0.792	rs525794	chr11:59903287	A/G	cg24026212	chr11:59952134	MS4A6A	-0.31	-5.66	-0.3	3.18e-8	Alzheimer's disease (late onset);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg13390975	chr5:34915890	BRIX1;RAD1	0.39	6.6	0.34	1.58e-10	Triglycerides;
LUSC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.75e-14	Melanoma;
LUSC	cis	rs12286929	0.736	rs11215397	chr11:115044076	G/A	cg04055981	chr11:115044050	NA	0.45	8.29	0.41	2.85e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg26102564	chr10:131424627	MGMT	0.39	6.16	0.32	2.05e-9	Response to temozolomide;
LUSC	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-1.03	-9.27	-0.45	2.31e-18	Mitochondrial DNA levels;
LUSC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg15017067	chr4:17643749	FAM184B	0.36	5.9	0.31	8.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7804356	0.953	rs3801829	chr7:26854996	G/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs2710642	0.779	rs360807	chr2:62926859	C/T	cg17519650	chr2:63277830	OTX1	-0.53	-7.44	-0.38	8.4e-13	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs79387448	0.745	rs1989399	chr2:103166742	G/A	cg09003973	chr2:102972529	NA	0.89	8.62	0.43	2.69e-16	Gut microbiota (bacterial taxa);
LUSC	trans	rs7178375	0.941	rs35497908	chr15:31224071	C/T	cg04373760	chr16:53404718	NA	0.63	8.78	0.43	8.35e-17	Hypertriglyceridemia;
LUSC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.8	13.27	0.59	1.43e-32	Aortic root size;
LUSC	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.73	13.59	0.6	8.93e-34	Obesity-related traits;
LUSC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg00530320	chr1:46809349	NSUN4	0.55	8.53	0.42	5.28e-16	Menopause (age at onset);
LUSC	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg23283495	chr1:209979779	IRF6	0.64	7.62	0.38	2.72e-13	Coronary artery disease;
LUSC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg21435336	chr19:17392852	ANKLE1	-0.47	-6.33	-0.33	7.95e-10	Systemic lupus erythematosus;
LUSC	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg00990874	chr7:1149470	C7orf50	-0.51	-6.46	-0.33	3.74e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs7000551	0.725	rs2461489	chr8:22370253	G/A	cg12081754	chr8:22256438	SLC39A14	0.42	6.26	0.32	1.15e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-10.42	-0.5	3.25e-22	Mean corpuscular volume;
LUSC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg25258033	chr6:167368657	RNASET2	-0.47	-7.87	-0.4	5.12e-14	Crohn's disease;
LUSC	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg13609457	chr4:120235615	NA	0.39	6.06	0.31	3.74e-9	Diastolic blood pressure;
LUSC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg05855489	chr10:104503620	C10orf26	-0.7	-10.37	-0.49	5.1e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.13	0.45	6.62e-18	Height;
LUSC	cis	rs3820928	1.000	rs10193404	chr2:227777757	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.16	-0.41	6.77e-15	Pulmonary function;
LUSC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg18230493	chr5:56204884	C5orf35	0.58	9.09	0.45	9.21e-18	Coronary artery disease;
LUSC	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-8.47	-0.42	7.97e-16	Body mass index;
LUSC	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg01884057	chr2:25150051	NA	0.39	8.68	0.43	1.74e-16	Body mass index in non-asthmatics;
LUSC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg01802117	chr1:53393560	SCP2	0.38	6.2	0.32	1.67e-9	Monocyte count;
LUSC	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.32	-6.25	-0.32	1.22e-9	Schizophrenia;
LUSC	cis	rs12122100	0.955	rs12142005	chr1:146506691	T/C	cg03526459	chr1:146549940	NA	-0.42	-6.75	-0.35	6.54e-11	HIV-1 control;
LUSC	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg05738196	chr6:26577821	NA	0.8	15.3	0.64	2.07e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-9.92	-0.48	1.68e-20	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2742417	0.603	rs2064062	chr3:45761115	G/C	cg04837898	chr3:45731254	SACM1L	-0.44	-7.19	-0.37	4.38e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg00509249	chr6:109615579	CCDC162	-0.33	-5.9	-0.31	9.06e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21224049	chr4:668623	ATP5I	0.5	8.2	0.41	5.06e-15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.74	-11.37	-0.53	1.47e-25	Menarche (age at onset);
LUSC	cis	rs612683	0.894	rs10875290	chr1:100853755	G/T	cg06223162	chr1:101003688	GPR88	0.37	6.81	0.35	4.45e-11	Breast cancer;
LUSC	cis	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg21775007	chr8:11205619	TDH	-0.5	-7.55	-0.38	4.18e-13	Systolic blood pressure;
LUSC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	trans	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg15556689	chr8:8085844	FLJ10661	0.47	7.07	0.36	9.15e-12	Retinal vascular caliber;
LUSC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg11632617	chr15:75315747	PPCDC	-0.51	-6.69	-0.34	9.31e-11	Blood trace element (Zn levels);
LUSC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-10.0	-0.48	9.37e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg20406979	chr6:167373233	NA	0.25	5.81	0.3	1.49e-8	Crohn's disease;
LUSC	cis	rs12422267	0.536	rs12303540	chr12:132609679	A/G	cg26561844	chr12:132562101	EP400	0.55	5.83	0.3	1.31e-8	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.63	-7.82	-0.39	6.96e-14	Iron status biomarkers;
LUSC	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18854424	chr1:2615690	NA	0.49	9.91	0.48	1.84e-20	Ulcerative colitis;
LUSC	cis	rs7608623	0.773	rs12469552	chr2:23923762	A/G	cg08917208	chr2:24149416	ATAD2B	-0.43	-5.88	-0.31	1e-8	Obesity-related traits;
LUSC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg15448220	chr1:150897856	SETDB1	0.39	5.74	0.3	2.18e-8	Tonsillectomy;
LUSC	trans	rs8073060	0.518	rs225285	chr17:33931084	G/C	cg19694781	chr19:47549865	TMEM160	-0.82	-12.84	-0.57	6.07e-31	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	cis	rs4474465	1.000	rs7950865	chr11:78157401	A/G	cg27205649	chr11:78285834	NARS2	-0.52	-6.13	-0.32	2.46e-9	Alzheimer's disease (survival time);
LUSC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg06740227	chr12:86229804	RASSF9	0.45	6.98	0.36	1.58e-11	Major depressive disorder;
LUSC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg18225595	chr11:63971243	STIP1	0.44	7.15	0.36	5.38e-12	Platelet count;
LUSC	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg00857998	chr1:205179979	DSTYK	0.62	9.4	0.46	8.87e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs2302464	1.000	rs73123625	chr4:15729173	A/T	cg17675199	chr6:35436792	RPL10A	-0.88	-6.15	-0.32	2.26e-9	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs926938	0.527	rs2335954	chr1:115534151	C/T	cg12756093	chr1:115239321	AMPD1	-0.48	-7.34	-0.37	1.59e-12	Autism;
LUSC	trans	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg13010199	chr12:38710504	ALG10B	0.52	7.91	0.4	3.72e-14	Morning vs. evening chronotype;
LUSC	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg22676075	chr6:135203613	NA	0.47	7.4	0.38	1.12e-12	Red blood cell count;
LUSC	cis	rs503734	0.643	rs2317749	chr3:101121980	C/T	cg20575173	chr3:101228308	SENP7	0.32	5.71	0.3	2.47e-8	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg17442961	chr17:78635428	RPTOR	-0.39	-6.59	-0.34	1.72e-10	N-glycan levels;
LUSC	cis	rs13385	0.769	rs59453051	chr5:139558212	T/G	cg26211634	chr5:139558579	C5orf32	0.45	6.54	0.34	2.25e-10	Atrial fibrillation;
LUSC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.65	0.47	1.38e-19	Bipolar disorder;
LUSC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg00343986	chr7:65444356	GUSB	0.47	7.12	0.36	6.76e-12	Aortic root size;
LUSC	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg05340658	chr4:99064831	C4orf37	0.46	7.28	0.37	2.39e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.48	-0.42	7.37e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26818010	chr10:134567672	INPP5A	-0.86	-11.07	-0.52	1.83e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.33	6.0	0.31	5.12e-9	IgG glycosylation;
LUSC	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.75	-11.09	-0.52	1.57e-24	Glomerular filtration rate;
LUSC	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.53	10.6	0.5	7.79e-23	Coronary artery disease;
LUSC	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg05294307	chr14:35346193	BAZ1A	-0.6	-6.49	-0.33	3.14e-10	Psoriasis;
LUSC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg11812906	chr14:75593930	NEK9	0.54	8.75	0.43	1.08e-16	Coronary artery disease;
LUSC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg04267008	chr7:1944627	MAD1L1	-0.57	-8.64	-0.43	2.29e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs6674970	0.966	rs4512652	chr1:151115690	G/C	cg03258749	chr1:151040405	MLLT11	-0.42	-6.36	-0.33	6.58e-10	Childhood ear infection;
LUSC	cis	rs12519773	0.555	rs2009416	chr5:92415111	C/T	cg18783429	chr5:92414398	NA	0.35	7.78	0.39	9.11e-14	Migraine;
LUSC	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.89	-0.31	9.5e-9	Neutrophil percentage of white cells;
LUSC	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.91e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7939886	0.920	rs11227729	chr11:56039901	G/A	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	trans	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg27275811	chr11:74457193	NA	-0.6	-6.02	-0.31	4.63e-9	Type 2 diabetes nephropathy;
LUSC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg03146154	chr1:46216737	IPP	0.51	7.55	0.38	4.21e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg10253484	chr15:75165896	SCAMP2	-0.42	-6.06	-0.31	3.67e-9	Caffeine consumption;
LUSC	cis	rs977987	0.843	rs4888427	chr16:75478447	A/G	cg03315344	chr16:75512273	CHST6	0.54	10.61	0.5	7.6e-23	Dupuytren's disease;
LUSC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00166722	chr3:10149974	C3orf24	0.62	8.72	0.43	1.32e-16	Alzheimer's disease;
LUSC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02475777	chr4:1388615	CRIPAK	0.62	9.3	0.45	1.88e-18	Longevity;
LUSC	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	0.57	11.98	0.55	9.15e-28	Obesity-related traits;
LUSC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.55	-7.92	-0.4	3.49e-14	Gut microbiome composition (summer);
LUSC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.3	-0.37	2.18e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs17632159	0.619	rs13160226	chr5:72434224	A/G	cg01170694	chr5:72431891	NA	-0.29	-5.88	-0.31	9.71e-9	Urate levels;
LUSC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-8.71	-0.43	1.45e-16	Hemoglobin concentration;
LUSC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21984481	chr17:79567631	NPLOC4	-0.67	-14.02	-0.61	1.9e-35	Eye color traits;
LUSC	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.49	7.96	0.4	2.68e-14	Alcohol dependence;
LUSC	cis	rs6700896	0.500	rs7540268	chr1:66085236	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.35	0.33	7.09e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22968622	chr17:43663579	NA	0.8	12.37	0.56	3.3600000000000003e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs4343996	1.000	rs12700789	chr7:3358276	T/C	cg21248987	chr7:3385318	SDK1	-0.38	-6.45	-0.33	3.91e-10	Motion sickness;
LUSC	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.84	14.6	0.62	1.06e-37	Metabolic syndrome;
LUSC	cis	rs7122539	0.646	rs594313	chr11:66608991	A/G	cg24851651	chr11:66362959	CCS	0.54	8.96	0.44	2.31e-17	HIV-1 susceptibility;
LUSC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg26677194	chr12:130822605	PIWIL1	0.59	8.79	0.43	7.9e-17	Menopause (age at onset);
LUSC	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg00376283	chr12:123451042	ABCB9	0.65	7.51	0.38	5.51e-13	Neutrophil percentage of white cells;
LUSC	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg20744362	chr22:50050164	C22orf34	0.39	7.66	0.39	2.01e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs3903072	0.528	rs7928652	chr11:65580228	A/C	cg17712092	chr4:129076599	LARP1B	0.54	7.13	0.36	6.4e-12	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19760225	chr17:27920361	ANKRD13B	0.49	6.7	0.34	8.81e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg01620082	chr3:125678407	NA	-0.77	-6.9	-0.35	2.57e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg23711669	chr6:146136114	FBXO30	0.77	13.91	0.61	5.36e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg12365402	chr11:9010492	NRIP3	0.36	6.2	0.32	1.66e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs3099143	1.000	rs3099142	chr15:77104909	C/T	cg21673338	chr15:77095150	SCAPER	-0.78	-7.47	-0.38	7.09e-13	Recalcitrant atopic dermatitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20096481	chr8:87355098	WWP1	0.44	6.2	0.32	1.67e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg15556689	chr8:8085844	FLJ10661	0.55	8.41	0.42	1.22e-15	Retinal vascular caliber;
LUSC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.64	-13.48	-0.59	2.22e-33	Monocyte percentage of white cells;
LUSC	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg16989719	chr2:238392110	NA	-0.41	-5.75	-0.3	2.01e-8	Prostate cancer;
LUSC	cis	rs780094	0.500	rs4665991	chr2:27766284	G/A	cg27432699	chr2:27873401	GPN1	0.4	5.65	0.3	3.43e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.35	5.66	0.3	3.28e-8	Cystic fibrosis severity;
LUSC	cis	rs12704876	0.509	rs6966856	chr7:96367627	G/A	cg03808172	chr7:96339361	SHFM1	0.51	7.73	0.39	1.3e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18943969	chr1:117209947	IGSF3	0.48	6.5	0.34	2.9e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	0.98	15.22	0.64	4.11e-40	Parkinson's disease;
LUSC	cis	rs4343996	0.807	rs6964838	chr7:3509969	A/G	cg21248987	chr7:3385318	SDK1	-0.35	-5.71	-0.3	2.48e-8	Motion sickness;
LUSC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg08888203	chr3:10149979	C3orf24	0.62	8.67	0.43	1.92e-16	Alzheimer's disease;
LUSC	trans	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.54	0.53	3.8e-26	Mean corpuscular volume;
LUSC	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg04851639	chr8:1020857	NA	-0.35	-7.05	-0.36	1.01e-11	Schizophrenia;
LUSC	cis	rs9650315	0.733	rs7838625	chr8:57187365	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	6.41	0.33	4.87e-10	Height;
LUSC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg11494091	chr17:61959527	GH2	0.63	13.45	0.59	3e-33	Prudent dietary pattern;
LUSC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.27	0.45	2.34e-18	Prudent dietary pattern;
LUSC	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg03732007	chr1:2071316	PRKCZ	-0.47	-7.45	-0.38	8.02e-13	Height;
LUSC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-10.4	-0.49	3.91e-22	Gut microbiome composition (summer);
LUSC	trans	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg10756647	chr7:56101905	PSPH	0.85	8.27	0.41	3.11e-15	Diabetic kidney disease;
LUSC	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg11473876	chr11:109292803	C11orf87	0.35	5.97	0.31	5.95e-9	Schizophrenia;
LUSC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.45	0.33	3.98e-10	Lung cancer;
LUSC	trans	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg25482853	chr8:67687455	SGK3	1.19	16.14	0.66	1.02e-43	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg06552810	chr11:31128660	NA	-0.4	-7.13	-0.36	6.38e-12	Red blood cell count;
LUSC	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.9	15.64	0.65	9.49e-42	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.92	0.31	8.05e-9	Self-reported allergy;
LUSC	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	9.01	0.44	1.65e-17	Cognitive test performance;
LUSC	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-10.2	-0.49	1.87e-21	Morning vs. evening chronotype;
LUSC	cis	rs3820068	0.626	rs61103742	chr1:15909153	A/C	cg17385448	chr1:15911702	AGMAT	0.37	5.98	0.31	5.64e-9	Systolic blood pressure;
LUSC	cis	rs17253792	0.822	rs78988988	chr14:56152404	G/A	cg01858014	chr14:56050164	KTN1	-0.82	-6.77	-0.35	5.9e-11	Putamen volume;
LUSC	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg03806693	chr22:41940476	POLR3H	-0.55	-7.52	-0.38	5.04e-13	Neuroticism;
LUSC	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs9549260	0.569	rs73174811	chr13:41315998	T/G	cg21288729	chr13:41239152	FOXO1	0.53	5.79	0.3	1.6e-8	Red blood cell count;
LUSC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-8.04	-0.4	1.62e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02711726	chr17:80685570	FN3KRP	-0.43	-6.49	-0.33	3.14e-10	Glycated hemoglobin levels;
LUSC	cis	rs3736594	0.513	rs60854669	chr2:27786929	T/C	cg27432699	chr2:27873401	GPN1	0.66	8.83	0.44	5.93e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg17294928	chr15:75287854	SCAMP5	-0.92	-13.07	-0.58	8.12e-32	Blood trace element (Zn levels);
LUSC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.69	-10.53	-0.5	1.42e-22	Aortic root size;
LUSC	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg14092571	chr14:90743983	NA	-0.35	-5.83	-0.3	1.29e-8	Mortality in heart failure;
LUSC	cis	rs45535039	1.000	rs1893034	chr11:119089390	C/G	cg16724696	chr11:118992527	HINFP	0.48	5.79	0.3	1.66e-8	Plateletcrit;
LUSC	cis	rs7903847	0.619	rs76094900	chr10:99158164	G/A	cg08345082	chr10:99160200	RRP12	-0.36	-7.07	-0.36	9.25e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg23815491	chr16:72088622	HP	0.34	5.97	0.31	6.12e-9	Fibrinogen levels;
LUSC	cis	rs4499344	0.730	rs392332	chr19:33105743	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.87	13.17	0.58	3.36e-32	Mean platelet volume;
LUSC	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.62	-0.38	2.61e-13	Morning vs. evening chronotype;
LUSC	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg04310649	chr10:35416472	CREM	-0.44	-6.58	-0.34	1.85e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08645402	chr16:4508243	NA	0.48	7.63	0.39	2.4e-13	Schizophrenia;
LUSC	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg23093090	chr10:104574429	C10orf26	-0.38	-6.55	-0.34	2.22e-10	Arsenic metabolism;
LUSC	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg08017756	chr2:100939284	LONRF2	0.42	7.68	0.39	1.82e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs73198271	0.694	rs73201840	chr8:8647067	G/T	cg01851573	chr8:8652454	MFHAS1	0.52	8.12	0.41	9.04e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg18196295	chr10:418757	DIP2C	0.51	8.41	0.42	1.17e-15	Psychosis in Alzheimer's disease;
LUSC	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg21775007	chr8:11205619	TDH	-0.65	-10.34	-0.49	6.55e-22	Retinal vascular caliber;
LUSC	cis	rs6066835	1.000	rs4516495	chr20:47316482	A/G	cg18078177	chr20:47281410	PREX1	0.71	6.5	0.34	2.92e-10	Multiple myeloma;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg07754938	chr3:48885314	PRKAR2A	0.46	6.23	0.32	1.37e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg10756647	chr7:56101905	PSPH	-0.84	-8.39	-0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.37	-0.33	6.35e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg05855489	chr10:104503620	C10orf26	-0.67	-9.67	-0.47	1.2e-19	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg09165964	chr15:75287851	SCAMP5	-0.88	-7.68	-0.39	1.79e-13	Lung cancer;
LUSC	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg05340658	chr4:99064831	C4orf37	0.58	8.87	0.44	4.39e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg04374321	chr14:90722782	PSMC1	0.76	12.04	0.55	5.82e-28	Mortality in heart failure;
LUSC	cis	rs7572644	0.699	rs7577342	chr2:28205581	A/G	cg27432699	chr2:27873401	GPN1	0.51	7.09	0.36	8.19e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	0.92	15.42	0.64	7.18e-41	Breast cancer;
LUSC	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg07828340	chr4:882639	GAK	1.0	10.76	0.51	2.16e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg10818794	chr15:86012489	AKAP13	-0.43	-6.81	-0.35	4.66e-11	Coronary artery disease;
LUSC	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg19773385	chr1:10388646	KIF1B	-0.53	-8.3	-0.41	2.57e-15	Hepatocellular carcinoma;
LUSC	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg04546413	chr19:29218101	NA	0.57	7.29	0.37	2.22e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs1358748	0.522	rs6588237	chr1:67558739	C/T	cg02640540	chr1:67518911	SLC35D1	0.64	6.3	0.33	9.51e-10	Tuberculosis;
LUSC	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.52	10.31	0.49	7.91e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12821546	chr22:41601310	L3MBTL2	0.45	6.31	0.33	8.63e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg05283184	chr6:79620031	NA	-0.57	-12.07	-0.55	4.49e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg25344623	chr2:136566232	LCT	0.37	5.65	0.3	3.47e-8	Mosquito bite size;
LUSC	cis	rs2030746	0.521	rs2311598	chr2:121331102	A/G	cg03661458	chr2:121334411	NA	-0.33	-6.4	-0.33	5.11e-10	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LUSC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	0.87	14.83	0.63	1.38e-38	Tonsillectomy;
LUSC	cis	rs12681287	0.547	rs7837569	chr8:87507366	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg22963979	chr7:1858916	MAD1L1	-0.56	-8.58	-0.42	3.65e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg24011408	chr12:48396354	COL2A1	-0.4	-5.77	-0.3	1.77e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg13393036	chr8:95962371	TP53INP1	-0.48	-10.43	-0.5	3.08e-22	Type 2 diabetes;
LUSC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg17330251	chr7:94953956	PON1	-0.37	-5.85	-0.31	1.15e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs10426930	0.700	rs8106479	chr19:5003940	G/C	cg25246084	chr19:4971487	KDM4B	-0.34	-6.17	-0.32	1.99e-9	Monocyte percentage of white cells;
LUSC	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg17120908	chr11:65337727	SSSCA1	-0.54	-9.41	-0.46	8.11e-19	Bone mineral density;
LUSC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.96	-0.36	1.83e-11	Total body bone mineral density;
LUSC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	0.93	17.54	0.69	2.66e-49	Heart rate;
LUSC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.18	0.41	5.91e-15	Height;
LUSC	trans	rs9944275	0.518	rs12903849	chr15:97189925	A/G	cg18834029	chr10:103349097	POLL;RP11-529I10.4	-0.6	-5.97	-0.31	6.23e-9	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LUSC	cis	rs367943	0.712	rs9326889	chr5:112731438	A/G	cg12552261	chr5:112820674	MCC	0.36	5.85	0.3	1.17e-8	Type 2 diabetes;
LUSC	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00631329	chr6:26305371	NA	-0.45	-8.86	-0.44	4.68e-17	Educational attainment;
LUSC	cis	rs8179	0.514	rs10269774	chr7:92253972	A/G	cg15732164	chr7:92237376	CDK6	0.38	5.96	0.31	6.55e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.21	-0.37	3.86e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg01503450	chr10:980765	NA	-0.39	-5.77	-0.3	1.82e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg03522245	chr20:25566470	NINL	0.36	5.86	0.31	1.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.43	-6.47	-0.33	3.46e-10	Tonsillectomy;
LUSC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg16434002	chr17:42200994	HDAC5	0.45	6.01	0.31	4.79e-9	Total body bone mineral density;
LUSC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg22535103	chr8:58192502	C8orf71	-0.85	-8.4	-0.42	1.28e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	7.93	0.4	3.38e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.06	0.36	9.5e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16680214	chr1:154839983	KCNN3	-0.56	-10.94	-0.51	5.23e-24	Prostate cancer;
LUSC	cis	rs934734	0.563	rs11695373	chr2:65581200	A/G	cg08085232	chr2:65598271	SPRED2	-0.43	-6.75	-0.35	6.74e-11	Rheumatoid arthritis;
LUSC	trans	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg27411982	chr8:10470053	RP1L1	0.49	7.67	0.39	1.93e-13	Mood instability;
LUSC	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-6.5	-0.34	2.86e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9341808	0.519	rs660888	chr6:80983212	A/T	cg08355045	chr6:80787529	NA	0.41	7.05	0.36	1.03e-11	Sitting height ratio;
LUSC	cis	rs243505	0.861	rs243531	chr7:148412513	A/G	cg09806900	chr7:148480153	CUL1	-0.46	-6.61	-0.34	1.51e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10788264	0.569	rs10749454	chr10:124029654	C/T	cg09507567	chr10:124027408	NA	0.56	10.11	0.48	3.83e-21	Total body bone mineral density;
LUSC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg15448220	chr1:150897856	SETDB1	0.4	5.87	0.31	1.02e-8	Tonsillectomy;
LUSC	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.49	7.86	0.39	5.49e-14	IgG glycosylation;
LUSC	trans	rs1493916	0.837	rs1493908	chr18:31411700	G/A	cg27147174	chr7:100797783	AP1S1	-0.55	-8.73	-0.43	1.21e-16	Life satisfaction;
LUSC	cis	rs1577917	0.883	rs1337854	chr6:86724015	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.42	6.17	0.32	1.92e-9	Response to antipsychotic treatment;
LUSC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02475777	chr4:1388615	CRIPAK	-0.61	-9.05	-0.44	1.22e-17	Longevity;
LUSC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg05754148	chr16:3507555	NAT15	-0.69	-8.17	-0.41	6.4e-15	Tuberculosis;
LUSC	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg20991723	chr1:152506922	NA	0.49	9.23	0.45	3.09e-18	Hair morphology;
LUSC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	8.12	0.41	9.28e-15	Electroencephalogram traits;
LUSC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg04450456	chr4:17643702	FAM184B	0.38	6.47	0.33	3.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg08975724	chr8:8085496	FLJ10661	0.44	6.56	0.34	2.01e-10	Retinal vascular caliber;
LUSC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg03806693	chr22:41940476	POLR3H	0.99	13.81	0.6	1.28e-34	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg08601574	chr20:25228251	PYGB	0.44	6.76	0.35	6.11e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.6	8.88	0.44	4.11e-17	Blood protein levels;
LUSC	trans	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.48	0.46	4.93e-19	Mean corpuscular volume;
LUSC	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg04998671	chr14:104000505	TRMT61A	-0.4	-5.83	-0.3	1.3e-8	Reticulocyte count;
LUSC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	7.68	0.39	1.75e-13	Cognitive function;
LUSC	cis	rs897080	0.589	rs1067380	chr2:44646834	A/C	cg00619915	chr2:44497795	NA	-0.42	-5.94	-0.31	6.97e-9	Height;
LUSC	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg22532475	chr10:104410764	TRIM8	-0.32	-7.15	-0.36	5.59e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg09654669	chr8:57350985	NA	-0.58	-7.84	-0.39	5.98e-14	Obesity-related traits;
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg24846343	chr22:24311635	DDTL	0.62	12.86	0.58	5.02e-31	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20656751	chr4:2061512	NAT8L	-0.38	-6.0	-0.31	5.1e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg26587870	chr6:27730563	NA	-0.57	-5.73	-0.3	2.21e-8	Depression;
LUSC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00166722	chr3:10149974	C3orf24	0.54	7.5	0.38	6e-13	Alzheimer's disease;
LUSC	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg13319975	chr6:146136371	FBXO30	0.45	6.99	0.36	1.51e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg07636037	chr3:49044803	WDR6	0.8	11.63	0.54	1.79e-26	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg25174290	chr11:3078921	CARS	-0.42	-6.3	-0.33	9.19e-10	Calcium levels;
LUSC	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.79	-0.43	8.23e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6840360	1.000	rs907237	chr4:152601146	T/G	cg22705602	chr4:152727874	NA	-0.27	-5.64	-0.3	3.55e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg24644049	chr4:85504048	CDS1	0.88	7.53	0.38	4.81e-13	Skin colour saturation;
LUSC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	1.03	19.81	0.74	2.52e-58	Cognitive function;
LUSC	cis	rs11608355	0.515	rs2287192	chr12:109931594	C/T	cg05360138	chr12:110035743	NA	0.9	11.97	0.55	1.02e-27	Neuroticism;
LUSC	cis	rs3857536	0.776	rs6941904	chr6:66931042	A/G	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.56e-10	Blood trace element (Cu levels);
LUSC	cis	rs3818285	0.959	rs492943	chr10:111629030	A/T	cg00817464	chr10:111662876	XPNPEP1	0.55	7.0	0.36	1.37e-11	Superior crus of antihelix expression;
LUSC	cis	rs6545883	0.894	rs2694639	chr2:61595291	G/A	cg15711740	chr2:61764176	XPO1	0.42	6.33	0.33	7.86e-10	Tuberculosis;
LUSC	cis	rs954108	0.809	rs1792022	chr13:29367967	A/G	cg11788234	chr13:29393811	NA	-0.38	-6.61	-0.34	1.49e-10	Obesity-related traits;
LUSC	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.08	0.52	1.68e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg01966878	chr4:90757139	SNCA	-0.33	-5.68	-0.3	2.97e-8	Dementia with Lewy bodies;
LUSC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	5.65	0.3	3.41e-8	Personality dimensions;
LUSC	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-38.27	-0.9	3.83e-124	Myeloid white cell count;
LUSC	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg00982548	chr2:198649783	BOLL	-0.59	-7.35	-0.37	1.51e-12	Ulcerative colitis;
LUSC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg14552801	chr7:65878734	NA	0.39	6.06	0.31	3.67e-9	Aortic root size;
LUSC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg23711669	chr6:146136114	FBXO30	0.83	14.71	0.63	4.06e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72772090	0.539	rs11747179	chr5:96112969	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.67	-0.34	1.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9346649	0.967	rs6915427	chr6:168490000	A/T	cg02770688	chr6:168491649	NA	0.4	7.67	0.39	1.96e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg17971929	chr21:40555470	PSMG1	0.78	13.12	0.58	5.26e-32	Cognitive function;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07336999	chr16:89939803	TCF25	-0.41	-6.8	-0.35	4.94e-11	Electrocardiographic conduction measures;
LUSC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg00815214	chr21:47717953	NA	-0.36	-5.68	-0.3	2.92e-8	Testicular germ cell tumor;
LUSC	cis	rs4601821	0.858	rs7945132	chr11:113262473	A/T	cg14159747	chr11:113255604	NA	0.26	6.06	0.31	3.67e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.88	0.6	6.55e-35	Cognitive test performance;
LUSC	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg01256987	chr12:42539512	GXYLT1	-0.41	-7.46	-0.38	7.71e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1941023	0.584	rs7935082	chr11:60155000	T/C	cg08716584	chr11:60157161	MS4A7	-0.65	-12.41	-0.56	2.42e-29	Congenital heart disease (maternal effect);
LUSC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.49	5.99	0.31	5.32e-9	Mean platelet volume;
LUSC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg24101359	chr6:42928495	GNMT	0.41	6.97	0.36	1.72e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg00945038	chr17:61921165	SMARCD2	0.52	9.22	0.45	3.31e-18	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg25664220	chr3:72788482	NA	0.69	12.13	0.55	2.72e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg19052272	chr2:3704530	ALLC	-0.48	-7.97	-0.4	2.59e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs1018836	0.505	rs7015030	chr8:91460331	T/C	cg16814680	chr8:91681699	NA	-0.48	-6.88	-0.35	3.01e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg13628971	chr7:2884303	GNA12	0.47	6.91	0.35	2.48e-11	Height;
LUSC	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg08999081	chr20:33150536	PIGU	0.39	6.84	0.35	3.8e-11	Coronary artery disease;
LUSC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg07507251	chr3:52567010	NT5DC2	0.34	6.73	0.35	7.51e-11	Bipolar disorder;
LUSC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00149659	chr3:10157352	C3orf10	0.91	12.69	0.57	2.26e-30	Alzheimer's disease;
LUSC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg03388025	chr16:89894329	SPIRE2	0.33	6.9	0.35	2.54e-11	Vitiligo;
LUSC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg06074448	chr4:187884817	NA	-0.39	-6.48	-0.33	3.29e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11039100	0.765	rs1032648	chr11:5782756	A/G	cg05234568	chr11:5960015	NA	-0.52	-5.76	-0.3	1.9e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg19610905	chr11:61596333	FADS2	-0.5	-7.49	-0.38	6.38e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.81	0.39	7.4e-14	Prudent dietary pattern;
LUSC	cis	rs812925	0.571	rs3087898	chr2:61765074	G/A	cg15711740	chr2:61764176	XPO1	-0.39	-5.98	-0.31	5.59e-9	Immature fraction of reticulocytes;
LUSC	cis	rs11640436	0.934	rs35478105	chr16:77325325	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.37	5.88	0.31	9.85e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg23172400	chr8:95962367	TP53INP1	0.29	5.72	0.3	2.38e-8	Type 2 diabetes;
LUSC	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg19743168	chr1:23544995	NA	0.48	10.4	0.49	3.81e-22	Height;
LUSC	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-7.42	-0.38	9.69e-13	Bone mineral density;
LUSC	cis	rs981844	0.775	rs55986083	chr4:154765640	A/C	cg14289246	chr4:154710475	SFRP2	0.51	6.72	0.35	7.76e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.43	6.41	0.33	4.93e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg01629716	chr15:45996671	NA	0.39	5.89	0.31	9.31e-9	Waist circumference;Weight;
LUSC	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg05340658	chr4:99064831	C4orf37	0.58	7.82	0.39	7.07e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg23601095	chr6:26197514	HIST1H3D	0.7	7.54	0.38	4.55e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs7605827	0.930	rs12692265	chr2:15544998	T/C	cg19274914	chr2:15703543	NA	0.46	8.71	0.43	1.38e-16	Educational attainment (years of education);
LUSC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.06e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.77	-0.3	1.81e-8	Lung cancer;
LUSC	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg11502198	chr6:26597334	ABT1	0.62	9.85	0.47	2.95e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg09307838	chr4:120376055	NA	0.8	11.6	0.54	2.28e-26	Corneal astigmatism;
LUSC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	7.11	0.36	7.31e-12	Personality dimensions;
LUSC	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg04607235	chr12:12878440	APOLD1	-0.56	-6.38	-0.33	5.81e-10	Systemic lupus erythematosus;
LUSC	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg09998033	chr7:158218633	PTPRN2	-0.38	-5.98	-0.31	5.58e-9	Obesity-related traits;
LUSC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10862848	chr6:42927986	GNMT	-0.28	-6.68	-0.34	1.01e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7178572	0.889	rs59153558	chr15:77806770	A/G	cg22256960	chr15:77711686	NA	-0.51	-8.21	-0.41	4.84e-15	Type 2 diabetes;
LUSC	trans	rs6920965	0.561	rs9401851	chr6:126181956	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.42	-6.33	-0.33	8.12e-10	High light scatter reticulocyte count;
LUSC	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg11843606	chr2:227700838	RHBDD1	-0.65	-10.41	-0.49	3.66e-22	Pulmonary function;
LUSC	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg13010344	chr12:123464640	ARL6IP4	0.43	5.82	0.3	1.38e-8	Neutrophil percentage of white cells;
LUSC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg24578937	chr1:2090814	PRKCZ	-0.42	-9.08	-0.45	9.36e-18	Height;
LUSC	trans	rs984440	0.542	rs1073348	chr8:139082730	T/C	cg03334052	chr1:168888044	NA	0.38	6.22	0.32	1.46e-9	Obesity-related traits;
LUSC	cis	rs7766436	0.885	rs3734215	chr6:22571323	T/C	cg13666174	chr6:22585274	NA	-0.41	-5.66	-0.3	3.35e-8	Coronary artery disease;
LUSC	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	10.46	0.5	2.52e-22	Homoarginine levels;
LUSC	cis	rs4343996	0.754	rs10807838	chr7:3344401	C/T	cg21248987	chr7:3385318	SDK1	-0.38	-6.48	-0.33	3.32e-10	Motion sickness;
LUSC	cis	rs1107366	0.722	rs2364368	chr3:125905080	A/T	cg01346077	chr3:125931526	NA	0.33	6.27	0.32	1.15e-9	Metabolite levels;
LUSC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg05313129	chr8:58192883	C8orf71	-0.51	-6.42	-0.33	4.67e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg16989719	chr2:238392110	NA	-0.41	-5.77	-0.3	1.85e-8	Prostate cancer;
LUSC	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	11.56	0.53	3.25e-26	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs3847687	1.000	rs34853396	chr12:131519265	G/T	cg13586425	chr12:131519906	GPR133	-0.27	-6.24	-0.32	1.36e-9	Longevity;
LUSC	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg02176678	chr2:219576539	TTLL4	-0.59	-10.45	-0.5	2.59e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg03806693	chr22:41940476	POLR3H	-0.61	-9.01	-0.44	1.62e-17	Vitiligo;
LUSC	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-9.83	-0.47	3.3e-20	Colorectal cancer;
LUSC	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg09092052	chr15:45571596	NA	0.46	6.41	0.33	5.09e-10	Glomerular filtration rate;
LUSC	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg27471124	chr11:109292789	C11orf87	0.43	7.61	0.38	2.86e-13	Schizophrenia;
LUSC	trans	rs12043259	1.000	rs12047348	chr1:204849727	G/A	cg23865240	chr7:27134109	HOXA1	-0.57	-6.01	-0.31	4.87e-9	Addiction;
LUSC	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-7.16	-0.36	5.02e-12	Axial length;
LUSC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-9.69	-0.47	9.62e-20	Gut microbiome composition (summer);
LUSC	trans	rs12210905	1.000	rs5030955	chr6:27213867	C/T	cg11837749	chr1:55047332	ACOT11	0.58	6.19	0.32	1.76e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg26384229	chr12:38710491	ALG10B	0.79	13.92	0.61	4.67e-35	Morning vs. evening chronotype;
LUSC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg27211696	chr2:191398769	TMEM194B	0.67	12.81	0.57	7.77e-31	Pulse pressure;
LUSC	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg15737290	chr11:93063684	CCDC67	0.66	8.22	0.41	4.59e-15	Pulmonary function decline;
LUSC	cis	rs3736594	0.959	rs10209020	chr2:27980944	C/T	cg27432699	chr2:27873401	GPN1	-0.64	-9.19	-0.45	4.17e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs2692947	0.567	rs4907276	chr2:96391109	G/T	cg22654517	chr2:96458247	NA	-0.32	-5.97	-0.31	5.99e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20086523	chr13:52378287	DHRS12	-0.48	-6.49	-0.33	3.05e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg00339695	chr16:24857497	SLC5A11	0.37	6.56	0.34	1.99e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg06640241	chr16:89574553	SPG7	-0.71	-11.59	-0.54	2.54e-26	Multiple myeloma (IgH translocation);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg02820810	chr13:47127418	LRCH1	0.45	5.99	0.31	5.48e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11631883	chr8:101964501	YWHAZ	-0.41	-6.06	-0.31	3.63e-9	Hepatitis;
LUSC	trans	rs7939886	0.920	rs11227670	chr11:56026737	A/C	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26264438	chr19:1039942	ABCA7	-0.4	-5.95	-0.31	6.7e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg23598886	chr18:12777645	NA	0.64	6.46	0.33	3.72e-10	Inflammatory skin disease;
LUSC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.4	0.38	1.14e-12	Motion sickness;
LUSC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.73	0.51	2.84e-23	Hip circumference adjusted for BMI;
LUSC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg15595755	chr5:1867978	NA	0.46	8.36	0.42	1.7e-15	Cardiovascular disease risk factors;
LUSC	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17916960	chr15:79447300	NA	-0.52	-10.32	-0.49	7.2e-22	Refractive error;
LUSC	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg02574844	chr11:5959923	NA	-0.42	-5.91	-0.31	8.4e-9	DNA methylation (variation);
LUSC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg08859206	chr1:53392774	SCP2	-0.39	-6.45	-0.33	3.82e-10	Monocyte count;
LUSC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg11645453	chr3:52864694	ITIH4	0.36	8.18	0.41	5.91e-15	Bipolar disorder;
LUSC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg11062466	chr8:58055876	NA	0.75	9.12	0.45	7.24e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.95	0.7	6.41e-51	Chronic sinus infection;
LUSC	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg21747405	chr11:67723411	NA	-0.48	-6.33	-0.33	7.7e-10	Blood pressure (smoking interaction);
LUSC	cis	rs6693567	0.565	rs10888584	chr1:150476406	C/G	cg15654264	chr1:150340011	RPRD2	0.45	7.16	0.36	5.27e-12	Migraine;
LUSC	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg13390004	chr1:15929781	NA	0.41	6.9	0.35	2.66e-11	Systolic blood pressure;
LUSC	cis	rs16937	0.503	rs76939335	chr1:205178610	T/C	cg00857998	chr1:205179979	DSTYK	0.47	6.66	0.34	1.16e-10	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg05313129	chr8:58192883	C8orf71	-0.5	-6.62	-0.34	1.46e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-5.95	-0.31	6.93e-9	Mood instability;
LUSC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.97	-0.51	4.15e-24	Alzheimer's disease;
LUSC	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg12559939	chr2:27858050	GPN1	0.41	6.38	0.33	6.04e-10	Oral cavity cancer;
LUSC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20307385	chr11:47447363	PSMC3	-0.46	-5.89	-0.31	9.27e-9	Subjective well-being;
LUSC	cis	rs12210905	1.000	rs72843609	chr6:27125877	G/A	cg11502198	chr6:26597334	ABT1	-0.78	-5.65	-0.3	3.43e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.83	14.43	0.62	4.83e-37	Metabolic syndrome;
LUSC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26314531	chr2:26401878	FAM59B	0.7	8.89	0.44	3.89e-17	Gut microbiome composition (summer);
LUSC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.07	-0.36	9.28e-12	Colorectal cancer;
LUSC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg12311346	chr5:56204834	C5orf35	-0.79	-12.1	-0.55	3.36e-28	Coronary artery disease;
LUSC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg10862848	chr6:42927986	GNMT	-0.28	-6.61	-0.34	1.5e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11958404	0.932	rs12517979	chr5:157428918	T/C	cg05962755	chr5:157440814	NA	0.51	6.13	0.32	2.53e-9	IgG glycosylation;
LUSC	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg03563238	chr19:33554763	RHPN2	-0.37	-5.97	-0.31	6.18e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg14004847	chr7:1930337	MAD1L1	-0.58	-9.1	-0.45	8.35e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg09436375	chr6:42928200	GNMT	-0.3	-6.86	-0.35	3.38e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	11.29	0.53	2.92e-25	Coronary artery disease;
LUSC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg16434002	chr17:42200994	HDAC5	0.44	5.98	0.31	5.59e-9	Total body bone mineral density;
LUSC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.14	0.32	2.33e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg13736514	chr6:26305472	NA	-0.46	-9.01	-0.44	1.61e-17	Educational attainment;
LUSC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.88	-16.54	-0.67	2.57e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4356932	0.691	rs4859413	chr4:76898250	A/G	cg00809888	chr4:76862425	NAAA	-0.37	-5.99	-0.31	5.41e-9	Blood protein levels;
LUSC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.52	0.57	9.28e-30	Motion sickness;
LUSC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-7.06	-0.36	9.65e-12	Mean platelet volume;
LUSC	trans	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg06238570	chr21:40685208	BRWD1	0.48	7.39	0.38	1.16e-12	Cognitive function;
LUSC	trans	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg21775007	chr8:11205619	TDH	0.46	6.74	0.35	6.76e-11	Mood instability;
LUSC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-10.01	-0.48	8.15e-21	Personality dimensions;
LUSC	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	8.84	0.44	5.58e-17	Bipolar disorder;
LUSC	trans	rs61931739	0.635	rs6488185	chr12:33933127	G/C	cg13010199	chr12:38710504	ALG10B	0.4	6.03	0.31	4.29e-9	Morning vs. evening chronotype;
LUSC	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg10596483	chr8:143751796	JRK	0.53	7.57	0.38	3.65e-13	Schizophrenia;
LUSC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg05896524	chr21:47604654	C21orf56	0.42	6.3	0.33	9.47e-10	Testicular germ cell tumor;
LUSC	cis	rs67696533	0.636	rs6119880	chr20:31105594	G/A	cg13636640	chr20:31349939	DNMT3B	0.47	6.38	0.33	5.83e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-9.9	-0.48	2.01e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-6.85	-0.35	3.51e-11	Fear of minor pain;
LUSC	cis	rs8179	0.645	rs6954221	chr7:92283262	A/G	cg15732164	chr7:92237376	CDK6	0.43	6.03	0.31	4.39e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg21827317	chr3:136751795	NA	0.39	6.96	0.36	1.83e-11	Neuroticism;
LUSC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg27121462	chr16:89883253	FANCA	0.53	8.57	0.42	3.85e-16	Vitiligo;
LUSC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg14552801	chr7:65878734	NA	0.44	6.27	0.32	1.12e-9	Aortic root size;
LUSC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.53	-0.38	4.74e-13	Personality dimensions;
LUSC	cis	rs6960043	0.818	rs2215383	chr7:15062983	T/C	cg19272540	chr7:15055459	NA	-0.32	-7.79	-0.39	8.77e-14	Type 2 diabetes;
LUSC	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg00105475	chr2:10696890	NA	0.38	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	1.07	15.49	0.65	3.75e-41	Primary sclerosing cholangitis;
LUSC	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg03474202	chr17:45855739	NA	-0.3	-6.93	-0.35	2.14e-11	IgG glycosylation;
LUSC	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg25214090	chr10:38739885	LOC399744	0.56	8.35	0.42	1.8e-15	Corneal astigmatism;
LUSC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.82	0.3	1.36e-8	Menopause (age at onset);
LUSC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26354017	chr1:205819088	PM20D1	0.73	12.13	0.55	2.55e-28	Menarche (age at onset);
LUSC	cis	rs3106136	0.967	rs11097411	chr4:95222626	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.14	-0.32	2.38e-9	Capecitabine sensitivity;
LUSC	cis	rs4589502	0.800	rs12595796	chr15:67202599	A/G	cg09911534	chr15:67153556	NA	0.5	6.5	0.34	2.92e-10	Lung cancer (smoking interaction);
LUSC	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg04362960	chr10:104952993	NT5C2	-0.6	-9.53	-0.46	3.29e-19	Arsenic metabolism;
LUSC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg11062466	chr8:58055876	NA	0.47	6.31	0.33	8.87e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg08270630	chr22:50330655	NA	-0.42	-6.46	-0.33	3.73e-10	Schizophrenia;
LUSC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg22166914	chr1:53195759	ZYG11B	0.6	9.8	0.47	4.26e-20	Monocyte count;
LUSC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg12257692	chr3:49977190	RBM6	-0.24	-6.42	-0.33	4.77e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg16647868	chr5:131706066	SLC22A5	-0.38	-5.81	-0.3	1.45e-8	Breast cancer;
LUSC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg07636037	chr3:49044803	WDR6	0.56	5.73	0.3	2.24e-8	Menarche (age at onset);
LUSC	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg00857998	chr1:205179979	DSTYK	0.66	10.24	0.49	1.44e-21	Red blood cell count;
LUSC	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg16850897	chr7:100343110	ZAN	-0.55	-7.69	-0.39	1.63e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg16928487	chr17:17741425	SREBF1	0.37	7.1	0.36	7.37e-12	Total body bone mineral density;
LUSC	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.57	9.39	0.46	9.91e-19	Height;
LUSC	cis	rs244293	0.965	rs244303	chr17:53238728	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.4	-5.79	-0.3	1.65e-8	Menarche (age at onset);
LUSC	cis	rs886126	1.000	rs886126	chr12:111679214	C/T	cg10833066	chr12:111807467	FAM109A	0.39	6.47	0.33	3.41e-10	Coronary heart disease;
LUSC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg17294928	chr15:75287854	SCAMP5	-0.93	-13.47	-0.59	2.47e-33	Blood trace element (Zn levels);
LUSC	cis	rs281408	0.559	rs281381	chr19:49214748	C/T	cg21064579	chr19:49206444	FUT2	0.34	5.96	0.31	6.54e-9	Urinary metabolites (H-NMR features);
LUSC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.5	7.66	0.39	2.05e-13	Eosinophil percentage of white cells;
LUSC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.75	13.71	0.6	3.03e-34	Calcium levels;
LUSC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg18099408	chr3:52552593	STAB1	0.34	5.87	0.31	1.05e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg06784218	chr1:46089804	CCDC17	0.48	9.39	0.46	1e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.44	-6.2	-0.32	1.66e-9	Osteoporosis;
LUSC	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg04362960	chr10:104952993	NT5C2	0.62	9.49	0.46	4.58e-19	Arsenic metabolism;
LUSC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg17507749	chr15:85114479	UBE2QP1	0.69	8.66	0.43	2.11e-16	Bipolar disorder lithium response (categorical) or schizophrenia;
LUSC	cis	rs4654899	0.897	rs3736880	chr1:21097727	G/A	cg01072550	chr1:21505969	NA	-0.47	-7.12	-0.36	6.76e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.84	-11.05	-0.52	2.1e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4285028	0.948	rs2332033	chr3:121699548	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.71	-9.1	-0.45	8.65e-18	Multiple sclerosis;
LUSC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg05896524	chr21:47604654	C21orf56	-0.57	-8.9	-0.44	3.65e-17	Testicular germ cell tumor;
LUSC	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-37.29	-0.9	4.27e-121	Myeloid white cell count;
LUSC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.67	0.54	1.3e-26	Hip circumference adjusted for BMI;
LUSC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg08859206	chr1:53392774	SCP2	0.46	7.68	0.39	1.78e-13	Monocyte count;
LUSC	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.32	-6.76	-0.35	6.16e-11	Dupuytren's disease;
LUSC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-9.23	-0.45	3.23e-18	Gut microbiome composition (summer);
LUSC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.4	-6.39	-0.33	5.68e-10	Total body bone mineral density;
LUSC	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg22437258	chr11:111473054	SIK2	0.5	6.87	0.35	3.14e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg12483005	chr1:23474871	LUZP1	0.41	6.08	0.32	3.19e-9	Height;
LUSC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg05802129	chr4:122689817	NA	-0.34	-5.97	-0.31	6.02e-9	Type 2 diabetes;
LUSC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg18357645	chr12:58087776	OS9	0.55	8.21	0.41	4.97e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg16339924	chr4:17578868	LAP3	-0.53	-7.92	-0.4	3.68e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	6.01	0.31	4.75e-9	Renal function-related traits (BUN);
LUSC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.62	11.16	0.52	8.3e-25	Breast cancer;
LUSC	trans	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg26043149	chr18:55253948	FECH	0.62	9.27	0.45	2.39e-18	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg13206674	chr6:150067644	NUP43	0.55	8.46	0.42	8.38e-16	Lung cancer;
LUSC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.26	0.59	1.63e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg10356904	chr22:49881777	NA	-0.28	-5.72	-0.3	2.41e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg25214090	chr10:38739885	LOC399744	0.43	6.7	0.34	9.07e-11	Corneal astigmatism;
LUSC	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.6	9.79	0.47	4.68e-20	Blood metabolite ratios;
LUSC	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg00012203	chr2:219082015	ARPC2	0.79	13.58	0.6	9.7e-34	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg06521331	chr12:34319734	NA	-0.37	-6.46	-0.33	3.79e-10	Morning vs. evening chronotype;
LUSC	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg06917634	chr15:78832804	PSMA4	-0.58	-7.03	-0.36	1.17e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs7980799	0.649	rs7972688	chr12:33653477	T/C	cg26384229	chr12:38710491	ALG10B	-0.56	-8.07	-0.4	1.24e-14	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg13010199	chr12:38710504	ALG10B	0.56	8.45	0.42	9.2e-16	Morning vs. evening chronotype;
LUSC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg23172400	chr8:95962367	TP53INP1	0.37	7.48	0.38	6.46e-13	Type 2 diabetes;
LUSC	cis	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg06521331	chr12:34319734	NA	-0.46	-7.3	-0.37	2.12e-12	Morning vs. evening chronotype;
LUSC	cis	rs7828089	0.935	rs4872485	chr8:22255990	G/T	cg12081754	chr8:22256438	SLC39A14	0.59	9.42	0.46	7.87e-19	Verbal declarative memory;
LUSC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg11752832	chr7:134001865	SLC35B4	0.56	8.39	0.42	1.44e-15	Mean platelet volume;
LUSC	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg13390004	chr1:15929781	NA	0.4	6.68	0.34	1e-10	Systolic blood pressure;
LUSC	cis	rs6496044	0.611	rs6496055	chr15:86070688	A/G	cg13263323	chr15:86062960	AKAP13	-0.38	-6.29	-0.33	9.78e-10	Interstitial lung disease;
LUSC	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg09307838	chr4:120376055	NA	0.72	10.4	0.49	3.93e-22	Corneal astigmatism;
LUSC	cis	rs9815354	0.516	rs75047809	chr3:42033437	T/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs16917546	1.000	rs16917546	chr10:64397538	T/C	cg03961010	chr10:64397487	ZNF365	-0.42	-6.73	-0.35	7.45e-11	Basal cell carcinoma;
LUSC	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	7.62	0.38	2.61e-13	Bone mineral density;
LUSC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.65	-0.47	1.33e-19	Type 2 diabetes;
LUSC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg26513180	chr16:89883248	FANCA	0.91	17.79	0.7	2.82e-50	Vitiligo;
LUSC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg16325326	chr1:53192061	ZYG11B	-0.83	-14.46	-0.62	3.87e-37	Monocyte count;
LUSC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.74	-0.43	1.19e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg06238570	chr21:40685208	BRWD1	0.49	7.32	0.37	1.86e-12	Cognitive function;
LUSC	cis	rs698813	0.572	rs6544749	chr2:44478077	G/A	cg00619915	chr2:44497795	NA	-0.53	-7.41	-0.38	1.03e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	trans	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.09	-0.36	7.79e-12	Menarche (age at onset);
LUSC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg17376030	chr22:41985996	PMM1	-0.51	-6.33	-0.33	7.87e-10	Vitiligo;
LUSC	trans	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-6.2	-0.32	1.67e-9	Obesity (extreme);
LUSC	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.11	0.52	1.29e-24	Hypertriglyceridemia;
LUSC	cis	rs3126085	0.935	rs12045496	chr1:152253910	A/G	cg26876637	chr1:152193138	HRNR	0.45	6.08	0.32	3.31e-9	Atopic dermatitis;
LUSC	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.13	26.74	0.83	5.26e-85	Triglycerides;
LUSC	cis	rs116988415	0.584	rs4902311	chr14:65241933	G/A	cg00114569	chr14:65239327	SPTB	0.66	6.4	0.33	5.23e-10	Daytime sleep phenotypes;
LUSC	cis	rs240764	0.658	rs12202621	chr6:101220056	C/A	cg09795085	chr6:101329169	ASCC3	-0.44	-6.24	-0.32	1.29e-9	Neuroticism;
LUSC	cis	rs12940923	1.000	rs11658637	chr17:56376508	A/G	cg19466818	chr17:56409534	MIR142	-0.38	-6.51	-0.34	2.71e-10	Circulating myeloperoxidase levels (plasma);
LUSC	trans	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg02113368	chr10:135107346	TUBGCP2	-0.34	-6.01	-0.31	4.92e-9	Dementia with Lewy bodies;
LUSC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-0.8	-13.29	-0.59	1.16e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg10523679	chr1:76189770	ACADM	-0.51	-7.46	-0.38	7.52e-13	Daytime sleep phenotypes;
LUSC	cis	rs534126	0.813	rs526867	chr7:142904427	G/A	cg04039957	chr7:143013207	CLCN1	0.31	5.92	0.31	8.18e-9	Cancer;
LUSC	cis	rs12470837	1	rs12470837	chr2:132582511	T/C	cg16789863	chr2:132589606	NA	0.41	6.24	0.32	1.32e-9	Cerebrospinal fluid clusterin levels in APOEe4+ carriers;Cerebrospinal fluid clusterin levels;
LUSC	trans	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg25482853	chr8:67687455	SGK3	0.8	11.01	0.52	2.92e-24	Obesity-related traits;
LUSC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg15921436	chr17:44337874	NA	-0.71	-10.77	-0.51	2.0500000000000001e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg23649088	chr2:200775458	C2orf69	-0.58	-7.07	-0.36	8.87e-12	Schizophrenia;
LUSC	cis	rs6967385	0.560	rs10254029	chr7:12343148	G/C	cg20607287	chr7:12443886	VWDE	0.46	6.88	0.35	2.89e-11	Response to taxane treatment (placlitaxel);
LUSC	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg13535736	chr9:111863775	C9orf5	0.37	5.98	0.31	5.58e-9	Menarche (age at onset);
LUSC	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg16240275	chr20:61666158	NCRNA00029	0.42	9.07	0.44	1.05e-17	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs587847	0.507	rs1563576	chr15:37793620	C/T	cg18296784	chr11:116147929	NA	-0.34	-6.09	-0.32	3.08e-9	Intraocular pressure;
LUSC	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg25237894	chr2:233734115	C2orf82	0.35	6.56	0.34	2.03e-10	Coronary artery disease;
LUSC	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.72	0.54	8.22e-27	Morning vs. evening chronotype;
LUSC	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-7.68	-0.39	1.79e-13	Monocyte percentage of white cells;
LUSC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg15103426	chr22:29168792	CCDC117	0.48	6.3	0.33	9.32e-10	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg03676636	chr4:99064102	C4orf37	0.36	7.69	0.39	1.7e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg03859395	chr2:55845619	SMEK2	0.86	15.64	0.65	9.08e-42	Metabolic syndrome;
LUSC	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.31	-5.77	-0.3	1.84e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7759001	0.857	rs6935116	chr6:27354949	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.74	0.3	2.1e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg06420324	chr11:73309256	FAM168A	-0.43	-5.97	-0.31	6.12e-9	Cognitive function;Information processing speed;
LUSC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.3	0.41	2.67e-15	Prudent dietary pattern;
LUSC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.47	-7.1	-0.36	7.72e-12	Neutrophil percentage of white cells;
LUSC	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg23625390	chr15:77176239	SCAPER	0.46	7.01	0.36	1.35e-11	Blood metabolite levels;
LUSC	trans	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	6.28	0.32	1.05e-9	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	0.8	14.09	0.61	1.04e-35	Cognitive function;
LUSC	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg14154082	chr13:112174009	NA	0.38	7.88	0.4	4.53e-14	Menarche (age at onset);
LUSC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.83	0.3	1.3e-8	Life satisfaction;
LUSC	cis	rs12458462	0.812	rs36073957	chr18:77488441	C/T	cg11879182	chr18:77439856	CTDP1	0.7	10.45	0.5	2.56e-22	Monocyte count;
LUSC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.23	14.01	0.61	2.04e-35	Diabetic kidney disease;
LUSC	cis	rs6469656	0.685	rs4629900	chr8:117767621	T/C	cg24004040	chr8:117650383	NA	-0.43	-6.17	-0.32	1.92e-9	Colorectal cancer;
LUSC	cis	rs73206853	0.841	rs17792048	chr12:110866543	C/A	cg12870014	chr12:110450643	ANKRD13A	0.65	6.08	0.32	3.25e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg04775059	chr7:64541387	NA	0.53	7.78	0.39	8.84e-14	Calcium levels;
LUSC	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.38	-0.33	5.93e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7707921	1.000	rs7707921	chr5:81538046	T/A	cg15871215	chr5:81402204	ATG10	0.44	6.54	0.34	2.36e-10	Breast cancer;
LUSC	cis	rs12681287	0.547	rs7837569	chr8:87507366	C/T	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05347473	chr6:146136440	FBXO30	0.56	9.66	0.47	1.23e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02475777	chr4:1388615	CRIPAK	-0.58	-8.81	-0.43	6.88e-17	Obesity-related traits;
LUSC	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg18132916	chr6:79620363	NA	-0.37	-5.7	-0.3	2.6e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg23985595	chr17:80112537	CCDC57	-0.3	-5.85	-0.31	1.15e-8	Life satisfaction;
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg25703541	chr22:24373054	LOC391322	-0.84	-12.47	-0.56	1.45e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.56	9.38	0.46	1.02e-18	Birth weight;
LUSC	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg20135002	chr11:47629003	NA	-0.43	-6.98	-0.36	1.6e-11	Subjective well-being;
LUSC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg00343986	chr7:65444356	GUSB	-0.43	-6.59	-0.34	1.71e-10	Aortic root size;
LUSC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg15147215	chr3:52552868	STAB1	-0.32	-6.31	-0.33	9e-10	Electroencephalogram traits;
LUSC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg09365446	chr1:150670422	GOLPH3L	0.51	7.45	0.38	7.94e-13	Melanoma;
LUSC	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg14154082	chr13:112174009	NA	0.38	7.76	0.39	1.03e-13	Menarche (age at onset);
LUSC	cis	rs7605827	0.930	rs6431696	chr2:15540009	C/A	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	0.98	13.74	0.6	2.26e-34	Eosinophil percentage of granulocytes;
LUSC	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-8.16	-0.41	6.68e-15	Morning vs. evening chronotype;
LUSC	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg05738196	chr6:26577821	NA	-0.49	-7.04	-0.36	1.09e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18943949	chr22:19842501	GNB1L;C22orf29	-0.44	-6.6	-0.34	1.57e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.93	0.44	2.95e-17	Prudent dietary pattern;
LUSC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-0.89	-11.99	-0.55	8.32e-28	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs2262909	0.962	rs55735642	chr19:22241176	C/T	cg17074339	chr11:11642133	GALNTL4	0.47	7.17	0.37	4.94e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg13010199	chr12:38710504	ALG10B	0.69	10.56	0.5	1.13e-22	Bladder cancer;
LUSC	cis	rs3820928	0.874	rs10933163	chr2:227815286	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.75	-0.39	1.14e-13	Pulmonary function;
LUSC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22509189	chr2:225307070	NA	-0.49	-6.35	-0.33	6.84e-10	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00475322	chr7:917719	C7orf20	0.44	6.52	0.34	2.6200000000000003e-10	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg16339924	chr4:17578868	LAP3	0.55	8.43	0.42	1.03e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7577851	0.625	rs55885494	chr2:69556144	A/C	cg10773587	chr2:69614142	GFPT1	0.59	6.41	0.33	5.08e-10	Parkinson's disease (age of onset);
LUSC	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-9.13	-0.45	6.65e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg09365446	chr1:150670422	GOLPH3L	0.49	7.17	0.37	4.77e-12	Melanoma;
LUSC	cis	rs9300255	0.679	rs28583837	chr12:123863620	G/A	cg13010344	chr12:123464640	ARL6IP4	0.52	6.41	0.33	4.94e-10	Neutrophil percentage of white cells;
LUSC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18854424	chr1:2615690	NA	0.49	9.44	0.46	6.81e-19	Ulcerative colitis;
LUSC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg08742575	chr21:47604166	C21orf56	-0.44	-6.78	-0.35	5.54e-11	Testicular germ cell tumor;
LUSC	cis	rs73416724	1.000	rs41281796	chr6:43323917	G/A	cg26312998	chr6:43337775	ZNF318	0.57	6.66	0.34	1.16e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1152591	0.643	rs3020449	chr14:64773392	C/T	cg21174375	chr14:64681225	SYNE2	-0.32	-5.9	-0.31	9.12e-9	Atrial fibrillation;
LUSC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.49e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4481887	0.800	rs4639798	chr1:248515703	A/G	cg26353448	chr1:248524236	OR2T4	-0.32	-6.01	-0.31	4.91e-9	Common traits (Other);
LUSC	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	0.89	16.94	0.68	7.06e-47	Heart rate;
LUSC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg07636037	chr3:49044803	WDR6	0.44	6.28	0.32	1.07e-9	Resting heart rate;
LUSC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg09365446	chr1:150670422	GOLPH3L	0.5	7.25	0.37	2.95e-12	Melanoma;
LUSC	trans	rs953492	0.672	rs10926964	chr1:243359347	G/A	cg25284624	chr1:224180302	NA	-0.5	-7.7	-0.39	1.56e-13	Diastolic blood pressure;
LUSC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-7.61	-0.38	2.91e-13	Chronic sinus infection;
LUSC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg06008330	chr7:65541103	ASL	0.37	5.68	0.3	2.98e-8	Aortic root size;
LUSC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06656553	chr16:89960601	TCF25	-0.65	-5.7	-0.3	2.63e-8	Skin colour saturation;
LUSC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18099408	chr3:52552593	STAB1	-0.48	-8.76	-0.43	1.02e-16	Cognitive function;
LUSC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06656553	chr16:89960601	TCF25	-0.63	-5.7	-0.3	2.68e-8	Skin colour saturation;
LUSC	cis	rs6920965	0.507	rs7754833	chr6:126190894	A/G	cg10911889	chr6:126070802	HEY2	0.39	5.66	0.3	3.34e-8	High light scatter reticulocyte count;
LUSC	cis	rs6901250	0.851	rs339324	chr6:117195024	C/T	cg12892004	chr6:117198278	RFX6	-0.45	-8.55	-0.42	4.56e-16	C-reactive protein levels;
LUSC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-7.49	-0.38	6.05e-13	Morning vs. evening chronotype;
LUSC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg24531977	chr5:56204891	C5orf35	0.61	8.99	0.44	1.84e-17	Coronary artery disease;
LUSC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.64	-0.47	1.4e-19	Gut microbiome composition (summer);
LUSC	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg13390004	chr1:15929781	NA	0.42	7.02	0.36	1.23e-11	Systolic blood pressure;
LUSC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg23711669	chr6:146136114	FBXO30	0.88	16.13	0.66	1.12e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs16937	0.662	rs12137294	chr1:205182872	A/C	cg00857998	chr1:205179979	DSTYK	0.4	5.83	0.3	1.34e-8	Schizophrenia;
LUSC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.63	0.85	1.69e-95	Chronic sinus infection;
LUSC	cis	rs240764	0.658	rs6909880	chr6:101179354	A/C	cg09795085	chr6:101329169	ASCC3	-0.46	-6.65	-0.34	1.2e-10	Neuroticism;
LUSC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg18230493	chr5:56204884	C5orf35	-0.65	-9.99	-0.48	1e-20	Coronary artery disease;
LUSC	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg27068330	chr11:65405492	SIPA1	0.65	9.82	0.47	3.71e-20	Acne (severe);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg22506841	chr1:200271513	NA	0.41	6.25	0.32	1.24e-9	N-glycan levels;
LUSC	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg22705602	chr4:152727874	NA	-0.33	-6.61	-0.34	1.53e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg26384229	chr12:38710491	ALG10B	0.72	11.22	0.52	5.39e-25	Morning vs. evening chronotype;
LUSC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg15145296	chr3:125709740	NA	-0.58	-6.5	-0.33	3e-10	Blood pressure (smoking interaction);
LUSC	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	1.04	12.49	0.56	1.28e-29	Schizophrenia;
LUSC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg18099408	chr3:52552593	STAB1	0.35	5.96	0.31	6.38e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg20935933	chr6:143382018	AIG1	0.51	7.4	0.38	1.08e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1832871	0.711	rs6906854	chr6:158695000	C/T	cg07165851	chr6:158734300	TULP4	0.5	7.8	0.39	7.87e-14	Height;
LUSC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-7.83	-0.39	6.56e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg20790798	chr5:1857306	NA	-0.5	-8.7	-0.43	1.52e-16	Cardiovascular disease risk factors;
LUSC	cis	rs4474465	0.850	rs10793328	chr11:78256868	A/G	cg27205649	chr11:78285834	NARS2	0.55	6.52	0.34	2.59e-10	Alzheimer's disease (survival time);
LUSC	cis	rs977987	0.806	rs7199132	chr16:75450039	C/T	cg03315344	chr16:75512273	CHST6	0.48	8.94	0.44	2.68e-17	Dupuytren's disease;
LUSC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.47	6.98	0.36	1.62e-11	Schizophrenia;
LUSC	cis	rs6591341	0.515	rs599301	chr11:68189945	G/C	cg01657329	chr11:68192670	LRP5	-0.47	-7.13	-0.36	6.43e-12	Lean body mass;
LUSC	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg24596788	chr1:163392923	NA	-0.44	-7.53	-0.38	4.62e-13	Motion sickness;
LUSC	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.81	0.43	6.77e-17	Axial length;
LUSC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg05084668	chr3:125655381	ALG1L	-0.49	-6.98	-0.36	1.61e-11	Blood pressure (smoking interaction);
LUSC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg06877462	chr1:205807181	PM20D1	0.39	7.32	0.37	1.86e-12	Menarche (age at onset);
LUSC	trans	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.29	0.41	2.71e-15	Ulcerative colitis;
LUSC	cis	rs6847149	0.810	rs2347134	chr4:110814457	A/T	cg07850274	chr4:110748770	RRH	0.5	7.03	0.36	1.19e-11	Exercise treadmill test traits;
LUSC	cis	rs354225	0.544	rs3796018	chr2:54807281	C/T	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	trans	rs2055729	0.634	rs6601390	chr8:9740657	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	6.0	0.31	5.08e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg22709100	chr7:91322751	NA	0.39	5.86	0.31	1.08e-8	Breast cancer;
LUSC	cis	rs2637266	1.000	rs2579761	chr10:78321040	C/T	cg18941641	chr10:78392320	NA	0.38	7.0	0.36	1.41e-11	Pulmonary function;
LUSC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.52	0.59	1.57e-33	Platelet count;
LUSC	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg21770322	chr7:97807741	LMTK2	0.41	7.28	0.37	2.45e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg05887092	chr17:76393375	PGS1	0.62	12.01	0.55	7.33e-28	HDL cholesterol;
LUSC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs1865721	0.771	rs7236311	chr18:73137450	A/G	cg26385618	chr18:73139727	C18orf62	-0.55	-10.15	-0.49	2.88e-21	Intelligence;
LUSC	cis	rs2078087	0.522	rs549191	chr1:183220937	A/G	cg13843938	chr1:183241246	NMNAT2	0.38	6.43	0.33	4.37e-10	Obesity-related traits;
LUSC	cis	rs968451	0.789	rs11089939	chr22:39680957	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.7	10.17	0.49	2.47e-21	Primary biliary cholangitis;
LUSC	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg24631222	chr15:78858424	CHRNA5	0.78	10.9	0.51	7.32e-24	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00529946	chr2:26568848	SELI;GPR113	-0.48	-6.27	-0.32	1.11e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg24558204	chr6:135376177	HBS1L	0.59	9.28	0.45	2.26e-18	Red blood cell count;
LUSC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg00012203	chr2:219082015	ARPC2	0.89	17.09	0.68	1.71e-47	Colorectal cancer;
LUSC	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg03733263	chr8:22462867	KIAA1967	0.99	18.14	0.7	1.19e-51	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg05340658	chr4:99064831	C4orf37	0.59	9.37	0.46	1.14e-18	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs417096	1.000	rs302604	chr6:39731420	A/C	cg17457912	chr17:1617102	C17orf91	0.31	5.99	0.31	5.43e-9	Hypospadias;
LUSC	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.24	0.37	3.07e-12	Morning vs. evening chronotype;
LUSC	cis	rs68170813	0.641	rs12534124	chr7:107119047	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.7	-0.3	2.61e-8	Coronary artery disease;
LUSC	cis	rs4409675	0.576	rs6703851	chr1:28237556	G/A	cg23691781	chr1:28212827	C1orf38	0.32	7.54	0.38	4.34e-13	Corneal astigmatism;
LUSC	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.69	0.47	9.71e-20	Coffee consumption (cups per day);
LUSC	trans	rs4553720	0.896	rs4383250	chr18:62177797	A/T	cg24311272	chr6:56820869	BEND6;DST	0.46	6.28	0.32	1.03e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LUSC	trans	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg27411982	chr8:10470053	RP1L1	0.41	6.12	0.32	2.65e-9	Neuroticism;
LUSC	cis	rs16989760	0.661	rs67935422	chr22:32020413	G/A	cg01338084	chr22:32026380	PISD	0.86	6.23	0.32	1.43e-9	Age-related hearing impairment;
LUSC	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg24375607	chr4:120327624	NA	0.76	12.27	0.56	8.02e-29	Educational attainment;
LUSC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-6.04	-0.31	4.02e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16680214	chr1:154839983	KCNN3	-0.52	-9.48	-0.46	4.88e-19	Prostate cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15995771	chr1:59250858	JUN	-0.49	-5.96	-0.31	6.27e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg08854313	chr1:11322531	MTOR	-0.87	-13.41	-0.59	4.38e-33	Body mass index;
LUSC	cis	rs981844	0.890	rs62325113	chr4:154692555	A/G	cg14289246	chr4:154710475	SFRP2	0.55	6.9	0.35	2.6e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.23	0.32	1.4e-9	Total body bone mineral density;
LUSC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.85	0.3	1.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg17385448	chr1:15911702	AGMAT	0.37	6.15	0.32	2.19e-9	Systolic blood pressure;
LUSC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg02153584	chr22:29168773	CCDC117	0.59	8.91	0.44	3.47e-17	Lymphocyte counts;
LUSC	cis	rs7189233	0.955	rs7184800	chr16:53509131	G/A	cg04059762	chr16:53544020	NA	-0.32	-5.75	-0.3	2.01e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.84	10.86	0.51	9.77e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg09035930	chr12:129282057	SLC15A4	0.74	16.25	0.66	3.7e-44	Systemic lupus erythematosus;
LUSC	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg06606381	chr12:133084897	FBRSL1	-0.92	-9.39	-0.46	9.67e-19	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7119167	0.686	rs7936102	chr11:73044215	T/C	cg17517138	chr11:73019481	ARHGEF17	0.49	5.71	0.3	2.49e-8	Blood protein levels;
LUSC	cis	rs6084875	0.812	rs2093386	chr20:4724313	A/G	cg07258627	chr20:4721683	PRNT	-0.35	-6.22	-0.32	1.52e-9	Systemic lupus erythematosus;
LUSC	trans	rs7170930	0.618	rs55677817	chr15:66541800	G/A	cg06396762	chr16:3202609	NA	-0.72	-5.98	-0.31	5.75e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	8.77	0.43	9.59e-17	Bipolar disorder;
LUSC	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg08645402	chr16:4508243	NA	0.53	8.21	0.41	4.76e-15	Schizophrenia;
LUSC	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg12564285	chr5:131593104	PDLIM4	-0.35	-6.14	-0.32	2.33e-9	Blood metabolite levels;
LUSC	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg12856521	chr11:46389249	DGKZ	0.43	6.28	0.32	1.04e-9	Leprosy;
LUSC	cis	rs58785573	0.624	rs337605	chr4:38647753	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.42	6.23	0.32	1.4e-9	Lymphocyte percentage of white cells;
LUSC	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg26102564	chr10:131424627	MGMT	0.42	6.6	0.34	1.64e-10	Response to temozolomide;
LUSC	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg20243544	chr17:37824526	PNMT	0.39	5.73	0.3	2.24e-8	Self-reported allergy;
LUSC	cis	rs2742234	0.541	rs11238479	chr10:43717423	C/T	cg15436174	chr10:43711423	RASGEF1A	0.45	7.34	0.37	1.69e-12	Hirschsprung disease;
LUSC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg15534755	chr11:117069859	TAGLN	0.34	5.92	0.31	7.78e-9	Blood protein levels;
LUSC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12667521	chr19:29218732	NA	0.62	8.6	0.43	3.11e-16	Methadone dose in opioid dependence;
LUSC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg14440974	chr22:39074834	NA	-0.36	-5.95	-0.31	6.89e-9	Menopause (age at onset);
LUSC	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	6.61	0.34	1.51e-10	Schizophrenia;
LUSC	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg00540400	chr15:79124168	NA	-0.48	-8.23	-0.41	4.18e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg09516651	chr1:89888402	LOC400759	0.4	7.12	0.36	6.57e-12	Carotid intima media thickness;
LUSC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.61	-0.57	4.37e-30	Chronic sinus infection;
LUSC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18758796	chr5:131593413	PDLIM4	0.53	9.17	0.45	4.99e-18	Acylcarnitine levels;
LUSC	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg26597838	chr10:835615	NA	0.79	9.73	0.47	7.58e-20	Eosinophil percentage of granulocytes;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02841933	chr7:129251651	NRF1	-0.44	-6.63	-0.34	1.39e-10	Electrocardiographic conduction measures;
LUSC	cis	rs911119	0.913	rs6048926	chr20:23580987	C/A	cg16589663	chr20:23618590	CST3	0.62	7.41	0.38	1.04e-12	Chronic kidney disease;
LUSC	cis	rs10904908	0.733	rs359298	chr10:17334176	C/T	cg01003015	chr10:17271136	VIM	0.43	6.32	0.33	8.26e-10	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs6120849	1.000	rs6120849	chr20:33730387	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	6.21	0.32	1.56e-9	Protein C levels;
LUSC	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg12884169	chr21:40033163	ERG	0.61	12.36	0.56	3.6e-29	Coronary artery disease;
LUSC	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-20.94	-0.75	8.99e-63	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.4	0.62	6.35e-37	Platelet count;
LUSC	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg25427524	chr10:38739819	LOC399744	0.48	6.21	0.32	1.61e-9	Obesity (extreme);
LUSC	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2573652	1.000	rs2581359	chr15:100513707	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.44	-8.06	-0.4	1.33e-14	Height;
LUSC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg02487422	chr3:49467188	NICN1	0.45	7.04	0.36	1.12e-11	Resting heart rate;
LUSC	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg27446573	chr6:127587934	RNF146	0.62	9.94	0.48	1.46e-20	Breast cancer;
LUSC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg17340268	chr14:105411764	AHNAK2	0.4	6.37	0.33	6.15e-10	Rheumatoid arthritis;
LUSC	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg05347473	chr6:146136440	FBXO30	0.55	9.47	0.46	5.29e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7432375	0.610	rs6793936	chr3:136509793	A/C	cg15507776	chr3:136538369	TMEM22	0.43	7.22	0.37	3.5e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4930561	0.714	rs1540209	chr11:67928520	A/C	cg04465784	chr11:67976953	SUV420H1	-0.29	-5.8	-0.3	1.53e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.79	-0.35	5.17e-11	Morning vs. evening chronotype;
LUSC	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg05855489	chr10:104503620	C10orf26	0.61	9.82	0.47	3.67e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.91	-0.4	3.82e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-6.86	-0.35	3.35e-11	Neuroticism;
LUSC	cis	rs6542838	0.641	rs7565510	chr2:99494833	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-6.04	-0.31	4e-9	Fear of minor pain;
LUSC	cis	rs7712401	0.755	rs4283786	chr5:122101050	T/C	cg19077854	chr5:122220652	SNX24	0.35	7.77	0.39	9.65e-14	Mean platelet volume;
LUSC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg10755058	chr3:40428713	ENTPD3	0.35	5.76	0.3	1.9e-8	Renal cell carcinoma;
LUSC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.71	12.72	0.57	1.68e-30	Prudent dietary pattern;
LUSC	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-8.14	-0.41	8.05e-15	Blood metabolite levels;
LUSC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs4474465	1.000	rs10793315	chr11:78190716	C/G	cg27205649	chr11:78285834	NARS2	-0.49	-5.79	-0.3	1.62e-8	Alzheimer's disease (survival time);
LUSC	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg13575925	chr12:9217583	LOC144571	0.35	6.43	0.33	4.38e-10	Sjögren's syndrome;
LUSC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg07507251	chr3:52567010	NT5DC2	0.37	6.79	0.35	5.22e-11	Bipolar disorder;
LUSC	cis	rs829883	1.000	rs249839	chr12:98872364	T/C	cg25150519	chr12:98850993	NA	0.65	10.19	0.49	2.13e-21	Colorectal adenoma (advanced);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18635552	chr5:3599719	IRX1	0.34	6.32	0.33	8.26e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11677416	1.000	rs1878318	chr2:113545185	A/G	cg27083787	chr2:113543245	IL1A	0.47	7.39	0.37	1.17e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg06917634	chr15:78832804	PSMA4	0.59	7.32	0.37	1.9e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs909002	0.849	rs10753257	chr1:32086089	G/A	cg01639898	chr1:32083012	HCRTR1	0.27	6.32	0.33	8.36e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12667521	chr19:29218732	NA	0.59	8.86	0.44	4.87e-17	Methadone dose in opioid dependence;
LUSC	cis	rs1957429	0.808	rs1467573	chr14:65347583	T/C	cg23373153	chr14:65346875	NA	1.07	12.89	0.58	3.85e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23598886	chr18:12777645	NA	0.65	6.6	0.34	1.61e-10	Inflammatory skin disease;
LUSC	cis	rs4478858	0.647	rs11581476	chr1:31717675	C/T	cg00250761	chr1:31883323	NA	-0.34	-8.23	-0.41	4.26e-15	Alcohol dependence;
LUSC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.85	10.95	0.51	4.87e-24	Gut microbiome composition (summer);
LUSC	trans	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg24209194	chr3:40518798	ZNF619	0.49	6.53	0.34	2.48e-10	Renal cell carcinoma;
LUSC	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.64	-0.47	1.44e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12493885	0.725	rs61791468	chr3:153739520	G/C	cg17054900	chr3:154042577	DHX36	-0.7	-7.37	-0.37	1.33e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs889312	0.923	rs12697152	chr5:56025716	A/G	cg18230493	chr5:56204884	C5orf35	0.39	5.76	0.3	1.92e-8	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg26647111	chr11:31128758	NA	-0.43	-6.13	-0.32	2.47e-9	Red blood cell count;
LUSC	cis	rs983392	0.805	rs7933805	chr11:59967526	A/G	cg24026212	chr11:59952134	MS4A6A	-0.38	-6.54	-0.34	2.26e-10	Alzheimer's disease (late onset);
LUSC	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-5.99	-0.31	5.41e-9	Body mass index;
LUSC	cis	rs1832871	0.711	rs7770047	chr6:158685696	A/G	cg07165851	chr6:158734300	TULP4	0.5	7.76	0.39	1.03e-13	Height;
LUSC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.74	-11.32	-0.53	2.39e-25	Menarche (age at onset);
LUSC	cis	rs2625529	0.824	rs4777470	chr15:72207518	T/A	cg16672083	chr15:72433130	SENP8	-0.5	-7.35	-0.37	1.56e-12	Red blood cell count;
LUSC	cis	rs6424115	1.000	rs7515969	chr1:24158398	G/A	cg15997130	chr1:24165203	NA	-0.56	-9.19	-0.45	4.43e-18	Immature fraction of reticulocytes;
LUSC	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg23544223	chr18:12777786	NA	0.58	6.15	0.32	2.18e-9	Inflammatory skin disease;
LUSC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg22166914	chr1:53195759	ZYG11B	0.47	7.49	0.38	6.33e-13	Monocyte count;
LUSC	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	0.82	12.44	0.56	1.96e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg19812747	chr11:111475976	SIK2	0.5	6.81	0.35	4.44e-11	Primary sclerosing cholangitis;
LUSC	trans	rs17133449	0.718	rs1901635	chr10:4751773	C/T	cg17844448	chr7:27782764	TAX1BP1	-0.36	-5.99	-0.31	5.3300000000000004e-09	Major depressive disorder;
LUSC	cis	rs10761482	0.861	rs9988785	chr10:62108992	C/T	cg18175470	chr10:62150864	ANK3	-0.49	-6.96	-0.36	1.84e-11	Schizophrenia;
LUSC	cis	rs2976388	0.647	rs1048831	chr8:143781858	G/A	cg17252645	chr8:143867129	LY6D	0.38	6.63	0.34	1.32e-10	Urinary tract infection frequency;
LUSC	cis	rs3126085	0.935	rs6670717	chr1:152249956	T/C	cg26876637	chr1:152193138	HRNR	-0.44	-5.83	-0.3	1.3e-8	Atopic dermatitis;
LUSC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg12935359	chr14:103987150	CKB	-0.52	-8.05	-0.4	1.51e-14	Body mass index;
LUSC	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg20701182	chr2:24300061	SF3B14	0.74	7.3	0.37	2.15e-12	Lymphocyte counts;
LUSC	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.97	-0.36	1.68e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.95	-0.31	6.78e-9	Alcohol dependence;
LUSC	cis	rs11039131	0.629	rs67871383	chr11:47335838	T/C	cg20135002	chr11:47629003	NA	-0.4	-5.76	-0.3	1.92e-8	Schizophrenia;
LUSC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg13395646	chr4:1353034	KIAA1530	0.59	9.03	0.44	1.44e-17	Obesity-related traits;
LUSC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.57	-0.46	2.49e-19	Type 2 diabetes;
LUSC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.58	-0.42	3.61e-16	Bipolar disorder;
LUSC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg20406979	chr6:167373233	NA	0.25	5.92	0.31	7.93e-9	Crohn's disease;
LUSC	cis	rs977987	0.836	rs8055974	chr16:75470986	C/G	cg03315344	chr16:75512273	CHST6	0.5	9.58	0.46	2.31e-19	Dupuytren's disease;
LUSC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg06808227	chr14:105710500	BRF1	-0.64	-9.56	-0.46	2.57e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9807841	0.592	rs11085743	chr19:10759442	G/A	cg17710535	chr19:10819994	QTRT1	0.42	6.93	0.35	2.2e-11	Inflammatory skin disease;
LUSC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg05347473	chr6:146136440	FBXO30	-0.47	-7.97	-0.4	2.61e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6062509	0.895	rs55946717	chr20:62363869	G/A	cg01176363	chr20:62369445	LIME1	-0.46	-6.96	-0.36	1.84e-11	Prostate cancer;
LUSC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.41	-6.27	-0.32	1.14e-9	Tonsillectomy;
LUSC	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg05340658	chr4:99064831	C4orf37	0.44	6.92	0.35	2.31e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs590121	0.876	rs6704	chr11:75283653	C/A	cg26104986	chr11:75275303	SERPINH1	-0.28	-5.77	-0.3	1.77e-8	Coronary artery disease;
LUSC	cis	rs4974559	0.947	rs10006381	chr4:1359309	C/T	cg02980000	chr4:1222292	CTBP1	0.79	7.51	0.38	5.37e-13	Systolic blood pressure;
LUSC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg06454157	chr6:167490870	NA	-0.28	-6.87	-0.35	3.1e-11	Primary biliary cholangitis;
LUSC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg07741184	chr6:167504864	NA	0.38	6.76	0.35	6.04e-11	Crohn's disease;
LUSC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg04450456	chr4:17643702	FAM184B	0.35	5.89	0.31	9.3e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.59	-5.79	-0.3	1.64e-8	Lung cancer;Intelligence (multi-trait analysis);
LUSC	cis	rs9902453	0.904	rs12948898	chr17:28410324	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-10.89	-0.51	7.67e-24	Coffee consumption (cups per day);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18268492	chr10:99185986	PGAM1	-0.5	-6.63	-0.34	1.38e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-7.46	-0.38	7.77e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg14552801	chr7:65878734	NA	0.37	5.71	0.3	2.56e-8	Aortic root size;
LUSC	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.1	-0.36	7.36e-12	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg03676636	chr4:99064102	C4orf37	0.36	7.88	0.4	4.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.6	10.8	0.51	1.56e-23	Bipolar disorder;
LUSC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg01802117	chr1:53393560	SCP2	-0.39	-6.37	-0.33	6.1e-10	Monocyte count;
LUSC	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.98	0.36	1.58e-11	Menarche (age at onset);
LUSC	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg26384229	chr12:38710491	ALG10B	0.72	10.12	0.48	3.66e-21	Resting heart rate;
LUSC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg03388025	chr16:89894329	SPIRE2	-0.34	-6.97	-0.36	1.65e-11	Vitiligo;
LUSC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	0.93	12.87	0.58	4.58e-31	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6681460	1.000	rs1329978	chr1:67116231	C/T	cg02459107	chr1:67143332	SGIP1	0.48	9.0	0.44	1.8e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.28	-0.37	2.45e-12	Morning vs. evening chronotype;
LUSC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg17764715	chr19:33622953	WDR88	0.61	8.31	0.41	2.45e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg11062466	chr8:58055876	NA	0.47	5.72	0.3	2.39e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.55	-0.53	3.33e-26	Colorectal cancer;
LUSC	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg04374321	chr14:90722782	PSMC1	0.7	10.68	0.5	4.34e-23	Mortality in heart failure;
LUSC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.71	12.48	0.56	1.38e-29	Aortic root size;
LUSC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.4	-5.73	-0.3	2.28e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg18538332	chr22:24372958	LOC391322	-0.41	-7.57	-0.38	3.73e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg23649088	chr2:200775458	C2orf69	0.52	7.1	0.36	7.75e-12	Schizophrenia;
LUSC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.09	-0.48	4.6e-21	Platelet count;
LUSC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21643547	chr1:205240462	TMCC2	-0.5	-9.27	-0.45	2.28e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg13683864	chr3:40499215	RPL14	-1.05	-19.5	-0.73	4.6e-57	Renal cell carcinoma;
LUSC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.38	7.15	0.36	5.66e-12	Schizophrenia;
LUSC	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.44	-10.36	-0.49	5.29e-22	Urate levels in overweight individuals;
LUSC	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg23260525	chr10:116636907	FAM160B1	0.42	8.54	0.42	4.79e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.19	-0.41	5.43e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg08847533	chr14:75593920	NEK9	0.8	13.95	0.61	3.72e-35	Height;
LUSC	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg09323728	chr8:95962352	TP53INP1	-0.31	-5.8	-0.3	1.52e-8	Type 2 diabetes;
LUSC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg25039879	chr17:56429692	SUPT4H1	0.7	9.23	0.45	3.21e-18	Cognitive test performance;
LUSC	cis	rs13223928	0.621	rs4722438	chr7:3155813	A/G	cg19214707	chr7:3157722	NA	0.42	8.68	0.43	1.73e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg08645402	chr16:4508243	NA	-0.42	-6.9	-0.35	2.65e-11	Schizophrenia;
LUSC	cis	rs1160297	0.576	rs12475542	chr2:53111504	A/G	cg07782112	chr2:53107842	NA	-0.37	-6.08	-0.32	3.26e-9	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg19592336	chr6:28129416	ZNF389	-0.52	-7.12	-0.36	6.71e-12	Depression;
LUSC	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21659725	chr3:3221576	CRBN	-0.65	-10.56	-0.5	1.07e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs735539	0.521	rs2818991	chr13:21397196	A/G	cg04906043	chr13:21280425	IL17D	-0.39	-5.81	-0.3	1.44e-8	Dental caries;
LUSC	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg12826209	chr6:26865740	GUSBL1	0.68	7.67	0.39	1.85e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.87	14.03	0.61	1.77e-35	Bladder cancer;
LUSC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-6.38	-0.33	5.92e-10	Personality dimensions;
LUSC	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg27411982	chr8:10470053	RP1L1	0.4	6.44	0.33	4.2e-10	Retinal vascular caliber;
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg27094323	chr7:1216898	NA	-0.45	-7.76	-0.39	1.07e-13	Longevity;Endometriosis;
LUSC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg25039879	chr17:56429692	SUPT4H1	0.66	8.88	0.44	4.12e-17	Cognitive test performance;
LUSC	cis	rs10484885	0.878	rs17506550	chr6:90508896	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.22	-0.41	4.65e-15	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg20684491	chr1:25596433	NA	0.37	5.86	0.31	1.12e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12826209	chr6:26865740	GUSBL1	-0.74	-8.93	-0.44	2.96e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg25258033	chr6:167368657	RNASET2	0.47	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg04352962	chr1:209979756	IRF6	0.55	6.46	0.33	3.73e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs7923609	0.846	rs10740115	chr10:65094990	G/A	cg01631684	chr10:65280961	REEP3	-0.41	-6.43	-0.33	4.53e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9815354	0.812	rs59583650	chr3:41809063	A/G	cg03022575	chr3:42003672	ULK4	0.83	8.34	0.41	2.04e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg22166914	chr1:53195759	ZYG11B	-0.55	-8.8	-0.43	7.56e-17	Monocyte count;
LUSC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.6	9.71	0.47	8.76e-20	Aortic root size;
LUSC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg13531842	chr10:38383804	ZNF37A	-0.46	-7.18	-0.37	4.53e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg27426351	chr10:43362370	NA	-0.43	-6.0	-0.31	5.26e-9	Blood protein levels;
LUSC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg17143192	chr8:8559678	CLDN23	0.63	8.99	0.44	1.82e-17	Obesity-related traits;
LUSC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg17948913	chr5:572064	NA	0.37	5.65	0.3	3.38e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14829155	chr15:31115871	NA	-0.57	-7.95	-0.4	2.82e-14	Huntington's disease progression;
LUSC	cis	rs4601821	1.000	rs877138	chr11:113256508	A/G	cg14159747	chr11:113255604	NA	-0.26	-6.12	-0.32	2.62e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.68	-10.35	-0.49	5.96e-22	Hip circumference adjusted for BMI;
LUSC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.85	-11.36	-0.53	1.62e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2540226	0.627	rs2192686	chr2:39928722	A/G	cg23576258	chr2:39999331	THUMPD2	0.35	5.94	0.31	7.14e-9	Personality dimensions;
LUSC	cis	rs1775715	0.835	rs11008701	chr10:32241096	A/G	cg18675610	chr10:32216311	ARHGAP12	0.27	5.71	0.3	2.55e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg23172400	chr8:95962367	TP53INP1	-0.47	-9.59	-0.46	2.13e-19	Type 2 diabetes;
LUSC	cis	rs1178968	1.000	rs4717085	chr7:72764807	C/T	cg25889504	chr7:72793014	NA	0.6	7.8	0.39	7.86e-14	Triglyceride levels;
LUSC	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg13683864	chr3:40499215	RPL14	0.72	11.5	0.53	5.29e-26	Renal cell carcinoma;
LUSC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23158103	chr7:148848205	ZNF398	-0.44	-7.16	-0.36	5.14e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	0.87	16.07	0.66	1.88e-43	Coronary artery disease;
LUSC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.8	14.15	0.61	6.15e-36	Blood protein levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27360527	chr16:85722694	GINS2	-0.49	-6.06	-0.31	3.75e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg08219700	chr8:58056026	NA	0.57	6.78	0.35	5.49e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4950928	0.774	rs4950931	chr1:203164075	G/A	cg17014757	chr1:203156097	CHI3L1	-0.43	-7.63	-0.39	2.46e-13	YKL-40 levels;
LUSC	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg16482183	chr6:26056742	HIST1H1C	0.56	8.34	0.42	2.02e-15	Height;
LUSC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.73	-10.13	-0.48	3.42e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs12681287	0.547	rs9297921	chr8:87542286	C/T	cg27223183	chr8:87520930	FAM82B	0.53	6.99	0.36	1.54e-11	Caudate activity during reward;
LUSC	cis	rs921665	0.831	rs6548167	chr2:3181062	A/G	cg16434511	chr2:3151078	NA	-0.62	-6.74	-0.35	7.05e-11	World class endurance athleticism;
LUSC	cis	rs6967385	0.867	rs2356167	chr7:12360805	T/C	cg06484146	chr7:12443880	VWDE	0.4	5.91	0.31	8.3e-9	Response to taxane treatment (placlitaxel);
LUSC	trans	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg26043149	chr18:55253948	FECH	-0.55	-7.88	-0.4	4.64e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg13397359	chr6:42928475	GNMT	-0.39	-6.23	-0.32	1.44e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg23985595	chr17:80112537	CCDC57	0.31	5.84	0.3	1.23e-8	Life satisfaction;
LUSC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.54	-7.79	-0.39	8.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg06521331	chr12:34319734	NA	-0.41	-6.48	-0.33	3.3e-10	Morning vs. evening chronotype;
LUSC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.63	8.14	0.41	7.98e-15	Huntington's disease progression;
LUSC	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg25344623	chr2:136566232	LCT	0.37	5.68	0.3	2.96e-8	Mosquito bite size;
LUSC	cis	rs10992471	0.528	rs10115290	chr9:95195858	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.37	-6.52	-0.34	2.54e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.46	8.79	0.43	7.8e-17	Glomerular filtration rate (creatinine);
LUSC	cis	rs2273669	0.588	rs2145767	chr6:109296185	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-6.46	-0.33	3.8e-10	Prostate cancer;
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	10.88	0.51	8.49e-24	Lymphocyte counts;
LUSC	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg17366294	chr4:99064904	C4orf37	0.53	8.62	0.43	2.75e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg05855489	chr10:104503620	C10orf26	0.52	7.86	0.4	5.22e-14	Arsenic metabolism;
LUSC	cis	rs10144321	1.000	rs28581530	chr14:100872263	C/T	cg14882082	chr14:100845427	WDR25	0.42	7.88	0.4	4.69e-14	Menarche (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05712126	chr22:29601860	EMID1	-0.51	-6.83	-0.35	3.95e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs1784581	1.000	rs1615717	chr6:162400612	C/T	cg17173639	chr6:162384350	PARK2	-0.81	-14.73	-0.63	3.48e-38	Itch intensity from mosquito bite;
LUSC	cis	rs3092073	0.617	rs3893276	chr20:44591089	G/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.38	-6.04	-0.31	4.04e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg08968635	chr6:28129556	ZNF389	0.45	5.67	0.3	3.06e-8	Parkinson's disease;
LUSC	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg23649088	chr2:200775458	C2orf69	-0.47	-6.31	-0.33	8.98e-10	Schizophrenia;
LUSC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.13	0.32	2.46e-9	Menopause (age at onset);
LUSC	cis	rs6669072	0.565	rs66467457	chr1:91271406	C/T	cg08895590	chr1:91227319	NA	-0.27	-5.81	-0.3	1.48e-8	Cognitive function;
LUSC	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg06784218	chr1:46089804	CCDC17	0.3	5.93	0.31	7.71e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.36e-10	Menopause (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00694512	chr3:126423063	CHCHD6	-0.38	-5.95	-0.31	6.83e-9	Electrocardiographic conduction measures;
LUSC	trans	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	8.76	0.43	9.74e-17	Exhaled nitric oxide output;
LUSC	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.12	-0.32	2.66e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg02493740	chr2:85810744	VAMP5	-0.38	-6.85	-0.35	3.65e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07167398	chr1:182808363	DHX9	-0.49	-7.46	-0.38	7.61e-13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg23093090	chr10:104574429	C10orf26	-0.37	-6.99	-0.36	1.52e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.66	14.83	0.63	1.47e-38	Hemoglobin concentration;
LUSC	cis	rs12493885	0.585	rs10513453	chr3:153640591	G/A	cg17054900	chr3:154042577	DHX36	-0.56	-5.94	-0.31	7.13e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg26677194	chr12:130822605	PIWIL1	0.6	8.96	0.44	2.29e-17	Menopause (age at onset);
LUSC	cis	rs713587	0.571	rs2917916	chr2:25316336	A/C	cg01884057	chr2:25150051	NA	-0.26	-5.72	-0.3	2.31e-8	Body mass index in non-asthmatics;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.57	0.34	1.93e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs34891900	0.507	rs5992088	chr22:18135912	C/T	cg08824373	chr22:18117835	NA	0.38	5.98	0.31	5.73e-9	Sum neutrophil eosinophil counts;
LUSC	cis	rs4964805	0.594	rs954920	chr12:104173310	A/T	cg02344784	chr12:104178138	NT5DC3	0.37	5.9	0.31	8.72e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.71	12.65	0.57	3.08e-30	Prudent dietary pattern;
LUSC	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg04414720	chr1:150670196	GOLPH3L	-0.43	-6.71	-0.34	8.58e-11	Monocyte chemoattractant protein-1 levels;
LUSC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	9.66	0.47	1.26e-19	Height;
LUSC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.78	12.97	0.58	1.89e-31	Longevity;
LUSC	cis	rs1559088	0.501	rs35599132	chr19:33570554	G/A	cg17764715	chr19:33622953	WDR88	0.59	6.61	0.34	1.55e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08219700	chr8:58056026	NA	0.56	7.66	0.39	2.04e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	4.73e-15	Homoarginine levels;
LUSC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	7.95	0.4	2.83e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs68170813	0.605	rs74632724	chr7:107136759	A/G	cg02696742	chr7:106810147	HBP1	-0.67	-9.82	-0.47	3.74e-20	Coronary artery disease;
LUSC	cis	rs3106136	0.967	rs2306802	chr4:95186055	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.16	-0.32	2.11e-9	Capecitabine sensitivity;
LUSC	cis	rs17095355	1.000	rs4565840	chr10:111717140	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.66	-0.39	1.97e-13	Biliary atresia;
LUSC	cis	rs10843647	1.000	rs4931280	chr12:30328012	A/G	cg12718339	chr12:29936407	TMTC1	-0.35	-5.82	-0.3	1.41e-8	Glucose homeostasis traits;
LUSC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.47	0.5	2.21e-22	Hip circumference adjusted for BMI;
LUSC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg03060546	chr3:49711283	APEH	0.7	11.77	0.54	5.47e-27	Resting heart rate;
LUSC	cis	rs977987	0.836	rs34673655	chr16:75323559	T/C	cg04384234	chr16:75411784	CFDP1	-0.37	-5.98	-0.31	5.9e-9	Dupuytren's disease;
LUSC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.52	0.42	5.56e-16	Prudent dietary pattern;
LUSC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	10.91	0.51	6.85e-24	Menopause (age at onset);
LUSC	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.63	10.03	0.48	7.07e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg27094323	chr7:1216898	NA	-0.37	-6.44	-0.33	4.14e-10	Longevity;Endometriosis;
LUSC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg18827107	chr12:86230957	RASSF9	-0.46	-6.96	-0.36	1.81e-11	Major depressive disorder;
LUSC	cis	rs8032315	0.965	rs1894400	chr15:91428955	C/T	cg06330618	chr15:91428456	FES	0.29	6.08	0.32	3.38e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg06640241	chr16:89574553	SPG7	0.92	17.33	0.69	1.86e-48	Multiple myeloma (IgH translocation);
LUSC	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	0.91	17.84	0.7	1.74e-50	Metabolite levels;
LUSC	cis	rs897984	0.553	rs2125293	chr16:30863875	T/C	cg02466173	chr16:30829666	NA	0.55	9.18	0.45	4.72e-18	Dementia with Lewy bodies;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07098151	chr1:229762071	URB2;TAF5L	0.41	6.97	0.36	1.74e-11	Triglycerides;
LUSC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.95	0.36	1.97e-11	Cystic fibrosis severity;
LUSC	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg05966235	chr16:28915196	ATP2A1	0.33	5.8	0.3	1.56e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg18238734	chr12:26986119	ITPR2	0.47	6.91	0.35	2.46e-11	Triglycerides;
LUSC	cis	rs9513627	0.749	rs73556143	chr13:100116907	G/A	cg25919922	chr13:100150906	NA	-0.74	-6.22	-0.32	1.52e-9	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg13560548	chr3:10150139	C3orf24	0.48	7.13	0.36	6.15e-12	Alzheimer's disease;
LUSC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg16624210	chr5:671434	TPPP	0.5	6.38	0.33	6.07e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg05026186	chr5:148520876	ABLIM3	-0.39	-6.14	-0.32	2.34e-9	Breast cancer;
LUSC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg26566898	chr11:117069891	TAGLN	0.49	8.97	0.44	2.16e-17	Blood protein levels;
LUSC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg25456477	chr12:86230367	RASSF9	0.33	5.71	0.3	2.53e-8	Major depressive disorder;
LUSC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.14	0.41	7.76e-15	Bipolar disorder;
LUSC	cis	rs4363385	0.510	rs7543689	chr1:153046803	A/T	cg25856811	chr1:152973957	SPRR3	-0.38	-6.23	-0.32	1.43e-9	Inflammatory skin disease;
LUSC	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-6.85	-0.35	3.46e-11	Blood metabolite levels;
LUSC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg14092988	chr3:52407081	DNAH1	0.31	5.97	0.31	5.97e-9	Bipolar disorder;
LUSC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg18765753	chr7:1198926	ZFAND2A	0.46	8.24	0.41	3.98e-15	Longevity;Endometriosis;
LUSC	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	7.48	0.38	6.55e-13	Height;
LUSC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg02487422	chr3:49467188	NICN1	0.48	7.63	0.39	2.46e-13	Resting heart rate;
LUSC	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg03342759	chr3:160939853	NMD3	-0.52	-8.74	-0.43	1.16e-16	Morning vs. evening chronotype;
LUSC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg12564285	chr5:131593104	PDLIM4	0.35	6.47	0.33	3.46e-10	Blood metabolite levels;
LUSC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg17294928	chr15:75287854	SCAMP5	-0.77	-10.2	-0.49	1.91e-21	Blood trace element (Zn levels);
LUSC	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-1.0	-18.99	-0.72	4.7e-55	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg19622623	chr12:86230825	RASSF9	0.4	5.84	0.3	1.21e-8	Major depressive disorder;
LUSC	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Bladder cancer;
LUSC	cis	rs2963155	1.000	rs2963155	chr5:142756004	C/T	cg17617527	chr5:142782415	NR3C1	-0.49	-7.09	-0.36	8.17e-12	Breast cancer;
LUSC	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg13010199	chr12:38710504	ALG10B	0.66	10.18	0.49	2.18e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs17604090	0.887	rs7795109	chr7:29666244	G/A	cg19413766	chr7:29689036	LOC646762	-0.62	-7.77	-0.39	9.47e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24739457	chr1:205821442	NA	0.35	6.02	0.31	4.47e-9	Menarche (age at onset);
LUSC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg26513180	chr16:89883248	FANCA	0.9	17.31	0.69	2.23e-48	Vitiligo;
LUSC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg21724239	chr8:58056113	NA	0.57	6.53	0.34	2.39e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4730250	0.669	rs6466160	chr7:106793175	T/A	cg02696742	chr7:106810147	HBP1	0.64	9.04	0.44	1.32e-17	Osteoarthritis;
LUSC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg02475777	chr4:1388615	CRIPAK	-0.41	-6.08	-0.32	3.34e-9	Obesity-related traits;
LUSC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg07636037	chr3:49044803	WDR6	0.45	6.4	0.33	5.13e-10	Resting heart rate;
LUSC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg25801113	chr15:45476975	SHF	-0.32	-6.43	-0.33	4.34e-10	Uric acid levels;
LUSC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.92	0.44	3.02e-17	Motion sickness;
LUSC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.25	0.52	4.04e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.71	-0.43	1.46e-16	Total cholesterol levels;
LUSC	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.65	8.81	0.43	6.91e-17	High light scatter reticulocyte count;
LUSC	trans	rs7951105	0.867	rs12287031	chr11:39257902	A/G	cg24085930	chr3:21832523	NA	0.48	6.02	0.31	4.72e-9	Free thyroxine concentration;
LUSC	cis	rs9398803	0.865	rs9385401	chr6:126789472	C/T	cg19875578	chr6:126661172	C6orf173	0.42	6.19	0.32	1.78e-9	Male-pattern baldness;
LUSC	cis	rs865483	0.895	rs1016678	chr17:35874192	A/G	cg06716730	chr17:35851459	DUSP14	0.26	5.74	0.3	2.09e-8	Monocyte count;
LUSC	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg10167463	chr7:75959203	YWHAG	-0.66	-10.07	-0.48	5.33e-21	Multiple sclerosis;
LUSC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-6.17	-0.32	1.99e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg24812749	chr6:127587940	RNF146	0.7	9.92	0.48	1.75e-20	Breast cancer;
LUSC	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.42	-0.38	9.85e-13	Mood instability;
LUSC	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-1.13	-18.66	-0.71	1.01e-53	Corneal structure;
LUSC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg03146154	chr1:46216737	IPP	0.56	8.5	0.42	6.44e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg13852791	chr20:30311386	BCL2L1	0.75	8.59	0.43	3.47e-16	Mean corpuscular hemoglobin;
LUSC	trans	rs7715474	0.656	rs7734839	chr5:120079467	T/C	cg12284098	chr8:1993893	MYOM2	0.32	5.99	0.31	5.3300000000000004e-09	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg09998033	chr7:158218633	PTPRN2	-0.6	-9.56	-0.46	2.64e-19	Obesity-related traits;
LUSC	cis	rs11645898	0.935	rs17603936	chr16:72169002	C/A	cg14768367	chr16:72042858	DHODH	-0.65	-7.11	-0.36	7.28e-12	Blood protein levels;
LUSC	cis	rs10761482	0.906	rs2219534	chr10:62094925	G/A	cg18175470	chr10:62150864	ANK3	-0.45	-6.57	-0.34	1.95e-10	Schizophrenia;
LUSC	cis	rs7771547	0.519	rs12190911	chr6:36378487	C/T	cg07856975	chr6:36356162	ETV7	-0.42	-6.37	-0.33	6.21e-10	Platelet distribution width;
LUSC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg05043794	chr9:111880884	C9orf5	-0.39	-8.23	-0.41	4.14e-15	Menarche (age at onset);
LUSC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg06618935	chr21:46677482	NA	-0.4	-8.06	-0.4	1.41e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6747952	0.866	rs6726348	chr2:239084119	C/T	cg17459225	chr2:239074497	NA	0.33	5.77	0.3	1.83e-8	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg05283184	chr6:79620031	NA	-0.57	-11.95	-0.55	1.16e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg13939156	chr17:80058883	NA	0.34	6.67	0.34	1.09e-10	Life satisfaction;
LUSC	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg12927641	chr6:109611667	NA	-0.35	-5.87	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.23e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-7.05	-0.36	1.03e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg25174290	chr11:3078921	CARS	-0.42	-6.16	-0.32	2.11e-9	Calcium levels;
LUSC	cis	rs727505	0.908	rs56155943	chr7:124606346	T/G	cg23710748	chr7:124431027	NA	-0.39	-6.83	-0.35	4e-11	Lewy body disease;
LUSC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg18681998	chr4:17616180	MED28	0.83	15.51	0.65	2.97e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg04064380	chr11:117688259	NA	-0.43	-5.66	-0.3	3.25e-8	Myopia;
LUSC	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.99	-18.53	-0.71	3.22e-53	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs16976116	0.803	rs28590021	chr15:55490993	C/T	cg11288833	chr15:55489084	RSL24D1	0.5	5.98	0.31	5.65e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg12179176	chr11:130786555	SNX19	0.59	8.9	0.44	3.7e-17	Schizophrenia;
LUSC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.95	-0.36	1.93e-11	Blood metabolite levels;
LUSC	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg13798780	chr7:105162888	PUS7	0.56	6.12	0.32	2.55e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7106204	0.534	rs4923167	chr11:24274441	G/T	ch.11.24196551F	chr11:24239977	NA	0.72	5.91	0.31	8.23e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.66	11.24	0.52	4.38e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs73058052	0.935	rs3745473	chr19:50086626	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.5	5.8	0.3	1.56e-8	Fibrinogen levels;
LUSC	trans	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg26043149	chr18:55253948	FECH	0.5	7.45	0.38	8.1e-13	Bone mineral density;
LUSC	trans	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg14791747	chr16:20752902	THUMPD1	0.72	9.58	0.46	2.35e-19	Cognitive test performance;
LUSC	cis	rs5771069	0.931	rs137864	chr22:50446988	C/T	cg27467552	chr22:50353597	PIM3	-0.43	-7.17	-0.37	4.84e-12	Ulcerative colitis;
LUSC	cis	rs13401104	0.754	rs10929175	chr2:237117204	A/C	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg17330251	chr7:94953956	PON1	-0.36	-5.84	-0.3	1.22e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg01620082	chr3:125678407	NA	-0.72	-6.85	-0.35	3.64e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04362095	chr11:63592001	C11orf84	-0.55	-8.53	-0.42	5.18e-16	Pulse pressure;
LUSC	cis	rs6700896	0.500	rs6690625	chr1:66077590	T/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	6.03	0.31	4.42e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg17848003	chr1:3704513	LRRC47	0.32	5.83	0.3	1.32e-8	Red cell distribution width;
LUSC	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-0.94	-18.4	-0.71	1.04e-52	Headache;
LUSC	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg19508488	chr2:152266495	RIF1	-0.52	-7.36	-0.37	1.46e-12	Lung cancer;
LUSC	cis	rs4853525	0.923	rs7570775	chr2:191729154	T/G	cg11845111	chr2:191398756	TMEM194B	-0.39	-5.76	-0.3	1.87e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	trans	rs11743006	0.626	rs1072158	chr5:136504666	A/C	cg07379741	chr17:7311030	NLGN2	0.42	6.34	0.33	7.6e-10	Mathematical ability;
LUSC	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	11.83	0.54	3.45e-27	Colorectal cancer;
LUSC	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.3	-0.37	2.1e-12	Bipolar disorder;
LUSC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg14895029	chr7:2775587	GNA12	-0.42	-6.55	-0.34	2.18e-10	Height;
LUSC	cis	rs72960926	0.744	rs72950506	chr6:74895922	A/G	cg03266952	chr6:74778945	NA	-0.76	-6.05	-0.31	3.85e-9	Metabolite levels (MHPG);
LUSC	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg00310523	chr12:86230176	RASSF9	0.4	7.31	0.37	1.94e-12	Major depressive disorder;
LUSC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.8	0.6	1.3600000000000001e-34	Chronic sinus infection;
LUSC	trans	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.66	-0.34	1.16e-10	Endometrial cancer;
LUSC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg12432903	chr7:1882776	MAD1L1	-0.37	-5.89	-0.31	9.45e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg21770322	chr7:97807741	LMTK2	0.39	6.89	0.35	2.72e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg06530960	chr19:49140787	SEC1;DBP	-0.55	-7.57	-0.38	3.76e-13	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg20283391	chr11:68216788	NA	-0.61	-8.43	-0.42	1.04e-15	Total body bone mineral density;
LUSC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.62	0.34	1.44e-10	Aortic root size;
LUSC	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.75	-0.35	6.42e-11	Triglycerides;
LUSC	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-5.93	-0.31	7.65e-9	Breast cancer;
LUSC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.92	0.31	7.89e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs17301259	0.729	rs2718396	chr7:88377422	T/A	cg21771463	chr3:44626400	ZNF660	-0.39	-6.21	-0.32	1.62e-9	Heschl's gyrus morphology;
LUSC	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg15423357	chr2:25149977	NA	0.4	7.74	0.39	1.16e-13	Body mass index in non-asthmatics;
LUSC	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.92	-0.35	2.29e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11608355	0.508	rs11066411	chr12:109804194	A/G	cg19025524	chr12:109796872	NA	-0.5	-8.86	-0.44	4.73e-17	Neuroticism;
LUSC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg13319975	chr6:146136371	FBXO30	0.45	6.8	0.35	4.81e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8114671	0.967	rs1577924	chr20:33784288	C/G	cg07148914	chr20:33460835	GGT7	-0.44	-6.63	-0.34	1.35e-10	Height;
LUSC	cis	rs7246967	0.673	rs12984634	chr19:22833744	C/T	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs7607369	0.559	rs4674343	chr2:219660346	C/T	cg02176678	chr2:219576539	TTLL4	0.53	9.4	0.46	9.25e-19	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	trans	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg04995722	chr7:26192034	NFE2L3	-0.43	-6.71	-0.34	8.55e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg18225595	chr11:63971243	STIP1	0.49	6.1	0.32	2.88e-9	Mean platelet volume;
LUSC	trans	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07923666	chr12:49932857	KCNH3	-0.53	-6.64	-0.34	1.24e-10	Resting heart rate;
LUSC	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg25174290	chr11:3078921	CARS	-0.4	-5.88	-0.31	9.72e-9	Calcium levels;
LUSC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.16	0.32	2.14e-9	Menopause (age at onset);
LUSC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg07507251	chr3:52567010	NT5DC2	0.37	7.53	0.38	4.66e-13	Electroencephalogram traits;
LUSC	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg25482853	chr8:67687455	SGK3	1.18	16.97	0.68	5.1e-47	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06636551	chr8:101224915	SPAG1	-0.44	-8.03	-0.4	1.63e-14	Atrioventricular conduction;
LUSC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg05585544	chr11:47624801	NA	-0.36	-6.55	-0.34	2.2e-10	Subjective well-being;
LUSC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg08270630	chr22:50330655	NA	-0.44	-6.67	-0.34	1.05e-10	Schizophrenia;
LUSC	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.22	-15.94	-0.66	6.41e-43	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg05347473	chr6:146136440	FBXO30	0.49	8.16	0.41	6.84e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg00191853	chr8:101177733	SPAG1	-0.38	-6.41	-0.33	4.87e-10	Atrioventricular conduction;
LUSC	cis	rs72615157	0.539	rs4729575	chr7:99686873	G/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.48	6.6	0.34	1.61e-10	Lung function (FEV1/FVC);
LUSC	cis	rs1983170	0.808	rs1546449	chr1:92017391	G/A	cg25838465	chr1:92012736	NA	0.43	5.96	0.31	6.48e-9	Eosinophil percentage of white cells;
LUSC	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.81	0.51	1.43e-23	Morning vs. evening chronotype;
LUSC	cis	rs977987	0.843	rs35737321	chr16:75439185	A/T	cg04384234	chr16:75411784	CFDP1	-0.44	-7.05	-0.36	1.03e-11	Dupuytren's disease;
LUSC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	0.96	13.66	0.6	4.88e-34	Primary sclerosing cholangitis;
LUSC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg24675658	chr1:53192096	ZYG11B	0.61	9.64	0.47	1.5e-19	Monocyte count;
LUSC	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg01579765	chr21:45077557	HSF2BP	0.42	8.7	0.43	1.49e-16	Mean corpuscular volume;
LUSC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg07936489	chr17:37558343	FBXL20	-0.71	-10.09	-0.48	4.59e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-7.18	-0.37	4.68e-12	Resting heart rate;
LUSC	cis	rs6084875	0.840	rs2025118	chr20:4723691	C/T	cg07258627	chr20:4721683	PRNT	-0.35	-6.21	-0.32	1.57e-9	Systemic lupus erythematosus;
LUSC	trans	rs4714291	0.963	rs4714292	chr6:40003679	A/C	cg02267698	chr19:7991119	CTXN1	0.47	6.66	0.34	1.15e-10	Strep throat;
LUSC	cis	rs4588572	0.643	rs1560197	chr5:77768302	T/C	cg11547950	chr5:77652471	NA	-0.52	-7.52	-0.38	5.01e-13	Triglycerides;
LUSC	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg09699651	chr6:150184138	LRP11	0.43	6.28	0.33	1.04e-9	Testicular germ cell tumor;
LUSC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg16447950	chr5:562315	NA	-0.55	-7.67	-0.39	1.88e-13	Lung disease severity in cystic fibrosis;
LUSC	cis	rs870825	0.581	rs28602720	chr4:185630598	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.06	0.58	8.67e-32	Blood protein levels;
LUSC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.17	-0.41	6.51e-15	Chronic sinus infection;
LUSC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg02475777	chr4:1388615	CRIPAK	0.4	6.07	0.32	3.53e-9	Obesity-related traits;
LUSC	trans	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.21	-0.32	1.57e-9	Depression;
LUSC	cis	rs4566357	0.964	rs6436648	chr2:227923004	C/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.75	-0.3	1.97e-8	Coronary artery disease;
LUSC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24549020	chr5:56110836	MAP3K1	0.48	5.66	0.3	3.3e-8	Initial pursuit acceleration;
LUSC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08439880	chr3:133502540	NA	-0.34	-6.08	-0.32	3.32e-9	Iron status biomarkers;
LUSC	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg22681709	chr2:178499509	PDE11A	-0.45	-6.65	-0.34	1.19e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg18811423	chr2:55921094	PNPT1	-0.63	-8.56	-0.42	4.12e-16	Metabolic syndrome;
LUSC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.55	0.42	4.56e-16	Motion sickness;
LUSC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4700695	0.719	rs27586	chr5:65445873	G/A	cg21114390	chr5:65439923	SFRS12	-0.64	-9.12	-0.45	7.01e-18	Facial morphology (factor 19);
LUSC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21862992	chr11:68658383	NA	-0.51	-8.29	-0.41	2.89e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6460942	0.908	rs6978367	chr7:12232347	A/G	cg06484146	chr7:12443880	VWDE	-0.56	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg27633287	chr12:130766243	NA	0.32	5.74	0.3	2.11e-8	Menopause (age at onset);
LUSC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg13275176	chr2:97534450	SEMA4C	0.5	6.11	0.32	2.79e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg01966878	chr4:90757139	SNCA	-0.34	-5.85	-0.3	1.17e-8	Dementia with Lewy bodies;
LUSC	cis	rs1256061	0.646	rs1256059	chr14:64710417	A/G	cg23250157	chr14:64679961	SYNE2	0.32	5.82	0.3	1.37e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.25	-0.59	1.75e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg05283184	chr6:79620031	NA	-0.58	-12.14	-0.55	2.34e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.49	-6.93	-0.35	2.16e-11	Mean platelet volume;
LUSC	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg24154853	chr7:158122151	PTPRN2	-0.42	-8.19	-0.41	5.57e-15	Calcium levels;
LUSC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg18681998	chr4:17616180	MED28	0.85	15.66	0.65	8.11e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg16512390	chr1:228756714	NA	0.73	9.67	0.47	1.19e-19	Chronic lymphocytic leukemia;
LUSC	cis	rs5769707	0.681	rs6009803	chr22:50051007	A/G	cg05373962	chr22:49881684	NA	-0.4	-8.25	-0.41	3.6e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg11416102	chr8:651193	ERICH1	-0.75	-6.76	-0.35	6.2e-11	IgG glycosylation;
LUSC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg18681998	chr4:17616180	MED28	0.87	16.62	0.67	1.22e-45	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg09365446	chr1:150670422	GOLPH3L	-0.43	-6.46	-0.33	3.79e-10	Tonsillectomy;
LUSC	trans	rs4664304	0.629	rs3828324	chr2:160834991	C/T	cg05371993	chr16:1458494	UNKL	-0.41	-6.07	-0.32	3.57e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.62	0.54	1.85e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg22681709	chr2:178499509	PDE11A	-0.44	-6.51	-0.34	2.81e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg18758796	chr5:131593413	PDLIM4	0.42	6.74	0.35	6.97e-11	Breast cancer;
LUSC	cis	rs1953600	0.870	rs2573353	chr10:81940917	A/C	cg00277334	chr10:82204260	NA	-0.46	-7.27	-0.37	2.63e-12	Sarcoidosis;
LUSC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg08270630	chr22:50330655	NA	0.4	5.9	0.31	9.13e-9	Schizophrenia;
LUSC	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.69e-9	Response to antipsychotic treatment;
LUSC	trans	rs10851478	0.872	rs12902960	chr15:49925041	T/C	cg23074453	chr15:44487924	FRMD5	-0.33	-6.08	-0.32	3.26e-9	Oral cavity cancer;
LUSC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.87	-0.35	3.23e-11	Menopause (age at onset);
LUSC	trans	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg00321850	chr1:175162397	KIAA0040	-0.45	-7.81	-0.39	7.35e-14	Alcohol dependence;
LUSC	cis	rs897984	0.647	rs7203999	chr16:31017554	T/C	cg02466173	chr16:30829666	NA	0.54	10.27	0.49	1.07e-21	Dementia with Lewy bodies;
LUSC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-6.06	-0.31	3.7e-9	Personality dimensions;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.34	-7.73	-0.39	1.26e-13	Lymphocyte counts;
LUSC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg13902645	chr11:5959945	NA	-0.55	-8.6	-0.43	3.15e-16	DNA methylation (variation);
LUSC	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.27	-0.32	1.1e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg19622623	chr12:86230825	RASSF9	0.4	5.75	0.3	2.02e-8	Major depressive disorder;
LUSC	cis	rs5167	0.566	rs934427	chr19:45478816	T/G	cg25746394	chr19:45450501	APOC2	0.31	5.87	0.31	1.03e-8	Blood protein levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07940793	chr17:79603854	NPLOC4	-0.47	-6.42	-0.33	4.59e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12474201	0.619	rs17821827	chr2:46918682	C/T	cg06386533	chr2:46925753	SOCS5	0.64	7.81	0.39	7.65e-14	Height;
LUSC	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg18806716	chr10:30721971	MAP3K8	0.62	10.24	0.49	1.45e-21	Inflammatory bowel disease;
LUSC	cis	rs2857891	0.817	rs2638096	chr11:6977916	T/A	cg04053776	chr11:6947353	ZNF215	0.42	5.76	0.3	1.94e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.14	-0.32	2.38e-9	Neutrophil percentage of white cells;
LUSC	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.45	5.76	0.3	1.93e-8	Renal function-related traits (BUN);
LUSC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06028605	chr16:24865363	SLC5A11	0.66	9.99	0.48	9.87e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.89	-11.16	-0.52	8.48e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg17425144	chr1:10567563	PEX14	0.64	13.54	0.6	1.36e-33	Breast cancer;
LUSC	cis	rs4072705	0.967	rs4287038	chr9:127369679	A/G	cg13476313	chr9:127244764	NR5A1	-0.29	-5.71	-0.3	2.5e-8	Menarche (age at onset);
LUSC	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg12826209	chr6:26865740	GUSBL1	0.68	7.53	0.38	4.76e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg15133208	chr4:90757351	SNCA	-0.53	-8.19	-0.41	5.6e-15	Neuroticism;
LUSC	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg19468946	chr17:37922297	IKZF3	-0.44	-6.87	-0.35	3.1e-11	Lymphocyte counts;
LUSC	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg06636001	chr8:8085503	FLJ10661	0.54	7.93	0.4	3.32e-14	Neuroticism;
LUSC	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg21918786	chr6:109611834	NA	-0.39	-6.77	-0.35	5.66e-11	Reticulocyte fraction of red cells;
LUSC	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg15704280	chr7:45808275	SEPT13	-0.46	-6.34	-0.33	7.57e-10	HDL cholesterol;
LUSC	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.53	0.57	8.96e-30	Height;
LUSC	trans	rs2392780	0.536	rs377649	chr8:128337241	G/T	cg10195415	chr17:73887371	TRIM65	0.42	6.67	0.34	1.08e-10	Breast cancer (early onset);
LUSC	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg25233709	chr10:116636983	FAM160B1	0.37	6.56	0.34	2.09e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs12412942	1.000	rs12412942	chr10:2357702	C/T	cg08626939	chr2:227656417	IRS1	0.39	5.95	0.31	6.96e-9	Schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg25261764	chr18:55288998	NARS	0.41	6.55	0.34	2.19e-10	Triglycerides;
LUSC	cis	rs1891275	0.515	rs7092745	chr10:93483820	C/T	cg07889827	chr10:93443413	NA	-0.39	-8.93	-0.44	2.81e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.77e-22	Eye color traits;
LUSC	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg00012203	chr2:219082015	ARPC2	0.81	13.69	0.6	3.57e-34	Colorectal cancer;
LUSC	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg03585969	chr10:35415529	CREM	0.64	9.51	0.46	4e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10144321	0.810	rs3742387	chr14:100847930	C/T	cg14882082	chr14:100845427	WDR25	-0.41	-7.92	-0.4	3.63e-14	Menarche (age at onset);
LUSC	cis	rs701145	0.585	rs1727953	chr3:153871392	G/T	cg17054900	chr3:154042577	DHX36	0.69	6.76	0.35	6.15e-11	Coronary artery disease;
LUSC	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg05110241	chr16:68378359	PRMT7	-0.65	-6.79	-0.35	5.13e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6785206	1.000	rs6785206	chr3:128412024	A/G	cg16766828	chr3:128327626	NA	-0.69	-7.64	-0.39	2.34e-13	Lymphocyte percentage of white cells;
LUSC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.4	0.33	5.33e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.09e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs73200209	0.744	rs56911341	chr12:116682872	A/C	cg01776926	chr12:116560359	MED13L	-0.49	-5.98	-0.31	5.81e-9	Total body bone mineral density;
LUSC	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg04352962	chr1:209979756	IRF6	0.52	5.77	0.3	1.83e-8	Coronary artery disease;
LUSC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg09455208	chr3:40491958	NA	0.57	10.34	0.49	6.55e-22	Renal cell carcinoma;
LUSC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-7.56	-0.38	3.87e-13	Personality dimensions;
LUSC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.24	-0.41	3.91e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	cis	rs6840360	0.806	rs11932383	chr4:152716136	T/C	cg22705602	chr4:152727874	NA	0.27	5.73	0.3	2.24e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2200578	1.000	rs2200578	chr2:99876244	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.57	6.55	0.34	2.16e-10	IgG glycosylation;
LUSC	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg26384229	chr12:38710491	ALG10B	0.93	15.61	0.65	1.21e-41	Bladder cancer;
LUSC	cis	rs16867335	1.000	rs76934807	chr2:181488585	T/A	cg23363182	chr2:181467187	NA	-0.47	-5.92	-0.31	7.92e-9	Survival in rectal cancer;
LUSC	trans	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg07817883	chr1:32538562	TMEM39B	0.56	6.55	0.34	2.17e-10	Monocyte percentage of white cells;
LUSC	cis	rs12541635	0.966	rs7812766	chr8:107057033	G/A	cg10147462	chr8:107024639	NA	0.55	9.92	0.48	1.69e-20	Age of smoking initiation;
LUSC	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg04691961	chr3:161091175	C3orf57	0.34	5.86	0.31	1.12e-8	Morning vs. evening chronotype;
LUSC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg15691649	chr6:25882328	NA	-0.39	-6.41	-0.33	4.84e-10	Blood metabolite levels;
LUSC	cis	rs977987	0.806	rs34996006	chr16:75479434	A/G	cg03315344	chr16:75512273	CHST6	0.5	9.67	0.47	1.17e-19	Dupuytren's disease;
LUSC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg18477163	chr1:228402036	OBSCN	0.57	9.59	0.46	2.12e-19	Diastolic blood pressure;
LUSC	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-7.1	-0.36	7.33e-12	Myopia (pathological);
LUSC	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.99	-20.86	-0.75	1.83e-62	Ulcerative colitis;
LUSC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg25258033	chr6:167368657	RNASET2	0.42	6.37	0.33	6.09e-10	Crohn's disease;
LUSC	cis	rs7095944	0.644	rs4962694	chr10:126436717	G/T	cg08799069	chr10:126477246	METTL10	-0.41	-6.27	-0.32	1.12e-9	Asthma;
LUSC	cis	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg05299278	chr17:33885742	SLFN14	0.29	6.33	0.33	7.72e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs62400317	0.762	rs72865923	chr6:44878942	T/G	cg20913747	chr6:44695427	NA	-0.48	-7.44	-0.38	8.79e-13	Total body bone mineral density;
LUSC	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg04362960	chr10:104952993	NT5C2	0.62	9.8	0.47	4.43e-20	Arsenic metabolism;
LUSC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.27	-0.49	1.06e-21	Gut microbiome composition (summer);
LUSC	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs36093844	0.898	rs11512932	chr11:85591130	T/G	cg25872744	chr11:85566296	CCDC83	-0.42	-6.2	-0.32	1.64e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs9653442	0.545	rs2009094	chr2:100765077	G/A	cg22139774	chr2:100720529	AFF3	-0.42	-7.25	-0.37	2.9e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-6.95	-0.36	1.92e-11	Systolic blood pressure;
LUSC	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg18477163	chr1:228402036	OBSCN	0.63	12.25	0.56	9.69e-29	Diastolic blood pressure;
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg22907277	chr7:1156413	C7orf50	0.51	7.53	0.38	4.75e-13	Longevity;Endometriosis;
LUSC	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg23711669	chr6:146136114	FBXO30	0.85	15.19	0.64	5.67e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg17467752	chr17:38218738	THRA	0.41	5.69	0.3	2.73e-8	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg06494592	chr3:125709126	NA	-0.52	-5.93	-0.31	7.44e-9	Blood pressure (smoking interaction);
LUSC	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.68	-10.64	-0.5	5.85e-23	Corneal astigmatism;
LUSC	trans	rs62238980	0.614	rs75805646	chr22:32441396	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg26384229	chr12:38710491	ALG10B	0.75	11.9	0.55	1.87e-27	Morning vs. evening chronotype;
LUSC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg11752832	chr7:134001865	SLC35B4	0.57	8.76	0.43	1.02e-16	Mean platelet volume;
LUSC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg06138931	chr13:21896616	NA	0.46	8.29	0.41	2.72e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs11214589	0.651	rs11214595	chr11:113259658	G/T	cg14159747	chr11:113255604	NA	0.29	7.72	0.39	1.37e-13	Neuroticism;
LUSC	cis	rs6546550	0.935	rs1377995	chr2:70064155	C/G	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.17	-0.37	4.87e-12	Prevalent atrial fibrillation;
LUSC	cis	rs467650	0.529	rs2549200	chr5:97996348	T/C	cg03885343	chr5:98108198	RGMB	0.32	5.76	0.3	1.95e-8	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs9309473	0.660	rs11686541	chr2:73704475	C/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.51	-0.34	2.69e-10	Metabolite levels;
LUSC	trans	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18876405	chr7:65276391	NA	0.48	7.55	0.38	4.22e-13	Corneal structure;
LUSC	cis	rs9341808	0.754	rs3805907	chr6:80973665	A/G	cg08355045	chr6:80787529	NA	-0.55	-9.7	-0.47	9.42e-20	Sitting height ratio;
LUSC	trans	rs3960554	0.529	rs7793844	chr7:75883147	C/T	cg19862616	chr7:65841803	NCRNA00174	0.59	7.36	0.37	1.46e-12	Eotaxin levels;
LUSC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg23625390	chr15:77176239	SCAPER	0.51	7.89	0.4	4.23e-14	Blood metabolite levels;
LUSC	cis	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg17187183	chr4:55093834	PDGFRA	0.38	5.72	0.3	2.31e-8	Corneal astigmatism;
LUSC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg17892150	chr10:133769511	PPP2R2D	0.67	9.52	0.46	3.59e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs977987	0.806	rs11640674	chr16:75394944	A/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.85	-0.35	3.47e-11	Dupuytren's disease;
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-8.48	-0.42	7.32e-16	Lymphocyte counts;
LUSC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.76	-0.3	1.93e-8	Depression;
LUSC	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg27284194	chr4:1044797	NA	0.58	8.7	0.43	1.57e-16	Recombination rate (females);
LUSC	cis	rs4285028	0.747	rs9824235	chr3:121432177	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-12.77	-0.57	1.07e-30	Multiple sclerosis;
LUSC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.74	0.43	1.15e-16	Lung cancer;
LUSC	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg16482183	chr6:26056742	HIST1H1C	1.0	12.85	0.58	5.41e-31	Iron status biomarkers;
LUSC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg18402987	chr7:1209562	NA	0.72	7.69	0.39	1.67e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs10788264	0.621	rs9633733	chr10:124056546	A/G	cg09507567	chr10:124027408	NA	-0.45	-7.76	-0.39	1.02e-13	Total body bone mineral density;
LUSC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg09034736	chr1:150693464	HORMAD1	0.43	5.92	0.31	7.89e-9	Melanoma;
LUSC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.09e-18	Menopause (age at onset);
LUSC	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	8.09	0.4	1.13e-14	Iron status biomarkers;
LUSC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-10.96	-0.51	4.24e-24	Menarche (age at onset);
LUSC	cis	rs2147959	0.882	rs4653551	chr1:228627913	A/G	cg18477163	chr1:228402036	OBSCN	0.44	6.21	0.32	1.61e-9	Adult asthma;
LUSC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg19257562	chr1:2043853	PRKCZ	0.33	6.6	0.34	1.64e-10	Height;
LUSC	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg05527609	chr1:210001259	C1orf107	0.85	11.3	0.53	2.73e-25	Orofacial clefts;
LUSC	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg18683606	chr7:100471612	SRRT	0.45	6.0	0.31	5.05e-9	Resting heart rate;
LUSC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.97	0.36	1.74e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4713675	0.546	rs3818521	chr6:33657246	C/T	cg14003231	chr6:33640908	ITPR3	0.32	6.1	0.32	2.98e-9	Plateletcrit;
LUSC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg06618935	chr21:46677482	NA	-0.39	-7.73	-0.39	1.29e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg05501817	chr11:14380813	RRAS2	-0.58	-9.0	-0.44	1.71e-17	Sense of smell;
LUSC	cis	rs9309473	1.000	rs6736866	chr2:73661986	C/G	cg20560298	chr2:73613845	ALMS1	-0.52	-7.47	-0.38	7.16e-13	Metabolite levels;
LUSC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05776053	chr2:74358815	NA	0.42	6.61	0.34	1.5e-10	Gestational age at birth (maternal effect);
LUSC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg21724239	chr8:58056113	NA	0.74	7.94	0.4	3.19e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6489882	0.867	rs7316586	chr12:113365828	C/T	cg20102336	chr12:113376681	OAS3	-0.4	-5.7	-0.3	2.59e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs7539409	0.915	rs6576945	chr1:84252882	A/G	cg10977910	chr1:84465055	TTLL7	0.73	5.85	0.3	1.19e-8	Alzheimer's disease;
LUSC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg11062466	chr8:58055876	NA	0.73	8.62	0.43	2.79e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs698813	0.604	rs12712916	chr2:44482099	A/C	cg00619915	chr2:44497795	NA	-0.52	-7.31	-0.37	1.95e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg24397884	chr7:158709396	WDR60	-0.78	-8.36	-0.42	1.67e-15	Height;
LUSC	cis	rs7424096	0.515	rs17497343	chr2:37173032	T/C	cg14987922	chr2:37194071	STRN	0.56	8.17	0.41	6.63e-15	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7923452	0.938	rs34930615	chr10:30761051	G/A	cg18806716	chr10:30721971	MAP3K8	0.57	6.89	0.35	2.78e-11	Itch intensity from mosquito bite;
LUSC	cis	rs6499755	0.932	rs12928690	chr16:55343565	C/T	cg02859129	chr16:55357253	IRX6	0.36	6.08	0.32	3.33e-9	Hypospadias;
LUSC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.51	7.2	0.37	4.01e-12	Tuberculosis;
LUSC	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg00999904	chr2:3704751	ALLC	-0.44	-6.76	-0.35	6.12e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg24562669	chr7:97807699	LMTK2	0.36	6.29	0.33	9.85e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.82	-15.21	-0.64	4.55e-40	Dental caries;
LUSC	cis	rs11605924	0.901	rs7105751	chr11:45856973	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.5	-7.4	-0.38	1.13e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg13453750	chr1:205783389	SLC41A1	-0.29	-5.85	-0.31	1.14e-8	Menarche (age at onset);
LUSC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg15017067	chr4:17643749	FAM184B	0.35	5.76	0.3	1.86e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg06096015	chr1:231504339	EGLN1	0.58	10.42	0.5	3.38e-22	Hemoglobin concentration;
LUSC	cis	rs13401104	0.796	rs11894483	chr2:237114619	T/C	cg19324714	chr2:237145437	ASB18	0.42	5.71	0.3	2.46e-8	Educational attainment;
LUSC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg01416388	chr22:39784598	NA	-0.46	-7.8	-0.39	7.98e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.13	0.58	4.77e-32	Prudent dietary pattern;
LUSC	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.81	12.05	0.55	5.27e-28	Corneal astigmatism;
LUSC	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg17127132	chr2:85788382	GGCX	0.42	6.06	0.31	3.62e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg26338869	chr17:61819248	STRADA	0.4	5.77	0.3	1.81e-8	Prudent dietary pattern;
LUSC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg19812747	chr11:111475976	SIK2	-0.52	-7.6	-0.38	2.92e-13	Primary sclerosing cholangitis;
LUSC	trans	rs61931739	0.533	rs7970871	chr12:33917301	G/A	cg13010199	chr12:38710504	ALG10B	0.4	6.03	0.31	4.34e-9	Morning vs. evening chronotype;
LUSC	trans	rs6869502	0.871	rs13354207	chr5:110151791	C/G	cg08170757	chr19:48867271	TMEM143;SYNGR4	-0.45	-5.95	-0.31	6.69e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.33	0.62	1.18e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	13.44	0.59	3.37e-33	Platelet count;
LUSC	cis	rs920590	0.796	rs7820520	chr8:19634864	A/G	cg03894339	chr8:19674705	INTS10	-0.43	-5.85	-0.3	1.17e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg27165867	chr14:105738592	BRF1	-0.51	-7.25	-0.37	2.86e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10465746	0.967	rs1570690	chr1:84377515	G/T	cg10977910	chr1:84465055	TTLL7	0.41	5.9	0.31	8.91e-9	Obesity-related traits;
LUSC	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg13390004	chr1:15929781	NA	0.41	6.9	0.35	2.66e-11	Systolic blood pressure;
LUSC	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.73	-0.3	2.25e-8	Depression;
LUSC	cis	rs6542838	0.673	rs1949424	chr2:99468341	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.47	6.3	0.33	9.25e-10	Fear of minor pain;
LUSC	cis	rs12476592	0.602	rs262504	chr2:63861235	C/G	cg10828910	chr2:63850056	LOC388955	0.49	5.78	0.3	1.71e-8	Childhood ear infection;
LUSC	cis	rs11979158	0.503	rs10256393	chr7:55027846	A/C	cg23757825	chr7:55092271	EGFR	0.62	8.14	0.41	7.99e-15	Glioma;
LUSC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.56	-8.32	-0.41	2.35e-15	Menarche (age at onset);
LUSC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.73	0.35	7.37e-11	Schizophrenia;
LUSC	trans	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg06606381	chr12:133084897	FBRSL1	0.47	6.47	0.33	3.41e-10	Depression;
LUSC	cis	rs4343996	0.840	rs1917689	chr7:3317586	G/A	cg21248987	chr7:3385318	SDK1	0.4	6.96	0.36	1.79e-11	Motion sickness;
LUSC	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg00745463	chr17:30367425	LRRC37B	-0.79	-8.77	-0.43	9.4e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg26876637	chr1:152193138	HRNR	-0.46	-6.31	-0.33	8.7e-10	Atopic dermatitis;
LUSC	trans	rs890100	0.902	rs2194801	chr2:56733863	A/C	cg08299783	chr2:48920986	GTF2A1L;LHCGR	-0.32	-6.23	-0.32	1.42e-9	Gut microbiome composition (summer);
LUSC	cis	rs16867321	0.614	rs10204086	chr2:181449668	G/T	cg23363182	chr2:181467187	NA	-0.58	-9.39	-0.46	9.42e-19	Obesity;
LUSC	cis	rs67539049	1.000	rs67526040	chr8:11302996	G/A	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.41	-6.31	-0.33	8.86e-10	Itch intensity from mosquito bite;
LUSC	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.46	9.69	0.47	1.02e-19	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs4474465	0.850	rs10899528	chr11:78207686	T/C	cg27205649	chr11:78285834	NARS2	0.51	6.0	0.31	5.16e-9	Alzheimer's disease (survival time);
LUSC	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg01017244	chr2:74357527	NA	0.74	14.39	0.62	7.35e-37	Gestational age at birth (maternal effect);
LUSC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	7.99	0.4	2.29e-14	Mean platelet volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20283668	chr1:87797390	LMO4	-0.44	-6.57	-0.34	1.91e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7580658	0.724	rs4662711	chr2:127990840	G/A	cg09760422	chr2:128146352	NA	-0.3	-6.73	-0.35	7.18e-11	Protein C levels;
LUSC	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg24006582	chr15:45444508	DUOX1	-0.61	-8.83	-0.44	5.89e-17	Uric acid levels;
LUSC	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg08000102	chr2:233561755	GIGYF2	-0.67	-11.06	-0.52	2.01e-24	Coronary artery disease;
LUSC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25072359	chr17:41440525	NA	0.69	9.65	0.47	1.36e-19	Menopause (age at onset);
LUSC	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg09904177	chr6:26538194	HMGN4	-0.75	-6.61	-0.34	1.51e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.7	10.76	0.51	2.14e-23	Aortic root size;
LUSC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg02951883	chr7:2050386	MAD1L1	-0.62	-12.19	-0.55	1.57e-28	Bipolar disorder and schizophrenia;
LUSC	cis	rs6740322	0.895	rs6544643	chr2:43560072	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-7.55	-0.38	4.07e-13	Coronary artery disease;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg18393173	chr6:34856135	ANKS1A;TAF11	0.42	6.61	0.34	1.56e-10	Triglycerides;
LUSC	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg14019146	chr3:50243930	SLC38A3	0.48	11.68	0.54	1.13e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs4290604	0.748	rs10929216	chr2:238080938	C/T	cg23555395	chr2:238036564	NA	-0.47	-6.41	-0.33	4.85e-10	Asthma;
LUSC	cis	rs6977660	0.714	rs10270468	chr7:19810559	T/C	cg07541023	chr7:19748670	TWISTNB	0.61	6.6	0.34	1.61e-10	Thyroid stimulating hormone;
LUSC	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg18683606	chr7:100471612	SRRT	0.44	5.78	0.3	1.74e-8	Resting heart rate;
LUSC	cis	rs11229555	0.645	rs34794607	chr11:58188401	A/T	cg15696309	chr11:58395628	NA	-0.67	-8.13	-0.41	8.64e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg17469321	chr7:55412551	NA	0.67	10.79	0.51	1.72e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs8181588	1.000	rs11602964	chr11:2825871	C/T	cg23136573	chr6:52230573	PAQR8	0.73	5.95	0.31	6.6e-9	Type 2 diabetes;
LUSC	trans	rs57046232	0.552	rs6076987	chr20:6351417	A/C	cg21095983	chr6:86352623	SYNCRIP	0.47	6.94	0.36	1.99e-11	Colorectal cancer;
LUSC	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg09998033	chr7:158218633	PTPRN2	-0.51	-8.24	-0.41	4.1e-15	Obesity-related traits;
LUSC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.7	-11.04	-0.52	2.34e-24	Aortic root size;
LUSC	cis	rs7831492	0.564	rs6981979	chr8:41612255	C/T	cg17182837	chr8:41585554	ANK1	-0.27	-5.65	-0.3	3.5e-8	Colorectal cancer;
LUSC	cis	rs12122100	0.742	rs12122092	chr1:146508874	C/G	cg03526459	chr1:146549940	NA	-0.41	-6.75	-0.35	6.44e-11	HIV-1 control;
LUSC	cis	rs9399401	0.626	rs3817928	chr6:142750516	A/G	cg03128060	chr6:142623767	GPR126	0.53	8.75	0.43	1.04e-16	Chronic obstructive pulmonary disease;
LUSC	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg22705602	chr4:152727874	NA	0.35	7.85	0.39	5.7e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg08118646	chr4:99850258	EIF4E	0.43	6.36	0.33	6.57e-10	Triglycerides;
LUSC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05025164	chr4:1340916	KIAA1530	0.54	8.5	0.42	6.4e-16	Obesity-related traits;
LUSC	cis	rs7945705	0.905	rs7947631	chr11:8844909	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-8.45	-0.42	8.95e-16	Hemoglobin concentration;
LUSC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg13047869	chr3:10149882	C3orf24	0.54	7.03	0.36	1.18e-11	Alzheimer's disease;
LUSC	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg24006582	chr15:45444508	DUOX1	-0.62	-9.14	-0.45	6.14e-18	Uric acid levels;
LUSC	cis	rs35079168	0.735	rs3118540	chr9:137307106	C/T	cg14344989	chr9:137329237	RXRA	-0.36	-5.92	-0.31	8.07e-9	Intelligence;
LUSC	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg27411982	chr8:10470053	RP1L1	0.42	6.45	0.33	3.99e-10	Retinal vascular caliber;
LUSC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg22437258	chr11:111473054	SIK2	0.52	7.44	0.38	8.76e-13	Primary sclerosing cholangitis;
LUSC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg25258033	chr6:167368657	RNASET2	-0.47	-7.78	-0.39	9.11e-14	Crohn's disease;
LUSC	cis	rs12824058	0.816	rs1874522	chr12:130816536	C/T	cg26677194	chr12:130822605	PIWIL1	-0.58	-9.03	-0.44	1.43e-17	Menopause (age at onset);
LUSC	cis	rs8113142	0.614	rs4805259	chr19:29171420	C/T	cg04546413	chr19:29218101	NA	0.45	6.01	0.31	4.82e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.03	-20.95	-0.75	8.07e-63	Ulcerative colitis;
LUSC	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.42	0.64	7.1e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg08888203	chr3:10149979	C3orf24	0.66	9.28	0.45	2.15e-18	Alzheimer's disease;
LUSC	cis	rs4561483	0.549	rs33659	chr16:11963361	A/G	cg08843971	chr16:11963173	GSPT1	-0.43	-6.68	-0.34	1.02e-10	Testicular germ cell tumor;
LUSC	cis	rs7189233	0.531	rs9929873	chr16:53490676	C/T	cg09728985	chr16:53543985	NA	-0.32	-6.14	-0.32	2.38e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.45	-7.15	-0.36	5.4e-12	Systemic lupus erythematosus;
LUSC	cis	rs617219	0.889	rs1533760	chr5:78438937	A/C	cg24856658	chr5:78533917	JMY	-0.3	-5.66	-0.3	3.29e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg05340658	chr4:99064831	C4orf37	0.44	6.92	0.35	2.32e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.33	-0.37	1.73e-12	Blood metabolite levels;
LUSC	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg05973401	chr12:123451056	ABCB9	-0.54	-5.72	-0.3	2.4e-8	Neutrophil percentage of white cells;
LUSC	cis	rs7674212	0.540	rs2720469	chr4:104086484	C/T	cg16532752	chr4:104119610	CENPE	-0.5	-7.34	-0.37	1.65e-12	Type 2 diabetes;
LUSC	trans	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg20935933	chr6:143382018	AIG1	0.5	7.33	0.37	1.71e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg03146154	chr1:46216737	IPP	-0.51	-7.46	-0.38	7.41e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08219700	chr8:58056026	NA	0.69	8.07	0.4	1.27e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2281558	0.837	rs67676850	chr20:25369417	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.63	9.64	0.47	1.44e-19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.71	9.98	0.48	1.1e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.62	6.06	0.31	3.63e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg01819863	chr10:32635814	EPC1	-1.05	-12.82	-0.57	6.9e-31	Sexual dysfunction (female);
LUSC	trans	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg06636001	chr8:8085503	FLJ10661	0.42	6.14	0.32	2.35e-9	Retinal vascular caliber;
LUSC	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg12927641	chr6:109611667	NA	-0.36	-6.11	-0.32	2.8e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg11861562	chr11:117069780	TAGLN	0.33	6.38	0.33	5.8e-10	Blood protein levels;
LUSC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg20398880	chr6:41068722	NFYA;LOC221442	0.4	6.34	0.33	7.58e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7580658	0.676	rs58475809	chr2:128002650	A/G	cg09760422	chr2:128146352	NA	-0.27	-5.9	-0.31	8.85e-9	Protein C levels;
LUSC	cis	rs600626	0.529	rs11236527	chr11:75469310	A/G	cg24262691	chr11:75473276	NA	-0.48	-6.34	-0.33	7.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg20016023	chr10:99160130	RRP12	-0.32	-7.98	-0.4	2.38e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg26958806	chr6:27640298	NA	0.72	5.79	0.3	1.6e-8	Depression;
LUSC	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg17644776	chr2:200775616	C2orf69	0.36	5.7	0.3	2.67e-8	Osteoporosis;
LUSC	cis	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg09904177	chr6:26538194	HMGN4	-0.75	-5.76	-0.3	1.95e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg11344533	chr11:111475393	SIK2	-0.49	-6.68	-0.34	1.01e-10	Primary sclerosing cholangitis;
LUSC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.99	-0.4	2.17e-14	Mean platelet volume;
LUSC	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg26924012	chr15:45694286	SPATA5L1	1.13	20.62	0.75	1.62e-61	Homoarginine levels;
LUSC	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg06784218	chr1:46089804	CCDC17	0.33	5.91	0.31	8.22e-9	Platelet count;
LUSC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10802521	chr3:52805072	NEK4	0.48	7.0	0.36	1.42e-11	Bipolar disorder;
LUSC	trans	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg27661571	chr11:113659931	NA	-0.56	-6.64	-0.34	1.25e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.39	-0.37	1.2e-12	Extrinsic epigenetic age acceleration;
LUSC	trans	rs12692738	0.526	rs355855	chr2:165628875	C/A	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	7.28	0.37	2.44e-12	Rheumatoid arthritis;
LUSC	trans	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg26566898	chr11:117069891	TAGLN	0.34	6.46	0.33	3.77e-10	Blood protein levels;
LUSC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg00310523	chr12:86230176	RASSF9	0.5	9.41	0.46	8.3e-19	Major depressive disorder;
LUSC	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.89	-0.44	3.97e-17	Coffee consumption (cups per day);
LUSC	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg24692254	chr21:30365293	RNF160	-0.7	-10.68	-0.5	4.38e-23	Pancreatic cancer;
LUSC	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg24851651	chr11:66362959	CCS	0.55	7.96	0.4	2.8e-14	Airway imaging phenotypes;
LUSC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg12935359	chr14:103987150	CKB	-0.51	-7.71	-0.39	1.46e-13	Body mass index;
LUSC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg20203395	chr5:56204925	C5orf35	-0.47	-6.72	-0.34	8.02e-11	Coronary artery disease;
LUSC	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg23950597	chr19:37808831	NA	-0.63	-7.51	-0.38	5.51e-13	Coronary artery calcification;
LUSC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg25767906	chr1:53392781	SCP2	0.48	8.66	0.43	1.98e-16	Monocyte count;
LUSC	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg00484396	chr16:3507460	NAT15	0.38	6.44	0.33	4.1e-10	Body mass index (adult);
LUSC	cis	rs59104589	0.583	rs61689231	chr2:242244583	G/A	cg14842376	chr2:242211374	HDLBP	0.56	6.25	0.32	1.22e-9	Fibrinogen levels;
LUSC	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg00857998	chr1:205179979	DSTYK	0.57	8.86	0.44	4.96e-17	Red blood cell count;
LUSC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.0	-0.36	1.44e-11	Alzheimer's disease (late onset);
LUSC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg10169327	chr19:45448959	APOC2	0.31	6.57	0.34	1.95e-10	Blood protein levels;
LUSC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	12.18	0.55	1.79e-28	Monocyte percentage of white cells;
LUSC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg19774624	chr17:42201019	HDAC5	-0.81	-13.27	-0.59	1.43e-32	Total body bone mineral density;
LUSC	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg23625390	chr15:77176239	SCAPER	-0.66	-9.96	-0.48	1.29e-20	Blood metabolite levels;
LUSC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg12463550	chr7:65579703	CRCP	-0.47	-6.96	-0.36	1.86e-11	Aortic root size;
LUSC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg10150615	chr22:24372951	LOC391322	-0.34	-5.77	-0.3	1.81e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.08	-0.36	8.53e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg19318889	chr4:1322082	MAEA	0.48	7.83	0.39	6.66e-14	Obesity-related traits;
LUSC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg14552801	chr7:65878734	NA	0.38	5.84	0.3	1.27e-8	Aortic root size;
LUSC	cis	rs739496	0.744	rs10849951	chr12:111910912	G/A	cg10833066	chr12:111807467	FAM109A	0.31	5.67	0.3	3.16e-8	Platelet count;
LUSC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg16479474	chr6:28041457	NA	0.32	5.72	0.3	2.31e-8	Parkinson's disease;
LUSC	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg18132916	chr6:79620363	NA	-0.41	-6.24	-0.32	1.36e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg26958806	chr6:27640298	NA	0.76	6.21	0.32	1.54e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg26061582	chr7:22766209	IL6	0.49	7.02	0.36	1.25e-11	Lung cancer;
LUSC	cis	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg06521331	chr12:34319734	NA	-0.46	-7.33	-0.37	1.73e-12	Morning vs. evening chronotype;
LUSC	cis	rs12220238	0.915	rs11001020	chr10:76139217	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.52	5.76	0.3	1.91e-8	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg02551604	chr5:131831745	NA	-0.42	-6.62	-0.34	1.39e-10	Asthma (sex interaction);
LUSC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg15103426	chr22:29168792	CCDC117	-0.47	-6.22	-0.32	1.5e-9	Lymphocyte counts;
LUSC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6489785	0.710	rs2393717	chr12:121220375	G/C	cg02419362	chr12:121203948	SPPL3	0.41	7.35	0.37	1.57e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9837602	1.000	rs1688766	chr3:99647850	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-5.93	-0.31	7.52e-9	Breast cancer;
LUSC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg18758796	chr5:131593413	PDLIM4	0.39	6.41	0.33	5.08e-10	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03855706	chr16:770778	FAM173A	0.47	6.91	0.35	2.49e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg09092052	chr15:45571596	NA	0.45	6.3	0.33	9.44e-10	Glomerular filtration rate;
LUSC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.88e-11	Primary biliary cholangitis;
LUSC	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.12	-0.36	6.8e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg12292205	chr6:26970375	C6orf41	0.66	11.49	0.53	5.81e-26	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg19468946	chr17:37922297	IKZF3	0.39	6.21	0.32	1.56e-9	Self-reported allergy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13611226	chr9:125027073	RBM18;MRRF	-0.43	-6.43	-0.33	4.34e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs656319	0.559	rs17689007	chr8:9974824	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.37	-0.33	6.15e-10	Myopia (pathological);
LUSC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.02	0.58	1.25e-31	Chronic sinus infection;
LUSC	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.25	0.52	4.16e-25	Fuchs's corneal dystrophy;
LUSC	trans	rs2018683	0.707	rs2391718	chr7:28974988	T/C	cg19402173	chr7:128379420	CALU	-0.47	-7.17	-0.37	4.86e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg21573476	chr21:45109991	RRP1B	0.4	6.44	0.33	4.14e-10	Mean corpuscular volume;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04827747	chr7:134855666	C7orf49	-0.44	-6.28	-0.32	1.08e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	10.03	0.48	7.04e-21	Lymphocyte counts;
LUSC	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07636037	chr3:49044803	WDR6	-0.66	-8.39	-0.42	1.36e-15	Menarche (age at onset);
LUSC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.25	-14.44	-0.62	4.77e-37	Gout;
LUSC	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.75	-14.34	-0.62	1.11e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.43	6.12	0.32	2.58e-9	Breast cancer;
LUSC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.39	0.56	2.97e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg23303369	chr20:44641161	MMP9	0.35	6.12	0.32	2.59e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06850241	chr22:41845214	NA	0.31	5.8	0.3	1.56e-8	Vitiligo;
LUSC	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg06784218	chr1:46089804	CCDC17	0.3	5.94	0.31	7.18e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg09035930	chr12:129282057	SLC15A4	-0.69	-14.79	-0.63	2.02e-38	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg24829409	chr8:58192753	C8orf71	-0.55	-6.01	-0.31	4.79e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg15309053	chr8:964076	NA	0.38	7.57	0.38	3.64e-13	Schizophrenia;
LUSC	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.29	-0.41	2.86e-15	Response to antipsychotic treatment;
LUSC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg12386194	chr3:101231763	SENP7	0.54	7.53	0.38	4.91e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-6.38	-0.33	5.88e-10	Eosinophil percentage of white cells;
LUSC	cis	rs4974559	0.739	rs10032327	chr4:1323537	C/T	cg02980000	chr4:1222292	CTBP1	1.04	9.6	0.46	2e-19	Systolic blood pressure;
LUSC	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.12	0.52	1.2e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg03788504	chr6:150331562	NA	-0.25	-5.74	-0.3	2.12e-8	Alopecia areata;
LUSC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00149659	chr3:10157352	C3orf10	0.9	12.52	0.57	9.79e-30	Alzheimer's disease;
LUSC	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg10547527	chr2:198650123	BOLL	-0.51	-5.97	-0.31	5.92e-9	Ulcerative colitis;
LUSC	cis	rs4704187	0.687	rs4704176	chr5:74420596	G/C	cg03227963	chr5:74354835	NA	0.32	6.89	0.35	2.72e-11	Response to amphetamines;
LUSC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg04450456	chr4:17643702	FAM184B	0.37	6.17	0.32	1.96e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4730250	0.707	rs10253291	chr7:106786550	C/A	cg02696742	chr7:106810147	HBP1	0.64	9.05	0.44	1.17e-17	Osteoarthritis;
LUSC	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg11965913	chr1:205819406	PM20D1	0.46	5.96	0.31	6.44e-9	Prostate-specific antigen levels;
LUSC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg16447950	chr5:562315	NA	-0.57	-7.3	-0.37	2.1e-12	Lung disease severity in cystic fibrosis;
LUSC	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs259282	0.560	rs4805786	chr19:33120265	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.78	12.08	0.55	4.05e-28	Schizophrenia;
LUSC	cis	rs926938	0.618	rs904292	chr1:115358421	C/T	cg12756093	chr1:115239321	AMPD1	0.52	7.73	0.39	1.27e-13	Autism;
LUSC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg01657329	chr11:68192670	LRP5	-0.44	-6.48	-0.33	3.21e-10	Total body bone mineral density;
LUSC	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg15556689	chr8:8085844	FLJ10661	0.65	9.89	0.48	2.14e-20	Mean corpuscular volume;
LUSC	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-5.78	-0.3	1.74e-8	IgG glycosylation;
LUSC	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.71	-0.39	1.41e-13	Type 2 diabetes;
LUSC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg06627628	chr2:24431161	ITSN2	-0.61	-7.29	-0.37	2.19e-12	Lymphocyte counts;
LUSC	cis	rs11048434	0.698	rs7300767	chr12:9123477	T/G	cg13575925	chr12:9217583	LOC144571	0.35	6.39	0.33	5.64e-10	Sjögren's syndrome;
LUSC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg17178900	chr1:205818956	PM20D1	0.51	8.18	0.41	6.13e-15	Menarche (age at onset);
LUSC	cis	rs2282300	0.956	rs1717773	chr11:30383154	T/C	cg25418670	chr11:30344373	C11orf46	-0.52	-7.25	-0.37	2.91e-12	Morning vs. evening chronotype;
LUSC	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.46	-0.33	3.79e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-9.51	-0.46	3.92e-19	Schizophrenia;
LUSC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs6840360	0.869	rs55668815	chr4:152473828	C/G	cg22705602	chr4:152727874	NA	-0.3	-6.2	-0.32	1.71e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg01448562	chr3:133502909	NA	-0.52	-7.75	-0.39	1.13e-13	Iron status biomarkers;
LUSC	cis	rs138918	0.772	rs138935	chr22:43567459	C/T	cg08909806	chr22:43548696	TSPO	0.36	6.23	0.32	1.38e-9	Monocyte count;
LUSC	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.75	-0.6	2.1e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	16.31	0.67	2.06e-44	Platelet count;
LUSC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg14196790	chr5:131705035	SLC22A5	0.45	7.28	0.37	2.4e-12	Breast cancer;Mosquito bite size;
LUSC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.77	-13.64	-0.6	5.71e-34	Monocyte count;
LUSC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg08847533	chr14:75593920	NEK9	-0.84	-15.07	-0.64	1.61e-39	Height;
LUSC	cis	rs11756438	0.572	rs2638552	chr6:118999412	C/T	cg21191810	chr6:118973309	C6orf204	0.35	5.91	0.31	8.34e-9	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs62238980	0.614	rs62240588	chr22:32358473	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.52	-6.07	-0.32	3.42e-9	Childhood ear infection;
LUSC	cis	rs3820928	0.874	rs1917122	chr2:227835681	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.42	-0.38	9.97e-13	Pulmonary function;
LUSC	cis	rs34638657	0.518	rs4889467	chr16:82169385	C/T	cg09439754	chr16:82129088	HSD17B2	-0.32	-5.83	-0.3	1.34e-8	Lung adenocarcinoma;
LUSC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg09035930	chr12:129282057	SLC15A4	0.74	16.25	0.66	3.74e-44	Systemic lupus erythematosus;
LUSC	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs3790645	0.958	rs7543005	chr1:26879376	T/C	cg17456097	chr1:26900765	RPS6KA1	0.41	6.01	0.31	4.81e-9	Glucose homeostasis traits;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06714284	chr1:235812840	GNG4	0.36	5.97	0.31	5.91e-9	Asthma;
LUSC	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg04998671	chr14:104000505	TRMT61A	-0.46	-7.13	-0.36	6.27e-12	Coronary artery disease;
LUSC	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06401114	chr19:19627257	NDUFA13;TSSK6	0.45	6.0	0.31	5.09e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08736216	chr1:53307985	ZYG11A	0.31	6.33	0.33	8.05e-10	Monocyte count;
LUSC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg19812747	chr11:111475976	SIK2	-0.55	-8.2	-0.41	5.19e-15	Primary sclerosing cholangitis;
LUSC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16680214	chr1:154839983	KCNN3	-0.53	-9.88	-0.48	2.25e-20	Prostate cancer;
LUSC	cis	rs813218	0.585	rs9860561	chr3:99917434	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.32	6.0	0.31	5.11e-9	Orofacial clefts;
LUSC	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg07862535	chr7:139043722	LUC7L2	0.55	6.83	0.35	4.08e-11	Diisocyanate-induced asthma;
LUSC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.91	-17.34	-0.69	1.69e-48	Colorectal cancer;
LUSC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg26769984	chr7:1090371	C7orf50	-0.56	-7.77	-0.39	9.54e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs67539049	1.000	rs2001462	chr8:11294810	A/G	cg02771117	chr8:11279352	FAM167A;C8orf12	0.41	6.42	0.33	4.6e-10	Itch intensity from mosquito bite;
LUSC	cis	rs28647808	0.786	rs28458971	chr9:136255736	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.55	-0.34	2.13e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9547692	1.000	rs493248	chr13:37473386	C/T	cg01493522	chr13:37497338	NA	-0.4	-6.07	-0.32	3.47e-9	Coronary artery disease;
LUSC	cis	rs9398803	0.965	rs2326387	chr6:126680489	G/A	cg19875578	chr6:126661172	C6orf173	0.39	5.83	0.3	1.31e-8	Male-pattern baldness;
LUSC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg02018176	chr4:1364513	KIAA1530	0.57	10.4	0.49	3.85e-22	Longevity;
LUSC	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg19557537	chr6:46620673	CYP39A1;SLC25A27	0.43	6.05	0.31	3.95e-9	Triglycerides;
LUSC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg24733560	chr20:60626293	TAF4	0.36	5.89	0.31	9.44e-9	Body mass index;
LUSC	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg17507749	chr15:85114479	UBE2QP1	0.67	8.67	0.43	1.96e-16	Schizophrenia;
LUSC	cis	rs7818345	1.000	rs12675717	chr8:19293177	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.37	7.15	0.36	5.67e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.11	-0.41	9.41e-15	Lung cancer;
LUSC	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg04117972	chr1:227635322	NA	0.61	6.94	0.35	2.08e-11	Major depressive disorder;
LUSC	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg05738196	chr6:26577821	NA	0.79	15.24	0.64	3.59e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs12928939	0.815	rs12446005	chr16:71655035	G/A	cg08717414	chr16:71523259	ZNF19	-0.43	-6.01	-0.31	4.88e-9	Post bronchodilator FEV1;
LUSC	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg26876637	chr1:152193138	HRNR	0.45	6.28	0.33	1.05e-9	Atopic dermatitis;
LUSC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03517284	chr6:25882590	NA	-0.52	-9.66	-0.47	1.25e-19	Blood metabolite levels;
LUSC	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg00898013	chr13:113819073	PROZ	0.54	8.04	0.4	1.59e-14	Platelet distribution width;
LUSC	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Bladder cancer;
LUSC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.86	16.48	0.67	4.59e-45	Mean platelet volume;
LUSC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-9.37	-0.46	1.11e-18	Gut microbiome composition (summer);
LUSC	trans	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.97	-0.31	6.19e-9	Dementia with Lewy bodies;
LUSC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg18477163	chr1:228402036	OBSCN	0.62	12.18	0.55	1.73e-28	Diastolic blood pressure;
LUSC	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg23752985	chr2:85803571	VAMP8	-0.27	-5.71	-0.3	2.45e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg27535305	chr1:53392650	SCP2	-0.38	-7.1	-0.36	7.42e-12	Monocyte count;
LUSC	cis	rs8099014	1.000	rs6566972	chr18:56123740	T/C	cg12907477	chr18:56117327	MIR122	0.44	7.06	0.36	9.47e-12	Platelet count;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15839673	chr15:90895473	ZNF774	0.74	5.99	0.31	5.48e-9	Cognitive performance;
LUSC	cis	rs17433780	0.808	rs12122780	chr1:89508916	T/C	cg09516651	chr1:89888402	LOC400759	0.61	11.67	0.54	1.25e-26	Carotid intima media thickness;
LUSC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	ch.11.42038R	chr11:967971	AP2A2	0.44	6.6	0.34	1.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg22676075	chr6:135203613	NA	0.46	7.15	0.36	5.34e-12	Red blood cell count;
LUSC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07741184	chr6:167504864	NA	0.37	6.49	0.33	3.19e-10	Primary biliary cholangitis;
LUSC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-7.99	-0.4	2.25e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs62056376	0.646	rs2857653	chr17:32575759	T/C	cg19986872	chr5:131347773	ACSL6	-0.41	-6.07	-0.32	3.57e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg03929089	chr4:120376271	NA	0.86	12.25	0.56	9.39e-29	Height;
LUSC	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18131467	chr2:239335373	ASB1	-1.04	-24.82	-0.81	7.94e-78	Multiple system atrophy;
LUSC	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg25554036	chr4:6271136	WFS1	0.63	13.31	0.59	1.01e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.59	5.7	0.3	2.6e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg04944784	chr2:26401820	FAM59B	-0.66	-9.52	-0.46	3.73e-19	Gut microbiome composition (summer);
LUSC	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-1.05	-22.5	-0.78	7.18e-69	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.27	-17.75	-0.7	4.04e-50	Hip circumference adjusted for BMI;
LUSC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.09	-0.4	1.1e-14	Lung cancer;
LUSC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg21435336	chr19:17392852	ANKLE1	-0.48	-6.51	-0.34	2.7e-10	Systemic lupus erythematosus;
LUSC	cis	rs8046696	1	rs8046696	chr16:75442143	T/G	cg03315344	chr16:75512273	CHST6	0.49	8.99	0.44	1.91e-17	Coronary artery disease;
LUSC	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	11.77	0.54	5.38e-27	Ileal carcinoids;
LUSC	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg24375607	chr4:120327624	NA	0.81	12.16	0.55	2.07e-28	Corneal astigmatism;
LUSC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	11.91	0.55	1.74e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12545109	0.800	rs1530218	chr8:57407864	C/G	cg09654669	chr8:57350985	NA	-0.52	-6.66	-0.34	1.1e-10	Obesity-related traits;
LUSC	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.34	7.02	0.36	1.22e-11	Hemoglobin concentration;
LUSC	cis	rs2299587	0.585	rs2299590	chr8:17802192	A/C	cg01800426	chr8:17659068	MTUS1	-0.49	-6.31	-0.33	8.64e-10	Economic and political preferences;
LUSC	cis	rs1957429	0.901	rs1957427	chr14:65354085	A/G	cg23373153	chr14:65346875	NA	0.96	11.48	0.53	6.33e-26	Pediatric areal bone mineral density (radius);
LUSC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg16325326	chr1:53192061	ZYG11B	-0.82	-14.32	-0.62	1.33e-36	Monocyte count;
LUSC	trans	rs12478296	0.534	rs67092377	chr2:243002171	T/G	cg01596870	chr19:55963115	NA	-0.55	-7.32	-0.37	1.91e-12	Obesity-related traits;
LUSC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.12	16.74	0.68	4.17e-46	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg11812906	chr14:75593930	NEK9	-0.65	-11.03	-0.52	2.54e-24	Height;
LUSC	cis	rs10887741	0.690	rs10509410	chr10:89440001	C/T	cg24243914	chr10:89418206	PAPSS2	0.34	6.87	0.35	3.24e-11	Exercise (leisure time);
LUSC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg00999904	chr2:3704751	ALLC	-0.62	-9.89	-0.48	2.13e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.53	-11.25	-0.52	4.07e-25	Sense of smell;
LUSC	cis	rs3947	1.000	rs1736082	chr8:11703420	C/T	cg00262122	chr8:11665843	FDFT1	-0.48	-5.7	-0.3	2.7e-8	Blood protein levels;
LUSC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg22638593	chr5:131593259	PDLIM4	0.39	5.76	0.3	1.9e-8	Breast cancer;
LUSC	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.7	0.34	8.92e-11	Lung cancer;
LUSC	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg21775007	chr8:11205619	TDH	-0.47	-6.67	-0.34	1.07e-10	Myopia (pathological);
LUSC	cis	rs1506636	0.646	rs805779	chr7:123214835	C/T	cg03229431	chr7:123269106	ASB15	-0.6	-9.11	-0.45	8.02e-18	Plateletcrit;Platelet count;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg26330133	chr20:35089838	DLGAP4	-0.5	-6.11	-0.32	2.84e-9	Cognitive function;Information processing speed;
LUSC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	7.05	0.36	1.02e-11	Personality dimensions;
LUSC	trans	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	10.47	0.5	2.28e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg05738196	chr6:26577821	NA	0.78	14.95	0.63	4.82e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs4343996	0.934	rs4607498	chr7:3368197	C/T	cg21248987	chr7:3385318	SDK1	-0.38	-6.42	-0.33	4.67e-10	Motion sickness;
LUSC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg19539972	chr4:7069911	GRPEL1	0.72	9.06	0.44	1.13e-17	Monocyte percentage of white cells;
LUSC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-0.82	-12.46	-0.56	1.59e-29	Gut microbiome composition (summer);
LUSC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.29	-0.37	2.29e-12	Extrinsic epigenetic age acceleration;
LUSC	trans	rs11743006	0.626	rs6859738	chr5:136500148	A/C	cg07379741	chr17:7311030	NLGN2	0.41	6.18	0.32	1.89e-9	Mathematical ability;
LUSC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25072359	chr17:41440525	NA	0.66	9.25	0.45	2.8e-18	Menopause (age at onset);
LUSC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	1.05	19.04	0.72	3.07e-55	Menopause (age at onset);
LUSC	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg15423357	chr2:25149977	NA	0.35	6.42	0.33	4.64e-10	Body mass index;
LUSC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg24585782	chr17:78113791	EIF4A3	-0.53	-7.79	-0.39	8.61e-14	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUSC	trans	rs7939886	0.920	rs61887958	chr11:55938234	A/G	cg03929089	chr4:120376271	NA	0.8	6.07	0.32	3.54e-9	Myopia (pathological);
LUSC	cis	rs7572644	0.665	rs4666017	chr2:28040525	C/A	cg27432699	chr2:27873401	GPN1	0.57	7.28	0.37	2.47e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg25036284	chr2:26402008	FAM59B	-0.69	-9.63	-0.47	1.6e-19	Gut microbiome composition (summer);
LUSC	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg08798685	chr6:27730294	NA	-0.64	-6.01	-0.31	4.93e-9	Breast cancer;
LUSC	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg24812749	chr6:127587940	RNF146	0.65	9.73	0.47	7.3e-20	Breast cancer;
LUSC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.7	-12.16	-0.55	2.05e-28	Dental caries;
LUSC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	0.97	19.32	0.73	2.27e-56	Cognitive function;
LUSC	trans	rs2055729	0.645	rs6989793	chr8:9744650	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.3	-0.33	9.23e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs6977940	0.818	rs73033457	chr7:2899235	C/A	cg19731401	chr7:2775893	GNA12	0.63	7.37	0.37	1.33e-12	White matter integrity;
LUSC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg04111992	chr7:158790115	NA	-0.38	-5.89	-0.31	9.65e-9	Facial morphology (factor 20);
LUSC	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.62	-7.26	-0.37	2.66e-12	Birth weight;
LUSC	cis	rs6982240	0.514	rs10095322	chr8:142262327	A/G	cg27411547	chr8:142287226	NA	-0.47	-8.02	-0.4	1.76e-14	Tonsillectomy;
LUSC	cis	rs9420	0.961	rs80304923	chr11:57522823	C/G	cg23127183	chr11:57508653	C11orf31	-0.57	-8.81	-0.43	6.86e-17	Schizophrenia;
LUSC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg23711669	chr6:146136114	FBXO30	0.89	16.83	0.68	1.88e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg12560992	chr17:57184187	TRIM37	-0.87	-16.64	-0.67	1.09e-45	Intelligence (multi-trait analysis);
LUSC	cis	rs116988415	0.584	rs75851540	chr14:65262909	C/T	cg00114569	chr14:65239327	SPTB	0.7	7.43	0.38	9.24e-13	Daytime sleep phenotypes;
LUSC	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-10.1	-0.48	4.07e-21	Morning vs. evening chronotype;
LUSC	cis	rs9549260	0.755	rs55920113	chr13:41222112	C/T	cg21288729	chr13:41239152	FOXO1	0.65	10.07	0.48	5.25e-21	Red blood cell count;
LUSC	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg23791538	chr6:167370224	RNASET2	0.39	6.28	0.33	1.05e-9	Crohn's disease;
LUSC	cis	rs240764	0.817	rs6922219	chr6:101153907	G/C	cg09795085	chr6:101329169	ASCC3	-0.43	-6.26	-0.32	1.2e-9	Neuroticism;
LUSC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg16606324	chr3:10149918	C3orf24	0.66	9.8	0.47	4.38e-20	Alzheimer's disease;
LUSC	cis	rs2294693	0.891	rs9367093	chr6:41012117	A/C	cg14769373	chr6:40998127	UNC5CL	-0.52	-6.93	-0.35	2.18e-11	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg24375607	chr4:120327624	NA	0.5	7.77	0.39	9.66e-14	Diastolic blood pressure;
LUSC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg15691649	chr6:25882328	NA	0.51	7.58	0.38	3.4e-13	Blood metabolite levels;
LUSC	cis	rs4948102	0.597	rs12669623	chr7:56139179	G/C	cg17215666	chr7:56131930	SUMF2	0.44	5.87	0.31	1.06e-8	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs7503807	0.935	rs62068348	chr17:78608575	T/C	cg09596252	chr17:78655493	RPTOR	0.46	7.82	0.39	7.03e-14	Obesity;
LUSC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	7.25	0.37	2.85e-12	Colorectal cancer;
LUSC	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs7582720	1.000	rs72934735	chr2:203740010	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.56	0.42	4.25e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs66716358	0.773	rs2054029	chr11:44325700	T/G	cg16977035	chr11:44330474	ALX4	0.36	5.87	0.31	1.06e-8	Monobrow;
LUSC	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg16339924	chr4:17578868	LAP3	-0.54	-7.9	-0.4	4.04e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.73	-13.31	-0.59	1.04e-32	Bipolar disorder;
LUSC	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.13	0.32	2.51e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg06238570	chr21:40685208	BRWD1	-0.57	-8.79	-0.43	8.32e-17	Menarche (age at onset);
LUSC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg03188948	chr7:1209495	NA	0.65	6.91	0.35	2.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.68	11.59	0.54	2.37e-26	Age-related hearing impairment;
LUSC	trans	rs9393777	0.777	rs56114371	chr6:27274834	C/T	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.31	-0.41	2.44e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg20887711	chr4:1340912	KIAA1530	0.49	7.93	0.4	3.3e-14	Longevity;
LUSC	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg02574844	chr11:5959923	NA	-0.44	-6.17	-0.32	2.03e-9	DNA methylation (variation);
LUSC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg12560992	chr17:57184187	TRIM37	0.83	15.19	0.64	5.68e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7542375	0.507	rs2484697	chr1:221094718	A/G	cg16008148	chr1:221062819	NA	0.43	8.29	0.41	2.89e-15	Obesity-related traits;
LUSC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg26335602	chr6:28129616	ZNF389	0.46	6.34	0.33	7.57e-10	Parkinson's disease;
LUSC	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg20307385	chr11:47447363	PSMC3	-0.44	-6.53	-0.34	2.4e-10	Subjective well-being;
LUSC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg13319975	chr6:146136371	FBXO30	-0.71	-11.31	-0.53	2.5e-25	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg14791747	chr16:20752902	THUMPD1	0.73	9.55	0.46	2.84e-19	Cognitive test performance;
LUSC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.82	13.74	0.6	2.25e-34	Aortic root size;
LUSC	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.52	9.33	0.45	1.49e-18	Bone mineral density;
LUSC	cis	rs1595825	1.000	rs73058834	chr2:198873779	T/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.31	-0.33	8.95e-10	Ulcerative colitis;
LUSC	trans	rs2018683	0.523	rs1499227	chr7:29025615	C/T	cg19402173	chr7:128379420	CALU	-0.43	-6.42	-0.33	4.72e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg12179176	chr11:130786555	SNX19	-0.64	-9.89	-0.48	2.06e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.06	-0.72	2.5e-55	Height;
LUSC	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.52	10.26	0.49	1.2e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02716147	chr3:126733173	PLXNA1	0.44	6.2	0.32	1.62e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10193935	0.901	rs10202848	chr2:42515661	A/G	cg27598129	chr2:42591480	NA	-0.59	-8.05	-0.4	1.44e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg22138327	chr13:27999177	GTF3A	0.71	9.57	0.46	2.41e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg08773314	chr2:239334832	ASB1	0.41	8.66	0.43	2.08e-16	Multiple system atrophy;
LUSC	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	0.88	14.74	0.63	3.15e-38	Schizophrenia;
LUSC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg26408565	chr15:76604113	ETFA	-0.45	-7.02	-0.36	1.22e-11	Blood metabolite levels;
LUSC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs6942756	1.000	rs17168512	chr7:128955033	A/G	cg02491457	chr7:128862824	NA	-0.47	-6.31	-0.33	9.1e-10	White matter hyperintensity burden;
LUSC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs113835537	0.529	rs61561111	chr11:66275923	T/C	cg24851651	chr11:66362959	CCS	0.53	7.95	0.4	2.91e-14	Airway imaging phenotypes;
LUSC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg09997546	chr11:8931473	C11orf17;ST5	0.37	7.8	0.39	8.25e-14	Hemoglobin concentration;
LUSC	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg26061582	chr7:22766209	IL6	-0.43	-5.96	-0.31	6.45e-9	Lung cancer;
LUSC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg12292205	chr6:26970375	C6orf41	0.67	11.35	0.53	1.77e-25	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs4650994	0.544	rs6664493	chr1:178494428	C/T	cg05059571	chr16:84539110	KIAA1609	-0.47	-8.88	-0.44	4.18e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg16405210	chr4:1374714	KIAA1530	0.55	8.2	0.41	5.09e-15	Obesity-related traits;
LUSC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.18	-0.37	4.54e-12	Subjective well-being;
LUSC	trans	rs2562456	0.833	rs4334427	chr19:21520892	A/G	cg00806126	chr19:22604979	ZNF98	-0.43	-6.21	-0.32	1.6e-9	Pain;
LUSC	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg20701182	chr2:24300061	SF3B14	0.88	11.42	0.53	1.05e-25	Lymphocyte counts;
LUSC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	0.77	13.36	0.59	6.68e-33	Cognitive function;
LUSC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg03806693	chr22:41940476	POLR3H	-0.9	-12.91	-0.58	3.35e-31	Vitiligo;
LUSC	cis	rs807669	0.505	rs2236759	chr22:19187427	C/G	cg02655711	chr22:19163373	SLC25A1	0.5	8.96	0.44	2.33e-17	Metabolite levels;
LUSC	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg05738196	chr6:26577821	NA	0.82	15.81	0.65	1.93e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg18512352	chr11:47633146	NA	0.28	5.84	0.3	1.26e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	trans	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs6076065	0.963	rs999072	chr20:23347553	C/T	cg11657817	chr20:23433608	CST11	0.44	8.73	0.43	1.23e-16	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13588640	chr5:77071865	TBCA	-0.41	-6.14	-0.32	2.33e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.16	-0.36	5.08e-12	Putamen volume;
LUSC	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg05373962	chr22:49881684	NA	-0.4	-8.66	-0.43	2.03e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg22325292	chr17:80708367	FN3K	-0.41	-6.82	-0.35	4.29e-11	Glycated hemoglobin levels;
LUSC	trans	rs8026898	1.000	rs919053	chr15:69990787	A/G	cg27385734	chr18:15003734	NA	0.31	6.26	0.32	1.17e-9	Rheumatoid arthritis;
LUSC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.44	0.53	8.33e-26	Menopause (age at onset);
LUSC	cis	rs870825	0.616	rs2696037	chr4:185610940	C/T	cg04058563	chr4:185651563	MLF1IP	-0.81	-11.99	-0.55	8.32e-28	Blood protein levels;
LUSC	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs62400317	0.859	rs11967630	chr6:45128524	G/C	cg18551225	chr6:44695536	NA	-0.42	-6.84	-0.35	3.81e-11	Total body bone mineral density;
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14893161	chr1:205819251	PM20D1	0.92	18.18	0.71	8.05e-52	Menarche (age at onset);
LUSC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg24060327	chr5:131705240	SLC22A5	-0.35	-5.91	-0.31	8.49e-9	Blood metabolite levels;
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.89	16.47	0.67	5.01e-45	Menarche (age at onset);
LUSC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg15117754	chr3:10150083	C3orf24	-0.41	-5.66	-0.3	3.27e-8	Alzheimer's disease;
LUSC	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	11.59	0.54	2.52e-26	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18854424	chr1:2615690	NA	0.48	9.33	0.45	1.53e-18	Ulcerative colitis;
LUSC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg11812906	chr14:75593930	NEK9	-0.64	-10.43	-0.5	3.05e-22	Height;
LUSC	cis	rs11997175	0.546	rs11775414	chr8:33615826	A/G	ch.8.33884649F	chr8:33765107	NA	0.51	8.12	0.41	9.29e-15	Body mass index;
LUSC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.14	-0.32	2.29e-9	Personality dimensions;
LUSC	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	8.08	0.4	1.17e-14	Coffee consumption (cups per day);
LUSC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg11062466	chr8:58055876	NA	0.58	7.61	0.38	2.8e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02895995	chr19:7554069	PEX11G	0.4	5.99	0.31	5.46e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-11.28	-0.53	3.13e-25	Menarche (age at onset);
LUSC	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg16950941	chr11:66035639	RAB1B	-0.48	-7.05	-0.36	1.06e-11	Gout;
LUSC	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg19700328	chr14:106028568	NA	-0.42	-6.93	-0.35	2.21e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	trans	rs11075138	0.693	rs1713488	chr16:12739070	G/A	cg07140468	chr10:44788627	NA	0.35	6.09	0.32	3.07e-9	Cerebral amyloid angiopathy;
LUSC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg01802117	chr1:53393560	SCP2	0.39	6.29	0.33	9.89e-10	Monocyte count;
LUSC	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-11.31	-0.53	2.45e-25	Alcohol dependence;
LUSC	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg14582100	chr15:45693742	SPATA5L1	0.57	10.28	0.49	1.04e-21	Homoarginine levels;
LUSC	cis	rs7805747	1.000	rs56012466	chr7:151406788	G/A	cg17611936	chr7:151411526	PRKAG2	0.44	5.84	0.3	1.22e-8	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUSC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.41	-6.41	-0.33	5.01e-10	Menarche (age at onset);
LUSC	cis	rs12620999	0.941	rs2078469	chr2:237983273	C/G	cg23555395	chr2:238036564	NA	0.52	9.2	0.45	3.97e-18	Systemic lupus erythematosus;
LUSC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg02782426	chr3:40428986	ENTPD3	0.32	6.13	0.32	2.44e-9	Renal cell carcinoma;
LUSC	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg17385448	chr1:15911702	AGMAT	0.34	5.84	0.3	1.27e-8	Systolic blood pressure;
LUSC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg07701084	chr6:150067640	NUP43	0.53	7.94	0.4	3.18e-14	Lung cancer;
LUSC	cis	rs6500395	0.962	rs9934626	chr16:48602761	G/C	cg04672837	chr16:48644449	N4BP1	0.45	6.53	0.34	2.48e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg07862535	chr7:139043722	LUC7L2	-0.57	-7.12	-0.36	6.84e-12	Diisocyanate-induced asthma;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01261044	chr14:35451962	SRP54	0.42	6.05	0.31	3.98e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg20503657	chr10:835505	NA	0.76	9.07	0.44	1.02e-17	Eosinophil percentage of granulocytes;
LUSC	trans	rs8085804	0.571	rs76491133	chr18:40305701	C/A	cg04486886	chr5:56784195	NA	-0.31	-5.95	-0.31	6.95e-9	Cognitive performance;
LUSC	cis	rs9309473	0.500	rs12996463	chr2:73655496	T/C	cg20560298	chr2:73613845	ALMS1	0.45	7.14	0.36	5.98e-12	Metabolite levels;
LUSC	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.39	0.46	9.62e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.55	8.68	0.43	1.75e-16	Aortic root size;
LUSC	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.47	-0.33	3.41e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4730250	0.707	rs257386	chr7:106807783	C/G	cg02696742	chr7:106810147	HBP1	-0.66	-9.21	-0.45	3.62e-18	Osteoarthritis;
LUSC	cis	rs354225	0.584	rs11898032	chr2:54821515	G/A	cg26097391	chr2:54893211	SPTBN1	0.41	6.27	0.32	1.12e-9	Schizophrenia;
LUSC	cis	rs59104589	0.583	rs73002176	chr2:242332438	T/C	cg14842376	chr2:242211374	HDLBP	0.57	6.62	0.34	1.48e-10	Fibrinogen levels;
LUSC	trans	rs2048656	0.600	rs1976671	chr8:9679634	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	6.91	0.35	2.45e-11	Schizophrenia;
LUSC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12311346	chr5:56204834	C5orf35	0.84	13.95	0.61	3.75e-35	Initial pursuit acceleration;
LUSC	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-6.53	-0.34	2.52e-10	Colorectal cancer;
LUSC	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg22437258	chr11:111473054	SIK2	0.51	6.91	0.35	2.42e-11	Primary sclerosing cholangitis;
LUSC	trans	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg10756647	chr7:56101905	PSPH	0.89	8.94	0.44	2.61e-17	Diabetic kidney disease;
LUSC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.7	12.62	0.57	3.94e-30	Prudent dietary pattern;
LUSC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.05	-0.31	3.93e-9	Platelet count;
LUSC	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg15506890	chr2:3487001	NA	-0.53	-8.47	-0.42	7.81e-16	Neurofibrillary tangles;
LUSC	cis	rs36051895	0.530	rs4142064	chr9:5221818	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-7.43	-0.38	9.11e-13	Pediatric autoimmune diseases;
LUSC	cis	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg06521331	chr12:34319734	NA	0.4	6.51	0.34	2.83e-10	Morning vs. evening chronotype;
LUSC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg13683864	chr3:40499215	RPL14	-1.11	-21.66	-0.76	1.32e-65	Renal cell carcinoma;
LUSC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg18230493	chr5:56204884	C5orf35	-0.85	-12.86	-0.58	5.13e-31	Initial pursuit acceleration;
LUSC	cis	rs72634258	0.945	rs35675666	chr1:8021973	G/T	cg26816564	chr1:7831052	VAMP3	0.47	5.68	0.3	2.96e-8	Inflammatory bowel disease;
LUSC	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.9	16.03	0.66	2.76e-43	Metabolic syndrome;
LUSC	cis	rs2637266	0.703	rs2583061	chr10:78558475	G/A	cg18941641	chr10:78392320	NA	0.37	6.56	0.34	2.11e-10	Pulmonary function;
LUSC	cis	rs7577696	0.924	rs7566162	chr2:32324072	T/C	cg02381751	chr2:32503542	YIPF4	-0.4	-5.76	-0.3	1.87e-8	Inflammatory biomarkers;
LUSC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.53e-9	Menopause (age at onset);
LUSC	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg17462356	chr17:80056334	FASN	0.47	6.14	0.32	2.35e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg12927641	chr6:109611667	NA	-0.44	-7.65	-0.39	2.22e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg03806693	chr22:41940476	POLR3H	0.86	12.66	0.57	2.85e-30	Vitiligo;
LUSC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.05	-0.31	3.99e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg18479299	chr3:125709523	NA	-0.5	-5.67	-0.3	3.03e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2637266	0.783	rs7900420	chr10:78476543	T/C	cg18941641	chr10:78392320	NA	0.34	6.22	0.32	1.52e-9	Pulmonary function;
LUSC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg10621924	chr7:39171070	POU6F2	0.51	7.91	0.4	3.76e-14	IgG glycosylation;
LUSC	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg18512352	chr11:47633146	NA	-0.28	-5.77	-0.3	1.8e-8	Subjective well-being;
LUSC	cis	rs34421088	0.506	rs2572428	chr8:11146672	T/A	cg21775007	chr8:11205619	TDH	0.48	7.14	0.36	5.83e-12	Neuroticism;
LUSC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.84	-0.35	3.71e-11	Total body bone mineral density;
LUSC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg22800045	chr5:56110881	MAP3K1	0.48	6.18	0.32	1.85e-9	Coronary artery disease;
LUSC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.83	0.44	5.96e-17	Lung cancer;
LUSC	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg04036182	chr15:45458818	NA	0.36	5.78	0.3	1.69e-8	Glomerular filtration rate;
LUSC	cis	rs7903847	0.642	rs10882910	chr10:99138043	G/A	cg08345082	chr10:99160200	RRP12	-0.37	-7.56	-0.38	3.89e-13	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs3857536	0.776	rs9342535	chr6:66932963	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.44e-9	Blood trace element (Cu levels);
LUSC	cis	rs6426558	0.537	rs12039370	chr1:227326472	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.55	-7.41	-0.38	1.02e-12	Neutrophil percentage of white cells;
LUSC	cis	rs13385	0.769	rs4913071	chr5:139560498	T/G	cg26211634	chr5:139558579	C5orf32	0.45	6.54	0.34	2.25e-10	Atrial fibrillation;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03004578	chr6:64346172	NA	-0.41	-6.37	-0.33	6.13e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg04511125	chr2:88470314	THNSL2	-0.44	-6.6	-0.34	1.62e-10	Response to metformin (IC50);
LUSC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg22467129	chr15:76604101	ETFA	0.54	8.65	0.43	2.14e-16	Blood metabolite levels;
LUSC	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg10840412	chr1:235813424	GNG4	0.57	7.34	0.37	1.61e-12	Bipolar disorder;
LUSC	trans	rs1941687	0.831	rs12965856	chr18:31344080	A/G	cg27147174	chr7:100797783	AP1S1	-0.47	-6.9	-0.35	2.61e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg05791153	chr7:19748676	TWISTNB	0.87	8.99	0.44	1.82e-17	Thyroid stimulating hormone;
LUSC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg02153584	chr22:29168773	CCDC117	0.58	8.72	0.43	1.35e-16	Lymphocyte counts;
LUSC	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22980127	chr19:33182716	NUDT19	0.92	12.28	0.56	7.57e-29	Red blood cell traits;
LUSC	cis	rs7589342	0.839	rs35812588	chr2:106432201	C/T	cg16077055	chr2:106428750	NCK2	0.38	7.2	0.37	4.02e-12	Addiction;
LUSC	cis	rs9534288	0.912	rs4941540	chr13:46604710	C/T	cg15192986	chr13:46630673	CPB2	-0.74	-11.78	-0.54	4.87e-27	Blood protein levels;
LUSC	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg13319975	chr6:146136371	FBXO30	0.49	7.36	0.37	1.42e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	0.9	14.57	0.62	1.4e-37	Gestational age at birth (maternal effect);
LUSC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-5.76	-0.3	1.88e-8	Personality dimensions;
LUSC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.71	0.57	1.82e-30	Prudent dietary pattern;
LUSC	cis	rs1160297	0.609	rs12622966	chr2:53078420	G/C	cg07782112	chr2:53107842	NA	0.4	6.5	0.33	2.97e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg04362960	chr10:104952993	NT5C2	0.62	9.83	0.47	3.35e-20	Arsenic metabolism;
LUSC	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	0.96	13.3	0.59	1.14e-32	Primary sclerosing cholangitis;
LUSC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg15649852	chr7:65879115	NA	0.41	5.78	0.3	1.67e-8	Aortic root size;
LUSC	cis	rs2219968	0.828	rs4412362	chr8:78930579	C/T	cg00738934	chr8:78996279	NA	-0.42	-7.56	-0.38	4.05e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg15001381	chr16:403314	AXIN1	0.33	6.19	0.32	1.74e-9	Bone mineral density (spine);Bone mineral density;
LUSC	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg24759859	chr6:86352639	SYNCRIP	0.41	6.09	0.32	3.17e-9	Smooth-surface caries;
LUSC	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg13755796	chr4:20253514	NA	-0.42	-6.46	-0.33	3.62e-10	Life satisfaction;
LUSC	cis	rs7712401	0.562	rs2927639	chr5:122279666	G/C	cg19077854	chr5:122220652	SNX24	0.41	9.17	0.45	4.86e-18	Mean platelet volume;
LUSC	cis	rs7119038	0.774	rs10892290	chr11:118653503	G/T	cg19308663	chr11:118741387	NA	0.39	6.64	0.34	1.25e-10	Sjögren's syndrome;
LUSC	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg18129178	chr5:148520854	ABLIM3	-0.75	-10.93	-0.51	5.42e-24	Breast cancer;
LUSC	cis	rs259282	0.605	rs17692992	chr19:33099430	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.66	9.83	0.47	3.45e-20	Schizophrenia;
LUSC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.26	-0.56	8.47e-29	Rheumatoid arthritis;
LUSC	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg24296786	chr1:45957014	TESK2	0.42	5.95	0.31	6.67e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs6743226	0.901	rs7599888	chr2:242248033	C/G	cg10021735	chr2:242295487	FARP2	-0.36	-5.65	-0.3	3.47e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LUSC	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	16.92	0.68	7.94e-47	Exhaled nitric oxide output;
LUSC	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.51	-0.34	2.68e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs534126	1.000	rs476826	chr7:142906434	C/T	cg04039957	chr7:143013207	CLCN1	-0.31	-6.12	-0.32	2.66e-9	Cancer;
LUSC	trans	rs2840044	0.534	rs321596	chr17:33885736	C/T	cg19694781	chr19:47549865	TMEM160	0.42	6.84	0.35	3.86e-11	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.77	-12.69	-0.57	2.12e-30	Aortic root size;
LUSC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	1.0	18.55	0.71	2.78e-53	Height;
LUSC	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.45	-8.18	-0.41	6.14e-15	Eosinophil percentage of white cells;
LUSC	trans	rs12210905	1.000	rs7757680	chr6:27005840	T/C	cg11837749	chr1:55047332	ACOT11	0.59	6.28	0.32	1.05e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1775715	0.737	rs2808072	chr10:32205504	A/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.75	0.35	6.4e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg00012203	chr2:219082015	ARPC2	-0.77	-13.08	-0.58	7.36e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs3916	0.955	rs35599677	chr12:121141458	G/A	cg27246729	chr12:121163418	ACADS	0.47	6.76	0.35	6.09e-11	Urinary metabolites (H-NMR features);
LUSC	cis	rs1044826	1.000	rs9818691	chr3:139113199	C/T	cg00490450	chr3:139108681	COPB2	0.58	7.71	0.39	1.45e-13	Obesity-related traits;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg03352322	chr19:52693048	PPP2R1A	0.4	6.39	0.33	5.55e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg04727924	chr7:799746	HEATR2	-0.52	-6.39	-0.33	5.54e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg23791538	chr6:167370224	RNASET2	-0.4	-6.37	-0.33	6.17e-10	Crohn's disease;
LUSC	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg03585969	chr10:35415529	CREM	0.64	9.49	0.46	4.61e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.55	0.5	1.17e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-7.12	-0.36	6.47e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2871473	1.000	rs1030024	chr2:103105769	A/T	cg09003973	chr2:102972529	NA	-0.63	-7.21	-0.37	3.75e-12	Blood protein levels;
LUSC	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg03929089	chr4:120376271	NA	-0.6	-7.24	-0.37	3.14e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7527798	0.592	rs2181694	chr1:207826776	G/A	cg09232269	chr1:207846808	CR1L	-0.3	-6.37	-0.33	6.19e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	7.33	0.37	1.75e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19866445	chr5:271553	PDCD6	-0.39	-5.96	-0.31	6.35e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.03	-0.31	4.24e-9	Resting heart rate;
LUSC	cis	rs3771570	0.901	rs28433352	chr2:242339656	A/G	cg21155796	chr2:242212141	HDLBP	0.52	6.31	0.33	8.9e-10	Prostate cancer;
LUSC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.29	-0.41	2.74e-15	Cystic fibrosis severity;
LUSC	cis	rs870825	0.616	rs4444872	chr4:185628405	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	12.96	0.58	2.17e-31	Blood protein levels;
LUSC	cis	rs9788721	0.806	rs4887056	chr15:78734585	A/G	cg18825076	chr15:78729989	IREB2	-0.59	-9.76	-0.47	5.72e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg03585969	chr10:35415529	CREM	0.62	9.22	0.45	3.54e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6693567	0.565	rs11205370	chr1:150397567	A/G	cg15654264	chr1:150340011	RPRD2	0.44	7.09	0.36	8.16e-12	Migraine;
LUSC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg01851573	chr8:8652454	MFHAS1	0.36	5.69	0.3	2.83e-8	Schizophrenia;
LUSC	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.56	0.6	1.12e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	8.1	0.41	1.03e-14	Coronary artery disease;
LUSC	cis	rs6545883	0.929	rs2694625	chr2:61616055	G/A	cg15711740	chr2:61764176	XPO1	0.44	6.69	0.34	9.61e-11	Tuberculosis;
LUSC	cis	rs7246967	0.673	rs8106180	chr19:22879360	G/A	cg23217946	chr19:22817039	ZNF492	0.47	6.46	0.33	3.69e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs800082	0.690	rs2118001	chr3:144336609	T/C	cg24215973	chr2:240111563	HDAC4	-0.58	-9.32	-0.45	1.58e-18	Smoking behavior;
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg08472276	chr7:1133186	C7orf50;GPER	-0.4	-6.56	-0.34	2.06e-10	Longevity;Endometriosis;
LUSC	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg06096015	chr1:231504339	EGLN1	0.56	9.86	0.47	2.61e-20	Hemoglobin concentration;
LUSC	cis	rs9283706	0.595	rs6866433	chr5:66324152	A/G	cg11590213	chr5:66331682	MAST4	0.47	7.51	0.38	5.52e-13	Coronary artery disease;
LUSC	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.8	-10.07	-0.48	5.09e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs800082	0.516	rs1178893	chr3:144239246	A/C	cg24215973	chr2:240111563	HDAC4	0.45	6.98	0.36	1.6e-11	Smoking behavior;
LUSC	cis	rs259282	0.605	rs35728696	chr19:33108096	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	9.51	0.46	3.97e-19	Schizophrenia;
LUSC	cis	rs4776059	0.724	rs8030141	chr15:52937689	G/A	cg22715398	chr15:52968154	KIAA1370	0.58	7.25	0.37	3e-12	Schizophrenia;
LUSC	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18854424	chr1:2615690	NA	0.5	9.97	0.48	1.12e-20	Ulcerative colitis;
LUSC	trans	rs10822407	0.710	rs10822363	chr10:66650703	C/T	cg26654559	chr16:86492912	NA	0.34	5.98	0.31	5.64e-9	Diastolic blood pressure;
LUSC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg06145435	chr7:1022769	CYP2W1	0.29	6.25	0.32	1.24e-9	Longevity;Endometriosis;
LUSC	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg05340658	chr4:99064831	C4orf37	0.59	8.75	0.43	1.04e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10779751	1.000	rs2300093	chr1:11266392	G/C	cg08854313	chr1:11322531	MTOR	0.91	16.32	0.67	1.93e-44	Body mass index;
LUSC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.58	-0.6	9.45e-34	Chronic sinus infection;
LUSC	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.37	0.37	1.39e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg13072238	chr3:49761600	GMPPB	0.39	6.43	0.33	4.47e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg00316803	chr15:76480434	C15orf27	-0.41	-6.96	-0.36	1.77e-11	Blood metabolite levels;
LUSC	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg10978503	chr1:24200527	CNR2	-0.47	-9.65	-0.47	1.32e-19	Immature fraction of reticulocytes;
LUSC	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.13	-19.86	-0.74	1.64e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-7.35	-0.37	1.53e-12	Renal function-related traits (BUN);
LUSC	cis	rs548181	0.736	rs556884	chr11:125550049	G/A	cg03464685	chr11:125439445	EI24	1.22	14.52	0.62	2.22e-37	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg12463550	chr7:65579703	CRCP	0.45	6.73	0.35	7.31e-11	Aortic root size;
LUSC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg03806693	chr22:41940476	POLR3H	0.99	13.85	0.6	9.09e-35	Vitiligo;
LUSC	cis	rs2279817	0.735	rs71644063	chr1:17987274	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.48	-5.73	-0.3	2.3e-8	Neuroticism;
LUSC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg11632617	chr15:75315747	PPCDC	-0.54	-7.12	-0.36	6.84e-12	Blood trace element (Zn levels);
LUSC	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.23	0.59	2.05e-32	Blood protein levels;
LUSC	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.56	-0.42	4.14e-16	Systolic blood pressure;
LUSC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.09	0.48	4.54e-21	Electroencephalogram traits;
LUSC	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg24450063	chr1:156163899	SLC25A44	1.1	21.87	0.77	2.05e-66	Testicular germ cell tumor;
LUSC	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.72	-0.47	7.9e-20	Coronary artery disease;
LUSC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg04414720	chr1:150670196	GOLPH3L	0.54	8.46	0.42	8.59e-16	Melanoma;
LUSC	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg08917208	chr2:24149416	ATAD2B	1.01	10.6	0.5	8.3300000000000006e-23	Lymphocyte counts;
LUSC	cis	rs6556937	0.562	rs26485	chr5:96016477	C/T	cg07690455	chr5:95997198	CAST	0.42	5.91	0.31	8.29e-9	Blood protein levels;
LUSC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-0.81	-11.07	-0.52	1.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.41	-0.49	3.71e-22	Eye color traits;
LUSC	cis	rs2279817	1.000	rs905389	chr1:18021406	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.48	6.74	0.35	7.09e-11	Neuroticism;
LUSC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.78	0.3	1.74e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg05855489	chr10:104503620	C10orf26	0.61	9.8	0.47	4.43e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg15704280	chr7:45808275	SEPT13	0.66	7.35	0.37	1.58e-12	Axial length;
LUSC	cis	rs981844	1.000	rs2606327	chr4:154653629	C/T	cg14289246	chr4:154710475	SFRP2	0.53	6.83	0.35	4.06e-11	Response to statins (LDL cholesterol change);
LUSC	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg11693508	chr17:37793320	STARD3	0.56	6.66	0.34	1.12e-10	Neuroticism;
LUSC	cis	rs6693567	0.545	rs11205382	chr1:150442466	G/A	cg15654264	chr1:150340011	RPRD2	-0.44	-7.1	-0.36	7.31e-12	Migraine;
LUSC	cis	rs7804356	0.861	rs114236648	chr7:26874639	A/G	cg03456212	chr7:26904342	SKAP2	-0.55	-6.37	-0.33	6.29e-10	Type 1 diabetes;
LUSC	cis	rs477692	1.000	rs473073	chr10:131429646	G/T	cg05714579	chr10:131428358	MGMT	0.51	7.54	0.38	4.54e-13	Response to temozolomide;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19607838	chr20:43594981	STK4	-0.45	-6.8	-0.35	4.7e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg03806693	chr22:41940476	POLR3H	-0.51	-6.93	-0.35	2.17e-11	Neuroticism;
LUSC	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	8.84	0.44	5.58e-17	Total cholesterol levels;
LUSC	trans	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg10756647	chr7:56101905	PSPH	0.86	8.39	0.42	1.36e-15	Diabetic kidney disease;
LUSC	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.01	0.31	4.92e-9	Morning vs. evening chronotype;
LUSC	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	1.0	12.96	0.58	2.06e-31	Blood pressure (smoking interaction);
LUSC	cis	rs10875746	0.903	rs11168401	chr12:48481519	T/C	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs2219968	1.000	rs2128014	chr8:78963292	T/C	cg00738934	chr8:78996279	NA	0.34	6.18	0.32	1.89e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	1.06	12.67	0.57	2.59e-30	Schizophrenia;
LUSC	cis	rs17255340	0.539	rs1170518	chr6:84011913	T/C	cg08257003	chr6:84140564	ME1	0.32	7.71	0.39	1.44e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	9.33	0.45	1.57e-18	Hemoglobin concentration;
LUSC	cis	rs887829	0.569	rs10179091	chr2:234657983	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-8.79	-0.43	7.88e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	trans	rs877282	0.583	rs7072970	chr10:822757	G/A	cg13042288	chr15:90349979	ANPEP	-0.41	-5.99	-0.31	5.3300000000000004e-09	Uric acid levels;
LUSC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg07703079	chr11:430292	ANO9	0.6	6.52	0.34	2.66e-10	Body mass index;
LUSC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.39	-0.37	1.2e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg18477163	chr1:228402036	OBSCN	0.62	12.2	0.56	1.49e-28	Diastolic blood pressure;
LUSC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.63	-9.23	-0.45	3.29e-18	Longevity;Endometriosis;
LUSC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11764359	chr7:65958608	NA	0.68	10.99	0.52	3.57e-24	Aortic root size;
LUSC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08677398	chr8:58056175	NA	0.54	7.01	0.36	1.34e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg10792982	chr14:105748885	BRF1	0.52	9.54	0.46	3e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	10.6	0.5	7.9399999999999994e-23	Coffee consumption (cups per day);
LUSC	cis	rs939658	0.805	rs11638004	chr15:79425765	A/C	cg17916960	chr15:79447300	NA	-0.53	-10.45	-0.5	2.58e-22	Refractive error;
LUSC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-8.02	-0.4	1.84e-14	Obesity-related traits;
LUSC	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg13962466	chr20:25176127	ENTPD6	0.52	8.51	0.42	5.91e-16	Colorectal or endometrial cancer;
LUSC	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	11.3	0.53	2.63e-25	Lung cancer in ever smokers;
LUSC	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg08027265	chr7:2291960	NA	-0.63	-11.37	-0.53	1.47e-25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg12963246	chr6:28129442	ZNF389	0.53	7.35	0.37	1.54e-12	Parkinson's disease;
LUSC	trans	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg07393940	chr7:158741817	NA	-0.34	-6.06	-0.31	3.58e-9	Life satisfaction;
LUSC	cis	rs262150	0.592	rs56062559	chr7:158769109	T/C	cg19418458	chr7:158789849	NA	0.58	7.18	0.37	4.59e-12	Facial morphology (factor 20);
LUSC	cis	rs7590368	0.683	rs56344711	chr2:10969688	C/T	cg15705551	chr2:10952987	PDIA6	0.62	6.71	0.34	8.52e-11	Educational attainment (years of education);
LUSC	cis	rs2282032	1.000	rs3742671	chr14:90756760	A/T	cg14092571	chr14:90743983	NA	0.56	7.13	0.36	6.3e-12	Longevity;
LUSC	trans	rs800082	1.000	rs4681363	chr3:144287355	A/G	cg24215973	chr2:240111563	HDAC4	-0.45	-6.7	-0.34	8.75e-11	Smoking behavior;
LUSC	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg24006582	chr15:45444508	DUOX1	0.67	9.67	0.47	1.16e-19	Uric acid levels;
LUSC	cis	rs62400317	0.826	rs12216308	chr6:45342305	T/G	cg20913747	chr6:44695427	NA	-0.49	-8.0	-0.4	2.02e-14	Total body bone mineral density;
LUSC	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg15423357	chr2:25149977	NA	0.4	7.93	0.4	3.24e-14	Body mass index;
LUSC	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg00520135	chr15:63333846	TPM1	-0.34	-6.79	-0.35	5.15e-11	Platelet count;
LUSC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.94	-0.36	2e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02905964	chr19:29704262	UQCRFS1	0.43	6.47	0.33	3.53e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6704768	0.545	rs5004510	chr2:233679275	A/C	cg08000102	chr2:233561755	GIGYF2	-0.78	-12.38	-0.56	3.18e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.72	0.35	8.08e-11	Corneal astigmatism;
LUSC	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-10.87	-0.51	9.4e-24	Alcohol dependence;
LUSC	cis	rs67981189	0.593	rs9806042	chr14:71530993	G/C	cg15816911	chr14:71606274	NA	0.33	5.85	0.3	1.19e-8	Schizophrenia;
LUSC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-0.83	-13.84	-0.6	9.33e-35	Tonsillectomy;
LUSC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.49	7.61	0.38	2.78e-13	Colorectal cancer;
LUSC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg06600287	chr1:53387719	ECHDC2	-0.31	-6.41	-0.33	5.09e-10	Monocyte count;
LUSC	cis	rs12980942	0.872	rs16958994	chr19:41824981	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.55	5.94	0.31	7.27e-9	Coronary artery disease;
LUSC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.39	5.69	0.3	2.78e-8	Renal function-related traits (BUN);
LUSC	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	0.6	9.54	0.46	3.18e-19	Breast cancer;
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg12419862	chr22:24373484	LOC391322	-0.95	-18.01	-0.7	3.81e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg17252645	chr8:143867129	LY6D	0.38	6.72	0.34	8.03e-11	Urinary tract infection frequency;
LUSC	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.87	-15.19	-0.64	5.53e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg26335602	chr6:28129616	ZNF389	-0.45	-6.28	-0.33	1.05e-9	Depression;
LUSC	cis	rs9815354	0.812	rs111967505	chr3:41873157	C/T	cg03022575	chr3:42003672	ULK4	0.84	8.86	0.44	4.79e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg16434002	chr17:42200994	HDAC5	-0.44	-6.0	-0.31	5.26e-9	Total body bone mineral density;
LUSC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg05025164	chr4:1340916	KIAA1530	0.43	6.64	0.34	1.26e-10	Longevity;
LUSC	trans	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.19	-0.32	1.76e-9	Depression;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	ch.6.143706070F	chr6:143664377	NA	0.33	6.06	0.31	3.67e-9	Tuberculosis;
LUSC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg06238570	chr21:40685208	BRWD1	0.5	7.5	0.38	5.85e-13	Cognitive function;
LUSC	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg26893861	chr17:41843967	DUSP3	0.94	14.36	0.62	9.27e-37	Triglycerides;
LUSC	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg20701182	chr2:24300061	SF3B14	0.76	7.7	0.39	1.51e-13	Lymphocyte counts;
LUSC	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg26647111	chr11:31128758	NA	-0.43	-6.12	-0.32	2.58e-9	Red blood cell count;
LUSC	cis	rs524023	0.958	rs12802649	chr11:64359627	C/T	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.69	-0.3	2.76e-8	Urate levels in obese individuals;
LUSC	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg04455712	chr21:45112962	RRP1B	0.48	8.87	0.44	4.6e-17	Mean corpuscular volume;
LUSC	cis	rs7005380	0.556	rs12548248	chr8:120932321	A/G	cg21744203	chr8:120868354	DSCC1	-0.47	-5.75	-0.3	1.97e-8	Interstitial lung disease;
LUSC	cis	rs9361491	0.508	rs7773448	chr6:79417356	C/T	cg05283184	chr6:79620031	NA	-0.39	-6.88	-0.35	2.88e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03156032	chr17:27717754	TAOK1	-0.41	-6.22	-0.32	1.45e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg02972257	chr16:68554789	NA	0.46	5.9	0.31	9.01e-9	Colorectal cancer;
LUSC	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.75	-0.35	6.5e-11	Monocyte percentage of white cells;
LUSC	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg15485101	chr11:133734466	NA	0.38	7.15	0.36	5.64e-12	Childhood ear infection;
LUSC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	7.78	0.39	8.86e-14	Schizophrenia;
LUSC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-11.49	-0.53	5.69e-26	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs3087591	0.708	rs2854307	chr17:29652147	G/A	cg24425628	chr17:29625626	OMG;NF1	0.46	6.93	0.35	2.21e-11	Hip circumference;
LUSC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.5	-8.38	-0.42	1.5e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.35	-6.07	-0.32	3.4e-9	Longevity;Endometriosis;
LUSC	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-0.86	-14.29	-0.62	1.69e-36	Headache;
LUSC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.08	0.32	3.34e-9	Menopause (age at onset);
LUSC	cis	rs7267979	0.668	rs2387977	chr20:25599776	C/T	cg03522245	chr20:25566470	NINL	-0.4	-6.47	-0.33	3.59e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg00864171	chr11:67383662	NA	0.34	5.97	0.31	5.93e-9	Mean corpuscular volume;
LUSC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.03	-0.31	4.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06112835	chr11:68658793	MRPL21	0.49	7.47	0.38	7.02e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.08	0.44	9.59e-18	Motion sickness;
LUSC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg01176363	chr20:62369445	LIME1	-0.47	-7.14	-0.36	5.85e-12	Prostate cancer;
LUSC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	10.74	0.51	2.71e-23	Chronic sinus infection;
LUSC	cis	rs921665	0.680	rs7591433	chr2:3180126	A/C	cg02624386	chr2:3182749	NA	0.6	6.69	0.34	9.7e-11	World class endurance athleticism;
LUSC	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-11.58	-0.54	2.66e-26	Colorectal cancer;
LUSC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg03161606	chr19:29218774	NA	0.63	9.73	0.47	7.39e-20	Methadone dose in opioid dependence;
LUSC	cis	rs9309473	0.950	rs6546858	chr2:73838613	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.63	-0.34	1.37e-10	Metabolite levels;
LUSC	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg26597838	chr10:835615	NA	-0.42	-6.13	-0.32	2.48e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs11608355	0.521	rs4766595	chr12:109846998	A/T	cg19025524	chr12:109796872	NA	-0.4	-7.33	-0.37	1.73e-12	Neuroticism;
LUSC	cis	rs4834770	1.000	rs2282688	chr4:120243722	T/C	cg24375607	chr4:120327624	NA	0.41	5.84	0.3	1.26e-8	Blood protein levels;
LUSC	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg03929089	chr4:120376271	NA	0.69	7.72	0.39	1.4e-13	Axial length;
LUSC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg21782813	chr7:2030301	MAD1L1	0.54	9.26	0.45	2.61e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.87	11.6	0.54	2.35e-26	Mean corpuscular hemoglobin;
LUSC	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	7.57	0.38	3.64e-13	Lung cancer in ever smokers;
LUSC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05535760	chr7:792225	HEATR2	0.75	8.8	0.43	7.39e-17	Cerebrospinal P-tau181p levels;
LUSC	cis	rs77140172	0.655	rs79387006	chr4:89672775	A/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.96	7.68	0.39	1.82e-13	Post bronchodilator FEV1;
LUSC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg02038168	chr22:39784481	NA	-0.49	-8.11	-0.41	9.96e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02187348	chr16:89574699	SPG7	0.64	10.5	0.5	1.8e-22	Multiple myeloma (IgH translocation);
LUSC	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg23241863	chr10:102295624	HIF1AN	0.5	5.98	0.31	5.63e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.01	-0.52	2.85e-24	Bipolar disorder;
LUSC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.64	0.43	2.34e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.77	-0.35	5.93e-11	Menopause (age at onset);
LUSC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg06462663	chr19:18546047	ISYNA1	-0.45	-7.66	-0.39	2.02e-13	Breast cancer;
LUSC	cis	rs11031096	0.666	rs1662173	chr11:4127649	C/G	cg18678763	chr11:4115507	RRM1	0.38	5.7	0.3	2.67e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg07703079	chr11:430292	ANO9	0.64	6.7	0.34	8.97e-11	Body mass index;
LUSC	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-9.81	-0.47	4.11e-20	Morning vs. evening chronotype;
LUSC	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.64	0.39	2.25e-13	Iron status biomarkers;
LUSC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg05347473	chr6:146136440	FBXO30	0.59	10.32	0.49	7.62e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4853525	1.000	rs4853525	chr2:191737464	T/C	cg11845111	chr2:191398756	TMEM194B	-0.4	-5.98	-0.31	5.65e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs12776158	0.591	rs12769200	chr10:71217784	A/G	cg12610070	chr10:71211762	TSPAN15	0.35	5.7	0.3	2.67e-8	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg12311346	chr5:56204834	C5orf35	-0.83	-12.93	-0.58	2.74e-31	Coronary artery disease;
LUSC	cis	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg06521331	chr12:34319734	NA	-0.48	-7.77	-0.39	9.54e-14	Morning vs. evening chronotype;
LUSC	cis	rs4474465	1.000	rs11604969	chr11:78179293	C/T	cg27205649	chr11:78285834	NARS2	0.47	5.65	0.3	3.38e-8	Alzheimer's disease (survival time);
LUSC	cis	rs4588572	0.643	rs13359053	chr5:77690224	T/C	cg11547950	chr5:77652471	NA	0.53	7.46	0.38	7.57e-13	Triglycerides;
LUSC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg14895029	chr7:2775587	GNA12	-0.4	-6.5	-0.34	2.94e-10	Height;
LUSC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.1	0.58	6.37e-32	Total body bone mineral density;
LUSC	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg07661805	chr8:143867942	LY6D	-0.26	-5.95	-0.31	6.81e-9	Urinary tract infection frequency;
LUSC	cis	rs10465746	0.967	rs10493744	chr1:84444752	C/T	cg10977910	chr1:84465055	TTLL7	-0.45	-6.53	-0.34	2.48e-10	Obesity-related traits;
LUSC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg00933542	chr6:150070202	PCMT1	0.3	6.05	0.31	3.79e-9	Lung cancer;
LUSC	trans	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.02	-0.36	1.25e-11	Triglycerides;
LUSC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.47	-8.99	-0.44	1.86e-17	Lung cancer;
LUSC	cis	rs7584330	0.554	rs113271883	chr2:238425594	A/G	cg16989719	chr2:238392110	NA	-0.43	-6.2	-0.32	1.63e-9	Prostate cancer;
LUSC	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg02527881	chr3:46936655	PTH1R	-0.57	-8.42	-0.42	1.12e-15	Birth weight;
LUSC	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.22	-0.32	1.52e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.41e-28	Motion sickness;
LUSC	cis	rs2481665	0.772	rs12730782	chr1:62537265	A/G	cg18591186	chr1:62594603	INADL	-0.42	-6.51	-0.34	2.82e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg07148914	chr20:33460835	GGT7	0.53	8.11	0.41	9.72e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg06212747	chr3:49208901	KLHDC8B	0.44	5.99	0.31	5.3e-9	Parkinson's disease;
LUSC	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg23601095	chr6:26197514	HIST1H3D	0.68	7.3	0.37	2.16e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.46	6.75	0.35	6.52e-11	Eosinophil percentage of white cells;
LUSC	cis	rs16854884	0.558	rs60367530	chr3:143719294	G/A	cg06585982	chr3:143692056	C3orf58	0.45	6.9	0.35	2.61e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg09021430	chr5:549028	NA	-0.54	-7.03	-0.36	1.2e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.58	-9.51	-0.46	4.03e-19	Aortic root size;
LUSC	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg04861640	chr6:28234605	ZNF187	0.4	7.12	0.36	6.45e-12	Tuberculosis;
LUSC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg06784218	chr1:46089804	CCDC17	0.48	9.5	0.46	4.15e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7719624	1.000	rs2107331	chr5:135377349	A/C	cg12897067	chr5:135418308	NA	-0.4	-6.05	-0.31	3.83e-9	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs7000551	0.725	rs2461483	chr8:22386479	C/T	cg12081754	chr8:22256438	SLC39A14	0.43	6.47	0.33	3.56e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1124376	0.688	rs11715447	chr3:20140129	A/C	cg05072819	chr3:20081367	KAT2B	0.97	9.43	0.46	7.39e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs2820315	0.965	rs8028	chr1:201865763	A/G	cg10061532	chr1:201886748	LMOD1	-0.27	-6.1	-0.32	2.95e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	7.62	0.38	2.6e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs17828380	0.920	rs17828224	chr15:63456749	T/C	cg05507819	chr15:63340323	TPM1	-0.75	-6.14	-0.32	2.35e-9	Social communication problems;
LUSC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg27170947	chr2:26402098	FAM59B	0.6	8.19	0.41	5.66e-15	Gut microbiome composition (summer);
LUSC	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg20713898	chr8:124780851	FAM91A1	-0.52	-7.32	-0.37	1.81e-12	Pancreatic cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg22328890	chr16:68298258	SLC7A6	0.48	6.65	0.34	1.21e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg08499158	chr17:42289980	UBTF	-0.48	-7.79	-0.39	8.46e-14	Total body bone mineral density;
LUSC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06481639	chr22:41940642	POLR3H	-0.55	-6.6	-0.34	1.65e-10	Vitiligo;
LUSC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00934597	chr7:893267	UNC84A	-0.47	-7.12	-0.36	6.61e-12	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs6960043	0.818	rs10487796	chr7:15063430	T/A	cg19272540	chr7:15055459	NA	0.33	8.01	0.4	1.91e-14	Type 2 diabetes;
LUSC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg13628971	chr7:2884303	GNA12	0.44	6.21	0.32	1.57e-9	Height;
LUSC	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg04545296	chr12:48745243	ZNF641	-0.37	-6.74	-0.35	6.81e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06634786	chr22:41940651	POLR3H	0.5	6.04	0.31	4.07e-9	Vitiligo;
LUSC	trans	rs2679649	1.000	rs1357056	chr6:122363734	C/T	cg00167820	chr8:131663355	NA	-0.46	-6.07	-0.32	3.42e-9	Subcutaneous adipose tissue;
LUSC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg04518342	chr5:131593106	PDLIM4	0.34	6.35	0.33	6.96e-10	Blood metabolite levels;
LUSC	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg06096015	chr1:231504339	EGLN1	0.57	9.93	0.48	1.56e-20	Hemoglobin concentration;
LUSC	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.23	-0.45	3.12e-18	Neuroticism;
LUSC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg14456004	chr13:21872349	NA	0.45	6.63	0.34	1.37e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg17173187	chr15:85201210	NMB	0.37	6.66	0.34	1.12e-10	Schizophrenia;
LUSC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-0.88	-16.5	-0.67	3.72e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.93	-0.48	1.61e-20	Hemoglobin concentration;
LUSC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg26513180	chr16:89883248	FANCA	0.78	6.39	0.33	5.68e-10	Skin colour saturation;
LUSC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg04455712	chr21:45112962	RRP1B	0.47	9.07	0.44	1.06e-17	Mean corpuscular volume;
LUSC	cis	rs2734839	0.964	rs2734838	chr11:113286501	A/G	cg14159747	chr11:113255604	NA	0.27	6.83	0.35	4.03e-11	Information processing speed;
LUSC	cis	rs716595	1.000	rs72830456	chr10:112008631	G/A	cg13996003	chr10:112034540	MXI1	-0.7	-5.68	-0.3	2.96e-8	Normalized brain volume;
LUSC	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.69	-10.77	-0.51	2.13e-23	Alcohol dependence;
LUSC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg09455208	chr3:40491958	NA	0.56	10.19	0.49	2.09e-21	Renal cell carcinoma;
LUSC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.74	12.11	0.55	3.11e-28	Coronary artery disease;
LUSC	cis	rs10465746	0.935	rs11807807	chr1:84424071	C/T	cg10977910	chr1:84465055	TTLL7	0.42	6.21	0.32	1.59e-9	Obesity-related traits;
LUSC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg03526776	chr6:41159608	TREML2	0.33	6.12	0.32	2.67e-9	Alzheimer's disease (late onset);
LUSC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg12311346	chr5:56204834	C5orf35	-0.63	-9.14	-0.45	6.15e-18	Coronary artery disease;
LUSC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-8.26	-0.41	3.37e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7590368	0.673	rs55648622	chr2:10932765	C/T	cg15705551	chr2:10952987	PDIA6	0.52	5.86	0.31	1.13e-8	Educational attainment (years of education);
LUSC	cis	rs4494114	1.000	rs10890491	chr1:39354602	G/A	cg25970120	chr1:39325951	RRAGC	-0.4	-6.19	-0.32	1.8e-9	Blood protein levels;
LUSC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg18681998	chr4:17616180	MED28	0.84	15.29	0.64	2.27e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg27661571	chr11:113659931	NA	-0.66	-7.51	-0.38	5.31e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18876405	chr7:65276391	NA	-0.56	-8.95	-0.44	2.53e-17	Aortic root size;
LUSC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.03	0.48	7.06e-21	Hemoglobin concentration;
LUSC	cis	rs1595825	0.735	rs113834557	chr2:198611624	A/G	cg00982548	chr2:198649783	BOLL	-0.59	-7.27	-0.37	2.63e-12	Ulcerative colitis;
LUSC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg16647868	chr5:131706066	SLC22A5	0.35	5.95	0.31	6.8e-9	Blood metabolite levels;
LUSC	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg18357645	chr12:58087776	OS9	0.43	6.47	0.33	3.48e-10	Multiple sclerosis;
LUSC	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg01256987	chr12:42539512	GXYLT1	0.34	6.23	0.32	1.39e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2970818	0.764	rs11063171	chr12:4576775	C/G	cg11146114	chr12:4671731	NA	-0.65	-6.31	-0.33	9.06e-10	Phosphorus levels;
LUSC	cis	rs7575217	0.849	rs7571554	chr2:101769917	T/G	cg23907051	chr2:101730305	TBC1D8	-0.29	-7.47	-0.38	7.26e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.89	-0.31	9.59e-9	Tonsillectomy;
LUSC	cis	rs9612	1.000	rs2074634	chr19:44238347	C/T	cg08581076	chr19:44259116	C19orf61	-0.52	-6.46	-0.33	3.62e-10	Exhaled nitric oxide output;
LUSC	cis	rs2200578	1.000	rs72954221	chr2:99899445	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	6.48	0.33	3.26e-10	IgG glycosylation;
LUSC	trans	rs2048656	0.570	rs7814635	chr8:9646620	G/A	cg06636001	chr8:8085503	FLJ10661	0.46	6.52	0.34	2.64e-10	Schizophrenia;
LUSC	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21659725	chr3:3221576	CRBN	-0.64	-10.69	-0.5	3.96e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.27	0.52	3.49e-25	Menopause (age at onset);
LUSC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg02158880	chr13:53174818	NA	0.57	9.95	0.48	1.39e-20	Lewy body disease;
LUSC	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg05925327	chr15:68127851	NA	0.33	5.94	0.31	7.06e-9	Restless legs syndrome;
LUSC	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg12863693	chr15:85201151	NMB	0.42	8.43	0.42	1.05e-15	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.67	-11.24	-0.52	4.52e-25	Cognitive function;
LUSC	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.19e-33	Morning vs. evening chronotype;
LUSC	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-10.4	-0.49	4.05e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs897984	0.762	rs12931046	chr16:30987144	G/A	cg02466173	chr16:30829666	NA	0.55	10.88	0.51	8.73e-24	Dementia with Lewy bodies;
LUSC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	11.96	0.55	1.09e-27	Hip circumference adjusted for BMI;
LUSC	cis	rs727505	1.000	rs10228201	chr7:124449895	A/G	cg23710748	chr7:124431027	NA	-0.42	-7.58	-0.38	3.53e-13	Lewy body disease;
LUSC	trans	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-8.34	-0.42	2.03e-15	Obesity-related traits;
LUSC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg17294928	chr15:75287854	SCAMP5	0.7	6.38	0.33	5.79e-10	Lung cancer;
LUSC	trans	rs1941687	0.509	rs6507060	chr18:31322278	C/T	cg27147174	chr7:100797783	AP1S1	0.53	8.32	0.41	2.32e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg27129171	chr3:47204927	SETD2	-0.57	-8.16	-0.41	7.07e-15	Birth weight;
LUSC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg03676636	chr4:99064102	C4orf37	-0.33	-7.49	-0.38	6.06e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7945718	0.839	rs2033908	chr11:12838286	G/T	cg25843174	chr11:12811716	TEAD1	0.32	7.36	0.37	1.49e-12	Educational attainment (years of education);
LUSC	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg05973401	chr12:123451056	ABCB9	0.52	6.43	0.33	4.29e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10150615	chr22:24372951	LOC391322	-0.38	-6.43	-0.33	4.44e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-12.13	-0.55	2.7e-28	Colorectal cancer;
LUSC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14893161	chr1:205819251	PM20D1	-0.46	-6.5	-0.34	2.9e-10	Parkinson's disease;
LUSC	cis	rs62408225	0.802	rs2325261	chr6:90921407	T/C	cg06866423	chr6:90926672	BACH2	0.44	6.83	0.35	3.91e-11	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6591341	0.515	rs599301	chr11:68189945	G/C	cg16797656	chr11:68205561	LRP5	0.46	8.14	0.41	7.92e-15	Lean body mass;
LUSC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.43	-5.7	-0.3	2.7e-8	Menarche (age at onset);
LUSC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.58	7.59	0.38	3.33e-13	Lung function (FEV1/FVC);
LUSC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11645453	chr3:52864694	ITIH4	0.34	7.99	0.4	2.19e-14	Electroencephalogram traits;
LUSC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg05714579	chr10:131428358	MGMT	0.5	7.43	0.38	9.36e-13	Response to temozolomide;
LUSC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.31	0.37	1.98e-12	Motion sickness;
LUSC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.83	0.44	6.01e-17	Schizophrenia;
LUSC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11890956	chr21:40555474	PSMG1	-0.66	-9.62	-0.47	1.65e-19	Menarche (age at onset);
LUSC	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg24375607	chr4:120327624	NA	-0.73	-10.77	-0.51	2.09e-23	Corneal astigmatism;
LUSC	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.55	-0.34	2.22e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs4851254	1.000	rs4851254	chr2:100762937	C/G	cg07810366	chr2:100720526	AFF3	-0.36	-5.66	-0.3	3.21e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12016809	chr21:47604291	C21orf56	0.39	5.69	0.3	2.81e-8	Testicular germ cell tumor;
LUSC	cis	rs2877187	0.511	rs9639867	chr7:43038272	A/G	cg00365680	chr7:42972339	MRPL32;PSMA2	-0.44	-5.89	-0.31	9.29e-9	Lung cancer in ever smokers;
LUSC	cis	rs7560272	0.723	rs62153184	chr2:73773869	G/C	cg20560298	chr2:73613845	ALMS1	-0.48	-7.43	-0.38	9.41e-13	Schizophrenia;
LUSC	cis	rs701145	0.585	rs1542254	chr3:153864296	C/T	cg17054900	chr3:154042577	DHX36	0.63	6.18	0.32	1.9e-9	Coronary artery disease;
LUSC	trans	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	6.09	0.32	3.15e-9	Myopia (pathological);
LUSC	cis	rs7089973	0.872	rs36036948	chr10:116631649	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	7.77	0.39	9.94e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg02569458	chr12:86230093	RASSF9	0.58	9.85	0.47	2.89e-20	Major depressive disorder;
LUSC	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21659725	chr3:3221576	CRBN	-0.61	-9.98	-0.48	1.05e-20	Intelligence (multi-trait analysis);
LUSC	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.46	-0.46	5.87e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg18904891	chr8:8559673	CLDN23	0.38	5.89	0.31	9.52e-9	Mood instability;
LUSC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg24578937	chr1:2090814	PRKCZ	0.45	10.15	0.49	2.74e-21	Height;
LUSC	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg00012203	chr2:219082015	ARPC2	-0.76	-13.09	-0.58	6.86e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	trans	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-8.72	-0.43	1.31e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg04944784	chr2:26401820	FAM59B	-0.7	-9.79	-0.47	4.69e-20	Gut microbiome composition (summer);
LUSC	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg22546130	chr22:19950026	COMT	0.26	5.75	0.3	2.02e-8	Blood metabolite levels;
LUSC	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.07	0.64	1.63e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg15691649	chr6:25882328	NA	-0.39	-6.32	-0.33	8.37e-10	Blood metabolite levels;
LUSC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.7	12.71	0.57	1.91e-30	Prudent dietary pattern;
LUSC	cis	rs6546537	0.915	rs4852866	chr2:69829916	T/C	cg10773587	chr2:69614142	GFPT1	-0.47	-7.38	-0.37	1.23e-12	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.83	13.05	0.58	9.57e-32	Obesity-related traits;
LUSC	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg04362960	chr10:104952993	NT5C2	0.61	8.9	0.44	3.71e-17	Immature fraction of reticulocytes;Schizophrenia;
LUSC	trans	rs71435601	0.657	rs1878512	chr2:21420358	C/A	cg20757404	chr19:378427	NA	-0.41	-6.32	-0.33	8.46e-10	Cholesterol, total;
LUSC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.4	0.62	6.35e-37	Platelet count;
LUSC	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg16070123	chr10:51489643	NA	-0.57	-9.49	-0.46	4.65e-19	Prostate-specific antigen levels;
LUSC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg14552801	chr7:65878734	NA	-0.37	-5.71	-0.3	2.46e-8	Aortic root size;
LUSC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.9	-0.4	4.02e-14	Glomerular filtration rate;
LUSC	cis	rs7200543	1.000	rs14347	chr16:15133889	T/G	cg03427771	chr16:15082598	PDXDC1	-0.41	-5.71	-0.3	2.53e-8	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.82	13.98	0.61	2.89e-35	Blood protein levels;
LUSC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.47	0.56	1.45e-29	Motion sickness;
LUSC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg03146154	chr1:46216737	IPP	0.56	8.37	0.42	1.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg16928487	chr17:17741425	SREBF1	-0.43	-8.34	-0.42	1.95e-15	Total body bone mineral density;
LUSC	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg07700843	chr1:2391317	NA	-0.44	-7.87	-0.4	5.12e-14	Schizophrenia;
LUSC	cis	rs868036	1.000	rs1026733	chr15:68095122	G/A	cg05925327	chr15:68127851	NA	-0.32	-5.7	-0.3	2.67e-8	Restless legs syndrome;
LUSC	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg21775007	chr8:11205619	TDH	-0.45	-6.73	-0.35	7.3e-11	Neuroticism;
LUSC	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg05855489	chr10:104503620	C10orf26	0.6	9.6	0.47	1.97e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg06784218	chr1:46089804	CCDC17	0.53	10.22	0.49	1.67e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2710642	0.962	rs6545972	chr2:63084682	G/A	cg17519650	chr2:63277830	OTX1	0.49	6.92	0.35	2.36e-11	LDL cholesterol levels;LDL cholesterol;
LUSC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.74	13.64	0.6	5.77e-34	Intelligence (multi-trait analysis);
LUSC	trans	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg13565492	chr6:43139072	SRF	-0.43	-6.37	-0.33	6.34e-10	Longevity;Endometriosis;
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg14004847	chr7:1930337	MAD1L1	-0.54	-8.45	-0.42	8.86e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg03433033	chr1:76189801	ACADM	-0.39	-5.77	-0.3	1.85e-8	Daytime sleep phenotypes;
LUSC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg05425664	chr17:57184151	TRIM37	0.54	7.95	0.4	2.9e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg24399712	chr22:39784796	NA	0.65	12.15	0.55	2.31e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg18477163	chr1:228402036	OBSCN	0.62	12.18	0.55	1.73e-28	Diastolic blood pressure;
LUSC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg18230493	chr5:56204884	C5orf35	-0.93	-13.83	-0.6	1.01e-34	Initial pursuit acceleration;
LUSC	cis	rs4728302	0.583	rs12707091	chr7:133185749	A/G	cg10665199	chr7:133106180	EXOC4	0.55	7.76	0.39	1.03e-13	Intelligence;Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26880073	chr19:48018745	NAPA	-0.44	-6.66	-0.34	1.11e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg06238570	chr21:40685208	BRWD1	0.6	9.88	0.48	2.35e-20	Cognitive function;
LUSC	cis	rs4845459	0.933	rs11205044	chr1:152593437	T/C	cg08895932	chr1:152778580	LCE1C	-0.38	-6.53	-0.34	2.46e-10	Psoriasis;
LUSC	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg13390004	chr1:15929781	NA	0.42	7.0	0.36	1.43e-11	Systolic blood pressure;
LUSC	cis	rs460214	0.528	rs4817954	chr21:40023857	C/T	cg05519781	chr21:40033154	ERG	-0.45	-6.01	-0.31	4.86e-9	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs2932538	0.883	rs6537740	chr1:113080084	T/G	cg22162597	chr1:113214053	CAPZA1	0.72	10.14	0.49	2.99e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs67072384	1.000	rs61489692	chr11:72445314	T/C	cg04827223	chr11:72435913	ARAP1	-0.82	-7.76	-0.39	1.04e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.88e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg25036284	chr2:26402008	FAM59B	-0.74	-10.56	-0.5	1.13e-22	Gut microbiome composition (summer);
LUSC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.38	0.33	5.95e-10	Menopause (age at onset);
LUSC	cis	rs193541	0.632	rs7729834	chr5:122122159	A/G	cg19077854	chr5:122220652	SNX24	0.38	7.84	0.39	5.98e-14	Glucose homeostasis traits;
LUSC	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg02751453	chr18:77725136	HSBP1L1	0.44	5.99	0.31	5.48e-9	Opioid sensitivity;
LUSC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs3764021	0.743	rs7973535	chr12:9880397	T/A	cg20894963	chr12:9885564	CLECL1	0.33	6.76	0.35	5.99e-11	Type 1 diabetes;
LUSC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg25036284	chr2:26402008	FAM59B	-0.7	-9.79	-0.47	4.68e-20	Gut microbiome composition (summer);
LUSC	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	1.04	12.26	0.56	8.79e-29	Schizophrenia;
LUSC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.11	-0.36	6.97e-12	Alzheimer's disease (late onset);
LUSC	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.98	19.14	0.72	1.17e-55	Diastolic blood pressure;
LUSC	cis	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-5.87	-0.31	1.04e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8010715	0.636	rs2277482	chr14:24587795	C/T	cg23112188	chr14:24563095	PCK2	-0.32	-5.86	-0.31	1.14e-8	IgG glycosylation;
LUSC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.53	0.38	4.76e-13	Colorectal cancer;
LUSC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03517284	chr6:25882590	NA	-0.52	-9.59	-0.46	2.05e-19	Blood metabolite levels;
LUSC	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.54	-0.34	2.32e-10	Response to antipsychotic treatment;
LUSC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg12365402	chr11:9010492	NRIP3	-0.51	-9.81	-0.47	4.04e-20	Hemoglobin concentration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10765857	chr11:6948101	ZNF215	0.44	6.82	0.35	4.23e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07080220	chr10:102295463	HIF1AN	0.67	9.14	0.45	6.38e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg18129178	chr5:148520854	ABLIM3	-0.66	-9.97	-0.48	1.13e-20	Breast cancer;
LUSC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	11.9	0.55	1.91e-27	Hip circumference adjusted for BMI;
LUSC	cis	rs11997175	0.626	rs6468189	chr8:33648189	C/A	ch.8.33884649F	chr8:33765107	NA	0.47	7.56	0.38	3.92e-13	Body mass index;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg00307073	chr7:116502428	CAPZA2	0.45	6.29	0.33	9.78e-10	Mosquito bite size;
LUSC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg14092988	chr3:52407081	DNAH1	0.33	6.32	0.33	8.52e-10	Bipolar disorder;
LUSC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg04871131	chr7:94954202	PON1	-0.4	-6.2	-0.32	1.67e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs4343996	0.536	rs10228046	chr7:3414735	G/A	cg21248987	chr7:3385318	SDK1	0.35	6.0	0.31	5.19e-9	Motion sickness;
LUSC	cis	rs11209002	0.571	rs7531772	chr1:67555516	T/C	cg02640540	chr1:67518911	SLC35D1	0.65	9.21	0.45	3.77e-18	Crohn's disease;
LUSC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.93	0.35	2.21e-11	Platelet count;
LUSC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	trans	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg25815440	chr2:42134162	NA	-0.26	-6.02	-0.31	4.51e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg19812747	chr11:111475976	SIK2	-0.52	-7.62	-0.39	2.57e-13	Primary sclerosing cholangitis;
LUSC	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg27147174	chr7:100797783	AP1S1	-0.65	-10.41	-0.49	3.75e-22	Life satisfaction;
LUSC	cis	rs2857891	0.817	rs2857899	chr11:6981668	A/C	cg04053776	chr11:6947353	ZNF215	0.41	5.7	0.3	2.7e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg17085576	chr10:5658249	NA	-0.44	-6.54	-0.34	2.34e-10	Breast cancer;
LUSC	trans	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg06521331	chr12:34319734	NA	0.4	6.32	0.33	8.45e-10	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.59	0.38	3.26e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-16.22	-0.66	4.98e-44	Gut microbiome composition (summer);
LUSC	cis	rs4073416	0.568	rs8012834	chr14:65966555	C/T	cg03016385	chr14:66212404	NA	-0.4	-6.14	-0.32	2.36e-9	N-glycan levels;
LUSC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	trans	rs7939886	0.920	rs12226441	chr11:55867822	G/A	cg03929089	chr4:120376271	NA	0.73	6.06	0.31	3.74e-9	Myopia (pathological);
LUSC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-10.77	-0.51	2e-23	Chronic sinus infection;
LUSC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.62	12.64	0.57	3.5e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.42	0.53	9.82e-26	Eye color traits;
LUSC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg14895029	chr7:2775587	GNA12	-0.37	-5.93	-0.31	7.62e-9	Height;
LUSC	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg15704280	chr7:45808275	SEPT13	0.54	6.65	0.34	1.2e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2742417	0.603	rs13059502	chr3:45781380	A/G	cg10512202	chr3:45649293	LIMD1	0.36	6.11	0.32	2.71e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs2736345	0.788	rs13277113	chr8:11349186	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	5.97	0.31	6.22e-9	Sjögren's syndrome;Systemic lupus erythematosus;
LUSC	cis	rs4664304	0.658	rs2667008	chr2:160865095	C/T	cg03641300	chr2:160917029	PLA2R1	-0.37	-6.15	-0.32	2.23e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg00784671	chr22:46762841	CELSR1	-0.48	-6.65	-0.34	1.18e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.93	-20.3	-0.74	3e-60	Post bronchodilator FEV1;
LUSC	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg23229984	chr5:148520753	ABLIM3	0.4	5.69	0.3	2.74e-8	Breast cancer;
LUSC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.25	-0.32	1.22e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06002616	chr8:101225028	SPAG1	-0.45	-7.33	-0.37	1.75e-12	Atrioventricular conduction;
LUSC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.73	-10.02	-0.48	8.06e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg03188948	chr7:1209495	NA	0.66	6.91	0.35	2.44e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg00945038	chr17:61921165	SMARCD2	0.39	6.05	0.31	3.94e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg20848291	chr7:100343083	ZAN	0.38	5.88	0.31	1.02e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs10992471	0.603	rs7850528	chr9:95208992	A/G	cg14631576	chr9:95140430	CENPP	-0.33	-6.21	-0.32	1.56e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.94	0.31	7.08e-9	Morning vs. evening chronotype;
LUSC	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.7	-0.3	2.59e-8	Bipolar disorder;
LUSC	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg17127132	chr2:85788382	GGCX	0.47	7.66	0.39	2.03e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg10840412	chr1:235813424	GNG4	0.47	6.02	0.31	4.71e-9	Bipolar disorder;
LUSC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg02079420	chr8:82753780	SNX16	0.38	5.7	0.3	2.68e-8	Diastolic blood pressure;
LUSC	cis	rs4843185	0.667	rs4143865	chr16:85716612	T/A	cg26571870	chr16:85723150	GINS2	-0.34	-5.95	-0.31	6.8e-9	Platelet distribution width;
LUSC	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg10253484	chr15:75165896	SCAMP2	-0.53	-7.09	-0.36	8.14e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg22535103	chr8:58192502	C8orf71	-0.69	-7.28	-0.37	2.35e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg13798780	chr7:105162888	PUS7	0.55	6.05	0.31	3.99e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg05738196	chr6:26577821	NA	0.79	15.24	0.64	3.59e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg00684032	chr4:1343700	KIAA1530	-0.37	-6.45	-0.33	3.93e-10	Obesity-related traits;
LUSC	cis	rs4654899	0.931	rs58762579	chr1:21257831	G/A	cg01072550	chr1:21505969	NA	-0.54	-7.99	-0.4	2.28e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6700896	0.500	rs57941031	chr1:66087742	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	6.31	0.33	8.83e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg04234412	chr22:24373322	LOC391322	-0.86	-13.97	-0.61	3.02e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.18	-0.55	1.69e-28	Alzheimer's disease;
LUSC	cis	rs9311676	0.656	rs62258102	chr3:58378784	T/C	cg26110898	chr3:58419937	PDHB	0.42	6.83	0.35	4.07e-11	Systemic lupus erythematosus;
LUSC	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg22709100	chr7:91322751	NA	-0.39	-5.76	-0.3	1.89e-8	Breast cancer;
LUSC	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	0.67	6.73	0.35	7.37e-11	Prostate cancer;
LUSC	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg17173187	chr15:85201210	NMB	0.49	9.43	0.46	7.37e-19	Schizophrenia;
LUSC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg05555928	chr11:63887634	MACROD1	0.35	6.66	0.34	1.15e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg12219531	chr12:120966889	COQ5	0.61	8.31	0.41	2.46e-15	High light scatter reticulocyte count;
LUSC	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.51	-10.11	-0.48	3.91e-21	Anterior chamber depth;
LUSC	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg00509249	chr6:109615579	CCDC162	-0.34	-6.03	-0.31	4.24e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs9303542	0.625	rs17703636	chr17:46566890	C/T	cg09704116	chr17:46666958	LOC404266	0.34	5.9	0.31	9.08e-9	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg24375607	chr4:120327624	NA	0.74	11.16	0.52	8.3e-25	Corneal astigmatism;
LUSC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg01802117	chr1:53393560	SCP2	0.38	6.2	0.32	1.62e-9	Monocyte count;
LUSC	trans	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.46	-0.38	7.62e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg01966878	chr4:90757139	SNCA	-0.42	-5.8	-0.3	1.58e-8	Neuroticism;
LUSC	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.17	-0.37	4.72e-12	Response to antipsychotic treatment;
LUSC	trans	rs6736587	0.785	rs11673909	chr2:81932827	A/T	cg14247332	chr9:132805979	FNBP1	0.44	6.17	0.32	2.02e-9	Orthostatic hypotension;
LUSC	cis	rs983392	0.679	rs7128450	chr11:60031270	G/C	cg20284999	chr11:59952153	MS4A6A	0.38	6.38	0.33	5.85e-10	Alzheimer's disease (late onset);
LUSC	cis	rs8017423	0.607	rs12885664	chr14:90845697	T/C	cg04374321	chr14:90722782	PSMC1	-0.41	-6.05	-0.31	3.87e-9	Mortality in heart failure;
LUSC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg05347473	chr6:146136440	FBXO30	-0.59	-10.57	-0.5	1.02e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2637266	0.783	rs846642	chr10:78522318	A/G	cg18941641	chr10:78392320	NA	-0.38	-6.79	-0.35	5.19e-11	Pulmonary function;
LUSC	trans	rs12643440	0.549	rs965572	chr4:17223625	G/A	cg03061682	chr15:28352098	NA	0.37	6.09	0.32	3.18e-9	Metabolite levels (Pyroglutamine);
LUSC	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg22732515	chr19:44031385	ETHE1	0.62	10.32	0.49	7.17e-22	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.47	8.1	0.41	1.06e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg21782813	chr7:2030301	MAD1L1	0.38	6.2	0.32	1.63e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2625529	0.730	rs2929528	chr15:72269337	C/A	cg16672083	chr15:72433130	SENP8	0.5	8.01	0.4	1.95e-14	Red blood cell count;
LUSC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg05313129	chr8:58192883	C8orf71	-0.48	-6.42	-0.33	4.56e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg27490568	chr2:178487706	NA	0.45	6.32	0.33	8.46e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10651300	chr12:53661859	ESPL1	0.43	6.14	0.32	2.37e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7605827	0.897	rs10432400	chr2:15667324	T/C	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.77e-16	Educational attainment (years of education);
LUSC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg23711669	chr6:146136114	FBXO30	0.82	14.71	0.63	3.97e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.54	9.55	0.46	2.88e-19	Birth weight;
LUSC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	1.03	18.74	0.72	4.56e-54	Menopause (age at onset);
LUSC	cis	rs6495367	1.000	rs13380104	chr15:79378821	C/T	cg17916960	chr15:79447300	NA	0.35	6.75	0.35	6.68e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.5	6.15	0.32	2.15e-9	Crohn's disease;
LUSC	cis	rs4792901	0.759	rs75491854	chr17:41574650	T/C	cg22562494	chr17:41607896	ETV4	-0.32	-6.02	-0.31	4.58e-9	Dupuytren's disease;
LUSC	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.69	0.34	9.29e-11	Corneal astigmatism;
LUSC	cis	rs7106204	0.686	rs12790317	chr11:24254405	T/C	ch.11.24196551F	chr11:24239977	NA	0.76	7.14	0.36	5.79e-12	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03637614	chr7:129691233	ZC3HC1	-0.42	-6.18	-0.32	1.82e-9	Hepatitis;
LUSC	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg09307838	chr4:120376055	NA	0.69	10.05	0.48	5.95e-21	Corneal astigmatism;
LUSC	cis	rs7914558	0.621	rs7896290	chr10:104656015	G/A	cg05855489	chr10:104503620	C10orf26	0.42	5.7	0.3	2.64e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg17264618	chr3:40429014	ENTPD3	-0.29	-6.34	-0.33	7.61e-10	Renal cell carcinoma;
LUSC	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg14186256	chr22:23484241	RTDR1	0.92	16.67	0.67	7.73e-46	Bone mineral density;
LUSC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	8.43	0.42	1.04e-15	Total body bone mineral density;
LUSC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg21724239	chr8:58056113	NA	0.59	7.09	0.36	8.15e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.44	-0.33	4.21e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg00277334	chr10:82204260	NA	-0.5	-7.26	-0.37	2.8e-12	Post bronchodilator FEV1;
LUSC	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg23093090	chr10:104574429	C10orf26	-0.47	-5.76	-0.3	1.93e-8	Arsenic metabolism;
LUSC	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg16586182	chr3:47516702	SCAP	-0.51	-7.93	-0.4	3.34e-14	Colorectal cancer;
LUSC	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.21	0.49	1.8e-21	Birth weight;
LUSC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg22823121	chr1:150693482	HORMAD1	0.6	9.13	0.45	6.6e-18	Tonsillectomy;
LUSC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	0.9	17.11	0.68	1.37e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9650657	0.683	rs7836366	chr8:10585683	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.4	-0.33	5.14e-10	Neuroticism;
LUSC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00339695	chr16:24857497	SLC5A11	0.39	6.73	0.35	7.55e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-1.06	-16.01	-0.66	3.25e-43	Initial pursuit acceleration;
LUSC	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg01065977	chr19:18549689	ISYNA1	-0.25	-6.14	-0.32	2.37e-9	Breast cancer;
LUSC	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg22189786	chr22:42395067	WBP2NL	0.43	5.75	0.3	1.97e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	trans	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg16011800	chr17:1958478	HIC1	-0.46	-6.06	-0.31	3.72e-9	Lymphocyte counts;Red cell distribution width;
LUSC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg13175981	chr1:150552382	MCL1	0.53	7.4	0.38	1.09e-12	Tonsillectomy;
LUSC	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg15654264	chr1:150340011	RPRD2	-0.64	-10.84	-0.51	1.19e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg01884057	chr2:25150051	NA	0.48	11.43	0.53	9.67e-26	Body mass index;
LUSC	cis	rs2017854	1.000	rs2017854	chr17:65488021	C/G	cg07622687	chr17:65503465	PITPNC1	-0.38	-6.53	-0.34	2.43e-10	Pulmonary function;
LUSC	cis	rs7572644	0.709	rs7592580	chr2:28121190	C/T	cg27432699	chr2:27873401	GPN1	0.52	6.43	0.33	4.31e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7572644	0.699	rs6547814	chr2:28102998	G/A	cg27432699	chr2:27873401	GPN1	0.52	7.0	0.36	1.43e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg17737641	chr12:71834466	LGR5	0.39	5.98	0.31	5.79e-9	Inflammatory bowel disease;
LUSC	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg24130564	chr14:104152367	KLC1	0.44	6.34	0.33	7.27e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg03684893	chr10:554711	DIP2C	-0.37	-6.76	-0.35	6.28e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs1322512	1.000	rs1744369	chr6:152946531	T/A	cg27316956	chr6:152958899	SYNE1	-0.33	-5.65	-0.3	3.45e-8	Tonometry;
LUSC	cis	rs8014204	0.816	rs11159107	chr14:75341266	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.55	-8.75	-0.43	1.07e-16	Caffeine consumption;
LUSC	cis	rs76793172	1.000	rs10406609	chr19:46345208	T/G	cg00442267	chr19:46317840	RSPH6A	-0.5	-5.7	-0.3	2.66e-8	Eosinophil counts;
LUSC	cis	rs116988415	0.584	rs17767466	chr14:65252095	G/T	cg00114569	chr14:65239327	SPTB	0.67	7.18	0.37	4.46e-12	Daytime sleep phenotypes;
LUSC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg04455712	chr21:45112962	RRP1B	0.45	8.61	0.43	2.97e-16	Mean corpuscular volume;
LUSC	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg10255544	chr17:80519551	FOXK2	0.41	6.69	0.34	9.4e-11	Reticulocyte fraction of red cells;
LUSC	trans	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg01128736	chr6:4461158	NA	0.34	6.03	0.31	4.35e-9	Tonsillectomy;
LUSC	cis	rs870825	0.616	rs7654208	chr4:185648877	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-8.0	-0.4	2.08e-14	Bipolar disorder;
LUSC	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.15	-0.45	5.74e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2012796	1.000	rs8009171	chr14:81820060	G/A	cg02996355	chr14:81879375	NA	0.5	7.24	0.37	3.08e-12	Night sleep phenotypes;
LUSC	cis	rs12681287	0.577	rs13257414	chr8:87494138	C/T	cg00550725	chr8:87521180	FAM82B	0.45	5.87	0.31	1.07e-8	Caudate activity during reward;
LUSC	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.37	3.79e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg12257692	chr3:49977190	RBM6	0.25	6.93	0.35	2.14e-11	Body mass index;
LUSC	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg00277334	chr10:82204260	NA	-0.53	-7.17	-0.37	4.8e-12	Post bronchodilator FEV1;
LUSC	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg27411982	chr8:10470053	RP1L1	0.39	6.05	0.31	3.84e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg07148914	chr20:33460835	GGT7	-0.54	-8.43	-0.42	1.04e-15	Height;
LUSC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	7.06	0.36	9.59e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2658782	0.901	rs7116173	chr11:93222311	C/T	cg15737290	chr11:93063684	CCDC67	-0.63	-7.62	-0.38	2.71e-13	Pulmonary function decline;
LUSC	trans	rs57046232	0.531	rs6054146	chr20:6335865	G/T	cg21095983	chr6:86352623	SYNCRIP	0.47	7.08	0.36	8.33e-12	Colorectal cancer;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg07529534	chr8:41511314	ANK1	0.37	6.28	0.32	1.04e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7000551	0.725	rs7430	chr8:22398414	C/G	cg12081754	chr8:22256438	SLC39A14	0.41	6.08	0.32	3.35e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg20307385	chr11:47447363	PSMC3	0.53	6.37	0.33	6.09e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7119	0.717	rs62009069	chr15:77817877	T/G	cg27398640	chr15:77910606	LINGO1	-0.31	-6.48	-0.33	3.3e-10	Type 2 diabetes;
LUSC	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg04362960	chr10:104952993	NT5C2	0.65	9.39	0.46	9.96e-19	Arsenic metabolism;
LUSC	cis	rs1127311	1.000	rs1127311	chr1:154556663	G/A	cg17218026	chr1:154582156	ADAR	0.57	9.84	0.47	3.15e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs4561483	0.583	rs1019814	chr16:11940764	T/C	cg08843971	chr16:11963173	GSPT1	0.38	5.79	0.3	1.62e-8	Testicular germ cell tumor;
LUSC	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg15485101	chr11:133734466	NA	0.43	7.72	0.39	1.32e-13	Childhood ear infection;
LUSC	cis	rs11645898	0.748	rs72787042	chr16:72067522	A/G	cg14768367	chr16:72042858	DHODH	-0.75	-8.07	-0.4	1.32e-14	Blood protein levels;
LUSC	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg03806693	chr22:41940476	POLR3H	-0.51	-6.96	-0.36	1.86e-11	Neuroticism;
LUSC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.24	0.37	3.14e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6574644	1.000	rs10873336	chr14:81779134	C/T	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs4285028	1.000	rs4285028	chr3:121660664	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.75	-10.13	-0.48	3.21e-21	Multiple sclerosis;
LUSC	cis	rs7851660	0.594	rs28703314	chr9:100660145	A/T	cg13688889	chr9:100608707	NA	-0.54	-8.36	-0.42	1.76e-15	Strep throat;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10715425	chr1:6052497	NPHP4	0.43	6.17	0.32	1.92e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg07395648	chr5:131743802	NA	0.44	7.13	0.36	6.08e-12	Blood metabolite levels;
LUSC	cis	rs10392	0.543	rs12626105	chr20:37534582	A/G	cg27552599	chr20:37590471	DHX35	0.44	6.95	0.36	1.9e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs1971762	0.583	rs3844370	chr12:54086137	G/C	cg23533419	chr12:54090519	NA	-0.36	-5.95	-0.31	6.87e-9	Height;
LUSC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg09904177	chr6:26538194	HMGN4	0.67	12.17	0.55	1.87e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.73	-12.85	-0.58	5.45e-31	White blood cell count (basophil);
LUSC	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.59	-0.34	1.7e-10	Neuroticism;
LUSC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg05729581	chr11:3078854	CARS	-0.53	-7.9	-0.4	4.01e-14	Type 2 diabetes;
LUSC	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg02023728	chr11:77925099	USP35	0.49	6.88	0.35	3.02e-11	Testicular germ cell tumor;
LUSC	cis	rs7493	0.950	rs7802171	chr7:95030321	A/G	cg17330251	chr7:94953956	PON1	-0.37	-5.85	-0.31	1.15e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg03894339	chr8:19674705	INTS10	-0.62	-8.63	-0.43	2.48e-16	Breast cancer;
LUSC	trans	rs9944715	0.954	rs6507677	chr18:43762557	T/C	cg01718231	chr17:29326311	RNF135	0.55	7.86	0.4	5.46e-14	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs12776158	0.901	rs12414706	chr10:71214729	G/A	cg12610070	chr10:71211762	TSPAN15	-0.46	-6.04	-0.31	4.07e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7193541	0.694	rs3896277	chr16:74480694	A/T	cg01733217	chr16:74700730	RFWD3	0.78	13.68	0.6	3.81e-34	Multiple myeloma;
LUSC	cis	rs6084875	0.785	rs2050370	chr20:4719781	G/T	cg07258627	chr20:4721683	PRNT	-0.34	-6.12	-0.32	2.69e-9	Systemic lupus erythematosus;
LUSC	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-17.52	-0.69	3.33e-49	Primary sclerosing cholangitis;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01580613	chr20:10015660	ANKRD5	-0.43	-6.53	-0.34	2.44e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg15448220	chr1:150897856	SETDB1	0.41	5.9	0.31	8.97e-9	Melanoma;
LUSC	cis	rs2637266	0.935	rs2583049	chr10:78403962	T/C	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.94e-13	Pulmonary function;
LUSC	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg25319279	chr11:5960081	NA	-0.44	-6.33	-0.33	7.95e-10	DNA methylation (variation);
LUSC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.31	0.37	1.99e-12	Motion sickness;
LUSC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3126085	1.000	rs3126095	chr1:152309683	G/A	cg26876637	chr1:152193138	HRNR	-0.44	-5.67	-0.3	3.13e-8	Atopic dermatitis;
LUSC	cis	rs6120849	0.754	rs3746435	chr20:33587198	G/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.91	0.35	2.47e-11	Protein C levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24596729	chr1:165345813	NA	-0.4	-7.31	-0.37	1.96e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg12311346	chr5:56204834	C5orf35	-0.67	-9.63	-0.47	1.54e-19	Coronary artery disease;
LUSC	trans	rs72674100	1.000	rs78448853	chr4:97966420	G/A	cg16405019	chr1:18959625	PAX7	-0.61	-6.0	-0.31	5.27e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg01557791	chr16:72042693	DHODH	-0.48	-7.04	-0.36	1.09e-11	Fibrinogen levels;
LUSC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg11632617	chr15:75315747	PPCDC	-0.52	-6.73	-0.35	7.58e-11	Blood trace element (Zn levels);
LUSC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg14552801	chr7:65878734	NA	-0.37	-5.72	-0.3	2.4e-8	Aortic root size;
LUSC	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg13010199	chr12:38710504	ALG10B	0.61	9.57	0.46	2.39e-19	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs16867335	1.000	rs34842451	chr2:181480525	C/T	cg23363182	chr2:181467187	NA	0.48	6.38	0.33	5.87e-10	Survival in rectal cancer;
LUSC	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg08017756	chr2:100939284	LONRF2	-0.43	-8.05	-0.4	1.48e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs3781871	0.891	rs12574049	chr11:107858027	C/G	cg09222123	chr1:89356608	GTF2B	-0.61	-5.99	-0.31	5.47e-9	Scarlet fever;
LUSC	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg09904177	chr6:26538194	HMGN4	-0.79	-6.17	-0.32	1.95e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.88	-0.35	3.04e-11	Daytime sleep phenotypes;
LUSC	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	11.03	0.52	2.43e-24	Hypertriglyceridemia;
LUSC	cis	rs654950	0.875	rs55865698	chr1:41986758	C/T	cg06885757	chr1:42089581	HIVEP3	-0.38	-7.52	-0.38	5.15e-13	Airway imaging phenotypes;
LUSC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg03388025	chr16:89894329	SPIRE2	0.31	6.45	0.33	3.92e-10	Vitiligo;
LUSC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg18904891	chr8:8559673	CLDN23	0.41	6.36	0.33	6.47e-10	Mood instability;
LUSC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg23985595	chr17:80112537	CCDC57	0.31	5.91	0.31	8.51e-9	Life satisfaction;
LUSC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg01557791	chr16:72042693	DHODH	-0.54	-7.92	-0.4	3.67e-14	Fibrinogen levels;
LUSC	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg08917208	chr2:24149416	ATAD2B	0.97	10.06	0.48	5.54e-21	Lymphocyte counts;
LUSC	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg09693106	chr22:46449821	C22orf26;LOC150381	0.48	7.97	0.4	2.47e-14	Dupuytren's disease;Subjective well-being;
LUSC	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg06636001	chr8:8085503	FLJ10661	0.68	11.39	0.53	1.28e-25	Mood instability;
LUSC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg05855489	chr10:104503620	C10orf26	-0.7	-10.37	-0.49	5.1e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11971779	0.793	rs11543827	chr7:139032693	G/A	cg07862535	chr7:139043722	LUC7L2	0.58	6.96	0.36	1.8e-11	Diisocyanate-induced asthma;
LUSC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg11871910	chr12:69753446	YEATS4	0.63	8.44	0.42	9.86e-16	Response to diuretic therapy;
LUSC	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg07195577	chr17:27052828	TLCD1	0.46	5.81	0.3	1.47e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg10483660	chr13:112241077	NA	0.39	7.09	0.36	7.92e-12	Menarche (age at onset);
LUSC	trans	rs12570744	0.688	rs11254449	chr10:6796502	G/T	cg11642127	chr8:142593671	NA	0.3	5.98	0.31	5.78e-9	Response to anti-TNF therapy in rheumatoid arthritis;
LUSC	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.67	-0.39	1.9e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.65	-11.3	-0.53	2.7e-25	Diastolic blood pressure;
LUSC	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-0.88	-15.73	-0.65	3.98e-42	Height;
LUSC	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-1.04	-12.47	-0.56	1.5e-29	Schizophrenia;
LUSC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg00074818	chr8:8560427	CLDN23	0.57	9.8	0.47	4.19e-20	Obesity-related traits;
LUSC	cis	rs13401104	0.633	rs72620804	chr2:237111501	T/A	cg19324714	chr2:237145437	ASB18	0.43	5.79	0.3	1.6e-8	Educational attainment;
LUSC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg14582100	chr15:45693742	SPATA5L1	0.58	10.66	0.5	4.78e-23	Homoarginine levels;
LUSC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6060717	0.610	rs2794383	chr20:34615152	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-6.37	-0.33	6.14e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.39e-8	Aortic root size;
LUSC	cis	rs7809950	1.000	rs2237672	chr7:107131563	A/C	cg23024343	chr7:107201750	COG5	-0.55	-8.87	-0.44	4.63e-17	Coronary artery disease;
LUSC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.33	6.04	0.31	4.1e-9	Obesity-related traits;
LUSC	cis	rs6120849	0.754	rs13433216	chr20:33616301	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	6.74	0.35	6.84e-11	Protein C levels;
LUSC	trans	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg26043149	chr18:55253948	FECH	-0.46	-6.93	-0.35	2.22e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg00431813	chr7:1051703	C7orf50	-0.36	-5.65	-0.3	3.47e-8	Longevity;Endometriosis;
LUSC	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg00745463	chr17:30367425	LRRC37B	-0.71	-8.74	-0.43	1.14e-16	Hip circumference adjusted for BMI;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg22599036	chr21:43934540	SLC37A1	0.56	7.35	0.37	1.56e-12	Cognitive function;Information processing speed;
LUSC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.88e-11	Primary biliary cholangitis;
LUSC	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg14121845	chr20:25566513	NINL	0.31	5.71	0.3	2.55e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7084921	0.640	rs12773244	chr10:101865344	G/A	cg02250046	chr10:101825185	CPN1	-0.33	-6.11	-0.32	2.82e-9	Bone mineral density;
LUSC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.82	14.21	0.61	3.48e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg24829409	chr8:58192753	C8orf71	-0.47	-5.71	-0.3	2.49e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg06740227	chr12:86229804	RASSF9	-0.36	-5.7	-0.3	2.61e-8	Major depressive disorder;
LUSC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg20283391	chr11:68216788	NA	-0.57	-8.1	-0.41	1.03e-14	Total body bone mineral density;
LUSC	cis	rs55665837	0.961	rs11023226	chr11:14458817	C/T	cg05501817	chr11:14380813	RRAS2	-0.41	-6.51	-0.34	2.72e-10	Vitamin D levels;
LUSC	cis	rs7075426	1.000	rs10887609	chr10:88206702	C/T	cg07322936	chr10:88137208	NA	-0.48	-7.5	-0.38	5.86e-13	Migraine without aura;
LUSC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.42	0.33	4.71e-10	Menopause (age at onset);
LUSC	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg04850211	chr1:228464232	OBSCN	-0.37	-6.2	-0.32	1.62e-9	Diastolic blood pressure;
LUSC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	9.25	0.45	2.72e-18	Height;
LUSC	cis	rs7712401	0.791	rs9327279	chr5:122122160	T/G	cg19077854	chr5:122220652	SNX24	0.35	7.76	0.39	1.02e-13	Mean platelet volume;
LUSC	cis	rs7095944	0.614	rs12570348	chr10:126438963	A/C	cg08799069	chr10:126477246	METTL10	0.43	6.64	0.34	1.24e-10	Asthma;
LUSC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg10360139	chr7:1886902	MAD1L1	-0.43	-6.46	-0.33	3.79e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs1015291	0.708	rs10743340	chr12:19994777	G/A	cg01501474	chr7:55323552	NA	0.46	5.96	0.31	6.32e-9	Diastolic blood pressure;
LUSC	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg15432903	chr11:17409602	KCNJ11	0.58	10.6	0.5	7.8e-23	Type 2 diabetes;
LUSC	cis	rs13315871	1.000	rs36097398	chr3:58367330	G/A	cg20936604	chr3:58311152	NA	-0.63	-5.85	-0.31	1.15e-8	Cholesterol, total;
LUSC	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	0.83	10.4	0.49	3.89e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.58	0.54	2.74e-26	Alzheimer's disease;
LUSC	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg23752985	chr2:85803571	VAMP8	-0.33	-6.5	-0.34	2.89e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg05347473	chr6:146136440	FBXO30	0.56	9.49	0.46	4.63e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.68	0.34	9.71e-11	Menopause (age at onset);
LUSC	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.94	-0.44	2.6e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-6.14	-0.32	2.39e-9	Crohn's disease;
LUSC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg05623727	chr3:50126028	RBM5	-0.34	-6.32	-0.33	8.55e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg08499158	chr17:42289980	UBTF	-0.54	-9.05	-0.44	1.23e-17	Total body bone mineral density;
LUSC	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg23649088	chr2:200775458	C2orf69	-0.49	-6.71	-0.34	8.12e-11	Schizophrenia;
LUSC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg16339924	chr4:17578868	LAP3	0.63	9.88	0.48	2.3e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg07460842	chr6:66804631	NA	0.47	5.8	0.3	1.53e-8	Metabolite levels;
LUSC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg08132940	chr7:1081526	C7orf50	-0.52	-6.22	-0.32	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.72	-10.11	-0.48	3.99e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs6942756	1.000	rs2718084	chr7:128897342	T/C	cg02491457	chr7:128862824	NA	0.56	8.07	0.4	1.29e-14	White matter hyperintensity burden;
LUSC	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.89	-15.02	-0.63	2.57e-39	Schizophrenia;
LUSC	cis	rs4409675	0.576	rs10751724	chr1:28215631	C/T	cg23691781	chr1:28212827	C1orf38	0.31	7.44	0.38	8.79e-13	Corneal astigmatism;
LUSC	cis	rs1983891	0.955	rs2025645	chr6:41519654	A/G	cg20194872	chr6:41519635	FOXP4	0.33	5.91	0.31	8.35e-9	Prostate cancer;
LUSC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.58	10.63	0.5	6.41e-23	Bone mineral density;
LUSC	cis	rs6681460	1.000	rs6681460	chr1:67123057	C/T	cg02459107	chr1:67143332	SGIP1	-0.48	-9.0	-0.44	1.74e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs10752881	0.602	rs9425569	chr1:182942202	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	9.56	0.46	2.6e-19	Colorectal cancer;
LUSC	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg14413466	chr17:79170920	AZI1	-0.38	-7.66	-0.39	2e-13	Frontotemporal dementia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22494142	chr15:40401263	BMF	0.51	7.1	0.36	7.55e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	trans	rs12317459	0.591	rs11115435	chr12:83200223	C/T	cg10237817	chr1:154519846	TDRD10	0.31	6.22	0.32	1.46e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.51	-6.95	-0.36	1.95e-11	Tuberculosis;
LUSC	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg04733989	chr22:42467013	NAGA	0.4	6.44	0.33	4.04e-10	Cognitive function;
LUSC	cis	rs9463078	0.605	rs4711799	chr6:44765780	A/T	cg25276700	chr6:44698697	NA	0.28	5.66	0.3	3.3e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg00701064	chr4:6280414	WFS1	0.6	14.2	0.61	3.95e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg06612196	chr6:6737390	NA	0.56	11.11	0.52	1.32e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg16346588	chr10:242978	ZMYND11	-0.45	-6.16	-0.32	2.06e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg02380750	chr20:61661411	NA	0.33	5.83	0.3	1.32e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs926938	0.527	rs360681	chr1:115496741	C/G	cg01522456	chr1:115632236	TSPAN2	-0.42	-6.49	-0.33	3.03e-10	Autism;
LUSC	cis	rs3761218	0.738	rs6084472	chr20:3771858	G/T	cg02737268	chr20:3780182	CDC25B	0.4	8.15	0.41	7.24e-15	Bipolar disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg23493127	chr6:144164392	LTV1	0.69	6.26	0.32	1.2e-9	Cognitive performance;
LUSC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg21573476	chr21:45109991	RRP1B	-0.38	-6.19	-0.32	1.76e-9	Mean corpuscular volume;
LUSC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	1.05	20.13	0.74	1.43e-59	Menopause (age at onset);
LUSC	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	1.1	14.72	0.63	3.81e-38	Nonalcoholic fatty liver disease;
LUSC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg02423579	chr7:2872169	GNA12	-0.46	-6.23	-0.32	1.44e-9	Height;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21530174	chr5:151031796	NA	0.49	7.8	0.39	8.17e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg07507251	chr3:52567010	NT5DC2	0.34	6.67	0.34	1.06e-10	Bipolar disorder;
LUSC	cis	rs4665630	0.522	rs4665626	chr2:23883120	A/T	cg08063864	chr2:24346004	PFN4;LOC375190	-0.66	-5.99	-0.31	5.42e-9	Hypertension;
LUSC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg09365446	chr1:150670422	GOLPH3L	0.47	7.18	0.37	4.62e-12	Melanoma;
LUSC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg05347473	chr6:146136440	FBXO30	-0.56	-9.79	-0.47	4.57e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg11645453	chr3:52864694	ITIH4	0.35	8.14	0.41	7.76e-15	Bipolar disorder;
LUSC	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.25	0.37	2.88e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21582582	chr3:182698605	DCUN1D1	0.44	7.64	0.39	2.27e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9463078	0.932	rs1324538	chr6:45080144	T/A	cg25276700	chr6:44698697	NA	-0.29	-5.64	-0.3	3.58e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs12286929	0.609	rs7479259	chr11:115090715	T/A	cg04055981	chr11:115044050	NA	0.36	6.51	0.34	2.8e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.29e-21	Lymphocyte counts;
LUSC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg17143192	chr8:8559678	CLDN23	0.61	8.73	0.43	1.28e-16	Obesity-related traits;
LUSC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg24733560	chr20:60626293	TAF4	0.43	8.03	0.4	1.71e-14	Body mass index;
LUSC	cis	rs6464929	0.956	rs4727005	chr7:148704869	C/T	cg23583168	chr7:148888333	NA	0.47	5.94	0.31	7.06e-9	Pediatric bone mineral content (hip);
LUSC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.7	-10.13	-0.48	3.24e-21	Systemic lupus erythematosus;
LUSC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.68	6.91	0.35	2.49e-11	Initial pursuit acceleration;
LUSC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00149659	chr3:10157352	C3orf10	1.01	14.42	0.62	5.3e-37	Alzheimer's disease;
LUSC	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.89e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9900062	0.546	rs2676289	chr17:62705738	A/G	cg02598441	chr17:62777298	LOC146880	0.54	7.17	0.37	4.75e-12	QT interval;
LUSC	cis	rs12220238	1.000	rs10824088	chr10:75921490	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.92	0.35	2.36e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.34	5.66	0.3	3.24e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg03351412	chr1:154909251	PMVK	0.47	7.07	0.36	9.29e-12	Prostate cancer;
LUSC	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg26876637	chr1:152193138	HRNR	0.42	5.96	0.31	6.41e-9	Atopic dermatitis;
LUSC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.18	0.37	4.56e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9325144	0.957	rs1995419	chr12:38950726	C/G	cg26384229	chr12:38710491	ALG10B	0.43	5.72	0.3	2.38e-8	Morning vs. evening chronotype;
LUSC	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg04362960	chr10:104952993	NT5C2	0.61	9.77	0.47	5.38e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg13902645	chr11:5959945	NA	-0.62	-8.58	-0.42	3.63e-16	DNA methylation (variation);
LUSC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg23711669	chr6:146136114	FBXO30	-0.82	-14.82	-0.63	1.52e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg21361702	chr7:150065534	REPIN1	0.49	6.53	0.34	2.41e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7833986	0.501	rs2667981	chr8:56894303	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	11.2	0.52	6.05e-25	Height;
LUSC	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg17385448	chr1:15911702	AGMAT	0.38	6.34	0.33	7.53e-10	Systolic blood pressure;
LUSC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.7	-12.57	-0.57	6.28e-30	Aortic root size;
LUSC	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg24375607	chr4:120327624	NA	0.79	11.91	0.55	1.72e-27	Corneal astigmatism;
LUSC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.08	0.55	4.01e-28	Prudent dietary pattern;
LUSC	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.87	0.35	3.08e-11	Lung cancer in ever smokers;
LUSC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10802521	chr3:52805072	NEK4	-0.55	-8.67	-0.43	1.92e-16	Bipolar disorder;
LUSC	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg12573674	chr2:1569213	NA	-0.52	-5.67	-0.3	3.07e-8	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg20573242	chr4:122745356	CCNA2	0.43	6.53	0.34	2.45e-10	Type 2 diabetes;
LUSC	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.83	-0.3	1.33e-8	Bipolar disorder;
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg25703541	chr22:24373054	LOC391322	-0.9	-14.58	-0.62	1.38e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	5.76	0.3	1.95e-8	IgG glycosylation;
LUSC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg18110333	chr6:292329	DUSP22	-0.55	-8.17	-0.41	6.66e-15	Menopause (age at onset);
LUSC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg13206674	chr6:150067644	NUP43	-0.6	-9.77	-0.47	5.42e-20	Lung cancer;
LUSC	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	5.98	0.31	5.78e-9	Schizophrenia;
LUSC	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-9.29	-0.45	2.05e-18	Monocyte percentage of white cells;
LUSC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg03351412	chr1:154909251	PMVK	0.53	8.35	0.42	1.9e-15	Prostate cancer;
LUSC	cis	rs8040855	0.657	rs6496733	chr15:85673176	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.38	5.86	0.31	1.08e-8	Bulimia nervosa;
LUSC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-0.88	-16.73	-0.68	4.63e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg24851651	chr11:66362959	CCS	0.55	8.03	0.4	1.72e-14	Airway imaging phenotypes;
LUSC	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg09998033	chr7:158218633	PTPRN2	0.45	7.14	0.36	5.82e-12	Obesity-related traits;
LUSC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg09650180	chr20:62225654	GMEB2	-0.68	-9.73	-0.47	7.21e-20	Glioblastoma;
LUSC	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg23625390	chr15:77176239	SCAPER	0.39	5.79	0.3	1.64e-8	Blood metabolite levels;
LUSC	trans	rs7556950	0.572	rs74507577	chr2:41931366	C/T	cg13792581	chr20:43590115	TOMM34	0.76	6.47	0.33	3.43e-10	Major depression and alcohol dependence;
LUSC	cis	rs4654899	0.758	rs17453044	chr1:21517361	A/G	cg01072550	chr1:21505969	NA	-0.55	-8.34	-0.42	2e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	12.44	0.56	1.93e-29	Ileal carcinoids;
LUSC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-7.58	-0.38	3.34e-13	Personality dimensions;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03887910	chr6:26156499	HIST1H1E	0.44	5.95	0.31	6.65e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00339695	chr16:24857497	SLC5A11	0.61	9.65	0.47	1.37e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg23711669	chr6:146136114	FBXO30	0.9	17.22	0.69	5.31e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.78	15.13	0.64	9.67e-40	Obesity (extreme);
LUSC	cis	rs10465746	0.967	rs1475263	chr1:84339497	A/T	cg10977910	chr1:84465055	TTLL7	0.45	6.39	0.33	5.52e-10	Obesity-related traits;
LUSC	cis	rs12220238	1.000	rs10824112	chr10:75969003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.22	0.37	3.42e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.34	-0.45	1.45e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-6.14	-0.32	2.28e-9	Fear of minor pain;
LUSC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.47	-6.73	-0.35	7.24e-11	Urate levels;
LUSC	cis	rs3106136	0.546	rs2664881	chr4:95143484	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.46	-0.42	8.25e-16	Capecitabine sensitivity;
LUSC	cis	rs752010	0.905	rs10890150	chr1:42095603	A/C	cg06885757	chr1:42089581	HIVEP3	0.49	9.93	0.48	1.56e-20	Lupus nephritis in systemic lupus erythematosus;
LUSC	trans	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	12.12	0.55	2.85e-28	Exhaled nitric oxide output;
LUSC	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.74	14.68	0.63	5.59e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs41271951	0.512	rs16832976	chr1:151038135	T/C	cg11822372	chr1:151115635	SEMA6C	-0.76	-6.95	-0.36	1.98e-11	Blood protein levels;
LUSC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg22532475	chr10:104410764	TRIM8	-0.29	-5.98	-0.31	5.8e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg04586622	chr2:25135609	ADCY3	0.42	8.88	0.44	4.22e-17	Body mass index;
LUSC	cis	rs2455601	0.608	rs59025804	chr11:8870301	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-7.64	-0.39	2.3e-13	Schizophrenia;
LUSC	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg01028140	chr2:1542097	TPO	-0.44	-6.92	-0.35	2.39e-11	IgG glycosylation;
LUSC	cis	rs9473147	0.543	rs4715019	chr6:47447041	T/A	cg12968598	chr6:47444699	CD2AP	0.53	8.18	0.41	6.12e-15	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg25204440	chr1:209979598	IRF6	0.53	7.08	0.36	8.6e-12	Cleft lip with or without cleft palate;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03657549	chr7:128116813	METTL2B	-0.53	-7.06	-0.36	9.85e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg05347473	chr6:146136440	FBXO30	-0.56	-9.61	-0.47	1.83e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6969780	0.915	rs3807597	chr7:27189195	C/T	cg26364809	chr7:27145159	NA	0.54	6.0	0.31	5.1e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-10.4	-0.49	3.86e-22	Migraine;Coronary artery disease;
LUSC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg18240062	chr17:79603768	NPLOC4	0.58	10.05	0.48	6.14e-21	Eye color traits;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08399230	chr16:4665037	FAM100A	-0.44	-6.34	-0.33	7.54e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg06784218	chr1:46089804	CCDC17	-0.36	-7.27	-0.37	2.53e-12	Red blood cell count;Reticulocyte count;
LUSC	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.84	-20.23	-0.74	5.51e-60	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs73416724	1.000	rs112336903	chr6:43338115	T/C	cg26312998	chr6:43337775	ZNF318	0.57	6.62	0.34	1.4e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg06462663	chr19:18546047	ISYNA1	0.44	7.67	0.39	1.91e-13	Breast cancer;
LUSC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg16405210	chr4:1374714	KIAA1530	-0.63	-10.13	-0.48	3.29e-21	Longevity;
LUSC	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg05340658	chr4:99064831	C4orf37	0.57	9.27	0.45	2.32e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-1.23	-13.21	-0.59	2.46e-32	Diabetic kidney disease;
LUSC	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-7.07	-0.36	8.87e-12	Schizophrenia;
LUSC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg17554472	chr22:41940697	POLR3H	0.47	5.84	0.3	1.27e-8	Vitiligo;
LUSC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg02079420	chr8:82753780	SNX16	0.38	5.72	0.3	2.33e-8	Diastolic blood pressure;
LUSC	cis	rs11997175	0.569	rs36034014	chr8:33814219	G/A	ch.8.33884649F	chr8:33765107	NA	-0.41	-6.14	-0.32	2.4e-9	Body mass index;
LUSC	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	1.12	18.03	0.7	3.2e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs3740713	1.000	rs75740864	chr11:18470689	C/G	cg07915343	chr11:18477680	LDHAL6A	-0.54	-6.74	-0.35	6.85e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg22431228	chr1:16359049	CLCNKA	0.44	8.5	0.42	6.23e-16	Dilated cardiomyopathy;
LUSC	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg27411982	chr8:10470053	RP1L1	0.4	5.91	0.31	8.34e-9	Neuroticism;
LUSC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg06640241	chr16:89574553	SPG7	0.7	11.26	0.52	3.74e-25	Multiple myeloma (IgH translocation);
LUSC	trans	rs3960554	0.529	rs6465049	chr7:75874489	A/G	cg19862616	chr7:65841803	NCRNA00174	0.61	7.44	0.38	8.43e-13	Eotaxin levels;
LUSC	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg16701003	chr16:89028210	CBFA2T3	0.33	5.95	0.31	6.81e-9	Social autistic-like traits;
LUSC	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg11584989	chr19:19387371	SF4	0.68	8.17	0.41	6.43e-15	Bipolar disorder;
LUSC	trans	rs6964492	0.576	rs17168006	chr7:134406000	A/G	cg17334389	chr17:637070	FAM57A	-0.26	-6.01	-0.31	4.95e-9	Tonsillectomy;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15804432	chr15:64454965	PPIB	-0.44	-5.95	-0.31	6.66e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg14893161	chr1:205819251	PM20D1	-0.48	-6.47	-0.33	3.54e-10	Menarche (age at onset);
LUSC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg03233332	chr7:66118400	NA	-0.4	-5.91	-0.31	8.4e-9	Aortic root size;
LUSC	cis	rs9462027	0.628	rs2814991	chr6:34615443	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.97	-0.31	6.1e-9	Systemic lupus erythematosus;
LUSC	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg08330031	chr10:104623503	C10orf32	0.31	5.64	0.3	3.54e-8	Arsenic metabolism;
LUSC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg21724239	chr8:58056113	NA	0.69	8.82	0.43	6.42e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg25258033	chr6:167368657	RNASET2	0.4	6.09	0.32	3.05e-9	Crohn's disease;
LUSC	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg05527609	chr1:210001259	C1orf107	0.9	11.59	0.54	2.39e-26	Orofacial clefts;
LUSC	cis	rs4308124	0.708	rs10179596	chr2:111970380	G/A	cg04571233	chr2:111982156	NA	-0.52	-6.75	-0.35	6.59e-11	Vitiligo;
LUSC	cis	rs7945718	0.875	rs9888179	chr11:12782601	G/T	cg25843174	chr11:12811716	TEAD1	0.32	7.3	0.37	2.13e-12	Educational attainment (years of education);
LUSC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg07895657	chr22:50616420	PANX2	-0.35	-5.99	-0.31	5.52e-9	Obesity-related traits;
LUSC	cis	rs2798269	0.604	rs9552438	chr13:22067809	A/C	cg18095732	chr13:22033692	ZDHHC20	-0.48	-7.84	-0.39	6.24e-14	PR segment;
LUSC	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg16049864	chr8:95962084	TP53INP1	-0.42	-6.98	-0.36	1.6e-11	Type 2 diabetes;
LUSC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg20849893	chr7:64541193	NA	-0.65	-5.7	-0.3	2.6e-8	Diabetic kidney disease;
LUSC	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg04586622	chr2:25135609	ADCY3	0.36	7.47	0.38	6.97e-13	Body mass index in non-asthmatics;
LUSC	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.75	-0.35	6.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.38	-0.33	5.88e-10	Lung cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15986590	chr19:1862404	KLF16	-0.48	-6.01	-0.31	4.98e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg24558204	chr6:135376177	HBS1L	0.59	9.14	0.45	6.29e-18	Red blood cell count;
LUSC	cis	rs4683142	0.518	rs4682801	chr3:46021218	G/T	cg18004856	chr3:46029278	FYCO1	0.37	5.88	0.31	1e-8	Methadone dose in opioid dependence;
LUSC	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg00898013	chr13:113819073	PROZ	0.51	7.51	0.38	5.44e-13	Platelet distribution width;
LUSC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.54	-8.44	-0.42	9.89e-16	Schizophrenia;
LUSC	cis	rs4964805	1.000	rs11111789	chr12:104191540	G/C	cg02344784	chr12:104178138	NT5DC3	0.45	7.15	0.36	5.34e-12	Attention deficit hyperactivity disorder;
LUSC	trans	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07923666	chr12:49932857	KCNH3	0.51	6.32	0.33	8.49e-10	Resting heart rate;
LUSC	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-8.18	-0.41	5.82e-15	Morning vs. evening chronotype;
LUSC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.8	-10.86	-0.51	9.65e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4664308	0.935	rs877200	chr2:160903723	G/C	cg03641300	chr2:160917029	PLA2R1	-0.65	-11.11	-0.52	1.35e-24	Idiopathic membranous nephropathy;
LUSC	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	8.24	0.41	4.06e-15	Axial length;
LUSC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg03146154	chr1:46216737	IPP	-0.53	-7.71	-0.39	1.43e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg17385448	chr1:15911702	AGMAT	0.35	5.88	0.31	1e-8	Systolic blood pressure;
LUSC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg15110403	chr19:17392923	ANKLE1	-0.52	-7.17	-0.37	4.89e-12	Systemic lupus erythematosus;
LUSC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg05872129	chr22:39784769	NA	-0.6	-10.92	-0.51	6.22e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg08807101	chr21:30365312	RNF160	0.7	11.13	0.52	1.09e-24	Selective IgA deficiency;
LUSC	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.35	-5.67	-0.3	3.1e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg21681030	chr2:46777652	RHOQ	0.45	6.34	0.33	7.3e-10	Height;
LUSC	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg01503450	chr10:980765	NA	-0.38	-5.7	-0.3	2.68e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg20283391	chr11:68216788	NA	-0.6	-8.37	-0.42	1.61e-15	Total body bone mineral density;
LUSC	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg03342759	chr3:160939853	NMD3	0.45	5.97	0.31	5.99e-9	Parkinson's disease;
LUSC	trans	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	12.02	0.55	6.46e-28	Mean corpuscular volume;
LUSC	cis	rs11608355	0.508	rs12817730	chr12:109799330	G/A	cg19025524	chr12:109796872	NA	-0.47	-8.59	-0.43	3.47e-16	Neuroticism;
LUSC	cis	rs8038465	0.550	rs11072431	chr15:73987642	T/A	cg15420318	chr15:73925796	NPTN	0.51	8.37	0.42	1.63e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11630290	0.736	rs7177695	chr15:64140228	C/T	cg12036633	chr15:63758958	NA	-0.69	-7.19	-0.37	4.32e-12	Iris characteristics;
LUSC	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg03522245	chr20:25566470	NINL	0.35	5.67	0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.86	11.5	0.53	5e-26	Obesity-related traits;
LUSC	cis	rs2692947	0.740	rs11695514	chr2:96548068	C/T	cg23100626	chr2:96804247	ASTL	0.29	6.66	0.34	1.12e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.66	0.39	1.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg13813247	chr22:41461852	NA	-0.37	-6.73	-0.35	7.5e-11	Neuroticism;
LUSC	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg10596483	chr8:143751796	JRK	0.61	9.41	0.46	8.19e-19	Schizophrenia;
LUSC	trans	rs11700980	0.551	rs56165045	chr21:30114027	G/A	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg26597838	chr10:835615	NA	0.58	6.86	0.35	3.32e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs10203711	0.933	rs10187441	chr2:239577654	C/G	cg14580085	chr2:239553406	NA	0.42	7.11	0.36	7.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg12552261	chr5:112820674	MCC	0.45	7.01	0.36	1.31e-11	Type 2 diabetes;
LUSC	cis	rs757081	0.667	rs12577418	chr11:17101554	C/G	cg15432903	chr11:17409602	KCNJ11	-0.4	-6.2	-0.32	1.69e-9	Systolic blood pressure;
LUSC	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg08601574	chr20:25228251	PYGB	0.49	7.55	0.38	4.23e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg22676075	chr6:135203613	NA	0.47	7.27	0.37	2.62e-12	Red blood cell count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05131957	chr20:5986808	CRLS1	0.44	6.66	0.34	1.11e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs240764	0.555	rs4840150	chr6:101183774	T/C	cg09795085	chr6:101329169	ASCC3	0.43	6.18	0.32	1.85e-9	Neuroticism;
LUSC	cis	rs4478858	0.684	rs12121165	chr1:31725542	G/A	cg00250761	chr1:31883323	NA	-0.34	-8.21	-0.41	4.89e-15	Alcohol dependence;
LUSC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg13854012	chr2:162103682	NA	-0.45	-7.97	-0.4	2.53e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg05844789	chr1:228464394	OBSCN	-0.3	-5.76	-0.3	1.89e-8	Diastolic blood pressure;
LUSC	cis	rs5167	0.534	rs56803710	chr19:45481884	C/T	cg13119609	chr19:45449297	APOC2	0.34	5.67	0.3	3.01e-8	Blood protein levels;
LUSC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.94	-0.55	1.26e-27	Mean corpuscular volume;
LUSC	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg24692254	chr21:30365293	RNF160	0.69	10.86	0.51	9.97e-24	Pancreatic cancer;
LUSC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.43	0.53	9.43e-26	Alzheimer's disease;
LUSC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg05785598	chr3:49045655	WDR6	0.33	5.85	0.3	1.17e-8	Parkinson's disease;
LUSC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.75	-13.11	-0.58	5.66e-32	Cognitive function;
LUSC	cis	rs62400317	0.859	rs12153922	chr6:45256159	T/C	cg18551225	chr6:44695536	NA	-0.43	-7.11	-0.36	7.02e-12	Total body bone mineral density;
LUSC	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.89	15.25	0.64	3.11e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg21280719	chr6:42927975	GNMT	-0.29	-7.14	-0.36	5.94e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2274273	0.564	rs3783649	chr14:55834410	G/A	cg04306507	chr14:55594613	LGALS3	0.49	9.78	0.47	4.81e-20	Protein biomarker;
LUSC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg06453172	chr10:134556979	INPP5A	-0.52	-6.33	-0.33	7.79e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs977987	0.778	rs62059846	chr16:75430809	T/A	cg04384234	chr16:75411784	CFDP1	-0.41	-6.77	-0.35	5.88e-11	Dupuytren's disease;
LUSC	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.71	-0.3	2.47e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs62238980	0.614	rs79343805	chr22:32522040	A/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.52	-5.98	-0.31	5.76e-9	Childhood ear infection;
LUSC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.42	-0.38	9.8e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.71	0.39	1.41e-13	Parkinson's disease;
LUSC	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-1.12	-15.55	-0.65	2.16e-41	Hip circumference adjusted for BMI;
LUSC	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.6	7.79	0.39	8.8e-14	Schizophrenia;
LUSC	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg01448562	chr3:133502909	NA	-0.59	-8.94	-0.44	2.63e-17	Iron status biomarkers;
LUSC	cis	rs9341835	0.518	rs6924479	chr6:64173940	A/G	cg03326410	chr6:64151739	NA	-0.36	-5.91	-0.31	8.23e-9	Schizophrenia;
LUSC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg14582100	chr15:45693742	SPATA5L1	0.58	10.56	0.5	1.11e-22	Homoarginine levels;
LUSC	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg08236123	chr12:132219811	SFRS8	-0.43	-6.65	-0.34	1.19e-10	Migraine;
LUSC	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg02176678	chr2:219576539	TTLL4	-0.66	-12.89	-0.58	4.08e-31	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs8077889	0.703	rs231532	chr17:41945769	C/T	cg26893861	chr17:41843967	DUSP3	-0.81	-10.69	-0.5	4.03e-23	Triglycerides;
LUSC	cis	rs7716219	0.578	rs7718675	chr5:54973702	A/C	cg24729983	chr5:54530114	CCNO	0.48	5.97	0.31	5.94e-9	Height;
LUSC	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg10604040	chr11:65559109	OVOL1	0.31	5.72	0.3	2.34e-8	Acne (severe);
LUSC	cis	rs11168618	0.846	rs11168580	chr12:48850424	G/T	cg24011408	chr12:48396354	COL2A1	0.37	5.87	0.31	1.03e-8	Adiponectin levels;
LUSC	cis	rs6750047	0.585	rs336033	chr2:38263808	A/G	cg07380506	chr2:38303506	CYP1B1	-0.44	-6.4	-0.33	5.17e-10	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg26536354	chr8:144654954	C8orf73	0.67	7.31	0.37	2.05e-12	Attention deficit hyperactivity disorder;
LUSC	trans	rs10158481	0.759	rs6681610	chr1:25488413	A/T	cg27042278	chr14:91720527	GPR68	-0.33	-6.23	-0.32	1.38e-9	Urate levels in obese individuals;
LUSC	cis	rs10908458	0.584	rs10908454	chr1:155066416	C/T	cg23973274	chr1:155060172	NA	-0.33	-6.71	-0.34	8.59e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs8092503	1.000	rs12606265	chr18:52492470	T/C	cg12377874	chr18:52495404	RAB27B	0.34	6.12	0.32	2.68e-9	Childhood body mass index;
LUSC	cis	rs72634258	0.945	rs397349	chr1:8074872	A/C	cg00042356	chr1:8021962	PARK7	0.63	8.37	0.42	1.65e-15	Inflammatory bowel disease;
LUSC	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg19700328	chr14:106028568	NA	-0.39	-6.29	-0.33	9.71e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	9.13	0.45	6.77e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg02030672	chr11:45687055	CHST1	-0.42	-6.61	-0.34	1.51e-10	Obesity-related traits;
LUSC	cis	rs9831754	0.906	rs2089934	chr3:78382448	T/C	cg06138941	chr3:78371609	NA	-0.68	-9.28	-0.45	2.24e-18	Calcium levels;
LUSC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg23262073	chr20:60523788	NA	-0.42	-6.04	-0.31	4.06e-9	Body mass index;
LUSC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg12310025	chr6:25882481	NA	-0.42	-7.47	-0.38	6.94e-13	Height;
LUSC	cis	rs7095944	0.585	rs11245357	chr10:126452042	A/G	cg08799069	chr10:126477246	METTL10	-0.42	-6.57	-0.34	1.94e-10	Asthma;
LUSC	cis	rs701145	0.938	rs189588	chr3:153995855	T/G	cg17054900	chr3:154042577	DHX36	0.84	8.49	0.42	6.84e-16	Coronary artery disease;
LUSC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg02428538	chr16:24856791	SLC5A11	-0.51	-6.0	-0.31	5.09e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg08470875	chr2:26401718	FAM59B	-0.66	-8.76	-0.43	1.02e-16	Gut microbiome composition (summer);
LUSC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	6.44	0.33	4.15e-10	Bipolar disorder;
LUSC	cis	rs3784262	0.757	rs74655564	chr15:58325512	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.35	-6.33	-0.33	7.71e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.8	13.2	0.59	2.64e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg18721089	chr20:30220636	NA	-0.39	-6.08	-0.32	3.28e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg21951975	chr1:209979733	IRF6	0.62	8.06	0.4	1.4e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15664640	chr17:80829946	TBCD	0.51	8.96	0.44	2.26e-17	Breast cancer;
LUSC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.99	-0.4	2.15e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs177542	1	rs177542	chr11:16922654	G/A	cg05701403	chr11:16947551	PLEKHA7	0.44	8.2	0.41	5.12e-15	Diastolic blood pressure;
LUSC	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.53	0.62	2.03e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	9.86	0.47	2.7e-20	Height;
LUSC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.11	-0.32	2.81e-9	Total body bone mineral density;
LUSC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg00933542	chr6:150070202	PCMT1	0.32	6.79	0.35	5.15e-11	Lung cancer;
LUSC	cis	rs1775715	0.737	rs2808078	chr10:32172552	C/T	cg03015672	chr10:32216066	ARHGAP12	0.34	6.09	0.32	3.14e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg04352962	chr1:209979756	IRF6	-0.41	-6.16	-0.32	2.04e-9	Orofacial clefts;
LUSC	cis	rs2073300	1.000	rs6048834	chr20:23462213	C/T	cg09953122	chr20:23471693	CST8	-0.76	-7.49	-0.38	6.37e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07807409	chr6:150184969	LRP11	-0.4	-5.95	-0.31	6.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg20129853	chr10:51489980	NA	0.35	7.19	0.37	4.26e-12	Prostate-specific antigen levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15938289	chr10:70091743	HNRNPH3;PBLD	-0.41	-6.24	-0.32	1.36e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg23691090	chr22:46449981	C22orf26;LOC150381	-0.38	-5.99	-0.31	5.3300000000000004e-09	Dupuytren's disease;
LUSC	trans	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	6.09	0.32	3.06e-9	Retinal vascular caliber;
LUSC	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg25922239	chr6:33757077	LEMD2	0.54	8.04	0.4	1.6e-14	Crohn's disease;
LUSC	cis	rs17253792	0.915	rs17832389	chr14:56185836	A/G	cg01858014	chr14:56050164	KTN1	-0.82	-6.98	-0.36	1.6e-11	Putamen volume;
LUSC	cis	rs877282	0.583	rs12356155	chr10:823940	C/T	cg13775593	chr10:823151	NA	0.31	6.17	0.32	1.96e-9	Uric acid levels;
LUSC	cis	rs3772130	0.923	rs4298081	chr3:121526037	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.21	0.49	1.78e-21	Cognitive performance;
LUSC	cis	rs4664304	0.802	rs1511224	chr2:160750861	C/T	cg23995753	chr2:160760732	LY75	-0.3	-5.77	-0.3	1.78e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg05714579	chr10:131428358	MGMT	0.51	7.55	0.38	4.31e-13	Response to temozolomide;
LUSC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg24209194	chr3:40518798	ZNF619	-0.41	-5.89	-0.31	9.26e-9	Renal cell carcinoma;
LUSC	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg00012203	chr2:219082015	ARPC2	-0.77	-13.8	-0.6	1.41e-34	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10779751	1.000	rs2024627	chr1:11298790	T/C	cg08854313	chr1:11322531	MTOR	0.87	15.22	0.64	4.09e-40	Body mass index;
LUSC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg27094323	chr7:1216898	NA	-0.32	-5.65	-0.3	3.52e-8	Longevity;Endometriosis;
LUSC	cis	rs17125944	0.686	rs6572868	chr14:53325090	C/T	cg00686598	chr14:53173677	PSMC6	-0.65	-5.82	-0.3	1.4e-8	Alzheimer's disease (late onset);
LUSC	cis	rs1322512	1.000	rs1727052	chr6:152947175	T/C	cg27316956	chr6:152958899	SYNE1	-0.33	-5.65	-0.3	3.45e-8	Tonometry;
LUSC	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.43	5.77	0.3	1.85e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs981844	0.712	rs1563461	chr4:154751913	C/T	cg14289246	chr4:154710475	SFRP2	-0.46	-6.3	-0.33	9.19e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg22638593	chr5:131593259	PDLIM4	0.49	7.46	0.38	7.65e-13	Acylcarnitine levels;
LUSC	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.63	9.59	0.46	2.07e-19	Corneal astigmatism;
LUSC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg00945038	chr17:61921165	SMARCD2	0.4	6.09	0.32	3.17e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs56283067	0.887	rs62437968	chr6:44729495	G/A	cg18551225	chr6:44695536	NA	-0.49	-8.41	-0.42	1.17e-15	Total body bone mineral density;
LUSC	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg25251562	chr2:3704773	ALLC	-0.39	-6.91	-0.35	2.42e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg03461704	chr1:205818484	PM20D1	0.39	6.69	0.34	9.32e-11	Menarche (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00094036	chr12:72057474	THAP2;ZFC3H1	-0.49	-7.37	-0.37	1.36e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	1.04	20.08	0.74	2.21e-59	Menopause (age at onset);
LUSC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg10664184	chr19:17420304	DDA1	0.5	6.45	0.33	3.95e-10	Systemic lupus erythematosus;
LUSC	cis	rs9815354	0.556	rs55953604	chr3:42004428	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.42	5.02e-16	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs12524093	0.541	rs76710331	chr6:143060357	G/A	cg22454011	chr18:13611439	C18orf1	0.68	5.98	0.31	5.76e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17467752	chr17:38218738	THRA	0.78	12.54	0.57	7.78e-30	Monocyte percentage of white cells;
LUSC	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg26727032	chr16:67993705	SLC12A4	-0.41	-6.35	-0.33	7.03e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg07167872	chr1:205819463	PM20D1	-0.43	-5.91	-0.31	8.44e-9	Menarche (age at onset);
LUSC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4664308	0.618	rs17830940	chr2:160891768	T/C	cg03641300	chr2:160917029	PLA2R1	-0.47	-7.82	-0.39	6.75e-14	Idiopathic membranous nephropathy;
LUSC	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	8.7	0.43	1.57e-16	Motion sickness;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05848811	chr11:47270335	ACP2;NR1H3	-0.5	-6.57	-0.34	1.88e-10	Hepatitis;
LUSC	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4851254	0.584	rs35774174	chr2:100655130	T/A	cg22139774	chr2:100720529	AFF3	-0.44	-5.75	-0.3	2.02e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7560272	0.538	rs4852977	chr2:73938295	C/T	cg20560298	chr2:73613845	ALMS1	0.42	6.55	0.34	2.17e-10	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg17366294	chr4:99064904	C4orf37	0.57	10.04	0.48	6.92e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10486158	0.790	rs1014419	chr7:7406081	C/G	cg01895333	chr3:109035405	DPPA2	0.37	6.01	0.31	4.98e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs314370	0.521	rs314308	chr7:100420878	C/T	cg10426581	chr7:100472382	SRRT	0.54	8.33	0.41	2.09e-15	Resting heart rate;
LUSC	cis	rs4478858	0.684	rs3766289	chr1:31760128	G/A	cg00250761	chr1:31883323	NA	-0.33	-7.95	-0.4	2.9e-14	Alcohol dependence;
LUSC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg05373962	chr22:49881684	NA	-0.44	-10.52	-0.5	1.55e-22	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg09509183	chr1:209979624	IRF6	0.42	5.7	0.3	2.69e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.1	0.48	4.18e-21	Bipolar disorder;
LUSC	trans	rs3858145	0.588	rs61854833	chr10:70037327	C/G	cg04882175	chr6:131122610	NA	-0.65	-8.67	-0.43	1.89e-16	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUSC	trans	rs62103177	0.564	rs3930043	chr18:77723832	G/A	cg05926928	chr17:57297772	GDPD1	1.0	11.17	0.52	7.84e-25	Opioid sensitivity;
LUSC	trans	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.96	0.48	1.25e-20	Mean corpuscular volume;
LUSC	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg00857998	chr1:205179979	DSTYK	0.59	9.04	0.44	1.34e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.86	16.11	0.66	1.27e-43	Mean platelet volume;
LUSC	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.88	-0.63	9.18e-39	Schizophrenia;
LUSC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23158103	chr7:148848205	ZNF398	-0.45	-7.28	-0.37	2.42e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg22681709	chr2:178499509	PDE11A	-0.57	-11.33	-0.53	2.19e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg20607287	chr7:12443886	VWDE	-0.61	-6.34	-0.33	7.27e-10	Coronary artery disease;
LUSC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-1.04	-20.22	-0.74	5.96e-60	Height;
LUSC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg17143192	chr8:8559678	CLDN23	0.6	8.66	0.43	2.05e-16	Obesity-related traits;
LUSC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg14552801	chr7:65878734	NA	0.46	6.63	0.34	1.3100000000000001e-10	Aortic root size;
LUSC	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg07636037	chr3:49044803	WDR6	0.55	5.69	0.3	2.82e-8	Menarche (age at onset);
LUSC	trans	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg01620082	chr3:125678407	NA	-0.85	-7.21	-0.37	3.87e-12	Depression;
LUSC	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg12179176	chr11:130786555	SNX19	0.58	9.0	0.44	1.81e-17	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.28	-5.74	-0.3	2.14e-8	Cognitive function;
LUSC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.04	0.55	5.81e-28	Prudent dietary pattern;
LUSC	cis	rs3791556	0.853	rs35245395	chr2:240107661	C/T	cg03281426	chr2:240109471	HDAC4	0.53	7.43	0.38	8.95e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.72	0.34	8.09e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg24060327	chr5:131705240	SLC22A5	-0.43	-7.15	-0.36	5.49e-12	Blood metabolite levels;
LUSC	cis	rs1065852	0.906	rs5751232	chr22:42564304	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.6	10.04	0.48	6.9299999999999992e-21	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs3126085	1.000	rs3126085	chr1:152300817	G/A	cg26876637	chr1:152193138	HRNR	-0.45	-5.83	-0.3	1.27e-8	Atopic dermatitis;
LUSC	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg10734432	chr8:145180544	NA	-0.68	-5.96	-0.31	6.29e-9	Blood metabolite levels;
LUSC	trans	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.94	0.44	2.62e-17	Diabetic kidney disease;
LUSC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.42	-0.67	7.56e-45	Monocyte count;
LUSC	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.38	-0.37	1.28e-12	NT-proBNP levels in acute coronary syndrome;
LUSC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg06618935	chr21:46677482	NA	-0.37	-7.27	-0.37	2.62e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-12.26	-0.56	8.72e-29	Platelet distribution width;
LUSC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg20203395	chr5:56204925	C5orf35	-0.57	-8.07	-0.4	1.3e-14	Coronary artery disease;
LUSC	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.12	-18.16	-0.7	9.73e-52	Primary sclerosing cholangitis;
LUSC	trans	rs4714291	0.698	rs2983144	chr6:40046724	G/A	cg02267698	chr19:7991119	CTXN1	-0.55	-7.99	-0.4	2.25e-14	Strep throat;
LUSC	cis	rs9517320	1.000	rs7996093	chr13:99133092	T/C	cg20487152	chr13:99095054	FARP1	0.34	6.23	0.32	1.38e-9	Longevity;
LUSC	cis	rs7605827	0.930	rs9287663	chr2:15596076	T/G	cg19274914	chr2:15703543	NA	0.47	9.02	0.44	1.51e-17	Educational attainment (years of education);
LUSC	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg27147174	chr7:100797783	AP1S1	-0.55	-8.59	-0.43	3.42e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg10755058	chr3:40428713	ENTPD3	0.35	5.78	0.3	1.69e-8	Renal cell carcinoma;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg26767954	chr21:43638975	ABCG1	0.39	5.98	0.31	5.75e-9	Asthma;
LUSC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg11062466	chr8:58055876	NA	0.59	7.34	0.37	1.65e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1346	0.552	rs10791821	chr11:65368323	A/G	cg17120908	chr11:65337727	SSSCA1	0.43	6.11	0.32	2.79e-9	Vertical cup-disc ratio;Optic cup area;
LUSC	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg23029597	chr12:123009494	RSRC2	-0.74	-9.44	-0.46	6.68e-19	Body mass index;
LUSC	cis	rs2985684	0.894	rs2883436	chr14:50013822	T/C	cg04989706	chr14:50066350	PPIL5	-0.46	-6.05	-0.31	3.99e-9	Carotid intima media thickness;
LUSC	cis	rs2273669	0.667	rs6899723	chr6:109362749	T/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg00277334	chr10:82204260	NA	-0.58	-8.73	-0.43	1.25e-16	Post bronchodilator FEV1;
LUSC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg14541582	chr5:601475	NA	-0.37	-5.65	-0.3	3.43e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.55	0.83	5.42e-88	Chronic sinus infection;
LUSC	cis	rs73206853	0.841	rs57726737	chr12:110843701	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	6.78	0.35	5.52e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.71	-0.3	2.53e-8	Tonsillectomy;
LUSC	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07636037	chr3:49044803	WDR6	-0.68	-8.3	-0.41	2.55e-15	Menarche (age at onset);
LUSC	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg13575925	chr12:9217583	LOC144571	0.35	6.66	0.34	1.12e-10	Sjögren's syndrome;
LUSC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg08847533	chr14:75593920	NEK9	-0.81	-14.58	-0.62	1.31e-37	Height;
LUSC	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg12483005	chr1:23474871	LUZP1	0.45	6.96	0.36	1.82e-11	Height;
LUSC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg13560548	chr3:10150139	C3orf24	-0.52	-7.65	-0.39	2.14e-13	Alzheimer's disease;
LUSC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg18827107	chr12:86230957	RASSF9	0.46	6.96	0.36	1.86e-11	Major depressive disorder;
LUSC	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.8	-6.75	-0.35	6.46e-11	Lung cancer in ever smokers;
LUSC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg09300795	chr16:4042428	ADCY9	0.41	7.34	0.37	1.65e-12	Body mass index;
LUSC	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg22705602	chr4:152727874	NA	-0.34	-6.8	-0.35	4.74e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12595990	chr12:49351331	ARF3	-0.52	-6.29	-0.33	1.02e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.25	-0.45	2.85e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg04576048	chr1:205797593	PM20D1	0.33	6.06	0.31	3.6e-9	Menarche (age at onset);
LUSC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg09165964	chr15:75287851	SCAMP5	0.47	7.11	0.36	6.9e-12	Breast cancer;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg00887547	chr12:118811020	TAOK3	0.5	5.96	0.31	6.29e-9	Cognitive function;Information processing speed;
LUSC	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg09184832	chr6:79620586	NA	-0.43	-7.01	-0.36	1.29e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.77	-0.35	5.91e-11	Response to antipsychotic treatment;
LUSC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.95e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg17971929	chr21:40555470	PSMG1	0.74	12.4	0.56	2.66e-29	Cognitive function;
LUSC	cis	rs3820928	0.874	rs13423714	chr2:227896652	C/G	cg11843606	chr2:227700838	RHBDD1	0.49	7.13	0.36	6.36e-12	Pulmonary function;
LUSC	cis	rs3105593	0.543	rs28582911	chr15:50729629	G/A	cg08437265	chr15:50716283	USP8	0.4	5.8	0.3	1.55e-8	QT interval;
LUSC	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg02569458	chr12:86230093	RASSF9	0.48	8.0	0.4	2.01e-14	Major depressive disorder;
LUSC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg10909506	chr17:38081995	ORMDL3	0.33	5.85	0.3	1.19e-8	Self-reported allergy;
LUSC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg20821713	chr7:1055600	C7orf50	-0.56	-7.39	-0.37	1.2e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs3784262	1.000	rs4646586	chr15:58305344	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.04	-0.31	4.18e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.52	-0.34	2.58e-10	Lung cancer;
LUSC	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg23625390	chr15:77176239	SCAPER	-0.53	-8.34	-0.42	1.94e-15	Blood metabolite levels;
LUSC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg19230755	chr7:65878503	NA	0.41	5.75	0.3	2e-8	Aortic root size;
LUSC	cis	rs9309473	0.950	rs10189885	chr2:73877055	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.44	-0.33	4.07e-10	Metabolite levels;
LUSC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg17507749	chr15:85114479	UBE2QP1	0.68	8.55	0.42	4.36e-16	Schizophrenia;
LUSC	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg00042356	chr1:8021962	PARK7	0.81	9.85	0.47	2.83e-20	Inflammatory bowel disease;
LUSC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg08219700	chr8:58056026	NA	0.49	6.06	0.31	3.61e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.45	-7.9	-0.4	3.95e-14	Eosinophil percentage of white cells;
LUSC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg13319975	chr6:146136371	FBXO30	0.48	7.3	0.37	2.09e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7095944	0.585	rs7080838	chr10:126419841	A/G	cg08799069	chr10:126477246	METTL10	0.45	7.2	0.37	3.89e-12	Asthma;
LUSC	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21659725	chr3:3221576	CRBN	0.63	10.41	0.49	3.61e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.65	-0.39	2.22e-13	Height;
LUSC	cis	rs2625529	0.689	rs2957742	chr15:72302894	C/G	cg16672083	chr15:72433130	SENP8	0.49	8.08	0.4	1.2e-14	Red blood cell count;
LUSC	cis	rs4478858	0.735	rs4622114	chr1:31772571	A/G	cg00250761	chr1:31883323	NA	-0.34	-8.46	-0.42	8.39e-16	Alcohol dependence;
LUSC	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.12	-0.36	6.56e-12	Monocyte count;
LUSC	cis	rs62400317	0.859	rs4498350	chr6:45268438	C/T	cg20913747	chr6:44695427	NA	-0.45	-7.42	-0.38	9.93e-13	Total body bone mineral density;
LUSC	cis	rs11677416	1.000	rs34015482	chr2:113525745	A/G	cg27083787	chr2:113543245	IL1A	0.46	7.07	0.36	9.13e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg05283184	chr6:79620031	NA	-0.55	-11.31	-0.53	2.57e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-17.35	-0.69	1.61e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg03732007	chr1:2071316	PRKCZ	-0.51	-9.06	-0.44	1.11e-17	Height;
LUSC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg14004847	chr7:1930337	MAD1L1	-0.67	-10.87	-0.51	9.44e-24	Bipolar disorder and schizophrenia;
LUSC	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.76	11.15	0.52	8.96e-25	Corneal astigmatism;
LUSC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.52	0.59	1.62e-33	Cognitive test performance;
LUSC	cis	rs10740039	0.804	rs1372714	chr10:62446398	C/T	cg18175470	chr10:62150864	ANK3	-0.43	-6.54	-0.34	2.28e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12467847	0.931	rs2708931	chr2:113693878	C/G	cg12858261	chr2:113808755	IL1F8	-0.4	-6.04	-0.31	4.02e-9	Response to amphetamines;
LUSC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.69	0.39	1.71e-13	Electroencephalogram traits;
LUSC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	8.67	0.43	1.91e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9378688	1.000	rs9378687	chr6:2218835	A/G	cg12303981	chr6:2244766	GMDS	-0.5	-5.92	-0.31	8.1e-9	Caudate nucleus volume;
LUSC	cis	rs6063312	1.000	rs11699576	chr20:47349878	A/C	cg18078177	chr20:47281410	PREX1	0.63	7.64	0.39	2.38e-13	Tonometry;
LUSC	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.11	-0.41	9.53e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg05043794	chr9:111880884	C9orf5	-0.35	-7.4	-0.38	1.14e-12	Menarche (age at onset);
LUSC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg04013166	chr16:89971882	TCF25	0.62	7.24	0.37	3.1e-12	Skin colour saturation;
LUSC	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg11693508	chr17:37793320	STARD3	0.53	6.56	0.34	2.04e-10	Bipolar disorder;
LUSC	trans	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg26043149	chr18:55253948	FECH	0.53	7.77	0.39	9.7e-14	Bone mineral density;
LUSC	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg06454157	chr6:167490870	NA	0.24	5.73	0.3	2.27e-8	Primary biliary cholangitis;
LUSC	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg03929089	chr4:120376271	NA	-0.59	-6.26	-0.32	1.19e-9	Axial length;
LUSC	trans	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg07211511	chr3:129823064	LOC729375	-0.77	-9.85	-0.47	2.89e-20	Blood pressure (smoking interaction);
LUSC	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.44	-0.46	6.62e-19	Body mass index;
LUSC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg07716408	chr11:68623521	NA	-0.32	-6.29	-0.33	9.79e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21545522	chr1:205238299	TMCC2	0.48	9.09	0.45	9.26e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg01557791	chr16:72042693	DHODH	-0.5	-7.17	-0.37	4.87e-12	Fibrinogen levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04314218	chr1:43919181	HYI	0.68	6.05	0.31	3.98e-9	Cognitive performance;
LUSC	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.55	0.65	2.12e-41	Bladder cancer;
LUSC	cis	rs4356932	0.967	rs4241581	chr4:76962055	G/A	cg00809888	chr4:76862425	NAAA	0.36	5.92	0.31	7.79e-9	Blood protein levels;
LUSC	cis	rs2067615	0.542	rs7133161	chr12:107139540	A/G	cg15890332	chr12:107067104	RFX4	0.35	6.39	0.33	5.71e-10	Heart rate;
LUSC	cis	rs3105593	0.547	rs3131559	chr15:50780214	C/A	cg08437265	chr15:50716283	USP8	0.41	5.9	0.31	8.98e-9	QT interval;
LUSC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg15445000	chr17:37608096	MED1	0.39	6.71	0.34	8.27e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs259282	0.605	rs2302970	chr19:33098632	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	9.67	0.47	1.13e-19	Schizophrenia;
LUSC	cis	rs17401966	0.558	rs17402762	chr1:10414470	T/C	cg19773385	chr1:10388646	KIF1B	-0.37	-6.49	-0.33	3.04e-10	Hepatocellular carcinoma;
LUSC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg27411982	chr8:10470053	RP1L1	0.49	7.65	0.39	2.13e-13	Monocyte count;
LUSC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg09365446	chr1:150670422	GOLPH3L	0.48	7.05	0.36	1.02e-11	Melanoma;
LUSC	trans	rs4649444	0.666	rs16858849	chr1:233339427	C/T	cg15547662	chr1:26324823	PAFAH2	0.44	5.99	0.31	5.55e-9	Homeostasis model assessment of beta-cell function (dietary factor interaction);
LUSC	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg18230493	chr5:56204884	C5orf35	-0.86	-12.8	-0.57	8.47e-31	Initial pursuit acceleration;
LUSC	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg16797656	chr11:68205561	LRP5	0.38	6.23	0.32	1.4e-9	Total body bone mineral density;
LUSC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.42	-0.33	4.68e-10	Life satisfaction;
LUSC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg07424592	chr7:64974309	NA	0.66	5.82	0.3	1.39e-8	Diabetic kidney disease;
LUSC	cis	rs12760731	0.720	rs34194793	chr1:178329065	G/T	cg00404053	chr1:178313656	RASAL2	0.57	6.07	0.32	3.44e-9	Obesity-related traits;
LUSC	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg05738196	chr6:26577821	NA	0.67	11.23	0.52	4.97e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs2012796	0.956	rs6574646	chr14:81819809	A/G	cg02996355	chr14:81879375	NA	0.5	7.24	0.37	3.08e-12	Night sleep phenotypes;
LUSC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.47	-7.36	-0.37	1.44e-12	IgG glycosylation;
LUSC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03934478	chr11:495069	RNH1	-0.85	-10.25	-0.49	1.32e-21	Body mass index;
LUSC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg21724239	chr8:58056113	NA	0.8	9.24	0.45	3.07e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg05768032	chr16:30646687	NA	0.4	5.92	0.31	7.93e-9	Multiple myeloma;
LUSC	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg03128945	chr5:622914	CEP72	-0.45	-6.46	-0.33	3.69e-10	Obesity-related traits;
LUSC	cis	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg06521331	chr12:34319734	NA	0.41	6.41	0.33	4.97e-10	Morning vs. evening chronotype;
LUSC	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg05472934	chr7:22766657	IL6	0.5	7.84	0.39	6.13e-14	Lung cancer;
LUSC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg05925327	chr15:68127851	NA	-0.43	-6.95	-0.36	1.91e-11	Restless legs syndrome;
LUSC	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.87	-0.31	1.05e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg16624210	chr5:671434	TPPP	0.49	6.27	0.32	1.09e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs259282	0.692	rs35972270	chr19:33128457	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.69	10.51	0.5	1.66e-22	Schizophrenia;
LUSC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg07870213	chr5:140052090	DND1	0.72	10.74	0.51	2.57e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.82	-0.39	6.95e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg06636551	chr8:101224915	SPAG1	0.46	8.47	0.42	7.81e-16	Atrioventricular conduction;
LUSC	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21659725	chr3:3221576	CRBN	0.62	8.77	0.43	9.04e-17	Resting heart rate;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23043438	chr9:103115132	TEX10	-0.44	-6.62	-0.34	1.4e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	0.92	16.31	0.67	2.09e-44	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs4243830	0.826	rs3908553	chr1:6621921	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.94	9.13	0.45	6.58e-18	Body mass index;
LUSC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.92e-10	Life satisfaction;
LUSC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg06008330	chr7:65541103	ASL	-0.4	-6.23	-0.32	1.43e-9	Aortic root size;
LUSC	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.74	-14.41	-0.62	6.01e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4566357	0.615	rs4675140	chr2:227908665	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.28	-0.41	2.96e-15	Coronary artery disease;
LUSC	cis	rs11608355	1.000	rs7970482	chr12:109862335	G/A	cg05360138	chr12:110035743	NA	0.47	6.43	0.33	4.52e-10	Neuroticism;
LUSC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.31	-0.33	9.11e-10	Lung cancer;
LUSC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24110177	chr3:50126178	RBM5	0.57	9.21	0.45	3.63e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs10740039	0.516	rs1442551	chr10:62324491	T/C	cg18175470	chr10:62150864	ANK3	-0.45	-6.78	-0.35	5.48e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	7.01	0.36	1.34e-11	Myopia (pathological);
LUSC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg19622623	chr12:86230825	RASSF9	-0.44	-6.26	-0.32	1.15e-9	Major depressive disorder;
LUSC	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg23788917	chr6:8435910	SLC35B3	-0.47	-5.98	-0.31	5.76e-9	Motion sickness;
LUSC	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg03806693	chr22:41940476	POLR3H	-0.55	-7.61	-0.38	2.84e-13	Neuroticism;
LUSC	cis	rs4363385	0.693	rs6690672	chr1:152930564	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-6.73	-0.35	7.32e-11	Inflammatory skin disease;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.59	9.59	0.46	2.07e-19	Lymphocyte counts;
LUSC	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg09479241	chr17:27052676	TLCD1	0.44	5.94	0.31	7.3e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg00587665	chr15:100533223	ADAMTS17	0.37	6.08	0.32	3.32e-9	Height;
LUSC	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.89	14.85	0.63	1.19e-38	Bladder cancer;
LUSC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg13319975	chr6:146136371	FBXO30	0.48	7.31	0.37	1.93e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4589502	1.000	rs79390908	chr15:67130924	C/T	cg09911534	chr15:67153556	NA	-0.69	-7.19	-0.37	4.15e-12	Lung cancer (smoking interaction);
LUSC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	19.1	0.72	1.79e-55	Chronic sinus infection;
LUSC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg16339924	chr4:17578868	LAP3	0.6	9.33	0.45	1.53e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs72960926	0.744	rs55764691	chr6:74924388	T/C	cg03266952	chr6:74778945	NA	-0.84	-7.01	-0.36	1.34e-11	Metabolite levels (MHPG);
LUSC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg08859206	chr1:53392774	SCP2	-0.54	-9.68	-0.47	1.07e-19	Monocyte count;
LUSC	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg16386425	chr10:429943	DIP2C	-0.39	-6.11	-0.32	2.78e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg20991723	chr1:152506922	NA	-0.48	-9.04	-0.44	1.28e-17	Hair morphology;
LUSC	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg07061783	chr6:25882402	NA	-0.38	-5.86	-0.31	1.14e-8	Blood metabolite levels;
LUSC	cis	rs73206853	0.764	rs56205958	chr12:111027361	G/C	cg12870014	chr12:110450643	ANKRD13A	0.69	7.58	0.38	3.37e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.47	0.59	2.6e-33	Cognitive test performance;
LUSC	trans	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-8.53	-0.42	5.13e-16	Obesity-related traits;
LUSC	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg25566285	chr7:158114605	PTPRN2	-0.34	-6.28	-0.32	1.06e-9	Calcium levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13315471	chr2:27258494	TMEM214	-0.42	-6.37	-0.33	6.29e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11871801	0.560	rs1905339	chr17:40582296	T/C	cg16308533	chr17:40838983	CNTNAP1	0.37	5.8	0.3	1.52e-8	Crohn's disease;
LUSC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11644478	chr21:40555479	PSMG1	0.59	9.53	0.46	3.39e-19	Cognitive function;
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.46	7.53	0.38	4.75e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs2299587	0.607	rs2237848	chr8:17874604	A/C	cg01800426	chr8:17659068	MTUS1	-0.43	-5.69	-0.3	2.82e-8	Economic and political preferences;
LUSC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg20608306	chr11:116969690	SIK3	-0.36	-6.01	-0.31	4.85e-9	Blood protein levels;
LUSC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	6.37	0.33	6.1e-10	Electroencephalogram traits;
LUSC	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg12863693	chr15:85201151	NMB	0.39	8.1	0.41	1.07e-14	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14467103	chr5:154317806	GEMIN5	-0.42	-6.18	-0.32	1.91e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.94	0.31	7.08e-9	Morning vs. evening chronotype;
LUSC	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.7	10.65	0.5	5.42e-23	Corneal astigmatism;
LUSC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg00810483	chr4:3375144	RGS12	-0.3	-5.7	-0.3	2.68e-8	Serum sulfate level;
LUSC	cis	rs6489785	0.522	rs2701177	chr12:121344490	G/T	cg02419362	chr12:121203948	SPPL3	-0.39	-6.78	-0.35	5.33e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg04545296	chr12:48745243	ZNF641	0.35	6.34	0.33	7.61e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg12310025	chr6:25882481	NA	-0.42	-7.42	-0.38	9.47e-13	Height;
LUSC	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.13	0.55	2.73e-28	Colorectal cancer;
LUSC	cis	rs12422267	0.536	rs61944635	chr12:132575652	C/T	cg05134918	chr12:132603531	EP400NL	-0.57	-6.58	-0.34	1.83e-10	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg22800045	chr5:56110881	MAP3K1	0.68	8.4	0.42	1.34e-15	Initial pursuit acceleration;
LUSC	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg15423357	chr2:25149977	NA	0.43	8.84	0.44	5.73e-17	Body mass index in non-asthmatics;
LUSC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg25319279	chr11:5960081	NA	-0.39	-5.87	-0.31	1.05e-8	DNA methylation (variation);
LUSC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg15839431	chr19:19639596	YJEFN3	0.44	6.19	0.32	1.78e-9	Tonsillectomy;
LUSC	cis	rs1005224	0.963	rs11623813	chr14:76138194	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-5.82	-0.3	1.37e-8	Large artery stroke;
LUSC	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg18232548	chr7:50535776	DDC	-0.54	-7.5	-0.38	5.76e-13	Malaria;
LUSC	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	0.93	12.34	0.56	4.58e-29	Primary sclerosing cholangitis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04673371	chr7:131012253	MKLN1	-0.45	-6.02	-0.31	4.5e-9	Hepatitis;
LUSC	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.4	-0.42	1.28e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs317689	1.000	rs317689	chr12:69727190	G/A	cg14784868	chr12:69753453	YEATS4	0.56	7.2	0.37	3.97e-12	Response to diuretic therapy;
LUSC	trans	rs2392780	0.512	rs373701	chr8:128334992	C/A	cg10897648	chr18:56338258	MALT1	-0.41	-6.17	-0.32	1.92e-9	Breast cancer (early onset);
LUSC	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg06917634	chr15:78832804	PSMA4	-0.54	-6.74	-0.35	6.96e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg13073564	chr4:8508604	NA	0.35	6.34	0.33	7.5e-10	Response to antineoplastic agents;
LUSC	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg23093090	chr10:104574429	C10orf26	-0.4	-6.8	-0.35	4.9e-11	Arsenic metabolism;
LUSC	cis	rs12956009	0.583	rs1821446	chr18:44894422	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.06	0.31	3.6e-9	Educational attainment (years of education);
LUSC	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-0.64	-6.62	-0.34	1.42e-10	Hair shape;
LUSC	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07080220	chr10:102295463	HIF1AN	0.67	8.75	0.43	1.11e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2274273	0.624	rs8005450	chr14:55799165	A/T	cg04306507	chr14:55594613	LGALS3	0.48	9.69	0.47	1e-19	Protein biomarker;
LUSC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg13607699	chr17:42295918	UBTF	-0.58	-8.73	-0.43	1.2e-16	Total body bone mineral density;
LUSC	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg11244672	chr19:19639970	YJEFN3	0.64	8.0	0.4	2.09e-14	Bipolar disorder;
LUSC	trans	rs57046232	0.511	rs6054143	chr20:6334697	C/T	cg21095983	chr6:86352623	SYNCRIP	0.47	7.02	0.36	1.26e-11	Colorectal cancer;
LUSC	cis	rs11214589	0.620	rs34601878	chr11:113260898	G/A	cg14159747	chr11:113255604	NA	0.29	7.66	0.39	1.97e-13	Neuroticism;
LUSC	cis	rs10208940	0.764	rs6737302	chr2:68782837	A/G	cg12452813	chr2:68675892	NA	0.56	5.81	0.3	1.45e-8	Urate levels in lean individuals;
LUSC	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	cis	rs67539049	1.000	rs67932868	chr8:11303445	G/A	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.41	-6.33	-0.33	7.98e-10	Itch intensity from mosquito bite;
LUSC	cis	rs11997175	0.550	rs10954943	chr8:33815972	A/G	ch.8.33884649F	chr8:33765107	NA	0.44	6.8	0.35	4.83e-11	Body mass index;
LUSC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg13939156	chr17:80058883	NA	-0.34	-6.64	-0.34	1.28e-10	Life satisfaction;
LUSC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.37	-0.42	1.56e-15	Mean platelet volume;
LUSC	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg11645453	chr3:52864694	ITIH4	0.5	11.24	0.52	4.42e-25	Schizophrenia;
LUSC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg18230493	chr5:56204884	C5orf35	0.85	12.67	0.57	2.54e-30	Initial pursuit acceleration;
LUSC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.3	0.56	6.22e-29	Motion sickness;
LUSC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg14092988	chr3:52407081	DNAH1	0.32	6.2	0.32	1.65e-9	Bipolar disorder;
LUSC	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg18357645	chr12:58087776	OS9	0.58	8.73	0.43	1.27e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg26924012	chr15:45694286	SPATA5L1	1.13	20.89	0.75	1.35e-62	Homoarginine levels;
LUSC	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg12559939	chr2:27858050	GPN1	-0.41	-6.21	-0.32	1.58e-9	Oral cavity cancer;
LUSC	cis	rs9807989	0.839	rs13392100	chr2:102982094	C/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.68	0.3	2.87e-8	Asthma;
LUSC	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg23205692	chr1:25664452	TMEM50A	-0.39	-5.77	-0.3	1.78e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg08000102	chr2:233561755	GIGYF2	0.68	11.42	0.53	1.04e-25	Coronary artery disease;
LUSC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg18479299	chr3:125709523	NA	-0.49	-5.67	-0.3	3.05e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg17294928	chr15:75287854	SCAMP5	-0.88	-12.84	-0.58	5.81e-31	Blood trace element (Zn levels);
LUSC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg00945038	chr17:61921165	SMARCD2	0.38	5.77	0.3	1.8e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg13939156	chr17:80058883	NA	-0.32	-6.37	-0.33	6.43e-10	Life satisfaction;
LUSC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg21856205	chr7:94953877	PON1	-0.36	-5.69	-0.3	2.72e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg03886242	chr7:26192032	NFE2L3	0.36	5.96	0.31	6.57e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg23029597	chr12:123009494	RSRC2	-0.63	-8.15	-0.41	7.2e-15	Body mass index;
LUSC	cis	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg05340658	chr4:99064831	C4orf37	-0.6	-9.4	-0.46	8.73e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6580649	0.941	rs4141065	chr12:48523499	G/A	cg24011408	chr12:48396354	COL2A1	-0.47	-6.34	-0.33	7.54e-10	Lung cancer;
LUSC	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg10845886	chr2:3471009	TTC15	0.55	7.2	0.37	4.09e-12	Neurofibrillary tangles;
LUSC	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg24851651	chr11:66362959	CCS	-0.36	-5.73	-0.3	2.25e-8	Educational attainment (years of education);
LUSC	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.82	-0.35	4.19e-11	Uric acid levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14983362	chr11:118901610	SLC37A4	-0.42	-6.13	-0.32	2.5e-9	Electrocardiographic conduction measures;
LUSC	cis	rs56399783	0.901	rs73049305	chr7:2778755	C/T	cg14895029	chr7:2775587	GNA12	0.52	5.72	0.3	2.43e-8	Childhood ear infection;
LUSC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg20573242	chr4:122745356	CCNA2	0.63	9.34	0.46	1.36e-18	Type 2 diabetes;
LUSC	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.43	-5.72	-0.3	2.39e-8	Coronary artery disease;
LUSC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.64	-0.43	2.38e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs1113500	0.862	rs2336129	chr1:108640669	A/G	cg11967332	chr1:108735228	SLC25A24	-0.39	-5.95	-0.31	6.86e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-0.89	-17.57	-0.69	2.08e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.22	0.32	1.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10754283	0.901	rs10922684	chr1:90117934	T/C	cg21401794	chr1:90099060	LRRC8C	0.61	8.77	0.43	9.6e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	6.59	0.34	1.77e-10	Lung cancer in ever smokers;
LUSC	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg23303369	chr20:44641161	MMP9	0.37	6.42	0.33	4.77e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs800082	0.516	rs12486830	chr3:144228339	A/T	cg24215973	chr2:240111563	HDAC4	0.44	6.64	0.34	1.26e-10	Smoking behavior;
LUSC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.85	0.31	1.15e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	0.94	10.64	0.5	5.74e-23	Nonalcoholic fatty liver disease;
LUSC	trans	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-8.69	-0.43	1.6e-16	Obesity-related traits;
LUSC	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg07701084	chr6:150067640	NUP43	0.47	7.08	0.36	8.6e-12	Lung cancer;
LUSC	cis	rs3784262	1.000	rs4646619	chr15:58258342	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.8	-0.3	1.58e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs858239	0.539	rs28624974	chr7:23188936	T/C	cg23682824	chr7:23144976	KLHL7	0.4	5.71	0.3	2.52e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4285028	0.747	rs12496318	chr3:121561500	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.89	10.67	0.5	4.4e-23	Multiple sclerosis;
LUSC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg15147215	chr3:52552868	STAB1	-0.29	-5.66	-0.3	3.24e-8	Electroencephalogram traits;
LUSC	cis	rs1005224	0.929	rs11625260	chr14:76162293	G/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.64	-8.87	-0.44	4.45e-17	Large artery stroke;
LUSC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg02782426	chr3:40428986	ENTPD3	0.32	6.17	0.32	2e-9	Renal cell carcinoma;
LUSC	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg24375607	chr4:120327624	NA	0.77	11.3	0.53	2.73e-25	Corneal astigmatism;
LUSC	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg00857998	chr1:205179979	DSTYK	0.57	8.85	0.44	5.28e-17	Red blood cell count;
LUSC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg20135002	chr11:47629003	NA	0.51	7.99	0.4	2.26e-14	Subjective well-being;
LUSC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg11843238	chr5:131593191	PDLIM4	0.5	8.73	0.43	1.21e-16	Acylcarnitine levels;
LUSC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.95	15.05	0.64	1.88e-39	Height;
LUSC	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg19743168	chr1:23544995	NA	0.41	8.05	0.4	1.51e-14	Height;
LUSC	cis	rs4363385	0.818	rs9659389	chr1:152989844	T/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.54e-13	Inflammatory skin disease;
LUSC	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg15848620	chr12:58087721	OS9	-0.53	-7.47	-0.38	6.89e-13	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs11264213	0.901	rs72661628	chr1:36406547	A/G	cg05872835	chr6:75796125	COL12A1	0.51	5.97	0.31	5.97e-9	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.93	0.51	5.58e-24	Menopause (age at onset);
LUSC	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.14	0.45	6.22e-18	Coronary artery disease;
LUSC	cis	rs10788972	0.508	rs6691549	chr1:54480903	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.3	-6.66	-0.34	1.14e-10	Parkinson disease and lewy body pathology;
LUSC	cis	rs806215	0.906	rs806195	chr7:127249178	A/G	cg25922125	chr7:127225783	GCC1	0.57	7.17	0.37	4.96e-12	Type 2 diabetes;
LUSC	cis	rs12760731	0.668	rs10913548	chr1:178372286	G/A	cg00404053	chr1:178313656	RASAL2	0.64	6.55	0.34	2.22e-10	Obesity-related traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21467513	chr18:33709444	SLC39A6;ELP2	-0.46	-6.75	-0.35	6.75e-11	Electrocardiographic conduction measures;
LUSC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.81	11.83	0.54	3.23e-27	Breast cancer;
LUSC	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg25801113	chr15:45476975	SHF	0.36	7.32	0.37	1.82e-12	Uric acid levels;
LUSC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.52e-24	Aortic root size;
LUSC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18876405	chr7:65276391	NA	0.54	8.36	0.42	1.69e-15	Aortic root size;
LUSC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg03188948	chr7:1209495	NA	0.66	6.93	0.35	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	14.7	0.63	4.66e-38	Menopause (age at onset);
LUSC	trans	rs10432489	0.708	rs10189224	chr2:181764318	A/C	cg04744134	chr19:8408128	KANK3	-0.85	-6.73	-0.35	7.49e-11	QT interval;
LUSC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-8.0	-0.4	2.04e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg00857998	chr1:205179979	DSTYK	0.65	9.82	0.47	3.69e-20	Red blood cell count;
LUSC	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg05294307	chr14:35346193	BAZ1A	-0.63	-7.57	-0.38	3.76e-13	Psoriasis;
LUSC	cis	rs3741151	1.000	rs7949364	chr11:73041077	A/G	cg17517138	chr11:73019481	ARHGEF17	0.95	8.89	0.44	3.99e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg02574844	chr11:5959923	NA	-0.45	-6.34	-0.33	7.63e-10	DNA methylation (variation);
LUSC	trans	rs7739264	0.602	rs2223362	chr6:19778171	C/A	cg13431028	chr2:169073609	STK39	0.38	6.4	0.33	5.22e-10	Endometriosis;
LUSC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg06212747	chr3:49208901	KLHDC8B	0.44	6.04	0.31	4.17e-9	Parkinson's disease;
LUSC	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	trans	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg00310523	chr12:86230176	RASSF9	0.54	10.06	0.48	5.54e-21	Major depressive disorder;
LUSC	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg03732007	chr1:2071316	PRKCZ	0.47	7.58	0.38	3.49e-13	Height;
LUSC	cis	rs6120849	0.754	rs8501	chr20:33590584	T/C	cg24642439	chr20:33292090	TP53INP2	0.62	6.85	0.35	3.66e-11	Protein C levels;
LUSC	cis	rs9815354	0.556	rs116717051	chr3:42027411	G/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9462027	0.651	rs6940395	chr6:34736553	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.91	-0.31	8.62e-9	Systemic lupus erythematosus;
LUSC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg26373071	chr5:1325741	CLPTM1L	0.42	7.64	0.39	2.39e-13	Lung cancer;
LUSC	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	0.97	17.77	0.7	3.26e-50	Alcohol dependence;
LUSC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-1.03	-20.25	-0.74	4.78e-60	Height;
LUSC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg18827107	chr12:86230957	RASSF9	-0.44	-6.56	-0.34	2.07e-10	Major depressive disorder;
LUSC	cis	rs7818345	1.000	rs11991105	chr8:19290655	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.37	7.29	0.37	2.28e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	trans	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7589342	0.628	rs62152201	chr2:106411664	C/T	cg14210321	chr2:106509881	NCK2	-0.46	-5.87	-0.31	1.04e-8	Addiction;
LUSC	cis	rs988712	0.622	rs7103411	chr11:27700125	C/T	cg10635145	chr11:27742435	BDNF	0.48	6.63	0.34	1.3100000000000001e-10	Obesity;
LUSC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg22823121	chr1:150693482	HORMAD1	0.49	7.13	0.36	6.37e-12	Melanoma;
LUSC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg09650180	chr20:62225654	GMEB2	-0.66	-9.68	-0.47	1.1e-19	Glioblastoma;
LUSC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19717773	chr7:2847554	GNA12	-0.35	-5.73	-0.3	2.19e-8	Height;
LUSC	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg20608306	chr11:116969690	SIK3	0.36	6.7	0.34	9e-11	Blood protein levels;
LUSC	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg23260525	chr10:116636907	FAM160B1	0.4	8.18	0.41	5.96e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9650657	0.615	rs6601536	chr8:10696311	C/G	cg27411982	chr8:10470053	RP1L1	-0.34	-5.68	-0.3	2.91e-8	Neuroticism;
LUSC	cis	rs13401104	0.796	rs56338351	chr2:237119104	G/A	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs6469656	1.000	rs7830860	chr8:117652174	C/T	cg24004040	chr8:117650383	NA	0.42	6.51	0.34	2.75e-10	Colorectal cancer;
LUSC	cis	rs6028335	0.674	rs66526549	chr20:37588360	A/G	cg27552599	chr20:37590471	DHX35	0.45	5.65	0.3	3.4e-8	Alcohol and nicotine co-dependence;
LUSC	trans	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg07393940	chr7:158741817	NA	-0.51	-8.05	-0.4	1.43e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg11766577	chr21:47581405	C21orf56	0.54	8.49	0.42	6.73e-16	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.73	-0.35	7.4e-11	Lung cancer;
LUSC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.18	29.84	0.85	3.02e-96	Testicular germ cell tumor;
LUSC	cis	rs983392	0.766	rs476722	chr11:59913806	T/C	cg24026212	chr11:59952134	MS4A6A	-0.31	-5.67	-0.3	3.14e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg15448220	chr1:150897856	SETDB1	0.41	6.02	0.31	4.48e-9	Melanoma;
LUSC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11764359	chr7:65958608	NA	0.69	11.16	0.52	8.79e-25	Aortic root size;
LUSC	cis	rs12541635	0.677	rs13439705	chr8:106967268	T/C	cg10147462	chr8:107024639	NA	0.65	13.14	0.58	4.55e-32	Age of smoking initiation;
LUSC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs4903214	0.895	rs10142706	chr14:74717304	A/G	cg08255017	chr14:74727001	VSX2	-0.44	-5.91	-0.31	8.43e-9	Inflammatory bowel disease;
LUSC	cis	rs1847202	0.826	rs11925587	chr3:72952227	A/G	cg25664220	chr3:72788482	NA	0.4	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg14668632	chr7:2872130	GNA12	-0.45	-6.59	-0.34	1.74e-10	Height;
LUSC	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg06636551	chr8:101224915	SPAG1	-0.4	-7.41	-0.38	1.03e-12	Atrioventricular conduction;
LUSC	cis	rs2290159	0.800	rs6766666	chr3:12690855	A/C	cg23032965	chr3:12705835	RAF1	-0.71	-8.88	-0.44	4.28e-17	Cholesterol, total;
LUSC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21724239	chr8:58056113	NA	0.81	8.84	0.44	5.66e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg05347473	chr6:146136440	FBXO30	0.57	10.06	0.48	5.51e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03576123	chr11:487126	PTDSS2	-0.95	-10.54	-0.5	1.29e-22	Body mass index;
LUSC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg13047869	chr3:10149882	C3orf24	0.61	8.04	0.4	1.61e-14	Alzheimer's disease;
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg25243455	chr2:114033360	PAX8;LOC440839	0.34	7.81	0.39	7.67e-14	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.96	0.48	1.2e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9296092	0.500	rs9469504	chr6:33527243	G/A	cg13560919	chr6:33536144	NA	-0.85	-16.44	-0.67	6.54e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg09876464	chr15:85330779	ZNF592	0.36	6.39	0.33	5.58e-10	P wave terminal force;
LUSC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23158103	chr7:148848205	ZNF398	-0.45	-7.25	-0.37	2.97e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs8030485	0.730	rs57488047	chr15:79403002	T/C	cg17916960	chr15:79447300	NA	0.34	6.12	0.32	2.67e-9	Left ventricle wall thickness;
LUSC	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	0.94	8.24	0.41	3.94e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg09904177	chr6:26538194	HMGN4	0.73	12.81	0.57	7.73e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs4746818	1.000	rs906217	chr10:70954661	T/C	cg11621586	chr10:70884670	VPS26A	1.13	11.04	0.52	2.31e-24	Left atrial antero-posterior diameter;
LUSC	cis	rs1322512	0.920	rs1407487	chr6:152945846	T/C	cg27316956	chr6:152958899	SYNE1	-0.33	-5.65	-0.3	3.45e-8	Tonometry;
LUSC	cis	rs360798	0.553	rs360804	chr2:62939397	C/T	cg17519650	chr2:63277830	OTX1	-0.5	-7.21	-0.37	3.85e-12	Coronary artery disease;
LUSC	cis	rs11031096	0.589	rs935130	chr11:4213530	A/G	cg08557956	chr11:4115526	RRM1	-0.42	-5.72	-0.3	2.33e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11997175	0.624	rs7464055	chr8:33679382	G/A	ch.8.33884649F	chr8:33765107	NA	0.47	7.08	0.36	8.78e-12	Body mass index;
LUSC	cis	rs28830936	0.934	rs4923915	chr15:42119606	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.78	-0.3	1.75e-8	Diastolic blood pressure;
LUSC	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg03474202	chr17:45855739	NA	-0.32	-7.23	-0.37	3.29e-12	IgG glycosylation;
LUSC	trans	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.26	-0.32	1.15e-9	Depression;
LUSC	cis	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.43	-0.42	1.05e-15	Morning vs. evening chronotype;
LUSC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg08888203	chr3:10149979	C3orf24	0.59	8.11	0.41	9.88e-15	Alzheimer's disease;
LUSC	cis	rs721399	0.539	rs10087857	chr8:18267461	G/C	cg18736775	chr8:18248649	NAT2	-0.59	-7.17	-0.37	4.78e-12	Blood metabolite levels;
LUSC	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg07169764	chr2:136633963	MCM6	0.87	11.94	0.55	1.26e-27	Mosquito bite size;
LUSC	cis	rs73195822	0.614	rs7309777	chr12:111213964	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	6.61	0.34	1.52e-10	Itch intensity from mosquito bite;
LUSC	cis	rs727505	1.000	rs7790856	chr7:124459852	C/T	cg23710748	chr7:124431027	NA	-0.4	-7.26	-0.37	2.71e-12	Lewy body disease;
LUSC	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg22878388	chr2:105853796	NA	-0.33	-6.32	-0.33	8.39e-10	Type 2 diabetes;
LUSC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg27284194	chr4:1044797	NA	-0.36	-5.86	-0.31	1.09e-8	Obesity-related traits;
LUSC	cis	rs9513627	1.000	rs7327068	chr13:100126965	A/G	cg25919922	chr13:100150906	NA	-0.74	-6.55	-0.34	2.2e-10	Obesity-related traits;
LUSC	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg08017756	chr2:100939284	LONRF2	-0.44	-8.31	-0.41	2.51e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7719624	0.870	rs10042825	chr5:135396084	A/T	cg12897067	chr5:135418308	NA	0.4	5.68	0.3	2.91e-8	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg05472934	chr7:22766657	IL6	0.5	7.56	0.38	4e-13	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUSC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.62	-0.39	2.57e-13	Electroencephalogram traits;
LUSC	cis	rs55665837	1.000	rs34382046	chr11:14451318	C/T	cg05501817	chr11:14380813	RRAS2	-0.41	-6.53	-0.34	2.5e-10	Vitamin D levels;
LUSC	cis	rs7760535	0.831	rs62420437	chr6:111748780	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.73	-0.35	7.4e-11	Metabolic traits;
LUSC	cis	rs735539	0.636	rs9579928	chr13:21274807	C/G	cg04906043	chr13:21280425	IL17D	0.38	6.44	0.33	4.27e-10	Dental caries;
LUSC	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg14696996	chr19:15285081	NOTCH3	0.99	9.07	0.44	1.06e-17	Pulse pressure;
LUSC	cis	rs273573	0.925	rs163882	chr11:30947681	C/G	cg14844989	chr11:31128820	NA	0.38	6.0	0.31	5.07e-9	Total body bone mineral density;
LUSC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	12.06	0.55	4.64e-28	Prudent dietary pattern;
LUSC	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg27165867	chr14:105738592	BRF1	-0.54	-7.63	-0.39	2.54e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg26441486	chr22:50317300	CRELD2	0.48	7.15	0.36	5.55e-12	Schizophrenia;
LUSC	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg19052272	chr2:3704530	ALLC	-0.49	-8.19	-0.41	5.6e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg00784671	chr22:46762841	CELSR1	-0.55	-6.68	-0.34	1.01e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs77633900	0.614	rs2629025	chr15:76943363	G/C	cg21673338	chr15:77095150	SCAPER	-0.75	-7.56	-0.38	4e-13	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg21366198	chr4:185655624	MLF1IP	-0.44	-6.23	-0.32	1.38e-9	Kawasaki disease;
LUSC	cis	rs7241530	0.662	rs2898715	chr18:75906351	T/C	cg14642773	chr18:75888474	NA	0.39	5.99	0.31	5.45e-9	Educational attainment (years of education);
LUSC	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg21775007	chr8:11205619	TDH	0.73	12.08	0.55	4.17e-28	Retinal vascular caliber;
LUSC	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg04374321	chr14:90722782	PSMC1	-0.44	-6.64	-0.34	1.26e-10	Mortality in heart failure;
LUSC	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg07541023	chr7:19748670	TWISTNB	0.67	7.16	0.36	5.25e-12	Thyroid stimulating hormone;
LUSC	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg07930552	chr6:133119739	C6orf192	0.95	8.84	0.44	5.5e-17	Type 2 diabetes nephropathy;
LUSC	cis	rs2227564	0.574	rs3849969	chr10:75525999	C/T	cg23231163	chr10:75533350	FUT11	0.45	6.62	0.34	1.46e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02290803	chr1:40997356	ZNF684	-0.42	-6.07	-0.32	3.48e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4417855	0.665	rs57335767	chr3:187410979	A/G	cg19198148	chr3:187451818	BCL6	0.57	10.26	0.49	1.2e-21	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.55	-9.13	-0.45	6.93e-18	Lymphocyte counts;
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg16031515	chr1:205743344	RAB7L1	-0.29	-6.34	-0.33	7.64e-10	Menarche (age at onset);
LUSC	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg26408565	chr15:76604113	ETFA	-0.44	-6.91	-0.35	2.44e-11	Blood metabolite levels;
LUSC	trans	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg21775007	chr8:11205619	TDH	-0.41	-6.24	-0.32	1.36e-9	Mood instability;
LUSC	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.43	6.6	0.34	1.58e-10	Dupuytren's disease;
LUSC	cis	rs593982	1.000	rs650619	chr11:65506483	G/A	cg08755490	chr11:65554678	OVOL1	1.41	17.33	0.69	1.95e-48	Atopic dermatitis;
LUSC	cis	rs34638657	0.702	rs62044258	chr16:82199461	C/T	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.47	-0.33	3.55e-10	Lung adenocarcinoma;
LUSC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg17420585	chr12:42539391	GXYLT1	-0.36	-6.84	-0.35	3.86e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs11871801	0.517	rs10454087	chr17:40735641	C/T	cg16308533	chr17:40838983	CNTNAP1	0.4	5.86	0.31	1.13e-8	Crohn's disease;
LUSC	cis	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg21775007	chr8:11205619	TDH	0.47	6.72	0.34	8.1e-11	Neuroticism;
LUSC	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	16.92	0.68	7.94e-47	Exhaled nitric oxide output;
LUSC	cis	rs17253792	0.822	rs78143160	chr14:56150097	A/G	cg01858014	chr14:56050164	KTN1	-0.81	-6.96	-0.36	1.84e-11	Putamen volume;
LUSC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.56e-13	Motion sickness;
LUSC	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.36	0.62	9.07e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg15445000	chr17:37608096	MED1	-0.38	-6.56	-0.34	2.06e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00149659	chr3:10157352	C3orf10	1.01	14.91	0.63	6.88e-39	Alzheimer's disease;
LUSC	cis	rs7572644	0.713	rs71441095	chr2:28089848	G/A	cg27432699	chr2:27873401	GPN1	0.55	6.51	0.34	2.73e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs8058578	0.614	rs2878304	chr16:30878366	C/T	cg02466173	chr16:30829666	NA	0.53	8.77	0.43	9.26e-17	Multiple myeloma;
LUSC	trans	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.39	-6.57	-0.34	1.97e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.77	-0.43	9.18e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7560272	0.512	rs12998980	chr2:73930726	A/C	cg20560298	chr2:73613845	ALMS1	0.37	5.7	0.3	2.6e-8	Schizophrenia;
LUSC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.6	8.25	0.41	3.66e-15	Response to diuretic therapy;
LUSC	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-20.57	-0.75	2.54e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.23	-0.37	3.22e-12	Blood metabolite levels;
LUSC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg13877915	chr19:58951672	ZNF132	0.5	7.85	0.39	5.73e-14	Uric acid clearance;
LUSC	cis	rs988712	0.662	rs11030100	chr11:27677586	G/T	cg10635145	chr11:27742435	BDNF	-0.46	-5.85	-0.3	1.16e-8	Obesity;
LUSC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg12442385	chr7:1034912	NA	-0.36	-6.26	-0.32	1.2e-9	Longevity;Endometriosis;
LUSC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.7	-0.39	1.59e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg01884057	chr2:25150051	NA	0.48	11.26	0.52	3.64e-25	Body mass index;
LUSC	trans	rs74417235	0.528	rs9324789	chr5:154074362	C/T	cg13111374	chr4:17812581	NCAPG;DCAF16	-0.56	-6.07	-0.32	3.4e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2625529	0.824	rs4777471	chr15:72207804	A/G	cg16672083	chr15:72433130	SENP8	-0.5	-7.35	-0.37	1.56e-12	Red blood cell count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00991755	chr18:46066406	KIAA0427	0.46	6.52	0.34	2.56e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg10556349	chr10:835070	NA	0.56	6.44	0.33	4.08e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg04455712	chr21:45112962	RRP1B	0.46	8.56	0.42	4.25e-16	Mean corpuscular volume;
LUSC	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg22705602	chr4:152727874	NA	-0.32	-6.54	-0.34	2.33e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.59	-9.49	-0.46	4.49e-19	Body mass index;
LUSC	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-6.21	-0.32	1.55e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4363385	0.747	rs4478766	chr1:152984906	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.88	-0.31	9.76e-9	Inflammatory skin disease;
LUSC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg08219700	chr8:58056026	NA	0.45	5.84	0.3	1.24e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	8.62	0.43	2.81e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg04287289	chr16:89883240	FANCA	0.79	13.86	0.6	8.24e-35	Vitiligo;
LUSC	cis	rs4789693	0.679	rs7213057	chr17:80378939	T/C	cg04308225	chr17:80449738	NA	0.4	6.1	0.32	2.86e-9	Glucocorticoid-induced osteonecrosis;
LUSC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg14789911	chr21:47582049	C21orf56	0.42	6.61	0.34	1.54e-10	Testicular germ cell tumor;
LUSC	cis	rs12618769	0.570	rs17444095	chr2:99075817	C/G	cg10123293	chr2:99228465	UNC50	0.46	7.74	0.39	1.22e-13	Bipolar disorder;
LUSC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25072359	chr17:41440525	NA	0.67	9.62	0.47	1.68e-19	Menopause (age at onset);
LUSC	cis	rs193541	0.507	rs7726207	chr5:122081277	C/T	cg19077854	chr5:122220652	SNX24	0.27	5.74	0.3	2.08e-8	Glucose homeostasis traits;
LUSC	cis	rs62400317	0.762	rs1329711	chr6:44963401	A/G	cg20913747	chr6:44695427	NA	-0.45	-7.1	-0.36	7.62e-12	Total body bone mineral density;
LUSC	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.87	-0.74	1.57e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2688608	0.967	rs9971038	chr10:75661149	C/T	cg23231163	chr10:75533350	FUT11	-0.37	-5.96	-0.31	6.29e-9	Inflammatory bowel disease;
LUSC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg11608241	chr8:8085544	FLJ10661	-0.39	-6.01	-0.31	4.88e-9	Mood instability;
LUSC	trans	rs961253	0.556	rs6054139	chr20:6327810	G/A	cg21095983	chr6:86352623	SYNCRIP	0.45	6.78	0.35	5.62e-11	Colorectal cancer;
LUSC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg18477163	chr1:228402036	OBSCN	0.62	12.19	0.55	1.61e-28	Diastolic blood pressure;
LUSC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg04414720	chr1:150670196	GOLPH3L	0.52	8.1	0.41	1.06e-14	Melanoma;
LUSC	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg09904177	chr6:26538194	HMGN4	-0.51	-5.71	-0.3	2.54e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg21051086	chr3:73046214	PPP4R2	-0.53	-8.13	-0.41	8.54e-15	Pancreatic cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04512383	chr10:121631600	C10orf119	0.4	6.17	0.32	1.95e-9	Triglycerides;
LUSC	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg04989706	chr14:50066350	PPIL5	-0.45	-5.79	-0.3	1.6e-8	Carotid intima media thickness;
LUSC	trans	rs10514688	1.000	rs4678726	chr3:34976020	A/G	cg12980127	chr5:2129874	NA	-0.38	-5.94	-0.31	7.04e-9	Tonometry;
LUSC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	0.93	16.12	0.66	1.16e-43	Menopause (age at onset);
LUSC	trans	rs1325195	0.920	rs2816204	chr1:179164558	T/C	cg11624085	chr17:8464688	MYH10	0.41	6.7	0.34	8.92e-11	IgE grass sensitization;
LUSC	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.67	-0.34	1.08e-10	Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-12.51	-0.56	1.04e-29	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10266483	0.639	rs6952592	chr7:63754045	G/A	cg24201672	chr7:64023550	ZNF680	-0.46	-5.94	-0.31	7.05e-9	Response to statin therapy;
LUSC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg17143192	chr8:8559678	CLDN23	0.37	5.85	0.3	1.16e-8	Mood instability;
LUSC	trans	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg09872104	chr7:134855509	C7orf49	0.71	6.06	0.31	3.77e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.15	0.32	2.21e-9	Corneal astigmatism;
LUSC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg13175981	chr1:150552382	MCL1	0.48	6.76	0.35	6.01e-11	Lymphocyte counts;
LUSC	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg15556689	chr8:8085844	FLJ10661	0.72	9.96	0.48	1.25e-20	Red cell distribution width;
LUSC	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-10.42	-0.5	3.25e-22	Migraine;Coronary artery disease;
LUSC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.75	0.35	6.67e-11	Menopause (age at onset);
LUSC	cis	rs7267979	0.586	rs6083776	chr20:25186116	G/A	cg08601574	chr20:25228251	PYGB	0.44	6.71	0.34	8.19e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg18827107	chr12:86230957	RASSF9	-0.43	-6.3	-0.33	9.25e-10	Major depressive disorder;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg01940439	chr12:132252573	SFRS8	-0.41	-6.51	-0.34	2.82e-10	N-glycan levels;
LUSC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg00814883	chr7:100076585	TSC22D4	0.7	9.93	0.48	1.57e-20	Platelet count;
LUSC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.69	-0.3	2.82e-8	Lung cancer;
LUSC	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg04733989	chr22:42467013	NAGA	-0.41	-6.66	-0.34	1.14e-10	Cognitive function;
LUSC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg22823121	chr1:150693482	HORMAD1	0.59	9.08	0.44	1e-17	Tonsillectomy;
LUSC	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg14675211	chr2:100938903	LONRF2	0.38	5.96	0.31	6.44e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg25204440	chr1:209979598	IRF6	0.49	6.3	0.33	9.57e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg19875535	chr5:140030758	IK	-0.53	-8.93	-0.44	3.01e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs76878669	0.516	rs7104570	chr11:66159098	A/G	cg18002602	chr11:66138449	SLC29A2	0.48	8.58	0.43	3.58e-16	Educational attainment (years of education);
LUSC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.77	-12.4	-0.56	2.74e-29	Hip circumference adjusted for BMI;
LUSC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.48	6.58	0.34	1.82e-10	Renal function-related traits (BUN);
LUSC	trans	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg20587970	chr11:113659929	NA	-0.63	-8.81	-0.43	6.9e-17	Hip circumference adjusted for BMI;
LUSC	trans	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.19	-0.32	1.76e-9	Depression;
LUSC	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-5.92	-0.31	7.93e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	6.31	0.33	9.12e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4308124	0.708	rs10178095	chr2:111972516	C/T	cg04571233	chr2:111982156	NA	-0.52	-6.81	-0.35	4.45e-11	Vitiligo;
LUSC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg16928487	chr17:17741425	SREBF1	0.45	8.92	0.44	3.14e-17	Total body bone mineral density;
LUSC	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	11.59	0.54	2.57e-26	Coronary artery disease;
LUSC	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg24375607	chr4:120327624	NA	0.71	10.36	0.49	5.29e-22	Corneal astigmatism;
LUSC	cis	rs4845570	1.000	rs11586946	chr1:151769806	G/A	cg07092448	chr1:151763213	TDRKH	-1.29	-14.75	-0.63	2.95e-38	Coronary artery disease;
LUSC	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg24313572	chr1:56050060	NA	-0.29	-5.95	-0.31	6.81e-9	Morning vs. evening chronotype;
LUSC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg11344533	chr11:111475393	SIK2	-0.49	-6.87	-0.35	3.18e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg03522245	chr20:25566470	NINL	0.35	5.66	0.3	3.26e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs17092148	1.000	rs2378260	chr20:33374897	G/A	cg16810054	chr20:33298113	TP53INP2	-0.43	-6.81	-0.35	4.68e-11	Neuroticism;
LUSC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg26513180	chr16:89883248	FANCA	-0.55	-8.64	-0.43	2.44e-16	Vitiligo;
LUSC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg00033643	chr7:134001901	SLC35B4	-0.42	-6.43	-0.33	4.41e-10	Mean platelet volume;
LUSC	cis	rs7727544	0.582	rs2301579	chr5:131553340	C/A	cg24060327	chr5:131705240	SLC22A5	-0.34	-5.68	-0.3	3e-8	Blood metabolite levels;
LUSC	cis	rs7560272	0.538	rs2421575	chr2:73919522	G/A	cg20560298	chr2:73613845	ALMS1	0.38	5.81	0.3	1.5e-8	Schizophrenia;
LUSC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.22	-0.32	1.49e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg04851639	chr8:1020857	NA	-0.39	-8.1	-0.41	1.02e-14	Schizophrenia;
LUSC	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg00530320	chr1:46809349	NSUN4	0.56	8.54	0.42	4.66e-16	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20102506	chr19:49621876	PPFIA3;C19orf73	0.43	6.45	0.33	3.98e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.79	-12.58	-0.57	5.52e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.18	0.41	5.98e-15	Lung cancer;
LUSC	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	13.13	0.58	4.9e-32	Blood protein levels;
LUSC	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg17127132	chr2:85788382	GGCX	0.44	7.04	0.36	1.08e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg06238570	chr21:40685208	BRWD1	0.49	7.64	0.39	2.29e-13	Cognitive function;
LUSC	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg17595323	chr11:93583763	C11orf90	-0.31	-5.78	-0.3	1.75e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21110739	chr6:160768369	SLC22A3	-0.4	-5.95	-0.31	6.79e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg26384229	chr12:38710491	ALG10B	0.51	7.66	0.39	2.02e-13	Morning vs. evening chronotype;
LUSC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.49	5.89	0.31	9.59e-9	Renal function-related traits (BUN);
LUSC	cis	rs61629263	0.531	rs11867362	chr17:41938082	A/T	cg26893861	chr17:41843967	DUSP3	-0.47	-5.79	-0.3	1.62e-8	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs2710642	0.821	rs56373728	chr2:63095792	G/A	cg17519650	chr2:63277830	OTX1	0.51	7.09	0.36	8.28e-12	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg02773041	chr1:40204384	PPIE	0.53	7.86	0.4	5.41e-14	Blood protein levels;
LUSC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.15	0.36	5.62e-12	Bipolar disorder;
LUSC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg06454157	chr6:167490870	NA	-0.26	-6.19	-0.32	1.75e-9	Crohn's disease;
LUSC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg02423579	chr7:2872169	GNA12	-0.46	-6.61	-0.34	1.55e-10	Height;
LUSC	cis	rs9788682	0.747	rs2869045	chr15:78718899	T/C	cg06917634	chr15:78832804	PSMA4	0.48	5.7	0.3	2.58e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01002995	chr12:8185077	FOXJ2	-0.4	-6.0	-0.31	5.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.75	-0.35	6.42e-11	Tonsillectomy;
LUSC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg06454157	chr6:167490870	NA	-0.29	-6.78	-0.35	5.52e-11	Crohn's disease;
LUSC	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.51	-0.34	2.79e-10	Menopause (age at onset);
LUSC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg24060327	chr5:131705240	SLC22A5	-0.51	-8.47	-0.42	7.99e-16	Breast cancer;
LUSC	cis	rs1982963	0.627	rs77101097	chr14:52494300	C/T	cg10843707	chr14:52510701	NID2	0.47	6.4	0.33	5.16e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.71	10.86	0.51	1.03e-23	Monocyte percentage of white cells;
LUSC	cis	rs7923609	0.846	rs10740116	chr10:65094992	T/C	cg01631684	chr10:65280961	REEP3	-0.41	-6.43	-0.33	4.53e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4400599	0.606	rs7542975	chr1:154204813	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-6.02	-0.31	4.47e-9	Platelet distribution width;
LUSC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg06718696	chr17:78121285	EIF4A3	0.78	11.49	0.53	5.84e-26	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg19046167	chr17:80928561	B3GNTL1	0.41	5.8	0.3	1.5e-8	Breast cancer;
LUSC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg19592336	chr6:28129416	ZNF389	0.51	6.58	0.34	1.8e-10	Depression;
LUSC	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.09	0.4	1.12e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9341808	0.650	rs6909546	chr6:80869923	C/G	cg08355045	chr6:80787529	NA	0.57	9.9	0.48	1.97e-20	Sitting height ratio;
LUSC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg17294928	chr15:75287854	SCAMP5	0.41	5.88	0.31	1e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg11845111	chr2:191398756	TMEM194B	0.85	11.27	0.52	3.56e-25	Diastolic blood pressure;
LUSC	cis	rs9640161	0.830	rs1051823	chr7:150070814	G/A	cg21361702	chr7:150065534	REPIN1	0.59	9.17	0.45	4.8e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6500395	0.963	rs961951	chr16:48716720	A/G	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg25214090	chr10:38739885	LOC399744	0.54	7.96	0.4	2.77e-14	Corneal astigmatism;
LUSC	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs2985684	0.901	rs57119148	chr14:50097226	T/C	cg04989706	chr14:50066350	PPIL5	-0.43	-5.66	-0.3	3.24e-8	Carotid intima media thickness;
LUSC	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg14159672	chr1:205819179	PM20D1	-0.41	-5.96	-0.31	6.41e-9	Menarche (age at onset);
LUSC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg08219700	chr8:58056026	NA	0.48	6.15	0.32	2.21e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4851254	0.660	rs1821830	chr2:100680279	C/T	cg07810366	chr2:100720526	AFF3	-0.47	-6.19	-0.32	1.81e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg05738196	chr6:26577821	NA	0.81	15.7	0.65	5.52e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs1395	1.000	rs1275537	chr2:27441302	C/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.42	6.99	0.36	1.46e-11	Blood metabolite levels;
LUSC	cis	rs4474465	0.790	rs10751293	chr11:78250956	A/T	cg27205649	chr11:78285834	NARS2	0.5	6.03	0.31	4.3e-9	Alzheimer's disease (survival time);
LUSC	cis	rs922692	0.744	rs11639044	chr15:79083814	C/T	cg00540400	chr15:79124168	NA	-0.44	-7.67	-0.39	1.88e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.22	0.52	5.24e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs62400317	0.859	rs12205523	chr6:45296618	T/C	cg20913747	chr6:44695427	NA	-0.47	-7.72	-0.39	1.35e-13	Total body bone mineral density;
LUSC	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.9	15.73	0.65	4.14e-42	Morning vs. evening chronotype;
LUSC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.5	7.66	0.39	2.06e-13	Cognitive test performance;
LUSC	cis	rs500891	0.525	rs750384	chr6:84030422	C/T	cg08257003	chr6:84140564	ME1	0.34	8.05	0.4	1.43e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	10.75	0.51	2.37e-23	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg17042849	chr6:26104293	HIST1H4C	-0.38	-5.66	-0.3	3.3e-8	Height;
LUSC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg17971929	chr21:40555470	PSMG1	-0.5	-7.49	-0.38	6.2800000000000005e-13	Menarche (age at onset);
LUSC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg04414720	chr1:150670196	GOLPH3L	-0.5	-8.15	-0.41	7.48e-15	Tonsillectomy;
LUSC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg18451016	chr1:38461880	NA	-0.49	-7.28	-0.37	2.37e-12	Coronary artery disease;
LUSC	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg24642439	chr20:33292090	TP53INP2	0.71	11.2	0.52	6e-25	Coronary artery disease;
LUSC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-8.64	-0.43	2.32e-16	Prudent dietary pattern;
LUSC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg21918786	chr6:109611834	NA	0.42	7.35	0.37	1.55e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs2354432	0.599	rs6693667	chr1:146817245	A/T	cg25205988	chr1:146714368	CHD1L	0.9	9.37	0.46	1.15e-18	Mitochondrial DNA levels;
LUSC	cis	rs6500395	0.926	rs8057777	chr16:48565643	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.52	0.34	2.66e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg19680485	chr15:31195859	MTMR15	0.5	6.55	0.34	2.23e-10	Huntington's disease progression;
LUSC	cis	rs7617773	0.779	rs1045482	chr3:48312229	A/G	cg11946769	chr3:48343235	NME6	0.75	11.45	0.53	7.65e-26	Coronary artery disease;
LUSC	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg15309053	chr8:964076	NA	0.43	8.82	0.43	6.26e-17	Schizophrenia;
LUSC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg11663144	chr21:46675770	NA	-0.41	-7.06	-0.36	9.82e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg21573476	chr21:45109991	RRP1B	-0.39	-6.32	-0.33	8.38e-10	Mean corpuscular volume;
LUSC	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg09579323	chr1:150459698	TARS2	0.4	5.68	0.3	2.99e-8	Migraine;
LUSC	cis	rs2219968	1.000	rs12679679	chr8:78974231	T/C	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	13.01	0.58	1.41e-31	Monocyte percentage of white cells;
LUSC	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg16077055	chr2:106428750	NCK2	0.33	6.15	0.32	2.19e-9	Addiction;
LUSC	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-8.19	-0.41	5.62e-15	Mood instability;
LUSC	cis	rs240764	0.853	rs1875400	chr6:101020968	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.19	-0.32	1.8e-9	Neuroticism;
LUSC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.53	-9.05	-0.44	1.19e-17	Homoarginine levels;
LUSC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg16606324	chr3:10149918	C3orf24	0.43	6.48	0.33	3.24e-10	Alzheimer's disease;
LUSC	cis	rs5753037	0.702	rs140101	chr22:30128380	C/T	cg11564601	chr22:30592435	NA	0.33	6.06	0.31	3.71e-9	Type 1 diabetes;
LUSC	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg12002119	chr2:101014098	CHST10	0.37	6.19	0.32	1.72e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg17507749	chr15:85114479	UBE2QP1	0.67	8.72	0.43	1.32e-16	Schizophrenia;
LUSC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg27284194	chr4:1044797	NA	0.36	5.83	0.3	1.28e-8	Obesity-related traits;
LUSC	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg13010199	chr12:38710504	ALG10B	-0.65	-11.12	-0.52	1.19e-24	Heart rate;
LUSC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-6.11	-0.32	2.84e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg12863693	chr15:85201151	NMB	0.35	7.24	0.37	3.1e-12	Schizophrenia;
LUSC	cis	rs5167	0.533	rs11083755	chr19:45490065	C/T	cg13119609	chr19:45449297	APOC2	0.34	5.67	0.3	3.01e-8	Blood protein levels;
LUSC	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.61	8.35	0.42	1.8e-15	Body mass index (adult);
LUSC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg04398451	chr17:18023971	MYO15A	-0.48	-7.72	-0.39	1.34e-13	Total body bone mineral density;
LUSC	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg08601574	chr20:25228251	PYGB	0.44	6.75	0.35	6.5e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.52	6.91	0.35	2.44e-11	Blood protein levels;
LUSC	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg24687543	chr11:63912206	MACROD1	0.46	5.84	0.3	1.21e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03264133	chr6:25882463	NA	-0.5	-9.15	-0.45	5.74e-18	Blood metabolite levels;
LUSC	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg25182066	chr10:30743637	MAP3K8	-0.44	-6.61	-0.34	1.55e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs12681287	0.640	rs6992287	chr8:87418960	G/A	cg27223183	chr8:87520930	FAM82B	0.55	7.52	0.38	4.95e-13	Caudate activity during reward;
LUSC	cis	rs4363385	0.747	rs9919333	chr1:152968744	G/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.74	-0.39	1.21e-13	Inflammatory skin disease;
LUSC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03352830	chr11:487213	PTDSS2	0.73	8.44	0.42	9.94e-16	Body mass index;
LUSC	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.6	9.1	0.45	8.47e-18	Breast cancer;
LUSC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg25258033	chr6:167368657	RNASET2	-0.47	-7.88	-0.4	4.79e-14	Crohn's disease;
LUSC	cis	rs2282802	0.685	rs13359519	chr5:139654664	G/A	cg26211634	chr5:139558579	C5orf32	0.44	8.34	0.42	1.95e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg13683864	chr3:40499215	RPL14	-1.15	-20.58	-0.75	2.36e-61	Renal cell carcinoma;
LUSC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-0.91	-16.56	-0.67	2.1e-45	Cognitive function;
LUSC	trans	rs9944715	0.954	rs7240354	chr18:43809614	G/A	cg01718231	chr17:29326311	RNF135	-0.5	-7.03	-0.36	1.15e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.74	-0.35	6.92e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg27535305	chr1:53392650	SCP2	-0.48	-9.51	-0.46	3.88e-19	Monocyte count;
LUSC	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg02696742	chr7:106810147	HBP1	-0.63	-9.28	-0.45	2.15e-18	Coronary artery disease;
LUSC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.73	0.35	7.36e-11	Lung cancer;
LUSC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg14552801	chr7:65878734	NA	-0.38	-5.9	-0.31	8.98e-9	Aortic root size;
LUSC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg23625390	chr15:77176239	SCAPER	0.5	7.77	0.39	9.94e-14	Blood metabolite levels;
LUSC	cis	rs1018836	0.886	rs7817954	chr8:91535105	G/A	cg16814680	chr8:91681699	NA	-0.77	-12.89	-0.58	3.84e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg23029597	chr12:123009494	RSRC2	-0.75	-9.46	-0.46	5.71e-19	Body mass index;
LUSC	cis	rs1045714	0.895	rs4719594	chr7:2639790	G/A	cg24848437	chr7:2645542	IQCE	0.61	6.71	0.34	8.34e-11	Urate levels in lean individuals;
LUSC	cis	rs1832871	0.711	rs12527510	chr6:158657299	T/G	cg07165851	chr6:158734300	TULP4	0.51	7.61	0.38	2.86e-13	Height;
LUSC	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	8.54	0.42	4.96e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg26384229	chr12:38710491	ALG10B	0.54	7.65	0.39	2.19e-13	Morning vs. evening chronotype;
LUSC	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg00277334	chr10:82204260	NA	-0.54	-7.92	-0.4	3.59e-14	Post bronchodilator FEV1;
LUSC	cis	rs1790761	0.505	rs17593068	chr11:67350932	G/T	cg24690094	chr11:67383802	NA	-0.3	-5.75	-0.3	1.98e-8	Mean corpuscular volume;
LUSC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.52	-0.53	4.54e-26	Schizophrenia;
LUSC	trans	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg18850127	chr7:39170497	POU6F2	0.58	9.12	0.45	7.12e-18	IgG glycosylation;
LUSC	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg14196790	chr5:131705035	SLC22A5	-0.42	-6.78	-0.35	5.61e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.61	7.93	0.4	3.42e-14	Schizophrenia;
LUSC	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg13206674	chr6:150067644	NUP43	0.55	8.11	0.41	9.51e-15	Lung cancer;
LUSC	cis	rs134594	0.569	rs134559	chr22:29458441	C/T	cg03665785	chr22:29458676	C22orf31	-0.38	-7.29	-0.37	2.21e-12	Birth weight;
LUSC	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg04850286	chr10:81895943	PLAC9	-0.39	-6.78	-0.35	5.35e-11	Sarcoidosis;
LUSC	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg24375607	chr4:120327624	NA	0.76	12.09	0.55	3.55e-28	Corneal astigmatism;
LUSC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg10909506	chr17:38081995	ORMDL3	0.32	5.75	0.3	2.06e-8	Self-reported allergy;
LUSC	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg00074818	chr8:8560427	CLDN23	0.59	9.92	0.48	1.71e-20	Obesity-related traits;
LUSC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg18904891	chr8:8559673	CLDN23	0.58	7.93	0.4	3.29e-14	Obesity-related traits;
LUSC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg16479474	chr6:28041457	NA	0.32	5.72	0.3	2.31e-8	Parkinson's disease;
LUSC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.5	0.42	6.19e-16	Prudent dietary pattern;
LUSC	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.82	-12.73	-0.57	1.58e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg23283495	chr1:209979779	IRF6	0.64	9.36	0.46	1.21e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs10865541	0.778	rs10779975	chr2:3420032	A/G	cg15807143	chr2:3452624	TTC15	0.32	5.67	0.3	3.09e-8	Obesity-related traits;
LUSC	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg10818794	chr15:86012489	AKAP13	-0.43	-6.84	-0.35	3.87e-11	Coronary artery disease;
LUSC	cis	rs2274273	0.840	rs66486619	chr14:55869555	T/G	cg04306507	chr14:55594613	LGALS3	0.55	12.42	0.56	2.26e-29	Protein biomarker;
LUSC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg05585544	chr11:47624801	NA	-0.42	-7.29	-0.37	2.21e-12	Subjective well-being;
LUSC	cis	rs62400317	0.859	rs17209678	chr6:45163601	C/T	cg20913747	chr6:44695427	NA	-0.48	-7.7	-0.39	1.56e-13	Total body bone mineral density;
LUSC	cis	rs12304921	0.639	rs7722	chr12:51455404	C/A	cg02675652	chr12:51477739	CSRNP2	-0.28	-5.8	-0.3	1.57e-8	Type 2 diabetes;
LUSC	cis	rs3784262	1.000	rs4646627	chr15:58255305	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.8	-0.3	1.51e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs7560272	0.723	rs7566315	chr2:73791808	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-7.4	-0.38	1.11e-12	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	0.64	13.71	0.6	2.91e-34	Prudent dietary pattern;
LUSC	cis	rs36093844	0.898	rs12361645	chr11:85595106	C/G	cg16165120	chr11:85566439	CCDC83	-0.37	-6.07	-0.32	3.51e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.77	-0.35	5.76e-11	Monocyte percentage of white cells;
LUSC	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	6.44	0.33	4.13e-10	Neuroticism;
LUSC	cis	rs4711336	1.000	rs4711336	chr6:33659046	A/G	cg15676125	chr6:33679581	C6orf125	-0.38	-5.69	-0.3	2.76e-8	Height;
LUSC	trans	rs2018683	0.932	rs4386882	chr7:28989270	C/T	cg19402173	chr7:128379420	CALU	-0.56	-8.79	-0.43	7.95e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs4588572	0.643	rs9293747	chr5:77705567	A/G	cg11547950	chr5:77652471	NA	-0.52	-7.62	-0.38	2.7e-13	Triglycerides;
LUSC	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg24296786	chr1:45957014	TESK2	-0.48	-6.91	-0.35	2.41e-11	High light scatter reticulocyte count;
LUSC	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.54	7.26	0.37	2.69e-12	Fear of minor pain;
LUSC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-13.05	-0.58	9.4e-32	Total body bone mineral density;
LUSC	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.78	11.23	0.52	4.88e-25	Corneal astigmatism;
LUSC	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	7.19	0.37	4.21e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg06671706	chr8:8559999	CLDN23	0.51	6.84	0.35	3.84e-11	Obesity-related traits;
LUSC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg03060546	chr3:49711283	APEH	0.48	6.42	0.33	4.68e-10	Menarche (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05889321	chr10:97416837	ALDH18A1	0.4	6.12	0.32	2.68e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg06462663	chr19:18546047	ISYNA1	0.46	7.47	0.38	6.86e-13	Breast cancer;
LUSC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.66	0.3	3.26e-8	Menopause (age at onset);
LUSC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.55	0.46	2.93e-19	Mean platelet volume;
LUSC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg20026190	chr17:76395443	PGS1	0.46	8.07	0.4	1.28e-14	HDL cholesterol levels;
LUSC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.25	-0.49	1.32e-21	Hemoglobin concentration;
LUSC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg21724239	chr8:58056113	NA	0.78	8.41	0.42	1.19e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg10756647	chr7:56101905	PSPH	0.87	8.84	0.44	5.54e-17	Diabetic kidney disease;
LUSC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.81	15.35	0.64	1.32e-40	Dental caries;
LUSC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg04871131	chr7:94954202	PON1	-0.39	-6.13	-0.32	2.44e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.46	0.75	6.72e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg21724239	chr8:58056113	NA	0.85	8.52	0.42	5.67e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg03859395	chr2:55845619	SMEK2	-0.71	-10.56	-0.5	1.11e-22	Metabolic syndrome;
LUSC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg14004847	chr7:1930337	MAD1L1	0.55	8.52	0.42	5.39e-16	Bipolar disorder and schizophrenia;
LUSC	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg01620082	chr3:125678407	NA	-0.79	-7.53	-0.38	4.89e-13	Depression;
LUSC	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg02403541	chr12:121454288	C12orf43	0.61	8.57	0.42	3.77e-16	N-glycan levels;
LUSC	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg24375607	chr4:120327624	NA	0.8	11.48	0.53	6.06e-26	Corneal astigmatism;
LUSC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg15445000	chr17:37608096	MED1	0.37	6.41	0.33	4.95e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg05347473	chr6:146136440	FBXO30	0.5	8.36	0.42	1.67e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.1	0.36	7.56e-12	Mean platelet volume;
LUSC	cis	rs6500395	1.000	rs8052640	chr16:48604096	G/T	cg04672837	chr16:48644449	N4BP1	0.46	6.87	0.35	3.19e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.19e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.69	-8.81	-0.43	7.17e-17	Huntington's disease progression;
LUSC	trans	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg02800362	chr5:177631904	HNRNPAB	0.88	13.12	0.58	5.45e-32	Obesity-related traits;
LUSC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.48	7.14	0.36	5.88e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg14154082	chr13:112174009	NA	0.37	7.7	0.39	1.54e-13	Menarche (age at onset);
LUSC	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.44	-5.97	-0.31	6.09e-9	IgG glycosylation;
LUSC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg01765077	chr12:122356316	WDR66	0.57	8.01	0.4	1.94e-14	Mean corpuscular volume;
LUSC	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg07080220	chr10:102295463	HIF1AN	0.59	7.68	0.39	1.83e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs735539	0.598	rs2149769	chr13:21266227	C/T	cg04906043	chr13:21280425	IL17D	0.4	6.7	0.34	8.64e-11	Dental caries;
LUSC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.86	-0.31	1.13e-8	Alzheimer's disease (late onset);
LUSC	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.57	0.38	3.75e-13	Blood metabolite levels;
LUSC	cis	rs2625529	0.730	rs2957737	chr15:72265410	A/G	cg16672083	chr15:72433130	SENP8	0.48	7.7	0.39	1.6e-13	Red blood cell count;
LUSC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	0.64	13.54	0.6	1.4e-33	Prudent dietary pattern;
LUSC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg13175981	chr1:150552382	MCL1	-0.49	-6.44	-0.33	4.2e-10	Urate levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09342330	chr14:89021109	PTPN21	-0.51	-6.27	-0.32	1.13e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3087591	1.000	rs2905877	chr17:29543269	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.57	-8.35	-0.42	1.79e-15	Hip circumference;
LUSC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg27165867	chr14:105738592	BRF1	-0.5	-7.08	-0.36	8.75e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg03676636	chr4:99064102	C4orf37	0.32	6.53	0.34	2.45e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.45	0.33	3.98e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9807989	0.729	rs10170583	chr2:102974764	G/A	cg09003973	chr2:102972529	NA	0.44	5.98	0.31	5.64e-9	Asthma;
LUSC	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg00484396	chr16:3507460	NAT15	0.49	7.18	0.37	4.59e-12	Body mass index (adult);
LUSC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg00033643	chr7:134001901	SLC35B4	-0.44	-6.75	-0.35	6.72e-11	Mean platelet volume;
LUSC	trans	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg25214090	chr10:38739885	LOC399744	0.48	6.98	0.36	1.59e-11	Corneal astigmatism;
LUSC	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg05501817	chr11:14380813	RRAS2	-0.56	-9.31	-0.45	1.74e-18	Sense of smell;
LUSC	cis	rs11264799	0.603	rs2224607	chr1:157571721	C/T	cg18268488	chr1:157545234	FCRL4	0.35	6.28	0.33	1.04e-9	IgA nephropathy;
LUSC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	0.91	12.24	0.56	1.04e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg24006582	chr15:45444508	DUOX1	-0.61	-8.96	-0.44	2.4e-17	Uric acid levels;
LUSC	cis	rs12541635	0.639	rs10955408	chr8:107020789	G/A	cg10147462	chr8:107024639	NA	0.68	14.26	0.62	2.2e-36	Age of smoking initiation;
LUSC	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg13010199	chr12:38710504	ALG10B	0.67	10.23	0.49	1.56e-21	Bladder cancer;
LUSC	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg03585969	chr10:35415529	CREM	-0.62	-9.18	-0.45	4.52e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7523050	0.908	rs17621644	chr1:109399023	C/T	cg08274380	chr1:109419600	GPSM2	0.92	9.73	0.47	7.24e-20	Fat distribution (HIV);
LUSC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg08847533	chr14:75593920	NEK9	-0.82	-14.8	-0.63	1.89e-38	Height;
LUSC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg09034736	chr1:150693464	HORMAD1	0.41	5.67	0.3	3.05e-8	Melanoma;
LUSC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.29	6.5	0.34	2.95e-10	Electroencephalogram traits;
LUSC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg13010344	chr12:123464640	ARL6IP4	-0.49	-7.95	-0.4	2.86e-14	Platelet count;
LUSC	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs5009270	0.553	rs62476688	chr7:112232716	C/T	cg27282281	chr7:112262583	NA	0.43	5.8	0.3	1.57e-8	Osteoarthritis (hip);
LUSC	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg11473876	chr11:109292803	C11orf87	0.42	6.53	0.34	2.51e-10	Schizophrenia;
LUSC	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-7.65	-0.39	2.18e-13	Total body bone mineral density;
LUSC	cis	rs11229555	0.645	rs11560908	chr11:58434545	A/C	cg15696309	chr11:58395628	NA	0.62	6.66	0.34	1.14e-10	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-0.89	-17.11	-0.68	1.39e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg05294307	chr14:35346193	BAZ1A	-0.57	-7.05	-0.36	1.01e-11	Psoriasis;
LUSC	cis	rs4664304	0.772	rs10183731	chr2:160740989	A/G	cg23995753	chr2:160760732	LY75	0.33	6.15	0.32	2.23e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg07777115	chr5:623756	CEP72	-0.47	-5.77	-0.3	1.78e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg27471124	chr11:109292789	C11orf87	0.43	7.46	0.38	7.48e-13	Schizophrenia;
LUSC	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg05855489	chr10:104503620	C10orf26	0.5	7.68	0.39	1.8e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs10740039	0.883	rs10761533	chr10:62398331	G/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.85	-0.35	3.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.73	-0.6	2.62e-34	Chronic sinus infection;
LUSC	cis	rs151234	0.565	rs11401	chr16:28602991	A/G	cg01378222	chr16:28622494	SULT1A1	-0.55	-8.07	-0.4	1.31e-14	Platelet distribution width;
LUSC	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-8.18	-0.41	5.82e-15	Morning vs. evening chronotype;
LUSC	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.5	0.56	1.09e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs868036	1.000	rs1026734	chr15:68100950	T/C	cg08079166	chr15:68083412	MAP2K5	0.4	8.28	0.41	3.04e-15	Restless legs syndrome;
LUSC	cis	rs10144321	0.729	rs10438233	chr14:100826200	C/T	cg14882082	chr14:100845427	WDR25	-0.39	-7.53	-0.38	4.86e-13	Menarche (age at onset);
LUSC	cis	rs6539267	0.885	rs34762209	chr12:106722466	T/C	cg00173435	chr12:106696525	TCP11L2	0.5	6.77	0.35	5.92e-11	Tourette syndrome;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg10150615	chr22:24372951	LOC391322	-0.42	-6.86	-0.35	3.4e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg25214090	chr10:38739885	LOC399744	0.5	7.45	0.38	8.19e-13	Corneal astigmatism;
LUSC	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg05738196	chr6:26577821	NA	0.54	8.49	0.42	6.82e-16	Schizophrenia;
LUSC	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg02696742	chr7:106810147	HBP1	0.64	9.78	0.47	5.05e-20	Coronary artery disease;
LUSC	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg22676075	chr6:135203613	NA	0.59	9.48	0.46	5e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg23815491	chr16:72088622	HP	0.37	6.57	0.34	1.9e-10	Fibrinogen levels;
LUSC	cis	rs500891	0.525	rs3778201	chr6:84081405	C/T	cg08257003	chr6:84140564	ME1	0.35	8.63	0.43	2.58e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg10820045	chr2:198174542	NA	-0.33	-6.1	-0.32	2.9e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-7.51	-0.38	5.46e-13	Breast cancer;
LUSC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg23887609	chr12:130822674	PIWIL1	0.48	7.05	0.36	1.04e-11	Menopause (age at onset);
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg17541715	chr7:1216824	NA	-0.4	-6.12	-0.32	2.57e-9	Longevity;Endometriosis;
LUSC	trans	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.93	-0.35	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05788437	chr3:197476880	FYTTD1;KIAA0226	-0.33	-5.97	-0.31	6.22e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.21	-13.88	-0.6	6.79e-35	Diabetic kidney disease;
LUSC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	0.92	17.26	0.69	3.59e-48	Cognitive function;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg08922808	chr11:47448170	PSMC3	0.72	6.06	0.31	3.57e-9	Body mass index;
LUSC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09961100	chr19:5978428	RANBP3	-0.41	-6.08	-0.32	3.32e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504073	0.669	rs341809	chr8:50042557	C/T	cg00325661	chr8:49890786	NA	0.6	9.65	0.47	1.32e-19	Blood metabolite ratios;
LUSC	cis	rs10193935	0.901	rs10174872	chr2:42459807	T/G	cg27598129	chr2:42591480	NA	-0.61	-8.32	-0.41	2.28e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg13175981	chr1:150552382	MCL1	0.52	7.38	0.37	1.24e-12	Tonsillectomy;
LUSC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg04155289	chr7:94953770	PON1	0.34	5.78	0.3	1.68e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs977987	0.771	rs4888387	chr16:75389755	T/G	cg04384234	chr16:75411784	CFDP1	-0.39	-6.24	-0.32	1.34e-9	Dupuytren's disease;
LUSC	cis	rs7804356	1.000	rs2031811	chr7:26890672	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg21724239	chr8:58056113	NA	0.8	8.44	0.42	9.52e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg26338869	chr17:61819248	STRADA	0.42	6.06	0.31	3.7e-9	Prudent dietary pattern;
LUSC	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg27411982	chr8:10470053	RP1L1	-0.39	-5.9	-0.31	9.02e-9	Neuroticism;
LUSC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg14552801	chr7:65878734	NA	0.38	6.0	0.31	5.06e-9	Aortic root size;
LUSC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.82	14.01	0.61	2.11e-35	Blood protein levels;
LUSC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg22117172	chr7:91764530	CYP51A1	0.32	5.72	0.3	2.42e-8	Breast cancer;
LUSC	cis	rs2455601	0.507	rs2568044	chr11:9002477	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.44	6.97	0.36	1.69e-11	Schizophrenia;
LUSC	cis	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg11879182	chr18:77439856	CTDP1	0.54	8.22	0.41	4.6e-15	Monocyte count;
LUSC	cis	rs11650494	0.516	rs117384420	chr17:47505383	G/C	cg08112188	chr17:47440006	ZNF652	1.07	8.34	0.41	2.03e-15	Prostate cancer;
LUSC	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg21100191	chr22:23484243	RTDR1	0.92	16.29	0.67	2.57e-44	Bone mineral density;
LUSC	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.4	5.94	0.31	7.05e-9	Lung cancer;
LUSC	cis	rs9648716	0.515	rs801127	chr7:140728075	T/C	cg23214464	chr7:140373596	ADCK2	-0.72	-6.24	-0.32	1.34e-9	Type 2 diabetes;
LUSC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg09034736	chr1:150693464	HORMAD1	0.46	6.68	0.34	9.8e-11	Melanoma;
LUSC	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg14458575	chr2:238380390	NA	0.55	6.43	0.33	4.33e-10	Prostate cancer;
LUSC	cis	rs1568889	0.775	rs35243076	chr11:28250618	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	12.81	0.57	7.89e-31	Bipolar disorder;
LUSC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.4	-0.33	5.22e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs977987	0.806	rs4888425	chr16:75476363	T/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.16	-0.36	5.2e-12	Dupuytren's disease;
LUSC	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	8.91	0.44	3.25e-17	Axial length;
LUSC	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-9.13	-0.45	6.88e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg10792982	chr14:105748885	BRF1	0.5	8.97	0.44	2.14e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2227564	0.620	rs7098573	chr10:75580014	G/A	cg23231163	chr10:75533350	FUT11	-0.43	-6.3	-0.33	9.56e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7914558	0.646	rs10883795	chr10:104654577	T/C	cg05855489	chr10:104503620	C10orf26	0.42	5.68	0.3	2.89e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.44	5.69	0.3	2.84e-8	Multiple sclerosis;
LUSC	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg02176678	chr2:219576539	TTLL4	-0.57	-10.1	-0.48	4.29e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg11584989	chr19:19387371	SF4	0.67	8.2	0.41	5.3e-15	Bipolar disorder;
LUSC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg04317338	chr11:64019027	PLCB3	0.66	7.49	0.38	6.38e-13	Mean platelet volume;
LUSC	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg09307838	chr4:120376055	NA	0.71	10.32	0.49	7.35e-22	Corneal astigmatism;
LUSC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg26513180	chr16:89883248	FANCA	0.92	17.48	0.69	4.71e-49	Vitiligo;
LUSC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.76	-10.31	-0.49	8.21e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.13	0.52	1.13e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.29	-5.78	-0.3	1.68e-8	Colorectal cancer;
LUSC	cis	rs3857536	0.813	rs9354403	chr6:66943426	A/G	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.51	-6.05	-0.31	3.99e-9	Body mass index;
LUSC	cis	rs6580649	0.883	rs1793955	chr12:48393106	G/T	cg24011408	chr12:48396354	COL2A1	0.58	7.7	0.39	1.53e-13	Lung cancer;
LUSC	cis	rs2708377	0.929	rs7298947	chr12:11311159	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg16928487	chr17:17741425	SREBF1	0.46	9.16	0.45	5.28e-18	Total body bone mineral density;
LUSC	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg04310649	chr10:35416472	CREM	-0.37	-5.85	-0.3	1.16e-8	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-9.8	-0.47	4.12e-20	Gut microbiome composition (summer);
LUSC	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg02466173	chr16:30829666	NA	0.55	11.19	0.52	6.81e-25	Dementia with Lewy bodies;
LUSC	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	6.26	0.32	1.2e-9	Resting heart rate;
LUSC	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg15423357	chr2:25149977	NA	0.35	6.43	0.33	4.46e-10	Body mass index;
LUSC	trans	rs62458065	0.640	rs79619897	chr7:32514819	C/T	cg00845942	chr12:64062724	DPY19L2	-0.57	-6.93	-0.35	2.24e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-8.56	-0.42	4.13e-16	Body mass index;
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.36	5.71	0.3	2.55e-8	Lymphocyte counts;
LUSC	trans	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg06521331	chr12:34319734	NA	-0.4	-6.09	-0.32	3.07e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9905704	0.627	rs6503867	chr17:56621359	T/C	cg19466818	chr17:56409534	MIR142	0.35	6.46	0.33	3.78e-10	Testicular germ cell tumor;
LUSC	cis	rs6977660	0.943	rs10254261	chr7:19846001	A/G	cg05791153	chr7:19748676	TWISTNB	-0.56	-6.31	-0.33	8.79e-10	Thyroid stimulating hormone;
LUSC	trans	rs10098647	0.632	rs72663292	chr8:61111863	T/G	cg09970348	chr3:183978600	ECE2;CAMK2N2	0.46	6.15	0.32	2.26e-9	Obesity-related traits;
LUSC	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.18	-0.32	1.84e-9	Type 2 diabetes;
LUSC	cis	rs28655083	0.529	rs4544253	chr16:77104774	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	7.11	0.36	7.24e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg05347473	chr6:146136440	FBXO30	-0.49	-8.28	-0.41	3.03e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg22906224	chr7:99728672	NA	0.52	7.67	0.39	1.92e-13	Coronary artery disease;
LUSC	cis	rs7818345	0.512	rs4922028	chr8:19303771	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.64	0.34	1.28e-10	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs4285028	0.747	rs1920299	chr3:121593769	A/G	cg11130432	chr3:121712080	ILDR1	0.59	8.99	0.44	1.88e-17	Multiple sclerosis;
LUSC	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	1.17	13.65	0.6	5.27e-34	Arsenic metabolism;
LUSC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	cis	rs7267979	0.565	rs6107060	chr20:25592476	C/G	cg03522245	chr20:25566470	NINL	0.38	5.96	0.31	6.44e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.73e-23	Bladder cancer;
LUSC	cis	rs9473147	0.516	rs13212790	chr6:47576367	T/C	cg20196966	chr6:47445060	CD2AP	0.43	6.09	0.32	3.06e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg06784218	chr1:46089804	CCDC17	-0.48	-9.21	-0.45	3.67e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg00520135	chr15:63333846	TPM1	-0.33	-6.66	-0.34	1.12e-10	Platelet count;
LUSC	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.06	-0.52	1.88e-24	Mean corpuscular volume;
LUSC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.28	0.41	3.03e-15	Tonsillectomy;
LUSC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg05855489	chr10:104503620	C10orf26	-0.67	-9.67	-0.47	1.2e-19	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	0.91	17.84	0.7	1.74e-50	Metabolite levels;
LUSC	cis	rs12220238	1.000	rs10824096	chr10:75937554	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.89	0.35	2.71e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg26513180	chr16:89883248	FANCA	0.78	6.39	0.33	5.68e-10	Skin colour saturation;
LUSC	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg25206134	chr2:45395956	NA	0.59	6.91	0.35	2.4e-11	Bipolar disorder;
LUSC	cis	rs11048434	0.736	rs56130437	chr12:9093001	G/A	cg13575925	chr12:9217583	LOC144571	0.31	5.85	0.3	1.17e-8	Sjögren's syndrome;
LUSC	cis	rs2455601	0.744	rs2163626	chr11:8983547	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-6.78	-0.35	5.54e-11	Schizophrenia;
LUSC	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg07402062	chr16:89894098	SPIRE2	-0.38	-5.96	-0.31	6.29e-9	Skin aging (microtopography measurement);
LUSC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.42	-0.33	4.63e-10	Total body bone mineral density;
LUSC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg01125463	chr6:42946178	PEX6	-0.36	-6.12	-0.32	2.64e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-12.43	-0.56	2.02e-29	Platelet distribution width;
LUSC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.66e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg22676075	chr6:135203613	NA	0.48	7.47	0.38	7.3e-13	Red blood cell count;
LUSC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg21665744	chr7:39171113	POU6F2	0.48	7.68	0.39	1.72e-13	IgG glycosylation;
LUSC	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.5	-7.08	-0.36	8.54e-12	Urate levels;
LUSC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.34	-0.56	4.38e-29	Rheumatoid arthritis;
LUSC	cis	rs3772130	0.962	rs4413346	chr3:121486310	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	10.02	0.48	7.71e-21	Cognitive performance;
LUSC	cis	rs7589342	0.536	rs1367405	chr2:106387141	G/A	cg09152813	chr2:106391379	NCK2	-0.38	-6.24	-0.32	1.31e-9	Addiction;
LUSC	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg13010199	chr12:38710504	ALG10B	0.52	7.72	0.39	1.34e-13	Morning vs. evening chronotype;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg15383120	chr6:291909	DUSP22	-0.66	-11.16	-0.52	8.5e-25	Menopause (age at onset);
LUSC	cis	rs1560104	0.709	rs2217271	chr16:12704480	C/A	cg02946846	chr16:12632861	SNX29	0.33	6.23	0.32	1.43e-9	Obesity-related traits;
LUSC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg27572855	chr1:25598939	RHD	0.45	7.97	0.4	2.57e-14	Erythrocyte sedimentation rate;
LUSC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.98	-0.44	1.99e-17	Gut microbiome composition (summer);
LUSC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.99	0.36	1.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.48	-8.05	-0.4	1.46e-14	Immature fraction of reticulocytes;
LUSC	trans	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.51	0.53	4.93e-26	Mean corpuscular volume;
LUSC	cis	rs6714788	0.503	rs11681737	chr2:100679024	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-6.03	-0.31	4.41e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg00852783	chr1:26633632	UBXN11	0.49	8.79	0.43	7.77e-17	Obesity-related traits;
LUSC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.13	15.81	0.65	1.94e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg07703079	chr11:430292	ANO9	0.61	6.63	0.34	1.3100000000000001e-10	Body mass index;
LUSC	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg22029157	chr1:209979665	IRF6	-0.36	-5.69	-0.3	2.85e-8	Monobrow;
LUSC	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg03859395	chr2:55845619	SMEK2	0.89	16.85	0.68	1.53e-46	Metabolic syndrome;
LUSC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg06671706	chr8:8559999	CLDN23	0.48	6.58	0.34	1.86e-10	Obesity-related traits;
LUSC	cis	rs2412208	0.609	rs10746465	chr1:7107231	C/A	cg20434152	chr1:7120926	CAMTA1	-0.31	-6.11	-0.32	2.74e-9	Survival in sporadic amyotrophic lateral sclerosis;
LUSC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00631329	chr6:26305371	NA	-0.47	-9.3	-0.45	1.92e-18	Educational attainment;
LUSC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg04455712	chr21:45112962	RRP1B	0.45	8.53	0.42	5.06e-16	Mean corpuscular volume;
LUSC	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg17757837	chr7:157058334	UBE3C	-0.9	-14.53	-0.62	2.07e-37	Body mass index;
LUSC	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg27432699	chr2:27873401	GPN1	0.8	15.03	0.64	2.42e-39	Oral cavity cancer;
LUSC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg22903471	chr2:27725779	GCKR	-0.42	-7.11	-0.36	6.92e-12	Total body bone mineral density;
LUSC	cis	rs7246967	0.551	rs7250608	chr19:22853056	C/A	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs500891	0.533	rs11969258	chr6:84127626	T/C	cg08257003	chr6:84140564	ME1	0.37	9.11	0.45	7.86e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg22244940	chr12:132335942	MMP17	0.45	6.79	0.35	5.11e-11	Migraine;
LUSC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg19318889	chr4:1322082	MAEA	0.45	7.41	0.38	1.06e-12	Obesity-related traits;
LUSC	cis	rs4845570	1.000	rs4845356	chr1:151759223	T/A	cg07092448	chr1:151763213	TDRKH	1.22	14.82	0.63	1.49e-38	Coronary artery disease;
LUSC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg07741184	chr6:167504864	NA	0.37	6.69	0.34	9.31e-11	Crohn's disease;
LUSC	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg00757033	chr12:89920650	WDR51B	-0.55	-9.31	-0.45	1.8e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg04362960	chr10:104952993	NT5C2	0.58	9.18	0.45	4.58e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg03929089	chr4:120376271	NA	0.67	7.39	0.37	1.2e-12	Axial length;
LUSC	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19717773	chr7:2847554	GNA12	-0.34	-5.76	-0.3	1.9e-8	Height;
LUSC	cis	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg05084668	chr3:125655381	ALG1L	-0.45	-6.02	-0.31	4.67e-9	Blood pressure (smoking interaction);
LUSC	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg03433033	chr1:76189801	ACADM	-0.48	-7.28	-0.37	2.43e-12	Daytime sleep phenotypes;
LUSC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.47	7.23	0.37	3.3e-12	Testicular germ cell tumor;
LUSC	trans	rs11681884	0.786	rs1992762	chr2:113810413	G/A	cg19632953	chr13:113635898	MCF2L	0.69	6.03	0.31	4.45e-9	Stroke;
LUSC	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg08601574	chr20:25228251	PYGB	0.47	7.28	0.37	2.43e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.09	21.92	0.77	1.22e-66	Cognitive ability;
LUSC	cis	rs7267979	0.586	rs6050431	chr20:25183908	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	12.48	0.56	1.32e-29	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1941687	0.505	rs8091920	chr18:31303557	C/G	cg27147174	chr7:100797783	AP1S1	-0.54	-8.27	-0.41	3.31e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08392591	chr16:89556376	ANKRD11	0.5	7.76	0.39	1.04e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs5758659	0.716	rs5758661	chr22:42624445	A/C	cg00645731	chr22:42541494	CYP2D7P1	-0.31	-6.41	-0.33	4.84e-10	Cognitive function;
LUSC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg05425664	chr17:57184151	TRIM37	0.52	7.73	0.39	1.31e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg06627628	chr2:24431161	ITSN2	-0.54	-7.79	-0.39	8.48e-14	Asthma;
LUSC	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg10840412	chr1:235813424	GNG4	0.57	7.34	0.37	1.61e-12	Bipolar disorder;
LUSC	cis	rs10193935	0.901	rs6733914	chr2:42674741	A/G	cg27598129	chr2:42591480	NA	0.61	8.29	0.41	2.74e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg13114125	chr14:105738426	BRF1	-0.96	-16.12	-0.66	1.23e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg13395646	chr4:1353034	KIAA1530	0.49	7.02	0.36	1.23e-11	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.95e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg15704280	chr7:45808275	SEPT13	-0.62	-8.11	-0.41	9.44e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2019216	0.500	rs908696	chr17:21940987	T/G	cg22648282	chr17:21454238	C17orf51	-0.49	-6.88	-0.35	2.93e-11	Pelvic organ prolapse;
LUSC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg04352962	chr1:209979756	IRF6	0.56	6.65	0.34	1.19e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.49	-8.47	-0.42	8.14e-16	Lymphocyte counts;
LUSC	cis	rs897080	0.552	rs1067388	chr2:44642482	G/A	cg00619915	chr2:44497795	NA	-0.41	-5.8	-0.3	1.51e-8	Height;
LUSC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.72	14.07	0.61	1.2e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg11502198	chr6:26597334	ABT1	0.64	10.07	0.48	5.3e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg09436375	chr6:42928200	GNMT	-0.3	-7.01	-0.36	1.29e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.06	0.31	3.58e-9	Corneal astigmatism;
LUSC	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg27471124	chr11:109292789	C11orf87	0.55	9.75	0.47	6.06e-20	Schizophrenia;
LUSC	cis	rs9880211	0.821	rs9832813	chr3:136065565	A/G	cg21827317	chr3:136751795	NA	-0.38	-5.94	-0.31	7.15e-9	Body mass index;Height;
LUSC	cis	rs4601821	0.823	rs17115439	chr11:113264272	T/C	cg14159747	chr11:113255604	NA	0.25	6.09	0.32	3.06e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs34734847	0.965	rs2005455	chr12:121128699	A/G	cg27246729	chr12:121163418	ACADS	0.47	7.43	0.38	8.96e-13	Mean corpuscular volume;
LUSC	cis	rs11785693	0.862	rs17435835	chr8:5000713	C/T	cg26367366	chr8:4980734	NA	-0.84	-9.75	-0.47	6.35e-20	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18387017	chr1:1167389	SDF4;B3GALT6	-0.42	-6.35	-0.33	6.92e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.63	-0.47	1.62e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10450586	0.965	rs10450589	chr11:27308819	A/C	cg08958251	chr11:27270390	NA	0.35	5.8	0.3	1.52e-8	Total body bone mineral density;
LUSC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	6.43	0.33	4.39e-10	Obesity-related traits;
LUSC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg14784868	chr12:69753453	YEATS4	-0.58	-7.42	-0.38	9.63e-13	Response to diuretic therapy;
LUSC	trans	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg18187862	chr3:45730750	SACM1L	-0.51	-6.3	-0.33	9.63e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7707921	0.881	rs324910	chr5:81400264	A/C	cg15871215	chr5:81402204	ATG10	-0.44	-6.35	-0.33	7.22e-10	Breast cancer;
LUSC	cis	rs174479	0.647	rs174461	chr11:61657401	A/C	cg01500311	chr11:61656094	FADS3	0.4	6.96	0.36	1.8e-11	Sphingolipid levels;
LUSC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg16680214	chr1:154839983	KCNN3	-0.51	-9.68	-0.47	1.08e-19	Prostate cancer;
LUSC	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg17366294	chr4:99064904	C4orf37	0.57	10.07	0.48	5.24e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg10556349	chr10:835070	NA	0.44	5.68	0.3	2.96e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg14552801	chr7:65878734	NA	-0.45	-6.52	-0.34	2.66e-10	Aortic root size;
LUSC	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	8.84	0.44	5.48e-17	Schizophrenia;
LUSC	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg16850897	chr7:100343110	ZAN	-0.61	-8.5	-0.42	6.61e-16	Other erythrocyte phenotypes;
LUSC	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg03929089	chr4:120376271	NA	-0.54	-6.15	-0.32	2.26e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg13010199	chr12:38710504	ALG10B	0.49	7.48	0.38	6.79e-13	Morning vs. evening chronotype;
LUSC	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg18753928	chr3:113234510	CCDC52	-0.44	-6.66	-0.34	1.14e-10	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs12956009	0.583	rs12960952	chr18:44857476	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.22	0.32	1.48e-9	Educational attainment (years of education);
LUSC	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg08645402	chr16:4508243	NA	0.51	8.42	0.42	1.15e-15	Schizophrenia;
LUSC	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg04990556	chr1:26633338	UBXN11	0.8	10.39	0.49	4.34e-22	Obesity-related traits;
LUSC	cis	rs7903847	0.642	rs11189204	chr10:99164394	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-7.37	-0.37	1.38e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1044826	1.000	rs3772878	chr3:139187375	T/C	cg00490450	chr3:139108681	COPB2	0.51	6.59	0.34	1.71e-10	Obesity-related traits;
LUSC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg03806693	chr22:41940476	POLR3H	-0.99	-14.04	-0.61	1.62e-35	Vitiligo;
LUSC	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.88	-0.44	4.32e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs62238980	0.614	rs117305417	chr22:32400975	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.58	-0.34	1.79e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1577917	0.839	rs1838956	chr6:86565263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.29	-0.33	9.98e-10	Response to antipsychotic treatment;
LUSC	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.82	14.35	0.62	1.04e-36	Metabolic syndrome;
LUSC	cis	rs7072216	0.770	rs1737	chr10:100176366	T/C	cg26618903	chr10:100175079	PYROXD2	-0.35	-6.99	-0.36	1.49e-11	Metabolite levels;
LUSC	cis	rs1881396	0.945	rs1881397	chr2:27832285	A/G	cg27432699	chr2:27873401	GPN1	0.57	7.85	0.39	5.61e-14	Nonalcoholic fatty liver disease;
LUSC	cis	rs10208940	0.920	rs72903979	chr2:68813938	C/T	cg12452813	chr2:68675892	NA	0.59	6.08	0.32	3.21e-9	Urate levels in lean individuals;
LUSC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg00409905	chr10:38381863	ZNF37A	-0.35	-5.98	-0.31	5.62e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6500395	1.000	rs12933948	chr16:48705825	C/G	cg04672837	chr16:48644449	N4BP1	-0.46	-6.8	-0.35	4.83e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.01	-0.4	1.87e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6977660	1.000	rs6973890	chr7:19820497	T/C	cg05791153	chr7:19748676	TWISTNB	0.53	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LUSC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	15.71	0.65	4.82e-42	Platelet count;
LUSC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg05552183	chr6:42928497	GNMT	0.48	8.09	0.4	1.11e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-1.13	-17.99	-0.7	4.71e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg23281280	chr6:28129359	ZNF389	0.45	5.86	0.31	1.14e-8	Parkinson's disease;
LUSC	cis	rs12042938	0.935	rs1417585	chr1:231803604	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.43	6.25	0.32	1.23e-9	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs1957429	0.520	rs72625641	chr14:65335761	C/T	cg23373153	chr14:65346875	NA	-0.87	-7.56	-0.38	4.04e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs983392	0.805	rs2081545	chr11:59958380	C/A	cg20284999	chr11:59952153	MS4A6A	-0.39	-6.38	-0.33	6.06e-10	Alzheimer's disease (late onset);
LUSC	cis	rs2235649	0.833	rs7189070	chr16:1850813	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.08	-0.32	3.22e-9	Blood metabolite levels;
LUSC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	0.79	13.82	0.6	1.1e-34	Cognitive function;
LUSC	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg06002616	chr8:101225028	SPAG1	0.39	6.57	0.34	1.97e-10	Atrioventricular conduction;
LUSC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg11812906	chr14:75593930	NEK9	-0.65	-10.95	-0.51	4.58e-24	Height;
LUSC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg02951883	chr7:2050386	MAD1L1	-0.61	-11.5	-0.53	5.37e-26	Bipolar disorder and schizophrenia;
LUSC	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg05784532	chr1:230284198	GALNT2	0.55	8.18	0.41	6.09e-15	Coronary artery disease;
LUSC	cis	rs6840360	0.967	rs6823423	chr4:152604723	T/C	cg22705602	chr4:152727874	NA	-0.28	-5.96	-0.31	6.43e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs870825	0.616	rs28416641	chr4:185617999	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg24812749	chr6:127587940	RNF146	-0.65	-9.68	-0.47	1.09e-19	Breast cancer;
LUSC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg25482853	chr8:67687455	SGK3	1.18	16.46	0.67	5.32e-45	Lung disease severity in cystic fibrosis;
LUSC	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg01444801	chr10:135216882	MTG1	-0.48	-6.59	-0.34	1.67e-10	Systemic lupus erythematosus;
LUSC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.67	0.34	1.07e-10	Menopause (age at onset);
LUSC	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg21095983	chr6:86352623	SYNCRIP	0.5	7.98	0.4	2.44e-14	Smooth-surface caries;
LUSC	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.59	-9.52	-0.46	3.68e-19	Body mass index;
LUSC	trans	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg26043149	chr18:55253948	FECH	-0.45	-7.1	-0.36	7.71e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17836109	chr8:99129518	POP1;HRSP12	-0.43	-6.34	-0.33	7.49e-10	Electrocardiographic conduction measures;
LUSC	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.21	-0.32	1.57e-9	Dupuytren's disease;
LUSC	cis	rs36093844	0.948	rs11234451	chr11:85573702	T/A	cg25872744	chr11:85566296	CCDC83	-0.5	-7.69	-0.39	1.67e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg26364809	chr7:27145159	NA	0.52	5.69	0.3	2.71e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-10.39	-0.49	4.12e-22	Mean corpuscular volume;
LUSC	cis	rs7193541	0.508	rs7188581	chr16:74672901	T/A	cg01733217	chr16:74700730	RFWD3	0.98	21.68	0.76	1.13e-65	Multiple myeloma;
LUSC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg24642844	chr7:1081250	C7orf50	-0.46	-7.57	-0.38	3.74e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs12692738	0.526	rs355868	chr2:165631194	C/T	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg09462578	chr12:12878428	APOLD1	-0.68	-8.1	-0.41	1.02e-14	Systemic lupus erythematosus;
LUSC	cis	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg02972257	chr16:68554789	NA	0.42	5.73	0.3	2.3e-8	Colorectal cancer;
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	0.8	13.47	0.59	2.48e-33	Menarche (age at onset);
LUSC	trans	rs13233308	0.836	rs6966166	chr7:87455155	C/T	cg11015188	chr12:123874456	SETD8	-0.44	-6.22	-0.32	1.46e-9	Schizophrenia;
LUSC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg23791538	chr6:167370224	RNASET2	0.4	6.57	0.34	1.98e-10	Crohn's disease;
LUSC	cis	rs701145	0.938	rs1515653	chr3:154076654	A/G	cg17054900	chr3:154042577	DHX36	0.78	7.81	0.39	7.31e-14	Coronary artery disease;
LUSC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.55	-0.42	4.48e-16	Personality dimensions;
LUSC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.53	-8.69	-0.43	1.66e-16	Tonsillectomy;
LUSC	cis	rs9547692	0.877	rs9652258	chr13:37476123	G/C	cg01493522	chr13:37497338	NA	-0.44	-6.36	-0.33	6.59e-10	Coronary artery disease;
LUSC	cis	rs9616064	0.506	rs3747255	chr22:47074281	G/A	cg05621596	chr22:47072043	GRAMD4	-0.59	-9.48	-0.46	4.88e-19	Urate levels in obese individuals;
LUSC	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	0.57	9.07	0.44	1.02e-17	Breast cancer;
LUSC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg27165867	chr14:105738592	BRF1	-0.5	-7.48	-0.38	6.57e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.83	-0.57	6.66e-31	Chronic sinus infection;
LUSC	trans	rs34844492	0.744	rs17072704	chr3:65271885	C/T	cg03649855	chr6:45576388	NA	0.66	6.38	0.33	6.03e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12210905	0.925	rs114172511	chr6:26964301	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs931812	0.535	rs3100053	chr8:101944559	T/A	cg20993868	chr7:22813445	NA	0.34	6.28	0.32	1.07e-9	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.99	-0.31	5.32e-9	Neuroticism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25223263	chr11:119020168	ABCG4	-0.48	-6.45	-0.33	3.88e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.93	0.35	2.16e-11	Rheumatoid arthritis;
LUSC	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg08999081	chr20:33150536	PIGU	-0.41	-7.49	-0.38	6.06e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-8.04	-0.4	1.62e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg15432903	chr11:17409602	KCNJ11	0.6	10.54	0.5	1.28e-22	Type 2 diabetes;
LUSC	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.03	0.48	7.25e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg09941381	chr10:64027924	RTKN2	-0.38	-7.0	-0.36	1.45e-11	Rheumatoid arthritis;
LUSC	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs13221852	0.714	rs34731314	chr7:3438362	T/C	cg21248987	chr7:3385318	SDK1	0.36	5.95	0.31	6.87e-9	Acute graft versus host disease in bone marrow transplantation (donor effect);
LUSC	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg15423357	chr2:25149977	NA	0.44	8.91	0.44	3.26e-17	Body mass index in non-asthmatics;
LUSC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.63	-13.2	-0.59	2.6e-32	Paraoxonase activity;
LUSC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg18681998	chr4:17616180	MED28	0.86	15.28	0.64	2.39e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7527798	0.592	rs1323722	chr1:207823405	C/T	cg09232269	chr1:207846808	CR1L	-0.3	-6.43	-0.33	4.37e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg25214090	chr10:38739885	LOC399744	0.5	7.67	0.39	1.86e-13	Corneal astigmatism;
LUSC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	13.71	0.6	2.98e-34	Platelet count;
LUSC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03264133	chr6:25882463	NA	-0.42	-7.28	-0.37	2.42e-12	Blood metabolite levels;
LUSC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-19.72	-0.73	6.12e-58	Coronary artery disease;
LUSC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg09877947	chr5:131593287	PDLIM4	0.43	7.31	0.37	1.99e-12	Blood metabolite levels;
LUSC	cis	rs34638657	0.828	rs7194734	chr16:82199980	C/T	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.0	-0.31	5.19e-9	Lung adenocarcinoma;
LUSC	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg12927641	chr6:109611667	NA	-0.37	-6.21	-0.32	1.56e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-9.09	-0.45	9.13e-18	Morning vs. evening chronotype;
LUSC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg02807482	chr3:125708958	NA	-0.51	-6.31	-0.33	9e-10	Blood pressure (smoking interaction);
LUSC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg23093090	chr10:104574429	C10orf26	-0.38	-7.22	-0.37	3.46e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg15423357	chr2:25149977	NA	0.45	9.13	0.45	6.59e-18	Body mass index;
LUSC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-1.05	-15.17	-0.64	6.42e-40	Vitiligo;
LUSC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06221963	chr1:154839813	KCNN3	-0.6	-13.52	-0.59	1.57e-33	Prostate cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07243161	chr6:136871709	MAP7	-0.4	-6.19	-0.32	1.81e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs62238980	0.522	rs117086479	chr22:32389342	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs858239	0.601	rs10278700	chr7:23160529	T/C	cg23682824	chr7:23144976	KLHL7	0.39	5.69	0.3	2.85e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg08048268	chr3:133502702	NA	-0.38	-6.82	-0.35	4.23e-11	Iron status biomarkers;
LUSC	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg24375607	chr4:120327624	NA	0.8	11.96	0.55	1.14e-27	Corneal astigmatism;
LUSC	cis	rs67072384	0.818	rs2291293	chr11:72470653	C/T	cg04827223	chr11:72435913	ARAP1	-0.86	-6.75	-0.35	6.36e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg03859395	chr2:55845619	SMEK2	0.88	16.43	0.67	6.84e-45	Metabolic syndrome;
LUSC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10802521	chr3:52805072	NEK4	-0.48	-7.61	-0.38	2.87e-13	Electroencephalogram traits;
LUSC	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.46	0.5	2.54e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9815354	0.767	rs73087378	chr3:41936827	G/A	cg03022575	chr3:42003672	ULK4	0.83	8.64	0.43	2.32e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg03733263	chr8:22462867	KIAA1967	0.84	14.18	0.61	4.64e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg12257692	chr3:49977190	RBM6	-0.26	-7.41	-0.38	1.03e-12	Body mass index;
LUSC	trans	rs12439619	0.693	rs28665836	chr15:82511296	G/T	cg04831495	chr15:85060580	GOLGA6L5	-0.49	-8.15	-0.41	7.64e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2667011	0.512	rs1995951	chr2:160800952	G/A	cg06573604	chr2:160760825	LY75	0.45	6.28	0.32	1.07e-9	Bilirubin levels;
LUSC	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg24375607	chr4:120327624	NA	0.74	11.16	0.52	8.3e-25	Corneal astigmatism;
LUSC	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg12927641	chr6:109611667	NA	0.34	5.81	0.3	1.5e-8	Reticulocyte fraction of red cells;
LUSC	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.64	-0.43	2.29e-16	Myopia (pathological);
LUSC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg06618935	chr21:46677482	NA	-0.4	-7.74	-0.39	1.16e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg24675056	chr1:15929824	NA	0.48	8.33	0.41	2.17e-15	Systolic blood pressure;
LUSC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg27432699	chr2:27873401	GPN1	-0.58	-8.68	-0.43	1.72e-16	Total body bone mineral density;
LUSC	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.1	-0.32	2.9e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3087591	0.960	rs4263003	chr17:29438508	G/T	cg24425628	chr17:29625626	OMG;NF1	0.54	7.5	0.38	5.66e-13	Hip circumference;
LUSC	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg05501817	chr11:14380813	RRAS2	-0.56	-9.23	-0.45	3.29e-18	Sense of smell;
LUSC	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg09307838	chr4:120376055	NA	0.75	10.89	0.51	7.5e-24	Corneal astigmatism;
LUSC	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.67	-0.3	3.1e-8	IgG glycosylation;
LUSC	cis	rs1014246	0.848	rs10787716	chr10:118459575	C/A	cg14919929	chr10:118506882	NA	0.45	7.19	0.37	4.23e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg24675056	chr1:15929824	NA	0.49	8.46	0.42	8.28e-16	Systolic blood pressure;
LUSC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-9.13	-0.45	6.74e-18	Longevity;Endometriosis;
LUSC	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg02466173	chr16:30829666	NA	0.52	8.36	0.42	1.75e-15	Dementia with Lewy bodies;
LUSC	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.54	-10.72	-0.51	2.94e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg05872129	chr22:39784769	NA	0.57	9.48	0.46	4.73e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg07080220	chr10:102295463	HIF1AN	0.7	8.39	0.42	1.39e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg08219700	chr8:58056026	NA	0.46	5.74	0.3	2.1e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2580764	0.632	rs2588510	chr2:55199248	A/G	cg09592903	chr2:55203963	RTN4	-0.48	-10.0	-0.48	8.82e-21	Mean platelet volume;
LUSC	cis	rs367943	1.000	rs348961	chr5:112819944	A/C	cg12552261	chr5:112820674	MCC	-0.54	-7.0	-0.36	1.45e-11	Type 2 diabetes;
LUSC	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg01858014	chr14:56050164	KTN1	-0.89	-7.32	-0.37	1.9e-12	Putamen volume;
LUSC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg24813613	chr7:1882135	MAD1L1	0.35	5.81	0.3	1.42e-8	Bipolar disorder and schizophrenia;
LUSC	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-1.14	-18.19	-0.71	7.14e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.2e-28	Corneal astigmatism;
LUSC	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg14835575	chr10:16859367	RSU1	0.72	10.05	0.48	5.94e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg06808227	chr14:105710500	BRF1	-0.65	-9.57	-0.46	2.42e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6709815	0.841	rs6740004	chr2:219663153	G/A	cg02176678	chr2:219576539	TTLL4	-0.51	-9.02	-0.44	1.46e-17	Reticulocyte count;High light scatter reticulocyte count;
LUSC	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg24375607	chr4:120327624	NA	0.79	11.99	0.55	8.46e-28	Corneal astigmatism;
LUSC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.5	-7.59	-0.38	3.2e-13	Menarche (age at onset);
LUSC	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg05340658	chr4:99064831	C4orf37	0.44	6.97	0.36	1.68e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg06238570	chr21:40685208	BRWD1	0.48	7.35	0.37	1.55e-12	Cognitive function;
LUSC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg24209194	chr3:40518798	ZNF619	0.44	5.9	0.31	8.9e-9	Renal cell carcinoma;
LUSC	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.6	-0.38	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.58	-8.57	-0.42	3.9e-16	Menarche (age at onset);
LUSC	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg13010199	chr12:38710504	ALG10B	-0.45	-6.62	-0.34	1.42e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg22508957	chr16:3507546	NAT15	0.43	6.15	0.32	2.21e-9	Body mass index (adult);
LUSC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg04727924	chr7:799746	HEATR2	-0.55	-6.67	-0.34	1.07e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg13010199	chr12:38710504	ALG10B	-0.52	-7.91	-0.4	3.93e-14	Bladder cancer;
LUSC	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.21	-0.37	3.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg02951883	chr7:2050386	MAD1L1	-0.59	-10.62	-0.5	6.87e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs9549260	0.683	rs35594717	chr13:41240783	G/A	cg21288729	chr13:41239152	FOXO1	0.57	6.34	0.33	7.56e-10	Red blood cell count;
LUSC	cis	rs4919687	0.550	rs12761195	chr10:104465374	T/C	cg05855489	chr10:104503620	C10orf26	0.71	11.49	0.53	5.76e-26	Colorectal cancer;
LUSC	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg12935359	chr14:103987150	CKB	-0.51	-7.86	-0.4	5.37e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.87	0.4	5.1e-14	Prudent dietary pattern;
LUSC	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.82	-0.35	4.34e-11	Response to antipsychotic treatment;
LUSC	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.21	0.49	1.83e-21	Bladder cancer;
LUSC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg13902645	chr11:5959945	NA	-0.6	-8.48	-0.42	7.55e-16	DNA methylation (variation);
LUSC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11764359	chr7:65958608	NA	-0.54	-7.11	-0.36	7.23e-12	Aortic root size;
LUSC	cis	rs727505	0.754	rs56056794	chr7:124783027	C/T	cg23710748	chr7:124431027	NA	-0.41	-7.13	-0.36	6.4e-12	Lewy body disease;
LUSC	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg14583973	chr4:3374767	RGS12	0.33	7.13	0.36	6.11e-12	Serum sulfate level;
LUSC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18932078	chr1:2524107	MMEL1	0.31	6.92	0.35	2.35e-11	Ulcerative colitis;
LUSC	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08704250	chr15:31115839	NA	-0.46	-6.72	-0.35	7.9e-11	Huntington's disease progression;
LUSC	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg04036182	chr15:45458818	NA	0.34	5.74	0.3	2.13e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	5.8	0.3	1.58e-8	Axial length;
LUSC	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg08213375	chr14:104286397	PPP1R13B	0.44	7.58	0.38	3.4e-13	Reticulocyte count;
LUSC	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg18825076	chr15:78729989	IREB2	0.45	6.03	0.31	4.4e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10986311	0.802	rs2416	chr9:127113660	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.45	7.21	0.37	3.67e-12	Vitiligo;
LUSC	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.61	8.3	0.41	2.59e-15	Body mass index (adult);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09154213	chr1:25756855	TMEM57	0.49	7.38	0.37	1.29e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg04117972	chr1:227635322	NA	0.79	7.96	0.4	2.69e-14	Major depressive disorder;
LUSC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.67	11.15	0.52	9.01e-25	Heart rate;
LUSC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.7	-0.3	2.66e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg10729496	chr3:10149963	C3orf24	0.54	7.15	0.36	5.46e-12	Alzheimer's disease;
LUSC	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg17173187	chr15:85201210	NMB	0.5	9.15	0.45	5.81e-18	Schizophrenia;
LUSC	cis	rs60154123	0.614	rs646512	chr1:210453938	C/T	cg22029157	chr1:209979665	IRF6	-0.5	-6.05	-0.31	3.83e-9	Coronary artery disease;
LUSC	cis	rs4343996	0.536	rs10258056	chr7:3414624	C/T	cg21248987	chr7:3385318	SDK1	0.36	6.17	0.32	2.02e-9	Motion sickness;
LUSC	cis	rs2625529	0.526	rs11637611	chr15:72551712	C/T	cg16672083	chr15:72433130	SENP8	0.46	7.76	0.39	1.02e-13	Red blood cell count;
LUSC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg03676636	chr4:99064102	C4orf37	0.34	7.35	0.37	1.5e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9650315	0.641	rs56054219	chr8:57186076	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	7.45	0.38	7.92e-13	Height;
LUSC	cis	rs11650494	0.706	rs76778410	chr17:47459877	A/T	cg08112188	chr17:47440006	ZNF652	1.31	10.82	0.51	1.41e-23	Prostate cancer;
LUSC	trans	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg18187862	chr3:45730750	SACM1L	-0.52	-6.49	-0.33	3.17e-10	Primary sclerosing cholangitis;
LUSC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	9.27	0.45	2.37e-18	Motion sickness;
LUSC	cis	rs2688608	0.967	rs2633299	chr10:75656754	T/G	cg17411546	chr10:75410026	SYNPO2L	-0.46	-6.84	-0.35	3.77e-11	Inflammatory bowel disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20151668	chr10:27150052	ABI1	0.52	8.19	0.41	5.49e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.83	-0.57	6.66e-31	Chronic sinus infection;
LUSC	trans	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg10756647	chr7:56101905	PSPH	0.89	8.94	0.44	2.61e-17	Diabetic kidney disease;
LUSC	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg21132104	chr15:45694354	SPATA5L1	0.57	8.01	0.4	1.93e-14	Homoarginine levels;
LUSC	cis	rs7572644	0.766	rs10188108	chr2:28192555	C/G	cg27432699	chr2:27873401	GPN1	-0.52	-6.45	-0.33	3.97e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15921099	chr2:121010219	RALB	-0.44	-6.62	-0.34	1.39e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg02018176	chr4:1364513	KIAA1530	0.57	10.15	0.49	2.91e-21	Obesity-related traits;
LUSC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg14403583	chr14:105418241	AHNAK2	-0.58	-9.65	-0.47	1.38e-19	Rheumatoid arthritis;
LUSC	cis	rs654950	0.792	rs625448	chr1:41988541	A/T	cg06885757	chr1:42089581	HIVEP3	0.34	6.63	0.34	1.33e-10	Airway imaging phenotypes;
LUSC	cis	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg17554472	chr22:41940697	POLR3H	0.48	5.91	0.31	8.32e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg22705602	chr4:152727874	NA	0.36	7.68	0.39	1.79e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs6445525	0.967	rs6782159	chr3:65993782	C/G	cg12639933	chr12:57626296	SHMT2	0.36	6.43	0.33	4.51e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg16405210	chr4:1374714	KIAA1530	0.46	5.67	0.3	3.02e-8	Recombination rate (females);
LUSC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.89	0.61	6.05e-35	Breast cancer;
LUSC	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg19196401	chr6:110721138	DDO	-0.43	-8.09	-0.4	1.1e-14	Platelet distribution width;
LUSC	cis	rs7043114	0.525	rs1053446	chr9:95146761	T/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.78	-0.35	5.6e-11	Height;
LUSC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg18225595	chr11:63971243	STIP1	0.62	10.08	0.48	5.04e-21	Platelet count;
LUSC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.79	14.23	0.61	2.92e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.73	-12.29	-0.56	7e-29	Motion sickness;
LUSC	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.66	-0.34	1.1e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9473147	0.543	rs9296559	chr6:47452270	T/C	cg12968598	chr6:47444699	CD2AP	0.53	8.14	0.41	8.1e-15	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.63	9.62	0.47	1.7e-19	Corneal astigmatism;
LUSC	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg02753203	chr1:228287806	NA	0.71	12.42	0.56	2.22e-29	Diastolic blood pressure;
LUSC	cis	rs1018697	1.000	rs7088711	chr10:104559266	A/G	cg04362960	chr10:104952993	NT5C2	-0.46	-6.4	-0.33	5.25e-10	Colorectal adenoma (advanced);
LUSC	cis	rs12049351	0.774	rs36021190	chr1:229697863	T/C	cg11742688	chr1:229674241	ABCB10	-0.4	-5.81	-0.3	1.43e-8	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg14500267	chr11:67383377	NA	0.34	6.51	0.34	2.75e-10	Mean corpuscular volume;
LUSC	cis	rs10875595	0.836	rs10067231	chr5:140673429	C/T	cg24830062	chr5:140700576	TAF7	-0.51	-6.24	-0.32	1.31e-9	Pulmonary function decline;
LUSC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-13.8	-0.6	1.42e-34	Intelligence (multi-trait analysis);
LUSC	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.3	0.37	2.12e-12	Neuroticism;
LUSC	trans	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.15	-0.32	2.16e-9	Depression;
LUSC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg20283391	chr11:68216788	NA	0.55	8.15	0.41	7.52e-15	Total body bone mineral density;
LUSC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.64	10.11	0.48	3.89e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1062746	0.520	rs17770965	chr16:87328597	G/A	cg02258303	chr16:87377426	FBXO31	-0.53	-7.88	-0.4	4.52e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg12091567	chr17:66097778	LOC651250	-0.75	-9.36	-0.46	1.21e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs1451375	1.000	rs4452748	chr7:50625056	A/C	cg18232548	chr7:50535776	DDC	-0.5	-7.56	-0.38	3.85e-13	Malaria;
LUSC	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg09904177	chr6:26538194	HMGN4	0.76	14.17	0.61	5.2e-36	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18497504	chr21:38639897	DSCR3	0.55	7.37	0.37	1.36e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg20503657	chr10:835505	NA	0.73	9.19	0.45	4.2e-18	Eosinophil percentage of granulocytes;
LUSC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg10207240	chr12:122356781	WDR66	-0.4	-5.8	-0.3	1.52e-8	Mean corpuscular volume;
LUSC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.79	9.31	0.45	1.73e-18	Gut microbiome composition (summer);
LUSC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg26335602	chr6:28129616	ZNF389	0.42	5.7	0.3	2.63e-8	Depression;
LUSC	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg07173049	chr1:7289937	CAMTA1	0.37	7.64	0.39	2.38e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7577696	0.524	rs212696	chr2:32441685	A/G	cg02381751	chr2:32503542	YIPF4	0.53	6.82	0.35	4.3e-11	Inflammatory biomarkers;
LUSC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.63	9.84	0.47	3.12e-20	Menarche (age at onset);
LUSC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs16910800	0.731	rs1065631	chr11:23186810	T/C	cg20040320	chr11:23191996	NA	-0.59	-7.63	-0.39	2.4e-13	Cancer;
LUSC	cis	rs7131987	0.650	rs67146951	chr12:29450553	C/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.57	-0.34	1.99e-10	QT interval;
LUSC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg14019146	chr3:50243930	SLC38A3	0.3	6.68	0.34	1.01e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	8.76	0.43	9.72e-17	Bipolar disorder;
LUSC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg22868518	chr11:507468	RNH1	-0.61	-5.98	-0.31	5.79e-9	Body mass index;
LUSC	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg05373962	chr22:49881684	NA	-0.41	-8.77	-0.43	9.37e-17	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.68	-0.34	1.03e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.85	-12.31	-0.56	5.48e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.19	-0.37	4.36e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg22618164	chr12:122356400	WDR66	0.58	8.53	0.42	5.02e-16	Mean corpuscular volume;
LUSC	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg21427119	chr20:30132790	HM13	-0.37	-5.79	-0.3	1.62e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg24459738	chr19:57751996	ZNF805	-0.54	-8.01	-0.4	1.88e-14	Hyperactive-impulsive symptoms;
LUSC	cis	rs9309473	0.615	rs74523560	chr2:73764185	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-6.76	-0.35	6.3e-11	Metabolite levels;
LUSC	cis	rs9807989	0.801	rs4851566	chr2:102972799	G/C	cg09003973	chr2:102972529	NA	0.44	6.01	0.31	4.74e-9	Asthma;
LUSC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg24829409	chr8:58192753	C8orf71	-0.56	-6.08	-0.32	3.35e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs724744	0.712	rs1205939	chr6:22357130	T/C	cg13807341	chr11:118445984	ARCN1	-0.36	-6.05	-0.31	3.89e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.8	-0.39	7.98e-14	Joint mobility (Beighton score);
LUSC	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg23029597	chr12:123009494	RSRC2	0.73	9.25	0.45	2.65e-18	Body mass index;
LUSC	cis	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg05084668	chr3:125655381	ALG1L	-0.7	-7.86	-0.39	5.44e-14	Blood pressure (smoking interaction);
LUSC	trans	rs62055045	0.929	rs6499512	chr16:71403235	C/T	cg05226518	chr14:54908796	CNIH	-0.51	-6.12	-0.32	2.6e-9	Schizophrenia;
LUSC	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.36	-0.33	6.73e-10	Systolic blood pressure;
LUSC	trans	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg22800045	chr5:56110881	MAP3K1	0.64	8.62	0.43	2.66e-16	Initial pursuit acceleration;
LUSC	cis	rs7180079	1.000	rs2062248	chr15:64672319	C/T	cg08069370	chr15:64387884	SNX1	0.63	6.19	0.32	1.77e-9	Monocyte count;
LUSC	cis	rs500891	0.525	rs7753311	chr6:84095038	T/C	cg08257003	chr6:84140564	ME1	0.35	8.51	0.42	5.77e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs939574	0.790	rs72955447	chr2:220098287	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.9	6.36	0.33	6.62e-10	Platelet distribution width;
LUSC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg18305652	chr10:134549665	INPP5A	0.44	6.66	0.34	1.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg21918786	chr6:109611834	NA	-0.37	-6.38	-0.33	6.02e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg01283332	chr5:1856932	NA	-0.33	-6.34	-0.33	7.54e-10	Cardiovascular disease risk factors;
LUSC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.18	0.88	4.53e-111	Chronic sinus infection;
LUSC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg03146154	chr1:46216737	IPP	-0.51	-7.46	-0.38	7.41e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7903847	0.619	rs10882912	chr10:99138077	C/T	cg08345082	chr10:99160200	RRP12	-0.37	-7.56	-0.38	3.89e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg14664628	chr15:75095509	CSK	0.44	6.23	0.32	1.4e-9	Systemic lupus erythematosus;
LUSC	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.43	5.82	0.3	1.37e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg01579765	chr21:45077557	HSF2BP	0.53	11.04	0.52	2.3e-24	Mean corpuscular volume;
LUSC	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg22800045	chr5:56110881	MAP3K1	0.43	6.08	0.32	3.29e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg17143192	chr8:8559678	CLDN23	0.64	9.33	0.45	1.54e-18	Obesity-related traits;
LUSC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg26659404	chr1:25747437	RHCE	-0.28	-5.75	-0.3	1.98e-8	Erythrocyte sedimentation rate;
LUSC	trans	rs4596713	0.538	rs10781440	chr9:71762766	A/G	cg25283916	chr1:242222868	NA	0.31	6.36	0.33	6.68e-10	Headache;
LUSC	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.31e-41	Bladder cancer;
LUSC	cis	rs9905704	0.831	rs12939500	chr17:56848677	T/C	cg12560992	chr17:57184187	TRIM37	0.56	8.04	0.4	1.57e-14	Testicular germ cell tumor;
LUSC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg09509183	chr1:209979624	IRF6	0.45	5.91	0.31	8.57e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.46	0.53	7.26e-26	Menopause (age at onset);
LUSC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg03233332	chr7:66118400	NA	0.41	5.95	0.31	6.8e-9	Aortic root size;
LUSC	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg24375607	chr4:120327624	NA	0.74	11.08	0.52	1.64e-24	Corneal astigmatism;
LUSC	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-7.22	-0.37	3.47e-12	Homocysteine levels;
LUSC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.2	13.62	0.6	6.4e-34	Diabetic kidney disease;
LUSC	trans	rs72674100	1.000	rs28392183	chr4:97949977	C/T	cg16405019	chr1:18959625	PAX7	-0.56	-6.05	-0.31	3.87e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg01294253	chr9:136912663	BRD3	-0.34	-6.21	-0.32	1.56e-9	Platelet distribution width;
LUSC	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.38	0.67	1.16e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs5753037	0.702	rs140100	chr22:30128240	C/T	cg11564601	chr22:30592435	NA	0.33	5.93	0.31	7.51e-9	Type 1 diabetes;
LUSC	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg19773385	chr1:10388646	KIF1B	-0.51	-8.87	-0.44	4.44e-17	Hepatocellular carcinoma;
LUSC	trans	rs17685	0.535	rs6953065	chr7:75601169	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.46	-6.23	-0.32	1.4e-9	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs17253792	0.822	rs76192881	chr14:56034654	C/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.04	-0.36	1.1e-11	Putamen volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13580321	chr1:93645478	TMED5;CCDC18	-0.4	-5.98	-0.31	5.65e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg13647721	chr17:30228624	UTP6	-0.69	-8.0	-0.4	2.05e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs59104589	0.617	rs56390510	chr2:242274489	G/C	cg14842376	chr2:242211374	HDLBP	0.53	6.06	0.31	3.69e-9	Fibrinogen levels;
LUSC	cis	rs672059	1.000	rs559476	chr1:183160704	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.06	0.4	1.37e-14	Hypertriglyceridemia;
LUSC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg04121214	chr22:50244548	NA	-0.34	-5.74	-0.3	2.14e-8	Schizophrenia;
LUSC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.92	0.58	3.13e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg11019008	chr10:131425282	MGMT	0.44	6.54	0.34	2.28e-10	Response to temozolomide;
LUSC	cis	rs9815354	0.556	rs56201224	chr3:42004427	A/C	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.42	5.02e-16	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg08975724	chr8:8085496	FLJ10661	0.47	6.66	0.34	1.16e-10	Neuroticism;
LUSC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.38	-0.37	1.29e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12016809	chr21:47604291	C21orf56	-0.47	-7.02	-0.36	1.27e-11	Testicular germ cell tumor;
LUSC	cis	rs7923609	0.871	rs12245149	chr10:65321147	C/A	cg01631684	chr10:65280961	REEP3	0.41	6.1	0.32	2.96e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9807989	0.507	rs7584093	chr2:102997721	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.27e-12	Asthma;
LUSC	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.54	0.5	1.35e-22	Morning vs. evening chronotype;
LUSC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg21435336	chr19:17392852	ANKLE1	-0.47	-6.22	-0.32	1.52e-9	Systemic lupus erythematosus;
LUSC	cis	rs2249625	0.545	rs55681410	chr6:72877859	G/A	cg18830697	chr6:72922368	RIMS1	0.37	7.4	0.38	1.14e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg14092988	chr3:52407081	DNAH1	0.31	5.93	0.31	7.63e-9	Bipolar disorder;
LUSC	cis	rs7760535	0.930	rs10872069	chr6:111861726	A/C	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.59	-0.34	1.74e-10	Metabolic traits;
LUSC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.43	0.33	4.44e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.37	5.67	0.3	3.05e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.92	0.44	3.02e-17	Motion sickness;
LUSC	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.83	-15.5	-0.65	3.3e-41	Longevity;
LUSC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg23630131	chr7:65973040	NA	0.21	5.77	0.3	1.83e-8	Aortic root size;
LUSC	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg07810366	chr2:100720526	AFF3	0.37	6.1	0.32	2.92e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg23750338	chr8:142222470	SLC45A4	0.58	11.29	0.53	2.93e-25	Immature fraction of reticulocytes;
LUSC	cis	rs10489202	0.608	rs6659593	chr1:168072152	A/T	cg24449463	chr1:168025552	DCAF6	-0.64	-9.75	-0.47	6.22e-20	Schizophrenia;
LUSC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.47	-0.42	8.09e-16	Gut microbiome composition (summer);
LUSC	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg03929089	chr4:120376271	NA	0.72	8.07	0.4	1.3e-14	Axial length;
LUSC	cis	rs2652834	0.851	rs1007076	chr15:63413371	T/C	cg05507819	chr15:63340323	TPM1	0.44	5.72	0.3	2.35e-8	HDL cholesterol;
LUSC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs7215564	0.908	rs2316067	chr17:78659720	C/T	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs10465746	0.725	rs4907188	chr1:84361608	C/T	cg10977910	chr1:84465055	TTLL7	0.52	7.45	0.38	7.96e-13	Obesity-related traits;
LUSC	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg23711669	chr6:146136114	FBXO30	0.86	15.46	0.65	4.91e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12725198	0.507	rs41393951	chr1:16053493	C/T	cg18133145	chr1:16060689	PLEKHM2	-0.44	-5.75	-0.3	2.02e-8	Cardiac Troponin-T levels;
LUSC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18876405	chr7:65276391	NA	0.54	8.23	0.41	4.27e-15	Aortic root size;
LUSC	trans	rs7939886	0.844	rs7106504	chr11:55932827	C/T	cg15704280	chr7:45808275	SEPT13	0.88	6.69	0.34	9.39e-11	Myopia (pathological);
LUSC	cis	rs2282802	0.635	rs269767	chr5:139536922	A/G	cg26211634	chr5:139558579	C5orf32	0.39	7.15	0.36	5.59e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7178572	0.633	rs12907746	chr15:77843326	A/G	cg22256960	chr15:77711686	NA	-0.47	-7.0	-0.36	1.37e-11	Type 2 diabetes;
LUSC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg14092988	chr3:52407081	DNAH1	0.31	6.12	0.32	2.57e-9	Bipolar disorder;
LUSC	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg02569458	chr12:86230093	RASSF9	0.39	6.32	0.33	8.23e-10	Major depressive disorder;
LUSC	cis	rs67366981	0.778	rs3952319	chr14:77684379	A/T	cg22824376	chr14:77648248	TMEM63C	0.91	9.38	0.46	1.02e-18	Obsessive-compulsive symptoms;
LUSC	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg18753928	chr3:113234510	CCDC52	0.48	7.48	0.38	6.49e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg07828340	chr4:882639	GAK	1.07	11.42	0.53	1.01e-25	Intelligence (multi-trait analysis);
LUSC	trans	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18876405	chr7:65276391	NA	-0.45	-6.03	-0.31	4.25e-9	Corneal structure;
LUSC	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-6.69	-0.34	9.68e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg24399712	chr22:39784796	NA	-0.64	-11.4	-0.53	1.19e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-9.27	-0.45	2.42e-18	Eye color traits;
LUSC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg04414720	chr1:150670196	GOLPH3L	0.46	7.41	0.38	1.03e-12	Melanoma;
LUSC	trans	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	5.95	0.31	6.6e-9	Cystic fibrosis severity;
LUSC	trans	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg13565492	chr6:43139072	SRF	-0.63	-6.57	-0.34	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06873352	chr17:61820015	STRADA	0.57	8.86	0.44	5.01e-17	Height;
LUSC	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg15660573	chr17:549704	VPS53	-0.52	-8.21	-0.41	4.91e-15	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1113500	0.933	rs12132785	chr1:108633083	A/T	cg11967332	chr1:108735228	SLC25A24	0.38	5.78	0.3	1.75e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg11645453	chr3:52864694	ITIH4	0.3	6.89	0.35	2.86e-11	Electroencephalogram traits;
LUSC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.17	0.55	1.86e-28	Motion sickness;
LUSC	trans	rs11082098	0.702	rs4799488	chr18:36240112	A/G	cg08128007	chr1:839435	NA	-0.65	-6.41	-0.33	4.88e-10	Smooth-surface caries;Pit-and-Fissure caries;
LUSC	cis	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg02508848	chr16:68573721	ZFP90	-0.42	-5.72	-0.3	2.31e-8	Ulcerative colitis;
LUSC	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.56	0.6	1.12e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg09462578	chr12:12878428	APOLD1	0.5	7.43	0.38	8.93e-13	Pulse pressure;
LUSC	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.84	-0.3	1.22e-8	Height;
LUSC	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg16797656	chr11:68205561	LRP5	0.46	8.26	0.41	3.43e-15	Total body bone mineral density;
LUSC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg26924012	chr15:45694286	SPATA5L1	1.13	20.5	0.75	4.96e-61	Homoarginine levels;
LUSC	cis	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg05626013	chr10:68685252	CTNNA3;LRRTM3	0.35	6.21	0.32	1.54e-9	Tuberculosis;
LUSC	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.94	-0.31	7.19e-9	Reticulocyte count;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg01719780	chr1:157126054	NA	0.38	6.23	0.32	1.43e-9	Mosquito bite size;
LUSC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	15.23	0.64	3.67e-40	Gut microbiome composition (summer);
LUSC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.3	-0.33	9.56e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg24006582	chr15:45444508	DUOX1	-0.62	-9.14	-0.45	6.18e-18	Uric acid levels;
LUSC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg21699342	chr2:239360505	ASB1	0.55	10.46	0.5	2.51e-22	Multiple system atrophy;
LUSC	cis	rs72634258	1.000	rs72634258	chr1:8150638	T/C	cg26816564	chr1:7831052	VAMP3	0.48	5.78	0.3	1.71e-8	Inflammatory bowel disease;
LUSC	trans	rs6725041	0.805	rs6745249	chr2:213130571	A/G	cg18266620	chr1:110882148	RBM15	-0.4	-6.04	-0.31	4.09e-9	QT interval (ambient particulate matter interaction);
LUSC	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.42	-0.42	1.12e-15	Body mass index;
LUSC	cis	rs12760731	0.565	rs11585355	chr1:178181219	T/G	cg00404053	chr1:178313656	RASAL2	0.68	6.89	0.35	2.73e-11	Obesity-related traits;
LUSC	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg09184832	chr6:79620586	NA	-0.36	-5.72	-0.3	2.41e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg23625390	chr15:77176239	SCAPER	-0.64	-9.93	-0.48	1.57e-20	Blood metabolite levels;
LUSC	cis	rs3789045	0.560	rs2271424	chr1:204403311	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.48	-5.85	-0.3	1.19e-8	Educational attainment (college completion);
LUSC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-10.0	-0.48	9.34e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg13813247	chr22:41461852	NA	-0.31	-5.74	-0.3	2.16e-8	Neuroticism;
LUSC	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg24449463	chr1:168025552	DCAF6	-0.64	-9.52	-0.46	3.62e-19	Schizophrenia;
LUSC	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg06197492	chr11:2016605	H19	0.42	6.85	0.35	3.5e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs10979	1.000	rs9496678	chr6:143896664	C/A	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	trans	rs76156646	0.623	rs9464052	chr6:54173889	A/G	cg05371498	chr16:10989530	CIITA	0.58	5.98	0.31	5.67e-9	Hepatitis B;
LUSC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg21280719	chr6:42927975	GNMT	-0.29	-7.0	-0.36	1.38e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg05373962	chr22:49881684	NA	-0.39	-8.48	-0.42	7.27e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.76	0.39	1.02e-13	Prudent dietary pattern;
LUSC	cis	rs977987	0.778	rs34222958	chr16:75398252	C/T	cg04384234	chr16:75411784	CFDP1	-0.42	-6.95	-0.36	1.94e-11	Dupuytren's disease;
LUSC	cis	rs4356932	1.000	rs4241580	chr4:76956188	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg12935359	chr14:103987150	CKB	0.67	10.68	0.5	4.38e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg03146154	chr1:46216737	IPP	0.52	7.57	0.38	3.58e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg07148914	chr20:33460835	GGT7	0.46	6.92	0.35	2.33e-11	Height;
LUSC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg25174290	chr11:3078921	CARS	0.6	9.77	0.47	5.36e-20	Longevity;
LUSC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26314531	chr2:26401878	FAM59B	0.63	8.67	0.43	1.95e-16	Gut microbiome composition (summer);
LUSC	cis	rs11247915	0.540	rs11582416	chr1:26677721	A/G	cg15628303	chr1:26608928	UBXN11	-0.38	-6.03	-0.31	4.29e-9	Obesity-related traits;
LUSC	cis	rs2290159	0.800	rs5746195	chr3:12653800	A/G	cg23032965	chr3:12705835	RAF1	0.74	8.95	0.44	2.58e-17	Cholesterol, total;
LUSC	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg09904177	chr6:26538194	HMGN4	-0.78	-5.94	-0.31	6.98e-9	Depression;
LUSC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.88	0.4	4.66e-14	Total body bone mineral density;
LUSC	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	8.94	0.44	2.64e-17	Axial length;
LUSC	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg25801113	chr15:45476975	SHF	0.34	7.18	0.37	4.62e-12	Uric acid levels;
LUSC	trans	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg13010199	chr12:38710504	ALG10B	-0.46	-7.4	-0.38	1.11e-12	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg26384229	chr12:38710491	ALG10B	0.7	11.03	0.52	2.5e-24	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg05347473	chr6:146136440	FBXO30	0.44	7.27	0.37	2.49e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4988958	0.584	rs7559845	chr2:103046214	T/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.06	0.36	9.92e-12	Asthma (childhood onset);
LUSC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.62	-7.82	-0.39	6.87e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg25976786	chr12:53662079	ESPL1	0.36	6.29	0.33	9.93e-10	Triglycerides;
LUSC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg25011763	chr5:6727354	POLS	-0.36	-6.18	-0.32	1.83e-9	Menopause (age at onset);
LUSC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg25767906	chr1:53392781	SCP2	0.48	8.7	0.43	1.54e-16	Monocyte count;
LUSC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg15848620	chr12:58087721	OS9	-0.56	-8.09	-0.4	1.1e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg07423050	chr13:99094983	FARP1	0.45	7.14	0.36	5.72e-12	Longevity;
LUSC	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg14196790	chr5:131705035	SLC22A5	0.47	7.68	0.39	1.79e-13	Blood metabolite levels;
LUSC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg16989086	chr20:62203971	PRIC285	0.44	6.23	0.32	1.38e-9	Glioblastoma;
LUSC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.29	0.33	1.02e-9	Menopause (age at onset);
LUSC	cis	rs1355223	1.000	rs11601923	chr11:34764354	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.79	-0.3	1.64e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs713477	0.617	rs11627405	chr14:55911657	T/C	cg13175173	chr14:55914753	NA	-0.3	-6.14	-0.32	2.31e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg11905131	chr22:24372483	LOC391322	-0.58	-9.61	-0.47	1.78e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg06627628	chr2:24431161	ITSN2	-0.59	-7.1	-0.36	7.61e-12	Lymphocyte counts;
LUSC	cis	rs394563	0.967	rs447025	chr6:149799128	A/C	cg07828024	chr6:149772892	ZC3H12D	-0.33	-7.2	-0.37	4.13e-12	Dupuytren's disease;
LUSC	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg15212455	chr7:39170539	POU6F2	0.56	9.23	0.45	3.18e-18	IgG glycosylation;
LUSC	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg21918786	chr6:109611834	NA	-0.39	-6.82	-0.35	4.33e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	11.91	0.55	1.72e-27	Mean corpuscular hemoglobin;
LUSC	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg01884057	chr2:25150051	NA	0.48	11.42	0.53	1e-25	Body mass index in non-asthmatics;
LUSC	cis	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.43	-0.42	1.05e-15	Morning vs. evening chronotype;
LUSC	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg04990556	chr1:26633338	UBXN11	-0.45	-5.94	-0.31	7.02e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1160297	0.576	rs1451458	chr2:53088905	G/C	cg07782112	chr2:53107842	NA	0.4	6.43	0.33	4.32e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.49	-6.77	-0.35	5.93e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.66	-10.27	-0.49	1.11e-21	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.63	-0.43	2.6e-16	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg23625390	chr15:77176239	SCAPER	-0.46	-7.11	-0.36	7.16e-12	Blood metabolite levels;
LUSC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.74	8.69	0.43	1.71e-16	Schizophrenia;
LUSC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg23205692	chr1:25664452	TMEM50A	0.38	5.76	0.3	1.96e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.67	9.16	0.45	5.19e-18	High light scatter reticulocyte count;
LUSC	cis	rs7759001	0.857	rs4455661	chr6:27373130	C/T	cg18711553	chr6:27366782	ZNF391	-0.4	-5.77	-0.3	1.81e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs1152591	0.524	rs1255990	chr14:64661523	A/G	cg21174375	chr14:64681225	SYNE2	-0.32	-5.79	-0.3	1.65e-8	Atrial fibrillation;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg17465130	chr10:135192054	PAOX	0.47	6.43	0.33	4.52e-10	Cognitive function;Information processing speed;
LUSC	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.57	9.41	0.46	8.1e-19	Breast cancer;
LUSC	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg01475377	chr6:109611718	NA	-0.41	-7.39	-0.37	1.22e-12	Reticulocyte fraction of red cells;
LUSC	trans	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-7.43	-0.38	8.88e-13	Morning vs. evening chronotype;
LUSC	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg05621596	chr22:47072043	GRAMD4	-0.54	-8.62	-0.43	2.75e-16	Urate levels in obese individuals;
LUSC	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg17757837	chr7:157058334	UBE3C	0.82	12.98	0.58	1.8e-31	Body mass index;
LUSC	cis	rs7089973	0.523	rs34170154	chr10:116740959	C/T	cg23260525	chr10:116636907	FAM160B1	0.3	5.79	0.3	1.61e-8	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg08355456	chr11:67383691	NA	0.35	6.59	0.34	1.74e-10	Mean corpuscular volume;
LUSC	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg15133208	chr4:90757351	SNCA	-0.53	-8.27	-0.41	3.2e-15	Neuroticism;
LUSC	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg09796270	chr17:17721594	SREBF1	0.43	7.86	0.4	5.36e-14	Total body bone mineral density;
LUSC	trans	rs13196614	0.756	rs9498110	chr6:148998775	A/C	cg01343097	chr1:248284971	OR2M1P	0.39	5.98	0.31	5.86e-9	Migraine;
LUSC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.72	0.35	7.92e-11	Aortic root size;
LUSC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg13319975	chr6:146136371	FBXO30	0.51	7.65	0.39	2.24e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-17.19	-0.69	6.68e-48	Exhaled nitric oxide output;
LUSC	cis	rs7799006	0.606	rs7792045	chr7:2316852	C/T	cg08027265	chr7:2291960	NA	-0.58	-10.22	-0.49	1.66e-21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1595825	0.891	rs7573687	chr2:198893376	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-6.3	-0.33	9.56e-10	Ulcerative colitis;
LUSC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.3	-0.33	9.31e-10	Sudden cardiac arrest;
LUSC	cis	rs6541297	0.887	rs6541295	chr1:230281698	A/G	cg05784532	chr1:230284198	GALNT2	0.61	7.62	0.38	2.69e-13	Coronary artery disease;
LUSC	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg11019008	chr10:131425282	MGMT	-0.39	-5.99	-0.31	5.34e-9	Response to temozolomide;
LUSC	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg11584989	chr19:19387371	SF4	0.63	7.04	0.36	1.11e-11	Bipolar disorder;
LUSC	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg13852791	chr20:30311386	BCL2L1	0.93	14.5	0.62	2.8e-37	Mean corpuscular hemoglobin;
LUSC	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.9	-10.62	-0.5	6.81e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg03806693	chr22:41940476	POLR3H	0.85	12.33	0.56	4.85e-29	Vitiligo;
LUSC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg02782426	chr3:40428986	ENTPD3	0.33	6.21	0.32	1.53e-9	Renal cell carcinoma;
LUSC	trans	rs9341835	0.518	rs2622294	chr6:64218316	T/A	cg19533977	chr17:57719682	CLTC	0.33	6.07	0.32	3.53e-9	Schizophrenia;
LUSC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg12564285	chr5:131593104	PDLIM4	0.34	6.27	0.32	1.09e-9	Blood metabolite levels;
LUSC	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	7.21	0.37	3.78e-12	Response to antipsychotic treatment;
LUSC	trans	rs9951602	0.703	rs2959407	chr18:76682915	A/G	cg02800362	chr5:177631904	HNRNPAB	0.54	6.31	0.33	8.99e-10	Obesity-related traits;
LUSC	cis	rs7180079	0.544	rs8038016	chr15:64995737	C/T	cg08069370	chr15:64387884	SNX1	0.52	5.72	0.3	2.32e-8	Monocyte count;
LUSC	cis	rs116988415	0.584	rs78748209	chr14:65255676	C/T	cg25083366	chr14:65239357	SPTB	0.68	6.92	0.35	2.27e-11	Daytime sleep phenotypes;
LUSC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg13535736	chr9:111863775	C9orf5	-0.4	-6.55	-0.34	2.16e-10	Menarche (age at onset);
LUSC	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg00806126	chr19:22604979	ZNF98	0.37	5.73	0.3	2.21e-8	Pain;
LUSC	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg18449964	chr18:72917101	ZADH2	0.48	5.77	0.3	1.83e-8	Vascular endothelial growth factor levels;
LUSC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg05896524	chr21:47604654	C21orf56	0.43	6.43	0.33	4.51e-10	Testicular germ cell tumor;
LUSC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	11.24	0.52	4.37e-25	Alzheimer's disease;
LUSC	cis	rs4622329	0.636	rs4764836	chr12:102287703	A/T	cg23541617	chr12:102225335	GNPTAB	0.26	6.08	0.32	3.23e-9	Systemic lupus erythematosus;
LUSC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg13206674	chr6:150067644	NUP43	0.58	9.29	0.45	2.09e-18	Lung cancer;
LUSC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.95	0.36	1.87e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg17623882	chr6:41773611	USP49	0.63	10.39	0.49	4.18e-22	Menarche (age at onset);
LUSC	cis	rs909341	0.710	rs2297433	chr20:62293460	T/C	cg16989086	chr20:62203971	PRIC285	-0.53	-7.38	-0.37	1.26e-12	Atopic dermatitis;
LUSC	cis	rs9309473	0.500	rs4852952	chr2:73869907	T/C	cg20560298	chr2:73613845	ALMS1	0.42	6.37	0.33	6.27e-10	Metabolite levels;
LUSC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg05729581	chr11:3078854	CARS	-0.58	-9.04	-0.44	1.27e-17	Longevity;
LUSC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-10.36	-0.49	5.48e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs981844	0.683	rs4696191	chr4:154740668	G/A	cg14289246	chr4:154710475	SFRP2	-0.44	-6.13	-0.32	2.5e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg04310649	chr10:35416472	CREM	-0.43	-6.69	-0.34	9.52e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	9.71	0.47	8.71e-20	Personality dimensions;
LUSC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.36	-0.56	3.64e-29	Type 2 diabetes;
LUSC	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg09173681	chr1:183549694	NCF2	0.63	11.24	0.52	4.38e-25	Systemic lupus erythematosus;
LUSC	cis	rs7953508	0.636	rs10859535	chr12:93979892	A/G	cg18151635	chr12:93972918	NA	-0.59	-8.15	-0.41	7.36e-15	Pubertal anthropometrics;
LUSC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg23985595	chr17:80112537	CCDC57	-0.31	-5.86	-0.31	1.12e-8	Life satisfaction;
LUSC	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg27411982	chr8:10470053	RP1L1	0.39	6.04	0.31	4.05e-9	Myopia (pathological);
LUSC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07677032	chr17:61819896	STRADA	0.53	8.86	0.44	4.89e-17	Prudent dietary pattern;
LUSC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.24	0.52	4.47e-25	Prudent dietary pattern;
LUSC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	1.04	20.0	0.74	4.54e-59	Menopause (age at onset);
LUSC	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.55	0.34	2.24e-10	IgG glycosylation;
LUSC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.37	-0.33	6.25e-10	Lung cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01648131	chr19:58838208	ZSCAN22	-0.42	-6.2	-0.32	1.62e-9	Electrocardiographic conduction measures;
LUSC	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg18678763	chr11:4115507	RRM1	-0.53	-7.5	-0.38	5.82e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.37	-0.46	1.15e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs524023	0.914	rs7932437	chr11:64373504	T/C	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.72	-0.3	2.32e-8	Urate levels in obese individuals;
LUSC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg05623727	chr3:50126028	RBM5	-0.33	-6.14	-0.32	2.32e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11645453	chr3:52864694	ITIH4	0.33	7.67	0.39	1.87e-13	Bipolar disorder;
LUSC	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg18827107	chr12:86230957	RASSF9	-0.49	-7.25	-0.37	2.85e-12	Major depressive disorder;
LUSC	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg21231944	chr12:82153410	PPFIA2	-0.4	-5.96	-0.31	6.25e-9	Resting heart rate;
LUSC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-7.55	-0.38	4.28e-13	Alzheimer's disease (late onset);
LUSC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg13119609	chr19:45449297	APOC2	0.5	10.17	0.49	2.48e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg15711740	chr2:61764176	XPO1	-0.49	-7.71	-0.39	1.47e-13	Tuberculosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05380522	chr12:53473279	SPRYD3	-0.41	-6.35	-0.33	7.08e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg00191853	chr8:101177733	SPAG1	-0.37	-6.28	-0.33	1.03e-9	Atrioventricular conduction;
LUSC	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg17385448	chr1:15911702	AGMAT	0.36	6.18	0.32	1.82e-9	Systolic blood pressure;
LUSC	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg25457927	chr22:38595422	NA	-0.34	-6.81	-0.35	4.62e-11	Cutaneous nevi;
LUSC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg05082376	chr22:42548792	NA	0.43	6.59	0.34	1.73e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19748678	chr4:122722346	EXOSC9	-0.49	-7.29	-0.37	2.25e-12	Type 2 diabetes;
LUSC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.51	0.53	4.8e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13394619	0.605	rs12476152	chr2:11747960	T/C	cg07314298	chr2:11723111	GREB1	0.44	7.46	0.38	7.48e-13	Endometriosis;
LUSC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg07936489	chr17:37558343	FBXL20	-0.71	-9.87	-0.48	2.41e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs61863818	0.557	rs7898743	chr10:99153540	T/G	cg08345082	chr10:99160200	RRP12	-0.3	-6.26	-0.32	1.21e-9	Monocyte percentage of white cells;
LUSC	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg18806716	chr10:30721971	MAP3K8	-0.7	-11.39	-0.53	1.32e-25	Inflammatory bowel disease;
LUSC	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg12473912	chr3:136751656	NA	0.4	7.13	0.36	6.2e-12	Neuroticism;
LUSC	cis	rs12681287	0.752	rs7846635	chr8:87304281	G/A	cg27223183	chr8:87520930	FAM82B	-0.47	-5.9	-0.31	8.75e-9	Caudate activity during reward;
LUSC	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg17507749	chr15:85114479	UBE2QP1	0.56	6.96	0.36	1.8e-11	Schizophrenia;
LUSC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.95	0.31	6.74e-9	Personality dimensions;
LUSC	cis	rs6960043	0.782	rs10228456	chr7:15063926	C/T	cg19272540	chr7:15055459	NA	-0.32	-7.79	-0.39	8.77e-14	Type 2 diabetes;
LUSC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg19046167	chr17:80928561	B3GNTL1	0.5	7.01	0.36	1.31e-11	Glycated hemoglobin levels;
LUSC	cis	rs7131987	0.718	rs7976961	chr12:29463088	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.63	-0.34	1.38e-10	QT interval;
LUSC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.37e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7181230	1.000	rs28587891	chr15:40365106	T/A	cg00868766	chr15:40364524	NA	0.34	6.01	0.31	4.94e-9	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg24562669	chr7:97807699	LMTK2	0.47	8.61	0.43	2.86e-16	Breast cancer;
LUSC	cis	rs77972916	0.611	rs10495899	chr2:43602304	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.77	-0.3	1.81e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg05347473	chr6:146136440	FBXO30	0.58	10.16	0.49	2.54e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs796364	0.570	rs4673491	chr2:200669108	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.62	6.84	0.35	3.9e-11	Schizophrenia;
LUSC	cis	rs7709377	0.597	rs10051072	chr5:115488499	C/T	cg23108291	chr5:115420582	COMMD10	0.41	5.79	0.3	1.59e-8	Metabolite levels  (X-11787);
LUSC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg06740227	chr12:86229804	RASSF9	-0.36	-5.7	-0.3	2.61e-8	Major depressive disorder;
LUSC	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg22681709	chr2:178499509	PDE11A	-0.45	-8.1	-0.41	1.05e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	11.71	0.54	9.2e-27	Coronary artery disease;
LUSC	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg03929089	chr4:120376271	NA	-0.45	-6.11	-0.32	2.81e-9	HDL cholesterol;
LUSC	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg05182265	chr7:156933206	UBE3C	0.41	6.16	0.32	2.03e-9	Body mass index;
LUSC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21862992	chr11:68658383	NA	-0.47	-7.41	-0.38	1.04e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg17120908	chr11:65337727	SSSCA1	-0.53	-9.28	-0.45	2.2e-18	Bone mineral density;
LUSC	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-17.83	-0.7	1.92e-50	Primary sclerosing cholangitis;
LUSC	cis	rs7759001	0.857	rs4713086	chr6:27350446	A/T	cg18711553	chr6:27366782	ZNF391	0.45	6.43	0.33	4.33e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08109568	chr15:31115862	NA	-0.59	-8.24	-0.41	3.89e-15	Huntington's disease progression;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06391300	chr11:119600292	PVRL1	0.49	7.51	0.38	5.3e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.0	0.52	3.23e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg20744362	chr22:50050164	C22orf34	0.39	8.1	0.41	1.04e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.76	-14.73	-0.63	3.36e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.46	-6.73	-0.35	7.2e-11	Menarche (age at onset);
LUSC	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg12435725	chr3:58293450	RPP14	-0.72	-7.38	-0.37	1.3e-12	Cholesterol, total;
LUSC	cis	rs72627509	0.951	rs17087335	chr4:57838583	G/T	cg26694713	chr4:57773883	REST	0.49	5.75	0.3	2.04e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg01657329	chr11:68192670	LRP5	-0.44	-6.59	-0.34	1.67e-10	Total body bone mineral density;
LUSC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg06784218	chr1:46089804	CCDC17	0.54	11.06	0.52	1.88e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4478858	0.684	rs17440445	chr1:31722562	C/T	cg00250761	chr1:31883323	NA	0.35	8.41	0.42	1.17e-15	Alcohol dependence;
LUSC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg17554472	chr22:41940697	POLR3H	-0.46	-5.77	-0.3	1.84e-8	Vitiligo;
LUSC	trans	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg25214090	chr10:38739885	LOC399744	-0.41	-6.28	-0.32	1.03e-9	Corneal astigmatism;
LUSC	cis	rs2901656	0.934	rs2285176	chr1:172421744	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.29	5.78	0.3	1.75e-8	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg10360139	chr7:1886902	MAD1L1	-0.45	-7.01	-0.36	1.36e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4363385	0.818	rs3806223	chr1:153002646	T/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.9	-0.4	4e-14	Inflammatory skin disease;
LUSC	trans	rs656319	0.580	rs17690549	chr8:9998538	C/G	cg21775007	chr8:11205619	TDH	-0.47	-6.55	-0.34	2.18e-10	Myopia (pathological);
LUSC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	1.03	17.91	0.7	9.02e-51	Parkinson's disease;
LUSC	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.18	-0.32	1.82e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.2	0.61	3.82e-36	Platelet count;
LUSC	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17467752	chr17:38218738	THRA	-0.71	-11.39	-0.53	1.31e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg26897989	chr16:1907736	C16orf73	-0.41	-6.44	-0.33	4.06e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg15212455	chr7:39170539	POU6F2	0.62	9.94	0.48	1.4e-20	IgG glycosylation;
LUSC	trans	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg03929089	chr4:120376271	NA	-0.65	-6.08	-0.32	3.25e-9	Axial length;
LUSC	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-9.87	-0.48	2.59e-20	Blood metabolite levels;
LUSC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.9	14.54	0.62	1.85e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg18357645	chr12:58087776	OS9	0.55	8.34	0.42	1.95e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg04450456	chr4:17643702	FAM184B	0.36	6.13	0.32	2.54e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs75804782	0.572	rs72982580	chr2:239447783	A/G	cg18131467	chr2:239335373	ASB1	-0.65	-6.01	-0.31	4.81e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.39	5.65	0.3	3.46e-8	Lung cancer;
LUSC	cis	rs977987	0.835	rs3851733	chr16:75370263	G/C	cg04384234	chr16:75411784	CFDP1	-0.45	-7.4	-0.38	1.14e-12	Dupuytren's disease;
LUSC	trans	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg24644049	chr4:85504048	CDS1	0.71	7.2	0.37	3.99e-12	Skin colour saturation;
LUSC	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg19628046	chr18:33552617	C18orf21	0.52	6.26	0.32	1.17e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg06713675	chr4:122721982	EXOSC9	-0.7	-12.04	-0.55	5.88e-28	Type 2 diabetes;
LUSC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06544989	chr22:39130855	UNC84B	0.33	5.67	0.3	3.02e-8	Menopause (age at onset);
LUSC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg05623727	chr3:50126028	RBM5	-0.33	-6.16	-0.32	2.08e-9	Body mass index;
LUSC	cis	rs4843185	0.576	rs380996	chr16:85728813	A/G	cg00168118	chr16:85669675	KIAA0182	-0.4	-6.54	-0.34	2.26e-10	Platelet distribution width;
LUSC	cis	rs7178375	0.607	rs34178381	chr15:31222585	G/C	cg03767031	chr15:31195708	MTMR15	0.79	6.41	0.33	5.05e-10	Hypertriglyceridemia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12509435	chr12:94853886	CCDC41;LOC144486	-0.4	-6.41	-0.33	4.94e-10	Electrocardiographic conduction measures;
LUSC	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg08668510	chr10:1095578	IDI1	-0.77	-6.96	-0.36	1.85e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06850241	chr22:41845214	NA	0.33	6.15	0.32	2.25e-9	Vitiligo;
LUSC	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg04586622	chr2:25135609	ADCY3	0.42	8.98	0.44	1.97e-17	Body mass index;
LUSC	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg21385522	chr1:16154831	NA	-0.56	-8.67	-0.43	1.95e-16	Systolic blood pressure;
LUSC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg17971929	chr21:40555470	PSMG1	-0.61	-9.93	-0.48	1.58e-20	Cognitive function;
LUSC	cis	rs7166081	0.688	rs12903168	chr15:67680209	T/C	cg05925327	chr15:68127851	NA	-0.36	-5.82	-0.3	1.41e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg26669825	chr2:232063251	ARMC9	0.4	5.94	0.31	7.04e-9	N-glycan levels;
LUSC	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	0.79	11.03	0.52	2.44e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.39	-0.49	4.23e-22	Electroencephalogram traits;
LUSC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.78	-0.35	5.51e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.37	-0.33	6.35e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-7.99	-0.4	2.25e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg16339924	chr4:17578868	LAP3	-0.57	-8.34	-0.42	2.02e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg05299278	chr17:33885742	SLFN14	0.31	6.29	0.33	9.88e-10	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg03806693	chr22:41940476	POLR3H	1.0	14.41	0.62	6.27e-37	Vitiligo;
LUSC	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg21918786	chr6:109611834	NA	-0.35	-5.9	-0.31	9.12e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs13315871	0.929	rs11720747	chr3:58267833	G/A	cg20936604	chr3:58311152	NA	-0.76	-6.86	-0.35	3.4e-11	Cholesterol, total;
LUSC	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg21095983	chr6:86352623	SYNCRIP	0.49	7.78	0.39	9.04e-14	Smooth-surface caries;
LUSC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg14541582	chr5:601475	NA	-0.38	-5.93	-0.31	7.36e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7264396	0.887	rs6060438	chr20:34077403	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.16	-0.32	2.12e-9	Total cholesterol levels;
LUSC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.94	0.36	2.01e-11	Tonsillectomy;
LUSC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg05896524	chr21:47604654	C21orf56	0.4	5.88	0.31	9.78e-9	Testicular germ cell tumor;
LUSC	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg19682013	chr15:45996608	NA	0.39	5.84	0.3	1.24e-8	Waist circumference;Weight;
LUSC	trans	rs156356	0.811	rs552067	chr20:1823326	C/G	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	0.39	6.04	0.31	4.22e-9	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs7980799	0.649	rs2389218	chr12:33680929	C/A	cg13010199	chr12:38710504	ALG10B	0.43	6.18	0.32	1.91e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg01475377	chr6:109611718	NA	-0.4	-6.92	-0.35	2.34e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg06784218	chr1:46089804	CCDC17	-0.57	-11.34	-0.53	1.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg22961513	chr11:14280813	SPON1	-0.35	-6.04	-0.31	4.03e-9	Mitochondrial DNA levels;
LUSC	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.64	-0.47	1.44e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7043114	0.525	rs6479416	chr9:95053871	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.46	-0.33	3.63e-10	Height;
LUSC	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg19812747	chr11:111475976	SIK2	-0.55	-8.15	-0.41	7.59e-15	Primary sclerosing cholangitis;
LUSC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg02428538	chr16:24856791	SLC5A11	-0.56	-6.27	-0.32	1.12e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.09	-0.32	3.05e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.6	-0.43	3.22e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	7.01	0.36	1.35e-11	Personality dimensions;
LUSC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.18	-0.37	4.67e-12	Schizophrenia;
LUSC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg13319975	chr6:146136371	FBXO30	0.51	7.75	0.39	1.15e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27103680	chr2:86423081	IMMT	0.42	6.14	0.32	2.39e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg25767906	chr1:53392781	SCP2	-0.51	-9.21	-0.45	3.7e-18	Monocyte count;
LUSC	cis	rs1564271	0.528	rs2489589	chr10:26983095	A/G	cg13837822	chr10:26931731	LOC731789	0.45	9.72	0.47	7.77e-20	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUSC	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs11997175	0.967	rs60586868	chr8:33776585	A/G	ch.8.33884649F	chr8:33765107	NA	0.5	7.82	0.39	7.15e-14	Body mass index;
LUSC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.38	-0.33	5.87e-10	Lung cancer;
LUSC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg08975724	chr8:8085496	FLJ10661	0.46	6.77	0.35	5.67e-11	Mood instability;
LUSC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.24	0.41	3.92e-15	Prudent dietary pattern;
LUSC	cis	rs55665837	1.000	rs12295888	chr11:14450531	T/C	cg19336497	chr11:14380999	RRAS2	-0.37	-7.53	-0.38	4.9e-13	Vitamin D levels;
LUSC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg01802117	chr1:53393560	SCP2	-0.38	-6.42	-0.33	4.81e-10	Monocyte count;
LUSC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.89	-0.4	4.42e-14	Joint mobility (Beighton score);
LUSC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg02569458	chr12:86230093	RASSF9	0.59	9.95	0.48	1.36e-20	Major depressive disorder;
LUSC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg13607699	chr17:42295918	UBTF	0.49	7.63	0.39	2.41e-13	Total body bone mineral density;
LUSC	trans	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg26043149	chr18:55253948	FECH	-0.45	-6.91	-0.35	2.52e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	0.95	19.28	0.73	3.26e-56	Cognitive function;
LUSC	cis	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2729354	0.953	rs2848625	chr11:57330650	G/C	cg24343310	chr11:57249947	NA	0.37	6.65	0.34	1.17e-10	Blood protein levels;
LUSC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-12.0	-0.55	7.85e-28	Chronic sinus infection;
LUSC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg21475434	chr5:93447410	FAM172A	0.82	10.15	0.49	2.79e-21	Diabetic retinopathy;
LUSC	cis	rs3812762	0.879	rs4929934	chr11:8777789	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.38	6.65	0.34	1.17e-10	Hypospadias;
LUSC	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg27427491	chr17:78079615	GAA	0.35	6.4	0.33	5.15e-10	Yeast infection;
LUSC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.79	-0.51	1.67e-23	Chronic sinus infection;
LUSC	cis	rs7255045	0.788	rs4804737	chr19:12947938	C/T	cg21491176	chr19:12958399	MAST1	0.33	5.81	0.3	1.44e-8	Mean corpuscular volume;
LUSC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg00376283	chr12:123451042	ABCB9	0.68	9.69	0.47	9.85e-20	Height;Educational attainment;Head circumference (infant);
LUSC	trans	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.41	-5.99	-0.31	5.45e-9	Platelet distribution width;
LUSC	cis	rs3772130	0.923	rs13434284	chr3:121482842	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.13	0.48	3.38e-21	Cognitive performance;
LUSC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg12641515	chr19:46296257	DMWD	0.48	7.11	0.36	7.23e-12	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05274755	chr14:33408401	NPAS3	0.55	7.9	0.4	3.95e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg07148914	chr20:33460835	GGT7	0.53	8.16	0.41	7.08e-15	Height;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21376831	chr17:40428526	STAT5B	-0.55	-6.59	-0.34	1.76e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg23758822	chr17:41437982	NA	-1.03	-20.67	-0.75	1.02e-61	Menopause (age at onset);
LUSC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg23590916	chr17:43697445	MGC57346	0.68	8.79	0.43	8.21e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs9693857	0.553	rs10100760	chr8:9370559	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.19	-0.32	1.72e-9	Systolic blood pressure;
LUSC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg02782426	chr3:40428986	ENTPD3	0.38	6.97	0.36	1.7e-11	Renal cell carcinoma;
LUSC	trans	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg02800362	chr5:177631904	HNRNPAB	0.88	13.05	0.58	9.85e-32	Obesity-related traits;
LUSC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg05313129	chr8:58192883	C8orf71	-0.5	-5.87	-0.31	1.05e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19717773	chr7:2847554	GNA12	-0.36	-5.78	-0.3	1.7e-8	Height;
LUSC	cis	rs997295	0.638	rs11854197	chr15:67977384	A/G	cg08079166	chr15:68083412	MAP2K5	-0.33	-6.56	-0.34	2.06e-10	Motion sickness;
LUSC	cis	rs2797160	0.967	rs28629380	chr6:126004197	A/G	cg05901451	chr6:126070800	HEY2	-0.55	-8.05	-0.4	1.5e-14	Endometrial cancer;
LUSC	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg07169764	chr2:136633963	MCM6	1.18	17.44	0.69	6.88e-49	Corneal structure;
LUSC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs7539409	0.651	rs979757	chr1:84296605	T/C	cg10977910	chr1:84465055	TTLL7	0.71	7.54	0.38	4.45e-13	Alzheimer's disease;
LUSC	cis	rs977987	0.806	rs4887823	chr16:75433074	T/A	cg03315344	chr16:75512273	CHST6	0.48	9.12	0.45	7.13e-18	Dupuytren's disease;
LUSC	cis	rs778371	0.722	rs1996342	chr2:233805499	A/G	cg08000102	chr2:233561755	GIGYF2	0.51	7.07	0.36	9.3e-12	Schizophrenia;
LUSC	cis	rs7818345	0.967	rs6999786	chr8:19277817	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.19	0.37	4.23e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	trans	rs225245	0.755	rs226441	chr17:34033072	C/T	cg19694781	chr19:47549865	TMEM160	-0.38	-6.09	-0.32	3.13e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg08601574	chr20:25228251	PYGB	-0.43	-6.59	-0.34	1.71e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg23950597	chr19:37808831	NA	-0.63	-7.8	-0.39	8.08e-14	Coronary artery calcification;
LUSC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg16743903	chr16:89593216	SPG7	-0.38	-5.97	-0.31	5.97e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-0.79	-9.59	-0.46	2.13e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs3857536	0.741	rs9363556	chr6:66934399	T/C	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-9.34	-0.45	1.44e-18	Monocyte percentage of white cells;
LUSC	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.62	9.89	0.48	2.09e-20	Blood metabolite ratios;
LUSC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.95	0.31	6.7e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg16339924	chr4:17578868	LAP3	-0.51	-7.35	-0.37	1.58e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg19812747	chr11:111475976	SIK2	-0.53	-7.42	-0.38	9.6e-13	Primary sclerosing cholangitis;
LUSC	trans	rs17039065	1.000	rs72889383	chr4:109391962	C/T	cg07444054	chr2:108107501	NA	0.43	6.3	0.33	9.24e-10	Gut microbiome composition (summer);
LUSC	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg15485101	chr11:133734466	NA	0.4	7.24	0.37	3.03e-12	Childhood ear infection;
LUSC	trans	rs2490361	1.000	rs2485595	chr1:237326756	G/A	cg15653282	chr18:11689218	GNAL	0.39	6.07	0.32	3.55e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg10434728	chr15:90938212	IQGAP1	-0.44	-8.84	-0.44	5.4e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.89	15.05	0.64	2.03e-39	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs73198271	0.515	rs76224322	chr8:8635841	C/G	cg01851573	chr8:8652454	MFHAS1	0.58	6.53	0.34	2.49e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs721399	0.539	rs2410561	chr8:18266774	G/A	cg18736775	chr8:18248649	NAT2	-0.6	-7.09	-0.36	7.9e-12	Blood metabolite levels;
LUSC	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg22189786	chr22:42395067	WBP2NL	0.43	5.75	0.3	2.06e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg12011299	chr4:100065546	ADH4	-0.72	-10.43	-0.5	3.12e-22	Alcohol dependence;
LUSC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg04546413	chr19:29218101	NA	0.71	11.42	0.53	1.03e-25	Methadone dose in opioid dependence;
LUSC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.45	-5.88	-0.31	9.79e-9	Blood protein levels;
LUSC	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.95	0.36	1.88e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg14092988	chr3:52407081	DNAH1	0.31	5.96	0.31	6.35e-9	Bipolar disorder;
LUSC	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg05784532	chr1:230284198	GALNT2	0.54	8.04	0.4	1.57e-14	Coronary artery disease;
LUSC	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg01966878	chr4:90757139	SNCA	-0.36	-6.22	-0.32	1.52e-9	Dementia with Lewy bodies;
LUSC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg14784868	chr12:69753453	YEATS4	0.63	9.25	0.45	2.82e-18	Blood protein levels;
LUSC	cis	rs12618769	0.597	rs12619665	chr2:99126551	A/T	cg10123293	chr2:99228465	UNC50	0.43	6.94	0.35	2.08e-11	Bipolar disorder;
LUSC	cis	rs617219	0.746	rs2591391	chr5:78546455	T/A	cg24856658	chr5:78533917	JMY	-0.3	-5.84	-0.3	1.24e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22433210	chr17:43662623	NA	0.75	10.95	0.51	4.87e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25072359	chr17:41440525	NA	0.64	9.02	0.44	1.51e-17	Menopause (age at onset);
LUSC	cis	rs35883536	0.584	rs56112014	chr1:101037431	A/G	cg06223162	chr1:101003688	GPR88	-0.46	-8.56	-0.42	4.21e-16	Monocyte count;
LUSC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg13642260	chr9:130955380	CIZ1	-0.57	-9.34	-0.46	1.35e-18	Attention deficit hyperactivity disorder;
LUSC	cis	rs1185460	0.967	rs11217137	chr11:118931030	A/G	cg23280166	chr11:118938394	VPS11	0.45	6.78	0.35	5.39e-11	Coronary artery disease;
LUSC	cis	rs57920188	0.513	rs4290031	chr1:4094701	A/G	cg20703997	chr1:4087676	NA	0.56	7.97	0.4	2.62e-14	Interleukin-17 levels;
LUSC	trans	rs2201841	0.529	rs1532502	chr1:67737650	G/A	cg16262963	chr14:104851903	NA	-0.23	-5.97	-0.31	6.09e-9	Ulcerative colitis;Psoriasis;Crohn's disease;
LUSC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	0.85	14.66	0.63	6.35e-38	Tonsillectomy;
LUSC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06656553	chr16:89960601	TCF25	-0.65	-5.7	-0.3	2.62e-8	Skin colour saturation;
LUSC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg09021430	chr5:549028	NA	-0.55	-7.57	-0.38	3.64e-13	Obesity-related traits;
LUSC	cis	rs62400317	0.859	rs10456542	chr6:45107579	G/A	cg18551225	chr6:44695536	NA	-0.43	-6.98	-0.36	1.63e-11	Total body bone mineral density;
LUSC	trans	rs783147	0.500	rs4252126	chr6:161152294	A/G	cg15416064	chr12:49209402	NA	-0.42	-6.12	-0.32	2.6e-9	Lp (a) levels;
LUSC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.55	-0.53	3.41e-26	Alzheimer's disease;
LUSC	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.56	0.38	3.9e-13	Iron status biomarkers;
LUSC	cis	rs7561273	0.545	rs12613951	chr2:24361962	G/A	cg08063864	chr2:24346004	PFN4;LOC375190	-0.42	-5.82	-0.3	1.39e-8	Quantitative traits;
LUSC	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg23711669	chr6:146136114	FBXO30	0.86	15.6	0.65	1.31e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs427941	0.703	rs201450	chr7:101739441	A/T	cg06246474	chr7:101738831	CUX1	-0.41	-6.8	-0.35	4.87e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.89	-0.44	3.79e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05901451	chr6:126070800	HEY2	0.57	8.54	0.42	4.71e-16	Endometrial cancer;
LUSC	cis	rs240764	0.717	rs151640	chr6:101111521	A/C	cg09795085	chr6:101329169	ASCC3	0.41	5.97	0.31	6.12e-9	Neuroticism;
LUSC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg00012203	chr2:219082015	ARPC2	-0.7	-11.57	-0.53	2.97e-26	Colorectal cancer;
LUSC	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg01557791	chr16:72042693	DHODH	-0.54	-7.83	-0.39	6.58e-14	Fibrinogen levels;
LUSC	cis	rs4961252	0.505	rs6990155	chr8:142098977	C/T	cg13924514	chr8:142070760	NA	0.34	5.83	0.3	1.29e-8	Isovolumetric relaxation time;Response to interferon beta therapy;
LUSC	trans	rs7178375	1.000	rs7169064	chr15:31210862	C/T	cg04373760	chr16:53404718	NA	0.64	8.63	0.43	2.52e-16	Hypertriglyceridemia;
LUSC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg06637938	chr14:75390232	RPS6KL1	0.52	8.33	0.41	2.07e-15	Height;
LUSC	cis	rs2820315	1.000	rs903678	chr1:201809918	G/A	cg10061532	chr1:201886748	LMOD1	0.26	5.93	0.31	7.44e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	6.76	0.35	6.02e-11	Height;
LUSC	cis	rs858239	0.632	rs13438452	chr7:23174182	A/G	cg23682824	chr7:23144976	KLHL7	0.4	5.89	0.31	9.46e-9	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	12.54	0.57	7.93e-30	Personality dimensions;
LUSC	cis	rs36051895	0.664	rs11793659	chr9:5109707	A/G	cg02405213	chr9:5042618	JAK2	-0.57	-8.48	-0.42	7.47e-16	Pediatric autoimmune diseases;
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg01238044	chr22:24384105	GSTT1	-0.48	-6.7	-0.34	9.06e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9807989	0.507	rs4851577	chr2:103028921	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.14e-12	Asthma;
LUSC	cis	rs8017423	0.866	rs10184	chr14:90744672	G/A	cg04374321	chr14:90722782	PSMC1	-0.68	-10.08	-0.48	4.79e-21	Mortality in heart failure;
LUSC	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg18129178	chr5:148520854	ABLIM3	-0.67	-10.77	-0.51	2.07e-23	Breast cancer;
LUSC	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.6	-0.43	3.09e-16	Axial length;
LUSC	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	9.73	0.47	7.58e-20	Lung cancer in ever smokers;
LUSC	cis	rs977987	0.806	rs11643410	chr16:75428306	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.01	-0.36	1.34e-11	Dupuytren's disease;
LUSC	cis	rs977987	0.806	rs1030262	chr16:75491327	C/A	cg04384234	chr16:75411784	CFDP1	-0.42	-6.95	-0.36	1.87e-11	Dupuytren's disease;
LUSC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg11752832	chr7:134001865	SLC35B4	0.59	9.29	0.45	2.08e-18	Mean platelet volume;
LUSC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg03948781	chr1:205179583	DSTYK	0.32	6.22	0.32	1.49e-9	Red blood cell count;
LUSC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.49	-0.73	4.84e-57	Height;
LUSC	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg13798780	chr7:105162888	PUS7	0.61	6.55	0.34	2.14e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg21427119	chr20:30132790	HM13	-0.42	-6.35	-0.33	6.96e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg25237894	chr2:233734115	C2orf82	0.35	6.5	0.33	3.01e-10	Coronary artery disease;
LUSC	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg16339924	chr4:17578868	LAP3	0.49	7.53	0.38	4.83e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.53	-0.38	4.64e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs738322	0.646	rs132972	chr22:38562056	T/C	cg17652424	chr22:38574118	PLA2G6	-0.3	-6.52	-0.34	2.66e-10	Cutaneous nevi;
LUSC	trans	rs9380880	0.826	rs12198307	chr6:39550197	C/T	cg14673904	chr12:46609063	SLC38A1	0.54	5.99	0.31	5.41e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg02475777	chr4:1388615	CRIPAK	0.39	5.91	0.31	8.3e-9	Obesity-related traits;
LUSC	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg01733217	chr16:74700730	RFWD3	0.76	12.27	0.56	8.26e-29	Testicular germ cell tumor;
LUSC	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.54	0.38	4.44e-13	Menarche (age at onset);
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg01238044	chr22:24384105	GSTT1	-0.51	-7.46	-0.38	7.42e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg05527609	chr1:210001259	C1orf107	-0.63	-9.19	-0.45	4.27e-18	Orofacial clefts;
LUSC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.66	15.12	0.64	1.07e-39	Hemoglobin concentration;
LUSC	cis	rs4930561	0.765	rs4930229	chr11:67944080	G/A	cg16338278	chr11:67432957	ALDH3B2	0.37	6.22	0.32	1.49e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg17054900	chr3:154042577	DHX36	0.44	5.91	0.31	8.36e-9	Coronary artery disease;
LUSC	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg00376283	chr12:123451042	ABCB9	0.66	8.32	0.41	2.27e-15	Neutrophil percentage of white cells;
LUSC	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg16989719	chr2:238392110	NA	-0.41	-7.25	-0.37	3e-12	Prostate cancer;
LUSC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg07169764	chr2:136633963	MCM6	-0.61	-8.02	-0.4	1.81e-14	Mosquito bite size;
LUSC	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg26816564	chr1:7831052	VAMP3	0.71	9.66	0.47	1.23e-19	Inflammatory bowel disease;
LUSC	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg18683606	chr7:100471612	SRRT	0.46	6.12	0.32	2.56e-9	Resting heart rate;
LUSC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg01879757	chr17:41196368	BRCA1	-0.47	-7.1	-0.36	7.7e-12	Menopause (age at onset);
LUSC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg13628971	chr7:2884303	GNA12	0.47	6.69	0.34	9.34e-11	Height;
LUSC	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg14092571	chr14:90743983	NA	0.35	5.71	0.3	2.5e-8	Mortality in heart failure;
LUSC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.95	-0.51	4.95e-24	Aortic root size;
LUSC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg08859206	chr1:53392774	SCP2	0.47	7.82	0.39	6.77e-14	Monocyte count;
LUSC	cis	rs9905704	0.918	rs302867	chr17:56752819	C/T	cg12560992	chr17:57184187	TRIM37	-0.52	-7.46	-0.38	7.5e-13	Testicular germ cell tumor;
LUSC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.66	11.23	0.52	4.95e-25	Cognitive function;
LUSC	cis	rs7572644	0.699	rs2337374	chr2:28200152	G/A	cg27432699	chr2:27873401	GPN1	-0.51	-6.99	-0.36	1.52e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	0.97	13.33	0.59	8.34e-33	Exhaled nitric oxide output;
LUSC	cis	rs3768617	0.706	rs9943067	chr1:182975102	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	8.45	0.42	9.21e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.68	10.47	0.5	2.3e-22	Lymphocyte counts;
LUSC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-7.45	-0.38	8e-13	Personality dimensions;
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.4	-0.38	1.12e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg20276088	chr3:133502917	NA	-0.44	-6.42	-0.33	4.57e-10	Iron status biomarkers;
LUSC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg06219351	chr7:158114137	PTPRN2	-0.52	-9.55	-0.46	2.92e-19	Calcium levels;
LUSC	cis	rs11585357	0.709	rs735281	chr1:17616194	T/C	cg08277548	chr1:17600880	PADI3	0.61	6.66	0.34	1.1e-10	Hair shape;
LUSC	cis	rs17030434	1.000	rs1456391	chr4:154720485	A/G	cg14289246	chr4:154710475	SFRP2	-0.52	-6.78	-0.35	5.3e-11	Electrocardiographic conduction measures;
LUSC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg04414720	chr1:150670196	GOLPH3L	0.57	9.22	0.45	3.31e-18	Tonsillectomy;
LUSC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg04025307	chr7:1156635	C7orf50	0.44	6.85	0.35	3.52e-11	Longevity;Endometriosis;
LUSC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	0.82	13.37	0.59	6.03e-33	Menopause (age at onset);
LUSC	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07160044	chr13:24735301	SPATA13;MIR2276	-0.47	-6.09	-0.32	3.09e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg27068330	chr11:65405492	SIPA1	-0.76	-10.88	-0.51	8.57e-24	Acne (severe);
LUSC	trans	rs13390641	0.614	rs72930600	chr2:104067482	A/G	cg03260781	chr1:16346299	HSPB7	-0.49	-6.3	-0.33	9.52e-10	Blood pressure;Blood pressure (anthropometric measures interaction);
LUSC	cis	rs1178968	0.901	rs1178958	chr7:72777384	G/A	cg25889504	chr7:72793014	NA	0.6	7.77	0.39	9.92e-14	Triglyceride levels;
LUSC	cis	rs7589342	0.831	rs11124062	chr2:106455967	G/A	cg16077055	chr2:106428750	NCK2	0.37	6.92	0.35	2.25e-11	Addiction;
LUSC	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-8.98	-0.44	2.06e-17	Eye color traits;
LUSC	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	8.98	0.44	2.08e-17	Response to bleomycin (chromatid breaks);
LUSC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg06108461	chr20:60628389	TAF4	0.61	7.84	0.39	6.14e-14	Obesity-related traits;
LUSC	trans	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg10756647	chr7:56101905	PSPH	0.88	8.91	0.44	3.39e-17	Diabetic kidney disease;
LUSC	cis	rs7712401	0.562	rs30053	chr5:122303643	C/G	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	trans	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg02113368	chr10:135107346	TUBGCP2	-0.34	-6.01	-0.31	4.92e-9	Dementia with Lewy bodies;
LUSC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg05425664	chr17:57184151	TRIM37	0.55	8.57	0.42	3.81e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg09509183	chr1:209979624	IRF6	0.5	5.71	0.3	2.55e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs2637266	0.783	rs846627	chr10:78539556	A/G	cg18941641	chr10:78392320	NA	0.37	6.63	0.34	1.33e-10	Pulmonary function;
LUSC	cis	rs4363385	0.818	rs370162	chr1:153005488	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.43e-12	Inflammatory skin disease;
LUSC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.08	-0.55	3.93e-28	Type 2 diabetes;
LUSC	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg04362960	chr10:104952993	NT5C2	0.58	9.18	0.45	4.58e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg04586622	chr2:25135609	ADCY3	0.32	6.14	0.32	2.4e-9	Body mass index;
LUSC	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg18753928	chr3:113234510	CCDC52	-0.52	-8.01	-0.4	1.99e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-6.57	-0.34	1.98e-10	Waist circumference;Hip circumference;
LUSC	cis	rs834811	0.871	rs834819	chr7:135895281	G/A	cg01726295	chr7:135938950	NA	0.36	6.24	0.32	1.31e-9	Post-traumatic stress disorder;
LUSC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg24813613	chr7:1882135	MAD1L1	-0.42	-7.15	-0.36	5.5e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg17517138	chr11:73019481	ARHGEF17	1.02	8.59	0.43	3.43e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.51	7.33	0.37	1.78e-12	Coronary heart disease;
LUSC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg21361702	chr7:150065534	REPIN1	0.5	6.5	0.34	2.92e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1950626	0.833	rs35436326	chr14:101396148	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.33	0.37	1.77e-12	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs9296095	0.948	rs75080135	chr6:33552707	A/C	cg14003231	chr6:33640908	ITPR3	0.48	7.1	0.36	7.7e-12	Platelet count;
LUSC	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg12935359	chr14:103987150	CKB	0.66	10.71	0.51	3.27e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg17385448	chr1:15911702	AGMAT	0.34	5.69	0.3	2.79e-8	Systolic blood pressure;
LUSC	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg23752985	chr2:85803571	VAMP8	0.37	8.0	0.4	2.03e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg05622550	chr15:74315474	PML	-0.39	-5.94	-0.31	6.97e-9	N-glycan levels;
LUSC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg24675658	chr1:53192096	ZYG11B	0.6	9.33	0.45	1.51e-18	Monocyte count;
LUSC	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg10483660	chr13:112241077	NA	-0.31	-5.68	-0.3	2.99e-8	Hepatitis;
LUSC	cis	rs6580649	0.783	rs7969749	chr12:48550755	C/T	cg24011408	chr12:48396354	COL2A1	0.46	6.3	0.33	9.31e-10	Lung cancer;
LUSC	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg18827107	chr12:86230957	RASSF9	-0.39	-5.79	-0.3	1.67e-8	Major depressive disorder;
LUSC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg14440974	chr22:39074834	NA	0.36	6.16	0.32	2.11e-9	Menopause (age at onset);
LUSC	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.71	-12.39	-0.56	2.99e-29	White blood cell count (basophil);
LUSC	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22516733	chr7:2281617	NUDT1;FTSJ2	-0.39	-5.96	-0.31	6.33e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg01802117	chr1:53393560	SCP2	-0.41	-6.83	-0.35	4.01e-11	Monocyte count;
LUSC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.35	0.53	1.79e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg08847533	chr14:75593920	NEK9	0.8	13.95	0.61	3.72e-35	Height;
LUSC	cis	rs66731853	0.769	rs476582	chr1:20894450	A/G	cg04087271	chr1:20915334	CDA	-0.52	-8.62	-0.43	2.77e-16	Mean corpuscular volume;
LUSC	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg02569458	chr12:86230093	RASSF9	0.48	7.64	0.39	2.37e-13	Major depressive disorder;
LUSC	trans	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.28e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08219700	chr8:58056026	NA	0.64	8.51	0.42	5.97e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg22143856	chr6:28129313	ZNF389	0.41	5.68	0.3	2.98e-8	Parkinson's disease;
LUSC	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.78	13.25	0.59	1.72e-32	Metabolic syndrome;
LUSC	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg15962314	chr1:44399869	ARTN	0.31	6.95	0.36	1.95e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-8.28	-0.41	2.93e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7106204	0.800	rs7120940	chr11:24236485	C/A	ch.11.24196551F	chr11:24239977	NA	1.14	14.25	0.61	2.52e-36	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-7.59	-0.38	3.23e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7760535	0.811	rs455732	chr6:111695268	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Metabolic traits;
LUSC	cis	rs7408868	0.706	rs2238642	chr19:15282237	T/C	cg14696996	chr19:15285081	NOTCH3	0.82	8.3	0.41	2.59e-15	Pulse pressure;
LUSC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg14196790	chr5:131705035	SLC22A5	-0.36	-5.95	-0.31	6.83e-9	Blood metabolite levels;
LUSC	trans	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg01475377	chr6:109611718	NA	0.36	6.46	0.33	3.77e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg08645402	chr16:4508243	NA	0.52	8.24	0.41	4.07e-15	Schizophrenia;
LUSC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05776053	chr2:74358815	NA	0.45	7.19	0.37	4.38e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg06363034	chr20:62225388	GMEB2	-0.46	-7.7	-0.39	1.51e-13	Glioblastoma;
LUSC	cis	rs2835872	0.828	rs2835839	chr21:38991034	A/G	cg20424643	chr21:39039972	KCNJ6	0.43	6.63	0.34	1.39e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg07937631	chr13:79184529	NA	-0.42	-6.85	-0.35	3.5e-11	Large artery stroke;
LUSC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg00750074	chr16:89608354	SPG7	0.45	7.83	0.39	6.69e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg14634687	chr17:47094252	IGF2BP1	0.31	6.61	0.34	1.55e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs4842666	0.850	rs11105328	chr12:89942390	A/G	cg00757033	chr12:89920650	WDR51B	0.46	6.57	0.34	1.94e-10	Blood pressure;
LUSC	trans	rs8020912	0.504	rs3759577	chr14:103850963	C/T	cg17675199	chr6:35436792	RPL10A	-0.47	-6.1	-0.32	3.01e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11264799	0.603	rs12731814	chr1:157585917	G/A	cg18268488	chr1:157545234	FCRL4	0.35	6.51	0.34	2.82e-10	IgA nephropathy;
LUSC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.4	-5.73	-0.3	2.2e-8	Tonsillectomy;
LUSC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg01475377	chr6:109611718	NA	-0.41	-7.33	-0.37	1.75e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg06784218	chr1:46089804	CCDC17	-0.47	-9.06	-0.44	1.09e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.81	0.54	3.97e-27	Cognitive ability;
LUSC	cis	rs7795096	0.743	rs9648729	chr7:151537759	G/C	cg17008978	chr7:151542804	PRKAG2	0.34	6.53	0.34	2.44e-10	Bipolar disorder (age of onset and psychotic symptoms);
LUSC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg07061783	chr6:25882402	NA	0.43	6.06	0.31	3.6e-9	Blood metabolite levels;
LUSC	cis	rs7572644	0.640	rs4666022	chr2:28057823	T/C	cg27432699	chr2:27873401	GPN1	0.51	6.96	0.36	1.78e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	12.56	0.57	6.5e-30	Cognitive test performance;
LUSC	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg13390004	chr1:15929781	NA	0.42	6.93	0.35	2.17e-11	Systolic blood pressure;
LUSC	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg05519781	chr21:40033154	ERG	0.77	13.3	0.59	1.09e-32	Coronary artery disease;
LUSC	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg27411982	chr8:10470053	RP1L1	0.41	6.32	0.33	8.46e-10	Neuroticism;
LUSC	cis	rs3820928	0.874	rs3752895	chr2:227886773	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.97	-0.4	2.46e-14	Pulmonary function;
LUSC	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg24342717	chr2:85555507	TGOLN2	-0.74	-12.28	-0.56	7.19e-29	Ear protrusion;
LUSC	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg03465714	chr1:152285911	FLG	-0.42	-5.88	-0.31	9.75e-9	Atopic dermatitis;
LUSC	cis	rs2067615	0.524	rs4964187	chr12:107080313	C/A	cg15890332	chr12:107067104	RFX4	0.35	6.13	0.32	2.51e-9	Heart rate;
LUSC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg10523860	chr14:103875565	MARK3	-0.37	-5.9	-0.31	9.07e-9	Body mass index;
LUSC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg04414720	chr1:150670196	GOLPH3L	0.57	8.71	0.43	1.44e-16	Melanoma;
LUSC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.71	-9.8	-0.47	4.37e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	0.95	10.39	0.49	4.15e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg08975724	chr8:8085496	FLJ10661	0.43	6.2	0.32	1.67e-9	Retinal vascular caliber;
LUSC	trans	rs1325195	0.920	rs2636274	chr1:179106899	A/G	cg11624085	chr17:8464688	MYH10	0.44	7.3	0.37	2.14e-12	IgE grass sensitization;
LUSC	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.07	15.32	0.64	1.77e-40	Uric acid levels;
LUSC	cis	rs2857891	0.695	rs2468986	chr11:6986027	G/C	cg04053776	chr11:6947353	ZNF215	0.39	5.78	0.3	1.73e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg05985134	chr18:33552581	C18orf21	0.52	6.97	0.36	1.65e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18357526	chr6:26021779	HIST1H4A	0.4	6.09	0.32	3.02e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg19676328	chr12:49525230	TUBA1B	-0.52	-8.57	-0.42	4.01e-16	Total cholesterol levels;
LUSC	trans	rs11039798	1.000	rs3902927	chr11:48581457	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.51	0.34	2.81e-10	Axial length;
LUSC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.97	-0.68	4.92e-47	Monocyte count;
LUSC	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg24375607	chr4:120327624	NA	0.76	12.19	0.55	1.64e-28	Corneal astigmatism;
LUSC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.67	-16.35	-0.67	1.5e-44	Prostate cancer;
LUSC	cis	rs11828289	0.660	rs17306398	chr11:23192235	G/T	cg20040320	chr11:23191996	NA	0.58	6.07	0.32	3.5e-9	Cancer;
LUSC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.48e-28	Motion sickness;
LUSC	cis	rs950881	0.932	rs72823632	chr2:102931534	C/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.36	0.33	6.7e-10	Allergy;
LUSC	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.59	11.06	0.52	1.95e-24	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs6574644	0.959	rs6574645	chr14:81778768	A/G	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.33	0.49	6.71e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.64	-0.34	1.26e-10	Response to antipsychotic treatment;
LUSC	cis	rs2274273	0.624	rs10146637	chr14:55744810	G/A	cg04306507	chr14:55594613	LGALS3	0.48	9.8	0.47	4.34e-20	Protein biomarker;
LUSC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.49e-34	Aortic root size;
LUSC	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg17127132	chr2:85788382	GGCX	0.43	6.23	0.32	1.39e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	8.26	0.41	3.52e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg25214090	chr10:38739885	LOC399744	0.45	6.6	0.34	1.61e-10	Corneal astigmatism;
LUSC	cis	rs9788721	0.868	rs17486278	chr15:78867482	A/C	cg06917634	chr15:78832804	PSMA4	-0.42	-5.81	-0.3	1.43e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg12560992	chr17:57184187	TRIM37	-0.85	-15.42	-0.64	6.9e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.72	-9.91	-0.48	1.76e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	7.53	0.38	4.74e-13	Schizophrenia;
LUSC	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.64	-0.34	1.26e-10	Neuroticism;
LUSC	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	10.45	0.5	2.65e-22	Hemoglobin concentration;
LUSC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg01416388	chr22:39784598	NA	-0.43	-7.17	-0.37	4.92e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg17385448	chr1:15911702	AGMAT	0.38	5.91	0.31	8.64e-9	Systolic blood pressure;
LUSC	cis	rs4786125	0.920	rs6500849	chr16:6895246	C/T	cg03623568	chr16:6915990	A2BP1	-0.44	-7.31	-0.37	2.01e-12	Heart rate variability traits (SDNN);
LUSC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg07936489	chr17:37558343	FBXL20	0.7	9.9	0.48	1.99e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs10465746	0.687	rs6576954	chr1:84323701	C/T	cg10977910	chr1:84465055	TTLL7	-0.4	-5.73	-0.3	2.26e-8	Obesity-related traits;
LUSC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg01657329	chr11:68192670	LRP5	-0.49	-7.72	-0.39	1.32e-13	Total body bone mineral density;
LUSC	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg14458575	chr2:238380390	NA	0.68	11.73	0.54	7.35e-27	Prostate cancer;
LUSC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg17911788	chr17:44343683	NA	-0.31	-5.96	-0.31	6.45e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg19592336	chr6:28129416	ZNF389	-0.43	-6.04	-0.31	4.04e-9	Depression;
LUSC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg20283391	chr11:68216788	NA	-0.58	-8.22	-0.41	4.56e-15	Total body bone mineral density;
LUSC	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg13902645	chr11:5959945	NA	-0.61	-8.38	-0.42	1.45e-15	DNA methylation (variation);
LUSC	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.46	-0.38	7.72e-13	Testicular germ cell tumor;
LUSC	cis	rs6435862	0.593	rs34732883	chr2:215674371	C/T	cg04004882	chr2:215674386	BARD1	-0.59	-8.71	-0.43	1.4e-16	Neuroblastoma (high-risk);
LUSC	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.37	-0.42	1.6e-15	Response to antipsychotic treatment;
LUSC	cis	rs936229	0.861	rs3935077	chr15:75120211	C/G	cg10253484	chr15:75165896	SCAMP2	-0.5	-6.56	-0.34	2e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg07393940	chr7:158741817	NA	0.36	6.58	0.34	1.84e-10	Life satisfaction;
LUSC	cis	rs2303282	0.664	rs2550310	chr16:56438110	C/T	cg00500540	chr16:56394104	NA	-0.39	-6.7	-0.34	8.91e-11	Breast cancer;
LUSC	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg06552810	chr11:31128660	NA	-0.42	-7.37	-0.37	1.37e-12	Red blood cell count;
LUSC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	0.88	15.48	0.65	3.97e-41	Cognitive function;
LUSC	trans	rs877282	0.583	rs12356155	chr10:823940	C/T	cg22713356	chr15:30763199	NA	0.78	10.12	0.48	3.54e-21	Uric acid levels;
LUSC	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg27490568	chr2:178487706	NA	-0.41	-5.81	-0.3	1.46e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.32	0.33	8.32e-10	Lung cancer;
LUSC	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.81	-0.39	7.65e-14	Schizophrenia;
LUSC	cis	rs290268	0.874	rs772407	chr9:93560850	A/C	cg02608019	chr9:93564028	SYK	0.55	9.32	0.45	1.58e-18	Platelet count;
LUSC	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg04374321	chr14:90722782	PSMC1	-0.44	-6.63	-0.34	1.34e-10	Mortality in heart failure;
LUSC	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	5.83	0.3	1.34e-8	Breast cancer;
LUSC	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg04362960	chr10:104952993	NT5C2	0.59	9.53	0.46	3.42e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg03929089	chr4:120376271	NA	-0.94	-16.46	-0.67	5.66e-45	Height;
LUSC	cis	rs6496667	0.533	rs2074584	chr15:91009381	C/T	cg22089800	chr15:90895588	ZNF774	0.51	7.35	0.37	1.5e-12	Rheumatoid arthritis;
LUSC	cis	rs9372498	0.536	rs62422224	chr6:118941116	G/A	cg18833306	chr6:118973337	C6orf204	-0.46	-5.74	-0.3	2.14e-8	Diastolic blood pressure;
LUSC	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg22089800	chr15:90895588	ZNF774	0.52	7.43	0.38	9.3e-13	Rheumatoid arthritis;
LUSC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg23262073	chr20:60523788	NA	-0.43	-6.16	-0.32	2.08e-9	Body mass index;
LUSC	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg15556689	chr8:8085844	FLJ10661	0.55	8.12	0.41	9.37e-15	Neuroticism;
LUSC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg25019033	chr10:957182	NA	-0.51	-6.44	-0.33	4.2e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs2224391	1.000	rs2753246	chr6:5261845	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.47	-6.65	-0.34	1.17e-10	Height;
LUSC	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg02023728	chr11:77925099	USP35	0.53	7.53	0.38	4.91e-13	Testicular germ cell tumor;
LUSC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.25	-0.32	1.26e-9	Initial pursuit acceleration;
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg02951883	chr7:2050386	MAD1L1	-0.46	-8.09	-0.4	1.14e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg20701182	chr2:24300061	SF3B14	0.75	7.54	0.38	4.62e-13	Lymphocyte percentage of white cells;
LUSC	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg11019008	chr10:131425282	MGMT	0.39	5.87	0.31	1.06e-8	Response to temozolomide;
LUSC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg06637938	chr14:75390232	RPS6KL1	0.54	8.55	0.42	4.57e-16	Height;
LUSC	cis	rs3101457	0.515	rs4658632	chr1:244516949	G/T	cg09033006	chr1:244517177	C1orf100	-0.44	-6.37	-0.33	6.19e-10	Smoking behavior;
LUSC	cis	rs7665590	1	rs7665590	chr4:99796784	T/C	cg12011299	chr4:100065546	ADH4	-0.36	-5.69	-0.3	2.75e-8	Primary biliary cholangitis;
LUSC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg18850127	chr7:39170497	POU6F2	0.66	10.63	0.5	6.52e-23	IgG glycosylation;
LUSC	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg03060546	chr3:49711283	APEH	0.64	8.35	0.42	1.83e-15	Resting heart rate;
LUSC	cis	rs731174	0.797	rs539585	chr1:38148123	T/G	cg14170840	chr1:38155120	C1orf109	-0.38	-5.97	-0.31	6.21e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg24130564	chr14:104152367	KLC1	0.46	6.55	0.34	2.17e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg04944784	chr2:26401820	FAM59B	-0.72	-10.02	-0.48	7.51e-21	Gut microbiome composition (summer);
LUSC	cis	rs12200782	0.872	rs3757149	chr6:26381316	C/T	cg23155468	chr6:27110703	HIST1H2BK	0.58	5.98	0.31	5.76e-9	Small cell lung carcinoma;
LUSC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg17376030	chr22:41985996	PMM1	-0.48	-6.02	-0.31	4.57e-9	Vitiligo;
LUSC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg26384229	chr12:38710491	ALG10B	-0.55	-8.3	-0.41	2.56e-15	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.36	-0.33	6.53e-10	Neuroticism;
LUSC	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.46	-6.21	-0.32	1.56e-9	IgG glycosylation;
LUSC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg13385521	chr17:29058706	SUZ12P	0.66	6.43	0.33	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs72802342	0.510	rs12932952	chr16:75365486	C/T	cg04384234	chr16:75411784	CFDP1	-0.64	-8.94	-0.44	2.73e-17	Advanced age-related macular degeneration;
LUSC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-10.92	-0.51	5.94e-24	Menarche (age at onset);
LUSC	cis	rs780094	0.500	rs4665382	chr2:27783801	T/C	cg27432699	chr2:27873401	GPN1	0.4	5.65	0.3	3.43e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg01448562	chr3:133502909	NA	-0.66	-10.84	-0.51	1.19e-23	Iron status biomarkers;
LUSC	cis	rs2742234	0.541	rs11238476	chr10:43711436	G/T	cg15436174	chr10:43711423	RASGEF1A	0.44	7.03	0.36	1.14e-11	Hirschsprung disease;
LUSC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.13	0.32	2.45e-9	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.77	0.47	5.49e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1550582	0.662	rs4909628	chr8:135502380	A/T	cg17885191	chr8:135476712	NA	-0.89	-14.27	-0.62	2.02e-36	Educational attainment;
LUSC	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg22705602	chr4:152727874	NA	-0.35	-7.56	-0.38	3.94e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg19920283	chr7:105172520	RINT1	0.6	6.35	0.33	7.01e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg25811766	chr13:21894605	NA	0.65	7.49	0.38	6.27e-13	White matter hyperintensity burden;
LUSC	trans	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg10756647	chr7:56101905	PSPH	-0.84	-8.49	-0.42	7.1e-16	Diabetic kidney disease;
LUSC	trans	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-9.77	-0.47	5.34e-20	Brugada syndrome;
LUSC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg23625390	chr15:77176239	SCAPER	0.5	7.68	0.39	1.77e-13	Blood metabolite levels;
LUSC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-0.91	-17.61	-0.69	1.5e-49	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2708977	1.000	rs10184209	chr2:97337491	G/T	cg01950434	chr2:97203154	ARID5A	0.57	8.75	0.43	1.1e-16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.7	10.91	0.51	6.34e-24	Breast cancer;
LUSC	cis	rs10208940	0.841	rs7581931	chr2:68791641	A/G	cg12452813	chr2:68675892	NA	0.57	5.92	0.31	7.99e-9	Urate levels in lean individuals;
LUSC	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg02569458	chr12:86230093	RASSF9	0.37	6.03	0.31	4.39e-9	Major depressive disorder;
LUSC	trans	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.88	0.35	3.01e-11	Endometrial cancer;
LUSC	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg27411982	chr8:10470053	RP1L1	0.35	5.67	0.3	3.04e-8	Retinal vascular caliber;
LUSC	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.88	15.06	0.64	1.82e-39	Bladder cancer;
LUSC	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.95	0.51	4.59e-24	Colorectal cancer;
LUSC	cis	rs7178572	0.568	rs12910480	chr15:77664212	G/C	cg22256960	chr15:77711686	NA	-0.51	-8.09	-0.4	1.11e-14	Type 2 diabetes;
LUSC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg01802117	chr1:53393560	SCP2	-0.37	-5.93	-0.31	7.62e-9	Monocyte count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05303728	chr8:32078368	NRG1	0.4	6.04	0.31	4.19e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg19717235	chr4:154170410	TRIM2	0.43	6.66	0.34	1.15e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
LUSC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13732083	chr21:47605072	C21orf56	0.43	6.25	0.32	1.27e-9	Testicular germ cell tumor;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19223106	chr19:58898630	RPS5	-0.38	-6.31	-0.33	8.84e-10	Electrocardiographic conduction measures;
LUSC	trans	rs7939886	0.920	rs11227321	chr11:55904828	A/G	cg15704280	chr7:45808275	SEPT13	0.83	6.64	0.34	1.27e-10	Myopia (pathological);
LUSC	cis	rs672059	0.513	rs572977	chr1:183164991	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	6.11	0.32	2.78e-9	Hypertriglyceridemia;
LUSC	cis	rs2963155	0.518	rs712189	chr5:142631258	C/T	cg17617527	chr5:142782415	NR3C1	0.71	8.42	0.42	1.14e-15	Breast cancer;
LUSC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg26380479	chr7:97908229	NA	-0.26	-5.94	-0.31	7.22e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9296092	0.538	rs62407567	chr6:33537213	A/G	cg13560919	chr6:33536144	NA	-0.89	-15.74	-0.65	3.75e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg00792783	chr2:198669748	PLCL1	0.43	5.77	0.3	1.78e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	cis	rs11158026	0.603	rs57667631	chr14:55443067	G/A	cg04306507	chr14:55594613	LGALS3	0.4	7.2	0.37	4.11e-12	Parkinson's disease;
LUSC	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-8.49	-0.42	6.93e-16	Body mass index;
LUSC	cis	rs35123781	0.502	rs261532	chr5:138949362	A/C	cg12205435	chr5:138714322	SLC23A1	0.45	6.66	0.34	1.11e-10	Schizophrenia;
LUSC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.69	-13.08	-0.58	7.38e-32	Bipolar disorder;
LUSC	cis	rs4478858	0.743	rs11578422	chr1:31707298	C/T	cg00250761	chr1:31883323	NA	-0.36	-9.38	-0.46	1.05e-18	Alcohol dependence;
LUSC	cis	rs9463078	0.547	rs9472336	chr6:44710392	G/A	cg25276700	chr6:44698697	NA	0.3	6.2	0.32	1.66e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2481665	0.765	rs2481678	chr1:62634020	T/C	cg18591186	chr1:62594603	INADL	-0.38	-5.81	-0.3	1.45e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2738048	0.545	rs2738168	chr8:6824577	G/T	cg24860332	chr8:6827800	DEFA10P	-0.42	-6.79	-0.35	5.3e-11	IgA nephropathy;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg12078486	chr1:155108334	RAG1AP1	0.51	6.09	0.32	3.07e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg27661571	chr11:113659931	NA	-0.7	-7.96	-0.4	2.78e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg20821713	chr7:1055600	C7orf50	-0.56	-7.36	-0.37	1.42e-12	Bronchopulmonary dysplasia;
LUSC	trans	rs12439619	0.693	rs9944185	chr15:82450268	G/T	cg04831495	chr15:85060580	GOLGA6L5	-0.43	-6.16	-0.32	2.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg05110241	chr16:68378359	PRMT7	-0.45	-5.96	-0.31	6.5e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs73200209	0.744	rs7133286	chr12:116483965	A/C	cg01776926	chr12:116560359	MED13L	-0.5	-5.97	-0.31	6.1e-9	Total body bone mineral density;
LUSC	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.14	0.36	5.87e-12	IgG glycosylation;
LUSC	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg07810366	chr2:100720526	AFF3	-0.53	-9.36	-0.46	1.19e-18	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg21605333	chr4:119757512	SEC24D	1.02	8.29	0.41	2.73e-15	Cannabis dependence symptom count;
LUSC	cis	rs2346177	0.875	rs4413204	chr2:46647092	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.35	5.87	0.31	1.06e-8	HDL cholesterol;
LUSC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg10792982	chr14:105748885	BRF1	0.47	8.47	0.42	7.83e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg04374321	chr14:90722782	PSMC1	-0.43	-6.6	-0.34	1.65e-10	Mortality in heart failure;
LUSC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg18305652	chr10:134549665	INPP5A	0.46	6.83	0.35	4.01e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg18806716	chr10:30721971	MAP3K8	0.72	11.51	0.53	4.65e-26	Inflammatory bowel disease;
LUSC	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg05925327	chr15:68127851	NA	0.32	5.73	0.3	2.28e-8	Restless legs syndrome;
LUSC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.72	-9.53	-0.46	3.31e-19	Refractive error;
LUSC	cis	rs4629710	0.568	rs9492883	chr6:131573872	A/T	cg12606694	chr6:131520996	AKAP7	0.62	9.42	0.46	7.5e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.47	6.94	0.35	2.05e-11	Schizophrenia;
LUSC	trans	rs1459104	0.866	rs35456973	chr11:54838812	C/A	cg15704280	chr7:45808275	SEPT13	0.71	6.34	0.33	7.62e-10	Body mass index;
LUSC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg03526776	chr6:41159608	TREML2	0.32	6.14	0.32	2.35e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3850699	0.609	rs12763720	chr10:104241983	T/C	cg04362960	chr10:104952993	NT5C2	0.52	6.51	0.34	2.7e-10	Prostate cancer;
LUSC	trans	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	10.79	0.51	1.76e-23	Mean corpuscular volume;
LUSC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg23711669	chr6:146136114	FBXO30	0.78	14.1	0.61	9.42e-36	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3903072	0.528	rs7928652	chr11:65580228	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.35	6.0	0.31	5.05e-9	Breast cancer;
LUSC	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg05501817	chr11:14380813	RRAS2	-0.55	-8.6	-0.43	3.25e-16	Sense of smell;
LUSC	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.33	0.53	2.18e-25	Coffee consumption (cups per day);
LUSC	trans	rs984440	0.621	rs35542762	chr8:139077352	C/T	cg03334052	chr1:168888044	NA	-0.4	-6.32	-0.33	8.35e-10	Obesity-related traits;
LUSC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg23711669	chr6:146136114	FBXO30	0.87	15.46	0.65	4.67e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.41	-0.33	4.83e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg06521331	chr12:34319734	NA	-0.44	-7.27	-0.37	2.54e-12	Morning vs. evening chronotype;
LUSC	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.38	-0.42	1.49e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.92	-0.44	3.02e-17	Monocyte percentage of white cells;
LUSC	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg13010199	chr12:38710504	ALG10B	0.54	8.45	0.42	9.36e-16	Morning vs. evening chronotype;
LUSC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	0.7	12.22	0.56	1.18e-28	Gestational age at birth (maternal effect);
LUSC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg08508325	chr11:3079039	CARS	-0.54	-13.44	-0.59	3.17e-33	Longevity;
LUSC	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg21433313	chr16:3507492	NAT15	0.77	9.51	0.46	3.83e-19	Tuberculosis;
LUSC	cis	rs6754311	0.551	rs313526	chr2:136445526	C/T	cg07169764	chr2:136633963	MCM6	0.55	7.29	0.37	2.32e-12	Mosquito bite size;
LUSC	cis	rs231513	1.000	rs231526	chr17:41951277	T/C	cg26893861	chr17:41843967	DUSP3	-0.58	-6.17	-0.32	1.95e-9	Cognitive function;
LUSC	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg04539111	chr16:67997858	SLC12A4	-0.45	-6.03	-0.31	4.27e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg01620082	chr3:125678407	NA	-0.79	-7.21	-0.37	3.81e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs17665859	0.844	rs17738513	chr8:446359	G/T	cg17960703	chr8:356704	FBXO25	-0.85	-8.01	-0.4	1.91e-14	Bilirubin levels;
LUSC	cis	rs4363385	0.553	rs1415972	chr1:152953552	A/G	cg00922841	chr1:152955080	SPRR1A	0.37	6.48	0.33	3.33e-10	Inflammatory skin disease;
LUSC	cis	rs5753037	0.803	rs131262	chr22:30133044	G/T	cg11564601	chr22:30592435	NA	0.33	6.03	0.31	4.39e-9	Type 1 diabetes;
LUSC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg20406979	chr6:167373233	NA	-0.26	-6.16	-0.32	2.1e-9	Crohn's disease;
LUSC	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.51	1.26e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg17971929	chr21:40555470	PSMG1	0.74	12.01	0.55	7.27e-28	Cognitive function;
LUSC	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg16482183	chr6:26056742	HIST1H1C	0.44	6.49	0.33	3.11e-10	Height;
LUSC	trans	rs10845606	0.581	rs11055015	chr12:12836679	T/G	cg15834202	chr5:58865918	PDE4D	0.37	5.97	0.31	6.13e-9	Systemic lupus erythematosus;
LUSC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg07741184	chr6:167504864	NA	0.39	6.88	0.35	2.9e-11	Primary biliary cholangitis;
LUSC	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg04362960	chr10:104952993	NT5C2	0.61	9.23	0.45	3.16e-18	Arsenic metabolism;
LUSC	cis	rs2290159	0.848	rs6771385	chr3:12639419	A/G	cg23032965	chr3:12705835	RAF1	0.54	7.01	0.36	1.32e-11	Cholesterol, total;
LUSC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg11798132	chr1:224302585	FBXO28	0.35	6.53	0.34	2.43e-10	Tuberculosis;
LUSC	cis	rs7202877	0.706	rs247436	chr16:75445971	T/G	cg03315344	chr16:75512273	CHST6	-0.44	-6.3	-0.33	9.59e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.14e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg24675658	chr1:53192096	ZYG11B	0.72	12.03	0.55	6.08e-28	Monocyte count;
LUSC	trans	rs61931739	0.635	rs3937819	chr12:33942715	A/G	cg26384229	chr12:38710491	ALG10B	0.51	7.63	0.39	2.43e-13	Morning vs. evening chronotype;
LUSC	cis	rs12922317	0.964	rs12930612	chr16:12072203	G/A	cg08843971	chr16:11963173	GSPT1	-0.39	-5.85	-0.3	1.18e-8	Schizophrenia;
LUSC	cis	rs113835537	0.529	rs4930378	chr11:66255515	T/C	cg24851651	chr11:66362959	CCS	0.54	8.14	0.41	7.86e-15	Airway imaging phenotypes;
LUSC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.42	0.33	4.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg15445000	chr17:37608096	MED1	0.39	6.63	0.34	1.37e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg06600287	chr1:53387719	ECHDC2	-0.3	-6.28	-0.33	1.04e-9	Monocyte count;
LUSC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg12615879	chr12:58013172	SLC26A10	-0.29	-5.94	-0.31	7.18e-9	Multiple sclerosis;
LUSC	cis	rs9326248	0.861	rs7120449	chr11:117042899	T/C	cg26566898	chr11:117069891	TAGLN	0.39	6.28	0.32	1.08e-9	Blood protein levels;
LUSC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.14	0.45	6.13e-18	Height;
LUSC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg05985134	chr18:33552581	C18orf21	0.52	7.04	0.36	1.13e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs870825	0.655	rs1527870	chr4:185616631	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.5	0.59	1.86e-33	Blood protein levels;
LUSC	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg23950597	chr19:37808831	NA	-0.62	-7.63	-0.39	2.54e-13	Coronary artery calcification;
LUSC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg05665937	chr4:1216051	CTBP1	0.39	6.26	0.32	1.2e-9	Obesity-related traits;
LUSC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg25258033	chr6:167368657	RNASET2	-0.45	-7.49	-0.38	6.31e-13	Crohn's disease;
LUSC	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-5.91	-0.31	8.45e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-0.53	-8.18	-0.41	6.03e-15	Breast cancer;
LUSC	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg11244672	chr19:19639970	YJEFN3	-0.62	-7.61	-0.38	2.76e-13	Bipolar disorder;
LUSC	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.24	-0.41	4e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs75804782	0.521	rs56176151	chr2:239440220	T/C	cg18131467	chr2:239335373	ASB1	-0.7	-6.01	-0.31	4.98e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs11955175	1.000	rs75929994	chr5:40821816	T/C	cg05478818	chr5:40835740	RPL37	0.75	5.83	0.3	1.28e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.52	0.42	5.41e-16	Endometrial cancer;
LUSC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg07424592	chr7:64974309	NA	0.7	6.15	0.32	2.24e-9	Diabetic kidney disease;
LUSC	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg22906224	chr7:99728672	NA	0.43	5.8	0.3	1.56e-8	Coronary artery disease;
LUSC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg03146154	chr1:46216737	IPP	-0.54	-8.28	-0.41	3.05e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2274273	0.837	rs59871474	chr14:55779363	T/C	cg04306507	chr14:55594613	LGALS3	0.54	12.05	0.55	5.23e-28	Protein biomarker;
LUSC	cis	rs4478037	1.000	rs4074416	chr3:33161729	A/G	cg19404215	chr3:33155277	CRTAP	0.96	10.11	0.48	4.01e-21	Major depressive disorder;
LUSC	cis	rs9815354	1.000	rs7632387	chr3:41853161	C/T	cg03022575	chr3:42003672	ULK4	0.55	6.17	0.32	1.94e-9	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg13206674	chr6:150067644	NUP43	0.43	6.56	0.34	2.01e-10	Testicular germ cell tumor;
LUSC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.74	-11.3	-0.53	2.67e-25	Menarche (age at onset);
LUSC	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg18302933	chr2:88491318	NA	-0.39	-7.41	-0.38	1.07e-12	Response to metformin (IC50);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23018242	chr22:31608245	LIMK2	-0.39	-6.79	-0.35	5.27e-11	Electrocardiographic conduction measures;
LUSC	cis	rs2692947	0.740	rs11695514	chr2:96548068	C/T	cg22654517	chr2:96458247	NA	0.35	6.51	0.34	2.78e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	0.92	15.86	0.66	1.26e-42	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg22467129	chr15:76604101	ETFA	-0.45	-7.22	-0.37	3.44e-12	Blood metabolite levels;
LUSC	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.22	-0.37	3.52e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.77	-0.43	9.4e-17	Bipolar disorder;
LUSC	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg16342193	chr10:102329863	NA	-0.35	-6.24	-0.32	1.32e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	0.92	17.78	0.7	3e-50	Heart rate;
LUSC	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.33	0.56	4.73e-29	Ileal carcinoids;
LUSC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.55	0.34	2.17e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg12927641	chr6:109611667	NA	-0.35	-5.85	-0.3	1.19e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs3087591	0.690	rs12103621	chr17:29607235	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.63	-9.03	-0.44	1.43e-17	Hip circumference;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	0.98	21.45	0.76	8.76e-65	Menarche (age at onset);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02275878	chr17:72919391	OTOP2;USH1G	-0.39	-6.15	-0.32	2.17e-9	Triglycerides;
LUSC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	5.76	0.3	1.93e-8	Schizophrenia;
LUSC	cis	rs9660992	1.000	rs3851296	chr1:205253839	A/C	cg21643547	chr1:205240462	TMCC2	-0.47	-9.08	-0.45	9.57e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg24069376	chr3:38537580	EXOG	0.36	6.47	0.33	3.53e-10	Electrocardiographic conduction measures;
LUSC	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg20744362	chr22:50050164	C22orf34	0.39	7.35	0.37	1.52e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17467752	chr17:38218738	THRA	-0.51	-7.18	-0.37	4.51e-12	White blood cell count;
LUSC	cis	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg02972257	chr16:68554789	NA	-0.5	-6.36	-0.33	6.76e-10	Ulcerative colitis;
LUSC	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg11584989	chr19:19387371	SF4	0.6	7.33	0.37	1.78e-12	Bipolar disorder;
LUSC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08470875	chr2:26401718	FAM59B	-0.64	-8.86	-0.44	4.7e-17	Gut microbiome composition (summer);
LUSC	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg09904177	chr6:26538194	HMGN4	-0.48	-6.97	-0.36	1.65e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6138458	0.847	rs56312312	chr20:24959386	C/A	cg26195577	chr20:24973756	C20orf3	1.12	17.61	0.69	1.5e-49	Blood protein levels;
LUSC	trans	rs10885582	0.818	rs11196793	chr10:116346929	T/C	cg01002288	chr1:43166549	YBX1	-0.36	-6.21	-0.32	1.59e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.67	0.65	7.43e-42	Bladder cancer;
LUSC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg13047869	chr3:10149882	C3orf24	0.58	7.94	0.4	3.03e-14	Alzheimer's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14136810	chr15:40213326	GPR176	-0.47	-6.11	-0.32	2.79e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.9	-0.35	2.58e-11	Morning vs. evening chronotype;
LUSC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg10792982	chr14:105748885	BRF1	0.5	9.2	0.45	3.93e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7804356	1.000	rs6964094	chr7:26834380	C/G	cg03456212	chr7:26904342	SKAP2	-0.55	-6.58	-0.34	1.86e-10	Type 1 diabetes;
LUSC	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26384229	chr12:38710491	ALG10B	0.9	15.32	0.64	1.65e-40	Morning vs. evening chronotype;
LUSC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.08	14.84	0.63	1.3e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.62	9.96	0.48	1.27e-20	Blood metabolite ratios;
LUSC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	7.6	0.38	3.01e-13	Multiple sclerosis;
LUSC	trans	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	9.13	0.45	6.87e-18	Type 2 diabetes;
LUSC	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg23625390	chr15:77176239	SCAPER	-0.6	-9.47	-0.46	5.24e-19	Blood metabolite levels;
LUSC	trans	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.76	-0.43	9.89e-17	Obesity-related traits;
LUSC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg22532475	chr10:104410764	TRIM8	-0.3	-6.61	-0.34	1.55e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg03929089	chr4:120376271	NA	-0.59	-6.27	-0.32	1.13e-9	Axial length;
LUSC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg02475777	chr4:1388615	CRIPAK	0.45	6.69	0.34	9.62e-11	Obesity-related traits;
LUSC	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.86	13.87	0.6	7.36e-35	Coronary artery disease;
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg16103275	chr6:290800	DUSP22	0.42	7.07	0.36	9e-12	Menopause (age at onset);
LUSC	cis	rs654950	0.934	rs641974	chr1:42002137	G/A	cg06885757	chr1:42089581	HIVEP3	-0.43	-8.17	-0.41	6.54e-15	Airway imaging phenotypes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17625409	chr5:72143790	TNPO1	-0.44	-6.07	-0.32	3.45e-9	Hepatitis;
LUSC	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	8.96	0.44	2.34e-17	Iron status biomarkers;
LUSC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	0.88	19.03	0.72	3.22e-55	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg16342193	chr10:102329863	NA	-0.39	-6.2	-0.32	1.69e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg13010199	chr12:38710504	ALG10B	0.69	10.65	0.5	5.27e-23	Bladder cancer;
LUSC	cis	rs2637266	1.000	rs12784382	chr10:78378348	G/T	cg18941641	chr10:78392320	NA	0.38	6.83	0.35	4.1e-11	Pulmonary function;
LUSC	cis	rs6845621	0.901	rs4269172	chr4:18901705	G/A	cg12196642	chr4:18937545	NA	-0.34	-6.46	-0.33	3.79e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs4356932	0.817	rs6826406	chr4:76973557	A/C	cg00809888	chr4:76862425	NAAA	0.35	5.82	0.3	1.37e-8	Blood protein levels;
LUSC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg13334819	chr7:99746414	C7orf59	-0.44	-5.84	-0.3	1.21e-8	Coronary artery disease;
LUSC	trans	rs7181230	1.000	rs28534747	chr15:40374269	T/C	cg22705835	chr10:65332833	REEP3	-0.4	-6.77	-0.35	5.87e-11	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs6500395	1.000	rs12599028	chr16:48713082	C/A	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7590368	0.673	rs56147885	chr2:10937095	T/A	cg15705551	chr2:10952987	PDIA6	0.52	5.79	0.3	1.66e-8	Educational attainment (years of education);
LUSC	cis	rs2455601	1.000	rs11042108	chr11:8906021	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.5	-7.66	-0.39	2e-13	Schizophrenia;
LUSC	trans	rs9886428	1.000	rs10099853	chr8:14115675	G/C	cg11959399	chr20:741723	C20orf54	-0.4	-6.45	-0.33	3.98e-10	IgG glycosylation;
LUSC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg11812906	chr14:75593930	NEK9	-0.64	-11.16	-0.52	8.32e-25	Height;
LUSC	cis	rs4588572	0.645	rs10059940	chr5:77680873	T/C	cg11547950	chr5:77652471	NA	0.53	7.57	0.38	3.75e-13	Triglycerides;
LUSC	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.78	-13.87	-0.6	7.18e-35	Brugada syndrome;
LUSC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg05623727	chr3:50126028	RBM5	0.35	6.7	0.34	8.72e-11	Body mass index;
LUSC	cis	rs7192380	1.000	rs11640319	chr16:69633515	G/A	cg26679644	chr16:69762563	NA	0.35	6.23	0.32	1.44e-9	Sjögren's syndrome;
LUSC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03352830	chr11:487213	PTDSS2	0.76	9.12	0.45	7.38e-18	Body mass index;
LUSC	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg08213375	chr14:104286397	PPP1R13B	0.54	10.84	0.51	1.13e-23	Schizophrenia;
LUSC	cis	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-6.85	-0.35	3.55e-11	Systolic blood pressure;
LUSC	cis	rs6542838	0.641	rs6757098	chr2:99471399	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-6.0	-0.31	5.03e-9	Fear of minor pain;
LUSC	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	1.1	17.25	0.69	3.83e-48	Exhaled nitric oxide output;
LUSC	cis	rs11039100	0.850	rs11039164	chr11:5843138	C/T	cg05234568	chr11:5960015	NA	-0.51	-5.81	-0.3	1.46e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs926938	0.505	rs2878573	chr1:115521602	A/G	cg12756093	chr1:115239321	AMPD1	0.46	7.0	0.36	1.43e-11	Autism;
LUSC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg23978390	chr7:1156363	C7orf50	0.42	6.06	0.31	3.63e-9	Longevity;Endometriosis;
LUSC	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.0	-0.44	1.72e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-8.39	-0.42	1.35e-15	Lymphocyte counts;
LUSC	cis	rs7715806	0.500	rs58968428	chr5:75004107	A/G	cg19683494	chr5:74908142	NA	0.57	7.68	0.39	1.83e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs17155006	0.746	rs366690	chr7:107749880	T/G	cg05962710	chr7:107745446	LAMB4	-0.35	-6.34	-0.33	7.62e-10	Pneumococcal bacteremia;
LUSC	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg15445000	chr17:37608096	MED1	0.38	6.5	0.34	2.95e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18099408	chr3:52552593	STAB1	-0.4	-7.03	-0.36	1.19e-11	Bipolar disorder;
LUSC	trans	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.73	-12.64	-0.57	3.51e-30	Brugada syndrome;
LUSC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg14552801	chr7:65878734	NA	0.44	6.31	0.33	8.81e-10	Aortic root size;
LUSC	cis	rs6087990	0.965	rs6058869	chr20:31348750	C/T	cg13636640	chr20:31349939	DNMT3B	1.03	23.09	0.78	3.49e-71	Ulcerative colitis;
LUSC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.03	-0.4	1.74e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.22	-0.41	4.67e-15	Bladder cancer;
LUSC	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg14664628	chr15:75095509	CSK	-1.01	-17.69	-0.7	7.27e-50	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.08	-0.32	3.21e-9	Neuroticism;
LUSC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg04025307	chr7:1156635	C7orf50	0.36	5.85	0.3	1.17e-8	Longevity;Endometriosis;
LUSC	cis	rs921665	0.831	rs80283188	chr2:3199209	T/C	cg02624386	chr2:3182749	NA	-0.62	-6.09	-0.32	3.04e-9	World class endurance athleticism;
LUSC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.61	0.5	7.35e-23	Monocyte percentage of white cells;
LUSC	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg00376283	chr12:123451042	ABCB9	0.68	8.6	0.43	3.1e-16	Neutrophil percentage of white cells;
LUSC	cis	rs77741769	0.571	rs3897746	chr12:121324727	A/G	cg02419362	chr12:121203948	SPPL3	0.45	8.39	0.42	1.35e-15	Mean corpuscular volume;
LUSC	cis	rs977987	0.872	rs7206665	chr16:75475287	A/C	cg03315344	chr16:75512273	CHST6	0.53	10.27	0.49	1.14e-21	Dupuytren's disease;
LUSC	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.76	-0.3	1.89e-8	Testicular germ cell tumor;
LUSC	cis	rs660498	0.507	rs34354872	chr10:27735673	T/G	cg04084786	chr10:27609163	NA	0.4	5.89	0.31	9.39e-9	Asthma (childhood onset);
LUSC	cis	rs9462027	0.628	rs11757370	chr6:34760736	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.11e-8	Systemic lupus erythematosus;
LUSC	cis	rs10186029	0.680	rs11689451	chr2:213937840	C/T	cg08319019	chr2:214017104	IKZF2	0.55	8.02	0.4	1.75e-14	Systemic sclerosis;
LUSC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.63	8.37	0.42	1.61e-15	High light scatter reticulocyte count;
LUSC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg18681998	chr4:17616180	MED28	0.87	16.28	0.67	2.73e-44	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.6	-9.92	-0.48	1.64e-20	Post bronchodilator FEV1;
LUSC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.33	0.33	7.78e-10	Platelet count;
LUSC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg05802129	chr4:122689817	NA	-0.37	-6.69	-0.34	9.68e-11	Type 2 diabetes;
LUSC	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg18678763	chr11:4115507	RRM1	-0.54	-7.64	-0.39	2.31e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	11.57	0.53	2.96e-26	Tonsillectomy;
LUSC	cis	rs1864400	0.690	rs7098237	chr10:43740513	T/A	cg02780029	chr10:43622663	RET	0.34	5.75	0.3	2.07e-8	Hirschsprung disease;
LUSC	cis	rs6494488	0.500	rs72741327	chr15:64730822	G/C	cg08069370	chr15:64387884	SNX1	-0.64	-5.67	-0.3	3.05e-8	Coronary artery disease;
LUSC	cis	rs78707713	0.560	rs55668536	chr10:71242655	A/G	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.39	-0.46	9.32e-19	Venous thromboembolism;
LUSC	cis	rs1595825	0.735	rs57603546	chr2:198918524	C/A	cg00982548	chr2:198649783	BOLL	-0.57	-6.9	-0.35	2.65e-11	Ulcerative colitis;
LUSC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg13918804	chr1:2043761	PRKCZ	0.26	5.65	0.3	3.44e-8	Height;
LUSC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.18	0.88	4.53e-111	Chronic sinus infection;
LUSC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	8.67	0.43	1.96e-16	Menopause (age at onset);
LUSC	cis	rs7605827	0.930	rs7608831	chr2:15605029	A/G	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01341218	chr17:43662625	NA	0.77	11.18	0.52	7.14e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg17279839	chr7:150038598	RARRES2	0.45	6.93	0.35	2.18e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2224391	1.000	rs2753247	chr6:5261987	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.47	-6.72	-0.35	7.76e-11	Height;
LUSC	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg11584989	chr19:19387371	SF4	0.67	7.76	0.39	1.05e-13	Bipolar disorder;
LUSC	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg24110177	chr3:50126178	RBM5	-0.42	-6.72	-0.34	8.08e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.27	0.49	1.13e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19710444	chr14:73360162	DPF3	-0.46	-6.05	-0.31	3.94e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg24399712	chr22:39784796	NA	-0.62	-11.39	-0.53	1.33e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs500891	0.525	rs1145902	chr6:84038531	A/G	cg08257003	chr6:84140564	ME1	0.33	7.8	0.39	7.82e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg19792802	chr11:65647270	CTSW	-0.41	-6.28	-0.32	1.05e-9	Crohn's disease;
LUSC	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg13042288	chr15:90349979	ANPEP	-0.49	-7.01	-0.36	1.32e-11	Uric acid levels;
LUSC	cis	rs8077889	0.750	rs72836564	chr17:41935064	G/A	cg26893861	chr17:41843967	DUSP3	0.93	11.83	0.54	3.21e-27	Triglycerides;
LUSC	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg00310523	chr12:86230176	RASSF9	0.45	8.0	0.4	2.1e-14	Major depressive disorder;
LUSC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg06008330	chr7:65541103	ASL	-0.39	-5.91	-0.31	8.27e-9	Aortic root size;
LUSC	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg22571038	chr17:48585470	MYCBPAP	0.48	6.02	0.31	4.58e-9	Visceral fat;
LUSC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg27068330	chr11:65405492	SIPA1	-0.77	-11.04	-0.52	2.38e-24	Acne (severe);
LUSC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg16362232	chr11:430036	ANO9	0.65	8.17	0.41	6.56e-15	Body mass index;
LUSC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg13628971	chr7:2884303	GNA12	0.49	6.87	0.35	3.18e-11	Height;
LUSC	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg06623918	chr6:96969491	KIAA0776	-0.83	-11.92	-0.55	1.51e-27	Migraine;Coronary artery disease;
LUSC	cis	rs1957429	0.520	rs72625647	chr14:65344106	T/C	cg23373153	chr14:65346875	NA	-0.88	-8.06	-0.4	1.4e-14	Pediatric areal bone mineral density (radius);
LUSC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg01616529	chr11:638424	DRD4	-0.34	-5.98	-0.31	5.7e-9	Systemic lupus erythematosus;
LUSC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21862992	chr11:68658383	NA	0.51	8.15	0.41	7.21e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7495211	0.509	rs11247363	chr15:98623942	C/T	cg25404375	chr15:99409942	IGF1R	-0.38	-5.65	-0.3	3.44e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg15997130	chr1:24165203	NA	-0.57	-9.33	-0.45	1.46e-18	Immature fraction of reticulocytes;
LUSC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-8.04	-0.4	1.6e-14	Lung function (FEV1/FVC);
LUSC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.19	-13.56	-0.6	1.16e-33	Diabetic kidney disease;
LUSC	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg11584989	chr19:19387371	SF4	0.6	7.06	0.36	9.47e-12	Bipolar disorder;
LUSC	cis	rs1775715	0.677	rs2491272	chr10:32186783	A/G	cg26784012	chr10:32216390	ARHGAP12	0.46	7.84	0.39	6.15e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg08470875	chr2:26401718	FAM59B	-0.71	-9.6	-0.47	1.92e-19	Gut microbiome composition (summer);
LUSC	cis	rs1461503	0.966	rs10892937	chr11:122841904	T/C	cg27398637	chr11:122830231	C11orf63	-0.41	-6.53	-0.34	2.4e-10	Menarche (age at onset);
LUSC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.08	16.38	0.67	1.13e-44	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg05925327	chr15:68127851	NA	-0.39	-6.1	-0.32	2.89e-9	Obesity;
LUSC	cis	rs8040855	0.627	rs11631548	chr15:85619248	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-5.75	-0.3	2.02e-8	Bulimia nervosa;
LUSC	cis	rs4356932	0.935	rs4129781	chr4:76959388	C/G	cg00809888	chr4:76862425	NAAA	0.34	5.75	0.3	1.98e-8	Blood protein levels;
LUSC	trans	rs12891047	0.966	rs12588401	chr14:68240948	T/C	cg09439754	chr16:82129088	HSD17B2	0.32	5.98	0.31	5.65e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg26102564	chr10:131424627	MGMT	0.46	7.05	0.36	1.03e-11	Response to temozolomide;
LUSC	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12292205	chr6:26970375	C6orf41	-0.58	-7.39	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6484504	0.625	rs7112412	chr11:31370271	T/C	cg06552810	chr11:31128660	NA	0.39	6.76	0.35	6.27e-11	Red blood cell count;
LUSC	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg08645402	chr16:4508243	NA	-0.5	-8.55	-0.42	4.51e-16	Schizophrenia;
LUSC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8113142	0.614	rs4804848	chr19:29139728	A/T	cg04546413	chr19:29218101	NA	0.43	5.91	0.31	8.41e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	ch.3.55501R	chr3:3184210	TRNT1	0.48	6.25	0.32	1.26e-9	Cognitive function;Information processing speed;
LUSC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-6.81	-0.35	4.67e-11	Chronic sinus infection;
LUSC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg00945038	chr17:61921165	SMARCD2	0.4	6.06	0.31	3.64e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg06784218	chr1:46089804	CCDC17	-0.5	-10.06	-0.48	5.57e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.99	0.4	2.24e-14	Mean platelet volume;
LUSC	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg24562669	chr7:97807699	LMTK2	0.45	7.96	0.4	2.71e-14	Breast cancer;
LUSC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.04	-0.31	4.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs2392780	0.536	rs606345	chr8:128334499	T/A	cg10897648	chr18:56338258	MALT1	-0.41	-6.23	-0.32	1.4e-9	Breast cancer (early onset);
LUSC	cis	rs56399783	0.901	rs55767077	chr7:2774608	C/T	cg14895029	chr7:2775587	GNA12	0.53	5.8	0.3	1.51e-8	Childhood ear infection;
LUSC	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg10978503	chr1:24200527	CNR2	-0.45	-10.71	-0.51	3.36e-23	Immature fraction of reticulocytes;
LUSC	cis	rs2219968	1.000	rs11783780	chr8:78971571	A/T	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.13	0.48	3.37e-21	Electroencephalogram traits;
LUSC	cis	rs4713675	0.565	rs942640	chr6:33686442	G/T	cg14003231	chr6:33640908	ITPR3	0.29	5.75	0.3	2.04e-8	Plateletcrit;
LUSC	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.54	-0.34	2.37e-10	Bipolar disorder;
LUSC	cis	rs4474465	1.000	rs10793319	chr11:78217237	G/A	cg27205649	chr11:78285834	NARS2	0.51	5.91	0.31	8.56e-9	Alzheimer's disease (survival time);
LUSC	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg00484396	chr16:3507460	NAT15	-0.71	-12.24	-0.56	1.01e-28	Tuberculosis;
LUSC	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs2637266	0.935	rs2583052	chr10:78403288	C/G	cg18941641	chr10:78392320	NA	0.42	7.62	0.38	2.67e-13	Pulmonary function;
LUSC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg26769984	chr7:1090371	C7orf50	0.58	7.77	0.39	9.47e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs7727544	0.557	rs2897096	chr5:131486284	A/G	cg14196790	chr5:131705035	SLC22A5	0.47	8.03	0.4	1.69e-14	Blood metabolite levels;
LUSC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-9.57	-0.46	2.44e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg24562669	chr7:97807699	LMTK2	0.46	8.18	0.41	6.15e-15	Breast cancer;
LUSC	trans	rs1486139	0.967	rs10238892	chr7:46281491	T/C	cg17534202	chr9:96721102	NA	-0.34	-5.96	-0.31	6.36e-9	Select biomarker traits;
LUSC	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg03676636	chr4:99064102	C4orf37	0.34	6.06	0.31	3.77e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg21770322	chr7:97807741	LMTK2	0.4	7.01	0.36	1.31e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg02493740	chr2:85810744	VAMP5	-0.5	-8.57	-0.42	3.91e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs16976116	0.901	rs1061873	chr15:55496756	T/C	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg25237894	chr2:233734115	C2orf82	0.34	6.33	0.33	7.67e-10	Coronary artery disease;
LUSC	cis	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg06521331	chr12:34319734	NA	-0.48	-7.83	-0.39	6.74e-14	Morning vs. evening chronotype;
LUSC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	7.72	0.39	1.35e-13	Schizophrenia;
LUSC	trans	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg10756647	chr7:56101905	PSPH	-0.86	-8.52	-0.42	5.52e-16	Diabetic kidney disease;
LUSC	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.3	6.63	0.34	1.37e-10	Coronary artery disease;
LUSC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	9.28	0.45	2.18e-18	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.9	-14.79	-0.63	2.07e-38	Lymphocyte percentage of white cells;
LUSC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	9.0	0.44	1.74e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.15	-0.36	5.64e-12	Bipolar disorder;
LUSC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg00343986	chr7:65444356	GUSB	0.42	6.38	0.33	5.92e-10	Aortic root size;
LUSC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	6.57	0.34	1.97e-10	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2262909	0.853	rs56207853	chr19:22292357	C/T	cg11619707	chr19:22235551	ZNF257	0.39	5.84	0.3	1.22e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg26384229	chr12:38710491	ALG10B	0.57	9.3	0.45	1.84e-18	Morning vs. evening chronotype;
LUSC	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg20135002	chr11:47629003	NA	-0.49	-7.52	-0.38	4.95e-13	Subjective well-being;
LUSC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg14773178	chr5:1868261	NA	0.31	5.65	0.3	3.44e-8	Cardiovascular disease risk factors;
LUSC	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg02403541	chr12:121454288	C12orf43	-0.55	-7.95	-0.4	2.87e-14	N-glycan levels;
LUSC	cis	rs7241530	0.636	rs72985797	chr18:75904096	C/T	cg14642773	chr18:75888474	NA	0.39	6.02	0.31	4.59e-9	Educational attainment (years of education);
LUSC	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg19468946	chr17:37922297	IKZF3	-0.43	-6.82	-0.35	4.17e-11	Self-reported allergy;
LUSC	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-0.85	-14.16	-0.61	5.78e-36	Headache;
LUSC	cis	rs9398803	0.865	rs4422634	chr6:126806676	A/G	cg19875578	chr6:126661172	C6orf173	0.41	6.03	0.31	4.43e-9	Male-pattern baldness;
LUSC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg26441486	chr22:50317300	CRELD2	0.49	7.25	0.37	2.87e-12	Schizophrenia;
LUSC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg01416388	chr22:39784598	NA	-0.43	-6.73	-0.35	7.48e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-6.63	-0.34	1.39e-10	Menopause (age at onset);
LUSC	cis	rs3741151	0.686	rs7125598	chr11:73160589	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.85	-8.2	-0.41	5.25e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	11.23	0.52	5.01e-25	Lung cancer in ever smokers;
LUSC	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg25237894	chr2:233734115	C2orf82	-0.35	-6.55	-0.34	2.18e-10	Coronary artery disease;
LUSC	cis	rs780094	0.500	rs7570476	chr2:27784658	C/T	cg27432699	chr2:27873401	GPN1	0.41	5.7	0.3	2.69e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg27398817	chr8:82754497	SNX16	-0.63	-7.98	-0.4	2.44e-14	Diastolic blood pressure;
LUSC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.51	-8.37	-0.42	1.6e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs12997796	0.503	rs4366909	chr2:87021001	G/A	cg25203885	chr2:87302643	LOC285074	-0.58	-5.67	-0.3	3.16e-8	Schizophrenia;
LUSC	cis	rs6061231	0.505	rs62199217	chr20:60929539	G/A	cg06026331	chr20:60912101	LAMA5	0.57	6.77	0.35	5.65e-11	Colorectal cancer;
LUSC	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg11901034	chr3:128598214	ACAD9	-0.41	-6.4	-0.33	5.17e-10	IgG glycosylation;
LUSC	cis	rs6599077	1.000	rs9832724	chr3:40097569	C/G	cg13683864	chr3:40499215	RPL14	-0.62	-7.54	-0.38	4.57e-13	Sleep-related phenotypes;
LUSC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg16325326	chr1:53192061	ZYG11B	0.97	19.12	0.72	1.4e-55	Monocyte count;
LUSC	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-9.15	-0.45	5.94e-18	Obesity-related traits;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg19648896	chr11:65337773	SSSCA1	0.72	6.67	0.34	1.06e-10	Body mass index;
LUSC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.36	-6.23	-0.32	1.39e-9	Breast cancer;
LUSC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg08683831	chr4:1404607	NA	0.37	6.31	0.33	8.84e-10	Obesity-related traits;
LUSC	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg13073564	chr4:8508604	NA	0.51	9.54	0.46	3.18e-19	Response to antineoplastic agents;
LUSC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg07701084	chr6:150067640	NUP43	0.54	8.02	0.4	1.82e-14	Lung cancer;
LUSC	cis	rs1808579	0.904	rs6507708	chr18:21101456	C/A	cg14672496	chr18:21087552	C18orf8	0.37	6.37	0.33	6.21e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs9650315	0.866	rs4636179	chr8:57186286	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.88	0.35	3.01e-11	Height;
LUSC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg15017067	chr4:17643749	FAM184B	0.36	5.9	0.31	8.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11756438	0.572	rs2638545	chr6:119000203	G/C	cg21191810	chr6:118973309	C6orf204	0.35	5.91	0.31	8.34e-9	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg17420585	chr12:42539391	GXYLT1	-0.31	-5.88	-0.31	9.92e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs977987	0.527	rs62059844	chr16:75429737	T/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.02	-0.36	1.26e-11	Dupuytren's disease;
LUSC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21016266	chr12:122356598	WDR66	0.54	7.69	0.39	1.62e-13	Mean corpuscular volume;
LUSC	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg07173049	chr1:7289937	CAMTA1	0.37	7.62	0.38	2.62e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs9462027	0.628	rs6942040	chr6:34761809	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.77	-0.3	1.84e-8	Systemic lupus erythematosus;
LUSC	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg05234568	chr11:5960015	NA	-0.6	-8.58	-0.42	3.64e-16	DNA methylation (variation);
LUSC	cis	rs7804356	0.906	rs17323934	chr7:26904330	C/G	cg03456212	chr7:26904342	SKAP2	0.59	6.74	0.35	7.11e-11	Type 1 diabetes;
LUSC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg04017836	chr7:65315216	NA	-0.37	-5.95	-0.31	6.75e-9	Height;
LUSC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg12564285	chr5:131593104	PDLIM4	-0.46	-7.96	-0.4	2.8e-14	Breast cancer;
LUSC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg27121462	chr16:89883253	FANCA	0.55	8.88	0.44	4.24e-17	Vitiligo;
LUSC	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-0.86	-16.62	-0.67	1.25e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7605827	0.930	rs3805103	chr2:15518352	A/G	cg19274914	chr2:15703543	NA	-0.47	-9.08	-0.44	9.76e-18	Educational attainment (years of education);
LUSC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.816	rs376742	chr20:25487417	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.81	16.69	0.67	6.38e-46	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg11578532	chr1:161008127	TSTD1	0.34	7.33	0.37	1.8e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7705502	0.855	rs17763083	chr5:173351488	C/T	cg18693985	chr5:173351052	CPEB4	-0.38	-5.97	-0.31	6.06e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs2637266	1.000	rs2395394	chr10:78360679	G/C	cg18941641	chr10:78392320	NA	0.39	7.12	0.36	6.84e-12	Pulmonary function;
LUSC	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg04851639	chr8:1020857	NA	-0.39	-7.75	-0.39	1.14e-13	Schizophrenia;
LUSC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg18306943	chr3:40428807	ENTPD3	0.36	5.8	0.3	1.51e-8	Renal cell carcinoma;
LUSC	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg04865166	chr7:105162814	PUS7	0.52	5.92	0.31	7.79e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg12924262	chr12:102091054	CHPT1	-0.44	-6.18	-0.32	1.85e-9	Blood protein levels;
LUSC	cis	rs2860975	1.000	rs10882514	chr10:96782898	T/C	cg09036531	chr10:96991505	NA	-0.41	-5.75	-0.3	2.06e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-7.96	-0.4	2.69e-14	Major depressive disorder;
LUSC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg13395646	chr4:1353034	KIAA1530	-0.66	-10.39	-0.49	4.22e-22	Obesity-related traits;
LUSC	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg13755796	chr4:20253514	NA	-0.38	-5.95	-0.31	6.64e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg12832228	chr8:28244096	ZNF395	0.48	6.1	0.32	3.01e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11229555	0.645	rs36002376	chr11:58204809	C/G	cg15696309	chr11:58395628	NA	-0.67	-8.13	-0.41	8.64e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg23435118	chr5:141488016	NDFIP1	-0.55	-7.75	-0.39	1.11e-13	Crohn's disease;
LUSC	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg25233709	chr10:116636983	FAM160B1	0.44	7.92	0.4	3.62e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2073300	1.000	rs6137977	chr20:23464191	G/T	cg12062639	chr20:23401060	NAPB	0.73	5.67	0.3	3.06e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-8.63	-0.43	2.48e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs12439619	0.530	rs28883606	chr15:82509054	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.49	-8.15	-0.41	7.64e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2294693	0.947	rs9381025	chr6:40986623	C/T	cg14769373	chr6:40998127	UNC5CL	-0.54	-8.33	-0.41	2.09e-15	Gastric cancer;Non-cardia gastric cancer;
LUSC	trans	rs7698623	0.850	rs1381960	chr4:88801652	A/T	cg27340350	chr19:49559583	CGB7	-0.66	-6.14	-0.32	2.33e-9	Cardiovascular disease risk factors;
LUSC	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg22705602	chr4:152727874	NA	0.36	7.98	0.4	2.36e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16659246	chr4:18023725	LCORL	-0.39	-6.15	-0.32	2.2e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18876405	chr7:65276391	NA	0.49	6.66	0.34	1.14e-10	Corneal structure;
LUSC	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg17420585	chr12:42539391	GXYLT1	-0.33	-6.16	-0.32	2.08e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg11494091	chr17:61959527	GH2	0.34	5.69	0.3	2.83e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg08847533	chr14:75593920	NEK9	-0.84	-15.37	-0.64	1.12e-40	Height;
LUSC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.57	8.78	0.43	8.95e-17	Longevity;
LUSC	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg20607287	chr7:12443886	VWDE	-0.64	-6.27	-0.32	1.09e-9	Coronary artery disease;
LUSC	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg06207120	chr15:45996521	NA	0.39	6.04	0.31	4.12e-9	Waist circumference;Weight;
LUSC	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg01973587	chr1:228161476	NA	-0.35	-5.66	-0.3	3.33e-8	Diastolic blood pressure;
LUSC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg22535103	chr8:58192502	C8orf71	-0.58	-7.09	-0.36	7.87e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	7.25	0.37	2.91e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.68	12.99	0.58	1.6e-31	Age-related hearing impairment;
LUSC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	6.24	0.32	1.34e-9	Electroencephalogram traits;
LUSC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.77	0.35	5.68e-11	Tonsillectomy;
LUSC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.11	14.24	0.61	2.64e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg08601574	chr20:25228251	PYGB	0.38	5.67	0.3	3.11e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg05347473	chr6:146136440	FBXO30	0.51	8.52	0.42	5.43e-16	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.38e-9	Bladder cancer;
LUSC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg25767906	chr1:53392781	SCP2	-0.5	-9.27	-0.45	2.43e-18	Monocyte count;
LUSC	trans	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg20935933	chr6:143382018	AIG1	0.51	7.43	0.38	8.96e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9865818	0.754	rs7613192	chr3:188109833	C/G	cg23651889	chr3:188115336	LPP	-0.39	-6.01	-0.31	4.8e-9	Allergic sensitization;
LUSC	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.47	6.5	0.34	2.89e-10	Lung disease severity in cystic fibrosis;
LUSC	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.53	-0.38	4.7e-13	Retinal vascular caliber;
LUSC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.91	0.31	8.29e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.690	rs11191369	chr10:104457456	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.45	6.17	0.32	2.02e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.04	-21.14	-0.76	1.47e-63	Ulcerative colitis;
LUSC	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.95	18.27	0.71	3.39e-52	Body mass index (adult);
LUSC	cis	rs8099014	0.861	rs2277722	chr18:56121280	G/C	cg12907477	chr18:56117327	MIR122	0.43	6.79	0.35	5.29e-11	Platelet count;
LUSC	cis	rs12681287	0.640	rs7820234	chr8:87350950	A/C	cg27223183	chr8:87520930	FAM82B	-0.54	-7.06	-0.36	9.96e-12	Caudate activity during reward;
LUSC	cis	rs2273669	0.667	rs1407241	chr6:109328432	G/A	cg05315195	chr6:109294784	ARMC2	-0.53	-5.89	-0.31	9.28e-9	Prostate cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16857181	chr7:32931955	KBTBD2	0.44	6.0	0.31	5.06e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg15448220	chr1:150897856	SETDB1	0.41	5.96	0.31	6.29e-9	Melanoma;
LUSC	cis	rs72634258	0.945	rs161800	chr1:8042402	A/T	cg26816564	chr1:7831052	VAMP3	0.43	5.85	0.3	1.16e-8	Inflammatory bowel disease;
LUSC	cis	rs6120849	0.754	rs1885116	chr20:33600560	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.67	0.34	1.05e-10	Protein C levels;
LUSC	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg05855489	chr10:104503620	C10orf26	0.48	7.3	0.37	2.16e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg18904891	chr8:8559673	CLDN23	0.59	8.16	0.41	7.1e-15	Obesity-related traits;
LUSC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg24060327	chr5:131705240	SLC22A5	-0.68	-11.54	-0.53	3.83e-26	Breast cancer;
LUSC	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg10172584	chr19:19639581	YJEFN3	-0.46	-5.65	-0.3	3.42e-8	Bipolar disorder;
LUSC	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.62	8.43	0.42	1.02e-15	Adiposity;
LUSC	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg27102117	chr16:15229624	NA	0.41	7.08	0.36	8.32e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.83	0.47	3.48e-20	Electroencephalogram traits;
LUSC	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg13334819	chr7:99746414	C7orf59	0.5	6.68	0.34	9.99e-11	Coronary artery disease;
LUSC	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg00277334	chr10:82204260	NA	-0.45	-6.24	-0.32	1.34e-9	Post bronchodilator FEV1;
LUSC	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg01193554	chr1:41846683	NA	-0.29	-6.07	-0.32	3.53e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7759001	0.817	rs9461380	chr6:27363557	G/T	cg18711553	chr6:27366782	ZNF391	0.39	5.66	0.3	3.26e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	1.05	19.6	0.73	1.82e-57	Menopause (age at onset);
LUSC	cis	rs9535307	0.799	rs2146143	chr13:50245620	A/C	cg04663916	chr13:50265991	EBPL	0.48	5.91	0.31	8.67e-9	Obesity-related traits;
LUSC	cis	rs56161922	0.915	rs12562739	chr1:207856658	T/A	cg11752769	chr1:207818423	CR1L	-0.71	-6.0	-0.31	5.07e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.59	10.04	0.48	6.41e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-17.45	-0.69	6.37e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg04287289	chr16:89883240	FANCA	-0.5	-7.69	-0.39	1.68e-13	Vitiligo;
LUSC	cis	rs1506636	1.000	rs60689684	chr7:123370403	C/T	cg03229431	chr7:123269106	ASB15	0.63	9.98	0.48	1.08e-20	Plateletcrit;Platelet count;
LUSC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.75	10.31	0.49	8e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg02569458	chr12:86230093	RASSF9	0.62	10.52	0.5	1.55e-22	Major depressive disorder;
LUSC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.07	-17.63	-0.69	1.25e-49	Primary sclerosing cholangitis;
LUSC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg03676636	chr4:99064102	C4orf37	0.32	7.01	0.36	1.34e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs757081	0.667	rs7108067	chr11:17200220	G/A	cg15432903	chr11:17409602	KCNJ11	-0.38	-5.89	-0.31	9.56e-9	Systolic blood pressure;
LUSC	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg20991723	chr1:152506922	NA	0.53	10.03	0.48	7.05e-21	Hair morphology;
LUSC	cis	rs8038465	0.615	rs62004616	chr15:73961176	C/T	cg15420318	chr15:73925796	NPTN	0.61	10.63	0.5	6.22e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg06454157	chr6:167490870	NA	-0.28	-6.72	-0.35	7.97e-11	Primary biliary cholangitis;
LUSC	cis	rs12541635	0.966	rs12674846	chr8:107007178	A/G	cg10147462	chr8:107024639	NA	0.55	9.97	0.48	1.16e-20	Age of smoking initiation;
LUSC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg25456477	chr12:86230367	RASSF9	-0.4	-7.12	-0.36	6.59e-12	Major depressive disorder;
LUSC	trans	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg06521331	chr12:34319734	NA	0.4	6.35	0.33	6.91e-10	Bladder cancer;
LUSC	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg20283391	chr11:68216788	NA	-0.6	-8.37	-0.42	1.6e-15	Total body bone mineral density;
LUSC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	0.72	14.21	0.61	3.6e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs9818941	0.824	rs7628186	chr3:157800499	T/C	cg08654915	chr3:157813417	NA	0.32	7.52	0.38	5.11e-13	Height;
LUSC	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg01475377	chr6:109611718	NA	-0.44	-7.84	-0.39	6.24e-14	Reticulocyte fraction of red cells;
LUSC	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.65	0.39	2.18e-13	Height;
LUSC	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg16329650	chr2:213403929	ERBB4	-0.57	-9.57	-0.46	2.49e-19	Symmetrical dimethylarginine levels;
LUSC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	0.95	14.84	0.63	1.32e-38	Body mass index;
LUSC	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.94	-18.24	-0.71	4.57e-52	Brugada syndrome;
LUSC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	ch.11.42038R	chr11:967971	AP2A2	0.44	6.6	0.34	1.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs2652834	0.519	rs4075584	chr15:63340292	C/T	cg05507819	chr15:63340323	TPM1	0.99	12.37	0.56	3.46e-29	HDL cholesterol;
LUSC	cis	rs1979679	0.573	rs7134807	chr12:28729250	A/G	cg13890972	chr12:28721907	NA	0.39	5.71	0.3	2.54e-8	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06221963	chr1:154839813	KCNN3	-0.59	-12.99	-0.58	1.61e-31	Prostate cancer;
LUSC	cis	rs2970818	0.831	rs11063189	chr12:4588248	C/T	cg11146114	chr12:4671731	NA	-0.6	-5.69	-0.3	2.83e-8	Phosphorus levels;
LUSC	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg16230307	chr14:35515116	FAM177A1	0.79	10.18	0.49	2.24e-21	Psoriasis;
LUSC	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.93	15.92	0.66	7.38e-43	Bladder cancer;
LUSC	cis	rs12545109	0.842	rs10958482	chr8:57389331	G/T	cg09654669	chr8:57350985	NA	-0.51	-6.96	-0.36	1.85e-11	Obesity-related traits;
LUSC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg09365446	chr1:150670422	GOLPH3L	0.44	6.7	0.34	8.89e-11	Melanoma;
LUSC	cis	rs9650315	0.852	rs5027177	chr8:57179659	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	6.82	0.35	4.17e-11	Height;
LUSC	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg23625390	chr15:77176239	SCAPER	-0.65	-10.08	-0.48	4.94e-21	Blood metabolite levels;
LUSC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.21	-13.88	-0.6	6.79e-35	Diabetic kidney disease;
LUSC	trans	rs941408	0.515	rs878893	chr19:2781325	A/G	cg22153745	chr1:153894579	GATAD2B	-0.52	-7.09	-0.36	7.86e-12	Total cholesterol levels;
LUSC	cis	rs6733011	0.519	rs11900176	chr2:99463536	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.45	6.12	0.32	2.55e-9	Bipolar disorder;
LUSC	cis	rs2692947	1.000	rs2692947	chr2:96674116	T/C	cg22654517	chr2:96458247	NA	0.33	6.51	0.34	2.7e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02176678	chr2:219576539	TTLL4	-0.7	-13.3	-0.59	1.09e-32	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.47	-0.42	8.08e-16	Response to antipsychotic treatment;
LUSC	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg06532163	chr17:45867833	NA	0.35	6.67	0.34	1.07e-10	IgG glycosylation;
LUSC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.68	0.34	9.71e-11	Menopause (age at onset);
LUSC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg03146154	chr1:46216737	IPP	0.53	7.79	0.39	8.74e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	1e-64	Prudent dietary pattern;
LUSC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.81	14.65	0.63	7.13e-38	Blood protein levels;
LUSC	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg17830980	chr10:43048298	ZNF37B	0.42	6.38	0.33	5.87e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg19077165	chr18:44547161	KATNAL2	0.45	6.67	0.34	1.04e-10	Personality dimensions;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14916095	chr14:52118110	FRMD6	0.46	6.28	0.32	1.08e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg23711669	chr6:146136114	FBXO30	-0.83	-14.87	-0.63	9.93e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg00383909	chr3:49044727	WDR6	1.1	9.62	0.47	1.66e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg24812749	chr6:127587940	RNF146	0.64	9.44	0.46	6.68e-19	Breast cancer;
LUSC	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg07701084	chr6:150067640	NUP43	0.46	6.86	0.35	3.28e-11	Testicular germ cell tumor;
LUSC	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23158103	chr7:148848205	ZNF398	-0.44	-6.81	-0.35	4.44e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26314531	chr2:26401878	FAM59B	-0.68	-9.19	-0.45	4.28e-18	Gut microbiome composition (summer);
LUSC	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.78	-0.43	8.45e-17	Response to antipsychotic treatment;
LUSC	cis	rs11166629	0.785	rs894343	chr8:135612595	A/G	cg27224718	chr8:135614730	ZFAT	0.64	10.14	0.49	3.11e-21	Smoking quantity;
LUSC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.61	-6.04	-0.31	4.02e-9	Cerebrospinal P-tau181p levels;
LUSC	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21659725	chr3:3221576	CRBN	-0.6	-8.58	-0.42	3.59e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.19	0.41	5.6e-15	Prudent dietary pattern;
LUSC	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg24578937	chr1:2090814	PRKCZ	0.6	13.87	0.6	7.21e-35	Height;
LUSC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg13206674	chr6:150067644	NUP43	0.61	9.65	0.47	1.39e-19	Lung cancer;
LUSC	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg00509249	chr6:109615579	CCDC162	-0.33	-5.95	-0.31	6.87e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg15790184	chr11:494944	RNH1	0.5	7.7	0.39	1.52e-13	Systemic lupus erythematosus;
LUSC	cis	rs7712401	0.601	rs246273	chr5:122280975	G/A	cg19077854	chr5:122220652	SNX24	0.41	9.17	0.45	4.86e-18	Mean platelet volume;
LUSC	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg12002119	chr2:101014098	CHST10	0.34	5.78	0.3	1.69e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg12549451	chr6:135224345	NA	0.36	5.82	0.3	1.37e-8	Red blood cell count;
LUSC	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg25206134	chr2:45395956	NA	0.55	6.32	0.33	8.54e-10	Bipolar disorder;
LUSC	cis	rs7178572	0.568	rs8030074	chr15:77654232	C/T	cg22256960	chr15:77711686	NA	-0.51	-8.11	-0.41	9.91e-15	Type 2 diabetes;
LUSC	trans	rs61931739	0.635	rs3937819	chr12:33942715	A/G	cg13010199	chr12:38710504	ALG10B	0.4	6.04	0.31	4.15e-9	Morning vs. evening chronotype;
LUSC	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg03605463	chr16:89740564	NA	0.57	9.26	0.45	2.58e-18	Hemoglobin concentration;
LUSC	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.33	0.41	2.18e-15	Lung cancer;
LUSC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-6.76	-0.35	6.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg26384229	chr12:38710491	ALG10B	0.75	11.78	0.54	5.09e-27	Morning vs. evening chronotype;
LUSC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22968622	chr17:43663579	NA	1.13	19.59	0.73	1.97e-57	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg06917634	chr15:78832804	PSMA4	0.47	5.91	0.31	8.65e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg07701084	chr6:150067640	NUP43	0.54	8.12	0.41	8.98e-15	Lung cancer;
LUSC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.61	0.6	7.09e-34	Cognitive test performance;
LUSC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.5	0.34	2.96e-10	Lung cancer;
LUSC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	0.94	18.56	0.71	2.36e-53	Cognitive function;
LUSC	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg18105134	chr13:113819100	PROZ	-0.73	-10.88	-0.51	8.33e-24	Platelet distribution width;
LUSC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg02931644	chr1:25747376	RHCE	0.33	6.04	0.31	4.11e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg17252645	chr8:143867129	LY6D	-0.38	-6.49	-0.33	3.1e-10	Urinary tract infection frequency;
LUSC	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg01028140	chr2:1542097	TPO	-0.6	-8.23	-0.41	4.3e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg04733989	chr22:42467013	NAGA	-0.62	-9.72	-0.47	7.81e-20	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg26384229	chr12:38710491	ALG10B	0.56	9.08	0.44	9.49e-18	Morning vs. evening chronotype;
LUSC	cis	rs9837602	1.000	rs62285461	chr3:99767642	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.89	-0.31	9.61e-9	Breast cancer;
LUSC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg09323728	chr8:95962352	TP53INP1	-0.4	-7.92	-0.4	3.44e-14	Type 2 diabetes;
LUSC	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.56	0.34	2.05e-10	IgG glycosylation;
LUSC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	0.92	17.45	0.69	6.63e-49	Heart rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02711976	chr1:36023590	NCDN;KIAA0319L	0.48	8.24	0.41	3.86e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02034447	chr16:89574710	SPG7	0.44	6.49	0.33	3.09e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.64	0.3	3.56e-8	Self-reported allergy;
LUSC	cis	rs4664308	0.935	rs17216980	chr2:160960932	G/A	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.56	-0.53	3.29e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg24531977	chr5:56204891	C5orf35	0.56	8.31	0.41	2.39e-15	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg01483505	chr11:975446	AP2A2	0.41	5.66	0.3	3.29e-8	Alzheimer's disease (late onset);
LUSC	cis	rs6669919	0.553	rs7527603	chr1:211668090	G/A	cg10512769	chr1:211675356	NA	-0.3	-7.02	-0.36	1.28e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.75	12.07	0.55	4.42e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08109568	chr15:31115862	NA	0.75	11.16	0.52	8.76e-25	Huntington's disease progression;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg26708280	chr2:190649305	PMS1;ORMDL1	0.48	6.32	0.33	8.6e-10	Cognitive function;Information processing speed;
LUSC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg08088566	chr11:430123	ANO9	0.71	7.61	0.38	2.76e-13	Body mass index;
LUSC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg18351406	chr4:77819688	ANKRD56	0.54	7.57	0.38	3.62e-13	Emphysema distribution in smoking;
LUSC	cis	rs1322512	0.917	rs2038617	chr6:153009584	T/A	cg27316956	chr6:152958899	SYNE1	0.37	6.27	0.32	1.09e-9	Tonometry;
LUSC	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	7.49	0.38	6.32e-13	Neuroticism;
LUSC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg04944784	chr2:26401820	FAM59B	0.78	11.16	0.52	8.66e-25	Gut microbiome composition (summer);
LUSC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06112835	chr11:68658793	MRPL21	0.5	7.69	0.39	1.64e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg04725166	chr1:7887271	PER3	-0.45	-6.2	-0.32	1.64e-9	Crohn's disease;
LUSC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.43	-7.86	-0.39	5.51e-14	Coronary artery disease;
LUSC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.77	0.35	5.68e-11	Tonsillectomy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20659025	chr11:126173961	DCPS	-0.45	-6.87	-0.35	3.24e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.64	-0.47	1.44e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	1.22	16.23	0.66	4.4e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg17541715	chr7:1216824	NA	-0.36	-5.8	-0.3	1.54e-8	Longevity;Endometriosis;
LUSC	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.34	0.49	6.17e-22	Bladder cancer;
LUSC	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg19628046	chr18:33552617	C18orf21	0.52	6.32	0.33	8.18e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs11971779	0.625	rs2355784	chr7:139072493	G/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6867032	0.839	rs4314451	chr5:2001859	T/C	cg26168224	chr5:2018326	NA	-0.75	-13.18	-0.58	3.2e-32	Gut microbiome composition (winter);
LUSC	cis	rs651907	0.617	rs797776	chr3:101610243	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.48	6.85	0.35	3.67e-11	Colorectal cancer;
LUSC	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	trans	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs617219	0.853	rs4703773	chr5:78520556	C/T	cg24856658	chr5:78533917	JMY	-0.3	-6.03	-0.31	4.26e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs897080	0.515	rs786405	chr2:44710367	G/T	cg00619915	chr2:44497795	NA	-0.44	-6.35	-0.33	7.09e-10	Height;
LUSC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg24250549	chr1:154909240	PMVK	0.44	6.76	0.35	6.35e-11	Prostate cancer;
LUSC	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg04362960	chr10:104952993	NT5C2	1.15	13.39	0.59	5.24e-33	Arsenic metabolism;
LUSC	trans	rs6600671	0.934	rs12060031	chr1:121243450	A/G	cg00646200	chr1:148855367	NA	-0.46	-7.2	-0.37	4.06e-12	Hip geometry;
LUSC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.85	-14.19	-0.61	4.47e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7577851	0.625	rs67052036	chr2:69599024	A/C	cg10773587	chr2:69614142	GFPT1	0.56	6.23	0.32	1.44e-9	Parkinson's disease (age of onset);
LUSC	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg22732515	chr19:44031385	ETHE1	0.63	10.46	0.5	2.5e-22	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg13010199	chr12:38710504	ALG10B	0.66	10.16	0.49	2.56e-21	Bladder cancer;
LUSC	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg11657440	chr19:46296263	DMWD	-0.75	-11.87	-0.54	2.31e-27	Coronary artery disease;
LUSC	trans	rs2055729	0.645	rs12544019	chr8:9742578	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	6.94	0.36	2.04e-11	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.41	7.06	0.36	9.83e-12	Schizophrenia;
LUSC	cis	rs2282300	1.000	rs12575085	chr11:30428262	G/T	cg25418670	chr11:30344373	C11orf46	-0.48	-6.36	-0.33	6.79e-10	Morning vs. evening chronotype;
LUSC	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	15.78	0.65	2.63e-42	Lung cancer in ever smokers;
LUSC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg06494592	chr3:125709126	NA	-0.52	-5.93	-0.31	7.44e-9	Blood pressure (smoking interaction);
LUSC	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-5.78	-0.3	1.73e-8	IgG glycosylation;
LUSC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.44	0.53	8.42e-26	Menopause (age at onset);
LUSC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg21951975	chr1:209979733	IRF6	0.59	7.71	0.39	1.49e-13	Cleft lip with or without cleft palate;
LUSC	cis	rs354225	0.544	rs10184128	chr2:54803816	A/G	cg26097391	chr2:54893211	SPTBN1	0.44	6.68	0.34	9.77e-11	Schizophrenia;
LUSC	cis	rs13082711	0.911	rs2887926	chr3:27494475	T/C	cg02860705	chr3:27208620	NA	0.47	7.92	0.4	3.65e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs4363385	0.693	rs6690549	chr1:152930426	C/T	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.06	-0.36	9.7e-12	Inflammatory skin disease;
LUSC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.75	-0.3	1.98e-8	Personality dimensions;
LUSC	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg03806693	chr22:41940476	POLR3H	-0.59	-8.66	-0.43	2e-16	Neuroticism;
LUSC	cis	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg27411982	chr8:10470053	RP1L1	0.41	6.35	0.33	7.01e-10	Neuroticism;
LUSC	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7589342	0.839	rs10192144	chr2:106439854	A/G	cg16077055	chr2:106428750	NCK2	0.37	7.04	0.36	1.11e-11	Addiction;
LUSC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	8.43	0.42	1.04e-15	Colorectal cancer;
LUSC	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg04586622	chr2:25135609	ADCY3	0.32	6.22	0.32	1.51e-9	Body mass index;
LUSC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg08270630	chr22:50330655	NA	0.4	5.9	0.31	8.83e-9	Schizophrenia;
LUSC	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg19875535	chr5:140030758	IK	0.47	7.66	0.39	2.01e-13	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg15704280	chr7:45808275	SEPT13	0.78	7.48	0.38	6.75e-13	Axial length;
LUSC	cis	rs7173743	0.756	rs8034804	chr15:79129600	C/T	cg00540400	chr15:79124168	NA	0.36	6.36	0.33	6.71e-10	Coronary artery disease;
LUSC	trans	rs75804782	0.641	rs57080728	chr2:239350487	T/C	cg01134436	chr17:81009848	B3GNTL1	0.66	6.4	0.33	5.11e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.46	0.59	2.76e-33	Platelet count;
LUSC	cis	rs2562456	0.793	rs2650819	chr19:21638873	C/T	cg00806126	chr19:22604979	ZNF98	0.38	5.94	0.31	6.99e-9	Pain;
LUSC	cis	rs12681288	0.576	rs7002793	chr8:963467	T/C	cg15309053	chr8:964076	NA	0.39	7.72	0.39	1.39e-13	Schizophrenia;
LUSC	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg06636551	chr8:101224915	SPAG1	-0.39	-7.35	-0.37	1.49e-12	Atrioventricular conduction;
LUSC	cis	rs73198271	0.531	rs112930476	chr8:8671551	G/A	cg01851573	chr8:8652454	MFHAS1	0.65	8.41	0.42	1.23e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg22709100	chr7:91322751	NA	0.45	6.52	0.34	2.66e-10	Breast cancer;
LUSC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg11663144	chr21:46675770	NA	-0.41	-7.2	-0.37	4.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.07	-0.36	9.03e-12	Colorectal cancer;
LUSC	cis	rs7804356	1.000	rs7804356	chr7:26891665	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.18	-0.32	1.92e-9	Type 1 diabetes;
LUSC	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg00857998	chr1:205179979	DSTYK	0.61	9.77	0.47	5.35e-20	Red blood cell count;
LUSC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg25258033	chr6:167368657	RNASET2	-0.42	-7.02	-0.36	1.21e-11	Crohn's disease;
LUSC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg21724239	chr8:58056113	NA	0.54	6.59	0.34	1.72e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.36	-0.33	6.78e-10	Myopia (pathological);
LUSC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18876405	chr7:65276391	NA	0.54	8.31	0.41	2.44e-15	Aortic root size;
LUSC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg12963246	chr6:28129442	ZNF389	0.38	5.85	0.3	1.16e-8	Cardiac Troponin-T levels;
LUSC	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15320075	chr8:145703422	NA	-0.64	-10.96	-0.51	4.33e-24	Age at first birth;
LUSC	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg25237894	chr2:233734115	C2orf82	0.35	6.5	0.34	2.87e-10	Coronary artery disease;
LUSC	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg13334819	chr7:99746414	C7orf59	0.44	5.85	0.3	1.2e-8	Coronary artery disease;
LUSC	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-10.12	-0.48	3.69e-21	Migraine;Coronary artery disease;
LUSC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.52	-0.42	5.62e-16	Obesity-related traits;
LUSC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.75e-10	Crohn's disease;
LUSC	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	9.23	0.45	3.27e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg13010199	chr12:38710504	ALG10B	0.48	7.37	0.37	1.34e-12	Morning vs. evening chronotype;
LUSC	trans	rs11039798	0.920	rs61448762	chr11:48923756	G/A	cg15704280	chr7:45808275	SEPT13	0.81	7.11	0.36	7.06e-12	Axial length;
LUSC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg13047869	chr3:10149882	C3orf24	0.62	8.66	0.43	1.98e-16	Alzheimer's disease;
LUSC	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg00310523	chr12:86230176	RASSF9	-0.37	-6.68	-0.34	9.84e-11	Major depressive disorder;
LUSC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	0.92	18.29	0.71	2.92e-52	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7715806	0.500	rs2307112	chr5:75003413	A/C	cg19683494	chr5:74908142	NA	0.58	7.75	0.39	1.15e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs62400317	0.762	rs6909047	chr6:44998915	C/G	cg18551225	chr6:44695536	NA	-0.41	-6.55	-0.34	2.14e-10	Total body bone mineral density;
LUSC	cis	rs4474465	0.920	rs10899535	chr11:78216237	G/A	cg27205649	chr11:78285834	NARS2	0.5	5.77	0.3	1.8e-8	Alzheimer's disease (survival time);
LUSC	cis	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05901451	chr6:126070800	HEY2	0.6	9.47	0.46	5.17e-19	Endometrial cancer;
LUSC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg11062466	chr8:58055876	NA	0.74	8.95	0.44	2.49e-17	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs12760731	0.720	rs67857740	chr1:178402250	A/G	cg00404053	chr1:178313656	RASAL2	0.57	6.23	0.32	1.39e-9	Obesity-related traits;
LUSC	cis	rs72960926	0.744	rs55784940	chr6:74923315	G/T	cg03266952	chr6:74778945	NA	-0.84	-7.01	-0.36	1.34e-11	Metabolite levels (MHPG);
LUSC	cis	rs10740039	0.810	rs10740036	chr10:62365974	C/T	cg18175470	chr10:62150864	ANK3	-0.47	-7.08	-0.36	8.72e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.66	0.34	1.16e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1595825	0.838	rs7603283	chr2:198517592	A/G	cg19156104	chr2:198669113	PLCL1	-0.46	-5.75	-0.3	2.02e-8	Ulcerative colitis;
LUSC	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg23460707	chr10:133558971	NA	0.35	6.01	0.31	4.86e-9	Survival in rectal cancer;
LUSC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.09	0.45	9.13e-18	Motion sickness;
LUSC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg08888203	chr3:10149979	C3orf24	0.61	8.29	0.41	2.8e-15	Alzheimer's disease;
LUSC	cis	rs16854884	0.657	rs7637912	chr3:143749777	G/A	cg06585982	chr3:143692056	C3orf58	0.5	7.91	0.4	3.89e-14	Economic and political preferences (feminism/equality);
LUSC	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg21775007	chr8:11205619	TDH	-0.46	-6.84	-0.35	3.83e-11	Neuroticism;
LUSC	cis	rs57502260	0.704	rs17149179	chr11:68351722	C/T	cg20283391	chr11:68216788	NA	-0.62	-5.87	-0.31	1.08e-8	Total body bone mineral density (age 45-60);
LUSC	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21659725	chr3:3221576	CRBN	0.63	8.92	0.44	3.14e-17	Resting heart rate;
LUSC	cis	rs2840044	0.517	rs2124247	chr17:33885468	G/A	cg05299278	chr17:33885742	SLFN14	0.35	7.91	0.4	3.8e-14	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs4343996	1.000	rs6980323	chr7:3356207	A/G	cg21248987	chr7:3385318	SDK1	-0.39	-6.58	-0.34	1.83e-10	Motion sickness;
LUSC	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg03342759	chr3:160939853	NMD3	-0.45	-6.33	-0.33	7.76e-10	Parkinson's disease;
LUSC	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg06219351	chr7:158114137	PTPRN2	-0.54	-9.85	-0.47	2.89e-20	Calcium levels;
LUSC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg18758796	chr5:131593413	PDLIM4	0.4	6.7	0.34	8.94e-11	Breast cancer;
LUSC	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18854424	chr1:2615690	NA	-0.49	-9.74	-0.47	6.6e-20	Ulcerative colitis;
LUSC	cis	rs977987	0.806	rs11862582	chr16:75431295	T/C	cg03315344	chr16:75512273	CHST6	0.48	9.04	0.44	1.31e-17	Dupuytren's disease;
LUSC	cis	rs870825	0.929	rs72689262	chr4:185590950	C/G	cg04058563	chr4:185651563	MLF1IP	0.83	11.29	0.53	2.87e-25	Blood protein levels;
LUSC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg05872129	chr22:39784769	NA	-0.59	-10.06	-0.48	5.52e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg27529037	chr20:44575021	PCIF1	-0.42	-7.38	-0.37	1.23e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25072359	chr17:41440525	NA	0.65	9.27	0.45	2.36e-18	Menopause (age at onset);
LUSC	cis	rs2361718	0.527	rs7211994	chr17:78152514	A/G	cg09238746	chr17:78121135	EIF4A3	0.48	6.87	0.35	3.21e-11	Yeast infection;
LUSC	cis	rs3925075	1.000	rs3925075	chr16:31347748	C/T	cg02846316	chr16:31340340	ITGAM	-0.36	-6.68	-0.34	1e-10	IgA nephropathy;
LUSC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg21132104	chr15:45694354	SPATA5L1	0.57	7.97	0.4	2.54e-14	Homoarginine levels;
LUSC	trans	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg25214090	chr10:38739885	LOC399744	0.46	6.7	0.34	8.76e-11	Corneal astigmatism;
LUSC	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg02527881	chr3:46936655	PTH1R	0.39	6.85	0.35	3.66e-11	Colorectal cancer;
LUSC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg18350739	chr11:68623251	NA	-0.37	-6.36	-0.33	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg00757033	chr12:89920650	WDR51B	0.6	10.35	0.49	5.9e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.46	-0.38	7.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2230307	0.536	rs2893426	chr1:100528200	G/T	cg24955406	chr1:100503596	HIAT1	0.56	6.07	0.32	3.5e-9	Carotid intima media thickness;
LUSC	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg01416388	chr22:39784598	NA	-0.42	-7.03	-0.36	1.16e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2820315	0.867	rs2644135	chr1:201856256	C/G	cg10061532	chr1:201886748	LMOD1	-0.26	-5.79	-0.3	1.65e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06656553	chr16:89960601	TCF25	-0.65	-5.7	-0.3	2.65e-8	Skin colour saturation;
LUSC	cis	rs12618769	0.597	rs55934321	chr2:99099417	G/A	cg10123293	chr2:99228465	UNC50	0.47	7.67	0.39	1.89e-13	Bipolar disorder;
LUSC	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg10356904	chr22:49881777	NA	-0.3	-6.65	-0.34	1.21e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg19628046	chr18:33552617	C18orf21	0.5	5.98	0.31	5.74e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.68	0.3	2.94e-8	Menopause (age at onset);
LUSC	cis	rs240764	0.658	rs1039030	chr6:101198707	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-6.27	-0.32	1.11e-9	Neuroticism;
LUSC	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg19920283	chr7:105172520	RINT1	0.58	6.22	0.32	1.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg01802117	chr1:53393560	SCP2	-0.39	-6.54	-0.34	2.27e-10	Monocyte count;
LUSC	cis	rs7000551	0.689	rs2469753	chr8:22383225	T/C	cg12081754	chr8:22256438	SLC39A14	0.43	6.5	0.34	2.86e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg05360138	chr12:110035743	NA	0.87	10.28	0.49	1.03e-21	Neuroticism;
LUSC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg24879335	chr3:133465180	TF	0.46	8.02	0.4	1.78e-14	Iron status biomarkers;
LUSC	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.18	-0.52	7.56e-25	Coffee consumption (cups per day);
LUSC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg06060754	chr5:176797920	RGS14	0.56	7.88	0.4	4.55e-14	Urate levels in lean individuals;
LUSC	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg05501817	chr11:14380813	RRAS2	-0.56	-9.31	-0.45	1.74e-18	Sense of smell;
LUSC	cis	rs9644630	0.696	rs7828025	chr8:19314693	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.48	8.09	0.4	1.1e-14	Oropharynx cancer;
LUSC	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.51	-6.09	-0.32	3.09e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs16917546	0.967	rs10995243	chr10:64391208	G/C	cg03961010	chr10:64397487	ZNF365	-0.43	-6.71	-0.34	8.26e-11	Basal cell carcinoma;
LUSC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg13722127	chr7:150037890	RARRES2	0.42	6.64	0.34	1.29e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg22508957	chr16:3507546	NAT15	-0.73	-9.29	-0.45	2.05e-18	Tuberculosis;
LUSC	cis	rs12738007	0.544	rs4654390	chr1:29439016	T/A	cg01925633	chr1:29338769	EPB41	0.39	6.01	0.31	4.8e-9	Schizophrenia;
LUSC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg24399712	chr22:39784796	NA	-0.57	-9.32	-0.45	1.62e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg21984481	chr17:79567631	NPLOC4	-0.59	-11.42	-0.53	1.02e-25	Eye color traits;
LUSC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-6.43	-0.33	4.33e-10	Neutrophil percentage of white cells;
LUSC	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg00757033	chr12:89920650	WDR51B	0.6	10.35	0.49	5.9e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg16325326	chr1:53192061	ZYG11B	0.89	16.36	0.67	1.39e-44	Monocyte count;
LUSC	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg19717773	chr7:2847554	GNA12	-0.42	-7.69	-0.39	1.71e-13	Height;
LUSC	trans	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs983392	0.678	rs4938931	chr11:60026613	G/T	cg02771260	chr11:59836817	MS4A3	0.37	6.07	0.32	3.39e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.09	-0.4	1.11e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	6.27	0.32	1.11e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs2274273	0.624	rs4580079	chr14:55780366	G/A	cg04306507	chr14:55594613	LGALS3	0.48	9.7	0.47	9.23e-20	Protein biomarker;
LUSC	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg13798780	chr7:105162888	PUS7	0.57	6.23	0.32	1.39e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg10665199	chr7:133106180	EXOC4	0.54	7.66	0.39	2.05e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg24209194	chr3:40518798	ZNF619	0.44	5.85	0.3	1.18e-8	Renal cell carcinoma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12721145	chr4:109571876	OSTC	-0.48	-7.04	-0.36	1.08e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6574644	1.000	rs1957543	chr14:81777074	G/A	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg04362960	chr10:104952993	NT5C2	0.62	9.75	0.47	6.31e-20	Arsenic metabolism;
LUSC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg21141812	chr3:48556323	PFKFB4	0.35	6.11	0.32	2.8e-9	Menarche (age at onset);
LUSC	cis	rs11690935	0.885	rs6727017	chr2:172766847	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.82	-13.22	-0.59	2.23e-32	Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25756398	chr11:93474621	C11orf54;TAF1D	-0.53	-6.73	-0.35	7.58e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.6	8.0	0.4	2.13e-14	High light scatter reticulocyte count;
LUSC	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.94	-0.31	7.31e-9	Neutrophil percentage of white cells;
LUSC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg23262073	chr20:60523788	NA	-0.47	-6.67	-0.34	1.08e-10	Body mass index;
LUSC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.62	-10.14	-0.49	2.97e-21	Body mass index;
LUSC	trans	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg01620082	chr3:125678407	NA	-0.85	-7.21	-0.37	3.87e-12	Depression;
LUSC	cis	rs10100465	0.961	rs10955822	chr8:118674331	C/G	cg09430518	chr8:118662568	NA	0.3	5.79	0.3	1.59e-8	Leprosy;
LUSC	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg13010199	chr12:38710504	ALG10B	0.53	7.95	0.4	2.88e-14	Morning vs. evening chronotype;
LUSC	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg12257692	chr3:49977190	RBM6	-0.21	-5.83	-0.3	1.29e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7202877	0.656	rs4888370	chr16:75308230	T/C	cg04384234	chr16:75411784	CFDP1	-0.66	-9.05	-0.44	1.21e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-14.15	-0.61	5.95e-36	Total body bone mineral density;
LUSC	trans	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.89	0.4	4.37e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg14440974	chr22:39074834	NA	-0.37	-6.08	-0.32	3.32e-9	Menopause (age at onset);
LUSC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg12463550	chr7:65579703	CRCP	0.52	7.46	0.38	7.59e-13	Aortic root size;
LUSC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.41	-6.2	-0.32	1.67e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg20406979	chr6:167373233	NA	0.26	6.13	0.32	2.5e-9	Crohn's disease;
LUSC	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.69	10.47	0.5	2.2e-22	Corneal astigmatism;
LUSC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg20203395	chr5:56204925	C5orf35	-0.79	-10.3	-0.49	8.54e-22	Initial pursuit acceleration;
LUSC	trans	rs4729127	0.708	rs17166230	chr7:94017794	G/C	cg20086523	chr13:52378287	DHRS12	0.59	6.58	0.34	1.78e-10	Intelligence;
LUSC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.61	0.6	7.09e-34	Cognitive test performance;
LUSC	trans	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg26043149	chr18:55253948	FECH	-0.44	-6.8	-0.35	4.9e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg02580895	chr19:2754563	NA	-0.45	-6.65	-0.34	1.19e-10	Total cholesterol levels;
LUSC	trans	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg07211511	chr3:129823064	LOC729375	-0.83	-11.93	-0.55	1.48e-27	Blood pressure (smoking interaction);
LUSC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg18099408	chr3:52552593	STAB1	0.37	6.2	0.32	1.64e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00797602	chr14:39901757	FBXO33	-0.43	-6.43	-0.33	4.49e-10	Electrocardiographic conduction measures;
LUSC	cis	rs9309473	0.519	rs7606947	chr2:73909818	C/T	cg20560298	chr2:73613845	ALMS1	-0.4	-6.32	-0.33	8.42e-10	Metabolite levels;
LUSC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.53	-8.88	-0.44	4.15e-17	Longevity;Endometriosis;
LUSC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	7.58	0.38	3.44e-13	Multiple sclerosis;
LUSC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg11062466	chr8:58055876	NA	0.47	6.37	0.33	6.36e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg23173402	chr1:227635558	NA	0.54	6.65	0.34	1.18e-10	Major depressive disorder;
LUSC	cis	rs1953600	0.754	rs2573348	chr10:81925785	C/T	cg04850286	chr10:81895943	PLAC9	-0.35	-6.01	-0.31	4.91e-9	Sarcoidosis;
LUSC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Depression;
LUSC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg16325326	chr1:53192061	ZYG11B	0.87	15.96	0.66	5.29e-43	Monocyte count;
LUSC	cis	rs62400317	0.826	rs4400216	chr6:45237955	T/G	cg18551225	chr6:44695536	NA	-0.44	-7.28	-0.37	2.46e-12	Total body bone mineral density;
LUSC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.27	0.41	3.21e-15	Menarche (age at onset);
LUSC	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg08975724	chr8:8085496	FLJ10661	0.46	6.65	0.34	1.23e-10	Mood instability;
LUSC	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg24375607	chr4:120327624	NA	0.75	11.05	0.52	2.18e-24	Corneal astigmatism;
LUSC	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18932078	chr1:2524107	MMEL1	0.28	6.15	0.32	2.18e-9	Ulcerative colitis;
LUSC	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.1	-0.32	2.92e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg26380479	chr7:97908229	NA	-0.29	-6.41	-0.33	4.85e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2282300	1.000	rs12799529	chr11:30408552	T/C	cg25418670	chr11:30344373	C11orf46	-0.49	-6.56	-0.34	2.08e-10	Morning vs. evening chronotype;
LUSC	cis	rs751728	1.000	rs6925273	chr6:33732448	A/G	cg25922239	chr6:33757077	LEMD2	0.55	8.19	0.41	5.74e-15	Crohn's disease;
LUSC	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg03688085	chr1:1910585	KIAA1751	-0.6	-10.19	-0.49	2.1e-21	Severe influenza A (H1N1) infection;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26972058	chr5:134369900	PITX1	-0.41	-6.32	-0.33	8.58e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg01065977	chr19:18549689	ISYNA1	-0.23	-5.77	-0.3	1.77e-8	Breast cancer;
LUSC	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg16482183	chr6:26056742	HIST1H1C	0.69	9.43	0.46	7.29e-19	Iron status biomarkers;
LUSC	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg10434728	chr15:90938212	IQGAP1	0.32	6.04	0.31	4.04e-9	Rheumatoid arthritis;
LUSC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg04518342	chr5:131593106	PDLIM4	0.33	5.75	0.3	1.98e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.41	-0.33	4.91e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs79387448	0.638	rs6741230	chr2:103069631	C/T	cg09003973	chr2:102972529	NA	0.98	9.8	0.47	4.24e-20	Gut microbiota (bacterial taxa);
LUSC	trans	rs769111	0.812	rs2908734	chr7:12070537	A/G	cg26383454	chr6:11104957	HERV-FRD;LOC221710	0.42	6.23	0.32	1.37e-9	Tourette syndrome;
LUSC	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg13010199	chr12:38710504	ALG10B	-0.49	-7.5	-0.38	5.96e-13	Morning vs. evening chronotype;
LUSC	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg03433033	chr1:76189801	ACADM	-0.45	-6.72	-0.35	7.63e-11	Daytime sleep phenotypes;
LUSC	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.39	5.95	0.31	6.66e-9	Height;
LUSC	cis	rs12530845	0.623	rs77454235	chr7:135341862	T/C	cg23117316	chr7:135346802	PL-5283	-0.63	-9.65	-0.47	1.31e-19	Red blood cell traits;
LUSC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-7.62	-0.38	2.64e-13	Colorectal cancer;
LUSC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	1.03	19.58	0.73	2.08e-57	Menopause (age at onset);
LUSC	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg26597838	chr10:835615	NA	0.59	7.72	0.39	1.36e-13	Eosinophil percentage of granulocytes;
LUSC	cis	rs17001868	0.568	rs9611312	chr22:40734790	T/C	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	cis	rs9905704	0.846	rs302877	chr17:56764018	G/A	cg12560992	chr17:57184187	TRIM37	0.55	8.02	0.4	1.81e-14	Testicular germ cell tumor;
LUSC	cis	rs2084881	0.521	rs1022088	chr17:46579790	T/A	cg09704116	chr17:46666958	LOC404266	0.26	5.8	0.3	1.56e-8	Ovarian cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg24707616	chr17:16342815	NCRNA00188;SNORD49B;SNORD49A	0.45	6.36	0.33	6.45e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg04554929	chr8:105342491	NA	-0.4	-7.22	-0.37	3.46e-12	Paget's disease;
LUSC	cis	rs829880	0.789	rs1096146	chr12:98850966	A/G	cg25150519	chr12:98850993	NA	0.69	11.16	0.52	8.77e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	6.03	0.31	4.22e-9	Parkinson's disease;
LUSC	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.84	13.48	0.59	2.22e-33	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg05340658	chr4:99064831	C4orf37	0.68	11.43	0.53	8.93e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.56	11.17	0.52	7.79e-25	Asthma (sex interaction);
LUSC	trans	rs62055045	0.528	rs7194638	chr16:71573818	A/G	cg09088153	chr15:96890598	NA	-0.41	-5.96	-0.31	6.4e-9	Schizophrenia;
LUSC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.27	0.45	2.32e-18	Monocyte percentage of white cells;
LUSC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10802521	chr3:52805072	NEK4	-0.54	-8.7	-0.43	1.54e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4443100	0.670	rs9612225	chr22:23406619	G/A	cg14186256	chr22:23484241	RTDR1	0.54	6.95	0.36	1.88e-11	Serum parathyroid hormone levels;
LUSC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg25258033	chr6:167368657	RNASET2	0.48	7.92	0.4	3.52e-14	Crohn's disease;
LUSC	cis	rs644148	0.730	rs2117383	chr19:44978298	A/C	cg15540054	chr19:45004280	ZNF180	0.46	6.14	0.32	2.35e-9	Personality dimensions;
LUSC	cis	rs9420	0.528	rs11607122	chr11:57389737	G/A	cg23127183	chr11:57508653	C11orf31	-0.46	-6.33	-0.33	7.94e-10	Schizophrenia;
LUSC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.45	6.75	0.35	6.52e-11	Systemic lupus erythematosus;
LUSC	trans	rs150992	0.593	rs34496	chr5:98299516	A/T	cg11769476	chr20:49410810	BCAS4	-0.31	-5.95	-0.31	6.72e-9	Body mass index;
LUSC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg22907277	chr7:1156413	C7orf50	0.45	7.12	0.36	6.61e-12	Longevity;Endometriosis;
LUSC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg22823121	chr1:150693482	HORMAD1	0.59	9.11	0.45	7.63e-18	Tonsillectomy;
LUSC	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs7572644	0.679	rs36035825	chr2:28018131	T/G	cg27432699	chr2:27873401	GPN1	0.54	6.89	0.35	2.82e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.36	-0.37	1.47e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg19230755	chr7:65878503	NA	-0.43	-5.94	-0.31	7.09e-9	Aortic root size;
LUSC	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg11984989	chr7:158649758	WDR60	1.12	13.43	0.59	3.46e-33	Height;
LUSC	trans	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg01620082	chr3:125678407	NA	-0.63	-6.22	-0.32	1.49e-9	Depression;
LUSC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.43	0.38	9.46e-13	Bipolar disorder;
LUSC	cis	rs9807989	0.811	rs7608638	chr2:102970289	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.88	0.31	9.76e-9	Asthma;
LUSC	cis	rs13089785	0.965	rs12488058	chr3:123599681	C/T	cg02012769	chr3:123398346	MYLK	0.32	5.9	0.31	8.9e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg06618935	chr21:46677482	NA	-0.37	-7.45	-0.38	7.79e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs12210905	0.688	rs72843177	chr6:27367414	A/G	cg14616345	chr9:133901267	LAMC3	-0.65	-5.95	-0.31	6.6e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg25767906	chr1:53392781	SCP2	-0.65	-12.85	-0.58	5.69e-31	Monocyte count;
LUSC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg05665937	chr4:1216051	CTBP1	0.38	6.17	0.32	1.99e-9	Obesity-related traits;
LUSC	cis	rs9653442	1.000	rs1160542	chr2:100832155	A/G	cg07810366	chr2:100720526	AFF3	0.44	7.8	0.39	7.92e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg26441486	chr22:50317300	CRELD2	0.46	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.19	0.32	1.72e-9	Menopause (age at onset);
LUSC	cis	rs1832871	0.672	rs9457345	chr6:158743098	A/G	cg07165851	chr6:158734300	TULP4	0.46	6.89	0.35	2.81e-11	Height;
LUSC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg15147215	chr3:52552868	STAB1	-0.34	-6.07	-0.32	3.55e-9	Bipolar disorder;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12581662	chr19:36706085	ZNF565;ZNF146	-0.39	-6.02	-0.31	4.7e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4654899	0.865	rs7532667	chr1:21438239	A/G	cg01072550	chr1:21505969	NA	-0.45	-6.69	-0.34	9.24e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg24006582	chr15:45444508	DUOX1	-0.61	-8.83	-0.44	5.89e-17	Uric acid levels;
LUSC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg17366294	chr4:99064904	C4orf37	0.49	8.39	0.42	1.36e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs864537	0.622	rs1214598	chr1:167426424	C/T	cg22356347	chr1:167427500	CD247	-0.33	-7.7	-0.39	1.56e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg21951975	chr1:209979733	IRF6	0.5	8.4	0.42	1.29e-15	Monobrow;
LUSC	cis	rs2219968	1.000	rs11776951	chr8:78971578	G/C	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg23601095	chr6:26197514	HIST1H3D	0.73	7.46	0.38	7.42e-13	Gout;Renal underexcretion gout;
LUSC	trans	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg27661571	chr11:113659931	NA	-0.59	-7.39	-0.37	1.16e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.85	-0.47	2.85e-20	Platelet count;
LUSC	trans	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg25214090	chr10:38739885	LOC399744	0.48	7.61	0.38	2.88e-13	Corneal astigmatism;
LUSC	trans	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg10756647	chr7:56101905	PSPH	0.87	8.39	0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs16937	0.711	rs10900461	chr1:205153208	C/T	cg00857998	chr1:205179979	DSTYK	0.48	6.85	0.35	3.66e-11	Schizophrenia;
LUSC	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.42	-0.38	1.01e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg04310649	chr10:35416472	CREM	-0.41	-6.49	-0.33	3.19e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg24324837	chr19:49891574	CCDC155	0.55	7.59	0.38	3.25e-13	Multiple sclerosis;
LUSC	trans	rs6601327	0.573	rs13278824	chr8:9646119	T/A	cg08975724	chr8:8085496	FLJ10661	0.44	6.44	0.33	4.14e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs61935443	0.832	rs7308359	chr12:95272904	G/T	cg21533806	chr12:95267307	NA	0.53	6.72	0.35	7.83e-11	Schizophrenia;
LUSC	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg06623918	chr6:96969491	KIAA0776	0.77	9.16	0.45	5.26e-18	Migraine;Coronary artery disease;
LUSC	trans	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg16473166	chr22:50639996	SELO	-0.56	-7.79	-0.39	8.78e-14	Obesity-related traits;
LUSC	cis	rs11696845	0.666	rs6103849	chr20:43365687	C/T	cg25301532	chr20:43378953	KCNK15	-0.36	-6.45	-0.33	3.83e-10	Obesity-related traits;
LUSC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.42	0.69	8.19e-49	Chronic sinus infection;
LUSC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26354017	chr1:205819088	PM20D1	0.8	13.54	0.6	1.34e-33	Menarche (age at onset);
LUSC	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg04414720	chr1:150670196	GOLPH3L	0.44	6.99	0.36	1.52e-11	Tonsillectomy;
LUSC	trans	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.09	-0.32	3.07e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4380275	1.000	rs6548253	chr2:773655	A/G	cg21665850	chr2:731073	NA	0.41	6.72	0.35	7.74e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24990803	chr7:38948533	VPS41	-0.45	-6.82	-0.35	4.18e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08280861	chr8:58055591	NA	0.57	6.48	0.33	3.34e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg03146154	chr1:46216737	IPP	-0.58	-8.39	-0.42	1.37e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg05347473	chr6:146136440	FBXO30	0.55	9.5	0.46	4.36e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg23598886	chr18:12777645	NA	0.65	6.58	0.34	1.83e-10	Inflammatory skin disease;
LUSC	cis	rs7180079	0.620	rs637748	chr15:64858492	A/G	cg08069370	chr15:64387884	SNX1	0.51	5.72	0.3	2.34e-8	Monocyte count;
LUSC	cis	rs6901250	0.851	rs6938235	chr6:117147946	G/T	cg12892004	chr6:117198278	RFX6	0.43	8.22	0.41	4.65e-15	C-reactive protein levels;
LUSC	cis	rs8179	0.761	rs42035	chr7:92239531	A/G	cg15732164	chr7:92237376	CDK6	-0.47	-6.53	-0.34	2.42e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.37	7.77	0.39	1e-13	Hemoglobin concentration;
LUSC	cis	rs7760535	0.826	rs3777905	chr6:111870588	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.83	-0.35	4.02e-11	Metabolic traits;
LUSC	cis	rs6942756	1.000	rs10954226	chr7:128953095	T/G	cg02491457	chr7:128862824	NA	-0.49	-6.77	-0.35	5.69e-11	White matter hyperintensity burden;
LUSC	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.0	0.61	2.3e-35	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg21175976	chr8:11421337	BLK	0.38	6.24	0.32	1.29e-9	Systemic lupus erythematosus;
LUSC	cis	rs11610422	1.000	rs12823902	chr12:31414290	A/G	cg14306366	chr12:31406441	NA	-0.51	-6.27	-0.32	1.09e-9	Coronary artery disease;
LUSC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.55	-8.39	-0.42	1.43e-15	Longevity;Endometriosis;
LUSC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-1.08	-15.81	-0.65	2.09e-42	Initial pursuit acceleration;
LUSC	cis	rs7804356	1.000	rs7804620	chr7:26891831	T/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg18753928	chr3:113234510	CCDC52	-0.51	-7.93	-0.4	3.26e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs12681287	0.752	rs4282548	chr8:87270792	A/T	cg27223183	chr8:87520930	FAM82B	-0.47	-5.93	-0.31	7.48e-9	Caudate activity during reward;
LUSC	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	14.23	0.61	2.9e-36	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg26677194	chr12:130822605	PIWIL1	-0.54	-8.2	-0.41	5.11e-15	Menopause (age at onset);
LUSC	cis	rs981844	0.712	rs1037650	chr4:154737657	G/A	cg14289246	chr4:154710475	SFRP2	-0.45	-6.26	-0.32	1.15e-9	Response to statins (LDL cholesterol change);
LUSC	trans	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg25482853	chr8:67687455	SGK3	-0.43	-6.6	-0.34	1.58e-10	Obesity-related traits;
LUSC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg12365402	chr11:9010492	NRIP3	-0.43	-7.97	-0.4	2.56e-14	Hemoglobin concentration;
LUSC	cis	rs2688608	0.967	rs72814394	chr10:75656325	C/T	cg23231163	chr10:75533350	FUT11	-0.38	-6.21	-0.32	1.57e-9	Inflammatory bowel disease;
LUSC	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg16482183	chr6:26056742	HIST1H1C	0.64	9.13	0.45	6.51e-18	Iron status biomarkers;
LUSC	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.84	-0.35	3.73e-11	Response to antipsychotic treatment;
LUSC	trans	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg13698153	chr12:118541722	VSIG10	-0.35	-5.99	-0.31	5.31e-9	Vitiligo;
LUSC	cis	rs11039100	0.850	rs34818213	chr11:5834591	C/T	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg11693508	chr17:37793320	STARD3	0.6	6.93	0.35	2.14e-11	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg24881330	chr22:46731750	TRMU	0.82	7.29	0.37	2.32e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.49	8.06	0.4	1.35e-14	IgG glycosylation;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15190599	chr6:26156487	HIST1H1E	-0.47	-7.83	-0.39	6.48e-14	Electrocardiographic conduction measures;
LUSC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg22907277	chr7:1156413	C7orf50	0.72	7.67	0.39	1.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg01579765	chr21:45077557	HSF2BP	-0.5	-10.51	-0.5	1.65e-22	Mean corpuscular volume;
LUSC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.77	11.37	0.53	1.57e-25	Corneal astigmatism;
LUSC	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	0.88	13.43	0.59	3.54e-33	Blood protein levels;
LUSC	trans	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg04995722	chr7:26192034	NFE2L3	0.42	6.59	0.34	1.67e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg03146154	chr1:46216737	IPP	0.55	8.25	0.41	3.82e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg04607235	chr12:12878440	APOLD1	-0.94	-15.58	-0.65	1.56e-41	Lymphocyte counts;
LUSC	trans	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.53	-0.53	4.11e-26	Colorectal cancer;
LUSC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-9.71	-0.47	8.52e-20	Mood instability;
LUSC	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.45	-0.42	9.25e-16	Response to antipsychotic treatment;
LUSC	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg09526685	chr4:187126073	CYP4V2	0.54	5.87	0.31	1.03e-8	Blood protein levels;
LUSC	cis	rs2274273	0.905	rs10134800	chr14:55635209	A/G	cg04306507	chr14:55594613	LGALS3	0.58	13.58	0.6	9.41e-34	Protein biomarker;
LUSC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13012494	chr21:47604986	C21orf56	0.47	7.18	0.37	4.52e-12	Testicular germ cell tumor;
LUSC	cis	rs7572644	0.782	rs4666030	chr2:28097222	C/T	cg27432699	chr2:27873401	GPN1	0.52	6.78	0.35	5.61e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.6	10.07	0.48	5.31e-21	Breast cancer;
LUSC	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg12473912	chr3:136751656	NA	0.45	7.91	0.4	3.75e-14	Schizophrenia;
LUSC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg13628971	chr7:2884303	GNA12	0.45	6.38	0.33	6.04e-10	Height;
LUSC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21582582	chr3:182698605	DCUN1D1	0.48	8.4	0.42	1.29e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-8.8	-0.43	7.61e-17	Obesity-related traits;
LUSC	cis	rs80282103	0.571	rs10047269	chr10:1103058	G/A	cg18964960	chr10:1102726	WDR37	0.72	6.52	0.34	2.57e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs4776059	0.761	rs61731670	chr15:52901283	T/C	cg22715398	chr15:52968154	KIAA1370	0.67	8.55	0.42	4.48e-16	Schizophrenia;
LUSC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg11211951	chr8:145729740	GPT	-0.54	-9.84	-0.47	3.23e-20	Age at first birth;
LUSC	cis	rs6499755	0.901	rs2042447	chr16:55352022	A/C	cg02859129	chr16:55357253	IRX6	-0.34	-6.0	-0.31	5.1e-9	Hypospadias;
LUSC	cis	rs7681440	0.543	rs2619370	chr4:90736585	C/T	cg06632027	chr4:90757378	SNCA	-0.36	-5.65	-0.3	3.4e-8	Dementia with Lewy bodies;
LUSC	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg22709100	chr7:91322751	NA	0.4	5.75	0.3	1.98e-8	Breast cancer;
LUSC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.24	0.45	2.96e-18	Bipolar disorder;
LUSC	trans	rs1973993	0.567	rs2800431	chr1:97000998	C/T	cg10631902	chr5:14652156	NA	0.47	7.74	0.39	1.16e-13	Weight;
LUSC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg02018176	chr4:1364513	KIAA1530	0.56	9.81	0.47	3.81e-20	Longevity;
LUSC	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs4594175	0.926	rs60234748	chr14:51630102	T/C	cg23942311	chr14:51606299	NA	0.3	5.79	0.3	1.6e-8	Cancer;
LUSC	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.6	-0.34	1.65e-10	Neuroticism;
LUSC	cis	rs2085601	0.519	rs1708679	chr4:89976963	T/C	cg17769793	chr4:89976368	FAM13A	-0.33	-5.68	-0.3	2.97e-8	Hair greying;
LUSC	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06636551	chr8:101224915	SPAG1	-0.45	-8.24	-0.41	4.04e-15	Atrioventricular conduction;
LUSC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg24642844	chr7:1081250	C7orf50	-0.46	-7.34	-0.37	1.64e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17030434	0.728	rs16998891	chr4:154646419	T/G	cg14289246	chr4:154710475	SFRP2	-0.5	-6.78	-0.35	5.5e-11	Electrocardiographic conduction measures;
LUSC	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.77	-0.39	9.55e-14	Joint mobility (Beighton score);
LUSC	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.26	-0.41	3.44e-15	Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03331490	chr10:120840461	EIF3A	-0.42	-6.13	-0.32	2.46e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg11344533	chr11:111475393	SIK2	-0.49	-6.87	-0.35	3.18e-11	Primary sclerosing cholangitis;
LUSC	trans	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg04995722	chr7:26192034	NFE2L3	-0.37	-6.01	-0.31	4.8e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4478858	0.735	rs6685728	chr1:31802550	T/C	cg00250761	chr1:31883323	NA	-0.36	-8.95	-0.44	2.49e-17	Alcohol dependence;
LUSC	cis	rs10419226	0.511	rs2214524	chr19:18787661	C/A	cg22001208	chr19:18782374	NA	-0.37	-6.07	-0.32	3.54e-9	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg20887711	chr4:1340912	KIAA1530	0.46	7.16	0.36	5.1e-12	Obesity-related traits;
LUSC	cis	rs9467160	0.734	rs10946702	chr6:24462672	A/G	cg20631270	chr6:24437470	GPLD1	-0.41	-5.79	-0.3	1.66e-8	Liver enzyme levels;
LUSC	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg22681709	chr2:178499509	PDE11A	-0.38	-5.75	-0.3	2.05e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.68	-10.51	-0.5	1.69e-22	Colorectal cancer;
LUSC	cis	rs7091068	0.802	rs10786121	chr10:95419796	G/A	cg20715218	chr10:95462985	C10orf4	0.57	6.48	0.33	3.22e-10	Urinary tract infection frequency;
LUSC	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg15704280	chr7:45808275	SEPT13	-0.57	-7.16	-0.36	5.13e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs80282103	0.764	rs10047382	chr10:1102868	T/C	cg23359895	chr10:1095482	IDI1	0.64	5.76	0.3	1.88e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7586879	0.828	rs12986610	chr2:25106265	A/G	cg01884057	chr2:25150051	NA	-0.41	-8.7	-0.43	1.57e-16	Body mass index;
LUSC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.93	0.31	7.45e-9	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04685880	chr19:55988027	ZNF628	-0.4	-5.97	-0.31	6.16e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7575217	0.961	rs733830	chr2:101778319	C/T	cg23907051	chr2:101730305	TBC1D8	0.27	6.95	0.36	1.9e-11	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.61	-7.6	-0.38	3.01e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9549260	0.816	rs7334318	chr13:41217410	C/G	cg21288729	chr13:41239152	FOXO1	0.66	10.17	0.49	2.4e-21	Red blood cell count;
LUSC	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg16070123	chr10:51489643	NA	0.52	8.38	0.42	1.48e-15	Prostate-specific antigen levels;
LUSC	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg16797656	chr11:68205561	LRP5	0.37	6.12	0.32	2.59e-9	Total body bone mineral density;
LUSC	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-0.99	-19.15	-0.72	1.06e-55	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg05896524	chr21:47604654	C21orf56	0.4	5.85	0.3	1.16e-8	Testicular germ cell tumor;
LUSC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg17971929	chr21:40555470	PSMG1	-0.51	-7.63	-0.39	2.41e-13	Menarche (age at onset);
LUSC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00339695	chr16:24857497	SLC5A11	0.59	8.78	0.43	8.37e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg03948781	chr1:205179583	DSTYK	0.32	6.15	0.32	2.21e-9	Red blood cell count;
LUSC	cis	rs9462027	0.628	rs6906759	chr6:34742990	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.69	-0.3	2.74e-8	Systemic lupus erythematosus;
LUSC	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg26513180	chr16:89883248	FANCA	-0.55	-8.59	-0.43	3.26e-16	Vitiligo;
LUSC	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg00898013	chr13:113819073	PROZ	-0.57	-8.65	-0.43	2.21e-16	Platelet distribution width;
LUSC	cis	rs2227564	0.597	rs12256103	chr10:75545251	A/G	cg17411546	chr10:75410026	SYNPO2L	-0.44	-5.74	-0.3	2.16e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg24505687	chr6:33548425	BAK1	0.36	6.08	0.32	3.37e-9	Platelet count;
LUSC	cis	rs7605827	0.930	rs12692264	chr2:15539229	T/A	cg19274914	chr2:15703543	NA	0.47	9.24	0.45	3.06e-18	Educational attainment (years of education);
LUSC	cis	rs4240897	0.835	rs4845891	chr1:12042506	T/C	cg13216073	chr1:12042593	MFN2	0.38	6.76	0.35	6.29e-11	Tuberculosis;
LUSC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg24250549	chr1:154909240	PMVK	0.66	11.1	0.52	1.36e-24	Prostate cancer;
LUSC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg04414720	chr1:150670196	GOLPH3L	0.55	8.93	0.44	2.84e-17	Tonsillectomy;
LUSC	cis	rs2430386	1.000	rs2430386	chr2:63178111	C/T	cg17519650	chr2:63277830	OTX1	0.65	9.46	0.46	5.73e-19	Prostate cancer;
LUSC	cis	rs3126085	0.935	rs4845429	chr1:152225376	G/C	cg03465714	chr1:152285911	FLG	-0.4	-5.68	-0.3	2.94e-8	Atopic dermatitis;
LUSC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg24375607	chr4:120327624	NA	-0.73	-11.54	-0.53	3.67e-26	Corneal astigmatism;
LUSC	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg13660082	chr14:53194042	PSMC6	-0.78	-6.81	-0.35	4.55e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.45	0.33	3.86e-10	Menopause (age at onset);
LUSC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg13175981	chr1:150552382	MCL1	0.52	7.38	0.37	1.23e-12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	8.58	0.42	3.51e-16	Neuroticism;
LUSC	cis	rs10992471	0.603	rs10114912	chr9:95307863	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.88	-0.35	2.92e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9807989	0.839	rs9808453	chr2:102971306	C/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.88	0.31	9.76e-9	Asthma;
LUSC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	7.52	0.38	5.03e-13	Parkinson's disease;
LUSC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg02269571	chr22:50332266	NA	0.59	8.74	0.43	1.13e-16	Schizophrenia;
LUSC	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg04155231	chr12:9217510	LOC144571	0.3	5.7	0.3	2.67e-8	Sjögren's syndrome;
LUSC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.92e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg10018233	chr7:150070692	REPIN1	0.34	6.08	0.32	3.33e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg12463550	chr7:65579703	CRCP	-0.46	-6.82	-0.35	4.21e-11	Aortic root size;
LUSC	cis	rs9326248	0.530	rs11216171	chr11:116749113	T/A	cg20608306	chr11:116969690	SIK3	0.38	6.33	0.33	8e-10	Blood protein levels;
LUSC	cis	rs9467160	0.651	rs9393557	chr6:24453195	C/G	cg20631270	chr6:24437470	GPLD1	0.41	6.34	0.33	7.38e-10	Liver enzyme levels;
LUSC	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg19812747	chr11:111475976	SIK2	-0.5	-7.04	-0.36	1.1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg04315214	chr1:2043799	PRKCZ	-0.4	-8.02	-0.4	1.74e-14	Height;
LUSC	cis	rs4478858	0.647	rs11577679	chr1:31726185	T/C	cg00250761	chr1:31883323	NA	-0.34	-8.21	-0.41	4.89e-15	Alcohol dependence;
LUSC	trans	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.43	-0.33	4.41e-10	Monocyte count;
LUSC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg18512352	chr11:47633146	NA	-0.47	-9.58	-0.46	2.37e-19	Subjective well-being;
LUSC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg16414030	chr3:133502952	NA	-0.42	-6.52	-0.34	2.66e-10	Iron status biomarkers;
LUSC	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.86	-12.9	-0.58	3.55e-31	Asthma;
LUSC	cis	rs9323205	0.798	rs2999392	chr14:51655145	A/G	cg23942311	chr14:51606299	NA	-0.39	-8.04	-0.4	1.57e-14	Cancer;
LUSC	cis	rs10986311	0.722	rs944339	chr9:127040978	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.4	-6.58	-0.34	1.87e-10	Vitiligo;
LUSC	cis	rs6961069	0.585	rs12667404	chr7:80251463	C/T	cg04458919	chr7:80252533	CD36	-0.39	-6.87	-0.35	3.23e-11	Platelet count;
LUSC	cis	rs7572644	0.640	rs13027666	chr2:28058433	T/C	cg27432699	chr2:27873401	GPN1	0.51	6.83	0.35	3.92e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.75	-0.35	6.62e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17712092	chr4:129076599	LARP1B	0.82	12.34	0.56	4.47e-29	Eosinophil percentage of white cells;
LUSC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg15147215	chr3:52552868	STAB1	-0.3	-6.0	-0.31	5.01e-9	Electroencephalogram traits;
LUSC	cis	rs78707713	0.535	rs3812705	chr10:71211146	A/G	cg14388049	chr10:71211838	TSPAN15	-0.33	-5.99	-0.31	5.28e-9	Venous thromboembolism;
LUSC	cis	rs10203711	1.000	rs4663941	chr2:239574279	A/G	cg14580085	chr2:239553406	NA	0.39	6.53	0.34	2.42e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4713118	0.868	rs35069907	chr6:27746692	T/C	cg20933634	chr6:27740509	NA	0.45	6.03	0.31	4.4e-9	Parkinson's disease;
LUSC	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg17971929	chr21:40555470	PSMG1	-0.53	-7.94	-0.4	3.06e-14	Menarche (age at onset);
LUSC	cis	rs4654899	0.865	rs61779075	chr1:21417027	T/C	cg01072550	chr1:21505969	NA	-0.52	-7.6	-0.38	2.99e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.37	-5.69	-0.3	2.77e-8	Ulcerative colitis;
LUSC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg04317338	chr11:64019027	PLCB3	0.6	6.32	0.33	8.27e-10	Mean platelet volume;
LUSC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24838063	chr12:130822603	PIWIL1	0.7	10.75	0.51	2.38e-23	Menopause (age at onset);
LUSC	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg08854313	chr1:11322531	MTOR	-0.89	-15.36	-0.64	1.17e-40	Body mass index;
LUSC	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg05340658	chr4:99064831	C4orf37	0.63	10.64	0.5	5.67e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	10.8	0.51	1.65e-23	Lymphocyte counts;
LUSC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.14	-25.13	-0.81	5.48e-79	Chronic sinus infection;
LUSC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.6	-0.38	3.03e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.41	0.33	4.97e-10	Lung cancer;
LUSC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg18230493	chr5:56204884	C5orf35	-0.95	-13.98	-0.61	2.77e-35	Initial pursuit acceleration;
LUSC	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg17845761	chr1:175162550	KIAA0040	-0.34	-6.57	-0.34	1.98e-10	Alcohol dependence;
LUSC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.72	-0.43	1.34e-16	Obesity-related traits;
LUSC	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg10604040	chr11:65559109	OVOL1	0.31	5.78	0.3	1.72e-8	Eosinophil percentage of white cells;
LUSC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg06453172	chr10:134556979	INPP5A	-0.49	-6.11	-0.32	2.78e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs11622475	1.000	rs1187446	chr14:104409896	C/T	cg12183467	chr14:104352244	NA	-0.43	-7.73	-0.39	1.27e-13	Bipolar disorder;
LUSC	cis	rs9420	0.961	rs71484468	chr11:57632799	G/C	cg23127183	chr11:57508653	C11orf31	-0.56	-8.36	-0.42	1.71e-15	Schizophrenia;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14672709	chr17:48133110	ITGA3	0.39	6.12	0.32	2.58e-9	Asthma;
LUSC	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg10172584	chr19:19639581	YJEFN3	-0.51	-5.85	-0.3	1.18e-8	Bipolar disorder;
LUSC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.3	-6.02	-0.31	4.61e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.31	-0.37	2e-12	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-0.84	-10.25	-0.49	1.25e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg11812906	chr14:75593930	NEK9	-0.62	-10.07	-0.48	5.2e-21	Height;
LUSC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg18230493	chr5:56204884	C5orf35	-0.89	-13.7	-0.6	3.17e-34	Initial pursuit acceleration;
LUSC	cis	rs17125944	0.615	rs7146179	chr14:53298853	A/G	cg00686598	chr14:53173677	PSMC6	-0.73	-6.61	-0.34	1.52e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg21545522	chr1:205238299	TMCC2	0.42	8.05	0.4	1.52e-14	Red blood cell count;
LUSC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.87	0.31	1.05e-8	Menopause (age at onset);
LUSC	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg08000102	chr2:233561755	GIGYF2	0.7	11.59	0.54	2.41e-26	Coronary artery disease;
LUSC	cis	rs7588746	0.521	rs73054585	chr2:201144386	T/A	cg23649088	chr2:200775458	C2orf69	-0.54	-7.22	-0.37	3.46e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg01879757	chr17:41196368	BRCA1	0.43	6.55	0.34	2.23e-10	Menopause (age at onset);
LUSC	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.9	-0.31	8.7e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs877282	0.735	rs111609055	chr10:826539	A/G	cg22713356	chr15:30763199	NA	0.76	9.94	0.48	1.43e-20	Uric acid levels;
LUSC	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg19875535	chr5:140030758	IK	0.48	7.62	0.38	2.71e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.61	7.75	0.39	1.09e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg15605315	chr1:45957053	TESK2	0.46	7.21	0.37	3.78e-12	High light scatter reticulocyte count;
LUSC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg02980000	chr4:1222292	CTBP1	-0.37	-5.67	-0.3	3.09e-8	Obesity-related traits;
LUSC	cis	rs4363385	0.703	rs4845517	chr1:153003893	T/A	cg00922841	chr1:152955080	SPRR1A	-0.4	-7.08	-0.36	8.6e-12	Inflammatory skin disease;
LUSC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.9	16.19	0.66	6.09e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11229555	0.645	rs11229430	chr11:58181104	G/C	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs983392	0.709	rs2015475	chr11:59998963	A/C	cg02771260	chr11:59836817	MS4A3	-0.36	-5.93	-0.31	7.71e-9	Alzheimer's disease (late onset);
LUSC	cis	rs12286929	0.617	rs12800807	chr11:115101353	T/C	cg04055981	chr11:115044050	NA	0.35	6.23	0.32	1.41e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg15145296	chr3:125709740	NA	-0.59	-6.56	-0.34	2.02e-10	Blood pressure (smoking interaction);
LUSC	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg23435118	chr5:141488016	NDFIP1	-0.53	-7.43	-0.38	8.98e-13	Crohn's disease;
LUSC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg23229984	chr5:148520753	ABLIM3	0.37	6.12	0.32	2.63e-9	Breast cancer;
LUSC	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.37	-6.89	-0.35	2.86e-11	Coronary artery disease;
LUSC	cis	rs9297145	0.761	rs62473005	chr7:98742510	G/C	cg05967295	chr7:98741636	SMURF1	0.99	14.77	0.63	2.38e-38	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg25272121	chr1:152190972	HRNR	-0.39	-6.75	-0.35	6.57e-11	Inflammatory skin disease;
LUSC	cis	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.41	-0.42	1.18e-15	Morning vs. evening chronotype;
LUSC	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg24375607	chr4:120327624	NA	0.76	11.48	0.53	6.02e-26	Corneal astigmatism;
LUSC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg15556689	chr8:8085844	FLJ10661	0.67	10.71	0.51	3.43e-23	Mood instability;
LUSC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg20203395	chr5:56204925	C5orf35	-0.46	-6.86	-0.35	3.41e-11	Coronary artery disease;
LUSC	trans	rs853679	0.546	rs200981	chr6:27833174	A/G	cg06606381	chr12:133084897	FBRSL1	-0.75	-7.52	-0.38	5.19e-13	Depression;
LUSC	cis	rs939658	0.805	rs1915726	chr15:79420620	C/G	cg17916960	chr15:79447300	NA	-0.53	-10.38	-0.49	4.61e-22	Refractive error;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14530560	chr19:41903684	BCKDHA;EXOSC5	-0.41	-5.95	-0.31	6.91e-9	Electrocardiographic conduction measures;
LUSC	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg00012203	chr2:219082015	ARPC2	-0.54	-8.41	-0.42	1.2e-15	Ulcerative colitis;
LUSC	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg00310523	chr12:86230176	RASSF9	0.46	8.35	0.42	1.86e-15	Major depressive disorder;
LUSC	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg14458575	chr2:238380390	NA	0.6	7.14	0.36	5.72e-12	Prostate cancer;
LUSC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg02475777	chr4:1388615	CRIPAK	0.45	6.77	0.35	5.72e-11	Obesity-related traits;
LUSC	cis	rs6430585	0.591	rs61187091	chr2:136468238	G/A	cg07169764	chr2:136633963	MCM6	1.08	14.33	0.62	1.21e-36	Corneal structure;
LUSC	cis	rs713477	0.505	rs9635232	chr14:55887880	T/C	cg13175173	chr14:55914753	NA	-0.31	-5.96	-0.31	6.5e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg11752832	chr7:134001865	SLC35B4	0.59	9.31	0.45	1.76e-18	Mean platelet volume;
LUSC	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.26	-27.67	-0.83	2e-88	Exhaled nitric oxide output;
LUSC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg13114125	chr14:105738426	BRF1	-0.9	-15.57	-0.65	1.81e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1376303	0.643	rs4723222	chr7:32957661	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.64	-5.67	-0.3	3.02e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.771	rs8048527	chr16:75422054	C/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.12	-0.36	6.65e-12	Dupuytren's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11353368	chr19:47363757	NA	-0.41	-6.06	-0.31	3.6e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1395	1.000	rs1275530	chr2:27432547	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.39	-6.41	-0.33	4.89e-10	Blood metabolite levels;
LUSC	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21643547	chr1:205240462	TMCC2	-0.52	-10.21	-0.49	1.77e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.76	20.5	0.75	4.67e-61	Anterior chamber depth;
LUSC	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.58	0.38	3.37e-13	Schizophrenia;
LUSC	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg05729581	chr11:3078854	CARS	0.4	5.85	0.3	1.16e-8	Calcium levels;
LUSC	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg00277334	chr10:82204260	NA	-0.51	-7.41	-0.38	1.05e-12	Post bronchodilator FEV1;
LUSC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg05025164	chr4:1340916	KIAA1530	-0.5	-7.63	-0.39	2.42e-13	Obesity-related traits;
LUSC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03517284	chr6:25882590	NA	-0.42	-7.21	-0.37	3.78e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.89	18.56	0.71	2.38e-53	Intelligence (multi-trait analysis);
LUSC	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-7.07	-0.36	9.02e-12	Bipolar disorder;
LUSC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	0.79	13.82	0.6	1.1e-34	Cognitive function;
LUSC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg19694781	chr19:47549865	TMEM160	-0.6	-9.68	-0.47	1.11e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.82	12.36	0.56	3.88e-29	Cognitive test performance;
LUSC	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg21827317	chr3:136751795	NA	0.39	7.17	0.37	4.88e-12	Neuroticism;
LUSC	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg00079169	chr19:2811669	THOP1	0.35	5.83	0.3	1.31e-8	Total cholesterol levels;
LUSC	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.37	0.49	4.87e-22	Schizophrenia;
LUSC	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg03806693	chr22:41940476	POLR3H	-0.83	-11.92	-0.55	1.59e-27	Vitiligo;
LUSC	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg04990556	chr1:26633338	UBXN11	-0.45	-5.94	-0.31	7.02e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2625529	0.652	rs2415128	chr15:72191073	T/C	cg16672083	chr15:72433130	SENP8	0.48	7.81	0.39	7.5e-14	Red blood cell count;
LUSC	cis	rs10740039	0.804	rs7093882	chr10:62394621	C/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27093425	chr17:79191690	AZI1	0.4	6.05	0.31	3.82e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg26811252	chr16:29126840	RRN3P2	0.58	9.33	0.45	1.5e-18	Menopause (age at onset);
LUSC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg21573476	chr21:45109991	RRP1B	-0.39	-6.23	-0.32	1.4e-9	Mean corpuscular volume;
LUSC	cis	rs9513627	1.000	rs7321381	chr13:100126156	G/A	cg25919922	chr13:100150906	NA	-0.74	-6.55	-0.34	2.24e-10	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.34	0.77	2.97e-68	Prudent dietary pattern;
LUSC	trans	rs11696501	0.688	rs6094192	chr20:44297796	G/A	cg03272292	chr12:48577362	C12orf68	0.5	5.98	0.31	5.85e-9	Brain structure;
LUSC	cis	rs2285947	0.967	rs2285944	chr7:21582964	A/T	cg04471919	chr7:21584483	DNAH11	0.35	7.75	0.39	1.1e-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.67	11.85	0.54	2.86e-27	Prudent dietary pattern;
LUSC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg23743428	chr13:21893420	NA	-0.44	-8.84	-0.44	5.57e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs870825	0.616	rs79884757	chr4:185621454	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg09307838	chr4:120376055	NA	0.67	9.63	0.47	1.62e-19	Corneal astigmatism;
LUSC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg25767906	chr1:53392781	SCP2	-0.51	-9.51	-0.46	3.86e-19	Monocyte count;
LUSC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-1.04	-20.33	-0.74	2.31e-60	Height;
LUSC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-1.11	-24.16	-0.8	2.82e-75	Height;
LUSC	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg24578937	chr1:2090814	PRKCZ	0.6	13.82	0.6	1.13e-34	Height;
LUSC	cis	rs4363385	0.550	rs6661932	chr1:152896734	T/C	cg25856811	chr1:152973957	SPRR3	-0.39	-6.21	-0.32	1.54e-9	Inflammatory skin disease;
LUSC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10208940	0.841	rs10172125	chr2:68787191	T/G	cg12452813	chr2:68675892	NA	0.57	5.92	0.31	7.99e-9	Urate levels in lean individuals;
LUSC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg16624210	chr5:671434	TPPP	0.5	6.38	0.33	6.07e-10	Obesity-related traits;
LUSC	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.68	0.39	1.83e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg18827107	chr12:86230957	RASSF9	0.45	6.86	0.35	3.4e-11	Major depressive disorder;
LUSC	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg23950597	chr19:37808831	NA	-0.64	-7.47	-0.38	6.98e-13	Coronary artery calcification;
LUSC	cis	rs16910800	1.000	rs2468648	chr11:23201494	C/G	cg20040320	chr11:23191996	NA	0.42	6.34	0.33	7.27e-10	Cancer;
LUSC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.26	0.32	1.19e-9	Mean platelet volume;
LUSC	cis	rs11608355	0.521	rs9888353	chr12:109843594	G/A	cg19025524	chr12:109796872	NA	-0.4	-7.37	-0.37	1.39e-12	Neuroticism;
LUSC	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg17623882	chr6:41773611	USP49	0.62	10.37	0.49	5.14e-22	Menarche (age at onset);
LUSC	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg08917208	chr2:24149416	ATAD2B	1.01	10.61	0.5	7.29e-23	Lymphocyte counts;
LUSC	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.82	-0.39	6.85e-14	Response to antipsychotic treatment;
LUSC	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg25214090	chr10:38739885	LOC399744	0.51	7.7	0.39	1.58e-13	Corneal astigmatism;
LUSC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg25206134	chr2:45395956	NA	0.57	6.55	0.34	2.14e-10	Bipolar disorder;
LUSC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.68	0.3	2.9e-8	Self-reported allergy;
LUSC	trans	rs7507204	0.723	rs12982194	chr19:3411947	G/A	cg08382705	chr11:45687319	CHST1	-0.52	-7.0	-0.36	1.38e-11	Height;
LUSC	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg09491104	chr22:46646882	C22orf40	-0.6	-8.82	-0.43	6.55e-17	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg22065733	chr8:11801320	NA	0.78	6.09	0.32	3.03e-9	Cognitive performance;
LUSC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg20608306	chr11:116969690	SIK3	0.39	6.66	0.34	1.12e-10	Blood protein levels;
LUSC	cis	rs11608355	0.515	rs7136048	chr12:109903926	A/G	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.34	0.64	1.46e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-7.46	-0.38	7.41e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.53	-0.38	4.71e-13	Bipolar disorder;
LUSC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg26380479	chr7:97908229	NA	-0.28	-6.25	-0.32	1.24e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1524927	0.966	rs2260	chr7:96364457	T/C	cg03808172	chr7:96339361	SHFM1	0.43	6.52	0.34	2.63e-10	Total body bone mineral density;
LUSC	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg24375607	chr4:120327624	NA	0.79	11.69	0.54	1.03e-26	Corneal astigmatism;
LUSC	cis	rs2677744	0.563	rs8024249	chr15:91494249	T/C	cg23684204	chr15:91497937	RCCD1	0.39	5.68	0.3	2.87e-8	Attention deficit hyperactivity disorder;
LUSC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg18135555	chr8:22132992	PIWIL2	0.39	7.83	0.39	6.33e-14	Hypertriglyceridemia;
LUSC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.62	10.19	0.49	2.02e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.36	-0.37	1.45e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg13010199	chr12:38710504	ALG10B	-0.6	-9.35	-0.46	1.32e-18	Bladder cancer;
LUSC	trans	rs9784649	0.891	rs57355285	chr5:25016384	C/G	cg08600765	chr20:34638493	LOC647979	-0.55	-6.36	-0.33	6.71e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6733011	0.628	rs981602	chr2:99464275	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.2	-0.32	1.71e-9	Bipolar disorder;
LUSC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg18357645	chr12:58087776	OS9	0.54	8.3	0.41	2.58e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg24060327	chr5:131705240	SLC22A5	0.5	7.69	0.39	1.63e-13	Acylcarnitine levels;
LUSC	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg21132104	chr15:45694354	SPATA5L1	0.4	5.83	0.3	1.32e-8	Glomerular filtration rate;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg17142723	chr17:41324085	NBR1	0.28	6.4	0.33	5.38e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.63	-0.43	2.59e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs7267979	0.714	rs3787082	chr20:25235736	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	12.25	0.56	9.41e-29	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2857891	0.773	rs2638100	chr11:6969676	C/G	cg04053776	chr11:6947353	ZNF215	0.41	5.74	0.3	2.09e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs17253792	0.822	rs74053651	chr14:56125366	C/T	cg01858014	chr14:56050164	KTN1	-0.69	-6.06	-0.31	3.61e-9	Putamen volume;
LUSC	cis	rs1662342	1.000	rs1662344	chr18:3251992	A/G	cg00760847	chr18:3262519	MYL12B	-0.58	-5.68	-0.3	2.97e-8	QRS duration;
LUSC	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg20019720	chr6:154832845	CNKSR3	0.63	8.78	0.43	8.57e-17	Lipoprotein (a) levels;
LUSC	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg22782873	chr19:19639568	YJEFN3	0.53	6.51	0.34	2.82e-10	Bipolar disorder;
LUSC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.93	14.9	0.63	7.79e-39	Coronary artery disease;
LUSC	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg10596483	chr8:143751796	JRK	0.52	7.33	0.37	1.73e-12	Schizophrenia;
LUSC	cis	rs10843647	0.875	rs12831489	chr12:30336349	A/G	cg12718339	chr12:29936407	TMTC1	0.34	5.67	0.3	3.02e-8	Glucose homeostasis traits;
LUSC	cis	rs11264213	0.901	rs79303353	chr1:36402056	G/A	cg27506609	chr1:36549197	TEKT2	0.7	8.04	0.4	1.62e-14	Schizophrenia;
LUSC	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg13256891	chr4:100009986	ADH5	0.51	7.03	0.36	1.21e-11	Alcohol dependence;
LUSC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg00310523	chr12:86230176	RASSF9	0.52	9.83	0.47	3.52e-20	Major depressive disorder;
LUSC	cis	rs9921338	0.961	rs7202814	chr16:11389774	C/T	cg00044050	chr16:11439710	C16orf75	-0.49	-6.79	-0.35	5.04e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs2067615	0.579	rs3910854	chr12:107165669	T/C	cg15890332	chr12:107067104	RFX4	0.34	6.18	0.32	1.87e-9	Heart rate;
LUSC	cis	rs9921338	0.924	rs7193645	chr16:11381036	A/G	cg00044050	chr16:11439710	C16orf75	-0.51	-6.97	-0.36	1.65e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-7.18	-0.37	4.67e-12	Coronary artery disease;
LUSC	cis	rs4666002	0.789	rs12998770	chr2:27913188	T/C	cg27432699	chr2:27873401	GPN1	0.51	6.9	0.35	2.63e-11	Phospholipid levels (plasma);
LUSC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.82	-0.3	1.38e-8	Monocyte count;
LUSC	cis	rs11605924	1.000	rs1401419	chr11:45879739	T/C	ch.11.939596F	chr11:45881766	CRY2	-0.55	-8.39	-0.42	1.38e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg08048268	chr3:133502702	NA	-0.38	-6.82	-0.35	4.23e-11	Iron status biomarkers;
LUSC	cis	rs8099014	1.000	rs4940697	chr18:56108485	G/A	cg12907477	chr18:56117327	MIR122	0.44	7.07	0.36	9.09e-12	Platelet count;
LUSC	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg18196295	chr10:418757	DIP2C	-0.45	-6.9	-0.35	2.63e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs2370759	0.945	rs3740237	chr10:32557592	G/C	cg01819863	chr10:32635814	EPC1	1.04	10.81	0.51	1.53e-23	Sexual dysfunction (female);
LUSC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.86	-14.89	-0.63	8.47e-39	Cognitive function;
LUSC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg16342193	chr10:102329863	NA	-0.37	-6.41	-0.33	4.83e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs60695258	0.594	rs6531946	chr4:87965391	T/A	cg10685359	chr4:87814065	C4orf36	-0.34	-6.06	-0.31	3.59e-9	Hematocrit;
LUSC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg10911889	chr6:126070802	HEY2	0.42	6.46	0.33	3.7e-10	Brugada syndrome;
LUSC	trans	rs1941687	0.800	rs17753910	chr18:31387643	T/C	cg27147174	chr7:100797783	AP1S1	-0.46	-6.75	-0.35	6.53e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg01879757	chr17:41196368	BRCA1	-0.45	-6.99	-0.36	1.54e-11	Menopause (age at onset);
LUSC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	trans	rs1194708	0.688	rs1561662	chr10:54240712	C/T	cg06772874	chr1:110090953	GNAI3	0.43	5.99	0.31	5.36e-9	Chin dimples;
LUSC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg17330251	chr7:94953956	PON1	-0.36	-5.88	-0.31	9.79e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg03522245	chr20:25566470	NINL	-0.35	-5.68	-0.3	2.89e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg02951883	chr7:2050386	MAD1L1	-0.51	-9.09	-0.45	9.24e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg21427119	chr20:30132790	HM13	-0.44	-6.69	-0.34	9.22e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg23711669	chr6:146136114	FBXO30	0.81	14.04	0.61	1.6e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2742417	1.000	rs2673035	chr3:45753665	C/G	cg09608765	chr3:45636137	LIMD1	-0.37	-7.39	-0.38	1.16e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.58	-0.57	5.63e-30	Alzheimer's disease;
LUSC	trans	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg16286249	chr1:33625400	TRIM62	0.5	6.06	0.31	3.68e-9	Menarche (age at onset);
LUSC	cis	rs134594	1.000	rs134609	chr22:29475583	C/T	cg03665785	chr22:29458676	C22orf31	0.28	5.69	0.3	2.78e-8	Birth weight;
LUSC	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg12826209	chr6:26865740	GUSBL1	0.52	7.51	0.38	5.41e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs7939886	0.920	rs11231794	chr11:55765776	T/C	cg03929089	chr4:120376271	NA	0.73	6.08	0.32	3.26e-9	Myopia (pathological);
LUSC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.18	-14.3	-0.62	1.62e-36	Breast cancer;
LUSC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg04455712	chr21:45112962	RRP1B	0.44	7.91	0.4	3.9e-14	Mean corpuscular volume;
LUSC	cis	rs865483	0.895	rs853211	chr17:35828164	T/C	cg06716730	chr17:35851459	DUSP14	0.28	6.18	0.32	1.91e-9	Monocyte count;
LUSC	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg26695010	chr11:65641043	EFEMP2	0.44	6.44	0.33	4.21e-10	Eosinophil percentage of white cells;
LUSC	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg25174290	chr11:3078921	CARS	-0.42	-6.21	-0.32	1.58e-9	Calcium levels;
LUSC	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg24642439	chr20:33292090	TP53INP2	-0.5	-7.48	-0.38	6.41e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg14092571	chr14:90743983	NA	0.36	5.78	0.3	1.69e-8	Mortality in heart failure;
LUSC	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg14154082	chr13:112174009	NA	0.38	7.76	0.39	1.03e-13	Menarche (age at onset);
LUSC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.99	0.4	2.22e-14	Bipolar disorder;
LUSC	trans	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg11057378	chr10:81107060	PPIF	0.39	6.15	0.32	2.23e-9	Height;
LUSC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg17507749	chr15:85114479	UBE2QP1	0.68	8.74	0.43	1.18e-16	Schizophrenia;
LUSC	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.69	-7.62	-0.38	2.68e-13	Lung cancer in ever smokers;
LUSC	trans	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg10756647	chr7:56101905	PSPH	0.89	8.62	0.43	2.81e-16	Diabetic kidney disease;
LUSC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72772090	0.539	rs11738810	chr5:96119055	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.58	-0.34	1.83e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg09904177	chr6:26538194	HMGN4	0.75	14.21	0.61	3.52e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg05714579	chr10:131428358	MGMT	0.53	7.84	0.39	6.06e-14	Response to temozolomide;
LUSC	cis	rs1775715	0.737	rs11008695	chr10:32216887	T/G	cg18675610	chr10:32216311	ARHGAP12	0.3	6.55	0.34	2.2e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg20302342	chr1:156215951	PAQR6	0.33	6.41	0.33	5.09e-10	Tonsillectomy;
LUSC	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg24642439	chr20:33292090	TP53INP2	-0.48	-7.39	-0.37	1.2e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-9.13	-0.45	6.6e-18	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg08470875	chr2:26401718	FAM59B	0.78	9.23	0.45	3.1e-18	Gut microbiome composition (summer);
LUSC	trans	rs747782	0.527	rs76142260	chr11:48331068	T/C	cg03929089	chr4:120376271	NA	0.7	5.94	0.31	7.05e-9	Intraocular pressure;
LUSC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg08999081	chr20:33150536	PIGU	0.44	8.04	0.4	1.57e-14	Coronary artery disease;
LUSC	trans	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-11.97	-0.55	9.98e-28	Colorectal cancer;
LUSC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.24	0.32	1.33e-9	Menopause (age at onset);
LUSC	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg27411982	chr8:10470053	RP1L1	0.37	5.84	0.3	1.27e-8	Retinal vascular caliber;
LUSC	cis	rs2262909	0.962	rs56369285	chr19:22267185	T/C	cg11619707	chr19:22235551	ZNF257	0.39	5.83	0.3	1.29e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs983392	0.805	rs11230183	chr11:59965725	C/T	cg20284999	chr11:59952153	MS4A6A	-0.38	-6.2	-0.32	1.66e-9	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18876405	chr7:65276391	NA	-0.55	-8.61	-0.43	2.96e-16	Aortic root size;
LUSC	trans	rs57502260	0.704	rs41478448	chr11:68181621	A/G	cg00664054	chr8:21998309	REEP4	0.39	6.08	0.32	3.29e-9	Total body bone mineral density (age 45-60);
LUSC	cis	rs6840360	1.000	rs6840678	chr4:152604331	C/G	cg22705602	chr4:152727874	NA	0.3	6.45	0.33	3.91e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs73058052	1.000	rs3760707	chr19:50084454	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.5	5.78	0.3	1.72e-8	Fibrinogen levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12573119	chr4:78977690	FRAS1	0.45	6.68	0.34	1.02e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg04155289	chr7:94953770	PON1	-0.34	-5.76	-0.3	1.9e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg20476274	chr7:133979776	SLC35B4	0.87	16.7	0.67	6.08e-46	Mean platelet volume;
LUSC	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg25801113	chr15:45476975	SHF	0.35	7.17	0.37	4.84e-12	Uric acid levels;
LUSC	cis	rs1775715	0.870	rs1755084	chr10:32253709	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.41	0.33	4.83e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.9	0.31	8.87e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg03354898	chr7:1950403	MAD1L1	-0.41	-8.36	-0.42	1.69e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg08807101	chr21:30365312	RNF160	-0.55	-8.17	-0.41	6.6e-15	Dental caries;
LUSC	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-7.21	-0.37	3.82e-12	Retinal vascular caliber;
LUSC	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg02423579	chr7:2872169	GNA12	-0.38	-5.99	-0.31	5.55e-9	Height;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg26755928	chr19:10363173	MRPL4	0.47	6.23	0.32	1.43e-9	Cognitive function;Information processing speed;
LUSC	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg20703242	chr1:230279135	GALNT2	0.54	8.43	0.42	1.05e-15	Coronary artery disease;
LUSC	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg15934090	chr1:100435551	SLC35A3	0.47	7.72	0.39	1.4e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg21285383	chr16:89894308	SPIRE2	-0.32	-6.71	-0.34	8.18e-11	Vitiligo;
LUSC	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg23711669	chr6:146136114	FBXO30	0.73	11.58	0.54	2.69e-26	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs740160	0.558	rs12538893	chr7:98908497	G/A	cg24650262	chr7:98904301	NA	0.63	6.74	0.35	6.87e-11	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-9.74	-0.47	7e-20	Monocyte count;
LUSC	cis	rs9811920	0.809	rs793443	chr3:99573547	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.37	-7.02	-0.36	1.26e-11	Axial length;
LUSC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24838063	chr12:130822603	PIWIL1	0.69	10.79	0.51	1.69e-23	Menopause (age at onset);
LUSC	cis	rs12220238	1.000	rs12358614	chr10:75906173	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.96	0.36	1.79e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	0.93	14.07	0.61	1.29e-35	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs7804356	1.000	rs3801816	chr7:26881177	G/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.12	-0.32	2.58e-9	Type 1 diabetes;
LUSC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	8.58	0.42	3.71e-16	Bipolar disorder;
LUSC	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg03938978	chr2:103052716	IL18RAP	-0.36	-6.85	-0.35	3.67e-11	Asthma;
LUSC	trans	rs80346118	0.925	rs2869677	chr20:47473948	G/C	cg16950247	chr11:62911616	SLC22A24	0.5	6.05	0.31	3.87e-9	Diastolic blood pressure;
LUSC	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.23	0.49	1.56e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg00049323	chr5:472564	LOC25845	-0.43	-6.7	-0.34	9.09e-11	Cystic fibrosis severity;
LUSC	cis	rs4481887	0.676	rs946761	chr1:248521032	T/C	cg26353448	chr1:248524236	OR2T4	-0.33	-6.17	-0.32	1.97e-9	Common traits (Other);
LUSC	cis	rs11690935	0.550	rs62183785	chr2:172866976	G/A	cg13550731	chr2:172543902	DYNC1I2	0.53	7.96	0.4	2.7e-14	Schizophrenia;
LUSC	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg21045802	chr8:109455806	TTC35	0.42	6.0	0.31	5.02e-9	Dupuytren's disease;
LUSC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.33	-0.37	1.79e-12	Bipolar disorder;
LUSC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg18230493	chr5:56204884	C5orf35	-0.74	-11.76	-0.54	5.87e-27	Coronary artery disease;
LUSC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-6.69	-0.34	9.68e-11	Major depressive disorder;
LUSC	trans	rs1982346	1.000	rs2553470	chr4:106713673	G/A	cg01484487	chr2:74726892	LBX2	0.52	6.12	0.32	2.55e-9	Lung function (FEV1);
LUSC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.7	-10.13	-0.48	3.24e-21	Systemic lupus erythematosus;
LUSC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.76	-0.3	1.87e-8	Depression;
LUSC	cis	rs2637266	1.000	rs2130795	chr10:78333892	C/G	cg18941641	chr10:78392320	NA	0.38	6.9	0.35	2.66e-11	Pulmonary function;
LUSC	trans	rs7939886	0.844	rs7106504	chr11:55932827	C/T	cg03929089	chr4:120376271	NA	0.8	6.07	0.32	3.54e-9	Myopia (pathological);
LUSC	trans	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-8.94	-0.44	2.73e-17	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg03983476	chr2:10830698	NOL10	0.37	5.77	0.3	1.81e-8	Prostate cancer;
LUSC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg25258033	chr6:167368657	RNASET2	0.38	5.9	0.31	9.03e-9	Primary biliary cholangitis;
LUSC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	6.27	0.32	1.12e-9	Bipolar disorder;
LUSC	cis	rs79387448	0.638	rs6759588	chr2:103040159	A/G	cg09003973	chr2:102972529	NA	1.06	10.98	0.52	3.59e-24	Gut microbiota (bacterial taxa);
LUSC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.13	0.77	1.9e-67	Prudent dietary pattern;
LUSC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06634786	chr22:41940651	POLR3H	-0.48	-6.01	-0.31	4.8e-9	Vitiligo;
LUSC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg04733989	chr22:42467013	NAGA	-0.62	-9.65	-0.47	1.39e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.64	-9.84	-0.47	3.09e-20	Breast cancer;
LUSC	cis	rs660498	0.507	rs2020155	chr10:27740194	C/T	cg25705717	chr10:27608719	NA	0.39	5.65	0.3	3.42e-8	Asthma (childhood onset);
LUSC	cis	rs2274273	0.840	rs7159144	chr14:55821324	G/A	cg04306507	chr14:55594613	LGALS3	0.56	13.0	0.58	1.48e-31	Protein biomarker;
LUSC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-12.02	-0.55	6.45e-28	Hemoglobin concentration;
LUSC	cis	rs62458065	1.000	rs1450868	chr7:32463666	G/A	cg20159608	chr7:32802032	NA	-0.57	-6.94	-0.35	2.07e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg20283391	chr11:68216788	NA	-0.57	-8.11	-0.41	9.78e-15	Total body bone mineral density;
LUSC	cis	rs2346177	0.844	rs34791442	chr2:46655169	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.6	-0.38	3e-13	HDL cholesterol;
LUSC	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.05	-0.91	1.39e-129	Myeloid white cell count;
LUSC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg16339924	chr4:17578868	LAP3	0.55	8.51	0.42	5.79e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg06618935	chr21:46677482	NA	-0.39	-7.92	-0.4	3.47e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg13755796	chr4:20253514	NA	-0.42	-6.52	-0.34	2.57e-10	Life satisfaction;
LUSC	cis	rs722599	0.683	rs7160852	chr14:75239424	T/C	cg08847533	chr14:75593920	NEK9	0.46	6.44	0.33	4.12e-10	IgG glycosylation;
LUSC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg13531842	chr10:38383804	ZNF37A	-0.45	-6.91	-0.35	2.53e-11	Extrinsic epigenetic age acceleration;
LUSC	trans	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.44	-0.33	4.23e-10	Menarche (age at onset);
LUSC	cis	rs6577655	0.517	rs4909294	chr8:135588020	C/T	cg17885191	chr8:135476712	NA	0.6	7.92	0.4	3.49e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg00310523	chr12:86230176	RASSF9	-0.43	-7.91	-0.4	3.85e-14	Major depressive disorder;
LUSC	cis	rs1160297	0.576	rs724859	chr2:53099305	C/T	cg07782112	chr2:53107842	NA	0.43	7.05	0.36	1.03e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24503407	chr1:205819492	PM20D1	0.9	16.99	0.68	4.27e-47	Menarche (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16705446	chr19:3751546	APBA3	0.47	6.75	0.35	6.54e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg25237894	chr2:233734115	C2orf82	0.35	6.47	0.33	3.4e-10	Coronary artery disease;
LUSC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.64	0.39	2.31e-13	Bipolar disorder;
LUSC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-15.94	-0.66	5.97e-43	Cognitive function;
LUSC	cis	rs4363385	0.818	rs377768	chr1:153016594	T/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.89	-0.4	4.44e-14	Inflammatory skin disease;
LUSC	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg11502198	chr6:26597334	ABT1	0.6	9.37	0.46	1.12e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg06600287	chr1:53387719	ECHDC2	-0.31	-6.41	-0.33	5.05e-10	Monocyte count;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04440769	chr16:4743732	NUDT16L1	0.81	6.98	0.36	1.55e-11	Cognitive performance;
LUSC	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.78	11.3	0.53	2.75e-25	Corneal astigmatism;
LUSC	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg11161011	chr14:65562177	MAX	-0.81	-12.51	-0.56	1.01e-29	Obesity-related traits;
LUSC	cis	rs35079168	0.735	rs3118540	chr9:137307106	C/T	cg24164254	chr9:137329341	RXRA	-0.36	-5.87	-0.31	1.03e-8	Intelligence;
LUSC	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg02958346	chr11:57425731	CLP1	-0.41	-6.04	-0.31	4.19e-9	Schizophrenia;
LUSC	cis	rs4751006	0.543	rs880761	chr10:128783906	C/T	cg05702161	chr10:128779687	DOCK1	-0.66	-6.1	-0.32	2.94e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3768617	0.811	rs10911205	chr1:183009277	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.54	0.42	4.75e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg02660097	chr11:68866761	NA	0.43	6.14	0.32	2.36e-9	Blond vs. brown hair color;
LUSC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	cis	rs1609391	0.543	rs2117009	chr3:136633571	A/T	cg15507776	chr3:136538369	TMEM22	-0.48	-7.81	-0.39	7.37e-14	Neuroticism;
LUSC	cis	rs2235649	0.833	rs9927047	chr16:1851927	A/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-5.96	-0.31	6.47e-9	Blood metabolite levels;
LUSC	cis	rs2997447	0.846	rs3008231	chr1:26402023	A/G	cg19633962	chr1:26362018	EXTL1	-0.47	-5.68	-0.3	2.88e-8	QRS complex (12-leadsum);
LUSC	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg17848003	chr1:3704513	LRRC47	0.33	6.03	0.31	4.45e-9	Red cell distribution width;
LUSC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg16393715	chr7:1948819	MAD1L1	-0.33	-5.89	-0.31	9.17e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7000551	0.581	rs11136030	chr8:22254235	C/T	cg12081754	chr8:22256438	SLC39A14	0.98	16.04	0.66	2.49e-43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.2	-35.46	-0.89	2.94e-115	Myeloid white cell count;
LUSC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg09655341	chr17:79618100	PDE6G	-0.28	-6.36	-0.33	6.81e-10	Eye color traits;
LUSC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg18512352	chr11:47633146	NA	-0.47	-9.36	-0.46	1.19e-18	Subjective well-being;
LUSC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08219700	chr8:58056026	NA	0.65	7.64	0.39	2.29e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	6.16	0.32	2.14e-9	Tonsillectomy;
LUSC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-14.85	-0.63	1.22e-38	Total body bone mineral density;
LUSC	cis	rs68170813	0.559	rs77829121	chr7:106968470	A/G	cg02696742	chr7:106810147	HBP1	-0.64	-9.47	-0.46	5.48e-19	Coronary artery disease;
LUSC	trans	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.45	6.03	0.31	4.41e-9	Multiple sclerosis;
LUSC	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	12.57	0.57	6.33e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg21573476	chr21:45109991	RRP1B	0.41	6.71	0.34	8.44e-11	Mean corpuscular volume;
LUSC	cis	rs2230307	0.536	rs522696	chr1:100476662	G/A	cg24955406	chr1:100503596	HIAT1	0.56	6.04	0.31	4.01e-9	Carotid intima media thickness;
LUSC	trans	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg06521331	chr12:34319734	NA	-0.39	-5.95	-0.31	6.77e-9	Bladder cancer;
LUSC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.11e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg05343316	chr1:45956843	TESK2	0.69	9.61	0.47	1.78e-19	Platelet count;
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11905131	chr22:24372483	LOC391322	0.58	9.68	0.47	1.08e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4974559	0.790	rs28712208	chr4:1316695	A/T	cg02980000	chr4:1222292	CTBP1	0.81	8.79	0.43	7.94e-17	Systolic blood pressure;
LUSC	cis	rs9494145	0.648	rs7758845	chr6:135428537	A/C	cg22676075	chr6:135203613	NA	0.56	8.07	0.4	1.25e-14	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.48	-0.33	3.3e-10	Morning vs. evening chronotype;
LUSC	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg20991723	chr1:152506922	NA	0.54	10.25	0.49	1.33e-21	Hair morphology;
LUSC	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg24130564	chr14:104152367	KLC1	-0.5	-7.15	-0.36	5.48e-12	Body mass index;
LUSC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg02423579	chr7:2872169	GNA12	-0.46	-6.58	-0.34	1.81e-10	Height;
LUSC	cis	rs1507153	0.549	rs236861	chr6:79334147	C/T	cg05283184	chr6:79620031	NA	0.39	7.09	0.36	7.83e-12	Sjögren's syndrome;
LUSC	trans	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.53e-10	Corneal astigmatism;
LUSC	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg27068330	chr11:65405492	SIPA1	-0.77	-10.68	-0.5	4.39e-23	Acne (severe);
LUSC	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg00339695	chr16:24857497	SLC5A11	0.57	8.72	0.43	1.33e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4845570	0.834	rs7007	chr1:151735576	T/C	cg07092448	chr1:151763213	TDRKH	-1.12	-11.56	-0.53	3.13e-26	Coronary artery disease;
LUSC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg24634471	chr8:143751801	JRK	0.59	9.01	0.44	1.66e-17	Schizophrenia;
LUSC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg23303369	chr20:44641161	MMP9	0.37	6.45	0.33	3.94e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs2736345	0.535	rs4366049	chr8:11398504	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	6.24	0.32	1.29e-9	Sjögren's syndrome;Systemic lupus erythematosus;
LUSC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg19748678	chr4:122722346	EXOSC9	0.5	7.81	0.39	7.55e-14	Type 2 diabetes;
LUSC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg27432699	chr2:27873401	GPN1	-0.56	-8.4	-0.42	1.34e-15	Total body bone mineral density;
LUSC	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg00530320	chr1:46809349	NSUN4	0.56	8.7	0.43	1.57e-16	Menopause (age at onset);
LUSC	trans	rs7939886	0.920	rs12224086	chr11:55798259	G/T	cg15704280	chr7:45808275	SEPT13	0.79	6.74	0.35	7.14e-11	Myopia (pathological);
LUSC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12973672	1.000	rs8101606	chr19:35774556	A/C	cg12095397	chr19:35769544	USF2	0.41	6.55	0.34	2.24e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg13560548	chr3:10150139	C3orf24	-0.48	-6.41	-0.33	4.95e-10	Alzheimer's disease;
LUSC	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg06026331	chr20:60912101	LAMA5	0.43	5.94	0.31	7.33e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9378688	1.000	rs9378686	chr6:2217173	G/A	cg12303981	chr6:2244766	GMDS	-0.5	-5.96	-0.31	6.43e-9	Caudate nucleus volume;
LUSC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg10729496	chr3:10149963	C3orf24	0.55	6.88	0.35	2.89e-11	Alzheimer's disease;
LUSC	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg08916839	chr5:415575	AHRR	0.74	6.78	0.35	5.57e-11	Fat distribution (HIV);
LUSC	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.83	-0.43	6.08e-17	Response to antipsychotic treatment;
LUSC	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg12179176	chr11:130786555	SNX19	0.6	9.03	0.44	1.41e-17	Schizophrenia;
LUSC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.51	7.96	0.4	2.78e-14	Cognitive test performance;
LUSC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg04756594	chr16:24857601	SLC5A11	0.34	5.66	0.3	3.25e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06670785	chr22:20073572	MIR1306;DGCR8	0.51	6.31	0.33	8.87e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.08	-0.48	4.83e-21	Obesity-related traits;
LUSC	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-8.41	-0.42	1.23e-15	Hemoglobin concentration;
LUSC	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.5	7.63	0.39	2.51e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.06	0.44	1.09e-17	Motion sickness;
LUSC	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg14631576	chr9:95140430	CENPP	-0.36	-6.16	-0.32	2.12e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	0.92	15.89	0.66	9.31e-43	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	13.63	0.6	6.2e-34	Platelet count;
LUSC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg09650180	chr20:62225654	GMEB2	-0.66	-9.69	-0.47	1.03e-19	Glioblastoma;
LUSC	cis	rs2729354	1.000	rs2729354	chr11:57355970	A/G	cg24343310	chr11:57249947	NA	0.35	6.46	0.33	3.6e-10	Blood protein levels;
LUSC	cis	rs10848704	1.000	rs10848704	chr12:2882544	A/G	cg19995117	chr12:2880862	NA	-0.6	-11.3	-0.53	2.62e-25	Quantitative traits;
LUSC	cis	rs155346	0.947	rs265160	chr5:139390914	A/C	cg01090482	chr5:139365336	NRG2	-0.38	-6.5	-0.34	2.87e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	trans	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.22	0.41	4.57e-15	Ulcerative colitis;
LUSC	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg01294253	chr9:136912663	BRD3	0.35	6.07	0.32	3.38e-9	Platelet distribution width;
LUSC	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.33e-21	Lymphocyte counts;
LUSC	cis	rs1595825	0.891	rs16824264	chr2:198675917	T/C	cg10547527	chr2:198650123	BOLL	-0.52	-6.03	-0.31	4.32e-9	Ulcerative colitis;
LUSC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg18301423	chr5:131593218	PDLIM4	0.37	6.1	0.32	2.94e-9	Blood metabolite levels;
LUSC	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg24556660	chr7:106842632	COG5;HBP1	0.41	5.7	0.3	2.64e-8	Coronary artery disease;
LUSC	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg16576597	chr16:28551801	NUPR1	0.3	6.01	0.31	4.73e-9	Mosquito bite size;
LUSC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg05855489	chr10:104503620	C10orf26	-0.62	-7.62	-0.38	2.7e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg22800045	chr5:56110881	MAP3K1	0.79	10.53	0.5	1.45e-22	Initial pursuit acceleration;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16519440	chr11:65655990	FIBP	-0.41	-6.24	-0.32	1.3e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4731207	0.967	rs3807544	chr7:124400705	G/A	cg14311320	chr7:124405732	GPR37	0.32	6.14	0.32	2.4e-9	Cutaneous malignant melanoma;
LUSC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg23173402	chr1:227635558	NA	0.75	7.96	0.4	2.7e-14	Major depressive disorder;
LUSC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.72	0.39	1.36e-13	Prudent dietary pattern;
LUSC	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12826209	chr6:26865740	GUSBL1	0.74	9.08	0.44	9.64e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg19812747	chr11:111475976	SIK2	0.54	7.79	0.39	8.59e-14	Primary sclerosing cholangitis;
LUSC	trans	rs4729127	1.000	rs57515158	chr7:94007842	T/G	cg20086523	chr13:52378287	DHRS12	0.56	6.48	0.33	3.35e-10	Intelligence;
LUSC	cis	rs9815354	0.812	rs73071212	chr3:41981856	C/A	cg03022575	chr3:42003672	ULK4	0.85	8.85	0.44	5.2e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg10523860	chr14:103875565	MARK3	-0.36	-5.67	-0.3	3.14e-8	Body mass index;
LUSC	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg00745463	chr17:30367425	LRRC37B	-0.77	-9.15	-0.45	5.65e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07636037	chr3:49044803	WDR6	0.69	9.06	0.44	1.1e-17	Menarche (age at onset);
LUSC	cis	rs13385	0.769	rs13178142	chr5:139596552	C/T	cg26211634	chr5:139558579	C5orf32	0.49	6.56	0.34	2.05e-10	Atrial fibrillation;
LUSC	cis	rs9393777	0.778	rs13212921	chr6:27205422	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.55	-6.35	-0.33	7.07e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.15	-0.36	5.48e-12	Bipolar disorder;
LUSC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg16606324	chr3:10149918	C3orf24	0.58	8.28	0.41	2.99e-15	Alzheimer's disease;
LUSC	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg21643547	chr1:205240462	TMCC2	-0.39	-6.86	-0.35	3.32e-11	Red blood cell count;
LUSC	cis	rs2970818	0.764	rs61909577	chr12:4568713	G/A	cg11146114	chr12:4671731	NA	-0.62	-5.87	-0.31	1.03e-8	Phosphorus levels;
LUSC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg23205692	chr1:25664452	TMEM50A	0.39	5.8	0.3	1.55e-8	Erythrocyte sedimentation rate;
LUSC	trans	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg10756647	chr7:56101905	PSPH	0.85	8.22	0.41	4.44e-15	Diabetic kidney disease;
LUSC	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg09904177	chr6:26538194	HMGN4	0.65	11.47	0.53	6.41e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.75	-0.35	6.42e-11	Morning vs. evening chronotype;
LUSC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg06640241	chr16:89574553	SPG7	0.66	9.78	0.47	5.03e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs6596100	0.538	rs34592321	chr5:132181675	G/C	cg02081065	chr5:132209139	LEAP2	-0.62	-5.99	-0.31	5.4e-9	Breast cancer;
LUSC	trans	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	6.33	0.33	7.73e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.48	0.38	6.75e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.69	0.43	1.6e-16	Lung cancer;
LUSC	trans	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg13010199	chr12:38710504	ALG10B	0.45	7.02	0.36	1.21e-11	Morning vs. evening chronotype;
LUSC	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg27205649	chr11:78285834	NARS2	-0.5	-5.85	-0.3	1.16e-8	Alzheimer's disease (survival time);
LUSC	cis	rs2282032	0.550	rs58363992	chr14:90766361	T/C	cg04374321	chr14:90722782	PSMC1	0.44	6.06	0.31	3.73e-9	Longevity;
LUSC	cis	rs7119	0.689	rs11630926	chr15:77819582	T/C	cg27398640	chr15:77910606	LINGO1	-0.31	-6.39	-0.33	5.48e-10	Type 2 diabetes;
LUSC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg15744005	chr10:104629667	AS3MT	-0.28	-6.1	-0.32	2.95e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg26597838	chr10:835615	NA	0.53	6.42	0.33	4.6e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg09835421	chr16:68378352	PRMT7	-0.54	-5.92	-0.31	7.97e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10045504	0.502	rs17456635	chr5:38745456	G/A	cg15396434	chr5:38725168	NA	-0.51	-5.73	-0.3	2.29e-8	Night sleep phenotypes;
LUSC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.67	-12.11	-0.55	3.2e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg24375607	chr4:120327624	NA	0.75	11.05	0.52	2.18e-24	Corneal astigmatism;
LUSC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.61	12.76	0.57	1.23e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg27411982	chr8:10470053	RP1L1	0.37	5.84	0.3	1.26e-8	Retinal vascular caliber;
LUSC	cis	rs10743315	0.778	rs7399032	chr12:19371546	T/C	cg02471346	chr12:19282374	PLEKHA5	-0.53	-6.68	-0.34	1.01e-10	Gut microbiota (bacterial taxa);
LUSC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg12935359	chr14:103987150	CKB	-0.52	-8.03	-0.4	1.68e-14	Body mass index;
LUSC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg12963246	chr6:28129442	ZNF389	0.52	7.24	0.37	3.17e-12	Depression;
LUSC	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg15790184	chr11:494944	RNH1	0.55	5.97	0.31	6.05e-9	Body mass index;
LUSC	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg11752832	chr7:134001865	SLC35B4	-0.48	-6.74	-0.35	6.85e-11	Mean platelet volume;
LUSC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg09796270	chr17:17721594	SREBF1	0.39	7.05	0.36	1.06e-11	Total body bone mineral density;
LUSC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-1.04	-20.22	-0.74	5.96e-60	Height;
LUSC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg20887711	chr4:1340912	KIAA1530	0.44	6.64	0.34	1.28e-10	Obesity-related traits;
LUSC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17509989	chr5:176798049	RGS14	0.69	11.21	0.52	5.78e-25	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs2898681	0.642	rs11538878	chr4:53728524	T/C	cg00338735	chr4:53728038	RASL11B	0.41	5.71	0.3	2.49e-8	Optic nerve measurement (cup area);
LUSC	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.73	-0.43	1.21e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4253772	0.938	rs10154348	chr22:46638159	C/A	cg18190219	chr22:46762943	CELSR1	-0.48	-5.81	-0.3	1.45e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9815354	0.767	rs79323474	chr3:42000973	C/T	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.21e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	ch.11.42038R	chr11:967971	AP2A2	0.42	6.23	0.32	1.41e-9	Alzheimer's disease (late onset);
LUSC	cis	rs12760731	0.720	rs10798607	chr1:178373110	C/T	cg00404053	chr1:178313656	RASAL2	0.64	6.55	0.34	2.22e-10	Obesity-related traits;
LUSC	cis	rs9326248	0.813	rs588534	chr11:117068504	A/G	cg16524733	chr11:117070046	TAGLN	0.37	5.8	0.3	1.55e-8	Blood protein levels;
LUSC	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg19508488	chr2:152266495	RIF1	0.4	5.85	0.3	1.17e-8	Lung cancer;
LUSC	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-7.57	-0.38	3.77e-13	Atrioventricular conduction;
LUSC	trans	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg13565492	chr6:43139072	SRF	-0.61	-6.4	-0.33	5.21e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	0.9	16.79	0.68	2.6e-46	Heart rate;
LUSC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg22638593	chr5:131593259	PDLIM4	0.36	5.79	0.3	1.61e-8	Blood metabolite levels;
LUSC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	7.19	0.37	4.33e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg17366294	chr4:99064904	C4orf37	0.57	10.05	0.48	6.03e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg09754948	chr16:28834200	ATXN2L	0.44	6.43	0.33	4.51e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg11663144	chr21:46675770	NA	-0.42	-7.3	-0.37	2.07e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9311676	0.632	rs11705721	chr3:58400414	T/C	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg16447950	chr5:562315	NA	-0.55	-7.1	-0.36	7.47e-12	Lung disease severity in cystic fibrosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20087303	chr14:70233840	SFRS5;LOC100289511	0.45	6.1	0.32	2.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg21545522	chr1:205238299	TMCC2	0.46	8.52	0.42	5.56e-16	Red blood cell count;
LUSC	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg12062639	chr20:23401060	NAPB	-0.78	-6.02	-0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23598886	chr18:12777645	NA	0.65	6.6	0.34	1.61e-10	Inflammatory skin disease;
LUSC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.63	0.47	1.62e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.53	0.38	4.8e-13	Morning vs. evening chronotype;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06190380	chr10:64576262	EGR2	0.75	6.38	0.33	5.9e-10	Cognitive performance;
LUSC	trans	rs9860340	0.730	rs55641563	chr3:87649547	T/C	cg03644585	chr7:884825	UNC84A	0.43	6.06	0.31	3.67e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	0.95	17.97	0.7	5.23e-51	Bone mineral density;
LUSC	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs7106204	0.764	rs57490470	chr11:24234370	A/G	ch.11.24196551F	chr11:24239977	NA	0.97	9.03	0.44	1.36e-17	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg00750074	chr16:89608354	SPG7	-0.56	-10.25	-0.49	1.29e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.83	14.06	0.61	1.39e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4363385	0.818	rs3806223	chr1:153002646	T/C	cg25856811	chr1:152973957	SPRR3	-0.36	-5.94	-0.31	6.97e-9	Inflammatory skin disease;
LUSC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10276381	0.786	rs10255700	chr7:28220228	C/T	cg23620719	chr7:28220237	JAZF1	0.63	6.76	0.35	6.21e-11	Crohn's disease;
LUSC	cis	rs7605827	0.930	rs1986279	chr2:15617390	G/A	cg19274914	chr2:15703543	NA	0.48	9.23	0.45	3.1e-18	Educational attainment (years of education);
LUSC	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	8.15	0.41	7.54e-15	Neuroticism;
LUSC	trans	rs11165623	0.602	rs12120893	chr1:97007132	C/T	cg03325851	chr11:6440480	APBB1	0.47	6.07	0.32	3.42e-9	Hip circumference;Waist circumference;
LUSC	cis	rs2882667	0.690	rs160401	chr5:138061341	C/T	cg04439458	chr5:138467593	SIL1	0.36	6.99	0.36	1.46e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs4474465	0.915	rs12288436	chr11:78161430	T/C	cg27205649	chr11:78285834	NARS2	-0.5	-5.89	-0.31	9.6e-9	Alzheimer's disease (survival time);
LUSC	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.32	-0.45	1.68e-18	Joint mobility (Beighton score);
LUSC	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg04310649	chr10:35416472	CREM	-0.41	-6.44	-0.33	4.26e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg09904177	chr6:26538194	HMGN4	-0.5	-7.94	-0.4	3.01e-14	Schizophrenia;
LUSC	cis	rs6960043	0.738	rs12538043	chr7:15058998	C/G	cg19272540	chr7:15055459	NA	0.35	8.22	0.41	4.67e-15	Type 2 diabetes;
LUSC	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg00806126	chr19:22604979	ZNF98	0.37	5.71	0.3	2.5e-8	Pain;
LUSC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg09034736	chr1:150693464	HORMAD1	0.45	6.48	0.33	3.36e-10	Tonsillectomy;
LUSC	cis	rs1775715	0.707	rs2808073	chr10:32179275	A/G	cg18675610	chr10:32216311	ARHGAP12	0.3	6.5	0.34	2.88e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg25319279	chr11:5960081	NA	-0.43	-5.98	-0.31	5.6e-9	DNA methylation (variation);
LUSC	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs3808502	0.527	rs2736389	chr8:11161310	C/A	cg15556689	chr8:8085844	FLJ10661	0.43	6.17	0.32	1.93e-9	Neuroticism;
LUSC	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg05973401	chr12:123451056	ABCB9	0.54	6.68	0.34	9.72e-11	Neutrophil percentage of white cells;
LUSC	cis	rs4664308	0.618	rs66667042	chr2:160886703	A/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-7.96	-0.4	2.79e-14	Idiopathic membranous nephropathy;
LUSC	trans	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.78	0.35	5.4e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs41271473	1.000	rs41270187	chr1:228878871	T/C	cg16512390	chr1:228756714	NA	0.46	5.71	0.3	2.5e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs12980942	0.935	rs34075897	chr19:41826598	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.55	5.94	0.31	7.27e-9	Coronary artery disease;
LUSC	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	6.78	0.35	5.41e-11	Height;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25289973	chr4:41362397	LIMCH1	-0.38	-6.37	-0.33	6.15e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15367106	chr12:96184558	NTN4	-0.44	-6.3	-0.33	9.61e-10	Electrocardiographic conduction measures;
LUSC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-10.47	-0.5	2.24e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.69	-0.5	3.93e-23	Alzheimer's disease;
LUSC	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.88	-0.31	1.02e-8	IgG glycosylation;
LUSC	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg01657329	chr11:68192670	LRP5	-0.4	-5.77	-0.3	1.85e-8	Total body bone mineral density;
LUSC	cis	rs12618769	0.597	rs3769741	chr2:99068204	G/T	cg10123293	chr2:99228465	UNC50	0.45	7.62	0.38	2.59e-13	Bipolar disorder;
LUSC	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.21	0.49	1.8e-21	Birth weight;
LUSC	cis	rs5009270	0.512	rs1024411	chr7:112247692	G/A	cg23628563	chr7:112262597	NA	0.43	5.97	0.31	6.01e-9	Osteoarthritis (hip);
LUSC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-8.88	-0.44	4.24e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg17971929	chr21:40555470	PSMG1	0.48	6.93	0.35	2.14e-11	Menarche (age at onset);
LUSC	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg02466173	chr16:30829666	NA	-0.53	-10.36	-0.49	5.3e-22	Dementia with Lewy bodies;
LUSC	cis	rs12900413	0.631	rs62023455	chr15:90301999	G/A	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.56e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg11812906	chr14:75593930	NEK9	-0.67	-11.34	-0.53	1.89e-25	Height;
LUSC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg02428538	chr16:24856791	SLC5A11	0.5	5.75	0.3	1.98e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	0.65	13.68	0.6	4.06e-34	Prudent dietary pattern;
LUSC	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04004882	chr2:215674386	BARD1	0.48	6.37	0.33	6.34e-10	Neuroblastoma;
LUSC	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg20701182	chr2:24300061	SF3B14	0.89	11.69	0.54	1.08e-26	Lymphocyte counts;
LUSC	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.43	-5.97	-0.31	5.94e-9	Reticulocyte count;
LUSC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg21573476	chr21:45109991	RRP1B	-0.36	-5.75	-0.3	2.02e-8	Mean corpuscular volume;
LUSC	cis	rs2455601	1.000	rs11042114	chr11:8919889	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.88	-0.35	3.02e-11	Schizophrenia;
LUSC	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg06627628	chr2:24431161	ITSN2	0.61	8.96	0.44	2.27e-17	Asthma;
LUSC	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.48	6.62	0.34	1.42e-10	IgG glycosylation;
LUSC	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg04117972	chr1:227635322	NA	0.74	7.79	0.39	8.75e-14	Major depressive disorder;
LUSC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-11.38	-0.53	1.43e-25	Total body bone mineral density;
LUSC	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg21361702	chr7:150065534	REPIN1	0.6	9.29	0.45	2.09e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg24579218	chr15:68104479	NA	-0.36	-6.45	-0.33	4.01e-10	Restless legs syndrome;
LUSC	cis	rs7809950	1.000	rs2107713	chr7:107232369	C/T	cg23024343	chr7:107201750	COG5	-0.51	-7.85	-0.39	5.55e-14	Coronary artery disease;
LUSC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg03146154	chr1:46216737	IPP	-0.55	-8.02	-0.4	1.79e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg05738196	chr6:26577821	NA	0.58	6.78	0.35	5.58e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg13010199	chr12:38710504	ALG10B	0.45	6.4	0.33	5.12e-10	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11779988	0.545	rs431961	chr8:17786204	T/G	cg01800426	chr8:17659068	MTUS1	-0.46	-5.7	-0.3	2.64e-8	Breast cancer;
LUSC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg04141948	chr7:1023156	CYP2W1	0.27	5.77	0.3	1.8e-8	Longevity;Endometriosis;
LUSC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg23985595	chr17:80112537	CCDC57	0.3	5.76	0.3	1.92e-8	Life satisfaction;
LUSC	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.47	6.6	0.34	1.63e-10	Lung cancer;
LUSC	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg12744634	chr1:26560303	CCDC21	0.39	5.84	0.3	1.25e-8	Obesity-related traits;
LUSC	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg02569458	chr12:86230093	RASSF9	0.54	8.82	0.43	6.7e-17	Major depressive disorder;
LUSC	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg19508488	chr2:152266495	RIF1	0.44	6.33	0.33	8.07e-10	Lung cancer;
LUSC	cis	rs155346	1.000	rs155346	chr5:139390377	C/T	cg01090482	chr5:139365336	NRG2	0.37	6.36	0.33	6.71e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21937244	chr14:103406412	CDC42BPB	-0.36	-6.61	-0.34	1.56e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.7	0.47	9.26e-20	Bipolar disorder;
LUSC	cis	rs9398803	0.799	rs1538170	chr6:126752874	C/T	cg19875578	chr6:126661172	C6orf173	0.41	5.96	0.31	6.26e-9	Male-pattern baldness;
LUSC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.76	-13.64	-0.6	5.41e-34	Dental caries;
LUSC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg11247378	chr22:39784982	NA	-0.68	-13.63	-0.6	6.14e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg24881330	chr22:46731750	TRMU	0.88	8.87	0.44	4.44e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg01871581	chr19:12707946	ZNF490	-0.6	-9.62	-0.47	1.73e-19	Bipolar disorder;
LUSC	cis	rs1595825	0.838	rs79381203	chr2:198573762	A/G	cg00982548	chr2:198649783	BOLL	-0.53	-6.72	-0.35	7.65e-11	Ulcerative colitis;
LUSC	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg24558204	chr6:135376177	HBS1L	0.68	10.81	0.51	1.43e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	7.04	0.36	1.1e-11	Colorectal cancer;
LUSC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg12463550	chr7:65579703	CRCP	0.55	8.21	0.41	4.85e-15	Aortic root size;
LUSC	cis	rs500891	0.525	rs3778205	chr6:84060477	G/T	cg08257003	chr6:84140564	ME1	0.34	8.09	0.4	1.08e-14	Platelet-derived growth factor BB levels;
LUSC	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg25482853	chr8:67687455	SGK3	1.19	19.12	0.72	1.43e-55	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg03676636	chr4:99064102	C4orf37	0.34	6.13	0.32	2.47e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9937943	0.667	rs12919002	chr16:74612377	A/G	cg01733217	chr16:74700730	RFWD3	0.62	6.78	0.35	5.3e-11	Neutrophil percentage of white cells;
LUSC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg10909506	chr17:38081995	ORMDL3	0.35	6.61	0.34	1.57e-10	Self-reported allergy;
LUSC	trans	rs2679649	1.000	rs2260078	chr6:122350567	C/T	cg00167820	chr8:131663355	NA	0.54	6.32	0.33	8.2e-10	Subcutaneous adipose tissue;
LUSC	cis	rs6741892	1.000	rs13006376	chr2:38914251	A/C	cg23643435	chr2:38893251	GALM	-0.7	-5.71	-0.3	2.56e-8	5-HTT brain serotonin transporter levels;
LUSC	cis	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg06521331	chr12:34319734	NA	-0.47	-7.54	-0.38	4.38e-13	Morning vs. evening chronotype;
LUSC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.42	6.42	0.33	4.79e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.32	0.37	1.81e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.62	-9.62	-0.47	1.64e-19	Platelet count;
LUSC	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg15704280	chr7:45808275	SEPT13	0.64	7.08	0.36	8.52e-12	Axial length;
LUSC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.89	14.12	0.61	8.05e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11039100	1.000	rs12362071	chr11:5828450	T/C	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg24596788	chr1:163392923	NA	-0.45	-7.45	-0.38	7.88e-13	Motion sickness;
LUSC	cis	rs1009647	0.645	rs72715709	chr14:55711692	C/T	cg04306507	chr14:55594613	LGALS3	0.44	5.98	0.31	5.72e-9	Testicular germ cell tumor;
LUSC	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02176678	chr2:219576539	TTLL4	0.64	11.7	0.54	9.61e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg00409905	chr10:38381863	ZNF37A	-0.35	-6.14	-0.32	2.35e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg08499158	chr17:42289980	UBTF	0.48	8.24	0.41	3.95e-15	Total body bone mineral density;
LUSC	cis	rs4771122	0.740	rs1006353	chr13:28047269	A/G	cg01674679	chr13:27998804	GTF3A	0.42	5.82	0.3	1.39e-8	Body mass index;
LUSC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.27	-0.32	1.1e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8113142	0.559	rs73028028	chr19:29137876	T/C	cg04546413	chr19:29218101	NA	0.41	5.76	0.3	1.95e-8	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg11189052	chr15:85197271	WDR73	-0.43	-6.25	-0.32	1.22e-9	P wave terminal force;
LUSC	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg19875535	chr5:140030758	IK	0.5	7.96	0.4	2.63e-14	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-1.03	-19.79	-0.73	3.14e-58	Height;
LUSC	cis	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg07460842	chr6:66804631	NA	-0.48	-6.72	-0.35	7.74e-11	Blood trace element (Cu levels);
LUSC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14159672	chr1:205819179	PM20D1	0.8	13.73	0.6	2.43e-34	Menarche (age at onset);
LUSC	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg24112000	chr20:60950667	NA	0.36	6.8	0.35	4.72e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs3742264	0.656	rs4460970	chr13:46540293	A/T	cg15192986	chr13:46630673	CPB2	-0.37	-5.65	-0.3	3.37e-8	Blood protein levels;
LUSC	cis	rs9322817	0.691	rs2486136	chr6:105285759	C/T	cg02098413	chr6:105308735	HACE1	0.27	5.66	0.3	3.21e-8	Thyroid stimulating hormone;
LUSC	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg27129171	chr3:47204927	SETD2	0.69	11.48	0.53	6.36e-26	Colorectal cancer;
LUSC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.77	10.35	0.49	5.71e-22	Gut microbiome composition (summer);
LUSC	cis	rs61935443	0.614	rs11107787	chr12:95311669	C/T	cg21533806	chr12:95267307	NA	0.49	5.74	0.3	2.12e-8	Schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00734800	chr3:50388182	TUSC4;CYB561D2	0.44	6.53	0.34	2.39e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.82	0.39	7.02e-14	Prudent dietary pattern;
LUSC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg09165964	chr15:75287851	SCAMP5	0.54	7.84	0.39	6.21e-14	Breast cancer;
LUSC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	22.79	0.78	5.28e-70	Height;
LUSC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg03146154	chr1:46216737	IPP	0.56	8.36	0.42	1.77e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.19e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg08742575	chr21:47604166	C21orf56	0.47	7.12	0.36	6.64e-12	Testicular germ cell tumor;
LUSC	cis	rs11785693	0.862	rs73183606	chr8:4986999	C/T	cg26367366	chr8:4980734	NA	0.79	9.32	0.45	1.64e-18	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg18132916	chr6:79620363	NA	-0.38	-5.85	-0.3	1.18e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs34779708	0.733	rs3936503	chr10:35549257	A/G	cg03585969	chr10:35415529	CREM	-0.52	-7.31	-0.37	1.97e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18876405	chr7:65276391	NA	0.54	8.27	0.41	3.22e-15	Aortic root size;
LUSC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.51	0.46	3.94e-19	Bipolar disorder;
LUSC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg02269571	chr22:50332266	NA	-0.4	-6.22	-0.32	1.45e-9	Schizophrenia;
LUSC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.63	8.44	0.42	9.92e-16	High light scatter reticulocyte count;
LUSC	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg15556689	chr8:8085844	FLJ10661	0.56	7.69	0.39	1.67e-13	Neuroticism;
LUSC	cis	rs834603	0.575	rs2462638	chr7:47471286	A/G	cg09696706	chr7:47479511	TNS3	0.32	5.83	0.3	1.31e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg11062466	chr8:58055876	NA	0.48	6.26	0.32	1.16e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs8040855	0.599	rs6496793	chr15:85725746	T/A	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.87	0.35	3.1e-11	Bulimia nervosa;
LUSC	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg17524180	chr13:113633600	MCF2L	-0.34	-6.6	-0.34	1.65e-10	Systolic blood pressure;
LUSC	cis	rs870825	0.616	rs6814278	chr4:185644417	G/C	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg18681998	chr4:17616180	MED28	0.85	15.84	0.65	1.54e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs2018683	0.683	rs12538606	chr7:28969408	T/C	cg19402173	chr7:128379420	CALU	-0.46	-6.92	-0.35	2.28e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs12681288	0.640	rs6985741	chr8:962858	C/T	cg04851639	chr8:1020857	NA	-0.37	-7.1	-0.36	7.61e-12	Schizophrenia;
LUSC	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg20608306	chr11:116969690	SIK3	0.4	6.57	0.34	1.95e-10	Blood protein levels;
LUSC	cis	rs981844	0.683	rs1105495	chr4:154756867	T/C	cg14289246	chr4:154710475	SFRP2	-0.47	-6.51	-0.34	2.69e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs6546886	0.957	rs4416242	chr2:74259894	A/T	cg14702570	chr2:74259524	NA	-0.31	-5.91	-0.31	8.36e-9	Dialysis-related mortality;
LUSC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.75	13.45	0.59	2.93e-33	Dental caries;
LUSC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18932078	chr1:2524107	MMEL1	0.28	6.2	0.32	1.68e-9	Ulcerative colitis;
LUSC	trans	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg25214090	chr10:38739885	LOC399744	0.43	6.49	0.33	3.12e-10	Corneal astigmatism;
LUSC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02353165	chr6:42928485	GNMT	0.67	11.53	0.53	4.18e-26	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11166629	1.000	rs2315838	chr8:135645968	C/T	cg21672855	chr8:135614777	ZFAT	0.35	5.72	0.3	2.32e-8	Smoking quantity;
LUSC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg03233332	chr7:66118400	NA	0.4	5.87	0.31	1.06e-8	Aortic root size;
LUSC	cis	rs2692947	0.673	rs3111873	chr2:96781986	G/C	cg22654517	chr2:96458247	NA	-0.31	-5.77	-0.3	1.78e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg27165867	chr14:105738592	BRF1	-0.51	-7.43	-0.38	9.37e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.62	-0.34	1.47e-10	Longevity;Endometriosis;
LUSC	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg19640130	chr10:64028056	RTKN2	-0.42	-7.46	-0.38	7.6e-13	Rheumatoid arthritis;
LUSC	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg15744005	chr10:104629667	AS3MT	-0.38	-7.81	-0.39	7.65e-14	Arsenic metabolism;
LUSC	cis	rs12410462	0.579	rs77529417	chr1:227547895	T/C	cg04117972	chr1:227635322	NA	0.62	6.74	0.35	7.04e-11	Major depressive disorder;
LUSC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg11845111	chr2:191398756	TMEM194B	-0.85	-10.9	-0.51	6.98e-24	Diastolic blood pressure;
LUSC	trans	rs7951105	1.000	rs7104592	chr11:39242244	C/A	cg24085930	chr3:21832523	NA	0.49	6.07	0.32	3.42e-9	Free thyroxine concentration;
LUSC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.38	-7.57	-0.38	3.68e-13	Coronary artery disease;
LUSC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg11812906	chr14:75593930	NEK9	0.67	11.68	0.54	1.14e-26	Height;
LUSC	trans	rs34421088	0.532	rs3808515	chr8:11156041	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	6.44	0.33	4.22e-10	Neuroticism;
LUSC	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg01191920	chr7:158217561	PTPRN2	-0.59	-12.32	-0.56	5.24e-29	Obesity-related traits;
LUSC	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg15557168	chr22:42548783	NA	-0.43	-7.27	-0.37	2.62e-12	Cognitive function;
LUSC	cis	rs73206853	0.686	rs7974047	chr12:111119631	C/T	cg12870014	chr12:110450643	ANKRD13A	0.61	6.17	0.32	1.97e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg24829409	chr8:58192753	C8orf71	-0.47	-5.95	-0.31	6.62e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3770081	1.000	rs75713195	chr2:86290659	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.84	-0.35	3.84e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs12681287	0.577	rs13257414	chr8:87494138	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.24	-0.37	3.19e-12	Caudate activity during reward;
LUSC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg17366294	chr4:99064904	C4orf37	0.55	9.59	0.46	2.07e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9807841	0.670	rs10948	chr19:10754905	G/T	cg09936142	chr19:10668400	KRI1	-0.42	-6.58	-0.34	1.81e-10	Inflammatory skin disease;
LUSC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.4	0.38	1.11e-12	Lung cancer in ever smokers;
LUSC	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg06713675	chr4:122721982	EXOSC9	0.37	6.07	0.32	3.54e-9	Type 2 diabetes;
LUSC	cis	rs73198271	0.531	rs56100346	chr8:8652844	C/T	cg01851573	chr8:8652454	MFHAS1	0.58	7.72	0.39	1.34e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg25554036	chr4:6271136	WFS1	0.62	13.45	0.59	2.88e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6977660	0.714	rs12672320	chr7:19813594	G/T	cg07541023	chr7:19748670	TWISTNB	0.67	7.24	0.37	3.2e-12	Thyroid stimulating hormone;
LUSC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg11752832	chr7:134001865	SLC35B4	0.59	9.53	0.46	3.26e-19	Mean platelet volume;
LUSC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6545883	0.868	rs2441381	chr2:61798829	C/T	cg15711740	chr2:61764176	XPO1	-0.45	-7.12	-0.36	6.51e-12	Tuberculosis;
LUSC	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.69	0.6	3.62e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1595825	0.732	rs77357334	chr2:198455607	G/A	cg00982548	chr2:198649783	BOLL	-0.53	-6.2	-0.32	1.65e-9	Ulcerative colitis;
LUSC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-7.04	-0.36	1.07e-11	HDL cholesterol;
LUSC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg22834771	chr12:69754056	YEATS4	-0.45	-6.39	-0.33	5.49e-10	Blood protein levels;
LUSC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg10253484	chr15:75165896	SCAMP2	-0.49	-7.21	-0.37	3.75e-12	Breast cancer;
LUSC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06634786	chr22:41940651	POLR3H	-0.53	-6.45	-0.33	3.85e-10	Vitiligo;
LUSC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg08219700	chr8:58056026	NA	0.49	6.06	0.31	3.73e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg12935359	chr14:103987150	CKB	0.66	10.79	0.51	1.81e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg24503407	chr1:205819492	PM20D1	-0.47	-6.32	-0.33	8.32e-10	Menarche (age at onset);
LUSC	cis	rs9807841	0.592	rs6511707	chr19:10767790	C/T	cg09936142	chr19:10668400	KRI1	-0.39	-6.25	-0.32	1.22e-9	Inflammatory skin disease;
LUSC	cis	rs2970818	0.831	rs11063217	chr12:4650782	G/A	cg11146114	chr12:4671731	NA	-0.6	-5.99	-0.31	5.42e-9	Phosphorus levels;
LUSC	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.05	0.31	3.87e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg27170947	chr2:26402098	FAM59B	0.72	10.82	0.51	1.41e-23	Gut microbiome composition (summer);
LUSC	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg05043794	chr9:111880884	C9orf5	-0.35	-7.31	-0.37	2.03e-12	Menarche (age at onset);
LUSC	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg24450063	chr1:156163899	SLC25A44	1.04	8.47	0.42	7.73e-16	Paclitaxel disposition in epithelial ovarian cancer;
LUSC	cis	rs10843647	0.967	rs1973269	chr12:30323516	A/C	cg12718339	chr12:29936407	TMTC1	-0.36	-5.91	-0.31	8.54e-9	Glucose homeostasis traits;
LUSC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.07	-0.4	1.31e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs117352156	0.943	rs10826543	chr10:29220500	C/T	cg06394621	chr10:29236369	NA	-0.45	-5.91	-0.31	8.29e-9	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg19743168	chr1:23544995	NA	0.41	7.94	0.4	3.14e-14	Height;
LUSC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.45	-5.96	-0.31	6.57e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg20811857	chr17:78079795	GAA	-0.32	-5.9	-0.31	8.98e-9	Yeast infection;
LUSC	cis	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg27411982	chr8:10470053	RP1L1	-0.49	-7.47	-0.38	7.29e-13	Morning vs. evening chronotype;
LUSC	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg08213375	chr14:104286397	PPP1R13B	0.44	7.91	0.4	3.73e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17401966	0.540	rs6674949	chr1:10458480	A/G	cg19773385	chr1:10388646	KIF1B	-0.4	-7.2	-0.37	3.96e-12	Hepatocellular carcinoma;
LUSC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.83	-0.35	4.1e-11	Lung cancer;
LUSC	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.69	-0.34	9.38e-11	Retinal vascular caliber;
LUSC	cis	rs16854884	0.657	rs1867608	chr3:143752938	G/A	cg06585982	chr3:143692056	C3orf58	0.5	7.88	0.4	4.71e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	13.28	0.59	1.26e-32	Total body bone mineral density;
LUSC	cis	rs6554196	0.508	rs11727273	chr4:55509748	C/T	cg18836493	chr4:55524333	KIT	-0.41	-7.02	-0.36	1.26e-11	Monocyte count;
LUSC	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg01294253	chr9:136912663	BRD3	0.34	5.73	0.3	2.29e-8	Platelet distribution width;
LUSC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.4	5.76	0.3	1.86e-8	Tonsillectomy;
LUSC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg11189052	chr15:85197271	WDR73	-0.52	-7.3	-0.37	2.1e-12	P wave terminal force;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19260885	chr1:113162159	ST7L;CAPZA1	-0.41	-6.14	-0.32	2.31e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.28	-0.32	1.08e-9	Monocyte count;
LUSC	cis	rs7760949	0.852	rs9475800	chr6:13932230	A/G	cg27413430	chr6:13925136	RNF182	0.61	9.01	0.44	1.61e-17	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg01557791	chr16:72042693	DHODH	-0.52	-7.54	-0.38	4.42e-13	Fibrinogen levels;
LUSC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg12568669	chr8:11666485	FDFT1	0.26	5.78	0.3	1.72e-8	Retinal vascular caliber;
LUSC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg00033643	chr7:134001901	SLC35B4	0.47	7.3	0.37	2.15e-12	Mean platelet volume;
LUSC	cis	rs9323205	0.954	rs4258524	chr14:51638739	A/T	cg23942311	chr14:51606299	NA	-0.41	-8.77	-0.43	9.5e-17	Cancer;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	ch.3.55501R	chr3:3184210	TRNT1	0.35	6.07	0.32	3.43e-9	Tuberculosis;
LUSC	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.76	13.77	0.6	1.83e-34	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg24634471	chr8:143751801	JRK	0.59	8.97	0.44	2.2e-17	Schizophrenia;
LUSC	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg23691090	chr22:46449981	C22orf26;LOC150381	0.4	6.09	0.32	3.15e-9	Dupuytren's disease;
LUSC	cis	rs1595825	0.732	rs79207930	chr2:198423111	G/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.23	-0.32	1.44e-9	Ulcerative colitis;
LUSC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg11062466	chr8:58055876	NA	0.65	8.6	0.43	3.23e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg03859395	chr2:55845619	SMEK2	-0.74	-11.83	-0.54	3.33e-27	Metabolic syndrome;
LUSC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg06454157	chr6:167490870	NA	-0.26	-6.09	-0.32	3.17e-9	Crohn's disease;
LUSC	cis	rs6469656	0.881	rs4335152	chr8:117651371	A/G	cg24004040	chr8:117650383	NA	-0.43	-6.22	-0.32	1.46e-9	Colorectal cancer;
LUSC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.28	0.45	2.23e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg26102564	chr10:131424627	MGMT	0.4	6.02	0.31	4.68e-9	Response to temozolomide;
LUSC	cis	rs1018836	0.892	rs10105142	chr8:91547420	C/T	cg16814680	chr8:91681699	NA	-0.65	-10.75	-0.51	2.47e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg25456477	chr12:86230367	RASSF9	0.33	5.73	0.3	2.21e-8	Major depressive disorder;
LUSC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg09365446	chr1:150670422	GOLPH3L	-0.4	-5.94	-0.31	7.35e-9	Tonsillectomy;
LUSC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg18876405	chr7:65276391	NA	-0.58	-9.31	-0.45	1.8e-18	Aortic root size;
LUSC	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg23283495	chr1:209979779	IRF6	0.69	7.96	0.4	2.69e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	0.99	18.35	0.71	1.72e-52	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs73198271	0.515	rs11906	chr8:8641259	C/T	cg01851573	chr8:8652454	MFHAS1	0.57	6.86	0.35	3.43e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9837602	1.000	rs6806178	chr3:99780393	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-6.03	-0.31	4.47e-9	Breast cancer;
LUSC	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg22508957	chr16:3507546	NAT15	-0.66	-10.33	-0.49	6.98e-22	Tuberculosis;
LUSC	cis	rs6906287	0.609	rs10457342	chr6:118948033	A/G	cg21191810	chr6:118973309	C6orf204	0.32	5.81	0.3	1.45e-8	Electrocardiographic conduction measures;
LUSC	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg14019146	chr3:50243930	SLC38A3	-0.53	-12.75	-0.57	1.28e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg06713675	chr4:122721982	EXOSC9	0.35	5.77	0.3	1.78e-8	Type 2 diabetes;
LUSC	cis	rs977987	0.806	rs11149833	chr16:75464002	G/C	cg03315344	chr16:75512273	CHST6	0.5	9.55	0.46	2.98e-19	Dupuytren's disease;
LUSC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg07703079	chr11:430292	ANO9	0.66	6.75	0.35	6.51e-11	Body mass index;
LUSC	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg13798780	chr7:105162888	PUS7	0.55	5.72	0.3	2.34e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg03289416	chr15:75166202	SCAMP2	0.45	6.99	0.36	1.5e-11	Breast cancer;
LUSC	trans	rs34421088	0.532	rs2409754	chr8:11155613	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	6.58	0.34	1.8e-10	Neuroticism;
LUSC	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg16230307	chr14:35515116	FAM177A1	0.78	9.88	0.48	2.39e-20	Psoriasis;
LUSC	cis	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg21775007	chr8:11205619	TDH	-0.5	-7.54	-0.38	4.51e-13	Systolic blood pressure;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22837499	chr11:18417924	LDHA	-0.46	-6.09	-0.32	3.12e-9	Hepatitis;
LUSC	trans	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg13010199	chr12:38710504	ALG10B	0.49	7.44	0.38	8.72e-13	Morning vs. evening chronotype;
LUSC	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.84	-15.93	-0.66	6.84e-43	Longevity;
LUSC	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg02493740	chr2:85810744	VAMP5	-0.52	-9.07	-0.44	1.07e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.8	-16.64	-0.67	1.03e-45	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg12473912	chr3:136751656	NA	0.38	6.79	0.35	5.14e-11	Neuroticism;
LUSC	trans	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg01620082	chr3:125678407	NA	-0.82	-7.65	-0.39	2.2e-13	Depression;
LUSC	cis	rs1595825	0.891	rs73061068	chr2:198908439	A/G	cg00982548	chr2:198649783	BOLL	-0.56	-7.0	-0.36	1.41e-11	Ulcerative colitis;
LUSC	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.89	0.48	2.22e-20	Coffee consumption (cups per day);
LUSC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg07507251	chr3:52567010	NT5DC2	0.35	6.81	0.35	4.69e-11	Bipolar disorder;
LUSC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg07952391	chr2:88470173	THNSL2	-0.4	-5.65	-0.3	3.45e-8	Response to metformin (IC50);
LUSC	cis	rs7119	0.667	rs4886889	chr15:77902347	T/C	cg27398640	chr15:77910606	LINGO1	0.38	8.96	0.44	2.25e-17	Type 2 diabetes;
LUSC	cis	rs7712401	0.601	rs30049	chr5:122306097	G/A	cg19077854	chr5:122220652	SNX24	0.43	9.67	0.47	1.14e-19	Mean platelet volume;
LUSC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg24562669	chr7:97807699	LMTK2	0.36	6.26	0.32	1.16e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17824933	1.000	rs17824933	chr11:60760612	C/G	cg16817237	chr11:60793675	NA	0.4	6.26	0.32	1.19e-9	Multiple sclerosis;
LUSC	cis	rs11051970	1.000	rs11051970	chr12:32537488	G/T	cg24626660	chr12:32551988	NA	0.37	6.26	0.32	1.16e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg14092571	chr14:90743983	NA	0.36	5.82	0.3	1.39e-8	Mortality in heart failure;
LUSC	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg09307838	chr4:120376055	NA	0.7	9.88	0.48	2.23e-20	Corneal astigmatism;
LUSC	trans	rs6561151	0.957	rs1932990	chr13:44460242	C/T	cg12856521	chr11:46389249	DGKZ	0.59	7.83	0.39	6.63e-14	Crohn's disease;
LUSC	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg27068330	chr11:65405492	SIPA1	0.62	9.4	0.46	9.16e-19	Acne (severe);
LUSC	cis	rs7605827	0.930	rs6715487	chr2:15540579	T/C	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg20203395	chr5:56204925	C5orf35	0.5	7.46	0.38	7.4e-13	Coronary artery disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23831110	chr14:102785987	ZNF839	-0.44	-6.02	-0.31	4.52e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3768617	0.624	rs34105373	chr1:183098387	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.71	0.43	1.39e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.75	9.58	0.46	2.24e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	8.65	0.43	2.24e-16	Motion sickness;
LUSC	cis	rs400736	0.930	rs226249	chr1:8021778	A/G	cg25007680	chr1:8021821	PARK7	0.61	9.54	0.46	3.13e-19	Response to antidepressants and depression;
LUSC	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg22676075	chr6:135203613	NA	0.47	7.27	0.37	2.62e-12	Red blood cell count;
LUSC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg17509989	chr5:176798049	RGS14	-0.66	-9.54	-0.46	3.2e-19	Urate levels in lean individuals;
LUSC	cis	rs2652834	1.000	rs2729784	chr15:63402735	T/C	cg05507819	chr15:63340323	TPM1	0.67	8.14	0.41	7.84e-15	HDL cholesterol;
LUSC	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg27124370	chr19:33622961	WDR88	0.51	6.66	0.34	1.14e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg21153622	chr11:89784906	NA	-0.4	-6.18	-0.32	1.91e-9	HDL cholesterol;
LUSC	cis	rs10992471	0.603	rs12336884	chr9:95234183	A/C	cg14631576	chr9:95140430	CENPP	-0.34	-6.17	-0.32	1.97e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs12776158	0.901	rs12414678	chr10:71214669	C/T	cg12610070	chr10:71211762	TSPAN15	-0.46	-5.9	-0.31	9.07e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9311676	0.586	rs73085867	chr3:58434791	C/T	cg13750441	chr3:58318267	PXK	0.35	6.86	0.35	3.26e-11	Systemic lupus erythematosus;
LUSC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08470875	chr2:26401718	FAM59B	0.73	9.83	0.47	3.35e-20	Gut microbiome composition (summer);
LUSC	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg12615879	chr12:58013172	SLC26A10	-0.31	-6.54	-0.34	2.33e-10	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-6.1	-0.32	2.9e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.78	-0.3	1.75e-8	Bipolar disorder;
LUSC	trans	rs1997103	0.954	rs6593235	chr7:55410986	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.38	0.37	1.26e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg00852783	chr1:26633632	UBXN11	-0.5	-5.86	-0.31	1.13e-8	Obesity-related traits;
LUSC	cis	rs12519773	1.000	rs4869412	chr5:92455655	A/G	cg18783429	chr5:92414398	NA	0.29	6.38	0.33	6.07e-10	Migraine;
LUSC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08048268	chr3:133502702	NA	-0.46	-8.9	-0.44	3.54e-17	Iron status biomarkers;
LUSC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg07274523	chr3:49395745	GPX1	0.64	9.89	0.48	2.19e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg00376283	chr12:123451042	ABCB9	0.7	10.74	0.51	2.58e-23	Platelet count;
LUSC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.58	8.28	0.41	2.93e-15	Night sleep phenotypes;
LUSC	cis	rs4478858	0.660	rs10798844	chr1:31819128	A/G	cg00250761	chr1:31883323	NA	-0.37	-8.72	-0.43	1.37e-16	Alcohol dependence;
LUSC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	0.87	14.83	0.63	1.38e-38	Tonsillectomy;
LUSC	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.29	0.33	1.01e-9	Lung cancer;
LUSC	cis	rs10779751	1.000	rs12032364	chr1:11286872	G/T	cg08854313	chr1:11322531	MTOR	0.87	14.68	0.63	5.48e-38	Body mass index;
LUSC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02018176	chr4:1364513	KIAA1530	-0.66	-11.57	-0.53	2.96e-26	Obesity-related traits;
LUSC	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.62	-0.57	4.01e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.69	0.83	1.71e-88	Chronic sinus infection;
LUSC	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23583168	chr7:148888333	NA	-0.8	-12.32	-0.56	5.37e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18876405	chr7:65276391	NA	0.49	6.62	0.34	1.41e-10	Corneal structure;
LUSC	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs422249	0.634	rs174610	chr11:61627833	A/G	cg06860612	chr11:61641270	FADS3	0.28	5.92	0.31	7.82e-9	Trans fatty acid levels;
LUSC	cis	rs12464559	0.522	rs10180065	chr2:152619007	A/G	cg01189475	chr2:152685088	ARL5A	-0.7	-7.46	-0.38	7.32e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.24	-0.41	4.05e-15	Lymphocyte counts;
LUSC	cis	rs2795502	0.554	rs1620395	chr10:43341185	G/A	cg20628663	chr10:43360327	NA	-0.41	-6.71	-0.34	8.47e-11	Blood protein levels;
LUSC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	9.52	0.46	3.54e-19	Mean platelet volume;
LUSC	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg23093090	chr10:104574429	C10orf26	-0.45	-5.65	-0.3	3.37e-8	Arsenic metabolism;
LUSC	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg05805236	chr11:65401703	PCNXL3	-0.39	-5.91	-0.31	8.27e-9	Breast cancer;
LUSC	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.86	-0.44	4.78e-17	Response to antipsychotic treatment;
LUSC	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg22980127	chr19:33182716	NUDT19	0.92	12.34	0.56	4.5e-29	Red blood cell traits;
LUSC	cis	rs672059	0.812	rs61418038	chr1:183155717	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.64	0.43	2.36e-16	Hypertriglyceridemia;
LUSC	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg04691961	chr3:161091175	C3orf57	-0.34	-5.9	-0.31	9.1e-9	Morning vs. evening chronotype;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg17683126	chr8:97247889	UQCRB	-0.45	-6.01	-0.31	4.73e-9	Neuroticism;
LUSC	cis	rs6076065	0.676	rs1419006	chr20:23336766	C/T	cg11657817	chr20:23433608	CST11	0.45	8.37	0.42	1.65e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg21775007	chr8:11205619	TDH	-0.47	-6.49	-0.33	3.09e-10	Triglycerides;
LUSC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	7.12	0.36	6.6e-12	Platelet count;
LUSC	trans	rs12310956	0.532	rs10772114	chr12:33853970	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.14	0.36	5.84e-12	Morning vs. evening chronotype;
LUSC	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg09516651	chr1:89888402	LOC400759	0.44	7.7	0.39	1.51e-13	Carotid intima media thickness;
LUSC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.87	14.22	0.61	3.21e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg13010199	chr12:38710504	ALG10B	-0.46	-7.17	-0.37	4.88e-12	Morning vs. evening chronotype;
LUSC	cis	rs829883	0.872	rs1641637	chr12:98890564	G/A	cg25150519	chr12:98850993	NA	0.64	9.84	0.47	3.15e-20	Colorectal adenoma (advanced);
LUSC	trans	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg20587970	chr11:113659929	NA	0.66	8.73	0.43	1.28e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	-0.31	-5.67	-0.3	3.05e-8	Lymphocyte counts;
LUSC	cis	rs9341808	0.538	rs615585	chr6:80986153	T/C	cg08355045	chr6:80787529	NA	-0.39	-6.71	-0.34	8.45e-11	Sitting height ratio;
LUSC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.16	-0.36	5.18e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg00509249	chr6:109615579	CCDC162	-0.33	-6.05	-0.31	3.86e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07080220	chr10:102295463	HIF1AN	0.64	8.53	0.42	5.28e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-1.06	-14.96	-0.63	4.34e-39	Vitiligo;
LUSC	cis	rs9815354	0.767	rs73077390	chr3:41860255	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.73	0.43	1.28e-16	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.88	-0.81	4.68e-78	Height;
LUSC	cis	rs7597155	0.806	rs11126244	chr2:69974873	C/A	cg02498382	chr2:70120550	SNRNP27	-0.24	-5.77	-0.3	1.83e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg17173187	chr15:85201210	NMB	-0.44	-7.91	-0.4	3.91e-14	Schizophrenia;
LUSC	trans	rs11700980	0.901	rs11701697	chr21:30127779	T/C	cg05609335	chr17:75789393	NA	0.4	6.19	0.32	1.76e-9	QRS complex (12-leadsum);
LUSC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg08683831	chr4:1404607	NA	0.37	6.3	0.33	9.43e-10	Obesity-related traits;
LUSC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg27284194	chr4:1044797	NA	0.34	5.65	0.3	3.38e-8	Obesity-related traits;
LUSC	cis	rs10128251	0.625	rs9424204	chr10:5726376	C/G	cg11519256	chr10:5708881	ASB13	0.41	6.23	0.32	1.44e-9	Childhood ear infection;
LUSC	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg11584989	chr19:19387371	SF4	0.6	7.12	0.36	6.69e-12	Bipolar disorder;
LUSC	cis	rs2742417	0.603	rs2742398	chr3:45759036	A/G	cg04837898	chr3:45731254	SACM1L	-0.44	-7.33	-0.37	1.78e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7106204	0.764	rs7933686	chr11:24246790	G/C	ch.11.24196551F	chr11:24239977	NA	0.93	7.78	0.39	9.19e-14	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg18825119	chr6:163149453	PACRG;PARK2	-0.34	-5.82	-0.3	1.37e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg19875535	chr5:140030758	IK	0.5	8.24	0.41	3.98e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04141948	chr7:1023156	CYP2W1	0.28	5.73	0.3	2.2e-8	Longevity;Endometriosis;
LUSC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.37	5.94	0.31	7.24e-9	IgG glycosylation;
LUSC	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg17127132	chr2:85788382	GGCX	0.45	7.08	0.36	8.69e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg05472934	chr7:22766657	IL6	0.42	6.04	0.31	4.17e-9	Lung cancer;
LUSC	cis	rs911119	0.818	rs12625182	chr20:23604023	G/T	cg16589663	chr20:23618590	CST3	0.57	6.82	0.35	4.18e-11	Chronic kidney disease;
LUSC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.88	-0.35	3.01e-11	Total body bone mineral density;
LUSC	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg05868516	chr6:26286170	HIST1H4H	0.36	5.99	0.31	5.35e-9	Educational attainment;
LUSC	cis	rs7584330	0.504	rs11891426	chr2:238434702	T/G	cg16989719	chr2:238392110	NA	-0.43	-6.44	-0.33	4.08e-10	Prostate cancer;
LUSC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.7	0.3	2.59e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs920590	0.600	rs4921678	chr8:19663449	A/G	cg03894339	chr8:19674705	INTS10	0.41	5.87	0.31	1.05e-8	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg13010199	chr12:38710504	ALG10B	0.53	7.34	0.37	1.65e-12	Resting heart rate;
LUSC	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.46	-0.46	5.87e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg05623727	chr3:50126028	RBM5	-0.34	-6.14	-0.32	2.31e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg17031739	chr1:67600172	NA	0.45	6.91	0.35	2.43e-11	Psoriasis;
LUSC	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.94	0.66	5.93e-43	Bladder cancer;
LUSC	cis	rs8114671	0.933	rs6142327	chr20:33793147	T/A	cg07148914	chr20:33460835	GGT7	-0.43	-6.41	-0.33	4.82e-10	Height;
LUSC	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg13319975	chr6:146136371	FBXO30	0.5	7.48	0.38	6.55e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg12483005	chr1:23474871	LUZP1	0.45	6.92	0.35	2.28e-11	Height;
LUSC	cis	rs2952156	0.959	rs11653998	chr17:37877447	C/G	cg00129232	chr17:37814104	STARD3	-0.48	-7.05	-0.36	1.05e-11	Asthma;
LUSC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	11.07	0.52	1.75e-24	Bone mineral density;
LUSC	cis	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.39	-0.33	5.57e-10	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10921517	chr11:1520881	HCCA2	-0.45	-6.5	-0.34	2.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-9.66	-0.47	1.21e-19	Morning vs. evening chronotype;
LUSC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-9.37	-0.46	1.11e-18	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11764359	chr7:65958608	NA	0.54	7.7	0.39	1.58e-13	Aortic root size;
LUSC	trans	rs35374984	0.920	rs16930800	chr10:30234268	A/C	cg14721108	chr8:142401867	NA	-0.65	-5.97	-0.31	6.06e-9	Emphysema distribution in smoking;
LUSC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.15	-0.32	2.26e-9	Neutrophil percentage of white cells;
LUSC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg13628971	chr7:2884303	GNA12	0.46	6.78	0.35	5.53e-11	Height;
LUSC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg11366901	chr6:160182831	ACAT2	0.92	12.15	0.55	2.31e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7809950	0.530	rs34021916	chr7:106817901	A/G	cg23024343	chr7:107201750	COG5	-0.5	-7.2	-0.37	4e-12	Coronary artery disease;
LUSC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg13699009	chr12:122356056	WDR66	0.48	7.5	0.38	5.99e-13	Mean corpuscular volume;
LUSC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg09021430	chr5:549028	NA	-0.55	-7.25	-0.37	2.95e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg20991723	chr1:152506922	NA	0.51	9.51	0.46	3.91e-19	Hair morphology;
LUSC	cis	rs1160297	0.585	rs12713228	chr2:53090032	T/C	cg07782112	chr2:53107842	NA	0.41	6.6	0.34	1.64e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg02023728	chr11:77925099	USP35	0.41	6.22	0.32	1.51e-9	Testicular germ cell tumor;
LUSC	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg01884057	chr2:25150051	NA	0.46	10.53	0.5	1.38e-22	Body mass index in non-asthmatics;
LUSC	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg11984989	chr7:158649758	WDR60	-0.99	-18.18	-0.71	7.89e-52	Height;
LUSC	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg00945038	chr17:61921165	SMARCD2	0.4	6.14	0.32	2.34e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6545883	0.894	rs2694634	chr2:61551435	T/C	cg15711740	chr2:61764176	XPO1	0.43	6.67	0.34	1.09e-10	Tuberculosis;
LUSC	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.67	0.34	1.03e-10	Corneal astigmatism;
LUSC	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg08601574	chr20:25228251	PYGB	0.4	5.95	0.31	6.73e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.73	0.39	1.26e-13	Bipolar disorder;
LUSC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg02951883	chr7:2050386	MAD1L1	-0.41	-7.15	-0.36	5.65e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs813218	0.585	rs9860514	chr3:99917359	G/T	cg27384355	chr3:99844353	C3orf26	-0.26	-5.64	-0.3	3.56e-8	Orofacial clefts;
LUSC	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	11.11	0.52	1.29e-24	Lung cancer in ever smokers;
LUSC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg13683864	chr3:40499215	RPL14	-0.93	-15.21	-0.64	4.75e-40	Renal cell carcinoma;
LUSC	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg15133208	chr4:90757351	SNCA	-0.53	-8.27	-0.41	3.2e-15	Neuroticism;
LUSC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg14668632	chr7:2872130	GNA12	-0.45	-6.57	-0.34	1.96e-10	Height;
LUSC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg08499158	chr17:42289980	UBTF	0.52	8.65	0.43	2.16e-16	Total body bone mineral density;
LUSC	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.81	-12.9	-0.58	3.53e-31	Schizophrenia;
LUSC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19346786	chr7:2764209	NA	-0.44	-7.56	-0.38	4.01e-13	Height;
LUSC	trans	rs1015291	0.708	rs1466687	chr12:19996058	A/G	cg01501474	chr7:55323552	NA	-0.45	-5.97	-0.31	6.09e-9	Diastolic blood pressure;
LUSC	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg02996355	chr14:81879375	NA	-0.78	-11.52	-0.53	4.5e-26	Prudent dietary pattern;
LUSC	cis	rs7582720	1.000	rs72936852	chr2:203775475	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.38	0.42	1.49e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg03886242	chr7:26192032	NFE2L3	-0.42	-6.69	-0.34	9.59e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs34421088	0.576	rs2572436	chr8:11099209	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.13	-0.32	2.49e-9	Neuroticism;
LUSC	cis	rs3105593	0.605	rs3131562	chr15:50772479	C/T	cg08437265	chr15:50716283	USP8	0.41	5.9	0.31	9.02e-9	QT interval;
LUSC	cis	rs7119	0.604	rs2271396	chr15:77907535	C/G	cg27398640	chr15:77910606	LINGO1	0.38	8.91	0.44	3.39e-17	Type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21273098	chr6:109762418	SMPD2;PPIL6	-0.42	-6.07	-0.32	3.38e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7267979	0.844	rs6083845	chr20:25388090	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.78	-16.35	-0.67	1.41e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2227930	0.506	rs13080394	chr3:142045889	C/T	cg16271453	chr3:142027066	XRN1	-0.55	-9.95	-0.48	1.35e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	trans	rs208520	0.955	rs208532	chr6:66961280	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-12.34	-0.56	4.42e-29	Exhaled nitric oxide output;
LUSC	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg17691542	chr6:26056736	HIST1H1C	0.71	8.56	0.42	4.1e-16	Iron status biomarkers;
LUSC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18854424	chr1:2615690	NA	-0.49	-9.97	-0.48	1.18e-20	Ulcerative colitis;
LUSC	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg10840412	chr1:235813424	GNG4	-0.46	-6.15	-0.32	2.2e-9	Bipolar disorder;
LUSC	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg20744362	chr22:50050164	C22orf34	0.39	7.31	0.37	1.98e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.79	-0.35	5.14e-11	Response to antipsychotic treatment;
LUSC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	1.02	17.3	0.69	2.41e-48	Coronary artery disease;
LUSC	cis	rs36051895	0.559	rs7850228	chr9:5210671	C/G	cg02405213	chr9:5042618	JAK2	0.57	8.48	0.42	7.14e-16	Pediatric autoimmune diseases;
LUSC	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg03563238	chr19:33554763	RHPN2	-0.4	-6.23	-0.32	1.43e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.55	0.46	2.95e-19	Prudent dietary pattern;
LUSC	cis	rs6500395	0.708	rs28449353	chr16:48555134	T/A	cg04672837	chr16:48644449	N4BP1	0.38	5.75	0.3	2.04e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg04369109	chr6:150039330	LATS1	-0.52	-7.5	-0.38	5.8e-13	Lung cancer;
LUSC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-7.22	-0.37	3.43e-12	Aortic root size;
LUSC	cis	rs6741892	0.536	rs7590835	chr2:38893950	A/G	cg23643435	chr2:38893251	GALM	0.54	6.07	0.32	3.41e-9	5-HTT brain serotonin transporter levels;
LUSC	cis	rs4654899	0.965	rs10753513	chr1:21492168	T/C	cg01072550	chr1:21505969	NA	0.53	8.11	0.41	9.91e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg08847533	chr14:75593920	NEK9	0.7	11.32	0.53	2.38e-25	Height;
LUSC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg27398817	chr8:82754497	SNX16	-0.64	-8.11	-0.41	9.86e-15	Diastolic blood pressure;
LUSC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg19774624	chr17:42201019	HDAC5	0.53	8.37	0.42	1.59e-15	Bone mineral density (hip);Bone mineral density;
LUSC	cis	rs472402	0.623	rs8192130	chr5:6636450	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.4	-5.98	-0.31	5.74e-9	Response to amphetamines;
LUSC	cis	rs11958404	0.860	rs72818111	chr5:157438361	A/G	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.83	-11.37	-0.53	1.59e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.72	0.54	8.55e-27	Prudent dietary pattern;
LUSC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.0	0.36	1.45e-11	Tonsillectomy;
LUSC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg11062466	chr8:58055876	NA	0.72	8.66	0.43	2.02e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs427941	0.659	rs2529373	chr7:101739618	A/G	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs4293296	0.525	rs17726476	chr14:54813815	A/C	cg02257953	chr14:54816093	NA	-0.46	-6.76	-0.35	6.23e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.65	-0.47	1.34e-19	Subjective well-being;
LUSC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg05802129	chr4:122689817	NA	-0.37	-6.69	-0.34	9.46e-11	Type 2 diabetes;
LUSC	cis	rs11031096	0.678	rs4606468	chr11:4183643	G/T	cg18678763	chr11:4115507	RRM1	-0.43	-6.09	-0.32	3.19e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18538332	chr22:24372958	LOC391322	0.43	7.72	0.39	1.4e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.47	-6.49	-0.33	3.08e-10	Reticulocyte count;
LUSC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg06096015	chr1:231504339	EGLN1	0.58	10.37	0.49	5e-22	Hemoglobin concentration;
LUSC	cis	rs887829	0.570	rs12623271	chr2:234599941	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.3	-0.33	9.47e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg09877947	chr5:131593287	PDLIM4	0.37	5.89	0.31	9.66e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg24675658	chr1:53192096	ZYG11B	0.59	8.8	0.43	7.24e-17	Monocyte count;
LUSC	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg08000102	chr2:233561755	GIGYF2	0.76	11.84	0.54	3.11e-27	Coronary artery disease;
LUSC	cis	rs62432291	0.681	rs419836	chr6:159659481	C/T	cg14500486	chr6:159655392	FNDC1	-0.54	-6.06	-0.31	3.76e-9	Joint mobility (Beighton score);
LUSC	trans	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07923666	chr12:49932857	KCNH3	-0.53	-6.43	-0.33	4.54e-10	Resting heart rate;
LUSC	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg10434728	chr15:90938212	IQGAP1	0.44	9.0	0.44	1.69e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg17143192	chr8:8559678	CLDN23	0.66	9.55	0.46	2.97e-19	Obesity-related traits;
LUSC	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg13390004	chr1:15929781	NA	0.41	6.94	0.36	2.03e-11	Systolic blood pressure;
LUSC	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg25427524	chr10:38739819	LOC399744	0.39	6.41	0.33	4.91e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg03354898	chr7:1950403	MAD1L1	0.43	8.74	0.43	1.13e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg15242686	chr22:24348715	GSTTP1	-0.44	-6.62	-0.34	1.44e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-8.65	-0.43	2.26e-16	Body mass index;
LUSC	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg05343316	chr1:45956843	TESK2	0.65	9.03	0.44	1.41e-17	Platelet count;
LUSC	cis	rs13006833	0.668	rs291461	chr2:191181644	T/G	cg21644426	chr2:191273491	MFSD6	0.43	6.16	0.32	2.13e-9	Urinary metabolites;
LUSC	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg12573674	chr2:1569213	NA	0.55	5.91	0.31	8.23e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.38	0.33	6.02e-10	Menopause (age at onset);
LUSC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.16	0.32	2.11e-9	Menopause (age at onset);
LUSC	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg00376283	chr12:123451042	ABCB9	-0.66	-7.62	-0.39	2.56e-13	Neutrophil percentage of white cells;
LUSC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-11.2	-0.52	5.98e-25	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21211418	chr9:34957783	KIAA1045	0.49	7.54	0.38	4.42e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7589342	1.000	rs7589342	chr2:106433478	C/T	cg14210321	chr2:106509881	NCK2	-0.54	-8.12	-0.41	9.28e-15	Addiction;
LUSC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg12963246	chr6:28129442	ZNF389	0.39	5.96	0.31	6.38e-9	Cardiac Troponin-T levels;
LUSC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.47e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg06640241	chr16:89574553	SPG7	0.88	15.84	0.65	1.5e-42	Multiple myeloma (IgH translocation);
LUSC	cis	rs6546550	0.901	rs12613947	chr2:70161342	A/G	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.22e-12	Prevalent atrial fibrillation;
LUSC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.71	-9.26	-0.45	2.63e-18	Refractive error;
LUSC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg06238570	chr21:40685208	BRWD1	0.53	8.1	0.41	1.07e-14	Cognitive function;
LUSC	cis	rs977987	0.800	rs1011121	chr16:75325933	A/G	cg03315344	chr16:75512273	CHST6	0.47	8.75	0.43	1.06e-16	Dupuytren's disease;
LUSC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07157834	chr1:205819609	PM20D1	0.8	13.7	0.6	3.4e-34	Menarche (age at onset);
LUSC	cis	rs981844	0.712	rs55656103	chr4:154757478	T/C	cg14289246	chr4:154710475	SFRP2	0.46	6.26	0.32	1.17e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs12541635	0.677	rs1496181	chr8:107027141	C/T	cg10147462	chr8:107024639	NA	0.67	14.1	0.61	9.6e-36	Age of smoking initiation;
LUSC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.31	0.37	1.98e-12	Motion sickness;
LUSC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg18301423	chr5:131593218	PDLIM4	0.35	5.75	0.3	2.06e-8	Blood metabolite levels;
LUSC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13770153	chr20:60521292	NA	-0.62	-8.34	-0.42	1.95e-15	Body mass index;
LUSC	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg11693508	chr17:37793320	STARD3	0.65	7.95	0.4	2.93e-14	Bipolar disorder;
LUSC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg00814883	chr7:100076585	TSC22D4	-0.66	-8.09	-0.4	1.13e-14	Platelet count;
LUSC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg13665263	chr7:135662016	MTPN;LUZP6	0.74	7.38	0.37	1.29e-12	Myocardial infarction;
LUSC	cis	rs1160297	0.576	rs74181216	chr2:53093194	G/C	cg07782112	chr2:53107842	NA	0.44	7.15	0.36	5.39e-12	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18760251	chr3:169684683	LOC100128164;SEC62	-0.4	-6.09	-0.32	3.03e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04122790	chr1:229762148	URB2;TAF5L	0.36	6.05	0.31	3.94e-9	Triglycerides;
LUSC	cis	rs4285028	0.699	rs6771068	chr3:121478745	A/T	cg11130432	chr3:121712080	ILDR1	0.59	8.5	0.42	6.59e-16	Multiple sclerosis;
LUSC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.52	-0.34	2.59e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg05373962	chr22:49881684	NA	-0.41	-8.61	-0.43	2.87e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.81	12.29	0.56	6.62e-29	Bladder cancer;
LUSC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg24399712	chr22:39784796	NA	-0.59	-9.87	-0.48	2.54e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg20476274	chr7:133979776	SLC35B4	0.83	15.15	0.64	7.59e-40	Mean platelet volume;
LUSC	cis	rs864537	0.646	rs1723016	chr1:167433056	T/C	cg22356347	chr1:167427500	CD247	-0.34	-8.19	-0.41	5.49e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs72772090	0.539	rs10515247	chr5:96111726	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.97	-0.36	1.67e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.4	-0.38	1.1e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs72960926	0.590	rs72959619	chr6:74995975	A/G	cg03266952	chr6:74778945	NA	-0.8	-6.78	-0.35	5.51e-11	Metabolite levels (MHPG);
LUSC	cis	rs7614311	0.731	rs73130534	chr3:63859813	A/G	cg22134162	chr3:63841271	THOC7	-0.5	-6.06	-0.31	3.72e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	6.86	0.35	3.42e-11	Mean platelet volume;
LUSC	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	7.17	0.37	4.74e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg08501292	chr6:25962987	TRIM38	0.66	5.69	0.3	2.78e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg26441486	chr22:50317300	CRELD2	0.46	6.79	0.35	5.18e-11	Schizophrenia;
LUSC	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg26395211	chr5:140044315	WDR55	-0.38	-5.74	-0.3	2.14e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg07817648	chr10:79422355	NA	-0.49	-6.68	-0.34	1.02e-10	Bone mineral density;
LUSC	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg21211680	chr2:198530	NA	0.6	7.53	0.38	4.62e-13	Blood protein levels;
LUSC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg07701084	chr6:150067640	NUP43	0.49	7.27	0.37	2.56e-12	Lung cancer;
LUSC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg17764715	chr19:33622953	WDR88	0.5	7.5	0.38	5.98e-13	Colorectal cancer;
LUSC	cis	rs3916	1.000	rs2014355	chr12:121175524	A/G	cg02419362	chr12:121203948	SPPL3	0.36	5.79	0.3	1.64e-8	Urinary metabolites (H-NMR features);
LUSC	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg20703242	chr1:230279135	GALNT2	0.57	8.88	0.44	4.15e-17	Coronary artery disease;
LUSC	cis	rs701145	0.585	rs447429	chr3:153909946	T/C	cg17054900	chr3:154042577	DHX36	0.68	6.76	0.35	5.99e-11	Coronary artery disease;
LUSC	cis	rs2274273	0.967	rs1009978	chr14:55603061	C/G	cg04306507	chr14:55594613	LGALS3	0.57	13.32	0.59	9.39e-33	Protein biomarker;
LUSC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.63	8.75	0.43	1.07e-16	Menarche (age at onset);
LUSC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg11645453	chr3:52864694	ITIH4	0.34	7.88	0.4	4.65e-14	Bipolar disorder;
LUSC	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg25801113	chr15:45476975	SHF	0.35	7.25	0.37	2.95e-12	Uric acid levels;
LUSC	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg20701182	chr2:24300061	SF3B14	0.75	7.62	0.38	2.73e-13	Lymphocyte counts;
LUSC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.61	-0.57	4.37e-30	Chronic sinus infection;
LUSC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg27284194	chr4:1044797	NA	0.34	5.74	0.3	2.17e-8	Obesity-related traits;
LUSC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg27170947	chr2:26402098	FAM59B	-0.72	-11.04	-0.52	2.26e-24	Gut microbiome composition (summer);
LUSC	cis	rs12681287	0.571	rs10097450	chr8:87358677	G/A	cg00550725	chr8:87521180	FAM82B	-0.42	-5.66	-0.3	3.3e-8	Caudate activity during reward;
LUSC	cis	rs9837602	0.938	rs10511177	chr3:99724873	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	6.46	0.33	3.61e-10	Breast cancer;
LUSC	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg27129171	chr3:47204927	SETD2	0.69	11.58	0.54	2.66e-26	Colorectal cancer;
LUSC	cis	rs1784581	0.651	rs3016568	chr6:162388158	G/A	cg17173639	chr6:162384350	PARK2	-0.68	-12.24	-0.56	1.07e-28	Itch intensity from mosquito bite;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00903010	chr14:23236465	OXA1L	-0.43	-6.22	-0.32	1.51e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.28e-9	Bladder cancer;
LUSC	cis	rs2282300	0.637	rs13642	chr11:30432220	A/T	cg25418670	chr11:30344373	C11orf46	-0.4	-6.24	-0.32	1.34e-9	Morning vs. evening chronotype;
LUSC	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.86	-0.44	4.94e-17	Metabolite levels;
LUSC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	7.03	0.36	1.2e-11	Platelet count;
LUSC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg03804128	chr16:635623	NA	0.29	5.77	0.3	1.8e-8	Height;
LUSC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg16325326	chr1:53192061	ZYG11B	0.7	11.4	0.53	1.19e-25	Monocyte count;
LUSC	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg24011408	chr12:48396354	COL2A1	0.56	7.48	0.38	6.66e-13	Lung cancer;
LUSC	cis	rs62408225	1.000	rs11752685	chr6:90966415	A/C	cg06866423	chr6:90926672	BACH2	0.4	5.82	0.3	1.37e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg18196295	chr10:418757	DIP2C	0.48	7.98	0.4	2.3e-14	Psychosis in Alzheimer's disease;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15089864	chr11:75946986	NA	-0.47	-6.15	-0.32	2.24e-9	Hepatitis;
LUSC	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-11.83	-0.54	3.35e-27	Colorectal cancer;
LUSC	trans	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg10756647	chr7:56101905	PSPH	0.85	8.22	0.41	4.44e-15	Diabetic kidney disease;
LUSC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	0.93	15.69	0.65	5.75e-42	Menopause (age at onset);
LUSC	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg18904891	chr8:8559673	CLDN23	0.38	5.69	0.3	2.75e-8	Joint mobility (Beighton score);
LUSC	cis	rs10992471	0.651	rs13296623	chr9:95301627	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.37	-6.56	-0.34	2.01e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs12701220	0.762	rs7777565	chr7:1003011	C/A	cg04102894	chr7:1000210	NA	-0.27	-6.37	-0.33	6.4e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg01849466	chr14:104193079	ZFYVE21	0.58	9.04	0.44	1.29e-17	Schizophrenia;
LUSC	cis	rs6674970	0.966	rs10788800	chr1:151104950	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.44	-5.91	-0.31	8.34e-9	Childhood ear infection;
LUSC	cis	rs6736093	0.862	rs11684321	chr2:112775750	C/T	cg12686935	chr2:112915763	FBLN7	-0.37	-6.03	-0.31	4.26e-9	Coronary artery disease;
LUSC	cis	rs7804356	1.000	rs115447617	chr7:26857751	T/C	cg03456212	chr7:26904342	SKAP2	-0.54	-6.31	-0.33	8.7e-10	Type 1 diabetes;
LUSC	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg22676075	chr6:135203613	NA	0.59	9.48	0.46	5e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg05084668	chr3:125655381	ALG1L	-0.9	-12.82	-0.57	7.39e-31	Blood pressure (smoking interaction);
LUSC	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg13939156	chr17:80058883	NA	0.36	7.09	0.36	7.98e-12	Life satisfaction;
LUSC	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg08355456	chr11:67383691	NA	-0.38	-6.42	-0.33	4.63e-10	Mean corpuscular volume;
LUSC	cis	rs9650315	0.929	rs7842347	chr8:57172272	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	6.82	0.35	4.17e-11	Height;
LUSC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg04317338	chr11:64019027	PLCB3	0.54	6.4	0.33	5.39e-10	Mean platelet volume;
LUSC	trans	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg04995722	chr7:26192034	NFE2L3	0.37	6.17	0.32	2.01e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.67	0.43	1.91e-16	Prudent dietary pattern;
LUSC	cis	rs7586879	0.639	rs6722022	chr2:25098859	A/G	cg04586622	chr2:25135609	ADCY3	0.39	7.95	0.4	2.99e-14	Body mass index;
LUSC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00166722	chr3:10149974	C3orf24	0.59	7.9	0.4	4.01e-14	Alzheimer's disease;
LUSC	cis	rs7084921	0.608	rs1853700	chr10:101862694	T/C	cg11888571	chr10:102027403	CWF19L1	-0.43	-5.89	-0.31	9.33e-9	Bone mineral density;
LUSC	trans	rs7939886	0.920	rs76934983	chr11:55993334	A/C	cg15704280	chr7:45808275	SEPT13	0.9	6.77	0.35	5.92e-11	Myopia (pathological);
LUSC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.9	0.31	9.02e-9	Menopause (age at onset);
LUSC	cis	rs6484504	0.576	rs208071	chr11:31144996	C/T	cg06552810	chr11:31128660	NA	-0.41	-7.37	-0.37	1.33e-12	Red blood cell count;
LUSC	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg24579218	chr15:68104479	NA	-0.39	-6.78	-0.35	5.61e-11	Restless legs syndrome;
LUSC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06481639	chr22:41940642	POLR3H	-0.51	-6.1	-0.32	2.89e-9	Vitiligo;
LUSC	cis	rs4845570	1.000	rs7416415	chr1:151757798	C/T	cg07092448	chr1:151763213	TDRKH	1.27	14.77	0.63	2.32e-38	Coronary artery disease;
LUSC	cis	rs9341808	0.718	rs11962614	chr6:80823306	A/T	cg08355045	chr6:80787529	NA	0.56	9.85	0.47	2.85e-20	Sitting height ratio;
LUSC	cis	rs4285028	0.898	rs12491991	chr3:121706021	A/C	cg11130432	chr3:121712080	ILDR1	0.62	9.96	0.48	1.22e-20	Multiple sclerosis;
LUSC	trans	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg20935933	chr6:143382018	AIG1	0.51	7.47	0.38	6.96e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg00339695	chr16:24857497	SLC5A11	0.55	7.52	0.38	5.09e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.82	-13.55	-0.6	1.28e-33	Morning vs. evening chronotype;
LUSC	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08564027	chr20:61660810	NA	0.92	17.15	0.68	1.02e-47	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.66	9.98	0.48	1.09e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	trans	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg24644049	chr4:85504048	CDS1	0.88	7.56	0.38	3.9e-13	Skin colour saturation;
LUSC	cis	rs55665837	1.000	rs10832271	chr11:14466919	C/G	cg19336497	chr11:14380999	RRAS2	-0.37	-7.54	-0.38	4.47e-13	Vitamin D levels;
LUSC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	1.9e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.36	5.78	0.3	1.71e-8	Menopause (age at onset);
LUSC	cis	rs7809950	1.000	rs2237677	chr7:107202502	A/C	cg23024343	chr7:107201750	COG5	-0.54	-8.45	-0.42	9.21e-16	Coronary artery disease;
LUSC	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg27446573	chr6:127587934	RNF146	0.62	9.8	0.47	4.28e-20	Breast cancer;
LUSC	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-0.66	-9.53	-0.46	3.35e-19	Platelet distribution width;
LUSC	cis	rs10992471	0.603	rs9299405	chr9:95284873	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.9	-0.35	2.68e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg06287003	chr12:125626642	AACS	-0.38	-6.16	-0.32	2.12e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg03146154	chr1:46216737	IPP	-0.52	-7.54	-0.38	4.62e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1790761	0.505	rs7106423	chr11:67314144	A/G	cg24690094	chr11:67383802	NA	-0.3	-5.71	-0.3	2.5e-8	Mean corpuscular volume;
LUSC	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg06784218	chr1:46089804	CCDC17	0.35	6.07	0.32	3.56e-9	Platelet count;
LUSC	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg11584989	chr19:19387371	SF4	0.6	6.86	0.35	3.36e-11	Bipolar disorder;
LUSC	cis	rs17685	0.961	rs41301394	chr7:75612803	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.42	-6.28	-0.33	1.03e-9	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	6.87	0.35	3.1e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	12.93	0.58	2.68e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg16482183	chr6:26056742	HIST1H1C	0.82	10.22	0.49	1.59e-21	Iron status biomarkers;
LUSC	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg16724585	chr3:197361211	NA	-0.62	-8.77	-0.43	9.17e-17	Pancreatic cancer;
LUSC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg17971929	chr21:40555470	PSMG1	-0.49	-7.09	-0.36	7.86e-12	Menarche (age at onset);
LUSC	cis	rs35000415	0.938	rs12536266	chr7:128611035	G/A	cg19972273	chr7:128594194	NA	0.69	6.97	0.36	1.69e-11	Systemic lupus erythematosus;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg06145435	chr7:1022769	CYP2W1	0.29	5.84	0.3	1.26e-8	Longevity;Endometriosis;
LUSC	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg25124228	chr12:125621409	AACS	-0.41	-5.68	-0.3	2.97e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07080220	chr10:102295463	HIF1AN	0.67	8.62	0.43	2.8e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	13.77	0.6	1.77e-34	Platelet count;
LUSC	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg24690094	chr11:67383802	NA	0.42	8.3	0.41	2.7e-15	Mean corpuscular volume;
LUSC	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg10523679	chr1:76189770	ACADM	-0.52	-7.59	-0.38	3.17e-13	Daytime sleep phenotypes;
LUSC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg22800045	chr5:56110881	MAP3K1	0.62	8.77	0.43	9.13e-17	Initial pursuit acceleration;
LUSC	cis	rs10392	0.543	rs57569873	chr20:37558293	T/C	cg27552599	chr20:37590471	DHX35	0.45	7.29	0.37	2.32e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs34638657	0.687	rs2303265	chr16:82203705	A/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.58	-0.34	1.78e-10	Lung adenocarcinoma;
LUSC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg22800045	chr5:56110881	MAP3K1	0.71	7.37	0.37	1.35e-12	Type 2 diabetes;
LUSC	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg04865166	chr7:105162814	PUS7	0.52	5.7	0.3	2.63e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg20135002	chr11:47629003	NA	-0.45	-7.41	-0.38	1.03e-12	Subjective well-being;
LUSC	cis	rs2658782	0.826	rs1975820	chr11:93081815	G/A	cg15737290	chr11:93063684	CCDC67	0.69	8.6	0.43	3.12e-16	Pulmonary function decline;
LUSC	cis	rs7113850	0.541	rs7116120	chr11:24235050	A/G	ch.11.24196551F	chr11:24239977	NA	0.97	9.03	0.44	1.37e-17	Bone fracture in osteoporosis;
LUSC	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.86	0.44	4.88e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11209185	0.509	rs9436357	chr1:68452488	C/T	cg22082780	chr1:68452167	NA	0.48	8.74	0.43	1.19e-16	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs2425143	1.000	rs7273815	chr20:34232415	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.22	-0.32	1.52e-9	Blood protein levels;
LUSC	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg24675056	chr1:15929824	NA	0.42	7.11	0.36	6.91e-12	Systolic blood pressure;
LUSC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.78	-0.3	1.73e-8	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg13395646	chr4:1353034	KIAA1530	-0.65	-10.2	-0.49	1.85e-21	Obesity-related traits;
LUSC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg26695010	chr11:65641043	EFEMP2	0.45	7.08	0.36	8.47e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg21251018	chr6:28226885	NKAPL	0.33	6.37	0.33	6.26e-10	Cardiac Troponin-T levels;
LUSC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg08847533	chr14:75593920	NEK9	-0.66	-10.85	-0.51	1.06e-23	Coronary artery disease;
LUSC	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg02376097	chr19:46275166	DMPK	0.39	6.79	0.35	5.23e-11	Coronary artery disease;
LUSC	cis	rs8112211	0.598	rs4802351	chr19:38848796	A/G	cg14299480	chr19:38876666	GGN	-0.44	-6.57	-0.34	1.9e-10	Blood protein levels;
LUSC	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg13256891	chr4:100009986	ADH5	-0.44	-6.1	-0.32	2.9e-9	Alcohol dependence;
LUSC	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg04352962	chr1:209979756	IRF6	0.58	6.38	0.33	5.91e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs7577696	0.568	rs7562653	chr2:32478629	T/C	cg02381751	chr2:32503542	YIPF4	0.53	7.1	0.36	7.38e-12	Inflammatory biomarkers;
LUSC	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	8.89	0.44	3.97e-17	Response to antipsychotic treatment;
LUSC	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg16989719	chr2:238392110	NA	-0.38	-6.66	-0.34	1.13e-10	Prostate cancer;
LUSC	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg26384229	chr12:38710491	ALG10B	0.8	13.73	0.6	2.62e-34	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg27170947	chr2:26402098	FAM59B	0.62	8.23	0.41	4.38e-15	Gut microbiome composition (summer);
LUSC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.73	-10.98	-0.52	3.62e-24	Menarche (age at onset);
LUSC	trans	rs80346118	0.925	rs17445063	chr20:47463731	G/T	cg16950247	chr11:62911616	SLC22A24	0.49	6.02	0.31	4.52e-9	Diastolic blood pressure;
LUSC	cis	rs2455601	0.786	rs2568068	chr11:8977830	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.44	-7.79	-0.39	8.42e-14	Schizophrenia;
LUSC	cis	rs240764	0.554	rs723742	chr6:101237174	T/A	cg09795085	chr6:101329169	ASCC3	0.44	6.27	0.32	1.13e-9	Neuroticism;
LUSC	cis	rs4144743	1.000	rs61312893	chr17:45325023	C/G	cg18085866	chr17:45331354	ITGB3	-0.74	-7.89	-0.4	4.35e-14	Body mass index;
LUSC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	0.98	13.36	0.59	6.59e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg19628046	chr18:33552617	C18orf21	0.51	6.4	0.33	5.27e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg26043149	chr18:55253948	FECH	0.55	8.31	0.41	2.41e-15	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg21951975	chr1:209979733	IRF6	0.59	7.62	0.38	2.7e-13	Cleft lip with or without cleft palate;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg16103275	chr6:290800	DUSP22	0.42	7.15	0.36	5.68e-12	Menopause (age at onset);
LUSC	cis	rs790123	0.933	rs1092556	chr3:122387354	T/G	cg17380795	chr3:122379686	NA	0.39	6.43	0.33	4.33e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs10875746	0.903	rs886588	chr12:48477422	A/G	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.47	-0.33	3.42e-10	Resting heart rate;
LUSC	cis	rs2607426	0.901	rs2607416	chr19:41260831	C/T	cg05508168	chr19:41255947	C19orf54;SNRPA	0.62	5.67	0.3	3.08e-8	Blood protein levels;
LUSC	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	7.08	0.36	8.61e-12	Resting heart rate;
LUSC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg11502198	chr6:26597334	ABT1	-0.63	-9.55	-0.46	2.87e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg11062466	chr8:58055876	NA	0.47	5.72	0.3	2.39e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg01516881	chr6:292596	DUSP22	-0.52	-7.69	-0.39	1.69e-13	Menopause (age at onset);
LUSC	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg06360820	chr2:242988706	NA	-0.88	-9.7	-0.47	9.02e-20	Obesity-related traits;
LUSC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	9.52	0.46	3.49e-19	Total body bone mineral density;
LUSC	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg14664628	chr15:75095509	CSK	0.44	6.28	0.33	1.04e-9	Systemic lupus erythematosus;
LUSC	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.53	-10.47	-0.5	2.33e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	0.92	15.33	0.64	1.52e-40	Breast cancer;
LUSC	cis	rs12208915	0.848	rs9350786	chr6:79517306	G/T	cg05283184	chr6:79620031	NA	0.42	5.68	0.3	2.92e-8	Left atrial antero-posterior diameter;
LUSC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg17372223	chr3:52568218	NT5DC2	0.38	6.11	0.32	2.73e-9	Electroencephalogram traits;
LUSC	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg23601095	chr6:26197514	HIST1H3D	0.73	7.46	0.38	7.42e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	8.94	0.44	2.77e-17	Height;
LUSC	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg05738196	chr6:26577821	NA	0.83	16.17	0.66	7.5e-44	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-0.95	-13.74	-0.6	2.35e-34	Vitiligo;
LUSC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.98	0.55	9.29e-28	Chronic sinus infection;
LUSC	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg03676636	chr4:99064102	C4orf37	0.36	7.71	0.39	1.48e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	12.71	0.57	1.77e-30	Cognitive test performance;
LUSC	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg04362960	chr10:104952993	NT5C2	0.59	9.43	0.46	7.3e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg04995722	chr7:26192034	NFE2L3	0.37	6.15	0.32	2.21e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg25036284	chr2:26402008	FAM59B	-0.69	-9.57	-0.46	2.39e-19	Gut microbiome composition (summer);
LUSC	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg02187348	chr16:89574699	SPG7	0.48	6.52	0.34	2.63e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	5.8	0.3	1.56e-8	Personality dimensions;
LUSC	trans	rs9944715	1.000	rs4574015	chr18:43802126	T/C	cg01718231	chr17:29326311	RNF135	-0.53	-7.43	-0.38	9.28e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg13390004	chr1:15929781	NA	0.43	7.27	0.37	2.61e-12	Systolic blood pressure;
LUSC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-14.42	-0.62	5.61e-37	Dental caries;
LUSC	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.83	0.68	1.9e-46	Exhaled nitric oxide output;
LUSC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg23711669	chr6:146136114	FBXO30	-0.72	-10.58	-0.5	9.62e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg20368463	chr18:77673604	PQLC1	-0.68	-7.43	-0.38	9.24e-13	Opioid sensitivity;
LUSC	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg14458575	chr2:238380390	NA	0.59	6.88	0.35	3.06e-11	Prostate cancer;
LUSC	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.67	-0.39	1.9e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4363385	0.818	rs4845335	chr1:152993955	G/A	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.72	-0.39	1.37e-13	Inflammatory skin disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17470347	chr1:93646398	CCDC18;TMED5	-0.38	-6.04	-0.31	4.11e-9	Electrocardiographic conduction measures;
LUSC	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg22906224	chr7:99728672	NA	-0.47	-6.6	-0.34	1.6e-10	Coronary artery disease;
LUSC	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg05985134	chr18:33552581	C18orf21	0.5	6.78	0.35	5.47e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg25703541	chr22:24373054	LOC391322	0.88	14.41	0.62	6.16e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.77	-12.29	-0.56	6.6e-29	Chronic sinus infection;
LUSC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg06877462	chr1:205807181	PM20D1	0.46	8.22	0.41	4.46e-15	Menarche (age at onset);
LUSC	cis	rs7216064	0.817	rs28609796	chr17:65855104	T/A	cg12091567	chr17:66097778	LOC651250	-0.74	-9.25	-0.45	2.79e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7577696	0.785	rs3851310	chr2:32367986	G/T	cg02381751	chr2:32503542	YIPF4	-0.43	-5.98	-0.31	5.68e-9	Inflammatory biomarkers;
LUSC	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg19875535	chr5:140030758	IK	-0.53	-8.76	-0.43	1.02e-16	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.59	0.78	3.14e-69	Prudent dietary pattern;
LUSC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.91	0.31	8.46e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.53	6.83	0.35	3.97e-11	Total cholesterol levels;
LUSC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-8.82	-0.43	6.32e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03517284	chr6:25882590	NA	-0.42	-7.12	-0.36	6.82e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7804356	1.000	rs1982995	chr7:26884135	A/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.08	-0.32	3.28e-9	Type 1 diabetes;
LUSC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg15848620	chr12:58087721	OS9	-0.55	-7.92	-0.4	3.5e-14	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg11608241	chr8:8085544	FLJ10661	-0.41	-5.99	-0.31	5.55e-9	Neuroticism;
LUSC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg25036284	chr2:26402008	FAM59B	0.68	8.68	0.43	1.71e-16	Gut microbiome composition (summer);
LUSC	cis	rs6066835	1.000	rs6095249	chr20:47321045	T/C	cg18078177	chr20:47281410	PREX1	0.71	5.96	0.31	6.29e-9	Multiple myeloma;
LUSC	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg12473912	chr3:136751656	NA	0.39	6.83	0.35	4.04e-11	Neuroticism;
LUSC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg21724239	chr8:58056113	NA	0.53	6.49	0.33	3.17e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-8.35	-0.42	1.87e-15	Menarche (age at onset);
LUSC	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg12935359	chr14:103987150	CKB	-0.57	-8.68	-0.43	1.73e-16	Body mass index;
LUSC	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.77	-0.35	5.66e-11	Inflammatory bowel disease;
LUSC	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg00012203	chr2:219082015	ARPC2	-0.7	-11.41	-0.53	1.08e-25	Colorectal cancer;
LUSC	cis	rs9650315	0.929	rs13260658	chr8:57165144	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.07	0.36	9.07e-12	Height;
LUSC	cis	rs11871801	0.517	rs668799	chr17:40716235	C/T	cg16308533	chr17:40838983	CNTNAP1	0.41	5.9	0.31	8.77e-9	Crohn's disease;
LUSC	cis	rs3820928	1.000	rs2163041	chr2:227772480	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.85	-0.39	5.89e-14	Pulmonary function;
LUSC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg07741184	chr6:167504864	NA	0.39	6.92	0.35	2.27e-11	Primary biliary cholangitis;
LUSC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg08975724	chr8:8085496	FLJ10661	0.49	7.24	0.37	3.03e-12	Mood instability;
LUSC	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg00310523	chr12:86230176	RASSF9	0.45	8.32	0.41	2.32e-15	Major depressive disorder;
LUSC	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg12483005	chr1:23474871	LUZP1	0.42	6.14	0.32	2.31e-9	Height;
LUSC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.49	9.23	0.45	3.23e-18	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02475777	chr4:1388615	CRIPAK	0.44	6.81	0.35	4.62e-11	Longevity;
LUSC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.72	-0.39	1.35e-13	Height;
LUSC	cis	rs1185460	0.967	rs1786690	chr11:118942067	A/G	cg23280166	chr11:118938394	VPS11	0.46	6.59	0.34	1.68e-10	Coronary artery disease;
LUSC	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg24112000	chr20:60950667	NA	0.36	6.68	0.34	9.74e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg22800045	chr5:56110881	MAP3K1	0.74	9.71	0.47	8.66e-20	Initial pursuit acceleration;
LUSC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg24562669	chr7:97807699	LMTK2	0.35	6.22	0.32	1.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg20026190	chr17:76395443	PGS1	0.45	8.05	0.4	1.49e-14	HDL cholesterol levels;
LUSC	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg08085267	chr17:45401833	C17orf57	0.59	9.85	0.47	2.96e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10886558	0.502	rs1334439	chr10:121826843	C/T	cg02041677	chr10:121771263	NA	-0.33	-5.97	-0.31	6.1e-9	Shingles;
LUSC	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg09184832	chr6:79620586	NA	-0.43	-6.85	-0.35	3.64e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.24	0.52	4.29e-25	Eye color traits;
LUSC	cis	rs4423214	0.592	rs10898193	chr11:71197083	A/G	cg05163923	chr11:71159392	DHCR7	0.64	6.9	0.35	2.69e-11	Vitamin D levels;
LUSC	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.46	11.38	0.53	1.4e-25	Urate levels in overweight individuals;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20284025	chr1:119683198	WARS2	0.82	6.62	0.34	1.4e-10	Cognitive performance;
LUSC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00166722	chr3:10149974	C3orf24	0.55	7.51	0.38	5.38e-13	Alzheimer's disease;
LUSC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg14019146	chr3:50243930	SLC38A3	0.36	8.27	0.41	3.11e-15	Body mass index;
LUSC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.61	9.66	0.47	1.26e-19	Mood instability;
LUSC	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.7	6.88	0.35	2.95e-11	Initial pursuit acceleration;
LUSC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.33	0.49	6.71e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.05	-0.36	1.04e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs17286411	0.750	rs4788575	chr16:71931126	T/G	cg03805757	chr16:71968109	PKD1L3	0.42	6.91	0.35	2.46e-11	Blood protein levels;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14893161	chr1:205819251	PM20D1	0.91	17.89	0.7	1.12e-50	Menarche (age at onset);
LUSC	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	5.9	0.31	8.85e-9	Neutrophil percentage of white cells;
LUSC	cis	rs4589502	0.841	rs56401320	chr15:67140517	C/G	cg09911534	chr15:67153556	NA	-0.64	-7.22	-0.37	3.52e-12	Lung cancer (smoking interaction);
LUSC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg18129178	chr5:148520854	ABLIM3	-0.69	-10.62	-0.5	6.72e-23	Breast cancer;
LUSC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg03233332	chr7:66118400	NA	-0.41	-6.07	-0.31	3.56e-9	Aortic root size;
LUSC	cis	rs6977660	0.943	rs10277755	chr7:19826843	C/A	cg05791153	chr7:19748676	TWISTNB	0.52	5.81	0.3	1.47e-8	Thyroid stimulating hormone;
LUSC	cis	rs225245	1.000	rs225245	chr17:33946107	A/G	cg05299278	chr17:33885742	SLFN14	0.28	6.0	0.31	5.04e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-1.11	-15.3	-0.64	1.99e-40	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	trans	rs2587949	0.615	rs2874813	chr3:4208715	T/G	cg15139668	chr4:4577005	NA	-0.41	-6.08	-0.32	3.23e-9	Periodontitis (DPAL);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21792150	chr3:101567884	NFKBIZ	0.46	6.18	0.32	1.91e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4073416	0.518	rs2210805	chr14:65892724	C/G	cg03016385	chr14:66212404	NA	-0.4	-6.18	-0.32	1.87e-9	N-glycan levels;
LUSC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg08219700	chr8:58056026	NA	0.47	5.94	0.31	7.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs865483	0.860	rs12603185	chr17:35868304	T/C	cg06716730	chr17:35851459	DUSP14	0.28	6.31	0.33	8.79e-10	Monocyte count;
LUSC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.74	-13.22	-0.59	2.21e-32	Cognitive function;
LUSC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg17911788	chr17:44343683	NA	-0.32	-6.07	-0.32	3.55e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg24399712	chr22:39784796	NA	-0.61	-10.86	-0.51	1.01e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg00945038	chr17:61921165	SMARCD2	0.52	8.8	0.43	7.26e-17	Prudent dietary pattern;
LUSC	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.74	-12.09	-0.55	3.66e-28	Lymphocyte percentage of white cells;
LUSC	cis	rs72634258	0.945	rs35675666	chr1:8021973	G/T	cg00042356	chr1:8021962	PARK7	0.85	10.24	0.49	1.44e-21	Inflammatory bowel disease;
LUSC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	0.92	15.21	0.64	4.64e-40	Breast cancer;
LUSC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-7.1	-0.36	7.32e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.68	-12.22	-0.56	1.26e-28	Aortic root size;
LUSC	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg08557956	chr11:4115526	RRM1	-0.45	-5.69	-0.3	2.74e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.63	-0.43	2.59e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg27094323	chr7:1216898	NA	-0.37	-6.42	-0.33	4.79e-10	Longevity;Endometriosis;
LUSC	cis	rs1322512	0.883	rs2758814	chr6:152966367	C/T	cg03415253	chr6:152958462	SYNE1	-0.38	-5.68	-0.3	2.95e-8	Tonometry;
LUSC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs73001065	0.901	rs73004962	chr19:19713069	A/T	cg03709012	chr19:19516395	GATAD2A	0.89	7.16	0.36	5.2e-12	LDL cholesterol;
LUSC	cis	rs4604732	0.631	rs12091081	chr1:247623064	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.48	7.04	0.36	1.08e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg04865166	chr7:105162814	PUS7	0.51	5.7	0.3	2.65e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6961069	0.550	rs62461695	chr7:80258208	T/G	cg04458919	chr7:80252533	CD36	0.4	7.01	0.36	1.31e-11	Platelet count;
LUSC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg22963979	chr7:1858916	MAD1L1	0.56	8.56	0.42	4.08e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs4363385	0.693	rs4845497	chr1:152904162	T/C	cg00922841	chr1:152955080	SPRR1A	-0.4	-6.55	-0.34	2.16e-10	Inflammatory skin disease;
LUSC	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg22961513	chr11:14280813	SPON1	0.34	5.73	0.3	2.28e-8	Mitochondrial DNA levels;
LUSC	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.78	-13.45	-0.59	2.96e-33	Heart rate;
LUSC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg15704280	chr7:45808275	SEPT13	0.93	13.42	0.59	3.7e-33	Coronary artery disease;
LUSC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg18681998	chr4:17616180	MED28	-0.84	-14.98	-0.63	3.73e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.94	-0.31	7.06e-9	Platelet count;
LUSC	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg21064579	chr19:49206444	FUT2	0.46	8.66	0.43	2.07e-16	Dietary macronutrient intake;
LUSC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg15145296	chr3:125709740	NA	-0.58	-6.56	-0.34	2.01e-10	Blood pressure (smoking interaction);
LUSC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.78	14.27	0.62	2.08e-36	Osteoporosis;
LUSC	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg04545296	chr12:48745243	ZNF641	0.33	6.04	0.31	4.14e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	0.96	17.69	0.7	7.15e-50	Heart rate;
LUSC	trans	rs7618314	0.571	rs882892	chr3:108498405	A/T	cg05749855	chr16:89472771	ANKRD11	0.59	6.0	0.31	5.2e-9	Airway responsiveness in chronic obstructive pulmonary disease;
LUSC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg25767906	chr1:53392781	SCP2	-0.49	-8.69	-0.43	1.63e-16	Monocyte count;
LUSC	cis	rs981844	1.000	rs2263434	chr4:154658312	A/G	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg05585544	chr11:47624801	NA	-0.43	-7.51	-0.38	5.37e-13	Subjective well-being;
LUSC	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg05623727	chr3:50126028	RBM5	-0.36	-6.71	-0.34	8.19e-11	Body mass index;
LUSC	cis	rs10792830	0.771	rs629343	chr11:85811138	C/T	cg07180834	chr11:85838833	NA	0.31	6.01	0.31	4.84e-9	Psychosis and Alzheimer's disease;
LUSC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	cis	rs4285028	0.656	rs2141487	chr3:121482765	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.9	12.46	0.56	1.54e-29	Multiple sclerosis;
LUSC	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-9.73	-0.47	7.36e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs55871839	0.684	rs6988143	chr8:59810572	C/T	cg07426533	chr8:59803705	TOX	-0.36	-5.93	-0.31	7.66e-9	Pneumonia;
LUSC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03264133	chr6:25882463	NA	0.4	6.81	0.35	4.45e-11	Blood metabolite levels;
LUSC	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg09976142	chr9:130955436	CIZ1	0.44	7.49	0.38	6.2e-13	Attention deficit hyperactivity disorder;
LUSC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-1.13	-24.87	-0.81	5.2e-78	Height;
LUSC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	1e-64	Prudent dietary pattern;
LUSC	cis	rs7267979	0.527	rs6076369	chr20:25576783	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-12.67	-0.57	2.71e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6163	0.540	rs11191385	chr10:104513049	G/T	cg05855489	chr10:104503620	C10orf26	0.74	11.43	0.53	9.28e-26	Waist circumference;Hip circumference;
LUSC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg03526776	chr6:41159608	TREML2	0.33	6.12	0.32	2.67e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4654899	0.865	rs12406144	chr1:21347228	A/C	cg01072550	chr1:21505969	NA	-0.54	-8.03	-0.4	1.67e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg22705602	chr4:152727874	NA	-0.38	-8.23	-0.41	4.18e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	0.98	14.93	0.63	5.84e-39	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17467752	chr17:38218738	THRA	-0.7	-11.27	-0.52	3.54e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.65e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	1.04	14.11	0.61	9.12e-36	Exhaled nitric oxide levels;
LUSC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg05802129	chr4:122689817	NA	-0.35	-6.13	-0.32	2.42e-9	Type 2 diabetes;
LUSC	cis	rs62400317	1.000	rs62400317	chr6:45284923	C/T	cg20913747	chr6:44695427	NA	-0.46	-7.48	-0.38	6.5e-13	Total body bone mineral density;
LUSC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg03289416	chr15:75166202	SCAMP2	0.45	6.83	0.35	4.11e-11	Breast cancer;
LUSC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-7.33	-0.37	1.74e-12	Aortic root size;
LUSC	cis	rs3820928	0.874	rs10207404	chr2:227794420	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.76	-0.39	1.07e-13	Pulmonary function;
LUSC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.42	6.06	0.31	3.69e-9	Height;
LUSC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.63	-0.34	1.32e-10	Aortic root size;
LUSC	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.35	-0.33	7.06e-10	Systolic blood pressure;
LUSC	cis	rs2677744	1.000	rs4773	chr15:91463842	G/A	cg00526711	chr15:91477898	UNC45A	0.3	6.06	0.31	3.6e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg12463550	chr7:65579703	CRCP	0.51	7.46	0.38	7.34e-13	Aortic root size;
LUSC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg13206674	chr6:150067644	NUP43	0.63	10.32	0.49	7.59e-22	Lung cancer;
LUSC	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17173187	chr15:85201210	NMB	-0.47	-9.06	-0.44	1.14e-17	Schizophrenia;
LUSC	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg27411982	chr8:10470053	RP1L1	0.4	6.13	0.32	2.45e-9	Mood instability;
LUSC	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg04374321	chr14:90722782	PSMC1	0.76	12.04	0.55	5.82e-28	Mortality in heart failure;
LUSC	cis	rs6500395	0.962	rs9927888	chr16:48557764	A/T	cg04672837	chr16:48644449	N4BP1	0.45	6.6	0.34	1.61e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	1.13	19.23	0.72	5.2e-56	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg07741184	chr6:167504864	NA	-0.42	-7.66	-0.39	2.06e-13	Crohn's disease;
LUSC	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg23795048	chr12:9217529	LOC144571	0.34	5.86	0.31	1.1e-8	Sjögren's syndrome;
LUSC	cis	rs3862435	0.518	rs2601189	chr15:90929874	G/A	cg22089800	chr15:90895588	ZNF774	0.56	5.96	0.31	6.33e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs75229567	0.618	rs78294090	chr12:70209959	G/T	cg10114359	chr12:70132523	RAB3IP	1.29	11.72	0.54	8.07e-27	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs73200209	0.626	rs56178625	chr12:116578048	A/G	cg01776926	chr12:116560359	MED13L	-0.51	-6.13	-0.32	2.45e-9	Total body bone mineral density;
LUSC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.76	-0.43	9.78e-17	Aortic root size;
LUSC	cis	rs9815354	0.716	rs76313799	chr3:41931751	A/C	cg03022575	chr3:42003672	ULK4	0.82	8.55	0.42	4.49e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs174479	0.677	rs174463	chr11:61657838	G/A	cg01500311	chr11:61656094	FADS3	0.4	6.96	0.36	1.8e-11	Sphingolipid levels;
LUSC	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg05234568	chr11:5960015	NA	-0.55	-7.78	-0.39	9.12e-14	DNA methylation (variation);
LUSC	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	0.82	15.09	0.64	1.3e-39	Ulcerative colitis;
LUSC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	8.0	0.4	2.05e-14	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg07541023	chr7:19748670	TWISTNB	-0.66	-7.34	-0.37	1.68e-12	Thyroid stimulating hormone;
LUSC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg16797656	chr11:68205561	LRP5	0.36	6.13	0.32	2.49e-9	Total body bone mineral density;
LUSC	cis	rs6714710	0.603	rs78006955	chr2:98455510	G/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs12973672	1.000	rs12973672	chr19:35767866	A/G	cg12095397	chr19:35769544	USF2	0.45	7.04	0.36	1.13e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg20703242	chr1:230279135	GALNT2	0.58	9.05	0.44	1.21e-17	Coronary artery disease;
LUSC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg00701064	chr4:6280414	WFS1	0.57	13.67	0.6	4.48e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13732083	chr21:47605072	C21orf56	-0.47	-6.98	-0.36	1.57e-11	Testicular germ cell tumor;
LUSC	cis	rs727505	0.754	rs55723877	chr7:124780899	T/A	cg23710748	chr7:124431027	NA	-0.4	-7.02	-0.36	1.24e-11	Lewy body disease;
LUSC	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg04117972	chr1:227635322	NA	0.61	6.88	0.35	2.9e-11	Major depressive disorder;
LUSC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg14092988	chr3:52407081	DNAH1	0.32	6.19	0.32	1.78e-9	Bipolar disorder;
LUSC	cis	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg09307838	chr4:120376055	NA	-0.48	-7.18	-0.37	4.45e-12	Diastolic blood pressure;
LUSC	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-7.67	-0.39	1.92e-13	Testicular germ cell tumor;
LUSC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	11.66	0.54	1.42e-26	Personality dimensions;
LUSC	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.5	-6.82	-0.35	4.37e-11	Adiposity;
LUSC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	0.91	13.55	0.6	1.23e-33	Breast cancer;
LUSC	cis	rs727505	0.954	rs66691367	chr7:124654217	G/T	cg23710748	chr7:124431027	NA	-0.38	-6.58	-0.34	1.79e-10	Lewy body disease;
LUSC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.48	0.33	3.32e-10	Lung cancer;
LUSC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg23985595	chr17:80112537	CCDC57	0.3	5.75	0.3	2.06e-8	Life satisfaction;
LUSC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg13114125	chr14:105738426	BRF1	-0.93	-16.05	-0.66	2.2e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.78	-0.3	1.7e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg03388025	chr16:89894329	SPIRE2	0.35	7.44	0.38	8.86e-13	Vitiligo;
LUSC	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg17764715	chr19:33622953	WDR88	0.58	7.82	0.39	7.14e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6967385	0.934	rs10259100	chr7:12384664	G/A	cg06484146	chr7:12443880	VWDE	0.39	5.71	0.3	2.5e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.52	-7.54	-0.38	4.6e-13	Resistin levels;
LUSC	cis	rs721399	0.539	rs10103029	chr8:18267338	A/G	cg18736775	chr8:18248649	NAT2	-0.6	-7.09	-0.36	7.9e-12	Blood metabolite levels;
LUSC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08280861	chr8:58055591	NA	0.54	6.39	0.33	5.52e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg03676636	chr4:99064102	C4orf37	0.39	8.0	0.4	2.06e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs71403859	0.502	rs12927456	chr16:71505706	A/G	cg08717414	chr16:71523259	ZNF19	-0.75	-8.71	-0.43	1.46e-16	Post bronchodilator FEV1;
LUSC	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg18132916	chr6:79620363	NA	-0.38	-5.73	-0.3	2.19e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg05234568	chr11:5960015	NA	0.61	8.96	0.44	2.35e-17	DNA methylation (variation);
LUSC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	8.23	0.41	4.39e-15	Initial pursuit acceleration;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04433306	chr7:129592730	UBE2H	-0.51	-6.02	-0.31	4.55e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-10.53	-0.5	1.44e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.43	6.72	0.34	8.06e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg05729581	chr11:3078854	CARS	0.4	5.85	0.3	1.16e-8	Calcium levels;
LUSC	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg03676636	chr4:99064102	C4orf37	0.3	5.99	0.31	5.55e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg06002616	chr8:101225028	SPAG1	-0.41	-6.84	-0.35	3.71e-11	Atrioventricular conduction;
LUSC	cis	rs7511006	0.798	rs11703673	chr22:50652427	A/G	cg16473166	chr22:50639996	SELO	-0.53	-7.02	-0.36	1.27e-11	Obesity-related traits;
LUSC	cis	rs12541635	0.966	rs55762012	chr8:107033218	T/C	cg10147462	chr8:107024639	NA	0.55	9.83	0.47	3.44e-20	Age of smoking initiation;
LUSC	cis	rs10905065	0.965	rs2890365	chr10:5773876	C/A	cg11519256	chr10:5708881	ASB13	-0.4	-5.83	-0.3	1.28e-8	Menopause (age at onset);
LUSC	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg20016023	chr10:99160130	RRP12	-0.33	-8.04	-0.4	1.57e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05535760	chr7:792225	HEATR2	-0.82	-7.86	-0.4	5.38e-14	Cerebrospinal P-tau181p levels;
LUSC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg09877947	chr5:131593287	PDLIM4	0.45	7.31	0.37	2.03e-12	Breast cancer;
LUSC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg00933542	chr6:150070202	PCMT1	0.33	6.92	0.35	2.35e-11	Lung cancer;
LUSC	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg17411546	chr10:75410026	SYNPO2L	-0.55	-8.31	-0.41	2.51e-15	Inflammatory bowel disease;
LUSC	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg13010199	chr12:38710504	ALG10B	0.43	6.48	0.33	3.29e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg07701084	chr6:150067640	NUP43	0.57	8.85	0.44	5.05e-17	Lung cancer;
LUSC	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.67	-0.3	3.14e-8	Bipolar disorder;
LUSC	cis	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg06521331	chr12:34319734	NA	0.4	6.56	0.34	1.99e-10	Morning vs. evening chronotype;
LUSC	cis	rs240764	0.782	rs12216199	chr6:101152723	C/A	cg09795085	chr6:101329169	ASCC3	-0.42	-6.15	-0.32	2.18e-9	Neuroticism;
LUSC	cis	rs8027181	0.839	rs2304597	chr15:73052431	A/G	cg25632853	chr15:73088954	NA	0.32	6.42	0.33	4.77e-10	Triglyceride levels;
LUSC	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.32	0.33	8.24e-10	IgG glycosylation;
LUSC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg05861140	chr6:150128134	PCMT1	-0.4	-6.25	-0.32	1.25e-9	Lung cancer;
LUSC	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg04362960	chr10:104952993	NT5C2	-0.59	-9.16	-0.45	5.52e-18	Arsenic metabolism;
LUSC	trans	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.08	-0.32	3.31e-9	Depression;
LUSC	cis	rs12410462	0.581	rs4329477	chr1:227552494	A/G	cg04117972	chr1:227635322	NA	-0.57	-6.79	-0.35	5.29e-11	Major depressive disorder;
LUSC	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg23933602	chr10:16859644	RSU1	0.54	6.51	0.34	2.83e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs259282	0.628	rs2287669	chr19:33110204	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	9.69	0.47	1e-19	Schizophrenia;
LUSC	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg03806693	chr22:41940476	POLR3H	-0.56	-7.49	-0.38	6.05e-13	Neuroticism;
LUSC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.64	0.6	5.58e-34	Cognitive test performance;
LUSC	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.48	-0.69	4.87e-49	Exhaled nitric oxide output;
LUSC	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg09307838	chr4:120376055	NA	0.74	10.36	0.49	5.54e-22	Corneal astigmatism;
LUSC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.89	14.47	0.62	3.69e-37	IgG glycosylation;
LUSC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg00677455	chr12:58241039	CTDSP2	0.61	8.47	0.42	7.68e-16	Multiple sclerosis;
LUSC	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg05925327	chr15:68127851	NA	-0.4	-5.97	-0.31	6.11e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg23625390	chr15:77176239	SCAPER	-0.67	-10.12	-0.48	3.55e-21	Blood metabolite levels;
LUSC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg01879757	chr17:41196368	BRCA1	-0.45	-6.83	-0.35	3.97e-11	Menopause (age at onset);
LUSC	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.88	0.31	9.9e-9	Breast cancer;
LUSC	trans	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.0	-0.36	1.38e-11	Breast cancer;
LUSC	cis	rs4423214	0.592	rs7130829	chr11:71237702	A/T	cg05163923	chr11:71159392	DHCR7	-0.66	-6.87	-0.35	3.23e-11	Vitamin D levels;
LUSC	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.67e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg00262122	chr8:11665843	FDFT1	0.52	7.9	0.4	4.17e-14	Morning vs. evening chronotype;
LUSC	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.72	0.35	7.98e-11	Intraocular pressure;
LUSC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.37	0.53	1.56e-25	Prudent dietary pattern;
LUSC	cis	rs7923609	1.000	rs2393969	chr10:65140440	A/C	cg01631684	chr10:65280961	REEP3	-0.38	-5.9	-0.31	9.15e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9296092	0.538	rs80012910	chr6:33519542	G/A	cg13560919	chr6:33536144	NA	-0.82	-15.74	-0.65	3.89e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7267979	0.586	rs6037057	chr20:25182089	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	12.71	0.57	1.82e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4964805	0.641	rs10861094	chr12:104159716	C/A	cg02344784	chr12:104178138	NT5DC3	0.37	5.96	0.31	6.51e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs597583	1.000	rs597583	chr11:117421799	C/G	cg27161313	chr11:117392002	DSCAML1	-0.43	-7.47	-0.38	7.25e-13	Putamen volume;
LUSC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.75	0.35	6.4e-11	Tonsillectomy;
LUSC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.4	-0.42	1.26e-15	Mean platelet volume;
LUSC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.58	-9.09	-0.45	9.29e-18	Lymphocyte counts;
LUSC	trans	rs2363709	0.881	rs1994609	chr3:67386701	T/C	cg23062198	chr2:14774063	FAM84A	0.57	6.14	0.32	2.31e-9	IgE levels;
LUSC	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg11812906	chr14:75593930	NEK9	-0.53	-8.67	-0.43	1.94e-16	Coronary artery disease;
LUSC	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.6e-11	Morning vs. evening chronotype;
LUSC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg15103426	chr22:29168792	CCDC117	0.59	8.3	0.41	2.69e-15	Lymphocyte counts;
LUSC	cis	rs72781680	0.566	rs55987381	chr2:23900938	T/C	cg08917208	chr2:24149416	ATAD2B	0.74	8.51	0.42	5.8e-16	Lymphocyte counts;
LUSC	cis	rs2154427	1.000	rs2833962	chr21:34174289	A/G	cg21871883	chr21:34145043	C21orf49;C21orf66	0.62	5.89	0.31	9.41e-9	Bilirubin levels;
LUSC	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg07423050	chr13:99094983	FARP1	-0.56	-10.54	-0.5	1.3e-22	Longevity;
LUSC	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg24562669	chr7:97807699	LMTK2	0.48	8.56	0.42	4.18e-16	Breast cancer;
LUSC	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	6.5	0.34	2.87e-10	Lung cancer in ever smokers;
LUSC	cis	rs977987	0.835	rs3851734	chr16:75371920	T/C	cg04384234	chr16:75411784	CFDP1	-0.4	-6.57	-0.34	1.94e-10	Dupuytren's disease;
LUSC	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-8.4	-0.42	1.28e-15	Schizophrenia;
LUSC	cis	rs6599077	0.950	rs9809788	chr3:40103734	T/C	cg13683864	chr3:40499215	RPL14	-0.61	-7.6	-0.38	3.09e-13	Sleep-related phenotypes;
LUSC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg22823121	chr1:150693482	HORMAD1	0.47	6.84	0.35	3.78e-11	Melanoma;
LUSC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.93	-0.4	3.28e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg23711669	chr6:146136114	FBXO30	-0.82	-14.57	-0.62	1.45e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg11663144	chr21:46675770	NA	-0.41	-7.21	-0.37	3.86e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs7940866	0.903	rs10791112	chr11:130870215	A/C	cg12179176	chr11:130786555	SNX19	-0.58	-8.9	-0.44	3.7e-17	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg22709100	chr7:91322751	NA	0.38	5.65	0.3	3.48e-8	Breast cancer;
LUSC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg24642439	chr20:33292090	TP53INP2	0.48	7.16	0.36	5.1e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs6847149	1.000	rs6852679	chr4:110804414	T/C	cg07850274	chr4:110748770	RRH	0.6	7.71	0.39	1.45e-13	Exercise treadmill test traits;
LUSC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg18850127	chr7:39170497	POU6F2	0.64	10.51	0.5	1.6e-22	IgG glycosylation;
LUSC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.97	0.51	4.04e-24	Monocyte percentage of white cells;
LUSC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.65	-11.14	-0.52	1.02e-24	Diastolic blood pressure;
LUSC	cis	rs9311676	0.656	rs62258081	chr3:58367705	A/C	cg26110898	chr3:58419937	PDHB	0.43	7.15	0.36	5.67e-12	Systemic lupus erythematosus;
LUSC	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.11e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg12463550	chr7:65579703	CRCP	-0.57	-8.46	-0.42	8.37e-16	Aortic root size;
LUSC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	1.05	19.12	0.72	1.42e-55	Menopause (age at onset);
LUSC	cis	rs500891	0.953	rs2145324	chr6:84194408	C/T	cg08257003	chr6:84140564	ME1	-0.35	-7.31	-0.37	1.95e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.18	-0.37	4.56e-12	Bipolar disorder;
LUSC	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg16512390	chr1:228756714	NA	0.46	6.34	0.33	7.31e-10	Chronic lymphocytic leukemia;
LUSC	trans	rs9503598	0.636	rs6596975	chr6:3465925	G/A	cg05722439	chr19:14072965	RFX1	-0.31	-6.04	-0.31	4.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg11901034	chr3:128598214	ACAD9	-0.41	-6.47	-0.33	3.39e-10	IgG glycosylation;
LUSC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg17948913	chr5:572064	NA	0.36	6.08	0.32	3.32e-9	Obesity-related traits;
LUSC	trans	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.02e-14	Corneal astigmatism;
LUSC	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg18721089	chr20:30220636	NA	-0.31	-5.68	-0.3	2.97e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg04414720	chr1:150670196	GOLPH3L	0.54	8.53	0.42	5.19e-16	Tonsillectomy;
LUSC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg06618935	chr21:46677482	NA	-0.4	-7.9	-0.4	4.09e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg18225595	chr11:63971243	STIP1	-0.53	-8.75	-0.43	1.06e-16	Platelet count;
LUSC	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.06	0.4	1.36e-14	Corneal astigmatism;
LUSC	cis	rs10979	0.931	rs9484770	chr6:143896758	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs2012796	0.957	rs8016255	chr14:81816121	C/G	cg02996355	chr14:81879375	NA	0.46	6.53	0.34	2.43e-10	Night sleep phenotypes;
LUSC	cis	rs6545883	0.525	rs2049747	chr2:61364154	G/A	cg15711740	chr2:61764176	XPO1	0.39	6.04	0.31	4.14e-9	Tuberculosis;
LUSC	cis	rs6987853	0.931	rs2923399	chr8:42439509	G/A	cg09913449	chr8:42400586	C8orf40	0.48	7.88	0.4	4.7e-14	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-9.06	-0.44	1.11e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.57	8.6	0.43	3.14e-16	Blood protein levels;
LUSC	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg13010199	chr12:38710504	ALG10B	0.67	10.58	0.5	9.58e-23	Morning vs. evening chronotype;
LUSC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22968622	chr17:43663579	NA	0.8	12.38	0.56	3.25e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs4478858	0.684	rs2271074	chr1:31734841	C/T	cg00250761	chr1:31883323	NA	-0.33	-8.06	-0.4	1.35e-14	Alcohol dependence;
LUSC	cis	rs3820928	0.874	rs10210997	chr2:227859108	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.54	-0.34	2.29e-10	Pulmonary function;
LUSC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.63	-8.77	-0.43	9.57e-17	Multiple sclerosis;
LUSC	cis	rs10979	0.679	rs9496680	chr6:143896915	G/A	cg25407410	chr6:143891975	LOC285740	-0.68	-9.53	-0.46	3.43e-19	Hypospadias;
LUSC	cis	rs7561273	0.561	rs35268318	chr2:24352824	A/T	cg20701182	chr2:24300061	SF3B14	0.46	5.87	0.31	1.05e-8	Quantitative traits;
LUSC	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg23241863	chr10:102295624	HIF1AN	0.49	5.97	0.31	6.01e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-5.83	-0.3	1.33e-8	Mood instability;
LUSC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	8.55	0.42	4.63e-16	Menarche (age at onset);
LUSC	cis	rs10465746	0.780	rs11163866	chr1:84367123	A/G	cg10977910	chr1:84465055	TTLL7	0.45	6.36	0.33	6.7e-10	Obesity-related traits;
LUSC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg05973401	chr12:123451056	ABCB9	0.52	7.1	0.36	7.72e-12	Neutrophil percentage of white cells;
LUSC	cis	rs690037	0.641	rs538525	chr3:16376279	A/G	cg23474789	chr3:16306055	DPH3;OXNAD1	0.39	6.06	0.31	3.76e-9	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
LUSC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	8.12	0.41	9.33e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg18478394	chr8:109455254	TTC35	0.43	6.76	0.35	5.99e-11	Dupuytren's disease;
LUSC	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg17385448	chr1:15911702	AGMAT	0.37	5.8	0.3	1.5e-8	Systolic blood pressure;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01084379	chr5:179160712	MAML1	-0.51	-6.62	-0.34	1.47e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10761482	0.861	rs10761485	chr10:62102660	T/C	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs273573	0.922	rs7930532	chr11:30811294	G/A	cg14844989	chr11:31128820	NA	-0.36	-5.72	-0.3	2.35e-8	Total body bone mineral density;
LUSC	cis	rs2274273	0.624	rs7155954	chr14:55750943	G/A	cg04306507	chr14:55594613	LGALS3	0.48	9.8	0.47	4.34e-20	Protein biomarker;
LUSC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg11941060	chr3:133502564	NA	-0.51	-7.79	-0.39	8.5e-14	Iron status biomarkers;
LUSC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg08392591	chr16:89556376	ANKRD11	0.46	6.92	0.35	2.38e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs75804782	0.641	rs72983853	chr2:239324210	C/T	cg18131467	chr2:239335373	ASB1	-0.71	-6.47	-0.33	3.41e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14169450	chr9:139327907	INPP5E	-0.45	-8.06	-0.4	1.35e-14	Monocyte percentage of white cells;
LUSC	cis	rs11601602	0.576	rs12576396	chr11:28555952	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.46	6.25	0.32	1.22e-9	Obesity-related traits;
LUSC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg11062466	chr8:58055876	NA	0.51	6.49	0.33	3.08e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.39	-6.51	-0.34	2.78e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg10755058	chr3:40428713	ENTPD3	0.34	5.85	0.3	1.19e-8	Renal cell carcinoma;
LUSC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg01125463	chr6:42946178	PEX6	-0.36	-6.11	-0.32	2.73e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	8.17	0.41	6.36e-15	Myopia (pathological);
LUSC	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.78	0.35	5.4e-11	IgG glycosylation;
LUSC	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg03733263	chr8:22462867	KIAA1967	0.85	14.49	0.62	2.9e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-0.99	-11.03	-0.52	2.5300000000000002e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg06484146	chr7:12443880	VWDE	-0.68	-7.26	-0.37	2.76e-12	Coronary artery disease;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07336999	chr16:89939803	TCF25	-0.35	-6.15	-0.32	2.21e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7177699	0.534	rs56683682	chr15:79112524	G/T	cg00540400	chr15:79124168	NA	-0.46	-7.9	-0.4	4.09e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg05941027	chr17:61774174	LIMD2	0.23	6.22	0.32	1.5e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg20302342	chr1:156215951	PAQR6	0.33	6.26	0.32	1.16e-9	Tonsillectomy;
LUSC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg04362960	chr10:104952993	NT5C2	0.58	9.38	0.46	1.06e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg14440974	chr22:39074834	NA	-0.36	-5.92	-0.31	7.79e-9	Menopause (age at onset);
LUSC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg11344533	chr11:111475393	SIK2	-0.47	-6.33	-0.33	7.71e-10	Primary sclerosing cholangitis;
LUSC	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg12615879	chr12:58013172	SLC26A10	-0.31	-7.59	-0.38	3.33e-13	Multiple sclerosis;
LUSC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg16624210	chr5:671434	TPPP	0.49	6.12	0.32	2.58e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-6.3	-0.33	9.17e-10	Resting heart rate;
LUSC	cis	rs10905065	0.965	rs10752110	chr10:5837038	T/C	cg11519256	chr10:5708881	ASB13	0.4	5.78	0.3	1.7e-8	Menopause (age at onset);
LUSC	cis	rs76935404	0.868	rs73034462	chr19:41418134	G/A	cg04176888	chr19:41596066	CYP2A13	0.39	6.02	0.31	4.51e-9	nicotine metabolite ratio in current smokers;
LUSC	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.79	-0.39	8.57e-14	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6570726	0.526	rs7755237	chr6:145731852	T/C	cg23711669	chr6:146136114	FBXO30	-0.51	-7.9	-0.4	4.05e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg26695010	chr11:65641043	EFEMP2	0.52	7.72	0.39	1.38e-13	Eosinophil percentage of white cells;
LUSC	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.41	-6.07	-0.32	3.46e-9	IgG glycosylation;
LUSC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	14.73	0.63	3.3e-38	Platelet count;
LUSC	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg08000102	chr2:233561755	GIGYF2	0.69	11.45	0.53	8.19e-26	Coronary artery disease;
LUSC	cis	rs9420	0.961	rs77993055	chr11:57522840	C/T	cg02958346	chr11:57425731	CLP1	-0.44	-6.44	-0.33	4.22e-10	Schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg16271017	chr6:7726349	BMP6	0.75	6.3	0.33	9.6e-10	Cognitive performance;
LUSC	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.77	0.39	9.81e-14	Iron status biomarkers;
LUSC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg16325326	chr1:53192061	ZYG11B	-0.87	-16.47	-0.67	4.97e-45	Monocyte count;
LUSC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg03233332	chr7:66118400	NA	-0.42	-6.1	-0.32	2.88e-9	Aortic root size;
LUSC	cis	rs911119	1.000	rs71334202	chr20:23618652	A/C	cg16589663	chr20:23618590	CST3	0.58	6.89	0.35	2.72e-11	Chronic kidney disease;
LUSC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg18538332	chr22:24372958	LOC391322	0.47	8.39	0.42	1.43e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6012953	0.967	rs4496379	chr20:49159944	A/T	cg13958625	chr20:49123093	NA	-0.29	-6.61	-0.34	1.55e-10	Vitiligo;
LUSC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg04369109	chr6:150039330	LATS1	-0.49	-7.12	-0.36	6.51e-12	Lung cancer;
LUSC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.27	-0.52	3.48e-25	Bipolar disorder;
LUSC	cis	rs9796	0.866	rs692155	chr15:41407061	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.06	-0.4	1.37e-14	Menopause (age at onset);
LUSC	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg05966235	chr16:28915196	ATP2A1	0.34	6.15	0.32	2.26e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.45	6.66	0.34	1.16e-10	Endometrial cancer;
LUSC	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.43	-6.4	-0.33	5.41e-10	Axial length;
LUSC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.5	-0.38	5.85e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	8.31	0.41	2.46e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg26811252	chr16:29126840	RRN3P2	0.57	9.08	0.44	9.35e-18	Menopause (age at onset);
LUSC	cis	rs73206853	0.563	rs4073472	chr12:111176494	A/G	cg12870014	chr12:110450643	ANKRD13A	0.69	7.34	0.37	1.62e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25249518	chr6:119399928	FAM184A	-0.42	-6.28	-0.32	1.05e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10170846	0.861	rs12694582	chr2:223521955	G/C	cg25565276	chr2:223520875	FARSB	0.64	9.7	0.47	9.46e-20	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs11971779	0.680	rs6949599	chr7:139054188	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.08	-0.32	3.35e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4919087	1.000	rs10786329	chr10:99074621	G/A	cg25902810	chr10:99078978	FRAT1	0.47	6.91	0.35	2.47e-11	Monocyte count;
LUSC	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	1.13	19.6	0.73	1.77e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10979	0.965	rs9376758	chr6:143886878	G/A	cg25407410	chr6:143891975	LOC285740	-0.7	-11.06	-0.52	1.96e-24	Hypospadias;
LUSC	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg19812747	chr11:111475976	SIK2	-0.51	-6.87	-0.35	3.24e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg24558204	chr6:135376177	HBS1L	-0.47	-6.91	-0.35	2.49e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg21918786	chr6:109611834	NA	-0.42	-7.29	-0.37	2.2e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg11342453	chr6:26196699	NA	0.58	6.07	0.32	3.4e-9	Gout;Renal underexcretion gout;
LUSC	trans	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.97	-0.31	5.95e-9	Morning vs. evening chronotype;
LUSC	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.45	-6.11	-0.32	2.73e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg22963979	chr7:1858916	MAD1L1	-0.63	-10.1	-0.48	4.03e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg26380479	chr7:97908229	NA	-0.28	-6.26	-0.32	1.19e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg04545296	chr12:48745243	ZNF641	-0.31	-5.78	-0.3	1.75e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs4073582	0.894	rs801733	chr11:65934549	A/C	cg16950941	chr11:66035639	RAB1B	0.44	5.74	0.3	2.1e-8	Gout;
LUSC	cis	rs12042938	0.935	rs1094653	chr1:231794794	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.4	5.84	0.3	1.21e-8	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg10356904	chr22:49881777	NA	-0.29	-5.84	-0.3	1.25e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.65	-0.34	1.21e-10	Lung cancer;
LUSC	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg12927641	chr6:109611667	NA	-0.35	-5.89	-0.31	9.49e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01571407	chr16:12009700	GSPT1	-0.4	-5.97	-0.31	6.11e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.23	-14.17	-0.61	5.08e-36	Gout;
LUSC	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg14675211	chr2:100938903	LONRF2	0.37	5.77	0.3	1.81e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg06917634	chr15:78832804	PSMA4	-0.47	-6.43	-0.33	4.35e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg18850127	chr7:39170497	POU6F2	0.41	5.99	0.31	5.5e-9	IgG glycosylation;
LUSC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.07	-0.4	1.28e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01172785	chr16:50092553	NA	0.53	6.47	0.33	3.57e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6693567	0.565	rs3754214	chr1:150478623	T/C	cg15654264	chr1:150340011	RPRD2	0.46	7.5	0.38	5.73e-13	Migraine;
LUSC	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg02423579	chr7:2872169	GNA12	-0.37	-5.89	-0.31	9.44e-9	Height;
LUSC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-9.7	-0.47	9.24e-20	Neuroticism;
LUSC	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-15.9	-0.66	8.8e-43	Heart rate;
LUSC	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg10596483	chr8:143751796	JRK	0.53	7.66	0.39	1.98e-13	Schizophrenia;
LUSC	trans	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs672059	1.000	rs544352	chr1:183157546	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.55	7.98	0.4	2.3e-14	Hypertriglyceridemia;
LUSC	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.94	-0.31	7.19e-9	Reticulocyte count;
LUSC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08645402	chr16:4508243	NA	0.48	7.49	0.38	6.2e-13	Schizophrenia;
LUSC	cis	rs2348418	0.647	rs938081	chr12:28720613	A/G	cg13890972	chr12:28721907	NA	-0.38	-6.6	-0.34	1.66e-10	Lung function (FVC);Lung function (FEV1);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03535439	chr6:42981950	MEA1;KLHDC3	-0.51	-6.05	-0.31	3.79e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg17385448	chr1:15911702	AGMAT	0.37	6.24	0.32	1.29e-9	Systolic blood pressure;
LUSC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.72	12.13	0.55	2.61e-28	Motion sickness;
LUSC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg23711669	chr6:146136114	FBXO30	0.75	13.48	0.59	2.26e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6599077	1.000	rs6768659	chr3:40097001	G/A	cg13683864	chr3:40499215	RPL14	-0.58	-7.39	-0.38	1.15e-12	Sleep-related phenotypes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22207900	chr11:64072031	ESRRA;C11orf20	-0.42	-6.15	-0.32	2.26e-9	Hepatitis;
LUSC	cis	rs77633900	0.614	rs279999	chr15:76945466	C/T	cg21673338	chr15:77095150	SCAPER	-0.74	-7.39	-0.37	1.19e-12	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg11244672	chr19:19639970	YJEFN3	-0.53	-6.65	-0.34	1.19e-10	Bipolar disorder;
LUSC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg11861562	chr11:117069780	TAGLN	-0.43	-7.83	-0.39	6.38e-14	Blood protein levels;
LUSC	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg01528321	chr10:82214614	TSPAN14	0.82	12.36	0.56	3.74e-29	Post bronchodilator FEV1;
LUSC	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg04315214	chr1:2043799	PRKCZ	-0.3	-5.88	-0.31	1.02e-8	Coronary artery disease;
LUSC	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	1.13	17.44	0.69	6.81e-49	Corneal structure;
LUSC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg20203395	chr5:56204925	C5orf35	-0.73	-9.96	-0.48	1.28e-20	Initial pursuit acceleration;
LUSC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06656553	chr16:89960601	TCF25	-0.63	-5.7	-0.3	2.68e-8	Skin colour saturation;
LUSC	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg12560992	chr17:57184187	TRIM37	-0.54	-8.7	-0.43	1.49e-16	Testicular germ cell tumor;
LUSC	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-5.86	-0.31	1.11e-8	Neutrophil percentage of white cells;
LUSC	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	8.3	0.41	2.7e-15	Height;
LUSC	cis	rs460214	0.564	rs464519	chr21:40024182	A/G	cg21578987	chr21:40029669	ERG	0.42	6.48	0.33	3.39e-10	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg00277334	chr10:82204260	NA	-0.54	-7.92	-0.4	3.59e-14	Post bronchodilator FEV1;
LUSC	cis	rs7264396	0.887	rs224419	chr20:34143092	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.99	-0.36	1.51e-11	Total cholesterol levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26643937	chr20:3869678	PANK2	0.77	6.05	0.31	3.81e-9	Cognitive performance;
LUSC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	cis	rs6433857	0.657	rs2368177	chr2:181501242	T/C	cg23363182	chr2:181467187	NA	-0.53	-8.44	-0.42	9.86e-16	Body mass index;
LUSC	cis	rs1385374	0.858	rs11059923	chr12:129293057	G/A	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.8	-0.35	4.96e-11	Systemic lupus erythematosus;
LUSC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg14019146	chr3:50243930	SLC38A3	0.32	6.93	0.35	2.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg20003494	chr4:90757398	SNCA	-0.33	-5.68	-0.3	2.91e-8	Dementia with Lewy bodies;
LUSC	cis	rs9372253	0.843	rs28721292	chr6:110719631	T/C	cg00083206	chr6:110721305	DDO	-0.46	-8.42	-0.42	1.1e-15	Platelet distribution width;
LUSC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.73	0.35	7.47e-11	Depression;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05131254	chr6:138188363	TNFAIP3	0.46	6.28	0.32	1.08e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg17264618	chr3:40429014	ENTPD3	0.31	6.65	0.34	1.19e-10	Renal cell carcinoma;
LUSC	cis	rs17818399	0.749	rs4142759	chr2:46783890	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-7.57	-0.38	3.56e-13	Height;
LUSC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25072359	chr17:41440525	NA	0.65	9.46	0.46	5.86e-19	Menopause (age at onset);
LUSC	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.84	-0.35	3.74e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg20587970	chr11:113659929	NA	-1.18	-11.77	-0.54	5.7e-27	Height;
LUSC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg18827107	chr12:86230957	RASSF9	-0.47	-6.96	-0.36	1.8e-11	Major depressive disorder;
LUSC	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg06096015	chr1:231504339	EGLN1	0.56	9.95	0.48	1.36e-20	Hemoglobin concentration;
LUSC	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg05234568	chr11:5960015	NA	-0.57	-8.29	-0.41	2.76e-15	DNA methylation (variation);
LUSC	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg09307838	chr4:120376055	NA	0.75	10.89	0.51	7.5e-24	Corneal astigmatism;
LUSC	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.25	0.32	1.28e-9	Menopause (age at onset);
LUSC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.72	-12.8	-0.57	8.73e-31	Personality dimensions;
LUSC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08392591	chr16:89556376	ANKRD11	0.44	6.73	0.35	7.29e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs7586879	0.796	rs916484	chr2:25082588	A/C	cg01884057	chr2:25150051	NA	0.39	7.93	0.4	3.42e-14	Body mass index;
LUSC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.75	-0.51	2.37e-23	Alzheimer's disease (late onset);
LUSC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.51e-14	Prudent dietary pattern;
LUSC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	11.08	0.52	1.69e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-1.04	-20.3	-0.74	2.97e-60	Height;
LUSC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-19.79	-0.73	3.07e-58	Coronary artery disease;
LUSC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg17366294	chr4:99064904	C4orf37	0.55	9.78	0.47	4.99e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9820353	1	rs9820353	chr3:142299926	A/G	cg16271453	chr3:142027066	XRN1	-0.35	-5.91	-0.31	8.62e-9	Mean corpuscular volume;
LUSC	trans	rs3857536	0.813	rs1029400	chr6:66952385	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-5.99	-0.31	5.34e-9	Blood trace element (Cu levels);
LUSC	cis	rs56804039	0.895	rs11776995	chr8:8385547	A/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.19	-0.37	4.18e-12	Cervical cancer;
LUSC	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg25214090	chr10:38739885	LOC399744	0.54	8.05	0.4	1.44e-14	Corneal astigmatism;
LUSC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs4363385	0.818	rs1591736	chr1:152987497	A/C	cg25856811	chr1:152973957	SPRR3	-0.35	-5.75	-0.3	2e-8	Inflammatory skin disease;
LUSC	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg15556689	chr8:8085844	FLJ10661	0.56	8.58	0.42	3.52e-16	Retinal vascular caliber;
LUSC	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg18904891	chr8:8559673	CLDN23	0.59	7.67	0.39	1.92e-13	Obesity-related traits;
LUSC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg25036284	chr2:26402008	FAM59B	-0.67	-9.69	-0.47	1.02e-19	Gut microbiome composition (summer);
LUSC	cis	rs888194	0.587	rs6606711	chr12:109849297	A/G	cg19025524	chr12:109796872	NA	-0.36	-6.21	-0.32	1.6e-9	Neuroticism;
LUSC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg14092988	chr3:52407081	DNAH1	0.32	6.34	0.33	7.25e-10	Bipolar disorder;
LUSC	cis	rs2742234	0.590	rs2565201	chr10:43618484	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.45	-7.48	-0.38	6.74e-13	Hirschsprung disease;
LUSC	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg10765909	chr12:53715428	AAAS	0.41	5.96	0.31	6.24e-9	Platelet distribution width;
LUSC	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg07080220	chr10:102295463	HIF1AN	0.61	8.15	0.41	7.58e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.6	0.38	3.08e-13	Bipolar disorder;
LUSC	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg20628663	chr10:43360327	NA	0.76	11.26	0.52	3.79e-25	Blood protein levels;
LUSC	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.92	0.35	2.31e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.53	-7.84	-0.39	5.95e-14	Longevity;Endometriosis;
LUSC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06505273	chr16:24850292	NA	0.4	5.77	0.3	1.8e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12900413	0.687	rs35060998	chr15:90310294	A/G	cg24249390	chr15:90295951	MESP1	-0.37	-5.91	-0.31	8.6e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs6087771	0.651	rs6060775	chr20:30286191	A/G	cg13852791	chr20:30311386	BCL2L1	0.63	9.23	0.45	3.17e-18	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-1.24	-13.96	-0.61	3.38e-35	Diabetic kidney disease;
LUSC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08045932	chr20:61659980	NA	0.59	10.39	0.49	4.41e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg23093090	chr10:104574429	C10orf26	-0.38	-7.13	-0.36	6.2e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg27411982	chr8:10470053	RP1L1	-0.42	-6.62	-0.34	1.46e-10	Monocyte count;
LUSC	cis	rs9399401	0.667	rs6903424	chr6:142699948	A/C	cg03128060	chr6:142623767	GPR126	0.57	9.5	0.46	4.18e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg23625390	chr15:77176239	SCAPER	-0.64	-9.7	-0.47	8.97e-20	Blood metabolite levels;
LUSC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.71	-0.3	2.55e-8	Life satisfaction;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg06382786	chr17:57297815	GDPD1	0.37	6.18	0.32	1.87e-9	Educational attainment (years of education);
LUSC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.7	-10.7	-0.51	3.47e-23	Aortic root size;
LUSC	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg03859395	chr2:55845619	SMEK2	0.88	16.5	0.67	3.62e-45	Metabolic syndrome;
LUSC	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg27539214	chr16:67997921	SLC12A4	-0.6	-7.17	-0.37	4.72e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.51	0.46	3.95e-19	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19815055	chr5:36876667	NIPBL	-0.49	-7.23	-0.37	3.28e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg22638593	chr5:131593259	PDLIM4	0.48	7.3	0.37	2.06e-12	Acylcarnitine levels;
LUSC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.49	-7.93	-0.4	3.27e-14	Platelet count;
LUSC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg09034736	chr1:150693464	HORMAD1	0.43	5.93	0.31	7.46e-9	Melanoma;
LUSC	trans	rs9409565	0.826	rs4744338	chr9:97158965	C/T	cg05679027	chr9:99775184	HIATL2	0.46	6.81	0.35	4.6e-11	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs7577696	0.597	rs56322034	chr2:32353013	T/C	cg02381751	chr2:32503542	YIPF4	-0.52	-6.98	-0.36	1.63e-11	Inflammatory biomarkers;
LUSC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.81	7.68	0.39	1.79e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.18	-0.37	4.47e-12	Type 2 diabetes;
LUSC	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg24690094	chr11:67383802	NA	-0.44	-8.31	-0.41	2.5e-15	Mean corpuscular volume;
LUSC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.1	0.48	4.14e-21	Electroencephalogram traits;
LUSC	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.41	-8.26	-0.41	3.47e-15	Late-onset Alzheimer's disease;
LUSC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg12559939	chr2:27858050	GPN1	0.41	6.44	0.33	4.16e-10	Oral cavity cancer;
LUSC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15664640	chr17:80829946	TBCD	-0.46	-7.63	-0.39	2.51e-13	Breast cancer;
LUSC	trans	rs1874124	0.836	rs17596947	chr1:220993464	A/C	cg00338749	chr11:1036677	MUC6	-0.39	-6.23	-0.32	1.44e-9	Cholesterol, total;
LUSC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg17031739	chr1:67600172	NA	-0.48	-7.68	-0.39	1.8e-13	Psoriasis;
LUSC	cis	rs2235544	0.565	rs650134	chr1:54467342	T/C	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs72772090	0.539	rs11749811	chr5:96115925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-6.78	-0.35	5.49e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7188861	0.724	rs12924957	chr16:11403766	C/T	cg00044050	chr16:11439710	C16orf75	0.58	6.2	0.32	1.67e-9	HDL cholesterol;
LUSC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.47e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1982963	1.000	rs753051	chr14:52505360	A/G	cg10843707	chr14:52510701	NID2	-0.41	-6.6	-0.34	1.62e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg06386533	chr2:46925753	SOCS5	0.52	6.75	0.35	6.57e-11	Height;
LUSC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg25344623	chr2:136566232	LCT	0.38	5.73	0.3	2.27e-8	Mosquito bite size;
LUSC	cis	rs367615	0.513	rs11741087	chr5:108807760	G/A	cg17395555	chr5:108820864	NA	0.62	11.28	0.53	3.27e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs45535039	0.506	rs2511856	chr11:119144148	A/C	cg23558831	chr11:118978103	C2CD2L	-0.41	-5.96	-0.31	6.38e-9	Plateletcrit;
LUSC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg24209194	chr3:40518798	ZNF619	0.45	6.06	0.31	3.69e-9	Renal cell carcinoma;
LUSC	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg21770322	chr7:97807741	LMTK2	0.47	8.0	0.4	2.04e-14	Breast cancer;
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg05064044	chr6:292385	DUSP22	-0.71	-11.55	-0.53	3.53e-26	Menopause (age at onset);
LUSC	cis	rs9462027	0.628	rs2814968	chr6:34713138	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.87	-0.31	1.02e-8	Systemic lupus erythematosus;
LUSC	cis	rs7605827	0.930	rs1990753	chr2:15612403	G/C	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg16606324	chr3:10149918	C3orf24	0.64	9.39	0.46	9.87e-19	Alzheimer's disease;
LUSC	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg05985134	chr18:33552581	C18orf21	0.5	6.73	0.35	7.22e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs2692947	0.711	rs56791141	chr2:96587496	C/T	cg22654517	chr2:96458247	NA	0.38	7.64	0.39	2.39e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	ch.11.42038R	chr11:967971	AP2A2	0.54	7.86	0.4	5.22e-14	Alzheimer's disease (late onset);
LUSC	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	6.91	0.35	2.39e-11	Lung cancer in ever smokers;
LUSC	cis	rs1775715	0.870	rs11008700	chr10:32236937	A/G	cg18675610	chr10:32216311	ARHGAP12	0.28	5.86	0.31	1.11e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg12963246	chr6:28129442	ZNF389	0.41	6.45	0.33	3.99e-10	Parkinson's disease;
LUSC	cis	rs977987	0.843	rs11641801	chr16:75455448	A/C	cg03315344	chr16:75512273	CHST6	0.49	9.24	0.45	2.9e-18	Dupuytren's disease;
LUSC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg06740227	chr12:86229804	RASSF9	0.44	7.05	0.36	1.01e-11	Major depressive disorder;
LUSC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg12463550	chr7:65579703	CRCP	0.56	8.33	0.41	2.17e-15	Aortic root size;
LUSC	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs983392	0.792	rs1303615	chr11:59885120	C/T	cg24026212	chr11:59952134	MS4A6A	-0.31	-5.8	-0.3	1.52e-8	Alzheimer's disease (late onset);
LUSC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg19318889	chr4:1322082	MAEA	0.47	7.52	0.38	4.99e-13	Obesity-related traits;
LUSC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.39	-0.42	1.43e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs2236293	0.754	rs10814276	chr9:35794913	T/A	cg11239633	chr3:37903682	CTDSPL	-0.36	-6.54	-0.34	2.34e-10	Blood protein levels;
LUSC	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.33	-17.68	-0.7	7.86e-50	Hip circumference adjusted for BMI;
LUSC	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg00074818	chr8:8560427	CLDN23	0.58	9.85	0.47	2.86e-20	Obesity-related traits;
LUSC	trans	rs72792513	1.000	rs7590019	chr2:22920470	A/G	cg05844895	chr16:88969569	CBFA2T3	0.5	6.2	0.32	1.69e-9	Hepatitis B;
LUSC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.83	0.3	1.3e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs926938	0.527	rs360580	chr1:115462334	A/G	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.44	-0.33	4.23e-10	Autism;
LUSC	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs2235649	0.798	rs9922462	chr16:1848011	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-5.97	-0.31	6.02e-9	Blood metabolite levels;
LUSC	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg15848620	chr12:58087721	OS9	-0.52	-7.56	-0.38	3.89e-13	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg03929089	chr4:120376271	NA	-0.94	-16.5	-0.67	3.92e-45	Height;
LUSC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg05347473	chr6:146136440	FBXO30	0.56	9.84	0.47	3.11e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.75	10.82	0.51	1.32e-23	Corneal astigmatism;
LUSC	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg17075019	chr10:79541650	NA	-0.78	-12.37	-0.56	3.35e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.64	-0.39	2.39e-13	Retinal vascular caliber;
LUSC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02018176	chr4:1364513	KIAA1530	0.74	13.47	0.59	2.59e-33	Longevity;
LUSC	trans	rs804280	1.000	rs804281	chr8:11611865	A/G	cg27411982	chr8:10470053	RP1L1	0.45	6.68	0.34	9.8e-11	Myopia (pathological);
LUSC	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-0.9	-12.91	-0.58	3.16e-31	Blood pressure (smoking interaction);
LUSC	cis	rs2224391	0.911	rs6925249	chr6:5262510	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.47	-6.72	-0.35	7.76e-11	Height;
LUSC	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg08355456	chr11:67383691	NA	0.38	7.08	0.36	8.31e-12	Mean corpuscular volume;
LUSC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg03806693	chr22:41940476	POLR3H	-1.03	-13.9	-0.61	5.73e-35	Vitiligo;
LUSC	cis	rs7523273	0.606	rs2724391	chr1:207953244	T/C	cg22525895	chr1:207977042	MIR29B2	0.43	6.92	0.35	2.28e-11	Schizophrenia;
LUSC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg26354017	chr1:205819088	PM20D1	-0.47	-7.23	-0.37	3.34e-12	Menarche (age at onset);
LUSC	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.14	-0.45	6.2e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs977987	0.806	rs12933281	chr16:75483064	T/G	cg03315344	chr16:75512273	CHST6	0.48	9.36	0.46	1.2e-18	Dupuytren's disease;
LUSC	cis	rs240764	0.817	rs239189	chr6:101128787	C/T	cg09795085	chr6:101329169	ASCC3	0.42	6.11	0.32	2.83e-9	Neuroticism;
LUSC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg15556689	chr8:8085844	FLJ10661	0.68	10.48	0.5	2.13e-22	Mood instability;
LUSC	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg17143192	chr8:8559678	CLDN23	0.64	9.14	0.45	6.38e-18	Obesity-related traits;
LUSC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-7.4	-0.38	1.1e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2273669	0.504	rs1539596	chr6:109408428	C/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.8	-0.3	1.57e-8	Prostate cancer;
LUSC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg12365402	chr11:9010492	NRIP3	-0.51	-9.81	-0.47	4.04e-20	Hemoglobin concentration;
LUSC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.81	11.76	0.54	5.83e-27	Breast cancer;
LUSC	cis	rs6545883	0.929	rs2252662	chr2:61670731	T/C	cg15711740	chr2:61764176	XPO1	-0.45	-6.84	-0.35	3.69e-11	Tuberculosis;
LUSC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-14.85	-0.63	1.22e-38	Total body bone mineral density;
LUSC	cis	rs11610422	1.000	rs34325065	chr12:31414505	C/G	cg14306366	chr12:31406441	NA	-0.55	-6.6	-0.34	1.58e-10	Coronary artery disease;
LUSC	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg21153622	chr11:89784906	NA	-0.44	-6.85	-0.35	3.55e-11	Coronary artery disease;
LUSC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg11344533	chr11:111475393	SIK2	0.46	6.25	0.32	1.25e-9	Primary sclerosing cholangitis;
LUSC	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	8.76	0.43	9.74e-17	Exhaled nitric oxide output;
LUSC	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	5.9	0.31	8.74e-9	Schizophrenia;
LUSC	trans	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.41	-0.33	5.01e-10	Bladder cancer;
LUSC	cis	rs1443512	0.588	rs3759162	chr12:54331154	G/C	cg17410650	chr12:54324560	NA	-0.43	-5.79	-0.3	1.61e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.82	-0.3	1.42e-8	Ulcerative colitis;
LUSC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg12963246	chr6:28129442	ZNF389	0.43	6.04	0.31	4.16e-9	Depression;
LUSC	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg14458575	chr2:238380390	NA	0.67	11.78	0.54	5.17e-27	Prostate cancer;
LUSC	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg25801113	chr15:45476975	SHF	0.36	7.32	0.37	1.82e-12	Uric acid levels;
LUSC	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.72	-0.47	7.9e-20	Coronary artery disease;
LUSC	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg26384229	chr12:38710491	ALG10B	0.9	15.67	0.65	7.43e-42	Bladder cancer;
LUSC	trans	rs12210905	0.925	rs115507154	chr6:26970811	C/A	cg11837749	chr1:55047332	ACOT11	0.57	6.09	0.32	3.07e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg10130564	chr11:117069849	TAGLN	0.31	6.0	0.31	5.07e-9	Blood protein levels;
LUSC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg03579872	chr1:53393473	SCP2	-0.39	-5.87	-0.31	1.05e-8	Monocyte count;
LUSC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg09655341	chr17:79618100	PDE6G	-0.29	-6.88	-0.35	3.01e-11	Eye color traits;
LUSC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg12311346	chr5:56204834	C5orf35	0.57	7.93	0.4	3.32e-14	Coronary artery disease;
LUSC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.49	-7.87	-0.4	4.85e-14	Melanoma;
LUSC	cis	rs12410462	0.581	rs111356515	chr1:227537236	C/G	cg23173402	chr1:227635558	NA	0.56	6.52	0.34	2.52e-10	Major depressive disorder;
LUSC	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg21100191	chr22:23484243	RTDR1	0.9	15.38	0.64	9.59e-41	Bone mineral density;
LUSC	cis	rs887829	0.641	rs10179094	chr2:234597825	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-6.72	-0.34	8.08e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg22601191	chr20:60968625	CABLES2	0.4	6.73	0.35	7.57e-11	Colorectal cancer;
LUSC	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg25427524	chr10:38739819	LOC399744	-0.52	-6.38	-0.33	5.9e-10	Obesity (extreme);
LUSC	cis	rs243505	0.762	rs734002	chr7:148505788	A/G	cg09806900	chr7:148480153	CUL1	0.55	8.08	0.4	1.16e-14	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.55	-10.71	-0.51	3.22e-23	Birth weight;
LUSC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg04369109	chr6:150039330	LATS1	-0.53	-7.93	-0.4	3.27e-14	Lung cancer;
LUSC	cis	rs12760731	0.720	rs2175254	chr1:178319105	G/A	cg00404053	chr1:178313656	RASAL2	0.61	6.31	0.33	8.63e-10	Obesity-related traits;
LUSC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg11764359	chr7:65958608	NA	0.8	12.76	0.57	1.17e-30	Aortic root size;
LUSC	cis	rs10186029	0.539	rs4672676	chr2:214001948	C/T	cg08319019	chr2:214017104	IKZF2	0.49	7.51	0.38	5.55e-13	Systemic sclerosis;
LUSC	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.3	-0.45	1.87e-18	Schizophrenia;
LUSC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg20701182	chr2:24300061	SF3B14	-0.88	-11.39	-0.53	1.34e-25	Lymphocyte counts;
LUSC	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.38	6.71	0.34	8.4e-11	Primary biliary cholangitis;
LUSC	cis	rs4664304	0.770	rs55860731	chr2:160875437	C/T	cg23995753	chr2:160760732	LY75	-0.34	-6.38	-0.33	5.9e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs11229555	0.874	rs10896788	chr11:58292976	G/A	cg15696309	chr11:58395628	NA	-0.7	-8.83	-0.43	6.16e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg02113368	chr10:135107346	TUBGCP2	-0.34	-6.0	-0.31	5.05e-9	Dementia with Lewy bodies;
LUSC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.22	-0.32	1.48e-9	Response to antipsychotic treatment;
LUSC	cis	rs80130819	0.515	rs1793956	chr12:48392914	C/G	cg05342945	chr12:48394962	COL2A1	-0.43	-5.72	-0.3	2.36e-8	Prostate cancer;
LUSC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24110177	chr3:50126178	RBM5	-0.61	-10.39	-0.49	4.29e-22	Body mass index;
LUSC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.4	1.97e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg22340644	chr7:75368344	HIP1	-0.52	-6.66	-0.34	1.14e-10	Neuroticism;
LUSC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg08270630	chr22:50330655	NA	-0.44	-6.71	-0.34	8.57e-11	Schizophrenia;
LUSC	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg00701064	chr4:6280414	WFS1	0.48	10.36	0.49	5.58e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.45	-7.68	-0.39	1.77e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg13395646	chr4:1353034	KIAA1530	-0.63	-10.15	-0.49	2.93e-21	Obesity-related traits;
LUSC	cis	rs11608355	0.515	rs61941631	chr12:109935475	C/T	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg08680598	chr22:49984980	NA	-0.33	-6.09	-0.32	3.16e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7336332	0.598	rs12018313	chr13:28012266	C/A	cg22138327	chr13:27999177	GTF3A	0.8	9.82	0.47	3.7e-20	Weight;
LUSC	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg05855489	chr10:104503620	C10orf26	0.64	9.06	0.44	1.15e-17	Arsenic metabolism;
LUSC	cis	rs4622329	0.636	rs7974969	chr12:102288423	A/G	cg23541617	chr12:102225335	GNPTAB	0.27	6.2	0.32	1.62e-9	Systemic lupus erythematosus;
LUSC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs6828577	0.862	rs298983	chr4:119604802	C/T	cg26518628	chr1:97050305	NA	0.41	6.03	0.31	4.37e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
LUSC	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg10523860	chr14:103875565	MARK3	0.39	6.4	0.33	5.11e-10	Body mass index;
LUSC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg00933542	chr6:150070202	PCMT1	0.33	6.84	0.35	3.82e-11	Lung cancer;
LUSC	cis	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05901451	chr6:126070800	HEY2	0.57	8.51	0.42	5.97e-16	Endometrial cancer;
LUSC	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.76	-13.99	-0.61	2.46e-35	Dental caries;
LUSC	trans	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	10.09	0.48	4.36e-21	Mean corpuscular volume;
LUSC	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg17173187	chr15:85201210	NMB	0.41	8.02	0.4	1.81e-14	Schizophrenia;
LUSC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.16	-0.36	5.16e-12	Platelet count;
LUSC	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg23711669	chr6:146136114	FBXO30	0.88	16.26	0.66	3.3e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.69	10.62	0.5	7.09e-23	Lymphocyte counts;
LUSC	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg03929089	chr4:120376271	NA	0.72	6.77	0.35	5.71e-11	Axial length;
LUSC	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.53	10.0	0.48	9.15e-21	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.2	-0.37	4.02e-12	Bipolar disorder;
LUSC	cis	rs4947962	0.585	rs759170	chr7:55155372	C/T	cg23757825	chr7:55092271	EGFR	-0.46	-5.66	-0.3	3.21e-8	Subjective response to lithium treatment;
LUSC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg22800045	chr5:56110881	MAP3K1	-0.63	-8.77	-0.43	9.14e-17	Initial pursuit acceleration;
LUSC	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.71	-0.3	2.47e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25020728	chr12:123011538	RSRC2;KNTC1	-0.4	-6.02	-0.31	4.53e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	7.63	0.39	2.52e-13	Coffee consumption (cups per day);
LUSC	cis	rs2658782	0.704	rs2605614	chr11:93232745	A/G	cg15737290	chr11:93063684	CCDC67	0.63	8.12	0.41	9.26e-15	Pulmonary function decline;
LUSC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg00343986	chr7:65444356	GUSB	0.46	6.63	0.34	1.39e-10	Aortic root size;
LUSC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.32	0.37	1.82e-12	Motion sickness;
LUSC	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg05985134	chr18:33552581	C18orf21	0.51	6.92	0.35	2.35e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg06636001	chr8:8085503	FLJ10661	0.49	7.16	0.36	5.1e-12	Neuroticism;
LUSC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	15.41	0.64	7.74e-41	Total body bone mineral density;
LUSC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.74	-13.37	-0.59	6.01e-33	Diastolic blood pressure;
LUSC	trans	rs12709013	0.636	rs1646268	chr16:58777196	A/G	cg19313373	chr1:162694184	DDR2	-0.35	-6.01	-0.31	4.91e-9	Blood metabolite ratios;
LUSC	cis	rs9811920	0.809	rs6806323	chr3:99722564	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.71	-0.34	8.18e-11	Axial length;
LUSC	cis	rs548181	0.604	rs11608103	chr11:125627917	G/A	cg03464685	chr11:125439445	EI24	-0.9	-10.92	-0.51	6.21e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.48	10.06	0.48	5.83e-21	Schizophrenia;
LUSC	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.41	-6.02	-0.31	4.47e-9	IgG glycosylation;
LUSC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg27144592	chr16:783916	NARFL	0.37	5.66	0.3	3.34e-8	Height;
LUSC	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg18904891	chr8:8559673	CLDN23	-0.39	-5.69	-0.3	2.77e-8	Mood instability;
LUSC	cis	rs1784581	1.000	rs1784582	chr6:162400712	A/G	cg17173639	chr6:162384350	PARK2	-0.81	-14.8	-0.63	1.77e-38	Itch intensity from mosquito bite;
LUSC	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg18825076	chr15:78729989	IREB2	-0.45	-6.24	-0.32	1.3e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg15534755	chr11:117069859	TAGLN	0.33	5.79	0.3	1.66e-8	Blood protein levels;
LUSC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg15145296	chr3:125709740	NA	-0.58	-6.57	-0.34	1.95e-10	Blood pressure (smoking interaction);
LUSC	cis	rs1983891	0.955	rs7753653	chr6:41548430	C/T	cg15051332	chr6:41514432	FOXP4	-0.39	-5.77	-0.3	1.84e-8	Prostate cancer;
LUSC	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg24692254	chr21:30365293	RNF160	-0.53	-8.01	-0.4	1.92e-14	Dental caries;
LUSC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg24209194	chr3:40518798	ZNF619	0.47	6.51	0.34	2.72e-10	Renal cell carcinoma;
LUSC	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.6	13.76	0.6	1.92e-34	Height;
LUSC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	5.67	0.3	3.1e-8	Schizophrenia;
LUSC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg22823121	chr1:150693482	HORMAD1	0.59	9.09	0.45	8.83e-18	Melanoma;
LUSC	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg27411982	chr8:10470053	RP1L1	-0.51	-8.08	-0.4	1.22e-14	Neuroticism;
LUSC	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg24069376	chr3:38537580	EXOG	-0.48	-10.23	-0.49	1.5e-21	Electrocardiographic conduction measures;
LUSC	cis	rs1322512	0.754	rs1405691	chr6:152936650	C/T	cg27316956	chr6:152958899	SYNE1	0.34	5.75	0.3	1.99e-8	Tonometry;
LUSC	cis	rs9309473	0.607	rs6546826	chr2:73599808	A/G	cg20560298	chr2:73613845	ALMS1	0.58	8.58	0.42	3.67e-16	Metabolite levels;
LUSC	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg00579200	chr11:133705235	NA	-0.38	-5.93	-0.31	7.44e-9	Childhood ear infection;
LUSC	cis	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg21775007	chr8:11205619	TDH	-0.44	-6.15	-0.32	2.27e-9	Monocyte count;
LUSC	cis	rs7674212	0.570	rs6841136	chr4:104103509	A/C	cg16532752	chr4:104119610	CENPE	-0.46	-7.05	-0.36	1.01e-11	Type 2 diabetes;
LUSC	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg05472934	chr7:22766657	IL6	0.5	7.84	0.39	6.13e-14	Lung cancer;
LUSC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19346786	chr7:2764209	NA	-0.51	-8.72	-0.43	1.29e-16	Height;
LUSC	cis	rs4478858	0.735	rs12408524	chr1:31835853	A/G	cg00250761	chr1:31883323	NA	-0.37	-8.85	-0.44	5.18e-17	Alcohol dependence;
LUSC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg21770322	chr7:97807741	LMTK2	-0.41	-7.2	-0.37	3.99e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.74	10.45	0.5	2.69e-22	Corneal astigmatism;
LUSC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.76	0.35	5.99e-11	Menopause (age at onset);
LUSC	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg06784218	chr1:46089804	CCDC17	0.34	5.85	0.3	1.16e-8	Platelet count;
LUSC	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.62	10.47	0.5	2.21e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg06637938	chr14:75390232	RPS6KL1	0.85	15.56	0.65	1.94e-41	Caffeine consumption;
LUSC	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg05855489	chr10:104503620	C10orf26	0.58	9.29	0.45	2.07e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7582720	1.000	rs72926781	chr2:203808835	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg26384229	chr12:38710491	ALG10B	0.59	9.16	0.45	5.44e-18	Morning vs. evening chronotype;
LUSC	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.33e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg22705602	chr4:152727874	NA	-0.32	-6.55	-0.34	2.19e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg12963246	chr6:28129442	ZNF389	0.49	7.19	0.37	4.21e-12	Parkinson's disease;
LUSC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21659725	chr3:3221576	CRBN	0.64	10.45	0.5	2.61e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg06808227	chr14:105710500	BRF1	-0.68	-10.71	-0.51	3.34e-23	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.63	-11.31	-0.53	2.53e-25	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg23985595	chr17:80112537	CCDC57	-0.3	-5.91	-0.31	8.55e-9	Life satisfaction;
LUSC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-9.11	-0.45	7.82e-18	Bipolar disorder;
LUSC	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg23422044	chr7:1970798	MAD1L1	-0.53	-6.39	-0.33	5.65e-10	Bipolar disorder;
LUSC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.77	-11.95	-0.55	1.19e-27	Tonsillectomy;
LUSC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	13.26	0.59	1.6e-32	Monocyte percentage of white cells;
LUSC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg22166914	chr1:53195759	ZYG11B	0.57	9.31	0.45	1.81e-18	Monocyte count;
LUSC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg18681998	chr4:17616180	MED28	0.89	16.64	0.67	1.07e-45	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg03289416	chr15:75166202	SCAMP2	0.45	7.06	0.36	9.73e-12	Breast cancer;
LUSC	cis	rs9905704	0.918	rs186221	chr17:56695967	C/T	cg12560992	chr17:57184187	TRIM37	0.55	7.87	0.4	5.02e-14	Testicular germ cell tumor;
LUSC	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg20503657	chr10:835505	NA	0.78	9.42	0.46	7.61e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-6.31	-0.33	8.83e-10	Vitiligo;
LUSC	cis	rs7149337	0.836	rs11622116	chr14:51670744	C/T	cg23942311	chr14:51606299	NA	0.48	10.53	0.5	1.39e-22	Cancer;
LUSC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg03146154	chr1:46216737	IPP	0.54	8.33	0.41	2.08e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18876405	chr7:65276391	NA	-0.54	-8.52	-0.42	5.68e-16	Aortic root size;
LUSC	cis	rs1595825	0.891	rs892512	chr2:198905910	C/A	cg00982548	chr2:198649783	BOLL	-0.52	-6.86	-0.35	3.4e-11	Ulcerative colitis;
LUSC	cis	rs9796	0.866	rs2928148	chr15:41401550	G/A	cg18705301	chr15:41695430	NDUFAF1	0.46	8.04	0.4	1.55e-14	Menopause (age at onset);
LUSC	trans	rs724744	0.772	rs1772081	chr6:22354351	G/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.19	-0.32	1.77e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg05729581	chr11:3078854	CARS	0.39	5.7	0.3	2.57e-8	Calcium levels;
LUSC	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.79	-13.21	-0.59	2.49e-32	Platelet distribution width;
LUSC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg16339924	chr4:17578868	LAP3	0.48	7.45	0.38	8.14e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.59	0.6	8.31e-34	Platelet count;
LUSC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	6.14	0.32	2.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs11039100	0.527	rs11038945	chr11:5779431	A/G	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg25214090	chr10:38739885	LOC399744	0.42	6.1	0.32	2.97e-9	Corneal astigmatism;
LUSC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06221963	chr1:154839813	KCNN3	-0.6	-13.52	-0.59	1.57e-33	Prostate cancer;
LUSC	cis	rs6489882	0.867	rs7304898	chr12:113365667	T/C	cg20102336	chr12:113376681	OAS3	-0.42	-5.94	-0.31	7.04e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.98	-0.36	1.58e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.9	-13.37	-0.59	6.19e-33	Initial pursuit acceleration;
LUSC	trans	rs8023715	1.000	rs28674917	chr15:97612127	G/A	cg09939392	chr16:90068365	NA	0.51	5.97	0.31	6.22e-9	Systemic lupus erythematosus;
LUSC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg15383120	chr6:291909	DUSP22	-0.43	-6.37	-0.33	6.11e-10	Menopause (age at onset);
LUSC	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg13010199	chr12:38710504	ALG10B	0.7	10.86	0.51	9.62e-24	Bladder cancer;
LUSC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.3	-0.41	2.54e-15	Platelet count;
LUSC	cis	rs654950	0.875	rs4660544	chr1:41996871	T/C	cg06885757	chr1:42089581	HIVEP3	-0.34	-6.54	-0.34	2.26e-10	Airway imaging phenotypes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22456539	chr1:11741693	MAD2L2	-0.44	-6.49	-0.33	3.02e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg18187862	chr3:45730750	SACM1L	-0.51	-6.17	-0.32	1.99e-9	Primary sclerosing cholangitis;
LUSC	cis	rs12286929	0.590	rs4936322	chr11:115061533	T/C	cg04055981	chr11:115044050	NA	0.45	7.91	0.4	3.93e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.32	0.64	1.71e-40	Morning vs. evening chronotype;
LUSC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg20276088	chr3:133502917	NA	-0.44	-6.49	-0.33	3.12e-10	Iron status biomarkers;
LUSC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	6.3	0.33	9.39e-10	Electroencephalogram traits;
LUSC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg16797656	chr11:68205561	LRP5	0.38	6.27	0.32	1.09e-9	Total body bone mineral density;
LUSC	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg10167463	chr7:75959203	YWHAG	-0.64	-9.63	-0.47	1.58e-19	Multiple sclerosis;
LUSC	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg01973587	chr1:228161476	NA	-0.35	-5.66	-0.3	3.34e-8	Diastolic blood pressure;
LUSC	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg15556689	chr8:8085844	FLJ10661	0.56	8.88	0.44	4.12e-17	Retinal vascular caliber;
LUSC	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs6554196	0.508	rs981959	chr4:55526962	G/T	cg18836493	chr4:55524333	KIT	-0.44	-7.47	-0.38	7.08e-13	Monocyte count;
LUSC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03934478	chr11:495069	RNH1	0.86	10.29	0.49	9.41e-22	Body mass index;
LUSC	trans	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg06606381	chr12:133084897	FBRSL1	-0.66	-6.94	-0.36	2.05e-11	Depression;
LUSC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg24130564	chr14:104152367	KLC1	-0.43	-6.11	-0.32	2.71e-9	Body mass index;
LUSC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg19318889	chr4:1322082	MAEA	0.59	10.36	0.49	5.24e-22	Longevity;
LUSC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.61	0.57	4.22e-30	Prudent dietary pattern;
LUSC	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.73	-10.9	-0.51	7.15e-24	Alcohol dependence;
LUSC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg04025307	chr7:1156635	C7orf50	0.42	5.87	0.31	1.06e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg15556689	chr8:8085844	FLJ10661	0.48	7.05	0.36	1.06e-11	Retinal vascular caliber;
LUSC	trans	rs3824451	0.945	rs7869364	chr9:101065212	G/T	cg02729030	chr7:110879415	IMMP2L	-0.47	-6.64	-0.34	1.3e-10	Schizophrenia;
LUSC	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg09754948	chr16:28834200	ATXN2L	0.43	6.35	0.33	7.17e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg21361702	chr7:150065534	REPIN1	0.52	6.68	0.34	1.03e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg18225595	chr11:63971243	STIP1	0.51	6.31	0.33	8.81e-10	Mean platelet volume;
LUSC	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-1.25	-20.35	-0.74	1.98e-60	Blood pressure (smoking interaction);
LUSC	cis	rs662064	0.962	rs585870	chr1:10549628	G/T	cg20482658	chr1:10539492	PEX14	-0.32	-6.64	-0.34	1.29e-10	Asthma;
LUSC	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.92	-0.4	3.45e-14	Triglycerides;
LUSC	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.77	-0.39	9.67e-14	Glomerular filtration rate;
LUSC	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg08000102	chr2:233561755	GIGYF2	-0.67	-10.96	-0.51	4.38e-24	Coronary artery disease;
LUSC	cis	rs7771547	0.519	rs9654588	chr6:36363923	A/C	cg07856975	chr6:36356162	ETV7	0.43	6.17	0.32	1.93e-9	Platelet distribution width;
LUSC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.17	0.55	1.94e-28	Prudent dietary pattern;
LUSC	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg22782873	chr19:19639568	YJEFN3	-0.48	-6.1	-0.32	2.86e-9	Bipolar disorder;
LUSC	cis	rs2729354	0.768	rs2581922	chr11:57265400	C/T	cg24343310	chr11:57249947	NA	0.38	7.3	0.37	2.16e-12	Blood protein levels;
LUSC	cis	rs16937	0.711	rs11240385	chr1:205173101	A/G	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.36e-10	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	0.56	8.97	0.44	2.2e-17	Breast cancer;
LUSC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	9.3	0.45	1.94e-18	Mean platelet volume;
LUSC	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg22467129	chr15:76604101	ETFA	-0.43	-6.9	-0.35	2.69e-11	Blood metabolite levels;
LUSC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg23711669	chr6:146136114	FBXO30	-0.83	-14.87	-0.63	9.93e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg26587870	chr6:27730563	NA	-0.66	-6.01	-0.31	4.92e-9	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs73206853	0.841	rs111612251	chr12:111017607	T/C	cg12870014	chr12:110450643	ANKRD13A	0.69	7.57	0.38	3.57e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs11088226	0.541	rs75873023	chr21:33910658	G/A	cg09050820	chr6:167586206	TCP10L2	0.43	5.99	0.31	5.45e-9	Gastritis;
LUSC	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.84	0.39	5.98e-14	Neuroticism;
LUSC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	10.36	0.49	5.54e-22	Hemoglobin concentration;
LUSC	cis	rs983392	0.868	rs7926954	chr11:59932579	G/A	cg20284999	chr11:59952153	MS4A6A	-0.37	-5.98	-0.31	5.8e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6489882	0.836	rs6489878	chr12:113368125	A/G	cg20102336	chr12:113376681	OAS3	-0.4	-5.74	-0.3	2.17e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg20307385	chr11:47447363	PSMC3	0.46	6.72	0.34	8.08e-11	Subjective well-being;
LUSC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg02475777	chr4:1388615	CRIPAK	0.44	6.62	0.34	1.42e-10	Obesity-related traits;
LUSC	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.73	12.04	0.55	5.8e-28	Alcohol dependence;
LUSC	cis	rs113835537	0.935	rs15969	chr11:66394387	C/T	cg24851651	chr11:66362959	CCS	0.53	6.55	0.34	2.14e-10	Airway imaging phenotypes;
LUSC	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg26195577	chr20:24973756	C20orf3	-1.12	-18.25	-0.71	4.21e-52	Blood protein levels;
LUSC	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg13628971	chr7:2884303	GNA12	0.39	5.68	0.3	2.94e-8	Height;
LUSC	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg02493740	chr2:85810744	VAMP5	-0.49	-8.43	-0.42	1.04e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg18357526	chr6:26021779	HIST1H4A	0.37	5.67	0.3	3.04e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg13685833	chr1:53393034	SCP2	0.45	6.63	0.34	1.38e-10	Monocyte count;
LUSC	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.56	-0.34	2.07e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg20243544	chr17:37824526	PNMT	0.38	5.72	0.3	2.42e-8	Self-reported allergy;
LUSC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-6.36	-0.33	6.75e-10	Colorectal cancer;
LUSC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg17279839	chr7:150038598	RARRES2	0.48	7.64	0.39	2.35e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11051970	0.636	rs10844198	chr12:32563479	G/T	cg02745156	chr12:32552066	NA	0.37	6.82	0.35	4.3e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9811920	0.625	rs9290003	chr3:99906993	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.34	6.35	0.33	7.07e-10	Axial length;
LUSC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-7.82	-0.39	7.05e-14	Colorectal cancer;
LUSC	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.71	-11.17	-0.52	7.69e-25	Alcohol dependence;
LUSC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-0.82	-15.16	-0.64	7.45e-40	Height;
LUSC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.58	10.73	0.51	2.73e-23	Bone mineral density;
LUSC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg08999081	chr20:33150536	PIGU	0.43	7.95	0.4	2.96e-14	Coronary artery disease;
LUSC	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg20628663	chr10:43360327	NA	-0.75	-11.33	-0.53	2.21e-25	Blood protein levels;
LUSC	cis	rs7106204	1.000	rs7925633	chr11:24214815	A/G	ch.11.24196551F	chr11:24239977	NA	0.99	9.81	0.47	4.07e-20	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7605827	0.836	rs13009246	chr2:15640237	A/G	cg19274914	chr2:15703543	NA	0.46	8.79	0.43	8.17e-17	Educational attainment (years of education);
LUSC	cis	rs6546550	0.901	rs897119	chr2:70160658	T/C	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.22e-12	Prevalent atrial fibrillation;
LUSC	cis	rs7523050	0.643	rs34920128	chr1:109400889	C/T	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	cis	rs9879311	0.966	rs4684685	chr3:10411553	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.48	8.03	0.4	1.66e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6722750	0.716	rs2422116	chr2:64420236	C/T	cg22352474	chr2:64371530	PELI1	-0.54	-8.05	-0.4	1.43e-14	Neuroticism;
LUSC	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg24596788	chr1:163392923	NA	0.45	7.59	0.38	3.24e-13	Motion sickness;
LUSC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.91	-0.35	2.41e-11	Lung cancer;
LUSC	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.7	-0.47	9.21e-20	Coronary artery disease;
LUSC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.88	0.48	2.23e-20	Mean corpuscular volume;
LUSC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg23711669	chr6:146136114	FBXO30	0.72	12.38	0.56	3.21e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.43	-6.82	-0.35	4.23e-11	Height;
LUSC	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg17366294	chr4:99064904	C4orf37	0.52	9.14	0.45	6.41e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg03806693	chr22:41940476	POLR3H	0.99	14.23	0.61	3.13e-36	Vitiligo;
LUSC	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg21775007	chr8:11205619	TDH	0.45	6.37	0.33	6.18e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg15704280	chr7:45808275	SEPT13	0.75	8.53	0.42	5.3e-16	Axial length;
LUSC	cis	rs73129298	0.551	rs1063210	chr20:48600809	G/A	cg25655593	chr20:48599521	SNAI1	0.6	6.43	0.33	4.49e-10	Inflammatory skin disease;
LUSC	cis	rs34779708	0.966	rs11010135	chr10:35518063	A/G	cg04310649	chr10:35416472	CREM	-0.4	-6.14	-0.32	2.37e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7336332	0.800	rs9805452	chr13:28047908	C/T	cg22138327	chr13:27999177	GTF3A	0.68	9.27	0.45	2.35e-18	Weight;
LUSC	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg02527881	chr3:46936655	PTH1R	0.41	7.16	0.36	5.19e-12	Colorectal cancer;
LUSC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	6.38	0.33	6.05e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg03146154	chr1:46216737	IPP	0.55	8.24	0.41	3.98e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7712401	0.601	rs454617	chr5:122321927	A/C	cg19077854	chr5:122220652	SNX24	-0.43	-9.48	-0.46	4.83e-19	Mean platelet volume;
LUSC	cis	rs16895831	0.531	rs56302029	chr6:42522409	T/G	cg10605015	chr6:42532144	UBR2	-0.52	-6.27	-0.32	1.11e-9	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg25204440	chr1:209979598	IRF6	0.53	7.08	0.36	8.6e-12	Cleft lip with or without cleft palate;
LUSC	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.89	-0.44	3.9e-17	Systolic blood pressure;
LUSC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg03188948	chr7:1209495	NA	0.66	6.91	0.35	2.44e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs977987	0.806	rs2865530	chr16:75414376	G/T	cg03315344	chr16:75512273	CHST6	0.49	9.25	0.45	2.65e-18	Dupuytren's disease;
LUSC	cis	rs9815354	0.812	rs73071330	chr3:41810553	T/G	cg03022575	chr3:42003672	ULK4	0.85	8.65	0.43	2.27e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs708547	0.647	rs4864609	chr4:57878141	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	7.64	0.39	2.31e-13	Response to bleomycin (chromatid breaks);
LUSC	trans	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg08975724	chr8:8085496	FLJ10661	0.48	6.86	0.35	3.42e-11	Retinal vascular caliber;
LUSC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.04	15.13	0.64	9.12e-40	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	5.86	0.31	1.13e-8	Rheumatoid arthritis;
LUSC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	0.94	13.86	0.6	8.14e-35	Vitiligo;
LUSC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg24675658	chr1:53192096	ZYG11B	-0.64	-9.92	-0.48	1.65e-20	Monocyte count;
LUSC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	8.34	0.41	2.04e-15	Bipolar disorder;
LUSC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.15	-0.41	7.46e-15	Lymphocyte counts;
LUSC	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg09184832	chr6:79620586	NA	-0.45	-7.28	-0.37	2.44e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg19774624	chr17:42201019	HDAC5	0.8	12.66	0.57	2.76e-30	Total body bone mineral density;
LUSC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg24209194	chr3:40518798	ZNF619	0.43	5.85	0.3	1.16e-8	Renal cell carcinoma;
LUSC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg04155289	chr7:94953770	PON1	-0.36	-5.95	-0.31	6.86e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg02508848	chr16:68573721	ZFP90	-0.42	-5.75	-0.3	2.07e-8	Ulcerative colitis;
LUSC	cis	rs2625529	0.556	rs55679065	chr15:72433395	C/T	cg16672083	chr15:72433130	SENP8	0.5	8.34	0.42	1.97e-15	Red blood cell count;
LUSC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg02117656	chr17:79614917	TSPAN10	-0.32	-5.86	-0.31	1.11e-8	Eye color traits;
LUSC	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg22189786	chr22:42395067	WBP2NL	0.43	5.74	0.3	2.13e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.52	-0.34	2.58e-10	Lung cancer;
LUSC	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21028142	chr17:79581711	NPLOC4	0.32	7.61	0.38	2.91e-13	Eye color traits;
LUSC	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg16482183	chr6:26056742	HIST1H1C	0.44	6.46	0.33	3.77e-10	Height;
LUSC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg22800045	chr5:56110881	MAP3K1	0.46	6.65	0.34	1.21e-10	Coronary artery disease;
LUSC	cis	rs6084875	0.840	rs2104143	chr20:4723157	G/A	cg26097573	chr20:4721490	PRNT	-0.31	-5.76	-0.3	1.87e-8	Systemic lupus erythematosus;
LUSC	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.69	10.49	0.5	1.93e-22	Corneal astigmatism;
LUSC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11644478	chr21:40555479	PSMG1	-0.61	-9.46	-0.46	5.55e-19	Menarche (age at onset);
LUSC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06634786	chr22:41940651	POLR3H	-0.57	-6.44	-0.33	4.11e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg07393940	chr7:158741817	NA	-0.38	-6.83	-0.35	4.02e-11	Life satisfaction;
LUSC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.76	-14.1	-0.61	9.79e-36	Dental caries;
LUSC	cis	rs7523050	0.643	rs7522324	chr1:109399644	T/C	cg08274380	chr1:109419600	GPSM2	1.1	10.69	0.51	3.76e-23	Fat distribution (HIV);
LUSC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18404041	chr3:52824283	ITIH1	-0.63	-11.65	-0.54	1.45e-26	Bipolar disorder;
LUSC	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.23	-0.41	4.21e-15	Total cholesterol levels;
LUSC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24110177	chr3:50126178	RBM5	0.66	11.3	0.53	2.71e-25	Body mass index;
LUSC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-1.05	-14.81	-0.63	1.65e-38	Vitiligo;
LUSC	cis	rs6433857	0.536	rs4625864	chr2:181353942	G/C	cg23363182	chr2:181467187	NA	-0.45	-7.27	-0.37	2.58e-12	Body mass index;
LUSC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20135002	chr11:47629003	NA	-0.5	-7.82	-0.39	7.01e-14	Subjective well-being;
LUSC	cis	rs17001868	0.527	rs11913132	chr22:40778778	A/G	cg07138101	chr22:40742427	ADSL	0.56	6.87	0.35	3.06e-11	Mammographic density (dense area);
LUSC	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg06917634	chr15:78832804	PSMA4	0.51	6.49	0.33	3.03e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	0.99	13.72	0.6	2.7200000000000002e-34	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.61	-0.5	7.2e-23	Chronic sinus infection;
LUSC	cis	rs12210905	0.688	rs12212389	chr6:27326397	T/C	cg08851530	chr6:28072375	NA	0.9	5.78	0.3	1.75e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg27494647	chr7:150038898	RARRES2	0.59	8.73	0.43	1.2e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg08499158	chr17:42289980	UBTF	-0.52	-8.65	-0.43	2.18e-16	Total body bone mineral density;
LUSC	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg11584989	chr19:19387371	SF4	0.66	7.85	0.39	5.57e-14	Bipolar disorder;
LUSC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg00012203	chr2:219082015	ARPC2	0.9	17.41	0.69	9.53e-49	Colorectal cancer;
LUSC	cis	rs3764563	0.660	rs8107923	chr19:15737899	A/T	cg20725493	chr19:15740067	CYP4F8	-0.64	-6.61	-0.34	1.53e-10	Inflammatory biomarkers;
LUSC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg27535305	chr1:53392650	SCP2	0.36	6.8	0.35	4.92e-11	Monocyte count;
LUSC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.25	-0.49	1.28e-21	Hemoglobin concentration;
LUSC	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg16482183	chr6:26056742	HIST1H1C	0.47	6.88	0.35	2.95e-11	Height;
LUSC	cis	rs7799006	0.606	rs34417375	chr7:2315105	C/T	cg02951883	chr7:2050386	MAD1L1	-0.36	-5.91	-0.31	8.5e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9469578	0.710	rs77213792	chr6:33713952	C/G	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.17	0.37	4.9e-12	Red cell distribution width;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01745690	chr7:43798100	BLVRA	-0.4	-5.98	-0.31	5.59e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg18811423	chr2:55921094	PNPT1	-0.62	-8.4	-0.42	1.29e-15	Metabolic syndrome;
LUSC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg01448562	chr3:133502909	NA	-0.69	-11.68	-0.54	1.2e-26	Iron status biomarkers;
LUSC	trans	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.91	0.35	2.53e-11	Endometrial cancer;
LUSC	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg09184832	chr6:79620586	NA	-0.45	-7.3	-0.37	2.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg19230755	chr7:65878503	NA	-0.42	-6.01	-0.31	4.89e-9	Aortic root size;
LUSC	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.71	-0.39	1.42e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg18753928	chr3:113234510	CCDC52	-0.51	-7.92	-0.4	3.48e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg09491104	chr22:46646882	C22orf40	-0.66	-8.76	-0.43	1.01e-16	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9462027	0.562	rs2814946	chr6:34651180	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.29	-0.33	1.01e-9	Systemic lupus erythematosus;
LUSC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg16405210	chr4:1374714	KIAA1530	-0.61	-9.53	-0.46	3.36e-19	Obesity-related traits;
LUSC	cis	rs1451375	0.794	rs11238134	chr7:50542927	A/C	cg18232548	chr7:50535776	DDC	-0.54	-8.3	-0.41	2.69e-15	Malaria;
LUSC	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg27411982	chr8:10470053	RP1L1	-0.5	-7.85	-0.39	5.81e-14	Monocyte count;
LUSC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.93	0.48	1.54e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg18002602	chr11:66138449	SLC29A2	-0.35	-6.27	-0.32	1.14e-9	HIV-1 susceptibility;
LUSC	cis	rs72772090	1.000	rs72772095	chr5:96053853	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.67	-7.49	-0.38	6.07e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg17675199	chr6:35436792	RPL10A	-0.43	-6.32	-0.33	8.21e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4478858	0.647	rs10798836	chr1:31709214	C/T	cg00250761	chr1:31883323	NA	-0.34	-8.09	-0.4	1.1e-14	Alcohol dependence;
LUSC	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.3	0.45	1.95e-18	Bipolar disorder;
LUSC	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg24130564	chr14:104152367	KLC1	-0.47	-6.87	-0.35	3.12e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg02951883	chr7:2050386	MAD1L1	-0.53	-9.33	-0.45	1.49e-18	Schizophrenia;
LUSC	cis	rs6066835	1.000	rs6066832	chr20:47354132	C/A	cg18078177	chr20:47281410	PREX1	0.71	6.21	0.32	1.61e-9	Multiple myeloma;
LUSC	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg11764359	chr7:65958608	NA	-0.51	-6.57	-0.34	1.94e-10	Aortic root size;
LUSC	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-9.31	-0.45	1.78e-18	Schizophrenia;
LUSC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg23283495	chr1:209979779	IRF6	0.71	9.41	0.46	8.49e-19	Cleft lip with or without cleft palate;
LUSC	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg16928487	chr17:17741425	SREBF1	0.48	9.61	0.47	1.8e-19	Total body bone mineral density;
LUSC	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg21951975	chr1:209979733	IRF6	-0.53	-6.7	-0.34	9e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.09	-0.32	3.05e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05985164	chr12:57881757	MARS	-0.52	-6.46	-0.33	3.77e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7833986	0.501	rs2719233	chr8:56886156	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	10.31	0.49	8.15e-22	Height;
LUSC	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg05855489	chr10:104503620	C10orf26	-0.48	-7.35	-0.37	1.53e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs2048656	0.605	rs7814507	chr8:9646560	G/A	cg15556689	chr8:8085844	FLJ10661	0.46	6.47	0.33	3.55e-10	Schizophrenia;
LUSC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg20295408	chr7:1910781	MAD1L1	-0.42	-5.9	-0.31	8.9e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg21427119	chr20:30132790	HM13	-0.46	-6.65	-0.34	1.2e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs2299587	0.531	rs28839855	chr8:17855983	T/C	cg01800426	chr8:17659068	MTUS1	-0.52	-6.67	-0.34	1.09e-10	Economic and political preferences;
LUSC	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg00277334	chr10:82204260	NA	0.49	6.71	0.34	8.14e-11	Post bronchodilator FEV1;
LUSC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg21782813	chr7:2030301	MAD1L1	0.38	6.22	0.32	1.5e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.84	-0.35	3.86e-11	Daytime sleep phenotypes;
LUSC	cis	rs13236689	0.516	rs1334512	chr7:80267904	G/T	cg04458919	chr7:80252533	CD36	-0.39	-6.65	-0.34	1.23e-10	Mean platelet volume;
LUSC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.76	-0.35	6.24e-11	Type 2 diabetes;
LUSC	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-7.86	-0.4	5.2e-14	Body mass index;
LUSC	cis	rs9359856	0.510	rs17293240	chr6:90396370	C/T	cg13799429	chr6:90582589	CASP8AP2	0.91	10.86	0.51	9.72e-24	Bipolar disorder;
LUSC	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.82	-0.43	6.24e-17	Uric acid levels;
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.8	13.48	0.59	2.24e-33	Menarche (age at onset);
LUSC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg01879757	chr17:41196368	BRCA1	-0.47	-7.12	-0.36	6.7e-12	Menopause (age at onset);
LUSC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.53	8.11	0.41	1.01e-14	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg13453750	chr1:205783389	SLC41A1	-0.32	-6.45	-0.33	3.83e-10	Menarche (age at onset);
LUSC	cis	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg05084668	chr3:125655381	ALG1L	-0.83	-11.71	-0.54	9.28e-27	Blood pressure (smoking interaction);
LUSC	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg25251562	chr2:3704773	ALLC	-0.49	-7.43	-0.38	9.3e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg17554472	chr22:41940697	POLR3H	-0.47	-5.76	-0.3	1.91e-8	Vitiligo;
LUSC	cis	rs394563	0.967	rs447025	chr6:149799128	A/C	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.41	-0.33	4.86e-10	Dupuytren's disease;
LUSC	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-8.94	-0.44	2.61e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.84	0.44	5.72e-17	Lung cancer in ever smokers;
LUSC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.99	-0.31	5.53e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	0.99	14.13	0.61	7.27e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg01017244	chr2:74357527	NA	0.73	14.1	0.61	9.17e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs911119	0.657	rs6114214	chr20:23627924	A/T	cg16589663	chr20:23618590	CST3	0.55	5.99	0.31	5.37e-9	Chronic kidney disease;
LUSC	cis	rs4409675	0.576	rs12062621	chr1:28230404	A/G	cg23691781	chr1:28212827	C1orf38	0.31	7.48	0.38	6.53e-13	Corneal astigmatism;
LUSC	trans	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.11	-0.32	2.83e-9	Depression;
LUSC	trans	rs10411161	0.702	rs6509592	chr19:52393150	G/A	cg22319618	chr22:45562946	NUP50	-0.52	-6.12	-0.32	2.64e-9	Breast cancer;
LUSC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg03388025	chr16:89894329	SPIRE2	0.3	6.31	0.33	8.74e-10	Vitiligo;
LUSC	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg09904177	chr6:26538194	HMGN4	0.76	14.41	0.62	5.82e-37	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.59	9.29	0.45	2.04e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs2580764	0.515	rs4672005	chr2:55246551	C/T	cg09592903	chr2:55203963	RTN4	-0.49	-10.1	-0.48	4.34e-21	Mean platelet volume;
LUSC	cis	rs9818941	0.824	rs11707532	chr3:157801867	T/C	cg08654915	chr3:157813417	NA	0.33	7.76	0.39	1.06e-13	Height;
LUSC	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg17168535	chr8:21777572	XPO7	-0.69	-11.83	-0.54	3.28e-27	Lung cancer in ever smokers;
LUSC	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg26102564	chr10:131424627	MGMT	0.4	6.24	0.32	1.34e-9	Response to temozolomide;
LUSC	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg23649088	chr2:200775458	C2orf69	0.56	8.27	0.41	3.25e-15	Schizophrenia;
LUSC	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.11	25.84	0.82	1.22e-81	Schizophrenia;
LUSC	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg02269571	chr22:50332266	NA	0.59	7.57	0.38	3.67e-13	Schizophrenia;
LUSC	cis	rs7195287	0.826	rs9925824	chr16:2827973	C/T	cg05687563	chr16:2837658	PRSS33	-0.33	-6.21	-0.32	1.53e-9	Eosinophil counts;
LUSC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg19592336	chr6:28129416	ZNF389	0.53	7.05	0.36	1.02e-11	Parkinson's disease;
LUSC	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg13010344	chr12:123464640	ARL6IP4	-0.5	-6.42	-0.33	4.76e-10	Neutrophil percentage of white cells;
LUSC	trans	rs10511400	0.618	rs9842302	chr3:119918358	C/T	cg02809009	chr19:50354510	PTOV1	-0.7	-6.21	-0.32	1.54e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg13072238	chr3:49761600	GMPPB	0.65	8.33	0.41	2.14e-15	Menarche (age at onset);
LUSC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.59	-0.5	8.37e-23	Gut microbiome composition (summer);
LUSC	cis	rs4629180	0.675	rs908132	chr2:102093096	A/G	cg04415270	chr2:102091202	RFX8	-0.46	-7.91	-0.4	3.88e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg17691542	chr6:26056736	HIST1H1C	0.44	6.7	0.34	9.04e-11	Height;
LUSC	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg09796270	chr17:17721594	SREBF1	0.43	7.55	0.38	4.29e-13	Total body bone mineral density;
LUSC	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg09789173	chr7:4769017	FOXK1	-0.55	-10.27	-0.49	1.14e-21	Mosquito bite size;
LUSC	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.67	-0.43	1.95e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10802521	chr3:52805072	NEK4	0.55	8.81	0.43	6.93e-17	Bipolar disorder;
LUSC	trans	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg21775007	chr8:11205619	TDH	0.45	6.63	0.34	1.34e-10	Mood instability;
LUSC	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg06002616	chr8:101225028	SPAG1	-0.41	-6.93	-0.35	2.21e-11	Atrioventricular conduction;
LUSC	cis	rs6847149	0.929	rs10857002	chr4:110773433	A/C	cg07850274	chr4:110748770	RRH	0.53	7.57	0.38	3.73e-13	Exercise treadmill test traits;
LUSC	cis	rs983392	0.680	rs56357056	chr11:59986817	A/G	cg02771260	chr11:59836817	MS4A3	-0.36	-5.91	-0.31	8.58e-9	Alzheimer's disease (late onset);
LUSC	cis	rs17102423	0.755	rs12880781	chr14:65576257	C/T	cg11161011	chr14:65562177	MAX	-0.81	-12.26	-0.56	8.99e-29	Obesity-related traits;
LUSC	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg25427524	chr10:38739819	LOC399744	0.54	7.63	0.39	2.55e-13	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg25214090	chr10:38739885	LOC399744	0.43	6.47	0.33	3.54e-10	Corneal astigmatism;
LUSC	trans	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg04995722	chr7:26192034	NFE2L3	-0.42	-6.44	-0.33	4.15e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	1.03	17.98	0.7	5.14e-51	Parkinson's disease;
LUSC	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg04586622	chr2:25135609	ADCY3	0.42	8.99	0.44	1.88e-17	Body mass index;
LUSC	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg12667521	chr19:29218732	NA	0.51	6.21	0.32	1.54e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9434723	0.844	rs9434729	chr1:9303940	G/C	cg04199779	chr1:9294473	H6PD	0.49	5.75	0.3	2.02e-8	Height;
LUSC	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.94	0.51	5.25e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg24531977	chr5:56204891	C5orf35	0.53	7.87	0.4	4.93e-14	Coronary artery disease;
LUSC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg18230493	chr5:56204884	C5orf35	-0.87	-12.96	-0.58	2.16e-31	Initial pursuit acceleration;
LUSC	cis	rs4663866	1.000	rs13026475	chr2:239178455	T/C	cg16914508	chr2:239161102	PER2	0.68	7.15	0.36	5.4e-12	Irritable bowel syndrome;
LUSC	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17467752	chr17:38218738	THRA	0.53	7.82	0.39	7.13e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg27398640	chr15:77910606	LINGO1	-0.28	-5.75	-0.3	1.99e-8	Type 2 diabetes;
LUSC	trans	rs6601327	0.571	rs7820675	chr8:9647748	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	7.11	0.36	7.28e-12	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9473147	0.516	rs9463342	chr6:47585106	A/T	cg02130027	chr6:47444894	CD2AP	0.36	5.76	0.3	1.86e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	6.07	0.32	3.45e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.53	0.42	5.2e-16	Lung cancer;
LUSC	cis	rs4654899	0.865	rs6426658	chr1:21361176	G/A	cg01072550	chr1:21505969	NA	-0.52	-7.64	-0.39	2.39e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg00225070	chr15:80189496	MTHFS	0.61	9.41	0.46	8.01e-19	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-20.03	-0.74	3.45e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg21545522	chr1:205238299	TMCC2	-0.45	-8.33	-0.41	2.18e-15	Red blood cell count;
LUSC	trans	rs1486139	0.935	rs10263960	chr7:46287653	T/C	cg17534202	chr9:96721102	NA	-0.37	-6.53	-0.34	2.47e-10	Select biomarker traits;
LUSC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg09455208	chr3:40491958	NA	0.55	10.24	0.49	1.36e-21	Renal cell carcinoma;
LUSC	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg04850211	chr1:228464232	OBSCN	-0.34	-5.97	-0.31	6.2e-9	Diastolic blood pressure;
LUSC	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg03859395	chr2:55845619	SMEK2	0.81	14.82	0.63	1.47e-38	Metabolic syndrome;
LUSC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg18876405	chr7:65276391	NA	-0.58	-9.31	-0.45	1.8e-18	Aortic root size;
LUSC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg17173187	chr15:85201210	NMB	0.37	6.65	0.34	1.19e-10	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.18	0.45	4.54e-18	Motion sickness;
LUSC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	7.77e-16	Aortic root size;
LUSC	cis	rs7000551	0.725	rs4871998	chr8:22308150	A/T	cg12081754	chr8:22256438	SLC39A14	0.52	8.34	0.41	2.04e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.3	-0.45	1.93e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.8	-0.3	1.52e-8	Ulcerative colitis;
LUSC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.19e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6050267	0.556	rs62217177	chr20:25012178	A/G	cg26195577	chr20:24973756	C20orf3	0.65	6.4	0.33	5.21e-10	Cognitive performance;
LUSC	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-1.01	-14.4	-0.62	6.88e-37	Exhaled nitric oxide output;
LUSC	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.65	11.08	0.52	1.65e-24	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg27661571	chr11:113659931	NA	-0.59	-6.5	-0.34	2.92e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-9.48	-0.46	5.01e-19	Platelet distribution width;
LUSC	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg06637938	chr14:75390232	RPS6KL1	0.63	10.13	0.48	3.28e-21	Caffeine consumption;
LUSC	cis	rs4561483	0.801	rs33637	chr16:11989875	A/T	cg08843971	chr16:11963173	GSPT1	-0.47	-6.99	-0.36	1.53e-11	Testicular germ cell tumor;
LUSC	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg26958806	chr6:27640298	NA	0.66	5.78	0.3	1.7e-8	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	8.97	0.44	2.13e-17	Bipolar disorder;
LUSC	cis	rs13401104	0.796	rs61160252	chr2:237119074	A/G	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg09184832	chr6:79620586	NA	-0.43	-6.85	-0.35	3.64e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.07	0.48	5.08e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg06637938	chr14:75390232	RPS6KL1	0.52	8.25	0.41	3.77e-15	Height;
LUSC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg00033643	chr7:134001901	SLC35B4	0.46	7.13	0.36	6.39e-12	Mean platelet volume;
LUSC	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg23752985	chr2:85803571	VAMP8	0.33	6.37	0.33	6.36e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10761482	0.601	rs10733764	chr10:62210345	C/G	cg18175470	chr10:62150864	ANK3	-0.53	-7.37	-0.37	1.32e-12	Schizophrenia;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14878842	chr13:113730426	MCF2L	-0.43	-6.89	-0.35	2.81e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg08975724	chr8:8085496	FLJ10661	0.55	7.19	0.37	4.2e-12	Red cell distribution width;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23586394	chr17:8286572	RPL26	-0.48	-6.36	-0.33	6.53e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7189233	0.531	rs7202621	chr16:53486037	G/A	cg09728985	chr16:53543985	NA	-0.33	-6.21	-0.32	1.54e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	8.59	0.43	3.41e-16	Total body bone mineral density;
LUSC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.69	12.03	0.55	6.24e-28	Age at first birth;
LUSC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg23034840	chr1:205782522	SLC41A1	0.57	7.86	0.4	5.23e-14	Menarche (age at onset);
LUSC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg03948781	chr1:205179583	DSTYK	0.32	6.21	0.32	1.53e-9	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18854424	chr1:2615690	NA	-0.49	-9.66	-0.47	1.21e-19	Ulcerative colitis;
LUSC	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg17366294	chr4:99064904	C4orf37	0.59	10.52	0.5	1.54e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs921665	0.680	rs4854132	chr2:3199378	T/A	cg02624386	chr2:3182749	NA	0.61	6.63	0.34	1.37e-10	World class endurance athleticism;
LUSC	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg12002119	chr2:101014098	CHST10	0.38	6.38	0.33	6.04e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.49	-0.33	3.16e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11764359	chr7:65958608	NA	0.68	10.96	0.51	4.39e-24	Aortic root size;
LUSC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg07700843	chr1:2391317	NA	-0.45	-7.28	-0.37	2.43e-12	Non-obstructive azoospermia;
LUSC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12667521	chr19:29218732	NA	0.62	8.6	0.43	3.11e-16	Methadone dose in opioid dependence;
LUSC	cis	rs10979	0.928	rs6924967	chr6:143906235	C/T	cg25407410	chr6:143891975	LOC285740	-0.68	-10.43	-0.5	3.07e-22	Hypospadias;
LUSC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg08499158	chr17:42289980	UBTF	-0.51	-8.72	-0.43	1.37e-16	Total body bone mineral density;
LUSC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11764359	chr7:65958608	NA	0.69	11.18	0.52	7.39e-25	Aortic root size;
LUSC	cis	rs10465746	0.967	rs6703382	chr1:84435700	G/A	cg10977910	chr1:84465055	TTLL7	0.42	6.23	0.32	1.41e-9	Obesity-related traits;
LUSC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg25767906	chr1:53392781	SCP2	0.52	9.52	0.46	3.62e-19	Monocyte count;
LUSC	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg10518543	chr12:38710700	ALG10B	0.42	5.84	0.3	1.22e-8	Morning vs. evening chronotype;
LUSC	cis	rs7523273	0.526	rs2745980	chr1:208018367	A/C	cg22525895	chr1:207977042	MIR29B2	0.41	6.91	0.35	2.46e-11	Schizophrenia;
LUSC	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	0.8	9.91	0.48	1.86e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.58	-9.39	-0.46	9.82e-19	Aortic root size;
LUSC	cis	rs6690583	0.623	rs11588160	chr1:85444226	T/G	cg22153463	chr1:85462885	MCOLN2	0.63	6.01	0.31	4.83e-9	Serum sulfate level;
LUSC	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg13010199	chr12:38710504	ALG10B	0.59	9.32	0.45	1.57e-18	Heart rate;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13603510	chr19:3626908	C19orf29	-0.46	-6.16	-0.32	2.05e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs28595532	0.702	rs72670252	chr4:119337546	A/C	cg02775129	chr4:119771670	NA	-0.76	-6.33	-0.33	7.79e-10	Cannabis dependence symptom count;
LUSC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg04414720	chr1:150670196	GOLPH3L	0.56	9.07	0.44	1.03e-17	Tonsillectomy;
LUSC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2580764	0.516	rs2860453	chr2:55270485	T/G	cg09592903	chr2:55203963	RTN4	0.5	10.14	0.49	3.06e-21	Mean platelet volume;
LUSC	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.49	0.38	6.2800000000000005e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7246967	0.673	rs34726149	chr19:22952111	A/G	cg23217946	chr19:22817039	ZNF492	0.43	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-0.77	-12.3	-0.56	6.04e-29	Height;
LUSC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg13206674	chr6:150067644	NUP43	0.6	9.35	0.46	1.26e-18	Lung cancer;
LUSC	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.92	0.7	8.72e-51	Chronic sinus infection;
LUSC	cis	rs7940866	0.903	rs11222411	chr11:130838682	A/G	cg12179176	chr11:130786555	SNX19	0.57	8.9	0.44	3.55e-17	Schizophrenia;
LUSC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg15494558	chr6:150152522	LRP11	0.33	5.81	0.3	1.46e-8	Lung cancer;
LUSC	trans	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg26384229	chr12:38710491	ALG10B	-0.57	-9.06	-0.44	1.1e-17	Morning vs. evening chronotype;
LUSC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg01097406	chr16:89675127	NA	-0.37	-7.24	-0.37	3.05e-12	Vitiligo;
LUSC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06850241	chr22:41845214	NA	0.32	5.9	0.31	9.16e-9	Vitiligo;
LUSC	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg11608241	chr8:8085544	FLJ10661	0.42	6.26	0.32	1.2e-9	Neuroticism;
LUSC	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.53	-0.38	4.67e-13	Type 2 diabetes;
LUSC	cis	rs7809950	1.000	rs2520271	chr7:107194949	C/T	cg23024343	chr7:107201750	COG5	-0.57	-8.95	-0.44	2.6e-17	Coronary artery disease;
LUSC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg06387496	chr7:2775674	GNA12	-0.35	-5.67	-0.3	3.15e-8	Height;
LUSC	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg19875535	chr5:140030758	IK	0.47	7.56	0.38	4.05e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22980127	chr19:33182716	NUDT19	0.89	12.1	0.55	3.47e-28	Red blood cell traits;
LUSC	cis	rs2742417	0.624	rs2673030	chr3:45757900	T/G	cg10512202	chr3:45649293	LIMD1	0.36	6.14	0.32	2.33e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg18904891	chr8:8559673	CLDN23	-0.57	-8.03	-0.4	1.73e-14	Obesity-related traits;
LUSC	cis	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg07460842	chr6:66804631	NA	0.88	8.88	0.44	4.07e-17	Exhaled nitric oxide output;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	10.24	0.49	1.4e-21	Lymphocyte counts;
LUSC	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg00757033	chr12:89920650	WDR51B	0.6	10.42	0.5	3.48e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11764359	chr7:65958608	NA	0.54	7.11	0.36	7.12e-12	Aortic root size;
LUSC	cis	rs7212590	0.655	rs8067568	chr17:57999215	A/G	cg10252138	chr17:58120427	NA	-0.74	-6.97	-0.36	1.67e-11	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08859206	chr1:53392774	SCP2	-0.6	-11.3	-0.53	2.77e-25	Monocyte count;
LUSC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg17376030	chr22:41985996	PMM1	-0.53	-6.8	-0.35	4.82e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs1459104	0.850	rs12802447	chr11:55039889	C/T	cg15704280	chr7:45808275	SEPT13	0.76	6.26	0.32	1.21e-9	Body mass index;
LUSC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg13395646	chr4:1353034	KIAA1530	0.54	7.98	0.4	2.41e-14	Longevity;
LUSC	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg05985134	chr18:33552581	C18orf21	-0.51	-6.9	-0.35	2.64e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	11.98	0.55	9.25e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs9359856	0.662	rs1179904	chr6:90322573	A/G	cg13799429	chr6:90582589	CASP8AP2	0.74	9.12	0.45	6.97e-18	Bipolar disorder;
LUSC	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg08213375	chr14:104286397	PPP1R13B	0.52	10.24	0.49	1.38e-21	Schizophrenia;
LUSC	cis	rs72781680	0.566	rs55987381	chr2:23900938	T/C	cg20701182	chr2:24300061	SF3B14	0.59	6.73	0.35	7.42e-11	Lymphocyte counts;
LUSC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg03146154	chr1:46216737	IPP	0.51	7.44	0.38	8.71e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.11	-0.58	5.87e-32	Platelet count;
LUSC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg22166914	chr1:53195759	ZYG11B	0.57	9.41	0.46	8.01e-19	Monocyte count;
LUSC	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg23229984	chr5:148520753	ABLIM3	0.38	6.13	0.32	2.54e-9	Breast cancer;
LUSC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg13114125	chr14:105738426	BRF1	0.92	16.22	0.66	5.02e-44	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4704187	0.640	rs4704188	chr5:74482675	A/T	cg03227963	chr5:74354835	NA	0.3	6.54	0.34	2.32e-10	Response to amphetamines;
LUSC	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	ch.11.42038R	chr11:967971	AP2A2	0.47	6.99	0.36	1.46e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.72	9.62	0.47	1.65e-19	Platelet count;
LUSC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	0.96	19.27	0.73	3.73e-56	Cognitive function;
LUSC	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg21775007	chr8:11205619	TDH	-0.48	-6.86	-0.35	3.42e-11	Morning vs. evening chronotype;
LUSC	trans	rs4942242	0.663	rs34978818	chr13:44214096	T/C	cg19169023	chr15:41853346	TYRO3	-0.6	-9.09	-0.45	8.95e-18	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-0.83	-11.71	-0.54	9.42e-27	Response to hepatitis C treatment;
LUSC	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14893161	chr1:205819251	PM20D1	0.45	6.32	0.33	8.41e-10	Parkinson's disease;
LUSC	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg06937882	chr20:24974362	C20orf3	-0.44	-7.67	-0.39	1.89e-13	Blood protein levels;
LUSC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg09904177	chr6:26538194	HMGN4	0.67	12.18	0.55	1.7e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg00012203	chr2:219082015	ARPC2	0.7	11.64	0.54	1.68e-26	Colorectal cancer;
LUSC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg25344623	chr2:136566232	LCT	-0.37	-5.66	-0.3	3.31e-8	Mosquito bite size;
LUSC	cis	rs2073300	0.793	rs6048814	chr20:23448411	A/C	cg09953122	chr20:23471693	CST8	-0.72	-6.61	-0.34	1.54e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg01416388	chr22:39784598	NA	-0.44	-7.34	-0.37	1.65e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.18	0.32	1.88e-9	Corneal astigmatism;
LUSC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06634786	chr22:41940651	POLR3H	0.54	6.27	0.32	1.12e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.56	8.68	0.43	1.84e-16	Neuroticism;Neuroticism (multi-trait analysis);
LUSC	cis	rs10979	1.000	rs9386036	chr6:143890709	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg23625390	chr15:77176239	SCAPER	-0.66	-10.09	-0.48	4.38e-21	Blood metabolite levels;
LUSC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	6.49	0.33	3.06e-10	Renal cell carcinoma;
LUSC	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg16850897	chr7:100343110	ZAN	0.37	5.89	0.31	9.47e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.18	-0.37	4.47e-12	Type 2 diabetes;
LUSC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08439880	chr3:133502540	NA	-0.35	-6.25	-0.32	1.24e-9	Iron status biomarkers;
LUSC	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg23950597	chr19:37808831	NA	-0.63	-7.68	-0.39	1.82e-13	Coronary artery calcification;
LUSC	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.4	-0.38	1.12e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-9.26	-0.45	2.58e-18	Schizophrenia;
LUSC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg06784218	chr1:46089804	CCDC17	-0.48	-9.21	-0.45	3.67e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10203711	1.000	rs907112	chr2:239566603	C/G	cg14580085	chr2:239553406	NA	0.42	7.11	0.36	7.06e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg09365446	chr1:150670422	GOLPH3L	0.46	6.87	0.35	3.12e-11	Melanoma;
LUSC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg18681998	chr4:17616180	MED28	0.77	13.81	0.6	1.24e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg01620082	chr3:125678407	NA	0.75	7.63	0.39	2.48e-13	Depression;
LUSC	cis	rs6700896	0.931	rs11208711	chr1:66147846	G/T	cg04111102	chr1:66153794	NA	0.33	7.38	0.37	1.24e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs240764	0.621	rs6925316	chr6:101209137	C/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.24	-0.32	1.32e-9	Neuroticism;
LUSC	cis	rs6700896	0.931	rs4655764	chr1:66126159	C/T	cg04111102	chr1:66153794	NA	0.31	6.58	0.34	1.86e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg22601191	chr20:60968625	CABLES2	0.36	5.91	0.31	8.33e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg18402987	chr7:1209562	NA	0.73	7.84	0.39	5.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg01528321	chr10:82214614	TSPAN14	0.61	9.07	0.44	1.06e-17	Post bronchodilator FEV1;
LUSC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg20790798	chr5:1857306	NA	-0.47	-8.14	-0.41	8.18e-15	Cardiovascular disease risk factors;
LUSC	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.7	0.39	1.61e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	6.19	0.32	1.79e-9	Breast cancer;
LUSC	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg15704280	chr7:45808275	SEPT13	0.67	7.27	0.37	2.5e-12	D-dimer levels;
LUSC	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.37	-5.67	-0.3	3.04e-8	Ulcerative colitis;
LUSC	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17830980	chr10:43048298	ZNF37B	-0.55	-9.01	-0.44	1.67e-17	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1712517	0.566	rs7917388	chr10:105054963	C/T	cg04362960	chr10:104952993	NT5C2	-0.5	-6.75	-0.35	6.74e-11	Migraine;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20263490	chr11:3013628	NAP1L4	-0.4	-6.1	-0.32	2.86e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg05555928	chr11:63887634	MACROD1	-0.49	-6.05	-0.31	3.95e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2303282	0.716	rs2550309	chr16:56434742	G/A	cg00500540	chr16:56394104	NA	-0.42	-7.14	-0.36	5.98e-12	Breast cancer;
LUSC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.4	-5.77	-0.3	1.8e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	1.93e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg07211511	chr3:129823064	LOC729375	-0.83	-11.89	-0.55	1.92e-27	Blood pressure (smoking interaction);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg15270950	chr3:30648819	TGFBR2	0.44	6.13	0.32	2.53e-9	Mosquito bite size;
LUSC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.74	-14.06	-0.61	1.38e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.24	-0.37	3.18e-12	Myopia (pathological);
LUSC	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg27398640	chr15:77910606	LINGO1	-0.28	-5.8	-0.3	1.56e-8	Type 2 diabetes;
LUSC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg06238570	chr21:40685208	BRWD1	-0.59	-9.17	-0.45	4.8e-18	Menarche (age at onset);
LUSC	cis	rs2292864	0.764	rs35265764	chr17:45363546	G/T	cg18085866	chr17:45331354	ITGB3	-0.73	-6.0	-0.31	5.26e-9	Left atrial antero-posterior diameter;
LUSC	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-11.76	-0.54	6.15e-27	Total body bone mineral density;
LUSC	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg26893861	chr17:41843967	DUSP3	0.94	14.48	0.62	3.22e-37	Triglycerides;
LUSC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03517284	chr6:25882590	NA	0.39	6.52	0.34	2.6e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.28	0.53	3.34e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	6.31	0.33	8.77e-10	Retinal vascular caliber;
LUSC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg12463550	chr7:65579703	CRCP	0.46	6.8	0.35	4.91e-11	Aortic root size;
LUSC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg24733560	chr20:60626293	TAF4	0.41	6.76	0.35	6.24e-11	Body mass index;
LUSC	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg27147174	chr7:100797783	AP1S1	-0.65	-10.5	-0.5	1.74e-22	Life satisfaction;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01100864	chr12:122750645	VPS33A	0.76	5.97	0.31	5.95e-9	Cognitive performance;
LUSC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg06671706	chr8:8559999	CLDN23	0.5	6.68	0.34	9.98e-11	Obesity-related traits;
LUSC	cis	rs7000551	0.663	rs7827093	chr8:22334610	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	6.36	0.33	6.73e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg02569458	chr12:86230093	RASSF9	0.38	6.09	0.32	3.09e-9	Major depressive disorder;
LUSC	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg13393036	chr8:95962371	TP53INP1	-0.35	-6.56	-0.34	2.03e-10	Type 2 diabetes;
LUSC	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg06346307	chr22:19949965	COMT	-0.35	-7.2	-0.37	3.91e-12	Blood metabolite levels;
LUSC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.84	0.6	9.61e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg15704280	chr7:45808275	SEPT13	-0.53	-7.44	-0.38	8.56e-13	Coronary artery disease;
LUSC	cis	rs13082711	0.516	rs1388785	chr3:27371843	T/C	cg02860705	chr3:27208620	NA	-0.54	-9.56	-0.46	2.62e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg16576597	chr16:28551801	NUPR1	0.34	6.73	0.35	7.35e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg25258033	chr6:167368657	RNASET2	0.49	8.12	0.41	8.93e-15	Crohn's disease;
LUSC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg27535305	chr1:53392650	SCP2	0.36	6.73	0.35	7.3e-11	Monocyte count;
LUSC	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg11984989	chr7:158649758	WDR60	0.87	10.19	0.49	2.12e-21	Height;
LUSC	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14690220	chr19:37861935	ZNF527	0.41	6.05	0.31	3.78e-9	Asthma;
LUSC	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.87	13.83	0.6	1.04e-34	Coronary artery disease;
LUSC	cis	rs6714788	0.503	rs11681737	chr2:100679024	T/C	cg22139774	chr2:100720529	AFF3	-0.38	-6.01	-0.31	4.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.53	-0.42	5.32e-16	Body mass index;
LUSC	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.44e-8	Breast cancer;
LUSC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.38	5.84	0.3	1.22e-8	Longevity;Endometriosis;
LUSC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.97	-0.31	5.97e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1358748	0.555	rs2815338	chr1:67535781	C/T	cg02640540	chr1:67518911	SLC35D1	0.62	6.52	0.34	2.6e-10	Tuberculosis;
LUSC	cis	rs7119	0.717	rs11639293	chr15:77810845	T/C	cg27398640	chr15:77910606	LINGO1	-0.3	-6.49	-0.33	3.14e-10	Type 2 diabetes;
LUSC	trans	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.52	0.53	4.31e-26	Mean corpuscular volume;
LUSC	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg06028605	chr16:24865363	SLC5A11	0.44	7.66	0.39	1.99e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1322512	0.959	rs2623954	chr6:152966001	G/A	cg27316956	chr6:152958899	SYNE1	-0.34	-5.87	-0.31	1.04e-8	Tonometry;
LUSC	cis	rs9796	0.663	rs11853192	chr15:41368515	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.44	-7.6	-0.38	3.03e-13	Menopause (age at onset);
LUSC	cis	rs3007168	1.000	rs3007079	chr14:51613517	A/G	cg23942311	chr14:51606299	NA	0.36	5.79	0.3	1.61e-8	Cancer;
LUSC	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	11.38	0.53	1.46e-25	Eye color traits;
LUSC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22307029	chr19:49891270	CCDC155	0.68	9.57	0.46	2.55e-19	Multiple sclerosis;
LUSC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.72	7.31	0.37	1.98e-12	Initial pursuit acceleration;
LUSC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg26335602	chr6:28129616	ZNF389	0.45	6.16	0.32	2.09e-9	Depression;
LUSC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22601191	chr20:60968625	CABLES2	0.6	9.67	0.47	1.15e-19	Colorectal cancer;
LUSC	cis	rs6424115	0.862	rs34845821	chr1:24066486	C/T	cg15997130	chr1:24165203	NA	-0.46	-6.45	-0.33	3.96e-10	Immature fraction of reticulocytes;
LUSC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.19	16.49	0.67	4.02e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08048268	chr3:133502702	NA	-0.46	-8.98	-0.44	2.05e-17	Iron status biomarkers;
LUSC	cis	rs6967385	0.934	rs2253353	chr7:12370657	A/G	cg20607287	chr7:12443886	VWDE	0.4	5.84	0.3	1.25e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs2273669	0.667	rs12215381	chr6:109363217	C/T	cg05315195	chr6:109294784	ARMC2	-0.53	-5.84	-0.3	1.22e-8	Prostate cancer;
LUSC	cis	rs74181299	0.964	rs2540949	chr2:65284231	A/T	cg05010058	chr2:65284262	CEP68	0.31	6.13	0.32	2.47e-9	Pulse pressure;
LUSC	cis	rs4746818	0.711	rs2491024	chr10:70847084	T/C	cg11621586	chr10:70884670	VPS26A	0.99	11.56	0.53	3.14e-26	Left atrial antero-posterior diameter;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11937541	chr2:170441360	PPIG	0.37	6.07	0.32	3.47e-9	Asthma;
LUSC	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg18129178	chr5:148520854	ABLIM3	-0.66	-10.32	-0.49	7.39e-22	Breast cancer;
LUSC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg17554472	chr22:41940697	POLR3H	-0.5	-6.06	-0.31	3.67e-9	Vitiligo;
LUSC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg16797656	chr11:68205561	LRP5	0.39	7.14	0.36	5.72e-12	Total body bone mineral density;
LUSC	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg19875535	chr5:140030758	IK	0.47	7.56	0.38	4.05e-13	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs7939886	0.920	rs11227145	chr11:55839278	C/A	cg15704280	chr7:45808275	SEPT13	0.79	6.65	0.34	1.23e-10	Myopia (pathological);
LUSC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg26668713	chr11:65405903	SIPA1	0.62	7.53	0.38	4.88e-13	Blood pressure (age interaction);
LUSC	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg05855489	chr10:104503620	C10orf26	0.59	9.51	0.46	3.79e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg12473912	chr3:136751656	NA	0.39	6.77	0.35	5.97e-11	Neuroticism;
LUSC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg04287289	chr16:89883240	FANCA	0.78	13.7	0.6	3.2e-34	Vitiligo;
LUSC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.85	10.76	0.51	2.21e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs981844	0.961	rs6827685	chr4:154662227	C/T	cg10279832	chr4:154682576	RNF175	-0.39	-5.81	-0.3	1.44e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg24130564	chr14:104152367	KLC1	-0.51	-7.43	-0.38	9.17e-13	Body mass index;
LUSC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg21972741	chr5:435613	AHRR	0.37	6.99	0.36	1.54e-11	Cystic fibrosis severity;
LUSC	cis	rs6840360	0.607	rs6815320	chr4:152432500	T/C	cg20465933	chr4:152376761	FAM160A1	0.33	5.94	0.31	7.18e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.86	0.54	2.63e-27	Cognitive ability;
LUSC	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg25817165	chr18:72167213	CNDP2	-0.59	-8.4	-0.42	1.27e-15	Refractive error;
LUSC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-7.81	-0.39	7.54e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg21951975	chr1:209979733	IRF6	0.4	6.67	0.34	1.08e-10	Monobrow;
LUSC	cis	rs4363385	0.510	rs6661063	chr1:153036048	C/A	cg25856811	chr1:152973957	SPRR3	-0.36	-6.1	-0.32	2.95e-9	Inflammatory skin disease;
LUSC	cis	rs1451375	0.607	rs7807335	chr7:50631862	A/C	cg18232548	chr7:50535776	DDC	-0.49	-6.61	-0.34	1.55e-10	Malaria;
LUSC	cis	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg17469321	chr7:55412551	NA	0.66	10.63	0.5	6.09e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6494488	0.500	rs72741325	chr15:64730384	T/C	cg08069370	chr15:64387884	SNX1	-0.64	-5.67	-0.3	3.05e-8	Coronary artery disease;
LUSC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.39	-6.13	-0.32	2.46e-9	Longevity;Endometriosis;
LUSC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.96	-0.36	1.84e-11	Aortic root size;
LUSC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-5.89	-0.31	9.52e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.11	-0.36	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg23711669	chr6:146136114	FBXO30	0.87	16.13	0.66	1.09e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg27661571	chr11:113659931	NA	0.59	6.42	0.33	4.67e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs3736594	0.513	rs2384627	chr2:27774449	G/A	cg27432699	chr2:27873401	GPN1	0.67	8.9	0.44	3.75e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg11247378	chr22:39784982	NA	-0.64	-12.57	-0.57	6.06e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg20887711	chr4:1340912	KIAA1530	-0.49	-7.37	-0.37	1.34e-12	Obesity-related traits;
LUSC	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg18825076	chr15:78729989	IREB2	-0.5	-7.81	-0.39	7.26e-14	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg22075328	chr22:23412381	RTDR1;GNAZ	0.48	5.96	0.31	6.45e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	10.16	0.49	2.7e-21	Lymphocyte counts;
LUSC	cis	rs7590368	0.924	rs72779464	chr2:10963159	T/C	cg15705551	chr2:10952987	PDIA6	0.57	7.8	0.39	8.2e-14	Educational attainment (years of education);
LUSC	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.27	0.71	3.52e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7011049	1.000	rs72640852	chr8:53838084	G/A	cg26025543	chr8:53854495	NA	0.53	6.34	0.33	7.27e-10	Systolic blood pressure;
LUSC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.64	0.6	5.58e-34	Cognitive test performance;
LUSC	cis	rs11958404	0.932	rs11949394	chr5:157425198	A/G	cg05962755	chr5:157440814	NA	0.5	6.07	0.32	3.45e-9	IgG glycosylation;
LUSC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg01879757	chr17:41196368	BRCA1	-0.45	-6.98	-0.36	1.58e-11	Menopause (age at onset);
LUSC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg15445000	chr17:37608096	MED1	0.4	6.76	0.35	6.31e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.88	0.31	9.88e-9	Menopause (age at onset);
LUSC	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg05340658	chr4:99064831	C4orf37	0.66	10.38	0.49	4.53e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg23750338	chr8:142222470	SLC45A4	-0.57	-11.1	-0.52	1.41e-24	Immature fraction of reticulocytes;
LUSC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg15445000	chr17:37608096	MED1	0.4	6.56	0.34	2e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.67	-10.29	-0.49	9.06e-22	Aortic root size;
LUSC	cis	rs1595825	0.891	rs2164070	chr2:198881730	G/C	cg00982548	chr2:198649783	BOLL	-0.56	-7.06	-0.36	9.65e-12	Ulcerative colitis;
LUSC	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg19700328	chr14:106028568	NA	-0.41	-6.94	-0.36	1.99e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg15997130	chr1:24165203	NA	-0.5	-7.41	-0.38	1.05e-12	Immature fraction of reticulocytes;
LUSC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-12.84	-0.57	5.91e-31	Alzheimer's disease;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg14341449	chr11:18034693	SERGEF	0.43	6.13	0.32	2.53e-9	Calcium levels;
LUSC	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.78	-0.51	1.91e-23	Glomerular filtration rate;
LUSC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg24829409	chr8:58192753	C8orf71	-0.52	-5.96	-0.31	6.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs427691	0.536	rs25916	chr5:108992465	A/G	cg17395555	chr5:108820864	NA	0.44	6.8	0.35	4.83e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9394438	0.593	rs10947679	chr6:37543524	C/G	cg00985040	chr6:37553208	NA	0.4	8.96	0.44	2.26e-17	IgG glycosylation;
LUSC	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg07936489	chr17:37558343	FBXL20	0.83	10.41	0.5	3.52e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.38	6.09	0.32	3.02e-9	Self-reported allergy;
LUSC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.5	0.62	2.79e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg25258033	chr6:167368657	RNASET2	0.46	7.36	0.37	1.48e-12	Crohn's disease;
LUSC	cis	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg06521331	chr12:34319734	NA	-0.47	-7.51	-0.38	5.28e-13	Morning vs. evening chronotype;
LUSC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.44	-6.17	-0.32	1.98e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11690935	0.550	rs11676438	chr2:172826668	G/A	cg13550731	chr2:172543902	DYNC1I2	0.49	7.31	0.37	1.97e-12	Schizophrenia;
LUSC	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg20503657	chr10:835505	NA	-0.41	-6.03	-0.31	4.37e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs9715521	0.719	rs11936702	chr4:59849081	G/A	cg11281224	chr4:60001000	NA	-0.46	-6.46	-0.33	3.79e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25427524	chr10:38739819	LOC399744	0.45	7.41	0.38	1.07e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18854424	chr1:2615690	NA	0.52	10.73	0.51	2.84e-23	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg23743428	chr13:21893420	NA	-0.44	-8.84	-0.44	5.57e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs2273669	0.667	rs12374658	chr6:109345930	T/C	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs9837602	1.000	rs9841186	chr3:99795651	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	6.08	0.32	3.21e-9	Breast cancer;
LUSC	cis	rs17824933	1.000	rs12797044	chr11:60768018	T/A	cg16817237	chr11:60793675	NA	0.41	6.58	0.34	1.79e-10	Multiple sclerosis;
LUSC	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg00310523	chr12:86230176	RASSF9	0.4	7.33	0.37	1.8e-12	Major depressive disorder;
LUSC	trans	rs72674100	1.000	rs10016008	chr4:97974457	A/G	cg09670535	chr1:18959427	PAX7	-0.56	-5.99	-0.31	5.44e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg18402987	chr7:1209562	NA	0.73	7.92	0.4	3.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.01	-0.31	4.93e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg00339695	chr16:24857497	SLC5A11	-0.37	-5.99	-0.31	5.51e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.36	-5.79	-0.3	1.63e-8	Total body bone mineral density;
LUSC	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg01557791	chr16:72042693	DHODH	-0.43	-6.38	-0.33	6.06e-10	Fibrinogen levels;
LUSC	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg27661571	chr11:113659931	NA	-0.63	-7.49	-0.38	6.33e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-1.19	-12.67	-0.57	2.71e-30	Diabetic kidney disease;
LUSC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.89	0.4	4.42e-14	Prudent dietary pattern;
LUSC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.73	-10.7	-0.51	3.46e-23	Cognitive test performance;
LUSC	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.78	11.28	0.53	3.11e-25	Corneal astigmatism;
LUSC	cis	rs778371	0.723	rs2592104	chr2:233645970	G/A	cg08000102	chr2:233561755	GIGYF2	0.79	12.77	0.57	1.1e-30	Schizophrenia;
LUSC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg23630131	chr7:65973040	NA	0.21	5.94	0.31	7.16e-9	Aortic root size;
LUSC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg09796270	chr17:17721594	SREBF1	0.39	6.81	0.35	4.55e-11	Total body bone mineral density;
LUSC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.46	6.87	0.35	3.18e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.79	0.35	5.15e-11	Lung cancer;
LUSC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg17800788	chr1:21766015	NBPF3	0.31	6.05	0.31	3.98e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.65	-0.39	2.16e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.52	0.34	2.57e-10	Lung cancer;
LUSC	cis	rs6580649	0.941	rs58046797	chr12:48487619	T/C	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	cis	rs10465746	0.725	rs12070578	chr1:84349607	A/G	cg10977910	chr1:84465055	TTLL7	0.53	7.56	0.38	3.98e-13	Obesity-related traits;
LUSC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08219700	chr8:58056026	NA	0.68	7.92	0.4	3.63e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs727505	0.954	rs2054586	chr7:124708414	C/T	cg23710748	chr7:124431027	NA	-0.41	-7.15	-0.36	5.55e-12	Lewy body disease;
LUSC	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg26647111	chr11:31128758	NA	0.43	6.16	0.32	2.13e-9	Red blood cell count;
LUSC	cis	rs722599	0.651	rs7159354	chr14:75253847	A/G	cg08847533	chr14:75593920	NEK9	0.42	5.85	0.3	1.17e-8	IgG glycosylation;
LUSC	cis	rs225245	0.782	rs161183	chr17:33919475	G/C	cg05299278	chr17:33885742	SLFN14	0.31	6.9	0.35	2.68e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs2233152	0.519	rs11083567	chr19:41318306	C/T	cg21869046	chr19:41225005	ITPKC	0.39	5.84	0.3	1.23e-8	Kawasaki disease;
LUSC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg16325326	chr1:53192061	ZYG11B	0.69	11.17	0.52	7.89e-25	Monocyte count;
LUSC	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg05855489	chr10:104503620	C10orf26	0.59	9.6	0.46	2.02e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.52	-8.77	-0.43	9.41e-17	Obesity-related traits;
LUSC	trans	rs72674100	0.867	rs7656650	chr4:97964570	A/G	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-6.85	-0.35	3.54e-11	Blood metabolite levels;
LUSC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg22903657	chr4:1355424	KIAA1530	0.36	6.07	0.32	3.45e-9	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg01503450	chr10:980765	NA	-0.4	-5.73	-0.3	2.2e-8	Eosinophil percentage of granulocytes;
LUSC	trans	rs9944715	0.954	rs6507676	chr18:43739730	T/C	cg01718231	chr17:29326311	RNF135	0.46	6.45	0.33	3.84e-10	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs2637266	1.000	rs10219107	chr10:78364369	T/C	cg18941641	chr10:78392320	NA	0.39	7.11	0.36	7.28e-12	Pulmonary function;
LUSC	cis	rs2282300	0.589	rs1717776	chr11:30415776	A/G	cg25418670	chr11:30344373	C11orf46	-0.42	-6.5	-0.34	2.95e-10	Morning vs. evening chronotype;
LUSC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg04800585	chr6:26043546	HIST1H2BB	0.4	5.96	0.31	6.32e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg13609457	chr4:120235615	NA	0.41	5.64	0.3	3.55e-8	Corneal astigmatism;
LUSC	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg04455712	chr21:45112962	RRP1B	0.43	8.05	0.4	1.47e-14	Mean corpuscular volume;
LUSC	cis	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05901451	chr6:126070800	HEY2	-0.57	-8.56	-0.42	4.29e-16	Endometrial cancer;
LUSC	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg12564285	chr5:131593104	PDLIM4	-0.31	-5.82	-0.3	1.37e-8	Blood metabolite levels;
LUSC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg11062466	chr8:58055876	NA	0.73	8.62	0.43	2.79e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.43	6.6	0.34	1.58e-10	Dupuytren's disease;
LUSC	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg16482183	chr6:26056742	HIST1H1C	0.63	8.97	0.44	2.11e-17	Iron status biomarkers;
LUSC	cis	rs8099014	0.911	rs4245269	chr18:56110730	G/A	cg12907477	chr18:56117327	MIR122	0.44	7.02	0.36	1.28e-11	Platelet count;
LUSC	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg09165964	chr15:75287851	SCAMP5	-0.93	-8.66	-0.43	2.11e-16	Lung cancer;
LUSC	cis	rs3741151	0.773	rs17310361	chr11:73233724	T/C	cg17517138	chr11:73019481	ARHGEF17	0.91	7.7	0.39	1.53e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg04310649	chr10:35416472	CREM	-0.44	-6.84	-0.35	3.85e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs17001868	0.568	rs3788579	chr22:40742989	T/C	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	trans	rs7637701	0.773	rs4098	chr3:156501063	T/C	cg11006288	chr14:69012387	RAD51L1	0.38	5.96	0.31	6.37e-9	Breast cancer;
LUSC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg26441486	chr22:50317300	CRELD2	-0.54	-8.2	-0.41	5.07e-15	Schizophrenia;
LUSC	cis	rs9815354	0.953	rs11717170	chr3:42002811	G/C	cg03022575	chr3:42003672	ULK4	-0.51	-5.79	-0.3	1.61e-8	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-6.53	-0.34	2.48e-10	Homocysteine levels;
LUSC	cis	rs477692	1.000	rs479478	chr10:131428959	G/A	cg26102564	chr10:131424627	MGMT	0.41	6.4	0.33	5.33e-10	Response to temozolomide;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg24859228	chr10:12391835	CAMK1D	0.42	6.16	0.32	2.12e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg01879757	chr17:41196368	BRCA1	-0.46	-7.0	-0.36	1.44e-11	Menopause (age at onset);
LUSC	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg00579200	chr11:133705235	NA	-0.39	-5.97	-0.31	6.21e-9	Childhood ear infection;
LUSC	trans	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.46	-0.33	3.73e-10	Retinal vascular caliber;
LUSC	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-6.88	-0.35	2.94e-11	Body mass index;
LUSC	cis	rs2282802	0.685	rs7717563	chr5:139689968	A/G	cg26211634	chr5:139558579	C5orf32	-0.41	-7.83	-0.39	6.34e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-5.73	-0.3	2.26e-8	Height;
LUSC	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg01097406	chr16:89675127	NA	0.35	6.94	0.35	2.09e-11	Hemoglobin concentration;
LUSC	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	0.97	10.86	0.51	1.02e-23	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg11901034	chr3:128598214	ACAD9	-0.42	-6.67	-0.34	1.09e-10	IgG glycosylation;
LUSC	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	7.88	0.4	4.66e-14	Neuroticism;
LUSC	cis	rs9462027	0.628	rs2814967	chr6:34712838	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.87	-0.31	1.02e-8	Systemic lupus erythematosus;
LUSC	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg03563238	chr19:33554763	RHPN2	-0.4	-6.36	-0.33	6.72e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.18	-0.49	2.2e-21	Obesity-related traits;
LUSC	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.63	-0.43	2.59e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1335645	0.570	rs6703407	chr1:111622807	G/A	cg00321911	chr1:111669324	DRAM2	-0.65	-6.55	-0.34	2.14e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.69	-10.45	-0.5	2.56e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg08088566	chr11:430123	ANO9	0.66	7.15	0.36	5.56e-12	Body mass index;
LUSC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg09165964	chr15:75287851	SCAMP5	-1.06	-16.07	-0.66	1.91e-43	Blood trace element (Zn levels);
LUSC	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg04362960	chr10:104952993	NT5C2	0.9	11.69	0.54	1.06e-26	Arsenic metabolism;
LUSC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg17971929	chr21:40555470	PSMG1	-0.61	-9.93	-0.48	1.62e-20	Cognitive function;
LUSC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-7.99	-0.4	2.26e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg13722127	chr7:150037890	RARRES2	0.38	5.68	0.3	2.98e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg20887711	chr4:1340912	KIAA1530	0.42	6.42	0.33	4.6e-10	Obesity-related traits;
LUSC	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg24675056	chr1:15929824	NA	0.48	8.32	0.41	2.33e-15	Systolic blood pressure;
LUSC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg23649088	chr2:200775458	C2orf69	0.53	7.25	0.37	2.9e-12	Schizophrenia;
LUSC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg13319975	chr6:146136371	FBXO30	-0.53	-7.94	-0.4	3.09e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg05234568	chr11:5960015	NA	-0.6	-8.66	-0.43	2.01e-16	DNA methylation (variation);
LUSC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg22638593	chr5:131593259	PDLIM4	0.42	6.34	0.33	7.37e-10	Blood metabolite levels;
LUSC	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg17031739	chr1:67600172	NA	0.46	7.07	0.36	9.18e-12	Psoriasis;
LUSC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg11062466	chr8:58055876	NA	0.69	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg08132940	chr7:1081526	C7orf50	-0.52	-6.22	-0.32	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6484504	0.625	rs10835766	chr11:31374329	C/A	cg06552810	chr11:31128660	NA	0.39	6.84	0.35	3.69e-11	Red blood cell count;
LUSC	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg03563238	chr19:33554763	RHPN2	-0.41	-6.52	-0.34	2.56e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg20848291	chr7:100343083	ZAN	-0.65	-8.69	-0.43	1.6e-16	Other erythrocyte phenotypes;
LUSC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg11812906	chr14:75593930	NEK9	-0.64	-11.16	-0.52	8.32e-25	Height;
LUSC	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg02023728	chr11:77925099	USP35	0.49	6.87	0.35	3.11e-11	Testicular germ cell tumor;
LUSC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg19257562	chr1:2043853	PRKCZ	0.32	6.49	0.33	3.08e-10	Height;
LUSC	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg24375607	chr4:120327624	NA	0.53	8.13	0.41	8.39e-15	Diastolic blood pressure;
LUSC	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.54	-0.38	4.51e-13	Retinal vascular caliber;
LUSC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.59	-0.38	3.28e-13	Personality dimensions;
LUSC	cis	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg17469321	chr7:55412551	NA	0.64	10.19	0.49	2.02e-21	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.62	-0.34	1.42e-10	Arsenic metabolism;
LUSC	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg06484146	chr7:12443880	VWDE	-0.7	-7.07	-0.36	9.26e-12	Coronary artery disease;
LUSC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.15	16.21	0.66	5.28e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg01251360	chr16:68772225	CDH1	-0.27	-6.33	-0.33	8.07e-10	Colorectal cancer;
LUSC	cis	rs7572644	0.640	rs6547820	chr2:28281545	G/A	cg27432699	chr2:27873401	GPN1	-0.54	-7.24	-0.37	3.12e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-10.59	-0.5	8.72e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg25206134	chr2:45395956	NA	0.6	6.39	0.33	5.67e-10	Neuroticism;
LUSC	cis	rs12681287	0.752	rs13256500	chr8:87247063	G/A	cg27223183	chr8:87520930	FAM82B	-0.46	-5.73	-0.3	2.19e-8	Caudate activity during reward;
LUSC	cis	rs6688613	0.694	rs12562794	chr1:166828957	A/G	cg07049167	chr1:166818506	POGK	0.54	7.79	0.39	8.39e-14	Refractive astigmatism;
LUSC	cis	rs9648716	0.515	rs38739	chr7:140710848	A/G	cg23214464	chr7:140373596	ADCK2	0.72	6.24	0.32	1.34e-9	Type 2 diabetes;
LUSC	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg08601574	chr20:25228251	PYGB	-0.44	-6.66	-0.34	1.13e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09677724	chr16:70488359	FUK	-0.44	-6.56	-0.34	2.05e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg05896524	chr21:47604654	C21orf56	-0.4	-6.07	-0.31	3.57e-9	Testicular germ cell tumor;
LUSC	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg18584368	chr5:314553	AHRR;PDCD6	0.71	5.82	0.3	1.36e-8	Breast cancer;
LUSC	trans	rs459571	0.635	rs379471	chr9:136890649	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-12.48	-0.56	1.34e-29	Platelet distribution width;
LUSC	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.65	-0.63	6.79e-38	Schizophrenia;
LUSC	cis	rs238295	0.881	rs6116869	chr20:5594432	G/T	cg15842884	chr20:5591925	RP5-1022P6.2	0.46	6.53	0.34	2.43e-10	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg06521331	chr12:34319734	NA	0.41	6.75	0.35	6.66e-11	Morning vs. evening chronotype;
LUSC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg00579200	chr11:133705235	NA	-0.39	-5.66	-0.3	3.35e-8	Childhood ear infection;
LUSC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg14895029	chr7:2775587	GNA12	0.42	6.6	0.34	1.61e-10	Height;
LUSC	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.81	-12.51	-0.56	1.03e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1775715	0.651	rs2808033	chr10:32194127	A/T	cg04359828	chr10:32216031	ARHGAP12	0.41	7.03	0.36	1.2e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg22535103	chr8:58192502	C8orf71	-0.66	-7.25	-0.37	3e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.72	11.06	0.52	1.99e-24	Alcohol dependence;
LUSC	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	0.82	12.44	0.56	1.96e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg04851639	chr8:1020857	NA	-0.37	-7.6	-0.38	2.99e-13	Schizophrenia;
LUSC	cis	rs4478858	0.647	rs7524117	chr1:31738416	A/G	cg00250761	chr1:31883323	NA	-0.33	-7.99	-0.4	2.22e-14	Alcohol dependence;
LUSC	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.21	-0.37	3.87e-12	Bipolar disorder;
LUSC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	7.91	0.4	3.92e-14	Total body bone mineral density;
LUSC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-12.35	-0.56	4.07e-29	Body mass index;
LUSC	cis	rs7590368	0.715	rs72779451	chr2:10959407	A/C	cg15705551	chr2:10952987	PDIA6	0.58	6.24	0.32	1.31e-9	Educational attainment (years of education);
LUSC	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg21775007	chr8:11205619	TDH	-0.7	-10.76	-0.51	2.14e-23	Retinal vascular caliber;
LUSC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg22907277	chr7:1156413	C7orf50	0.7	10.25	0.49	1.28e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg16473166	chr22:50639996	SELO	0.58	8.09	0.4	1.1e-14	Obesity-related traits;
LUSC	cis	rs3925075	1.000	rs4889543	chr16:31340216	C/T	cg02846316	chr16:31340340	ITGAM	0.35	6.41	0.33	5.01e-10	IgA nephropathy;
LUSC	cis	rs4704187	0.687	rs7711762	chr5:74461675	C/T	cg03227963	chr5:74354835	NA	0.32	6.83	0.35	4.02e-11	Response to amphetamines;
LUSC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	0.9	15.33	0.64	1.52e-40	Menopause (age at onset);
LUSC	trans	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg07211511	chr3:129823064	LOC729375	-0.76	-9.88	-0.48	2.36e-20	Blood pressure (smoking interaction);
LUSC	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg12863693	chr15:85201151	NMB	0.4	8.45	0.42	8.81e-16	Schizophrenia;
LUSC	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg13010199	chr12:38710504	ALG10B	0.61	9.56	0.46	2.59e-19	Bladder cancer;
LUSC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	0.79	13.89	0.61	6.06e-35	Cognitive function;
LUSC	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	trans	rs11671005	0.504	rs3794963	chr19:59071051	C/G	cg22037779	chr5:139682734	PFDN1	0.53	7.32	0.37	1.89e-12	Mean platelet volume;
LUSC	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.35	-0.42	1.81e-15	Response to antipsychotic treatment;
LUSC	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg27284194	chr4:1044797	NA	0.6	8.85	0.44	5.26e-17	Recombination rate (females);
LUSC	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg05784532	chr1:230284198	GALNT2	-0.63	-9.01	-0.44	1.59e-17	Coronary artery disease;
LUSC	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg08917208	chr2:24149416	ATAD2B	0.97	10.04	0.48	6.83e-21	Lymphocyte counts;
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg23034840	chr1:205782522	SLC41A1	0.59	8.15	0.41	7.31e-15	Menarche (age at onset);
LUSC	cis	rs7712401	0.601	rs30028	chr5:122283269	G/T	cg19077854	chr5:122220652	SNX24	0.42	9.4	0.46	8.87e-19	Mean platelet volume;
LUSC	cis	rs2075165	0.901	rs7542798	chr1:156224304	A/G	cg20302342	chr1:156215951	PAQR6	0.33	6.42	0.33	4.62e-10	Tonsillectomy;
LUSC	cis	rs7215564	0.818	rs4889776	chr17:78592385	C/T	cg09596252	chr17:78655493	RPTOR	0.57	6.09	0.32	3.02e-9	Myopia (pathological);
LUSC	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg17252645	chr8:143867129	LY6D	-0.36	-6.31	-0.33	9.04e-10	Urinary tract infection frequency;
LUSC	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg15117754	chr3:10150083	C3orf24	0.44	5.79	0.3	1.59e-8	Alzheimer's disease;
LUSC	cis	rs240993	0.548	rs1040382	chr6:111902079	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.34	6.06	0.31	3.58e-9	Inflammatory skin disease;Psoriasis;
LUSC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg06453172	chr10:134556979	INPP5A	-0.5	-6.31	-0.33	9.06e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.617	rs4842569	chr12:86468609	T/G	cg02569458	chr12:86230093	RASSF9	-0.35	-5.65	-0.3	3.38e-8	Major depressive disorder;
LUSC	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg16576597	chr16:28551801	NUPR1	0.29	5.8	0.3	1.55e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs73200209	0.744	rs55837280	chr12:116645483	A/G	cg01776926	chr12:116560359	MED13L	-0.5	-6.12	-0.32	2.63e-9	Total body bone mineral density;
LUSC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-1.19	-12.84	-0.57	5.85e-31	Diabetic kidney disease;
LUSC	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg26816564	chr1:7831052	VAMP3	0.5	6.1	0.32	3e-9	Inflammatory bowel disease;
LUSC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg13206674	chr6:150067644	NUP43	0.61	9.83	0.47	3.4e-20	Lung cancer;
LUSC	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.57	-11.78	-0.54	5.12e-27	Sense of smell;
LUSC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg00310523	chr12:86230176	RASSF9	0.49	9.39	0.46	9.64e-19	Major depressive disorder;
LUSC	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.36	-7.08	-0.36	8.54e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs9811920	0.660	rs7619512	chr3:99729132	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.34	-6.51	-0.34	2.78e-10	Axial length;
LUSC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.65	-10.18	-0.49	2.18e-21	Menarche (age at onset);
LUSC	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.97	0.4	2.5e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.07	0.32	3.41e-9	Lung cancer;
LUSC	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg14186256	chr22:23484241	RTDR1	0.92	16.48	0.67	4.4e-45	Bone mineral density;
LUSC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg03036452	chr22:46663545	TTC38	0.52	5.7	0.3	2.62e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.86	0.4	5.28e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	0.92	15.08	0.64	1.44e-39	Breast cancer;
LUSC	cis	rs1044826	0.642	rs432387	chr3:139231853	T/G	cg15131784	chr3:139108705	COPB2	-0.39	-6.33	-0.33	7.67e-10	Obesity-related traits;
LUSC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00339695	chr16:24857497	SLC5A11	0.6	8.81	0.43	6.73e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg27411982	chr8:10470053	RP1L1	0.41	6.27	0.32	1.14e-9	Mood instability;
LUSC	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg10840412	chr1:235813424	GNG4	0.54	7.09	0.36	8.24e-12	Bipolar disorder;
LUSC	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg20991723	chr1:152506922	NA	0.52	9.77	0.47	5.39e-20	Hair morphology;
LUSC	cis	rs2637266	1.000	rs1873461	chr10:78338966	A/C	cg18941641	chr10:78392320	NA	-0.36	-6.44	-0.33	4.07e-10	Pulmonary function;
LUSC	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg25801113	chr15:45476975	SHF	0.34	7.07	0.36	9.18e-12	Uric acid levels;
LUSC	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.36e-14	Retinal vascular caliber;
LUSC	cis	rs7043114	0.507	rs10761154	chr9:95144086	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.78	-0.35	5.6e-11	Height;
LUSC	cis	rs9653442	0.564	rs4851253	chr2:100762786	T/G	cg07810366	chr2:100720526	AFF3	-0.44	-7.31	-0.37	2.01e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2692947	0.616	rs2301707	chr2:96931846	T/C	cg23100626	chr2:96804247	ASTL	0.3	7.16	0.36	5.07e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg13939156	chr17:80058883	NA	-0.34	-6.76	-0.35	6.08e-11	Life satisfaction;
LUSC	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg00310523	chr12:86230176	RASSF9	0.47	8.53	0.42	5.16e-16	Major depressive disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08033548	chr16:75529105	CHST6	-0.47	-6.33	-0.33	8.05e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg02574844	chr11:5959923	NA	-0.44	-6.31	-0.33	8.96e-10	DNA methylation (variation);
LUSC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7605827	0.897	rs13014906	chr2:15614404	T/C	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.37e-17	Educational attainment (years of education);
LUSC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg21724239	chr8:58056113	NA	0.55	6.37	0.33	6.1e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20307385	chr11:47447363	PSMC3	0.43	5.72	0.3	2.36e-8	Subjective well-being;
LUSC	cis	rs16976116	0.901	rs28526269	chr15:55499190	A/G	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg24642439	chr20:33292090	TP53INP2	0.48	7.2	0.37	4e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs2932538	0.883	rs6701351	chr1:113139196	G/A	cg22162597	chr1:113214053	CAPZA1	0.53	7.67	0.39	1.96e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	0.93	18.94	0.72	7.53e-55	Menarche (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17409405	chr7:5085485	RBAK	-0.41	-6.18	-0.32	1.87e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg10978503	chr1:24200527	CNR2	-0.45	-9.37	-0.46	1.11e-18	Immature fraction of reticulocytes;
LUSC	cis	rs526231	0.543	rs152123	chr5:102531919	A/G	cg23492399	chr5:102201601	PAM	0.45	5.77	0.3	1.78e-8	Primary biliary cholangitis;
LUSC	cis	rs7615316	1.000	rs2140432	chr3:142343552	A/G	cg16271453	chr3:142027066	XRN1	0.35	5.91	0.31	8.55e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9837602	0.872	rs34996634	chr3:99738219	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	5.74	0.3	2.12e-8	Breast cancer;
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-7.99	-0.4	2.23e-14	Lymphocyte counts;
LUSC	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg18005901	chr6:33739558	LEMD2	-0.4	-5.88	-0.31	1e-8	Schizophrenia;
LUSC	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg17385448	chr1:15911702	AGMAT	0.37	6.01	0.31	4.9e-9	Systolic blood pressure;
LUSC	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg09835421	chr16:68378352	PRMT7	-0.83	-8.84	-0.44	5.53e-17	Schizophrenia;
LUSC	cis	rs716595	1.000	rs72830457	chr10:112010671	A/C	cg13996003	chr10:112034540	MXI1	-0.69	-5.97	-0.31	6.14e-9	Normalized brain volume;
LUSC	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg22437258	chr11:111473054	SIK2	0.5	6.83	0.35	4.11e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg05347473	chr6:146136440	FBXO30	0.4	6.81	0.35	4.57e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.42	-5.66	-0.3	3.31e-8	Longevity;Endometriosis;
LUSC	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg16850897	chr7:100343110	ZAN	0.37	5.89	0.31	9.47e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg20891283	chr12:69753455	YEATS4	0.66	10.44	0.5	2.94e-22	Blood protein levels;
LUSC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	7.41	0.38	1.05e-12	Mood instability;
LUSC	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg05973401	chr12:123451056	ABCB9	0.55	6.81	0.35	4.68e-11	Neutrophil percentage of white cells;
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.47	-6.26	-0.32	1.17e-9	Longevity;Endometriosis;
LUSC	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg20607287	chr7:12443886	VWDE	-0.57	-6.17	-0.32	1.98e-9	Coronary artery disease;
LUSC	cis	rs10934753	0.632	rs1447661	chr3:125924981	A/G	cg01346077	chr3:125931526	NA	0.48	8.99	0.44	1.88e-17	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-7.52	-0.38	4.95e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.94	-0.36	2.02e-11	Response to antipsychotic treatment;
LUSC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	6.51	0.34	2.71e-10	Menarche (age at onset);
LUSC	cis	rs4901869	0.864	rs12891575	chr14:59334342	T/A	cg02291164	chr14:59296302	NA	0.58	10.93	0.51	5.63e-24	Panic disorder;
LUSC	cis	rs9788721	0.900	rs4243084	chr15:78911672	G/C	cg18825076	chr15:78729989	IREB2	-0.49	-7.71	-0.39	1.48e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg21862992	chr11:68658383	NA	0.51	8.11	0.41	9.65e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	1.03	19.58	0.73	2.08e-57	Menopause (age at onset);
LUSC	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg10560079	chr2:191398806	TMEM194B	0.7	8.82	0.43	6.58e-17	Diastolic blood pressure;
LUSC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg23950597	chr19:37808831	NA	-0.63	-7.8	-0.39	8.08e-14	Coronary artery calcification;
LUSC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg25258033	chr6:167368657	RNASET2	0.47	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg27165867	chr14:105738592	BRF1	-0.51	-7.5	-0.38	5.75e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8032315	0.965	rs4932373	chr15:91429287	A/C	cg04510874	chr15:91427884	FES	0.33	6.49	0.33	3.03e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05929132	chr15:66586024	DIS3L	-0.51	-6.17	-0.32	2.02e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg02187348	chr16:89574699	SPG7	0.47	7.05	0.36	1.04e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.6	-0.38	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg23172400	chr8:95962367	TP53INP1	0.36	6.76	0.35	6.31e-11	Type 2 diabetes;
LUSC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg12564285	chr5:131593104	PDLIM4	0.33	6.04	0.31	4.16e-9	Blood metabolite levels;
LUSC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg22535103	chr8:58192502	C8orf71	-0.69	-7.28	-0.37	2.35e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs243505	0.762	rs2007404	chr7:148487395	A/G	cg09806900	chr7:148480153	CUL1	0.55	8.15	0.41	7.35e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg04374321	chr14:90722782	PSMC1	0.75	12.09	0.55	3.85e-28	Mortality in heart failure;
LUSC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg05347473	chr6:146136440	FBXO30	-0.59	-10.57	-0.5	1.02e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311676	0.632	rs11719192	chr3:58431817	C/G	cg26110898	chr3:58419937	PDHB	0.41	6.69	0.34	9.7e-11	Systemic lupus erythematosus;
LUSC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.27	-0.49	1.06e-21	Gut microbiome composition (summer);
LUSC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg11657440	chr19:46296263	DMWD	-0.68	-10.24	-0.49	1.34e-21	Coronary artery disease;
LUSC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg02475777	chr4:1388615	CRIPAK	0.43	6.39	0.33	5.68e-10	Obesity-related traits;
LUSC	cis	rs751728	0.626	rs4711348	chr6:33736295	G/A	cg25922239	chr6:33757077	LEMD2	0.43	6.39	0.33	5.73e-10	Crohn's disease;
LUSC	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg09184832	chr6:79620586	NA	-0.42	-6.8	-0.35	4.71e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg19592336	chr6:28129416	ZNF389	0.5	6.57	0.34	1.94e-10	Parkinson's disease;
LUSC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg21699342	chr2:239360505	ASB1	0.56	10.48	0.5	2.04e-22	Multiple system atrophy;
LUSC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	0.94	15.86	0.66	1.24e-42	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17467752	chr17:38218738	THRA	0.77	12.44	0.56	1.94e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	trans	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.71e-10	Life satisfaction;
LUSC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08677398	chr8:58056175	NA	0.5	7.85	0.39	5.58e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08280861	chr8:58055591	NA	0.59	7.3	0.37	2.12e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg26752003	chr8:145688521	CYHR1	-0.41	-6.53	-0.34	2.41e-10	Age at first birth;
LUSC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg07741184	chr6:167504864	NA	0.38	6.8	0.35	4.7e-11	Crohn's disease;
LUSC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.02	20.48	0.75	5.84e-61	Cognitive function;
LUSC	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg24342717	chr2:85555507	TGOLN2	-0.74	-11.94	-0.55	1.29e-27	Ear protrusion;
LUSC	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg12935359	chr14:103987150	CKB	-0.65	-10.61	-0.5	7.5e-23	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08512882	chr17:42402347	SLC25A39	-0.48	-7.07	-0.36	8.91e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg12963246	chr6:28129442	ZNF389	0.52	7.09	0.36	7.99e-12	Depression;
LUSC	cis	rs3774830	0.748	rs17367445	chr4:5464903	C/T	cg26943120	chr4:5472116	STK32B	0.29	5.77	0.3	1.84e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg10253484	chr15:75165896	SCAMP2	-0.49	-7.46	-0.38	7.54e-13	Breast cancer;
LUSC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg10840412	chr1:235813424	GNG4	0.6	7.73	0.39	1.26e-13	Bipolar disorder;
LUSC	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.82e-13	Type 2 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14551182	chr11:16626476	NA	-0.44	-5.99	-0.31	5.3e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg22029157	chr1:209979665	IRF6	0.74	8.74	0.43	1.14e-16	Coronary artery disease;
LUSC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26314531	chr2:26401878	FAM59B	-0.7	-9.67	-0.47	1.16e-19	Gut microbiome composition (summer);
LUSC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg24675658	chr1:53192096	ZYG11B	0.58	9.14	0.45	6.02e-18	Monocyte count;
LUSC	cis	rs377070	0.966	rs411043	chr4:123633221	G/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.5	7.34	0.37	1.64e-12	Mosquito bite size;
LUSC	cis	rs12541635	0.966	rs114386112	chr8:107036340	G/A	cg10147462	chr8:107024639	NA	0.55	9.83	0.47	3.36e-20	Age of smoking initiation;
LUSC	trans	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.23	0.32	1.42e-9	Corneal astigmatism;
LUSC	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg11473876	chr11:109292803	C11orf87	0.41	6.58	0.34	1.82e-10	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7809950	1.000	rs2057837	chr7:107222725	C/G	cg23024343	chr7:107201750	COG5	0.52	8.16	0.41	7.01e-15	Coronary artery disease;
LUSC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.74	10.58	0.5	9.68e-23	Type 2 diabetes;
LUSC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	9.84	0.47	3.12e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.6	-5.75	-0.3	2.01e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2235544	0.565	rs620907	chr1:54468166	T/G	cg25741118	chr1:54482237	LDLRAD1	0.28	5.98	0.31	5.61e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg05347473	chr6:146136440	FBXO30	0.41	6.89	0.35	2.73e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg01420254	chr6:26195488	NA	0.68	7.52	0.38	5.21e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs6690583	0.623	rs7522239	chr1:85484366	C/T	cg11262906	chr1:85462892	MCOLN2	0.67	6.8	0.35	4.78e-11	Serum sulfate level;
LUSC	cis	rs4917300	0.605	rs10108708	chr8:143102886	A/G	cg25363559	chr8:143086065	NA	-0.32	-7.17	-0.37	4.91e-12	Amyotrophic lateral sclerosis;
LUSC	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg01528321	chr10:82214614	TSPAN14	0.98	14.61	0.62	1.03e-37	Post bronchodilator FEV1;
LUSC	trans	rs1027479	0.813	rs1391198	chr8:109723998	A/T	cg14904725	chr13:113777045	F10	-0.25	-6.12	-0.32	2.58e-9	Facial morphology (factor 6, height of vermillion lower lip);
LUSC	cis	rs17095355	1.000	rs11194917	chr10:111692552	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.91	-0.35	2.48e-11	Biliary atresia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17193163	chr11:66056724	YIF1A	0.41	6.38	0.33	5.93e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs10885122	0.850	rs10509937	chr10:113029061	A/C	cg13719885	chr3:127795394	NA	-0.52	-6.14	-0.32	2.31e-9	Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;Fasting blood glucose;
LUSC	cis	rs2544523	0.511	rs2544536	chr2:15906854	T/C	cg26669897	chr2:15909070	NA	0.34	7.13	0.36	6.08e-12	Asthma or chronic obstructive pulmonary disease;
LUSC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19717773	chr7:2847554	GNA12	-0.35	-5.68	-0.3	2.96e-8	Height;
LUSC	cis	rs4363385	0.747	rs4319267	chr1:152972699	T/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.83	-0.39	6.43e-14	Inflammatory skin disease;
LUSC	cis	rs68170813	0.559	rs4730232	chr7:106942382	G/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.71	-0.47	8.2e-20	Coronary artery disease;
LUSC	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.69	-11.26	-0.52	3.92e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.76	13.54	0.6	1.31e-33	Calcium levels;
LUSC	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg22709100	chr7:91322751	NA	0.39	5.86	0.31	1.11e-8	Breast cancer;
LUSC	cis	rs4820539	1.000	rs1051875	chr22:23466031	G/A	cg14186256	chr22:23484241	RTDR1	0.93	16.97	0.68	4.93e-47	Bone mineral density;
LUSC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.12	17.03	0.68	2.85e-47	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg07424592	chr7:64974309	NA	0.7	6.15	0.32	2.24e-9	Diabetic kidney disease;
LUSC	cis	rs6700896	0.500	rs67051863	chr1:66114975	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	6.36	0.33	6.62e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs57920188	0.568	rs12137595	chr1:4094068	C/T	cg20703997	chr1:4087676	NA	0.67	8.08	0.4	1.16e-14	Interleukin-17 levels;
LUSC	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg05855489	chr10:104503620	C10orf26	0.59	9.51	0.46	3.79e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.43	5.96	0.31	6.24e-9	Osteoporosis;
LUSC	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.87	14.9	0.63	7.8e-39	Bladder cancer;
LUSC	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg27446573	chr6:127587934	RNF146	0.47	7.15	0.36	5.51e-12	Breast cancer;
LUSC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.16	-0.32	2.13e-9	Life satisfaction;
LUSC	cis	rs356992	0.957	rs356979	chr2:60747743	T/C	cg08426369	chr2:60753602	BCL11A	0.44	6.01	0.31	4.76e-9	Educational attainment (years of education);
LUSC	cis	rs9905704	0.633	rs8068455	chr17:56589381	C/T	cg12560992	chr17:57184187	TRIM37	-0.5	-5.88	-0.31	1e-8	Testicular germ cell tumor;
LUSC	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.52	0.34	2.67e-10	Testicular germ cell tumor;
LUSC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg06453172	chr10:134556979	INPP5A	-0.5	-6.35	-0.33	6.9e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.68	12.13	0.55	2.6e-28	Aortic root size;
LUSC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg24642844	chr7:1081250	C7orf50	-0.48	-7.66	-0.39	2.07e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.85	0.68	1.53e-46	Exhaled nitric oxide output;
LUSC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg04398451	chr17:18023971	MYO15A	-0.48	-7.65	-0.39	2.12e-13	Total body bone mineral density;
LUSC	cis	rs4891159	0.790	rs660029	chr18:74149668	A/G	cg24786174	chr18:74118243	ZNF516	0.9	18.48	0.71	4.92e-53	Longevity;
LUSC	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg06784218	chr1:46089804	CCDC17	-0.3	-5.87	-0.31	1.04e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg05294307	chr14:35346193	BAZ1A	-0.49	-5.71	-0.3	2.55e-8	Psoriasis;
LUSC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg21548813	chr6:291882	DUSP22	-0.48	-7.02	-0.36	1.28e-11	Menopause (age at onset);
LUSC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.4	1.9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg13319975	chr6:146136371	FBXO30	0.54	8.23	0.41	4.12e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-35.46	-0.89	2.79e-115	Myeloid white cell count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19844325	chr19:18314808	RAB3A	-0.5	-6.14	-0.32	2.31e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23888375	chr2:203776317	ALS2CR8;WDR12	-0.51	-6.38	-0.33	5.79e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1997103	1.000	rs10224446	chr7:55413147	C/G	cg17469321	chr7:55412551	NA	0.65	10.53	0.5	1.45e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11310125	chr2:113239311	TTL	-0.47	-6.09	-0.32	3.11e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7712401	0.580	rs185008	chr5:122274734	T/C	cg19077854	chr5:122220652	SNX24	0.42	9.32	0.45	1.68e-18	Mean platelet volume;
LUSC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.58	0.5	9.76e-23	Schizophrenia;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20136444	chr3:183903974	ABCF3	0.36	6.03	0.31	4.33e-9	Asthma;
LUSC	trans	rs6601327	0.602	rs7829463	chr8:9649691	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.49	-0.33	3.13e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg05084668	chr3:125655381	ALG1L	-0.49	-6.86	-0.35	3.26e-11	Blood pressure (smoking interaction);
LUSC	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.86	-15.23	-0.64	3.98e-40	Ulcerative colitis;
LUSC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg25039879	chr17:56429692	SUPT4H1	0.71	9.48	0.46	4.81e-19	Cognitive test performance;
LUSC	cis	rs7605827	0.930	rs4410258	chr2:15594984	A/C	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.26e-17	Educational attainment (years of education);
LUSC	cis	rs5758511	0.773	rs11913631	chr22:42347371	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.42	6.91	0.35	2.4e-11	Birth weight;
LUSC	cis	rs8044868	0.586	rs8182213	chr16:72080005	C/T	cg16579770	chr16:72058938	DHODH	0.34	5.79	0.3	1.65e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg14664628	chr15:75095509	CSK	-0.58	-9.06	-0.44	1.12e-17	Breast cancer;
LUSC	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg13010199	chr12:38710504	ALG10B	-0.59	-9.26	-0.45	2.54e-18	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-7.73	-0.39	1.31e-13	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg07701084	chr6:150067640	NUP43	0.54	8.03	0.4	1.71e-14	Lung cancer;
LUSC	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg10326726	chr10:51549505	MSMB	-0.34	-5.9	-0.31	9.14e-9	Prostate-specific antigen levels;
LUSC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	7.74	0.39	1.18e-13	Total body bone mineral density;
LUSC	cis	rs1832871	0.672	rs6899322	chr6:158753669	G/T	cg07165851	chr6:158734300	TULP4	0.47	7.17	0.37	4.79e-12	Height;
LUSC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg10057126	chr4:77819792	ANKRD56	0.53	7.88	0.4	4.75e-14	Emphysema distribution in smoking;
LUSC	cis	rs240764	0.782	rs7748644	chr6:101166809	T/G	cg09795085	chr6:101329169	ASCC3	-0.41	-5.88	-0.31	1e-8	Neuroticism;
LUSC	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-7.69	-0.39	1.62e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg24558204	chr6:135376177	HBS1L	-0.59	-8.67	-0.43	1.9e-16	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg17330251	chr7:94953956	PON1	-0.37	-5.87	-0.31	1.06e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2637266	0.749	rs4979830	chr10:78457484	C/T	cg18941641	chr10:78392320	NA	0.34	6.12	0.32	2.59e-9	Pulmonary function;
LUSC	cis	rs9473147	0.543	rs4715025	chr6:47483653	C/G	cg12968598	chr6:47444699	CD2AP	0.53	8.07	0.4	1.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg05025164	chr4:1340916	KIAA1530	0.53	8.44	0.42	9.9e-16	Longevity;
LUSC	cis	rs2742234	0.590	rs2075912	chr10:43622217	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.34	-0.37	1.67e-12	Hirschsprung disease;
LUSC	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg00310523	chr12:86230176	RASSF9	0.35	6.31	0.33	8.79e-10	Major depressive disorder;
LUSC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.59	9.72	0.47	8.19e-20	Aortic root size;
LUSC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08677398	chr8:58056175	NA	0.54	7.01	0.36	1.34e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs877282	0.853	rs7069720	chr10:754487	A/G	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs7000551	0.663	rs7827118	chr8:22334669	T/G	cg12081754	chr8:22256438	SLC39A14	0.45	6.75	0.35	6.5e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs983392	0.678	rs4938931	chr11:60026613	G/T	cg20284999	chr11:59952153	MS4A6A	0.37	6.3	0.33	9.38e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9534288	0.797	rs9526134	chr13:46618046	G/T	cg15192986	chr13:46630673	CPB2	-0.66	-10.57	-0.5	1.01e-22	Blood protein levels;
LUSC	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg08017756	chr2:100939284	LONRF2	0.46	8.56	0.42	4.31e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs2153535	1.000	rs2153535	chr6:8369679	C/G	cg07606381	chr6:8435919	SLC35B3	-0.5	-7.53	-0.38	4.86e-13	Motion sickness;
LUSC	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.52	8.06	0.4	1.41e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10493773	0.502	rs12061951	chr1:86081453	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.36	-7.74	-0.39	1.22e-13	Urate levels in overweight individuals;
LUSC	cis	rs6574644	1.000	rs12588234	chr14:81773032	C/A	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg13042288	chr15:90349979	ANPEP	-0.41	-6.23	-0.32	1.43e-9	Uric acid levels;
LUSC	cis	rs12928939	0.815	rs1345868	chr16:71669624	G/T	cg03805757	chr16:71968109	PKD1L3	-0.39	-5.72	-0.3	2.31e-8	Post bronchodilator FEV1;
LUSC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-7.42	-0.38	9.65e-13	Hemoglobin concentration;
LUSC	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg13813247	chr22:41461852	NA	-0.36	-6.41	-0.33	4.96e-10	Neuroticism;
LUSC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg07389463	chr12:132296394	NA	0.47	8.95	0.44	2.58e-17	Migraine;
LUSC	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg23601095	chr6:26197514	HIST1H3D	0.68	7.42	0.38	9.69e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs7605827	0.930	rs3792579	chr2:15534723	A/G	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs870825	0.655	rs10033035	chr4:185630880	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.12	0.58	5.24e-32	Blood protein levels;
LUSC	cis	rs17255340	0.577	rs34639488	chr6:84107888	G/T	cg08257003	chr6:84140564	ME1	0.32	7.2	0.37	4.02e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs6556937	0.627	rs10067766	chr5:96002020	A/G	cg07690455	chr5:95997198	CAST	0.46	6.39	0.33	5.57e-10	Blood protein levels;
LUSC	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg18196295	chr10:418757	DIP2C	0.48	8.05	0.4	1.49e-14	Psychosis in Alzheimer's disease;
LUSC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg05373962	chr22:49881684	NA	-0.43	-10.23	-0.49	1.53e-21	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.48	-0.33	3.21e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-12.33	-0.56	4.72e-29	Platelet count;
LUSC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.74	-13.38	-0.59	5.27e-33	Aortic root size;
LUSC	cis	rs6740322	0.895	rs6760797	chr2:43559612	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-7.53	-0.38	4.87e-13	Coronary artery disease;
LUSC	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg24011408	chr12:48396354	COL2A1	-0.43	-7.22	-0.37	3.61e-12	Plateletcrit;
LUSC	cis	rs10992471	0.603	rs7864575	chr9:95304647	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-6.98	-0.36	1.57e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg02800362	chr5:177631904	HNRNPAB	0.83	12.44	0.56	1.95e-29	Obesity-related traits;
LUSC	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg08798685	chr6:27730294	NA	-0.59	-5.71	-0.3	2.49e-8	Breast cancer;
LUSC	cis	rs35883536	0.647	rs10875328	chr1:101169328	C/T	cg06223162	chr1:101003688	GPR88	-0.44	-7.79	-0.39	8.4e-14	Monocyte count;
LUSC	cis	rs9487051	0.768	rs399561	chr6:109524979	G/A	cg00509249	chr6:109615579	CCDC162	-0.33	-5.74	-0.3	2.09e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4619890	0.528	rs28558196	chr4:7880360	T/A	cg24250820	chr4:7887609	AFAP1	0.36	6.13	0.32	2.52e-9	Glaucoma (primary open-angle);
LUSC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg27494647	chr7:150038898	RARRES2	0.43	6.5	0.33	3e-10	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg10756647	chr7:56101905	PSPH	0.87	8.85	0.44	5.16e-17	Diabetic kidney disease;
LUSC	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg18478394	chr8:109455254	TTC35	0.41	6.29	0.33	9.7e-10	Dupuytren's disease;
LUSC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg03790207	chr6:42947109	PEX6	-0.46	-7.06	-0.36	9.53e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg08313168	chr12:7315531	NA	0.46	6.02	0.31	4.48e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs17095355	0.579	rs72828224	chr10:111702047	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.67	-0.39	1.93e-13	Biliary atresia;
LUSC	trans	rs4714291	0.963	rs1743969	chr6:40096918	A/G	cg02267698	chr19:7991119	CTXN1	0.53	7.4	0.38	1.15e-12	Strep throat;
LUSC	cis	rs17253792	0.749	rs74979160	chr14:56097568	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg08017756	chr2:100939284	LONRF2	-0.42	-7.87	-0.4	4.97e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6714788	0.503	rs1370356	chr2:100675241	G/C	cg22139774	chr2:100720529	AFF3	-0.38	-6.01	-0.31	4.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	7.24	0.37	3.18e-12	Response to antipsychotic treatment;
LUSC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg08847533	chr14:75593920	NEK9	-0.47	-6.84	-0.35	3.74e-11	IgG glycosylation;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00656289	chr6:158653327	NA	-0.44	-6.71	-0.34	8.31e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	13.62	0.6	6.38e-34	Alzheimer's disease;
LUSC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg00310523	chr12:86230176	RASSF9	0.54	10.05	0.48	5.93e-21	Major depressive disorder;
LUSC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.17	-0.32	1.95e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg17366294	chr4:99064904	C4orf37	0.57	9.91	0.48	1.76e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.36	-0.33	6.46e-10	Total body bone mineral density;
LUSC	cis	rs9311676	0.632	rs7624283	chr3:58369897	G/A	cg13750441	chr3:58318267	PXK	0.35	6.7	0.34	8.72e-11	Systemic lupus erythematosus;
LUSC	cis	rs250677	0.522	rs10042466	chr5:148393634	T/C	cg18129178	chr5:148520854	ABLIM3	-0.55	-8.07	-0.4	1.3e-14	Breast cancer;
LUSC	trans	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg13010199	chr12:38710504	ALG10B	0.46	6.38	0.33	5.81e-10	Resting heart rate;
LUSC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.7e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg03812724	chr21:15588363	RBM11	0.43	6.24	0.32	1.3e-9	Bladder cancer;
LUSC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10802521	chr3:52805072	NEK4	-0.53	-8.57	-0.42	3.93e-16	Bipolar disorder;
LUSC	cis	rs151234	0.741	rs10521145	chr16:28596884	A/G	cg01378222	chr16:28622494	SULT1A1	0.59	8.21	0.41	4.72e-15	Platelet distribution width;
LUSC	cis	rs8027181	0.839	rs9460	chr15:73044575	C/T	cg25632853	chr15:73088954	NA	0.31	6.32	0.33	8.51e-10	Triglyceride levels;
LUSC	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.71	0.3	2.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4654899	0.931	rs2275468	chr1:21220375	T/G	cg01072550	chr1:21505969	NA	0.52	7.72	0.39	1.32e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg06212747	chr3:49208901	KLHDC8B	0.43	5.76	0.3	1.95e-8	Parkinson's disease;
LUSC	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-8.1	-0.41	1.01e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	22.74	0.78	8.36e-70	Height;
LUSC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg26659404	chr1:25747437	RHCE	-0.29	-6.13	-0.32	2.49e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg00810483	chr4:3375144	RGS12	0.3	5.83	0.3	1.28e-8	Serum sulfate level;
LUSC	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.72	0.35	8.08e-11	Corneal astigmatism;
LUSC	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.62	10.39	0.49	4.27e-22	Blood metabolite ratios;
LUSC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	1.0	17.97	0.7	5.22e-51	Cognitive function;
LUSC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg23630131	chr7:65973040	NA	0.2	5.68	0.3	2.95e-8	Aortic root size;
LUSC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg00599273	chr12:58146742	CDK4	0.31	5.81	0.3	1.48e-8	Multiple sclerosis;
LUSC	cis	rs77372450	0.636	rs10066519	chr5:157017429	A/G	cg25387487	chr5:157003181	ADAM19	-0.47	-5.67	-0.3	3.05e-8	Bipolar disorder (body mass index interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24259688	chr15:91414844	FURIN	0.45	6.53	0.34	2.46e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-9.23	-0.45	3.2e-18	Monocyte count;
LUSC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg12463550	chr7:65579703	CRCP	0.53	7.59	0.38	3.29e-13	Aortic root size;
LUSC	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg04607235	chr12:12878440	APOLD1	-0.48	-5.67	-0.3	3.1e-8	Systemic lupus erythematosus;
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg16031515	chr1:205743344	RAB7L1	-0.3	-6.36	-0.33	6.52e-10	Menarche (age at onset);
LUSC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg00255919	chr5:131827918	IRF1	0.43	8.28	0.41	3.11e-15	Asthma (sex interaction);
LUSC	cis	rs1577917	0.883	rs1415749	chr6:86779084	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.41	5.95	0.31	6.89e-9	Response to antipsychotic treatment;
LUSC	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg13057898	chr1:3703894	LRRC47	0.48	8.12	0.41	9.34e-15	Red cell distribution width;
LUSC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg07507251	chr3:52567010	NT5DC2	0.37	7.63	0.39	2.49e-13	Electroencephalogram traits;
LUSC	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg02018176	chr4:1364513	KIAA1530	0.41	5.65	0.3	3.44e-8	Recombination rate (females);
LUSC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	0.98	21.07	0.76	2.86e-63	Menarche (age at onset);
LUSC	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs12891047	0.840	rs72725103	chr14:68297100	G/T	cg20999565	chr14:68265668	ZFYVE26	0.38	5.8	0.3	1.54e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2708977	0.671	rs582014	chr2:97075826	A/G	cg01950434	chr2:97203154	ARID5A	-0.45	-6.24	-0.32	1.36e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	trans	rs11165623	0.564	rs7523597	chr1:97000989	A/G	cg10631902	chr5:14652156	NA	-0.41	-6.06	-0.31	3.69e-9	Hip circumference;Waist circumference;
LUSC	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.6	-0.43	3.09e-16	Body mass index;
LUSC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg18963800	chr10:38644991	HSD17B7P2	-0.51	-7.47	-0.38	6.88e-13	Breast cancer;
LUSC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.57	-10.02	-0.48	7.76e-21	Extrinsic epigenetic age acceleration;
LUSC	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg22800045	chr5:56110881	MAP3K1	0.47	6.33	0.33	7.67e-10	Coronary artery disease;
LUSC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg02269571	chr22:50332266	NA	0.59	8.71	0.43	1.44e-16	Schizophrenia;
LUSC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg02487422	chr3:49467188	NICN1	0.47	7.56	0.38	3.83e-13	Resting heart rate;
LUSC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg16647868	chr5:131706066	SLC22A5	0.38	5.87	0.31	1.07e-8	Breast cancer;
LUSC	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg17411546	chr10:75410026	SYNPO2L	-0.5	-7.63	-0.39	2.4e-13	Inflammatory bowel disease;
LUSC	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-9.58	-0.46	2.23e-19	Migraine;Coronary artery disease;
LUSC	trans	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07923666	chr12:49932857	KCNH3	-0.53	-6.43	-0.33	4.54e-10	Resting heart rate;
LUSC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.07	-0.4	1.31e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	0.89	16.68	0.67	7.5e-46	Heart rate;
LUSC	cis	rs11997175	0.595	rs7386404	chr8:33762842	T/C	ch.8.33884649F	chr8:33765107	NA	0.43	6.14	0.32	2.4e-9	Body mass index;
LUSC	cis	rs12210905	0.925	rs17345718	chr6:26964258	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.98	0.51	3.77e-24	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg23241863	chr10:102295624	HIF1AN	0.49	5.98	0.31	5.84e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg20637307	chr2:213403960	ERBB4	0.44	7.67	0.39	1.85e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg03806693	chr22:41940476	POLR3H	-0.87	-12.28	-0.56	7.15e-29	Vitiligo;
LUSC	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg25214090	chr10:38739885	LOC399744	0.53	7.75	0.39	1.12e-13	Corneal astigmatism;
LUSC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg05084668	chr3:125655381	ALG1L	-0.5	-7.07	-0.36	9.09e-12	Blood pressure (smoking interaction);
LUSC	cis	rs6977660	0.714	rs7798760	chr7:19803487	T/C	cg05791153	chr7:19748676	TWISTNB	0.68	7.28	0.37	2.43e-12	Thyroid stimulating hormone;
LUSC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg13535736	chr9:111863775	C9orf5	-0.4	-6.6	-0.34	1.59e-10	Menarche (age at onset);
LUSC	cis	rs11229555	0.645	rs11229489	chr11:58244917	A/G	cg15696309	chr11:58395628	NA	-0.71	-8.55	-0.42	4.53e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2625529	0.652	rs2930069	chr15:72226977	G/A	cg16672083	chr15:72433130	SENP8	0.49	8.12	0.41	8.94e-15	Red blood cell count;
LUSC	cis	rs12711979	0.584	rs11694096	chr2:3868113	G/A	cg17052675	chr2:3827356	NA	-0.64	-12.82	-0.57	7.35e-31	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.62	-8.05	-0.4	1.49e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg25036284	chr2:26402008	FAM59B	0.72	9.28	0.45	2.27e-18	Gut microbiome composition (summer);
LUSC	cis	rs7119	0.717	rs12904348	chr15:77815738	G/C	cg27398640	chr15:77910606	LINGO1	-0.32	-6.84	-0.35	3.81e-11	Type 2 diabetes;
LUSC	cis	rs838147	0.760	rs412712	chr19:49234299	A/T	cg21064579	chr19:49206444	FUT2	-0.33	-5.68	-0.3	2.91e-8	Dietary macronutrient intake;
LUSC	cis	rs4780355	1.000	rs4780355	chr16:11347858	T/C	cg00044050	chr16:11439710	C16orf75	0.51	7.3	0.37	2.08e-12	Crohn's disease and psoriasis;
LUSC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg03526776	chr6:41159608	TREML2	0.32	6.12	0.32	2.68e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg02353165	chr6:42928485	GNMT	0.48	6.58	0.34	1.83e-10	Blood protein levels;
LUSC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04850017	chr11:63683019	RCOR2	0.29	5.79	0.3	1.6e-8	Pulse pressure;
LUSC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg14664628	chr15:75095509	CSK	-0.55	-8.4	-0.42	1.26e-15	Breast cancer;
LUSC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg10729496	chr3:10149963	C3orf24	0.55	7.59	0.38	3.3e-13	Alzheimer's disease;
LUSC	cis	rs9547692	0.938	rs12427600	chr13:37460648	C/T	cg01493522	chr13:37497338	NA	0.42	6.48	0.33	3.37e-10	Coronary artery disease;
LUSC	cis	rs9479482	0.648	rs912558	chr6:150385730	G/T	cg25797454	chr6:150327115	RAET1K	-0.28	-6.3	-0.33	9.14e-10	Alopecia areata;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05170515	chr14:24899109	CBLN3;KHNYN	-0.35	-5.95	-0.31	6.75e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.15	15.59	0.65	1.5e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg22166914	chr1:53195759	ZYG11B	0.48	7.61	0.38	2.74e-13	Monocyte count;
LUSC	cis	rs62432291	0.681	rs425906	chr6:159657575	C/T	cg14500486	chr6:159655392	FNDC1	-0.54	-6.06	-0.31	3.64e-9	Joint mobility (Beighton score);
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg02245743	chr17:8114003	AURKB	0.42	6.52	0.34	2.6200000000000003e-10	Educational attainment (years of education);
LUSC	cis	rs6700896	0.931	rs12042807	chr1:66134052	T/C	cg04111102	chr1:66153794	NA	0.33	7.26	0.37	2.81e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs4664304	0.629	rs955388	chr2:160837921	A/G	cg05371993	chr16:1458494	UNKL	0.41	5.96	0.31	6.59e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.54	0.5	1.25e-22	Morning vs. evening chronotype;
LUSC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14829155	chr15:31115871	NA	0.64	9.38	0.46	1.02e-18	Huntington's disease progression;
LUSC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.4	-0.42	1.27e-15	Obesity-related traits;
LUSC	cis	rs12220238	1.000	rs10824078	chr10:75892120	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.14	0.36	5.91e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	13.63	0.6	5.91e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2742417	0.603	rs2064063	chr3:45759924	T/A	cg04837898	chr3:45731254	SACM1L	-0.44	-7.19	-0.37	4.38e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs7215564	0.908	rs2316062	chr17:78663558	C/T	cg09596252	chr17:78655493	RPTOR	0.53	5.85	0.31	1.15e-8	Myopia (pathological);
LUSC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg05425664	chr17:57184151	TRIM37	0.55	8.14	0.41	7.84e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	1.02	18.56	0.71	2.49e-53	Cognitive function;
LUSC	cis	rs2708977	0.666	rs17685664	chr2:97315570	C/T	cg01950434	chr2:97203154	ARID5A	0.53	7.9	0.4	4.01e-14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs710216	0.917	rs3754223	chr1:43419091	A/T	cg03128534	chr1:43423976	SLC2A1	0.43	5.91	0.31	8.51e-9	Red cell distribution width;
LUSC	cis	rs17401966	0.522	rs7368073	chr1:10314962	G/T	cg19773385	chr1:10388646	KIF1B	-0.34	-5.95	-0.31	6.59e-9	Hepatocellular carcinoma;
LUSC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg10792982	chr14:105748885	BRF1	0.52	9.43	0.46	7.25e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	0.92	15.4	0.64	8.35e-41	Breast cancer;
LUSC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg08132940	chr7:1081526	C7orf50	-0.47	-6.02	-0.31	4.64e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg20406979	chr6:167373233	NA	0.25	5.81	0.3	1.49e-8	Crohn's disease;
LUSC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg09365446	chr1:150670422	GOLPH3L	0.47	7.05	0.36	1.02e-11	Melanoma;
LUSC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg13206674	chr6:150067644	NUP43	0.58	9.24	0.45	3.02e-18	Lung cancer;
LUSC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg13647721	chr17:30228624	UTP6	0.59	5.84	0.3	1.21e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg00024416	chr22:24240387	NA	-0.33	-5.67	-0.3	3.09e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-12.07	-0.55	4.24e-28	Platelet count;
LUSC	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg07936489	chr17:37558343	FBXL20	0.69	9.58	0.46	2.38e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg18964960	chr10:1102726	WDR37	-0.44	-5.93	-0.31	7.47e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.72	-11.24	-0.52	4.47e-25	Menarche (age at onset);
LUSC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.94	14.98	0.63	3.51e-39	Coronary artery disease;
LUSC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg00033643	chr7:134001901	SLC35B4	0.42	6.58	0.34	1.77e-10	Mean platelet volume;
LUSC	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg12365402	chr11:9010492	NRIP3	-0.49	-9.37	-0.46	1.15e-18	Hemoglobin concentration;
LUSC	cis	rs977987	0.843	rs10514396	chr16:75422903	T/C	cg03315344	chr16:75512273	CHST6	0.53	10.35	0.49	6.07e-22	Dupuytren's disease;
LUSC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.64	0.39	2.28e-13	Obesity-related traits;
LUSC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg22143856	chr6:28129313	ZNF389	0.42	5.78	0.3	1.73e-8	Parkinson's disease;
LUSC	cis	rs9311676	0.656	rs4681682	chr3:58337833	A/G	cg13750441	chr3:58318267	PXK	-0.32	-6.08	-0.32	3.19e-9	Systemic lupus erythematosus;
LUSC	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg08917208	chr2:24149416	ATAD2B	1.01	10.61	0.5	7.29e-23	Lymphocyte counts;
LUSC	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	9.99	0.48	9.57e-21	Lung cancer in ever smokers;
LUSC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-9.82	-0.47	3.77e-20	Bipolar disorder;
LUSC	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg18850127	chr7:39170497	POU6F2	0.58	9.17	0.45	4.96e-18	IgG glycosylation;
LUSC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg17264618	chr3:40429014	ENTPD3	0.35	7.19	0.37	4.15e-12	Renal cell carcinoma;
LUSC	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-8.5	-0.42	6.58e-16	Morning vs. evening chronotype;
LUSC	cis	rs12681288	0.576	rs6990403	chr8:963471	C/A	cg15309053	chr8:964076	NA	0.39	7.57	0.38	3.7e-13	Schizophrenia;
LUSC	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg21775007	chr8:11205619	TDH	0.83	13.49	0.59	2.12e-33	Retinal vascular caliber;
LUSC	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-7.01	-0.36	1.31e-11	Retinal vascular caliber;
LUSC	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.41	-6.05	-0.31	3.9e-9	IgG glycosylation;
LUSC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.42	5.95	0.31	6.93e-9	Renal function-related traits (BUN);
LUSC	cis	rs2414856	0.510	rs72756980	chr15:64574780	G/A	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs1712517	0.771	rs61869827	chr10:105079439	T/C	cg05636881	chr10:105038444	INA	0.39	6.39	0.33	5.47e-10	Migraine;
LUSC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.54	0.76	3.92e-65	Prudent dietary pattern;
LUSC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg19592336	chr6:28129416	ZNF389	0.5	6.7	0.34	8.76e-11	Depression;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00360718	chr10:104192479	CUEDC2	-0.48	-6.23	-0.32	1.43e-9	Hepatitis;
LUSC	trans	rs2229238	0.911	rs73020232	chr1:154482669	C/T	cg25273160	chr11:56955011	LRRC55	0.31	5.96	0.31	6.37e-9	Coronary heart disease;
LUSC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.05	-0.31	3.82e-9	Monocyte count;
LUSC	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg05340658	chr4:99064831	C4orf37	-0.47	-7.43	-0.38	8.98e-13	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs16866061	1.000	rs34345163	chr2:225459080	A/G	cg12698349	chr2:225449008	CUL3	0.85	13.68	0.6	4.04e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg09359103	chr1:154839909	KCNN3	0.72	16.13	0.66	1.06e-43	Prostate cancer;
LUSC	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg16240275	chr20:61666158	NCRNA00029	0.42	8.89	0.44	3.82e-17	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1775715	0.677	rs2491272	chr10:32186783	A/G	cg03015672	chr10:32216066	ARHGAP12	0.34	6.12	0.32	2.65e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06634786	chr22:41940651	POLR3H	-0.53	-6.47	-0.33	3.45e-10	Vitiligo;
LUSC	cis	rs2970818	0.831	rs2970812	chr12:4625836	C/T	cg11146114	chr12:4671731	NA	-0.59	-6.33	-0.33	7.79e-10	Phosphorus levels;
LUSC	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs72781680	0.651	rs13019016	chr2:23894773	C/G	cg20701182	chr2:24300061	SF3B14	0.57	5.89	0.31	9.57e-9	Lymphocyte counts;
LUSC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs28785552	0.897	rs34244888	chr19:53242228	T/A	cg22067481	chr19:53234126	ZNF611	-0.53	-7.36	-0.37	1.4e-12	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	0.63	13.38	0.59	5.59e-33	Prudent dietary pattern;
LUSC	cis	rs56399783	0.803	rs7811164	chr7:2822416	G/A	cg14895029	chr7:2775587	GNA12	0.47	5.92	0.31	7.95e-9	Childhood ear infection;
LUSC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	2.98e-10	Life satisfaction;
LUSC	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg27068297	chr22:50451975	IL17REL	0.29	6.07	0.32	3.53e-9	Ulcerative colitis;
LUSC	cis	rs3126085	0.935	rs4511113	chr1:152222192	G/A	cg26876637	chr1:152193138	HRNR	0.45	6.19	0.32	1.73e-9	Atopic dermatitis;
LUSC	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	7.79	0.39	8.78e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-0.55	-8.63	-0.43	2.47e-16	Breast cancer;
LUSC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg19230755	chr7:65878503	NA	0.43	5.97	0.31	6.12e-9	Aortic root size;
LUSC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.72	-14.25	-0.61	2.59e-36	Type 2 diabetes;
LUSC	cis	rs7760949	0.888	rs9296853	chr6:13893945	T/A	cg27413430	chr6:13925136	RNF182	0.53	7.89	0.4	4.25e-14	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.14	-0.8	3.2e-75	Height;
LUSC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg00800038	chr16:89945340	TCF25	-0.76	-6.58	-0.34	1.78e-10	Skin colour saturation;
LUSC	cis	rs3820928	1.000	rs4675119	chr2:227774635	A/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.9	-0.4	3.95e-14	Pulmonary function;
LUSC	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg14458575	chr2:238380390	NA	0.46	5.76	0.3	1.95e-8	Prostate cancer;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg16876192	chr8:144550601	ZC3H3	-0.39	-6.02	-0.31	4.52e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg16362232	chr11:430036	ANO9	0.6	7.87	0.4	4.86e-14	Body mass index;
LUSC	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg13042288	chr15:90349979	ANPEP	-0.49	-7.01	-0.36	1.34e-11	Uric acid levels;
LUSC	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg13789015	chr9:136890014	NCRNA00094	0.7	13.0	0.58	1.45e-31	Platelet distribution width;
LUSC	cis	rs12760731	0.565	rs10913519	chr1:178196094	A/T	cg00404053	chr1:178313656	RASAL2	0.68	6.9	0.35	2.55e-11	Obesity-related traits;
LUSC	cis	rs9905704	0.918	rs11655808	chr17:56854517	T/C	cg12560992	chr17:57184187	TRIM37	0.54	7.55	0.38	4.22e-13	Testicular germ cell tumor;
LUSC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg07424592	chr7:64974309	NA	-0.45	-6.42	-0.33	4.78e-10	Calcium levels;
LUSC	cis	rs356992	0.915	rs356977	chr2:60748758	A/G	cg08426369	chr2:60753602	BCL11A	0.4	5.65	0.3	3.47e-8	Educational attainment (years of education);
LUSC	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg13798780	chr7:105162888	PUS7	0.56	6.08	0.32	3.26e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg21775007	chr8:11205619	TDH	-0.47	-6.51	-0.34	2.7e-10	Subjective well-being;
LUSC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg12463550	chr7:65579703	CRCP	0.52	7.46	0.38	7.64e-13	Aortic root size;
LUSC	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.12	-0.45	7.17e-18	Schizophrenia;
LUSC	cis	rs9309473	0.898	rs7587577	chr2:73832786	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-6.3	-0.33	9.52e-10	Metabolite levels;
LUSC	trans	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.36	-0.33	6.45e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	5.71	0.3	2.44e-8	Breast cancer;
LUSC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.62	12.64	0.57	3.5e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs117623576	1.000	rs117623576	chr10:32387808	C/T	cg03047570	chr10:32398778	NA	-0.71	-6.72	-0.35	7.85e-11	Anti-saccade response;
LUSC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg17425144	chr1:10567563	PEX14	0.66	13.59	0.6	8.94e-34	Breast size;
LUSC	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs2970818	0.764	rs4323977	chr12:4615481	C/T	cg11146114	chr12:4671731	NA	0.58	5.9	0.31	9.04e-9	Phosphorus levels;
LUSC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg27535305	chr1:53392650	SCP2	-0.4	-7.57	-0.38	3.57e-13	Monocyte count;
LUSC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg18681998	chr4:17616180	MED28	0.86	15.34	0.64	1.39e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg23985595	chr17:80112537	CCDC57	-0.3	-5.72	-0.3	2.32e-8	Life satisfaction;
LUSC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg00484396	chr16:3507460	NAT15	0.68	12.12	0.55	2.93e-28	Tuberculosis;
LUSC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg24209194	chr3:40518798	ZNF619	-0.41	-5.74	-0.3	2.14e-8	Renal cell carcinoma;
LUSC	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.52	-0.42	5.44e-16	Retinal vascular caliber;
LUSC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg11266682	chr4:10021025	SLC2A9	0.49	9.11	0.45	7.9e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7089973	0.934	rs68085797	chr10:116632130	A/T	cg23260525	chr10:116636907	FAM160B1	0.39	7.38	0.37	1.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	0.93	17.02	0.68	3.36e-47	Headache;
LUSC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg23887609	chr12:130822674	PIWIL1	0.49	7.34	0.37	1.64e-12	Menopause (age at onset);
LUSC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	7.19	0.37	4.32e-12	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	0.99	14.19	0.61	4.28e-36	Eosinophil percentage of granulocytes;
LUSC	trans	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg26811252	chr16:29126840	RRN3P2	-0.59	-9.69	-0.47	9.61e-20	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg02176678	chr2:219576539	TTLL4	-0.57	-9.98	-0.48	1.06e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg09835421	chr16:68378352	PRMT7	-0.55	-6.22	-0.32	1.45e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.5	-7.02	-0.36	1.24e-11	Gut microbiome composition (summer);
LUSC	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	7.56	0.38	3.9e-13	Height;
LUSC	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg13813247	chr22:41461852	NA	-0.36	-6.52	-0.34	2.59e-10	Neuroticism;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg23131131	chr22:24373011	LOC391322	-0.51	-7.4	-0.38	1.08e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.88	14.94	0.63	5.21e-39	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg09003973	chr2:102972529	NA	1.08	10.62	0.5	6.86e-23	Gut microbiota (bacterial taxa);
LUSC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.53	0.46	3.39e-19	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.67	11.44	0.53	8.41e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg06671706	chr8:8559999	CLDN23	0.49	6.61	0.34	1.48e-10	Obesity-related traits;
LUSC	cis	rs78707713	0.592	rs3829182	chr10:71251384	A/G	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.55	-0.46	2.85e-19	Venous thromboembolism;
LUSC	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.55	8.8	0.43	7.65e-17	Birth weight;
LUSC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg03354898	chr7:1950403	MAD1L1	-0.31	-5.78	-0.3	1.7e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08736216	chr1:53307985	ZYG11A	0.29	6.03	0.31	4.36e-9	Monocyte count;
LUSC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg05785598	chr3:49045655	WDR6	0.33	5.84	0.3	1.23e-8	Parkinson's disease;
LUSC	cis	rs2637266	1.000	rs2395390	chr10:78357734	C/G	cg18941641	chr10:78392320	NA	0.39	7.04	0.36	1.1e-11	Pulmonary function;
LUSC	cis	rs73200209	0.703	rs57060349	chr12:116579304	T/C	cg01776926	chr12:116560359	MED13L	-0.51	-6.13	-0.32	2.45e-9	Total body bone mineral density;
LUSC	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg11502198	chr6:26597334	ABT1	0.73	12.28	0.56	7.5e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.84	-0.44	5.48e-17	Chronic sinus infection;
LUSC	cis	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.17	-0.32	1.95e-9	Neuroticism;
LUSC	cis	rs71403859	0.730	rs12446333	chr16:71752157	T/C	cg08717414	chr16:71523259	ZNF19	-0.65	-7.13	-0.36	6.35e-12	Post bronchodilator FEV1;
LUSC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg16339924	chr4:17578868	LAP3	0.63	9.88	0.48	2.3e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15135638	chr3:183947356	VWA5B2	-0.43	-6.39	-0.33	5.58e-10	Electrocardiographic conduction measures;
LUSC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg03289416	chr15:75166202	SCAMP2	0.43	6.89	0.35	2.86e-11	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09766628	chr17:4634728	MED11	0.46	6.64	0.34	1.26e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg26260369	chr14:68141723	VTI1B	0.39	6.43	0.33	4.47e-10	Triglycerides;
LUSC	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2.04e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg04450456	chr4:17643702	FAM184B	0.39	6.67	0.34	1.09e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg06784218	chr1:46089804	CCDC17	0.53	11.02	0.52	2.64e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg25767906	chr1:53392781	SCP2	0.4	6.91	0.35	2.48e-11	Monocyte count;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12595647	chr1:54411915	LRRC42;HSPB11	-0.45	-6.2	-0.32	1.71e-9	Hepatitis;
LUSC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-7.9	-0.4	4.12e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11777782	chr19:18284937	IFI30	0.45	6.48	0.33	3.37e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg17724175	chr1:150552817	MCL1	0.31	5.66	0.3	3.21e-8	Melanoma;
LUSC	cis	rs11630290	0.592	rs12594446	chr15:64156674	G/T	cg12036633	chr15:63758958	NA	0.52	6.64	0.34	1.26e-10	Iris characteristics;
LUSC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg01528321	chr10:82214614	TSPAN14	0.62	8.98	0.44	2.09e-17	Post bronchodilator FEV1;
LUSC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg02450064	chr17:40260053	DHX58	0.47	6.41	0.33	4.97e-10	Fibrinogen levels;
LUSC	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg10483660	chr13:112241077	NA	-0.41	-7.04	-0.36	1.07e-11	Menarche (age at onset);
LUSC	cis	rs12940923	1.000	rs11659092	chr17:56364269	C/T	cg19466818	chr17:56409534	MIR142	-0.39	-6.86	-0.35	3.35e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg18230493	chr5:56204884	C5orf35	-0.68	-10.44	-0.5	2.79e-22	Coronary artery disease;
LUSC	cis	rs4343996	0.566	rs4236326	chr7:3400105	C/T	cg21248987	chr7:3385318	SDK1	-0.34	-5.76	-0.3	1.9e-8	Motion sickness;
LUSC	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg08017756	chr2:100939284	LONRF2	-0.4	-7.4	-0.38	1.1e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg17986701	chr20:44574422	PCIF1	0.37	6.55	0.34	2.22e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg18827107	chr12:86230957	RASSF9	0.45	6.86	0.35	3.4e-11	Major depressive disorder;
LUSC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.44	6.02	0.31	4.65e-9	Platelet count;
LUSC	cis	rs911119	0.955	rs59059917	chr20:23595675	C/T	cg16589663	chr20:23618590	CST3	0.62	7.44	0.38	8.74e-13	Chronic kidney disease;
LUSC	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-25.58	-0.81	1.12e-80	Exhaled nitric oxide output;
LUSC	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-7.96	-0.4	2.67e-14	Lymphocyte counts;
LUSC	trans	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg15704280	chr7:45808275	SEPT13	-0.67	-6.31	-0.33	8.99e-10	Axial length;
LUSC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg18402987	chr7:1209562	NA	0.73	7.84	0.39	5.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4363385	0.934	rs6667418	chr1:152969685	A/G	cg00922841	chr1:152955080	SPRR1A	-0.49	-8.33	-0.41	2.17e-15	Inflammatory skin disease;
LUSC	cis	rs11608355	0.846	rs60945232	chr12:109854401	A/G	cg19025524	chr12:109796872	NA	-0.39	-5.72	-0.3	2.35e-8	Neuroticism;
LUSC	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.45	-0.46	6.32e-19	Body mass index;
LUSC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg11062466	chr8:58055876	NA	0.5	6.57	0.34	1.89e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg08000102	chr2:233561755	GIGYF2	-0.72	-11.79	-0.54	4.76e-27	Coronary artery disease;
LUSC	trans	rs2975734	0.680	rs10503406	chr8:10108972	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.21	-0.32	1.61e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg16647868	chr5:131706066	SLC22A5	0.4	6.12	0.32	2.6e-9	Breast cancer;
LUSC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg05025164	chr4:1340916	KIAA1530	0.4	5.91	0.31	8.66e-9	Obesity-related traits;
LUSC	cis	rs977987	0.806	rs1549306	chr16:75415341	A/G	cg04384234	chr16:75411784	CFDP1	-0.4	-6.68	-0.34	9.74e-11	Dupuytren's disease;
LUSC	cis	rs7119	0.717	rs8042307	chr15:77804013	A/G	cg27398640	chr15:77910606	LINGO1	-0.29	-6.2	-0.32	1.7e-9	Type 2 diabetes;
LUSC	cis	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6845621	0.745	rs16897766	chr4:18869945	A/G	cg12196642	chr4:18937545	NA	-0.32	-6.0	-0.31	5.11e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.82	-15.21	-0.64	4.55e-40	Dental caries;
LUSC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	0.95	18.99	0.72	4.85e-55	Cognitive function;
LUSC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.56	8.72	0.43	1.29e-16	Menopause (age at onset);
LUSC	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.85	0.44	5.14e-17	Schizophrenia;
LUSC	cis	rs4132509	0.744	rs59953491	chr1:243894953	C/T	cg21452805	chr1:244014465	NA	0.63	6.97	0.36	1.75e-11	RR interval (heart rate);
LUSC	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.75	-0.43	1.04e-16	Uric acid levels;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	0.99	21.68	0.76	1.07e-65	Menarche (age at onset);
LUSC	cis	rs9837602	0.872	rs1489816	chr3:99769088	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.36	-5.71	-0.3	2.48e-8	Breast cancer;
LUSC	cis	rs4908769	0.624	rs301789	chr1:8469337	A/G	cg00546117	chr1:8445545	RERE	-0.28	-5.65	-0.3	3.37e-8	Allergy;
LUSC	cis	rs1865721	1.000	rs72977879	chr18:73193696	T/C	cg26385618	chr18:73139727	C18orf62	-0.48	-8.1	-0.41	1.04e-14	Intelligence;
LUSC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg18230493	chr5:56204884	C5orf35	-0.67	-10.6	-0.5	8.02e-23	Coronary artery disease;
LUSC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.43	-6.95	-0.36	1.93e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg13010344	chr12:123464640	ARL6IP4	0.54	6.67	0.34	1.06e-10	Neutrophil percentage of white cells;
LUSC	cis	rs3760047	0.609	rs2541639	chr16:205035	C/T	cg08400316	chr16:204221	HBZ	0.55	6.88	0.35	2.9e-11	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg13722127	chr7:150037890	RARRES2	0.4	5.99	0.31	5.48e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.91	12.42	0.56	2.22e-29	Mean corpuscular hemoglobin;
LUSC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-12.21	-0.56	1.35e-28	Chronic sinus infection;
LUSC	cis	rs6596100	0.538	rs113848378	chr5:132192372	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.02	-0.31	4.6e-9	Breast cancer;
LUSC	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg17507749	chr15:85114479	UBE2QP1	0.5	5.98	0.31	5.75e-9	Schizophrenia;
LUSC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg15556689	chr8:8085844	FLJ10661	0.67	11.32	0.53	2.22e-25	Systolic blood pressure;
LUSC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.85	-15.52	-0.65	2.75e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg15448220	chr1:150897856	SETDB1	0.43	6.23	0.32	1.43e-9	Melanoma;
LUSC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg04025307	chr7:1156635	C7orf50	0.42	5.87	0.31	1.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.34	-6.5	-0.34	2.95e-10	Coronary artery disease;
LUSC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg24324837	chr19:49891574	CCDC155	0.56	7.72	0.39	1.41e-13	Multiple sclerosis;
LUSC	cis	rs3768617	0.811	rs4285667	chr1:182970225	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	8.25	0.41	3.64e-15	Fuchs's corneal dystrophy;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg09409496	chr21:38738374	DYRK1A	0.4	6.09	0.32	3.06e-9	Mosquito bite size;
LUSC	cis	rs9309473	0.948	rs13391552	chr2:73818936	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-6.4	-0.33	5.22e-10	Metabolite levels;
LUSC	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.47	6.28	0.32	1.08e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4953404	0.613	rs6734725	chr2:46897570	G/A	cg09399716	chr2:46890238	NA	-0.31	-7.05	-0.36	1.03e-11	Pulse pressure (alcohol consumption interaction);
LUSC	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	7.61	0.38	2.77e-13	Body mass index;
LUSC	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.47	-0.46	5.16e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs11051970	0.659	rs904917	chr12:32591302	G/A	cg02745156	chr12:32552066	NA	0.38	5.87	0.31	1.05e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4561483	0.801	rs33619	chr16:12008941	T/G	cg08843971	chr16:11963173	GSPT1	-0.49	-7.36	-0.37	1.47e-12	Testicular germ cell tumor;
LUSC	cis	rs2944591	0.505	rs2592118	chr2:233792425	C/T	cg11972305	chr2:233791962	NGEF	-0.33	-6.44	-0.33	4.15e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs793571	0.502	rs411007	chr15:59078502	G/C	cg05156742	chr15:59063176	FAM63B	0.55	8.73	0.43	1.22e-16	Schizophrenia;
LUSC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.55	8.58	0.42	3.72e-16	Aortic root size;
LUSC	cis	rs9420	0.961	rs7936998	chr11:57639017	G/A	cg23127183	chr11:57508653	C11orf31	-0.56	-8.39	-0.42	1.37e-15	Schizophrenia;
LUSC	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg02750262	chr18:72916776	ZADH2	0.68	7.54	0.38	4.43e-13	Vascular endothelial growth factor levels;
LUSC	cis	rs12101261	0.925	rs2300519	chr14:81458762	T/A	cg06600135	chr14:81408086	NA	0.43	6.24	0.32	1.3e-9	Graves' disease;
LUSC	cis	rs7614311	0.681	rs57766205	chr3:63895303	G/C	cg22134162	chr3:63841271	THOC7	-0.45	-5.81	-0.3	1.43e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs500891	0.868	rs62419325	chr6:84143892	A/G	cg08257003	chr6:84140564	ME1	0.35	7.27	0.37	2.56e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	9.32	0.45	1.58e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.13	0.41	8.56e-15	Axial length;
LUSC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05535760	chr7:792225	HEATR2	0.93	9.7	0.47	8.89e-20	Cerebrospinal P-tau181p levels;
LUSC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg11965913	chr1:205819406	PM20D1	0.59	10.34	0.49	6.33e-22	Menarche (age at onset);
LUSC	cis	rs4363385	0.818	rs10788852	chr1:153000491	C/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-6.97	-0.36	1.75e-11	Inflammatory skin disease;
LUSC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg25039879	chr17:56429692	SUPT4H1	0.68	9.14	0.45	6.1e-18	Cognitive test performance;
LUSC	cis	rs2463822	0.748	rs2513038	chr11:62081329	A/C	cg06239285	chr11:62104954	ASRGL1	0.95	10.44	0.5	2.94e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs80130819	0.515	rs6580656	chr12:48570604	C/T	cg24011408	chr12:48396354	COL2A1	0.47	6.5	0.34	2.93e-10	Prostate cancer;
LUSC	cis	rs4764124	0.571	rs11830399	chr12:14956932	G/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.38	5.87	0.31	1.05e-8	Pubertal anthropometrics;
LUSC	cis	rs11167764	0.638	rs7729747	chr5:141478055	C/A	cg23435118	chr5:141488016	NDFIP1	-0.58	-7.86	-0.4	5.37e-14	Crohn's disease;
LUSC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg17376030	chr22:41985996	PMM1	-0.48	-6.02	-0.31	4.57e-9	Vitiligo;
LUSC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	0.94	19.08	0.72	1.99e-55	Cognitive function;
LUSC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.35	0.46	1.28e-18	Monocyte percentage of white cells;
LUSC	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg24634471	chr8:143751801	JRK	0.6	8.99	0.44	1.83e-17	Schizophrenia;
LUSC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.66	8.51	0.42	6.09e-16	Schizophrenia;
LUSC	cis	rs12220238	1.000	rs115418388	chr10:75976296	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.3	0.37	2.12e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs2637266	0.685	rs7098713	chr10:78452828	C/T	cg18941641	chr10:78392320	NA	0.33	5.97	0.31	5.95e-9	Pulmonary function;
LUSC	trans	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-10.02	-0.48	7.65e-21	Bone mineral density;
LUSC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.27	-0.41	3.33e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg03929089	chr4:120376271	NA	0.72	6.86	0.35	3.37e-11	Axial length;
LUSC	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg11812906	chr14:75593930	NEK9	0.65	11.35	0.53	1.79e-25	Height;
LUSC	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg22508957	chr16:3507546	NAT15	-0.37	-6.08	-0.32	3.22e-9	Body mass index (adult);
LUSC	cis	rs859767	0.741	rs11684785	chr2:135393110	C/T	cg12500956	chr2:135428796	TMEM163	-0.28	-6.3	-0.33	9.48e-10	Neuroticism;
LUSC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg01475377	chr6:109611718	NA	-0.45	-8.21	-0.41	4.87e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs72960926	0.744	rs768509	chr6:75005487	G/A	cg03266952	chr6:74778945	NA	-0.76	-6.65	-0.34	1.21e-10	Metabolite levels (MHPG);
LUSC	cis	rs12980942	0.872	rs7258749	chr19:41806647	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.62	6.77	0.35	5.89e-11	Coronary artery disease;
LUSC	cis	rs7808935	0.789	rs2040668	chr7:27958773	G/T	cg22168087	chr7:27702803	HIBADH	-0.62	-7.56	-0.38	3.83e-13	Prostate cancer;
LUSC	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg05855489	chr10:104503620	C10orf26	0.59	9.5	0.46	4.35e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg05147244	chr20:61493195	TCFL5	0.9	7.55	0.38	4.07e-13	Obesity-related traits;
LUSC	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.39	0.49	4.43e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.81	-11.1	-0.52	1.44e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Depression;
LUSC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg00750074	chr16:89608354	SPG7	-0.54	-9.94	-0.48	1.41e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg12751644	chr20:60527061	NA	-0.34	-5.98	-0.31	5.71e-9	Body mass index;
LUSC	cis	rs662064	0.748	rs2506889	chr1:10596022	C/T	cg20482658	chr1:10539492	PEX14	0.32	6.45	0.33	3.89e-10	Asthma;
LUSC	trans	rs11610422	1.000	rs34325065	chr12:31414505	C/G	cg02734259	chr12:9559402	NA	-0.61	-6.48	-0.33	3.38e-10	Coronary artery disease;
LUSC	cis	rs7267979	0.816	rs374701	chr20:25483616	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.25	0.66	3.75e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	10.31	0.49	7.82e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.0	0.55	8.02e-28	Menopause (age at onset);
LUSC	cis	rs11168618	1.000	rs12815544	chr12:48949608	A/G	cg24011408	chr12:48396354	COL2A1	0.4	6.29	0.33	9.82e-10	Adiponectin levels;
LUSC	cis	rs1018836	0.739	rs6993715	chr8:91531188	G/C	cg16814680	chr8:91681699	NA	-0.72	-11.17	-0.52	7.62e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg23093090	chr10:104574429	C10orf26	0.35	6.6	0.34	1.65e-10	Arsenic metabolism;
LUSC	cis	rs9653442	0.510	rs13415583	chr2:100764087	T/G	cg22139774	chr2:100720529	AFF3	-0.42	-7.3	-0.37	2.16e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg27284194	chr4:1044797	NA	-0.56	-8.13	-0.41	8.4e-15	Recombination rate (females);
LUSC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.43	-7.11	-0.36	7.28e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg11764359	chr7:65958608	NA	-0.52	-6.78	-0.35	5.48e-11	Aortic root size;
LUSC	cis	rs910873	0.505	rs7261964	chr20:33205011	C/T	cg16810054	chr20:33298113	TP53INP2	-0.38	-5.67	-0.3	3.11e-8	Melanoma;
LUSC	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.86	-0.63	1.03e-38	Schizophrenia;
LUSC	cis	rs9399401	0.961	rs6909857	chr6:142701158	A/G	cg03128060	chr6:142623767	GPR126	0.34	6.1	0.32	2.93e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs9921338	0.961	rs7195536	chr16:11442028	T/C	cg00044050	chr16:11439710	C16orf75	-0.51	-6.81	-0.35	4.58e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg10523860	chr14:103875565	MARK3	-0.37	-5.8	-0.3	1.55e-8	Body mass index;
LUSC	trans	rs4868731	0.656	rs1421629	chr5:163531125	A/T	cg10167512	chr13:112838934	NA	-0.33	-6.24	-0.32	1.36e-9	Common carotid intima-media thickness;
LUSC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg04369109	chr6:150039330	LATS1	-0.53	-7.86	-0.39	5.51e-14	Lung cancer;
LUSC	cis	rs7267979	0.714	rs6115107	chr20:25237390	A/G	cg08601574	chr20:25228251	PYGB	0.48	7.45	0.38	8.3e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.62	0.43	2.77e-16	Menarche (age at onset);
LUSC	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	18.25	0.71	4.01e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg07870213	chr5:140052090	DND1	0.77	11.51	0.53	4.78e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg25319279	chr11:5960081	NA	-0.42	-6.38	-0.33	5.82e-10	DNA methylation (variation);
LUSC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08677398	chr8:58056175	NA	0.54	6.39	0.33	5.43e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg14458575	chr2:238380390	NA	0.67	11.78	0.54	5.17e-27	Prostate cancer;
LUSC	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.61	0.54	2.09e-26	Coffee consumption (cups per day);
LUSC	cis	rs240764	0.658	rs35967345	chr6:101187858	T/G	cg09795085	chr6:101329169	ASCC3	-0.43	-6.32	-0.33	8.51e-10	Neuroticism;
LUSC	cis	rs7582720	1.000	rs72932557	chr2:203846817	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.35	0.42	1.88e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.69	0.6	3.62e-34	Breast cancer;
LUSC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg16006841	chr5:176797999	RGS14	0.66	10.58	0.5	9.46e-23	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.35	0.46	1.3e-18	Prudent dietary pattern;
LUSC	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg27411982	chr8:10470053	RP1L1	0.37	5.87	0.31	1.05e-8	Retinal vascular caliber;
LUSC	cis	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg06521331	chr12:34319734	NA	0.4	6.57	0.34	1.97e-10	Morning vs. evening chronotype;
LUSC	cis	rs6977660	0.941	rs5017197	chr7:19819967	T/A	cg07541023	chr7:19748670	TWISTNB	0.51	5.74	0.3	2.14e-8	Thyroid stimulating hormone;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25978167	chr4:57301353	PAICS;PPAT	0.46	6.69	0.34	9.45e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs3849570	0.961	rs3772912	chr3:81698481	A/G	cg07356753	chr3:81810745	GBE1	-0.49	-7.55	-0.38	4.16e-13	Waist circumference;Body mass index;
LUSC	trans	rs6601327	0.607	rs35316422	chr8:9575129	G/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.12	-0.32	2.64e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg14019146	chr3:50243930	SLC38A3	-0.37	-8.76	-0.43	1.02e-16	Body mass index;
LUSC	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg03859395	chr2:55845619	SMEK2	0.86	16.22	0.66	4.87e-44	Metabolic syndrome;
LUSC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-10.73	-0.51	2.92e-23	Alzheimer's disease;
LUSC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.65e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6088813	0.961	rs6060373	chr20:33914208	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.39	6.38	0.33	5.89e-10	Height;
LUSC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg08219700	chr8:58056026	NA	0.49	6.21	0.32	1.59e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-9.12	-0.45	7.16e-18	Mood instability;
LUSC	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg06060754	chr5:176797920	RGS14	0.67	8.69	0.43	1.71e-16	Urate levels in lean individuals;
LUSC	cis	rs7236492	0.532	rs3786184	chr18:77195885	A/C	cg15644404	chr18:77186268	NFATC1	-0.51	-7.02	-0.36	1.27e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24838063	chr12:130822603	PIWIL1	-0.68	-10.47	-0.5	2.22e-22	Menopause (age at onset);
LUSC	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-0.88	-15.64	-0.65	9.54e-42	Height;
LUSC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg04450456	chr4:17643702	FAM184B	0.34	5.65	0.3	3.4e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg15133208	chr4:90757351	SNCA	-0.32	-5.66	-0.3	3.23e-8	Dementia with Lewy bodies;
LUSC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg16584290	chr5:462447	EXOC3	0.48	8.77	0.43	9.28e-17	Cystic fibrosis severity;
LUSC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg05347473	chr6:146136440	FBXO30	0.51	9.03	0.44	1.37e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9646944	0.519	rs1041973	chr2:102955468	A/C	cg20060108	chr2:102954350	IL1RL1	-0.38	-5.82	-0.3	1.4e-8	Blood protein levels;
LUSC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg15649852	chr7:65879115	NA	-0.41	-5.78	-0.3	1.74e-8	Aortic root size;
LUSC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06112835	chr11:68658793	MRPL21	0.51	7.8	0.39	8.21e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs701145	0.585	rs1713846	chr3:153787632	C/T	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	cis	rs2012796	1.000	rs7153469	chr14:81820979	T/G	cg02996355	chr14:81879375	NA	0.49	7.1	0.36	7.5e-12	Night sleep phenotypes;
LUSC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg16606324	chr3:10149918	C3orf24	0.65	9.17	0.45	4.87e-18	Alzheimer's disease;
LUSC	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg13642260	chr9:130955380	CIZ1	0.47	7.57	0.38	3.73e-13	Attention deficit hyperactivity disorder;
LUSC	trans	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.53e-10	Corneal astigmatism;
LUSC	cis	rs17433780	0.836	rs61798917	chr1:89506093	G/A	cg09516651	chr1:89888402	LOC400759	0.58	11.11	0.52	1.33e-24	Carotid intima media thickness;
LUSC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	15.61	0.65	1.21e-41	Platelet count;
LUSC	cis	rs4588572	0.601	rs10942855	chr5:77737529	G/A	cg11547950	chr5:77652471	NA	-0.54	-7.86	-0.39	5.5e-14	Triglycerides;
LUSC	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.09	-0.36	7.85e-12	Triglycerides;
LUSC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg03929089	chr4:120376271	NA	-0.96	-16.75	-0.68	3.68e-46	Height;
LUSC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	8.11	0.41	9.88e-15	Cognitive test performance;
LUSC	cis	rs1385374	0.858	rs12298615	chr12:129286756	G/A	cg09035930	chr12:129282057	SLC15A4	-0.63	-6.85	-0.35	3.63e-11	Systemic lupus erythematosus;
LUSC	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg04310649	chr10:35416472	CREM	-0.4	-6.14	-0.32	2.34e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.41	-6.22	-0.32	1.52e-9	Prudent dietary pattern;
LUSC	trans	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.36	0.53	1.62e-25	Mean corpuscular volume;
LUSC	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg19418458	chr7:158789849	NA	-0.56	-8.89	-0.44	3.98e-17	Facial morphology (factor 20);
LUSC	trans	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg04146151	chr16:2155961	PKD1	-0.42	-5.99	-0.31	5.51e-9	Triglycerides;
LUSC	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg12927641	chr6:109611667	NA	-0.37	-6.21	-0.32	1.55e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg16624210	chr5:671434	TPPP	0.47	5.92	0.31	8.21e-9	Lung disease severity in cystic fibrosis;
LUSC	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.43	0.42	1.06e-15	Retinal vascular caliber;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg05848811	chr11:47270335	ACP2;NR1H3	0.44	6.01	0.31	4.88e-9	Mosquito bite size;
LUSC	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg16346588	chr10:242978	ZMYND11	-0.46	-6.2	-0.32	1.66e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs16854884	0.526	rs7643341	chr3:143726980	C/T	cg01302019	chr3:143689584	C3orf58	-0.37	-6.56	-0.34	2.07e-10	Economic and political preferences (feminism/equality);
LUSC	trans	rs1819054	0.806	rs1528351	chr7:121167875	C/T	cg12484325	chr11:3688985	CHRNA10	-0.43	-6.07	-0.32	3.38e-9	Hand grip strength;
LUSC	cis	rs6484504	0.600	rs10835763	chr11:31345574	G/A	cg26647111	chr11:31128758	NA	0.4	5.74	0.3	2.17e-8	Red blood cell count;
LUSC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.44	-7.46	-0.38	7.51e-13	Total body bone mineral density;
LUSC	cis	rs9378688	0.654	rs2505663	chr6:2325931	A/G	cg12303981	chr6:2244766	GMDS	-0.41	-5.79	-0.3	1.63e-8	Caudate nucleus volume;
LUSC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-9.22	-0.45	3.55e-18	Gut microbiome composition (summer);
LUSC	cis	rs3820928	0.904	rs10188570	chr2:227792540	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.56	-0.38	4.04e-13	Pulmonary function;
LUSC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.81	-0.3	1.49e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg01528321	chr10:82214614	TSPAN14	0.82	12.46	0.56	1.53e-29	Post bronchodilator FEV1;
LUSC	cis	rs1113500	0.933	rs1414674	chr1:108625947	A/G	cg06207961	chr1:108661230	NA	0.41	7.57	0.38	3.58e-13	Growth-regulated protein alpha levels;
LUSC	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21659725	chr3:3221576	CRBN	-0.57	-8.26	-0.41	3.41e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.91	-0.44	3.3e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg23791538	chr6:167370224	RNASET2	-0.43	-6.95	-0.36	1.93e-11	Crohn's disease;
LUSC	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg06784218	chr1:46089804	CCDC17	0.35	6.18	0.32	1.84e-9	Platelet count;
LUSC	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg03233332	chr7:66118400	NA	0.4	5.93	0.31	7.49e-9	Aortic root size;
LUSC	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg16049864	chr8:95962084	TP53INP1	-0.42	-7.0	-0.36	1.37e-11	Type 2 diabetes;
LUSC	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg26061582	chr7:22766209	IL6	0.38	5.96	0.31	6.34e-9	Lung cancer;
LUSC	cis	rs7220711	1.000	rs59303349	chr17:41793668	A/G	cg26893861	chr17:41843967	DUSP3	0.42	5.88	0.31	9.83e-9	Bone mineral density (spine);Bone mineral density (hip);
LUSC	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.28	0.32	1.08e-9	Corneal astigmatism;
LUSC	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.41	-0.33	4.97e-10	Arsenic metabolism;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg24133106	chr7:129690864	ZC3HC1	0.36	5.95	0.31	6.63e-9	Tuberculosis;
LUSC	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg05738196	chr6:26577821	NA	-0.6	-7.21	-0.37	3.78e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg27432699	chr2:27873401	GPN1	0.79	14.77	0.63	2.31e-38	Oral cavity cancer;
LUSC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11645453	chr3:52864694	ITIH4	0.33	7.81	0.39	7.22e-14	Bipolar disorder;
LUSC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg00129232	chr17:37814104	STARD3	-0.5	-7.4	-0.38	1.09e-12	Asthma;
LUSC	cis	rs7216064	1.000	rs55896768	chr17:65913358	T/C	cg12091567	chr17:66097778	LOC651250	-0.72	-9.62	-0.47	1.68e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg00033643	chr7:134001901	SLC35B4	0.37	5.76	0.3	1.89e-8	Mean platelet volume;
LUSC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-11.86	-0.54	2.59e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12618769	0.652	rs3754877	chr2:99184019	A/G	cg10123293	chr2:99228465	UNC50	0.45	7.19	0.37	4.34e-12	Bipolar disorder;
LUSC	cis	rs909002	0.849	rs10914458	chr1:32096746	T/C	cg01639898	chr1:32083012	HCRTR1	0.27	6.19	0.32	1.78e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.39	-6.0	-0.31	5.25e-9	Platelet count;
LUSC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg08472276	chr7:1133186	C7orf50;GPER	0.39	6.53	0.34	2.49e-10	Longevity;Endometriosis;
LUSC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg23711669	chr6:146136114	FBXO30	0.87	16.35	0.67	1.52e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg08000102	chr2:233561755	GIGYF2	-0.67	-11.05	-0.52	2.13e-24	Coronary artery disease;
LUSC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-14.81	-0.63	1.65e-38	Vitiligo;
LUSC	cis	rs9650315	0.733	rs58705840	chr8:57206157	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.33	0.37	1.73e-12	Height;
LUSC	cis	rs17253792	0.822	rs76164147	chr14:56140369	T/C	cg01858014	chr14:56050164	KTN1	-0.79	-6.72	-0.35	7.8e-11	Putamen volume;
LUSC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-9.83	-0.47	3.5e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg00757033	chr12:89920650	WDR51B	0.59	10.34	0.49	6.32e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg12463550	chr7:65579703	CRCP	0.45	6.62	0.34	1.44e-10	Aortic root size;
LUSC	cis	rs939574	0.790	rs114196239	chr2:220094307	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	6.07	0.32	3.4e-9	Platelet distribution width;
LUSC	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg24531977	chr5:56204891	C5orf35	-0.58	-8.58	-0.43	3.5e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.73	12.84	0.57	6.05e-31	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg16103275	chr6:290800	DUSP22	0.42	6.96	0.36	1.84e-11	Menopause (age at onset);
LUSC	cis	rs7827545	1.000	rs4909911	chr8:135565255	G/A	cg17885191	chr8:135476712	NA	0.56	8.32	0.41	2.34e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08859206	chr1:53392774	SCP2	0.56	9.34	0.46	1.38e-18	Monocyte count;
LUSC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06850241	chr22:41845214	NA	0.34	6.22	0.32	1.46e-9	Vitiligo;
LUSC	trans	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg19862616	chr7:65841803	NCRNA00174	0.83	9.74	0.47	6.94e-20	Eotaxin levels;
LUSC	cis	rs7605827	0.930	rs2049720	chr2:15514982	T/C	cg19274914	chr2:15703543	NA	0.47	9.07	0.44	1.03e-17	Educational attainment (years of education);
LUSC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.2	0.41	5.24e-15	Homoarginine levels;
LUSC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg19812747	chr11:111475976	SIK2	-0.57	-8.28	-0.41	2.94e-15	Primary sclerosing cholangitis;
LUSC	cis	rs136211	0.619	rs9607337	chr22:36758849	A/T	cg10790723	chr22:36903033	FOXRED2	0.39	5.79	0.3	1.6e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs113835537	0.529	rs11227502	chr11:66274148	T/G	cg24851651	chr11:66362959	CCS	0.54	8.22	0.41	4.61e-15	Airway imaging phenotypes;
LUSC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12516959	chr21:47718080	NA	-0.47	-7.37	-0.37	1.34e-12	Testicular germ cell tumor;
LUSC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg12463550	chr7:65579703	CRCP	0.52	7.54	0.38	4.45e-13	Aortic root size;
LUSC	cis	rs4702	0.591	rs7183988	chr15:91428589	T/G	cg05469396	chr15:91419421	FURIN	0.46	8.18	0.41	6.19e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.21	0.37	3.85e-12	Platelet count;
LUSC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.8	13.3	0.59	1.14e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11756438	0.572	rs2638545	chr6:119000203	G/C	cg18833306	chr6:118973337	C6orf204	0.36	5.73	0.3	2.2e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs78663649	0.540	rs7252709	chr19:16721183	T/G	cg05286348	chr19:16641544	CHERP	-1.37	-11.54	-0.53	3.65e-26	White blood cell count;
LUSC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg16797656	chr11:68205561	LRP5	0.35	5.94	0.31	7.28e-9	Total body bone mineral density;
LUSC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg07677032	chr17:61819896	STRADA	-0.48	-8.19	-0.41	5.68e-15	Prudent dietary pattern;
LUSC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg20307385	chr11:47447363	PSMC3	-0.47	-6.12	-0.32	2.57e-9	Subjective well-being;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03133917	chr7:155436674	RBM33	-0.48	-6.65	-0.34	1.17e-10	Hepatitis;
LUSC	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg00701064	chr4:6280414	WFS1	0.55	12.87	0.58	4.65e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs17014483	1.000	rs3017914	chr4:89654165	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.67	5.69	0.3	2.77e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16920991	chr12:100536345	UHRF1BP1L	0.42	6.15	0.32	2.25e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs5769707	0.681	rs739240	chr22:50052607	C/A	cg07959070	chr22:50026188	C22orf34	-0.31	-5.7	-0.3	2.68e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9473147	0.516	rs7754971	chr6:47590476	C/T	cg12968598	chr6:47444699	CD2AP	0.53	8.1	0.41	1.06e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs524023	0.914	rs555456	chr11:64418259	T/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.46	-0.5	2.42e-22	Urate levels in obese individuals;
LUSC	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.16	-0.41	6.96e-15	Bone mineral density;
LUSC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08645402	chr16:4508243	NA	0.47	7.37	0.37	1.35e-12	Schizophrenia;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07444005	chr13:21678461	NA	-0.4	-6.1	-0.32	2.95e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.63	7.43	0.38	9.05e-13	Mammographic density (dense area);
LUSC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.13	-0.41	8.34e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs6543140	0.964	rs10196334	chr2:103090041	T/C	cg09003973	chr2:102972529	NA	0.54	6.83	0.35	4.07e-11	Blood protein levels;
LUSC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg13319975	chr6:146136371	FBXO30	0.5	7.52	0.38	5.18e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg19747945	chr6:42946146	PEX6	-0.35	-5.78	-0.3	1.73e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.74	0.84	1.09e-88	Chronic sinus infection;
LUSC	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg03678062	chr6:149772716	ZC3H12D	0.3	6.03	0.31	4.46e-9	Dupuytren's disease;
LUSC	cis	rs2860975	0.905	rs10882516	chr10:96791217	A/C	cg09036531	chr10:96991505	NA	-0.45	-6.31	-0.33	8.62e-10	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg16230307	chr14:35515116	FAM177A1	0.79	10.05	0.48	6.13e-21	Psoriasis;
LUSC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs4889855	0.556	rs11651818	chr17:78530300	A/G	cg16591659	chr17:78472290	NA	0.31	5.8	0.3	1.55e-8	Fractional excretion of uric acid;
LUSC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg04362960	chr10:104952993	NT5C2	0.6	9.4	0.46	8.81e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1376303	0.558	rs41479949	chr7:32946363	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.66	-5.88	-0.31	1.02e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	1.17	13.71	0.6	3.13e-34	Arsenic metabolism;
LUSC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg12311346	chr5:56204834	C5orf35	0.6	9.31	0.45	1.81e-18	Coronary artery disease;
LUSC	cis	rs4722404	0.800	rs6943609	chr7:3141596	G/A	cg19214707	chr7:3157722	NA	0.35	6.5	0.33	3e-10	Atopic dermatitis;
LUSC	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.71	-0.34	8.15e-11	Response to antipsychotic treatment;
LUSC	cis	rs4969178	0.965	rs8071884	chr17:76398058	C/G	cg20026190	chr17:76395443	PGS1	0.44	7.64	0.39	2.25e-13	HDL cholesterol levels;
LUSC	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14169450	chr9:139327907	INPP5E	0.44	7.81	0.39	7.37e-14	Monocyte percentage of white cells;
LUSC	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	7.58	0.38	3.34e-13	Height;
LUSC	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg18806716	chr10:30721971	MAP3K8	-0.61	-9.9	-0.48	1.98e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg18232548	chr7:50535776	DDC	-0.67	-10.42	-0.5	3.2800000000000002e-22	Response to zileuton treatment in asthma (FEV1 change interaction);
LUSC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg23711669	chr6:146136114	FBXO30	-0.91	-17.88	-0.7	1.27e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.89	-0.31	9.5e-9	Neutrophil percentage of white cells;
LUSC	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg08085267	chr17:45401833	C17orf57	-0.48	-6.75	-0.35	6.7e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18404041	chr3:52824283	ITIH1	-0.62	-12.0	-0.55	7.62e-28	Bipolar disorder;
LUSC	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg05373962	chr22:49881684	NA	-0.41	-8.59	-0.43	3.46e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg15848620	chr12:58087721	OS9	-0.46	-6.68	-0.34	9.93e-11	Rheumatoid arthritis;
LUSC	cis	rs68170813	0.559	rs2395880	chr7:107074264	A/G	cg02696742	chr7:106810147	HBP1	-0.62	-8.92	-0.44	3.19e-17	Coronary artery disease;
LUSC	cis	rs79387448	0.626	rs80256362	chr2:103025501	A/G	cg09003973	chr2:102972529	NA	0.97	10.06	0.48	5.93e-21	Gut microbiota (bacterial taxa);
LUSC	cis	rs11785400	1.000	rs10108059	chr8:143750028	G/T	cg24634471	chr8:143751801	JRK	-0.58	-8.79	-0.43	8.11e-17	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg04369109	chr6:150039330	LATS1	-0.54	-8.08	-0.4	1.22e-14	Lung cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25675393	chr21:46494274	ADARB1;C21orf122	-0.49	-6.06	-0.31	3.64e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.6	8.96	0.44	2.25e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs806215	0.826	rs712699	chr7:127250597	G/A	cg25922125	chr7:127225783	GCC1	0.56	6.98	0.36	1.62e-11	Type 2 diabetes;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg25382848	chr3:107809996	CD47	0.47	6.07	0.32	3.44e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg12432903	chr7:1882776	MAD1L1	0.44	6.06	0.31	3.71e-9	Bipolar disorder;
LUSC	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg20243544	chr17:37824526	PNMT	0.39	5.92	0.31	7.97e-9	Self-reported allergy;
LUSC	trans	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg06808227	chr14:105710500	BRF1	-0.63	-9.13	-0.45	6.81e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs3789045	0.560	rs4553256	chr1:204411144	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.51	-5.89	-0.31	9.64e-9	Educational attainment (college completion);
LUSC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.72	-12.75	-0.57	1.27e-30	Dental caries;
LUSC	cis	rs2629540	0.847	rs11245342	chr10:126414084	C/T	cg08799069	chr10:126477246	METTL10	0.63	8.54	0.42	4.78e-16	Cocaine dependence;
LUSC	cis	rs2835872	0.965	rs1787330	chr21:39002787	G/A	cg20424643	chr21:39039972	KCNJ6	-0.4	-6.12	-0.32	2.59e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.66	-11.99	-0.55	8.63e-28	Breast cancer;
LUSC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22968622	chr17:43663579	NA	0.79	12.19	0.55	1.61e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs4868731	0.656	rs6884233	chr5:163532624	C/T	cg10167512	chr13:112838934	NA	0.33	6.16	0.32	2.14e-9	Common carotid intima-media thickness;
LUSC	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg26597838	chr10:835615	NA	0.8	9.93	0.48	1.6e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg14440974	chr22:39074834	NA	-0.37	-6.0	-0.31	5.03e-9	Menopause (age at onset);
LUSC	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg12473912	chr3:136751656	NA	0.39	6.83	0.35	3.96e-11	Neuroticism;
LUSC	cis	rs10740039	0.810	rs1372709	chr10:62381424	A/G	cg18175470	chr10:62150864	ANK3	-0.45	-6.6	-0.34	1.58e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg03676636	chr4:99064102	C4orf37	0.33	7.07	0.36	9.14e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg20608306	chr11:116969690	SIK3	0.37	6.97	0.36	1.73e-11	Blood protein levels;
LUSC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg08270630	chr22:50330655	NA	-0.45	-6.77	-0.35	5.64e-11	Schizophrenia;
LUSC	cis	rs7202877	0.706	rs247438	chr16:75432649	C/G	cg04384234	chr16:75411784	CFDP1	0.67	9.87	0.48	2.49e-20	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg18225595	chr11:63971243	STIP1	0.43	6.95	0.36	1.98e-11	Platelet count;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.94	17.99	0.7	4.59e-51	Menarche (age at onset);
LUSC	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg24375607	chr4:120327624	NA	0.5	7.48	0.38	6.46e-13	Diastolic blood pressure;
LUSC	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.83	-0.35	4.12e-11	Monocyte percentage of white cells;
LUSC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.75	13.55	0.6	1.23e-33	Aortic root size;
LUSC	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg05855489	chr10:104503620	C10orf26	0.5	7.61	0.38	2.88e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg09365446	chr1:150670422	GOLPH3L	0.47	6.7	0.34	8.79e-11	Melanoma;
LUSC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.63	0.85	1.69e-95	Chronic sinus infection;
LUSC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg13939156	chr17:80058883	NA	-0.34	-6.86	-0.35	3.32e-11	Life satisfaction;
LUSC	cis	rs4604732	0.631	rs60311891	chr1:247623127	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.42	6.25	0.32	1.23e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.42	0.33	4.76e-10	Lung cancer;
LUSC	cis	rs11264799	0.520	rs849816	chr1:157542074	A/C	cg18268488	chr1:157545234	FCRL4	0.38	7.53	0.38	4.67e-13	IgA nephropathy;
LUSC	cis	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg26958806	chr6:27640298	NA	0.77	6.55	0.34	2.23e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.88	0.63	8.61e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6700896	0.500	rs66470832	chr1:66130631	T/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.93	0.31	7.6e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs1351696	1	rs1351696	chr11:48382471	A/G	cg15704280	chr7:45808275	SEPT13	-0.68	-6.43	-0.33	4.36e-10	D-dimer levels;
LUSC	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg05855489	chr10:104503620	C10orf26	0.47	6.48	0.33	3.34e-10	Arsenic metabolism;
LUSC	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-9.78	-0.47	5.08e-20	Morning vs. evening chronotype;
LUSC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg27094323	chr7:1216898	NA	-0.43	-7.36	-0.37	1.48e-12	Longevity;Endometriosis;
LUSC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.76	0.57	1.21e-30	Prudent dietary pattern;
LUSC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.53	6.72	0.35	7.91e-11	Diabetic retinopathy;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg10445487	chr16:75599896	GABARAPL2	0.36	6.06	0.31	3.72e-9	Tuberculosis;
LUSC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.76	10.24	0.49	1.44e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg23229984	chr5:148520753	ABLIM3	0.41	6.48	0.33	3.22e-10	Breast cancer;
LUSC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg23649088	chr2:200775458	C2orf69	-0.57	-6.72	-0.35	7.73e-11	Schizophrenia;
LUSC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg18225595	chr11:63971243	STIP1	0.43	6.99	0.36	1.47e-11	Platelet count;
LUSC	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg13789015	chr9:136890014	NCRNA00094	0.71	13.3	0.59	1.1e-32	Platelet distribution width;
LUSC	cis	rs6669072	0.565	rs12743498	chr1:91267791	C/A	cg08895590	chr1:91227319	NA	-0.27	-5.75	-0.3	1.99e-8	Cognitive function;
LUSC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg09826364	chr7:158789723	NA	-0.38	-6.03	-0.31	4.24e-9	Facial morphology (factor 20);
LUSC	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg00277334	chr10:82204260	NA	-0.57	-8.53	-0.42	5.19e-16	Post bronchodilator FEV1;
LUSC	cis	rs62400317	0.859	rs12191566	chr6:45160002	T/C	cg18551225	chr6:44695536	NA	-0.44	-7.2	-0.37	4.1e-12	Total body bone mineral density;
LUSC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.11	0.32	2.79e-9	Schizophrenia;
LUSC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.51	-7.26	-0.37	2.65e-12	Cognitive ability;
LUSC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	0.91	18.67	0.71	8.51e-54	Dental caries;
LUSC	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg10523860	chr14:103875565	MARK3	-0.4	-6.3	-0.33	9.36e-10	Body mass index;
LUSC	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg15556689	chr8:8085844	FLJ10661	0.56	8.21	0.41	4.73e-15	Morning vs. evening chronotype;
LUSC	trans	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg02800362	chr5:177631904	HNRNPAB	0.83	12.44	0.56	1.95e-29	Obesity-related traits;
LUSC	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg23283495	chr1:209979779	IRF6	0.7	9.08	0.44	9.71e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg04234412	chr22:24373322	LOC391322	0.77	9.78	0.47	4.82e-20	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs727505	1.000	rs10271646	chr7:124549573	T/C	cg23710748	chr7:124431027	NA	-0.4	-7.19	-0.37	4.36e-12	Lewy body disease;
LUSC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.05	0.64	1.96e-39	Platelet count;
LUSC	cis	rs7827545	1.000	rs4909481	chr8:135564555	A/G	cg17885191	chr8:135476712	NA	0.56	8.32	0.41	2.34e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg13535736	chr9:111863775	C9orf5	-0.41	-6.58	-0.34	1.84e-10	Menarche (age at onset);
LUSC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.5	6.3	0.33	9.35e-10	Renal function-related traits (BUN);
LUSC	cis	rs963731	0.649	rs10186762	chr2:39219361	A/G	cg04010122	chr2:39346883	SOS1	-0.79	-5.73	-0.3	2.2e-8	Corticobasal degeneration;
LUSC	cis	rs73416724	1.000	rs80193186	chr6:43362324	G/T	cg26312998	chr6:43337775	ZNF318	0.55	6.51	0.34	2.7e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1832871	0.711	rs56043101	chr6:158682277	A/G	cg07165851	chr6:158734300	TULP4	0.51	7.8	0.39	7.72e-14	Height;
LUSC	trans	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.58	-10.04	-0.48	6.77e-21	Mean corpuscular volume;
LUSC	cis	rs1577917	0.917	rs1579886	chr6:86557191	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg14582100	chr15:45693742	SPATA5L1	0.46	8.62	0.43	2.7e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg05855489	chr10:104503620	C10orf26	0.49	7.4	0.38	1.1e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs500891	0.525	rs13215578	chr6:84107234	C/T	cg08257003	chr6:84140564	ME1	0.34	8.29	0.41	2.85e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15369054	chr17:80825471	TBCD	0.7	11.61	0.54	2.08e-26	Breast cancer;
LUSC	cis	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.33	-0.41	2.11e-15	Morning vs. evening chronotype;
LUSC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.47	10.13	0.48	3.42e-21	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg15335139	chr3:50242325	SLC38A3	-0.25	-5.64	-0.3	3.57e-8	Body mass index;
LUSC	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg12002119	chr2:101014098	CHST10	0.35	5.8	0.3	1.5e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.29	-0.41	2.74e-15	Cystic fibrosis severity;
LUSC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12516959	chr21:47718080	NA	0.49	7.86	0.39	5.45e-14	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs477692	0.569	rs10764882	chr10:131306496	C/G	cg25636556	chr4:3505128	NA	0.31	5.98	0.31	5.63e-9	Response to temozolomide;
LUSC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.71	0.6	3.09e-34	Cognitive test performance;
LUSC	trans	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg26384229	chr12:38710491	ALG10B	0.54	8.61	0.43	3e-16	Morning vs. evening chronotype;
LUSC	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.27	-0.32	1.11e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9469578	1.000	rs16869464	chr6:33715127	A/G	cg18708504	chr6:33715942	IP6K3	0.72	8.8	0.43	7.52e-17	Phosphorus levels;
LUSC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.44	-0.46	6.6e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs405956	1.000	rs1338020	chr6:105577686	C/T	cg22580625	chr6:105627791	POPDC3	-0.59	-5.77	-0.3	1.84e-8	QT interval;
LUSC	cis	rs7131987	0.903	rs2194520	chr12:29423712	C/T	cg09582351	chr12:29534625	ERGIC2	-0.31	-6.74	-0.35	6.79e-11	QT interval;
LUSC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg10556349	chr10:835070	NA	-0.58	-6.42	-0.33	4.74e-10	Eosinophil percentage of granulocytes;
LUSC	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-25.88	-0.82	8.37e-82	Exhaled nitric oxide output;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg03359731	chr4:48833388	OCIAD1	0.47	6.96	0.36	1.84e-11	Triglycerides;
LUSC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg23711669	chr6:146136114	FBXO30	0.76	13.43	0.59	3.68e-33	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg06797661	chr2:48338981	NA	0.41	6.13	0.32	2.42e-9	Triglycerides;
LUSC	cis	rs6901250	1.000	rs993394	chr6:117117143	G/A	cg12892004	chr6:117198278	RFX6	0.44	7.92	0.4	3.52e-14	C-reactive protein levels;
LUSC	cis	rs2573652	1.000	rs2581345	chr15:100514291	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.43	-8.03	-0.4	1.68e-14	Height;
LUSC	cis	rs727505	0.909	rs7810427	chr7:124645103	C/T	cg23710748	chr7:124431027	NA	-0.37	-6.46	-0.33	3.71e-10	Lewy body disease;
LUSC	cis	rs10864907	0.614	rs12711745	chr2:113700355	T/C	cg06156847	chr2:113672199	IL1F7	-0.28	-5.83	-0.3	1.32e-8	Pulmonary function;
LUSC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg19678392	chr7:94953810	PON1	-0.38	-6.09	-0.32	3.07e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg12863693	chr15:85201151	NMB	0.34	6.23	0.32	1.37e-9	Schizophrenia;
LUSC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg01483505	chr11:975446	AP2A2	0.4	5.81	0.3	1.44e-8	Alzheimer's disease (late onset);
LUSC	trans	rs28588043	0.593	rs61816052	chr1:170953309	A/G	cg07135042	chr19:56905152	ZNF582	-0.62	-6.3	-0.33	9.37e-10	Number of children (6+ vs. 0 or 1);
LUSC	trans	rs71537559	1	rs71537559	chr6:27309779	G/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.92	-0.44	3.13e-17	Squamous cell lung carcinoma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10433104	chr11:18417767	LDHA	-0.42	-6.26	-0.32	1.18e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7106204	0.764	rs7949823	chr11:24213668	C/G	ch.11.24196551F	chr11:24239977	NA	0.91	7.76	0.39	1.02e-13	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	10.22	0.49	1.68e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg01879757	chr17:41196368	BRCA1	-0.45	-6.99	-0.36	1.54e-11	Menopause (age at onset);
LUSC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg09491104	chr22:46646882	C22orf40	-0.58	-6.23	-0.32	1.39e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg07741184	chr6:167504864	NA	-0.35	-6.19	-0.32	1.76e-9	Primary biliary cholangitis;
LUSC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg07701084	chr6:150067640	NUP43	0.52	7.78	0.39	9.16e-14	Lung cancer;
LUSC	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	13.37	0.59	5.93e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2076222	1.000	rs2076349	chr1:209800230	C/T	cg00257659	chr1:209800214	LAMB3	-1.01	-8.3	-0.41	2.68e-15	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08356097	chr3:75484209	FAM86D	-0.47	-6.62	-0.34	1.47e-10	Electrocardiographic conduction measures;
LUSC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.9	0.31	9.03e-9	Menopause (age at onset);
LUSC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	9.7	0.47	9.13e-20	Personality dimensions;
LUSC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg06808227	chr14:105710500	BRF1	-0.7	-11.0	-0.52	3.29e-24	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg25767906	chr1:53392781	SCP2	-0.61	-11.73	-0.54	7.42e-27	Monocyte count;
LUSC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg23625390	chr15:77176239	SCAPER	0.39	5.65	0.3	3.36e-8	Blood metabolite levels;
LUSC	cis	rs4253772	0.872	rs45576140	chr22:46638216	C/G	cg24881330	chr22:46731750	TRMU	0.63	5.85	0.31	1.15e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	10.42	0.5	3.2800000000000002e-22	Homoarginine levels;
LUSC	cis	rs6693567	0.545	rs4446975	chr1:150456169	C/T	cg15654264	chr1:150340011	RPRD2	0.41	6.73	0.35	7.51e-11	Migraine;
LUSC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg06784218	chr1:46089804	CCDC17	0.54	11.06	0.52	1.88e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg17173187	chr15:85201210	NMB	0.37	6.56	0.34	2.08e-10	Schizophrenia;
LUSC	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.44	-6.42	-0.33	4.74e-10	Schizophrenia;
LUSC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18404041	chr3:52824283	ITIH1	0.58	10.99	0.52	3.56e-24	Bipolar disorder;
LUSC	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.94	0.51	5.25e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg25258033	chr6:167368657	RNASET2	0.37	5.83	0.3	1.28e-8	Primary biliary cholangitis;
LUSC	trans	rs17767294	0.708	rs72848754	chr6:27878458	T/A	cg19566879	chr6:16334128	ATXN1	0.66	5.98	0.31	5.71e-9	Parkinson's disease;
LUSC	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg17294928	chr15:75287854	SCAMP5	-0.71	-6.4	-0.33	5.27e-10	Lung cancer;
LUSC	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.87	0.31	1.03e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.65	0.3	3.4e-8	Breast cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15715881	chr1:145209236	NOTCH2NL	-0.42	-6.19	-0.32	1.73e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2652834	0.507	rs7175973	chr15:63425027	T/A	cg05507819	chr15:63340323	TPM1	0.47	6.03	0.31	4.35e-9	HDL cholesterol;
LUSC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg05585544	chr11:47624801	NA	-0.41	-7.01	-0.36	1.29e-11	Subjective well-being;
LUSC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg16680214	chr1:154839983	KCNN3	-0.51	-9.63	-0.47	1.55e-19	Prostate cancer;
LUSC	trans	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17712092	chr4:129076599	LARP1B	0.81	12.19	0.55	1.59e-28	Eosinophil percentage of white cells;
LUSC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg26380479	chr7:97908229	NA	-0.26	-5.93	-0.31	7.48e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.93	0.48	1.53e-20	Bipolar disorder;
LUSC	cis	rs10504229	0.516	rs11781671	chr8:57992733	T/C	cg11062466	chr8:58055876	NA	0.39	5.79	0.3	1.58e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg08508325	chr11:3079039	CARS	-0.53	-13.47	-0.59	2.53e-33	Longevity;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23888281	chr1:45476762	HECTD3;UROD	-0.46	-6.01	-0.31	4.88e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg24562669	chr7:97807699	LMTK2	0.35	6.04	0.31	4.21e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg09324608	chr17:30823087	MYO1D	0.35	5.75	0.3	1.97e-8	Schizophrenia;
LUSC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	8.09	0.4	1.1e-14	Height;
LUSC	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	1.23	19.55	0.73	2.84e-57	Corneal structure;
LUSC	cis	rs10489525	0.599	rs34710929	chr1:115606608	G/A	cg01522456	chr1:115632236	TSPAN2	0.51	7.58	0.38	3.51e-13	Autism;
LUSC	cis	rs7605827	0.930	rs6753645	chr2:15539556	G/C	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs2625529	0.617	rs16956369	chr15:72182813	C/T	cg16672083	chr15:72433130	SENP8	0.5	8.14	0.41	7.88e-15	Red blood cell count;
LUSC	cis	rs10072221	0.836	rs6453217	chr5:75708442	C/T	cg03132911	chr5:75698732	IQGAP2	0.36	6.06	0.31	3.74e-9	Mean platelet volume;
LUSC	cis	rs4947962	0.617	rs10488140	chr7:55138388	A/G	cg23757825	chr7:55092271	EGFR	0.49	6.64	0.34	1.28e-10	Subjective response to lithium treatment;
LUSC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg21972741	chr5:435613	AHRR	0.36	6.8	0.35	4.8e-11	Cystic fibrosis severity;
LUSC	cis	rs17255340	0.539	rs1144195	chr6:83978225	A/C	cg08257003	chr6:84140564	ME1	0.33	8.21	0.41	5.02e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg20917491	chr3:195578259	NA	-0.42	-7.07	-0.36	8.88e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs790123	0.666	rs790124	chr3:122388605	A/G	cg00926285	chr3:122398533	PARP14	-0.39	-5.66	-0.3	3.3e-8	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18932078	chr1:2524107	MMEL1	0.32	7.04	0.36	1.13e-11	Ulcerative colitis;
LUSC	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.27	-0.32	1.14e-9	Type 2 diabetes;
LUSC	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg13390004	chr1:15929781	NA	0.42	7.03	0.36	1.18e-11	Systolic blood pressure;
LUSC	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7119167	0.802	rs11235743	chr11:73124826	A/G	cg17517138	chr11:73019481	ARHGEF17	0.52	5.93	0.31	7.51e-9	Blood protein levels;
LUSC	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg23029597	chr12:123009494	RSRC2	-0.75	-9.41	-0.46	8.04e-19	Body mass index;
LUSC	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg10596483	chr8:143751796	JRK	0.53	7.59	0.38	3.17e-13	Schizophrenia;
LUSC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg16479474	chr6:28041457	NA	0.34	5.93	0.31	7.45e-9	Parkinson's disease;
LUSC	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg13319975	chr6:146136371	FBXO30	0.48	7.05	0.36	1.04e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg13263323	chr15:86062960	AKAP13	-0.35	-5.64	-0.3	3.57e-8	Coronary artery disease;
LUSC	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06002616	chr8:101225028	SPAG1	-0.47	-7.61	-0.38	2.86e-13	Atrioventricular conduction;
LUSC	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg12935359	chr14:103987150	CKB	0.66	10.79	0.51	1.68e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.98	-0.31	5.72e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03264133	chr6:25882463	NA	-0.48	-8.95	-0.44	2.51e-17	Blood metabolite levels;
LUSC	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14442939	chr10:27389572	ANKRD26	0.84	9.84	0.47	3.2e-20	Breast cancer;
LUSC	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.53	10.0	0.48	9.15e-21	Bone mineral density;
LUSC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.66	8.75	0.43	1.1e-16	Schizophrenia;
LUSC	cis	rs6942756	0.713	rs691158	chr7:129129982	G/T	cg02491457	chr7:128862824	NA	-0.41	-5.77	-0.3	1.77e-8	White matter hyperintensity burden;
LUSC	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.75	-12.48	-0.56	1.3e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg04733989	chr22:42467013	NAGA	0.39	6.55	0.34	2.2e-10	Cognitive function;
LUSC	cis	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.87	-0.35	3.18e-11	Morning vs. evening chronotype;
LUSC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg22823121	chr1:150693482	HORMAD1	0.6	9.28	0.45	2.21e-18	Tonsillectomy;
LUSC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	1.02	19.7	0.73	7.26e-58	Menopause (age at onset);
LUSC	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg00645731	chr22:42541494	CYP2D7P1	0.54	7.76	0.39	1.07e-13	Birth weight;
LUSC	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg14530993	chr4:882597	GAK	0.67	6.78	0.35	5.48e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg02175503	chr12:58329896	NA	0.48	6.91	0.35	2.43e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg26924012	chr15:45694286	SPATA5L1	1.01	15.63	0.65	9.91e-42	Homoarginine levels;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg13453750	chr1:205783389	SLC41A1	-0.31	-6.12	-0.32	2.56e-9	Menarche (age at onset);
LUSC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.69	-11.53	-0.53	4.06e-26	Cognitive function;
LUSC	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg08645402	chr16:4508243	NA	-0.42	-6.98	-0.36	1.6e-11	Schizophrenia;
LUSC	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg03859395	chr2:55845619	SMEK2	0.79	14.18	0.61	4.51e-36	Metabolic syndrome;
LUSC	cis	rs4930561	0.765	rs34493482	chr11:67969508	T/C	cg16338278	chr11:67432957	ALDH3B2	0.4	6.73	0.35	7.48e-11	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.82	14.87	0.63	9.95e-39	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg06363034	chr20:62225388	GMEB2	-0.46	-7.7	-0.39	1.53e-13	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUSC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.83	0.44	5.81e-17	Prudent dietary pattern;
LUSC	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg21775007	chr8:11205619	TDH	-0.49	-6.93	-0.35	2.21e-11	Neuroticism;
LUSC	cis	rs10792830	0.706	rs563773	chr11:85673270	C/T	cg07180834	chr11:85838833	NA	-0.3	-5.73	-0.3	2.19e-8	Psychosis and Alzheimer's disease;
LUSC	trans	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Bladder cancer;
LUSC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24531977	chr5:56204891	C5orf35	0.89	14.35	0.62	1.08e-36	Initial pursuit acceleration;
LUSC	cis	rs3784262	1.000	rs7178497	chr15:58240333	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.99	-0.31	5.54e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07080220	chr10:102295463	HIF1AN	0.64	8.46	0.42	8.25e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.21	0.32	1.58e-9	Total body bone mineral density;
LUSC	cis	rs9473147	0.543	rs9367279	chr6:47448336	A/G	cg12968598	chr6:47444699	CD2AP	0.53	8.18	0.41	6.12e-15	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg10326726	chr10:51549505	MSMB	0.34	5.88	0.31	9.99e-9	Prostate-specific antigen levels;
LUSC	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg05941027	chr17:61774174	LIMD2	0.22	5.76	0.3	1.95e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs939574	0.790	rs72955439	chr2:220090804	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	6.07	0.32	3.4e-9	Platelet distribution width;
LUSC	cis	rs936229	0.813	rs4886629	chr15:75072558	G/C	cg14664628	chr15:75095509	CSK	-1.0	-16.86	-0.68	1.45e-46	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	9.03	0.44	1.36e-17	Lung cancer in ever smokers;
LUSC	trans	rs10486158	0.843	rs7797517	chr7:7389587	A/C	cg01895333	chr3:109035405	DPPA2	-0.38	-6.03	-0.31	4.33e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02176678	chr2:219576539	TTLL4	0.63	11.63	0.54	1.76e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3755132	0.852	rs6711424	chr2:15745333	T/G	cg12888861	chr2:15731646	DDX1	0.5	7.27	0.37	2.55e-12	Wilms tumor;
LUSC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg01065977	chr19:18549689	ISYNA1	-0.23	-5.74	-0.3	2.14e-8	Breast cancer;
LUSC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg00990874	chr7:1149470	C7orf50	-0.46	-6.16	-0.32	2.06e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21643547	chr1:205240462	TMCC2	-0.49	-9.3	-0.45	1.88e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg22676075	chr6:135203613	NA	0.47	7.27	0.37	2.62e-12	Red blood cell count;
LUSC	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg08999081	chr20:33150536	PIGU	0.45	8.01	0.4	1.92e-14	Coronary artery disease;
LUSC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg09491104	chr22:46646882	C22orf40	-0.64	-7.39	-0.37	1.22e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg19665696	chr7:949154	ADAP1	0.47	6.23	0.32	1.38e-9	Bronchopulmonary dysplasia;
LUSC	trans	rs9944715	1.000	rs6507693	chr18:43829137	G/A	cg01718231	chr17:29326311	RNF135	-0.52	-7.3	-0.37	2.12e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg06494592	chr3:125709126	NA	-0.51	-5.79	-0.3	1.6e-8	Blood pressure (smoking interaction);
LUSC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg07424592	chr7:64974309	NA	0.7	6.05	0.31	3.99e-9	Diabetic kidney disease;
LUSC	cis	rs11997175	0.631	rs7826866	chr8:33665090	A/T	ch.8.33884649F	chr8:33765107	NA	0.4	6.16	0.32	2.13e-9	Body mass index;
LUSC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg22907277	chr7:1156413	C7orf50	0.69	7.34	0.37	1.59e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.17	-0.37	4.95e-12	Neuroticism;
LUSC	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-7.62	-0.38	2.69e-13	Neuroticism;
LUSC	cis	rs10743315	0.643	rs75398828	chr12:19340053	T/C	cg02471346	chr12:19282374	PLEKHA5	0.59	5.81	0.3	1.46e-8	Gut microbiota (bacterial taxa);
LUSC	trans	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.57	-8.72	-0.43	1.31e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg16482183	chr6:26056742	HIST1H1C	0.56	8.22	0.41	4.57e-15	Height;
LUSC	cis	rs4356932	0.729	rs6855257	chr4:76964788	T/C	cg00809888	chr4:76862425	NAAA	0.34	5.68	0.3	2.94e-8	Blood protein levels;
LUSC	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg23029597	chr12:123009494	RSRC2	-0.73	-9.05	-0.44	1.24e-17	Body mass index;
LUSC	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg21141812	chr3:48556323	PFKFB4	0.33	6.05	0.31	3.98e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs4285028	0.796	rs12638492	chr3:121711763	G/A	cg11130432	chr3:121712080	ILDR1	-0.66	-10.09	-0.48	4.69e-21	Multiple sclerosis;
LUSC	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg08917208	chr2:24149416	ATAD2B	1.02	10.65	0.5	5.21e-23	Lymphocyte counts;
LUSC	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.53	-0.34	2.42e-10	Recombination measurement;
LUSC	trans	rs11700980	0.551	rs2832018	chr21:30111639	T/C	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.31e-9	QRS complex (12-leadsum);
LUSC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.8	-13.44	-0.59	3.28e-33	Menarche (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02307953	chr2:99797349	MRPL30;MITD1	-0.42	-6.37	-0.33	6.16e-10	Electrocardiographic conduction measures;
LUSC	cis	rs55665837	1.000	rs10047429	chr11:14439032	C/T	cg19336497	chr11:14380999	RRAS2	-0.37	-7.53	-0.38	4.9e-13	Vitamin D levels;
LUSC	cis	rs11997175	0.846	rs34860600	chr8:33761566	C/A	ch.8.33884649F	chr8:33765107	NA	0.58	9.35	0.46	1.32e-18	Body mass index;
LUSC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.58	-9.48	-0.46	5.03e-19	IgG glycosylation;
LUSC	cis	rs6460942	0.915	rs6965564	chr7:12306013	C/T	cg06484146	chr7:12443880	VWDE	-0.51	-6.24	-0.32	1.32e-9	Coronary artery disease;
LUSC	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.01e-14	Retinal vascular caliber;
LUSC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg11663144	chr21:46675770	NA	-0.36	-5.92	-0.31	7.91e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.84	-0.3	1.23e-8	Total body bone mineral density;
LUSC	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.79	15.09	0.64	1.41e-39	Endometriosis;
LUSC	cis	rs10740039	0.586	rs7068462	chr10:62395998	A/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg24130564	chr14:104152367	KLC1	-0.7	-11.34	-0.53	1.9e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.815	rs11149818	chr16:75419373	G/A	cg04384234	chr16:75411784	CFDP1	-0.46	-7.58	-0.38	3.49e-13	Dupuytren's disease;
LUSC	cis	rs6700896	0.500	rs11208707	chr1:66139513	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	6.03	0.31	4.34e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg06740227	chr12:86229804	RASSF9	0.45	7.2	0.37	4.14e-12	Major depressive disorder;
LUSC	cis	rs2742417	0.603	rs2673075	chr3:45778288	C/A	cg04837898	chr3:45731254	SACM1L	-0.46	-7.43	-0.38	9.02e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08219700	chr8:58056026	NA	0.63	7.54	0.38	4.52e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2637266	0.967	rs7900230	chr10:78366879	A/G	cg18941641	chr10:78392320	NA	0.39	7.11	0.36	7.28e-12	Pulmonary function;
LUSC	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.8	-0.35	4.74e-11	Monocyte percentage of white cells;
LUSC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg11645453	chr3:52864694	ITIH4	0.36	7.0	0.36	1.44e-11	Bipolar disorder;
LUSC	cis	rs9815354	0.812	rs73075234	chr3:42051801	G/A	cg03022575	chr3:42003672	ULK4	0.61	6.52	0.34	2.61e-10	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19816011	chr2:113012631	ZC3H8	-0.41	-6.02	-0.31	4.57e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg14019146	chr3:50243930	SLC38A3	-0.37	-8.21	-0.41	5.02e-15	Body mass index;
LUSC	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg06191203	chr2:152266755	RIF1	0.53	7.06	0.36	9.87e-12	Lung cancer;
LUSC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg08088566	chr11:430123	ANO9	0.63	7.05	0.36	1.01e-11	Body mass index;
LUSC	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg17366294	chr4:99064904	C4orf37	0.51	8.29	0.41	2.78e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg22800045	chr5:56110881	MAP3K1	0.76	9.84	0.47	3.24e-20	Initial pursuit acceleration;
LUSC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	10.57	0.5	1.01e-22	Chronic sinus infection;
LUSC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.43	0.53	8.95e-26	Prudent dietary pattern;
LUSC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg13628971	chr7:2884303	GNA12	0.5	6.93	0.35	2.23e-11	Height;
LUSC	cis	rs757278	0.552	rs4730793	chr7:117311117	C/T	cg10524701	chr7:117356490	CTTNBP2	0.4	5.75	0.3	1.99e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.58	-8.56	-0.42	4.07e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg23172400	chr8:95962367	TP53INP1	-0.41	-8.5	-0.42	6.51e-16	Type 2 diabetes;
LUSC	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.63	9.55	0.46	2.8e-19	Corneal astigmatism;
LUSC	cis	rs977987	0.778	rs4888426	chr16:75476451	G/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.16	-0.36	5.2e-12	Dupuytren's disease;
LUSC	cis	rs9921338	0.924	rs72773831	chr16:11412927	G/A	cg00044050	chr16:11439710	C16orf75	-0.5	-6.75	-0.35	6.64e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg22681709	chr2:178499509	PDE11A	-0.56	-10.64	-0.5	5.72e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6845621	0.745	rs1517995	chr4:18863110	A/G	cg12196642	chr4:18937545	NA	-0.32	-5.88	-0.31	9.96e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.46	0.38	7.32e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg25214090	chr10:38739885	LOC399744	0.39	5.96	0.31	6.43e-9	Corneal astigmatism;
LUSC	cis	rs3764021	0.870	rs10772085	chr12:9876877	C/G	cg20894963	chr12:9885564	CLECL1	0.34	7.06	0.36	9.92e-12	Type 1 diabetes;
LUSC	trans	rs12458462	0.665	rs2035085	chr18:77485280	C/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.48	-6.55	-0.34	2.15e-10	Monocyte count;
LUSC	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg04398451	chr17:18023971	MYO15A	0.41	6.43	0.33	4.36e-10	Total body bone mineral density;
LUSC	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.39	-0.46	9.99e-19	Neuroticism;
LUSC	cis	rs7577696	0.962	rs4952250	chr2:32343699	T/G	cg02381751	chr2:32503542	YIPF4	-0.4	-5.71	-0.3	2.47e-8	Inflammatory biomarkers;
LUSC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03576123	chr11:487126	PTDSS2	-0.95	-10.55	-0.5	1.22e-22	Body mass index;
LUSC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg18402987	chr7:1209562	NA	0.72	7.69	0.39	1.67e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg04414720	chr1:150670196	GOLPH3L	-0.41	-6.27	-0.32	1.14e-9	Tonsillectomy;
LUSC	trans	rs61931739	0.635	rs1405024	chr12:33937939	A/T	cg13010199	chr12:38710504	ALG10B	-0.41	-6.15	-0.32	2.23e-9	Morning vs. evening chronotype;
LUSC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13089785	0.965	rs1920221	chr3:123606952	A/G	cg02012769	chr3:123398346	MYLK	0.34	6.38	0.33	6.06e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3806933	0.522	rs13179305	chr5:110444474	G/A	cg04022379	chr5:110408740	TSLP	0.64	9.3	0.45	1.83e-18	Eosinophilic esophagitis;
LUSC	cis	rs6977660	0.714	rs6943204	chr7:19818671	A/G	cg07541023	chr7:19748670	TWISTNB	0.6	6.53	0.34	2.48e-10	Thyroid stimulating hormone;
LUSC	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg00792783	chr2:198669748	PLCL1	-0.45	-5.99	-0.31	5.43e-9	Intracranial aneurysm;
LUSC	cis	rs3931020	0.688	rs277374	chr1:75200486	G/A	cg21906852	chr1:75198582	TYW3;CRYZ	-0.45	-5.86	-0.31	1.09e-8	Resistin levels;
LUSC	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg00825309	chr19:58991885	ZNF446	-0.49	-7.03	-0.36	1.17e-11	Uric acid clearance;
LUSC	cis	rs2369473	1	rs2369473	chr1:160210727	C/A	cg02974968	chr1:160236444	NA	-0.38	-6.82	-0.35	4.2e-11	Squamous cell lung carcinoma;
LUSC	cis	rs12476592	0.602	rs10469944	chr2:63816672	C/G	cg10828910	chr2:63850056	LOC388955	0.5	5.81	0.3	1.49e-8	Childhood ear infection;
LUSC	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg03806693	chr22:41940476	POLR3H	0.84	12.18	0.55	1.75e-28	Vitiligo;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22801400	chr10:93170010	LOC100188947;HECTD2	-0.45	-6.58	-0.34	1.77e-10	Electrocardiographic conduction measures;
LUSC	trans	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg18187862	chr3:45730750	SACM1L	0.57	7.3	0.37	2.18e-12	Primary sclerosing cholangitis;
LUSC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg14668632	chr7:2872130	GNA12	-0.52	-7.4	-0.38	1.14e-12	Height;
LUSC	cis	rs240764	0.658	rs10872628	chr6:101176349	A/G	cg09795085	chr6:101329169	ASCC3	-0.43	-6.27	-0.32	1.12e-9	Neuroticism;
LUSC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg08270630	chr22:50330655	NA	-0.42	-6.29	-0.33	1e-9	Schizophrenia;
LUSC	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg05985134	chr18:33552581	C18orf21	0.51	7.05	0.36	1.01e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-7.44	-0.38	8.56e-13	Chronic sinus infection;
LUSC	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.47	-0.33	3.53e-10	Platelet count;
LUSC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg00857998	chr1:205179979	DSTYK	-0.63	-9.59	-0.46	2.21e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg22535103	chr8:58192502	C8orf71	-0.56	-6.71	-0.34	8.29e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs644148	0.730	rs2571044	chr19:44985573	G/A	cg15540054	chr19:45004280	ZNF180	-0.51	-6.97	-0.36	1.73e-11	Personality dimensions;
LUSC	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg01966878	chr4:90757139	SNCA	-0.34	-5.86	-0.31	1.11e-8	Dementia with Lewy bodies;
LUSC	cis	rs9467160	0.559	rs2753911	chr6:24442288	C/T	cg20631270	chr6:24437470	GPLD1	0.39	6.16	0.32	2.13e-9	Liver enzyme levels;
LUSC	cis	rs965513	1.000	rs7030280	chr9:100535267	C/T	cg13688889	chr9:100608707	NA	-0.55	-8.33	-0.41	2.07e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg03732007	chr1:2071316	PRKCZ	-0.51	-8.88	-0.44	4.17e-17	Height;
LUSC	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg09307838	chr4:120376055	NA	0.63	9.5	0.46	4.35e-19	Corneal astigmatism;
LUSC	cis	rs3820928	0.874	rs55959848	chr2:227805426	C/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.75	-0.39	1.14e-13	Pulmonary function;
LUSC	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg13647721	chr17:30228624	UTP6	0.58	6.31	0.33	8.95e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.28	0.32	1.07e-9	Total body bone mineral density;
LUSC	cis	rs483180	0.532	rs561931	chr1:120254506	A/G	cg19096424	chr1:120255104	PHGDH	0.52	7.4	0.38	1.12e-12	Macular telangiectasia type 2;
LUSC	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg03342759	chr3:160939853	NMD3	-0.44	-6.8	-0.35	4.85e-11	Morning vs. evening chronotype;
LUSC	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.3	-0.37	2.06e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs13011075	0.919	rs34196827	chr2:68621427	G/A	cg14221825	chr19:46271408	SIX5	0.43	6.19	0.32	1.73e-9	Mean corpuscular volume;
LUSC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg06808227	chr14:105710500	BRF1	-0.67	-10.31	-0.49	8.31e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	trans	rs9929218	0.954	rs12919719	chr16:68822341	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.78	-0.54	5.16e-27	Colorectal cancer;
LUSC	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg15485101	chr11:133734466	NA	0.4	7.43	0.38	8.9e-13	Childhood ear infection;
LUSC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg08847533	chr14:75593920	NEK9	0.83	14.61	0.62	9.66e-38	Height;
LUSC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.16	0.36	5.13e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.55	-0.34	2.14e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13732083	chr21:47605072	C21orf56	-0.42	-6.1	-0.32	3.01e-9	Testicular germ cell tumor;
LUSC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.74	9.68	0.47	1.07e-19	Menarche (age at onset);
LUSC	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg09904177	chr6:26538194	HMGN4	0.75	14.22	0.61	3.36e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs12476592	0.516	rs196124	chr2:63854138	A/G	cg10828910	chr2:63850056	LOC388955	0.49	5.76	0.3	1.89e-8	Childhood ear infection;
LUSC	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg06002616	chr8:101225028	SPAG1	-0.4	-6.7	-0.34	8.89e-11	Atrioventricular conduction;
LUSC	cis	rs11030122	0.673	rs10835601	chr11:4106416	G/A	cg18678763	chr11:4115507	RRM1	-0.5	-6.59	-0.34	1.69e-10	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1983891	0.955	rs6917270	chr6:41548755	A/G	cg15051332	chr6:41514432	FOXP4	0.39	5.65	0.3	3.5e-8	Prostate cancer;
LUSC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg22681709	chr2:178499509	PDE11A	0.57	11.77	0.54	5.33e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg18306943	chr3:40428807	ENTPD3	0.39	5.93	0.31	7.72e-9	Renal cell carcinoma;
LUSC	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	10.4	0.49	3.92e-22	Mean corpuscular hemoglobin;
LUSC	cis	rs6714788	0.503	rs1370356	chr2:100675241	G/C	cg07810366	chr2:100720526	AFF3	-0.38	-6.03	-0.31	4.41e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg07741184	chr6:167504864	NA	0.35	6.23	0.32	1.41e-9	Crohn's disease;
LUSC	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg19812747	chr11:111475976	SIK2	0.47	6.62	0.34	1.48e-10	Primary sclerosing cholangitis;
LUSC	cis	rs12681287	0.640	rs7460650	chr8:87474085	A/G	cg27223183	chr8:87520930	FAM82B	-0.56	-7.73	-0.39	1.24e-13	Caudate activity during reward;
LUSC	trans	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg14791747	chr16:20752902	THUMPD1	0.73	9.55	0.46	2.84e-19	Cognitive test performance;
LUSC	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.65	-0.63	6.79e-38	Schizophrenia;
LUSC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg19592336	chr6:28129416	ZNF389	0.48	6.3	0.33	9.46e-10	Depression;
LUSC	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg23280166	chr11:118938394	VPS11	0.48	7.62	0.39	2.57e-13	Coronary artery disease;
LUSC	cis	rs68170813	0.523	rs12154285	chr7:106993573	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.56	-0.46	2.74e-19	Coronary artery disease;
LUSC	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg26924012	chr15:45694286	SPATA5L1	0.79	12.5	0.56	1.13e-29	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs1486139	1.000	rs9639945	chr7:46268593	T/C	cg17534202	chr9:96721102	NA	-0.34	-6.09	-0.32	3.18e-9	Select biomarker traits;
LUSC	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg03522245	chr20:25566470	NINL	-0.35	-5.72	-0.3	2.36e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.85	0.39	5.82e-14	Retinal vascular caliber;
LUSC	cis	rs1113500	0.933	rs10494089	chr1:108626695	T/G	cg11967332	chr1:108735228	SLC25A24	0.38	5.76	0.3	1.92e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-0.78	-12.1	-0.55	3.48e-28	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg23711669	chr6:146136114	FBXO30	0.93	18.15	0.7	1e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9653442	0.564	rs4850924	chr2:100782273	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-7.03	-0.36	1.17e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9653442	0.564	rs4851256	chr2:100775045	A/G	cg22139774	chr2:100720529	AFF3	-0.39	-6.69	-0.34	9.69e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg09365446	chr1:150670422	GOLPH3L	0.46	6.9	0.35	2.59e-11	Melanoma;
LUSC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg18190219	chr22:46762943	CELSR1	-0.55	-6.0	-0.31	5.1e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.9	0.77	1.58e-66	Prudent dietary pattern;
LUSC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.84	13.91	0.61	5.19e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19346786	chr7:2764209	NA	-0.47	-7.95	-0.4	2.99e-14	Height;
LUSC	cis	rs6664467	1	rs6664467	chr1:151738403	G/A	cg07092448	chr1:151763213	TDRKH	-1.23	-12.17	-0.55	1.89e-28	Carotid plaque burden;
LUSC	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-9.75	-0.47	6.19e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg18721089	chr20:30220636	NA	-0.35	-5.92	-0.31	8.06e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs2797160	0.522	rs6925158	chr6:125940188	T/G	cg05901451	chr6:126070800	HEY2	-0.43	-6.05	-0.31	3.96e-9	Endometrial cancer;
LUSC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg23887609	chr12:130822674	PIWIL1	0.49	7.33	0.37	1.78e-12	Menopause (age at onset);
LUSC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg04414720	chr1:150670196	GOLPH3L	0.5	7.8	0.39	8.1e-14	Melanoma;
LUSC	cis	rs3087591	0.639	rs2342053	chr17:29722196	A/G	cg24425628	chr17:29625626	OMG;NF1	0.47	7.05	0.36	1.06e-11	Hip circumference;
LUSC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.73	0.3	2.25e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg01475377	chr6:109611718	NA	0.46	8.45	0.42	9.08e-16	Reticulocyte fraction of red cells;
LUSC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg22166914	chr1:53195759	ZYG11B	-0.67	-11.74	-0.54	7.29e-27	Monocyte count;
LUSC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg09021430	chr5:549028	NA	-0.54	-7.07	-0.36	8.97e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6060717	0.610	rs6058393	chr20:34608664	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.4	-0.33	5.25e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26706201	chr11:57103334	SSRP1	-0.43	-7.4	-0.38	1.1e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.44	-6.63	-0.34	1.35e-10	Cognitive test performance;
LUSC	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg04240660	chr16:89714849	CHMP1A	-0.38	-6.01	-0.31	4.92e-9	Hemoglobin concentration;
LUSC	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.23	0.49	1.52e-21	Birth weight;
LUSC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg13683864	chr3:40499215	RPL14	-0.94	-15.99	-0.66	3.83e-43	Renal cell carcinoma;
LUSC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-10.63	-0.5	6.41e-23	Bipolar disorder;
LUSC	cis	rs3790515	1.000	rs12145375	chr1:151785229	T/C	cg07092448	chr1:151763213	TDRKH	-0.89	-6.92	-0.35	2.37e-11	Depressive symptoms (SSRI exposure interaction);
LUSC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg05313129	chr8:58192883	C8orf71	-0.51	-6.98	-0.36	1.55e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs55675132	0.620	rs2798470	chr1:115636403	A/T	cg01522456	chr1:115632236	TSPAN2	0.47	6.49	0.33	3.02e-10	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	12.61	0.57	4.55e-30	Motion sickness;
LUSC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08677398	chr8:58056175	NA	0.54	7.01	0.36	1.34e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9925964	0.933	rs9923231	chr16:31107689	C/T	cg02466173	chr16:30829666	NA	0.35	6.32	0.33	8.39e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg11764359	chr7:65958608	NA	-0.51	-6.57	-0.34	1.94e-10	Aortic root size;
LUSC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07677032	chr17:61819896	STRADA	0.52	8.8	0.43	7.73e-17	Prudent dietary pattern;
LUSC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	cis	rs2285947	0.935	rs10258022	chr7:21583667	A/G	cg04471919	chr7:21584483	DNAH11	0.35	7.71	0.39	1.5e-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg23630131	chr7:65973040	NA	-0.22	-6.03	-0.31	4.35e-9	Aortic root size;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20033598	chr7:112579757	C7orf60	0.4	6.59	0.34	1.71e-10	Asthma;
LUSC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg08847533	chr14:75593920	NEK9	0.84	15.38	0.64	9.75e-41	Height;
LUSC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	7.93	0.4	3.31e-14	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs73200209	0.744	rs2392968	chr12:116533861	A/C	cg01776926	chr12:116560359	MED13L	-0.49	-6.16	-0.32	2.14e-9	Total body bone mineral density;
LUSC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.9	0.35	2.69e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg00105475	chr2:10696890	NA	0.36	6.01	0.31	4.93e-9	Prostate cancer;
LUSC	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg25930673	chr12:123319894	HIP1R	-0.62	-6.16	-0.32	2.04e-9	Schizophrenia;
LUSC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg11845111	chr2:191398756	TMEM194B	-0.54	-9.18	-0.45	4.54e-18	Pulse pressure;
LUSC	cis	rs1961456	0.542	rs75501607	chr8:18244753	C/T	cg18736775	chr8:18248649	NAT2	-0.55	-6.57	-0.34	1.88e-10	Total cholesterol levels;
LUSC	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg13318129	chr22:45737514	FAM118A	0.77	8.93	0.44	2.94e-17	Tonsillectomy;
LUSC	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg12863693	chr15:85201151	NMB	0.42	8.43	0.42	1.05e-15	Schizophrenia;
LUSC	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	5.05e-15	Homoarginine levels;
LUSC	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg05925327	chr15:68127851	NA	-0.4	-6.11	-0.32	2.7e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs6142102	0.923	rs6059586	chr20:32540501	G/A	cg08999081	chr20:33150536	PIGU	0.33	5.75	0.3	2e-8	Skin pigmentation;
LUSC	cis	rs3741151	0.773	rs79915238	chr11:73272947	C/T	cg17517138	chr11:73019481	ARHGEF17	0.98	8.18	0.41	6.04e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs4654899	1.000	rs6683542	chr1:21369610	T/C	cg01072550	chr1:21505969	NA	-0.56	-8.54	-0.42	4.74e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	0.89	12.01	0.55	7.2e-28	Eosinophil percentage of granulocytes;
LUSC	trans	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.77	0.47	5.4e-20	Mean corpuscular volume;
LUSC	cis	rs3087591	0.960	rs2953000	chr17:29509791	C/T	cg24425628	chr17:29625626	OMG;NF1	0.55	8.08	0.4	1.22e-14	Hip circumference;
LUSC	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg11965913	chr1:205819406	PM20D1	-0.48	-6.68	-0.34	1.02e-10	Menarche (age at onset);
LUSC	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg12179176	chr11:130786555	SNX19	0.58	8.77	0.43	9.33e-17	Schizophrenia;
LUSC	cis	rs9341808	0.556	rs2223875	chr6:81045452	C/T	cg08355045	chr6:80787529	NA	0.46	8.04	0.4	1.53e-14	Sitting height ratio;
LUSC	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.34	-7.47	-0.38	7.05e-13	Cystic fibrosis severity;
LUSC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg13395646	chr4:1353034	KIAA1530	-0.63	-9.84	-0.47	3.24e-20	Obesity-related traits;
LUSC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs2348418	0.966	rs11049698	chr12:28688287	C/T	cg13890972	chr12:28721907	NA	-0.34	-5.79	-0.3	1.66e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg05110241	chr16:68378359	PRMT7	-0.53	-6.16	-0.32	2.11e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11074549	chr14:75642944	TMED10	-0.47	-6.16	-0.32	2.11e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7241530	0.662	rs924888	chr18:75900840	G/A	cg14642773	chr18:75888474	NA	0.4	6.11	0.32	2.71e-9	Educational attainment (years of education);
LUSC	cis	rs60695258	0.550	rs2007132	chr4:87972585	G/T	cg10685359	chr4:87814065	C4orf36	-0.35	-6.24	-0.32	1.3e-9	Hematocrit;
LUSC	cis	rs6982240	0.514	rs2060357	chr8:142259829	G/A	cg00131261	chr8:142287264	NA	-0.37	-6.12	-0.32	2.68e-9	Tonsillectomy;
LUSC	cis	rs61935443	0.673	rs11107770	chr12:95275147	C/T	cg21533806	chr12:95267307	NA	-0.54	-6.85	-0.35	3.56e-11	Schizophrenia;
LUSC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg04944784	chr2:26401820	FAM59B	-0.74	-10.67	-0.5	4.46e-23	Gut microbiome composition (summer);
LUSC	cis	rs11971779	0.616	rs6965143	chr7:139026608	C/G	cg07862535	chr7:139043722	LUC7L2	0.53	6.58	0.34	1.84e-10	Diisocyanate-induced asthma;
LUSC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg13206674	chr6:150067644	NUP43	0.58	8.97	0.44	2.19e-17	Lung cancer;
LUSC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	8.83	0.44	6.02e-17	Monocyte percentage of white cells;
LUSC	cis	rs3862435	0.572	rs9796504	chr15:90927939	C/T	cg22089800	chr15:90895588	ZNF774	0.55	6.21	0.32	1.59e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg11843238	chr5:131593191	PDLIM4	0.51	9.06	0.44	1.14e-17	Acylcarnitine levels;
LUSC	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	19.01	0.72	3.91e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg01483505	chr11:975446	AP2A2	0.43	6.06	0.31	3.77e-9	Alzheimer's disease (late onset);
LUSC	cis	rs17125944	0.686	rs7144029	chr14:53333616	G/T	cg00686598	chr14:53173677	PSMC6	-0.67	-6.13	-0.32	2.41e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg18512352	chr11:47633146	NA	0.27	5.7	0.3	2.65e-8	Subjective well-being;
LUSC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg06784218	chr1:46089804	CCDC17	0.49	9.83	0.47	3.31e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18404041	chr3:52824283	ITIH1	-0.52	-9.84	-0.47	3.18e-20	Bipolar disorder;
LUSC	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg00012203	chr2:219082015	ARPC2	-0.54	-8.51	-0.42	6.01e-16	Ulcerative colitis;
LUSC	cis	rs55675132	0.704	rs12119227	chr1:115589615	G/A	cg01522456	chr1:115632236	TSPAN2	-0.46	-5.72	-0.3	2.35e-8	Schizophrenia;
LUSC	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg23131131	chr22:24373011	LOC391322	-0.5	-7.13	-0.36	6.42e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7336332	0.598	rs10220056	chr13:28003781	T/G	cg22138327	chr13:27999177	GTF3A	0.82	9.95	0.48	1.34e-20	Weight;
LUSC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg15103426	chr22:29168792	CCDC117	-0.44	-5.77	-0.3	1.78e-8	Lymphocyte counts;
LUSC	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.18	-0.41	6.02e-15	Neuroticism;
LUSC	trans	rs71435601	0.628	rs312936	chr2:21408647	T/A	cg20757404	chr19:378427	NA	0.38	5.99	0.31	5.36e-9	Cholesterol, total;
LUSC	trans	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg18187862	chr3:45730750	SACM1L	-0.53	-6.43	-0.33	4.3e-10	Primary sclerosing cholangitis;
LUSC	cis	rs12220238	1.000	rs7909664	chr10:75869754	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.65	7.85	0.39	5.54e-14	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg08917208	chr2:24149416	ATAD2B	0.99	10.09	0.48	4.53e-21	Lymphocyte counts;
LUSC	cis	rs9811920	0.683	rs813218	chr3:99592596	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.34	6.5	0.34	2.87e-10	Axial length;
LUSC	cis	rs9928842	0.941	rs1808427	chr16:75241394	T/C	cg09066997	chr16:75300724	BCAR1	0.53	6.4	0.33	5.15e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs9653442	0.900	rs6754937	chr2:100827720	T/G	cg22139774	chr2:100720529	AFF3	-0.46	-7.94	-0.4	3.12e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	8.8	0.43	7.57e-17	Mean platelet volume;
LUSC	cis	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg06521331	chr12:34319734	NA	-0.38	-6.49	-0.33	3.01e-10	Morning vs. evening chronotype;
LUSC	cis	rs4964805	0.773	rs4964623	chr12:104222742	G/A	cg02344784	chr12:104178138	NT5DC3	0.42	6.51	0.34	2.82e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.38	-6.97	-0.36	1.67e-11	Reticulocyte count;
LUSC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.63	0.34	1.38e-10	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12760731	0.623	rs11584977	chr1:178387283	A/G	cg00404053	chr1:178313656	RASAL2	0.48	5.76	0.3	1.91e-8	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.66	0.3	3.26e-8	Menopause (age at onset);
LUSC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg18681998	chr4:17616180	MED28	0.88	15.94	0.66	6.07e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.85	-0.35	3.57e-11	Monocyte percentage of white cells;
LUSC	cis	rs317865	0.737	rs55949632	chr4:16207072	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.61	5.84	0.3	1.22e-8	Kidney disease (early stage) in type 1 diabetes;
LUSC	trans	rs2018683	0.770	rs10951208	chr7:29022504	G/T	cg19402173	chr7:128379420	CALU	-0.59	-9.5	-0.46	4.24e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs16949788	1.000	rs16949849	chr15:66682709	A/G	cg08120210	chr15:66682733	MAP2K1	-0.59	-5.93	-0.31	7.77e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg06784218	chr1:46089804	CCDC17	0.48	9.41	0.46	8.23e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00828689	chr3:196697064	PIGZ	-0.42	-6.12	-0.32	2.58e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg08807101	chr21:30365312	RNF160	-0.66	-10.17	-0.49	2.34e-21	Pancreatic cancer;
LUSC	cis	rs9311676	0.632	rs6777066	chr3:58361603	T/C	cg26110898	chr3:58419937	PDHB	0.41	6.64	0.34	1.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs4132509	0.744	rs12047209	chr1:243954407	A/C	cg21452805	chr1:244014465	NA	0.58	5.79	0.3	1.58e-8	RR interval (heart rate);
LUSC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.36	-5.78	-0.3	1.75e-8	Total body bone mineral density;
LUSC	trans	rs7939886	0.920	rs11227428	chr11:55941972	C/G	cg15704280	chr7:45808275	SEPT13	0.88	6.69	0.34	9.39e-11	Myopia (pathological);
LUSC	cis	rs7428	0.924	rs908304	chr2:85573049	G/A	cg24342717	chr2:85555507	TGOLN2	-0.62	-8.99	-0.44	1.93e-17	Ear protrusion;
LUSC	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg26856596	chr11:1961893	NA	-0.34	-6.5	-0.34	2.91e-10	DNA methylation (variation);
LUSC	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg05283184	chr6:79620031	NA	-0.55	-11.32	-0.53	2.35e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs2932538	0.846	rs7546203	chr1:113154529	C/A	cg22162597	chr1:113214053	CAPZA1	0.69	9.99	0.48	9.74e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg27068330	chr11:65405492	SIPA1	-0.8	-11.33	-0.53	2.13e-25	Acne (severe);
LUSC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg00310523	chr12:86230176	RASSF9	0.49	9.35	0.46	1.28e-18	Major depressive disorder;
LUSC	cis	rs7578035	0.500	rs17021941	chr2:99384299	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-5.77	-0.3	1.84e-8	Bipolar disorder;
LUSC	cis	rs939574	1.000	rs79013471	chr2:220096122	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.07	8.71	0.43	1.42e-16	Platelet distribution width;
LUSC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.73	14.28	0.62	1.86e-36	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.58	8.0	0.4	2.01e-14	Response to diuretic therapy;
LUSC	cis	rs2297797	0.660	rs3820667	chr1:109968410	A/C	cg08367326	chr1:110052010	AMIGO1	0.39	5.86	0.31	1.13e-8	Cognitive function;
LUSC	trans	rs12677056	0.739	rs12677528	chr8:113308722	T/C	cg12159992	chr12:102059490	MYBPC1	0.37	6.16	0.32	2.05e-9	Peripheral artery disease;
LUSC	cis	rs9677476	0.863	rs7601741	chr2:232062351	C/T	cg07929768	chr2:232055508	NA	0.35	6.51	0.34	2.81e-10	Food antigen IgG levels;
LUSC	cis	rs3772130	0.545	rs7340674	chr3:121574215	T/C	cg20356878	chr3:121714668	ILDR1	0.61	9.79	0.47	4.6e-20	Cognitive performance;
LUSC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.1	-0.45	8.23e-18	Bipolar disorder;
LUSC	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.53	-7.8	-0.39	7.74e-14	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs11871801	0.560	rs8068844	chr17:40571284	T/C	cg16308533	chr17:40838983	CNTNAP1	0.37	5.75	0.3	2e-8	Crohn's disease;
LUSC	cis	rs642803	0.613	rs489574	chr11:65542739	C/T	cg02870584	chr11:65547924	DKFZp761E198	0.43	5.79	0.3	1.59e-8	Urate levels;
LUSC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11644478	chr21:40555479	PSMG1	0.62	9.68	0.47	1.06e-19	Menarche (age at onset);
LUSC	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg14500267	chr11:67383377	NA	0.34	6.51	0.34	2.77e-10	Mean corpuscular volume;
LUSC	cis	rs2692947	0.832	rs2438978	chr2:96679740	G/C	cg23100626	chr2:96804247	ASTL	0.31	7.38	0.37	1.25e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9309473	0.687	rs7576824	chr2:73611281	C/T	cg20560298	chr2:73613845	ALMS1	0.62	9.78	0.47	4.92e-20	Metabolite levels;
LUSC	cis	rs977987	0.806	rs2865530	chr16:75414376	G/T	cg04384234	chr16:75411784	CFDP1	-0.44	-7.34	-0.37	1.61e-12	Dupuytren's disease;
LUSC	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.31	-21.85	-0.77	2.39e-66	Type 1 diabetes nephropathy;
LUSC	cis	rs11677370	0.574	rs10209122	chr2:3871186	C/A	cg17052675	chr2:3827356	NA	-0.62	-9.47	-0.46	5.31e-19	Type 2 diabetes;
LUSC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg01657329	chr11:68192670	LRP5	-0.43	-6.41	-0.33	4.96e-10	Total body bone mineral density;
LUSC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg12311346	chr5:56204834	C5orf35	-0.64	-9.86	-0.47	2.73e-20	Coronary artery disease;
LUSC	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg14092571	chr14:90743983	NA	0.36	5.77	0.3	1.85e-8	Mortality in heart failure;
LUSC	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.26	-0.62	2.3e-36	Schizophrenia;
LUSC	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06634786	chr22:41940651	POLR3H	-0.55	-6.46	-0.33	3.75e-10	Vitiligo;
LUSC	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.59	10.49	0.5	1.97e-22	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg13319975	chr6:146136371	FBXO30	0.45	6.71	0.34	8.28e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg06917634	chr15:78832804	PSMA4	0.48	6.51	0.34	2.8e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	17.67	0.69	8.86e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs7584330	0.554	rs79213383	chr2:238426890	A/G	cg16989719	chr2:238392110	NA	-0.43	-6.2	-0.32	1.65e-9	Prostate cancer;
LUSC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg23625390	chr15:77176239	SCAPER	0.51	7.77	0.39	9.83e-14	Blood metabolite levels;
LUSC	cis	rs9318086	0.673	rs7981928	chr13:24435180	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.43	6.38	0.33	5.79e-10	Myopia (pathological);
LUSC	cis	rs11809207	0.903	rs17257148	chr1:26526348	G/C	cg00300879	chr1:26503847	CNKSR1	0.32	6.37	0.33	6.17e-10	Height;
LUSC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs2282300	0.739	rs1717772	chr11:30340133	C/T	cg25418670	chr11:30344373	C11orf46	-0.64	-9.23	-0.45	3.29e-18	Morning vs. evening chronotype;
LUSC	cis	rs11625487	0.609	rs74063385	chr14:77966859	C/T	cg16049707	chr14:77965284	ISM2	-0.6	-6.56	-0.34	2.01e-10	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg03676636	chr4:99064102	C4orf37	0.36	7.7	0.39	1.5700000000000001e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg04851639	chr8:1020857	NA	-0.36	-7.68	-0.39	1.81e-13	Schizophrenia;
LUSC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg18850127	chr7:39170497	POU6F2	0.65	9.91	0.48	1.82e-20	IgG glycosylation;
LUSC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg09165964	chr15:75287851	SCAMP5	-1.12	-18.05	-0.7	2.72e-51	Blood trace element (Zn levels);
LUSC	cis	rs3772130	0.886	rs9825248	chr3:121568711	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.7	10.02	0.48	7.94e-21	Cognitive performance;
LUSC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs1018836	0.544	rs10112371	chr8:91457626	C/T	cg16814680	chr8:91681699	NA	0.48	6.84	0.35	3.71e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.27	-0.56	8.26e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15506890	chr2:3487001	NA	-0.58	-9.58	-0.46	2.23e-19	Neurofibrillary tangles;
LUSC	cis	rs10276381	0.786	rs10272155	chr7:28246989	A/G	cg23620719	chr7:28220237	JAZF1	0.64	6.7	0.34	8.86e-11	Crohn's disease;
LUSC	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg23127183	chr11:57508653	C11orf31	0.51	7.28	0.37	2.44e-12	Schizophrenia;
LUSC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	12.9	0.58	3.54e-31	Platelet count;
LUSC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06850241	chr22:41845214	NA	-0.31	-5.74	-0.3	2.1e-8	Vitiligo;
LUSC	cis	rs7215564	0.558	rs4889876	chr17:78657071	T/G	cg09596252	chr17:78655493	RPTOR	0.55	6.04	0.31	4.18e-9	Myopia (pathological);
LUSC	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	0.85	13.72	0.6	2.86e-34	Prostate cancer;
LUSC	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg18132916	chr6:79620363	NA	-0.41	-6.28	-0.32	1.06e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4964805	0.954	rs11111786	chr12:104189057	T/C	cg02344784	chr12:104178138	NT5DC3	0.45	7.15	0.36	5.34e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs1595825	0.786	rs75415672	chr2:198535679	G/A	cg00982548	chr2:198649783	BOLL	-0.53	-6.55	-0.34	2.2e-10	Ulcerative colitis;
LUSC	cis	rs11997175	0.597	rs4472473	chr8:33610255	A/G	ch.8.33884649F	chr8:33765107	NA	0.41	6.47	0.33	3.47e-10	Body mass index;
LUSC	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	7.04	0.36	1.07e-11	Multiple sclerosis;
LUSC	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg24069376	chr3:38537580	EXOG	-0.34	-6.6	-0.34	1.65e-10	Electrocardiographic conduction measures;
LUSC	cis	rs727505	1.000	rs56356267	chr7:124557549	A/G	cg23710748	chr7:124431027	NA	-0.42	-7.58	-0.38	3.43e-13	Lewy body disease;
LUSC	cis	rs9653442	0.564	rs2309753	chr2:100775920	C/A	cg22139774	chr2:100720529	AFF3	-0.42	-7.25	-0.37	2.96e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg12560992	chr17:57184187	TRIM37	0.83	15.26	0.64	2.95e-40	Intelligence (multi-trait analysis);
LUSC	trans	rs1973993	0.662	rs2057427	chr1:96888897	C/G	cg10631902	chr5:14652156	NA	-0.54	-8.04	-0.4	1.63e-14	Weight;
LUSC	cis	rs9517320	1.000	rs7996093	chr13:99133092	T/C	cg07423050	chr13:99094983	FARP1	0.33	6.37	0.33	6.21e-10	Longevity;
LUSC	cis	rs3126085	0.877	rs10888472	chr1:152206896	C/G	cg26876637	chr1:152193138	HRNR	-0.42	-5.72	-0.3	2.34e-8	Atopic dermatitis;
LUSC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg06600287	chr1:53387719	ECHDC2	0.28	5.68	0.3	3.01e-8	Monocyte count;
LUSC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg13531842	chr10:38383804	ZNF37A	-0.43	-6.55	-0.34	2.17e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg26668828	chr6:292823	DUSP22	-0.51	-7.71	-0.39	1.47e-13	Menopause (age at onset);
LUSC	cis	rs1198872	0.503	rs1627163	chr2:10954844	A/G	cg15705551	chr2:10952987	PDIA6	0.41	5.8	0.3	1.52e-8	Cardiac Troponin-T levels;
LUSC	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg05294307	chr14:35346193	BAZ1A	-0.6	-6.98	-0.36	1.63e-11	Psoriasis;
LUSC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	7.96e-13	Motion sickness;
LUSC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.89	-18.1	-0.7	1.6e-51	Intelligence (multi-trait analysis);
LUSC	cis	rs12618769	0.625	rs3769733	chr2:99100716	A/G	cg10123293	chr2:99228465	UNC50	0.45	7.26	0.37	2.67e-12	Bipolar disorder;
LUSC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg14664628	chr15:75095509	CSK	-0.42	-6.04	-0.31	4.06e-9	Caffeine consumption;
LUSC	cis	rs2219968	1.000	rs4639505	chr8:78971658	A/G	cg00738934	chr8:78996279	NA	0.35	6.32	0.33	8.21e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.47	-7.04	-0.36	1.11e-11	Neutrophil percentage of white cells;
LUSC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg24829409	chr8:58192753	C8orf71	-0.51	-5.98	-0.31	5.6e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg20701182	chr2:24300061	SF3B14	0.58	6.19	0.32	1.72e-9	Lymphocyte counts;
LUSC	cis	rs7179456	0.547	rs6494036	chr15:59015961	A/T	cg05156742	chr15:59063176	FAM63B	0.52	7.52	0.38	5.25e-13	Asperger disorder;
LUSC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	1.21	40.72	0.91	1.46e-131	Myeloid white cell count;
LUSC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg25838465	chr1:92012736	NA	-0.75	-15.45	-0.65	5.22e-41	Breast cancer;
LUSC	cis	rs977987	0.806	rs8051407	chr16:75448659	A/G	cg03315344	chr16:75512273	CHST6	0.48	8.92	0.44	3.16e-17	Dupuytren's disease;
LUSC	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg07929629	chr2:241523174	NA	0.63	11.67	0.54	1.23e-26	Bipolar disorder;
LUSC	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.62	0.34	1.39e-10	IgG glycosylation;
LUSC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg23711669	chr6:146136114	FBXO30	-0.82	-14.69	-0.63	5.14e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.92	0.44	3.11e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.91	15.38	0.64	9.49e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.31	-0.33	8.73e-10	Resting heart rate;
LUSC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25072359	chr17:41440525	NA	0.64	9.06	0.44	1.15e-17	Menopause (age at onset);
LUSC	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.88	-0.4	4.75e-14	Blood metabolite levels;
LUSC	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg08079166	chr15:68083412	MAP2K5	-0.42	-8.61	-0.43	2.9e-16	Restless legs syndrome;
LUSC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18404041	chr3:52824283	ITIH1	-0.63	-11.65	-0.54	1.46e-26	Bipolar disorder;
LUSC	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg23280166	chr11:118938394	VPS11	0.48	7.57	0.38	3.62e-13	Coronary artery disease;
LUSC	cis	rs10743315	0.557	rs117033327	chr12:19373040	G/T	cg02471346	chr12:19282374	PLEKHA5	0.76	6.02	0.31	4.61e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs11997175	0.603	rs66828270	chr8:33790155	C/G	ch.8.33884649F	chr8:33765107	NA	0.51	7.81	0.39	7.52e-14	Body mass index;
LUSC	cis	rs9473147	0.516	rs13212790	chr6:47576367	T/C	cg02130027	chr6:47444894	CD2AP	0.36	5.72	0.3	2.33e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.49	-7.7	-0.39	1.55e-13	Tonsillectomy;
LUSC	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.75	-12.36	-0.56	3.79e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg23950597	chr19:37808831	NA	-0.52	-5.66	-0.3	3.33e-8	Coronary artery calcification;
LUSC	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs870825	0.616	rs7678849	chr4:185648868	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs7660520	1.000	rs7660520	chr4:183745321	C/T	cg20639618	chr4:183729073	NA	0.38	5.66	0.3	3.28e-8	Pediatric autoimmune diseases;
LUSC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg08132940	chr7:1081526	C7orf50	-0.5	-5.93	-0.31	7.41e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.84	-15.73	-0.65	4.2e-42	Heart rate;
LUSC	cis	rs4343996	0.935	rs4385365	chr7:3360860	C/T	cg21248987	chr7:3385318	SDK1	-0.38	-6.5	-0.34	2.92e-10	Motion sickness;
LUSC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg25767906	chr1:53392781	SCP2	-0.51	-9.52	-0.46	3.54e-19	Monocyte count;
LUSC	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.59	-0.43	3.48e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg00784671	chr22:46762841	CELSR1	-0.51	-6.44	-0.33	4.21e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg05855489	chr10:104503620	C10orf26	-0.69	-10.14	-0.49	2.99e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs1973993	0.717	rs55650017	chr1:96952142	G/A	cg10631902	chr5:14652156	NA	-0.45	-6.66	-0.34	1.15e-10	Weight;
LUSC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg21770322	chr7:97807741	LMTK2	0.44	7.54	0.38	4.56e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg23752985	chr2:85803571	VAMP8	0.33	6.52	0.34	2.61e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg13699009	chr12:122356056	WDR66	0.5	7.74	0.39	1.21e-13	Mean corpuscular volume;
LUSC	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg16482183	chr6:26056742	HIST1H1C	0.6	8.33	0.41	2.13e-15	Iron status biomarkers;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg11816918	chr18:2656305	SMCHD1	0.4	6.03	0.31	4.26e-9	Schizophrenia;
LUSC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg22549504	chr19:17448937	GTPBP3	-0.57	-7.54	-0.38	4.56e-13	Systemic lupus erythematosus;
LUSC	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg13057898	chr1:3703894	LRRC47	-0.5	-8.91	-0.44	3.45e-17	Red cell distribution width;
LUSC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22968622	chr17:43663579	NA	-0.78	-12.04	-0.55	5.64e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.42	-0.38	1.01e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7520050	0.807	rs28378621	chr1:46189554	T/C	cg06784218	chr1:46089804	CCDC17	0.3	5.93	0.31	7.59e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg17173187	chr15:85201210	NMB	0.5	9.51	0.46	4.01e-19	Schizophrenia;
LUSC	cis	rs4664308	1.000	rs62175517	chr2:160911575	C/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-11.33	-0.53	2.16e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs643955	0.609	rs13259465	chr8:9982953	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-5.82	-0.3	1.37e-8	Systemic lupus erythematosus;
LUSC	cis	rs6545883	0.894	rs6734628	chr2:61451260	T/C	cg15711740	chr2:61764176	XPO1	0.44	6.61	0.34	1.55e-10	Tuberculosis;
LUSC	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.85	0.35	3.47e-11	Rheumatoid arthritis;
LUSC	cis	rs1506636	0.646	rs805776	chr7:123212561	T/C	cg03229431	chr7:123269106	ASB15	-0.59	-8.87	-0.44	4.37e-17	Plateletcrit;Platelet count;
LUSC	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg03433033	chr1:76189801	ACADM	-0.41	-6.13	-0.32	2.47e-9	Daytime sleep phenotypes;
LUSC	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg23752985	chr2:85803571	VAMP8	0.31	6.06	0.31	3.7e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-12.64	-0.57	3.39e-30	Platelet count;
LUSC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg18404041	chr3:52824283	ITIH1	0.37	6.69	0.34	9.59e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg25767906	chr1:53392781	SCP2	-0.32	-5.64	-0.3	3.56e-8	Monocyte count;
LUSC	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg20307385	chr11:47447363	PSMC3	0.45	6.5	0.34	2.87e-10	Subjective well-being;
LUSC	cis	rs4901869	0.897	rs12878587	chr14:59339378	C/G	cg02291164	chr14:59296302	NA	0.58	11.11	0.52	1.33e-24	Panic disorder;
LUSC	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg21466736	chr12:48725269	NA	0.31	5.77	0.3	1.85e-8	Glycated hemoglobin levels;
LUSC	trans	rs6601327	0.606	rs9644707	chr8:9590116	A/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.43	-0.33	4.36e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs36093844	0.752	rs77497327	chr11:85586941	G/A	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs1775715	0.737	rs55859032	chr10:32213239	C/T	cg26784012	chr10:32216390	ARHGAP12	0.44	7.51	0.38	5.48e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6574644	1.000	rs7153538	chr14:81779507	G/T	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs524023	0.958	rs11231825	chr11:64360274	T/C	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.76	-0.3	1.91e-8	Urate levels in obese individuals;
LUSC	cis	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg14024893	chr9:139943146	ENTPD2	-0.56	-9.77	-0.47	5.53e-20	Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg08219700	chr8:58056026	NA	0.49	6.08	0.32	3.35e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.47e-8	Extrinsic epigenetic age acceleration;
LUSC	trans	rs76248362	1.000	rs7324410	chr13:24437465	G/A	cg26511321	chr7:27196790	HOXA7	0.53	6.18	0.32	1.87e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg04310649	chr10:35416472	CREM	-0.4	-6.27	-0.32	1.13e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs698813	0.674	rs4953080	chr2:44500849	C/A	cg00619915	chr2:44497795	NA	-0.52	-7.01	-0.36	1.3e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.25	0.32	1.25e-9	Platelet count;
LUSC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	0.98	16.67	0.67	8e-46	Cognitive function;
LUSC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs2658782	0.951	rs2608215	chr11:93148817	G/A	cg15737290	chr11:93063684	CCDC67	0.64	7.99	0.4	2.27e-14	Pulmonary function decline;
LUSC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg16434002	chr17:42200994	HDAC5	-0.45	-6.08	-0.32	3.24e-9	Total body bone mineral density;
LUSC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	13.28	0.59	1.32e-32	Tonsillectomy;
LUSC	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg08975724	chr8:8085496	FLJ10661	0.44	6.51	0.34	2.81e-10	Retinal vascular caliber;
LUSC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg10360323	chr17:41437877	NA	0.41	5.74	0.3	2.17e-8	Menopause (age at onset);
LUSC	cis	rs7833986	1.000	rs66796428	chr8:57094797	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	9.2	0.45	3.84e-18	Height;
LUSC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg25174290	chr11:3078921	CARS	0.57	8.58	0.42	3.72e-16	Type 2 diabetes;
LUSC	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg11161011	chr14:65562177	MAX	-0.7	-10.93	-0.51	5.69e-24	Obesity-related traits;
LUSC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08677398	chr8:58056175	NA	0.52	6.08	0.32	3.29e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg23625390	chr15:77176239	SCAPER	-0.65	-9.87	-0.48	2.56e-20	Blood metabolite levels;
LUSC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg03526776	chr6:41159608	TREML2	0.32	6.38	0.33	5.92e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg02807482	chr3:125708958	NA	-0.48	-5.7	-0.3	2.63e-8	Blood pressure (smoking interaction);
LUSC	cis	rs57502260	1.000	rs56312530	chr11:68219415	G/A	cg20283391	chr11:68216788	NA	-0.59	-5.72	-0.3	2.42e-8	Total body bone mineral density (age 45-60);
LUSC	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg16797656	chr11:68205561	LRP5	0.38	6.19	0.32	1.77e-9	Total body bone mineral density;
LUSC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg21535247	chr6:8435926	SLC35B3	0.56	8.57	0.42	3.79e-16	Motion sickness;
LUSC	trans	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg25482853	chr8:67687455	SGK3	1.11	15.63	0.65	9.88e-42	Obesity-related traits;
LUSC	cis	rs7712401	0.601	rs431878	chr5:122261791	G/T	cg19077854	chr5:122220652	SNX24	-0.44	-9.66	-0.47	1.28e-19	Mean platelet volume;
LUSC	cis	rs9865818	0.669	rs13079689	chr3:188102112	A/T	cg23651889	chr3:188115336	LPP	-0.38	-5.76	-0.3	1.91e-8	Allergic sensitization;
LUSC	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg09998033	chr7:158218633	PTPRN2	-0.61	-9.8	-0.47	4.38e-20	Obesity-related traits;
LUSC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg22823121	chr1:150693482	HORMAD1	0.51	7.47	0.38	7.01e-13	Melanoma;
LUSC	cis	rs10761482	0.861	rs4620673	chr10:62104704	A/G	cg18175470	chr10:62150864	ANK3	0.46	6.56	0.34	2.02e-10	Schizophrenia;
LUSC	trans	rs13008689	0.875	rs12616139	chr2:8522651	C/T	cg21637561	chr17:37074902	LASP1	0.35	6.05	0.31	3.91e-9	Longevity;
LUSC	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-7.3	-0.37	2.14e-12	Neuroticism;
LUSC	cis	rs72848980	0.512	rs56984020	chr10:105386275	C/A	cg00126946	chr10:105363258	SH3PXD2A	0.39	5.76	0.3	1.9e-8	White matter hyperintensity burden;
LUSC	cis	rs4499344	0.633	rs259239	chr19:33141090	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	12.14	0.55	2.37e-28	Mean platelet volume;
LUSC	cis	rs116988415	0.584	rs4902310	chr14:65241906	T/C	cg25083366	chr14:65239357	SPTB	0.66	6.37	0.33	6.41e-10	Daytime sleep phenotypes;
LUSC	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg09876464	chr15:85330779	ZNF592	0.36	6.71	0.34	8.3e-11	P wave terminal force;
LUSC	cis	rs9296092	0.517	rs9461877	chr6:33516667	C/T	cg13560919	chr6:33536144	NA	-0.82	-15.45	-0.65	5.48e-41	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs2976388	0.692	rs2585175	chr8:143781289	G/C	cg17252645	chr8:143867129	LY6D	0.39	6.71	0.34	8.6e-11	Urinary tract infection frequency;
LUSC	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg26958806	chr6:27640298	NA	0.78	5.84	0.3	1.21e-8	Breast cancer;
LUSC	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg04362960	chr10:104952993	NT5C2	0.59	9.34	0.46	1.42e-18	Arsenic metabolism;
LUSC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.15	-0.32	2.26e-9	Neutrophil percentage of white cells;
LUSC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.57	0.42	3.86e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1322512	0.917	rs2623953	chr6:152965857	A/G	cg27316956	chr6:152958899	SYNE1	-0.37	-6.34	-0.33	7.64e-10	Tonometry;
LUSC	cis	rs35123781	1.000	rs34510678	chr5:139064835	C/T	cg00976381	chr5:138713954	SLC23A1	-0.38	-5.73	-0.3	2.23e-8	Schizophrenia;
LUSC	cis	rs1775715	0.674	rs2778670	chr10:32161676	G/A	cg03015672	chr10:32216066	ARHGAP12	0.33	6.01	0.31	4.87e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg15711740	chr2:61764176	XPO1	-0.51	-7.98	-0.4	2.31e-14	Tuberculosis;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.84	14.53	0.62	2.02e-37	Menarche (age at onset);
LUSC	trans	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg01620082	chr3:125678407	NA	-0.51	-6.24	-0.32	1.33e-9	Depression;
LUSC	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	5.9	0.31	8.71e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19717773	chr7:2847554	GNA12	-0.37	-6.07	-0.32	3.53e-9	Height;
LUSC	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg12386194	chr3:101231763	SENP7	0.39	5.64	0.3	3.58e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.9	0.31	9.03e-9	Menopause (age at onset);
LUSC	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg06606381	chr12:133084897	FBRSL1	-0.95	-9.13	-0.45	6.49e-18	Depression;
LUSC	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg22709100	chr7:91322751	NA	-0.4	-5.84	-0.3	1.21e-8	Breast cancer;
LUSC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.43	-0.38	9.29e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg01294253	chr9:136912663	BRD3	0.36	6.24	0.32	1.34e-9	Platelet distribution width;
LUSC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg27532560	chr4:187881888	NA	0.38	6.32	0.33	8.18e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.87	-12.41	-0.56	2.44e-29	Initial pursuit acceleration;
LUSC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03576123	chr11:487126	PTDSS2	-1.0	-10.64	-0.5	6.03e-23	Body mass index;
LUSC	trans	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08645402	chr16:4508243	NA	0.53	8.98	0.44	2.03e-17	Schizophrenia;
LUSC	cis	rs6987853	0.787	rs2974314	chr8:42457043	C/T	cg09913449	chr8:42400586	C8orf40	0.46	7.72	0.39	1.35e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7851660	0.805	rs7038998	chr9:100662396	C/G	cg13688889	chr9:100608707	NA	-0.54	-8.49	-0.42	6.73e-16	Strep throat;
LUSC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.48	-7.47	-0.38	6.93e-13	Height;
LUSC	trans	rs72792324	1.000	rs4151697	chr5:140743661	C/T	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.43	5.96	0.31	6.57e-9	Mean platelet volume;
LUSC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg02551604	chr5:131831745	NA	-0.4	-6.27	-0.32	1.1e-9	Asthma (sex interaction);
LUSC	cis	rs3125734	0.633	rs6479804	chr10:64048327	T/C	cg19640130	chr10:64028056	RTKN2	-0.38	-6.63	-0.34	1.35e-10	Rheumatoid arthritis;
LUSC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg10356904	chr22:49881777	NA	-0.33	-7.51	-0.38	5.49e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.69	-10.76	-0.51	2.31e-23	Colorectal cancer;
LUSC	cis	rs422249	0.720	rs174455	chr11:61656117	A/G	cg01500311	chr11:61656094	FADS3	-0.44	-8.62	-0.43	2.69e-16	Trans fatty acid levels;
LUSC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.77	0.47	5.19e-20	Bipolar disorder;
LUSC	cis	rs10193935	1.000	rs13391906	chr2:42538617	C/G	cg27598129	chr2:42591480	NA	-0.6	-8.17	-0.41	6.36e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.13	0.32	2.44e-9	Bipolar disorder;
LUSC	cis	rs929596	0.793	rs2741046	chr2:234580249	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-6.96	-0.36	1.82e-11	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	0.93	17.43	0.69	7.74e-49	Heart rate;
LUSC	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg25922239	chr6:33757077	LEMD2	0.51	7.5	0.38	5.69e-13	Crohn's disease;
LUSC	cis	rs9469578	1.000	rs60447213	chr6:33715159	G/T	cg18708504	chr6:33715942	IP6K3	0.72	8.8	0.43	7.52e-17	Phosphorus levels;
LUSC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg14004847	chr7:1930337	MAD1L1	-0.67	-10.94	-0.51	5.07e-24	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg08859206	chr1:53392774	SCP2	0.52	9.03	0.44	1.44e-17	Monocyte count;
LUSC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg24733560	chr20:60626293	TAF4	0.42	7.82	0.39	6.93e-14	Body mass index;
LUSC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.57	0.46	2.47e-19	Mean platelet volume;
LUSC	cis	rs11158026	0.603	rs66820631	chr14:55465553	T/A	cg04306507	chr14:55594613	LGALS3	0.39	7.12	0.36	6.46e-12	Parkinson's disease;
LUSC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg02574844	chr11:5959923	NA	-0.44	-6.32	-0.33	8.18e-10	DNA methylation (variation);
LUSC	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg00857998	chr1:205179979	DSTYK	0.63	9.56	0.46	2.64e-19	Red blood cell count;
LUSC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg22834771	chr12:69754056	YEATS4	0.46	5.85	0.3	1.17e-8	Response to diuretic therapy;
LUSC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs9815354	0.812	rs77047799	chr3:41958895	T/C	cg03022575	chr3:42003672	ULK4	0.85	8.85	0.44	5.2e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4363385	0.647	rs56412380	chr1:153000705	T/C	cg00922841	chr1:152955080	SPRR1A	-0.39	-6.5	-0.33	2.97e-10	Inflammatory skin disease;
LUSC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg16928487	chr17:17741425	SREBF1	-0.34	-6.29	-0.33	1.01e-9	Total body bone mineral density;
LUSC	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.55	-0.38	4.07e-13	Retinal vascular caliber;
LUSC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.31	-7.73	-0.39	1.24e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11648785	0.777	rs12932473	chr16:90100389	C/T	cg16611967	chr16:90144006	NA	0.44	5.77	0.3	1.86e-8	Tanning;
LUSC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg22907277	chr7:1156413	C7orf50	0.7	8.21	0.41	5e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2637266	0.663	rs846581	chr10:78497984	C/T	cg18941641	chr10:78392320	NA	0.4	7.28	0.37	2.35e-12	Pulmonary function;
LUSC	cis	rs62458065	0.850	rs7785999	chr7:32461262	G/T	cg20159608	chr7:32802032	NA	-0.62	-7.32	-0.37	1.87e-12	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08280861	chr8:58055591	NA	-0.58	-7.1	-0.36	7.46e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs12406019	0.548	rs11579434	chr1:78610022	T/C	cg20826526	chr3:156266748	SSR3	-0.46	-6.83	-0.35	3.95e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8017423	0.935	rs7144335	chr14:90732280	A/G	cg04374321	chr14:90722782	PSMC1	-0.7	-10.68	-0.5	4.18e-23	Mortality in heart failure;
LUSC	cis	rs2274273	0.682	rs10145268	chr14:55504514	T/C	cg04306507	chr14:55594613	LGALS3	0.51	11.06	0.52	1.92e-24	Protein biomarker;
LUSC	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg09479241	chr17:27052676	TLCD1	-0.4	-5.65	-0.3	3.37e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg15848620	chr12:58087721	OS9	-0.4	-5.74	-0.3	2.12e-8	Multiple sclerosis;
LUSC	cis	rs12530845	1.000	rs56060450	chr7:135331777	C/T	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg13939156	chr17:80058883	NA	0.33	6.48	0.33	3.24e-10	Life satisfaction;
LUSC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg02503808	chr4:7069936	GRPEL1	1.02	14.65	0.63	7.03e-38	Monocyte percentage of white cells;
LUSC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.95	0.31	6.92e-9	Menopause (age at onset);
LUSC	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.23e-8	Breast cancer;
LUSC	trans	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	8.05	0.4	1.51e-14	Type 2 diabetes;
LUSC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	9.81	0.47	4.01e-20	Bipolar disorder;
LUSC	cis	rs11608355	1.000	rs7958625	chr12:109869218	A/T	cg19025524	chr12:109796872	NA	-0.37	-5.67	-0.3	3.16e-8	Neuroticism;
LUSC	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	0.59	9.43	0.46	7.37e-19	Breast cancer;
LUSC	cis	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg24375607	chr4:120327624	NA	-0.47	-7.25	-0.37	2.96e-12	Diastolic blood pressure;
LUSC	trans	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg24313572	chr1:56050060	NA	-0.29	-5.96	-0.31	6.59e-9	Morning vs. evening chronotype;
LUSC	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg21251018	chr6:28226885	NKAPL	0.31	5.83	0.3	1.3e-8	Pubertal anthropometrics;
LUSC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg13560548	chr3:10150139	C3orf24	0.49	6.89	0.35	2.83e-11	Alzheimer's disease;
LUSC	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.32	0.56	5.19e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg16325326	chr1:53192061	ZYG11B	-0.99	-19.96	-0.74	6.94e-59	Monocyte count;
LUSC	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg15605315	chr1:45957053	TESK2	-0.41	-6.09	-0.32	3.12e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs4642101	0.561	rs7638333	chr3:12806142	T/C	cg05775895	chr3:12838266	CAND2	0.48	7.41	0.38	1.02e-12	QRS complex (12-leadsum);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg08102658	chr17:79283123	C17orf55	0.7	6.05	0.31	3.87e-9	Cognitive performance;
LUSC	cis	rs6969780	1.000	rs73071550	chr7:27149099	T/C	cg26364809	chr7:27145159	NA	-0.59	-5.91	-0.31	8.35e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg21138405	chr5:131827807	IRF1	-0.34	-6.01	-0.31	4.93e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.85	-0.35	3.62e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg04518342	chr5:131593106	PDLIM4	0.55	10.37	0.49	4.93e-22	Acylcarnitine levels;
LUSC	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-7.31	-0.37	1.94e-12	Daytime sleep phenotypes;
LUSC	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg00012203	chr2:219082015	ARPC2	-0.56	-9.08	-0.45	9.47e-18	Ulcerative colitis;
LUSC	cis	rs80282103	0.764	rs12247818	chr10:1110464	G/A	cg18964960	chr10:1102726	WDR37	0.69	5.88	0.31	1e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg21548813	chr6:291882	DUSP22	-0.51	-7.64	-0.39	2.36e-13	Menopause (age at onset);
LUSC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg21918786	chr6:109611834	NA	-0.36	-6.19	-0.32	1.8e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	10.18	0.49	2.32e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	trans	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg25214090	chr10:38739885	LOC399744	0.5	7.32	0.37	1.88e-12	Corneal astigmatism;
LUSC	cis	rs1014246	0.848	rs10787715	chr10:118459571	C/T	cg14919929	chr10:118506882	NA	0.46	7.17	0.37	4.93e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs13253111	1.000	rs13253111	chr8:28061974	C/T	cg26534493	chr8:28060551	NA	-0.46	-8.96	-0.44	2.36e-17	Childhood body mass index;
LUSC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	10.69	0.5	4.01e-23	Homoarginine levels;
LUSC	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	9.54	0.46	3.01e-19	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg22508957	chr16:3507546	NAT15	-0.42	-6.68	-0.34	1.03e-10	Body mass index (adult);
LUSC	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg17749961	chr2:30669863	LCLAT1	0.62	7.62	0.38	2.62e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg13852791	chr20:30311386	BCL2L1	0.9	13.39	0.59	4.82e-33	Mean corpuscular hemoglobin;
LUSC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg03233332	chr7:66118400	NA	-0.39	-5.86	-0.31	1.12e-8	Aortic root size;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17571279	chr8:22526738	BIN3	-0.53	-6.21	-0.32	1.57e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs240764	0.578	rs9399688	chr6:101215786	C/T	cg09795085	chr6:101329169	ASCC3	0.43	6.1	0.32	2.92e-9	Neuroticism;
LUSC	cis	rs1568889	0.838	rs7131053	chr11:28143312	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.7	0.57	2.01e-30	Bipolar disorder;
LUSC	cis	rs7808935	0.628	rs72598551	chr7:27939885	C/T	cg22168087	chr7:27702803	HIBADH	0.7	8.29	0.41	2.84e-15	Prostate cancer;
LUSC	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg14582100	chr15:45693742	SPATA5L1	0.46	8.52	0.42	5.49e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg19920283	chr7:105172520	RINT1	0.58	5.94	0.31	7.27e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17712092	chr4:129076599	LARP1B	-0.86	-13.46	-0.59	2.74e-33	Eosinophil percentage of white cells;
LUSC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.5	6.23	0.32	1.4e-9	Renal function-related traits (BUN);
LUSC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.55	8.64	0.43	2.41e-16	Alzheimer's disease (late onset);
LUSC	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-1.23	-16.37	-0.67	1.18e-44	Hip circumference adjusted for BMI;
LUSC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg19077165	chr18:44547161	KATNAL2	0.42	6.33	0.33	7.85e-10	Personality dimensions;
LUSC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg22029157	chr1:209979665	IRF6	-0.74	-9.33	-0.45	1.56e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04141948	chr7:1023156	CYP2W1	0.28	5.73	0.3	2.19e-8	Longevity;Endometriosis;
LUSC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg08999081	chr20:33150536	PIGU	0.43	7.81	0.39	7.28e-14	Coronary artery disease;
LUSC	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.99	-0.4	2.21e-14	Glomerular filtration rate;
LUSC	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-5.75	-0.3	2e-8	Retinal vascular caliber;
LUSC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.81	13.64	0.6	5.83e-34	Aortic root size;
LUSC	trans	rs75804782	0.641	rs77448526	chr2:239353487	A/C	cg01134436	chr17:81009848	B3GNTL1	0.66	6.4	0.33	5.11e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.72	0.65	4.58e-42	Platelet count;
LUSC	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg12927641	chr6:109611667	NA	-0.34	-5.87	-0.31	1.04e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg19682013	chr15:45996608	NA	0.39	6.0	0.31	5.09e-9	Waist circumference;Weight;
LUSC	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg00982548	chr2:198649783	BOLL	-0.57	-7.13	-0.36	6.43e-12	Ulcerative colitis;
LUSC	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.51	0.38	5.48e-13	Iron status biomarkers;
LUSC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-0.8	-15.66	-0.65	7.98e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg20129853	chr10:51489980	NA	-0.33	-6.57	-0.34	1.95e-10	Prostate-specific antigen levels;
LUSC	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.88	11.94	0.55	1.3e-27	Mean corpuscular hemoglobin;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg19977241	chr2:74692637	MOGS	0.72	6.02	0.31	4.56e-9	Cognitive performance;
LUSC	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg19812747	chr11:111475976	SIK2	0.42	6.34	0.33	7.4e-10	Primary sclerosing cholangitis;
LUSC	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg15557168	chr22:42548783	NA	-0.33	-5.67	-0.3	3.03e-8	Cognitive function;
LUSC	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.86	-0.35	3.3e-11	Menopause (age at onset);
LUSC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21963583	chr11:68658836	MRPL21	0.55	8.14	0.41	7.91e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7181230	1.000	rs7181230	chr15:40360741	A/G	cg00868766	chr15:40364524	NA	0.34	6.13	0.32	2.46e-9	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs71403859	0.568	rs12149489	chr16:71813780	G/T	cg08717414	chr16:71523259	ZNF19	-0.58	-6.64	-0.34	1.24e-10	Post bronchodilator FEV1;
LUSC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg06046430	chr4:77819534	ANKRD56	0.48	6.97	0.36	1.73e-11	Emphysema distribution in smoking;
LUSC	cis	rs7828089	0.715	rs11136029	chr8:22253485	A/G	cg12081754	chr8:22256438	SLC39A14	-0.6	-9.88	-0.48	2.29e-20	Verbal declarative memory;
LUSC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg12751644	chr20:60527061	NA	-0.41	-7.12	-0.36	6.53e-12	Obesity-related traits;
LUSC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg06877462	chr1:205807181	PM20D1	0.49	8.71	0.43	1.46e-16	Menarche (age at onset);
LUSC	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg17595323	chr11:93583763	C11orf90	-0.32	-5.86	-0.31	1.13e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg27129171	chr3:47204927	SETD2	0.72	12.42	0.56	2.16e-29	Colorectal cancer;
LUSC	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.9	-0.31	8.73e-9	Ileal carcinoids;
LUSC	cis	rs7246967	0.541	rs74169641	chr19:22830576	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg12863693	chr15:85201151	NMB	0.39	8.05	0.4	1.49e-14	Schizophrenia;
LUSC	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg09911534	chr15:67153556	NA	-0.56	-6.76	-0.35	6.28e-11	Lung cancer (smoking interaction);
LUSC	cis	rs6005807	0.719	rs9625520	chr22:29037864	C/A	cg12565055	chr22:29076175	TTC28	0.54	5.85	0.31	1.15e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-6.06	-0.31	3.68e-9	Longevity;
LUSC	cis	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05901451	chr6:126070800	HEY2	-0.58	-8.59	-0.43	3.43e-16	Endometrial cancer;
LUSC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg13628971	chr7:2884303	GNA12	0.45	6.43	0.33	4.32e-10	Height;
LUSC	cis	rs3126085	0.935	rs4845431	chr1:152227977	A/G	cg03465714	chr1:152285911	FLG	-0.39	-5.64	-0.3	3.55e-8	Atopic dermatitis;
LUSC	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg07936489	chr17:37558343	FBXL20	-0.7	-9.74	-0.47	6.83e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg08975724	chr8:8085496	FLJ10661	0.65	9.66	0.47	1.27e-19	Neuroticism;
LUSC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg24296786	chr1:45957014	TESK2	0.54	8.23	0.41	4.22e-15	High light scatter reticulocyte count;
LUSC	cis	rs2742234	0.541	rs1879310	chr10:43734775	A/G	cg15436174	chr10:43711423	RASGEF1A	0.43	7.09	0.36	8.12e-12	Hirschsprung disease;
LUSC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7903847	0.642	rs11189159	chr10:99113964	G/A	cg20016023	chr10:99160130	RRP12	-0.29	-6.26	-0.32	1.17e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6686643	0.762	rs61800372	chr1:165611981	T/C	cg16553119	chr1:165599451	MGST3	-0.46	-6.48	-0.33	3.32e-10	Total ventricular volume;
LUSC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg00857998	chr1:205179979	DSTYK	0.64	9.87	0.48	2.45e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs9409565	0.826	rs9409564	chr9:97248166	C/T	cg05679027	chr9:99775184	HIATL2	-0.44	-6.16	-0.32	2.06e-9	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs1476670	0.710	rs4660763	chr1:44503576	T/C	cg09470012	chr1:44509516	NA	0.29	5.66	0.3	3.33e-8	Eotaxin levels;
LUSC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.71	10.66	0.5	5.06e-23	Aortic root size;
LUSC	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg02527881	chr3:46936655	PTH1R	-0.71	-13.72	-0.6	2.77e-34	Birth weight;
LUSC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg06008330	chr7:65541103	ASL	-0.4	-6.22	-0.32	1.52e-9	Aortic root size;
LUSC	trans	rs61931739	0.612	rs1906137	chr12:33939676	T/A	cg13010199	chr12:38710504	ALG10B	0.4	6.04	0.31	4.15e-9	Morning vs. evening chronotype;
LUSC	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg04362960	chr10:104952993	NT5C2	0.58	9.29	0.45	2.02e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg25457927	chr22:38595422	NA	-0.35	-6.97	-0.36	1.74e-11	Cutaneous nevi;
LUSC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg09491104	chr22:46646882	C22orf40	-0.7	-9.18	-0.45	4.47e-18	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg12463550	chr7:65579703	CRCP	0.42	6.04	0.31	4.11e-9	Calcium levels;
LUSC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.68	-11.74	-0.54	7.31e-27	Lung cancer;
LUSC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg11262906	chr1:85462892	MCOLN2	-0.71	-8.86	-0.44	4.83e-17	Serum sulfate level;
LUSC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.72	-12.17	-0.55	1.95e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.45	-0.38	7.83e-13	Morning vs. evening chronotype;
LUSC	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg06917634	chr15:78832804	PSMA4	0.49	6.05	0.31	3.95e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg12615879	chr12:58013172	SLC26A10	-0.27	-5.66	-0.3	3.22e-8	Multiple sclerosis;
LUSC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.9	0.31	9.02e-9	Menopause (age at onset);
LUSC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.74	-0.3	2.16e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg16558253	chr16:72132732	DHX38	-0.41	-5.85	-0.31	1.14e-8	Blood protein levels;
LUSC	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.54	-0.34	2.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	ch.11.42038R	chr11:967971	AP2A2	0.41	5.99	0.31	5.3300000000000004e-09	Alzheimer's disease (late onset);
LUSC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	0.94	17.98	0.7	4.92e-51	Heart rate;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06115851	chr18:34408868	C18orf10;KIAA1328	0.41	6.48	0.33	3.38e-10	Asthma;
LUSC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg10360139	chr7:1886902	MAD1L1	-0.45	-6.96	-0.36	1.83e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg00484396	chr16:3507460	NAT15	-0.47	-6.99	-0.36	1.48e-11	Body mass index (adult);
LUSC	cis	rs2625529	0.556	rs35603965	chr15:72523043	C/T	cg16672083	chr15:72433130	SENP8	0.47	7.86	0.4	5.33e-14	Red blood cell count;
LUSC	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.94	0.36	2.02e-11	Height;
LUSC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.99	0.4	2.24e-14	Mean platelet volume;
LUSC	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg08917208	chr2:24149416	ATAD2B	0.99	10.36	0.49	5.38e-22	Lymphocyte counts;
LUSC	cis	rs9311676	0.656	rs9881869	chr3:58333255	G/A	cg26110898	chr3:58419937	PDHB	-0.43	-6.96	-0.36	1.85e-11	Systemic lupus erythematosus;
LUSC	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg03254818	chr6:169586852	NA	-0.44	-6.2	-0.32	1.71e-9	Pulse pressure;
LUSC	cis	rs977987	0.778	rs8057849	chr16:75443816	T/C	cg03315344	chr16:75512273	CHST6	0.48	8.98	0.44	2.08e-17	Dupuytren's disease;
LUSC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	trans	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-6.87	-0.35	3.06e-11	Menarche (age at onset);
LUSC	cis	rs2708977	0.637	rs654224	chr2:97080123	A/C	cg01950434	chr2:97203154	ARID5A	-0.44	-6.25	-0.32	1.27e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.8	-0.39	7.87e-14	Gut microbiome composition (summer);
LUSC	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.75	14.64	0.63	7.48e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2303282	0.716	rs2587873	chr16:56412734	C/G	cg00500540	chr16:56394104	NA	-0.45	-7.67	-0.39	1.96e-13	Breast cancer;
LUSC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.88	-0.31	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.83	-0.44	6.02e-17	Bipolar disorder;
LUSC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg02569458	chr12:86230093	RASSF9	0.58	9.93	0.48	1.56e-20	Major depressive disorder;
LUSC	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg23752985	chr2:85803571	VAMP8	0.32	6.2	0.32	1.7e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2235649	0.833	rs9933168	chr16:1848361	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-6.25	-0.32	1.27e-9	Blood metabolite levels;
LUSC	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg03585969	chr10:35415529	CREM	0.61	8.94	0.44	2.75e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg27170947	chr2:26402098	FAM59B	0.72	11.04	0.52	2.26e-24	Gut microbiome composition (summer);
LUSC	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg07169764	chr2:136633963	MCM6	0.98	13.27	0.59	1.39e-32	Corneal structure;
LUSC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-9.22	-0.45	3.55e-18	Gut microbiome composition (summer);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg13610622	chr10:11504551	USP6NL	0.43	5.96	0.31	6.45e-9	Cognitive function;Information processing speed;
LUSC	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg20307385	chr11:47447363	PSMC3	0.64	9.37	0.46	1.13e-18	Mean corpuscular hemoglobin;
LUSC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg02508848	chr16:68573721	ZFP90	-0.43	-5.73	-0.3	2.23e-8	Ulcerative colitis;
LUSC	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg22681709	chr2:178499509	PDE11A	-0.57	-10.81	-0.51	1.44e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg23173402	chr1:227635558	NA	0.59	7.23	0.37	3.41e-12	Major depressive disorder;
LUSC	cis	rs7180079	1.000	rs4777181	chr15:64670566	T/C	cg02848875	chr15:64387786	SNX1	0.42	5.74	0.3	2.11e-8	Monocyte count;
LUSC	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg04352962	chr1:209979756	IRF6	-0.54	-6.07	-0.32	3.41e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs7608623	0.773	rs3795946	chr2:23920646	G/C	cg08917208	chr2:24149416	ATAD2B	-0.42	-5.74	-0.3	2.12e-8	Obesity-related traits;
LUSC	cis	rs4786125	0.665	rs1492371	chr16:6921285	A/C	cg03623568	chr16:6915990	A2BP1	-0.5	-8.41	-0.42	1.22e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs72960926	0.744	rs114317207	chr6:74955867	C/T	cg03266952	chr6:74778945	NA	-0.77	-6.84	-0.35	3.73e-11	Metabolite levels (MHPG);
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11060661	chr22:24314208	DDT;DDTL	-0.49	-8.08	-0.4	1.21e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-1.16	-12.82	-0.57	6.95e-31	Diabetic kidney disease;
LUSC	cis	rs62400317	0.859	rs12205523	chr6:45296618	T/C	cg18551225	chr6:44695536	NA	-0.45	-7.44	-0.38	8.38e-13	Total body bone mineral density;
LUSC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg12560992	chr17:57184187	TRIM37	0.84	15.48	0.65	3.82e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19653624	chr11:20408972	PRMT3	-0.7	-8.94	-0.44	2.76e-17	Pursuit maintenance gain;
LUSC	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg10820045	chr2:198174542	NA	-0.31	-5.78	-0.3	1.7e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	cis	rs72781680	0.679	rs718138	chr2:23976324	G/A	cg08917208	chr2:24149416	ATAD2B	0.58	6.49	0.33	3.15e-10	Lymphocyte counts;
LUSC	cis	rs1564271	1.000	rs1564271	chr10:27011112	G/A	cg13837822	chr10:26931731	LOC731789	0.45	8.91	0.44	3.27e-17	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.68	10.44	0.5	2.84e-22	Lymphocyte counts;
LUSC	cis	rs67981189	0.593	rs7160958	chr14:71442526	C/A	cg15816911	chr14:71606274	NA	0.33	5.82	0.3	1.37e-8	Schizophrenia;
LUSC	cis	rs1413885	0.549	rs10889546	chr1:65851759	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	6.75	0.35	6.37e-11	Anticoagulant levels;
LUSC	cis	rs2273669	0.667	rs12196010	chr6:109302173	C/A	cg05315195	chr6:109294784	ARMC2	-0.56	-6.21	-0.32	1.54e-9	Prostate cancer;
LUSC	cis	rs13006833	0.739	rs172366	chr2:191191233	G/T	cg21644426	chr2:191273491	MFSD6	0.44	6.36	0.33	6.81e-10	Urinary metabolites;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17014947	chr15:35529521	LOC723972	0.42	6.28	0.32	1.06e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	0.97	21.55	0.76	3.54e-65	Longevity;
LUSC	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg27102117	chr16:15229624	NA	0.58	9.57	0.46	2.44e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.59	12.19	0.55	1.6e-28	Asthma (sex interaction);
LUSC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg19318889	chr4:1322082	MAEA	-0.54	-8.87	-0.44	4.63e-17	Obesity-related traits;
LUSC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg00814883	chr7:100076585	TSC22D4	-0.66	-7.79	-0.39	8.6e-14	Platelet count;
LUSC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg06784218	chr1:46089804	CCDC17	-0.55	-10.92	-0.51	5.97e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg06636001	chr8:8085503	FLJ10661	0.45	6.5	0.34	2.91e-10	Retinal vascular caliber;
LUSC	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.7	12.64	0.57	3.3e-30	Superior crus of antihelix expression;
LUSC	cis	rs4499344	0.526	rs10412141	chr19:33034189	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.76	-10.21	-0.49	1.7e-21	Mean platelet volume;
LUSC	cis	rs1322512	1.000	rs2800623	chr6:153003720	A/G	cg27316956	chr6:152958899	SYNE1	0.36	6.19	0.32	1.81e-9	Tonometry;
LUSC	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg26384229	chr12:38710491	ALG10B	0.7	10.74	0.51	2.52e-23	Morning vs. evening chronotype;
LUSC	cis	rs7804356	1.000	rs6461980	chr7:26894123	T/G	cg03456212	chr7:26904342	SKAP2	-0.52	-6.07	-0.32	3.45e-9	Type 1 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02666073	chr12:110562471	IFT81	0.47	6.27	0.32	1.11e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg11608241	chr8:8085544	FLJ10661	0.47	6.68	0.34	9.87e-11	Neuroticism;
LUSC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg14019146	chr3:50243930	SLC38A3	0.31	6.85	0.35	3.58e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.52	0.69	3.21e-49	Chronic sinus infection;
LUSC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.58	-11.79	-0.54	4.71e-27	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg22029157	chr1:209979665	IRF6	0.74	8.76	0.43	9.93e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.89	0.35	2.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg24531977	chr5:56204891	C5orf35	-0.69	-10.13	-0.48	3.33e-21	Coronary artery disease;
LUSC	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg03477792	chr4:77819574	ANKRD56	0.45	6.1	0.32	2.92e-9	Emphysema distribution in smoking;
LUSC	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.21	-0.32	1.59e-9	Neutrophil percentage of white cells;
LUSC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg03579872	chr1:53393473	SCP2	0.38	5.64	0.3	3.54e-8	Monocyte count;
LUSC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg26441486	chr22:50317300	CRELD2	0.49	7.28	0.37	2.45e-12	Schizophrenia;
LUSC	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg13647721	chr17:30228624	UTP6	0.62	8.25	0.41	3.73e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-9.9	-0.48	2.01e-20	Platelet distribution width;
LUSC	cis	rs965469	1.000	rs6037567	chr20:3332160	C/A	cg25506879	chr20:3388711	C20orf194	-0.51	-5.65	-0.3	3.48e-8	IFN-related cytopenia;
LUSC	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg02196655	chr2:10830764	NOL10	0.34	5.79	0.3	1.64e-8	Prostate cancer;
LUSC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg16606324	chr3:10149918	C3orf24	0.61	8.9	0.44	3.56e-17	Alzheimer's disease;
LUSC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	10.65	0.5	5.52e-23	Homoarginine levels;
LUSC	cis	rs4919087	0.892	rs2065861	chr10:99004608	C/T	cg25902810	chr10:99078978	FRAT1	0.47	6.84	0.35	3.73e-11	Monocyte count;
LUSC	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg18132916	chr6:79620363	NA	-0.37	-5.7	-0.3	2.6e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4722404	0.835	rs6965630	chr7:3138656	A/G	cg19214707	chr7:3157722	NA	-0.32	-5.88	-0.31	1e-8	Atopic dermatitis;
LUSC	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg05343316	chr1:45956843	TESK2	0.7	9.34	0.46	1.39e-18	Platelet count;
LUSC	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-8.51	-0.42	6.13e-16	HDL cholesterol;
LUSC	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg24562669	chr7:97807699	LMTK2	-0.37	-6.01	-0.31	4.88e-9	Breast cancer;
LUSC	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg21153622	chr11:89784906	NA	-0.39	-6.0	-0.31	5.01e-9	HDL cholesterol;
LUSC	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg18833306	chr6:118973337	C6orf204	-0.45	-5.78	-0.3	1.67e-8	Diastolic blood pressure;
LUSC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg20573242	chr4:122745356	CCNA2	0.44	6.74	0.35	7e-11	Type 2 diabetes;
LUSC	cis	rs796825	0.530	rs34014378	chr3:119946506	T/A	cg21790991	chr3:120137480	FSTL1	-0.33	-5.92	-0.31	7.79e-9	HIV-1 susceptibility;
LUSC	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg25730555	chr22:47059586	GRAMD4	0.45	7.07	0.36	9.34e-12	Urate levels in obese individuals;
LUSC	cis	rs2387326	0.671	rs10829346	chr10:129946104	C/T	cg16087940	chr10:129947807	NA	-0.4	-6.1	-0.32	2.87e-9	Select biomarker traits;
LUSC	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.56	8.71	0.43	1.42e-16	Menopause (age at onset);
LUSC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg16325326	chr1:53192061	ZYG11B	0.83	15.05	0.64	1.91e-39	Monocyte count;
LUSC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.18	0.45	4.46e-18	Prudent dietary pattern;
LUSC	cis	rs4700695	0.697	rs251319	chr5:65239468	A/G	cg21114390	chr5:65439923	SFRS12	0.51	6.06	0.31	3.74e-9	Facial morphology (factor 19);
LUSC	cis	rs9398803	0.932	rs9401876	chr6:126669479	C/A	cg19875578	chr6:126661172	C6orf173	0.41	6.12	0.32	2.66e-9	Male-pattern baldness;
LUSC	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg02696742	chr7:106810147	HBP1	-0.63	-9.54	-0.46	3.16e-19	Coronary artery disease;
LUSC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.95	15.43	0.65	6.5e-41	Coronary artery disease;
LUSC	cis	rs4363385	0.720	rs11205150	chr1:152959266	C/T	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.27	-0.37	2.55e-12	Inflammatory skin disease;
LUSC	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg27471124	chr11:109292789	C11orf87	0.37	6.74	0.35	6.99e-11	Schizophrenia;
LUSC	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg17691542	chr6:26056736	HIST1H1C	0.39	5.88	0.31	9.87e-9	Schizophrenia;
LUSC	cis	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg21775007	chr8:11205619	TDH	-0.49	-7.04	-0.36	1.11e-11	Morning vs. evening chronotype;
LUSC	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg16850897	chr7:100343110	ZAN	-0.57	-7.81	-0.39	7.66e-14	Other erythrocyte phenotypes;
LUSC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg14664628	chr15:75095509	CSK	-0.49	-7.01	-0.36	1.32e-11	Breast cancer;
LUSC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg05347473	chr6:146136440	FBXO30	0.59	10.57	0.5	1.02e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	8.85	0.44	5.38e-17	Menarche (age at onset);
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg07332563	chr6:291687	DUSP22	-0.71	-11.82	-0.54	3.71e-27	Menopause (age at onset);
LUSC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg21251018	chr6:28226885	NKAPL	0.34	6.65	0.34	1.17e-10	Pubertal anthropometrics;
LUSC	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-0.87	-14.59	-0.62	1.21e-37	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18252515	chr7:66147081	NA	-0.53	-7.28	-0.37	2.35e-12	Corneal structure;
LUSC	cis	rs1775715	0.870	rs1419168	chr10:32257332	A/C	cg04359828	chr10:32216031	ARHGAP12	0.37	5.98	0.31	5.68e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.3	-7.57	-0.38	3.61e-13	Lymphocyte counts;
LUSC	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.57	10.42	0.5	3.29e-22	Bone mineral density;
LUSC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg25767906	chr1:53392781	SCP2	0.71	14.16	0.61	5.77e-36	Monocyte count;
LUSC	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.93	-0.44	2.97e-17	Neuroticism;
LUSC	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg17294928	chr15:75287854	SCAMP5	-0.77	-8.86	-0.44	4.7e-17	Blood trace element (Zn levels);
LUSC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.63	10.68	0.5	4.18e-23	Blood metabolite levels;
LUSC	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	0.86	14.14	0.61	6.84e-36	Body mass index;
LUSC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg24154853	chr7:158122151	PTPRN2	0.45	8.87	0.44	4.48e-17	Calcium levels;
LUSC	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg00277334	chr10:82204260	NA	-0.56	-8.16	-0.41	6.72e-15	Post bronchodilator FEV1;
LUSC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11645453	chr3:52864694	ITIH4	0.32	7.46	0.38	7.53e-13	Bipolar disorder;
LUSC	trans	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg06521331	chr12:34319734	NA	-0.4	-6.33	-0.33	7.95e-10	Bladder cancer;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.6	-10.06	-0.48	5.7e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23158103	chr7:148848205	ZNF398	0.47	7.72	0.39	1.33e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9517320	0.967	rs2274056	chr13:99134839	G/C	cg20487152	chr13:99095054	FARP1	0.35	6.54	0.34	2.37e-10	Longevity;
LUSC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg20849893	chr7:64541193	NA	0.45	6.41	0.33	4.98e-10	Calcium levels;
LUSC	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.88	-0.63	9.18e-39	Schizophrenia;
LUSC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg24399712	chr22:39784796	NA	-0.61	-9.9	-0.48	2.03e-20	Post bronchodilator FEV1;
LUSC	cis	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg05313129	chr8:58192883	C8orf71	-0.51	-6.64	-0.34	1.26e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg13852791	chr20:30311386	BCL2L1	0.9	13.63	0.6	6.1e-34	Mean corpuscular hemoglobin;
LUSC	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg23891712	chr17:75136828	SEC14L1	0.73	6.11	0.32	2.75e-9	Cognitive performance;
LUSC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg12463550	chr7:65579703	CRCP	0.45	6.62	0.34	1.44e-10	Aortic root size;
LUSC	cis	rs9309473	0.950	rs6740766	chr2:73780913	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.45	-0.33	4.02e-10	Metabolite levels;
LUSC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.29	-0.37	2.29e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	0.79	9.79	0.47	4.5e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg07169764	chr2:136633963	MCM6	1.2	18.29	0.71	3.01e-52	Corneal structure;
LUSC	cis	rs6063312	1.000	rs6063313	chr20:47343532	G/A	cg18078177	chr20:47281410	PREX1	0.59	6.97	0.36	1.72e-11	Tonometry;
LUSC	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg17173187	chr15:85201210	NMB	0.37	6.4	0.33	5.31e-10	Schizophrenia;
LUSC	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg20701182	chr2:24300061	SF3B14	0.56	6.03	0.31	4.36e-9	Lymphocyte counts;
LUSC	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg21361702	chr7:150065534	REPIN1	0.58	8.23	0.41	4.15e-15	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg09487167	chr14:55518661	MAPK1IP1L	0.4	6.19	0.32	1.8e-9	Schizophrenia;
LUSC	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg10018233	chr7:150070692	REPIN1	0.4	7.18	0.37	4.64e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg13798780	chr7:105162888	PUS7	0.56	5.89	0.31	9.41e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01594214	chr6:123110554	SMPDL3A	-0.46	-6.05	-0.31	3.81e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3772130	0.564	rs28760466	chr3:121601510	A/G	cg20356878	chr3:121714668	ILDR1	0.61	9.89	0.48	2.21e-20	Cognitive performance;
LUSC	cis	rs7586879	0.828	rs9631061	chr2:25109804	C/T	cg01884057	chr2:25150051	NA	0.41	8.62	0.43	2.67e-16	Body mass index;
LUSC	cis	rs7777754	1.000	rs7778258	chr7:50666378	G/A	cg18232548	chr7:50535776	DDC	0.49	6.35	0.33	7.17e-10	Response to zileuton treatment in asthma (FEV1 change interaction);
LUSC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg27124370	chr19:33622961	WDR88	0.53	7.72	0.39	1.34e-13	Bone properties (heel);
LUSC	trans	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04565464	chr8:145669602	NFKBIL2	0.36	6.01	0.31	4.75e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.09	-0.32	3.02e-9	Monocyte count;
LUSC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.64	0.39	2.28e-13	Vitiligo;
LUSC	cis	rs62400317	0.859	rs12199871	chr6:45307682	C/T	cg20913747	chr6:44695427	NA	-0.49	-7.89	-0.4	4.31e-14	Total body bone mineral density;
LUSC	cis	rs6967385	0.580	rs6962273	chr7:12330166	G/C	cg20607287	chr7:12443886	VWDE	0.37	5.78	0.3	1.72e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg15654264	chr1:150340011	RPRD2	0.61	10.04	0.48	6.57e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15664640	chr17:80829946	TBCD	0.71	12.56	0.57	6.79e-30	Breast cancer;
LUSC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg14895029	chr7:2775587	GNA12	-0.42	-6.14	-0.32	2.3e-9	Height;
LUSC	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg15704280	chr7:45808275	SEPT13	-0.6	-7.34	-0.37	1.68e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg02574844	chr11:5959923	NA	-0.4	-6.34	-0.33	7.39e-10	DNA methylation (variation);
LUSC	cis	rs11039100	0.850	rs35746872	chr11:5834335	T/A	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.09	14.64	0.63	7.93e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-6.8	-0.35	4.89e-11	Self-reported allergy;
LUSC	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.07	14.17	0.61	5.24e-36	Uric acid levels;
LUSC	cis	rs360798	0.512	rs2058566	chr2:63179076	C/T	cg17519650	chr2:63277830	OTX1	0.51	7.05	0.36	1.01e-11	Coronary artery disease;
LUSC	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg02428538	chr16:24856791	SLC5A11	0.49	5.68	0.3	2.93e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.4	0.53	1.16e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs62400317	0.762	rs12202704	chr6:44819614	G/T	cg18551225	chr6:44695536	NA	-0.47	-7.51	-0.38	5.4e-13	Total body bone mineral density;
LUSC	trans	rs1459104	0.570	rs56152290	chr11:54858073	C/T	cg03929089	chr4:120376271	NA	0.66	6.03	0.31	4.44e-9	Body mass index;
LUSC	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg00409905	chr10:38381863	ZNF37A	-0.33	-5.86	-0.31	1.11e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg11843606	chr2:227700838	RHBDD1	-0.68	-10.8	-0.51	1.58e-23	Pulmonary function;
LUSC	cis	rs6429082	0.749	rs3819974	chr1:235601958	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.62	-8.56	-0.42	4.05e-16	Adiposity;
LUSC	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg17173187	chr15:85201210	NMB	0.38	6.68	0.34	9.72e-11	Schizophrenia;
LUSC	trans	rs7680126	0.596	rs4698009	chr4:10284993	A/G	cg26043149	chr18:55253948	FECH	-0.47	-5.98	-0.31	5.64e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUSC	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg15654264	chr1:150340011	RPRD2	0.63	10.53	0.5	1.35e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg03453431	chr7:157225567	NA	-0.67	-12.56	-0.57	6.74e-30	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg01966878	chr4:90757139	SNCA	-0.35	-6.12	-0.32	2.56e-9	Dementia with Lewy bodies;
LUSC	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.73	-12.39	-0.56	2.92e-29	Monocyte count;
LUSC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg09699651	chr6:150184138	LRP11	0.39	5.73	0.3	2.28e-8	Lung cancer;
LUSC	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg18129178	chr5:148520854	ABLIM3	-0.76	-10.52	-0.5	1.54e-22	Breast cancer;
LUSC	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg18758796	chr5:131593413	PDLIM4	0.34	5.65	0.3	3.38e-8	Blood metabolite levels;
LUSC	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg25643088	chr3:52874325	TMEM110	-0.39	-5.87	-0.31	1.05e-8	Schizophrenia;
LUSC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg03885332	chr11:832357	CD151	-0.35	-5.9	-0.31	8.82e-9	Mean platelet volume;
LUSC	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg03929089	chr4:120376271	NA	0.7	6.68	0.34	9.95e-11	Axial length;
LUSC	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg22437258	chr11:111473054	SIK2	-0.44	-5.73	-0.3	2.25e-8	Primary sclerosing cholangitis;
LUSC	cis	rs922692	1.000	rs922692	chr15:78984214	C/A	cg00540400	chr15:79124168	NA	-0.34	-5.68	-0.3	2.88e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg22638593	chr5:131593259	PDLIM4	0.41	6.04	0.31	4.05e-9	Breast cancer;
LUSC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00475322	chr7:917719	C7orf20	0.45	6.65	0.34	1.19e-10	Perceived unattractiveness to mosquitoes;
LUSC	trans	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.06	0.48	5.79e-21	Mean corpuscular volume;
LUSC	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg13010199	chr12:38710504	ALG10B	0.66	10.17	0.49	2.5e-21	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21986422	chr20:44519582	CTSA;NEURL2	-0.47	-6.28	-0.32	1.04e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg17848003	chr1:3704513	LRRC47	0.31	5.71	0.3	2.51e-8	Red cell distribution width;
LUSC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg22903657	chr4:1355424	KIAA1530	-0.48	-8.06	-0.4	1.37e-14	Obesity-related traits;
LUSC	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-5.94	-0.31	7.35e-9	Fear of minor pain;
LUSC	cis	rs2348418	0.715	rs1912782	chr12:28721707	A/C	cg13890972	chr12:28721907	NA	-0.37	-6.41	-0.33	4.96e-10	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	cis	rs4356932	0.934	rs4859603	chr4:76965747	A/G	cg00809888	chr4:76862425	NAAA	0.34	5.68	0.3	2.94e-8	Blood protein levels;
LUSC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg00933542	chr6:150070202	PCMT1	0.33	6.85	0.35	3.55e-11	Lung cancer;
LUSC	cis	rs6960043	0.764	rs7798124	chr7:15055616	A/G	cg19272540	chr7:15055459	NA	-0.35	-8.81	-0.43	6.83e-17	Type 2 diabetes;
LUSC	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg14416269	chr4:6271139	WFS1	0.52	10.78	0.51	1.96e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.18	0.49	2.27e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07963361	chr7:87505792	SLC25A40;DBF4	0.4	6.65	0.34	1.21e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs2321744	0.573	rs12857276	chr13:34622773	A/C	cg27316626	chr8:73450762	KCNB2	0.46	6.03	0.31	4.28e-9	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg18306943	chr3:40428807	ENTPD3	0.38	5.73	0.3	2.2e-8	Renal cell carcinoma;
LUSC	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg03599575	chr15:90893182	GABARAPL3	0.35	6.08	0.32	3.37e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg14552801	chr7:65878734	NA	0.37	5.68	0.3	2.98e-8	Aortic root size;
LUSC	cis	rs10746514	1.000	rs11122416	chr1:232249928	A/G	cg09506761	chr1:232265262	NA	0.47	7.63	0.39	2.4e-13	Response to statin therapy;
LUSC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg14346243	chr4:90757452	SNCA	-0.41	-5.96	-0.31	6.43e-9	Neuroticism;
LUSC	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg08213375	chr14:104286397	PPP1R13B	0.38	6.24	0.32	1.29e-9	Reticulocyte count;
LUSC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.74	-14.08	-0.61	1.14e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg02475777	chr4:1388615	CRIPAK	0.38	5.73	0.3	2.23e-8	Obesity-related traits;
LUSC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg18132916	chr6:79620363	NA	-0.38	-5.81	-0.3	1.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg16797656	chr11:68205561	LRP5	-0.34	-5.76	-0.3	1.88e-8	Total body bone mineral density;
LUSC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg00343986	chr7:65444356	GUSB	-0.41	-6.2	-0.32	1.62e-9	Aortic root size;
LUSC	cis	rs6546550	0.933	rs57278310	chr2:70093647	T/C	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.16	-0.36	5.28e-12	Prevalent atrial fibrillation;
LUSC	trans	rs7980799	0.649	rs12819439	chr12:33684509	A/C	cg13010199	chr12:38710504	ALG10B	0.43	6.14	0.32	2.35e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08219700	chr8:58056026	NA	0.66	8.37	0.42	1.58e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.76	-14.28	-0.62	1.92e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.81	14.78	0.63	2.17e-38	Cognitive function;
LUSC	cis	rs11958404	0.860	rs72818114	chr5:157440207	A/C	cg05962755	chr5:157440814	NA	0.53	6.3	0.33	9.34e-10	IgG glycosylation;
LUSC	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg18232548	chr7:50535776	DDC	-0.59	-8.38	-0.42	1.51e-15	Systemic sclerosis;
LUSC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg19302996	chr17:73780495	UNK	-0.49	-7.05	-0.36	1.01e-11	White matter hyperintensity burden;
LUSC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg22467129	chr15:76604101	ETFA	-0.5	-8.13	-0.41	8.38e-15	Blood metabolite levels;
LUSC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.5	0.34	2.96e-10	Menopause (age at onset);
LUSC	cis	rs1524927	0.643	rs12704882	chr7:96429251	A/C	cg03808172	chr7:96339361	SHFM1	0.36	5.65	0.3	3.36e-8	Total body bone mineral density;
LUSC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg23625390	chr15:77176239	SCAPER	0.47	7.2	0.37	4.02e-12	Blood metabolite levels;
LUSC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg15448220	chr1:150897856	SETDB1	0.43	6.17	0.32	1.94e-9	Melanoma;
LUSC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.99	-0.48	1.01e-20	Hemoglobin concentration;
LUSC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.67	-0.39	1.88e-13	Height;
LUSC	cis	rs231513	0.911	rs231525	chr17:41951283	C/T	cg26893861	chr17:41843967	DUSP3	-0.53	-6.11	-0.32	2.8e-9	Cognitive function;
LUSC	cis	rs9815354	1.000	rs6599176	chr3:41788492	G/T	cg03022575	chr3:42003672	ULK4	-0.54	-5.82	-0.3	1.38e-8	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg00166722	chr3:10149974	C3orf24	0.39	5.84	0.3	1.24e-8	Alzheimer's disease;
LUSC	cis	rs10746514	0.813	rs9724918	chr1:232248087	C/T	cg09506761	chr1:232265262	NA	0.52	8.41	0.42	1.23e-15	Response to statin therapy;
LUSC	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg27284194	chr4:1044797	NA	0.55	6.53	0.34	2.47e-10	Recombination rate (females);
LUSC	trans	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.63	-0.43	2.58e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2573652	0.698	rs12916269	chr15:100530216	A/T	cg09918751	chr15:100517450	ADAMTS17	0.35	6.74	0.35	7e-11	Height;
LUSC	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.49	-8.17	-0.41	6.23e-15	Asthma;
LUSC	cis	rs12493885	0.585	rs787814	chr3:153621740	T/A	cg17054900	chr3:154042577	DHX36	-0.56	-6.01	-0.31	4.9e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	cis	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg17325771	chr7:75508891	RHBDD2	-0.41	-5.84	-0.3	1.27e-8	Eotaxin levels;
LUSC	cis	rs73195822	0.614	rs1123852	chr12:111221408	C/G	cg12870014	chr12:110450643	ANKRD13A	0.67	7.37	0.37	1.35e-12	Itch intensity from mosquito bite;
LUSC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg05973401	chr12:123451056	ABCB9	-0.61	-8.81	-0.43	7.14e-17	Platelet count;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24946133	chr1:59249665	JUN	-0.45	-5.95	-0.31	6.95e-9	Hepatitis;
LUSC	cis	rs829883	0.659	rs10860342	chr12:98941223	C/T	cg25150519	chr12:98850993	NA	0.63	8.28	0.41	3.01e-15	Colorectal adenoma (advanced);
LUSC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg16325326	chr1:53192061	ZYG11B	0.7	11.39	0.53	1.33e-25	Monocyte count;
LUSC	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg15556689	chr8:8085844	FLJ10661	0.53	7.96	0.4	2.79e-14	Neuroticism;
LUSC	cis	rs7043114	0.525	rs710162	chr9:95059790	A/T	cg13798575	chr9:95087839	CENPP;NOL8	0.37	6.56	0.34	2.09e-10	Height;
LUSC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg08888203	chr3:10149979	C3orf24	0.63	8.66	0.43	2.01e-16	Alzheimer's disease;
LUSC	cis	rs9462027	0.628	rs2477507	chr6:34703599	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.31	-5.65	-0.3	3.46e-8	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.52	0.5	1.5e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg00310523	chr12:86230176	RASSF9	0.39	7.11	0.36	7.01e-12	Major depressive disorder;
LUSC	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-6.41	-0.33	4.91e-10	Red blood cell count;Reticulocyte count;
LUSC	trans	rs4729127	1.000	rs17166205	chr7:94003841	T/A	cg14660007	chr13:78271894	SLAIN1	0.49	6.22	0.32	1.52e-9	Intelligence;
LUSC	trans	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.13	-0.36	6.2e-12	Triglycerides;
LUSC	cis	rs240764	0.658	rs1336244	chr6:101197953	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-6.27	-0.32	1.11e-9	Neuroticism;
LUSC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg03579872	chr1:53393473	SCP2	-0.39	-5.78	-0.3	1.74e-8	Monocyte count;
LUSC	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg15423357	chr2:25149977	NA	0.35	6.36	0.33	6.54e-10	Body mass index;
LUSC	cis	rs10779751	0.960	rs11121712	chr1:11320329	G/C	cg08854313	chr1:11322531	MTOR	0.92	16.17	0.66	7.91e-44	Body mass index;
LUSC	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg20744362	chr22:50050164	C22orf34	0.4	7.32	0.37	1.9e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg20135002	chr11:47629003	NA	-0.52	-8.15	-0.41	7.62e-15	Subjective well-being;
LUSC	cis	rs10207628	0.698	rs7594230	chr2:127873568	G/A	cg06223080	chr2:127868745	NA	0.38	6.51	0.34	2.8e-10	Psychosis and Alzheimer's disease;
LUSC	cis	rs240764	0.817	rs2036052	chr6:101154909	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-6.25	-0.32	1.22e-9	Neuroticism;
LUSC	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg01420254	chr6:26195488	NA	0.64	7.05	0.36	1.04e-11	Gout;Renal underexcretion gout;
LUSC	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg06026331	chr20:60912101	LAMA5	-0.63	-7.54	-0.38	4.39e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg17507749	chr15:85114479	UBE2QP1	0.65	8.15	0.41	7.64e-15	Schizophrenia;
LUSC	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.05	0.52	2.14e-24	Hypertriglyceridemia;
LUSC	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg18350739	chr11:68623251	NA	-0.38	-6.74	-0.35	7.09e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.85	-0.35	3.46e-11	Mood instability;
LUSC	cis	rs9419702	0.538	rs9419628	chr10:133539299	A/C	cg04492858	chr10:133558786	NA	0.41	6.64	0.34	1.28e-10	Survival in rectal cancer;
LUSC	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg06740227	chr12:86229804	RASSF9	-0.36	-5.88	-0.31	9.93e-9	Major depressive disorder;
LUSC	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg02023728	chr11:77925099	USP35	0.43	6.22	0.32	1.46e-9	Testicular germ cell tumor;
LUSC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.66	11.92	0.55	1.54e-27	Birth weight;
LUSC	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.93	0.35	2.18e-11	Rheumatoid arthritis;
LUSC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg12564285	chr5:131593104	PDLIM4	0.43	7.94	0.4	3.08e-14	Breast cancer;
LUSC	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg18357645	chr12:58087776	OS9	0.6	9.02	0.44	1.51e-17	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.38	0.42	1.49e-15	Coffee consumption (cups per day);
LUSC	trans	rs2018683	0.649	rs221193	chr7:29015784	G/T	cg19402173	chr7:128379420	CALU	-0.43	-6.42	-0.33	4.67e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg10434728	chr15:90938212	IQGAP1	0.31	5.97	0.31	6.02e-9	Rheumatoid arthritis;
LUSC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.1	0.41	1.05e-14	Prudent dietary pattern;
LUSC	cis	rs10871290	0.881	rs11649338	chr16:74471420	C/T	cg01733217	chr16:74700730	RFWD3	-0.52	-7.53	-0.38	4.91e-13	Breast cancer;
LUSC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg08645402	chr16:4508243	NA	0.51	7.72	0.39	1.33e-13	Schizophrenia;
LUSC	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg06191203	chr2:152266755	RIF1	-0.53	-7.3	-0.37	2.17e-12	Lung cancer;
LUSC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00149659	chr3:10157352	C3orf10	1.0	14.48	0.62	3.22e-37	Alzheimer's disease;
LUSC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18932078	chr1:2524107	MMEL1	-0.33	-7.17	-0.37	4.74e-12	Ulcerative colitis;
LUSC	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg24375607	chr4:120327624	NA	0.76	12.2	0.56	1.45e-28	Corneal astigmatism;
LUSC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06873352	chr17:61820015	STRADA	0.56	8.62	0.43	2.81e-16	Height;
LUSC	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg13755796	chr4:20253514	NA	-0.43	-6.6	-0.34	1.59e-10	Life satisfaction;
LUSC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg13319975	chr6:146136371	FBXO30	0.51	7.55	0.38	4.09e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11958404	0.932	rs59246968	chr5:157418180	T/C	cg05962755	chr5:157440814	NA	0.5	6.14	0.32	2.34e-9	IgG glycosylation;
LUSC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.83	0.35	4.1e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg23791538	chr6:167370224	RNASET2	-0.38	-5.8	-0.3	1.5e-8	Crohn's disease;
LUSC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	0.92	15.52	0.65	2.79e-41	Menopause (age at onset);
LUSC	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg11752832	chr7:134001865	SLC35B4	0.4	5.79	0.3	1.65e-8	Mean platelet volume;
LUSC	cis	rs9653442	0.545	rs11900482	chr2:100758709	G/C	cg07810366	chr2:100720526	AFF3	-0.45	-7.68	-0.39	1.82e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg16414030	chr3:133502952	NA	0.46	7.14	0.36	5.92e-12	Iron status biomarkers;
LUSC	cis	rs11997175	0.766	rs7387133	chr8:33727045	C/G	ch.8.33884649F	chr8:33765107	NA	-0.4	-6.26	-0.32	1.19e-9	Body mass index;
LUSC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-1.03	-13.99	-0.61	2.43e-35	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs3820928	0.874	rs12467261	chr2:227888838	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.83	-0.39	6.56e-14	Pulmonary function;
LUSC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg07959070	chr22:50026188	C22orf34	-0.34	-6.93	-0.35	2.19e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg12064134	chr16:90016061	DEF8	0.38	6.05	0.31	3.84e-9	Squamous cell carcinoma;
LUSC	cis	rs7712401	0.601	rs27976	chr5:122206460	C/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.89	-0.48	2.12e-20	Mean platelet volume;
LUSC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg04414720	chr1:150670196	GOLPH3L	0.53	8.23	0.41	4.4e-15	Melanoma;
LUSC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg01871581	chr19:12707946	ZNF490	-0.56	-8.99	-0.44	1.82e-17	Bipolar disorder;
LUSC	cis	rs7615316	0.934	rs9808943	chr3:142241123	T/C	cg16271453	chr3:142027066	XRN1	-0.39	-6.82	-0.35	4.3e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg25214090	chr10:38739885	LOC399744	0.53	7.68	0.39	1.76e-13	Corneal astigmatism;
LUSC	trans	rs2055729	0.645	rs12056944	chr8:9742525	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.7	0.34	8.86e-11	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25552655	chr19:33864476	CEBPG	-0.45	-6.75	-0.35	6.74e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg11693508	chr17:37793320	STARD3	-0.49	-6.0	-0.31	5.15e-9	Bipolar disorder;
LUSC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.63	-0.39	2.47e-13	Personality dimensions;
LUSC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg25456477	chr12:86230367	RASSF9	0.35	6.21	0.32	1.56e-9	Major depressive disorder;
LUSC	cis	rs1113500	0.933	rs11185255	chr1:108633191	T/A	cg11967332	chr1:108735228	SLC25A24	0.39	5.92	0.31	7.86e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs4363385	0.574	rs4845505	chr1:152960943	T/A	cg25856811	chr1:152973957	SPRR3	-0.36	-6.01	-0.31	4.84e-9	Inflammatory skin disease;
LUSC	cis	rs11030122	0.702	rs4910868	chr11:3980224	A/C	cg08557956	chr11:4115526	RRM1	-0.46	-5.72	-0.3	2.39e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg12463550	chr7:65579703	CRCP	0.51	7.52	0.38	5.19e-13	Aortic root size;
LUSC	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg06636001	chr8:8085503	FLJ10661	0.51	6.91	0.35	2.41e-11	Neuroticism;
LUSC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.4	6.26	0.32	1.2e-9	Total body bone mineral density;
LUSC	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg10207240	chr12:122356781	WDR66	0.45	6.24	0.32	1.31e-9	Mean corpuscular volume;
LUSC	cis	rs6546550	0.694	rs12467361	chr2:70019127	G/A	cg02498382	chr2:70120550	SNRNP27	-0.27	-6.5	-0.34	2.87e-10	Prevalent atrial fibrillation;
LUSC	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg25237894	chr2:233734115	C2orf82	0.35	6.41	0.33	4.94e-10	Coronary artery disease;
LUSC	cis	rs11166629	1.000	rs7818331	chr8:135639653	C/T	cg27224718	chr8:135614730	ZFAT	0.66	11.21	0.52	5.49e-25	Smoking quantity;
LUSC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.85	-14.0	-0.61	2.22e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9865818	0.728	rs1915930	chr3:188100256	G/T	cg23651889	chr3:188115336	LPP	-0.37	-5.65	-0.3	3.36e-8	Allergic sensitization;
LUSC	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg13010199	chr12:38710504	ALG10B	0.68	10.81	0.51	1.49e-23	Morning vs. evening chronotype;
LUSC	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.54	-0.42	4.88e-16	Depression;
LUSC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg09365446	chr1:150670422	GOLPH3L	0.47	6.74	0.35	6.85e-11	Melanoma;
LUSC	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg08755490	chr11:65554678	OVOL1	0.4	5.84	0.3	1.24e-8	Acne (severe);
LUSC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg04398451	chr17:18023971	MYO15A	0.5	7.97	0.4	2.45e-14	Total body bone mineral density;
LUSC	cis	rs7215564	0.908	rs57778244	chr17:78653798	T/G	cg23238734	chr17:78661607	RPTOR	0.49	6.28	0.32	1.08e-9	Myopia (pathological);
LUSC	cis	rs16949788	1.000	rs79097157	chr15:66764814	C/A	cg08120210	chr15:66682733	MAP2K1	-0.63	-6.48	-0.33	3.32e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs17490626	0.568	rs12416520	chr10:71211945	A/G	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.43	-0.46	7e-19	Thrombosis;
LUSC	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg16342193	chr10:102329863	NA	-0.34	-6.05	-0.31	3.87e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs2262909	1.000	rs2175366	chr19:22128279	C/T	cg17074339	chr11:11642133	GALNTL4	-0.41	-6.19	-0.32	1.8e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.48	-5.81	-0.3	1.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg23093090	chr10:104574429	C10orf26	-0.38	-7.05	-0.36	1.05e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1451375	0.652	rs1470747	chr7:50627009	C/T	cg18232548	chr7:50535776	DDC	0.48	6.62	0.34	1.43e-10	Malaria;
LUSC	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg22875332	chr1:76189707	ACADM	-0.4	-5.92	-0.31	8.19e-9	Daytime sleep phenotypes;
LUSC	cis	rs11608355	0.846	rs12581637	chr12:109855429	G/A	cg05360138	chr12:110035743	NA	0.6	8.03	0.4	1.73e-14	Neuroticism;
LUSC	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg18200150	chr17:30822561	MYO1D	0.3	5.86	0.31	1.11e-8	Schizophrenia;
LUSC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg04450456	chr4:17643702	FAM184B	0.39	6.64	0.34	1.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg17143192	chr8:8559678	CLDN23	0.64	9.02	0.44	1.47e-17	Obesity-related traits;
LUSC	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg03264133	chr6:25882463	NA	-0.34	-5.71	-0.3	2.44e-8	Height;
LUSC	cis	rs4363385	0.693	rs6690672	chr1:152930564	C/T	cg07796016	chr1:152779584	LCE1C	-0.45	-6.4	-0.33	5.25e-10	Inflammatory skin disease;
LUSC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	1.21	16.13	0.66	1.08e-43	Eosinophil percentage of granulocytes;
LUSC	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.87	-14.18	-0.61	4.69e-36	Schizophrenia;
LUSC	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg23188684	chr11:67383651	NA	0.35	6.19	0.32	1.76e-9	Mean corpuscular volume;
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11905131	chr22:24372483	LOC391322	-0.52	-8.7	-0.43	1.53e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs354225	0.544	rs10187447	chr2:54806711	A/T	cg26097391	chr2:54893211	SPTBN1	0.42	6.39	0.33	5.6e-10	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.82	0.35	4.17e-11	Platelet count;
LUSC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-1.01	-18.16	-0.7	9.36e-52	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs9784649	1.000	rs56205870	chr5:24958870	A/G	cg08600765	chr20:34638493	LOC647979	-0.56	-6.2	-0.32	1.64e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg26384229	chr12:38710491	ALG10B	0.72	11.22	0.52	5.39e-25	Morning vs. evening chronotype;
LUSC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg02380750	chr20:61661411	NA	0.34	5.96	0.31	6.5e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs231513	0.954	rs425135	chr17:41984517	A/C	cg10566589	chr6:111927040	TRAF3IP2	0.53	6.05	0.31	3.97e-9	Cognitive function;
LUSC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg07148914	chr20:33460835	GGT7	0.56	8.56	0.42	4.04e-16	Height;
LUSC	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.79	-0.3	1.62e-8	IgG glycosylation;
LUSC	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.46	0.46	5.81e-19	Blood protein levels;
LUSC	trans	rs11039798	0.764	rs11040208	chr11:49012509	A/G	cg03929089	chr4:120376271	NA	0.77	6.33	0.33	8.04e-10	Axial length;
LUSC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg19318889	chr4:1322082	MAEA	-0.54	-8.8	-0.43	7.35e-17	Obesity-related traits;
LUSC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.35	5.89	0.31	9.36e-9	Menopause (age at onset);
LUSC	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.51	-0.91	6.17e-131	Myeloid white cell count;
LUSC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00166722	chr3:10149974	C3orf24	0.59	8.25	0.41	3.57e-15	Alzheimer's disease;
LUSC	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00791764	chr4:53727839	RASL11B	0.56	7.79	0.39	8.62e-14	Optic nerve measurement (cup area);
LUSC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	ch.11.42038R	chr11:967971	AP2A2	0.54	8.37	0.42	1.56e-15	Alzheimer's disease (late onset);
LUSC	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg21427119	chr20:30132790	HM13	-0.46	-6.65	-0.34	1.2e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.83	-7.74	-0.39	1.19e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-10.96	-0.51	4.43e-24	Heart rate;
LUSC	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	10.54	0.5	1.29e-22	Homoarginine levels;
LUSC	cis	rs1375194	0.606	rs10188817	chr2:33815471	A/G	cg04131969	chr2:33951647	MYADML	-0.64	-8.95	-0.44	2.47e-17	Response to antidepressants in depression;
LUSC	cis	rs6120849	0.617	rs12480442	chr20:33648388	C/G	cg24642439	chr20:33292090	TP53INP2	0.61	6.71	0.34	8.49e-11	Protein C levels;
LUSC	cis	rs4363385	0.818	rs2339492	chr1:152985552	G/C	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.16	-0.36	5.23e-12	Inflammatory skin disease;
LUSC	cis	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg21775007	chr8:11205619	TDH	0.47	6.66	0.34	1.12e-10	Neuroticism;
LUSC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg14343924	chr8:8086146	FLJ10661	0.44	6.23	0.32	1.41e-9	Myopia (pathological);
LUSC	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.61	0.62	1.05e-37	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg11764359	chr7:65958608	NA	-0.69	-10.44	-0.5	2.96e-22	Aortic root size;
LUSC	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	9.13	0.45	6.77e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg14582100	chr15:45693742	SPATA5L1	0.6	10.95	0.51	4.7e-24	Homoarginine levels;
LUSC	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg04374321	chr14:90722782	PSMC1	-0.44	-6.63	-0.34	1.34e-10	Mortality in heart failure;
LUSC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.99	-0.31	5.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.62	9.67	0.47	1.14e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg05501817	chr11:14380813	RRAS2	-0.46	-7.29	-0.37	2.28e-12	Sense of smell;
LUSC	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg18850127	chr7:39170497	POU6F2	0.42	5.95	0.31	6.81e-9	IgG glycosylation;
LUSC	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg12311346	chr5:56204834	C5orf35	-0.6	-9.29	-0.45	2.02e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg21361702	chr7:150065534	REPIN1	0.46	5.87	0.31	1.04e-8	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg26384229	chr12:38710491	ALG10B	0.75	11.76	0.54	5.82e-27	Morning vs. evening chronotype;
LUSC	cis	rs58749629	1.000	rs3827066	chr20:44586023	C/T	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.54	-6.04	-0.31	4.2e-9	Abdominal aortic aneurysm;
LUSC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg04317338	chr11:64019027	PLCB3	0.71	8.02	0.4	1.76e-14	Mean platelet volume;
LUSC	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.76	-0.35	6.01e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg06618935	chr21:46677482	NA	-0.4	-8.06	-0.4	1.41e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs11676348	0.772	rs11687200	chr2:218944615	A/G	cg00012203	chr2:219082015	ARPC2	-0.5	-7.72	-0.39	1.4e-13	Ulcerative colitis;
LUSC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.45	0.5	2.69e-22	Alzheimer's disease;
LUSC	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg27411982	chr8:10470053	RP1L1	0.43	7.13	0.36	6.28e-12	Mood instability;
LUSC	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg24558204	chr6:135376177	HBS1L	0.59	9.28	0.45	2.26e-18	Red blood cell count;
LUSC	cis	rs72772090	0.908	rs72772091	chr5:96040122	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-7.44	-0.38	8.8e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4363385	0.626	rs12062770	chr1:153062837	A/C	cg00922841	chr1:152955080	SPRR1A	-0.35	-5.99	-0.31	5.32e-9	Inflammatory skin disease;
LUSC	trans	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.21	-0.37	3.82e-12	Neuroticism;
LUSC	cis	rs75804782	0.581	rs13415491	chr2:239319901	C/T	cg18131467	chr2:239335373	ASB1	-0.74	-6.64	-0.34	1.28e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg22166914	chr1:53195759	ZYG11B	-0.69	-12.08	-0.55	4.17e-28	Monocyte count;
LUSC	cis	rs7072216	0.727	rs7901577	chr10:100164442	A/G	cg26618903	chr10:100175079	PYROXD2	-0.46	-8.44	-0.42	1e-15	Metabolite levels;
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.39	-6.28	-0.32	1.07e-9	Longevity;Endometriosis;
LUSC	cis	rs3820928	0.874	rs10169717	chr2:227796911	T/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.72	-0.39	1.38e-13	Pulmonary function;
LUSC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg02187348	chr16:89574699	SPG7	0.57	9.24	0.45	2.86e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.31	-0.56	5.64e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs61863818	0.842	rs11189214	chr10:99181008	A/G	cg08345082	chr10:99160200	RRP12	0.34	6.12	0.32	2.58e-9	Monocyte percentage of white cells;
LUSC	cis	rs926938	0.618	rs516985	chr1:115495011	G/A	cg12756093	chr1:115239321	AMPD1	0.48	7.26	0.37	2.78e-12	Autism;
LUSC	cis	rs67696533	0.957	rs293567	chr20:31098565	A/C	cg13636640	chr20:31349939	DNMT3B	-0.42	-6.2	-0.32	1.62e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs17095355	0.818	rs72828263	chr10:111785703	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.58	-6.72	-0.34	8.01e-11	Biliary atresia;
LUSC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.03	0.48	6.95e-21	Hemoglobin concentration;
LUSC	trans	rs62238980	0.614	rs4821016	chr22:32402598	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.96	-0.68	5.59e-47	Exhaled nitric oxide output;
LUSC	cis	rs78663649	0.908	rs79083128	chr19:16556222	G/C	cg05286348	chr19:16641544	CHERP	-0.61	-5.85	-0.3	1.16e-8	White blood cell count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01719123	chr8:28244050	ZNF395	0.44	6.56	0.34	2.03e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg26102564	chr10:131424627	MGMT	0.4	6.1	0.32	2.94e-9	Response to temozolomide;
LUSC	cis	rs78707713	0.560	rs17569412	chr10:71237536	C/A	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.6	-0.47	1.96e-19	Venous thromboembolism;
LUSC	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-6.53	-0.34	2.48e-10	Homocysteine levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27488370	chr7:128046294	IMPDH1	0.38	6.01	0.31	4.99e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg22618164	chr12:122356400	WDR66	-0.61	-9.36	-0.46	1.21e-18	Mean corpuscular volume;
LUSC	cis	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg05299278	chr17:33885742	SLFN14	0.29	6.35	0.33	7.12e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg15704280	chr7:45808275	SEPT13	-0.7	-10.33	-0.49	6.71e-22	Coronary artery disease;
LUSC	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.63	-11.62	-0.54	1.96e-26	Itch intensity from mosquito bite;
LUSC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg27572855	chr1:25598939	RHD	0.41	7.29	0.37	2.26e-12	Erythrocyte sedimentation rate;
LUSC	trans	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg10756647	chr7:56101905	PSPH	-0.84	-8.42	-0.42	1.14e-15	Diabetic kidney disease;
LUSC	cis	rs6460942	0.915	rs72584550	chr7:12304990	G/A	cg06484146	chr7:12443880	VWDE	-0.52	-6.31	-0.33	9.12e-10	Coronary artery disease;
LUSC	cis	rs9653442	0.564	rs12992234	chr2:100767886	G/A	cg22139774	chr2:100720529	AFF3	-0.42	-7.07	-0.36	9.09e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1211375	0.607	rs1203978	chr16:257211	A/C	cg00126636	chr16:237282	NA	0.42	6.58	0.34	1.82e-10	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.57	9.55	0.46	2.99e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	0.58	9.25	0.45	2.71e-18	Breast cancer;
LUSC	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-6.89	-0.35	2.73e-11	Blood metabolite levels;
LUSC	cis	rs6722750	0.933	rs4671555	chr2:64411137	C/G	cg22352474	chr2:64371530	PELI1	-0.52	-7.76	-0.39	1.06e-13	Neuroticism;
LUSC	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.61	-0.34	1.53e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg24247370	chr13:99142703	STK24	-0.35	-6.49	-0.33	3.15e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg13010199	chr12:38710504	ALG10B	0.43	6.07	0.32	3.39e-9	Morning vs. evening chronotype;
LUSC	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg06627628	chr2:24431161	ITSN2	0.61	8.88	0.44	4.24e-17	Asthma;
LUSC	cis	rs9921338	0.961	rs77552156	chr16:11426399	C/A	cg00044050	chr16:11439710	C16orf75	-0.5	-6.66	-0.34	1.14e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg05082376	chr22:42548792	NA	-0.39	-5.85	-0.3	1.17e-8	Schizophrenia;
LUSC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.59	0.5	8.56e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg12002119	chr2:101014098	CHST10	0.35	5.65	0.3	3.35e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1005224	0.853	rs12898082	chr14:76306359	A/C	cg04684003	chr14:76127793	TTLL5;C14orf1	0.56	7.78	0.39	9.29e-14	Large artery stroke;
LUSC	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg13393036	chr8:95962371	TP53INP1	0.42	8.84	0.44	5.71e-17	Type 2 diabetes;
LUSC	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg06917634	chr15:78832804	PSMA4	-0.49	-5.99	-0.31	5.54e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3784262	0.904	rs17820823	chr15:58239358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.78	-0.3	1.74e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg14092571	chr14:90743983	NA	-0.37	-5.98	-0.31	5.8e-9	Mortality in heart failure;
LUSC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg25174290	chr11:3078921	CARS	0.58	9.3	0.45	1.91e-18	Longevity;
LUSC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg22166914	chr1:53195759	ZYG11B	-0.55	-8.78	-0.43	8.88e-17	Monocyte count;
LUSC	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg24558204	chr6:135376177	HBS1L	0.59	9.0	0.44	1.77e-17	Red blood cell count;
LUSC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg03146154	chr1:46216737	IPP	0.53	8.04	0.4	1.55e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11039100	0.765	rs72896130	chr11:5834405	C/T	cg13902645	chr11:5959945	NA	-0.53	-5.86	-0.31	1.09e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg23758822	chr17:41437982	NA	1.03	20.39	0.74	1.38e-60	Menopause (age at onset);
LUSC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08704250	chr15:31115839	NA	-0.47	-7.03	-0.36	1.17e-11	Huntington's disease progression;
LUSC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg16584290	chr5:462447	EXOC3	-0.37	-6.43	-0.33	4.39e-10	Cystic fibrosis severity;
LUSC	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg13072238	chr3:49761600	GMPPB	0.68	8.72	0.43	1.32e-16	Menarche (age at onset);
LUSC	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg14462750	chr9:136913113	BRD3	-0.36	-5.69	-0.3	2.72e-8	Platelet distribution width;
LUSC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg09491104	chr22:46646882	C22orf40	-0.67	-7.09	-0.36	8.06e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg06238570	chr21:40685208	BRWD1	-0.62	-10.42	-0.5	3.42e-22	Cognitive function;
LUSC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg05347473	chr6:146136440	FBXO30	0.66	11.61	0.54	2.02e-26	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg20608306	chr11:116969690	SIK3	0.36	6.79	0.35	5.04e-11	Blood protein levels;
LUSC	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg24375607	chr4:120327624	NA	0.74	10.89	0.51	7.53e-24	Corneal astigmatism;
LUSC	cis	rs79911532	0.515	rs79859948	chr7:75679099	A/G	cg03592824	chr7:75666768	STYXL1	0.7	6.84	0.35	3.84e-11	Mononucleosis;
LUSC	cis	rs2820315	1.000	rs2250377	chr1:201860626	A/G	cg10061532	chr1:201886748	LMOD1	-0.27	-5.96	-0.31	6.42e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg10253484	chr15:75165896	SCAMP2	-0.47	-6.61	-0.34	1.52e-10	Breast cancer;
LUSC	cis	rs2731664	0.792	rs163199	chr5:176890067	A/G	cg23176889	chr5:176863531	GRK6	-0.68	-14.3	-0.62	1.62e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg13798780	chr7:105162888	PUS7	0.58	6.15	0.32	2.21e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg20887711	chr4:1340912	KIAA1530	-0.49	-7.34	-0.37	1.65e-12	Obesity-related traits;
LUSC	trans	rs7739264	0.602	rs1121384	chr6:19771507	A/G	cg16463452	chr13:29195249	NA	0.3	6.04	0.31	4.09e-9	Endometriosis;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg07724433	chr4:147443257	SLC10A7	0.49	6.32	0.33	8.43e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	0.97	13.49	0.59	2.05e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.31	0.37	1.96e-12	Motion sickness;
LUSC	cis	rs7809950	1.000	rs4727681	chr7:107096144	T/C	cg23024343	chr7:107201750	COG5	-0.54	-8.59	-0.43	3.49e-16	Coronary artery disease;
LUSC	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg26647111	chr11:31128758	NA	-0.41	-6.01	-0.31	4.9e-9	Red blood cell count;
LUSC	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg05865280	chr17:75406074	SEPT9	0.48	10.28	0.49	9.84e-22	Airflow obstruction;
LUSC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.73	0.43	1.28e-16	Lung cancer;
LUSC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	1.03	20.37	0.74	1.6e-60	Cognitive function;
LUSC	cis	rs909341	0.868	rs2236508	chr20:62333115	G/A	cg09650180	chr20:62225654	GMEB2	-0.45	-5.83	-0.3	1.32e-8	Atopic dermatitis;
LUSC	cis	rs2067615	0.507	rs1922432	chr12:107077232	G/A	cg15890332	chr12:107067104	RFX4	0.34	5.77	0.3	1.84e-8	Heart rate;
LUSC	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg12884169	chr21:40033163	ERG	-0.56	-11.14	-0.52	1e-24	Coronary artery disease;
LUSC	cis	rs7084921	0.640	rs12773244	chr10:101865344	G/A	cg11888571	chr10:102027403	CWF19L1	-0.42	-5.9	-0.31	8.71e-9	Bone mineral density;
LUSC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18854424	chr1:2615690	NA	0.5	10.01	0.48	8.46e-21	Ulcerative colitis;
LUSC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	8.13	0.41	8.23e-15	Colorectal cancer;
LUSC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg07741184	chr6:167504864	NA	-0.36	-6.55	-0.34	2.14e-10	Crohn's disease;
LUSC	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg20283391	chr11:68216788	NA	-0.6	-8.38	-0.42	1.53e-15	Total body bone mineral density;
LUSC	cis	rs9419702	0.538	rs9419628	chr10:133539299	A/C	cg23460707	chr10:133558971	NA	0.34	5.82	0.3	1.41e-8	Survival in rectal cancer;
LUSC	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg22139774	chr2:100720529	AFF3	-0.51	-9.16	-0.45	5.44e-18	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7760949	0.963	rs9382681	chr6:13915051	A/G	cg27413430	chr6:13925136	RNF182	0.55	8.15	0.41	7.28e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08219700	chr8:58056026	NA	-0.7	-8.27	-0.41	3.22e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	0.6	9.45	0.46	5.98e-19	Breast cancer;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	1.02	24.79	0.8	1.05e-77	Menarche (age at onset);
LUSC	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	8.87	0.44	4.39e-17	Height;
LUSC	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.8	14.16	0.61	5.55e-36	Heart rate;
LUSC	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg11189052	chr15:85197271	WDR73	0.49	5.98	0.31	5.78e-9	Schizophrenia;
LUSC	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.31	0.45	1.77e-18	Blood protein levels;
LUSC	cis	rs12677618	0.623	rs28506950	chr8:142261967	C/T	cg00131261	chr8:142287264	NA	-0.36	-6.0	-0.31	5.24e-9	Plateletcrit;
LUSC	cis	rs16917546	1.000	rs7905030	chr10:64421600	G/C	cg03961010	chr10:64397487	ZNF365	-0.42	-6.68	-0.34	9.82e-11	Basal cell carcinoma;
LUSC	cis	rs9487051	0.735	rs396000	chr6:109519611	A/G	cg01475377	chr6:109611718	NA	0.36	6.23	0.32	1.4e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	8.37	0.42	1.56e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs240764	0.817	rs239238	chr6:101094880	G/T	cg09795085	chr6:101329169	ASCC3	0.41	5.96	0.31	6.4e-9	Neuroticism;
LUSC	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg22681709	chr2:178499509	PDE11A	-0.46	-7.63	-0.39	2.45e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg09877947	chr5:131593287	PDLIM4	0.37	6.0	0.31	5.04e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs55883249	1.000	rs62119392	chr2:9714033	G/C	cg23886495	chr2:9695866	ADAM17	0.49	5.66	0.3	3.24e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg17366294	chr4:99064904	C4orf37	0.57	10.18	0.49	2.27e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1044573	0.514	rs2268879	chr20:25177805	C/T	cg08601574	chr20:25228251	PYGB	-0.38	-5.8	-0.3	1.52e-8	Allergic rhinitis;
LUSC	trans	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg21659725	chr3:3221576	CRBN	-0.69	-8.35	-0.42	1.83e-15	Menarche (age at onset);
LUSC	cis	rs7605827	0.897	rs1990756	chr2:15616030	C/T	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg21427119	chr20:30132790	HM13	-0.43	-6.38	-0.33	5.88e-10	Mean corpuscular hemoglobin;
LUSC	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.77	-0.35	5.76e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.78	-9.64	-0.47	1.45e-19	Refractive error;
LUSC	cis	rs3736594	0.643	rs2384655	chr2:27952235	A/T	cg27432699	chr2:27873401	GPN1	-0.64	-9.09	-0.45	9.03e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg06637938	chr14:75390232	RPS6KL1	0.67	11.38	0.53	1.38e-25	Caffeine consumption;
LUSC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs2219968	0.961	rs4460363	chr8:78962903	G/A	cg00738934	chr8:78996279	NA	0.37	6.76	0.35	6.34e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg16339924	chr4:17578868	LAP3	0.52	7.89	0.4	4.26e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3007168	0.780	rs4531642	chr14:51632063	A/T	cg23942311	chr14:51606299	NA	-0.36	-6.71	-0.34	8.28e-11	Cancer;
LUSC	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg22117172	chr7:91764530	CYP51A1	-0.32	-5.82	-0.3	1.41e-8	Breast cancer;
LUSC	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.57	0.65	1.71e-41	Morning vs. evening chronotype;
LUSC	cis	rs2219968	1.000	rs12056614	chr8:78962648	A/T	cg00738934	chr8:78996279	NA	0.34	6.18	0.32	1.89e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3740713	1.000	rs73440615	chr11:18467283	T/C	cg07915343	chr11:18477680	LDHAL6A	-0.54	-6.64	-0.34	1.27e-10	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg20573242	chr4:122745356	CCNA2	0.64	9.03	0.44	1.36e-17	Type 2 diabetes;
LUSC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg07507251	chr3:52567010	NT5DC2	0.33	6.61	0.34	1.49e-10	Bipolar disorder;
LUSC	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.59	-0.34	1.74e-10	Neuroticism;
LUSC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg10729496	chr3:10149963	C3orf24	0.57	7.44	0.38	8.46e-13	Alzheimer's disease;
LUSC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg12463550	chr7:65579703	CRCP	0.41	5.66	0.3	3.21e-8	Aortic root size;
LUSC	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg21231944	chr12:82153410	PPFIA2	-0.41	-6.22	-0.32	1.52e-9	Resting heart rate;
LUSC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg00945038	chr17:61921165	SMARCD2	-0.42	-7.18	-0.37	4.45e-12	Prudent dietary pattern;
LUSC	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg06637938	chr14:75390232	RPS6KL1	0.51	7.77	0.39	9.7e-14	Height;
LUSC	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg11632617	chr15:75315747	PPCDC	-0.46	-6.16	-0.32	2.12e-9	Blood trace element (Zn levels);
LUSC	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg23260525	chr10:116636907	FAM160B1	0.47	10.26	0.49	1.19e-21	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg08807101	chr21:30365312	RNF160	-0.49	-6.57	-0.34	1.97e-10	Cognitive test performance;
LUSC	trans	rs6601327	0.670	rs12545250	chr8:9420566	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	6.41	0.33	5.08e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg07507251	chr3:52567010	NT5DC2	0.36	7.14	0.36	5.97e-12	Electroencephalogram traits;
LUSC	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-0.52	-7.99	-0.4	2.17e-14	Breast cancer;
LUSC	cis	rs1775715	0.707	rs2808088	chr10:32146150	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	7.09	0.36	8.13e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg13647721	chr17:30228624	UTP6	0.62	6.7	0.34	8.95e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg06671706	chr8:8559999	CLDN23	-0.51	-6.83	-0.35	4.09e-11	Obesity-related traits;
LUSC	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg18678763	chr11:4115507	RRM1	-0.46	-6.0	-0.31	5.13e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1178968	0.901	rs4999954	chr7:72755520	A/G	cg25889504	chr7:72793014	NA	0.59	8.19	0.41	5.57e-15	Triglyceride levels;
LUSC	trans	rs11696501	0.739	rs6073820	chr20:44249272	T/A	cg03272292	chr12:48577362	C12orf68	0.52	6.4	0.33	5.18e-10	Brain structure;
LUSC	cis	rs1982963	0.950	rs2645738	chr14:52513202	G/A	cg10843707	chr14:52510701	NID2	-0.41	-7.24	-0.37	3.15e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg21775007	chr8:11205619	TDH	-0.51	-7.73	-0.39	1.24e-13	Retinal vascular caliber;
LUSC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.45	-7.15	-0.36	5.4e-12	Systemic lupus erythematosus;
LUSC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.23	14.01	0.61	2.04e-35	Diabetic kidney disease;
LUSC	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg09835421	chr16:68378352	PRMT7	-0.75	-8.32	-0.41	2.31e-15	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg03146154	chr1:46216737	IPP	-0.5	-7.23	-0.37	3.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg24829409	chr8:58192753	C8orf71	-0.55	-6.21	-0.32	1.55e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	8.77	0.43	9.36e-17	Iron status biomarkers;
LUSC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg00933542	chr6:150070202	PCMT1	0.34	7.04	0.36	1.07e-11	Lung cancer;
LUSC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.62	10.05	0.48	6e-21	Mood instability;
LUSC	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg17749961	chr2:30669863	LCLAT1	0.63	7.73	0.39	1.25e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs2239815	0.515	rs6005917	chr22:29233486	A/G	cg02153584	chr22:29168773	CCDC117	0.54	6.39	0.33	5.56e-10	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg22676075	chr6:135203613	NA	0.49	7.66	0.39	2.09e-13	Red blood cell count;
LUSC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.22	0.52	5.24e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg04450456	chr4:17643702	FAM184B	0.39	6.54	0.34	2.34e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-6.79	-0.35	5.06e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.69	-0.34	9.51e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-8.41	-0.42	1.25e-15	Lymphocyte counts;
LUSC	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.19	-0.32	1.79e-9	Blood protein levels;
LUSC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg24642844	chr7:1081250	C7orf50	-0.46	-7.45	-0.38	8.07e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg24375607	chr4:120327624	NA	0.75	11.25	0.52	3.99e-25	Corneal astigmatism;
LUSC	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-6.2	-0.32	1.64e-9	Psoriasis;
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.6	-8.28	-0.41	3e-15	Longevity;Endometriosis;
LUSC	cis	rs17407555	0.518	rs16891234	chr4:9946163	A/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.67	-0.34	1.09e-10	Schizophrenia (age at onset);
LUSC	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg15704280	chr7:45808275	SEPT13	-0.62	-8.09	-0.4	1.09e-14	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs62238980	0.521	rs80342684	chr22:32380494	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg11473876	chr11:109292803	C11orf87	0.39	6.33	0.33	7.97e-10	Schizophrenia;
LUSC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	12.64	0.57	3.41e-30	Menopause (age at onset);
LUSC	cis	rs2377585	0.524	rs11612882	chr12:8843133	A/G	cg03761649	chr12:8850719	RIMKLB	-0.48	-6.62	-0.34	1.41e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg21361702	chr7:150065534	REPIN1	0.51	6.59	0.34	1.68e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20135002	chr11:47629003	NA	0.49	7.7	0.39	1.53e-13	Subjective well-being;
LUSC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg24209194	chr3:40518798	ZNF619	0.49	6.5	0.34	2.87e-10	Renal cell carcinoma;
LUSC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.27	-0.32	1.11e-9	Menopause (age at onset);
LUSC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06558623	chr16:89946397	TCF25	1.08	9.74	0.47	6.73e-20	Skin colour saturation;
LUSC	cis	rs2857891	0.695	rs2857884	chr11:6984879	C/G	cg04053776	chr11:6947353	ZNF215	0.41	6.06	0.31	3.65e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg09365446	chr1:150670422	GOLPH3L	0.47	7.0	0.36	1.4e-11	Melanoma;
LUSC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg03146154	chr1:46216737	IPP	0.51	7.71	0.39	1.5e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1950626	0.796	rs7152870	chr14:101389987	T/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.41	-7.47	-0.38	6.93e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.7	-12.17	-0.55	1.85e-28	Dental caries;
LUSC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21028142	chr17:79581711	NPLOC4	0.32	7.79	0.39	8.41e-14	Eye color traits;
LUSC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.82	13.69	0.6	3.52e-34	Aortic root size;
LUSC	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg24130564	chr14:104152367	KLC1	-0.51	-7.29	-0.37	2.27e-12	Body mass index;
LUSC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg04518342	chr5:131593106	PDLIM4	-0.41	-6.95	-0.36	1.88e-11	Breast cancer;
LUSC	cis	rs9929218	0.954	rs2961	chr16:68818903	T/C	cg02972257	chr16:68554789	NA	0.43	5.93	0.31	7.62e-9	Colorectal cancer;
LUSC	cis	rs8099014	1.000	rs6566970	chr18:56122507	A/G	cg12907477	chr18:56117327	MIR122	0.43	7.04	0.36	1.07e-11	Platelet count;
LUSC	trans	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg26384229	chr12:38710491	ALG10B	0.57	8.81	0.43	7.18e-17	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26314531	chr2:26401878	FAM59B	-0.71	-9.84	-0.47	3.17e-20	Gut microbiome composition (summer);
LUSC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	0.91	18.67	0.71	8.51e-54	Dental caries;
LUSC	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg20608306	chr11:116969690	SIK3	-0.37	-6.98	-0.36	1.56e-11	Blood protein levels;
LUSC	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg22676075	chr6:135203613	NA	0.47	7.34	0.37	1.66e-12	Red blood cell count;
LUSC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg25767906	chr1:53392781	SCP2	0.6	11.66	0.54	1.39e-26	Monocyte count;
LUSC	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.31	-0.33	8.67e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00149659	chr3:10157352	C3orf10	1.01	14.37	0.62	8.51e-37	Alzheimer's disease;
LUSC	cis	rs155346	0.948	rs265141	chr5:139396375	G/A	cg01090482	chr5:139365336	NRG2	-0.36	-5.98	-0.31	5.7e-9	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.26	0.52	3.78e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	9.29	0.45	1.98e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs11630290	0.628	rs72752941	chr15:64181604	G/C	cg12036633	chr15:63758958	NA	-0.67	-6.91	-0.35	2.43e-11	Iris characteristics;
LUSC	cis	rs7945718	0.934	rs7114040	chr11:12781659	C/T	cg25843174	chr11:12811716	TEAD1	-0.32	-7.35	-0.37	1.51e-12	Educational attainment (years of education);
LUSC	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg00784671	chr22:46762841	CELSR1	-0.49	-5.92	-0.31	7.96e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.53	0.34	2.46e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg12432903	chr7:1882776	MAD1L1	-0.42	-6.8	-0.35	4.75e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg19046167	chr17:80928561	B3GNTL1	0.4	6.44	0.33	4.21e-10	Breast cancer;
LUSC	cis	rs4356932	1.000	rs10000130	chr4:76939335	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.87	0.31	1.08e-8	Blood protein levels;
LUSC	cis	rs1005224	0.895	rs11624114	chr14:76131800	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.64	-8.76	-0.43	1.03e-16	Large artery stroke;
LUSC	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg20734569	chr3:48348370	SPINK8	-0.47	-8.21	-0.41	4.82e-15	Coronary artery disease;
LUSC	cis	rs6723226	0.739	rs2069213	chr2:32743084	C/T	cg02381751	chr2:32503542	YIPF4	0.59	9.02	0.44	1.46e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs1044826	1.000	rs12695698	chr3:139175781	A/G	cg00490450	chr3:139108681	COPB2	-0.52	-7.03	-0.36	1.2e-11	Obesity-related traits;
LUSC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	0.92	12.58	0.57	5.65e-30	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg20701182	chr2:24300061	SF3B14	0.57	5.87	0.31	1.04e-8	Lymphocyte counts;
LUSC	trans	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg25815440	chr2:42134162	NA	-0.25	-5.96	-0.31	6.49e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs3087591	0.922	rs2905879	chr17:29545431	T/A	cg24425628	chr17:29625626	OMG;NF1	0.56	8.21	0.41	5.04e-15	Hip circumference;
LUSC	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg07435449	chr11:120005650	TRIM29	0.36	6.26	0.32	1.15e-9	Stroke (pediatric);
LUSC	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.79	11.57	0.53	2.96e-26	Corneal astigmatism;
LUSC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg12560992	chr17:57184187	TRIM37	0.83	14.9	0.63	7.77e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.37	-0.33	6.21e-10	Resting heart rate;
LUSC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg06134567	chr22:46658398	PKDREJ	-0.53	-5.93	-0.31	7.54e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1322512	0.958	rs12195158	chr6:153006544	T/C	cg03415253	chr6:152958462	SYNE1	0.38	5.65	0.3	3.38e-8	Tonometry;
LUSC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg03605463	chr16:89740564	NA	0.58	9.2	0.45	3.93e-18	Vitiligo;
LUSC	cis	rs9937943	0.667	rs9938426	chr16:74523739	C/G	cg01733217	chr16:74700730	RFWD3	-0.6	-6.97	-0.36	1.67e-11	Neutrophil percentage of white cells;
LUSC	cis	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg14895029	chr7:2775587	GNA12	-0.45	-6.69	-0.34	9.21e-11	Height;
LUSC	cis	rs17102423	0.755	rs8009396	chr14:65573438	C/G	cg11161011	chr14:65562177	MAX	-0.81	-12.19	-0.55	1.57e-28	Obesity-related traits;
LUSC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.98	-0.44	2.02e-17	Bipolar disorder;
LUSC	cis	rs7119	0.717	rs12910951	chr15:77806797	A/G	cg27398640	chr15:77910606	LINGO1	-0.29	-6.12	-0.32	2.58e-9	Type 2 diabetes;
LUSC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg15145296	chr3:125709740	NA	-0.57	-6.42	-0.33	4.8e-10	Blood pressure (smoking interaction);
LUSC	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg19628046	chr18:33552617	C18orf21	0.5	6.12	0.32	2.56e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs4363385	0.510	rs6686526	chr1:153044996	T/C	cg00922841	chr1:152955080	SPRR1A	-0.36	-6.07	-0.32	3.4e-9	Inflammatory skin disease;
LUSC	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg25214090	chr10:38739885	LOC399744	0.54	7.98	0.4	2.39e-14	Corneal astigmatism;
LUSC	cis	rs2637266	0.714	rs4475870	chr10:78450724	T/A	cg18941641	chr10:78392320	NA	0.33	5.98	0.31	5.67e-9	Pulmonary function;
LUSC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg06637938	chr14:75390232	RPS6KL1	0.53	8.41	0.42	1.23e-15	Height;
LUSC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.59	-0.34	1.71e-10	Schizophrenia;
LUSC	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg03465714	chr1:152285911	FLG	-0.4	-5.67	-0.3	3.09e-8	Atopic dermatitis;
LUSC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.7	0.34	8.76e-11	Depression;
LUSC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-1.25	-13.99	-0.61	2.56e-35	Diabetic kidney disease;
LUSC	trans	rs6747952	0.899	rs4663856	chr2:239089624	C/A	cg17763188	chr8:6692148	XKR5	0.37	5.97	0.31	6.13e-9	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7106204	0.609	rs12276488	chr11:24250211	G/A	ch.11.24196551F	chr11:24239977	NA	0.76	7.19	0.37	4.39e-12	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg15133208	chr4:90757351	SNCA	-0.54	-8.45	-0.42	9.02e-16	Neuroticism;
LUSC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg22907277	chr7:1156413	C7orf50	0.51	7.73	0.39	1.25e-13	Longevity;Endometriosis;
LUSC	cis	rs870825	0.655	rs7683556	chr4:185632019	T/A	cg04058563	chr4:185651563	MLF1IP	0.87	13.33	0.59	8.18e-33	Blood protein levels;
LUSC	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg00530320	chr1:46809349	NSUN4	0.56	8.59	0.43	3.45e-16	Menopause (age at onset);
LUSC	cis	rs13266463	1.000	rs13266463	chr8:143403693	A/G	cg16886403	chr8:143471632	TSNARE1	-0.6	-8.98	-0.44	2.04e-17	Schizophrenia;
LUSC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.2	22.43	0.78	1.32e-68	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg00530320	chr1:46809349	NSUN4	0.56	8.67	0.43	1.89e-16	Menopause (age at onset);
LUSC	cis	rs448720	0.806	rs11071966	chr15:68163774	G/A	cg08079166	chr15:68083412	MAP2K5	-0.28	-5.68	-0.3	2.87e-8	Cognitive performance;
LUSC	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg02503808	chr4:7069936	GRPEL1	-0.86	-6.14	-0.32	2.29e-9	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.72	-0.39	1.36e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg12365402	chr11:9010492	NRIP3	0.43	7.7	0.39	1.56e-13	Hemoglobin concentration;
LUSC	cis	rs4654899	0.743	rs61781069	chr1:21130735	T/C	cg02927042	chr1:21476669	EIF4G3	-0.38	-5.97	-0.31	6.1e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.88	-0.44	4.17e-17	Lung cancer;
LUSC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-16.23	-0.66	4.23e-44	Primary sclerosing cholangitis;
LUSC	trans	rs1486139	1.000	rs723289	chr7:46283474	C/T	cg17534202	chr9:96721102	NA	-0.37	-6.56	-0.34	2.01e-10	Select biomarker traits;
LUSC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-7.29	-0.37	2.27e-12	Aortic root size;
LUSC	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg23231163	chr10:75533350	FUT11	-0.46	-7.39	-0.37	1.17e-12	Inflammatory bowel disease;
LUSC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg14440974	chr22:39074834	NA	-0.35	-5.79	-0.3	1.6e-8	Menopause (age at onset);
LUSC	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg01657329	chr11:68192670	LRP5	-0.48	-7.42	-0.38	9.63e-13	Total body bone mineral density;
LUSC	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg13390004	chr1:15929781	NA	0.42	6.95	0.36	1.92e-11	Systolic blood pressure;
LUSC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg21724239	chr8:58056113	NA	-0.78	-8.8	-0.43	7.23e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.92	-12.08	-0.55	4.17e-28	Exhaled nitric oxide output;
LUSC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg02423579	chr7:2872169	GNA12	-0.45	-6.33	-0.33	8.07e-10	Height;
LUSC	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg24675056	chr1:15929824	NA	0.49	8.51	0.42	6.13e-16	Systolic blood pressure;
LUSC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.66	-6.43	-0.33	4.49e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1044826	0.642	rs295473	chr3:139215585	T/C	cg00490450	chr3:139108681	COPB2	0.46	7.03	0.36	1.19e-11	Obesity-related traits;
LUSC	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg12927641	chr6:109611667	NA	-0.35	-5.87	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs28785552	0.800	rs10853854	chr19:53232128	A/G	cg10871876	chr19:53194124	ZNF83	-0.55	-8.57	-0.42	3.78e-16	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg09904177	chr6:26538194	HMGN4	0.65	11.61	0.54	2.14e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	0.77	13.46	0.59	2.8e-33	Cognitive function;
LUSC	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg21361702	chr7:150065534	REPIN1	0.57	8.02	0.4	1.85e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3087591	0.960	rs2905872	chr17:29525027	C/A	cg24425628	chr17:29625626	OMG;NF1	0.55	8.0	0.4	2.02e-14	Hip circumference;
LUSC	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg20307385	chr11:47447363	PSMC3	-0.46	-6.74	-0.35	6.93e-11	Subjective well-being;
LUSC	trans	rs1376359	0.537	rs506864	chr1:103281950	A/T	cg17154563	chr19:40477487	PSMC4	0.47	5.95	0.31	6.82e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg05313129	chr8:58192883	C8orf71	-0.52	-5.9	-0.31	9.1e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	7.63	0.39	2.51e-13	Height;
LUSC	cis	rs2227564	0.700	rs2688613	chr10:75653045	C/T	cg23231163	chr10:75533350	FUT11	-0.42	-5.93	-0.31	7.45e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg03526776	chr6:41159608	TREML2	0.33	6.33	0.33	7.7e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18404041	chr3:52824283	ITIH1	-0.53	-10.19	-0.49	2.01e-21	Electroencephalogram traits;
LUSC	cis	rs7246967	0.673	rs3853649	chr19:22880460	C/G	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg20573242	chr4:122745356	CCNA2	-0.45	-7.07	-0.36	9.27e-12	Type 2 diabetes;
LUSC	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg24375607	chr4:120327624	NA	0.76	11.3	0.53	2.66e-25	Corneal astigmatism;
LUSC	cis	rs2274273	0.870	rs946059	chr14:55847466	A/G	cg04306507	chr14:55594613	LGALS3	0.56	12.98	0.58	1.81e-31	Protein biomarker;
LUSC	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	8.08	0.4	1.17e-14	Coffee consumption (cups per day);
LUSC	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23158103	chr7:148848205	ZNF398	-0.39	-6.01	-0.31	4.77e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg10150615	chr22:24372951	LOC391322	-0.35	-5.74	-0.3	2.09e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.38	-6.19	-0.32	1.8e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9815354	0.812	rs73081370	chr3:41916258	G/C	cg03022575	chr3:42003672	ULK4	0.83	8.57	0.42	3.85e-16	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs2018683	0.624	rs2286220	chr7:28998699	G/C	cg19402173	chr7:128379420	CALU	-0.51	-7.55	-0.38	4.11e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg13319975	chr6:146136371	FBXO30	-0.41	-6.15	-0.32	2.16e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg04998671	chr14:104000505	TRMT61A	-0.47	-7.15	-0.36	5.44e-12	Coronary artery disease;
LUSC	cis	rs4664308	0.870	rs55959207	chr2:161016981	A/C	cg03641300	chr2:160917029	PLA2R1	-0.64	-10.92	-0.51	6.16e-24	Idiopathic membranous nephropathy;
LUSC	cis	rs2274273	0.967	rs10137409	chr14:55611441	A/C	cg04306507	chr14:55594613	LGALS3	0.54	11.95	0.55	1.23e-27	Protein biomarker;
LUSC	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg02023728	chr11:77925099	USP35	0.48	6.89	0.35	2.87e-11	Testicular germ cell tumor;
LUSC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg18350739	chr11:68623251	NA	-0.38	-6.56	-0.34	2.01e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg07148914	chr20:33460835	GGT7	0.55	8.25	0.41	3.64e-15	Height;
LUSC	cis	rs1832871	0.672	rs62437159	chr6:158697705	C/T	cg07165851	chr6:158734300	TULP4	0.5	7.78	0.39	9.42e-14	Height;
LUSC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg17366294	chr4:99064904	C4orf37	0.58	10.43	0.5	3.19e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3903072	0.528	rs12800497	chr11:65579762	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.35	5.77	0.3	1.77e-8	Breast cancer;
LUSC	cis	rs9905704	0.681	rs1468540	chr17:56561942	C/T	cg19466818	chr17:56409534	MIR142	0.35	6.44	0.33	4.06e-10	Testicular germ cell tumor;
LUSC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg06671706	chr8:8559999	CLDN23	0.49	6.73	0.35	7.55e-11	Obesity-related traits;
LUSC	cis	rs7572644	0.766	rs6758799	chr2:28284633	T/C	cg27432699	chr2:27873401	GPN1	-0.54	-6.9	-0.35	2.67e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.9	0.55	1.88e-27	Exhaled nitric oxide output;
LUSC	cis	rs7923609	0.934	rs2893919	chr10:65134778	G/A	cg01631684	chr10:65280961	REEP3	-0.38	-5.89	-0.31	9.62e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs75804782	0.581	rs13415491	chr2:239319901	C/T	cg01134436	chr17:81009848	B3GNTL1	0.64	6.08	0.32	3.37e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.74	-0.3	2.14e-8	Depression;
LUSC	trans	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.53	-8.17	-0.41	6.23e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6084875	0.812	rs2050369	chr20:4719493	C/T	cg07258627	chr20:4721683	PRNT	-0.33	-6.05	-0.31	3.99e-9	Systemic lupus erythematosus;
LUSC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.84	-0.51	1.18e-23	Aortic root size;
LUSC	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg02023728	chr11:77925099	USP35	0.53	7.25	0.37	3e-12	Testicular germ cell tumor;
LUSC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06634786	chr22:41940651	POLR3H	0.51	5.91	0.31	8.59e-9	Vitiligo;
LUSC	cis	rs2235544	0.579	rs11804837	chr1:54482915	G/A	cg25741118	chr1:54482237	LDLRAD1	-0.33	-7.57	-0.38	3.6e-13	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg16325326	chr1:53192061	ZYG11B	-0.92	-17.21	-0.69	5.71e-48	Monocyte count;
LUSC	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg27219399	chr15:67835830	MAP2K5	0.36	5.9	0.31	9.02e-9	Obesity;
LUSC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg09904177	chr6:26538194	HMGN4	0.47	7.48	0.38	6.76e-13	Schizophrenia;
LUSC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs16976116	0.855	rs11856010	chr15:55495008	A/G	cg11288833	chr15:55489084	RSL24D1	0.49	5.8	0.3	1.53e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.29	-0.33	9.86e-10	QT interval;
LUSC	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	10.37	0.49	4.99e-22	Mean corpuscular hemoglobin;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg03651680	chr2:46926842	SOCS5	0.36	5.96	0.31	6.51e-9	Triglycerides;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19354851	chr1:94375246	GCLM	-0.42	-6.33	-0.33	7.75e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg24579218	chr15:68104479	NA	-0.39	-6.78	-0.35	5.39e-11	Restless legs syndrome;
LUSC	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.82	10.81	0.51	1.42e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06221963	chr1:154839813	KCNN3	-0.61	-13.83	-0.6	1.03e-34	Prostate cancer;
LUSC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg06740227	chr12:86229804	RASSF9	0.45	7.09	0.36	7.86e-12	Major depressive disorder;
LUSC	cis	rs1113500	0.787	rs473704	chr1:108637310	T/C	cg06207961	chr1:108661230	NA	-0.31	-5.74	-0.3	2.13e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg08888203	chr3:10149979	C3orf24	0.64	8.67	0.43	1.9e-16	Alzheimer's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04505727	chr17:79885823	LOC92659;MAFG	-0.41	-6.25	-0.32	1.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.28	-0.41	2.93e-15	Obesity-related traits;
LUSC	cis	rs12900413	0.687	rs7176948	chr15:90315707	A/C	cg24249390	chr15:90295951	MESP1	-0.37	-5.75	-0.3	2.05e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg11764359	chr7:65958608	NA	0.49	6.09	0.32	3.19e-9	Aortic root size;
LUSC	trans	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-6.74	-0.35	6.9e-11	Endometrial cancer;
LUSC	cis	rs2692947	0.800	rs2692936	chr2:96745729	G/A	cg22654517	chr2:96458247	NA	0.33	6.13	0.32	2.51e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg01475377	chr6:109611718	NA	-0.46	-8.44	-0.42	9.54e-16	Reticulocyte fraction of red cells;
LUSC	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg20628663	chr10:43360327	NA	0.74	10.68	0.5	4.23e-23	Blood protein levels;
LUSC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-18.08	-0.7	2.04e-51	Coronary artery disease;
LUSC	cis	rs922692	0.744	rs1825087	chr15:79077114	A/G	cg00540400	chr15:79124168	NA	-0.41	-7.06	-0.36	9.95e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs10761482	0.861	rs1903204	chr10:62100231	G/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg22709100	chr7:91322751	NA	0.4	5.85	0.31	1.15e-8	Breast cancer;
LUSC	trans	rs4650994	0.507	rs12405456	chr1:178512331	T/G	cg05059571	chr16:84539110	KIAA1609	-0.45	-8.64	-0.43	2.35e-16	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg08873628	chr1:175162347	KIAA0040	0.39	5.67	0.3	3.14e-8	Alcohol dependence;
LUSC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg03579872	chr1:53393473	SCP2	0.39	5.71	0.3	2.49e-8	Monocyte count;
LUSC	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg13902645	chr11:5959945	NA	-0.64	-9.11	-0.45	7.48e-18	DNA methylation (variation);
LUSC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-12.95	-0.58	2.36e-31	Platelet count;
LUSC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.69	-12.3	-0.56	6.19e-29	Aortic root size;
LUSC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-6.74	-0.35	6.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06544989	chr22:39130855	UNC84B	0.35	6.11	0.32	2.72e-9	Menopause (age at onset);
LUSC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg05729581	chr11:3078854	CARS	-0.51	-7.91	-0.4	3.86e-14	Longevity;
LUSC	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.45e-8	Lymphocyte counts;
LUSC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.71	10.84	0.51	1.18e-23	Type 2 diabetes;
LUSC	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg21100191	chr22:23484243	RTDR1	0.91	16.03	0.66	2.81e-43	Bone mineral density;
LUSC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	8.23	0.41	4.38e-15	Bipolar disorder;
LUSC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg19318889	chr4:1322082	MAEA	0.55	9.09	0.45	8.89e-18	Obesity-related traits;
LUSC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg22800045	chr5:56110881	MAP3K1	0.58	7.81	0.39	7.43e-14	Coronary artery disease;
LUSC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg00701064	chr4:6280414	WFS1	0.58	14.2	0.61	3.82e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.71	-0.43	1.43e-16	Bipolar disorder;
LUSC	cis	rs2147959	0.714	rs6659690	chr1:228628170	A/G	cg18477163	chr1:228402036	OBSCN	-0.42	-5.86	-0.31	1.08e-8	Adult asthma;
LUSC	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg04036182	chr15:45458818	NA	-0.35	-5.76	-0.3	1.96e-8	Glomerular filtration rate;
LUSC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.61	8.74	0.43	1.17e-16	Menopause (age at onset);
LUSC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg09941381	chr10:64027924	RTKN2	-0.37	-6.92	-0.35	2.38e-11	Rheumatoid arthritis;
LUSC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg00857998	chr1:205179979	DSTYK	0.64	9.81	0.47	4.01e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.56	0.53	3.14e-26	Menopause (age at onset);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg17303459	chr19:54606023	NDUFA3	0.44	6.98	0.36	1.61e-11	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs3925075	1.000	rs3925074	chr16:31347807	G/A	cg02846316	chr16:31340340	ITGAM	0.36	6.76	0.35	6.34e-11	IgA nephropathy;
LUSC	cis	rs11158026	0.526	rs11626210	chr14:55349549	C/T	cg04306507	chr14:55594613	LGALS3	0.4	6.4	0.33	5.16e-10	Parkinson's disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16426870	chr16:23652487	PALB2;DCTN5	-0.36	-5.95	-0.31	6.85e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg27266027	chr21:40555129	PSMG1	-0.41	-5.93	-0.31	7.65e-9	Cognitive function;
LUSC	cis	rs3755132	0.929	rs6724800	chr2:15786243	A/G	cg12888861	chr2:15731646	DDX1	0.53	7.51	0.38	5.53e-13	Wilms tumor;
LUSC	cis	rs77633900	0.614	rs2930681	chr15:76995150	G/A	cg21673338	chr15:77095150	SCAPER	-0.81	-8.33	-0.41	2.19e-15	Non-glioblastoma glioma;Glioma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08275802	chr7:155137875	NA	-0.38	-5.94	-0.31	7.01e-9	Electrocardiographic conduction measures;
LUSC	cis	rs8099014	1.000	rs12608175	chr18:56129976	T/C	cg12907477	chr18:56117327	MIR122	0.44	7.04	0.36	1.11e-11	Platelet count;
LUSC	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	0.93	17.58	0.69	1.94e-49	Headache;
LUSC	cis	rs240764	0.578	rs6925065	chr6:101178856	C/T	cg09795085	chr6:101329169	ASCC3	0.44	6.32	0.33	8.43e-10	Neuroticism;
LUSC	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.34	6.54	0.34	2.26e-10	Platelet count;
LUSC	cis	rs2580764	0.565	rs6545466	chr2:55228392	C/T	cg20993754	chr2:55226987	RTN4	0.34	5.81	0.3	1.5e-8	Mean platelet volume;
LUSC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	7.97	0.4	2.54e-14	Homoarginine levels;
LUSC	trans	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg13010199	chr12:38710504	ALG10B	0.5	7.48	0.38	6.51e-13	Morning vs. evening chronotype;
LUSC	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg04896959	chr15:78267971	NA	-0.42	-6.72	-0.34	8.09e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg02466173	chr16:30829666	NA	-0.68	-16.06	-0.66	2.09e-43	Dementia with Lewy bodies;
LUSC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg20908204	chr19:46285434	DMPK	-0.46	-8.85	-0.44	5.11e-17	Coronary artery disease;
LUSC	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg22437258	chr11:111473054	SIK2	0.47	6.38	0.33	6.07e-10	Primary sclerosing cholangitis;
LUSC	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.83	-8.66	-0.43	2.11e-16	Lung cancer in ever smokers;
LUSC	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	10.0	0.48	9.03e-21	Height;
LUSC	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg24675056	chr1:15929824	NA	0.46	8.03	0.4	1.69e-14	Systolic blood pressure;
LUSC	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg18681998	chr4:17616180	MED28	0.78	13.81	0.6	1.26e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg02423579	chr7:2872169	GNA12	-0.41	-6.08	-0.32	3.34e-9	Height;
LUSC	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	12.31	0.56	5.94e-29	Blood protein levels;
LUSC	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25072359	chr17:41440525	NA	0.65	9.4	0.46	9.22e-19	Menopause (age at onset);
LUSC	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	6.7	0.34	9.05e-11	Monocyte percentage of white cells;
LUSC	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg00277334	chr10:82204260	NA	-0.42	-5.78	-0.3	1.69e-8	Post bronchodilator FEV1;
LUSC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg04287289	chr16:89883240	FANCA	0.53	8.02	0.4	1.76e-14	Vitiligo;
LUSC	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg03030879	chr14:75389066	RPS6KL1	0.39	7.42	0.38	9.79e-13	Caffeine consumption;
LUSC	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg00310523	chr12:86230176	RASSF9	0.39	7.0	0.36	1.4e-11	Major depressive disorder;
LUSC	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg24642439	chr20:33292090	TP53INP2	0.41	5.93	0.31	7.42e-9	Height;
LUSC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg10207240	chr12:122356781	WDR66	0.46	6.61	0.34	1.49e-10	Mean corpuscular volume;
LUSC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-1.13	-24.87	-0.81	5.13e-78	Height;
LUSC	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.69	-11.11	-0.52	1.28e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg16558253	chr16:72132732	DHX38	0.44	6.74	0.35	7.17e-11	Fibrinogen levels;
LUSC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.07e-12	Motion sickness;
LUSC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	11.58	0.54	2.63e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg09904177	chr6:26538194	HMGN4	-0.76	-5.9	-0.31	8.78e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7586879	0.828	rs13387053	chr2:25103025	G/A	cg01884057	chr2:25150051	NA	0.41	8.53	0.42	5.31e-16	Body mass index;
LUSC	trans	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg07211511	chr3:129823064	LOC729375	-0.53	-6.1	-0.32	2.86e-9	Blood pressure (smoking interaction);
LUSC	cis	rs72627509	0.904	rs17081933	chr4:57822869	T/A	cg26694713	chr4:57773883	REST	0.49	5.88	0.31	1.01e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg12292205	chr6:26970375	C6orf41	-0.67	-11.36	-0.53	1.61e-25	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.62	-0.67	1.2e-45	Monocyte count;
LUSC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg04756594	chr16:24857601	SLC5A11	0.33	5.65	0.3	3.41e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	10.05	0.48	6.05e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg03733263	chr8:22462867	KIAA1967	0.97	16.67	0.67	7.76e-46	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg00225070	chr15:80189496	MTHFS	0.57	8.91	0.44	3.39e-17	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg09184832	chr6:79620586	NA	-0.36	-5.72	-0.3	2.39e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs28830936	1.000	rs9672360	chr15:41912411	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.28	-0.32	1.06e-9	Diastolic blood pressure;
LUSC	cis	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg07460842	chr6:66804631	NA	-0.48	-6.72	-0.35	7.74e-11	Blood trace element (Cu levels);
LUSC	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg00520135	chr15:63333846	TPM1	-0.33	-6.66	-0.34	1.12e-10	Platelet count;
LUSC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg11102782	chr19:18549136	ISYNA1	-0.37	-6.98	-0.36	1.56e-11	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05203659	chr16:12009378	GSPT1	0.46	7.03	0.36	1.14e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg06008330	chr7:65541103	ASL	-0.4	-6.22	-0.32	1.46e-9	Aortic root size;
LUSC	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg02993010	chr8:124780839	FAM91A1	-0.47	-5.67	-0.3	3.02e-8	Pancreatic cancer;
LUSC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg27170947	chr2:26402098	FAM59B	0.66	8.94	0.44	2.78e-17	Gut microbiome composition (summer);
LUSC	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17173187	chr15:85201210	NMB	0.48	9.17	0.45	4.85e-18	Schizophrenia;
LUSC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg16049864	chr8:95962084	TP53INP1	-0.61	-11.34	-0.53	1.95e-25	Type 2 diabetes;
LUSC	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg18200150	chr17:30822561	MYO1D	0.31	6.01	0.31	4.88e-9	Schizophrenia;
LUSC	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.25	-0.37	2.99e-12	Neuroticism;
LUSC	cis	rs727505	0.789	rs9641761	chr7:124735205	A/T	cg23710748	chr7:124431027	NA	-0.4	-6.96	-0.36	1.79e-11	Lewy body disease;
LUSC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg13699009	chr12:122356056	WDR66	0.49	7.72	0.39	1.39e-13	Mean corpuscular volume;
LUSC	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.9	0.44	3.72e-17	Menopause (age at onset);
LUSC	cis	rs7113850	0.541	rs7935630	chr11:24222206	A/C	ch.11.24196551F	chr11:24239977	NA	0.99	8.89	0.44	3.77e-17	Bone fracture in osteoporosis;
LUSC	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg13813247	chr22:41461852	NA	-0.32	-5.92	-0.31	7.95e-9	Neuroticism;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg26716323	chr7:22862328	TOMM7	0.39	6.02	0.31	4.63e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg18904891	chr8:8559673	CLDN23	0.62	8.63	0.43	2.49e-16	Obesity-related traits;
LUSC	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.46	9.61	0.47	1.86e-19	Airflow obstruction;
LUSC	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.8	14.61	0.62	1.02e-37	Heart rate;
LUSC	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg08270630	chr22:50330655	NA	-0.44	-6.59	-0.34	1.75e-10	Schizophrenia;
LUSC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06634786	chr22:41940651	POLR3H	0.53	6.19	0.32	1.79e-9	Vitiligo;
LUSC	cis	rs2637266	0.626	rs846619	chr10:78545449	A/G	cg18941641	chr10:78392320	NA	0.38	6.75	0.35	6.54e-11	Pulmonary function;
LUSC	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg26566898	chr11:117069891	TAGLN	0.34	6.56	0.34	2.01e-10	Blood protein levels;
LUSC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	11.91	0.55	1.63e-27	Hip circumference adjusted for BMI;
LUSC	cis	rs262150	0.566	rs262159	chr7:158772172	C/T	cg22153799	chr7:158819822	NA	-0.34	-6.07	-0.31	3.57e-9	Facial morphology (factor 20);
LUSC	cis	rs2274273	0.712	rs9806049	chr14:55525589	C/A	cg04306507	chr14:55594613	LGALS3	0.48	10.38	0.49	4.52e-22	Protein biomarker;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15190599	chr6:26156487	HIST1H1E	0.42	6.57	0.34	1.95e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs240764	0.817	rs239219	chr6:101116146	C/T	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.69e-9	Neuroticism;
LUSC	cis	rs12681287	0.640	rs67123356	chr8:87453992	A/C	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg00262122	chr8:11665843	FDFT1	0.39	5.82	0.3	1.37e-8	Neuroticism;
LUSC	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg19508488	chr2:152266495	RIF1	0.54	7.64	0.39	2.33e-13	Lung cancer;
LUSC	cis	rs6714710	0.580	rs13032265	chr2:98409565	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	13.73	0.6	2.5e-34	Total body bone mineral density;
LUSC	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg24130564	chr14:104152367	KLC1	-0.47	-6.64	-0.34	1.24e-10	Body mass index;
LUSC	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg18357645	chr12:58087776	OS9	0.5	7.42	0.38	9.78e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg18230493	chr5:56204884	C5orf35	-0.93	-13.74	-0.6	2.25e-34	Initial pursuit acceleration;
LUSC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.92	15.6	0.65	1.41e-41	Bladder cancer;
LUSC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08470875	chr2:26401718	FAM59B	0.73	9.87	0.48	2.53e-20	Gut microbiome composition (summer);
LUSC	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-8.83	-0.43	6.18e-17	Response to antipsychotic treatment;
LUSC	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg11693508	chr17:37793320	STARD3	0.51	6.27	0.32	1.09e-9	Bipolar disorder;
LUSC	trans	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg14791747	chr16:20752902	THUMPD1	0.76	13.09	0.58	7.07e-32	Cognitive test performance;
LUSC	cis	rs72634258	1.000	rs72634258	chr1:8150638	T/C	cg00042356	chr1:8021962	PARK7	0.84	10.18	0.49	2.24e-21	Inflammatory bowel disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03809994	chr4:75023664	MTHFD2L	-0.48	-6.33	-0.33	8.11e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg14458575	chr2:238380390	NA	0.67	11.84	0.54	3e-27	Prostate cancer;
LUSC	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg09904177	chr6:26538194	HMGN4	-0.5	-7.86	-0.39	5.42e-14	Schizophrenia;
LUSC	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg21427119	chr20:30132790	HM13	-0.43	-6.19	-0.32	1.77e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.69	-10.91	-0.51	6.53e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg23791538	chr6:167370224	RNASET2	-0.41	-6.63	-0.34	1.32e-10	Crohn's disease;
LUSC	trans	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-13.19	-0.59	2.98e-32	Colorectal cancer;
LUSC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg02569458	chr12:86230093	RASSF9	0.58	9.9	0.48	1.97e-20	Major depressive disorder;
LUSC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06634786	chr22:41940651	POLR3H	-0.51	-6.27	-0.32	1.14e-9	Vitiligo;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14312959	chr17:79008933	FLJ90757;BAIAP2	-0.48	-6.04	-0.31	4.09e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	1.06	13.11	0.58	6.04e-32	Nonalcoholic fatty liver disease;
LUSC	trans	rs12310956	0.510	rs10743832	chr12:33884146	A/C	cg26384229	chr12:38710491	ALG10B	0.55	8.48	0.42	7.29e-16	Morning vs. evening chronotype;
LUSC	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg17507749	chr15:85114479	UBE2QP1	0.66	8.29	0.41	2.85e-15	Schizophrenia;
LUSC	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg12062639	chr20:23401060	NAPB	0.94	8.06	0.4	1.33e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg19592336	chr6:28129416	ZNF389	0.45	5.81	0.3	1.46e-8	Depression;
LUSC	cis	rs7572644	0.713	rs11127127	chr2:28066904	G/T	cg27432699	chr2:27873401	GPN1	0.53	6.79	0.35	5.07e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.65	-0.34	1.21e-10	Response to antipsychotic treatment;
LUSC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2637266	0.967	rs7477607	chr10:78358768	G/T	cg18941641	chr10:78392320	NA	0.38	7.01	0.36	1.35e-11	Pulmonary function;
LUSC	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg27087555	chr16:88793112	FAM38A	-1.38	-13.78	-0.6	1.66e-34	Plateletcrit;
LUSC	trans	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg10756647	chr7:56101905	PSPH	0.83	9.4	0.46	8.92e-19	Diabetic kidney disease;
LUSC	cis	rs4853525	0.859	rs1882396	chr2:191716012	T/G	cg11845111	chr2:191398756	TMEM194B	-0.42	-6.18	-0.32	1.91e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs78707713	0.512	rs12772559	chr10:71184356	C/G	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.65	-0.47	1.34e-19	Venous thromboembolism;
LUSC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03576123	chr11:487126	PTDSS2	-0.95	-10.54	-0.5	1.29e-22	Body mass index;
LUSC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg05347473	chr6:146136440	FBXO30	0.51	8.31	0.41	2.46e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	6.05	0.31	3.93e-9	Tonsillectomy;
LUSC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg18230493	chr5:56204884	C5orf35	0.58	9.2	0.45	3.92e-18	Coronary artery disease;
LUSC	cis	rs11030122	0.702	rs12223176	chr11:3982537	T/G	cg18678763	chr11:4115507	RRM1	-0.47	-6.0	-0.31	5.25e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.27e-31	Prudent dietary pattern;
LUSC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.57	-8.65	-0.43	2.21e-16	Lymphocyte counts;
LUSC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg22815214	chr1:201083145	CACNA1S	-0.43	-5.88	-0.31	9.71e-9	Permanent tooth development;
LUSC	cis	rs57590327	0.555	rs3755713	chr3:81811224	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-10.25	-0.49	1.26e-21	Extraversion;
LUSC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg12927641	chr6:109611667	NA	0.43	7.41	0.38	1.05e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg12292205	chr6:26970375	C6orf41	0.51	8.56	0.42	4.11e-16	Schizophrenia;
LUSC	cis	rs4499344	0.623	rs259278	chr19:33161126	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.97	16.49	0.67	4.1e-45	Mean platelet volume;
LUSC	cis	rs8092503	1.000	rs2014237	chr18:52494583	T/C	cg12377874	chr18:52495404	RAB27B	-0.34	-6.18	-0.32	1.9e-9	Childhood body mass index;
LUSC	cis	rs17253792	0.822	rs58589065	chr14:56152478	T/C	cg01858014	chr14:56050164	KTN1	-0.75	-6.59	-0.34	1.7e-10	Putamen volume;
LUSC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.49	0.42	6.97e-16	Prudent dietary pattern;
LUSC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	1.04	20.08	0.74	2.21e-59	Menopause (age at onset);
LUSC	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg23649088	chr2:200775458	C2orf69	-0.55	-6.52	-0.34	2.6e-10	Schizophrenia;
LUSC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.95	-20.09	-0.74	2e-59	Post bronchodilator FEV1;
LUSC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.58	-9.59	-0.46	2.11e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg22907277	chr7:1156413	C7orf50	0.72	7.61	0.38	2.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg02972257	chr16:68554789	NA	-0.53	-6.76	-0.35	6.31e-11	Ulcerative colitis;
LUSC	cis	rs113835537	0.569	rs17496586	chr11:66315512	G/C	cg24851651	chr11:66362959	CCS	0.51	7.41	0.38	1.03e-12	Airway imaging phenotypes;
LUSC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg21963583	chr11:68658836	MRPL21	0.58	9.11	0.45	7.56e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-7.85	-0.39	5.73e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9818941	0.824	rs2712325	chr3:157787473	G/C	cg08654915	chr3:157813417	NA	-0.34	-7.86	-0.4	5.32e-14	Height;
LUSC	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg06917634	chr15:78832804	PSMA4	-0.59	-7.17	-0.37	4.74e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg13535736	chr9:111863775	C9orf5	-0.41	-6.51	-0.34	2.72e-10	Menarche (age at onset);
LUSC	cis	rs11048434	0.736	rs1049925	chr12:9086898	A/G	cg13575925	chr12:9217583	LOC144571	0.32	5.8	0.3	1.53e-8	Sjögren's syndrome;
LUSC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.39	0.53	1.28e-25	Prudent dietary pattern;
LUSC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg17264618	chr3:40429014	ENTPD3	-0.33	-7.28	-0.37	2.4e-12	Renal cell carcinoma;
LUSC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg23711669	chr6:146136114	FBXO30	0.92	17.7	0.7	6.72e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4308124	0.708	rs28766030	chr2:111962429	T/C	cg04571233	chr2:111982156	NA	-0.5	-6.55	-0.34	2.11e-10	Vitiligo;
LUSC	cis	rs911119	0.913	rs12710327	chr20:23569689	C/T	cg16589663	chr20:23618590	CST3	0.62	7.35	0.37	1.54e-12	Chronic kidney disease;
LUSC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	trans	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.28	-0.32	1.05e-9	Neuroticism;
LUSC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg08499158	chr17:42289980	UBTF	-0.49	-8.31	-0.41	2.46e-15	Total body bone mineral density;
LUSC	cis	rs9811920	0.809	rs4928151	chr3:99767553	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.37	-7.0	-0.36	1.45e-11	Axial length;
LUSC	cis	rs11997175	0.546	rs1561913	chr8:33587002	A/T	ch.8.33884649F	chr8:33765107	NA	0.49	7.75	0.39	1.14e-13	Body mass index;
LUSC	cis	rs3820928	1.000	rs10204368	chr2:227774244	G/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.85	-0.39	5.89e-14	Pulmonary function;
LUSC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	8.87	0.44	4.57e-17	Menopause (age at onset);
LUSC	cis	rs3774830	0.748	rs7698146	chr4:5465476	G/A	cg26943120	chr4:5472116	STK32B	0.29	5.78	0.3	1.68e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9905704	0.708	rs304263	chr17:56749941	C/T	cg12560992	chr17:57184187	TRIM37	0.57	8.37	0.42	1.58e-15	Testicular germ cell tumor;
LUSC	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg00383909	chr3:49044727	WDR6	1.44	10.13	0.48	3.33e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg01528321	chr10:82214614	TSPAN14	1.03	16.28	0.67	2.76e-44	Post bronchodilator FEV1;
LUSC	cis	rs5009270	0.512	rs6977807	chr7:112249863	C/T	cg27282281	chr7:112262583	NA	0.44	6.04	0.31	4.07e-9	Osteoarthritis (hip);
LUSC	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg15654264	chr1:150340011	RPRD2	0.65	10.77	0.51	1.97e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	0.93	17.47	0.69	5.11e-49	Headache;
LUSC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.03	15.77	0.65	2.97e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.86e-9	Major depressive disorder;
LUSC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg12311346	chr5:56204834	C5orf35	-0.61	-9.45	-0.46	6.26e-19	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg24687543	chr11:63912206	MACROD1	0.46	5.73	0.3	2.24e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg00933542	chr6:150070202	PCMT1	0.28	5.74	0.3	2.08e-8	Lung cancer;
LUSC	cis	rs3862435	0.764	rs2283444	chr15:91002201	G/A	cg22089800	chr15:90895588	ZNF774	0.55	5.72	0.3	2.42e-8	Response to exercise (triglyceride level interaction);
LUSC	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.41	0.53	1.09e-25	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg10360139	chr7:1886902	MAD1L1	-0.44	-6.91	-0.35	2.42e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-9.41	-0.46	8.43e-19	Platelet distribution width;
LUSC	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg21775007	chr8:11205619	TDH	0.49	7.06	0.36	9.95e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg08213375	chr14:104286397	PPP1R13B	0.44	8.11	0.41	9.52e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.7e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11608355	0.597	rs12579285	chr12:109832712	T/C	cg19025524	chr12:109796872	NA	-0.46	-8.8	-0.43	7.27e-17	Neuroticism;
LUSC	cis	rs7597155	0.811	rs11126245	chr2:69975000	C/T	cg02498382	chr2:70120550	SNRNP27	-0.24	-5.77	-0.3	1.83e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg09509183	chr1:209979624	IRF6	0.48	5.78	0.3	1.7e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.73	0.39	1.29e-13	Iron status biomarkers;
LUSC	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.7	10.47	0.5	2.23e-22	Corneal astigmatism;
LUSC	cis	rs6005807	0.719	rs12166475	chr22:28860167	T/G	cg12565055	chr22:29076175	TTC28	0.57	5.93	0.31	7.42e-9	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.61	9.72	0.47	7.75e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg22508957	chr16:3507546	NAT15	0.42	5.99	0.31	5.34e-9	Body mass index (adult);
LUSC	cis	rs10875746	0.855	rs10875731	chr12:48432743	G/A	cg13454099	chr12:49076203	C12orf41	-0.5	-5.65	-0.3	3.48e-8	Longevity (90 years and older);
LUSC	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg04539111	chr16:67997858	SLC12A4	0.46	5.67	0.3	3.12e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9359856	0.623	rs7742602	chr6:90327385	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.83	-10.29	-0.49	9.05e-22	Bipolar disorder;
LUSC	cis	rs965469	0.843	rs6037597	chr20:3408374	A/G	cg25506879	chr20:3388711	C20orf194	-0.51	-6.04	-0.31	4.18e-9	IFN-related cytopenia;
LUSC	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.35	0.33	7.18e-10	Rheumatoid arthritis;
LUSC	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg12091567	chr17:66097778	LOC651250	-0.68	-9.13	-0.45	6.75e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg26380479	chr7:97908229	NA	-0.27	-6.14	-0.32	2.37e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg17178900	chr1:205818956	PM20D1	0.81	13.49	0.59	2.08e-33	Menarche (age at onset);
LUSC	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg04998671	chr14:104000505	TRMT61A	-0.39	-5.72	-0.3	2.42e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4073416	0.542	rs2411820	chr14:65946744	C/T	cg03016385	chr14:66212404	NA	-0.39	-5.97	-0.31	6.05e-9	N-glycan levels;
LUSC	cis	rs1107366	0.722	rs9851577	chr3:125908310	C/T	cg01346077	chr3:125931526	NA	0.35	6.58	0.34	1.84e-10	Metabolite levels;
LUSC	cis	rs4629180	1.000	rs4629180	chr2:102088370	G/A	cg01388757	chr2:102091195	RFX8	-0.45	-7.1	-0.36	7.61e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs17092148	1.000	rs57131731	chr20:33392739	C/T	cg16810054	chr20:33298113	TP53INP2	0.43	6.81	0.35	4.68e-11	Neuroticism;
LUSC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg20811857	chr17:78079795	GAA	0.37	6.39	0.33	5.54e-10	Yeast infection;
LUSC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg14552801	chr7:65878734	NA	-0.45	-6.48	-0.33	3.25e-10	Aortic root size;
LUSC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.81	0.35	4.68e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.37	-5.92	-0.31	8.1e-9	Response to antipsychotic treatment;
LUSC	cis	rs45535039	0.506	rs2511856	chr11:119144148	A/C	cg16724696	chr11:118992527	HINFP	-0.52	-7.15	-0.36	5.47e-12	Plateletcrit;
LUSC	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg00757033	chr12:89920650	WDR51B	0.51	8.93	0.44	3.01e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.45	0.38	8.31e-13	Colorectal cancer;
LUSC	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg23280166	chr11:118938394	VPS11	-0.48	-7.72	-0.39	1.33e-13	Coronary artery disease;
LUSC	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg16339924	chr4:17578868	LAP3	0.49	7.53	0.38	4.83e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.04	0.58	1.07e-31	Chronic sinus infection;
LUSC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.39	0.67	1.04e-44	Platelet count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12165782	chr19:1675947	NA	-0.42	-6.01	-0.31	4.88e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg02772935	chr3:125709198	NA	-0.49	-5.92	-0.31	7.84e-9	Blood pressure (smoking interaction);
LUSC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg02574844	chr11:5959923	NA	-0.41	-6.34	-0.33	7.42e-10	DNA methylation (variation);
LUSC	cis	rs9921338	0.887	rs6498183	chr16:11430908	C/T	cg00044050	chr16:11439710	C16orf75	-0.51	-6.78	-0.35	5.47e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg23649088	chr2:200775458	C2orf69	0.53	7.23	0.37	3.26e-12	Schizophrenia;
LUSC	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.47	10.38	0.49	4.45e-22	Airflow obstruction;
LUSC	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg17031739	chr1:67600172	NA	-0.46	-7.27	-0.37	2.51e-12	Psoriasis;
LUSC	cis	rs952623	0.649	rs6462887	chr7:39067636	A/G	cg15212455	chr7:39170539	POU6F2	0.37	6.04	0.31	4.14e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs57590327	0.612	rs820272	chr3:81554345	T/C	cg07356753	chr3:81810745	GBE1	0.48	5.95	0.31	6.82e-9	Extraversion;
LUSC	cis	rs877282	0.853	rs7092652	chr10:756109	G/A	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs28647808	0.881	rs4962047	chr9:136262916	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs2274273	0.840	rs2341622	chr14:55737243	C/A	cg04306507	chr14:55594613	LGALS3	0.56	13.2	0.59	2.66e-32	Protein biomarker;
LUSC	cis	rs308403	0.600	rs309364	chr4:123658859	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.77	-10.59	-0.5	8.73e-23	Blood protein levels;
LUSC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg14552801	chr7:65878734	NA	0.43	5.89	0.31	9.32e-9	Aortic root size;
LUSC	cis	rs5167	0.677	rs12709889	chr19:45453239	A/G	cg25746394	chr19:45450501	APOC2	-0.31	-5.94	-0.31	7.27e-9	Blood protein levels;
LUSC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.37	-0.33	6.13e-10	Total body bone mineral density;
LUSC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.69	-11.54	-0.53	3.77e-26	Systemic lupus erythematosus;
LUSC	cis	rs5009270	0.512	rs1024411	chr7:112247692	G/A	cg27282281	chr7:112262583	NA	0.44	5.96	0.31	6.49e-9	Osteoarthritis (hip);
LUSC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08439880	chr3:133502540	NA	0.38	6.68	0.34	9.95e-11	Iron status biomarkers;
LUSC	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg04310649	chr10:35416472	CREM	-0.42	-6.45	-0.33	3.9e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg20302533	chr7:39170763	POU6F2	0.48	7.73	0.39	1.25e-13	IgG glycosylation;
LUSC	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.5	0.34	2.86e-10	Schizophrenia;
LUSC	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.57	-0.46	2.5e-19	Systolic blood pressure;
LUSC	cis	rs7771547	0.605	rs659726	chr6:36467791	C/G	cg07856975	chr6:36356162	ETV7	0.38	6.65	0.34	1.2e-10	Platelet distribution width;
LUSC	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg00579200	chr11:133705235	NA	0.4	5.86	0.31	1.13e-8	Childhood ear infection;
LUSC	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg09998033	chr7:158218633	PTPRN2	-0.6	-9.67	-0.47	1.16e-19	Obesity-related traits;
LUSC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg04450456	chr4:17643702	FAM184B	0.35	5.8	0.3	1.56e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.92	18.2	0.71	6.58e-52	Menarche (age at onset);
LUSC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.4e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	10.24	0.49	1.35e-21	Menarche (age at onset);
LUSC	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg00792783	chr2:198669748	PLCL1	0.43	5.87	0.31	1.04e-8	Dermatomyositis;
LUSC	trans	rs3942852	0.910	rs11603850	chr11:48140900	G/A	cg15704280	chr7:45808275	SEPT13	-0.56	-6.38	-0.33	6.07e-10	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs12210905	0.925	rs7740207	chr6:27001623	C/T	cg11837749	chr1:55047332	ACOT11	0.56	6.07	0.32	3.42e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.51	-0.38	5.49e-13	Longevity;Endometriosis;
LUSC	trans	rs61931739	0.635	rs4442626	chr12:33912530	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.75	0.39	1.1e-13	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15076191	chr7:75677508	STYXL1;MDH2	-0.4	-5.97	-0.31	6.15e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.4	-5.75	-0.3	2.02e-8	Platelet count;
LUSC	cis	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg09307838	chr4:120376055	NA	0.46	6.92	0.35	2.25e-11	Diastolic blood pressure;
LUSC	cis	rs983392	0.631	rs7107627	chr11:60041296	T/A	cg20284999	chr11:59952153	MS4A6A	0.39	6.43	0.33	4.45e-10	Alzheimer's disease (late onset);
LUSC	cis	rs56283067	0.847	rs1552196	chr6:44698265	A/G	cg18551225	chr6:44695536	NA	0.39	6.4	0.33	5.35e-10	Total body bone mineral density;
LUSC	cis	rs7131987	0.650	rs7973786	chr12:29462744	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.63	-0.34	1.38e-10	QT interval;
LUSC	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-10.8	-0.51	1.6e-23	Mean corpuscular volume;
LUSC	trans	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-13.47	-0.59	2.5e-33	Brugada syndrome;
LUSC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg16447950	chr5:562315	NA	0.52	9.1	0.45	8.36e-18	Obesity-related traits;
LUSC	cis	rs67366981	1.000	rs17105547	chr14:77698358	G/A	cg22824376	chr14:77648248	TMEM63C	0.82	7.49	0.38	6.41e-13	Obsessive-compulsive symptoms;
LUSC	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg25930673	chr12:123319894	HIP1R	-0.72	-7.27	-0.37	2.57e-12	Schizophrenia;
LUSC	cis	rs1021993	0.597	rs17014320	chr1:209512173	T/C	cg24446417	chr1:209558027	NA	-0.35	-5.73	-0.3	2.25e-8	Gut microbiome composition (winter);
LUSC	trans	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-8.98	-0.44	2.05e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.93	15.74	0.65	3.9e-42	Bladder cancer;
LUSC	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.71	11.53	0.53	3.92e-26	Retinal vascular caliber;
LUSC	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg17986701	chr20:44574422	PCIF1	0.37	6.55	0.34	2.22e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2063714	0.967	rs9322586	chr6:157195220	T/C	cg23222435	chr6:157204239	ARID1B	-0.49	-7.92	-0.4	3.55e-14	Sitting height ratio;
LUSC	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.68	-0.39	1.83e-13	Height;
LUSC	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-8.72	-0.43	1.29e-16	Morning vs. evening chronotype;
LUSC	cis	rs4561483	0.583	rs11645213	chr16:11942924	C/A	cg08843971	chr16:11963173	GSPT1	0.39	5.95	0.31	6.85e-9	Testicular germ cell tumor;
LUSC	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg20628663	chr10:43360327	NA	-0.76	-11.4	-0.53	1.23e-25	Blood protein levels;
LUSC	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	12.63	0.57	3.62e-30	Electrocardiographic conduction measures;
LUSC	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg17507749	chr15:85114479	UBE2QP1	0.67	8.58	0.43	3.57e-16	Schizophrenia;
LUSC	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg13072238	chr3:49761600	GMPPB	-0.4	-6.49	-0.33	3.1e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg16447950	chr5:562315	NA	-0.58	-7.11	-0.36	7.26e-12	Obesity-related traits;
LUSC	cis	rs1030877	0.515	rs2576742	chr2:105898822	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.67	9.19	0.45	4.29e-18	Obesity-related traits;
LUSC	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.67	-0.39	1.9e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10754283	0.967	rs2390763	chr1:90105688	A/G	cg21401794	chr1:90099060	LRRC8C	0.65	9.8	0.47	4.22e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs10193935	0.901	rs222483	chr2:42652184	T/G	cg27598129	chr2:42591480	NA	-0.61	-8.32	-0.41	2.34e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg06197492	chr11:2016605	H19	0.42	6.91	0.35	2.52e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs8114671	0.647	rs6060267	chr20:33734012	A/G	cg24642439	chr20:33292090	TP53INP2	0.4	5.74	0.3	2.08e-8	Height;
LUSC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	13.63	0.6	6.19e-34	Platelet count;
LUSC	cis	rs9473147	0.516	rs9395283	chr6:47551444	T/C	cg02130027	chr6:47444894	CD2AP	0.35	5.76	0.3	1.92e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg11062466	chr8:58055876	NA	0.51	6.7	0.34	8.73e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg18187862	chr3:45730750	SACM1L	-0.51	-6.27	-0.32	1.1e-9	Primary sclerosing cholangitis;
LUSC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.39	0.37	1.23e-12	Motion sickness;
LUSC	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg06207120	chr15:45996521	NA	0.39	6.09	0.32	3.08e-9	Waist circumference;Weight;
LUSC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg06096015	chr1:231504339	EGLN1	0.58	10.37	0.49	5e-22	Hemoglobin concentration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26022992	chr1:145507616	RBM8A	0.42	6.05	0.31	3.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg12179176	chr11:130786555	SNX19	0.87	14.66	0.63	6.69e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.47	6.99	0.36	1.53e-11	Endometrial cancer;
LUSC	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg26727032	chr16:67993705	SLC12A4	-0.41	-6.48	-0.33	3.21e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs747782	0.646	rs61914719	chr11:48059091	C/T	cg20307385	chr11:47447363	PSMC3	-0.64	-5.64	-0.3	3.54e-8	Intraocular pressure;
LUSC	cis	rs3755132	0.929	rs3770471	chr2:15770775	C/T	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10802521	chr3:52805072	NEK4	-0.53	-7.61	-0.38	2.88e-13	Bipolar disorder;
LUSC	cis	rs9807989	0.839	rs4988957	chr2:102968075	C/T	cg03938978	chr2:103052716	IL18RAP	-0.31	-5.72	-0.3	2.33e-8	Asthma;
LUSC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.77	13.86	0.6	8.2e-35	Aortic root size;
LUSC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.14	-0.36	5.86e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg26338869	chr17:61819248	STRADA	0.41	5.94	0.31	7.17e-9	Prudent dietary pattern;
LUSC	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg00376283	chr12:123451042	ABCB9	-0.55	-7.38	-0.37	1.24e-12	Neutrophil percentage of white cells;
LUSC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-0.96	-14.14	-0.61	6.9e-36	Initial pursuit acceleration;
LUSC	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg24006582	chr15:45444508	DUOX1	-0.61	-9.01	-0.44	1.56e-17	Uric acid levels;
LUSC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg11871910	chr12:69753446	YEATS4	0.61	9.0	0.44	1.72e-17	Response to diuretic therapy;
LUSC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.67	-0.43	1.84e-16	Lung cancer;
LUSC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg13722127	chr7:150037890	RARRES2	0.38	5.66	0.3	3.29e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10802521	chr3:52805072	NEK4	0.48	8.04	0.4	1.62e-14	Electroencephalogram traits;
LUSC	trans	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg26043149	chr18:55253948	FECH	0.48	7.41	0.38	1.03e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs240764	0.853	rs4461738	chr6:100977940	T/C	cg09795085	chr6:101329169	ASCC3	-0.41	-5.91	-0.31	8.42e-9	Neuroticism;
LUSC	cis	rs9625935	0.957	rs36604	chr22:30340138	C/A	cg11564601	chr22:30592435	NA	0.38	5.66	0.3	3.18e-8	Tonsillectomy;
LUSC	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg20628663	chr10:43360327	NA	-0.76	-11.4	-0.53	1.23e-25	Blood protein levels;
LUSC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg08888203	chr3:10149979	C3orf24	0.57	8.06	0.4	1.33e-14	Alzheimer's disease;
LUSC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg06212747	chr3:49208901	KLHDC8B	0.46	6.45	0.33	3.87e-10	Parkinson's disease;
LUSC	cis	rs7202877	0.561	rs4888369	chr16:75307277	T/C	cg03315344	chr16:75512273	CHST6	0.47	6.72	0.35	7.69e-11	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg09462578	chr12:12878428	APOLD1	-0.53	-6.38	-0.33	6e-10	Systemic lupus erythematosus;
LUSC	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg06937882	chr20:24974362	C20orf3	-0.44	-7.67	-0.39	1.89e-13	Blood protein levels;
LUSC	cis	rs36093844	0.800	rs79276445	chr11:85587827	G/T	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs2281558	0.876	rs6107025	chr20:25279880	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.62	9.26	0.45	2.46e-18	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg09455208	chr3:40491958	NA	0.57	10.18	0.49	2.19e-21	Renal cell carcinoma;
LUSC	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg20487152	chr13:99095054	FARP1	-0.43	-7.65	-0.39	2.18e-13	Longevity;
LUSC	trans	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg07393940	chr7:158741817	NA	-0.37	-6.52	-0.34	2.55e-10	Life satisfaction;
LUSC	cis	rs9815354	0.638	rs56008529	chr3:42026755	A/T	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg08917208	chr2:24149416	ATAD2B	1.02	10.65	0.5	5.21e-23	Lymphocyte counts;
LUSC	cis	rs4589502	0.588	rs12438505	chr15:67213830	C/G	cg09911534	chr15:67153556	NA	0.42	5.72	0.3	2.31e-8	Lung cancer (smoking interaction);
LUSC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg21770322	chr7:97807741	LMTK2	0.4	6.88	0.35	2.89e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs75920871	0.588	rs7101763	chr11:116941985	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-6.74	-0.35	6.96e-11	Subjective well-being;
LUSC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg01879757	chr17:41196368	BRCA1	-0.46	-7.0	-0.36	1.42e-11	Menopause (age at onset);
LUSC	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg23950597	chr19:37808831	NA	-0.65	-7.63	-0.39	2.41e-13	Coronary artery calcification;
LUSC	cis	rs17092148	1.000	rs6088594	chr20:33343157	A/G	cg16810054	chr20:33298113	TP53INP2	0.4	6.37	0.33	6.28e-10	Neuroticism;
LUSC	cis	rs2274273	0.837	rs7148171	chr14:55770744	G/C	cg04306507	chr14:55594613	LGALS3	0.56	13.23	0.59	2.05e-32	Protein biomarker;
LUSC	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg25205988	chr1:146714368	CHD1L	1.07	12.63	0.57	3.82e-30	Mitochondrial DNA levels;
LUSC	cis	rs55665837	1.000	rs11023227	chr11:14459087	T/C	cg05501817	chr11:14380813	RRAS2	-0.41	-6.51	-0.34	2.72e-10	Vitamin D levels;
LUSC	cis	rs9815354	0.812	rs59476821	chr3:41946481	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.49	0.42	6.81e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2414856	0.510	rs72756998	chr15:64609871	T/C	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg09640425	chr7:158790006	NA	-0.45	-6.95	-0.36	1.91e-11	Facial morphology (factor 20);
LUSC	cis	rs6845621	0.745	rs1914606	chr4:18851242	C/T	cg12196642	chr4:18937545	NA	0.32	5.87	0.31	1.04e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg00376283	chr12:123451042	ABCB9	0.66	8.29	0.41	2.81e-15	Neutrophil percentage of white cells;
LUSC	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg02503808	chr4:7069936	GRPEL1	0.45	6.51	0.34	2.77e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg10578777	chr12:7781093	NA	0.56	6.11	0.32	2.82e-9	HDL cholesterol levels;
LUSC	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg06784218	chr1:46089804	CCDC17	0.3	5.95	0.31	6.92e-9	Red blood cell count;Reticulocyte count;
LUSC	trans	rs7939886	0.920	rs12226441	chr11:55867822	G/A	cg15704280	chr7:45808275	SEPT13	0.79	6.65	0.34	1.23e-10	Myopia (pathological);
LUSC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg14196790	chr5:131705035	SLC22A5	0.42	7.12	0.36	6.49e-12	Blood metabolite levels;
LUSC	cis	rs6906287	0.647	rs11153752	chr6:118834771	A/T	cg21191810	chr6:118973309	C6orf204	0.32	5.83	0.3	1.27e-8	Electrocardiographic conduction measures;
LUSC	cis	rs9513627	1.000	rs7322368	chr13:100213990	T/C	cg25919922	chr13:100150906	NA	0.83	6.62	0.34	1.39e-10	Obesity-related traits;
LUSC	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.39	0.49	4.22e-22	Colorectal cancer;
LUSC	cis	rs7091068	0.706	rs620043	chr10:95405257	T/C	cg20715218	chr10:95462985	C10orf4	-0.6	-6.09	-0.32	3.15e-9	Urinary tract infection frequency;
LUSC	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.57	-0.34	1.94e-10	Response to antipsychotic treatment;
LUSC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.24	-0.32	1.3e-9	Bipolar disorder;
LUSC	cis	rs752010	0.695	rs10789407	chr1:42106538	G/T	cg06885757	chr1:42089581	HIVEP3	0.44	8.59	0.43	3.36e-16	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.66	11.12	0.52	1.15e-24	Total body bone mineral density;
LUSC	cis	rs2607426	0.581	rs2545763	chr19:41307170	G/A	cg05508168	chr19:41255947	C19orf54;SNRPA	0.95	6.43	0.33	4.35e-10	Blood protein levels;
LUSC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	11.75	0.54	6.68e-27	Menopause (age at onset);
LUSC	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg11584989	chr19:19387371	SF4	0.59	6.99	0.36	1.46e-11	Bipolar disorder;
LUSC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg08847533	chr14:75593920	NEK9	-0.83	-15.44	-0.65	5.86e-41	Height;
LUSC	cis	rs1712517	0.771	rs10883858	chr10:105127708	G/A	cg05636881	chr10:105038444	INA	0.4	6.74	0.35	7.02e-11	Migraine;
LUSC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg12463550	chr7:65579703	CRCP	-0.49	-7.02	-0.36	1.24e-11	Aortic root size;
LUSC	cis	rs829883	0.664	rs829876	chr12:98842138	A/G	cg25150519	chr12:98850993	NA	0.8	13.63	0.6	6.18e-34	Colorectal adenoma (advanced);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21008671	chr4:26322419	RBPJ	-0.41	-6.06	-0.31	3.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg05925327	chr15:68127851	NA	-0.43	-6.82	-0.35	4.18e-11	Obesity;
LUSC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg00310523	chr12:86230176	RASSF9	0.51	9.65	0.47	1.33e-19	Major depressive disorder;
LUSC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg18230493	chr5:56204884	C5orf35	-0.92	-13.85	-0.6	8.41e-35	Initial pursuit acceleration;
LUSC	cis	rs3755132	0.929	rs4668454	chr2:15740128	A/C	cg12888861	chr2:15731646	DDX1	0.5	7.34	0.37	1.68e-12	Wilms tumor;
LUSC	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg17691542	chr6:26056736	HIST1H1C	0.47	6.93	0.35	2.18e-11	Height;
LUSC	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg16576597	chr16:28551801	NUPR1	0.28	5.69	0.3	2.76e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.62	0.38	2.61e-13	Prudent dietary pattern;
LUSC	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg20587970	chr11:113659929	NA	-1.35	-19.08	-0.72	2.06e-55	Hip circumference adjusted for BMI;
LUSC	cis	rs1712517	0.904	rs7905968	chr10:105135319	C/T	cg05636881	chr10:105038444	INA	0.4	6.59	0.34	1.7e-10	Migraine;
LUSC	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.45	0.5	2.65e-22	Bladder cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23296058	chr5:86708877	CCNH	-0.49	-6.44	-0.33	4.22e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg27411982	chr8:10470053	RP1L1	0.42	6.32	0.33	8.54e-10	Monocyte count;
LUSC	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	11.57	0.53	3e-26	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6494488	0.500	rs67533952	chr15:65024574	G/C	cg08069370	chr15:64387884	SNX1	-0.61	-5.76	-0.3	1.92e-8	Coronary artery disease;
LUSC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.51	0.34	2.78e-10	Lung cancer;
LUSC	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-10.71	-0.51	3.27e-23	Pancreatic cancer;
LUSC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02353165	chr6:42928485	GNMT	0.68	11.84	0.54	3.07e-27	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9644630	0.897	rs13266857	chr8:19364515	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.34	-5.88	-0.31	1e-8	Oropharynx cancer;
LUSC	cis	rs7178375	0.607	rs12903674	chr15:31194552	G/C	cg15020726	chr15:31196382	MTMR15	0.9	7.46	0.38	7.57e-13	Hypertriglyceridemia;
LUSC	cis	rs6733011	0.600	rs1568213	chr2:99432063	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.79	-0.3	1.58e-8	Bipolar disorder;
LUSC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg11502198	chr6:26597334	ABT1	0.75	11.72	0.54	8.53e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-17.32	-0.69	2.1e-48	Coronary artery disease;
LUSC	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg07828024	chr6:149772892	ZC3H12D	0.33	6.92	0.35	2.27e-11	Dupuytren's disease;
LUSC	cis	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg06521331	chr12:34319734	NA	-0.47	-7.66	-0.39	2.08e-13	Morning vs. evening chronotype;
LUSC	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg22532475	chr10:104410764	TRIM8	-0.32	-7.09	-0.36	8.12e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.08	0.52	1.71e-24	Hypertriglyceridemia;
LUSC	cis	rs250677	0.524	rs40521	chr5:148439639	C/T	cg18129178	chr5:148520854	ABLIM3	0.57	9.73	0.47	7.22e-20	Breast cancer;
LUSC	cis	rs10887741	0.606	rs3824722	chr10:89435723	C/G	cg13926569	chr10:89418898	PAPSS2	0.32	6.86	0.35	3.27e-11	Exercise (leisure time);
LUSC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.3	-6.0	-0.31	5.09e-9	Lymphocyte counts;
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg09704166	chr2:114031854	PAX8;LOC440839	0.46	7.77	0.39	9.93e-14	Lymphocyte counts;
LUSC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08645402	chr16:4508243	NA	0.55	9.44	0.46	6.49e-19	Schizophrenia;
LUSC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	0.98	13.57	0.6	1.03e-33	Vitiligo;
LUSC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg16479474	chr6:28041457	NA	0.31	5.76	0.3	1.88e-8	Parkinson's disease;
LUSC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg24101359	chr6:42928495	GNMT	0.38	6.35	0.33	6.9e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs727505	0.954	rs67870530	chr7:124591878	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.9	-0.35	2.56e-11	Lewy body disease;
LUSC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg06238570	chr21:40685208	BRWD1	-0.59	-9.38	-0.46	1.06e-18	Menarche (age at onset);
LUSC	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg24375607	chr4:120327624	NA	0.79	11.95	0.55	1.24e-27	Corneal astigmatism;
LUSC	cis	rs9549260	0.755	rs2701869	chr13:41157372	G/A	cg21288729	chr13:41239152	FOXO1	0.61	9.43	0.46	7.1e-19	Red blood cell count;
LUSC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg05535760	chr7:792225	HEATR2	0.81	9.45	0.46	6.31e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.73	-11.22	-0.52	5.11e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-9.14	-0.45	6.4e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg20476274	chr7:133979776	SLC35B4	0.79	13.87	0.6	7.39e-35	Mean platelet volume;
LUSC	cis	rs34891900	0.507	rs12167771	chr22:18124332	G/A	cg19898043	chr22:18121309	BCL2L13	0.41	6.26	0.32	1.18e-9	Sum neutrophil eosinophil counts;
LUSC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg18512352	chr11:47633146	NA	-0.46	-9.47	-0.46	5.09e-19	Subjective well-being;
LUSC	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-6.49	-0.33	3.14e-10	Monocyte percentage of white cells;
LUSC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg04944784	chr2:26401820	FAM59B	-0.72	-10.74	-0.51	2.55e-23	Gut microbiome composition (summer);
LUSC	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.77	12.76	0.57	1.2e-30	Metabolic syndrome;
LUSC	cis	rs73200209	0.744	rs41452748	chr12:116509432	A/T	cg01776926	chr12:116560359	MED13L	-0.49	-5.92	-0.31	7.8e-9	Total body bone mineral density;
LUSC	cis	rs3106136	0.546	rs2276910	chr4:95129238	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.71	-0.34	8.37e-11	Capecitabine sensitivity;
LUSC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg18135555	chr8:22132992	PIWIL2	0.38	7.65	0.39	2.17e-13	Hypertriglyceridemia;
LUSC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg20607798	chr8:58055168	NA	0.53	5.78	0.3	1.73e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg21782813	chr7:2030301	MAD1L1	0.43	7.28	0.37	2.41e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg23978390	chr7:1156363	C7orf50	0.5	5.8	0.3	1.57e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs3771570	1.000	rs17386555	chr2:242371825	G/A	cg21155796	chr2:242212141	HDLBP	0.61	6.67	0.34	1.05e-10	Prostate cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg11835582	chr4:175205044	FBXO8;KIAA1712	0.42	6.79	0.35	5.28e-11	Triglycerides;
LUSC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg08847533	chr14:75593920	NEK9	0.84	15.27	0.64	2.63e-40	Height;
LUSC	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-17.78	-0.7	3.02e-50	Primary sclerosing cholangitis;
LUSC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	1.1	16.06	0.66	2.03e-43	Blood trace element (Zn levels);
LUSC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.36	5.79	0.3	1.64e-8	Menopause (age at onset);
LUSC	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg04586622	chr2:25135609	ADCY3	-0.39	-8.12	-0.41	8.8e-15	Body mass index;
LUSC	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg13010199	chr12:38710504	ALG10B	0.71	10.93	0.51	5.63e-24	Bladder cancer;
LUSC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg24596788	chr1:163392923	NA	-0.4	-6.88	-0.35	2.9100000000000002e-11	Motion sickness;
LUSC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	7.07	0.36	9.07e-12	Schizophrenia;
LUSC	cis	rs61935443	0.832	rs11107768	chr12:95274182	A/T	cg21533806	chr12:95267307	NA	-0.55	-6.99	-0.36	1.48e-11	Schizophrenia;
LUSC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-12.22	-0.56	1.23e-28	Chronic sinus infection;
LUSC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.12	0.36	6.48e-12	Blood metabolite levels;
LUSC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18404041	chr3:52824283	ITIH1	-0.46	-8.23	-0.41	4.26e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg25703541	chr22:24373054	LOC391322	-0.87	-14.04	-0.61	1.57e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11958404	0.932	rs56065211	chr5:157439386	C/T	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21862992	chr11:68658383	NA	-0.51	-8.18	-0.41	5.99e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	trans	rs7713972	0.588	rs13181692	chr5:40607998	A/G	cg01842719	chr2:241658550	KIF1A	0.46	6.02	0.31	4.67e-9	Blood protein levels;
LUSC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg24562669	chr7:97807699	LMTK2	0.36	6.27	0.32	1.15e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg10909506	chr17:38081995	ORMDL3	0.34	6.15	0.32	2.26e-9	Self-reported allergy;
LUSC	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.42	-0.46	7.56e-19	Total cholesterol levels;
LUSC	cis	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10397063	chr6:136611015	BCLAF1	-0.4	-5.99	-0.31	5.29e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg25319279	chr11:5960081	NA	-0.45	-6.41	-0.33	4.99e-10	DNA methylation (variation);
LUSC	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg01973587	chr1:228161476	NA	0.47	8.55	0.42	4.63e-16	Diastolic blood pressure;
LUSC	cis	rs9341835	0.772	rs4445042	chr6:64139997	C/T	cg03326410	chr6:64151739	NA	-0.36	-5.79	-0.3	1.6e-8	Schizophrenia;
LUSC	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.6	-11.81	-0.54	3.82e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs10221833	0.602	rs355882	chr2:165633761	T/C	cg26993132	chr16:89239499	CDH15	0.31	5.97	0.31	6.09e-9	Response to statin therapy;
LUSC	trans	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.17	-0.32	1.99e-9	Depression;
LUSC	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.27e-8	Breast cancer;
LUSC	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.02e-21	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.57	-0.38	3.74e-13	Neuroticism;
LUSC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Parkinson's disease;
LUSC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs11608355	0.515	rs11613718	chr12:109912332	C/T	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.85	-0.44	5.26e-17	Gut microbiome composition (summer);
LUSC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11645453	chr3:52864694	ITIH4	0.35	8.43	0.42	1.08e-15	Bipolar disorder;
LUSC	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg19743168	chr1:23544995	NA	0.46	9.2	0.45	3.87e-18	Height;
LUSC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10193935	0.681	rs13396880	chr2:42374700	G/T	cg27598129	chr2:42591480	NA	-0.6	-7.32	-0.37	1.83e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg21724239	chr8:58056113	NA	0.59	7.28	0.37	2.48e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6060717	0.610	rs2794382	chr20:34613651	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.34	-0.33	7.64e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs8017423	1.000	rs10129210	chr14:90668379	G/T	cg04374321	chr14:90722782	PSMC1	0.7	10.83	0.51	1.25e-23	Mortality in heart failure;
LUSC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.65	10.64	0.5	5.7e-23	Bone mineral density;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12317151	chr18:3012764	LPIN2	0.92	7.33	0.37	1.71e-12	Cognitive performance;
LUSC	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.22e-15	Neuroticism;
LUSC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg04944784	chr2:26401820	FAM59B	0.7	9.12	0.45	7.24e-18	Gut microbiome composition (summer);
LUSC	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg05901451	chr6:126070800	HEY2	-0.54	-7.77	-0.39	9.45e-14	High light scatter reticulocyte count;
LUSC	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg00495681	chr13:53174319	NA	0.52	7.64	0.39	2.25e-13	Lewy body disease;
LUSC	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg23649088	chr2:200775458	C2orf69	-0.54	-6.53	-0.34	2.39e-10	Schizophrenia;
LUSC	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.53	8.93	0.44	2.85e-17	IgG glycosylation;
LUSC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg25428297	chr7:1022841	CYP2W1	0.28	5.69	0.3	2.78e-8	Longevity;Endometriosis;
LUSC	cis	rs11958404	0.932	rs55943686	chr5:157439591	G/C	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg22777020	chr22:31556080	RNF185	-0.5	-6.85	-0.35	3.65e-11	Paclitaxel-induced neuropathy;
LUSC	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg03732007	chr1:2071316	PRKCZ	0.47	7.61	0.38	2.85e-13	Height;
LUSC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg05313129	chr8:58192883	C8orf71	-0.49	-6.77	-0.35	5.9e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6489882	0.867	rs7134391	chr12:113366691	A/G	cg20102336	chr12:113376681	OAS3	0.41	6.07	0.32	3.55e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg01028140	chr2:1542097	TPO	-0.6	-8.23	-0.41	4.3e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs12200782	1.000	rs6456741	chr6:26617058	C/T	cg11502198	chr6:26597334	ABT1	-0.76	-5.8	-0.3	1.53e-8	Small cell lung carcinoma;
LUSC	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.53	-0.34	2.41e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg21211680	chr2:198530	NA	-0.53	-6.53	-0.34	2.39e-10	Blood protein levels;
LUSC	cis	rs9928842	0.771	rs4888363	chr16:75277344	A/T	cg09066997	chr16:75300724	BCAR1	0.5	6.66	0.34	1.1e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs6087990	0.806	rs875041	chr20:31383530	C/T	cg13636640	chr20:31349939	DNMT3B	0.92	18.96	0.72	6.33e-55	Ulcerative colitis;
LUSC	cis	rs2281558	0.793	rs6115227	chr20:25591377	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.6	8.83	0.44	5.9e-17	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg05283184	chr6:79620031	NA	-0.57	-12.12	-0.55	2.99e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg21211680	chr2:198530	NA	0.73	7.58	0.38	3.37e-13	Blood protein levels;
LUSC	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	9.13	0.45	6.54e-18	Lymphocyte counts;Red cell distribution width;
LUSC	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg25206134	chr2:45395956	NA	-0.5	-6.26	-0.32	1.21e-9	Bipolar disorder;
LUSC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-10.8	-0.51	1.64e-23	Schizophrenia;
LUSC	cis	rs9942416	0.660	rs17649055	chr5:74984269	C/T	cg19683494	chr5:74908142	NA	0.41	6.32	0.33	8.61e-10	Age-related disease endophenotypes;
LUSC	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-17.52	-0.69	3.22e-49	Exhaled nitric oxide output;
LUSC	trans	rs7951105	1.000	rs976910	chr11:39247626	G/A	cg24085930	chr3:21832523	NA	0.49	6.06	0.31	3.58e-9	Free thyroxine concentration;
LUSC	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg01475377	chr6:109611718	NA	-0.4	-7.16	-0.36	5.27e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg03806693	chr22:41940476	POLR3H	-0.54	-7.42	-0.38	1.01e-12	Neuroticism;
LUSC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.63	9.18	0.45	4.62e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs3824867	0.920	rs7130693	chr11:47452321	T/C	cg20307385	chr11:47447363	PSMC3	-0.65	-9.65	-0.47	1.35e-19	Mean corpuscular hemoglobin;
LUSC	trans	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg25214090	chr10:38739885	LOC399744	0.48	7.26	0.37	2.7e-12	Corneal astigmatism;
LUSC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg20295408	chr7:1910781	MAD1L1	0.4	5.74	0.3	2.12e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-7.44	-0.38	8.32e-13	Schizophrenia;
LUSC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08219700	chr8:58056026	NA	0.64	7.5	0.38	5.68e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg03929089	chr4:120376271	NA	0.72	6.77	0.35	5.71e-11	Axial length;
LUSC	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg07506560	chr2:240697449	NA	0.45	7.16	0.36	5.23e-12	Obesity-related traits;
LUSC	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg15556689	chr8:8085844	FLJ10661	0.52	7.86	0.4	5.21e-14	Myopia (pathological);
LUSC	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg16928487	chr17:17741425	SREBF1	0.47	9.31	0.45	1.78e-18	Total body bone mineral density;
LUSC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	14.34	0.62	1.1e-36	Tonsillectomy;
LUSC	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg12856521	chr11:46389249	DGKZ	0.47	6.77	0.35	5.74e-11	Leprosy;
LUSC	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg08079166	chr15:68083412	MAP2K5	0.33	5.78	0.3	1.74e-8	Obesity;
LUSC	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.4	0.38	1.11e-12	Lung cancer in ever smokers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04021745	chr1:236445389	ERO1LB	-0.43	-6.12	-0.32	2.62e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4654899	0.802	rs1530946	chr1:21182540	A/G	cg01072550	chr1:21505969	NA	0.44	6.54	0.34	2.26e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg23711669	chr6:146136114	FBXO30	0.87	16.34	0.67	1.68e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg08854313	chr1:11322531	MTOR	0.8	12.45	0.56	1.6800000000000001e-29	Body mass index;
LUSC	cis	rs7122539	0.646	rs9633985	chr11:66520608	A/T	cg24851651	chr11:66362959	CCS	0.47	7.58	0.38	3.43e-13	HIV-1 susceptibility;
LUSC	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg27147174	chr7:100797783	AP1S1	-0.58	-9.15	-0.45	5.86e-18	Life satisfaction;
LUSC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.52	-7.66	-0.39	2.03e-13	Blood protein levels;
LUSC	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg02569458	chr12:86230093	RASSF9	0.49	8.22	0.41	4.69e-15	Major depressive disorder;
LUSC	cis	rs3099143	1.000	rs10431768	chr15:77162158	A/G	cg21673338	chr15:77095150	SCAPER	0.79	7.51	0.38	5.28e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs8141797	0.901	rs5760201	chr22:24474704	A/G	cg00411358	chr22:24577142	SUSD2	-0.55	-5.74	-0.3	2.09e-8	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs7799006	0.691	rs10447541	chr7:2301578	T/G	cg12823233	chr7:2316876	SNX8	-0.46	-7.8	-0.39	7.86e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg06641503	chr3:48959341	ARIH2	-0.38	-5.88	-0.31	9.77e-9	Parkinson's disease;
LUSC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg21951975	chr1:209979733	IRF6	0.59	8.81	0.43	6.9e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.66	11.04	0.52	2.22e-24	Lymphocyte counts;
LUSC	cis	rs6504340	0.600	rs2325946	chr17:46584631	G/C	cg09704116	chr17:46666958	LOC404266	0.31	5.95	0.31	6.69e-9	Primary tooth development (number of teeth);
LUSC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.84	0.3	1.22e-8	Menopause (age at onset);
LUSC	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-6.76	-0.35	6.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg16898833	chr6:26189333	HIST1H4D	0.65	6.04	0.31	4.22e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.18	-0.32	1.84e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg11663144	chr21:46675770	NA	-0.34	-5.65	-0.3	3.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1499972	0.941	rs62264779	chr3:117654731	G/T	cg07612923	chr3:117604196	NA	0.65	6.05	0.31	3.94e-9	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg06784218	chr1:46089804	CCDC17	0.47	9.4	0.46	8.69e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg24250549	chr1:154909240	PMVK	0.66	11.06	0.52	2.01e-24	Prostate cancer;
LUSC	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg18196295	chr10:418757	DIP2C	-0.55	-9.33	-0.45	1.46e-18	Psychosis in Alzheimer's disease;
LUSC	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.45	-0.33	4e-10	Cutaneous nevi;
LUSC	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-0.6	-9.3	-0.45	1.87e-18	Breast cancer;
LUSC	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.63	10.87	0.51	8.88e-24	Schizophrenia;
LUSC	cis	rs2573652	1.000	rs2727196	chr15:100513529	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.4	-7.38	-0.37	1.23e-12	Height;
LUSC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7572644	0.582	rs7570730	chr2:28022675	G/A	cg27432699	chr2:27873401	GPN1	0.56	7.36	0.37	1.46e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg19694781	chr19:47549865	TMEM160	0.59	9.54	0.46	3.02e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-6.5	-0.33	2.98e-10	Colorectal cancer;
LUSC	cis	rs96067	0.805	rs4653160	chr1:36599547	C/T	cg24686825	chr1:36642396	MAP7D1	-0.42	-5.84	-0.3	1.21e-8	Corneal structure;
LUSC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-0.97	-16.84	-0.68	1.74e-46	Body mass index;
LUSC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	1.17	15.97	0.66	4.58e-43	Eosinophil percentage of granulocytes;
LUSC	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg23992470	chr4:843637	GAK	0.6	6.4	0.33	5.14e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs953492	0.624	rs4469702	chr1:243365196	T/C	cg25284624	chr1:224180302	NA	-0.48	-7.4	-0.38	1.12e-12	Diastolic blood pressure;
LUSC	cis	rs17818399	0.735	rs11894342	chr2:46836439	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.42	-6.21	-0.32	1.57e-9	Height;
LUSC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg16482183	chr6:26056742	HIST1H1C	0.56	8.34	0.42	2.02e-15	Height;
LUSC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.52	-6.09	-0.32	3.13e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.81	11.76	0.54	5.83e-27	Breast cancer;
LUSC	cis	rs9925964	0.933	rs12448321	chr16:31048280	C/T	cg02466173	chr16:30829666	NA	0.36	6.57	0.34	1.91e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1784581	0.500	rs9355379	chr6:162421466	C/T	cg17173639	chr6:162384350	PARK2	0.66	9.04	0.44	1.28e-17	Itch intensity from mosquito bite;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	10.87	0.51	9.4e-24	Lymphocyte counts;
LUSC	cis	rs2273669	0.667	rs10457185	chr6:109322477	G/C	cg05315195	chr6:109294784	ARMC2	-0.56	-6.21	-0.32	1.54e-9	Prostate cancer;
LUSC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg05347473	chr6:146136440	FBXO30	-0.49	-8.27	-0.41	3.29e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7590720	1.000	rs4674058	chr2:216909368	A/G	cg12620499	chr2:216877984	MREG	0.92	13.47	0.59	2.46e-33	Alcohol dependence;
LUSC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg06640241	chr16:89574553	SPG7	0.72	11.79	0.54	4.73e-27	Multiple myeloma (IgH translocation);
LUSC	cis	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.53	-0.34	2.43e-10	Morning vs. evening chronotype;
LUSC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg06618935	chr21:46677482	NA	-0.39	-8.11	-0.41	9.92e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs17092148	1.000	rs1884432	chr20:33342439	A/G	cg16810054	chr20:33298113	TP53INP2	-0.37	-5.72	-0.3	2.32e-8	Neuroticism;
LUSC	cis	rs11587682	0.714	rs41264059	chr1:150460842	A/C	cg11822372	chr1:151115635	SEMA6C	-0.42	-5.71	-0.3	2.53e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg17187183	chr4:55093834	PDGFRA	0.39	5.84	0.3	1.25e-8	Corneal astigmatism;
LUSC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg05082376	chr22:42548792	NA	-0.39	-5.77	-0.3	1.77e-8	Schizophrenia;
LUSC	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg23029597	chr12:123009494	RSRC2	0.75	9.5	0.46	4.15e-19	Body mass index;
LUSC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06850241	chr22:41845214	NA	0.34	6.3	0.33	9.5e-10	Vitiligo;
LUSC	cis	rs72799341	1.000	rs7200879	chr16:30947572	A/G	cg02466173	chr16:30829666	NA	-0.51	-7.79	-0.39	8.48e-14	Diastolic blood pressure;
LUSC	cis	rs11645898	0.872	rs72787093	chr16:72190766	C/T	cg14768367	chr16:72042858	DHODH	-0.67	-7.32	-0.37	1.82e-12	Blood protein levels;
LUSC	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg14169450	chr9:139327907	INPP5E	0.43	7.6	0.38	3e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7680126	0.586	rs7689060	chr4:10305463	C/G	cg26043149	chr18:55253948	FECH	0.48	6.01	0.31	4.81e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUSC	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg06096015	chr1:231504339	EGLN1	0.56	9.88	0.48	2.27e-20	Hemoglobin concentration;
LUSC	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-10.96	-0.51	4.43e-24	Heart rate;
LUSC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.36	-6.2	-0.32	1.66e-9	Longevity;Endometriosis;
LUSC	cis	rs13401104	0.680	rs11894606	chr2:237114834	T/G	cg19324714	chr2:237145437	ASB18	0.43	5.87	0.31	1.06e-8	Educational attainment;
LUSC	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-6.81	-0.35	4.57e-11	Insulin-like growth factors;
LUSC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg20821713	chr7:1055600	C7orf50	-0.47	-7.58	-0.38	3.45e-13	Longevity;Endometriosis;
LUSC	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	0.93	17.02	0.68	3.36e-47	Headache;
LUSC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	12.0	0.55	7.98e-28	Prudent dietary pattern;
LUSC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg01097406	chr16:89675127	NA	0.3	5.69	0.3	2.85e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.27	-0.45	2.34e-18	Acne (severe);
LUSC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg04733989	chr22:42467013	NAGA	0.62	9.62	0.47	1.73e-19	Schizophrenia;
LUSC	trans	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.2	-0.41	5.37e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.81	0.43	7.03e-17	Prudent dietary pattern;
LUSC	cis	rs9296092	0.538	rs9461879	chr6:33516907	C/T	cg13560919	chr6:33536144	NA	-0.82	-15.66	-0.65	7.89e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg11663144	chr21:46675770	NA	-0.42	-7.25	-0.37	2.93e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg22903657	chr4:1355424	KIAA1530	-0.41	-7.17	-0.37	4.77e-12	Longevity;
LUSC	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg00376283	chr12:123451042	ABCB9	-0.72	-8.23	-0.41	4.37e-15	Neutrophil percentage of white cells;
LUSC	cis	rs3733418	0.929	rs12512234	chr4:165908865	C/T	cg11630554	chr4:165878136	TRIM61;C4orf39	-0.51	-5.83	-0.3	1.34e-8	Obesity-related traits;
LUSC	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg03806693	chr22:41940476	POLR3H	0.86	12.69	0.57	2.2e-30	Vitiligo;
LUSC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg13939156	chr17:80058883	NA	-0.32	-6.37	-0.33	6.34e-10	Life satisfaction;
LUSC	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg01989461	chr14:81687754	GTF2A1	0.74	13.65	0.6	4.98e-34	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg11062466	chr8:58055876	NA	0.72	8.66	0.43	2.02e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg07507251	chr3:52567010	NT5DC2	0.37	7.63	0.39	2.48e-13	Electroencephalogram traits;
LUSC	cis	rs4363385	0.567	rs7551791	chr1:153024267	A/T	cg25856811	chr1:152973957	SPRR3	-0.37	-6.06	-0.31	3.63e-9	Inflammatory skin disease;
LUSC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg24250549	chr1:154909240	PMVK	0.6	9.43	0.46	7.15e-19	Prostate cancer;
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg00106254	chr7:1943704	MAD1L1	-0.4	-5.81	-0.3	1.42e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	0.76	14.83	0.63	1.37e-38	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg27068330	chr11:65405492	SIPA1	0.64	9.66	0.47	1.28e-19	Acne (severe);
LUSC	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg00383909	chr3:49044727	WDR6	1.14	10.61	0.5	7.19e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	0.98	13.46	0.59	2.73e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg24450063	chr1:156163899	SLC25A44	1.03	8.59	0.43	3.31e-16	Paclitaxel disposition in epithelial ovarian cancer;
LUSC	cis	rs5771225	0.544	rs13055135	chr22:50672479	A/G	cg16473166	chr22:50639996	SELO	0.69	9.51	0.46	4e-19	Late-onset Alzheimer's disease;
LUSC	cis	rs10740039	0.883	rs6479722	chr10:62417681	A/G	cg18175470	chr10:62150864	ANK3	-0.43	-6.79	-0.35	5.23e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg04827223	chr11:72435913	ARAP1	-0.67	-8.39	-0.42	1.37e-15	Type 2 diabetes;
LUSC	cis	rs926938	0.527	rs1391484	chr1:115522366	A/G	cg12756093	chr1:115239321	AMPD1	0.46	7.0	0.36	1.43e-11	Autism;
LUSC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14829155	chr15:31115871	NA	-0.57	-7.96	-0.4	2.7e-14	Huntington's disease progression;
LUSC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	8.09e-13	Motion sickness;
LUSC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg07061783	chr6:25882402	NA	-0.37	-5.87	-0.31	1.04e-8	Blood metabolite levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14791866	chr10:82168295	C10orf58	-0.39	-5.96	-0.31	6.27e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24549020	chr5:56110836	MAP3K1	0.49	5.71	0.3	2.48e-8	Initial pursuit acceleration;
LUSC	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg23202291	chr11:1979235	NA	0.49	7.81	0.39	7.62e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10864318	chr6:117002220	KPNA5	0.46	6.33	0.33	8.03e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12620999	0.941	rs7593758	chr2:237980920	G/T	cg23555395	chr2:238036564	NA	-0.47	-8.52	-0.42	5.69e-16	Systemic lupus erythematosus;
LUSC	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg10253484	chr15:75165896	SCAMP2	-0.51	-6.72	-0.35	7.86e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-9.79	-0.47	4.54e-20	Monocyte count;
LUSC	cis	rs4919687	0.550	rs7904396	chr10:104456838	C/T	cg04362960	chr10:104952993	NT5C2	0.44	6.35	0.33	7.1e-10	Colorectal cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00710617	chr20:50808543	ZFP64	-0.43	-6.24	-0.32	1.33e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg19628046	chr18:33552617	C18orf21	0.51	6.11	0.32	2.76e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg04374321	chr14:90722782	PSMC1	0.77	12.24	0.56	1.01e-28	Mortality in heart failure;
LUSC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs34891900	0.507	rs2008085	chr22:18204316	T/G	cg19898043	chr22:18121309	BCL2L13	0.38	5.85	0.3	1.19e-8	Sum neutrophil eosinophil counts;
LUSC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg21132104	chr15:45694354	SPATA5L1	0.57	7.99	0.4	2.17e-14	Homoarginine levels;
LUSC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg12463550	chr7:65579703	CRCP	-0.55	-8.12	-0.41	9.02e-15	Aortic root size;
LUSC	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.34	-5.69	-0.3	2.73e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2932538	0.961	rs12126494	chr1:113228623	G/A	cg22162597	chr1:113214053	CAPZA1	0.7	9.79	0.47	4.76e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7267979	0.586	rs6050445	chr20:25195394	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.69	13.16	0.58	3.87e-32	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.52	-8.18	-0.41	6.03e-15	Melanoma;
LUSC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg04369109	chr6:150039330	LATS1	-0.6	-8.83	-0.43	6.2e-17	Lung cancer;
LUSC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs897984	0.806	rs11150600	chr16:30940331	C/T	cg02466173	chr16:30829666	NA	0.55	10.96	0.51	4.25e-24	Dementia with Lewy bodies;
LUSC	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-9.76	-0.47	6.01e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg11062466	chr8:58055876	NA	0.54	7.32	0.37	1.85e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg02023728	chr11:77925099	USP35	0.47	6.87	0.35	3.22e-11	Testicular germ cell tumor;
LUSC	trans	rs853679	0.517	rs868987	chr6:28110148	A/G	cg06606381	chr12:133084897	FBRSL1	0.45	6.23	0.32	1.4e-9	Depression;
LUSC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg04267008	chr7:1944627	MAD1L1	-0.46	-6.57	-0.34	1.96e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs2354432	0.607	rs6658763	chr1:146692373	C/T	cg25205988	chr1:146714368	CHD1L	-0.99	-8.79	-0.43	8.13e-17	Mitochondrial DNA levels;
LUSC	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.41	-6.49	-0.33	3.1e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg22532475	chr10:104410764	TRIM8	-0.25	-6.01	-0.31	4.97e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg10792982	chr14:105748885	BRF1	0.49	8.35	0.42	1.89e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg13798912	chr7:905769	UNC84A	-0.55	-5.7	-0.3	2.58e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06112835	chr11:68658793	MRPL21	0.5	7.87	0.4	4.85e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06112835	chr11:68658793	MRPL21	0.52	8.21	0.41	4.95e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4722404	0.800	rs10266726	chr7:3146081	C/T	cg19214707	chr7:3157722	NA	0.33	5.98	0.31	5.85e-9	Atopic dermatitis;
LUSC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg13685833	chr1:53393034	SCP2	0.45	6.61	0.34	1.49e-10	Monocyte count;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg10433910	chr8:145137259	GPAA1	0.5	6.12	0.32	2.61e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1358748	0.522	rs1830513	chr1:67575549	A/G	cg02640540	chr1:67518911	SLC35D1	0.63	6.1	0.32	2.9e-9	Tuberculosis;
LUSC	cis	rs7264396	0.561	rs2064725	chr20:34569142	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.76	-0.35	6.25e-11	Total cholesterol levels;
LUSC	cis	rs11997175	0.516	rs6981283	chr8:33619363	A/G	ch.8.33884649F	chr8:33765107	NA	0.51	8.15	0.41	7.39e-15	Body mass index;
LUSC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg27572855	chr1:25598939	RHD	0.41	7.27	0.37	2.55e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.33	-5.66	-0.3	3.21e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4845459	0.967	rs6700290	chr1:152592978	T/A	cg08895932	chr1:152778580	LCE1C	-0.38	-6.53	-0.34	2.46e-10	Psoriasis;
LUSC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg02807482	chr3:125708958	NA	-0.52	-6.49	-0.33	3.08e-10	Blood pressure (smoking interaction);
LUSC	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg13390004	chr1:15929781	NA	0.42	7.1	0.36	7.7e-12	Systolic blood pressure;
LUSC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg03433033	chr1:76189801	ACADM	0.73	9.58	0.46	2.23e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	11.12	0.52	1.19e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-11.17	-0.52	8.06e-25	Bipolar disorder and schizophrenia;
LUSC	cis	rs9434723	0.920	rs11801562	chr1:9293156	G/A	cg04199779	chr1:9294473	H6PD	0.59	6.56	0.34	2.07e-10	Height;
LUSC	cis	rs1670533	1.000	rs2290410	chr4:1052078	A/T	cg02018176	chr4:1364513	KIAA1530	0.46	6.29	0.33	9.78e-10	Recombination rate (females);
LUSC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6087990	0.899	rs1333469	chr20:31361249	C/T	cg13636640	chr20:31349939	DNMT3B	1.0	22.63	0.78	2.14e-69	Ulcerative colitis;
LUSC	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	7.67	0.39	1.93e-13	Reticulocyte count;
LUSC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.33	6.25	0.32	1.25e-9	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg24006582	chr15:45444508	DUOX1	-0.61	-8.95	-0.44	2.44e-17	Uric acid levels;
LUSC	cis	rs7950696	1	rs7950696	chr11:47481533	T/C	cg20307385	chr11:47447363	PSMC3	0.44	6.35	0.33	7.02e-10	Platelet count;
LUSC	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.26e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18404041	chr3:52824283	ITIH1	-0.5	-9.49	-0.46	4.7e-19	Electroencephalogram traits;
LUSC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.74	-0.39	1.21e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg10756647	chr7:56101905	PSPH	-0.83	-8.3	-0.41	2.64e-15	Diabetic kidney disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03309838	chr22:41215494	SLC25A17	0.44	6.99	0.36	1.47e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	8.82	0.43	6.32e-17	Menarche (age at onset);
LUSC	trans	rs1456305	0.514	rs4571699	chr8:128099269	A/G	cg22517681	chr1:24995876	SRRM1	0.65	7.39	0.37	1.21e-12	Prostate cancer;
LUSC	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.79	11.36	0.53	1.63e-25	Corneal astigmatism;
LUSC	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg00509249	chr6:109615579	CCDC162	-0.34	-5.97	-0.31	5.97e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08677398	chr8:58056175	NA	0.58	6.95	0.36	1.96e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg01989461	chr14:81687754	GTF2A1	0.74	13.65	0.6	5.14e-34	Schizophrenia;
LUSC	cis	rs7011049	1.000	rs72640865	chr8:53842471	C/T	cg26025543	chr8:53854495	NA	0.53	6.4	0.33	5.18e-10	Systolic blood pressure;
LUSC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06850241	chr22:41845214	NA	-0.32	-6.02	-0.31	4.52e-9	Vitiligo;
LUSC	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.9	0.61	5.49e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7246967	0.673	rs4932782	chr19:22812801	A/G	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs926392	0.965	rs714108	chr20:37687838	G/A	cg27552599	chr20:37590471	DHX35	0.33	5.64	0.3	3.56e-8	Dialysis-related mortality;
LUSC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg03605463	chr16:89740564	NA	0.59	9.26	0.45	2.57e-18	Vitiligo;
LUSC	cis	rs7210086	0.821	rs3935123	chr17:70641183	C/T	cg04206342	chr17:70636940	NA	0.36	6.23	0.32	1.39e-9	Ulcerative colitis;
LUSC	cis	rs3820068	0.626	rs11580170	chr1:15909744	C/T	cg17385448	chr1:15911702	AGMAT	0.37	6.0	0.31	5.16e-9	Systolic blood pressure;
LUSC	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.93	15.6	0.65	1.38e-41	Bladder cancer;
LUSC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg14440974	chr22:39074834	NA	-0.35	-5.84	-0.3	1.26e-8	Menopause (age at onset);
LUSC	cis	rs1572072	0.762	rs9510775	chr13:24129102	C/G	cg24350296	chr13:24144486	TNFRSF19	-0.3	-5.76	-0.3	1.93e-8	Nasopharyngeal carcinoma;
LUSC	cis	rs2625529	0.652	rs8023788	chr15:72459847	A/G	cg16672083	chr15:72433130	SENP8	0.48	7.92	0.4	3.5e-14	Red blood cell count;
LUSC	cis	rs2290159	0.706	rs6442319	chr3:12647029	G/A	cg23032965	chr3:12705835	RAF1	0.74	8.96	0.44	2.42e-17	Cholesterol, total;
LUSC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	7.99	0.4	2.2e-14	Menarche (age at onset);
LUSC	trans	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.42	6.55	0.34	2.21e-10	Cystic fibrosis severity;
LUSC	trans	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.02	13.99	0.61	2.52e-35	Exhaled nitric oxide levels;
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.3	7.53	0.38	4.93e-13	Lymphocyte counts;
LUSC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg16447950	chr5:562315	NA	-0.57	-6.94	-0.36	2.02e-11	Obesity-related traits;
LUSC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg23172400	chr8:95962367	TP53INP1	-0.39	-7.88	-0.4	4.63e-14	Type 2 diabetes;
LUSC	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.8	0.3	1.56e-8	Lymphocyte counts;
LUSC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg08470875	chr2:26401718	FAM59B	-0.69	-9.19	-0.45	4.4e-18	Gut microbiome composition (summer);
LUSC	cis	rs6906287	0.631	rs2798321	chr6:118991602	G/T	cg21191810	chr6:118973309	C6orf204	0.33	6.05	0.31	3.95e-9	Electrocardiographic conduction measures;
LUSC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18876405	chr7:65276391	NA	-0.54	-8.5	-0.42	6.26e-16	Aortic root size;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg05702448	chr1:167905194	DCAF6;BRP44	0.34	6.16	0.32	2.03e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs12545109	0.879	rs2670015	chr8:57376607	T/A	cg09654669	chr8:57350985	NA	-0.57	-7.46	-0.38	7.7e-13	Obesity-related traits;
LUSC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.89	15.49	0.65	3.73e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg03340356	chr1:67600835	NA	0.43	6.71	0.34	8.16e-11	Psoriasis;
LUSC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg04450456	chr4:17643702	FAM184B	0.38	6.55	0.34	2.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2230307	0.536	rs700533	chr1:100483822	A/G	cg24955406	chr1:100503596	HIAT1	0.57	6.14	0.32	2.35e-9	Carotid intima media thickness;
LUSC	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg08000102	chr2:233561755	GIGYF2	0.68	11.43	0.53	9.24e-26	Coronary artery disease;
LUSC	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg18904891	chr8:8559673	CLDN23	-0.4	-5.97	-0.31	6.22e-9	Neuroticism;
LUSC	cis	rs11608355	0.545	rs4766475	chr12:109908373	G/A	cg05360138	chr12:110035743	NA	0.89	11.55	0.53	3.47e-26	Neuroticism;
LUSC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg08132940	chr7:1081526	C7orf50	-0.46	-5.7	-0.3	2.59e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.81	-0.3	1.47e-8	Tonsillectomy;
LUSC	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg15704280	chr7:45808275	SEPT13	0.65	7.19	0.37	4.24e-12	Axial length;
LUSC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06221963	chr1:154839813	KCNN3	-0.62	-13.89	-0.61	6.01e-35	Prostate cancer;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg09412528	chr12:98987242	SLC25A3	0.49	5.94	0.31	7.06e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg23505145	chr19:12996616	KLF1	0.65	10.98	0.51	3.66e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg16325326	chr1:53192061	ZYG11B	-0.71	-11.05	-0.52	2.05e-24	Monocyte count;
LUSC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	13.33	0.59	8.66e-33	Monocyte percentage of white cells;
LUSC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.71	10.04	0.48	6.73e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs2048656	0.605	rs7837008	chr8:9646506	T/C	cg06636001	chr8:8085503	FLJ10661	0.45	6.3	0.33	9.56e-10	Schizophrenia;
LUSC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg14552801	chr7:65878734	NA	0.38	5.91	0.31	8.29e-9	Aortic root size;
LUSC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.59	-0.46	2.15e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg15432903	chr11:17409602	KCNJ11	0.46	7.83	0.39	6.69e-14	Type 2 diabetes;
LUSC	cis	rs3126085	0.935	rs11204939	chr1:152200942	G/C	cg03465714	chr1:152285911	FLG	-0.41	-5.86	-0.31	1.09e-8	Atopic dermatitis;
LUSC	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	cis	rs4474465	0.850	rs4482052	chr11:78263331	A/G	cg27205649	chr11:78285834	NARS2	0.52	6.13	0.32	2.45e-9	Alzheimer's disease (survival time);
LUSC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.86	-0.35	3.28e-11	Total body bone mineral density;
LUSC	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg25214090	chr10:38739885	LOC399744	0.57	8.42	0.42	1.14e-15	Corneal astigmatism;
LUSC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.54	-8.54	-0.42	4.75e-16	Obesity-related traits;
LUSC	cis	rs7759001	0.857	rs9468115	chr6:27363587	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.66	0.3	3.26e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.14	-0.36	5.89e-12	Blood metabolite levels;
LUSC	cis	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg05299278	chr17:33885742	SLFN14	0.29	6.44	0.33	4.11e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg02117656	chr17:79614917	TSPAN10	0.32	5.81	0.3	1.46e-8	Eye color traits;
LUSC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg14159672	chr1:205819179	PM20D1	0.47	6.75	0.35	6.45e-11	Prostate-specific antigen levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18895155	chr7:99214691	ZNF498	0.39	5.98	0.31	5.81e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12493885	0.872	rs9840371	chr3:153796829	C/T	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg10811474	chr19:8428787	ANGPTL4	-0.39	-5.97	-0.31	6.16e-9	HDL cholesterol;
LUSC	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.55	8.23	0.41	4.13e-15	Cognitive test performance;
LUSC	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg16950941	chr11:66035639	RAB1B	0.53	7.8	0.39	7.82e-14	Gout;
LUSC	cis	rs55665837	1.000	rs10047429	chr11:14439032	C/T	cg05501817	chr11:14380813	RRAS2	-0.41	-6.61	-0.34	1.51e-10	Vitamin D levels;
LUSC	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg21300267	chr1:26547059	NA	-0.24	-5.66	-0.3	3.3e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg27398817	chr8:82754497	SNX16	-0.54	-7.65	-0.39	2.13e-13	Diastolic blood pressure;
LUSC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg13685833	chr1:53393034	SCP2	0.4	6.0	0.31	5.27e-9	Monocyte count;
LUSC	cis	rs6681460	1.000	rs6588207	chr1:67066555	A/G	cg02459107	chr1:67143332	SGIP1	0.48	8.93	0.44	2.91e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs73206853	0.640	rs871921	chr12:111115113	G/C	cg12870014	chr12:110450643	ANKRD13A	0.75	9.66	0.47	1.3e-19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7959663	1	rs7959663	chr12:109884367	G/C	cg05360138	chr12:110035743	NA	0.67	9.11	0.45	7.65e-18	Bipolar disorder lithium response (categorical) or schizophrenia;
LUSC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg01579765	chr21:45077557	HSF2BP	0.55	11.3	0.53	2.72e-25	Mean corpuscular volume;
LUSC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	9.05	0.44	1.25e-17	Total body bone mineral density;
LUSC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg07157834	chr1:205819609	PM20D1	-0.42	-5.69	-0.3	2.85e-8	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg20243544	chr17:37824526	PNMT	0.51	7.24	0.37	3.05e-12	Asthma;
LUSC	trans	rs7493	1.000	rs7493	chr7:95034775	C/G	cg23291145	chr4:41648620	LIMCH1	0.38	5.96	0.31	6.52e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11645453	chr3:52864694	ITIH4	-0.42	-10.35	-0.49	5.63e-22	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9463078	0.764	rs9357464	chr6:44952441	T/C	cg25276700	chr6:44698697	NA	-0.28	-5.85	-0.3	1.16e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg27432699	chr2:27873401	GPN1	0.57	8.67	0.43	1.92e-16	Total body bone mineral density;
LUSC	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-0.79	-11.77	-0.54	5.53e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.57e-8	Breast cancer;
LUSC	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg17411546	chr10:75410026	SYNPO2L	0.53	8.05	0.4	1.43e-14	Inflammatory bowel disease;
LUSC	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg05714579	chr10:131428358	MGMT	-0.66	-10.46	-0.5	2.39e-22	Response to temozolomide;
LUSC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12292205	chr6:26970375	C6orf41	-0.58	-7.35	-0.37	1.49e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7793919	0.726	rs4720401	chr7:4780943	G/A	cg00064840	chr7:4784485	FOXK1	0.31	5.88	0.31	9.82e-9	Mosquito bite size;
LUSC	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.24	0.37	3.02e-12	Iron status biomarkers;
LUSC	trans	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg17567195	chr5:167378696	ODZ2	-0.37	-5.97	-0.31	5.97e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs12692738	0.526	rs355873	chr2:165632464	T/C	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7107174	0.681	rs10899499	chr11:78124797	A/G	cg02023728	chr11:77925099	USP35	-0.45	-6.78	-0.35	5.42e-11	Testicular germ cell tumor;
LUSC	trans	rs2229238	0.911	rs11490956	chr1:154487258	G/T	cg25273160	chr11:56955011	LRRC55	0.32	6.23	0.32	1.44e-9	Coronary heart disease;
LUSC	cis	rs9304742	0.573	rs10415950	chr19:53465100	C/T	cg09915433	chr19:53449742	NA	-0.43	-6.9	-0.35	2.64e-11	Psoriasis;
LUSC	cis	rs17001868	0.568	rs10854729	chr22:40750612	T/C	cg07138101	chr22:40742427	ADSL	0.52	6.36	0.33	6.53e-10	Mammographic density (dense area);
LUSC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.36	0.56	3.74e-29	Cognitive test performance;
LUSC	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg17691542	chr6:26056736	HIST1H1C	0.57	7.92	0.4	3.62e-14	Iron status biomarkers;
LUSC	cis	rs12618769	0.597	rs4851142	chr2:99133611	A/C	cg10123293	chr2:99228465	UNC50	0.44	7.33	0.37	1.77e-12	Bipolar disorder;
LUSC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg00383909	chr3:49044727	WDR6	0.42	5.71	0.3	2.51e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	6.87	0.35	3.08e-11	Multiple sclerosis;
LUSC	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg00071950	chr4:10020882	SLC2A9	-0.57	-9.22	-0.45	3.33e-18	Bone mineral density;
LUSC	cis	rs2219968	1.000	rs6473084	chr8:78972524	T/C	cg00738934	chr8:78996279	NA	0.35	6.23	0.32	1.37e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7903847	0.642	rs7092499	chr10:99140313	A/G	cg08345082	chr10:99160200	RRP12	-0.34	-7.0	-0.36	1.37e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg00277334	chr10:82204260	NA	-0.49	-6.77	-0.35	5.89e-11	Post bronchodilator FEV1;
LUSC	trans	rs10221833	1.000	rs441414	chr2:165675693	A/G	cg04527071	chr11:1473128	BRSK2	-0.52	-6.16	-0.32	2.14e-9	Response to statin therapy;
LUSC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.12e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.08	-0.36	8.35e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg09184832	chr6:79620586	NA	-0.45	-7.29	-0.37	2.24e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg06636551	chr8:101224915	SPAG1	-0.39	-7.27	-0.37	2.64e-12	Atrioventricular conduction;
LUSC	cis	rs9652601	0.959	rs9746695	chr16:11207894	C/T	cg04616529	chr16:11181986	CLEC16A	-0.33	-5.68	-0.3	2.94e-8	Systemic lupus erythematosus;
LUSC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg12463550	chr7:65579703	CRCP	-0.55	-8.19	-0.41	5.55e-15	Aortic root size;
LUSC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg07414643	chr4:187882934	NA	-0.54	-10.28	-0.49	1.05e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.32e-11	Uric acid levels;
LUSC	cis	rs977987	0.736	rs11865296	chr16:75473693	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.23	-0.37	3.35e-12	Dupuytren's disease;
LUSC	cis	rs231513	0.954	rs231524	chr17:41953212	G/A	cg26893861	chr17:41843967	DUSP3	-0.51	-5.96	-0.31	6.5e-9	Cognitive function;
LUSC	cis	rs1160297	0.575	rs10865272	chr2:53093447	C/T	cg07782112	chr2:53107842	NA	0.37	6.23	0.32	1.38e-9	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24702147	chr12:7071814	MIR141;MIR200C	-0.24	-6.17	-0.32	1.95e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg17366294	chr4:99064904	C4orf37	0.54	9.54	0.46	3.1400000000000002e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs243505	0.668	rs2072406	chr7:148483760	G/A	cg09806900	chr7:148480153	CUL1	0.59	8.68	0.43	1.72e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	9.09	0.45	8.72e-18	Response to antipsychotic treatment;
LUSC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg06784218	chr1:46089804	CCDC17	0.48	9.49	0.46	4.5e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs4266144	0.592	rs1545854	chr3:156840138	A/G	cg14969094	chr3:156848003	NA	0.35	5.72	0.3	2.38e-8	Coronary artery disease;
LUSC	cis	rs7202877	0.706	rs8055609	chr16:75402088	C/T	cg03315344	chr16:75512273	CHST6	0.42	6.24	0.32	1.32e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.9	0.48	2e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-5.85	-0.3	1.16e-8	Systolic blood pressure;
LUSC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08945467	chr1:58522070	DAB1	0.48	6.06	0.31	3.65e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.46	-6.68	-0.34	1.02e-10	Breast cancer;
LUSC	cis	rs3820068	0.608	rs12091644	chr1:16044945	G/A	cg13390004	chr1:15929781	NA	0.42	6.64	0.34	1.3100000000000001e-10	Systolic blood pressure;
LUSC	trans	rs156356	0.811	rs552067	chr20:1823326	C/G	cg04365817	chr1:101491640	DPH5	0.43	6.15	0.32	2.16e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg07741184	chr6:167504864	NA	0.35	6.23	0.32	1.41e-9	Crohn's disease;
LUSC	cis	rs9653442	0.545	rs11123813	chr2:100765692	C/T	cg22139774	chr2:100720529	AFF3	-0.42	-7.32	-0.37	1.81e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs8141797	0.901	rs176157	chr22:24503987	C/T	cg00411358	chr22:24577142	SUSD2	-0.61	-6.3	-0.33	9.43e-10	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs75804782	0.641	rs1030786	chr2:239361150	A/G	cg18131467	chr2:239335373	ASB1	-0.72	-6.6	-0.34	1.64e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-7.17	-0.37	4.88e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg04362960	chr10:104952993	NT5C2	0.6	9.4	0.46	9.01e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1018697	0.518	rs2250301	chr10:104548393	G/A	cg04362960	chr10:104952993	NT5C2	-0.65	-7.65	-0.39	2.18e-13	Colorectal adenoma (advanced);
LUSC	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	1.01	21.83	0.77	2.97e-66	Platelet distribution width;
LUSC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.69	9.72	0.47	7.73e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg10560079	chr2:191398806	TMEM194B	-0.68	-8.64	-0.43	2.45e-16	Diastolic blood pressure;
LUSC	cis	rs7572644	0.640	rs4555299	chr2:28071190	A/G	cg27432699	chr2:27873401	GPN1	0.51	6.89	0.35	2.76e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.13	-0.32	2.51e-9	Resting heart rate;
LUSC	trans	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg26384229	chr12:38710491	ALG10B	0.57	9.05	0.44	1.24e-17	Morning vs. evening chronotype;
LUSC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg23630131	chr7:65973040	NA	-0.2	-5.73	-0.3	2.2e-8	Aortic root size;
LUSC	cis	rs6723226	0.721	rs3769600	chr2:32616879	G/A	cg02381751	chr2:32503542	YIPF4	-0.56	-8.68	-0.43	1.82e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg03732007	chr1:2071316	PRKCZ	0.48	7.76	0.39	1.05e-13	Height;
LUSC	cis	rs76878669	0.561	rs10750784	chr11:66110666	A/G	cg18002602	chr11:66138449	SLC29A2	-0.49	-8.75	-0.43	1.09e-16	Educational attainment (years of education);
LUSC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.49	0.38	6.36e-13	Bipolar disorder;
LUSC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg04756594	chr16:24857601	SLC5A11	0.34	5.66	0.3	3.25e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.8	0.39	8.05e-14	Gut microbiome composition (summer);
LUSC	cis	rs9473147	0.516	rs7749271	chr6:47485002	T/C	cg20196966	chr6:47445060	CD2AP	0.42	5.83	0.3	1.31e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18099408	chr3:52552593	STAB1	0.42	7.73	0.39	1.27e-13	Electroencephalogram traits;
LUSC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg09655341	chr17:79618100	PDE6G	0.3	7.0	0.36	1.45e-11	Eye color traits;
LUSC	trans	rs72834455	0.925	rs72834464	chr2:119517615	G/T	cg02397686	chr17:73851076	WBP2	-0.65	-6.09	-0.32	3.19e-9	Tonsillectomy;
LUSC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-8.12	-0.41	9.14e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg04455712	chr21:45112962	RRP1B	0.51	9.75	0.47	6.24e-20	Mean corpuscular volume;
LUSC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg21171335	chr12:122356390	WDR66	0.57	8.22	0.41	4.56e-15	Mean corpuscular volume;
LUSC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg09455208	chr3:40491958	NA	0.51	8.87	0.44	4.38e-17	Renal cell carcinoma;
LUSC	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg20283391	chr11:68216788	NA	0.61	8.47	0.42	7.8e-16	Total body bone mineral density;
LUSC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06544989	chr22:39130855	UNC84B	0.33	5.71	0.3	2.49e-8	Menopause (age at onset);
LUSC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg20887711	chr4:1340912	KIAA1530	0.46	7.04	0.36	1.07e-11	Obesity-related traits;
LUSC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-6.63	-0.34	1.3100000000000001e-10	Platelet count;
LUSC	cis	rs3741151	0.686	rs17132115	chr11:73264656	C/T	cg17517138	chr11:73019481	ARHGEF17	0.82	7.65	0.39	2.15e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	0.77	11.17	0.52	7.68e-25	Gut microbiome composition (summer);
LUSC	cis	rs367615	0.552	rs10042721	chr5:108713970	C/T	cg17395555	chr5:108820864	NA	-0.47	-8.2	-0.41	5.06e-15	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg04369109	chr6:150039330	LATS1	-0.6	-8.74	-0.43	1.16e-16	Lung cancer;
LUSC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg21361702	chr7:150065534	REPIN1	0.48	6.44	0.33	4.16e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7119	0.651	rs17394732	chr15:77835657	A/G	cg27398640	chr15:77910606	LINGO1	0.31	6.5	0.34	2.93e-10	Type 2 diabetes;
LUSC	cis	rs593982	0.843	rs680948	chr11:65472394	C/G	cg08755490	chr11:65554678	OVOL1	1.52	13.05	0.58	9.92e-32	Atopic dermatitis;
LUSC	trans	rs225245	0.817	rs225284	chr17:33933006	A/C	cg19694781	chr19:47549865	TMEM160	-0.44	-7.01	-0.36	1.29e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg18904891	chr8:8559673	CLDN23	0.6	8.23	0.41	4.27e-15	Obesity-related traits;
LUSC	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg22705602	chr4:152727874	NA	-0.3	-5.95	-0.31	6.96e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7131987	0.650	rs16934135	chr12:29483963	T/G	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.68	-0.34	9.9e-11	QT interval;
LUSC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg05313129	chr8:58192883	C8orf71	-0.51	-5.79	-0.3	1.62e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08704250	chr15:31115839	NA	-0.59	-9.24	-0.45	2.97e-18	Huntington's disease progression;
LUSC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg26441486	chr22:50317300	CRELD2	0.48	7.21	0.37	3.88e-12	Schizophrenia;
LUSC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07092213	chr7:1199455	ZFAND2A	0.43	6.66	0.34	1.14e-10	Longevity;Endometriosis;
LUSC	trans	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-6.8	-0.35	4.8e-11	Monocyte count;
LUSC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg13010199	chr12:38710504	ALG10B	0.67	9.99	0.48	9.58e-21	Bladder cancer;
LUSC	cis	rs2279817	0.913	rs11203436	chr1:18019016	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.54	6.96	0.36	1.85e-11	Neuroticism;
LUSC	cis	rs72781680	0.784	rs12616678	chr2:24181159	G/T	cg08917208	chr2:24149416	ATAD2B	0.6	6.94	0.35	2.07e-11	Lymphocyte counts;
LUSC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21016266	chr12:122356598	WDR66	-0.5	-7.33	-0.37	1.77e-12	Mean corpuscular volume;
LUSC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.51	-6.83	-0.35	4.14e-11	Tonsillectomy;
LUSC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06112835	chr11:68658793	MRPL21	0.49	7.59	0.38	3.21e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg06784218	chr1:46089804	CCDC17	0.52	10.14	0.49	2.96e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9462027	0.628	rs7769961	chr6:34760162	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.11e-8	Systemic lupus erythematosus;
LUSC	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg16558253	chr16:72132732	DHX38	-0.37	-5.79	-0.3	1.58e-8	Fibrinogen levels;
LUSC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg00431813	chr7:1051703	C7orf50	-0.45	-7.86	-0.39	5.5e-14	Longevity;Endometriosis;
LUSC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.29	-0.41	2.74e-15	Cystic fibrosis severity;
LUSC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg20283391	chr11:68216788	NA	0.54	8.21	0.41	4.74e-15	Total body bone mineral density;
LUSC	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg00540400	chr15:79124168	NA	0.48	8.41	0.42	1.25e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.89	-0.35	2.72e-11	Response to antipsychotic treatment;
LUSC	cis	rs7592578	0.603	rs12476782	chr2:191472880	G/A	cg10560079	chr2:191398806	TMEM194B	-0.52	-6.5	-0.33	2.98e-10	Diastolic blood pressure;
LUSC	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg03929089	chr4:120376271	NA	-0.79	-12.8	-0.57	8.41e-31	Height;
LUSC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02034447	chr16:89574710	SPG7	0.42	6.25	0.32	1.24e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg05373962	chr22:49881684	NA	-0.39	-8.25	-0.41	3.62e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1018836	0.923	rs2157607	chr8:91600268	A/G	cg16814680	chr8:91681699	NA	-0.77	-12.79	-0.57	9.61e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.56	-0.34	2.11e-10	Monocyte percentage of white cells;
LUSC	cis	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.76	-0.39	1.06e-13	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.18	0.55	1.79e-28	Motion sickness;
LUSC	cis	rs7727544	0.582	rs4361509	chr5:131536753	A/G	cg14196790	chr5:131705035	SLC22A5	-0.45	-7.51	-0.38	5.43e-13	Blood metabolite levels;
LUSC	trans	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.84	-0.35	3.74e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03713592	chr11:72463424	ARAP1	0.83	9.68	0.47	1.1e-19	Type 2 diabetes;
LUSC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg21782813	chr7:2030301	MAD1L1	0.36	5.84	0.3	1.27e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg12463550	chr7:65579703	CRCP	-0.52	-7.45	-0.38	8.2e-13	Aortic root size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23223044	chr19:49990882	RPL13AP5;RPL13A	0.43	6.29	0.33	1.02e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.89	15.63	0.65	1.03e-41	Metabolic syndrome;
LUSC	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg16230307	chr14:35515116	FAM177A1	0.78	10.15	0.49	2.9e-21	Psoriasis;
LUSC	cis	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg21775007	chr8:11205619	TDH	0.45	6.83	0.35	4.13e-11	Retinal vascular caliber;
LUSC	cis	rs2742417	1.000	rs1877933	chr3:45753487	C/T	cg09608765	chr3:45636137	LIMD1	-0.38	-7.53	-0.38	4.87e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg14668632	chr7:2872130	GNA12	-0.44	-6.44	-0.33	4.16e-10	Height;
LUSC	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg20701182	chr2:24300061	SF3B14	0.57	6.02	0.31	4.55e-9	Lymphocyte counts;
LUSC	cis	rs60154123	0.730	rs4844989	chr1:210460086	C/T	cg22029157	chr1:209979665	IRF6	0.52	5.81	0.3	1.46e-8	Coronary artery disease;
LUSC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.78	7.71	0.39	1.47e-13	Initial pursuit acceleration;
LUSC	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg09092052	chr15:45571596	NA	0.46	6.41	0.33	5.09e-10	Glomerular filtration rate;
LUSC	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg08999081	chr20:33150536	PIGU	-0.4	-7.35	-0.37	1.56e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs778371	0.676	rs4973563	chr2:233716421	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-12.26	-0.56	8.95e-29	Schizophrenia;
LUSC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.36e-10	Menopause (age at onset);
LUSC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.17	-0.32	1.98e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-1.05	-15.38	-0.64	9.96e-41	Initial pursuit acceleration;
LUSC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.35	0.42	1.82e-15	Lung cancer;
LUSC	trans	rs7939886	0.920	rs17149859	chr11:55795356	G/A	cg03929089	chr4:120376271	NA	0.74	6.25	0.32	1.29e-9	Myopia (pathological);
LUSC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg13047869	chr3:10149882	C3orf24	0.62	8.71	0.43	1.39e-16	Alzheimer's disease;
LUSC	cis	rs72634258	0.786	rs4268374	chr1:8174083	G/T	cg00042356	chr1:8021962	PARK7	-0.54	-6.6	-0.34	1.65e-10	Inflammatory bowel disease;
LUSC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg12927641	chr6:109611667	NA	-0.43	-7.62	-0.38	2.71e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs2425143	1.000	rs17093027	chr20:34319118	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.27	-0.32	1.14e-9	Blood protein levels;
LUSC	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-7.13	-0.36	6.32e-12	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.54	-0.34	2.36e-10	Endometrial cancer;
LUSC	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg08085267	chr17:45401833	C17orf57	-0.56	-9.09	-0.45	9.09e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	0.95	13.94	0.61	3.88e-35	Uric acid levels;
LUSC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17219203	chr10:38645113	HSD17B7P2	-0.52	-7.59	-0.38	3.13e-13	Breast cancer;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01516881	chr6:292596	DUSP22	-0.7	-11.12	-0.52	1.2e-24	Menopause (age at onset);
LUSC	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg14829155	chr15:31115871	NA	-0.54	-7.12	-0.36	6.62e-12	Huntington's disease progression;
LUSC	cis	rs652260	0.663	rs580984	chr19:7881030	C/T	cg26014689	chr19:7917955	EVI5L	-0.39	-6.1	-0.32	2.94e-9	Menarche (age at onset);
LUSC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.72	-0.43	1.32e-16	Bipolar disorder;
LUSC	cis	rs4356932	1.000	rs7688306	chr4:76982046	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.76	0.3	1.93e-8	Blood protein levels;
LUSC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg16447950	chr5:562315	NA	-0.58	-7.3	-0.37	2.1e-12	Obesity-related traits;
LUSC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	0.97	9.55	0.46	2.87e-19	Plasma clusterin levels;
LUSC	cis	rs2219968	1.000	rs7818353	chr8:78972826	C/A	cg00738934	chr8:78996279	NA	0.35	6.23	0.32	1.37e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-1.13	-15.1	-0.64	1.19e-39	Breast cancer;
LUSC	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg20302342	chr1:156215951	PAQR6	-0.32	-6.32	-0.33	8.34e-10	Tonsillectomy;
LUSC	cis	rs394563	0.601	rs391875	chr6:149795136	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.38	-7.93	-0.4	3.37e-14	Dupuytren's disease;
LUSC	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg13057898	chr1:3703894	LRRC47	0.52	8.86	0.44	4.96e-17	Red cell distribution width;
LUSC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.84	15.31	0.64	1.93e-40	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg07810366	chr2:100720526	AFF3	-0.41	-6.79	-0.35	5.24e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7712401	0.562	rs383638	chr5:122324678	A/C	cg19077854	chr5:122220652	SNX24	-0.43	-9.48	-0.46	4.83e-19	Mean platelet volume;
LUSC	cis	rs9807989	0.839	rs7603730	chr2:102974371	A/C	cg09003973	chr2:102972529	NA	0.43	5.88	0.31	9.84e-9	Asthma;
LUSC	cis	rs34421088	0.532	rs2736388	chr8:11159588	T/C	cg27411982	chr8:10470053	RP1L1	0.37	5.64	0.3	3.57e-8	Neuroticism;
LUSC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.72	-12.16	-0.55	2e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28735056	0.509	rs4799094	chr18:77621727	T/C	cg17174613	chr18:77631625	KCNG2	0.31	6.5	0.34	2.94e-10	Schizophrenia;
LUSC	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	22.76	0.78	6.44e-70	Colorectal cancer;
LUSC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg27432699	chr2:27873401	GPN1	-0.51	-7.42	-0.38	9.52e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.2	16.31	0.67	2.22e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg07636037	chr3:49044803	WDR6	0.57	6.07	0.32	3.39e-9	Menarche (age at onset);
LUSC	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.13	-0.36	6.22e-12	Major depressive disorder;
LUSC	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.62	-0.38	2.63e-13	Depression;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08172935	chr17:66244127	AMZ2	-0.43	-6.56	-0.34	2.02e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs68170813	0.617	rs10464499	chr7:107137571	C/T	cg24556660	chr7:106842632	COG5;HBP1	-0.46	-5.7	-0.3	2.7e-8	Coronary artery disease;
LUSC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg20821713	chr7:1055600	C7orf50	-0.38	-5.92	-0.31	7.85e-9	Longevity;Endometriosis;
LUSC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg24558204	chr6:135376177	HBS1L	-0.59	-8.67	-0.43	1.9e-16	High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg13042288	chr15:90349979	ANPEP	-0.46	-6.6	-0.34	1.63e-10	Uric acid levels;
LUSC	cis	rs12760731	0.565	rs12027396	chr1:178149200	T/C	cg00404053	chr1:178313656	RASAL2	0.66	6.8	0.35	4.85e-11	Obesity-related traits;
LUSC	cis	rs2979489	0.740	rs17554408	chr8:30427531	A/G	cg26383811	chr8:30366931	RBPMS	0.43	6.59	0.34	1.69e-10	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs4380275	1.000	rs4268954	chr2:772834	A/G	cg21665850	chr2:731073	NA	0.41	6.7	0.34	8.85e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21545522	chr1:205238299	TMCC2	0.5	9.3	0.45	1.9e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.5	7.73	0.39	1.3e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs11165623	0.765	rs11807955	chr1:96891623	C/T	cg10631902	chr5:14652156	NA	-0.56	-9.06	-0.44	1.11e-17	Hip circumference;Waist circumference;
LUSC	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06634786	chr22:41940651	POLR3H	0.49	5.72	0.3	2.38e-8	Vitiligo;
LUSC	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.55e-13	Putamen volume;
LUSC	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg00757033	chr12:89920650	WDR51B	0.59	10.22	0.49	1.69e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.52e-9	Menopause (age at onset);
LUSC	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg06636001	chr8:8085503	FLJ10661	0.48	6.57	0.34	1.96e-10	Neuroticism;
LUSC	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.85	-0.3	1.15e-8	Resting heart rate;
LUSC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.77	-0.35	5.93e-11	Menopause (age at onset);
LUSC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	12.59	0.57	5.35e-30	Cognitive ability;
LUSC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg11645453	chr3:52864694	ITIH4	-0.38	-8.84	-0.44	5.69e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg21704491	chr20:388519	RBCK1	0.37	6.09	0.32	3.04e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg23625390	chr15:77176239	SCAPER	0.48	7.28	0.37	2.37e-12	Blood metabolite levels;
LUSC	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	0.81	9.98	0.48	1.09e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg06008330	chr7:65541103	ASL	-0.4	-6.31	-0.33	8.86e-10	Aortic root size;
LUSC	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg08048268	chr3:133502702	NA	-0.37	-6.46	-0.33	3.74e-10	Iron status biomarkers;
LUSC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg03188948	chr7:1209495	NA	0.45	6.03	0.31	4.28e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.45	-0.33	3.93e-10	Arsenic metabolism;
LUSC	cis	rs4700695	0.719	rs27087	chr5:65453050	G/A	cg21114390	chr5:65439923	SFRS12	-0.63	-8.98	-0.44	2.07e-17	Facial morphology (factor 19);
LUSC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs35123781	1.000	rs601336	chr5:139057167	T/C	cg10513866	chr5:139070639	NA	0.46	8.9	0.44	3.62e-17	Schizophrenia;
LUSC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.8	-13.13	-0.58	4.83e-32	Aortic root size;
LUSC	cis	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg06521331	chr12:34319734	NA	-0.38	-5.69	-0.3	2.84e-8	Resting heart rate;
LUSC	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.74	14.55	0.62	1.7e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	7.72	0.39	1.36e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.79	0.39	8.76e-14	Parkinson's disease;
LUSC	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg15934090	chr1:100435551	SLC35A3	0.47	7.72	0.39	1.4e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23598886	chr18:12777645	NA	0.65	6.58	0.34	1.83e-10	Inflammatory skin disease;
LUSC	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.8	-0.43	7.38e-17	Response to antipsychotic treatment;
LUSC	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.71	10.85	0.51	1.08e-23	Smoking initiation;
LUSC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	33.83	0.88	6.29e-110	Chronic sinus infection;
LUSC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.69	0.3	2.71e-8	Personality dimensions;
LUSC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg04450456	chr4:17643702	FAM184B	0.39	6.78	0.35	5.59e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg22532475	chr10:104410764	TRIM8	0.26	6.16	0.32	2.1e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg10018233	chr7:150070692	REPIN1	0.34	6.01	0.31	4.93e-9	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17748167	chr1:31769917	ZCCHC17;SNRNP40	-0.53	-6.31	-0.33	8.79e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6977940	0.598	rs73033411	chr7:2881550	G/C	cg14895029	chr7:2775587	GNA12	0.51	5.91	0.31	8.61e-9	White matter integrity;
LUSC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg08773314	chr2:239334832	ASB1	0.42	9.26	0.45	2.6e-18	Multiple system atrophy;
LUSC	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg05985134	chr18:33552581	C18orf21	0.51	6.86	0.35	3.43e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs1493916	0.748	rs34501189	chr18:31314196	A/G	cg13755796	chr4:20253514	NA	-0.39	-6.06	-0.31	3.75e-9	Life satisfaction;
LUSC	cis	rs77633900	0.892	rs4489970	chr15:76631027	A/G	cg21673338	chr15:77095150	SCAPER	0.62	5.74	0.3	2.12e-8	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.15	0.64	7.62e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.27	-0.45	2.39e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg00321850	chr1:175162397	KIAA0040	0.44	7.63	0.39	2.46e-13	Alcohol dependence;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg26218726	chr12:122018391	KDM2B	0.42	6.17	0.32	1.94e-9	N-glycan levels;
LUSC	cis	rs12618769	0.543	rs72819980	chr2:99040522	A/G	cg10123293	chr2:99228465	UNC50	0.45	7.64	0.39	2.31e-13	Bipolar disorder;
LUSC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg25258033	chr6:167368657	RNASET2	0.46	7.75	0.39	1.1e-13	Crohn's disease;
LUSC	cis	rs925255	0.743	rs7589485	chr2:28645120	C/A	cg01273330	chr2:28605224	NA	-0.38	-6.13	-0.32	2.46e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11191270	0.554	rs10444022	chr10:104084889	A/G	cg15320455	chr10:103880129	LDB1	0.58	6.0	0.31	5.22e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07923666	chr12:49932857	KCNH3	-0.53	-6.56	-0.34	2.05e-10	Resting heart rate;
LUSC	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.46	-8.46	-0.42	8.3e-16	Monocyte percentage of white cells;
LUSC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.67	8.05	0.4	1.44e-14	Lung function (FEV1/FVC);
LUSC	cis	rs295140	1.000	rs13005573	chr2:201164696	G/C	cg04283868	chr2:201171347	SPATS2L	0.44	6.63	0.34	1.36e-10	QT interval;
LUSC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	4.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08109568	chr15:31115862	NA	-0.74	-11.09	-0.52	1.47e-24	Huntington's disease progression;
LUSC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	11.05	0.52	2.07e-24	Hip circumference adjusted for BMI;
LUSC	cis	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg00262122	chr8:11665843	FDFT1	-0.41	-6.11	-0.32	2.73e-9	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg23982607	chr1:1823379	GNB1	-0.73	-15.01	-0.63	2.78e-39	Body mass index;
LUSC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.5	-6.68	-0.34	9.86e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg05110241	chr16:68378359	PRMT7	-0.58	-6.62	-0.34	1.41e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg06740227	chr12:86229804	RASSF9	-0.37	-5.87	-0.31	1.05e-8	Major depressive disorder;
LUSC	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg05768032	chr16:30646687	NA	0.42	6.2	0.32	1.63e-9	Multiple myeloma;
LUSC	cis	rs9326248	0.861	rs4938352	chr11:117027481	G/A	cg16524733	chr11:117070046	TAGLN	0.36	5.71	0.3	2.47e-8	Blood protein levels;
LUSC	cis	rs6456156	0.805	rs6909252	chr6:167527097	C/T	cg07741184	chr6:167504864	NA	-0.35	-6.15	-0.32	2.18e-9	Primary biliary cholangitis;
LUSC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg23711669	chr6:146136114	FBXO30	0.88	16.1	0.66	1.48e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.52	-7.2	-0.37	4.11e-12	Tonsillectomy;
LUSC	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg08000102	chr2:233561755	GIGYF2	-0.66	-10.77	-0.51	1.99e-23	Coronary artery disease;
LUSC	cis	rs7179456	0.513	rs593742	chr15:59045774	A/G	cg05156742	chr15:59063176	FAM63B	0.48	6.97	0.36	1.69e-11	Asperger disorder;
LUSC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.22	-14.14	-0.61	6.82e-36	Diabetic kidney disease;
LUSC	cis	rs62400317	0.859	rs6927213	chr6:45206283	A/G	cg20913747	chr6:44695427	NA	0.42	6.04	0.31	4.13e-9	Total body bone mineral density;
LUSC	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23158103	chr7:148848205	ZNF398	-0.5	-8.11	-0.41	9.69e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs7581030	0.527	rs4852252	chr2:71539301	T/C	cg06465196	chr4:154387603	KIAA0922	0.41	5.96	0.31	6.45e-9	Testicular germ cell tumor;
LUSC	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.57	-0.34	1.92e-10	Arsenic metabolism;
LUSC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg13560548	chr3:10150139	C3orf24	0.52	7.07	0.36	8.87e-12	Alzheimer's disease;
LUSC	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg21479132	chr6:26055353	NA	-0.62	-5.77	-0.3	1.81e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg24375607	chr4:120327624	NA	0.75	12.07	0.55	4.56e-28	Corneal astigmatism;
LUSC	cis	rs9650657	0.707	rs4841452	chr8:10687121	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.21	-0.32	1.62e-9	Neuroticism;
LUSC	cis	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg20159608	chr7:32802032	NA	-0.7	-9.09	-0.45	8.7e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg20283391	chr11:68216788	NA	-0.57	-8.13	-0.41	8.28e-15	Total body bone mineral density;
LUSC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.21	0.45	3.73e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg17279839	chr7:150038598	RARRES2	0.39	5.86	0.31	1.12e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg06915202	chr7:98029285	BAIAP2L1	0.31	6.19	0.32	1.73e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7503807	1.000	rs7503807	chr17:78591111	G/T	cg09596252	chr17:78655493	RPTOR	-0.44	-7.62	-0.38	2.67e-13	Obesity;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11802172	chr6:36953962	MTCH1	-0.43	-6.35	-0.33	7.05e-10	Electrocardiographic conduction measures;
LUSC	trans	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07923666	chr12:49932857	KCNH3	-0.5	-6.15	-0.32	2.25e-9	Resting heart rate;
LUSC	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	9.47	0.46	5.23e-19	Bipolar disorder;
LUSC	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.84	-0.3	1.26e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.91	-0.44	3.36e-17	Breast cancer;
LUSC	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg23029597	chr12:123009494	RSRC2	-0.62	-8.08	-0.4	1.17e-14	Body mass index;
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg11905131	chr22:24372483	LOC391322	-0.58	-9.66	-0.47	1.27e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg18350739	chr11:68623251	NA	-0.41	-7.19	-0.37	4.39e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.88	-15.62	-0.65	1.12e-41	Cognitive function;
LUSC	cis	rs8114671	0.773	rs3746438	chr20:33584289	C/T	cg07148914	chr20:33460835	GGT7	-0.42	-6.09	-0.32	3.06e-9	Height;
LUSC	cis	rs6558174	0.630	rs6558176	chr8:22522502	C/T	cg03733263	chr8:22462867	KIAA1967	-0.5	-6.48	-0.33	3.24e-10	Breast cancer;
LUSC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.7	-11.81	-0.54	3.88e-27	Prudent dietary pattern;
LUSC	cis	rs2377585	0.563	rs11046832	chr12:8847970	T/G	cg03761649	chr12:8850719	RIMKLB	0.46	6.23	0.32	1.39e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25338204	chr5:175955105	RNF44	-0.38	-5.97	-0.31	6.03e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.4	0.38	1.14e-12	Motion sickness;
LUSC	cis	rs11030122	0.645	rs11493482	chr11:4034772	A/G	cg08557956	chr11:4115526	RRM1	-0.47	-5.97	-0.31	6.08e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	trans	rs11186	0.556	rs7419288	chr2:189950871	C/T	cg18242712	chr11:20182324	DBX1	-0.52	-6.15	-0.32	2.18e-9	Parkinson's disease;
LUSC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg17971929	chr21:40555470	PSMG1	-0.5	-7.41	-0.38	1.01e-12	Menarche (age at onset);
LUSC	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg06239285	chr11:62104954	ASRGL1	-0.89	-8.46	-0.42	8.58e-16	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg03886242	chr7:26192032	NFE2L3	-0.42	-6.66	-0.34	1.1e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg25025879	chr12:53359317	NA	-0.54	-8.17	-0.41	6.44e-15	Cancer (pleiotropy);
LUSC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08219700	chr8:58056026	NA	0.7	7.95	0.4	2.95e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg23172400	chr8:95962367	TP53INP1	0.3	5.95	0.31	6.71e-9	Type 2 diabetes;
LUSC	cis	rs9549260	0.620	rs4325427	chr13:41216534	C/T	cg21288729	chr13:41239152	FOXO1	0.58	8.88	0.44	4.03e-17	Red blood cell count;
LUSC	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg09307838	chr4:120376055	NA	0.69	9.98	0.48	1.05e-20	Corneal astigmatism;
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	0.98	22.85	0.78	3.06e-70	Menarche (age at onset);
LUSC	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-10.76	-0.51	2.21e-23	Coffee consumption (cups per day);
LUSC	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg23093090	chr10:104574429	C10orf26	-0.37	-6.95	-0.36	1.93e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg26380479	chr7:97908229	NA	-0.27	-6.14	-0.32	2.28e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10740039	0.516	rs1442549	chr10:62334300	C/T	cg18175470	chr10:62150864	ANK3	-0.45	-6.81	-0.35	4.41e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs35000415	0.938	rs13227075	chr7:128643297	T/C	cg19972273	chr7:128594194	NA	0.68	6.79	0.35	5.04e-11	Systemic lupus erythematosus;
LUSC	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg00784671	chr22:46762841	CELSR1	-0.71	-7.58	-0.38	3.53e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2274273	0.967	rs67756714	chr14:55589823	G/A	cg04306507	chr14:55594613	LGALS3	0.53	11.61	0.54	2e-26	Protein biomarker;
LUSC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10802521	chr3:52805072	NEK4	-0.46	-7.3	-0.37	2.18e-12	Electroencephalogram traits;
LUSC	cis	rs8099014	1.000	rs3744868	chr18:56123059	C/T	cg12907477	chr18:56117327	MIR122	0.43	6.84	0.35	3.84e-11	Platelet count;
LUSC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.76	-10.36	-0.49	5.26e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg24562669	chr7:97807699	LMTK2	0.48	8.64	0.43	2.31e-16	Prostate cancer (SNP x SNP interaction);Prostate cancer;
LUSC	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg13010199	chr12:38710504	ALG10B	0.46	7.13	0.36	6.3e-12	Heart rate;
LUSC	cis	rs2274273	0.901	rs17674563	chr14:55831125	G/A	cg04306507	chr14:55594613	LGALS3	0.54	11.8	0.54	4.35e-27	Protein biomarker;
LUSC	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.16	-0.41	6.84e-15	Height;
LUSC	cis	rs6504340	0.739	rs4793939	chr17:46665235	G/A	cg09704116	chr17:46666958	LOC404266	-0.37	-5.73	-0.3	2.22e-8	Primary tooth development (number of teeth);
LUSC	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.83	-8.16	-0.41	6.94e-15	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.78	0.35	5.42e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg07741184	chr6:167504864	NA	0.4	6.53	0.34	2.51e-10	Crohn's disease;
LUSC	cis	rs56399783	0.708	rs56208415	chr7:2813806	G/A	cg14895029	chr7:2775587	GNA12	0.47	5.82	0.3	1.41e-8	Childhood ear infection;
LUSC	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg10253484	chr15:75165896	SCAMP2	-0.57	-7.5	-0.38	5.66e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs941898	0.836	rs8016001	chr14:100598691	A/G	cg26002632	chr14:100625216	DEGS2	-0.34	-6.64	-0.34	1.29e-10	White matter hyperintensity burden;
LUSC	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg15309053	chr8:964076	NA	0.38	7.57	0.38	3.64e-13	Schizophrenia;
LUSC	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg14036092	chr11:66035641	RAB1B	0.41	5.81	0.3	1.49e-8	Gout;
LUSC	cis	rs7588746	0.621	rs1816541	chr2:201151011	T/C	cg23649088	chr2:200775458	C2orf69	-0.42	-5.91	-0.31	8.36e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	8.08	0.4	1.23e-14	Menarche (age at onset);
LUSC	cis	rs7827545	1.000	rs4909909	chr8:135564627	T/C	cg17885191	chr8:135476712	NA	0.56	8.32	0.41	2.34e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs35995292	0.500	rs7776996	chr7:38919762	G/C	cg19327137	chr7:38886074	VPS41	0.55	10.26	0.49	1.21e-21	Subjective well-being (multi-trait analysis);
LUSC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg06637938	chr14:75390232	RPS6KL1	0.51	7.86	0.4	5.32e-14	Height;
LUSC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.57	-0.42	3.87e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	7.24	0.37	3.14e-12	Obesity-related traits;
LUSC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg15557168	chr22:42548783	NA	0.46	7.12	0.36	6.7e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2279817	0.780	rs35588575	chr1:18007045	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.2	-0.32	1.71e-9	Neuroticism;
LUSC	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg08017634	chr8:144659831	NAPRT1	0.72	6.12	0.32	2.59e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg16797656	chr11:68205561	LRP5	0.4	7.15	0.36	5.54e-12	Total body bone mineral density;
LUSC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg01802117	chr1:53393560	SCP2	-0.37	-6.13	-0.32	2.52e-9	Monocyte count;
LUSC	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.88	15.14	0.64	8.97e-40	Bladder cancer;
LUSC	cis	rs12760731	0.720	rs12755909	chr1:178305298	G/A	cg00404053	chr1:178313656	RASAL2	0.6	6.34	0.33	7.4e-10	Obesity-related traits;
LUSC	cis	rs10761482	0.500	rs1892546	chr10:62294016	T/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.24	-0.37	3.11e-12	Schizophrenia;
LUSC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg22823121	chr1:150693482	HORMAD1	0.58	8.88	0.44	4.07e-17	Tonsillectomy;
LUSC	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg03859395	chr2:55845619	SMEK2	0.88	16.66	0.67	8.58e-46	Metabolic syndrome;
LUSC	cis	rs7681423	1.000	rs7654093	chr4:155545072	A/T	cg20735720	chr4:155535218	FGG	-0.49	-7.25	-0.37	2.95e-12	Fibrinogen;
LUSC	cis	rs4474465	1.000	rs7928933	chr11:78193921	T/C	cg27205649	chr11:78285834	NARS2	-0.5	-5.88	-0.31	1.01e-8	Alzheimer's disease (survival time);
LUSC	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.68	11.57	0.53	2.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24983561	chr5:54603725	DHX29;SKIV2L2	-0.42	-6.08	-0.32	3.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg18187862	chr3:45730750	SACM1L	0.54	7.05	0.36	1.05e-11	Primary sclerosing cholangitis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20809690	chr4:2757764	TNIP2	-0.48	-6.11	-0.32	2.81e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg04871131	chr7:94954202	PON1	-0.39	-6.13	-0.32	2.44e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg19920283	chr7:105172520	RINT1	0.59	6.02	0.31	4.72e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs965604	0.965	rs4299116	chr15:78766194	T/A	cg18825076	chr15:78729989	IREB2	-0.42	-6.83	-0.35	3.99e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg21724239	chr8:58056113	NA	0.75	8.4	0.42	1.27e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.38	-0.33	6.04e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.76	-0.39	1.03e-13	Type 2 diabetes;
LUSC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg24675658	chr1:53192096	ZYG11B	0.65	10.7	0.51	3.57e-23	Monocyte count;
LUSC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.09	0.32	3.1e-9	Personality dimensions;
LUSC	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg23711669	chr6:146136114	FBXO30	-0.64	-9.55	-0.46	2.81e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg05347473	chr6:146136440	FBXO30	0.53	8.82	0.43	6.31e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-10.62	-0.5	7.1e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-12.84	-0.57	5.96e-31	Platelet count;
LUSC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.66	-0.6	4.79e-34	Chronic sinus infection;
LUSC	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg09307838	chr4:120376055	NA	0.69	9.98	0.48	1.05e-20	Corneal astigmatism;
LUSC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg24829409	chr8:58192753	C8orf71	-0.45	-5.65	-0.3	3.37e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	10.72	0.51	3.01e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7188861	0.813	rs2867936	chr16:11398698	C/T	cg00044050	chr16:11439710	C16orf75	0.54	5.9	0.31	8.71e-9	HDL cholesterol;
LUSC	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg05472934	chr7:22766657	IL6	0.54	8.46	0.42	8.54e-16	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
LUSC	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-15.07	-0.64	1.64e-39	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs9409154	0.617	rs7470135	chr9:118394038	T/C	cg06386307	chr6:100895211	SIM1	0.35	6.26	0.32	1.19e-9	Visceral adipose tissue adjusted for BMI;
LUSC	trans	rs236907	0.859	rs7536142	chr1:171770336	A/G	cg13482142	chr2:234261155	NA	0.5	6.16	0.32	2.07e-9	Mean platelet volume;
LUSC	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg23750338	chr8:142222470	SLC45A4	0.58	11.26	0.52	3.94e-25	Immature fraction of reticulocytes;
LUSC	cis	rs2629540	0.765	rs4962687	chr10:126404141	G/A	cg08799069	chr10:126477246	METTL10	-0.48	-7.41	-0.38	1.06e-12	Cocaine dependence;
LUSC	cis	rs227833	0.729	rs687878	chr6:44706790	T/C	cg20913747	chr6:44695427	NA	0.38	6.04	0.31	4.13e-9	Monobrow;
LUSC	cis	rs6963495	0.745	rs73192150	chr7:105211610	A/C	cg19920283	chr7:105172520	RINT1	0.58	5.94	0.31	7.27e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg16447950	chr5:562315	NA	-0.54	-7.65	-0.39	2.18e-13	Obesity-related traits;
LUSC	cis	rs17818399	0.708	rs1531133	chr2:46843631	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.36	6.1	0.32	3e-9	Height;
LUSC	cis	rs6060717	0.536	rs11167279	chr20:34509107	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.74	-0.3	2.13e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.05	0.64	1.94e-39	Platelet count;
LUSC	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg20891283	chr12:69753455	YEATS4	0.43	5.78	0.3	1.67e-8	Response to diuretic therapy;
LUSC	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg09953122	chr20:23471693	CST8	-0.93	-7.37	-0.37	1.32e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21659725	chr3:3221576	CRBN	-0.65	-10.56	-0.5	1.07e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg03060546	chr3:49711283	APEH	0.64	7.69	0.39	1.67e-13	Menarche (age at onset);
LUSC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg08847533	chr14:75593920	NEK9	-0.82	-14.81	-0.63	1.74e-38	Height;
LUSC	trans	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-6.61	-0.34	1.55e-10	Axial length;
LUSC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg13319975	chr6:146136371	FBXO30	-0.72	-11.26	-0.52	3.93e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	0.65	13.29	0.59	1.22e-32	Prudent dietary pattern;
LUSC	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.81	-0.3	1.49e-8	IgG glycosylation;
LUSC	cis	rs7512552	0.803	rs11205385	chr1:150476516	G/A	cg15654264	chr1:150340011	RPRD2	0.65	10.68	0.5	4.27e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08704250	chr15:31115839	NA	-0.48	-7.12	-0.36	6.63e-12	Huntington's disease progression;
LUSC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26314531	chr2:26401878	FAM59B	-0.71	-9.73	-0.47	7.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg00074818	chr8:8560427	CLDN23	0.58	9.74	0.47	7e-20	Obesity-related traits;
LUSC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg22638593	chr5:131593259	PDLIM4	0.41	6.54	0.34	2.36e-10	Blood metabolite levels;
LUSC	cis	rs2625529	0.586	rs7170456	chr15:72469946	G/C	cg16672083	chr15:72433130	SENP8	0.48	8.0	0.4	2.14e-14	Red blood cell count;
LUSC	trans	rs11610422	1.000	rs11610422	chr12:31412669	C/T	cg02734259	chr12:9559402	NA	0.54	6.01	0.31	4.77e-9	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.65	10.99	0.52	3.31e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.19	0.32	1.77e-9	Total body bone mineral density;
LUSC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02788857	chr8:22132959	PIWIL2	-0.37	-7.36	-0.37	1.48e-12	Hypertriglyceridemia;
LUSC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg06784218	chr1:46089804	CCDC17	0.47	9.26	0.45	2.6e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs240764	0.817	rs239190	chr6:101129067	C/T	cg09795085	chr6:101329169	ASCC3	0.42	6.11	0.32	2.83e-9	Neuroticism;
LUSC	cis	rs2742417	0.935	rs2248991	chr3:45754749	G/A	cg09608765	chr3:45636137	LIMD1	-0.38	-7.53	-0.38	4.87e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18929903	chr10:101418993	ENTPD7	-0.41	-6.05	-0.31	3.82e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-9.68	-0.47	1.06e-19	Morning vs. evening chronotype;
LUSC	cis	rs9837602	1.000	rs4279135	chr3:99733096	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.09	-0.32	3.14e-9	Breast cancer;
LUSC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.88	-16.27	-0.66	3.04e-44	Neuroticism;
LUSC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg13395646	chr4:1353034	KIAA1530	-0.59	-8.45	-0.42	9.09e-16	Longevity;
LUSC	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg13010199	chr12:38710504	ALG10B	0.65	10.2	0.49	1.87e-21	Morning vs. evening chronotype;
LUSC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg23172400	chr8:95962367	TP53INP1	-0.39	-8.25	-0.41	3.73e-15	Type 2 diabetes;
LUSC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	0.5	6.87	0.35	3.17e-11	Menarche (age at onset);
LUSC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg14019146	chr3:50243930	SLC38A3	-0.33	-7.33	-0.37	1.73e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12618769	0.597	rs10496327	chr2:99066827	A/G	cg10123293	chr2:99228465	UNC50	0.45	7.39	0.37	1.19e-12	Bipolar disorder;
LUSC	trans	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg26043149	chr18:55253948	FECH	0.48	6.99	0.36	1.48e-11	Bone mineral density;
LUSC	trans	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	9.66	0.47	1.22e-19	Eotaxin levels;
LUSC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg11843238	chr5:131593191	PDLIM4	-0.39	-6.31	-0.33	8.96e-10	Breast cancer;
LUSC	trans	rs2248359	0.770	rs2208588	chr20:52796971	A/T	cg01847206	chr5:14165995	TRIO	-0.35	-6.07	-0.32	3.44e-9	Multiple sclerosis;
LUSC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-6.18	-0.32	1.82e-9	Total body bone mineral density;
LUSC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.82	-13.06	-0.58	9.04e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg26408565	chr15:76604113	ETFA	-0.44	-6.94	-0.36	2.03e-11	Blood metabolite levels;
LUSC	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg06191203	chr2:152266755	RIF1	-0.56	-7.32	-0.37	1.81e-12	Lung cancer;
LUSC	cis	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg06521331	chr12:34319734	NA	-0.35	-5.99	-0.31	5.57e-9	Morning vs. evening chronotype;
LUSC	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg22676075	chr6:135203613	NA	0.46	7.27	0.37	2.56e-12	Red blood cell count;
LUSC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg13560548	chr3:10150139	C3orf24	0.51	7.29	0.37	2.19e-12	Alzheimer's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07550334	chr14:75518271	MLH3	0.42	6.24	0.32	1.34e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-1.01	-18.85	-0.72	1.71e-54	Height;
LUSC	cis	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg06521331	chr12:34319734	NA	-0.37	-6.32	-0.33	8.26e-10	Morning vs. evening chronotype;
LUSC	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.73	-0.3	2.3e-8	Coronary artery disease;
LUSC	cis	rs7215564	0.818	rs901063	chr17:78595696	A/T	cg09596252	chr17:78655493	RPTOR	-0.53	-5.81	-0.3	1.44e-8	Myopia (pathological);
LUSC	cis	rs6939532	0.522	rs9366652	chr6:26354219	C/G	cg05738196	chr6:26577821	NA	-0.43	-6.16	-0.32	2.11e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs4343996	0.869	rs6651070	chr7:3465411	G/C	cg21248987	chr7:3385318	SDK1	0.37	6.19	0.32	1.79e-9	Motion sickness;
LUSC	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	11.78	0.54	4.92e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg04362960	chr10:104952993	NT5C2	0.66	9.13	0.45	6.81e-18	Arsenic metabolism;
LUSC	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.64	10.47	0.5	2.18e-22	HDL cholesterol;
LUSC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg03188948	chr7:1209495	NA	0.66	6.93	0.35	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs734999	0.588	rs867435	chr1:2523706	C/T	cg18854424	chr1:2615690	NA	0.48	9.36	0.46	1.24e-18	Ulcerative colitis;
LUSC	cis	rs1609391	0.543	rs1347209	chr3:136626697	G/T	cg15507776	chr3:136538369	TMEM22	0.5	8.25	0.41	3.79e-15	Neuroticism;
LUSC	cis	rs6469656	1.000	rs3088140	chr8:117786603	T/C	cg24004040	chr8:117650383	NA	0.41	5.65	0.3	3.51e-8	Colorectal cancer;
LUSC	cis	rs6066835	0.702	rs6095228	chr20:47279876	A/G	cg18078177	chr20:47281410	PREX1	-0.68	-5.7	-0.3	2.63e-8	Multiple myeloma;
LUSC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg05623727	chr3:50126028	RBM5	-0.33	-6.26	-0.32	1.16e-9	Body mass index;
LUSC	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg15556689	chr8:8085844	FLJ10661	0.72	9.96	0.48	1.25e-20	Red cell distribution width;
LUSC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-19.49	-0.73	4.84e-57	Height;
LUSC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg19628046	chr18:33552617	C18orf21	0.5	6.11	0.32	2.83e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs12891047	0.804	rs10135927	chr14:68313209	G/A	cg20999565	chr14:68265668	ZFYVE26	0.38	5.85	0.3	1.18e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2303282	0.726	rs4541073	chr16:56451900	C/T	cg00500540	chr16:56394104	NA	-0.43	-7.37	-0.37	1.37e-12	Breast cancer;
LUSC	cis	rs870825	0.616	rs28618216	chr4:185648998	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	0.91	18.54	0.71	3.03e-53	Dental caries;
LUSC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-9.66	-0.47	1.24e-19	Platelet distribution width;
LUSC	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg03647239	chr10:116582469	FAM160B1	0.44	7.15	0.36	5.58e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs354225	0.544	rs4616509	chr2:54807982	T/C	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03517284	chr6:25882590	NA	0.44	7.78	0.39	9.2e-14	Blood metabolite levels;
LUSC	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2708977	0.899	rs12992413	chr2:97277489	A/G	cg01950434	chr2:97203154	ARID5A	0.58	8.83	0.44	5.93e-17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg27572855	chr1:25598939	RHD	0.43	7.78	0.39	9.24e-14	Erythrocyte sedimentation rate;
LUSC	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg16359550	chr11:109292809	C11orf87	0.41	7.18	0.37	4.64e-12	Schizophrenia;
LUSC	cis	rs3126085	0.935	rs55942250	chr1:152251914	G/A	cg26876637	chr1:152193138	HRNR	-0.43	-5.69	-0.3	2.85e-8	Atopic dermatitis;
LUSC	cis	rs2970818	0.831	rs10849083	chr12:4642572	G/T	cg11146114	chr12:4671731	NA	-0.57	-6.06	-0.31	3.63e-9	Phosphorus levels;
LUSC	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.44	-0.42	9.78e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg12963246	chr6:28129442	ZNF389	0.53	7.41	0.38	1.04e-12	Parkinson's disease;
LUSC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg01657329	chr11:68192670	LRP5	0.48	7.84	0.39	6.22e-14	Total body bone mineral density;
LUSC	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg10356904	chr22:49881777	NA	-0.3	-5.94	-0.31	7.14e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.44	7.04	0.36	1.08e-11	Vitiligo;
LUSC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.56	-0.34	2.05e-10	Lung cancer;
LUSC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.63	-10.26	-0.49	1.19e-21	Height;
LUSC	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg17366294	chr4:99064904	C4orf37	0.57	9.91	0.48	1.76e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4356932	1.000	rs6844097	chr4:76950757	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.59e-8	Blood protein levels;
LUSC	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg21984481	chr17:79567631	NPLOC4	-0.69	-13.85	-0.6	8.44e-35	Eye color traits;
LUSC	cis	rs3764021	0.868	rs7306304	chr12:9877196	G/A	cg20894963	chr12:9885564	CLECL1	0.35	7.1	0.36	7.47e-12	Type 1 diabetes;
LUSC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg18827107	chr12:86230957	RASSF9	-0.5	-7.29	-0.37	2.32e-12	Major depressive disorder;
LUSC	cis	rs7617773	0.832	rs6775114	chr3:48182620	G/C	cg20734569	chr3:48348370	SPINK8	0.45	8.23	0.41	4.14e-15	Coronary artery disease;
LUSC	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg08807101	chr21:30365312	RNF160	-0.47	-6.08	-0.32	3.37e-9	Cognitive test performance;
LUSC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg16339924	chr4:17578868	LAP3	0.64	10.13	0.48	3.35e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg11247378	chr22:39784982	NA	-0.63	-12.21	-0.56	1.34e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg14416269	chr4:6271139	WFS1	0.49	9.78	0.47	5.09e-20	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2742417	0.603	rs2531755	chr3:45772742	T/C	cg04837898	chr3:45731254	SACM1L	-0.45	-7.25	-0.37	2.97e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs9329221	0.576	rs1986972	chr8:10268805	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.91	0.35	2.54e-11	Neuroticism;
LUSC	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg05855489	chr10:104503620	C10orf26	0.62	8.74	0.43	1.15e-16	Arsenic metabolism;
LUSC	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg09904177	chr6:26538194	HMGN4	-0.52	-5.81	-0.3	1.45e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg19052272	chr2:3704530	ALLC	-0.36	-6.79	-0.35	5.05e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg06917634	chr15:78832804	PSMA4	-0.43	-5.8	-0.3	1.51e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg09307838	chr4:120376055	NA	0.64	9.52	0.46	3.54e-19	Corneal astigmatism;
LUSC	cis	rs2625529	0.818	rs2246225	chr15:72115230	C/T	cg16672083	chr15:72433130	SENP8	0.44	6.39	0.33	5.54e-10	Red blood cell count;
LUSC	trans	rs7939886	0.688	rs11227290	chr11:55896577	A/G	cg15704280	chr7:45808275	SEPT13	0.79	6.69	0.34	9.58e-11	Myopia (pathological);
LUSC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg05802129	chr4:122689817	NA	-0.51	-8.72	-0.43	1.38e-16	Type 2 diabetes;
LUSC	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.7	-0.47	9.45e-20	Coronary artery disease;
LUSC	cis	rs2742417	1.000	rs2742422	chr3:45732820	G/A	cg09608765	chr3:45636137	LIMD1	-0.36	-7.17	-0.37	4.82e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg20129853	chr10:51489980	NA	-0.33	-6.61	-0.34	1.49e-10	Prostate-specific antigen levels;
LUSC	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg24375607	chr4:120327624	NA	0.76	11.68	0.54	1.16e-26	Corneal astigmatism;
LUSC	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg04374321	chr14:90722782	PSMC1	0.75	12.12	0.55	2.92e-28	Mortality in heart failure;
LUSC	cis	rs3087591	1.000	rs2051506	chr17:29699860	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.56	-8.02	-0.4	1.81e-14	Hip circumference;
LUSC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs1832871	0.711	rs9457264	chr6:158689367	G/A	cg07165851	chr6:158734300	TULP4	0.5	7.79	0.39	8.78e-14	Height;
LUSC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-7.22	-0.37	3.47e-12	Mean platelet volume;
LUSC	cis	rs454510	0.857	rs838990	chr1:120193252	A/G	cg16322792	chr1:120165303	ZNF697	0.34	5.73	0.3	2.23e-8	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg15147215	chr3:52552868	STAB1	-0.33	-6.51	-0.34	2.72e-10	Electroencephalogram traits;
LUSC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.97	0.44	2.18e-17	Motion sickness;
LUSC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg00033643	chr7:134001901	SLC35B4	-0.44	-6.89	-0.35	2.82e-11	Mean platelet volume;
LUSC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6714710	0.580	rs11690737	chr2:98461953	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	8.5	0.42	6.32e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.53	-8.85	-0.44	5.06e-17	Immature fraction of reticulocytes;
LUSC	cis	rs56283067	0.578	rs12203052	chr6:45398958	C/G	cg20913747	chr6:44695427	NA	-0.41	-5.96	-0.31	6.53e-9	Total body bone mineral density;
LUSC	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.62	-11.64	-0.54	1.63e-26	Congenital heart disease (maternal effect);
LUSC	trans	rs4650994	0.525	rs4650997	chr1:178530744	T/A	cg05059571	chr16:84539110	KIAA1609	-0.48	-9.01	-0.44	1.57e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg21733973	chr7:65235735	NA	-0.41	-6.0	-0.31	5.19e-9	Calcium levels;
LUSC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.99	0.58	1.69e-31	Alzheimer's disease;
LUSC	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg19743168	chr1:23544995	NA	0.55	10.72	0.51	2.96e-23	Height;
LUSC	cis	rs7766436	0.885	rs12111204	chr6:22578227	C/T	cg13666174	chr6:22585274	NA	-0.42	-5.71	-0.3	2.54e-8	Coronary artery disease;
LUSC	cis	rs7432375	0.580	rs4678441	chr3:136532828	T/C	cg15507776	chr3:136538369	TMEM22	0.44	7.37	0.37	1.34e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg10523679	chr1:76189770	ACADM	-0.44	-6.48	-0.33	3.26e-10	Daytime sleep phenotypes;
LUSC	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg10518543	chr12:38710700	ALG10B	0.41	5.79	0.3	1.6e-8	Morning vs. evening chronotype;
LUSC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg11941060	chr3:133502564	NA	-0.52	-7.84	-0.39	5.93e-14	Iron status biomarkers;
LUSC	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg23544223	chr18:12777786	NA	0.58	6.15	0.32	2.18e-9	Inflammatory skin disease;
LUSC	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.6	-8.17	-0.41	6.55e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs727505	1.000	rs7806680	chr7:124433079	G/A	cg23710748	chr7:124431027	NA	-0.4	-7.26	-0.37	2.78e-12	Lewy body disease;
LUSC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.8	13.63	0.6	5.87e-34	Aortic root size;
LUSC	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg03522245	chr20:25566470	NINL	0.38	6.19	0.32	1.74e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6545883	0.929	rs2600663	chr2:61540687	A/G	cg15711740	chr2:61764176	XPO1	0.47	7.57	0.38	3.79e-13	Tuberculosis;
LUSC	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.99	0.36	1.46e-11	Rheumatoid arthritis;
LUSC	trans	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.75	13.28	0.59	1.31e-32	Platelet distribution width;
LUSC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18876405	chr7:65276391	NA	-0.56	-8.68	-0.43	1.77e-16	Aortic root size;
LUSC	cis	rs4409675	0.576	rs6691656	chr1:28221130	C/G	cg23691781	chr1:28212827	C1orf38	0.32	7.59	0.38	3.2e-13	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06966617	chr2:74406040	MOBKL1B	-0.41	-6.02	-0.31	4.71e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg07169764	chr2:136633963	MCM6	1.01	15.41	0.64	7.48e-41	Corneal structure;
LUSC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.9	-0.48	1.96e-20	Type 2 diabetes;
LUSC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg22823121	chr1:150693482	HORMAD1	-0.59	-9.02	-0.44	1.5e-17	Tonsillectomy;
LUSC	cis	rs11209002	0.614	rs12140736	chr1:67586671	T/C	cg02640540	chr1:67518911	SLC35D1	0.59	8.13	0.41	8.21e-15	Crohn's disease;
LUSC	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.58	8.74	0.43	1.19e-16	Blood protein levels;
LUSC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02018176	chr4:1364513	KIAA1530	0.71	12.61	0.57	4.25e-30	Longevity;
LUSC	cis	rs2463822	0.669	rs72919480	chr11:62043133	G/A	cg06239285	chr11:62104954	ASRGL1	-0.75	-7.26	-0.37	2.74e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9815354	0.812	rs73071239	chr3:41992610	C/A	cg03022575	chr3:42003672	ULK4	0.85	8.86	0.44	4.72e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg11871910	chr12:69753446	YEATS4	0.71	11.97	0.55	1.05e-27	Blood protein levels;
LUSC	cis	rs3755132	0.929	rs3770470	chr2:15770507	G/T	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg04352962	chr1:209979756	IRF6	0.53	6.2	0.32	1.68e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs11690935	0.589	rs6729945	chr2:172864695	C/G	cg13550731	chr2:172543902	DYNC1I2	0.54	8.05	0.4	1.5e-14	Schizophrenia;
LUSC	trans	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg10840412	chr1:235813424	GNG4	0.67	8.91	0.44	3.33e-17	Bipolar disorder;
LUSC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	12.89	0.58	3.77e-31	Motion sickness;
LUSC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg13685833	chr1:53393034	SCP2	0.39	5.88	0.31	1.01e-8	Monocyte count;
LUSC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.24	0.52	4.35e-25	Menopause (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08292968	chr12:111020671	PPTC7	-0.53	-6.52	-0.34	2.53e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08280861	chr8:58055591	NA	0.54	6.5	0.34	2.96e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg08601574	chr20:25228251	PYGB	0.41	6.25	0.32	1.22e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.67	14.94	0.63	5.16e-39	Hemoglobin concentration;
LUSC	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg25214090	chr10:38739885	LOC399744	0.58	8.47	0.42	8.08e-16	Corneal astigmatism;
LUSC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg05347473	chr6:146136440	FBXO30	0.56	9.82	0.47	3.7e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg09796270	chr17:17721594	SREBF1	-0.45	-7.84	-0.39	5.94e-14	Total body bone mineral density;
LUSC	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg12062639	chr20:23401060	NAPB	0.78	6.04	0.31	4.01e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.77	11.69	0.54	1.06e-26	Tonsillectomy;
LUSC	cis	rs2988277	0.737	rs2949668	chr1:167434721	T/C	cg22356347	chr1:167427500	CD247	-0.26	-6.06	-0.31	3.77e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18425377	chr14:105167727	INF2	0.39	6.28	0.32	1.08e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.62	-0.47	1.71e-19	Coronary artery disease;
LUSC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg12927641	chr6:109611667	NA	-0.38	-6.4	-0.33	5.13e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs9837602	1.000	rs35669453	chr3:99766063	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.88	-0.31	1.02e-8	Breast cancer;
LUSC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg16482183	chr6:26056742	HIST1H1C	0.44	6.52	0.34	2.67e-10	Height;
LUSC	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg04455712	chr21:45112962	RRP1B	0.45	8.35	0.42	1.82e-15	Mean corpuscular volume;
LUSC	cis	rs67072384	0.786	rs60497375	chr11:72452645	A/G	cg04827223	chr11:72435913	ARAP1	-0.8	-7.39	-0.37	1.18e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs62400317	0.723	rs12196188	chr6:44976426	G/C	cg20913747	chr6:44695427	NA	-0.46	-7.23	-0.37	3.41e-12	Total body bone mineral density;
LUSC	cis	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg06521331	chr12:34319734	NA	-0.46	-7.69	-0.39	1.71e-13	Morning vs. evening chronotype;
LUSC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19346786	chr7:2764209	NA	-0.4	-7.13	-0.36	6.44e-12	Height;
LUSC	trans	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg20587970	chr11:113659929	NA	0.83	9.83	0.47	3.45e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs9807841	0.592	rs2043304	chr19:10772112	T/C	cg09936142	chr19:10668400	KRI1	-0.4	-6.44	-0.33	4.08e-10	Inflammatory skin disease;
LUSC	cis	rs2067615	0.524	rs4964483	chr12:107099057	T/C	cg15890332	chr12:107067104	RFX4	0.35	6.15	0.32	2.24e-9	Heart rate;
LUSC	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg24130564	chr14:104152367	KLC1	0.47	6.77	0.35	5.68e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg11062466	chr8:58055876	NA	0.64	7.88	0.4	4.55e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg17385448	chr1:15911702	AGMAT	0.35	5.93	0.31	7.36e-9	Systolic blood pressure;
LUSC	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg19622623	chr12:86230825	RASSF9	-0.41	-5.71	-0.3	2.44e-8	Major depressive disorder;
LUSC	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg02176678	chr2:219576539	TTLL4	-0.56	-9.81	-0.47	4.09e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-6.46	-0.33	3.72e-10	Renal function-related traits (BUN);
LUSC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg23283495	chr1:209979779	IRF6	0.75	9.51	0.46	3.86e-19	Cleft lip with or without cleft palate;
LUSC	cis	rs796825	0.548	rs12494395	chr3:119987430	G/A	cg21790991	chr3:120137480	FSTL1	-0.34	-6.1	-0.32	2.93e-9	HIV-1 susceptibility;
LUSC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.74	-13.34	-0.59	7.93e-33	Aortic root size;
LUSC	cis	rs4908769	0.624	rs1763838	chr1:8473331	G/A	cg00546117	chr1:8445545	RERE	-0.3	-6.04	-0.31	4.18e-9	Allergy;
LUSC	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.92	-0.44	3.11e-17	Response to antipsychotic treatment;
LUSC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg08847533	chr14:75593920	NEK9	0.84	15.43	0.65	6.51e-41	Height;
LUSC	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg12292205	chr6:26970375	C6orf41	0.51	8.54	0.42	4.91e-16	Schizophrenia;
LUSC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23158103	chr7:148848205	ZNF398	-0.48	-8.0	-0.4	2.13e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg21775007	chr8:11205619	TDH	-0.43	-6.18	-0.32	1.89e-9	Joint mobility (Beighton score);
LUSC	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.5	-0.46	4.06e-19	Total cholesterol levels;
LUSC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20887711	chr4:1340912	KIAA1530	0.51	7.95	0.4	2.89e-14	Longevity;
LUSC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.91	15.38	0.64	9.49e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg14541582	chr5:601475	NA	-0.37	-5.8	-0.3	1.56e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2742234	0.541	rs10899782	chr10:43736361	A/T	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.92	-0.31	8.07e-9	Hirschsprung disease;
LUSC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg06219351	chr7:158114137	PTPRN2	-0.49	-8.81	-0.43	7.11e-17	Calcium levels;
LUSC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg02423579	chr7:2872169	GNA12	-0.48	-6.69	-0.34	9.62e-11	Height;
LUSC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg00049323	chr5:472564	LOC25845	-0.43	-6.71	-0.34	8.18e-11	Cystic fibrosis severity;
LUSC	cis	rs807669	0.770	rs807458	chr22:19220648	G/T	cg02655711	chr22:19163373	SLC25A1	0.45	8.11	0.41	9.82e-15	Metabolite levels;
LUSC	cis	rs6728642	0.908	rs6576996	chr2:97623312	T/C	cg26665480	chr2:98280029	ACTR1B	-0.69	-6.14	-0.32	2.33e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-0.76	-10.62	-0.5	6.75e-23	Gut microbiome composition (summer);
LUSC	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg04733989	chr22:42467013	NAGA	0.4	6.59	0.34	1.67e-10	Cognitive function;
LUSC	cis	rs548181	0.577	rs569766	chr11:125532369	G/A	cg03464685	chr11:125439445	EI24	1.15	13.9	0.61	5.42e-35	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg02800362	chr5:177631904	HNRNPAB	0.88	13.16	0.58	3.72e-32	Obesity-related traits;
LUSC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg21017887	chr14:105400489	NA	0.69	13.07	0.58	8.32e-32	Rheumatoid arthritis;
LUSC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg16060761	chr17:80687452	NA	-0.53	-8.09	-0.4	1.13e-14	Glycated hemoglobin levels;
LUSC	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg08917208	chr2:24149416	ATAD2B	0.9	10.11	0.48	3.82e-21	Lymphocyte counts;
LUSC	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg27489772	chr12:121021490	NA	0.59	7.84	0.39	6.09e-14	Type 1 diabetes nephropathy;
LUSC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-8.53	-0.42	5.26e-16	Bipolar disorder;
LUSC	cis	rs11971779	0.680	rs10273527	chr7:139036598	A/C	cg23387468	chr7:139079360	LUC7L2	-0.39	-5.91	-0.31	8.43e-9	Diisocyanate-induced asthma;
LUSC	cis	rs11971779	0.680	rs17691238	chr7:139052284	A/G	cg07862535	chr7:139043722	LUC7L2	-0.53	-6.71	-0.34	8.5e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	8.26	0.41	3.48e-15	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg15704280	chr7:45808275	SEPT13	-0.63	-7.59	-0.38	3.18e-13	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg06606381	chr12:133084897	FBRSL1	-0.62	-6.69	-0.34	9.53e-11	Depression;
LUSC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg18230493	chr5:56204884	C5orf35	-0.66	-10.22	-0.49	1.66e-21	Coronary artery disease;
LUSC	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg04036182	chr15:45458818	NA	0.35	5.75	0.3	2.01e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs710216	0.917	rs900837	chr1:43412793	A/G	cg03128534	chr1:43423976	SLC2A1	-0.45	-5.9	-0.31	8.85e-9	Red cell distribution width;
LUSC	trans	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg10756647	chr7:56101905	PSPH	0.89	9.05	0.44	1.19e-17	Diabetic kidney disease;
LUSC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.79	13.37	0.59	5.74e-33	Cognitive function;
LUSC	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg16482183	chr6:26056742	HIST1H1C	0.66	9.22	0.45	3.37e-18	Iron status biomarkers;
LUSC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08704250	chr15:31115839	NA	0.6	9.29	0.45	2.1e-18	Huntington's disease progression;
LUSC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.96	0.7	5.97e-51	Chronic sinus infection;
LUSC	cis	rs10788264	0.504	rs7898942	chr10:124024608	G/T	cg09507567	chr10:124027408	NA	-0.53	-9.23	-0.45	3.22e-18	Total body bone mineral density;
LUSC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg22166914	chr1:53195759	ZYG11B	-0.62	-10.21	-0.49	1.73e-21	Monocyte count;
LUSC	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg05731713	chr7:157510257	PTPRN2	0.49	9.54	0.46	3e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs2708977	0.966	rs2708978	chr2:97202243	A/C	cg01950434	chr2:97203154	ARID5A	-0.57	-8.55	-0.42	4.5e-16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.3	-0.41	2.58e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg18099408	chr3:52552593	STAB1	0.36	5.93	0.31	7.72e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs977987	0.843	rs17696749	chr16:75403062	C/G	cg04384234	chr16:75411784	CFDP1	-0.45	-7.56	-0.38	3.85e-13	Dupuytren's disease;
LUSC	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.93	-0.44	2.81e-17	Response to antipsychotic treatment;
LUSC	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg22356347	chr1:167427500	CD247	-0.32	-7.86	-0.39	5.42e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs2273669	0.667	rs12197912	chr6:109338147	C/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	8.89e-9	Prostate cancer;
LUSC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.49	0.59	2.14e-33	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.62	10.15	0.49	2.72e-21	Bone mineral density;
LUSC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.43	0.53	9.29e-26	Prudent dietary pattern;
LUSC	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg02175503	chr12:58329896	NA	0.41	5.85	0.3	1.17e-8	Multiple sclerosis;
LUSC	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg24375607	chr4:120327624	NA	0.78	11.54	0.53	3.63e-26	Corneal astigmatism;
LUSC	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	6.99	0.36	1.53e-11	Menarche (age at onset);
LUSC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg26695010	chr11:65641043	EFEMP2	0.58	8.64	0.43	2.41e-16	Eosinophil percentage of white cells;
LUSC	cis	rs7712401	0.601	rs425573	chr5:122326008	G/C	cg19077854	chr5:122220652	SNX24	-0.43	-9.48	-0.46	4.83e-19	Mean platelet volume;
LUSC	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg04362960	chr10:104952993	NT5C2	0.91	11.75	0.54	6.36e-27	Arsenic metabolism;
LUSC	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg20016023	chr10:99160130	RRP12	-0.32	-7.97	-0.4	2.49e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg03684893	chr10:554711	DIP2C	-0.39	-7.03	-0.36	1.2e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg10862848	chr6:42927986	GNMT	-0.3	-7.28	-0.37	2.36e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.68	0.3	2.87e-8	Self-reported allergy;
LUSC	trans	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg08645402	chr16:4508243	NA	0.49	7.33	0.37	1.71e-12	Schizophrenia;
LUSC	cis	rs6845621	0.745	rs6814138	chr4:18854323	A/G	cg12196642	chr4:18937545	NA	-0.31	-5.78	-0.3	1.72e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7084921	0.608	rs11598979	chr10:101833720	C/T	cg02250046	chr10:101825185	CPN1	-0.33	-6.06	-0.31	3.69e-9	Bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25041148	chr19:58838420	ZSCAN22	-0.41	-6.14	-0.32	2.33e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg17372223	chr3:52568218	NT5DC2	0.38	6.04	0.31	4.16e-9	Electroencephalogram traits;
LUSC	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.96	-0.48	1.2e-20	Coronary artery disease;
LUSC	cis	rs6489785	0.562	rs494632	chr12:121189116	C/T	cg02419362	chr12:121203948	SPPL3	0.46	8.58	0.42	3.65e-16	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1788820	0.917	rs1788826	chr18:21154024	G/A	cg14672496	chr18:21087552	C18orf8	0.43	7.09	0.36	8.14e-12	Body mass index;
LUSC	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-8.16	-0.41	6.97e-15	Axial length;
LUSC	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg01851573	chr8:8652454	MFHAS1	0.53	8.45	0.42	8.97e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg20476274	chr7:133979776	SLC35B4	0.73	12.21	0.56	1.36e-28	Mean platelet volume;
LUSC	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg24375607	chr4:120327624	NA	0.73	10.64	0.5	5.66e-23	Corneal astigmatism;
LUSC	cis	rs1044826	0.642	rs295470	chr3:139213903	A/G	cg15131784	chr3:139108705	COPB2	0.41	6.67	0.34	1.08e-10	Obesity-related traits;
LUSC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg22834771	chr12:69754056	YEATS4	-0.48	-7.26	-0.37	2.67e-12	Blood protein levels;
LUSC	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg15309053	chr8:964076	NA	0.33	6.45	0.33	3.84e-10	Schizophrenia;
LUSC	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	0.86	13.32	0.59	9.34e-33	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg08601574	chr20:25228251	PYGB	0.47	7.3	0.37	2.12e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7267979	0.528	rs6076366	chr20:25564626	G/T	cg03522245	chr20:25566470	NINL	-0.4	-6.1	-0.32	2.96e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg07393940	chr7:158741817	NA	0.53	8.26	0.41	3.36e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg03146154	chr1:46216737	IPP	0.51	7.65	0.39	2.18e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	8.86e-24	Morning vs. evening chronotype;
LUSC	cis	rs6693567	0.545	rs7411534	chr1:150447269	C/T	cg15654264	chr1:150340011	RPRD2	0.44	7.16	0.36	5.06e-12	Migraine;
LUSC	cis	rs6961069	0.585	rs2691200	chr7:80240188	C/T	cg04458919	chr7:80252533	CD36	-0.41	-7.37	-0.37	1.32e-12	Platelet count;
LUSC	cis	rs3106136	0.967	rs61004493	chr4:95163317	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.08	-0.32	3.26e-9	Capecitabine sensitivity;
LUSC	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg21643547	chr1:205240462	TMCC2	-0.41	-7.53	-0.38	4.7e-13	Red blood cell count;
LUSC	cis	rs16976116	0.901	rs1061823	chr15:55496043	T/A	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.9e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg04518342	chr5:131593106	PDLIM4	0.5	8.88	0.44	4.09e-17	Acylcarnitine levels;
LUSC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.51	7.88	0.4	4.61e-14	Eosinophil percentage of white cells;
LUSC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.0	0.44	1.77e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3105593	0.933	rs4775894	chr15:50903600	C/T	cg08437265	chr15:50716283	USP8	0.4	5.96	0.31	6.54e-9	QT interval;
LUSC	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg03651054	chr13:50194643	NA	0.36	6.23	0.32	1.38e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg07661805	chr8:143867942	LY6D	0.27	6.17	0.32	2.03e-9	Urinary tract infection frequency;
LUSC	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg09307838	chr4:120376055	NA	0.73	10.33	0.49	6.88e-22	Corneal astigmatism;
LUSC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg27068330	chr11:65405492	SIPA1	-0.76	-11.03	-0.52	2.56e-24	Acne (severe);
LUSC	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg03647239	chr10:116582469	FAM160B1	0.47	7.63	0.39	2.44e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.13	26.15	0.82	8.17e-83	Schizophrenia;
LUSC	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg13010199	chr12:38710504	ALG10B	0.42	6.02	0.31	4.48e-9	Morning vs. evening chronotype;
LUSC	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.4	-0.38	1.08e-12	Depression;
LUSC	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	1.12	18.97	0.72	5.86e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7633770	0.805	rs12330414	chr3:46662428	T/C	cg11219411	chr3:46661640	NA	0.49	10.32	0.49	7.64e-22	Coronary artery disease;
LUSC	cis	rs6977660	0.507	rs4719580	chr7:19784847	G/T	cg05791153	chr7:19748676	TWISTNB	0.67	6.98	0.36	1.63e-11	Thyroid stimulating hormone;
LUSC	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.4	-0.56	2.57e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	11.22	0.52	5.31e-25	Alzheimer's disease;
LUSC	cis	rs2845885	1.000	rs2845885	chr11:63869062	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.67	6.11	0.32	2.73e-9	Body mass index;
LUSC	cis	rs7923452	0.688	rs117895480	chr10:30788921	A/G	cg25182066	chr10:30743637	MAP3K8	0.55	6.02	0.31	4.53e-9	Itch intensity from mosquito bite;
LUSC	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23158103	chr7:148848205	ZNF398	-0.4	-5.77	-0.3	1.85e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg05527609	chr1:210001259	C1orf107	0.93	12.05	0.55	5.19e-28	Orofacial clefts;
LUSC	cis	rs11625487	0.957	rs7156032	chr14:77951364	G/A	cg20045696	chr14:77926864	AHSA1	-0.55	-7.38	-0.37	1.28e-12	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs4072705	0.615	rs4838189	chr9:127248926	C/A	cg13476313	chr9:127244764	NR5A1	0.33	6.25	0.32	1.22e-9	Menarche (age at onset);
LUSC	cis	rs4499344	0.769	rs114289041	chr19:33083746	A/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.59	-7.7	-0.39	1.52e-13	Mean platelet volume;
LUSC	cis	rs1823874	0.962	rs12906206	chr15:100359126	A/T	cg16400843	chr15:100339927	C15orf51	0.42	8.25	0.41	3.77e-15	IgG glycosylation;
LUSC	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.5	7.75	0.39	1.13e-13	Cognitive test performance;
LUSC	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg26536354	chr8:144654954	C8orf73	0.65	7.23	0.37	3.27e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.69e-9	Response to antipsychotic treatment;
LUSC	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.56e-22	Colorectal cancer;
LUSC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg07424592	chr7:64974309	NA	1.05	6.47	0.33	3.41e-10	Diabetic kidney disease;
LUSC	cis	rs6690583	0.623	rs61770879	chr1:85504938	A/C	cg11262906	chr1:85462892	MCOLN2	0.63	6.0	0.31	5.08e-9	Serum sulfate level;
LUSC	cis	rs4946717	0.740	rs6941301	chr6:106472457	T/C	cg02270332	chr6:106475062	NA	0.46	9.44	0.46	6.72e-19	Inflammatory bowel disease;
LUSC	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg20016023	chr10:99160130	RRP12	-0.3	-7.57	-0.38	3.68e-13	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg10756647	chr7:56101905	PSPH	-0.86	-8.52	-0.42	5.52e-16	Diabetic kidney disease;
LUSC	cis	rs116139393	0.561	rs62439737	chr7:6779810	A/G	cg09896999	chr7:6746977	ZNF12	-0.5	-7.04	-0.36	1.12e-11	Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs877282	0.898	rs12357016	chr10:765675	C/T	cg17470449	chr10:769945	NA	0.53	7.09	0.36	8.21e-12	Uric acid levels;
LUSC	cis	rs7712401	0.601	rs246285	chr5:122244968	C/G	cg19077854	chr5:122220652	SNX24	-0.4	-9.09	-0.45	8.72e-18	Mean platelet volume;
LUSC	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg09941381	chr10:64027924	RTKN2	-0.38	-7.05	-0.36	1.02e-11	Rheumatoid arthritis;
LUSC	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg17168535	chr8:21777572	XPO7	0.81	14.62	0.62	9.18e-38	Mean corpuscular volume;
LUSC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	14.42	0.62	5.73e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25263898	chr1:36774223	C1orf113	0.49	5.96	0.31	6.33e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg18232548	chr7:50535776	DDC	-0.53	-7.39	-0.37	1.22e-12	Malaria;
LUSC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg04455712	chr21:45112962	RRP1B	0.49	9.12	0.45	7.25e-18	Coronary artery disease;
LUSC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg14019146	chr3:50243930	SLC38A3	0.31	6.95	0.36	1.93e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg08601574	chr20:25228251	PYGB	0.43	6.62	0.34	1.47e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.4	5.75	0.3	2e-8	Tonsillectomy;
LUSC	cis	rs1784581	0.588	rs6455790	chr6:162418447	C/T	cg17173639	chr6:162384350	PARK2	-0.55	-9.6	-0.46	1.99e-19	Itch intensity from mosquito bite;
LUSC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18876405	chr7:65276391	NA	-0.56	-8.88	-0.44	4.05e-17	Aortic root size;
LUSC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	8.85	0.44	5.31e-17	Prudent dietary pattern;
LUSC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.68	9.91	0.48	1.8899999999999998e-20	Aortic root size;
LUSC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg25258033	chr6:167368657	RNASET2	0.37	5.83	0.3	1.28e-8	Primary biliary cholangitis;
LUSC	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-8.16	-0.41	6.68e-15	Morning vs. evening chronotype;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01516881	chr6:292596	DUSP22	0.71	11.41	0.53	1.07e-25	Menopause (age at onset);
LUSC	cis	rs9653442	0.545	rs13032454	chr2:100756009	T/C	cg22139774	chr2:100720529	AFF3	-0.43	-7.25	-0.37	2.95e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.16	0.32	2.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	7.28	0.37	2.39e-12	Schizophrenia;
LUSC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg02951883	chr7:2050386	MAD1L1	-0.56	-10.05	-0.48	6.26e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs9549260	0.755	rs2721067	chr13:41156708	C/T	cg21288729	chr13:41239152	FOXO1	0.61	9.43	0.46	7.1e-19	Red blood cell count;
LUSC	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg23093090	chr10:104574429	C10orf26	-0.46	-8.4	-0.42	1.28e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs983392	0.709	rs2015475	chr11:59998963	A/C	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.16	-0.32	2.04e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg17691542	chr6:26056736	HIST1H1C	0.54	8.13	0.41	8.71e-15	Height;
LUSC	trans	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.17	-0.32	1.92e-9	Mood instability;
LUSC	cis	rs7432375	0.580	rs4678442	chr3:136532971	A/G	cg15507776	chr3:136538369	TMEM22	0.44	7.37	0.37	1.34e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg06008330	chr7:65541103	ASL	-0.4	-6.17	-0.32	1.94e-9	Aortic root size;
LUSC	cis	rs7043114	0.563	rs7848391	chr9:95337520	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.32	-5.8	-0.3	1.55e-8	Height;
LUSC	cis	rs9283706	0.689	rs11956654	chr5:66318196	A/G	cg11590213	chr5:66331682	MAST4	0.48	6.89	0.35	2.78e-11	Coronary artery disease;
LUSC	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg15571903	chr15:79123663	NA	-0.33	-6.13	-0.32	2.47e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4680	0.737	rs2239393	chr22:19950428	A/G	cg23601416	chr22:19950040	COMT	-0.44	-9.17	-0.45	5.16e-18	Blood metabolite levels;
LUSC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg25258033	chr6:167368657	RNASET2	0.48	7.8	0.39	7.93e-14	Crohn's disease;
LUSC	cis	rs7809950	0.637	rs3801964	chr7:106836242	T/C	cg23024343	chr7:107201750	COG5	-0.61	-8.91	-0.44	3.29e-17	Coronary artery disease;
LUSC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg04287289	chr16:89883240	FANCA	0.77	12.96	0.58	2.14e-31	Vitiligo;
LUSC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.32	-5.93	-0.31	7.69e-9	IgG glycosylation;
LUSC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.45	-7.43	-0.38	8.91e-13	Pulse pressure;
LUSC	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg21643547	chr1:205240462	TMCC2	-0.49	-9.37	-0.46	1.08e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg15432903	chr11:17409602	KCNJ11	0.61	10.76	0.51	2.15e-23	Type 2 diabetes;
LUSC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg24675658	chr1:53192096	ZYG11B	0.58	9.11	0.45	7.6e-18	Monocyte count;
LUSC	cis	rs7119	0.931	rs7176875	chr15:77832675	A/G	cg27398640	chr15:77910606	LINGO1	0.32	7.3	0.37	2.06e-12	Type 2 diabetes;
LUSC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg00049323	chr5:472564	LOC25845	-0.42	-6.54	-0.34	2.34e-10	Cystic fibrosis severity;
LUSC	trans	rs2786098	0.656	rs10494758	chr1:197528149	A/G	cg16005942	chr6:160526640	IGF2R	0.51	6.03	0.31	4.34e-9	Asthma;
LUSC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg13628971	chr7:2884303	GNA12	0.38	5.85	0.31	1.15e-8	Height;
LUSC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06850241	chr22:41845214	NA	0.31	5.73	0.3	2.23e-8	Vitiligo;
LUSC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg23102388	chr7:1867652	MAD1L1	-0.3	-5.68	-0.3	2.97e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg04486885	chr5:176823424	SLC34A1	-0.38	-5.86	-0.31	1.14e-8	Hemoglobin concentration;Hematocrit;
LUSC	trans	rs117147772	0.579	rs9916504	chr17:52050771	A/G	cg14684068	chr11:63894400	MACROD1	-0.53	-5.99	-0.31	5.51e-9	Photic sneeze reflex;
LUSC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.76	-10.29	-0.49	9.54e-22	Coronary artery disease;
LUSC	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg13010199	chr12:38710504	ALG10B	0.66	10.05	0.48	5.98e-21	Bladder cancer;
LUSC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.06	-0.31	3.68e-9	Total body bone mineral density;
LUSC	cis	rs6565180	0.525	rs1132812	chr16:30198151	A/G	cg17640201	chr16:30407289	ZNF48	0.63	10.23	0.49	1.46e-21	Tonsillectomy;
LUSC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	0.66	13.94	0.61	3.9e-35	Prudent dietary pattern;
LUSC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg21573476	chr21:45109991	RRP1B	-0.4	-6.26	-0.32	1.2e-9	Mean corpuscular volume;
LUSC	cis	rs7607369	0.536	rs7600248	chr2:219665963	C/T	cg02176678	chr2:219576539	TTLL4	-0.51	-9.02	-0.44	1.52e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.73	0.54	7.69e-27	Alzheimer's disease;
LUSC	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.0	-0.48	8.83e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11031096	0.868	rs2923953	chr11:4045757	G/A	cg18678763	chr11:4115507	RRM1	0.39	5.69	0.3	2.82e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10193935	0.901	rs2374405	chr2:42479874	A/C	cg27598129	chr2:42591480	NA	-0.61	-8.24	-0.41	3.89e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7615316	0.789	rs9846960	chr3:142308070	G/A	cg16271453	chr3:142027066	XRN1	-0.36	-6.03	-0.31	4.41e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg04352962	chr1:209979756	IRF6	-0.43	-6.52	-0.34	2.52e-10	Monobrow;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11327054	chr11:6502632	FXC1;ARFIP2	-0.41	-5.96	-0.31	6.45e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg21699342	chr2:239360505	ASB1	0.56	10.54	0.5	1.28e-22	Multiple system atrophy;
LUSC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg24881330	chr22:46731750	TRMU	0.84	7.39	0.37	1.22e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg23029597	chr12:123009494	RSRC2	-0.7	-9.37	-0.46	1.11e-18	Body mass index;
LUSC	trans	rs1325195	0.920	rs915337	chr1:179223751	A/G	cg11624085	chr17:8464688	MYH10	-0.41	-6.82	-0.35	4.34e-11	IgE grass sensitization;
LUSC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.24	0.41	3.84e-15	Melanoma;
LUSC	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg04851639	chr8:1020857	NA	-0.35	-7.01	-0.36	1.29e-11	Schizophrenia;
LUSC	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.94	-0.58	2.45e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10779751	0.575	rs2791655	chr1:11128654	A/G	cg08854313	chr1:11322531	MTOR	-0.69	-10.45	-0.5	2.72e-22	Body mass index;
LUSC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24531977	chr5:56204891	C5orf35	0.72	10.9	0.51	7.29e-24	Type 2 diabetes;
LUSC	cis	rs12286929	0.668	rs17304149	chr11:115049180	C/T	cg04055981	chr11:115044050	NA	0.41	7.32	0.37	1.9e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-14.21	-0.61	3.72e-36	Type 2 diabetes;
LUSC	trans	rs7189501	1.000	rs9646296	chr16:6170195	C/T	cg04663720	chr19:8454898	RAB11B	0.37	5.95	0.31	6.83e-9	Body mass index;
LUSC	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg27205649	chr11:78285834	NARS2	0.51	6.26	0.32	1.16e-9	Alzheimer's disease (survival time);
LUSC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg25019033	chr10:957182	NA	-0.53	-6.1	-0.32	2.91e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg13699009	chr12:122356056	WDR66	0.47	7.51	0.38	5.37e-13	Mean corpuscular volume;
LUSC	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg04450456	chr4:17643702	FAM184B	-0.39	-6.39	-0.33	5.7e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg06134567	chr22:46658398	PKDREJ	-0.53	-5.69	-0.3	2.73e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4654899	0.802	rs17449966	chr1:21203996	A/G	cg01072550	chr1:21505969	NA	-0.52	-7.72	-0.39	1.37e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.71	-8.58	-0.42	3.64e-16	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs12200782	1.000	rs10456330	chr6:26436692	C/T	cg11837749	chr1:55047332	ACOT11	0.58	6.23	0.32	1.41e-9	Small cell lung carcinoma;
LUSC	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg21280719	chr6:42927975	GNMT	0.26	6.18	0.32	1.91e-9	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
LUSC	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg01989461	chr14:81687754	GTF2A1	0.7	12.4	0.56	2.65e-29	Schizophrenia;
LUSC	cis	rs1858037	0.867	rs876933	chr2:65609437	C/T	cg08085232	chr2:65598271	SPRED2	-0.43	-6.33	-0.33	7.79e-10	Rheumatoid arthritis;
LUSC	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg17168535	chr8:21777572	XPO7	0.67	10.34	0.49	6.42e-22	Mean corpuscular volume;
LUSC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20135002	chr11:47629003	NA	0.5	7.81	0.39	7.45e-14	Subjective well-being;
LUSC	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg13010199	chr12:38710504	ALG10B	0.63	9.21	0.45	3.83e-18	Morning vs. evening chronotype;
LUSC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg09365446	chr1:150670422	GOLPH3L	0.55	8.44	0.42	9.59e-16	Tonsillectomy;
LUSC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.2	-0.37	3.9e-12	Bipolar disorder;
LUSC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.47	-0.5	2.33e-22	Bipolar disorder;
LUSC	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg20019720	chr6:154832845	CNKSR3	0.62	8.69	0.43	1.63e-16	Lipoprotein (a) levels;
LUSC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg12560992	chr17:57184187	TRIM37	0.84	15.33	0.64	1.53e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs10744422	0.800	rs839363	chr12:123276924	C/T	cg25930673	chr12:123319894	HIP1R	-0.6	-5.99	-0.31	5.57e-9	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.54	0.5	1.27e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg23711669	chr6:146136114	FBXO30	0.72	11.15	0.52	9.19e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.89	14.2	0.61	4.07e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.01	-0.4	1.95e-14	Body mass index;
LUSC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.1	0.41	1.03e-14	Melanoma;
LUSC	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg15556689	chr8:8085844	FLJ10661	0.59	8.85	0.44	5.14e-17	Systolic blood pressure;
LUSC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	0.92	15.28	0.64	2.55e-40	Breast cancer;
LUSC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.45	-6.95	-0.36	1.94e-11	Prudent dietary pattern;
LUSC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.4	-0.33	5.22e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg16325326	chr1:53192061	ZYG11B	0.88	15.41	0.64	7.38e-41	Monocyte count;
LUSC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.37	-0.37	1.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg14582100	chr15:45693742	SPATA5L1	0.6	10.95	0.51	4.7e-24	Homoarginine levels;
LUSC	cis	rs78707713	0.560	rs35060419	chr10:71229539	A/G	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.58	-0.46	2.31e-19	Venous thromboembolism;
LUSC	trans	rs9944715	0.911	rs8085138	chr18:43768751	G/A	cg01718231	chr17:29326311	RNF135	-0.51	-7.31	-0.37	2.04e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-7.07	-0.36	8.87e-12	Schizophrenia;
LUSC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg06238570	chr21:40685208	BRWD1	-0.56	-9.03	-0.44	1.37e-17	Menarche (age at onset);
LUSC	cis	rs981844	0.775	rs62323975	chr4:154737617	A/G	cg14289246	chr4:154710475	SFRP2	0.47	6.34	0.33	7.27e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg04398451	chr17:18023971	MYO15A	-0.54	-8.8	-0.43	7.66e-17	Total body bone mineral density;
LUSC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.42	0.38	9.97e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-1.0	-16.83	-0.68	1.77e-46	Systemic lupus erythematosus;
LUSC	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg05187965	chr10:45406764	TMEM72	-0.37	-8.45	-0.42	9.04e-16	Mean corpuscular volume;
LUSC	cis	rs13315871	1.000	rs13078787	chr3:58430487	C/T	cg12435725	chr3:58293450	RPP14	-0.7	-6.93	-0.35	2.21e-11	Cholesterol, total;
LUSC	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg08355456	chr11:67383691	NA	0.37	6.92	0.35	2.31e-11	Mean corpuscular volume;
LUSC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg25174290	chr11:3078921	CARS	0.6	9.38	0.46	1.07e-18	Longevity;
LUSC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg18225595	chr11:63971243	STIP1	0.53	9.06	0.44	1.11e-17	Platelet count;
LUSC	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	0.93	17.58	0.69	1.94e-49	Headache;
LUSC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.94	0.36	2.05e-11	Cystic fibrosis severity;
LUSC	cis	rs4343996	0.869	rs10256740	chr7:3481667	G/A	cg21248987	chr7:3385318	SDK1	0.36	5.96	0.31	6.51e-9	Motion sickness;
LUSC	cis	rs11997175	0.625	rs17698353	chr8:33592241	A/G	ch.8.33884649F	chr8:33765107	NA	0.42	6.66	0.34	1.15e-10	Body mass index;
LUSC	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	7.01	0.36	1.31e-11	Coronary artery disease;
LUSC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg03060546	chr3:49711283	APEH	0.67	7.45	0.38	8.01e-13	Menarche (age at onset);
LUSC	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg05163923	chr11:71159392	DHCR7	-0.76	-9.95	-0.48	1.32e-20	Vitamin D levels;
LUSC	trans	rs4948088	1.000	rs2876901	chr7:51018071	T/C	cg26816907	chr1:197890812	LHX9	0.56	6.22	0.32	1.47e-9	Type 1 diabetes;
LUSC	cis	rs9463078	0.605	rs1578676	chr6:44906861	G/A	cg25276700	chr6:44698697	NA	0.3	6.18	0.32	1.87e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg12365402	chr11:9010492	NRIP3	0.36	6.29	0.33	1.01e-9	Hemoglobin concentration;
LUSC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.43e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	0.65	11.4	0.53	1.23e-25	Blood metabolite levels;
LUSC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.87	0.31	1.05e-8	Menopause (age at onset);
LUSC	cis	rs2282300	0.739	rs1717775	chr11:30350254	T/G	cg25418670	chr11:30344373	C11orf46	-0.64	-9.27	-0.45	2.28e-18	Morning vs. evening chronotype;
LUSC	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21643547	chr1:205240462	TMCC2	-0.53	-10.11	-0.48	3.74e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.44	-5.68	-0.3	2.95e-8	Coronary artery disease;
LUSC	cis	rs68170813	0.652	rs11532774	chr7:107201579	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-8.6	-0.43	3.11e-16	Coronary artery disease;
LUSC	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg08645402	chr16:4508243	NA	0.53	8.96	0.44	2.31e-17	Schizophrenia;
LUSC	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.21	-0.45	3.77e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.1	0.58	6.58e-32	Cognitive test performance;
LUSC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-7.43	-0.38	9.27e-13	Platelet count;
LUSC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg23711669	chr6:146136114	FBXO30	-0.75	-11.86	-0.54	2.61e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.55	0.38	4.06e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07677032	chr17:61819896	STRADA	0.54	8.53	0.42	5.07e-16	Prudent dietary pattern;
LUSC	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	9.3	0.45	1.89e-18	Response to antipsychotic treatment;
LUSC	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.72	0.3	2.32e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9837602	1.000	rs9832186	chr3:99728503	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.18	0.32	1.82e-9	Breast cancer;
LUSC	cis	rs859767	0.704	rs7570717	chr2:135361035	C/T	cg12500956	chr2:135428796	TMEM163	-0.28	-6.59	-0.34	1.72e-10	Neuroticism;
LUSC	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.4	0.38	1.11e-12	Lung cancer in ever smokers;
LUSC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.49	-8.92	-0.44	3.03e-17	Urinary metabolites;
LUSC	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg08085267	chr17:45401833	C17orf57	0.54	8.85	0.44	5.16e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg14711859	chr11:8959438	ASCL3	0.38	5.86	0.31	1.13e-8	Hematocrit;
LUSC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18404041	chr3:52824283	ITIH1	-0.61	-11.88	-0.54	2.22e-27	Bipolar disorder;
LUSC	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg14458575	chr2:238380390	NA	0.62	7.38	0.37	1.23e-12	Prostate cancer;
LUSC	cis	rs1018836	0.608	rs2142147	chr8:91468200	A/G	cg16814680	chr8:91681699	NA	-0.54	-7.84	-0.39	6e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9807989	0.801	rs10176664	chr2:102976172	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.74	0.3	2.08e-8	Asthma;
LUSC	cis	rs3820068	0.608	rs12734937	chr1:16047726	T/C	cg24675056	chr1:15929824	NA	0.42	6.83	0.35	3.94e-11	Systolic blood pressure;
LUSC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg20243544	chr17:37824526	PNMT	0.48	5.86	0.31	1.08e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg00316803	chr15:76480434	C15orf27	0.4	7.09	0.36	7.81e-12	Blood metabolite levels;
LUSC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.3	0.45	1.9e-18	Prudent dietary pattern;
LUSC	cis	rs6982240	0.514	rs28588820	chr8:142285342	C/T	cg00131261	chr8:142287264	NA	-0.35	-5.7	-0.3	2.62e-8	Tonsillectomy;
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.4	6.2	0.32	1.69e-9	Longevity;Endometriosis;
LUSC	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg00579200	chr11:133705235	NA	-0.42	-6.23	-0.32	1.38e-9	Childhood ear infection;
LUSC	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg00277334	chr10:82204260	NA	-0.56	-7.47	-0.38	7.21e-13	Post bronchodilator FEV1;
LUSC	cis	rs250677	0.522	rs10040798	chr5:148367324	A/G	cg18129178	chr5:148520854	ABLIM3	0.54	7.74	0.39	1.19e-13	Breast cancer;
LUSC	cis	rs75920871	0.557	rs11216275	chr11:116975704	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.16	-0.32	2.04e-9	Subjective well-being;
LUSC	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-9.01	-0.44	1.66e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg24425727	chr6:36645648	CDKN1A	-0.29	-6.2	-0.32	1.66e-9	Coronary artery disease;
LUSC	cis	rs9309473	0.950	rs73947808	chr2:73721250	A/C	cg20560298	chr2:73613845	ALMS1	-0.52	-7.56	-0.38	4e-13	Metabolite levels;
LUSC	trans	rs6480314	0.542	rs12572960	chr10:70030723	C/G	cg04882175	chr6:131122610	NA	-0.54	-6.18	-0.32	1.91e-9	Optic nerve measurement (disc area);
LUSC	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg24069376	chr3:38537580	EXOG	-0.38	-7.4	-0.38	1.09e-12	Electrocardiographic conduction measures;
LUSC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg01802117	chr1:53393560	SCP2	-0.4	-6.61	-0.34	1.5e-10	Monocyte count;
LUSC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg07424592	chr7:64974309	NA	-0.64	-5.71	-0.3	2.46e-8	Diabetic kidney disease;
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg09033563	chr22:24373618	LOC391322	0.49	6.95	0.36	1.97e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4845570	0.850	rs4504897	chr1:151766851	T/A	cg07092448	chr1:151763213	TDRKH	1.29	17.94	0.7	6.87e-51	Coronary artery disease;
LUSC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	18.98	0.72	5.41e-55	Chronic sinus infection;
LUSC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg16447950	chr5:562315	NA	-0.58	-7.3	-0.37	2.1e-12	Obesity-related traits;
LUSC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.84	-0.44	5.51e-17	Obesity-related traits;
LUSC	cis	rs9462027	0.628	rs6457795	chr6:34819366	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.82	-0.3	1.35e-8	Systemic lupus erythematosus;
LUSC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	18.1	0.7	1.66e-51	Chronic sinus infection;
LUSC	cis	rs2475553	0.520	rs62437129	chr6:158655757	T/G	cg07165851	chr6:158734300	TULP4	0.48	6.85	0.35	3.53e-11	Lipoprotein (a) - cholesterol levels;
LUSC	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg01028140	chr2:1542097	TPO	-0.37	-5.98	-0.31	5.6e-9	IgG glycosylation;
LUSC	cis	rs56399783	0.901	rs73049327	chr7:2795544	T/G	cg14895029	chr7:2775587	GNA12	0.52	5.66	0.3	3.34e-8	Childhood ear infection;
LUSC	cis	rs240764	0.782	rs239222	chr6:101112817	T/A	cg09795085	chr6:101329169	ASCC3	0.4	5.85	0.3	1.18e-8	Neuroticism;
LUSC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.29	-0.37	2.22e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4474465	0.915	rs12272791	chr11:78159426	G/A	cg27205649	chr11:78285834	NARS2	-0.54	-6.25	-0.32	1.22e-9	Alzheimer's disease (survival time);
LUSC	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg04374321	chr14:90722782	PSMC1	0.75	12.08	0.55	4e-28	Mortality in heart failure;
LUSC	cis	rs2970818	0.831	rs2907495	chr12:4638164	T/C	cg11146114	chr12:4671731	NA	-0.57	-6.06	-0.31	3.63e-9	Phosphorus levels;
LUSC	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg08079166	chr15:68083412	MAP2K5	-0.42	-7.46	-0.38	7.46e-13	Restless legs syndrome;
LUSC	cis	rs4704187	0.640	rs7707246	chr5:74354875	G/T	cg03227963	chr5:74354835	NA	0.32	6.94	0.36	2.03e-11	Response to amphetamines;
LUSC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg20203395	chr5:56204925	C5orf35	-0.56	-8.14	-0.41	7.65e-15	Initial pursuit acceleration;
LUSC	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg05347473	chr6:146136440	FBXO30	0.52	8.87	0.44	4.42e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6542838	0.641	rs6757098	chr2:99471399	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.51	-0.34	2.79e-10	Fear of minor pain;
LUSC	cis	rs7106204	0.609	rs35037636	chr11:24299533	C/G	ch.11.24196551F	chr11:24239977	NA	0.69	5.68	0.3	2.86e-8	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs1751857	0.826	rs2802512	chr13:40972166	T/C	cg24642820	chr3:13462465	NUP210	0.62	5.97	0.31	6.2e-9	Body mass index (change over time) in chronic obstructive pulmonary disease;
LUSC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.58	7.62	0.38	2.63e-13	Lung function (FEV1/FVC);
LUSC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg25019033	chr10:957182	NA	-0.52	-7.1	-0.36	7.75e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	5.68	0.3	2.92e-8	Schizophrenia;
LUSC	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Bladder cancer;
LUSC	cis	rs10740039	0.883	rs7069814	chr10:62396759	C/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg03790207	chr6:42947109	PEX6	-0.45	-6.79	-0.35	5.08e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.02e-14	Corneal astigmatism;
LUSC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg06238570	chr21:40685208	BRWD1	-0.59	-9.22	-0.45	3.36e-18	Menarche (age at onset);
LUSC	cis	rs75804782	0.641	rs55740938	chr2:239332647	G/A	cg18131467	chr2:239335373	ASB1	-0.79	-6.72	-0.35	7.63e-11	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.81	-13.99	-0.61	2.61e-35	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg18230493	chr5:56204884	C5orf35	-0.94	-13.77	-0.6	1.82e-34	Initial pursuit acceleration;
LUSC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg00074818	chr8:8560427	CLDN23	0.59	9.9	0.48	1.99e-20	Obesity-related traits;
LUSC	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs73198271	0.595	rs55874147	chr8:8591954	T/C	cg01851573	chr8:8652454	MFHAS1	0.46	5.77	0.3	1.83e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg08085267	chr17:45401833	C17orf57	-0.54	-8.67	-0.43	1.95e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	7.57	0.38	3.7e-13	Prudent dietary pattern;
LUSC	cis	rs11677416	1.000	rs2071375	chr2:113535438	C/T	cg27083787	chr2:113543245	IL1A	0.48	7.37	0.37	1.39e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs12681287	0.604	rs7017716	chr8:87429001	A/C	cg00550725	chr8:87521180	FAM82B	0.42	5.68	0.3	2.89e-8	Caudate activity during reward;
LUSC	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg20848291	chr7:100343083	ZAN	-0.58	-7.02	-0.36	1.21e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6987853	0.787	rs2974309	chr8:42426961	G/A	cg09913449	chr8:42400586	C8orf40	0.53	9.23	0.45	3.16e-18	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26147372	chr3:49130904	QRICH1	0.43	5.96	0.31	6.35e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08280861	chr8:58055591	NA	0.56	6.05	0.31	3.96e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg00310523	chr12:86230176	RASSF9	-0.44	-8.28	-0.41	3.05e-15	Major depressive disorder;
LUSC	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg00310523	chr12:86230176	RASSF9	0.44	7.86	0.4	5.31e-14	Major depressive disorder;
LUSC	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg16586182	chr3:47516702	SCAP	-0.51	-7.16	-0.36	5.25e-12	Birth weight;
LUSC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.59	-8.54	-0.42	4.8e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg12311346	chr5:56204834	C5orf35	0.64	9.86	0.47	2.64e-20	Coronary artery disease;
LUSC	cis	rs2742234	0.955	rs1272142	chr10:43695484	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.36	-6.66	-0.34	1.16e-10	Hirschsprung disease;
LUSC	trans	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs2692947	0.832	rs4907212	chr2:96410048	T/A	cg23100626	chr2:96804247	ASTL	0.26	6.38	0.33	6.08e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.83	-0.3	1.34e-8	Bipolar disorder;
LUSC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg10792982	chr14:105748885	BRF1	0.46	8.2	0.41	5.2e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.13	0.55	2.54e-28	Cognitive test performance;
LUSC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	trans	rs3127573	0.843	rs3127579	chr6:160674632	G/A	cg17033287	chr1:3056542	PRDM16	0.41	6.08	0.32	3.27e-9	Creatinine levels;
LUSC	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-6.67	-0.34	1.07e-10	Neuroticism;
LUSC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg05425664	chr17:57184151	TRIM37	-0.57	-8.39	-0.42	1.35e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.02	-21.6	-0.76	2.32e-65	Ulcerative colitis;
LUSC	trans	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.53	0.5	1.4e-22	Mean corpuscular volume;
LUSC	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg23093090	chr10:104574429	C10orf26	-0.39	-7.5	-0.38	5.84e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9443189	0.570	rs276684	chr6:76427065	A/G	cg01950844	chr6:76311363	SENP6	-0.71	-7.11	-0.36	7.15e-12	Prostate cancer;
LUSC	cis	rs9361491	0.534	rs10943568	chr6:79404207	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.64	-0.3	3.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6456156	0.774	rs2021999	chr6:167529766	G/C	cg07741184	chr6:167504864	NA	-0.36	-6.34	-0.33	7.42e-10	Primary biliary cholangitis;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02178630	chr2:218678534	TNS1	0.45	5.96	0.31	6.35e-9	Neuroticism;
LUSC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg02951883	chr7:2050386	MAD1L1	-0.46	-7.9	-0.4	4.17e-14	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	trans	rs6601327	0.775	rs12156017	chr8:9406837	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.31	-0.33	8.79e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg09092052	chr15:45571596	NA	0.47	6.53	0.34	2.42e-10	Glomerular filtration rate;
LUSC	cis	rs11039100	0.850	rs34161300	chr11:5830740	G/C	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg04414720	chr1:150670196	GOLPH3L	0.49	7.78	0.39	9.11e-14	Melanoma;
LUSC	trans	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg03146154	chr1:46216737	IPP	0.5	7.41	0.38	1.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg11473876	chr11:109292803	C11orf87	0.34	5.76	0.3	1.88e-8	Schizophrenia;
LUSC	trans	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg26043149	chr18:55253948	FECH	-0.46	-7.11	-0.36	7.25e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg20701182	chr2:24300061	SF3B14	0.89	11.68	0.54	1.21e-26	Lymphocyte counts;
LUSC	cis	rs9463078	0.547	rs2038555	chr6:44744033	A/G	cg25276700	chr6:44698697	NA	0.3	6.33	0.33	7.67e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg04865166	chr7:105162814	PUS7	0.52	5.92	0.31	7.79e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs59698941	0.765	rs66822519	chr5:132167742	C/T	cg02081065	chr5:132209139	LEAP2	-0.62	-6.06	-0.31	3.66e-9	Apolipoprotein A-IV levels;
LUSC	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	6.25	0.32	1.22e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg26513180	chr16:89883248	FANCA	0.9	17.38	0.69	1.18e-48	Vitiligo;
LUSC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	1.14	17.95	0.7	6.69e-51	Monocyte percentage of white cells;
LUSC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg00033643	chr7:134001901	SLC35B4	0.47	7.3	0.37	2.15e-12	Mean platelet volume;
LUSC	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.81	0.43	6.77e-17	Axial length;
LUSC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg03351412	chr1:154909251	PMVK	0.39	5.8	0.3	1.56e-8	Prostate cancer;
LUSC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg25036284	chr2:26402008	FAM59B	-0.69	-9.95	-0.48	1.35e-20	Gut microbiome composition (summer);
LUSC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg17264618	chr3:40429014	ENTPD3	-0.3	-6.6	-0.34	1.58e-10	Renal cell carcinoma;
LUSC	cis	rs12760731	0.565	rs57247289	chr1:178090138	G/A	cg00404053	chr1:178313656	RASAL2	0.62	6.37	0.33	6.44e-10	Obesity-related traits;
LUSC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.71	13.33	0.59	8.23e-33	Height;
LUSC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.61	12.9	0.58	3.53e-31	Monocyte percentage of white cells;
LUSC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	0.83	11.5	0.53	5.19e-26	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg05925327	chr15:68127851	NA	0.37	6.62	0.34	1.4e-10	Restless legs syndrome;
LUSC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg26384229	chr12:38710491	ALG10B	0.56	8.52	0.42	5.64e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7605827	0.930	rs1318980	chr2:15549890	G/T	cg19274914	chr2:15703543	NA	0.46	8.88	0.44	4.23e-17	Educational attainment (years of education);
LUSC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.67	0.76	1.2e-65	Prudent dietary pattern;
LUSC	cis	rs9513627	0.920	rs7334943	chr13:100121287	C/G	cg25919922	chr13:100150906	NA	0.74	6.36	0.33	6.54e-10	Obesity-related traits;
LUSC	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.32	-0.37	1.83e-12	Morning vs. evening chronotype;
LUSC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg26354017	chr1:205819088	PM20D1	0.42	5.68	0.3	2.99e-8	Parkinson's disease;
LUSC	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg02023728	chr11:77925099	USP35	0.48	6.76	0.35	6.33e-11	Testicular germ cell tumor;
LUSC	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg23625390	chr15:77176239	SCAPER	-0.6	-9.36	-0.46	1.23e-18	Blood metabolite levels;
LUSC	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	5.77	0.3	1.8e-8	Educational attainment;
LUSC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.29	0.33	9.99e-10	Menopause (age at onset);
LUSC	cis	rs10203711	0.933	rs11885493	chr2:239584919	G/T	cg14580085	chr2:239553406	NA	0.39	6.47	0.33	3.56e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07677032	chr17:61819896	STRADA	0.52	8.7	0.43	1.53e-16	Prudent dietary pattern;
LUSC	cis	rs73206853	0.609	rs61582364	chr12:110967847	T/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.5	0.38	5.91e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9372498	0.536	rs10484286	chr6:118956447	T/C	cg18833306	chr6:118973337	C6orf204	-0.46	-5.84	-0.3	1.24e-8	Diastolic blood pressure;
LUSC	cis	rs6977660	0.607	rs13239423	chr7:19816571	T/C	cg07541023	chr7:19748670	TWISTNB	0.64	6.87	0.35	3.18e-11	Thyroid stimulating hormone;
LUSC	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg06092702	chr1:163392909	NA	0.46	7.77	0.39	9.92e-14	Motion sickness;
LUSC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg00074818	chr8:8560427	CLDN23	0.59	10.06	0.48	5.87e-21	Obesity-related traits;
LUSC	trans	rs12699921	0.599	rs6973480	chr7:17978129	C/T	cg23114746	chr17:47492438	PHB	0.39	6.01	0.31	4.83e-9	Fibrinogen levels;
LUSC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-0.98	-13.99	-0.61	2.6e-35	Vitiligo;
LUSC	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg12552261	chr5:112820674	MCC	-0.44	-7.06	-0.36	9.68e-12	Type 2 diabetes;
LUSC	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-7.81	-0.39	7.7e-14	Reticulocyte count;
LUSC	cis	rs2315504	0.626	rs769071	chr17:39030392	T/C	cg17985300	chr17:38952333	KRT28	-0.3	-6.04	-0.31	4.19e-9	Height;
LUSC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-7.61	-0.38	2.77e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6005807	0.719	rs12168765	chr22:29033308	G/C	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs10465746	0.967	rs28567085	chr1:84428859	G/A	cg10977910	chr1:84465055	TTLL7	0.43	6.29	0.33	1.01e-9	Obesity-related traits;
LUSC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	13.38	0.59	5.33e-33	Platelet count;
LUSC	cis	rs41308713	0.606	rs77984335	chr20:37073286	G/A	cg09132763	chr20:37064059	LOC388796;SNORA71D	0.93	6.36	0.33	6.65e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs6084875	0.840	rs2422936	chr20:4720830	C/T	cg26097573	chr20:4721490	PRNT	-0.31	-5.7	-0.3	2.68e-8	Systemic lupus erythematosus;
LUSC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.69	-0.5	3.93e-23	Alzheimer's disease;
LUSC	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg04733989	chr22:42467013	NAGA	0.39	6.54	0.34	2.32e-10	Cognitive function;
LUSC	trans	rs629535	0.814	rs477200	chr8:70059584	A/G	cg21567404	chr3:27674614	NA	0.9	13.79	0.6	1.46e-34	Dupuytren's disease;
LUSC	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg01528321	chr10:82214614	TSPAN14	0.84	12.19	0.55	1.62e-28	Post bronchodilator FEV1;
LUSC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg02153584	chr22:29168773	CCDC117	0.59	8.92	0.44	3.05e-17	Lymphocyte counts;
LUSC	cis	rs28647808	0.748	rs114667516	chr9:136258537	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg11439826	chr17:76250004	NA	0.4	6.34	0.33	7.49e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs3781663	0.581	rs10793018	chr11:70004396	G/A	cg06393558	chr11:69982916	ANO1	-0.41	-6.1	-0.32	2.9e-9	Survival in rectal cancer;
LUSC	trans	rs9929218	0.954	rs34097984	chr16:68824148	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.09	-0.52	1.52e-24	Colorectal cancer;
LUSC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg05425664	chr17:57184151	TRIM37	-0.53	-7.87	-0.4	5e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-9.22	-0.45	3.52e-18	Coffee consumption (cups per day);
LUSC	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg09092052	chr15:45571596	NA	0.46	6.37	0.33	6.42e-10	Glomerular filtration rate;
LUSC	cis	rs2729354	0.909	rs2729374	chr11:57326927	C/T	cg24343310	chr11:57249947	NA	0.35	6.38	0.33	6.05e-10	Blood protein levels;
LUSC	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.73	-0.7	4.71e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg06219351	chr7:158114137	PTPRN2	-0.52	-9.57	-0.46	2.44e-19	Calcium levels;
LUSC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg09034736	chr1:150693464	HORMAD1	0.51	7.51	0.38	5.57e-13	Tonsillectomy;
LUSC	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg18240062	chr17:79603768	NPLOC4	0.78	15.33	0.64	1.6e-40	Eye color traits;
LUSC	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.88	15.37	0.64	1.1e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg06547715	chr2:218990976	CXCR2	0.33	6.49	0.33	3.15e-10	Ulcerative colitis;
LUSC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22307029	chr19:49891270	CCDC155	0.69	9.55	0.46	2.9e-19	Multiple sclerosis;
LUSC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.86	15.91	0.66	7.83e-43	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9815354	0.951	rs9849393	chr3:41875369	G/C	cg03022575	chr3:42003672	ULK4	0.64	7.02	0.36	1.21e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.07	-0.44	1.06e-17	Monocyte percentage of white cells;
LUSC	cis	rs8040855	0.659	rs8037886	chr15:85686764	C/A	cg04831495	chr15:85060580	GOLGA6L5	0.39	5.78	0.3	1.75e-8	Bulimia nervosa;
LUSC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg11632617	chr15:75315747	PPCDC	-0.52	-6.78	-0.35	5.39e-11	Blood trace element (Zn levels);
LUSC	cis	rs7180079	1.000	rs7180079	chr15:64629873	A/G	cg02848875	chr15:64387786	SNX1	0.41	5.84	0.3	1.27e-8	Monocyte count;
LUSC	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.74	0.35	6.83e-11	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg05347473	chr6:146136440	FBXO30	0.46	7.91	0.4	3.77e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs870825	0.616	rs67409049	chr4:185623989	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg24130564	chr14:104152367	KLC1	-0.54	-7.8	-0.39	8.13e-14	Body mass index;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg03009463	chr7:17980271	SNX13	0.46	6.24	0.32	1.3e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs3741798	0.908	rs61922046	chr12:12495675	A/T	cg08615371	chr12:12503544	MANSC1	1.09	11.15	0.52	9.57e-25	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	10.19	0.49	2.05e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	5.74	0.3	2.16e-8	Rheumatoid arthritis;
LUSC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg04450456	chr4:17643702	FAM184B	0.35	5.81	0.3	1.47e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg23625390	chr15:77176239	SCAPER	0.53	8.42	0.42	1.09e-15	Blood metabolite levels;
LUSC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.33	0.37	1.76e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg05555928	chr11:63887634	MACROD1	-0.48	-6.19	-0.32	1.74e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15974085	chr18:71815641	C18orf55;FBXO15	-0.44	-6.24	-0.32	1.34e-9	Hepatitis;
LUSC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07636037	chr3:49044803	WDR6	0.59	7.13	0.36	6.16e-12	Menarche (age at onset);
LUSC	cis	rs754133	0.507	rs10876531	chr12:54443718	A/C	cg10005224	chr12:54424964	HOXC4;HOXC5	0.32	5.74	0.3	2.11e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
LUSC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg05082376	chr22:42548792	NA	-0.42	-6.53	-0.34	2.48e-10	Schizophrenia;
LUSC	cis	rs977987	0.806	rs11640473	chr16:75403289	C/A	cg04384234	chr16:75411784	CFDP1	-0.42	-6.85	-0.35	3.47e-11	Dupuytren's disease;
LUSC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.19	-13.56	-0.6	1.16e-33	Diabetic kidney disease;
LUSC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg21138405	chr5:131827807	IRF1	0.32	5.81	0.3	1.46e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.07	0.44	1.01e-17	Prudent dietary pattern;
LUSC	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg23649088	chr2:200775458	C2orf69	-0.57	-6.51	-0.34	2.83e-10	Schizophrenia;
LUSC	cis	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg21775007	chr8:11205619	TDH	0.8	13.44	0.59	3.1e-33	Retinal vascular caliber;
LUSC	cis	rs2361718	0.590	rs4527052	chr17:78140910	A/G	cg09238746	chr17:78121135	EIF4A3	-0.76	-11.32	-0.53	2.32e-25	Yeast infection;
LUSC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.37	-0.37	1.35e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg24531977	chr5:56204891	C5orf35	-0.6	-8.9	-0.44	3.51e-17	Coronary artery disease;
LUSC	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg16928487	chr17:17741425	SREBF1	-0.45	-9.03	-0.44	1.41e-17	Total body bone mineral density;
LUSC	cis	rs9905704	0.801	rs2013182	chr17:56637770	G/A	cg12560992	chr17:57184187	TRIM37	-0.59	-8.46	-0.42	8.56e-16	Testicular germ cell tumor;
LUSC	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg17470723	chr8:74884337	TCEB1	0.52	8.19	0.41	5.44e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs617219	0.819	rs2591389	chr5:78555208	C/T	cg24856658	chr5:78533917	JMY	-0.31	-5.95	-0.31	6.75e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs4700695	0.719	rs27079	chr5:65443966	C/T	cg21114390	chr5:65439923	SFRS12	-0.63	-8.97	-0.44	2.12e-17	Facial morphology (factor 19);
LUSC	cis	rs16912285	0.688	rs59246618	chr11:24315201	G/T	ch.11.24196551F	chr11:24239977	NA	0.91	9.97	0.48	1.15e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24549020	chr5:56110836	MAP3K1	0.49	5.81	0.3	1.46e-8	Initial pursuit acceleration;
LUSC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.18	0.32	1.85e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.82	-0.3	1.42e-8	Ulcerative colitis;
LUSC	cis	rs6785206	1.000	rs2712370	chr3:128425204	C/G	cg16766828	chr3:128327626	NA	-0.65	-6.91	-0.35	2.48e-11	Lymphocyte percentage of white cells;
LUSC	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg08508325	chr11:3079039	CARS	0.38	8.46	0.42	8.48e-16	Calcium levels;
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg11645453	chr3:52864694	ITIH4	0.29	6.71	0.34	8.6e-11	Electroencephalogram traits;
LUSC	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.6	13.68	0.6	3.82e-34	Height;
LUSC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg08088566	chr11:430123	ANO9	0.66	7.31	0.37	1.98e-12	Body mass index;
LUSC	cis	rs977987	0.806	rs1364077	chr16:75396991	C/T	cg03315344	chr16:75512273	CHST6	0.48	9.18	0.45	4.78e-18	Dupuytren's disease;
LUSC	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg21051086	chr3:73046214	PPP4R2	-0.52	-7.96	-0.4	2.63e-14	Pancreatic cancer;
LUSC	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg03342759	chr3:160939853	NMD3	-0.47	-7.75	-0.39	1.14e-13	Morning vs. evening chronotype;
LUSC	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg00806126	chr19:22604979	ZNF98	0.38	5.91	0.31	8.64e-9	Pain;
LUSC	cis	rs1858037	0.867	rs953312	chr2:65567690	C/T	cg08085232	chr2:65598271	SPRED2	-0.39	-5.76	-0.3	1.87e-8	Rheumatoid arthritis;
LUSC	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg04310649	chr10:35416472	CREM	-0.43	-6.56	-0.34	2.02e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9549260	0.564	rs6563844	chr13:41298190	T/C	cg21288729	chr13:41239152	FOXO1	0.52	7.74	0.39	1.23e-13	Red blood cell count;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg03414732	chr18:32870301	ZNF271;ZNF397OS	0.58	6.84	0.35	3.76e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7267979	0.565	rs6107059	chr20:25592431	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-12.59	-0.57	5.25e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg15448220	chr1:150897856	SETDB1	0.4	5.87	0.31	1.02e-8	Tonsillectomy;
LUSC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg12311346	chr5:56204834	C5orf35	-0.82	-13.08	-0.58	7.72e-32	Coronary artery disease;
LUSC	trans	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg06636001	chr8:8085503	FLJ10661	0.45	6.55	0.34	2.11e-10	Retinal vascular caliber;
LUSC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg26566898	chr11:117069891	TAGLN	-0.48	-8.4	-0.42	1.29e-15	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15268184	chr6:170893863	PDCD2	-0.44	-6.59	-0.34	1.69e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs721399	0.542	rs10085931	chr8:18245449	A/G	cg18736775	chr8:18248649	NAT2	-0.5	-5.87	-0.31	1.03e-8	Blood metabolite levels;
LUSC	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg22705602	chr4:152727874	NA	-0.32	-6.59	-0.34	1.73e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg04944784	chr2:26401820	FAM59B	-0.75	-11.0	-0.52	3.24e-24	Gut microbiome composition (summer);
LUSC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg09021430	chr5:549028	NA	-0.53	-7.47	-0.38	7.23e-13	Lung disease severity in cystic fibrosis;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06188019	chr1:3541438	TPRG1L	-0.42	-6.02	-0.31	4.5e-9	Electrocardiographic conduction measures;
LUSC	cis	rs8077577	0.895	rs11654741	chr17:18124470	C/A	cg16794390	chr17:18148240	FLII	0.42	5.81	0.3	1.43e-8	Obesity-related traits;
LUSC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg03146154	chr1:46216737	IPP	0.57	8.23	0.41	4.16e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11645453	chr3:52864694	ITIH4	0.3	6.89	0.35	2.81e-11	Cognitive function;
LUSC	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg14458575	chr2:238380390	NA	0.61	7.12	0.36	6.85e-12	Prostate cancer;
LUSC	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg04865166	chr7:105162814	PUS7	0.53	5.69	0.3	2.82e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg05623727	chr3:50126028	RBM5	0.31	5.73	0.3	2.27e-8	Body mass index;
LUSC	cis	rs34734847	1.000	rs3021338	chr12:121162989	A/G	cg21892295	chr12:121157589	UNC119B	-0.52	-9.58	-0.46	2.37e-19	Mean corpuscular volume;
LUSC	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.16	-0.45	5.33e-18	Monocyte percentage of white cells;
LUSC	cis	rs80130819	0.748	rs10747531	chr12:48632280	A/G	cg24011408	chr12:48396354	COL2A1	0.47	5.95	0.31	6.87e-9	Prostate cancer;
LUSC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg00129232	chr17:37814104	STARD3	-0.47	-6.93	-0.35	2.19e-11	Asthma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00052422	chr3:41240987	CTNNB1	-0.41	-6.26	-0.32	1.15e-9	Electrocardiographic conduction measures;
LUSC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg02475777	chr4:1388615	CRIPAK	0.44	6.5	0.34	2.92e-10	Obesity-related traits;
LUSC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-1.25	-13.65	-0.6	5.24e-34	Diabetic kidney disease;
LUSC	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg11861562	chr11:117069780	TAGLN	0.32	6.2	0.32	1.64e-9	Blood protein levels;
LUSC	cis	rs2692947	0.740	rs60452119	chr2:96420050	T/C	cg22654517	chr2:96458247	NA	0.37	7.48	0.38	6.63e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.48	-7.49	-0.38	6.35e-13	IgG glycosylation;
LUSC	cis	rs7586879	0.765	rs11683429	chr2:25120733	T/A	cg01884057	chr2:25150051	NA	0.43	8.95	0.44	2.49e-17	Body mass index;
LUSC	cis	rs78572108	0.858	rs13384444	chr2:42265449	G/C	cg00607755	chr2:42274082	PKDCC	0.36	6.52	0.34	2.61e-10	Total body bone mineral density;
LUSC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs870825	0.549	rs28542773	chr4:185617935	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg22532475	chr10:104410764	TRIM8	-0.39	-8.14	-0.41	8.16e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg11130432	chr3:121712080	ILDR1	-0.63	-9.54	-0.46	3.19e-19	Multiple sclerosis;
LUSC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7119	0.689	rs12907630	chr15:77812906	G/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.58	-0.34	1.82e-10	Type 2 diabetes;
LUSC	cis	rs2857891	0.817	rs2239732	chr11:6976689	C/G	cg04053776	chr11:6947353	ZNF215	0.42	5.82	0.3	1.39e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	0.91	17.07	0.68	2.09e-47	Cognitive function;
LUSC	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	8.72	0.43	1.32e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs983392	0.709	rs2162254	chr11:60039917	T/A	cg20284999	chr11:59952153	MS4A6A	0.39	6.48	0.33	3.2e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg06623918	chr6:96969491	KIAA0776	0.8	9.9	0.48	2e-20	Migraine;Coronary artery disease;
LUSC	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg11608241	chr8:8085544	FLJ10661	-0.48	-6.75	-0.35	6.67e-11	Neuroticism;
LUSC	trans	rs7607980	0.929	rs78970517	chr2:165554302	C/T	cg21604450	chr1:66998563	SGIP1	0.54	6.18	0.32	1.84e-9	Fasting blood insulin (BMI interaction);Fasting blood insulin;Type 2 diabetes;
LUSC	cis	rs9517320	1.000	rs9513430	chr13:99127252	C/G	cg20487152	chr13:99095054	FARP1	0.34	6.3	0.33	9.42e-10	Longevity;
LUSC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg08308459	chr2:38893161	GALM	-0.57	-5.65	-0.3	3.41e-8	5-HTT brain serotonin transporter levels;
LUSC	cis	rs757081	0.637	rs34941502	chr11:17155432	G/A	cg15432903	chr11:17409602	KCNJ11	-0.38	-5.94	-0.31	7.29e-9	Systolic blood pressure;
LUSC	cis	rs4786125	0.588	rs1473516	chr16:6923077	C/T	cg03623568	chr16:6915990	A2BP1	-0.51	-8.43	-0.42	1.04e-15	Heart rate variability traits (SDNN);
LUSC	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.54	-0.38	4.51e-13	Retinal vascular caliber;
LUSC	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg05110241	chr16:68378359	PRMT7	-0.47	-6.07	-0.32	3.45e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-10.7	-0.51	3.63e-23	Gut microbiome composition (summer);
LUSC	cis	rs35995292	0.857	rs6946859	chr7:38957432	A/G	cg19327137	chr7:38886074	VPS41	0.35	5.7	0.3	2.62e-8	Subjective well-being (multi-trait analysis);
LUSC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg18904891	chr8:8559673	CLDN23	0.6	8.35	0.42	1.8e-15	Obesity-related traits;
LUSC	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg05707623	chr12:122985044	ZCCHC8	0.65	8.46	0.42	8.65e-16	Body mass index;
LUSC	cis	rs612683	0.560	rs491675	chr1:100902936	A/G	cg06223162	chr1:101003688	GPR88	0.43	7.9	0.4	4.09e-14	Breast cancer;
LUSC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg05709478	chr1:6581295	PLEKHG5	0.51	6.03	0.31	4.36e-9	Body mass index;
LUSC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg16060761	chr17:80687452	NA	-0.51	-8.01	-0.4	1.97e-14	Glycated hemoglobin levels;
LUSC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.89	0.35	2.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg17385448	chr1:15911702	AGMAT	0.34	5.68	0.3	2.97e-8	Systolic blood pressure;
LUSC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19717773	chr7:2847554	GNA12	-0.38	-6.2	-0.32	1.68e-9	Height;
LUSC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-13.81	-0.6	1.23e-34	Alzheimer's disease;
LUSC	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-7.74	-0.39	1.16e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg20703242	chr1:230279135	GALNT2	0.52	8.2	0.41	5.22e-15	Coronary artery disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03916864	chr12:109535384	UNG	-0.46	-7.07	-0.36	9.11e-12	Electrocardiographic conduction measures;
LUSC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.18	0.58	3.19e-32	Cognitive test performance;
LUSC	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg24375607	chr4:120327624	NA	0.75	11.42	0.53	9.94e-26	Corneal astigmatism;
LUSC	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-10.6	-0.5	7.74e-23	Monocyte percentage of white cells;
LUSC	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg05283184	chr6:79620031	NA	-0.57	-12.02	-0.55	6.96e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg10756647	chr7:56101905	PSPH	0.88	8.91	0.44	3.39e-17	Diabetic kidney disease;
LUSC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	10.67	0.5	4.63e-23	Cognitive test performance;
LUSC	cis	rs4356932	0.656	rs13126007	chr4:76862255	G/A	cg00809888	chr4:76862425	NAAA	-0.36	-5.72	-0.3	2.36e-8	Blood protein levels;
LUSC	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg18478394	chr8:109455254	TTC35	0.44	6.81	0.35	4.63e-11	Dupuytren's disease;
LUSC	cis	rs8032158	1.000	rs11632096	chr15:56210499	A/G	cg02198044	chr15:56286336	NEDD4	-0.36	-5.72	-0.3	2.36e-8	Keloid;
LUSC	cis	rs9905704	0.589	rs2632509	chr17:56487887	C/T	cg19466818	chr17:56409534	MIR142	0.32	6.06	0.31	3.58e-9	Testicular germ cell tumor;
LUSC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.58	10.41	0.49	3.7e-22	Bone mineral density;
LUSC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg12310025	chr6:25882481	NA	-0.45	-7.8	-0.39	7.82e-14	Blood metabolite levels;
LUSC	cis	rs11645898	1.000	rs11645898	chr16:72229532	A/G	cg14768367	chr16:72042858	DHODH	-0.57	-6.38	-0.33	5.78e-10	Blood protein levels;
LUSC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg13770153	chr20:60521292	NA	-0.61	-8.39	-0.42	1.43e-15	Body mass index;
LUSC	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg11161011	chr14:65562177	MAX	-0.81	-12.02	-0.55	6.74e-28	Obesity-related traits;
LUSC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	0.84	11.63	0.54	1.82e-26	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg11871910	chr12:69753446	YEATS4	0.81	14.04	0.61	1.62e-35	Blood protein levels;
LUSC	cis	rs1784581	0.507	rs1790020	chr6:162366266	C/T	cg17173639	chr6:162384350	PARK2	-0.64	-10.92	-0.51	5.91e-24	Itch intensity from mosquito bite;
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg27143824	chr4:184580738	C4orf41;RWDD4A	0.41	6.3	0.33	9.44e-10	Eotaxin levels;
LUSC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-7.09	-0.36	8.04e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08048268	chr3:133502702	NA	0.47	8.83	0.43	6.16e-17	Iron status biomarkers;
LUSC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg26924012	chr15:45694286	SPATA5L1	1.12	20.66	0.75	1.16e-61	Homoarginine levels;
LUSC	cis	rs1322512	1.000	rs2758777	chr6:153007467	G/T	cg27316956	chr6:152958899	SYNE1	0.34	5.98	0.31	5.72e-9	Tonometry;
LUSC	cis	rs4947962	0.617	rs1013127	chr7:55139068	A/G	cg23757825	chr7:55092271	EGFR	-0.5	-6.61	-0.34	1.56e-10	Subjective response to lithium treatment;
LUSC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg11843238	chr5:131593191	PDLIM4	0.39	6.57	0.34	1.89e-10	Breast cancer;
LUSC	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg24692254	chr21:30365293	RNF160	-0.69	-10.96	-0.51	4.4e-24	Pancreatic cancer;
LUSC	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg04374321	chr14:90722782	PSMC1	0.72	11.5	0.53	5.41e-26	Mortality in heart failure;
LUSC	cis	rs13082711	0.911	rs34422761	chr3:27513366	C/A	cg02860705	chr3:27208620	NA	0.47	7.92	0.4	3.58e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs9462027	0.628	rs9348950	chr6:34673678	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.35	6.28	0.33	1.04e-9	Systemic lupus erythematosus;
LUSC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6840360	1.000	rs1105535	chr4:152605170	A/G	cg22705602	chr4:152727874	NA	-0.27	-5.74	-0.3	2.15e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	0.64	13.37	0.59	5.97e-33	Prudent dietary pattern;
LUSC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg13918804	chr1:2043761	PRKCZ	0.27	5.66	0.3	3.22e-8	Height;
LUSC	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	0.85	15.02	0.64	2.45e-39	Prostate cancer;
LUSC	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg19773385	chr1:10388646	KIF1B	-0.5	-8.66	-0.43	2.11e-16	Hepatocellular carcinoma;
LUSC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg22166914	chr1:53195759	ZYG11B	0.5	7.97	0.4	2.55e-14	Monocyte count;
LUSC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06481639	chr22:41940642	POLR3H	0.5	5.72	0.3	2.42e-8	Vitiligo;
LUSC	cis	rs2637266	0.783	rs1797500	chr10:78510400	G/A	cg18941641	chr10:78392320	NA	0.39	7.14	0.36	5.99e-12	Pulmonary function;
LUSC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg23283495	chr1:209979779	IRF6	0.73	9.47	0.46	5.2e-19	Cleft lip with or without cleft palate;
LUSC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg14558114	chr2:88469736	THNSL2	0.8	7.13	0.36	6.19e-12	Plasma clusterin levels;
LUSC	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg23029597	chr12:123009494	RSRC2	-0.76	-9.55	-0.46	2.94e-19	Body mass index;
LUSC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	7.19	0.37	4.15e-12	Parkinson's disease;
LUSC	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11791136	chr19:42788257	CIC	-0.44	-6.26	-0.32	1.21e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	14.86	0.63	1.07e-38	Platelet count;
LUSC	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg04455712	chr21:45112962	RRP1B	0.46	8.69	0.43	1.69e-16	Mean corpuscular volume;
LUSC	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg26395211	chr5:140044315	WDR55	-0.38	-5.74	-0.3	2.14e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg11584989	chr19:19387371	SF4	0.57	6.88	0.35	2.92e-11	Bipolar disorder;
LUSC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg15605315	chr1:45957053	TESK2	0.51	8.54	0.42	4.98e-16	High light scatter reticulocyte count;
LUSC	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg22029157	chr1:209979665	IRF6	0.77	9.48	0.46	4.95e-19	Cleft lip with or without cleft palate;
LUSC	cis	rs73198271	0.694	rs113694763	chr8:8647076	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.32	-0.33	8.29e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg22117172	chr7:91764530	CYP51A1	-0.33	-5.88	-0.31	9.88e-9	Breast cancer;
LUSC	cis	rs11209002	0.592	rs4655672	chr1:67553543	C/T	cg02640540	chr1:67518911	SLC35D1	0.65	9.14	0.45	6.23e-18	Crohn's disease;
LUSC	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg12863693	chr15:85201151	NMB	0.36	7.28	0.37	2.44e-12	Schizophrenia;
LUSC	cis	rs9584850	0.834	rs745638	chr13:99119307	C/G	cg07423050	chr13:99094983	FARP1	-0.39	-6.49	-0.33	3.02e-10	Neuroticism;
LUSC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	0.92	15.3	0.64	2.12e-40	Breast cancer;
LUSC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg20406979	chr6:167373233	NA	-0.26	-6.16	-0.32	2.1e-9	Crohn's disease;
LUSC	cis	rs71327718	1	rs71327718	chr3:125592857	C/G	cg05084668	chr3:125655381	ALG1L	-0.86	-11.84	-0.54	3.15e-27	Metabolite levels (HVA/5-HIAA ratio);
LUSC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg04315214	chr1:2043799	PRKCZ	0.47	9.54	0.46	3.23e-19	Height;
LUSC	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg13010199	chr12:38710504	ALG10B	0.62	9.48	0.46	4.72e-19	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg21521518	chr4:53727714	RASL11B	0.49	6.11	0.32	2.7e-9	Optic nerve measurement (cup area);
LUSC	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg17425144	chr1:10567563	PEX14	0.59	11.46	0.53	7.42e-26	Prostate cancer;
LUSC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	1.23	16.89	0.68	1.03e-46	Eosinophil percentage of granulocytes;
LUSC	cis	rs17604090	0.756	rs113829432	chr7:29725069	C/T	cg19413766	chr7:29689036	LOC646762	-0.68	-8.5	-0.42	6.57e-16	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg15790184	chr11:494944	RNH1	0.53	6.05	0.31	3.83e-9	Body mass index;
LUSC	cis	rs12900413	0.562	rs2118849	chr15:90302399	G/T	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.56e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.48	7.18	0.37	4.7e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03934478	chr11:495069	RNH1	0.82	9.84	0.47	3.08e-20	Body mass index;
LUSC	cis	rs886126	0.761	rs10774615	chr12:111659096	T/C	cg10833066	chr12:111807467	FAM109A	0.41	6.33	0.33	7.74e-10	Coronary heart disease;
LUSC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg17948913	chr5:572064	NA	0.37	5.68	0.3	3.01e-8	Obesity-related traits;
LUSC	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg01420254	chr6:26195488	NA	0.71	7.5	0.38	5.86e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs10465746	0.780	rs11163872	chr1:84421969	G/T	cg10977910	chr1:84465055	TTLL7	0.46	6.71	0.34	8.3e-11	Obesity-related traits;
LUSC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg23788917	chr6:8435910	SLC35B3	0.51	7.58	0.38	3.38e-13	Motion sickness;
LUSC	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.66	0.54	1.35e-26	Cognitive ability;
LUSC	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg02549819	chr16:58548995	SETD6	0.96	9.04	0.44	1.29e-17	Schizophrenia;
LUSC	cis	rs3772130	0.923	rs28674947	chr3:121529421	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.21	0.49	1.78e-21	Cognitive performance;
LUSC	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.68	10.54	0.5	1.25e-22	Mean corpuscular volume;
LUSC	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.84	-0.74	1.97e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs367615	0.552	rs2963010	chr5:108737043	T/C	cg17395555	chr5:108820864	NA	-0.5	-8.75	-0.43	1.1e-16	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs6577655	0.517	rs11998030	chr8:135585325	C/T	cg17885191	chr8:135476712	NA	0.55	7.35	0.37	1.56e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2858942	0.602	rs1211375	chr16:240280	G/T	cg00126636	chr16:237282	NA	0.44	6.91	0.35	2.51e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg03060546	chr3:49711283	APEH	0.7	11.5	0.53	5.08e-26	Resting heart rate;
LUSC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg15448220	chr1:150897856	SETDB1	0.41	6.06	0.31	3.69e-9	Melanoma;
LUSC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg04362960	chr10:104952993	NT5C2	0.52	6.54	0.34	2.35e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-6.5	-0.34	2.94e-10	Daytime sleep phenotypes;
LUSC	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg04586622	chr2:25135609	ADCY3	0.43	9.06	0.44	1.09e-17	Body mass index;
LUSC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg20203395	chr5:56204925	C5orf35	-0.58	-8.11	-0.41	9.99e-15	Initial pursuit acceleration;
LUSC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-7.81	-0.39	7.61e-14	Longevity;Endometriosis;
LUSC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg09826364	chr7:158789723	NA	-0.38	-5.91	-0.31	8.56e-9	Facial morphology (factor 20);
LUSC	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.13e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg23281280	chr6:28129359	ZNF389	0.45	5.67	0.3	3.04e-8	Parkinson's disease;
LUSC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg03396347	chr1:1875803	NA	-0.55	-12.3	-0.56	6.11e-29	Body mass index;
LUSC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg23719950	chr11:63933701	MACROD1	-0.62	-8.06	-0.4	1.42e-14	Mean platelet volume;
LUSC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg09877947	chr5:131593287	PDLIM4	0.42	6.69	0.34	9.17e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07362569	chr17:61921086	SMARCD2	0.37	7.6	0.38	2.92e-13	Prudent dietary pattern;
LUSC	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg21770322	chr7:97807741	LMTK2	-0.49	-7.99	-0.4	2.29e-14	Breast cancer;
LUSC	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg05347473	chr6:146136440	FBXO30	-0.38	-6.24	-0.32	1.35e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7809950	0.953	rs2253271	chr7:107201252	G/C	cg23024343	chr7:107201750	COG5	-0.56	-8.88	-0.44	4.33e-17	Coronary artery disease;
LUSC	cis	rs12541635	0.801	rs28709304	chr8:107106368	T/G	cg10147462	chr8:107024639	NA	-0.45	-7.99	-0.4	2.18e-14	Age of smoking initiation;
LUSC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg05347473	chr6:146136440	FBXO30	0.52	9.04	0.44	1.29e-17	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.61	0.67	1.39e-45	Exhaled nitric oxide output;
LUSC	trans	rs11657269	0.518	rs8070021	chr17:6326214	A/G	cg04615859	chr17:7762123	CYB5D1;LSMD1	-0.34	-6.02	-0.31	4.67e-9	TRAIL levels;
LUSC	cis	rs7123876	0.587	rs11601122	chr11:72362718	A/G	cg03713592	chr11:72463424	ARAP1	0.76	8.01	0.4	1.88e-14	Body mass index;
LUSC	cis	rs10189230	0.967	rs7573758	chr2:222357326	G/T	cg14652038	chr2:222343519	EPHA4	0.32	5.71	0.3	2.46e-8	Urate levels in lean individuals;
LUSC	cis	rs9473147	0.516	rs9463342	chr6:47585106	A/T	cg20196966	chr6:47445060	CD2AP	0.43	6.08	0.32	3.24e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.86	-11.73	-0.54	7.69e-27	Asthma;
LUSC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg25039879	chr17:56429692	SUPT4H1	0.66	8.88	0.44	4.12e-17	Cognitive test performance;
LUSC	cis	rs472402	0.560	rs2288444	chr5:6619923	A/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.51	-7.41	-0.38	1.06e-12	Response to amphetamines;
LUSC	cis	rs2708377	0.860	rs2708336	chr12:11273406	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	trans	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.02	14.05	0.61	1.55e-35	Exhaled nitric oxide levels;
LUSC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.17	-0.32	2.03e-9	Monocyte count;
LUSC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg09858108	chr8:58055024	NA	0.45	6.16	0.32	2.11e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.4	0.53	1.19e-25	Morning vs. evening chronotype;
LUSC	cis	rs7589342	0.839	rs12997003	chr2:106436413	C/T	cg16077055	chr2:106428750	NCK2	0.38	7.18	0.37	4.52e-12	Addiction;
LUSC	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg05527609	chr1:210001259	C1orf107	1.03	14.75	0.63	2.95e-38	Orofacial clefts;
LUSC	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg26162295	chr17:38119207	GSDMA	-0.26	-6.07	-0.32	3.55e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs66716358	0.676	rs1869481	chr11:44319905	T/C	cg16977035	chr11:44330474	ALX4	-0.34	-5.76	-0.3	1.88e-8	Monobrow;
LUSC	cis	rs7188861	0.768	rs529866	chr16:11373320	A/G	cg00044050	chr16:11439710	C16orf75	-0.54	-6.18	-0.32	1.82e-9	HDL cholesterol;
LUSC	cis	rs61990749	0.544	rs12435761	chr14:78246077	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	6.69	0.34	9.25e-11	Fibroblast growth factor basic levels;
LUSC	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg09365446	chr1:150670422	GOLPH3L	0.53	8.01	0.4	1.9e-14	Melanoma;
LUSC	cis	rs3755132	0.929	rs16862799	chr2:15742260	G/A	cg12888861	chr2:15731646	DDX1	0.5	7.36	0.37	1.41e-12	Wilms tumor;
LUSC	trans	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg18335740	chr13:41363409	SLC25A15	0.77	13.73	0.6	2.47e-34	Lewy body disease;
LUSC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg27266027	chr21:40555129	PSMG1	-0.4	-5.84	-0.3	1.24e-8	Cognitive function;
LUSC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg26924012	chr15:45694286	SPATA5L1	1.01	16.17	0.66	7.93e-44	Homoarginine levels;
LUSC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-6.43	-0.33	4.39e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg11102782	chr19:18549136	ISYNA1	-0.36	-6.89	-0.35	2.82e-11	Breast cancer;
LUSC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg23711669	chr6:146136114	FBXO30	0.76	13.64	0.6	5.66e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg21775007	chr8:11205619	TDH	0.47	6.71	0.34	8.45e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg15571903	chr15:79123663	NA	-0.31	-5.84	-0.3	1.25e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2281845	0.533	rs10753891	chr1:201100482	A/G	cg06714761	chr1:201096289	NA	0.37	7.33	0.37	1.78e-12	Permanent tooth development;
LUSC	cis	rs936229	0.813	rs72730503	chr15:75086386	G/A	cg14664628	chr15:75095509	CSK	-1.01	-17.02	-0.68	3.11e-47	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs8061121	1.000	rs8061121	chr16:87193084	A/G	cg10047845	chr16:87184939	NA	0.49	5.69	0.3	2.8e-8	Congenital left-sided heart lesions;
LUSC	trans	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg01620082	chr3:125678407	NA	-0.78	-6.87	-0.35	3.13e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg13263323	chr15:86062960	AKAP13	-0.34	-5.65	-0.3	3.37e-8	Coronary artery disease;
LUSC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.49	6.13	0.32	2.43e-9	Schizophrenia;
LUSC	cis	rs9534288	0.912	rs3736944	chr13:46619316	T/C	cg15192986	chr13:46630673	CPB2	-0.74	-11.41	-0.53	1.1e-25	Blood protein levels;
LUSC	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.82e-12	Blood metabolite levels;
LUSC	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg03806693	chr22:41940476	POLR3H	-0.81	-11.41	-0.53	1.12e-25	Vitiligo;
LUSC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-7.35	-0.37	1.51e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.93	-0.35	2.15e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg05347473	chr6:146136440	FBXO30	-0.41	-6.91	-0.35	2.48e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	0.64	13.57	0.6	1.06e-33	Prudent dietary pattern;
LUSC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg23791538	chr6:167370224	RNASET2	-0.42	-6.83	-0.35	3.97e-11	Crohn's disease;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg26102512	chr17:1619670	WDR81;C17orf91	-0.49	-6.34	-0.33	7.4e-10	Cognitive function;Information processing speed;
LUSC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg15790184	chr11:494944	RNH1	0.61	6.44	0.33	4.27e-10	Body mass index;
LUSC	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.45	0.46	5.93e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg09307838	chr4:120376055	NA	0.64	9.62	0.47	1.69e-19	Corneal astigmatism;
LUSC	cis	rs2274273	0.837	rs11625968	chr14:55801004	G/C	cg04306507	chr14:55594613	LGALS3	0.57	12.71	0.57	1.92e-30	Protein biomarker;
LUSC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.98	0.55	9.29e-28	Chronic sinus infection;
LUSC	cis	rs7119	0.689	rs11630557	chr15:77820712	A/G	cg27398640	chr15:77910606	LINGO1	-0.31	-6.55	-0.34	2.14e-10	Type 2 diabetes;
LUSC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg02569458	chr12:86230093	RASSF9	0.6	10.37	0.49	5.12e-22	Major depressive disorder;
LUSC	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg06636001	chr8:8085503	FLJ10661	0.52	7.82	0.39	7.09e-14	Retinal vascular caliber;
LUSC	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg04586622	chr2:25135609	ADCY3	0.4	8.31	0.41	2.39e-15	Body mass index in non-asthmatics;
LUSC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.26	-0.45	2.51e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg25281562	chr12:121454272	C12orf43	-0.43	-5.79	-0.3	1.64e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	trans	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg02800362	chr5:177631904	HNRNPAB	0.88	13.12	0.58	5.45e-32	Obesity-related traits;
LUSC	cis	rs7760535	0.794	rs12529158	chr6:111822447	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.4	7.56	0.38	3.95e-13	Metabolic traits;
LUSC	cis	rs7192380	0.964	rs55780735	chr16:69740374	A/G	cg26679644	chr16:69762563	NA	-0.36	-6.16	-0.32	2.04e-9	Sjögren's syndrome;
LUSC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.85	0.63	1.19e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg12463550	chr7:65579703	CRCP	0.5	7.02	0.36	1.22e-11	Aortic root size;
LUSC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg04414720	chr1:150670196	GOLPH3L	0.57	9.22	0.45	3.31e-18	Tonsillectomy;
LUSC	cis	rs2637266	0.686	rs1660915	chr10:78525318	T/A	cg18941641	chr10:78392320	NA	0.38	7.02	0.36	1.23e-11	Pulmonary function;
LUSC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg08088566	chr11:430123	ANO9	-0.63	-7.3	-0.37	2.12e-12	Body mass index;
LUSC	cis	rs7072216	0.770	rs1061115	chr10:100177049	G/A	cg26618903	chr10:100175079	PYROXD2	-0.35	-6.97	-0.36	1.75e-11	Metabolite levels;
LUSC	trans	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg04995722	chr7:26192034	NFE2L3	-0.37	-6.07	-0.32	3.38e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg00990874	chr7:1149470	C7orf50	-0.5	-5.97	-0.31	5.96e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-7.55	-0.38	4.21e-13	Aortic root size;
LUSC	cis	rs1950626	0.705	rs34991312	chr14:101435167	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.77	0.39	9.83e-14	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg16070123	chr10:51489643	NA	-0.55	-9.01	-0.44	1.59e-17	Prostate-specific antigen levels;
LUSC	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg24375607	chr4:120327624	NA	0.77	11.25	0.52	4.16e-25	Corneal astigmatism;
LUSC	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg16006841	chr5:176797999	RGS14	-0.65	-10.37	-0.49	4.94e-22	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.77	0.35	5.97e-11	Tonsillectomy;
LUSC	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg05887092	chr17:76393375	PGS1	0.62	11.81	0.54	3.85e-27	HDL cholesterol levels;
LUSC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-7.01	-0.36	1.34e-11	Menopause (age at onset);
LUSC	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg20283391	chr11:68216788	NA	-0.61	-8.55	-0.42	4.43e-16	Total body bone mineral density;
LUSC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg20243544	chr17:37824526	PNMT	0.57	7.77	0.39	9.72e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg26566898	chr11:117069891	TAGLN	0.33	6.33	0.33	7.76e-10	Blood protein levels;
LUSC	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.89	0.44	3.9e-17	Lung cancer in ever smokers;
LUSC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg25019033	chr10:957182	NA	-0.5	-6.28	-0.32	1.07e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs9420	0.925	rs488769	chr11:57450720	A/C	cg02958346	chr11:57425731	CLP1	-0.43	-6.27	-0.32	1.09e-9	Schizophrenia;
LUSC	cis	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg17187183	chr4:55093834	PDGFRA	0.39	5.89	0.31	9.61e-9	Corneal astigmatism;
LUSC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06481639	chr22:41940642	POLR3H	-0.52	-5.98	-0.31	5.75e-9	Vitiligo;
LUSC	cis	rs6469656	0.892	rs6469658	chr8:117685265	A/C	cg24004040	chr8:117650383	NA	-0.45	-6.62	-0.34	1.45e-10	Colorectal cancer;
LUSC	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg22709100	chr7:91322751	NA	0.42	6.16	0.32	2.09e-9	Breast cancer;
LUSC	cis	rs12760731	0.623	rs1342848	chr1:178296461	A/G	cg00404053	chr1:178313656	RASAL2	0.47	5.81	0.3	1.48e-8	Obesity-related traits;
LUSC	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg09904177	chr6:26538194	HMGN4	-0.51	-5.71	-0.3	2.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-17.16	-0.68	8.97e-48	Primary sclerosing cholangitis;
LUSC	cis	rs1775715	0.769	rs2799030	chr10:32172935	G/T	cg03015672	chr10:32216066	ARHGAP12	0.34	6.12	0.32	2.62e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg07424592	chr7:64974309	NA	-0.64	-5.72	-0.3	2.34e-8	Diabetic kidney disease;
LUSC	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg12927641	chr6:109611667	NA	-0.36	-6.14	-0.32	2.38e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.29	-6.09	-0.32	3.13e-9	Cognitive function;
LUSC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg09904177	chr6:26538194	HMGN4	-0.53	-6.37	-0.33	6.43e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2070433	0.706	rs2268524	chr21:47838700	C/T	cg12379764	chr21:47803548	PCNT	0.76	8.92	0.44	3.04e-17	Lymphocyte counts;
LUSC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg07061783	chr6:25882402	NA	0.43	6.1	0.32	2.89e-9	Blood metabolite levels;
LUSC	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.9e-20	Migraine;Coronary artery disease;
LUSC	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.74	14.33	0.62	1.24e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9677476	0.779	rs10177091	chr2:232109889	C/T	cg07929768	chr2:232055508	NA	0.37	6.27	0.32	1.09e-9	Food antigen IgG levels;
LUSC	cis	rs56283067	0.847	rs10807302	chr6:44710152	G/C	cg20913747	chr6:44695427	NA	-0.5	-8.31	-0.41	2.46e-15	Total body bone mineral density;
LUSC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg09033563	chr22:24373618	LOC391322	-0.49	-6.82	-0.35	4.29e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.2	0.52	6.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg03878208	chr11:72483293	STARD10	0.37	5.79	0.3	1.67e-8	Body mass index;
LUSC	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.77	11.37	0.53	1.57e-25	Corneal astigmatism;
LUSC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg11663144	chr21:46675770	NA	-0.37	-6.01	-0.31	4.98e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.81	12.97	0.58	1.93e-31	Breast cancer;
LUSC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.83	-0.35	4.1e-11	Neutrophil percentage of white cells;
LUSC	cis	rs7189233	0.955	rs7184800	chr16:53509131	G/A	cg09728985	chr16:53543985	NA	-0.35	-6.31	-0.33	8.82e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.45	-7.1	-0.36	7.32e-12	Systemic lupus erythematosus;
LUSC	cis	rs9473147	0.516	rs13212790	chr6:47576367	T/C	cg12968598	chr6:47444699	CD2AP	0.53	8.13	0.41	8.66e-15	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18876405	chr7:65276391	NA	0.54	8.24	0.41	3.93e-15	Aortic root size;
LUSC	cis	rs9362426	0.943	rs242291	chr6:88077083	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-5.71	-0.3	2.44e-8	Depressive episodes in bipolar disorder;
LUSC	cis	rs6690583	0.623	rs61769366	chr1:85534062	G/A	cg11262906	chr1:85462892	MCOLN2	0.69	5.78	0.3	1.71e-8	Serum sulfate level;
LUSC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg26335602	chr6:28129616	ZNF389	-0.45	-6.14	-0.32	2.39e-9	Depression;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14295955	chr11:57479323	MED19;TMX2	0.44	6.45	0.33	3.89e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg04518342	chr5:131593106	PDLIM4	0.32	5.73	0.3	2.27e-8	Blood metabolite levels;
LUSC	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg19508488	chr2:152266495	RIF1	0.54	7.74	0.39	1.21e-13	Lung cancer;
LUSC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10802521	chr3:52805072	NEK4	0.43	5.87	0.31	1.05e-8	Bipolar disorder;
LUSC	cis	rs8048589	0.615	rs34598762	chr16:12234958	A/G	cg02910054	chr16:12241554	SNX29	0.48	5.94	0.31	7.35e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg01475377	chr6:109611718	NA	-0.46	-8.37	-0.42	1.59e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg15654264	chr1:150340011	RPRD2	0.63	10.4	0.49	3.9e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9303542	0.559	rs1042818	chr17:46620111	T/C	cg09704116	chr17:46666958	LOC404266	-0.38	-6.54	-0.34	2.34e-10	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg00376283	chr12:123451042	ABCB9	-0.6	-7.42	-0.38	9.79e-13	Neutrophil percentage of white cells;
LUSC	cis	rs2303282	0.690	rs2550302	chr16:56392932	C/T	cg00500540	chr16:56394104	NA	-0.43	-7.42	-0.38	9.82e-13	Breast cancer;
LUSC	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg02175503	chr12:58329896	NA	0.75	11.4	0.53	1.16e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg23029597	chr12:123009494	RSRC2	-0.74	-9.58	-0.46	2.27e-19	Body mass index;
LUSC	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg04990556	chr1:26633338	UBXN11	-0.45	-5.97	-0.31	5.9e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.84e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg02023728	chr11:77925099	USP35	0.49	6.87	0.35	3.11e-11	Testicular germ cell tumor;
LUSC	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.96	13.78	0.6	1.66e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs367943	0.712	rs6867397	chr5:112725759	C/T	cg12552261	chr5:112820674	MCC	-0.37	-6.0	-0.31	5.14e-9	Type 2 diabetes;
LUSC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg24675658	chr1:53192096	ZYG11B	0.59	9.22	0.45	3.51e-18	Monocyte count;
LUSC	cis	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg16928487	chr17:17741425	SREBF1	-0.35	-6.54	-0.34	2.3e-10	Total body bone mineral density;
LUSC	cis	rs11166629	1.000	rs1036820	chr8:135646571	C/T	cg21672855	chr8:135614777	ZFAT	-0.36	-5.84	-0.3	1.26e-8	Smoking quantity;
LUSC	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg18825076	chr15:78729989	IREB2	-0.5	-7.86	-0.39	5.49e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg09184832	chr6:79620586	NA	-0.44	-7.01	-0.36	1.33e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	9.3	0.45	1.84e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg26924012	chr15:45694286	SPATA5L1	1.14	20.94	0.75	9e-63	Homoarginine levels;
LUSC	cis	rs6496044	0.568	rs4842888	chr15:86063133	C/T	cg13263323	chr15:86062960	AKAP13	0.37	6.14	0.32	2.35e-9	Interstitial lung disease;
LUSC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.69	11.39	0.53	1.28e-25	Heart rate;
LUSC	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.12	0.45	7.4e-18	Red blood cell count;
LUSC	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.69	-0.3	2.8e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03576123	chr11:487126	PTDSS2	-1.06	-11.69	-0.54	1.08e-26	Body mass index;
LUSC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg18758796	chr5:131593413	PDLIM4	0.44	7.24	0.37	3.2e-12	Acylcarnitine levels;
LUSC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.54	-7.78	-0.39	9.17e-14	Urate levels;
LUSC	cis	rs9513627	0.665	rs79036236	chr13:100116405	C/T	cg25919922	chr13:100150906	NA	-0.78	-6.34	-0.33	7.42e-10	Obesity-related traits;
LUSC	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg17462356	chr17:80056334	FASN	0.45	6.07	0.32	3.54e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg24675658	chr1:53192096	ZYG11B	-0.62	-10.25	-0.49	1.31e-21	Monocyte count;
LUSC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg05754148	chr16:3507555	NAT15	0.8	9.51	0.46	3.86e-19	Tuberculosis;
LUSC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.63	-8.2	-0.41	5.18e-15	Schizophrenia;
LUSC	cis	rs3772130	0.962	rs6776670	chr3:121543120	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	10.31	0.49	7.77e-22	Cognitive performance;
LUSC	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05901451	chr6:126070800	HEY2	0.77	12.49	0.56	1.24e-29	Endometrial cancer;
LUSC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg16423285	chr20:60520624	NA	-0.46	-5.71	-0.3	2.45e-8	Body mass index;
LUSC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg03806693	chr22:41940476	POLR3H	-0.96	-12.87	-0.58	4.78e-31	Vitiligo;
LUSC	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg22482690	chr17:47019901	SNF8	-0.39	-7.39	-0.37	1.18e-12	Type 2 diabetes;
LUSC	cis	rs56283067	0.577	rs114009236	chr6:44897517	T/C	cg18551225	chr6:44695536	NA	-0.48	-7.86	-0.4	5.3e-14	Total body bone mineral density;
LUSC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg01448562	chr3:133502909	NA	-0.76	-13.24	-0.59	1.95e-32	Iron status biomarkers;
LUSC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg02018176	chr4:1364513	KIAA1530	0.51	8.83	0.44	5.97e-17	Obesity-related traits;
LUSC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg22903657	chr4:1355424	KIAA1530	-0.4	-6.8	-0.35	4.85e-11	Longevity;
LUSC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	6.35	0.33	6.91e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9311676	0.632	rs11130630	chr3:58360800	A/G	cg13750441	chr3:58318267	PXK	0.34	6.66	0.34	1.1e-10	Systemic lupus erythematosus;
LUSC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg07507251	chr3:52567010	NT5DC2	0.34	6.66	0.34	1.1e-10	Bipolar disorder;
LUSC	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.63	-9.28	-0.45	2.19e-18	Platelet distribution width;
LUSC	trans	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg18827107	chr12:86230957	RASSF9	-0.38	-5.67	-0.3	3.15e-8	Major depressive disorder;
LUSC	cis	rs6961069	0.645	rs7795092	chr7:80227548	T/C	cg04458919	chr7:80252533	CD36	-0.41	-7.24	-0.37	3.12e-12	Platelet count;
LUSC	cis	rs748404	0.697	rs501884	chr15:43553982	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.41	5.88	0.31	1e-8	Lung cancer;
LUSC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg07424592	chr7:64974309	NA	0.65	5.83	0.3	1.32e-8	Diabetic kidney disease;
LUSC	cis	rs10979	0.894	rs6924940	chr6:143906183	C/T	cg25407410	chr6:143891975	LOC285740	-0.64	-9.76	-0.47	5.96e-20	Hypospadias;
LUSC	cis	rs7178572	0.633	rs907369	chr15:77843560	A/G	cg22256960	chr15:77711686	NA	-0.49	-7.38	-0.37	1.29e-12	Type 2 diabetes;
LUSC	cis	rs7572644	0.564	rs12995865	chr2:28025066	A/C	cg27432699	chr2:27873401	GPN1	0.56	7.3	0.37	2.09e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	0.91	16.67	0.67	7.86e-46	Cognitive function;
LUSC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06850241	chr22:41845214	NA	0.34	6.15	0.32	2.25e-9	Vitiligo;
LUSC	cis	rs62408225	1.000	rs6454805	chr6:90986353	A/G	cg06866423	chr6:90926672	BACH2	0.4	5.78	0.3	1.75e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs13394619	0.775	rs10200851	chr2:11722082	C/T	cg07314298	chr2:11723111	GREB1	-0.54	-9.4	-0.46	9.12e-19	Endometriosis;
LUSC	cis	rs7119	0.651	rs12904823	chr15:77837662	G/A	cg27398640	chr15:77910606	LINGO1	-0.31	-6.41	-0.33	4.82e-10	Type 2 diabetes;
LUSC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg05791153	chr7:19748676	TWISTNB	0.85	8.49	0.42	6.86e-16	Thyroid stimulating hormone;
LUSC	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg12179176	chr11:130786555	SNX19	0.65	9.8	0.47	4.14e-20	Schizophrenia;
LUSC	cis	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg17469321	chr7:55412551	NA	0.65	10.41	0.5	3.51e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg06454157	chr6:167490870	NA	-0.26	-6.08	-0.32	3.25e-9	Crohn's disease;
LUSC	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg25214090	chr10:38739885	LOC399744	0.55	8.12	0.41	9.17e-15	Corneal astigmatism;
LUSC	cis	rs9399401	0.593	rs262117	chr6:142807093	G/A	cg03128060	chr6:142623767	GPR126	0.56	9.28	0.45	2.21e-18	Chronic obstructive pulmonary disease;
LUSC	trans	rs12050412	1.000	rs12050412	chr14:83378003	G/T	cg25644150	chr5:133968296	SAR1B	-0.44	-6.16	-0.32	2.06e-9	Word reading;
LUSC	cis	rs12541491	0.506	rs11250007	chr8:10285086	C/G	cg02319733	chr8:10282549	MSRA	-0.35	-5.84	-0.3	1.21e-8	Schizophrenia;
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg23131131	chr22:24373011	LOC391322	-0.4	-5.86	-0.31	1.12e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg06223162	chr1:101003688	GPR88	-0.48	-9.03	-0.44	1.4e-17	Monocyte count;
LUSC	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg02574844	chr11:5959923	NA	-0.4	-5.76	-0.3	1.95e-8	DNA methylation (variation);
LUSC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg06671706	chr8:8559999	CLDN23	0.51	6.71	0.34	8.45e-11	Obesity-related traits;
LUSC	cis	rs10740039	0.883	rs10740038	chr10:62403237	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.92	-0.35	2.38e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg20573242	chr4:122745356	CCNA2	0.6	8.45	0.42	9.21e-16	Type 2 diabetes;
LUSC	cis	rs2073300	1.000	rs6036411	chr20:23441706	A/C	cg09953122	chr20:23471693	CST8	-0.8	-7.42	-0.38	9.81e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs858239	0.632	rs7811903	chr7:23119056	A/G	cg23682824	chr7:23144976	KLHL7	0.4	5.83	0.3	1.27e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg20243544	chr17:37824526	PNMT	0.4	6.14	0.32	2.38e-9	Self-reported allergy;
LUSC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg20887711	chr4:1340912	KIAA1530	0.43	6.71	0.34	8.29e-11	Obesity-related traits;
LUSC	cis	rs1941023	0.503	rs7952244	chr11:60132164	G/A	cg08716584	chr11:60157161	MS4A7	-0.63	-11.76	-0.54	5.85e-27	Congenital heart disease (maternal effect);
LUSC	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg15704280	chr7:45808275	SEPT13	-0.44	-6.0	-0.31	5.15e-9	HDL cholesterol;
LUSC	cis	rs5769707	0.681	rs8137111	chr22:50043750	G/A	cg20744362	chr22:50050164	C22orf34	0.39	7.29	0.37	2.23e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg05714579	chr10:131428358	MGMT	-0.49	-7.45	-0.38	7.85e-13	Response to temozolomide;
LUSC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg06008330	chr7:65541103	ASL	0.4	6.14	0.32	2.29e-9	Aortic root size;
LUSC	cis	rs147499554	1	rs147499554	chr15:78900650	C/T	cg18825076	chr15:78729989	IREB2	-0.51	-7.91	-0.4	3.77e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.42	0.5	3.24e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs2229238	0.911	rs4390168	chr1:154509096	A/G	cg25273160	chr11:56955011	LRRC55	0.32	6.11	0.32	2.79e-9	Coronary heart disease;
LUSC	trans	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.2	0.49	1.84e-21	Mean corpuscular volume;
LUSC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg23711669	chr6:146136114	FBXO30	0.76	13.47	0.59	2.45e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg02018176	chr4:1364513	KIAA1530	0.56	9.74	0.47	6.96e-20	Longevity;
LUSC	trans	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg13565492	chr6:43139072	SRF	-0.62	-6.56	-0.34	2.09e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8018808	0.935	rs8018513	chr14:77928288	T/C	cg20045696	chr14:77926864	AHSA1	0.34	5.73	0.3	2.28e-8	Myeloid white cell count;
LUSC	cis	rs9807989	0.507	rs6710034	chr2:103023678	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.72e-12	Asthma;
LUSC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	10.42	0.5	3.31e-22	Homoarginine levels;
LUSC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg00945038	chr17:61921165	SMARCD2	0.54	9.57	0.46	2.42e-19	Prudent dietary pattern;
LUSC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05564831	chr3:52568323	NT5DC2	0.36	6.54	0.34	2.31e-10	Electroencephalogram traits;
LUSC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg00701064	chr4:6280414	WFS1	0.51	10.78	0.51	1.87e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.95	-13.24	-0.59	1.83e-32	Platelet count;
LUSC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19346786	chr7:2764209	NA	-0.5	-8.31	-0.41	2.47e-15	Height;
LUSC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.99	-0.31	5.53e-9	Reticulocyte count;
LUSC	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.49	-6.59	-0.34	1.68e-10	Schizophrenia;
LUSC	trans	rs225245	0.755	rs226432	chr17:34043825	G/A	cg19694781	chr19:47549865	TMEM160	0.4	6.3	0.33	9.54e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg21775007	chr8:11205619	TDH	0.41	6.09	0.32	3.12e-9	Mood instability;
LUSC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg11247378	chr22:39784982	NA	-0.62	-11.18	-0.52	7.53e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	0.83	9.68	0.47	1.1e-19	Type 2 diabetes;
LUSC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg20476274	chr7:133979776	SLC35B4	0.87	17.01	0.68	3.4e-47	Mean platelet volume;
LUSC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	trans	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg07923666	chr12:49932857	KCNH3	-0.52	-6.42	-0.33	4.79e-10	Resting heart rate;
LUSC	cis	rs2901656	0.640	rs9425316	chr1:172400860	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.37	7.71	0.39	1.42e-13	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg00310523	chr12:86230176	RASSF9	-0.43	-7.91	-0.4	3.85e-14	Major depressive disorder;
LUSC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg12311346	chr5:56204834	C5orf35	-0.62	-8.84	-0.44	5.69e-17	Coronary artery disease;
LUSC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.42	-0.33	4.69e-10	Joint mobility (Beighton score);
LUSC	trans	rs12546962	0.705	rs17149279	chr8:9195638	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.05	0.31	3.86e-9	Body mass index;
LUSC	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg06092702	chr1:163392909	NA	-0.45	-7.36	-0.37	1.4e-12	Motion sickness;
LUSC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.75	11.6	0.54	2.29e-26	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs3737883	1.000	rs7538696	chr1:203034309	G/A	cg00805880	chr1:203045044	PPFIA4	-0.29	-5.76	-0.3	1.95e-8	Early onset atrial fibrillation;
LUSC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06022373	chr22:39101656	GTPBP1	0.85	14.17	0.61	5.06e-36	Menopause (age at onset);
LUSC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08859206	chr1:53392774	SCP2	-0.54	-9.57	-0.46	2.44e-19	Monocyte count;
LUSC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03576123	chr11:487126	PTDSS2	-1.04	-10.97	-0.51	4.1e-24	Body mass index;
LUSC	cis	rs12618769	0.597	rs6753515	chr2:99128965	T/A	cg10123293	chr2:99228465	UNC50	0.45	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.53	-0.42	5.22e-16	Response to antipsychotic treatment;
LUSC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	0.95	19.47	0.73	5.96e-57	Menarche (age at onset);
LUSC	cis	rs722599	0.715	rs2080086	chr14:75338408	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.4	-5.9	-0.31	9.01e-9	IgG glycosylation;
LUSC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg16624210	chr5:671434	TPPP	0.5	6.38	0.33	6.07e-10	Obesity-related traits;
LUSC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg17892150	chr10:133769511	PPP2R2D	0.59	8.59	0.43	3.32e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg05147244	chr20:61493195	TCFL5	0.96	7.01	0.36	1.31e-11	Obesity-related traits;
LUSC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.45	-0.42	9.42e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs57920188	0.703	rs3813810	chr1:4088339	G/T	cg20703997	chr1:4087676	NA	0.56	8.58	0.42	3.73e-16	Interleukin-17 levels;
LUSC	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	13.19	0.59	2.77e-32	Lung cancer in ever smokers;
LUSC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.38	0.59	5.5e-33	Platelet count;
LUSC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11645453	chr3:52864694	ITIH4	0.32	7.53	0.38	4.64e-13	Bipolar disorder;
LUSC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.51	7.81	0.39	7.49e-14	Eosinophil percentage of white cells;
LUSC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.38	-6.18	-0.32	1.89e-9	Alzheimer's disease (late onset);
LUSC	cis	rs721399	0.539	rs10103148	chr8:18267429	A/C	cg18736775	chr8:18248649	NAT2	-0.6	-7.09	-0.36	7.9e-12	Blood metabolite levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20409466	chr11:9635889	NA	-0.44	-6.56	-0.34	2.02e-10	Hepatitis;
LUSC	trans	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.58	-9.48	-0.46	4.85e-19	Brugada syndrome;
LUSC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.39	-6.02	-0.31	4.58e-9	Platelet count;
LUSC	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg04310649	chr10:35416472	CREM	0.42	6.53	0.34	2.43e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg04455712	chr21:45112962	RRP1B	-0.47	-8.86	-0.44	4.92e-17	Mean corpuscular volume;
LUSC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg20307385	chr11:47447363	PSMC3	0.45	5.82	0.3	1.37e-8	Subjective well-being;
LUSC	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg11019008	chr10:131425282	MGMT	-0.39	-5.78	-0.3	1.69e-8	Response to temozolomide;
LUSC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg09396181	chr3:13921839	WNT7A	0.39	6.28	0.32	1.05e-9	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg23093090	chr10:104574429	C10orf26	-0.35	-6.35	-0.33	6.93e-10	Arsenic metabolism;
LUSC	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg26769984	chr7:1090371	C7orf50	0.66	8.67	0.43	1.85e-16	Bronchopulmonary dysplasia;
LUSC	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg04362960	chr10:104952993	NT5C2	0.65	9.41	0.46	8.54e-19	Arsenic metabolism;
LUSC	cis	rs273573	0.961	rs175399	chr11:30930374	A/C	cg06552810	chr11:31128660	NA	0.32	5.69	0.3	2.78e-8	Total body bone mineral density;
LUSC	cis	rs4478858	0.684	rs16834336	chr1:31751512	G/A	cg00250761	chr1:31883323	NA	-0.34	-8.15	-0.41	7.26e-15	Alcohol dependence;
LUSC	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	8.55	0.42	4.63e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.64	10.93	0.51	5.65e-24	Bone mineral density;
LUSC	cis	rs7091068	1.000	rs7091068	chr10:95420385	G/T	cg20715218	chr10:95462985	C10orf4	0.58	6.09	0.32	3.06e-9	Urinary tract infection frequency;
LUSC	cis	rs7712401	0.601	rs246321	chr5:122308299	A/G	cg19077854	chr5:122220652	SNX24	0.43	9.65	0.47	1.39e-19	Mean platelet volume;
LUSC	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07080220	chr10:102295463	HIF1AN	0.69	9.38	0.46	1.06e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg21433313	chr16:3507492	NAT15	0.41	5.88	0.31	1e-8	Body mass index (adult);
LUSC	cis	rs9463078	0.683	rs227855	chr6:44702352	T/C	cg25276700	chr6:44698697	NA	0.31	6.25	0.32	1.22e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg03676636	chr4:99064102	C4orf37	0.29	6.19	0.32	1.74e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg23649088	chr2:200775458	C2orf69	-0.54	-6.53	-0.34	2.39e-10	Schizophrenia;
LUSC	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg13010199	chr12:38710504	ALG10B	0.54	8.05	0.4	1.46e-14	Morning vs. evening chronotype;
LUSC	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg03433033	chr1:76189801	ACADM	-0.45	-6.84	-0.35	3.86e-11	Daytime sleep phenotypes;
LUSC	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21545522	chr1:205238299	TMCC2	-0.49	-9.34	-0.46	1.37e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs926938	0.563	rs360645	chr1:115427218	A/G	cg12756093	chr1:115239321	AMPD1	0.39	5.77	0.3	1.81e-8	Autism;
LUSC	cis	rs56399783	0.901	rs17132741	chr7:2868997	C/T	cg14895029	chr7:2775587	GNA12	-0.46	-6.07	-0.32	3.56e-9	Childhood ear infection;
LUSC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06634786	chr22:41940651	POLR3H	-0.6	-6.81	-0.35	4.48e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg19678392	chr7:94953810	PON1	-0.36	-5.91	-0.31	8.37e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg15105969	chr2:36825350	FEZ2	-0.42	-5.86	-0.31	1.14e-8	Height;
LUSC	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14240646	chr10:27532245	ACBD5	-0.72	-9.52	-0.46	3.66e-19	Breast cancer;
LUSC	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg08807101	chr21:30365312	RNF160	0.71	11.42	0.53	1.04e-25	Pancreatic cancer;
LUSC	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg05347473	chr6:146136440	FBXO30	0.41	6.82	0.35	4.18e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17253792	0.822	rs8009239	chr14:56062490	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.96	-0.36	1.81e-11	Putamen volume;
LUSC	cis	rs642803	0.613	rs565427	chr11:65532825	G/A	cg27068330	chr11:65405492	SIPA1	0.55	7.58	0.38	3.37e-13	Urate levels;
LUSC	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06002616	chr8:101225028	SPAG1	-0.44	-7.3	-0.37	2.18e-12	Atrioventricular conduction;
LUSC	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg02574844	chr11:5959923	NA	-0.42	-6.06	-0.31	3.65e-9	DNA methylation (variation);
LUSC	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.61	-0.43	2.87e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs983392	0.679	rs672399	chr11:60020112	T/G	cg20284999	chr11:59952153	MS4A6A	0.39	6.45	0.33	3.93e-10	Alzheimer's disease (late onset);
LUSC	cis	rs926938	0.563	rs360635	chr1:115420518	A/C	cg12756093	chr1:115239321	AMPD1	0.45	6.57	0.34	1.98e-10	Autism;
LUSC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.88	0.44	4.29e-17	Lung cancer;
LUSC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	1.02	19.72	0.73	5.91e-58	Menopause (age at onset);
LUSC	cis	rs500891	0.525	rs1145898	chr6:84039566	T/C	cg08257003	chr6:84140564	ME1	0.34	8.2	0.41	5.18e-15	Platelet-derived growth factor BB levels;
LUSC	trans	rs874040	0.962	rs7673206	chr4:26126838	C/T	cg09985802	chr10:126234119	LHPP	-0.29	-5.95	-0.31	6.93e-9	Rheumatoid arthritis;
LUSC	cis	rs2387326	0.717	rs10829338	chr10:129943625	C/T	cg16087940	chr10:129947807	NA	-0.39	-5.78	-0.3	1.7e-8	Select biomarker traits;
LUSC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg14784868	chr12:69753453	YEATS4	0.55	8.39	0.42	1.41e-15	Response to diuretic therapy;
LUSC	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg17127132	chr2:85788382	GGCX	0.49	7.93	0.4	3.4e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	7.56	0.38	3.88e-13	Retinal vascular caliber;
LUSC	cis	rs3849570	0.615	rs9817070	chr3:81982936	A/G	cg07356753	chr3:81810745	GBE1	-0.44	-6.47	-0.33	3.56e-10	Waist circumference;Body mass index;
LUSC	cis	rs4363385	0.818	rs532773	chr1:153011750	T/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg18681998	chr4:17616180	MED28	0.92	17.41	0.69	9.18e-49	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg19792802	chr11:65647270	CTSW	0.47	6.45	0.33	4e-10	Crohn's disease;
LUSC	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg22089800	chr15:90895588	ZNF774	-0.62	-9.34	-0.46	1.39e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs67981189	0.634	rs221896	chr14:71606668	C/G	cg15816911	chr14:71606274	NA	-0.35	-6.13	-0.32	2.49e-9	Schizophrenia;
LUSC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg05623727	chr3:50126028	RBM5	-0.35	-6.66	-0.34	1.1e-10	Body mass index;
LUSC	cis	rs4834770	0.792	rs6823331	chr4:120180790	T/C	cg24375607	chr4:120327624	NA	0.42	5.82	0.3	1.39e-8	Blood protein levels;
LUSC	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg00310523	chr12:86230176	RASSF9	0.36	6.57	0.34	1.98e-10	Major depressive disorder;
LUSC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08219700	chr8:58056026	NA	0.66	7.82	0.39	7.08e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg05163923	chr11:71159392	DHCR7	0.76	10.91	0.51	6.73e-24	Vitamin D levels;
LUSC	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.61	-0.43	3.01e-16	Retinal vascular caliber;
LUSC	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg23750338	chr8:142222470	SLC45A4	-0.57	-11.29	-0.53	2.84e-25	Immature fraction of reticulocytes;
LUSC	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg06092702	chr1:163392909	NA	-0.42	-7.14	-0.36	5.95e-12	Motion sickness;
LUSC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-0.94	-16.94	-0.68	6.62e-47	Cognitive function;
LUSC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg24399712	chr22:39784796	NA	-0.64	-11.51	-0.53	4.76e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg15556689	chr8:8085844	FLJ10661	0.56	9.01	0.44	1.57e-17	Mood instability;
LUSC	cis	rs12042107	0.818	rs12046000	chr1:91192396	G/T	cg13456504	chr1:91191583	NA	0.42	7.07	0.36	8.9e-12	Educational attainment;
LUSC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08048268	chr3:133502702	NA	-0.44	-8.65	-0.43	2.25e-16	Iron status biomarkers;
LUSC	cis	rs1953600	0.870	rs2236557	chr10:81923961	A/G	cg04850286	chr10:81895943	PLAC9	0.33	5.74	0.3	2.13e-8	Sarcoidosis;
LUSC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.49	7.56	0.38	3.98e-13	Eosinophil percentage of white cells;
LUSC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26314531	chr2:26401878	FAM59B	-0.68	-9.32	-0.45	1.67e-18	Gut microbiome composition (summer);
LUSC	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg02503808	chr4:7069936	GRPEL1	1.02	14.02	0.61	1.87e-35	Monocyte percentage of white cells;
LUSC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg18351406	chr4:77819688	ANKRD56	0.44	6.11	0.32	2.85e-9	Emphysema distribution in smoking;
LUSC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg15212455	chr7:39170539	POU6F2	0.59	10.21	0.49	1.71e-21	IgG glycosylation;
LUSC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.47	6.98	0.36	1.62e-11	Schizophrenia;
LUSC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.37	-6.25	-0.32	1.23e-9	Breast cancer;
LUSC	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.78	13.07	0.58	8.16e-32	Metabolic syndrome;
LUSC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg18904891	chr8:8559673	CLDN23	-0.38	-5.72	-0.3	2.39e-8	Mood instability;
LUSC	trans	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg26043149	chr18:55253948	FECH	-0.46	-7.1	-0.36	7.46e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23501767	chr5:133340570	VDAC1	-0.43	-6.41	-0.33	4.89e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs259282	0.605	rs3760937	chr19:33106893	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	9.64	0.47	1.49e-19	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	0.7	14.78	0.63	2.12e-38	Prudent dietary pattern;
LUSC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.42	-0.5	3.27e-22	Coffee consumption (cups per day);
LUSC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.68	12.02	0.55	6.86e-28	Aortic root size;
LUSC	cis	rs72901758	0.661	rs56683270	chr17:76247827	T/C	cg25512537	chr17:76250053	NA	0.41	7.58	0.38	3.51e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.56	-0.42	4.06e-16	Neuroticism;
LUSC	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg15556689	chr8:8085844	FLJ10661	0.69	11.21	0.52	5.75e-25	Joint mobility (Beighton score);
LUSC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg04166393	chr7:2884313	GNA12	0.41	5.71	0.3	2.48e-8	Height;
LUSC	cis	rs6545883	0.894	rs2694632	chr2:61558682	T/C	cg15711740	chr2:61764176	XPO1	0.42	6.52	0.34	2.6200000000000003e-10	Tuberculosis;
LUSC	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	0.89	14.86	0.63	1.04e-38	Schizophrenia;
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11060661	chr22:24314208	DDT;DDTL	-0.44	-6.91	-0.35	2.46e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.72	-6.72	-0.35	7.85e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs17604090	0.715	rs73088359	chr7:29647678	T/C	cg19413766	chr7:29689036	LOC646762	-0.5	-5.99	-0.31	5.31e-9	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg06713675	chr4:122721982	EXOSC9	-0.66	-11.42	-0.53	1.02e-25	Type 2 diabetes;
LUSC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.99	0.55	8.55e-28	Chronic sinus infection;
LUSC	cis	rs3741151	0.773	rs6592526	chr11:73208911	C/T	cg17517138	chr11:73019481	ARHGEF17	0.96	8.24	0.41	3.97e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.72	13.59	0.6	8.89e-34	HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg09307838	chr4:120376055	NA	-0.47	-7.23	-0.37	3.42e-12	Diastolic blood pressure;
LUSC	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg00677455	chr12:58241039	CTDSP2	0.69	10.34	0.49	6.09e-22	Multiple sclerosis;
LUSC	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg03948781	chr1:205179583	DSTYK	0.29	5.74	0.3	2.14e-8	Red blood cell count;
LUSC	cis	rs3771570	1.000	rs6752050	chr2:242228780	T/C	cg21155796	chr2:242212141	HDLBP	0.65	7.14	0.36	5.86e-12	Prostate cancer;
LUSC	cis	rs2274273	0.905	rs17128183	chr14:55579513	C/T	cg04306507	chr14:55594613	LGALS3	-0.55	-12.64	-0.57	3.33e-30	Protein biomarker;
LUSC	cis	rs897080	0.552	rs1067369	chr2:44652654	A/T	cg00619915	chr2:44497795	NA	-0.42	-6.08	-0.32	3.24e-9	Height;
LUSC	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-8.14	-0.41	7.94e-15	Axial length;
LUSC	cis	rs62408225	1.000	rs17513531	chr6:90951239	C/T	cg06866423	chr6:90926672	BACH2	0.4	5.74	0.3	2.16e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg17120908	chr11:65337727	SSSCA1	0.58	9.6	0.47	1.93e-19	Bone mineral density;
LUSC	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs11677416	1.000	rs1878321	chr2:113544434	A/G	cg27083787	chr2:113543245	IL1A	0.45	7.13	0.36	6.29e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.05	-0.31	3.85e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18932078	chr1:2524107	MMEL1	0.32	6.98	0.36	1.58e-11	Ulcerative colitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05887047	chr13:114270659	TFDP1	-0.41	-6.01	-0.31	4.99e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg24812749	chr6:127587940	RNF146	0.62	9.16	0.45	5.54e-18	Breast cancer;
LUSC	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.67	-10.38	-0.49	4.59e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs977987	0.843	rs59155720	chr16:75483806	A/G	cg04384234	chr16:75411784	CFDP1	-0.43	-7.15	-0.36	5.35e-12	Dupuytren's disease;
LUSC	cis	rs939574	1.000	rs939574	chr2:220118531	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.02	-8.86	-0.44	4.81e-17	Platelet distribution width;
LUSC	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg15711740	chr2:61764176	XPO1	-0.48	-7.46	-0.38	7.69e-13	Tuberculosis;
LUSC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.57	-0.34	1.99e-10	Schizophrenia;
LUSC	trans	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg24313572	chr1:56050060	NA	-0.3	-6.32	-0.33	8.52e-10	Morning vs. evening chronotype;
LUSC	cis	rs7941600	0.786	rs7925418	chr11:9197500	T/C	cg19415743	chr11:9336845	TMEM41B	0.59	5.91	0.31	8.62e-9	Coronary artery disease;
LUSC	trans	rs750134	0.901	rs17040895	chr12:109093713	C/T	cg23338993	chr2:234600423	UGT1A10;UGT1A6;UGT1A9;UGT1A7;UGT1A8	0.5	6.13	0.32	2.47e-9	Low high density lipoprotein cholesterol levels;
LUSC	cis	rs4925114	0.568	rs941448	chr17:17654542	C/G	cg09796270	chr17:17721594	SREBF1	-0.43	-7.32	-0.37	1.87e-12	Body mass index;
LUSC	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg15744005	chr10:104629667	AS3MT	-0.28	-6.02	-0.31	4.53e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg23711669	chr6:146136114	FBXO30	0.77	13.91	0.61	5.36e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6460942	0.730	rs7780477	chr7:12233750	G/C	cg06484146	chr7:12443880	VWDE	-0.58	-6.09	-0.32	3.08e-9	Coronary artery disease;
LUSC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	9.0	0.44	1.69e-17	Motion sickness;
LUSC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.1	-0.32	2.85e-9	Initial pursuit acceleration;
LUSC	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg13877915	chr19:58951672	ZNF132	0.49	7.73	0.39	1.26e-13	Uric acid clearance;
LUSC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	-0.35	-5.68	-0.3	3e-8	Cystic fibrosis severity;
LUSC	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg14530993	chr4:882597	GAK	0.71	7.06	0.36	9.85e-12	Parkinson's disease;
LUSC	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg25214090	chr10:38739885	LOC399744	0.5	7.39	0.37	1.19e-12	Corneal astigmatism;
LUSC	cis	rs2742234	0.590	rs2435376	chr10:43684963	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.03	-0.36	1.17e-11	Hirschsprung disease;
LUSC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	0.98	14.69	0.63	5.01e-38	Initial pursuit acceleration;
LUSC	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.34	0.46	1.36e-18	Coffee consumption (cups per day);
LUSC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.76	0.47	5.92e-20	Bipolar disorder;
LUSC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg11247378	chr22:39784982	NA	-0.65	-12.86	-0.58	5.13e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg23711669	chr6:146136114	FBXO30	0.88	16.37	0.67	1.21e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg02038168	chr22:39784481	NA	-0.5	-8.25	-0.41	3.72e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg07061783	chr6:25882402	NA	-0.38	-5.94	-0.31	7.17e-9	Blood metabolite levels;
LUSC	cis	rs12681287	0.609	rs13281414	chr8:87495254	A/C	cg00550725	chr8:87521180	FAM82B	0.45	5.87	0.31	1.07e-8	Caudate activity during reward;
LUSC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg09455208	chr3:40491958	NA	0.57	10.33	0.49	6.86e-22	Renal cell carcinoma;
LUSC	trans	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg12856521	chr11:46389249	DGKZ	0.4	6.35	0.33	7.17e-10	Leprosy;
LUSC	cis	rs11997175	0.766	rs4273817	chr8:33702686	C/T	ch.8.33884649F	chr8:33765107	NA	0.37	5.8	0.3	1.5e-8	Body mass index;
LUSC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-9.58	-0.46	2.35e-19	Gut microbiome composition (summer);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21062897	chr14:50999680	MAP4K5;ATL1	-0.52	-6.89	-0.35	2.79e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6961069	0.658	rs7806711	chr7:80217290	T/G	cg04458919	chr7:80252533	CD36	-0.4	-7.0	-0.36	1.41e-11	Platelet count;
LUSC	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.7	-9.28	-0.45	2.26e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.48	-6.54	-0.34	2.3e-10	Schizophrenia;
LUSC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg08470875	chr2:26401718	FAM59B	-0.69	-9.37	-0.46	1.16e-18	Gut microbiome composition (summer);
LUSC	cis	rs7538876	1.000	rs4920603	chr1:17727379	C/G	cg07965774	chr1:17746286	RCC2	-0.3	-5.75	-0.3	2.02e-8	Basal cell carcinoma;
LUSC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-0.94	-13.95	-0.61	3.67e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.1	-0.45	8.23e-18	Bipolar disorder;
LUSC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg17264618	chr3:40429014	ENTPD3	-0.31	-6.54	-0.34	2.26e-10	Renal cell carcinoma;
LUSC	cis	rs12620999	1.000	rs4558538	chr2:238055975	C/T	cg23555395	chr2:238036564	NA	-0.51	-8.74	-0.43	1.18e-16	Systemic lupus erythematosus;
LUSC	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg05868516	chr6:26286170	HIST1H4H	-0.35	-5.78	-0.3	1.76e-8	Educational attainment;
LUSC	cis	rs5167	0.601	rs892131	chr19:45496996	C/T	cg25746394	chr19:45450501	APOC2	0.31	5.77	0.3	1.83e-8	Blood protein levels;
LUSC	cis	rs11955175	1.000	rs11953942	chr5:40674713	C/A	cg05478818	chr5:40835740	RPL37	0.7	5.77	0.3	1.81e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9815354	0.812	rs73071203	chr3:41977464	A/C	cg03022575	chr3:42003672	ULK4	0.85	8.85	0.44	5.2e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.04	-0.31	4.2e-9	Height;
LUSC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26314531	chr2:26401878	FAM59B	-0.69	-9.39	-0.46	9.76e-19	Gut microbiome composition (summer);
LUSC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg17279839	chr7:150038598	RARRES2	0.54	8.14	0.41	7.95e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11051970	0.879	rs950079	chr12:32588620	A/G	cg02745156	chr12:32552066	NA	0.43	7.29	0.37	2.29e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	1.1	13.31	0.59	9.96e-33	Arsenic metabolism;
LUSC	trans	rs57046232	0.552	rs2009127	chr20:6341680	C/T	cg21095983	chr6:86352623	SYNCRIP	0.48	7.14	0.36	5.84e-12	Colorectal cancer;
LUSC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg24324837	chr19:49891574	CCDC155	0.56	7.72	0.39	1.41e-13	Multiple sclerosis;
LUSC	cis	rs9341808	0.587	rs3805859	chr6:81048946	C/A	cg08355045	chr6:80787529	NA	0.46	8.03	0.4	1.72e-14	Sitting height ratio;
LUSC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg24531977	chr5:56204891	C5orf35	-0.6	-9.11	-0.45	7.84e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg04166393	chr7:2884313	GNA12	0.42	5.75	0.3	2.06e-8	Height;
LUSC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.78	12.18	0.55	1.69e-28	Pancreatic cancer;
LUSC	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg08508325	chr11:3079039	CARS	0.35	7.76	0.39	1.03e-13	Calcium levels;
LUSC	cis	rs10761482	0.861	rs10761484	chr10:62098458	T/C	cg18175470	chr10:62150864	ANK3	-0.5	-7.06	-0.36	9.52e-12	Schizophrenia;
LUSC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07080220	chr10:102295463	HIF1AN	0.68	9.2	0.45	3.94e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12421382	0.659	rs1439511	chr11:109392839	G/T	cg11473876	chr11:109292803	C11orf87	-0.45	-6.82	-0.35	4.18e-11	Schizophrenia;
LUSC	cis	rs5167	0.566	rs60876330	chr19:45488133	C/T	cg25746394	chr19:45450501	APOC2	0.32	6.07	0.32	3.55e-9	Blood protein levels;
LUSC	cis	rs4938330	0.681	rs12271169	chr11:116980021	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-6.86	-0.35	3.42e-11	Blood protein levels;
LUSC	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg08917208	chr2:24149416	ATAD2B	0.89	10.1	0.48	4.26e-21	Lymphocyte counts;
LUSC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg17554472	chr22:41940697	POLR3H	-0.5	-5.89	-0.31	9.24e-9	Vitiligo;
LUSC	cis	rs981844	0.683	rs2405423	chr4:154749823	C/A	cg14289246	chr4:154710475	SFRP2	-0.46	-6.32	-0.33	8.22e-10	Response to statins (LDL cholesterol change);
LUSC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-1.1	-21.59	-0.76	2.55e-65	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02158565	chr7:150788256	AGAP3	-0.35	-5.96	-0.31	6.48e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6558174	0.965	rs6558172	chr8:22492052	C/T	cg03733263	chr8:22462867	KIAA1967	0.49	6.52	0.34	2.63e-10	Breast cancer;
LUSC	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	7.7	0.39	1.53e-13	Mood instability;
LUSC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.67	0.43	1.91e-16	Prudent dietary pattern;
LUSC	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.34	-0.37	1.65e-12	Psoriasis;
LUSC	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg26384229	chr12:38710491	ALG10B	-0.54	-8.15	-0.41	7.3e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg04733989	chr22:42467013	NAGA	0.39	6.58	0.34	1.85e-10	Cognitive function;
LUSC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21738971	chr2:106810986	UXS1	-0.43	-6.2	-0.32	1.67e-9	Electrocardiographic conduction measures;
LUSC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.47	5.99	0.31	5.5e-9	Huntington's disease progression;
LUSC	cis	rs1113500	0.933	rs10494089	chr1:108626695	T/G	cg06207961	chr1:108661230	NA	0.4	7.45	0.38	8.2e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.44	-0.33	4.08e-10	Alzheimer's disease (late onset);
LUSC	cis	rs28655083	0.509	rs679263	chr16:77103829	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	7.04	0.36	1.12e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg21782813	chr7:2030301	MAD1L1	0.41	6.84	0.35	3.8e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg00409905	chr10:38381863	ZNF37A	0.4	6.83	0.35	4.09e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg12863693	chr15:85201151	NMB	0.42	8.65	0.43	2.14e-16	Schizophrenia;
LUSC	cis	rs12620999	1.000	rs28727919	chr2:238003313	C/T	cg23555395	chr2:238036564	NA	0.53	8.83	0.43	6.22e-17	Systemic lupus erythematosus;
LUSC	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	11.02	0.52	2.75e-24	Lung cancer in ever smokers;
LUSC	cis	rs9815354	0.904	rs73073235	chr3:42012693	C/A	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.5e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg08355456	chr11:67383691	NA	0.36	6.79	0.35	5.1e-11	Mean corpuscular volume;
LUSC	trans	rs2587949	0.615	rs1444059	chr3:4228369	C/G	cg15139668	chr4:4577005	NA	-0.41	-6.1	-0.32	2.88e-9	Periodontitis (DPAL);
LUSC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg02931644	chr1:25747376	RHCE	-0.34	-6.2	-0.32	1.64e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg23093090	chr10:104574429	C10orf26	-0.48	-5.8	-0.3	1.53e-8	Arsenic metabolism;
LUSC	cis	rs75229567	0.618	rs75389984	chr12:70212879	A/G	cg10114359	chr12:70132523	RAB3IP	1.4	12.47	0.56	1.46e-29	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	6.16	0.32	2.1e-9	Blood metabolite levels;
LUSC	trans	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.13	0.32	2.51e-9	Joint mobility (Beighton score);
LUSC	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg13010199	chr12:38710504	ALG10B	0.65	10.07	0.48	5.45e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11676348	0.808	rs4674267	chr2:219046437	C/T	cg23569941	chr2:219139048	TMBIM1;PNKD	0.37	5.95	0.31	6.87e-9	Ulcerative colitis;
LUSC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg13319975	chr6:146136371	FBXO30	0.5	7.42	0.38	9.54e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg22681709	chr2:178499509	PDE11A	-0.57	-10.56	-0.5	1.11e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.66	14.68	0.63	5.4e-38	Hemoglobin concentration;
LUSC	cis	rs459482	1.000	rs459498	chr21:42795027	G/A	cg14166395	chr21:42792516	MX1	0.58	8.36	0.42	1.68e-15	IgG glycosylation;
LUSC	trans	rs656319	0.564	rs11776035	chr8:10071527	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.06	-0.31	3.59e-9	Myopia (pathological);
LUSC	cis	rs1461503	0.966	rs7944630	chr11:122838844	G/A	cg27398637	chr11:122830231	C11orf63	-0.4	-6.37	-0.33	6.12e-10	Menarche (age at onset);
LUSC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg23649088	chr2:200775458	C2orf69	0.55	7.44	0.38	8.44e-13	Schizophrenia;
LUSC	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	11.31	0.53	2.5e-25	Lung cancer in ever smokers;
LUSC	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg01097406	chr16:89675127	NA	-0.34	-6.73	-0.35	7.48e-11	Vitiligo;
LUSC	cis	rs4845459	0.967	rs4845450	chr1:152591200	T/C	cg08895932	chr1:152778580	LCE1C	-0.36	-6.3	-0.33	9.62e-10	Psoriasis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00057317	chr8:11725492	CTSB	-0.47	-6.25	-0.32	1.26e-9	Hepatitis;
LUSC	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg13175981	chr1:150552382	MCL1	-0.4	-5.64	-0.3	3.55e-8	Tonsillectomy;
LUSC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11764359	chr7:65958608	NA	-0.63	-9.55	-0.46	2.94e-19	Aortic root size;
LUSC	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg11130432	chr3:121712080	ILDR1	-0.64	-9.83	-0.47	3.38e-20	Multiple sclerosis;
LUSC	trans	rs9910292	0.591	rs8081966	chr17:31358333	T/C	cg03789507	chr8:136667083	NA	0.48	6.13	0.32	2.44e-9	Mosquito bite size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20127549	chr11:118868876	CCDC84	0.44	6.18	0.32	1.91e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg04450456	chr4:17643702	FAM184B	0.36	5.76	0.3	1.92e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.66	10.18	0.49	2.25e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.84	-0.44	5.49e-17	Monocyte percentage of white cells;
LUSC	cis	rs6736093	0.966	rs11685190	chr2:112748704	T/C	cg12686935	chr2:112915763	FBLN7	-0.37	-6.03	-0.31	4.39e-9	Coronary artery disease;
LUSC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.3	-6.19	-0.32	1.79e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2282802	0.685	rs13177186	chr5:139640476	A/G	cg26211634	chr5:139558579	C5orf32	0.44	8.3	0.41	2.59e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg11843238	chr5:131593191	PDLIM4	0.39	7.18	0.37	4.69e-12	Blood metabolite levels;
LUSC	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg15848620	chr12:58087721	OS9	-0.41	-5.85	-0.3	1.2e-8	Multiple sclerosis;
LUSC	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg24130564	chr14:104152367	KLC1	-0.54	-7.86	-0.4	5.23e-14	Body mass index;
LUSC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	8.97	0.44	2.15e-17	Menarche (age at onset);
LUSC	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.9	-0.35	2.62e-11	Platelet count;
LUSC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.71	-13.26	-0.59	1.53e-32	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.23	-0.32	1.42e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6960043	0.689	rs12538003	chr7:15058692	G/A	cg19272540	chr7:15055459	NA	0.34	8.24	0.41	4.03e-15	Type 2 diabetes;
LUSC	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.58	-0.34	1.87e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg16606324	chr3:10149918	C3orf24	0.67	9.99	0.48	9.9e-21	Alzheimer's disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25187088	chr17:36714684	SRCIN1	-0.41	-6.01	-0.31	4.97e-9	Electrocardiographic conduction measures;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22273015	chr11:207531	RIC8A;BET1L	-0.44	-6.43	-0.33	4.35e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-5.97	-0.31	6.23e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg22508957	chr16:3507546	NAT15	-0.41	-5.84	-0.3	1.21e-8	Body mass index (adult);
LUSC	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg27411982	chr8:10470053	RP1L1	0.44	6.94	0.36	2.08e-11	Mood instability;
LUSC	cis	rs6087990	1.000	rs2424901	chr20:31344512	A/G	cg13636640	chr20:31349939	DNMT3B	1.04	23.38	0.79	2.63e-72	Ulcerative colitis;
LUSC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg12564285	chr5:131593104	PDLIM4	-0.44	-7.57	-0.38	3.6e-13	Breast cancer;
LUSC	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg22437258	chr11:111473054	SIK2	0.47	6.38	0.33	6.07e-10	Primary sclerosing cholangitis;
LUSC	cis	rs71403859	0.730	rs12922775	chr16:71584354	C/T	cg08717414	chr16:71523259	ZNF19	-0.75	-8.27	-0.41	3.24e-15	Post bronchodilator FEV1;
LUSC	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg03676636	chr4:99064102	C4orf37	0.35	7.6	0.38	3.03e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8114671	0.647	rs945959	chr20:33734905	G/C	cg24642439	chr20:33292090	TP53INP2	0.4	5.74	0.3	2.08e-8	Height;
LUSC	cis	rs7072216	0.922	rs59667296	chr10:100146313	A/T	cg26618903	chr10:100175079	PYROXD2	-0.3	-5.79	-0.3	1.65e-8	Metabolite levels;
LUSC	cis	rs965604	1.000	rs12916801	chr15:78769130	A/G	cg18825076	chr15:78729989	IREB2	-0.42	-6.83	-0.35	3.99e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1044826	0.642	rs295481	chr3:139228811	C/T	cg15131784	chr3:139108705	COPB2	0.39	6.34	0.33	7.33e-10	Obesity-related traits;
LUSC	trans	rs961253	0.522	rs6085496	chr20:6315656	C/T	cg17788362	chr6:86352627	SYNCRIP	0.46	6.44	0.33	4.21e-10	Colorectal cancer;
LUSC	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg06636001	chr8:8085503	FLJ10661	0.47	6.96	0.36	1.83e-11	Neuroticism;
LUSC	cis	rs41271473	0.750	rs72751931	chr1:228887129	G/T	cg10167378	chr1:228756711	NA	0.54	6.65	0.34	1.18e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg05343316	chr1:45956843	TESK2	-0.64	-9.1	-0.45	8.24e-18	Platelet count;
LUSC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg08601574	chr20:25228251	PYGB	0.42	6.4	0.33	5.16e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-5.99	-0.31	5.34e-9	Retinal vascular caliber;
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.92	18.2	0.71	6.58e-52	Menarche (age at onset);
LUSC	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	1.17	13.71	0.6	3.13e-34	Arsenic metabolism;
LUSC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	cis	rs3754214	0.857	rs9126	chr1:150259400	A/C	cg15654264	chr1:150340011	RPRD2	-0.45	-7.3	-0.37	2.14e-12	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg11887960	chr12:57824829	NA	0.54	6.8	0.35	4.89e-11	Obesity-related traits;
LUSC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg26380479	chr7:97908229	NA	-0.27	-5.97	-0.31	6.22e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	6.52	0.34	2.61e-10	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06240896	chr7:100136768	AGFG2	0.41	6.43	0.33	4.53e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.46	6.5	0.34	2.93e-10	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2625529	0.526	rs8032222	chr15:72479178	C/G	cg16672083	chr15:72433130	SENP8	0.47	7.85	0.39	5.76e-14	Red blood cell count;
LUSC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11764359	chr7:65958608	NA	0.54	7.7	0.39	1.58e-13	Calcium levels;
LUSC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.77	-0.35	5.69e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs3857067	0.806	rs1876918	chr4:95099424	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.33	-5.69	-0.3	2.76e-8	QT interval;
LUSC	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg17633681	chr16:88106987	BANP	0.51	9.54	0.46	3.05e-19	Menopause (age at onset);
LUSC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg04414720	chr1:150670196	GOLPH3L	0.49	7.78	0.39	9.11e-14	Melanoma;
LUSC	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg21132104	chr15:45694354	SPATA5L1	0.41	5.81	0.3	1.44e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg20684491	chr1:25596433	NA	0.4	6.61	0.34	1.54e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs244293	0.729	rs2332313	chr17:53018825	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.89	-0.31	9.55e-9	Menarche (age at onset);
LUSC	cis	rs9549260	0.755	rs9532577	chr13:41231542	A/G	cg21288729	chr13:41239152	FOXO1	0.64	9.95	0.48	1.3e-20	Red blood cell count;
LUSC	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg26384229	chr12:38710491	ALG10B	0.73	11.46	0.53	7.46e-26	Morning vs. evening chronotype;
LUSC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg11494091	chr17:61959527	GH2	0.7	14.93	0.63	5.68e-39	Prudent dietary pattern;
LUSC	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg26102564	chr10:131424627	MGMT	0.43	6.58	0.34	1.82e-10	Response to temozolomide;
LUSC	cis	rs77741769	0.571	rs3861797	chr12:121255334	T/C	cg02419362	chr12:121203948	SPPL3	0.45	8.49	0.42	6.8e-16	Mean corpuscular volume;
LUSC	cis	rs9857275	0.501	rs13072100	chr3:141196647	G/A	cg00789793	chr3:141329863	RASA2	0.4	5.72	0.3	2.4e-8	Prion diseases;
LUSC	cis	rs796825	0.530	rs34998142	chr3:119939802	T/C	cg21790991	chr3:120137480	FSTL1	-0.33	-5.83	-0.3	1.32e-8	HIV-1 susceptibility;
LUSC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg12863693	chr15:85201151	NMB	0.34	6.82	0.35	4.26e-11	Schizophrenia;
LUSC	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.84	-0.39	6.07e-14	Neuroticism;
LUSC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.68	0.34	9.71e-11	Menopause (age at onset);
LUSC	cis	rs12760731	0.623	rs7547158	chr1:178309399	A/G	cg00404053	chr1:178313656	RASAL2	0.47	5.82	0.3	1.39e-8	Obesity-related traits;
LUSC	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg22681709	chr2:178499509	PDE11A	-0.55	-11.03	-0.52	2.5300000000000002e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg21775007	chr8:11205619	TDH	-0.56	-7.9	-0.4	4.08e-14	Neuroticism;
LUSC	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg03878208	chr11:72483293	STARD10	0.58	7.71	0.39	1.46e-13	Type 2 diabetes;
LUSC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg26335602	chr6:28129616	ZNF389	0.46	6.34	0.33	7.57e-10	Parkinson's disease;
LUSC	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.09	0.36	8.04e-12	Morning vs. evening chronotype;
LUSC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg18477163	chr1:228402036	OBSCN	-0.55	-10.03	-0.48	7.34e-21	Diastolic blood pressure;
LUSC	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg00086871	chr4:6988644	TBC1D14	0.81	8.72	0.43	1.35e-16	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05901451	chr6:126070800	HEY2	0.89	16.86	0.68	1.42e-46	Brugada syndrome;
LUSC	cis	rs7107174	0.786	rs4945266	chr11:78027488	A/G	cg02023728	chr11:77925099	USP35	0.48	6.83	0.35	4.04e-11	Testicular germ cell tumor;
LUSC	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg06008330	chr7:65541103	ASL	0.4	6.17	0.32	1.96e-9	Aortic root size;
LUSC	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg01073479	chr16:3509474	NAT15	0.39	5.65	0.3	3.46e-8	Tuberculosis;
LUSC	cis	rs1775715	0.835	rs1419169	chr10:32257204	C/G	cg26784012	chr10:32216390	ARHGAP12	0.41	6.64	0.34	1.29e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21659725	chr3:3221576	CRBN	0.55	8.75	0.43	1.04e-16	Body mass index;
LUSC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg05347473	chr6:146136440	FBXO30	-0.48	-7.99	-0.4	2.25e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2236918	0.965	rs2488472	chr1:242019919	T/C	cg17736920	chr1:242011382	EXO1	0.46	7.19	0.37	4.4e-12	Menopause (age at onset);
LUSC	trans	rs7632427	0.901	rs35124509	chr3:89521693	A/G	cg15657888	chr2:113735612	IL1F9	0.26	6.04	0.31	4.15e-9	Orofacial clefts;
LUSC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg23625390	chr15:77176239	SCAPER	0.46	6.85	0.35	3.54e-11	Blood metabolite levels;
LUSC	cis	rs4595586	0.679	rs4768473	chr12:39326256	A/G	cg26384229	chr12:38710491	ALG10B	0.44	5.97	0.31	6.12e-9	Morning vs. evening chronotype;
LUSC	trans	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04565464	chr8:145669602	NFKBIL2	0.4	6.64	0.34	1.26e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4478858	0.684	rs7544946	chr1:31749736	T/C	cg00250761	chr1:31883323	NA	-0.33	-7.95	-0.4	2.9e-14	Alcohol dependence;
LUSC	cis	rs11168618	1.000	rs10875833	chr12:48953368	C/T	cg24011408	chr12:48396354	COL2A1	0.41	6.43	0.33	4.46e-10	Adiponectin levels;
LUSC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.76	-0.3	1.94e-8	Personality dimensions;
LUSC	cis	rs2235544	0.565	rs12758219	chr1:54466145	G/A	cg25741118	chr1:54482237	LDLRAD1	0.28	6.03	0.31	4.41e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg18357645	chr12:58087776	OS9	0.51	7.6	0.38	3.05e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.24	0.45	3.06e-18	Motion sickness;
LUSC	cis	rs834603	0.575	rs834609	chr7:47456846	T/C	cg09696706	chr7:47479511	TNS3	0.32	5.76	0.3	1.94e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.65	-10.44	-0.5	2.96e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg16327482	chr19:10226339	EIF3G	0.39	7.18	0.37	4.44e-12	Narcolepsy;
LUSC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg12463550	chr7:65579703	CRCP	0.51	7.52	0.38	5.19e-13	Aortic root size;
LUSC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.9	15.7	0.65	5.45e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2652834	0.851	rs1126310	chr15:63428765	G/A	cg05507819	chr15:63340323	TPM1	0.45	5.77	0.3	1.82e-8	HDL cholesterol;
LUSC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg21724239	chr8:58056113	NA	0.66	7.4	0.38	1.14e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.36e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg09795085	chr6:101329169	ASCC3	0.49	7.25	0.37	2.9e-12	Neuroticism;
LUSC	cis	rs7119	0.717	rs12904212	chr15:77815833	C/A	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs943466	0.513	rs755497	chr6:33734419	C/T	cg25922239	chr6:33757077	LEMD2	-0.4	-5.65	-0.3	3.47e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUSC	cis	rs78663649	0.708	rs79268770	chr19:16601411	A/T	cg05286348	chr19:16641544	CHERP	-1.34	-10.65	-0.5	5.16e-23	White blood cell count;
LUSC	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.9e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg05673287	chr15:77411982	SGK269	-0.44	-6.98	-0.36	1.6e-11	Type 2 diabetes;
LUSC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg12963246	chr6:28129442	ZNF389	0.51	7.06	0.36	9.69e-12	Depression;
LUSC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg11871910	chr12:69753446	YEATS4	0.58	7.88	0.4	4.75e-14	Response to diuretic therapy;
LUSC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.18	0.37	4.63e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7923609	0.869	rs9971352	chr10:65265108	A/T	cg01631684	chr10:65280961	REEP3	-0.43	-6.55	-0.34	2.24e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs977987	0.843	rs11149820	chr16:75422760	G/A	cg04384234	chr16:75411784	CFDP1	-0.46	-7.65	-0.39	2.21e-13	Dupuytren's disease;
LUSC	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg26408565	chr15:76604113	ETFA	-0.49	-7.84	-0.39	6.1e-14	Blood metabolite levels;
LUSC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg00310523	chr12:86230176	RASSF9	-0.44	-8.28	-0.41	3.05e-15	Major depressive disorder;
LUSC	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.66	-0.43	2.01e-16	Rheumatoid arthritis;
LUSC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.82e-10	Bipolar disorder;
LUSC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.9	-0.35	2.57e-11	Total body bone mineral density;
LUSC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg21017887	chr14:105400489	NA	0.68	13.09	0.58	7.04e-32	Rheumatoid arthritis;
LUSC	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg07148914	chr20:33460835	GGT7	-0.48	-7.2	-0.37	3.97e-12	Height;
LUSC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08280861	chr8:58055591	NA	0.52	5.68	0.3	2.99e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs68170813	0.641	rs61511581	chr7:106948091	T/A	cg02696742	chr7:106810147	HBP1	-0.62	-9.39	-0.46	9.75e-19	Coronary artery disease;
LUSC	cis	rs7000551	0.663	rs11778831	chr8:22335088	C/T	cg12081754	chr8:22256438	SLC39A14	0.43	6.28	0.33	1.04e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg22907277	chr7:1156413	C7orf50	0.72	10.4	0.49	3.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9611519	1.000	rs5758267	chr22:41619350	A/T	cg13813247	chr22:41461852	NA	0.33	6.19	0.32	1.77e-9	Neuroticism;
LUSC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg03351412	chr1:154909251	PMVK	0.55	8.7	0.43	1.52e-16	Prostate cancer;
LUSC	cis	rs2074585	0.583	rs28406958	chr15:91069364	C/A	cg22089800	chr15:90895588	ZNF774	-0.57	-8.03	-0.4	1.68e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs977987	0.806	rs4888418	chr16:75460306	C/G	cg04384234	chr16:75411784	CFDP1	-0.43	-6.99	-0.36	1.54e-11	Dupuytren's disease;
LUSC	cis	rs600231	0.542	rs34527830	chr11:65240863	G/A	cg17120908	chr11:65337727	SSSCA1	-0.62	-8.95	-0.44	2.47e-17	Bone mineral density;
LUSC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg26408565	chr15:76604113	ETFA	0.47	7.47	0.38	7.1e-13	Blood metabolite levels;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15482792	chr1:91870014	HFM1	0.42	6.1	0.32	2.95e-9	Calcium levels;
LUSC	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg08999081	chr20:33150536	PIGU	0.37	6.69	0.34	9.61e-11	Height;
LUSC	cis	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg18209359	chr17:80159595	CCDC57	-0.36	-5.82	-0.3	1.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg05729581	chr11:3078854	CARS	0.41	5.95	0.31	6.91e-9	Calcium levels;
LUSC	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.11	-0.41	9.41e-15	Lung cancer;
LUSC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg13607699	chr17:42295918	UBTF	-0.47	-7.37	-0.37	1.32e-12	Total body bone mineral density;
LUSC	trans	rs931812	0.825	rs35515344	chr8:101896769	C/G	cg20993868	chr7:22813445	NA	0.6	10.46	0.5	2.54e-22	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.8	9.68	0.47	1.04e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg23093090	chr10:104574429	C10orf26	-0.38	-7.17	-0.37	4.96e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.82	13.74	0.6	2.25e-34	Aortic root size;
LUSC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.58	9.04	0.44	1.29e-17	Menopause (age at onset);
LUSC	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg20573242	chr4:122745356	CCNA2	-0.45	-6.73	-0.35	7.38e-11	Type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18672446	chr16:23160676	USP31	0.47	6.1	0.32	3.01e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg09693106	chr22:46449821	C22orf26;LOC150381	0.39	5.9	0.31	9.04e-9	Dupuytren's disease;
LUSC	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg23601095	chr6:26197514	HIST1H3D	0.71	7.35	0.37	1.57e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg24130564	chr14:104152367	KLC1	0.45	6.51	0.34	2.72e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs62238980	0.614	rs117338422	chr22:32399226	C/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.02	-0.31	4.68e-9	Childhood ear infection;
LUSC	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	cis	rs4663866	0.901	rs35713061	chr2:239183774	C/T	cg16914508	chr2:239161102	PER2	0.66	6.99	0.36	1.46e-11	Irritable bowel syndrome;
LUSC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.62	-14.31	-0.62	1.47e-36	Prostate cancer;
LUSC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg09367891	chr1:107599246	PRMT6	-0.54	-8.5	-0.42	6.26e-16	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs2979489	0.891	rs2915624	chr8:30381245	T/C	cg26383811	chr8:30366931	RBPMS	-0.53	-8.18	-0.41	6.08e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08645402	chr16:4508243	NA	0.48	8.15	0.41	7.22e-15	Schizophrenia;
LUSC	cis	rs10865541	0.902	rs33997548	chr2:3419366	A/G	cg15807143	chr2:3452624	TTC15	0.32	5.67	0.3	3.09e-8	Obesity-related traits;
LUSC	cis	rs11605275	1.000	rs78687006	chr11:20032176	G/A	cg14835545	chr11:20032148	NAV2	-0.86	-6.53	-0.34	2.43e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg02228329	chr11:64053129	BAD;GPR137	0.44	6.23	0.32	1.37e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg14416269	chr4:6271139	WFS1	0.54	11.14	0.52	1e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg08975724	chr8:8085496	FLJ10661	0.51	7.95	0.4	2.84e-14	Mood instability;
LUSC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	0.71	11.9	0.55	1.8e-27	Methadone dose in opioid dependence;
LUSC	cis	rs7428496	0.528	rs12639363	chr3:142292518	C/T	cg16271453	chr3:142027066	XRN1	0.5	8.56	0.42	4.26e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.56e-10	Menopause (age at onset);
LUSC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.86	0.44	4.97e-17	Motion sickness;
LUSC	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	0.86	13.23	0.59	2.07e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs4356932	1.000	rs10025102	chr4:76955358	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg07828340	chr4:882639	GAK	1.01	10.45	0.5	2.66e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.88	-0.4	4.75e-14	Blood metabolite levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18851521	chr18:268131	THOC1	-0.48	-6.37	-0.33	6.23e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg06637938	chr14:75390232	RPS6KL1	0.66	11.13	0.52	1.11e-24	Caffeine consumption;
LUSC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.46e-35	Breast cancer;
LUSC	trans	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg27411982	chr8:10470053	RP1L1	-0.36	-6.05	-0.31	3.93e-9	Mood instability;
LUSC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.43	-7.46	-0.38	7.49e-13	Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg01879757	chr17:41196368	BRCA1	-0.45	-6.85	-0.35	3.63e-11	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14341449	chr11:18034693	SERGEF	0.48	6.8	0.35	4.94e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.51	-7.79	-0.39	8.61e-14	Lymphocyte counts;
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.93	19.06	0.72	2.57e-55	Menarche (age at onset);
LUSC	cis	rs7113850	0.541	rs78737372	chr11:24233984	G/A	ch.11.24196551F	chr11:24239977	NA	1.01	9.09	0.45	8.71e-18	Bone fracture in osteoporosis;
LUSC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07080220	chr10:102295463	HIF1AN	0.66	9.26	0.45	2.63e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.53	10.46	0.5	2.5e-22	Coronary artery disease;
LUSC	cis	rs2116941	0.523	rs8104608	chr19:10370133	G/A	cg01850179	chr19:10340795	S1PR2	0.62	9.81	0.47	3.91e-20	Pulse pressure;
LUSC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	12.66	0.57	2.74e-30	Cognitive test performance;
LUSC	cis	rs7945718	0.806	rs7480572	chr11:12787048	T/C	cg25843174	chr11:12811716	TEAD1	0.33	7.48	0.38	6.62e-13	Educational attainment (years of education);
LUSC	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg03060546	chr3:49711283	APEH	0.56	7.79	0.39	8.65e-14	Resting heart rate;
LUSC	trans	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg06606381	chr12:133084897	FBRSL1	-0.61	-5.95	-0.31	6.75e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.59	-0.5	9.01e-23	Schizophrenia;
LUSC	cis	rs870825	0.616	rs4444873	chr4:185628406	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	12.82	0.57	7.31e-31	Blood protein levels;
LUSC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg04450456	chr4:17643702	FAM184B	-0.41	-6.74	-0.35	7.06e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs74338693	0.666	rs7608672	chr2:166924851	G/A	cg02187259	chr2:16804452	FAM49A	0.31	5.97	0.31	5.99e-9	Schizophrenia;
LUSC	trans	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.68	0.34	9.89e-11	Corneal astigmatism;
LUSC	trans	rs3857536	0.813	rs9354405	chr6:66948575	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-5.97	-0.31	5.9e-9	Blood trace element (Cu levels);
LUSC	cis	rs7945718	1.000	rs7945719	chr11:12748820	A/C	cg25843174	chr11:12811716	TEAD1	0.32	7.04	0.36	1.09e-11	Educational attainment (years of education);
LUSC	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.89	-0.4	4.34e-14	Glomerular filtration rate;
LUSC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.67	0.43	1.92e-16	Cognitive test performance;
LUSC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg05472934	chr7:22766657	IL6	0.5	7.85	0.39	5.69e-14	Lung cancer;
LUSC	cis	rs2307022	0.548	rs1465471	chr16:68396377	C/T	cg02226672	chr16:68398533	SMPD3	0.32	6.05	0.31	3.84e-9	Body mass index;
LUSC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg06453172	chr10:134556979	INPP5A	0.51	6.47	0.33	3.48e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg06627628	chr2:24431161	ITSN2	0.55	7.75	0.39	1.13e-13	Asthma;
LUSC	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.16	0.45	5.47e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg18357645	chr12:58087776	OS9	-0.5	-6.67	-0.34	1.03e-10	Multiple sclerosis;
LUSC	cis	rs2346177	0.874	rs35462976	chr2:46649049	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.36	6.16	0.32	2.05e-9	HDL cholesterol;
LUSC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg27535305	chr1:53392650	SCP2	0.36	6.78	0.35	5.43e-11	Monocyte count;
LUSC	trans	rs853679	0.599	rs202906	chr6:28011652	C/T	cg01620082	chr3:125678407	NA	0.58	6.68	0.34	1.01e-10	Depression;
LUSC	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.65	10.96	0.51	4.28e-24	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16628904	chr6:126661274	C6orf173	-0.45	-6.45	-0.33	3.92e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10761482	0.813	rs7087726	chr10:62162582	G/C	cg18175470	chr10:62150864	ANK3	-0.57	-8.51	-0.42	6.1e-16	Schizophrenia;
LUSC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg08355456	chr11:67383691	NA	0.37	6.43	0.33	4.54e-10	Mean corpuscular volume;
LUSC	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg08085267	chr17:45401833	C17orf57	0.54	8.62	0.43	2.68e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.84	-0.3	1.23e-8	Total body bone mineral density;
LUSC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg27541892	chr1:1571801	CDK11B	-0.53	-8.39	-0.42	1.35e-15	Body mass index;
LUSC	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.24	0.37	3.1e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2708377	0.929	rs2597990	chr12:11203459	G/A	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.8	-7.83	-0.39	6.58e-14	Bitter taste perception;
LUSC	cis	rs9815354	0.638	rs73073302	chr3:42029879	T/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg18209359	chr17:80159595	CCDC57	-0.36	-5.82	-0.3	1.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg01256987	chr12:42539512	GXYLT1	-0.39	-7.22	-0.37	3.59e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg13902645	chr11:5959945	NA	-0.56	-7.94	-0.4	3.1e-14	DNA methylation (variation);
LUSC	cis	rs7911264	0.703	rs7894183	chr10:94382040	G/A	cg25093409	chr10:94429542	NA	0.36	6.21	0.32	1.59e-9	Inflammatory bowel disease;
LUSC	cis	rs4901869	0.966	rs9972206	chr14:59336095	A/G	cg02291164	chr14:59296302	NA	0.57	10.88	0.51	8.53e-24	Panic disorder;
LUSC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg13047869	chr3:10149882	C3orf24	0.62	8.64	0.43	2.39e-16	Alzheimer's disease;
LUSC	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg05373962	chr22:49881684	NA	-0.42	-10.04	-0.48	6.56e-21	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.47	-7.19	-0.37	4.4e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06636551	chr8:101224915	SPAG1	0.38	7.07	0.36	9.17e-12	Atrioventricular conduction;
LUSC	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05165339	chr4:1420672	NA	-0.3	-7.03	-0.36	1.18e-11	Longevity;
LUSC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	12.33	0.56	4.97e-29	Chronic sinus infection;
LUSC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg15448220	chr1:150897856	SETDB1	0.43	6.23	0.32	1.43e-9	Melanoma;
LUSC	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg15839431	chr19:19639596	YJEFN3	-0.66	-6.93	-0.35	2.2e-11	Bipolar disorder;
LUSC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06634786	chr22:41940651	POLR3H	-0.57	-6.89	-0.35	2.71e-11	Vitiligo;
LUSC	cis	rs240764	0.782	rs369125	chr6:101118400	G/A	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.69e-9	Neuroticism;
LUSC	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/T	cg04362960	chr10:104952993	NT5C2	1.03	11.72	0.54	8.13e-27	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.5	-7.2	-0.37	3.95e-12	Colorectal cancer;
LUSC	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.19	23.81	0.79	5.99e-74	Exhaled nitric oxide output;
LUSC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg09877947	chr5:131593287	PDLIM4	0.49	8.45	0.42	9.38e-16	Blood metabolite levels;
LUSC	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg03929089	chr4:120376271	NA	0.64	6.98	0.36	1.61e-11	Axial length;
LUSC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg08499158	chr17:42289980	UBTF	0.42	6.44	0.33	4.18e-10	Total body bone mineral density;
LUSC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg14403583	chr14:105418241	AHNAK2	-0.57	-9.68	-0.47	1.1e-19	Rheumatoid arthritis;
LUSC	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04004882	chr2:215674386	BARD1	-0.43	-5.79	-0.3	1.64e-8	Neuroblastoma;
LUSC	cis	rs6005807	0.640	rs73432205	chr22:29028132	C/T	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs9362426	0.708	rs7753821	chr6:88100010	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	6.3	0.33	9.54e-10	Depressive episodes in bipolar disorder;
LUSC	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg11019008	chr10:131425282	MGMT	0.39	5.84	0.3	1.26e-8	Response to temozolomide;
LUSC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg06454157	chr6:167490870	NA	-0.28	-6.71	-0.34	8.57e-11	Primary biliary cholangitis;
LUSC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg15534755	chr11:117069859	TAGLN	0.35	6.06	0.31	3.72e-9	Blood protein levels;
LUSC	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg18681998	chr4:17616180	MED28	0.78	13.81	0.6	1.26e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11039100	0.607	rs34317277	chr11:5782186	A/C	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg12751644	chr20:60527061	NA	-0.34	-6.0	-0.31	5.25e-9	Body mass index;
LUSC	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg24596788	chr1:163392923	NA	-0.39	-6.48	-0.33	3.25e-10	Motion sickness;
LUSC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg04871131	chr7:94954202	PON1	-0.39	-6.11	-0.32	2.7e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg00129232	chr17:37814104	STARD3	-0.48	-7.23	-0.37	3.27e-12	Asthma;
LUSC	cis	rs4690686	0.769	rs11133146	chr4:177278878	C/T	cg17059388	chr4:177262070	NA	-0.37	-7.33	-0.37	1.71e-12	Essential tremor;
LUSC	cis	rs11608355	0.545	rs12818120	chr12:109901916	C/T	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.15e-26	Neuroticism;
LUSC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.76	0.35	6.21e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg16339924	chr4:17578868	LAP3	-0.58	-8.38	-0.42	1.53e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs61931739	0.635	rs1601627	chr12:33962420	G/A	cg26384229	chr12:38710491	ALG10B	0.51	7.62	0.38	2.61e-13	Morning vs. evening chronotype;
LUSC	trans	rs877282	0.583	rs11253425	chr10:815173	G/A	cg22713356	chr15:30763199	NA	0.73	9.32	0.45	1.67e-18	Uric acid levels;
LUSC	cis	rs56283067	0.887	rs9463042	chr6:44770527	T/C	cg20913747	chr6:44695427	NA	-0.44	-6.98	-0.36	1.6e-11	Total body bone mineral density;
LUSC	cis	rs909002	0.925	rs7524405	chr1:32108579	A/C	cg01639898	chr1:32083012	HCRTR1	-0.25	-5.87	-0.31	1.08e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs17039065	0.920	rs79622192	chr4:109419632	G/A	cg07444054	chr2:108107501	NA	0.45	6.29	0.33	1.01e-9	Gut microbiome composition (summer);
LUSC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-11.27	-0.52	3.48e-25	Cognitive function;
LUSC	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg24642439	chr20:33292090	TP53INP2	0.43	6.22	0.32	1.52e-9	Height;
LUSC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	10.81	0.51	1.44e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg08742575	chr21:47604166	C21orf56	-0.42	-6.26	-0.32	1.2e-9	Testicular germ cell tumor;
LUSC	cis	rs12519773	0.525	rs57542119	chr5:92538853	T/C	cg18783429	chr5:92414398	NA	0.35	7.4	0.38	1.08e-12	Migraine;
LUSC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg11663144	chr21:46675770	NA	-0.4	-6.94	-0.36	2.04e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg10483660	chr13:112241077	NA	0.37	6.8	0.35	4.88e-11	Menarche (age at onset);
LUSC	cis	rs2282802	0.685	rs7715538	chr5:139665181	T/C	cg26211634	chr5:139558579	C5orf32	0.44	8.09	0.4	1.14e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg23791538	chr6:167370224	RNASET2	-0.41	-6.56	-0.34	2.05e-10	Crohn's disease;
LUSC	cis	rs73200209	0.744	rs57085207	chr12:116579289	T/C	cg01776926	chr12:116560359	MED13L	-0.51	-6.11	-0.32	2.71e-9	Total body bone mineral density;
LUSC	trans	rs1268789	0.501	rs3762844	chr4:79365152	G/A	cg06112894	chr8:141469983	TRAPPC9	0.22	5.96	0.31	6.33e-9	Hair shape;Hair morphology;
LUSC	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg18681998	chr4:17616180	MED28	-0.82	-14.54	-0.62	1.84e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7408868	0.520	rs1043994	chr19:15302844	T/C	cg14696996	chr19:15285081	NOTCH3	0.78	7.52	0.38	5.23e-13	Pulse pressure;
LUSC	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg24450063	chr1:156163899	SLC25A44	1.1	22.24	0.77	6.99e-68	Testicular germ cell tumor;
LUSC	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.55	-7.34	-0.37	1.6e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	trans	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg14227996	chr4:17616232	MED28	-0.54	-6.08	-0.32	3.37e-9	Opioid sensitivity;
LUSC	cis	rs752010	0.644	rs6700390	chr1:42112554	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	9.81	0.47	4.1e-20	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs3126085	0.935	rs1858478	chr1:152257457	C/T	cg26876637	chr1:152193138	HRNR	-0.45	-6.08	-0.32	3.31e-9	Atopic dermatitis;
LUSC	trans	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg10756647	chr7:56101905	PSPH	0.88	8.95	0.44	2.46e-17	Diabetic kidney disease;
LUSC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg22907277	chr7:1156413	C7orf50	0.49	7.51	0.38	5.46e-13	Longevity;Endometriosis;
LUSC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg00431813	chr7:1051703	C7orf50	-0.43	-7.37	-0.37	1.35e-12	Longevity;Endometriosis;
LUSC	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg09904177	chr6:26538194	HMGN4	0.68	11.46	0.53	7.03e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.93	-12.9	-0.58	3.58e-31	Cognitive ability;
LUSC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18876405	chr7:65276391	NA	0.55	8.79	0.43	8.1e-17	Aortic root size;
LUSC	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-7.98	-0.4	2.39e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg03929089	chr4:120376271	NA	-0.67	-9.56	-0.46	2.6e-19	Coronary artery disease;
LUSC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.49	0.59	2.14e-33	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs3771570	1.000	rs62193204	chr2:242315443	A/G	cg21155796	chr2:242212141	HDLBP	0.62	6.67	0.34	1.07e-10	Prostate cancer;
LUSC	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg04374321	chr14:90722782	PSMC1	0.76	12.08	0.55	4.07e-28	Mortality in heart failure;
LUSC	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg06096015	chr1:231504339	EGLN1	0.56	9.88	0.48	2.27e-20	Hemoglobin concentration;
LUSC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.54	-0.46	3.1e-19	Chronic sinus infection;
LUSC	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.68	-0.47	1.09e-19	Total cholesterol levels;
LUSC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg12564285	chr5:131593104	PDLIM4	-0.48	-8.29	-0.41	2.8e-15	Breast cancer;
LUSC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11764359	chr7:65958608	NA	-0.53	-7.28	-0.37	2.34e-12	Aortic root size;
LUSC	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1832871	0.672	rs56326208	chr6:158762944	C/T	cg07165851	chr6:158734300	TULP4	0.46	6.95	0.36	1.98e-11	Height;
LUSC	cis	rs1451375	0.572	rs66792686	chr7:50651239	T/C	cg18232548	chr7:50535776	DDC	0.47	6.13	0.32	2.54e-9	Malaria;
LUSC	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg00268967	chr12:58002603	GEFT;DTX3	-0.36	-5.77	-0.3	1.77e-8	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7523050	0.730	rs72984614	chr1:109435848	T/C	cg08274380	chr1:109419600	GPSM2	1.13	11.51	0.53	4.76e-26	Fat distribution (HIV);
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg15242686	chr22:24348715	GSTTP1	0.43	6.46	0.33	3.6e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs6957923	0.655	rs6949019	chr7:23594050	A/G	cg21014120	chr2:203736523	ICA1L	-0.42	-6.19	-0.32	1.79e-9	Height;
LUSC	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg15131784	chr3:139108705	COPB2	0.4	6.46	0.33	3.79e-10	Obesity-related traits;
LUSC	cis	rs2637266	1.000	rs7896379	chr10:78366247	C/T	cg18941641	chr10:78392320	NA	0.39	7.11	0.36	7.28e-12	Pulmonary function;
LUSC	cis	rs939658	0.683	rs1560895	chr15:79468082	A/G	cg17916960	chr15:79447300	NA	-0.42	-7.97	-0.4	2.59e-14	Refractive error;
LUSC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08704250	chr15:31115839	NA	0.49	7.95	0.4	2.97e-14	Huntington's disease progression;
LUSC	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-6.99	-0.36	1.51e-11	Blood metabolite levels;
LUSC	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg15704280	chr7:45808275	SEPT13	-0.44	-6.1	-0.32	3e-9	HDL cholesterol;
LUSC	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg15445000	chr17:37608096	MED1	0.41	6.91	0.35	2.41e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg15445000	chr17:37608096	MED1	-0.38	-6.5	-0.34	2.88e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg23985595	chr17:80112537	CCDC57	0.3	5.75	0.3	2.06e-8	Life satisfaction;
LUSC	cis	rs77633900	0.772	rs2944377	chr15:76699652	C/A	cg21673338	chr15:77095150	SCAPER	-0.7	-5.99	-0.31	5.4e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.52	-8.61	-0.43	2.96e-16	Lymphocyte counts;
LUSC	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.04	-16.32	-0.67	2.01e-44	Primary sclerosing cholangitis;
LUSC	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg08779649	chr13:50194554	NA	0.41	6.92	0.35	2.27e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs10203711	0.933	rs7591829	chr2:239586185	A/T	cg14580085	chr2:239553406	NA	0.39	6.47	0.33	3.56e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg13798912	chr7:905769	UNC84A	-0.56	-5.89	-0.31	9.24e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.34e-12	Tonsillectomy;
LUSC	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.74	-10.08	-0.48	4.84e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs225245	0.782	rs321599	chr17:33905745	C/T	cg19694781	chr19:47549865	TMEM160	-0.41	-6.61	-0.34	1.51e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg16586182	chr3:47516702	SCAP	-0.48	-7.46	-0.38	7.78e-13	Colorectal cancer;
LUSC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg23625390	chr15:77176239	SCAPER	0.43	6.45	0.33	3.81e-10	Blood metabolite levels;
LUSC	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg13010199	chr12:38710504	ALG10B	0.65	9.81	0.47	3.95e-20	Bladder cancer;
LUSC	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg10483660	chr13:112241077	NA	-0.35	-6.17	-0.32	2.03e-9	Menarche (age at onset);
LUSC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg11861562	chr11:117069780	TAGLN	0.44	7.9	0.4	4.17e-14	Blood protein levels;
LUSC	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg12292205	chr6:26970375	C6orf41	-0.56	-6.82	-0.35	4.3e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.3	0.33	9.38e-10	Corneal astigmatism;
LUSC	cis	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg24375607	chr4:120327624	NA	-0.46	-7.03	-0.36	1.18e-11	Plateletcrit;
LUSC	cis	rs12618769	0.597	rs1847550	chr2:99052299	C/T	cg10123293	chr2:99228465	UNC50	0.45	7.64	0.39	2.31e-13	Bipolar disorder;
LUSC	trans	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04565464	chr8:145669602	NFKBIL2	0.41	6.53	0.34	2.44e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-8.5	-0.42	6.18e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg01475377	chr6:109611718	NA	-0.45	-8.27	-0.41	3.13e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg23093090	chr10:104574429	C10orf26	-0.38	-6.13	-0.32	2.43e-9	Arsenic metabolism;
LUSC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg14061069	chr19:46274453	DMPK	-0.51	-8.56	-0.42	4.28e-16	Coronary artery disease;
LUSC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs6460942	1.000	rs75333414	chr7:12303829	T/A	cg06484146	chr7:12443880	VWDE	-0.57	-6.03	-0.31	4.23e-9	Coronary artery disease;
LUSC	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.54	-0.5	1.26e-22	Eye color traits;
LUSC	cis	rs10492096	0.947	rs12371184	chr12:6632925	A/G	cg13857086	chr12:6580257	VAMP1	0.55	6.67	0.34	1.06e-10	Hip geometry;
LUSC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg04944784	chr2:26401820	FAM59B	-0.74	-10.91	-0.51	6.48e-24	Gut microbiome composition (summer);
LUSC	cis	rs59104589	0.617	rs60178325	chr2:242300651	A/T	cg14842376	chr2:242211374	HDLBP	0.58	6.57	0.34	1.92e-10	Fibrinogen levels;
LUSC	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg26893861	chr17:41843967	DUSP3	0.98	14.71	0.63	4.09e-38	Triglycerides;
LUSC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08392591	chr16:89556376	ANKRD11	0.44	6.55	0.34	2.16e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg26338869	chr17:61819248	STRADA	0.41	5.95	0.31	6.66e-9	Prudent dietary pattern;
LUSC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	0.83	15.71	0.65	4.76e-42	Gestational age at birth (maternal effect);
LUSC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.92	0.31	8.01e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.43	0.42	1.08e-15	Prudent dietary pattern;
LUSC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg12257692	chr3:49977190	RBM6	-0.24	-6.6	-0.34	1.66e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs28647808	0.786	rs4962134	chr9:136256626	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs55675132	0.879	rs12130654	chr1:115626392	G/C	cg01522456	chr1:115632236	TSPAN2	-0.47	-6.09	-0.32	3.05e-9	Schizophrenia;
LUSC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	13.19	0.59	2.84e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg06074448	chr4:187884817	NA	-0.41	-6.91	-0.35	2.47e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	10.56	0.5	1.11e-22	Homoarginine levels;
LUSC	cis	rs6906287	0.647	rs7758614	chr6:118889894	T/C	cg21191810	chr6:118973309	C6orf204	0.32	5.98	0.31	5.63e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6546550	0.901	rs11902198	chr2:70144596	C/A	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	9.99	0.48	9.66e-21	Electrocardiographic conduction measures;
LUSC	cis	rs11958404	0.932	rs112993559	chr5:157414712	A/C	cg05962755	chr5:157440814	NA	0.5	6.14	0.32	2.38e-9	IgG glycosylation;
LUSC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg24250549	chr1:154909240	PMVK	0.44	6.58	0.34	1.87e-10	Prostate cancer;
LUSC	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.59	-9.43	-0.46	7.17e-19	Type 2 diabetes;
LUSC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg01181863	chr3:195395398	SDHAP2	-0.59	-8.08	-0.4	1.21e-14	Pancreatic cancer;
LUSC	cis	rs8133932	0.608	rs382195	chr21:47339222	G/A	cg14185626	chr21:47401492	COL6A1	-0.45	-5.78	-0.3	1.75e-8	Schizophrenia;
LUSC	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg09479241	chr17:27052676	TLCD1	0.4	5.71	0.3	2.5e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs1927790	0.643	rs9556574	chr13:97011649	T/G	cg03198741	chr6:1003969	LOC285768	-0.39	-5.96	-0.31	6.5e-9	Body mass index;
LUSC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-0.92	-17.41	-0.69	9.48e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.26	0.64	2.91e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg19920283	chr7:105172520	RINT1	0.6	6.38	0.33	5.9e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs73001065	0.688	rs59148799	chr19:19484008	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	8.66	0.43	2.11e-16	LDL cholesterol;
LUSC	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17467752	chr17:38218738	THRA	-0.51	-7.3	-0.37	2.09e-12	White blood cell count;
LUSC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	7.57	0.38	3.63e-13	Multiple sclerosis;
LUSC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg06238570	chr21:40685208	BRWD1	0.44	6.67	0.34	1.07e-10	Cognitive function;
LUSC	cis	rs12776158	1.000	rs12776158	chr10:71218094	T/C	cg12610070	chr10:71211762	TSPAN15	-0.5	-6.81	-0.35	4.52e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg04036182	chr15:45458818	NA	-0.35	-5.65	-0.3	3.42e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg01733217	chr16:74700730	RFWD3	0.98	22.16	0.77	1.52e-67	Multiple myeloma;
LUSC	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-0.96	-10.27	-0.49	1.13e-21	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.68	0.47	1.09e-19	Bipolar disorder;
LUSC	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg24558204	chr6:135376177	HBS1L	0.56	8.56	0.42	4.17e-16	Red blood cell count;
LUSC	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg21918786	chr6:109611834	NA	-0.4	-6.93	-0.35	2.14e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.1	16.88	0.68	1.19e-46	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7180079	1.000	rs2062249	chr15:64672159	C/A	cg08069370	chr15:64387884	SNX1	0.63	6.19	0.32	1.77e-9	Monocyte count;
LUSC	cis	rs75920871	0.528	rs11216255	chr11:116929995	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-6.15	-0.32	2.24e-9	Subjective well-being;
LUSC	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg13010199	chr12:38710504	ALG10B	0.43	6.07	0.32	3.39e-9	Morning vs. evening chronotype;
LUSC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg07507251	chr3:52567010	NT5DC2	0.34	6.68	0.34	1e-10	Bipolar disorder;
LUSC	cis	rs6700896	0.500	rs4655556	chr1:66080563	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.35	0.33	7.09e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg16524733	chr11:117070046	TAGLN	0.43	7.62	0.38	2.64e-13	Blood protein levels;
LUSC	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg02569458	chr12:86230093	RASSF9	0.42	6.73	0.35	7.42e-11	Major depressive disorder;
LUSC	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg23950597	chr19:37808831	NA	-0.62	-7.31	-0.37	2e-12	Coronary artery calcification;
LUSC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg12463550	chr7:65579703	CRCP	0.51	7.37	0.37	1.33e-12	Aortic root size;
LUSC	trans	rs72674100	1.000	rs60708023	chr4:97984500	A/G	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6933660	0.610	rs71549125	chr6:151770796	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.78	12.63	0.57	3.7e-30	Menarche (age at onset);
LUSC	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg22800045	chr5:56110881	MAP3K1	0.46	6.44	0.33	4.08e-10	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.82	0.43	6.31e-17	Axial length;
LUSC	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-7.72	-0.39	1.38e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg02018176	chr4:1364513	KIAA1530	0.46	6.53	0.34	2.46e-10	Recombination rate (females);
LUSC	trans	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg06521331	chr12:34319734	NA	-0.44	-6.61	-0.34	1.54e-10	Bladder cancer;
LUSC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg16339924	chr4:17578868	LAP3	0.64	10.13	0.48	3.18e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.74	0.51	2.63e-23	Hip circumference adjusted for BMI;
LUSC	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg23711669	chr6:146136114	FBXO30	0.86	15.5	0.65	3.42e-41	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs76248362	1.000	rs9510908	chr13:24435768	C/T	cg26511321	chr7:27196790	HOXA7	0.54	6.24	0.32	1.35e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs6987853	0.666	rs2923403	chr8:42447748	G/T	cg09913449	chr8:42400586	C8orf40	0.49	8.47	0.42	7.97e-16	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg02153584	chr22:29168773	CCDC117	0.59	8.8	0.43	7.31e-17	Lymphocyte counts;
LUSC	cis	rs9549260	0.755	rs4943797	chr13:41201633	A/G	cg21288729	chr13:41239152	FOXO1	-0.61	-9.39	-0.46	9.97e-19	Red blood cell count;
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg12419862	chr22:24373484	LOC391322	-0.99	-18.41	-0.71	9.9e-53	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.14	-0.45	6.18e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg11102782	chr19:18549136	ISYNA1	-0.37	-6.96	-0.36	1.76e-11	Breast cancer;
LUSC	cis	rs7833986	1.000	rs36103212	chr8:57101475	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	8.88	0.44	4.2e-17	Height;
LUSC	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.16	-0.32	2.09e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg08997352	chr12:9597637	DDX12	-0.6	-9.39	-0.46	9.78e-19	Breast size;
LUSC	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg13010344	chr12:123464640	ARL6IP4	0.49	6.44	0.33	4.06e-10	Neutrophil percentage of white cells;
LUSC	cis	rs8113142	0.614	rs59394095	chr19:29192112	C/A	cg04546413	chr19:29218101	NA	0.47	6.37	0.33	6.15e-10	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.36e-10	Menopause (age at onset);
LUSC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-7.2	-0.37	4.02e-12	Alzheimer's disease (late onset);
LUSC	cis	rs4604732	0.588	rs9943231	chr1:247629829	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.79	0.35	5.06e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-14.08	-0.61	1.14e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12292205	chr6:26970375	C6orf41	-0.58	-7.39	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-7.21	-0.37	3.82e-12	Obesity-related traits;
LUSC	cis	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg06521331	chr12:34319734	NA	-0.46	-7.59	-0.38	3.27e-13	Morning vs. evening chronotype;
LUSC	cis	rs7575217	0.767	rs6543018	chr2:101730288	A/G	cg23907051	chr2:101730305	TBC1D8	0.3	8.24	0.41	3.85e-15	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg21827317	chr3:136751795	NA	0.39	6.91	0.35	2.41e-11	Neuroticism;
LUSC	trans	rs1459104	0.866	rs12804916	chr11:54831763	G/A	cg15704280	chr7:45808275	SEPT13	0.76	6.64	0.34	1.24e-10	Body mass index;
LUSC	trans	rs2729385	1.000	rs2729385	chr11:57262993	C/T	cg07172676	chr8:144997714	PLEC1	-0.47	-6.05	-0.31	3.97e-9	Interleukin-18 levels;
LUSC	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg15997130	chr1:24165203	NA	0.52	8.58	0.42	3.67e-16	Immature fraction of reticulocytes;
LUSC	cis	rs1983891	1.000	rs4714486	chr6:41542417	C/T	cg20194872	chr6:41519635	FOXP4	0.37	6.49	0.33	3.11e-10	Prostate cancer;
LUSC	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.89	0.4	4.34e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg26395211	chr5:140044315	WDR55	0.44	6.81	0.35	4.6e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg24813613	chr7:1882135	MAD1L1	-0.36	-5.86	-0.31	1.08e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg13047869	chr3:10149882	C3orf24	0.57	7.95	0.4	2.83e-14	Alzheimer's disease;
LUSC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	0.9	14.86	0.63	1.12e-38	Breast cancer;
LUSC	cis	rs4919694	0.615	rs78384860	chr10:105003019	G/T	cg04362960	chr10:104952993	NT5C2	1.22	13.15	0.58	4.2e-32	Arsenic metabolism;
LUSC	cis	rs10823500	0.748	rs7072230	chr10:71978144	A/G	cg02100629	chr10:71892760	AIFM2	-0.36	-5.79	-0.3	1.66e-8	Blood protein levels;
LUSC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg01448562	chr3:133502909	NA	-0.53	-7.8	-0.39	8.02e-14	Iron status biomarkers;
LUSC	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg21775007	chr8:11205619	TDH	-0.56	-8.29	-0.41	2.72e-15	Neuroticism;
LUSC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.51	0.42	6.06e-16	Prudent dietary pattern;
LUSC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.9	16.22	0.66	4.63e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7246967	0.673	rs2112610	chr19:22916851	C/T	cg23217946	chr19:22817039	ZNF492	0.44	6.09	0.32	3.08e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs72627509	0.680	rs66790703	chr4:57773908	G/A	cg26694713	chr4:57773883	REST	0.52	6.36	0.33	6.73e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg23283495	chr1:209979779	IRF6	0.62	7.66	0.39	1.99e-13	Cleft lip with or without cleft palate;
LUSC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg04414720	chr1:150670196	GOLPH3L	0.53	8.23	0.41	4.4e-15	Melanoma;
LUSC	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg00857998	chr1:205179979	DSTYK	0.53	7.98	0.4	2.42e-14	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	1.06	15.17	0.64	6.53e-40	Uric acid levels;
LUSC	cis	rs9534288	0.699	rs1409432	chr13:46668302	C/T	cg15192986	chr13:46630673	CPB2	-0.7	-10.16	-0.49	2.51e-21	Blood protein levels;
LUSC	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg17376030	chr22:41985996	PMM1	-0.47	-5.94	-0.31	7.32e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg00024416	chr22:24240387	NA	0.47	7.22	0.37	3.58e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg19812747	chr11:111475976	SIK2	-0.55	-8.08	-0.4	1.16e-14	Primary sclerosing cholangitis;
LUSC	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg21427119	chr20:30132790	HM13	0.38	5.89	0.31	9.29e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs1891275	0.515	rs7092884	chr10:93483872	A/C	cg07889827	chr10:93443413	NA	0.41	9.47	0.46	5.11e-19	Intelligence (multi-trait analysis);
LUSC	trans	rs62238980	0.614	rs78593283	chr22:32365433	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.52	-5.99	-0.31	5.43e-9	Childhood ear infection;
LUSC	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.54	-7.98	-0.4	2.3e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00864171	chr11:67383662	NA	-0.37	-6.55	-0.34	2.15e-10	Mean corpuscular volume;
LUSC	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.55e-13	Putamen volume;
LUSC	cis	rs11031096	0.711	rs12270809	chr11:4206537	G/A	cg18678763	chr11:4115507	RRM1	-0.42	-5.96	-0.31	6.32e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1595825	0.786	rs79490184	chr2:198894219	T/A	cg10547527	chr2:198650123	BOLL	-0.52	-6.25	-0.32	1.23e-9	Ulcerative colitis;
LUSC	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg18225595	chr11:63971243	STIP1	0.52	6.06	0.31	3.67e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.61	8.36	0.42	1.67e-15	Adiposity;
LUSC	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.58	-8.27	-0.41	3.13e-15	Homoarginine levels;
LUSC	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg09703963	chr11:616879	IRF7;MUPCDH	-0.43	-6.7	-0.34	9.04e-11	Systemic lupus erythematosus;
LUSC	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-8.8	-0.43	7.7e-17	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg17848003	chr1:3704513	LRRC47	0.32	5.81	0.3	1.46e-8	Red cell distribution width;
LUSC	cis	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg21775007	chr8:11205619	TDH	-0.46	-5.94	-0.31	7.31e-9	Neuroticism;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01585723	chr16:33734837	NA	-0.44	-7.61	-0.38	2.74e-13	Menopause (age at onset);
LUSC	cis	rs2354432	0.607	rs9782976	chr1:146825049	A/G	cg25205988	chr1:146714368	CHD1L	0.88	9.17	0.45	5.1e-18	Mitochondrial DNA levels;
LUSC	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg10326726	chr10:51549505	MSMB	-0.35	-6.12	-0.32	2.58e-9	Prostate-specific antigen levels;
LUSC	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.42	-0.38	9.65e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg17385448	chr1:15911702	AGMAT	0.37	5.86	0.31	1.08e-8	Systolic blood pressure;
LUSC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg05347473	chr6:146136440	FBXO30	0.46	7.96	0.4	2.72e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg15839431	chr19:19639596	YJEFN3	-0.66	-7.28	-0.37	2.39e-12	Bipolar disorder;
LUSC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg25036284	chr2:26402008	FAM59B	-0.73	-10.66	-0.5	4.85e-23	Gut microbiome composition (summer);
LUSC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg13683864	chr3:40499215	RPL14	-1.13	-21.27	-0.76	4.56e-64	Renal cell carcinoma;
LUSC	trans	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg13010199	chr12:38710504	ALG10B	0.39	6.2	0.32	1.64e-9	Morning vs. evening chronotype;
LUSC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg15691649	chr6:25882328	NA	-0.38	-6.11	-0.32	2.8e-9	Blood metabolite levels;
LUSC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24531977	chr5:56204891	C5orf35	-0.89	-13.75	-0.6	2.2e-34	Initial pursuit acceleration;
LUSC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg02269571	chr22:50332266	NA	0.59	8.72	0.43	1.32e-16	Schizophrenia;
LUSC	cis	rs9361491	0.657	rs13198615	chr6:79430552	A/G	cg05283184	chr6:79620031	NA	-0.33	-5.9	-0.31	8.93e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	0.82	12.44	0.56	1.96e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg03351412	chr1:154909251	PMVK	0.53	8.34	0.42	1.98e-15	Prostate cancer;
LUSC	cis	rs6005807	0.563	rs9620811	chr22:29058409	T/C	cg12565055	chr22:29076175	TTC28	0.54	5.86	0.31	1.12e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	8.55	0.42	4.56e-16	Motion sickness;
LUSC	trans	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg26043149	chr18:55253948	FECH	0.43	6.71	0.34	8.19e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg25664220	chr3:72788482	NA	-0.69	-11.14	-0.52	1.05e-24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.67	0.6	4.46e-34	Cognitive test performance;
LUSC	cis	rs12220238	0.818	rs10430521	chr10:75913590	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.96	0.36	1.79e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-6.72	-0.35	7.76e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg02176678	chr2:219576539	TTLL4	0.62	11.0	0.52	3.13e-24	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs931812	0.757	rs35569317	chr8:101907971	T/C	cg20993868	chr7:22813445	NA	0.53	9.95	0.48	1.33e-20	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs9815354	0.812	rs59873855	chr3:41929538	T/C	cg03022575	chr3:42003672	ULK4	0.7	7.5	0.38	5.93e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg23598886	chr18:12777645	NA	0.65	6.6	0.34	1.61e-10	Inflammatory skin disease;
LUSC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg21665744	chr7:39171113	POU6F2	0.43	6.95	0.36	1.96e-11	IgG glycosylation;
LUSC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg17764715	chr19:33622953	WDR88	0.52	7.76	0.39	1.03e-13	Bone properties (heel);
LUSC	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg09469691	chr10:81107165	PPIF	0.65	9.25	0.45	2.75e-18	Height;
LUSC	cis	rs7119038	0.774	rs73005426	chr11:118681083	A/G	cg19308663	chr11:118741387	NA	0.34	6.09	0.32	3.07e-9	Sjögren's syndrome;
LUSC	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg26395211	chr5:140044315	WDR55	-0.39	-5.98	-0.31	5.69e-9	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02652260	chr21:18985383	BTG3	0.76	6.2	0.32	1.64e-9	Cognitive performance;
LUSC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg16797656	chr11:68205561	LRP5	0.36	6.1	0.32	2.96e-9	Total body bone mineral density;
LUSC	cis	rs469568	0.562	rs11741099	chr5:178664463	A/G	cg08999896	chr5:178685787	ADAMTS2	0.43	8.28	0.41	3.02e-15	Stroke (pediatric);
LUSC	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.5	-0.42	6.28e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg19920283	chr7:105172520	RINT1	0.58	6.12	0.32	2.65e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg26958806	chr6:27640298	NA	0.77	5.91	0.31	8.37e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.4	-5.73	-0.3	2.2e-8	Tonsillectomy;
LUSC	cis	rs6750047	0.647	rs11124632	chr2:38276412	G/C	cg07380506	chr2:38303506	CYP1B1	0.47	6.59	0.34	1.72e-10	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg16099169	chr2:106886729	NA	-0.58	-6.81	-0.35	4.59e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUSC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg00945038	chr17:61921165	SMARCD2	0.54	9.67	0.47	1.13e-19	Prudent dietary pattern;
LUSC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg02038168	chr22:39784481	NA	-0.47	-7.86	-0.4	5.34e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4704187	0.687	rs6869345	chr5:74378742	C/T	cg03227963	chr5:74354835	NA	0.31	6.73	0.35	7.4e-11	Response to amphetamines;
LUSC	cis	rs240764	0.658	rs4840155	chr6:101253942	G/T	cg09795085	chr6:101329169	ASCC3	-0.46	-6.56	-0.34	2.01e-10	Neuroticism;
LUSC	cis	rs1062746	0.558	rs889608	chr16:87337543	A/G	cg02258303	chr16:87377426	FBXO31	-0.54	-8.65	-0.43	2.19e-16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	12.66	0.57	2.76e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2348418	0.831	rs1581074	chr12:28723964	C/T	cg13890972	chr12:28721907	NA	-0.36	-6.14	-0.32	2.32e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs4253772	0.872	rs45552534	chr22:46638171	G/A	cg24881330	chr22:46731750	TRMU	0.63	5.85	0.31	1.15e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.83	0.44	5.94e-17	Diabetic kidney disease;
LUSC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg13206674	chr6:150067644	NUP43	0.52	7.94	0.4	3.01e-14	Lung cancer;
LUSC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg05973401	chr12:123451056	ABCB9	0.64	9.38	0.46	1.04e-18	Platelet count;
LUSC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.07	0.4	1.3e-14	Melanoma;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.4	6.35	0.33	6.96e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg09021430	chr5:549028	NA	-0.55	-7.18	-0.37	4.44e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-7.08	-0.36	8.55e-12	Menopause (age at onset);
LUSC	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg22676075	chr6:135203613	NA	0.47	7.38	0.37	1.3e-12	Red blood cell count;
LUSC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg26335602	chr6:28129616	ZNF389	0.42	5.7	0.3	2.63e-8	Depression;
LUSC	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg22532475	chr10:104410764	TRIM8	-0.37	-7.68	-0.39	1.8e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7572644	0.766	rs10168171	chr2:28232087	C/T	cg27432699	chr2:27873401	GPN1	0.53	6.63	0.34	1.35e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg27129171	chr3:47204927	SETD2	-0.57	-8.21	-0.41	4.78e-15	Birth weight;
LUSC	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg00785112	chr22:46450059	C22orf26;LOC150381	0.41	6.47	0.33	3.43e-10	Dupuytren's disease;Subjective well-being;
LUSC	cis	rs6700896	0.931	rs10889569	chr1:66086194	A/T	cg04111102	chr1:66153794	NA	0.32	7.07	0.36	8.85e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg22431228	chr1:16359049	CLCNKA	-0.37	-7.57	-0.38	3.62e-13	Dilated cardiomyopathy;
LUSC	cis	rs3850699	0.683	rs67646802	chr10:104303748	C/T	cg04362960	chr10:104952993	NT5C2	0.48	6.45	0.33	3.9e-10	Prostate cancer;
LUSC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg14773178	chr5:1868261	NA	0.31	5.72	0.3	2.38e-8	Cardiovascular disease risk factors;
LUSC	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg17691542	chr6:26056736	HIST1H1C	0.47	7.0	0.36	1.44e-11	Height;
LUSC	cis	rs10489525	0.583	rs6691374	chr1:115642818	T/C	cg01522456	chr1:115632236	TSPAN2	0.69	10.08	0.48	4.95e-21	Autism;
LUSC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.75	0.77	5.71e-66	Prudent dietary pattern;
LUSC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.4	0.56	2.61e-29	Prudent dietary pattern;
LUSC	cis	rs28647808	0.881	rs71483208	chr9:136258824	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.7	11.72	0.54	8.25e-27	Colorectal cancer;
LUSC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.25	-0.45	2.85e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg25767906	chr1:53392781	SCP2	-0.34	-5.7	-0.3	2.59e-8	Monocyte count;
LUSC	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg04450456	chr4:17643702	FAM184B	0.36	6.05	0.31	3.87e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg05802129	chr4:122689817	NA	-0.52	-8.77	-0.43	9.01e-17	Type 2 diabetes;
LUSC	cis	rs11166629	1.000	rs6992668	chr8:135645129	T/C	cg21672855	chr8:135614777	ZFAT	0.36	5.78	0.3	1.7e-8	Smoking quantity;
LUSC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.3e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06221963	chr1:154839813	KCNN3	-0.62	-13.98	-0.61	2.77e-35	Prostate cancer;
LUSC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.43	-0.33	4.4e-10	Life satisfaction;
LUSC	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg05738196	chr6:26577821	NA	0.81	15.71	0.65	4.98e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg26102564	chr10:131424627	MGMT	0.41	6.4	0.33	5.35e-10	Response to temozolomide;
LUSC	cis	rs870825	0.929	rs72689272	chr4:185592515	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	11.77	0.54	5.29e-27	Blood protein levels;
LUSC	cis	rs752010	0.806	rs6696511	chr1:42110888	T/C	cg06885757	chr1:42089581	HIVEP3	0.57	11.64	0.54	1.69e-26	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.21	-0.32	1.58e-9	Bipolar disorder;
LUSC	cis	rs4253772	0.872	rs41362646	chr22:46633505	G/A	cg18190219	chr22:46762943	CELSR1	-0.51	-5.93	-0.31	7.62e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4285028	0.898	rs4305455	chr3:121619774	T/C	cg11130432	chr3:121712080	ILDR1	-0.62	-9.63	-0.47	1.55e-19	Multiple sclerosis;
LUSC	cis	rs4845570	1.000	rs11585294	chr1:151769887	A/C	cg07092448	chr1:151763213	TDRKH	-1.28	-14.36	-0.62	9.27e-37	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg17366294	chr4:99064904	C4orf37	0.56	9.77	0.47	5.22e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7789940	0.904	rs56919252	chr7:75937520	T/C	cg15798862	chr7:76129360	DTX2	-0.46	-7.46	-0.38	7.36e-13	Multiple sclerosis;
LUSC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.14	-0.32	2.39e-9	Initial pursuit acceleration;
LUSC	cis	rs10992471	0.528	rs7037194	chr9:95216745	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.27	-0.32	1.14e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs10221833	0.602	rs355887	chr2:165634262	T/C	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.44e-9	Response to statin therapy;
LUSC	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg24558204	chr6:135376177	HBS1L	0.59	9.26	0.45	2.63e-18	Reticulocyte count;High light scatter reticulocyte count;
LUSC	cis	rs76878669	0.561	rs11823140	chr11:66098322	G/T	cg24851651	chr11:66362959	CCS	0.4	6.25	0.32	1.25e-9	Educational attainment (years of education);
LUSC	cis	rs911119	0.955	rs7270413	chr20:23593821	C/G	cg16589663	chr20:23618590	CST3	0.58	6.79	0.35	4.99e-11	Chronic kidney disease;
LUSC	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg08917208	chr2:24149416	ATAD2B	0.98	9.92	0.48	1.76e-20	Lymphocyte counts;
LUSC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.07	15.92	0.66	7.59e-43	Gut microbiome composition (summer);
LUSC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg09323728	chr8:95962352	TP53INP1	0.35	7.3	0.37	2.08e-12	Type 2 diabetes;
LUSC	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.15	-0.36	5.59e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11637445	0.627	rs72751453	chr15:68124665	C/A	cg08079166	chr15:68083412	MAP2K5	-0.37	-7.47	-0.38	6.95e-13	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	7.19	0.37	4.23e-12	Tonsillectomy;
LUSC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg05347473	chr6:146136440	FBXO30	0.56	9.54	0.46	3.19e-19	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2392780	0.536	rs606345	chr8:128334499	T/A	cg10195415	chr17:73887371	TRIM65	0.41	6.57	0.34	1.93e-10	Breast cancer (early onset);
LUSC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.3	-0.45	1.91e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.41	-5.96	-0.31	6.45e-9	Platelet distribution width;
LUSC	cis	rs77633900	0.614	rs280028	chr15:77031466	A/G	cg21673338	chr15:77095150	SCAPER	-0.82	-8.07	-0.4	1.26e-14	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.47	6.6	0.34	1.63e-10	Lung cancer;
LUSC	cis	rs1729407	0.659	rs2542050	chr11:116697117	C/A	cg08985259	chr11:116699649	APOC3	-0.25	-5.71	-0.3	2.48e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.0	0.66	3.55e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.85	0.51	1.06e-23	Monocyte percentage of white cells;
LUSC	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg15704280	chr7:45808275	SEPT13	0.73	8.39	0.42	1.38e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23158103	chr7:148848205	ZNF398	-0.48	-8.05	-0.4	1.5e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.36	-0.37	1.45e-12	Height;
LUSC	cis	rs6728642	0.572	rs13387563	chr2:97600916	C/A	cg26665480	chr2:98280029	ACTR1B	-0.76	-7.61	-0.38	2.78e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs554111	0.656	rs12021529	chr1:21306161	C/T	cg01072550	chr1:21505969	NA	-0.41	-6.49	-0.33	3.17e-10	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg27427491	chr17:78079615	GAA	-0.35	-6.78	-0.35	5.37e-11	Yeast infection;
LUSC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-8.77	-0.43	9.44e-17	Personality dimensions;
LUSC	trans	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-12.04	-0.55	5.8e-28	Colorectal cancer;
LUSC	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	9.14	0.45	6.15e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg26335602	chr6:28129616	ZNF389	0.42	5.7	0.3	2.65e-8	Depression;
LUSC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg11752832	chr7:134001865	SLC35B4	0.55	8.66	0.43	2.09e-16	Mean platelet volume;
LUSC	trans	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg27350398	chr10:3214550	PITRM1	-0.65	-6.01	-0.31	4.86e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4974559	0.739	rs4333131	chr4:1323789	A/G	cg02980000	chr4:1222292	CTBP1	0.85	9.71	0.47	8.27e-20	Systolic blood pressure;
LUSC	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg26395211	chr5:140044315	WDR55	-0.37	-5.72	-0.3	2.43e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg09654669	chr8:57350985	NA	-0.51	-6.76	-0.35	6.09e-11	Obesity-related traits;
LUSC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg17330251	chr7:94953956	PON1	-0.37	-5.96	-0.31	6.32e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg01629716	chr15:45996671	NA	0.39	5.96	0.31	6.31e-9	Waist circumference;Weight;
LUSC	trans	rs1941687	0.797	rs9963397	chr18:31395015	A/T	cg27147174	chr7:100797783	AP1S1	-0.44	-6.46	-0.33	3.71e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs7633857	0.512	rs733948	chr3:160652784	C/G	cg03342759	chr3:160939853	NMD3	-0.41	-6.3	-0.33	9.23e-10	Educational attainment (years of education);
LUSC	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg04896959	chr15:78267971	NA	-0.48	-10.07	-0.48	5.18e-21	Coronary artery disease or large artery stroke;
LUSC	cis	rs357618	1.000	rs357620	chr5:150847121	A/T	cg03212797	chr5:150827313	SLC36A1	-0.4	-5.92	-0.31	7.85e-9	Basophil percentage of white cells;
LUSC	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg18825076	chr15:78729989	IREB2	-0.5	-7.79	-0.39	8.76e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs3862435	0.572	rs2601167	chr15:90912567	G/A	cg22089800	chr15:90895588	ZNF774	0.55	5.85	0.31	1.14e-8	Response to exercise (triglyceride level interaction);
LUSC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.79	-14.6	-0.62	1.15e-37	Dental caries;
LUSC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg16405210	chr4:1374714	KIAA1530	-0.53	-8.02	-0.4	1.84e-14	Obesity-related traits;
LUSC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.38	0.67	1.11e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg22681709	chr2:178499509	PDE11A	0.37	5.72	0.3	2.4e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg08807101	chr21:30365312	RNF160	-0.52	-6.54	-0.34	2.3e-10	Cognitive test performance;
LUSC	cis	rs7903847	0.619	rs10786336	chr10:99134953	A/C	cg20016023	chr10:99160130	RRP12	-0.34	-8.41	-0.42	1.2e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11758351	0.660	rs6918339	chr6:26211780	G/C	cg01420254	chr6:26195488	NA	0.47	5.93	0.31	7.59e-9	Gout;Renal underexcretion gout;
LUSC	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg18964960	chr10:1102726	WDR37	0.71	6.49	0.33	3.04e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.13	15.37	0.64	1.05e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg17652424	chr22:38574118	PLA2G6	0.28	5.88	0.31	1.02e-8	Cutaneous nevi;
LUSC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	cis	rs11676855	1.000	rs6710499	chr2:235898590	A/G	cg14917874	chr2:235941519	SH3BP4	0.5	8.16	0.41	7.05e-15	Dialysis-related mortality;
LUSC	trans	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg03886242	chr7:26192032	NFE2L3	0.37	6.26	0.32	1.18e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13997140	chr7:86849809	C7orf23	-0.45	-6.85	-0.35	3.49e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	13.5	0.59	1.97e-33	Platelet count;
LUSC	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg26384229	chr12:38710491	ALG10B	0.52	7.36	0.37	1.42e-12	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg21782813	chr7:2030301	MAD1L1	0.59	10.38	0.49	4.56e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.77	-0.43	9.15e-17	Monocyte percentage of white cells;
LUSC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg16743903	chr16:89593216	SPG7	0.43	6.03	0.31	4.34e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg07936489	chr17:37558343	FBXL20	-0.71	-9.75	-0.47	6.18e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg03585969	chr10:35415529	CREM	0.64	9.13	0.45	6.65e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.47	-7.34	-0.37	1.59e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9549260	0.564	rs7998086	chr13:41268924	T/C	cg21288729	chr13:41239152	FOXO1	0.53	7.97	0.4	2.6e-14	Red blood cell count;
LUSC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg20203395	chr5:56204925	C5orf35	0.47	7.17	0.37	4.98e-12	Coronary artery disease;
LUSC	cis	rs834603	0.575	rs834597	chr7:47464488	A/T	cg09696706	chr7:47479511	TNS3	0.32	5.73	0.3	2.24e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	trans	rs2679649	1.000	rs2684271	chr6:122352137	G/A	cg00167820	chr8:131663355	NA	0.54	6.35	0.33	6.96e-10	Subcutaneous adipose tissue;
LUSC	cis	rs7180079	1.000	rs1117087	chr15:64598823	T/G	cg08069370	chr15:64387884	SNX1	0.54	5.71	0.3	2.44e-8	Monocyte count;
LUSC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg18402987	chr7:1209562	NA	0.55	6.07	0.32	3.45e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg15790184	chr11:494944	RNH1	0.59	6.42	0.33	4.77e-10	Body mass index;
LUSC	cis	rs858239	0.600	rs10235786	chr7:23139940	T/C	cg05407003	chr7:23246146	NA	-0.39	-5.73	-0.3	2.3e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg17211192	chr8:82754475	SNX16	-0.76	-10.04	-0.48	6.74e-21	Diastolic blood pressure;
LUSC	cis	rs4663866	1.000	rs4663865	chr2:239145960	C/T	cg16914508	chr2:239161102	PER2	-0.63	-6.96	-0.36	1.8e-11	Irritable bowel syndrome;
LUSC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg25767906	chr1:53392781	SCP2	0.48	8.58	0.42	3.71e-16	Monocyte count;
LUSC	cis	rs16949788	1.000	rs74894249	chr15:66818647	G/T	cg08120210	chr15:66682733	MAP2K1	-0.57	-5.92	-0.31	7.82e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2742417	0.603	rs2064063	chr3:45759924	T/A	cg10512202	chr3:45649293	LIMD1	0.36	6.04	0.31	4.18e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24503407	chr1:205819492	PM20D1	-0.79	-15.53	-0.65	2.45e-41	Monocyte percentage of white cells;
LUSC	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.73	-12.97	-0.58	1.9e-31	Lung cancer;
LUSC	cis	rs3755132	0.929	rs3815689	chr2:15742310	G/T	cg12888861	chr2:15731646	DDX1	-0.51	-7.47	-0.38	7.04e-13	Wilms tumor;
LUSC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.9	-0.44	3.74e-17	Longevity;
LUSC	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg19920283	chr7:105172520	RINT1	0.58	6.21	0.32	1.61e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg20608306	chr11:116969690	SIK3	0.37	6.09	0.32	3.1e-9	Blood protein levels;
LUSC	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg21772509	chr8:41503840	NKX6-3	0.67	11.26	0.52	3.89e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs2742417	1.000	rs2742437	chr3:45743277	G/A	cg09608765	chr3:45636137	LIMD1	-0.38	-7.48	-0.38	6.61e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg17830980	chr10:43048298	ZNF37B	-0.39	-6.23	-0.32	1.4e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6500395	1.000	rs8059905	chr16:48629934	C/T	cg04672837	chr16:48644449	N4BP1	0.53	7.95	0.4	2.87e-14	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs10511400	0.850	rs902790	chr3:119886776	A/T	cg02809009	chr19:50354510	PTOV1	-0.68	-6.58	-0.34	1.84e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	8.46	0.42	8.29e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	1.09	24.11	0.8	4.1e-75	Schizophrenia;
LUSC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.27	-0.41	3.16e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg22676075	chr6:135203613	NA	0.49	7.63	0.39	2.49e-13	Red blood cell count;
LUSC	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg01620082	chr3:125678407	NA	-0.78	-7.2	-0.37	4.02e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg24675056	chr1:15929824	NA	0.47	8.06	0.4	1.41e-14	Systolic blood pressure;
LUSC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg25039879	chr17:56429692	SUPT4H1	0.68	8.86	0.44	5e-17	Cognitive test performance;
LUSC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.68	12.3	0.56	6.15e-29	Prudent dietary pattern;
LUSC	cis	rs11030122	0.702	rs10767715	chr11:3951409	G/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.82	-0.3	1.34e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg08508325	chr11:3079039	CARS	-0.47	-11.14	-0.52	1.03e-24	Longevity;
LUSC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.72	-8.41	-0.42	1.19e-15	Refractive error;
LUSC	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg08917208	chr2:24149416	ATAD2B	0.53	5.97	0.31	6e-9	Lymphocyte counts;
LUSC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg06784218	chr1:46089804	CCDC17	-0.47	-9.14	-0.45	6.34e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg01919652	chr6:150259930	NA	0.39	6.45	0.33	3.99e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	8.99	0.44	1.91e-17	Menarche (age at onset);
LUSC	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	8.73	0.43	1.27e-16	Retinal vascular caliber;
LUSC	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg02569458	chr12:86230093	RASSF9	0.4	6.53	0.34	2.48e-10	Major depressive disorder;
LUSC	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.38	-0.37	1.23e-12	Psoriasis;
LUSC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg21951975	chr1:209979733	IRF6	0.4	6.67	0.34	1.08e-10	Monobrow;
LUSC	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg19628046	chr18:33552617	C18orf21	0.52	6.26	0.32	1.15e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06108461	chr20:60628389	TAF4	-0.96	-16.07	-0.66	1.98e-43	Body mass index;
LUSC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06544989	chr22:39130855	UNC84B	-0.35	-6.34	-0.33	7.24e-10	Menopause (age at onset);
LUSC	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.83	-0.74	2.23e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg20848291	chr7:100343083	ZAN	0.38	5.88	0.31	1.02e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg21724239	chr8:58056113	NA	0.78	9.78	0.47	5.05e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg02038168	chr22:39784481	NA	-0.5	-8.16	-0.41	6.77e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg11812906	chr14:75593930	NEK9	0.66	11.4	0.53	1.24e-25	Height;
LUSC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg20203395	chr5:56204925	C5orf35	0.49	7.32	0.37	1.88e-12	Coronary artery disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05920998	chr6:656504	HUS1B;EXOC2	-0.76	-6.09	-0.32	3.02e-9	Cognitive performance;
LUSC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-16.92	-0.68	7.95e-47	Gut microbiome composition (summer);
LUSC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg05802129	chr4:122689817	NA	-0.37	-6.56	-0.34	2.03e-10	Type 2 diabetes;
LUSC	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg12559939	chr2:27858050	GPN1	0.41	6.33	0.33	8.01e-10	Oral cavity cancer;
LUSC	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg06547715	chr2:218990976	CXCR2	0.34	6.44	0.33	4.21e-10	Ulcerative colitis;
LUSC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21963583	chr11:68658836	MRPL21	0.55	8.44	0.42	9.5e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs74338693	0.778	rs3749030	chr2:166774101	T/C	cg07963046	chr1:155764892	GON4L	0.47	6.01	0.31	4.97e-9	Schizophrenia;
LUSC	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg15704280	chr7:45808275	SEPT13	0.82	7.82	0.39	6.96e-14	Axial length;
LUSC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.47	-0.33	3.58e-10	Life satisfaction;
LUSC	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg19920283	chr7:105172520	RINT1	0.58	6.21	0.32	1.61e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1784581	0.674	rs1789989	chr6:162408138	C/T	cg17173639	chr6:162384350	PARK2	0.61	11.22	0.52	5.43e-25	Itch intensity from mosquito bite;
LUSC	trans	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg06636001	chr8:8085503	FLJ10661	0.45	6.48	0.33	3.22e-10	Retinal vascular caliber;
LUSC	cis	rs96067	0.805	rs2296268	chr1:36603165	G/A	cg24686825	chr1:36642396	MAP7D1	-0.43	-6.03	-0.31	4.28e-9	Corneal structure;
LUSC	cis	rs9534288	0.742	rs1022953	chr13:46649126	G/T	cg15192986	chr13:46630673	CPB2	-0.78	-11.49	-0.53	5.76e-26	Blood protein levels;
LUSC	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg09163369	chr1:210001066	C1orf107	-0.54	-6.13	-0.32	2.49e-9	Orofacial clefts;
LUSC	cis	rs7000551	0.556	rs35359294	chr8:22249755	G/A	cg12081754	chr8:22256438	SLC39A14	0.99	16.07	0.66	1.97e-43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.9	20.74	0.75	5.32e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs7119038	0.774	rs11217037	chr11:118677086	G/A	cg19308663	chr11:118741387	NA	0.36	6.34	0.33	7.29e-10	Sjögren's syndrome;
LUSC	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg20019720	chr6:154832845	CNKSR3	0.6	8.6	0.43	3.17e-16	Lipoprotein (a) levels;
LUSC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg03806693	chr22:41940476	POLR3H	0.99	14.12	0.61	8.14e-36	Vitiligo;
LUSC	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07080220	chr10:102295463	HIF1AN	0.65	8.72	0.43	1.3e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	9.91e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.28	-0.33	1.04e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	0.72	14.33	0.62	1.24e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs7570971	0.517	rs10187402	chr2:135771974	C/G	cg07169764	chr2:136633963	MCM6	0.53	7.0	0.36	1.41e-11	Blood metabolite levels;Body mass index;Cholesterol, total;
LUSC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg12311346	chr5:56204834	C5orf35	-0.68	-10.63	-0.5	6.4e-23	Coronary artery disease;
LUSC	cis	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg21775007	chr8:11205619	TDH	-0.7	-11.09	-0.52	1.46e-24	Retinal vascular caliber;
LUSC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12609467	chr3:49508289	DAG1	-0.47	-7.23	-0.37	3.25e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1595825	0.838	rs58576043	chr2:198524149	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.63	-0.34	1.34e-10	Ulcerative colitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07106325	chr12:120740337	SIRT4	0.42	6.34	0.33	7.39e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg14552801	chr7:65878734	NA	0.45	6.37	0.33	6.28e-10	Aortic root size;
LUSC	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg04871131	chr7:94954202	PON1	-0.35	-5.65	-0.3	3.52e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg26102564	chr10:131424627	MGMT	-0.38	-5.8	-0.3	1.55e-8	Response to temozolomide;
LUSC	cis	rs1461503	0.932	rs10790542	chr11:122838243	C/T	cg27398637	chr11:122830231	C11orf63	-0.42	-6.71	-0.34	8.41e-11	Menarche (age at onset);
LUSC	cis	rs6733011	0.500	rs11123754	chr2:99433782	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-6.82	-0.35	4.26e-11	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9650657	0.737	rs4841436	chr8:10594474	A/C	cg27411982	chr8:10470053	RP1L1	0.39	6.23	0.32	1.39e-9	Neuroticism;
LUSC	trans	rs11700980	0.551	rs62222158	chr21:30110372	A/G	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.31e-9	QRS complex (12-leadsum);
LUSC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg23711669	chr6:146136114	FBXO30	0.88	16.81	0.68	2.24e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	23.7	0.79	1.61e-73	Colorectal cancer;
LUSC	trans	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg13565492	chr6:43139072	SRF	-0.63	-6.57	-0.34	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg19539972	chr4:7069911	GRPEL1	0.72	8.66	0.43	2.07e-16	Monocyte percentage of white cells;
LUSC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg21573476	chr21:45109991	RRP1B	-0.36	-5.74	-0.3	2.11e-8	Mean corpuscular volume;
LUSC	cis	rs67072384	0.818	rs2291292	chr11:72467013	C/T	cg04827223	chr11:72435913	ARAP1	-0.73	-6.35	-0.33	7.13e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs7236492	0.748	rs7228738	chr18:77231307	C/T	cg15644404	chr18:77186268	NFATC1	-0.57	-5.89	-0.31	9.52e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20135002	chr11:47629003	NA	0.48	7.71	0.39	1.42e-13	Subjective well-being;
LUSC	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg09307838	chr4:120376055	NA	0.76	11.04	0.52	2.31e-24	Corneal astigmatism;
LUSC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06238570	chr21:40685208	BRWD1	-0.44	-6.79	-0.35	5.07e-11	Cognitive function;
LUSC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.87	0.68	1.25e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	1.06	13.03	0.58	1.14e-31	Mitochondrial DNA levels;
LUSC	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg12927641	chr6:109611667	NA	-0.35	-5.99	-0.31	5.47e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg20887711	chr4:1340912	KIAA1530	-0.65	-9.98	-0.48	1.02e-20	Obesity-related traits;
LUSC	cis	rs73200209	0.744	rs61936954	chr12:116473408	T/A	cg01776926	chr12:116560359	MED13L	-0.5	-5.88	-0.31	1.01e-8	Total body bone mineral density;
LUSC	cis	rs4771122	0.596	rs7334690	chr13:28081535	C/T	cg22138327	chr13:27999177	GTF3A	0.47	6.98	0.36	1.58e-11	Body mass index;
LUSC	cis	rs9303280	0.806	rs36095411	chr17:38031865	T/G	cg20243544	chr17:37824526	PNMT	0.41	5.99	0.31	5.46e-9	Self-reported allergy;
LUSC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg13699009	chr12:122356056	WDR66	-0.48	-7.43	-0.38	9.29e-13	Mean corpuscular volume;
LUSC	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg18678763	chr11:4115507	RRM1	-0.46	-6.0	-0.31	5.13e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg08470875	chr2:26401718	FAM59B	0.61	8.54	0.42	4.66e-16	Gut microbiome composition (summer);
LUSC	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg20487152	chr13:99095054	FARP1	-0.42	-7.13	-0.36	6.29e-12	Longevity;
LUSC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg12639453	chr1:2035780	PRKCZ	-0.31	-6.63	-0.34	1.33e-10	Height;
LUSC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg08859206	chr1:53392774	SCP2	-0.51	-8.78	-0.43	8.93e-17	Monocyte count;
LUSC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg05110241	chr16:68378359	PRMT7	-0.51	-6.12	-0.32	2.69e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg10596483	chr8:143751796	JRK	0.61	9.41	0.46	8.19e-19	Schizophrenia;
LUSC	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg19743168	chr1:23544995	NA	0.48	10.44	0.5	2.84e-22	Height;
LUSC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18876405	chr7:65276391	NA	-0.54	-8.5	-0.42	6.21e-16	Aortic root size;
LUSC	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg03676636	chr4:99064102	C4orf37	0.35	7.67	0.39	1.9e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03352830	chr11:487213	PTDSS2	0.68	8.61	0.43	2.91e-16	Body mass index;
LUSC	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg08917208	chr2:24149416	ATAD2B	0.56	6.43	0.33	4.43e-10	Lymphocyte counts;
LUSC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg20119798	chr7:94954144	PON1	-0.36	-7.09	-0.36	7.93e-12	Paraoxonase activity;
LUSC	cis	rs3857536	0.813	rs62415859	chr6:66934278	G/A	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.57	7.61	0.38	2.76e-13	High light scatter reticulocyte count;
LUSC	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg07856975	chr6:36356162	ETV7	0.34	6.21	0.32	1.61e-9	Platelet distribution width;
LUSC	cis	rs240764	0.604	rs9373590	chr6:101212001	A/T	cg09795085	chr6:101329169	ASCC3	0.43	6.1	0.32	2.9e-9	Neuroticism;
LUSC	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	12.46	0.56	1.61e-29	Height;
LUSC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.45	-0.46	6.09e-19	Electroencephalogram traits;
LUSC	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg22089800	chr15:90895588	ZNF774	0.61	9.12	0.45	6.97e-18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	6.0	0.31	5.21e-9	Axial length;
LUSC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.85	0.54	2.71e-27	Prudent dietary pattern;
LUSC	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	8.44	0.42	9.69e-16	Response to antipsychotic treatment;
LUSC	cis	rs9311676	0.632	rs6774577	chr3:58361716	A/G	cg13750441	chr3:58318267	PXK	0.35	6.75	0.35	6.39e-11	Systemic lupus erythematosus;
LUSC	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg19812747	chr11:111475976	SIK2	-0.5	-7.04	-0.36	1.1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2932538	0.922	rs4838961	chr1:113163967	T/C	cg22162597	chr1:113214053	CAPZA1	-0.69	-9.87	-0.48	2.41e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg12463550	chr7:65579703	CRCP	0.46	6.61	0.34	1.5e-10	Aortic root size;
LUSC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg04850211	chr1:228464232	OBSCN	0.32	5.69	0.3	2.81e-8	Diastolic blood pressure;
LUSC	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg05855489	chr10:104503620	C10orf26	0.53	7.96	0.4	2.77e-14	Arsenic metabolism;
LUSC	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg07157834	chr1:205819609	PM20D1	-0.43	-5.69	-0.3	2.78e-8	Menarche (age at onset);
LUSC	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg15848620	chr12:58087721	OS9	-0.4	-5.8	-0.3	1.57e-8	Multiple sclerosis;
LUSC	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.42	6.56	0.34	2.04e-10	Dupuytren's disease;
LUSC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg07936489	chr17:37558343	FBXL20	-0.71	-10.16	-0.49	2.55e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.3	-0.33	9.56e-10	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26364903	chr2:67624840	ETAA1	0.45	6.43	0.33	4.4e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg03585969	chr10:35415529	CREM	0.64	9.17	0.45	4.82e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg23711669	chr6:146136114	FBXO30	-0.82	-14.71	-0.63	3.97e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6669072	1.000	rs3845561	chr1:91246342	A/G	cg08895590	chr1:91227319	NA	0.36	8.17	0.41	6.37e-15	Cognitive function;
LUSC	cis	rs75920871	0.588	rs4938321	chr11:116852507	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-6.57	-0.34	1.9e-10	Subjective well-being;
LUSC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.02	-0.4	1.78e-14	Longevity;
LUSC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03517284	chr6:25882590	NA	0.39	6.55	0.34	2.13e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7553864	0.605	rs7531038	chr1:87605049	C/G	cg17420885	chr1:87600446	LOC339524	-0.47	-6.53	-0.34	2.38e-10	Smoking behavior;
LUSC	cis	rs9311676	0.656	rs11718352	chr3:58401480	G/A	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.11e-10	Systemic lupus erythematosus;
LUSC	cis	rs4930561	0.739	rs12225316	chr11:67976003	T/C	cg16338278	chr11:67432957	ALDH3B2	0.4	6.75	0.35	6.73e-11	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg19920283	chr7:105172520	RINT1	0.61	6.78	0.35	5.38e-11	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg01238044	chr22:24384105	GSTT1	-0.51	-7.46	-0.38	7.42e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg08684580	chr7:98029266	BAIAP2L1	0.39	5.81	0.3	1.42e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17401966	1.000	rs12757820	chr1:10266671	A/T	cg19773385	chr1:10388646	KIF1B	-0.51	-8.01	-0.4	1.87e-14	Hepatocellular carcinoma;
LUSC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg17143192	chr8:8559678	CLDN23	0.61	8.65	0.43	2.18e-16	Obesity-related traits;
LUSC	cis	rs12681287	0.640	rs12550142	chr8:87471861	C/A	cg27223183	chr8:87520930	FAM82B	-0.54	-7.45	-0.38	7.92e-13	Caudate activity during reward;
LUSC	cis	rs9815354	0.597	rs17283481	chr3:41924015	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.7	0.43	1.48e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-9.84	-0.47	3.09e-20	Gut microbiome composition (summer);
LUSC	cis	rs28830936	0.967	rs9672671	chr15:41917075	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.31	-0.33	8.79e-10	Diastolic blood pressure;
LUSC	cis	rs2708977	0.667	rs772156	chr2:97029830	G/A	cg01950434	chr2:97203154	ARID5A	-0.46	-6.17	-0.32	2.01e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs7267979	0.565	rs13040726	chr20:25559881	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-12.63	-0.57	3.54e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.59	-9.49	-0.46	4.67e-19	Body mass index;
LUSC	cis	rs11166629	1.000	rs4909330	chr8:135644369	T/C	cg21672855	chr8:135614777	ZFAT	0.36	5.84	0.3	1.26e-8	Smoking quantity;
LUSC	cis	rs2274273	0.624	rs8014540	chr14:55841688	C/A	cg04306507	chr14:55594613	LGALS3	0.48	9.57	0.46	2.41e-19	Protein biomarker;
LUSC	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg05163923	chr11:71159392	DHCR7	0.74	11.04	0.52	2.38e-24	Vitamin D levels;
LUSC	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg25457927	chr22:38595422	NA	-0.42	-8.93	-0.44	2.9e-17	Cutaneous nevi;
LUSC	cis	rs7147624	1.000	rs10135969	chr14:65982345	C/T	cg03016385	chr14:66212404	NA	-0.85	-9.52	-0.46	3.58e-19	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.54	6.8	0.35	4.85e-11	Renal function-related traits (BUN);
LUSC	cis	rs6546550	0.935	rs10202159	chr2:70062454	G/T	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.17	-0.37	4.97e-12	Prevalent atrial fibrillation;
LUSC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06061049	chr2:17934875	GEN1;SMC6	0.46	6.31	0.33	9.1e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg11102782	chr19:18549136	ISYNA1	-0.33	-6.19	-0.32	1.74e-9	Breast cancer;
LUSC	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg23795048	chr12:9217529	LOC144571	0.33	5.77	0.3	1.8e-8	Sjögren's syndrome;
LUSC	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	0.56	8.97	0.44	2.15e-17	Breast cancer;
LUSC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg11663144	chr21:46675770	NA	-0.43	-7.57	-0.38	3.74e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9503598	0.636	rs6596975	chr6:3465925	G/A	cg00476032	chr6:3446245	SLC22A23	0.3	5.99	0.31	5.5e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg00800038	chr16:89945340	TCF25	-0.75	-6.56	-0.34	2.08e-10	Skin colour saturation;
LUSC	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg17691542	chr6:26056736	HIST1H1C	0.47	7.04	0.36	1.12e-11	Height;
LUSC	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg09092052	chr15:45571596	NA	0.46	6.41	0.33	5.09e-10	Glomerular filtration rate;
LUSC	cis	rs113835537	0.559	rs57045447	chr11:66339683	A/G	cg24851651	chr11:66362959	CCS	0.58	9.05	0.44	1.21e-17	Airway imaging phenotypes;
LUSC	trans	rs1325195	0.537	rs4651014	chr1:179073039	C/G	cg11624085	chr17:8464688	MYH10	-0.44	-6.59	-0.34	1.71e-10	IgE grass sensitization;
LUSC	cis	rs6977660	0.714	rs10257947	chr7:19824099	A/C	cg05791153	chr7:19748676	TWISTNB	0.68	7.07	0.36	9.39e-12	Thyroid stimulating hormone;
LUSC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.48e-28	Motion sickness;
LUSC	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg03859395	chr2:55845619	SMEK2	0.84	15.01	0.63	2.9e-39	Metabolic syndrome;
LUSC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.87	0.31	1.07e-8	Menopause (age at onset);
LUSC	trans	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg16724585	chr3:197361211	NA	-0.6	-8.28	-0.41	3.01e-15	Pancreatic cancer;
LUSC	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.39	0.46	9.37e-19	Bipolar disorder;
LUSC	cis	rs6740322	0.748	rs13432574	chr2:43544328	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-7.32	-0.37	1.89e-12	Coronary artery disease;
LUSC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.67	11.49	0.53	5.69e-26	Aortic root size;
LUSC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	13.59	0.6	8.79e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg15704280	chr7:45808275	SEPT13	0.76	8.47	0.42	8.13e-16	Axial length;
LUSC	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.39e-8	Aortic root size;
LUSC	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg20891283	chr12:69753455	YEATS4	0.45	5.95	0.31	6.83e-9	Response to diuretic therapy;
LUSC	cis	rs1113500	0.933	rs4590700	chr1:108638344	G/T	cg06207961	chr1:108661230	NA	0.41	7.55	0.38	4.29e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs8179	0.553	rs42235	chr7:92248076	C/T	cg15732164	chr7:92237376	CDK6	-0.39	-5.93	-0.31	7.62e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.52	-0.34	2.59e-10	Neuroticism;
LUSC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg26513180	chr16:89883248	FANCA	0.6	5.69	0.3	2.72e-8	Skin colour saturation;
LUSC	cis	rs7572644	0.766	rs4233720	chr2:28079775	A/G	cg27432699	chr2:27873401	GPN1	0.51	6.47	0.33	3.46e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg21433313	chr16:3507492	NAT15	0.79	9.94	0.48	1.41e-20	Tuberculosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21501234	chr15:64683155	TRIP4	-0.52	-6.47	-0.33	3.48e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg27426351	chr10:43362370	NA	0.42	5.82	0.3	1.4e-8	Blood protein levels;
LUSC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg26338869	chr17:61819248	STRADA	0.41	6.03	0.31	4.42e-9	Prudent dietary pattern;
LUSC	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.39e-13	Type 2 diabetes;
LUSC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04565464	chr8:145669602	NFKBIL2	0.41	6.89	0.35	2.86e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.91	-0.68	9.28e-47	Monocyte count;
LUSC	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg01884057	chr2:25150051	NA	0.44	10.05	0.48	6.33e-21	Body mass index in non-asthmatics;
LUSC	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg12863693	chr15:85201151	NMB	0.39	8.1	0.41	1.07e-14	Schizophrenia;
LUSC	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg15605315	chr1:45957053	TESK2	0.46	7.31	0.37	2.04e-12	High light scatter reticulocyte count;
LUSC	cis	rs9469578	0.792	rs73743329	chr6:33713943	T/A	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.93	17.54	0.69	2.7e-49	Diastolic blood pressure;Systolic blood pressure;
LUSC	trans	rs3936340	0.607	rs10416064	chr19:48522033	A/G	cg11947395	chr12:58088432	OS9	-0.51	-6.06	-0.31	3.75e-9	Intelligence;
LUSC	cis	rs8027181	1.000	rs12900863	chr15:73094671	C/T	cg25632853	chr15:73088954	NA	0.34	6.64	0.34	1.24e-10	Triglyceride levels;
LUSC	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg21775007	chr8:11205619	TDH	0.46	6.6	0.34	1.66e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg02269571	chr22:50332266	NA	-0.59	-9.17	-0.45	5.12e-18	Schizophrenia;
LUSC	trans	rs7893279	0.822	rs4748465	chr10:18712393	G/A	cg01840055	chr3:141338555	NA	0.52	6.33	0.33	7.75e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs13720	0.915	rs163782	chr20:57565943	G/C	cg23907860	chr20:57583709	CTSZ	-0.43	-5.68	-0.3	2.87e-8	Platelet distribution width;
LUSC	cis	rs8040855	0.542	rs2342122	chr15:85728535	C/G	cg04831495	chr15:85060580	GOLGA6L5	0.4	6.54	0.34	2.33e-10	Bulimia nervosa;
LUSC	cis	rs1697139	0.583	rs11960733	chr5:66538715	C/T	cg11553311	chr5:66541588	NA	0.33	6.26	0.32	1.21e-9	Breast cancer;
LUSC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.08	20.92	0.75	1.06e-62	Cognitive ability;
LUSC	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg07274523	chr3:49395745	GPX1	-0.36	-5.7	-0.3	2.62e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12410462	0.581	rs75219436	chr1:227546617	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.66	-6.47	-0.33	3.44e-10	Major depressive disorder;
LUSC	cis	rs2084898	0.506	rs488672	chr11:120047745	A/G	cg07435449	chr11:120005650	TRIM29	-0.38	-6.74	-0.35	6.82e-11	Stroke (pediatric);
LUSC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg09359103	chr1:154839909	KCNN3	-0.7	-15.69	-0.65	6.19e-42	Prostate cancer;
LUSC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25072359	chr17:41440525	NA	0.6	8.64	0.43	2.42e-16	Menopause (age at onset);
LUSC	cis	rs2348418	0.831	rs7137119	chr12:28717991	G/T	cg13890972	chr12:28721907	NA	-0.34	-5.93	-0.31	7.37e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg00990874	chr7:1149470	C7orf50	-0.55	-6.77	-0.35	5.64e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg27094323	chr7:1216898	NA	-0.47	-8.22	-0.41	4.6e-15	Longevity;Endometriosis;
LUSC	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg19875535	chr5:140030758	IK	-0.54	-9.02	-0.44	1.46e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1358748	0.555	rs2093334	chr1:67536967	G/A	cg02640540	chr1:67518911	SLC35D1	0.62	6.52	0.34	2.6e-10	Tuberculosis;
LUSC	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg25838465	chr1:92012736	NA	0.48	6.92	0.35	2.37e-11	Eosinophil percentage of white cells;
LUSC	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg04989706	chr14:50066350	PPIL5	-0.48	-6.41	-0.33	4.82e-10	Carotid intima media thickness;
LUSC	trans	rs459571	0.920	rs417142	chr9:136891370	G/T	cg10765909	chr12:53715428	AAAS	-0.42	-6.06	-0.31	3.64e-9	Platelet distribution width;
LUSC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	1.04	20.11	0.74	1.65e-59	Menopause (age at onset);
LUSC	cis	rs1728785	0.681	rs4783649	chr16:68558467	G/A	cg02508848	chr16:68573721	ZFP90	0.45	5.73	0.3	2.3e-8	Ulcerative colitis;
LUSC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg06600287	chr1:53387719	ECHDC2	-0.3	-6.18	-0.32	1.91e-9	Monocyte count;
LUSC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg14416269	chr4:6271139	WFS1	0.53	11.29	0.53	2.9e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg08859206	chr1:53392774	SCP2	-0.68	-12.93	-0.58	2.87e-31	Monocyte count;
LUSC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg00800038	chr16:89945340	TCF25	-0.75	-6.56	-0.34	2.08e-10	Skin colour saturation;
LUSC	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.34	0.53	2.01e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg15423357	chr2:25149977	NA	0.45	8.98	0.44	1.98e-17	Body mass index;
LUSC	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg03672933	chr12:100661444	SCYL2;DEPDC4	0.37	5.95	0.31	6.62e-9	Schizophrenia (age at onset);
LUSC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.02	-0.36	1.25e-11	Bipolar disorder;
LUSC	cis	rs9807989	0.811	rs11688559	chr2:102969913	C/T	cg09003973	chr2:102972529	NA	0.44	6.04	0.31	4.15e-9	Asthma;
LUSC	cis	rs1775715	0.870	rs1775737	chr10:32256871	T/C	cg04359828	chr10:32216031	ARHGAP12	0.38	6.25	0.32	1.27e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs61931739	0.817	rs188588	chr12:34215277	G/A	cg06521331	chr12:34319734	NA	-0.38	-6.55	-0.34	2.15e-10	Morning vs. evening chronotype;
LUSC	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg17652424	chr22:38574118	PLA2G6	-0.31	-6.71	-0.34	8.58e-11	Cutaneous nevi;
LUSC	cis	rs240764	0.817	rs240113	chr6:101058886	G/A	cg09795085	chr6:101329169	ASCC3	0.42	6.14	0.32	2.29e-9	Neuroticism;
LUSC	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg12165864	chr7:66369176	NA	0.52	7.04	0.36	1.11e-11	Corneal structure;
LUSC	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg17623882	chr6:41773611	USP49	0.66	10.98	0.51	3.82e-24	Menarche (age at onset);
LUSC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10802521	chr3:52805072	NEK4	0.45	6.81	0.35	4.43e-11	Bipolar disorder;
LUSC	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs7089973	0.966	rs12772800	chr10:116630962	A/G	cg23260525	chr10:116636907	FAM160B1	0.39	7.47	0.38	7.18e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.89	15.52	0.65	2.78e-41	Morning vs. evening chronotype;
LUSC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg15145296	chr3:125709740	NA	-0.56	-6.31	-0.33	8.81e-10	Blood pressure (smoking interaction);
LUSC	cis	rs62400317	0.859	rs62400326	chr6:45287465	T/C	cg20913747	chr6:44695427	NA	-0.46	-7.44	-0.38	8.4e-13	Total body bone mineral density;
LUSC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg08088566	chr11:430123	ANO9	0.62	7.18	0.37	4.66e-12	Body mass index;
LUSC	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg22676075	chr6:135203613	NA	0.46	7.23	0.37	3.39e-12	Red blood cell count;
LUSC	cis	rs9811920	0.809	rs4928151	chr3:99767553	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.67	-0.34	1.08e-10	Axial length;
LUSC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg11645453	chr3:52864694	ITIH4	0.35	8.11	0.41	9.43e-15	Bipolar disorder;
LUSC	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg14530993	chr4:882597	GAK	0.72	7.4	0.38	1.1e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.66	-10.32	-0.49	7.69e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg11812906	chr14:75593930	NEK9	0.41	6.21	0.32	1.57e-9	Caffeine consumption;
LUSC	cis	rs11229555	0.609	rs7928676	chr11:58188022	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.59	-0.38	3.26e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs965469	0.545	rs6051846	chr20:3403824	A/G	cg25506879	chr20:3388711	C20orf194	0.46	6.03	0.31	4.43e-9	IFN-related cytopenia;
LUSC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg04414720	chr1:150670196	GOLPH3L	0.57	8.82	0.43	6.42e-17	Melanoma;
LUSC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-9.12	-0.45	7.13e-18	Bipolar disorder;
LUSC	cis	rs500891	0.570	rs35606488	chr6:83916502	C/T	cg08257003	chr6:84140564	ME1	0.32	6.82	0.35	4.21e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.84	15.08	0.64	1.48e-39	Menarche (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22416021	chr22:50177941	BRD1	0.41	6.31	0.33	8.94e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg12573674	chr2:1569213	NA	-0.55	-6.09	-0.32	3.04e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg05187965	chr10:45406764	TMEM72	-0.37	-8.71	-0.43	1.43e-16	Mean corpuscular volume;
LUSC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg17747265	chr1:1875780	NA	0.74	17.32	0.69	2.09e-48	Body mass index;
LUSC	trans	rs7939886	0.920	rs1552151	chr11:55780951	A/G	cg03929089	chr4:120376271	NA	-0.79	-6.81	-0.35	4.59e-11	Myopia (pathological);
LUSC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg06212747	chr3:49208901	KLHDC8B	0.48	6.08	0.32	3.33e-9	Parkinson's disease;
LUSC	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg24578937	chr1:2090814	PRKCZ	0.6	13.6	0.6	7.67e-34	Height;
LUSC	cis	rs12476592	0.602	rs6546019	chr2:63817440	A/G	cg10828910	chr2:63850056	LOC388955	0.5	5.81	0.3	1.49e-8	Childhood ear infection;
LUSC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	8.5	0.42	6.34e-16	Colorectal cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03069383	chr2:18741691	RDH14	-0.48	-6.18	-0.32	1.92e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21659725	chr3:3221576	CRBN	-0.59	-8.14	-0.41	7.87e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg04310649	chr10:35416472	CREM	-0.42	-6.45	-0.33	3.9e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg06191203	chr2:152266755	RIF1	0.54	7.28	0.37	2.35e-12	Lung cancer;
LUSC	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg15556689	chr8:8085844	FLJ10661	0.55	8.21	0.41	4.87e-15	Monocyte count;
LUSC	cis	rs11264799	0.603	rs2208753	chr1:157584301	A/C	cg18268488	chr1:157545234	FCRL4	0.34	6.32	0.33	8.61e-10	IgA nephropathy;
LUSC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg20887711	chr4:1340912	KIAA1530	0.44	6.61	0.34	1.51e-10	Obesity-related traits;
LUSC	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg06552810	chr11:31128660	NA	0.41	7.39	0.37	1.17e-12	Red blood cell count;
LUSC	cis	rs2063714	1.000	rs2063714	chr6:157195980	C/G	cg23222435	chr6:157204239	ARID1B	-0.49	-7.96	-0.4	2.69e-14	Sitting height ratio;
LUSC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.03	0.36	1.16e-11	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg26338869	chr17:61819248	STRADA	0.42	6.17	0.32	1.99e-9	Prudent dietary pattern;
LUSC	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.48	6.6	0.34	1.58e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg13798780	chr7:105162888	PUS7	0.56	6.07	0.32	3.43e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6076065	0.723	rs2424539	chr20:23384904	C/T	cg11657817	chr20:23433608	CST11	-0.43	-8.19	-0.41	5.63e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9398803	0.865	rs1578060	chr6:126712247	G/C	cg19875578	chr6:126661172	C6orf173	0.42	6.27	0.32	1.1e-9	Male-pattern baldness;
LUSC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg05064044	chr6:292385	DUSP22	-0.52	-7.68	-0.39	1.76e-13	Menopause (age at onset);
LUSC	cis	rs7586879	0.828	rs9631062	chr2:25110084	C/T	cg01884057	chr2:25150051	NA	0.42	8.78	0.43	8.83e-17	Body mass index;
LUSC	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg19875535	chr5:140030758	IK	-0.48	-7.88	-0.4	4.52e-14	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-1.01	-20.23	-0.74	5.68e-60	Dilated cardiomyopathy;
LUSC	cis	rs983392	0.805	rs11230183	chr11:59965725	C/T	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.2	-0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24838063	chr12:130822603	PIWIL1	0.69	10.73	0.51	2.84e-23	Menopause (age at onset);
LUSC	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.82	0.3	1.4e-8	Platelet count;
LUSC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg22907277	chr7:1156413	C7orf50	0.46	6.82	0.35	4.24e-11	Longevity;Endometriosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24009358	chr15:66797395	ZWILCH;RPL4	-0.42	-6.22	-0.32	1.52e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg25767906	chr1:53392781	SCP2	-0.5	-9.2	-0.45	4.11e-18	Monocyte count;
LUSC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg22907277	chr7:1156413	C7orf50	0.6	9.36	0.46	1.22e-18	Longevity;Endometriosis;
LUSC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg12560992	chr17:57184187	TRIM37	0.9	17.68	0.7	7.53e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs34638657	0.797	rs7203990	chr16:82185320	A/G	cg09439754	chr16:82129088	HSD17B2	-0.4	-6.41	-0.33	5.08e-10	Lung adenocarcinoma;
LUSC	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg23840854	chr1:161414152	NA	-0.92	-11.2	-0.52	6.13e-25	Rheumatoid arthritis;
LUSC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.38	-0.33	5.83e-10	Schizophrenia;
LUSC	trans	rs800082	0.734	rs1726538	chr3:144248888	A/G	cg24215973	chr2:240111563	HDAC4	0.41	6.03	0.31	4.37e-9	Smoking behavior;
LUSC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg11645453	chr3:52864694	ITIH4	0.32	7.5	0.38	5.87e-13	Electroencephalogram traits;
LUSC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg17420585	chr12:42539391	GXYLT1	-0.34	-6.49	-0.33	3.06e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6460942	0.915	rs6460907	chr7:12304449	G/A	cg06484146	chr7:12443880	VWDE	-0.52	-6.29	-0.33	9.98e-10	Coronary artery disease;
LUSC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg11871910	chr12:69753446	YEATS4	0.82	14.74	0.63	3.03e-38	Blood protein levels;
LUSC	trans	rs2275620	0.535	rs11188172	chr10:96831207	C/T	cg08498836	chr3:149292366	WWTR1	0.35	5.98	0.31	5.75e-9	Gout;
LUSC	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22980127	chr19:33182716	NUDT19	0.88	12.68	0.57	2.5e-30	Red blood cell traits;
LUSC	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	6.72	0.35	7.92e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.56	7.84	0.39	6.1e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	13.08	0.58	7.83e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg14664628	chr15:75095509	CSK	0.44	6.38	0.33	6.06e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03934478	chr11:495069	RNH1	0.77	9.35	0.46	1.27e-18	Body mass index;
LUSC	cis	rs909341	0.710	rs6011016	chr20:62302650	C/G	cg16989086	chr20:62203971	PRIC285	-0.54	-7.42	-0.38	9.94e-13	Atopic dermatitis;
LUSC	cis	rs806215	1.000	rs712704	chr7:127258208	A/G	cg25922125	chr7:127225783	GCC1	-0.6	-7.44	-0.38	8.65e-13	Type 2 diabetes;
LUSC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg14196790	chr5:131705035	SLC22A5	0.36	6.0	0.31	5.02e-9	Blood metabolite levels;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg09375034	chr10:5437414	TUBAL3	-0.34	-6.04	-0.31	4.17e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg24130564	chr14:104152367	KLC1	-0.47	-6.88	-0.35	2.99e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.31	-0.41	2.35e-15	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg25512537	chr17:76250053	NA	0.51	8.8	0.43	7.57e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg20573242	chr4:122745356	CCNA2	0.64	9.47	0.46	5.31e-19	Type 2 diabetes;
LUSC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.65	-0.39	2.2e-13	Type 2 diabetes;
LUSC	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg07211511	chr3:129823064	LOC729375	-1.22	-20.76	-0.75	4.52e-62	Blood pressure (smoking interaction);
LUSC	cis	rs654950	0.783	rs640688	chr1:42001831	A/G	cg06885757	chr1:42089581	HIVEP3	-0.34	-6.49	-0.33	3.15e-10	Airway imaging phenotypes;
LUSC	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg17385448	chr1:15911702	AGMAT	0.36	6.2	0.32	1.69e-9	Systolic blood pressure;
LUSC	cis	rs4629710	0.568	rs9492880	chr6:131565962	G/T	cg12606694	chr6:131520996	AKAP7	0.6	9.09	0.45	9.02e-18	Multiple myeloma (IgH translocation);
LUSC	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.67	-0.39	1.92e-13	Retinal vascular caliber;
LUSC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg02038168	chr22:39784481	NA	-0.43	-6.39	-0.33	5.62e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg01000954	chr5:140821244	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.42	-6.1	-0.32	2.9e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg12559939	chr2:27858050	GPN1	-0.39	-6.03	-0.31	4.25e-9	Oral cavity cancer;
LUSC	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg13010199	chr12:38710504	ALG10B	0.69	10.89	0.51	7.65e-24	Heart rate;
LUSC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08109568	chr15:31115862	NA	0.62	9.48	0.46	5.06e-19	Huntington's disease progression;
LUSC	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.26	0.52	3.81e-25	Coffee consumption (cups per day);
LUSC	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg03342759	chr3:160939853	NMD3	-0.51	-8.5	-0.42	6.58e-16	Morning vs. evening chronotype;
LUSC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	10.17	0.49	2.38e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg26408565	chr15:76604113	ETFA	0.52	8.18	0.41	6.17e-15	Blood metabolite levels;
LUSC	cis	rs4478137	0.839	rs3967763	chr4:164239273	G/C	cg06758707	chr4:164254230	NPY1R	0.63	9.8	0.47	4.14e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.45	0.33	3.87e-10	Schizophrenia;
LUSC	cis	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg08601574	chr20:25228251	PYGB	-0.42	-6.26	-0.32	1.21e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2274273	0.588	rs58296156	chr14:55828327	C/T	cg04306507	chr14:55594613	LGALS3	0.49	9.82	0.47	3.79e-20	Protein biomarker;
LUSC	cis	rs10979	1.000	rs9376763	chr6:143887386	C/T	cg25407410	chr6:143891975	LOC285740	-0.74	-12.01	-0.55	7.28e-28	Hypospadias;
LUSC	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-0.87	-12.45	-0.56	1.7e-29	Dilated cardiomyopathy;
LUSC	cis	rs2625529	0.775	rs4777484	chr15:72376543	T/C	cg16672083	chr15:72433130	SENP8	-0.52	-7.59	-0.38	3.22e-13	Red blood cell count;
LUSC	cis	rs75804782	0.641	rs72985387	chr2:239336589	G/A	cg18131467	chr2:239335373	ASB1	-0.72	-6.54	-0.34	2.25e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg19592336	chr6:28129416	ZNF389	0.46	6.37	0.33	6.12e-10	Parkinson's disease;
LUSC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg24733560	chr20:60626293	TAF4	0.43	7.99	0.4	2.16e-14	Body mass index;
LUSC	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg26754761	chr2:177040938	NA	-0.39	-7.66	-0.39	2.09e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg04851639	chr8:1020857	NA	-0.37	-7.9	-0.4	4.19e-14	Schizophrenia;
LUSC	cis	rs62400317	0.787	rs10456547	chr6:45219526	T/C	cg18551225	chr6:44695536	NA	-0.43	-6.93	-0.35	2.11e-11	Total body bone mineral density;
LUSC	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg17830980	chr10:43048298	ZNF37B	0.42	6.62	0.34	1.47e-10	Extrinsic epigenetic age acceleration;
LUSC	trans	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg20935933	chr6:143382018	AIG1	0.51	7.38	0.37	1.26e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg06784218	chr1:46089804	CCDC17	0.55	11.19	0.52	6.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7267979	0.816	rs422148	chr20:25512604	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.74	14.8	0.63	1.89e-38	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg07703079	chr11:430292	ANO9	0.66	6.75	0.35	6.51e-11	Body mass index;
LUSC	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.85	14.12	0.61	8.34e-36	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg09904177	chr6:26538194	HMGN4	-0.5	-5.82	-0.3	1.38e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.74	-11.44	-0.53	8.75e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs2073300	1.000	rs6048833	chr20:23462185	G/A	cg09953122	chr20:23471693	CST8	-0.76	-7.49	-0.38	6.37e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	0.65	9.14	0.45	6.14e-18	Methadone dose in opioid dependence;
LUSC	cis	rs977987	0.806	rs35552529	chr16:75405879	G/C	cg03315344	chr16:75512273	CHST6	0.48	9.24	0.45	3.06e-18	Dupuytren's disease;
LUSC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-17.06	-0.68	2.25e-47	Gut microbiome composition (summer);
LUSC	cis	rs9815354	0.638	rs17218866	chr3:42017634	T/C	cg03022575	chr3:42003672	ULK4	0.76	7.6	0.38	3e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03352830	chr11:487213	PTDSS2	-0.72	-9.16	-0.45	5.55e-18	Body mass index;
LUSC	cis	rs7608623	0.742	rs6756280	chr2:23921055	A/G	cg08917208	chr2:24149416	ATAD2B	-0.42	-5.74	-0.3	2.12e-8	Obesity-related traits;
LUSC	cis	rs981844	0.712	rs62325150	chr4:154728117	T/G	cg14289246	chr4:154710475	SFRP2	0.44	5.91	0.31	8.36e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.26	0.52	3.78e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg01324343	chr3:183735012	ABCC5	-0.59	-9.26	-0.45	2.53e-18	Body mass index;
LUSC	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.34	-0.42	2.03e-15	Response to antipsychotic treatment;
LUSC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg00990874	chr7:1149470	C7orf50	-0.58	-7.51	-0.38	5.41e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs1595825	0.891	rs79845692	chr2:198523541	T/C	cg00982548	chr2:198649783	BOLL	-0.52	-6.63	-0.34	1.34e-10	Ulcerative colitis;
LUSC	cis	rs524023	0.914	rs526338	chr11:64418900	G/A	cg19131476	chr11:64387923	NRXN2	-0.38	-10.48	-0.5	2.08e-22	Urate levels in obese individuals;
LUSC	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg04374321	chr14:90722782	PSMC1	-0.75	-12.14	-0.55	2.35e-28	Mortality in heart failure;
LUSC	cis	rs72634258	0.519	rs2071984	chr1:7928656	C/T	cg00042356	chr1:8021962	PARK7	0.61	7.21	0.37	3.75e-12	Inflammatory bowel disease;
LUSC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg23711669	chr6:146136114	FBXO30	0.86	15.5	0.65	3.4e-41	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg18187862	chr3:45730750	SACM1L	0.53	7.03	0.36	1.16e-11	Primary sclerosing cholangitis;
LUSC	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg00750074	chr16:89608354	SPG7	-0.54	-9.48	-0.46	5e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.7	11.4	0.53	1.18e-25	Heart rate;
LUSC	trans	rs11949289	1.000	rs6884749	chr5:28338714	T/C	cg18220921	chr1:242687527	PLD5	0.35	5.96	0.31	6.55e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs3741151	0.892	rs7102787	chr11:73012614	A/G	cg17517138	chr11:73019481	ARHGEF17	0.92	8.39	0.42	1.44e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg03676636	chr4:99064102	C4orf37	0.3	5.96	0.31	6.52e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg23711669	chr6:146136114	FBXO30	0.8	13.9	0.61	5.63e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.45	-0.38	7.92e-13	Aortic root size;
LUSC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg17372223	chr3:52568218	NT5DC2	0.4	6.33	0.33	7.71e-10	Electroencephalogram traits;
LUSC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg06618935	chr21:46677482	NA	-0.38	-7.57	-0.38	3.79e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs977987	0.806	rs35683383	chr16:75479277	G/T	cg04384234	chr16:75411784	CFDP1	-0.42	-7.03	-0.36	1.14e-11	Dupuytren's disease;
LUSC	cis	rs500891	0.500	rs62421760	chr6:83915335	T/C	cg08257003	chr6:84140564	ME1	0.3	6.34	0.33	7.52e-10	Platelet-derived growth factor BB levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23719950	chr11:63933701	MACROD1	-0.47	-6.3	-0.33	9.13e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg22571038	chr17:48585470	MYCBPAP	-0.56	-7.91	-0.4	3.9e-14	Visceral fat;
LUSC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.77e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4911259	0.552	rs13038881	chr20:31468113	T/C	cg13636640	chr20:31349939	DNMT3B	-0.81	-15.77	-0.65	2.8e-42	Inflammatory bowel disease;
LUSC	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg01677386	chr11:118938358	VPS11	-0.49	-6.83	-0.35	3.91e-11	Coronary artery disease;
LUSC	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg05941027	chr17:61774174	LIMD2	0.24	6.12	0.32	2.7e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg21665744	chr7:39171113	POU6F2	0.49	7.78	0.39	8.99e-14	IgG glycosylation;
LUSC	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg04414720	chr1:150670196	GOLPH3L	-0.45	-6.92	-0.35	2.31e-11	Tonsillectomy;
LUSC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg06877462	chr1:205807181	PM20D1	0.39	7.38	0.37	1.25e-12	Menarche (age at onset);
LUSC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.12	17.39	0.69	1.06e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg05896524	chr21:47604654	C21orf56	0.53	8.26	0.41	3.46e-15	Testicular germ cell tumor;
LUSC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg00431813	chr7:1051703	C7orf50	-0.43	-6.95	-0.36	1.9e-11	Longevity;Endometriosis;
LUSC	cis	rs4285028	0.747	rs3732410	chr3:121415720	T/C	cg11130432	chr3:121712080	ILDR1	-0.53	-7.75	-0.39	1.12e-13	Multiple sclerosis;
LUSC	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg08213375	chr14:104286397	PPP1R13B	0.35	5.92	0.31	8.09e-9	Reticulocyte count;
LUSC	cis	rs2637266	0.714	rs7082421	chr10:78446313	G/A	cg18941641	chr10:78392320	NA	0.33	5.88	0.31	9.83e-9	Pulmonary function;
LUSC	cis	rs9341808	0.591	rs7741013	chr6:80916330	G/A	cg08355045	chr6:80787529	NA	0.46	7.97	0.4	2.62e-14	Sitting height ratio;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10819733	chr22:24237672	NA	-0.38	-5.73	-0.3	2.21e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12208915	0.848	rs77415956	chr6:79514757	G/A	cg05283184	chr6:79620031	NA	0.42	5.67	0.3	3.09e-8	Left atrial antero-posterior diameter;
LUSC	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.67	-0.34	1.08e-10	Monocyte percentage of white cells;
LUSC	cis	rs2377585	0.563	rs10842109	chr12:8841077	G/A	cg03761649	chr12:8850719	RIMKLB	0.47	6.05	0.31	3.94e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg26335602	chr6:28129616	ZNF389	0.46	6.34	0.33	7.57e-10	Parkinson's disease;
LUSC	cis	rs1448094	0.617	rs10863162	chr12:86474122	C/T	cg00310523	chr12:86230176	RASSF9	-0.33	-5.97	-0.31	5.98e-9	Major depressive disorder;
LUSC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.53	10.2	0.49	1.95e-21	Monocyte count;
LUSC	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21545522	chr1:205238299	TMCC2	0.49	9.2	0.45	3.93e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2479724	0.636	rs2265139	chr6:41819407	C/G	cg17623882	chr6:41773611	USP49	-0.55	-7.61	-0.38	2.78e-13	Menarche (age at onset);
LUSC	cis	rs612683	0.524	rs584350	chr1:100908324	A/G	cg06223162	chr1:101003688	GPR88	0.42	7.74	0.39	1.23e-13	Breast cancer;
LUSC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.35	6.36	0.33	6.72e-10	Obesity-related traits;
LUSC	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22590775	chr19:49891494	CCDC155	0.5	6.73	0.35	7.24e-11	Multiple sclerosis;
LUSC	cis	rs12891047	0.866	rs181570	chr14:68275342	A/G	cg20999565	chr14:68265668	ZFYVE26	0.37	5.67	0.3	3.04e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-1.03	-14.79	-0.63	2.09e-38	Vitiligo;
LUSC	trans	rs2229238	0.866	rs112231452	chr1:154504900	G/A	cg25273160	chr11:56955011	LRRC55	0.31	6.05	0.31	3.94e-9	Coronary heart disease;
LUSC	cis	rs5758511	0.731	rs12158579	chr22:42351289	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.46	-5.73	-0.3	2.21e-8	Birth weight;
LUSC	trans	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.62	7.29	0.37	2.2e-12	Menarche (age at onset);
LUSC	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.52	-0.34	2.64e-10	Fear of minor pain;
LUSC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18876405	chr7:65276391	NA	-0.57	-9.18	-0.45	4.69e-18	Aortic root size;
LUSC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7538876	0.903	rs6688886	chr1:17753639	G/A	cg07965774	chr1:17746286	RCC2	0.31	5.87	0.31	1.06e-8	Basal cell carcinoma;
LUSC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg22868518	chr11:507468	RNH1	-0.61	-5.94	-0.31	7.1e-9	Body mass index;
LUSC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg21251018	chr6:28226885	NKAPL	-0.35	-6.56	-0.34	2.03e-10	Cardiac Troponin-T levels;
LUSC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg14664628	chr15:75095509	CSK	-0.56	-8.82	-0.43	6.28e-17	Breast cancer;
LUSC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.8	-0.3	1.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg24296786	chr1:45957014	TESK2	0.46	6.76	0.35	6.29e-11	High light scatter reticulocyte count;
LUSC	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	7.16	0.36	5.1e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs1950500	1.000	rs12590407	chr14:24835115	A/G	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.45	-6.19	-0.32	1.74e-9	Height;
LUSC	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg22491629	chr6:157744540	C6orf35	0.79	9.81	0.47	4.05e-20	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9398803	0.965	rs9388486	chr6:126661154	C/T	cg19875578	chr6:126661172	C6orf173	-0.41	-6.01	-0.31	4.93e-9	Male-pattern baldness;
LUSC	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-6.67	-0.34	1.04e-10	Blood metabolite levels;
LUSC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg03146154	chr1:46216737	IPP	0.53	7.71	0.39	1.43e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg24562669	chr7:97807699	LMTK2	0.35	6.06	0.31	3.68e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2455601	0.638	rs2248245	chr11:8988350	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-5.94	-0.31	7.28e-9	Schizophrenia;
LUSC	cis	rs4356932	0.967	rs13111790	chr4:76972402	G/C	cg00809888	chr4:76862425	NAAA	0.35	5.86	0.31	1.11e-8	Blood protein levels;
LUSC	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.64	7.85	0.39	5.57e-14	Post bronchodilator FEV1;
LUSC	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.23e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11677416	1.000	rs3783559	chr2:113529837	A/G	cg27083787	chr2:113543245	IL1A	0.46	7.26	0.37	2.77e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg07701084	chr6:150067640	NUP43	0.46	6.97	0.36	1.7e-11	Lung cancer;
LUSC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg06784218	chr1:46089804	CCDC17	-0.47	-8.92	-0.44	3.06e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg24558204	chr6:135376177	HBS1L	0.59	9.15	0.45	5.91e-18	Red blood cell count;
LUSC	cis	rs10887741	0.966	rs7085195	chr10:89429897	T/C	cg13926569	chr10:89418898	PAPSS2	0.33	6.59	0.34	1.75e-10	Exercise (leisure time);
LUSC	trans	rs9409154	0.617	rs7859870	chr9:118367195	C/T	cg06386307	chr6:100895211	SIM1	0.34	6.3	0.33	9.51e-10	Visceral adipose tissue adjusted for BMI;
LUSC	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg05347473	chr6:146136440	FBXO30	0.52	8.78	0.43	8.54e-17	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg24247370	chr13:99142703	STK24	-0.34	-6.17	-0.32	1.96e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs1922233	0.943	rs1922226	chr4:92413671	A/G	cg24250684	chr1:219729030	NA	-0.34	-6.47	-0.33	3.57e-10	Gut microbiome composition (summer and winter);
LUSC	cis	rs9287719	0.601	rs12995465	chr2:10716828	G/A	cg00105475	chr2:10696890	NA	0.35	5.8	0.3	1.58e-8	Prostate cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09300980	chr6:17601309	FAM8A1	-0.41	-6.21	-0.32	1.56e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.12	-18.16	-0.7	9.73e-52	Primary sclerosing cholangitis;
LUSC	trans	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg25214090	chr10:38739885	LOC399744	0.43	6.58	0.34	1.77e-10	Corneal astigmatism;
LUSC	cis	rs3820928	0.874	rs3769646	chr2:227896330	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.49	-0.38	6.31e-13	Pulmonary function;
LUSC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg11859384	chr17:80120422	CCDC57	0.36	5.71	0.3	2.51e-8	Life satisfaction;
LUSC	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.69	-0.3	2.8e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03878208	chr11:72483293	STARD10	0.57	7.35	0.37	1.55e-12	Type 2 diabetes;
LUSC	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg11161011	chr14:65562177	MAX	-0.65	-9.85	-0.47	2.93e-20	Obesity-related traits;
LUSC	cis	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.37e-9	Ulcerative colitis;
LUSC	cis	rs7246967	0.673	rs12980342	chr19:22849357	T/C	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs4478858	0.698	rs6655946	chr1:31805728	G/A	cg00250761	chr1:31883323	NA	-0.37	-9.16	-0.45	5.22e-18	Alcohol dependence;
LUSC	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.28	-0.37	2.41e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs656319	0.513	rs1484641	chr8:9986524	A/C	cg27411982	chr8:10470053	RP1L1	0.41	6.06	0.31	3.68e-9	Myopia (pathological);
LUSC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg08470875	chr2:26401718	FAM59B	-0.61	-7.55	-0.38	4.21e-13	Gut microbiome composition (summer);
LUSC	trans	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04565464	chr8:145669602	NFKBIL2	0.4	6.61	0.34	1.53e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4853525	0.923	rs4853521	chr2:191730184	G/A	cg11845111	chr2:191398756	TMEM194B	-0.41	-5.97	-0.31	5.99e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg04414720	chr1:150670196	GOLPH3L	0.52	8.1	0.41	1.06e-14	Melanoma;
LUSC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06634786	chr22:41940651	POLR3H	0.52	6.16	0.32	2.11e-9	Vitiligo;
LUSC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.26	0.37	2.8e-12	Platelet count;
LUSC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.35	0.59	7.34e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2688608	0.901	rs2459446	chr10:75601596	C/T	cg23231163	chr10:75533350	FUT11	0.41	6.53	0.34	2.41e-10	Inflammatory bowel disease;
LUSC	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.43e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs459571	0.959	rs456205	chr9:136911146	G/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.42	-6.14	-0.32	2.4e-9	Platelet distribution width;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.82	-13.2	-0.59	2.59e-32	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg01689657	chr7:91764605	CYP51A1	0.33	5.98	0.31	5.67e-9	Breast cancer;
LUSC	cis	rs6076065	1.000	rs6076065	chr20:23368411	C/A	cg11657817	chr20:23433608	CST11	0.44	8.66	0.43	2.12e-16	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg18681998	chr4:17616180	MED28	0.78	13.71	0.6	3.02e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg21171335	chr12:122356390	WDR66	0.54	7.77	0.39	9.57e-14	Mean corpuscular volume;
LUSC	cis	rs6489882	0.867	rs4767032	chr12:113363077	T/G	cg20102336	chr12:113376681	OAS3	-0.42	-5.93	-0.31	7.36e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg21775007	chr8:11205619	TDH	0.81	13.68	0.6	3.88e-34	Retinal vascular caliber;
LUSC	cis	rs6741892	0.536	rs13024840	chr2:38895920	T/A	cg23643435	chr2:38893251	GALM	-0.67	-6.84	-0.35	3.74e-11	5-HTT brain serotonin transporter levels;
LUSC	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg08668359	chr10:1443807	ADARB2	0.41	6.19	0.32	1.77e-9	Radiation response;
LUSC	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg08558340	chr7:100472263	SRRT	0.51	6.41	0.33	5e-10	Resting heart rate;
LUSC	trans	rs8073060	0.519	rs8065286	chr17:33864479	A/G	cg19694781	chr19:47549865	TMEM160	0.56	8.75	0.43	1.04e-16	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg08601574	chr20:25228251	PYGB	0.43	6.65	0.34	1.17e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	6.74	0.35	7.17e-11	Lung cancer in ever smokers;
LUSC	cis	rs7106204	0.764	rs58215218	chr11:24234720	G/T	ch.11.24196551F	chr11:24239977	NA	1.0	9.11	0.45	7.77e-18	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg09516651	chr1:89888402	LOC400759	0.44	7.95	0.4	2.92e-14	Carotid intima media thickness;
LUSC	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-1.0	-24.12	-0.8	3.83e-75	Urate levels in lean individuals;
LUSC	cis	rs9403521	0.898	rs12207002	chr6:143975422	G/A	cg18240653	chr6:144019428	PHACTR2	-0.5	-6.07	-0.32	3.51e-9	Obesity-related traits;
LUSC	cis	rs17125944	0.615	rs1886786	chr14:53312189	A/T	cg00686598	chr14:53173677	PSMC6	-0.62	-5.85	-0.3	1.17e-8	Alzheimer's disease (late onset);
LUSC	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg04374321	chr14:90722782	PSMC1	0.75	12.08	0.55	4e-28	Mortality in heart failure;
LUSC	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.81	12.4	0.56	2.75e-29	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.92	14.54	0.62	1.94e-37	Lymphocyte percentage of white cells;
LUSC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg07870213	chr5:140052090	DND1	0.77	11.51	0.53	4.78e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs668210	0.793	rs622779	chr11:65744247	G/A	cg04700828	chr11:65773979	NA	0.39	5.66	0.3	3.18e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.89	10.69	0.51	3.75e-23	Primary sclerosing cholangitis;
LUSC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg18681998	chr4:17616180	MED28	0.86	15.71	0.65	4.97e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.69	-11.6	-0.54	2.23e-26	Colorectal cancer;
LUSC	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.4	6.35	0.33	6.88e-10	Cystic fibrosis severity;
LUSC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg15704280	chr7:45808275	SEPT13	0.93	13.42	0.59	3.7e-33	Coronary artery disease;
LUSC	cis	rs3087591	0.960	rs4795593	chr17:29613600	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.57	-8.27	-0.41	3.11e-15	Hip circumference;
LUSC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg10729496	chr3:10149963	C3orf24	-0.57	-7.92	-0.4	3.63e-14	Alzheimer's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17707966	chr8:144718525	ZNF623	-0.4	-5.98	-0.31	5.69e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	trans	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg26043149	chr18:55253948	FECH	-0.53	-7.8	-0.39	8.08e-14	Bone mineral density;
LUSC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.38	5.77	0.3	1.82e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg06074448	chr4:187884817	NA	-0.41	-6.82	-0.35	4.28e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg09904177	chr6:26538194	HMGN4	0.51	6.02	0.31	4.68e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg09479241	chr17:27052676	TLCD1	0.43	5.96	0.31	6.29e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg01620082	chr3:125678407	NA	-0.77	-7.19	-0.37	4.16e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg19302996	chr17:73780495	UNK	-0.49	-7.07	-0.36	9.28e-12	White matter hyperintensity burden;
LUSC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg07936489	chr17:37558343	FBXL20	0.74	10.22	0.49	1.63e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.11	0.32	2.71e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7851660	0.775	rs7034336	chr9:100661100	C/T	cg13688889	chr9:100608707	NA	-0.54	-8.44	-0.42	9.53e-16	Strep throat;
LUSC	trans	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.59	-8.43	-0.42	1.07e-15	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.7	0.3	2.59e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg19812747	chr11:111475976	SIK2	0.42	5.69	0.3	2.81e-8	Primary sclerosing cholangitis;
LUSC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	0.92	15.38	0.64	1.02e-40	Breast cancer;
LUSC	cis	rs9393777	0.778	rs67457459	chr6:27198343	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.55	-6.35	-0.33	6.95e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg23303369	chr20:44641161	MMP9	0.39	6.63	0.34	1.33e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg03396347	chr1:1875803	NA	-0.43	-9.19	-0.45	4.15e-18	Body mass index;
LUSC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07157834	chr1:205819609	PM20D1	0.54	8.8	0.43	7.55e-17	Menarche (age at onset);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg06837731	chr10:101945906	ERLIN1	0.42	6.03	0.31	4.33e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg06074448	chr4:187884817	NA	-0.41	-6.89	-0.35	2.85e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg13010199	chr12:38710504	ALG10B	-0.45	-7.04	-0.36	1.1e-11	Morning vs. evening chronotype;
LUSC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg14895029	chr7:2775587	GNA12	-0.38	-6.0	-0.31	5.21e-9	Height;
LUSC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg25767906	chr1:53392781	SCP2	0.45	7.9	0.4	4e-14	Monocyte count;
LUSC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg17264618	chr3:40429014	ENTPD3	0.33	7.1	0.36	7.64e-12	Renal cell carcinoma;
LUSC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg11236850	chr4:8443022	ACOX3	0.42	6.33	0.33	7.8e-10	Mosquito bite size;
LUSC	cis	rs7804356	1.000	rs3823934	chr7:26853934	T/C	cg03456212	chr7:26904342	SKAP2	-0.54	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs9905704	0.633	rs2680713	chr17:56523900	G/T	cg19466818	chr17:56409534	MIR142	-0.35	-6.41	-0.33	4.87e-10	Testicular germ cell tumor;
LUSC	cis	rs1775715	0.737	rs2778650	chr10:32106851	A/G	cg04359828	chr10:32216031	ARHGAP12	0.39	6.75	0.35	6.68e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs12681287	0.577	rs11992955	chr8:87530485	A/G	cg27223183	chr8:87520930	FAM82B	0.53	6.94	0.36	2.04e-11	Caudate activity during reward;
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.67	-10.97	-0.51	4.17e-24	Longevity;Endometriosis;
LUSC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.57	0.38	3.61e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs61021925	1	rs61021925	chr12:122863659	T/C	cg23029597	chr12:123009494	RSRC2	0.44	6.37	0.33	6.17e-10	Schizophrenia;
LUSC	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg11657440	chr19:46296263	DMWD	-0.64	-9.47	-0.46	5.2e-19	Coronary artery disease;
LUSC	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg24375607	chr4:120327624	NA	-0.72	-11.21	-0.52	5.61e-25	Corneal astigmatism;
LUSC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg27170947	chr2:26402098	FAM59B	-0.69	-9.97	-0.48	1.18e-20	Gut microbiome composition (summer);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06740039	chr3:106959657	LOC344595;LOC100302640	-0.49	-6.38	-0.33	5.77e-10	Hepatitis;
LUSC	cis	rs3770081	1.000	rs78032828	chr2:86309032	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-7.48	-0.38	6.53e-13	Facial emotion recognition (sad faces);
LUSC	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg19773385	chr1:10388646	KIF1B	-0.55	-8.46	-0.42	8.49e-16	Hepatocellular carcinoma;
LUSC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg06600287	chr1:53387719	ECHDC2	-0.31	-6.53	-0.34	2.41e-10	Monocyte count;
LUSC	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg00686598	chr14:53173677	PSMC6	1.06	9.66	0.47	1.27e-19	Alzheimer's disease (late onset);
LUSC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg13319975	chr6:146136371	FBXO30	0.5	7.51	0.38	5.44e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg15737290	chr11:93063684	CCDC67	0.65	8.21	0.41	4.92e-15	Pulmonary function decline;
LUSC	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg16482183	chr6:26056742	HIST1H1C	0.58	8.05	0.4	1.46e-14	Iron status biomarkers;
LUSC	cis	rs12928939	0.769	rs1056303	chr16:71670066	C/T	cg03805757	chr16:71968109	PKD1L3	-0.41	-5.96	-0.31	6.44e-9	Post bronchodilator FEV1;
LUSC	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg11812906	chr14:75593930	NEK9	0.64	10.47	0.5	2.34e-22	Height;
LUSC	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.45	6.45	0.33	3.85e-10	Breast cancer;
LUSC	cis	rs9309473	0.607	rs10198301	chr2:73581600	T/A	cg20560298	chr2:73613845	ALMS1	-0.57	-8.3	-0.41	2.62e-15	Metabolite levels;
LUSC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg05623727	chr3:50126028	RBM5	0.31	5.7	0.3	2.61e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.79	-0.39	8.52e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg26043149	chr18:55253948	FECH	0.47	6.95	0.36	1.93e-11	Bone mineral density;
LUSC	cis	rs7589342	0.517	rs6726571	chr2:106390251	T/C	cg14210321	chr2:106509881	NCK2	-0.4	-5.79	-0.3	1.63e-8	Addiction;
LUSC	cis	rs921665	0.831	rs2368672	chr2:3188893	A/C	cg16434511	chr2:3151078	NA	-0.63	-6.78	-0.35	5.3e-11	World class endurance athleticism;
LUSC	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg00262122	chr8:11665843	FDFT1	-0.38	-5.66	-0.3	3.2e-8	Myopia (pathological);
LUSC	cis	rs7432375	0.609	rs835637	chr3:136673157	A/T	cg15507776	chr3:136538369	TMEM22	0.4	6.77	0.35	5.71e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg24375607	chr4:120327624	NA	0.73	10.38	0.49	4.58e-22	Corneal astigmatism;
LUSC	trans	rs4714291	0.802	rs2983143	chr6:40044850	G/T	cg02267698	chr19:7991119	CTXN1	-0.55	-7.99	-0.4	2.25e-14	Strep throat;
LUSC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	7.11	0.36	7.09e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08109568	chr15:31115862	NA	0.73	11.22	0.52	5.4e-25	Huntington's disease progression;
LUSC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	12.6	0.57	4.65e-30	Hip circumference adjusted for BMI;
LUSC	cis	rs2299587	0.642	rs2073570	chr8:17782627	C/G	cg01800426	chr8:17659068	MTUS1	-0.42	-5.66	-0.3	3.21e-8	Economic and political preferences;
LUSC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg11764359	chr7:65958608	NA	0.49	6.1	0.32	2.93e-9	Aortic root size;
LUSC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg26408565	chr15:76604113	ETFA	-0.52	-8.3	-0.41	2.6e-15	Blood metabolite levels;
LUSC	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg05855489	chr10:104503620	C10orf26	0.6	9.56	0.46	2.74e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.36e-10	Menopause (age at onset);
LUSC	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg12002119	chr2:101014098	CHST10	0.35	5.95	0.31	6.92e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26149032	chr3:158519514	MFSD1	0.4	6.18	0.32	1.92e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2108225	0.900	rs2395930	chr7:107451677	T/C	cg18560240	chr7:107437656	SLC26A3	-0.4	-6.2	-0.32	1.71e-9	Ulcerative colitis;
LUSC	cis	rs714027	0.585	rs960987	chr22:30343477	C/T	cg11564601	chr22:30592435	NA	0.35	6.01	0.31	4.75e-9	Lymphocyte counts;
LUSC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.45	-0.56	1.77e-29	Alzheimer's disease;
LUSC	cis	rs4917833	0.510	rs754586	chr10:100224362	A/G	cg19043522	chr10:100227446	HPSE2	0.45	6.56	0.34	1.99e-10	Pediatric bone mineral density (femoral neck);
LUSC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg17279839	chr7:150038598	RARRES2	0.48	7.17	0.37	4.92e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9549260	0.567	rs7332730	chr13:41265979	C/A	cg21288729	chr13:41239152	FOXO1	0.56	8.36	0.42	1.67e-15	Red blood cell count;
LUSC	cis	rs11748023	0.605	rs156090	chr5:139521684	T/C	cg26211634	chr5:139558579	C5orf32	0.32	5.69	0.3	2.81e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.78	0.35	5.5e-11	Platelet count;
LUSC	cis	rs6545883	0.868	rs28749199	chr2:61827052	A/G	cg15711740	chr2:61764176	XPO1	-0.47	-7.22	-0.37	3.49e-12	Tuberculosis;
LUSC	cis	rs1335645	0.570	rs56273356	chr1:111664041	C/T	cg00321911	chr1:111669324	DRAM2	-0.61	-6.77	-0.35	5.84e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9549260	0.522	rs4245401	chr13:41277736	G/T	cg21288729	chr13:41239152	FOXO1	0.54	8.31	0.41	2.35e-15	Red blood cell count;
LUSC	cis	rs6540559	0.673	rs114467813	chr1:210017785	G/A	cg23283495	chr1:209979779	IRF6	0.68	8.02	0.4	1.77e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.29	-0.45	2.04e-18	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg17376030	chr22:41985996	PMM1	-0.47	-5.89	-0.31	9.6e-9	Vitiligo;
LUSC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.38	0.37	1.25e-12	Motion sickness;
LUSC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.24	0.32	1.33e-9	Menopause (age at onset);
LUSC	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	10.95	0.51	4.92e-24	Lung cancer in ever smokers;
LUSC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-10.95	-0.51	4.74e-24	Coffee consumption (cups per day);
LUSC	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg04058563	chr4:185651563	MLF1IP	0.79	10.63	0.5	6.35e-23	Blood protein levels;
LUSC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg20283391	chr11:68216788	NA	-0.59	-8.34	-0.42	2.01e-15	Total body bone mineral density;
LUSC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg27572855	chr1:25598939	RHD	0.47	8.49	0.42	7.09e-16	Erythrocyte sedimentation rate;
LUSC	cis	rs7707921	0.881	rs17243791	chr5:81322547	A/G	cg15871215	chr5:81402204	ATG10	-0.44	-6.41	-0.33	4.87e-10	Breast cancer;
LUSC	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.26	0.49	1.16e-21	Bladder cancer;
LUSC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg05084668	chr3:125655381	ALG1L	-0.52	-7.89	-0.4	4.38e-14	Blood pressure (smoking interaction);
LUSC	cis	rs77633900	0.772	rs2957607	chr15:76686527	A/G	cg21673338	chr15:77095150	SCAPER	0.7	5.99	0.31	5.4e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg22601191	chr20:60968625	CABLES2	0.43	6.11	0.32	2.73e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg00933542	chr6:150070202	PCMT1	0.33	6.76	0.35	6.34e-11	Lung cancer;
LUSC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs4891159	0.790	rs1787448	chr18:74113179	T/C	cg24786174	chr18:74118243	ZNF516	0.83	15.26	0.64	2.93e-40	Longevity;
LUSC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg19468946	chr17:37922297	IKZF3	-0.43	-6.89	-0.35	2.86e-11	Self-reported allergy;
LUSC	cis	rs3125734	0.719	rs3852410	chr10:64037563	A/G	cg09941381	chr10:64027924	RTKN2	0.35	6.3	0.33	9.47e-10	Rheumatoid arthritis;
LUSC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-11.57	-0.53	2.96e-26	Monocyte count;
LUSC	cis	rs10207060	0.500	rs11884577	chr2:240702216	C/G	cg20333904	chr2:240724165	NA	-0.36	-6.26	-0.32	1.17e-9	Obesity-related traits;
LUSC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	13.28	0.59	1.28e-32	Total body bone mineral density;
LUSC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-0.84	-15.53	-0.65	2.51e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg01733217	chr16:74700730	RFWD3	0.97	21.87	0.77	1.96e-66	Multiple myeloma;
LUSC	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.86	-0.4	5.34e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg04374321	chr14:90722782	PSMC1	0.7	10.94	0.51	5.08e-24	Mortality in heart failure;
LUSC	cis	rs4730250	0.655	rs75243311	chr7:106890791	C/T	cg02696742	chr7:106810147	HBP1	-0.63	-9.43	-0.46	7.2e-19	Osteoarthritis;
LUSC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.39	0.46	9.85e-19	Prudent dietary pattern;
LUSC	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg23711669	chr6:146136114	FBXO30	0.74	13.07	0.58	7.88e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs68170813	0.562	rs7810216	chr7:107000353	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.51	-0.46	3.76e-19	Coronary artery disease;
LUSC	cis	rs9644630	0.696	rs35736969	chr8:19319620	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.32	5.85	0.31	1.14e-8	Oropharynx cancer;
LUSC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.09	0.52	1.49e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.81	13.62	0.6	6.38e-34	Aortic root size;
LUSC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.25e-9	Life satisfaction;
LUSC	cis	rs4746818	0.688	rs951718	chr10:70928044	A/G	cg11621586	chr10:70884670	VPS26A	1.07	13.28	0.59	1.33e-32	Left atrial antero-posterior diameter;
LUSC	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg14227996	chr4:17616232	MED28	0.79	7.68	0.39	1.76e-13	Opioid sensitivity;
LUSC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg27588902	chr6:42928151	GNMT	-0.29	-6.46	-0.33	3.78e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7851660	0.874	rs13299924	chr9:100627562	C/T	cg13688889	chr9:100608707	NA	-0.56	-8.94	-0.44	2.73e-17	Strep throat;
LUSC	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg13010199	chr12:38710504	ALG10B	0.48	7.28	0.37	2.47e-12	Heart rate;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg21240523	chr9:130965902	CIZ1;DNM1	-0.49	-6.05	-0.31	3.98e-9	Height;
LUSC	trans	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.47	0.38	6.96e-13	Ulcerative colitis;
LUSC	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.87	-0.7	1.34e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	6.15	0.32	2.15e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg02018176	chr4:1364513	KIAA1530	0.52	8.97	0.44	2.25e-17	Obesity-related traits;
LUSC	cis	rs968451	0.865	rs5757610	chr22:39707979	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	9.04	0.44	1.28e-17	Primary biliary cholangitis;
LUSC	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.33	-0.33	7.98e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9311676	0.656	rs11923253	chr3:58376992	G/A	cg26110898	chr3:58419937	PDHB	0.42	6.68	0.34	9.75e-11	Systemic lupus erythematosus;
LUSC	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg08079166	chr15:68083412	MAP2K5	0.41	7.23	0.37	3.29e-12	Restless legs syndrome;
LUSC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg17480646	chr11:65405466	SIPA1	-0.44	-5.7	-0.3	2.62e-8	Acne (severe);
LUSC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.62	0.62	8.89e-38	Platelet count;
LUSC	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg11244672	chr19:19639970	YJEFN3	-0.56	-6.87	-0.35	3.14e-11	Bipolar disorder;
LUSC	cis	rs2580764	0.565	rs7562292	chr2:55230219	C/T	cg20993754	chr2:55226987	RTN4	0.35	5.84	0.3	1.25e-8	Mean platelet volume;
LUSC	cis	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg13609457	chr4:120235615	NA	0.4	6.16	0.32	2.12e-9	Diastolic blood pressure;
LUSC	cis	rs3820928	0.874	rs56324594	chr2:227868854	C/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-7.15	-0.36	5.36e-12	Pulmonary function;
LUSC	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.66	10.53	0.5	1.43e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg04374321	chr14:90722782	PSMC1	0.75	12.12	0.55	2.92e-28	Mortality in heart failure;
LUSC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20135002	chr11:47629003	NA	-0.51	-7.84	-0.39	5.97e-14	Subjective well-being;
LUSC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21171335	chr12:122356390	WDR66	0.64	9.43	0.46	7.09e-19	Mean corpuscular volume;
LUSC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg13206674	chr6:150067644	NUP43	0.59	9.47	0.46	5.18e-19	Lung cancer;
LUSC	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	cis	rs2692947	0.630	rs1168966	chr2:96798510	G/A	cg23100626	chr2:96804247	ASTL	0.26	6.43	0.33	4.48e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.76	0.54	6.2e-27	Prudent dietary pattern;
LUSC	cis	rs7712401	0.580	rs10076327	chr5:122367347	A/G	cg19077854	chr5:122220652	SNX24	0.38	7.95	0.4	2.97e-14	Mean platelet volume;
LUSC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg01416388	chr22:39784598	NA	-0.45	-7.62	-0.38	2.69e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs12410462	0.581	rs73102371	chr1:227554880	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.59	-5.79	-0.3	1.65e-8	Major depressive disorder;
LUSC	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-5.82	-0.3	1.41e-8	Breast cancer;
LUSC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03264133	chr6:25882463	NA	-0.51	-9.34	-0.46	1.37e-18	Blood metabolite levels;
LUSC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg20608306	chr11:116969690	SIK3	0.37	5.7	0.3	2.67e-8	Blood protein levels;
LUSC	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg02018176	chr4:1364513	KIAA1530	0.43	6.18	0.32	1.89e-9	Recombination rate (females);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26985142	chr8:135724921	ZFAT	-0.46	-6.94	-0.36	2.08e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.55	9.23	0.45	3.15e-18	Bone mineral density;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03952484	chr1:149899818	SF3B4	0.42	6.3	0.33	9.55e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg17691542	chr6:26056736	HIST1H1C	0.56	7.89	0.4	4.46e-14	Iron status biomarkers;
LUSC	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.77	-0.35	5.91e-11	Response to antipsychotic treatment;
LUSC	cis	rs11958404	0.932	rs72816592	chr5:157435246	A/G	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs9807989	0.811	rs11688573	chr2:102969971	C/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.79	0.3	1.58e-8	Asthma;
LUSC	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg14438399	chr17:27053147	TLCD1	0.52	5.75	0.3	2.05e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	9.69	0.47	1.02e-19	Personality dimensions;
LUSC	cis	rs10266483	0.739	rs682662	chr7:63766485	C/T	cg24201672	chr7:64023550	ZNF680	-0.49	-6.56	-0.34	2.03e-10	Response to statin therapy;
LUSC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11644478	chr21:40555479	PSMG1	0.63	10.23	0.49	1.49e-21	Cognitive function;
LUSC	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg07936489	chr17:37558343	FBXL20	0.71	9.69	0.47	1e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.58	0.46	2.35e-19	Personality dimensions;
LUSC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.97	0.44	2.22e-17	Motion sickness;
LUSC	cis	rs524023	1.000	rs10792441	chr11:64360629	C/T	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.76	-0.3	1.91e-8	Urate levels in obese individuals;
LUSC	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.38	4.39e-13	Morning vs. evening chronotype;
LUSC	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	5.99	0.31	5.57e-9	Recombination rate (females);
LUSC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg26769984	chr7:1090371	C7orf50	0.54	7.4	0.38	1.15e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.81	14.01	0.61	2.04e-35	Metabolic syndrome;
LUSC	cis	rs17604090	0.877	rs57253003	chr7:29686556	T/C	cg19413766	chr7:29689036	LOC646762	-0.58	-6.93	-0.35	2.12e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	trans	rs225245	0.817	rs225273	chr17:33970935	A/T	cg19694781	chr19:47549865	TMEM160	-0.41	-6.48	-0.33	3.21e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs1459104	0.866	rs28822225	chr11:54818606	C/G	cg15704280	chr7:45808275	SEPT13	0.72	6.27	0.32	1.14e-9	Body mass index;
LUSC	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg05926586	chr15:74592786	CCDC33	0.31	6.36	0.33	6.63e-10	Airflow obstruction;
LUSC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg05347473	chr6:146136440	FBXO30	-0.67	-11.39	-0.53	1.34e-25	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg25214090	chr10:38739885	LOC399744	-0.38	-6.06	-0.31	3.66e-9	Diastolic blood pressure;
LUSC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03352830	chr11:487213	PTDSS2	0.68	8.61	0.43	2.91e-16	Body mass index;
LUSC	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg10547527	chr2:198650123	BOLL	-0.5	-5.86	-0.31	1.12e-8	Ulcerative colitis;
LUSC	cis	rs7224314	1.000	rs8070284	chr17:65387400	A/G	cg01507342	chr17:65387096	PITPNC1	-0.44	-7.79	-0.39	8.5e-14	Diisocyanate-induced asthma;
LUSC	cis	rs7712401	0.601	rs397731	chr5:122322959	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.48	-0.46	4.83e-19	Mean platelet volume;
LUSC	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg27087555	chr16:88793112	FAM38A	-1.37	-10.73	-0.51	2.82e-23	Plateletcrit;
LUSC	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.44	-5.92	-0.31	7.93e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg17724175	chr1:150552817	MCL1	-0.34	-5.84	-0.3	1.25e-8	Tonsillectomy;
LUSC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg23743428	chr13:21893420	NA	-0.42	-8.77	-0.43	9.44e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.96	-12.45	-0.56	1.77e-29	Exhaled nitric oxide output;
LUSC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg15649852	chr7:65879115	NA	-0.41	-5.79	-0.3	1.6e-8	Aortic root size;
LUSC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.65	13.64	0.6	5.57e-34	Monocyte percentage of white cells;
LUSC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08048268	chr3:133502702	NA	-0.46	-8.87	-0.44	4.36e-17	Iron status biomarkers;
LUSC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg06618935	chr21:46677482	NA	-0.37	-7.26	-0.37	2.69e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg06606381	chr12:133084897	FBRSL1	-0.92	-8.75	-0.43	1.06e-16	Depression;
LUSC	cis	rs9649213	0.511	rs6950994	chr7:97887872	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.51	-0.38	5.3e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg23630131	chr7:65973040	NA	-0.21	-5.93	-0.31	7.77e-9	Aortic root size;
LUSC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg18477163	chr1:228402036	OBSCN	-0.56	-10.21	-0.49	1.83e-21	Diastolic blood pressure;
LUSC	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg23711669	chr6:146136114	FBXO30	-0.86	-15.24	-0.64	3.42e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg26408565	chr15:76604113	ETFA	-0.49	-7.82	-0.39	6.87e-14	Blood metabolite levels;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg00024416	chr22:24240387	NA	-0.33	-5.72	-0.3	2.32e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg08999081	chr20:33150536	PIGU	0.46	8.32	0.41	2.2e-15	Coronary artery disease;
LUSC	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.92e-20	Coronary artery disease;
LUSC	cis	rs6062496	0.631	rs6062300	chr20:62303794	G/A	cg27236539	chr20:62289627	RTEL1	0.7	10.9	0.51	7.21e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	7.23	0.37	3.31e-12	Cognitive ability;
LUSC	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg23601416	chr22:19950040	COMT	-0.42	-8.63	-0.43	2.48e-16	Blood metabolite levels;
LUSC	cis	rs9462027	0.628	rs58671447	chr6:34752351	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.11e-8	Systemic lupus erythematosus;
LUSC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.51	0.59	1.77e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8018967	1.000	rs8018967	chr14:73976934	A/G	cg08936952	chr14:74026160	HEATR4	0.42	7.31	0.37	2.01e-12	Blood metabolite ratios;
LUSC	cis	rs10744422	0.843	rs3896870	chr12:123333611	T/C	cg25930673	chr12:123319894	HIP1R	-0.69	-6.93	-0.35	2.22e-11	Schizophrenia;
LUSC	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg05343316	chr1:45956843	TESK2	0.63	9.1	0.45	8.39e-18	Platelet count;
LUSC	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	trans	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.71e-10	Life satisfaction;
LUSC	trans	rs225245	0.817	rs225269	chr17:33967931	G/T	cg19694781	chr19:47549865	TMEM160	-0.42	-6.6	-0.34	1.66e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs926938	0.501	rs360686	chr1:115502524	C/T	cg01522456	chr1:115632236	TSPAN2	-0.44	-6.77	-0.35	5.98e-11	Autism;
LUSC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg08125733	chr17:73851984	WBP2	0.5	7.01	0.36	1.31e-11	White matter hyperintensity burden;
LUSC	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08045932	chr20:61659980	NA	0.55	9.23	0.45	3.17e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg21849932	chr20:62369462	LIME1	-0.4	-5.84	-0.3	1.22e-8	Prostate cancer;
LUSC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg27535305	chr1:53392650	SCP2	-0.4	-7.53	-0.38	4.72e-13	Monocyte count;
LUSC	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg27411982	chr8:10470053	RP1L1	0.4	6.1	0.32	3.02e-9	Retinal vascular caliber;
LUSC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11764359	chr7:65958608	NA	0.68	10.96	0.51	4.39e-24	Aortic root size;
LUSC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-0.64	-13.61	-0.6	7.4e-34	Prudent dietary pattern;
LUSC	cis	rs13315871	1.000	rs9821570	chr3:58335919	C/G	cg12435725	chr3:58293450	RPP14	-0.71	-7.65	-0.39	2.21e-13	Cholesterol, total;
LUSC	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg11887960	chr12:57824829	NA	0.58	7.11	0.36	7.27e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.82	-15.21	-0.64	4.55e-40	Dental caries;
LUSC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.79	-0.35	5.05e-11	Lung cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07792560	chr11:66056572	YIF1A	0.73	6.18	0.32	1.91e-9	Cognitive performance;
LUSC	trans	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.66	-0.34	1.16e-10	Endometrial cancer;
LUSC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg19912559	chr1:40204330	PPIE	-0.52	-8.0	-0.4	2.01e-14	Blood protein levels;
LUSC	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg00825309	chr19:58991885	ZNF446	-0.5	-7.22	-0.37	3.64e-12	Uric acid clearance;
LUSC	cis	rs11997175	0.603	rs7464053	chr8:33786938	C/A	ch.8.33884649F	chr8:33765107	NA	0.44	6.57	0.34	1.97e-10	Body mass index;
LUSC	cis	rs662064	0.852	rs617728	chr1:10566522	C/T	cg20482658	chr1:10539492	PEX14	0.32	6.44	0.33	4.11e-10	Asthma;
LUSC	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07169764	chr2:136633963	MCM6	-0.7	-10.23	-0.49	1.52e-21	Mosquito bite size;
LUSC	trans	rs11039798	0.920	rs11039848	chr11:48598243	C/T	cg15704280	chr7:45808275	SEPT13	0.75	6.42	0.33	4.65e-10	Axial length;
LUSC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.62	-0.34	1.42e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-8.02	-0.4	1.78e-14	Obesity-related traits;
LUSC	cis	rs1577917	0.958	rs1838958	chr6:86563968	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs7851660	0.809	rs7032086	chr9:100656402	T/G	cg13688889	chr9:100608707	NA	-0.55	-8.51	-0.42	6.16e-16	Strep throat;
LUSC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg01416388	chr22:39784598	NA	-0.46	-7.83	-0.39	6.56e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05901451	chr6:126070800	HEY2	0.87	16.25	0.66	3.79e-44	Brugada syndrome;
LUSC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg21724239	chr8:58056113	NA	0.78	9.27	0.45	2.34e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs34638657	0.673	rs11645286	chr16:82201898	C/A	cg09439754	chr16:82129088	HSD17B2	-0.34	-5.72	-0.3	2.41e-8	Lung adenocarcinoma;
LUSC	cis	rs977987	0.806	rs35683383	chr16:75479277	G/T	cg03315344	chr16:75512273	CHST6	0.53	10.45	0.5	2.61e-22	Dupuytren's disease;
LUSC	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg23711669	chr6:146136114	FBXO30	-0.83	-14.87	-0.63	9.93e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg07382826	chr16:28625726	SULT1A1	0.27	5.86	0.31	1.12e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.13	17.23	0.69	4.9e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg21573476	chr21:45109991	RRP1B	0.41	6.56	0.34	2.03e-10	Mean corpuscular volume;
LUSC	cis	rs7567389	0.510	rs1473623	chr2:128196220	T/C	cg06038358	chr2:128176007	PROC	-0.3	-5.98	-0.31	5.71e-9	Self-rated health;
LUSC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg26335602	chr6:28129616	ZNF389	0.43	5.91	0.31	8.24e-9	Parkinson's disease;
LUSC	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg02018176	chr4:1364513	KIAA1530	0.47	6.13	0.32	2.53e-9	Recombination rate (females);
LUSC	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg23241863	chr10:102295624	HIF1AN	0.49	5.98	0.31	5.84e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg03340356	chr1:67600835	NA	0.41	6.63	0.34	1.36e-10	Psoriasis;
LUSC	cis	rs12681287	0.547	rs7461366	chr8:87511685	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs2710642	0.962	rs7567923	chr2:63085848	C/T	cg17519650	chr2:63277830	OTX1	-0.49	-6.93	-0.35	2.14e-11	LDL cholesterol levels;LDL cholesterol;
LUSC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg23590916	chr17:43697445	MGC57346	-0.49	-6.61	-0.34	1.52e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg17376030	chr22:41985996	PMM1	0.5	6.31	0.33	9.09e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.34	-0.37	1.65e-12	Psoriasis;
LUSC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg22823121	chr1:150693482	HORMAD1	0.59	9.05	0.44	1.17e-17	Tonsillectomy;
LUSC	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg23719950	chr11:63933701	MACROD1	-0.63	-8.07	-0.4	1.24e-14	Mean platelet volume;
LUSC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.97	-0.44	2.16e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.51	0.69	3.59e-49	Chronic sinus infection;
LUSC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg26304593	chr6:42947056	PEX6	-0.46	-7.0	-0.36	1.44e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg25214090	chr10:38739885	LOC399744	0.42	6.54	0.34	2.27e-10	Corneal astigmatism;
LUSC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.7	0.39	1.61e-13	Prudent dietary pattern;
LUSC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg27588902	chr6:42928151	GNMT	0.28	6.41	0.33	4.82e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	0.93	17.54	0.69	2.66e-49	Heart rate;
LUSC	cis	rs2274273	0.870	rs10139000	chr14:55849876	G/T	cg04306507	chr14:55594613	LGALS3	0.53	11.9	0.55	1.9e-27	Protein biomarker;
LUSC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.46	-0.33	3.71e-10	Total body bone mineral density;
LUSC	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg17054900	chr3:154042577	DHX36	0.44	5.73	0.3	2.3e-8	Coronary artery disease;
LUSC	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg05147244	chr20:61493195	TCFL5	0.88	6.59	0.34	1.69e-10	Obesity-related traits;
LUSC	trans	rs2392780	0.536	rs622556	chr8:128333197	C/T	cg10195415	chr17:73887371	TRIM65	-0.4	-6.4	-0.33	5.21e-10	Breast cancer (early onset);
LUSC	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg07936489	chr17:37558343	FBXL20	0.71	9.91	0.48	1.88e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs16854884	0.586	rs6440212	chr3:143748526	T/C	cg06585982	chr3:143692056	C3orf58	0.52	8.29	0.41	2.86e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.94	-0.31	6.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12101261	1.000	rs17111346	chr14:81452172	G/A	cg06600135	chr14:81408086	NA	0.43	6.27	0.32	1.09e-9	Graves' disease;
LUSC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.74	8.67	0.43	1.88e-16	Schizophrenia;
LUSC	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg24296786	chr1:45957014	TESK2	-0.49	-7.23	-0.37	3.35e-12	High light scatter reticulocyte count;
LUSC	cis	rs2446066	0.799	rs11610326	chr12:53841854	G/T	cg20730629	chr12:53886622	MAP3K12	-0.43	-5.79	-0.3	1.63e-8	Red blood cell count;
LUSC	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg05855489	chr10:104503620	C10orf26	0.58	8.69	0.43	1.62e-16	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.53	-8.04	-0.4	1.62e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-7.02	-0.36	1.24e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg16482183	chr6:26056742	HIST1H1C	0.56	8.01	0.4	1.89e-14	Iron status biomarkers;
LUSC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg12310025	chr6:25882481	NA	-0.52	-9.54	-0.46	3.22e-19	Blood metabolite levels;
LUSC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg06740227	chr12:86229804	RASSF9	0.42	6.55	0.34	2.21e-10	Major depressive disorder;
LUSC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	trans	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg25214090	chr10:38739885	LOC399744	0.5	7.47	0.38	6.93e-13	Corneal astigmatism;
LUSC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg13010199	chr12:38710504	ALG10B	0.68	10.59	0.5	8.44e-23	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9815354	0.857	rs12108064	chr3:42016217	C/T	cg03022575	chr3:42003672	ULK4	0.56	5.92	0.31	7.96e-9	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4700695	0.719	rs36922	chr5:65464856	C/T	cg21114390	chr5:65439923	SFRS12	-0.65	-9.28	-0.45	2.12e-18	Facial morphology (factor 19);
LUSC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg26695010	chr11:65641043	EFEMP2	-0.51	-7.72	-0.39	1.35e-13	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	ch.11.42038R	chr11:967971	AP2A2	0.41	6.16	0.32	2.14e-9	Alzheimer's disease (late onset);
LUSC	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg10356904	chr22:49881777	NA	-0.34	-7.43	-0.38	8.98e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg08975724	chr8:8085496	FLJ10661	0.46	6.74	0.35	6.94e-11	Retinal vascular caliber;
LUSC	trans	rs867371	0.519	rs1566559	chr15:82524461	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.33	-0.33	7.96e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs4132509	0.739	rs10927033	chr1:243695539	C/A	cg21452805	chr1:244014465	NA	0.61	6.21	0.32	1.57e-9	RR interval (heart rate);
LUSC	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg04586622	chr2:25135609	ADCY3	0.42	8.99	0.44	1.87e-17	Body mass index;
LUSC	trans	rs7980799	0.649	rs7972688	chr12:33653477	T/C	cg13010199	chr12:38710504	ALG10B	-0.42	-6.03	-0.31	4.25e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs8133932	0.690	rs432338	chr21:47347757	C/T	cg14185626	chr21:47401492	COL6A1	-0.44	-5.65	-0.3	3.37e-8	Schizophrenia;
LUSC	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg00277334	chr10:82204260	NA	-0.55	-7.36	-0.37	1.44e-12	Post bronchodilator FEV1;
LUSC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17971929	chr21:40555470	PSMG1	-0.57	-9.08	-0.44	1e-17	Cognitive function;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20338300	chr2:56411534	CCDC85A	0.7	6.34	0.33	7.45e-10	Cognitive performance;
LUSC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg04315214	chr1:2043799	PRKCZ	-0.38	-7.54	-0.38	4.59e-13	Height;
LUSC	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg10547527	chr2:198650123	BOLL	-0.5	-5.85	-0.3	1.16e-8	Ulcerative colitis;
LUSC	cis	rs400736	0.930	rs2745722	chr1:8056669	G/A	cg25007680	chr1:8021821	PARK7	0.58	9.16	0.45	5.22e-18	Response to antidepressants and depression;
LUSC	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg05342945	chr12:48394962	COL2A1	-0.46	-6.22	-0.32	1.52e-9	Lung cancer;
LUSC	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg20701182	chr2:24300061	SF3B14	0.88	11.42	0.53	1.05e-25	Lymphocyte counts;
LUSC	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg10857441	chr5:6722123	POLS	-0.45	-8.31	-0.41	2.44e-15	Menopause (age at onset);
LUSC	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg08807101	chr21:30365312	RNF160	-0.66	-10.55	-0.5	1.2e-22	Pancreatic cancer;
LUSC	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg26597838	chr10:835615	NA	0.45	5.84	0.3	1.23e-8	Response to angiotensin II receptor blocker therapy;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg17888837	chr1:27986674	NA	0.62	6.06	0.31	3.65e-9	Body mass index;
LUSC	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg06547715	chr2:218990976	CXCR2	-0.32	-6.22	-0.32	1.5e-9	Ulcerative colitis;
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg12034118	chr1:209979487	IRF6	0.74	14.11	0.61	8.8e-36	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.47	0.59	2.55e-33	Morning vs. evening chronotype;
LUSC	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.96	15.61	0.65	1.2e-41	Lymphocyte percentage of white cells;
LUSC	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg20307385	chr11:47447363	PSMC3	0.46	6.77	0.35	5.93e-11	Subjective well-being;
LUSC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00166722	chr3:10149974	C3orf24	0.55	7.63	0.39	2.48e-13	Alzheimer's disease;
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg17450446	chr1:160002111	PIGM	0.4	6.1	0.32	2.95e-9	Eotaxin levels;
LUSC	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg09654669	chr8:57350985	NA	-0.57	-7.87	-0.4	5.1e-14	Obesity-related traits;
LUSC	cis	rs7512552	0.839	rs12040949	chr1:150447462	C/T	cg15654264	chr1:150340011	RPRD2	0.65	10.78	0.51	1.9e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg26354017	chr1:205819088	PM20D1	0.52	8.56	0.42	4.21e-16	Menarche (age at onset);
LUSC	trans	rs10432489	0.708	rs12693263	chr2:181740210	A/G	cg11196870	chr8:41386826	GINS4	-0.88	-5.96	-0.31	6.38e-9	QT interval;
LUSC	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg03929089	chr4:120376271	NA	-0.82	-11.24	-0.52	4.28e-25	Coronary artery disease;
LUSC	cis	rs240764	0.680	rs239234	chr6:101101234	G/A	cg09795085	chr6:101329169	ASCC3	0.41	5.97	0.31	6.12e-9	Neuroticism;
LUSC	trans	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.84	0.39	6.22e-14	Colorectal cancer;
LUSC	cis	rs9640161	0.783	rs2021871	chr7:150071156	T/C	cg17279839	chr7:150038598	RARRES2	0.35	5.76	0.3	1.92e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg05738196	chr6:26577821	NA	-0.66	-10.51	-0.5	1.62e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7903847	0.620	rs2297988	chr10:99118382	A/G	cg08345082	chr10:99160200	RRP12	-0.35	-6.96	-0.36	1.82e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg13206674	chr6:150067644	NUP43	0.57	9.11	0.45	7.79e-18	Lung cancer;
LUSC	cis	rs9487051	0.768	rs461487	chr6:109525504	A/G	cg01475377	chr6:109611718	NA	-0.35	-5.89	-0.31	9.21e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs12912251	1.000	rs12901215	chr15:38992893	G/A	cg01338139	chr15:38987640	C15orf53	-0.51	-6.89	-0.35	2.74e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19346786	chr7:2764209	NA	-0.38	-6.58	-0.34	1.82e-10	Height;
LUSC	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.78	11.15	0.52	9.7e-25	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg15145296	chr3:125709740	NA	-0.58	-6.56	-0.34	2.01e-10	Blood pressure (smoking interaction);
LUSC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg06742321	chr12:123595122	PITPNM2	0.37	5.68	0.3	2.88e-8	Platelet count;
LUSC	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg03859395	chr2:55845619	SMEK2	-0.84	-15.01	-0.63	2.9e-39	Metabolic syndrome;
LUSC	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg13798780	chr7:105162888	PUS7	0.55	5.72	0.3	2.34e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-10.32	-0.49	7.39e-22	Bipolar disorder;
LUSC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-7.31	-0.37	2e-12	Total body bone mineral density;
LUSC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg20887711	chr4:1340912	KIAA1530	0.54	8.27	0.41	3.22e-15	Obesity-related traits;
LUSC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg12463550	chr7:65579703	CRCP	0.56	8.35	0.42	1.79e-15	Aortic root size;
LUSC	cis	rs727505	1.000	rs34986416	chr7:124441017	A/G	cg23710748	chr7:124431027	NA	-0.44	-7.84	-0.39	5.92e-14	Lewy body disease;
LUSC	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg09092052	chr15:45571596	NA	0.47	6.53	0.34	2.4e-10	Glomerular filtration rate;
LUSC	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg25575065	chr22:51066394	ARSA	-0.42	-5.81	-0.3	1.46e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9039	0.550	rs12924785	chr16:9219285	T/G	cg08831531	chr16:9218945	NA	-0.55	-8.93	-0.44	2.9e-17	Menopause (age at onset);
LUSC	trans	rs7568069	0.864	rs7609266	chr2:71530558	G/C	cg06465196	chr4:154387603	KIAA0922	0.42	6.04	0.31	4.18e-9	Height;
LUSC	trans	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	13.77	0.6	1.75e-34	Exhaled nitric oxide levels;
LUSC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg00784671	chr22:46762841	CELSR1	-0.48	-5.97	-0.31	6.04e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07167872	chr1:205819463	PM20D1	0.89	17.21	0.69	5.49e-48	Menarche (age at onset);
LUSC	cis	rs7241530	0.636	rs8096302	chr18:75909790	T/A	cg14642773	chr18:75888474	NA	0.39	5.74	0.3	2.17e-8	Educational attainment (years of education);
LUSC	cis	rs9311676	0.656	rs12496906	chr3:58390490	A/C	cg26110898	chr3:58419937	PDHB	0.4	6.42	0.33	4.56e-10	Systemic lupus erythematosus;
LUSC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg03929089	chr4:120376271	NA	-0.85	-11.71	-0.54	9.13e-27	Coronary artery disease;
LUSC	trans	rs9860340	0.730	rs1509781	chr3:87641568	A/T	cg03644585	chr7:884825	UNC84A	0.42	6.03	0.31	4.35e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs2262909	0.962	rs436662	chr19:22232107	C/T	cg11619707	chr19:22235551	ZNF257	-0.38	-5.7	-0.3	2.7e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg00310523	chr12:86230176	RASSF9	-0.43	-8.03	-0.4	1.67e-14	Major depressive disorder;
LUSC	cis	rs62400317	0.859	rs12193030	chr6:45175210	G/A	cg20913747	chr6:44695427	NA	-0.48	-7.69	-0.39	1.64e-13	Total body bone mineral density;
LUSC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg19318889	chr4:1322082	MAEA	0.47	7.68	0.39	1.78e-13	Obesity-related traits;
LUSC	cis	rs9653442	0.545	rs1821826	chr2:100764711	C/T	cg07810366	chr2:100720526	AFF3	-0.45	-7.68	-0.39	1.83e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg21775007	chr8:11205619	TDH	-0.48	-6.54	-0.34	2.3e-10	Triglycerides;
LUSC	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg15997130	chr1:24165203	NA	0.52	8.58	0.43	3.6e-16	Immature fraction of reticulocytes;
LUSC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg03146154	chr1:46216737	IPP	-0.57	-8.19	-0.41	5.73e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg13206674	chr6:150067644	NUP43	0.61	9.82	0.47	3.55e-20	Lung cancer;
LUSC	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg03975922	chr5:140080575	ZMAT2	0.34	6.26	0.32	1.21e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-7.5	-0.38	6e-13	Axial length;
LUSC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg18225595	chr11:63971243	STIP1	0.5	6.28	0.32	1.06e-9	Mean platelet volume;
LUSC	cis	rs10193935	0.901	rs10171643	chr2:42532912	C/T	cg27598129	chr2:42591480	NA	-0.58	-8.14	-0.41	7.94e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	0.83	11.39	0.53	1.26e-25	Menopause (age at onset);
LUSC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	12.16	0.55	2.13e-28	Cognitive test performance;
LUSC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07677032	chr17:61819896	STRADA	0.55	9.25	0.45	2.78e-18	Prudent dietary pattern;
LUSC	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg14552801	chr7:65878734	NA	-0.43	-6.09	-0.32	3.05e-9	Aortic root size;
LUSC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg11062466	chr8:58055876	NA	0.58	8.18	0.41	6.01e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg09034736	chr1:150693464	HORMAD1	0.46	6.74	0.35	6.87e-11	Tonsillectomy;
LUSC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.89	12.33	0.56	5.01e-29	Smoking behavior;
LUSC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.31	-0.37	1.96e-12	Menopause (age at onset);
LUSC	cis	rs6494488	0.500	rs1133357	chr15:64987570	G/A	cg08069370	chr15:64387884	SNX1	-0.68	-5.9	-0.31	8.97e-9	Coronary artery disease;
LUSC	cis	rs11997175	0.524	rs10954932	chr8:33650176	A/C	ch.8.33884649F	chr8:33765107	NA	0.51	8.34	0.42	1.94e-15	Body mass index;
LUSC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg10018233	chr7:150070692	REPIN1	-0.39	-7.0	-0.36	1.37e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs865483	0.929	rs853194	chr17:35848045	A/C	cg06716730	chr17:35851459	DUSP14	0.28	6.21	0.32	1.54e-9	Monocyte count;
LUSC	cis	rs9650315	0.866	rs7822536	chr8:57168085	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	6.87	0.35	3.07e-11	Height;
LUSC	cis	rs6977660	0.714	rs12530537	chr7:19822641	A/G	cg07541023	chr7:19748670	TWISTNB	-0.56	-6.12	-0.32	2.61e-9	Thyroid stimulating hormone;
LUSC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.72	-9.95	-0.48	1.38e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg25930673	chr12:123319894	HIP1R	-0.63	-6.23	-0.32	1.41e-9	Schizophrenia;
LUSC	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg00757033	chr12:89920650	WDR51B	0.54	9.46	0.46	5.91e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19372772	chr2:264904	ACP1;SH3YL1	-0.45	-6.41	-0.33	4.86e-10	Electrocardiographic conduction measures;
LUSC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg22535103	chr8:58192502	C8orf71	-0.79	-8.06	-0.4	1.36e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	14.04	0.61	1.6e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg21918786	chr6:109611834	NA	-0.42	-7.34	-0.37	1.6e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2708377	0.858	rs73051630	chr12:11147188	G/A	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.83	8.18	0.41	5.97e-15	Bitter taste perception;
LUSC	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg03676636	chr4:99064102	C4orf37	0.36	8.04	0.4	1.54e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg17644776	chr2:200775616	C2orf69	0.4	6.27	0.32	1.12e-9	Schizophrenia;
LUSC	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	1.13	19.9	0.74	1.14e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg02403541	chr12:121454288	C12orf43	0.59	8.45	0.42	8.98e-16	N-glycan levels;
LUSC	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.21	-0.37	3.65e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg12863693	chr15:85201151	NMB	0.36	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg24250549	chr1:154909240	PMVK	-0.42	-6.34	-0.33	7.36e-10	Prostate cancer;
LUSC	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg23625390	chr15:77176239	SCAPER	0.53	8.31	0.41	2.43e-15	Blood metabolite levels;
LUSC	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg22852734	chr6:133119734	C6orf192	1.25	10.76	0.51	2.15e-23	Type 2 diabetes nephropathy;
LUSC	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	1.03	12.16	0.55	2.04e-28	Schizophrenia;
LUSC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.17	0.58	3.43e-32	Chronic sinus infection;
LUSC	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg25019033	chr10:957182	NA	-0.58	-7.64	-0.39	2.3e-13	Eosinophil percentage of granulocytes;
LUSC	cis	rs55665837	1.000	rs10832256	chr11:14442875	G/A	cg05501817	chr11:14380813	RRAS2	-0.41	-6.61	-0.34	1.51e-10	Vitamin D levels;
LUSC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.27e-31	Prudent dietary pattern;
LUSC	cis	rs9650315	0.866	rs72656034	chr8:57194766	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	7.13	0.36	6.25e-12	Height;
LUSC	trans	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.78	-0.39	8.95e-14	Morning vs. evening chronotype;
LUSC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg27170947	chr2:26402098	FAM59B	-0.66	-9.56	-0.46	2.57e-19	Gut microbiome composition (summer);
LUSC	cis	rs9399401	0.634	rs984932	chr6:142803037	C/T	cg03128060	chr6:142623767	GPR126	0.41	6.82	0.35	4.39e-11	Chronic obstructive pulmonary disease;
LUSC	cis	rs11866815	0.817	rs9935993	chr16:401209	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.4	-6.34	-0.33	7.24e-10	Body mass index;
LUSC	cis	rs7188861	0.768	rs423674	chr16:11373405	G/T	cg00044050	chr16:11439710	C16orf75	0.54	6.1	0.32	2.87e-9	HDL cholesterol;
LUSC	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg03585969	chr10:35415529	CREM	0.58	8.67	0.43	1.87e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.57	-0.38	3.74e-13	Tonsillectomy;
LUSC	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg08079166	chr15:68083412	MAP2K5	0.35	5.97	0.31	5.96e-9	Obesity;
LUSC	cis	rs7605827	0.930	rs11692624	chr2:15499127	C/T	cg19274914	chr2:15703543	NA	0.46	8.88	0.44	4.15e-17	Educational attainment (years of education);
LUSC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08859206	chr1:53392774	SCP2	-0.68	-12.93	-0.58	2.87e-31	Monocyte count;
LUSC	trans	rs4800353	0.929	rs9952389	chr18:19608773	T/G	cg01841828	chr16:69166849	CHTF8;CIRH1A	-0.58	-6.05	-0.31	3.85e-9	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs6469656	1.000	rs6469656	chr8:117647788	G/A	cg24004040	chr8:117650383	NA	-0.43	-6.19	-0.32	1.81e-9	Colorectal cancer;
LUSC	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.72	-10.45	-0.5	2.7e-22	Smoking initiation;
LUSC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.72	-6.82	-0.35	4.31e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs12474201	0.928	rs17822019	chr2:46934505	T/C	cg06386533	chr2:46925753	SOCS5	0.78	11.76	0.54	6.14e-27	Height;
LUSC	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg02696742	chr7:106810147	HBP1	-0.63	-9.51	-0.46	3.83e-19	Coronary artery disease;
LUSC	cis	rs4363385	0.530	rs10888529	chr1:153050654	G/T	cg00922841	chr1:152955080	SPRR1A	-0.39	-6.64	-0.34	1.27e-10	Inflammatory skin disease;
LUSC	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg27284194	chr4:1044797	NA	0.49	7.68	0.39	1.8e-13	Recombination rate (males);
LUSC	cis	rs17739794	0.517	rs6559193	chr8:775451	C/T	cg01971667	chr8:817044	NA	-0.41	-6.53	-0.34	2.51e-10	Clozapine-induced cytotoxicity;
LUSC	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.95	-0.36	1.91e-11	Schizophrenia;
LUSC	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.8	-0.39	8.23e-14	Triglycerides;
LUSC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg26566898	chr11:117069891	TAGLN	0.48	8.57	0.42	3.81e-16	Blood protein levels;
LUSC	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg07945448	chr16:4304224	NA	0.46	6.58	0.34	1.77e-10	Prostate-specific antigen levels;
LUSC	cis	rs9403521	1.000	rs7776119	chr6:144003643	A/G	cg18240653	chr6:144019428	PHACTR2	-0.48	-5.93	-0.31	7.7e-9	Obesity-related traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04794120	chr7:48019205	HUS1	-0.37	-6.11	-0.32	2.84e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7598759	0.527	rs12987949	chr2:232367511	A/G	cg19187155	chr2:232395269	NMUR1	0.93	16.05	0.66	2.33e-43	Noise-induced hearing loss;
LUSC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.46	-0.38	7.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7809950	0.817	rs2712195	chr7:107127496	C/T	cg23024343	chr7:107201750	COG5	-0.68	-10.18	-0.49	2.17e-21	Coronary artery disease;
LUSC	cis	rs4343996	1.000	rs6966619	chr7:3359491	A/T	cg21248987	chr7:3385318	SDK1	0.39	6.5	0.33	2.98e-10	Motion sickness;
LUSC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.14	-0.32	2.38e-9	Neutrophil percentage of white cells;
LUSC	cis	rs524023	0.914	rs7932437	chr11:64373504	T/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.5	-0.5	1.8e-22	Urate levels in obese individuals;
LUSC	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	7.21	0.37	3.7e-12	HDL cholesterol;
LUSC	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.63	-9.82	-0.47	3.7799999999999997e-20	Morning vs. evening chronotype;
LUSC	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg12163867	chr12:51592794	POU6F1	0.37	6.09	0.32	3.17e-9	Cisplatin-induced ototoxicity;
LUSC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg15790184	chr11:494944	RNH1	0.59	6.36	0.33	6.8e-10	Body mass index;
LUSC	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg24006582	chr15:45444508	DUOX1	-0.61	-8.95	-0.44	2.44e-17	Uric acid levels;
LUSC	cis	rs2348418	0.715	rs12307709	chr12:28719700	G/A	cg13890972	chr12:28721907	NA	-0.39	-6.87	-0.35	3.24e-11	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs2425143	1.000	rs11696947	chr20:34312658	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.27	-0.32	1.14e-9	Blood protein levels;
LUSC	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg25319279	chr11:5960081	NA	-0.44	-6.2	-0.32	1.63e-9	DNA methylation (variation);
LUSC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg05025164	chr4:1340916	KIAA1530	-0.5	-7.63	-0.39	2.48e-13	Obesity-related traits;
LUSC	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	12.25	0.56	9.92e-29	Electrocardiographic conduction measures;
LUSC	cis	rs11264799	0.603	rs12118837	chr1:157561302	G/A	cg18268488	chr1:157545234	FCRL4	0.35	6.23	0.32	1.39e-9	IgA nephropathy;
LUSC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg11211951	chr8:145729740	GPT	-0.54	-10.75	-0.51	2.5e-23	Age at first birth;
LUSC	trans	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	7.41	0.38	1.05e-12	Menarche (age at onset);
LUSC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg04450456	chr4:17643702	FAM184B	0.39	6.73	0.35	7.39e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg21053147	chr12:120880522	NA	-0.48	-5.83	-0.3	1.33e-8	Type 1 diabetes nephropathy;
LUSC	cis	rs7605827	0.930	rs11902167	chr2:15494391	C/T	cg19274914	chr2:15703543	NA	0.44	8.31	0.41	2.47e-15	Educational attainment (years of education);
LUSC	cis	rs10489202	1.000	rs4656564	chr1:167928992	T/C	cg24449463	chr1:168025552	DCAF6	-0.57	-7.28	-0.37	2.47e-12	Schizophrenia;
LUSC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.64	8.49	0.42	7.04e-16	High light scatter reticulocyte count;
LUSC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg03146154	chr1:46216737	IPP	0.51	7.68	0.39	1.8e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.94	0.55	1.27e-27	Personality dimensions;
LUSC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg18230493	chr5:56204884	C5orf35	-0.87	-13.23	-0.59	2.01e-32	Initial pursuit acceleration;
LUSC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg04691961	chr3:161091175	C3orf57	-0.36	-6.12	-0.32	2.6e-9	Morning vs. evening chronotype;
LUSC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-0.93	-15.59	-0.65	1.53e-41	Body mass index;
LUSC	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg18478394	chr8:109455254	TTC35	0.41	6.33	0.33	7.89e-10	Dupuytren's disease;
LUSC	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg23711669	chr6:146136114	FBXO30	0.81	14.15	0.61	5.9e-36	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg09877947	chr5:131593287	PDLIM4	0.42	6.86	0.35	3.42e-11	Blood metabolite levels;
LUSC	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg13575925	chr12:9217583	LOC144571	0.35	6.29	0.33	9.93e-10	Sjögren's syndrome;
LUSC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg05347473	chr6:146136440	FBXO30	-0.48	-8.04	-0.4	1.55e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11645453	chr3:52864694	ITIH4	0.56	13.65	0.6	5.3e-34	Schizophrenia;
LUSC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	0.93	16.05	0.66	2.27e-43	Menopause (age at onset);
LUSC	cis	rs8051149	0.576	rs731710	chr16:87884547	A/G	cg01412419	chr16:87856264	NA	0.4	6.59	0.34	1.76e-10	Blood metabolite levels;
LUSC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg05872129	chr22:39784769	NA	-0.54	-8.03	-0.4	1.64e-14	IgG glycosylation;
LUSC	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	7.53	0.38	4.9e-13	Schizophrenia;
LUSC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.62	11.17	0.52	7.65e-25	Birth weight;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17747171	chr20:2633605	NOP56;SNORD110	-0.47	-6.39	-0.33	5.62e-10	Hepatitis;
LUSC	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg13852791	chr20:30311386	BCL2L1	0.73	8.39	0.42	1.35e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs6977660	1.000	rs714238	chr7:19803925	C/T	cg07541023	chr7:19748670	TWISTNB	0.53	6.07	0.32	3.48e-9	Thyroid stimulating hormone;
LUSC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-1.23	-13.41	-0.59	4.23e-33	Diabetic kidney disease;
LUSC	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg24375607	chr4:120327624	NA	0.76	11.41	0.53	1.09e-25	Corneal astigmatism;
LUSC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.59	7.86	0.4	5.19e-14	Lung function (FEV1/FVC);
LUSC	trans	rs57046232	0.552	rs1305008	chr20:6324198	T/G	cg21095983	chr6:86352623	SYNCRIP	0.49	7.27	0.37	2.59e-12	Colorectal cancer;
LUSC	cis	rs354225	0.584	rs11898033	chr2:54821518	G/A	cg01766943	chr2:54829624	SPTBN1	0.49	8.01	0.4	1.91e-14	Schizophrenia;
LUSC	cis	rs72949976	0.646	rs4673731	chr2:214028544	C/T	cg08319019	chr2:214017104	IKZF2	0.68	11.28	0.53	3.09e-25	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs2070433	0.800	rs2073380	chr21:47863757	A/C	cg12379764	chr21:47803548	PCNT	0.77	9.71	0.47	8.83e-20	Lymphocyte counts;
LUSC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.2	-0.37	3.92e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg07507251	chr3:52567010	NT5DC2	0.32	6.25	0.32	1.25e-9	Bipolar disorder;
LUSC	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg20891283	chr12:69753455	YEATS4	0.45	6.18	0.32	1.82e-9	Response to diuretic therapy;
LUSC	trans	rs2018683	1.000	rs740252	chr7:28997765	C/G	cg19402173	chr7:128379420	CALU	-0.58	-9.4	-0.46	9.23e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs3820928	1.000	rs61067328	chr2:227761256	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.96	-0.4	2.72e-14	Pulmonary function;
LUSC	cis	rs17490626	0.568	rs12413523	chr10:71211664	C/G	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.43	-0.46	7e-19	Thrombosis;
LUSC	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.86	15.12	0.64	1.06e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs10193935	0.901	rs222463	chr2:42644080	A/G	cg27598129	chr2:42591480	NA	-0.59	-8.0	-0.4	2.03e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2492906	0.600	rs1907396	chr10:28064886	A/G	cg18538961	chr14:101363192	MEG8	0.4	6.19	0.32	1.81e-9	Prostate-specific antigen levels (conditioned on lead SNPs);
LUSC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg21862992	chr11:68658383	NA	0.5	7.7	0.39	1.55e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs35883536	0.609	rs12747197	chr1:101036831	A/C	cg09408571	chr1:101003634	GPR88	-0.3	-5.82	-0.3	1.35e-8	Monocyte count;
LUSC	cis	rs9359856	0.956	rs6934804	chr6:90316020	A/G	cg13799429	chr6:90582589	CASP8AP2	0.51	6.0	0.31	5.1e-9	Bipolar disorder;
LUSC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg17279839	chr7:150038598	RARRES2	0.54	7.96	0.4	2.72e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9894429	0.527	rs7405469	chr17:79566596	G/C	cg18240062	chr17:79603768	NPLOC4	-0.55	-8.34	-0.42	2.01e-15	Eye color traits;
LUSC	cis	rs9650657	0.655	rs4841434	chr8:10586123	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-6.32	-0.33	8.31e-10	Neuroticism;
LUSC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg22676075	chr6:135203613	NA	0.48	7.51	0.38	5.47e-13	Red blood cell count;
LUSC	trans	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg23094728	chr5:56110263	MAP3K1	0.45	5.99	0.31	5.53e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.51	-0.38	5.33e-13	Electroencephalogram traits;
LUSC	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg04218760	chr10:45406644	TMEM72	-0.28	-6.85	-0.35	3.52e-11	Mean corpuscular volume;
LUSC	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg18681998	chr4:17616180	MED28	0.85	15.44	0.65	5.73e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg00990874	chr7:1149470	C7orf50	-0.59	-6.82	-0.35	4.4e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	9.02	0.44	1.52e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7617773	0.746	rs4130995	chr3:48358255	C/T	cg20734569	chr3:48348370	SPINK8	-0.42	-7.3	-0.37	2.09e-12	Coronary artery disease;
LUSC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg15103426	chr22:29168792	CCDC117	0.58	7.95	0.4	2.91e-14	Lymphocyte counts;
LUSC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg17279839	chr7:150038598	RARRES2	0.56	8.37	0.42	1.66e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.6	0.78	2.79e-69	Prudent dietary pattern;
LUSC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg01973587	chr1:228161476	NA	0.47	8.51	0.42	6.11e-16	Diastolic blood pressure;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07316298	chr16:32823289	NA	0.48	6.5	0.34	2.95e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	8.73	0.43	1.23e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg05343316	chr1:45956843	TESK2	-0.6	-8.22	-0.41	4.7e-15	Platelet count;
LUSC	cis	rs11676348	0.805	rs12694428	chr2:218958820	G/A	cg06547715	chr2:218990976	CXCR2	0.31	5.84	0.3	1.22e-8	Ulcerative colitis;
LUSC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.54	9.16	0.45	5.24e-18	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2692947	0.760	rs2438924	chr2:96645069	A/G	cg23100626	chr2:96804247	ASTL	0.23	5.76	0.3	1.93e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg02415014	chr8:143852576	LYNX1	-0.27	-6.06	-0.31	3.67e-9	Urinary tract infection frequency;
LUSC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg22907277	chr7:1156413	C7orf50	0.71	7.56	0.38	3.84e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs509208	0.818	rs679040	chr3:166031056	C/G	cg11340785	chr5:61374735	NA	0.38	5.96	0.31	6.55e-9	Alzheimer's disease biomarkers;
LUSC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg18225595	chr11:63971243	STIP1	0.49	6.08	0.32	3.24e-9	Mean platelet volume;
LUSC	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg05784532	chr1:230284198	GALNT2	0.49	7.39	0.38	1.16e-12	Coronary artery disease;
LUSC	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.72	10.6	0.5	8.19e-23	Smoking initiation;
LUSC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg02782426	chr3:40428986	ENTPD3	0.38	6.97	0.36	1.7e-11	Renal cell carcinoma;
LUSC	cis	rs28829049	0.535	rs12565185	chr1:19498309	G/A	cg13387374	chr1:19411106	UBR4	0.44	6.13	0.32	2.44e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs1595825	0.679	rs11685247	chr2:198466462	C/A	cg00982548	chr2:198649783	BOLL	-0.52	-6.52	-0.34	2.53e-10	Ulcerative colitis;
LUSC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg12310025	chr6:25882481	NA	-0.52	-9.63	-0.47	1.59e-19	Blood metabolite levels;
LUSC	cis	rs1775715	0.870	rs1251400	chr10:32235145	A/G	cg04359828	chr10:32216031	ARHGAP12	0.4	6.88	0.35	3.05e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg00049323	chr5:472564	LOC25845	0.5	7.77	0.39	9.86e-14	Cystic fibrosis severity;
LUSC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg05941027	chr17:61774174	LIMD2	0.23	6.4	0.33	5.39e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.03	-0.31	4.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg27170947	chr2:26402098	FAM59B	0.68	10.27	0.49	1.11e-21	Gut microbiome composition (summer);
LUSC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-1.07	-15.83	-0.65	1.64e-42	Initial pursuit acceleration;
LUSC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg11663144	chr21:46675770	NA	-0.4	-6.98	-0.36	1.57e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg24562669	chr7:97807699	LMTK2	0.35	6.23	0.32	1.4e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.28	0.32	1.07e-9	Corneal astigmatism;
LUSC	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg13010199	chr12:38710504	ALG10B	0.65	10.07	0.48	5.33e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg27068330	chr11:65405492	SIPA1	-0.76	-10.88	-0.51	8.57e-24	Acne (severe);
LUSC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	9.82	0.47	3.76e-20	Menopause (age at onset);
LUSC	cis	rs3770081	0.793	rs58186343	chr2:86218400	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.06	-6.77	-0.35	5.96e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg00012203	chr2:219082015	ARPC2	-0.71	-11.87	-0.54	2.36e-27	Colorectal cancer;
LUSC	cis	rs9341808	0.621	rs2322627	chr6:80806341	T/A	cg08355045	chr6:80787529	NA	0.61	11.51	0.53	4.97e-26	Sitting height ratio;
LUSC	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19717773	chr7:2847554	GNA12	-0.34	-6.0	-0.31	5.09e-9	Height;
LUSC	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.36	0.33	6.6e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg15468180	chr1:107600409	PRMT6	0.36	5.67	0.3	3.1e-8	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg00757033	chr12:89920650	WDR51B	0.59	10.22	0.49	1.69e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	6.72	0.35	7.91e-11	Schizophrenia;
LUSC	cis	rs7605827	0.930	rs13002869	chr2:15674389	C/T	cg19274914	chr2:15703543	NA	0.46	8.86	0.44	4.79e-17	Educational attainment (years of education);
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.9	16.83	0.68	1.82e-46	Menarche (age at onset);
LUSC	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg16342193	chr10:102329863	NA	0.31	5.78	0.3	1.67e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.27	-0.49	1.08e-21	Gut microbiome composition (summer);
LUSC	cis	rs1035144	0.524	rs8009260	chr14:81408591	G/T	cg06600135	chr14:81408086	NA	0.54	8.26	0.41	3.51e-15	Male sexual orientation;
LUSC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg07424592	chr7:64974309	NA	-0.65	-5.85	-0.3	1.19e-8	Diabetic kidney disease;
LUSC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.47	6.36	0.33	6.79e-10	Renal function-related traits (BUN);
LUSC	cis	rs6977660	0.619	rs10263780	chr7:19778086	A/G	cg07541023	chr7:19748670	TWISTNB	-0.68	-7.54	-0.38	4.62e-13	Thyroid stimulating hormone;
LUSC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-6.99	-0.36	1.53e-11	Menarche (age at onset);
LUSC	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	0.89	16.91	0.68	8.9e-47	Heart rate;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15535636	chr19:41284070	RAB4B	-0.4	-6.09	-0.32	3.14e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	0.57	8.88	0.44	4.09e-17	Breast cancer;
LUSC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	-0.45	-6.71	-0.34	8.25e-11	Systemic lupus erythematosus;
LUSC	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.79	-0.3	1.62e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg24069376	chr3:38537580	EXOG	0.47	9.34	0.45	1.44e-18	Electrocardiographic conduction measures;
LUSC	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.36	-0.33	6.77e-10	Response to antipsychotic treatment;
LUSC	trans	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg11887960	chr12:57824829	NA	0.53	6.58	0.34	1.83e-10	Obesity-related traits;
LUSC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-7.85	-0.39	5.8e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg23630131	chr7:65973040	NA	0.21	5.83	0.3	1.33e-8	Aortic root size;
LUSC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg06028605	chr16:24865363	SLC5A11	-0.58	-9.57	-0.46	2.51e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.720	rs1415968	chr1:152970219	C/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.79	-0.39	8.81e-14	Inflammatory skin disease;
LUSC	cis	rs8016982	0.674	rs3815953	chr14:81685482	G/A	cg01989461	chr14:81687754	GTF2A1	0.72	12.92	0.58	3.13e-31	Schizophrenia;
LUSC	cis	rs12410462	0.710	rs74140145	chr1:227423946	C/T	cg23173402	chr1:227635558	NA	0.47	5.9	0.31	8.93e-9	Major depressive disorder;
LUSC	trans	rs7939886	0.920	rs74699881	chr11:55913852	A/T	cg03929089	chr4:120376271	NA	0.75	5.95	0.31	6.62e-9	Myopia (pathological);
LUSC	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-1.26	-20.3	-0.74	3.11e-60	Blood pressure (smoking interaction);
LUSC	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg27284194	chr4:1044797	NA	0.59	8.84	0.44	5.65e-17	Recombination rate (females);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06620269	chr17:2952258	NA	-0.46	-6.16	-0.32	2.12e-9	Hepatitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01916762	chr5:59996028	DEPDC1B	-0.41	-6.12	-0.32	2.66e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.49	-6.95	-0.36	1.95e-11	Mean platelet volume;
LUSC	cis	rs13006833	0.668	rs2582746	chr2:191163784	T/C	cg21644426	chr2:191273491	MFSD6	0.44	6.31	0.33	8.8e-10	Urinary metabolites;
LUSC	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg07895657	chr22:50616420	PANX2	-0.36	-6.1	-0.32	2.94e-9	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27612695	chr17:29059191	SUZ12P	0.45	6.85	0.35	3.59e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9361491	0.543	rs1507153	chr6:79484386	C/A	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.06	-0.31	3.66e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12681287	0.547	rs9942793	chr8:87509091	C/T	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.55	-9.08	-0.45	9.43e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2932538	1.000	rs2932538	chr1:113216543	A/G	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.7	-0.47	9.01e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-1.19	-12.84	-0.57	5.85e-31	Diabetic kidney disease;
LUSC	cis	rs2637266	0.599	rs846574	chr10:78503082	G/A	cg18941641	chr10:78392320	NA	0.39	7.04	0.36	1.09e-11	Pulmonary function;
LUSC	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	trans	rs72674100	1.000	rs17026349	chr4:97979935	A/C	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19596991	chr10:126432951	FAM53B	-0.42	-6.5	-0.34	2.95e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg18904891	chr8:8559673	CLDN23	0.56	7.58	0.38	3.53e-13	Obesity-related traits;
LUSC	cis	rs9473147	0.543	rs9296559	chr6:47452270	T/C	cg20196966	chr6:47445060	CD2AP	0.42	5.94	0.31	7.29e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	9.29	0.45	2.02e-18	Lung cancer in ever smokers;
LUSC	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg04607235	chr12:12878440	APOLD1	-0.47	-5.65	-0.3	3.49e-8	Systemic lupus erythematosus;
LUSC	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.23	-0.32	1.39e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2979489	0.891	rs2915625	chr8:30382651	G/A	cg26383811	chr8:30366931	RBPMS	-0.53	-8.16	-0.41	6.95e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg05658215	chr7:157211628	NA	0.32	5.86	0.31	1.13e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg19789473	chr17:27170043	C17orf63	0.31	6.19	0.32	1.79e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs926938	0.563	rs360635	chr1:115420518	A/C	cg01522456	chr1:115632236	TSPAN2	-0.38	-5.77	-0.3	1.82e-8	Autism;
LUSC	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg00012203	chr2:219082015	ARPC2	0.81	14.0	0.61	2.22e-35	Colorectal cancer;
LUSC	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg17691542	chr6:26056736	HIST1H1C	0.49	7.7	0.39	1.53e-13	Height;
LUSC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg00339695	chr16:24857497	SLC5A11	0.37	6.65	0.34	1.23e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg23625390	chr15:77176239	SCAPER	0.47	7.23	0.37	3.29e-12	Blood metabolite levels;
LUSC	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg09904177	chr6:26538194	HMGN4	0.76	14.13	0.61	7.08e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	0.789	rs6076347	chr20:25398790	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.76	-15.01	-0.63	2.89e-39	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg04450456	chr4:17643702	FAM184B	0.39	6.56	0.34	2.01e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs62238980	0.614	rs79592323	chr22:32442742	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.84	-0.44	5.62e-17	Metabolite levels;
LUSC	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg11901034	chr3:128598214	ACAD9	-0.42	-6.66	-0.34	1.16e-10	IgG glycosylation;
LUSC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg22535103	chr8:58192502	C8orf71	-0.71	-7.44	-0.38	8.77e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg06784218	chr1:46089804	CCDC17	0.48	9.3	0.45	1.9e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	10.72	0.51	3.17e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg12863693	chr15:85201151	NMB	0.41	8.44	0.42	9.94e-16	Schizophrenia;
LUSC	cis	rs9905704	0.681	rs2531728	chr17:56539792	T/C	cg19466818	chr17:56409534	MIR142	-0.35	-6.52	-0.34	2.53e-10	Testicular germ cell tumor;
LUSC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-10.97	-0.51	4.07e-24	Schizophrenia;
LUSC	cis	rs12997796	0.556	rs34933869	chr2:86922397	T/C	cg25203885	chr2:87302643	LOC285074	-0.81	-8.39	-0.42	1.42e-15	Schizophrenia;
LUSC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.32	-0.41	2.29e-15	Personality dimensions;
LUSC	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.53	11.34	0.53	1.88e-25	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg17554472	chr22:41940697	POLR3H	0.47	5.84	0.3	1.27e-8	Vitiligo;
LUSC	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.19	0.59	2.82e-32	Blood protein levels;
LUSC	cis	rs6732160	0.619	rs12105975	chr2:73406049	T/A	cg24220031	chr2:73402428	NA	-0.23	-5.66	-0.3	3.26e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs897984	0.762	rs12930545	chr16:30938811	A/G	cg02466173	chr16:30829666	NA	0.56	11.25	0.52	4.19e-25	Dementia with Lewy bodies;
LUSC	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg19682013	chr15:45996608	NA	0.39	6.0	0.31	5.09e-9	Waist circumference;Weight;
LUSC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg02221750	chr19:17393354	ANKLE1	-0.91	-13.72	-0.6	2.84e-34	Systemic lupus erythematosus;
LUSC	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg00864171	chr11:67383662	NA	0.35	6.15	0.32	2.26e-9	Mean corpuscular volume;
LUSC	cis	rs9287719	0.578	rs10168852	chr2:10746323	C/A	cg00105475	chr2:10696890	NA	0.35	5.8	0.3	1.55e-8	Prostate cancer;
LUSC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.79	-14.42	-0.62	5.61e-37	Dental caries;
LUSC	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg14505434	chr11:89522851	NA	0.38	6.05	0.31	3.93e-9	White blood cell types;
LUSC	cis	rs137603	0.603	rs137581	chr22:39677838	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.51	-7.97	-0.4	2.62e-14	Primary biliary cholangitis;
LUSC	cis	rs9807989	0.571	rs10208293	chr2:102966310	G/A	cg09003973	chr2:102972529	NA	0.47	5.9	0.31	9.15e-9	Asthma;
LUSC	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg26647111	chr11:31128758	NA	-0.42	-6.09	-0.32	3.12e-9	Red blood cell count;
LUSC	cis	rs7255	0.538	rs2289081	chr2:20881840	G/C	cg05481257	chr2:20870211	GDF7	-0.34	-5.74	-0.3	2.18e-8	Barrett's esophagus  or Esophageal adenocarcinoma;Esophageal adenocarcinoma;
LUSC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13126279	chr21:47581558	C21orf56	0.57	8.75	0.43	1.08e-16	Testicular germ cell tumor;
LUSC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.63	-0.43	2.55e-16	Gut microbiome composition (summer);
LUSC	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00631329	chr6:26305371	NA	-0.48	-9.09	-0.45	9.17e-18	Educational attainment;
LUSC	trans	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg26384229	chr12:38710491	ALG10B	0.68	10.62	0.5	6.6e-23	Morning vs. evening chronotype;
LUSC	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.92	0.35	2.31e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.49	-6.83	-0.35	3.95e-11	Mean platelet volume;
LUSC	trans	rs800082	1.000	rs9882503	chr3:144321296	A/T	cg24215973	chr2:240111563	HDAC4	-0.46	-7.03	-0.36	1.19e-11	Smoking behavior;
LUSC	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	1.18	13.93	0.61	4.45e-35	Arsenic metabolism;
LUSC	cis	rs4629180	0.675	rs10184144	chr2:102104978	C/T	cg01388757	chr2:102091195	RFX8	-0.36	-6.25	-0.32	1.24e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs76248362	1.000	rs4770506	chr13:24434703	T/C	cg26511321	chr7:27196790	HOXA7	0.54	6.24	0.32	1.35e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	0.95	17.42	0.69	8.24e-49	Heart rate;
LUSC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.82	14.81	0.63	1.76e-38	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg19567339	chr10:100142640	NA	0.38	5.79	0.3	1.59e-8	Metabolite levels;
LUSC	cis	rs9359856	0.564	rs7754145	chr6:90283237	C/T	cg13799429	chr6:90582589	CASP8AP2	0.47	5.97	0.31	6.09e-9	Bipolar disorder;
LUSC	cis	rs11048434	0.698	rs7300767	chr12:9123477	T/G	cg23795048	chr12:9217529	LOC144571	0.34	5.8	0.3	1.51e-8	Sjögren's syndrome;
LUSC	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-7.25	-0.37	2.99e-12	Morning vs. evening chronotype;
LUSC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.89	-18.59	-0.71	1.87e-53	Intelligence (multi-trait analysis);
LUSC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.59	-7.22	-0.37	3.49e-12	Lung function (FEV1/FVC);
LUSC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg23791538	chr6:167370224	RNASET2	-0.37	-5.88	-0.31	9.78e-9	Crohn's disease;
LUSC	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.17	0.52	8.24e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg21100191	chr22:23484243	RTDR1	0.91	16.0	0.66	3.71e-43	Bone mineral density;
LUSC	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg05805236	chr11:65401703	PCNXL3	-0.62	-10.03	-0.48	7.38e-21	Acne (severe);
LUSC	cis	rs9646944	0.501	rs3213733	chr2:102997884	C/A	cg20060108	chr2:102954350	IL1RL1	0.47	6.32	0.33	8.2e-10	Blood protein levels;
LUSC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	12.61	0.57	4.55e-30	Motion sickness;
LUSC	cis	rs877282	0.583	rs11253429	chr10:823234	A/C	cg13775593	chr10:823151	NA	0.31	6.06	0.31	3.75e-9	Uric acid levels;
LUSC	cis	rs2236918	1.000	rs2236919	chr1:242017731	A/G	cg17736920	chr1:242011382	EXO1	0.45	7.12	0.36	6.71e-12	Menopause (age at onset);
LUSC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg22681709	chr2:178499509	PDE11A	-0.6	-12.07	-0.55	4.52e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg04287289	chr16:89883240	FANCA	0.41	6.0	0.31	5.22e-9	Vitiligo;
LUSC	cis	rs16854884	0.657	rs10513235	chr3:143698664	T/C	cg06585982	chr3:143692056	C3orf58	0.45	6.81	0.35	4.66e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.84	0.3	1.25e-8	Tonsillectomy;
LUSC	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg17470449	chr10:769945	NA	0.51	7.07	0.36	9.06e-12	Uric acid levels;
LUSC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg09324608	chr17:30823087	MYO1D	0.35	5.68	0.3	2.99e-8	Schizophrenia;
LUSC	cis	rs6499755	0.965	rs9888978	chr16:55352984	T/G	cg02859129	chr16:55357253	IRX6	0.35	5.9	0.31	8.94e-9	Hypospadias;
LUSC	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.61	-0.34	1.51e-10	Arsenic metabolism;
LUSC	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg24733560	chr20:60626293	TAF4	0.42	7.68	0.39	1.74e-13	Body mass index;
LUSC	trans	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	12.22	0.56	1.23e-28	Exhaled nitric oxide output;
LUSC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg11941060	chr3:133502564	NA	-0.43	-6.19	-0.32	1.75e-9	Iron status biomarkers;
LUSC	cis	rs713477	0.654	rs61976568	chr14:55906218	A/G	cg13175173	chr14:55914753	NA	-0.31	-6.2	-0.32	1.65e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs2637266	0.756	rs846623	chr10:78542819	C/T	cg18941641	chr10:78392320	NA	0.39	6.99	0.36	1.54e-11	Pulmonary function;
LUSC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg17554472	chr22:41940697	POLR3H	-0.48	-5.87	-0.31	1.05e-8	Vitiligo;
LUSC	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	cis	rs6494488	0.500	rs72744739	chr15:65049926	T/C	cg08069370	chr15:64387884	SNX1	-0.65	-5.91	-0.31	8.23e-9	Coronary artery disease;
LUSC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.5	-10.82	-0.51	1.32e-23	Type 2 diabetes;
LUSC	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg25801113	chr15:45476975	SHF	-0.33	-6.7	-0.34	8.73e-11	Uric acid levels;
LUSC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-1.01	-15.01	-0.63	2.75e-39	Initial pursuit acceleration;
LUSC	cis	rs240764	0.621	rs9404052	chr6:101249718	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-6.65	-0.34	1.2e-10	Neuroticism;
LUSC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg06740227	chr12:86229804	RASSF9	-0.37	-5.87	-0.31	1.05e-8	Major depressive disorder;
LUSC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg17554472	chr22:41940697	POLR3H	0.47	5.84	0.3	1.27e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs57590327	0.503	rs6764261	chr3:81620370	T/G	cg07356753	chr3:81810745	GBE1	-0.48	-6.51	-0.34	2.79e-10	Extraversion;
LUSC	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.81	14.05	0.61	1.44e-35	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.79	-0.39	8.52e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg04518342	chr5:131593106	PDLIM4	-0.32	-5.99	-0.31	5.41e-9	Blood metabolite levels;
LUSC	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg15704280	chr7:45808275	SEPT13	0.78	7.46	0.38	7.71e-13	Axial length;
LUSC	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.21	0.49	1.83e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg21280719	chr6:42927975	GNMT	-0.26	-5.71	-0.3	2.44e-8	Blood protein levels;
LUSC	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-10.74	-0.51	2.54e-23	Coffee consumption (cups per day);
LUSC	trans	rs564343	0.688	rs539046	chr11:65843778	A/T	cg26701943	chr11:108369231	KDELC2	-0.44	-6.24	-0.32	1.34e-9	Obesity (early onset extreme);
LUSC	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg03433033	chr1:76189801	ACADM	-0.39	-5.89	-0.31	9.48e-9	Daytime sleep phenotypes;
LUSC	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.08	0.52	1.68e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg05855489	chr10:104503620	C10orf26	-0.68	-10.07	-0.48	5.32e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9815354	0.761	rs57638657	chr3:41809238	G/C	cg03022575	chr3:42003672	ULK4	0.83	8.34	0.41	2.04e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.04	21.25	0.76	5.24e-64	Cognitive function;
LUSC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-7.98	-0.4	2.3e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03475776	chr2:240114298	HDAC4	0.38	6.54	0.34	2.32e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs877282	0.898	rs12358513	chr10:757571	A/G	cg22713356	chr15:30763199	NA	1.03	13.61	0.6	7.56e-34	Uric acid levels;
LUSC	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg00083206	chr6:110721305	DDO	0.42	7.61	0.38	2.82e-13	Platelet distribution width;
LUSC	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.14	-0.32	2.35e-9	Coronary artery disease;
LUSC	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg24812749	chr6:127587940	RNF146	0.73	10.51	0.5	1.66e-22	Breast cancer;
LUSC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg24675658	chr1:53192096	ZYG11B	-0.65	-10.03	-0.48	7.31e-21	Monocyte count;
LUSC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.82	13.74	0.6	2.25e-34	Aortic root size;
LUSC	cis	rs17253792	0.822	rs75016910	chr14:56050466	C/G	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	8.91e-12	Putamen volume;
LUSC	cis	rs1775715	0.737	rs2799015	chr10:32107712	C/T	cg26784012	chr10:32216390	ARHGAP12	0.46	7.67	0.39	1.89e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs17092148	0.731	rs35507767	chr20:33361364	A/T	cg16810054	chr20:33298113	TP53INP2	-0.43	-6.81	-0.35	4.68e-11	Neuroticism;
LUSC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg04315214	chr1:2043799	PRKCZ	0.46	9.52	0.46	3.7e-19	Height;
LUSC	cis	rs240764	0.604	rs9377234	chr6:101263035	C/T	cg09795085	chr6:101329169	ASCC3	0.44	6.24	0.32	1.35e-9	Neuroticism;
LUSC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11764359	chr7:65958608	NA	0.62	9.47	0.46	5.16e-19	Calcium levels;
LUSC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg07703079	chr11:430292	ANO9	0.6	6.52	0.34	2.66e-10	Body mass index;
LUSC	cis	rs34734847	0.965	rs2005455	chr12:121128699	A/G	cg21892295	chr12:121157589	UNC119B	-0.46	-8.26	-0.41	3.46e-15	Mean corpuscular volume;
LUSC	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg00012203	chr2:219082015	ARPC2	0.6	10.08	0.48	5.07e-21	Ulcerative colitis;
LUSC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.14	0.52	9.97e-25	Prudent dietary pattern;
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg25703541	chr22:24373054	LOC391322	-0.87	-14.04	-0.61	1.57e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg23711669	chr6:146136114	FBXO30	-0.77	-12.37	-0.56	3.54e-29	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg07393940	chr7:158741817	NA	0.37	6.85	0.35	3.56e-11	Life satisfaction;
LUSC	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg24692254	chr21:30365293	RNF160	-0.58	-7.22	-0.37	3.57e-12	Cognitive test performance;
LUSC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg25767906	chr1:53392781	SCP2	-0.51	-9.28	-0.45	2.23e-18	Monocyte count;
LUSC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18854424	chr1:2615690	NA	-0.5	-9.91	-0.48	1.85e-20	Ulcerative colitis;
LUSC	cis	rs1461503	0.966	rs7113725	chr11:122843511	G/T	cg27398637	chr11:122830231	C11orf63	-0.4	-6.5	-0.34	2.93e-10	Menarche (age at onset);
LUSC	cis	rs34638657	0.702	rs12599946	chr16:82199831	T/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.47	-0.33	3.55e-10	Lung adenocarcinoma;
LUSC	cis	rs12753569	0.934	rs6676370	chr1:76490185	G/T	cg00791851	chr1:76518896	NA	-0.32	-6.19	-0.32	1.75e-9	Personality dimensions;
LUSC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.39	0.56	2.99e-29	Motion sickness;
LUSC	cis	rs2294693	0.945	rs9369252	chr6:40986028	C/T	cg14769373	chr6:40998127	UNC5CL	0.54	7.37	0.37	1.36e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg03188948	chr7:1209495	NA	0.66	6.93	0.35	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2976388	1.000	rs2294010	chr8:143762430	A/G	cg17252645	chr8:143867129	LY6D	-0.36	-6.31	-0.33	9.04e-10	Urinary tract infection frequency;
LUSC	trans	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04565464	chr8:145669602	NFKBIL2	0.38	6.15	0.32	2.21e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9837602	1.000	rs7610486	chr3:99732564	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.22	-0.32	1.5e-9	Breast cancer;
LUSC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg01483505	chr11:975446	AP2A2	0.42	5.91	0.31	8.68e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6736093	1.000	rs11673729	chr2:112665961	T/A	cg12686935	chr2:112915763	FBLN7	-0.36	-5.77	-0.3	1.86e-8	Coronary artery disease;
LUSC	cis	rs3772130	1.000	rs13087578	chr3:121369207	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.65	9.54	0.46	3.2e-19	Cognitive performance;
LUSC	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg20243544	chr17:37824526	PNMT	0.42	6.48	0.33	3.38e-10	Self-reported allergy;
LUSC	cis	rs11677416	0.961	rs3783557	chr2:113530712	C/T	cg27083787	chr2:113543245	IL1A	0.47	7.07	0.36	9.09e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg08085267	chr17:45401833	C17orf57	-0.55	-8.32	-0.41	2.29e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4363385	0.667	rs756303	chr1:152908222	C/T	cg00922841	chr1:152955080	SPRR1A	-0.4	-6.81	-0.35	4.48e-11	Inflammatory skin disease;
LUSC	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg16586182	chr3:47516702	SCAP	-0.52	-8.13	-0.41	8.41e-15	Colorectal cancer;
LUSC	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg04450456	chr4:17643702	FAM184B	0.41	6.98	0.36	1.62e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.28	-0.67	2.76e-44	Monocyte count;
LUSC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg05347473	chr6:146136440	FBXO30	0.38	6.3	0.33	9.48e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg22437258	chr11:111473054	SIK2	0.51	7.02	0.36	1.25e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg07701084	chr6:150067640	NUP43	0.49	7.36	0.37	1.42e-12	Lung cancer;
LUSC	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	0.89	16.94	0.68	7.06e-47	Heart rate;
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg15242686	chr22:24348715	GSTTP1	0.4	5.98	0.31	5.7e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg10018233	chr7:150070692	REPIN1	-0.39	-7.08	-0.36	8.51e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg11584989	chr19:19387371	SF4	0.57	6.78	0.35	5.44e-11	Bipolar disorder;
LUSC	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg24692254	chr21:30365293	RNF160	0.53	7.75	0.39	1.1e-13	Pancreatic cancer;
LUSC	cis	rs2455601	0.935	rs12049908	chr11:8919309	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-7.86	-0.4	5.21e-14	Schizophrenia;
LUSC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.63	-10.26	-0.49	1.15e-21	Menarche (age at onset);
LUSC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg20276088	chr3:133502917	NA	-0.41	-6.02	-0.31	4.6e-9	Iron status biomarkers;
LUSC	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg12940439	chr1:67600707	NA	0.38	6.31	0.33	8.62e-10	Psoriasis;
LUSC	cis	rs858239	0.601	rs1558313	chr7:23156079	G/A	cg23682824	chr7:23144976	KLHL7	0.39	5.68	0.3	2.92e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-6.37	-0.33	6.19e-10	Psoriasis;
LUSC	cis	rs4776059	1.000	rs11070909	chr15:52931601	A/G	cg22715398	chr15:52968154	KIAA1370	-0.63	-8.94	-0.44	2.75e-17	Schizophrenia;
LUSC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05535760	chr7:792225	HEATR2	-0.74	-7.41	-0.38	1.01e-12	Cerebrospinal P-tau181p levels;
LUSC	cis	rs78773383	0.505	rs13123782	chr4:39377405	A/C	cg12062995	chr4:39368212	RFC1	0.41	6.17	0.32	1.94e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7071206	0.704	rs11002234	chr10:79434458	A/G	cg07817648	chr10:79422355	NA	-0.44	-5.8	-0.3	1.51e-8	Bone mineral density;
LUSC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg04369109	chr6:150039330	LATS1	-0.54	-8.03	-0.4	1.7e-14	Lung cancer;
LUSC	cis	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg06521331	chr12:34319734	NA	0.45	7.43	0.38	9.19e-13	Morning vs. evening chronotype;
LUSC	cis	rs13082711	0.911	rs34307140	chr3:27467875	A/C	cg02860705	chr3:27208620	NA	0.5	8.41	0.42	1.2e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	trans	rs1922233	0.891	rs9307096	chr4:92411848	C/G	cg24250684	chr1:219729030	NA	-0.32	-6.19	-0.32	1.74e-9	Gut microbiome composition (summer and winter);
LUSC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg04414720	chr1:150670196	GOLPH3L	0.54	8.63	0.43	2.56e-16	Tonsillectomy;
LUSC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg23711669	chr6:146136114	FBXO30	0.72	12.63	0.57	3.85e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.34	-5.79	-0.3	1.6e-8	Longevity;Endometriosis;
LUSC	cis	rs240764	0.658	rs9390681	chr6:101218994	A/T	cg09795085	chr6:101329169	ASCC3	-0.44	-6.26	-0.32	1.19e-9	Neuroticism;
LUSC	cis	rs1044826	1.000	rs34623690	chr3:139194385	A/G	cg00490450	chr3:139108681	COPB2	0.52	6.78	0.35	5.37e-11	Obesity-related traits;
LUSC	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg19748678	chr4:122722346	EXOSC9	0.47	6.32	0.33	8.18e-10	Type 2 diabetes;
LUSC	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-7.21	-0.37	3.73e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13909320	chr9:125026858	MRRF;RBM18	-0.44	-6.0	-0.31	5.13e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg09826364	chr7:158789723	NA	-0.38	-5.91	-0.31	8.56e-9	Facial morphology (factor 20);
LUSC	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg20933634	chr6:27740509	NA	-0.44	-5.93	-0.31	7.7e-9	Parkinson's disease;
LUSC	cis	rs7246967	0.551	rs35740274	chr19:22831413	C/T	cg23217946	chr19:22817039	ZNF492	0.49	6.94	0.35	2.09e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12379764	chr21:47803548	PCNT	-0.45	-6.29	-0.33	9.94e-10	Testicular germ cell tumor;
LUSC	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.02	0.31	4.65e-9	Corneal astigmatism;
LUSC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg20406979	chr6:167373233	NA	0.26	6.19	0.32	1.73e-9	Crohn's disease;
LUSC	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg08085267	chr17:45401833	C17orf57	-0.55	-8.34	-0.42	2e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg22782873	chr19:19639568	YJEFN3	0.53	6.45	0.33	3.94e-10	Bipolar disorder;
LUSC	cis	rs983392	0.679	rs7121656	chr11:60024008	C/T	cg24026212	chr11:59952134	MS4A6A	0.38	6.64	0.34	1.24e-10	Alzheimer's disease (late onset);
LUSC	cis	rs10465746	0.714	rs12730621	chr1:84433745	C/G	cg10977910	chr1:84465055	TTLL7	0.43	6.29	0.33	9.94e-10	Obesity-related traits;
LUSC	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg02158880	chr13:53174818	NA	0.58	10.42	0.5	3.39e-22	Lewy body disease;
LUSC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg16647868	chr5:131706066	SLC22A5	0.38	5.97	0.31	6e-9	Breast cancer;
LUSC	cis	rs4499344	0.730	rs10413061	chr19:33103278	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	6.24	0.32	1.31e-9	Schizophrenia;
LUSC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.14	0.32	2.33e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg13010199	chr12:38710504	ALG10B	0.61	9.55	0.46	2.89e-19	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8022179	0.580	rs6575979	chr14:103841018	A/G	cg12935359	chr14:103987150	CKB	-0.6	-8.3	-0.41	2.53e-15	Monocyte count;
LUSC	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-15.19	-0.64	5.5e-40	Exhaled nitric oxide output;
LUSC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg26039829	chr8:22132926	PIWIL2	0.44	8.12	0.41	9.21e-15	Hypertriglyceridemia;
LUSC	cis	rs1506636	1.000	rs2402671	chr7:123355483	T/C	cg03229431	chr7:123269106	ASB15	-0.64	-10.57	-0.5	1.05e-22	Plateletcrit;Platelet count;
LUSC	cis	rs12541635	0.801	rs12155859	chr8:107105384	C/T	cg10147462	chr8:107024639	NA	-0.45	-7.99	-0.4	2.18e-14	Age of smoking initiation;
LUSC	cis	rs11039100	0.573	rs34335913	chr11:5793979	C/T	cg13902645	chr11:5959945	NA	-0.53	-5.82	-0.3	1.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg15839431	chr19:19639596	YJEFN3	0.43	6.1	0.32	2.86e-9	Tonsillectomy;
LUSC	cis	rs17604090	0.793	rs10241305	chr7:29689929	T/C	cg19413766	chr7:29689036	LOC646762	-0.56	-7.08	-0.36	8.41e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg22800045	chr5:56110881	MAP3K1	0.46	6.17	0.32	1.96e-9	Coronary artery disease;
LUSC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.08	-0.4	1.16e-14	Chronic sinus infection;
LUSC	cis	rs7215564	0.908	rs35584560	chr17:78668256	G/A	cg23238734	chr17:78661607	RPTOR	0.49	6.43	0.33	4.46e-10	Myopia (pathological);
LUSC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg04414720	chr1:150670196	GOLPH3L	0.5	7.73	0.39	1.24e-13	Melanoma;
LUSC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg08742575	chr21:47604166	C21orf56	-0.48	-7.25	-0.37	2.89e-12	Testicular germ cell tumor;
LUSC	cis	rs6076065	0.723	rs4813493	chr20:23367373	G/C	cg11657817	chr20:23433608	CST11	0.43	8.07	0.4	1.25e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg13206674	chr6:150067644	NUP43	0.59	9.28	0.45	2.26e-18	Lung cancer;
LUSC	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg19875535	chr5:140030758	IK	0.47	7.52	0.38	5.19e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4704187	0.687	rs7720620	chr5:74366023	A/G	cg03227963	chr5:74354835	NA	0.33	7.02	0.36	1.27e-11	Response to amphetamines;
LUSC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg06637938	chr14:75390232	RPS6KL1	0.54	8.76	0.43	9.83e-17	Height;
LUSC	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg21573476	chr21:45109991	RRP1B	-0.36	-5.69	-0.3	2.74e-8	Mean corpuscular volume;
LUSC	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-9.23	-0.45	3.19e-18	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs1044826	0.667	rs295471	chr3:139213922	G/C	cg00490450	chr3:139108681	COPB2	0.46	7.03	0.36	1.19e-11	Obesity-related traits;
LUSC	cis	rs427941	0.585	rs201511	chr7:101767653	A/G	cg06246474	chr7:101738831	CUX1	0.38	6.25	0.32	1.26e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs1595825	0.891	rs16826895	chr2:198901642	A/G	cg10547527	chr2:198650123	BOLL	-0.53	-6.24	-0.32	1.34e-9	Ulcerative colitis;
LUSC	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg13699009	chr12:122356056	WDR66	0.46	6.93	0.35	2.24e-11	Mean corpuscular volume;
LUSC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg27494647	chr7:150038898	RARRES2	0.53	8.05	0.4	1.46e-14	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs12210905	0.688	rs12212348	chr6:27361242	T/C	cg11837749	chr1:55047332	ACOT11	0.68	6.07	0.32	3.38e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg18512352	chr11:47633146	NA	-0.46	-9.19	-0.45	4.42e-18	Subjective well-being;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25818522	chr17:25621101	WSB1	0.72	6.14	0.32	2.28e-9	Cognitive performance;
LUSC	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17691542	chr6:26056736	HIST1H1C	0.99	12.42	0.56	2.28e-29	Iron status biomarkers;
LUSC	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.74	13.88	0.6	6.62e-35	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg02569458	chr12:86230093	RASSF9	0.46	7.49	0.38	6.2e-13	Major depressive disorder;
LUSC	cis	rs2637266	0.846	rs2637263	chr10:78322442	G/A	cg18941641	chr10:78392320	NA	0.38	6.99	0.36	1.49e-11	Pulmonary function;
LUSC	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.31	-5.89	-0.31	9.44e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.96e-9	Prostate cancer;
LUSC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg05072774	chr3:49840536	C3orf54	-0.43	-5.93	-0.31	7.5e-9	Resting heart rate;
LUSC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.46	6.68	0.34	1.02e-10	Eosinophil percentage of white cells;
LUSC	cis	rs9715521	0.588	rs11731207	chr4:59852246	G/A	cg11281224	chr4:60001000	NA	-0.5	-6.92	-0.35	2.28e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7929679	0.551	rs10836303	chr11:34792702	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.91	0.31	8.29e-9	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	cis	rs877282	0.838	rs11253374	chr10:774961	C/T	cg17470449	chr10:769945	NA	0.55	7.8	0.39	7.79e-14	Uric acid levels;
LUSC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03264133	chr6:25882463	NA	-0.4	-7.08	-0.36	8.34e-12	Height;
LUSC	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg22189786	chr22:42395067	WBP2NL	0.43	5.77	0.3	1.84e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.86	-11.07	-0.52	1.83e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg06636001	chr8:8085503	FLJ10661	0.47	7.05	0.36	1.06e-11	Triglycerides;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14043925	chr11:3013809	NAP1L4	0.47	6.37	0.33	6.37e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10425738	0.536	rs10426903	chr19:41417719	T/C	cg04176888	chr19:41596066	CYP2A13	0.39	6.72	0.35	7.63e-11	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LUSC	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06002616	chr8:101225028	SPAG1	-0.45	-7.33	-0.37	1.72e-12	Atrioventricular conduction;
LUSC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	1.04	19.21	0.72	6.53e-56	Menopause (age at onset);
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg27228074	chr10:104678015	CNNM2	0.44	6.22	0.32	1.5e-9	Calcium levels;
LUSC	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg22875332	chr1:76189707	ACADM	-0.39	-5.86	-0.31	1.1e-8	Daytime sleep phenotypes;
LUSC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg10909506	chr17:38081995	ORMDL3	0.34	6.07	0.32	3.48e-9	Self-reported allergy;
LUSC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08677398	chr8:58056175	NA	-0.58	-7.5	-0.38	5.77e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg10756647	chr7:56101905	PSPH	0.83	8.14	0.41	8e-15	Diabetic kidney disease;
LUSC	cis	rs1506636	1.000	rs7779099	chr7:123295964	C/T	cg03229431	chr7:123269106	ASB15	-0.65	-10.62	-0.5	6.66e-23	Plateletcrit;Platelet count;
LUSC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06505273	chr16:24850292	NA	0.4	5.76	0.3	1.94e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	0.92	13.87	0.6	7.61e-35	Breast cancer;
LUSC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg11645453	chr3:52864694	ITIH4	-0.3	-7.24	-0.37	3.19e-12	Electroencephalogram traits;
LUSC	cis	rs4919087	0.892	rs10882880	chr10:99008068	G/A	cg25902810	chr10:99078978	FRAT1	0.46	6.72	0.35	7.68e-11	Monocyte count;
LUSC	cis	rs6464929	0.955	rs13247593	chr7:148723269	A/G	cg23583168	chr7:148888333	NA	0.46	5.76	0.3	1.94e-8	Pediatric bone mineral content (hip);
LUSC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.1e-18	Menopause (age at onset);
LUSC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.8	0.6	1.3600000000000001e-34	Chronic sinus infection;
LUSC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg13206674	chr6:150067644	NUP43	0.59	9.28	0.45	2.26e-18	Lung cancer;
LUSC	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg08917208	chr2:24149416	ATAD2B	0.99	9.9	0.48	1.94e-20	Lymphocyte counts;
LUSC	cis	rs2625529	0.526	rs62022789	chr15:72564492	C/T	cg16672083	chr15:72433130	SENP8	0.46	7.6	0.38	3.02e-13	Red blood cell count;
LUSC	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	6.68	0.34	1.03e-10	Retinal vascular caliber;
LUSC	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.69	-0.34	9.68e-11	Hemoglobin concentration;
LUSC	cis	rs2075165	0.901	rs759329	chr1:156230936	A/G	cg20302342	chr1:156215951	PAQR6	0.32	6.18	0.32	1.9e-9	Tonsillectomy;
LUSC	cis	rs17401966	0.838	rs912963	chr1:10348042	C/T	cg19773385	chr1:10388646	KIF1B	-0.5	-8.73	-0.43	1.27e-16	Hepatocellular carcinoma;
LUSC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.47	-7.18	-0.37	4.65e-12	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg23788917	chr6:8435910	SLC35B3	0.51	7.58	0.38	3.38e-13	Motion sickness;
LUSC	trans	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg25214090	chr10:38739885	LOC399744	0.39	5.98	0.31	5.71e-9	Corneal astigmatism;
LUSC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg11062466	chr8:58055876	NA	0.48	6.46	0.33	3.65e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	12.32	0.56	5.39e-29	Chronic sinus infection;
LUSC	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg17507749	chr15:85114479	UBE2QP1	0.7	8.98	0.44	1.97e-17	Schizophrenia;
LUSC	cis	rs11585357	0.895	rs72646797	chr1:17613838	C/G	cg08277548	chr1:17600880	PADI3	-0.64	-6.62	-0.34	1.42e-10	Hair shape;
LUSC	cis	rs3772130	1.000	rs34086988	chr3:121352745	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	9.61	0.47	1.77e-19	Cognitive performance;
LUSC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.51	8.11	0.41	9.65e-15	Response to antipsychotic treatment;
LUSC	cis	rs3931020	0.962	rs2185695	chr1:75257881	T/C	cg10128416	chr1:75198403	TYW3;CRYZ	0.42	5.69	0.3	2.84e-8	Resistin levels;
LUSC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	0.93	16.17	0.66	7.55e-44	Menopause (age at onset);
LUSC	trans	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.43	-0.33	4.34e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	7.18	0.37	4.47e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9436747	0.510	rs12091826	chr1:66008158	A/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.44	-6.04	-0.31	4.18e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg11247378	chr22:39784982	NA	-0.64	-12.72	-0.57	1.7e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg07806771	chr7:64541737	NA	0.45	6.42	0.33	4.69e-10	Calcium levels;
LUSC	cis	rs6920965	0.507	rs9385389	chr6:126215486	G/C	cg10911889	chr6:126070802	HEY2	0.4	5.9	0.31	8.75e-9	High light scatter reticulocyte count;
LUSC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.85	15.25	0.64	3.1e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg22532475	chr10:104410764	TRIM8	-0.32	-7.09	-0.36	8.12e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24110177	chr3:50126178	RBM5	0.57	9.53	0.46	3.46e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.78	-15.83	-0.65	1.63e-42	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.2	0.37	4.12e-12	Mean platelet volume;
LUSC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.84	0.3	1.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg05340658	chr4:99064831	C4orf37	0.64	10.17	0.49	2.45e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.31	-0.62	1.45e-36	Schizophrenia;
LUSC	trans	rs7939886	0.920	rs1482009	chr11:55884690	T/G	cg15704280	chr7:45808275	SEPT13	0.82	6.77	0.35	5.73e-11	Myopia (pathological);
LUSC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.73	-10.1	-0.48	4.22e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.84	-0.44	5.45e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18099408	chr3:52552593	STAB1	-0.41	-6.9	-0.35	2.57e-11	Bipolar disorder;
LUSC	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg04545296	chr12:48745243	ZNF641	0.37	6.78	0.35	5.33e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs4919087	0.810	rs1468069	chr10:98988759	A/C	cg25902810	chr10:99078978	FRAT1	0.43	6.36	0.33	6.69e-10	Monocyte count;
LUSC	trans	rs62458065	0.850	rs28693551	chr7:32469387	G/A	cg00845942	chr12:64062724	DPY19L2	-0.52	-6.11	-0.32	2.84e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7572644	0.664	rs10173848	chr2:28143017	G/T	cg27432699	chr2:27873401	GPN1	-0.52	-6.31	-0.33	8.83e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg25173405	chr17:45401733	C17orf57	0.36	5.72	0.3	2.36e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg06521331	chr12:34319734	NA	0.4	6.62	0.34	1.44e-10	Morning vs. evening chronotype;
LUSC	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg05043794	chr9:111880884	C9orf5	-0.37	-7.68	-0.39	1.74e-13	Menarche (age at onset);
LUSC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg22800045	chr5:56110881	MAP3K1	0.45	6.53	0.34	2.47e-10	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.08	0.4	1.17e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.82	-11.69	-0.54	1.08e-26	Coronary artery disease;
LUSC	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg07828340	chr4:882639	GAK	1.07	11.31	0.53	2.41e-25	Intelligence (multi-trait analysis);
LUSC	trans	rs72674100	1.000	rs10010641	chr4:97966171	C/T	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.03e-17	Prudent dietary pattern;
LUSC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07677032	chr17:61819896	STRADA	0.54	8.95	0.44	2.58e-17	Prudent dietary pattern;
LUSC	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg16342193	chr10:102329863	NA	-0.33	-5.98	-0.31	5.69e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10892173	0.782	rs6421566	chr11:117671398	G/A	cg21640587	chr11:117668038	DSCAML1	0.36	5.72	0.3	2.36e-8	Myopia;
LUSC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg20307385	chr11:47447363	PSMC3	0.45	5.82	0.3	1.37e-8	Subjective well-being;
LUSC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg16049864	chr8:95962084	TP53INP1	0.41	7.16	0.36	5.26e-12	Alzheimer's disease (late onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18364837	chr5:148737347	PCYOX1L	0.44	6.71	0.34	8.57e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-8.32	-0.41	2.3e-15	Menarche (age at onset);
LUSC	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	12.59	0.57	5.09e-30	Primary sclerosing cholangitis;
LUSC	cis	rs34779708	0.649	rs34421369	chr10:35550275	G/C	cg03585969	chr10:35415529	CREM	0.53	7.37	0.37	1.32e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs12043259	1.000	rs10900427	chr1:204848187	C/G	cg23865240	chr7:27134109	HOXA1	-0.57	-6.01	-0.31	4.86e-9	Addiction;
LUSC	trans	rs2587949	0.615	rs1319844	chr3:4229928	T/C	cg15139668	chr4:4577005	NA	-0.4	-6.06	-0.31	3.62e-9	Periodontitis (DPAL);
LUSC	cis	rs748404	0.697	rs475227	chr15:43546446	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.42	6.04	0.31	4.03e-9	Lung cancer;
LUSC	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.74	0.3	2.17e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.4	-6.69	-0.34	9.5e-11	Prudent dietary pattern;
LUSC	cis	rs2898681	0.581	rs936690	chr4:53691035	A/G	cg00338735	chr4:53728038	RASL11B	0.42	5.87	0.31	1.05e-8	Optic nerve measurement (cup area);
LUSC	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg17507749	chr15:85114479	UBE2QP1	0.71	8.82	0.43	6.56e-17	Schizophrenia;
LUSC	trans	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg25214090	chr10:38739885	LOC399744	0.5	7.32	0.37	1.88e-12	Corneal astigmatism;
LUSC	cis	rs7561273	0.545	rs13035774	chr2:24358652	C/T	cg08063864	chr2:24346004	PFN4;LOC375190	-0.42	-5.82	-0.3	1.37e-8	Quantitative traits;
LUSC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.84	-0.39	6.11e-14	Personality dimensions;
LUSC	trans	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg07393940	chr7:158741817	NA	0.51	8.0	0.4	2.07e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg14429012	chr9:34458458	C9orf25;DNAI1	0.74	6.1	0.32	2.95e-9	Cognitive performance;
LUSC	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg22705602	chr4:152727874	NA	-0.33	-6.63	-0.34	1.36e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs12534701	0.904	rs3817518	chr7:154672809	C/T	cg24255201	chr7:154684926	DPP6	0.39	5.85	0.3	1.16e-8	Colorectal cancer (diet interaction);
LUSC	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg03929089	chr4:120376271	NA	0.67	7.39	0.37	1.2e-12	Axial length;
LUSC	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg08999081	chr20:33150536	PIGU	-0.36	-6.46	-0.33	3.62e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs9942416	0.660	rs193344	chr5:74977854	T/C	cg19683494	chr5:74908142	NA	-0.42	-6.6	-0.34	1.58e-10	Age-related disease endophenotypes;
LUSC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs11051970	0.879	rs2651362	chr12:32587851	G/C	cg24626660	chr12:32551988	NA	0.33	5.66	0.3	3.2e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg25427524	chr10:38739819	LOC399744	-0.5	-7.01	-0.36	1.32e-11	Obesity (extreme);
LUSC	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17691542	chr6:26056736	HIST1H1C	0.83	11.27	0.52	3.55e-25	Iron status biomarkers;
LUSC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg00255919	chr5:131827918	IRF1	-0.43	-8.16	-0.41	6.83e-15	Asthma (sex interaction);
LUSC	cis	rs4704187	0.687	rs1903838	chr5:74479999	G/A	cg03227963	chr5:74354835	NA	0.29	6.24	0.32	1.32e-9	Response to amphetamines;
LUSC	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg01620082	chr3:125678407	NA	-0.72	-7.04	-0.36	1.07e-11	Depression;
LUSC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.43e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.47	7.66	0.39	2.01e-13	Alcohol dependence;
LUSC	trans	rs7170930	0.618	rs8040520	chr15:66556154	A/G	cg06396762	chr16:3202609	NA	-0.72	-5.98	-0.31	5.75e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	8.86e-24	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg05347473	chr6:146136440	FBXO30	0.5	8.41	0.42	1.17e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7575217	0.884	rs1192787	chr2:101783029	C/T	cg23907051	chr2:101730305	TBC1D8	-0.27	-6.56	-0.34	2.06e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-7.55	-0.38	4.23e-13	Morning vs. evening chronotype;
LUSC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.03	0.4	1.69e-14	Melanoma;
LUSC	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	5.96	0.31	6.38e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.41	-7.64	-0.39	2.29e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg07661805	chr8:143867942	LY6D	-0.26	-5.87	-0.31	1.07e-8	Urinary tract infection frequency;
LUSC	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg09654669	chr8:57350985	NA	-0.44	-5.87	-0.31	1.04e-8	Obesity-related traits;
LUSC	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg04989706	chr14:50066350	PPIL5	-0.47	-6.09	-0.32	3.12e-9	Carotid intima media thickness;
LUSC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg25019033	chr10:957182	NA	-0.52	-5.98	-0.31	5.87e-9	Eosinophil percentage of granulocytes;
LUSC	trans	rs1325195	0.520	rs3122378	chr1:179234045	A/C	cg11624085	chr17:8464688	MYH10	0.43	6.73	0.35	7.6e-11	IgE grass sensitization;
LUSC	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg05855489	chr10:104503620	C10orf26	-0.68	-10.06	-0.48	5.7e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.72	-0.39	1.35e-13	Retinal vascular caliber;
LUSC	cis	rs2219968	1.000	rs36124379	chr8:78963505	T/C	cg00738934	chr8:78996279	NA	0.34	6.18	0.32	1.89e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9341808	0.714	rs9448911	chr6:80913859	A/G	cg08355045	chr6:80787529	NA	0.48	8.36	0.42	1.7e-15	Sitting height ratio;
LUSC	trans	rs62055045	0.528	rs62056195	chr16:71549485	A/G	cg23742233	chr15:96890880	NA	-0.48	-6.35	-0.33	7.08e-10	Schizophrenia;
LUSC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.15	-0.45	5.77e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg23422044	chr7:1970798	MAD1L1	0.59	6.96	0.36	1.81e-11	Bipolar disorder;
LUSC	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg01733217	chr16:74700730	RFWD3	-0.6	-9.15	-0.45	5.88e-18	Breast cancer;
LUSC	cis	rs7707921	0.881	rs324914	chr5:81389950	C/T	cg15871215	chr5:81402204	ATG10	0.44	6.66	0.34	1.14e-10	Breast cancer;
LUSC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg25019033	chr10:957182	NA	-0.52	-6.55	-0.34	2.19e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs8050260	0.500	rs4783650	chr16:68558528	T/C	cg02508848	chr16:68573721	ZFP90	0.45	5.71	0.3	2.55e-8	Plateletcrit;
LUSC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	13.92	0.61	4.85e-35	Alzheimer's disease;
LUSC	cis	rs61935443	0.720	rs10859784	chr12:95288926	G/A	cg21533806	chr12:95267307	NA	0.52	6.43	0.33	4.5e-10	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.58	-0.42	3.51e-16	Retinal vascular caliber;
LUSC	trans	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg05926928	chr17:57297772	GDPD1	0.44	6.23	0.32	1.36e-9	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.93	0.48	1.53e-20	Bipolar disorder;
LUSC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-5.76	-0.3	1.92e-8	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg15556689	chr8:8085844	FLJ10661	0.57	8.69	0.43	1.7e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs4948102	0.599	rs2230197	chr7:56126360	T/C	cg17215666	chr7:56131930	SUMF2	0.45	5.98	0.31	5.75e-9	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs728616	0.558	rs12414691	chr10:82156982	A/T	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.8	-0.3	1.57e-8	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg16423285	chr20:60520624	NA	-0.46	-5.86	-0.31	1.12e-8	Body mass index;
LUSC	cis	rs7719624	0.692	rs2237065	chr5:135367220	C/T	cg12897067	chr5:135418308	NA	-0.43	-6.31	-0.33	9.09e-10	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	6.13	0.32	2.5e-9	Educational attainment;
LUSC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	13.96	0.61	3.17e-35	Platelet count;
LUSC	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	1.13	18.42	0.71	8.74e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg22532475	chr10:104410764	TRIM8	0.24	5.65	0.3	3.45e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7605827	0.930	rs11684001	chr2:15513120	C/T	cg19274914	chr2:15703543	NA	0.46	8.94	0.44	2.66e-17	Educational attainment (years of education);
LUSC	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	0.98	14.93	0.63	5.84e-39	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.67	11.48	0.53	5.96e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg26380479	chr7:97908229	NA	-0.27	-5.84	-0.3	1.23e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg00033643	chr7:134001901	SLC35B4	-0.41	-6.4	-0.33	5.14e-10	Mean platelet volume;
LUSC	trans	rs877282	0.628	rs11253435	chr10:824169	T/C	cg22713356	chr15:30763199	NA	0.79	10.17	0.49	2.4e-21	Uric acid levels;
LUSC	cis	rs12681287	0.711	rs28506490	chr8:87246118	T/C	cg27223183	chr8:87520930	FAM82B	-0.46	-5.8	-0.3	1.54e-8	Caudate activity during reward;
LUSC	cis	rs911119	0.955	rs1011226	chr20:23605833	G/T	cg16589663	chr20:23618590	CST3	-0.58	-7.02	-0.36	1.23e-11	Chronic kidney disease;
LUSC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg14416269	chr4:6271139	WFS1	-0.54	-10.55	-0.5	1.22e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs67981189	0.593	rs221925	chr14:71579629	T/G	cg15816911	chr14:71606274	NA	-0.34	-5.94	-0.31	6.99e-9	Schizophrenia;
LUSC	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg15423357	chr2:25149977	NA	-0.36	-7.15	-0.36	5.41e-12	Body mass index in non-asthmatics;
LUSC	trans	rs11918654	0.840	rs7614778	chr3:5202793	T/C	cg24725692	chr4:140478735	SETD7	0.3	5.98	0.31	5.63e-9	Disc degeneration (lumbar);
LUSC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.19	-27.11	-0.83	2.32e-86	Chronic sinus infection;
LUSC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg26408565	chr15:76604113	ETFA	-0.47	-7.42	-0.38	9.75e-13	Blood metabolite levels;
LUSC	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg25233709	chr10:116636983	FAM160B1	0.37	6.59	0.34	1.69e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg26335602	chr6:28129616	ZNF389	0.4	5.64	0.3	3.57e-8	Parkinson's disease;
LUSC	cis	rs56399783	0.901	rs17132624	chr7:2778496	G/A	cg14895029	chr7:2775587	GNA12	0.52	5.72	0.3	2.43e-8	Childhood ear infection;
LUSC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06022373	chr22:39101656	GTPBP1	0.84	13.27	0.59	1.44e-32	Menopause (age at onset);
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg00431813	chr7:1051703	C7orf50	-0.44	-7.02	-0.36	1.21e-11	Longevity;Endometriosis;
LUSC	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg13010199	chr12:38710504	ALG10B	0.64	9.79	0.47	4.49e-20	Bladder cancer;
LUSC	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg03929089	chr4:120376271	NA	0.66	6.22	0.32	1.47e-9	Axial length;
LUSC	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	7.68	0.39	1.81e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs4714291	0.802	rs2984430	chr6:39983741	A/G	cg02267698	chr19:7991119	CTXN1	-0.53	-7.85	-0.39	5.68e-14	Strep throat;
LUSC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg25703541	chr22:24373054	LOC391322	0.82	10.45	0.5	2.64e-22	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	0.89	15.67	0.65	7.27e-42	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	0.81	15.62	0.65	1.12e-41	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg10956904	chr3:52443970	BAP1;PHF7	0.4	6.76	0.35	6.13e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg13047869	chr3:10149882	C3orf24	0.6	8.5	0.42	6.41e-16	Alzheimer's disease;
LUSC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg11214544	chr1:2391121	NA	-0.59	-9.85	-0.47	3e-20	Non-obstructive azoospermia;
LUSC	cis	rs789859	0.611	rs1077729	chr3:194418126	A/G	cg21106136	chr3:194405973	FAM43A	0.4	6.57	0.34	1.98e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.58	-7.33	-0.37	1.75e-12	Body mass index;
LUSC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg09034736	chr1:150693464	HORMAD1	0.42	5.81	0.3	1.49e-8	Melanoma;
LUSC	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06636551	chr8:101224915	SPAG1	-0.44	-7.91	-0.4	3.71e-14	Atrioventricular conduction;
LUSC	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg05855489	chr10:104503620	C10orf26	-0.61	-7.76	-0.39	1.07e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg05340658	chr4:99064831	C4orf37	0.68	11.43	0.53	8.93e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2303282	0.716	rs2587870	chr16:56410831	C/T	cg00500540	chr16:56394104	NA	-0.44	-7.6	-0.38	3.04e-13	Breast cancer;
LUSC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg04317338	chr11:64019027	PLCB3	0.66	7.5	0.38	5.84e-13	Mean platelet volume;
LUSC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06634786	chr22:41940651	POLR3H	0.49	5.72	0.3	2.34e-8	Vitiligo;
LUSC	trans	rs4948088	1.000	rs2329565	chr7:51017653	T/C	cg26816907	chr1:197890812	LHX9	0.56	6.22	0.32	1.47e-9	Type 1 diabetes;
LUSC	cis	rs2236918	0.643	rs1776139	chr1:242027363	T/G	cg17736920	chr1:242011382	EXO1	0.39	6.16	0.32	2.13e-9	Menopause (age at onset);
LUSC	cis	rs9467773	0.566	rs66972160	chr6:26359306	T/C	cg09904177	chr6:26538194	HMGN4	-0.52	-8.16	-0.41	6.82e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg09307838	chr4:120376055	NA	-0.65	-9.31	-0.45	1.78e-18	Corneal astigmatism;
LUSC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.78	10.04	0.48	6.51e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.68	10.16	0.49	2.61e-21	Corneal astigmatism;
LUSC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg13560548	chr3:10150139	C3orf24	0.54	7.74	0.39	1.17e-13	Alzheimer's disease;
LUSC	cis	rs3781458	0.803	rs11245321	chr10:126323279	C/T	cg20435097	chr10:126320824	FAM53B	0.23	6.02	0.31	4.64e-9	Male-pattern baldness;
LUSC	cis	rs738321	0.757	rs2235345	chr22:38518177	C/T	cg25457927	chr22:38595422	NA	-0.37	-7.05	-0.36	1.04e-11	Breast cancer;
LUSC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.47	-6.31	-0.33	8.84e-10	Renal function-related traits (BUN);
LUSC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg02079420	chr8:82753780	SNX16	0.42	7.15	0.36	5.48e-12	Diastolic blood pressure;
LUSC	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg13334819	chr7:99746414	C7orf59	0.5	6.68	0.34	9.99e-11	Coronary artery disease;
LUSC	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg21775007	chr8:11205619	TDH	-0.41	-5.9	-0.31	9.14e-9	Triglycerides;
LUSC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	16.84	0.68	1.64e-46	Gut microbiome composition (summer);
LUSC	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	6.96	0.36	1.81e-11	Schizophrenia;
LUSC	cis	rs10203711	1.000	rs4663940	chr2:239570382	C/T	cg14580085	chr2:239553406	NA	0.43	7.32	0.37	1.85e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg01802117	chr1:53393560	SCP2	0.38	6.2	0.32	1.67e-9	Monocyte count;
LUSC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg25456477	chr12:86230367	RASSF9	0.41	7.31	0.37	2.04e-12	Major depressive disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18104674	chr18:60190218	ZCCHC2	-0.42	-6.23	-0.32	1.42e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	1.03	17.71	0.7	6.06e-50	Coronary artery disease;
LUSC	cis	rs6700896	0.966	rs4655729	chr1:66082471	A/G	cg04111102	chr1:66153794	NA	0.31	6.92	0.35	2.3e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg23942311	chr14:51606299	NA	0.49	11.44	0.53	8.76e-26	Cancer;
LUSC	cis	rs3101457	0.515	rs4658629	chr1:244516754	G/T	cg09033006	chr1:244517177	C1orf100	-0.42	-6.18	-0.32	1.92e-9	Smoking behavior;
LUSC	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg11266682	chr4:10021025	SLC2A9	0.55	10.04	0.48	6.83e-21	Bone mineral density;
LUSC	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg09165964	chr15:75287851	SCAMP5	-0.96	-11.82	-0.54	3.63e-27	Blood trace element (Zn levels);
LUSC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18876405	chr7:65276391	NA	0.55	8.56	0.42	4.15e-16	Aortic root size;
LUSC	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg25214090	chr10:38739885	LOC399744	0.53	7.95	0.4	2.95e-14	Corneal astigmatism;
LUSC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg13175981	chr1:150552382	MCL1	0.47	6.7	0.34	8.66e-11	Tonsillectomy;
LUSC	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg19622623	chr12:86230825	RASSF9	-0.42	-5.82	-0.3	1.36e-8	Major depressive disorder;
LUSC	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg22482690	chr17:47019901	SNF8	0.4	7.47	0.38	7.15e-13	Type 2 diabetes;
LUSC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11644478	chr21:40555479	PSMG1	0.93	17.46	0.69	5.9e-49	Cognitive function;
LUSC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	16.2	0.66	5.64e-44	Platelet count;
LUSC	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg26856596	chr11:1961893	NA	0.34	6.36	0.33	6.61e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.45	-0.38	7.98e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	9.35	0.46	1.28e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs8032315	0.965	rs35346340	chr15:91427872	G/C	cg04510874	chr15:91427884	FES	0.31	6.01	0.31	4.77e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs71636778	0.509	rs71636795	chr1:27241025	A/G	cg12203394	chr1:27248618	NUDC	0.53	5.65	0.3	3.47e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs5758659	0.729	rs134866	chr22:42650663	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.3	-6.24	-0.32	1.34e-9	Cognitive function;
LUSC	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg08601574	chr20:25228251	PYGB	-0.42	-6.35	-0.33	7.19e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg11189052	chr15:85197271	WDR73	-0.66	-10.13	-0.48	3.38e-21	P wave terminal force;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05827267	chr22:42084837	NHP2L1	-0.43	-6.45	-0.33	3.92e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg15147215	chr3:52552868	STAB1	-0.3	-6.02	-0.31	4.62e-9	Electroencephalogram traits;
LUSC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg22535103	chr8:58192502	C8orf71	-0.67	-7.57	-0.38	3.68e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.21	-0.49	1.82e-21	Hemoglobin concentration;
LUSC	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg06609049	chr19:2785107	THOP1	0.67	10.68	0.5	4.07e-23	Total cholesterol levels;
LUSC	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	6.53	0.34	2.44e-10	Resting heart rate;
LUSC	cis	rs12973672	0.812	rs2280744	chr19:35755386	G/A	cg12095397	chr19:35769544	USF2	0.41	6.14	0.32	2.31e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs977987	0.762	rs1364079	chr16:75393131	C/A	cg03315344	chr16:75512273	CHST6	0.53	10.28	0.49	1.03e-21	Dupuytren's disease;
LUSC	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-8.55	-0.42	4.35e-16	Bone mineral density;
LUSC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg21724239	chr8:58056113	NA	0.58	7.26	0.37	2.82e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg03563238	chr19:33554763	RHPN2	0.34	5.85	0.3	1.16e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg02023728	chr11:77925099	USP35	0.46	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	cis	rs9283706	0.623	rs1159201	chr5:66311339	C/T	cg11590213	chr5:66331682	MAST4	-0.4	-5.93	-0.31	7.6e-9	Coronary artery disease;
LUSC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg05729581	chr11:3078854	CARS	-0.55	-8.48	-0.42	7.43e-16	Longevity;
LUSC	cis	rs9811920	0.809	rs7649349	chr3:99725629	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-7.1	-0.36	7.36e-12	Axial length;
LUSC	cis	rs7588746	0.621	rs2060122	chr2:201153177	A/G	cg23649088	chr2:200775458	C2orf69	-0.42	-5.91	-0.31	8.36e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg23625390	chr15:77176239	SCAPER	0.46	7.06	0.36	9.57e-12	Blood metabolite levels;
LUSC	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07741184	chr6:167504864	NA	0.39	6.92	0.35	2.34e-11	Crohn's disease;
LUSC	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg04218760	chr10:45406644	TMEM72	-0.29	-6.99	-0.36	1.49e-11	Mean corpuscular volume;
LUSC	cis	rs617219	0.853	rs57587638	chr5:78513167	C/T	cg24856658	chr5:78533917	JMY	-0.3	-6.02	-0.31	4.54e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs6736093	0.796	rs34128716	chr2:112812856	C/G	cg12686935	chr2:112915763	FBLN7	-0.4	-6.35	-0.33	7.04e-10	Coronary artery disease;
LUSC	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg03806693	chr22:41940476	POLR3H	-0.59	-8.66	-0.43	2e-16	Neuroticism;
LUSC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg18758796	chr5:131593413	PDLIM4	0.51	8.61	0.43	2.93e-16	Acylcarnitine levels;
LUSC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.37	-6.22	-0.32	1.46e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs308403	0.509	rs7690133	chr4:123673809	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.94	16.09	0.66	1.63e-43	Blood protein levels;
LUSC	cis	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg06521331	chr12:34319734	NA	-0.39	-5.74	-0.3	2.14e-8	Resting heart rate;
LUSC	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.72	13.06	0.58	8.81e-32	Platelet distribution width;
LUSC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg10664184	chr19:17420304	DDA1	0.47	6.13	0.32	2.46e-9	Systemic lupus erythematosus;
LUSC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.64	7.91	0.4	3.71e-14	Lung function (FEV1/FVC);
LUSC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	1.23	16.69	0.67	6.75e-46	Eosinophil percentage of granulocytes;
LUSC	cis	rs1595825	0.891	rs16826791	chr2:198895133	C/G	cg00982548	chr2:198649783	BOLL	-0.54	-6.89	-0.35	2.72e-11	Ulcerative colitis;
LUSC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	1.05	21.01	0.75	4.75e-63	Menopause (age at onset);
LUSC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg00599273	chr12:58146742	CDK4	0.31	5.81	0.3	1.48e-8	Multiple sclerosis;
LUSC	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.79	-0.35	5.27e-11	Response to antipsychotic treatment;
LUSC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.48	0.53	5.99e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg11861562	chr11:117069780	TAGLN	-0.45	-8.14	-0.41	8.15e-15	Blood protein levels;
LUSC	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.61	0.5	7.45e-23	Coffee consumption (cups per day);
LUSC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	7.65e-16	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13246654	chr4:114682613	CAMK2D	-0.42	-6.01	-0.31	4.75e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15388598	chr13:95953941	ABCC4	-0.42	-6.06	-0.31	3.6e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg05887092	chr17:76393375	PGS1	0.51	9.14	0.45	6.32e-18	HDL cholesterol levels;
LUSC	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.24	-0.37	3.14e-12	Neuroticism;
LUSC	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg00531865	chr16:30841666	NA	-0.34	-6.14	-0.32	2.36e-9	Dementia with Lewy bodies;
LUSC	cis	rs10489202	0.608	rs10918826	chr1:168075316	C/T	cg24449463	chr1:168025552	DCAF6	-0.64	-9.82	-0.47	3.58e-20	Schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21890592	chr7:5013639	RNF216L	-0.41	-5.96	-0.31	6.48e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg03806693	chr22:41940476	POLR3H	-0.85	-12.2	-0.56	1.48e-28	Vitiligo;
LUSC	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg00310523	chr12:86230176	RASSF9	0.4	7.33	0.37	1.8e-12	Major depressive disorder;
LUSC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg14092988	chr3:52407081	DNAH1	0.33	6.41	0.33	4.93e-10	Bipolar disorder;
LUSC	cis	rs4343996	0.967	rs4316064	chr7:3358580	A/G	cg21248987	chr7:3385318	SDK1	0.34	5.84	0.3	1.27e-8	Motion sickness;
LUSC	cis	rs6700559	0.654	rs12061556	chr1:200650239	G/C	cg07804481	chr1:200639085	DDX59	0.41	5.77	0.3	1.85e-8	Coronary artery disease;
LUSC	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg08917208	chr2:24149416	ATAD2B	0.98	9.95	0.48	1.34e-20	Lymphocyte counts;
LUSC	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg03929089	chr4:120376271	NA	-0.44	-6.15	-0.32	2.24e-9	HDL cholesterol;
LUSC	cis	rs7681440	0.583	rs2583966	chr4:90741519	G/A	cg06632027	chr4:90757378	SNCA	-0.36	-5.7	-0.3	2.57e-8	Dementia with Lewy bodies;
LUSC	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg09904177	chr6:26538194	HMGN4	0.65	11.47	0.53	6.41e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg01982873	chr5:490308	SLC9A3	0.35	6.46	0.33	3.81e-10	Cystic fibrosis severity;
LUSC	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.59	-0.38	3.31e-13	Neuroticism;
LUSC	cis	rs2137920	0.945	rs2466751	chr10:50239936	A/G	cg27141751	chr10:50231850	C10orf72	0.39	5.79	0.3	1.62e-8	Migraine with aura;
LUSC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg18190219	chr22:46762943	CELSR1	-0.45	-6.16	-0.32	2.11e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg03585969	chr10:35415529	CREM	0.58	8.43	0.42	1.02e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg01733217	chr16:74700730	RFWD3	1.0	22.71	0.78	1.04e-69	Multiple myeloma;
LUSC	cis	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg17325771	chr7:75508891	RHBDD2	-0.41	-5.84	-0.3	1.27e-8	Eotaxin levels;
LUSC	cis	rs6577655	0.517	rs4909293	chr8:135587888	G/A	cg17885191	chr8:135476712	NA	0.6	7.78	0.39	9.33e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.71	11.99	0.55	8.83e-28	Motion sickness;
LUSC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg13072238	chr3:49761600	GMPPB	0.68	8.35	0.42	1.87e-15	Menarche (age at onset);
LUSC	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg13010199	chr12:38710504	ALG10B	0.68	10.59	0.5	8.44e-23	Bladder cancer;
LUSC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg22535103	chr8:58192502	C8orf71	-0.79	-8.22	-0.41	4.44e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs354225	0.544	rs13403284	chr2:54805749	A/G	cg26097391	chr2:54893211	SPTBN1	0.46	6.95	0.36	1.88e-11	Schizophrenia;
LUSC	cis	rs1712517	0.771	rs11191664	chr10:105118476	C/T	cg05636881	chr10:105038444	INA	0.4	6.74	0.35	7.11e-11	Migraine;
LUSC	cis	rs9309473	0.898	rs6546851	chr2:73833283	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.51	-0.34	2.77e-10	Metabolite levels;
LUSC	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.57	0.65	1.85e-41	Bladder cancer;
LUSC	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18252515	chr7:66147081	NA	-0.57	-7.9	-0.4	4.08e-14	Corneal structure;
LUSC	cis	rs62408225	0.963	rs45553631	chr6:90981657	C/T	cg06866423	chr6:90926672	BACH2	0.41	5.92	0.31	7.99e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9399401	0.626	rs6906468	chr6:142769386	A/G	cg04461802	chr6:142623433	GPR126	0.45	6.15	0.32	2.27e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg19592336	chr6:28129416	ZNF389	0.53	7.05	0.36	1.02e-11	Parkinson's disease;
LUSC	cis	rs4400599	1.000	rs4400599	chr1:154127100	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.35	-5.71	-0.3	2.52e-8	Platelet distribution width;
LUSC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg19812747	chr11:111475976	SIK2	-0.51	-7.4	-0.38	1.1e-12	Primary sclerosing cholangitis;
LUSC	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.6	0.38	3.1e-13	Iron status biomarkers;
LUSC	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg08975724	chr8:8085496	FLJ10661	0.46	7.16	0.36	5.15e-12	Mood instability;
LUSC	cis	rs6489882	0.703	rs10850097	chr12:113361117	C/T	cg20102336	chr12:113376681	OAS3	-0.42	-6.07	-0.32	3.43e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg16362232	chr11:430036	ANO9	0.66	8.29	0.41	2.74e-15	Body mass index;
LUSC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg24562669	chr7:97807699	LMTK2	0.34	6.06	0.31	3.66e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg20307385	chr11:47447363	PSMC3	0.44	6.3	0.33	9.23e-10	Subjective well-being;
LUSC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg06740227	chr12:86229804	RASSF9	0.44	7.12	0.36	6.75e-12	Major depressive disorder;
LUSC	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg11057378	chr10:81107060	PPIF	0.37	6.21	0.32	1.57e-9	Height;
LUSC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.85	15.3	0.64	2.01e-40	Menarche (age at onset);
LUSC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg01802117	chr1:53393560	SCP2	0.4	6.66	0.34	1.11e-10	Monocyte count;
LUSC	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg10356904	chr22:49881777	NA	-0.3	-6.71	-0.34	8.17e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.13	-0.36	6.32e-12	Menopause (age at onset);
LUSC	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.36	-19.2	-0.72	6.89e-56	Hip circumference adjusted for BMI;
LUSC	cis	rs2227564	0.672	rs10824042	chr10:75645628	C/T	cg23231163	chr10:75533350	FUT11	-0.43	-5.94	-0.31	7.3e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs1568889	1.000	rs12800354	chr11:28047723	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	8.94	0.44	2.63e-17	Bipolar disorder;
LUSC	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.59	8.21	0.41	4.89e-15	Body mass index (adult);
LUSC	cis	rs6977660	0.714	rs12334267	chr7:19810265	A/G	cg05791153	chr7:19748676	TWISTNB	0.66	7.04	0.36	1.11e-11	Thyroid stimulating hormone;
LUSC	trans	rs11935423	0.778	rs6841211	chr4:100501690	T/C	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.05	-0.31	3.97e-9	Gut microbiome composition (summer);
LUSC	cis	rs7107174	1.000	rs7939646	chr11:78111613	C/T	cg02023728	chr11:77925099	USP35	-0.44	-6.52	-0.34	2.61e-10	Testicular germ cell tumor;
LUSC	cis	rs1107366	0.505	rs12489314	chr3:125976864	A/G	cg01346077	chr3:125931526	NA	0.3	5.67	0.3	3.02e-8	Metabolite levels;
LUSC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.87	-0.35	3.2e-11	Lung cancer;
LUSC	trans	rs731565	1.000	rs731565	chr7:147406262	C/T	cg20906291	chr6:10382103	NA	-0.54	-6.13	-0.32	2.55e-9	Diabetic kidney disease;
LUSC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.7	-12.66	-0.57	2.88e-30	Aortic root size;
LUSC	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg02117656	chr17:79614917	TSPAN10	0.31	5.75	0.3	1.98e-8	Eye color traits;
LUSC	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.16	-0.36	5.08e-12	Coronary artery disease;
LUSC	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg01689657	chr7:91764605	CYP51A1	0.34	6.12	0.32	2.69e-9	Breast cancer;
LUSC	cis	rs7267979	0.586	rs6083776	chr20:25186116	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	12.63	0.57	3.63e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg11845111	chr2:191398756	TMEM194B	-0.83	-11.09	-0.52	1.53e-24	Diastolic blood pressure;
LUSC	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg09307838	chr4:120376055	NA	0.7	10.54	0.5	1.25e-22	Corneal astigmatism;
LUSC	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	7.92	0.4	3.62e-14	Height;
LUSC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg04025307	chr7:1156635	C7orf50	0.47	7.4	0.38	1.15e-12	Longevity;Endometriosis;
LUSC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg00684032	chr4:1343700	KIAA1530	0.37	6.51	0.34	2.82e-10	Obesity-related traits;
LUSC	cis	rs6690583	0.623	rs74761855	chr1:85432947	A/C	cg11262906	chr1:85462892	MCOLN2	0.7	6.73	0.35	7.37e-11	Serum sulfate level;
LUSC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08280861	chr8:58055591	NA	0.54	6.52	0.34	2.65e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.52	10.68	0.5	4.11e-23	Iron status biomarkers;
LUSC	trans	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04565464	chr8:145669602	NFKBIL2	0.38	6.19	0.32	1.76e-9	Schizophrenia;
LUSC	cis	rs11866815	0.901	rs758033	chr16:397044	G/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.39	6.15	0.32	2.23e-9	Body mass index;
LUSC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.86	0.39	5.51e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.95	0.36	1.95e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.75	10.1	0.48	4.06e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg25554036	chr4:6271136	WFS1	0.56	10.67	0.5	4.58e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg25460059	chr11:9595544	WEE1	0.49	6.12	0.32	2.6e-9	Cognitive function;Information processing speed;
LUSC	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg16339924	chr4:17578868	LAP3	-0.53	-7.46	-0.38	7.36e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3772130	0.564	rs35178434	chr3:121595936	G/A	cg20356878	chr3:121714668	ILDR1	0.6	9.74	0.47	6.85e-20	Cognitive performance;
LUSC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-9.21	-0.45	3.74e-18	Gut microbiome composition (summer);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08693705	chr5:179719171	MAPK9	0.46	6.39	0.33	5.64e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	7.3	0.37	2.08e-12	Bipolar disorder;
LUSC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg20790798	chr5:1857306	NA	-0.5	-8.73	-0.43	1.26e-16	Cardiovascular disease risk factors;
LUSC	cis	rs12421382	0.639	rs12791519	chr11:109486754	A/G	cg27471124	chr11:109292789	C11orf87	0.38	6.65	0.34	1.18e-10	Schizophrenia;
LUSC	trans	rs61931739	0.817	rs188588	chr12:34215277	G/A	cg24313572	chr1:56050060	NA	-0.3	-6.3	-0.33	9.43e-10	Morning vs. evening chronotype;
LUSC	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg05887092	chr17:76393375	PGS1	0.51	8.94	0.44	2.62e-17	HDL cholesterol levels;
LUSC	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg27535305	chr1:53392650	SCP2	-0.43	-8.63	-0.43	2.49e-16	Monocyte count;
LUSC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.47	-0.8	1.71e-76	Height;
LUSC	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg16950941	chr11:66035639	RAB1B	0.52	7.7	0.39	1.5700000000000001e-13	Gout;
LUSC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg02423579	chr7:2872169	GNA12	-0.47	-7.06	-0.36	9.55e-12	Height;
LUSC	cis	rs10904908	0.733	rs359288	chr10:17330180	A/G	cg01003015	chr10:17271136	VIM	-0.39	-5.79	-0.3	1.62e-8	Total cholesterol levels;Cholesterol, total;
LUSC	trans	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.51	8.02	0.4	1.79e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs800082	0.516	rs9813164	chr3:144227590	A/G	cg24215973	chr2:240111563	HDAC4	0.45	6.76	0.35	6.1e-11	Smoking behavior;
LUSC	cis	rs2932538	0.961	rs3013441	chr1:113192605	C/T	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.27	-0.45	2.3e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7945718	0.935	rs1609442	chr11:12795418	T/A	cg25843174	chr11:12811716	TEAD1	0.33	7.31	0.37	2.03e-12	Educational attainment (years of education);
LUSC	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.47	7.3	0.37	2.11e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9650657	0.584	rs28613656	chr8:10695419	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.25	-0.32	1.28e-9	Neuroticism;
LUSC	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.7	0.75	7.91e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.64	7.85	0.39	5.88e-14	Lung function (FEV1/FVC);
LUSC	cis	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.29	-0.41	2.72e-15	Coronary artery disease;
LUSC	cis	rs7633770	0.965	rs6804112	chr3:46686248	C/T	cg11219411	chr3:46661640	NA	0.38	7.76	0.39	1.06e-13	Coronary artery disease;
LUSC	cis	rs4737010	0.501	rs34342524	chr8:41633857	G/A	cg17182837	chr8:41585554	ANK1	0.38	6.54	0.34	2.36e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg24069376	chr3:38537580	EXOG	0.38	7.22	0.37	3.52e-12	Electrocardiographic conduction measures;
LUSC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg22963979	chr7:1858916	MAD1L1	-0.64	-10.19	-0.49	2.04e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg25039879	chr17:56429692	SUPT4H1	0.68	9.14	0.45	6.1e-18	Cognitive test performance;
LUSC	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	6.39	0.33	5.64e-10	Schizophrenia;
LUSC	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg02660097	chr11:68866761	NA	0.43	6.1	0.32	2.9e-9	Blond vs. brown hair color;
LUSC	cis	rs7705502	1.000	rs72812840	chr5:173374655	A/G	cg18693985	chr5:173351052	CPEB4	-0.37	-5.86	-0.31	1.11e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.35	-0.33	7.03e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-9.44	-0.46	6.61e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-0.87	-13.36	-0.59	6.37e-33	Blood protein levels;
LUSC	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.49	-6.11	-0.32	2.82e-9	Smoking behavior;
LUSC	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg21545522	chr1:205238299	TMCC2	0.46	8.53	0.42	5.15e-16	Red blood cell count;
LUSC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg00933542	chr6:150070202	PCMT1	0.34	6.99	0.36	1.52e-11	Lung cancer;
LUSC	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg12826209	chr6:26865740	GUSBL1	-0.69	-6.31	-0.33	9.11e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg11189052	chr15:85197271	WDR73	0.46	5.66	0.3	3.26e-8	Schizophrenia;
LUSC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg16447950	chr5:562315	NA	-0.58	-7.11	-0.36	7.26e-12	Obesity-related traits;
LUSC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg23630131	chr7:65973040	NA	0.21	5.81	0.3	1.42e-8	Aortic root size;
LUSC	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	7.34	0.37	1.62e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19346786	chr7:2764209	NA	-0.45	-7.77	-0.39	9.87e-14	Height;
LUSC	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.65	-0.6	5.22e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg20887711	chr4:1340912	KIAA1530	0.69	10.4	0.49	4.04e-22	Longevity;
LUSC	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg03929089	chr4:120376271	NA	0.74	6.95	0.36	1.87e-11	Axial length;
LUSC	cis	rs72781680	0.706	rs72794290	chr2:23896106	A/T	cg20701182	chr2:24300061	SF3B14	0.77	7.42	0.38	9.57e-13	Lymphocyte counts;
LUSC	cis	rs8114671	0.935	rs633198	chr20:33778434	T/C	cg07148914	chr20:33460835	GGT7	-0.45	-6.64	-0.34	1.28e-10	Height;
LUSC	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg08048268	chr3:133502702	NA	-0.35	-6.52	-0.34	2.57e-10	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.16	-0.36	5.13e-12	Bipolar disorder;
LUSC	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.15	-0.45	5.6e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.89	15.05	0.64	2.03e-39	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs12310956	0.531	rs10772110	chr12:33841755	A/G	cg26384229	chr12:38710491	ALG10B	0.48	7.08	0.36	8.44e-12	Morning vs. evening chronotype;
LUSC	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.52	8.24	0.41	4.06e-15	Birth weight;
LUSC	cis	rs11247915	0.583	rs66569416	chr1:26659737	C/G	cg04990556	chr1:26633338	UBXN11	-0.49	-6.75	-0.35	6.4e-11	Obesity-related traits;
LUSC	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.88	0.31	9.93e-9	Rheumatoid arthritis;
LUSC	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	0.54	8.3	0.41	2.62e-15	Breast cancer;
LUSC	trans	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg01620082	chr3:125678407	NA	-0.59	-6.55	-0.34	2.21e-10	Depression;
LUSC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg05025164	chr4:1340916	KIAA1530	0.55	8.62	0.43	2.72e-16	Longevity;
LUSC	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg12924262	chr12:102091054	CHPT1	0.43	6.12	0.32	2.57e-9	Blood protein levels;
LUSC	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg25427524	chr10:38739819	LOC399744	-0.49	-6.61	-0.34	1.53e-10	Obesity (extreme);
LUSC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg14895029	chr7:2775587	GNA12	-0.43	-6.54	-0.34	2.26e-10	Height;
LUSC	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg13615516	chr5:77269221	NA	0.39	6.52	0.34	2.54e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg14689365	chr7:158441557	NCAPG2	0.53	7.54	0.38	4.35e-13	Height;
LUSC	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.74	10.76	0.51	2.3e-23	Corneal astigmatism;
LUSC	cis	rs11039100	0.607	rs35527801	chr11:5782540	G/A	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.65	-10.17	-0.49	2.36e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg07097265	chr17:17727093	SREBF1	0.35	6.21	0.32	1.61e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg27266027	chr21:40555129	PSMG1	-0.39	-5.68	-0.3	2.94e-8	Cognitive function;
LUSC	cis	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg07460842	chr6:66804631	NA	-0.48	-6.72	-0.35	7.74e-11	Blood trace element (Cu levels);
LUSC	cis	rs55910451	0.549	rs72772358	chr10:5817627	T/A	cg11519256	chr10:5708881	ASB13	-0.5	-6.33	-0.33	7.84e-10	Breast cancer;
LUSC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg10018233	chr7:150070692	REPIN1	0.4	6.69	0.34	9.18e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03517284	chr6:25882590	NA	-0.43	-7.39	-0.38	1.16e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg05623727	chr3:50126028	RBM5	0.32	6.04	0.31	4.04e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.7	-10.63	-0.5	6.55e-23	Aortic root size;
LUSC	cis	rs1577917	0.883	rs9450348	chr6:86598036	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-6.36	-0.33	6.51e-10	Response to antipsychotic treatment;
LUSC	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg13660082	chr14:53194042	PSMC6	-0.77	-7.01	-0.36	1.3e-11	Alzheimer's disease (late onset);
LUSC	cis	rs13006833	0.668	rs291449	chr2:191177467	A/G	cg21644426	chr2:191273491	MFSD6	-0.42	-5.94	-0.31	7.09e-9	Urinary metabolites;
LUSC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-7.54	-0.38	4.53e-13	Aortic root size;
LUSC	cis	rs981844	0.816	rs62325147	chr4:154727568	G/A	cg14289246	chr4:154710475	SFRP2	0.48	6.3	0.33	9.33e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05902063	chr12:96794315	CDK17	-0.45	-6.48	-0.33	3.37e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs11031096	0.655	rs12293706	chr11:4211581	C/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.71	-0.3	2.5e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs13253111	0.624	rs1979330	chr8:28096051	T/A	cg26534493	chr8:28060551	NA	0.39	7.01	0.36	1.35e-11	Childhood body mass index;
LUSC	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg09699651	chr6:150184138	LRP11	0.45	7.15	0.36	5.64e-12	Testicular germ cell tumor;
LUSC	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg13565492	chr6:43139072	SRF	-0.57	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.48	-0.33	3.32e-10	Morning vs. evening chronotype;
LUSC	cis	rs2692947	0.770	rs58730124	chr2:96413338	T/C	cg23100626	chr2:96804247	ASTL	0.29	6.89	0.35	2.78e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06553422	chr19:15560234	WIZ;MIR1470	0.76	6.65	0.34	1.23e-10	Cognitive performance;
LUSC	trans	rs1864729	0.901	rs2451114	chr8:98273762	G/A	cg08679828	chr8:102218111	ZNF706	-0.74	-6.83	-0.35	4.03e-11	Estradiol plasma levels (breast cancer);
LUSC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg17376030	chr22:41985996	PMM1	-0.46	-5.84	-0.3	1.26e-8	Vitiligo;
LUSC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg19592336	chr6:28129416	ZNF389	0.48	6.27	0.32	1.11e-9	Depression;
LUSC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13770153	chr20:60521292	NA	-0.53	-7.1	-0.36	7.73e-12	Body mass index;
LUSC	cis	rs4409675	0.576	rs12070659	chr1:28227175	G/A	cg23691781	chr1:28212827	C1orf38	0.31	7.48	0.38	6.53e-13	Corneal astigmatism;
LUSC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-8.31	-0.41	2.37e-15	Alzheimer's disease;
LUSC	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg00012203	chr2:219082015	ARPC2	-0.77	-13.07	-0.58	8.24e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg08742575	chr21:47604166	C21orf56	0.45	6.93	0.35	2.19e-11	Testicular germ cell tumor;
LUSC	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg08213375	chr14:104286397	PPP1R13B	0.52	10.24	0.49	1.38e-21	Schizophrenia;
LUSC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-0.97	-15.59	-0.65	1.43e-41	Dupuytren's disease;
LUSC	trans	rs2288327	0.557	rs60488846	chr2:179357842	C/T	cg14011486	chr1:26737247	LIN28	0.77	9.66	0.47	1.22e-19	Atrial fibrillation;
LUSC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.87	-0.31	1.05e-8	Personality dimensions;
LUSC	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg19610905	chr11:61596333	FADS2	-0.54	-8.09	-0.4	1.13e-14	Trans fatty acid levels;
LUSC	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-17.58	-0.69	1.84e-49	Primary sclerosing cholangitis;
LUSC	cis	rs9463078	0.683	rs12215252	chr6:44736265	C/T	cg25276700	chr6:44698697	NA	0.32	6.35	0.33	7.1e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg22153463	chr1:85462885	MCOLN2	0.61	7.98	0.4	2.42e-14	Serum sulfate level;
LUSC	cis	rs138918	0.772	rs138937	chr22:43568060	C/G	cg08909806	chr22:43548696	TSPO	0.35	5.98	0.31	5.81e-9	Monocyte count;
LUSC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg16423285	chr20:60520624	NA	-0.46	-5.84	-0.3	1.23e-8	Body mass index;
LUSC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg13607699	chr17:42295918	UBTF	0.5	8.03	0.4	1.66e-14	Total body bone mineral density;
LUSC	cis	rs7106204	0.609	rs34376029	chr11:24291233	C/T	ch.11.24196551F	chr11:24239977	NA	0.69	5.74	0.3	2.14e-8	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2692947	0.683	rs62153700	chr2:96581338	C/T	cg23100626	chr2:96804247	ASTL	0.3	7.0	0.36	1.44e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4343996	0.870	rs4722712	chr7:3389147	C/T	cg21248987	chr7:3385318	SDK1	-0.42	-7.24	-0.37	3.15e-12	Motion sickness;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10916625	chr20:48330123	B4GALT5	-0.4	-5.94	-0.31	6.99e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-7.85	-0.39	5.74e-14	Chronic sinus infection;
LUSC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs4664304	0.900	rs17231993	chr2:160741415	C/T	cg23995753	chr2:160760732	LY75	-0.33	-6.09	-0.32	3.07e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4805272	0.582	rs11083652	chr19:29231569	G/C	cg14983838	chr19:29218262	NA	-0.42	-6.27	-0.32	1.09e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	trans	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg09788866	chr2:128051348	ERCC3	-0.39	-5.95	-0.31	6.67e-9	Mean corpuscular volume;
LUSC	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg25237894	chr2:233734115	C2orf82	0.36	6.74	0.35	7.17e-11	Coronary artery disease;
LUSC	cis	rs2109514	0.902	rs7810505	chr7:116111078	G/T	cg12739419	chr7:116140593	CAV2	-0.27	-5.92	-0.31	7.84e-9	Prevalent atrial fibrillation;
LUSC	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg23625390	chr15:77176239	SCAPER	-0.65	-9.66	-0.47	1.25e-19	Blood metabolite levels;
LUSC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg00933542	chr6:150070202	PCMT1	0.32	6.58	0.34	1.86e-10	Lung cancer;
LUSC	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	trans	rs6982636	1.000	rs2980855	chr8:126477476	T/C	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.35	-6.68	-0.34	1e-10	Lipid metabolism phenotypes;
LUSC	cis	rs3099143	1.000	rs1114717	chr15:77086078	A/G	cg21673338	chr15:77095150	SCAPER	0.77	7.82	0.39	7.04e-14	Recalcitrant atopic dermatitis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05628496	chr17:17991167	DRG2	0.4	5.95	0.31	6.81e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs17125944	0.686	rs78623109	chr14:53383077	G/T	cg00686598	chr14:53173677	PSMC6	0.84	7.58	0.38	3.44e-13	Alzheimer's disease (late onset);
LUSC	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg24812749	chr6:127587940	RNF146	0.63	9.49	0.46	4.62e-19	Breast cancer;
LUSC	cis	rs2233152	0.610	rs10405596	chr19:41314720	C/T	cg21869046	chr19:41225005	ITPKC	0.45	6.18	0.32	1.85e-9	Kawasaki disease;
LUSC	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.63	10.03	0.48	7.4e-21	Morning vs. evening chronotype;
LUSC	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg14036092	chr11:66035641	RAB1B	0.42	6.11	0.32	2.85e-9	Gout;
LUSC	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg16262614	chr3:133464971	TF	0.43	7.51	0.38	5.41e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs7903847	0.642	rs4635018	chr10:99137839	C/G	cg20016023	chr10:99160130	RRP12	0.34	8.0	0.4	2.08e-14	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg26043149	chr18:55253948	FECH	-0.54	-7.99	-0.4	2.25e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg04871131	chr7:94954202	PON1	-0.37	-6.02	-0.31	4.59e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	8.22	0.41	4.58e-15	Axial length;
LUSC	cis	rs701145	0.586	rs181443	chr3:153959028	G/T	cg10247383	chr3:153839028	SGEF	-0.5	-6.11	-0.32	2.79e-9	Coronary artery disease;
LUSC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.39e-22	Alzheimer's disease (late onset);
LUSC	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg20701182	chr2:24300061	SF3B14	0.58	6.19	0.32	1.72e-9	Lymphocyte counts;
LUSC	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.5	8.4	0.42	1.29e-15	Alcohol dependence;
LUSC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08280861	chr8:58055591	NA	0.59	7.24	0.37	3.21e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg10756647	chr7:56101905	PSPH	-0.83	-8.16	-0.41	7.1e-15	Diabetic kidney disease;
LUSC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	9.29	0.45	2.08e-18	Mean platelet volume;
LUSC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg24733560	chr20:60626293	TAF4	0.41	6.73	0.35	7.47e-11	Body mass index;
LUSC	cis	rs12286929	0.617	rs11607801	chr11:115077367	A/C	cg04055981	chr11:115044050	NA	0.44	7.88	0.4	4.71e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11958404	0.929	rs60700182	chr5:157438376	A/G	cg05962755	chr5:157440814	NA	0.53	6.3	0.33	9.34e-10	IgG glycosylation;
LUSC	cis	rs4852324	0.541	rs7568898	chr2:74271577	C/T	cg05890377	chr2:74357713	NA	0.46	5.71	0.3	2.48e-8	Systemic lupus erythematosus;
LUSC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg05347473	chr6:146136440	FBXO30	0.53	8.91	0.44	3.27e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	0.93	18.36	0.71	1.51e-52	Cognitive function;
LUSC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg01125463	chr6:42946178	PEX6	-0.35	-5.81	-0.3	1.42e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23120805	chr2:43453872	LOC100129726;ZFP36L2	-0.39	-5.96	-0.31	6.45e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.6	-10.06	-0.48	5.7e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2625529	0.590	rs713048	chr15:72543084	G/A	cg16672083	chr15:72433130	SENP8	-0.5	-7.65	-0.39	2.15e-13	Red blood cell count;
LUSC	cis	rs7072216	0.691	rs7910973	chr10:100166732	G/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg01363383	chr10:111967257	MXI1	0.41	5.99	0.31	5.43e-9	Triglycerides;
LUSC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg23172400	chr8:95962367	TP53INP1	-0.43	-8.82	-0.43	6.61e-17	Type 2 diabetes;
LUSC	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-1.13	-17.64	-0.69	1.06e-49	Exhaled nitric oxide output;
LUSC	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg25566285	chr7:158114605	PTPRN2	-0.32	-5.73	-0.3	2.29e-8	Calcium levels;
LUSC	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg21064579	chr19:49206444	FUT2	0.45	8.48	0.42	7.34e-16	Dietary macronutrient intake;
LUSC	cis	rs1957429	0.901	rs1467570	chr14:65347858	A/G	cg23373153	chr14:65346875	NA	1.07	12.89	0.58	3.85e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs500891	0.525	rs4706991	chr6:84109088	C/T	cg08257003	chr6:84140564	ME1	0.35	8.38	0.42	1.48e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg14789911	chr21:47582049	C21orf56	0.36	5.64	0.3	3.57e-8	Testicular germ cell tumor;
LUSC	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.79	13.37	0.59	5.73e-33	Coronary artery disease;
LUSC	cis	rs7572733	0.534	rs58374969	chr2:198764363	C/T	cg00792783	chr2:198669748	PLCL1	0.45	5.87	0.31	1.04e-8	Dermatomyositis;
LUSC	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.31	0.64	1.87e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs4363385	0.720	rs9325996	chr1:152965347	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.66	-0.39	2.08e-13	Inflammatory skin disease;
LUSC	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg09307838	chr4:120376055	NA	0.68	9.65	0.47	1.32e-19	Corneal astigmatism;
LUSC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg09877947	chr5:131593287	PDLIM4	0.39	6.39	0.33	5.68e-10	Blood metabolite levels;
LUSC	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.57	-6.64	-0.34	1.27e-10	Iron status biomarkers;
LUSC	cis	rs2742417	1.000	rs2673065	chr3:45771222	C/T	cg18779283	chr3:45636154	LIMD1	-0.33	-5.65	-0.3	3.52e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs2229238	0.911	rs73020234	chr1:154482767	C/A	cg25273160	chr11:56955011	LRRC55	0.31	5.96	0.31	6.37e-9	Coronary heart disease;
LUSC	cis	rs2041895	0.509	rs2072559	chr12:107307287	T/G	cg13944111	chr12:107296891	NA	0.37	6.37	0.33	6.16e-10	Glaucoma (low intraocular pressure);
LUSC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.41	-0.42	1.21e-15	Lung cancer;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg09033563	chr22:24373618	LOC391322	-0.47	-6.58	-0.34	1.84e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.61	-8.73	-0.43	1.2e-16	Bipolar disorder;
LUSC	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg22029157	chr1:209979665	IRF6	-0.71	-8.64	-0.43	2.28e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs677665	0.537	rs12121476	chr1:9335327	C/G	cg25755851	chr1:9335794	NA	0.8	12.42	0.56	2.15e-29	Eosinophil percentage of white cells;
LUSC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.71	-0.3	2.47e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13315871	1.000	rs9850717	chr3:58351875	C/T	cg20936604	chr3:58311152	NA	-0.59	-5.91	-0.31	8.65e-9	Cholesterol, total;
LUSC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg17691542	chr6:26056736	HIST1H1C	0.49	7.19	0.37	4.26e-12	Height;
LUSC	trans	rs330071	0.500	rs17662123	chr8:9246837	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	7.52	0.38	5.25e-13	Acne (severe);
LUSC	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-0.83	-12.1	-0.55	3.35e-28	Migraine;Coronary artery disease;
LUSC	cis	rs1865721	1.000	rs17283692	chr18:73193911	T/C	cg26385618	chr18:73139727	C18orf62	-0.48	-8.1	-0.41	1.04e-14	Intelligence;
LUSC	cis	rs13385	0.769	rs4913072	chr5:139608353	T/C	cg26211634	chr5:139558579	C5orf32	0.46	6.91	0.35	2.53e-11	Atrial fibrillation;
LUSC	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg15556689	chr8:8085844	FLJ10661	0.57	8.48	0.42	7.31e-16	Myopia (pathological);
LUSC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg22143856	chr6:28129313	ZNF389	0.42	5.78	0.3	1.73e-8	Parkinson's disease;
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-8.12	-0.41	9.16e-15	Lymphocyte counts;
LUSC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.03e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7923609	0.870	rs10822156	chr10:65080727	T/C	cg01631684	chr10:65280961	REEP3	-0.41	-6.43	-0.33	4.51e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10383028	chr17:48638097	CACNA1G	-0.41	-6.16	-0.32	2.04e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.22	0.45	3.34e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311676	0.656	rs56384862	chr3:58395863	A/G	cg26110898	chr3:58419937	PDHB	0.4	6.46	0.33	3.65e-10	Systemic lupus erythematosus;
LUSC	cis	rs4363385	0.747	rs2879489	chr1:152970465	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.79	-0.39	8.81e-14	Inflammatory skin disease;
LUSC	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.53	8.17	0.41	6.61e-15	Schizophrenia;
LUSC	cis	rs7178572	0.568	rs12912050	chr15:77689423	C/T	cg22256960	chr15:77711686	NA	-0.48	-7.59	-0.38	3.26e-13	Type 2 diabetes;
LUSC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.98	-14.46	-0.62	3.73e-37	Initial pursuit acceleration;
LUSC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.84	-15.34	-0.64	1.37e-40	Dental caries;
LUSC	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg27284194	chr4:1044797	NA	0.58	8.9	0.44	3.65e-17	Recombination rate (females);
LUSC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg08499158	chr17:42289980	UBTF	-0.52	-8.58	-0.42	3.63e-16	Total body bone mineral density;
LUSC	cis	rs2235649	0.833	rs9927047	chr16:1851927	A/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.42	-6.02	-0.31	4.48e-9	Blood metabolite levels;
LUSC	cis	rs5758511	0.524	rs738257	chr22:42569298	C/A	cg00645731	chr22:42541494	CYP2D7P1	0.59	10.05	0.48	6.04e-21	Birth weight;
LUSC	cis	rs4363385	0.747	rs1415960	chr1:152973571	G/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.88	-0.4	4.72e-14	Inflammatory skin disease;
LUSC	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	10.27	0.49	1.1e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg04017836	chr7:65315216	NA	-0.37	-5.95	-0.31	6.75e-9	Height;
LUSC	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.73	-9.47	-0.46	5.35e-19	Multiple sclerosis;
LUSC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.35	0.59	7.02e-33	Cognitive test performance;
LUSC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.27	0.45	2.39e-18	Monocyte percentage of white cells;
LUSC	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg26384229	chr12:38710491	ALG10B	0.68	10.62	0.5	7e-23	Morning vs. evening chronotype;
LUSC	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.49	-8.43	-0.42	1.05e-15	Axial length;
LUSC	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg05163923	chr11:71159392	DHCR7	0.76	11.45	0.53	8.11e-26	Vitamin D levels;
LUSC	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg08779649	chr13:50194554	NA	0.41	6.92	0.35	2.27e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.76	-0.51	2.14e-23	Alzheimer's disease;
LUSC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.52e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.29	-0.33	9.9e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg05585544	chr11:47624801	NA	-0.43	-7.51	-0.38	5.31e-13	Subjective well-being;
LUSC	cis	rs9341808	0.529	rs4706840	chr6:81057769	T/A	cg08355045	chr6:80787529	NA	0.47	7.83	0.39	6.65e-14	Sitting height ratio;
LUSC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.0	-0.36	1.44e-11	Alzheimer's disease (late onset);
LUSC	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.55	-0.46	2.96e-19	Joint mobility (Beighton score);
LUSC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg19592336	chr6:28129416	ZNF389	0.52	7.22	0.37	3.42e-12	Parkinson's disease;
LUSC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-1.06	-15.36	-0.64	1.17e-40	Vitiligo;
LUSC	cis	rs9462027	0.628	rs6905393	chr6:34776626	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.75	-0.3	2.03e-8	Systemic lupus erythematosus;
LUSC	trans	rs800082	0.593	rs4349542	chr3:144176717	A/G	cg24215973	chr2:240111563	HDAC4	0.4	5.97	0.31	6.2e-9	Smoking behavior;
LUSC	cis	rs7923609	1.000	rs4399232	chr10:64999490	C/T	cg01631684	chr10:65280961	REEP3	-0.41	-6.46	-0.33	3.7e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00684032	chr4:1343700	KIAA1530	0.34	5.8	0.3	1.55e-8	Obesity-related traits;
LUSC	trans	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-8.94	-0.44	2.73e-17	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	1.14	19.75	0.73	4.69e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-12.22	-0.56	1.23e-28	Chronic sinus infection;
LUSC	cis	rs981844	0.712	rs1350189	chr4:154744951	A/T	cg14289246	chr4:154710475	SFRP2	-0.44	-6.11	-0.32	2.84e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.92	-0.31	8.08e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4077468	1.000	rs9662221	chr1:205915745	G/T	cg14893161	chr1:205819251	PM20D1	-0.42	-6.04	-0.31	4.15e-9	Cystic fibrosis-related diabetes;
LUSC	cis	rs1729407	0.625	rs2727789	chr11:116696887	G/T	cg08985259	chr11:116699649	APOC3	-0.24	-5.7	-0.3	2.7e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg17173187	chr15:85201210	NMB	0.5	9.39	0.46	9.83e-19	Schizophrenia;
LUSC	cis	rs12476592	0.602	rs1255	chr2:63825934	T/C	cg10828910	chr2:63850056	LOC388955	0.5	5.81	0.3	1.49e-8	Childhood ear infection;
LUSC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg06008330	chr7:65541103	ASL	-0.37	-5.69	-0.3	2.79e-8	Aortic root size;
LUSC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg26384229	chr12:38710491	ALG10B	0.8	13.67	0.6	4.37e-34	Morning vs. evening chronotype;
LUSC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18854424	chr1:2615690	NA	-0.5	-10.01	-0.48	8.46e-21	Ulcerative colitis;
LUSC	trans	rs12210905	0.920	rs9368500	chr6:27290981	A/C	cg11837749	chr1:55047332	ACOT11	0.66	6.3	0.33	9.13e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg26876637	chr1:152193138	HRNR	0.47	6.82	0.35	4.29e-11	Atopic dermatitis;
LUSC	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg21775007	chr8:11205619	TDH	-0.5	-7.39	-0.37	1.2e-12	Neuroticism;
LUSC	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	0.97	10.96	0.51	4.58e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2074585	0.517	rs11637971	chr15:91079863	A/C	cg22089800	chr15:90895588	ZNF774	-0.57	-8.08	-0.4	1.17e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg16447950	chr5:562315	NA	-0.61	-7.13	-0.36	6.23e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs73206853	0.841	rs60219027	chr12:110759843	T/G	cg12870014	chr12:110450643	ANKRD13A	0.68	6.44	0.33	4.21e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg22676075	chr6:135203613	NA	0.56	8.8	0.43	7.39e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10203711	1.000	rs4994753	chr2:239567253	T/C	cg14580085	chr2:239553406	NA	0.41	6.99	0.36	1.53e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2625529	0.652	rs8036307	chr15:72175120	A/G	cg16672083	chr15:72433130	SENP8	0.48	7.91	0.4	3.87e-14	Red blood cell count;
LUSC	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.41	-0.38	1.04e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg26513180	chr16:89883248	FANCA	0.91	17.61	0.69	1.5e-49	Vitiligo;
LUSC	cis	rs877282	0.733	rs7092976	chr10:756358	G/A	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg15704280	chr7:45808275	SEPT13	-0.44	-6.16	-0.32	2.08e-9	Height;
LUSC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg05729581	chr11:3078854	CARS	0.5	7.96	0.4	2.69e-14	Longevity;
LUSC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12667521	chr19:29218732	NA	0.52	6.95	0.36	1.96e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.7	-0.47	9.35e-20	Neuroticism;
LUSC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16744531	chr19:17905626	B3GNT3	0.43	6.36	0.33	6.73e-10	Tumor biomarkers;
LUSC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg10755058	chr3:40428713	ENTPD3	0.35	5.74	0.3	2.17e-8	Renal cell carcinoma;
LUSC	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg01973587	chr1:228161476	NA	-0.36	-6.02	-0.31	4.61e-9	Diastolic blood pressure;
LUSC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg22709100	chr7:91322751	NA	0.39	5.78	0.3	1.67e-8	Breast cancer;
LUSC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg22834771	chr12:69754056	YEATS4	-0.49	-7.39	-0.37	1.22e-12	Blood protein levels;
LUSC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg17376030	chr22:41985996	PMM1	-0.46	-5.79	-0.3	1.65e-8	Vitiligo;
LUSC	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg24375607	chr4:120327624	NA	0.79	11.67	0.54	1.27e-26	Corneal astigmatism;
LUSC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.23	0.45	3.28e-18	Menarche (age at onset);
LUSC	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	7.54	0.38	4.36e-13	Educational attainment;
LUSC	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg24130564	chr14:104152367	KLC1	-0.41	-5.73	-0.3	2.21e-8	Body mass index;
LUSC	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg01483505	chr11:975446	AP2A2	0.41	5.7	0.3	2.58e-8	Alzheimer's disease (late onset);
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11060661	chr22:24314208	DDT;DDTL	0.48	7.82	0.39	6.95e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03517284	chr6:25882590	NA	-0.53	-8.73	-0.43	1.27e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4776059	1.000	rs4776059	chr15:52886962	C/T	cg25063058	chr15:52860530	ARPP19	0.46	6.29	0.33	1.01e-9	Schizophrenia;
LUSC	cis	rs1775715	0.870	rs10827003	chr10:32266216	A/G	cg26784012	chr10:32216390	ARHGAP12	0.41	6.71	0.34	8.4e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg08601574	chr20:25228251	PYGB	0.45	6.81	0.35	4.56e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7923609	1.000	rs12355784	chr10:65121565	G/T	cg01631684	chr10:65280961	REEP3	-0.4	-6.27	-0.32	1.11e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg18825076	chr15:78729989	IREB2	0.47	6.21	0.32	1.57e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg27661571	chr11:113659931	NA	0.63	6.03	0.31	4.37e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9807989	0.801	rs72823663	chr2:102968738	G/C	cg09003973	chr2:102972529	NA	0.44	6.01	0.31	4.83e-9	Asthma;
LUSC	trans	rs6600671	1.000	rs10903159	chr1:121181997	G/T	cg00646200	chr1:148855367	NA	0.45	7.16	0.36	5.21e-12	Hip geometry;
LUSC	cis	rs17095355	0.818	rs12571549	chr10:111770013	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.6	-6.93	-0.35	2.19e-11	Biliary atresia;
LUSC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg26958806	chr6:27640298	NA	0.67	5.88	0.31	1.01e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12826209	chr6:26865740	GUSBL1	0.73	9.34	0.45	1.45e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9398803	0.865	rs2184967	chr6:126773487	C/T	cg19875578	chr6:126661172	C6orf173	0.42	6.18	0.32	1.9e-9	Male-pattern baldness;
LUSC	cis	rs4950928	0.712	rs7518666	chr1:203163590	C/T	cg17014757	chr1:203156097	CHI3L1	-0.43	-7.63	-0.39	2.46e-13	YKL-40 levels;
LUSC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg13319975	chr6:146136371	FBXO30	0.51	7.69	0.39	1.66e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg00021532	chr16:4324280	TFAP4	0.8	14.63	0.62	8.48e-38	Prostate-specific antigen levels;
LUSC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18404041	chr3:52824283	ITIH1	0.5	9.53	0.46	3.47e-19	Bipolar disorder;
LUSC	cis	rs925550	0.932	rs7678116	chr4:123571118	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.56	5.94	0.31	7.29e-9	Primary biliary cholangitis;
LUSC	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg24375607	chr4:120327624	NA	0.69	10.58	0.5	9.19e-23	Corneal astigmatism;
LUSC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.47	-9.29	-0.45	2e-18	Monocyte percentage of white cells;
LUSC	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg08330031	chr10:104623503	C10orf32	0.32	5.82	0.3	1.36e-8	Arsenic metabolism;
LUSC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.88e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.23	-0.49	1.46e-21	Hemoglobin concentration;
LUSC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.7	10.56	0.5	1.1e-22	Corneal astigmatism;
LUSC	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg04310649	chr10:35416472	CREM	-0.41	-6.47	-0.33	3.55e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg05775895	chr3:12838266	CAND2	-0.52	-8.53	-0.42	5.31e-16	QRS complex (12-leadsum);
LUSC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-7.61	-0.38	2.77e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg04865166	chr7:105162814	PUS7	0.54	6.05	0.31	3.95e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-0.93	-19.58	-0.73	2.18e-57	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs13092825	1.000	rs6808951	chr3:113274334	A/T	cg18753928	chr3:113234510	CCDC52	-0.38	-5.65	-0.3	3.45e-8	Dental caries;
LUSC	trans	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg24313572	chr1:56050060	NA	-0.31	-6.45	-0.33	4.02e-10	Morning vs. evening chronotype;
LUSC	cis	rs7567389	0.704	rs4662714	chr2:127995213	A/G	cg09760422	chr2:128146352	NA	-0.31	-6.52	-0.34	2.66e-10	Self-rated health;
LUSC	cis	rs59698941	0.943	rs67437142	chr5:132306722	T/C	cg14825688	chr5:132208181	LEAP2	-0.54	-5.72	-0.3	2.39e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs7188861	0.768	rs441349	chr16:11371759	C/T	cg00044050	chr16:11439710	C16orf75	0.55	6.05	0.31	3.79e-9	HDL cholesterol;
LUSC	cis	rs4654899	0.627	rs637990	chr1:21047616	A/G	cg01072550	chr1:21505969	NA	0.4	6.06	0.31	3.64e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg23229984	chr5:148520753	ABLIM3	0.37	5.69	0.3	2.83e-8	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14122358	chr17:79829466	ARHGDIA	-0.43	-6.37	-0.33	6.43e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg16482183	chr6:26056742	HIST1H1C	0.64	9.14	0.45	6.03e-18	Iron status biomarkers;
LUSC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-10.39	-0.49	4.39e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.11	0.32	2.79e-9	Schizophrenia;
LUSC	cis	rs11971779	0.941	rs6954453	chr7:139031794	C/T	cg07862535	chr7:139043722	LUC7L2	0.73	8.2	0.41	5.39e-15	Diisocyanate-induced asthma;
LUSC	trans	rs731565	1.000	rs1525254	chr7:147406140	C/T	cg12847240	chr6:10382088	NA	-0.6	-6.61	-0.34	1.51e-10	Diabetic kidney disease;
LUSC	cis	rs6690583	0.623	rs111687161	chr1:85443533	A/G	cg22153463	chr1:85462885	MCOLN2	0.63	6.01	0.31	4.83e-9	Serum sulfate level;
LUSC	cis	rs41271951	0.512	rs34761930	chr1:151089523	T/C	cg11822372	chr1:151115635	SEMA6C	-0.76	-6.95	-0.36	1.98e-11	Blood protein levels;
LUSC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg22963979	chr7:1858916	MAD1L1	-0.57	-8.91	-0.44	3.44e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.47	-0.53	6.71e-26	Mean corpuscular volume;
LUSC	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg05294307	chr14:35346193	BAZ1A	0.53	6.18	0.32	1.87e-9	Psoriasis;
LUSC	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg22907277	chr7:1156413	C7orf50	0.68	7.31	0.37	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	0.92	15.38	0.64	1.02e-40	Breast cancer;
LUSC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	8.8	0.43	7.57e-17	Mean platelet volume;
LUSC	cis	rs12801636	0.512	rs7119750	chr11:65422591	C/T	cg26668713	chr11:65405903	SIPA1	0.6	5.94	0.31	7.24e-9	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg03647239	chr10:116582469	FAM160B1	0.48	7.67	0.39	1.96e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.21	-0.49	1.83e-21	Eye color traits;
LUSC	cis	rs10887741	0.646	rs7097212	chr10:89430067	G/A	cg13926569	chr10:89418898	PAPSS2	0.33	7.0	0.36	1.39e-11	Exercise (leisure time);
LUSC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg11941060	chr3:133502564	NA	-0.51	-7.77	-0.39	1.01e-13	Iron status biomarkers;
LUSC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg21361702	chr7:150065534	REPIN1	0.45	6.34	0.33	7.52e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03264133	chr6:25882463	NA	-0.46	-8.69	-0.43	1.67e-16	Blood metabolite levels;
LUSC	cis	rs12476592	0.602	rs262495	chr2:63848607	G/A	cg10828910	chr2:63850056	LOC388955	0.48	5.7	0.3	2.69e-8	Childhood ear infection;
LUSC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg06134567	chr22:46658398	PKDREJ	-0.52	-5.97	-0.31	6.19e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6087990	0.842	rs4911253	chr20:31352585	A/G	cg13636640	chr20:31349939	DNMT3B	0.95	19.65	0.73	1.14e-57	Ulcerative colitis;
LUSC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg04315214	chr1:2043799	PRKCZ	0.5	10.44	0.5	2.8e-22	Height;
LUSC	cis	rs36096196	0.891	rs12082516	chr1:2251160	C/T	cg06784691	chr1:2245988	NA	0.31	5.71	0.3	2.51e-8	Coronary artery disease;
LUSC	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg20703242	chr1:230279135	GALNT2	0.52	8.2	0.41	5.22e-15	Coronary artery disease;
LUSC	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-7.12	-0.36	6.78e-12	Total body bone mineral density;
LUSC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg17330251	chr7:94953956	PON1	-0.37	-5.96	-0.31	6.32e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg27068330	chr11:65405492	SIPA1	-0.79	-11.26	-0.52	3.84e-25	Acne (severe);
LUSC	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg17052675	chr2:3827356	NA	-0.64	-10.2	-0.49	1.87e-21	Type 2 diabetes;
LUSC	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg24375607	chr4:120327624	NA	0.79	11.93	0.55	1.43e-27	Corneal astigmatism;
LUSC	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	0.59	9.77	0.47	5.41e-20	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg00484396	chr16:3507460	NAT15	-0.46	-6.75	-0.35	6.7e-11	Body mass index (adult);
LUSC	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg13073564	chr4:8508604	NA	0.47	8.82	0.43	6.58e-17	Response to antineoplastic agents;
LUSC	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.73	10.36	0.49	5.62e-22	Corneal astigmatism;
LUSC	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs62238980	0.614	rs76177859	chr22:32390135	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs6733011	0.500	rs2280142	chr2:99434872	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-6.89	-0.35	2.86e-11	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05788437	chr3:197476880	FYTTD1;KIAA0226	0.38	6.6	0.34	1.62e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg17764715	chr19:33622953	WDR88	-0.61	-9.15	-0.45	5.78e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg25214090	chr10:38739885	LOC399744	0.52	7.7	0.39	1.51e-13	Corneal astigmatism;
LUSC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-12.01	-0.55	7.05e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.66	10.17	0.49	2.47e-21	Colorectal cancer;
LUSC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.88	11.07	0.52	1.79e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.6	6.75	0.35	6.62e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg18350739	chr11:68623251	NA	-0.36	-6.33	-0.33	7.68e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg04691961	chr3:161091175	C3orf57	-0.35	-5.97	-0.31	6.09e-9	Morning vs. evening chronotype;
LUSC	cis	rs7210086	0.768	rs4395115	chr17:70640382	G/C	cg04206342	chr17:70636940	NA	-0.34	-5.76	-0.3	1.92e-8	Ulcerative colitis;
LUSC	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs7119	0.717	rs8032405	chr15:77825344	A/G	cg27398640	chr15:77910606	LINGO1	-0.32	-6.78	-0.35	5.49e-11	Type 2 diabetes;
LUSC	cis	rs68170813	0.522	rs12531187	chr7:106963650	C/G	cg02696742	chr7:106810147	HBP1	-0.64	-9.46	-0.46	5.6e-19	Coronary artery disease;
LUSC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-7.5	-0.38	5.87e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9473147	0.516	rs4715018	chr6:47441871	T/C	cg20196966	chr6:47445060	CD2AP	0.42	5.75	0.3	1.97e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg24550644	chr17:30846204	MYO1D	-0.35	-5.74	-0.3	2.11e-8	Schizophrenia;
LUSC	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg06532163	chr17:45867833	NA	0.34	6.41	0.33	4.93e-10	IgG glycosylation;
LUSC	cis	rs295140	1.000	rs1367856	chr2:201160739	T/A	cg04283868	chr2:201171347	SPATS2L	0.44	6.68	0.34	9.75e-11	QT interval;
LUSC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg15921436	chr17:44337874	NA	0.74	11.24	0.52	4.32e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg07148914	chr20:33460835	GGT7	0.54	8.28	0.41	2.9e-15	Height;
LUSC	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.09	-0.32	3.08e-9	Neuroticism;
LUSC	cis	rs1044826	0.642	rs7652860	chr3:139205818	T/A	cg00490450	chr3:139108681	COPB2	0.46	6.96	0.36	1.86e-11	Obesity-related traits;
LUSC	cis	rs9815354	0.812	rs73073226	chr3:42005838	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.42	5.02e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9807841	0.592	rs10415961	chr19:10759981	G/C	cg17710535	chr19:10819994	QTRT1	0.41	6.67	0.34	1.06e-10	Inflammatory skin disease;
LUSC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg06096015	chr1:231504339	EGLN1	0.56	10.02	0.48	7.65e-21	Hemoglobin concentration;
LUSC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg12823233	chr7:2316876	SNX8	-0.35	-5.8	-0.3	1.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg21918786	chr6:109611834	NA	-0.4	-6.88	-0.35	2.97e-11	Reticulocyte fraction of red cells;
LUSC	trans	rs445114	0.509	rs386883	chr8:128336871	G/A	cg10897648	chr18:56338258	MALT1	-0.42	-6.38	-0.33	5.94e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11526424	chr10:98617461	LCOR	-0.66	-5.99	-0.31	5.57e-9	Cognitive performance;
LUSC	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg06718696	chr17:78121285	EIF4A3	0.59	8.84	0.44	5.42e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs12681287	0.547	rs13260345	chr8:87483721	T/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.36	6.24e-12	Caudate activity during reward;
LUSC	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg05925327	chr15:68127851	NA	-0.48	-7.03	-0.36	1.19e-11	Restless legs syndrome;
LUSC	cis	rs62400317	0.859	rs62436778	chr6:45120666	A/G	cg18551225	chr6:44695536	NA	-0.42	-6.8	-0.35	4.79e-11	Total body bone mineral density;
LUSC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.62	0.34	1.4e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1595825	0.891	rs73061069	chr2:198908825	A/G	cg00982548	chr2:198649783	BOLL	-0.55	-6.97	-0.36	1.69e-11	Ulcerative colitis;
LUSC	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg05985134	chr18:33552581	C18orf21	0.49	6.58	0.34	1.86e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	13.16	0.58	3.88e-32	Lung cancer in ever smokers;
LUSC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.89	-0.35	2.73e-11	Lung cancer;
LUSC	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.29	0.53	3e-25	Eye color traits;
LUSC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.19	15.48	0.65	4.17e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg04756594	chr16:24857601	SLC5A11	0.44	6.37	0.33	6.39e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg18681998	chr4:17616180	MED28	-0.85	-15.85	-0.66	1.44e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.59	10.64	0.5	5.72e-23	Bone mineral density;
LUSC	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-15.56	-0.65	2.01e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs894344	0.584	rs7010948	chr8:135629029	T/C	cg27224718	chr8:135614730	ZFAT	0.36	5.83	0.3	1.29e-8	Systolic blood pressure;
LUSC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg24634471	chr8:143751801	JRK	0.5	6.95	0.36	1.88e-11	Schizophrenia;
LUSC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.45	0.33	3.89e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs2048656	0.605	rs13249234	chr8:9650401	T/C	cg15556689	chr8:8085844	FLJ10661	0.48	6.69	0.34	9.5e-11	Schizophrenia;
LUSC	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg20607287	chr7:12443886	VWDE	-0.66	-6.5	-0.33	2.99e-10	Coronary artery disease;
LUSC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-5.74	-0.3	2.09e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6500395	1.000	rs7190106	chr16:48705542	C/T	cg04672837	chr16:48644449	N4BP1	0.54	8.1	0.41	1.02e-14	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg09699651	chr6:150184138	LRP11	0.46	7.25	0.37	2.89e-12	Testicular germ cell tumor;
LUSC	cis	rs955333	1.000	rs955333	chr6:154947408	A/G	cg20019720	chr6:154832845	CNKSR3	0.44	5.73	0.3	2.29e-8	Diabetic kidney disease;
LUSC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg06618935	chr21:46677482	NA	0.39	8.13	0.41	8.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.97	0.44	2.22e-17	Prudent dietary pattern;
LUSC	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg24579218	chr15:68104479	NA	-0.41	-6.69	-0.34	9.3e-11	Restless legs syndrome;
LUSC	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg27490568	chr2:178487706	NA	0.36	5.72	0.3	2.38e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg24642844	chr7:1081250	C7orf50	-0.79	-10.72	-0.51	3.05e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.37	-5.79	-0.3	1.6e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs78773383	0.505	rs13123782	chr4:39377405	A/C	cg16714752	chr4:39368184	RFC1	0.4	5.81	0.3	1.44e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs240764	0.604	rs9322173	chr6:101203889	G/A	cg09795085	chr6:101329169	ASCC3	0.44	6.14	0.32	2.39e-9	Neuroticism;
LUSC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg16586182	chr3:47516702	SCAP	0.52	8.08	0.4	1.16e-14	Colorectal cancer;
LUSC	cis	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg13443165	chr9:33130375	B4GALT1	-0.36	-5.7	-0.3	2.61e-8	IgG glycosylation;
LUSC	cis	rs7615316	1.000	rs9856302	chr3:142336361	T/C	cg16271453	chr3:142027066	XRN1	-0.36	-6.12	-0.32	2.6e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10892173	0.765	rs1892902	chr11:117669794	T/G	cg21640587	chr11:117668038	DSCAML1	0.36	5.82	0.3	1.39e-8	Myopia;
LUSC	cis	rs7005380	0.531	rs7388491	chr8:120925877	G/A	cg21744203	chr8:120868354	DSCC1	-0.48	-5.82	-0.3	1.41e-8	Interstitial lung disease;
LUSC	cis	rs7072216	0.763	rs45523432	chr10:100167436	T/C	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15921587	chr2:73144353	EMX1	-0.47	-6.35	-0.33	7.2e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg05738196	chr6:26577821	NA	0.54	8.53	0.42	5.28e-16	Schizophrenia;
LUSC	cis	rs12210905	1.000	rs72838266	chr6:27015052	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-5.88	-0.31	1.02e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg05272587	chr13:111038400	COL4A2	0.42	7.12	0.36	6.51e-12	White matter hyperintensity burden;
LUSC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg05941027	chr17:61774174	LIMD2	0.22	5.84	0.3	1.23e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18854424	chr1:2615690	NA	0.51	10.18	0.49	2.18e-21	Ulcerative colitis;
LUSC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Schizophrenia;
LUSC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg18404041	chr3:52824283	ITIH1	-0.59	-9.97	-0.48	1.17e-20	Bipolar disorder;
LUSC	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg05340658	chr4:99064831	C4orf37	0.42	6.78	0.35	5.34e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs72674100	1.000	rs7695114	chr4:97968711	C/T	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4919087	1.000	rs61863767	chr10:99084426	C/T	cg25902810	chr10:99078978	FRAT1	0.51	7.58	0.38	3.46e-13	Monocyte count;
LUSC	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg13390004	chr1:15929781	NA	0.39	6.48	0.33	3.31e-10	Systolic blood pressure;
LUSC	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07636037	chr3:49044803	WDR6	0.71	9.64	0.47	1.48e-19	Menarche (age at onset);
LUSC	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21659725	chr3:3221576	CRBN	-0.64	-10.41	-0.49	3.65e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg05941027	chr17:61774174	LIMD2	0.23	6.13	0.32	2.52e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg20935933	chr6:143382018	AIG1	-0.5	-7.26	-0.37	2.74e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs11971779	0.553	rs7799742	chr7:139051878	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg16624210	chr5:671434	TPPP	0.48	6.07	0.32	3.42e-9	Obesity-related traits;
LUSC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg09365446	chr1:150670422	GOLPH3L	0.47	7.01	0.36	1.34e-11	Melanoma;
LUSC	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg19773385	chr1:10388646	KIF1B	-0.57	-9.61	-0.47	1.81e-19	Hepatocellular carcinoma;
LUSC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-0.9	-16.35	-0.67	1.45e-44	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg13736514	chr6:26305472	NA	0.45	9.03	0.44	1.44e-17	Educational attainment;
LUSC	cis	rs3087591	0.659	rs757376	chr17:29717909	A/G	cg24425628	chr17:29625626	OMG;NF1	0.47	7.08	0.36	8.33e-12	Hip circumference;
LUSC	cis	rs1124376	0.816	rs62243131	chr3:20141308	A/G	cg05072819	chr3:20081367	KAT2B	0.65	7.63	0.39	2.51e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg16535667	chr11:65410126	SIPA1	-0.48	-5.95	-0.31	6.66e-9	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.68	-0.39	1.74e-13	Triglycerides;
LUSC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11764359	chr7:65958608	NA	0.68	10.96	0.51	4.39e-24	Aortic root size;
LUSC	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg19789473	chr17:27170043	C17orf63	-0.29	-5.67	-0.3	3.13e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg02780029	chr10:43622663	RET	-0.35	-5.85	-0.3	1.16e-8	Hirschsprung disease;
LUSC	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg22532475	chr10:104410764	TRIM8	0.24	5.64	0.3	3.58e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	8.55	0.42	4.46e-16	Menarche (age at onset);
LUSC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	1.19	16.28	0.67	2.87e-44	Eosinophil percentage of granulocytes;
LUSC	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg20587970	chr11:113659929	NA	-1.28	-17.56	-0.69	2.31e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg02534363	chr3:47050950	NBEAL2	-0.37	-5.97	-0.31	6.06e-9	Colorectal cancer;
LUSC	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg21775007	chr8:11205619	TDH	-0.67	-10.57	-0.5	9.86e-23	Retinal vascular caliber;
LUSC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg02269571	chr22:50332266	NA	-0.57	-8.54	-0.42	4.87e-16	Schizophrenia;
LUSC	cis	rs78366141	0.649	rs7674009	chr4:89683324	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	-0.84	-7.28	-0.37	2.44e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs74544699	1.000	rs11574452	chr4:74846661	A/C	cg02530824	chr4:74847766	PF4	-0.77	-5.67	-0.3	3.07e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21643547	chr1:205240462	TMCC2	-0.49	-9.3	-0.45	1.88e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs4478858	0.684	rs10798839	chr1:31731758	C/G	cg00250761	chr1:31883323	NA	-0.33	-7.86	-0.4	5.29e-14	Alcohol dependence;
LUSC	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg23277830	chr1:3704460	LRRC47	0.34	6.38	0.33	5.9e-10	Red cell distribution width;
LUSC	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg12473912	chr3:136751656	NA	0.39	6.94	0.36	2.03e-11	Neuroticism;
LUSC	cis	rs10875746	0.951	rs11168433	chr12:48558064	C/G	cg13454099	chr12:49076203	C12orf41	-0.52	-6.08	-0.32	3.33e-9	Longevity (90 years and older);
LUSC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg18850127	chr7:39170497	POU6F2	0.69	10.98	0.51	3.81e-24	IgG glycosylation;
LUSC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg26149032	chr3:158519514	MFSD1	-0.37	-6.08	-0.32	3.28e-9	Cognitive function;
LUSC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.45	6.88	0.35	2.97e-11	Longevity;Endometriosis;
LUSC	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg23711669	chr6:146136114	FBXO30	0.82	14.38	0.62	8.11e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg05865280	chr17:75406074	SEPT9	0.43	9.12	0.45	7.04e-18	Airflow obstruction;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03447080	chr4:142142038	ZNF330	0.43	6.49	0.33	3.16e-10	Asthma;
LUSC	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg05714579	chr10:131428358	MGMT	0.49	7.1	0.36	7.7e-12	Response to temozolomide;
LUSC	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg27411982	chr8:10470053	RP1L1	0.43	6.86	0.35	3.37e-11	Mood instability;
LUSC	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg24733560	chr20:60626293	TAF4	0.43	7.76	0.39	1.07e-13	Body mass index;
LUSC	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg09307838	chr4:120376055	NA	0.64	9.67	0.47	1.19e-19	Corneal astigmatism;
LUSC	cis	rs2235544	0.588	rs662603	chr1:54467767	T/C	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg09307838	chr4:120376055	NA	0.69	10.03	0.48	7.01e-21	Corneal astigmatism;
LUSC	cis	rs7131987	0.903	rs10843373	chr12:29420608	A/T	cg09582351	chr12:29534625	ERGIC2	-0.31	-6.39	-0.33	5.44e-10	QT interval;
LUSC	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg07636037	chr3:49044803	WDR6	-0.67	-8.53	-0.42	5.25e-16	Menarche (age at onset);
LUSC	cis	rs7605827	0.930	rs10168299	chr2:15615063	A/G	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs2652834	0.851	rs2652820	chr15:63430901	T/C	cg05507819	chr15:63340323	TPM1	0.47	6.04	0.31	4.08e-9	HDL cholesterol;
LUSC	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg24375607	chr4:120327624	NA	0.79	11.91	0.55	1.72e-27	Corneal astigmatism;
LUSC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg08859206	chr1:53392774	SCP2	-0.38	-6.46	-0.33	3.72e-10	Monocyte count;
LUSC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-0.94	-12.62	-0.57	4.05e-30	Vitiligo;
LUSC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.54	-0.42	4.67e-16	Bipolar disorder;
LUSC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg09976142	chr9:130955436	CIZ1	-0.53	-9.22	-0.45	3.5e-18	Attention deficit hyperactivity disorder;
LUSC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-0.99	-16.76	-0.68	3.51e-46	Body mass index;
LUSC	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	8.42	0.42	1.09e-15	Lung cancer in ever smokers;
LUSC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.75	0.35	6.62e-11	Platelet count;
LUSC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg20607287	chr7:12443886	VWDE	-0.65	-6.44	-0.33	4.12e-10	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg20283391	chr11:68216788	NA	-0.59	-8.18	-0.41	5.9e-15	Total body bone mineral density;
LUSC	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg07936489	chr17:37558343	FBXL20	0.72	9.94	0.48	1.47e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg10756647	chr7:56101905	PSPH	-0.86	-8.52	-0.42	5.52e-16	Diabetic kidney disease;
LUSC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	1.03	17.83	0.7	1.9e-50	Parkinson's disease;
LUSC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg05347473	chr6:146136440	FBXO30	0.39	6.61	0.34	1.53e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7923609	0.902	rs10740136	chr10:65329622	A/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.59	-0.34	1.77e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7119038	0.818	rs56043232	chr11:118648373	C/T	cg19308663	chr11:118741387	NA	0.37	6.33	0.33	7.82e-10	Sjögren's syndrome;
LUSC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.2	0.52	6.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	1.12	14.83	0.63	1.36e-38	Nonalcoholic fatty liver disease;
LUSC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg08270630	chr22:50330655	NA	0.4	5.9	0.31	9.13e-9	Schizophrenia;
LUSC	cis	rs2274273	0.554	rs3742564	chr14:55530120	C/T	cg04306507	chr14:55594613	LGALS3	-0.48	-10.34	-0.49	6.38e-22	Protein biomarker;
LUSC	trans	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg21775007	chr8:11205619	TDH	0.5	7.2	0.37	3.9e-12	Systolic blood pressure;
LUSC	cis	rs2607426	0.681	rs1455434	chr19:41257046	G/T	cg05508168	chr19:41255947	C19orf54;SNRPA	0.89	6.29	0.33	9.68e-10	Blood protein levels;
LUSC	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg24642439	chr20:33292090	TP53INP2	0.47	7.18	0.37	4.46e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs17824933	0.848	rs74860834	chr11:60778513	T/C	cg16817237	chr11:60793675	NA	0.39	6.17	0.32	1.98e-9	Multiple sclerosis;
LUSC	cis	rs6087990	0.735	rs910083	chr20:31378690	A/C	cg13636640	chr20:31349939	DNMT3B	0.91	18.53	0.71	3.14e-53	Ulcerative colitis;
LUSC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08219700	chr8:58056026	NA	0.69	8.02	0.4	1.79e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6565180	1.000	rs68051857	chr16:30360011	A/G	cg17640201	chr16:30407289	ZNF48	-0.87	-15.42	-0.64	6.95e-41	Tonsillectomy;
LUSC	cis	rs1185460	0.934	rs10892328	chr11:118942654	T/A	cg23280166	chr11:118938394	VPS11	0.46	6.79	0.35	5.2e-11	Coronary artery disease;
LUSC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21171335	chr12:122356390	WDR66	0.64	9.64	0.47	1.45e-19	Mean corpuscular volume;
LUSC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg00509249	chr6:109615579	CCDC162	-0.32	-5.74	-0.3	2.17e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg23711669	chr6:146136114	FBXO30	0.76	13.53	0.6	1.43e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg23172400	chr8:95962367	TP53INP1	-0.4	-7.82	-0.39	6.95e-14	Type 2 diabetes;
LUSC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.23	-0.32	1.39e-9	Neutrophil percentage of white cells;
LUSC	cis	rs3126085	0.935	rs12760382	chr1:152260287	G/T	cg26876637	chr1:152193138	HRNR	-0.44	-5.91	-0.31	8.63e-9	Atopic dermatitis;
LUSC	cis	rs155346	1.000	rs265142	chr5:139396998	C/T	cg01090482	chr5:139365336	NRG2	-0.37	-6.07	-0.32	3.5e-9	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg14019146	chr3:50243930	SLC38A3	0.36	8.27	0.41	3.11e-15	Body mass index;
LUSC	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg12927641	chr6:109611667	NA	-0.35	-5.88	-0.31	1.01e-8	Reticulocyte fraction of red cells;
LUSC	trans	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.85	0.35	3.55e-11	Endometrial cancer;
LUSC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg06008330	chr7:65541103	ASL	0.41	6.32	0.33	8.55e-10	Aortic root size;
LUSC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7674212	0.541	rs2623070	chr4:104037388	A/G	cg16532752	chr4:104119610	CENPE	0.48	6.63	0.34	1.36e-10	Type 2 diabetes;
LUSC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.45	6.39	0.33	5.47e-10	Osteoporosis;
LUSC	cis	rs4853525	0.522	rs7574840	chr2:191584236	C/G	cg11845111	chr2:191398756	TMEM194B	-0.42	-5.66	-0.3	3.24e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg09835421	chr16:68378352	PRMT7	0.62	6.48	0.33	3.26e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08898568	chr1:17338409	ATP13A2	-0.41	-6.32	-0.33	8.36e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg04518342	chr5:131593106	PDLIM4	0.45	8.26	0.41	3.5e-15	Breast cancer;
LUSC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg08200582	chr11:442649	ANO9	-0.5	-5.7	-0.3	2.7e-8	Body mass index;
LUSC	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.51e-22	Colorectal cancer;
LUSC	cis	rs9837602	0.810	rs35885423	chr3:99813218	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.43	-6.13	-0.32	2.47e-9	Breast cancer;
LUSC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-9.9	-0.48	1.96e-20	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.76	-0.43	9.87e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg05985134	chr18:33552581	C18orf21	0.51	6.95	0.36	1.89e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	12.24	0.56	1.05e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg19610905	chr11:61596333	FADS2	-0.53	-7.95	-0.4	2.88e-14	Trans fatty acid levels;
LUSC	trans	rs1325195	0.920	rs2793797	chr1:179097206	A/G	cg11624085	chr17:8464688	MYH10	0.44	7.4	0.38	1.1e-12	IgE grass sensitization;
LUSC	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg11502198	chr6:26597334	ABT1	-0.48	-6.73	-0.35	7.59e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg16434002	chr17:42200994	HDAC5	0.45	6.25	0.32	1.27e-9	Total body bone mineral density;
LUSC	trans	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg10756647	chr7:56101905	PSPH	0.85	8.28	0.41	3.01e-15	Diabetic kidney disease;
LUSC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg27121462	chr16:89883253	FANCA	0.56	9.01	0.44	1.57e-17	Vitiligo;
LUSC	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg26898376	chr11:64110657	CCDC88B	0.36	6.7	0.34	8.64e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg21548813	chr6:291882	DUSP22	-0.52	-7.84	-0.39	6.12e-14	Menopause (age at onset);
LUSC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06850241	chr22:41845214	NA	-0.3	-5.71	-0.3	2.46e-8	Vitiligo;
LUSC	trans	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-7.4	-0.38	1.15e-12	Morning vs. evening chronotype;
LUSC	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg09165964	chr15:75287851	SCAMP5	-0.75	-6.85	-0.35	3.48e-11	Lung cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19182908	chr22:38204192	GCAT	0.4	6.02	0.31	4.64e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg15155738	chr12:121454335	C12orf43	0.42	5.83	0.3	1.29e-8	N-glycan levels;
LUSC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	8.08	0.4	1.21e-14	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4629710	0.645	rs35561719	chr6:131551244	G/A	cg12606694	chr6:131520996	AKAP7	0.62	9.37	0.46	1.12e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg26893861	chr17:41843967	DUSP3	0.87	13.45	0.59	2.87e-33	Triglycerides;
LUSC	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.08e-14	Corneal astigmatism;
LUSC	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg22676075	chr6:135203613	NA	0.47	7.4	0.38	1.12e-12	Red blood cell count;
LUSC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg23711669	chr6:146136114	FBXO30	0.73	12.96	0.58	2.13e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg04414720	chr1:150670196	GOLPH3L	0.56	9.06	0.44	1.14e-17	Tonsillectomy;
LUSC	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg22532475	chr10:104410764	TRIM8	-0.34	-7.58	-0.38	3.48e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.75	12.61	0.57	4.55e-30	Motion sickness;
LUSC	cis	rs9392556	0.829	rs9328220	chr6:4120181	A/C	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.36	-6.21	-0.32	1.58e-9	Blood metabolite levels;
LUSC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg17554472	chr22:41940697	POLR3H	0.47	5.73	0.3	2.22e-8	Vitiligo;
LUSC	cis	rs11785693	0.862	rs11786657	chr8:5001792	T/C	cg26367366	chr8:4980734	NA	0.73	8.36	0.42	1.71e-15	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs73195822	0.667	rs73194055	chr12:111216292	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	6.59	0.34	1.76e-10	Itch intensity from mosquito bite;
LUSC	cis	rs2109514	1.000	rs2270189	chr7:116140616	A/G	cg12739419	chr7:116140593	CAV2	-0.29	-6.3	-0.33	9.14e-10	Prevalent atrial fibrillation;
LUSC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08219700	chr8:58056026	NA	0.66	7.44	0.38	8.4e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg14456004	chr13:21872349	NA	0.43	6.02	0.31	4.68e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg22089800	chr15:90895588	ZNF774	-0.64	-9.63	-0.47	1.61e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg02038168	chr22:39784481	NA	0.47	7.76	0.39	1.05e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg23590916	chr17:43697445	MGC57346	-0.49	-6.68	-0.34	1e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg27411982	chr8:10470053	RP1L1	0.41	6.37	0.33	6.2e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7399018	0.739	rs7953955	chr12:51608467	A/G	cg12163867	chr12:51592794	POU6F1	-0.47	-8.67	-0.43	1.87e-16	Cisplatin-induced ototoxicity;
LUSC	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg18827107	chr12:86230957	RASSF9	-0.44	-6.61	-0.34	1.55e-10	Major depressive disorder;
LUSC	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg14664628	chr15:75095509	CSK	0.43	6.25	0.32	1.27e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg24977027	chr2:88469347	THNSL2	0.56	5.97	0.31	6.18e-9	Plasma clusterin levels;
LUSC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg19318889	chr4:1322082	MAEA	0.48	7.79	0.39	8.41e-14	Obesity-related traits;
LUSC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.97	-0.31	6.13e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-0.8	-13.32	-0.59	9.35e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.74	0.54	7.04e-27	Mean corpuscular volume;
LUSC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.16	0.36	5.25e-12	Major depressive disorder;
LUSC	cis	rs778371	0.752	rs283487	chr2:233644011	A/G	cg08000102	chr2:233561755	GIGYF2	0.78	12.39	0.56	2.88e-29	Schizophrenia;
LUSC	trans	rs10096351	0.574	rs684254	chr8:128338693	G/A	cg10897648	chr18:56338258	MALT1	-0.42	-6.35	-0.33	6.95e-10	Breast cancer;
LUSC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.59	0.46	2.07e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9581857	0.556	rs9581861	chr13:28039991	C/T	cg22138327	chr13:27999177	GTF3A	0.7	9.5	0.46	4.1e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.65	-0.34	1.22e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg19824325	chr16:58548873	SETD6	0.94	9.15	0.45	5.56e-18	Schizophrenia;
LUSC	cis	rs6546550	0.901	rs6725425	chr2:70150674	T/C	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06850241	chr22:41845214	NA	-0.31	-6.04	-0.31	4.02e-9	Vitiligo;
LUSC	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.42	-0.46	7.95e-19	Mood instability;
LUSC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg18827107	chr12:86230957	RASSF9	-0.46	-6.7	-0.34	8.87e-11	Major depressive disorder;
LUSC	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg08601574	chr20:25228251	PYGB	0.55	8.84	0.44	5.56e-17	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15937634	chr12:122459934	BCL7A	0.45	6.07	0.32	3.5e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9905704	0.633	rs2021733	chr17:56489168	C/T	cg19466818	chr17:56409534	MIR142	0.32	6.06	0.31	3.73e-9	Testicular germ cell tumor;
LUSC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.87	14.11	0.61	8.79e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.35	0.59	7.08e-33	Cognitive test performance;
LUSC	cis	rs73198271	0.530	rs11778326	chr8:8651566	T/G	cg01851573	chr8:8652454	MFHAS1	0.6	8.1	0.41	1.03e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg11752832	chr7:134001865	SLC35B4	-0.51	-7.73	-0.39	1.29e-13	Mean platelet volume;
LUSC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-14.9	-0.63	7.32e-39	Total body bone mineral density;
LUSC	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg08807101	chr21:30365312	RNF160	-0.54	-8.2	-0.41	5.09e-15	Dental caries;
LUSC	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.79	-0.3	1.66e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg18681998	chr4:17616180	MED28	0.79	13.56	0.6	1.14e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg16325326	chr1:53192061	ZYG11B	-1.0	-20.14	-0.74	1.24e-59	Monocyte count;
LUSC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg11663144	chr21:46675770	NA	-0.46	-8.24	-0.41	3.91e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg13736514	chr6:26305472	NA	-0.36	-6.71	-0.34	8.54e-11	Educational attainment;
LUSC	cis	rs10740039	0.732	rs10160182	chr10:62362451	A/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.87	-0.35	3.23e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9905704	0.681	rs2108911	chr17:56570500	C/T	cg19466818	chr17:56409534	MIR142	0.39	7.34	0.37	1.68e-12	Testicular germ cell tumor;
LUSC	cis	rs12541635	0.966	rs34177605	chr8:107065105	G/A	cg10147462	chr8:107024639	NA	0.55	9.81	0.47	3.91e-20	Age of smoking initiation;
LUSC	trans	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.61	8.34	0.41	2.03e-15	Adiposity;
LUSC	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg15997130	chr1:24165203	NA	0.53	8.68	0.43	1.81e-16	Immature fraction of reticulocytes;
LUSC	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg01966878	chr4:90757139	SNCA	-0.35	-6.12	-0.32	2.56e-9	Dementia with Lewy bodies;
LUSC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg00376283	chr12:123451042	ABCB9	0.7	9.84	0.47	3.03e-20	Neutrophil percentage of white cells;
LUSC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg03351412	chr1:154909251	PMVK	0.4	6.03	0.31	4.28e-9	Prostate cancer;
LUSC	cis	rs6967385	0.560	rs10272105	chr7:12358122	C/A	cg06484146	chr7:12443880	VWDE	0.45	6.66	0.34	1.14e-10	Response to taxane treatment (placlitaxel);
LUSC	trans	rs4650994	0.525	rs17361286	chr1:178521916	C/G	cg05059571	chr16:84539110	KIAA1609	-0.47	-8.92	-0.44	3.11e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	14.27	0.62	2.13e-36	Platelet count;
LUSC	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg11161011	chr14:65562177	MAX	-0.72	-11.0	-0.52	3.28e-24	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25072359	chr17:41440525	NA	0.66	9.34	0.45	1.43e-18	Menopause (age at onset);
LUSC	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg02415014	chr8:143852576	LYNX1	0.32	7.37	0.37	1.36e-12	Urinary tract infection frequency;
LUSC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.49	-0.59	2.14e-33	Alzheimer's disease;
LUSC	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg17143192	chr8:8559678	CLDN23	0.63	9.07	0.44	1.02e-17	Obesity-related traits;
LUSC	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.56	-9.27	-0.45	2.45e-18	Breast cancer;
LUSC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.58	0.34	1.83e-10	Lung cancer;
LUSC	cis	rs7143963	1.000	rs4906267	chr14:103305077	G/T	cg21920469	chr14:103375193	NA	-0.43	-5.77	-0.3	1.85e-8	Body mass index;
LUSC	cis	rs12208915	0.767	rs12208017	chr6:79823371	G/T	cg05283184	chr6:79620031	NA	-0.4	-5.93	-0.31	7.51e-9	Left atrial antero-posterior diameter;
LUSC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg02073558	chr3:44770973	ZNF501	0.53	8.8	0.43	7.43e-17	Depressive symptoms;
LUSC	cis	rs7246967	0.611	rs62118823	chr19:22844066	A/G	cg23217946	chr19:22817039	ZNF492	0.48	6.17	0.32	1.95e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs2797160	0.967	rs1739358	chr6:126019736	G/A	cg05901451	chr6:126070800	HEY2	0.57	8.51	0.42	5.79e-16	Endometrial cancer;
LUSC	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.59	6.44	0.33	4.08e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs10203711	0.932	rs4353597	chr2:239597772	C/G	cg14580085	chr2:239553406	NA	0.42	7.15	0.36	5.56e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs113835537	0.529	rs10896125	chr11:66288733	G/C	cg24851651	chr11:66362959	CCS	0.53	7.97	0.4	2.58e-14	Airway imaging phenotypes;
LUSC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.68	-11.78	-0.54	4.97e-27	Calcium levels;
LUSC	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg17145862	chr1:211918768	LPGAT1	0.23	6.1	0.32	2.97e-9	Leprosy;
LUSC	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-0.92	-14.19	-0.61	4.37e-36	Corneal structure;
LUSC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.5	-0.46	4.24e-19	Chronic sinus infection;
LUSC	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg20936604	chr3:58311152	NA	-0.72	-6.92	-0.35	2.36e-11	Cholesterol, total;
LUSC	trans	rs12210905	0.925	rs7753284	chr6:26991615	G/C	cg11837749	chr1:55047332	ACOT11	0.57	6.13	0.32	2.51e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.61	-0.43	2.86e-16	Monocyte count;
LUSC	cis	rs6961069	0.585	rs1464792	chr7:80243252	T/C	cg04458919	chr7:80252533	CD36	-0.39	-6.91	-0.35	2.42e-11	Platelet count;
LUSC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg13047869	chr3:10149882	C3orf24	0.64	8.22	0.41	4.62e-15	Alzheimer's disease;
LUSC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	0.99	14.14	0.61	6.88e-36	Vitiligo;
LUSC	trans	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-8.04	-0.4	1.62e-14	Parkinson's disease;
LUSC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg23985595	chr17:80112537	CCDC57	0.3	5.78	0.3	1.69e-8	Life satisfaction;
LUSC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg17279839	chr7:150038598	RARRES2	0.45	7.05	0.36	1.03e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg11632617	chr15:75315747	PPCDC	-0.5	-6.45	-0.33	4.03e-10	Blood trace element (Zn levels);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg22072063	chr11:73087715	RELT	0.42	6.2	0.32	1.71e-9	Mosquito bite size;
LUSC	cis	rs8017423	0.565	rs4904681	chr14:90835566	A/T	cg04374321	chr14:90722782	PSMC1	-0.42	-6.17	-0.32	2.03e-9	Mortality in heart failure;
LUSC	cis	rs3738772	0.633	rs919958	chr1:110053148	C/G	cg08367326	chr1:110052010	AMIGO1	-0.48	-7.19	-0.37	4.2e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.74	11.89	0.55	2.07e-27	Colorectal cancer;
LUSC	cis	rs9308433	0.553	rs9308435	chr1:214500166	C/T	cg06198575	chr1:214491504	SMYD2	0.45	6.96	0.36	1.83e-11	IgG glycosylation;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg14792983	chr20:18447909	C20orf12;POLR3F	0.52	6.09	0.32	3.07e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6681460	0.549	rs7547857	chr1:67031890	A/G	cg02459107	chr1:67143332	SGIP1	0.31	5.69	0.3	2.85e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs16854884	0.657	rs6783089	chr3:143738034	T/C	cg06585982	chr3:143692056	C3orf58	0.5	7.93	0.4	3.36e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs137603	0.644	rs137620	chr22:39709776	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.52	-8.19	-0.41	5.76e-15	Primary biliary cholangitis;
LUSC	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg08798685	chr6:27730294	NA	-0.66	-6.19	-0.32	1.8e-9	Depression;
LUSC	cis	rs4443100	0.958	rs9620213	chr22:23395411	A/C	cg21100191	chr22:23484243	RTDR1	0.5	6.09	0.32	3.11e-9	Serum parathyroid hormone levels;
LUSC	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg21016266	chr12:122356598	WDR66	0.56	8.07	0.4	1.26e-14	Mean corpuscular volume;
LUSC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.98	0.44	1.95e-17	Menopause (age at onset);
LUSC	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-6.81	-0.35	4.61e-11	Coronary artery disease;
LUSC	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	9.02	0.44	1.52e-17	Response to bleomycin (chromatid breaks);
LUSC	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.59	-0.43	3.49e-16	Axial length;
LUSC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	6.5	0.34	2.93e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg09165964	chr15:75287851	SCAMP5	-1.01	-15.29	-0.64	2.16e-40	Blood trace element (Zn levels);
LUSC	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg27068330	chr11:65405492	SIPA1	-0.76	-10.88	-0.51	8.57e-24	Acne (severe);
LUSC	cis	rs9309473	0.539	rs7574268	chr2:73904872	C/T	cg20560298	chr2:73613845	ALMS1	0.46	6.89	0.35	2.72e-11	Metabolite levels;
LUSC	trans	rs9393366	0.598	rs10456272	chr6:23154345	A/G	cg01144275	chr17:79478508	ACTG1	0.45	6.0	0.31	5.22e-9	Tourette syndrome;
LUSC	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.86	-14.14	-0.61	6.56e-36	Schizophrenia;
LUSC	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.01	-20.2	-0.74	7.19e-60	Ulcerative colitis;
LUSC	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	0.89	13.13	0.58	5.06e-32	Obesity-related traits;
LUSC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg12292205	chr6:26970375	C6orf41	-0.69	-12.15	-0.55	2.25e-28	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6714710	0.603	rs34974566	chr2:98552299	C/G	cg26665480	chr2:98280029	ACTR1B	0.6	8.76	0.43	9.72e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg04267008	chr7:1944627	MAD1L1	-0.51	-7.64	-0.39	2.31e-13	Bipolar disorder and schizophrenia;
LUSC	trans	rs73193808	0.639	rs2832237	chr21:30547683	C/G	cg14791747	chr16:20752902	THUMPD1	-0.46	-6.23	-0.32	1.42e-9	Coronary artery disease;
LUSC	cis	rs9303542	0.512	rs67412921	chr17:46636625	C/A	cg09704116	chr17:46666958	LOC404266	-0.38	-6.02	-0.31	4.54e-9	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08677398	chr8:58056175	NA	0.54	6.65	0.34	1.23e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg17757837	chr7:157058334	UBE3C	-0.9	-15.07	-0.64	1.6e-39	Body mass index;
LUSC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg17264618	chr3:40429014	ENTPD3	-0.3	-6.63	-0.34	1.36e-10	Renal cell carcinoma;
LUSC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03264133	chr6:25882463	NA	0.52	9.58	0.46	2.29e-19	Blood metabolite levels;
LUSC	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.51	-8.02	-0.4	1.76e-14	Coffee consumption (cups per day);
LUSC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg18302933	chr2:88491318	NA	-0.36	-6.19	-0.32	1.81e-9	Response to metformin (IC50);
LUSC	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg12863693	chr15:85201151	NMB	0.37	7.32	0.37	1.87e-12	Schizophrenia;
LUSC	trans	rs2018683	0.870	rs13232487	chr7:28985119	C/A	cg19402173	chr7:128379420	CALU	-0.55	-8.66	-0.43	2.04e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.17	0.58	3.43e-32	Chronic sinus infection;
LUSC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg08270630	chr22:50330655	NA	-0.45	-6.64	-0.34	1.25e-10	Schizophrenia;
LUSC	cis	rs12900463	0.813	rs186266	chr15:85402795	A/G	cg17173187	chr15:85201210	NMB	0.32	5.76	0.3	1.96e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);
LUSC	cis	rs6845621	0.901	rs1377153	chr4:18923066	A/G	cg12196642	chr4:18937545	NA	0.37	6.91	0.35	2.46e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.38	-5.65	-0.3	3.39e-8	Height;
LUSC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg09365446	chr1:150670422	GOLPH3L	0.54	8.42	0.42	1.16e-15	Tonsillectomy;
LUSC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg06618935	chr21:46677482	NA	-0.37	-7.33	-0.37	1.75e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7771547	0.573	rs522179	chr6:36391605	G/A	cg07856975	chr6:36356162	ETV7	0.34	6.21	0.32	1.61e-9	Platelet distribution width;
LUSC	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg05731713	chr7:157510257	PTPRN2	0.49	9.51	0.46	3.77e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg27535305	chr1:53392650	SCP2	0.47	9.26	0.45	2.59e-18	Monocyte count;
LUSC	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg03929089	chr4:120376271	NA	-0.5	-7.06	-0.36	9.63e-12	HDL cholesterol;
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-8.49	-0.42	7.07e-16	Lymphocyte counts;
LUSC	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg21963583	chr11:68658836	MRPL21	-0.43	-7.02	-0.36	1.21e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12891047	1.000	rs4569184	chr14:68253298	C/G	cg20999565	chr14:68265668	ZFYVE26	0.37	5.87	0.31	1.07e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg22676075	chr6:135203613	NA	0.48	7.51	0.38	5.47e-13	Red blood cell count;
LUSC	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg03060546	chr3:49711283	APEH	0.56	7.63	0.39	2.43e-13	Resting heart rate;
LUSC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.67	11.93	0.55	1.38e-27	Aortic root size;
LUSC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.68	-10.5	-0.5	1.84e-22	Aortic root size;
LUSC	cis	rs4266144	0.562	rs56357317	chr3:156835174	T/A	cg14969094	chr3:156848003	NA	-0.36	-5.75	-0.3	1.97e-8	Coronary artery disease;
LUSC	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg00071950	chr4:10020882	SLC2A9	0.65	10.85	0.51	1.11e-23	Bone mineral density;
LUSC	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg24296786	chr1:45957014	TESK2	0.44	6.19	0.32	1.72e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg12751644	chr20:60527061	NA	-0.35	-6.27	-0.32	1.14e-9	Body mass index;
LUSC	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.84	0.51	1.15e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg07636037	chr3:49044803	WDR6	0.67	8.12	0.41	9.08e-15	Menarche (age at onset);
LUSC	cis	rs11785693	0.909	rs11784246	chr8:4970497	A/G	cg26367366	chr8:4980734	NA	0.84	9.14	0.45	6.24e-18	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15540553	chr11:64018643	PLCB3	-0.46	-6.14	-0.32	2.37e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23524709	chr19:4636345	NA	0.44	7.45	0.38	8.14e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2282300	0.739	rs34044331	chr11:30264486	T/C	cg25418670	chr11:30344373	C11orf46	-0.65	-9.32	-0.45	1.69e-18	Morning vs. evening chronotype;
LUSC	trans	rs3134353	0.541	rs3134380	chr8:101943319	G/A	cg20993868	chr7:22813445	NA	0.34	6.29	0.33	1.01e-9	Body mass index;
LUSC	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.45	-0.42	9.25e-16	Response to antipsychotic treatment;
LUSC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.1	13.98	0.61	2.89e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg05535760	chr7:792225	HEATR2	-0.75	-7.55	-0.38	4.27e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg00944433	chr1:107599041	PRMT6	-0.35	-6.26	-0.32	1.16e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs6692729	0.966	rs1794035	chr1:227048758	T/C	cg10327440	chr1:227177885	CDC42BPA	0.51	7.28	0.37	2.44e-12	Electrodermal activity;
LUSC	cis	rs2840044	0.534	rs2124246	chr17:33885431	G/A	cg05299278	chr17:33885742	SLFN14	0.35	7.91	0.4	3.8e-14	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08677398	chr8:58056175	NA	0.52	6.24	0.32	1.34e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.53	-10.53	-0.5	1.36e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg04362960	chr10:104952993	NT5C2	0.59	9.38	0.46	1.04e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9359856	1.000	rs2094487	chr6:90314072	T/A	cg13799429	chr6:90582589	CASP8AP2	0.57	6.75	0.35	6.5e-11	Bipolar disorder;
LUSC	trans	rs57502260	0.704	rs923346	chr11:68182375	T/C	cg00664054	chr8:21998309	REEP4	0.39	6.19	0.32	1.8e-9	Total body bone mineral density (age 45-60);
LUSC	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg09491104	chr22:46646882	C22orf40	-0.68	-6.37	-0.33	6.11e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg02038168	chr22:39784481	NA	-0.49	-8.08	-0.4	1.22e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg21361702	chr7:150065534	REPIN1	0.49	6.53	0.34	2.42e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg05340658	chr4:99064831	C4orf37	0.61	9.15	0.45	5.87e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.03	15.77	0.65	2.97e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg00343986	chr7:65444356	GUSB	0.44	6.8	0.35	4.95e-11	Aortic root size;
LUSC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.54	-0.34	2.29e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.88	-0.4	4.77e-14	Obesity-related traits;
LUSC	cis	rs6961069	0.716	rs11771152	chr7:80271327	T/C	cg04458919	chr7:80252533	CD36	0.35	6.15	0.32	2.22e-9	Platelet count;
LUSC	cis	rs11676348	0.808	rs12694430	chr2:219015799	T/C	cg00012203	chr2:219082015	ARPC2	-0.56	-8.59	-0.43	3.31e-16	Ulcerative colitis;
LUSC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg11843238	chr5:131593191	PDLIM4	0.36	6.67	0.34	1.05e-10	Blood metabolite levels;
LUSC	trans	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg07393940	chr7:158741817	NA	0.36	6.43	0.33	4.48e-10	Life satisfaction;
LUSC	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg24006582	chr15:45444508	DUOX1	-0.62	-9.12	-0.45	7.21e-18	Uric acid levels;
LUSC	cis	rs2303282	0.933	rs11647104	chr16:56547254	C/T	cg00500540	chr16:56394104	NA	-0.44	-7.18	-0.37	4.68e-12	Breast cancer;
LUSC	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg09904177	chr6:26538194	HMGN4	0.75	14.34	0.62	1.14e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg22089800	chr15:90895588	ZNF774	0.62	9.36	0.46	1.22e-18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg21545522	chr1:205238299	TMCC2	0.46	8.69	0.43	1.66e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg17143192	chr8:8559678	CLDN23	0.64	8.85	0.44	5.26e-17	Obesity-related traits;
LUSC	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.88	-0.55	2.17e-27	Mean corpuscular volume;
LUSC	cis	rs367943	0.723	rs1965429	chr5:112679373	G/T	cg12552261	chr5:112820674	MCC	-0.38	-6.26	-0.32	1.16e-9	Type 2 diabetes;
LUSC	cis	rs4409675	0.576	rs6564	chr1:28212975	A/G	cg23691781	chr1:28212827	C1orf38	-0.31	-7.31	-0.37	1.97e-12	Corneal astigmatism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21886851	chr18:47340405	SCARNA17;ACAA2	0.43	6.02	0.31	4.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg18305652	chr10:134549665	INPP5A	0.46	7.31	0.37	2.01e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.84	-0.39	6.1e-14	Blood metabolite levels;
LUSC	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg10978503	chr1:24200527	CNR2	0.45	10.08	0.48	4.74e-21	Immature fraction of reticulocytes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08105378	chr19:19040175	HOMER3	0.39	6.0	0.31	5.21e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17691542	chr6:26056736	HIST1H1C	0.84	11.19	0.52	6.5e-25	Iron status biomarkers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04407520	chr19:3506228	FZR1	-0.44	-6.55	-0.34	2.22e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg02972257	chr16:68554789	NA	0.51	6.39	0.33	5.6e-10	Ulcerative colitis;
LUSC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg13319975	chr6:146136371	FBXO30	-0.51	-7.63	-0.39	2.45e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg09998033	chr7:158218633	PTPRN2	-0.48	-7.58	-0.38	3.41e-13	Obesity-related traits;
LUSC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.27	-0.62	2.03e-36	Eye color traits;
LUSC	trans	rs2262909	1.000	rs2017962	chr19:22208751	T/C	cg17074339	chr11:11642133	GALNTL4	-0.41	-6.2	-0.32	1.68e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.17	0.58	3.55e-32	Cognitive test performance;
LUSC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg10729496	chr3:10149963	C3orf24	0.53	7.07	0.36	9.35e-12	Alzheimer's disease;
LUSC	trans	rs16823866	0.847	rs77513726	chr2:145316727	A/T	cg04212021	chr5:180231084	MGAT1	0.52	5.96	0.31	6.53e-9	White blood cell count (basophil);
LUSC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs10740039	1.000	rs10740040	chr10:62414743	G/A	cg18175470	chr10:62150864	ANK3	-0.43	-6.78	-0.35	5.52e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg13575925	chr12:9217583	LOC144571	0.36	6.63	0.34	1.34e-10	Sjögren's syndrome;
LUSC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03517284	chr6:25882590	NA	0.37	6.11	0.32	2.85e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg15831613	chr1:212780972	ATF3	0.37	6.3	0.33	9.19e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg17467752	chr17:38218738	THRA	0.41	5.69	0.3	2.73e-8	Myeloid white cell count;
LUSC	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-0.51	-7.8	-0.39	8.02e-14	Breast cancer;
LUSC	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.41	-0.33	5.01e-10	Bladder cancer;
LUSC	cis	rs2599510	0.840	rs466146	chr2:32539236	A/C	cg02381751	chr2:32503542	YIPF4	0.38	5.68	0.3	2.87e-8	Interleukin-18 levels;
LUSC	cis	rs2625529	0.730	rs2957725	chr15:72248205	C/A	cg16672083	chr15:72433130	SENP8	0.5	8.07	0.4	1.32e-14	Red blood cell count;
LUSC	cis	rs317865	0.737	rs73234629	chr4:16169776	G/A	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.6	5.64	0.3	3.55e-8	Kidney disease (early stage) in type 1 diabetes;
LUSC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg15145296	chr3:125709740	NA	-0.58	-6.5	-0.33	3e-10	Blood pressure (smoking interaction);
LUSC	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg09044154	chr16:88155775	NA	-0.56	-7.43	-0.38	9.11e-13	Menopause (age at onset);
LUSC	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.52	8.3	0.41	2.67e-15	Breast cancer;
LUSC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.35	-0.46	1.33e-18	Gut microbiome composition (summer);
LUSC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg21285383	chr16:89894308	SPIRE2	0.32	6.77	0.35	5.69e-11	Vitiligo;
LUSC	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg01960748	chr1:24522592	NA	-0.64	-9.27	-0.45	2.3e-18	Psoriasis vulgaris;
LUSC	cis	rs2835872	0.793	rs73220482	chr21:38986286	C/T	cg20424643	chr21:39039972	KCNJ6	0.36	5.7	0.3	2.63e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.86	-12.07	-0.55	4.48e-28	Asthma;
LUSC	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg09044154	chr16:88155775	NA	-0.53	-6.93	-0.35	2.16e-11	Menopause (age at onset);
LUSC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg07677032	chr17:61819896	STRADA	-0.52	-8.79	-0.43	8.27e-17	Prudent dietary pattern;
LUSC	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg01689657	chr7:91764605	CYP51A1	0.31	5.65	0.3	3.48e-8	Breast cancer;
LUSC	cis	rs9420	0.961	rs12805841	chr11:57443842	G/A	cg23127183	chr11:57508653	C11orf31	-0.58	-9.06	-0.44	1.08e-17	Schizophrenia;
LUSC	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg24130564	chr14:104152367	KLC1	-0.48	-7.14	-0.36	5.71e-12	Body mass index;
LUSC	cis	rs12594515	1.000	rs35182335	chr15:45995184	C/G	cg06207120	chr15:45996521	NA	0.39	5.86	0.31	1.11e-8	Waist circumference;Weight;
LUSC	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg00745463	chr17:30367425	LRRC37B	0.58	6.66	0.34	1.14e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.37	1.18e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs9398803	0.687	rs9388507	chr6:126970895	G/T	cg19875578	chr6:126661172	C6orf173	0.39	5.65	0.3	3.39e-8	Male-pattern baldness;
LUSC	cis	rs9815354	0.680	rs73073292	chr3:42028023	C/A	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg26647111	chr11:31128758	NA	0.41	6.04	0.31	4.05e-9	Red blood cell count;
LUSC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg06494592	chr3:125709126	NA	-0.51	-6.24	-0.32	1.32e-9	Blood pressure (smoking interaction);
LUSC	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg08645402	chr16:4508243	NA	0.48	7.23	0.37	3.34e-12	Schizophrenia;
LUSC	cis	rs7804356	1.000	rs17375272	chr7:26866497	C/T	cg03456212	chr7:26904342	SKAP2	-0.56	-6.44	-0.33	4.23e-10	Type 1 diabetes;
LUSC	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg19784903	chr17:45786737	TBKBP1	-0.42	-6.73	-0.35	7.19e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11229555	0.645	rs56228632	chr11:58187444	A/G	cg15696309	chr11:58395628	NA	-0.64	-7.78	-0.39	9.19e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.26	0.32	1.15e-9	Mean platelet volume;
LUSC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.75	-0.43	1.08e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg10434728	chr15:90938212	IQGAP1	0.32	6.05	0.31	3.94e-9	Rheumatoid arthritis;
LUSC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.44	-0.38	8.58e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.93	-0.48	1.61e-20	Hemoglobin concentration;
LUSC	cis	rs3741151	1.000	rs7930880	chr11:73068769	A/C	cg17517138	chr11:73019481	ARHGEF17	0.81	7.62	0.38	2.68e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.49	0.53	5.73e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	8.75	0.43	1.08e-16	Menopause (age at onset);
LUSC	cis	rs7119	0.717	rs8033654	chr15:77825250	T/C	cg27398640	chr15:77910606	LINGO1	-0.32	-6.68	-0.34	9.78e-11	Type 2 diabetes;
LUSC	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg10523679	chr1:76189770	ACADM	-0.47	-6.71	-0.34	8.21e-11	Daytime sleep phenotypes;
LUSC	cis	rs12530845	0.673	rs73725437	chr7:135327853	G/A	cg23117316	chr7:135346802	PL-5283	-0.62	-9.56	-0.46	2.64e-19	Red blood cell traits;
LUSC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs931127	0.658	rs4930305	chr11:65464000	A/G	cg05805236	chr11:65401703	PCNXL3	0.41	6.94	0.35	2.11e-11	Systemic lupus erythematosus;
LUSC	cis	rs9469578	1.000	rs16869456	chr6:33714622	G/A	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg20283391	chr11:68216788	NA	-0.61	-8.51	-0.42	5.91e-16	Total body bone mineral density;
LUSC	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg18129178	chr5:148520854	ABLIM3	-0.69	-10.62	-0.5	6.72e-23	Breast cancer;
LUSC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.05	-15.82	-0.65	1.8e-42	Platelet count;
LUSC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.49	0.38	6.35e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg19875535	chr5:140030758	IK	-0.53	-8.78	-0.43	8.59e-17	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs710987	0.815	rs698147	chr5:3513485	A/G	cg27629735	chr1:3556483	WDR8	-0.37	-6.13	-0.32	2.5e-9	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
LUSC	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-0.85	-12.51	-0.56	9.97e-30	Triglycerides;
LUSC	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg21545522	chr1:205238299	TMCC2	0.52	9.66	0.47	1.28e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs4566357	0.615	rs10178098	chr2:227914425	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.2	-0.41	5.4e-15	Coronary artery disease;
LUSC	cis	rs2677744	0.719	rs1266492	chr15:91456102	T/C	cg08740748	chr15:91446511	MAN2A2	-0.42	-5.73	-0.3	2.21e-8	Attention deficit hyperactivity disorder;
LUSC	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg16797656	chr11:68205561	LRP5	0.36	6.01	0.31	4.74e-9	Total body bone mineral density;
LUSC	cis	rs9398803	0.965	rs17754780	chr6:126664333	C/T	cg19875578	chr6:126661172	C6orf173	0.41	6.11	0.32	2.71e-9	Male-pattern baldness;
LUSC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg21433313	chr16:3507492	NAT15	0.79	9.84	0.47	3.14e-20	Tuberculosis;
LUSC	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg08917208	chr2:24149416	ATAD2B	0.51	5.76	0.3	1.92e-8	Lymphocyte counts;
LUSC	trans	rs7170930	0.618	rs7165111	chr15:66540873	T/C	cg06396762	chr16:3202609	NA	-0.72	-5.98	-0.31	5.75e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs9296092	0.538	rs9461881	chr6:33520041	C/T	cg13560919	chr6:33536144	NA	-0.82	-15.74	-0.65	3.89e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg25664220	chr3:72788482	NA	-0.71	-12.16	-0.55	1.99e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-6.01	-0.31	4.78e-9	Bipolar disorder;
LUSC	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg02380750	chr20:61661411	NA	0.35	5.9	0.31	8.87e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg21427119	chr20:30132790	HM13	-0.5	-7.02	-0.36	1.25e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg23229984	chr5:148520753	ABLIM3	0.37	6.13	0.32	2.55e-9	Breast cancer;
LUSC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg24562669	chr7:97807699	LMTK2	0.34	5.95	0.31	6.83e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg12463550	chr7:65579703	CRCP	0.57	8.52	0.42	5.72e-16	Aortic root size;
LUSC	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg23795048	chr12:9217529	LOC144571	0.34	5.91	0.31	8.5e-9	Sjögren's syndrome;
LUSC	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.6	0.38	3.03e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg06636001	chr8:8085503	FLJ10661	0.54	7.97	0.4	2.45e-14	Myopia (pathological);
LUSC	cis	rs1113500	0.933	rs11185259	chr1:108635062	A/G	cg11967332	chr1:108735228	SLC25A24	-0.42	-6.14	-0.32	2.33e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg00310523	chr12:86230176	RASSF9	-0.44	-8.28	-0.41	3.05e-15	Major depressive disorder;
LUSC	cis	rs9532580	0.656	rs2721068	chr13:41139712	T/C	cg21288729	chr13:41239152	FOXO1	0.58	7.95	0.4	2.93e-14	Mean corpuscular hemoglobin;
LUSC	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg19812747	chr11:111475976	SIK2	-0.5	-7.04	-0.36	1.1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg23711669	chr6:146136114	FBXO30	-0.83	-14.79	-0.63	1.93e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs500891	0.533	rs6901074	chr6:84173944	A/G	cg08257003	chr6:84140564	ME1	0.33	8.01	0.4	1.87e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.55	-0.34	2.2e-10	Longevity;Endometriosis;
LUSC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.8	-0.47	4.39e-20	Platelet count;
LUSC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.62	0.34	1.45e-10	Lung cancer;
LUSC	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.43	5.66	0.3	3.27e-8	Cognitive ability;
LUSC	cis	rs11955175	1.000	rs45480797	chr5:40680964	C/G	cg05478818	chr5:40835740	RPL37	0.71	5.73	0.3	2.24e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7215564	0.730	rs2171023	chr17:78608913	A/T	cg09596252	chr17:78655493	RPTOR	0.54	6.03	0.31	4.3e-9	Myopia (pathological);
LUSC	cis	rs7215564	0.908	rs2316063	chr17:78663360	G/A	cg09596252	chr17:78655493	RPTOR	0.53	5.85	0.31	1.15e-8	Myopia (pathological);
LUSC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.44e-8	Breast cancer;
LUSC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg03929089	chr4:120376271	NA	-0.53	-7.42	-0.38	9.89e-13	HDL cholesterol;
LUSC	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.85	-15.05	-0.64	1.96e-39	Ulcerative colitis;
LUSC	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg00484396	chr16:3507460	NAT15	-0.42	-6.79	-0.35	5.25e-11	Body mass index (adult);
LUSC	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg27219399	chr15:67835830	MAP2K5	0.34	5.66	0.3	3.33e-8	Restless legs syndrome;
LUSC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.39	-0.42	1.36e-15	Height;
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.51	-6.98	-0.36	1.64e-11	Longevity;Endometriosis;
LUSC	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg21427119	chr20:30132790	HM13	-0.39	-5.71	-0.3	2.45e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.29	-5.76	-0.3	1.88e-8	Total body bone mineral density;
LUSC	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg22852734	chr6:133119734	C6orf192	1.23	14.2	0.61	3.89e-36	Type 2 diabetes nephropathy;
LUSC	cis	rs896543	0.702	rs12692189	chr2:237496112	A/G	cg25295825	chr2:237489920	CXCR7	-0.52	-6.27	-0.32	1.12e-9	Alcohol dependence (age at onset);
LUSC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.11	-0.32	2.84e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	5.88	0.31	1.01e-8	Personality dimensions;
LUSC	cis	rs909341	0.818	rs2750483	chr20:62345470	A/G	cg09650180	chr20:62225654	GMEB2	-0.44	-5.79	-0.3	1.62e-8	Atopic dermatitis;
LUSC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg13683864	chr3:40499215	RPL14	1.03	16.65	0.67	9.6e-46	Renal cell carcinoma;
LUSC	cis	rs78572108	0.858	rs4952570	chr2:42263259	G/A	cg00607755	chr2:42274082	PKDCC	0.36	6.49	0.33	3.05e-10	Total body bone mineral density;
LUSC	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg20243544	chr17:37824526	PNMT	-0.41	-6.14	-0.32	2.38e-9	Self-reported allergy;
LUSC	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.47	-0.38	6.9e-13	Extrinsic epigenetic age acceleration;
LUSC	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg01989461	chr14:81687754	GTF2A1	0.73	13.51	0.59	1.69e-33	Schizophrenia;
LUSC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg02772935	chr3:125709198	NA	-0.47	-5.66	-0.3	3.26e-8	Blood pressure (smoking interaction);
LUSC	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg03733263	chr8:22462867	KIAA1967	0.77	12.42	0.56	2.29e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.7	-0.51	3.47e-23	Aortic root size;
LUSC	cis	rs12928939	0.768	rs71386932	chr16:71816191	G/A	cg03805757	chr16:71968109	PKD1L3	-0.46	-6.65	-0.34	1.23e-10	Post bronchodilator FEV1;
LUSC	cis	rs6700896	0.931	rs1938497	chr1:66100450	G/A	cg04111102	chr1:66153794	NA	0.32	7.08	0.36	8.57e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg05855489	chr10:104503620	C10orf26	0.58	9.28	0.45	2.17e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg01475377	chr6:109611718	NA	-0.45	-8.27	-0.41	3.13e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs752010	0.871	rs10890149	chr1:42092791	T/A	cg06885757	chr1:42089581	HIVEP3	0.45	8.79	0.43	7.99e-17	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.25	-14.44	-0.62	4.77e-37	Gout;
LUSC	cis	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg17325771	chr7:75508891	RHBDD2	-0.42	-6.09	-0.32	3.17e-9	Eotaxin levels;
LUSC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	6.25	0.32	1.25e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg11812906	chr14:75593930	NEK9	0.67	11.56	0.53	3.11e-26	Height;
LUSC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	11.11	0.52	1.28e-24	Prudent dietary pattern;
LUSC	cis	rs2070433	0.851	rs10854484	chr21:47926702	T/C	cg12379764	chr21:47803548	PCNT	0.7	9.24	0.45	2.92e-18	Lymphocyte counts;
LUSC	cis	rs4666002	0.917	rs2068834	chr2:27839539	A/G	cg27432699	chr2:27873401	GPN1	0.39	5.67	0.3	3.1e-8	Phospholipid levels (plasma);
LUSC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.87	0.4	5.1e-14	Prudent dietary pattern;
LUSC	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg10840412	chr1:235813424	GNG4	0.67	9.02	0.44	1.49e-17	Bipolar disorder;
LUSC	cis	rs62400317	0.859	rs10948221	chr6:45236707	T/G	cg20913747	chr6:44695427	NA	-0.47	-7.65	-0.39	2.2e-13	Total body bone mineral density;
LUSC	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.57	-9.23	-0.45	3.19e-18	Breast cancer;
LUSC	cis	rs600626	0.636	rs10899109	chr11:75451201	G/A	cg24262691	chr11:75473276	NA	0.48	6.38	0.33	6.06e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.73	-12.85	-0.58	5.33e-31	White blood cell count (basophil);
LUSC	cis	rs7577696	0.962	rs7581340	chr2:32337391	C/T	cg02381751	chr2:32503542	YIPF4	-0.39	-5.66	-0.3	3.18e-8	Inflammatory biomarkers;
LUSC	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	8.4	0.42	1.26e-15	Systemic lupus erythematosus;
LUSC	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg16989719	chr2:238392110	NA	-0.41	-7.18	-0.37	4.43e-12	Prostate cancer;
LUSC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.0	0.44	1.75e-17	Motion sickness;
LUSC	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs983392	0.836	rs7946992	chr11:59944810	T/C	cg02771260	chr11:59836817	MS4A3	-0.36	-5.86	-0.31	1.13e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7523050	0.643	rs12741359	chr1:109400489	T/C	cg08274380	chr1:109419600	GPSM2	1.1	10.69	0.51	3.76e-23	Fat distribution (HIV);
LUSC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.38	7.39e-13	Bipolar disorder;
LUSC	cis	rs7760949	0.889	rs9382688	chr6:13926746	A/T	cg27413430	chr6:13925136	RNF182	0.6	8.64	0.43	2.39e-16	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg27068330	chr11:65405492	SIPA1	0.55	6.52	0.34	2.55e-10	Blood pressure (age interaction);
LUSC	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.14	-0.36	5.74e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08971981	chr7:44163271	POLD2	-0.42	-6.23	-0.32	1.42e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24531977	chr5:56204891	C5orf35	0.87	13.85	0.6	8.87e-35	Initial pursuit acceleration;
LUSC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg04317338	chr11:64019027	PLCB3	0.66	7.51	0.38	5.28e-13	Mean platelet volume;
LUSC	trans	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg17675199	chr6:35436792	RPL10A	-0.43	-6.42	-0.33	4.61e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs240764	0.717	rs183566	chr6:101142605	A/T	cg09795085	chr6:101329169	ASCC3	0.41	5.93	0.31	7.56e-9	Neuroticism;
LUSC	cis	rs73200209	0.701	rs61939684	chr12:116509365	G/A	cg01776926	chr12:116560359	MED13L	-0.49	-6.03	-0.31	4.4e-9	Total body bone mineral density;
LUSC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.59	-0.46	2.15e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg08132940	chr7:1081526	C7orf50	-0.51	-6.04	-0.31	4.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg07810366	chr2:100720526	AFF3	-0.42	-6.98	-0.36	1.59e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg01557791	chr16:72042693	DHODH	-0.54	-7.92	-0.4	3.67e-14	Fibrinogen levels;
LUSC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.85	-0.3	1.18e-8	Total body bone mineral density;
LUSC	cis	rs9837602	0.938	rs9815439	chr3:99785206	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.2	0.32	1.67e-9	Breast cancer;
LUSC	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg14092571	chr14:90743983	NA	-0.36	-5.86	-0.31	1.11e-8	Mortality in heart failure;
LUSC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.78	0.51	1.94e-23	Monocyte percentage of white cells;
LUSC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg02534363	chr3:47050950	NBEAL2	0.35	5.72	0.3	2.36e-8	Colorectal cancer;
LUSC	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg26384229	chr12:38710491	ALG10B	0.62	9.93	0.48	1.53e-20	Morning vs. evening chronotype;
LUSC	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg17385448	chr1:15911702	AGMAT	0.38	6.06	0.31	3.59e-9	Systolic blood pressure;
LUSC	trans	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg02030672	chr11:45687055	CHST1	0.5	8.09	0.4	1.1e-14	Obesity-related traits;
LUSC	cis	rs889512	0.642	rs8048529	chr16:75275630	C/T	cg04987608	chr16:75300043	BCAR1	-0.5	-5.77	-0.3	1.84e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.8	-0.3	1.56e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2324229	0.861	rs1180207	chr6:83954588	A/G	cg08257003	chr6:84140564	ME1	0.26	6.03	0.31	4.38e-9	Platelet-derived growth factor BB levels;
LUSC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.52	-0.34	2.6200000000000003e-10	Lung cancer;
LUSC	cis	rs7818345	0.935	rs12542575	chr8:19286558	A/T	cg11303988	chr8:19266685	CSGALNACT1	0.37	7.16	0.36	5.17e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.84	0.44	5.72e-17	Lung cancer in ever smokers;
LUSC	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.74	12.12	0.55	2.8e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs1941687	0.797	rs9954214	chr18:31390754	T/C	cg27147174	chr7:100797783	AP1S1	-0.45	-6.56	-0.34	2.04e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg11871910	chr12:69753446	YEATS4	0.83	14.65	0.63	7.16e-38	Blood protein levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22250642	chr22:38349509	C22orf23;POLR2F	-0.42	-6.38	-0.33	6.03e-10	Electrocardiographic conduction measures;
LUSC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg12963246	chr6:28129442	ZNF389	0.53	7.41	0.38	1.04e-12	Parkinson's disease;
LUSC	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg03585969	chr10:35415529	CREM	0.59	8.74	0.43	1.16e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-10.19	-0.49	2.02e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9815354	0.812	rs55748698	chr3:41805233	G/A	cg03022575	chr3:42003672	ULK4	0.83	8.52	0.42	5.39e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7202877	0.706	rs37599	chr16:75502132	C/T	cg04384234	chr16:75411784	CFDP1	0.64	8.71	0.43	1.45e-16	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.88	15.21	0.64	4.41e-40	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs2392780	0.536	rs430693	chr8:128338594	G/T	cg10195415	chr17:73887371	TRIM65	0.41	6.64	0.34	1.3100000000000001e-10	Breast cancer (early onset);
LUSC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	9.0	0.44	1.75e-17	Motion sickness;
LUSC	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.25	-0.59	1.75e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg13902645	chr11:5959945	NA	-0.57	-7.89	-0.4	4.46e-14	DNA methylation (variation);
LUSC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	14.45	0.62	4.24e-37	Platelet count;
LUSC	cis	rs116988415	0.584	rs74859785	chr14:65249684	C/T	cg00114569	chr14:65239327	SPTB	0.64	6.94	0.35	2.1e-11	Daytime sleep phenotypes;
LUSC	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg17366294	chr4:99064904	C4orf37	0.52	9.14	0.45	6.41e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg05373962	chr22:49881684	NA	-0.41	-8.64	-0.43	2.4e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg11019008	chr10:131425282	MGMT	0.37	5.73	0.3	2.25e-8	Response to temozolomide;
LUSC	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg01657329	chr11:68192670	LRP5	-0.41	-5.82	-0.3	1.39e-8	Total body bone mineral density;
LUSC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg04369109	chr6:150039330	LATS1	-0.53	-7.62	-0.38	2.68e-13	Lung cancer;
LUSC	trans	rs9650657	0.740	rs2277130	chr8:10677601	G/C	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.59	-0.34	1.75e-10	Neuroticism;
LUSC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.7	-0.3	2.6e-8	Breast cancer;
LUSC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg13789015	chr9:136890014	NCRNA00094	0.67	12.31	0.56	5.87e-29	Platelet distribution width;
LUSC	cis	rs2279817	0.863	rs12749985	chr1:18026004	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.44	-6.59	-0.34	1.68e-10	Neuroticism;
LUSC	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg19773385	chr1:10388646	KIF1B	-0.51	-8.86	-0.44	4.99e-17	Hepatocellular carcinoma;
LUSC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg02782426	chr3:40428986	ENTPD3	-0.3	-6.0	-0.31	5.23e-9	Renal cell carcinoma;
LUSC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.7	12.67	0.57	2.52e-30	Prudent dietary pattern;
LUSC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg06027949	chr8:82754900	SNX16	0.43	5.73	0.3	2.22e-8	Diastolic blood pressure;
LUSC	trans	rs9662633	1.000	rs7517037	chr1:3647877	T/C	cg06237983	chr7:27187269	HOXA6	-0.66	-6.13	-0.32	2.52e-9	Visceral adipose tissue adjusted for BMI;
LUSC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg03146154	chr1:46216737	IPP	-0.54	-8.3	-0.41	2.66e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.87	-16.73	-0.68	4.4e-46	Longevity;
LUSC	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg23711669	chr6:146136114	FBXO30	-0.83	-14.85	-0.63	1.13e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg06917634	chr15:78832804	PSMA4	-0.7	-12.0	-0.55	8.21e-28	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs6500395	0.963	rs6500404	chr16:48690083	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21659725	chr3:3221576	CRBN	-0.65	-10.87	-0.51	8.98e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs7575217	0.654	rs62155196	chr2:101701022	A/G	cg23907051	chr2:101730305	TBC1D8	0.29	7.72	0.39	1.34e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs2386661	0.516	rs61832676	chr10:5646337	G/A	cg17085576	chr10:5658249	NA	-0.43	-6.25	-0.32	1.26e-9	Breast cancer;
LUSC	cis	rs3857536	0.785	rs1935895	chr6:66936606	T/G	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs7614311	0.552	rs73117078	chr3:63942084	G/A	cg22134162	chr3:63841271	THOC7	-0.47	-5.94	-0.31	7e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs13418410	0.539	rs1545399	chr2:33843801	A/G	cg04131969	chr2:33951647	MYADML	-0.75	-10.98	-0.52	3.68e-24	Non-response to antidepressants and depression;
LUSC	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg13755796	chr4:20253514	NA	-0.43	-6.59	-0.34	1.69e-10	Life satisfaction;
LUSC	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg24634471	chr8:143751801	JRK	0.5	7.09	0.36	8.08e-12	Schizophrenia;
LUSC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg00383909	chr3:49044727	WDR6	1.17	10.42	0.5	3.3e-22	Parkinson's disease;
LUSC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg08888203	chr3:10149979	C3orf24	0.59	8.21	0.41	4.83e-15	Alzheimer's disease;
LUSC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06221963	chr1:154839813	KCNN3	-0.65	-15.85	-0.66	1.38e-42	Prostate cancer;
LUSC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06544989	chr22:39130855	UNC84B	0.35	5.83	0.3	1.28e-8	Menopause (age at onset);
LUSC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.2	0.45	4.02e-18	Motion sickness;
LUSC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg24503407	chr1:205819492	PM20D1	0.56	9.27	0.45	2.31e-18	Menarche (age at onset);
LUSC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.69	-13.82	-0.6	1.12e-34	Longevity;Endometriosis;
LUSC	cis	rs62400317	0.731	rs72867436	chr6:44975488	T/G	cg18551225	chr6:44695536	NA	-0.43	-6.89	-0.35	2.83e-11	Total body bone mineral density;
LUSC	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.27	0.37	2.53e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7560272	0.723	rs4852927	chr2:73641557	C/T	cg20560298	chr2:73613845	ALMS1	0.46	7.1	0.36	7.76e-12	Schizophrenia;
LUSC	cis	rs12190007	0.547	rs2981945	chr6:169819839	G/A	ch.6.169577133F	chr6:169835210	NA	-0.39	-5.83	-0.3	1.32e-8	Obesity-related traits;
LUSC	cis	rs3126085	0.935	rs12738889	chr1:152257688	G/A	cg26876637	chr1:152193138	HRNR	-0.45	-6.08	-0.32	3.31e-9	Atopic dermatitis;
LUSC	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg27284194	chr4:1044797	NA	0.6	7.99	0.4	2.28e-14	Recombination rate (females);
LUSC	cis	rs7264396	0.832	rs224416	chr20:34138406	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.5	-0.34	2.85e-10	Total cholesterol levels;
LUSC	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg24375607	chr4:120327624	NA	0.76	11.3	0.53	2.72e-25	Corneal astigmatism;
LUSC	cis	rs4919687	0.550	rs7904252	chr10:104456725	A/C	cg04362960	chr10:104952993	NT5C2	-0.41	-6.02	-0.31	4.55e-9	Colorectal cancer;
LUSC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg03161606	chr19:29218774	NA	0.62	8.83	0.44	6.02e-17	Methadone dose in opioid dependence;
LUSC	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-5.76	-0.3	1.86e-8	Joint mobility (Beighton score);
LUSC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg02423579	chr7:2872169	GNA12	-0.43	-6.47	-0.33	3.51e-10	Height;
LUSC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg06636001	chr8:8085503	FLJ10661	0.61	9.39	0.46	9.43e-19	Mood instability;
LUSC	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.21	0.32	1.58e-9	Total body bone mineral density;
LUSC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg09796270	chr17:17721594	SREBF1	0.4	6.92	0.35	2.33e-11	Total body bone mineral density;
LUSC	cis	rs7582720	1.000	rs72932573	chr2:203861113	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	8.37	0.42	1.63e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	0.88	12.29	0.56	7.03e-29	Vitiligo;
LUSC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg04025307	chr7:1156635	C7orf50	0.44	5.93	0.31	7.47e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2282300	0.739	rs1222216	chr11:30346052	C/T	cg25418670	chr11:30344373	C11orf46	-0.64	-9.18	-0.45	4.63e-18	Morning vs. evening chronotype;
LUSC	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg26587870	chr6:27730563	NA	-0.67	-6.23	-0.32	1.42e-9	Depression;
LUSC	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg04691961	chr3:161091175	C3orf57	-0.36	-6.24	-0.32	1.34e-9	Morning vs. evening chronotype;
LUSC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.55	-0.34	2.2e-10	Alzheimer's disease (late onset);
LUSC	cis	rs12997796	0.556	rs7558827	chr2:86923178	A/G	cg25203885	chr2:87302643	LOC285074	-0.75	-8.13	-0.41	8.47e-15	Schizophrenia;
LUSC	trans	rs10432489	0.708	rs11687566	chr2:181744418	T/C	cg25678491	chr13:101327172	TMTC4	-0.86	-6.32	-0.33	8.58e-10	QT interval;
LUSC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg25767906	chr1:53392781	SCP2	-0.63	-12.69	-0.57	2.14e-30	Monocyte count;
LUSC	cis	rs12760731	0.565	rs7541122	chr1:178199214	G/C	cg00404053	chr1:178313656	RASAL2	0.66	6.86	0.35	3.32e-11	Obesity-related traits;
LUSC	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.98	-0.48	1.1e-20	Migraine;Coronary artery disease;
LUSC	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg20701182	chr2:24300061	SF3B14	0.7	7.52	0.38	5.12e-13	Lymphocyte counts;
LUSC	cis	rs7927771	0.524	rs3816605	chr11:47857253	T/C	cg20307385	chr11:47447363	PSMC3	0.44	6.36	0.33	6.67e-10	Subjective well-being;
LUSC	cis	rs3770081	1.000	rs1036554	chr2:86236099	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.78	-5.68	-0.3	3e-8	Facial emotion recognition (sad faces);
LUSC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02353165	chr6:42928485	GNMT	0.68	11.84	0.54	3.07e-27	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg17480646	chr11:65405466	SIPA1	-0.46	-5.94	-0.31	7.01e-9	Acne (severe);
LUSC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg20573242	chr4:122745356	CCNA2	0.44	6.77	0.35	5.65e-11	Type 2 diabetes;
LUSC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	16.58	0.67	1.84e-45	Platelet count;
LUSC	cis	rs11674184	0.659	rs11679605	chr2:11722468	G/A	cg07314298	chr2:11723111	GREB1	-0.71	-11.45	-0.53	8.14e-26	Endometriosis;
LUSC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg12365402	chr11:9010492	NRIP3	0.48	8.75	0.43	1.11e-16	Hemoglobin concentration;
LUSC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.6	9.66	0.47	1.23e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg04310649	chr10:35416472	CREM	-0.42	-6.43	-0.33	4.33e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9308433	0.505	rs6695148	chr1:214497861	G/T	cg06198575	chr1:214491504	SMYD2	0.45	6.99	0.36	1.53e-11	IgG glycosylation;
LUSC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08564027	chr20:61660810	NA	0.9	17.32	0.69	2.14e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08704250	chr15:31115839	NA	-0.46	-6.84	-0.35	3.89e-11	Huntington's disease progression;
LUSC	cis	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg21775007	chr8:11205619	TDH	-0.48	-6.16	-0.32	2.12e-9	Neuroticism;
LUSC	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg03585969	chr10:35415529	CREM	0.6	8.76	0.43	9.64e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg19622623	chr12:86230825	RASSF9	-0.43	-5.98	-0.31	5.85e-9	Major depressive disorder;
LUSC	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg06484146	chr7:12443880	VWDE	-0.62	-6.23	-0.32	1.37e-9	Coronary artery disease;
LUSC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg16606324	chr3:10149918	C3orf24	-0.63	-7.89	-0.4	4.49e-14	Alzheimer's disease;
LUSC	cis	rs2262909	0.962	rs409439	chr19:22227432	C/T	cg11619707	chr19:22235551	ZNF257	-0.38	-5.7	-0.3	2.7e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.8	0.3	1.53e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9341835	0.709	rs9359467	chr6:64154975	G/C	cg03326410	chr6:64151739	NA	-0.37	-5.98	-0.31	5.76e-9	Schizophrenia;
LUSC	trans	rs1459104	0.641	rs4454742	chr11:54840592	A/T	cg15704280	chr7:45808275	SEPT13	0.77	6.69	0.34	9.3e-11	Body mass index;
LUSC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.74	-0.3	2.17e-8	Tonsillectomy;
LUSC	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg22705602	chr4:152727874	NA	-0.34	-6.86	-0.35	3.31e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs75920871	0.545	rs7939934	chr11:116861268	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-6.76	-0.35	6.12e-11	Subjective well-being;
LUSC	cis	rs6977660	0.714	rs6970798	chr7:19816741	G/C	cg07541023	chr7:19748670	TWISTNB	0.63	6.84	0.35	3.87e-11	Thyroid stimulating hormone;
LUSC	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg17168535	chr8:21777572	XPO7	0.67	10.29	0.49	9.63e-22	Mean corpuscular volume;
LUSC	cis	rs2625529	0.668	rs12914070	chr15:72334279	T/C	cg16672083	chr15:72433130	SENP8	-0.51	-7.51	-0.38	5.41e-13	Red blood cell count;
LUSC	cis	rs12973672	1.000	rs28365136	chr19:35769561	T/G	cg12095397	chr19:35769544	USF2	0.44	6.91	0.35	2.42e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg15691649	chr6:25882328	NA	-0.41	-5.95	-0.31	6.71e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.56	-8.75	-0.43	1.11e-16	Personality dimensions;
LUSC	cis	rs12464559	0.522	rs6715027	chr2:152626657	T/C	cg01189475	chr2:152685088	ARL5A	0.62	6.7	0.34	8.8e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	0.98	14.03	0.61	1.75e-35	Eosinophil percentage of granulocytes;
LUSC	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg03929089	chr4:120376271	NA	0.6	6.35	0.33	7.17e-10	Axial length;
LUSC	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.43	5.99	0.31	5.34e-9	Lung cancer;
LUSC	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	0.83	14.48	0.62	3.21e-37	Metabolic syndrome;
LUSC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg16339924	chr4:17578868	LAP3	0.68	10.99	0.52	3.57e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2882667	0.522	rs7731574	chr5:138454192	A/G	cg04439458	chr5:138467593	SIL1	0.37	7.73	0.39	1.28e-13	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.46	0.38	7.35e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg18402987	chr7:1209562	NA	0.73	7.84	0.39	5.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg25173405	chr17:45401733	C17orf57	0.36	5.76	0.3	1.95e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12956009	0.518	rs11663852	chr18:44887542	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.42	0.33	4.66e-10	Educational attainment (years of education);
LUSC	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.95	-12.41	-0.56	2.52e-29	Exhaled nitric oxide output;
LUSC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg08859206	chr1:53392774	SCP2	-0.42	-6.78	-0.35	5.41e-11	Monocyte count;
LUSC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.49	0.33	3.09e-10	Menarche (age at onset);
LUSC	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg14675211	chr2:100938903	LONRF2	0.37	5.74	0.3	2.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg06627628	chr2:24431161	ITSN2	0.51	7.27	0.37	2.53e-12	Asthma;
LUSC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg16049864	chr8:95962084	TP53INP1	-0.62	-11.6	-0.54	2.2e-26	Type 2 diabetes;
LUSC	cis	rs2153904	0.793	rs12132270	chr1:205660940	C/T	cg23034840	chr1:205782522	SLC41A1	-0.65	-6.73	-0.35	7.2e-11	Prostate-specific antigen levels;
LUSC	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.88	15.31	0.64	1.87e-40	Metabolic syndrome;
LUSC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.41e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg17724175	chr1:150552817	MCL1	-0.33	-5.67	-0.3	3.16e-8	Tonsillectomy;
LUSC	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.87	-0.35	3.17e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.7	0.75	7.91e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs983392	0.792	rs595481	chr11:59914267	T/C	cg24026212	chr11:59952134	MS4A6A	-0.31	-5.67	-0.3	3.14e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg19812747	chr11:111475976	SIK2	-0.57	-8.23	-0.41	4.18e-15	Primary sclerosing cholangitis;
LUSC	cis	rs73198271	0.562	rs17154743	chr8:8650787	A/G	cg01851573	chr8:8652454	MFHAS1	0.64	9.11	0.45	7.52e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg03351412	chr1:154909251	PMVK	0.52	8.04	0.4	1.53e-14	Prostate cancer;
LUSC	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg18099408	chr3:52552593	STAB1	0.36	5.97	0.31	6.15e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	0.96	13.18	0.58	3.15e-32	Eosinophil percentage of granulocytes;
LUSC	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg03585969	chr10:35415529	CREM	0.62	8.97	0.44	2.2e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2979489	0.891	rs2979498	chr8:30375251	T/A	cg26383811	chr8:30366931	RBPMS	-0.53	-8.18	-0.41	6.08e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs7336332	0.628	rs9581855	chr13:28018014	G/A	cg22138327	chr13:27999177	GTF3A	0.77	9.83	0.47	3.36e-20	Weight;
LUSC	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg17143192	chr8:8559678	CLDN23	0.65	8.96	0.44	2.31e-17	Obesity-related traits;
LUSC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.56	-9.02	-0.44	1.49e-17	Longevity;Endometriosis;
LUSC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	0.92	13.69	0.6	3.62e-34	Breast cancer;
LUSC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.31	-0.33	9e-10	Blood metabolite levels;
LUSC	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg22532475	chr10:104410764	TRIM8	-0.25	-6.01	-0.31	4.97e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.59	-0.38	3.28e-13	Personality dimensions;
LUSC	cis	rs68170813	0.652	rs75136686	chr7:107180949	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-8.63	-0.43	2.46e-16	Coronary artery disease;
LUSC	cis	rs12122100	0.651	rs6665411	chr1:146547095	A/G	cg03526459	chr1:146549940	NA	0.42	6.97	0.36	1.7e-11	HIV-1 control;
LUSC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg14552801	chr7:65878734	NA	-0.43	-5.89	-0.31	9.49e-9	Aortic root size;
LUSC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-1.1	-16.16	-0.66	8.62e-44	Initial pursuit acceleration;
LUSC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg07414643	chr4:187882934	NA	0.55	10.53	0.5	1.41e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg04369109	chr6:150039330	LATS1	-0.51	-7.46	-0.38	7.73e-13	Lung cancer;
LUSC	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	0.58	8.8	0.43	7.52e-17	Breast cancer;
LUSC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg16989086	chr20:62203971	PRIC285	0.47	6.58	0.34	1.81e-10	Glioblastoma;
LUSC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.5	0.62	2.71e-37	Platelet count;
LUSC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26314531	chr2:26401878	FAM59B	-0.69	-9.37	-0.46	1.12e-18	Gut microbiome composition (summer);
LUSC	trans	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	1.05	18.49	0.71	4.64e-53	Parkinson's disease;
LUSC	cis	rs2224391	1.000	rs2224391	chr6:5260936	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-7.24	-0.37	3.15e-12	Height;
LUSC	cis	rs9581857	0.547	rs9581876	chr13:28101113	T/C	cg22138327	chr13:27999177	GTF3A	0.69	6.98	0.36	1.6e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg07716408	chr11:68623521	NA	-0.3	-5.82	-0.3	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg21643547	chr1:205240462	TMCC2	-0.51	-9.93	-0.48	1.55e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	12.56	0.57	6.58e-30	Menarche (age at onset);
LUSC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg06637938	chr14:75390232	RPS6KL1	0.54	8.65	0.43	2.27e-16	Height;
LUSC	cis	rs722599	0.715	rs8008785	chr14:75307600	G/A	cg08847533	chr14:75593920	NEK9	-0.44	-6.26	-0.32	1.2e-9	IgG glycosylation;
LUSC	cis	rs73195822	0.614	rs17793540	chr12:111215575	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	7.04	0.36	1.13e-11	Itch intensity from mosquito bite;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03776541	chr10:99400533	PI4K2A	-0.46	-6.8	-0.35	4.89e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2587949	0.615	rs2600115	chr3:4225026	G/T	cg15139668	chr4:4577005	NA	-0.42	-6.22	-0.32	1.51e-9	Periodontitis (DPAL);
LUSC	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg25214090	chr10:38739885	LOC399744	0.58	8.47	0.42	8.08e-16	Corneal astigmatism;
LUSC	trans	rs72674100	1.000	rs28457587	chr4:97991521	T/C	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg03886242	chr7:26192032	NFE2L3	-0.41	-6.25	-0.32	1.28e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12519773	1.000	rs959922	chr5:92450649	C/T	cg18783429	chr5:92414398	NA	-0.3	-6.73	-0.35	7.41e-11	Migraine;
LUSC	cis	rs34375054	0.525	rs12316499	chr12:125593318	G/A	cg09839279	chr12:125627357	AACS	-0.36	-6.5	-0.34	2.87e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.29	0.59	1.23e-32	Cognitive test performance;
LUSC	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	9.17	0.45	5.15e-18	Response to antipsychotic treatment;
LUSC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg16362232	chr11:430036	ANO9	0.62	8.09	0.4	1.08e-14	Body mass index;
LUSC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg23791538	chr6:167370224	RNASET2	0.43	6.93	0.35	2.11e-11	Crohn's disease;
LUSC	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg20476274	chr7:133979776	SLC35B4	0.85	16.05	0.66	2.18e-43	Mean platelet volume;
LUSC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	1.21	16.6	0.67	1.46e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs4363385	0.818	rs946095	chr1:153006470	T/C	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.44e-12	Inflammatory skin disease;
LUSC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.7	-0.34	8.88e-11	Tonsillectomy;
LUSC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg25258033	chr6:167368657	RNASET2	0.46	7.36	0.37	1.48e-12	Crohn's disease;
LUSC	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg15212455	chr7:39170539	POU6F2	0.41	6.21	0.32	1.56e-9	IgG glycosylation;
LUSC	cis	rs62400317	0.762	rs62436376	chr6:44885817	C/T	cg20913747	chr6:44695427	NA	-0.48	-7.51	-0.38	5.55e-13	Total body bone mineral density;
LUSC	cis	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.49	-0.38	6.17e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	ch.11.42038R	chr11:967971	AP2A2	0.46	6.56	0.34	2.05e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6543140	1.000	rs6543140	chr2:103074274	G/T	cg09003973	chr2:102972529	NA	0.54	7.02	0.36	1.25e-11	Blood protein levels;
LUSC	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg05714579	chr10:131428358	MGMT	-0.46	-6.68	-0.34	9.94e-11	Response to temozolomide;
LUSC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs6430585	0.527	rs2304366	chr2:136467119	C/T	cg07169764	chr2:136633963	MCM6	1.05	13.73	0.6	2.45e-34	Corneal structure;
LUSC	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-5.99	-0.31	5.41e-9	Fear of minor pain;
LUSC	trans	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg21775007	chr8:11205619	TDH	0.44	6.0	0.31	5.07e-9	Neuroticism;
LUSC	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg12454169	chr2:30669597	LCLAT1	0.71	8.83	0.43	6.06e-17	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg27535305	chr1:53392650	SCP2	-0.4	-7.49	-0.38	6.15e-13	Monocyte count;
LUSC	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg18404041	chr3:52824283	ITIH1	0.58	9.38	0.46	1.06e-18	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	1.05	19.12	0.72	1.42e-55	Menopause (age at onset);
LUSC	trans	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg08975724	chr8:8085496	FLJ10661	0.45	5.98	0.31	5.87e-9	Neuroticism;
LUSC	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.91	0.31	8.5e-9	Rheumatoid arthritis;
LUSC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.44	0.56	1.86e-29	Motion sickness;
LUSC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg22508957	chr16:3507546	NAT15	0.63	10.29	0.49	9.04e-22	Tuberculosis;
LUSC	trans	rs2018683	0.707	rs1021689	chr7:28974223	G/T	cg19402173	chr7:128379420	CALU	-0.47	-7.24	-0.37	3.06e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.43	-0.42	1.03e-15	Breast cancer;
LUSC	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg10840412	chr1:235813424	GNG4	0.54	7.09	0.36	8.24e-12	Bipolar disorder;
LUSC	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-0.85	-14.16	-0.61	5.78e-36	Headache;
LUSC	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg22709100	chr7:91322751	NA	-0.47	-6.87	-0.35	3.19e-11	Breast cancer;
LUSC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg25258033	chr6:167368657	RNASET2	-0.45	-7.26	-0.37	2.76e-12	Crohn's disease;
LUSC	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.05	-0.44	1.19e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.22	0.71	5.32e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1005224	0.963	rs12887886	chr14:76167846	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.62	-8.58	-0.42	3.62e-16	Large artery stroke;
LUSC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs735860	0.726	rs209510	chr6:53202035	T/C	cg10236188	chr6:53219634	NA	0.38	5.66	0.3	3.3e-8	Glaucoma;
LUSC	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17467752	chr17:38218738	THRA	-0.71	-11.39	-0.53	1.31e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg22823121	chr1:150693482	HORMAD1	0.51	7.44	0.38	8.56e-13	Melanoma;
LUSC	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.6	6.9	0.35	2.62e-11	Schizophrenia;
LUSC	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg13535736	chr9:111863775	C9orf5	-0.42	-6.85	-0.35	3.64e-11	Menarche (age at onset);
LUSC	trans	rs7980799	0.649	rs2389215	chr12:33649457	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.92	-0.4	3.67e-14	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg13206674	chr6:150067644	NUP43	0.56	8.38	0.42	1.47e-15	Lung cancer;
LUSC	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg21890820	chr11:65308645	LTBP3	0.49	7.28	0.37	2.37e-12	Bone mineral density;
LUSC	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg22705602	chr4:152727874	NA	-0.3	-6.11	-0.32	2.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg18678763	chr11:4115507	RRM1	-0.46	-6.02	-0.31	4.53e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-7.81	-0.39	7.68e-14	Chronic sinus infection;
LUSC	cis	rs1298908	1.000	rs1298908	chr10:82013134	A/G	cg01528321	chr10:82214614	TSPAN14	-0.52	-7.7	-0.39	1.5700000000000001e-13	Diabetic kidney disease;
LUSC	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs13315871	0.929	rs71311853	chr3:58319152	C/T	cg20936604	chr3:58311152	NA	-0.76	-7.25	-0.37	2.83e-12	Cholesterol, total;
LUSC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg21665744	chr7:39171113	POU6F2	0.48	7.63	0.39	2.56e-13	IgG glycosylation;
LUSC	cis	rs10979	1.000	rs13198159	chr6:143891953	C/T	cg25407410	chr6:143891975	LOC285740	-0.74	-11.93	-0.55	1.41e-27	Hypospadias;
LUSC	cis	rs12760731	0.720	rs12022185	chr1:178279653	A/G	cg00404053	chr1:178313656	RASAL2	0.64	6.73	0.35	7.36e-11	Obesity-related traits;
LUSC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg16928487	chr17:17741425	SREBF1	0.45	8.84	0.44	5.67e-17	Total body bone mineral density;
LUSC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-9.79	-0.47	4.59e-20	Gut microbiome composition (summer);
LUSC	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg13010199	chr12:38710504	ALG10B	-0.58	-9.11	-0.45	8.04e-18	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.33	0.45	1.46e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg23711669	chr6:146136114	FBXO30	-0.81	-14.85	-0.63	1.16e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg16339924	chr4:17578868	LAP3	0.54	8.26	0.41	3.44e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg13628971	chr7:2884303	GNA12	0.49	6.98	0.36	1.62e-11	Height;
LUSC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg22638593	chr5:131593259	PDLIM4	0.42	6.12	0.32	2.64e-9	Breast cancer;
LUSC	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.85	-0.35	3.67e-11	Menopause (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01103590	chr12:71833534	LGR5	0.66	6.08	0.32	3.22e-9	Cognitive performance;
LUSC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.98	0.31	5.84e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06873352	chr17:61820015	STRADA	0.54	8.29	0.41	2.74e-15	Height;
LUSC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.43	-0.46	7.21e-19	Gut microbiome composition (summer);
LUSC	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg16339924	chr4:17578868	LAP3	0.5	7.57	0.38	3.57e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.87	11.91	0.55	1.73e-27	Platelet count;
LUSC	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg12935359	chr14:103987150	CKB	0.66	10.79	0.51	1.68e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs3740540	0.530	rs2362506	chr10:126290751	C/G	cg04949429	chr10:126290192	LHPP	0.36	7.64	0.39	2.29e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg21775007	chr8:11205619	TDH	-0.65	-10.36	-0.49	5.25e-22	Retinal vascular caliber;
LUSC	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg00745463	chr17:30367425	LRRC37B	-0.74	-9.03	-0.44	1.41e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11764359	chr7:65958608	NA	0.7	11.5	0.53	5.14e-26	Aortic root size;
LUSC	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg04058563	chr4:185651563	MLF1IP	-0.44	-7.47	-0.38	6.91e-13	Kawasaki disease;
LUSC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.39	5.74	0.3	2.13e-8	Schizophrenia;
LUSC	cis	rs9796	0.745	rs2947493	chr15:41375694	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.27	-0.41	3.13e-15	Menopause (age at onset);
LUSC	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.57	-8.99	-0.44	1.81e-17	Schizophrenia;
LUSC	cis	rs1775715	0.870	rs1755084	chr10:32253709	C/T	cg18675610	chr10:32216311	ARHGAP12	0.29	6.03	0.31	4.39e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.46	-0.5	2.51e-22	Eye color traits;
LUSC	cis	rs977987	0.586	rs12920883	chr16:75432681	T/C	cg03315344	chr16:75512273	CHST6	0.48	8.93	0.44	2.98e-17	Dupuytren's disease;
LUSC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.47	0.53	6.9e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg08200582	chr11:442649	ANO9	-0.56	-5.96	-0.31	6.34e-9	Body mass index;
LUSC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.83	-11.06	-0.52	2.02e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.56	11.5	0.53	5.38e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg15790184	chr11:494944	RNH1	0.59	6.34	0.33	7.35e-10	Body mass index;
LUSC	cis	rs8040855	0.599	rs6496791	chr15:85725659	C/T	cg04831495	chr15:85060580	GOLGA6L5	0.42	6.97	0.36	1.72e-11	Bulimia nervosa;
LUSC	cis	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg06521331	chr12:34319734	NA	-0.46	-7.6	-0.38	2.95e-13	Morning vs. evening chronotype;
LUSC	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.71	-12.52	-0.57	9.7e-30	White blood cell count (basophil);
LUSC	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg07701084	chr6:150067640	NUP43	0.47	6.93	0.35	2.16e-11	Testicular germ cell tumor;
LUSC	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.35	5.91	0.31	8.66e-9	Depressive symptoms;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg23034840	chr1:205782522	SLC41A1	0.67	9.97	0.48	1.17e-20	Menarche (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00030291	chr7:8302094	ICA1	-0.48	-6.12	-0.32	2.64e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08704250	chr15:31115839	NA	-0.47	-7.07	-0.36	9.16e-12	Huntington's disease progression;
LUSC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg14440974	chr22:39074834	NA	-0.36	-6.16	-0.32	2.08e-9	Menopause (age at onset);
LUSC	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg16482183	chr6:26056742	HIST1H1C	0.56	8.34	0.42	2.02e-15	Height;
LUSC	cis	rs4953318	0.894	rs10495928	chr2:46353166	A/G	cg12428440	chr2:46370979	PRKCE	0.37	6.6	0.34	1.66e-10	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg22166914	chr1:53195759	ZYG11B	0.6	9.8	0.47	4.26e-20	Monocyte count;
LUSC	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06636551	chr8:101224915	SPAG1	0.43	7.89	0.4	4.26e-14	Atrioventricular conduction;
LUSC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.98	-0.31	5.72e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.29	-0.41	2.74e-15	Cystic fibrosis severity;
LUSC	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg01097406	chr16:89675127	NA	0.38	7.92	0.4	3.68e-14	Vitiligo;
LUSC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21028142	chr17:79581711	NPLOC4	0.33	8.03	0.4	1.7e-14	Eye color traits;
LUSC	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg05501817	chr11:14380813	RRAS2	-0.56	-8.85	-0.44	5.34e-17	Sense of smell;
LUSC	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg11502198	chr6:26597334	ABT1	0.59	9.37	0.46	1.16e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg15691649	chr6:25882328	NA	0.35	5.65	0.3	3.42e-8	Blood metabolite levels;
LUSC	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.4	-6.2	-0.32	1.64e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10986311	0.862	rs10818950	chr9:127130137	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.38	-6.0	-0.31	5e-9	Vitiligo;
LUSC	cis	rs7712401	0.601	rs2910140	chr5:122264395	T/A	cg19077854	chr5:122220652	SNX24	0.41	8.93	0.44	2.84e-17	Mean platelet volume;
LUSC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg21724239	chr8:58056113	NA	0.58	7.17	0.37	4.74e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs751728	1.000	rs11752297	chr6:33735154	G/C	cg25922239	chr6:33757077	LEMD2	0.52	7.68	0.39	1.83e-13	Crohn's disease;
LUSC	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg18827107	chr12:86230957	RASSF9	-0.4	-5.99	-0.31	5.31e-9	Major depressive disorder;
LUSC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg00701064	chr4:6280414	WFS1	0.59	14.24	0.61	2.82e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg00999904	chr2:3704751	ALLC	-0.43	-6.79	-0.35	5.02e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg02475777	chr4:1388615	CRIPAK	0.38	5.83	0.3	1.29e-8	Obesity-related traits;
LUSC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05025164	chr4:1340916	KIAA1530	-0.63	-10.0	-0.48	8.78e-21	Obesity-related traits;
LUSC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	6.53	0.34	2.48e-10	Bipolar disorder;
LUSC	trans	rs2164273	0.565	rs2736387	chr8:11157371	A/C	cg15556689	chr8:8085844	FLJ10661	0.43	6.39	0.33	5.59e-10	Extraversion;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22080282	chr18:72920932	ZADH2	-0.47	-6.31	-0.33	8.91e-10	Hepatitis;
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-8.03	-0.4	1.71e-14	Lymphocyte counts;
LUSC	cis	rs7727544	0.582	rs2301579	chr5:131553340	C/A	cg14196790	chr5:131705035	SLC22A5	0.43	7.18	0.37	4.66e-12	Blood metabolite levels;
LUSC	cis	rs3764563	0.799	rs7249233	chr19:15723591	T/C	cg20725493	chr19:15740067	CYP4F8	-0.66	-6.99	-0.36	1.5e-11	Inflammatory biomarkers;
LUSC	cis	rs72772090	0.539	rs17481856	chr5:96116808	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-6.61	-0.34	1.53e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg24642844	chr7:1081250	C7orf50	-0.68	-6.41	-0.33	5.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg05187965	chr10:45406764	TMEM72	-0.36	-8.42	-0.42	1.11e-15	Mean corpuscular volume;
LUSC	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03713592	chr11:72463424	ARAP1	0.82	9.55	0.46	2.89e-19	Type 2 diabetes;
LUSC	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg06360820	chr2:242988706	NA	-0.85	-10.17	-0.49	2.47e-21	Obesity-related traits;
LUSC	cis	rs2607426	0.681	rs10420651	chr19:41235038	C/G	cg05508168	chr19:41255947	C19orf54;SNRPA	0.92	6.83	0.35	3.91e-11	Blood protein levels;
LUSC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-9.15	-0.45	5.71e-18	Schizophrenia;
LUSC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.44	-7.32	-0.37	1.92e-12	IgG glycosylation;
LUSC	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg23241863	chr10:102295624	HIF1AN	0.48	5.91	0.31	8.26e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.83	0.47	3.46e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg09307838	chr4:120376055	NA	0.64	9.64	0.47	1.4e-19	Corneal astigmatism;
LUSC	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.3	-0.37	2.19e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs10140922	0.931	rs4982261	chr14:35822159	C/T	cg07166546	chr14:35805898	NA	-0.24	-5.86	-0.31	1.12e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs1111571	0.576	rs1465469	chr16:68397916	T/G	cg02226672	chr16:68398533	SMPD3	0.31	5.65	0.3	3.52e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg16342193	chr10:102329863	NA	-0.37	-6.49	-0.33	3.04e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg05425664	chr17:57184151	TRIM37	-0.53	-7.96	-0.4	2.77e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6977660	0.714	rs6959039	chr7:19818182	T/C	cg05791153	chr7:19748676	TWISTNB	0.66	7.0	0.36	1.38e-11	Thyroid stimulating hormone;
LUSC	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-8.98	-0.44	2.08e-17	Coffee consumption (cups per day);
LUSC	cis	rs3741151	0.773	rs7931767	chr11:73239207	A/G	cg17517138	chr11:73019481	ARHGEF17	0.96	8.06	0.4	1.35e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.57	9.44	0.46	6.61e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg20891558	chr2:74357851	NA	0.79	14.23	0.61	3.02e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg16405210	chr4:1374714	KIAA1530	-0.52	-7.67	-0.39	1.92e-13	Obesity-related traits;
LUSC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg06238570	chr21:40685208	BRWD1	-0.58	-9.24	-0.45	3.03e-18	Menarche (age at onset);
LUSC	trans	rs7637701	0.713	rs9867857	chr3:156491160	C/T	cg11006288	chr14:69012387	RAD51L1	0.39	6.23	0.32	1.37e-9	Breast cancer;
LUSC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-5.97	-0.31	5.96e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	9.9	0.48	2.01e-20	Mood instability;
LUSC	cis	rs34638657	0.732	rs61111557	chr16:82201102	A/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.33	-0.33	7.89e-10	Lung adenocarcinoma;
LUSC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00149659	chr3:10157352	C3orf10	0.94	12.49	0.56	1.18e-29	Alzheimer's disease;
LUSC	cis	rs10740039	0.768	rs7895268	chr10:62463237	T/C	cg18175470	chr10:62150864	ANK3	-0.43	-6.58	-0.34	1.77e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg00376283	chr12:123451042	ABCB9	-0.67	-7.77	-0.39	9.99e-14	Neutrophil percentage of white cells;
LUSC	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg05110241	chr16:68378359	PRMT7	-0.5	-6.35	-0.33	7.05e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3812762	0.917	rs10743087	chr11:8786058	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.4	7.09	0.36	8.09e-12	Hypospadias;
LUSC	cis	rs679087	0.659	rs302318	chr12:29921667	T/C	cg14258853	chr12:29935411	TMTC1	-0.72	-10.69	-0.5	4.02e-23	Schizophrenia;
LUSC	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.95	0.51	4.95e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	7.07	0.36	8.93e-12	Rheumatoid arthritis;
LUSC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.75	0.35	6.46e-11	Tonsillectomy;
LUSC	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg22676075	chr6:135203613	NA	0.47	7.27	0.37	2.62e-12	Red blood cell count;
LUSC	trans	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-9.73	-0.47	7.05e-20	Brugada syndrome;
LUSC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg26924012	chr15:45694286	SPATA5L1	1.13	20.84	0.75	2.15e-62	Homoarginine levels;
LUSC	cis	rs1662342	1.000	rs1791106	chr18:3251862	G/A	cg00760847	chr18:3262519	MYL12B	-0.58	-5.68	-0.3	2.97e-8	QRS duration;
LUSC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg05623727	chr3:50126028	RBM5	0.32	6.07	0.32	3.52e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg26727032	chr16:67993705	SLC12A4	-0.42	-6.24	-0.32	1.3e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6681460	1.000	rs6656912	chr1:67083671	A/G	cg02459107	chr1:67143332	SGIP1	0.43	7.48	0.38	6.78e-13	Presence of antiphospholipid antibodies;
LUSC	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-6.91	-0.35	2.4e-11	Menopause (age at onset);
LUSC	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg21775007	chr8:11205619	TDH	-0.75	-12.42	-0.56	2.23e-29	Retinal vascular caliber;
LUSC	trans	rs11933661	0.528	rs1022008	chr4:130966269	C/G	cg23838308	chr17:57785056	PTRH2;TMEM49	0.4	6.15	0.32	2.16e-9	Alcohol dependence;
LUSC	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg16797656	chr11:68205561	LRP5	0.37	6.16	0.32	2.13e-9	Total body bone mineral density;
LUSC	cis	rs34638657	0.702	rs62044259	chr16:82199523	A/T	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.47	-0.33	3.55e-10	Lung adenocarcinoma;
LUSC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.91	14.19	0.61	4.36e-36	Coronary artery disease;
LUSC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg16031515	chr1:205743344	RAB7L1	-0.27	-5.69	-0.3	2.83e-8	Menarche (age at onset);
LUSC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg25767906	chr1:53392781	SCP2	0.48	8.66	0.43	1.98e-16	Monocyte count;
LUSC	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg26395211	chr5:140044315	WDR55	-0.37	-5.7	-0.3	2.69e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9905704	0.874	rs28483505	chr17:56844109	G/C	cg12560992	chr17:57184187	TRIM37	0.55	7.84	0.39	6.19e-14	Testicular germ cell tumor;
LUSC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.17	0.37	4.94e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21016266	chr12:122356598	WDR66	0.58	8.79	0.43	8.29e-17	Mean corpuscular volume;
LUSC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg17718321	chr1:152188247	HRNR	-0.37	-6.71	-0.34	8.31e-11	Inflammatory skin disease;
LUSC	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.34	-6.47	-0.33	3.42e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.14	-0.36	5.81e-12	Blood metabolite levels;
LUSC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg20283391	chr11:68216788	NA	-0.55	-8.19	-0.41	5.61e-15	Total body bone mineral density;
LUSC	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.84	-0.35	3.88e-11	Menopause (age at onset);
LUSC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg17376030	chr22:41985996	PMM1	-0.47	-5.89	-0.31	9.6e-9	Vitiligo;
LUSC	cis	rs41298997	1	rs41298997	chr1:206655331	C/T	cg11166312	chr1:206654246	IKBKE	0.62	9.26	0.45	2.59e-18	Psoriasis;
LUSC	trans	rs2262909	1.000	rs436039	chr19:22214873	T/C	cg17074339	chr11:11642133	GALNTL4	-0.41	-6.2	-0.32	1.68e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13127421	chr17:48202128	SAMD14	-0.56	-9.36	-0.46	1.22e-18	Temporomandibular joint disorder;
LUSC	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg04450456	chr4:17643702	FAM184B	0.38	6.41	0.33	5.02e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02018176	chr4:1364513	KIAA1530	0.74	13.19	0.59	2.85e-32	Longevity;
LUSC	trans	rs72674100	0.737	rs28461925	chr4:97991609	G/T	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg22800045	chr5:56110881	MAP3K1	0.77	10.07	0.48	5.15e-21	Initial pursuit acceleration;
LUSC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg08859206	chr1:53392774	SCP2	0.46	7.75	0.39	1.13e-13	Monocyte count;
LUSC	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg13256891	chr4:100009986	ADH5	0.52	7.09	0.36	8.03e-12	Smoking initiation;
LUSC	cis	rs644148	0.836	rs2686775	chr19:45000059	C/T	cg15540054	chr19:45004280	ZNF180	-0.63	-9.32	-0.45	1.6e-18	Personality dimensions;
LUSC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.94	0.51	5.08e-24	Menopause (age at onset);
LUSC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-9.41	-0.46	8.39e-19	Gut microbiome composition (summer);
LUSC	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.36	6.53	0.34	2.5e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg22823121	chr1:150693482	HORMAD1	0.46	6.58	0.34	1.82e-10	Melanoma;
LUSC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.3e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.38	6.11	0.32	2.85e-9	Self-reported allergy;
LUSC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.74	-0.39	1.18e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg27089754	chr16:75590036	TMEM231	0.79	6.14	0.32	2.37e-9	Cognitive performance;
LUSC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11690462	0.528	rs6710942	chr2:26636390	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.48	6.23	0.32	1.41e-9	Coronary artery disease;
LUSC	cis	rs662064	0.748	rs2506896	chr1:10603716	T/C	cg20482658	chr1:10539492	PEX14	0.29	5.81	0.3	1.44e-8	Asthma;
LUSC	cis	rs5167	0.566	rs2075620	chr19:45480037	C/T	cg13119609	chr19:45449297	APOC2	-0.35	-5.98	-0.31	5.66e-9	Blood protein levels;
LUSC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	8.37	0.42	1.64e-15	Colorectal cancer;
LUSC	cis	rs9815354	0.812	rs12186050	chr3:41836879	G/C	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9462027	0.527	rs11755393	chr6:34824636	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.83	-0.3	1.31e-8	Systemic lupus erythematosus;
LUSC	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg05340658	chr4:99064831	C4orf37	0.46	7.28	0.37	2.39e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg23093090	chr10:104574429	C10orf26	-0.35	-6.41	-0.33	4.97e-10	Arsenic metabolism;
LUSC	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg19920283	chr7:105172520	RINT1	0.59	6.21	0.32	1.56e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4356932	0.691	rs6532078	chr4:76920809	A/G	cg00809888	chr4:76862425	NAAA	0.36	5.74	0.3	2.13e-8	Blood protein levels;
LUSC	cis	rs7043114	0.525	rs2274966	chr9:95155563	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.89	-0.35	2.77e-11	Height;
LUSC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.05e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs877282	0.898	rs11253356	chr10:768604	G/A	cg17470449	chr10:769945	NA	0.47	6.63	0.34	1.34e-10	Uric acid levels;
LUSC	trans	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg08975724	chr8:8085496	FLJ10661	0.42	6.1	0.32	2.99e-9	Retinal vascular caliber;
LUSC	cis	rs9650315	0.789	rs36126100	chr8:57188731	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	6.41	0.33	4.87e-10	Height;
LUSC	trans	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.74	0.39	1.17e-13	Ulcerative colitis;
LUSC	cis	rs3857536	0.706	rs1418854	chr6:66893284	C/T	cg07460842	chr6:66804631	NA	-0.48	-6.71	-0.34	8.12e-11	Blood trace element (Cu levels);
LUSC	cis	rs601339	1.000	rs525215	chr12:123179771	G/A	cg11919336	chr12:123188078	GPR109A	0.43	6.52	0.34	2.64e-10	Adiponectin levels;
LUSC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg06600287	chr1:53387719	ECHDC2	0.29	6.14	0.32	2.29e-9	Monocyte count;
LUSC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11644478	chr21:40555479	PSMG1	0.63	10.23	0.49	1.46e-21	Cognitive function;
LUSC	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.34	-5.66	-0.3	3.24e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7851660	0.809	rs10984235	chr9:100660896	C/T	cg13688889	chr9:100608707	NA	-0.54	-8.44	-0.42	9.53e-16	Strep throat;
LUSC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg16230307	chr14:35515116	FAM177A1	0.54	7.23	0.37	3.26e-12	Psoriasis;
LUSC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08109568	chr15:31115862	NA	-0.58	-8.17	-0.41	6.41e-15	Huntington's disease progression;
LUSC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.23	0.41	4.25e-15	Tonsillectomy;
LUSC	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg17127132	chr2:85788382	GGCX	0.43	6.07	0.32	3.46e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7586879	0.796	rs36071142	chr2:25080570	C/T	cg01884057	chr2:25150051	NA	0.38	7.92	0.4	3.57e-14	Body mass index;
LUSC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg07169764	chr2:136633963	MCM6	-0.58	-7.55	-0.38	4.27e-13	Mosquito bite size;
LUSC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg01420254	chr6:26195488	NA	-0.68	-7.28	-0.37	2.35e-12	Gout;Renal underexcretion gout;
LUSC	trans	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg18187862	chr3:45730750	SACM1L	0.53	6.9	0.35	2.6e-11	Primary sclerosing cholangitis;
LUSC	cis	rs870825	0.616	rs7659101	chr4:185632158	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	13.44	0.59	3.34e-33	Blood protein levels;
LUSC	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.54	0.34	2.28e-10	Testicular germ cell tumor;
LUSC	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg05973401	chr12:123451056	ABCB9	0.6	8.62	0.43	2.66e-16	Platelet count;
LUSC	cis	rs7973719	1.000	rs1839622	chr12:7334534	G/C	cg07052231	chr12:7363540	PEX5	0.51	8.79	0.43	8.07e-17	IgG glycosylation;
LUSC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg11062466	chr8:58055876	NA	0.73	8.62	0.43	2.79e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-6.01	-0.31	4.78e-9	Bipolar disorder;
LUSC	cis	rs28655083	1.000	rs11864710	chr16:77075284	A/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.39	-6.13	-0.32	2.43e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg05855489	chr10:104503620	C10orf26	-0.53	-8.02	-0.4	1.8e-14	Arsenic metabolism;
LUSC	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	8.79	0.43	8.07e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.89	-0.55	1.97e-27	Type 2 diabetes;
LUSC	cis	rs7428	1.000	rs72840063	chr2:85550396	T/A	cg24342717	chr2:85555507	TGOLN2	-0.61	-8.93	-0.44	2.98e-17	Ear protrusion;
LUSC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.71	12.66	0.57	2.84e-30	Prudent dietary pattern;
LUSC	cis	rs2742234	0.541	rs11238483	chr10:43728780	A/G	cg15436174	chr10:43711423	RASGEF1A	0.44	7.08	0.36	8.82e-12	Hirschsprung disease;
LUSC	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg22089800	chr15:90895588	ZNF774	-0.66	-10.06	-0.48	5.77e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18252515	chr7:66147081	NA	-0.58	-7.98	-0.4	2.31e-14	Corneal structure;
LUSC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.49	-0.73	4.84e-57	Height;
LUSC	cis	rs9815354	0.680	rs73075231	chr3:42051694	T/C	cg03022575	chr3:42003672	ULK4	0.78	7.85	0.39	5.64e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10746514	0.833	rs867844	chr1:232266278	A/T	cg09506761	chr1:232265262	NA	0.56	9.73	0.47	7.5599999999999994e-20	Response to statin therapy;
LUSC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg03806693	chr22:41940476	POLR3H	1.01	14.5	0.62	2.65e-37	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9815354	0.812	rs73071343	chr3:41826877	G/C	cg03022575	chr3:42003672	ULK4	0.85	8.62	0.43	2.78e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	0.92	13.3	0.59	1.06e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg06387496	chr7:2775674	GNA12	-0.36	-5.69	-0.3	2.83e-8	Height;
LUSC	cis	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-6.29	-0.33	9.92e-10	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LUSC	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg03522245	chr20:25566470	NINL	-0.35	-5.69	-0.3	2.85e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg27494647	chr7:150038898	RARRES2	0.51	7.86	0.4	5.3e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg22532475	chr10:104410764	TRIM8	0.24	5.7	0.3	2.59e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	trans	rs61931739	0.612	rs1906137	chr12:33939676	T/A	cg26384229	chr12:38710491	ALG10B	0.51	7.63	0.39	2.43e-13	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg23711669	chr6:146136114	FBXO30	0.89	16.33	0.67	1.72e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg14530993	chr4:882597	GAK	0.73	7.39	0.37	1.22e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.37	0.56	3.55e-29	Cognitive test performance;
LUSC	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg02023728	chr11:77925099	USP35	0.47	7.0	0.36	1.42e-11	Testicular germ cell tumor;
LUSC	cis	rs9653442	0.527	rs13003982	chr2:100759078	T/C	cg07810366	chr2:100720526	AFF3	-0.44	-7.56	-0.38	4.02e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg02380750	chr20:61661411	NA	0.34	5.93	0.31	7.57e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg00982548	chr2:198649783	BOLL	-0.59	-7.3	-0.37	2.19e-12	Ulcerative colitis;
LUSC	cis	rs4566357	0.615	rs2272204	chr2:227915601	G/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.11	-0.41	9.41e-15	Coronary artery disease;
LUSC	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg04539111	chr16:67997858	SLC12A4	-0.42	-5.86	-0.31	1.09e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg15848620	chr12:58087721	OS9	-0.53	-7.62	-0.39	2.58e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg05347473	chr6:146136440	FBXO30	0.55	9.73	0.47	7.59e-20	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4714291	0.925	rs847747	chr6:40080069	G/T	cg02267698	chr19:7991119	CTXN1	0.55	7.91	0.4	3.69e-14	Strep throat;
LUSC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.6	0.34	1.64e-10	Joint mobility (Beighton score);
LUSC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg13072238	chr3:49761600	GMPPB	-0.65	-8.46	-0.42	8.31e-16	Menarche (age at onset);
LUSC	cis	rs3737883	1.000	rs10753933	chr1:203026214	T/G	cg00805880	chr1:203045044	PPFIA4	-0.3	-5.99	-0.31	5.58e-9	Early onset atrial fibrillation;
LUSC	cis	rs4792901	0.659	rs8073121	chr17:41542922	A/C	cg22562494	chr17:41607896	ETV4	-0.33	-6.21	-0.32	1.56e-9	Dupuytren's disease;
LUSC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg21280719	chr6:42927975	GNMT	0.3	6.07	0.32	3.54e-9	Blood protein levels;
LUSC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg08888203	chr3:10149979	C3orf24	0.45	6.79	0.35	5.25e-11	Alzheimer's disease;
LUSC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.93	-0.4	3.26e-14	Chronic sinus infection;
LUSC	cis	rs6594499	0.872	rs10043631	chr5:110443228	C/T	cg04022379	chr5:110408740	TSLP	0.44	6.68	0.34	1.01e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs11039798	1.000	rs7479655	chr11:48576714	G/T	cg15704280	chr7:45808275	SEPT13	0.69	6.51	0.34	2.81e-10	Axial length;
LUSC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg21775007	chr8:11205619	TDH	-0.53	-7.96	-0.4	2.72e-14	Neuroticism;
LUSC	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg05855489	chr10:104503620	C10orf26	0.49	7.36	0.37	1.46e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	trans	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	7.0	0.36	1.37e-11	Endometrial cancer;
LUSC	cis	rs12681287	0.547	rs56752411	chr8:87515156	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.35	-0.37	1.52e-12	Caudate activity during reward;
LUSC	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg08847533	chr14:75593920	NEK9	-0.39	-5.68	-0.3	2.92e-8	Caffeine consumption;
LUSC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg08219700	chr8:58056026	NA	0.5	6.4	0.33	5.22e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs240768	1.000	rs77642814	chr6:101118450	C/T	cg12253828	chr6:101329408	ASCC3	0.86	5.95	0.31	6.94e-9	Economic and political preferences (immigration/crime);
LUSC	cis	rs1832871	0.672	rs9457362	chr6:158772052	C/T	cg07165851	chr6:158734300	TULP4	0.47	7.16	0.36	5.2e-12	Height;
LUSC	cis	rs9472414	0.510	rs227853	chr6:44699746	T/C	cg20913747	chr6:44695427	NA	0.37	5.82	0.3	1.42e-8	Height;
LUSC	cis	rs3862435	0.572	rs2601183	chr15:90925721	T/G	cg22089800	chr15:90895588	ZNF774	0.57	6.09	0.32	3.14e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg00310523	chr12:86230176	RASSF9	-0.43	-7.91	-0.4	3.85e-14	Major depressive disorder;
LUSC	cis	rs3820068	0.608	rs58140482	chr1:16043979	A/G	cg24675056	chr1:15929824	NA	0.41	6.84	0.35	3.9e-11	Systolic blood pressure;
LUSC	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg08975724	chr8:8085496	FLJ10661	0.53	7.68	0.39	1.81e-13	Mood instability;
LUSC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.75	-9.0	-0.44	1.8e-17	Refractive error;
LUSC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg13560548	chr3:10150139	C3orf24	0.55	7.42	0.38	9.5e-13	Alzheimer's disease;
LUSC	cis	rs7940866	0.903	rs1433980	chr11:130870956	A/G	cg12179176	chr11:130786555	SNX19	0.58	9.23	0.45	3.19e-18	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg24642844	chr7:1081250	C7orf50	-0.79	-10.46	-0.5	2.44e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg15423357	chr2:25149977	NA	0.48	9.53	0.46	3.25e-19	Body mass index in non-asthmatics;
LUSC	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg23752985	chr2:85803571	VAMP8	0.31	6.38	0.33	5.84e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg03146154	chr1:46216737	IPP	0.52	7.63	0.39	2.52e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.51	-0.34	2.75e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7215564	0.818	rs1531946	chr17:78630807	G/A	cg09596252	chr17:78655493	RPTOR	0.56	5.76	0.3	1.88e-8	Myopia (pathological);
LUSC	cis	rs12980942	0.872	rs7248164	chr19:41807700	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.6	6.56	0.34	2.08e-10	Coronary artery disease;
LUSC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.45	-0.42	9.42e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs10207060	0.500	rs72992168	chr2:240712932	G/A	cg07506560	chr2:240697449	NA	0.44	6.9	0.35	2.67e-11	Obesity-related traits;
LUSC	cis	rs617219	0.853	rs58150362	chr5:78519538	A/T	cg24856658	chr5:78533917	JMY	-0.3	-5.98	-0.31	5.84e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs9341808	0.538	rs7756067	chr6:81019794	C/T	cg08355045	chr6:80787529	NA	-0.4	-6.95	-0.36	1.93e-11	Sitting height ratio;
LUSC	cis	rs8179	0.645	rs11771637	chr7:92260161	G/A	cg15732164	chr7:92237376	CDK6	-0.43	-5.92	-0.31	8.06e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg06494592	chr3:125709126	NA	-0.5	-5.76	-0.3	1.87e-8	Blood pressure (smoking interaction);
LUSC	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-0.87	-15.13	-0.64	9.36e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	trans	rs9929218	0.911	rs4783685	chr16:68834107	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.12	-0.52	1.18e-24	Colorectal cancer;
LUSC	cis	rs36093844	0.800	rs78681528	chr11:85588156	T/G	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.19	-0.37	4.35e-12	Bipolar disorder;
LUSC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg16325326	chr1:53192061	ZYG11B	0.97	19.12	0.72	1.4e-55	Monocyte count;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg13942604	chr11:14542103	PSMA1	0.52	6.11	0.32	2.72e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg02023728	chr11:77925099	USP35	0.46	6.85	0.35	3.58e-11	Testicular germ cell tumor;
LUSC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.78	0.35	5.37e-11	Platelet count;
LUSC	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg25703541	chr22:24373054	LOC391322	-1.01	-19.76	-0.73	4.07e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4740619	0.590	rs4247294	chr9:16030960	C/T	cg14451791	chr9:16040625	NA	-0.31	-5.89	-0.31	9.28e-9	Body mass index;
LUSC	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg13073564	chr4:8508604	NA	0.34	6.23	0.32	1.44e-9	Response to antineoplastic agents;
LUSC	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.61	-10.03	-0.48	7e-21	Body mass index;
LUSC	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg00857998	chr1:205179979	DSTYK	0.52	7.83	0.39	6.48e-14	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg24631222	chr15:78858424	CHRNA5	-0.68	-9.07	-0.44	1.07e-17	Post bronchodilator FEV1;
LUSC	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg00083937	chr22:51039805	MAPK8IP2	-0.5	-8.27	-0.41	3.19e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg07507251	chr3:52567010	NT5DC2	0.29	5.66	0.3	3.28e-8	Bipolar disorder;
LUSC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg05313129	chr8:58192883	C8orf71	-0.53	-6.85	-0.35	3.6e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg17264618	chr3:40429014	ENTPD3	0.36	7.35	0.37	1.54e-12	Renal cell carcinoma;
LUSC	cis	rs9815354	0.767	rs73079325	chr3:41864565	G/A	cg03022575	chr3:42003672	ULK4	0.58	6.52	0.34	2.6e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.4	6.19	0.32	1.72e-9	Menopause (age at onset);
LUSC	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg09323728	chr8:95962352	TP53INP1	-0.38	-7.75	-0.39	1.14e-13	Type 2 diabetes;
LUSC	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg22782873	chr19:19639568	YJEFN3	-0.48	-6.11	-0.32	2.7e-9	Bipolar disorder;
LUSC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg18512352	chr11:47633146	NA	-0.47	-9.32	-0.45	1.62e-18	Subjective well-being;
LUSC	cis	rs6087990	0.568	rs853854	chr20:31420757	T/A	cg13636640	chr20:31349939	DNMT3B	0.86	16.69	0.67	6.46e-46	Ulcerative colitis;
LUSC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg25456477	chr12:86230367	RASSF9	-0.32	-5.69	-0.3	2.83e-8	Major depressive disorder;
LUSC	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.73	14.19	0.61	4.47e-36	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.07	0.48	5.08e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18404041	chr3:52824283	ITIH1	-0.47	-8.96	-0.44	2.33e-17	Bipolar disorder;
LUSC	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	9.5	0.46	4.33e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg04141948	chr7:1023156	CYP2W1	0.29	5.7	0.3	2.66e-8	Longevity;Endometriosis;
LUSC	cis	rs72627509	0.951	rs72627508	chr4:57831564	C/G	cg26694713	chr4:57773883	REST	0.48	5.67	0.3	3.08e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg08999081	chr20:33150536	PIGU	0.44	8.0	0.4	2.02e-14	Coronary artery disease;
LUSC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.79	13.53	0.59	1.51e-33	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.27	0.45	2.38e-18	Mean corpuscular volume;
LUSC	cis	rs710216	0.917	rs4660691	chr1:43417150	T/G	cg03128534	chr1:43423976	SLC2A1	-0.45	-5.92	-0.31	8.03e-9	Red cell distribution width;
LUSC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg12927641	chr6:109611667	NA	-0.43	-7.47	-0.38	7.04e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs977987	0.815	rs4887829	chr16:75488935	C/T	cg04384234	chr16:75411784	CFDP1	-0.45	-7.42	-0.38	9.51e-13	Dupuytren's disease;
LUSC	cis	rs4356932	0.967	rs13113455	chr4:76972447	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.86	0.31	1.11e-8	Blood protein levels;
LUSC	cis	rs6087990	0.735	rs6119946	chr20:31329704	A/G	cg13636640	chr20:31349939	DNMT3B	-0.95	-20.02	-0.74	3.75e-59	Ulcerative colitis;
LUSC	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg16339924	chr4:17578868	LAP3	-0.49	-7.47	-0.38	7.22e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.93	-0.35	2.23e-11	Lung cancer;
LUSC	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	12.47	0.56	1.46e-29	Primary sclerosing cholangitis;
LUSC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg25036284	chr2:26402008	FAM59B	-0.69	-9.7	-0.47	9.48e-20	Gut microbiome composition (summer);
LUSC	cis	rs2637266	0.626	rs846616	chr10:78547311	A/G	cg18941641	chr10:78392320	NA	0.39	7.18	0.37	4.46e-12	Pulmonary function;
LUSC	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.59	0.43	3.35e-16	Coffee consumption (cups per day);
LUSC	cis	rs11587400	0.593	rs2336365	chr1:115175415	G/T	cg12756093	chr1:115239321	AMPD1	-0.42	-6.4	-0.33	5.12e-10	Autism;
LUSC	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.59	-9.27	-0.45	2.29e-18	HDL cholesterol;
LUSC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg25456477	chr12:86230367	RASSF9	0.44	7.87	0.4	4.92e-14	Major depressive disorder;
LUSC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.44	6.65	0.34	1.2e-10	Menarche (age at onset);
LUSC	trans	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.09	0.45	8.94e-18	Mean corpuscular volume;
LUSC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg26695010	chr11:65641043	EFEMP2	-0.47	-6.93	-0.35	2.18e-11	Eosinophil percentage of white cells;
LUSC	cis	rs6546886	0.912	rs10191539	chr2:74269926	T/C	cg14702570	chr2:74259524	NA	-0.31	-5.79	-0.3	1.65e-8	Dialysis-related mortality;
LUSC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21171335	chr12:122356390	WDR66	-0.62	-9.68	-0.47	1.06e-19	Mean corpuscular volume;
LUSC	cis	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg21775007	chr8:11205619	TDH	-0.49	-7.47	-0.38	7.1e-13	Retinal vascular caliber;
LUSC	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.37	-6.24	-0.32	1.33e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg12002119	chr2:101014098	CHST10	0.34	5.7	0.3	2.63e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4964805	0.626	rs4964827	chr12:104177081	G/T	cg02344784	chr12:104178138	NT5DC3	0.41	6.6	0.34	1.62e-10	Attention deficit hyperactivity disorder;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg16103275	chr6:290800	DUSP22	0.41	6.87	0.35	3.12e-11	Menopause (age at onset);
LUSC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg23711669	chr6:146136114	FBXO30	0.9	16.67	0.67	7.62e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.45	6.25	0.32	1.22e-9	Multiple sclerosis;
LUSC	trans	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg13010199	chr12:38710504	ALG10B	-0.4	-6.01	-0.31	4.91e-9	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-9.6	-0.47	1.94e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg19116668	chr7:99932089	PMS2L1	-0.33	-5.66	-0.3	3.25e-8	Coronary artery disease;
LUSC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg25456477	chr12:86230367	RASSF9	0.44	7.87	0.4	4.91e-14	Major depressive disorder;
LUSC	cis	rs10779751	1.000	rs4845859	chr1:11304873	A/G	cg08854313	chr1:11322531	MTOR	0.87	14.95	0.63	4.62e-39	Body mass index;
LUSC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg09034736	chr1:150693464	HORMAD1	0.46	6.49	0.33	3.16e-10	Melanoma;
LUSC	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg08847533	chr14:75593920	NEK9	-0.55	-8.18	-0.41	6.01e-15	Neuroticism;
LUSC	trans	rs2926702	0.810	rs2958368	chr8:71167612	G/A	cg16517358	chr11:46164796	NA	-0.4	-6.01	-0.31	4.99e-9	Non-small cell lung cancer;
LUSC	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.65	-0.34	1.21e-10	Response to antipsychotic treatment;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04197313	chr15:67547198	IQCH;AAGAB	-0.38	-6.62	-0.34	1.43e-10	Electrocardiographic conduction measures;
LUSC	cis	rs11072804	1	rs11072804	chr15:79078486	T/G	cg00540400	chr15:79124168	NA	-0.4	-6.99	-0.36	1.46e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.65	0.43	2.18e-16	Prudent dietary pattern;
LUSC	trans	rs853679	0.713	rs200991	chr6:27815494	A/C	cg06606381	chr12:133084897	FBRSL1	0.53	6.05	0.31	3.94e-9	Depression;
LUSC	cis	rs12137294	0.761	rs1172150	chr1:205221861	A/G	cg21643547	chr1:205240462	TMCC2	-0.35	-6.4	-0.33	5.2e-10	Red cell distribution width;
LUSC	cis	rs9303542	0.559	rs12603976	chr17:46617163	C/A	cg09704116	chr17:46666958	LOC404266	-0.38	-6.69	-0.34	9.51e-11	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg00012203	chr2:219082015	ARPC2	0.69	11.37	0.53	1.56e-25	Colorectal cancer;
LUSC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg12463550	chr7:65579703	CRCP	0.42	5.79	0.3	1.58e-8	Aortic root size;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14751398	chr6:20402153	E2F3	0.45	6.29	0.33	9.91e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11955175	0.850	rs111959286	chr5:40704141	A/T	cg04002187	chr5:40835754	RPL37	0.68	5.78	0.3	1.69e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg11062466	chr8:58055876	NA	0.67	8.14	0.41	7.83e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.53	-8.53	-0.42	5.3e-16	Longevity;Endometriosis;
LUSC	trans	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg26043149	chr18:55253948	FECH	-0.45	-6.99	-0.36	1.47e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7215564	0.908	rs4243241	chr17:78660502	A/C	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg19901468	chr14:105411992	AHNAK2	0.73	12.97	0.58	1.91e-31	Rheumatoid arthritis;
LUSC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg03146154	chr1:46216737	IPP	-0.52	-7.39	-0.37	1.21e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.35	2.06e-11	Monocyte percentage of white cells;
LUSC	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.35	6.53	0.34	2.47e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg16989719	chr2:238392110	NA	-0.42	-7.45	-0.38	7.96e-13	Prostate cancer;
LUSC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.88e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12575480	0.709	rs7107076	chr11:2094303	C/T	cg15541987	chr11:2077307	NA	-0.45	-6.79	-0.35	5.05e-11	Pursuit maintenance gain;
LUSC	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg24579218	chr15:68104479	NA	-0.37	-6.34	-0.33	7.64e-10	Obesity;
LUSC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg27121462	chr16:89883253	FANCA	0.55	9.02	0.44	1.52e-17	Vitiligo;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22481535	chr5:14581529	FAM105A	-0.4	-6.1	-0.32	2.91e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.95	0.31	6.78e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg21724239	chr8:58056113	NA	0.59	6.82	0.35	4.19e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg12927641	chr6:109611667	NA	-0.43	-7.58	-0.38	3.41e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg16423285	chr20:60520624	NA	-0.47	-5.82	-0.3	1.38e-8	Body mass index;
LUSC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.31	-0.41	2.49e-15	Total body bone mineral density;
LUSC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg05347473	chr6:146136440	FBXO30	0.46	7.89	0.4	4.32e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg08132940	chr7:1081526	C7orf50	-0.52	-6.22	-0.32	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg06636551	chr8:101224915	SPAG1	-0.38	-7.13	-0.36	6.31e-12	Atrioventricular conduction;
LUSC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg03538708	chr1:25844672	NA	-0.37	-6.11	-0.32	2.71e-9	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.56	0.34	2.09e-10	Menopause (age at onset);
LUSC	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg03585969	chr10:35415529	CREM	0.6	8.96	0.44	2.37e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4654899	0.865	rs10916927	chr1:21385795	T/C	cg01072550	chr1:21505969	NA	-0.49	-7.11	-0.36	6.9e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.78	-0.3	1.7e-8	IgG glycosylation;
LUSC	cis	rs497273	0.534	rs13746	chr12:121201167	C/T	cg02419362	chr12:121203948	SPPL3	0.44	8.0	0.4	2.09e-14	Systemic lupus erythematosus;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.57	-9.6	-0.46	2.01e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.84	-0.47	3.09e-20	Gut microbiome composition (summer);
LUSC	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.09	15.62	0.65	1.13e-41	Uric acid levels;
LUSC	cis	rs7914558	0.646	rs1046778	chr10:104661484	T/C	cg05855489	chr10:104503620	C10orf26	0.42	5.76	0.3	1.92e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg13010344	chr12:123464640	ARL6IP4	0.45	6.83	0.35	3.99e-11	Neutrophil percentage of white cells;
LUSC	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg18825076	chr15:78729989	IREB2	0.51	8.14	0.41	8.11e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg04414720	chr1:150670196	GOLPH3L	-0.41	-6.26	-0.32	1.2e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg06740227	chr12:86229804	RASSF9	0.44	6.92	0.35	2.29e-11	Major depressive disorder;
LUSC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13732083	chr21:47605072	C21orf56	0.41	5.93	0.31	7.66e-9	Testicular germ cell tumor;
LUSC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.6	10.63	0.5	6.43e-23	Menopause (age at onset);
LUSC	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg23625390	chr15:77176239	SCAPER	-0.66	-10.06	-0.48	5.61e-21	Blood metabolite levels;
LUSC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg14019146	chr3:50243930	SLC38A3	0.32	6.91	0.35	2.49e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6500395	1.000	rs36077931	chr16:48594221	A/G	cg04672837	chr16:48644449	N4BP1	0.43	6.47	0.33	3.44e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-0.74	-12.0	-0.55	8.21e-28	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg16558253	chr16:72132732	DHX38	-0.43	-6.58	-0.34	1.86e-10	Fibrinogen levels;
LUSC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.57	-9.34	-0.45	1.44e-18	Height;
LUSC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	1.17	13.71	0.6	3.13e-34	Arsenic metabolism;
LUSC	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg05283184	chr6:79620031	NA	-0.58	-12.44	-0.56	1.93e-29	Intelligence (multi-trait analysis);
LUSC	trans	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg06521331	chr12:34319734	NA	-0.4	-6.03	-0.31	4.34e-9	Bladder cancer;
LUSC	trans	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs3764021	0.840	rs12304510	chr12:9885526	C/T	cg20894963	chr12:9885564	CLECL1	0.34	6.98	0.36	1.64e-11	Type 1 diabetes;
LUSC	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-5.9	-0.31	8.95e-9	Neuroticism;
LUSC	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg09699651	chr6:150184138	LRP11	0.38	5.95	0.31	6.81e-9	Testicular germ cell tumor;
LUSC	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-12.49	-0.56	1.23e-29	Total body bone mineral density;
LUSC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg09021430	chr5:549028	NA	-0.56	-7.58	-0.38	3.35e-13	Obesity-related traits;
LUSC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg24503407	chr1:205819492	PM20D1	0.52	7.58	0.38	3.41e-13	Prostate-specific antigen levels;
LUSC	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg12559939	chr2:27858050	GPN1	0.41	6.26	0.32	1.21e-9	Oral cavity cancer;
LUSC	trans	rs9951602	1.000	rs7232284	chr18:76667529	A/G	cg02800362	chr5:177631904	HNRNPAB	0.74	7.97	0.4	2.51e-14	Obesity-related traits;
LUSC	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.74	11.61	0.54	2.03e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg27535305	chr1:53392650	SCP2	-0.4	-7.43	-0.38	9.16e-13	Monocyte count;
LUSC	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg23029597	chr12:123009494	RSRC2	0.6	8.61	0.43	2.93e-16	Body mass index;
LUSC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17261708	chr5:176794207	RGS14	0.34	6.0	0.31	5.11e-9	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs4950928	0.823	rs7541061	chr1:203163367	G/T	cg17014757	chr1:203156097	CHI3L1	0.42	7.38	0.37	1.28e-12	YKL-40 levels;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.55	8.64	0.43	2.38e-16	Longevity;Endometriosis;
LUSC	trans	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg21659725	chr3:3221576	CRBN	-0.48	-7.29	-0.37	2.29e-12	Menarche (age at onset);
LUSC	trans	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg07923666	chr12:49932857	KCNH3	-0.52	-6.46	-0.33	3.8e-10	Resting heart rate;
LUSC	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg04352962	chr1:209979756	IRF6	0.53	6.16	0.32	2.08e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs965469	1.000	rs6051792	chr20:3343519	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-5.68	-0.3	2.87e-8	IFN-related cytopenia;
LUSC	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg27446573	chr6:127587934	RNF146	0.62	9.83	0.47	3.32e-20	Breast cancer;
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg27094323	chr7:1216898	NA	-0.46	-8.14	-0.41	8.08e-15	Longevity;Endometriosis;
LUSC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg24209194	chr3:40518798	ZNF619	0.45	6.1	0.32	2.87e-9	Renal cell carcinoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24185116	chr15:52044314	LYSMD2;TMOD2	0.4	6.16	0.32	2.12e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26421286	chr17:16439070	NA	0.73	6.26	0.32	1.19e-9	Cognitive performance;
LUSC	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg23752985	chr2:85803571	VAMP8	0.34	6.5	0.34	2.86e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6901250	0.851	rs7760125	chr6:117123391	A/C	cg12892004	chr6:117198278	RFX6	0.43	8.12	0.41	9.06e-15	C-reactive protein levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14777817	chr13:80055594	NDFIP2	-0.47	-6.16	-0.32	2.06e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.8	0.51	1.65e-23	Colorectal cancer;
LUSC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-9.32	-0.45	1.67e-18	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.13	0.36	6.07e-12	Bipolar disorder;
LUSC	cis	rs4363385	0.818	rs4845335	chr1:152993955	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.7	-0.3	2.66e-8	Inflammatory skin disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg20314438	chr6:126661369	C6orf173	0.45	7.0	0.36	1.43e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg12442385	chr7:1034912	NA	-0.34	-5.68	-0.3	2.88e-8	Longevity;Endometriosis;
LUSC	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg06064525	chr11:970664	AP2A2	0.28	5.69	0.3	2.83e-8	Alzheimer's disease (late onset);
LUSC	cis	rs1160297	0.609	rs7577692	chr2:53105969	T/C	cg07782112	chr2:53107842	NA	0.42	6.79	0.35	5.01e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.5	-0.38	5.86e-13	Bipolar disorder;
LUSC	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	1.18	13.88	0.6	7.01e-35	Arsenic metabolism;
LUSC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs244293	0.695	rs9303360	chr17:53001456	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-6.1	-0.32	2.88e-9	Menarche (age at onset);
LUSC	trans	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-8.66	-0.43	2e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg14004847	chr7:1930337	MAD1L1	-0.57	-8.8	-0.43	7.73e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg11342453	chr6:26196699	NA	0.59	6.12	0.32	2.6e-9	Gout;Renal underexcretion gout;
LUSC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1185460	0.934	rs10892328	chr11:118942654	T/A	cg01677386	chr11:118938358	VPS11	-0.48	-6.42	-0.33	4.75e-10	Coronary artery disease;
LUSC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg20712883	chr12:51590929	POU6F1	0.46	6.6	0.34	1.65e-10	Cisplatin-induced ototoxicity;
LUSC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg13628971	chr7:2884303	GNA12	0.5	7.15	0.36	5.48e-12	Height;
LUSC	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.74	-0.39	1.19e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4919087	1.000	rs7067835	chr10:99074649	T/C	cg25902810	chr10:99078978	FRAT1	0.47	6.91	0.35	2.47e-11	Monocyte count;
LUSC	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg18478394	chr8:109455254	TTC35	0.43	6.79	0.35	5.05e-11	Dupuytren's disease;
LUSC	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg19418458	chr7:158789849	NA	0.51	6.75	0.35	6.5500000000000006e-11	Facial morphology (factor 20);
LUSC	cis	rs1163251	0.869	rs629735	chr1:120206932	G/T	cg19096424	chr1:120255104	PHGDH	-0.49	-6.83	-0.35	4.15e-11	Blood metabolite levels;
LUSC	cis	rs59698941	0.943	rs56927472	chr5:132226038	T/A	cg02081065	chr5:132209139	LEAP2	-0.65	-6.75	-0.35	6.45e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs7202877	0.611	rs7187263	chr16:75308978	C/A	cg03315344	chr16:75512273	CHST6	0.43	6.2	0.32	1.71e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg17294928	chr15:75287854	SCAMP5	-0.94	-13.55	-0.6	1.27e-33	Blood trace element (Zn levels);
LUSC	cis	rs4363385	0.818	rs472076	chr1:153013742	G/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.15	-0.36	5.38e-12	Inflammatory skin disease;
LUSC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.27	0.41	3.24e-15	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs6601327	0.641	rs12155819	chr8:9572679	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.29	-0.33	1e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg22705602	chr4:152727874	NA	-0.39	-8.43	-0.42	1.05e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs427941	0.667	rs34247954	chr7:101740993	C/T	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg24375607	chr4:120327624	NA	0.63	9.81	0.47	3.88e-20	Corneal astigmatism;
LUSC	cis	rs7712401	0.584	rs30037	chr5:122277990	T/C	cg19077854	chr5:122220652	SNX24	0.41	9.16	0.45	5.23e-18	Mean platelet volume;
LUSC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg13939156	chr17:80058883	NA	-0.33	-6.65	-0.34	1.22e-10	Life satisfaction;
LUSC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg11062466	chr8:58055876	NA	0.49	6.3	0.33	9.37e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg24687543	chr11:63912206	MACROD1	0.46	5.93	0.31	7.47e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.24	-11.41	-0.53	1.14e-25	Reticulocyte fraction of red cells;Reticulocyte count;
LUSC	trans	rs853679	0.599	rs156743	chr6:27967089	T/C	cg06606381	chr12:133084897	FBRSL1	-0.65	-6.88	-0.35	3.02e-11	Depression;
LUSC	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg08085267	chr17:45401833	C17orf57	0.47	7.41	0.38	1.04e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2219968	0.884	rs9643433	chr8:78952371	T/A	cg00738934	chr8:78996279	NA	0.37	6.64	0.34	1.28e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7608623	0.773	rs11683876	chr2:23921170	G/A	cg08917208	chr2:24149416	ATAD2B	-0.42	-5.74	-0.3	2.12e-8	Obesity-related traits;
LUSC	trans	rs800082	0.501	rs9873732	chr3:144191665	C/T	cg24215973	chr2:240111563	HDAC4	0.51	7.78	0.39	9.25e-14	Smoking behavior;
LUSC	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg10483660	chr13:112241077	NA	0.38	6.92	0.35	2.36e-11	Menarche (age at onset);
LUSC	cis	rs11605924	0.935	rs6485645	chr11:45862353	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.5	-7.33	-0.37	1.75e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	7.11	0.36	7.24e-12	Resting heart rate;
LUSC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg06558623	chr16:89946397	TCF25	0.96	10.22	0.49	1.66e-21	Skin colour saturation;
LUSC	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg18964960	chr10:1102726	WDR37	-0.44	-5.87	-0.31	1.05e-8	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs4363385	0.510	rs11205187	chr1:153053323	T/C	cg00922841	chr1:152955080	SPRR1A	-0.4	-6.63	-0.34	1.33e-10	Inflammatory skin disease;
LUSC	cis	rs611744	0.563	rs7815105	chr8:109298794	C/T	cg21045802	chr8:109455806	TTC35	0.46	6.71	0.34	8.21e-11	Dupuytren's disease;
LUSC	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.83	-15.64	-0.65	9.29e-42	Heart rate;
LUSC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3857536	0.813	rs2040591	chr6:66945915	A/G	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg10523679	chr1:76189770	ACADM	-0.44	-6.31	-0.33	8.67e-10	Daytime sleep phenotypes;
LUSC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.58	-8.86	-0.44	4.84e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.82	13.74	0.6	2.25e-34	Aortic root size;
LUSC	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.02e-14	Corneal astigmatism;
LUSC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg21017887	chr14:105400489	NA	0.7	13.23	0.59	1.99e-32	Rheumatoid arthritis;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10694539	chr12:42538536	GXYLT1	-0.44	-6.44	-0.33	4.2e-10	Electrocardiographic conduction measures;
LUSC	cis	rs76935404	0.811	rs4609955	chr19:41433613	T/C	cg04176888	chr19:41596066	CYP2A13	0.36	5.74	0.3	2.13e-8	nicotine metabolite ratio in current smokers;
LUSC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9925964	0.935	rs12597511	chr16:31145219	C/T	cg02466173	chr16:30829666	NA	0.33	6.13	0.32	2.52e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	12.77	0.57	1.12e-30	Chronic sinus infection;
LUSC	cis	rs977987	0.806	rs8056236	chr16:75448273	C/T	cg04384234	chr16:75411784	CFDP1	-0.41	-6.62	-0.34	1.4e-10	Dupuytren's disease;
LUSC	cis	rs7572644	0.739	rs10204488	chr2:28132250	G/A	cg27432699	chr2:27873401	GPN1	-0.53	-6.89	-0.35	2.87e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg20406979	chr6:167373233	NA	-0.26	-6.0	-0.31	5.13e-9	Crohn's disease;
LUSC	cis	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg26958806	chr6:27640298	NA	0.75	6.01	0.31	4.76e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg21724239	chr8:58056113	NA	0.81	9.65	0.47	1.4e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg24550644	chr17:30846204	MYO1D	-0.36	-5.71	-0.3	2.47e-8	Schizophrenia;
LUSC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg23711669	chr6:146136114	FBXO30	-0.77	-12.41	-0.56	2.45e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg12639453	chr1:2035780	PRKCZ	-0.32	-6.58	-0.34	1.84e-10	Height;
LUSC	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg05791153	chr7:19748676	TWISTNB	0.91	8.99	0.44	1.91e-17	Thyroid stimulating hormone;
LUSC	cis	rs4851254	0.618	rs13033732	chr2:100644797	A/G	cg07810366	chr2:100720526	AFF3	-0.46	-5.95	-0.31	6.76e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs500891	0.525	rs1144179	chr6:84026572	C/G	cg08257003	chr6:84140564	ME1	0.35	8.25	0.41	3.68e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg26395211	chr5:140044315	WDR55	-0.39	-5.95	-0.31	6.75e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	1.09	23.59	0.79	4.2e-73	Triglycerides;
LUSC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg19257562	chr1:2043853	PRKCZ	0.33	6.74	0.35	7.03e-11	Height;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07537819	chr6:156886127	NA	-0.36	-6.09	-0.32	3.14e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg03354898	chr7:1950403	MAD1L1	-0.36	-6.93	-0.35	2.15e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg04369109	chr6:150039330	LATS1	-0.58	-8.56	-0.42	4.25e-16	Lung cancer;
LUSC	cis	rs7106204	0.590	rs28864378	chr11:24206582	C/A	ch.11.24196551F	chr11:24239977	NA	1.09	12.65	0.57	3.2e-30	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg19622623	chr12:86230825	RASSF9	0.43	6.3	0.33	9.65e-10	Major depressive disorder;
LUSC	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.01e-14	Retinal vascular caliber;
LUSC	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg03060546	chr3:49711283	APEH	-0.52	-7.57	-0.38	3.66e-13	Resting heart rate;
LUSC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.71	-0.34	8.14e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	11.0	0.52	3.18e-24	Hypertriglyceridemia;
LUSC	cis	rs790123	0.842	rs2650958	chr3:122396187	A/T	cg17380795	chr3:122379686	NA	0.36	5.79	0.3	1.66e-8	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs7113850	0.541	rs76166238	chr11:24235418	G/A	ch.11.24196551F	chr11:24239977	NA	1.0	9.09	0.45	9.2e-18	Bone fracture in osteoporosis;
LUSC	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg05985134	chr18:33552581	C18orf21	0.52	7.27	0.37	2.62e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.18	-0.32	1.84e-9	Breast cancer;
LUSC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg23188684	chr11:67383651	NA	0.41	7.32	0.37	1.85e-12	Mean corpuscular volume;
LUSC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	0.96	17.39	0.69	1.06e-48	Cognitive function;
LUSC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg02423579	chr7:2872169	GNA12	-0.42	-6.21	-0.32	1.6e-9	Height;
LUSC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.78	0.57	9.82e-31	Motion sickness;
LUSC	cis	rs67539049	1.000	rs73546310	chr8:11302501	A/G	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.39	-5.97	-0.31	6.07e-9	Itch intensity from mosquito bite;
LUSC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg19318889	chr4:1322082	MAEA	0.47	7.67	0.39	1.93e-13	Obesity-related traits;
LUSC	cis	rs6681460	1.000	rs2147777	chr1:67129254	A/T	cg02459107	chr1:67143332	SGIP1	0.48	9.04	0.44	1.34e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	0.87	14.72	0.63	3.76e-38	Tonsillectomy;
LUSC	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.95	0.36	1.93e-11	Rheumatoid arthritis;
LUSC	cis	rs8038465	1.000	rs8038465	chr15:73978337	A/G	cg15420318	chr15:73925796	NPTN	-0.4	-6.44	-0.33	4.24e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs977987	0.800	rs4888378	chr16:75332041	A/G	cg04384234	chr16:75411784	CFDP1	-0.37	-5.94	-0.31	7.31e-9	Dupuytren's disease;
LUSC	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.08	0.52	1.68e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg15147215	chr3:52552868	STAB1	-0.3	-5.68	-0.3	2.96e-8	Bipolar disorder;
LUSC	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.46	-0.5	2.51e-22	Eye color traits;
LUSC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16386425	chr10:429943	DIP2C	-0.44	-7.03	-0.36	1.14e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg16325326	chr1:53192061	ZYG11B	0.78	12.57	0.57	6.05e-30	Monocyte count;
LUSC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg26690034	chr1:75198963	CRYZ;TYW3	0.38	5.72	0.3	2.33e-8	Resistin levels;
LUSC	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg16342193	chr10:102329863	NA	-0.35	-5.97	-0.31	5.98e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-12.96	-0.58	2.14e-31	Chronic sinus infection;
LUSC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.79	-10.62	-0.5	6.95e-23	Refractive error;
LUSC	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg05347473	chr6:146136440	FBXO30	0.47	7.75	0.39	1.1e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-10.0	-0.48	9.04e-21	Migraine;Coronary artery disease;
LUSC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg05082376	chr22:42548792	NA	0.39	5.83	0.3	1.29e-8	Schizophrenia;
LUSC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.45	7.45	0.38	8.21e-13	Pulse pressure;
LUSC	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.78	-13.13	-0.58	4.78e-32	Schizophrenia;
LUSC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg13939156	chr17:80058883	NA	-0.33	-6.52	-0.34	2.63e-10	Life satisfaction;
LUSC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.71	0.54	8.73e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg05729581	chr11:3078854	CARS	0.4	5.99	0.31	5.55e-9	Calcium levels;
LUSC	cis	rs6845621	0.745	rs1517996	chr4:18863232	G/T	cg12196642	chr4:18937545	NA	-0.31	-5.82	-0.3	1.39e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg22029157	chr1:209979665	IRF6	-0.72	-8.69	-0.43	1.62e-16	Coronary artery disease;
LUSC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg09904177	chr6:26538194	HMGN4	-0.48	-5.94	-0.31	7.23e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg15242686	chr22:24348715	GSTTP1	0.42	6.21	0.32	1.53e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14229702	chr15:89164377	AEN	0.42	6.19	0.32	1.73e-9	Triglycerides;
LUSC	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg20608306	chr11:116969690	SIK3	0.39	7.29	0.37	2.27e-12	Blood protein levels;
LUSC	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.51	-10.33	-0.49	7e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs3755132	0.929	rs6734471	chr2:15765425	C/T	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg27284194	chr4:1044797	NA	0.35	5.83	0.3	1.32e-8	Obesity-related traits;
LUSC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg16339924	chr4:17578868	LAP3	0.54	8.09	0.4	1.14e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg24296786	chr1:45957014	TESK2	-0.41	-5.83	-0.3	1.29e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg03351412	chr1:154909251	PMVK	0.54	8.6	0.43	3.1e-16	Prostate cancer;
LUSC	cis	rs796825	0.530	rs4146299	chr3:119999820	A/G	cg21790991	chr3:120137480	FSTL1	0.32	6.01	0.31	4.77e-9	HIV-1 susceptibility;
LUSC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg15556689	chr8:8085844	FLJ10661	0.69	11.67	0.54	1.29e-26	Mood instability;
LUSC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg00522288	chr12:125625016	AACS	-0.31	-6.02	-0.31	4.57e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg05368731	chr17:41323189	NBR1	0.92	15.78	0.65	2.7e-42	Menopause (age at onset);
LUSC	cis	rs9905704	0.681	rs2531730	chr17:56545069	T/G	cg19466818	chr17:56409534	MIR142	0.35	6.52	0.34	2.53e-10	Testicular germ cell tumor;
LUSC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg25258033	chr6:167368657	RNASET2	0.38	5.82	0.3	1.38e-8	Primary biliary cholangitis;
LUSC	cis	rs899997	0.906	rs1994018	chr15:79025584	G/A	cg04896959	chr15:78267971	NA	-0.53	-9.98	-0.48	1.05e-20	Coronary artery disease or large artery stroke;
LUSC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.77	-13.54	-0.6	1.34e-33	Cognitive function;
LUSC	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg27102117	chr16:15229624	NA	0.41	7.05	0.36	1.03e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.42	-5.79	-0.3	1.59e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg21782813	chr7:2030301	MAD1L1	0.49	8.35	0.42	1.8e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg27411982	chr8:10470053	RP1L1	-0.43	-6.61	-0.34	1.51e-10	Monocyte count;
LUSC	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg13010199	chr12:38710504	ALG10B	0.68	10.59	0.5	8.44e-23	Bladder cancer;
LUSC	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg00310523	chr12:86230176	RASSF9	-0.36	-6.48	-0.33	3.27e-10	Major depressive disorder;
LUSC	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg11693508	chr17:37793320	STARD3	0.59	7.39	0.37	1.21e-12	Bipolar disorder;
LUSC	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.92	0.35	2.31e-11	IgG glycosylation;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg08589821	chr5:55033950	DDX4	-0.42	-6.12	-0.32	2.67e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs9650657	0.740	rs6980805	chr8:10679842	G/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.26	-0.32	1.16e-9	Neuroticism;
LUSC	trans	rs877282	0.583	rs7072970	chr10:822757	G/A	cg22713356	chr15:30763199	NA	0.79	10.15	0.49	2.85e-21	Uric acid levels;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg10089324	chr1:51984752	EPS15	0.49	6.28	0.32	1.04e-9	Cognitive function;Information processing speed;
LUSC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg17747265	chr1:1875780	NA	-0.74	-17.19	-0.69	7.15e-48	Body mass index;
LUSC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.56	-0.34	2.03e-10	Menarche (age at onset);
LUSC	cis	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg06521331	chr12:34319734	NA	-0.47	-7.7	-0.39	1.55e-13	Morning vs. evening chronotype;
LUSC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.81	-0.35	4.66e-11	Obesity-related traits;
LUSC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.74	-0.39	1.17e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg03188948	chr7:1209495	NA	0.68	7.14	0.36	5.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs988712	0.550	rs988748	chr11:27724745	C/G	cg10635145	chr11:27742435	BDNF	0.49	6.55	0.34	2.15e-10	Obesity;
LUSC	cis	rs7759001	0.857	rs2393932	chr6:27353197	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	1.97e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs11166629	1.000	rs7818331	chr8:135639653	C/T	cg21672855	chr8:135614777	ZFAT	0.36	5.78	0.3	1.68e-8	Smoking quantity;
LUSC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.1	0.58	6.37e-32	Total body bone mineral density;
LUSC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg02228675	chr17:40259724	DHX58	0.49	6.65	0.34	1.17e-10	Fibrinogen levels;
LUSC	trans	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	cis	rs9815354	0.812	rs7639859	chr3:42001987	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.42	5.02e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.79	0.35	5.02e-11	Tonsillectomy;
LUSC	cis	rs10992471	0.603	rs10992342	chr9:95212068	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.77	-0.39	9.99e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10740039	0.883	rs7918897	chr10:62403512	T/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.92	-0.35	2.38e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg01294253	chr9:136912663	BRD3	0.35	6.09	0.32	3.1e-9	Platelet distribution width;
LUSC	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg02696742	chr7:106810147	HBP1	-0.63	-9.42	-0.46	7.8e-19	Coronary artery disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25439973	chr20:1206758	RAD21L1	0.69	6.23	0.32	1.43e-9	Cognitive performance;
LUSC	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	ch.11.42038R	chr11:967971	AP2A2	0.53	7.76	0.39	1.05e-13	Alzheimer's disease (late onset);
LUSC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.12	0.41	9.02e-15	Prudent dietary pattern;
LUSC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18404041	chr3:52824283	ITIH1	-0.61	-11.94	-0.55	1.36e-27	Bipolar disorder;
LUSC	cis	rs472402	0.580	rs3822430	chr5:6651970	A/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.54	-7.77	-0.39	1.01e-13	Response to amphetamines;
LUSC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg05973401	chr12:123451056	ABCB9	0.55	6.81	0.35	4.68e-11	Neutrophil percentage of white cells;
LUSC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg10802521	chr3:52805072	NEK4	-0.41	-6.37	-0.33	6.31e-10	Electroencephalogram traits;
LUSC	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg05340658	chr4:99064831	C4orf37	-0.44	-6.95	-0.36	1.94e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs240764	0.746	rs239197	chr6:101133600	T/C	cg09795085	chr6:101329169	ASCC3	0.42	6.21	0.32	1.56e-9	Neuroticism;
LUSC	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg22437258	chr11:111473054	SIK2	-0.48	-6.23	-0.32	1.41e-9	Primary sclerosing cholangitis;
LUSC	cis	rs977987	0.806	rs11149832	chr16:75462713	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.39e-11	Dupuytren's disease;
LUSC	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg27471124	chr11:109292789	C11orf87	0.38	6.94	0.35	2.08e-11	Schizophrenia;
LUSC	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg09754948	chr16:28834200	ATXN2L	0.44	6.43	0.33	4.51e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg13010199	chr12:38710504	ALG10B	0.49	7.5	0.38	5.96e-13	Morning vs. evening chronotype;
LUSC	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	11.53	0.53	4.02e-26	Blood protein levels;
LUSC	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg10523860	chr14:103875565	MARK3	-0.37	-5.82	-0.3	1.37e-8	Body mass index;
LUSC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08677398	chr8:58056175	NA	0.5	5.85	0.3	1.17e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg08847533	chr14:75593920	NEK9	0.85	15.73	0.65	4.01e-42	Height;
LUSC	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg12165864	chr7:66369176	NA	-0.52	-6.93	-0.35	2.19e-11	Corneal structure;
LUSC	cis	rs5009270	0.553	rs6947690	chr7:112233386	C/G	cg27282281	chr7:112262583	NA	0.43	5.72	0.3	2.32e-8	Osteoarthritis (hip);
LUSC	cis	rs12956009	0.583	rs1115360	chr18:44894550	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.14	0.32	2.36e-9	Educational attainment (years of education);
LUSC	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg04362960	chr10:104952993	NT5C2	0.61	9.5	0.46	4.08e-19	Arsenic metabolism;
LUSC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg03676636	chr4:99064102	C4orf37	0.33	7.28	0.37	2.38e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs427941	0.668	rs201459	chr7:101741502	G/A	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg12432903	chr7:1882776	MAD1L1	0.54	6.77	0.35	5.81e-11	Bipolar disorder;
LUSC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg03609598	chr5:56110824	MAP3K1	0.41	5.93	0.31	7.7e-9	Initial pursuit acceleration;
LUSC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg02079420	chr8:82753780	SNX16	0.43	7.37	0.37	1.39e-12	Diastolic blood pressure;
LUSC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.89	0.31	9.52e-9	Menopause (age at onset);
LUSC	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg18755752	chr8:142205143	DENND3	-0.72	-12.95	-0.58	2.4e-31	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	trans	rs236907	0.859	rs35631282	chr1:171760682	C/T	cg13482142	chr2:234261155	NA	0.52	6.19	0.32	1.81e-9	Mean platelet volume;
LUSC	cis	rs12220238	1.000	rs10824125	chr10:75997498	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.09	0.36	8.18e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg15571903	chr15:79123663	NA	-0.36	-6.58	-0.34	1.8e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4791641	1.000	rs4791641	chr17:8161149	C/T	cg06726167	chr17:8076949	TMEM107	0.39	6.21	0.32	1.54e-9	LDL cholesterol levels;Hematocrit;Hemoglobin concentration;Red blood cell count;LDL cholesterol;
LUSC	cis	rs12422267	0.536	rs7976530	chr12:132609140	C/T	cg09764611	chr12:132620959	NA	-0.58	-8.73	-0.43	1.24e-16	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.84	0.44	5.5e-17	Heart rate;
LUSC	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg15704280	chr7:45808275	SEPT13	0.72	8.18	0.41	5.93e-15	Axial length;
LUSC	cis	rs16958440	0.581	rs11875768	chr18:44689360	T/G	cg17192377	chr18:44677553	HDHD2	0.52	6.12	0.32	2.6e-9	Sitting height ratio;
LUSC	cis	rs11779988	0.503	rs411173	chr8:17768264	G/A	cg01800426	chr8:17659068	MTUS1	-0.45	-5.83	-0.3	1.3e-8	Breast cancer;
LUSC	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg20701182	chr2:24300061	SF3B14	0.56	6.05	0.31	3.84e-9	Lymphocyte counts;
LUSC	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg09479241	chr17:27052676	TLCD1	0.43	5.93	0.31	7.51e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg24813613	chr7:1882135	MAD1L1	-0.37	-6.13	-0.32	2.46e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg19875535	chr5:140030758	IK	0.49	8.14	0.41	7.85e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.87	-14.41	-0.62	5.82e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg22980127	chr19:33182716	NUDT19	0.94	12.81	0.57	8.02e-31	Red blood cell traits;
LUSC	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg26597838	chr10:835615	NA	0.44	6.18	0.32	1.91e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg09307838	chr4:120376055	NA	0.53	8.0	0.4	2.13e-14	Diastolic blood pressure;
LUSC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg02931644	chr1:25747376	RHCE	0.32	5.79	0.3	1.59e-8	Erythrocyte sedimentation rate;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg10253022	chr22:19929467	TXNRD2;COMT	0.37	6.01	0.31	4.73e-9	Mosquito bite size;
LUSC	cis	rs9296092	0.538	rs9461875	chr6:33516644	C/T	cg13560919	chr6:33536144	NA	-0.82	-15.45	-0.65	5.48e-41	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs1032466	0.783	rs6572681	chr14:51117059	C/T	cg26011998	chr14:51135199	SAV1	0.45	5.86	0.31	1.14e-8	Dupuytren's disease;
LUSC	cis	rs11039100	0.850	rs34818213	chr11:5834591	C/T	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs243505	0.691	rs243484	chr7:148448655	G/T	cg09806900	chr7:148480153	CUL1	-0.53	-7.04	-0.36	1.11e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg13902645	chr11:5959945	NA	-0.62	-8.52	-0.42	5.7e-16	DNA methylation (variation);
LUSC	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg04102894	chr7:1000210	NA	-0.27	-6.61	-0.34	1.53e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs4664308	0.875	rs60908067	chr2:161004983	T/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-11.58	-0.54	2.78e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs11051970	0.679	rs2931554	chr12:32556162	G/A	cg24626660	chr12:32551988	NA	0.31	5.73	0.3	2.28e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7809950	0.861	rs10264412	chr7:107183877	G/A	cg23024343	chr7:107201750	COG5	-0.7	-10.17	-0.49	2.38e-21	Coronary artery disease;
LUSC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg23815491	chr16:72088622	HP	0.35	6.09	0.32	3.11e-9	Fibrinogen levels;
LUSC	trans	rs7980799	0.653	rs10844613	chr12:33605362	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-8.27	-0.41	3.15e-15	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs1957429	0.520	rs72625643	chr14:65340964	C/G	cg23373153	chr14:65346875	NA	-0.89	-7.7	-0.39	1.53e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg19230755	chr7:65878503	NA	0.43	6.04	0.31	4.17e-9	Aortic root size;
LUSC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg24250549	chr1:154909240	PMVK	0.66	11.05	0.52	2.07e-24	Prostate cancer;
LUSC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.81	-13.46	-0.59	2.79e-33	Bladder cancer;
LUSC	cis	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg06521331	chr12:34319734	NA	-0.41	-6.33	-0.33	7.7e-10	Morning vs. evening chronotype;
LUSC	cis	rs806215	0.950	rs989099	chr7:127220827	A/G	cg25922125	chr7:127225783	GCC1	-0.6	-7.57	-0.38	3.63e-13	Type 2 diabetes;
LUSC	cis	rs711244	0.532	rs2540998	chr2:37255015	C/T	cg14987922	chr2:37194071	STRN	0.42	5.8	0.3	1.55e-8	Mean platelet volume;
LUSC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg04362960	chr10:104952993	NT5C2	-0.51	-5.96	-0.31	6.46e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg04310649	chr10:35416472	CREM	-0.43	-6.62	-0.34	1.45e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs427941	0.562	rs6950791	chr7:101780458	C/T	cg06246474	chr7:101738831	CUX1	0.38	6.11	0.32	2.76e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg11584989	chr19:19387371	SF4	0.67	7.99	0.4	2.27e-14	Bipolar disorder;
LUSC	trans	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg06437703	chr8:37914619	EIF4EBP1	0.52	6.49	0.33	3.02e-10	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs68170813	0.652	rs75136686	chr7:107180949	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.45	-5.65	-0.3	3.52e-8	Coronary artery disease;
LUSC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg08088566	chr11:430123	ANO9	0.63	6.97	0.36	1.68e-11	Body mass index;
LUSC	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg21545522	chr1:205238299	TMCC2	0.42	7.99	0.4	2.15e-14	Red blood cell count;
LUSC	trans	rs3960554	0.529	rs1859795	chr7:75877354	A/G	cg19862616	chr7:65841803	NCRNA00174	0.64	7.88	0.4	4.66e-14	Eotaxin levels;
LUSC	cis	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg02508848	chr16:68573721	ZFP90	-0.43	-5.82	-0.3	1.42e-8	Ulcerative colitis;
LUSC	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21659725	chr3:3221576	CRBN	0.59	8.43	0.42	1.01e-15	Resting heart rate;
LUSC	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.58	-0.34	1.78e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	1.05	22.88	0.78	2.2e-70	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-10.45	-0.5	2.61e-22	Mood instability;
LUSC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg22681709	chr2:178499509	PDE11A	-0.59	-11.79	-0.54	4.53e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4865169	1.000	rs4865169	chr4:57879792	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.38	-5.73	-0.3	2.24e-8	Breast cancer;
LUSC	cis	rs16854884	0.586	rs11914731	chr3:143725594	A/G	cg06585982	chr3:143692056	C3orf58	0.53	8.45	0.42	9.21e-16	Economic and political preferences (feminism/equality);
LUSC	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg21132104	chr15:45694354	SPATA5L1	0.42	6.1	0.32	2.89e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg21770322	chr7:97807741	LMTK2	0.4	7.07	0.36	9.16e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2281558	0.876	rs6115135	chr20:25279878	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.63	9.57	0.46	2.5e-19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	0.92	19.37	0.73	1.41e-56	Dental caries;
LUSC	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg17633681	chr16:88106987	BANP	-0.51	-9.87	-0.48	2.56e-20	Menopause (age at onset);
LUSC	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.24	0.45	3.03e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.05e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg07772605	chr3:195384752	SDHAP2	0.44	6.18	0.32	1.87e-9	Eotaxin levels;
LUSC	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	9.18	0.45	4.53e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10189230	0.967	rs1864460	chr2:222347655	A/C	cg14652038	chr2:222343519	EPHA4	0.36	6.38	0.33	5.83e-10	Urate levels in lean individuals;
LUSC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg12615879	chr12:58013172	SLC26A10	-0.27	-5.82	-0.3	1.34e-8	Multiple sclerosis;
LUSC	cis	rs6426558	0.502	rs10916080	chr1:227232040	A/G	cg10327440	chr1:227177885	CDC42BPA	0.56	7.51	0.38	5.49e-13	Neutrophil percentage of white cells;
LUSC	trans	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.55	-7.35	-0.37	1.58e-12	Ulcerative colitis;
LUSC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg27124370	chr19:33622961	WDR88	0.58	7.63	0.39	2.56e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg13010199	chr12:38710504	ALG10B	0.69	11.49	0.53	5.88e-26	Heart rate;
LUSC	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.02	-0.31	4.56e-9	Breast cancer;
LUSC	cis	rs9311676	0.656	rs6775710	chr3:58336201	A/G	cg26110898	chr3:58419937	PDHB	-0.46	-6.98	-0.36	1.62e-11	Systemic lupus erythematosus;
LUSC	cis	rs6429082	0.764	rs2481095	chr1:235695756	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.57	-7.77	-0.39	9.77e-14	Adiposity;
LUSC	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.71	-10.9	-0.51	7.13e-24	Alcohol dependence;
LUSC	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08645402	chr16:4508243	NA	-0.48	-7.68	-0.39	1.8e-13	Schizophrenia;
LUSC	cis	rs6700896	0.500	rs4655754	chr1:66114747	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-6.38	-0.33	5.8e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	6.57	0.34	1.92e-10	Height;
LUSC	cis	rs10979	1.000	rs13197332	chr6:143888095	T/A	cg25407410	chr6:143891975	LOC285740	-0.74	-11.93	-0.55	1.4e-27	Hypospadias;
LUSC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg02951883	chr7:2050386	MAD1L1	0.42	7.3	0.37	2.13e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg18758796	chr5:131593413	PDLIM4	0.43	7.29	0.37	2.25e-12	Blood metabolite levels;
LUSC	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg08798685	chr6:27730294	NA	-0.64	-5.89	-0.31	9.23e-9	Depression;
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18404041	chr3:52824283	ITIH1	-0.47	-8.85	-0.44	5.36e-17	Electroencephalogram traits;
LUSC	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.43	-0.33	4.32e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg10756647	chr7:56101905	PSPH	0.88	8.42	0.42	1.09e-15	Diabetic kidney disease;
LUSC	cis	rs2425143	1.000	rs6058311	chr20:34321895	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.18	-0.32	1.83e-9	Blood protein levels;
LUSC	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.88	15.05	0.64	1.87e-39	Bladder cancer;
LUSC	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.64	-9.99	-0.48	9.81e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25072359	chr17:41440525	NA	0.69	9.65	0.47	1.36e-19	Menopause (age at onset);
LUSC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg18305652	chr10:134549665	INPP5A	0.46	6.95	0.36	1.9e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg17173187	chr15:85201210	NMB	0.36	6.51	0.34	2.83e-10	Schizophrenia;
LUSC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg18632100	chr19:59028615	ZBTB45	-0.66	-6.02	-0.31	4.62e-9	Myocardial infarction;
LUSC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg22800045	chr5:56110881	MAP3K1	0.58	7.94	0.4	3.11e-14	Coronary artery disease;
LUSC	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg19875535	chr5:140030758	IK	-0.47	-7.7	-0.39	1.54e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-5.97	-0.31	6.03e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21659725	chr3:3221576	CRBN	0.62	10.21	0.49	1.78e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.67	-0.3	3.17e-8	Life satisfaction;
LUSC	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg13334819	chr7:99746414	C7orf59	0.52	6.96	0.36	1.76e-11	Coronary artery disease;
LUSC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08859206	chr1:53392774	SCP2	-0.55	-9.61	-0.47	1.81e-19	Monocyte count;
LUSC	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	0.85	11.39	0.53	1.3e-25	Menopause (age at onset);
LUSC	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.13	-20.08	-0.74	2.19e-59	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg21385522	chr1:16154831	NA	-0.54	-8.6	-0.43	3.14e-16	Systolic blood pressure;
LUSC	cis	rs12986413	0.967	rs4807211	chr19:2174643	G/A	cg09261902	chr19:2140048	AP3D1	0.31	5.93	0.31	7.51e-9	Height;
LUSC	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg13206674	chr6:150067644	NUP43	0.56	8.73	0.43	1.21e-16	Lung cancer;
LUSC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	11.0	0.52	3.11e-24	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.4	-0.33	5.18e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg07870213	chr5:140052090	DND1	-0.75	-11.11	-0.52	1.26e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg02023728	chr11:77925099	USP35	0.45	6.54	0.34	2.32e-10	Testicular germ cell tumor;
LUSC	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg05163923	chr11:71159392	DHCR7	0.66	9.73	0.47	7.55e-20	Vitamin D levels;
LUSC	trans	rs629535	0.590	rs56200825	chr8:70123450	G/A	cg21567404	chr3:27674614	NA	-0.92	-13.31	-0.59	9.85e-33	Dupuytren's disease;
LUSC	cis	rs11676348	0.808	rs61700947	chr2:219046171	C/G	cg06547715	chr2:218990976	CXCR2	-0.32	-6.12	-0.32	2.57e-9	Ulcerative colitis;
LUSC	cis	rs7712401	0.601	rs34348084	chr5:122335114	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.22	-0.45	3.4e-18	Mean platelet volume;
LUSC	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.46	-0.46	5.87e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg06784218	chr1:46089804	CCDC17	0.54	11.06	0.52	1.87e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3741798	1.000	rs61922025	chr12:12486263	G/A	cg08615371	chr12:12503544	MANSC1	1.07	10.74	0.51	2.7e-23	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg05425664	chr17:57184151	TRIM37	-0.53	-7.82	-0.39	6.86e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1507153	0.651	rs9350781	chr6:79481815	A/T	cg05283184	chr6:79620031	NA	-0.43	-7.55	-0.38	4.11e-13	Sjögren's syndrome;
LUSC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg13395646	chr4:1353034	KIAA1530	-0.62	-10.04	-0.48	6.69e-21	Obesity-related traits;
LUSC	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg03563238	chr19:33554763	RHPN2	-0.4	-6.47	-0.33	3.5e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.66	0.57	2.85e-30	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.77	0.47	5.22e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg26384229	chr12:38710491	ALG10B	0.56	8.97	0.44	2.14e-17	Morning vs. evening chronotype;
LUSC	cis	rs12545109	1.000	rs1975284	chr8:57314663	A/G	cg09654669	chr8:57350985	NA	-0.51	-6.75	-0.35	6.48e-11	Obesity-related traits;
LUSC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg01416388	chr22:39784598	NA	-0.44	-7.2	-0.37	3.95e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-7.47	-0.38	7.11e-13	Atrioventricular conduction;
LUSC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.61	-0.34	1.51e-10	Longevity;Endometriosis;
LUSC	cis	rs17030434	1.000	rs75418383	chr4:154719084	A/G	cg14289246	chr4:154710475	SFRP2	-0.53	-6.84	-0.35	3.69e-11	Electrocardiographic conduction measures;
LUSC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg10523860	chr14:103875565	MARK3	-0.38	-6.15	-0.32	2.24e-9	Body mass index;
LUSC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs62238980	0.614	rs117486425	chr22:32441850	A/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg18721089	chr20:30220636	NA	0.34	5.92	0.31	7.87e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs983392	0.667	rs624663	chr11:59945065	C/T	cg24026212	chr11:59952134	MS4A6A	0.34	6.03	0.31	4.27e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg04944784	chr2:26401820	FAM59B	0.79	11.29	0.53	2.95e-25	Gut microbiome composition (summer);
LUSC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.61	8.11	0.41	9.99e-15	High light scatter reticulocyte count;
LUSC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.52	-0.46	3.59e-19	Chronic sinus infection;
LUSC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs6469656	0.803	rs4472547	chr8:117683846	C/T	cg24004040	chr8:117650383	NA	-0.45	-6.48	-0.33	3.3e-10	Colorectal cancer;
LUSC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg00033643	chr7:134001901	SLC35B4	0.45	7.11	0.36	7.22e-12	Mean platelet volume;
LUSC	cis	rs6982240	0.514	rs9324543	chr8:142275662	T/C	cg27411547	chr8:142287226	NA	-0.47	-8.02	-0.4	1.77e-14	Tonsillectomy;
LUSC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg21862992	chr11:68658383	NA	0.51	7.84	0.39	6.16e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg13939156	chr17:80058883	NA	-0.32	-6.38	-0.33	5.99e-10	Life satisfaction;
LUSC	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg09796270	chr17:17721594	SREBF1	-0.44	-7.71	-0.39	1.43e-13	Total body bone mineral density;
LUSC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.62	7.92	0.4	3.55e-14	Schizophrenia;
LUSC	trans	rs12310956	0.510	rs10129020	chr12:33858936	T/G	cg26384229	chr12:38710491	ALG10B	0.54	8.25	0.41	3.61e-15	Morning vs. evening chronotype;
LUSC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg04315214	chr1:2043799	PRKCZ	-0.36	-7.08	-0.36	8.34e-12	Height;
LUSC	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg25801113	chr15:45476975	SHF	0.35	7.27	0.37	2.49e-12	Uric acid levels;
LUSC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg08798685	chr6:27730294	NA	-0.68	-6.14	-0.32	2.38e-9	Depression;
LUSC	cis	rs4851254	0.660	rs59447631	chr2:100691493	T/C	cg07810366	chr2:100720526	AFF3	-0.45	-6.01	-0.31	4.74e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg01879757	chr17:41196368	BRCA1	-0.45	-6.99	-0.36	1.54e-11	Menopause (age at onset);
LUSC	cis	rs3741151	0.773	rs11235770	chr11:73184002	C/T	cg17517138	chr11:73019481	ARHGEF17	0.83	7.6	0.38	2.94e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg08917208	chr2:24149416	ATAD2B	0.88	9.59	0.46	2.06e-19	Lymphocyte counts;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01921777	chr1:40839564	SMAP2	-0.38	-6.11	-0.32	2.84e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1832871	0.655	rs4273715	chr6:158722847	T/C	cg07165851	chr6:158734300	TULP4	0.5	7.76	0.39	1.03e-13	Height;
LUSC	trans	rs71435601	0.628	rs34125138	chr2:21418756	A/G	cg20757404	chr19:378427	NA	-0.41	-6.33	-0.33	8.06e-10	Cholesterol, total;
LUSC	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-5.84	-0.3	1.27e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4919087	0.962	rs10748694	chr10:99056190	A/T	cg25902810	chr10:99078978	FRAT1	0.47	6.65	0.34	1.22e-10	Monocyte count;
LUSC	cis	rs2235649	0.663	rs113908028	chr16:1848915	G/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-5.96	-0.31	6.24e-9	Blood metabolite levels;
LUSC	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg18002602	chr11:66138449	SLC29A2	0.45	8.12	0.41	8.95e-15	Educational attainment (years of education);
LUSC	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg20701182	chr2:24300061	SF3B14	0.57	6.17	0.32	1.99e-9	Lymphocyte counts;
LUSC	trans	rs800082	0.516	rs1527237	chr3:144230196	G/A	cg24215973	chr2:240111563	HDAC4	0.45	6.79	0.35	5.21e-11	Smoking behavior;
LUSC	cis	rs2307022	0.586	rs3785125	chr16:68388392	T/A	cg02226672	chr16:68398533	SMPD3	0.3	5.68	0.3	2.95e-8	Body mass index;
LUSC	cis	rs4834770	0.792	rs7676969	chr4:120173724	C/T	cg24375607	chr4:120327624	NA	0.42	5.82	0.3	1.39e-8	Blood protein levels;
LUSC	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-8.67	-0.43	1.97e-16	Neuroticism;
LUSC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.63	6.19	0.32	1.77e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.58	-10.28	-0.49	1.02e-21	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11229555	0.645	rs12294062	chr11:58175603	G/T	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9296092	0.538	rs9469486	chr6:33516849	G/A	cg13560919	chr6:33536144	NA	-0.82	-15.73	-0.65	4.02e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg05072774	chr3:49840536	C3orf54	-0.43	-5.96	-0.31	6.27e-9	Resting heart rate;
LUSC	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg16586182	chr3:47516702	SCAP	-0.54	-8.61	-0.43	2.97e-16	Colorectal cancer;
LUSC	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.57	-0.46	2.57e-19	Total cholesterol levels;
LUSC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg12963246	chr6:28129442	ZNF389	0.43	5.83	0.3	1.27e-8	Depression;
LUSC	cis	rs3772130	1.000	rs62268732	chr3:121370455	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	9.97	0.48	1.13e-20	Cognitive performance;
LUSC	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.57	-11.07	-0.52	1.85e-24	Height;
LUSC	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.64	-9.77	-0.47	5.22e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs78707713	0.560	rs2394563	chr10:71238618	G/A	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.6	-0.47	1.96e-19	Venous thromboembolism;
LUSC	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg11214544	chr1:2391121	NA	-0.6	-9.69	-0.47	9.71e-20	Non-obstructive azoospermia;
LUSC	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg04362960	chr10:104952993	NT5C2	0.56	8.7	0.43	1.51e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.1	0.58	6.35e-32	Cognitive test performance;
LUSC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06481639	chr22:41940642	POLR3H	0.51	5.93	0.31	7.37e-9	Vitiligo;
LUSC	cis	rs7580658	0.963	rs62157555	chr2:128107176	C/T	cg09760422	chr2:128146352	NA	-0.33	-7.25	-0.37	2.91e-12	Protein C levels;
LUSC	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg20991723	chr1:152506922	NA	0.49	9.23	0.45	3.09e-18	Hair morphology;
LUSC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg14196790	chr5:131705035	SLC22A5	0.43	7.18	0.37	4.66e-12	Blood metabolite levels;
LUSC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.5	-9.69	-0.47	1.01e-19	Monocyte percentage of white cells;
LUSC	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg13256891	chr4:100009986	ADH5	-0.49	-6.37	-0.33	6.11e-10	Alcohol dependence;
LUSC	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg24596788	chr1:163392923	NA	-0.44	-7.46	-0.38	7.41e-13	Motion sickness;
LUSC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.47	6.93	0.35	2.22e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg01657329	chr11:68192670	LRP5	-0.44	-6.56	-0.34	2.02e-10	Total body bone mineral density;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21056992	chr19:17392414	ANKLE1	0.7	6.3	0.33	9.45e-10	Cognitive performance;
LUSC	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg12863693	chr15:85201151	NMB	0.38	8.02	0.4	1.82e-14	Schizophrenia;
LUSC	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg06271696	chr7:157225062	NA	0.4	6.99	0.36	1.48e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg23752985	chr2:85803571	VAMP8	0.34	7.32	0.37	1.91e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2835872	0.758	rs7278101	chr21:39035873	T/C	cg20424643	chr21:39039972	KCNJ6	0.45	7.3	0.37	2.09e-12	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg19812747	chr11:111475976	SIK2	-0.43	-6.07	-0.32	3.43e-9	Primary sclerosing cholangitis;
LUSC	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.56	0.34	2.06e-10	Corneal astigmatism;
LUSC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg04414720	chr1:150670196	GOLPH3L	0.55	8.99	0.44	1.82e-17	Tonsillectomy;
LUSC	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.9e-20	Migraine;Coronary artery disease;
LUSC	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.23	-0.45	3.31e-18	Coronary artery disease;
LUSC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.09	0.4	1.15e-14	Prudent dietary pattern;
LUSC	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	1.08	16.83	0.68	1.78e-46	Exhaled nitric oxide output;
LUSC	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg11502198	chr6:26597334	ABT1	0.73	11.92	0.55	1.52e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	6.85	0.35	3.49e-11	Height;
LUSC	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg00191853	chr8:101177733	SPAG1	0.35	5.8	0.3	1.5e-8	Atrioventricular conduction;
LUSC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg26695010	chr11:65641043	EFEMP2	-0.47	-7.1	-0.36	7.44e-12	Eosinophil percentage of white cells;
LUSC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg26513180	chr16:89883248	FANCA	-0.61	-10.0	-0.48	9.43e-21	Vitiligo;
LUSC	trans	rs72674100	1.000	rs12386408	chr4:97977807	T/A	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-9.11	-0.45	7.8e-18	Asthma;
LUSC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg24503407	chr1:205819492	PM20D1	0.43	5.86	0.31	1.14e-8	Parkinson's disease;
LUSC	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg24579218	chr15:68104479	NA	-0.37	-6.46	-0.33	3.68e-10	Obesity;
LUSC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-12.09	-0.55	3.73e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7113850	0.541	rs7118538	chr11:24223615	C/T	ch.11.24196551F	chr11:24239977	NA	0.99	9.06	0.44	1.09e-17	Bone fracture in osteoporosis;
LUSC	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.87	-15.65	-0.65	8.26e-42	Tonsillectomy;
LUSC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	13.33	0.59	8.66e-33	Monocyte percentage of white cells;
LUSC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.46	0.46	5.6e-19	Prudent dietary pattern;
LUSC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24110177	chr3:50126178	RBM5	-0.55	-8.98	-0.44	2.05e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13510114	chr14:64971263	ZBTB25;ZBTB1	-0.5	-6.09	-0.32	3.18e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.01	-0.48	8.51e-21	Platelet count;
LUSC	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.88	15.04	0.64	2.2e-39	Bladder cancer;
LUSC	cis	rs778371	0.722	rs2102788	chr2:233805812	G/A	cg08000102	chr2:233561755	GIGYF2	0.52	6.92	0.35	2.27e-11	Schizophrenia;
LUSC	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.49	-0.33	3.02e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6977940	0.818	rs11772176	chr7:2894941	G/A	cg19731401	chr7:2775893	GNA12	0.68	7.53	0.38	4.83e-13	White matter integrity;
LUSC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg14092988	chr3:52407081	DNAH1	0.31	5.97	0.31	5.92e-9	Bipolar disorder;
LUSC	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg09408571	chr1:101003634	GPR88	0.29	5.67	0.3	3.12e-8	Monocyte count;
LUSC	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg20587970	chr11:113659929	NA	-1.11	-15.3	-0.64	1.99e-40	Hip circumference adjusted for BMI;
LUSC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.92	11.97	0.55	1.05e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg05347473	chr6:146136440	FBXO30	0.46	7.99	0.4	2.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06850241	chr22:41845214	NA	-0.3	-5.77	-0.3	1.82e-8	Vitiligo;
LUSC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg00106254	chr7:1943704	MAD1L1	0.42	6.09	0.32	3.19e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs240764	0.717	rs6916468	chr6:101160325	G/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.08	-0.32	3.22e-9	Neuroticism;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg06074332	chr11:111473729	SIK2	0.41	6.54	0.34	2.33e-10	Mosquito bite size;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg19223541	chr18:21033234	RIOK3	0.69	5.97	0.31	6.07e-9	Cognitive performance;
LUSC	cis	rs4654899	0.802	rs17410008	chr1:21220701	G/C	cg02927042	chr1:21476669	EIF4G3	-0.36	-5.66	-0.3	3.2e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs865483	0.929	rs853214	chr17:35860964	T/C	cg06716730	chr17:35851459	DUSP14	0.28	6.33	0.33	8.12e-10	Monocyte count;
LUSC	cis	rs2354432	0.556	rs6593777	chr1:146884013	C/G	cg25205988	chr1:146714368	CHD1L	0.85	7.33	0.37	1.73e-12	Mitochondrial DNA levels;
LUSC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	7.69	0.39	1.7e-13	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6740322	0.895	rs10210125	chr2:43556433	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-7.75	-0.39	1.09e-13	Coronary artery disease;
LUSC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg08270630	chr22:50330655	NA	-0.39	-5.89	-0.31	9.67e-9	Schizophrenia;
LUSC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.44	-0.33	4.21e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11039131	0.929	rs1685404	chr11:47243665	C/G	cg20307385	chr11:47447363	PSMC3	-0.53	-6.72	-0.35	7.67e-11	Schizophrenia;
LUSC	cis	rs2742234	0.910	rs2505513	chr10:43633537	C/G	cg02780029	chr10:43622663	RET	-0.35	-6.7	-0.34	8.96e-11	Hirschsprung disease;
LUSC	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.68	-0.34	9.74e-11	Mood instability;
LUSC	cis	rs3741151	0.773	rs113465107	chr11:73210416	T/G	cg17517138	chr11:73019481	ARHGEF17	0.96	8.24	0.41	3.97e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs3755132	0.929	rs7594392	chr2:15750852	A/G	cg12888861	chr2:15731646	DDX1	0.52	7.48	0.38	6.45e-13	Wilms tumor;
LUSC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg22907277	chr7:1156413	C7orf50	0.69	7.34	0.37	1.59e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg12310025	chr6:25882481	NA	-0.43	-7.4	-0.38	1.12e-12	Blood metabolite levels;
LUSC	cis	rs9341808	0.714	rs4256394	chr6:80882142	C/T	cg08355045	chr6:80787529	NA	0.44	7.67	0.39	1.93e-13	Sitting height ratio;
LUSC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.71	-0.43	1.41e-16	Type 2 diabetes;
LUSC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg01879757	chr17:41196368	BRCA1	0.48	7.82	0.39	6.99e-14	Menopause (age at onset);
LUSC	cis	rs41271473	0.750	rs17352829	chr1:228889664	A/G	cg16512390	chr1:228756714	NA	0.48	5.68	0.3	2.99e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs308403	0.509	rs309382	chr4:123669772	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.98	18.67	0.71	8.5e-54	Blood protein levels;
LUSC	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg17845761	chr1:175162550	KIAA0040	-0.31	-5.95	-0.31	6.59e-9	Alcohol dependence;
LUSC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.25	-14.44	-0.62	4.77e-37	Gout;
LUSC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg06640241	chr16:89574553	SPG7	0.72	11.64	0.54	1.58e-26	Multiple myeloma (IgH translocation);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08107767	chr7:56019574	MRPS17	-0.41	-6.08	-0.32	3.33e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg12257692	chr3:49977190	RBM6	0.25	7.12	0.36	6.71e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg26513180	chr16:89883248	FANCA	-0.58	-9.45	-0.46	5.96e-19	Vitiligo;
LUSC	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg15704280	chr7:45808275	SEPT13	0.69	6.48	0.33	3.28e-10	Axial length;
LUSC	cis	rs10986311	0.775	rs1984001	chr9:127137801	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.45	7.23	0.37	3.22e-12	Vitiligo;
LUSC	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg27661571	chr11:113659931	NA	-0.53	-6.56	-0.34	2.07e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs988712	0.705	rs4923457	chr11:27648580	A/T	cg10635145	chr11:27742435	BDNF	-0.46	-5.97	-0.31	6.2e-9	Obesity;
LUSC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg22963979	chr7:1858916	MAD1L1	-0.74	-12.57	-0.57	6.08e-30	Bipolar disorder and schizophrenia;
LUSC	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg14458575	chr2:238380390	NA	-0.71	-12.32	-0.56	5.09e-29	Prostate cancer;
LUSC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.04	20.99	0.75	5.49e-63	Cognitive function;
LUSC	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg08000102	chr2:233561755	GIGYF2	-0.63	-9.47	-0.46	5.34e-19	Schizophrenia;
LUSC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg00745463	chr17:30367425	LRRC37B	0.72	8.56	0.42	4.06e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg16447950	chr5:562315	NA	-0.57	-6.87	-0.35	3.21e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg08213375	chr14:104286397	PPP1R13B	0.36	5.86	0.31	1.11e-8	Reticulocyte count;
LUSC	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg22681709	chr2:178499509	PDE11A	-0.55	-11.03	-0.52	2.5300000000000002e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg04511125	chr2:88470314	THNSL2	0.63	6.41	0.33	4.94e-10	Plasma clusterin levels;
LUSC	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg03929089	chr4:120376271	NA	-0.89	-13.59	-0.6	9.03e-34	Height;
LUSC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-8.4	-0.42	1.29e-15	Alzheimer's disease;
LUSC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg16362232	chr11:430036	ANO9	0.6	7.9	0.4	3.97e-14	Body mass index;
LUSC	cis	rs6977660	1.000	rs7779902	chr7:19803491	G/A	cg05791153	chr7:19748676	TWISTNB	0.55	6.12	0.32	2.6e-9	Thyroid stimulating hormone;
LUSC	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.73	10.36	0.49	5.62e-22	Corneal astigmatism;
LUSC	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg19812747	chr11:111475976	SIK2	-0.49	-6.99	-0.36	1.48e-11	Primary sclerosing cholangitis;
LUSC	cis	rs713477	0.505	rs10131672	chr14:55905091	A/T	cg13175173	chr14:55914753	NA	-0.31	-5.89	-0.31	9.22e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.32	-0.37	1.82e-12	Glomerular filtration rate (creatinine);
LUSC	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg03929089	chr4:120376271	NA	-0.75	-9.24	-0.45	2.86e-18	Coronary artery disease;
LUSC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg23630131	chr7:65973040	NA	0.2	5.73	0.3	2.29e-8	Aortic root size;
LUSC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg06096015	chr1:231504339	EGLN1	0.54	9.38	0.46	1.02e-18	Hemoglobin concentration;
LUSC	cis	rs1335645	0.570	rs10494126	chr1:111671707	A/C	cg00321911	chr1:111669324	DRAM2	0.63	6.79	0.35	5.05e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg08807101	chr21:30365312	RNF160	-0.53	-6.68	-0.34	9.85e-11	Cognitive test performance;
LUSC	cis	rs6940638	0.606	rs6456771	chr6:27232395	G/A	cg05738196	chr6:26577821	NA	-0.51	-6.86	-0.35	3.3e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs72700829	0.507	rs11204766	chr1:151018060	G/C	cg11822372	chr1:151115635	SEMA6C	-0.77	-7.02	-0.36	1.26e-11	Schizophrenia;
LUSC	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	11.73	0.54	7.36e-27	Coronary artery disease;
LUSC	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.46	-0.42	8.29e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg21724239	chr8:58056113	NA	0.79	9.59	0.46	2.07e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg25428297	chr7:1022841	CYP2W1	0.3	6.25	0.32	1.22e-9	Longevity;Endometriosis;
LUSC	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg00701064	chr4:6280414	WFS1	-0.52	-11.54	-0.53	3.63e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.73	0.54	7.78e-27	Prudent dietary pattern;
LUSC	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs7523273	0.606	rs761275	chr1:207972154	A/C	cg22525895	chr1:207977042	MIR29B2	-0.38	-6.12	-0.32	2.67e-9	Schizophrenia;
LUSC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08219700	chr8:58056026	NA	0.65	7.21	0.37	3.67e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4400599	0.618	rs1194580	chr1:154219485	G/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.39	-6.41	-0.33	4.86e-10	Platelet distribution width;
LUSC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	0.89	16.91	0.68	8.97e-47	Gestational age at birth (maternal effect);
LUSC	cis	rs7254114	0.578	rs35248735	chr19:11312238	G/A	cg02815516	chr19:11306319	KANK2	-0.41	-8.62	-0.43	2.81e-16	Immature fraction of reticulocytes;
LUSC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg22764044	chr5:178986830	RUFY1	-0.57	-9.57	-0.46	2.44e-19	Lung cancer;
LUSC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg02018176	chr4:1364513	KIAA1530	0.49	8.41	0.42	1.18e-15	Obesity-related traits;
LUSC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg17971929	chr21:40555470	PSMG1	0.79	13.71	0.6	3.07e-34	Cognitive function;
LUSC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.4	-0.38	1.11e-12	Subjective well-being;
LUSC	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg27426351	chr10:43362370	NA	-0.43	-5.92	-0.31	8.17e-9	Blood protein levels;
LUSC	cis	rs7523273	0.526	rs1204708	chr1:208024062	G/C	cg22525895	chr1:207977042	MIR29B2	-0.38	-6.13	-0.32	2.48e-9	Schizophrenia;
LUSC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.73	0.43	1.22e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9473147	0.516	rs1931837	chr6:47442377	C/T	cg12968598	chr6:47444699	CD2AP	0.54	8.07	0.4	1.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	5.9e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs61931739	0.635	rs10743836	chr12:33961680	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.62	0.38	2.61e-13	Morning vs. evening chronotype;
LUSC	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg01528321	chr10:82214614	TSPAN14	0.83	12.55	0.57	7.61e-30	Post bronchodilator FEV1;
LUSC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg05132306	chr1:1846340	CALML6	-0.24	-5.8	-0.3	1.54e-8	Body mass index;
LUSC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg20203395	chr5:56204925	C5orf35	-0.81	-10.71	-0.51	3.32e-23	Initial pursuit acceleration;
LUSC	cis	rs7590368	0.651	rs56093996	chr2:10931302	T/C	cg15705551	chr2:10952987	PDIA6	0.52	5.86	0.31	1.13e-8	Educational attainment (years of education);
LUSC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg09165964	chr15:75287851	SCAMP5	0.54	7.84	0.39	6.21e-14	Breast cancer;
LUSC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg12463550	chr7:65579703	CRCP	0.52	7.54	0.38	4.36e-13	Aortic root size;
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.55	-8.44	-0.42	9.99e-16	Longevity;Endometriosis;
LUSC	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.82	-0.3	1.35e-8	Bipolar disorder;
LUSC	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg27129171	chr3:47204927	SETD2	0.7	11.83	0.54	3.24e-27	Colorectal cancer;
LUSC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg27284194	chr4:1044797	NA	0.37	6.03	0.31	4.46e-9	Longevity;
LUSC	cis	rs17253792	0.749	rs45458197	chr14:56145018	A/T	cg01858014	chr14:56050164	KTN1	-0.79	-6.72	-0.35	7.8e-11	Putamen volume;
LUSC	trans	rs2587949	0.615	rs2166023	chr3:4211752	C/T	cg15139668	chr4:4577005	NA	0.41	6.08	0.32	3.23e-9	Periodontitis (DPAL);
LUSC	cis	rs9311676	0.586	rs73085867	chr3:58434791	C/T	cg26110898	chr3:58419937	PDHB	0.41	6.68	0.34	1.02e-10	Systemic lupus erythematosus;
LUSC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg18404041	chr3:52824283	ITIH1	0.4	7.2	0.37	3.96e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg16325326	chr1:53192061	ZYG11B	0.96	18.33	0.71	2e-52	Monocyte count;
LUSC	trans	rs11039798	1.000	rs10838942	chr11:48557163	C/G	cg15704280	chr7:45808275	SEPT13	0.69	6.56	0.34	2.06e-10	Axial length;
LUSC	cis	rs9473147	0.516	rs2151974	chr6:47515630	G/A	cg02130027	chr6:47444894	CD2AP	0.36	5.74	0.3	2.09e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg11189052	chr15:85197271	WDR73	-0.46	-5.66	-0.3	3.34e-8	Schizophrenia;
LUSC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg10018233	chr7:150070692	REPIN1	0.46	9.38	0.46	1.06e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9311676	0.656	rs4339119	chr3:58389462	A/G	cg13750441	chr3:58318267	PXK	0.35	6.72	0.35	7.86e-11	Systemic lupus erythematosus;
LUSC	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg14092571	chr14:90743983	NA	0.35	5.67	0.3	3.07e-8	Mortality in heart failure;
LUSC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.76	-0.3	1.96e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3862260	0.905	rs3850870	chr1:120161037	C/T	cg16322792	chr1:120165303	ZNF697	0.5	9.59	0.46	2.2e-19	Systemic lupus erythematosus;
LUSC	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg13852791	chr20:30311386	BCL2L1	0.93	14.05	0.61	1.47e-35	Mean corpuscular hemoglobin;
LUSC	cis	rs73206853	0.764	rs16940909	chr12:111054591	G/C	cg12870014	chr12:110450643	ANKRD13A	0.7	7.81	0.39	7.23e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg20587970	chr11:113659929	NA	1.23	12.71	0.57	1.86e-30	Hip circumference adjusted for BMI;
LUSC	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg21033440	chr11:65409861	SIPA1	-0.52	-7.17	-0.37	4.76e-12	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs7264396	0.887	rs736032	chr20:34048661	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.72	-0.35	7.94e-11	Total cholesterol levels;
LUSC	cis	rs10489525	0.599	rs910622	chr1:115600424	A/G	cg17147537	chr1:115611705	TSPAN2	-0.29	-5.95	-0.31	6.84e-9	Autism;
LUSC	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg24011408	chr12:48396354	COL2A1	-0.46	-7.59	-0.38	3.32e-13	Plateletcrit;
LUSC	cis	rs2692947	0.727	rs1657502	chr2:96795608	A/C	cg22654517	chr2:96458247	NA	0.36	7.24	0.37	3.08e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg09941381	chr10:64027924	RTKN2	-0.39	-7.14	-0.36	5.75e-12	Rheumatoid arthritis;
LUSC	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg00310523	chr12:86230176	RASSF9	0.47	8.39	0.42	1.37e-15	Major depressive disorder;
LUSC	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg08079166	chr15:68083412	MAP2K5	0.41	7.54	0.38	4.59e-13	Restless legs syndrome;
LUSC	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg01733217	chr16:74700730	RFWD3	0.75	12.29	0.56	6.92e-29	Testicular germ cell tumor;
LUSC	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-5.69	-0.3	2.73e-8	Major depressive disorder;
LUSC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg17554472	chr22:41940697	POLR3H	-0.45	-5.66	-0.3	3.31e-8	Vitiligo;
LUSC	cis	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.92	-0.44	3.11e-17	Morning vs. evening chronotype;
LUSC	cis	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg21775007	chr8:11205619	TDH	0.44	5.96	0.31	6.52e-9	Monocyte count;
LUSC	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg23950597	chr19:37808831	NA	-0.6	-7.26	-0.37	2.8e-12	Coronary artery calcification;
LUSC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg25124228	chr12:125621409	AACS	-0.48	-7.1	-0.36	7.77e-12	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	13.03	0.58	1.12e-31	Cognitive test performance;
LUSC	trans	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg20935933	chr6:143382018	AIG1	0.5	7.32	0.37	1.92e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs16976116	0.851	rs28889339	chr15:55503205	T/G	cg11288833	chr15:55489084	RSL24D1	0.51	6.16	0.32	2.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.96	-0.48	1.2e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-0.86	-12.53	-0.57	8.97e-30	Asthma;
LUSC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-6.0	-0.31	5.17e-9	Renal cell carcinoma;
LUSC	cis	rs10207060	0.500	rs6731870	chr2:240708096	C/A	cg20333904	chr2:240724165	NA	-0.36	-6.12	-0.32	2.56e-9	Obesity-related traits;
LUSC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.65	-8.73	-0.43	1.22e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08280861	chr8:58055591	NA	0.54	6.49	0.33	3.18e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg02269571	chr22:50332266	NA	-0.64	-9.48	-0.46	4.8e-19	Schizophrenia;
LUSC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.17	0.37	4.89e-12	Multiple sclerosis;
LUSC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg25767906	chr1:53392781	SCP2	0.44	7.73	0.39	1.28e-13	Monocyte count;
LUSC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg11062466	chr8:58055876	NA	0.58	8.23	0.41	4.14e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14893161	chr1:205819251	PM20D1	0.46	6.14	0.32	2.29e-9	Parkinson's disease;
LUSC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg05347473	chr6:146136440	FBXO30	-0.56	-9.63	-0.47	1.61e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9462027	0.628	rs9469889	chr6:34763900	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.76	-0.3	1.89e-8	Systemic lupus erythematosus;
LUSC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg01448562	chr3:133502909	NA	-0.6	-9.93	-0.48	1.62e-20	Iron status biomarkers;
LUSC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg02221750	chr19:17393354	ANKLE1	-0.91	-13.72	-0.6	2.84e-34	Systemic lupus erythematosus;
LUSC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.39	7.54	0.38	4.55e-13	Axial length;
LUSC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg19230755	chr7:65878503	NA	0.41	5.76	0.3	1.95e-8	Aortic root size;
LUSC	cis	rs2667011	0.818	rs2667025	chr2:160839341	A/G	cg06573604	chr2:160760825	LY75	0.46	5.95	0.31	6.73e-9	Bilirubin levels;
LUSC	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.61	-14.16	-0.61	5.7e-36	Sense of smell;
LUSC	cis	rs12928939	0.911	rs11645725	chr16:71826883	C/T	cg03805757	chr16:71968109	PKD1L3	-0.46	-6.65	-0.34	1.23e-10	Post bronchodilator FEV1;
LUSC	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg23933602	chr10:16859644	RSU1	0.99	19.98	0.74	5.76e-59	Platelet distribution width;
LUSC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg16606324	chr3:10149918	C3orf24	0.63	9.48	0.46	4.89e-19	Alzheimer's disease;
LUSC	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.38	-0.42	1.49e-15	Response to antipsychotic treatment;
LUSC	cis	rs1448094	0.617	rs1502799	chr12:86474921	T/C	cg00310523	chr12:86230176	RASSF9	-0.33	-5.97	-0.31	5.98e-9	Major depressive disorder;
LUSC	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg17385448	chr1:15911702	AGMAT	0.37	6.38	0.33	5.82e-10	Systolic blood pressure;
LUSC	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.71	-11.31	-0.53	2.54e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs36093844	0.898	rs895255	chr11:85534546	A/C	cg25872744	chr11:85566296	CCDC83	0.44	6.48	0.33	3.2e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs73206853	0.698	rs871922	chr12:111114942	T/C	cg12870014	chr12:110450643	ANKRD13A	0.7	7.49	0.38	6.2800000000000005e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7084921	0.520	rs2902377	chr10:101876770	G/A	cg02250046	chr10:101825185	CPN1	-0.31	-5.73	-0.3	2.25e-8	Bone mineral density;
LUSC	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07080220	chr10:102295463	HIF1AN	0.7	9.62	0.47	1.72e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1775715	0.966	rs1755067	chr10:32296195	C/T	cg26784012	chr10:32216390	ARHGAP12	-0.38	-6.24	-0.32	1.36e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-6.27	-0.32	1.12e-9	IgG glycosylation;
LUSC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24549020	chr5:56110836	MAP3K1	0.5	6.06	0.31	3.63e-9	Initial pursuit acceleration;
LUSC	cis	rs1358748	0.522	rs6588241	chr1:67586913	T/C	cg02640540	chr1:67518911	SLC35D1	0.63	6.08	0.32	3.31e-9	Tuberculosis;
LUSC	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg13852791	chr20:30311386	BCL2L1	0.94	14.42	0.62	5.67e-37	Mean corpuscular hemoglobin;
LUSC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	0.92	18.7	0.72	6.55e-54	Dental caries;
LUSC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-6.06	-0.31	3.7e-9	Personality dimensions;
LUSC	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg05283184	chr6:79620031	NA	-0.57	-12.14	-0.55	2.5e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9650315	0.866	rs35294340	chr8:57199992	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.28	0.37	2.42e-12	Height;
LUSC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-9.89	-0.48	2.14e-20	Chronic sinus infection;
LUSC	cis	rs11971779	0.616	rs10269683	chr7:139100868	G/A	cg07862535	chr7:139043722	LUC7L2	0.57	7.13	0.36	6.42e-12	Diisocyanate-induced asthma;
LUSC	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.78	-0.35	5.46e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-10.74	-0.51	2.59e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg25036284	chr2:26402008	FAM59B	-0.69	-9.84	-0.47	3.24e-20	Gut microbiome composition (summer);
LUSC	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg01689657	chr7:91764605	CYP51A1	-0.32	-5.77	-0.3	1.79e-8	Breast cancer;
LUSC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg25036284	chr2:26402008	FAM59B	0.78	11.06	0.52	1.94e-24	Gut microbiome composition (summer);
LUSC	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg14019695	chr9:139328340	INPP5E	0.45	8.17	0.41	6.4e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2580764	0.540	rs10210840	chr2:55226009	G/A	cg20993754	chr2:55226987	RTN4	0.36	6.07	0.32	3.46e-9	Mean platelet volume;
LUSC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	8.21	0.41	4.78e-15	Height;
LUSC	cis	rs6967385	0.560	rs10272105	chr7:12358122	C/A	cg20607287	chr7:12443886	VWDE	0.43	6.32	0.33	8.53e-10	Response to taxane treatment (placlitaxel);
LUSC	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.24	-0.52	4.38e-25	Coffee consumption (cups per day);
LUSC	trans	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg26043149	chr18:55253948	FECH	-0.46	-7.09	-0.36	7.93e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.59	-0.54	2.5e-26	Schizophrenia;
LUSC	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg24375607	chr4:120327624	NA	0.77	12.24	0.56	1.04e-28	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.23	-0.32	1.42e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10887741	0.646	rs11202499	chr10:89433211	C/G	cg13926569	chr10:89418898	PAPSS2	0.33	7.12	0.36	6.83e-12	Exercise (leisure time);
LUSC	trans	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg24247370	chr13:99142703	STK24	-0.33	-6.08	-0.32	3.2e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg17507749	chr15:85114479	UBE2QP1	0.54	6.66	0.34	1.15e-10	Schizophrenia;
LUSC	cis	rs4363385	0.643	rs11576457	chr1:152918556	C/T	cg08895932	chr1:152778580	LCE1C	0.33	5.81	0.3	1.48e-8	Inflammatory skin disease;
LUSC	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg22601191	chr20:60968625	CABLES2	-0.48	-6.93	-0.35	2.13e-11	Colorectal cancer;
LUSC	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.92	12.56	0.57	6.87e-30	Primary sclerosing cholangitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18013782	chr17:65240863	HELZ	0.41	6.09	0.32	3.17e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg00191853	chr8:101177733	SPAG1	0.35	5.84	0.3	1.25e-8	Atrioventricular conduction;
LUSC	cis	rs2274273	0.934	rs10137307	chr14:55845185	T/C	cg04306507	chr14:55594613	LGALS3	0.52	11.48	0.53	6.28e-26	Protein biomarker;
LUSC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg07061783	chr6:25882402	NA	-0.38	-5.86	-0.31	1.12e-8	Blood metabolite levels;
LUSC	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.87	-14.38	-0.62	7.9e-37	Schizophrenia;
LUSC	cis	rs1461503	0.512	rs4293126	chr11:122804133	A/G	cg27398637	chr11:122830231	C11orf63	0.36	5.8	0.3	1.55e-8	Menarche (age at onset);
LUSC	cis	rs2108225	0.658	rs1476673	chr7:107435945	C/G	cg18560240	chr7:107437656	SLC26A3	-0.44	-6.82	-0.35	4.28e-11	Ulcerative colitis;
LUSC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg18681998	chr4:17616180	MED28	0.85	15.67	0.65	6.85e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs73200209	0.744	rs1344863	chr12:116408257	A/T	cg01776926	chr12:116560359	MED13L	-0.52	-5.86	-0.31	1.14e-8	Total body bone mineral density;
LUSC	cis	rs2580764	0.678	rs2580765	chr2:55204028	A/C	cg09592903	chr2:55203963	RTN4	0.48	9.92	0.48	1.64e-20	Mean platelet volume;
LUSC	cis	rs1891275	0.515	rs1080496	chr10:93444262	C/T	cg07889827	chr10:93443413	NA	0.37	8.27	0.41	3.24e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg21545522	chr1:205238299	TMCC2	0.47	8.81	0.43	7.18e-17	Red blood cell count;
LUSC	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg02023728	chr11:77925099	USP35	0.43	6.2	0.32	1.66e-9	Testicular germ cell tumor;
LUSC	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.98	-0.48	1.09e-20	Migraine;Coronary artery disease;
LUSC	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.13	-0.36	6.33e-12	Response to antipsychotic treatment;
LUSC	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg06636001	chr8:8085503	FLJ10661	0.55	8.09	0.4	1.12e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg05855489	chr10:104503620	C10orf26	-0.67	-9.79	-0.47	4.6e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.64	-10.5	-0.5	1.73e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9796	0.621	rs2928142	chr15:41470449	T/C	cg18705301	chr15:41695430	NDUFAF1	0.48	8.53	0.42	5.24e-16	Menopause (age at onset);
LUSC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	8.81	0.43	7e-17	Schizophrenia;
LUSC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg18827107	chr12:86230957	RASSF9	-0.47	-7.06	-0.36	9.99e-12	Major depressive disorder;
LUSC	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.63	-0.34	1.33e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg17173187	chr15:85201210	NMB	-0.32	-6.7	-0.34	8.67e-11	P wave terminal force;
LUSC	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	7.85	0.39	5.73e-14	Response to antipsychotic treatment;
LUSC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg10578777	chr12:7781093	NA	0.58	6.39	0.33	5.59e-10	HDL cholesterol levels;
LUSC	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg04310649	chr10:35416472	CREM	-0.41	-6.4	-0.33	5.33e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg12863693	chr15:85201151	NMB	0.35	7.14	0.36	6e-12	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18838581	chr19:2269401	OAZ1	-0.41	-5.97	-0.31	5.94e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.53	0.34	2.39e-10	Joint mobility (Beighton score);
LUSC	trans	rs61931739	0.635	rs10772123	chr12:33975557	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.68	0.39	1.78e-13	Morning vs. evening chronotype;
LUSC	cis	rs295140	0.681	rs6435048	chr2:201167854	C/T	cg04283868	chr2:201171347	SPATS2L	0.43	6.24	0.32	1.34e-9	QT interval;
LUSC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg26380479	chr7:97908229	NA	-0.28	-6.1	-0.32	2.87e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg09021430	chr5:549028	NA	-0.56	-7.67	-0.39	1.96e-13	Obesity-related traits;
LUSC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg06784218	chr1:46089804	CCDC17	-0.48	-9.21	-0.45	3.67e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg07701084	chr6:150067640	NUP43	0.46	6.88	0.35	2.9100000000000002e-11	Lung cancer;
LUSC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-8.58	-0.43	3.5e-16	Mean corpuscular volume;
LUSC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25072359	chr17:41440525	NA	0.65	9.22	0.45	3.32e-18	Menopause (age at onset);
LUSC	cis	rs55665837	1.000	rs11023214	chr11:14436259	G/C	cg19336497	chr11:14380999	RRAS2	-0.37	-7.51	-0.38	5.34e-13	Vitamin D levels;
LUSC	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg02023728	chr11:77925099	USP35	0.44	6.58	0.34	1.77e-10	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg03676636	chr4:99064102	C4orf37	0.32	6.85	0.35	3.6e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg26924012	chr15:45694286	SPATA5L1	0.77	11.42	0.53	1.04e-25	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs4811340	0.533	rs6068253	chr20:51180425	C/A	cg15736553	chr3:11610338	VGLL4	-0.33	-5.95	-0.31	6.7e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg22166914	chr1:53195759	ZYG11B	0.57	9.35	0.46	1.33e-18	Monocyte count;
LUSC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg19539972	chr4:7069911	GRPEL1	-0.7	-7.34	-0.37	1.64e-12	Monocyte percentage of white cells;
LUSC	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	0.85	12.21	0.56	1.37e-28	Resting heart rate;
LUSC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9398803	0.965	rs9388489	chr6:126698719	C/T	cg19875578	chr6:126661172	C6orf173	-0.42	-6.24	-0.32	1.35e-9	Male-pattern baldness;
LUSC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg16447950	chr5:562315	NA	-0.57	-6.87	-0.35	3.21e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg21775007	chr8:11205619	TDH	-0.72	-11.35	-0.53	1.78e-25	Retinal vascular caliber;
LUSC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.51	-0.38	5.42e-13	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25616684	chr1:38478508	UTP11L	0.41	6.09	0.32	3.12e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13242816	1.000	rs2188243	chr7:116109293	G/A	cg16553024	chr7:116138462	CAV2	-0.54	-5.92	-0.31	7.84e-9	P wave duration;
LUSC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg02475777	chr4:1388615	CRIPAK	0.45	6.69	0.34	9.62e-11	Obesity-related traits;
LUSC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg07424592	chr7:64974309	NA	0.66	5.82	0.3	1.38e-8	Diabetic kidney disease;
LUSC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	16.3	0.67	2.38e-44	Platelet count;
LUSC	cis	rs6840360	0.642	rs56301462	chr4:152452128	T/G	cg20465933	chr4:152376761	FAM160A1	0.35	6.33	0.33	8e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6681460	0.966	rs9659879	chr1:67121434	T/C	cg02459107	chr1:67143332	SGIP1	0.47	8.94	0.44	2.71e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs7169223	0.615	rs11630027	chr15:79096983	C/A	cg21242079	chr15:79101063	ADAMTS7	0.39	5.88	0.31	9.81e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg23711669	chr6:146136114	FBXO30	0.77	13.91	0.61	5.14e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9921338	0.961	rs7206017	chr16:11440861	C/T	cg00044050	chr16:11439710	C16orf75	-0.51	-6.68	-0.34	9.91e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs7833787	1.000	rs7833787	chr8:18707871	A/G	cg17701159	chr8:18705777	PSD3	-0.4	-6.56	-0.34	2.11e-10	Obesity-related traits;
LUSC	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg20701182	chr2:24300061	SF3B14	0.47	5.68	0.3	2.97e-8	Asthma;
LUSC	cis	rs367615	0.918	rs10070104	chr5:108866438	C/T	cg17395555	chr5:108820864	NA	-0.41	-6.08	-0.32	3.31e-9	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg19628046	chr18:33552617	C18orf21	0.51	6.29	0.33	1e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg04518342	chr5:131593106	PDLIM4	0.41	6.35	0.33	7.13e-10	Breast cancer;
LUSC	cis	rs258324	0.790	rs8062346	chr16:89732668	G/A	cg04287289	chr16:89883240	FANCA	0.69	6.13	0.32	2.48e-9	Height;
LUSC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg12963246	chr6:28129442	ZNF389	0.42	6.11	0.32	2.74e-9	Depression;
LUSC	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg12559939	chr2:27858050	GPN1	-0.41	-6.31	-0.33	8.82e-10	Oral cavity cancer;
LUSC	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.14	-0.32	2.35e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.39	0.33	5.48e-10	Menopause (age at onset);
LUSC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg04267008	chr7:1944627	MAD1L1	0.5	7.53	0.38	4.92e-13	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg25482853	chr8:67687455	SGK3	1.18	16.74	0.68	4.07e-46	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg05347473	chr6:146136440	FBXO30	0.47	8.03	0.4	1.63e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg05738196	chr6:26577821	NA	0.79	15.07	0.64	1.6e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs62027291	1.000	rs62027291	chr15:77266051	G/A	cg26408565	chr15:76604113	ETFA	0.6	6.78	0.35	5.55e-11	Plateletcrit;
LUSC	cis	rs2594714	0.538	rs895819	chr19:13947292	A/G	cg18576835	chr19:13944261	NA	-0.49	-7.9	-0.4	3.94e-14	Breast cancer;
LUSC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg03060546	chr3:49711283	APEH	0.71	11.95	0.55	1.23e-27	Resting heart rate;
LUSC	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	7.16	0.36	5.26e-12	Height;
LUSC	cis	rs4363385	0.574	rs4041402	chr1:152947397	T/C	cg00922841	chr1:152955080	SPRR1A	-0.36	-6.05	-0.31	3.85e-9	Inflammatory skin disease;
LUSC	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	0.59	9.29	0.45	2.06e-18	Breast cancer;
LUSC	cis	rs2580764	0.598	rs2580772	chr2:55218805	G/T	cg09592903	chr2:55203963	RTN4	0.47	9.72	0.47	8.09e-20	Mean platelet volume;
LUSC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg13175981	chr1:150552382	MCL1	0.43	6.16	0.32	2.05e-9	Tonsillectomy;
LUSC	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg07148914	chr20:33460835	GGT7	-0.46	-6.8	-0.35	4.88e-11	Height;
LUSC	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg24375607	chr4:120327624	NA	0.5	7.56	0.38	3.95e-13	Diastolic blood pressure;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13411897	chr3:12526166	TSEN2	-0.46	-5.99	-0.31	5.46e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	16.14	0.66	9.94e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2607426	0.681	rs2607411	chr19:41268555	A/G	cg05508168	chr19:41255947	C19orf54;SNRPA	0.85	6.72	0.35	7.9e-11	Blood protein levels;
LUSC	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg01884057	chr2:25150051	NA	0.48	11.28	0.53	3.09e-25	Body mass index;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	10.96	0.51	4.44e-24	Lymphocyte counts;
LUSC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.88e-11	Primary biliary cholangitis;
LUSC	cis	rs7923452	0.688	rs8177029	chr10:30748498	C/T	cg25182066	chr10:30743637	MAP3K8	-0.64	-5.69	-0.3	2.77e-8	Itch intensity from mosquito bite;
LUSC	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg06917634	chr15:78832804	PSMA4	-0.53	-6.53	-0.34	2.44e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg23422044	chr7:1970798	MAD1L1	-0.65	-7.31	-0.37	1.94e-12	Bipolar disorder;
LUSC	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg20016023	chr10:99160130	RRP12	-0.33	-8.06	-0.4	1.41e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9534288	0.619	rs6561292	chr13:46683560	G/T	cg15192986	chr13:46630673	CPB2	0.75	10.91	0.51	6.43e-24	Blood protein levels;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24449302	chr15:66679100	MAP2K1	-0.31	-6.05	-0.31	3.79e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs10492096	0.947	rs11064231	chr12:6604415	T/G	cg13857086	chr12:6580257	VAMP1	0.61	7.25	0.37	2.89e-12	Hip geometry;
LUSC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-1.13	-18.17	-0.71	8.74e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg14552801	chr7:65878734	NA	0.37	5.67	0.3	3.09e-8	Aortic root size;
LUSC	trans	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg24247370	chr13:99142703	STK24	-0.33	-6.12	-0.32	2.66e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	trans	rs2786098	0.571	rs6677361	chr1:197521877	T/C	cg16005942	chr6:160526640	IGF2R	-0.49	-6.07	-0.32	3.38e-9	Asthma;
LUSC	cis	rs9296092	0.560	rs62407561	chr6:33528103	T/C	cg13560919	chr6:33536144	NA	-0.85	-16.44	-0.67	6.54e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg25036284	chr2:26402008	FAM59B	0.63	8.91	0.44	3.42e-17	Gut microbiome composition (summer);
LUSC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg17724175	chr1:150552817	MCL1	-0.43	-7.66	-0.39	2.08e-13	Blood protein levels;
LUSC	cis	rs7524258	0.868	rs6577428	chr1:7314655	C/T	cg07173049	chr1:7289937	CAMTA1	-0.29	-5.78	-0.3	1.71e-8	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg13010199	chr12:38710504	ALG10B	-0.58	-9.17	-0.45	5.12e-18	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg07150166	chr2:30669952	LCLAT1	0.54	6.33	0.33	7.79e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs12493885	0.628	rs61790905	chr3:153653032	A/G	cg17054900	chr3:154042577	DHX36	-0.54	-5.66	-0.3	3.23e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs3125734	0.633	rs1873685	chr10:64032126	C/T	cg19640130	chr10:64028056	RTKN2	-0.41	-7.22	-0.37	3.44e-12	Rheumatoid arthritis;
LUSC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg26579491	chr7:65878976	NA	0.42	5.71	0.3	2.54e-8	Aortic root size;
LUSC	cis	rs4478858	0.684	rs12403136	chr1:31728920	A/G	cg00250761	chr1:31883323	NA	-0.36	-8.46	-0.42	8.54e-16	Alcohol dependence;
LUSC	cis	rs3771570	0.901	rs3815262	chr2:242352582	A/T	cg21155796	chr2:242212141	HDLBP	0.52	6.38	0.33	5.76e-10	Prostate cancer;
LUSC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg02951883	chr7:2050386	MAD1L1	0.61	11.99	0.55	8.56e-28	Bipolar disorder and schizophrenia;
LUSC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg15839431	chr19:19639596	YJEFN3	-0.4	-5.69	-0.3	2.76e-8	Tonsillectomy;
LUSC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg05585544	chr11:47624801	NA	0.41	7.15	0.36	5.36e-12	Subjective well-being;
LUSC	cis	rs7709377	0.595	rs12109104	chr5:115615708	A/G	cg23108291	chr5:115420582	COMMD10	0.4	5.74	0.3	2.11e-8	Metabolite levels  (X-11787);
LUSC	cis	rs9398803	0.865	rs4897181	chr6:126753564	C/T	cg19875578	chr6:126661172	C6orf173	0.42	6.13	0.32	2.53e-9	Male-pattern baldness;
LUSC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.77	12.46	0.56	1.53e-29	N-glycan levels;
LUSC	cis	rs36093844	0.747	rs17817314	chr11:85594972	T/C	cg25872744	chr11:85566296	CCDC83	-0.46	-6.04	-0.31	4.16e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.84	-13.0	-0.58	1.48e-31	Coronary artery disease;
LUSC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.71	-10.82	-0.51	1.39e-23	Aortic root size;
LUSC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	7.26	0.37	2.66e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09460159	chr17:30771470	PSMD11	-0.48	-6.34	-0.33	7.43e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs72674100	1.000	rs10010641	chr4:97966171	C/T	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg06618935	chr21:46677482	NA	-0.39	-7.95	-0.4	2.88e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.56e-10	Menopause (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25275331	chr1:40723935	ZMPSTE24	-0.53	-6.77	-0.35	5.96e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9309473	0.948	rs11884776	chr2:73746923	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-6.43	-0.33	4.37e-10	Metabolite levels;
LUSC	cis	rs2481665	0.902	rs1013293	chr1:62570321	G/A	cg18591186	chr1:62594603	INADL	-0.51	-7.97	-0.4	2.58e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.55	-7.47	-0.38	7e-13	Body mass index (adult);
LUSC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg19678392	chr7:94953810	PON1	-0.36	-5.91	-0.31	8.37e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.58	-7.96	-0.4	2.7e-14	Red cell distribution width;
LUSC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg13699009	chr12:122356056	WDR66	0.51	7.9	0.4	4.12e-14	Mean corpuscular volume;
LUSC	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.55	9.85	0.47	2.83e-20	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUSC	cis	rs9905704	0.918	rs2567901	chr17:56783255	C/T	cg12560992	chr17:57184187	TRIM37	0.54	7.75	0.39	1.15e-13	Testicular germ cell tumor;
LUSC	trans	rs1941687	0.797	rs9965563	chr18:31398985	T/G	cg27147174	chr7:100797783	AP1S1	-0.44	-6.34	-0.33	7.57e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg18681998	chr4:17616180	MED28	0.86	15.66	0.65	7.88e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Schizophrenia;
LUSC	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg26384229	chr12:38710491	ALG10B	-0.88	-15.17	-0.64	6.65e-40	Bladder cancer;
LUSC	cis	rs9341835	0.542	rs4710430	chr6:64165344	C/A	cg03326410	chr6:64151739	NA	-0.37	-6.01	-0.31	4.85e-9	Schizophrenia;
LUSC	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19748678	chr4:122722346	EXOSC9	-0.5	-7.53	-0.38	4.93e-13	Type 2 diabetes;
LUSC	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg00012203	chr2:219082015	ARPC2	-0.56	-9.03	-0.44	1.38e-17	Ulcerative colitis;
LUSC	trans	rs9944715	0.954	rs7245091	chr18:43743081	C/T	cg01718231	chr17:29326311	RNF135	-0.44	-6.26	-0.32	1.15e-9	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg05340658	chr4:99064831	C4orf37	0.44	6.97	0.36	1.68e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg06096015	chr1:231504339	EGLN1	0.58	10.37	0.49	5e-22	Hemoglobin concentration;
LUSC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.61	-0.43	2.96e-16	Breast cancer;
LUSC	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg02023728	chr11:77925099	USP35	0.52	7.06	0.36	9.72e-12	Testicular germ cell tumor;
LUSC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg09359103	chr1:154839909	KCNN3	-0.7	-16.23	-0.66	4.49e-44	Prostate cancer;
LUSC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.32	0.59	8.9e-33	Platelet count;
LUSC	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg21427119	chr20:30132790	HM13	-0.34	-5.7	-0.3	2.63e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.26	0.52	3.74e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs75920871	0.588	rs1815788	chr11:116834971	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-6.47	-0.33	3.47e-10	Subjective well-being;
LUSC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg17330251	chr7:94953956	PON1	-0.41	-6.67	-0.34	1.08e-10	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.47	0.53	6.9e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.37	8.03	0.4	1.71e-14	Tonsillectomy;
LUSC	trans	rs2562456	0.833	rs11880624	chr19:21523830	C/T	cg00806126	chr19:22604979	ZNF98	-0.43	-6.19	-0.32	1.78e-9	Pain;
LUSC	cis	rs6489882	0.902	rs10774679	chr12:113374748	A/G	cg20102336	chr12:113376681	OAS3	0.41	6.02	0.31	4.56e-9	Chronic lymphocytic leukemia;
LUSC	trans	rs6600671	0.899	rs11249432	chr1:121283476	T/A	cg00646200	chr1:148855367	NA	0.48	7.52	0.38	5.26e-13	Hip geometry;
LUSC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg06096015	chr1:231504339	EGLN1	0.56	10.01	0.48	8.18e-21	Hemoglobin concentration;
LUSC	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg22139774	chr2:100720529	AFF3	-0.47	-8.11	-0.41	9.86e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	7.95	0.4	2.83e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg05729581	chr11:3078854	CARS	-0.56	-8.71	-0.43	1.48e-16	Longevity;
LUSC	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg00677455	chr12:58241039	CTDSP2	-0.69	-10.66	-0.5	5.01e-23	Multiple sclerosis;
LUSC	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg06544989	chr22:39130855	UNC84B	0.33	5.68	0.3	2.91e-8	Menopause (age at onset);
LUSC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg14416269	chr4:6271139	WFS1	-0.5	-10.33	-0.49	6.79e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg17971929	chr21:40555470	PSMG1	-0.63	-10.31	-0.49	8.12e-22	Cognitive function;
LUSC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg08470875	chr2:26401718	FAM59B	-0.68	-9.35	-0.46	1.32e-18	Gut microbiome composition (summer);
LUSC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.66	-0.39	1.97e-13	Height;
LUSC	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.61	10.29	0.49	9.22e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg08807101	chr21:30365312	RNF160	-0.54	-8.2	-0.41	5.09e-15	Dental caries;
LUSC	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.38	-0.42	1.49e-15	Total cholesterol levels;
LUSC	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg22906224	chr7:99728672	NA	0.48	6.68	0.34	1.03e-10	Coronary artery disease;
LUSC	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg10523679	chr1:76189770	ACADM	-0.49	-7.06	-0.36	9.81e-12	Daytime sleep phenotypes;
LUSC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	0.99	14.05	0.61	1.5e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-0.93	-13.76	-0.6	1.95e-34	Vitiligo;
LUSC	cis	rs16917546	1.000	rs10995249	chr10:64396916	C/T	cg03961010	chr10:64397487	ZNF365	-0.41	-6.53	-0.34	2.45e-10	Basal cell carcinoma;
LUSC	cis	rs13315871	0.929	rs11130628	chr3:58315835	T/C	cg20936604	chr3:58311152	NA	-0.72	-6.95	-0.36	1.87e-11	Cholesterol, total;
LUSC	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg26384229	chr12:38710491	ALG10B	0.58	8.76	0.43	1.03e-16	Bladder cancer;
LUSC	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg23649088	chr2:200775458	C2orf69	-0.58	-7.07	-0.36	8.87e-12	Schizophrenia;
LUSC	cis	rs62458065	0.713	rs62463968	chr7:32501242	G/A	cg20159608	chr7:32802032	NA	-0.73	-9.28	-0.45	2.15e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.19	30.8	0.86	1.26e-99	Testicular germ cell tumor;
LUSC	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg16576597	chr16:28551801	NUPR1	0.33	6.51	0.34	2.83e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	7.82	0.39	6.91e-14	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19346786	chr7:2764209	NA	-0.46	-7.72	-0.39	1.39e-13	Height;
LUSC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.53	7.8	0.39	7.88e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg24851651	chr11:66362959	CCS	0.55	8.0	0.4	2.09e-14	Airway imaging phenotypes;
LUSC	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg03465714	chr1:152285911	FLG	-0.4	-5.67	-0.3	3.07e-8	Atopic dermatitis;
LUSC	cis	rs6723226	0.772	rs2366894	chr2:32713706	A/T	cg02381751	chr2:32503542	YIPF4	0.58	8.86	0.44	4.85e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg12935359	chr14:103987150	CKB	-0.56	-8.67	-0.43	1.92e-16	Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09413313	chr11:28131866	METT5D1	-0.49	-7.42	-0.38	9.93e-13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.87	0.48	2.54e-20	Mean corpuscular volume;
LUSC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg13114125	chr14:105738426	BRF1	-0.9	-15.31	-0.64	1.85e-40	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	0.67	10.79	0.51	1.72e-23	Longevity;
LUSC	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg21293242	chr8:11204541	TDH	0.32	5.97	0.31	5.93e-9	Retinal vascular caliber;
LUSC	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg19743168	chr1:23544995	NA	0.4	7.96	0.4	2.78e-14	Height;
LUSC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg18350739	chr11:68623251	NA	-0.38	-6.72	-0.35	7.94e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg14525755	chr12:132671672	NA	0.34	6.1	0.32	2.92e-9	Anti-saccade response;
LUSC	cis	rs6845621	0.901	rs4697204	chr4:18921835	A/G	cg12196642	chr4:18937545	NA	0.35	6.63	0.34	1.36e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg18811423	chr2:55921094	PNPT1	-0.63	-8.52	-0.42	5.56e-16	Metabolic syndrome;
LUSC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	10.83	0.51	1.23e-23	Menopause (age at onset);
LUSC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.38	6.34	0.33	7.57e-10	Menopause (age at onset);
LUSC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg16584290	chr5:462447	EXOC3	-0.37	-6.38	-0.33	5.84e-10	Cystic fibrosis severity;
LUSC	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg19743168	chr1:23544995	NA	0.47	10.23	0.49	1.53e-21	Height;
LUSC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg05623727	chr3:50126028	RBM5	0.33	6.13	0.32	2.53e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg12480416	chr8:128806471	PVT1	0.39	6.06	0.31	3.71e-9	Triglycerides;
LUSC	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg02493740	chr2:85810744	VAMP5	0.36	6.47	0.33	3.48e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10789491	0.953	rs1866770	chr1:47182468	G/T	cg15501359	chr1:47185051	KIAA0494	0.81	11.35	0.53	1.79e-25	Response to hepatitis C treatment;
LUSC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg17279839	chr7:150038598	RARRES2	-0.41	-6.34	-0.33	7.28e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4664304	0.966	rs1397707	chr2:160760972	C/T	cg03641300	chr2:160917029	PLA2R1	-0.4	-6.49	-0.33	3.1e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg04450456	chr4:17643702	FAM184B	0.39	6.69	0.34	9.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.42	6.27	0.32	1.09e-9	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg00898013	chr13:113819073	PROZ	0.52	7.51	0.38	5.62e-13	Platelet distribution width;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg02666966	chr16:28857347	TUFM	0.41	6.48	0.33	3.21e-10	Asthma;
LUSC	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg00409905	chr10:38381863	ZNF37A	-0.35	-5.98	-0.31	5.62e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.63	0.34	1.34e-10	Lung cancer;
LUSC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg14784868	chr12:69753453	YEATS4	0.63	8.79	0.43	8.24e-17	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg24675056	chr1:15929824	NA	0.46	8.03	0.4	1.69e-14	Systolic blood pressure;
LUSC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.54	-0.53	3.66e-26	Mean corpuscular volume;
LUSC	cis	rs12681287	0.640	rs13251006	chr8:87469105	C/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.45	-0.38	7.92e-13	Caudate activity during reward;
LUSC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg13047869	chr3:10149882	C3orf24	0.61	8.57	0.42	4.03e-16	Alzheimer's disease;
LUSC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg09021430	chr5:549028	NA	0.55	7.55	0.38	4.13e-13	Obesity-related traits;
LUSC	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.62	-9.43	-0.46	7.08e-19	Response to antineoplastic agents;
LUSC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg12935359	chr14:103987150	CKB	0.6	9.56	0.46	2.72e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg21251018	chr6:28226885	NKAPL	0.3	5.66	0.3	3.21e-8	Pubertal anthropometrics;
LUSC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.21	30.68	0.86	3.34e-99	Testicular germ cell tumor;
LUSC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.09e-18	Menopause (age at onset);
LUSC	cis	rs6545883	0.965	rs3771261	chr2:61762161	A/G	cg15711740	chr2:61764176	XPO1	-0.49	-7.77	-0.39	9.91e-14	Tuberculosis;
LUSC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg09034736	chr1:150693464	HORMAD1	0.51	7.51	0.38	5.57e-13	Tonsillectomy;
LUSC	cis	rs7523050	0.730	rs67312582	chr1:109423976	A/G	cg08274380	chr1:109419600	GPSM2	1.13	11.51	0.53	4.76e-26	Fat distribution (HIV);
LUSC	cis	rs16867335	1.000	rs72884242	chr2:181465486	A/T	cg23363182	chr2:181467187	NA	-0.46	-5.87	-0.31	1.05e-8	Survival in rectal cancer;
LUSC	cis	rs12541635	0.513	rs7841482	chr8:106992286	T/C	cg10147462	chr8:107024639	NA	0.4	5.86	0.31	1.08e-8	Age of smoking initiation;
LUSC	trans	rs877282	0.853	rs4579862	chr10:753298	A/C	cg22713356	chr15:30763199	NA	0.96	12.36	0.56	3.6e-29	Uric acid levels;
LUSC	trans	rs10098647	0.603	rs11774878	chr8:61111576	G/A	cg09970348	chr3:183978600	ECE2;CAMK2N2	0.46	6.15	0.32	2.26e-9	Obesity-related traits;
LUSC	cis	rs2708377	0.929	rs73053785	chr12:11162411	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.82	8.17	0.41	6.33e-15	Bitter taste perception;
LUSC	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg02023728	chr11:77925099	USP35	0.46	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg22437258	chr11:111473054	SIK2	0.51	6.91	0.35	2.42e-11	Primary sclerosing cholangitis;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03132089	chr20:55926498	RAE1	0.78	6.35	0.33	6.9e-10	Cognitive performance;
LUSC	cis	rs1808579	1.000	rs1808579	chr18:21104888	C/T	cg14672496	chr18:21087552	C18orf8	0.35	6.02	0.31	4.65e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg00982548	chr2:198649783	BOLL	-0.58	-7.2	-0.37	3.9e-12	Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg11062466	chr8:58055876	NA	0.65	8.33	0.41	2.12e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg00806126	chr19:22604979	ZNF98	0.37	5.75	0.3	1.97e-8	Pain;
LUSC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.01	-0.31	4.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12760731	0.720	rs10913552	chr1:178411543	G/A	cg00404053	chr1:178313656	RASAL2	0.55	6.21	0.32	1.55e-9	Obesity-related traits;
LUSC	cis	rs4845570	0.920	rs10788809	chr1:151760792	A/G	cg07092448	chr1:151763213	TDRKH	1.27	14.77	0.63	2.37e-38	Coronary artery disease;
LUSC	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg06627628	chr2:24431161	ITSN2	-0.86	-12.07	-0.55	4.48e-28	Asthma;
LUSC	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg05283184	chr6:79620031	NA	-0.57	-12.13	-0.55	2.55e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg25258033	chr6:167368657	RNASET2	0.46	7.67	0.39	1.91e-13	Crohn's disease;
LUSC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg01097406	chr16:89675127	NA	-0.34	-6.82	-0.35	4.39e-11	Vitiligo;
LUSC	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg15557168	chr22:42548783	NA	0.35	5.82	0.3	1.41e-8	Cognitive function;
LUSC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08280861	chr8:58055591	NA	0.54	5.66	0.3	3.23e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21582582	chr3:182698605	DCUN1D1	0.46	8.24	0.41	3.84e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.11	-0.55	3.12e-28	Mean corpuscular volume;
LUSC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg08859206	chr1:53392774	SCP2	0.51	8.82	0.43	6.65e-17	Monocyte count;
LUSC	cis	rs72949976	0.646	rs13029384	chr2:214029164	G/A	cg08319019	chr2:214017104	IKZF2	0.67	11.14	0.52	1.02e-24	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs4903604	0.581	rs4903606	chr14:78036935	A/G	cg18872420	chr14:78023429	SPTLC2	0.38	5.87	0.31	1.04e-8	Gut microbiome composition (winter);
LUSC	trans	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg02113368	chr10:135107346	TUBGCP2	-0.34	-5.95	-0.31	6.71e-9	Dementia with Lewy bodies;
LUSC	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg23093090	chr10:104574429	C10orf26	-0.47	-8.34	-0.42	2.02e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg09904177	chr6:26538194	HMGN4	0.76	14.14	0.61	6.79e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs2274273	0.588	rs2297816	chr14:55833038	A/G	cg04306507	chr14:55594613	LGALS3	0.47	9.11	0.45	7.86e-18	Protein biomarker;
LUSC	cis	rs7949030	0.964	rs2957122	chr11:62392100	G/C	cg11742103	chr11:62369870	EML3;MTA2	-0.48	-8.14	-0.41	7.78e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.24	-0.45	2.89e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg11716681	chr21:18884682	CXADR	-0.41	-6.01	-0.31	4.82e-9	Parental extreme longevity (95 years and older);
LUSC	cis	rs11608355	1.000	rs11608355	chr12:109879292	T/C	cg05360138	chr12:110035743	NA	0.45	6.26	0.32	1.15e-9	Neuroticism;
LUSC	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.11	-0.36	7.29e-12	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.74	0.3	2.08e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-9.16	-0.45	5.26e-18	Neuroticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09302904	chr17:62340561	TEX2	0.41	6.03	0.31	4.39e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs68170813	0.563	rs6979198	chr7:107197694	T/G	cg02696742	chr7:106810147	HBP1	-0.68	-9.94	-0.48	1.48e-20	Coronary artery disease;
LUSC	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.46	-0.42	8.33e-16	Response to antipsychotic treatment;
LUSC	trans	rs7939886	0.920	rs79521305	chr11:55811332	G/A	cg15704280	chr7:45808275	SEPT13	0.83	6.92	0.35	2.38e-11	Myopia (pathological);
LUSC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg20908204	chr19:46285434	DMPK	-0.45	-8.37	-0.42	1.61e-15	Coronary artery disease;
LUSC	trans	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg18187862	chr3:45730750	SACM1L	-0.52	-6.3	-0.33	9.38e-10	Primary sclerosing cholangitis;
LUSC	cis	rs11676348	0.808	rs4674261	chr2:219005009	G/C	cg06547715	chr2:218990976	CXCR2	0.31	5.86	0.31	1.14e-8	Ulcerative colitis;
LUSC	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg10356904	chr22:49881777	NA	-0.28	-5.72	-0.3	2.34e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg09184832	chr6:79620586	NA	-0.44	-6.84	-0.35	3.73e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg25039879	chr17:56429692	SUPT4H1	0.65	8.58	0.42	3.66e-16	Cognitive test performance;
LUSC	cis	rs1775715	0.870	rs1755080	chr10:32255195	G/A	cg04359828	chr10:32216031	ARHGAP12	0.38	6.24	0.32	1.33e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg21211680	chr2:198530	NA	0.53	6.44	0.33	4.26e-10	Blood protein levels;
LUSC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.68	-11.48	-0.53	6.36e-26	Systemic lupus erythematosus;
LUSC	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg16329650	chr2:213403929	ERBB4	0.86	18.62	0.71	1.47e-53	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg12856521	chr11:46389249	DGKZ	0.41	6.52	0.34	2.54e-10	Leprosy;
LUSC	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.12e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg26528668	chr16:1614120	IFT140	0.42	7.12	0.36	6.79e-12	Coronary artery disease;
LUSC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg22903471	chr2:27725779	GCKR	-0.41	-6.92	-0.35	2.3e-11	Total body bone mineral density;
LUSC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg14552801	chr7:65878734	NA	0.38	6.0	0.31	5.06e-9	Aortic root size;
LUSC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	6.81	0.35	4.56e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.24	-0.41	4.07e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs73206853	0.698	rs1018133	chr12:111121302	G/C	cg12870014	chr12:110450643	ANKRD13A	0.67	7.36	0.37	1.45e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg08000102	chr2:233561755	GIGYF2	-0.51	-7.86	-0.39	5.45e-14	Coronary artery disease;
LUSC	cis	rs28830936	1.000	rs11070343	chr15:41940146	T/A	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.5	-0.34	2.95e-10	Diastolic blood pressure;
LUSC	cis	rs4474465	0.850	rs7122676	chr11:78268525	A/G	cg27205649	chr11:78285834	NARS2	0.53	6.3	0.33	9.42e-10	Alzheimer's disease (survival time);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13110350	chr12:46383601	SFRS2IP	-0.39	-5.95	-0.31	6.75e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7799006	0.964	rs3757440	chr7:2272936	A/G	cg08027265	chr7:2291960	NA	-0.39	-6.86	-0.35	3.35e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.47	7.48	0.38	6.58e-13	Menarche (age at onset);
LUSC	cis	rs7568458	0.516	rs62166769	chr2:85812784	T/A	cg17127132	chr2:85788382	GGCX	0.41	6.0	0.31	5.13e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.61	-0.38	2.77e-13	Morning vs. evening chronotype;
LUSC	cis	rs1018836	0.773	rs7837109	chr8:91639178	C/T	cg16814680	chr8:91681699	NA	-0.78	-13.01	-0.58	1.39e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg07460842	chr6:66804631	NA	0.47	5.8	0.3	1.53e-8	Metabolite levels;
LUSC	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg23625390	chr15:77176239	SCAPER	0.53	8.37	0.42	1.55e-15	Blood metabolite levels;
LUSC	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg13010199	chr12:38710504	ALG10B	-0.62	-10.36	-0.49	5.5e-22	Heart rate;
LUSC	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-6.15	-0.32	2.27e-9	IgG glycosylation;
LUSC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	1.11	25.05	0.81	1.11e-78	Testicular germ cell tumor;
LUSC	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.02	-0.36	1.24e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-5.91	-0.31	8.33e-9	Bipolar disorder;
LUSC	cis	rs12472274	0.536	rs12619455	chr2:239080149	A/C	cg17459225	chr2:239074497	NA	0.57	7.57	0.38	3.71e-13	Phospholipid levels (plasma);
LUSC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg10130564	chr11:117069849	TAGLN	0.38	6.65	0.34	1.17e-10	Blood protein levels;
LUSC	cis	rs193541	0.626	rs6869140	chr5:122088686	A/G	cg19077854	chr5:122220652	SNX24	-0.29	-6.4	-0.33	5.3e-10	Glucose homeostasis traits;
LUSC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23221052	chr5:179740743	GFPT2	-0.56	-8.73	-0.43	1.2e-16	Height;
LUSC	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg24579218	chr15:68104479	NA	-0.4	-7.05	-0.36	1.02e-11	Restless legs syndrome;
LUSC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg05393297	chr12:53359155	NA	-0.74	-11.43	-0.53	9e-26	Cancer (pleiotropy);
LUSC	cis	rs1595825	0.735	rs6434955	chr2:198946551	G/A	cg00982548	chr2:198649783	BOLL	-0.54	-6.67	-0.34	1.08e-10	Ulcerative colitis;
LUSC	trans	rs9910292	0.591	rs8074010	chr17:31358083	A/G	cg03789507	chr8:136667083	NA	0.48	6.13	0.32	2.44e-9	Mosquito bite size;
LUSC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	trans	rs1973993	0.651	rs60776572	chr1:96960121	C/T	cg10631902	chr5:14652156	NA	-0.46	-6.8	-0.35	4.72e-11	Weight;
LUSC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.89	14.57	0.62	1.41e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs2580764	0.540	rs10174838	chr2:55241216	A/T	cg09592903	chr2:55203963	RTN4	-0.49	-9.99	-0.48	1.02e-20	Mean platelet volume;
LUSC	cis	rs7202877	0.610	rs1010631	chr16:75328590	C/G	cg04384234	chr16:75411784	CFDP1	-0.62	-8.66	-0.43	2.05e-16	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.7	0.3	2.62e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.03	0.36	1.18e-11	Multiple sclerosis;
LUSC	cis	rs3808502	0.534	rs1529858	chr8:11145662	G/T	cg21775007	chr8:11205619	TDH	0.5	7.03	0.36	1.15e-11	Neuroticism;
LUSC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg25811766	chr13:21894605	NA	0.62	9.56	0.46	2.6e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg20703242	chr1:230279135	GALNT2	0.57	8.71	0.43	1.39e-16	Coronary artery disease;
LUSC	trans	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.95	0.36	1.87e-11	Endometrial cancer;
LUSC	cis	rs113835537	0.935	rs79106199	chr11:66420518	T/C	cg24851651	chr11:66362959	CCS	0.53	6.54	0.34	2.38e-10	Airway imaging phenotypes;
LUSC	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-1.15	-18.02	-0.7	3.41e-51	Exhaled nitric oxide output;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04869497	chr17:20059225	CYTSB	-0.44	-6.28	-0.32	1.03e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	14.15	0.61	6.37e-36	Alzheimer's disease;
LUSC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.86	-13.29	-0.59	1.22e-32	Cognitive test performance;
LUSC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg12927641	chr6:109611667	NA	-0.43	-7.47	-0.38	7.04e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-6.36	-0.33	6.49e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02176678	chr2:219576539	TTLL4	0.64	11.53	0.53	4.11e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg04362960	chr10:104952993	NT5C2	0.66	9.15	0.45	5.6e-18	Arsenic metabolism;
LUSC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.85	-14.19	-0.61	4.47e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11264799	0.603	rs12733062	chr1:157585932	C/A	cg18268488	chr1:157545234	FCRL4	0.35	6.51	0.34	2.82e-10	IgA nephropathy;
LUSC	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.81	0.51	1.45e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg13256891	chr4:100009986	ADH5	0.51	6.96	0.36	1.79e-11	Smoking initiation;
LUSC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02353165	chr6:42928485	GNMT	0.76	13.76	0.6	1.94e-34	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1790761	0.967	rs1808279	chr11:67211569	T/C	cg24690094	chr11:67383802	NA	-0.32	-5.86	-0.31	1.12e-8	Mean corpuscular volume;
LUSC	cis	rs9616064	0.889	rs7284276	chr22:46996137	G/C	cg25730555	chr22:47059586	GRAMD4	0.44	6.57	0.34	1.88e-10	Urate levels in obese individuals;
LUSC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	0.63	13.45	0.59	2.99e-33	Prudent dietary pattern;
LUSC	cis	rs3772130	0.540	rs7627354	chr3:121562434	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.83	13.54	0.6	1.29e-33	Cognitive performance;
LUSC	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg23601095	chr6:26197514	HIST1H3D	0.7	7.53	0.38	4.89e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs6066835	1.000	rs6063314	chr20:47353106	T/C	cg18078177	chr20:47281410	PREX1	0.71	6.21	0.32	1.61e-9	Multiple myeloma;
LUSC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg22535103	chr8:58192502	C8orf71	-0.62	-6.98	-0.36	1.62e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg09754948	chr16:28834200	ATXN2L	0.43	6.24	0.32	1.34e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg11502198	chr6:26597334	ABT1	0.6	9.37	0.46	1.15e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs4343996	0.714	rs10268837	chr7:3467366	T/C	cg21248987	chr7:3385318	SDK1	0.34	5.7	0.3	2.64e-8	Motion sickness;
LUSC	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg06191203	chr2:152266755	RIF1	-0.53	-7.1	-0.36	7.36e-12	Lung cancer;
LUSC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.49	-7.96	-0.4	2.64e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg14830002	chr1:247616686	OR2B11	0.51	7.05	0.36	1.06e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg02772935	chr3:125709198	NA	-0.49	-5.87	-0.31	1.06e-8	Blood pressure (smoking interaction);
LUSC	cis	rs17828380	1.000	rs35446744	chr15:63509930	T/C	cg05507819	chr15:63340323	TPM1	-0.7	-5.9	-0.31	8.94e-9	Social communication problems;
LUSC	cis	rs1322512	0.874	rs1407483	chr6:152963780	C/T	cg27316956	chr6:152958899	SYNE1	-0.37	-6.32	-0.33	8.6e-10	Tonometry;
LUSC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07157834	chr1:205819609	PM20D1	-0.53	-8.23	-0.41	4.31e-15	Menarche (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24953233	chr5:892707	TRIP13;BRD9	-0.42	-6.41	-0.33	4.84e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs72674100	1.000	rs17026376	chr4:97993847	G/A	cg09670535	chr1:18959427	PAX7	-0.61	-6.23	-0.32	1.41e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10193935	0.892	rs7574609	chr2:42388468	C/A	cg27598129	chr2:42591480	NA	-0.59	-8.1	-0.41	1.01e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11958404	0.932	rs72818109	chr5:157438340	A/T	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg23625390	chr15:77176239	SCAPER	-0.47	-6.9	-0.35	2.55e-11	Blood metabolite levels;
LUSC	cis	rs3106136	0.934	rs2902979	chr4:95177874	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.36	-6.31	-0.33	9.01e-10	Capecitabine sensitivity;
LUSC	cis	rs295140	0.605	rs34693942	chr2:201184348	T/C	cg04283868	chr2:201171347	SPATS2L	0.39	5.72	0.3	2.34e-8	QT interval;
LUSC	cis	rs477692	0.967	rs496692	chr10:131429100	C/T	cg26102564	chr10:131424627	MGMT	0.41	6.4	0.33	5.33e-10	Response to temozolomide;
LUSC	cis	rs13401104	0.796	rs72620807	chr2:237114205	T/G	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.35e-8	Educational attainment;
LUSC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg00012203	chr2:219082015	ARPC2	-0.69	-11.35	-0.53	1.78e-25	Colorectal cancer;
LUSC	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg24851651	chr11:66362959	CCS	-0.38	-6.07	-0.32	3.42e-9	Educational attainment (years of education);
LUSC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg06064525	chr11:970664	AP2A2	-0.35	-7.16	-0.36	5.14e-12	Alzheimer's disease (late onset);
LUSC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg11211951	chr8:145729740	GPT	-0.58	-11.23	-0.52	4.97e-25	Age at first birth;
LUSC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg04944784	chr2:26401820	FAM59B	0.72	8.76	0.43	9.83e-17	Gut microbiome composition (summer);
LUSC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg16447950	chr5:562315	NA	-0.59	-7.06	-0.36	9.96e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.87	10.06	0.48	5.67e-21	Body mass index;
LUSC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg21963583	chr11:68658836	MRPL21	0.55	8.23	0.41	4.19e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg22532475	chr10:104410764	TRIM8	-0.35	-7.76	-0.39	1.01e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6076065	0.894	rs2243448	chr20:23378345	G/A	cg11657817	chr20:23433608	CST11	0.53	11.03	0.52	2.42e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg19678392	chr7:94953810	PON1	-0.36	-5.68	-0.3	3.01e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.52	-8.11	-0.41	1e-14	Platelet count;
LUSC	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg25206134	chr2:45395956	NA	0.52	6.06	0.31	3.71e-9	Bipolar disorder;
LUSC	cis	rs9788721	0.775	rs12914385	chr15:78898723	C/T	cg18825076	chr15:78729989	IREB2	-0.51	-7.96	-0.4	2.75e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs6969780	0.778	rs79619106	chr7:27146328	A/C	cg26364809	chr7:27145159	NA	-0.59	-5.98	-0.31	5.69e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs73198271	0.694	rs114184516	chr8:8647082	A/G	cg01851573	chr8:8652454	MFHAS1	0.52	8.12	0.41	9.04e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	9.36	0.46	1.17e-18	Menopause (age at onset);
LUSC	cis	rs7523273	0.606	rs2796263	chr1:207915978	T/C	cg22525895	chr1:207977042	MIR29B2	0.4	6.62	0.34	1.42e-10	Schizophrenia;
LUSC	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg08917208	chr2:24149416	ATAD2B	0.87	9.69	0.47	9.99e-20	Lymphocyte counts;
LUSC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg09608765	chr3:45636137	LIMD1	-0.39	-7.83	-0.39	6.72e-14	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg25643088	chr3:52874325	TMEM110	0.39	5.82	0.3	1.4e-8	Schizophrenia;
LUSC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.67	11.9	0.55	1.85e-27	Aortic root size;
LUSC	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	9.24	0.45	3.04e-18	Neuroticism;
LUSC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg25743719	chr2:10443138	HPCAL1	-0.47	-6.19	-0.32	1.75e-9	Height;
LUSC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.8	-14.45	-0.62	4.18e-37	Cognitive function;
LUSC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg06671706	chr8:8559999	CLDN23	0.51	6.86	0.35	3.32e-11	Obesity-related traits;
LUSC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg03146154	chr1:46216737	IPP	0.51	7.6	0.38	3.05e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs911119	1.000	rs1064039	chr20:23618427	C/T	cg16589663	chr20:23618590	CST3	0.6	7.08	0.36	8.36e-12	Chronic kidney disease;
LUSC	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg06623918	chr6:96969491	KIAA0776	-0.67	-7.83	-0.39	6.38e-14	Migraine;Coronary artery disease;
LUSC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.96	-15.49	-0.65	3.54e-41	Coronary artery disease;
LUSC	cis	rs77861329	1.000	rs352148	chr3:52208898	A/G	cg08692210	chr3:52188851	WDR51A	0.86	7.38	0.37	1.27e-12	Macrophage inflammatory protein 1b levels;
LUSC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg03804128	chr16:635623	NA	0.32	6.51	0.34	2.8e-10	Height;
LUSC	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg07150166	chr2:30669952	LCLAT1	0.63	6.86	0.35	3.41e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg16060761	chr17:80687452	NA	-0.4	-6.2	-0.32	1.65e-9	Breast cancer;
LUSC	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.23	0.52	4.84e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg15605315	chr1:45957053	TESK2	0.51	8.5	0.42	6.26e-16	High light scatter reticulocyte count;
LUSC	cis	rs3733606	0.503	rs11731274	chr4:6891455	T/G	cg05012661	chr4:6891264	NA	0.56	7.93	0.4	3.28e-14	Platelet count;
LUSC	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.59	-8.27	-0.41	3.31e-15	Gut microbiome composition (winter);
LUSC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.69	-10.09	-0.48	4.37e-21	Systemic lupus erythematosus;
LUSC	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.64	9.71	0.47	8.83e-20	Schizophrenia;
LUSC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	13.18	0.58	3.15e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.52	3.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2820315	1.000	rs2644107	chr1:201818629	T/C	cg10061532	chr1:201886748	LMOD1	0.25	5.67	0.3	3.07e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs2055729	1.000	rs2055729	chr8:9792662	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.06	-0.31	3.74e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9311676	0.656	rs62258102	chr3:58378784	T/C	cg13750441	chr3:58318267	PXK	0.36	7.06	0.36	9.88e-12	Systemic lupus erythematosus;
LUSC	cis	rs7177699	0.557	rs12898712	chr15:79112622	G/T	cg00540400	chr15:79124168	NA	0.46	7.98	0.4	2.33e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs738322	0.810	rs4820323	chr22:38599767	C/G	cg17652424	chr22:38574118	PLA2G6	0.28	5.68	0.3	2.9e-8	Cutaneous nevi;
LUSC	cis	rs2797160	1.000	rs77678056	chr6:126019738	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.55	0.42	4.55e-16	Endometrial cancer;
LUSC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9463078	0.605	rs9472409	chr6:44926431	A/G	cg25276700	chr6:44698697	NA	0.28	5.92	0.31	8.11e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs1808579	0.904	rs1788761	chr18:21133084	A/G	cg14672496	chr18:21087552	C18orf8	0.38	6.68	0.34	9.81e-11	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs11166629	1.000	rs6577713	chr8:135645592	C/A	cg27224718	chr8:135614730	ZFAT	0.65	10.8	0.51	1.64e-23	Smoking quantity;
LUSC	cis	rs75920871	0.528	rs7935834	chr11:116944437	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.52	-0.34	2.56e-10	Subjective well-being;
LUSC	cis	rs76878669	0.561	rs10750784	chr11:66110666	A/G	cg24851651	chr11:66362959	CCS	0.36	5.7	0.3	2.67e-8	Educational attainment (years of education);
LUSC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.79	-12.47	-0.56	1.41e-29	Pancreatic cancer;
LUSC	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg04998671	chr14:104000505	TRMT61A	0.4	5.81	0.3	1.44e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg25767906	chr1:53392781	SCP2	0.39	6.64	0.34	1.29e-10	Monocyte count;
LUSC	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg05110241	chr16:68378359	PRMT7	0.69	7.39	0.38	1.16e-12	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs2490361	1.000	rs2485595	chr1:237326756	G/A	cg21969473	chr17:17140219	FLCN	0.37	6.07	0.32	3.41e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.77	-0.51	2.07e-23	Eye color traits;
LUSC	cis	rs1712517	0.771	rs10883857	chr10:105127587	A/C	cg05636881	chr10:105038444	INA	-0.38	-6.3	-0.33	9.33e-10	Migraine;
LUSC	cis	rs11997175	0.646	rs67480501	chr8:33736315	C/T	ch.8.33884649F	chr8:33765107	NA	0.53	8.04	0.4	1.6e-14	Body mass index;
LUSC	cis	rs75920871	0.502	rs7124996	chr11:116928006	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-6.32	-0.33	8.51e-10	Subjective well-being;
LUSC	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg13010199	chr12:38710504	ALG10B	0.62	9.23	0.45	3.2e-18	Bladder cancer;
LUSC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg14416269	chr4:6271139	WFS1	0.53	11.29	0.53	2.9e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg26528668	chr16:1614120	IFT140	0.42	7.12	0.36	6.79e-12	Coronary artery disease;
LUSC	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg15103426	chr22:29168792	CCDC117	0.51	6.41	0.33	4.97e-10	Lymphocyte counts;
LUSC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.84	-0.35	3.84e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7727544	0.582	rs2278398	chr5:131530441	C/T	cg14196790	chr5:131705035	SLC22A5	-0.42	-7.13	-0.36	6.29e-12	Blood metabolite levels;
LUSC	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-9.1	-0.45	8.5e-18	Response to antipsychotic treatment;
LUSC	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	0.99	20.51	0.75	4.32e-61	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.21	0.32	1.54e-9	Personality dimensions;
LUSC	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg04310649	chr10:35416472	CREM	-0.41	-6.47	-0.33	3.48e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12145833	0.596	rs12134228	chr1:243447618	C/T	cg02356786	chr1:243265016	LOC731275	0.66	6.32	0.33	8.59e-10	Obesity (early onset extreme);
LUSC	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg15133208	chr4:90757351	SNCA	-0.54	-8.24	-0.41	3.96e-15	Neuroticism;
LUSC	cis	rs10979	1.000	rs12191231	chr6:143891114	A/C	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg20283391	chr11:68216788	NA	0.54	8.12	0.41	9.02e-15	Total body bone mineral density;
LUSC	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg05887092	chr17:76393375	PGS1	0.53	9.36	0.46	1.22e-18	HDL cholesterol levels;
LUSC	cis	rs6893807	0.778	rs35991856	chr5:87968347	C/A	cg02225085	chr5:87975992	LOC645323	-0.47	-5.94	-0.31	7.31e-9	Body mass index;
LUSC	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg02269571	chr22:50332266	NA	0.58	7.48	0.38	6.75e-13	Schizophrenia;
LUSC	cis	rs8141797	0.901	rs8138467	chr22:24458096	A/G	cg00411358	chr22:24577142	SUSD2	0.62	6.08	0.32	3.31e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-8.01	-0.4	1.91e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.38	-5.64	-0.3	3.58e-8	Schizophrenia;
LUSC	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg11693508	chr17:37793320	STARD3	0.52	6.43	0.33	4.41e-10	Bipolar disorder;
LUSC	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg16701003	chr16:89028210	CBFA2T3	0.32	5.67	0.3	3.04e-8	Social autistic-like traits;
LUSC	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21545522	chr1:205238299	TMCC2	0.51	9.63	0.47	1.51e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg26876637	chr1:152193138	HRNR	-0.43	-6.2	-0.32	1.67e-9	Atopic dermatitis;
LUSC	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg16099169	chr2:106886729	NA	-0.55	-7.08	-0.36	8.48e-12	Facial morphology (factor 23);
LUSC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg00784671	chr22:46762841	CELSR1	-0.48	-6.49	-0.33	3.15e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs35995292	0.534	rs11980627	chr7:38907533	T/C	cg19327137	chr7:38886074	VPS41	0.54	10.32	0.49	7.22e-22	Subjective well-being (multi-trait analysis);
LUSC	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-0.63	-9.85	-0.47	2.99e-20	Response to antineoplastic agents;
LUSC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg08088566	chr11:430123	ANO9	0.6	7.04	0.36	1.09e-11	Body mass index;
LUSC	cis	rs7119	0.717	rs12904584	chr15:77815991	C/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.84	-17.3	-0.69	2.58e-48	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs66887589	0.776	rs10518337	chr4:120574874	A/C	cg09307838	chr4:120376055	NA	-0.48	-6.9	-0.35	2.67e-11	Diastolic blood pressure;
LUSC	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg09092052	chr15:45571596	NA	0.45	6.26	0.32	1.18e-9	Glomerular filtration rate;
LUSC	cis	rs116988415	0.584	rs17180252	chr14:65239316	G/A	cg00114569	chr14:65239327	SPTB	0.7	6.78	0.35	5.46e-11	Daytime sleep phenotypes;
LUSC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg26384229	chr12:38710491	ALG10B	-0.83	-14.16	-0.61	5.82e-36	Morning vs. evening chronotype;
LUSC	cis	rs4523957	0.890	rs9895551	chr17:2115922	C/G	cg16513277	chr17:2031491	SMG6	0.58	9.53	0.46	3.27e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs728616	0.558	rs34268041	chr10:82148639	A/G	cg05935833	chr10:81318306	SFTPA2	-0.43	-5.73	-0.3	2.28e-8	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	0.98	21.45	0.76	8.76e-65	Menarche (age at onset);
LUSC	cis	rs7927771	0.524	rs2242081	chr11:47500267	T/C	cg20307385	chr11:47447363	PSMC3	0.44	6.45	0.33	4.01e-10	Subjective well-being;
LUSC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.73	-11.36	-0.53	1.72e-25	Corneal astigmatism;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg04625536	chr6:42533006	UBR2	0.36	6.23	0.32	1.37e-9	Tuberculosis;
LUSC	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg23625390	chr15:77176239	SCAPER	0.54	8.49	0.42	6.9e-16	Blood metabolite levels;
LUSC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-1.06	-20.24	-0.74	5.15e-60	Coronary artery disease;
LUSC	cis	rs73198271	0.515	rs11779327	chr8:8624955	G/C	cg01851573	chr8:8652454	MFHAS1	0.62	7.15	0.36	5.52e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.83	-0.39	6.48e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg21775007	chr8:11205619	TDH	-0.44	-6.05	-0.31	3.98e-9	Myopia (pathological);
LUSC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Depression;
LUSC	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-0.8	-13.39	-0.59	5.02e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg13010199	chr12:38710504	ALG10B	0.48	7.4	0.38	1.13e-12	Morning vs. evening chronotype;
LUSC	cis	rs9309473	0.606	rs78941213	chr2:73885137	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-5.87	-0.31	1.06e-8	Metabolite levels;
LUSC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.67	6.4	0.33	5.12e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	11.71	0.54	8.69e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2274273	0.624	rs7151581	chr14:55788445	A/G	cg04306507	chr14:55594613	LGALS3	-0.49	-9.73	-0.47	7.06e-20	Protein biomarker;
LUSC	cis	rs7584330	0.554	rs9646716	chr2:238443784	C/T	cg14458575	chr2:238380390	NA	0.43	5.73	0.3	2.27e-8	Prostate cancer;
LUSC	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg10523679	chr1:76189770	ACADM	-0.45	-6.52	-0.34	2.53e-10	Daytime sleep phenotypes;
LUSC	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg17366294	chr4:99064904	C4orf37	0.56	8.71	0.43	1.43e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.45	-0.33	3.94e-10	Bladder cancer;
LUSC	cis	rs7589342	0.509	rs10168944	chr2:106386067	T/C	cg09152813	chr2:106391379	NCK2	-0.37	-6.07	-0.32	3.43e-9	Addiction;
LUSC	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.69	-0.34	9.45e-11	Breast cancer;
LUSC	cis	rs3862435	0.572	rs2601163	chr15:90908200	A/G	cg22089800	chr15:90895588	ZNF774	-0.55	-6.08	-0.32	3.25e-9	Response to exercise (triglyceride level interaction);
LUSC	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg27661571	chr11:113659931	NA	-0.59	-7.18	-0.37	4.61e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg16624210	chr5:671434	TPPP	0.49	6.41	0.33	5.06e-10	Obesity-related traits;
LUSC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg01879757	chr17:41196368	BRCA1	-0.48	-7.71	-0.39	1.49e-13	Menopause (age at onset);
LUSC	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg20607287	chr7:12443886	VWDE	-0.63	-6.23	-0.32	1.44e-9	Coronary artery disease;
LUSC	cis	rs1113500	0.862	rs3853494	chr1:108637334	G/A	cg11967332	chr1:108735228	SLC25A24	0.39	5.97	0.31	6.23e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs7818345	0.874	rs12674938	chr8:19300813	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	7.37	0.37	1.36e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.46	-0.38	7.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.26	-0.32	1.2e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg00898013	chr13:113819073	PROZ	0.54	8.2	0.41	5.35e-15	Platelet distribution width;
LUSC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg05347473	chr6:146136440	FBXO30	0.53	8.91	0.44	3.27e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg24476569	chr13:95954382	ABCC4	-0.48	-7.81	-0.39	7.4e-14	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4683142	0.518	rs4682801	chr3:46021218	G/T	cg19145607	chr3:45983792	CXCR6;FYCO1	0.36	5.96	0.31	6.3e-9	Methadone dose in opioid dependence;
LUSC	cis	rs11676348	0.755	rs62183956	chr2:219046122	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.39	6.12	0.32	2.66e-9	Ulcerative colitis;
LUSC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg16606324	chr3:10149918	C3orf24	0.71	9.96	0.48	1.2e-20	Alzheimer's disease;
LUSC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26314531	chr2:26401878	FAM59B	-0.72	-9.87	-0.48	2.4e-20	Gut microbiome composition (summer);
LUSC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.06e-12	Motion sickness;
LUSC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.38	0.33	5.92e-10	Obesity-related traits;
LUSC	trans	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg18187862	chr3:45730750	SACM1L	0.53	6.82	0.35	4.28e-11	Primary sclerosing cholangitis;
LUSC	cis	rs4722585	0.533	rs2158359	chr7:26193309	A/C	cg07876897	chr7:26191696	NFE2L3	-0.43	-6.3	-0.33	9.13e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUSC	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg14092571	chr14:90743983	NA	0.37	6.05	0.31	3.79e-9	Mortality in heart failure;
LUSC	cis	rs8064299	0.655	rs12797	chr17:72766993	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.55	9.06	0.44	1.12e-17	Monocyte count;
LUSC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.96	0.4	2.64e-14	Prudent dietary pattern;
LUSC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.67	-0.39	1.9e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs4280164	0.551	rs2295300	chr14:24805117	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.56	-7.07	-0.36	9.27e-12	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs4523957	0.928	rs749240	chr17:2186100	A/G	cg16513277	chr17:2031491	SMG6	0.59	9.65	0.47	1.39e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs8030485	0.571	rs10775219	chr15:79443894	G/A	cg17916960	chr15:79447300	NA	0.33	5.74	0.3	2.16e-8	Left ventricle wall thickness;
LUSC	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.53	10.54	0.5	1.32e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg22437258	chr11:111473054	SIK2	-0.5	-6.31	-0.33	9.1e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.64	9.7	0.47	9.01e-20	Schizophrenia;
LUSC	trans	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.07	0.32	3.42e-9	Joint mobility (Beighton score);
LUSC	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	0.67	6.69	0.34	9.16e-11	Prostate cancer;
LUSC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg20849893	chr7:64541193	NA	-0.48	-7.12	-0.36	6.81e-12	Calcium levels;
LUSC	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.67	-0.3	3.03e-8	Recombination rate (females);
LUSC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1981331	1.000	rs79694455	chr21:47983979	C/T	cg23283320	chr21:48055893	PRMT2	1.12	8.03	0.4	1.68e-14	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg01802117	chr1:53393560	SCP2	0.38	6.21	0.32	1.53e-9	Monocyte count;
LUSC	cis	rs508618	0.638	rs479200	chr1:231543780	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-6.8	-0.35	4.72e-11	Red blood cell count;
LUSC	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg00277334	chr10:82204260	NA	-0.42	-5.95	-0.31	6.8e-9	Post bronchodilator FEV1;
LUSC	cis	rs67981189	0.593	rs12896829	chr14:71463676	G/C	cg15816911	chr14:71606274	NA	0.34	5.99	0.31	5.41e-9	Schizophrenia;
LUSC	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg02023728	chr11:77925099	USP35	0.47	7.06	0.36	9.75e-12	Testicular germ cell tumor;
LUSC	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.27	0.49	1.06e-21	Schizophrenia;
LUSC	cis	rs11608355	0.515	rs61941592	chr12:109930497	G/A	cg05360138	chr12:110035743	NA	0.92	12.2	0.56	1.41e-28	Neuroticism;
LUSC	cis	rs193541	0.632	rs400207	chr5:122318497	C/T	cg19077854	chr5:122220652	SNX24	-0.4	-8.45	-0.42	9.27e-16	Glucose homeostasis traits;
LUSC	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg23260525	chr10:116636907	FAM160B1	0.39	7.98	0.4	2.37e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg22437258	chr11:111473054	SIK2	0.51	6.91	0.35	2.42e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7523273	0.526	rs2724375	chr1:207997973	C/A	cg22525895	chr1:207977042	MIR29B2	-0.41	-6.74	-0.35	7.02e-11	Schizophrenia;
LUSC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	0.91	16.11	0.66	1.33e-43	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6543140	0.855	rs4851591	chr2:103077423	T/C	cg09003973	chr2:102972529	NA	0.55	7.04	0.36	1.09e-11	Blood protein levels;
LUSC	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.62	10.87	0.51	8.76e-24	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg09835421	chr16:68378352	PRMT7	0.82	8.96	0.44	2.33e-17	Schizophrenia;
LUSC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg11247378	chr22:39784982	NA	-0.67	-13.7	-0.6	3.21e-34	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg19812747	chr11:111475976	SIK2	-0.57	-8.44	-0.42	9.47e-16	Primary sclerosing cholangitis;
LUSC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg00933542	chr6:150070202	PCMT1	0.31	6.34	0.33	7.54e-10	Lung cancer;
LUSC	cis	rs7739264	0.602	rs9350179	chr6:19764095	G/A	cg02404759	chr6:19790362	NA	-0.43	-6.79	-0.35	5.16e-11	Endometriosis;
LUSC	cis	rs2282300	0.739	rs3858428	chr11:30296550	T/C	cg25418670	chr11:30344373	C11orf46	0.64	9.09	0.45	9.01e-18	Morning vs. evening chronotype;
LUSC	cis	rs701145	0.938	rs355776	chr3:154035626	A/T	cg17054900	chr3:154042577	DHX36	0.84	8.81	0.43	7.07e-17	Coronary artery disease;
LUSC	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg25797454	chr6:150327115	RAET1K	0.37	8.56	0.42	4.17e-16	Alopecia areata;
LUSC	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg13010199	chr12:38710504	ALG10B	-0.39	-6.26	-0.32	1.18e-9	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06634786	chr22:41940651	POLR3H	-0.57	-6.91	-0.35	2.52e-11	Vitiligo;
LUSC	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg16447950	chr5:562315	NA	-0.55	-7.64	-0.39	2.29e-13	Obesity-related traits;
LUSC	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg15556689	chr8:8085844	FLJ10661	0.56	8.54	0.42	4.93e-16	Retinal vascular caliber;
LUSC	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	6.92	0.35	2.36e-11	Response to antipsychotic treatment;
LUSC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg14552801	chr7:65878734	NA	0.46	6.58	0.34	1.79e-10	Aortic root size;
LUSC	cis	rs2279817	0.863	rs2354291	chr1:18027554	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.42	-6.39	-0.33	5.62e-10	Neuroticism;
LUSC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg18240062	chr17:79603768	NPLOC4	0.68	12.86	0.58	5.28e-31	Eye color traits;
LUSC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.59	-0.38	3.21e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg17366294	chr4:99064904	C4orf37	0.5	8.7	0.43	1.54e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1030268	0.607	rs34218501	chr7:133210375	G/A	cg10665199	chr7:133106180	EXOC4	0.57	6.57	0.34	1.99e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08109568	chr15:31115862	NA	-0.6	-8.31	-0.41	2.46e-15	Huntington's disease progression;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21528136	chr17:73901016	MRPL38	-0.5	-5.98	-0.31	5.7e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7178375	0.607	rs12903674	chr15:31194552	G/C	cg03767031	chr15:31195708	MTMR15	0.81	6.46	0.33	3.64e-10	Hypertriglyceridemia;
LUSC	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg14696996	chr19:15285081	NOTCH3	1.02	9.38	0.46	1.03e-18	Pulse pressure;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10886005	chr2:98612331	TMEM131	-0.41	-6.0	-0.31	5.03e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23158103	chr7:148848205	ZNF398	-0.43	-6.72	-0.35	7.88e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26365885	chr17:64188403	CCDC46	-0.43	-6.53	-0.34	2.42e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg16680214	chr1:154839983	KCNN3	-0.52	-9.76	-0.47	5.77e-20	Prostate cancer;
LUSC	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg04058563	chr4:185651563	MLF1IP	-0.41	-6.75	-0.35	6.6e-11	Kawasaki disease;
LUSC	cis	rs6942756	0.747	rs691124	chr7:129098439	A/G	cg02491457	chr7:128862824	NA	-0.42	-5.97	-0.31	6.12e-9	White matter hyperintensity burden;
LUSC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22590775	chr19:49891494	CCDC155	0.61	8.67	0.43	1.85e-16	Multiple sclerosis;
LUSC	cis	rs4919087	0.561	rs61861820	chr10:98998974	G/A	cg25902810	chr10:99078978	FRAT1	-0.42	-5.82	-0.3	1.41e-8	Monocyte count;
LUSC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg05084668	chr3:125655381	ALG1L	-0.49	-6.9	-0.35	2.55e-11	Blood pressure (smoking interaction);
LUSC	cis	rs72781680	0.752	rs72796110	chr2:23905658	T/A	cg20701182	chr2:24300061	SF3B14	0.73	7.05	0.36	1.06e-11	Lymphocyte counts;
LUSC	cis	rs500891	0.525	rs1145901	chr6:84038605	T/C	cg08257003	chr6:84140564	ME1	0.34	8.09	0.4	1.15e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg09650180	chr20:62225654	GMEB2	-0.66	-9.48	-0.46	4.74e-19	Glioblastoma;
LUSC	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg03342759	chr3:160939853	NMD3	-0.47	-7.98	-0.4	2.45e-14	Morning vs. evening chronotype;
LUSC	cis	rs3791556	0.661	rs3791539	chr2:240102327	C/T	cg03281426	chr2:240109471	HDAC4	0.45	6.62	0.34	1.43e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg23630131	chr7:65973040	NA	0.21	5.81	0.3	1.42e-8	Aortic root size;
LUSC	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg07148914	chr20:33460835	GGT7	-0.52	-8.11	-0.41	1e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	trans	rs9886428	1.000	rs4831569	chr8:14121952	C/A	cg11959399	chr20:741723	C20orf54	-0.4	-6.22	-0.32	1.48e-9	IgG glycosylation;
LUSC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg18758796	chr5:131593413	PDLIM4	0.34	5.74	0.3	2.09e-8	Blood metabolite levels;
LUSC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.09	-0.32	3.14e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs1171606	0.731	rs1171651	chr10:61449817	C/A	cg14119616	chr11:17099403	RPS13	-0.41	-6.17	-0.32	1.94e-9	Acylcarnitine levels;
LUSC	cis	rs4851254	0.579	rs78633727	chr2:100669457	T/C	cg07810366	chr2:100720526	AFF3	-0.47	-6.21	-0.32	1.59e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg06454157	chr6:167490870	NA	-0.26	-5.88	-0.31	1.02e-8	Primary biliary cholangitis;
LUSC	cis	rs9296092	0.538	rs7761464	chr6:33519417	C/A	cg13560919	chr6:33536144	NA	-0.82	-15.68	-0.65	6.59e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg10523679	chr1:76189770	ACADM	-0.49	-7.16	-0.36	5.33e-12	Daytime sleep phenotypes;
LUSC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.14e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg15556689	chr8:8085844	FLJ10661	0.68	11.06	0.52	1.88e-24	Mood instability;
LUSC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg04287289	chr16:89883240	FANCA	0.79	13.93	0.61	4.45e-35	Vitiligo;
LUSC	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07080220	chr10:102295463	HIF1AN	0.66	8.39	0.42	1.43e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2540226	0.816	rs13428837	chr2:39996457	C/T	cg23576258	chr2:39999331	THUMPD2	0.34	5.79	0.3	1.66e-8	Personality dimensions;
LUSC	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.9	-0.35	2.64e-11	Mood instability;
LUSC	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg05343316	chr1:45956843	TESK2	0.68	9.18	0.45	4.76e-18	Platelet count;
LUSC	trans	rs7757969	1.000	rs28566870	chr6:112118932	T/C	cg27172877	chr11:124806777	HEPACAM	0.66	6.38	0.33	5.95e-10	Schizophrenia;
LUSC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg16405210	chr4:1374714	KIAA1530	0.55	8.21	0.41	4.98e-15	Obesity-related traits;
LUSC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg16647868	chr5:131706066	SLC22A5	-0.35	-5.91	-0.31	8.33e-9	Blood metabolite levels;
LUSC	cis	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.98	-0.31	5.63e-9	Resting heart rate;
LUSC	cis	rs6681460	1.000	rs6659968	chr1:67123459	C/T	cg02459107	chr1:67143332	SGIP1	0.47	8.95	0.44	2.48e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs240764	0.658	rs6570922	chr6:101177262	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-6.64	-0.34	1.25e-10	Neuroticism;
LUSC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-9.69	-0.47	9.62e-20	Gut microbiome composition (summer);
LUSC	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs9403521	1.000	rs6907410	chr6:143995142	A/G	cg18240653	chr6:144019428	PHACTR2	-0.51	-6.26	-0.32	1.19e-9	Obesity-related traits;
LUSC	cis	rs2200578	1.000	rs72961173	chr2:99886868	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	6.48	0.33	3.26e-10	IgG glycosylation;
LUSC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg26677194	chr12:130822605	PIWIL1	0.59	8.8	0.43	7.28e-17	Menopause (age at onset);
LUSC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg08270630	chr22:50330655	NA	-0.43	-6.45	-0.33	3.93e-10	Schizophrenia;
LUSC	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg12863693	chr15:85201151	NMB	0.41	8.49	0.42	7.03e-16	Schizophrenia;
LUSC	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg26566898	chr11:117069891	TAGLN	0.35	6.6	0.34	1.63e-10	Blood protein levels;
LUSC	cis	rs3784262	0.935	rs4646563	chr15:58353335	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-5.99	-0.31	5.42e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg25072359	chr17:41440525	NA	0.57	8.3	0.41	2.54e-15	Menopause (age at onset);
LUSC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg22903471	chr2:27725779	GCKR	-0.39	-6.53	-0.34	2.42e-10	Total body bone mineral density;
LUSC	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg05472934	chr7:22766657	IL6	0.37	6.25	0.32	1.26e-9	Lung cancer;
LUSC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.87	0.7	1.29e-50	Chronic sinus infection;
LUSC	cis	rs2348418	0.681	rs10843207	chr12:28722862	A/G	cg13890972	chr12:28721907	NA	-0.39	-6.89	-0.35	2.81e-11	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg19257562	chr1:2043853	PRKCZ	0.33	6.55	0.34	2.11e-10	Height;
LUSC	cis	rs10843647	1.000	rs1533718	chr12:30341507	T/G	cg12718339	chr12:29936407	TMTC1	-0.35	-5.72	-0.3	2.42e-8	Glucose homeostasis traits;
LUSC	cis	rs12620999	0.941	rs13005377	chr2:238037759	T/C	cg23555395	chr2:238036564	NA	-0.53	-8.99	-0.44	1.82e-17	Systemic lupus erythematosus;
LUSC	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg19468946	chr17:37922297	IKZF3	-0.37	-5.78	-0.3	1.73e-8	Self-reported allergy;
LUSC	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg17366294	chr4:99064904	C4orf37	0.58	10.36	0.49	5.35e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg16325326	chr1:53192061	ZYG11B	0.74	12.76	0.57	1.16e-30	Monocyte count;
LUSC	cis	rs16854884	1.000	rs1961542	chr3:143765503	G/A	cg06585982	chr3:143692056	C3orf58	0.49	7.11	0.36	7.03e-12	Economic and political preferences (feminism/equality);
LUSC	cis	rs6756513	0.509	rs11686934	chr2:70172116	C/T	cg02498382	chr2:70120550	SNRNP27	0.25	6.1	0.32	2.86e-9	Breast cancer;Platelet count;
LUSC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg27572855	chr1:25598939	RHD	0.47	8.49	0.42	6.9e-16	Erythrocyte sedimentation rate;
LUSC	cis	rs3931020	0.688	rs1051122	chr1:75190452	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.46	5.88	0.31	1.01e-8	Resistin levels;
LUSC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08736216	chr1:53307985	ZYG11A	0.3	6.16	0.32	2.04e-9	Monocyte count;
LUSC	cis	rs4356932	1.000	rs7665152	chr4:76960205	T/G	cg00809888	chr4:76862425	NAAA	0.36	5.95	0.31	6.75e-9	Blood protein levels;
LUSC	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs7577696	0.924	rs6747488	chr2:32311284	C/T	cg02381751	chr2:32503542	YIPF4	-0.4	-5.73	-0.3	2.22e-8	Inflammatory biomarkers;
LUSC	cis	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg06521331	chr12:34319734	NA	-0.41	-6.3	-0.33	9.37e-10	Morning vs. evening chronotype;
LUSC	cis	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.33	-0.33	8.04e-10	Morning vs. evening chronotype;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11328022	chr20:34207568	SPAG4	-0.44	-6.19	-0.32	1.72e-9	Hepatitis;
LUSC	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	7.01	0.36	1.31e-11	Schizophrenia;
LUSC	cis	rs977987	0.778	rs4887821	chr16:75398574	G/A	cg03315344	chr16:75512273	CHST6	0.48	9.19	0.45	4.25e-18	Dupuytren's disease;
LUSC	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.46	-7.02	-0.36	1.21e-11	Immature fraction of reticulocytes;
LUSC	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.72	-0.35	7.69e-11	Response to antipsychotic treatment;
LUSC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg00933542	chr6:150070202	PCMT1	0.31	6.45	0.33	3.87e-10	Lung cancer;
LUSC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg11645453	chr3:52864694	ITIH4	0.29	6.72	0.35	7.72e-11	Electroencephalogram traits;
LUSC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7940866	0.874	rs1433979	chr11:130871617	G/A	cg12179176	chr11:130786555	SNX19	0.62	9.66	0.47	1.23e-19	Schizophrenia;
LUSC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg15839431	chr19:19639596	YJEFN3	0.43	6.1	0.32	2.86e-9	Tonsillectomy;
LUSC	cis	rs7804356	0.953	rs28617235	chr7:26854671	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.97	0.36	1.73e-11	Menarche (age at onset);
LUSC	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.56	-9.25	-0.45	2.75e-18	Breast cancer;
LUSC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.67	11.85	0.54	2.92e-27	Aortic root size;
LUSC	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg00701064	chr4:6280414	WFS1	0.5	10.33	0.49	6.64e-22	Cisplatin-induced ototoxicity;
LUSC	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg22029157	chr1:209979665	IRF6	-0.71	-8.88	-0.44	4.17e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg01733217	chr16:74700730	RFWD3	0.78	13.16	0.58	3.71e-32	Testicular germ cell tumor;
LUSC	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg23795048	chr12:9217529	LOC144571	0.34	6.0	0.31	5.08e-9	Sjögren's syndrome;
LUSC	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-11.28	-0.53	3.32e-25	Migraine;Coronary artery disease;
LUSC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg18350739	chr11:68623251	NA	-0.38	-6.48	-0.33	3.36e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs911119	0.866	rs2405393	chr20:23569392	G/C	cg16589663	chr20:23618590	CST3	0.63	7.33	0.37	1.74e-12	Chronic kidney disease;
LUSC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.84	0.35	3.69e-11	Platelet count;
LUSC	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.6	-0.34	1.57e-10	Arsenic metabolism;
LUSC	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.51	-6.22	-0.32	1.51e-9	Smoking behavior;
LUSC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg25039879	chr17:56429692	SUPT4H1	0.68	8.98	0.44	2.03e-17	Cognitive test performance;
LUSC	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg15423357	chr2:25149977	NA	-0.44	-8.93	-0.44	2.82e-17	Body mass index;
LUSC	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	8.26	0.41	3.52e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg19610905	chr11:61596333	FADS2	-0.54	-8.23	-0.41	4.22e-15	Trans fatty acid levels;
LUSC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg21951975	chr1:209979733	IRF6	0.4	6.67	0.34	1.08e-10	Monobrow;
LUSC	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg00898013	chr13:113819073	PROZ	-0.58	-8.41	-0.42	1.24e-15	Platelet distribution width;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27433451	chr1:51443332	NA	-0.39	-6.04	-0.31	4.18e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs737008	0.960	rs949429	chr16:11376029	C/T	cg00044050	chr16:11439710	C16orf75	-0.45	-6.69	-0.34	9.59e-11	Obesity-related traits;
LUSC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg03396347	chr1:1875803	NA	-0.54	-11.9	-0.55	1.87e-27	Body mass index;
LUSC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg26441486	chr22:50317300	CRELD2	-0.51	-7.69	-0.39	1.65e-13	Schizophrenia;
LUSC	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.75	0.39	1.11e-13	Corneal astigmatism;
LUSC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.59	10.79	0.51	1.81e-23	Homoarginine levels;
LUSC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg15110403	chr19:17392923	ANKLE1	-0.51	-7.19	-0.37	4.16e-12	Systemic lupus erythematosus;
LUSC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04025307	chr7:1156635	C7orf50	0.38	6.06	0.31	3.72e-9	Longevity;Endometriosis;
LUSC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24549020	chr5:56110836	MAP3K1	0.5	6.06	0.31	3.63e-9	Initial pursuit acceleration;
LUSC	cis	rs7119	0.679	rs12902698	chr15:77809010	A/C	cg27398640	chr15:77910606	LINGO1	-0.3	-6.38	-0.33	5.83e-10	Type 2 diabetes;
LUSC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05025164	chr4:1340916	KIAA1530	-0.65	-10.13	-0.48	3.27e-21	Obesity-related traits;
LUSC	cis	rs28655083	0.956	rs35848061	chr16:77101327	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.45	-6.79	-0.35	5e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.75	-0.43	1.04e-16	Uric acid levels;
LUSC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-0.97	-15.08	-0.64	1.48e-39	Initial pursuit acceleration;
LUSC	trans	rs1376359	0.537	rs674479	chr1:103259724	C/T	cg17154563	chr19:40477487	PSMC4	0.48	6.06	0.31	3.61e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg01528321	chr10:82214614	TSPAN14	1.07	16.7	0.67	6.18e-46	Post bronchodilator FEV1;
LUSC	cis	rs1982963	0.951	rs56834750	chr14:52509483	T/C	cg10843707	chr14:52510701	NID2	-0.4	-6.92	-0.35	2.34e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6785206	0.667	rs2253125	chr3:128329793	T/C	cg16766828	chr3:128327626	NA	-0.62	-7.37	-0.37	1.39e-12	Lymphocyte percentage of white cells;
LUSC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg01097406	chr16:89675127	NA	0.45	9.32	0.45	1.61e-18	Vitiligo;
LUSC	cis	rs9677476	0.863	rs62197323	chr2:232063714	A/G	cg07929768	chr2:232055508	NA	0.37	6.87	0.35	3.13e-11	Food antigen IgG levels;
LUSC	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.24	-0.37	3.08e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.46	-6.53	-0.34	2.49e-10	Total body bone mineral density;
LUSC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.42	0.56	2.2e-29	Motion sickness;
LUSC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg25258033	chr6:167368657	RNASET2	0.39	6.3	0.33	9.49e-10	Crohn's disease;
LUSC	cis	rs4072705	0.967	rs4838209	chr9:127528842	C/T	cg13476313	chr9:127244764	NR5A1	0.3	5.67	0.3	3.13e-8	Menarche (age at onset);
LUSC	cis	rs4730250	0.654	rs12705405	chr7:106792517	C/T	cg02696742	chr7:106810147	HBP1	0.64	9.04	0.44	1.32e-17	Osteoarthritis;
LUSC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg26304593	chr6:42947056	PEX6	-0.49	-7.33	-0.37	1.79e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg03806693	chr22:41940476	POLR3H	0.85	12.47	0.56	1.5e-29	Cannabis dependence symptom count;
LUSC	cis	rs11031096	0.782	rs4910889	chr11:4153231	T/C	cg18678763	chr11:4115507	RRM1	-0.5	-7.32	-0.37	1.81e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2573652	0.722	rs12595247	chr15:100541689	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.3	-5.82	-0.3	1.37e-8	Height;
LUSC	cis	rs9837602	0.935	rs9810235	chr3:99736538	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.18	0.32	1.82e-9	Breast cancer;
LUSC	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg01557791	chr16:72042693	DHODH	-0.54	-7.78	-0.39	9.01e-14	Fibrinogen levels;
LUSC	cis	rs7814319	0.966	rs6993518	chr8:97256341	T/A	cg20787634	chr8:97240163	UQCRB	-0.35	-6.12	-0.32	2.68e-9	Lung function (FVC);
LUSC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg16414030	chr3:133502952	NA	-0.42	-6.51	-0.34	2.81e-10	Iron status biomarkers;
LUSC	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg10247383	chr3:153839028	SGEF	-0.48	-5.83	-0.3	1.28e-8	Coronary artery disease;
LUSC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.8	-14.19	-0.61	4.14e-36	Iron status biomarkers;
LUSC	cis	rs7220711	0.967	rs4792909	chr17:41798824	G/T	cg26893861	chr17:41843967	DUSP3	0.42	5.93	0.31	7.56e-9	Bone mineral density (spine);Bone mineral density (hip);
LUSC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.03	0.31	4.3e-9	Schizophrenia;
LUSC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs6982240	0.514	rs10089212	chr8:142265380	T/A	cg27411547	chr8:142287226	NA	-0.47	-8.0	-0.4	2.12e-14	Tonsillectomy;
LUSC	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.9	-0.35	2.61e-11	Blood metabolite levels;
LUSC	cis	rs4903604	0.513	rs12880891	chr14:78035233	T/C	cg18872420	chr14:78023429	SPTLC2	0.38	5.87	0.31	1.05e-8	Gut microbiome composition (winter);
LUSC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg27121462	chr16:89883253	FANCA	0.54	8.61	0.43	2.84e-16	Vitiligo;
LUSC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg08888203	chr3:10149979	C3orf24	0.65	9.24	0.45	3.01e-18	Alzheimer's disease;
LUSC	cis	rs9420	0.961	rs77993055	chr11:57522840	C/T	cg23127183	chr11:57508653	C11orf31	-0.57	-8.81	-0.43	6.86e-17	Schizophrenia;
LUSC	cis	rs4713118	0.739	rs2893931	chr6:27748010	G/A	cg20933634	chr6:27740509	NA	0.42	5.89	0.31	9.49e-9	Parkinson's disease;
LUSC	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg25797454	chr6:150327115	RAET1K	0.36	8.23	0.41	4.15e-15	Alopecia areata;
LUSC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.07	-0.4	1.3e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs2692947	0.770	rs62153678	chr2:96558346	C/T	cg23100626	chr2:96804247	ASTL	0.3	7.03	0.36	1.18e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6700896	0.500	rs6700421	chr1:66082135	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.35	0.33	7.09e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg03806693	chr22:41940476	POLR3H	-0.83	-11.79	-0.54	4.76e-27	Vitiligo;
LUSC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05665937	chr4:1216051	CTBP1	-0.37	-5.86	-0.31	1.13e-8	Obesity-related traits;
LUSC	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg21427119	chr20:30132790	HM13	-0.36	-5.67	-0.3	3.14e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs66716358	0.773	rs10769035	chr11:44318786	G/A	cg02785814	chr11:44338707	NA	0.4	6.09	0.32	3.18e-9	Monobrow;
LUSC	cis	rs11642862	0.901	rs77604316	chr16:30921487	G/A	cg02466173	chr16:30829666	NA	-0.62	-6.21	-0.32	1.59e-9	Tonsillectomy;
LUSC	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg03161606	chr19:29218774	NA	-0.55	-6.81	-0.35	4.58e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg03146154	chr1:46216737	IPP	0.54	7.78	0.39	9.14e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg24060327	chr5:131705240	SLC22A5	-0.52	-8.23	-0.41	4.37e-15	Acylcarnitine levels;
LUSC	cis	rs8038465	0.615	rs11634399	chr15:73949210	A/G	cg15420318	chr15:73925796	NPTN	0.62	10.73	0.51	2.75e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg17173187	chr15:85201210	NMB	0.36	6.59	0.34	1.72e-10	Schizophrenia;
LUSC	cis	rs11209185	0.509	rs12142271	chr1:68446837	A/G	cg22082780	chr1:68452167	NA	0.44	7.26	0.37	2.7e-12	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg13319975	chr6:146136371	FBXO30	-0.66	-9.81	-0.47	4.07e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg23093090	chr10:104574429	C10orf26	-0.37	-6.87	-0.35	3.08e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg04369109	chr6:150039330	LATS1	-0.54	-8.06	-0.4	1.33e-14	Lung cancer;
LUSC	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.94	-0.44	2.75e-17	Breast cancer;
LUSC	cis	rs698813	0.604	rs10865200	chr2:44482884	G/C	cg00619915	chr2:44497795	NA	-0.5	-7.02	-0.36	1.22e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg21100191	chr22:23484243	RTDR1	0.91	15.73	0.65	3.99e-42	Bone mineral density;
LUSC	cis	rs3820928	0.869	rs2396436	chr2:227795464	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.72	-0.39	1.38e-13	Pulmonary function;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06713297	chr1:242011104	EXO1	0.45	6.73	0.35	7.55e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs748404	0.697	rs546722	chr15:43580819	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.43	6.02	0.31	4.7e-9	Lung cancer;
LUSC	cis	rs6469656	1.000	rs4623456	chr8:117683771	A/G	cg24004040	chr8:117650383	NA	-0.43	-6.31	-0.33	9.04e-10	Colorectal cancer;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg04297258	chr16:88772664	RNF166;CTU2	0.51	6.71	0.34	8.29e-11	Cognitive function;Information processing speed;
LUSC	trans	rs2018683	0.899	rs10479816	chr7:28978021	G/A	cg19402173	chr7:128379420	CALU	-0.55	-8.82	-0.43	6.31e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	8.64	0.43	2.43e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17621444	0.522	rs10886577	chr10:121795683	T/C	cg02041677	chr10:121771263	NA	-0.35	-6.44	-0.33	4.19e-10	IgG glycosylation;
LUSC	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg24375607	chr4:120327624	NA	0.52	8.07	0.4	1.28e-14	Educational attainment;
LUSC	cis	rs4363385	0.588	rs6698361	chr1:153023184	T/G	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.46e-8	Inflammatory skin disease;
LUSC	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	1.09	10.67	0.5	4.6e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.38	-8.5	-0.42	6.61e-16	Cystic fibrosis severity;
LUSC	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg03732007	chr1:2071316	PRKCZ	0.46	7.33	0.37	1.77e-12	Height;
LUSC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg02807482	chr3:125708958	NA	-0.5	-6.28	-0.33	1.03e-9	Blood pressure (smoking interaction);
LUSC	cis	rs8170	1.000	rs34084277	chr19:17387176	A/G	cg04749549	chr19:17459798	NA	-0.33	-5.81	-0.3	1.46e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUSC	cis	rs2398668	0.570	rs4721548	chr7:2330496	A/G	cg08027265	chr7:2291960	NA	-0.52	-8.97	-0.44	2.11e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.71	10.76	0.51	2.23e-23	Smoking initiation;
LUSC	cis	rs9309473	0.950	rs6756885	chr2:73805172	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-7.11	-0.36	7.12e-12	Metabolite levels;
LUSC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg05896524	chr21:47604654	C21orf56	0.42	6.14	0.32	2.35e-9	Testicular germ cell tumor;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	0.96	20.06	0.74	2.64e-59	Menarche (age at onset);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12679050	chr1:3773316	DFFB;KIAA0562	0.37	6.0	0.31	5.23e-9	Asthma;
LUSC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10862848	chr6:42927986	GNMT	-0.28	-6.7	-0.34	8.86e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.52	-9.49	-0.46	4.69e-19	Bipolar disorder;
LUSC	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg17168535	chr8:21777572	XPO7	0.85	15.57	0.65	1.7e-41	Mean corpuscular volume;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg21478123	chr6:1836850	GMDS	0.48	6.75	0.35	6.45e-11	Neuroticism;
LUSC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	5.74	0.3	2.08e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg15423357	chr2:25149977	NA	0.46	9.24	0.45	3.07e-18	Body mass index;
LUSC	cis	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.21	-0.32	1.56e-9	Resting heart rate;
LUSC	cis	rs3733418	0.697	rs13111010	chr4:165956741	C/T	cg11630554	chr4:165878136	TRIM61;C4orf39	-0.45	-5.79	-0.3	1.6e-8	Obesity-related traits;
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg01238044	chr22:24384105	GSTT1	0.73	12.42	0.56	2.19e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2078087	0.522	rs2477436	chr1:183209086	G/T	cg13843938	chr1:183241246	NMNAT2	0.41	6.68	0.34	9.82e-11	Obesity-related traits;
LUSC	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-9.52	-0.46	3.74e-19	Response to antipsychotic treatment;
LUSC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.1	0.77	2.43e-67	Prudent dietary pattern;
LUSC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg01677386	chr11:118938358	VPS11	-0.48	-6.8	-0.35	4.93e-11	Coronary artery disease;
LUSC	cis	rs12980942	1.000	rs1865053	chr19:41814412	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.03	0.31	4.3e-9	Coronary artery disease;
LUSC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg02018176	chr4:1364513	KIAA1530	0.45	7.39	0.37	1.19e-12	Obesity-related traits;
LUSC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.83	10.56	0.5	1.09e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg24692254	chr21:30365293	RNF160	0.68	10.73	0.51	2.77e-23	Pancreatic cancer;
LUSC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-6.15	-0.32	2.25e-9	Vitiligo;
LUSC	cis	rs7189233	0.531	rs62048526	chr16:53511926	G/A	cg09728985	chr16:53543985	NA	-0.33	-6.21	-0.32	1.53e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3850699	0.609	rs12763720	chr10:104241983	T/C	cg05855489	chr10:104503620	C10orf26	0.69	9.25	0.45	2.76e-18	Prostate cancer;
LUSC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg02487422	chr3:49467188	NICN1	0.48	7.63	0.39	2.46e-13	Resting heart rate;
LUSC	cis	rs612683	0.694	rs6688364	chr1:101000874	G/A	cg09408571	chr1:101003634	GPR88	0.32	5.95	0.31	6.87e-9	Breast cancer;
LUSC	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg05110241	chr16:68378359	PRMT7	-0.76	-8.7	-0.43	1.59e-16	Magnesium levels;
LUSC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.8	12.86	0.58	5.1e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg13047869	chr3:10149882	C3orf24	0.65	9.49	0.46	4.69e-19	Alzheimer's disease;
LUSC	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg09307838	chr4:120376055	NA	0.76	11.09	0.52	1.5e-24	Corneal astigmatism;
LUSC	trans	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.65	-9.51	-0.46	3.93e-19	Obesity-related traits;
LUSC	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg00334542	chr7:100209784	MOSPD3	-0.49	-5.74	-0.3	2.11e-8	Other erythrocyte phenotypes;
LUSC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg18904891	chr8:8559673	CLDN23	0.55	7.58	0.38	3.34e-13	Obesity-related traits;
LUSC	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg22601191	chr20:60968625	CABLES2	-0.39	-6.45	-0.33	3.86e-10	Colorectal cancer;
LUSC	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg19774624	chr17:42201019	HDAC5	-0.73	-10.52	-0.5	1.52e-22	Total body bone mineral density;
LUSC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg07395648	chr5:131743802	NA	0.37	5.8	0.3	1.52e-8	Asthma (sex interaction);
LUSC	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg13010199	chr12:38710504	ALG10B	0.55	8.48	0.42	7.35e-16	Morning vs. evening chronotype;
LUSC	cis	rs6489882	0.934	rs1859330	chr12:113376388	G/A	cg20102336	chr12:113376681	OAS3	-0.4	-6.01	-0.31	4.87e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg04362960	chr10:104952993	NT5C2	0.59	8.92	0.44	3.08e-17	Arsenic metabolism;
LUSC	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg06636001	chr8:8085503	FLJ10661	0.51	7.66	0.39	2.06e-13	Retinal vascular caliber;
LUSC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-11.13	-0.52	1.09e-24	Alzheimer's disease;
LUSC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg06238570	chr21:40685208	BRWD1	0.53	8.43	0.42	1.07e-15	Cognitive function;
LUSC	trans	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	14.02	0.61	1.94e-35	Exhaled nitric oxide levels;
LUSC	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg22782873	chr19:19639568	YJEFN3	-0.48	-5.79	-0.3	1.64e-8	Bipolar disorder;
LUSC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.59	-8.36	-0.42	1.66e-15	Diastolic blood pressure;
LUSC	trans	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.51	7.32	0.37	1.85e-12	Coronary heart disease;
LUSC	trans	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	8.8	0.43	7.26e-17	Mean corpuscular volume;
LUSC	cis	rs12956009	0.583	rs35970525	chr18:44882625	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	6.01	0.31	4.97e-9	Educational attainment (years of education);
LUSC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	8.02	0.4	1.76e-14	Schizophrenia;
LUSC	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg23625390	chr15:77176239	SCAPER	-0.66	-10.15	-0.49	2.86e-21	Blood metabolite levels;
LUSC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg22618164	chr12:122356400	WDR66	0.63	9.11	0.45	7.88e-18	Mean corpuscular volume;
LUSC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.46	-0.42	8.43e-16	Aortic root size;
LUSC	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.51	7.91	0.4	3.75e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.55	0.38	4.06e-13	Iron status biomarkers;
LUSC	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	7.06	0.36	9.8e-12	Rheumatoid arthritis;
LUSC	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10779751	0.734	rs6701726	chr1:11126941	C/T	cg08854313	chr1:11322531	MTOR	0.81	12.1	0.55	3.52e-28	Body mass index;
LUSC	cis	rs7605827	0.897	rs6708187	chr2:15684964	T/A	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.32e-17	Educational attainment (years of education);
LUSC	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg24631222	chr15:78858424	CHRNA5	-0.68	-9.48	-0.46	4.75e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.31	-0.37	2.01e-12	Bipolar disorder;
LUSC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg08270630	chr22:50330655	NA	-0.42	-6.44	-0.33	4.24e-10	Schizophrenia;
LUSC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg25039879	chr17:56429692	SUPT4H1	0.68	9.14	0.45	6.1e-18	Cognitive test performance;
LUSC	cis	rs2019216	0.500	rs1356483	chr17:21934029	A/C	cg22648282	chr17:21454238	C17orf51	-0.53	-7.91	-0.4	3.88e-14	Pelvic organ prolapse;
LUSC	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	7.74	0.39	1.21e-13	Retinal vascular caliber;
LUSC	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg23029597	chr12:123009494	RSRC2	-0.73	-9.72	-0.47	7.8e-20	Body mass index;
LUSC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg04733989	chr22:42467013	NAGA	0.61	9.5	0.46	4.27e-19	Schizophrenia;
LUSC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg10978503	chr1:24200527	CNR2	0.53	13.15	0.58	4.1e-32	Immature fraction of reticulocytes;
LUSC	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.94	-0.31	7.31e-9	Neutrophil percentage of white cells;
LUSC	trans	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg18187862	chr3:45730750	SACM1L	-0.52	-6.33	-0.33	7.7e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg08873628	chr1:175162347	KIAA0040	0.39	5.7	0.3	2.59e-8	Alcohol dependence;
LUSC	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.17	0.61	5.27e-36	Exhaled nitric oxide levels;
LUSC	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.39	-0.33	5.47e-10	Resting heart rate;
LUSC	cis	rs9925964	0.687	rs12917722	chr16:30948397	A/G	cg02466173	chr16:30829666	NA	0.39	7.37	0.37	1.34e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs16854884	0.837	rs4362712	chr3:143801076	G/A	cg06585982	chr3:143692056	C3orf58	0.46	6.78	0.35	5.52e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08219700	chr8:58056026	NA	0.63	8.13	0.41	8.37e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg22535103	chr8:58192502	C8orf71	-0.69	-7.28	-0.37	2.35e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.21	-0.37	3.68e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg17252645	chr8:143867129	LY6D	0.38	6.65	0.34	1.23e-10	Urinary tract infection frequency;
LUSC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.7	11.69	0.54	1.1e-26	Menarche (age at onset);
LUSC	cis	rs6700896	0.897	rs28480230	chr1:66124075	C/T	cg04111102	chr1:66153794	NA	0.33	7.26	0.37	2.81e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg03465714	chr1:152285911	FLG	-0.42	-5.79	-0.3	1.64e-8	Atopic dermatitis;
LUSC	cis	rs6736093	1.000	rs7349221	chr2:112668341	A/G	cg12686935	chr2:112915763	FBLN7	-0.35	-5.72	-0.3	2.41e-8	Coronary artery disease;
LUSC	cis	rs9905704	0.628	rs2531735	chr17:56551139	A/G	cg12560992	chr17:57184187	TRIM37	-0.5	-5.75	-0.3	2.01e-8	Testicular germ cell tumor;
LUSC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.62	-5.96	-0.31	6.58e-9	Cerebrospinal P-tau181p levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19835839	chr12:120966954	COQ5	0.49	7.19	0.37	4.22e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg15704280	chr7:45808275	SEPT13	-0.56	-6.94	-0.36	2.09e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.07	-23.82	-0.79	5.59e-74	Ulcerative colitis;
LUSC	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19346786	chr7:2764209	NA	-0.33	-6.01	-0.31	4.76e-9	Height;
LUSC	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg27068330	chr11:65405492	SIPA1	0.62	9.33	0.45	1.54e-18	Acne (severe);
LUSC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	cis	rs9463078	0.528	rs12214778	chr6:44924412	A/G	cg25276700	chr6:44698697	NA	0.28	5.78	0.3	1.69e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg22532475	chr10:104410764	TRIM8	0.28	5.7	0.3	2.65e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12922032	chr2:32582209	BIRC6	0.46	6.82	0.35	4.25e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9807989	0.839	rs3771166	chr2:102986222	G/A	cg09003973	chr2:102972529	NA	0.44	6.04	0.31	4.11e-9	Asthma;
LUSC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg06808227	chr14:105710500	BRF1	-0.66	-10.09	-0.48	4.5e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg11843238	chr5:131593191	PDLIM4	0.51	9.04	0.44	1.32e-17	Acylcarnitine levels;
LUSC	cis	rs6087990	0.735	rs2424922	chr20:31386449	T/C	cg13636640	chr20:31349939	DNMT3B	0.91	18.58	0.71	2.11e-53	Ulcerative colitis;
LUSC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.31	-0.41	2.42e-15	Gut microbiome composition (summer);
LUSC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg25809561	chr17:30822961	MYO1D	0.45	7.53	0.38	4.63e-13	Schizophrenia;
LUSC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	5.96e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs735860	0.737	rs2115564	chr6:53173482	C/A	cg10236188	chr6:53219634	NA	-0.38	-5.99	-0.31	5.32e-9	Glaucoma;
LUSC	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.35	-0.42	1.79e-15	Body mass index;
LUSC	cis	rs2230307	0.536	rs575971	chr1:100546591	T/C	cg24955406	chr1:100503596	HIAT1	0.59	6.4	0.33	5.37e-10	Carotid intima media thickness;
LUSC	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg17366294	chr4:99064904	C4orf37	0.5	8.7	0.43	1.54e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	0.9	17.25	0.69	3.85e-48	Heart rate;
LUSC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg09796270	chr17:17721594	SREBF1	-0.38	-6.33	-0.33	7.87e-10	Total body bone mineral density;
LUSC	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	12.97	0.58	1.94e-31	Bipolar disorder;
LUSC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg25767906	chr1:53392781	SCP2	-0.65	-12.85	-0.58	5.69e-31	Monocyte count;
LUSC	trans	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg24644049	chr4:85504048	CDS1	0.88	7.56	0.38	3.9e-13	Skin colour saturation;
LUSC	cis	rs34421088	0.603	rs10086064	chr8:11583841	A/G	cg00262122	chr8:11665843	FDFT1	0.41	6.16	0.32	2.03e-9	Neuroticism;
LUSC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.35	0.33	7.17e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs10904908	0.829	rs359280	chr10:17319707	C/T	cg01003015	chr10:17271136	VIM	0.4	5.93	0.31	7.77e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs4776059	0.958	rs35505902	chr15:52888493	A/G	cg25063058	chr15:52860530	ARPP19	0.46	6.29	0.33	1.01e-9	Schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04058639	chr4:169930757	CBR4	0.43	6.61	0.34	1.57e-10	Triglycerides;
LUSC	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21293242	chr8:11204541	TDH	0.32	5.97	0.31	6.23e-9	Retinal vascular caliber;
LUSC	cis	rs10186029	0.680	rs12694293	chr2:213937221	T/C	cg08319019	chr2:214017104	IKZF2	0.55	8.02	0.4	1.75e-14	Systemic sclerosis;
LUSC	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.68	-0.54	1.16e-26	Coffee consumption (cups per day);
LUSC	cis	rs9398803	0.865	rs7738135	chr6:126829981	G/A	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	1.97e-9	Male-pattern baldness;
LUSC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11764359	chr7:65958608	NA	-0.58	-8.99	-0.44	1.87e-17	Aortic root size;
LUSC	trans	rs9341835	0.518	rs2758237	chr6:64218297	G/A	cg19533977	chr17:57719682	CLTC	0.33	6.07	0.32	3.53e-9	Schizophrenia;
LUSC	cis	rs12136530	0.727	rs4911998	chr1:19765834	C/T	cg01832549	chr1:19774989	CAPZB	-0.31	-5.7	-0.3	2.6e-8	Lead levels in blood;
LUSC	cis	rs72634258	0.519	rs2071984	chr1:7928656	C/T	cg26816564	chr1:7831052	VAMP3	0.61	7.96	0.4	2.8e-14	Inflammatory bowel disease;
LUSC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs12493885	0.725	rs4679728	chr3:153732761	G/C	cg17054900	chr3:154042577	DHX36	-0.7	-7.37	-0.37	1.32e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs898097	0.690	rs3785520	chr17:80895745	T/C	cg15369054	chr17:80825471	TBCD	-0.63	-9.18	-0.45	4.65e-18	Breast cancer;
LUSC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg27494647	chr7:150038898	RARRES2	0.57	8.43	0.42	1.07e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6982240	0.514	rs11778579	chr8:142261621	C/T	cg27411547	chr8:142287226	NA	-0.47	-7.97	-0.4	2.48e-14	Tonsillectomy;
LUSC	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg02466173	chr16:30829666	NA	-0.5	-9.55	-0.46	2.91e-19	Dementia with Lewy bodies;
LUSC	cis	rs4588572	0.606	rs2362828	chr5:77718835	C/T	cg11547950	chr5:77652471	NA	-0.45	-6.87	-0.35	3.08e-11	Triglycerides;
LUSC	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg22437258	chr11:111473054	SIK2	0.53	7.21	0.37	3.69e-12	Primary sclerosing cholangitis;
LUSC	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg24375607	chr4:120327624	NA	0.77	11.22	0.52	5.34e-25	Corneal astigmatism;
LUSC	cis	rs12210905	0.688	rs12212348	chr6:27361242	T/C	cg08851530	chr6:28072375	NA	0.94	6.3	0.33	9.63e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg27074985	chr4:111118232	ELOVL6	0.44	6.15	0.32	2.17e-9	Mosquito bite size;
LUSC	cis	rs41271473	1.000	rs41271473	chr1:228880296	G/A	cg10167378	chr1:228756711	NA	0.5	6.16	0.32	2.12e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs7523050	0.908	rs17621536	chr1:109396908	A/G	cg08274380	chr1:109419600	GPSM2	0.87	9.52	0.46	3.5e-19	Fat distribution (HIV);
LUSC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26314531	chr2:26401878	FAM59B	-0.66	-9.12	-0.45	7.39e-18	Gut microbiome composition (summer);
LUSC	cis	rs9811920	0.809	rs6802817	chr3:99779264	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	5.84	0.3	1.25e-8	Axial length;
LUSC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	0.9	13.3	0.59	1.15e-32	IgG glycosylation;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg25703541	chr22:24373054	LOC391322	-0.91	-14.88	-0.63	8.75e-39	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06634786	chr22:41940651	POLR3H	-0.52	-6.43	-0.33	4.45e-10	Vitiligo;
LUSC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	8.62	0.43	2.75e-16	Menarche (age at onset);
LUSC	cis	rs2692947	0.832	rs2438978	chr2:96679740	G/C	cg22654517	chr2:96458247	NA	0.34	6.38	0.33	5.84e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1790761	0.505	rs6591256	chr11:67349899	A/G	cg24690094	chr11:67383802	NA	-0.3	-5.72	-0.3	2.37e-8	Mean corpuscular volume;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg08428129	chr22:19744239	TBX1	0.39	6.68	0.34	1e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs16976116	0.951	rs3809540	chr15:55489412	A/C	cg11288833	chr15:55489084	RSL24D1	0.54	6.55	0.34	2.19e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg18758796	chr5:131593413	PDLIM4	0.34	5.84	0.3	1.23e-8	Blood metabolite levels;
LUSC	cis	rs7605827	0.857	rs9973946	chr2:15631022	C/T	cg19274914	chr2:15703543	NA	0.47	9.15	0.45	5.75e-18	Educational attainment (years of education);
LUSC	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.54	0.42	4.94e-16	Lung cancer in ever smokers;
LUSC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.52	-0.57	9.7e-30	Rheumatoid arthritis;
LUSC	cis	rs7131987	0.650	rs7957339	chr12:29456495	T/C	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.72	-0.34	7.98e-11	QT interval;
LUSC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg09367891	chr1:107599246	PRMT6	-0.54	-8.39	-0.42	1.39e-15	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs72772090	0.908	rs11750510	chr5:96042095	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-7.2	-0.37	3.93e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs1973993	0.567	rs2800433	chr1:96998126	T/A	cg10631902	chr5:14652156	NA	0.47	7.66	0.39	2.08e-13	Weight;
LUSC	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg20848291	chr7:100343083	ZAN	0.39	6.14	0.32	2.33e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs12980942	1.000	rs7257310	chr19:41827120	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.15	0.32	2.17e-9	Coronary artery disease;
LUSC	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	9.02	0.44	1.46e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs988712	0.672	rs12419948	chr11:27666984	T/A	cg10635145	chr11:27742435	BDNF	-0.46	-5.96	-0.31	6.27e-9	Obesity;
LUSC	cis	rs2840044	1.000	rs225259	chr17:33958168	A/G	cg05299278	chr17:33885742	SLFN14	0.3	6.14	0.32	2.29e-9	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.44	0.5	2.94e-22	Hypertriglyceridemia;
LUSC	cis	rs11158026	0.603	rs4335711	chr14:55470863	G/C	cg04306507	chr14:55594613	LGALS3	0.39	7.12	0.36	6.46e-12	Parkinson's disease;
LUSC	cis	rs7615316	1.000	rs7631313	chr3:142354408	A/G	cg16271453	chr3:142027066	XRN1	-0.34	-5.88	-0.31	9.73e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg22638593	chr5:131593259	PDLIM4	-0.41	-5.89	-0.31	9.42e-9	Breast cancer;
LUSC	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg00277334	chr10:82204260	NA	-0.45	-6.26	-0.32	1.19e-9	Post bronchodilator FEV1;
LUSC	cis	rs9815354	0.761	rs73083329	chr3:41927151	C/T	cg03022575	chr3:42003672	ULK4	0.82	8.74	0.43	1.14e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs4947962	1.000	rs4947962	chr7:55075807	C/G	cg23757825	chr7:55092271	EGFR	0.66	6.96	0.36	1.78e-11	Subjective response to lithium treatment;
LUSC	cis	rs34375054	0.573	rs12831151	chr12:125656263	C/T	cg25124228	chr12:125621409	AACS	-0.52	-6.8	-0.35	4.95e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg04944784	chr2:26401820	FAM59B	-0.7	-9.77	-0.47	5.51e-20	Gut microbiome composition (summer);
LUSC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg09904177	chr6:26538194	HMGN4	-0.39	-5.68	-0.3	2.93e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.44	-0.38	8.82e-13	Blood metabolite levels;
LUSC	cis	rs4343996	0.666	rs10257982	chr7:3334597	C/T	cg21248987	chr7:3385318	SDK1	-0.37	-6.4	-0.33	5.17e-10	Motion sickness;
LUSC	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.28	0.49	1.05e-21	Bladder cancer;
LUSC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.88	0.44	4.05e-17	Motion sickness;
LUSC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg08677398	chr8:58056175	NA	0.41	5.74	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg17168535	chr8:21777572	XPO7	0.84	15.57	0.65	1.71e-41	Mean corpuscular volume;
LUSC	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg16989719	chr2:238392110	NA	-0.41	-7.22	-0.37	3.45e-12	Prostate cancer;
LUSC	cis	rs1215050	0.660	rs3864229	chr4:98714323	A/G	cg05340658	chr4:99064831	C4orf37	0.38	5.65	0.3	3.41e-8	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	10.0	0.48	9.15e-21	Bone mineral density;
LUSC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.58	-8.28	-0.41	2.93e-15	Diastolic blood pressure;
LUSC	cis	rs926938	0.563	rs360655	chr1:115447867	T/C	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.28	-0.32	1.05e-9	Autism;
LUSC	cis	rs10203711	0.705	rs4663946	chr2:239610287	C/T	cg14580085	chr2:239553406	NA	-0.4	-6.65	-0.34	1.18e-10	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg12856521	chr11:46389249	DGKZ	0.42	6.54	0.34	2.31e-10	Leprosy;
LUSC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg06784218	chr1:46089804	CCDC17	-0.52	-9.87	-0.48	2.51e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg15790184	chr11:494944	RNH1	0.42	6.21	0.32	1.61e-9	Systemic lupus erythematosus;
LUSC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.63	10.55	0.5	1.17e-22	Blood metabolite levels;
LUSC	cis	rs3771570	1.000	rs62190367	chr2:242376276	G/A	cg21155796	chr2:242212141	HDLBP	0.61	6.71	0.34	8.57e-11	Prostate cancer;
LUSC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg02187348	chr16:89574699	SPG7	-0.51	-8.12	-0.41	9.09e-15	Multiple myeloma (IgH translocation);
LUSC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.9	0.44	3.49e-17	Prudent dietary pattern;
LUSC	cis	rs2274273	0.870	rs17741542	chr14:55805861	A/G	cg04306507	chr14:55594613	LGALS3	-0.54	-12.12	-0.55	2.94e-28	Protein biomarker;
LUSC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg03146154	chr1:46216737	IPP	0.56	8.35	0.42	1.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg20283391	chr11:68216788	NA	-0.52	-7.19	-0.37	4.15e-12	Total body bone mineral density;
LUSC	cis	rs4700695	0.641	rs386949	chr5:65231061	G/A	cg21114390	chr5:65439923	SFRS12	0.52	5.66	0.3	3.21e-8	Facial morphology (factor 19);
LUSC	cis	rs12541635	0.967	rs4734896	chr8:107075454	T/C	cg10147462	chr8:107024639	NA	-0.48	-8.62	-0.43	2.66e-16	Age of smoking initiation;
LUSC	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg19257562	chr1:2043853	PRKCZ	0.32	6.46	0.33	3.77e-10	Height;
LUSC	cis	rs7589342	0.929	rs12053259	chr2:106428720	G/A	cg14210321	chr2:106509881	NCK2	-0.55	-8.27	-0.41	3.26e-15	Addiction;
LUSC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	0.71	11.91	0.55	1.64e-27	Methadone dose in opioid dependence;
LUSC	trans	rs28595532	0.702	rs72670238	chr4:119322751	C/T	cg26518628	chr1:97050305	NA	-0.76	-5.95	-0.31	6.67e-9	Cannabis dependence symptom count;
LUSC	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg08847533	chr14:75593920	NEK9	-0.84	-15.15	-0.64	8.06e-40	Height;
LUSC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.79	-0.39	8.52e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg19875535	chr5:140030758	IK	0.51	8.36	0.42	1.76e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.77	11.37	0.53	1.52e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.78	0.39	9.04e-14	Gut microbiome composition (summer);
LUSC	cis	rs6906287	0.647	rs12211576	chr6:118872080	G/A	cg21191810	chr6:118973309	C6orf204	0.33	6.04	0.31	4.16e-9	Electrocardiographic conduction measures;
LUSC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.69	0.54	1.11e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs611744	0.870	rs613179	chr8:109166006	G/A	cg18478394	chr8:109455254	TTC35	0.42	6.32	0.33	8.15e-10	Dupuytren's disease;
LUSC	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg12573674	chr2:1569213	NA	-0.49	-5.74	-0.3	2.16e-8	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs6542838	0.597	rs35107109	chr2:99386210	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.23	-0.32	1.44e-9	Fear of minor pain;
LUSC	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	11.08	0.52	1.61e-24	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg07167872	chr1:205819463	PM20D1	0.45	5.71	0.3	2.51e-8	Prostate-specific antigen levels;
LUSC	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.48	0.42	7.52e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.36e-8	Visceral adipose tissue adjusted for BMI;
LUSC	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg08017756	chr2:100939284	LONRF2	-0.44	-8.42	-0.42	1.16e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg17052675	chr2:3827356	NA	0.57	11.27	0.52	3.42e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg00316803	chr15:76480434	C15orf27	-0.39	-6.73	-0.35	7.24e-11	Blood metabolite levels;
LUSC	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg11244672	chr19:19639970	YJEFN3	-0.54	-6.59	-0.34	1.76e-10	Bipolar disorder;
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.57	-10.73	-0.51	2.78e-23	Longevity;Endometriosis;
LUSC	cis	rs10769945	0.679	rs2137322	chr11:1917354	A/G	cg06197492	chr11:2016605	H19	-0.4	-6.93	-0.35	2.14e-11	DNA methylation (variation);
LUSC	cis	rs4787491	0.679	rs12933575	chr16:30022564	A/G	cg06326092	chr16:30034487	C16orf92	0.23	5.68	0.3	2.89e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg06784218	chr1:46089804	CCDC17	0.35	6.04	0.31	4.14e-9	Platelet count;
LUSC	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg22681709	chr2:178499509	PDE11A	-0.48	-8.71	-0.43	1.42e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg17968037	chr7:100024898	ZCWPW1	-0.4	-5.89	-0.31	9.45e-9	Platelet count;
LUSC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg07716408	chr11:68623521	NA	-0.32	-6.35	-0.33	6.83e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg08017634	chr8:144659831	NAPRT1	0.72	6.17	0.32	2.03e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg15921436	chr17:44337874	NA	0.72	10.98	0.52	3.6e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg16414030	chr3:133502952	NA	0.53	8.84	0.44	5.47e-17	Iron status biomarkers;
LUSC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-11.61	-0.54	2.05e-26	Gut microbiome composition (summer);
LUSC	cis	rs10743315	0.643	rs4077883	chr12:19333359	C/A	cg02471346	chr12:19282374	PLEKHA5	0.66	6.65	0.34	1.16e-10	Gut microbiota (bacterial taxa);
LUSC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg11843238	chr5:131593191	PDLIM4	0.42	6.99	0.36	1.52e-11	Acylcarnitine levels;
LUSC	cis	rs4363385	0.588	rs12082627	chr1:153023650	G/A	cg00922841	chr1:152955080	SPRR1A	-0.36	-5.95	-0.31	6.82e-9	Inflammatory skin disease;
LUSC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.02	0.31	4.51e-9	Schizophrenia;
LUSC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg15103426	chr22:29168792	CCDC117	0.58	8.11	0.41	9.78e-15	Lymphocyte counts;
LUSC	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg10327440	chr1:227177885	CDC42BPA	0.64	6.24	0.32	1.31e-9	Major depressive disorder;
LUSC	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg23950597	chr19:37808831	NA	-0.63	-7.58	-0.38	3.49e-13	Coronary artery calcification;
LUSC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg03233332	chr7:66118400	NA	0.43	6.21	0.32	1.59e-9	Aortic root size;
LUSC	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.59	-13.8	-0.6	1.37e-34	Height;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg26189035	chr5:180661257	TRIM41	-0.4	-6.12	-0.32	2.67e-9	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs2562456	0.793	rs7259396	chr19:21523463	G/A	cg00806126	chr19:22604979	ZNF98	-0.43	-6.21	-0.32	1.54e-9	Pain;
LUSC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg24130564	chr14:104152367	KLC1	-0.42	-6.06	-0.31	3.71e-9	Body mass index;
LUSC	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg09754948	chr16:28834200	ATXN2L	0.41	5.84	0.3	1.25e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs356992	1.000	rs356992	chr2:60753593	C/G	cg08426369	chr2:60753602	BCL11A	0.46	6.6	0.34	1.59e-10	Educational attainment (years of education);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20376421	chr12:56546193	MYL6B	-0.4	-6.33	-0.33	7.81e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9341808	0.667	rs806783	chr6:80942943	A/C	cg08355045	chr6:80787529	NA	-0.4	-6.78	-0.35	5.53e-11	Sitting height ratio;
LUSC	cis	rs9283706	0.689	rs6889240	chr5:66320940	A/G	cg11590213	chr5:66331682	MAST4	0.5	7.28	0.37	2.47e-12	Coronary artery disease;
LUSC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg24209194	chr3:40518798	ZNF619	0.45	6.26	0.32	1.21e-9	Renal cell carcinoma;
LUSC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg08027265	chr7:2291960	NA	-0.37	-6.1	-0.32	2.98e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg25767906	chr1:53392781	SCP2	0.39	6.68	0.34	9.86e-11	Monocyte count;
LUSC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg05234568	chr11:5960015	NA	-0.6	-8.64	-0.43	2.43e-16	DNA methylation (variation);
LUSC	cis	rs3770081	0.590	rs57367442	chr2:86453398	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.07	-7.19	-0.37	4.25e-12	Facial emotion recognition (sad faces);
LUSC	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg01657329	chr11:68192670	LRP5	0.47	6.15	0.32	2.27e-9	Bone mineral density (spine);
LUSC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg11663144	chr21:46675770	NA	-0.39	-6.29	-0.33	9.82e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.18	0.37	4.65e-12	Mean platelet volume;
LUSC	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs4631830	0.863	rs2843550	chr10:51521452	C/T	cg20129853	chr10:51489980	NA	-0.32	-6.39	-0.33	5.63e-10	Prostate-specific antigen levels;
LUSC	cis	rs713477	0.967	rs4901570	chr14:55915249	T/C	cg13175173	chr14:55914753	NA	-0.3	-6.4	-0.33	5.2e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg05785598	chr3:49045655	WDR6	0.37	6.3	0.33	9.28e-10	Parkinson's disease;
LUSC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg00343986	chr7:65444356	GUSB	-0.38	-5.73	-0.3	2.29e-8	Aortic root size;
LUSC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg10609677	chr17:41278573	BRCA1;NBR2	0.35	5.67	0.3	3.08e-8	Menopause (age at onset);
LUSC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg23711669	chr6:146136114	FBXO30	0.8	14.41	0.62	6.03e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.59	0.38	3.24e-13	Bipolar disorder;
LUSC	trans	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-8.53	-0.42	5.13e-16	Obesity-related traits;
LUSC	cis	rs7605827	0.897	rs6431715	chr2:15717917	C/A	cg19274914	chr2:15703543	NA	0.46	8.88	0.44	4.13e-17	Educational attainment (years of education);
LUSC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.82	-0.39	6.91e-14	Personality dimensions;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg09352202	chr2:102314757	MAP4K4	0.47	5.96	0.31	6.55e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.23	-0.37	3.4e-12	Alzheimer's disease (late onset);
LUSC	cis	rs13089785	0.965	rs12493045	chr3:123620718	C/A	cg02012769	chr3:123398346	MYLK	0.32	5.95	0.31	6.78e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3862435	0.666	rs2601202	chr15:90958089	G/A	cg22089800	chr15:90895588	ZNF774	0.59	6.4	0.33	5.17e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg23887609	chr12:130822674	PIWIL1	0.48	7.08	0.36	8.43e-12	Menopause (age at onset);
LUSC	cis	rs17102423	0.623	rs2898862	chr14:65612144	G/A	cg11161011	chr14:65562177	MAX	-0.63	-8.76	-0.43	1e-16	Obesity-related traits;
LUSC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg11752832	chr7:134001865	SLC35B4	0.53	8.18	0.41	5.88e-15	Mean platelet volume;
LUSC	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg09165964	chr15:75287851	SCAMP5	-0.45	-6.63	-0.34	1.34e-10	Caffeine consumption;
LUSC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg10057126	chr4:77819792	ANKRD56	0.53	7.74	0.39	1.19e-13	Emphysema distribution in smoking;
LUSC	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg16482183	chr6:26056742	HIST1H1C	0.45	6.46	0.33	3.65e-10	Height;
LUSC	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg19920283	chr7:105172520	RINT1	0.58	6.25	0.32	1.25e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	10.93	0.51	5.65e-24	Bone mineral density;
LUSC	cis	rs17407555	0.606	rs59871456	chr4:10014441	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-6.24	-0.32	1.3e-9	Schizophrenia (age at onset);
LUSC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg10356904	chr22:49881777	NA	-0.32	-7.02	-0.36	1.21e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg02269571	chr22:50332266	NA	-0.58	-8.72	-0.43	1.33e-16	Schizophrenia;
LUSC	cis	rs6500395	0.962	rs17826468	chr16:48568271	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.19	0.32	1.72e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7818345	0.967	rs35029660	chr8:19308126	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.63	0.34	1.32e-10	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.47	-0.42	7.86e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg23711669	chr6:146136114	FBXO30	0.85	15.16	0.64	6.93e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg09904177	chr6:26538194	HMGN4	-0.73	-6.73	-0.35	7.34e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg03433033	chr1:76189801	ACADM	-0.43	-6.39	-0.33	5.51e-10	Daytime sleep phenotypes;
LUSC	cis	rs4076764	0.522	rs4265409	chr1:163414559	C/T	cg06092702	chr1:163392909	NA	-0.37	-6.45	-0.33	3.91e-10	Motion sickness;
LUSC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg07507251	chr3:52567010	NT5DC2	0.34	6.61	0.34	1.5e-10	Bipolar disorder;
LUSC	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg00105475	chr2:10696890	NA	0.38	6.27	0.32	1.11e-9	Prostate cancer;
LUSC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	16.06	0.66	2.05e-43	Platelet count;
LUSC	cis	rs2481665	0.740	rs2457831	chr1:62633581	C/T	cg18591186	chr1:62594603	INADL	0.39	6.17	0.32	1.95e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs240764	0.658	rs12210255	chr6:101187540	G/C	cg09795085	chr6:101329169	ASCC3	-0.45	-6.44	-0.33	4.08e-10	Neuroticism;
LUSC	cis	rs10207628	0.738	rs7575209	chr2:127884123	A/C	cg06223080	chr2:127868745	NA	0.39	6.8	0.35	4.77e-11	Psychosis and Alzheimer's disease;
LUSC	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg15485101	chr11:133734466	NA	0.38	7.17	0.37	4.98e-12	Childhood ear infection;
LUSC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg00310523	chr12:86230176	RASSF9	0.52	9.83	0.47	3.52e-20	Major depressive disorder;
LUSC	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg22709100	chr7:91322751	NA	0.4	5.85	0.3	1.17e-8	Breast cancer;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg15242686	chr22:24348715	GSTTP1	0.43	6.46	0.33	3.6e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg04518342	chr5:131593106	PDLIM4	0.42	8.07	0.4	1.3e-14	Blood metabolite levels;
LUSC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg10523679	chr1:76189770	ACADM	-0.48	-7.13	-0.36	6.37e-12	Daytime sleep phenotypes;
LUSC	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg09658497	chr7:2847517	GNA12	-0.33	-5.91	-0.31	8.53e-9	Height;
LUSC	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-15.22	-0.64	4.25e-40	Heart rate;
LUSC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg01416388	chr22:39784598	NA	-0.46	-7.59	-0.38	3.28e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs12545109	0.800	rs1467125	chr8:57418638	C/T	cg09654669	chr8:57350985	NA	-0.52	-6.7	-0.34	8.66e-11	Obesity-related traits;
LUSC	cis	rs3738772	0.633	rs2483789	chr1:110053945	G/T	cg08367326	chr1:110052010	AMIGO1	-0.49	-7.1	-0.36	7.58e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9296095	1.000	rs5745568	chr6:33548394	G/T	cg14003231	chr6:33640908	ITPR3	0.46	6.99	0.36	1.51e-11	Platelet count;
LUSC	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	1.09	23.59	0.79	4.2e-73	Triglycerides;
LUSC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.37	-0.49	4.82e-22	Hemoglobin concentration;
LUSC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.01	-0.48	8.34e-21	Hemoglobin concentration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16645584	chr1:59247487	JUN	0.46	7.17	0.37	4.77e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg23114746	chr17:47492438	PHB	0.46	6.21	0.32	1.61e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg05855489	chr10:104503620	C10orf26	-0.71	-10.0	-0.48	8.76e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg15448220	chr1:150897856	SETDB1	0.38	5.69	0.3	2.84e-8	Tonsillectomy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00923919	chr22:26879581	HPS4;SRRD	0.41	6.08	0.32	3.28e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg05887092	chr17:76393375	PGS1	-0.47	-8.24	-0.41	4.03e-15	HDL cholesterol levels;
LUSC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg24829409	chr8:58192753	C8orf71	0.55	5.97	0.31	6.02e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs62238980	0.614	rs17683011	chr22:32445946	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs7560272	0.538	rs12052539	chr2:73937153	C/T	cg20560298	chr2:73613845	ALMS1	-0.4	-6.13	-0.32	2.53e-9	Schizophrenia;
LUSC	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg06271696	chr7:157225062	NA	-0.42	-8.2	-0.41	5.18e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs501916	0.796	rs628501	chr15:48027328	C/G	cg16110827	chr15:48056943	SEMA6D	-0.43	-6.7	-0.34	8.85e-11	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12516959	chr21:47718080	NA	-0.37	-5.87	-0.31	1.07e-8	Testicular germ cell tumor;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19493827	chr11:118966130	H2AFX	0.4	6.14	0.32	2.32e-9	Asthma;
LUSC	cis	rs6750795	0.870	rs6754952	chr2:232381245	G/T	cg19187155	chr2:232395269	NMUR1	-0.93	-17.34	-0.69	1.81e-48	Height;
LUSC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.92	0.31	7.86e-9	Menopause (age at onset);
LUSC	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg04455712	chr21:45112962	RRP1B	0.5	9.4	0.46	8.91e-19	Mean corpuscular volume;
LUSC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.24	-0.73	4.98e-56	Height;
LUSC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg01973587	chr1:228161476	NA	-0.4	-7.24	-0.37	3.09e-12	Diastolic blood pressure;
LUSC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18876405	chr7:65276391	NA	0.56	8.84	0.44	5.64e-17	Aortic root size;
LUSC	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.43	6.05	0.31	3.91e-9	Lung cancer;
LUSC	trans	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg18335740	chr13:41363409	SLC25A15	0.76	13.95	0.61	3.58e-35	Lewy body disease;
LUSC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg22800045	chr5:56110881	MAP3K1	0.77	9.99	0.48	9.62e-21	Initial pursuit acceleration;
LUSC	trans	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.99	-0.31	5.47e-9	Dementia with Lewy bodies;
LUSC	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg13535736	chr9:111863775	C9orf5	-0.37	-6.15	-0.32	2.17e-9	Menarche (age at onset);
LUSC	cis	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg05084668	chr3:125655381	ALG1L	-0.83	-11.71	-0.54	9.28e-27	Blood pressure (smoking interaction);
LUSC	cis	rs2882667	0.690	rs288028	chr5:138221989	C/G	cg04439458	chr5:138467593	SIL1	-0.42	-7.71	-0.39	1.48e-13	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg19077165	chr18:44547161	KATNAL2	-0.4	-6.03	-0.31	4.39e-9	Personality dimensions;
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.41	6.14	0.32	2.34e-9	Longevity;Endometriosis;
LUSC	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg20587970	chr11:113659929	NA	-1.2	-16.46	-0.67	5.34e-45	Hip circumference adjusted for BMI;
LUSC	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg24130564	chr14:104152367	KLC1	-0.47	-6.82	-0.35	4.31e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9311676	0.681	rs4681846	chr3:58332543	T/C	cg26110898	chr3:58419937	PDHB	-0.43	-6.96	-0.36	1.85e-11	Systemic lupus erythematosus;
LUSC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.67	0.6	4.29e-34	Platelet count;
LUSC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg12963246	chr6:28129442	ZNF389	0.53	7.35	0.37	1.52e-12	Depression;
LUSC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg03188948	chr7:1209495	NA	0.44	6.01	0.31	4.93e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.14e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12190007	0.508	rs6605538	chr6:169731432	G/A	cg16388071	chr6:169726476	NA	0.39	6.34	0.33	7.31e-10	Obesity-related traits;
LUSC	cis	rs4664304	0.900	rs62176692	chr2:160743463	C/T	cg03641300	chr2:160917029	PLA2R1	-0.4	-6.42	-0.33	4.63e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs1325195	0.881	rs3210839	chr1:179069429	C/T	cg11624085	chr17:8464688	MYH10	-0.44	-7.03	-0.36	1.2e-11	IgE grass sensitization;
LUSC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg03289416	chr15:75166202	SCAMP2	0.44	6.81	0.35	4.49e-11	Breast cancer;
LUSC	cis	rs17030434	0.906	rs12643219	chr4:154670798	T/C	cg14289246	chr4:154710475	SFRP2	-0.48	-6.39	-0.33	5.52e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg07393940	chr7:158741817	NA	-0.53	-8.69	-0.43	1.68e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs908922	0.887	rs7535188	chr1:152475899	G/A	cg20991723	chr1:152506922	NA	0.54	9.49	0.46	4.58e-19	Hair morphology;
LUSC	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg15704280	chr7:45808275	SEPT13	-0.46	-6.34	-0.33	7.64e-10	HDL cholesterol;
LUSC	cis	rs9341835	0.772	rs9344090	chr6:64135830	G/A	cg03326410	chr6:64151739	NA	-0.38	-6.26	-0.32	1.15e-9	Schizophrenia;
LUSC	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.79	11.39	0.53	1.27e-25	Corneal astigmatism;
LUSC	trans	rs6104690	0.967	rs6040286	chr20:10985143	T/C	cg07172334	chr21:31655261	KRTAP24-1	-0.34	-6.12	-0.32	2.56e-9	Bladder cancer;
LUSC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg12365402	chr11:9010492	NRIP3	0.48	8.81	0.43	6.84e-17	Hemoglobin concentration;
LUSC	cis	rs4889855	0.530	rs12946972	chr17:78618922	A/G	cg16591659	chr17:78472290	NA	-0.32	-5.95	-0.31	6.8e-9	Fractional excretion of uric acid;
LUSC	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	5.89	0.31	9.54e-9	Schizophrenia;
LUSC	cis	rs2070433	0.800	rs11700596	chr21:47874054	G/C	cg12379764	chr21:47803548	PCNT	0.79	10.34	0.49	6.57e-22	Lymphocyte counts;
LUSC	cis	rs10100465	0.961	rs10108248	chr8:118679410	T/G	cg09430518	chr8:118662568	NA	0.3	5.82	0.3	1.38e-8	Leprosy;
LUSC	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg23711669	chr6:146136114	FBXO30	-0.72	-12.17	-0.55	1.81e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9925964	0.933	rs749671	chr16:31088347	G/A	cg02466173	chr16:30829666	NA	0.36	6.4	0.33	5.33e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg06552810	chr11:31128660	NA	-0.4	-7.03	-0.36	1.15e-11	Red blood cell count;
LUSC	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg12615879	chr12:58013172	SLC26A10	-0.41	-10.11	-0.48	3.84e-21	Multiple sclerosis;
LUSC	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg14893161	chr1:205819251	PM20D1	-0.46	-6.03	-0.31	4.41e-9	Parkinson's disease;
LUSC	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg13385521	chr17:29058706	SUZ12P	0.69	6.79	0.35	5.27e-11	Body mass index;
LUSC	cis	rs4853525	0.923	rs2355575	chr2:191728404	T/G	cg11845111	chr2:191398756	TMEM194B	-0.41	-6.0	-0.31	5.16e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg24642844	chr7:1081250	C7orf50	-0.69	-9.87	-0.48	2.55e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg19894588	chr14:64061835	NA	0.51	7.25	0.37	2.87e-12	Glioblastoma;Glioma;
LUSC	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg18681998	chr4:17616180	MED28	0.78	13.82	0.6	1.1e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11608355	0.545	rs56144717	chr12:109902304	T/C	cg05360138	chr12:110035743	NA	0.91	11.65	0.54	1.48e-26	Neuroticism;
LUSC	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.93	0.31	7.55e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg03188948	chr7:1209495	NA	0.66	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9323205	0.834	rs12434435	chr14:51667524	G/T	cg23942311	chr14:51606299	NA	0.37	7.59	0.38	3.22e-13	Cancer;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg18236224	chr12:54718547	COPZ1	0.41	6.04	0.31	4.22e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg00191853	chr8:101177733	SPAG1	0.36	5.98	0.31	5.64e-9	Atrioventricular conduction;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12817154	chr4:864995	GAK	-0.67	-6.21	-0.32	1.56e-9	Cognitive performance;
LUSC	cis	rs7705502	0.962	rs72810995	chr5:173331851	A/G	cg18693985	chr5:173351052	CPEB4	-0.38	-5.87	-0.31	1.05e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs3092073	0.617	rs3746513	chr20:44594228	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.38	-5.95	-0.31	6.94e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6460942	0.556	rs2287067	chr7:12370533	T/C	cg06484146	chr7:12443880	VWDE	-0.51	-6.24	-0.32	1.32e-9	Coronary artery disease;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00694512	chr3:126423063	CHCHD6	-0.37	-6.04	-0.31	4e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.07e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1784581	0.651	rs1784593	chr6:162386096	A/T	cg17173639	chr6:162384350	PARK2	-0.66	-11.93	-0.55	1.39e-27	Itch intensity from mosquito bite;
LUSC	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg15704280	chr7:45808275	SEPT13	0.76	7.89	0.4	4.36e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg22563815	chr15:78856949	CHRNA5	-0.25	-6.16	-0.32	2.11e-9	Sudden cardiac arrest;
LUSC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg17366294	chr4:99064904	C4orf37	0.56	9.85	0.47	2.83e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg00933542	chr6:150070202	PCMT1	0.32	6.7	0.34	8.68e-11	Lung cancer;
LUSC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg00343986	chr7:65444356	GUSB	0.47	7.12	0.36	6.6e-12	Calcium levels;
LUSC	cis	rs9650315	0.530	rs68005065	chr8:57090308	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.54	8.36	0.42	1.66e-15	Height;
LUSC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg05535760	chr7:792225	HEATR2	-0.77	-7.65	-0.39	2.16e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.69	11.46	0.53	7.01e-26	Heart rate;
LUSC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg04398451	chr17:18023971	MYO15A	0.37	5.87	0.31	1.07e-8	Total body bone mineral density;
LUSC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2067615	0.579	rs7486905	chr12:107160169	G/A	cg15890332	chr12:107067104	RFX4	0.34	6.2	0.32	1.66e-9	Heart rate;
LUSC	cis	rs7241530	0.662	rs35857611	chr18:75901744	C/G	cg14642773	chr18:75888474	NA	0.41	6.27	0.32	1.14e-9	Educational attainment (years of education);
LUSC	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg05343316	chr1:45956843	TESK2	0.67	8.96	0.44	2.29e-17	Platelet count;
LUSC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg08270630	chr22:50330655	NA	-0.45	-6.77	-0.35	5.64e-11	Schizophrenia;
LUSC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg27121462	chr16:89883253	FANCA	0.56	9.24	0.45	2.87e-18	Vitiligo;
LUSC	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.22e-15	Neuroticism;
LUSC	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg09165964	chr15:75287851	SCAMP5	-0.48	-6.94	-0.36	2e-11	Caffeine consumption;
LUSC	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg22875332	chr1:76189707	ACADM	-0.42	-6.2	-0.32	1.64e-9	Daytime sleep phenotypes;
LUSC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg14552801	chr7:65878734	NA	0.37	5.75	0.3	1.97e-8	Aortic root size;
LUSC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg06784218	chr1:46089804	CCDC17	0.48	9.18	0.45	4.71e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg11062466	chr8:58055876	NA	0.5	6.43	0.33	4.37e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1018697	1.000	rs7896903	chr10:104566417	A/G	cg04362960	chr10:104952993	NT5C2	0.5	6.98	0.36	1.61e-11	Colorectal adenoma (advanced);
LUSC	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	6.65	0.34	1.17e-10	Lung cancer in ever smokers;
LUSC	cis	rs6674176	0.542	rs803679	chr1:44349405	G/A	cg13246856	chr1:44399776	ARTN	0.28	5.78	0.3	1.68e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs11997175	0.846	rs11776207	chr8:33765126	G/T	ch.8.33884649F	chr8:33765107	NA	-0.46	-6.93	-0.35	2.22e-11	Body mass index;
LUSC	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg23202291	chr11:1979235	NA	0.39	6.1	0.32	2.96e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg04756594	chr16:24857601	SLC5A11	0.34	5.85	0.31	1.15e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7809950	0.678	rs2301801	chr7:106870746	T/C	cg23024343	chr7:107201750	COG5	-0.65	-9.56	-0.46	2.59e-19	Coronary artery disease;
LUSC	trans	rs6601327	1.000	rs6601327	chr8:9395532	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.96	-0.31	6.57e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs968451	0.951	rs12627838	chr22:39733521	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	8.57	0.42	3.96e-16	Primary biliary cholangitis;
LUSC	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg22709100	chr7:91322751	NA	-0.39	-5.68	-0.3	2.88e-8	Breast cancer;
LUSC	cis	rs7605827	0.930	rs763356	chr2:15518816	G/T	cg19274914	chr2:15703543	NA	0.45	8.73	0.43	1.27e-16	Educational attainment (years of education);
LUSC	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg01851573	chr8:8652454	MFHAS1	0.53	8.45	0.42	8.97e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs724744	0.742	rs1205936	chr6:22358116	A/G	cg13807341	chr11:118445984	ARCN1	-0.36	-6.07	-0.32	3.43e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.2e-13	Corneal astigmatism;
LUSC	cis	rs16937	0.711	rs11240390	chr1:205179457	A/G	cg21643547	chr1:205240462	TMCC2	-0.33	-5.7	-0.3	2.64e-8	Schizophrenia;
LUSC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.72	-9.87	-0.48	2.59e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg18352616	chr4:3374830	RGS12	-0.32	-6.42	-0.33	4.57e-10	Serum sulfate level;
LUSC	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.64	9.41	0.46	8.09e-19	IgG glycosylation;
LUSC	cis	rs7215564	0.908	rs9972968	chr17:78652569	T/C	cg09596252	chr17:78655493	RPTOR	0.57	6.12	0.32	2.65e-9	Myopia (pathological);
LUSC	cis	rs11168618	0.846	rs11168592	chr12:48865079	C/T	cg24011408	chr12:48396354	COL2A1	0.38	5.95	0.31	6.65e-9	Adiponectin levels;
LUSC	cis	rs7590368	0.715	rs55863332	chr2:10958976	A/G	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05608694	chr5:141303209	KIAA0141	-0.5	-6.35	-0.33	6.95e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.98	-0.48	1.08e-20	Joint mobility (Beighton score);
LUSC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg02018176	chr4:1364513	KIAA1530	0.51	8.83	0.43	6.12e-17	Obesity-related traits;
LUSC	cis	rs6546550	0.935	rs2305523	chr2:70039677	G/T	cg02498382	chr2:70120550	SNRNP27	0.28	6.9	0.35	2.59e-11	Prevalent atrial fibrillation;
LUSC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.23e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.88	0.31	1.01e-8	Menopause (age at onset);
LUSC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg11764359	chr7:65958608	NA	0.53	6.99	0.36	1.5e-11	Aortic root size;
LUSC	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg10523679	chr1:76189770	ACADM	0.76	9.46	0.46	5.83e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg06454157	chr6:167490870	NA	-0.27	-6.48	-0.33	3.25e-10	Primary biliary cholangitis;
LUSC	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg20487152	chr13:99095054	FARP1	-0.45	-7.96	-0.4	2.72e-14	Longevity;
LUSC	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg16482183	chr6:26056742	HIST1H1C	0.65	9.13	0.45	6.68e-18	Iron status biomarkers;
LUSC	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg04539111	chr16:67997858	SLC12A4	-0.48	-6.37	-0.33	6.35e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs1027479	0.842	rs3019347	chr8:109725416	T/C	cg14904725	chr13:113777045	F10	-0.25	-5.95	-0.31	6.67e-9	Facial morphology (factor 6, height of vermillion lower lip);
LUSC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg08684580	chr7:98029266	BAIAP2L1	0.43	8.02	0.4	1.82e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.89	0.44	3.86e-17	Schizophrenia;
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.33	-0.41	2.17e-15	Lymphocyte counts;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02666966	chr16:28857347	TUFM	0.72	6.22	0.32	1.48e-9	Cognitive performance;
LUSC	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.35	-7.53	-0.38	4.67e-13	Cystic fibrosis severity;
LUSC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00321850	chr1:175162397	KIAA0040	0.46	7.86	0.4	5.38e-14	Diastolic blood pressure;
LUSC	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg04545296	chr12:48745243	ZNF641	0.33	6.17	0.32	2e-9	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs1044826	1.000	rs2233815	chr3:139195177	C/T	cg00490450	chr3:139108681	COPB2	0.52	6.78	0.35	5.37e-11	Obesity-related traits;
LUSC	cis	rs17539620	0.808	rs6904264	chr6:154878380	C/G	cg20019720	chr6:154832845	CNKSR3	-0.42	-6.17	-0.32	1.92e-9	Lipoprotein (a) levels;
LUSC	cis	rs1322512	1.000	rs2996635	chr6:153011163	C/T	cg27316956	chr6:152958899	SYNE1	0.34	5.99	0.31	5.4e-9	Tonometry;
LUSC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08677398	chr8:58056175	NA	0.54	6.56	0.34	2.1e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	10.61	0.5	7.15e-23	Response to antipsychotic treatment;
LUSC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg03609598	chr5:56110824	MAP3K1	-0.41	-5.92	-0.31	7.83e-9	Initial pursuit acceleration;
LUSC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg12463550	chr7:65579703	CRCP	0.52	7.54	0.38	4.45e-13	Aortic root size;
LUSC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	1.03	20.73	0.75	5.79e-62	Menopause (age at onset);
LUSC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.51	0.53	4.85e-26	Menopause (age at onset);
LUSC	cis	rs11997175	0.655	rs7833512	chr8:33662884	C/T	ch.8.33884649F	chr8:33765107	NA	0.39	6.11	0.32	2.73e-9	Body mass index;
LUSC	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg08017756	chr2:100939284	LONRF2	-0.45	-8.5	-0.42	6.25e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-10.95	-0.51	4.69e-24	Menarche (age at onset);
LUSC	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs4474465	0.541	rs11237527	chr11:78219664	C/A	cg27205649	chr11:78285834	NARS2	0.49	5.69	0.3	2.74e-8	Alzheimer's disease (survival time);
LUSC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg16606324	chr3:10149918	C3orf24	0.59	8.59	0.43	3.27e-16	Alzheimer's disease;
LUSC	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.59	-7.68	-0.39	1.79e-13	Schizophrenia;
LUSC	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg12179176	chr11:130786555	SNX19	0.63	9.82	0.47	3.7e-20	Schizophrenia;
LUSC	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.91	0.35	2.52e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg25797454	chr6:150327115	RAET1K	0.37	8.47	0.42	7.99e-16	Alopecia areata;
LUSC	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg19875535	chr5:140030758	IK	0.49	7.97	0.4	2.6e-14	Schizophrenia;
LUSC	cis	rs2580764	0.678	rs2588521	chr2:55203931	C/G	cg09592903	chr2:55203963	RTN4	0.49	10.17	0.49	2.39e-21	Mean platelet volume;
LUSC	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.91	-0.35	2.45e-11	Response to antipsychotic treatment;
LUSC	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.72	-11.29	-0.53	2.86e-25	Alcohol dependence;
LUSC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.99	-0.31	5.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg24006582	chr15:45444508	DUOX1	-0.61	-8.95	-0.44	2.44e-17	Uric acid levels;
LUSC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg25019033	chr10:957182	NA	-0.52	-6.58	-0.34	1.77e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg12564285	chr5:131593104	PDLIM4	0.54	10.11	0.48	3.78e-21	Acylcarnitine levels;
LUSC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-9.04	-0.44	1.31e-17	Breast cancer;
LUSC	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg15485101	chr11:133734466	NA	0.38	7.17	0.37	4.98e-12	Childhood ear infection;
LUSC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg00074818	chr8:8560427	CLDN23	0.56	9.62	0.47	1.69e-19	Obesity-related traits;
LUSC	cis	rs939574	0.790	rs72955444	chr2:220094673	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	6.07	0.32	3.4e-9	Platelet distribution width;
LUSC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.73	-11.17	-0.52	8.16e-25	Hip circumference adjusted for BMI;
LUSC	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg13852791	chr20:30311386	BCL2L1	0.71	8.05	0.4	1.49e-14	Mean corpuscular hemoglobin;
LUSC	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg15704280	chr7:45808275	SEPT13	0.78	7.46	0.38	7.71e-13	Axial length;
LUSC	cis	rs2742417	0.603	rs2742449	chr3:45764544	T/C	cg04837898	chr3:45731254	SACM1L	-0.46	-7.35	-0.37	1.53e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7119	0.635	rs2682910	chr15:77880114	C/A	cg27398640	chr15:77910606	LINGO1	0.35	8.39	0.42	1.35e-15	Type 2 diabetes;
LUSC	trans	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg10756647	chr7:56101905	PSPH	0.89	9.05	0.44	1.19e-17	Diabetic kidney disease;
LUSC	cis	rs9905704	0.918	rs12942969	chr17:56892872	A/T	cg12560992	chr17:57184187	TRIM37	0.55	7.84	0.39	6.19e-14	Testicular germ cell tumor;
LUSC	cis	rs4843185	0.516	rs374029	chr16:85725953	G/A	cg00168118	chr16:85669675	KIAA0182	0.38	6.11	0.32	2.84e-9	Platelet distribution width;
LUSC	cis	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg20848291	chr7:100343083	ZAN	0.37	5.84	0.3	1.22e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs9837602	1.000	rs62285462	chr3:99769834	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.3	0.33	9.59e-10	Breast cancer;
LUSC	cis	rs7759001	0.857	rs4711147	chr6:27344496	A/G	cg18711553	chr6:27366782	ZNF391	0.41	5.95	0.31	6.67e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-7.17	-0.37	4.72e-12	Menopause (age at onset);
LUSC	cis	rs2637266	1.000	rs7478008	chr10:78355575	T/A	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-6.81	-0.35	4.44e-11	Response to bleomycin (chromatid breaks);
LUSC	trans	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg05926928	chr17:57297772	GDPD1	-1.14	-13.46	-0.59	2.75e-33	Opioid sensitivity;
LUSC	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21659725	chr3:3221576	CRBN	0.64	10.6	0.5	7.9e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg07952391	chr2:88470173	THNSL2	0.77	6.84	0.35	3.74e-11	Plasma clusterin levels;
LUSC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12310025	chr6:25882481	NA	-0.47	-8.08	-0.4	1.16e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.96	-0.36	1.83e-11	Total body bone mineral density;
LUSC	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg20307385	chr11:47447363	PSMC3	-0.5	-6.36	-0.33	6.51e-10	Subjective well-being;
LUSC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.15	-0.32	2.18e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18404041	chr3:52824283	ITIH1	-0.62	-12.13	-0.55	2.61e-28	Bipolar disorder;
LUSC	cis	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.21e-8	Resting heart rate;
LUSC	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.83	10.18	0.49	2.15e-21	Exhaled nitric oxide output;
LUSC	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06636551	chr8:101224915	SPAG1	-0.46	-8.29	-0.41	2.77e-15	Atrioventricular conduction;
LUSC	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-7.96	-0.4	2.71e-14	Schizophrenia;
LUSC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.24	-0.37	3.05e-12	Blood metabolite levels;
LUSC	cis	rs34375054	0.573	rs12811438	chr12:125653490	C/T	cg25124228	chr12:125621409	AACS	-0.51	-6.47	-0.33	3.42e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg09904177	chr6:26538194	HMGN4	0.68	12.18	0.55	1.72e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.67	8.73	0.43	1.25e-16	Menarche (age at onset);
LUSC	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg03340356	chr1:67600835	NA	0.42	6.63	0.34	1.37e-10	Psoriasis;
LUSC	trans	rs877282	0.583	rs11253424	chr10:813426	C/T	cg22713356	chr15:30763199	NA	0.66	9.26	0.45	2.52e-18	Uric acid levels;
LUSC	cis	rs4654899	0.802	rs10916903	chr1:21247944	T/C	cg02927042	chr1:21476669	EIF4G3	-0.37	-5.71	-0.3	2.48e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs701145	0.878	rs433903	chr3:153980130	A/G	cg17054900	chr3:154042577	DHX36	0.82	8.49	0.42	7.02e-16	Coronary artery disease;
LUSC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg06636001	chr8:8085503	FLJ10661	0.67	11.06	0.52	1.97e-24	Mood instability;
LUSC	cis	rs2279817	1.000	rs2279816	chr1:18021867	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.47	6.54	0.34	2.32e-10	Neuroticism;
LUSC	cis	rs9309473	0.606	rs62149777	chr2:73795364	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.56	-0.34	2.02e-10	Metabolite levels;
LUSC	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg03585969	chr10:35415529	CREM	0.59	8.83	0.43	6.14e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18932078	chr1:2524107	MMEL1	0.33	7.31	0.37	2.03e-12	Multiple sclerosis;
LUSC	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	6.74	0.35	6.94e-11	Retinal vascular caliber;
LUSC	cis	rs870825	0.860	rs72703525	chr4:185605154	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	10.26	0.49	1.17e-21	Blood protein levels;
LUSC	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.71	-10.89	-0.51	7.73e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs1979679	0.608	rs6487691	chr12:28724216	T/C	cg13890972	chr12:28721907	NA	-0.42	-6.01	-0.31	4.75e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs56283067	0.887	rs9472365	chr6:44770214	C/G	cg18551225	chr6:44695536	NA	0.43	6.92	0.35	2.27e-11	Total body bone mineral density;
LUSC	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg03676636	chr4:99064102	C4orf37	0.37	7.8	0.39	8.22e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.14	-0.72	1.16e-55	Height;
LUSC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg17971929	chr21:40555470	PSMG1	-0.65	-10.63	-0.5	6.09e-23	Cognitive function;
LUSC	cis	rs13315871	1.000	rs71311855	chr3:58320507	A/G	cg20936604	chr3:58311152	NA	-0.76	-7.26	-0.37	2.66e-12	Cholesterol, total;
LUSC	cis	rs354225	0.626	rs6740893	chr2:54834380	G/A	cg01766943	chr2:54829624	SPTBN1	0.44	6.83	0.35	4.13e-11	Schizophrenia;
LUSC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.58	-9.38	-0.46	1.08e-18	Aortic root size;
LUSC	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.14e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg27432699	chr2:27873401	GPN1	0.78	14.13	0.61	7.32e-36	Oral cavity cancer;
LUSC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg23283495	chr1:209979779	IRF6	0.65	9.35	0.46	1.28e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	0.91	8.77	0.43	9.47e-17	Mitochondrial DNA levels;
LUSC	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.32	0.45	1.64e-18	Lung cancer in ever smokers;
LUSC	cis	rs308403	0.568	rs1512975	chr4:123657342	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.78	10.09	0.48	4.57e-21	Blood protein levels;
LUSC	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg03806693	chr22:41940476	POLR3H	0.85	12.45	0.56	1.78e-29	Vitiligo;
LUSC	cis	rs2710642	0.815	rs6545971	chr2:63074986	A/T	cg17519650	chr2:63277830	OTX1	0.52	7.36	0.37	1.41e-12	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg13073564	chr4:8508604	NA	-0.47	-8.82	-0.43	6.42e-17	Response to antineoplastic agents;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18088653	chr15:71407757	CT62	-0.4	-6.44	-0.33	4.23e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg19230755	chr7:65878503	NA	0.43	6.06	0.31	3.67e-9	Aortic root size;
LUSC	trans	rs4714291	0.832	rs1524087	chr6:40057504	A/G	cg02267698	chr19:7991119	CTXN1	-0.56	-8.45	-0.42	9.07e-16	Strep throat;
LUSC	cis	rs9549260	0.709	rs4943795	chr13:41173433	C/T	cg21288729	chr13:41239152	FOXO1	-0.58	-8.05	-0.4	1.51e-14	Red blood cell count;
LUSC	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg01065977	chr19:18549689	ISYNA1	-0.22	-5.78	-0.3	1.73e-8	Breast cancer;
LUSC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg12310025	chr6:25882481	NA	-0.52	-9.44	-0.46	6.81e-19	Blood metabolite levels;
LUSC	cis	rs710216	0.752	rs1770810	chr1:43406113	G/A	cg22176566	chr1:43424700	SLC2A1	0.5	6.08	0.32	3.2e-9	Red cell distribution width;
LUSC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg13319975	chr6:146136371	FBXO30	-0.53	-8.04	-0.4	1.62e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg11693508	chr17:37793320	STARD3	0.56	6.7	0.34	8.71e-11	Bipolar disorder;
LUSC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg09904177	chr6:26538194	HMGN4	0.5	6.19	0.32	1.78e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9309473	0.500	rs1528169	chr2:73669186	T/C	cg20560298	chr2:73613845	ALMS1	0.47	7.38	0.37	1.25e-12	Metabolite levels;
LUSC	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg13852791	chr20:30311386	BCL2L1	0.94	14.4	0.62	6.36e-37	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs2857891	0.695	rs2857895	chr11:6982992	C/G	cg14883916	chr11:6947541	ZNF215	-0.41	-5.78	-0.3	1.75e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.42	-0.42	1.13e-15	Lymphocyte counts;
LUSC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg15147215	chr3:52552868	STAB1	-0.3	-5.95	-0.31	6.85e-9	Bipolar disorder;
LUSC	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.32	5.79	0.3	1.6e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.11	-0.41	9.63e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg04455712	chr21:45112962	RRP1B	-0.48	-9.29	-0.45	2e-18	Mean corpuscular volume;
LUSC	cis	rs11630290	0.667	rs6494441	chr15:64166877	A/G	cg12036633	chr15:63758958	NA	0.5	6.06	0.31	3.73e-9	Iris characteristics;
LUSC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg03676636	chr4:99064102	C4orf37	0.34	7.47	0.38	7.02e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.56	-0.42	4.22e-16	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg13565492	chr6:43139072	SRF	-0.57	-6.05	-0.31	3.93e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg22777020	chr22:31556080	RNF185	-0.46	-5.8	-0.3	1.55e-8	Colorectal cancer;
LUSC	cis	rs76935404	0.811	rs8100418	chr19:41414363	A/T	cg04176888	chr19:41596066	CYP2A13	0.39	6.06	0.31	3.69e-9	nicotine metabolite ratio in current smokers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18091465	chr15:82551086	EFTUD1	0.49	6.15	0.32	2.26e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	0.93	15.91	0.66	7.9e-43	Menopause (age at onset);
LUSC	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg05738196	chr6:26577821	NA	-0.48	-6.81	-0.35	4.52e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg02527881	chr3:46936655	PTH1R	-0.42	-7.49	-0.38	6.18e-13	Colorectal cancer;
LUSC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg20283391	chr11:68216788	NA	-0.59	-8.31	-0.41	2.46e-15	Total body bone mineral density;
LUSC	cis	rs1595825	0.891	rs75373125	chr2:198657044	G/A	cg00982548	chr2:198649783	BOLL	-0.56	-6.58	-0.34	1.78e-10	Ulcerative colitis;
LUSC	cis	rs3774830	0.714	rs7685158	chr4:5462776	C/T	cg26943120	chr4:5472116	STK32B	0.3	5.67	0.3	3.12e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2933343	0.951	rs9871612	chr3:128570402	C/T	cg11901034	chr3:128598214	ACAD9	-0.4	-5.66	-0.3	3.22e-8	IgG glycosylation;
LUSC	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.43	7.23	0.37	3.32e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg26380479	chr7:97908229	NA	-0.26	-5.8	-0.3	1.54e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.59e-9	Menopause (age at onset);
LUSC	trans	rs758324	0.947	rs559971	chr5:131316164	A/G	cg21450652	chr3:46875436	PRSS42	-0.43	-6.09	-0.32	3.14e-9	Alzheimer's disease in APOE e4- carriers;
LUSC	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg02016764	chr4:38805732	TLR1	-0.54	-5.74	-0.3	2.17e-8	Breast cancer;
LUSC	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg13615516	chr5:77269221	NA	0.39	6.69	0.34	9.25e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	10.81	0.51	1.42e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg21724239	chr8:58056113	NA	0.61	7.21	0.37	3.7e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg16482183	chr6:26056742	HIST1H1C	-0.59	-8.47	-0.42	7.86e-16	Iron status biomarkers;
LUSC	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.5	0.5	1.79e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07469949	chr19:17378240	C19orf62	0.74	6.46	0.33	3.79e-10	Cognitive performance;
LUSC	cis	rs62400317	0.859	rs12209161	chr6:45104321	G/A	cg18551225	chr6:44695536	NA	-0.42	-6.89	-0.35	2.73e-11	Total body bone mineral density;
LUSC	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg10523679	chr1:76189770	ACADM	-0.5	-7.26	-0.37	2.68e-12	Daytime sleep phenotypes;
LUSC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg27535305	chr1:53392650	SCP2	-0.37	-6.91	-0.35	2.46e-11	Monocyte count;
LUSC	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg21665744	chr7:39171113	POU6F2	0.44	6.78	0.35	5.34e-11	IgG glycosylation;
LUSC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg23093090	chr10:104574429	C10orf26	0.45	8.55	0.42	4.38e-16	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.21	-0.41	4.93e-15	Coronary artery disease;
LUSC	cis	rs4363385	0.510	rs17627288	chr1:152923848	C/T	cg00922841	chr1:152955080	SPRR1A	-0.36	-5.96	-0.31	6.58e-9	Inflammatory skin disease;
LUSC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg16228356	chr17:43848958	NA	-0.27	-6.28	-0.33	1.03e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg23791538	chr6:167370224	RNASET2	0.52	8.64	0.43	2.31e-16	Crohn's disease;
LUSC	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg00012203	chr2:219082015	ARPC2	-0.68	-11.04	-0.52	2.26e-24	Colorectal cancer;
LUSC	cis	rs965604	0.965	rs36146269	chr15:78779510	T/A	cg18825076	chr15:78729989	IREB2	-0.43	-6.82	-0.35	4.31e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs877282	0.842	rs7092986	chr10:756373	G/A	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs722599	0.748	rs59112602	chr14:75358817	C/G	cg08847533	chr14:75593920	NEK9	-0.48	-6.84	-0.35	3.72e-11	IgG glycosylation;
LUSC	cis	rs1113500	0.787	rs11185266	chr1:108642664	G/A	cg06207961	chr1:108661230	NA	0.31	5.71	0.3	2.47e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.51	7.85	0.39	5.55e-14	Eosinophil percentage of white cells;
LUSC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg26335602	chr6:28129616	ZNF389	0.44	5.88	0.31	9.91e-9	Parkinson's disease;
LUSC	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg05347473	chr6:146136440	FBXO30	0.48	7.9	0.4	4.04e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.52	0.34	2.54e-10	Schizophrenia;
LUSC	cis	rs308403	0.568	rs13138426	chr4:123652580	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.78	10.11	0.48	3.96e-21	Blood protein levels;
LUSC	cis	rs3781663	0.553	rs875108	chr11:70004695	G/A	cg24276624	chr11:69982941	ANO1	-0.44	-6.77	-0.35	5.87e-11	Survival in rectal cancer;
LUSC	cis	rs7589342	0.929	rs7562054	chr2:106433513	G/C	cg14210321	chr2:106509881	NCK2	-0.54	-8.12	-0.41	9.28e-15	Addiction;
LUSC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-15.34	-0.64	1.46e-40	Height;
LUSC	cis	rs4474465	1.000	rs7121283	chr11:78149340	T/A	cg27205649	chr11:78285834	NARS2	-0.5	-5.86	-0.31	1.08e-8	Alzheimer's disease (survival time);
LUSC	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-0.57	-8.75	-0.43	1.07e-16	Breast cancer;
LUSC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-6.07	-0.32	3.4e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.42	-5.76	-0.3	1.92e-8	Gut microbiome composition (summer);
LUSC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg13902645	chr11:5959945	NA	-0.56	-8.63	-0.43	2.47e-16	DNA methylation (variation);
LUSC	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg08000102	chr2:233561755	GIGYF2	0.52	8.15	0.41	7.49e-15	Coronary artery disease;
LUSC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10802521	chr3:52805072	NEK4	-0.52	-8.63	-0.43	2.5e-16	Electroencephalogram traits;
LUSC	cis	rs7172677	0.960	rs8026273	chr15:75413766	T/A	cg14664628	chr15:75095509	CSK	-0.47	-5.98	-0.31	5.64e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs10740039	0.883	rs2119911	chr10:62399566	T/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs963731	0.649	rs4142729	chr2:39222915	A/G	cg04010122	chr2:39346883	SOS1	-0.75	-5.8	-0.3	1.51e-8	Corticobasal degeneration;
LUSC	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg03909863	chr11:638404	DRD4	-0.41	-6.19	-0.32	1.81e-9	Systemic lupus erythematosus;
LUSC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg15595755	chr5:1867978	NA	0.47	8.6	0.43	3.09e-16	Cardiovascular disease risk factors;
LUSC	cis	rs2734839	0.929	rs2734835	chr11:113291343	T/G	cg14159747	chr11:113255604	NA	0.24	6.06	0.31	3.59e-9	Information processing speed;
LUSC	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	0.87	14.02	0.61	1.97e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	0.59	9.38	0.46	1.07e-18	Breast cancer;
LUSC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg00376283	chr12:123451042	ABCB9	0.67	8.44	0.42	9.73e-16	Neutrophil percentage of white cells;
LUSC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg14456004	chr13:21872349	NA	1.16	15.6	0.65	1.34e-41	White matter hyperintensity burden;
LUSC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.65	-10.06	-0.48	5.63e-21	Menarche (age at onset);
LUSC	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg06532163	chr17:45867833	NA	0.35	6.53	0.34	2.45e-10	IgG glycosylation;
LUSC	cis	rs7572644	0.640	rs34181670	chr2:28019856	T/C	cg27432699	chr2:27873401	GPN1	0.55	7.26	0.37	2.74e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg26384229	chr12:38710491	ALG10B	0.75	11.76	0.54	5.82e-27	Morning vs. evening chronotype;
LUSC	cis	rs870825	0.932	rs10034861	chr4:185577450	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	11.46	0.53	7.47e-26	Blood protein levels;
LUSC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs17253792	0.822	rs78432811	chr14:56051545	T/C	cg01858014	chr14:56050164	KTN1	-0.83	-6.3	-0.33	9.21e-10	Putamen volume;
LUSC	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg07423050	chr13:99094983	FARP1	0.59	12.03	0.55	6.33e-28	Neuroticism;
LUSC	cis	rs354225	0.544	rs13391522	chr2:54805854	T/C	cg01766943	chr2:54829624	SPTBN1	0.48	7.65	0.39	2.14e-13	Schizophrenia;
LUSC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.39	6.15	0.32	2.24e-9	Bipolar disorder;
LUSC	cis	rs9549260	0.564	rs9549279	chr13:41315582	C/G	cg21288729	chr13:41239152	FOXO1	-0.5	-7.51	-0.38	5.32e-13	Red blood cell count;
LUSC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg13560548	chr3:10150139	C3orf24	0.55	7.4	0.38	1.08e-12	Alzheimer's disease;
LUSC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg11764359	chr7:65958608	NA	-0.52	-6.81	-0.35	4.44e-11	Aortic root size;
LUSC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg11062466	chr8:58055876	NA	0.65	8.33	0.41	2.12e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg26380479	chr7:97908229	NA	-0.26	-5.84	-0.3	1.23e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg21141812	chr3:48556323	PFKFB4	0.35	5.9	0.31	9.14e-9	Menarche (age at onset);
LUSC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-16.53	-0.67	2.89e-45	Body mass index;
LUSC	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg26384229	chr12:38710491	ALG10B	0.71	9.99	0.48	1.01e-20	Resting heart rate;
LUSC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg01657329	chr11:68192670	LRP5	-0.44	-6.62	-0.34	1.41e-10	Total body bone mineral density;
LUSC	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg26597838	chr10:835615	NA	0.79	9.84	0.47	3.08e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg24675056	chr1:15929824	NA	0.46	8.02	0.4	1.83e-14	Systolic blood pressure;
LUSC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg03388025	chr16:89894329	SPIRE2	0.34	7.03	0.36	1.18e-11	Vitiligo;
LUSC	cis	rs7465272	0.515	rs34087536	chr8:143720876	G/A	cg24634471	chr8:143751801	JRK	0.48	6.51	0.34	2.8e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg26513180	chr16:89883248	FANCA	0.78	6.39	0.33	5.68e-10	Skin colour saturation;
LUSC	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg27661571	chr11:113659931	NA	-0.62	-7.42	-0.38	1.01e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs4363385	0.510	rs61815707	chr1:152909018	T/C	cg25856811	chr1:152973957	SPRR3	-0.38	-6.17	-0.32	1.93e-9	Inflammatory skin disease;
LUSC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg04287289	chr16:89883240	FANCA	-0.43	-6.19	-0.32	1.79e-9	Vitiligo;
LUSC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg08859206	chr1:53392774	SCP2	-0.44	-7.41	-0.38	1.02e-12	Monocyte count;
LUSC	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg05163923	chr11:71159392	DHCR7	0.74	10.95	0.51	4.71e-24	Vitamin D levels;
LUSC	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.52	0.42	5.66e-16	Lung cancer in ever smokers;
LUSC	cis	rs72949976	0.584	rs12471471	chr2:214023052	C/T	cg08319019	chr2:214017104	IKZF2	-0.68	-11.75	-0.54	6.67e-27	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs6987853	0.661	rs4641053	chr8:42352161	G/A	cg09913449	chr8:42400586	C8orf40	-0.45	-7.58	-0.38	3.49e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg23093090	chr10:104574429	C10orf26	-0.37	-6.08	-0.32	3.29e-9	Arsenic metabolism;
LUSC	trans	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg26043149	chr18:55253948	FECH	-0.53	-7.7	-0.39	1.6e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg08949735	chr16:89699720	DPEP1	-0.23	-6.02	-0.31	4.51e-9	Vitiligo;
LUSC	trans	rs9944715	0.954	rs7234695	chr18:43762182	T/A	cg01718231	chr17:29326311	RNF135	0.52	7.41	0.38	1.04e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg13393036	chr8:95962371	TP53INP1	-0.47	-9.57	-0.46	2.48e-19	Type 2 diabetes;
LUSC	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.39	-6.91	-0.35	2.42e-11	Eosinophil percentage of white cells;
LUSC	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.33	0.64	1.53e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg17075019	chr10:79541650	NA	-0.8	-12.84	-0.57	5.95e-31	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg26061582	chr7:22766209	IL6	0.43	6.33	0.33	7.85e-10	Lung cancer;
LUSC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg11584989	chr19:19387371	SF4	0.58	6.97	0.36	1.74e-11	Bipolar disorder;
LUSC	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg27539214	chr16:67997921	SLC12A4	-0.53	-6.88	-0.35	3.01e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.84	14.42	0.62	5.48e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg06096015	chr1:231504339	EGLN1	-0.51	-9.22	-0.45	3.42e-18	Hemoglobin concentration;
LUSC	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg25730555	chr22:47059586	GRAMD4	0.45	7.08	0.36	8.77e-12	Urate levels in obese individuals;
LUSC	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg03146154	chr1:46216737	IPP	0.5	7.49	0.38	6.02e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2979489	0.773	rs10954993	chr8:30303388	C/T	cg26383811	chr8:30366931	RBPMS	0.48	7.35	0.37	1.55e-12	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	trans	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg05926928	chr17:57297772	GDPD1	1.0	11.33	0.53	2.11e-25	Opioid sensitivity;
LUSC	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg12756686	chr19:29218302	NA	0.57	6.35	0.33	7.04e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs6580649	0.941	rs7957764	chr12:48429701	C/T	cg24011408	chr12:48396354	COL2A1	-0.51	-6.79	-0.35	5.07e-11	Lung cancer;
LUSC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-0.99	-14.45	-0.62	4.26e-37	Initial pursuit acceleration;
LUSC	cis	rs2692947	0.832	rs2438972	chr2:96690873	T/C	cg22654517	chr2:96458247	NA	0.33	6.61	0.34	1.48e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg16558253	chr16:72132732	DHX38	-0.4	-6.08	-0.32	3.3e-9	Fibrinogen levels;
LUSC	trans	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg13010199	chr12:38710504	ALG10B	0.42	6.58	0.34	1.87e-10	Morning vs. evening chronotype;
LUSC	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg18681998	chr4:17616180	MED28	0.77	13.41	0.59	4.22e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-7.13	-0.36	6.31e-12	Retinal vascular caliber;
LUSC	cis	rs6815814	0.950	rs56357984	chr4:38806462	G/A	cg02016764	chr4:38805732	TLR1	-0.56	-5.72	-0.3	2.31e-8	Breast cancer;
LUSC	cis	rs2235544	0.565	rs677481	chr1:54468837	A/C	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	trans	rs17076896	1.000	rs115410128	chr13:19757170	C/T	cg01891818	chr17:73008509	ICT1	0.5	6.17	0.32	1.97e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.07	-0.36	8.95e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg24375607	chr4:120327624	NA	0.77	10.99	0.52	3.44e-24	Corneal astigmatism;
LUSC	trans	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg07923666	chr12:49932857	KCNH3	-0.52	-6.51	-0.34	2.74e-10	Resting heart rate;
LUSC	cis	rs12760731	0.623	rs12691482	chr1:178421901	T/G	cg00404053	chr1:178313656	RASAL2	0.48	5.79	0.3	1.62e-8	Obesity-related traits;
LUSC	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	7.79	0.39	8.71e-14	Iron status biomarkers;
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.52	-8.69	-0.43	1.7e-16	Lymphocyte counts;
LUSC	cis	rs11585357	0.947	rs72646795	chr1:17612120	C/T	cg08277548	chr1:17600880	PADI3	-0.63	-6.54	-0.34	2.29e-10	Hair shape;
LUSC	cis	rs9811920	0.809	rs793437	chr3:99559854	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-7.22	-0.37	3.64e-12	Axial length;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg13695877	chr6:163835251	QKI	0.46	6.14	0.32	2.33e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg23711669	chr6:146136114	FBXO30	0.82	14.37	0.62	8.27e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg02475777	chr4:1388615	CRIPAK	0.39	5.97	0.31	6.06e-9	Obesity-related traits;
LUSC	cis	rs4363385	0.667	rs2066004	chr1:152922896	A/G	cg07796016	chr1:152779584	LCE1C	-0.46	-6.64	-0.34	1.26e-10	Inflammatory skin disease;
LUSC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg03128945	chr5:622914	CEP72	-0.39	-6.09	-0.32	3.13e-9	Obesity-related traits;
LUSC	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	9.2	0.45	3.94e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2860975	1.000	rs7070074	chr10:96786886	T/C	cg09036531	chr10:96991505	NA	-0.41	-5.75	-0.3	2.06e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.89	-0.35	2.73e-11	Lung cancer;
LUSC	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg06532163	chr17:45867833	NA	0.34	6.34	0.33	7.6e-10	IgG glycosylation;
LUSC	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg14829155	chr15:31115871	NA	-0.56	-7.61	-0.38	2.74e-13	Huntington's disease progression;
LUSC	cis	rs17401966	0.540	rs4846219	chr1:10463888	C/A	cg17425144	chr1:10567563	PEX14	-0.33	-5.75	-0.3	2.06e-8	Hepatocellular carcinoma;
LUSC	cis	rs2346177	1.000	rs11125074	chr2:46655260	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-8.83	-0.44	6.04e-17	HDL cholesterol;
LUSC	cis	rs735539	0.645	rs1052209	chr13:21216850	C/T	cg04906043	chr13:21280425	IL17D	-0.43	-6.92	-0.35	2.38e-11	Dental caries;
LUSC	cis	rs17540621	1.000	rs79562419	chr2:47232633	C/T	cg23978866	chr2:47230407	TTC7A	-0.97	-6.63	-0.34	1.38e-10	Response to statin therapy;
LUSC	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg02269571	chr22:50332266	NA	0.59	7.55	0.38	4.13e-13	Schizophrenia;
LUSC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg27532560	chr4:187881888	NA	0.44	6.99	0.36	1.51e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg19116668	chr7:99932089	PMS2L1	-0.33	-5.66	-0.3	3.25e-8	Coronary artery disease;
LUSC	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg06532163	chr17:45867833	NA	0.35	6.53	0.34	2.49e-10	IgG glycosylation;
LUSC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	13.33	0.59	8.66e-33	Monocyte percentage of white cells;
LUSC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg20406979	chr6:167373233	NA	-0.26	-6.29	-0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs4363385	0.747	rs4845334	chr1:152982998	T/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.35e-13	Inflammatory skin disease;
LUSC	cis	rs11055008	0.620	rs2111941	chr12:12829404	A/T	cg09462578	chr12:12878428	APOLD1	0.43	6.28	0.33	1.05e-9	Pulse pressure;
LUSC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.49	7.82	0.39	6.99e-14	Uric acid clearance;
LUSC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.82	-0.47	3.69e-20	Chronic sinus infection;
LUSC	cis	rs9473147	0.543	rs9349407	chr6:47453378	C/G	cg20196966	chr6:47445060	CD2AP	0.45	6.28	0.33	1.03e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.24	0.32	1.36e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg24513937	chr3:184016857	PSMD2	0.4	6.04	0.31	4.12e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg15445000	chr17:37608096	MED1	-0.39	-6.73	-0.35	7.38e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg10862848	chr6:42927986	GNMT	-0.29	-6.81	-0.35	4.44e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6087990	1.000	rs6087990	chr20:31349908	T/C	cg13636640	chr20:31349939	DNMT3B	1.05	24.5	0.8	1.36e-76	Ulcerative colitis;
LUSC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-1.04	-20.21	-0.74	7.12e-60	Height;
LUSC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	1.04	19.44	0.73	7.67e-57	Menopause (age at onset);
LUSC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg12963246	chr6:28129442	ZNF389	0.49	6.74	0.35	6.8e-11	Depression;
LUSC	cis	rs2599510	0.755	rs67257914	chr2:32804018	G/A	cg02381751	chr2:32503542	YIPF4	0.4	5.7	0.3	2.64e-8	Interleukin-18 levels;
LUSC	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.61	9.71	0.47	8.65e-20	Alcohol dependence;
LUSC	cis	rs1020064	0.945	rs1030878	chr2:105910598	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.65	8.82	0.43	6.52e-17	AIDS;
LUSC	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.6	0.54	2.25e-26	Cognitive ability;
LUSC	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.03	-0.31	4.24e-9	Resting heart rate;
LUSC	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg12091567	chr17:66097778	LOC651250	-0.72	-9.53	-0.46	3.34e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-6.86	-0.35	3.36e-11	Multiple sclerosis;
LUSC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-1.25	-14.0	-0.61	2.4e-35	Diabetic kidney disease;
LUSC	cis	rs6933660	0.512	rs13202634	chr6:151800630	C/T	cg03627880	chr6:151815985	C6orf97	-0.55	-5.93	-0.31	7.46e-9	Menarche (age at onset);
LUSC	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg04362960	chr10:104952993	NT5C2	0.58	7.8	0.39	8.17e-14	Arsenic metabolism;
LUSC	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.69	-11.2	-0.52	6.3e-25	Sudden cardiac arrest;
LUSC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-6.99	-0.36	1.47e-11	Blood metabolite levels;
LUSC	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg27147174	chr7:100797783	AP1S1	-0.65	-10.5	-0.5	1.74e-22	Life satisfaction;
LUSC	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.84	-14.09	-0.61	1.07e-35	Height;
LUSC	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg26195577	chr20:24973756	C20orf3	1.12	18.26	0.71	3.78e-52	Blood protein levels;
LUSC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00166722	chr3:10149974	C3orf24	0.54	7.45	0.38	7.83e-13	Alzheimer's disease;
LUSC	cis	rs9815354	0.761	rs12186109	chr3:41836920	T/C	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.81	0.3	1.44e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg15571903	chr15:79123663	NA	-0.33	-6.13	-0.32	2.47e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7953508	0.506	rs3782415	chr12:93967755	T/C	cg18151635	chr12:93972918	NA	-0.62	-8.96	-0.44	2.35e-17	Pubertal anthropometrics;
LUSC	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	0.51	7.32	0.37	1.85e-12	Breast cancer;
LUSC	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg16482183	chr6:26056742	HIST1H1C	0.65	9.05	0.44	1.21e-17	Iron status biomarkers;
LUSC	cis	rs3733418	0.929	rs13149738	chr4:165905697	T/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-5.92	-0.31	7.89e-9	Obesity-related traits;
LUSC	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg20578329	chr17:80767326	TBCD	-0.61	-8.33	-0.41	2.08e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LUSC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	12.07	0.55	4.28e-28	Colorectal cancer;
LUSC	cis	rs13385	0.769	rs10045510	chr5:139613188	T/C	cg26211634	chr5:139558579	C5orf32	0.46	7.05	0.36	1.04e-11	Atrial fibrillation;
LUSC	trans	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	5.95	0.31	6.6e-9	Cystic fibrosis severity;
LUSC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg00343986	chr7:65444356	GUSB	0.47	7.04	0.36	1.12e-11	Aortic root size;
LUSC	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg27539214	chr16:67997921	SLC12A4	-0.53	-6.62	-0.34	1.42e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.69	-0.34	9.51e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.67	11.74	0.54	7.23e-27	Aortic root size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24413235	chr2:27851648	CCDC121;GPN1	0.45	6.79	0.35	5.06e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08219700	chr8:58056026	NA	0.65	7.64	0.39	2.29e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg27661571	chr11:113659931	NA	-0.55	-6.73	-0.35	7.54e-11	Hip circumference adjusted for BMI;
LUSC	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg08600765	chr20:34638493	LOC647979	-0.61	-7.57	-0.38	3.69e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg12365402	chr11:9010492	NRIP3	0.45	8.39	0.42	1.38e-15	Hemoglobin concentration;
LUSC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18252515	chr7:66147081	NA	-0.39	-5.66	-0.3	3.22e-8	Aortic root size;
LUSC	cis	rs790123	1.000	rs790117	chr3:122380888	C/T	cg00926285	chr3:122398533	PARP14	-0.38	-5.93	-0.31	7.62e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg12552261	chr5:112820674	MCC	-0.44	-7.02	-0.36	1.25e-11	Type 2 diabetes;
LUSC	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg03469805	chr14:105330648	KIAA0284	-0.32	-7.32	-0.37	1.89e-12	IgG glycosylation;
LUSC	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg24154853	chr7:158122151	PTPRN2	0.43	8.3	0.41	2.62e-15	Calcium levels;
LUSC	cis	rs17621444	0.522	rs4373837	chr10:121809352	A/T	cg02041677	chr10:121771263	NA	-0.34	-6.31	-0.33	8.87e-10	IgG glycosylation;
LUSC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.06	0.36	9.78e-12	Melanoma;
LUSC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-0.96	-13.6	-0.6	8e-34	Vitiligo;
LUSC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.37	6.03	0.31	4.26e-9	Self-reported allergy;
LUSC	cis	rs17014483	1.000	rs2278877	chr4:89668210	G/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.65	5.81	0.3	1.43e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7640424	0.721	rs326355	chr3:107824663	T/C	cg09227934	chr3:107805635	CD47	0.38	6.02	0.31	4.55e-9	Body mass index;
LUSC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.08	16.32	0.67	1.97e-44	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	5.91	0.31	8.39e-9	Schizophrenia;
LUSC	cis	rs7605827	0.930	rs7574879	chr2:15698083	C/G	cg19274914	chr2:15703543	NA	0.48	9.2	0.45	3.97e-18	Educational attainment (years of education);
LUSC	trans	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg00750074	chr16:89608354	SPG7	-0.53	-9.59	-0.46	2.13e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs6076065	0.925	rs2281430	chr20:23399314	T/C	cg11657817	chr20:23433608	CST11	0.46	8.9	0.44	3.7e-17	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg14844989	chr11:31128820	NA	-0.37	-5.75	-0.3	2e-8	Red blood cell count;
LUSC	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.84	14.47	0.62	3.51e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg11941060	chr3:133502564	NA	-0.46	-6.66	-0.34	1.11e-10	Iron status biomarkers;
LUSC	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg18678763	chr11:4115507	RRM1	-0.53	-7.58	-0.38	3.43e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg02038168	chr22:39784481	NA	-0.46	-6.9	-0.35	2.55e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2235649	0.833	rs9939766	chr16:1852808	C/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.44	-6.02	-0.31	4.57e-9	Blood metabolite levels;
LUSC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.89	0.55	2.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.08	0.32	3.24e-9	Recombination rate (females);
LUSC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg13647721	chr17:30228624	UTP6	0.58	5.66	0.3	3.23e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	6.82	0.35	4.18e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg11843238	chr5:131593191	PDLIM4	0.37	6.32	0.33	8.44e-10	Breast cancer;
LUSC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7605827	0.930	rs12692272	chr2:15680801	C/T	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.27e-17	Educational attainment (years of education);
LUSC	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg22980127	chr19:33182716	NUDT19	0.94	12.81	0.57	7.79e-31	Red blood cell traits;
LUSC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg06784218	chr1:46089804	CCDC17	-0.52	-9.87	-0.48	2.51e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12493885	0.818	rs10935971	chr3:153773945	C/T	cg17054900	chr3:154042577	DHX36	-0.74	-7.55	-0.38	4.06e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14159672	chr1:205819179	PM20D1	0.53	8.71	0.43	1.43e-16	Menarche (age at onset);
LUSC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg05347473	chr6:146136440	FBXO30	-0.58	-10.07	-0.48	5.2e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg14154082	chr13:112174009	NA	0.38	7.76	0.39	1.03e-13	Menarche (age at onset);
LUSC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.22	0.52	5.23e-25	Menopause (age at onset);
LUSC	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg17385448	chr1:15911702	AGMAT	0.37	6.23	0.32	1.41e-9	Systolic blood pressure;
LUSC	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg07148914	chr20:33460835	GGT7	0.57	8.6	0.43	3.21e-16	Height;
LUSC	cis	rs34734847	1.000	rs56273049	chr12:121156041	A/T	cg21892295	chr12:121157589	UNC119B	-0.52	-9.38	-0.46	1.01e-18	Mean corpuscular volume;
LUSC	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg21775007	chr8:11205619	TDH	-0.65	-10.2	-0.49	1.94e-21	Retinal vascular caliber;
LUSC	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg01475377	chr6:109611718	NA	-0.47	-8.64	-0.43	2.29e-16	Reticulocyte fraction of red cells;
LUSC	cis	rs9341808	0.935	rs1535825	chr6:80938586	C/T	cg08355045	chr6:80787529	NA	-0.48	-8.73	-0.43	1.21e-16	Sitting height ratio;
LUSC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg23283495	chr1:209979779	IRF6	0.44	7.16	0.36	5.23e-12	Monobrow;
LUSC	cis	rs12545109	0.765	rs2576594	chr8:57412126	T/G	cg09654669	chr8:57350985	NA	-0.52	-6.66	-0.34	1.11e-10	Obesity-related traits;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13906968	chr16:29831676	MVP;C16orf53	-0.45	-6.16	-0.32	2.04e-9	Hepatitis;
LUSC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs3087591	0.960	rs7212264	chr17:29454766	C/T	cg24425628	chr17:29625626	OMG;NF1	0.56	7.93	0.4	3.23e-14	Hip circumference;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg06815965	chr1:205818668	PM20D1	0.39	6.08	0.32	3.28e-9	Menarche (age at onset);
LUSC	trans	rs57046232	0.552	rs1571216	chr20:6316328	A/C	cg17788362	chr6:86352627	SYNCRIP	-0.45	-6.3	-0.33	9.25e-10	Colorectal cancer;
LUSC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg14019146	chr3:50243930	SLC38A3	0.32	7.09	0.36	8.27e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.94	-0.31	7.19e-9	Reticulocyte count;
LUSC	cis	rs7582720	0.887	rs115600411	chr2:204121145	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.75	7.92	0.4	3.68e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg14092571	chr14:90743983	NA	-0.35	-5.77	-0.3	1.84e-8	Mortality in heart failure;
LUSC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg09165964	chr15:75287851	SCAMP5	0.5	7.38	0.37	1.3e-12	Breast cancer;
LUSC	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg04374321	chr14:90722782	PSMC1	0.76	12.09	0.55	3.72e-28	Mortality in heart failure;
LUSC	cis	rs7809950	0.861	rs2701682	chr7:107295835	G/A	cg23024343	chr7:107201750	COG5	0.67	9.39	0.46	9.57e-19	Coronary artery disease;
LUSC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg01416388	chr22:39784598	NA	-0.42	-6.94	-0.35	2.11e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg02034447	chr16:89574710	SPG7	0.44	6.33	0.33	7.95e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7923452	0.938	rs753173	chr10:30778738	T/C	cg25182066	chr10:30743637	MAP3K8	0.58	6.58	0.34	1.8e-10	Itch intensity from mosquito bite;
LUSC	cis	rs4363385	0.510	rs6673356	chr1:153041903	C/T	cg00922841	chr1:152955080	SPRR1A	0.37	6.26	0.32	1.2e-9	Inflammatory skin disease;
LUSC	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg02997394	chr19:33096574	ANKRD27	0.8	9.1	0.45	8.16e-18	Eosinophilic esophagitis;
LUSC	cis	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg05299278	chr17:33885742	SLFN14	0.31	6.81	0.35	4.51e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs17507216	1.000	rs17356118	chr15:83237899	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.45	-6.3	-0.33	9.65e-10	Excessive daytime sleepiness;
LUSC	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.35	-0.42	1.87e-15	Total cholesterol levels;
LUSC	cis	rs6906287	0.647	rs6569020	chr6:118795522	C/T	cg21191810	chr6:118973309	C6orf204	0.32	5.79	0.3	1.63e-8	Electrocardiographic conduction measures;
LUSC	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07080220	chr10:102295463	HIF1AN	0.68	9.07	0.44	1.04e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.51	-0.34	2.81e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7809950	0.817	rs4727678	chr7:107083635	C/G	cg23024343	chr7:107201750	COG5	-0.71	-10.45	-0.5	2.73e-22	Coronary artery disease;
LUSC	cis	rs1451375	0.657	rs7802148	chr7:50648284	T/C	cg18232548	chr7:50535776	DDC	0.5	7.58	0.38	3.49e-13	Malaria;
LUSC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg13607699	chr17:42295918	UBTF	0.5	7.83	0.39	6.75e-14	Total body bone mineral density;
LUSC	cis	rs4664308	0.594	rs4665141	chr2:160890795	A/T	cg03641300	chr2:160917029	PLA2R1	-0.48	-8.0	-0.4	2.13e-14	Idiopathic membranous nephropathy;
LUSC	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.43	-5.95	-0.31	6.69e-9	Reticulocyte count;
LUSC	cis	rs4888262	0.545	rs8052923	chr16:74680105	C/T	cg01733217	chr16:74700730	RFWD3	0.79	12.98	0.58	1.72e-31	Testicular germ cell tumor;
LUSC	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.21	-0.37	3.87e-12	Bipolar disorder;
LUSC	cis	rs7178572	0.568	rs4243045	chr15:77455914	A/C	cg22256960	chr15:77711686	NA	-0.5	-7.95	-0.4	2.97e-14	Type 2 diabetes;
LUSC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg03579872	chr1:53393473	SCP2	0.39	5.72	0.3	2.35e-8	Monocyte count;
LUSC	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg22491629	chr6:157744540	C6orf35	0.85	10.24	0.49	1.43e-21	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs1983170	0.736	rs12127718	chr1:91997490	A/T	cg25838465	chr1:92012736	NA	0.47	5.97	0.31	5.96e-9	Eosinophil percentage of white cells;
LUSC	cis	rs7189233	0.955	rs8058684	chr16:53515118	G/A	cg09728985	chr16:53543985	NA	-0.34	-6.21	-0.32	1.55e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg02153584	chr22:29168773	CCDC117	0.57	8.9	0.44	3.57e-17	Lymphocyte counts;
LUSC	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg05768032	chr16:30646687	NA	0.4	5.94	0.31	7.1e-9	Multiple myeloma;
LUSC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs6494488	0.500	rs34758599	chr15:64706332	A/G	cg08069370	chr15:64387884	SNX1	-0.64	-5.67	-0.3	3.05e-8	Coronary artery disease;
LUSC	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg13256891	chr4:100009986	ADH5	-0.43	-6.0	-0.31	5.06e-9	Alcohol dependence;
LUSC	trans	rs7939886	0.920	rs11227180	chr11:55855611	G/C	cg15704280	chr7:45808275	SEPT13	0.79	6.65	0.34	1.23e-10	Myopia (pathological);
LUSC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg18196295	chr10:418757	DIP2C	-0.43	-6.52	-0.34	2.54e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg06623918	chr6:96969491	KIAA0776	0.79	11.74	0.54	6.98e-27	Migraine;Coronary artery disease;
LUSC	cis	rs7212590	0.529	rs60283440	chr17:57994248	T/C	cg10252138	chr17:58120427	NA	-0.78	-7.19	-0.37	4.2e-12	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2273669	0.667	rs12212402	chr6:109306681	T/C	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.61	-0.34	1.53e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10779751	0.734	rs1130683	chr1:11132217	G/A	cg08854313	chr1:11322531	MTOR	0.8	12.45	0.56	1.6800000000000001e-29	Body mass index;
LUSC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg03146154	chr1:46216737	IPP	-0.51	-7.7	-0.39	1.6e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg06784218	chr1:46089804	CCDC17	0.3	5.95	0.31	6.92e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1461503	0.512	rs3816621	chr11:122818311	A/G	cg27398637	chr11:122830231	C11orf63	-0.39	-6.47	-0.33	3.59e-10	Menarche (age at onset);
LUSC	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22980127	chr19:33182716	NUDT19	0.94	12.81	0.57	8.08e-31	Red blood cell traits;
LUSC	cis	rs4662750	0.619	rs2244042	chr2:128404998	A/G	cg03462943	chr2:128407068	GPR17;LIMS2	-0.39	-6.24	-0.32	1.36e-9	Renal cell carcinoma;
LUSC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-11.37	-0.53	1.48e-25	Platelet count;
LUSC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20307385	chr11:47447363	PSMC3	-0.46	-5.89	-0.31	9.27e-9	Subjective well-being;
LUSC	cis	rs2191566	0.960	rs367209	chr19:44506249	A/G	cg03039196	chr19:44506973	ZNF230	-0.38	-6.1	-0.32	2.93e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.19	-0.49	2.13e-21	Platelet count;
LUSC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg00343986	chr7:65444356	GUSB	-0.46	-6.8	-0.35	4.74e-11	Aortic root size;
LUSC	trans	rs4252134	0.687	rs45475797	chr6:161237891	G/A	cg15977026	chr12:53661908	ESPL1	-0.51	-5.97	-0.31	6.18e-9	Giant cell arteritis;
LUSC	trans	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.97	0.48	1.18e-20	Mean corpuscular volume;
LUSC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.94	-0.35	2.1e-11	Total body bone mineral density;
LUSC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.23	0.56	1.09e-28	Prudent dietary pattern;
LUSC	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.89	-0.31	9.23e-9	Height;
LUSC	cis	rs6977660	1.000	rs12673970	chr7:19813018	T/C	cg07541023	chr7:19748670	TWISTNB	0.54	6.17	0.32	1.99e-9	Thyroid stimulating hormone;
LUSC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg13206674	chr6:150067644	NUP43	0.62	10.17	0.49	2.43e-21	Lung cancer;
LUSC	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg07148914	chr20:33460835	GGT7	-0.46	-6.74	-0.35	7.17e-11	Height;
LUSC	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14240646	chr10:27532245	ACBD5	-0.64	-7.55	-0.38	4.27e-13	Breast cancer;
LUSC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg20811857	chr17:78079795	GAA	0.46	7.94	0.4	3.01e-14	Yeast infection;
LUSC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.14e-35	Breast cancer;
LUSC	cis	rs240764	0.658	rs12174806	chr6:101219581	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.89	-0.31	9.4e-9	Neuroticism;
LUSC	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg14092571	chr14:90743983	NA	-0.4	-6.73	-0.35	7.55e-11	Mortality in heart failure;
LUSC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.76	0.3	1.93e-8	Tonsillectomy;
LUSC	cis	rs250677	0.524	rs40521	chr5:148439639	C/T	cg12140854	chr5:148520817	ABLIM3	0.34	6.32	0.33	8.42e-10	Breast cancer;
LUSC	cis	rs10861661	0.569	rs10778514	chr12:107303577	G/A	cg13944111	chr12:107296891	NA	0.37	6.5	0.34	2.91e-10	Triglyceride levels;
LUSC	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg13939156	chr17:80058883	NA	0.37	7.44	0.38	8.81e-13	Life satisfaction;
LUSC	cis	rs4629180	0.675	rs10183203	chr2:102095080	C/T	cg01388757	chr2:102091195	RFX8	0.35	5.97	0.31	6.09e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg05084668	chr3:125655381	ALG1L	0.48	6.8	0.35	4.73e-11	Blood pressure (smoking interaction);
LUSC	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg10104451	chr8:143696006	ARC	-0.61	-8.74	-0.43	1.18e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.42	0.69	8.19e-49	Chronic sinus infection;
LUSC	trans	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.94	0.55	1.29e-27	Exhaled nitric oxide output;
LUSC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.63	-0.57	3.55e-30	Chronic sinus infection;
LUSC	cis	rs2463822	0.583	rs72919467	chr11:62040102	G/A	cg06239285	chr11:62104954	ASRGL1	-0.59	-6.0	-0.31	5.11e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21545522	chr1:205238299	TMCC2	0.49	9.2	0.45	3.93e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs977987	0.806	rs6564258	chr16:75447363	G/A	cg04384234	chr16:75411784	CFDP1	-0.41	-6.62	-0.34	1.4e-10	Dupuytren's disease;
LUSC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-9.84	-0.47	3.09e-20	Gut microbiome composition (summer);
LUSC	trans	rs12165098	0.636	rs4287637	chr18:36744896	T/C	cg23858286	chr9:138135095	NA	-0.42	-6.09	-0.32	3.15e-9	Sleep duration;
LUSC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.23	-0.32	1.42e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg14019146	chr3:50243930	SLC38A3	0.37	8.29	0.41	2.88e-15	Body mass index;
LUSC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg05347473	chr6:146136440	FBXO30	0.47	8.03	0.4	1.63e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg09640425	chr7:158790006	NA	-0.53	-8.51	-0.42	6.11e-16	Facial morphology (factor 20);
LUSC	cis	rs6087990	1.000	rs2018002	chr20:31351623	A/T	cg13636640	chr20:31349939	DNMT3B	1.06	24.53	0.8	1.02e-76	Ulcerative colitis;
LUSC	cis	rs4077515	0.839	rs10781518	chr9:139300547	C/T	cg14169450	chr9:139327907	INPP5E	-0.42	-7.2	-0.37	4.09e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs5758511	0.573	rs1883205	chr22:42243020	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-7.51	-0.38	5.28e-13	Birth weight;
LUSC	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg20129853	chr10:51489980	NA	-0.35	-7.17	-0.37	4.86e-12	Prostate-specific antigen levels;
LUSC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.44	6.62	0.34	1.47e-10	Systemic lupus erythematosus;
LUSC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg24977027	chr2:88469347	THNSL2	0.57	5.83	0.3	1.3e-8	Plasma clusterin levels;
LUSC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.72	13.02	0.58	1.22e-31	Prudent dietary pattern;
LUSC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg25281562	chr12:121454272	C12orf43	-0.44	-5.87	-0.31	1.07e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg21045802	chr8:109455806	TTC35	0.46	7.15	0.36	5.42e-12	Dupuytren's disease;
LUSC	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg25237894	chr2:233734115	C2orf82	0.35	6.49	0.33	3.17e-10	Coronary artery disease;
LUSC	cis	rs7759001	0.857	rs2393931	chr6:27353114	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	1.97e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg06915202	chr7:98029285	BAIAP2L1	0.31	6.15	0.32	2.18e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.71	11.13	0.52	1.1e-24	Menopause (age at onset);
LUSC	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg02023728	chr11:77925099	USP35	0.44	6.37	0.33	6.19e-10	Testicular germ cell tumor;
LUSC	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg00277334	chr10:82204260	NA	-0.51	-7.41	-0.38	1.05e-12	Post bronchodilator FEV1;
LUSC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg12963246	chr6:28129442	ZNF389	-0.48	-6.86	-0.35	3.3e-11	Depression;
LUSC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06656553	chr16:89960601	TCF25	-0.55	-5.66	-0.3	3.24e-8	Skin colour saturation;
LUSC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg25036284	chr2:26402008	FAM59B	0.79	11.11	0.52	1.26e-24	Mean corpuscular hemoglobin;
LUSC	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg05294307	chr14:35346193	BAZ1A	-0.57	-6.87	-0.35	3.07e-11	Psoriasis;
LUSC	trans	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg20935933	chr6:143382018	AIG1	0.5	7.27	0.37	2.61e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	0.95	18.06	0.7	2.27e-51	Bone mineral density;
LUSC	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg22709100	chr7:91322751	NA	0.39	5.79	0.3	1.64e-8	Breast cancer;
LUSC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08736216	chr1:53307985	ZYG11A	0.29	6.03	0.31	4.36e-9	Monocyte count;
LUSC	cis	rs28655083	0.828	rs9938028	chr16:77127830	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.49	7.59	0.38	3.1400000000000003e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.57	-0.38	3.68e-13	Hemoglobin concentration;
LUSC	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg09654669	chr8:57350985	NA	-0.58	-7.88	-0.4	4.68e-14	Obesity-related traits;
LUSC	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg19156104	chr2:198669113	PLCL1	-0.49	-5.88	-0.31	9.82e-9	Ulcerative colitis;
LUSC	cis	rs1682825	0.547	rs17028925	chr3:10777632	A/G	cg23512531	chr3:10780469	NA	0.43	5.68	0.3	2.94e-8	Economic and political preferences (feminism/equality);
LUSC	cis	rs738321	0.757	rs3788534	chr22:38533971	A/T	cg25457927	chr22:38595422	NA	-0.37	-7.23	-0.37	3.26e-12	Breast cancer;
LUSC	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg00999904	chr2:3704751	ALLC	0.43	7.2	0.37	4.13e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs6960043	0.818	rs10950546	chr7:15050391	C/T	cg19272540	chr7:15055459	NA	0.35	8.48	0.42	7.62e-16	Type 2 diabetes;
LUSC	trans	rs7939886	0.920	rs12223014	chr11:55878290	G/A	cg15704280	chr7:45808275	SEPT13	0.79	6.68	0.34	9.84e-11	Myopia (pathological);
LUSC	cis	rs11650494	0.710	rs16948071	chr17:47468706	T/G	cg08112188	chr17:47440006	ZNF652	1.07	8.75	0.43	1.07e-16	Prostate cancer;
LUSC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	0.65	13.71	0.6	3.1e-34	Prudent dietary pattern;
LUSC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg00310523	chr12:86230176	RASSF9	0.52	9.81	0.47	3.84e-20	Major depressive disorder;
LUSC	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg00484396	chr16:3507460	NAT15	-0.47	-6.93	-0.35	2.18e-11	Body mass index (adult);
LUSC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.2	-0.32	1.69e-9	Total body bone mineral density;
LUSC	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg22482690	chr17:47019901	SNF8	0.37	6.96	0.36	1.86e-11	Type 2 diabetes;
LUSC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg02475777	chr4:1388615	CRIPAK	0.41	6.12	0.32	2.62e-9	Obesity-related traits;
LUSC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.29	-0.33	1e-9	Personality dimensions;
LUSC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg20476274	chr7:133979776	SLC35B4	0.85	15.95	0.66	5.43e-43	Mean platelet volume;
LUSC	cis	rs7605827	0.930	rs13384921	chr2:15602840	C/T	cg19274914	chr2:15703543	NA	0.45	8.74	0.43	1.12e-16	Educational attainment (years of education);
LUSC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg12419862	chr22:24373484	LOC391322	-0.89	-15.78	-0.65	2.64e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7264396	0.561	rs6142474	chr20:34574914	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	6.71	0.34	8.22e-11	Total cholesterol levels;
LUSC	cis	rs6496667	0.683	rs2589973	chr15:90892293	C/T	cg03599575	chr15:90893182	GABARAPL3	0.35	5.78	0.3	1.73e-8	Rheumatoid arthritis;
LUSC	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg03605463	chr16:89740564	NA	0.6	9.36	0.46	1.22e-18	Vitiligo;
LUSC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg14092988	chr3:52407081	DNAH1	0.31	5.92	0.31	7.82e-9	Bipolar disorder;
LUSC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg21285383	chr16:89894308	SPIRE2	0.35	7.33	0.37	1.76e-12	Vitiligo;
LUSC	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg22875332	chr1:76189707	ACADM	-0.42	-6.31	-0.33	8.94e-10	Daytime sleep phenotypes;
LUSC	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-12.35	-0.56	4.11e-29	Platelet distribution width;
LUSC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08859206	chr1:53392774	SCP2	-0.55	-9.72	-0.47	8.16e-20	Monocyte count;
LUSC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.53	0.38	4.76e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg16928487	chr17:17741425	SREBF1	0.47	9.2	0.45	3.98e-18	Total body bone mineral density;
LUSC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg02709834	chr1:75198841	CRYZ;TYW3	0.38	5.81	0.3	1.46e-8	Resistin levels;
LUSC	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg25173405	chr17:45401733	C17orf57	0.38	6.13	0.32	2.52e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11267619	chr7:29604021	PRR15	-0.38	-6.04	-0.31	4.08e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg14458575	chr2:238380390	NA	0.68	12.14	0.55	2.41e-28	Prostate cancer;
LUSC	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg04362960	chr10:104952993	NT5C2	1.1	12.9	0.58	3.57e-31	Arsenic metabolism;
LUSC	cis	rs62400317	0.859	rs12198376	chr6:45153681	G/C	cg18551225	chr6:44695536	NA	-0.42	-6.87	-0.35	3.24e-11	Total body bone mineral density;
LUSC	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg14582100	chr15:45693742	SPATA5L1	0.45	8.34	0.42	1.95e-15	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	0.96	8.01	0.4	1.94e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg08017756	chr2:100939284	LONRF2	-0.45	-8.35	-0.42	1.82e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10823500	0.636	rs7082396	chr10:71945511	C/A	cg02100629	chr10:71892760	AIFM2	-0.41	-6.88	-0.35	2.97e-11	Blood protein levels;
LUSC	cis	rs13401104	0.796	rs719544	chr2:237118282	A/C	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg06784218	chr1:46089804	CCDC17	-0.47	-8.88	-0.44	4.2e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg12615879	chr12:58013172	SLC26A10	-0.3	-6.38	-0.33	5.76e-10	Multiple sclerosis;
LUSC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg12310025	chr6:25882481	NA	0.41	6.79	0.35	5.02e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs11051970	0.879	rs2728669	chr12:32590651	C/T	cg02745156	chr12:32552066	NA	0.42	7.12	0.36	6.75e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.29	-0.53	2.97e-25	Mean corpuscular volume;
LUSC	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg23283495	chr1:209979779	IRF6	0.39	6.03	0.31	4.24e-9	Monobrow;
LUSC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg08219700	chr8:58056026	NA	0.5	6.24	0.32	1.32e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs8027181	0.959	rs11631352	chr15:73086473	A/G	cg25632853	chr15:73088954	NA	-0.34	-6.79	-0.35	5.16e-11	Triglyceride levels;
LUSC	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg05347473	chr6:146136440	FBXO30	0.38	6.38	0.33	5.87e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg05110241	chr16:68378359	PRMT7	-0.64	-6.99	-0.36	1.46e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12042107	0.818	rs6428600	chr1:91192297	C/G	cg13456504	chr1:91191583	NA	0.43	7.21	0.37	3.87e-12	Educational attainment;
LUSC	cis	rs7683537	0.692	rs56368159	chr4:185654827	T/G	cg07424746	chr4:185654737	MLF1IP	-0.52	-5.76	-0.3	1.95e-8	Systemic lupus erythematosus;
LUSC	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg11789530	chr4:8429930	ACOX3	0.57	9.12	0.45	7.26e-18	Response to antineoplastic agents;
LUSC	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg27219399	chr15:67835830	MAP2K5	-0.36	-6.05	-0.31	3.92e-9	Restless legs syndrome;
LUSC	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg24130564	chr14:104152367	KLC1	-0.51	-7.43	-0.38	9.17e-13	Body mass index;
LUSC	cis	rs6977660	1.000	rs13231036	chr7:19806141	G/A	cg07541023	chr7:19748670	TWISTNB	0.53	6.09	0.32	3.14e-9	Thyroid stimulating hormone;
LUSC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.54	8.37	0.42	1.63e-15	Lymphocyte counts;
LUSC	cis	rs7572644	0.553	rs4233717	chr2:28034680	A/T	cg27432699	chr2:27873401	GPN1	0.58	7.38	0.37	1.26e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg22676075	chr6:135203613	NA	0.46	7.13	0.36	6.1e-12	Red blood cell count;
LUSC	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg24130564	chr14:104152367	KLC1	-0.49	-7.78	-0.39	9.15e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10150615	chr22:24372951	LOC391322	-0.38	-6.32	-0.33	8.35e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg04362960	chr10:104952993	NT5C2	0.61	9.01	0.44	1.64e-17	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg07936489	chr17:37558343	FBXL20	-0.72	-9.91	-0.48	1.76e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg25482853	chr8:67687455	SGK3	1.2	17.16	0.68	9.11e-48	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg05347473	chr6:146136440	FBXO30	0.53	9.08	0.44	1e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg15133208	chr4:90757351	SNCA	-0.56	-8.46	-0.42	8.77e-16	Neuroticism;
LUSC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg09034736	chr1:150693464	HORMAD1	0.4	5.72	0.3	2.37e-8	Melanoma;
LUSC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.48	0.46	5e-19	Mean platelet volume;
LUSC	cis	rs68170813	0.559	rs7793594	chr7:106891829	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.27e-20	Coronary artery disease;
LUSC	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg05347473	chr6:146136440	FBXO30	0.52	8.74	0.43	1.13e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.71	0.54	9.35e-27	Alzheimer's disease;
LUSC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.38	7.62e-13	Bipolar disorder;
LUSC	cis	rs727505	1.000	rs9655845	chr7:124513355	G/C	cg23710748	chr7:124431027	NA	-0.41	-7.39	-0.38	1.16e-12	Lewy body disease;
LUSC	cis	rs9309473	1.000	rs7584575	chr2:73666402	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.49	-0.33	3.07e-10	Metabolite levels;
LUSC	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.58	0.38	3.43e-13	Morning vs. evening chronotype;
LUSC	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.65	-8.57	-0.42	3.93e-16	Glomerular filtration rate;
LUSC	cis	rs6961069	0.585	rs10268417	chr7:80239837	C/A	cg04458919	chr7:80252533	CD36	-0.4	-7.32	-0.37	1.91e-12	Platelet count;
LUSC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.79	-0.51	1.74e-23	Aortic root size;
LUSC	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg22709100	chr7:91322751	NA	0.39	5.77	0.3	1.86e-8	Breast cancer;
LUSC	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22857025	chr5:266934	NA	-1.14	-14.7	-0.63	4.52e-38	Breast cancer;
LUSC	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg00071950	chr4:10020882	SLC2A9	0.46	7.49	0.38	6.08e-13	Bone mineral density;
LUSC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.53	0.5	1.44e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg13256891	chr4:100009986	ADH5	-0.45	-6.23	-0.32	1.43e-9	Alcohol dependence;
LUSC	cis	rs12618769	0.597	rs961242	chr2:99138979	G/A	cg10123293	chr2:99228465	UNC50	0.45	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg08499158	chr17:42289980	UBTF	0.41	6.28	0.32	1.05e-9	Total body bone mineral density;
LUSC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg02018176	chr4:1364513	KIAA1530	0.51	8.98	0.44	1.99e-17	Obesity-related traits;
LUSC	cis	rs2267681	0.544	rs10237429	chr7:139528596	C/G	cg14116596	chr7:139528673	TBXAS1	0.36	6.23	0.32	1.42e-9	Cervical cancer;
LUSC	cis	rs28647808	0.881	rs71483207	chr9:136258698	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg21782813	chr7:2030301	MAD1L1	0.48	8.02	0.4	1.84e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs6700896	0.966	rs11208689	chr1:66083197	G/A	cg04111102	chr1:66153794	NA	0.31	6.92	0.35	2.3e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg14552801	chr7:65878734	NA	-0.37	-5.68	-0.3	2.97e-8	Aortic root size;
LUSC	cis	rs12220238	1.000	rs11000894	chr10:75906598	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.96	0.36	1.79e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg03676636	chr4:99064102	C4orf37	0.34	7.34	0.37	1.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9296092	0.538	rs115770720	chr6:33517032	A/T	cg13560919	chr6:33536144	NA	-0.82	-15.73	-0.65	4.02e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg03161606	chr19:29218774	NA	0.6	8.79	0.43	7.77e-17	Methadone dose in opioid dependence;
LUSC	cis	rs7615316	0.902	rs6799752	chr3:142311712	T/C	cg16271453	chr3:142027066	XRN1	-0.36	-6.12	-0.32	2.58e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2282032	0.527	rs57011283	chr14:90767165	G/T	cg04374321	chr14:90722782	PSMC1	0.44	6.14	0.32	2.32e-9	Longevity;
LUSC	cis	rs73416724	1.000	rs75782458	chr6:43340810	G/A	cg26312998	chr6:43337775	ZNF318	0.57	6.62	0.34	1.4e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6087990	0.735	rs2064350	chr20:31390533	T/C	cg13636640	chr20:31349939	DNMT3B	0.93	18.92	0.72	9.01e-55	Ulcerative colitis;
LUSC	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg16342193	chr10:102329863	NA	-0.37	-6.31	-0.33	9.07e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.98	0.36	1.62e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg23711669	chr6:146136114	FBXO30	0.76	13.72	0.6	2.76e-34	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25958857	chr12:53448399	TENC1	-0.37	-7.05	-0.36	1.02e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1044826	0.642	rs6787649	chr3:139193321	C/T	cg00490450	chr3:139108681	COPB2	0.46	7.02	0.36	1.27e-11	Obesity-related traits;
LUSC	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg04369109	chr6:150039330	LATS1	-0.58	-8.59	-0.43	3.3e-16	Lung cancer;
LUSC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17261708	chr5:176794207	RGS14	0.33	5.72	0.3	2.43e-8	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg15445000	chr17:37608096	MED1	0.38	6.52	0.34	2.54e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	0.91	19.01	0.72	3.92e-55	Platelet distribution width;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg00021166	chr12:27676702	PPFIBP1	0.42	6.61	0.34	1.57e-10	Triglycerides;
LUSC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	0.95	19.4	0.73	1.07e-56	Cognitive function;
LUSC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg24690094	chr11:67383802	NA	0.52	11.03	0.52	2.4e-24	Mean corpuscular volume;
LUSC	trans	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg26384229	chr12:38710491	ALG10B	-0.58	-8.7	-0.43	1.5e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg23280166	chr11:118938394	VPS11	0.48	7.43	0.38	9.21e-13	Coronary artery disease;
LUSC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg06808227	chr14:105710500	BRF1	-0.6	-8.7	-0.43	1.58e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg13206674	chr6:150067644	NUP43	0.56	8.68	0.43	1.76e-16	Lung cancer;
LUSC	trans	rs6480314	0.542	rs12572967	chr10:70030630	G/A	cg04882175	chr6:131122610	NA	-0.54	-6.19	-0.32	1.77e-9	Optic nerve measurement (disc area);
LUSC	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg02023728	chr11:77925099	USP35	0.43	6.59	0.34	1.68e-10	Testicular germ cell tumor;
LUSC	cis	rs1595825	0.786	rs1902247	chr2:198492826	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.54	-0.34	2.3e-10	Ulcerative colitis;
LUSC	cis	rs6594499	0.872	rs10038058	chr5:110443281	A/G	cg04022379	chr5:110408740	TSLP	0.41	6.05	0.31	3.96e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1639906	0.965	rs1637742	chr7:2236432	G/A	cg18044113	chr7:2236405	MAD1L1	-0.31	-5.9	-0.31	8.71e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs931127	0.658	rs4244812	chr11:65480768	A/G	cg05805236	chr11:65401703	PCNXL3	-0.45	-7.56	-0.38	3.96e-13	Systemic lupus erythematosus;
LUSC	cis	rs13082711	0.555	rs7627508	chr3:27252495	A/C	cg02860705	chr3:27208620	NA	0.67	11.7	0.54	1.01e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg20476274	chr7:133979776	SLC35B4	0.83	15.23	0.64	3.81e-40	Mean platelet volume;
LUSC	cis	rs7091068	0.616	rs6583905	chr10:95504022	T/G	cg20715218	chr10:95462985	C10orf4	0.61	6.69	0.34	9.4e-11	Urinary tract infection frequency;
LUSC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.73	-10.03	-0.48	7.03e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg23711669	chr6:146136114	FBXO30	0.82	14.57	0.62	1.5e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg04455712	chr21:45112962	RRP1B	0.45	8.44	0.42	9.65e-16	Mean corpuscular volume;
LUSC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg12963246	chr6:28129442	ZNF389	0.52	7.18	0.37	4.53e-12	Depression;
LUSC	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg24642844	chr7:1081250	C7orf50	-0.68	-6.38	-0.33	5.82e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4363385	0.818	rs653332	chr1:153010481	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.67e-12	Inflammatory skin disease;
LUSC	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg00745463	chr17:30367425	LRRC37B	-0.8	-8.52	-0.42	5.56e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.35	-0.37	1.54e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7220711	1.000	rs12602349	chr17:41792236	T/C	cg26893861	chr17:41843967	DUSP3	0.42	5.88	0.31	9.89e-9	Bone mineral density (spine);Bone mineral density (hip);
LUSC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg08200582	chr11:442649	ANO9	-0.53	-5.74	-0.3	2.07e-8	Body mass index;
LUSC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06022373	chr22:39101656	GTPBP1	-0.78	-12.08	-0.55	4.15e-28	Menopause (age at onset);
LUSC	cis	rs7605827	0.930	rs12692267	chr2:15572834	A/G	cg19274914	chr2:15703543	NA	-0.5	-9.69	-0.47	1.01e-19	Educational attainment (years of education);
LUSC	cis	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.39	-0.33	5.71e-10	Morning vs. evening chronotype;
LUSC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg15468180	chr1:107600409	PRMT6	-0.38	-6.08	-0.32	3.28e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs55871839	0.640	rs4738734	chr8:59814330	A/T	cg07426533	chr8:59803705	TOX	-0.37	-6.08	-0.32	3.27e-9	Pneumonia;
LUSC	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg08085267	chr17:45401833	C17orf57	-0.55	-8.55	-0.42	4.52e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs244293	1.000	rs2628313	chr17:53235352	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.43	-6.11	-0.32	2.74e-9	Menarche (age at onset);
LUSC	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg14169450	chr9:139327907	INPP5E	0.42	7.68	0.39	1.78e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6920965	0.563	rs1544292	chr6:126175093	G/C	cg05901451	chr6:126070800	HEY2	-0.39	-5.66	-0.3	3.26e-8	High light scatter reticulocyte count;
LUSC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg12292205	chr6:26970375	C6orf41	0.68	11.99	0.55	8.26e-28	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.53	0.57	8.85e-30	Motion sickness;
LUSC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.7	0.34	8.92e-11	Tonsillectomy;
LUSC	trans	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg12856521	chr11:46389249	DGKZ	0.42	6.69	0.34	9.38e-11	Leprosy;
LUSC	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg12483005	chr1:23474871	LUZP1	0.41	6.15	0.32	2.18e-9	Height;
LUSC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	11.27	0.52	3.52e-25	Bone mineral density;
LUSC	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05472934	chr7:22766657	IL6	0.47	7.63	0.39	2.4e-13	Lung cancer;
LUSC	trans	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg26043149	chr18:55253948	FECH	-0.45	-7.02	-0.36	1.23e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs72792513	1.000	rs3860475	chr2:22912603	C/A	cg05844895	chr16:88969569	CBFA2T3	0.52	6.1	0.32	2.9e-9	Hepatitis B;
LUSC	cis	rs9653442	0.564	rs13013594	chr2:100784190	A/G	cg07810366	chr2:100720526	AFF3	-0.44	-7.49	-0.38	6.12e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg15704280	chr7:45808275	SEPT13	0.73	8.25	0.41	3.75e-15	Axial length;
LUSC	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg07578070	chr6:150326732	RAET1K	0.41	6.4	0.33	5.14e-10	Alopecia areata;
LUSC	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-7.12	-0.36	6.85e-12	Axial length;
LUSC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg24675658	chr1:53192096	ZYG11B	0.6	9.54	0.46	3.17e-19	Monocyte count;
LUSC	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg16386425	chr10:429943	DIP2C	0.41	6.46	0.33	3.78e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg08345082	chr10:99160200	RRP12	-0.35	-7.11	-0.36	7.29e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg24375607	chr4:120327624	NA	0.77	11.32	0.53	2.32e-25	Corneal astigmatism;
LUSC	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg15896084	chr13:114927664	NA	0.41	7.5	0.38	5.81e-13	Schizophrenia;
LUSC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.14	0.45	6.43e-18	Height;
LUSC	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg23202291	chr11:1979235	NA	0.4	6.15	0.32	2.19e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-9.97	-0.48	1.12e-20	Mean corpuscular volume;
LUSC	trans	rs1941687	0.765	rs11877423	chr18:31390368	G/A	cg27147174	chr7:100797783	AP1S1	-0.45	-6.56	-0.34	2.04e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	trans	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg26043149	chr18:55253948	FECH	0.45	6.78	0.35	5.46e-11	Bone mineral density;
LUSC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.44	-0.38	8.52e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.79	0.65	2.33e-42	Bladder cancer;
LUSC	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg24596788	chr1:163392923	NA	-0.45	-7.58	-0.38	3.37e-13	Motion sickness;
LUSC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg13531842	chr10:38383804	ZNF37A	-0.46	-7.19	-0.37	4.35e-12	Extrinsic epigenetic age acceleration;
LUSC	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	1.15	18.32	0.71	2.27e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg21427119	chr20:30132790	HM13	-0.44	-6.18	-0.32	1.83e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg25174290	chr11:3078921	CARS	0.6	9.36	0.46	1.19e-18	Longevity;
LUSC	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg11244672	chr19:19639970	YJEFN3	-0.55	-6.84	-0.35	3.86e-11	Bipolar disorder;
LUSC	cis	rs3858704	0.517	rs7297186	chr12:111778178	C/T	cg10833066	chr12:111807467	FAM109A	-0.64	-13.27	-0.59	1.39e-32	Idiopathic osteonecrosis of the femoral head;
LUSC	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg03929089	chr4:120376271	NA	0.59	6.51	0.34	2.77e-10	Axial length;
LUSC	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg21643547	chr1:205240462	TMCC2	-0.49	-9.28	-0.45	2.22e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6700896	0.897	rs11208701	chr1:66134698	C/T	cg04111102	chr1:66153794	NA	0.33	7.26	0.37	2.81e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg07636037	chr3:49044803	WDR6	-0.67	-5.77	-0.3	1.79e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18876405	chr7:65276391	NA	0.49	7.62	0.38	2.72e-13	Corneal structure;
LUSC	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg17252645	chr8:143867129	LY6D	-0.55	-10.37	-0.49	4.92e-22	Urinary tract infection frequency;
LUSC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg06618935	chr21:46677482	NA	-0.37	-7.33	-0.37	1.75e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg22868518	chr11:507468	RNH1	-0.63	-5.96	-0.31	6.47e-9	Body mass index;
LUSC	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg25457927	chr22:38595422	NA	-0.41	-8.8	-0.43	7.72e-17	Cutaneous nevi;
LUSC	cis	rs7923452	0.938	rs67812762	chr10:30759479	G/T	cg25182066	chr10:30743637	MAP3K8	0.58	6.8	0.35	4.9e-11	Itch intensity from mosquito bite;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25858983	chr17:42295711	UBTF	0.43	6.85	0.35	3.56e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3849570	0.961	rs10154945	chr3:81833766	A/C	cg07356753	chr3:81810745	GBE1	-0.68	-11.09	-0.52	1.46e-24	Waist circumference;Body mass index;
LUSC	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.14	0.64	8.56e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg24209194	chr3:40518798	ZNF619	0.47	6.52	0.34	2.55e-10	Renal cell carcinoma;
LUSC	cis	rs68170813	0.523	rs75999022	chr7:107017135	C/T	cg02696742	chr7:106810147	HBP1	-0.64	-9.61	-0.47	1.82e-19	Coronary artery disease;
LUSC	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg14019695	chr9:139328340	INPP5E	0.43	8.1	0.41	1.06e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10761482	0.954	rs10443926	chr10:62065993	C/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.43	-0.33	4.41e-10	Schizophrenia;
LUSC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.16	0.32	2.14e-9	Menopause (age at onset);
LUSC	cis	rs7215564	0.818	rs35929483	chr17:78635944	C/A	cg23238734	chr17:78661607	RPTOR	0.49	6.2	0.32	1.66e-9	Myopia (pathological);
LUSC	cis	rs11030122	0.632	rs11030599	chr11:4031677	A/G	cg08557956	chr11:4115526	RRM1	-0.46	-5.88	-0.31	1e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-7.4	-0.38	1.09e-12	Bone mineral density;
LUSC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg01879757	chr17:41196368	BRCA1	-0.46	-7.13	-0.36	6.39e-12	Menopause (age at onset);
LUSC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-0.8	-10.18	-0.49	2.3e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg08493051	chr2:3487164	NA	-0.56	-8.81	-0.43	6.76e-17	Neurofibrillary tangles;
LUSC	cis	rs1941023	0.503	rs4939348	chr11:60135871	A/C	cg08716584	chr11:60157161	MS4A7	-0.62	-11.74	-0.54	6.8e-27	Congenital heart disease (maternal effect);
LUSC	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg11245181	chr6:149772854	ZC3H12D	0.3	6.38	0.33	6.07e-10	Dupuytren's disease;
LUSC	cis	rs2242663	0.798	rs607736	chr11:66328877	G/A	cg18002602	chr11:66138449	SLC29A2	-0.36	-6.31	-0.33	8.82e-10	Bipolar disorder;
LUSC	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg22437258	chr11:111473054	SIK2	0.51	6.91	0.35	2.42e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg13010199	chr12:38710504	ALG10B	0.65	10.13	0.48	3.32e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12541635	0.966	rs7819327	chr8:106986003	A/C	cg10147462	chr8:107024639	NA	0.56	9.74	0.47	6.89e-20	Age of smoking initiation;
LUSC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.99	0.55	8.55e-28	Chronic sinus infection;
LUSC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	8.98	0.44	2.09e-17	Post bronchodilator FEV1;
LUSC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.91	-0.48	1.85e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg06145435	chr7:1022769	CYP2W1	0.34	5.75	0.3	1.98e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs10740039	0.883	rs1975442	chr10:62410919	G/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.85	-0.35	3.61e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2067615	0.542	rs10861654	chr12:107122896	A/G	cg15890332	chr12:107067104	RFX4	0.34	6.15	0.32	2.22e-9	Heart rate;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg22184145	chr4:57845401	POLR2B	0.4	6.17	0.32	1.97e-9	Triglycerides;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10446143	chr21:44394730	PKNOX1	0.41	6.17	0.32	2e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.79	0.3	1.6e-8	Breast cancer;
LUSC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25072359	chr17:41440525	NA	-0.62	-9.19	-0.45	4.43e-18	Menopause (age at onset);
LUSC	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg00495681	chr13:53174319	NA	0.53	8.91	0.44	3.33e-17	Lewy body disease;
LUSC	trans	rs1493916	0.748	rs2040203	chr18:31307420	G/T	cg27147174	chr7:100797783	AP1S1	-0.55	-8.58	-0.42	3.57e-16	Life satisfaction;
LUSC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg05535760	chr7:792225	HEATR2	-0.73	-7.52	-0.38	5.18e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs3744061	0.505	rs9907915	chr17:74651236	A/G	cg27546012	chr17:74684504	MXRA7	-0.4	-6.88	-0.35	2.93e-11	Retinal arteriolar caliber;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13886124	chr9:130186480	ZNF79	0.45	6.12	0.32	2.67e-9	Neuroticism;
LUSC	cis	rs12220238	1.000	rs11000890	chr10:75904073	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	7.05	0.36	1.05e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs11039100	0.850	rs11039118	chr11:5832601	A/G	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	8.23	0.41	4.11e-15	Axial length;
LUSC	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg17385448	chr1:15911702	AGMAT	0.37	6.37	0.33	6.3e-10	Systolic blood pressure;
LUSC	cis	rs6545883	0.929	rs2593635	chr2:61634706	A/C	cg15711740	chr2:61764176	XPO1	0.44	6.64	0.34	1.26e-10	Tuberculosis;
LUSC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.13	0.41	8.5e-15	Prudent dietary pattern;
LUSC	trans	rs2221154	0.648	rs7620147	chr3:28959712	C/T	cg16413675	chr16:2520055	NTN3	0.29	6.12	0.32	2.63e-9	Alzheimer's disease;
LUSC	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg24634471	chr8:143751801	JRK	0.51	7.25	0.37	2.97e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08859206	chr1:53392774	SCP2	-0.68	-12.93	-0.58	2.87e-31	Monocyte count;
LUSC	cis	rs2070433	0.799	rs7279002	chr21:47910523	C/T	cg12379764	chr21:47803548	PCNT	-0.69	-9.41	-0.46	8.01e-19	Lymphocyte counts;
LUSC	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg05855489	chr10:104503620	C10orf26	0.51	7.9	0.4	3.95e-14	Arsenic metabolism;
LUSC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg12564285	chr5:131593104	PDLIM4	0.35	6.31	0.33	8.93e-10	Breast cancer;Mosquito bite size;
LUSC	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg05425664	chr17:57184151	TRIM37	-0.51	-7.63	-0.39	2.46e-13	Testicular germ cell tumor;
LUSC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg16339924	chr4:17578868	LAP3	0.57	8.72	0.43	1.38e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7712401	0.601	rs62377430	chr5:122334688	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.22	-0.45	3.4e-18	Mean platelet volume;
LUSC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg01483505	chr11:975446	AP2A2	0.41	5.66	0.3	3.29e-8	Alzheimer's disease (late onset);
LUSC	cis	rs6076065	0.644	rs2424535	chr20:23381196	T/C	cg11657817	chr20:23433608	CST11	0.41	7.81	0.39	7.57e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	0.71	11.96	0.55	1.14e-27	Methadone dose in opioid dependence;
LUSC	cis	rs9653442	1.000	rs9653442	chr2:100825367	A/G	cg07810366	chr2:100720526	AFF3	0.43	7.6	0.38	3.04e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	7.66	0.39	2.03e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9837602	0.938	rs9814359	chr3:99797013	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.32	0.33	8.18e-10	Breast cancer;
LUSC	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg01191920	chr7:158217561	PTPRN2	-0.49	-10.29	-0.49	9.55e-22	Obesity-related traits;
LUSC	trans	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.43	-0.33	4.38e-10	Retinal vascular caliber;
LUSC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.03	15.77	0.65	2.97e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg18904891	chr8:8559673	CLDN23	0.56	7.63	0.39	2.53e-13	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg10729496	chr3:10149963	C3orf24	0.56	7.25	0.37	2.92e-12	Alzheimer's disease;
LUSC	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg03585969	chr10:35415529	CREM	0.65	9.25	0.45	2.78e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.15	-0.36	5.65e-12	Bipolar disorder;
LUSC	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg10523679	chr1:76189770	ACADM	-0.49	-7.2	-0.37	4e-12	Daytime sleep phenotypes;
LUSC	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg20734569	chr3:48348370	SPINK8	0.46	8.08	0.4	1.16e-14	Coronary artery disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19998654	chr2:37458983	CEBPZ;C2orf56	-0.47	-6.35	-0.33	7.09e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26361928	chr5:151151522	G3BP1	0.47	6.45	0.33	4.04e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.52	-7.47	-0.38	6.96e-13	Gut microbiome composition (summer);
LUSC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg09835421	chr16:68378352	PRMT7	-0.56	-6.13	-0.32	2.43e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg04362960	chr10:104952993	NT5C2	0.51	7.14	0.36	5.71e-12	Colorectal cancer;
LUSC	cis	rs672059	0.966	rs689375	chr1:183160973	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.06	0.4	1.37e-14	Hypertriglyceridemia;
LUSC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.36	-0.33	6.78e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.6	8.08	0.4	1.2e-14	High light scatter reticulocyte count;
LUSC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg03146154	chr1:46216737	IPP	0.5	7.41	0.38	1.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg24644049	chr4:85504048	CDS1	0.87	7.49	0.38	6.2e-13	Skin colour saturation;
LUSC	cis	rs6539267	0.885	rs12579099	chr12:106765727	A/G	cg00173435	chr12:106696525	TCP11L2	0.46	6.49	0.33	3.06e-10	Tourette syndrome;
LUSC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	0.82	12.36	0.56	3.58e-29	Gut microbiome composition (summer);
LUSC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.26	0.37	2.72e-12	Motion sickness;
LUSC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg08132940	chr7:1081526	C7orf50	-0.52	-6.15	-0.32	2.27e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg16325326	chr1:53192061	ZYG11B	0.97	20.79	0.75	3.46e-62	Monocyte count;
LUSC	cis	rs6969780	0.915	rs17471520	chr7:27178790	T/C	cg26364809	chr7:27145159	NA	-0.57	-5.8	-0.3	1.52e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg16386425	chr10:429943	DIP2C	0.37	5.68	0.3	2.98e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	trans	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg18187862	chr3:45730750	SACM1L	0.52	6.83	0.35	4e-11	Primary sclerosing cholangitis;
LUSC	cis	rs8135665	0.625	rs8142185	chr22:38451080	A/C	cg13116946	chr22:38479732	SLC16A8	0.41	6.44	0.33	4.26e-10	Advanced age-related macular degeneration;Age-related macular degeneration;
LUSC	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg05768032	chr16:30646687	NA	0.4	5.81	0.3	1.48e-8	Multiple myeloma;
LUSC	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05901451	chr6:126070800	HEY2	-0.76	-12.67	-0.57	2.54e-30	Brugada syndrome;
LUSC	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg07423050	chr13:99094983	FARP1	-0.55	-10.05	-0.48	5.96e-21	Longevity;
LUSC	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg06627628	chr2:24431161	ITSN2	-0.59	-7.24	-0.37	3.06e-12	Lymphocyte counts;
LUSC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg08508325	chr11:3079039	CARS	-0.51	-12.69	-0.57	2.16e-30	Longevity;
LUSC	cis	rs7542375	0.930	rs7523735	chr1:221064780	C/G	cg16008148	chr1:221062819	NA	0.37	6.61	0.34	1.49e-10	Obesity-related traits;
LUSC	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.42	-0.33	4.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.31	0.53	2.45e-25	Menopause (age at onset);
LUSC	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg09699651	chr6:150184138	LRP11	0.45	7.12	0.36	6.69e-12	Testicular germ cell tumor;
LUSC	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.7	-10.08	-0.48	4.89e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg00105475	chr2:10696890	NA	0.38	6.27	0.32	1.11e-9	Prostate cancer;
LUSC	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07636037	chr3:49044803	WDR6	-0.61	-7.81	-0.39	7.65e-14	Menarche (age at onset);
LUSC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08045932	chr20:61659980	NA	0.59	10.51	0.5	1.65e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg13010199	chr12:38710504	ALG10B	-0.44	-6.58	-0.34	1.82e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg02079420	chr8:82753780	SNX16	0.4	6.12	0.32	2.62e-9	Diastolic blood pressure;
LUSC	cis	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg06521331	chr12:34319734	NA	0.41	6.75	0.35	6.66e-11	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg08677398	chr8:58056175	NA	0.41	5.71	0.3	2.51e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-10.95	-0.51	4.95e-24	Mean corpuscular volume;
LUSC	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg05347473	chr6:146136440	FBXO30	0.54	9.34	0.46	1.39e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.46	-7.48	-0.38	6.61e-13	IgG glycosylation;
LUSC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10053473	chr17:62856997	LRRC37A3	0.67	10.63	0.5	6.51e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg17788362	chr6:86352627	SYNCRIP	0.48	7.34	0.37	1.61e-12	Smooth-surface caries;
LUSC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	9.53	0.46	3.4e-19	IgG glycosylation;
LUSC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.96	-0.31	6.47e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.3	6.07	0.32	3.48e-9	Lymphocyte counts;
LUSC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.2	0.41	5.24e-15	Homoarginine levels;
LUSC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg23711669	chr6:146136114	FBXO30	-0.7	-12.1	-0.55	3.5e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg13010199	chr12:38710504	ALG10B	-0.54	-8.24	-0.41	4.07e-15	Morning vs. evening chronotype;
LUSC	cis	rs6906287	0.647	rs2213857	chr6:118806780	A/G	cg21191810	chr6:118973309	C6orf204	0.33	5.9	0.31	8.9e-9	Electrocardiographic conduction measures;
LUSC	trans	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg20935933	chr6:143382018	AIG1	0.5	7.27	0.37	2.61e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg07679203	chr4:1993400	WHSC2	-0.38	-6.25	-0.32	1.28e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.52	5.95	0.31	6.75e-9	Schizophrenia;
LUSC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg16414030	chr3:133502952	NA	0.44	6.71	0.34	8.42e-11	Iron status biomarkers;
LUSC	cis	rs9400467	0.528	rs11153288	chr6:111715238	T/A	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.36	2e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.54	-9.35	-0.46	1.31e-18	Menopause (age at onset);
LUSC	cis	rs9807989	0.729	rs10170583	chr2:102974764	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.7	0.3	2.63e-8	Asthma;
LUSC	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.56	10.87	0.51	8.98e-24	Hemoglobin concentration;
LUSC	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg09173681	chr1:183549694	NCF2	-0.62	-11.03	-0.52	2.51e-24	Systemic lupus erythematosus;
LUSC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg05754148	chr16:3507555	NAT15	-0.83	-9.01	-0.44	1.59e-17	Tuberculosis;
LUSC	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg16586182	chr3:47516702	SCAP	0.53	8.33	0.41	2.05e-15	Colorectal cancer;
LUSC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.74	0.35	7.06e-11	Tonsillectomy;
LUSC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.02	0.48	7.73e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg05072774	chr3:49840536	C3orf54	-0.43	-5.96	-0.31	6.27e-9	Resting heart rate;
LUSC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg06145435	chr7:1022769	CYP2W1	0.31	6.34	0.33	7.49e-10	Longevity;Endometriosis;
LUSC	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg06671706	chr8:8559999	CLDN23	0.49	6.57	0.34	1.94e-10	Obesity-related traits;
LUSC	cis	rs8040855	0.579	rs6496797	chr15:85726855	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.42	6.94	0.35	2.08e-11	Bulimia nervosa;
LUSC	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg27411982	chr8:10470053	RP1L1	0.39	5.98	0.31	5.7e-9	Retinal vascular caliber;
LUSC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-1.04	-20.3	-0.74	2.97e-60	Height;
LUSC	cis	rs10896135	0.554	rs3741364	chr11:66451178	C/T	cg24851651	chr11:66362959	CCS	0.49	6.66	0.34	1.1e-10	Bipolar disorder;
LUSC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-9.71	-0.47	8.23e-20	Menarche (age at onset);
LUSC	cis	rs367943	0.712	rs6896650	chr5:112681048	T/C	cg12552261	chr5:112820674	MCC	0.37	6.12	0.32	2.62e-9	Type 2 diabetes;
LUSC	cis	rs2540226	0.844	rs12620957	chr2:40006430	A/C	cg23576258	chr2:39999331	THUMPD2	0.35	5.93	0.31	7.46e-9	Personality dimensions;
LUSC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12738007	0.544	rs12408688	chr1:29431072	C/T	cg01925633	chr1:29338769	EPB41	0.39	6.01	0.31	4.79e-9	Schizophrenia;
LUSC	cis	rs308403	0.532	rs309386	chr4:123665991	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.98	18.61	0.71	1.54e-53	Blood protein levels;
LUSC	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg27087555	chr16:88793112	FAM38A	-1.39	-15.52	-0.65	2.77e-41	Plateletcrit;
LUSC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.31	0.33	8.99e-10	Systolic blood pressure;
LUSC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.36	-6.18	-0.32	1.92e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg27411982	chr8:10470053	RP1L1	0.46	6.99	0.36	1.46e-11	Neuroticism;
LUSC	trans	rs1325195	0.920	rs377785	chr1:179224067	T/A	cg11624085	chr17:8464688	MYH10	0.41	6.72	0.35	7.76e-11	IgE grass sensitization;
LUSC	cis	rs2688608	1.000	rs2688610	chr10:75654931	A/G	cg23231163	chr10:75533350	FUT11	0.39	6.6	0.34	1.61e-10	Inflammatory bowel disease;
LUSC	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7241530	0.610	rs7230650	chr18:75892679	A/G	cg14642773	chr18:75888474	NA	0.37	5.65	0.3	3.53e-8	Educational attainment (years of education);
LUSC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg09021430	chr5:549028	NA	-0.55	-7.25	-0.37	2.95e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs10207060	0.500	rs7566489	chr2:240703985	C/T	cg07506560	chr2:240697449	NA	0.44	6.87	0.35	3.12e-11	Obesity-related traits;
LUSC	cis	rs6977660	0.714	rs12537283	chr7:19817658	G/T	cg05791153	chr7:19748676	TWISTNB	0.67	7.09	0.36	8.17e-12	Thyroid stimulating hormone;
LUSC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.22	0.88	3.18e-111	Chronic sinus infection;
LUSC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg02018176	chr4:1364513	KIAA1530	0.48	8.4	0.42	1.28e-15	Obesity-related traits;
LUSC	cis	rs41271951	0.512	rs116666233	chr1:151056058	C/T	cg11822372	chr1:151115635	SEMA6C	-0.78	-7.18	-0.37	4.51e-12	Blood protein levels;
LUSC	cis	rs68170813	0.559	rs113211438	chr7:106969198	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.57	-0.46	2.53e-19	Coronary artery disease;
LUSC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg12963246	chr6:28129442	ZNF389	0.56	7.89	0.4	4.28e-14	Parkinson's disease;
LUSC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg26408565	chr15:76604113	ETFA	-0.5	-7.98	-0.4	2.4e-14	Blood metabolite levels;
LUSC	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg26408565	chr15:76604113	ETFA	-0.48	-7.58	-0.38	3.51e-13	Blood metabolite levels;
LUSC	cis	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg06521331	chr12:34319734	NA	-0.46	-7.32	-0.37	1.82e-12	Morning vs. evening chronotype;
LUSC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg16447950	chr5:562315	NA	-0.54	-6.84	-0.35	3.69e-11	Obesity-related traits;
LUSC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg11859384	chr17:80120422	CCDC57	0.36	5.68	0.3	2.86e-8	Life satisfaction;
LUSC	cis	rs4961252	0.505	rs4961327	chr8:142102053	C/T	cg09914555	chr8:142094789	NA	-0.48	-7.1	-0.36	7.74e-12	Isovolumetric relaxation time;Response to interferon beta therapy;
LUSC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg09455208	chr3:40491958	NA	0.58	10.46	0.5	2.38e-22	Renal cell carcinoma;
LUSC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.67	6.42	0.33	4.68e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs56804039	1.000	rs17616779	chr8:8382374	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.92	0.35	2.25e-11	Cervical cancer;
LUSC	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.67e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11794814	chr19:40791331	AKT2	0.46	6.18	0.32	1.9e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs597583	0.715	rs4938400	chr11:117399604	C/A	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.02	-0.4	1.81e-14	Putamen volume;
LUSC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg04166393	chr7:2884313	GNA12	0.42	5.86	0.31	1.09e-8	Height;
LUSC	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.69	-0.39	1.67e-13	Blood metabolite levels;
LUSC	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	13.82	0.6	1.13e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10740039	0.883	rs1837946	chr10:62393434	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg13647721	chr17:30228624	UTP6	-0.69	-7.5	-0.38	5.71e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.55	0.38	4.06e-13	Iron status biomarkers;
LUSC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.92	13.28	0.59	1.37e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.58	10.67	0.5	4.63e-23	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.78	0.51	1.85e-23	Lung cancer in ever smokers;
LUSC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-7.3	-0.37	2.11e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg21775007	chr8:11205619	TDH	-0.5	-6.95	-0.36	1.9e-11	Triglycerides;
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.55	-8.42	-0.42	1.12e-15	Lymphocyte counts;
LUSC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg11062466	chr8:58055876	NA	0.69	8.13	0.41	8.64e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7589342	0.628	rs10496403	chr2:106419622	T/G	cg14210321	chr2:106509881	NCK2	-0.45	-5.78	-0.3	1.75e-8	Addiction;
LUSC	trans	rs12165098	0.636	rs4511605	chr18:36744974	T/C	cg23858286	chr9:138135095	NA	-0.42	-6.07	-0.32	3.44e-9	Sleep duration;
LUSC	cis	rs13082711	0.911	rs66694067	chr3:27477337	C/T	cg02860705	chr3:27208620	NA	0.5	7.99	0.4	2.25e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg13575925	chr12:9217583	LOC144571	-0.32	-5.92	-0.31	7.91e-9	Sjögren's syndrome;
LUSC	cis	rs4478858	0.735	rs10798842	chr1:31778648	A/G	cg00250761	chr1:31883323	NA	-0.35	-8.54	-0.42	4.8e-16	Alcohol dependence;
LUSC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg24733560	chr20:60626293	TAF4	0.35	5.68	0.3	2.91e-8	Body mass index;
LUSC	trans	rs2786098	0.656	rs10922262	chr1:197559835	G/A	cg16005942	chr6:160526640	IGF2R	0.5	6.04	0.31	4.16e-9	Asthma;
LUSC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg18350739	chr11:68623251	NA	-0.4	-6.98	-0.36	1.57e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg24375607	chr4:120327624	NA	0.81	12.25	0.56	9.55e-29	Corneal astigmatism;
LUSC	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg00857998	chr1:205179979	DSTYK	0.62	9.52	0.46	3.48e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07981845	chr10:104154074	NFKB2	-0.4	-6.01	-0.31	4.86e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2637266	0.600	rs2395430	chr10:78465471	G/A	cg18941641	chr10:78392320	NA	0.33	5.93	0.31	7.61e-9	Pulmonary function;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22296620	chr15:45315419	SORD	-0.43	-6.09	-0.32	3.03e-9	Electrocardiographic conduction measures;
LUSC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.46	-0.33	3.71e-10	Menopause (age at onset);
LUSC	cis	rs7408868	1.000	rs10420466	chr19:15261371	G/T	cg14696996	chr19:15285081	NOTCH3	0.98	8.93	0.44	3.01e-17	Pulse pressure;
LUSC	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg16989719	chr2:238392110	NA	-0.42	-7.19	-0.37	4.35e-12	Prostate cancer;
LUSC	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg18827107	chr12:86230957	RASSF9	0.45	6.93	0.35	2.18e-11	Major depressive disorder;
LUSC	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg18827107	chr12:86230957	RASSF9	0.46	7.06	0.36	9.54e-12	Major depressive disorder;
LUSC	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.65e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14240646	chr10:27532245	ACBD5	-0.66	-7.91	-0.4	3.77e-14	Breast cancer;
LUSC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	6.08	0.32	3.27e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7712401	0.818	rs13166350	chr5:122153569	C/T	cg19077854	chr5:122220652	SNX24	0.35	8.08	0.4	1.19e-14	Mean platelet volume;
LUSC	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg00745463	chr17:30367425	LRRC37B	-0.76	-9.31	-0.45	1.74e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs7760949	0.963	rs9349840	chr6:13903809	G/A	cg27413430	chr6:13925136	RNF182	0.5	7.46	0.38	7.54e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg10560079	chr2:191398806	TMEM194B	-0.65	-8.14	-0.41	8.06e-15	Diastolic blood pressure;
LUSC	cis	rs116988415	0.539	rs17180350	chr14:65249066	C/T	cg25083366	chr14:65239357	SPTB	0.62	6.65	0.34	1.21e-10	Daytime sleep phenotypes;
LUSC	trans	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.6	0.38	3.08e-13	Ulcerative colitis;
LUSC	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg21433313	chr16:3507492	NAT15	-0.38	-5.99	-0.31	5.43e-9	Body mass index (adult);
LUSC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg03161606	chr19:29218774	NA	0.61	9.03	0.44	1.38e-17	Methadone dose in opioid dependence;
LUSC	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg24130564	chr14:104152367	KLC1	-0.46	-6.34	-0.33	7.27e-10	Body mass index;
LUSC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg21699342	chr2:239360505	ASB1	0.58	10.78	0.51	1.95e-23	Multiple system atrophy;
LUSC	cis	rs8077577	0.789	rs11078411	chr17:18088094	C/T	cg16794390	chr17:18148240	FLII	0.4	5.68	0.3	2.96e-8	Obesity-related traits;
LUSC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	12.07	0.55	4.28e-28	Colorectal cancer;
LUSC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg25767906	chr1:53392781	SCP2	-0.38	-6.44	-0.33	4.17e-10	Monocyte count;
LUSC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.98	0.36	1.57e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs800082	0.690	rs6440260	chr3:144289214	C/A	cg24215973	chr2:240111563	HDAC4	-0.61	-9.75	-0.47	6.38e-20	Smoking behavior;
LUSC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg06671706	chr8:8559999	CLDN23	0.48	6.52	0.34	2.67e-10	Obesity-related traits;
LUSC	cis	rs6541297	0.645	rs4846919	chr1:230301451	A/G	cg20703242	chr1:230279135	GALNT2	0.48	5.72	0.3	2.31e-8	Coronary artery disease;
LUSC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.7	11.32	0.53	2.23e-25	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7577696	0.752	rs12614686	chr2:32363171	A/G	cg02381751	chr2:32503542	YIPF4	-0.44	-6.22	-0.32	1.53e-9	Inflammatory biomarkers;
LUSC	cis	rs7215564	0.730	rs4889877	chr17:78662459	A/C	cg09596252	chr17:78655493	RPTOR	0.54	5.86	0.31	1.13e-8	Myopia (pathological);
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	1.05	27.5	0.83	7.93e-88	Menarche (age at onset);
LUSC	trans	rs17039065	1.000	rs72889364	chr4:109383977	C/T	cg07444054	chr2:108107501	NA	0.43	6.3	0.33	9.24e-10	Gut microbiome composition (summer);
LUSC	trans	rs1422110	0.543	rs768240	chr5:85420954	C/T	cg01787110	chr1:109008453	NBPF6	-0.5	-9.21	-0.45	3.65e-18	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs965469	1.000	rs2281497	chr20:3258874	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-6.01	-0.31	4.98e-9	IFN-related cytopenia;
LUSC	cis	rs10744422	1.000	rs3852537	chr12:123361501	T/C	cg25930673	chr12:123319894	HIP1R	-0.63	-6.21	-0.32	1.6e-9	Schizophrenia;
LUSC	cis	rs59698941	0.943	rs59634464	chr5:132178735	A/G	cg02081065	chr5:132209139	LEAP2	-0.62	-6.02	-0.31	4.62e-9	Apolipoprotein A-IV levels;
LUSC	cis	rs7524258	0.900	rs6577426	chr1:7306451	A/G	cg07173049	chr1:7289937	CAMTA1	0.32	6.59	0.34	1.74e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs3790645	1.000	rs35245195	chr1:26884039	C/G	cg17456097	chr1:26900765	RPS6KA1	0.43	6.15	0.32	2.21e-9	Glucose homeostasis traits;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18000306	chr6:288505	NA	0.33	6.33	0.33	7.73e-10	Menopause (age at onset);
LUSC	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg17507749	chr15:85114479	UBE2QP1	0.54	5.97	0.31	5.93e-9	Schizophrenia;
LUSC	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.84	-0.39	6.28e-14	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07336754	chr12:48921782	OR8S1	0.34	5.96	0.31	6.33e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12906019	chr1:228594265	TRIM11	0.48	7.05	0.36	1.02e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg26850624	chr5:429559	AHRR	-0.38	-7.02	-0.36	1.21e-11	Cystic fibrosis severity;
LUSC	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg10523860	chr14:103875565	MARK3	-0.37	-5.68	-0.3	2.93e-8	Body mass index;
LUSC	cis	rs9309473	1.000	rs13383871	chr2:73631779	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-6.25	-0.32	1.23e-9	Metabolite levels;
LUSC	cis	rs4776059	0.798	rs7167494	chr15:52928453	C/G	cg22715398	chr15:52968154	KIAA1370	0.63	7.97	0.4	2.56e-14	Schizophrenia;
LUSC	trans	rs11723530	0.513	rs6853761	chr4:170809568	G/T	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.14	-0.32	2.37e-9	Myopia (pathological);
LUSC	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg11130432	chr3:121712080	ILDR1	-0.64	-9.78	-0.47	4.84e-20	Multiple sclerosis;
LUSC	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg10792982	chr14:105748885	BRF1	0.49	8.86	0.44	4.85e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg01097406	chr16:89675127	NA	-0.35	-7.01	-0.36	1.32e-11	Vitiligo;
LUSC	cis	rs9467773	0.572	rs3846846	chr6:26445039	A/G	cg05738196	chr6:26577821	NA	-0.52	-7.73	-0.39	1.28e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg26677194	chr12:130822605	PIWIL1	0.6	8.98	0.44	1.97e-17	Menopause (age at onset);
LUSC	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg02023728	chr11:77925099	USP35	0.48	7.06	0.36	9.41e-12	Testicular germ cell tumor;
LUSC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02463440	chr8:22132932	PIWIL2	0.42	7.52	0.38	5.16e-13	Hypertriglyceridemia;
LUSC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	trans	rs208520	1.000	rs208527	chr6:66957209	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-12.34	-0.56	4.42e-29	Exhaled nitric oxide output;
LUSC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.79	-13.0	-0.58	1.46e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg15073853	chr19:18549131	ISYNA1	-0.31	-5.75	-0.3	2.02e-8	Breast cancer;
LUSC	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg20243544	chr17:37824526	PNMT	0.51	7.38	0.37	1.24e-12	Asthma;
LUSC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-1.01	-17.41	-0.69	9.34e-49	Body mass index;
LUSC	cis	rs11997175	0.545	rs66584807	chr8:33667609	A/G	ch.8.33884649F	chr8:33765107	NA	0.49	6.94	0.36	2.02e-11	Body mass index;
LUSC	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg02660097	chr11:68866761	NA	0.43	6.02	0.31	4.63e-9	Blond vs. brown hair color;
LUSC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	0.93	16.16	0.66	8.07e-44	Menopause (age at onset);
LUSC	cis	rs6494488	0.500	rs72744707	chr15:65012000	G/C	cg08069370	chr15:64387884	SNX1	-0.65	-5.92	-0.31	7.91e-9	Coronary artery disease;
LUSC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg14541582	chr5:601475	NA	-0.4	-6.14	-0.32	2.39e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg05025164	chr4:1340916	KIAA1530	0.4	6.14	0.32	2.31e-9	Obesity-related traits;
LUSC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06022373	chr22:39101656	GTPBP1	0.83	13.96	0.61	3.44e-35	Menopause (age at onset);
LUSC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.42	-0.56	2.2e-29	Chronic sinus infection;
LUSC	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg13010199	chr12:38710504	ALG10B	0.47	7.3	0.37	2.09e-12	Morning vs. evening chronotype;
LUSC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg11941060	chr3:133502564	NA	-0.42	-6.12	-0.32	2.68e-9	Iron status biomarkers;
LUSC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.76	12.34	0.56	4.34e-29	N-glycan levels;
LUSC	cis	rs983392	0.667	rs634475	chr11:59942081	G/A	cg20284999	chr11:59952153	MS4A6A	0.35	6.08	0.32	3.34e-9	Alzheimer's disease (late onset);
LUSC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.2	-0.32	1.66e-9	Total body bone mineral density;
LUSC	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg23505145	chr19:12996616	KLF1	-0.57	-9.55	-0.46	2.87e-19	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10727759	chr12:50017361	PRPF40B	-0.51	-6.75	-0.35	6.41e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs80130819	0.636	rs2732451	chr12:48719946	T/C	cg24011408	chr12:48396354	COL2A1	0.45	5.81	0.3	1.42e-8	Prostate cancer;
LUSC	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg00277334	chr10:82204260	NA	-0.51	-7.66	-0.39	2.08e-13	Post bronchodilator FEV1;
LUSC	cis	rs12753569	0.934	rs6593523	chr1:76486908	C/T	cg00791851	chr1:76518896	NA	-0.31	-5.89	-0.31	9.56e-9	Personality dimensions;
LUSC	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-9.46	-0.46	5.63e-19	Morning vs. evening chronotype;
LUSC	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg04398451	chr17:18023971	MYO15A	0.46	7.23	0.37	3.26e-12	Total body bone mineral density;
LUSC	cis	rs1594829	0.553	rs2046225	chr8:26151802	A/C	cg11498726	chr8:26250323	BNIP3L	0.34	5.72	0.3	2.42e-8	Height;
LUSC	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.36	-0.33	6.81e-10	Dupuytren's disease;
LUSC	cis	rs6681460	1.000	rs6689864	chr1:67068112	T/C	cg02459107	chr1:67143332	SGIP1	0.47	8.7	0.43	1.54e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg11502198	chr6:26597334	ABT1	-0.51	-7.69	-0.39	1.7e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7674212	0.865	rs1481279	chr4:103977938	A/T	cg16532752	chr4:104119610	CENPE	0.47	6.71	0.34	8.36e-11	Type 2 diabetes;
LUSC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.55	9.02	0.44	1.56e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.87	-0.31	1.07e-8	Platelet count;
LUSC	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg11244672	chr19:19639970	YJEFN3	-0.62	-7.33	-0.37	1.78e-12	Bipolar disorder;
LUSC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	8.56	0.42	4.32e-16	Electroencephalogram traits;
LUSC	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.28	-0.37	2.36e-12	Retinal vascular caliber;
LUSC	cis	rs9837602	0.938	rs793457	chr3:99518987	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.37	-5.71	-0.3	2.46e-8	Breast cancer;
LUSC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	14.5	0.62	2.75e-37	Alzheimer's disease;
LUSC	cis	rs4499344	0.920	rs2868149	chr19:33086096	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.6	-7.86	-0.4	5.19e-14	Mean platelet volume;
LUSC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-11.06	-0.52	1.97e-24	Bipolar disorder and schizophrenia;
LUSC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg25258033	chr6:167368657	RNASET2	0.38	5.82	0.3	1.38e-8	Primary biliary cholangitis;
LUSC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg11062466	chr8:58055876	NA	-0.74	-9.15	-0.45	5.76e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg06740227	chr12:86229804	RASSF9	0.44	7.09	0.36	7.84e-12	Major depressive disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg23889236	chr11:706100	EPS8L2	0.73	6.07	0.32	3.52e-9	Cognitive performance;
LUSC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg10621924	chr7:39171070	POU6F2	0.41	6.16	0.32	2.13e-9	IgG glycosylation;
LUSC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg03948781	chr1:205179583	DSTYK	0.3	5.7	0.3	2.6e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg05973401	chr12:123451056	ABCB9	-0.51	-6.89	-0.35	2.77e-11	Neutrophil percentage of white cells;
LUSC	trans	rs6127471	1.000	rs1053931	chr20:36841293	A/G	cg07165616	chr12:498868	KDM5A;CCDC77	-0.37	-5.95	-0.31	6.66e-9	Heart rate;
LUSC	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg24558204	chr6:135376177	HBS1L	0.62	8.6	0.43	3.15e-16	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg04851639	chr8:1020857	NA	-0.4	-7.97	-0.4	2.56e-14	Schizophrenia;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg25703541	chr22:24373054	LOC391322	-0.89	-14.5	-0.62	2.8e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs17095355	1.000	rs75079039	chr10:111745121	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.65	-7.55	-0.38	4.18e-13	Biliary atresia;
LUSC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg00750074	chr16:89608354	SPG7	0.55	10.22	0.49	1.6e-21	Multiple myeloma (IgH translocation);
LUSC	trans	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg26043149	chr18:55253948	FECH	0.5	7.75	0.39	1.14e-13	Bone mineral density;
LUSC	cis	rs4566357	1.000	rs12612535	chr2:227926998	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.89	-0.31	9.43e-9	Coronary artery disease;
LUSC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg22532475	chr10:104410764	TRIM8	-0.32	-6.94	-0.36	2.03e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11608355	0.538	rs10850074	chr12:109800531	T/C	cg19025524	chr12:109796872	NA	-0.42	-7.73	-0.39	1.31e-13	Neuroticism;
LUSC	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15541040	chr2:3486749	NA	-0.53	-7.99	-0.4	2.27e-14	Neurofibrillary tangles;
LUSC	cis	rs7215564	0.908	rs4536520	chr17:78660239	C/T	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs977987	0.966	rs6564261	chr16:75492242	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.4	0.46	8.68e-19	Dupuytren's disease;
LUSC	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg11812906	chr14:75593930	NEK9	0.66	10.94	0.51	5.29e-24	Height;
LUSC	cis	rs5753618	0.561	rs5753609	chr22:31819212	A/G	cg02404636	chr22:31891804	SFI1	0.44	6.52	0.34	2.54e-10	Colorectal cancer;
LUSC	cis	rs12760731	0.565	rs11585236	chr1:178108441	G/A	cg00404053	chr1:178313656	RASAL2	0.66	6.86	0.35	3.32e-11	Obesity-related traits;
LUSC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	-0.65	-9.91	-0.48	1.84e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs868036	0.918	rs4238411	chr15:68079424	A/T	cg05925327	chr15:68127851	NA	-0.33	-5.96	-0.31	6.38e-9	Restless legs syndrome;
LUSC	cis	rs9322817	0.503	rs6571205	chr6:105208813	A/C	cg02098413	chr6:105308735	HACE1	-0.28	-5.72	-0.3	2.42e-8	Thyroid stimulating hormone;
LUSC	trans	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg25482853	chr8:67687455	SGK3	1.1	15.74	0.65	3.91e-42	Obesity-related traits;
LUSC	cis	rs116988415	0.584	rs78748209	chr14:65255676	C/T	cg00114569	chr14:65239327	SPTB	0.71	7.41	0.38	1.03e-12	Daytime sleep phenotypes;
LUSC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg12463550	chr7:65579703	CRCP	0.63	5.7	0.3	2.58e-8	Gout;
LUSC	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg14343924	chr8:8086146	FLJ10661	0.44	6.04	0.31	4.1e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2573652	1.000	rs2581358	chr15:100513725	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.4	-7.36	-0.37	1.41e-12	Height;
LUSC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg04315214	chr1:2043799	PRKCZ	0.4	7.98	0.4	2.33e-14	Height;
LUSC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg16647868	chr5:131706066	SLC22A5	-0.4	-6.04	-0.31	4.03e-9	Blood metabolite levels;
LUSC	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.09	-17.73	-0.7	4.82e-50	Primary sclerosing cholangitis;
LUSC	cis	rs11229555	0.574	rs11229454	chr11:58203682	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg16339924	chr4:17578868	LAP3	0.49	7.53	0.38	4.83e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-7.37	-0.37	1.33e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs4851254	0.660	rs35869550	chr2:100684578	T/A	cg22139774	chr2:100720529	AFF3	-0.44	-5.82	-0.3	1.37e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg03676636	chr4:99064102	C4orf37	0.33	5.95	0.31	6.66e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg06008330	chr7:65541103	ASL	0.39	6.14	0.32	2.38e-9	Aortic root size;
LUSC	cis	rs2235649	0.592	rs2429186	chr16:1969939	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-5.76	-0.3	1.95e-8	Blood metabolite levels;
LUSC	cis	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg02508848	chr16:68573721	ZFP90	-0.43	-5.82	-0.3	1.42e-8	Ulcerative colitis;
LUSC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg21856205	chr7:94953877	PON1	-0.36	-5.8	-0.3	1.56e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs73198271	0.628	rs56188408	chr8:8592158	G/C	cg01851573	chr8:8652454	MFHAS1	0.46	5.77	0.3	1.83e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs965469	0.895	rs6051839	chr20:3391191	C/T	cg25506879	chr20:3388711	C20orf194	0.55	6.28	0.33	1.04e-9	IFN-related cytopenia;
LUSC	cis	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg27411982	chr8:10470053	RP1L1	-0.41	-6.66	-0.34	1.13e-10	Systolic blood pressure;
LUSC	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg13010199	chr12:38710504	ALG10B	-0.62	-9.73	-0.47	7.43e-20	Morning vs. evening chronotype;
LUSC	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.7	12.65	0.57	3.08e-30	White blood cell count;
LUSC	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg12935359	chr14:103987150	CKB	-0.51	-7.81	-0.39	7.69e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg16447950	chr5:562315	NA	-0.55	-7.1	-0.36	7.47e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7577696	0.962	rs212746	chr2:32413067	T/C	cg02381751	chr2:32503542	YIPF4	0.42	6.02	0.31	4.65e-9	Inflammatory biomarkers;
LUSC	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg00173435	chr12:106696525	TCP11L2	-0.55	-7.51	-0.38	5.46e-13	Tourette syndrome;
LUSC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18404041	chr3:52824283	ITIH1	-0.52	-10.19	-0.49	2.09e-21	Bipolar disorder;
LUSC	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg00191853	chr8:101177733	SPAG1	-0.39	-6.47	-0.33	3.49e-10	Atrioventricular conduction;
LUSC	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.68	-11.94	-0.55	1.37e-27	Electrocardiographic conduction measures;
LUSC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg00339695	chr16:24857497	SLC5A11	0.37	6.6	0.34	1.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.89	-0.35	2.85e-11	Lung cancer;
LUSC	cis	rs7827545	1.000	rs4909910	chr8:135565201	T/C	cg17885191	chr8:135476712	NA	0.56	8.32	0.41	2.34e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.77	-0.35	5.91e-11	Response to antipsychotic treatment;
LUSC	cis	rs907612	0.638	rs907611	chr11:1874072	G/A	cg07277017	chr11:1874093	LSP1	0.34	6.0	0.31	5.23e-9	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.72	11.82	0.54	3.45e-27	Coronary artery disease;
LUSC	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21659725	chr3:3221576	CRBN	0.63	10.53	0.5	1.38e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-5.85	-0.31	1.14e-8	IgG glycosylation;
LUSC	cis	rs7577851	0.715	rs12612489	chr2:69640722	C/A	cg10773587	chr2:69614142	GFPT1	0.57	7.11	0.36	7.1e-12	Parkinson's disease (age of onset);
LUSC	cis	rs9323205	0.765	rs2999389	chr14:51654510	G/A	cg23942311	chr14:51606299	NA	0.32	6.67	0.34	1.06e-10	Cancer;
LUSC	cis	rs3820928	0.845	rs2177596	chr2:227890283	A/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.64	-0.39	2.33e-13	Pulmonary function;
LUSC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg20607798	chr8:58055168	NA	-0.53	-5.95	-0.31	6.79e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg04374321	chr14:90722782	PSMC1	0.71	11.26	0.52	3.82e-25	Mortality in heart failure;
LUSC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg18681998	chr4:17616180	MED28	0.81	14.81	0.63	1.65e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25339705	chr17:48074418	NA	-0.41	-6.13	-0.32	2.5e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9463078	0.817	rs3799978	chr6:44837532	A/G	cg25276700	chr6:44698697	NA	-0.3	-5.74	-0.3	2.12e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs1692580	0.870	rs263532	chr1:2164116	T/C	cg03732007	chr1:2071316	PRKCZ	0.36	5.85	0.3	1.16e-8	Coronary artery disease;
LUSC	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.26	-0.62	2.3e-36	Schizophrenia;
LUSC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	7.03	0.36	1.2e-11	Tonsillectomy;
LUSC	cis	rs1775715	0.677	rs2808074	chr10:32179184	A/C	cg18675610	chr10:32216311	ARHGAP12	0.3	6.65	0.34	1.22e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg16456906	chr16:69373271	NIP7;COG8	0.36	6.06	0.31	3.62e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg26338869	chr17:61819248	STRADA	0.42	6.17	0.32	1.99e-9	Prudent dietary pattern;
LUSC	cis	rs13242816	1.000	rs35538349	chr7:116117896	C/T	cg16553024	chr7:116138462	CAV2	-0.52	-5.69	-0.3	2.81e-8	P wave duration;
LUSC	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.02	-0.44	1.5e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg05283184	chr6:79620031	NA	-0.46	-8.69	-0.43	1.71e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.87	-0.31	1.07e-8	Platelet count;
LUSC	cis	rs1577917	0.883	rs13212415	chr6:86608083	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.25	-0.32	1.22e-9	Response to antipsychotic treatment;
LUSC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	14.15	0.61	6.13e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-7.99	-0.4	2.21e-14	Monocyte percentage of white cells;
LUSC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs2282802	0.685	rs1347143	chr5:139669386	A/G	cg26211634	chr5:139558579	C5orf32	-0.38	-7.13	-0.36	6.07e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4776059	1.000	rs12914047	chr15:52970993	G/A	cg22715398	chr15:52968154	KIAA1370	-0.67	-9.55	-0.46	2.87e-19	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.27	0.56	7.85e-29	Motion sickness;
LUSC	cis	rs75920871	0.588	rs6589580	chr11:116819873	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-6.01	-0.31	4.84e-9	Subjective well-being;
LUSC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg12560992	chr17:57184187	TRIM37	-0.82	-14.75	-0.63	2.92e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg23188684	chr11:67383651	NA	0.34	6.02	0.31	4.67e-9	Mean corpuscular volume;
LUSC	cis	rs710216	0.827	rs841850	chr1:43402054	T/C	cg03128534	chr1:43423976	SLC2A1	0.46	5.88	0.31	9.93e-9	Red cell distribution width;
LUSC	cis	rs9807989	0.839	rs10192036	chr2:102968211	C/A	cg09003973	chr2:102972529	NA	0.44	6.01	0.31	4.83e-9	Asthma;
LUSC	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg00898013	chr13:113819073	PROZ	-0.57	-8.06	-0.4	1.38e-14	Platelet distribution width;
LUSC	trans	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg24643429	chr1:3562429	WDR8	0.33	6.04	0.31	4.2e-9	Monocyte count;
LUSC	trans	rs9401746	0.564	rs494258	chr6:124785014	G/A	cg16857858	chr7:27213984	HOXA10	0.53	6.13	0.32	2.48e-9	Bone mineral density (Ward's triangle area);
LUSC	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg08755490	chr11:65554678	OVOL1	-0.41	-5.94	-0.31	7.31e-9	Acne (severe);
LUSC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13401104	0.796	rs1466206	chr2:237121221	G/C	cg19324714	chr2:237145437	ASB18	0.44	5.66	0.3	3.34e-8	Educational attainment;
LUSC	cis	rs4343996	0.967	rs7791820	chr7:3353180	T/G	cg21248987	chr7:3385318	SDK1	-0.39	-6.56	-0.34	2.05e-10	Motion sickness;
LUSC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg22800045	chr5:56110881	MAP3K1	0.43	5.78	0.3	1.74e-8	Coronary artery disease;
LUSC	cis	rs3126085	0.935	rs4845429	chr1:152225376	G/C	cg26876637	chr1:152193138	HRNR	0.44	6.41	0.33	5.05e-10	Atopic dermatitis;
LUSC	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg18721089	chr20:30220636	NA	-0.39	-6.06	-0.31	3.74e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs12594515	1.000	rs56220882	chr15:45997075	C/G	cg01629716	chr15:45996671	NA	0.39	5.82	0.3	1.37e-8	Waist circumference;Weight;
LUSC	cis	rs10489525	0.599	rs34710929	chr1:115606608	G/A	cg17147537	chr1:115611705	TSPAN2	0.29	5.99	0.31	5.35e-9	Autism;
LUSC	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg16586182	chr3:47516702	SCAP	0.51	7.68	0.39	1.8e-13	Colorectal cancer;
LUSC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.04	20.95	0.75	8.37e-63	Cognitive function;
LUSC	cis	rs11690935	0.589	rs2271758	chr2:172701157	T/G	cg13550731	chr2:172543902	DYNC1I2	0.57	8.77	0.43	9.02e-17	Schizophrenia;
LUSC	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg05110241	chr16:68378359	PRMT7	-0.76	-7.88	-0.4	4.78e-14	Schizophrenia;
LUSC	cis	rs3087591	0.708	rs1129506	chr17:29646032	G/A	cg24425628	chr17:29625626	OMG;NF1	0.49	7.3	0.37	2.09e-12	Hip circumference;
LUSC	cis	rs10979	0.546	rs9496686	chr6:143908735	G/C	cg25407410	chr6:143891975	LOC285740	-0.65	-8.17	-0.41	6.6e-15	Hypospadias;
LUSC	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg23601095	chr6:26197514	HIST1H3D	0.72	7.61	0.38	2.89e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06028605	chr16:24865363	SLC5A11	-0.68	-10.39	-0.49	4.11e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs4285028	0.848	rs4118376	chr3:121636450	G/A	cg11130432	chr3:121712080	ILDR1	-0.65	-10.01	-0.48	8.72e-21	Multiple sclerosis;
LUSC	cis	rs9359856	0.636	rs1179896	chr6:90318610	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-8.07	-0.4	1.27e-14	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21724239	chr8:58056113	NA	0.85	9.53	0.46	3.26e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs6546537	0.955	rs35947226	chr2:69845829	C/G	cg10773587	chr2:69614142	GFPT1	-0.54	-8.18	-0.41	5.83e-15	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs7586879	0.828	rs7597157	chr2:25089166	C/T	cg01884057	chr2:25150051	NA	0.4	8.15	0.41	7.46e-15	Body mass index;
LUSC	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg08557956	chr11:4115526	RRM1	-0.45	-5.69	-0.3	2.74e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg04998671	chr14:104000505	TRMT61A	-0.44	-6.98	-0.36	1.62e-11	Coronary artery disease;
LUSC	cis	rs6500395	1.000	rs3848319	chr16:48610933	T/C	cg04672837	chr16:48644449	N4BP1	0.48	7.24	0.37	3.21e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg09365446	chr1:150670422	GOLPH3L	-0.42	-6.24	-0.32	1.3e-9	Tonsillectomy;
LUSC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.09e-18	Menopause (age at onset);
LUSC	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.62	0.38	2.71e-13	Corneal astigmatism;
LUSC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg22907277	chr7:1156413	C7orf50	0.57	8.75	0.43	1.08e-16	Longevity;Endometriosis;
LUSC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg01444801	chr10:135216882	MTG1	-0.48	-6.32	-0.33	8.31e-10	Systemic lupus erythematosus;
LUSC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg00343986	chr7:65444356	GUSB	-0.43	-6.55	-0.34	2.22e-10	Aortic root size;
LUSC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.81	-14.63	-0.62	8.75e-38	Cognitive function;
LUSC	cis	rs9807989	0.839	rs9308857	chr2:102979624	G/A	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.5e-9	Asthma;
LUSC	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg05340658	chr4:99064831	C4orf37	-0.44	-6.95	-0.36	1.94e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.2	-0.32	1.62e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg16434002	chr17:42200994	HDAC5	0.43	5.75	0.3	1.99e-8	Total body bone mineral density;
LUSC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.88e-11	Primary biliary cholangitis;
LUSC	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.3	-0.37	2.06e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs76419734	0.510	rs2216516	chr4:106749857	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.54	-6.01	-0.31	4.8e-9	Post bronchodilator FEV1;
LUSC	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg01989461	chr14:81687754	GTF2A1	0.73	13.51	0.59	1.79e-33	Schizophrenia;
LUSC	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	0.7	11.16	0.52	8.89e-25	Blood metabolite ratios;
LUSC	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg00277334	chr10:82204260	NA	-0.48	-6.6	-0.34	1.65e-10	Post bronchodilator FEV1;
LUSC	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg04691961	chr3:161091175	C3orf57	-0.35	-5.97	-0.31	6.09e-9	Morning vs. evening chronotype;
LUSC	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg05855489	chr10:104503620	C10orf26	-0.49	-7.47	-0.38	7.25e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg26924012	chr15:45694286	SPATA5L1	1.13	20.62	0.75	1.62e-61	Homoarginine levels;
LUSC	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.59	-9.01	-0.44	1.68e-17	Eye color traits;
LUSC	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg00857998	chr1:205179979	DSTYK	0.59	9.03	0.44	1.39e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.63	-0.34	1.37e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg04310649	chr10:35416472	CREM	-0.4	-6.22	-0.32	1.52e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg22532475	chr10:104410764	TRIM8	0.26	6.13	0.32	2.5e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.86	-0.44	4.94e-17	Metabolite levels;
LUSC	cis	rs9905704	0.918	rs2611783	chr17:56808530	A/G	cg12560992	chr17:57184187	TRIM37	0.56	8.01	0.4	1.92e-14	Testicular germ cell tumor;
LUSC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs2731664	0.756	rs4976695	chr5:176862963	T/A	cg23176889	chr5:176863531	GRK6	-0.7	-14.28	-0.62	1.87e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg22532475	chr10:104410764	TRIM8	0.29	6.82	0.35	4.41e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg05425664	chr17:57184151	TRIM37	0.55	7.98	0.4	2.38e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg05355328	chr19:33096524	ANKRD27	0.59	5.65	0.3	3.36e-8	Eosinophilic esophagitis;
LUSC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.89	0.31	9.65e-9	Menopause (age at onset);
LUSC	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg23093090	chr10:104574429	C10orf26	-0.45	-8.35	-0.42	1.9e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	12.71	0.57	1.77e-30	Cognitive test performance;
LUSC	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.75e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.53	-7.22	-0.37	3.63e-12	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.59	-11.87	-0.54	2.4e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg24130564	chr14:104152367	KLC1	0.46	6.55	0.34	2.17e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04865506	chr17:29422776	NF1	0.5	7.0	0.36	1.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs73198271	0.740	rs10110711	chr8:8650456	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	8.45	0.42	9.33e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs6084875	0.840	rs6084858	chr20:4731109	A/G	cg26257163	chr5:25190441	NA	0.36	6.07	0.32	3.41e-9	Systemic lupus erythematosus;
LUSC	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg13010199	chr12:38710504	ALG10B	0.53	7.92	0.4	3.45e-14	Morning vs. evening chronotype;
LUSC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg06784218	chr1:46089804	CCDC17	0.48	9.34	0.45	1.43e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.05	-0.4	1.48e-14	Glomerular filtration rate;
LUSC	cis	rs1375194	0.606	rs13393407	chr2:33818198	C/T	cg04131969	chr2:33951647	MYADML	-0.59	-8.09	-0.4	1.1e-14	Response to antidepressants in depression;
LUSC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg02772935	chr3:125709198	NA	-0.47	-5.66	-0.3	3.26e-8	Blood pressure (smoking interaction);
LUSC	cis	rs78545713	0.649	rs74928264	chr6:26224343	C/G	cg23601095	chr6:26197514	HIST1H3D	0.66	5.79	0.3	1.64e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.95	-0.31	6.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg25214090	chr10:38739885	LOC399744	0.43	6.53	0.34	2.51e-10	Corneal astigmatism;
LUSC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.7	10.95	0.51	4.71e-24	Aortic root size;
LUSC	cis	rs7241530	0.775	rs11081529	chr18:75902735	C/T	cg14642773	chr18:75888474	NA	-0.34	-5.74	-0.3	2.18e-8	Educational attainment (years of education);
LUSC	cis	rs28680850	1.000	rs28680850	chr8:1373720	G/A	cg06016156	chr8:1399969	NA	-0.41	-5.73	-0.3	2.29e-8	Triglycerides;
LUSC	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg05925327	chr15:68127851	NA	-0.41	-6.2	-0.32	1.65e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg11019008	chr10:131425282	MGMT	0.39	5.93	0.31	7.58e-9	Response to temozolomide;
LUSC	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-5.79	-0.3	1.63e-8	Retinal vascular caliber;
LUSC	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	12.12	0.55	2.99e-28	Height;
LUSC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg05234568	chr11:5960015	NA	-0.6	-8.66	-0.43	2.01e-16	DNA methylation (variation);
LUSC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.9	16.2	0.66	6.04e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13770153	chr20:60521292	NA	-0.58	-7.69	-0.39	1.61e-13	Body mass index;
LUSC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.86	0.44	4.97e-17	Motion sickness;
LUSC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.1	0.48	4.18e-21	Bipolar disorder;
LUSC	cis	rs4363385	0.510	rs61815707	chr1:152909018	T/C	cg00922841	chr1:152955080	SPRR1A	-0.39	-6.49	-0.33	3.05e-10	Inflammatory skin disease;
LUSC	cis	rs7809950	1.000	rs2712214	chr7:107188031	G/A	cg23024343	chr7:107201750	COG5	-0.57	-8.96	-0.44	2.29e-17	Coronary artery disease;
LUSC	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg18705301	chr15:41695430	NDUFAF1	0.44	7.7	0.39	1.6e-13	Menopause (age at onset);
LUSC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg00310523	chr12:86230176	RASSF9	0.45	8.34	0.42	2.01e-15	Major depressive disorder;
LUSC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	7.59	0.38	3.1400000000000003e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs13006833	0.668	rs2582736	chr2:191144892	A/T	cg21644426	chr2:191273491	MFSD6	0.44	6.28	0.33	1.03e-9	Urinary metabolites;
LUSC	cis	rs56283067	0.847	rs60328783	chr6:44693099	C/G	cg20913747	chr6:44695427	NA	-0.49	-7.97	-0.4	2.54e-14	Total body bone mineral density;
LUSC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg23711669	chr6:146136114	FBXO30	0.91	17.83	0.7	1.94e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg09796270	chr17:17721594	SREBF1	0.41	7.21	0.37	3.75e-12	Total body bone mineral density;
LUSC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	1.05	20.5	0.75	4.99e-61	Menopause (age at onset);
LUSC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg16797656	chr11:68205561	LRP5	0.48	8.89	0.44	3.96e-17	Total body bone mineral density;
LUSC	cis	rs6500395	0.925	rs9933148	chr16:48672099	C/T	cg04672837	chr16:48644449	N4BP1	0.47	6.94	0.35	2.06e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6486730	0.508	rs7133440	chr12:129269244	A/C	cg09035930	chr12:129282057	SLC15A4	-0.46	-8.24	-0.41	3.99e-15	Systemic lupus erythematosus;
LUSC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg06713675	chr4:122721982	EXOSC9	-0.72	-12.31	-0.56	5.85e-29	Type 2 diabetes;
LUSC	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.21	0.49	1.8e-21	Birth weight;
LUSC	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg05855489	chr10:104503620	C10orf26	0.59	9.42	0.46	7.54e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3820068	0.871	rs11585808	chr1:15805662	C/T	cg17385448	chr1:15911702	AGMAT	0.41	5.7	0.3	2.57e-8	Systolic blood pressure;
LUSC	cis	rs4948275	0.550	rs7904815	chr10:63136612	G/A	cg02461363	chr10:63212496	TMEM26	-0.36	-5.85	-0.3	1.17e-8	Night sleep phenotypes;
LUSC	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg22089800	chr15:90895588	ZNF774	0.63	9.7	0.47	9.47e-20	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs1878931	0.559	rs11643501	chr16:3392752	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.63	10.06	0.48	5.88e-21	Body mass index (adult);
LUSC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.24	0.52	4.63e-25	Prudent dietary pattern;
LUSC	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21984481	chr17:79567631	NPLOC4	-0.72	-15.09	-0.64	1.31e-39	Eye color traits;
LUSC	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg24578937	chr1:2090814	PRKCZ	0.61	13.84	0.6	9.41e-35	Height;
LUSC	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg16745616	chr19:8428856	ANGPTL4	-0.39	-5.86	-0.31	1.09e-8	HDL cholesterol;
LUSC	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.73e-23	Bladder cancer;
LUSC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2625529	0.938	rs4776579	chr15:72132608	C/T	cg16672083	chr15:72433130	SENP8	-0.5	-7.53	-0.38	4.9e-13	Red blood cell count;
LUSC	cis	rs75804782	0.521	rs72994970	chr2:239426992	G/A	cg18131467	chr2:239335373	ASB1	-0.7	-6.01	-0.31	4.98e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs9341808	0.529	rs9352826	chr6:81059371	C/T	cg08355045	chr6:80787529	NA	0.47	7.86	0.4	5.35e-14	Sitting height ratio;
LUSC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg25124228	chr12:125621409	AACS	-0.59	-9.86	-0.47	2.67e-20	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4654899	0.758	rs6658679	chr1:21376451	T/C	cg01072550	chr1:21505969	NA	-0.52	-7.95	-0.4	2.94e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.44	6.62	0.34	1.43e-10	Systemic lupus erythematosus;
LUSC	cis	rs9346649	0.630	rs4708643	chr6:168491681	A/G	cg02770688	chr6:168491649	NA	0.48	9.05	0.44	1.23e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg06618935	chr21:46677482	NA	-0.37	-7.39	-0.37	1.21e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.5	0.38	5.86e-13	Corneal astigmatism;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg08130266	chr15:100890462	FLJ42289	0.38	6.06	0.31	3.67e-9	Mosquito bite size;
LUSC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.68	9.3	0.45	1.84e-18	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7709377	0.574	rs10063392	chr5:115499800	C/T	cg23108291	chr5:115420582	COMMD10	0.41	5.88	0.31	9.74e-9	Metabolite levels  (X-11787);
LUSC	cis	rs2274273	0.564	rs10140164	chr14:55406123	A/G	cg04306507	chr14:55594613	LGALS3	0.39	8.44	0.42	9.63e-16	Protein biomarker;
LUSC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg09904177	chr6:26538194	HMGN4	0.49	7.46	0.38	7.63e-13	Schizophrenia;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18934581	chr7:89976026	GTPBP10	-0.45	-6.75	-0.35	6.62e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7178572	0.568	rs12911371	chr15:77689050	C/T	cg22256960	chr15:77711686	NA	-0.5	-7.92	-0.4	3.57e-14	Type 2 diabetes;
LUSC	cis	rs2274273	0.624	rs7157308	chr14:55782043	A/G	cg04306507	chr14:55594613	LGALS3	0.47	9.47	0.46	5.46e-19	Protein biomarker;
LUSC	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg04374321	chr14:90722782	PSMC1	-0.72	-10.42	-0.5	3.26e-22	Mortality in heart failure;
LUSC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.11	-0.48	3.97e-21	Obesity-related traits;
LUSC	cis	rs4704187	0.712	rs7701262	chr5:74365986	C/T	cg03227963	chr5:74354835	NA	0.33	7.01	0.36	1.32e-11	Response to amphetamines;
LUSC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.49	9.23	0.45	3.23e-18	Eosinophil percentage of white cells;
LUSC	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg18811423	chr2:55921094	PNPT1	-0.63	-8.58	-0.43	3.57e-16	Metabolic syndrome;
LUSC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg06784218	chr1:46089804	CCDC17	-0.51	-9.86	-0.47	2.72e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1881797	0.527	rs78486847	chr1:247638515	C/T	cg14830002	chr1:247616686	OR2B11	0.65	7.46	0.38	7.62e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2273669	0.667	rs12195378	chr6:109284255	A/G	cg05315195	chr6:109294784	ARMC2	-0.58	-6.47	-0.33	3.44e-10	Prostate cancer;
LUSC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg04317338	chr11:64019027	PLCB3	0.71	8.02	0.4	1.84e-14	Mean platelet volume;
LUSC	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg11693508	chr17:37793320	STARD3	0.51	6.3	0.33	9.61e-10	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-0.81	-11.13	-0.52	1.06e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs427941	0.632	rs201526	chr7:101774333	T/G	cg06246474	chr7:101738831	CUX1	0.37	6.04	0.31	4.12e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg01884057	chr2:25150051	NA	0.43	9.18	0.45	4.46e-18	Body mass index;
LUSC	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.57	10.52	0.5	1.49e-22	Bone mineral density;
LUSC	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg26061582	chr7:22766209	IL6	0.5	7.16	0.36	5.25e-12	Lung cancer;
LUSC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg12257692	chr3:49977190	RBM6	0.24	6.57	0.34	1.89e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.37	-0.42	1.59e-15	Retinal vascular caliber;
LUSC	cis	rs12940923	1.000	rs11079343	chr17:56369007	T/C	cg19466818	chr17:56409534	MIR142	-0.39	-6.87	-0.35	3.19e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg22601191	chr20:60968625	CABLES2	0.41	6.92	0.35	2.37e-11	Colorectal cancer;
LUSC	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.89	0.35	2.76e-11	Lung cancer in ever smokers;
LUSC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.66	11.02	0.52	2.68e-24	Tuberculosis;
LUSC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg05347473	chr6:146136440	FBXO30	-0.5	-8.52	-0.42	5.58e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg17724175	chr1:150552817	MCL1	0.37	6.79	0.35	5.02e-11	Tonsillectomy;
LUSC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.6	0.47	1.93e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6977940	0.730	rs11770451	chr7:2887990	G/T	cg19346786	chr7:2764209	NA	0.54	5.96	0.31	6.28e-9	White matter integrity;
LUSC	cis	rs4654899	0.802	rs17416732	chr1:21256368	T/C	cg01072550	chr1:21505969	NA	-0.48	-7.01	-0.36	1.35e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg24375607	chr4:120327624	NA	0.74	11.32	0.53	2.24e-25	Corneal astigmatism;
LUSC	cis	rs6426558	0.537	rs56219094	chr1:227340191	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.54	-7.3	-0.37	2.18e-12	Neutrophil percentage of white cells;
LUSC	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg18827107	chr12:86230957	RASSF9	-0.4	-5.92	-0.31	8.09e-9	Major depressive disorder;
LUSC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg22800045	chr5:56110881	MAP3K1	0.8	10.13	0.48	3.29e-21	Initial pursuit acceleration;
LUSC	cis	rs10746514	0.833	rs1888601	chr1:232266922	C/T	cg09506761	chr1:232265262	NA	-0.56	-9.71	-0.47	8.29e-20	Response to statin therapy;
LUSC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg07870213	chr5:140052090	DND1	-0.75	-11.05	-0.52	2.15e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs10045504	0.502	rs17352898	chr5:38745498	C/T	cg15396434	chr5:38725168	NA	-0.51	-5.73	-0.3	2.29e-8	Night sleep phenotypes;
LUSC	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg23649088	chr2:200775458	C2orf69	-0.57	-7.0	-0.36	1.41e-11	Schizophrenia;
LUSC	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	7.22	0.37	3.45e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs7582720	0.943	rs72932559	chr2:203847382	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.39	0.42	1.36e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg06606381	chr12:133084897	FBRSL1	-0.66	-7.19	-0.37	4.3e-12	Depression;
LUSC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg12560992	chr17:57184187	TRIM37	0.89	17.59	0.69	1.84e-49	Intelligence (multi-trait analysis);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg14209926	chr17:79849790	ANAPC11;THOC4	-0.5	-6.27	-0.32	1.1e-9	Cognitive function;Information processing speed;
LUSC	cis	rs7973719	0.865	rs12820829	chr12:7347534	G/A	cg07052231	chr12:7363540	PEX5	0.53	9.2	0.45	4.11e-18	IgG glycosylation;
LUSC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg12463550	chr7:65579703	CRCP	0.57	8.47	0.42	7.7e-16	Aortic root size;
LUSC	cis	rs4363385	0.791	rs512198	chr1:153006245	C/T	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.41	-0.38	1.03e-12	Inflammatory skin disease;
LUSC	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg20701182	chr2:24300061	SF3B14	0.74	7.28	0.37	2.48e-12	Lymphocyte counts;
LUSC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg04369109	chr6:150039330	LATS1	-0.54	-7.97	-0.4	2.49e-14	Lung cancer;
LUSC	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	0.81	14.91	0.63	6.61e-39	Ulcerative colitis;
LUSC	trans	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Bladder cancer;
LUSC	trans	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.9	0.35	2.57e-11	Endometrial cancer;
LUSC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg05738196	chr6:26577821	NA	0.47	6.8	0.35	4.7e-11	Schizophrenia;
LUSC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.69	10.73	0.51	2.91e-23	Aortic root size;
LUSC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-6.13	-0.32	2.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11997175	0.624	rs4593494	chr8:33692621	C/T	ch.8.33884649F	chr8:33765107	NA	0.42	5.87	0.31	1.03e-8	Body mass index;
LUSC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.57	0.46	2.47e-19	Bipolar disorder;
LUSC	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg21433313	chr16:3507492	NAT15	0.41	5.85	0.3	1.17e-8	Body mass index (adult);
LUSC	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.4	6.49	0.33	3.08e-10	Alcohol dependence;
LUSC	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg13647721	chr17:30228624	UTP6	-0.69	-7.48	-0.38	6.54e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.96	15.61	0.65	1.2e-41	Lymphocyte percentage of white cells;
LUSC	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg00310523	chr12:86230176	RASSF9	0.4	7.33	0.37	1.8e-12	Major depressive disorder;
LUSC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00166722	chr3:10149974	C3orf24	0.62	8.73	0.43	1.27e-16	Alzheimer's disease;
LUSC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg18357645	chr12:58087776	OS9	0.49	7.08	0.36	8.66e-12	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	11.78	0.54	4.92e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg17173187	chr15:85201210	NMB	-0.34	-6.96	-0.36	1.78e-11	P wave terminal force;
LUSC	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg08601574	chr20:25228251	PYGB	0.41	6.21	0.32	1.61e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg06092702	chr1:163392909	NA	-0.47	-7.82	-0.39	7.14e-14	Motion sickness;
LUSC	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.45	-0.5	2.55e-22	Eye color traits;
LUSC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg21724239	chr8:58056113	NA	0.55	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg07507251	chr3:52567010	NT5DC2	0.34	6.72	0.35	7.76e-11	Bipolar disorder;
LUSC	cis	rs2227564	0.729	rs2675676	chr10:75648287	A/C	cg23231163	chr10:75533350	FUT11	-0.44	-6.11	-0.32	2.81e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.63	9.87	0.48	2.54e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg00376283	chr12:123451042	ABCB9	-0.72	-7.79	-0.39	8.48e-14	Neutrophil percentage of white cells;
LUSC	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.59	-0.43	3.43e-16	Mood instability;
LUSC	cis	rs4356932	1.000	rs7684461	chr4:76962996	G/T	cg00809888	chr4:76862425	NAAA	-0.36	-6.03	-0.31	4.29e-9	Blood protein levels;
LUSC	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.6	-9.73	-0.47	7.38e-20	Body mass index;
LUSC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg06134567	chr22:46658398	PKDREJ	-0.46	-5.65	-0.3	3.48e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg06191203	chr2:152266755	RIF1	-0.54	-6.75	-0.35	6.75e-11	Lung cancer;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13769672	chr14:23398313	PRMT5	-0.47	-6.17	-0.32	2.01e-9	Hepatitis;
LUSC	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg26102564	chr10:131424627	MGMT	0.44	6.97	0.36	1.75e-11	Response to temozolomide;
LUSC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg16447950	chr5:562315	NA	-0.58	-6.97	-0.36	1.66e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9296092	0.538	rs9461880	chr6:33518714	C/T	cg13560919	chr6:33536144	NA	-0.82	-15.72	-0.65	4.63e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg14530993	chr4:882597	GAK	0.69	6.88	0.35	2.95e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	0.66	13.88	0.6	6.84e-35	Prudent dietary pattern;
LUSC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg07959070	chr22:50026188	C22orf34	0.38	7.98	0.4	2.44e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs62400317	0.859	rs2038765	chr6:45076494	A/G	cg20913747	chr6:44695427	NA	-0.46	-7.42	-0.38	9.56e-13	Total body bone mineral density;
LUSC	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg23840854	chr1:161414152	NA	-0.92	-11.27	-0.53	3.36e-25	Rheumatoid arthritis;
LUSC	cis	rs11971779	0.648	rs4732367	chr7:139028102	A/C	cg23387468	chr7:139079360	LUC7L2	0.42	6.28	0.32	1.06e-9	Diisocyanate-induced asthma;
LUSC	cis	rs4363385	0.747	rs946100	chr1:152971663	C/T	cg00922841	chr1:152955080	SPRR1A	0.46	8.08	0.4	1.23e-14	Inflammatory skin disease;
LUSC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg14583973	chr4:3374767	RGS12	0.37	8.08	0.4	1.21e-14	Serum sulfate level;
LUSC	cis	rs2274273	0.682	rs1187876	chr14:55495199	A/T	cg04306507	chr14:55594613	LGALS3	-0.49	-10.86	-0.51	1.01e-23	Protein biomarker;
LUSC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	12.95	0.58	2.35e-31	Cognitive test performance;
LUSC	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	6.02	0.31	4.55e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs601339	0.536	rs575171	chr12:123194635	C/T	cg11919336	chr12:123188078	GPR109A	0.4	5.75	0.3	2.02e-8	Adiponectin levels;
LUSC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg26408565	chr15:76604113	ETFA	-0.5	-8.05	-0.4	1.46e-14	Blood metabolite levels;
LUSC	cis	rs3771570	1.000	rs1984598	chr2:242284824	G/A	cg21155796	chr2:242212141	HDLBP	0.53	6.1	0.32	3e-9	Prostate cancer;
LUSC	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.42	-0.62	5.36e-37	Schizophrenia;
LUSC	cis	rs17095355	1.000	rs734164	chr10:111698160	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.6	-0.38	2.95e-13	Biliary atresia;
LUSC	cis	rs4631830	1.000	rs4631830	chr10:51543344	C/T	cg20129853	chr10:51489980	NA	-0.31	-6.12	-0.32	2.6e-9	Prostate-specific antigen levels;
LUSC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.2	13.69	0.6	3.51e-34	Diabetic kidney disease;
LUSC	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-9.53	-0.46	3.28e-19	Response to antipsychotic treatment;
LUSC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg06671706	chr8:8559999	CLDN23	0.49	6.61	0.34	1.52e-10	Obesity-related traits;
LUSC	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.72	-0.43	1.34e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg10911889	chr6:126070802	HEY2	0.42	6.49	0.33	3.07e-10	Brugada syndrome;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12942139	chr22:37823517	ELFN2	0.45	6.12	0.32	2.59e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg18225595	chr11:63971243	STIP1	0.55	9.53	0.46	3.44e-19	Platelet count;
LUSC	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.73	-0.43	1.22e-16	Response to antipsychotic treatment;
LUSC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.68	11.47	0.53	6.49e-26	Cognitive function;
LUSC	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg09998033	chr7:158218633	PTPRN2	0.46	7.23	0.37	3.27e-12	Obesity-related traits;
LUSC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg24631222	chr15:78858424	CHRNA5	0.83	11.48	0.53	5.98e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9399401	0.667	rs11759653	chr6:142720354	G/A	cg03128060	chr6:142623767	GPR126	0.58	9.64	0.47	1.45e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.73	-10.03	-0.48	7.27e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs2835872	0.828	rs2835837	chr21:38990443	C/T	cg20424643	chr21:39039972	KCNJ6	0.38	5.98	0.31	5.62e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.49	-0.53	5.85e-26	Mean corpuscular volume;
LUSC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.88	-0.31	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg17376030	chr22:41985996	PMM1	-0.48	-5.9	-0.31	8.9e-9	Vitiligo;
LUSC	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.21	-0.41	4.81e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg22509179	chr1:25234806	RUNX3	-0.6	-10.08	-0.48	4.72e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.9e-20	Migraine;Coronary artery disease;
LUSC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg07424592	chr7:64974309	NA	0.66	5.83	0.3	1.32e-8	Diabetic kidney disease;
LUSC	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.68	-9.68	-0.47	1.09e-19	Corneal astigmatism;
LUSC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-1.03	-20.16	-0.74	1.07e-59	Height;
LUSC	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg24851651	chr11:66362959	CCS	-0.38	-6.06	-0.31	3.72e-9	Educational attainment (years of education);
LUSC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-0.98	-17.61	-0.69	1.49e-49	Height;
LUSC	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.64	6.73	0.35	7.46e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-8.37	-0.42	1.57e-15	Gut microbiome composition (summer);
LUSC	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg00277334	chr10:82204260	NA	-0.56	-8.95	-0.44	2.58e-17	Post bronchodilator FEV1;
LUSC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-6.66	-0.34	1.1e-10	Mean platelet volume;
LUSC	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg24558204	chr6:135376177	HBS1L	0.67	10.05	0.48	6.35e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	15.25	0.64	3.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg19812747	chr11:111475976	SIK2	0.5	6.81	0.35	4.44e-11	Primary sclerosing cholangitis;
LUSC	cis	rs12999616	0.817	rs17695937	chr2:98327875	A/G	cg26665480	chr2:98280029	ACTR1B	0.53	6.05	0.31	3.91e-9	Colorectal cancer;
LUSC	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg15309053	chr8:964076	NA	0.34	6.89	0.35	2.87e-11	Schizophrenia;
LUSC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg23630131	chr7:65973040	NA	-0.21	-6.01	-0.31	4.93e-9	Aortic root size;
LUSC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg13683864	chr3:40499215	RPL14	-0.94	-15.96	-0.66	5.24e-43	Renal cell carcinoma;
LUSC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg09455208	chr3:40491958	NA	0.52	9.62	0.47	1.74e-19	Renal cell carcinoma;
LUSC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.43	0.33	4.34e-10	Menopause (age at onset);
LUSC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg11871910	chr12:69753446	YEATS4	0.94	17.4	0.69	1.05e-48	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9494145	0.680	rs9389269	chr6:135427159	T/C	cg22676075	chr6:135203613	NA	0.63	8.9	0.44	3.53e-17	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs3820928	1.000	rs978909	chr2:227771389	A/C	cg11843606	chr2:227700838	RHBDD1	-0.57	-8.34	-0.42	1.93e-15	Pulmonary function;
LUSC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg22907277	chr7:1156413	C7orf50	0.45	6.82	0.35	4.19e-11	Longevity;Endometriosis;
LUSC	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg00898013	chr13:113819073	PROZ	-0.53	-7.85	-0.39	5.78e-14	Platelet distribution width;
LUSC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg03732007	chr1:2071316	PRKCZ	0.55	9.97	0.48	1.12e-20	Height;
LUSC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg04727924	chr7:799746	HEATR2	-0.57	-6.06	-0.31	3.75e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	0.97	12.93	0.58	2.68e-31	Eosinophil percentage of granulocytes;
LUSC	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg06197492	chr11:2016605	H19	0.42	6.94	0.35	2.08e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.39	-0.33	5.59e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs77741769	0.553	rs12372231	chr12:121351729	T/A	cg02419362	chr12:121203948	SPPL3	0.45	8.4	0.42	1.31e-15	Mean corpuscular volume;
LUSC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg02709834	chr1:75198841	CRYZ;TYW3	0.37	5.65	0.3	3.43e-8	Resistin levels;
LUSC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	trans	rs17086172	0.841	rs76001318	chr18:70271977	G/A	cg15710198	chr8:55370334	SOX17	-0.67	-6.11	-0.32	2.82e-9	Airflow obstruction;
LUSC	cis	rs9311676	0.632	rs62258075	chr3:58359851	G/A	cg13750441	chr3:58318267	PXK	0.34	6.5	0.34	2.86e-10	Systemic lupus erythematosus;
LUSC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.74	11.3	0.53	2.7e-25	Tonsillectomy;
LUSC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	7.78	0.39	9.25e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs17154702	0.506	rs78790499	chr8:8628827	T/C	cg01851573	chr8:8652454	MFHAS1	0.61	7.0	0.36	1.39e-11	Neurocognitive impairment in HIV-1 infection (continuous);
LUSC	cis	rs35883536	0.626	rs7545966	chr1:101047633	G/A	cg06223162	chr1:101003688	GPR88	-0.47	-8.81	-0.43	6.81e-17	Monocyte count;
LUSC	cis	rs4474465	0.920	rs10899526	chr11:78206157	T/C	cg27205649	chr11:78285834	NARS2	0.5	5.97	0.31	5.93e-9	Alzheimer's disease (survival time);
LUSC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg24881330	chr22:46731750	TRMU	0.85	7.57	0.38	3.77e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.13	0.55	2.73e-28	Prudent dietary pattern;
LUSC	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg23188684	chr11:67383651	NA	0.35	6.19	0.32	1.81e-9	Mean corpuscular volume;
LUSC	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg10253484	chr15:75165896	SCAMP2	-0.43	-6.03	-0.31	4.43e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg11861562	chr11:117069780	TAGLN	0.33	6.19	0.32	1.81e-9	Blood protein levels;
LUSC	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg09876464	chr15:85330779	ZNF592	0.35	6.6	0.34	1.62e-10	P wave terminal force;
LUSC	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg27411982	chr8:10470053	RP1L1	0.45	7.35	0.37	1.52e-12	Mood instability;
LUSC	trans	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg25482853	chr8:67687455	SGK3	0.79	10.99	0.52	3.39e-24	Obesity-related traits;
LUSC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg16447950	chr5:562315	NA	-0.53	-7.11	-0.36	7.28e-12	Obesity-related traits;
LUSC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg26566898	chr11:117069891	TAGLN	0.48	8.37	0.42	1.58e-15	Blood protein levels;
LUSC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg08132940	chr7:1081526	C7orf50	-0.48	-6.28	-0.33	1.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg14416269	chr4:6271139	WFS1	0.51	10.86	0.51	9.78e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs981844	0.775	rs17299246	chr4:154743504	C/T	cg14289246	chr4:154710475	SFRP2	0.48	6.33	0.33	7.69e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg10207240	chr12:122356781	WDR66	0.45	6.44	0.33	4.25e-10	Mean corpuscular volume;
LUSC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg12365402	chr11:9010492	NRIP3	0.47	8.62	0.43	2.64e-16	Hemoglobin concentration;
LUSC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg15145296	chr3:125709740	NA	-0.57	-6.36	-0.33	6.67e-10	Blood pressure (smoking interaction);
LUSC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.41	5.85	0.3	1.16e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.85	-0.3	1.19e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg06238570	chr21:40685208	BRWD1	0.46	7.08	0.36	8.78e-12	Cognitive function;
LUSC	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	7.73	0.39	1.29e-13	Iron status biomarkers;
LUSC	cis	rs9807989	0.507	rs1420096	chr2:103010912	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.54e-12	Asthma;
LUSC	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg06606381	chr12:133084897	FBRSL1	-1.05	-9.08	-0.44	9.63e-18	Lung cancer;
LUSC	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg08345082	chr10:99160200	RRP12	-0.34	-7.03	-0.36	1.16e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.75	0.35	6.4e-11	Tonsillectomy;
LUSC	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.96	-0.4	2.74e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	20.1	0.74	1.86e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs868036	0.560	rs12443086	chr15:68080454	C/A	cg08079166	chr15:68083412	MAP2K5	0.37	7.79	0.39	8.48e-14	Restless legs syndrome;
LUSC	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg05072774	chr3:49840536	C3orf54	-0.43	-5.96	-0.31	6.27e-9	Resting heart rate;
LUSC	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg04733989	chr22:42467013	NAGA	0.44	7.24	0.37	3.05e-12	Cognitive function;
LUSC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00339695	chr16:24857497	SLC5A11	0.39	6.64	0.34	1.28e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg03929089	chr4:120376271	NA	-0.58	-7.49	-0.38	6.14e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	10.51	0.5	1.67e-22	Mean corpuscular hemoglobin;
LUSC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08704250	chr15:31115839	NA	-0.59	-8.9	-0.44	3.68e-17	Huntington's disease progression;
LUSC	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg11861562	chr11:117069780	TAGLN	0.32	6.2	0.32	1.64e-9	Blood protein levels;
LUSC	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg22546130	chr22:19950026	COMT	-0.37	-7.8	-0.39	8.04e-14	Blood metabolite levels;
LUSC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg16339924	chr4:17578868	LAP3	0.67	10.81	0.51	1.43e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.81	14.1	0.61	9.37e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6969780	0.915	rs12666926	chr7:27189561	A/G	cg26364809	chr7:27145159	NA	0.54	6.0	0.31	5.1e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg13560548	chr3:10150139	C3orf24	0.54	7.68	0.39	1.8e-13	Alzheimer's disease;
LUSC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg22437258	chr11:111473054	SIK2	-0.44	-5.84	-0.3	1.23e-8	Primary sclerosing cholangitis;
LUSC	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg26408565	chr15:76604113	ETFA	-0.47	-7.48	-0.38	6.44e-13	Blood metabolite levels;
LUSC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-7.73	-0.39	1.29e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs12760731	0.720	rs1994233	chr1:178269823	C/T	cg00404053	chr1:178313656	RASAL2	-0.59	-6.5	-0.33	3e-10	Obesity-related traits;
LUSC	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg08213375	chr14:104286397	PPP1R13B	0.47	9.18	0.45	4.76e-18	Schizophrenia;
LUSC	cis	rs73198271	0.562	rs3827810	chr8:8659040	T/G	cg01851573	chr8:8652454	MFHAS1	0.67	8.92	0.44	3.16e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.62	0.5	6.58e-23	Colorectal cancer;
LUSC	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg09835421	chr16:68378352	PRMT7	-0.45	-5.91	-0.31	8.47e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.01	20.01	0.74	4.2e-59	Cognitive function;
LUSC	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg05621596	chr22:47072043	GRAMD4	-0.59	-9.3	-0.45	1.89e-18	Urate levels in obese individuals;
LUSC	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg17063962	chr7:91808500	NA	0.56	8.55	0.42	4.59e-16	Breast cancer;
LUSC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.07e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg15423357	chr2:25149977	NA	0.44	8.93	0.44	2.98e-17	Body mass index;
LUSC	cis	rs9311676	0.632	rs6774577	chr3:58361716	A/G	cg26110898	chr3:58419937	PDHB	0.41	6.52	0.34	2.53e-10	Systemic lupus erythematosus;
LUSC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg12311346	chr5:56204834	C5orf35	-0.57	-8.75	-0.43	1.09e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg03526459	chr1:146549940	NA	-0.4	-7.11	-0.36	7.12e-12	HIV-1 control;
LUSC	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg12559939	chr2:27858050	GPN1	0.41	6.38	0.33	5.85e-10	Oral cavity cancer;
LUSC	cis	rs9287719	0.649	rs10207885	chr2:10733188	C/T	cg00105475	chr2:10696890	NA	0.35	5.78	0.3	1.7e-8	Prostate cancer;
LUSC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg08499158	chr17:42289980	UBTF	0.42	6.38	0.33	5.78e-10	Total body bone mineral density;
LUSC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.51	-0.42	6e-16	Bipolar disorder;
LUSC	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07080220	chr10:102295463	HIF1AN	0.62	8.3	0.41	2.57e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.85	14.77	0.63	2.42e-38	Neuroticism;
LUSC	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.75	-0.6	2.1e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs500891	0.553	rs3812142	chr6:84141393	T/C	cg08257003	chr6:84140564	ME1	0.38	9.32	0.45	1.58e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg00071950	chr4:10020882	SLC2A9	0.5	8.37	0.42	1.63e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.82	-0.3	1.41e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg04944784	chr2:26401820	FAM59B	0.7	9.88	0.48	2.3e-20	Gut microbiome composition (summer);
LUSC	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg12002119	chr2:101014098	CHST10	0.34	5.65	0.3	3.48e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg13042288	chr15:90349979	ANPEP	-0.47	-6.42	-0.33	4.59e-10	Uric acid levels;
LUSC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg17971929	chr21:40555470	PSMG1	0.77	13.03	0.58	1.14e-31	Cognitive function;
LUSC	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19748678	chr4:122722346	EXOSC9	-0.5	-7.38	-0.37	1.23e-12	Type 2 diabetes;
LUSC	cis	rs7524258	0.901	rs11120884	chr1:7305361	C/A	cg07173049	chr1:7289937	CAMTA1	0.33	6.76	0.35	6.26e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	trans	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg06606381	chr12:133084897	FBRSL1	-0.52	-5.95	-0.31	6.76e-9	Lung cancer in ever smokers;
LUSC	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.55	-0.34	2.16e-10	Blood metabolite levels;
LUSC	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.15	-0.45	5.74e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.54	11.08	0.52	1.69e-24	Coronary artery disease;
LUSC	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.9	-0.4	4.02e-14	Glomerular filtration rate;
LUSC	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.71	11.33	0.53	2.17e-25	Sudden cardiac arrest;
LUSC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg17366294	chr4:99064904	C4orf37	0.54	8.53	0.42	5.3e-16	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg26446717	chr5:175788958	KIAA1191	0.4	6.05	0.31	3.8e-9	Schizophrenia (age at onset);
LUSC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.78	0.3	1.69e-8	Self-reported allergy;
LUSC	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg19187155	chr2:232395269	NMUR1	0.79	13.67	0.6	4.13e-34	Height;
LUSC	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg23029597	chr12:123009494	RSRC2	-0.7	-9.13	-0.45	6.8e-18	Body mass index;
LUSC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.44	7.46	0.38	7.7e-13	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg04850211	chr1:228464232	OBSCN	0.31	5.68	0.3	2.86e-8	Diastolic blood pressure;
LUSC	trans	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg15445000	chr17:37608096	MED1	-0.38	-6.46	-0.33	3.79e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs4356932	0.967	rs10016135	chr4:76974579	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.83	0.3	1.33e-8	Blood protein levels;
LUSC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg03213289	chr20:61660250	NA	-0.67	-13.36	-0.59	6.69e-33	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg22535103	chr8:58192502	C8orf71	0.71	7.81	0.39	7.52e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.54	-0.38	4.51e-13	Retinal vascular caliber;
LUSC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.81	-15.08	-0.64	1.53e-39	Dental caries;
LUSC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.7	9.77	0.47	5.43e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg15468180	chr1:107600409	PRMT6	-0.35	-5.72	-0.3	2.33e-8	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs2012796	0.956	rs10450940	chr14:81825326	C/A	cg02996355	chr14:81879375	NA	0.5	7.25	0.37	2.83e-12	Night sleep phenotypes;
LUSC	trans	rs2048656	0.523	rs1976673	chr8:9679780	T/A	cg06636001	chr8:8085503	FLJ10661	0.47	6.58	0.34	1.82e-10	Schizophrenia;
LUSC	cis	rs3741151	0.686	rs7118982	chr11:73110668	T/C	cg17517138	chr11:73019481	ARHGEF17	0.82	7.84	0.39	6.15e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg13755796	chr4:20253514	NA	-0.43	-6.8	-0.35	4.7e-11	Life satisfaction;
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg25703541	chr22:24373054	LOC391322	1.0	19.79	0.73	3.25e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg12963246	chr6:28129442	ZNF389	0.45	5.94	0.31	7e-9	Depression;
LUSC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg04518342	chr5:131593106	PDLIM4	0.52	9.47	0.46	5.25e-19	Acylcarnitine levels;
LUSC	cis	rs113835537	0.529	rs80100524	chr11:66245936	C/T	cg24851651	chr11:66362959	CCS	0.55	8.16	0.41	6.79e-15	Airway imaging phenotypes;
LUSC	cis	rs10779751	0.610	rs2486921	chr1:11124943	G/A	cg04508216	chr1:11107452	MASP2	0.33	5.87	0.31	1.03e-8	Body mass index;
LUSC	trans	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg11887960	chr12:57824829	NA	0.53	6.6	0.34	1.59e-10	Obesity-related traits;
LUSC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.82	-14.63	-0.63	8.24e-38	Cognitive function;
LUSC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg20135002	chr11:47629003	NA	-0.53	-8.43	-0.42	1.03e-15	Subjective well-being;
LUSC	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg03859395	chr2:55845619	SMEK2	0.91	16.85	0.68	1.56e-46	Metabolic syndrome;
LUSC	cis	rs7582720	1.000	rs72934753	chr2:203750272	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg14664628	chr15:75095509	CSK	0.43	6.16	0.32	2.11e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs4343996	0.727	rs10951159	chr7:3370465	G/T	cg21248987	chr7:3385318	SDK1	-0.35	-6.02	-0.31	4.66e-9	Motion sickness;
LUSC	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg05163923	chr11:71159392	DHCR7	-0.77	-10.02	-0.48	7.56e-21	Vitamin D levels;
LUSC	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg20587970	chr11:113659929	NA	1.12	13.33	0.59	8.6e-33	Hip circumference adjusted for BMI;
LUSC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg20476274	chr7:133979776	SLC35B4	0.86	16.25	0.66	3.8e-44	Mean platelet volume;
LUSC	cis	rs4740619	0.967	rs7032755	chr9:15640025	G/T	cg14451791	chr9:16040625	NA	0.31	5.75	0.3	2.03e-8	Body mass index;
LUSC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg07777115	chr5:623756	CEP72	-0.47	-5.85	-0.3	1.18e-8	Obesity-related traits;
LUSC	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg23587288	chr2:27483067	SLC30A3	-0.3	-5.87	-0.31	1.04e-8	Blood metabolite levels;
LUSC	cis	rs859767	0.501	rs6745983	chr2:135430709	C/T	cg12500956	chr2:135428796	TMEM163	-0.29	-6.93	-0.35	2.13e-11	Neuroticism;
LUSC	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg05234568	chr11:5960015	NA	-0.59	-8.49	-0.42	6.77e-16	DNA methylation (variation);
LUSC	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg19773385	chr1:10388646	KIF1B	-0.5	-8.7	-0.43	1.56e-16	Hepatocellular carcinoma;
LUSC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.16	-0.32	2.06e-9	Total body bone mineral density;
LUSC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg19046167	chr17:80928561	B3GNTL1	0.43	6.36	0.33	6.54e-10	Breast cancer;
LUSC	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	1.16	18.33	0.71	1.92e-52	Primary sclerosing cholangitis;
LUSC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg22800045	chr5:56110881	MAP3K1	0.77	9.8	0.47	4.21e-20	Initial pursuit acceleration;
LUSC	cis	rs11051970	0.879	rs1500874	chr12:32589407	G/A	cg24626660	chr12:32551988	NA	0.33	5.66	0.3	3.2e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2692947	0.826	rs7423942	chr2:96645257	G/A	cg23100626	chr2:96804247	ASTL	0.23	5.76	0.3	1.93e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg17173187	chr15:85201210	NMB	0.5	9.39	0.46	9.83e-19	Schizophrenia;
LUSC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg23283495	chr1:209979779	IRF6	0.64	9.36	0.46	1.21e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs66887589	0.776	rs10518337	chr4:120574874	A/C	cg24375607	chr4:120327624	NA	-0.46	-6.63	-0.34	1.38e-10	Diastolic blood pressure;
LUSC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg07741184	chr6:167504864	NA	0.49	8.55	0.42	4.42e-16	Rheumatoid arthritis;
LUSC	cis	rs977987	0.843	rs67409275	chr16:75457212	T/C	cg03315344	chr16:75512273	CHST6	0.54	10.32	0.49	7.18e-22	Dupuytren's disease;
LUSC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg18402987	chr7:1209562	NA	0.68	7.46	0.38	7.42e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9865818	0.702	rs2030520	chr3:188119582	C/T	cg23651889	chr3:188115336	LPP	-0.38	-5.96	-0.31	6.38e-9	Allergic sensitization;
LUSC	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg16342193	chr10:102329863	NA	-0.34	-6.2	-0.32	1.68e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg24375607	chr4:120327624	NA	0.78	11.7	0.54	9.85e-27	Corneal astigmatism;
LUSC	cis	rs9807989	0.507	rs3732124	chr2:103018052	A/G	cg03938978	chr2:103052716	IL18RAP	-0.37	-7.02	-0.36	1.23e-11	Asthma;
LUSC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.69	11.49	0.53	5.84e-26	Prudent dietary pattern;
LUSC	cis	rs1953600	0.870	rs2789695	chr10:81946840	C/T	cg00277334	chr10:82204260	NA	0.45	7.08	0.36	8.35e-12	Sarcoidosis;
LUSC	trans	rs61931739	0.635	rs7138254	chr12:33914422	G/T	cg26384229	chr12:38710491	ALG10B	0.52	7.78	0.39	8.87e-14	Morning vs. evening chronotype;
LUSC	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	6.57	0.34	1.95e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-25.08	-0.81	8.21e-79	Height;
LUSC	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg06671706	chr8:8559999	CLDN23	0.49	6.52	0.34	2.66e-10	Obesity-related traits;
LUSC	cis	rs3812111	0.510	rs6930059	chr6:116577623	T/C	cg18828861	chr6:116576566	TSPYL4	0.38	6.75	0.35	6.41e-11	Age-related macular degeneration;
LUSC	trans	rs61931739	0.614	rs6488172	chr12:33745669	A/G	cg26384229	chr12:38710491	ALG10B	0.45	6.7	0.34	8.62e-11	Morning vs. evening chronotype;
LUSC	cis	rs9473147	0.543	rs1872505	chr6:47480975	C/G	cg12968598	chr6:47444699	CD2AP	0.53	7.97	0.4	2.49e-14	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs76248362	1.000	rs1886972	chr13:24436230	C/T	cg26511321	chr7:27196790	HOXA7	0.54	6.24	0.32	1.35e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg07382826	chr16:28625726	SULT1A1	0.28	5.86	0.31	1.14e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg20503657	chr10:835505	NA	1.2	16.38	0.67	1.09e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg21775007	chr8:11205619	TDH	-0.46	-6.32	-0.33	8.3e-10	Morning vs. evening chronotype;
LUSC	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg04450456	chr4:17643702	FAM184B	0.37	6.34	0.33	7.37e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg26924012	chr15:45694286	SPATA5L1	1.12	20.31	0.74	2.75e-60	Homoarginine levels;
LUSC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03517284	chr6:25882590	NA	-0.45	-8.13	-0.41	8.64e-15	Blood metabolite levels;
LUSC	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg01294253	chr9:136912663	BRD3	-0.33	-5.66	-0.3	3.27e-8	Platelet distribution width;
LUSC	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg04733989	chr22:42467013	NAGA	0.39	6.62	0.34	1.45e-10	Cognitive function;
LUSC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.85	0.54	2.87e-27	Personality dimensions;
LUSC	cis	rs6977660	1.000	rs13231036	chr7:19806141	G/A	cg05791153	chr7:19748676	TWISTNB	0.56	6.32	0.33	8.32e-10	Thyroid stimulating hormone;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16705446	chr19:3751546	APBA3	-0.4	-6.22	-0.32	1.53e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg05340658	chr4:99064831	C4orf37	0.62	9.96	0.48	1.26e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg21100191	chr22:23484243	RTDR1	0.91	15.8	0.65	2.24e-42	Bone mineral density;
LUSC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.41	0.49	3.7e-22	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg16386425	chr10:429943	DIP2C	0.44	6.83	0.35	3.92e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.33	-0.41	2.19e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs6964492	0.576	rs2347716	chr7:134416085	G/A	cg17334389	chr17:637070	FAM57A	0.26	5.98	0.31	5.72e-9	Tonsillectomy;
LUSC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg05347473	chr6:146136440	FBXO30	0.45	7.69	0.39	1.63e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg00277334	chr10:82204260	NA	-0.58	-8.71	-0.43	1.47e-16	Post bronchodilator FEV1;
LUSC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.95	0.31	6.78e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07923666	chr12:49932857	KCNH3	-0.54	-6.63	-0.34	1.38e-10	Resting heart rate;
LUSC	cis	rs738321	0.794	rs5756940	chr22:38558842	C/T	cg25457927	chr22:38595422	NA	-0.37	-7.11	-0.36	7.05e-12	Breast cancer;
LUSC	cis	rs6906287	0.647	rs7769001	chr6:118934509	A/G	cg21191810	chr6:118973309	C6orf204	0.32	5.91	0.31	8.23e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21028142	chr17:79581711	NPLOC4	-0.32	-7.59	-0.38	3.25e-13	Eye color traits;
LUSC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg27170947	chr2:26402098	FAM59B	-0.66	-9.56	-0.46	2.57e-19	Gut microbiome composition (summer);
LUSC	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg00852783	chr1:26633632	UBXN11	0.46	7.99	0.4	2.28e-14	Obesity-related traits;
LUSC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg20243544	chr17:37824526	PNMT	-0.49	-5.97	-0.31	5.91e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg21770322	chr7:97807741	LMTK2	0.41	7.13	0.36	6.18e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.98	0.31	5.65e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.29	0.53	2.92e-25	Morning vs. evening chronotype;
LUSC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg10636054	chr15:40330586	SRP14	0.81	7.89	0.4	4.31e-14	Corneal curvature;
LUSC	cis	rs11209002	0.956	rs2013772	chr1:67581445	A/T	cg02640540	chr1:67518911	SLC35D1	0.69	7.58	0.38	3.42e-13	Crohn's disease;
LUSC	cis	rs12210905	0.688	rs72845232	chr6:27428126	T/G	cg08851530	chr6:28072375	NA	0.92	5.75	0.3	1.99e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.98	0.51	3.81e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg05059571	chr16:84539110	KIAA1609	-0.47	-8.92	-0.44	3.21e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg25206134	chr2:45395956	NA	0.51	6.13	0.32	2.52e-9	Bipolar disorder;
LUSC	trans	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-13.15	-0.58	4.02e-32	Colorectal cancer;
LUSC	cis	rs10740039	0.883	rs7089287	chr10:62393764	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg21862992	chr11:68658383	NA	0.5	8.09	0.4	1.1e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7715806	0.500	rs72633982	chr5:75001321	C/T	cg19683494	chr5:74908142	NA	0.57	7.71	0.39	1.43e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	6.71	0.34	8.57e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg17376030	chr22:41985996	PMM1	-0.47	-6.05	-0.31	3.85e-9	Vitiligo;
LUSC	cis	rs2322633	0.515	rs1892474	chr6:80862349	G/A	cg08355045	chr6:80787529	NA	0.4	6.73	0.35	7.3e-11	Height;
LUSC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-1.04	-19.98	-0.74	5.38e-59	Height;
LUSC	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg15423357	chr2:25149977	NA	0.37	7.36	0.37	1.41e-12	Body mass index in non-asthmatics;
LUSC	trans	rs6499188	1.000	rs6499188	chr16:68674788	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	8.07	0.4	1.3e-14	Ulcerative colitis;
LUSC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg12963246	chr6:28129442	ZNF389	0.48	6.73	0.35	7.46e-11	Depression;
LUSC	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.47	-5.88	-0.31	1e-8	Neutrophil percentage of white cells;
LUSC	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg18004175	chr5:140027590	IK;NDUFA2	0.36	5.75	0.3	2.04e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.3	0.33	9.5e-10	Menopause (age at onset);
LUSC	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg17410650	chr12:54324560	NA	0.62	10.37	0.49	5.11e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg22532475	chr10:104410764	TRIM8	-0.32	-7.06	-0.36	9.71e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs6982636	1.000	rs2001844	chr8:126478745	A/G	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.34	-6.43	-0.33	4.44e-10	Lipid metabolism phenotypes;
LUSC	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.51	-0.38	5.49e-13	Joint mobility (Beighton score);
LUSC	cis	rs9914988	0.509	rs12453166	chr17:27298709	A/G	cg10538030	chr17:27276405	PHF12	-0.56	-5.71	-0.3	2.55e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg20991723	chr1:152506922	NA	0.51	9.53	0.46	3.42e-19	Hair morphology;
LUSC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.74	7.42	0.38	1e-12	Initial pursuit acceleration;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11528995	chr1:117210575	IGSF3	-0.48	-6.4	-0.33	5.19e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02475777	chr4:1388615	CRIPAK	0.39	5.75	0.3	2.07e-8	Longevity;
LUSC	cis	rs6500395	1.000	rs4493038	chr16:48683920	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.84	0.35	3.77e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.26	-0.37	2.81e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg24375607	chr4:120327624	NA	0.75	11.48	0.53	6.19e-26	Corneal astigmatism;
LUSC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg05082376	chr22:42548792	NA	-0.4	-6.41	-0.33	4.97e-10	Schizophrenia;
LUSC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.52	-0.5	1.46e-22	Alzheimer's disease (late onset);
LUSC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg19318889	chr4:1322082	MAEA	-0.55	-9.03	-0.44	1.42e-17	Obesity-related traits;
LUSC	cis	rs77633900	0.772	rs75253262	chr15:76657124	G/A	cg21673338	chr15:77095150	SCAPER	-0.72	-6.18	-0.32	1.91e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-9.66	-0.47	1.26e-19	Coffee consumption (cups per day);
LUSC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.47	-0.42	8.13e-16	Obesity-related traits;
LUSC	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg13852791	chr20:30311386	BCL2L1	0.96	14.98	0.63	3.5e-39	Mean corpuscular hemoglobin;
LUSC	trans	rs744016	0.594	rs4822751	chr22:27009128	G/T	cg24724084	chr15:48011382	SEMA6D	-0.54	-6.03	-0.31	4.37e-9	RR interval (heart rate);
LUSC	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.44	6.25	0.32	1.26e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs925255	0.711	rs12478126	chr2:28645948	C/T	cg01273330	chr2:28605224	NA	-0.37	-6.01	-0.31	4.88e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg13453750	chr1:205783389	SLC41A1	-0.3	-5.98	-0.31	5.73e-9	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.95	0.48	1.35e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.7	11.61	0.54	2.08e-26	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-1.03	-19.84	-0.74	2.02e-58	Height;
LUSC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.39	-0.49	4.39e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.79	-10.87	-0.51	9.06e-24	Refractive error;
LUSC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg21141812	chr3:48556323	PFKFB4	0.35	6.07	0.32	3.42e-9	Menarche (age at onset);
LUSC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14159672	chr1:205819179	PM20D1	0.8	13.62	0.6	6.42e-34	Menarche (age at onset);
LUSC	cis	rs2637266	0.967	rs4581393	chr10:78376123	A/C	cg18941641	chr10:78392320	NA	0.38	6.94	0.36	2.04e-11	Pulmonary function;
LUSC	cis	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg09307838	chr4:120376055	NA	-0.49	-7.48	-0.38	6.81e-13	Diastolic blood pressure;
LUSC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg04455712	chr21:45112962	RRP1B	0.47	8.99	0.44	1.9e-17	Mean corpuscular volume;
LUSC	cis	rs10489202	1.000	rs12407660	chr1:167954363	C/T	cg24449463	chr1:168025552	DCAF6	-0.58	-7.37	-0.37	1.32e-12	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21039822	chr17:79869136	PCYT2	0.5	6.92	0.35	2.35e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg12257692	chr3:49977190	RBM6	-0.24	-6.68	-0.34	1.01e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg07936489	chr17:37558343	FBXL20	0.78	9.96	0.48	1.27e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs921665	0.831	rs6548168	chr2:3181784	T/C	cg16434511	chr2:3151078	NA	-0.61	-6.89	-0.35	2.74e-11	World class endurance athleticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25140945	chr1:3816479	C1orf174;LOC100133612	0.46	6.48	0.33	3.38e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg11752832	chr7:134001865	SLC35B4	0.54	8.13	0.41	8.64e-15	Mean platelet volume;
LUSC	cis	rs56283067	0.578	rs12197755	chr6:45387495	T/G	cg20913747	chr6:44695427	NA	-0.42	-6.02	-0.31	4.61e-9	Total body bone mineral density;
LUSC	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg22875332	chr1:76189707	ACADM	-0.42	-6.22	-0.32	1.48e-9	Daytime sleep phenotypes;
LUSC	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.95	0.31	6.7e-9	Schizophrenia;
LUSC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.59	-11.05	-0.52	2.07e-24	Longevity;Endometriosis;
LUSC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg27165867	chr14:105738592	BRF1	-0.53	-7.57	-0.38	3.64e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.84	-0.35	3.67e-11	Total body bone mineral density;
LUSC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.51	-0.38	5.54e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02984193	chr15:91260561	BLM	-0.46	-6.2	-0.32	1.71e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6424115	1.000	rs7515969	chr1:24158398	G/A	cg10978503	chr1:24200527	CNR2	-0.51	-11.96	-0.55	1.15e-27	Immature fraction of reticulocytes;
LUSC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.45	-8.14	-0.41	7.93e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg12288994	chr5:1860383	NA	0.3	6.95	0.36	1.93e-11	Cardiovascular disease risk factors;
LUSC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg18351406	chr4:77819688	ANKRD56	0.58	8.49	0.42	7.11e-16	Emphysema distribution in smoking;
LUSC	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.45	-0.33	3.95e-10	Uric acid levels;
LUSC	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg17376030	chr22:41985996	PMM1	0.46	6.35	0.33	6.91e-10	Vitiligo;
LUSC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg26304593	chr6:42947056	PEX6	-0.52	-7.95	-0.4	2.96e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg05855489	chr10:104503620	C10orf26	0.52	7.88	0.4	4.72e-14	Arsenic metabolism;
LUSC	cis	rs77633900	0.772	rs182253	chr15:76800755	C/T	cg21673338	chr15:77095150	SCAPER	-0.69	-5.89	-0.31	9.57e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.36	0.49	5.24e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7216064	1.000	rs9912084	chr17:65868035	A/C	cg12091567	chr17:66097778	LOC651250	-0.73	-9.37	-0.46	1.13e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs6840360	0.642	rs1443089	chr4:152450300	A/G	cg20465933	chr4:152376761	FAM160A1	0.33	5.94	0.31	7.18e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21862992	chr11:68658383	NA	0.51	7.94	0.4	3.06e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg24375607	chr4:120327624	NA	0.66	11.07	0.52	1.72e-24	Corneal astigmatism;
LUSC	cis	rs1172822	0.828	rs11668309	chr19:55833460	A/G	cg04391588	chr19:55832610	TMEM150B	-0.3	-5.66	-0.3	3.22e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg25110126	chr1:46999211	NA	0.77	10.91	0.51	6.86e-24	Monobrow;
LUSC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg04414720	chr1:150670196	GOLPH3L	0.56	9.1	0.45	8.47e-18	Tonsillectomy;
LUSC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.83	12.78	0.57	9.76e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08645402	chr16:4508243	NA	-0.47	-7.51	-0.38	5.49e-13	Schizophrenia;
LUSC	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.77	-12.95	-0.58	2.23e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9837602	0.938	rs10511177	chr3:99724873	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-6.22	-0.32	1.52e-9	Breast cancer;
LUSC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.9	0.61	5.47e-35	Breast cancer;
LUSC	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg02423579	chr7:2872169	GNA12	0.42	6.56	0.34	2.07e-10	Height;
LUSC	cis	rs7940866	0.874	rs11222406	chr11:130814093	A/G	cg12179176	chr11:130786555	SNX19	0.62	9.24	0.45	3.04e-18	Schizophrenia;
LUSC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg20203395	chr5:56204925	C5orf35	-0.73	-9.9	-0.48	1.9e-20	Initial pursuit acceleration;
LUSC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg23978390	chr7:1156363	C7orf50	0.47	5.77	0.3	1.8e-8	Bronchopulmonary dysplasia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22075671	chr5:133747798	CDKN2AIPNL	-0.4	-5.96	-0.31	6.35e-9	Hepatitis;
LUSC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	8.63	0.43	2.55e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2070433	0.660	rs11701034	chr21:47793235	A/G	cg12379764	chr21:47803548	PCNT	0.77	9.7	0.47	9.2e-20	Lymphocyte counts;
LUSC	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg04896959	chr15:78267971	NA	-0.45	-7.12	-0.36	6.62e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg02782426	chr3:40428986	ENTPD3	0.41	7.77	0.39	9.59e-14	Renal cell carcinoma;
LUSC	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06634786	chr22:41940651	POLR3H	-0.49	-5.75	-0.3	2e-8	Vitiligo;
LUSC	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg08917208	chr2:24149416	ATAD2B	0.98	9.95	0.48	1.34e-20	Birth weight;
LUSC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.15	0.41	7.33e-15	Homoarginine levels;
LUSC	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-39.91	-0.91	3.76e-129	Myeloid white cell count;
LUSC	cis	rs2688608	0.967	rs2675663	chr10:75660270	T/G	cg17411546	chr10:75410026	SYNPO2L	-0.43	-6.29	-0.33	9.7e-10	Inflammatory bowel disease;
LUSC	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.9	-15.3	-0.64	2.02e-40	Schizophrenia;
LUSC	cis	rs1535500	1.000	rs35099099	chr6:39284857	G/A	cg06347083	chr6:39282316	KCNK17	-0.27	-5.81	-0.3	1.43e-8	Type 2 diabetes;
LUSC	cis	rs4713675	0.546	rs2296739	chr6:33656969	G/A	cg14003231	chr6:33640908	ITPR3	0.33	6.23	0.32	1.44e-9	Plateletcrit;
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg11235426	chr6:292522	DUSP22	-0.66	-10.46	-0.5	2.45e-22	Menopause (age at onset);
LUSC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.92	13.28	0.59	1.37e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6120849	0.754	rs1885117	chr20:33600740	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.67	0.34	1.05e-10	Protein C levels;
LUSC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-11.9	-0.55	1.77e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03611598	chr17:48586076	MYCBPAP	-0.62	-8.74	-0.43	1.13e-16	Visceral fat;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13329889	chr7:5705264	RNF216	0.41	6.68	0.34	9.8e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.24	-0.45	2.91e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs62238980	0.614	rs80272272	chr22:32475924	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg02176678	chr2:219576539	TTLL4	0.61	10.83	0.51	1.25e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.59	-9.45	-0.46	6.32e-19	Body mass index;
LUSC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.07e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	5.94	0.31	6.99e-9	Schizophrenia;
LUSC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18404041	chr3:52824283	ITIH1	-0.52	-9.81	-0.47	4.05e-20	Intelligence (multi-trait analysis);
LUSC	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.58	10.54	0.5	1.25e-22	Weight;
LUSC	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg25237894	chr2:233734115	C2orf82	0.36	6.16	0.32	2.14e-9	Coronary artery disease;
LUSC	cis	rs12618769	0.543	rs56357378	chr2:99032455	T/G	cg10123293	chr2:99228465	UNC50	0.48	8.19	0.41	5.54e-15	Bipolar disorder;
LUSC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-1.22	-13.35	-0.59	7.04e-33	Diabetic kidney disease;
LUSC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	1.01	14.16	0.61	5.63e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg18357645	chr12:58087776	OS9	-0.5	-7.52	-0.38	5.14e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	11.54	0.53	3.72e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.19	-0.32	1.79e-9	Monocyte count;
LUSC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg23093090	chr10:104574429	C10orf26	-0.35	-6.35	-0.33	7.16e-10	Arsenic metabolism;
LUSC	trans	rs62238980	0.614	rs78781151	chr22:32375462	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs10203711	1.000	rs12692240	chr2:239558688	A/G	cg14580085	chr2:239553406	NA	0.4	6.8	0.35	4.78e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg17173187	chr15:85201210	NMB	0.51	9.61	0.47	1.88e-19	Schizophrenia;
LUSC	trans	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg27275811	chr11:74457193	NA	0.63	6.14	0.32	2.33e-9	Type 2 diabetes nephropathy;
LUSC	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg24675056	chr1:15929824	NA	0.47	8.02	0.4	1.75e-14	Systolic blood pressure;
LUSC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg20933634	chr6:27740509	NA	0.4	5.7	0.3	2.6e-8	Parkinson's disease;
LUSC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg03563238	chr19:33554763	RHPN2	-0.33	-5.74	-0.3	2.14e-8	Colorectal cancer;
LUSC	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg09955084	chr16:413813	NA	0.26	5.77	0.3	1.83e-8	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg10578777	chr12:7781093	NA	0.59	6.47	0.33	3.44e-10	HDL cholesterol levels;
LUSC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg02038168	chr22:39784481	NA	-0.48	-7.72	-0.39	1.35e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs713477	0.692	rs10146713	chr14:55911597	T/C	cg13175173	chr14:55914753	NA	-0.3	-6.06	-0.31	3.59e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg16386425	chr10:429943	DIP2C	-0.39	-6.13	-0.32	2.42e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.86	-0.47	2.63e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg00785112	chr22:46450059	C22orf26;LOC150381	0.46	7.3	0.37	2.13e-12	Dupuytren's disease;Subjective well-being;
LUSC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs10511400	0.764	rs9811483	chr3:119936972	G/A	cg02809009	chr19:50354510	PTOV1	-0.69	-5.99	-0.31	5.46e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg11244672	chr19:19639970	YJEFN3	-0.38	-5.75	-0.3	1.98e-8	Tonsillectomy;
LUSC	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg16989719	chr2:238392110	NA	-0.41	-7.04	-0.36	1.1e-11	Prostate cancer;
LUSC	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg03060546	chr3:49711283	APEH	0.64	7.68	0.39	1.82e-13	Menarche (age at onset);
LUSC	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg01528321	chr10:82214614	TSPAN14	1.03	16.08	0.66	1.68e-43	Post bronchodilator FEV1;
LUSC	cis	rs62400317	0.762	rs12190313	chr6:44903902	T/G	cg18551225	chr6:44695536	NA	-0.48	-7.69	-0.39	1.68e-13	Total body bone mineral density;
LUSC	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.79	-0.3	1.62e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.03	0.31	4.46e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg22903471	chr2:27725779	GCKR	-0.41	-6.89	-0.35	2.75e-11	Total body bone mineral density;
LUSC	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg13010199	chr12:38710504	ALG10B	0.69	10.78	0.51	1.89e-23	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.9	15.74	0.65	3.85e-42	Morning vs. evening chronotype;
LUSC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.78	0.3	1.74e-8	Menopause (age at onset);
LUSC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg04369109	chr6:150039330	LATS1	-0.53	-7.57	-0.38	3.78e-13	Lung cancer;
LUSC	cis	rs4654899	0.865	rs12123300	chr1:21323568	T/C	cg01072550	chr1:21505969	NA	-0.54	-7.97	-0.4	2.5e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.78	-0.3	1.73e-8	Recombination rate (females);
LUSC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg04315214	chr1:2043799	PRKCZ	0.48	10.16	0.49	2.65e-21	Height;
LUSC	cis	rs9905704	0.918	rs12952362	chr17:56900870	A/G	cg12560992	chr17:57184187	TRIM37	0.57	8.05	0.4	1.47e-14	Testicular germ cell tumor;
LUSC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg23262073	chr20:60523788	NA	-0.43	-6.29	-0.33	1e-9	Body mass index;
LUSC	cis	rs61990749	0.597	rs4632066	chr14:78247282	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.62	-6.76	-0.35	6.19e-11	Fibroblast growth factor basic levels;
LUSC	cis	rs8092503	1.000	rs12454336	chr18:52497204	C/T	cg12377874	chr18:52495404	RAB27B	-0.34	-6.27	-0.32	1.14e-9	Childhood body mass index;
LUSC	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.51e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg18240062	chr17:79603768	NPLOC4	0.79	15.32	0.64	1.65e-40	Eye color traits;
LUSC	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg21427119	chr20:30132790	HM13	-0.42	-6.27	-0.32	1.1e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs9682041	0.877	rs10804841	chr3:170072031	T/A	cg11886554	chr3:170076028	SKIL	0.7	8.59	0.43	3.46e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LUSC	cis	rs11997175	0.838	rs10954934	chr8:33669637	T/C	ch.8.33884649F	chr8:33765107	NA	0.47	7.22	0.37	3.55e-12	Body mass index;
LUSC	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg08999081	chr20:33150536	PIGU	0.32	5.65	0.3	3.51e-8	Height;
LUSC	cis	rs381815	1.000	rs381815	chr11:16902268	C/T	cg05701403	chr11:16947551	PLEKHA7	0.38	5.77	0.3	1.78e-8	Diastolic blood pressure;Systolic blood pressure;Blood pressure;
LUSC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08677398	chr8:58056175	NA	0.58	7.01	0.36	1.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.55	-0.46	2.94e-19	Joint mobility (Beighton score);
LUSC	cis	rs6456156	0.774	rs6930998	chr6:167526940	A/C	cg07741184	chr6:167504864	NA	-0.35	-6.14	-0.32	2.36e-9	Primary biliary cholangitis;
LUSC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg11764359	chr7:65958608	NA	0.51	6.67	0.34	1.08e-10	Aortic root size;
LUSC	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg05527609	chr1:210001259	C1orf107	0.7	10.07	0.48	5.22e-21	Orofacial clefts;
LUSC	cis	rs9394152	0.845	rs9296092	chr6:33478496	C/T	cg13560919	chr6:33536144	NA	-0.58	-10.53	-0.5	1.45e-22	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg09165964	chr15:75287851	SCAMP5	-0.73	-6.73	-0.35	7.21e-11	Lung cancer;
LUSC	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	0.93	8.06	0.4	1.33e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg18512352	chr11:47633146	NA	-0.46	-9.28	-0.45	2.25e-18	Subjective well-being;
LUSC	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.64	-12.18	-0.55	1.66e-28	Survival in pancreatic cancer;
LUSC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg05347473	chr6:146136440	FBXO30	0.45	7.69	0.39	1.66e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg05855489	chr10:104503620	C10orf26	0.49	7.52	0.38	4.99e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs3857536	0.776	rs4710316	chr6:66935097	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg27539214	chr16:67997921	SLC12A4	-0.54	-7.27	-0.37	2.56e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10992471	0.603	rs4743873	chr9:95270781	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.39	6.76	0.35	6.22e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs1325195	0.881	rs3813642	chr1:179070120	C/T	cg11624085	chr17:8464688	MYH10	-0.42	-6.9	-0.35	2.57e-11	IgE grass sensitization;
LUSC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00149659	chr3:10157352	C3orf10	-0.96	-14.29	-0.62	1.78e-36	Alzheimer's disease;
LUSC	trans	rs2363709	0.892	rs9832987	chr3:67418396	C/A	cg23062198	chr2:14774063	FAM84A	-0.54	-5.98	-0.31	5.77e-9	IgE levels;
LUSC	cis	rs9653442	0.545	rs11681227	chr2:100754997	A/G	cg22139774	chr2:100720529	AFF3	-0.43	-7.29	-0.37	2.3e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-8.19	-0.41	5.44e-15	Morning vs. evening chronotype;
LUSC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg05623727	chr3:50126028	RBM5	-0.32	-5.96	-0.31	6.34e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg05373962	chr22:49881684	NA	-0.4	-8.46	-0.42	8.69e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs13082711	0.911	rs3755652	chr3:27472936	A/G	cg02860705	chr3:27208620	NA	-0.47	-7.61	-0.38	2.9e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs77633900	0.772	rs4886491	chr15:76661925	C/T	cg21673338	chr15:77095150	SCAPER	-0.65	-5.8	-0.3	1.53e-8	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18854424	chr1:2615690	NA	0.5	10.01	0.48	8.46e-21	Ulcerative colitis;
LUSC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05535760	chr7:792225	HEATR2	0.91	9.61	0.47	1.88e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg27129171	chr3:47204927	SETD2	0.68	11.47	0.53	6.92e-26	Colorectal cancer;
LUSC	cis	rs7000551	0.689	rs10110254	chr8:22309551	G/T	cg12081754	chr8:22256438	SLC39A14	0.49	7.54	0.38	4.34e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs11630290	0.518	rs56247655	chr15:64171627	G/A	cg12036633	chr15:63758958	NA	-0.56	-6.59	-0.34	1.75e-10	Iris characteristics;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg06383048	chr11:118401878	TMEM25	0.39	6.02	0.31	4.65e-9	Schizophrenia;
LUSC	trans	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.08	-0.36	8.49e-12	Triglycerides;
LUSC	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.61	13.92	0.61	4.89e-35	Height;
LUSC	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg20283391	chr11:68216788	NA	-0.6	-8.37	-0.42	1.6e-15	Total body bone mineral density;
LUSC	cis	rs73198271	0.562	rs73519953	chr8:8660278	G/T	cg01851573	chr8:8652454	MFHAS1	0.64	8.88	0.44	4.33e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg13042288	chr15:90349979	ANPEP	-0.5	-7.47	-0.38	7.3e-13	Uric acid levels;
LUSC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.16	-0.32	2.04e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg22535103	chr8:58192502	C8orf71	-0.69	-7.61	-0.38	2.77e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg16414030	chr3:133502952	NA	0.42	6.39	0.33	5.67e-10	Iron status biomarkers;
LUSC	cis	rs17253792	0.822	rs80174205	chr14:56058694	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-6.96	-0.36	1.81e-11	Putamen volume;
LUSC	cis	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg21775007	chr8:11205619	TDH	0.54	7.77	0.39	9.57e-14	Triglycerides;
LUSC	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg27398817	chr8:82754497	SNX16	-0.65	-8.05	-0.4	1.43e-14	Diastolic blood pressure;
LUSC	cis	rs16854884	0.538	rs61359084	chr3:143738362	T/C	cg06585982	chr3:143692056	C3orf58	0.51	8.06	0.4	1.33e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs2235544	0.542	rs585269	chr1:54469976	C/T	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg00484396	chr16:3507460	NAT15	0.73	12.48	0.56	1.34e-29	Tuberculosis;
LUSC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-6.43	-0.33	4.33e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1775715	0.707	rs2808088	chr10:32146150	A/G	cg18675610	chr10:32216311	ARHGAP12	0.31	6.87	0.35	3.21e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.68	-10.23	-0.49	1.51e-21	Monocyte percentage of white cells;
LUSC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg04553112	chr3:125709451	NA	-0.5	-5.66	-0.3	3.27e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg22834771	chr12:69754056	YEATS4	-0.49	-7.41	-0.38	1.02e-12	Blood protein levels;
LUSC	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg05340658	chr4:99064831	C4orf37	0.41	6.42	0.33	4.64e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.75	-0.3	2e-8	Ulcerative colitis;
LUSC	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.35e-33	Morning vs. evening chronotype;
LUSC	cis	rs6840360	0.967	rs6832562	chr4:152602798	A/G	cg22705602	chr4:152727874	NA	-0.27	-5.72	-0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18876405	chr7:65276391	NA	-0.55	-8.79	-0.43	8.32e-17	Aortic root size;
LUSC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.57	-8.38	-0.42	1.51e-15	Obesity-related traits;
LUSC	cis	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg05299278	chr17:33885742	SLFN14	-0.31	-6.38	-0.33	5.92e-10	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs501916	0.634	rs531596	chr15:48058214	C/T	cg16110827	chr15:48056943	SEMA6D	-0.38	-5.9	-0.31	8.75e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.35	-6.57	-0.34	1.97e-10	Coronary artery disease;
LUSC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg05368731	chr17:41323189	NBR1	0.82	13.29	0.59	1.16e-32	Menopause (age at onset);
LUSC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg25258033	chr6:167368657	RNASET2	0.44	7.05	0.36	1.02e-11	Crohn's disease;
LUSC	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.59	-0.43	3.43e-16	Mood instability;
LUSC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg20573242	chr4:122745356	CCNA2	0.45	6.89	0.35	2.72e-11	Type 2 diabetes;
LUSC	cis	rs11158026	0.757	rs7146285	chr14:55412869	T/C	cg04306507	chr14:55594613	LGALS3	0.34	6.37	0.33	6.1e-10	Parkinson's disease;
LUSC	cis	rs12532214	1.000	rs12532214	chr7:3169890	C/G	cg19214707	chr7:3157722	NA	-0.4	-6.31	-0.33	8.95e-10	Itch intensity from mosquito bite;
LUSC	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	9.57	0.46	2.52e-19	Lung cancer in ever smokers;
LUSC	cis	rs7584330	0.554	rs13395743	chr2:238437554	C/T	cg14458575	chr2:238380390	NA	0.46	5.79	0.3	1.6e-8	Prostate cancer;
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23978390	chr7:1156363	C7orf50	0.5	7.06	0.36	9.93e-12	Longevity;Endometriosis;
LUSC	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg16070123	chr10:51489643	NA	-0.5	-7.91	-0.4	3.72e-14	Prostate-specific antigen levels;
LUSC	cis	rs2979489	0.945	rs17627903	chr8:30351812	T/C	cg26383811	chr8:30366931	RBPMS	-0.55	-8.58	-0.42	3.73e-16	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs1941023	0.584	rs10897057	chr11:60172273	A/T	cg08716584	chr11:60157161	MS4A7	-0.62	-11.34	-0.53	2.02e-25	Congenital heart disease (maternal effect);
LUSC	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg13010199	chr12:38710504	ALG10B	0.55	9.23	0.45	3.1e-18	Heart rate;
LUSC	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg11057378	chr10:81107060	PPIF	0.39	6.36	0.33	6.81e-10	Height;
LUSC	trans	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.78	-0.39	9.18e-14	Morning vs. evening chronotype;
LUSC	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg22676075	chr6:135203613	NA	-0.48	-7.58	-0.38	3.38e-13	Red blood cell count;
LUSC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg00033643	chr7:134001901	SLC35B4	0.45	7.09	0.36	7.88e-12	Mean platelet volume;
LUSC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15320075	chr8:145703422	NA	0.65	11.41	0.53	1.07e-25	Age at first birth;
LUSC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.84	-0.3	1.21e-8	Neutrophil percentage of white cells;
LUSC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs6681460	1.000	rs10889641	chr1:67138367	C/T	cg02459107	chr1:67143332	SGIP1	0.49	9.11	0.45	7.64e-18	Presence of antiphospholipid antibodies;
LUSC	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg07541023	chr7:19748670	TWISTNB	0.81	8.41	0.42	1.19e-15	Thyroid stimulating hormone;
LUSC	trans	rs2786098	0.616	rs10801614	chr1:197520273	T/C	cg16005942	chr6:160526640	IGF2R	-0.5	-6.23	-0.32	1.4e-9	Asthma;
LUSC	cis	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg06521331	chr12:34319734	NA	-0.52	-8.62	-0.43	2.69e-16	Morning vs. evening chronotype;
LUSC	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.66	-11.17	-0.52	8.07e-25	Lung cancer;
LUSC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.63	0.62	8.8e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg23791538	chr6:167370224	RNASET2	0.44	7.1	0.36	7.43e-12	Crohn's disease;
LUSC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg01427869	chr13:113580562	NA	0.57	6.35	0.33	6.97e-10	Schizophrenia;
LUSC	cis	rs12940923	1.000	rs35444528	chr17:56367065	A/C	cg19466818	chr17:56409534	MIR142	-0.39	-6.87	-0.35	3.19e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs3736594	0.513	rs6751087	chr2:27778016	T/C	cg27432699	chr2:27873401	GPN1	0.67	8.9	0.44	3.75e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs12980942	0.630	rs7257825	chr19:41788344	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.59	6.49	0.33	3.13e-10	Coronary artery disease;
LUSC	cis	rs965469	0.895	rs6037595	chr20:3401128	T/G	cg25506879	chr20:3388711	C20orf194	-0.54	-6.14	-0.32	2.29e-9	IFN-related cytopenia;
LUSC	cis	rs59104589	0.617	rs3755395	chr2:242294116	A/G	cg14842376	chr2:242211374	HDLBP	0.63	6.88	0.35	2.97e-11	Fibrinogen levels;
LUSC	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg05855489	chr10:104503620	C10orf26	0.69	10.01	0.48	8.35e-21	Arsenic metabolism;
LUSC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.83	12.43	0.56	2.1e-29	Cognitive test performance;
LUSC	cis	rs2692947	0.683	rs1813381	chr2:96422939	C/T	cg23100626	chr2:96804247	ASTL	-0.29	-6.58	-0.34	1.77e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg06600287	chr1:53387719	ECHDC2	-0.27	-5.81	-0.3	1.49e-8	Monocyte count;
LUSC	cis	rs4964805	0.632	rs11111782	chr12:104188476	A/G	cg02344784	chr12:104178138	NT5DC3	-0.45	-8.52	-0.42	5.53e-16	Attention deficit hyperactivity disorder;
LUSC	trans	rs9944275	0.860	rs36094086	chr15:97192674	A/G	cg18834029	chr10:103349097	POLL;RP11-529I10.4	-0.6	-5.97	-0.31	6.23e-9	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.89	12.61	0.57	4.5e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg22705602	chr4:152727874	NA	-0.33	-7.16	-0.36	5.22e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.97	0.36	1.66e-11	Platelet count;
LUSC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg23719950	chr11:63933701	MACROD1	-0.61	-7.99	-0.4	2.22e-14	Mean platelet volume;
LUSC	trans	rs629535	0.911	rs688612	chr8:70011887	C/T	cg21567404	chr3:27674614	NA	-0.95	-15.08	-0.64	1.48e-39	Dupuytren's disease;
LUSC	cis	rs3820068	0.608	rs2057304	chr1:16017710	A/G	cg24675056	chr1:15929824	NA	0.41	6.84	0.35	3.9e-11	Systolic blood pressure;
LUSC	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg03522245	chr20:25566470	NINL	0.35	5.67	0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg11019008	chr10:131425282	MGMT	0.42	6.34	0.33	7.48e-10	Response to temozolomide;
LUSC	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-0.82	-13.63	-0.6	6.05e-34	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.09	15.15	0.64	7.93e-40	Uric acid levels;
LUSC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18131467	chr2:239335373	ASB1	1.04	25.08	0.81	8.88e-79	Multiple system atrophy;
LUSC	cis	rs7945718	0.967	rs7931147	chr11:12748884	C/A	cg25843174	chr11:12811716	TEAD1	0.33	7.32	0.37	1.91e-12	Educational attainment (years of education);
LUSC	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	18.63	0.71	1.33e-53	Body mass index (adult);
LUSC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg05347473	chr6:146136440	FBXO30	-0.57	-9.71	-0.47	8.71e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg06640241	chr16:89574553	SPG7	0.66	9.82	0.47	3.8e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs10979	1.000	rs9496673	chr6:143885393	C/G	cg25407410	chr6:143891975	LOC285740	-0.74	-12.02	-0.55	6.53e-28	Hypospadias;
LUSC	cis	rs13385	0.769	rs7707814	chr5:139583728	C/G	cg26211634	chr5:139558579	C5orf32	0.44	6.59	0.34	1.76e-10	Atrial fibrillation;
LUSC	trans	rs1998174	0.509	rs4916402	chr1:171815948	C/T	cg13482142	chr2:234261155	NA	0.41	6.05	0.31	3.83e-9	Platelet distribution width;
LUSC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg06212747	chr3:49208901	KLHDC8B	0.45	5.89	0.31	9.48e-9	Parkinson's disease;
LUSC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg26924012	chr15:45694286	SPATA5L1	1.13	19.8	0.73	2.9e-58	Homoarginine levels;
LUSC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg15691649	chr6:25882328	NA	-0.39	-6.37	-0.33	6.27e-10	Blood metabolite levels;
LUSC	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.9	15.75	0.65	3.58e-42	Morning vs. evening chronotype;
LUSC	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg20908204	chr19:46285434	DMPK	-0.45	-8.45	-0.42	9.12e-16	Coronary artery disease;
LUSC	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg20243544	chr17:37824526	PNMT	0.39	5.96	0.31	6.59e-9	Self-reported allergy;
LUSC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.13	0.48	3.25e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg13206674	chr6:150067644	NUP43	0.6	9.67	0.47	1.15e-19	Lung cancer;
LUSC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20135002	chr11:47629003	NA	-0.48	-7.52	-0.38	5.13e-13	Subjective well-being;
LUSC	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg11861562	chr11:117069780	TAGLN	0.34	6.61	0.34	1.5e-10	Blood protein levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04590956	chr2:70057467	GMCL1	0.52	7.75	0.39	1.09e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg18357645	chr12:58087776	OS9	0.54	8.3	0.41	2.58e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg14289826	chr9:140003911	NA	-0.35	-6.99	-0.36	1.48e-11	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg15571903	chr15:79123663	NA	-0.33	-6.13	-0.32	2.47e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg23985595	chr17:80112537	CCDC57	-0.33	-6.48	-0.33	3.24e-10	Life satisfaction;
LUSC	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.7	-0.47	9.19e-20	Hemoglobin concentration;
LUSC	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg15704280	chr7:45808275	SEPT13	-0.58	-7.11	-0.36	7.12e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.66	6.53	0.34	2.5e-10	Initial pursuit acceleration;
LUSC	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg21573476	chr21:45109991	RRP1B	-0.39	-6.46	-0.33	3.64e-10	Mean corpuscular volume;
LUSC	trans	rs71435601	0.628	rs11897480	chr2:21419320	C/G	cg20757404	chr19:378427	NA	-0.41	-6.33	-0.33	8.06e-10	Cholesterol, total;
LUSC	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg24692254	chr21:30365293	RNF160	-0.58	-7.22	-0.37	3.57e-12	Cognitive test performance;
LUSC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg14440974	chr22:39074834	NA	-0.37	-6.06	-0.31	3.71e-9	Menopause (age at onset);
LUSC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg24399712	chr22:39784796	NA	-0.61	-10.86	-0.51	1.01e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.9	0.35	2.7e-11	Testicular germ cell tumor;
LUSC	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg15819921	chr19:927150	ARID3A	-0.42	-6.28	-0.32	1.06e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21659725	chr3:3221576	CRBN	0.63	8.74	0.43	1.19e-16	Resting heart rate;
LUSC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.46	7.17	0.37	4.76e-12	Alzheimer's disease (late onset);
LUSC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-6.27	-0.32	1.12e-9	Height;
LUSC	trans	rs4729127	1.000	rs61235767	chr7:94016764	T/C	cg20086523	chr13:52378287	DHRS12	0.62	6.69	0.34	9.44e-11	Intelligence;
LUSC	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg06636001	chr8:8085503	FLJ10661	0.52	7.65	0.39	2.16e-13	Systolic blood pressure;
LUSC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg09035930	chr12:129282057	SLC15A4	-0.66	-13.27	-0.59	1.4e-32	Systemic lupus erythematosus;
LUSC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	0.96	19.15	0.72	1.11e-55	Cognitive function;
LUSC	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.34	0.33	7.32e-10	Corneal astigmatism;
LUSC	trans	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.54	0.46	3.16e-19	Mean corpuscular volume;
LUSC	cis	rs11785693	0.602	rs73190403	chr8:4954798	T/C	cg26367366	chr8:4980734	NA	0.7	7.36	0.37	1.4e-12	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22000725	chr19:8478147	MARCH2	0.44	6.12	0.32	2.69e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.69	-0.43	1.65e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	5.84	0.3	1.24e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs13223928	0.666	rs9986825	chr7:3151177	C/T	cg19214707	chr7:3157722	NA	0.52	10.45	0.5	2.73e-22	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-6.52	-0.34	2.6200000000000003e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7216064	1.000	rs9915108	chr17:65874463	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-9.37	-0.46	1.13e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	0.71	11.19	0.52	6.91e-25	Blood metabolite ratios;
LUSC	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg25237894	chr2:233734115	C2orf82	-0.35	-6.41	-0.33	4.93e-10	Coronary artery disease;
LUSC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.62	11.09	0.52	1.56e-24	Extrinsic epigenetic age acceleration;
LUSC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg02018176	chr4:1364513	KIAA1530	0.48	8.42	0.42	1.16e-15	Obesity-related traits;
LUSC	cis	rs2348418	1.000	rs2348418	chr12:28689514	T/C	cg13890972	chr12:28721907	NA	-0.34	-5.87	-0.31	1.05e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.09	-0.32	3.02e-9	Initial pursuit acceleration;
LUSC	cis	rs4917300	0.647	rs4917223	chr8:143115548	C/T	cg25363559	chr8:143086065	NA	-0.29	-6.61	-0.34	1.56e-10	Amyotrophic lateral sclerosis;
LUSC	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg07606381	chr6:8435919	SLC35B3	-0.5	-7.5	-0.38	5.93e-13	Motion sickness;
LUSC	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.39	-0.46	9.83e-19	Schizophrenia;
LUSC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg12963246	chr6:28129442	ZNF389	0.54	7.68	0.39	1.78e-13	Depression;
LUSC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.53	-7.48	-0.38	6.55e-13	Multiple sclerosis;
LUSC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.56	-11.42	-0.53	1.01e-25	Sense of smell;
LUSC	cis	rs9494145	0.680	rs4895440	chr6:135426558	A/T	cg22676075	chr6:135203613	NA	0.58	8.56	0.42	4.3e-16	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.3	0.45	1.9e-18	Prudent dietary pattern;
LUSC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	6.22	0.32	1.51e-9	Renal cell carcinoma;
LUSC	cis	rs2559856	0.967	rs2559863	chr12:102087108	C/T	cg12924262	chr12:102091054	CHPT1	0.43	5.98	0.31	5.66e-9	Blood protein levels;
LUSC	cis	rs922692	0.967	rs11633351	chr15:79056815	C/T	cg00540400	chr15:79124168	NA	-0.35	-5.93	-0.31	7.67e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg11941060	chr3:133502564	NA	0.49	7.55	0.38	4.08e-13	Iron status biomarkers;
LUSC	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg18196295	chr10:418757	DIP2C	0.45	7.37	0.37	1.32e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	7.52	0.38	5.18e-13	Breast cancer;
LUSC	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg17595323	chr11:93583763	C11orf90	-0.31	-5.67	-0.3	3.09e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06544989	chr22:39130855	UNC84B	0.37	6.4	0.33	5.2400000000000005e-10	Menopause (age at onset);
LUSC	cis	rs4629180	0.586	rs57563359	chr2:102125309	A/G	cg04415270	chr2:102091202	RFX8	-0.44	-7.64	-0.39	2.36e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.82	-0.43	6.37e-17	Type 2 diabetes;
LUSC	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg04315214	chr1:2043799	PRKCZ	0.47	9.93	0.48	1.51e-20	Height;
LUSC	cis	rs9818941	1.000	rs9845687	chr3:157682536	T/C	cg08654915	chr3:157813417	NA	-0.25	-6.25	-0.32	1.23e-9	Height;
LUSC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.02	0.58	1.28e-31	Chronic sinus infection;
LUSC	cis	rs983392	0.836	rs72918674	chr11:59944580	C/T	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.19	-0.32	1.73e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg15744005	chr10:104629667	AS3MT	-0.28	-5.95	-0.31	6.91e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9341835	0.518	rs9361816	chr6:64174439	T/A	cg03326410	chr6:64151739	NA	-0.37	-6.0	-0.31	5.11e-9	Schizophrenia;
LUSC	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.54	0.5	1.27e-22	Colorectal cancer;
LUSC	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.9	15.47	0.65	4.28e-41	Bladder cancer;
LUSC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg06494592	chr3:125709126	NA	-0.5	-5.68	-0.3	2.89e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6669072	0.669	rs814545	chr1:91240551	C/G	cg08895590	chr1:91227319	NA	-0.39	-8.68	-0.43	1.81e-16	Cognitive function;
LUSC	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg13010199	chr12:38710504	ALG10B	-0.59	-9.18	-0.45	4.74e-18	Bladder cancer;
LUSC	cis	rs9303280	0.747	rs1453559	chr17:38020419	T/C	cg20243544	chr17:37824526	PNMT	0.4	6.05	0.31	3.9e-9	Self-reported allergy;
LUSC	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg20701182	chr2:24300061	SF3B14	0.75	7.46	0.38	7.57e-13	Lymphocyte counts;
LUSC	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg18302933	chr2:88491318	NA	-0.34	-6.53	-0.34	2.39e-10	Response to metformin (IC50);
LUSC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg08999081	chr20:33150536	PIGU	0.5	9.95	0.48	1.31e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.42	0.42	1.16e-15	Prudent dietary pattern;
LUSC	cis	rs7809950	0.678	rs12670688	chr7:106821016	A/G	cg23024343	chr7:107201750	COG5	0.61	8.16	0.41	6.96e-15	Coronary artery disease;
LUSC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg07424592	chr7:64974309	NA	0.67	5.88	0.31	9.86e-9	Diabetic kidney disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11196904	chr1:10491304	APITD1	-0.46	-6.17	-0.32	2.02e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg10356904	chr22:49881777	NA	-0.32	-7.1	-0.36	7.49e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg07856975	chr6:36356162	ETV7	0.34	6.21	0.32	1.61e-9	Mean platelet volume;
LUSC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg20307385	chr11:47447363	PSMC3	0.43	5.66	0.3	3.33e-8	Subjective well-being;
LUSC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.46	6.74	0.35	6.79e-11	Systemic lupus erythematosus;
LUSC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg04518342	chr5:131593106	PDLIM4	0.42	8.07	0.4	1.3e-14	Blood metabolite levels;
LUSC	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg14092571	chr14:90743983	NA	-0.36	-5.94	-0.31	7.26e-9	Mortality in heart failure;
LUSC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg02487422	chr3:49467188	NICN1	0.45	7.18	0.37	4.63e-12	Resting heart rate;
LUSC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.56	0.53	3.14e-26	Menopause (age at onset);
LUSC	cis	rs4356932	1.000	rs4371639	chr4:76946569	G/T	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs735860	0.726	rs209519	chr6:53208680	G/A	cg10236188	chr6:53219634	NA	0.38	5.7	0.3	2.58e-8	Glaucoma;
LUSC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.63	8.44	0.42	9.92e-16	High light scatter reticulocyte count;
LUSC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg08048268	chr3:133502702	NA	-0.41	-7.41	-0.38	1.07e-12	Iron status biomarkers;
LUSC	cis	rs6960043	0.818	rs10264063	chr7:15053193	G/C	cg19272540	chr7:15055459	NA	0.33	8.28	0.41	2.97e-15	Type 2 diabetes;
LUSC	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg22705602	chr4:152727874	NA	-0.3	-6.01	-0.31	4.87e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2315504	1.000	rs2524300	chr17:39040877	C/T	cg17985300	chr17:38952333	KRT28	-0.32	-6.67	-0.34	1.05e-10	Height;
LUSC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.07	0.4	1.25e-14	Parkinson's disease;
LUSC	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg17279839	chr7:150038598	RARRES2	0.36	5.83	0.3	1.33e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg01475377	chr6:109611718	NA	-0.41	-7.35	-0.37	1.54e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs4851254	0.920	rs11686599	chr2:100753475	A/G	cg07810366	chr2:100720526	AFF3	-0.38	-5.93	-0.31	7.58e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs643955	0.609	rs13259465	chr8:9982953	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.2	-0.32	1.66e-9	Systemic lupus erythematosus;
LUSC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.92	-14.53	-0.62	2.07e-37	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04832844	chr4:26321136	RBPJ	-0.43	-6.71	-0.34	8.36e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg17252645	chr8:143867129	LY6D	-0.55	-10.5	-0.5	1.75e-22	Urinary tract infection frequency;
LUSC	cis	rs4851254	0.660	rs114552491	chr2:100709533	C/T	cg07810366	chr2:100720526	AFF3	-0.46	-6.16	-0.32	2.05e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	10.01	0.48	8.69e-21	Lymphocyte counts;
LUSC	cis	rs62400317	0.614	rs12210292	chr6:44925293	A/G	cg20913747	chr6:44695427	NA	-0.42	-6.08	-0.32	3.37e-9	Total body bone mineral density;
LUSC	trans	rs7572263	0.724	rs10497896	chr2:209049899	G/C	cg21778348	chr7:27194614	HOXA7	-0.47	-6.31	-0.33	9.11e-10	Glioma;Non-glioblastoma glioma;
LUSC	cis	rs2797369	0.546	rs11963911	chr6:101308421	T/C	cg12253828	chr6:101329408	ASCC3	0.45	5.74	0.3	2.15e-8	Renal function-related traits (eGRFcrea);
LUSC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.96	-0.44	2.37e-17	Gut microbiome composition (summer);
LUSC	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg13010199	chr12:38710504	ALG10B	0.59	9.2	0.45	3.95e-18	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.37	5.79	0.3	1.62e-8	Platelet count;
LUSC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg03188948	chr7:1209495	NA	0.46	6.11	0.32	2.83e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg11693508	chr17:37793320	STARD3	0.51	6.12	0.32	2.69e-9	Bipolar disorder;
LUSC	trans	rs61931739	0.649	rs815028	chr12:33718591	T/C	cg26384229	chr12:38710491	ALG10B	0.42	6.13	0.32	2.54e-9	Morning vs. evening chronotype;
LUSC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg14019146	chr3:50243930	SLC38A3	0.36	7.98	0.4	2.3e-14	Body mass index;
LUSC	cis	rs55871839	0.708	rs2326213	chr8:59812459	A/G	cg07426533	chr8:59803705	TOX	-0.36	-5.93	-0.31	7.66e-9	Pneumonia;
LUSC	cis	rs61990749	0.597	rs759808	chr14:78250845	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	6.66	0.34	1.11e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs7180079	0.925	rs56246583	chr15:64534123	A/T	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs58749629	1.000	rs7270354	chr20:44607661	C/T	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.55	-6.24	-0.32	1.33e-9	Abdominal aortic aneurysm;
LUSC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg07741184	chr6:167504864	NA	0.39	6.88	0.35	2.93e-11	Primary biliary cholangitis;
LUSC	cis	rs9815354	1.000	rs1716993	chr3:41974556	G/C	cg03022575	chr3:42003672	ULK4	-0.58	-6.4	-0.33	5.41e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg25801113	chr15:45476975	SHF	0.34	7.04	0.36	1.13e-11	Uric acid levels;
LUSC	trans	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg19894588	chr14:64061835	NA	-0.51	-6.59	-0.34	1.73e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs11696845	0.787	rs6017408	chr20:43363529	A/G	cg25301532	chr20:43378953	KCNK15	0.35	6.41	0.33	5.04e-10	Obesity-related traits;
LUSC	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg18232548	chr7:50535776	DDC	0.5	7.49	0.38	6.04e-13	Malaria;
LUSC	cis	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg01251360	chr16:68772225	CDH1	-0.29	-6.7	-0.34	8.93e-11	Colorectal cancer;
LUSC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg22800045	chr5:56110881	MAP3K1	0.76	9.57	0.46	2.44e-19	Initial pursuit acceleration;
LUSC	trans	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg05926928	chr17:57297772	GDPD1	-0.8	-9.23	-0.45	3.24e-18	Opioid sensitivity;
LUSC	trans	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.41	-0.33	4.96e-10	Blood trace element (Cu levels);
LUSC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08219700	chr8:58056026	NA	0.66	7.3	0.37	2.11e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2282802	0.685	rs7730245	chr5:139628163	C/A	cg26211634	chr5:139558579	C5orf32	0.43	8.1	0.41	1.07e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg00191853	chr8:101177733	SPAG1	-0.41	-6.53	-0.34	2.46e-10	Atrioventricular conduction;
LUSC	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	0.79	12.29	0.56	6.95e-29	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs11971779	0.648	rs66463279	chr7:139118661	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.16	0.36	5.18e-12	Diisocyanate-induced asthma;
LUSC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg24578937	chr1:2090814	PRKCZ	-0.43	-9.26	-0.45	2.47e-18	Height;
LUSC	cis	rs1413885	0.516	rs11208637	chr1:65836553	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.49	7.16	0.36	5.09e-12	Anticoagulant levels;
LUSC	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg06637938	chr14:75390232	RPS6KL1	0.65	10.91	0.51	6.45e-24	Caffeine consumption;
LUSC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.19	-0.52	6.61e-25	Alzheimer's disease;
LUSC	cis	rs1775715	0.707	rs2799019	chr10:32142850	C/T	cg26784012	chr10:32216390	ARHGAP12	0.45	7.62	0.38	2.69e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7215564	0.908	rs74000899	chr17:78653542	T/C	cg23238734	chr17:78661607	RPTOR	0.49	6.28	0.32	1.08e-9	Myopia (pathological);
LUSC	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg10326726	chr10:51549505	MSMB	-0.37	-6.38	-0.33	5.77e-10	Prostate-specific antigen levels;
LUSC	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg23625390	chr15:77176239	SCAPER	0.46	7.04	0.36	1.09e-11	Blood metabolite levels;
LUSC	cis	rs6005807	0.719	rs9625523	chr22:29045745	T/C	cg12565055	chr22:29076175	TTC28	0.54	5.86	0.31	1.12e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg17252645	chr8:143867129	LY6D	0.38	6.75	0.35	6.53e-11	Urinary tract infection frequency;
LUSC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg23711669	chr6:146136114	FBXO30	0.9	17.11	0.68	1.48e-47	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.22	0.41	4.57e-15	Ulcerative colitis;
LUSC	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg17173187	chr15:85201210	NMB	0.51	9.44	0.46	6.57e-19	Schizophrenia;
LUSC	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg18904891	chr8:8559673	CLDN23	-0.38	-5.66	-0.3	3.19e-8	Mood instability;
LUSC	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	0.94	16.27	0.66	3.01e-44	Height;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18457491	chr10:104829517	CNNM2	-0.4	-6.1	-0.32	2.87e-9	Hepatitis;
LUSC	cis	rs4363385	0.667	rs2050674	chr1:152913356	C/G	cg00922841	chr1:152955080	SPRR1A	0.41	7.14	0.36	5.9e-12	Inflammatory skin disease;
LUSC	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg16576597	chr16:28551801	NUPR1	0.31	6.24	0.32	1.29e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.61	-9.34	-0.46	1.41e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg05555928	chr11:63887634	MACROD1	-0.45	-5.66	-0.3	3.23e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.53	-11.22	-0.52	5.31e-25	Vitamin D levels;
LUSC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg06060754	chr5:176797920	RGS14	0.6	9.58	0.46	2.26e-19	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.47	-0.42	7.85e-16	Total cholesterol levels;
LUSC	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg20701182	chr2:24300061	SF3B14	0.74	7.48	0.38	6.68e-13	Lymphocyte counts;
LUSC	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg22532475	chr10:104410764	TRIM8	-0.35	-7.62	-0.38	2.72e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.92	11.97	0.55	1.05e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg07701084	chr6:150067640	NUP43	0.47	7.03	0.36	1.15e-11	Testicular germ cell tumor;
LUSC	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg02023728	chr11:77925099	USP35	0.41	6.02	0.31	4.61e-9	Testicular germ cell tumor;
LUSC	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02176678	chr2:219576539	TTLL4	0.64	11.53	0.53	4.11e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg06600287	chr1:53387719	ECHDC2	0.31	6.18	0.32	1.88e-9	Monocyte count;
LUSC	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg26566898	chr11:117069891	TAGLN	0.37	7.0	0.36	1.45e-11	Blood protein levels;
LUSC	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg12560992	chr17:57184187	TRIM37	0.64	10.44	0.5	2.97e-22	Testicular germ cell tumor;
LUSC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg16325326	chr1:53192061	ZYG11B	0.89	16.28	0.67	2.74e-44	Monocyte count;
LUSC	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.45	-0.33	3.82e-10	Breast cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18555811	chr3:193852889	HES1	-0.42	-6.51	-0.34	2.75e-10	Electrocardiographic conduction measures;
LUSC	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-9.88	-0.48	2.32e-20	HDL cholesterol;
LUSC	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.5	7.2	0.37	3.9e-12	Coronary heart disease;
LUSC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg00933542	chr6:150070202	PCMT1	0.32	6.52	0.34	2.54e-10	Lung cancer;
LUSC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg11859384	chr17:80120422	CCDC57	-0.37	-5.76	-0.3	1.89e-8	Life satisfaction;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg04385144	chr22:27053419	MIAT	0.34	6.01	0.31	4.86e-9	Educational attainment (years of education);
LUSC	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg12856521	chr11:46389249	DGKZ	0.41	6.38	0.33	6.02e-10	Leprosy;
LUSC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg21724239	chr8:58056113	NA	0.55	6.37	0.33	6.1e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg26043149	chr18:55253948	FECH	0.53	7.83	0.39	6.53e-14	Bone mineral density;
LUSC	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.82	12.73	0.57	1.52e-30	Body mass index;
LUSC	cis	rs7113850	0.541	rs77227176	chr11:24208375	T/C	ch.11.24196551F	chr11:24239977	NA	0.96	7.47	0.38	7.26e-13	Bone fracture in osteoporosis;
LUSC	cis	rs16854884	0.657	rs62268458	chr3:143736219	T/C	cg06585982	chr3:143692056	C3orf58	0.46	7.02	0.36	1.28e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs2970818	0.831	rs2907498	chr12:4628899	T/C	cg11146114	chr12:4671731	NA	-0.58	-5.9	-0.31	9.04e-9	Phosphorus levels;
LUSC	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg12091567	chr17:66097778	LOC651250	-0.74	-9.32	-0.45	1.62e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs9931543	0.678	rs876245	chr16:56291212	A/G	cg00991179	chr16:56000067	NA	-0.34	-5.8	-0.3	1.53e-8	Subjective well-being;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg13395035	chr17:19912177	NA	0.48	6.39	0.33	5.63e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2172802	0.659	rs28713421	chr4:62497085	C/T	cg04118610	chr4:62707027	LPHN3	0.45	6.17	0.32	1.94e-9	Partial epilepsies;
LUSC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg01483505	chr11:975446	AP2A2	0.4	5.75	0.3	1.99e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg22852734	chr6:133119734	C6orf192	1.34	10.6	0.5	8.1e-23	Type 2 diabetes nephropathy;
LUSC	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg04362960	chr10:104952993	NT5C2	0.6	8.82	0.43	6.56e-17	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg18402987	chr7:1209562	NA	0.72	7.69	0.39	1.67e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	0.79	12.53	0.57	8.71e-30	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs2798269	1.000	rs2798269	chr13:22131897	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.13	-0.32	2.42e-9	PR segment;
LUSC	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg19554555	chr3:13937349	NA	-0.38	-5.68	-0.3	2.87e-8	Ovarian reserve;
LUSC	cis	rs7980687	0.678	rs7132277	chr12:123593382	C/T	cg13010344	chr12:123464640	ARL6IP4	0.56	6.67	0.34	1.07e-10	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg08270630	chr22:50330655	NA	-0.44	-6.61	-0.34	1.48e-10	Schizophrenia;
LUSC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23158103	chr7:148848205	ZNF398	-0.49	-8.02	-0.4	1.74e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg26597838	chr10:835615	NA	0.45	5.99	0.31	5.35e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg17644776	chr2:200775616	C2orf69	0.45	6.72	0.35	7.83e-11	LDL cholesterol to HDL cholesterol ratio;
LUSC	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg08017756	chr2:100939284	LONRF2	-0.33	-5.9	-0.31	8.83e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs4714291	0.963	rs1721411	chr6:40102390	T/G	cg02267698	chr19:7991119	CTXN1	0.5	6.9	0.35	2.7e-11	Strep throat;
LUSC	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg13385521	chr17:29058706	SUZ12P	-0.61	-5.79	-0.3	1.62e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.06	14.16	0.61	5.36e-36	Uric acid levels;
LUSC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	5.96e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.5	-7.09	-0.36	7.89e-12	Mean platelet volume;
LUSC	cis	rs4964805	0.505	rs15918	chr12:104167024	T/C	cg02344784	chr12:104178138	NT5DC3	0.37	5.91	0.31	8.25e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06002616	chr8:101225028	SPAG1	0.43	7.26	0.37	2.77e-12	Atrioventricular conduction;
LUSC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08736216	chr1:53307985	ZYG11A	0.29	6.03	0.31	4.36e-9	Monocyte count;
LUSC	trans	rs61931739	0.578	rs12582423	chr12:33596502	G/C	cg26384229	chr12:38710491	ALG10B	-0.41	-6.14	-0.32	2.32e-9	Morning vs. evening chronotype;
LUSC	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.3	-0.37	2.19e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6681460	1.000	rs4655648	chr1:67114309	C/T	cg02459107	chr1:67143332	SGIP1	0.46	8.52	0.42	5.66e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs36715	1.000	rs40527	chr5:127550252	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	6.06	0.31	3.6e-9	Breast cancer;
LUSC	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg05865280	chr17:75406074	SEPT9	0.49	10.45	0.5	2.7e-22	Airflow obstruction;
LUSC	cis	rs6750047	0.566	rs1157184	chr2:38285774	C/G	cg07380506	chr2:38303506	CYP1B1	0.48	6.69	0.34	9.63e-11	Cutaneous malignant melanoma;Melanoma;
LUSC	trans	rs9886428	0.615	rs1365648	chr8:14106151	A/T	cg01904776	chr16:2153834	PKD1	-0.36	-6.34	-0.33	7.32e-10	IgG glycosylation;
LUSC	cis	rs308403	0.600	rs309367	chr4:123662211	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.36	0.53	1.72e-25	Blood protein levels;
LUSC	cis	rs11168618	1.000	rs10875830	chr12:48937510	C/T	cg24011408	chr12:48396354	COL2A1	0.39	6.25	0.32	1.26e-9	Adiponectin levels;
LUSC	cis	rs4974559	0.895	rs12646130	chr4:1330530	G/C	cg02980000	chr4:1222292	CTBP1	0.76	7.38	0.37	1.24e-12	Systolic blood pressure;
LUSC	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	8.74	0.43	1.19e-16	Hemoglobin concentration;
LUSC	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg06671706	chr8:8559999	CLDN23	0.49	6.5	0.34	2.87e-10	Obesity-related traits;
LUSC	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg16339924	chr4:17578868	LAP3	0.5	7.32	0.37	1.9e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.15	16.21	0.66	5.28e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1775715	0.737	rs12256714	chr10:32216262	A/G	cg18675610	chr10:32216311	ARHGAP12	-0.29	-6.32	-0.33	8.4e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg10377582	chr12:51612794	POU6F1	-0.38	-6.02	-0.31	4.63e-9	Cisplatin-induced ototoxicity;
LUSC	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.69	10.53	0.5	1.43e-22	Corneal astigmatism;
LUSC	cis	rs7799006	0.606	rs7792045	chr7:2316852	C/T	cg12823233	chr7:2316876	SNX8	-0.43	-7.26	-0.37	2.82e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg12927641	chr6:109611667	NA	-0.35	-5.88	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs4805272	0.582	rs11083652	chr19:29231569	G/C	cg04546413	chr19:29218101	NA	-0.47	-7.99	-0.4	2.18e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg25457927	chr22:38595422	NA	0.38	7.82	0.39	6.97e-14	Cutaneous nevi;
LUSC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg25272121	chr1:152190972	HRNR	-0.39	-6.78	-0.35	5.44e-11	Inflammatory skin disease;
LUSC	cis	rs7575217	0.588	rs2278729	chr2:101668857	C/T	cg23907051	chr2:101730305	TBC1D8	0.26	6.43	0.33	4.53e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs4499344	0.633	rs259271	chr19:33157100	A/G	cg22980127	chr19:33182716	NUDT19	-0.44	-6.45	-0.33	3.88e-10	Mean platelet volume;
LUSC	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.75	0.51	2.35e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.37	-0.42	1.57e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg04287289	chr16:89883240	FANCA	0.74	5.86	0.31	1.1e-8	Skin colour saturation;
LUSC	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-9.55	-0.46	2.88e-19	Blood metabolite levels;
LUSC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	7.57	0.38	3.58e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4132509	0.793	rs9428579	chr1:243690034	C/T	cg21452805	chr1:244014465	NA	0.58	6.24	0.32	1.3e-9	RR interval (heart rate);
LUSC	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg22089800	chr15:90895588	ZNF774	0.61	9.31	0.45	1.74e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg08888203	chr3:10149979	C3orf24	0.6	8.28	0.41	3e-15	Alzheimer's disease;
LUSC	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.39	6.78	0.35	5.61e-11	Depressive symptoms;
LUSC	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.73	9.13	0.45	6.67e-18	Type 2 diabetes;
LUSC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg07395648	chr5:131743802	NA	-0.4	-6.05	-0.31	3.84e-9	Breast cancer;
LUSC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06028605	chr16:24865363	SLC5A11	0.7	10.72	0.51	2.99e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.5	0.46	4.05e-19	Bipolar disorder;
LUSC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg25039879	chr17:56429692	SUPT4H1	0.66	8.97	0.44	2.22e-17	Cognitive test performance;
LUSC	trans	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg25482853	chr8:67687455	SGK3	1.03	16.33	0.67	1.71e-44	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7241530	0.662	rs12454671	chr18:75908918	G/C	cg14642773	chr18:75888474	NA	0.39	5.65	0.3	3.43e-8	Educational attainment (years of education);
LUSC	cis	rs2109514	1.000	rs2270188	chr7:116140524	G/T	cg12739419	chr7:116140593	CAV2	-0.29	-6.3	-0.33	9.14e-10	Prevalent atrial fibrillation;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17365369	chr19:52773256	ZNF766	-0.46	-6.08	-0.32	3.38e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg06917634	chr15:78832804	PSMA4	-0.48	-6.61	-0.34	1.56e-10	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	7.09	0.36	7.97e-12	Colorectal cancer;
LUSC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-10.13	-0.48	3.31e-21	Gut microbiome composition (summer);
LUSC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.21	-13.94	-0.61	4.07e-35	Diabetic kidney disease;
LUSC	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg24562669	chr7:97807699	LMTK2	-0.41	-7.19	-0.37	4.15e-12	Breast cancer;
LUSC	trans	rs35275482	0.573	rs7163623	chr15:60060482	C/T	cg17779764	chr5:159685142	CCNJL	0.44	6.59	0.34	1.7e-10	Gut microbiota (bacterial taxa);
LUSC	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg12292205	chr6:26970375	C6orf41	0.38	6.1	0.32	2.97e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.27	0.32	1.09e-9	Corneal astigmatism;
LUSC	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03878208	chr11:72483293	STARD10	0.58	7.45	0.38	8.3e-13	Type 2 diabetes;
LUSC	trans	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.62	0.34	1.45e-10	Lung cancer;
LUSC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-11.9	-0.55	1.77e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg23752985	chr2:85803571	VAMP8	-0.33	-6.37	-0.33	6.09e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2273669	0.667	rs12195836	chr6:109357701	T/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	8.88	0.44	4.22e-17	Monocyte count;
LUSC	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.54	0.53	3.75e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg21132104	chr15:45694354	SPATA5L1	0.56	7.82	0.39	7.06e-14	Homoarginine levels;
LUSC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.96	0.4	2.78e-14	Parkinson's disease;
LUSC	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg13755796	chr4:20253514	NA	-0.42	-6.61	-0.34	1.55e-10	Life satisfaction;
LUSC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg06640241	chr16:89574553	SPG7	0.87	15.62	0.65	1.08e-41	Multiple myeloma (IgH translocation);
LUSC	cis	rs2286885	1.000	rs10819171	chr9:129253074	G/A	cg15282417	chr9:129245246	FAM125B	0.42	7.06	0.36	9.62e-12	Intraocular pressure;
LUSC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg02574844	chr11:5959923	NA	-0.48	-7.21	-0.37	3.74e-12	DNA methylation (variation);
LUSC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg23788917	chr6:8435910	SLC35B3	0.51	7.48	0.38	6.83e-13	Motion sickness;
LUSC	cis	rs698813	0.674	rs3738985	chr2:44502788	A/C	cg00619915	chr2:44497795	NA	-0.49	-6.76	-0.35	6.06e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs2573652	0.722	rs12908133	chr15:100544405	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.37	-6.64	-0.34	1.24e-10	Height;
LUSC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-9.86	-0.47	2.69e-20	Electroencephalogram traits;
LUSC	cis	rs4343996	0.902	rs4336505	chr7:3373740	A/C	cg21248987	chr7:3385318	SDK1	-0.38	-6.42	-0.33	4.75e-10	Motion sickness;
LUSC	cis	rs2742417	0.624	rs2673030	chr3:45757900	T/G	cg04837898	chr3:45731254	SACM1L	-0.43	-6.96	-0.36	1.79e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7215564	0.908	rs901066	chr17:78659617	C/G	cg09596252	chr17:78655493	RPTOR	0.52	6.18	0.32	1.9e-9	Myopia (pathological);
LUSC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.43	0.53	9.43e-26	Alzheimer's disease;
LUSC	trans	rs2262909	0.962	rs55735642	chr19:22241176	C/T	cg05197062	chr11:11642011	GALNTL4	0.56	7.88	0.4	4.75e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.78	-0.39	9.28e-14	Personality dimensions;
LUSC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg01483505	chr11:975446	AP2A2	0.41	5.87	0.31	1.03e-8	Alzheimer's disease (late onset);
LUSC	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-9.05	-0.44	1.23e-17	Response to antipsychotic treatment;
LUSC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg02951883	chr7:2050386	MAD1L1	-0.38	-6.51	-0.34	2.68e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6445967	1.000	rs6777105	chr3:58307644	A/G	cg13750441	chr3:58318267	PXK	-0.29	-5.84	-0.3	1.27e-8	Platelet count;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg04296578	chr1:45671659	ZSWIM5	0.35	6.24	0.32	1.36e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg17691542	chr6:26056736	HIST1H1C	0.46	6.56	0.34	2.02e-10	Iron status biomarkers;
LUSC	cis	rs9807841	0.670	rs8113002	chr19:10776606	A/T	cg09936142	chr19:10668400	KRI1	-0.41	-6.51	-0.34	2.74e-10	Inflammatory skin disease;
LUSC	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg16342193	chr10:102329863	NA	-0.36	-6.56	-0.34	2.08e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg13560548	chr3:10150139	C3orf24	0.53	7.43	0.38	9.1e-13	Alzheimer's disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03771185	chr4:775700	NA	0.48	7.24	0.37	3.04e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg20476274	chr7:133979776	SLC35B4	0.88	16.76	0.68	3.47e-46	Mean platelet volume;
LUSC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.28	-0.53	3.08e-25	Schizophrenia;
LUSC	cis	rs9925964	0.933	rs11150604	chr16:31037020	A/T	cg02466173	chr16:30829666	NA	0.38	6.87	0.35	3.1e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.89	14.89	0.63	8.25e-39	Bladder cancer;
LUSC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.8	-0.57	8.83e-31	Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20421914	chr13:100153689	TM9SF2	0.44	5.99	0.31	5.49e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	11.44	0.53	8.89e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg02454025	chr1:11042201	C1orf127	0.91	16.95	0.68	6.13e-47	Ewing sarcoma;
LUSC	cis	rs3771570	0.901	rs73006381	chr2:242406654	G/C	cg21155796	chr2:242212141	HDLBP	0.61	6.96	0.36	1.8e-11	Prostate cancer;
LUSC	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg27087555	chr16:88793112	FAM38A	-1.45	-12.59	-0.57	5.26e-30	Plateletcrit;
LUSC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg01416388	chr22:39784598	NA	-0.4	-6.06	-0.31	3.57e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg05872129	chr22:39784769	NA	0.58	10.96	0.51	4.5e-24	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg02476566	chr12:106696527	TCP11L2	0.52	6.58	0.34	1.83e-10	Tourette syndrome;
LUSC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg13047869	chr3:10149882	C3orf24	0.59	7.65	0.39	2.1e-13	Alzheimer's disease;
LUSC	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	11.72	0.54	8e-27	Coronary artery disease;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg16778527	chr15:45406477	DUOX2;DUOXA2	0.38	6.16	0.32	2.14e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg02772935	chr3:125709198	NA	-0.48	-6.16	-0.32	2.03e-9	Blood pressure (smoking interaction);
LUSC	cis	rs4285028	0.747	rs1128163	chr3:121350573	A/G	cg11130432	chr3:121712080	ILDR1	-0.57	-8.25	-0.41	3.67e-15	Multiple sclerosis;
LUSC	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg11502198	chr6:26597334	ABT1	0.92	11.43	0.53	9.62e-26	Small cell lung carcinoma;
LUSC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02475777	chr4:1388615	CRIPAK	0.63	9.44	0.46	6.66e-19	Longevity;
LUSC	cis	rs7909074	0.509	rs2026427	chr10:45389704	T/C	cg05187965	chr10:45406764	TMEM72	-0.29	-5.81	-0.3	1.49e-8	Mean corpuscular volume;
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.6	-9.66	-0.47	1.28e-19	Longevity;Endometriosis;
LUSC	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg09654669	chr8:57350985	NA	-0.59	-8.32	-0.41	2.27e-15	Obesity-related traits;
LUSC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg13628971	chr7:2884303	GNA12	0.48	6.72	0.35	7.76e-11	Height;
LUSC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.47	6.8e-20	Gut microbiome composition (summer);
LUSC	cis	rs7572644	0.679	rs6745545	chr2:28021845	C/G	cg27432699	chr2:27873401	GPN1	0.57	7.39	0.37	1.2e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Depression;
LUSC	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg22601191	chr20:60968625	CABLES2	0.45	6.28	0.32	1.07e-9	Colorectal cancer;
LUSC	cis	rs7851660	0.844	rs13287360	chr9:100637681	A/G	cg13688889	chr9:100608707	NA	-0.55	-8.34	-0.42	1.91e-15	Strep throat;
LUSC	cis	rs17661538	0.504	rs34074414	chr10:18467874	T/C	cg03634479	chr10:18430412	CACNB2	0.63	5.92	0.31	8.04e-9	Response to antipsychotic treatment;
LUSC	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg22508957	chr16:3507546	NAT15	-0.37	-6.0	-0.31	5.08e-9	Body mass index (adult);
LUSC	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg01475377	chr6:109611718	NA	-0.41	-7.31	-0.37	1.97e-12	Reticulocyte fraction of red cells;
LUSC	trans	rs7448080	0.510	rs10519745	chr5:123347613	C/T	cg10068417	chr13:50706583	NA	0.43	6.33	0.33	7.68e-10	Alcohol dependence (age at onset);
LUSC	trans	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.56	8.89	0.44	3.96e-17	Brugada syndrome;
LUSC	cis	rs1568889	1.000	rs12808162	chr11:28067027	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	9.28	0.45	2.27e-18	Bipolar disorder;
LUSC	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg08017756	chr2:100939284	LONRF2	-0.42	-7.82	-0.39	6.79e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19197750	chr7:43966251	URGCP;UBE2D4	-0.41	-5.97	-0.31	6.06e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9653442	0.564	rs2309756	chr2:100780269	G/C	cg22139774	chr2:100720529	AFF3	-0.41	-7.12	-0.36	6.51e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg12002119	chr2:101014098	CHST10	0.37	6.19	0.32	1.78e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08645402	chr16:4508243	NA	-0.46	-7.22	-0.37	3.49e-12	Schizophrenia;
LUSC	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21640587	chr11:117668038	DSCAML1	0.67	9.85	0.47	2.8e-20	Myopia;
LUSC	trans	rs8040855	0.965	rs1961276	chr15:85714217	C/T	cg00988175	chr11:59481031	OR10V1	0.29	6.38	0.33	5.82e-10	Bulimia nervosa;
LUSC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.33	0.37	1.8e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg21970626	chr13:21893289	NA	-0.43	-5.77	-0.3	1.85e-8	White matter hyperintensity burden;
LUSC	cis	rs2235649	0.833	rs9929185	chr16:1852070	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-5.94	-0.31	7.18e-9	Blood metabolite levels;
LUSC	cis	rs3768617	1.000	rs3820697	chr1:183100226	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.87	0.44	4.47e-17	Fuchs's corneal dystrophy;
LUSC	cis	rs10904908	0.795	rs359283	chr10:17326254	A/G	cg01003015	chr10:17271136	VIM	0.39	5.65	0.3	3.37e-8	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg22166914	chr1:53195759	ZYG11B	0.55	8.95	0.44	2.45e-17	Monocyte count;
LUSC	cis	rs6977660	0.714	rs4719585	chr7:19823727	C/G	cg05791153	chr7:19748676	TWISTNB	0.67	6.93	0.35	2.24e-11	Thyroid stimulating hormone;
LUSC	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg13010199	chr12:38710504	ALG10B	0.68	10.81	0.51	1.43e-23	Morning vs. evening chronotype;
LUSC	cis	rs909341	0.909	rs2872881	chr20:62342801	G/A	cg09650180	chr20:62225654	GMEB2	-0.44	-5.67	-0.3	3.13e-8	Atopic dermatitis;
LUSC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00152838	chr16:24741724	TNRC6A	0.45	5.68	0.3	3.01e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs3736485	0.966	rs10775144	chr15:51891134	C/T	cg09125779	chr4:57547999	HOPX	0.33	5.97	0.31	5.97e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-5.96	-0.31	6.49e-9	IgG glycosylation;
LUSC	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg03342759	chr3:160939853	NMD3	-0.48	-8.18	-0.41	5.83e-15	Morning vs. evening chronotype;
LUSC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg26597838	chr10:835615	NA	1.24	15.78	0.65	2.58e-42	Eosinophil percentage of granulocytes;
LUSC	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.73	12.08	0.55	4.1e-28	Monocyte count;
LUSC	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg22601191	chr20:60968625	CABLES2	0.41	5.95	0.31	6.76e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg22638593	chr5:131593259	PDLIM4	-0.41	-5.88	-0.31	9.89e-9	Breast cancer;
LUSC	cis	rs9326248	0.652	rs7128382	chr11:117023487	A/C	cg16524733	chr11:117070046	TAGLN	0.37	5.88	0.31	1.01e-8	Blood protein levels;
LUSC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg19592336	chr6:28129416	ZNF389	0.48	6.25	0.32	1.22e-9	Depression;
LUSC	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.27	0.32	1.14e-9	Recombination rate (females);
LUSC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.58	0.34	1.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg00255919	chr5:131827918	IRF1	0.43	8.28	0.41	3.11e-15	Asthma (sex interaction);
LUSC	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg26384229	chr12:38710491	ALG10B	0.79	13.51	0.59	1.72e-33	Morning vs. evening chronotype;
LUSC	cis	rs7572644	0.640	rs6744348	chr2:28018025	A/C	cg27432699	chr2:27873401	GPN1	0.56	7.27	0.37	2.54e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg08847533	chr14:75593920	NEK9	-0.81	-13.83	-0.6	1.08e-34	Height;
LUSC	cis	rs34366173	1	rs34366173	chr15:63998914	CTT/C	cg14776518	chr15:63892607	FBXL22	0.38	6.09	0.32	3.03e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14169450	chr9:139327907	INPP5E	0.41	7.23	0.37	3.38e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12667521	chr19:29218732	NA	0.62	8.6	0.43	3.11e-16	Methadone dose in opioid dependence;
LUSC	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.52	-0.34	2.61e-10	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg24247370	chr13:99142703	STK24	-0.34	-6.27	-0.32	1.08e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs12524093	0.541	rs75512107	chr6:143041952	T/G	cg22454011	chr18:13611439	C18orf1	0.68	5.96	0.31	6.53e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.71	10.66	0.5	4.98e-23	Menarche (age at onset);
LUSC	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	6.14	0.32	2.35e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-7.21	-0.37	3.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6541297	0.645	rs4846919	chr1:230301451	A/G	cg05784532	chr1:230284198	GALNT2	0.57	6.73	0.35	7.4e-11	Coronary artery disease;
LUSC	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	0.98	14.53	0.62	2.08e-37	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.38	8.03	0.4	1.68e-14	Hemoglobin concentration;
LUSC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-10.0	-0.48	8.83e-21	Longevity;Endometriosis;
LUSC	cis	rs11676855	0.893	rs6721399	chr2:235936607	A/G	cg14917874	chr2:235941519	SH3BP4	0.51	8.7	0.43	1.56e-16	Dialysis-related mortality;
LUSC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.47	-0.33	3.41e-10	High light scatter reticulocyte count;
LUSC	cis	rs983392	0.836	rs7946992	chr11:59944810	T/C	cg24026212	chr11:59952134	MS4A6A	-0.37	-6.23	-0.32	1.41e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg23752985	chr2:85803571	VAMP8	0.36	7.52	0.38	5.03e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02463440	chr8:22132932	PIWIL2	0.44	8.0	0.4	2.1e-14	Hypertriglyceridemia;
LUSC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg12365402	chr11:9010492	NRIP3	-0.47	-8.98	-0.44	2.03e-17	Hemoglobin concentration;
LUSC	cis	rs34375054	0.641	rs34624329	chr12:125608028	T/G	cg25124228	chr12:125621409	AACS	-0.48	-7.67	-0.39	1.9e-13	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg16325326	chr1:53192061	ZYG11B	0.93	17.71	0.7	6.01e-50	Monocyte count;
LUSC	cis	rs2273669	0.667	rs76732622	chr6:109318280	A/T	cg05315195	chr6:109294784	ARMC2	-0.55	-5.87	-0.31	1.03e-8	Prostate cancer;
LUSC	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg05110241	chr16:68378359	PRMT7	-0.78	-8.89	-0.44	3.82e-17	Magnesium levels;
LUSC	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg17507749	chr15:85114479	UBE2QP1	0.69	8.73	0.43	1.23e-16	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7605827	0.823	rs11689269	chr2:15621917	C/G	cg19274914	chr2:15703543	NA	0.46	8.82	0.43	6.51e-17	Educational attainment (years of education);
LUSC	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg09044154	chr16:88155775	NA	-0.55	-7.49	-0.38	6.21e-13	Menopause (age at onset);
LUSC	cis	rs9359856	0.879	rs4707552	chr6:90300841	A/G	cg13799429	chr6:90582589	CASP8AP2	0.57	6.67	0.34	1.04e-10	Bipolar disorder;
LUSC	trans	rs6600671	0.967	rs11249349	chr1:121179169	G/C	cg00646200	chr1:148855367	NA	0.47	7.52	0.38	5.11e-13	Hip geometry;
LUSC	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg21361702	chr7:150065534	REPIN1	0.57	8.02	0.4	1.77e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.51	-0.34	2.71e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg01966878	chr4:90757139	SNCA	-0.4	-5.69	-0.3	2.78e-8	Neuroticism;
LUSC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg07716408	chr11:68623521	NA	-0.33	-6.38	-0.33	6.04e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.34	-0.56	4.38e-29	Rheumatoid arthritis;
LUSC	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg13319975	chr6:146136371	FBXO30	-0.67	-10.51	-0.5	1.69e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.87	-0.4	4.85e-14	Blood metabolite levels;
LUSC	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg13010199	chr12:38710504	ALG10B	0.58	9.18	0.45	4.57e-18	Morning vs. evening chronotype;
LUSC	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg01475377	chr6:109611718	NA	-0.38	-6.69	-0.34	9.16e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg16228356	chr17:43848958	NA	0.28	6.46	0.33	3.75e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg24250549	chr1:154909240	PMVK	0.65	10.87	0.51	9.05e-24	Prostate cancer;
LUSC	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg02569458	chr12:86230093	RASSF9	0.48	7.64	0.39	2.37e-13	Major depressive disorder;
LUSC	cis	rs9815354	0.812	rs73069209	chr3:41939781	G/A	cg03022575	chr3:42003672	ULK4	0.82	8.59	0.43	3.4e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg00431813	chr7:1051703	C7orf50	-0.43	-6.96	-0.36	1.83e-11	Longevity;Endometriosis;
LUSC	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg06740227	chr12:86229804	RASSF9	0.37	5.91	0.31	8.3e-9	Major depressive disorder;
LUSC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.76	0.35	6.02e-11	Lung cancer;
LUSC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-5.97	-0.31	5.96e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	0.89	15.67	0.65	7.27e-42	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	0.49	7.75	0.39	1.12e-13	Uric acid clearance;
LUSC	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg22601191	chr20:60968625	CABLES2	0.42	5.91	0.31	8.6e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg04315214	chr1:2043799	PRKCZ	0.48	10.2	0.49	1.92e-21	Height;
LUSC	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg06627628	chr2:24431161	ITSN2	0.63	9.31	0.45	1.78e-18	Asthma;
LUSC	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.14	0.41	8.16e-15	Axial length;
LUSC	cis	rs4474465	1.000	rs10751290	chr11:78192707	G/A	cg27205649	chr11:78285834	NARS2	-0.53	-6.13	-0.32	2.43e-9	Alzheimer's disease (survival time);
LUSC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.05e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	6.79	0.35	5.27e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg10729496	chr3:10149963	C3orf24	0.56	6.97	0.36	1.7e-11	Alzheimer's disease;
LUSC	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	7.4	0.38	1.12e-12	Acne (severe);
LUSC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg19592336	chr6:28129416	ZNF389	0.49	6.56	0.34	2e-10	Depression;
LUSC	cis	rs6058796	1.000	rs6087972	chr20:31268102	A/G	cg13636640	chr20:31349939	DNMT3B	0.54	5.75	0.3	1.99e-8	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg23791538	chr6:167370224	RNASET2	0.42	6.82	0.35	4.24e-11	Crohn's disease;
LUSC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg07217954	chr7:1067459	C7orf50	0.53	5.68	0.3	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg21238619	chr17:78079768	GAA	-0.3	-5.97	-0.31	6.2e-9	Yeast infection;
LUSC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg15448220	chr1:150897856	SETDB1	-0.41	-6.15	-0.32	2.27e-9	Melanoma;
LUSC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.94	-0.4	3.13e-14	Mean platelet volume;
LUSC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.27	0.59	1.47e-32	Total body bone mineral density;
LUSC	cis	rs11608355	1.000	rs11066523	chr12:109851899	A/G	cg05360138	chr12:110035743	NA	-0.46	-6.31	-0.33	8.91e-10	Neuroticism;
LUSC	cis	rs7580658	0.891	rs3768866	chr2:128045415	G/A	cg09760422	chr2:128146352	NA	-0.33	-7.18	-0.37	4.46e-12	Protein C levels;
LUSC	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg07148914	chr20:33460835	GGT7	-0.46	-6.86	-0.35	3.38e-11	Height;
LUSC	cis	rs11051970	0.545	rs2651375	chr12:32582652	G/T	cg02745156	chr12:32552066	NA	-0.36	-6.51	-0.34	2.73e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	12.45	0.56	1.79e-29	Chronic sinus infection;
LUSC	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg07148914	chr20:33460835	GGT7	0.47	6.93	0.35	2.24e-11	Height;
LUSC	cis	rs4845459	0.935	rs4845449	chr1:152591024	A/T	cg08895932	chr1:152778580	LCE1C	-0.36	-6.22	-0.32	1.47e-9	Psoriasis;
LUSC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg27165867	chr14:105738592	BRF1	0.52	7.7	0.39	1.59e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.59	-0.34	1.69e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg19554555	chr3:13937349	NA	-0.38	-5.71	-0.3	2.47e-8	Ovarian reserve;
LUSC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	8.11	0.41	9.68e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7189233	0.531	rs1072910	chr16:53499599	A/G	cg09728985	chr16:53543985	NA	-0.31	-5.87	-0.31	1.08e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg02782426	chr3:40428986	ENTPD3	0.4	7.57	0.38	3.69e-13	Renal cell carcinoma;
LUSC	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg13647721	chr17:30228624	UTP6	-0.62	-5.89	-0.31	9.27e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.75	13.1	0.58	6.12e-32	Sudden cardiac arrest;
LUSC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg09365446	chr1:150670422	GOLPH3L	0.48	6.99	0.36	1.47e-11	Melanoma;
LUSC	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg15212455	chr7:39170539	POU6F2	0.57	9.32	0.45	1.68e-18	IgG glycosylation;
LUSC	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-9.48	-0.46	4.76e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg25258033	chr6:167368657	RNASET2	0.45	6.79	0.35	5.29e-11	Crohn's disease;
LUSC	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg05925327	chr15:68127851	NA	-0.43	-6.77	-0.35	5.91e-11	Obesity;
LUSC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg17376030	chr22:41985996	PMM1	-0.47	-6.01	-0.31	4.91e-9	Vitiligo;
LUSC	cis	rs6982240	0.514	rs892362	chr8:142269214	A/G	cg00131261	chr8:142287264	NA	0.38	6.36	0.33	6.68e-10	Tonsillectomy;
LUSC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.89	0.51	8.06e-24	Monocyte percentage of white cells;
LUSC	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg09699651	chr6:150184138	LRP11	0.46	7.29	0.37	2.25e-12	Testicular germ cell tumor;
LUSC	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.11	-17.83	-0.7	1.92e-50	Primary sclerosing cholangitis;
LUSC	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg04691961	chr3:161091175	C3orf57	-0.35	-6.08	-0.32	3.22e-9	Morning vs. evening chronotype;
LUSC	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.68	-0.43	1.71e-16	Body mass index;
LUSC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00166722	chr3:10149974	C3orf24	0.63	8.71	0.43	1.47e-16	Alzheimer's disease;
LUSC	cis	rs62400317	0.859	rs12191751	chr6:45282111	G/T	cg18551225	chr6:44695536	NA	-0.42	-7.06	-0.36	9.47e-12	Total body bone mineral density;
LUSC	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg07679836	chr6:33548423	BAK1	0.51	8.07	0.4	1.3e-14	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
LUSC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg21724239	chr8:58056113	NA	0.8	8.59	0.43	3.29e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.94	0.36	2.01e-11	Tonsillectomy;
LUSC	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg01657329	chr11:68192670	LRP5	-0.4	-5.73	-0.3	2.24e-8	Total body bone mineral density;
LUSC	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg16558253	chr16:72132732	DHX38	-0.38	-5.92	-0.31	7.95e-9	Fibrinogen levels;
LUSC	cis	rs10489202	0.954	rs12403023	chr1:168086999	A/G	cg24449463	chr1:168025552	DCAF6	-0.56	-7.14	-0.36	6.01e-12	Schizophrenia;
LUSC	cis	rs7973719	0.833	rs11044332	chr12:7358768	C/A	cg07052231	chr12:7363540	PEX5	0.54	9.42	0.46	7.85e-19	IgG glycosylation;
LUSC	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.35	-0.42	1.79e-15	Bone mineral density;
LUSC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg07741184	chr6:167504864	NA	0.43	7.56	0.38	3.86e-13	Crohn's disease;
LUSC	cis	rs35079168	0.923	rs12115573	chr9:137288782	G/A	cg13941235	chr9:137270186	RXRA	-0.32	-5.68	-0.3	2.91e-8	Intelligence;
LUSC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg22823121	chr1:150693482	HORMAD1	0.49	7.18	0.37	4.69e-12	Melanoma;
LUSC	cis	rs17095355	1.000	rs12265204	chr10:111752163	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.65	-8.04	-0.4	1.55e-14	Biliary atresia;
LUSC	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-8.0	-0.4	2e-14	Systolic blood pressure;
LUSC	cis	rs11971779	0.616	rs6467836	chr7:139023517	C/G	cg23387468	chr7:139079360	LUC7L2	0.42	6.36	0.33	6.67e-10	Diisocyanate-induced asthma;
LUSC	cis	rs7582720	1.000	rs76298043	chr2:203814694	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg24851651	chr11:66362959	CCS	-0.53	-6.61	-0.34	1.49e-10	Airway imaging phenotypes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16909824	chr1:151299438	PI4KB	0.44	5.97	0.31	6.04e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.81	12.4	0.56	2.75e-29	Diastolic blood pressure;Systolic blood pressure;
LUSC	trans	rs236907	0.859	rs2143369	chr1:171767372	A/G	cg13482142	chr2:234261155	NA	0.49	6.16	0.32	2.09e-9	Mean platelet volume;
LUSC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-0.77	-11.41	-0.53	1.12e-25	Gut microbiome composition (summer);
LUSC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg00677455	chr12:58241039	CTDSP2	-0.59	-8.53	-0.42	5.25e-16	Multiple sclerosis;
LUSC	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg05673287	chr15:77411982	SGK269	-0.43	-6.73	-0.35	7.53e-11	Type 2 diabetes;
LUSC	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.69e-9	Response to antipsychotic treatment;
LUSC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg14092988	chr3:52407081	DNAH1	0.33	6.42	0.33	4.7e-10	Bipolar disorder;
LUSC	cis	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg07460842	chr6:66804631	NA	-0.48	-6.72	-0.35	7.74e-11	Blood trace element (Cu levels);
LUSC	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.38	-9.34	-0.46	1.35e-18	Diastolic blood pressure;
LUSC	cis	rs3136441	0.892	rs4752936	chr11:46821078	A/C	cg01183595	chr11:46746236	F2	0.36	5.77	0.3	1.81e-8	HDL cholesterol;
LUSC	trans	rs12210905	0.688	rs12374607	chr6:27343620	A/G	cg02699829	chr19:13216355	TRMT1	-0.56	-6.23	-0.32	1.39e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg18404041	chr3:52824283	ITIH1	0.42	7.23	0.37	3.38e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9311676	0.632	rs7610312	chr3:58374029	A/G	cg13750441	chr3:58318267	PXK	0.36	6.93	0.35	2.12e-11	Systemic lupus erythematosus;
LUSC	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg22676075	chr6:135203613	NA	0.48	7.61	0.38	2.8e-13	Red blood cell count;
LUSC	cis	rs7246967	0.673	rs2099341	chr19:22834360	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.41	-0.33	5e-10	Cutaneous nevi;
LUSC	cis	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.65	0.43	2.22e-16	Endometrial cancer;
LUSC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.03e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg11843238	chr5:131593191	PDLIM4	0.44	7.75	0.39	1.14e-13	Blood metabolite levels;
LUSC	cis	rs4930561	0.739	rs7118045	chr11:67978734	C/G	cg04465784	chr11:67976953	SUV420H1	-0.28	-5.65	-0.3	3.48e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs2997447	0.706	rs2783713	chr1:26429351	C/A	cg19633962	chr1:26362018	EXTL1	-0.48	-5.71	-0.3	2.43e-8	QRS complex (12-leadsum);
LUSC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg19230755	chr7:65878503	NA	-0.43	-6.15	-0.32	2.16e-9	Aortic root size;
LUSC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	8.16	0.41	6.89e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg03684893	chr10:554711	DIP2C	-0.43	-8.05	-0.4	1.5e-14	Psychosis in Alzheimer's disease;
LUSC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-0.82	-14.08	-0.61	1.18e-35	Longevity;
LUSC	cis	rs1568889	0.592	rs17652117	chr11:28483645	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.51	-6.45	-0.33	3.88e-10	Bipolar disorder;
LUSC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.73	-12.74	-0.57	1.38e-30	Aortic root size;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04696171	chr16:89787876	C16orf7;ZNF276	-0.54	-6.86	-0.35	3.35e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7267979	0.844	rs2474780	chr20:25285835	G/A	cg14121845	chr20:25566513	NINL	0.31	5.77	0.3	1.81e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg01065977	chr19:18549689	ISYNA1	-0.23	-5.94	-0.31	7.17e-9	Breast cancer;
LUSC	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg04455712	chr21:45112962	RRP1B	0.46	8.67	0.43	1.85e-16	Mean corpuscular volume;
LUSC	trans	rs1728785	0.892	rs9928950	chr16:68557114	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-6.98	-0.36	1.64e-11	Ulcerative colitis;
LUSC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.89	0.61	6.16e-35	Cognitive test performance;
LUSC	cis	rs11608355	0.618	rs60819157	chr12:109795766	G/A	cg19025524	chr12:109796872	NA	-0.48	-9.16	-0.45	5.46e-18	Neuroticism;
LUSC	cis	rs17253792	0.822	rs79747476	chr14:56160485	C/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.82	-0.35	4.21e-11	Putamen volume;
LUSC	cis	rs4343996	0.727	rs12537528	chr7:3375910	A/G	cg21248987	chr7:3385318	SDK1	0.33	5.65	0.3	3.45e-8	Motion sickness;
LUSC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06112835	chr11:68658793	MRPL21	0.51	7.82	0.39	7.13e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.63	0.86	5.12e-99	Chronic sinus infection;
LUSC	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg02886208	chr11:14281011	SPON1	-0.32	-5.75	-0.3	2.01e-8	Mitochondrial DNA levels;
LUSC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00166722	chr3:10149974	C3orf24	0.55	7.51	0.38	5.38e-13	Alzheimer's disease;
LUSC	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg13010199	chr12:38710504	ALG10B	0.69	10.56	0.5	1.13e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg06718696	chr17:78121285	EIF4A3	0.78	11.61	0.54	2.07e-26	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg20637307	chr2:213403960	ERBB4	0.44	7.51	0.38	5.38e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg01256987	chr12:42539512	GXYLT1	0.36	6.59	0.34	1.71e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg02569458	chr12:86230093	RASSF9	0.41	6.58	0.34	1.77e-10	Major depressive disorder;
LUSC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg16606324	chr3:10149918	C3orf24	0.68	9.86	0.47	2.63e-20	Alzheimer's disease;
LUSC	cis	rs6723226	0.698	rs13409142	chr2:32666137	C/T	cg02381751	chr2:32503542	YIPF4	0.57	8.39	0.42	1.35e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	7.5	0.38	5.92e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg22676075	chr6:135203613	NA	0.47	7.4	0.38	1.12e-12	Red blood cell count;
LUSC	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.67	-0.34	1.08e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12863693	chr15:85201151	NMB	0.27	5.95	0.31	6.74e-9	P wave terminal force;
LUSC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.67	11.6	0.54	2.2e-26	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg00225070	chr15:80189496	MTHFS	0.43	6.37	0.33	6.41e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	9.42	0.46	7.89e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg23942311	chr14:51606299	NA	-0.62	-14.83	-0.63	1.43e-38	Cancer;
LUSC	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.21	-0.72	6.43e-56	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg03146154	chr1:46216737	IPP	0.52	7.6	0.38	3.01e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.75	-0.35	6.74e-11	Personality dimensions;
LUSC	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg23260525	chr10:116636907	FAM160B1	0.4	8.24	0.41	3.88e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg14844989	chr11:31128820	NA	0.38	6.17	0.32	1.93e-9	Red blood cell count;
LUSC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg20607798	chr8:58055168	NA	0.49	5.92	0.31	8.14e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg00310523	chr12:86230176	RASSF9	0.47	8.48	0.42	7.39e-16	Major depressive disorder;
LUSC	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg00191853	chr8:101177733	SPAG1	-0.39	-6.43	-0.33	4.3e-10	Atrioventricular conduction;
LUSC	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.61	8.37	0.42	1.58e-15	Adiposity;
LUSC	cis	rs2970818	0.831	rs73037770	chr12:4637864	G/T	cg11146114	chr12:4671731	NA	-0.59	-5.88	-0.31	1.01e-8	Phosphorus levels;
LUSC	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg03929089	chr4:120376271	NA	0.54	6.79	0.35	5e-11	Intraocular pressure;
LUSC	cis	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.68	-0.3	2.88e-8	Resting heart rate;
LUSC	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.44	-6.6	-0.34	1.6e-10	Axial length;
LUSC	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.99	-0.36	1.5e-11	Monocyte percentage of white cells;
LUSC	trans	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg07211511	chr3:129823064	LOC729375	-0.83	-11.96	-0.55	1.14e-27	Blood pressure (smoking interaction);
LUSC	cis	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg01251360	chr16:68772225	CDH1	-0.26	-6.05	-0.31	3.95e-9	Colorectal cancer;
LUSC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.37	6.0	0.31	5.11e-9	Self-reported allergy;
LUSC	cis	rs7180079	0.620	rs2101225	chr15:64731679	G/A	cg08069370	chr15:64387884	SNX1	0.51	5.65	0.3	3.41e-8	Monocyte count;
LUSC	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg05343316	chr1:45956843	TESK2	0.62	9.01	0.44	1.62e-17	Platelet count;
LUSC	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.53	-0.42	5.32e-16	Body mass index;
LUSC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.24e-19	Prudent dietary pattern;
LUSC	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.7	-11.35	-0.53	1.74e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs977987	0.806	rs4993970	chr16:75411619	G/A	cg03315344	chr16:75512273	CHST6	0.49	9.32	0.45	1.6e-18	Dupuytren's disease;
LUSC	cis	rs75804782	0.521	rs55690022	chr2:239407783	C/T	cg18131467	chr2:239335373	ASB1	-0.68	-6.28	-0.33	1.03e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7759001	0.857	rs2223463	chr6:27356193	G/C	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	1.97e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.45	-0.42	8.88e-16	Aortic root size;
LUSC	cis	rs4889855	0.556	rs4890043	chr17:78526831	C/T	cg16591659	chr17:78472290	NA	0.31	5.76	0.3	1.88e-8	Fractional excretion of uric acid;
LUSC	cis	rs1609391	0.561	rs9289523	chr3:136635589	C/G	cg15507776	chr3:136538369	TMEM22	0.53	8.71	0.43	1.38e-16	Neuroticism;
LUSC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.45	-7.15	-0.36	5.4e-12	Systemic lupus erythematosus;
LUSC	cis	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg17469321	chr7:55412551	NA	0.66	10.62	0.5	6.87e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg05868516	chr6:26286170	HIST1H4H	0.37	6.07	0.32	3.38e-9	Educational attainment;
LUSC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	8.87	0.44	4.45e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg01879757	chr17:41196368	BRCA1	-0.48	-7.57	-0.38	3.62e-13	Menopause (age at onset);
LUSC	trans	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg25482853	chr8:67687455	SGK3	1.03	15.45	0.65	5.41e-41	Obesity-related traits;
LUSC	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg01858014	chr14:56050164	KTN1	-0.82	-7.11	-0.36	7.29e-12	Putamen volume;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg04975205	chr1:24127260	GALE	0.39	6.25	0.32	1.27e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs11214589	0.747	rs7939992	chr11:113229665	T/C	cg14159747	chr11:113255604	NA	0.24	5.83	0.3	1.31e-8	Neuroticism;
LUSC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg06784218	chr1:46089804	CCDC17	0.53	10.53	0.5	1.4e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg13145458	chr22:31556086	RNF185	0.44	5.75	0.3	2.04e-8	Paclitaxel-induced neuropathy;
LUSC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.8	-0.39	8.23e-14	Bipolar disorder;
LUSC	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg04989706	chr14:50066350	PPIL5	-0.45	-6.01	-0.31	4.9e-9	Carotid intima media thickness;
LUSC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg26695010	chr11:65641043	EFEMP2	-0.47	-6.86	-0.35	3.43e-11	Eosinophil percentage of white cells;
LUSC	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg06462663	chr19:18546047	ISYNA1	0.45	7.45	0.38	8e-13	Breast cancer;
LUSC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	6.05	0.31	3.98e-9	Breast cancer;
LUSC	cis	rs151234	0.741	rs151229	chr16:28584937	G/A	cg01378222	chr16:28622494	SULT1A1	-0.63	-8.53	-0.42	5.08e-16	Platelet distribution width;
LUSC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12493885	0.769	rs61791510	chr3:153754666	G/T	cg17054900	chr3:154042577	DHX36	-0.67	-7.06	-0.36	9.76e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg24562669	chr7:97807699	LMTK2	0.48	8.56	0.42	4.18e-16	Breast cancer;
LUSC	cis	rs727505	1.000	rs28844358	chr7:124562695	A/C	cg23710748	chr7:124431027	NA	-0.41	-7.44	-0.38	8.67e-13	Lewy body disease;
LUSC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg11062466	chr8:58055876	NA	0.68	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg10645314	chr2:3704589	ALLC	-0.47	-7.18	-0.37	4.47e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7809950	0.784	rs7803102	chr7:107248929	T/G	cg23024343	chr7:107201750	COG5	0.55	8.59	0.43	3.38e-16	Coronary artery disease;
LUSC	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg25214090	chr10:38739885	LOC399744	-0.53	-7.83	-0.39	6.71e-14	Corneal astigmatism;
LUSC	cis	rs9329289	0.510	rs11251283	chr10:2555784	C/G	cg15501526	chr10:2543763	NA	0.53	9.29	0.45	2.1e-18	Age-related hearing impairment;
LUSC	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.77e-15	Bladder cancer;
LUSC	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-0.87	-13.99	-0.61	2.62e-35	Headache;
LUSC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg21132104	chr15:45694354	SPATA5L1	0.59	8.19	0.41	5.77e-15	Homoarginine levels;
LUSC	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg03676636	chr4:99064102	C4orf37	0.36	8.07	0.4	1.27e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-10.85	-0.51	1.06e-23	Mean corpuscular volume;
LUSC	cis	rs7605378	1.000	rs2689766	chr2:200697539	A/T	cg23649088	chr2:200775458	C2orf69	0.53	8.18	0.41	6.16e-15	Osteoporosis;
LUSC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.68	-9.99	-0.48	1.02e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Smoking initiation;
LUSC	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.78	0.3	1.69e-8	Breast cancer;
LUSC	cis	rs77633900	0.614	rs2468122	chr15:76918686	A/C	cg21673338	chr15:77095150	SCAPER	-0.66	-6.73	-0.35	7.61e-11	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg08888203	chr3:10149979	C3orf24	0.65	9.04	0.44	1.34e-17	Alzheimer's disease;
LUSC	cis	rs27434	0.561	rs151910	chr5:96156956	C/A	cg16492584	chr5:96139282	ERAP1	-0.57	-7.61	-0.38	2.89e-13	Ankylosing spondylitis;
LUSC	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-8.17	-0.41	6.61e-15	Schizophrenia;
LUSC	cis	rs10754283	0.756	rs17441836	chr1:90135433	C/T	cg21401794	chr1:90099060	LRRC8C	0.55	8.01	0.4	1.88e-14	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.4	0.71	1.02e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg09640425	chr7:158790006	NA	-0.53	-8.27	-0.41	3.2e-15	Facial morphology (factor 20);
LUSC	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.38	-0.91	1.44e-130	Myeloid white cell count;
LUSC	cis	rs62400317	0.826	rs4544895	chr6:45271917	A/T	cg18551225	chr6:44695536	NA	-0.42	-6.95	-0.36	1.89e-11	Total body bone mineral density;
LUSC	cis	rs3764021	0.870	rs2192437	chr12:9879235	T/A	cg20894963	chr12:9885564	CLECL1	0.34	6.85	0.35	3.58e-11	Type 1 diabetes;
LUSC	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.75	-0.47	6.2e-20	Multiple sclerosis;
LUSC	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	0.55	8.26	0.41	3.48e-15	Breast cancer;
LUSC	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.8	11.11	0.52	1.33e-24	HIV-1 control;
LUSC	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg27147174	chr7:100797783	AP1S1	-0.64	-10.31	-0.49	8.31e-22	Life satisfaction;
LUSC	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg02466173	chr16:30829666	NA	-0.5	-9.55	-0.46	2.91e-19	Dementia with Lewy bodies;
LUSC	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-7.99	-0.4	2.25e-14	Axial length;
LUSC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg06074448	chr4:187884817	NA	-0.41	-6.89	-0.35	2.85e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6691722	0.503	rs1142057	chr1:24706292	C/T	cg18323236	chr1:24743029	NIPAL3	-0.36	-5.79	-0.3	1.63e-8	Response to interferon beta in multiple sclerosis;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg07562458	chr1:224622430	WDR26	-0.46	-6.56	-0.34	2.09e-10	Cognitive function;Information processing speed;
LUSC	cis	rs714027	0.585	rs2007446	chr22:30388601	C/T	cg11564601	chr22:30592435	NA	0.34	5.82	0.3	1.38e-8	Lymphocyte counts;
LUSC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.17	-29.86	-0.85	2.67e-96	Testicular germ cell tumor;
LUSC	cis	rs12999616	0.696	rs56035334	chr2:98329047	T/G	cg26665480	chr2:98280029	ACTR1B	0.52	5.93	0.31	7.76e-9	Colorectal cancer;
LUSC	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.93	0.35	2.16e-11	IgG glycosylation;
LUSC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg24399712	chr22:39784796	NA	-0.63	-11.5	-0.53	5.01e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs7605827	0.930	rs9287661	chr2:15595901	G/A	cg19274914	chr2:15703543	NA	0.46	8.73	0.43	1.2e-16	Educational attainment (years of education);
LUSC	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg08799069	chr10:126477246	METTL10	0.6	8.24	0.41	3.98e-15	Cocaine dependence;
LUSC	trans	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.28e-9	Bladder cancer;
LUSC	cis	rs11997175	0.653	rs7005254	chr8:33641781	A/T	ch.8.33884649F	chr8:33765107	NA	0.47	7.48	0.38	6.64e-13	Body mass index;
LUSC	cis	rs3820928	0.874	rs4675138	chr2:227884118	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.78	-0.39	9.39e-14	Pulmonary function;
LUSC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	0.99	16.55	0.67	2.35e-45	Coronary artery disease;
LUSC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg13939156	chr17:80058883	NA	0.34	6.61	0.34	1.52e-10	Life satisfaction;
LUSC	cis	rs2290159	0.800	rs6792773	chr3:12668726	C/T	cg23032965	chr3:12705835	RAF1	0.74	9.11	0.45	7.89e-18	Cholesterol, total;
LUSC	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg21293242	chr8:11204541	TDH	0.34	6.38	0.33	6.01e-10	Retinal vascular caliber;
LUSC	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg01528321	chr10:82214614	TSPAN14	0.98	14.61	0.62	9.9e-38	Post bronchodilator FEV1;
LUSC	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg14458575	chr2:238380390	NA	0.66	11.37	0.53	1.48e-25	Prostate cancer;
LUSC	trans	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	6.76	0.35	6.1e-11	Retinal vascular caliber;
LUSC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg09436375	chr6:42928200	GNMT	-0.29	-6.74	-0.35	7.01e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg26338869	chr17:61819248	STRADA	0.42	6.09	0.32	3.11e-9	Prudent dietary pattern;
LUSC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg16006841	chr5:176797999	RGS14	0.62	8.69	0.43	1.6e-16	Urate levels in lean individuals;
LUSC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg05347473	chr6:146136440	FBXO30	0.53	9.06	0.44	1.13e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg05973401	chr12:123451056	ABCB9	-0.52	-7.22	-0.37	3.58e-12	Neutrophil percentage of white cells;
LUSC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg19468946	chr17:37922297	IKZF3	-0.44	-6.92	-0.35	2.36e-11	Self-reported allergy;
LUSC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.96	0.7	5.97e-51	Chronic sinus infection;
LUSC	cis	rs6977660	0.714	rs10236607	chr7:19818620	A/G	cg07541023	chr7:19748670	TWISTNB	0.59	6.36	0.33	6.62e-10	Thyroid stimulating hormone;
LUSC	cis	rs6456156	0.774	rs6931530	chr6:167527200	A/C	cg07741184	chr6:167504864	NA	-0.36	-6.34	-0.33	7.54e-10	Primary biliary cholangitis;
LUSC	cis	rs4293296	0.525	rs12323811	chr14:54811735	C/A	cg02257953	chr14:54816093	NA	-0.44	-6.49	-0.33	3.15e-10	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg11789530	chr4:8429930	ACOX3	0.53	7.84	0.39	5.91e-14	Response to antineoplastic agents;
LUSC	trans	rs10221833	0.602	rs355883	chr2:165633925	A/T	cg26993132	chr16:89239499	CDH15	0.31	5.98	0.31	5.64e-9	Response to statin therapy;
LUSC	cis	rs7681440	0.583	rs2736993	chr4:90772851	A/C	cg06632027	chr4:90757378	SNCA	-0.37	-5.8	-0.3	1.54e-8	Dementia with Lewy bodies;
LUSC	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.98	0.4	2.31e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	0.64	13.37	0.59	5.97e-33	Prudent dietary pattern;
LUSC	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-0.79	-14.15	-0.61	6.28e-36	Brugada syndrome;
LUSC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg23630131	chr7:65973040	NA	-0.21	-5.82	-0.3	1.38e-8	Aortic root size;
LUSC	cis	rs7113850	0.541	rs7927067	chr11:24232604	G/A	ch.11.24196551F	chr11:24239977	NA	1.0	9.14	0.45	6e-18	Bone fracture in osteoporosis;
LUSC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg13319975	chr6:146136371	FBXO30	0.49	7.55	0.38	4.15e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg02018176	chr4:1364513	KIAA1530	0.48	8.32	0.41	2.22e-15	Obesity-related traits;
LUSC	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg10560079	chr2:191398806	TMEM194B	-0.66	-8.3	-0.41	2.61e-15	Diastolic blood pressure;
LUSC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg03146154	chr1:46216737	IPP	0.57	8.47	0.42	8e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg03233332	chr7:66118400	NA	-0.42	-6.14	-0.32	2.33e-9	Aortic root size;
LUSC	cis	rs7113850	0.541	rs114370606	chr11:24232247	C/T	ch.11.24196551F	chr11:24239977	NA	0.99	9.08	0.44	1e-17	Bone fracture in osteoporosis;
LUSC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	10.14	0.49	3.14e-21	Exhaled nitric oxide output;
LUSC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.57	-0.34	1.94e-10	Schizophrenia;
LUSC	cis	rs12824058	0.737	rs873663	chr12:130816316	C/T	cg23887609	chr12:130822674	PIWIL1	0.45	6.29	0.33	9.93e-10	Menopause (age at onset);
LUSC	trans	rs11989744	0.597	rs11135768	chr8:23573278	A/G	cg03492747	chr16:86543808	FOXF1	0.61	10.24	0.49	1.44e-21	Waist-hip ratio;
LUSC	cis	rs2882667	0.690	rs176382	chr5:138226767	A/G	cg04439458	chr5:138467593	SIL1	-0.38	-7.43	-0.38	8.95e-13	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	11.42	0.53	1.05e-25	Ileal carcinoids;
LUSC	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-10.47	-0.5	2.2e-22	Multiple sclerosis;Ankylosing spondylitis;
LUSC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.56	-11.87	-0.54	2.36e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs4619890	0.528	rs28622214	chr4:7879440	C/T	cg24250820	chr4:7887609	AFAP1	0.36	6.16	0.32	2.06e-9	Glaucoma (primary open-angle);
LUSC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg09491104	chr22:46646882	C22orf40	-0.64	-7.29	-0.37	2.33e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg01966878	chr4:90757139	SNCA	-0.43	-6.22	-0.32	1.49e-9	Neuroticism;
LUSC	cis	rs11191205	0.774	rs11191203	chr10:103824920	C/T	cg15320455	chr10:103880129	LDB1	0.52	5.93	0.31	7.56e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	0.621	rs38798	chr7:92044539	C/A	cg17063962	chr7:91808500	NA	-0.49	-7.35	-0.37	1.5e-12	Breast cancer;
LUSC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs13427251	0.653	rs11123787	chr2:100156940	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.8	-0.35	4.71e-11	Chronic sinus infection;
LUSC	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg17366294	chr4:99064904	C4orf37	0.6	10.58	0.5	9.38e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg22903471	chr2:27725779	GCKR	-0.41	-7.07	-0.36	9.12e-12	Total body bone mineral density;
LUSC	cis	rs939658	0.935	rs954292	chr15:79449237	C/T	cg17916960	chr15:79447300	NA	0.48	9.76	0.47	5.81e-20	Refractive error;
LUSC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	7.66	0.39	2.05e-13	Prudent dietary pattern;
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-7.96	-0.4	2.67e-14	Lymphocyte counts;
LUSC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05535760	chr7:792225	HEATR2	-0.79	-8.97	-0.44	2.11e-17	Cerebrospinal P-tau181p levels;
LUSC	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.56	0.5	1.08e-22	Colorectal cancer;
LUSC	cis	rs12980942	0.591	rs11879429	chr19:41757444	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.7	7.36	0.37	1.42e-12	Coronary artery disease;
LUSC	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg02569458	chr12:86230093	RASSF9	0.42	6.85	0.35	3.49e-11	Major depressive disorder;
LUSC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06544989	chr22:39130855	UNC84B	0.37	6.36	0.33	6.53e-10	Menopause (age at onset);
LUSC	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg04450456	chr4:17643702	FAM184B	0.38	6.24	0.32	1.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs68170813	0.617	rs17481842	chr7:107121862	C/T	cg02696742	chr7:106810147	HBP1	-0.63	-8.25	-0.41	3.76e-15	Coronary artery disease;
LUSC	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg26061582	chr7:22766209	IL6	0.48	6.9	0.35	2.61e-11	Lung cancer;
LUSC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg17554472	chr22:41940697	POLR3H	0.49	5.98	0.31	5.86e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg01629716	chr15:45996671	NA	0.4	6.12	0.32	2.56e-9	Waist circumference;Weight;
LUSC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg05973401	chr12:123451056	ABCB9	0.64	9.29	0.45	1.98e-18	Platelet count;
LUSC	cis	rs7809950	0.954	rs2894466	chr7:107242909	G/A	cg23024343	chr7:107201750	COG5	0.57	9.02	0.44	1.54e-17	Coronary artery disease;
LUSC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.52	-0.34	2.53e-10	Life satisfaction;
LUSC	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.54	-14.93	-0.63	5.86e-39	Urate levels in overweight individuals;
LUSC	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg00579484	chr14:23475993	C14orf93	0.39	5.66	0.3	3.23e-8	Cognitive ability (multi-trait analysis);
LUSC	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg09163369	chr1:210001066	C1orf107	0.5	6.02	0.31	4.7e-9	Orofacial clefts;
LUSC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-1.23	-13.8	-0.6	1.39e-34	Diabetic kidney disease;
LUSC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg06671706	chr8:8559999	CLDN23	0.5	6.83	0.35	4.14e-11	Obesity-related traits;
LUSC	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.08	-0.91	1.14e-129	Myeloid white cell count;
LUSC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18876405	chr7:65276391	NA	-0.58	-9.36	-0.46	1.22e-18	Aortic root size;
LUSC	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-8.17	-0.41	6.34e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg07382826	chr16:28625726	SULT1A1	0.28	6.07	0.32	3.47e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg03146154	chr1:46216737	IPP	0.49	7.35	0.37	1.49e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg01884057	chr2:25150051	NA	0.48	11.42	0.53	1e-25	Body mass index;
LUSC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg05802129	chr4:122689817	NA	-0.52	-8.77	-0.43	9.01e-17	Type 2 diabetes;
LUSC	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg13057898	chr1:3703894	LRRC47	0.51	9.16	0.45	5.47e-18	Red cell distribution width;
LUSC	trans	rs7181230	1.000	rs28587891	chr15:40365106	T/A	cg22705835	chr10:65332833	REEP3	-0.43	-7.34	-0.37	1.65e-12	Dehydroepiandrosterone sulphate levels;
LUSC	trans	rs4714291	0.963	rs761801	chr6:39997176	G/A	cg02267698	chr19:7991119	CTXN1	0.52	7.3	0.37	2.06e-12	Strep throat;
LUSC	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.83	-0.43	6.13e-17	Monocyte percentage of white cells;
LUSC	cis	rs3106136	0.527	rs2865345	chr4:95156565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.48	-0.42	7.38e-16	Capecitabine sensitivity;
LUSC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	6.83	0.35	3.93e-11	Bipolar disorder;
LUSC	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg05973401	chr12:123451056	ABCB9	0.56	6.85	0.35	3.49e-11	Neutrophil percentage of white cells;
LUSC	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg21427119	chr20:30132790	HM13	-0.44	-6.34	-0.33	7.29e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg23788917	chr6:8435910	SLC35B3	0.51	7.56	0.38	3.86e-13	Motion sickness;
LUSC	cis	rs17034641	1.000	rs10495930	chr2:46372675	A/G	cg12428440	chr2:46370979	PRKCE	0.46	6.15	0.32	2.17e-9	Hemoglobin;Hematocrit;
LUSC	cis	rs9309473	0.579	rs6728128	chr2:73595982	T/C	cg20560298	chr2:73613845	ALMS1	-0.56	-8.25	-0.41	3.76e-15	Metabolite levels;
LUSC	cis	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg21775007	chr8:11205619	TDH	0.49	6.52	0.34	2.57e-10	Neuroticism;
LUSC	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.58	8.87	0.44	4.4e-17	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.65	0.39	2.21e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.7	-10.7	-0.51	3.51e-23	Platelet count;
LUSC	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg12091567	chr17:66097778	LOC651250	0.66	9.0	0.44	1.76e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	8.42	0.42	1.11e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-7.49	-0.38	6.18e-13	Colorectal cancer;
LUSC	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.05	0.31	3.91e-9	Recombination rate (females);
LUSC	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg25233709	chr10:116636983	FAM160B1	0.45	8.12	0.41	9.24e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs16895831	0.519	rs16895843	chr6:42541802	G/C	cg10605015	chr6:42532144	UBR2	-0.5	-5.95	-0.31	6.67e-9	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs9788721	0.836	rs2009746	chr15:78754102	A/G	cg18825076	chr15:78729989	IREB2	-0.6	-9.94	-0.48	1.47e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs6489882	0.807	rs61266553	chr12:113371977	A/G	cg20102336	chr12:113376681	OAS3	-0.42	-6.1	-0.32	2.9e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	7.77	0.39	9.83e-14	Menarche (age at onset);
LUSC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.41	5.78	0.3	1.74e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg27432699	chr2:27873401	GPN1	0.8	15.0	0.63	3.04e-39	Oral cavity cancer;
LUSC	cis	rs611744	0.870	rs596703	chr8:109160146	A/G	cg18478394	chr8:109455254	TTC35	-0.43	-6.42	-0.33	4.63e-10	Dupuytren's disease;
LUSC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	0.94	18.8	0.72	2.63e-54	Cognitive function;
LUSC	trans	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	11.93	0.55	1.4e-27	Exhaled nitric oxide output;
LUSC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	1.05	19.67	0.73	9.29e-58	Menopause (age at onset);
LUSC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	1.05	20.56	0.75	2.89e-61	Menopause (age at onset);
LUSC	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg22676075	chr6:135203613	NA	0.52	8.3	0.41	2.68e-15	Red blood cell count;
LUSC	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.52	8.06	0.4	1.41e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.52	8.59	0.43	3.29e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg11766577	chr21:47581405	C21orf56	0.57	8.77	0.43	9.37e-17	Testicular germ cell tumor;
LUSC	cis	rs7809950	0.817	rs10224503	chr7:107075569	A/C	cg23024343	chr7:107201750	COG5	-0.68	-9.96	-0.48	1.28e-20	Coronary artery disease;
LUSC	cis	rs2637266	0.678	rs1797495	chr10:78577602	G/A	cg18941641	chr10:78392320	NA	0.32	5.71	0.3	2.55e-8	Pulmonary function;
LUSC	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg02820040	chr2:241836501	C2orf54	0.27	5.79	0.3	1.58e-8	Urinary metabolites;
LUSC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.29e-12	Urate levels;
LUSC	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg04362960	chr10:104952993	NT5C2	0.59	9.47	0.46	5.32e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg12483005	chr1:23474871	LUZP1	-0.41	-6.33	-0.33	7.86e-10	Height;
LUSC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	6.38	0.33	5.99e-10	Bipolar disorder;
LUSC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg03146154	chr1:46216737	IPP	0.49	7.37	0.37	1.39e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg10434728	chr15:90938212	IQGAP1	-0.46	-9.34	-0.46	1.4e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg15423357	chr2:25149977	NA	0.44	8.97	0.44	2.11e-17	Body mass index;
LUSC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11764359	chr7:65958608	NA	-0.62	-9.45	-0.46	6.04e-19	Aortic root size;
LUSC	cis	rs2692947	0.702	rs7604842	chr2:96777340	C/T	cg22654517	chr2:96458247	NA	-0.32	-5.88	-0.31	9.97e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9815354	0.812	rs73830532	chr3:41898814	T/C	cg03022575	chr3:42003672	ULK4	0.84	8.74	0.43	1.14e-16	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7106204	0.609	rs12790279	chr11:24286221	C/G	ch.11.24196551F	chr11:24239977	NA	0.7	6.47	0.33	3.45e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg00277334	chr10:82204260	NA	-0.58	-8.71	-0.43	1.47e-16	Post bronchodilator FEV1;
LUSC	cis	rs7106204	0.514	rs12291514	chr11:24360203	T/C	ch.11.24196551F	chr11:24239977	NA	0.79	8.43	0.42	1.07e-15	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs28647808	0.748	rs28502181	chr9:136257792	T/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs7503807	0.967	rs7215486	chr17:78612034	C/T	cg09596252	chr17:78655493	RPTOR	0.46	7.91	0.4	3.88e-14	Obesity;
LUSC	cis	rs5770917	1.000	rs2269384	chr22:51011115	C/T	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.65	-5.7	-0.3	2.65e-8	Narcolepsy;
LUSC	cis	rs72960926	1.000	rs72950597	chr6:74921367	T/C	cg03266952	chr6:74778945	NA	-0.73	-6.47	-0.33	3.56e-10	Metabolite levels (MHPG);
LUSC	trans	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7980799	0.649	rs11559754	chr12:33649229	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-7.92	-0.4	3.67e-14	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg09835421	chr16:68378352	PRMT7	-0.59	-6.31	-0.33	8.82e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs738322	0.810	rs4821764	chr22:38599364	G/A	cg25457927	chr22:38595422	NA	0.48	10.03	0.48	7.15e-21	Cutaneous nevi;
LUSC	cis	rs7833986	0.501	rs2719245	chr8:56894359	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	11.2	0.52	6.05e-25	Height;
LUSC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08048268	chr3:133502702	NA	-0.47	-9.08	-0.44	9.95e-18	Iron status biomarkers;
LUSC	cis	rs11677416	0.813	rs4848299	chr2:113523454	C/A	cg27083787	chr2:113543245	IL1A	0.43	6.71	0.34	8.24e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg02023728	chr11:77925099	USP35	0.51	7.49	0.38	6.18e-13	Testicular germ cell tumor;
LUSC	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg08917208	chr2:24149416	ATAD2B	0.95	9.92	0.48	1.72e-20	Lymphocyte counts;
LUSC	trans	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg11887960	chr12:57824829	NA	0.54	6.74	0.35	7.11e-11	Obesity-related traits;
LUSC	cis	rs2446066	0.872	rs10876452	chr12:53814258	T/A	cg20730629	chr12:53886622	MAP3K12	-0.4	-5.69	-0.3	2.72e-8	Red blood cell count;
LUSC	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg20744362	chr22:50050164	C22orf34	0.4	8.33	0.41	2.15e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg06740227	chr12:86229804	RASSF9	0.38	6.11	0.32	2.83e-9	Major depressive disorder;
LUSC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg13206674	chr6:150067644	NUP43	0.61	9.64	0.47	1.46e-19	Lung cancer;
LUSC	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg06627628	chr2:24431161	ITSN2	0.72	9.98	0.48	1.04e-20	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs262150	0.851	rs2657326	chr7:158766262	C/T	cg09640425	chr7:158790006	NA	-0.41	-6.64	-0.34	1.29e-10	Facial morphology (factor 20);
LUSC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.63	0.34	1.38e-10	Testicular germ cell tumor;
LUSC	trans	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	8.91	0.44	3.33e-17	Type 2 diabetes;
LUSC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg21361702	chr7:150065534	REPIN1	-0.57	-9.14	-0.45	6.33e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg07741184	chr6:167504864	NA	0.4	7.01	0.36	1.3e-11	Primary biliary cholangitis;
LUSC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.44	-6.38	-0.33	6.06e-10	Platelet count;
LUSC	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg09092052	chr15:45571596	NA	0.47	6.53	0.34	2.51e-10	Glomerular filtration rate;
LUSC	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg12935359	chr14:103987150	CKB	-0.65	-10.61	-0.5	7.5e-23	Intelligence (multi-trait analysis);
LUSC	trans	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.0	-0.31	5.12e-9	Bladder cancer;
LUSC	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-6.01	-0.31	4.87e-9	Fear of minor pain;
LUSC	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.54	-0.62	1.86e-37	Schizophrenia;
LUSC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-13.36	-0.59	6.62e-33	Chronic sinus infection;
LUSC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg11062466	chr8:58055876	NA	0.58	7.39	0.37	1.21e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7712401	0.562	rs30073	chr5:122290509	A/T	cg19077854	chr5:122220652	SNX24	0.44	9.9	0.48	2.02e-20	Mean platelet volume;
LUSC	cis	rs6546886	0.912	rs13021880	chr2:74310787	C/G	cg14702570	chr2:74259524	NA	-0.3	-5.75	-0.3	2.05e-8	Dialysis-related mortality;
LUSC	cis	rs3936840	0.565	rs8006911	chr14:102975265	A/G	cg18135206	chr14:102964638	TECPR2	0.52	7.01	0.36	1.32e-11	Plateletcrit;
LUSC	trans	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.89	-0.35	2.86e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.44	6.03	0.31	4.33e-9	Lung cancer;
LUSC	trans	rs62458065	0.850	rs73096034	chr7:32472048	A/G	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.08	-0.32	3.33e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg24375607	chr4:120327624	NA	0.76	11.36	0.53	1.66e-25	Corneal astigmatism;
LUSC	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg00277334	chr10:82204260	NA	-0.5	-7.21	-0.37	3.83e-12	Post bronchodilator FEV1;
LUSC	cis	rs2677744	0.626	rs2001216	chr15:91498130	T/C	cg20750528	chr15:91474456	HDDC3;UNC45A	-0.32	-5.69	-0.3	2.75e-8	Attention deficit hyperactivity disorder;
LUSC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.71	0.3	2.49e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-6.73	-0.35	7.51e-11	Major depressive disorder;
LUSC	cis	rs12980942	0.935	rs16958996	chr19:41825138	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.19	0.32	1.74e-9	Coronary artery disease;
LUSC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.82	-15.21	-0.64	4.55e-40	Dental caries;
LUSC	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg17075019	chr10:79541650	NA	-0.76	-12.26	-0.56	8.47e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg03060546	chr3:49711283	APEH	0.64	6.96	0.36	1.76e-11	Menarche (age at onset);
LUSC	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg20573242	chr4:122745356	CCNA2	-0.44	-6.76	-0.35	6.05e-11	Type 2 diabetes;
LUSC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.59	9.05	0.44	1.16e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.68	-0.47	1.04e-19	Coronary artery disease;
LUSC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	ch.11.42038R	chr11:967971	AP2A2	0.54	8.24	0.41	4.01e-15	Alzheimer's disease (late onset);
LUSC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.42	0.5	3.24e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg16624210	chr5:671434	TPPP	0.5	6.38	0.33	6.07e-10	Obesity-related traits;
LUSC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg15485101	chr11:133734466	NA	0.4	7.15	0.36	5.64e-12	Childhood ear infection;
LUSC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg17279839	chr7:150038598	RARRES2	0.54	8.1	0.41	1.06e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7973719	1.000	rs12828421	chr12:7335217	C/T	cg07052231	chr12:7363540	PEX5	-0.52	-9.14	-0.45	6.28e-18	IgG glycosylation;
LUSC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg05084668	chr3:125655381	ALG1L	-0.49	-6.86	-0.35	3.26e-11	Blood pressure (smoking interaction);
LUSC	cis	rs55665837	1.000	rs12283797	chr11:14442262	C/G	cg19336497	chr11:14380999	RRAS2	-0.37	-7.53	-0.38	4.9e-13	Vitamin D levels;
LUSC	trans	rs7193541	0.550	rs28607667	chr16:74476015	C/T	cg03033975	chr20:60776546	GTPBP5	0.33	6.11	0.32	2.85e-9	Multiple myeloma;
LUSC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.66	8.12	0.41	9.32e-15	Lung function (FEV1/FVC);
LUSC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg25767906	chr1:53392781	SCP2	-0.49	-8.92	-0.44	3.09e-17	Monocyte count;
LUSC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg07701084	chr6:150067640	NUP43	0.51	7.56	0.38	3.97e-13	Lung cancer;
LUSC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg12463550	chr7:65579703	CRCP	-0.47	-6.96	-0.36	1.84e-11	Aortic root size;
LUSC	cis	rs1957429	0.731	rs28370916	chr14:65346094	A/G	cg23373153	chr14:65346875	NA	1.09	12.7	0.57	2.03e-30	Pediatric areal bone mineral density (radius);
LUSC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.79	0.6	1.47e-34	Alzheimer's disease;
LUSC	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg03342759	chr3:160939853	NMD3	0.53	9.01	0.44	1.67e-17	Morning vs. evening chronotype;
LUSC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.72	11.16	0.52	8.41e-25	Tonometry;
LUSC	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg05925327	chr15:68127851	NA	-0.38	-6.01	-0.31	4.85e-9	Obesity;
LUSC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.84	13.7	0.6	3.38e-34	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.26	-0.32	1.19e-9	Breast cancer;
LUSC	cis	rs1440410	0.835	rs11722027	chr4:144050017	G/A	cg01719995	chr4:144104893	USP38	0.32	5.74	0.3	2.09e-8	Ischemic stroke;
LUSC	cis	rs7094131	0.549	rs10219113	chr10:22875788	T/C	cg19500236	chr10:22911537	PIP4K2A	0.36	6.13	0.32	2.53e-9	Obesity-related traits;
LUSC	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg05855489	chr10:104503620	C10orf26	0.52	8.02	0.4	1.85e-14	Arsenic metabolism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06523340	chr1:231376895	GNPAT;C1orf131	-0.42	-6.25	-0.32	1.23e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg25039879	chr17:56429692	SUPT4H1	0.69	9.04	0.44	1.26e-17	Cognitive test performance;
LUSC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	6.36	0.33	6.48e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1267303	0.798	rs1267302	chr1:46990545	G/C	cg25110126	chr1:46999211	NA	-0.66	-9.14	-0.45	6.25e-18	Monobrow;
LUSC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg08219700	chr8:58056026	NA	0.44	5.82	0.3	1.35e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs250677	0.522	rs11954893	chr5:148392362	A/G	cg18129178	chr5:148520854	ABLIM3	-0.54	-7.87	-0.4	5.01e-14	Breast cancer;
LUSC	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	trans	rs9567307	1	rs9567307	chr13:44471877	A/G	cg12856521	chr11:46389249	DGKZ	0.57	7.47	0.38	7.2e-13	Leprosy;
LUSC	trans	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg11887960	chr12:57824829	NA	0.54	6.74	0.35	7.11e-11	Obesity-related traits;
LUSC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-1.0	-16.54	-0.67	2.57e-45	Systemic lupus erythematosus;
LUSC	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg11502198	chr6:26597334	ABT1	0.62	9.85	0.47	2.95e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg05340658	chr4:99064831	C4orf37	0.63	10.01	0.48	8.32e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg18758796	chr5:131593413	PDLIM4	0.4	6.61	0.34	1.49e-10	Blood metabolite levels;
LUSC	cis	rs6424115	0.546	rs35993651	chr1:24180613	C/G	cg10978503	chr1:24200527	CNR2	-0.52	-12.47	-0.56	1.48e-29	Immature fraction of reticulocytes;
LUSC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg21535247	chr6:8435926	SLC35B3	-0.58	-8.99	-0.44	1.9e-17	Motion sickness;
LUSC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.83	-0.47	3.42e-20	Chronic sinus infection;
LUSC	cis	rs6596100	0.538	rs59682592	chr5:132196800	C/T	cg02081065	chr5:132209139	LEAP2	-0.62	-5.9	-0.31	9.1e-9	Breast cancer;
LUSC	cis	rs12519773	0.526	rs4869415	chr5:92522764	A/G	cg18783429	chr5:92414398	NA	0.33	7.3	0.37	2.17e-12	Migraine;
LUSC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.8	13.31	0.59	9.95e-33	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg03806693	chr22:41940476	POLR3H	-0.54	-7.39	-0.38	1.15e-12	Neuroticism;
LUSC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-7.19	-0.37	4.24e-12	Alzheimer's disease (late onset);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg09363194	chr3:197282902	BDH1	0.37	5.95	0.31	6.64e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs11229555	0.645	rs11229549	chr11:58395914	T/C	cg15696309	chr11:58395628	NA	-0.69	-7.29	-0.37	2.21e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00166722	chr3:10149974	C3orf24	0.6	8.29	0.41	2.75e-15	Alzheimer's disease;
LUSC	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg17507749	chr15:85114479	UBE2QP1	0.56	6.91	0.35	2.45e-11	Schizophrenia;
LUSC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.9	0.4	4.17e-14	Prudent dietary pattern;
LUSC	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg16329650	chr2:213403929	ERBB4	0.86	18.45	0.71	6.91e-53	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1668873	0.562	rs10157145	chr1:205261963	T/C	cg21545522	chr1:205238299	TMCC2	-0.34	-6.45	-0.33	3.95e-10	Mean platelet volume;
LUSC	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg14584255	chr6:163149320	PACRG;PARK2	-0.33	-6.3	-0.33	9.63e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg02800362	chr5:177631904	HNRNPAB	0.88	13.05	0.58	9.85e-32	Obesity-related traits;
LUSC	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg17145862	chr1:211918768	LPGAT1	0.23	6.1	0.32	2.97e-9	Leprosy;
LUSC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	7.14	0.36	5.94e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg25797454	chr6:150327115	RAET1K	0.35	8.26	0.41	3.36e-15	Alopecia areata;
LUSC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	16.04	0.66	2.51e-43	Platelet count;
LUSC	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg03060546	chr3:49711283	APEH	-0.55	-6.68	-0.34	9.71e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	trans	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg27411982	chr8:10470053	RP1L1	0.43	7.08	0.36	8.55e-12	Joint mobility (Beighton score);
LUSC	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.45	6.38	0.33	5.9e-10	Blood metabolite levels;
LUSC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.28	-5.72	-0.3	2.31e-8	Longevity;Endometriosis;
LUSC	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.45	0.5	2.62e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1044826	0.619	rs7375091	chr3:139090389	T/A	cg15131784	chr3:139108705	COPB2	-0.43	-7.09	-0.36	8.16e-12	Obesity-related traits;
LUSC	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg05673287	chr15:77411982	SGK269	0.45	6.96	0.36	1.85e-11	Type 2 diabetes;
LUSC	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-8.33	-0.41	2.18e-15	Coffee consumption (cups per day);
LUSC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg25036284	chr2:26402008	FAM59B	-0.72	-10.05	-0.48	6.06e-21	Gut microbiome composition (summer);
LUSC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg00484396	chr16:3507460	NAT15	0.87	11.57	0.54	2.8e-26	Tuberculosis;
LUSC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11764359	chr7:65958608	NA	-0.59	-9.26	-0.45	2.48e-18	Aortic root size;
LUSC	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg12656391	chr1:43425156	SLC2A1	-0.46	-7.26	-0.37	2.65e-12	Monocyte count;
LUSC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg08680598	chr22:49984980	NA	-0.33	-6.04	-0.31	4.16e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg09877947	chr5:131593287	PDLIM4	0.49	8.1	0.41	1.06e-14	Breast cancer;
LUSC	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg17252645	chr8:143867129	LY6D	-0.45	-8.04	-0.4	1.56e-14	Urinary tract infection frequency;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10516465	chr14:102695515	RAGE	0.55	7.79	0.39	8.57e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg13256891	chr4:100009986	ADH5	0.46	6.39	0.33	5.71e-10	Alcohol dependence;
LUSC	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg25797454	chr6:150327115	RAET1K	-0.32	-7.09	-0.36	7.79e-12	Alopecia areata;
LUSC	cis	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg17633681	chr16:88106987	BANP	0.53	10.1	0.48	4.24e-21	Menopause (age at onset);
LUSC	trans	rs7094131	0.542	rs7071306	chr10:22867339	A/G	cg15415259	chr6:134158982	MGC34034	0.37	6.31	0.33	9.09e-10	Obesity-related traits;
LUSC	cis	rs4776059	1.000	rs12915981	chr15:52901433	C/T	cg22715398	chr15:52968154	KIAA1370	-0.69	-10.3	-0.49	8.61e-22	Schizophrenia;
LUSC	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg13160058	chr8:26243215	BNIP3L	-0.41	-7.2	-0.37	4.12e-12	Red cell distribution width;
LUSC	trans	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg03886242	chr7:26192032	NFE2L3	0.41	6.53	0.34	2.43e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs3126085	0.935	rs4845751	chr1:152208997	T/C	cg26876637	chr1:152193138	HRNR	0.45	6.29	0.33	9.81e-10	Atopic dermatitis;
LUSC	cis	rs4865169	0.595	rs4865165	chr4:57765546	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.38	-5.83	-0.3	1.33e-8	Breast cancer;
LUSC	trans	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg17675199	chr6:35436792	RPL10A	-0.4	-5.95	-0.31	6.75e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg05738196	chr6:26577821	NA	0.8	15.3	0.64	2.07e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs909002	0.800	rs1061770	chr1:32096265	A/G	cg01639898	chr1:32083012	HCRTR1	0.31	7.36	0.37	1.48e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2637266	0.703	rs2583062	chr10:78558472	T/C	cg18941641	chr10:78392320	NA	0.37	6.7	0.34	8.79e-11	Pulmonary function;
LUSC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.77	-0.3	1.8e-8	Aortic root size;
LUSC	cis	rs4363385	0.791	rs489323	chr1:153006047	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.45e-8	Inflammatory skin disease;
LUSC	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.55	-0.34	2.16e-10	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs2853333	0.622	rs2853332	chr19:35746706	A/G	cg12287945	chr19:35758300	LSR	-0.39	-5.7	-0.3	2.71e-8	Red blood cell count;
LUSC	cis	rs11971779	0.680	rs10242419	chr7:139089380	A/G	cg23387468	chr7:139079360	LUC7L2	-0.42	-6.39	-0.33	5.71e-10	Diisocyanate-induced asthma;
LUSC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg12165864	chr7:66369176	NA	-0.48	-6.5	-0.33	2.97e-10	Corneal structure;
LUSC	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg20991723	chr1:152506922	NA	0.5	9.28	0.45	2.18e-18	Hair morphology;
LUSC	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	7.64	0.39	2.28e-13	Body mass index;
LUSC	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Bladder cancer;
LUSC	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg19743168	chr1:23544995	NA	0.4	7.93	0.4	3.22e-14	Height;
LUSC	cis	rs1030877	0.515	rs2679895	chr2:105906480	C/G	cg02079111	chr2:105885981	TGFBRAP1	0.65	9.12	0.45	7.11e-18	Obesity-related traits;
LUSC	trans	rs1325195	0.840	rs2816178	chr1:179249538	G/C	cg11624085	chr17:8464688	MYH10	0.45	7.37	0.37	1.34e-12	IgE grass sensitization;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03562264	chr6:36646551	CDKN1A	-0.38	-6.37	-0.33	6.42e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg03676636	chr4:99064102	C4orf37	0.32	7.05	0.36	1.06e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg08847533	chr14:75593920	NEK9	-0.76	-12.7	-0.57	2.1000000000000002e-30	Height;
LUSC	cis	rs8014204	0.657	rs2884668	chr14:75281576	T/A	cg06637938	chr14:75390232	RPS6KL1	0.51	8.09	0.4	1.12e-14	Caffeine consumption;
LUSC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.29e-12	Tonsillectomy;
LUSC	cis	rs1144713	0.531	rs2683491	chr12:32250865	A/T	cg01321189	chr12:32259338	BICD1	0.51	6.9	0.35	2.69e-11	Obesity-related traits;
LUSC	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg23029597	chr12:123009494	RSRC2	-0.73	-9.77	-0.47	5.58e-20	Body mass index;
LUSC	cis	rs9837602	1.000	rs62285478	chr3:99822135	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.43	-6.13	-0.32	2.47e-9	Breast cancer;
LUSC	cis	rs2108225	0.900	rs4518594	chr7:107451060	G/C	cg18560240	chr7:107437656	SLC26A3	-0.43	-6.48	-0.33	3.34e-10	Ulcerative colitis;
LUSC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg03060546	chr3:49711283	APEH	0.66	7.33	0.37	1.74e-12	Menarche (age at onset);
LUSC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.46	-7.88	-0.4	4.57e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.3	-0.33	9.22e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1595825	0.786	rs16826740	chr2:198893927	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-6.25	-0.32	1.23e-9	Ulcerative colitis;
LUSC	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.7	-13.07	-0.58	8.09e-32	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12760731	0.623	rs12691480	chr1:178328790	T/A	cg00404053	chr1:178313656	RASAL2	0.47	5.75	0.3	2.03e-8	Obesity-related traits;
LUSC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg06238570	chr21:40685208	BRWD1	-0.61	-10.25	-0.49	1.24e-21	Cognitive function;
LUSC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.94	0.31	7.17e-9	Menopause (age at onset);
LUSC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.15	-0.32	2.2e-9	Lung cancer;
LUSC	cis	rs3790645	1.000	rs383913	chr1:26893306	A/G	cg17456097	chr1:26900765	RPS6KA1	0.42	6.08	0.32	3.36e-9	Glucose homeostasis traits;
LUSC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg22907277	chr7:1156413	C7orf50	0.68	7.31	0.37	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-12.2	-0.56	1.41e-28	Body mass index;
LUSC	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg19682013	chr15:45996608	NA	0.4	6.02	0.31	4.62e-9	Waist circumference;Weight;
LUSC	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg02018176	chr4:1364513	KIAA1530	0.55	9.68	0.47	1.09e-19	Longevity;
LUSC	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg22431228	chr1:16359049	CLCNKA	0.4	7.31	0.37	2.05e-12	Dilated cardiomyopathy;
LUSC	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.68	-0.43	1.81e-16	Body mass index;
LUSC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	7.28	0.37	2.43e-12	Height;
LUSC	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.05	-0.36	1.06e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs859767	0.501	rs10210052	chr2:135417350	C/T	cg12500956	chr2:135428796	TMEM163	-0.28	-6.65	-0.34	1.17e-10	Neuroticism;
LUSC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08280861	chr8:58055591	NA	0.58	6.38	0.33	6.01e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs4942242	0.663	rs9525817	chr13:44225189	C/T	cg19169023	chr15:41853346	TYRO3	0.61	9.31	0.45	1.77e-18	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11018904	0.906	rs10501713	chr11:89953013	G/A	cg26138821	chr11:89956704	CHORDC1	-0.58	-6.93	-0.35	2.24e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg05855489	chr10:104503620	C10orf26	0.5	7.48	0.38	6.66e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs1461503	0.966	rs11218908	chr11:122841687	A/G	cg27398637	chr11:122830231	C11orf63	-0.41	-6.54	-0.34	2.29e-10	Menarche (age at onset);
LUSC	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg01475377	chr6:109611718	NA	-0.44	-7.82	-0.39	6.88e-14	Reticulocyte fraction of red cells;
LUSC	trans	rs747782	0.527	rs7129364	chr11:48150576	G/A	cg15704280	chr7:45808275	SEPT13	0.72	6.48	0.33	3.37e-10	Intraocular pressure;
LUSC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg06640241	chr16:89574553	SPG7	0.91	16.57	0.67	2.07e-45	Multiple myeloma (IgH translocation);
LUSC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.54	-0.42	4.67e-16	Systolic blood pressure;
LUSC	cis	rs10100465	0.889	rs7815693	chr8:118684198	A/G	cg09430518	chr8:118662568	NA	0.32	6.04	0.31	4.07e-9	Leprosy;
LUSC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg04317338	chr11:64019027	PLCB3	0.71	8.04	0.4	1.57e-14	Mean platelet volume;
LUSC	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-5.84	-0.3	1.21e-8	Height;
LUSC	cis	rs360798	0.532	rs1022110	chr2:63046039	T/G	cg17519650	chr2:63277830	OTX1	-0.47	-6.52	-0.34	2.6200000000000003e-10	Coronary artery disease;
LUSC	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg04414720	chr1:150670196	GOLPH3L	0.53	8.11	0.41	9.43e-15	Melanoma;
LUSC	cis	rs4812048	0.689	rs151360	chr20:57613373	T/C	cg14073986	chr20:57617431	SLMO2	0.5	5.79	0.3	1.58e-8	Mean platelet volume;
LUSC	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg03433313	chr16:819064	MIR662	-0.53	-8.74	-0.43	1.15e-16	Mean corpuscular volume;
LUSC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg09796270	chr17:17721594	SREBF1	0.39	6.78	0.35	5.48e-11	Total body bone mineral density;
LUSC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg09323728	chr8:95962352	TP53INP1	-0.4	-7.93	-0.4	3.44e-14	Type 2 diabetes;
LUSC	cis	rs11601602	0.576	rs4075635	chr11:28511643	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.46	6.18	0.32	1.91e-9	Obesity-related traits;
LUSC	cis	rs6087990	0.965	rs2424904	chr20:31352316	T/C	cg13636640	chr20:31349939	DNMT3B	1.04	23.39	0.79	2.56e-72	Ulcerative colitis;
LUSC	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-7.06	-0.36	9.45e-12	Fear of minor pain;
LUSC	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.5	7.2	0.37	3.9e-12	Coronary heart disease;
LUSC	cis	rs6714710	0.557	rs17490429	chr2:98449024	G/A	cg26665480	chr2:98280029	ACTR1B	0.61	8.91	0.44	3.25e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs2625529	0.824	rs4131630	chr15:72355398	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.52	-0.38	5.01e-13	Red blood cell count;
LUSC	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg08999081	chr20:33150536	PIGU	0.38	6.79	0.35	5.22e-11	Height;
LUSC	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg11584989	chr19:19387371	SF4	0.59	6.99	0.36	1.46e-11	Bipolar disorder;
LUSC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg26441486	chr22:50317300	CRELD2	0.52	7.95	0.4	2.85e-14	Schizophrenia;
LUSC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg06640241	chr16:89574553	SPG7	0.89	16.03	0.66	2.6900000000000002e-43	Multiple myeloma (IgH translocation);
LUSC	cis	rs59698941	0.943	rs4705978	chr5:132245433	C/T	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg13319975	chr6:146136371	FBXO30	-0.71	-11.4	-0.53	1.19e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.29	0.62	1.69e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg06784218	chr1:46089804	CCDC17	-0.54	-10.93	-0.51	5.7e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg09796270	chr17:17721594	SREBF1	-0.4	-6.95	-0.36	1.88e-11	Total body bone mineral density;
LUSC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg12560992	chr17:57184187	TRIM37	0.8	13.87	0.6	7.05e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs1030877	0.521	rs2576747	chr2:105978676	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.54	9.08	0.44	9.97e-18	Obesity-related traits;
LUSC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg06238570	chr21:40685208	BRWD1	-0.55	-8.67	-0.43	1.87e-16	Menarche (age at onset);
LUSC	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.57	9.63	0.47	1.62e-19	Bone mineral density;
LUSC	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg16482183	chr6:26056742	HIST1H1C	0.65	9.13	0.45	6.68e-18	Iron status biomarkers;
LUSC	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-6.72	-0.35	7.83e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg00191853	chr8:101177733	SPAG1	-0.4	-6.42	-0.33	4.77e-10	Atrioventricular conduction;
LUSC	cis	rs4363385	0.553	rs28924721	chr1:152974254	C/T	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.48	-0.33	3.3e-10	Inflammatory skin disease;
LUSC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg21854759	chr1:92012499	NA	-0.51	-8.58	-0.43	3.57e-16	Breast cancer;
LUSC	cis	rs790123	0.565	rs112785037	chr3:122386128	A/T	cg00926285	chr3:122398533	PARP14	-0.46	-6.0	-0.31	5.11e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25072359	chr17:41440525	NA	0.64	9.06	0.44	1.15e-17	Menopause (age at onset);
LUSC	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.33	-0.37	1.74e-12	Neuroticism;
LUSC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	10.79	0.51	1.68e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.49	-0.5	1.95e-22	Hemoglobin concentration;
LUSC	cis	rs225245	0.694	rs321616	chr17:33882720	C/T	cg05299278	chr17:33885742	SLFN14	0.31	6.95	0.36	1.94e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs28785552	0.589	rs11669056	chr19:53244443	G/A	cg10871876	chr19:53194124	ZNF83	0.55	8.04	0.4	1.55e-14	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg17328964	chr8:145687451	CYHR1	-0.65	-10.79	-0.51	1.79e-23	Age at first birth;
LUSC	cis	rs7106204	0.688	rs4462347	chr11:24218865	G/A	ch.11.24196551F	chr11:24239977	NA	0.95	9.31	0.45	1.8e-18	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs76878669	0.561	rs7948058	chr11:66148111	T/A	cg18002602	chr11:66138449	SLC29A2	-0.49	-8.59	-0.43	3.27e-16	Educational attainment (years of education);
LUSC	cis	rs13315871	1.000	rs74834816	chr3:58321828	G/A	cg20936604	chr3:58311152	NA	-0.76	-7.25	-0.37	2.83e-12	Cholesterol, total;
LUSC	trans	rs11039798	1.000	rs9667626	chr11:48485877	T/C	cg03929089	chr4:120376271	NA	0.65	6.0	0.31	5.21e-9	Axial length;
LUSC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.84	-15.46	-0.65	4.82e-41	Dental caries;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26859586	chr10:104953231	NT5C2	-0.49	-6.12	-0.32	2.58e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg04871131	chr7:94954202	PON1	0.38	6.09	0.32	3.04e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.52	7.37	0.37	1.37e-12	Tonsillectomy;
LUSC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg00049323	chr5:472564	LOC25845	0.48	7.57	0.38	3.68e-13	Cystic fibrosis severity;
LUSC	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg05855489	chr10:104503620	C10orf26	0.57	9.18	0.45	4.79e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	5.84	0.3	1.23e-8	Breast cancer;
LUSC	cis	rs7799006	0.929	rs71525363	chr7:2268792	G/A	cg12823233	chr7:2316876	SNX8	-0.36	-6.0	-0.31	5.1e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg01579765	chr21:45077557	HSF2BP	-0.46	-9.62	-0.47	1.67e-19	Mean corpuscular volume;
LUSC	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg26408565	chr15:76604113	ETFA	-0.49	-7.72	-0.39	1.38e-13	Blood metabolite levels;
LUSC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg02972257	chr16:68554789	NA	0.44	5.77	0.3	1.85e-8	Colorectal cancer;
LUSC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg26513180	chr16:89883248	FANCA	-0.53	-7.93	-0.4	3.42e-14	Vitiligo;
LUSC	trans	rs11989744	0.597	rs2033788	chr8:23574847	G/T	cg03492747	chr16:86543808	FOXF1	-0.61	-10.84	-0.51	1.16e-23	Waist-hip ratio;
LUSC	cis	rs1461503	0.932	rs10790544	chr11:122838330	T/C	cg27398637	chr11:122830231	C11orf63	-0.42	-6.68	-0.34	9.97e-11	Menarche (age at onset);
LUSC	cis	rs2274273	0.901	rs10140801	chr14:55730404	C/T	cg04306507	chr14:55594613	LGALS3	0.54	12.34	0.56	4.24e-29	Protein biomarker;
LUSC	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg20026190	chr17:76395443	PGS1	0.45	8.17	0.41	6.52e-15	HDL cholesterol levels;
LUSC	cis	rs3820928	0.775	rs10179756	chr2:227897076	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.73	-0.39	1.25e-13	Pulmonary function;
LUSC	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg05973401	chr12:123451056	ABCB9	0.52	6.56	0.34	2e-10	Neutrophil percentage of white cells;
LUSC	trans	rs724744	0.772	rs714590	chr6:22360029	A/G	cg13807341	chr11:118445984	ARCN1	-0.35	-5.97	-0.31	6.14e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.7e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7605827	0.897	rs6753675	chr2:15539706	C/T	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.55	-8.28	-0.41	3.08e-15	IgG glycosylation;
LUSC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.42	0.42	1.16e-15	Prudent dietary pattern;
LUSC	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-6.17	-0.32	1.93e-9	Fear of minor pain;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18030774	chr17:26733294	SLC46A1	-0.42	-6.08	-0.32	3.29e-9	Hepatitis;
LUSC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg15145296	chr3:125709740	NA	-0.58	-6.53	-0.34	2.4e-10	Blood pressure (smoking interaction);
LUSC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-6.01	-0.31	4.86e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs9322817	0.691	rs4504502	chr6:105325332	A/G	cg02098413	chr6:105308735	HACE1	0.27	5.8	0.3	1.52e-8	Thyroid stimulating hormone;
LUSC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg08888203	chr3:10149979	C3orf24	0.64	8.54	0.42	4.67e-16	Alzheimer's disease;
LUSC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg01652190	chr22:50026171	C22orf34	-0.3	-6.32	-0.33	8.5e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.76	13.23	0.59	1.95e-32	Aortic root size;
LUSC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg16743903	chr16:89593216	SPG7	-0.39	-6.05	-0.31	3.86e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24838063	chr12:130822603	PIWIL1	0.71	11.02	0.52	2.72e-24	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-0.86	-11.63	-0.54	1.82e-26	Menopause (age at onset);
LUSC	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg20637307	chr2:213403960	ERBB4	0.44	7.51	0.38	5.38e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg23260525	chr10:116636907	FAM160B1	0.4	8.18	0.41	5.96e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.46	7.83	0.39	6.4e-14	Lymphocyte counts;
LUSC	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg16928487	chr17:17741425	SREBF1	-0.45	-9.11	-0.45	7.85e-18	Total body bone mineral density;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03800012	chr7:35734842	HERPUD2	0.67	6.01	0.31	4.81e-9	Cognitive performance;
LUSC	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg23625390	chr15:77176239	SCAPER	0.46	7.04	0.36	1.07e-11	Blood metabolite levels;
LUSC	cis	rs231513	0.911	rs231476	chr17:41985845	A/G	cg26893861	chr17:41843967	DUSP3	-0.57	-6.44	-0.33	4.17e-10	Cognitive function;
LUSC	cis	rs4073416	0.568	rs7145759	chr14:65884537	C/A	cg03016385	chr14:66212404	NA	-0.4	-5.93	-0.31	7.76e-9	N-glycan levels;
LUSC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg25019033	chr10:957182	NA	-0.52	-6.99	-0.36	1.53e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs4706831	0.647	rs9350847	chr6:80889017	C/T	cg08355045	chr6:80787529	NA	0.46	8.01	0.4	1.96e-14	Joint mobility (Beighton score);
LUSC	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg25482853	chr8:67687455	SGK3	1.18	16.97	0.68	5.1e-47	Lung disease severity in cystic fibrosis;
LUSC	cis	rs151234	0.741	rs11644791	chr16:28601186	G/C	cg01378222	chr16:28622494	SULT1A1	-0.64	-8.55	-0.42	4.58e-16	Platelet distribution width;
LUSC	cis	rs2625529	0.689	rs4526973	chr15:72138719	A/G	cg16672083	chr15:72433130	SENP8	-0.48	-8.01	-0.4	1.98e-14	Red blood cell count;
LUSC	cis	rs2976388	1.000	rs2976396	chr8:143764001	A/G	cg17252645	chr8:143867129	LY6D	0.35	6.08	0.32	3.32e-9	Urinary tract infection frequency;
LUSC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25072359	chr17:41440525	NA	0.66	9.25	0.45	2.81e-18	Menopause (age at onset);
LUSC	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-8.41	-0.42	1.24e-15	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7264396	1.000	rs224418	chr20:34142527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.75	-0.35	6.68e-11	Total cholesterol levels;
LUSC	cis	rs6942756	1.000	rs12112374	chr7:128950071	A/G	cg02491457	chr7:128862824	NA	-0.48	-6.63	-0.34	1.32e-10	White matter hyperintensity burden;
LUSC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.49	-7.99	-0.4	2.23e-14	Tonsillectomy;
LUSC	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg14582100	chr15:45693742	SPATA5L1	0.46	8.67	0.43	1.87e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-11.44	-0.53	8.54e-26	Chronic sinus infection;
LUSC	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg24881330	chr22:46731750	TRMU	0.82	7.29	0.37	2.32e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.63	0.86	5.12e-99	Chronic sinus infection;
LUSC	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg04283868	chr2:201171347	SPATS2L	-0.42	-6.17	-0.32	1.99e-9	QT interval;
LUSC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	8.35	0.42	1.86e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25072359	chr17:41440525	NA	0.62	9.02	0.44	1.53e-17	Menopause (age at onset);
LUSC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.29	0.37	2.31e-12	Motion sickness;
LUSC	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.84	13.73	0.6	2.55e-34	Obesity-related traits;
LUSC	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.32	-18.42	-0.71	8.8e-53	Hip circumference adjusted for BMI;
LUSC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg18230493	chr5:56204884	C5orf35	-0.92	-13.72	-0.6	2.86e-34	Initial pursuit acceleration;
LUSC	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	0.89	16.7	0.67	5.82e-46	Heart rate;
LUSC	cis	rs698813	0.763	rs698764	chr2:44573658	T/C	cg00619915	chr2:44497795	NA	-0.39	-5.72	-0.3	2.4e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.48	0.33	3.28e-10	Lung cancer;
LUSC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.84	-16.25	-0.66	3.64e-44	Prudent dietary pattern;
LUSC	cis	rs1403694	0.695	rs1050274	chr3:186435370	G/A	cg12454167	chr3:186435060	KNG1	0.34	8.47	0.42	8.11e-16	Blood protein levels;
LUSC	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg06462663	chr19:18546047	ISYNA1	0.47	7.74	0.39	1.18e-13	Breast cancer;
LUSC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.07	13.24	0.59	1.89e-32	Sexual dysfunction (female);
LUSC	cis	rs259282	0.538	rs6510270	chr19:33114514	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.74	10.75	0.51	2.43e-23	Schizophrenia;
LUSC	cis	rs2067615	0.579	rs7964605	chr12:107205413	C/T	cg15890332	chr12:107067104	RFX4	-0.33	-5.9	-0.31	8.76e-9	Heart rate;
LUSC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24549020	chr5:56110836	MAP3K1	0.5	5.9	0.31	9.09e-9	Initial pursuit acceleration;
LUSC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23158103	chr7:148848205	ZNF398	0.45	7.37	0.37	1.31e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg10172584	chr19:19639581	YJEFN3	-0.49	-5.76	-0.3	1.92e-8	Bipolar disorder;
LUSC	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg21775007	chr8:11205619	TDH	0.78	12.63	0.57	3.63e-30	Retinal vascular caliber;
LUSC	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.96	-0.48	1.22e-20	Schizophrenia;
LUSC	cis	rs3737883	1.000	rs4590732	chr1:203028711	C/G	cg00805880	chr1:203045044	PPFIA4	-0.31	-6.2	-0.32	1.66e-9	Early onset atrial fibrillation;
LUSC	cis	rs7705502	1.000	rs72812850	chr5:173378286	T/G	cg18693985	chr5:173351052	CPEB4	-0.39	-6.02	-0.31	4.5e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18404041	chr3:52824283	ITIH1	-0.48	-8.94	-0.44	2.67e-17	Cognitive function;
LUSC	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg02016764	chr4:38805732	TLR1	-0.53	-5.74	-0.3	2.16e-8	Breast cancer;
LUSC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.55	7.45	0.38	8.11e-13	Lung function (FEV1/FVC);
LUSC	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg23752985	chr2:85803571	VAMP8	0.34	7.14	0.36	5.9e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg23188684	chr11:67383651	NA	0.34	6.01	0.31	4.91e-9	Mean corpuscular volume;
LUSC	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg27411982	chr8:10470053	RP1L1	0.4	6.36	0.33	6.46e-10	Retinal vascular caliber;
LUSC	cis	rs4566357	0.615	rs2396445	chr2:227917726	C/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.19	-0.41	5.78e-15	Coronary artery disease;
LUSC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02475777	chr4:1388615	CRIPAK	-0.58	-8.58	-0.43	3.56e-16	Obesity-related traits;
LUSC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg11843238	chr5:131593191	PDLIM4	0.46	7.94	0.4	3.15e-14	Acylcarnitine levels;
LUSC	cis	rs137603	0.602	rs137654	chr22:39732413	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.5	-7.91	-0.4	3.7e-14	Primary biliary cholangitis;
LUSC	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg18196295	chr10:418757	DIP2C	0.38	6.05	0.31	3.84e-9	Psychosis in Alzheimer's disease;
LUSC	trans	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg11887960	chr12:57824829	NA	0.53	6.56	0.34	2.03e-10	Obesity-related traits;
LUSC	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg17467752	chr17:38218738	THRA	0.41	5.69	0.3	2.73e-8	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg02038168	chr22:39784481	NA	-0.49	-8.2	-0.41	5.38e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg06784218	chr1:46089804	CCDC17	0.54	10.88	0.51	8.41e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg08975724	chr8:8085496	FLJ10661	0.44	6.39	0.33	5.57e-10	Myopia (pathological);
LUSC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg18404041	chr3:52824283	ITIH1	-0.54	-8.48	-0.42	7.41e-16	Bipolar disorder;
LUSC	cis	rs62400317	0.826	rs12203466	chr6:45330263	T/A	cg20913747	chr6:44695427	NA	-0.48	-7.8	-0.39	7.82e-14	Total body bone mineral density;
LUSC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg09436375	chr6:42928200	GNMT	-0.29	-6.58	-0.34	1.83e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg26924012	chr15:45694286	SPATA5L1	0.77	11.93	0.55	1.43e-27	Glomerular filtration rate;
LUSC	cis	rs10979	1.000	rs3748072	chr6:143889757	C/T	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg15485101	chr11:133734466	NA	-0.37	-7.06	-0.36	9.75e-12	Childhood ear infection;
LUSC	cis	rs7605827	0.930	rs11681044	chr2:15717058	G/A	cg19274914	chr2:15703543	NA	0.45	8.55	0.42	4.47e-16	Educational attainment (years of education);
LUSC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg03948781	chr1:205179583	DSTYK	0.3	5.74	0.3	2.08e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.15	-0.49	2.8e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.51	-8.06	-0.4	1.37e-14	Melanoma;
LUSC	cis	rs4789693	0.679	rs7217570	chr17:80379332	G/T	cg04308225	chr17:80449738	NA	-0.41	-6.35	-0.33	6.92e-10	Glucocorticoid-induced osteonecrosis;
LUSC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-13.72	-0.6	2.75e-34	Total body bone mineral density;
LUSC	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg06484146	chr7:12443880	VWDE	-0.68	-7.08	-0.36	8.67e-12	Coronary artery disease;
LUSC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg03526776	chr6:41159608	TREML2	0.34	6.53	0.34	2.51e-10	Alzheimer's disease (late onset);
LUSC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.06e-12	Motion sickness;
LUSC	cis	rs4363385	0.818	rs2711	chr1:153005156	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.43e-12	Inflammatory skin disease;
LUSC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	15.37	0.64	1.09e-40	Platelet count;
LUSC	cis	rs1775715	0.835	rs113450267	chr10:32223728	G/A	cg26784012	chr10:32216390	ARHGAP12	0.41	6.76	0.35	6.06e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12292205	chr6:26970375	C6orf41	-0.56	-6.6	-0.34	1.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.12	0.32	2.59e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs800082	1.000	rs1007564	chr3:144311843	C/T	cg24215973	chr2:240111563	HDAC4	-0.47	-7.24	-0.37	3.08e-12	Smoking behavior;
LUSC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.76	-0.43	1.02e-16	Lung cancer;
LUSC	cis	rs12421382	0.659	rs1439511	chr11:109392839	G/T	cg16359550	chr11:109292809	C11orf87	-0.41	-6.42	-0.33	4.67e-10	Schizophrenia;
LUSC	cis	rs62400317	0.762	rs12198308	chr6:44911886	C/T	cg20913747	chr6:44695427	NA	-0.48	-7.4	-0.38	1.09e-12	Total body bone mineral density;
LUSC	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs2742234	1.000	rs1864399	chr10:43610455	T/C	cg02780029	chr10:43622663	RET	-0.34	-6.22	-0.32	1.44e-9	Hirschsprung disease;
LUSC	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.64	-0.43	2.35e-16	Joint mobility (Beighton score);
LUSC	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg01966878	chr4:90757139	SNCA	-0.36	-6.26	-0.32	1.16e-9	Dementia with Lewy bodies;
LUSC	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg10840412	chr1:235813424	GNG4	0.57	7.34	0.37	1.61e-12	Bipolar disorder;
LUSC	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg24558204	chr6:135376177	HBS1L	0.58	8.83	0.44	5.98e-17	Red blood cell count;
LUSC	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.68	12.94	0.58	2.53e-31	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7681440	0.583	rs1551980	chr4:90774724	G/A	cg06632027	chr4:90757378	SNCA	-0.37	-5.75	-0.3	1.99e-8	Dementia with Lewy bodies;
LUSC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg06713675	chr4:122721982	EXOSC9	-0.72	-12.59	-0.57	5.26e-30	Type 2 diabetes;
LUSC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-11.2	-0.52	6.05e-25	Schizophrenia;
LUSC	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg22782873	chr19:19639568	YJEFN3	0.49	5.81	0.3	1.48e-8	Bipolar disorder;
LUSC	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.81	0.3	1.49e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	trans	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg06521331	chr12:34319734	NA	-0.41	-6.39	-0.33	5.5e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06634786	chr22:41940651	POLR3H	0.48	5.96	0.31	6.59e-9	Cannabis dependence symptom count;
LUSC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.28	-0.49	1.04e-21	Platelet count;
LUSC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg06784218	chr1:46089804	CCDC17	0.48	9.58	0.46	2.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg27661571	chr11:113659931	NA	-0.69	-7.91	-0.4	3.77e-14	Hip circumference adjusted for BMI;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03344030	chr19:48673649	LIG1	-0.49	-5.95	-0.31	6.79e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.98	-16.38	-0.67	1.14e-44	Coronary artery disease;
LUSC	cis	rs34734847	0.766	rs3794214	chr12:121168245	C/T	cg27246729	chr12:121163418	ACADS	-0.42	-6.63	-0.34	1.38e-10	Mean corpuscular volume;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg18538332	chr22:24372958	LOC391322	-0.39	-7.19	-0.37	4.22e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.93	-0.35	2.22e-11	Joint mobility (Beighton score);
LUSC	trans	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg26043149	chr18:55253948	FECH	-0.45	-6.93	-0.35	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg04450456	chr4:17643702	FAM184B	0.39	6.52	0.34	2.63e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24583770	chr6:163836718	QKI	-0.46	-6.94	-0.36	2.03e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg12552261	chr5:112820674	MCC	-0.44	-6.99	-0.36	1.49e-11	Type 2 diabetes;
LUSC	cis	rs7107174	1.000	rs10899485	chr11:78072383	C/T	cg02023728	chr11:77925099	USP35	-0.42	-6.29	-0.33	1.01e-9	Testicular germ cell tumor;
LUSC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-11.64	-0.54	1.6e-26	Systemic lupus erythematosus;
LUSC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg00343986	chr7:65444356	GUSB	-0.48	-7.29	-0.37	2.19e-12	Aortic root size;
LUSC	cis	rs7607369	0.536	rs6436089	chr2:219668813	A/G	cg02176678	chr2:219576539	TTLL4	-0.52	-9.15	-0.45	5.72e-18	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg08468370	chr19:39903678	PLEKHG2	0.41	6.25	0.32	1.28e-9	Schizophrenia;
LUSC	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.25	0.52	4.11e-25	Eye color traits;
LUSC	cis	rs7605827	0.930	rs2058868	chr2:15679609	A/T	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.77e-16	Educational attainment (years of education);
LUSC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg06454157	chr6:167490870	NA	-0.27	-6.64	-0.34	1.28e-10	Primary biliary cholangitis;
LUSC	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg24375607	chr4:120327624	NA	0.79	11.91	0.55	1.72e-27	Corneal astigmatism;
LUSC	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg04117972	chr1:227635322	NA	0.57	6.58	0.34	1.78e-10	Major depressive disorder;
LUSC	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.65	-9.71	-0.47	8.79e-20	Glaucoma (primary open-angle);
LUSC	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg08807101	chr21:30365312	RNF160	-0.68	-10.94	-0.51	5.08e-24	Pancreatic cancer;
LUSC	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg14689365	chr7:158441557	NCAPG2	-0.43	-6.03	-0.31	4.25e-9	Height;
LUSC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg14196790	chr5:131705035	SLC22A5	0.48	8.18	0.41	6.2e-15	Blood metabolite levels;
LUSC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	14.04	0.61	1.64e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.56	-0.38	3.86e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	13.26	0.59	1.6e-32	Monocyte percentage of white cells;
LUSC	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg19812747	chr11:111475976	SIK2	0.53	7.37	0.37	1.34e-12	Primary sclerosing cholangitis;
LUSC	cis	rs4889911	0.544	rs2587498	chr17:77830737	G/A	cg00646381	chr17:77835854	NA	0.6	9.75	0.47	6.38e-20	Electroencephalogram traits;
LUSC	cis	rs7712401	0.601	rs415534	chr5:122325301	C/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.48	-0.46	4.83e-19	Mean platelet volume;
LUSC	cis	rs2708977	0.965	rs13019986	chr2:97243058	C/T	cg01950434	chr2:97203154	ARID5A	0.57	8.8	0.43	7.21e-17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11645453	chr3:52864694	ITIH4	0.34	7.87	0.4	5.04e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18252515	chr7:66147081	NA	-0.57	-7.91	-0.4	3.93e-14	Corneal structure;
LUSC	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	11.73	0.54	7.4e-27	Mean corpuscular hemoglobin;
LUSC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12310025	chr6:25882481	NA	-0.47	-8.17	-0.41	6.38e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg01420254	chr6:26195488	NA	0.71	7.5	0.38	5.86e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg08645402	chr16:4508243	NA	0.52	8.5	0.42	6.45e-16	Schizophrenia;
LUSC	cis	rs1712517	0.588	rs12220267	chr10:105075712	C/T	cg04362960	chr10:104952993	NT5C2	-0.5	-6.66	-0.34	1.1e-10	Migraine;
LUSC	trans	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-6.57	-0.34	1.98e-10	Monocyte count;
LUSC	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.2e-28	Corneal astigmatism;
LUSC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22496380	chr5:211416	CCDC127	0.67	8.06	0.4	1.34e-14	Breast cancer;
LUSC	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12541635	0.902	rs62525696	chr8:106968703	C/T	cg10147462	chr8:107024639	NA	0.55	9.55	0.46	2.83e-19	Age of smoking initiation;
LUSC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.19	-0.32	1.79e-9	Total body bone mineral density;
LUSC	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg23752985	chr2:85803571	VAMP8	0.33	7.06	0.36	9.49e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg03233332	chr7:66118400	NA	-0.4	-5.92	-0.31	8.15e-9	Aortic root size;
LUSC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg23102388	chr7:1867652	MAD1L1	-0.31	-5.93	-0.31	7.76e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs2262909	0.849	rs2666447	chr19:22132868	T/A	cg17074339	chr11:11642133	GALNTL4	-0.41	-6.21	-0.32	1.54e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.24	0.45	3.04e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg07952391	chr2:88470173	THNSL2	0.75	6.68	0.34	1.03e-10	Plasma clusterin levels;
LUSC	cis	rs10892173	1.000	rs10892173	chr11:117672561	C/T	cg21640587	chr11:117668038	DSCAML1	0.38	5.75	0.3	2.05e-8	Myopia;
LUSC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	7.26	0.37	2.75e-12	Colorectal cancer;
LUSC	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.28	-0.41	3.02e-15	Mood instability;
LUSC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg11062466	chr8:58055876	NA	0.72	8.93	0.44	2.94e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.41	-0.38	1.04e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg04546413	chr19:29218101	NA	0.59	7.26	0.37	2.72e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg25039879	chr17:56429692	SUPT4H1	0.69	9.08	0.44	9.99e-18	Cognitive test performance;
LUSC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.49	8.12	0.41	9.06e-15	IgG glycosylation;
LUSC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg02018176	chr4:1364513	KIAA1530	0.5	8.54	0.42	4.76e-16	Obesity-related traits;
LUSC	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg27147174	chr7:100797783	AP1S1	-0.64	-10.29	-0.49	9.09e-22	Life satisfaction;
LUSC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.86	-18.08	-0.7	1.89e-51	Intelligence (multi-trait analysis);
LUSC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-1.07	-26.09	-0.82	1.35e-82	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7191700	0.836	rs12708722	chr16:11428905	T/A	cg00044050	chr16:11439710	C16orf75	0.57	8.34	0.42	1.98e-15	Multiple sclerosis;
LUSC	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg26384229	chr12:38710491	ALG10B	0.71	11.22	0.52	5.05e-25	Morning vs. evening chronotype;
LUSC	cis	rs524023	0.957	rs538737	chr11:64355772	C/G	cg19131476	chr11:64387923	NRXN2	0.36	9.45	0.46	5.91e-19	Urate levels in obese individuals;
LUSC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg27398817	chr8:82754497	SNX16	-0.66	-8.42	-0.42	1.13e-15	Diastolic blood pressure;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01382936	chr19:44716836	ZNF227	-0.41	-6.17	-0.32	1.99e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08045932	chr20:61659980	NA	0.59	10.39	0.49	4.41e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.47e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg14993813	chr1:46806288	NSUN4	-0.55	-7.41	-0.38	1.07e-12	Menopause (age at onset);
LUSC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg06096015	chr1:231504339	EGLN1	0.57	9.98	0.48	1.08e-20	Hemoglobin concentration;
LUSC	cis	rs7011049	1.000	rs11997774	chr8:53833370	T/A	cg26025543	chr8:53854495	NA	0.51	6.28	0.32	1.05e-9	Systolic blood pressure;
LUSC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg00431813	chr7:1051703	C7orf50	-0.45	-7.25	-0.37	2.92e-12	Longevity;Endometriosis;
LUSC	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.71	-12.37	-0.56	3.47e-29	White blood cell count (basophil);
LUSC	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.37	-7.0	-0.36	1.41e-11	Axial length;
LUSC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg11766577	chr21:47581405	C21orf56	-0.48	-7.16	-0.36	5.32e-12	Testicular germ cell tumor;
LUSC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.1	16.88	0.68	1.19e-46	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.26e-9	Life satisfaction;
LUSC	cis	rs9650657	0.740	rs12676417	chr8:10668634	C/T	cg27411982	chr8:10470053	RP1L1	0.36	5.88	0.31	1.01e-8	Neuroticism;
LUSC	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg05110241	chr16:68378359	PRMT7	-0.56	-6.39	-0.33	5.45e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg05373962	chr22:49881684	NA	-0.45	-11.03	-0.52	2.43e-24	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg27539214	chr16:67997921	SLC12A4	-0.39	-5.97	-0.31	5.99e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg22705602	chr4:152727874	NA	-0.3	-6.11	-0.32	2.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.09	-0.32	3.05e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.88	14.28	0.62	1.99e-36	Coronary artery disease;
LUSC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.11	-0.58	6e-32	Platelet count;
LUSC	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-10.4	-0.49	3.86e-22	Migraine;Coronary artery disease;
LUSC	cis	rs61332075	0.518	rs72994950	chr2:239422993	T/C	cg18131467	chr2:239335373	ASB1	-0.7	-6.22	-0.32	1.49e-9	Lung function (FEV1/FVC);
LUSC	cis	rs4132509	1.000	rs10754807	chr1:243804158	G/A	cg21452805	chr1:244014465	NA	0.52	6.11	0.32	2.81e-9	RR interval (heart rate);
LUSC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02034447	chr16:89574710	SPG7	0.41	6.05	0.31	3.84e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs4363385	0.510	rs7532166	chr1:153046851	C/G	cg00922841	chr1:152955080	SPRR1A	-0.36	-6.07	-0.32	3.4e-9	Inflammatory skin disease;
LUSC	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05901451	chr6:126070800	HEY2	0.58	8.67	0.43	1.84e-16	Endometrial cancer;
LUSC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10802521	chr3:52805072	NEK4	-0.55	-8.98	-0.44	2.02e-17	Bipolar disorder;
LUSC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg06494592	chr3:125709126	NA	-0.5	-5.75	-0.3	2.04e-8	Blood pressure (smoking interaction);
LUSC	cis	rs909341	0.909	rs1758205	chr20:62355756	G/A	cg09650180	chr20:62225654	GMEB2	-0.47	-6.11	-0.32	2.75e-9	Atopic dermatitis;
LUSC	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg05347473	chr6:146136440	FBXO30	0.52	8.69	0.43	1.64e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7605827	0.930	rs6728145	chr2:15573489	C/G	cg19274914	chr2:15703543	NA	0.47	8.93	0.44	2.86e-17	Educational attainment (years of education);
LUSC	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg00857998	chr1:205179979	DSTYK	0.63	9.74	0.47	7.01e-20	Red blood cell count;
LUSC	cis	rs738321	0.723	rs9622726	chr22:38506688	A/G	cg25457927	chr22:38595422	NA	-0.33	-6.39	-0.33	5.43e-10	Breast cancer;
LUSC	cis	rs11209185	0.509	rs9436791	chr1:68452857	A/C	cg22082780	chr1:68452167	NA	0.48	8.79	0.43	8.09e-17	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg21724239	chr8:58056113	NA	0.85	8.56	0.42	4.27e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg00898013	chr13:113819073	PROZ	-0.58	-8.4	-0.42	1.3e-15	Platelet distribution width;
LUSC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg25036284	chr2:26402008	FAM59B	-0.75	-10.98	-0.52	3.59e-24	Gut microbiome composition (summer);
LUSC	cis	rs6456156	0.774	rs2022001	chr6:167529509	C/T	cg07741184	chr6:167504864	NA	-0.36	-6.34	-0.33	7.42e-10	Primary biliary cholangitis;
LUSC	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	1.0	15.01	0.63	2.71e-39	Gout;Urate levels;Serum uric acid levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09393705	chr13:73356207	PIBF1;DIS3	-0.41	-6.06	-0.31	3.61e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg20135002	chr11:47629003	NA	-0.52	-8.1	-0.41	1.04e-14	Subjective well-being;
LUSC	cis	rs701145	0.537	rs1713842	chr3:153786243	T/A	cg17054900	chr3:154042577	DHX36	-0.64	-6.69	-0.34	9.46e-11	Coronary artery disease;
LUSC	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.8	0.73	3e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg05283184	chr6:79620031	NA	-0.57	-12.04	-0.55	5.67e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.56	-0.42	4.24e-16	Total cholesterol levels;
LUSC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.87	0.4	4.97e-14	Prudent dietary pattern;
LUSC	cis	rs11039100	1.000	rs35863965	chr11:5824256	G/T	cg05234568	chr11:5960015	NA	-0.51	-5.72	-0.3	2.35e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs11608355	0.515	rs11611011	chr12:109936948	C/T	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs16937	0.711	rs6675633	chr1:205100480	G/A	cg00857998	chr1:205179979	DSTYK	0.46	6.56	0.34	1.99e-10	Schizophrenia;
LUSC	cis	rs11610422	1.000	rs12824070	chr12:31414280	C/T	cg14306366	chr12:31406441	NA	-0.51	-6.27	-0.32	1.09e-9	Coronary artery disease;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.28	-7.01	-0.36	1.3e-11	Lymphocyte counts;
LUSC	cis	rs72829446	0.530	rs4796421	chr17:7379650	C/T	cg02795151	chr17:7402630	POLR2A	0.57	6.78	0.35	5.34e-11	Androgen levels;
LUSC	cis	rs16854884	1.000	rs16854884	chr3:143778708	A/C	cg06585982	chr3:143692056	C3orf58	0.47	6.61	0.34	1.56e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg08601574	chr20:25228251	PYGB	0.41	6.18	0.32	1.91e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg14458575	chr2:238380390	NA	0.68	12.06	0.55	4.8e-28	Prostate cancer;
LUSC	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg24733560	chr20:60626293	TAF4	0.36	5.95	0.31	6.73e-9	Body mass index;
LUSC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs7178375	1.000	rs28881289	chr15:31223955	A/G	cg04373760	chr16:53404718	NA	0.63	8.78	0.43	8.35e-17	Hypertriglyceridemia;
LUSC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.2	-0.32	1.7e-9	Sudden cardiac arrest;
LUSC	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.24	-0.41	3.91e-15	Body mass index;
LUSC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg19318889	chr4:1322082	MAEA	-0.47	-7.62	-0.38	2.69e-13	Obesity-related traits;
LUSC	cis	rs6084875	0.840	rs2077519	chr20:4720750	A/G	cg26097573	chr20:4721490	PRNT	-0.31	-5.75	-0.3	2.03e-8	Systemic lupus erythematosus;
LUSC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.51	-7.5	-0.38	5.92e-13	Gut microbiome composition (summer);
LUSC	cis	rs1568889	1.000	rs12803655	chr11:28060785	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.51	0.46	3.95e-19	Bipolar disorder;
LUSC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg03676636	chr4:99064102	C4orf37	0.29	6.37	0.33	6.31e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg12091567	chr17:66097778	LOC651250	-0.75	-9.43	-0.46	6.89e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs17227506	0.704	rs13263028	chr8:13453490	C/A	cg03566418	chr8:13424080	C8orf48	0.4	6.02	0.31	4.53e-9	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg06917634	chr15:78832804	PSMA4	0.65	10.55	0.5	1.23e-22	Sudden cardiac arrest;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14671004	chr19:39227758	CAPN12	0.45	6.99	0.36	1.52e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg00074818	chr8:8560427	CLDN23	0.58	9.78	0.47	4.93e-20	Obesity-related traits;
LUSC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg05025164	chr4:1340916	KIAA1530	0.46	7.07	0.36	9.08e-12	Obesity-related traits;
LUSC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg07716408	chr11:68623521	NA	-0.29	-5.68	-0.3	2.97e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.27e-20	Coronary artery disease;
LUSC	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-15.34	-0.64	1.44e-40	Exhaled nitric oxide output;
LUSC	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.81	-14.09	-0.61	9.99e-36	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs907612	0.638	rs907613	chr11:1874292	G/A	cg05305434	chr11:1874049	LSP1	0.34	6.17	0.32	1.95e-9	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs12313068	0.709	rs10849698	chr12:110504798	C/G	cg12870014	chr12:110450643	ANKRD13A	0.66	9.66	0.47	1.25e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg05966235	chr16:28915196	ATP2A1	0.32	5.7	0.3	2.59e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg16339924	chr4:17578868	LAP3	0.67	10.34	0.49	6.19e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	9.51	0.46	4.03e-19	Lung cancer in ever smokers;
LUSC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.34	-0.49	6.17e-22	Gut microbiome composition (summer);
LUSC	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg24130564	chr14:104152367	KLC1	-0.54	-7.86	-0.4	5.23e-14	Body mass index;
LUSC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.72	-9.88	-0.48	2.35e-20	Gut microbiome composition (summer);
LUSC	cis	rs75920871	0.702	rs7946869	chr11:116963312	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.83	-0.3	1.29e-8	Subjective well-being;
LUSC	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg24631222	chr15:78858424	CHRNA5	0.61	8.54	0.42	4.97e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg18479299	chr3:125709523	NA	-0.5	-5.67	-0.3	3.03e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg03609598	chr5:56110824	MAP3K1	-0.42	-5.96	-0.31	6.37e-9	Initial pursuit acceleration;
LUSC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg27121462	chr16:89883253	FANCA	0.58	9.47	0.46	5.2e-19	Vitiligo;
LUSC	cis	rs859767	0.741	rs4954155	chr2:135383504	T/C	cg12500956	chr2:135428796	TMEM163	-0.28	-6.23	-0.32	1.42e-9	Neuroticism;
LUSC	trans	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.0	0.44	1.79e-17	Mean corpuscular volume;
LUSC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.28	0.45	2.15e-18	Prudent dietary pattern;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02690643	chr2:139259163	SPOPL	-0.46	-7.14	-0.36	5.71e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg12573674	chr2:1569213	NA	-0.55	-6.13	-0.32	2.52e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg22166914	chr1:53195759	ZYG11B	0.69	11.53	0.53	4.03e-26	Monocyte count;
LUSC	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.49	-9.35	-0.46	1.34e-18	Axial length;
LUSC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg16339924	chr4:17578868	LAP3	0.51	7.83	0.39	6.63e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg11494091	chr17:61959527	GH2	0.4	7.03	0.36	1.18e-11	Height;
LUSC	cis	rs9341808	0.718	rs3805920	chr6:80892745	T/C	cg08355045	chr6:80787529	NA	0.58	10.07	0.48	5.31e-21	Sitting height ratio;
LUSC	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg04920474	chr2:44395004	PPM1B	0.6	7.83	0.39	6.63e-14	Height;
LUSC	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg11473876	chr11:109292803	C11orf87	0.37	5.67	0.3	3.06e-8	Schizophrenia;
LUSC	trans	rs72674100	1.000	rs2002117	chr4:97992122	C/T	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg14458575	chr2:238380390	NA	0.71	8.53	0.42	5.19e-16	Prostate cancer;
LUSC	cis	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg05340658	chr4:99064831	C4orf37	0.44	6.92	0.35	2.39e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg10792982	chr14:105748885	BRF1	0.49	8.53	0.42	5.15e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg25457927	chr22:38595422	NA	-0.35	-6.82	-0.35	4.17e-11	Cutaneous nevi;
LUSC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg23719950	chr11:63933701	MACROD1	-0.58	-7.72	-0.39	1.33e-13	Mean platelet volume;
LUSC	cis	rs273573	1.000	rs273571	chr11:30911936	C/G	cg14844989	chr11:31128820	NA	0.35	5.68	0.3	2.87e-8	Total body bone mineral density;
LUSC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs3760982	1.000	rs11665924	chr19:44286982	G/A	cg11993925	chr19:44307056	LYPD5	0.28	6.25	0.32	1.25e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs2387326	0.717	rs12266400	chr10:129944536	C/G	cg16087940	chr10:129947807	NA	0.4	6.15	0.32	2.16e-9	Select biomarker traits;
LUSC	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	6.25	0.32	1.26e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs9807989	0.765	rs6704565	chr2:102967431	G/A	cg09003973	chr2:102972529	NA	0.45	6.19	0.32	1.8e-9	Asthma;
LUSC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg26408565	chr15:76604113	ETFA	-0.51	-8.18	-0.41	5.95e-15	Blood metabolite levels;
LUSC	cis	rs2729354	1.000	rs2848630	chr11:57356907	T/C	cg24343310	chr11:57249947	NA	0.36	6.47	0.33	3.4e-10	Blood protein levels;
LUSC	cis	rs2742234	0.656	rs1864400	chr10:43610366	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.45	-7.52	-0.38	5.21e-13	Hirschsprung disease;
LUSC	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg20573242	chr4:122745356	CCNA2	-0.43	-6.25	-0.32	1.25e-9	Type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg21724239	chr8:58056113	NA	0.58	6.7	0.34	8.97e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg05489143	chr3:40498640	RPL14	0.41	7.29	0.37	2.22e-12	Triglycerides;
LUSC	trans	rs10432489	0.708	rs10178270	chr2:181773395	G/C	cg07312954	chr1:153914453	DENND4B	-0.83	-6.07	-0.32	3.54e-9	QT interval;
LUSC	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg27539214	chr16:67997921	SLC12A4	-0.54	-7.43	-0.38	9e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10904908	0.862	rs359279	chr10:17319115	C/T	cg01003015	chr10:17271136	VIM	0.4	5.89	0.31	9.43e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg05283184	chr6:79620031	NA	-0.58	-12.21	-0.56	1.39e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	10.14	0.49	3.14e-21	Exhaled nitric oxide output;
LUSC	cis	rs7202877	0.706	rs40217	chr16:75480066	C/A	cg03315344	chr16:75512273	CHST6	-0.45	-6.3	-0.33	9.63e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg12927641	chr6:109611667	NA	-0.34	-5.77	-0.3	1.81e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg26373071	chr5:1325741	CLPTM1L	0.39	7.06	0.36	9.72e-12	Lung cancer;
LUSC	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg11019008	chr10:131425282	MGMT	0.47	7.06	0.36	9.87e-12	Response to temozolomide;
LUSC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.77	0.3	1.77e-8	Menopause (age at onset);
LUSC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg12560992	chr17:57184187	TRIM37	-0.85	-15.08	-0.64	1.45e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs68149176	0.772	rs997762	chr16:87879562	C/A	cg03553613	chr16:87879502	SLC7A5	-0.43	-5.66	-0.3	3.27e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6901250	0.655	rs636252	chr6:117157774	A/G	cg12892004	chr6:117198278	RFX6	-0.4	-7.57	-0.38	3.59e-13	C-reactive protein levels;
LUSC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-1.05	-23.43	-0.79	1.68e-72	IgG glycosylation;
LUSC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-6.26	-0.32	1.17e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs666930	0.967	rs637868	chr1:120257110	A/G	cg19096424	chr1:120255104	PHGDH	0.4	6.25	0.32	1.22e-9	Breast cancer;
LUSC	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.38	6.26	0.32	1.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg16359550	chr11:109292809	C11orf87	0.48	8.13	0.41	8.71e-15	Schizophrenia;
LUSC	cis	rs9323205	0.677	rs61987261	chr14:51723879	G/A	cg23942311	chr14:51606299	NA	-0.39	-7.25	-0.37	2.92e-12	Cancer;
LUSC	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg08508325	chr11:3079039	CARS	0.38	8.46	0.42	8.77e-16	Calcium levels;
LUSC	trans	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg22153745	chr1:153894579	GATAD2B	-0.54	-8.34	-0.42	2.04e-15	Total cholesterol levels;
LUSC	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.88	0.4	4.64e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-10.38	-0.49	4.45e-22	Platelet distribution width;
LUSC	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.21	-0.32	1.56e-9	Retinal vascular caliber;
LUSC	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg01444801	chr10:135216882	MTG1	-0.51	-6.75	-0.35	6.46e-11	Systemic lupus erythematosus;
LUSC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.84	15.34	0.64	1.48e-40	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02176678	chr2:219576539	TTLL4	0.64	11.85	0.54	2.83e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4478858	0.735	rs6670067	chr1:31842947	C/T	cg00250761	chr1:31883323	NA	-0.35	-8.32	-0.41	2.22e-15	Alcohol dependence;
LUSC	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg25214090	chr10:38739885	LOC399744	-0.55	-7.95	-0.4	2.84e-14	Corneal astigmatism;
LUSC	cis	rs3772130	0.962	rs17742508	chr3:121559895	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	9.91	0.48	1.88e-20	Cognitive performance;
LUSC	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06634786	chr22:41940651	POLR3H	-0.48	-5.75	-0.3	2.04e-8	Vitiligo;
LUSC	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.86	-0.44	4.89e-17	Body mass index;
LUSC	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.56	-10.76	-0.51	2.29e-23	Sense of smell;
LUSC	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.54	-8.32	-0.41	2.34e-15	Cognitive test performance;
LUSC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg10117171	chr1:25599238	RHD	-0.38	-5.82	-0.3	1.36e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg00409905	chr10:38381863	ZNF37A	0.35	6.12	0.32	2.64e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg22709100	chr7:91322751	NA	0.39	5.8	0.3	1.56e-8	Breast cancer;
LUSC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	5.67	0.3	3.05e-8	Rheumatoid arthritis;
LUSC	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg05738196	chr6:26577821	NA	0.79	14.91	0.63	6.82e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs9311676	0.632	rs11130637	chr3:58405573	C/G	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.1e-10	Systemic lupus erythematosus;
LUSC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg00074818	chr8:8560427	CLDN23	0.58	9.81	0.47	3.98e-20	Obesity-related traits;
LUSC	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg01528321	chr10:82214614	TSPAN14	0.86	13.08	0.58	7.25e-32	Post bronchodilator FEV1;
LUSC	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	0.93	13.38	0.59	5.54e-33	Inflammatory bowel disease;
LUSC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.94	0.36	2.01e-11	Tonsillectomy;
LUSC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11764359	chr7:65958608	NA	0.68	10.96	0.51	4.39e-24	Aortic root size;
LUSC	cis	rs2070433	0.904	rs11701571	chr21:47963149	A/G	cg12379764	chr21:47803548	PCNT	0.64	8.1	0.41	1.06e-14	Lymphocyte counts;
LUSC	cis	rs9682041	0.877	rs10755126	chr3:170071694	C/G	cg11886554	chr3:170076028	SKIL	-0.73	-9.1	-0.45	8.39e-18	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LUSC	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg00484396	chr16:3507460	NAT15	0.48	7.26	0.37	2.78e-12	Body mass index (adult);
LUSC	cis	rs6692729	0.901	rs4653470	chr1:227082726	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.5	-7.06	-0.36	9.96e-12	Electrodermal activity;
LUSC	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg26924012	chr15:45694286	SPATA5L1	1.13	19.69	0.73	7.64e-58	Homoarginine levels;
LUSC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg02569458	chr12:86230093	RASSF9	-0.5	-8.56	-0.42	4.06e-16	Major depressive disorder;
LUSC	cis	rs17095355	1.000	rs9630101	chr10:111738451	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.57	-7.36	-0.37	1.43e-12	Biliary atresia;
LUSC	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg05673287	chr15:77411982	SGK269	-0.43	-6.89	-0.35	2.76e-11	Type 2 diabetes;
LUSC	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.02	0.31	4.61e-9	Neuroticism;
LUSC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg05805236	chr11:65401703	PCNXL3	-0.56	-8.86	-0.44	4.89e-17	Acne (severe);
LUSC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg12412775	chr1:25698385	RHCE	-0.29	-5.94	-0.31	7.29e-9	Erythrocyte sedimentation rate;
LUSC	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg22491629	chr6:157744540	C6orf35	-0.91	-10.85	-0.51	1.06e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs17253792	0.730	rs77079997	chr14:56155250	A/G	cg01858014	chr14:56050164	KTN1	-0.73	-6.26	-0.32	1.18e-9	Putamen volume;
LUSC	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg04691961	chr3:161091175	C3orf57	-0.35	-6.11	-0.32	2.74e-9	Morning vs. evening chronotype;
LUSC	trans	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.72	0.39	1.39e-13	Ulcerative colitis;
LUSC	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg14458575	chr2:238380390	NA	0.68	11.58	0.54	2.63e-26	Prostate cancer;
LUSC	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.4	5.98	0.31	5.85e-9	Schizophrenia;
LUSC	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-10.94	-0.51	5.0600000000000004e-24	Heart rate;
LUSC	cis	rs9362426	1.000	rs173334	chr6:88080223	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	6.18	0.32	1.9e-9	Depressive episodes in bipolar disorder;
LUSC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.36	0.56	3.74e-29	Cognitive test performance;
LUSC	cis	rs73206853	0.563	rs7968913	chr12:111138558	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	6.64	0.34	1.29e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7589342	0.929	rs2060036	chr2:106436101	G/A	cg14210321	chr2:106509881	NCK2	-0.55	-8.15	-0.41	7.61e-15	Addiction;
LUSC	cis	rs7582720	1.000	rs72936882	chr2:203794439	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg24006582	chr15:45444508	DUOX1	-0.6	-8.77	-0.43	9.28e-17	Uric acid levels;
LUSC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg03351412	chr1:154909251	PMVK	-0.51	-7.64	-0.39	2.28e-13	Prostate cancer;
LUSC	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.12	-0.41	8.92e-15	Menopause (age at onset);
LUSC	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.67	-10.52	-0.5	1.46e-22	Morning vs. evening chronotype;
LUSC	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg03929089	chr4:120376271	NA	0.74	6.91	0.35	2.4e-11	Axial length;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24201716	chr10:115933917	C10orf118;MIR2110	-0.4	-6.13	-0.32	2.5e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-17.18	-0.68	7.43e-48	Body mass index;
LUSC	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.46	6.32	0.33	8.54e-10	Fear of minor pain;
LUSC	cis	rs4588572	0.601	rs1529500	chr5:77721643	C/T	cg11547950	chr5:77652471	NA	-0.55	-7.91	-0.4	3.82e-14	Triglycerides;
LUSC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg15691649	chr6:25882328	NA	0.5	7.52	0.38	5.12e-13	Blood metabolite levels;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13770088	chr11:32851361	PRRG4	-0.39	-5.96	-0.31	6.28e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.04	0.31	4.08e-9	Retinal vascular caliber;
LUSC	trans	rs3942852	0.955	rs1503190	chr11:48117873	A/G	cg15704280	chr7:45808275	SEPT13	-0.54	-6.26	-0.32	1.22e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg13660082	chr14:53194042	PSMC6	-0.79	-6.95	-0.36	1.97e-11	Alzheimer's disease (late onset);
LUSC	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg13575925	chr12:9217583	LOC144571	0.35	6.43	0.33	4.51e-10	Sjögren's syndrome;
LUSC	trans	rs877282	0.898	rs12356744	chr10:757477	G/C	cg22713356	chr15:30763199	NA	1.03	13.61	0.6	7.56e-34	Uric acid levels;
LUSC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	0.93	15.77	0.65	2.76e-42	Menopause (age at onset);
LUSC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16787284	chr2:242255278	SEPT2;HDLBP	-0.42	-6.16	-0.32	2.06e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2274273	0.837	rs56949365	chr14:55790078	T/C	cg04306507	chr14:55594613	LGALS3	0.54	11.81	0.54	3.98e-27	Protein biomarker;
LUSC	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06002616	chr8:101225028	SPAG1	0.44	7.26	0.37	2.71e-12	Atrioventricular conduction;
LUSC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.85	-0.3	1.15e-8	Extrinsic epigenetic age acceleration;
LUSC	trans	rs62344088	1.000	rs7715867	chr5:129059	C/T	cg11454300	chr2:2256402	MYT1L	0.75	6.03	0.31	4.35e-9	Asthma (childhood onset);
LUSC	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.4	6.35	0.33	6.88e-10	Cystic fibrosis severity;
LUSC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg06221963	chr1:154839813	KCNN3	-0.63	-14.54	-0.62	1.83e-37	Prostate cancer;
LUSC	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg26566898	chr11:117069891	TAGLN	0.45	7.42	0.38	9.69e-13	Blood protein levels;
LUSC	cis	rs7712401	0.623	rs30057	chr5:122298118	C/T	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg13010199	chr12:38710504	ALG10B	0.42	6.11	0.32	2.75e-9	Morning vs. evening chronotype;
LUSC	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.52	-6.95	-0.36	1.93e-11	Schizophrenia;
LUSC	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg16989086	chr20:62203971	PRIC285	0.45	6.3	0.33	9.31e-10	Glioblastoma;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11239019	chr17:40172096	NKIRAS2	0.68	5.95	0.31	6.82e-9	Cognitive performance;
LUSC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg18350739	chr11:68623251	NA	-0.38	-6.45	-0.33	3.95e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg01879757	chr17:41196368	BRCA1	-0.39	-5.9	-0.31	8.83e-9	Menopause (age at onset);
LUSC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.47	-6.14	-0.32	2.28e-9	Renal function-related traits (BUN);
LUSC	cis	rs34779708	0.733	rs7081597	chr10:35546331	G/C	cg03585969	chr10:35415529	CREM	0.54	7.67	0.39	1.89e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg15103426	chr22:29168792	CCDC117	0.58	7.91	0.4	3.73e-14	Lymphocyte counts;
LUSC	cis	rs887829	0.641	rs7586110	chr2:234590527	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-6.55	-0.34	2.23e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs11051970	0.659	rs1809913	chr12:32591626	A/G	cg02745156	chr12:32552066	NA	0.38	5.87	0.31	1.05e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg26380479	chr7:97908229	NA	-0.28	-6.15	-0.32	2.26e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.84	0.51	1.17e-23	Menopause (age at onset);
LUSC	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg22431228	chr1:16359049	CLCNKA	-0.4	-8.17	-0.41	6.56e-15	Systolic blood pressure;
LUSC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg12257692	chr3:49977190	RBM6	0.25	6.92	0.35	2.29e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7589342	0.536	rs7562892	chr2:106396212	C/T	cg09152813	chr2:106391379	NCK2	-0.39	-6.29	-0.33	1e-9	Addiction;
LUSC	cis	rs2177596	0.534	rs3923085	chr2:227948746	C/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.68	-0.3	2.92e-8	Body mass index;
LUSC	cis	rs6845621	0.870	rs1377150	chr4:18922754	C/G	cg12196642	chr4:18937545	NA	0.34	6.42	0.33	4.68e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg08213375	chr14:104286397	PPP1R13B	0.35	5.96	0.31	6.27e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg20701182	chr2:24300061	SF3B14	0.77	7.87	0.4	4.89e-14	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg17366294	chr4:99064904	C4orf37	0.55	9.82	0.47	3.61e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.19	0.45	4.24e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6669072	0.565	rs35797670	chr1:91267334	T/C	cg08895590	chr1:91227319	NA	-0.27	-5.75	-0.3	1.99e-8	Cognitive function;
LUSC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg27572855	chr1:25598939	RHD	0.45	8.13	0.41	8.56e-15	Erythrocyte sedimentation rate;
LUSC	cis	rs28647808	0.881	rs28625799	chr9:136264557	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	14.07	0.61	1.24e-35	Platelet count;
LUSC	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.79	-13.74	-0.6	2.34e-34	Morning vs. evening chronotype;
LUSC	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg21775007	chr8:11205619	TDH	0.71	11.75	0.54	6.7399999999999993e-27	Retinal vascular caliber;
LUSC	cis	rs7131987	0.650	rs11050208	chr12:29510369	T/G	cg09582351	chr12:29534625	ERGIC2	-0.34	-6.61	-0.34	1.54e-10	QT interval;
LUSC	cis	rs7681440	0.715	rs17016305	chr4:90791381	A/G	cg01966878	chr4:90757139	SNCA	-0.36	-5.9	-0.31	8.77e-9	Dementia with Lewy bodies;
LUSC	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg24579218	chr15:68104479	NA	-0.36	-5.86	-0.31	1.1e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs4961252	0.505	rs12680168	chr8:142102522	A/T	cg13924514	chr8:142070760	NA	-0.34	-5.66	-0.3	3.26e-8	Isovolumetric relaxation time;Response to interferon beta therapy;
LUSC	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.22	-15.95	-0.66	5.6e-43	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9309711	0.961	rs11686236	chr2:3471549	G/A	cg10845886	chr2:3471009	TTC15	-0.63	-8.23	-0.41	4.18e-15	Neurofibrillary tangles;
LUSC	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21659725	chr3:3221576	CRBN	0.63	10.36	0.49	5.2e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg25811766	chr13:21894605	NA	0.67	11.15	0.52	9.21e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg20848291	chr7:100343083	ZAN	0.39	6.05	0.31	3.89e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs8014204	0.762	rs2359237	chr14:75245002	G/A	cg06637938	chr14:75390232	RPS6KL1	0.52	8.14	0.41	7.77e-15	Caffeine consumption;
LUSC	trans	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg06606381	chr12:133084897	FBRSL1	0.57	6.49	0.33	3.17e-10	Depression;
LUSC	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg25182066	chr10:30743637	MAP3K8	-0.42	-6.06	-0.31	3.58e-9	Inflammatory bowel disease;
LUSC	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg15423357	chr2:25149977	NA	0.35	6.42	0.33	4.64e-10	Body mass index;
LUSC	trans	rs9401746	0.564	rs659343	chr6:124803351	T/C	cg16857858	chr7:27213984	HOXA10	0.54	6.09	0.32	3.11e-9	Bone mineral density (Ward's triangle area);
LUSC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.99	0.44	1.91e-17	Lung cancer;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg23873654	chr17:26733358	SLC46A1	0.41	6.38	0.33	5.91e-10	Educational attainment (years of education);
LUSC	cis	rs61931739	0.635	rs10743837	chr12:33982162	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.97	-0.36	1.67e-11	Morning vs. evening chronotype;
LUSC	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg09904177	chr6:26538194	HMGN4	0.75	14.27	0.62	2.05e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs7590368	1.000	rs13429247	chr2:10960529	A/G	cg15705551	chr2:10952987	PDIA6	0.58	8.0	0.4	2.11e-14	Educational attainment (years of education);
LUSC	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg16482183	chr6:26056742	HIST1H1C	0.6	8.56	0.42	4.07e-16	Iron status biomarkers;
LUSC	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg20307385	chr11:47447363	PSMC3	0.46	6.72	0.35	7.85e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg20135002	chr11:47629003	NA	-0.52	-8.12	-0.41	8.82e-15	Subjective well-being;
LUSC	cis	rs59698941	0.943	rs67462411	chr5:132220031	C/T	cg02081065	chr5:132209139	LEAP2	-0.65	-6.75	-0.35	6.45e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs501916	0.634	rs1561479	chr15:48070157	C/G	cg16110827	chr15:48056943	SEMA6D	-0.38	-6.01	-0.31	4.9e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg27494647	chr7:150038898	RARRES2	0.46	6.96	0.36	1.77e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11018904	0.906	rs35286339	chr11:89965679	A/G	cg26138821	chr11:89956704	CHORDC1	-0.58	-7.18	-0.37	4.67e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg02423579	chr7:2872169	GNA12	-0.48	-7.04	-0.36	1.08e-11	Height;
LUSC	cis	rs858239	0.632	rs6952947	chr7:23121042	C/G	cg23682824	chr7:23144976	KLHL7	-0.39	-5.79	-0.3	1.67e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	7.53	0.38	4.72e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg20283391	chr11:68216788	NA	-0.57	-8.14	-0.41	7.95e-15	Total body bone mineral density;
LUSC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg13607699	chr17:42295918	UBTF	0.52	7.9	0.4	4.06e-14	Total body bone mineral density;
LUSC	cis	rs11630290	0.736	rs4777239	chr15:64148098	T/A	cg12036633	chr15:63758958	NA	0.6	6.74	0.35	6.79e-11	Iris characteristics;
LUSC	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg00677455	chr12:58241039	CTDSP2	0.71	11.07	0.52	1.74e-24	Multiple sclerosis;
LUSC	cis	rs983392	0.679	rs636341	chr11:60019161	A/C	cg20284999	chr11:59952153	MS4A6A	0.39	6.55	0.34	2.16e-10	Alzheimer's disease (late onset);
LUSC	cis	rs12474201	0.928	rs13429704	chr2:46960329	G/T	cg06386533	chr2:46925753	SOCS5	0.73	11.1	0.52	1.46e-24	Height;
LUSC	cis	rs73198271	0.700	rs10090152	chr8:8652104	C/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.88	-0.31	9.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.95	-0.36	1.92e-11	Reticulocyte count;
LUSC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg03929089	chr4:120376271	NA	-0.94	-16.48	-0.67	4.53e-45	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00244654	chr2:9983430	TAF1B	-0.42	-6.29	-0.33	1.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26314531	chr2:26401878	FAM59B	-0.69	-9.3	-0.45	1.95e-18	Gut microbiome composition (summer);
LUSC	cis	rs1797885	0.651	rs1552485	chr3:12580283	C/T	cg09856107	chr3:12701776	RAF1	0.31	5.69	0.3	2.73e-8	Immature fraction of reticulocytes;
LUSC	trans	rs800082	0.690	rs2717392	chr3:144280080	T/C	cg24215973	chr2:240111563	HDAC4	0.59	9.33	0.45	1.54e-18	Smoking behavior;
LUSC	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.35	-6.65	-0.34	1.18e-10	Coronary artery disease;
LUSC	cis	rs7681440	0.583	rs2737022	chr4:90739662	A/C	cg06632027	chr4:90757378	SNCA	-0.36	-5.69	-0.3	2.71e-8	Dementia with Lewy bodies;
LUSC	cis	rs9648716	0.515	rs2930322	chr7:140424582	G/C	cg23214464	chr7:140373596	ADCK2	0.75	6.15	0.32	2.2e-9	Type 2 diabetes;
LUSC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg22638593	chr5:131593259	PDLIM4	0.41	5.96	0.31	6.45e-9	Acylcarnitine levels;
LUSC	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.27e-8	Breast cancer;
LUSC	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg12863693	chr15:85201151	NMB	0.3	6.61	0.34	1.56e-10	Schizophrenia;
LUSC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg06713675	chr4:122721982	EXOSC9	-0.46	-8.07	-0.4	1.27e-14	Type 2 diabetes;
LUSC	cis	rs2274273	0.624	rs7150763	chr14:55839801	A/G	cg04306507	chr14:55594613	LGALS3	0.49	9.98	0.48	1.04e-20	Protein biomarker;
LUSC	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg05110241	chr16:68378359	PRMT7	-0.76	-8.86	-0.44	4.68e-17	Schizophrenia;
LUSC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	trans	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg00845942	chr12:64062724	DPY19L2	0.6	7.63	0.39	2.49e-13	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17467752	chr17:38218738	THRA	0.78	12.64	0.57	3.5e-30	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs3820928	0.845	rs10165767	chr2:227781863	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.01	-0.4	1.99e-14	Pulmonary function;
LUSC	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg03289416	chr15:75166202	SCAMP2	0.45	6.71	0.34	8.6e-11	Breast cancer;
LUSC	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg27539214	chr16:67997921	SLC12A4	-0.45	-5.99	-0.31	5.44e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg13246856	chr1:44399776	ARTN	0.29	6.23	0.32	1.4e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg17691542	chr6:26056736	HIST1H1C	0.5	7.26	0.37	2.71e-12	Height;
LUSC	cis	rs12530845	0.887	rs79100776	chr7:135315817	G/A	cg23117316	chr7:135346802	PL-5283	-0.58	-9.31	-0.45	1.82e-18	Red blood cell traits;
LUSC	trans	rs12200782	1.000	rs4292511	chr6:26622290	G/T	cg11837749	chr1:55047332	ACOT11	0.57	5.98	0.31	5.64e-9	Small cell lung carcinoma;
LUSC	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg12924262	chr12:102091054	CHPT1	0.43	6.11	0.32	2.71e-9	Blood protein levels;
LUSC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg19912559	chr1:40204330	PPIE	0.51	7.78	0.39	8.95e-14	Blood protein levels;
LUSC	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.13	-0.36	6.22e-12	Major depressive disorder;
LUSC	cis	rs9650657	0.836	rs1073913	chr8:10611708	A/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.16	-0.32	2.08e-9	Neuroticism;
LUSC	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg00376283	chr12:123451042	ABCB9	0.69	9.81	0.47	3.98e-20	Neutrophil percentage of white cells;
LUSC	cis	rs11209002	0.592	rs6672126	chr1:67558063	C/G	cg02640540	chr1:67518911	SLC35D1	0.64	9.04	0.44	1.28e-17	Crohn's disease;
LUSC	cis	rs4663866	0.901	rs2304672	chr2:239186589	C/G	cg16914508	chr2:239161102	PER2	-0.66	-7.31	-0.37	2e-12	Irritable bowel syndrome;
LUSC	cis	rs10208940	0.841	rs6731066	chr2:68796618	A/G	cg12452813	chr2:68675892	NA	0.6	6.1	0.32	2.99e-9	Urate levels in lean individuals;
LUSC	cis	rs7560272	0.723	rs7562047	chr2:73725168	G/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.2	-0.37	4.06e-12	Schizophrenia;
LUSC	cis	rs1957429	0.808	rs4899150	chr14:65344400	A/G	cg23373153	chr14:65346875	NA	0.94	10.65	0.5	5.2e-23	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg02023728	chr11:77925099	USP35	0.44	6.72	0.35	7.74e-11	Testicular germ cell tumor;
LUSC	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg25457927	chr22:38595422	NA	0.44	9.3	0.45	1.82e-18	Cutaneous nevi;
LUSC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg01125463	chr6:42946178	PEX6	-0.35	-5.7	-0.3	2.6e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-1.05	-15.51	-0.65	2.96e-41	Initial pursuit acceleration;
LUSC	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg02574844	chr11:5959923	NA	-0.41	-5.81	-0.3	1.42e-8	DNA methylation (variation);
LUSC	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg09307838	chr4:120376055	NA	0.74	10.88	0.51	8.49e-24	Corneal astigmatism;
LUSC	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg02023728	chr11:77925099	USP35	0.49	6.88	0.35	3.02e-11	Testicular germ cell tumor;
LUSC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg11812906	chr14:75593930	NEK9	-0.62	-10.06	-0.48	5.64e-21	Height;
LUSC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.63	-0.5	6.39e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-6.6	-0.34	1.62e-10	Waist circumference;Hip circumference;
LUSC	cis	rs10992471	0.603	rs1121978	chr9:95140351	T/G	cg14631576	chr9:95140430	CENPP	-0.37	-6.5	-0.33	3e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs11809207	0.951	rs111772533	chr1:26523404	C/G	cg00300879	chr1:26503847	CNKSR1	0.3	5.78	0.3	1.76e-8	Height;
LUSC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg01475377	chr6:109611718	NA	-0.45	-8.21	-0.41	4.87e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg15556689	chr8:8085844	FLJ10661	0.54	8.33	0.41	2.16e-15	Joint mobility (Beighton score);
LUSC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.77	-0.8	1.22e-77	Height;
LUSC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-10.55	-0.5	1.17e-22	Platelet count;
LUSC	cis	rs12541635	1.000	rs1896918	chr8:107090500	G/A	cg10147462	chr8:107024639	NA	-0.48	-8.76	-0.43	1.03e-16	Age of smoking initiation;
LUSC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.48	-7.22	-0.37	3.44e-12	Neutrophil percentage of white cells;
LUSC	cis	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.65	-0.3	3.52e-8	Eotaxin levels;
LUSC	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg08000102	chr2:233561755	GIGYF2	0.81	13.87	0.6	7.47e-35	Schizophrenia;
LUSC	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.2	0.41	5.08e-15	Homoarginine levels;
LUSC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.85	0.35	3.51e-11	Tonsillectomy;
LUSC	cis	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg21175976	chr8:11421337	BLK	-0.35	-6.01	-0.31	4.95e-9	Systemic lupus erythematosus;
LUSC	cis	rs2230307	0.536	rs526128	chr1:100473427	T/A	cg24955406	chr1:100503596	HIAT1	0.56	6.04	0.31	4.01e-9	Carotid intima media thickness;
LUSC	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18404041	chr3:52824283	ITIH1	-0.53	-9.99	-0.48	9.79e-21	Bipolar disorder;
LUSC	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg25182066	chr10:30743637	MAP3K8	0.44	6.55	0.34	2.22e-10	Inflammatory bowel disease;
LUSC	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg16482183	chr6:26056742	HIST1H1C	0.58	8.02	0.4	1.86e-14	Iron status biomarkers;
LUSC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg22508957	chr16:3507546	NAT15	-0.9	-10.47	-0.5	2.18e-22	Tuberculosis;
LUSC	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.75	12.41	0.56	2.47e-29	Alcohol dependence;
LUSC	cis	rs4499344	0.657	rs2868146	chr19:33050047	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.74	-9.67	-0.47	1.16e-19	Mean platelet volume;
LUSC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg21535247	chr6:8435926	SLC35B3	-0.57	-8.64	-0.43	2.29e-16	Motion sickness;
LUSC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg10523860	chr14:103875565	MARK3	-0.38	-6.19	-0.32	1.75e-9	Body mass index;
LUSC	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.41	-5.72	-0.3	2.38e-8	Schizophrenia;
LUSC	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg25301532	chr20:43378953	KCNK15	-0.36	-6.27	-0.32	1.1e-9	Obesity-related traits;
LUSC	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-7.66	-0.39	2e-13	Response to antipsychotic treatment;
LUSC	cis	rs2953174	1.000	rs2953176	chr2:241520754	T/A	cg07929629	chr2:241523174	NA	0.46	5.82	0.3	1.39e-8	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg05340658	chr4:99064831	C4orf37	0.68	11.61	0.54	2.11e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2463822	0.925	rs17157227	chr11:62169772	A/G	cg06239285	chr11:62104954	ASRGL1	0.94	10.25	0.49	1.3e-21	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11702148	0.552	rs3787708	chr21:34906039	C/T	cg14850771	chr21:34775459	IFNGR2	0.38	5.7	0.3	2.6e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs929596	0.755	rs887829	chr2:234668570	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.66	11.29	0.53	3.07e-25	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	8.86e-24	Morning vs. evening chronotype;
LUSC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg19678392	chr7:94953810	PON1	-0.36	-5.65	-0.3	3.48e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7605378	1.000	rs2689766	chr2:200697539	A/T	cg17644776	chr2:200775616	C2orf69	0.37	5.97	0.31	6.15e-9	Osteoporosis;
LUSC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.84	0.63	1.31e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9886651	0.935	rs13248719	chr8:128802751	T/C	cg07795030	chr8:128802207	NA	-0.35	-6.33	-0.33	7.72e-10	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LUSC	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg27411982	chr8:10470053	RP1L1	0.41	6.63	0.34	1.32e-10	Mood instability;
LUSC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02187348	chr16:89574699	SPG7	0.59	9.47	0.46	5.16e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg12386194	chr3:101231763	SENP7	0.53	7.42	0.38	9.66e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7246657	0.551	rs62108899	chr19:37595183	C/T	cg23950597	chr19:37808831	NA	-0.53	-5.66	-0.3	3.24e-8	Coronary artery calcification;
LUSC	cis	rs6424115	0.862	rs34845821	chr1:24066486	C/T	cg10978503	chr1:24200527	CNR2	-0.45	-8.84	-0.44	5.71e-17	Immature fraction of reticulocytes;
LUSC	cis	rs10823500	0.640	rs7077538	chr10:71993094	T/G	cg02100629	chr10:71892760	AIFM2	-0.37	-5.9	-0.31	9.02e-9	Blood protein levels;
LUSC	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-11.61	-0.54	2.12e-26	Chronic sinus infection;
LUSC	trans	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18876405	chr7:65276391	NA	0.49	7.8	0.39	8.19e-14	Corneal structure;
LUSC	cis	rs10465746	0.967	rs12120160	chr1:84342835	T/G	cg10977910	chr1:84465055	TTLL7	0.45	6.39	0.33	5.52e-10	Obesity-related traits;
LUSC	cis	rs877282	0.853	rs7079299	chr10:756455	A/G	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.16	0.41	6.66e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-9.35	-0.46	1.34e-18	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg23630131	chr7:65973040	NA	-0.22	-5.99	-0.31	5.28e-9	Aortic root size;
LUSC	cis	rs9463078	0.809	rs10948195	chr6:44957965	T/C	cg25276700	chr6:44698697	NA	-0.29	-5.68	-0.3	2.88e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs981844	0.712	rs4696507	chr4:154753702	G/A	cg14289246	chr4:154710475	SFRP2	-0.46	-6.26	-0.32	1.16e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg27141850	chr2:20869434	GDF7	-0.35	-8.09	-0.4	1.09e-14	Abdominal aortic aneurysm;
LUSC	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg10255544	chr17:80519551	FOXK2	0.4	6.57	0.34	1.89e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg15445000	chr17:37608096	MED1	-0.39	-6.8	-0.35	4.94e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07080220	chr10:102295463	HIF1AN	-0.58	-7.93	-0.4	3.42e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	0.93	15.63	0.65	1.01e-41	Menopause (age at onset);
LUSC	cis	rs1865721	1.000	rs3813080	chr18:73186227	C/T	cg26385618	chr18:73139727	C18orf62	-0.49	-8.13	-0.41	8.32e-15	Intelligence;
LUSC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.09	-0.4	1.12e-14	Type 2 diabetes;
LUSC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg15145296	chr3:125709740	NA	-0.58	-6.41	-0.33	4.91e-10	Blood pressure (smoking interaction);
LUSC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg21782813	chr7:2030301	MAD1L1	0.51	8.6	0.43	3.25e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs9902453	0.899	rs8067580	chr17:28471248	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.19	0.41	5.57e-15	Coffee consumption (cups per day);
LUSC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.05e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg24060327	chr5:131705240	SLC22A5	0.64	11.65	0.54	1.55e-26	Breast cancer;
LUSC	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg15704280	chr7:45808275	SEPT13	0.81	7.73	0.39	1.27e-13	Axial length;
LUSC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2219968	0.962	rs1471585	chr8:78945590	C/T	cg00738934	chr8:78996279	NA	-0.36	-6.41	-0.33	5.04e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg22618164	chr12:122356400	WDR66	0.42	5.98	0.31	5.76e-9	Mean corpuscular volume;
LUSC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg18876405	chr7:65276391	NA	-0.56	-8.79	-0.43	8.32e-17	Aortic root size;
LUSC	cis	rs11168618	0.846	rs7958521	chr12:48877400	G/A	cg24011408	chr12:48396354	COL2A1	0.39	6.13	0.32	2.42e-9	Adiponectin levels;
LUSC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.55	0.34	2.22e-10	Lung cancer;
LUSC	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg05754148	chr16:3507555	NAT15	0.79	9.61	0.47	1.8e-19	Tuberculosis;
LUSC	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg16482183	chr6:26056742	HIST1H1C	0.63	8.96	0.44	2.34e-17	Iron status biomarkers;
LUSC	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg17294928	chr15:75287854	SCAMP5	-0.72	-5.92	-0.31	7.8e-9	Lung cancer;
LUSC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11645453	chr3:52864694	ITIH4	0.33	7.63	0.39	2.55e-13	Bipolar disorder;
LUSC	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg26441486	chr22:50317300	CRELD2	-0.59	-5.69	-0.3	2.84e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.39e-8	Aortic root size;
LUSC	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg25427524	chr10:38739819	LOC399744	-0.35	-5.69	-0.3	2.77e-8	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.98	-0.36	1.64e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6690583	0.623	rs12042845	chr1:85429801	A/G	cg11262906	chr1:85462892	MCOLN2	0.69	6.76	0.35	6.02e-11	Serum sulfate level;
LUSC	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg03929089	chr4:120376271	NA	0.66	6.13	0.32	2.48e-9	Axial length;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00890378	chr1:33816159	PHC2	0.38	5.98	0.31	5.68e-9	Asthma;
LUSC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg12564285	chr5:131593104	PDLIM4	0.46	8.23	0.41	4.12e-15	Breast cancer;
LUSC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-0.8	-15.5	-0.65	3.24e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.43	6.2	0.32	1.63e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg21906852	chr1:75198582	TYW3;CRYZ	0.36	5.7	0.3	2.62e-8	Resistin levels;
LUSC	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg09307838	chr4:120376055	NA	0.5	7.71	0.39	1.5e-13	Diastolic blood pressure;
LUSC	cis	rs7560272	0.695	rs780393	chr2:73701669	T/A	cg20560298	chr2:73613845	ALMS1	0.45	7.14	0.36	5.99e-12	Schizophrenia;
LUSC	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4666002	0.956	rs2384656	chr2:27832055	A/G	cg27432699	chr2:27873401	GPN1	0.41	5.84	0.3	1.22e-8	Phospholipid levels (plasma);
LUSC	cis	rs7119	0.931	rs59418918	chr15:77833110	A/C	cg27398640	chr15:77910606	LINGO1	-0.32	-7.2	-0.37	4.01e-12	Type 2 diabetes;
LUSC	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.44	0.5	2.94e-22	Colorectal cancer;
LUSC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg11871910	chr12:69753446	YEATS4	0.45	5.9	0.31	9.14e-9	Response to diuretic therapy;
LUSC	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg06627628	chr2:24431161	ITSN2	-0.61	-7.4	-0.38	1.09e-12	Lymphocyte counts;
LUSC	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg11764359	chr7:65958608	NA	-0.44	-6.42	-0.33	4.66e-10	Aortic root size;
LUSC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-7.33	-0.37	1.74e-12	Fibrinogen levels;
LUSC	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg27432699	chr2:27873401	GPN1	0.8	15.0	0.63	3.16e-39	Oral cavity cancer;
LUSC	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.24e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg21017887	chr14:105400489	NA	0.69	13.27	0.59	1.45e-32	Rheumatoid arthritis;
LUSC	cis	rs9473147	0.516	rs10456570	chr6:47559451	A/G	cg02130027	chr6:47444894	CD2AP	0.35	5.7	0.3	2.68e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs4343996	0.869	rs4544975	chr7:3385384	G/T	cg21248987	chr7:3385318	SDK1	-0.41	-6.95	-0.36	1.91e-11	Motion sickness;
LUSC	cis	rs13315871	1.000	rs9824965	chr3:58433505	T/A	cg20936604	chr3:58311152	NA	-0.72	-6.77	-0.35	5.83e-11	Cholesterol, total;
LUSC	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.77	-0.43	9.17e-17	Response to antipsychotic treatment;
LUSC	cis	rs67601088	0.517	rs878903	chr7:29916772	A/T	cg19413766	chr7:29689036	LOC646762	-0.43	-5.69	-0.3	2.81e-8	Pediatric bone mineral density (spine);
LUSC	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg22906224	chr7:99728672	NA	-0.6	-8.82	-0.43	6.47e-17	Coronary artery disease;
LUSC	cis	rs61931739	0.635	rs1852225	chr12:33963004	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.72	-0.35	7.9e-11	Morning vs. evening chronotype;
LUSC	cis	rs7589342	0.862	rs12613864	chr2:106515869	G/A	cg14210321	chr2:106509881	NCK2	-0.62	-9.58	-0.46	2.37e-19	Addiction;
LUSC	trans	rs10511400	0.618	rs2035671	chr3:119875948	C/T	cg02809009	chr19:50354510	PTOV1	-0.67	-6.11	-0.32	2.71e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-10.19	-0.49	2.09e-21	Bipolar disorder;
LUSC	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg13010199	chr12:38710504	ALG10B	0.67	10.33	0.49	6.8e-22	Bladder cancer;
LUSC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18876405	chr7:65276391	NA	-0.56	-8.9	-0.44	3.55e-17	Aortic root size;
LUSC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs62400317	0.686	rs860741	chr6:44808435	G/A	cg20913747	chr6:44695427	NA	0.43	6.88	0.35	2.99e-11	Total body bone mineral density;
LUSC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.77	-12.16	-0.55	2.1e-28	Tonsillectomy;
LUSC	cis	rs6009527	1.000	rs4315635	chr22:49571530	G/T	cg12746016	chr22:49560550	NA	-0.41	-7.14	-0.36	5.95e-12	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs9837602	1.000	rs793472	chr3:99546110	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	5.78	0.3	1.74e-8	Breast cancer;
LUSC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.79	-0.43	8.19e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs1459104	0.706	rs35228933	chr11:55027673	G/A	cg15704280	chr7:45808275	SEPT13	0.72	5.97	0.31	5.93e-9	Body mass index;
LUSC	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg17652424	chr22:38574118	PLA2G6	-0.3	-6.48	-0.33	3.36e-10	Cutaneous nevi;
LUSC	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.75	-0.35	6.36e-11	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08635118	chr7:6144369	USP42	-0.44	-6.55	-0.34	2.23e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.53	7.78	0.39	9.42e-14	Night sleep phenotypes;
LUSC	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.06	-0.36	9.78e-12	Coronary artery disease;
LUSC	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-7.31	-0.37	1.98e-12	Axial length;
LUSC	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg09904177	chr6:26538194	HMGN4	-0.47	-6.78	-0.35	5.32e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9309473	1.000	rs6753344	chr2:73653138	C/T	cg20560298	chr2:73613845	ALMS1	0.44	6.23	0.32	1.44e-9	Metabolite levels;
LUSC	cis	rs4713675	0.584	rs6938056	chr6:33669577	C/T	cg14003231	chr6:33640908	ITPR3	0.31	5.96	0.31	6.53e-9	Plateletcrit;
LUSC	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg17595323	chr11:93583763	C11orf90	-0.31	-5.66	-0.3	3.26e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg14552801	chr7:65878734	NA	0.38	5.84	0.3	1.24e-8	Aortic root size;
LUSC	cis	rs4423214	1.000	rs909217	chr11:71146577	G/A	cg05163923	chr11:71159392	DHCR7	0.7	10.36	0.49	5.45e-22	Vitamin D levels;
LUSC	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg17168535	chr8:21777572	XPO7	0.82	14.89	0.63	7.87e-39	Mean corpuscular volume;
LUSC	cis	rs9921338	0.961	rs72773832	chr16:11413123	G/A	cg00044050	chr16:11439710	C16orf75	-0.5	-6.75	-0.35	6.64e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg11244672	chr19:19639970	YJEFN3	-0.54	-6.59	-0.34	1.76e-10	Bipolar disorder;
LUSC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg09323728	chr8:95962352	TP53INP1	-0.42	-8.81	-0.43	7.18e-17	Type 2 diabetes;
LUSC	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-0.78	-12.4	-0.56	2.72e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs17767294	0.708	rs17693877	chr6:27707046	G/A	cg08851530	chr6:28072375	NA	1.09	7.4	0.38	1.11e-12	Parkinson's disease;
LUSC	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg02176678	chr2:219576539	TTLL4	0.59	10.61	0.5	7.29e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.28	-0.32	1.07e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2324229	0.927	rs1180199	chr6:83959023	T/C	cg08257003	chr6:84140564	ME1	0.3	7.02	0.36	1.28e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs75920871	0.748	rs7106662	chr11:116951385	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.4	-0.33	5.21e-10	Subjective well-being;
LUSC	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14395844	chr9:139980277	LOC100289341;MAN1B1	-0.43	-6.77	-0.35	5.66e-11	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2667011	0.512	rs62176720	chr2:160822201	G/T	cg06573604	chr2:160760825	LY75	0.46	6.34	0.33	7.48e-10	Bilirubin levels;
LUSC	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.61	-0.34	1.55e-10	Retinal vascular caliber;
LUSC	cis	rs11030122	0.673	rs4910597	chr11:4094923	G/A	cg18678763	chr11:4115507	RRM1	-0.47	-6.09	-0.32	3.1e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs12760731	0.720	rs11805590	chr1:178308911	A/G	cg00404053	chr1:178313656	RASAL2	0.49	5.97	0.31	6.15e-9	Obesity-related traits;
LUSC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg19318889	chr4:1322082	MAEA	0.57	9.55	0.46	2.87e-19	Longevity;
LUSC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg00677455	chr12:58241039	CTDSP2	0.59	8.57	0.42	3.9e-16	Multiple sclerosis;
LUSC	cis	rs754466	1.000	rs12220902	chr10:79682918	C/T	cg17075019	chr10:79541650	NA	-0.64	-8.55	-0.42	4.46e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13126279	chr21:47581558	C21orf56	-0.45	-6.81	-0.35	4.46e-11	Testicular germ cell tumor;
LUSC	cis	rs6464929	0.956	rs11980538	chr7:148706163	T/C	cg23583168	chr7:148888333	NA	0.47	5.99	0.31	5.41e-9	Pediatric bone mineral content (hip);
LUSC	cis	rs2742234	0.541	rs11528481	chr10:43737767	C/A	cg15436174	chr10:43711423	RASGEF1A	0.44	7.09	0.36	8.1e-12	Hirschsprung disease;
LUSC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-10.94	-0.51	5.27e-24	Bipolar disorder;
LUSC	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg08313168	chr12:7315531	NA	0.46	5.98	0.31	5.65e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg11019008	chr10:131425282	MGMT	0.46	6.98	0.36	1.6e-11	Response to temozolomide;
LUSC	cis	rs4664308	0.905	rs62177860	chr2:160960571	C/T	cg03641300	chr2:160917029	PLA2R1	-0.69	-11.7	-0.54	1e-26	Idiopathic membranous nephropathy;
LUSC	trans	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg07211511	chr3:129823064	LOC729375	-0.78	-10.28	-0.49	9.94e-22	Blood pressure (smoking interaction);
LUSC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg02423579	chr7:2872169	GNA12	-0.5	-7.26	-0.37	2.74e-12	Height;
LUSC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.87	0.4	4.97e-14	Prudent dietary pattern;
LUSC	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg06636001	chr8:8085503	FLJ10661	0.52	7.65	0.39	2.16e-13	Systolic blood pressure;
LUSC	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg01966878	chr4:90757139	SNCA	-0.37	-6.37	-0.33	6.18e-10	Dementia with Lewy bodies;
LUSC	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg13334819	chr7:99746414	C7orf59	0.5	6.79	0.35	5.04e-11	Coronary artery disease;
LUSC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-7.16	-0.36	5.23e-12	Hemoglobin concentration;
LUSC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg01579765	chr21:45077557	HSF2BP	-0.46	-9.48	-0.46	5e-19	Mean corpuscular volume;
LUSC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg18230493	chr5:56204884	C5orf35	0.57	9.09	0.45	9.08e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs6828523	0.698	rs59276855	chr4:175861215	T/C	cg16870595	chr4:175839423	ADAM29	0.53	5.88	0.31	9.99e-9	Breast cancer;
LUSC	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-1.06	-12.75	-0.57	1.28e-30	Schizophrenia;
LUSC	cis	rs4343996	0.902	rs9969270	chr7:3368974	C/T	cg21248987	chr7:3385318	SDK1	-0.39	-6.6	-0.34	1.65e-10	Motion sickness;
LUSC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg07741184	chr6:167504864	NA	0.34	6.16	0.32	2.13e-9	Crohn's disease;
LUSC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	11.46	0.53	7.28e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	1.13	17.53	0.69	2.98e-49	Corneal structure;
LUSC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg16558253	chr16:72132732	DHX38	-0.42	-6.48	-0.33	3.28e-10	Fibrinogen levels;
LUSC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.74	-13.92	-0.61	4.61e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg20283391	chr11:68216788	NA	-0.61	-8.55	-0.42	4.43e-16	Total body bone mineral density;
LUSC	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg11245181	chr6:149772854	ZC3H12D	0.27	5.86	0.31	1.11e-8	Dupuytren's disease;
LUSC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg22920501	chr2:26401640	FAM59B	-0.73	-10.24	-0.49	1.38e-21	Gut microbiome composition (summer);
LUSC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10802521	chr3:52805072	NEK4	0.5	8.12	0.41	9.27e-15	Bipolar disorder;
LUSC	cis	rs13242816	1.000	rs56180538	chr7:116079711	C/T	cg16553024	chr7:116138462	CAV2	-0.53	-5.74	-0.3	2.18e-8	P wave duration;
LUSC	cis	rs11779988	0.545	rs415840	chr8:17782134	C/T	cg01800426	chr8:17659068	MTUS1	-0.5	-6.14	-0.32	2.34e-9	Breast cancer;
LUSC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.5	6.74	0.35	7.15e-11	Cognitive ability;
LUSC	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg08999081	chr20:33150536	PIGU	-0.4	-7.53	-0.38	4.82e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg00376283	chr12:123451042	ABCB9	0.66	8.32	0.41	2.27e-15	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg26924012	chr15:45694286	SPATA5L1	-1.02	-16.19	-0.66	6.48e-44	Homoarginine levels;
LUSC	cis	rs698813	0.774	rs2304769	chr2:44569474	G/A	cg00619915	chr2:44497795	NA	-0.39	-5.72	-0.3	2.4e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs9905704	0.628	rs2531735	chr17:56551139	A/G	cg19466818	chr17:56409534	MIR142	0.37	6.7	0.34	8.86e-11	Testicular germ cell tumor;
LUSC	trans	rs9944715	0.954	rs8086956	chr18:43773903	A/G	cg01718231	chr17:29326311	RNF135	-0.48	-6.81	-0.35	4.62e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg04450456	chr4:17643702	FAM184B	0.38	6.12	0.32	2.56e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs67072384	1.000	rs12271961	chr11:72453596	G/A	cg04827223	chr11:72435913	ARAP1	-0.78	-6.8	-0.35	4.98e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg09035930	chr12:129282057	SLC15A4	0.66	13.28	0.59	1.37e-32	Systemic lupus erythematosus;
LUSC	cis	rs1461503	0.932	rs7107575	chr11:122845406	C/T	cg27398637	chr11:122830231	C11orf63	0.4	6.4	0.33	5.28e-10	Menarche (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25220625	chr8:21868116	NA	0.75	6.34	0.33	7.41e-10	Cognitive performance;
LUSC	cis	rs9341835	0.772	rs9341841	chr6:64135010	G/A	cg00787780	chr6:64151745	NA	-0.34	-5.78	-0.3	1.72e-8	Schizophrenia;
LUSC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg09699651	chr6:150184138	LRP11	0.46	7.35	0.37	1.58e-12	Testicular germ cell tumor;
LUSC	cis	rs9937943	0.616	rs12923487	chr16:74644112	G/T	cg01733217	chr16:74700730	RFWD3	0.63	6.5	0.34	2.84e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6076065	0.963	rs2424543	chr20:23389955	G/T	cg11657817	chr20:23433608	CST11	0.43	8.75	0.43	1.04e-16	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.65	9.21	0.45	3.62e-18	High light scatter reticulocyte count;
LUSC	cis	rs1506636	0.854	rs6466879	chr7:123276197	G/A	cg03229431	chr7:123269106	ASB15	-0.68	-11.3	-0.53	2.71e-25	Plateletcrit;Platelet count;
LUSC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.91	0.55	1.76e-27	Prudent dietary pattern;
LUSC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.32	0.56	5.14e-29	Prudent dietary pattern;
LUSC	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.32	0.56	5.35e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg06096015	chr1:231504339	EGLN1	0.54	9.31	0.45	1.7e-18	Hemoglobin concentration;
LUSC	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg04719120	chr6:96025338	MANEA	0.47	5.85	0.3	1.16e-8	Behavioural disinhibition (generation interaction);
LUSC	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.62	-0.34	1.47e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8050755	0.649	rs1800720	chr16:2105400	C/T	cg04515572	chr16:2107413	TSC2	-0.72	-6.97	-0.36	1.7e-11	Major depressive disorder;
LUSC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg13647721	chr17:30228624	UTP6	0.59	5.84	0.3	1.21e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-7.3	-0.37	2.11e-12	Neuroticism;
LUSC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.45	0.46	6.01e-19	Bipolar disorder;
LUSC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	trans	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg21293242	chr8:11204541	TDH	0.32	6.01	0.31	4.86e-9	Retinal vascular caliber;
LUSC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg27494647	chr7:150038898	RARRES2	0.54	7.85	0.39	5.85e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11764359	chr7:65958608	NA	0.64	9.69	0.47	9.82e-20	Aortic root size;
LUSC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.61	-11.14	-0.52	1.01e-24	Type 2 diabetes;
LUSC	cis	rs6599077	0.616	rs9878321	chr3:40174858	A/G	cg13683864	chr3:40499215	RPL14	-0.51	-6.53	-0.34	2.52e-10	Sleep-related phenotypes;
LUSC	cis	rs55871839	0.708	rs10112089	chr8:59813429	C/T	cg07426533	chr8:59803705	TOX	-0.36	-5.93	-0.31	7.66e-9	Pneumonia;
LUSC	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg16070123	chr10:51489643	NA	-0.52	-8.4	-0.42	1.26e-15	Prostate-specific antigen levels;
LUSC	cis	rs11166629	1.000	rs3739423	chr8:135614705	A/G	cg21672855	chr8:135614777	ZFAT	0.38	5.99	0.31	5.31e-9	Smoking quantity;
LUSC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg06808227	chr14:105710500	BRF1	-0.65	-10.01	-0.48	8.32e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.64	-0.39	2.36e-13	Blood metabolite levels;
LUSC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14893161	chr1:205819251	PM20D1	-0.44	-6.11	-0.32	2.75e-9	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs6969780	1.000	rs1801085	chr7:27168590	A/G	cg26364809	chr7:27145159	NA	-0.56	-5.73	-0.3	2.28e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07080220	chr10:102295463	HIF1AN	0.67	9.33	0.45	1.54e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	0.92	15.42	0.64	7.18e-41	Breast cancer;
LUSC	cis	rs2742417	1.000	rs2673058	chr3:45735618	A/C	cg09608765	chr3:45636137	LIMD1	-0.37	-7.29	-0.37	2.23e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg14582100	chr15:45693742	SPATA5L1	0.46	8.73	0.43	1.2e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg13263323	chr15:86062960	AKAP13	-0.35	-5.72	-0.3	2.38e-8	Coronary artery disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26439071	chr12:124155620	TCTN2	0.75	5.96	0.31	6.49e-9	Cognitive performance;
LUSC	cis	rs9283706	0.950	rs10053810	chr5:66281898	C/G	cg11590213	chr5:66331682	MAST4	-0.41	-6.18	-0.32	1.89e-9	Coronary artery disease;
LUSC	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg16235748	chr6:149772707	ZC3H12D	0.28	5.75	0.3	2.05e-8	Dupuytren's disease;
LUSC	cis	rs1564271	0.528	rs2209350	chr10:26987779	A/G	cg13837822	chr10:26931731	LOC731789	0.45	9.91	0.48	1.83e-20	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUSC	cis	rs8077577	0.895	rs11655588	chr17:18107451	C/T	cg16794390	chr17:18148240	FLII	-0.44	-6.2	-0.32	1.71e-9	Obesity-related traits;
LUSC	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg26384229	chr12:38710491	ALG10B	0.73	11.89	0.55	2.03e-27	Morning vs. evening chronotype;
LUSC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg09640425	chr7:158790006	NA	-0.52	-8.19	-0.41	5.5e-15	Facial morphology (factor 20);
LUSC	trans	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg06606381	chr12:133084897	FBRSL1	-1.01	-8.96	-0.44	2.39e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3762318	0.525	rs4655520	chr1:67591660	G/A	cg02640540	chr1:67518911	SLC35D1	0.61	6.3	0.33	9.32e-10	Leprosy;
LUSC	cis	rs13385	0.769	rs17286613	chr5:139581205	T/G	cg26211634	chr5:139558579	C5orf32	0.44	6.31	0.33	8.82e-10	Atrial fibrillation;
LUSC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg04369109	chr6:150039330	LATS1	-0.58	-8.61	-0.43	2.83e-16	Lung cancer;
LUSC	cis	rs9929218	0.911	rs4783685	chr16:68834107	C/T	cg02972257	chr16:68554789	NA	0.42	5.7	0.3	2.68e-8	Colorectal cancer;
LUSC	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18854424	chr1:2615690	NA	0.5	10.04	0.48	6.64e-21	Ulcerative colitis;
LUSC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg10862848	chr6:42927986	GNMT	0.26	5.95	0.31	6.68e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg07148914	chr20:33460835	GGT7	0.54	8.43	0.42	1.03e-15	Height;
LUSC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.27	0.59	1.41e-32	Hip circumference adjusted for BMI;
LUSC	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	0.86	11.38	0.53	1.4e-25	Coronary artery disease;
LUSC	trans	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg24644049	chr4:85504048	CDS1	0.86	7.56	0.38	3.83e-13	Skin colour saturation;
LUSC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg18135555	chr8:22132992	PIWIL2	0.4	7.91	0.4	3.77e-14	Hypertriglyceridemia;
LUSC	cis	rs2637266	0.745	rs2579733	chr10:78441896	C/T	cg18941641	chr10:78392320	NA	-0.33	-5.79	-0.3	1.61e-8	Pulmonary function;
LUSC	trans	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg03886242	chr7:26192032	NFE2L3	0.37	6.26	0.32	1.18e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg22907277	chr7:1156413	C7orf50	0.48	7.13	0.36	6.37e-12	Longevity;Endometriosis;
LUSC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg09796270	chr17:17721594	SREBF1	-0.4	-7.0	-0.36	1.37e-11	Total body bone mineral density;
LUSC	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.64	-0.39	2.34e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg24675056	chr1:15929824	NA	0.48	8.24	0.41	3.92e-15	Systolic blood pressure;
LUSC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg13798912	chr7:905769	UNC84A	-0.56	-5.77	-0.3	1.85e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg00376283	chr12:123451042	ABCB9	0.69	8.71	0.43	1.4e-16	Neutrophil percentage of white cells;
LUSC	cis	rs2953174	0.786	rs2953146	chr2:241515252	A/G	cg07929629	chr2:241523174	NA	-0.5	-7.94	-0.4	3.2e-14	Bipolar disorder;
LUSC	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg05283184	chr6:79620031	NA	-0.57	-12.11	-0.55	3.08e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg26043149	chr18:55253948	FECH	-0.53	-7.64	-0.39	2.26e-13	Bone mineral density;
LUSC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.04	-0.52	2.32e-24	Bipolar disorder;
LUSC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg25036284	chr2:26402008	FAM59B	0.71	10.06	0.48	5.58e-21	Gut microbiome composition (summer);
LUSC	cis	rs2274273	0.934	rs8021940	chr14:55719715	G/A	cg04306507	chr14:55594613	LGALS3	0.57	13.47	0.59	2.39e-33	Protein biomarker;
LUSC	cis	rs7267979	0.714	rs2474763	chr20:25241295	A/G	cg08601574	chr20:25228251	PYGB	0.48	7.42	0.38	9.92e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg19812747	chr11:111475976	SIK2	-0.56	-8.11	-0.41	9.51e-15	Primary sclerosing cholangitis;
LUSC	cis	rs1775715	0.870	rs1775737	chr10:32256871	T/C	cg26784012	chr10:32216390	ARHGAP12	0.41	6.64	0.34	1.29e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg19683494	chr5:74908142	NA	0.58	7.75	0.39	1.11e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-10.4	-0.49	3.86e-22	Migraine;Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	cis	rs3741151	0.686	rs12290701	chr11:73271988	T/C	cg17517138	chr11:73019481	ARHGEF17	0.82	7.65	0.39	2.15e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9287719	0.745	rs4997810	chr2:10755540	T/A	cg03983476	chr2:10830698	NOL10	-0.38	-5.77	-0.3	1.83e-8	Prostate cancer;
LUSC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg15848620	chr12:58087721	OS9	-0.57	-8.04	-0.4	1.56e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21862992	chr11:68658383	NA	0.49	7.74	0.39	1.23e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	9.02	0.44	1.5e-17	Motion sickness;
LUSC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg09034736	chr1:150693464	HORMAD1	0.51	7.51	0.38	5.57e-13	Tonsillectomy;
LUSC	trans	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	cis	rs9356171	0.572	rs11756250	chr6:164325686	A/G	cg25752492	chr6:164341247	NA	-0.39	-6.68	-0.34	9.82e-11	Diisocyanate-induced asthma;
LUSC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg23887609	chr12:130822674	PIWIL1	0.49	7.34	0.37	1.64e-12	Menopause (age at onset);
LUSC	cis	rs56283067	0.887	rs9463042	chr6:44770527	T/C	cg18551225	chr6:44695536	NA	-0.47	-7.67	-0.39	1.9e-13	Total body bone mineral density;
LUSC	cis	rs9811920	0.535	rs792837	chr3:99477182	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.31	-5.85	-0.31	1.15e-8	Axial length;
LUSC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2742234	0.590	rs1254962	chr10:43696992	G/A	cg15436174	chr10:43711423	RASGEF1A	0.43	7.01	0.36	1.32e-11	Hirschsprung disease;
LUSC	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg08645402	chr16:4508243	NA	0.51	8.44	0.42	9.54e-16	Schizophrenia;
LUSC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg06671660	chr6:41068741	NFYA;LOC221442	0.39	5.78	0.3	1.7e-8	Alzheimer's disease (late onset);
LUSC	cis	rs17401966	0.838	rs2105212	chr1:10281012	T/C	cg19773385	chr1:10388646	KIF1B	-0.53	-9.15	-0.45	5.94e-18	Hepatocellular carcinoma;
LUSC	cis	rs2282802	0.685	rs6870103	chr5:139692515	G/T	cg26211634	chr5:139558579	C5orf32	-0.42	-8.08	-0.4	1.22e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg00945038	chr17:61921165	SMARCD2	0.39	5.8	0.3	1.5e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.2e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg03342759	chr3:160939853	NMD3	-0.42	-6.18	-0.32	1.88e-9	Morning vs. evening chronotype;
LUSC	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg17385448	chr1:15911702	AGMAT	0.39	6.13	0.32	2.51e-9	Systolic blood pressure;
LUSC	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg15309053	chr8:964076	NA	0.38	7.84	0.39	5.98e-14	Schizophrenia;
LUSC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg12463550	chr7:65579703	CRCP	-0.43	-6.2	-0.32	1.7e-9	Aortic root size;
LUSC	cis	rs2235649	0.843	rs9932890	chr16:1847868	G/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.44	5.89	0.31	9.52e-9	Blood metabolite levels;
LUSC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg13206674	chr6:150067644	NUP43	-0.57	-8.89	-0.44	3.79e-17	Lung cancer;
LUSC	cis	rs6906287	0.647	rs67832971	chr6:118832205	C/T	cg21191810	chr6:118973309	C6orf204	0.32	5.83	0.3	1.27e-8	Electrocardiographic conduction measures;
LUSC	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.51	0.38	5.48e-13	Iron status biomarkers;
LUSC	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg27539214	chr16:67997921	SLC12A4	-0.46	-5.93	-0.31	7.38e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg02176678	chr2:219576539	TTLL4	0.6	10.67	0.5	4.48e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg04414720	chr1:150670196	GOLPH3L	0.5	7.94	0.4	3.04e-14	Melanoma;
LUSC	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg10523679	chr1:76189770	ACADM	-0.42	-6.28	-0.32	1.08e-9	Daytime sleep phenotypes;
LUSC	cis	rs6500395	1.000	rs12597928	chr16:48714366	G/A	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs71403859	0.803	rs17282500	chr16:71633653	C/A	cg08717414	chr16:71523259	ZNF19	-0.72	-7.94	-0.4	3.11e-14	Post bronchodilator FEV1;
LUSC	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg01943577	chr7:158741284	NA	-0.42	-6.06	-0.31	3.76e-9	Height;
LUSC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg18850127	chr7:39170497	POU6F2	0.67	11.0	0.52	3.13e-24	IgG glycosylation;
LUSC	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	0.68	8.42	0.42	1.15e-15	Pulmonary function decline;
LUSC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs3824867	0.920	rs7948705	chr11:47447955	C/G	cg20307385	chr11:47447363	PSMC3	-0.64	-9.52	-0.46	3.67e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs2387326	0.717	rs10829334	chr10:129943402	C/T	cg16087940	chr10:129947807	NA	-0.39	-5.81	-0.3	1.48e-8	Select biomarker traits;
LUSC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.69	0.57	2.2e-30	Cognitive test performance;
LUSC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg14440974	chr22:39074834	NA	-0.36	-5.8	-0.3	1.55e-8	Menopause (age at onset);
LUSC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.77	-10.32	-0.49	7.64e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg05283184	chr6:79620031	NA	-0.54	-11.17	-0.52	7.97e-25	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.620	rs61927756	chr12:33709931	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-6.13	-0.32	2.44e-9	Morning vs. evening chronotype;
LUSC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg08470875	chr2:26401718	FAM59B	-0.64	-8.78	-0.43	8.42e-17	Gut microbiome composition (summer);
LUSC	cis	rs6494488	0.500	rs72744710	chr15:65014078	G/A	cg08069370	chr15:64387884	SNX1	-0.66	-5.78	-0.3	1.71e-8	Coronary artery disease;
LUSC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.69	0.3	2.79e-8	Personality dimensions;
LUSC	cis	rs2227564	0.729	rs2675675	chr10:75649048	G/A	cg23231163	chr10:75533350	FUT11	-0.43	-5.82	-0.3	1.37e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7814319	0.933	rs13261747	chr8:97238769	A/G	cg20787634	chr8:97240163	UQCRB	-0.35	-6.1	-0.32	2.87e-9	Lung function (FVC);
LUSC	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	9.03	0.44	1.36e-17	Bipolar disorder;
LUSC	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg17691542	chr6:26056736	HIST1H1C	0.47	7.0	0.36	1.43e-11	Height;
LUSC	trans	rs73019876	0.805	rs2522106	chr19:22140621	T/A	cg16204205	chr18:19753432	GATA6	0.31	5.94	0.31	7.01e-9	Testicular germ cell tumor;
LUSC	cis	rs4478037	0.822	rs9865342	chr3:33118631	G/A	cg19404215	chr3:33155277	CRTAP	0.99	9.82	0.47	3.79e-20	Major depressive disorder;
LUSC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg00012203	chr2:219082015	ARPC2	0.71	11.8	0.54	4.15e-27	Colorectal cancer;
LUSC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg22875332	chr1:76189707	ACADM	0.76	10.23	0.49	1.48e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7712401	0.791	rs154507	chr5:122200907	C/G	cg19077854	chr5:122220652	SNX24	-0.35	-8.13	-0.41	8.32e-15	Mean platelet volume;
LUSC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.42	5.83	0.3	1.29e-8	Height;
LUSC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg08866814	chr16:89351500	ANKRD11	-0.67	-6.28	-0.32	1.03e-9	Myocardial infarction;
LUSC	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.35	-5.67	-0.3	3.1e-8	Body mass index;
LUSC	trans	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg26043149	chr18:55253948	FECH	0.5	7.31	0.37	1.96e-12	Bone mineral density;
LUSC	trans	rs459571	0.606	rs457420	chr9:136909261	A/G	cg10765909	chr12:53715428	AAAS	0.44	6.75	0.35	6.44e-11	Platelet distribution width;
LUSC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg16423285	chr20:60520624	NA	-0.47	-5.84	-0.3	1.22e-8	Body mass index;
LUSC	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.79	-15.55	-0.65	2.16e-41	Ulcerative colitis;
LUSC	cis	rs3125734	0.633	rs10761616	chr10:64009076	G/A	cg19640130	chr10:64028056	RTKN2	-0.4	-7.1	-0.36	7.48e-12	Rheumatoid arthritis;
LUSC	cis	rs11247915	0.540	rs11582416	chr1:26677721	A/G	cg04990556	chr1:26633338	UBXN11	0.47	6.36	0.33	6.56e-10	Obesity-related traits;
LUSC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.7	-0.67	5.93e-46	Exhaled nitric oxide output;
LUSC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	1.02	19.7	0.73	7.26e-58	Menopause (age at onset);
LUSC	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.16	-0.41	6.77e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs5771225	0.505	rs2341111	chr22:50690322	G/C	cg16473166	chr22:50639996	SELO	0.6	7.98	0.4	2.45e-14	Late-onset Alzheimer's disease;
LUSC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.57	-0.38	3.65e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg12292205	chr6:26970375	C6orf41	0.71	12.15	0.55	2.25e-28	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6489882	0.867	rs7958379	chr12:113363284	A/G	cg20102336	chr12:113376681	OAS3	-0.42	-5.92	-0.31	7.96e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg22782873	chr19:19639568	YJEFN3	0.5	6.11	0.32	2.84e-9	Bipolar disorder;
LUSC	cis	rs12422267	0.536	rs12303484	chr12:132609558	G/A	cg09764611	chr12:132620959	NA	-0.58	-8.66	-0.43	2.06e-16	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs80130819	0.636	rs4760623	chr12:48619256	A/C	cg24011408	chr12:48396354	COL2A1	0.47	5.88	0.31	1.01e-8	Prostate cancer;
LUSC	cis	rs909341	0.868	rs1291206	chr20:62329169	G/A	cg09650180	chr20:62225654	GMEB2	-0.46	-6.03	-0.31	4.39e-9	Atopic dermatitis;
LUSC	cis	rs6733011	0.519	rs12990579	chr2:99457447	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.01	-0.31	4.8e-9	Bipolar disorder;
LUSC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg08270630	chr22:50330655	NA	-0.41	-6.16	-0.32	2.14e-9	Schizophrenia;
LUSC	trans	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.52	8.02	0.4	1.8e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg04865166	chr7:105162814	PUS7	0.53	5.87	0.31	1.06e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.86	0.54	2.63e-27	Cognitive ability;
LUSC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.89	0.55	1.95e-27	Prudent dietary pattern;
LUSC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg00343986	chr7:65444356	GUSB	0.47	7.12	0.36	6.71e-12	Aortic root size;
LUSC	trans	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.57	0.38	3.58e-13	Ulcerative colitis;
LUSC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg02018176	chr4:1364513	KIAA1530	0.47	7.65	0.39	2.19e-13	Obesity-related traits;
LUSC	cis	rs6580649	0.831	rs1635528	chr12:48395900	C/T	cg24011408	chr12:48396354	COL2A1	0.54	7.11	0.36	7.25e-12	Lung cancer;
LUSC	cis	rs9311676	0.656	rs11712139	chr3:58384775	C/T	cg13750441	chr3:58318267	PXK	0.34	6.57	0.34	1.9e-10	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg11062466	chr8:58055876	NA	0.51	6.44	0.33	4.15e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7589342	0.791	rs4438504	chr2:106461035	A/C	cg16077055	chr2:106428750	NCK2	0.33	6.17	0.32	1.92e-9	Addiction;
LUSC	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.51	-0.46	3.9e-19	Mood instability;
LUSC	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg23173402	chr1:227635558	NA	0.58	7.0	0.36	1.45e-11	Major depressive disorder;
LUSC	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.7	-11.13	-0.52	1.08e-24	Colorectal cancer;
LUSC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.96	-14.61	-0.62	1.02e-37	Initial pursuit acceleration;
LUSC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-0.99	-17.41	-0.69	9.5e-49	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25125898	chr5:5422196	KIAA0947	-0.45	-6.75	-0.35	6.39e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg00316803	chr15:76480434	C15orf27	-0.4	-6.8	-0.35	4.95e-11	Blood metabolite levels;
LUSC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.42	-7.67	-0.39	1.85e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg14154082	chr13:112174009	NA	0.4	8.2	0.41	5.06e-15	Menarche (age at onset);
LUSC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1572438	1.000	rs873560	chr6:875559	A/G	cg13447295	chr6:887704	NA	-0.39	-5.79	-0.3	1.61e-8	Aging;
LUSC	trans	rs629535	0.773	rs569064	chr8:70065967	A/G	cg21567404	chr3:27674614	NA	0.97	15.48	0.65	3.82e-41	Dupuytren's disease;
LUSC	trans	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg20935933	chr6:143382018	AIG1	0.5	7.27	0.37	2.61e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg01028140	chr2:1542097	TPO	-0.37	-6.07	-0.32	3.51e-9	IgG glycosylation;
LUSC	cis	rs939574	1.000	rs56927225	chr2:220100922	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.09	8.72	0.43	1.31e-16	Platelet distribution width;
LUSC	cis	rs722599	1.000	rs722599	chr14:75327443	T/C	cg08847533	chr14:75593920	NEK9	-0.41	-5.96	-0.31	6.38e-9	IgG glycosylation;
LUSC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg13319975	chr6:146136371	FBXO30	0.5	7.52	0.38	5.18e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3803170	0.513	rs4766573	chr12:111830809	C/A	cg10833066	chr12:111807467	FAM109A	0.38	7.17	0.37	4.88e-12	Mean corpuscular hemoglobin;
LUSC	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	1.14	18.04	0.7	2.84e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg04374321	chr14:90722782	PSMC1	0.73	11.62	0.54	1.87e-26	Mortality in heart failure;
LUSC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg05802129	chr4:122689817	NA	-0.52	-8.78	-0.43	8.4e-17	Type 2 diabetes;
LUSC	trans	rs800082	1.000	rs28847402	chr3:144316893	C/G	cg24215973	chr2:240111563	HDAC4	-0.46	-6.98	-0.36	1.62e-11	Smoking behavior;
LUSC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg19774624	chr17:42201019	HDAC5	0.71	10.48	0.5	2.07e-22	Total body bone mineral density;
LUSC	cis	rs11650494	0.908	rs11650087	chr17:47362923	T/A	cg08112188	chr17:47440006	ZNF652	1.22	10.33	0.49	6.95e-22	Prostate cancer;
LUSC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.49	-6.79	-0.35	5.21e-11	Cognitive ability;
LUSC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg21951975	chr1:209979733	IRF6	0.57	8.52	0.42	5.74e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg17470449	chr10:769945	NA	0.53	7.12	0.36	6.81e-12	Uric acid levels;
LUSC	trans	rs225245	0.791	rs720774	chr17:34017453	T/G	cg19694781	chr19:47549865	TMEM160	-0.41	-6.39	-0.33	5.58e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg03929089	chr4:120376271	NA	-0.69	-7.74	-0.39	1.19e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg07148914	chr20:33460835	GGT7	0.54	8.27	0.41	3.18e-15	Height;
LUSC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg19747945	chr6:42946146	PEX6	-0.35	-5.67	-0.3	3.11e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs4964805	0.580	rs10861097	chr12:104170474	C/T	cg02344784	chr12:104178138	NT5DC3	0.37	5.97	0.31	6.08e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs7267979	0.844	rs2474780	chr20:25285835	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.77	16.24	0.66	4.1e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3741151	0.656	rs56884659	chr11:73252947	C/G	cg17517138	chr11:73019481	ARHGEF17	0.97	8.12	0.41	8.78e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.58	-8.65	-0.43	2.2e-16	Monocyte count;
LUSC	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.88	-0.35	2.88e-11	Mood instability;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22934568	chr3:48884614	PRKAR2A	-0.5	-6.23	-0.32	1.42e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg02569458	chr12:86230093	RASSF9	0.58	9.78	0.47	4.91e-20	Major depressive disorder;
LUSC	cis	rs12410462	0.581	rs4329477	chr1:227552494	A/G	cg10327440	chr1:227177885	CDC42BPA	0.61	6.38	0.33	5.98e-10	Major depressive disorder;
LUSC	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg17470449	chr10:769945	NA	0.55	7.78	0.39	9.07e-14	Uric acid levels;
LUSC	trans	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg21775007	chr8:11205619	TDH	-0.43	-6.09	-0.32	3.14e-9	Joint mobility (Beighton score);
LUSC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg27165867	chr14:105738592	BRF1	0.53	7.67	0.39	1.86e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg08999081	chr20:33150536	PIGU	0.32	5.66	0.3	3.24e-8	Height;
LUSC	cis	rs12541635	0.639	rs6415444	chr8:107043797	G/A	cg10147462	chr8:107024639	NA	0.66	13.76	0.6	1.86e-34	Age of smoking initiation;
LUSC	trans	rs7944735	0.517	rs11039538	chr11:48154990	A/T	cg15704280	chr7:45808275	SEPT13	0.72	6.58	0.34	1.86e-10	Intraocular pressure;
LUSC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg25767906	chr1:53392781	SCP2	0.48	8.69	0.43	1.67e-16	Monocyte count;
LUSC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg18827107	chr12:86230957	RASSF9	-0.5	-7.29	-0.37	2.3e-12	Major depressive disorder;
LUSC	cis	rs2692947	0.864	rs2579518	chr2:96675259	G/A	cg23100626	chr2:96804247	ASTL	0.26	6.58	0.34	1.78e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-8.06	-0.4	1.38e-14	Systemic lupus erythematosus;
LUSC	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg05501817	chr11:14380813	RRAS2	-0.56	-9.17	-0.45	4.98e-18	Sense of smell;
LUSC	cis	rs11264799	0.765	rs12144103	chr1:157620499	A/G	cg18268488	chr1:157545234	FCRL4	0.33	5.81	0.3	1.49e-8	IgA nephropathy;
LUSC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg27170947	chr2:26402098	FAM59B	-0.63	-9.4	-0.46	9.08e-19	Gut microbiome composition (summer);
LUSC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg03806693	chr22:41940476	POLR3H	1.01	13.86	0.6	8.07e-35	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.59	-0.54	2.5e-26	Schizophrenia;
LUSC	cis	rs4964805	0.773	rs35746861	chr12:104225284	C/T	cg02344784	chr12:104178138	NT5DC3	0.42	6.51	0.34	2.82e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs2067615	0.524	rs10778504	chr12:107120424	C/T	cg15890332	chr12:107067104	RFX4	0.34	6.05	0.31	3.78e-9	Heart rate;
LUSC	cis	rs9549260	0.709	rs4581585	chr13:41203905	C/T	cg21288729	chr13:41239152	FOXO1	0.61	9.59	0.46	2.13e-19	Red blood cell count;
LUSC	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg10523679	chr1:76189770	ACADM	-0.44	-6.26	-0.32	1.16e-9	Daytime sleep phenotypes;
LUSC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.58	-0.38	3.35e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2979489	0.891	rs7822839	chr8:30354453	A/G	cg26383811	chr8:30366931	RBPMS	0.48	7.8	0.39	7.76e-14	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg06627628	chr2:24431161	ITSN2	0.61	9.09	0.45	9.2e-18	Asthma;
LUSC	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-17.83	-0.7	1.92e-50	Primary sclerosing cholangitis;
LUSC	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg26384229	chr12:38710491	ALG10B	-0.67	-10.46	-0.5	2.39e-22	Bladder cancer;
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-8.12	-0.41	9.03e-15	Longevity;Endometriosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24123563	chr14:77924517	C14orf133;AHSA1	0.44	6.1	0.32	2.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.52	-7.93	-0.4	3.39e-14	Schizophrenia;
LUSC	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg01601518	chr4:2404284	ZFYVE28	0.47	5.77	0.3	1.79e-8	Influenza A (H1N1) severity;
LUSC	trans	rs12439619	0.508	rs11856561	chr15:82453756	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.46	-7.16	-0.36	5.1e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs783147	0.500	rs4252130	chr6:161153080	A/C	cg00639886	chr12:54943102	PDE1B	-0.46	-6.46	-0.33	3.69e-10	Lp (a) levels;
LUSC	cis	rs7246967	0.673	rs8103012	chr19:22879285	C/T	cg23217946	chr19:22817039	ZNF492	0.39	5.64	0.3	3.56e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs2820315	1.000	rs8024	chr1:201845575	C/A	cg10061532	chr1:201886748	LMOD1	0.26	5.87	0.31	1.05e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg25019033	chr10:957182	NA	-0.53	-6.84	-0.35	3.74e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.67	-0.54	1.26e-26	Coffee consumption (cups per day);
LUSC	cis	rs983392	0.709	rs11603507	chr11:59982470	T/A	cg02771260	chr11:59836817	MS4A3	-0.36	-5.92	-0.31	8.12e-9	Alzheimer's disease (late onset);
LUSC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.51e-14	Prudent dietary pattern;
LUSC	cis	rs6977660	0.943	rs10225293	chr7:19840636	C/T	cg05791153	chr7:19748676	TWISTNB	-0.55	-6.22	-0.32	1.47e-9	Thyroid stimulating hormone;
LUSC	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg25233709	chr10:116636983	FAM160B1	0.37	6.59	0.34	1.69e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.4	-0.33	5.22e-10	Extrinsic epigenetic age acceleration;
LUSC	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.47	-5.83	-0.3	1.29e-8	Birth weight;
LUSC	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-7.76	-0.39	1.01e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.73	0.39	1.26e-13	Bipolar disorder;
LUSC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg07741184	chr6:167504864	NA	0.43	7.63	0.39	2.43e-13	Crohn's disease;
LUSC	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg04545296	chr12:48745243	ZNF641	0.32	5.88	0.31	1.02e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-0.99	-14.45	-0.62	4.26e-37	Initial pursuit acceleration;
LUSC	cis	rs4499344	0.730	rs380320	chr19:33105904	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	12.86	0.58	4.89e-31	Mean platelet volume;
LUSC	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg19875535	chr5:140030758	IK	0.47	7.68	0.39	1.78e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19717773	chr7:2847554	GNA12	-0.4	-6.35	-0.33	6.98e-10	Height;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03982507	chr18:44496911	PIAS2	-0.47	-6.25	-0.32	1.26e-9	Hepatitis;
LUSC	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.86	-12.45	-0.56	1.73e-29	Asthma;
LUSC	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg18854424	chr1:2615690	NA	0.46	9.54	0.46	3.1400000000000002e-19	Ulcerative colitis;
LUSC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg02038168	chr22:39784481	NA	-0.43	-6.47	-0.33	3.47e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs13720	0.722	rs191490	chr20:57576180	A/G	cg23907860	chr20:57583709	CTSZ	-0.46	-6.03	-0.31	4.27e-9	Platelet distribution width;
LUSC	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.71	-11.18	-0.52	7.32e-25	Migraine;
LUSC	cis	rs9905704	0.681	rs4793949	chr17:56571950	C/T	cg19466818	chr17:56409534	MIR142	-0.36	-6.93	-0.35	2.2e-11	Testicular germ cell tumor;
LUSC	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	1.1	17.21	0.69	5.83e-48	Exhaled nitric oxide output;
LUSC	cis	rs2540226	0.816	rs4670958	chr2:39980724	A/G	cg23576258	chr2:39999331	THUMPD2	-0.37	-6.28	-0.33	1.03e-9	Personality dimensions;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.44	-5.95	-0.31	6.91e-9	Longevity;Endometriosis;
LUSC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.89	-14.27	-0.62	2.11e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.61e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg06494592	chr3:125709126	NA	-0.52	-6.01	-0.31	4.85e-9	Blood pressure (smoking interaction);
LUSC	cis	rs3015497	0.631	rs17718908	chr14:51005213	A/G	cg26011998	chr14:51135199	SAV1	0.46	5.7	0.3	2.7e-8	Mean platelet volume;
LUSC	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.13	-0.52	1.1e-24	Mean corpuscular volume;
LUSC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg22437258	chr11:111473054	SIK2	0.52	7.46	0.38	7.5e-13	Primary sclerosing cholangitis;
LUSC	cis	rs7923609	1.000	rs7910927	chr10:65138910	T/G	cg01631684	chr10:65280961	REEP3	-0.38	-5.89	-0.31	9.62e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	0.58	9.15	0.45	5.95e-18	Breast cancer;
LUSC	cis	rs7246967	0.673	rs16999519	chr19:22814076	A/G	cg23217946	chr19:22817039	ZNF492	-0.42	-6.25	-0.32	1.24e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg16482183	chr6:26056742	HIST1H1C	0.85	11.43	0.53	9.3e-26	Iron status biomarkers;
LUSC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg17264618	chr3:40429014	ENTPD3	0.3	6.42	0.33	4.71e-10	Renal cell carcinoma;
LUSC	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.87	-0.35	3.13e-11	Response to antipsychotic treatment;
LUSC	cis	rs12986413	0.967	rs2108524	chr19:2170764	A/G	cg09261902	chr19:2140048	AP3D1	0.31	5.89	0.31	9.44e-9	Height;
LUSC	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg20503657	chr10:835505	NA	0.78	9.73	0.47	7.08e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg15445000	chr17:37608096	MED1	0.39	6.69	0.34	9.35e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-9.17	-0.45	5.02e-18	Obesity-related traits;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15302530	chr7:108210038	THAP5;DNAJB9	-0.45	-6.17	-0.32	1.93e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg23711669	chr6:146136114	FBXO30	0.92	17.39	0.69	1.06e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg10621924	chr7:39171070	POU6F2	0.43	6.77	0.35	5.76e-11	IgG glycosylation;
LUSC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.56	0.42	4.3e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-0.76	-9.18	-0.45	4.79e-18	Refractive error;
LUSC	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-6.45	-0.33	4.04e-10	Neuroticism;
LUSC	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.68	-9.83	-0.47	3.37e-20	Systemic sclerosis;
LUSC	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg00290607	chr11:67383545	NA	-0.38	-6.42	-0.33	4.74e-10	Mean corpuscular volume;
LUSC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.72	-7.23	-0.37	3.41e-12	Diabetic retinopathy;
LUSC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.41	-0.46	8.21e-19	Platelet count;
LUSC	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	0.96	8.01	0.4	1.94e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs3924048	0.559	rs4075304	chr1:12626803	C/T	cg23650765	chr1:12612165	NA	0.29	5.88	0.31	9.88e-9	Optic cup area;
LUSC	cis	rs10465746	0.935	rs12133778	chr1:84367626	A/G	cg10977910	chr1:84465055	TTLL7	0.42	5.9	0.31	9.13e-9	Obesity-related traits;
LUSC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.6	-8.92	-0.44	3.07e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	0.94	16.26	0.66	3.47e-44	Menopause (age at onset);
LUSC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg16624210	chr5:671434	TPPP	0.5	6.41	0.33	5.1e-10	Obesity-related traits;
LUSC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.58	9.51	0.46	3.99e-19	Aortic root size;
LUSC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.45	-8.8	-0.43	7.65e-17	Colorectal cancer;
LUSC	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg24069376	chr3:38537580	EXOG	0.41	7.88	0.4	4.77e-14	Electrocardiographic conduction measures;
LUSC	cis	rs8099014	0.906	rs4245268	chr18:56096515	A/G	cg12907477	chr18:56117327	MIR122	-0.41	-6.64	-0.34	1.27e-10	Platelet count;
LUSC	trans	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Depression;
LUSC	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg27284194	chr4:1044797	NA	0.59	8.84	0.44	5.65e-17	Recombination rate (females);
LUSC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg22868518	chr11:507468	RNH1	-0.59	-5.8	-0.3	1.56e-8	Body mass index;
LUSC	cis	rs7759001	0.857	rs6904883	chr6:27357308	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.72	0.3	2.39e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10089247	chr2:201754140	NIF3L1;PPIL3	-0.43	-6.39	-0.33	5.71e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7177699	0.526	rs7165733	chr15:79123505	G/A	cg15571903	chr15:79123663	NA	0.34	6.34	0.33	7.41e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs1355223	1.000	rs1396879	chr11:34766653	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.75	-0.3	2.04e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg08048268	chr3:133502702	NA	-0.41	-7.4	-0.38	1.08e-12	Iron status biomarkers;
LUSC	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg06484146	chr7:12443880	VWDE	-0.62	-6.24	-0.32	1.36e-9	Coronary artery disease;
LUSC	cis	rs1561176	0.783	rs1124175	chr7:155015124	A/C	cg25063631	chr7:155025500	NA	0.49	6.29	0.33	9.81e-10	Personality dimensions;
LUSC	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	8.43	0.42	1.06e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24623068	chr5:154317667	GEMIN5	-0.55	-6.64	-0.34	1.3100000000000001e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-0.8	-13.61	-0.6	7.51e-34	Longevity;
LUSC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg18904891	chr8:8559673	CLDN23	0.61	8.18	0.41	6.04e-15	Obesity-related traits;
LUSC	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.21	0.37	3.85e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9811920	0.809	rs4928153	chr3:99808445	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.44	-6.51	-0.34	2.71e-10	Axial length;
LUSC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg05861140	chr6:150128134	PCMT1	0.42	6.73	0.35	7.38e-11	Lung cancer;
LUSC	cis	rs2651899	0.934	rs1627080	chr1:3081309	T/C	cg22674798	chr1:3096360	PRDM16	0.3	6.72	0.35	7.9e-11	Migraine;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg09436375	chr6:42928200	GNMT	-0.31	-7.29	-0.37	2.26e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg10117171	chr1:25599238	RHD	-0.39	-6.07	-0.32	3.45e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg05084668	chr3:125655381	ALG1L	-0.77	-11.86	-0.54	2.63e-27	Blood pressure (smoking interaction);
LUSC	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.75e-15	Morning vs. evening chronotype;
LUSC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.16	0.41	6.91e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.26	-0.37	2.65e-12	Bipolar disorder;
LUSC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.03	20.65	0.75	1.23e-61	Cognitive function;
LUSC	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.86	-0.39	5.45e-14	Glomerular filtration rate;
LUSC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg16339924	chr4:17578868	LAP3	0.61	9.29	0.45	2.07e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2235544	0.579	rs1537321	chr1:54482236	C/A	cg25741118	chr1:54482237	LDLRAD1	-0.34	-7.67	-0.39	1.89e-13	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg14895029	chr7:2775587	GNA12	-0.4	-6.12	-0.32	2.57e-9	Height;
LUSC	cis	rs7851660	0.809	rs12550872	chr9:100653128	G/A	cg13688889	chr9:100608707	NA	-0.53	-8.06	-0.4	1.36e-14	Strep throat;
LUSC	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg05283184	chr6:79620031	NA	-0.46	-8.73	-0.43	1.26e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg00325919	chr1:156595847	NA	0.41	6.26	0.32	1.16e-9	N-glycan levels;
LUSC	cis	rs372883	0.935	rs1153294	chr21:30701096	A/G	cg24692254	chr21:30365293	RNF160	-0.42	-5.95	-0.31	6.93e-9	Pancreatic cancer;
LUSC	cis	rs16912285	0.688	rs35683920	chr11:24358521	A/G	ch.11.24196551F	chr11:24239977	NA	0.85	8.18	0.41	6.13e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1376303	0.643	rs12701264	chr7:32965040	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.64	5.72	0.3	2.4e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.45	0.5	2.62e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.7	-10.98	-0.52	3.64e-24	Aortic root size;
LUSC	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	7.33	0.37	1.76e-12	Schizophrenia;
LUSC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg17554472	chr22:41940697	POLR3H	-0.45	-5.77	-0.3	1.77e-8	Vitiligo;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03172651	chr20:13201655	ISM1	0.74	6.6	0.34	1.6e-10	Cognitive performance;
LUSC	cis	rs983392	0.678	rs1426253	chr11:59981218	A/C	cg20284999	chr11:59952153	MS4A6A	-0.36	-6.08	-0.32	3.24e-9	Alzheimer's disease (late onset);
LUSC	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg17691542	chr6:26056736	HIST1H1C	0.5	7.01	0.36	1.3e-11	Iron status biomarkers;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg02796970	chr10:39023768	NA	-0.48	-7.64	-0.39	2.24e-13	Menopause (age at onset);
LUSC	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.96	15.61	0.65	1.2e-41	Lymphocyte percentage of white cells;
LUSC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg21545522	chr1:205238299	TMCC2	0.46	8.63	0.43	2.51e-16	Red blood cell count;
LUSC	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	8.42	0.42	1.15e-15	Retinal vascular caliber;
LUSC	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.49	16.86	0.68	1.38e-46	Opioid sensitivity;
LUSC	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-8.36	-0.42	1.67e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs1113500	0.933	rs11185250	chr1:108616417	A/G	cg11967332	chr1:108735228	SLC25A24	0.4	5.88	0.31	1.01e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	0.77	13.53	0.6	1.44e-33	Cognitive function;
LUSC	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg18721089	chr20:30220636	NA	-0.41	-6.85	-0.35	3.62e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg12292205	chr6:26970375	C6orf41	-0.39	-5.73	-0.3	2.3e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg00945038	chr17:61921165	SMARCD2	0.51	8.74	0.43	1.12e-16	Prudent dietary pattern;
LUSC	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg10224037	chr5:178157518	ZNF354A	-0.88	-12.92	-0.58	3.12e-31	Neutrophil percentage of white cells;
LUSC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.89	-0.35	2.77e-11	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg13206674	chr6:150067644	NUP43	0.57	9.01	0.44	1.6e-17	Lung cancer;
LUSC	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg13256891	chr4:100009986	ADH5	0.51	7.03	0.36	1.21e-11	Smoking initiation;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26035323	chr1:44871156	RNF220	-0.5	-6.39	-0.33	5.55e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	12.56	0.57	6.99e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg21427119	chr20:30132790	HM13	-0.35	-5.75	-0.3	2.06e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs11676348	0.772	rs12694427	chr2:218945045	C/T	cg06547715	chr2:218990976	CXCR2	0.3	5.78	0.3	1.7e-8	Ulcerative colitis;
LUSC	trans	rs9650657	0.707	rs4841452	chr8:10687121	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.13	-0.32	2.42e-9	Neuroticism;
LUSC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.81	0.43	7.03e-17	Prudent dietary pattern;
LUSC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg22800045	chr5:56110881	MAP3K1	0.46	6.16	0.32	2.05e-9	Coronary artery disease;
LUSC	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-0.89	-13.28	-0.59	1.29e-32	Asthma;
LUSC	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg16586182	chr3:47516702	SCAP	0.52	8.18	0.41	6.15e-15	Colorectal cancer;
LUSC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg03676636	chr4:99064102	C4orf37	0.33	7.22	0.37	3.42e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4776059	1.000	rs11857150	chr15:52922216	G/A	cg22715398	chr15:52968154	KIAA1370	-0.65	-9.54	-0.46	3.02e-19	Schizophrenia;
LUSC	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg23649088	chr2:200775458	C2orf69	0.5	7.55	0.38	4.27e-13	Osteoporosis;
LUSC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg06238570	chr21:40685208	BRWD1	0.6	9.89	0.48	2.14e-20	Cognitive function;
LUSC	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg00071950	chr4:10020882	SLC2A9	0.53	8.89	0.44	3.85e-17	Bone mineral density;
LUSC	cis	rs17095355	0.818	rs10509907	chr10:111781715	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-6.72	-0.34	8.01e-11	Biliary atresia;
LUSC	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg05926586	chr15:74592786	CCDC33	0.3	5.99	0.31	5.39e-9	Airflow obstruction;
LUSC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg11494091	chr17:61959527	GH2	0.38	6.63	0.34	1.36e-10	Height;
LUSC	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg18477163	chr1:228402036	OBSCN	0.57	9.83	0.47	3.47e-20	Diastolic blood pressure;
LUSC	cis	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg06521331	chr12:34319734	NA	-0.48	-7.71	-0.39	1.43e-13	Morning vs. evening chronotype;
LUSC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18099408	chr3:52552593	STAB1	0.39	6.97	0.36	1.65e-11	Electroencephalogram traits;
LUSC	trans	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg21775007	chr8:11205619	TDH	0.44	6.53	0.34	2.51e-10	Mood instability;
LUSC	cis	rs13253111	0.624	rs7357359	chr8:28094835	T/C	cg26534493	chr8:28060551	NA	0.38	6.91	0.35	2.47e-11	Childhood body mass index;
LUSC	cis	rs11170631	0.507	rs12307701	chr12:54090724	A/C	cg23533419	chr12:54090519	NA	-0.38	-6.22	-0.32	1.45e-9	Height;
LUSC	cis	rs8062405	0.698	rs8046545	chr16:28915217	G/A	cg05966235	chr16:28915196	ATP2A1	-0.36	-6.07	-0.32	3.53e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs295140	0.506	rs295136	chr2:201141002	G/C	cg23649088	chr2:200775458	C2orf69	0.4	5.98	0.31	5.89e-9	QT interval;
LUSC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.14e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg24375607	chr4:120327624	NA	0.73	10.73	0.51	2.81e-23	Corneal astigmatism;
LUSC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	10.39	0.49	4.2e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.39	-0.42	1.35e-15	Coffee consumption (cups per day);
LUSC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg20243544	chr17:37824526	PNMT	0.48	6.06	0.31	3.67e-9	Glomerular filtration rate (creatinine);
LUSC	trans	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg18187862	chr3:45730750	SACM1L	0.51	6.52	0.34	2.59e-10	Primary sclerosing cholangitis;
LUSC	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg08557956	chr11:4115526	RRM1	-0.41	-5.65	-0.3	3.52e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg24846343	chr22:24311635	DDTL	0.41	6.47	0.33	3.56e-10	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg00933542	chr6:150070202	PCMT1	0.33	7.04	0.36	1.11e-11	Lung cancer;
LUSC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg16647868	chr5:131706066	SLC22A5	0.42	6.58	0.34	1.81e-10	Breast cancer;
LUSC	cis	rs908922	0.887	rs4845783	chr1:152492559	G/A	cg20991723	chr1:152506922	NA	0.52	9.06	0.44	1.15e-17	Hair morphology;
LUSC	cis	rs7200543	0.883	rs4985148	chr16:15147788	A/C	cg03427771	chr16:15082598	PDXDC1	-0.41	-5.94	-0.31	7.2e-9	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.84	-0.3	1.22e-8	Platelet count;
LUSC	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.2	-0.32	1.7e-9	Resting heart rate;
LUSC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg18402987	chr7:1209562	NA	0.71	7.55	0.38	4.11e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.37	-0.33	6.24e-10	Neuroticism;
LUSC	cis	rs2637266	0.783	rs7914756	chr10:78476406	A/T	cg18941641	chr10:78392320	NA	-0.34	-6.15	-0.32	2.16e-9	Pulmonary function;
LUSC	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg05347473	chr6:146136440	FBXO30	-0.38	-6.31	-0.33	9.11e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1018836	0.770	rs12543806	chr8:91664011	C/T	cg16814680	chr8:91681699	NA	-0.98	-18.94	-0.72	7.58e-55	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19127360	chr2:242089945	PPP1R7;PASK	-0.41	-6.22	-0.32	1.47e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg21100191	chr22:23484243	RTDR1	-0.86	-14.83	-0.63	1.42e-38	Bone mineral density;
LUSC	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-0.85	-12.48	-0.56	1.3e-29	Migraine;Coronary artery disease;
LUSC	cis	rs4812048	1.000	rs6070692	chr20:57586374	A/G	cg14073986	chr20:57617431	SLMO2	0.59	6.28	0.33	1.04e-9	Mean platelet volume;
LUSC	cis	rs7106204	0.609	rs10500976	chr11:24335921	A/G	ch.11.24196551F	chr11:24239977	NA	-0.64	-6.07	-0.32	3.46e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6500395	0.925	rs6500396	chr16:48625458	A/T	cg04672837	chr16:48644449	N4BP1	0.5	7.42	0.38	9.77e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg05347473	chr6:146136440	FBXO30	-0.59	-10.32	-0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.62	10.3	0.49	8.96e-22	Blood metabolite ratios;
LUSC	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg09307838	chr4:120376055	NA	0.73	10.22	0.49	1.58e-21	Corneal astigmatism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17017152	chr1:61547389	NFIA	0.44	6.52	0.34	2.64e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs757081	0.637	rs586785	chr11:17208714	T/C	cg15432903	chr11:17409602	KCNJ11	-0.38	-5.91	-0.31	8.41e-9	Systolic blood pressure;
LUSC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg05861140	chr6:150128134	PCMT1	-0.39	-6.15	-0.32	2.26e-9	Lung cancer;
LUSC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6681460	1.000	rs7521123	chr1:67121663	T/C	cg02459107	chr1:67143332	SGIP1	0.48	8.99	0.44	1.94e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs1775715	0.677	rs2808074	chr10:32179184	A/C	cg04359828	chr10:32216031	ARHGAP12	0.39	6.65	0.34	1.17e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg07777115	chr5:623756	CEP72	-0.45	-5.68	-0.3	2.98e-8	Obesity-related traits;
LUSC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs9346649	0.616	rs1873337	chr6:168492160	T/G	cg02770688	chr6:168491649	NA	0.48	9.08	0.45	9.54e-18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs78572108	0.858	rs4952583	chr2:42268688	C/T	cg00607755	chr2:42274082	PKDCC	0.35	5.93	0.31	7.47e-9	Total body bone mineral density;
LUSC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg05368731	chr17:41323189	NBR1	0.83	13.9	0.61	5.72e-35	Menopause (age at onset);
LUSC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg05347473	chr6:146136440	FBXO30	0.53	8.91	0.44	3.27e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs62400317	0.859	rs10948219	chr6:45229307	A/T	cg20913747	chr6:44695427	NA	-0.47	-7.65	-0.39	2.2e-13	Total body bone mineral density;
LUSC	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.55	-0.42	4.48e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6009527	1.000	rs737834	chr22:49573190	C/T	cg12746016	chr22:49560550	NA	0.36	6.09	0.32	3.09e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs12541635	0.677	rs7460291	chr8:107057861	A/G	cg10147462	chr8:107024639	NA	0.66	13.77	0.6	1.77e-34	Age of smoking initiation;
LUSC	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg15839431	chr19:19639596	YJEFN3	0.66	7.28	0.37	2.39e-12	Bipolar disorder;
LUSC	cis	rs2282802	0.685	rs1529693	chr5:139678213	A/G	cg26211634	chr5:139558579	C5orf32	0.38	7.13	0.36	6.33e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg25767906	chr1:53392781	SCP2	-0.52	-9.58	-0.46	2.27e-19	Monocyte count;
LUSC	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg26116260	chr4:7069785	GRPEL1	-0.71	-6.52	-0.34	2.67e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26314531	chr2:26401878	FAM59B	0.68	8.53	0.42	5.02e-16	Gut microbiome composition (summer);
LUSC	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.45	6.24	0.32	1.33e-9	Multiple sclerosis;
LUSC	trans	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	20.29	0.74	3.32e-60	Colorectal cancer;
LUSC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.66	-0.34	1.14e-10	Monocyte percentage of white cells;
LUSC	cis	rs17661538	0.542	rs11592688	chr10:18422535	T/G	cg03634479	chr10:18430412	CACNB2	0.59	5.78	0.3	1.7e-8	Response to antipsychotic treatment;
LUSC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.36e-10	Menopause (age at onset);
LUSC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.13	0.41	8.57e-15	Homoarginine levels;
LUSC	trans	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg19894588	chr14:64061835	NA	-0.51	-6.61	-0.34	1.48e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs4363385	0.510	rs11205187	chr1:153053323	T/C	cg25856811	chr1:152973957	SPRR3	-0.38	-6.22	-0.32	1.52e-9	Inflammatory skin disease;
LUSC	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg17470723	chr8:74884337	TCEB1	0.53	8.16	0.41	6.81e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18450072	chr4:40058936	LOC344967;N4BP2	-0.48	-6.11	-0.32	2.84e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs17407555	0.697	rs73212821	chr4:10069451	T/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.44	-0.33	4.12e-10	Schizophrenia (age at onset);
LUSC	cis	rs10979	1.000	rs9390110	chr6:143893413	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-12.14	-0.55	2.4e-28	Hypospadias;
LUSC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg11764359	chr7:65958608	NA	-0.78	-12.7	-0.57	2.07e-30	Aortic root size;
LUSC	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg21643547	chr1:205240462	TMCC2	-0.49	-9.36	-0.46	1.17e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19346786	chr7:2764209	NA	-0.39	-6.99	-0.36	1.54e-11	Height;
LUSC	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg22705602	chr4:152727874	NA	-0.34	-7.58	-0.38	3.36e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg00310523	chr12:86230176	RASSF9	0.44	8.2	0.41	5.3e-15	Major depressive disorder;
LUSC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	14.04	0.61	1.66e-35	Total body bone mineral density;
LUSC	trans	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.19	0.45	4.38e-18	Mean corpuscular volume;
LUSC	cis	rs7180079	0.844	rs11071791	chr15:64602270	C/A	cg08069370	chr15:64387884	SNX1	0.53	5.72	0.3	2.32e-8	Monocyte count;
LUSC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg07777115	chr5:623756	CEP72	-0.47	-5.9	-0.31	9.07e-9	Obesity-related traits;
LUSC	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg15934090	chr1:100435551	SLC35A3	0.48	8.26	0.41	3.47e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9427116	0.502	rs3766922	chr1:154577055	A/C	cg17218026	chr1:154582156	ADAR	0.55	10.07	0.48	5.33e-21	Blood protein levels;
LUSC	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg24011408	chr12:48396354	COL2A1	0.55	7.6	0.38	3.01e-13	Lung cancer;
LUSC	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.33	-0.37	1.73e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs61990749	0.597	rs117131659	chr14:78131126	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.58	-6.26	-0.32	1.16e-9	Fibroblast growth factor basic levels;
LUSC	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg00495681	chr13:53174319	NA	0.48	7.62	0.38	2.6e-13	Lewy body disease;
LUSC	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg27490568	chr2:178487706	NA	0.4	6.0	0.31	5.19e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.32	-0.33	8.54e-10	Lung cancer;
LUSC	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-6.02	-0.31	4.51e-9	Platelet count;
LUSC	cis	rs7508	0.618	rs13266287	chr8:17871598	T/A	cg01800426	chr8:17659068	MTUS1	-0.41	-5.99	-0.31	5.51e-9	Atrial fibrillation;
LUSC	cis	rs77741769	0.571	rs11065311	chr12:121324115	A/T	cg02419362	chr12:121203948	SPPL3	-0.41	-7.56	-0.38	4.02e-13	Mean corpuscular volume;
LUSC	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg23649088	chr2:200775458	C2orf69	-0.54	-6.53	-0.34	2.39e-10	Schizophrenia;
LUSC	cis	rs11605275	0.792	rs2568131	chr11:20046407	G/T	cg14835545	chr11:20032148	NAV2	0.6	6.02	0.31	4.59e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg25237894	chr2:233734115	C2orf82	-0.36	-6.81	-0.35	4.67e-11	Coronary artery disease;
LUSC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.31	-7.75	-0.39	1.13e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	0.98	14.18	0.61	4.77e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs2932538	0.922	rs6658555	chr1:113098534	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	9.89	0.48	2.21e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg00701064	chr4:6280414	WFS1	0.61	15.07	0.64	1.62e-39	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-5.74	-0.3	2.18e-8	Vitiligo;
LUSC	cis	rs34638657	0.732	rs62045964	chr16:82200920	T/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.31	-0.33	8.83e-10	Lung adenocarcinoma;
LUSC	cis	rs2932538	0.922	rs11102508	chr1:113141175	T/C	cg22162597	chr1:113214053	CAPZA1	0.53	7.64	0.39	2.37e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg25173405	chr17:45401733	C17orf57	0.36	5.72	0.3	2.32e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg17633681	chr16:88106987	BANP	0.5	9.45	0.46	5.93e-19	Menopause (age at onset);
LUSC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-11.74	-0.54	7.33e-27	Systemic lupus erythematosus;
LUSC	cis	rs7945705	0.846	rs11042055	chr11:8756856	G/A	cg12365402	chr11:9010492	NRIP3	0.44	7.57	0.38	3.74e-13	Hemoglobin concentration;
LUSC	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg11663144	chr21:46675770	NA	-0.41	-7.23	-0.37	3.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7089973	0.966	rs36089581	chr10:116623059	G/C	cg23260525	chr10:116636907	FAM160B1	0.39	7.57	0.38	3.74e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20018234	chr1:156084659	LMNA	0.74	6.01	0.31	4.8e-9	Cognitive performance;
LUSC	trans	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-12.24	-0.56	1.03e-28	Colorectal cancer;
LUSC	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg26384229	chr12:38710491	ALG10B	0.7	10.87	0.51	9.4e-24	Morning vs. evening chronotype;
LUSC	trans	rs9929218	0.954	rs12599393	chr16:68829021	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-10.87	-0.51	8.82e-24	Colorectal cancer;
LUSC	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg04374321	chr14:90722782	PSMC1	-0.44	-6.61	-0.34	1.57e-10	Mortality in heart failure;
LUSC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.46	0.53	7.44e-26	Menopause (age at onset);
LUSC	cis	rs4076764	0.522	rs10799914	chr1:163353205	A/G	cg24596788	chr1:163392923	NA	-0.34	-5.72	-0.3	2.34e-8	Motion sickness;
LUSC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg19592336	chr6:28129416	ZNF389	0.49	6.78	0.35	5.54e-11	Parkinson's disease;
LUSC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.69	0.34	9.15e-11	Tonsillectomy;
LUSC	trans	rs2950393	0.804	rs2958130	chr12:57140506	G/A	cg14367344	chr1:146644336	PRKAB2	-0.42	-5.99	-0.31	5.57e-9	Platelet distribution width;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08868379	chr11:75946452	NA	-0.4	-6.09	-0.32	3.13e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg12463550	chr7:65579703	CRCP	0.42	6.0	0.31	5.11e-9	Calcium levels;
LUSC	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg00530320	chr1:46809349	NSUN4	0.56	8.72	0.43	1.29e-16	Menopause (age at onset);
LUSC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg26924012	chr15:45694286	SPATA5L1	1.07	17.48	0.69	4.61e-49	Homoarginine levels;
LUSC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg13628971	chr7:2884303	GNA12	0.43	6.27	0.32	1.11e-9	Height;
LUSC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg11663144	chr21:46675770	NA	-0.42	-7.34	-0.37	1.66e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg06937882	chr20:24974362	C20orf3	-0.42	-7.22	-0.37	3.45e-12	Blood protein levels;
LUSC	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.49	-7.36	-0.37	1.41e-12	Reticulocyte count;
LUSC	cis	rs911119	1.000	rs3787499	chr20:23616807	G/A	cg16589663	chr20:23618590	CST3	0.6	6.99	0.36	1.48e-11	Chronic kidney disease;
LUSC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22307029	chr19:49891270	CCDC155	0.67	9.59	0.46	2.12e-19	Multiple sclerosis;
LUSC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26354017	chr1:205819088	PM20D1	0.79	15.1	0.64	1.22e-39	Monocyte percentage of white cells;
LUSC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg27068330	chr11:65405492	SIPA1	-0.46	-6.0	-0.31	5.25e-9	Breast cancer;
LUSC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg16325326	chr1:53192061	ZYG11B	-1.0	-20.85	-0.75	1.94e-62	Monocyte count;
LUSC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.76	-0.3	1.92e-8	Personality dimensions;
LUSC	cis	rs12681287	0.546	rs11539113	chr8:87497176	G/A	cg00550725	chr8:87521180	FAM82B	0.44	5.81	0.3	1.48e-8	Caudate activity during reward;
LUSC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.84	0.51	1.21e-23	Heart rate;
LUSC	trans	rs2282032	1.000	rs75722521	chr14:90760478	T/C	cg11965331	chr8:7651924	NA	0.42	5.97	0.31	6.07e-9	Longevity;
LUSC	cis	rs9517320	1.000	rs7996629	chr13:99128037	C/T	cg07423050	chr13:99094983	FARP1	0.34	6.33	0.33	8.08e-10	Longevity;
LUSC	cis	rs9920506	0.536	rs11636605	chr15:78928878	A/G	cg24631222	chr15:78858424	CHRNA5	-0.56	-7.14	-0.36	5.72e-12	Post bronchodilator FEV1;
LUSC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg22437258	chr11:111473054	SIK2	0.53	7.53	0.38	4.93e-13	Primary sclerosing cholangitis;
LUSC	cis	rs2882667	0.690	rs825747	chr5:138136585	C/T	cg04439458	chr5:138467593	SIL1	0.4	7.18	0.37	4.6e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg18681998	chr4:17616180	MED28	-0.82	-14.58	-0.62	1.34e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08859206	chr1:53392774	SCP2	0.5	8.51	0.42	6.03e-16	Monocyte count;
LUSC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.12	-0.32	2.69e-9	Resting heart rate;
LUSC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08280861	chr8:58055591	NA	0.53	5.73	0.3	2.22e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.47	-6.84	-0.35	3.75e-11	Menarche (age at onset);
LUSC	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.39	5.75	0.3	2.04e-8	Neutrophil percentage of white cells;
LUSC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.09	-0.32	3.04e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2708377	0.929	rs1817043	chr12:11215852	G/A	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs4343996	0.565	rs13246563	chr7:3438243	C/G	cg21248987	chr7:3385318	SDK1	0.34	5.66	0.3	3.27e-8	Motion sickness;
LUSC	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg25319279	chr11:5960081	NA	-0.41	-5.76	-0.3	1.93e-8	DNA methylation (variation);
LUSC	cis	rs354225	0.584	rs9677089	chr2:54794927	A/C	cg26097391	chr2:54893211	SPTBN1	0.4	6.06	0.31	3.64e-9	Schizophrenia;
LUSC	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg25482853	chr8:67687455	SGK3	1.1	15.65	0.65	8.75e-42	Obesity-related traits;
LUSC	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-0.9	-17.73	-0.7	4.8e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11018904	0.906	rs11603498	chr11:89928783	C/A	cg26138821	chr11:89956704	CHORDC1	-0.6	-6.87	-0.35	3.24e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.39	5.79	0.3	1.66e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10733682	0.659	rs4358894	chr9:129464802	C/G	cg00232160	chr9:129468157	NA	0.39	6.95	0.36	1.9e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg05347473	chr6:146136440	FBXO30	0.54	9.3	0.45	1.87e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7709377	0.597	rs7732346	chr5:115502248	A/T	cg23108291	chr5:115420582	COMMD10	0.42	5.96	0.31	6.35e-9	Metabolite levels  (X-11787);
LUSC	cis	rs2354432	0.607	rs2297752	chr1:146765454	C/G	cg25205988	chr1:146714368	CHD1L	-1.02	-10.76	-0.51	2.28e-23	Mitochondrial DNA levels;
LUSC	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg04691961	chr3:161091175	C3orf57	-0.35	-5.94	-0.31	7.08e-9	Morning vs. evening chronotype;
LUSC	cis	rs6977660	0.652	rs10274428	chr7:19850592	C/T	cg07541023	chr7:19748670	TWISTNB	0.54	5.68	0.3	2.89e-8	Thyroid stimulating hormone;
LUSC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg21724239	chr8:58056113	NA	0.8	8.44	0.42	9.52e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg17724175	chr1:150552817	MCL1	0.32	5.74	0.3	2.08e-8	Melanoma;
LUSC	trans	rs2262909	1.000	rs2359821	chr19:22208314	C/T	cg17074339	chr11:11642133	GALNTL4	-0.41	-6.2	-0.32	1.68e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-0.9	-16.12	-0.66	1.16e-43	Height;
LUSC	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg24675056	chr1:15929824	NA	0.5	8.74	0.43	1.18e-16	Systolic blood pressure;
LUSC	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.56	10.53	0.5	1.42e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Parkinson's disease;
LUSC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00149659	chr3:10157352	C3orf10	0.89	12.11	0.55	3.04e-28	Alzheimer's disease;
LUSC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg11663144	chr21:46675770	NA	-0.41	-7.03	-0.36	1.15e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg08975724	chr8:8085496	FLJ10661	0.54	8.11	0.41	9.83e-15	Neuroticism;
LUSC	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg20703242	chr1:230279135	GALNT2	0.52	8.2	0.41	5.22e-15	Coronary artery disease;
LUSC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg06008330	chr7:65541103	ASL	-0.36	-5.65	-0.3	3.53e-8	Aortic root size;
LUSC	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg17691542	chr6:26056736	HIST1H1C	0.52	7.04	0.36	1.07e-11	Height;
LUSC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.5	7.81	0.39	7.61e-14	Colorectal cancer;
LUSC	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.8	-0.39	7.99e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs12760731	0.623	rs12239670	chr1:178377761	G/T	cg00404053	chr1:178313656	RASAL2	0.48	5.74	0.3	2.16e-8	Obesity-related traits;
LUSC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg13397359	chr6:42928475	GNMT	0.57	9.57	0.46	2.4e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-6.8	-0.35	4.8e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg08601574	chr20:25228251	PYGB	0.43	6.53	0.34	2.4e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2262909	0.925	rs73019838	chr19:22247732	T/A	cg11619707	chr19:22235551	ZNF257	0.39	5.84	0.3	1.22e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg02038168	chr22:39784481	NA	0.49	8.2	0.41	5.4e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.44	0.33	4.04e-10	Corneal astigmatism;
LUSC	trans	rs7980799	0.772	rs6488162	chr12:33593127	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.51	-0.34	2.83e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs2303282	0.664	rs2617846	chr16:56397153	G/A	cg00500540	chr16:56394104	NA	-0.4	-6.96	-0.36	1.76e-11	Breast cancer;
LUSC	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg18932078	chr1:2524107	MMEL1	0.29	6.43	0.33	4.29e-10	Ulcerative colitis;
LUSC	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.69	9.97	0.48	1.11e-20	Cognitive ability;
LUSC	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg18477163	chr1:228402036	OBSCN	0.57	9.57	0.46	2.49e-19	Diastolic blood pressure;
LUSC	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg18132916	chr6:79620363	NA	-0.38	-5.74	-0.3	2.18e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7091068	0.706	rs1147644	chr10:95400947	A/G	cg20715218	chr10:95462985	C10orf4	-0.52	-5.69	-0.3	2.76e-8	Urinary tract infection frequency;
LUSC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg06060754	chr5:176797920	RGS14	0.58	9.08	0.45	9.43e-18	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg09365446	chr1:150670422	GOLPH3L	-0.53	-7.79	-0.39	8.71e-14	Melanoma;
LUSC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg25019033	chr10:957182	NA	-0.53	-6.81	-0.35	4.62e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-10.09	-0.48	4.36e-21	Electroencephalogram traits;
LUSC	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg11502198	chr6:26597334	ABT1	0.71	11.81	0.54	3.94e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	9.69	0.47	9.79e-20	Lung cancer in ever smokers;
LUSC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	8.19	0.41	5.73e-15	Schizophrenia;
LUSC	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg03651054	chr13:50194643	NA	0.36	6.24	0.32	1.29e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.69	0.39	1.71e-13	Electroencephalogram traits;
LUSC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-6.06	-0.31	3.74e-9	Fear of minor pain;
LUSC	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	0.66	6.56	0.34	2.08e-10	Prostate cancer;
LUSC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	6.5	0.34	2.95e-10	Platelet count;
LUSC	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg19920283	chr7:105172520	RINT1	0.58	6.25	0.32	1.25e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.18	0.41	5.96e-15	Corneal astigmatism;
LUSC	trans	rs1493916	0.601	rs7237379	chr18:31322540	C/T	cg27147174	chr7:100797783	AP1S1	0.56	8.79	0.43	7.87e-17	Life satisfaction;
LUSC	cis	rs28595532	0.702	rs72670252	chr4:119337546	A/C	cg21605333	chr4:119757512	SEC24D	1.02	8.34	0.42	1.96e-15	Cannabis dependence symptom count;
LUSC	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.41	-0.33	5e-10	Cutaneous nevi;
LUSC	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.66	-0.34	1.1e-10	Total cholesterol levels;
LUSC	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.55	-10.49	-0.5	1.86e-22	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9928842	0.882	rs9927264	chr16:75260241	T/C	cg09066997	chr16:75300724	BCAR1	0.52	6.57	0.34	1.93e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-8.91	-0.44	3.36e-17	Response to antipsychotic treatment;
LUSC	cis	rs16921914	0.565	rs286650	chr11:31230207	T/C	cg06552810	chr11:31128660	NA	-0.4	-7.08	-0.36	8.78e-12	Bone mineral density (spine);
LUSC	cis	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg27411982	chr8:10470053	RP1L1	0.43	6.83	0.35	4.14e-11	Systolic blood pressure;
LUSC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg17178900	chr1:205818956	PM20D1	0.74	11.88	0.55	2.16e-27	Menarche (age at onset);
LUSC	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg25214090	chr10:38739885	LOC399744	0.53	7.68	0.39	1.73e-13	Corneal astigmatism;
LUSC	trans	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg24313572	chr1:56050060	NA	-0.31	-6.38	-0.33	5.9e-10	Morning vs. evening chronotype;
LUSC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg08847533	chr14:75593920	NEK9	-0.66	-10.86	-0.51	9.51e-24	Coronary artery disease;
LUSC	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg21770322	chr7:97807741	LMTK2	0.57	10.55	0.5	1.2e-22	Breast cancer;
LUSC	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg10978503	chr1:24200527	CNR2	0.54	13.3	0.59	1.11e-32	Immature fraction of reticulocytes;
LUSC	cis	rs907683	0.584	rs1058284	chr2:220286142	G/A	cg15015639	chr2:220282977	DES	-0.31	-7.23	-0.37	3.27e-12	Resting heart rate;
LUSC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg12463550	chr7:65579703	CRCP	0.51	7.38	0.37	1.26e-12	Aortic root size;
LUSC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg05313129	chr8:58192883	C8orf71	-0.45	-5.92	-0.31	8.01e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11214589	0.905	rs1078	chr11:113241877	C/T	cg14159747	chr11:113255604	NA	0.29	7.02	0.36	1.22e-11	Neuroticism;
LUSC	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg08213375	chr14:104286397	PPP1R13B	0.36	5.94	0.31	7.22e-9	Reticulocyte count;
LUSC	cis	rs11031096	0.782	rs10835684	chr11:4168308	G/T	cg18678763	chr11:4115507	RRM1	-0.51	-7.52	-0.38	5.19e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.74	-0.35	7.14e-11	Axial length;
LUSC	cis	rs34779708	0.966	rs1213392	chr10:35430285	C/T	cg04310649	chr10:35416472	CREM	-0.4	-6.28	-0.32	1.06e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.68	0.39	1.72e-13	Schizophrenia;
LUSC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.97	-0.44	2.21e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	12.27	0.56	8.05e-29	Electrocardiographic conduction measures;
LUSC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg04282206	chr17:62833786	PLEKHM1P	-0.41	-6.02	-0.31	4.53e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg17724175	chr1:150552817	MCL1	0.36	6.51	0.34	2.7e-10	Tonsillectomy;
LUSC	trans	rs11088226	0.846	rs13047501	chr21:33924660	G/A	cg09050820	chr6:167586206	TCP10L2	0.65	9.85	0.47	2.91e-20	Gastritis;
LUSC	cis	rs9807989	0.507	rs4851579	chr2:103028984	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.14e-12	Asthma;
LUSC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	10.83	0.51	1.26e-23	Bone mineral density;
LUSC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.87	-0.35	3.23e-11	Menarche (age at onset);
LUSC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.94	0.44	2.75e-17	Prudent dietary pattern;
LUSC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12667521	chr19:29218732	NA	0.58	8.62	0.43	2.75e-16	Methadone dose in opioid dependence;
LUSC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.7	-10.7	-0.51	3.47e-23	Aortic root size;
LUSC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg02018176	chr4:1364513	KIAA1530	0.52	8.87	0.44	4.63e-17	Obesity-related traits;
LUSC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg05623727	chr3:50126028	RBM5	0.34	6.36	0.33	6.74e-10	Body mass index;
LUSC	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg05855489	chr10:104503620	C10orf26	0.59	9.38	0.46	1.01e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.49	-7.39	-0.37	1.2e-12	Menarche (age at onset);
LUSC	cis	rs259282	0.562	rs28505804	chr19:33110047	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.63	9.38	0.46	1.05e-18	Schizophrenia;
LUSC	cis	rs2153904	0.590	rs823106	chr1:205656453	G/C	cg23034840	chr1:205782522	SLC41A1	0.65	7.05	0.36	1.02e-11	Prostate-specific antigen levels;
LUSC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-0.87	-9.49	-0.46	4.54e-19	Breast cancer;
LUSC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.39	-0.33	5.59e-10	Schizophrenia;
LUSC	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.86	0.31	1.1e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs367943	0.688	rs10063452	chr5:112734165	C/T	cg12552261	chr5:112820674	MCC	0.35	5.78	0.3	1.7e-8	Type 2 diabetes;
LUSC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg03188948	chr7:1209495	NA	0.45	6.07	0.32	3.51e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg04362960	chr10:104952993	NT5C2	0.6	9.64	0.47	1.44e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9644630	1.000	rs9644630	chr8:19370598	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.35	6.42	0.33	4.79e-10	Oropharynx cancer;
LUSC	trans	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg16724585	chr3:197361211	NA	-0.58	-8.18	-0.41	6.01e-15	Pancreatic cancer;
LUSC	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg03342759	chr3:160939853	NMD3	-0.43	-7.31	-0.37	2.04e-12	Morning vs. evening chronotype;
LUSC	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.76	-12.21	-0.56	1.37e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.71	-9.73	-0.47	7.58e-20	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg06637938	chr14:75390232	RPS6KL1	0.64	10.18	0.49	2.25e-21	Caffeine consumption;
LUSC	cis	rs4423214	0.569	rs12806918	chr11:71119018	G/T	cg05163923	chr11:71159392	DHCR7	0.52	7.7	0.39	1.59e-13	Vitamin D levels;
LUSC	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg22705602	chr4:152727874	NA	-0.39	-8.55	-0.42	4.45e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.79	0.47	4.5e-20	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	0.91	15.88	0.66	1.03e-42	Menopause (age at onset);
LUSC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg13206674	chr6:150067644	NUP43	0.57	8.82	0.43	6.37e-17	Lung cancer;
LUSC	cis	rs6740322	0.841	rs10211126	chr2:43551416	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-7.48	-0.38	6.54e-13	Coronary artery disease;
LUSC	cis	rs2115536	0.935	rs11854390	chr15:80224817	C/T	cg00225070	chr15:80189496	MTHFS	0.6	8.99	0.44	1.89e-17	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg22491629	chr6:157744540	C6orf35	0.92	10.65	0.5	5.23e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs6977660	0.607	rs12113916	chr7:19781424	G/T	cg05791153	chr7:19748676	TWISTNB	0.76	7.51	0.38	5.62e-13	Thyroid stimulating hormone;
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg27094323	chr7:1216898	NA	-0.46	-7.86	-0.39	5.47e-14	Longevity;Endometriosis;
LUSC	cis	rs13089785	1.000	rs13081955	chr3:123600144	A/G	cg02012769	chr3:123398346	MYLK	0.32	5.91	0.31	8.64e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg11766577	chr21:47581405	C21orf56	-0.54	-8.39	-0.42	1.43e-15	Testicular germ cell tumor;
LUSC	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.8e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.49	-6.97	-0.36	1.66e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9928842	1.000	rs9928842	chr16:75242867	T/C	cg09066997	chr16:75300724	BCAR1	0.54	6.51	0.34	2.79e-10	Alcoholic chronic pancreatitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10433231	chr8:29940842	TMEM66	-0.42	-6.25	-0.32	1.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg01503450	chr10:980765	NA	-0.4	-5.85	-0.3	1.15e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg01966878	chr4:90757139	SNCA	-0.4	-5.78	-0.3	1.73e-8	Neuroticism;
LUSC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.47e-30	Motion sickness;
LUSC	trans	rs9944715	1.000	rs9944767	chr18:43831057	A/G	cg01718231	chr17:29326311	RNF135	0.51	7.19	0.37	4.33e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-0.6	-9.13	-0.45	6.61e-18	Breast cancer;
LUSC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10053473	chr17:62856997	LRRC37A3	0.68	10.88	0.51	8.2e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg07741184	chr6:167504864	NA	-0.34	-5.94	-0.31	7.23e-9	Crohn's disease;
LUSC	cis	rs3755132	0.929	rs61314003	chr2:15748524	A/G	cg12888861	chr2:15731646	DDX1	0.5	7.3	0.37	2.16e-12	Wilms tumor;
LUSC	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	1.13	17.44	0.69	6.81e-49	Corneal structure;
LUSC	cis	rs500891	0.533	rs3757009	chr6:84131194	G/A	cg08257003	chr6:84140564	ME1	0.36	8.7	0.43	1.51e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.46	0.38	7.75e-13	Motion sickness;
LUSC	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.33e-21	Lymphocyte counts;
LUSC	cis	rs11630290	0.589	rs2120251	chr15:64168772	T/C	cg12036633	chr15:63758958	NA	0.48	5.98	0.31	5.6e-9	Iris characteristics;
LUSC	cis	rs10761482	0.813	rs10821735	chr10:62104980	A/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.12	-0.36	6.69e-12	Schizophrenia;
LUSC	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.92	-0.35	2.28e-11	Menopause (age at onset);
LUSC	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg24634471	chr8:143751801	JRK	0.5	7.19	0.37	4.17e-12	Schizophrenia;
LUSC	trans	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg26043149	chr18:55253948	FECH	0.51	7.52	0.38	5.09e-13	Bone mineral density;
LUSC	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.71	-0.43	1.4e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24549020	chr5:56110836	MAP3K1	0.47	5.8	0.3	1.58e-8	Initial pursuit acceleration;
LUSC	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg03859395	chr2:55845619	SMEK2	0.88	16.5	0.67	3.62e-45	Metabolic syndrome;
LUSC	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.42	-6.06	-0.31	3.76e-9	Lung cancer;
LUSC	trans	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.85	0.35	3.56e-11	Endometrial cancer;
LUSC	cis	rs472402	0.560	rs6874005	chr5:6624371	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.51	-7.32	-0.37	1.87e-12	Response to amphetamines;
LUSC	cis	rs61935443	0.720	rs10859785	chr12:95295081	A/T	cg21533806	chr12:95267307	NA	0.5	6.19	0.32	1.79e-9	Schizophrenia;
LUSC	trans	rs6076960	0.681	rs4487157	chr20:6249581	G/A	cg17788362	chr6:86352627	SYNCRIP	0.44	6.29	0.33	9.71e-10	Smooth-surface caries;
LUSC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06873352	chr17:61820015	STRADA	0.55	8.56	0.42	4.22e-16	Height;
LUSC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg03146154	chr1:46216737	IPP	0.55	8.25	0.41	3.82e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.73e-23	Bladder cancer;
LUSC	trans	rs34421088	0.506	rs4841519	chr8:11146228	A/T	cg15556689	chr8:8085844	FLJ10661	0.44	6.85	0.35	3.56e-11	Neuroticism;
LUSC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.02	0.58	1.28e-31	Chronic sinus infection;
LUSC	cis	rs2227564	0.729	rs2633304	chr10:75650650	T/C	cg23231163	chr10:75533350	FUT11	-0.43	-5.88	-0.31	9.97e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-1.23	-13.29	-0.59	1.17e-32	Diabetic kidney disease;
LUSC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg09034736	chr1:150693464	HORMAD1	0.49	7.11	0.36	7.09e-12	Tonsillectomy;
LUSC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.66	8.39	0.42	1.4e-15	Lung function (FEV1/FVC);
LUSC	trans	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg25214090	chr10:38739885	LOC399744	0.52	7.65	0.39	2.22e-13	Corneal astigmatism;
LUSC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg12560992	chr17:57184187	TRIM37	0.83	15.26	0.64	2.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg03563238	chr19:33554763	RHPN2	-0.4	-6.26	-0.32	1.16e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg15704280	chr7:45808275	SEPT13	0.69	7.64	0.39	2.3e-13	Axial length;
LUSC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.05e-14	Crohn's disease;
LUSC	trans	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.48	-0.33	3.26e-10	Bladder cancer;
LUSC	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg10596483	chr8:143751796	JRK	0.52	7.56	0.38	3.9e-13	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg26338869	chr17:61819248	STRADA	0.42	6.23	0.32	1.44e-9	Prudent dietary pattern;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26067897	chr5:41904347	C5orf51	0.42	6.3	0.33	9.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs35000415	0.938	rs12706861	chr7:128616582	C/T	cg19972273	chr7:128594194	NA	0.67	6.84	0.35	3.77e-11	Systemic lupus erythematosus;
LUSC	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg23649088	chr2:200775458	C2orf69	-0.53	-6.46	-0.33	3.79e-10	Schizophrenia;
LUSC	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-7.48	-0.38	6.82e-13	Fear of minor pain;
LUSC	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.38	-0.42	1.47e-15	Schizophrenia;
LUSC	cis	rs73206853	0.841	rs3026483	chr12:110780905	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg26384229	chr12:38710491	ALG10B	0.55	8.74	0.43	1.16e-16	Morning vs. evening chronotype;
LUSC	cis	rs2425143	0.730	rs6579259	chr20:34462550	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.67	-0.3	3.14e-8	Blood protein levels;
LUSC	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg22676075	chr6:135203613	NA	0.45	7.22	0.37	3.44e-12	Red blood cell count;
LUSC	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.26	0.52	3.78e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs911119	0.955	rs17751897	chr20:23592714	T/C	cg16589663	chr20:23618590	CST3	0.57	6.79	0.35	5.04e-11	Chronic kidney disease;
LUSC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	10.68	0.5	4.11e-23	Hip circumference adjusted for BMI;
LUSC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	13.52	0.59	1.6e-33	Menarche (age at onset);
LUSC	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17916960	chr15:79447300	NA	-0.54	-10.92	-0.51	5.97e-24	Refractive error;
LUSC	cis	rs10992471	0.528	rs6479423	chr9:95265580	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.2	-0.32	1.69e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9399401	0.626	rs7776356	chr6:142777029	A/G	cg03128060	chr6:142623767	GPR126	0.53	9.12	0.45	6.95e-18	Chronic obstructive pulmonary disease;
LUSC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-1.06	-15.2	-0.64	5.19e-40	Initial pursuit acceleration;
LUSC	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg03526776	chr6:41159608	TREML2	0.47	8.27	0.41	3.31e-15	Alzheimer's disease (late onset);
LUSC	cis	rs1044826	0.647	rs4683463	chr3:139196946	T/G	cg15131784	chr3:139108705	COPB2	0.4	6.38	0.33	5.77e-10	Obesity-related traits;
LUSC	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg21251018	chr6:28226885	NKAPL	0.32	5.76	0.3	1.92e-8	Cardiac Troponin-T levels;
LUSC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg04369109	chr6:150039330	LATS1	-0.57	-8.41	-0.42	1.21e-15	Lung cancer;
LUSC	cis	rs1028488	0.511	rs6934743	chr6:170696385	A/G	cg20370364	chr6:170703943	FAM120B	-0.48	-7.17	-0.37	4.98e-12	Interferon alpha levels in systemic lupus erythematosus;
LUSC	cis	rs6714710	0.603	rs12988571	chr2:98405695	C/T	cg26665480	chr2:98280029	ACTR1B	0.61	8.97	0.44	2.12e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.13e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg23711669	chr6:146136114	FBXO30	-0.52	-8.06	-0.4	1.38e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	9.65	0.47	1.4e-19	Menopause (age at onset);
LUSC	cis	rs138918	0.772	rs138932	chr22:43565443	C/T	cg08909806	chr22:43548696	TSPO	0.36	6.19	0.32	1.8e-9	Monocyte count;
LUSC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg03732007	chr1:2071316	PRKCZ	-0.54	-9.54	-0.46	3.16e-19	Height;
LUSC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg02931644	chr1:25747376	RHCE	0.35	6.37	0.33	6.26e-10	Erythrocyte sedimentation rate;
LUSC	trans	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg10756647	chr7:56101905	PSPH	0.89	8.61	0.43	2.86e-16	Diabetic kidney disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20066120	chr12:120554733	RAB35	-0.42	-6.04	-0.31	4.1e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg04944784	chr2:26401820	FAM59B	-0.72	-9.92	-0.48	1.68e-20	Gut microbiome composition (summer);
LUSC	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.47	-0.38	6.92e-13	Retinal vascular caliber;
LUSC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg02951883	chr7:2050386	MAD1L1	-0.57	-10.86	-0.51	1.02e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.13	15.2	0.64	5.07e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.51	0.42	6.06e-16	Prudent dietary pattern;
LUSC	cis	rs4704187	0.687	rs6898116	chr5:74486778	T/G	cg03227963	chr5:74354835	NA	0.3	6.54	0.34	2.32e-10	Response to amphetamines;
LUSC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4478137	0.931	rs12509756	chr4:164237464	A/T	cg06758707	chr4:164254230	NPY1R	0.66	10.1	0.48	4.13e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg04117972	chr1:227635322	NA	0.61	6.88	0.35	2.9e-11	Major depressive disorder;
LUSC	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17467752	chr17:38218738	THRA	0.77	12.47	0.56	1.47e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg04990556	chr1:26633338	UBXN11	0.85	11.14	0.52	9.76e-25	Obesity-related traits;
LUSC	cis	rs9837602	1.000	rs35669453	chr3:99766063	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.11	0.32	2.75e-9	Breast cancer;
LUSC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg10057126	chr4:77819792	ANKRD56	0.44	6.46	0.33	3.72e-10	Emphysema distribution in smoking;
LUSC	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Smoking initiation;
LUSC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg08859206	chr1:53392774	SCP2	-0.41	-6.71	-0.34	8.17e-11	Monocyte count;
LUSC	trans	rs7939886	0.920	rs11231901	chr11:55811529	A/G	cg03929089	chr4:120376271	NA	0.77	6.36	0.33	6.46e-10	Myopia (pathological);
LUSC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-0.94	-14.06	-0.61	1.39e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs13315871	0.929	rs77487951	chr3:58290892	G/A	cg12435725	chr3:58293450	RPP14	-0.77	-7.45	-0.38	8.27e-13	Cholesterol, total;
LUSC	cis	rs6750047	0.585	rs62136319	chr2:38272950	G/A	cg07380506	chr2:38303506	CYP1B1	0.44	6.07	0.32	3.45e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	trans	rs11610422	1.000	rs12824459	chr12:31414435	C/T	cg02734259	chr12:9559402	NA	-0.6	-6.39	-0.33	5.69e-10	Coronary artery disease;
LUSC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.11	-0.36	7.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	1.09	23.38	0.79	2.65e-72	Testicular germ cell tumor;
LUSC	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg00982548	chr2:198649783	BOLL	-0.6	-7.29	-0.37	2.2e-12	Ulcerative colitis;
LUSC	trans	rs61931739	0.649	rs864174	chr12:33729352	C/A	cg26384229	chr12:38710491	ALG10B	0.42	6.07	0.32	3.51e-9	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs741013	0.502	rs13322726	chr3:64335926	C/T	cg22101924	chr15:79574964	ANKRD34C	0.4	5.94	0.31	7.06e-9	Coronary artery calcification;
LUSC	cis	rs2708377	0.789	rs3911150	chr12:11202248	A/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.8	-8.03	-0.4	1.74e-14	Bitter taste perception;
LUSC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.32	0.37	1.83e-12	Motion sickness;
LUSC	cis	rs11792861	0.566	rs6477687	chr9:111837791	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.41	-6.89	-0.35	2.71e-11	Menarche (age at onset);
LUSC	trans	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg12856521	chr11:46389249	DGKZ	0.44	6.82	0.35	4.34e-11	Leprosy;
LUSC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24549020	chr5:56110836	MAP3K1	0.49	5.99	0.31	5.58e-9	Initial pursuit acceleration;
LUSC	cis	rs7833787	1.000	rs6586778	chr8:18706170	G/C	cg17701159	chr8:18705777	PSD3	-0.38	-6.21	-0.32	1.56e-9	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg17366294	chr4:99064904	C4orf37	0.59	10.5	0.5	1.81e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6545883	0.894	rs35292974	chr2:61522047	T/C	cg15711740	chr2:61764176	XPO1	0.47	7.43	0.38	9.45e-13	Tuberculosis;
LUSC	cis	rs17155006	0.655	rs433534	chr7:107727440	A/G	cg05962710	chr7:107745446	LAMB4	-0.33	-5.84	-0.3	1.27e-8	Pneumococcal bacteremia;
LUSC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg16797656	chr11:68205561	LRP5	0.4	7.08	0.36	8.41e-12	Total body bone mineral density;
LUSC	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.63	-8.62	-0.43	2.74e-16	Body mass index (adult);
LUSC	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg17173187	chr15:85201210	NMB	0.37	6.52	0.34	2.61e-10	Schizophrenia;
LUSC	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg19812747	chr11:111475976	SIK2	0.47	6.62	0.34	1.39e-10	Primary sclerosing cholangitis;
LUSC	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg21775007	chr8:11205619	TDH	0.43	6.18	0.32	1.89e-9	Mood instability;
LUSC	cis	rs9815354	0.812	rs10510731	chr3:41853310	C/T	cg03022575	chr3:42003672	ULK4	0.85	8.74	0.43	1.19e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg06238570	chr21:40685208	BRWD1	-0.58	-8.99	-0.44	1.93e-17	Menarche (age at onset);
LUSC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.74	0.39	1.15e-13	Prudent dietary pattern;
LUSC	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg14385985	chr10:70587144	STOX1	-0.47	-6.22	-0.32	1.46e-9	Pancreatic cancer;
LUSC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg02475777	chr4:1388615	CRIPAK	0.44	6.56	0.34	2.1e-10	Obesity-related traits;
LUSC	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg15654264	chr1:150340011	RPRD2	0.61	10.15	0.49	2.84e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.3	6.07	0.32	3.48e-9	Lymphocyte counts;
LUSC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg20135002	chr11:47629003	NA	-0.5	-7.78	-0.39	9.29e-14	Subjective well-being;
LUSC	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-20.1	-0.74	1.91e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.84	12.26	0.56	8.63e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg24733560	chr20:60626293	TAF4	0.44	8.04	0.4	1.56e-14	Body mass index;
LUSC	cis	rs4285028	0.747	rs7648340	chr3:121426188	G/C	cg11130432	chr3:121712080	ILDR1	-0.53	-7.84	-0.39	6.07e-14	Multiple sclerosis;
LUSC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg07424592	chr7:64974309	NA	0.67	5.9	0.31	9.11e-9	Diabetic kidney disease;
LUSC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg13393036	chr8:95962371	TP53INP1	0.35	6.47	0.33	3.53e-10	Type 2 diabetes;
LUSC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.24	0.32	1.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18295930	chr20:46130624	NCOA3	0.45	6.0	0.31	5.09e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs72960926	0.744	rs1552568	chr6:75035349	G/T	cg03266952	chr6:74778945	NA	-0.66	-6.16	-0.32	2.1e-9	Metabolite levels (MHPG);
LUSC	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg08917208	chr2:24149416	ATAD2B	0.55	6.25	0.32	1.24e-9	Lymphocyte counts;
LUSC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.6	-0.46	2.04e-19	Chronic sinus infection;
LUSC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.81	-0.51	1.5e-23	Alzheimer's disease (late onset);
LUSC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg13175981	chr1:150552382	MCL1	-0.41	-5.66	-0.3	3.35e-8	Tonsillectomy;
LUSC	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg06207120	chr15:45996521	NA	0.39	6.09	0.32	3.07e-9	Waist circumference;Weight;
LUSC	cis	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg17325771	chr7:75508891	RHBDD2	-0.42	-5.92	-0.31	7.79e-9	Eotaxin levels;
LUSC	cis	rs1007190	0.881	rs9914884	chr17:42955589	T/C	cg15406952	chr17:42872593	NA	0.55	5.68	0.3	2.97e-8	DNA methylation (variation);
LUSC	trans	rs4674124	1.000	rs1179689	chr2:217763115	A/G	cg18563886	chr10:135203102	PAOX	-0.42	-5.97	-0.31	5.95e-9	Breast cancer;
LUSC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg18240062	chr17:79603768	NPLOC4	0.7	13.1	0.58	6.34e-32	Eye color traits;
LUSC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.88	-0.31	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg14552801	chr7:65878734	NA	0.37	5.86	0.31	1.12e-8	Aortic root size;
LUSC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg14668632	chr7:2872130	GNA12	-0.48	-7.4	-0.38	1.1e-12	Height;
LUSC	trans	rs656319	0.513	rs6985941	chr8:9983179	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.34	-0.33	7.27e-10	Myopia (pathological);
LUSC	cis	rs1011108	0.518	rs935172	chr2:26804247	A/G	cg18742855	chr2:26800399	C2orf70	-0.41	-8.1	-0.41	1.03e-14	Periodontal microbiota;
LUSC	trans	rs800082	1.000	rs1961653	chr3:144286098	C/T	cg24215973	chr2:240111563	HDAC4	-0.47	-7.2	-0.37	3.93e-12	Smoking behavior;
LUSC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg15147215	chr3:52552868	STAB1	-0.33	-5.86	-0.31	1.09e-8	Bipolar disorder;
LUSC	cis	rs3847687	0.966	rs3847689	chr12:131525534	T/G	cg13586425	chr12:131519906	GPR133	-0.25	-5.8	-0.3	1.51e-8	Longevity;
LUSC	cis	rs6736093	0.966	rs13020304	chr2:112741535	A/G	cg12686935	chr2:112915763	FBLN7	-0.37	-6.03	-0.31	4.39e-9	Coronary artery disease;
LUSC	cis	rs2446066	0.872	rs10876451	chr12:53813424	A/C	cg20730629	chr12:53886622	MAP3K12	-0.4	-5.72	-0.3	2.38e-8	Red blood cell count;
LUSC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.5	0.5	1.85e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4285028	0.948	rs76593525	chr3:121690477	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.64	-0.47	1.43e-19	Multiple sclerosis;
LUSC	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg15556689	chr8:8085844	FLJ10661	0.52	7.93	0.4	3.38e-14	Neuroticism;
LUSC	cis	rs7246967	0.611	rs8104327	chr19:22867159	C/G	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-7.34	-0.37	1.6e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg09835421	chr16:68378352	PRMT7	-0.56	-6.78	-0.35	5.6e-11	Schizophrenia;
LUSC	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	6.63	0.34	1.38e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg05187965	chr10:45406764	TMEM72	-0.37	-8.66	-0.43	2.07e-16	Mean corpuscular volume;
LUSC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg23719950	chr11:63933701	MACROD1	-0.63	-7.68	-0.39	1.82e-13	Mean platelet volume;
LUSC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11764359	chr7:65958608	NA	0.68	10.89	0.51	7.94e-24	Aortic root size;
LUSC	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.87e-9	Lymphocyte counts;
LUSC	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-6.26	-0.32	1.18e-9	Height;
LUSC	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.51	-0.34	2.74e-10	Neuroticism;
LUSC	cis	rs2235544	0.565	rs676562	chr1:54468638	C/G	cg25741118	chr1:54482237	LDLRAD1	0.28	5.99	0.31	5.28e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs2637266	0.626	rs846603	chr10:78570793	A/G	cg18941641	chr10:78392320	NA	-0.37	-6.78	-0.35	5.3e-11	Pulmonary function;
LUSC	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg16473166	chr22:50639996	SELO	0.59	7.77	0.39	9.49e-14	Obesity-related traits;
LUSC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11644478	chr21:40555479	PSMG1	0.76	9.56	0.46	2.66e-19	Cognitive function;
LUSC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg08773314	chr2:239334832	ASB1	0.41	9.0	0.44	1.69e-17	Multiple system atrophy;
LUSC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-10.15	-0.49	2.88e-21	Gut microbiome composition (summer);
LUSC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.34e-12	Tonsillectomy;
LUSC	cis	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg21775007	chr8:11205619	TDH	0.47	6.66	0.34	1.11e-10	Neuroticism;
LUSC	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg11244672	chr19:19639970	YJEFN3	0.59	7.24	0.37	3.17e-12	Bipolar disorder;
LUSC	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg13010199	chr12:38710504	ALG10B	0.65	9.81	0.47	3.95e-20	Bladder cancer;
LUSC	cis	rs9815354	0.812	rs56332587	chr3:42012714	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.5e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg06238570	chr21:40685208	BRWD1	0.52	7.94	0.4	3.04e-14	Cognitive function;
LUSC	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg18806716	chr10:30721971	MAP3K8	-0.48	-7.93	-0.4	3.24e-14	Inflammatory bowel disease;
LUSC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08219700	chr8:58056026	NA	0.66	8.37	0.42	1.58e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs6722750	0.846	rs13394665	chr2:64391431	A/C	cg22352474	chr2:64371530	PELI1	-0.62	-10.03	-0.48	7.44e-21	Neuroticism;
LUSC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg16606324	chr3:10149918	C3orf24	0.65	9.18	0.45	4.63e-18	Alzheimer's disease;
LUSC	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.68	8.22	0.41	4.61e-15	Body mass index;
LUSC	cis	rs6693567	0.565	rs834225	chr1:150300727	T/C	cg15654264	chr1:150340011	RPRD2	0.46	7.35	0.37	1.5e-12	Migraine;
LUSC	cis	rs9815354	0.812	rs17215883	chr3:41841873	C/T	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg15147215	chr3:52552868	STAB1	-0.3	-5.95	-0.31	6.85e-9	Bipolar disorder;
LUSC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08439880	chr3:133502540	NA	0.39	7.34	0.37	1.65e-12	Iron status biomarkers;
LUSC	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.02	0.31	4.61e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs2485376	1.000	rs772021	chr10:104036449	A/T	cg15216925	chr5:179921655	CNOT6	0.35	5.98	0.31	5.79e-9	QT interval;
LUSC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg09365446	chr1:150670422	GOLPH3L	0.47	7.02	0.36	1.24e-11	Melanoma;
LUSC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.7	-10.94	-0.51	5.32e-24	Aortic root size;
LUSC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.43	6.12	0.32	2.58e-9	Breast cancer;
LUSC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg15445000	chr17:37608096	MED1	0.39	6.68	0.34	9.76e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	ch.11.42038R	chr11:967971	AP2A2	0.42	6.13	0.32	2.48e-9	Alzheimer's disease (late onset);
LUSC	trans	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg07211511	chr3:129823064	LOC729375	-1.05	-12.96	-0.58	2.17e-31	Blood pressure (smoking interaction);
LUSC	cis	rs870825	0.860	rs72703529	chr4:185607351	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	10.13	0.48	3.2e-21	Blood protein levels;
LUSC	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-0.86	-15.58	-0.65	1.64e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7192380	0.965	rs3848278	chr16:69640867	T/C	cg26679644	chr16:69762563	NA	0.35	6.2	0.32	1.7e-9	Sjögren's syndrome;
LUSC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg26335602	chr6:28129616	ZNF389	0.46	6.21	0.32	1.6e-9	Parkinson's disease;
LUSC	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.59	-6.41	-0.33	4.99e-10	Fibroblast growth factor basic levels;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg07961406	chr16:67193646	FBXL8;TRADD	0.36	6.11	0.32	2.78e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs7580658	0.963	rs12479003	chr2:128118553	C/T	cg09760422	chr2:128146352	NA	-0.33	-7.25	-0.37	2.91e-12	Protein C levels;
LUSC	cis	rs9311676	0.609	rs62258077	chr3:58363371	T/C	cg13750441	chr3:58318267	PXK	0.34	6.65	0.34	1.22e-10	Systemic lupus erythematosus;
LUSC	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg09092052	chr15:45571596	NA	-0.41	-5.68	-0.3	2.87e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg08125733	chr17:73851984	WBP2	0.49	6.92	0.35	2.38e-11	White matter hyperintensity burden;
LUSC	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.59	9.02	0.44	1.48e-17	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25245506	chr22:39052398	LOC646851;CBY1	-0.45	-6.59	-0.34	1.73e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg18904891	chr8:8559673	CLDN23	0.6	8.24	0.41	3.84e-15	Obesity-related traits;
LUSC	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg12317470	chr15:67143691	NA	0.6	6.27	0.32	1.1e-9	Lung cancer (smoking interaction);
LUSC	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg25319279	chr11:5960081	NA	-0.47	-6.59	-0.34	1.76e-10	DNA methylation (variation);
LUSC	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg12863693	chr15:85201151	NMB	0.4	8.02	0.4	1.79e-14	Schizophrenia;
LUSC	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.58	-0.42	3.71e-16	Rheumatoid arthritis;
LUSC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.74	-0.3	2.14e-8	Depression;
LUSC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.88e-11	Primary biliary cholangitis;
LUSC	cis	rs7011049	1.000	rs117708010	chr8:53844026	G/A	cg26025543	chr8:53854495	NA	0.53	6.35	0.33	7.13e-10	Systolic blood pressure;
LUSC	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg12292205	chr6:26970375	C6orf41	-0.6	-7.42	-0.38	9.95e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7523273	0.606	rs859705	chr1:207959665	A/G	cg22525895	chr1:207977042	MIR29B2	0.41	6.67	0.34	1.04e-10	Schizophrenia;
LUSC	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg24558204	chr6:135376177	HBS1L	0.59	9.14	0.45	6.29e-18	Red blood cell count;
LUSC	cis	rs11031096	0.754	rs3817657	chr11:4142592	T/C	cg18678763	chr11:4115507	RRM1	-0.49	-7.24	-0.37	3.12e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.33	-0.33	7.94e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg19318889	chr4:1322082	MAEA	0.81	14.74	0.63	3.17e-38	Longevity;
LUSC	cis	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.45e-10	Ulcerative colitis;
LUSC	cis	rs2273669	0.667	rs117941557	chr6:109298135	G/A	cg05315195	chr6:109294784	ARMC2	-0.58	-6.47	-0.33	3.39e-10	Prostate cancer;
LUSC	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg05187965	chr10:45406764	TMEM72	-0.31	-6.93	-0.35	2.21e-11	Mean corpuscular volume;
LUSC	cis	rs6063312	1.000	rs6063312	chr20:47343059	G/T	cg18078177	chr20:47281410	PREX1	0.6	7.21	0.37	3.83e-12	Tonometry;
LUSC	cis	rs4423214	0.879	rs12803256	chr11:71132868	A/G	cg05163923	chr11:71159392	DHCR7	0.69	10.11	0.48	3.72e-21	Vitamin D levels;
LUSC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.29	0.33	9.99e-10	Menopause (age at onset);
LUSC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg08949735	chr16:89699720	DPEP1	-0.24	-5.91	-0.31	8.29e-9	Vitiligo;
LUSC	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg18753928	chr3:113234510	CCDC52	-0.51	-7.93	-0.4	3.26e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg11752832	chr7:134001865	SLC35B4	0.6	9.37	0.46	1.09e-18	Mean platelet volume;
LUSC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.86	-0.31	1.11e-8	Platelet count;
LUSC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.39	0.37	1.21e-12	Schizophrenia;
LUSC	cis	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.4e-9	Ulcerative colitis;
LUSC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg15145296	chr3:125709740	NA	-0.56	-6.27	-0.32	1.15e-9	Blood pressure (smoking interaction);
LUSC	cis	rs77741769	1.000	rs77741769	chr12:121363835	C/T	cg02403541	chr12:121454288	C12orf43	0.5	7.31	0.37	2.02e-12	Mean corpuscular volume;
LUSC	cis	rs7577696	0.597	rs34197800	chr2:32389646	C/A	cg02381751	chr2:32503542	YIPF4	-0.52	-6.91	-0.35	2.46e-11	Inflammatory biomarkers;
LUSC	cis	rs12286929	0.589	rs4938190	chr11:115087750	C/T	cg04055981	chr11:115044050	NA	0.39	6.81	0.35	4.44e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg20607798	chr8:58055168	NA	0.52	5.7	0.3	2.57e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs701145	1.000	rs701145	chr3:154054799	T/C	cg17054900	chr3:154042577	DHX36	0.81	8.69	0.43	1.7e-16	Coronary artery disease;
LUSC	cis	rs983392	0.805	rs2081545	chr11:59958380	C/A	cg24026212	chr11:59952134	MS4A6A	-0.37	-6.28	-0.33	1.05e-9	Alzheimer's disease (late onset);
LUSC	cis	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg06521331	chr12:34319734	NA	-0.39	-6.78	-0.35	5.43e-11	Morning vs. evening chronotype;
LUSC	cis	rs3774830	0.714	rs55816120	chr4:5463350	C/T	cg26943120	chr4:5472116	STK32B	0.3	5.93	0.31	7.39e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.49	-0.46	4.47e-19	Type 2 diabetes;
LUSC	cis	rs6500395	0.963	rs4785248	chr16:48687947	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.23	0.45	3.24e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7575217	0.961	rs1192788	chr2:101782978	C/T	cg23907051	chr2:101730305	TBC1D8	-0.27	-6.61	-0.34	1.5e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs71403859	0.730	rs12931191	chr16:71621373	A/T	cg08717414	chr16:71523259	ZNF19	0.72	7.87	0.4	4.83e-14	Post bronchodilator FEV1;
LUSC	cis	rs2629540	0.924	rs2629541	chr10:126425866	G/A	cg08799069	chr10:126477246	METTL10	0.65	8.92	0.44	3.06e-17	Cocaine dependence;
LUSC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	12.46	0.56	1.59e-29	Cognitive test performance;
LUSC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg12560992	chr17:57184187	TRIM37	0.69	12.23	0.56	1.11e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.84	0.3	1.24e-8	Menopause (age at onset);
LUSC	trans	rs4714291	0.802	rs1474870	chr6:39980359	C/T	cg02267698	chr19:7991119	CTXN1	0.51	7.61	0.38	2.81e-13	Strep throat;
LUSC	cis	rs654950	0.875	rs116747365	chr1:41994792	C/T	cg06885757	chr1:42089581	HIVEP3	-0.34	-6.55	-0.34	2.24e-10	Airway imaging phenotypes;
LUSC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg06718696	chr17:78121285	EIF4A3	-0.45	-6.48	-0.33	3.33e-10	Yeast infection;
LUSC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg13560548	chr3:10150139	C3orf24	0.48	6.77	0.35	5.72e-11	Alzheimer's disease;
LUSC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg08847533	chr14:75593920	NEK9	-0.8	-13.7	-0.6	3.38e-34	Height;
LUSC	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg01579765	chr21:45077557	HSF2BP	-0.47	-9.76	-0.47	6e-20	Mean corpuscular volume;
LUSC	cis	rs6005807	0.719	rs9620810	chr22:29053727	T/C	cg12565055	chr22:29076175	TTC28	0.54	5.86	0.31	1.12e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs652260	1.000	rs590394	chr19:7902505	C/T	cg26014689	chr19:7917955	EVI5L	-0.48	-8.49	-0.42	6.66e-16	Menarche (age at onset);
LUSC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg14552801	chr7:65878734	NA	-0.45	-6.34	-0.33	7.34e-10	Aortic root size;
LUSC	cis	rs75804782	0.521	rs55915157	chr2:239424273	T/C	cg18131467	chr2:239335373	ASB1	-0.65	-5.95	-0.31	6.71e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	0.97	10.96	0.51	4.58e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs72799341	1.000	rs7185007	chr16:30927509	C/T	cg02466173	chr16:30829666	NA	-0.51	-7.79	-0.39	8.38e-14	Diastolic blood pressure;
LUSC	cis	rs6120849	0.754	rs36003887	chr20:33589107	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	6.85	0.35	3.66e-11	Protein C levels;
LUSC	cis	rs6545883	0.894	rs10496092	chr2:61524679	C/T	cg15711740	chr2:61764176	XPO1	0.47	7.17	0.37	4.71e-12	Tuberculosis;
LUSC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg05347473	chr6:146136440	FBXO30	0.54	9.33	0.45	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21659725	chr3:3221576	CRBN	0.53	8.42	0.42	1.11e-15	Body mass index;
LUSC	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg06636001	chr8:8085503	FLJ10661	0.55	8.12	0.41	9.29e-15	Monocyte count;
LUSC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11764359	chr7:65958608	NA	0.64	9.84	0.47	3.18e-20	Aortic root size;
LUSC	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.38	-0.33	5.98e-10	Bipolar disorder;
LUSC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg12311346	chr5:56204834	C5orf35	-0.6	-8.5	-0.42	6.57e-16	Coronary artery disease;
LUSC	cis	rs10207060	0.500	rs72992164	chr2:240711780	G/A	cg07506560	chr2:240697449	NA	0.47	7.27	0.37	2.59e-12	Obesity-related traits;
LUSC	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg18806716	chr10:30721971	MAP3K8	0.49	7.99	0.4	2.16e-14	Inflammatory bowel disease;
LUSC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.84	15.03	0.64	2.36e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg25182066	chr10:30743637	MAP3K8	0.42	6.03	0.31	4.31e-9	Inflammatory bowel disease;
LUSC	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg21775007	chr8:11205619	TDH	0.44	6.5	0.33	3.01e-10	Triglycerides;
LUSC	cis	rs77633900	0.614	rs2454453	chr15:76913976	T/A	cg21673338	chr15:77095150	SCAPER	-0.72	-6.99	-0.36	1.48e-11	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs10193935	0.786	rs72796504	chr2:42406728	T/C	cg27598129	chr2:42591480	NA	-0.58	-7.82	-0.39	7.22e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	10.81	0.51	1.47e-23	Coffee consumption (cups per day);
LUSC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg25039879	chr17:56429692	SUPT4H1	0.72	9.82	0.47	3.63e-20	Cognitive test performance;
LUSC	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg19610905	chr11:61596333	FADS2	-0.53	-7.96	-0.4	2.8e-14	Bipolar disorder;
LUSC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg00343986	chr7:65444356	GUSB	-0.38	-5.73	-0.3	2.29e-8	Aortic root size;
LUSC	trans	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg14392985	chr9:129345450	NA	-0.27	-5.96	-0.31	6.52e-9	Obesity-related traits;
LUSC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg08799069	chr10:126477246	METTL10	0.6	7.98	0.4	2.44e-14	Cocaine dependence;
LUSC	cis	rs8016982	0.630	rs61980900	chr14:81686436	T/C	cg01989461	chr14:81687754	GTF2A1	0.72	12.99	0.58	1.62e-31	Schizophrenia;
LUSC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg00431813	chr7:1051703	C7orf50	-0.44	-7.23	-0.37	3.42e-12	Longevity;Endometriosis;
LUSC	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg18904891	chr8:8559673	CLDN23	0.59	8.34	0.42	2e-15	Obesity-related traits;
LUSC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg22875332	chr1:76189707	ACADM	0.76	10.23	0.49	1.48e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg04106633	chr4:1044584	NA	-0.33	-6.04	-0.31	4.04e-9	Recombination rate (males);
LUSC	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg04310649	chr10:35416472	CREM	-0.42	-6.62	-0.34	1.41e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg16584290	chr5:462447	EXOC3	0.44	7.58	0.38	3.45e-13	Cystic fibrosis severity;
LUSC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg13395646	chr4:1353034	KIAA1530	-0.67	-11.29	-0.53	3.04e-25	Longevity;
LUSC	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-6.0	-0.31	5.24e-9	Bipolar disorder;
LUSC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg09034736	chr1:150693464	HORMAD1	0.5	7.31	0.37	2.02e-12	Tonsillectomy;
LUSC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.35	-0.37	1.5e-12	Aortic root size;
LUSC	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.84	-13.72	-0.6	2.8e-34	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.07	0.48	5.23e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg11812906	chr14:75593930	NEK9	0.67	11.72	0.54	8.64e-27	Height;
LUSC	cis	rs7191700	0.511	rs8043625	chr16:11361895	C/G	cg00044050	chr16:11439710	C16orf75	-0.7	-12.43	-0.56	2.04e-29	Multiple sclerosis;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.87	-14.28	-0.62	1.84e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.66	-5.81	-0.3	1.46e-8	Narcolepsy;
LUSC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg17372223	chr3:52568218	NT5DC2	0.39	6.14	0.32	2.3e-9	Electroencephalogram traits;
LUSC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg13628971	chr7:2884303	GNA12	0.45	6.41	0.33	5e-10	Height;
LUSC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg00012203	chr2:219082015	ARPC2	-0.7	-11.59	-0.54	2.53e-26	Colorectal cancer;
LUSC	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.69	13.23	0.59	2.06e-32	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs16854884	0.657	rs35796781	chr3:143731662	T/C	cg06585982	chr3:143692056	C3orf58	0.46	7.18	0.37	4.44e-12	Economic and political preferences (feminism/equality);
LUSC	cis	rs1595825	0.891	rs16825181	chr2:198740276	G/T	cg00982548	chr2:198649783	BOLL	-0.53	-6.32	-0.33	8.14e-10	Ulcerative colitis;
LUSC	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.59	10.12	0.48	3.57e-21	Birth weight;
LUSC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-6.94	-0.36	2.02e-11	Blood metabolite levels;
LUSC	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg04455712	chr21:45112962	RRP1B	0.47	8.86	0.44	4.7e-17	Mean corpuscular volume;
LUSC	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-35.46	-0.89	2.9e-115	Myeloid white cell count;
LUSC	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.61	-0.43	2.94e-16	Neuroticism;
LUSC	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg21775007	chr8:11205619	TDH	0.72	11.49	0.53	5.59e-26	Retinal vascular caliber;
LUSC	cis	rs1358748	0.522	rs1321152	chr1:67583666	A/T	cg02640540	chr1:67518911	SLC35D1	0.67	6.53	0.34	2.5e-10	Tuberculosis;
LUSC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.43	-8.17	-0.41	6.58e-15	Lung cancer;
LUSC	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg14092571	chr14:90743983	NA	-0.35	-5.67	-0.3	3.16e-8	Mortality in heart failure;
LUSC	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.62	9.37	0.46	1.09e-18	Response to antineoplastic agents;
LUSC	cis	rs9800506	0.584	rs9470056	chr6:35522145	A/G	cg03566752	chr6:35512600	NA	-0.35	-7.96	-0.4	2.73e-14	Neutrophil percentage of granulocytes;
LUSC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	16.67	0.67	7.84e-46	Cognitive ability;
LUSC	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg13390004	chr1:15929781	NA	0.4	6.65	0.34	1.19e-10	Systolic blood pressure;
LUSC	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.1	25.67	0.81	5.28e-81	Schizophrenia;
LUSC	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg20307385	chr11:47447363	PSMC3	-0.43	-6.38	-0.33	6e-10	Subjective well-being;
LUSC	trans	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07923666	chr12:49932857	KCNH3	-0.51	-6.27	-0.32	1.15e-9	Resting heart rate;
LUSC	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg17173187	chr15:85201210	NMB	0.5	9.31	0.45	1.77e-18	Schizophrenia;
LUSC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg05585544	chr11:47624801	NA	0.41	7.25	0.37	2.92e-12	Subjective well-being;
LUSC	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg03563238	chr19:33554763	RHPN2	-0.4	-6.43	-0.33	4.3e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs612683	0.690	rs11166440	chr1:100808363	C/T	cg06223162	chr1:101003688	GPR88	-0.33	-5.83	-0.3	1.34e-8	Breast cancer;
LUSC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg17971929	chr21:40555470	PSMG1	-0.47	-7.13	-0.36	6.12e-12	Menarche (age at onset);
LUSC	cis	rs11608355	0.545	rs11609019	chr12:109895958	G/A	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.13	-19.54	-0.73	3.21e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9837602	0.935	rs17392948	chr3:99754498	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-5.72	-0.3	2.35e-8	Breast cancer;
LUSC	cis	rs10170846	0.861	rs7571732	chr2:223538316	A/C	cg25565276	chr2:223520875	FARSB	-0.62	-9.3	-0.45	1.93e-18	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg05925327	chr15:68127851	NA	-0.4	-6.47	-0.33	3.41e-10	Restless legs syndrome;
LUSC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg13647721	chr17:30228624	UTP6	0.64	6.9	0.35	2.68e-11	Hip circumference adjusted for BMI;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10192369	chr8:42195962	POLB	-0.4	-5.95	-0.31	6.72e-9	Electrocardiographic conduction measures;
LUSC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.8	12.53	0.57	8.45e-30	Menopause (age at onset);
LUSC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg16414030	chr3:133502952	NA	-0.43	-6.59	-0.34	1.72e-10	Iron status biomarkers;
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.86	14.15	0.61	6.16e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	0.94	15.78	0.65	2.53e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs7712401	0.601	rs246268	chr5:122256342	C/T	cg19077854	chr5:122220652	SNX24	0.45	10.63	0.5	6.52e-23	Mean platelet volume;
LUSC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg19418458	chr7:158789849	NA	-0.63	-10.4	-0.49	4.1e-22	Facial morphology (factor 20);
LUSC	cis	rs11166629	0.637	rs10283108	chr8:135575046	A/G	cg27224718	chr8:135614730	ZFAT	0.52	7.56	0.38	4.01e-13	Smoking quantity;
LUSC	cis	rs3925075	0.966	rs7195945	chr16:31344309	T/C	cg02846316	chr16:31340340	ITGAM	0.35	6.53	0.34	2.48e-10	IgA nephropathy;
LUSC	cis	rs2219968	0.638	rs10504672	chr8:78995199	G/C	cg00738934	chr8:78996279	NA	0.41	7.3	0.37	2.16e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs240764	0.853	rs12206182	chr6:101033379	A/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.06	-0.31	3.78e-9	Neuroticism;
LUSC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg19678392	chr7:94953810	PON1	-0.36	-5.92	-0.31	8.15e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.84	-0.35	3.74e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6500395	0.775	rs7185541	chr16:48664681	A/G	cg04672837	chr16:48644449	N4BP1	0.47	7.02	0.36	1.22e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7084921	0.578	rs11592631	chr10:101878219	G/A	cg11888571	chr10:102027403	CWF19L1	-0.46	-6.15	-0.32	2.24e-9	Bone mineral density;
LUSC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-7.09	-0.36	8.01e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg17554472	chr22:41940697	POLR3H	-0.47	-5.82	-0.3	1.4e-8	Vitiligo;
LUSC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	9.59	0.46	2.12e-19	Mood instability;
LUSC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-9.29	-0.45	1.97e-18	Gut microbiome composition (summer);
LUSC	cis	rs11055008	0.620	rs12816452	chr12:12833006	A/T	cg04607235	chr12:12878440	APOLD1	-0.48	-7.54	-0.38	4.42e-13	Pulse pressure;
LUSC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00166722	chr3:10149974	C3orf24	0.62	8.7	0.43	1.55e-16	Alzheimer's disease;
LUSC	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg21635203	chr3:181429911	SOX2;SOX2OT	-0.4	-6.01	-0.31	4.86e-9	Electroencephalogram traits;
LUSC	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06544989	chr22:39130855	UNC84B	0.33	5.67	0.3	3.08e-8	Menopause (age at onset);
LUSC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.57	-9.23	-0.45	3.24e-18	Aortic root size;
LUSC	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg07395648	chr5:131743802	NA	0.47	7.53	0.38	4.88e-13	Breast cancer;Mosquito bite size;
LUSC	cis	rs12760731	0.720	rs71628282	chr1:178449993	C/G	cg00404053	chr1:178313656	RASAL2	0.65	6.81	0.35	4.46e-11	Obesity-related traits;
LUSC	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg26384229	chr12:38710491	ALG10B	0.74	12.08	0.55	4.07e-28	Morning vs. evening chronotype;
LUSC	cis	rs727505	0.954	rs55768077	chr7:124663216	A/G	cg23710748	chr7:124431027	NA	-0.39	-6.87	-0.35	3.17e-11	Lewy body disease;
LUSC	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-0.8	-12.83	-0.57	6.6e-31	Schizophrenia;
LUSC	cis	rs4356932	0.691	rs4859582	chr4:76907213	T/C	cg00809888	chr4:76862425	NAAA	0.36	5.79	0.3	1.58e-8	Blood protein levels;
LUSC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg24675658	chr1:53192096	ZYG11B	-0.73	-12.0	-0.55	8.02e-28	Monocyte count;
LUSC	cis	rs6681460	0.549	rs963140	chr1:67037576	T/G	cg02459107	chr1:67143332	SGIP1	0.31	5.66	0.3	3.3e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs793571	0.669	rs28864995	chr15:58945671	T/G	cg05156742	chr15:59063176	FAM63B	0.59	8.44	0.42	9.75e-16	Schizophrenia;
LUSC	cis	rs17540621	1.000	rs78201922	chr2:47246771	A/G	cg23978866	chr2:47230407	TTC7A	-0.89	-6.27	-0.32	1.13e-9	Response to statin therapy;
LUSC	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg09655341	chr17:79618100	PDE6G	-0.27	-6.12	-0.32	2.68e-9	Eye color traits;
LUSC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg22963979	chr7:1858916	MAD1L1	-0.59	-8.97	-0.44	2.22e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg03579872	chr1:53393473	SCP2	-0.39	-5.66	-0.3	3.27e-8	Monocyte count;
LUSC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg12863693	chr15:85201151	NMB	0.33	6.62	0.34	1.43e-10	Schizophrenia;
LUSC	cis	rs9815354	1.000	rs9855965	chr3:41860508	C/T	cg03022575	chr3:42003672	ULK4	0.58	6.52	0.34	2.55e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.53	9.93	0.48	1.52e-20	Bone mineral density;
LUSC	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg12311346	chr5:56204834	C5orf35	-0.58	-9.06	-0.44	1.16e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7914558	0.646	rs10883799	chr10:104663310	G/A	cg05855489	chr10:104503620	C10orf26	0.42	5.76	0.3	1.92e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.7	13.81	0.6	1.25e-34	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7916697	0.947	rs1900004	chr10:70000881	C/T	cg06988349	chr10:69991859	ATOH7	0.37	6.6	0.34	1.58e-10	Optic disc area;
LUSC	cis	rs7075426	0.669	rs10887607	chr10:88190354	A/G	cg07322936	chr10:88137208	NA	0.44	6.34	0.33	7.27e-10	Migraine without aura;
LUSC	cis	rs7582720	1.000	rs72934729	chr2:203737770	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.56	0.42	4.25e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg21770322	chr7:97807741	LMTK2	0.41	7.01	0.36	1.32e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.9	-0.58	3.72e-31	Alzheimer's disease;
LUSC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg09455208	chr3:40491958	NA	0.52	8.95	0.44	2.6e-17	Renal cell carcinoma;
LUSC	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg25801113	chr15:45476975	SHF	-0.34	-6.7	-0.34	8.69e-11	Uric acid levels;
LUSC	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg05973401	chr12:123451056	ABCB9	0.53	6.59	0.34	1.73e-10	Neutrophil percentage of white cells;
LUSC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.7	11.61	0.54	2.02e-26	Heart rate;
LUSC	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg24596788	chr1:163392923	NA	-0.45	-7.62	-0.38	2.6e-13	Motion sickness;
LUSC	cis	rs59724122	0.542	rs28633173	chr8:27446980	A/G	cg19442470	chr8:27470225	CLU	0.33	5.74	0.3	2.16e-8	Bipolar disorder lithium response (categorical) or schizophrenia;
LUSC	cis	rs9314323	0.767	rs6557915	chr8:26209062	C/A	cg11498726	chr8:26250323	BNIP3L	-0.43	-6.1	-0.32	2.96e-9	Red cell distribution width;
LUSC	cis	rs4363385	0.669	rs2937264	chr1:153011026	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.02	0.31	4.49e-9	Menopause (age at onset);
LUSC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg02153584	chr22:29168773	CCDC117	0.65	10.24	0.49	1.39e-21	Lymphocyte counts;
LUSC	cis	rs10754283	0.967	rs7528433	chr1:90114071	T/C	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-10.23	-0.49	1.47e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08219700	chr8:58056026	NA	0.69	8.07	0.4	1.27e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg05347473	chr6:146136440	FBXO30	0.42	7.25	0.37	3.01e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg26384229	chr12:38710491	ALG10B	0.74	11.9	0.55	1.78e-27	Morning vs. evening chronotype;
LUSC	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg26061582	chr7:22766209	IL6	0.49	7.02	0.36	1.25e-11	Lung cancer;
LUSC	trans	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg17145862	chr1:211918768	LPGAT1	-0.23	-6.26	-0.32	1.16e-9	Leprosy;
LUSC	cis	rs9905704	0.836	rs302875	chr17:56767874	A/G	cg12560992	chr17:57184187	TRIM37	-0.52	-7.22	-0.37	3.62e-12	Testicular germ cell tumor;
LUSC	cis	rs11229555	1.000	rs1938598	chr11:58413910	T/C	cg15696309	chr11:58395628	NA	-0.67	-8.87	-0.44	4.44e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg11645453	chr3:52864694	ITIH4	0.35	8.09	0.4	1.09e-14	Bipolar disorder;
LUSC	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg17652424	chr22:38574118	PLA2G6	0.27	5.77	0.3	1.82e-8	Cutaneous nevi;
LUSC	cis	rs4443100	0.837	rs6003490	chr22:23388447	G/A	cg14186256	chr22:23484241	RTDR1	0.5	6.15	0.32	2.16e-9	Serum parathyroid hormone levels;
LUSC	cis	rs3741151	0.686	rs7927344	chr11:73207517	T/C	cg17517138	chr11:73019481	ARHGEF17	0.83	7.71	0.39	1.48e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs36051895	0.623	rs1555476	chr9:5233054	T/C	cg02405213	chr9:5042618	JAK2	-0.58	-8.0	-0.4	2.07e-14	Pediatric autoimmune diseases;
LUSC	trans	rs7094131	0.542	rs7071306	chr10:22867339	A/G	cg05996795	chr6:134159303	MGC34034	0.42	6.39	0.33	5.63e-10	Obesity-related traits;
LUSC	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg04455712	chr21:45112962	RRP1B	-0.44	-8.38	-0.42	1.49e-15	Mean corpuscular volume;
LUSC	cis	rs7809950	1.000	rs2237673	chr7:107131580	T/C	cg23024343	chr7:107201750	COG5	-0.55	-8.91	-0.44	3.39e-17	Coronary artery disease;
LUSC	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg12559939	chr2:27858050	GPN1	0.41	6.24	0.32	1.32e-9	Oral cavity cancer;
LUSC	cis	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg24375607	chr4:120327624	NA	-0.49	-7.51	-0.38	5.59e-13	Diastolic blood pressure;
LUSC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.39	-0.49	4.23e-22	Electroencephalogram traits;
LUSC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-12.69	-0.57	2.2e-30	Platelet count;
LUSC	cis	rs7106204	0.534	rs7928616	chr11:24296060	T/C	ch.11.24196551F	chr11:24239977	NA	0.87	9.27	0.45	2.38e-18	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg25214090	chr10:38739885	LOC399744	0.49	7.14	0.36	5.83e-12	Corneal astigmatism;
LUSC	cis	rs7072216	0.763	rs10883091	chr10:100167239	C/T	cg26618903	chr10:100175079	PYROXD2	-0.46	-8.71	-0.43	1.39e-16	Metabolite levels;
LUSC	cis	rs4851254	0.618	rs35730185	chr2:100648085	G/A	cg07810366	chr2:100720526	AFF3	-0.46	-5.95	-0.31	6.76e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12681287	0.640	rs10098356	chr8:87442667	A/G	cg27223183	chr8:87520930	FAM82B	0.54	7.47	0.38	6.96e-13	Caudate activity during reward;
LUSC	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg16342193	chr10:102329863	NA	-0.37	-6.26	-0.32	1.21e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg08017756	chr2:100939284	LONRF2	-0.44	-8.23	-0.41	4.12e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4295623	0.507	rs2256241	chr8:11494657	C/T	cg00262122	chr8:11665843	FDFT1	-0.38	-5.87	-0.31	1.04e-8	Morning vs. evening chronotype;
LUSC	cis	rs41271473	1.000	rs4993975	chr1:228878669	A/C	cg10167378	chr1:228756711	NA	0.54	6.59	0.34	1.72e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.24	-0.32	1.3e-9	Bipolar disorder;
LUSC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg25251562	chr2:3704773	ALLC	-0.75	-12.42	-0.56	2.26e-29	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg07169764	chr2:136633963	MCM6	1.03	15.71	0.65	4.82e-42	Corneal structure;
LUSC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	0.99	14.14	0.61	6.88e-36	Vitiligo;
LUSC	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg26893861	chr17:41843967	DUSP3	0.87	13.1	0.58	6.35e-32	Triglycerides;
LUSC	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg27124370	chr19:33622961	WDR88	0.56	7.34	0.37	1.67e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs3857536	0.813	rs9354404	chr6:66948408	C/T	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg19773385	chr1:10388646	KIF1B	-0.53	-8.23	-0.41	4.24e-15	Hepatocellular carcinoma;
LUSC	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	9.72	0.47	8.05e-20	Lymphocyte counts;
LUSC	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg26597838	chr10:835615	NA	0.79	9.6	0.47	1.9e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg06618935	chr21:46677482	NA	0.37	7.45	0.38	8.21e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg10792982	chr14:105748885	BRF1	0.49	8.88	0.44	4.19e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05901451	chr6:126070800	HEY2	0.57	8.52	0.42	5.4e-16	Endometrial cancer;
LUSC	cis	rs1160297	0.609	rs12713231	chr2:53105695	C/G	cg07782112	chr2:53107842	NA	0.38	6.47	0.33	3.59e-10	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg01620082	chr3:125678407	NA	-0.87	-7.55	-0.38	4.28e-13	Depression;
LUSC	cis	rs965469	1.000	rs6051712	chr20:3265029	T/A	cg25506879	chr20:3388711	C20orf194	-0.52	-5.84	-0.3	1.27e-8	IFN-related cytopenia;
LUSC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.74	-12.65	-0.57	2.98e-30	Height;
LUSC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg25019033	chr10:957182	NA	-0.53	-6.64	-0.34	1.24e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs7712401	0.601	rs436546	chr5:122322790	G/A	cg19077854	chr5:122220652	SNX24	-0.43	-9.54	-0.46	3.21e-19	Mean platelet volume;
LUSC	cis	rs72781680	0.799	rs2551332	chr2:23988950	T/C	cg08917208	chr2:24149416	ATAD2B	0.6	6.86	0.35	3.27e-11	Lymphocyte counts;
LUSC	cis	rs6087990	0.765	rs6058900	chr20:31400673	T/C	cg13636640	chr20:31349939	DNMT3B	0.96	19.82	0.74	2.37e-58	Ulcerative colitis;
LUSC	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg13319975	chr6:146136371	FBXO30	0.71	11.11	0.52	1.24e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg08917208	chr2:24149416	ATAD2B	0.98	10.26	0.49	1.15e-21	Lymphocyte counts;
LUSC	cis	rs2076222	1.000	rs2076350	chr1:209800341	C/T	cg00257659	chr1:209800214	LAMB3	-1.06	-8.58	-0.42	3.73e-16	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03578331	chr2:161350329	RBMS1	-0.41	-6.54	-0.34	2.29e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.38	7.98	0.4	2.31e-14	Hemoglobin concentration;
LUSC	cis	rs3812762	0.868	rs7952335	chr11:8754031	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.37	6.49	0.33	3.17e-10	Hypospadias;
LUSC	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.27	0.45	2.34e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg21573476	chr21:45109991	RRP1B	-0.41	-6.83	-0.35	4.1e-11	Mean corpuscular volume;
LUSC	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg24634471	chr8:143751801	JRK	0.5	7.18	0.37	4.56e-12	Schizophrenia;
LUSC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.87	11.46	0.53	7.29e-26	Alzheimer's disease;
LUSC	trans	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg07211511	chr3:129823064	LOC729375	-0.53	-6.1	-0.32	2.86e-9	Blood pressure (smoking interaction);
LUSC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg08888203	chr3:10149979	C3orf24	0.61	8.44	0.42	9.76e-16	Alzheimer's disease;
LUSC	cis	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg02428538	chr16:24856791	SLC5A11	-0.51	-5.87	-0.31	1.05e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg06096015	chr1:231504339	EGLN1	0.57	9.97	0.48	1.16e-20	Hemoglobin concentration;
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	10.94	0.51	5.17e-24	Lymphocyte counts;
LUSC	cis	rs2290159	0.752	rs73130368	chr3:12667374	C/T	cg23032965	chr3:12705835	RAF1	0.74	9.09	0.45	8.97e-18	Cholesterol, total;
LUSC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18404041	chr3:52824283	ITIH1	-0.56	-10.63	-0.5	6.41e-23	Bipolar disorder;
LUSC	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg07080220	chr10:102295463	HIF1AN	0.69	8.93	0.44	2.8e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00235645	chr15:40886408	CASC5	-0.46	-6.84	-0.35	3.82e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.98	0.58	1.83e-31	Prudent dietary pattern;
LUSC	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg24375607	chr4:120327624	NA	0.76	12.17	0.55	1.85e-28	Corneal astigmatism;
LUSC	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.99	0.36	1.47e-11	IgG glycosylation;
LUSC	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg05855489	chr10:104503620	C10orf26	-0.71	-8.54	-0.42	4.85e-16	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1045714	0.836	rs56246161	chr7:2644679	G/A	cg24848437	chr7:2645542	IQCE	0.59	6.58	0.34	1.84e-10	Urate levels in lean individuals;
LUSC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.45	-8.2	-0.41	5.2e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg03647239	chr10:116582469	FAM160B1	0.43	6.92	0.35	2.3e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1335645	0.570	rs7514887	chr1:111667158	T/C	cg00321911	chr1:111669324	DRAM2	-0.63	-6.49	-0.33	3.19e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Depression;
LUSC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.39	0.33	5.46e-10	Renal cell carcinoma;
LUSC	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.88	14.33	0.62	1.26e-36	Bladder cancer;
LUSC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg03676636	chr4:99064102	C4orf37	-0.34	-7.53	-0.38	4.89e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg15839431	chr19:19639596	YJEFN3	0.61	6.6	0.34	1.63e-10	Bipolar disorder;
LUSC	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg25173405	chr17:45401733	C17orf57	0.36	5.72	0.3	2.36e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.1	-0.58	6.15e-32	Platelet count;
LUSC	cis	rs2625529	0.824	rs4776586	chr15:72430503	C/A	cg16672083	chr15:72433130	SENP8	-0.52	-7.57	-0.38	3.79e-13	Red blood cell count;
LUSC	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	8.76	0.43	9.63e-17	Systolic blood pressure;
LUSC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-11.43	-0.53	9.22e-26	Mood instability;
LUSC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg21361702	chr7:150065534	REPIN1	0.46	6.31	0.33	8.81e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.26e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg05738196	chr6:26577821	NA	-0.54	-8.48	-0.42	7.42e-16	Schizophrenia;
LUSC	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	0.96	10.08	0.48	5.04e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.92	-15.64	-0.65	9.34e-42	Bladder cancer;
LUSC	trans	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg19676328	chr12:49525230	TUBA1B	-0.51	-7.37	-0.37	1.35e-12	Total cholesterol levels;
LUSC	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg20503657	chr10:835505	NA	-0.52	-7.14	-0.36	6.05e-12	Response to angiotensin II receptor blocker therapy;
LUSC	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg15704280	chr7:45808275	SEPT13	-0.84	-11.72	-0.54	8.17e-27	Coronary artery disease;
LUSC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.5	-6.91	-0.35	2.52e-11	Multiple sclerosis;
LUSC	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg14583973	chr4:3374767	RGS12	0.26	5.81	0.3	1.46e-8	Parental longevity (mother's age at death);
LUSC	cis	rs9976767	0.637	rs2156309	chr21:43824529	G/A	cg23042151	chr21:43824109	UBASH3A	-0.35	-6.73	-0.35	7.21e-11	Type 1 diabetes;
LUSC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg08027265	chr7:2291960	NA	-0.39	-6.27	-0.32	1.14e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg08601574	chr20:25228251	PYGB	-0.42	-6.43	-0.33	4.39e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.68	-0.3	3.01e-8	Resting heart rate;
LUSC	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg24375607	chr4:120327624	NA	0.69	10.58	0.5	9.19e-23	Corneal astigmatism;
LUSC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-5.93	-0.31	7.45e-9	Huntington's disease progression;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01045986	chr18:29671767	RNF138	0.43	6.23	0.32	1.42e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg11887960	chr12:57824829	NA	0.56	6.73	0.35	7.6e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg08601574	chr20:25228251	PYGB	0.48	7.41	0.38	1.03e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10465746	0.967	rs4907191	chr1:84444165	A/G	cg10977910	chr1:84465055	TTLL7	-0.41	-6.05	-0.31	3.92e-9	Obesity-related traits;
LUSC	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg13010199	chr12:38710504	ALG10B	0.66	11.52	0.53	4.55e-26	Heart rate;
LUSC	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg06532163	chr17:45867833	NA	0.34	6.22	0.32	1.52e-9	IgG glycosylation;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg10361922	chr17:40925790	VPS25	0.36	5.95	0.31	6.65e-9	Mosquito bite size;
LUSC	cis	rs7202877	0.706	rs8054586	chr16:75410705	G/C	cg04384234	chr16:75411784	CFDP1	-0.65	-9.27	-0.45	2.43e-18	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs12986413	0.934	rs6510645	chr19:2158398	T/C	cg09261902	chr19:2140048	AP3D1	0.33	6.15	0.32	2.25e-9	Height;
LUSC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.7	0.34	9.06e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs57590327	0.503	rs2372906	chr3:81504673	G/A	cg07356753	chr3:81810745	GBE1	0.46	6.07	0.32	3.38e-9	Extraversion;
LUSC	cis	rs16854884	0.586	rs4527375	chr3:143735515	A/T	cg06585982	chr3:143692056	C3orf58	-0.52	-8.57	-0.42	3.85e-16	Economic and political preferences (feminism/equality);
LUSC	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg11887960	chr12:57824829	NA	0.55	6.69	0.34	9.64e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg16950941	chr11:66035639	RAB1B	0.49	7.13	0.36	6.41e-12	Gout;
LUSC	cis	rs7527798	0.592	rs11118360	chr1:207858586	G/A	cg09232269	chr1:207846808	CR1L	-0.3	-6.34	-0.33	7.3e-10	Erythrocyte sedimentation rate;
LUSC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-13.62	-0.6	6.89e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.69	0.3	2.81e-8	Self-reported allergy;
LUSC	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg15997130	chr1:24165203	NA	-0.48	-7.22	-0.37	3.44e-12	Immature fraction of reticulocytes;
LUSC	cis	rs2580764	0.565	rs35631428	chr2:55244438	G/A	cg09592903	chr2:55203963	RTN4	-0.47	-9.5	-0.46	4.28e-19	Mean platelet volume;
LUSC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	0.97	13.28	0.59	1.29e-32	Eosinophil percentage of granulocytes;
LUSC	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg22467129	chr15:76604101	ETFA	-0.42	-6.69	-0.34	9.56e-11	Blood metabolite levels;
LUSC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg19257562	chr1:2043853	PRKCZ	0.32	6.4	0.33	5.18e-10	Height;
LUSC	trans	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.77	-0.35	5.85e-11	Bone mineral density;
LUSC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg23262073	chr20:60523788	NA	-0.39	-5.69	-0.3	2.81e-8	Body mass index;
LUSC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	11.73	0.54	7.92e-27	Menarche (age at onset);
LUSC	cis	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg01585723	chr16:33734837	NA	0.35	5.7	0.3	2.66e-8	Menopause (age at onset);
LUSC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg07507251	chr3:52567010	NT5DC2	0.34	6.48	0.33	3.32e-10	Bipolar disorder;
LUSC	cis	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg06360820	chr2:242988706	NA	-0.64	-8.32	-0.41	2.32e-15	Obesity-related traits;
LUSC	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg09323728	chr8:95962352	TP53INP1	-0.37	-7.62	-0.38	2.62e-13	Type 2 diabetes;
LUSC	cis	rs7215564	0.818	rs34756632	chr17:78618859	C/T	cg09596252	chr17:78655493	RPTOR	0.55	5.89	0.31	9.17e-9	Myopia (pathological);
LUSC	cis	rs6009527	1.000	rs6009188	chr22:49572751	G/A	cg12746016	chr22:49560550	NA	0.37	6.22	0.32	1.51e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg11789530	chr4:8429930	ACOX3	-0.4	-5.98	-0.31	5.59e-9	Response to antineoplastic agents;
LUSC	cis	rs55665837	1.000	rs12295723	chr11:14450201	T/C	cg05501817	chr11:14380813	RRAS2	-0.41	-6.61	-0.34	1.51e-10	Vitamin D levels;
LUSC	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.33e-21	Lymphocyte counts;
LUSC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs7799006	0.782	rs2159044	chr7:2262941	C/A	cg08027265	chr7:2291960	NA	-0.36	-6.02	-0.31	4.65e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9341808	0.718	rs7740627	chr6:80916347	A/G	cg08355045	chr6:80787529	NA	0.58	10.18	0.49	2.23e-21	Sitting height ratio;
LUSC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg27535305	chr1:53392650	SCP2	-0.47	-9.1	-0.45	8.12e-18	Monocyte count;
LUSC	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg12140854	chr5:148520817	ABLIM3	-0.35	-5.79	-0.3	1.66e-8	Breast cancer;
LUSC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.29	0.37	2.21e-12	Motion sickness;
LUSC	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.55	-0.34	2.11e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs13089785	1.000	rs2332682	chr3:123654633	C/T	cg19611163	chr3:123411211	MYLK	0.35	6.08	0.32	3.2e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs10744422	0.800	rs1696320	chr12:123269814	A/G	cg25930673	chr12:123319894	HIP1R	-0.58	-5.98	-0.31	5.68e-9	Schizophrenia;
LUSC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg13699009	chr12:122356056	WDR66	0.5	7.86	0.4	5.39e-14	Mean corpuscular volume;
LUSC	cis	rs7084921	0.608	rs11596883	chr10:101861622	T/C	cg11888571	chr10:102027403	CWF19L1	-0.42	-5.71	-0.3	2.47e-8	Bone mineral density;
LUSC	cis	rs155346	1.000	rs155345	chr5:139397250	C/T	cg01090482	chr5:139365336	NRG2	-0.38	-6.18	-0.32	1.88e-9	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg11062466	chr8:58055876	NA	0.7	9.34	0.46	1.41e-18	Developmental language disorder (linguistic errors);
LUSC	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21659725	chr3:3221576	CRBN	-0.52	-8.37	-0.42	1.61e-15	Body mass index;
LUSC	cis	rs7011049	1.000	rs11995106	chr8:53834768	C/T	cg26025543	chr8:53854495	NA	0.51	6.3	0.33	9.53e-10	Systolic blood pressure;
LUSC	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg13755796	chr4:20253514	NA	-0.42	-6.61	-0.34	1.49e-10	Life satisfaction;
LUSC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.44	-0.33	4.21e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg15557168	chr22:42548783	NA	-0.43	-6.49	-0.33	3.09e-10	Schizophrenia;
LUSC	cis	rs11214589	0.875	rs10891540	chr11:113239082	A/G	cg14159747	chr11:113255604	NA	-0.27	-7.08	-0.36	8.78e-12	Neuroticism;
LUSC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.18	0.41	5.91e-15	Height;
LUSC	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg03676636	chr4:99064102	C4orf37	0.34	6.21	0.32	1.58e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-12.24	-0.56	1.01e-28	Body mass index;
LUSC	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4729127	1.000	rs4729118	chr7:93982877	T/C	cg20086523	chr13:52378287	DHRS12	0.57	6.12	0.32	2.61e-9	Intelligence;
LUSC	cis	rs2262909	0.962	rs1526884	chr19:22303651	A/G	cg11619707	chr19:22235551	ZNF257	0.39	5.89	0.31	9.62e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs500891	0.533	rs945238	chr6:84165856	C/T	cg08257003	chr6:84140564	ME1	0.39	9.78	0.47	5.12e-20	Platelet-derived growth factor BB levels;
LUSC	cis	rs1506636	0.511	rs62484466	chr7:123174880	T/A	cg03229431	chr7:123269106	ASB15	0.47	6.9	0.35	2.68e-11	Plateletcrit;Platelet count;
LUSC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-8.51	-0.42	5.89e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs1358748	0.573	rs7529446	chr1:67581576	A/C	cg02640540	chr1:67518911	SLC35D1	0.67	6.53	0.34	2.5e-10	Tuberculosis;
LUSC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs757081	0.667	rs1987694	chr11:17107648	G/C	cg15432903	chr11:17409602	KCNJ11	-0.39	-6.04	-0.31	4e-9	Systolic blood pressure;
LUSC	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg25237894	chr2:233734115	C2orf82	0.34	6.21	0.32	1.59e-9	Coronary artery disease;
LUSC	cis	rs7267979	0.565	rs4815432	chr20:25556403	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.7	-12.67	-0.57	2.7e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs887829	0.570	rs7608175	chr2:234599089	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.4	6.54	0.34	2.35e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	trans	rs72674100	0.867	rs3974980	chr4:97963716	T/C	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg27121462	chr16:89883253	FANCA	0.43	6.64	0.34	1.25e-10	Vitiligo;
LUSC	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg25174290	chr11:3078921	CARS	-0.42	-6.27	-0.32	1.11e-9	Calcium levels;
LUSC	trans	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg17675199	chr6:35436792	RPL10A	-0.41	-6.11	-0.32	2.73e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg13319975	chr6:146136371	FBXO30	0.45	6.78	0.35	5.49e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.72	0.43	1.34e-16	Prudent dietary pattern;
LUSC	trans	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.23	0.45	3.1e-18	Mean corpuscular volume;
LUSC	cis	rs2273669	0.667	rs76367548	chr6:109356589	C/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg00684032	chr4:1343700	KIAA1530	0.33	5.84	0.3	1.25e-8	Obesity-related traits;
LUSC	cis	rs354225	0.584	rs11898032	chr2:54821515	G/A	cg01766943	chr2:54829624	SPTBN1	0.49	8.01	0.4	1.91e-14	Schizophrenia;
LUSC	trans	rs4729127	1.000	rs4727297	chr7:93984947	C/T	cg20086523	chr13:52378287	DHRS12	0.57	6.12	0.32	2.64e-9	Intelligence;
LUSC	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg24069376	chr3:38537580	EXOG	0.37	7.33	0.37	1.72e-12	Electrocardiographic conduction measures;
LUSC	trans	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.15	-0.32	2.19e-9	Depression;
LUSC	cis	rs548181	0.736	rs540436	chr11:125512619	A/G	cg03464685	chr11:125439445	EI24	1.04	12.18	0.55	1.78e-28	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg19187155	chr2:232395269	NMUR1	0.8	13.92	0.61	4.61e-35	Height;
LUSC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	6.38	0.33	6.05e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg08355456	chr11:67383691	NA	-0.37	-6.46	-0.33	3.62e-10	Mean corpuscular volume;
LUSC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02010894	chr19:16653629	CHERP	0.77	6.08	0.32	3.33e-9	Cognitive performance;
LUSC	cis	rs6736093	0.966	rs11692445	chr2:112704033	T/G	cg12686935	chr2:112915763	FBLN7	-0.37	-5.87	-0.31	1.02e-8	Coronary artery disease;
LUSC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.85	15.67	0.65	6.91e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.88e-11	Primary biliary cholangitis;
LUSC	cis	rs8135665	0.600	rs8139025	chr22:38450881	G/C	cg13116946	chr22:38479732	SLC16A8	0.42	6.22	0.32	1.52e-9	Advanced age-related macular degeneration;Age-related macular degeneration;
LUSC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.0	0.58	1.45e-31	Cognitive test performance;
LUSC	cis	rs9928842	0.823	rs2870472	chr16:75278841	C/G	cg09066997	chr16:75300724	BCAR1	0.5	6.51	0.34	2.71e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg02175503	chr12:58329896	NA	0.49	7.16	0.36	5.03e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg09365446	chr1:150670422	GOLPH3L	0.46	6.74	0.35	7.09e-11	Melanoma;
LUSC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	1.22	16.05	0.66	2.2e-43	Eosinophil percentage of granulocytes;
LUSC	trans	rs970548	0.738	rs61854124	chr10:46077158	T/C	cg14222797	chr10:16859974	RSU1	-0.57	-6.04	-0.31	4.07e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs12900413	0.802	rs11634377	chr15:90295583	C/T	cg24249390	chr15:90295951	MESP1	-0.48	-7.25	-0.37	2.83e-12	Coronary artery aneurysm in Kawasaki disease;
LUSC	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	8.01	0.4	1.95e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	6.0	0.31	5.03e-9	Breast cancer;
LUSC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg25039879	chr17:56429692	SUPT4H1	0.68	9.11	0.45	7.7e-18	Cognitive test performance;
LUSC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08736216	chr1:53307985	ZYG11A	-0.29	-6.04	-0.31	4.11e-9	Monocyte count;
LUSC	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg08277548	chr1:17600880	PADI3	-0.59	-6.21	-0.32	1.56e-9	Hair shape;
LUSC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg14456004	chr13:21872349	NA	1.26	19.3	0.73	2.74e-56	White matter hyperintensity burden;
LUSC	trans	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.68	-0.34	1.02e-10	Life satisfaction;
LUSC	cis	rs2658782	0.789	rs2658775	chr11:93126799	C/T	cg15737290	chr11:93063684	CCDC67	0.64	7.92	0.4	3.59e-14	Pulmonary function decline;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17465063	chr10:111985564	MXI1	-0.42	-6.27	-0.32	1.08e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg12560992	chr17:57184187	TRIM37	0.83	15.22	0.64	4.28e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs9400467	0.528	rs455335	chr6:111675516	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs1020064	0.609	rs2576748	chr2:105911258	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.44	-6.24	-0.32	1.3e-9	AIDS;
LUSC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.51	7.2	0.37	4.08e-12	Gut microbiome composition (summer);
LUSC	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg13256891	chr4:100009986	ADH5	0.46	6.32	0.33	8.54e-10	Alcohol dependence;
LUSC	cis	rs1014246	0.848	rs758362	chr10:118457905	G/A	cg14919929	chr10:118506882	NA	0.45	7.19	0.37	4.15e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7189233	0.955	rs8044205	chr16:53515093	T/C	cg04059762	chr16:53544020	NA	-0.32	-5.79	-0.3	1.67e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg16325326	chr1:53192061	ZYG11B	-0.92	-17.21	-0.69	5.71e-48	Monocyte count;
LUSC	cis	rs7512552	0.803	rs13294	chr1:150484987	G/A	cg15654264	chr1:150340011	RPRD2	0.57	9.15	0.45	5.83e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4654899	0.802	rs12123910	chr1:21233316	C/T	cg02927042	chr1:21476669	EIF4G3	-0.38	-5.96	-0.31	6.51e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg13010344	chr12:123464640	ARL6IP4	0.48	5.84	0.3	1.25e-8	Neutrophil percentage of white cells;
LUSC	cis	rs1113500	0.933	rs11185259	chr1:108635062	A/G	cg06207961	chr1:108661230	NA	-0.41	-7.38	-0.37	1.24e-12	Growth-regulated protein alpha levels;
LUSC	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg00484396	chr16:3507460	NAT15	-0.47	-7.01	-0.36	1.29e-11	Body mass index (adult);
LUSC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg25894440	chr7:65020034	NA	0.39	6.14	0.32	2.33e-9	Calcium levels;
LUSC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg10130564	chr11:117069849	TAGLN	-0.33	-5.69	-0.3	2.82e-8	Blood protein levels;
LUSC	cis	rs11630290	0.613	rs925251	chr15:64175124	C/G	cg12036633	chr15:63758958	NA	0.51	6.43	0.33	4.34e-10	Iris characteristics;
LUSC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg25767906	chr1:53392781	SCP2	-0.64	-12.71	-0.57	1.89e-30	Monocyte count;
LUSC	cis	rs1775715	0.870	rs1775731	chr10:32253512	A/G	cg03015672	chr10:32216066	ARHGAP12	0.33	5.66	0.3	3.31e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7553864	0.667	rs6576866	chr1:87601471	T/C	cg17420885	chr1:87600446	LOC339524	-0.46	-6.28	-0.33	1.05e-9	Smoking behavior;
LUSC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg10729496	chr3:10149963	C3orf24	0.56	7.11	0.36	7.2e-12	Alzheimer's disease;
LUSC	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg04511125	chr2:88470314	THNSL2	0.68	6.42	0.33	4.76e-10	Plasma clusterin levels;
LUSC	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg21775007	chr8:11205619	TDH	-0.65	-10.34	-0.49	6.55e-22	Retinal vascular caliber;
LUSC	cis	rs1113500	0.548	rs6583062	chr1:108656463	G/A	cg11967332	chr1:108735228	SLC25A24	0.44	5.95	0.31	6.7e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs469568	0.935	rs468723	chr5:178667778	A/G	cg08999896	chr5:178685787	ADAMTS2	0.3	6.19	0.32	1.72e-9	Stroke (pediatric);
LUSC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.38	0.37	1.3e-12	Bipolar disorder;
LUSC	cis	rs4631830	0.896	rs7077830	chr10:51522276	C/G	cg16070123	chr10:51489643	NA	0.48	7.75	0.39	1.11e-13	Prostate-specific antigen levels;
LUSC	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg06026331	chr20:60912101	LAMA5	0.56	6.73	0.35	7.56e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.11	0.52	1.27e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-6.53	-0.34	2.48e-10	Homocysteine levels;
LUSC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg27170947	chr2:26402098	FAM59B	-0.7	-10.61	-0.5	7.11e-23	Gut microbiome composition (summer);
LUSC	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg04111992	chr7:158790115	NA	0.35	5.7	0.3	2.64e-8	Facial morphology (factor 20);
LUSC	cis	rs11622475	1.000	rs7143682	chr14:104413455	C/T	cg12183467	chr14:104352244	NA	-0.43	-7.68	-0.39	1.82e-13	Bipolar disorder;
LUSC	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg14433983	chr11:636460	DRD4	-0.35	-5.88	-0.31	9.78e-9	Systemic lupus erythematosus;
LUSC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg25124228	chr12:125621409	AACS	-0.6	-9.98	-0.48	1.06e-20	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg13010199	chr12:38710504	ALG10B	0.68	10.71	0.51	3.28e-23	Bladder cancer;
LUSC	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg05507819	chr15:63340323	TPM1	0.64	8.98	0.44	1.95e-17	Platelet count;
LUSC	cis	rs6960043	1.000	rs6962498	chr7:15050305	C/G	cg19272540	chr7:15055459	NA	-0.31	-7.41	-0.38	1.01e-12	Type 2 diabetes;
LUSC	cis	rs76419734	0.510	rs2544417	chr4:106745405	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.54	-6.0	-0.31	5.21e-9	Post bronchodilator FEV1;
LUSC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.98	-16.45	-0.67	6.2e-45	Systemic lupus erythematosus;
LUSC	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg00310523	chr12:86230176	RASSF9	0.45	8.0	0.4	2.1e-14	Major depressive disorder;
LUSC	cis	rs9323205	0.871	rs2999393	chr14:51655167	G/T	cg23942311	chr14:51606299	NA	0.4	8.15	0.41	7.36e-15	Cancer;
LUSC	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg17279839	chr7:150038598	RARRES2	0.44	6.9	0.35	2.6e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4285028	0.747	rs1127412	chr3:121414061	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.88	-12.4	-0.56	2.65e-29	Multiple sclerosis;
LUSC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg22029157	chr1:209979665	IRF6	0.76	11.16	0.52	8.66e-25	Cleft lip with or without cleft palate;
LUSC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs9653442	0.900	rs2309837	chr2:100837567	T/C	cg22139774	chr2:100720529	AFF3	-0.45	-7.9	-0.4	3.97e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.31	5.9	0.31	9.05e-9	Schizophrenia;
LUSC	trans	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg10756647	chr7:56101905	PSPH	0.88	8.96	0.44	2.32e-17	Gout;
LUSC	cis	rs10904908	1.000	rs7920112	chr10:17259863	T/C	cg01003015	chr10:17271136	VIM	-0.42	-6.04	-0.31	4.02e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.59	10.72	0.51	3.01e-23	Bone mineral density;
LUSC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg16362232	chr11:430036	ANO9	0.64	8.17	0.41	6.27e-15	Body mass index;
LUSC	cis	rs73200209	0.744	rs56869346	chr12:116514538	T/C	cg01776926	chr12:116560359	MED13L	-0.49	-6.03	-0.31	4.4e-9	Total body bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19164917	chr7:99102197	ZKSCAN5	-0.42	-6.23	-0.32	1.42e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6599077	1.000	rs9870930	chr3:40097971	A/G	cg13683864	chr3:40499215	RPL14	-0.61	-7.25	-0.37	2.94e-12	Sleep-related phenotypes;
LUSC	trans	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg19894588	chr14:64061835	NA	0.54	7.74	0.39	1.19e-13	Glioblastoma;Glioma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08031094	chr2:54013912	LOC100302652;ASB3;ERLEC1	0.41	6.13	0.32	2.44e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	1.02	13.75	0.6	2.16e-34	Exhaled nitric oxide levels;
LUSC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg07424592	chr7:64974309	NA	-0.64	-5.79	-0.3	1.65e-8	Diabetic kidney disease;
LUSC	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg08270630	chr22:50330655	NA	-0.41	-6.19	-0.32	1.79e-9	Schizophrenia;
LUSC	cis	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg05084668	chr3:125655381	ALG1L	-0.79	-11.78	-0.54	4.85e-27	Blood pressure (smoking interaction);
LUSC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02187348	chr16:89574699	SPG7	0.61	10.07	0.48	5.4e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	7.78	0.39	9.16e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg24296786	chr1:45957014	TESK2	-0.41	-5.81	-0.3	1.47e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg23711669	chr6:146136114	FBXO30	0.75	13.32	0.59	9.55e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg01884057	chr2:25150051	NA	0.48	11.43	0.53	9.67e-26	Body mass index;
LUSC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg23281280	chr6:28129359	ZNF389	0.43	5.67	0.3	3.04e-8	Depression;
LUSC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.79	12.84	0.57	5.82e-31	Aortic root size;
LUSC	cis	rs9322817	0.625	rs2499655	chr6:105307435	G/A	cg02098413	chr6:105308735	HACE1	0.27	5.8	0.3	1.52e-8	Thyroid stimulating hormone;
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg25428297	chr7:1022841	CYP2W1	0.28	5.66	0.3	3.22e-8	Longevity;Endometriosis;
LUSC	cis	rs9677476	0.863	rs58383275	chr2:232063946	T/C	cg07929768	chr2:232055508	NA	0.37	6.85	0.35	3.49e-11	Food antigen IgG levels;
LUSC	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.84	0.44	5.76e-17	Lung cancer in ever smokers;
LUSC	cis	rs1975974	0.872	rs17052344	chr17:21717543	A/G	cg18423549	chr17:21743878	NA	0.53	7.96	0.4	2.63e-14	Psoriasis;
LUSC	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06636551	chr8:101224915	SPAG1	0.39	7.26	0.37	2.82e-12	Atrioventricular conduction;
LUSC	cis	rs7804356	0.953	rs10241234	chr7:26869887	T/A	cg03456212	chr7:26904342	SKAP2	-0.56	-6.46	-0.33	3.63e-10	Type 1 diabetes;
LUSC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg16447950	chr5:562315	NA	-0.53	-6.6	-0.34	1.63e-10	Obesity-related traits;
LUSC	cis	rs2742417	1.000	rs2251954	chr3:45731784	A/G	cg09608765	chr3:45636137	LIMD1	-0.33	-6.47	-0.33	3.47e-10	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg02018176	chr4:1364513	KIAA1530	0.44	6.02	0.31	4.62e-9	Recombination rate (females);
LUSC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg13770153	chr20:60521292	NA	-0.65	-9.13	-0.45	6.8e-18	Body mass index;
LUSC	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg12379764	chr21:47803548	PCNT	0.79	12.27	0.56	8.16e-29	Lymphocyte counts;
LUSC	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg02023728	chr11:77925099	USP35	0.54	7.76	0.39	1.03e-13	Testicular germ cell tumor;
LUSC	cis	rs10992471	0.651	rs7043984	chr9:95529408	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.69	-0.34	9.49e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg08917208	chr2:24149416	ATAD2B	0.96	10.09	0.48	4.61e-21	Lymphocyte counts;
LUSC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg22907277	chr7:1156413	C7orf50	0.69	7.41	0.38	1.02e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.14	0.32	2.31e-9	Schizophrenia;
LUSC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.7	-10.65	-0.5	5.29e-23	Aortic root size;
LUSC	cis	rs308403	0.640	rs34518478	chr4:123719999	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	10.23	0.49	1.5e-21	Blood protein levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg17227680	chr17:46048473	CDK5RAP3	0.78	6.7	0.34	8.69e-11	Cognitive performance;
LUSC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg21951975	chr1:209979733	IRF6	0.52	7.44	0.38	8.83e-13	Cleft lip with or without cleft palate;
LUSC	cis	rs7572644	0.713	rs1458397	chr2:28219608	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-6.45	-0.33	3.97e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs4474465	0.688	rs4277140	chr11:78285096	G/T	cg27205649	chr11:78285834	NARS2	-0.54	-6.69	-0.34	9.39e-11	Alzheimer's disease (survival time);
LUSC	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.45	9.66	0.47	1.23e-19	Airflow obstruction;
LUSC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg21951975	chr1:209979733	IRF6	0.57	8.52	0.42	5.74e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg11342453	chr6:26196699	NA	0.54	5.67	0.3	3.13e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.82	0.35	4.37e-11	Height;
LUSC	cis	rs4478858	0.735	rs10798843	chr1:31797094	A/G	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs4654899	1.000	rs6682368	chr1:21506914	G/A	cg01072550	chr1:21505969	NA	-0.55	-8.49	-0.42	7e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg18402987	chr7:1209562	NA	0.73	7.92	0.4	3.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.86	-0.47	2.63e-20	Migraine;Coronary artery disease;
LUSC	cis	rs12989701	0.877	rs12994718	chr2:127874226	T/A	cg08168897	chr2:127865431	BIN1	0.71	9.36	0.46	1.2e-18	Alzheimer's disease (late onset);
LUSC	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg00999904	chr2:3704751	ALLC	-0.44	-6.76	-0.35	6.12e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg26043149	chr18:55253948	FECH	0.51	7.53	0.38	4.93e-13	Bone mineral density;
LUSC	trans	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg26811252	chr16:29126840	RRN3P2	0.63	9.89	0.48	2.18e-20	Menopause (age at onset);
LUSC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg04315214	chr1:2043799	PRKCZ	0.48	9.96	0.48	1.29e-20	Height;
LUSC	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg20203395	chr5:56204925	C5orf35	-0.47	-6.89	-0.35	2.72e-11	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18251222	chr2:10183620	KLF11	0.51	6.85	0.35	3.64e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg24733560	chr20:60626293	TAF4	0.43	7.85	0.39	5.57e-14	Body mass index;
LUSC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg23649088	chr2:200775458	C2orf69	-0.53	-7.17	-0.37	4.94e-12	Schizophrenia;
LUSC	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg17420585	chr12:42539391	GXYLT1	-0.38	-7.51	-0.38	5.57e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1775715	0.769	rs2808102	chr10:32117749	A/T	cg03015672	chr10:32216066	ARHGAP12	0.35	6.15	0.32	2.23e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7712401	0.562	rs30052	chr5:122305009	A/T	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-8.67	-0.43	1.95e-16	Monocyte percentage of white cells;
LUSC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg08847533	chr14:75593920	NEK9	0.79	13.45	0.59	2.99e-33	Height;
LUSC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg05373962	chr22:49881684	NA	-0.44	-10.56	-0.5	1.13e-22	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg12463550	chr7:65579703	CRCP	-0.46	-6.82	-0.35	4.21e-11	Aortic root size;
LUSC	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg05110241	chr16:68378359	PRMT7	-0.53	-6.16	-0.32	2.11e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg15423357	chr2:25149977	NA	-0.39	-7.83	-0.39	6.4e-14	Body mass index;
LUSC	cis	rs16976116	0.901	rs8027098	chr15:55492269	C/T	cg11288833	chr15:55489084	RSL24D1	0.49	5.87	0.31	1.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg18232548	chr7:50535776	DDC	-0.51	-7.83	-0.39	6.32e-14	Malaria;
LUSC	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg03060546	chr3:49711283	APEH	-0.63	-7.36	-0.37	1.49e-12	Menarche (age at onset);
LUSC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg15557168	chr22:42548783	NA	-0.47	-7.33	-0.37	1.73e-12	Schizophrenia;
LUSC	trans	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.47e-10	Corneal astigmatism;
LUSC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.28	0.56	7.31e-29	Prudent dietary pattern;
LUSC	cis	rs727505	1.000	rs10244817	chr7:124467470	T/C	cg23710748	chr7:124431027	NA	-0.42	-7.66	-0.39	2.06e-13	Lewy body disease;
LUSC	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg24733560	chr20:60626293	TAF4	0.41	7.35	0.37	1.58e-12	Body mass index;
LUSC	cis	rs7246967	0.673	rs34795935	chr19:22865188	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs1044826	1.000	rs114427693	chr3:139121721	G/A	cg00490450	chr3:139108681	COPB2	0.55	7.32	0.37	1.82e-12	Obesity-related traits;
LUSC	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.61	-10.12	-0.48	3.47e-21	Bone mineral density;
LUSC	cis	rs2274273	0.870	rs59629906	chr14:55781189	T/C	cg04306507	chr14:55594613	LGALS3	0.54	11.81	0.54	3.97e-27	Protein biomarker;
LUSC	cis	rs137603	0.644	rs137621	chr22:39710244	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.52	-8.22	-0.41	4.71e-15	Primary biliary cholangitis;
LUSC	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg10596483	chr8:143751796	JRK	0.53	7.66	0.39	1.98e-13	Schizophrenia;
LUSC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.49	-9.19	-0.45	4.31e-18	Urinary metabolites;
LUSC	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg05585544	chr11:47624801	NA	-0.41	-7.02	-0.36	1.21e-11	Subjective well-being;
LUSC	cis	rs6690583	0.623	rs55721024	chr1:85454447	A/C	cg11262906	chr1:85462892	MCOLN2	0.68	6.56	0.34	2.02e-10	Serum sulfate level;
LUSC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.68	-0.34	1e-10	Longevity;Endometriosis;
LUSC	cis	rs62384625	1.000	rs17208670	chr5:141497239	A/G	cg23435118	chr5:141488016	NDFIP1	0.35	6.06	0.31	3.74e-9	White blood cell count (basophil);
LUSC	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg02466173	chr16:30829666	NA	-0.58	-10.9	-0.51	7.02e-24	Multiple myeloma;
LUSC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg11062466	chr8:58055876	NA	0.66	8.52	0.42	5.58e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg05043794	chr9:111880884	C9orf5	-0.3	-6.34	-0.33	7.54e-10	Menarche (age at onset);
LUSC	cis	rs2932538	0.961	rs2932539	chr1:113215786	A/G	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.7	-0.47	9.01e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg05738196	chr6:26577821	NA	-0.5	-7.61	-0.38	2.89e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg23791538	chr6:167370224	RNASET2	0.5	8.27	0.41	3.19e-15	Crohn's disease;
LUSC	cis	rs2073300	1.000	rs6048835	chr20:23462343	G/C	cg09953122	chr20:23471693	CST8	-0.76	-7.49	-0.38	6.37e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs354225	0.513	rs10187338	chr2:54806611	A/G	cg26097391	chr2:54893211	SPTBN1	0.42	6.39	0.33	5.6e-10	Schizophrenia;
LUSC	cis	rs1044826	1.000	rs12494806	chr3:139067595	G/A	cg00490450	chr3:139108681	COPB2	0.57	7.61	0.38	2.77e-13	Obesity-related traits;
LUSC	cis	rs727505	0.607	rs17387389	chr7:124784751	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.95	-0.36	1.93e-11	Lewy body disease;
LUSC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg11752832	chr7:134001865	SLC35B4	0.52	8.01	0.4	1.89e-14	Mean platelet volume;
LUSC	cis	rs1941023	0.503	rs11230288	chr11:60128968	G/A	cg08716584	chr11:60157161	MS4A7	-0.61	-11.47	-0.53	6.92e-26	Congenital heart disease (maternal effect);
LUSC	cis	rs9341808	0.754	rs978814	chr6:80959912	G/T	cg08355045	chr6:80787529	NA	0.56	9.61	0.47	1.84e-19	Sitting height ratio;
LUSC	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg25173405	chr17:45401733	C17orf57	-0.39	-5.92	-0.31	7.86e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg23241863	chr10:102295624	HIF1AN	0.49	6.07	0.32	3.38e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1957429	0.808	rs2357866	chr14:65336517	C/T	cg23373153	chr14:65346875	NA	0.97	10.99	0.52	3.53e-24	Pediatric areal bone mineral density (radius);
LUSC	cis	rs2963155	0.518	rs853179	chr5:142634773	G/T	cg17617527	chr5:142782415	NR3C1	0.71	8.42	0.42	1.14e-15	Breast cancer;
LUSC	cis	rs590121	0.876	rs650241	chr11:75277757	C/G	cg26104986	chr11:75275303	SERPINH1	-0.29	-6.06	-0.31	3.74e-9	Coronary artery disease;
LUSC	cis	rs796364	0.507	rs13035874	chr2:201109553	G/A	cg04283868	chr2:201171347	SPATS2L	0.45	6.05	0.31	3.99e-9	Schizophrenia;
LUSC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	8.84	0.44	5.48e-17	Schizophrenia;
LUSC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg07212818	chr11:638076	DRD4	-0.41	-7.05	-0.36	1e-11	Systemic lupus erythematosus;
LUSC	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg08999081	chr20:33150536	PIGU	-0.36	-6.46	-0.33	3.62e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg25797454	chr6:150327115	RAET1K	0.37	8.48	0.42	7.48e-16	Alopecia areata;
LUSC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg22907277	chr7:1156413	C7orf50	0.68	8.11	0.41	9.63e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg06532163	chr17:45867833	NA	0.34	6.33	0.33	8.11e-10	IgG glycosylation;
LUSC	trans	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg26384229	chr12:38710491	ALG10B	-0.58	-9.32	-0.45	1.69e-18	Morning vs. evening chronotype;
LUSC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg03340356	chr1:67600835	NA	0.43	6.75	0.35	6.57e-11	Psoriasis;
LUSC	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	11.85	0.54	2.72e-27	Blood protein levels;
LUSC	cis	rs2677744	0.626	rs11857545	chr15:91489705	G/A	cg23684204	chr15:91497937	RCCD1	0.53	7.33	0.37	1.73e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg00310523	chr12:86230176	RASSF9	0.4	7.33	0.37	1.8e-12	Major depressive disorder;
LUSC	cis	rs16976116	0.806	rs117064453	chr15:55492319	T/A	cg11288833	chr15:55489084	RSL24D1	0.5	5.88	0.31	1.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs55665837	0.961	rs60622588	chr11:14456998	T/C	cg05501817	chr11:14380813	RRAS2	-0.41	-6.53	-0.34	2.5e-10	Vitamin D levels;
LUSC	cis	rs669446	0.533	rs2158956	chr1:44211697	T/C	cg15962314	chr1:44399869	ARTN	0.24	5.66	0.3	3.33e-8	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs1775715	0.707	rs2065443	chr10:32164236	C/G	cg03015672	chr10:32216066	ARHGAP12	0.34	6.12	0.32	2.62e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg00310523	chr12:86230176	RASSF9	0.47	8.62	0.43	2.74e-16	Major depressive disorder;
LUSC	cis	rs4423214	0.592	rs10898191	chr11:71194601	G/A	cg05163923	chr11:71159392	DHCR7	-0.66	-7.09	-0.36	8.08e-12	Vitamin D levels;
LUSC	cis	rs1506636	1.000	rs767637	chr7:123321978	C/A	cg03229431	chr7:123269106	ASB15	-0.64	-10.57	-0.5	1.05e-22	Plateletcrit;Platelet count;
LUSC	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg06223162	chr1:101003688	GPR88	0.49	9.44	0.46	6.6e-19	Monocyte count;
LUSC	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg07169764	chr2:136633963	MCM6	0.58	7.42	0.38	9.99e-13	Mosquito bite size;
LUSC	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg03806693	chr22:41940476	POLR3H	-0.63	-9.57	-0.46	2.46e-19	Alzheimer's disease biomarkers;
LUSC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg18225595	chr11:63971243	STIP1	0.47	5.98	0.31	5.86e-9	Mean platelet volume;
LUSC	trans	rs72674100	1.000	rs28520218	chr4:97966557	T/C	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00152838	chr16:24741724	TNRC6A	-0.46	-5.69	-0.3	2.74e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6669919	0.530	rs11587621	chr1:211668400	C/T	cg10512769	chr1:211675356	NA	0.28	6.71	0.34	8.34e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.62	-8.86	-0.44	4.81e-17	Mean platelet volume;
LUSC	cis	rs6076065	0.748	rs2424542	chr20:23386800	C/T	cg11657817	chr20:23433608	CST11	0.53	11.03	0.52	2.42e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg00509249	chr6:109615579	CCDC162	0.32	5.79	0.3	1.61e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.76	-12.62	-0.57	3.87e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13253111	0.603	rs28605937	chr8:28099179	A/G	cg26534493	chr8:28060551	NA	0.37	6.78	0.35	5.48e-11	Childhood body mass index;
LUSC	cis	rs427394	1.000	rs427394	chr5:6745875	A/G	cg10857441	chr5:6722123	POLS	-0.4	-7.55	-0.38	4.2e-13	Menopause (age at onset);
LUSC	cis	rs4704187	0.687	rs7735937	chr5:74441700	G/A	cg03227963	chr5:74354835	NA	0.31	6.63	0.34	1.35e-10	Response to amphetamines;
LUSC	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg07211511	chr3:129823064	LOC729375	-1.24	-20.25	-0.74	4.86e-60	Blood pressure (smoking interaction);
LUSC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg24675658	chr1:53192096	ZYG11B	-0.64	-10.02	-0.48	7.94e-21	Monocyte count;
LUSC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.67	-0.43	1.97e-16	Joint mobility (Beighton score);
LUSC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg16743903	chr16:89593216	SPG7	-0.38	-5.88	-0.31	9.98e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.31	-6.16	-0.32	2.07e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	0.65	13.71	0.6	3.1e-34	Prudent dietary pattern;
LUSC	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg12568669	chr8:11666485	FDFT1	-0.24	-5.66	-0.3	3.24e-8	Retinal vascular caliber;
LUSC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg24562669	chr7:97807699	LMTK2	0.33	5.75	0.3	1.99e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.89	0.31	9.52e-9	Menopause (age at onset);
LUSC	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.33	-0.37	1.78e-12	Triglycerides;
LUSC	cis	rs3947	0.687	rs1736065	chr8:11685453	A/G	cg00262122	chr8:11665843	FDFT1	-0.47	-5.86	-0.31	1.08e-8	Blood protein levels;
LUSC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg01125463	chr6:42946178	PEX6	-0.34	-5.66	-0.3	3.19e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs865483	0.895	rs7501983	chr17:35783812	A/G	cg06716730	chr17:35851459	DUSP14	-0.26	-5.73	-0.3	2.2e-8	Monocyte count;
LUSC	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg12559939	chr2:27858050	GPN1	0.41	6.44	0.33	4.16e-10	Oral cavity cancer;
LUSC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs190945449	1	rs190945449	chr6:26828359	C/T	cg06606381	chr12:133084897	FBRSL1	-0.84	-7.64	-0.39	2.38e-13	Urinary tract infection frequency;
LUSC	cis	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg27411982	chr8:10470053	RP1L1	0.47	7.06	0.36	9.53e-12	Neuroticism;
LUSC	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg02176678	chr2:219576539	TTLL4	-0.57	-10.08	-0.48	4.89e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7903847	0.619	rs10882912	chr10:99138077	C/T	cg20016023	chr10:99160130	RRP12	-0.34	-8.25	-0.41	3.65e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs983392	0.680	rs7929589	chr11:59975078	C/T	cg02771260	chr11:59836817	MS4A3	-0.37	-5.96	-0.31	6.25e-9	Alzheimer's disease (late onset);
LUSC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.05	0.31	3.81e-9	Schizophrenia;
LUSC	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg01528321	chr10:82214614	TSPAN14	0.94	14.4	0.62	6.41e-37	Post bronchodilator FEV1;
LUSC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	12.94	0.58	2.61e-31	Platelet count;
LUSC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26314531	chr2:26401878	FAM59B	0.71	9.73	0.47	7.41e-20	Gut microbiome composition (summer);
LUSC	cis	rs62481355	0.680	rs11563620	chr7:127059236	C/T	cg25922125	chr7:127225783	GCC1	-0.42	-5.73	-0.3	2.29e-8	Type 2 diabetes;
LUSC	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24838063	chr12:130822603	PIWIL1	0.69	10.79	0.51	1.69e-23	Menopause (age at onset);
LUSC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg25767906	chr1:53392781	SCP2	0.45	7.9	0.4	4.06e-14	Monocyte count;
LUSC	cis	rs4731207	0.594	rs6968500	chr7:124431722	G/C	cg14311320	chr7:124405732	GPR37	-0.32	-6.01	-0.31	4.81e-9	Cutaneous malignant melanoma;
LUSC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg11062466	chr8:58055876	NA	-0.74	-8.91	-0.44	3.31e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg24813613	chr7:1882135	MAD1L1	-0.35	-5.71	-0.3	2.52e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.25	0.56	9.59e-29	Height;
LUSC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg27588902	chr6:42928151	GNMT	-0.3	-6.56	-0.34	2e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg24503407	chr1:205819492	PM20D1	-0.44	-6.07	-0.32	3.47e-9	Parkinson's disease;
LUSC	cis	rs77140172	0.677	rs77860352	chr4:89627774	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.0	7.48	0.38	6.84e-13	Post bronchodilator FEV1;
LUSC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.43	-7.23	-0.37	3.3e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs4919087	1.000	rs7076523	chr10:99089296	T/C	cg25902810	chr10:99078978	FRAT1	-0.46	-6.66	-0.34	1.15e-10	Monocyte count;
LUSC	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg00334542	chr7:100209784	MOSPD3	-0.49	-5.74	-0.3	2.11e-8	Other erythrocyte phenotypes;
LUSC	cis	rs6690583	0.623	rs12047435	chr1:85452927	T/G	cg22153463	chr1:85462885	MCOLN2	0.63	6.0	0.31	5.24e-9	Serum sulfate level;
LUSC	trans	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.53	-0.53	4.11e-26	Colorectal cancer;
LUSC	cis	rs4792901	0.685	rs9898065	chr17:41562473	T/G	cg22562494	chr17:41607896	ETV4	-0.33	-6.34	-0.33	7.62e-10	Dupuytren's disease;
LUSC	cis	rs2237234	0.542	rs7755997	chr6:26483048	G/A	cg09904177	chr6:26538194	HMGN4	0.5	7.74	0.39	1.21e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg21906852	chr1:75198582	TYW3;CRYZ	0.37	5.72	0.3	2.32e-8	Resistin levels;
LUSC	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg17330251	chr7:94953956	PON1	-0.37	-5.86	-0.31	1.1e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs724744	0.742	rs1205934	chr6:22358196	G/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.07	-0.32	3.43e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg03188948	chr7:1209495	NA	0.67	7.1	0.36	7.38e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg27284194	chr4:1044797	NA	0.36	5.98	0.31	5.86e-9	Obesity-related traits;
LUSC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg22508957	chr16:3507546	NAT15	0.64	10.6	0.5	7.9399999999999994e-23	Tuberculosis;
LUSC	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg20203395	chr5:56204925	C5orf35	-0.46	-6.85	-0.35	3.61e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24549020	chr5:56110836	MAP3K1	0.47	5.69	0.3	2.83e-8	Initial pursuit acceleration;
LUSC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg06637938	chr14:75390232	RPS6KL1	0.52	8.26	0.41	3.33e-15	Height;
LUSC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.71	11.19	0.52	6.78e-25	Aortic root size;
LUSC	cis	rs7246967	0.673	rs34425596	chr19:22899779	T/C	cg23217946	chr19:22817039	ZNF492	0.41	5.69	0.3	2.85e-8	Bronchopulmonary dysplasia;
LUSC	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg15819921	chr19:927150	ARID3A	-0.42	-6.19	-0.32	1.79e-9	Life satisfaction;
LUSC	cis	rs983392	0.805	rs7933805	chr11:59967526	A/G	cg02771260	chr11:59836817	MS4A3	-0.36	-5.86	-0.31	1.11e-8	Alzheimer's disease (late onset);
LUSC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.27	-0.62	2.03e-36	Eye color traits;
LUSC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.21	30.68	0.86	3.34e-99	Testicular germ cell tumor;
LUSC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10802521	chr3:52805072	NEK4	-0.52	-7.65	-0.39	2.12e-13	Bipolar disorder;
LUSC	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg23711669	chr6:146136114	FBXO30	0.88	16.35	0.67	1.48e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.9	0.51	6.98e-24	Hypertriglyceridemia;
LUSC	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg24579218	chr15:68104479	NA	-0.4	-6.29	-0.33	9.87e-10	Restless legs syndrome;
LUSC	cis	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg21775007	chr8:11205619	TDH	0.44	5.95	0.31	6.59e-9	Neuroticism;
LUSC	cis	rs16910800	1.000	rs2468646	chr11:23202166	T/C	cg20040320	chr11:23191996	NA	0.44	6.47	0.33	3.59e-10	Cancer;
LUSC	cis	rs2692947	0.726	rs13009727	chr2:96769883	C/G	cg23100626	chr2:96804247	ASTL	-0.26	-6.36	-0.33	6.54e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg12560992	chr17:57184187	TRIM37	0.85	15.53	0.65	2.58e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs6754311	0.861	rs12475139	chr2:136786651	A/T	cg07169764	chr2:136633963	MCM6	0.48	6.63	0.34	1.33e-10	Mosquito bite size;
LUSC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg09796270	chr17:17721594	SREBF1	0.43	7.6	0.38	2.97e-13	Total body bone mineral density;
LUSC	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.76	-0.3	1.92e-8	Height;
LUSC	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg07828340	chr4:882639	GAK	1.07	11.34	0.53	1.99e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.15	-0.49	2.88e-21	Obesity-related traits;
LUSC	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg12927641	chr6:109611667	NA	-0.36	-6.13	-0.32	2.46e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs73001065	0.636	rs73002960	chr19:19582992	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	8.57	0.42	3.78e-16	LDL cholesterol;
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg25703541	chr22:24373054	LOC391322	0.84	12.95	0.58	2.31e-31	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.87	0.35	3.22e-11	Recombination measurement;
LUSC	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02176678	chr2:219576539	TTLL4	0.59	10.78	0.51	1.92e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7804356	1.000	rs7791513	chr7:26893357	A/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.13	-0.32	2.54e-9	Type 1 diabetes;
LUSC	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg08999081	chr20:33150536	PIGU	0.43	7.43	0.38	9.41e-13	Coronary artery disease;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05019311	chr17:4807065	CHRNE	-0.47	-6.04	-0.31	4.1e-9	Hepatitis;
LUSC	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg06360820	chr2:242988706	NA	-0.83	-9.66	-0.47	1.25e-19	Obesity-related traits;
LUSC	cis	rs113835537	0.529	rs3892818	chr11:66240191	C/T	cg24851651	chr11:66362959	CCS	0.56	8.77	0.43	9.26e-17	Airway imaging phenotypes;
LUSC	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-0.51	-7.84	-0.39	6.22e-14	Breast cancer;
LUSC	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg19812747	chr11:111475976	SIK2	-0.5	-7.04	-0.36	1.1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg03342759	chr3:160939853	NMD3	-0.49	-8.15	-0.41	7.57e-15	Morning vs. evening chronotype;
LUSC	cis	rs4690686	0.509	rs11730559	chr4:177259257	A/T	cg17059388	chr4:177262070	NA	0.44	7.95	0.4	2.9e-14	Essential tremor;
LUSC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg21856205	chr7:94953877	PON1	-0.36	-5.73	-0.3	2.29e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg05564831	chr3:52568323	NT5DC2	0.37	6.76	0.35	6.06e-11	Electroencephalogram traits;
LUSC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.18	0.32	1.87e-9	Height;
LUSC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg00012203	chr2:219082015	ARPC2	0.8	13.84	0.6	9.57e-35	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.82	10.86	0.51	9.72e-24	Mean corpuscular hemoglobin;
LUSC	trans	rs12210905	0.614	rs12199685	chr6:27323486	G/A	cg02699829	chr19:13216355	TRMT1	-0.56	-6.23	-0.32	1.39e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	1.0	17.03	0.68	2.91e-47	Coronary artery disease;
LUSC	cis	rs67397200	0.590	rs12327712	chr19:17424947	T/G	cg04248312	chr19:17393744	ANKLE1	-0.41	-5.99	-0.31	5.52e-9	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
LUSC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg19266014	chr7:2183958	MAD1L1	-0.34	-5.73	-0.3	2.26e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg27205649	chr11:78285834	NARS2	-0.51	-5.87	-0.31	1.04e-8	Testicular germ cell tumor;
LUSC	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.47	-0.42	7.8e-16	Response to antipsychotic treatment;
LUSC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21643547	chr1:205240462	TMCC2	-0.5	-9.31	-0.45	1.7e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg19774624	chr17:42201019	HDAC5	-0.81	-12.99	-0.58	1.61e-31	Total body bone mineral density;
LUSC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg08601574	chr20:25228251	PYGB	0.41	6.25	0.32	1.22e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg00857998	chr1:205179979	DSTYK	0.65	10.16	0.49	2.65e-21	Red blood cell count;
LUSC	cis	rs62400317	0.859	rs4443508	chr6:45235952	C/T	cg18551225	chr6:44695536	NA	-0.44	-7.28	-0.37	2.46e-12	Total body bone mineral density;
LUSC	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg23711669	chr6:146136114	FBXO30	0.82	14.65	0.63	7.15e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12541635	0.677	rs12546875	chr8:107012915	C/T	cg10147462	chr8:107024639	NA	0.68	14.28	0.62	1.94e-36	Age of smoking initiation;
LUSC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	1.07	15.55	0.65	2.08e-41	Initial pursuit acceleration;
LUSC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg21724239	chr8:58056113	NA	0.73	8.03	0.4	1.73e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs721399	0.539	rs10088333	chr8:18267878	G/A	cg18736775	chr8:18248649	NAT2	-0.58	-6.82	-0.35	4.22e-11	Blood metabolite levels;
LUSC	cis	rs698813	0.604	rs4953077	chr2:44481207	C/T	cg00619915	chr2:44497795	NA	-0.54	-7.63	-0.39	2.41e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.15	0.49	2.77e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg00225070	chr15:80189496	MTHFS	0.62	9.63	0.47	1.56e-19	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.42	-0.38	9.82e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72634258	0.945	rs12735338	chr1:8078569	T/C	cg00042356	chr1:8021962	PARK7	0.77	9.68	0.47	1.1e-19	Inflammatory bowel disease;
LUSC	trans	rs617791	0.530	rs735942	chr11:65749337	A/G	cg17712092	chr4:129076599	LARP1B	-0.72	-10.11	-0.48	3.92e-21	Breast cancer;
LUSC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg01879757	chr17:41196368	BRCA1	-0.39	-5.84	-0.3	1.22e-8	Menopause (age at onset);
LUSC	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg04733989	chr22:42467013	NAGA	0.39	6.5	0.33	3e-10	Cognitive function;
LUSC	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg22532475	chr10:104410764	TRIM8	-0.31	-6.96	-0.36	1.81e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg18129178	chr5:148520854	ABLIM3	-0.75	-11.22	-0.52	5.15e-25	Breast cancer;
LUSC	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg18681998	chr4:17616180	MED28	-0.88	-15.35	-0.64	1.25e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg21535247	chr6:8435926	SLC35B3	0.6	9.14	0.45	6.03e-18	Motion sickness;
LUSC	cis	rs4654899	1.000	rs6700718	chr1:21299363	A/C	cg01072550	chr1:21505969	NA	0.51	7.8	0.39	7.73e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.73	12.78	0.57	9.89e-31	Colorectal cancer;
LUSC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	9.06	0.44	1.16e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg23241863	chr10:102295624	HIF1AN	0.48	5.72	0.3	2.38e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-0.66	-9.29	-0.45	2.06e-18	Platelet distribution width;
LUSC	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg22852734	chr6:133119734	C6orf192	1.07	9.14	0.45	6.38e-18	Type 2 diabetes nephropathy;
LUSC	trans	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.14	-0.36	5.95e-12	Neuroticism;
LUSC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg19077165	chr18:44547161	KATNAL2	0.45	6.67	0.34	1.04e-10	Personality dimensions;
LUSC	cis	rs6062509	0.929	rs55791529	chr20:62363858	C/T	cg01176363	chr20:62369445	LIME1	-0.46	-6.96	-0.36	1.84e-11	Prostate cancer;
LUSC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.19	-0.32	1.8e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg23262073	chr20:60523788	NA	-0.4	-5.93	-0.31	7.71e-9	Body mass index;
LUSC	trans	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg06636001	chr8:8085503	FLJ10661	0.5	7.31	0.37	2.03e-12	Triglycerides;
LUSC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.22e-30	Aortic root size;
LUSC	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21775007	chr8:11205619	TDH	0.71	11.41	0.53	1.14e-25	Retinal vascular caliber;
LUSC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs926938	0.618	rs360587	chr1:115467553	A/G	cg12756093	chr1:115239321	AMPD1	0.48	7.38	0.37	1.27e-12	Autism;
LUSC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.64	0.54	1.62e-26	Prudent dietary pattern;
LUSC	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg02176678	chr2:219576539	TTLL4	0.61	11.04	0.52	2.37e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-5.84	-0.3	1.22e-8	Fear of minor pain;
LUSC	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg23933602	chr10:16859644	RSU1	0.58	6.81	0.35	4.63e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs12956009	0.518	rs4458096	chr18:44819555	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-6.67	-0.34	1.05e-10	Educational attainment (years of education);
LUSC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	6.35	0.33	7.02e-10	Personality dimensions;
LUSC	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg22907277	chr7:1156413	C7orf50	0.69	7.34	0.37	1.59e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.64	0.34	1.3e-10	IgG glycosylation;
LUSC	cis	rs500891	0.533	rs9444075	chr6:84171930	A/G	cg08257003	chr6:84140564	ME1	0.36	8.65	0.43	2.27e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs12900413	0.687	rs34484228	chr15:90304067	A/G	cg24249390	chr15:90295951	MESP1	-0.36	-5.69	-0.3	2.82e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	1.02	17.62	0.69	1.3e-49	Coronary artery disease;
LUSC	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg14036092	chr11:66035641	RAB1B	0.45	6.51	0.34	2.75e-10	Gout;
LUSC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg17948913	chr5:572064	NA	0.38	6.44	0.33	4.26e-10	Obesity-related traits;
LUSC	cis	rs17401966	0.540	rs4846216	chr1:10447792	A/T	cg17425144	chr1:10567563	PEX14	0.36	6.38	0.33	5.84e-10	Hepatocellular carcinoma;
LUSC	cis	rs7123876	0.587	rs55765314	chr11:72360935	C/A	cg03713592	chr11:72463424	ARAP1	0.69	7.18	0.37	4.5e-12	Body mass index;
LUSC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg27398817	chr8:82754497	SNX16	-0.47	-6.36	-0.33	6.61e-10	Diastolic blood pressure;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02466933	chr2:9770529	YWHAQ	-0.49	-6.47	-0.33	3.51e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6906287	0.647	rs4027880	chr6:118734134	A/T	cg21191810	chr6:118973309	C6orf204	0.34	6.15	0.32	2.19e-9	Electrocardiographic conduction measures;
LUSC	cis	rs12940923	0.810	rs16942910	chr17:56363513	C/T	cg19466818	chr17:56409534	MIR142	-0.38	-6.89	-0.35	2.81e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs193541	0.632	rs34486978	chr5:122312543	G/A	cg19077854	chr5:122220652	SNX24	-0.4	-8.54	-0.42	4.78e-16	Glucose homeostasis traits;
LUSC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg02487422	chr3:49467188	NICN1	0.45	7.13	0.36	6.24e-12	Resting heart rate;
LUSC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg03146154	chr1:46216737	IPP	-0.52	-7.39	-0.37	1.21e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs727505	1.000	rs10230610	chr7:124425398	A/C	cg23710748	chr7:124431027	NA	-0.44	-7.92	-0.4	3.66e-14	Lewy body disease;
LUSC	cis	rs6693567	0.565	rs10157197	chr1:150250636	G/A	cg15654264	chr1:150340011	RPRD2	-0.44	-6.79	-0.35	5.13e-11	Migraine;
LUSC	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.2e-13	Corneal astigmatism;
LUSC	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg00898013	chr13:113819073	PROZ	-0.57	-8.06	-0.4	1.38e-14	Platelet distribution width;
LUSC	cis	rs57590327	0.503	rs6776737	chr3:81513729	T/C	cg07356753	chr3:81810745	GBE1	0.46	6.1	0.32	3.01e-9	Extraversion;
LUSC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	11.49	0.53	5.78e-26	Colorectal cancer;
LUSC	cis	rs10992471	0.603	rs1121978	chr9:95140351	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-8.08	-0.4	1.17e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9311676	0.656	rs12496906	chr3:58390490	A/C	cg13750441	chr3:58318267	PXK	0.35	6.75	0.35	6.64e-11	Systemic lupus erythematosus;
LUSC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg21280719	chr6:42927975	GNMT	-0.32	-7.91	-0.4	3.69e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1107366	0.513	rs10934761	chr3:125973585	G/T	cg01346077	chr3:125931526	NA	0.37	6.5	0.33	3e-10	Metabolite levels;
LUSC	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.11	-0.32	2.7e-9	Neuroticism;
LUSC	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.52	-0.34	2.65e-10	Mood instability;
LUSC	cis	rs10419226	0.555	rs12976113	chr19:18767480	A/G	cg22001208	chr19:18782374	NA	-0.38	-6.36	-0.33	6.5e-10	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg22907277	chr7:1156413	C7orf50	0.64	9.98	0.48	1.05e-20	Longevity;Endometriosis;
LUSC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg06618935	chr21:46677482	NA	-0.39	-7.95	-0.4	2.83e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs68170813	0.652	rs76924513	chr7:107205887	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-8.53	-0.42	5.3e-16	Coronary artery disease;
LUSC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg27398817	chr8:82754497	SNX16	0.66	8.41	0.42	1.18e-15	Diastolic blood pressure;
LUSC	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg18721089	chr20:30220636	NA	-0.31	-5.67	-0.3	3.02e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg10596483	chr8:143751796	JRK	0.52	7.62	0.38	2.61e-13	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13520315	chr14:24740853	RABGGTA	-0.4	-6.04	-0.31	4.05e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4622329	0.595	rs7978722	chr12:102288952	G/T	cg23541617	chr12:102225335	GNPTAB	0.27	6.21	0.32	1.55e-9	Systemic lupus erythematosus;
LUSC	cis	rs244293	0.931	rs244306	chr17:53237683	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-5.93	-0.31	7.63e-9	Menarche (age at onset);
LUSC	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg09307838	chr4:120376055	NA	-0.6	-8.77	-0.43	8.98e-17	Corneal astigmatism;
LUSC	cis	rs72960926	0.744	rs72959615	chr6:74991323	C/T	cg03266952	chr6:74778945	NA	-0.8	-6.78	-0.35	5.51e-11	Metabolite levels (MHPG);
LUSC	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg19920283	chr7:105172520	RINT1	0.59	6.15	0.32	2.24e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg17764715	chr19:33622953	WDR88	0.53	7.91	0.4	3.9e-14	Colorectal cancer;
LUSC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.69	11.38	0.53	1.39e-25	Heart rate;
LUSC	cis	rs4839421	0.646	rs11102123	chr1:111016796	A/G	cg06880108	chr1:111021908	CYMP	0.35	5.83	0.3	1.32e-8	Response to bupropion in depression;
LUSC	cis	rs9650315	0.733	rs13260127	chr8:57202941	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.34	0.37	1.64e-12	Height;
LUSC	trans	rs9784649	0.760	rs17403440	chr5:25054004	C/T	cg08600765	chr20:34638493	LOC647979	-0.53	-6.78	-0.35	5.56e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	trans	rs12080794	1.000	rs12736630	chr1:9153885	A/T	cg11315153	chr6:62996299	KHDRBS2	-0.51	-6.1	-0.32	2.88e-9	Response to antidepressant treatment (citalopram);
LUSC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-5.98	-0.31	5.71e-9	Personality dimensions;
LUSC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-10.67	-0.5	4.46e-23	Gut microbiome composition (summer);
LUSC	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg13010199	chr12:38710504	ALG10B	0.67	10.23	0.49	1.56e-21	Bladder cancer;
LUSC	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg00049323	chr5:472564	LOC25845	-0.44	-6.94	-0.35	2.05e-11	Cystic fibrosis severity;
LUSC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg04455712	chr21:45112962	RRP1B	0.5	9.42	0.46	7.53e-19	Mean corpuscular volume;
LUSC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg17554472	chr22:41940697	POLR3H	-0.48	-5.87	-0.31	1.05e-8	Vitiligo;
LUSC	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.71	-12.08	-0.55	3.93e-28	White blood cell count (basophil);
LUSC	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg11887960	chr12:57824829	NA	0.57	7.01	0.36	1.3e-11	Lung disease severity in cystic fibrosis;
LUSC	trans	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-9.0	-0.44	1.77e-17	Obesity-related traits;
LUSC	cis	rs17818399	0.926	rs7590693	chr2:46823992	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-6.29	-0.33	9.92e-10	Height;
LUSC	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.45	-0.33	3.96e-10	Neuroticism;
LUSC	cis	rs6120849	0.754	rs6120819	chr20:33653038	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	6.53	0.34	2.5e-10	Protein C levels;
LUSC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.61	0.43	2.91e-16	Prudent dietary pattern;
LUSC	cis	rs10950821	0.505	rs6949755	chr7:20688042	C/G	cg02470904	chr7:20686108	ABCB5	0.34	6.39	0.33	5.65e-10	Response to statin therapy;
LUSC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.69	0.5	3.96e-23	Schizophrenia;
LUSC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-6.49	-0.33	3.07e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs8022206	1.000	rs72725138	chr14:68387979	C/T	cg15809352	chr2:121748218	GLI2	0.44	6.25	0.32	1.28e-9	Platelet count;Mean platelet volume;
LUSC	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg11189052	chr15:85197271	WDR73	0.49	5.98	0.31	5.78e-9	Schizophrenia;
LUSC	trans	rs724744	0.742	rs714589	chr6:22359969	A/G	cg13807341	chr11:118445984	ARCN1	-0.35	-5.97	-0.31	6.14e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs12410462	0.681	rs113984727	chr1:227553917	C/A	cg04117972	chr1:227635322	NA	0.58	6.44	0.33	4.21e-10	Major depressive disorder;
LUSC	cis	rs7224314	1.000	rs62084081	chr17:65387148	G/C	cg01507342	chr17:65387096	PITPNC1	-0.44	-7.81	-0.39	7.54e-14	Diisocyanate-induced asthma;
LUSC	cis	rs9309473	1.000	rs7598396	chr2:73652628	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-6.4	-0.33	5.36e-10	Metabolite levels;
LUSC	cis	rs870825	0.655	rs35764203	chr4:185639078	C/A	cg04058563	chr4:185651563	MLF1IP	0.87	13.55	0.6	1.23e-33	Blood protein levels;
LUSC	cis	rs4604732	0.536	rs12049066	chr1:247642655	C/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.38	5.67	0.3	3.07e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	1.0	14.18	0.61	4.66e-36	Orofacial clefts;
LUSC	cis	rs9865818	0.754	rs11706429	chr3:188099242	G/A	cg23651889	chr3:188115336	LPP	0.39	5.82	0.3	1.4e-8	Allergic sensitization;
LUSC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg14456004	chr13:21872349	NA	0.46	6.52	0.34	2.64e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg18477163	chr1:228402036	OBSCN	-0.55	-10.34	-0.49	6.38e-22	Diastolic blood pressure;
LUSC	cis	rs13223928	0.605	rs10951052	chr7:3155301	A/G	cg19214707	chr7:3157722	NA	-0.53	-10.38	-0.49	4.73e-22	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg23093090	chr10:104574429	C10orf26	-0.39	-7.25	-0.37	2.91e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.74	-0.35	6.87e-11	Response to antipsychotic treatment;
LUSC	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg22437258	chr11:111473054	SIK2	-0.48	-6.23	-0.32	1.41e-9	Primary sclerosing cholangitis;
LUSC	cis	rs11997175	0.624	rs6996590	chr8:33680486	A/G	ch.8.33884649F	chr8:33765107	NA	0.47	7.05	0.36	1.01e-11	Body mass index;
LUSC	cis	rs7833986	0.501	rs72653917	chr8:56892844	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	11.13	0.52	1.12e-24	Height;
LUSC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.11	-0.36	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs13082711	0.555	rs73149363	chr3:27265394	C/A	cg02860705	chr3:27208620	NA	0.66	11.31	0.53	2.6e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg12863693	chr15:85201151	NMB	0.36	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg20887711	chr4:1340912	KIAA1530	0.47	7.15	0.36	5.57e-12	Obesity-related traits;
LUSC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.56	-0.53	3.06e-26	Mean corpuscular volume;
LUSC	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg21280719	chr6:42927975	GNMT	-0.3	-7.53	-0.38	4.9e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2425143	1.000	rs2378409	chr20:34392464	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.87	-0.31	1.03e-8	Blood protein levels;
LUSC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.05e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-1.18	-13.0	-0.58	1.52e-31	Diabetic kidney disease;
LUSC	cis	rs698813	0.674	rs6544751	chr2:44495845	A/G	cg00619915	chr2:44497795	NA	-0.51	-6.95	-0.36	1.95e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg13010199	chr12:38710504	ALG10B	0.52	7.72	0.39	1.34e-13	Morning vs. evening chronotype;
LUSC	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg25214090	chr10:38739885	LOC399744	0.54	7.94	0.4	3.01e-14	Corneal astigmatism;
LUSC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-9.89	-0.48	2.17e-20	Schizophrenia;
LUSC	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg07578070	chr6:150326732	RAET1K	-0.36	-5.68	-0.3	2.86e-8	Alopecia areata;
LUSC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	10.22	0.49	1.59e-21	Mood instability;
LUSC	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	7.6	0.38	2.94e-13	Bone mineral density;
LUSC	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-8.23	-0.41	4.27e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.42	0.42	1.16e-15	Tonsillectomy;
LUSC	cis	rs17604090	0.646	rs10258473	chr7:29690439	A/C	cg19413766	chr7:29689036	LOC646762	-0.6	-7.26	-0.37	2.77e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	7.15	0.36	5.38e-12	Rheumatoid arthritis;
LUSC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg09365446	chr1:150670422	GOLPH3L	0.54	8.28	0.41	2.91e-15	Tonsillectomy;
LUSC	cis	rs9646944	0.501	rs3771161	chr2:103003961	C/A	cg20060108	chr2:102954350	IL1RL1	0.48	6.38	0.33	5.79e-10	Blood protein levels;
LUSC	cis	rs2236918	1.000	rs2797605	chr1:242025245	A/T	cg17736920	chr1:242011382	EXO1	0.44	6.94	0.36	2e-11	Menopause (age at onset);
LUSC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	28.93	0.85	5.33e-93	Chronic sinus infection;
LUSC	cis	rs2898681	0.642	rs62336790	chr4:53728000	T/C	cg00338735	chr4:53728038	RASL11B	0.41	5.71	0.3	2.49e-8	Optic nerve measurement (cup area);
LUSC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg12257692	chr3:49977190	RBM6	0.24	6.67	0.34	1.06e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg03948781	chr1:205179583	DSTYK	0.31	5.79	0.3	1.63e-8	Red blood cell count;
LUSC	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.4	0.38	1.14e-12	Motion sickness;
LUSC	trans	rs72674100	0.867	rs10017627	chr4:97983818	T/G	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	0.92	17.62	0.69	1.4e-49	Heart rate;
LUSC	cis	rs4953404	0.613	rs1531132	chr2:46892315	A/G	cg09399716	chr2:46890238	NA	-0.32	-7.25	-0.37	2.88e-12	Pulse pressure (alcohol consumption interaction);
LUSC	cis	rs62400317	0.701	rs12194924	chr6:44961513	T/C	cg18551225	chr6:44695536	NA	-0.44	-7.03	-0.36	1.19e-11	Total body bone mineral density;
LUSC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg15556689	chr8:8085844	FLJ10661	0.59	9.16	0.45	5.29e-18	Mood instability;
LUSC	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg00105475	chr2:10696890	NA	0.37	6.09	0.32	3.03e-9	Prostate cancer;
LUSC	cis	rs7727544	0.545	rs3916443	chr5:131369079	T/C	cg14196790	chr5:131705035	SLC22A5	0.41	6.49	0.33	3.17e-10	Blood metabolite levels;
LUSC	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg23950597	chr19:37808831	NA	-0.63	-7.68	-0.39	1.82e-13	Coronary artery calcification;
LUSC	trans	rs1223397	0.702	rs13191897	chr6:13288428	G/A	cg13974761	chr1:152670598	LCE2A	0.37	5.96	0.31	6.56e-9	Blood pressure;
LUSC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21028142	chr17:79581711	NPLOC4	0.32	7.79	0.39	8.41e-14	Eye color traits;
LUSC	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg04851639	chr8:1020857	NA	-0.39	-8.18	-0.41	6.06e-15	Schizophrenia;
LUSC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg09365446	chr1:150670422	GOLPH3L	0.47	7.01	0.36	1.33e-11	Melanoma;
LUSC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg21951975	chr1:209979733	IRF6	0.63	8.04	0.4	1.53e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg06623918	chr6:96969491	KIAA0776	-0.82	-10.0	-0.48	9.04e-21	Migraine;Coronary artery disease;
LUSC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.74	-11.11	-0.52	1.3e-24	Menarche (age at onset);
LUSC	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg00383909	chr3:49044727	WDR6	1.39	10.54	0.5	1.35e-22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg02493740	chr2:85810744	VAMP5	-0.36	-6.43	-0.33	4.46e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	1.04	19.81	0.74	2.6e-58	Menopause (age at onset);
LUSC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg11752832	chr7:134001865	SLC35B4	0.6	9.32	0.45	1.62e-18	Mean platelet volume;
LUSC	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-6.91	-0.35	2.41e-11	Coronary artery disease;
LUSC	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg09307838	chr4:120376055	NA	0.75	10.89	0.51	7.5e-24	Corneal astigmatism;
LUSC	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg08773314	chr2:239334832	ASB1	0.39	8.34	0.42	2.02e-15	Multiple system atrophy;
LUSC	cis	rs12220238	1.000	rs11000897	chr10:75911276	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.89	0.35	2.82e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.71	-12.48	-0.56	1.29e-29	Pulse pressure;
LUSC	cis	rs2898681	0.580	rs41279517	chr4:53729771	T/C	cg00791764	chr4:53727839	RASL11B	0.57	7.24	0.37	3.1e-12	Optic nerve measurement (cup area);
LUSC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg06808227	chr14:105710500	BRF1	-0.65	-10.01	-0.48	8.32e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg06454157	chr6:167490870	NA	-0.29	-6.61	-0.34	1.5e-10	Crohn's disease;
LUSC	cis	rs4499344	0.921	rs4805776	chr19:33087759	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.61	-7.83	-0.39	6.39e-14	Mean platelet volume;
LUSC	cis	rs7246967	0.611	rs1835993	chr19:22833037	T/C	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs3857536	0.813	rs9360189	chr6:66933424	A/C	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.56e-10	Blood trace element (Cu levels);
LUSC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.79	0.7	2.73e-50	Chronic sinus infection;
LUSC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg23985595	chr17:80112537	CCDC57	-0.3	-5.75	-0.3	2.05e-8	Life satisfaction;
LUSC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.45	-0.46	5.92e-19	Type 2 diabetes;
LUSC	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg24556660	chr7:106842632	COG5;HBP1	-0.44	-5.71	-0.3	2.54e-8	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg18187862	chr3:45730750	SACM1L	-0.53	-6.51	-0.34	2.69e-10	Primary sclerosing cholangitis;
LUSC	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.36e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs77972916	0.611	rs6709988	chr2:43601317	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.44	-5.75	-0.3	2.02e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-1.11	-17.44	-0.69	6.67e-49	Exhaled nitric oxide output;
LUSC	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	0.8	11.38	0.53	1.41e-25	Response to hepatitis C treatment;
LUSC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	11.01	0.52	3.04e-24	Cognitive test performance;
LUSC	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg03709012	chr19:19516395	GATAD2A	0.92	10.27	0.49	1.13e-21	Nonalcoholic fatty liver disease;
LUSC	cis	rs10489525	0.583	rs6660550	chr1:115650850	C/G	cg01522456	chr1:115632236	TSPAN2	0.68	10.06	0.48	5.9e-21	Autism;
LUSC	cis	rs11264213	0.901	rs74879824	chr1:36413117	T/A	cg27506609	chr1:36549197	TEKT2	0.7	7.98	0.4	2.39e-14	Schizophrenia;
LUSC	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg12560992	chr17:57184187	TRIM37	0.45	6.98	0.36	1.61e-11	Cognitive function;
LUSC	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.4	5.99	0.31	5.32e-9	Height;
LUSC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	cis	rs3761218	1.000	rs3761218	chr20:3776175	A/G	cg02737268	chr20:3780182	CDC25B	-0.32	-6.31	-0.33	8.91e-10	Bipolar disorder;
LUSC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-6.51	-0.34	2.84e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg26384229	chr12:38710491	ALG10B	0.67	10.61	0.5	7.65e-23	Morning vs. evening chronotype;
LUSC	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg16235748	chr6:149772707	ZC3H12D	-0.32	-6.47	-0.33	3.42e-10	Dupuytren's disease;
LUSC	cis	rs909002	0.800	rs3134718	chr1:32089839	C/T	cg01639898	chr1:32083012	HCRTR1	0.31	7.59	0.38	3.32e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4862307	0.720	rs12650935	chr4:184989565	G/A	cg06737308	chr4:185021514	ENPP6	0.47	6.98	0.36	1.6e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUSC	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg01256987	chr12:42539512	GXYLT1	0.36	6.49	0.33	3.14e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6554196	0.644	rs7655709	chr4:55499386	C/G	cg18836493	chr4:55524333	KIT	-0.34	-5.67	-0.3	3.06e-8	Monocyte count;
LUSC	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg09835421	chr16:68378352	PRMT7	-0.56	-6.56	-0.34	2.05e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg00800038	chr16:89945340	TCF25	-0.75	-6.64	-0.34	1.26e-10	Skin colour saturation;
LUSC	cis	rs10492096	1.000	rs11064210	chr12:6576721	C/T	cg13857086	chr12:6580257	VAMP1	0.72	8.23	0.41	4.15e-15	Hip geometry;
LUSC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-10.27	-0.49	1.06e-21	Mood instability;
LUSC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg04455712	chr21:45112962	RRP1B	0.45	8.37	0.42	1.62e-15	Mean corpuscular volume;
LUSC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21963583	chr11:68658836	MRPL21	0.51	7.8	0.39	8.13e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.65	-0.3	3.5e-8	Coronary artery disease;
LUSC	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg21535247	chr6:8435926	SLC35B3	-0.47	-7.01	-0.36	1.29e-11	Motion sickness;
LUSC	cis	rs7903847	0.620	rs61863813	chr10:99112786	T/C	cg08345082	chr10:99160200	RRP12	-0.36	-7.01	-0.36	1.35e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg05872129	chr22:39784769	NA	0.51	8.44	0.42	9.44e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-7.51	-0.38	5.39e-13	Fear of minor pain;
LUSC	cis	rs6714710	0.603	rs1875699	chr2:98580724	G/T	cg26665480	chr2:98280029	ACTR1B	0.58	8.43	0.42	1.04e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg00334542	chr7:100209784	MOSPD3	-0.67	-7.51	-0.38	5.61e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs354225	0.544	rs7599241	chr2:54801856	G/A	cg01766943	chr2:54829624	SPTBN1	0.47	7.56	0.38	3.95e-13	Schizophrenia;
LUSC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg03146154	chr1:46216737	IPP	0.56	8.32	0.41	2.35e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs41271473	1.000	rs1062060	chr1:228880021	A/G	cg10167378	chr1:228756711	NA	-0.49	-5.9	-0.31	9.06e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.23e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11168618	0.776	rs7955785	chr12:48862538	T/A	cg24011408	chr12:48396354	COL2A1	0.38	5.94	0.31	7.32e-9	Adiponectin levels;
LUSC	cis	rs1997103	0.954	rs2177807	chr7:55391002	G/T	cg17469321	chr7:55412551	NA	-0.64	-11.03	-0.52	2.52e-24	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg10167378	chr1:228756711	NA	0.76	9.78	0.47	5.16e-20	Chronic lymphocytic leukemia;
LUSC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.62	9.62	0.47	1.75e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg16989719	chr2:238392110	NA	-0.47	-7.56	-0.38	4.01e-13	Prostate cancer;
LUSC	cis	rs30380	0.632	rs26491	chr5:96134113	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-7.56	-0.38	3.94e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg20887711	chr4:1340912	KIAA1530	-0.45	-7.1	-0.36	7.58e-12	Obesity-related traits;
LUSC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg11645453	chr3:52864694	ITIH4	0.35	8.0	0.4	2.1e-14	Bipolar disorder;
LUSC	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg15556689	chr8:8085844	FLJ10661	0.58	9.09	0.45	8.82e-18	Neuroticism;
LUSC	cis	rs1712517	0.873	rs1712516	chr10:105033628	G/A	cg05636881	chr10:105038444	INA	0.4	6.67	0.34	1.06e-10	Migraine;
LUSC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-9.37	-0.46	1.15e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs722599	0.599	rs3825708	chr14:75200697	C/T	cg08847533	chr14:75593920	NEK9	0.42	6.06	0.31	3.61e-9	IgG glycosylation;
LUSC	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg13010199	chr12:38710504	ALG10B	0.66	10.18	0.49	2.16e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	8.29	0.41	2.85e-15	Response to antipsychotic treatment;
LUSC	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18252515	chr7:66147081	NA	-0.39	-6.0	-0.31	5e-9	Corneal structure;
LUSC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg26513180	chr16:89883248	FANCA	-0.54	-8.06	-0.4	1.39e-14	Vitiligo;
LUSC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-6.9	-0.35	2.59e-11	Alzheimer's disease (late onset);
LUSC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02018176	chr4:1364513	KIAA1530	-0.73	-13.42	-0.59	3.88e-33	Longevity;
LUSC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.58	-9.6	-0.47	1.92e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.78	-0.35	5.54e-11	Monocyte percentage of white cells;
LUSC	cis	rs9311676	0.632	rs62258139	chr3:58406836	C/T	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.1e-10	Systemic lupus erythematosus;
LUSC	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.04	0.31	4.19e-9	Schizophrenia;
LUSC	cis	rs59104589	0.617	rs3771550	chr2:242302811	A/G	cg14842376	chr2:242211374	HDLBP	0.53	5.99	0.31	5.3e-9	Fibrinogen levels;
LUSC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg17264618	chr3:40429014	ENTPD3	0.35	7.08	0.36	8.58e-12	Renal cell carcinoma;
LUSC	trans	rs10221833	0.530	rs355888	chr2:165634551	A/G	cg26993132	chr16:89239499	CDH15	0.31	5.99	0.31	5.47e-9	Response to statin therapy;
LUSC	trans	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg13010199	chr12:38710504	ALG10B	0.41	6.37	0.33	6.44e-10	Morning vs. evening chronotype;
LUSC	cis	rs1882538	0.564	rs12707090	chr7:133115163	G/A	cg10665199	chr7:133106180	EXOC4	0.57	8.04	0.4	1.57e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6961069	0.713	rs3211821	chr7:80278563	A/G	cg04458919	chr7:80252533	CD36	0.34	6.16	0.32	2.09e-9	Platelet count;
LUSC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.87	-0.48	2.48e-20	Hemoglobin concentration;
LUSC	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg12573674	chr2:1569213	NA	-0.52	-5.67	-0.3	3.07e-8	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs722599	0.748	rs61978932	chr14:75342954	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.41	-6.07	-0.32	3.46e-9	IgG glycosylation;
LUSC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg00409905	chr10:38381863	ZNF37A	0.4	6.89	0.35	2.84e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg16049864	chr8:95962084	TP53INP1	-0.42	-7.14	-0.36	5.8e-12	Type 2 diabetes;
LUSC	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg06258179	chr7:92463261	CDK6	0.39	5.99	0.31	5.31e-9	Bladder cancer;
LUSC	cis	rs6012953	0.560	rs4811079	chr20:49157052	G/C	cg13958625	chr20:49123093	NA	-0.27	-5.69	-0.3	2.82e-8	Vitiligo;
LUSC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	0.8	14.09	0.61	1.04e-35	Cognitive function;
LUSC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg10802521	chr3:52805072	NEK4	-0.42	-6.57	-0.34	1.9e-10	Electroencephalogram traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05662500	chr3:32147877	GPD1L	0.39	6.09	0.32	3.17e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg12744634	chr1:26560303	CCDC21	-0.39	-5.78	-0.3	1.74e-8	Obesity-related traits;
LUSC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg22166914	chr1:53195759	ZYG11B	-0.62	-10.21	-0.49	1.73e-21	Monocyte count;
LUSC	trans	rs890100	0.803	rs4672120	chr2:56722404	A/G	cg08299783	chr2:48920986	GTF2A1L;LHCGR	-0.31	-5.99	-0.31	5.38e-9	Gut microbiome composition (summer);
LUSC	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg13010199	chr12:38710504	ALG10B	-0.58	-9.17	-0.45	4.95e-18	Bladder cancer;
LUSC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg01879757	chr17:41196368	BRCA1	0.51	8.36	0.42	1.69e-15	Menopause (age at onset);
LUSC	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	18.86	0.72	1.61e-54	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg18477163	chr1:228402036	OBSCN	0.54	9.12	0.45	7.43e-18	Diastolic blood pressure;
LUSC	cis	rs2224391	0.628	rs2773316	chr6:5254448	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.48	-6.39	-0.33	5.73e-10	Height;
LUSC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.5	0.34	2.94e-10	Lung cancer;
LUSC	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg17757837	chr7:157058334	UBE3C	0.83	13.32	0.59	9.03e-33	Body mass index;
LUSC	cis	rs4499344	0.693	rs382416	chr19:33107938	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.81	-11.64	-0.54	1.66e-26	Mean platelet volume;
LUSC	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg15395560	chr15:45543142	SLC28A2	0.33	5.66	0.3	3.25e-8	Uric acid levels;
LUSC	cis	rs7202877	0.706	rs40217	chr16:75480066	C/A	cg04384234	chr16:75411784	CFDP1	0.67	8.85	0.44	5.04e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-5.77	-0.3	1.79e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.31	0.64	1.87e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg21775007	chr8:11205619	TDH	0.45	6.26	0.32	1.16e-9	Morning vs. evening chronotype;
LUSC	cis	rs6987853	0.787	rs2974354	chr8:42413943	A/G	cg09913449	chr8:42400586	C8orf40	0.5	8.49	0.42	7.07e-16	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7215564	0.908	rs7501674	chr17:78662177	C/T	cg09596252	chr17:78655493	RPTOR	0.56	6.15	0.32	2.27e-9	Myopia (pathological);
LUSC	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.38	0.53	1.44e-25	Coffee consumption (cups per day);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13696300	chr17:18162128	FLII	-0.45	-6.79	-0.35	5.14e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg02187348	chr16:89574699	SPG7	-0.47	-7.07	-0.36	9.27e-12	Multiple myeloma (IgH translocation);
LUSC	trans	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg24644049	chr4:85504048	CDS1	0.86	7.56	0.38	3.83e-13	Skin colour saturation;
LUSC	trans	rs62055045	0.528	rs62056195	chr16:71549485	A/G	cg09088153	chr15:96890598	NA	-0.48	-6.56	-0.34	2.06e-10	Schizophrenia;
LUSC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	6.88	0.35	2.89e-11	Menarche (age at onset);
LUSC	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22857025	chr5:266934	NA	-1.14	-15.9	-0.66	8.73e-43	Breast cancer;
LUSC	cis	rs427941	0.703	rs201445	chr7:101737921	G/T	cg06246474	chr7:101738831	CUX1	0.41	6.71	0.34	8.45e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs2667011	0.512	rs1995950	chr2:160800628	A/G	cg06573604	chr2:160760825	LY75	0.44	6.17	0.32	1.98e-9	Bilirubin levels;
LUSC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg00033643	chr7:134001901	SLC35B4	0.45	7.05	0.36	1.02e-11	Mean platelet volume;
LUSC	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg20744362	chr22:50050164	C22orf34	0.39	7.94	0.4	3.13e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg12463550	chr7:65579703	CRCP	0.43	6.2	0.32	1.71e-9	Aortic root size;
LUSC	trans	rs7155454	0.935	rs11627531	chr14:65487796	T/C	cg18497238	chr14:75083495	NA	-0.25	-5.94	-0.31	6.97e-9	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LUSC	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg25237894	chr2:233734115	C2orf82	0.35	6.5	0.33	2.99e-10	Coronary artery disease;
LUSC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-11.76	-0.54	5.89e-27	Chronic sinus infection;
LUSC	cis	rs7215564	0.818	rs34929663	chr17:78617212	C/T	cg23238734	chr17:78661607	RPTOR	0.48	6.17	0.32	1.96e-9	Myopia (pathological);
LUSC	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-1.0	-14.23	-0.61	3.12e-36	Exhaled nitric oxide output;
LUSC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.9	0.35	2.56e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.69	-0.47	1e-19	Bipolar disorder;
LUSC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.54	-8.47	-0.42	8.04e-16	Personality dimensions;
LUSC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.44	-6.97	-0.36	1.75e-11	Bipolar disorder;
LUSC	cis	rs7589342	0.628	rs35482041	chr2:106409436	A/G	cg14210321	chr2:106509881	NCK2	-0.45	-5.73	-0.3	2.23e-8	Addiction;
LUSC	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg00105475	chr2:10696890	NA	0.37	6.28	0.33	1.04e-9	Prostate cancer;
LUSC	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg01256987	chr12:42539512	GXYLT1	-0.41	-7.56	-0.38	3.98e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg07148914	chr20:33460835	GGT7	0.55	8.4	0.42	1.33e-15	Height;
LUSC	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg19628046	chr18:33552617	C18orf21	0.51	6.13	0.32	2.47e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg10018233	chr7:150070692	REPIN1	0.38	6.62	0.34	1.42e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.6	0.69	1.6e-49	Chronic sinus infection;
LUSC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg17420585	chr12:42539391	GXYLT1	-0.3	-5.75	-0.3	2.03e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg06454157	chr6:167490870	NA	-0.29	-6.89	-0.35	2.84e-11	Crohn's disease;
LUSC	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-9.62	-0.47	1.75e-19	Schizophrenia;
LUSC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.65	-11.16	-0.52	8.81e-25	Lung cancer;
LUSC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg18230493	chr5:56204884	C5orf35	-0.88	-13.23	-0.59	2.03e-32	Initial pursuit acceleration;
LUSC	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg25258033	chr6:167368657	RNASET2	-0.36	-5.79	-0.3	1.63e-8	Crohn's disease;
LUSC	cis	rs354225	0.513	rs10187338	chr2:54806611	A/G	cg01766943	chr2:54829624	SPTBN1	0.49	7.94	0.4	3.16e-14	Schizophrenia;
LUSC	cis	rs11229555	0.874	rs11605269	chr11:58350872	A/G	cg15696309	chr11:58395628	NA	-0.71	-9.19	-0.45	4.43e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10911363	0.592	rs2702178	chr1:183452545	G/A	cg09173681	chr1:183549694	NCF2	0.66	12.24	0.56	1.08e-28	Systemic lupus erythematosus;
LUSC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg20203395	chr5:56204925	C5orf35	0.44	6.51	0.34	2.74e-10	Coronary artery disease;
LUSC	cis	rs2303282	0.664	rs2440474	chr16:56432435	G/T	cg00500540	chr16:56394104	NA	-0.43	-7.32	-0.37	1.88e-12	Breast cancer;
LUSC	cis	rs4853525	0.818	rs4853520	chr2:191719498	A/G	cg11845111	chr2:191398756	TMEM194B	-0.42	-6.18	-0.32	1.91e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs1950626	0.833	rs34463495	chr14:101411186	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.46	0.38	7.73e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg04450456	chr4:17643702	FAM184B	0.41	6.96	0.36	1.78e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7772697	0.508	rs6570924	chr6:149365050	C/T	cg22609380	chr12:98849379	NA	0.36	6.58	0.34	1.78e-10	Diabetic retinopathy;
LUSC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.8	15.16	0.64	7.39e-40	Dental caries;
LUSC	cis	rs4746818	1.000	rs10823301	chr10:70885875	G/A	cg11621586	chr10:70884670	VPS26A	1.15	14.56	0.62	1.52e-37	Left atrial antero-posterior diameter;
LUSC	cis	rs6942756	1.000	rs2012919	chr7:128890812	C/T	cg02491457	chr7:128862824	NA	-0.52	-7.43	-0.38	9.06e-13	White matter hyperintensity burden;
LUSC	cis	rs1005224	0.889	rs12717566	chr14:76147507	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.66	-8.86	-0.44	4.89e-17	Large artery stroke;
LUSC	cis	rs7707921	0.705	rs226194	chr5:81585026	G/T	cg15871215	chr5:81402204	ATG10	0.45	7.08	0.36	8.34e-12	Breast cancer;
LUSC	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg19077165	chr18:44547161	KATNAL2	0.4	5.76	0.3	1.95e-8	Educational attainment;
LUSC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg23205692	chr1:25664452	TMEM50A	0.39	5.74	0.3	2.08e-8	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs7512552	0.803	rs9436125	chr1:150487961	C/G	cg15654264	chr1:150340011	RPRD2	0.61	9.84	0.47	3.16e-20	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13732083	chr21:47605072	C21orf56	0.42	6.28	0.32	1.07e-9	Testicular germ cell tumor;
LUSC	cis	rs7605827	0.897	rs6745917	chr2:15537924	G/C	cg19274914	chr2:15703543	NA	0.46	8.95	0.44	2.44e-17	Educational attainment (years of education);
LUSC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14829155	chr15:31115871	NA	-0.58	-8.1	-0.41	1.03e-14	Huntington's disease progression;
LUSC	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg05714579	chr10:131428358	MGMT	0.5	7.43	0.38	9.36e-13	Response to temozolomide;
LUSC	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.6	11.06	0.52	1.95e-24	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10489525	0.599	rs2335724	chr1:115608444	T/C	cg01522456	chr1:115632236	TSPAN2	0.49	6.98	0.36	1.56e-11	Autism;
LUSC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg12365402	chr11:9010492	NRIP3	0.44	8.11	0.41	9.62e-15	Hemoglobin concentration;
LUSC	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg13647721	chr17:30228624	UTP6	-0.69	-7.5	-0.38	5.71e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs73416724	1.000	rs76823934	chr6:43359424	G/A	cg26312998	chr6:43337775	ZNF318	0.56	6.67	0.34	1.04e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg22549504	chr19:17448937	GTPBP3	0.54	6.74	0.35	6.84e-11	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg05868516	chr6:26286170	HIST1H4H	0.35	5.78	0.3	1.69e-8	Educational attainment;
LUSC	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg02569458	chr12:86230093	RASSF9	0.42	6.79	0.35	5.11e-11	Major depressive disorder;
LUSC	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg24579218	chr15:68104479	NA	-0.35	-5.82	-0.3	1.38e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg09877947	chr5:131593287	PDLIM4	0.44	7.35	0.37	1.58e-12	Breast cancer;
LUSC	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	1.05	19.04	0.72	3.07e-55	Menopause (age at onset);
LUSC	cis	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.07	-0.32	3.47e-9	Neuroticism;
LUSC	cis	rs6977660	1.000	rs12672557	chr7:19804237	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	6.28	0.33	1.05e-9	Thyroid stimulating hormone;
LUSC	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg08213375	chr14:104286397	PPP1R13B	0.39	6.33	0.33	7.82e-10	Reticulocyte count;
LUSC	cis	rs911119	0.866	rs6048925	chr20:23579056	C/A	cg16589663	chr20:23618590	CST3	0.6	7.17	0.37	4.97e-12	Chronic kidney disease;
LUSC	cis	rs983392	0.649	rs7936120	chr11:60000574	T/A	cg02771260	chr11:59836817	MS4A3	-0.36	-5.97	-0.31	6.15e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1044826	0.619	rs57357132	chr3:139118358	A/T	cg15131784	chr3:139108705	COPB2	-0.42	-6.95	-0.36	1.89e-11	Obesity-related traits;
LUSC	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg25838465	chr1:92012736	NA	-0.45	-6.3	-0.33	9.58e-10	Eosinophil percentage of white cells;
LUSC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg27068330	chr11:65405492	SIPA1	-0.76	-10.93	-0.51	5.64e-24	Acne (severe);
LUSC	cis	rs10740039	0.842	rs2119913	chr10:62395389	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg04240660	chr16:89714849	CHMP1A	-0.45	-7.13	-0.36	6.17e-12	Hemoglobin concentration;
LUSC	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg17143192	chr8:8559678	CLDN23	0.62	9.13	0.45	6.45e-18	Obesity-related traits;
LUSC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg20908204	chr19:46285434	DMPK	0.41	8.24	0.41	4.04e-15	Coronary artery disease;
LUSC	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.19	0.52	6.75e-25	Coffee consumption (cups per day);
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg18530950	chr2:128284093	IWS1	-0.47	-5.94	-0.31	7.02e-9	Height;
LUSC	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg14092571	chr14:90743983	NA	-0.89	-18.83	-0.72	2.03e-54	Gut microbiota (bacterial taxa);
LUSC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-17.17	-0.68	8.19e-48	Body mass index;
LUSC	cis	rs12210905	0.610	rs12216370	chr6:26878930	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.64	-5.66	-0.3	3.25e-8	Hip circumference adjusted for BMI;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg20386705	chr6:38607295	BTBD9	0.42	5.96	0.31	6.3e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6998277	0.830	rs6981007	chr8:103598257	G/C	cg10187029	chr8:103597600	NA	0.77	11.83	0.54	3.41e-27	Migraine;
LUSC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg25036284	chr2:26402008	FAM59B	-0.74	-10.56	-0.5	1.13e-22	Gut microbiome composition (summer);
LUSC	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-7.99	-0.4	2.23e-14	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg02153584	chr22:29168773	CCDC117	0.5	7.75	0.39	1.08e-13	Red cell distribution width;
LUSC	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00321850	chr1:175162397	KIAA0040	-0.46	-7.88	-0.4	4.74e-14	Alcohol dependence;
LUSC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.78	-0.57	1.02e-30	Platelet count;
LUSC	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-10.88	-0.51	8.15e-24	Response to antipsychotic treatment;
LUSC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11644478	chr21:40555479	PSMG1	-0.61	-9.53	-0.46	3.45e-19	Menarche (age at onset);
LUSC	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg01765077	chr12:122356316	WDR66	0.5	7.12	0.36	6.81e-12	Mean corpuscular volume;
LUSC	cis	rs2795502	0.564	rs11239844	chr10:43453365	G/A	cg08461752	chr10:43522343	NA	-0.53	-6.52	-0.34	2.63e-10	Blood protein levels;
LUSC	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-10.52	-0.5	1.46e-22	Morning vs. evening chronotype;
LUSC	cis	rs4474465	1.000	rs7950813	chr11:78215082	A/T	cg27205649	chr11:78285834	NARS2	0.53	6.07	0.32	3.38e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg09626299	chr10:82213104	TSPAN14	-0.2	-6.01	-0.31	4.78e-9	Post bronchodilator FEV1;
LUSC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-0.82	-14.59	-0.62	1.25e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg05457628	chr5:178986728	RUFY1	0.56	9.58	0.46	2.29e-19	Lung cancer;
LUSC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-5.73	-0.3	2.29e-8	Vitiligo;
LUSC	cis	rs56399783	0.901	rs56007918	chr7:2826205	A/G	cg14895029	chr7:2775587	GNA12	0.51	6.31	0.33	9.01e-10	Childhood ear infection;
LUSC	cis	rs2219968	0.692	rs9657044	chr8:78942084	A/G	cg00738934	chr8:78996279	NA	-0.4	-7.22	-0.37	3.56e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4343996	0.754	rs7789887	chr7:3350051	C/G	cg21248987	chr7:3385318	SDK1	0.37	6.27	0.32	1.14e-9	Motion sickness;
LUSC	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg03676636	chr4:99064102	C4orf37	0.35	7.79	0.39	8.28e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13082711	0.863	rs34611823	chr3:27500344	A/G	cg02860705	chr3:27208620	NA	0.49	8.41	0.42	1.18e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	trans	rs1552272	1.000	rs1552272	chr16:85452695	A/G	cg08438366	chr20:37230612	C20orf95	0.28	6.0	0.31	5.13e-9	Platelet distribution width;
LUSC	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	8.89	0.44	3.84e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs4730250	0.707	rs6977868	chr7:106790555	T/G	cg02696742	chr7:106810147	HBP1	0.65	9.18	0.45	4.72e-18	Osteoarthritis;
LUSC	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	5.7	0.3	2.68e-8	Educational attainment;
LUSC	trans	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg19894588	chr14:64061835	NA	-0.52	-6.7	-0.34	9.13e-11	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs7089973	0.523	rs7093330	chr10:116744574	T/A	cg23260525	chr10:116636907	FAM160B1	0.3	5.79	0.3	1.61e-8	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg07701084	chr6:150067640	NUP43	0.57	8.87	0.44	4.55e-17	Lung cancer;
LUSC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.3	-0.37	2.16e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg10356904	chr22:49881777	NA	-0.29	-5.78	-0.3	1.75e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6942756	1.000	rs6467235	chr7:128939150	A/G	cg02491457	chr7:128862824	NA	0.46	5.92	0.31	7.84e-9	White matter hyperintensity burden;
LUSC	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg22676075	chr6:135203613	NA	0.59	9.48	0.46	5e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs16854884	0.837	rs6767236	chr3:143758399	A/C	cg06585982	chr3:143692056	C3orf58	0.47	6.95	0.36	1.96e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg10360139	chr7:1886902	MAD1L1	-0.38	-5.68	-0.3	2.87e-8	Bipolar disorder and schizophrenia;
LUSC	trans	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	8.87	0.44	4.63e-17	Exhaled nitric oxide output;
LUSC	cis	rs977987	0.800	rs1011121	chr16:75325933	A/G	cg04384234	chr16:75411784	CFDP1	-0.38	-6.04	-0.31	4.05e-9	Dupuytren's disease;
LUSC	cis	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg27411982	chr8:10470053	RP1L1	-0.45	-6.73	-0.35	7.5e-11	Morning vs. evening chronotype;
LUSC	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg22903657	chr4:1355424	KIAA1530	-0.38	-6.2	-0.32	1.65e-9	Longevity;
LUSC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg15790184	chr11:494944	RNH1	0.53	6.01	0.31	4.84e-9	Body mass index;
LUSC	trans	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-12.41	-0.56	2.38e-29	Platelet distribution width;
LUSC	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.98	-0.36	1.57e-11	Bipolar disorder;
LUSC	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg15704280	chr7:45808275	SEPT13	0.75	8.33	0.41	2.14e-15	Axial length;
LUSC	cis	rs10887741	0.546	rs7078618	chr10:89440911	A/G	cg13926569	chr10:89418898	PAPSS2	0.26	5.72	0.3	2.32e-8	Exercise (leisure time);
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg02551882	chr22:31365455	MORC2;TUG1	0.76	6.44	0.33	4.21e-10	Body mass index;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06446895	chr17:79829189	ARHGDIA	-0.38	-6.64	-0.34	1.26e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9837602	1.000	rs1688771	chr3:99503359	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-6.04	-0.31	4.08e-9	Breast cancer;
LUSC	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg03465714	chr1:152285911	FLG	-0.41	-5.89	-0.31	9.28e-9	Atopic dermatitis;
LUSC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	8.11	0.41	9.9e-15	Bipolar disorder;
LUSC	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg08601574	chr20:25228251	PYGB	0.52	8.18	0.41	5.81e-15	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.64	11.56	0.53	3.06e-26	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs6489882	0.703	rs10850093	chr12:113360468	C/T	cg20102336	chr12:113376681	OAS3	-0.4	-5.71	-0.3	2.46e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg05585544	chr11:47624801	NA	-0.41	-7.23	-0.37	3.22e-12	Subjective well-being;
LUSC	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg00105475	chr2:10696890	NA	0.36	5.95	0.31	6.6e-9	Prostate cancer;
LUSC	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.07	-0.68	2.08e-47	Exhaled nitric oxide output;
LUSC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg01475377	chr6:109611718	NA	-0.47	-8.65	-0.43	2.25e-16	Reticulocyte fraction of red cells;
LUSC	cis	rs977987	0.750	rs4888407	chr16:75432390	T/C	cg03315344	chr16:75512273	CHST6	0.52	10.09	0.48	4.42e-21	Dupuytren's disease;
LUSC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	12.88	0.58	4.13e-31	Platelet count;
LUSC	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.92	0.51	6.12e-24	Hypertriglyceridemia;
LUSC	cis	rs10193935	0.901	rs7594010	chr2:42534896	C/T	cg27598129	chr2:42591480	NA	-0.6	-8.2	-0.41	5.18e-15	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg25214090	chr10:38739885	LOC399744	0.41	6.12	0.32	2.67e-9	Corneal astigmatism;
LUSC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg20243544	chr17:37824526	PNMT	-0.38	-5.78	-0.3	1.72e-8	Self-reported allergy;
LUSC	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-10.82	-0.51	1.33e-23	Response to antipsychotic treatment;
LUSC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.23	-0.41	4.3e-15	Bipolar disorder;
LUSC	trans	rs970548	0.688	rs10900228	chr10:46082128	A/G	cg20477318	chr10:51623047	TIMM23	0.58	5.96	0.31	6.38e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs7577696	0.626	rs3769603	chr2:32360887	G/T	cg02381751	chr2:32503542	YIPF4	-0.45	-6.27	-0.32	1.12e-9	Inflammatory biomarkers;
LUSC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg10560079	chr2:191398806	TMEM194B	-0.51	-6.63	-0.34	1.39e-10	Diastolic blood pressure;
LUSC	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-6.89	-0.35	2.73e-11	Arsenic metabolism;
LUSC	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg06207120	chr15:45996521	NA	0.39	6.09	0.32	3.08e-9	Waist circumference;Weight;
LUSC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-1.04	-15.68	-0.65	6.73e-42	Initial pursuit acceleration;
LUSC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg05425664	chr17:57184151	TRIM37	0.58	8.01	0.4	1.96e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23329156	chr3:190231815	IL1RAP	-0.45	-6.55	-0.34	2.15e-10	Electrocardiographic conduction measures;
LUSC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg03396347	chr1:1875803	NA	-0.53	-11.79	-0.54	4.59e-27	Body mass index;
LUSC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.64	10.99	0.52	3.39e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7605827	0.930	rs2287276	chr2:15660254	A/G	cg19274914	chr2:15703543	NA	0.46	8.83	0.43	6.22e-17	Educational attainment (years of education);
LUSC	cis	rs6901250	0.851	rs607372	chr6:117155929	A/G	cg12892004	chr6:117198278	RFX6	-0.44	-8.21	-0.41	4.87e-15	C-reactive protein levels;
LUSC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.09	14.43	0.62	5.1e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg24247370	chr13:99142703	STK24	-0.34	-6.17	-0.32	2e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg26566898	chr11:117069891	TAGLN	-0.35	-6.67	-0.34	1.04e-10	Blood protein levels;
LUSC	cis	rs13161895	1.000	rs4129403	chr5:179476610	A/G	cg02702477	chr5:179499311	RNF130	0.5	5.7	0.3	2.67e-8	LDL cholesterol;
LUSC	cis	rs4409675	0.576	rs2295367	chr1:28224312	C/T	cg23691781	chr1:28212827	C1orf38	0.3	7.25	0.37	2.98e-12	Corneal astigmatism;
LUSC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg25019033	chr10:957182	NA	-0.51	-6.36	-0.33	6.56e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs7586879	0.828	rs11685125	chr2:25092104	A/G	cg01884057	chr2:25150051	NA	0.4	8.18	0.41	5.98e-15	Body mass index;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02410524	chr20:36156167	BLCAP	0.72	6.33	0.33	7.87e-10	Cognitive performance;
LUSC	trans	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg02030672	chr11:45687055	CHST1	0.43	6.44	0.33	4.05e-10	Obesity-related traits;
LUSC	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg21427119	chr20:30132790	HM13	-0.38	-5.91	-0.31	8.67e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs10097669	0.642	rs2725069	chr8:4439602	T/G	cg16451306	chr5:71475356	MAP1B	0.29	5.95	0.31	6.75e-9	Trans fatty acid levels;
LUSC	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg16606324	chr3:10149918	C3orf24	0.63	8.88	0.44	4.09e-17	Alzheimer's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05263790	chr21:38739726	DYRK1A	0.47	6.44	0.33	4.25e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs62400317	0.762	rs12215263	chr6:44831364	C/A	cg20913747	chr6:44695427	NA	-0.48	-7.5	-0.38	5.98e-13	Total body bone mineral density;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg20243626	chr1:220263520	BPNT1	0.44	6.36	0.33	6.6e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg16606324	chr3:10149918	C3orf24	0.58	8.37	0.42	1.55e-15	Alzheimer's disease;
LUSC	trans	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-13.08	-0.58	7.28e-32	Colorectal cancer;
LUSC	cis	rs4919687	0.550	rs17784294	chr10:104479385	G/T	cg04362960	chr10:104952993	NT5C2	0.45	6.46	0.33	3.78e-10	Colorectal cancer;
LUSC	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg09835421	chr16:68378352	PRMT7	-0.51	-6.24	-0.32	1.33e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2274273	0.837	rs10131913	chr14:55787420	A/G	cg04306507	chr14:55594613	LGALS3	0.56	12.99	0.58	1.58e-31	Protein biomarker;
LUSC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg09904177	chr6:26538194	HMGN4	-0.53	-6.18	-0.32	1.91e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9361491	0.657	rs9341742	chr6:79440229	C/T	cg05283184	chr6:79620031	NA	-0.34	-6.2	-0.32	1.66e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg24342717	chr2:85555507	TGOLN2	-0.76	-12.6	-0.57	4.93e-30	Ear protrusion;
LUSC	cis	rs7577851	0.672	rs12477398	chr2:69628491	T/G	cg10773587	chr2:69614142	GFPT1	0.56	6.3	0.33	9.29e-10	Parkinson's disease (age of onset);
LUSC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.69	-0.34	9.49e-11	Alzheimer's disease (late onset);
LUSC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.59	-0.5	8.37e-23	Gut microbiome composition (summer);
LUSC	cis	rs921665	0.831	rs2167962	chr2:3192427	G/A	cg16434511	chr2:3151078	NA	-0.61	-6.86	-0.35	3.42e-11	World class endurance athleticism;
LUSC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg11062466	chr8:58055876	NA	0.67	8.06	0.4	1.41e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg03146154	chr1:46216737	IPP	-0.51	-7.57	-0.38	3.61e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg18806716	chr10:30721971	MAP3K8	0.48	7.95	0.4	2.82e-14	Inflammatory bowel disease;
LUSC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg09165964	chr15:75287851	SCAMP5	-0.47	-6.84	-0.35	3.71e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	trans	rs1422110	0.513	rs1422105	chr5:85448371	A/C	cg01787110	chr1:109008453	NBPF6	0.44	8.08	0.4	1.16e-14	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	9.31	0.45	1.72e-18	Response to antipsychotic treatment;
LUSC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-0.8	-11.08	-0.52	1.72e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2249625	0.504	rs2496508	chr6:72891398	A/G	cg18830697	chr6:72922368	RIMS1	-0.38	-7.64	-0.39	2.39e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs6700896	0.500	rs11208699	chr1:66131377	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.93	0.31	7.6e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs7951105	1.000	rs12099337	chr11:39242600	C/A	cg24085930	chr3:21832523	NA	0.49	6.06	0.31	3.58e-9	Free thyroxine concentration;
LUSC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg19774624	chr17:42201019	HDAC5	-0.81	-13.41	-0.59	4.34e-33	Total body bone mineral density;
LUSC	cis	rs10743315	0.643	rs75189071	chr12:19329505	C/T	cg02471346	chr12:19282374	PLEKHA5	0.78	6.14	0.32	2.29e-9	Gut microbiota (bacterial taxa);
LUSC	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-6.97	-0.36	1.68e-11	D-dimer levels;
LUSC	cis	rs62400317	0.859	rs114017772	chr6:45113862	T/C	cg18551225	chr6:44695536	NA	-0.42	-6.82	-0.35	4.2e-11	Total body bone mineral density;
LUSC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg13685833	chr1:53393034	SCP2	-0.39	-5.86	-0.31	1.11e-8	Monocyte count;
LUSC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg12963246	chr6:28129442	ZNF389	0.51	7.06	0.36	9.81e-12	Depression;
LUSC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg03146154	chr1:46216737	IPP	0.56	8.37	0.42	1.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs727505	1.000	rs10265763	chr7:124451514	G/A	cg23710748	chr7:124431027	NA	-0.42	-7.57	-0.38	3.56e-13	Lewy body disease;
LUSC	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg02158880	chr13:53174818	NA	0.41	5.96	0.31	6.35e-9	Lewy body disease;
LUSC	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg27068330	chr11:65405492	SIPA1	0.68	8.54	0.42	4.67e-16	Glomerular filtration rate (creatinine);Chronic kidney disease;
LUSC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg16447950	chr5:562315	NA	-0.57	-6.95	-0.36	1.97e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs11822910	0.953	rs11827928	chr11:57197890	A/G	cg00522883	chr11:57194120	SLC43A3	0.45	6.39	0.33	5.67e-10	Platelet distribution width;
LUSC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg17971929	chr21:40555470	PSMG1	-0.5	-7.39	-0.37	1.19e-12	Menarche (age at onset);
LUSC	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg05805236	chr11:65401703	PCNXL3	0.4	6.84	0.35	3.82e-11	Acne (severe);
LUSC	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg20933634	chr6:27740509	NA	0.41	5.85	0.31	1.15e-8	Parkinson's disease;
LUSC	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg08493051	chr2:3487164	NA	-0.51	-7.8	-0.39	8.08e-14	Neurofibrillary tangles;
LUSC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg00815214	chr21:47717953	NA	-0.35	-5.65	-0.3	3.42e-8	Testicular germ cell tumor;
LUSC	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg02574844	chr11:5959923	NA	-0.43	-6.13	-0.32	2.54e-9	DNA methylation (variation);
LUSC	cis	rs1595825	0.891	rs16824376	chr2:198684342	C/T	cg00982548	chr2:198649783	BOLL	-0.59	-7.27	-0.37	2.62e-12	Ulcerative colitis;
LUSC	cis	rs1322512	0.837	rs2800627	chr6:153006507	C/A	cg27316956	chr6:152958899	SYNE1	0.35	6.09	0.32	3.07e-9	Tonometry;
LUSC	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg19640130	chr10:64028056	RTKN2	-0.41	-7.31	-0.37	1.98e-12	Rheumatoid arthritis;
LUSC	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg07169764	chr2:136633963	MCM6	-0.59	-7.76	-0.39	1.02e-13	Mosquito bite size;
LUSC	cis	rs9369695	0.842	rs9395262	chr6:47465267	T/C	cg20196966	chr6:47445060	CD2AP	0.42	5.81	0.3	1.49e-8	Reticulocyte count;
LUSC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg02117656	chr17:79614917	TSPAN10	0.3	5.67	0.3	3.16e-8	Eye color traits;
LUSC	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg13385521	chr17:29058706	SUZ12P	0.69	6.79	0.35	5.27e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7923609	0.841	rs10740131	chr10:65271488	A/T	cg01631684	chr10:65280961	REEP3	-0.42	-6.43	-0.33	4.35e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.04	-0.36	1.07e-11	Bipolar disorder;
LUSC	cis	rs2820315	0.867	rs2819351	chr1:201885157	C/T	cg10061532	chr1:201886748	LMOD1	0.28	6.41	0.33	5.09e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg11502198	chr6:26597334	ABT1	0.75	11.72	0.54	8.53e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg05267876	chr1:229644265	NUP133	-0.56	-6.08	-0.32	3.25e-9	Lung cancer in ever smokers;
LUSC	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg07080220	chr10:102295463	HIF1AN	0.68	9.2	0.45	3.94e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.04	0.4	1.62e-14	Lung cancer in ever smokers;
LUSC	cis	rs887829	0.667	rs7577677	chr2:234590616	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.41	-6.54	-0.34	2.35e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.2	24.22	0.8	1.65e-75	Exhaled nitric oxide output;
LUSC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	0.65	13.92	0.61	4.91e-35	Prudent dietary pattern;
LUSC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03526776	chr6:41159608	TREML2	0.5	9.77	0.47	5.48e-20	Alzheimer's disease (late onset);
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg02951883	chr7:2050386	MAD1L1	-0.46	-8.03	-0.4	1.74e-14	Bipolar disorder and schizophrenia;
LUSC	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg13010199	chr12:38710504	ALG10B	0.55	8.3	0.41	2.7e-15	Morning vs. evening chronotype;
LUSC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.47	5.84	0.3	1.21e-8	Renal function-related traits (BUN);
LUSC	cis	rs10754283	0.901	rs6663526	chr1:90110862	T/C	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs1376359	0.503	rs610502	chr1:103274928	A/C	cg17154563	chr19:40477487	PSMC4	0.47	5.97	0.31	5.95e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg12463550	chr7:65579703	CRCP	0.57	8.47	0.42	7.7e-16	Aortic root size;
LUSC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.98	-0.31	5.72e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10992471	0.603	rs10992349	chr9:95233887	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.68	-0.39	1.78e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg14664628	chr15:75095509	CSK	-0.55	-8.46	-0.42	8.72e-16	Breast cancer;
LUSC	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg24675056	chr1:15929824	NA	0.48	8.24	0.41	3.92e-15	Systolic blood pressure;
LUSC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-1.0	-14.93	-0.63	5.9e-39	Initial pursuit acceleration;
LUSC	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	0.99	19.53	0.73	3.23e-57	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg05025164	chr4:1340916	KIAA1530	0.46	7.07	0.36	9.08e-12	Obesity-related traits;
LUSC	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg19682013	chr15:45996608	NA	0.39	5.9	0.31	8.82e-9	Waist circumference;Weight;
LUSC	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg22852734	chr6:133119734	C6orf192	1.33	10.41	0.49	3.74e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg27284194	chr4:1044797	NA	0.59	8.97	0.44	2.1e-17	Recombination rate (females);
LUSC	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg04362960	chr10:104952993	NT5C2	0.58	8.22	0.41	4.55e-15	Arsenic metabolism;
LUSC	trans	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg04995722	chr7:26192034	NFE2L3	-0.43	-6.7	-0.34	8.92e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg11790438	chr9:140317161	NOXA1;EXD3	0.42	6.32	0.33	8.17e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg18196295	chr10:418757	DIP2C	-0.51	-8.5	-0.42	6.37e-16	Psychosis in Alzheimer's disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11087358	chr12:57940980	DCTN2	0.46	6.65	0.34	1.18e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs3824867	0.920	rs7107853	chr11:47453518	T/C	cg20307385	chr11:47447363	PSMC3	-0.65	-9.65	-0.47	1.35e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs9462027	0.628	rs2814942	chr6:34644261	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.28	-0.32	1.07e-9	Systemic lupus erythematosus;
LUSC	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.6	-10.51	-0.5	1.63e-22	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11608355	0.515	rs1045263	chr12:109974191	A/G	cg05360138	chr12:110035743	NA	0.93	12.3	0.56	5.99e-29	Neuroticism;
LUSC	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.62	-0.34	1.44e-10	Monocyte percentage of white cells;
LUSC	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg25482853	chr8:67687455	SGK3	1.1	15.65	0.65	8.75e-42	Obesity-related traits;
LUSC	cis	rs3820928	0.874	rs2272198	chr2:227893017	A/G	cg11843606	chr2:227700838	RHBDD1	0.51	7.51	0.38	5.31e-13	Pulmonary function;
LUSC	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.06	0.4	1.35e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs508618	0.731	rs12033229	chr1:231545703	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.56	6.83	0.35	4.01e-11	Red blood cell count;
LUSC	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg17691542	chr6:26056736	HIST1H1C	0.4	5.97	0.31	5.96e-9	Schizophrenia;
LUSC	trans	rs12210905	0.858	rs72838249	chr6:26998489	A/G	cg11837749	chr1:55047332	ACOT11	0.57	6.13	0.32	2.51e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.58	0.38	3.35e-13	Prudent dietary pattern;
LUSC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11764359	chr7:65958608	NA	0.63	9.61	0.47	1.85e-19	Aortic root size;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg01655898	chr14:21439243	NA	0.43	6.66	0.34	1.12e-10	N-glycan levels;
LUSC	trans	rs656319	0.559	rs17689037	chr8:9974858	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.6	-0.34	1.65e-10	Myopia (pathological);
LUSC	cis	rs936229	0.749	rs8042694	chr15:75225415	G/A	cg10253484	chr15:75165896	SCAMP2	-0.58	-7.8	-0.39	7.76e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg13010199	chr12:38710504	ALG10B	0.42	6.01	0.31	4.72e-9	Morning vs. evening chronotype;
LUSC	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg04586622	chr2:25135609	ADCY3	0.43	9.22	0.45	3.32e-18	Body mass index;
LUSC	cis	rs16976116	0.851	rs13380400	chr15:55490518	A/G	cg11288833	chr15:55489084	RSL24D1	0.5	5.98	0.31	5.65e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg16423285	chr20:60520624	NA	-0.47	-5.92	-0.31	8.15e-9	Body mass index;
LUSC	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.37	-0.46	1.1e-18	Type 2 diabetes;
LUSC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg26335602	chr6:28129616	ZNF389	0.41	5.78	0.3	1.74e-8	Parkinson's disease;
LUSC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.19	-0.32	1.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6977660	0.714	rs12536561	chr7:19816659	G/A	cg05791153	chr7:19748676	TWISTNB	0.68	7.22	0.37	3.49e-12	Thyroid stimulating hormone;
LUSC	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg18827107	chr12:86230957	RASSF9	-0.4	-5.96	-0.31	6.38e-9	Major depressive disorder;
LUSC	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg13789015	chr9:136890014	NCRNA00094	0.66	12.24	0.56	1.02e-28	Platelet distribution width;
LUSC	cis	rs6960043	0.791	rs2191346	chr7:15053878	C/G	cg19272540	chr7:15055459	NA	-0.33	-8.22	-0.41	4.41e-15	Type 2 diabetes;
LUSC	trans	rs2587949	0.571	rs2248969	chr3:4230023	T/C	cg15139668	chr4:4577005	NA	-0.42	-6.13	-0.32	2.49e-9	Periodontitis (DPAL);
LUSC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	0.8	13.99	0.61	2.6e-35	Cognitive function;
LUSC	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg01557791	chr16:72042693	DHODH	-0.49	-6.49	-0.33	3.12e-10	Blood protein levels;
LUSC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.86	14.2	0.61	4.1e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11764359	chr7:65958608	NA	0.63	9.66	0.47	1.2e-19	Aortic root size;
LUSC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.41	-6.06	-0.31	3.65e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg14689365	chr7:158441557	NCAPG2	-0.45	-6.13	-0.32	2.55e-9	Height;
LUSC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg17420585	chr12:42539391	GXYLT1	-0.4	-8.02	-0.4	1.82e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs17255340	0.501	rs1145916	chr6:83988986	G/T	cg08257003	chr6:84140564	ME1	0.33	8.04	0.4	1.59e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg17366294	chr4:99064904	C4orf37	0.56	10.0	0.48	8.92e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.78	-0.35	5.48e-11	Neutrophil percentage of white cells;
LUSC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg00074818	chr8:8560427	CLDN23	0.57	9.81	0.47	4.05e-20	Obesity-related traits;
LUSC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	6.36	0.33	6.75e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.38	-7.04	-0.36	1.08e-11	Testicular germ cell tumor;
LUSC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.61	8.11	0.41	9.99e-15	High light scatter reticulocyte count;
LUSC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.61	-0.57	4.44e-30	Type 2 diabetes;
LUSC	cis	rs2019216	0.500	rs71371082	chr17:21889647	T/C	cg22648282	chr17:21454238	C17orf51	-0.54	-7.82	-0.39	6.97e-14	Pelvic organ prolapse;
LUSC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg23630131	chr7:65973040	NA	0.2	5.73	0.3	2.29e-8	Aortic root size;
LUSC	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg06096015	chr1:231504339	EGLN1	0.56	9.91	0.48	1.86e-20	Hemoglobin concentration;
LUSC	cis	rs11650494	0.908	rs75904857	chr17:47370449	T/G	cg08112188	chr17:47440006	ZNF652	1.22	10.51	0.5	1.6e-22	Prostate cancer;
LUSC	cis	rs12220238	1.000	rs11000905	chr10:75925532	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.88	0.35	2.97e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg22532475	chr10:104410764	TRIM8	-0.35	-7.76	-0.39	1.01e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19346786	chr7:2764209	NA	-0.39	-6.8	-0.35	4.84e-11	Height;
LUSC	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg09877947	chr5:131593287	PDLIM4	0.41	6.68	0.34	1.03e-10	Blood metabolite levels;
LUSC	cis	rs7089973	0.549	rs34434610	chr10:116739745	A/G	cg23260525	chr10:116636907	FAM160B1	0.29	5.71	0.3	2.43e-8	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8017423	1.000	rs11622075	chr14:90669894	G/T	cg04374321	chr14:90722782	PSMC1	0.69	10.89	0.51	7.84e-24	Mortality in heart failure;
LUSC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg03188948	chr7:1209495	NA	0.66	6.92	0.35	2.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg14583973	chr4:3374767	RGS12	0.35	7.51	0.38	5.51e-13	Serum sulfate level;
LUSC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.47	7.23	0.37	3.25e-12	Colorectal cancer;
LUSC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg22963979	chr7:1858916	MAD1L1	0.4	5.91	0.31	8.33e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs611744	0.573	rs1457210	chr8:109261562	A/G	cg18478394	chr8:109455254	TTC35	-0.41	-6.56	-0.34	2.01e-10	Dupuytren's disease;
LUSC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	7.0	0.36	1.39e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg15711740	chr2:61764176	XPO1	-0.52	-8.47	-0.42	7.99e-16	Tuberculosis;
LUSC	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg00033643	chr7:134001901	SLC35B4	0.42	6.07	0.32	3.5e-9	Mean platelet volume;
LUSC	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg00898013	chr13:113819073	PROZ	0.67	9.46	0.46	5.87e-19	Platelet distribution width;
LUSC	cis	rs9942416	0.533	rs4704235	chr5:75024380	A/C	cg19683494	chr5:74908142	NA	0.48	6.74	0.35	7.12e-11	Age-related disease endophenotypes;
LUSC	cis	rs2297440	0.527	rs4809318	chr20:62264760	G/A	cg16989086	chr20:62203971	PRIC285	0.46	6.47	0.33	3.45e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUSC	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.75	-0.35	6.53e-11	Monocyte percentage of white cells;
LUSC	cis	rs1030268	0.651	rs13222377	chr7:133466346	C/T	cg10665199	chr7:133106180	EXOC4	0.51	5.72	0.3	2.33e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05654404	chr1:45452166	EIF2B3	0.48	7.41	0.38	1.06e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	7.65	0.39	2.24e-13	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg07169764	chr2:136633963	MCM6	0.58	7.58	0.38	3.47e-13	Mosquito bite size;
LUSC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24531977	chr5:56204891	C5orf35	-0.85	-13.03	-0.58	1.12e-31	Coronary artery disease;
LUSC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	6.31	0.33	8.74e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg09034736	chr1:150693464	HORMAD1	-0.4	-5.75	-0.3	2.05e-8	Tonsillectomy;
LUSC	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.84	-13.81	-0.6	1.25e-34	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.92	-0.35	2.31e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg07741184	chr6:167504864	NA	0.4	7.14	0.36	5.87e-12	Crohn's disease;
LUSC	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg20734569	chr3:48348370	SPINK8	-0.47	-8.17	-0.41	6.44e-15	Coronary artery disease;
LUSC	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg14830002	chr1:247616686	OR2B11	0.49	7.05	0.36	1.05e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-7.62	-0.38	2.62e-13	Colorectal cancer;
LUSC	cis	rs7712401	0.601	rs152039	chr5:122220665	C/T	cg19077854	chr5:122220652	SNX24	0.42	9.49	0.46	4.54e-19	Mean platelet volume;
LUSC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg18305652	chr10:134549665	INPP5A	0.45	6.76	0.35	6.08e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs13315871	0.929	rs9837903	chr3:58301906	A/T	cg12435725	chr3:58293450	RPP14	-0.74	-7.47	-0.38	7.23e-13	Cholesterol, total;
LUSC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.46	6.91	0.35	2.51e-11	Platelet count;
LUSC	cis	rs11657217	0.638	rs4313839	chr17:77698619	C/T	cg06901238	chr17:77706717	ENPP7	-0.5	-9.69	-0.47	1.01e-19	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06793798	chr10:62538126	CDK1;CDC2	0.43	6.44	0.33	4.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.51	-7.97	-0.4	2.58e-14	Platelet count;
LUSC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg22907277	chr7:1156413	C7orf50	0.71	7.44	0.38	8.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs865483	0.895	rs853192	chr17:35821931	C/G	cg06716730	chr17:35851459	DUSP14	0.27	6.03	0.31	4.28e-9	Monocyte count;
LUSC	cis	rs7539542	0.556	rs10753926	chr1:202876085	C/T	cg19681188	chr1:202830198	LOC148709	0.39	5.77	0.3	1.86e-8	Mean platelet volume;
LUSC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.16e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg07936489	chr17:37558343	FBXL20	0.69	9.69	0.47	1.01e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs9535307	0.929	rs6561550	chr13:50249423	C/T	cg04663916	chr13:50265991	EBPL	0.49	5.7	0.3	2.63e-8	Obesity-related traits;
LUSC	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg06207120	chr15:45996521	NA	0.4	6.23	0.32	1.38e-9	Waist circumference;Weight;
LUSC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	9.07	0.44	1.02e-17	Total body bone mineral density;
LUSC	cis	rs3820928	0.839	rs4675123	chr2:227800205	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.65	-0.39	2.11e-13	Pulmonary function;
LUSC	cis	rs1561176	0.783	rs1124175	chr7:155015124	A/C	cg08570118	chr7:155025533	NA	0.46	6.19	0.32	1.8e-9	Personality dimensions;
LUSC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg02551604	chr5:131831745	NA	-0.42	-6.62	-0.34	1.39e-10	Asthma (sex interaction);
LUSC	cis	rs1595825	0.891	rs60582020	chr2:198520555	A/C	cg00982548	chr2:198649783	BOLL	-0.52	-6.63	-0.34	1.34e-10	Ulcerative colitis;
LUSC	cis	rs926392	0.896	rs7268772	chr20:37684501	A/G	cg27552599	chr20:37590471	DHX35	0.34	5.94	0.31	6.98e-9	Dialysis-related mortality;
LUSC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.79	-0.54	4.47e-27	Chronic sinus infection;
LUSC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.56	8.42	0.42	1.1e-15	Total body bone mineral density;
LUSC	cis	rs7561273	0.586	rs12477718	chr2:24330539	A/G	cg20701182	chr2:24300061	SF3B14	0.51	6.55	0.34	2.19e-10	Quantitative traits;
LUSC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg08677398	chr8:58056175	NA	0.44	6.05	0.31	3.87e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.0	0.31	5.04e-9	Recombination rate (females);
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg15383120	chr6:291909	DUSP22	-0.66	-10.91	-0.51	6.8e-24	Menopause (age at onset);
LUSC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9653442	0.545	rs12712067	chr2:100763900	A/C	cg07810366	chr2:100720526	AFF3	0.44	7.37	0.37	1.34e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2742417	1.000	rs2673047	chr3:45743113	A/G	cg04837898	chr3:45731254	SACM1L	-0.35	-5.66	-0.3	3.28e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg27205649	chr11:78285834	NARS2	-0.51	-5.87	-0.31	1.05e-8	Testicular germ cell tumor;
LUSC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg03354898	chr7:1950403	MAD1L1	-0.32	-6.38	-0.33	5.9e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg22166914	chr1:53195759	ZYG11B	-0.42	-6.22	-0.32	1.52e-9	Monocyte count;
LUSC	cis	rs865483	0.895	rs4795200	chr17:35817105	A/G	cg06716730	chr17:35851459	DUSP14	0.28	6.29	0.33	9.73e-10	Monocyte count;
LUSC	cis	rs11051970	0.879	rs950080	chr12:32588503	G/A	cg02745156	chr12:32552066	NA	0.43	7.29	0.37	2.29e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	1.06	14.7	0.63	4.38e-38	Exhaled nitric oxide levels;
LUSC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.82	-0.3	1.42e-8	Depression;
LUSC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg27398640	chr15:77910606	LINGO1	0.28	5.84	0.3	1.22e-8	Type 2 diabetes;
LUSC	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg05714579	chr10:131428358	MGMT	0.45	6.3	0.33	9.35e-10	Response to temozolomide;
LUSC	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	6.81	0.35	4.53e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11645453	chr3:52864694	ITIH4	-0.49	-10.99	-0.52	3.31e-24	Schizophrenia;
LUSC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-6.7	-0.34	8.86e-11	Major depressive disorder;
LUSC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.69	-10.77	-0.51	2.01e-23	Aortic root size;
LUSC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg21017887	chr14:105400489	NA	0.69	13.27	0.59	1.45e-32	Rheumatoid arthritis;
LUSC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg06494592	chr3:125709126	NA	-0.49	-5.65	-0.3	3.46e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg08000102	chr2:233561755	GIGYF2	0.68	11.26	0.52	3.91e-25	Coronary artery disease;
LUSC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.42	-6.24	-0.32	1.3e-9	Tonsillectomy;
LUSC	cis	rs9733	0.681	rs7412746	chr1:150860471	C/T	cg13175981	chr1:150552382	MCL1	0.46	6.39	0.33	5.67e-10	Tonsillectomy;
LUSC	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg08601574	chr20:25228251	PYGB	-0.42	-6.43	-0.33	4.42e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg16447950	chr5:562315	NA	-0.59	-7.08	-0.36	8.42e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.74	12.25	0.56	9.86e-29	Coronary artery disease;
LUSC	cis	rs6782228	0.606	rs1127030	chr3:128338953	T/C	cg16766828	chr3:128327626	NA	-0.31	-5.66	-0.3	3.3e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs1499972	0.941	rs73168388	chr3:117645824	C/T	cg07612923	chr3:117604196	NA	0.65	5.87	0.31	1.03e-8	Schizophrenia;
LUSC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg16586182	chr3:47516702	SCAP	0.52	7.95	0.4	3e-14	Colorectal cancer;
LUSC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg09455208	chr3:40491958	NA	0.54	9.73	0.47	7.2e-20	Renal cell carcinoma;
LUSC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-6.91	-0.35	2.52e-11	Crohn's disease;
LUSC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg06074448	chr4:187884817	NA	-0.39	-6.52	-0.34	2.56e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg20503657	chr10:835505	NA	1.22	16.74	0.68	4.37e-46	Eosinophil percentage of granulocytes;
LUSC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg01973587	chr1:228161476	NA	0.47	8.6	0.43	3.05e-16	Diastolic blood pressure;
LUSC	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.82	10.81	0.51	1.42e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-8.69	-0.43	1.69e-16	Chronic sinus infection;
LUSC	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03168497	chr17:48586147	MYCBPAP	0.5	6.66	0.34	1.15e-10	Visceral fat;
LUSC	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.03	-0.4	1.68e-14	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg02423579	chr7:2872169	GNA12	-0.46	-6.5	-0.34	2.84e-10	Height;
LUSC	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg08847533	chr14:75593920	NEK9	-0.5	-7.19	-0.37	4.17e-12	IgG glycosylation;
LUSC	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	1.1	17.27	0.69	3.31e-48	Exhaled nitric oxide output;
LUSC	cis	rs12136530	0.774	rs883961	chr1:19781155	G/C	cg01832549	chr1:19774989	CAPZB	-0.32	-5.85	-0.3	1.15e-8	Lead levels in blood;
LUSC	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg21427119	chr20:30132790	HM13	-0.46	-6.65	-0.34	1.23e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg04317338	chr11:64019027	PLCB3	0.68	7.7	0.39	1.52e-13	Mean platelet volume;
LUSC	cis	rs11158026	0.722	rs2840268	chr14:55471983	C/G	cg04306507	chr14:55594613	LGALS3	0.37	7.32	0.37	1.84e-12	Parkinson's disease;
LUSC	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.4	5.65	0.3	3.46e-8	Bipolar disorder;
LUSC	cis	rs6669072	1.000	rs3904677	chr1:91252126	C/T	cg08895590	chr1:91227319	NA	-0.37	-8.2	-0.41	5.18e-15	Cognitive function;
LUSC	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.71	-0.91	1.49e-128	Myeloid white cell count;
LUSC	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg15711740	chr2:61764176	XPO1	-0.5	-7.97	-0.4	2.48e-14	Tuberculosis;
LUSC	cis	rs62432291	0.681	rs423533	chr6:159664516	G/T	cg14500486	chr6:159655392	FNDC1	-0.54	-6.1	-0.32	2.86e-9	Joint mobility (Beighton score);
LUSC	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.32	0.53	2.37e-25	Colorectal cancer;
LUSC	cis	rs3740540	0.530	rs10794163	chr10:126291398	A/G	cg04949429	chr10:126290192	LHPP	0.36	7.54	0.38	4.51e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2692947	0.630	rs1168966	chr2:96798510	G/A	cg22654517	chr2:96458247	NA	0.38	7.62	0.38	2.58e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg03233332	chr7:66118400	NA	-0.41	-6.02	-0.31	4.61e-9	Aortic root size;
LUSC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.28	0.56	7.31e-29	Prudent dietary pattern;
LUSC	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg17470449	chr10:769945	NA	0.53	7.12	0.36	6.81e-12	Uric acid levels;
LUSC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg12463550	chr7:65579703	CRCP	0.57	8.52	0.42	5.51e-16	Aortic root size;
LUSC	trans	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.22	-0.32	1.49e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	5.96e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11809207	0.953	rs17163666	chr1:26525383	A/G	cg00300879	chr1:26503847	CNKSR1	0.31	5.95	0.31	6.67e-9	Height;
LUSC	cis	rs727505	0.866	rs67132333	chr7:124719801	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.96	-0.36	1.79e-11	Lewy body disease;
LUSC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08677398	chr8:58056175	NA	0.52	6.87	0.35	3.18e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg15839431	chr19:19639596	YJEFN3	0.44	6.19	0.32	1.78e-9	Tonsillectomy;
LUSC	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg22676075	chr6:135203613	NA	0.58	9.25	0.45	2.84e-18	Red blood cell count;
LUSC	cis	rs7572644	0.766	rs2337372	chr2:28140349	G/A	cg27432699	chr2:27873401	GPN1	0.52	6.43	0.33	4.31e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg00530320	chr1:46809349	NSUN4	0.55	8.47	0.42	7.65e-16	Menopause (age at onset);
LUSC	cis	rs1018836	0.700	rs4735201	chr8:91528313	C/T	cg16814680	chr8:91681699	NA	-0.73	-11.41	-0.53	1.13e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg13010199	chr12:38710504	ALG10B	0.64	9.79	0.47	4.49e-20	Bladder cancer;
LUSC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-0.98	-14.56	-0.62	1.53e-37	Initial pursuit acceleration;
LUSC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	15.59	0.65	1.47e-41	Platelet count;
LUSC	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg20243544	chr17:37824526	PNMT	0.49	6.95	0.36	1.92e-11	Asthma;
LUSC	trans	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg06521331	chr12:34319734	NA	-0.41	-6.48	-0.33	3.26e-10	Morning vs. evening chronotype;
LUSC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg26513180	chr16:89883248	FANCA	0.63	5.86	0.31	1.11e-8	Skin colour saturation;
LUSC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg17173187	chr15:85201210	NMB	-0.37	-6.72	-0.34	8.03e-11	Schizophrenia;
LUSC	cis	rs6554196	0.508	rs2237037	chr4:55525930	A/C	cg18836493	chr4:55524333	KIT	-0.44	-7.55	-0.38	4.21e-13	Monocyte count;
LUSC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg11764359	chr7:65958608	NA	0.73	11.46	0.53	7.42e-26	Aortic root size;
LUSC	trans	rs1941687	0.800	rs12968906	chr18:31378307	G/A	cg27147174	chr7:100797783	AP1S1	-0.47	-6.92	-0.35	2.3e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.34	5.67	0.3	3.12e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg04511125	chr2:88470314	THNSL2	0.68	6.42	0.33	4.76e-10	Plasma clusterin levels;
LUSC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.33	0.56	4.75e-29	Prudent dietary pattern;
LUSC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Depression;
LUSC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	6.83	0.35	4.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	0.69	11.03	0.52	2.58e-24	Blood metabolite ratios;
LUSC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg03526776	chr6:41159608	TREML2	0.33	6.26	0.32	1.2e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg04518342	chr5:131593106	PDLIM4	-0.45	-7.53	-0.38	4.66e-13	Breast cancer;
LUSC	cis	rs2742234	0.955	rs2503849	chr10:43672776	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.36	-6.34	-0.33	7.48e-10	Hirschsprung disease;
LUSC	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg15839431	chr19:19639596	YJEFN3	-0.67	-7.36	-0.37	1.44e-12	Bipolar disorder;
LUSC	trans	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	12.24	0.56	1.06e-28	Mean corpuscular volume;
LUSC	cis	rs10740039	0.883	rs7898504	chr10:62417991	T/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.95	-0.36	1.97e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.53	-8.01	-0.4	1.99e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.19	30.8	0.86	1.26e-99	Testicular germ cell tumor;
LUSC	cis	rs9309473	0.948	rs10183818	chr2:73714556	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-7.1	-0.36	7.47e-12	Metabolite levels;
LUSC	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.51	7.78	0.39	9.12e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	0.76	12.41	0.56	2.37e-29	Cognitive function;
LUSC	cis	rs72799341	1.000	rs1458201	chr16:30916129	G/A	cg02466173	chr16:30829666	NA	-0.53	-7.99	-0.4	2.28e-14	Diastolic blood pressure;
LUSC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg12310025	chr6:25882481	NA	-0.42	-7.11	-0.36	7.24e-12	Blood metabolite levels;
LUSC	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.6	10.2	0.49	1.85e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg09359103	chr1:154839909	KCNN3	-0.7	-16.24	-0.66	4.09e-44	Prostate cancer;
LUSC	cis	rs1062746	0.683	rs891094	chr16:87378001	C/G	cg02258303	chr16:87377426	FBXO31	0.57	9.32	0.45	1.62e-18	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg12072164	chr19:44306565	LYPD5	0.3	6.27	0.32	1.09e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs7246967	0.551	rs34907478	chr19:22928831	T/C	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.04e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg08975724	chr8:8085496	FLJ10661	0.48	7.02	0.36	1.21e-11	Mood instability;
LUSC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg13560548	chr3:10150139	C3orf24	0.48	6.71	0.34	8.2e-11	Alzheimer's disease;
LUSC	cis	rs3744061	0.530	rs2079778	chr17:74647097	C/T	cg27546012	chr17:74684504	MXRA7	-0.35	-6.0	-0.31	5.16e-9	Retinal arteriolar caliber;
LUSC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00934597	chr7:893267	UNC84A	-0.45	-6.63	-0.34	1.35e-10	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg16745616	chr19:8428856	ANGPTL4	-0.4	-6.03	-0.31	4.41e-9	HDL cholesterol;
LUSC	trans	rs731565	0.737	rs6948030	chr7:147394199	C/T	cg12847240	chr6:10382088	NA	-0.54	-6.3	-0.33	9.21e-10	Diabetic kidney disease;
LUSC	cis	rs5769707	0.681	rs739236	chr22:50041602	A/G	cg05373962	chr22:49881684	NA	-0.4	-8.29	-0.41	2.85e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1371867	0.810	rs3020182	chr8:101233008	T/C	cg06002616	chr8:101225028	SPAG1	0.47	7.69	0.39	1.7e-13	Atrioventricular conduction;
LUSC	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg14092571	chr14:90743983	NA	0.36	5.89	0.31	9.62e-9	Mortality in heart failure;
LUSC	cis	rs17604090	0.536	rs112165062	chr7:29687592	C/T	cg19413766	chr7:29689036	LOC646762	-0.58	-6.93	-0.35	2.12e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs6546550	0.901	rs7419837	chr2:70146625	T/C	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg18681998	chr4:17616180	MED28	-0.83	-14.35	-0.62	9.86e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs911119	0.913	rs34792920	chr20:23581876	C/T	cg16589663	chr20:23618590	CST3	0.65	7.73	0.39	1.29e-13	Chronic kidney disease;
LUSC	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg19622623	chr12:86230825	RASSF9	-0.41	-5.69	-0.3	2.73e-8	Major depressive disorder;
LUSC	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg06623918	chr6:96969491	KIAA0776	0.73	8.64	0.43	2.33e-16	Migraine;Coronary artery disease;
LUSC	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg17691542	chr6:26056736	HIST1H1C	0.76	9.88	0.48	2.38e-20	Iron status biomarkers;
LUSC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.38	-0.37	1.23e-12	Bipolar disorder;
LUSC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-1.06	-15.24	-0.64	3.65e-40	Vitiligo;
LUSC	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg12292205	chr6:26970375	C6orf41	0.5	8.3	0.41	2.6e-15	Schizophrenia;
LUSC	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07741184	chr6:167504864	NA	0.37	6.49	0.33	3.19e-10	Primary biliary cholangitis;
LUSC	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg05925327	chr15:68127851	NA	-0.41	-6.46	-0.33	3.79e-10	Restless legs syndrome;
LUSC	cis	rs12472274	0.646	rs34465035	chr2:239114093	C/A	cg17459225	chr2:239074497	NA	0.57	7.86	0.4	5.33e-14	Phospholipid levels (plasma);
LUSC	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06360820	chr2:242988706	NA	-0.91	-10.0	-0.48	8.84e-21	Obesity-related traits;
LUSC	trans	rs76248362	0.748	rs943061	chr13:24431968	C/T	cg08934785	chr7:27196759	HOXA7	-0.65	-6.97	-0.36	1.68e-11	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg07936489	chr17:37558343	FBXL20	0.7	9.8	0.47	4.14e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07923666	chr12:49932857	KCNH3	-0.52	-6.75	-0.35	6.56e-11	Resting heart rate;
LUSC	cis	rs6500395	1.000	rs1558816	chr16:48704868	T/A	cg04672837	chr16:48644449	N4BP1	-0.46	-6.87	-0.35	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg02038168	chr22:39784481	NA	-0.41	-6.57	-0.34	1.99e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.92	15.82	0.65	1.85e-42	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.31	-0.33	8.87e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-8.91	-0.44	3.25e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs11690935	0.550	rs55653103	chr2:172861816	T/C	cg13550731	chr2:172543902	DYNC1I2	0.54	8.02	0.4	1.75e-14	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg22117172	chr7:91764530	CYP51A1	-0.32	-5.82	-0.3	1.41e-8	Breast cancer;
LUSC	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.7	12.51	0.56	1.05e-29	Superior crus of antihelix expression;
LUSC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.29	-0.37	2.23e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg01652190	chr22:50026171	C22orf34	-0.31	-6.41	-0.33	5.03e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.99	-17.63	-0.69	1.24e-49	Coronary artery disease;
LUSC	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg21053147	chr12:120880522	NA	-0.48	-5.93	-0.31	7.41e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg10729496	chr3:10149963	C3orf24	0.55	7.42	0.38	9.54e-13	Alzheimer's disease;
LUSC	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg13010199	chr12:38710504	ALG10B	0.57	9.09	0.45	9.21e-18	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg27170947	chr2:26402098	FAM59B	0.72	10.72	0.51	3.18e-23	Gut microbiome composition (summer);
LUSC	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg00206168	chr11:65308501	LTBP3	1.26	8.19	0.41	5.76e-15	Height;
LUSC	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg15103426	chr22:29168792	CCDC117	-0.46	-5.66	-0.3	3.32e-8	Lymphocyte counts;
LUSC	cis	rs17092148	0.887	rs6059915	chr20:33147737	C/G	cg16810054	chr20:33298113	TP53INP2	-0.36	-5.79	-0.3	1.64e-8	Neuroticism;
LUSC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	cis	rs3741151	1.000	rs61037777	chr11:73046663	A/G	cg17517138	chr11:73019481	ARHGEF17	0.91	8.52	0.42	5.7e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.03	0.4	1.69e-14	Parkinson's disease;
LUSC	cis	rs4776059	1.000	rs11070907	chr15:52924231	G/T	cg22715398	chr15:52968154	KIAA1370	-0.66	-9.48	-0.46	4.87e-19	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg05926928	chr17:57297772	GDPD1	1.22	14.88	0.63	9.18e-39	Opioid sensitivity;
LUSC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00149659	chr3:10157352	C3orf10	0.98	14.23	0.61	2.91e-36	Alzheimer's disease;
LUSC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg12927641	chr6:109611667	NA	-0.4	-6.92	-0.35	2.37e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg06521331	chr12:34319734	NA	-0.39	-5.83	-0.3	1.33e-8	Resting heart rate;
LUSC	cis	rs859767	0.741	rs6729090	chr2:135401878	G/A	cg12500956	chr2:135428796	TMEM163	-0.28	-6.31	-0.33	9.04e-10	Neuroticism;
LUSC	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21659725	chr3:3221576	CRBN	0.63	10.4	0.49	3.79e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.79	12.99	0.58	1.66e-31	Selective IgA deficiency;
LUSC	cis	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs7178572	0.568	rs12901739	chr15:77395491	C/T	cg22256960	chr15:77711686	NA	-0.5	-7.86	-0.4	5.17e-14	Type 2 diabetes;
LUSC	cis	rs9653442	0.564	rs11687586	chr2:100789346	A/G	cg07810366	chr2:100720526	AFF3	-0.43	-7.28	-0.37	2.43e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4285028	0.747	rs4048703	chr3:121374361	G/A	cg11130432	chr3:121712080	ILDR1	-0.57	-8.17	-0.41	6.35e-15	Multiple sclerosis;
LUSC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	0.64	13.66	0.6	4.76e-34	Prudent dietary pattern;
LUSC	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17467752	chr17:38218738	THRA	-0.52	-7.44	-0.38	8.46e-13	White blood cell count;
LUSC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13770153	chr20:60521292	NA	-0.64	-8.62	-0.43	2.74e-16	Body mass index;
LUSC	cis	rs6545883	0.929	rs2593626	chr2:61665184	C/A	cg15711740	chr2:61764176	XPO1	-0.46	-7.12	-0.36	6.47e-12	Tuberculosis;
LUSC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg15790184	chr11:494944	RNH1	0.5	7.43	0.38	9.4e-13	Systemic lupus erythematosus;
LUSC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05025164	chr4:1340916	KIAA1530	-0.65	-10.11	-0.48	3.82e-21	Obesity-related traits;
LUSC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg17968037	chr7:100024898	ZCWPW1	-0.44	-6.31	-0.33	8.82e-10	Platelet count;
LUSC	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.51	1.26e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.72	8.69	0.43	1.63e-16	Lung function (FEV1/FVC);
LUSC	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg01677386	chr11:118938358	VPS11	-0.49	-7.01	-0.36	1.29e-11	Coronary artery disease;
LUSC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.66	9.11	0.45	7.8e-18	High light scatter reticulocyte count;
LUSC	cis	rs727505	0.866	rs56216989	chr7:124729068	T/A	cg23710748	chr7:124431027	NA	-0.4	-6.96	-0.36	1.79e-11	Lewy body disease;
LUSC	cis	rs2694528	0.686	rs6864253	chr5:59862743	A/G	cg11474532	chr5:59995715	DEPDC1B	0.81	6.43	0.33	4.46e-10	Parkinson's disease;
LUSC	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.82	-14.07	-0.61	1.23e-35	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.97	0.44	2.22e-17	Motion sickness;
LUSC	cis	rs7809950	0.817	rs58052742	chr7:107210003	A/G	cg23024343	chr7:107201750	COG5	0.67	9.64	0.47	1.45e-19	Coronary artery disease;
LUSC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg23985595	chr17:80112537	CCDC57	0.31	5.88	0.31	9.82e-9	Life satisfaction;
LUSC	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg17788362	chr6:86352627	SYNCRIP	0.45	6.92	0.35	2.26e-11	Smooth-surface caries;
LUSC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.21	-0.37	3.84e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg24675056	chr1:15929824	NA	0.48	8.27	0.41	3.15e-15	Systolic blood pressure;
LUSC	cis	rs7759001	0.857	rs980961	chr6:27361019	A/G	cg18711553	chr6:27366782	ZNF391	0.39	5.69	0.3	2.77e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs2219968	0.828	rs28764193	chr8:78942561	T/G	cg00738934	chr8:78996279	NA	-0.4	-7.22	-0.37	3.56e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs259282	0.605	rs60968670	chr19:33108982	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	9.65	0.47	1.39e-19	Schizophrenia;
LUSC	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg21252483	chr19:49399788	TULP2	-0.48	-6.75	-0.35	6.68e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs77633900	0.614	rs2468113	chr15:76851421	G/C	cg21673338	chr15:77095150	SCAPER	-0.8	-7.32	-0.37	1.87e-12	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs56283067	0.578	rs10948233	chr6:45364096	A/T	cg20913747	chr6:44695427	NA	0.45	6.74	0.35	7.01e-11	Total body bone mineral density;
LUSC	cis	rs9925964	0.869	rs749670	chr16:31088625	A/G	cg02466173	chr16:30829666	NA	0.35	6.34	0.33	7.61e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg06064525	chr11:970664	AP2A2	-0.47	-10.41	-0.49	3.77e-22	Alzheimer's disease (late onset);
LUSC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.25	0.45	2.85e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.88	0.31	9.91e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg25110126	chr1:46999211	NA	0.73	9.98	0.48	1.09e-20	Monobrow;
LUSC	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.83	-14.0	-0.61	2.35e-35	Morning vs. evening chronotype;
LUSC	cis	rs1775715	0.870	rs1615256	chr10:32254101	T/C	cg26784012	chr10:32216390	ARHGAP12	0.4	6.45	0.33	3.85e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs11229555	0.645	rs34530191	chr11:58200854	A/G	cg15696309	chr11:58395628	NA	-0.67	-8.13	-0.41	8.64e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg08999081	chr20:33150536	PIGU	0.37	6.69	0.34	9.38e-11	Height;
LUSC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	8.97	0.44	2.23e-17	Bipolar disorder and schizophrenia;
LUSC	trans	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Depression;
LUSC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.64	0.47	1.43e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2729354	0.768	rs1001956	chr11:57266949	C/G	cg24343310	chr11:57249947	NA	0.43	8.14	0.41	7.72e-15	Blood protein levels;
LUSC	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg17691542	chr6:26056736	HIST1H1C	0.39	5.88	0.31	9.77e-9	Schizophrenia;
LUSC	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg21573476	chr21:45109991	RRP1B	-0.4	-6.41	-0.33	4.97e-10	Mean corpuscular volume;
LUSC	cis	rs1014246	0.778	rs12256473	chr10:118478448	G/A	cg14919929	chr10:118506882	NA	0.45	6.67	0.34	1.07e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg02030672	chr11:45687055	CHST1	-0.39	-6.06	-0.31	3.73e-9	Obesity-related traits;
LUSC	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg15744005	chr10:104629667	AS3MT	-0.28	-6.05	-0.31	3.84e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg07716408	chr11:68623521	NA	-0.33	-6.44	-0.33	4.23e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.38	-0.49	4.77e-22	Platelet count;
LUSC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.71	-11.09	-0.52	1.47e-24	Menarche (age at onset);
LUSC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11764359	chr7:65958608	NA	-0.68	-10.93	-0.51	5.47e-24	Aortic root size;
LUSC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg20744362	chr22:50050164	C22orf34	0.39	7.33	0.37	1.75e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.86	-0.44	4.78e-17	Response to antipsychotic treatment;
LUSC	cis	rs5167	0.677	rs2238682	chr19:45458593	C/T	cg25746394	chr19:45450501	APOC2	0.32	5.95	0.31	6.75e-9	Blood protein levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01797567	chr14:50087093	MGAT2;RPL36AL	-0.43	-6.08	-0.32	3.29e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.87	-0.4	5.04e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12681287	0.640	rs13258126	chr8:87453378	G/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	0.65	13.92	0.61	4.91e-35	Prudent dietary pattern;
LUSC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg01689657	chr7:91764605	CYP51A1	0.33	6.03	0.31	4.29e-9	Breast cancer;
LUSC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg07424592	chr7:64974309	NA	0.64	5.75	0.3	2e-8	Diabetic kidney disease;
LUSC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg02023728	chr11:77925099	USP35	0.52	7.26	0.37	2.76e-12	Testicular germ cell tumor;
LUSC	cis	rs11779988	0.545	rs409217	chr8:17816597	C/G	cg01800426	chr8:17659068	MTUS1	-0.5	-6.29	-0.33	9.96e-10	Breast cancer;
LUSC	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg17507749	chr15:85114479	UBE2QP1	0.53	6.54	0.34	2.25e-10	Schizophrenia;
LUSC	cis	rs6580649	0.941	rs4760683	chr12:48516296	T/C	cg24011408	chr12:48396354	COL2A1	-0.48	-6.45	-0.33	4.01e-10	Lung cancer;
LUSC	cis	rs2692947	0.763	rs7570074	chr2:96407037	T/C	cg22654517	chr2:96458247	NA	0.37	7.48	0.38	6.63e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg09323728	chr8:95962352	TP53INP1	-0.29	-5.69	-0.3	2.72e-8	Type 2 diabetes;
LUSC	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.45	-0.33	3.95e-10	Uric acid levels;
LUSC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.67e-12	Motion sickness;
LUSC	cis	rs7851660	0.809	rs3808893	chr9:100663745	C/T	cg13688889	chr9:100608707	NA	-0.54	-8.42	-0.42	1.11e-15	Strep throat;
LUSC	cis	rs6599077	0.950	rs11706046	chr3:40104137	T/C	cg13683864	chr3:40499215	RPL14	-0.61	-7.6	-0.38	3.09e-13	Sleep-related phenotypes;
LUSC	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg12292205	chr6:26970375	C6orf41	-0.51	-8.5	-0.42	6.34e-16	Schizophrenia;
LUSC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	0.92	13.96	0.61	3.32e-35	Breast cancer;
LUSC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg04398451	chr17:18023971	MYO15A	-0.49	-7.99	-0.4	2.29e-14	Total body bone mineral density;
LUSC	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg21770322	chr7:97807741	LMTK2	0.56	10.08	0.48	4.99e-21	Breast cancer;
LUSC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.68	10.12	0.48	3.58e-21	Migraine;Coronary artery disease;
LUSC	cis	rs11229555	0.874	rs11605683	chr11:58350794	T/A	cg15696309	chr11:58395628	NA	-0.71	-9.19	-0.45	4.43e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg05585544	chr11:47624801	NA	-0.42	-7.31	-0.37	2.04e-12	Subjective well-being;
LUSC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.48	-8.01	-0.4	1.98e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs17401966	0.522	rs946504	chr1:10308597	T/C	cg19773385	chr1:10388646	KIF1B	-0.37	-6.46	-0.33	3.77e-10	Hepatocellular carcinoma;
LUSC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg07507251	chr3:52567010	NT5DC2	0.31	6.2	0.32	1.7e-9	Bipolar disorder;
LUSC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg11752832	chr7:134001865	SLC35B4	0.55	8.66	0.43	2.09e-16	Mean platelet volume;
LUSC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	22.52	0.78	5.83e-69	Height;
LUSC	cis	rs7582720	1.000	rs116382857	chr2:203751932	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg26384229	chr12:38710491	ALG10B	0.7	10.84	0.51	1.12e-23	Morning vs. evening chronotype;
LUSC	cis	rs6901250	0.851	rs7740481	chr6:117149307	G/C	cg12892004	chr6:117198278	RFX6	0.43	8.16	0.41	7.04e-15	C-reactive protein levels;
LUSC	cis	rs3092073	0.819	rs3848715	chr20:44564682	G/A	cg27529037	chr20:44575021	PCIF1	-0.34	-5.77	-0.3	1.8e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg05313129	chr8:58192883	C8orf71	-0.51	-6.52	-0.34	2.59e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.46e-10	Subjective well-being;
LUSC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.19	0.37	4.41e-12	Hip circumference adjusted for BMI;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05377162	chr1:185286996	IVNS1ABP	-0.44	-5.97	-0.31	6.14e-9	Hepatitis;
LUSC	cis	rs62458065	0.850	rs7804998	chr7:32461197	T/C	cg20159608	chr7:32802032	NA	-0.64	-7.57	-0.38	3.72e-13	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08258788	chr8:109455865	TTC35	0.48	7.17	0.37	4.71e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs67539049	1.000	rs55764254	chr8:11294184	A/G	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.4	-6.13	-0.32	2.51e-9	Itch intensity from mosquito bite;
LUSC	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.45	-0.38	7.98e-13	Retinal vascular caliber;
LUSC	trans	rs7178375	0.678	rs34678577	chr15:31177465	A/C	cg04373760	chr16:53404718	NA	0.62	8.15	0.41	7.19e-15	Hypertriglyceridemia;
LUSC	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.35e-33	Morning vs. evening chronotype;
LUSC	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg22532475	chr10:104410764	TRIM8	-0.35	-7.76	-0.39	1.01e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10276381	1.000	rs10260837	chr7:28181129	C/T	cg23620719	chr7:28220237	JAZF1	0.57	6.23	0.32	1.44e-9	Crohn's disease;
LUSC	trans	rs9944715	0.954	rs9807157	chr18:43817755	T/C	cg01718231	chr17:29326311	RNF135	-0.54	-7.71	-0.39	1.45e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs6736093	1.000	rs10496439	chr2:112664631	C/G	cg12686935	chr2:112915763	FBLN7	-0.36	-5.8	-0.3	1.56e-8	Coronary artery disease;
LUSC	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg03465714	chr1:152285911	FLG	-0.41	-5.78	-0.3	1.71e-8	Atopic dermatitis;
LUSC	cis	rs1950626	0.833	rs12897114	chr14:101395140	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.29	0.37	2.2e-12	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-0.86	-15.86	-0.66	1.32e-42	Height;
LUSC	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg18105134	chr13:113819100	PROZ	0.61	8.8	0.43	7.6e-17	Platelet distribution width;
LUSC	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg17366294	chr4:99064904	C4orf37	0.54	9.49	0.46	4.38e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg24449463	chr1:168025552	DCAF6	-0.64	-9.52	-0.46	3.62e-19	Schizophrenia;
LUSC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13732083	chr21:47605072	C21orf56	-0.45	-6.7	-0.34	8.72e-11	Testicular germ cell tumor;
LUSC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg16647868	chr5:131706066	SLC22A5	0.35	5.87	0.31	1.03e-8	Blood metabolite levels;
LUSC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg00343986	chr7:65444356	GUSB	0.48	7.27	0.37	2.51e-12	Aortic root size;
LUSC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.96	0.61	3.28e-35	Cognitive test performance;
LUSC	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg23093090	chr10:104574429	C10orf26	-0.43	-7.79	-0.39	8.73e-14	Arsenic metabolism;
LUSC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15320075	chr8:145703422	NA	-0.66	-11.35	-0.53	1.8e-25	Age at first birth;
LUSC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.67	-9.12	-0.45	7.28e-18	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.63	8.18	0.41	5.85e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-11.86	-0.54	2.5e-27	Exhaled nitric oxide output;
LUSC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg07507251	chr3:52567010	NT5DC2	0.33	6.53	0.34	2.5e-10	Bipolar disorder;
LUSC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.04	0.36	1.12e-11	Bipolar disorder;
LUSC	cis	rs2463822	0.669	rs72919475	chr11:62042361	T/A	cg06239285	chr11:62104954	ASRGL1	-0.65	-6.65	-0.34	1.19e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg04455712	chr21:45112962	RRP1B	0.44	8.39	0.42	1.42e-15	Mean corpuscular volume;
LUSC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg06641503	chr3:48959341	ARIH2	-0.39	-5.88	-0.31	9.73e-9	Parkinson's disease;
LUSC	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg23387468	chr7:139079360	LUC7L2	-0.42	-6.32	-0.33	8.29e-10	Diisocyanate-induced asthma;
LUSC	trans	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.65	0.39	2.18e-13	Ulcerative colitis;
LUSC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg26395211	chr5:140044315	WDR55	-0.37	-5.78	-0.3	1.74e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg24642439	chr20:33292090	TP53INP2	-0.51	-7.77	-0.39	1.01e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	0.94	8.24	0.41	3.94e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2857891	0.817	rs2638102	chr11:6968610	T/C	cg14883916	chr11:6947541	ZNF215	0.45	5.87	0.31	1.03e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg13393036	chr8:95962371	TP53INP1	-0.44	-9.42	-0.46	7.64e-19	Type 2 diabetes;
LUSC	cis	rs12042938	0.507	rs1765776	chr1:231731607	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-11.92	-0.55	1.54e-27	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs9399401	0.667	rs6912639	chr6:142770548	T/C	cg03128060	chr6:142623767	GPR126	0.53	9.12	0.45	6.95e-18	Chronic obstructive pulmonary disease;
LUSC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg14440974	chr22:39074834	NA	-0.36	-5.96	-0.31	6.56e-9	Menopause (age at onset);
LUSC	cis	rs7011049	1.000	rs11985185	chr8:53834494	T/C	cg26025543	chr8:53854495	NA	0.51	6.3	0.33	9.53e-10	Systolic blood pressure;
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.72	-14.73	-0.63	3.3e-38	Longevity;Endometriosis;
LUSC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg25025879	chr12:53359317	NA	-0.55	-8.18	-0.41	5.96e-15	Cancer (pleiotropy);
LUSC	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg06627628	chr2:24431161	ITSN2	-0.6	-7.16	-0.36	5.19e-12	Lymphocyte counts;
LUSC	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.3	-6.2	-0.32	1.7e-9	Dupuytren's disease;
LUSC	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg15704280	chr7:45808275	SEPT13	-0.87	-14.83	-0.63	1.35e-38	Height;
LUSC	cis	rs78366141	0.536	rs78517451	chr4:89650437	C/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.95	7.09	0.36	7.79e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	6.25	0.32	1.23e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-0.87	-17.7	-0.7	6.24e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg05738196	chr6:26577821	NA	0.82	15.43	0.65	6.47e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs710216	0.763	rs12029931	chr1:43456880	C/T	cg03128534	chr1:43423976	SLC2A1	0.46	6.47	0.33	3.53e-10	Red cell distribution width;
LUSC	cis	rs929596	0.517	rs3806592	chr2:234625936	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-8.82	-0.43	6.26e-17	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.05	-0.36	1.06e-11	Blood metabolite levels;
LUSC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.95	-0.31	6.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3960554	0.808	rs112372188	chr7:75723376	G/A	cg17325771	chr7:75508891	RHBDD2	-0.41	-5.71	-0.3	2.49e-8	Eotaxin levels;
LUSC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg06618935	chr21:46677482	NA	-0.42	-8.33	-0.41	2.07e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs57046232	0.552	rs2009127	chr20:6341680	C/T	cg17788362	chr6:86352627	SYNCRIP	0.43	6.09	0.32	3.05e-9	Colorectal cancer;
LUSC	cis	rs4654899	1.000	rs7535895	chr1:21439239	T/A	cg01072550	chr1:21505969	NA	-0.53	-8.1	-0.41	1.06e-14	Superior frontal gyrus grey matter volume;
LUSC	trans	rs979233	0.502	rs10053179	chr5:42109207	A/G	cg07010552	chr17:7358735	CHRNB1	-0.41	-6.01	-0.31	4.86e-9	Systemic lupus erythematosus;
LUSC	cis	rs7818345	0.967	rs13258090	chr8:19285726	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.37	-7.05	-0.36	1.01e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	trans	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg21775007	chr8:11205619	TDH	-0.42	-6.36	-0.33	6.56e-10	Mood instability;
LUSC	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.88	-0.4	4.78e-14	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9815354	0.767	rs73077375	chr3:41853058	C/T	cg03022575	chr3:42003672	ULK4	0.85	8.74	0.43	1.19e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	5.82	0.3	1.35e-8	Rheumatoid arthritis;
LUSC	cis	rs9311676	0.632	rs62258078	chr3:58363432	G/A	cg26110898	chr3:58419937	PDHB	0.42	6.76	0.35	6.24e-11	Systemic lupus erythematosus;
LUSC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06481639	chr22:41940642	POLR3H	-0.52	-6.33	-0.33	7.88e-10	Vitiligo;
LUSC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-10.89	-0.51	8.03e-24	Bipolar disorder;
LUSC	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg20003494	chr4:90757398	SNCA	-0.33	-5.7	-0.3	2.6e-8	Dementia with Lewy bodies;
LUSC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg10792982	chr14:105748885	BRF1	-0.47	-8.49	-0.42	7.01e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.13	17.23	0.69	4.9e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg13575925	chr12:9217583	LOC144571	0.35	6.42	0.33	4.65e-10	Sjögren's syndrome;
LUSC	cis	rs9937943	0.667	rs35126294	chr16:74651005	T/C	cg01733217	chr16:74700730	RFWD3	0.65	7.16	0.36	5.23e-12	Neutrophil percentage of white cells;
LUSC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.05	0.44	1.21e-17	Motion sickness;
LUSC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg05896524	chr21:47604654	C21orf56	-0.57	-8.9	-0.44	3.65e-17	Testicular germ cell tumor;
LUSC	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg06092702	chr1:163392909	NA	0.36	6.14	0.32	2.35e-9	Motion sickness;
LUSC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg05855489	chr10:104503620	C10orf26	0.62	8.22	0.41	4.66e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg02175503	chr12:58329896	NA	-0.46	-6.57	-0.34	1.88e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs12681288	0.576	rs7002793	chr8:963467	T/C	cg04851639	chr8:1020857	NA	-0.39	-7.66	-0.39	2.01e-13	Schizophrenia;
LUSC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06544989	chr22:39130855	UNC84B	0.34	5.91	0.31	8.34e-9	Menopause (age at onset);
LUSC	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg15556689	chr8:8085844	FLJ10661	0.57	9.33	0.45	1.5e-18	Mood instability;
LUSC	cis	rs7129556	0.539	rs1945747	chr11:77277387	A/T	cg12586386	chr11:77299805	AQP11	0.23	5.69	0.3	2.84e-8	Weight loss (gastric bypass surgery);
LUSC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg26513180	chr16:89883248	FANCA	0.9	16.77	0.68	3.15e-46	Vitiligo;
LUSC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg13683864	chr3:40499215	RPL14	0.93	15.78	0.65	2.7e-42	Renal cell carcinoma;
LUSC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	6.3	0.33	9.55e-10	Mean platelet volume;
LUSC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.6	-12.41	-0.56	2.39e-29	Age at first birth;
LUSC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18099408	chr3:52552593	STAB1	-0.41	-7.0	-0.36	1.41e-11	Bipolar disorder;
LUSC	trans	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg22153745	chr1:153894579	GATAD2B	-0.56	-8.32	-0.41	2.32e-15	Total cholesterol levels;
LUSC	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg16797656	chr11:68205561	LRP5	0.35	5.84	0.3	1.23e-8	Total body bone mineral density;
LUSC	trans	rs2018683	0.649	rs12536605	chr7:28970500	C/T	cg19402173	chr7:128379420	CALU	-0.47	-7.13	-0.36	6.22e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs9811920	0.515	rs792836	chr3:99476384	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.31	-5.85	-0.31	1.15e-8	Axial length;
LUSC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg06637938	chr14:75390232	RPS6KL1	0.5	7.67	0.39	1.92e-13	Height;
LUSC	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-0.79	-11.37	-0.53	1.55e-25	Vitiligo;
LUSC	cis	rs10986311	0.802	rs1330811	chr9:127117346	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.46	7.37	0.37	1.33e-12	Vitiligo;
LUSC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg27535305	chr1:53392650	SCP2	-0.43	-8.69	-0.43	1.62e-16	Monocyte count;
LUSC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07677032	chr17:61819896	STRADA	0.52	8.71	0.43	1.45e-16	Prudent dietary pattern;
LUSC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.14	0.36	5.8e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.11	16.38	0.67	1.12e-44	Gut microbiome composition (summer);
LUSC	cis	rs1113500	0.836	rs1539553	chr1:108589998	C/T	cg06207961	chr1:108661230	NA	-0.33	-6.09	-0.32	3.07e-9	Growth-regulated protein alpha levels;
LUSC	trans	rs1927790	0.643	rs927710	chr13:97004796	T/G	cg03198741	chr6:1003969	LOC285768	-0.41	-6.22	-0.32	1.5e-9	Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07111501	chr17:62207504	ERN1	-0.45	-6.71	-0.34	8.11e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3087591	0.887	rs2905875	chr17:29541339	A/T	cg24425628	chr17:29625626	OMG;NF1	0.59	8.5	0.42	6.53e-16	Hip circumference;
LUSC	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.94	0.51	5.25e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.89	0.4	4.37e-14	Iron status biomarkers;
LUSC	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg03585969	chr10:35415529	CREM	0.65	9.29	0.45	2.04e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg15501526	chr10:2543763	NA	-0.59	-9.54	-0.46	3.16e-19	Age-related hearing impairment;
LUSC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.71	13.28	0.59	1.29e-32	Height;
LUSC	cis	rs1506636	0.962	rs629474	chr7:123399684	C/T	cg03229431	chr7:123269106	ASB15	0.65	10.7	0.51	3.66e-23	Plateletcrit;Platelet count;
LUSC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg00129232	chr17:37814104	STARD3	-0.48	-7.09	-0.36	8.24e-12	Asthma;
LUSC	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg12758973	chr1:247694275	LOC148824;OR2C3	0.37	5.66	0.3	3.23e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg14440974	chr22:39074834	NA	-0.36	-5.92	-0.31	7.79e-9	Menopause (age at onset);
LUSC	cis	rs4423214	0.592	rs79634040	chr11:71230169	G/C	cg05163923	chr11:71159392	DHCR7	-0.68	-7.02	-0.36	1.22e-11	Vitamin D levels;
LUSC	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.6	-0.38	2.97e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs9815354	0.680	rs112310714	chr3:42024797	A/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg26384229	chr12:38710491	ALG10B	0.72	11.42	0.53	9.87e-26	Morning vs. evening chronotype;
LUSC	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg24450063	chr1:156163899	SLC25A44	1.03	8.59	0.43	3.31e-16	Paclitaxel disposition in epithelial ovarian cancer;
LUSC	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg22437258	chr11:111473054	SIK2	0.51	6.91	0.35	2.42e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg11502198	chr6:26597334	ABT1	0.59	9.3	0.45	1.85e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08219700	chr8:58056026	NA	0.72	7.76	0.39	1.04e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2979489	0.891	rs17626867	chr8:30311177	G/T	cg26383811	chr8:30366931	RBPMS	-0.48	-7.6	-0.38	3.05e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs308403	0.509	rs13117125	chr4:123670824	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.93	16.46	0.67	5.22e-45	Blood protein levels;
LUSC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.76	-0.47	5.88e-20	Platelet count;
LUSC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.8	0.39	8.21e-14	Parkinson's disease;
LUSC	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.57	-0.46	2.51e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg02527881	chr3:46936655	PTH1R	0.41	7.19	0.37	4.41e-12	Colorectal cancer;
LUSC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg07701084	chr6:150067640	NUP43	0.57	8.84	0.44	5.51e-17	Lung cancer;
LUSC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.81	0.3	1.42e-8	Menopause (age at onset);
LUSC	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg24375607	chr4:120327624	NA	0.72	11.47	0.53	6.89e-26	Corneal astigmatism;
LUSC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg06697600	chr4:7070879	GRPEL1	-0.36	-5.77	-0.3	1.85e-8	Monocyte percentage of white cells;
LUSC	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg03258749	chr1:151040405	MLLT11	-0.58	-7.42	-0.38	9.51e-13	Blood trace element (Cu levels);
LUSC	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.5	6.66	0.34	1.15e-10	Corneal astigmatism;
LUSC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg20243544	chr17:37824526	PNMT	0.48	6.87	0.35	3.24e-11	Asthma;
LUSC	cis	rs2573652	0.722	rs12914180	chr15:100544416	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.38	-6.77	-0.35	5.66e-11	Height;
LUSC	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg22467129	chr15:76604101	ETFA	-0.44	-7.03	-0.36	1.16e-11	Blood metabolite levels;
LUSC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.99	0.36	1.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg05535760	chr7:792225	HEATR2	-0.78	-7.77	-0.39	1e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg13319975	chr6:146136371	FBXO30	0.43	6.34	0.33	7.65e-10	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg13565492	chr6:43139072	SRF	-0.63	-6.63	-0.34	1.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.55	8.39	0.42	1.37e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg27124370	chr19:33622961	WDR88	0.5	6.31	0.33	9.08e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg22903657	chr4:1355424	KIAA1530	-0.35	-5.78	-0.3	1.76e-8	Obesity-related traits;
LUSC	cis	rs1981331	1.000	rs75843712	chr21:47976115	A/G	cg23283320	chr21:48055893	PRMT2	1.13	8.24	0.41	3.91e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg16230307	chr14:35515116	FAM177A1	0.68	8.18	0.41	5.81e-15	Psoriasis;
LUSC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg17464271	chr1:1447047	ATAD3A	0.53	5.99	0.31	5.51e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg05729581	chr11:3078854	CARS	0.39	5.74	0.3	2.11e-8	Calcium levels;
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	0.91	17.86	0.7	1.54e-50	Menarche (age at onset);
LUSC	cis	rs2274273	0.624	rs67386901	chr14:55757364	C/T	cg04306507	chr14:55594613	LGALS3	0.48	9.88	0.48	2.24e-20	Protein biomarker;
LUSC	cis	rs2346177	0.806	rs56048837	chr2:46656647	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.39	6.7	0.34	8.76e-11	HDL cholesterol;
LUSC	cis	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.74	-0.3	2.11e-8	Eotaxin levels;
LUSC	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.52e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08109568	chr15:31115862	NA	-0.58	-8.12	-0.41	9.22e-15	Huntington's disease progression;
LUSC	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.22	-0.32	1.45e-9	Response to antipsychotic treatment;
LUSC	cis	rs7188861	0.768	rs430966	chr16:11389482	C/T	cg00044050	chr16:11439710	C16orf75	0.57	6.18	0.32	1.87e-9	HDL cholesterol;
LUSC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg13685833	chr1:53393034	SCP2	-0.4	-6.02	-0.31	4.59e-9	Monocyte count;
LUSC	cis	rs2262909	0.962	rs422344	chr19:22230956	C/G	cg11619707	chr19:22235551	ZNF257	0.38	5.78	0.3	1.75e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs72960926	0.744	rs11752717	chr6:74954435	G/A	cg03266952	chr6:74778945	NA	-0.85	-7.14	-0.36	5.86e-12	Metabolite levels (MHPG);
LUSC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg14668632	chr7:2872130	GNA12	0.49	7.66	0.39	1.97e-13	Height;
LUSC	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.56	0.46	2.6e-19	Lung cancer in ever smokers;
LUSC	trans	rs975739	0.868	rs5351	chr13:78475313	C/T	cg24007552	chr7:39989862	CDK13	-0.39	-6.53	-0.34	2.41e-10	Hair color;
LUSC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.92	12.05	0.55	5.3e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.48	6.43	0.33	4.45e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-1.24	-13.61	-0.6	7.43e-34	Diabetic kidney disease;
LUSC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg06238570	chr21:40685208	BRWD1	-0.62	-10.39	-0.49	4.36e-22	Cognitive function;
LUSC	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg12927641	chr6:109611667	NA	-0.35	-5.87	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg19812747	chr11:111475976	SIK2	-0.51	-7.4	-0.38	1.1e-12	Primary sclerosing cholangitis;
LUSC	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg05347473	chr6:146136440	FBXO30	0.42	7.22	0.37	3.47e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg11568697	chr18:72916393	ZADH2	0.62	6.81	0.35	4.62e-11	Vascular endothelial growth factor levels;
LUSC	cis	rs3007168	1.000	rs3007168	chr14:51608293	G/A	cg23942311	chr14:51606299	NA	0.36	5.99	0.31	5.57e-9	Cancer;
LUSC	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg17517138	chr11:73019481	ARHGEF17	1.09	9.0	0.44	1.69e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg06784218	chr1:46089804	CCDC17	0.47	9.27	0.45	2.42e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg19682013	chr15:45996608	NA	0.38	5.75	0.3	2.03e-8	Waist circumference;Weight;
LUSC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg20891283	chr12:69753455	YEATS4	0.66	10.48	0.5	2.09e-22	Blood protein levels;
LUSC	cis	rs4595586	0.679	rs7312898	chr12:39346833	T/C	cg26384229	chr12:38710491	ALG10B	0.43	5.95	0.31	6.75e-9	Morning vs. evening chronotype;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21426974	chr4:140005758	ELF2	-0.38	-6.13	-0.32	2.52e-9	Electrocardiographic conduction measures;
LUSC	cis	rs193541	0.586	rs11241662	chr5:122181975	A/G	cg19077854	chr5:122220652	SNX24	-0.37	-8.05	-0.4	1.46e-14	Glucose homeostasis traits;
LUSC	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.6	9.35	0.46	1.28e-18	Heart rate;
LUSC	cis	rs7000551	0.751	rs2461490	chr8:22370115	G/C	cg12081754	chr8:22256438	SLC39A14	0.46	6.9	0.35	2.56e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg19622623	chr12:86230825	RASSF9	-0.44	-6.2	-0.32	1.64e-9	Major depressive disorder;
LUSC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.93	-0.4	3.36e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg24130564	chr14:104152367	KLC1	-0.53	-7.69	-0.39	1.71e-13	Body mass index;
LUSC	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg21890820	chr11:65308645	LTBP3	-0.6	-8.62	-0.43	2.72e-16	Bone mineral density;
LUSC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg13560548	chr3:10150139	C3orf24	0.51	7.2	0.37	4.08e-12	Alzheimer's disease;
LUSC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg22800045	chr5:56110881	MAP3K1	-0.42	-5.87	-0.31	1.06e-8	Coronary artery disease;
LUSC	cis	rs2637266	0.729	rs1099883	chr10:78516158	G/T	cg18941641	chr10:78392320	NA	0.4	7.23	0.37	3.3e-12	Pulmonary function;
LUSC	cis	rs62400317	0.859	rs10456548	chr6:45219699	T/C	cg18551225	chr6:44695536	NA	-0.45	-7.47	-0.38	7.03e-13	Total body bone mineral density;
LUSC	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg05110241	chr16:68378359	PRMT7	-0.73	-8.01	-0.4	1.95e-14	Magnesium levels;
LUSC	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg16339924	chr4:17578868	LAP3	0.55	8.15	0.41	7.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg05785598	chr3:49045655	WDR6	0.33	5.89	0.31	9.26e-9	Parkinson's disease;
LUSC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg20790798	chr5:1857306	NA	-0.49	-8.36	-0.42	1.66e-15	Cardiovascular disease risk factors;
LUSC	cis	rs56283067	0.740	rs111810959	chr6:44709460	C/A	cg18551225	chr6:44695536	NA	-0.49	-8.57	-0.42	3.95e-16	Total body bone mineral density;
LUSC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg17264618	chr3:40429014	ENTPD3	0.35	7.24	0.37	3.04e-12	Renal cell carcinoma;
LUSC	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg09594475	chr20:60884601	LAMA5	-0.43	-5.76	-0.3	1.96e-8	Colorectal cancer;
LUSC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.15	-0.32	2.27e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	trans	rs11165623	0.564	rs7525803	chr1:97000791	T/C	cg10631902	chr5:14652156	NA	-0.41	-6.06	-0.31	3.69e-9	Hip circumference;Waist circumference;
LUSC	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg07541023	chr7:19748670	TWISTNB	-0.65	-7.17	-0.37	4.77e-12	Thyroid stimulating hormone;
LUSC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg02574844	chr11:5959923	NA	-0.46	-6.42	-0.33	4.66e-10	DNA methylation (variation);
LUSC	cis	rs62458065	0.850	rs7785659	chr7:32461015	C/T	cg20159608	chr7:32802032	NA	-0.64	-7.57	-0.38	3.72e-13	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg22823121	chr1:150693482	HORMAD1	0.59	9.11	0.45	7.69e-18	Tonsillectomy;
LUSC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg17294928	chr15:75287854	SCAMP5	-0.83	-11.27	-0.52	3.6e-25	Blood trace element (Zn levels);
LUSC	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.51	-10.37	-0.49	5.03e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg13072238	chr3:49761600	GMPPB	0.7	8.8	0.43	7.46e-17	Menarche (age at onset);
LUSC	cis	rs4363385	0.747	rs2339491	chr1:152985322	T/C	cg25856811	chr1:152973957	SPRR3	-0.35	-5.87	-0.31	1.07e-8	Inflammatory skin disease;
LUSC	cis	rs427394	1.000	rs427394	chr5:6745875	A/G	cg25011763	chr5:6727354	POLS	-0.34	-5.87	-0.31	1.02e-8	Menopause (age at onset);
LUSC	cis	rs7804356	0.954	rs10227673	chr7:26865299	G/A	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.05e-9	Type 1 diabetes;
LUSC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg11941060	chr3:133502564	NA	-0.53	-8.19	-0.41	5.61e-15	Iron status biomarkers;
LUSC	cis	rs896543	0.702	rs6715324	chr2:237495510	C/T	cg25295825	chr2:237489920	CXCR7	0.51	6.31	0.33	9.02e-10	Alcohol dependence (age at onset);
LUSC	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14019695	chr9:139328340	INPP5E	-0.47	-9.12	-0.45	7.29e-18	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg03929089	chr4:120376271	NA	0.71	6.74	0.35	7.11e-11	Axial length;
LUSC	cis	rs7712401	0.691	rs62377436	chr5:122353702	C/G	cg19077854	chr5:122220652	SNX24	-0.4	-8.56	-0.42	4.22e-16	Mean platelet volume;
LUSC	cis	rs12190007	0.547	rs3006181	chr6:169809117	T/A	cg15038512	chr6:170123185	PHF10	-0.38	-6.14	-0.32	2.34e-9	Obesity-related traits;
LUSC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03264133	chr6:25882463	NA	-0.52	-9.58	-0.46	2.38e-19	Blood metabolite levels;
LUSC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg05347473	chr6:146136440	FBXO30	0.48	7.99	0.4	2.23e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-6.77	-0.35	5.9e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs701145	0.585	rs357480	chr3:153891182	A/G	cg10247383	chr3:153839028	SGEF	-0.61	-5.74	-0.3	2.09e-8	Coronary artery disease;
LUSC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	14.09	0.61	1.05e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.23	0.32	1.4e-9	Total body bone mineral density;
LUSC	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg06197492	chr11:2016605	H19	0.42	6.97	0.36	1.68e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs6693567	0.545	rs2012751	chr1:150438266	T/C	cg15654264	chr1:150340011	RPRD2	0.44	7.11	0.36	7.28e-12	Migraine;
LUSC	cis	rs3771570	0.901	rs62190407	chr2:242405772	G/A	cg21155796	chr2:242212141	HDLBP	0.51	6.13	0.32	2.43e-9	Prostate cancer;
LUSC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15369054	chr17:80825471	TBCD	-0.42	-6.81	-0.35	4.42e-11	Breast cancer;
LUSC	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg17385448	chr1:15911702	AGMAT	0.37	6.29	0.33	9.81e-10	Systolic blood pressure;
LUSC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg16325326	chr1:53192061	ZYG11B	0.71	11.6	0.54	2.19e-26	Monocyte count;
LUSC	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.87	-0.35	3.1e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.8	12.86	0.58	5.1e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.68	-10.54	-0.5	1.25e-22	Colorectal cancer;
LUSC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg25258033	chr6:167368657	RNASET2	0.45	7.1	0.36	7.58e-12	Crohn's disease;
LUSC	cis	rs354225	0.544	rs4616509	chr2:54807982	T/C	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10802521	chr3:52805072	NEK4	-0.47	-7.36	-0.37	1.43e-12	Bipolar disorder;
LUSC	trans	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.26	-0.32	1.15e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12999616	0.948	rs35958372	chr2:98330858	T/C	cg26665480	chr2:98280029	ACTR1B	0.65	6.91	0.35	2.44e-11	Colorectal cancer;
LUSC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg08847533	chr14:75593920	NEK9	-0.8	-13.57	-0.6	9.99e-34	Height;
LUSC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg10792982	chr14:105748885	BRF1	0.51	9.51	0.46	3.91e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs73198271	1.000	rs55971558	chr8:8614403	G/T	cg01851573	chr8:8652454	MFHAS1	0.59	8.55	0.42	4.37e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	0.98	10.97	0.51	4.05e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs16910800	0.689	rs4491218	chr11:23163977	G/A	cg20040320	chr11:23191996	NA	-0.61	-7.64	-0.39	2.32e-13	Cancer;
LUSC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg26380479	chr7:97908229	NA	-0.28	-6.27	-0.32	1.12e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34734847	0.750	rs3829290	chr12:121126438	T/C	cg21892295	chr12:121157589	UNC119B	-0.36	-6.31	-0.33	9.04e-10	Mean corpuscular volume;
LUSC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	0.6	9.42	0.46	7.55e-19	Breast cancer;
LUSC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg09517075	chr8:22133004	PIWIL2	0.43	8.54	0.42	4.77e-16	Hypertriglyceridemia;
LUSC	trans	rs16848425	1.000	rs58319662	chr4:73524244	A/G	cg15289899	chr11:2397255	CD81	0.67	5.95	0.31	6.78e-9	Height;
LUSC	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.31	-0.33	8.81e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg11632617	chr15:75315747	PPCDC	-0.52	-6.68	-0.34	9.84e-11	Blood trace element (Zn levels);
LUSC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg03188948	chr7:1209495	NA	0.59	6.9	0.35	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg17749961	chr2:30669863	LCLAT1	0.71	8.14	0.41	8.03e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg11062466	chr8:58055876	NA	0.55	7.36	0.37	1.41e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg18904891	chr8:8559673	CLDN23	0.6	8.13	0.41	8.64e-15	Obesity-related traits;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.58	9.66	0.47	1.29e-19	Lymphocyte counts;
LUSC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.09	16.29	0.67	2.45e-44	Gut microbiome composition (summer);
LUSC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg09796270	chr17:17721594	SREBF1	0.42	7.43	0.38	9.16e-13	Total body bone mineral density;
LUSC	cis	rs1003719	0.628	rs2252402	chr21:38520720	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.54	8.18	0.41	5.81e-15	Eye color traits;
LUSC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg23034840	chr1:205782522	SLC41A1	0.56	7.78	0.39	9.23e-14	Menarche (age at onset);
LUSC	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.83	0.54	3.25e-27	Ileal carcinoids;
LUSC	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg18681998	chr4:17616180	MED28	0.78	13.54	0.6	1.34e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg00945038	chr17:61921165	SMARCD2	0.54	9.3	0.45	1.95e-18	Prudent dietary pattern;
LUSC	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg23711669	chr6:146136114	FBXO30	0.87	16.23	0.66	4.29e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg16989719	chr2:238392110	NA	-0.41	-6.86	-0.35	3.42e-11	Prostate cancer;
LUSC	cis	rs6545883	0.931	rs11125885	chr2:61755728	G/C	cg15711740	chr2:61764176	XPO1	-0.5	-7.85	-0.39	5.9e-14	Tuberculosis;
LUSC	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11764359	chr7:65958608	NA	0.55	7.23	0.37	3.32e-12	Aortic root size;
LUSC	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg14664628	chr15:75095509	CSK	-0.55	-8.03	-0.4	1.66e-14	Breast cancer;
LUSC	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.11	25.95	0.82	4.49e-82	Schizophrenia;
LUSC	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.51	-0.34	2.68e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg10840412	chr1:235813424	GNG4	0.51	6.18	0.32	1.87e-9	Neuroticism;
LUSC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg13628971	chr7:2884303	GNA12	0.46	6.81	0.35	4.48e-11	Height;
LUSC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg17279839	chr7:150038598	RARRES2	0.42	6.51	0.34	2.71e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs17604090	0.938	rs10241566	chr7:29690179	T/C	cg19413766	chr7:29689036	LOC646762	-0.6	-7.26	-0.37	2.77e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs12410462	0.581	rs112572966	chr1:227553905	C/T	cg23173402	chr1:227635558	NA	0.54	6.37	0.33	6.19e-10	Major depressive disorder;
LUSC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06850241	chr22:41845214	NA	0.31	5.74	0.3	2.17e-8	Vitiligo;
LUSC	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.88	-16.31	-0.67	2.12e-44	Brugada syndrome;
LUSC	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.87	-17.07	-0.68	2.07e-47	Longevity;
LUSC	cis	rs1957429	0.808	rs6573581	chr14:65331955	G/A	cg23373153	chr14:65346875	NA	0.95	10.83	0.51	1.25e-23	Pediatric areal bone mineral density (radius);
LUSC	cis	rs9581857	0.547	rs1235848	chr13:28111559	G/T	cg22138327	chr13:27999177	GTF3A	-0.53	-6.09	-0.32	3.1e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.1	-0.32	2.86e-9	Resting heart rate;
LUSC	cis	rs977987	0.585	rs62059845	chr16:75430713	A/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.77	-0.35	5.88e-11	Dupuytren's disease;
LUSC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28785552	0.800	rs10853855	chr19:53232293	A/G	cg10871876	chr19:53194124	ZNF83	0.55	8.46	0.42	8.24e-16	Response to paliperidone in schizophrenia (PANSS score);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20930060	chr6:163835395	QKI	-0.42	-6.13	-0.32	2.45e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg22431228	chr1:16359049	CLCNKA	-0.47	-9.53	-0.46	3.27e-19	Dilated cardiomyopathy;
LUSC	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg21709803	chr11:61594965	FADS2	-0.39	-5.68	-0.3	2.89e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs4478037	0.643	rs9875798	chr3:33120448	G/C	cg19404215	chr3:33155277	CRTAP	0.99	9.67	0.47	1.17e-19	Major depressive disorder;
LUSC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	8.25	0.41	3.64e-15	Colorectal cancer;
LUSC	cis	rs1775715	0.737	rs2799000	chr10:32124894	C/T	cg03015672	chr10:32216066	ARHGAP12	0.33	5.84	0.3	1.22e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.49	7.69	0.39	1.71e-13	Colorectal cancer;
LUSC	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg04374321	chr14:90722782	PSMC1	-0.44	-6.54	-0.34	2.26e-10	Mortality in heart failure;
LUSC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg05084668	chr3:125655381	ALG1L	-0.5	-6.98	-0.36	1.58e-11	Blood pressure (smoking interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25739137	chr3:183851986	EIF2B5	-0.48	-6.01	-0.31	4.97e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17830980	chr10:43048298	ZNF37B	-0.47	-7.04	-0.36	1.07e-11	Breast cancer;
LUSC	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	0.97	15.32	0.64	1.75e-40	Dupuytren's disease;
LUSC	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-25.53	-0.81	1.79e-80	Exhaled nitric oxide output;
LUSC	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg00564555	chr16:1970112	NA	0.38	6.45	0.33	3.84e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg06454157	chr6:167490870	NA	-0.27	-6.65	-0.34	1.22e-10	Primary biliary cholangitis;
LUSC	cis	rs3733418	0.929	rs12507869	chr4:165895674	T/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.46	-6.13	-0.32	2.42e-9	Obesity-related traits;
LUSC	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg13072238	chr3:49761600	GMPPB	-0.4	-6.52	-0.34	2.6e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.82	-13.45	-0.59	2.98e-33	Schizophrenia;
LUSC	cis	rs965469	1.000	rs2236087	chr20:3255905	C/T	cg25506879	chr20:3388711	C20orf194	-0.54	-6.13	-0.32	2.44e-9	IFN-related cytopenia;
LUSC	cis	rs10823500	0.748	rs12355080	chr10:71963608	G/A	cg02100629	chr10:71892760	AIFM2	-0.38	-6.07	-0.32	3.45e-9	Blood protein levels;
LUSC	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg05805236	chr11:65401703	PCNXL3	-0.63	-10.33	-0.49	6.71e-22	Acne (severe);
LUSC	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.26	-0.59	1.54e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg11161011	chr14:65562177	MAX	-0.71	-10.82	-0.51	1.37e-23	Obesity-related traits;
LUSC	cis	rs11018904	0.636	rs61903695	chr11:89922417	A/G	cg26834418	chr11:89957033	CHORDC1	-0.46	-6.08	-0.32	3.36e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg24879335	chr3:133465180	TF	0.45	7.74	0.39	1.21e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.03	-0.31	4.36e-9	Neutrophil percentage of white cells;
LUSC	cis	rs6577655	0.517	rs62525562	chr8:135587076	C/T	cg17885191	chr8:135476712	NA	0.58	7.57	0.38	3.62e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg13775593	chr10:823151	NA	0.3	5.7	0.3	2.61e-8	Uric acid levels;
LUSC	trans	rs9401746	0.564	rs658429	chr6:124803536	C/T	cg16857858	chr7:27213984	HOXA10	-0.53	-5.99	-0.31	5.4e-9	Bone mineral density (Ward's triangle area);
LUSC	cis	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg06521331	chr12:34319734	NA	-0.48	-7.77	-0.39	9.54e-14	Morning vs. evening chronotype;
LUSC	cis	rs9815354	0.812	rs35263917	chr3:41952852	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.55e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg01884057	chr2:25150051	NA	0.48	10.99	0.52	3.41e-24	Body mass index;
LUSC	cis	rs790123	0.692	rs790129	chr3:122385170	C/T	cg00926285	chr3:122398533	PARP14	0.38	5.71	0.3	2.5e-8	Response to angiotensin II receptor blocker therapy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22585957	chr12:8234808	NECAP1	0.47	7.01	0.36	1.31e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg09658497	chr7:2847517	GNA12	-0.35	-6.17	-0.32	2e-9	Height;
LUSC	cis	rs9341835	0.772	rs9294197	chr6:64135648	A/G	cg03326410	chr6:64151739	NA	-0.37	-6.16	-0.32	2.09e-9	Schizophrenia;
LUSC	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.67	-0.43	1.84e-16	Uric acid levels;
LUSC	cis	rs6901250	0.851	rs339362	chr6:117165370	A/C	cg12892004	chr6:117198278	RFX6	-0.45	-8.52	-0.42	5.53e-16	C-reactive protein levels;
LUSC	cis	rs10392	0.543	rs4300896	chr20:37580130	A/C	cg27552599	chr20:37590471	DHX35	0.43	6.99	0.36	1.53e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs11779988	0.543	rs410445	chr8:17882304	C/T	cg01800426	chr8:17659068	MTUS1	-0.52	-6.41	-0.33	5.06e-10	Breast cancer;
LUSC	cis	rs7590368	0.926	rs12621237	chr2:10957538	T/C	cg15705551	chr2:10952987	PDIA6	0.53	7.38	0.37	1.25e-12	Educational attainment (years of education);
LUSC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg23791538	chr6:167370224	RNASET2	-0.37	-5.74	-0.3	2.1e-8	Crohn's disease;
LUSC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg21770322	chr7:97807741	LMTK2	0.42	7.35	0.37	1.52e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11997175	0.574	rs9642707	chr8:33645789	C/G	ch.8.33884649F	chr8:33765107	NA	0.52	8.52	0.42	5.73e-16	Body mass index;
LUSC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg22638593	chr5:131593259	PDLIM4	0.49	7.48	0.38	6.76e-13	Acylcarnitine levels;
LUSC	trans	rs4650994	0.524	rs2476558	chr1:178580953	C/T	cg05059571	chr16:84539110	KIAA1609	0.46	8.86	0.44	4.98e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg13010199	chr12:38710504	ALG10B	0.7	10.81	0.51	1.44e-23	Bladder cancer;
LUSC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-8.48	-0.42	7.45e-16	Longevity;Endometriosis;
LUSC	cis	rs28647808	0.881	rs7029256	chr9:136263655	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs79387448	0.745	rs72995652	chr2:103171651	C/A	cg09003973	chr2:102972529	NA	0.89	8.64	0.43	2.37e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg00579200	chr11:133705235	NA	-0.4	-6.02	-0.31	4.57e-9	Childhood ear infection;
LUSC	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg09693106	chr22:46449821	C22orf26;LOC150381	0.39	6.38	0.33	5.94e-10	Dupuytren's disease;Subjective well-being;
LUSC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.52	6.86	0.35	3.39e-11	Blood protein levels;
LUSC	cis	rs6845621	0.600	rs35850168	chr4:18913277	T/A	cg12196642	chr4:18937545	NA	-0.34	-6.3	-0.33	9.55e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg20887711	chr4:1340912	KIAA1530	0.44	6.64	0.34	1.28e-10	Obesity-related traits;
LUSC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.76	-0.43	1.02e-16	Lung cancer;
LUSC	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg08501292	chr6:25962987	TRIM38	0.62	5.72	0.3	2.36e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2637266	0.685	rs2395427	chr10:78462535	G/A	cg18941641	chr10:78392320	NA	0.34	5.8	0.3	1.51e-8	Pulmonary function;
LUSC	cis	rs10193935	0.901	rs222464	chr2:42643889	C/T	cg27598129	chr2:42591480	NA	-0.61	-8.21	-0.41	4.76e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg13206674	chr6:150067644	NUP43	0.63	10.28	0.49	1.02e-21	Lung cancer;
LUSC	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg13256891	chr4:100009986	ADH5	0.48	7.11	0.36	7.05e-12	Alcohol dependence;
LUSC	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg24375607	chr4:120327624	NA	0.79	11.69	0.54	1.03e-26	Corneal astigmatism;
LUSC	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg15557168	chr22:42548783	NA	-0.43	-7.27	-0.37	2.62e-12	Cognitive function;
LUSC	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-17.63	-0.69	1.17e-49	Primary sclerosing cholangitis;
LUSC	cis	rs4589502	1.000	rs12440279	chr15:67133339	G/A	cg09911534	chr15:67153556	NA	-0.69	-7.45	-0.38	7.98e-13	Lung cancer (smoking interaction);
LUSC	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg08807101	chr21:30365312	RNF160	-0.66	-10.28	-0.49	1.05e-21	Pancreatic cancer;
LUSC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg04518342	chr5:131593106	PDLIM4	0.4	7.13	0.36	6.38e-12	Breast cancer;
LUSC	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg19628046	chr18:33552617	C18orf21	-0.54	-6.5	-0.33	2.97e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg18232548	chr7:50535776	DDC	0.52	8.07	0.4	1.32e-14	Malaria;
LUSC	cis	rs6723226	0.961	rs13010404	chr2:32848854	T/G	cg02381751	chr2:32503542	YIPF4	-0.57	-8.44	-0.42	9.44e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1124376	1.000	rs9819628	chr3:20140837	A/G	cg05072819	chr3:20081367	KAT2B	-0.66	-7.68	-0.39	1.76e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs3741151	0.773	rs73544783	chr11:73221256	C/G	cg17517138	chr11:73019481	ARHGEF17	0.96	8.13	0.41	8.27e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	13.84	0.6	9.53e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg27535305	chr1:53392650	SCP2	-0.49	-9.6	-0.47	1.96e-19	Monocyte count;
LUSC	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg08847533	chr14:75593920	NEK9	-0.48	-6.99	-0.36	1.51e-11	IgG glycosylation;
LUSC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg20135002	chr11:47629003	NA	-0.52	-8.08	-0.4	1.17e-14	Subjective well-being;
LUSC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg18357645	chr12:58087776	OS9	0.55	8.29	0.41	2.87e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7106204	1.000	rs7931691	chr11:24221123	C/A	ch.11.24196551F	chr11:24239977	NA	0.99	9.97	0.48	1.12e-20	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs16918636	0.704	rs2356863	chr11:29127095	C/G	cg01414886	chr20:62551784	DNAJC5	-0.42	-5.99	-0.31	5.44e-9	Menarche (age at onset);
LUSC	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg03647239	chr10:116582469	FAM160B1	-0.42	-6.55	-0.34	2.12e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	0.98	15.66	0.65	7.7e-42	Dupuytren's disease;
LUSC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg24675658	chr1:53192096	ZYG11B	0.57	8.92	0.44	3.22e-17	Monocyte count;
LUSC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg23283495	chr1:209979779	IRF6	0.51	8.21	0.41	5.02e-15	Monobrow;
LUSC	cis	rs6120849	0.707	rs6088694	chr20:33652371	G/A	cg24642439	chr20:33292090	TP53INP2	0.58	6.5	0.34	2.87e-10	Protein C levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27649522	chr12:12877729	APOLD1	0.43	6.27	0.32	1.13e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg23711669	chr6:146136114	FBXO30	0.87	15.63	0.65	1.03e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg14462750	chr9:136913113	BRD3	0.37	5.68	0.3	2.92e-8	Platelet distribution width;
LUSC	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg18232548	chr7:50535776	DDC	0.55	7.48	0.38	6.45e-13	Malaria;
LUSC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg12560992	chr17:57184187	TRIM37	0.83	15.03	0.64	2.42e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18404041	chr3:52824283	ITIH1	0.52	10.01	0.48	8.37e-21	Electroencephalogram traits;
LUSC	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg04315214	chr1:2043799	PRKCZ	0.47	9.93	0.48	1.51e-20	Height;
LUSC	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.19	-0.32	1.8e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.63	10.04	0.48	6.9299999999999992e-21	Morning vs. evening chronotype;
LUSC	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg09904177	chr6:26538194	HMGN4	-0.65	-10.57	-0.5	1.01e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg10360323	chr17:41437877	NA	0.46	5.91	0.31	8.44e-9	Menopause (age at onset);
LUSC	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg10978503	chr1:24200527	CNR2	0.54	13.12	0.58	5.28e-32	Immature fraction of reticulocytes;
LUSC	cis	rs7572644	1.000	rs7572644	chr2:28320033	C/T	cg27432699	chr2:27873401	GPN1	-0.48	-5.83	-0.3	1.33e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs10979	1.000	rs9373394	chr6:143890776	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.71	0.34	8.22e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg13647721	chr17:30228624	UTP6	-0.68	-7.96	-0.4	2.8e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs28595532	0.748	rs66615663	chr4:119336701	C/T	cg21605333	chr4:119757512	SEC24D	0.95	7.97	0.4	2.59e-14	Cannabis dependence symptom count;
LUSC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08645402	chr16:4508243	NA	0.51	8.67	0.43	1.91e-16	Schizophrenia;
LUSC	trans	rs3960554	0.932	rs76873475	chr7:75829199	C/A	cg19862616	chr7:65841803	NCRNA00174	0.88	9.98	0.48	1.04e-20	Eotaxin levels;
LUSC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.54	-8.15	-0.41	7.27e-15	IgG glycosylation;
LUSC	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18854424	chr1:2615690	NA	-0.49	-9.67	-0.47	1.15e-19	Ulcerative colitis;
LUSC	cis	rs6460942	0.730	rs73053536	chr7:12323131	C/G	cg06484146	chr7:12443880	VWDE	-0.64	-5.83	-0.3	1.3e-8	Coronary artery disease;
LUSC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg12564285	chr5:131593104	PDLIM4	0.44	8.0	0.4	2.08e-14	Breast cancer;
LUSC	cis	rs7177699	0.581	rs7181432	chr15:79123779	C/T	cg15571903	chr15:79123663	NA	0.34	6.32	0.33	8.21e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg24829409	chr8:58192753	C8orf71	-0.45	-5.67	-0.3	3.05e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07362569	chr17:61921086	SMARCD2	0.37	7.67	0.39	1.92e-13	Prudent dietary pattern;
LUSC	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg16342193	chr10:102329863	NA	-0.32	-5.94	-0.31	7.16e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg21782813	chr7:2030301	MAD1L1	0.47	7.93	0.4	3.39e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg01657329	chr11:68192670	LRP5	-0.45	-7.18	-0.37	4.64e-12	Total body bone mineral density;
LUSC	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg23950597	chr19:37808831	NA	-0.62	-7.37	-0.37	1.31e-12	Coronary artery calcification;
LUSC	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg26597838	chr10:835615	NA	-0.47	-6.4	-0.33	5.37e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg25258033	chr6:167368657	RNASET2	0.38	5.82	0.3	1.42e-8	Primary biliary cholangitis;
LUSC	cis	rs472402	0.580	rs3736316	chr5:6656210	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.46	-6.68	-0.34	9.79e-11	Response to amphetamines;
LUSC	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.59	8.88	0.44	4.24e-17	Heart rate;
LUSC	cis	rs231513	0.954	rs11654245	chr17:41992650	T/C	cg26893861	chr17:41843967	DUSP3	0.55	5.82	0.3	1.36e-8	Cognitive function;
LUSC	cis	rs4737010	0.501	rs2032736	chr8:41639266	C/A	cg17182837	chr8:41585554	ANK1	0.4	6.87	0.35	3.23e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg13010199	chr12:38710504	ALG10B	0.57	8.64	0.43	2.29e-16	Bladder cancer;
LUSC	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg13010199	chr12:38710504	ALG10B	-0.58	-9.17	-0.45	4.85e-18	Bladder cancer;
LUSC	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg16240275	chr20:61666158	NCRNA00029	0.42	8.89	0.44	3.82e-17	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	8.43	0.42	1.05e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.11	-0.36	6.97e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs72634258	0.554	rs4908699	chr1:7905274	G/A	cg00042356	chr1:8021962	PARK7	0.52	5.67	0.3	3.1e-8	Inflammatory bowel disease;
LUSC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.58	0.34	1.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.78	0.47	5.13e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4664304	0.900	rs3828327	chr2:160742095	G/A	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.22	-0.32	1.46e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08280861	chr8:58055591	NA	0.54	6.3	0.33	9.15e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs72674100	1.000	rs2865776	chr4:97971736	C/T	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg09835421	chr16:68378352	PRMT7	-0.53	-6.11	-0.32	2.83e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9341808	0.718	rs9352803	chr6:80864667	G/T	cg08355045	chr6:80787529	NA	0.56	9.59	0.46	2.07e-19	Sitting height ratio;
LUSC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg09699651	chr6:150184138	LRP11	0.37	5.78	0.3	1.7e-8	Lung cancer;
LUSC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg05373962	chr22:49881684	NA	-0.44	-10.55	-0.5	1.24e-22	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg25072359	chr17:41440525	NA	0.59	8.37	0.42	1.62e-15	Menopause (age at onset);
LUSC	cis	rs10934753	0.632	rs13070856	chr3:125909415	A/G	cg01346077	chr3:125931526	NA	-0.47	-8.9	-0.44	3.52e-17	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg05717871	chr11:638507	DRD4	-0.35	-6.1	-0.32	3.01e-9	Systemic lupus erythematosus;
LUSC	cis	rs4285028	0.747	rs9808981	chr3:121429561	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-12.85	-0.58	5.58e-31	Multiple sclerosis;
LUSC	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.74	-13.21	-0.59	2.32e-32	Obesity-related traits;
LUSC	cis	rs1346	0.580	rs2298615	chr11:65352062	C/T	cg17120908	chr11:65337727	SSSCA1	-0.44	-6.3	-0.33	9.23e-10	Vertical cup-disc ratio;Optic cup area;
LUSC	cis	rs4363385	0.553	rs11580383	chr1:152942192	A/G	cg25856811	chr1:152973957	SPRR3	-0.35	-5.77	-0.3	1.77e-8	Inflammatory skin disease;
LUSC	cis	rs988712	0.622	rs2030323	chr11:27728539	A/C	cg10635145	chr11:27742435	BDNF	0.48	6.46	0.33	3.66e-10	Obesity;
LUSC	cis	rs3736594	0.513	rs62138964	chr2:27814438	C/T	cg27432699	chr2:27873401	GPN1	0.65	8.74	0.43	1.17e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg01191920	chr7:158217561	PTPRN2	-0.59	-12.05	-0.55	5.03e-28	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08243778	chr1:212458726	PPP2R5A	0.44	6.06	0.31	3.77e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg07621104	chr11:117668040	DSCAML1	0.49	6.41	0.33	4.91e-10	Myopia;
LUSC	cis	rs12425451	0.544	rs28623776	chr12:3147631	C/T	cg05389053	chr12:3131226	TEAD4	-0.44	-5.91	-0.31	8.45e-9	Narcolepsy with cataplexy;
LUSC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.18e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg11502198	chr6:26597334	ABT1	0.6	9.37	0.46	1.11e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs524023	0.874	rs7105665	chr11:64396568	T/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.37	-0.49	4.89e-22	Urate levels in obese individuals;
LUSC	cis	rs3862435	0.764	rs2589948	chr15:90952232	G/A	cg22089800	chr15:90895588	ZNF774	0.58	6.32	0.33	8.53e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.27	-0.37	2.57e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg16850897	chr7:100343110	ZAN	0.37	5.89	0.31	9.66e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs6998277	1.000	rs16869658	chr8:103633762	C/T	cg10187029	chr8:103597600	NA	0.62	7.75	0.39	1.14e-13	Migraine;
LUSC	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg03585969	chr10:35415529	CREM	0.6	9.01	0.44	1.64e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg05347473	chr6:146136440	FBXO30	0.55	9.23	0.45	3.28e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.21	-0.37	3.87e-12	Schizophrenia;
LUSC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg02187348	chr16:89574699	SPG7	0.51	7.52	0.38	4.97e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs9283706	0.623	rs10055631	chr5:66305438	A/C	cg11590213	chr5:66331682	MAST4	0.46	7.11	0.36	7.19e-12	Coronary artery disease;
LUSC	trans	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg07393940	chr7:158741817	NA	0.36	6.48	0.33	3.24e-10	Life satisfaction;
LUSC	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg06096015	chr1:231504339	EGLN1	0.55	9.62	0.47	1.75e-19	Hemoglobin concentration;
LUSC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg13047869	chr3:10149882	C3orf24	-0.59	-8.41	-0.42	1.21e-15	Alzheimer's disease;
LUSC	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg15423357	chr2:25149977	NA	0.38	7.46	0.38	7.58e-13	Body mass index in non-asthmatics;
LUSC	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-1.19	-12.9	-0.58	3.46e-31	Diabetic kidney disease;
LUSC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg08088566	chr11:430123	ANO9	0.59	6.84	0.35	3.72e-11	Body mass index;
LUSC	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	5.82	0.3	1.36e-8	Schizophrenia;
LUSC	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg02574844	chr11:5959923	NA	-0.44	-6.11	-0.32	2.72e-9	DNA methylation (variation);
LUSC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg06600287	chr1:53387719	ECHDC2	-0.28	-5.73	-0.3	2.26e-8	Monocyte count;
LUSC	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg25930673	chr12:123319894	HIP1R	-0.72	-7.24	-0.37	3.14e-12	Schizophrenia;
LUSC	cis	rs4363385	0.626	rs12062847	chr1:153062994	A/G	cg00922841	chr1:152955080	SPRR1A	-0.34	-5.88	-0.31	1e-8	Inflammatory skin disease;
LUSC	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.05	0.31	3.85e-9	Corneal astigmatism;
LUSC	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg23262073	chr20:60523788	NA	-0.41	-6.02	-0.31	4.7e-9	Body mass index;
LUSC	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg20811857	chr17:78079795	GAA	-0.32	-5.95	-0.31	6.82e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs6977660	0.941	rs6953957	chr7:19820560	A/G	cg07541023	chr7:19748670	TWISTNB	0.51	5.73	0.3	2.3e-8	Thyroid stimulating hormone;
LUSC	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.44	-5.85	-0.31	1.15e-8	Height;
LUSC	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-10.35	-0.49	5.81e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12928939	0.815	rs61753635	chr16:71660404	G/A	cg03805757	chr16:71968109	PKD1L3	-0.4	-5.72	-0.3	2.35e-8	Post bronchodilator FEV1;
LUSC	cis	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	trans	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg26384229	chr12:38710491	ALG10B	0.68	10.67	0.5	4.61e-23	Morning vs. evening chronotype;
LUSC	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.57	-8.19	-0.41	5.58e-15	Homoarginine levels;
LUSC	cis	rs2857891	0.817	rs1491829	chr11:6968941	T/A	cg14883916	chr11:6947541	ZNF215	0.44	5.86	0.31	1.11e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-8.43	-0.42	1.05e-15	Gut microbiome composition (summer);
LUSC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg04369109	chr6:150039330	LATS1	-0.5	-7.2	-0.37	4.14e-12	Lung cancer;
LUSC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg24642844	chr7:1081250	C7orf50	-0.8	-10.96	-0.51	4.5e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.82	0.39	7.02e-14	Prudent dietary pattern;
LUSC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg09655341	chr17:79618100	PDE6G	0.27	6.31	0.33	9.05e-10	Eye color traits;
LUSC	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg12927641	chr6:109611667	NA	-0.36	-6.12	-0.32	2.57e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.51	7.24	0.37	3.2e-12	Gut microbiome composition (summer);
LUSC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	6.72	0.35	7.81e-11	Coronary artery disease;
LUSC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.49	7.69	0.39	1.7e-13	Colorectal cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06745235	chr1:180471494	ACBD6	0.45	6.76	0.35	6.08e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg26924012	chr15:45694286	SPATA5L1	1.14	20.79	0.75	3.36e-62	Homoarginine levels;
LUSC	cis	rs2857891	0.650	rs2638087	chr11:6990516	C/T	cg04053776	chr11:6947353	ZNF215	0.43	6.15	0.32	2.27e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03264133	chr6:25882463	NA	0.38	6.29	0.33	9.97e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs829883	0.966	rs249853	chr12:98864908	A/C	cg25150519	chr12:98850993	NA	0.53	7.6	0.38	2.99e-13	Colorectal adenoma (advanced);
LUSC	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.86	-0.35	3.39e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg25815440	chr2:42134162	NA	-0.26	-6.02	-0.31	4.47e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg02023728	chr11:77925099	USP35	0.45	6.6	0.34	1.6e-10	Testicular germ cell tumor;
LUSC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.1	15.52	0.65	2.72e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs76878669	0.519	rs10791869	chr11:66117113	C/T	cg18002602	chr11:66138449	SLC29A2	-0.48	-8.44	-0.42	9.66e-16	Educational attainment (years of education);
LUSC	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-1.14	-18.05	-0.7	2.57e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg07061783	chr6:25882402	NA	-0.38	-5.94	-0.31	7.17e-9	Blood metabolite levels;
LUSC	cis	rs12681287	0.888	rs13042	chr8:87484913	G/A	cg27223183	chr8:87520930	FAM82B	-0.49	-6.83	-0.35	3.91e-11	Caudate activity during reward;
LUSC	cis	rs6580649	0.769	rs60629297	chr12:48438290	T/A	cg24011408	chr12:48396354	COL2A1	-0.47	-6.22	-0.32	1.47e-9	Lung cancer;
LUSC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg05855489	chr10:104503620	C10orf26	-0.63	-8.18	-0.41	5.81e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg01528321	chr10:82214614	TSPAN14	-0.87	-13.22	-0.59	2.19e-32	Post bronchodilator FEV1;
LUSC	cis	rs11971779	0.680	rs6947215	chr7:139026638	A/G	cg07862535	chr7:139043722	LUC7L2	0.52	7.17	0.37	4.75e-12	Diisocyanate-induced asthma;
LUSC	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg00012203	chr2:219082015	ARPC2	-0.57	-9.14	-0.45	6.3e-18	Ulcerative colitis;
LUSC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg20607798	chr8:58055168	NA	0.51	5.67	0.3	3.06e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg16989719	chr2:238392110	NA	-0.36	-5.9	-0.31	9.01e-9	Prostate cancer;
LUSC	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	5.78	0.3	1.72e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg01733217	chr16:74700730	RFWD3	0.97	22.15	0.77	1.61e-67	Multiple myeloma;
LUSC	cis	rs7520050	0.966	rs2275426	chr1:46487552	G/A	cg06784218	chr1:46089804	CCDC17	-0.29	-5.69	-0.3	2.83e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs9653442	0.593	rs4851273	chr2:100848321	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-6.72	-0.35	7.72e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9399401	0.922	rs9496369	chr6:142724918	C/T	cg03128060	chr6:142623767	GPR126	0.33	6.0	0.31	5.15e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg09307838	chr4:120376055	NA	0.75	10.89	0.51	7.5e-24	Corneal astigmatism;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg18538332	chr22:24372958	LOC391322	-0.46	-8.14	-0.41	8.15e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg00321850	chr1:175162397	KIAA0040	-0.38	-6.5	-0.33	2.98e-10	Alcohol dependence;
LUSC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	0.96	11.89	0.55	1.93e-27	Menarche (age at onset);
LUSC	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg13736514	chr6:26305472	NA	-0.49	-9.75	-0.47	6.16e-20	Educational attainment;
LUSC	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg18854424	chr1:2615690	NA	0.47	9.34	0.46	1.4e-18	Ulcerative colitis;
LUSC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-8.44	-0.42	1.01e-15	Hemoglobin concentration;
LUSC	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg16339924	chr4:17578868	LAP3	-0.44	-6.46	-0.33	3.69e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg14582100	chr15:45693742	SPATA5L1	0.57	10.28	0.49	1.04e-21	Homoarginine levels;
LUSC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg14895029	chr7:2775587	GNA12	-0.37	-5.79	-0.3	1.62e-8	Height;
LUSC	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg13789015	chr9:136890014	NCRNA00094	0.67	12.44	0.56	1.96e-29	Platelet distribution width;
LUSC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	29.12	0.85	1.14e-93	Chronic sinus infection;
LUSC	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-7.94	-0.4	3.11e-14	Bladder cancer;
LUSC	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg04362960	chr10:104952993	NT5C2	0.58	9.49	0.46	4.46e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg02508848	chr16:68573721	ZFP90	-0.43	-5.8	-0.3	1.52e-8	Ulcerative colitis;
LUSC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	9.62	0.47	1.7e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs4474465	0.831	rs10899510	chr11:78170841	G/A	cg27205649	chr11:78285834	NARS2	-0.49	-5.83	-0.3	1.3e-8	Alzheimer's disease (survival time);
LUSC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.03	0.55	6.29e-28	Motion sickness;
LUSC	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-10.27	-0.49	1.11e-21	Morning vs. evening chronotype;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg27384338	chr17:2031545	SMG6	-0.42	-6.98	-0.36	1.59e-11	N-glycan levels;
LUSC	cis	rs6723226	0.804	rs17428810	chr2:32736043	T/C	cg02381751	chr2:32503542	YIPF4	-0.67	-9.77	-0.47	5.3e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	6.48	0.33	3.37e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9309473	1.000	rs13428235	chr2:73633430	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-6.83	-0.35	3.95e-11	Metabolite levels;
LUSC	cis	rs6840360	0.642	rs2053566	chr4:152445831	A/C	cg20465933	chr4:152376761	FAM160A1	0.33	5.97	0.31	6.02e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg06238570	chr21:40685208	BRWD1	0.65	10.91	0.51	6.68e-24	Cognitive function;
LUSC	cis	rs9715521	0.775	rs62301198	chr4:59848776	C/T	cg11281224	chr4:60001000	NA	-0.46	-6.47	-0.33	3.55e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1858037	0.867	rs55945621	chr2:65615354	G/A	cg08085232	chr2:65598271	SPRED2	-0.42	-6.29	-0.33	9.78e-10	Rheumatoid arthritis;
LUSC	cis	rs7246967	0.673	rs8103430	chr19:22931498	A/G	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.04e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg23649088	chr2:200775458	C2orf69	-0.54	-6.94	-0.36	2e-11	Schizophrenia;
LUSC	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg12863693	chr15:85201151	NMB	0.43	8.74	0.43	1.12e-16	Schizophrenia;
LUSC	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg04310649	chr10:35416472	CREM	-0.41	-6.31	-0.33	8.89e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg01629716	chr15:45996671	NA	0.4	6.01	0.31	4.9e-9	Waist circumference;Weight;
LUSC	cis	rs4363385	0.747	rs1577965	chr1:152968294	T/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.8	-0.39	8.1e-14	Inflammatory skin disease;
LUSC	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg27432699	chr2:27873401	GPN1	0.81	15.35	0.64	1.26e-40	Oral cavity cancer;
LUSC	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.55	8.29	0.41	2.72e-15	Colorectal cancer;
LUSC	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg11608241	chr8:8085544	FLJ10661	0.38	5.67	0.3	3.04e-8	Parkinson's disease;
LUSC	cis	rs170557	0.573	rs2484034	chr1:210254787	A/G	cg21951975	chr1:209979733	IRF6	0.41	5.87	0.31	1.04e-8	Alopecia areata;
LUSC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.43	6.5	0.33	2.96e-10	Systemic lupus erythematosus;
LUSC	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg09184832	chr6:79620586	NA	-0.44	-7.04	-0.36	1.07e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg10523860	chr14:103875565	MARK3	0.4	6.47	0.33	3.44e-10	Body mass index;
LUSC	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.07e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg12826209	chr6:26865740	GUSBL1	0.55	8.07	0.4	1.26e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.54	0.5	1.27e-22	Colorectal cancer;
LUSC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg22823121	chr1:150693482	HORMAD1	0.61	9.49	0.46	4.64e-19	Tonsillectomy;
LUSC	cis	rs12190007	0.508	rs6605539	chr6:169731997	A/T	cg16388071	chr6:169726476	NA	0.38	6.18	0.32	1.87e-9	Obesity-related traits;
LUSC	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg09904177	chr6:26538194	HMGN4	-0.74	-6.66	-0.34	1.1e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg11502198	chr6:26597334	ABT1	0.71	11.9	0.55	1.84e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg19694781	chr19:47549865	TMEM160	-0.39	-6.2	-0.32	1.66e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg27129171	chr3:47204927	SETD2	-0.44	-6.43	-0.33	4.4e-10	Birth weight;
LUSC	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg10356904	chr22:49881777	NA	-0.29	-5.86	-0.31	1.12e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00631329	chr6:26305371	NA	-0.49	-9.57	-0.46	2.41e-19	Educational attainment;
LUSC	cis	rs981844	0.740	rs10024619	chr4:154684441	A/T	cg14289246	chr4:154710475	SFRP2	-0.52	-7.43	-0.38	9.38e-13	Response to statins (LDL cholesterol change);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19566272	chr6:139695824	CITED2	0.46	6.24	0.32	1.34e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2279817	1.000	rs35148872	chr1:18020184	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.49	-6.72	-0.35	7.82e-11	Neuroticism;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg09033563	chr22:24373618	LOC391322	-0.54	-7.78	-0.39	9.32e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg01884057	chr2:25150051	NA	0.42	9.02	0.44	1.46e-17	Body mass index;
LUSC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg17691542	chr6:26056736	HIST1H1C	0.79	9.74	0.47	6.83e-20	Iron status biomarkers;
LUSC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-8.92	-0.44	3.16e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7180079	1.000	rs62024567	chr15:64494826	T/A	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg12560992	chr17:57184187	TRIM37	0.62	9.93	0.48	1.62e-20	Testicular germ cell tumor;
LUSC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.64	-9.55	-0.46	2.81e-19	Hip circumference adjusted for BMI;
LUSC	trans	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg10756647	chr7:56101905	PSPH	0.87	8.46	0.42	8.27e-16	Diabetic kidney disease;
LUSC	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg08213375	chr14:104286397	PPP1R13B	0.52	10.17	0.49	2.35e-21	Schizophrenia;
LUSC	cis	rs977987	0.843	rs6564260	chr16:75447426	A/G	cg03315344	chr16:75512273	CHST6	0.48	8.92	0.44	3.16e-17	Dupuytren's disease;
LUSC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg20608306	chr11:116969690	SIK3	0.37	6.33	0.33	7.85e-10	Blood protein levels;
LUSC	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg25427524	chr10:38739819	LOC399744	-0.55	-7.23	-0.37	3.36e-12	Obesity (extreme);
LUSC	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg26566898	chr11:117069891	TAGLN	0.34	6.46	0.33	3.77e-10	Blood protein levels;
LUSC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg10621924	chr7:39171070	POU6F2	0.44	6.53	0.34	2.51e-10	IgG glycosylation;
LUSC	cis	rs11051970	0.704	rs2733694	chr12:32555230	A/G	cg24626660	chr12:32551988	NA	0.31	5.72	0.3	2.39e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.52	0.5	1.55e-22	Schizophrenia;
LUSC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01616529	chr11:638424	DRD4	-0.32	-5.65	-0.3	3.4e-8	Systemic lupus erythematosus;
LUSC	cis	rs6772849	0.930	rs7639400	chr3:128323356	T/C	cg16766828	chr3:128327626	NA	-0.31	-5.76	-0.3	1.89e-8	Monocyte percentage of white cells;Monocyte count;
LUSC	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.03e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.72	-0.47	8.09e-20	Total cholesterol levels;
LUSC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.34	0.37	1.61e-12	Motion sickness;
LUSC	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg11262906	chr1:85462892	MCOLN2	-0.7	-8.64	-0.43	2.28e-16	Serum sulfate level;
LUSC	trans	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg06636001	chr8:8085503	FLJ10661	0.46	6.38	0.33	5.76e-10	Monocyte count;
LUSC	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.18	-0.37	4.63e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg16339924	chr4:17578868	LAP3	0.55	8.37	0.42	1.57e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg12257692	chr3:49977190	RBM6	-0.25	-6.91	-0.35	2.48e-11	Body mass index;
LUSC	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg18209359	chr17:80159595	CCDC57	0.38	6.52	0.34	2.65e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.45	-6.05	-0.31	3.93e-9	Childhood ear infection;
LUSC	cis	rs9341835	0.740	rs9294198	chr6:64136993	T/C	cg00787780	chr6:64151745	NA	-0.33	-5.77	-0.3	1.82e-8	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07184439	chr14:50087799	RPL36AL;MGAT2	0.5	6.86	0.35	3.35e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg21211680	chr2:198530	NA	0.56	6.76	0.35	6.18e-11	Blood protein levels;
LUSC	trans	rs10882873	0.503	rs1253407	chr10:98969068	A/G	cg03566752	chr6:35512600	NA	-0.24	-5.97	-0.31	6.17e-9	Lymphocyte percentage of white cells;
LUSC	cis	rs6700896	0.931	rs4655584	chr1:66155515	T/G	cg04111102	chr1:66153794	NA	0.33	7.38	0.37	1.25e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg15605315	chr1:45957053	TESK2	0.51	8.49	0.42	6.93e-16	High light scatter reticulocyte count;
LUSC	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg24642439	chr20:33292090	TP53INP2	0.53	8.39	0.42	1.41e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs6736093	0.796	rs4848980	chr2:112816348	A/G	cg12686935	chr2:112915763	FBLN7	-0.4	-6.47	-0.33	3.47e-10	Coronary artery disease;
LUSC	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg27490568	chr2:178487706	NA	-0.41	-6.07	-0.32	3.45e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg09367891	chr1:107599246	PRMT6	-0.54	-8.46	-0.42	8.55e-16	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.38	7.62e-13	Bipolar disorder;
LUSC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg23791538	chr6:167370224	RNASET2	-0.43	-6.95	-0.36	1.93e-11	Crohn's disease;
LUSC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg12560992	chr17:57184187	TRIM37	0.83	15.25	0.64	3.12e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg23625390	chr15:77176239	SCAPER	-0.61	-9.39	-0.46	9.41e-19	Blood metabolite levels;
LUSC	cis	rs8114671	0.935	rs6142313	chr20:33780427	A/G	cg07148914	chr20:33460835	GGT7	-0.42	-6.32	-0.33	8.3e-10	Height;
LUSC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg19774624	chr17:42201019	HDAC5	-0.8	-13.44	-0.59	3.23e-33	Total body bone mineral density;
LUSC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg24562669	chr7:97807699	LMTK2	0.35	6.16	0.32	2.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-8.69	-0.43	1.64e-16	Menarche (age at onset);
LUSC	cis	rs7202877	0.610	rs3851735	chr16:75372092	A/G	cg03315344	chr16:75512273	CHST6	0.4	5.7	0.3	2.7e-8	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg13395646	chr4:1353034	KIAA1530	-0.59	-9.07	-0.44	1.08e-17	Obesity-related traits;
LUSC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg02931644	chr1:25747376	RHCE	0.37	6.8	0.35	4.83e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg07169764	chr2:136633963	MCM6	0.56	7.49	0.38	6.24e-13	Mosquito bite size;
LUSC	cis	rs6693567	0.565	rs7513182	chr1:150442612	A/G	cg15654264	chr1:150340011	RPRD2	-0.44	-7.07	-0.36	8.88e-12	Migraine;
LUSC	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	7.46	0.38	7.67e-13	Response to antipsychotic treatment;
LUSC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.52	-7.72	-0.39	1.35e-13	Lymphocyte counts;
LUSC	trans	rs2262909	0.962	rs56369285	chr19:22267185	T/C	cg17074339	chr11:11642133	GALNTL4	0.47	7.17	0.37	4.94e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg07061783	chr6:25882402	NA	-0.38	-5.86	-0.31	1.12e-8	Blood metabolite levels;
LUSC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg08975724	chr8:8085496	FLJ10661	0.43	6.09	0.32	3.06e-9	Systolic blood pressure;
LUSC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg13175981	chr1:150552382	MCL1	0.5	7.15	0.36	5.6e-12	Tonsillectomy;
LUSC	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.44	6.29	0.33	1.01e-9	Lung cancer;
LUSC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.4	0.62	6.35e-37	Platelet count;
LUSC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg21132104	chr15:45694354	SPATA5L1	0.57	7.96	0.4	2.63e-14	Homoarginine levels;
LUSC	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg13775593	chr10:823151	NA	0.3	5.7	0.3	2.61e-8	Uric acid levels;
LUSC	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg15133208	chr4:90757351	SNCA	0.55	8.14	0.41	8.08e-15	Neuroticism;
LUSC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg19592336	chr6:28129416	ZNF389	0.48	6.3	0.33	9.46e-10	Depression;
LUSC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.31	-0.45	1.71e-18	Platelet count;
LUSC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg12560992	chr17:57184187	TRIM37	0.83	15.26	0.64	2.95e-40	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00504756	chr16:74330795	PSMD7	-0.46	-5.97	-0.31	6.18e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg17691542	chr6:26056736	HIST1H1C	0.53	8.08	0.4	1.17e-14	Iron status biomarkers;
LUSC	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	6.96	0.36	1.81e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg07393940	chr7:158741817	NA	0.51	8.0	0.4	2.07e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.87	14.09	0.61	1.09e-35	Bladder cancer;
LUSC	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.4	0.42	1.28e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs17401966	0.522	rs10864450	chr1:10333959	G/T	cg17425144	chr1:10567563	PEX14	-0.33	-5.96	-0.31	6.31e-9	Hepatocellular carcinoma;
LUSC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg22823121	chr1:150693482	HORMAD1	0.61	9.33	0.45	1.48e-18	Urate levels;
LUSC	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg04362960	chr10:104952993	NT5C2	0.59	8.98	0.44	2.07e-17	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg26380479	chr7:97908229	NA	-0.27	-5.95	-0.31	6.69e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg17042849	chr6:26104293	HIST1H4C	-0.39	-5.74	-0.3	2.1e-8	Height;
LUSC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg11663144	chr21:46675770	NA	-0.4	-6.89	-0.35	2.74e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg17143192	chr8:8559678	CLDN23	0.59	8.54	0.42	4.85e-16	Obesity-related traits;
LUSC	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg14458575	chr2:238380390	NA	0.68	8.33	0.41	2.15e-15	Prostate cancer;
LUSC	cis	rs7215564	0.908	rs56078934	chr17:78658849	A/C	cg23238734	chr17:78661607	RPTOR	0.48	6.16	0.32	2.07e-9	Myopia (pathological);
LUSC	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg24579218	chr15:68104479	NA	-0.38	-6.68	-0.34	9.8e-11	Restless legs syndrome;
LUSC	trans	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg26043149	chr18:55253948	FECH	-0.52	-7.36	-0.37	1.43e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	10.83	0.51	1.25e-23	Homoarginine levels;
LUSC	cis	rs7119	0.717	rs12898656	chr15:77807995	C/T	cg27398640	chr15:77910606	LINGO1	0.28	5.87	0.31	1.03e-8	Type 2 diabetes;
LUSC	cis	rs4474465	0.850	rs10899551	chr11:78256998	A/C	cg27205649	chr11:78285834	NARS2	-0.48	-5.73	-0.3	2.2e-8	Alzheimer's disease (survival time);
LUSC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg22089800	chr15:90895588	ZNF774	0.6	9.35	0.46	1.28e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10053149	chr1:28908509	SNHG12;SNORA44;SNORA16A	0.39	6.0	0.31	5.06e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22496380	chr5:211416	CCDC127	-0.85	-8.89	-0.44	3.85e-17	Breast cancer;
LUSC	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg10518572	chr11:65560635	OVOL1	-0.25	-5.75	-0.3	1.97e-8	Acne (severe);
LUSC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg10729496	chr3:10149963	C3orf24	0.55	7.29	0.37	2.23e-12	Alzheimer's disease;
LUSC	cis	rs738322	0.775	rs4820324	chr22:38599857	G/C	cg25457927	chr22:38595422	NA	0.48	10.04	0.48	6.43e-21	Cutaneous nevi;
LUSC	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.78	-11.04	-0.52	2.35e-24	Corneal astigmatism;
LUSC	cis	rs7460090	0.620	rs13276221	chr8:57210878	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	7.34	0.37	1.63e-12	Height;
LUSC	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg23625390	chr15:77176239	SCAPER	0.51	8.04	0.4	1.57e-14	Blood metabolite levels;
LUSC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg07343612	chr16:622815	PIGQ	-0.44	-5.91	-0.31	8.26e-9	Height;
LUSC	cis	rs7572644	0.723	rs7578052	chr2:28318879	G/A	cg27432699	chr2:27873401	GPN1	0.45	5.94	0.31	7e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.81	12.04	0.55	5.49e-28	Corneal astigmatism;
LUSC	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	12.08	0.55	4.14e-28	Menarche (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11947801	chr19:49016810	LMTK3	-0.4	-5.97	-0.31	6.1e-9	Electrocardiographic conduction measures;
LUSC	cis	rs12474201	0.775	rs7584870	chr2:46973400	A/T	cg06386533	chr2:46925753	SOCS5	0.64	9.79	0.47	4.71e-20	Height;
LUSC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg00310523	chr12:86230176	RASSF9	0.51	9.63	0.47	1.52e-19	Major depressive disorder;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg20930514	chr14:77499758	NA	0.45	6.74	0.35	7.14e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg19318889	chr4:1322082	MAEA	0.47	7.67	0.39	1.88e-13	Obesity-related traits;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26169320	chr13:77901010	MYCBP2	-0.44	-6.02	-0.31	4.47e-9	Hepatitis;
LUSC	cis	rs67696533	0.957	rs293566	chr20:31097877	T/C	cg13636640	chr20:31349939	DNMT3B	0.41	5.98	0.31	5.67e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs7560272	0.501	rs11126417	chr2:73974315	A/G	cg20560298	chr2:73613845	ALMS1	-0.38	-5.67	-0.3	3.02e-8	Schizophrenia;
LUSC	cis	rs12541635	0.934	rs10955407	chr8:107020648	G/A	cg10147462	chr8:107024639	NA	0.55	9.92	0.48	1.71e-20	Age of smoking initiation;
LUSC	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg03732007	chr1:2071316	PRKCZ	-0.36	-6.07	-0.32	3.48e-9	Coronary artery disease;
LUSC	trans	rs4729127	1.000	rs9641132	chr7:94011381	G/T	cg20086523	chr13:52378287	DHRS12	0.55	6.43	0.33	4.48e-10	Intelligence;
LUSC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg22800045	chr5:56110881	MAP3K1	0.7	9.28	0.45	2.27e-18	Initial pursuit acceleration;
LUSC	cis	rs7267979	0.714	rs1555329	chr20:25231858	G/A	cg08601574	chr20:25228251	PYGB	0.48	7.44	0.38	8.75e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-1.19	-12.9	-0.58	3.46e-31	Diabetic kidney disease;
LUSC	cis	rs9807841	0.555	rs6511708	chr19:10788813	A/G	cg17710535	chr19:10819994	QTRT1	0.4	6.34	0.33	7.34e-10	Inflammatory skin disease;
LUSC	trans	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg07663200	chr17:42030104	NA	-0.37	-6.17	-0.32	1.99e-9	Post bronchodilator FEV1;
LUSC	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	7.32	0.37	1.83e-12	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg07061783	chr6:25882402	NA	-0.38	-5.94	-0.31	7.15e-9	Blood metabolite levels;
LUSC	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg27129171	chr3:47204927	SETD2	-0.69	-11.58	-0.54	2.66e-26	Colorectal cancer;
LUSC	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg20503657	chr10:835505	NA	0.78	9.74	0.47	6.96e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.23	-0.45	3.26e-18	Morning vs. evening chronotype;
LUSC	trans	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg25214090	chr10:38739885	LOC399744	-0.41	-6.2	-0.32	1.62e-9	Corneal astigmatism;
LUSC	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-6.96	-0.36	1.82e-11	Cystic fibrosis severity;
LUSC	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg24634471	chr8:143751801	JRK	0.51	7.23	0.37	3.35e-12	Schizophrenia;
LUSC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg02951883	chr7:2050386	MAD1L1	-0.59	-11.17	-0.52	8.06e-25	Bipolar disorder and schizophrenia;
LUSC	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	8.33	0.41	2.1e-15	Lung cancer in ever smokers;
LUSC	cis	rs7605827	0.866	rs13417550	chr2:15533895	A/G	cg19274914	chr2:15703543	NA	0.46	9.07	0.44	1.07e-17	Educational attainment (years of education);
LUSC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg01475377	chr6:109611718	NA	-0.41	-7.38	-0.37	1.3e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs2346177	1.000	rs12619985	chr2:46641627	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-9.27	-0.45	2.41e-18	HDL cholesterol;
LUSC	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg15309053	chr8:964076	NA	0.4	8.23	0.41	4.34e-15	Schizophrenia;
LUSC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg15691649	chr6:25882328	NA	-0.38	-6.19	-0.32	1.75e-9	Blood metabolite levels;
LUSC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs4654899	0.714	rs12401630	chr1:21495049	G/A	cg02927042	chr1:21476669	EIF4G3	-0.36	-5.65	-0.3	3.5e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6690583	0.623	rs111687161	chr1:85443533	A/G	cg11262906	chr1:85462892	MCOLN2	0.69	6.56	0.34	2.1e-10	Serum sulfate level;
LUSC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.88	-0.4	4.77e-14	Obesity-related traits;
LUSC	cis	rs4478858	0.735	rs4949393	chr1:31851875	G/A	cg00250761	chr1:31883323	NA	-0.35	-8.41	-0.42	1.17e-15	Alcohol dependence;
LUSC	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg05973401	chr12:123451056	ABCB9	0.52	6.58	0.34	1.85e-10	Neutrophil percentage of white cells;
LUSC	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.95	0.31	6.85e-9	Rheumatoid arthritis;
LUSC	cis	rs4363385	0.747	rs946099	chr1:152971618	A/G	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.83	-0.39	6.52e-14	Inflammatory skin disease;
LUSC	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.14	0.36	5.87e-12	IgG glycosylation;
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg06815965	chr1:205818668	PM20D1	0.39	6.09	0.32	3.16e-9	Menarche (age at onset);
LUSC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.54	0.34	2.28e-10	Bipolar disorder;
LUSC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg04756594	chr16:24857601	SLC5A11	0.46	6.64	0.34	1.25e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	5.9e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg04155231	chr12:9217510	LOC144571	0.31	5.7	0.3	2.67e-8	Sjögren's syndrome;
LUSC	trans	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg07211511	chr3:129823064	LOC729375	-1.0	-12.35	-0.56	3.95e-29	Blood pressure (smoking interaction);
LUSC	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg04865166	chr7:105162814	PUS7	0.51	5.84	0.3	1.25e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.42	5.96	0.31	6.45e-9	Corneal astigmatism;
LUSC	cis	rs6060960	0.537	rs6089103	chr20:30464919	G/T	cg06102403	chr20:30458708	TTLL9;DUSP15	0.43	5.88	0.31	1.02e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.74	0.39	1.22e-13	Mean platelet volume;
LUSC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.65	-11.16	-0.52	8.28e-25	Diastolic blood pressure;
LUSC	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg24154853	chr7:158122151	PTPRN2	0.44	8.52	0.42	5.45e-16	Calcium levels;
LUSC	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.9	0.48	2e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12210905	0.688	rs12212632	chr6:27472416	T/C	cg08851530	chr6:28072375	NA	0.95	6.15	0.32	2.21e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg16660971	chr17:78860029	RPTOR	0.37	6.01	0.31	4.88e-9	Major depressive disorder;
LUSC	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg23840854	chr1:161414152	NA	-0.92	-11.2	-0.52	6.13e-25	Rheumatoid arthritis;
LUSC	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg13010199	chr12:38710504	ALG10B	0.67	10.23	0.49	1.56e-21	Bladder cancer;
LUSC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.19	-0.32	1.76e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg26384229	chr12:38710491	ALG10B	0.56	9.07	0.44	1.05e-17	Morning vs. evening chronotype;
LUSC	cis	rs11039100	1.000	rs12366070	chr11:5828394	C/T	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg15691649	chr6:25882328	NA	0.5	7.52	0.38	5.12e-13	Blood metabolite levels;
LUSC	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	9.17	0.45	5.13e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg25251562	chr2:3704773	ALLC	-0.75	-12.42	-0.56	2.26e-29	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg20935933	chr6:143382018	AIG1	0.51	7.36	0.37	1.45e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg13798780	chr7:105162888	PUS7	-0.56	-6.08	-0.32	3.36e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg13397359	chr6:42928475	GNMT	0.58	9.56	0.46	2.58e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6828523	0.640	rs74589934	chr4:175868757	G/A	cg16870595	chr4:175839423	ADAM29	0.57	6.31	0.33	8.67e-10	Breast cancer;
LUSC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs611744	0.870	rs634216	chr8:109174803	A/G	cg18478394	chr8:109455254	TTC35	0.41	6.11	0.32	2.82e-9	Dupuytren's disease;
LUSC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg06028605	chr16:24865363	SLC5A11	0.46	8.1	0.41	1.02e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-1.25	-13.9	-0.61	5.41e-35	Diabetic kidney disease;
LUSC	cis	rs9473147	0.516	rs9381579	chr6:47556680	C/T	cg02130027	chr6:47444894	CD2AP	0.35	5.7	0.3	2.68e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.89	0.48	2.14e-20	Bipolar disorder;
LUSC	cis	rs4474465	0.850	rs7938816	chr11:78266227	T/C	cg27205649	chr11:78285834	NARS2	0.54	6.17	0.32	2.03e-9	Alzheimer's disease (survival time);
LUSC	cis	rs10823500	0.636	rs7082396	chr10:71945511	C/A	cg26699283	chr10:71892715	AIFM2	-0.4	-6.36	-0.33	6.64e-10	Blood protein levels;
LUSC	cis	rs72615157	0.539	rs2261360	chr7:99692993	G/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.48	6.61	0.34	1.48e-10	Lung function (FEV1/FVC);
LUSC	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.76	0.35	6.11e-11	Rheumatoid arthritis;
LUSC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg18230493	chr5:56204884	C5orf35	-0.65	-9.99	-0.48	1e-20	Coronary artery disease;
LUSC	trans	rs11696501	0.688	rs6073851	chr20:44306978	C/T	cg03272292	chr12:48577362	C12orf68	0.5	5.98	0.31	5.74e-9	Brain structure;
LUSC	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg03522245	chr20:25566470	NINL	0.35	5.67	0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7712401	0.755	rs6595407	chr5:122100398	C/T	cg19077854	chr5:122220652	SNX24	0.35	7.77	0.39	9.65e-14	Mean platelet volume;
LUSC	trans	rs7939886	0.920	rs59300271	chr11:55961792	G/A	cg15704280	chr7:45808275	SEPT13	0.89	6.81	0.35	4.56e-11	Myopia (pathological);
LUSC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	11.16	0.52	8.47e-25	Menopause (age at onset);
LUSC	cis	rs2835872	0.709	rs1709819	chr21:39036115	A/C	cg20424643	chr21:39039972	KCNJ6	-0.45	-7.56	-0.38	3.89e-13	Electroencephalographic traits in alcoholism;
LUSC	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg22732515	chr19:44031385	ETHE1	0.63	10.24	0.49	1.36e-21	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs10986311	0.832	rs9695388	chr9:127141727	C/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.38	-6.07	-0.31	3.57e-9	Vitiligo;
LUSC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg15691649	chr6:25882328	NA	-0.39	-6.34	-0.33	7.61e-10	Blood metabolite levels;
LUSC	cis	rs9311676	0.632	rs11714389	chr3:58447299	C/T	cg13750441	chr3:58318267	PXK	0.32	6.27	0.32	1.12e-9	Systemic lupus erythematosus;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24225259	chr2:219575488	TTLL4	-0.41	-6.09	-0.32	3.08e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg06636001	chr8:8085503	FLJ10661	0.62	9.23	0.45	3.23e-18	Mood instability;
LUSC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg04362960	chr10:104952993	NT5C2	0.59	9.39	0.46	1e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg23978390	chr7:1156363	C7orf50	0.49	6.07	0.32	3.51e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg03340356	chr1:67600835	NA	0.4	6.38	0.33	5.74e-10	Psoriasis;
LUSC	cis	rs7149337	0.804	rs4131981	chr14:51667504	A/T	cg23942311	chr14:51606299	NA	-0.45	-9.89	-0.48	2.09e-20	Cancer;
LUSC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg16060761	chr17:80687452	NA	-0.52	-8.07	-0.4	1.27e-14	Glycated hemoglobin levels;
LUSC	cis	rs7072216	0.727	rs942807	chr10:100168219	G/A	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.82	-0.43	6.31e-17	Metabolite levels;
LUSC	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg17366294	chr4:99064904	C4orf37	0.56	8.94	0.44	2.61e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	10.88	0.51	8.49e-24	Lymphocyte counts;
LUSC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg04546413	chr19:29218101	NA	0.7	11.81	0.54	3.88e-27	Methadone dose in opioid dependence;
LUSC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg02782426	chr3:40428986	ENTPD3	0.39	6.99	0.36	1.49e-11	Renal cell carcinoma;
LUSC	cis	rs911555	0.655	rs10149470	chr14:104017953	A/G	cg12935359	chr14:103987150	CKB	-0.54	-9.07	-0.44	1.01e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7674212	0.539	rs2866635	chr4:104121576	G/A	cg16532752	chr4:104119610	CENPE	-0.47	-6.8	-0.35	4.81e-11	Type 2 diabetes;
LUSC	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.53	10.53	0.5	1.36e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.9	-0.31	8.72e-9	Retinal vascular caliber;
LUSC	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.61	-11.28	-0.53	3.24e-25	Longevity;Endometriosis;
LUSC	cis	rs3099143	1.000	rs1398241	chr15:77153386	C/T	cg21673338	chr15:77095150	SCAPER	-0.8	-7.55	-0.38	4.27e-13	Recalcitrant atopic dermatitis;
LUSC	trans	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg05926928	chr17:57297772	GDPD1	-0.88	-10.12	-0.48	3.55e-21	Opioid sensitivity;
LUSC	trans	rs1493916	0.837	rs4992177	chr18:31407020	C/T	cg27147174	chr7:100797783	AP1S1	-0.55	-8.73	-0.43	1.21e-16	Life satisfaction;
LUSC	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg12826209	chr6:26865740	GUSBL1	0.68	7.67	0.39	1.85e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.42	-6.17	-0.32	1.93e-9	Systemic lupus erythematosus;
LUSC	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg21775007	chr8:11205619	TDH	-0.67	-10.41	-0.5	3.53e-22	Retinal vascular caliber;
LUSC	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21294209	chr1:46713444	RAD54L	-0.42	-6.15	-0.32	2.23e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg13206674	chr6:150067644	NUP43	0.5	7.5	0.38	5.68e-13	Lung cancer;
LUSC	cis	rs9811920	0.535	rs704577	chr3:99487375	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.3	-5.76	-0.3	1.87e-8	Axial length;
LUSC	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg08017756	chr2:100939284	LONRF2	0.43	8.01	0.4	1.87e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.78	-0.3	1.71e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-7.14	-0.36	5.97e-12	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg03146154	chr1:46216737	IPP	0.5	7.66	0.39	2.08e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg08213375	chr14:104286397	PPP1R13B	0.43	7.51	0.38	5.47e-13	Reticulocyte count;
LUSC	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23158103	chr7:148848205	ZNF398	-0.46	-7.4	-0.38	1.12e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg00316803	chr15:76480434	C15orf27	-0.39	-6.68	-0.34	9.79e-11	Blood metabolite levels;
LUSC	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg02176678	chr2:219576539	TTLL4	0.59	10.77	0.51	2.08e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.55	-10.18	-0.49	2.26e-21	Homoarginine levels;
LUSC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg26380479	chr7:97908229	NA	-0.27	-5.93	-0.31	7.44e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08859206	chr1:53392774	SCP2	0.55	9.75	0.47	6.49e-20	Monocyte count;
LUSC	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg03342759	chr3:160939853	NMD3	-0.49	-8.16	-0.41	6.68e-15	Morning vs. evening chronotype;
LUSC	cis	rs1160297	0.576	rs6746666	chr2:53089346	C/T	cg07782112	chr2:53107842	NA	0.37	6.32	0.33	8.21e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.6e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg06917634	chr15:78832804	PSMA4	-0.59	-7.08	-0.36	8.37e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	13.77	0.6	1.75e-34	Exhaled nitric oxide levels;
LUSC	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg05855489	chr10:104503620	C10orf26	-0.65	-8.42	-0.42	1.1e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg15309053	chr8:964076	NA	0.42	8.68	0.43	1.73e-16	Schizophrenia;
LUSC	cis	rs9341808	0.519	rs59232999	chr6:81018783	T/C	cg08355045	chr6:80787529	NA	-0.42	-7.18	-0.37	4.55e-12	Sitting height ratio;
LUSC	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg12935359	chr14:103987150	CKB	-0.65	-10.61	-0.5	7.5e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6987853	0.749	rs2974367	chr8:42431194	G/C	cg09913449	chr8:42400586	C8orf40	0.5	8.39	0.42	1.41e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg18827107	chr12:86230957	RASSF9	-0.48	-7.13	-0.36	6.17e-12	Major depressive disorder;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23429847	chr5:128430259	ISOC1	-0.41	-5.96	-0.31	6.53e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg13390004	chr1:15929781	NA	0.4	6.74	0.35	7.14e-11	Systolic blood pressure;
LUSC	trans	rs2164273	0.565	rs2736387	chr8:11157371	A/C	cg06636001	chr8:8085503	FLJ10661	0.46	6.89	0.35	2.71e-11	Extraversion;
LUSC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg16447950	chr5:562315	NA	-0.54	-6.28	-0.32	1.06e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg11901034	chr3:128598214	ACAD9	-0.4	-6.21	-0.32	1.57e-9	IgG glycosylation;
LUSC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-15.31	-0.64	1.92e-40	Exhaled nitric oxide output;
LUSC	cis	rs11229555	1.000	rs12787765	chr11:58400686	G/A	cg15696309	chr11:58395628	NA	-0.7	-9.28	-0.45	2.12e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.68	-10.61	-0.5	7.54e-23	Hip circumference adjusted for BMI;
LUSC	cis	rs7119	0.700	rs60701760	chr15:77888152	G/A	cg27398640	chr15:77910606	LINGO1	0.37	8.6	0.43	3.26e-16	Type 2 diabetes;
LUSC	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg15848620	chr12:58087721	OS9	-0.56	-8.06	-0.4	1.34e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.71	0.43	1.41e-16	Menopause (age at onset);
LUSC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg16405210	chr4:1374714	KIAA1530	-0.56	-8.69	-0.43	1.65e-16	Obesity-related traits;
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.42	8.49e-16	Lymphocyte counts;
LUSC	cis	rs6961069	0.806	rs1761665	chr7:80242079	A/G	cg04458919	chr7:80252533	CD36	-0.34	-6.17	-0.32	1.93e-9	Platelet count;
LUSC	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg12002119	chr2:101014098	CHST10	0.34	5.7	0.3	2.66e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg07703079	chr11:430292	ANO9	0.65	6.66	0.34	1.11e-10	Body mass index;
LUSC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11945232	1.000	rs28372775	chr4:88343704	G/A	cg23841344	chr4:88312519	HSD17B11	-0.66	-10.18	-0.49	2.19e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs9638182	0.697	rs12539316	chr7:72977898	C/T	cg07452164	chr7:72993570	TBL2	-0.45	-6.43	-0.33	4.32e-10	Triglycerides;
LUSC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg02269571	chr22:50332266	NA	-0.55	-8.2	-0.41	5.16e-15	Schizophrenia;
LUSC	cis	rs75229567	0.618	rs77168443	chr12:70208563	G/A	cg10114359	chr12:70132523	RAB3IP	1.4	12.47	0.56	1.42e-29	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs12936587	0.595	rs9911672	chr17:17528670	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.46	7.37	0.37	1.33e-12	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LUSC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.59	0.43	3.5e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs16912285	0.688	rs12801480	chr11:24270146	G/A	ch.11.24196551F	chr11:24239977	NA	0.89	9.68	0.47	1.05e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg23630131	chr7:65973040	NA	-0.21	-5.91	-0.31	8.39e-9	Aortic root size;
LUSC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.89	-0.31	9.61e-9	Personality dimensions;
LUSC	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg21385522	chr1:16154831	NA	-0.55	-8.29	-0.41	2.72e-15	Systolic blood pressure;
LUSC	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.07	-0.4	1.33e-14	Lung cancer;
LUSC	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg13072238	chr3:49761600	GMPPB	-0.38	-6.33	-0.33	8.04e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	1.11	9.74	0.47	6.79e-20	Skin colour saturation;
LUSC	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg17173187	chr15:85201210	NMB	0.37	6.37	0.33	6.23e-10	Schizophrenia;
LUSC	cis	rs6969780	0.778	rs2428433	chr7:27145517	T/C	cg26364809	chr7:27145159	NA	-0.59	-5.98	-0.31	5.69e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.66	-0.34	1.11e-10	Arsenic metabolism;
LUSC	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg20283391	chr11:68216788	NA	-0.55	-8.13	-0.41	8.23e-15	Total body bone mineral density;
LUSC	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	0.58	9.34	0.46	1.35e-18	Breast cancer;
LUSC	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg11584989	chr19:19387371	SF4	0.59	6.95	0.36	1.98e-11	Bipolar disorder;
LUSC	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.71	11.07	0.52	1.75e-24	Alcohol dependence;
LUSC	trans	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg01620082	chr3:125678407	NA	-0.65	-7.09	-0.36	7.84e-12	Breast cancer;
LUSC	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	trans	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg05926928	chr17:57297772	GDPD1	-0.96	-10.67	-0.5	4.73e-23	Opioid sensitivity;
LUSC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.73	-0.35	7.44e-11	Vitiligo;
LUSC	cis	rs6845621	0.901	rs1079812	chr4:18925913	A/C	cg12196642	chr4:18937545	NA	-0.35	-6.57	-0.34	1.91e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg07061783	chr6:25882402	NA	0.43	6.07	0.32	3.5e-9	Blood metabolite levels;
LUSC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg13010199	chr12:38710504	ALG10B	0.66	10.03	0.48	7.06e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-9.3	-0.45	1.88e-18	Gut microbiome composition (summer);
LUSC	cis	rs96067	0.652	rs274137	chr1:36577945	A/G	cg27506609	chr1:36549197	TEKT2	-0.66	-9.15	-0.45	5.72e-18	Corneal structure;
LUSC	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg27411982	chr8:10470053	RP1L1	0.41	6.55	0.34	2.19e-10	Morning vs. evening chronotype;
LUSC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.75	-13.03	-0.58	1.21e-31	Cognitive function;
LUSC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg08270630	chr22:50330655	NA	0.41	6.05	0.31	3.98e-9	Schizophrenia;
LUSC	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	20.23	0.74	5.89e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg18190219	chr22:46762943	CELSR1	-0.55	-6.38	-0.33	5.88e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg03188948	chr7:1209495	NA	0.62	6.51	0.34	2.73e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	1.1	17.18	0.68	7.82e-48	Exhaled nitric oxide output;
LUSC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg05802129	chr4:122689817	NA	-0.47	-7.92	-0.4	3.55e-14	Type 2 diabetes;
LUSC	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg24881330	chr22:46731750	TRMU	0.82	6.01	0.31	4.92e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg04944784	chr2:26401820	FAM59B	-0.74	-10.67	-0.5	4.6e-23	Gut microbiome composition (summer);
LUSC	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg10857441	chr5:6722123	POLS	-0.47	-9.08	-0.44	9.73e-18	Menopause (age at onset);
LUSC	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.79	11.89	0.55	1.95e-27	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21950561	chr5:61699692	DIMT1L	-0.41	-6.08	-0.32	3.28e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11640436	0.651	rs11643318	chr16:77322757	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.37	5.72	0.3	2.31e-8	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs877282	0.583	rs112372193	chr10:826602	A/G	cg22713356	chr15:30763199	NA	0.77	10.03	0.48	7.44e-21	Uric acid levels;
LUSC	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg08000102	chr2:233561755	GIGYF2	0.68	11.36	0.53	1.61e-25	Coronary artery disease;
LUSC	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg23173402	chr1:227635558	NA	0.77	8.17	0.41	6.32e-15	Major depressive disorder;
LUSC	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg13057898	chr1:3703894	LRRC47	0.5	8.35	0.42	1.9e-15	Red cell distribution width;
LUSC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg13531842	chr10:38383804	ZNF37A	-0.45	-6.99	-0.36	1.48e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg01483505	chr11:975446	AP2A2	-0.4	-5.82	-0.3	1.38e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg02493740	chr2:85810744	VAMP5	0.41	7.47	0.38	7.08e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs12464559	0.649	rs4664496	chr2:152522556	T/C	cg01189475	chr2:152685088	ARL5A	-0.57	-6.26	-0.32	1.18e-9	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.69	-8.87	-0.44	4.43e-17	Huntington's disease progression;
LUSC	cis	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg05084668	chr3:125655381	ALG1L	-0.45	-6.02	-0.31	4.67e-9	Blood pressure (smoking interaction);
LUSC	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.31	-0.33	8.95e-10	Bipolar disorder;
LUSC	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.81	-0.35	4.52e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg06532163	chr17:45867833	NA	0.36	6.63	0.34	1.37e-10	IgG glycosylation;
LUSC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg01657329	chr11:68192670	LRP5	0.45	6.69	0.34	9.28e-11	Total body bone mineral density;
LUSC	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg20991723	chr1:152506922	NA	0.49	9.23	0.45	3.09e-18	Hair morphology;
LUSC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg08888203	chr3:10149979	C3orf24	0.66	9.28	0.45	2.15e-18	Alzheimer's disease;
LUSC	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg01620082	chr3:125678407	NA	-0.82	-7.32	-0.37	1.84e-12	Depression;
LUSC	cis	rs500891	0.553	rs2154295	chr6:84170784	C/G	cg08257003	chr6:84140564	ME1	0.35	8.67	0.43	1.87e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg19622623	chr12:86230825	RASSF9	-0.43	-6.14	-0.32	2.34e-9	Major depressive disorder;
LUSC	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg14675211	chr2:100938903	LONRF2	0.37	5.76	0.3	1.89e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg12601414	chr9:115249737	KIAA1958	-0.56	-6.36	-0.33	6.58e-10	Height;
LUSC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg14893161	chr1:205819251	PM20D1	0.42	5.69	0.3	2.78e-8	Parkinson's disease;
LUSC	cis	rs4363385	0.510	rs17627288	chr1:152923848	C/T	cg25856811	chr1:152973957	SPRR3	-0.38	-6.25	-0.32	1.22e-9	Inflammatory skin disease;
LUSC	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg04362960	chr10:104952993	NT5C2	0.59	9.23	0.45	3.21e-18	Arsenic metabolism;
LUSC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg06096015	chr1:231504339	EGLN1	0.57	10.04	0.48	6.89e-21	Hemoglobin concentration;
LUSC	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.59	-10.1	-0.48	4.14e-21	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7246967	0.673	rs12979173	chr19:22820681	C/T	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.47e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4595586	0.756	rs1400283	chr12:39364596	G/C	cg26384229	chr12:38710491	ALG10B	0.5	6.99	0.36	1.48e-11	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	0.64	13.48	0.59	2.35e-33	Prudent dietary pattern;
LUSC	cis	rs7512552	0.780	rs2794681	chr1:150321951	C/T	cg15654264	chr1:150340011	RPRD2	0.68	11.51	0.53	4.95e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg25643088	chr3:52874325	TMEM110	0.4	6.14	0.32	2.37e-9	Schizophrenia;
LUSC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.62	6.04	0.31	4.07e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg03806693	chr22:41940476	POLR3H	-0.47	-6.45	-0.33	3.82e-10	Neuroticism;
LUSC	cis	rs11264799	0.520	rs849820	chr1:157541565	G/C	cg18268488	chr1:157545234	FCRL4	0.38	7.37	0.37	1.38e-12	IgA nephropathy;
LUSC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg16447950	chr5:562315	NA	-0.56	-6.88	-0.35	2.9e-11	Obesity-related traits;
LUSC	trans	rs9561329	0.528	rs1323986	chr13:93999772	A/G	cg19275536	chr6:52926650	ICK	0.49	6.27	0.32	1.13e-9	Neuroticism (age interaction);
LUSC	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg08000102	chr2:233561755	GIGYF2	0.71	11.67	0.54	1.3e-26	Coronary artery disease;
LUSC	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg03474202	chr17:45855739	NA	-0.29	-6.69	-0.34	9.51e-11	IgG glycosylation;
LUSC	trans	rs10843647	0.935	rs2351219	chr12:30319380	C/T	cg16899367	chr7:73097788	WBSCR22;DNAJC30	0.64	6.11	0.32	2.71e-9	Glucose homeostasis traits;
LUSC	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.65	-0.47	1.39e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs722599	0.715	rs2300598	chr14:75359229	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.96	-0.31	6.42e-9	IgG glycosylation;
LUSC	trans	rs7567288	0.636	rs12993449	chr2:134463168	G/C	cg12381416	chr3:14359266	NA	0.53	5.99	0.31	5.3e-9	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06170053	chr6:21596959	SOX4	-0.44	-6.42	-0.33	4.8e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs72792513	1.000	rs72796597	chr2:22883689	G/A	cg05844895	chr16:88969569	CBFA2T3	0.52	6.2	0.32	1.63e-9	Hepatitis B;
LUSC	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.13	-0.32	2.42e-9	Response to antipsychotic treatment;
LUSC	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg26727032	chr16:67993705	SLC12A4	-0.4	-5.99	-0.31	5.32e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.49	0.38	6.35e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs243505	0.898	rs243532	chr7:148412371	A/G	cg09806900	chr7:148480153	CUL1	-0.47	-6.62	-0.34	1.41e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04267008	chr7:1944627	MAD1L1	-0.51	-7.5	-0.38	5.93e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg25205988	chr1:146714368	CHD1L	1.07	12.63	0.57	3.82e-30	Mitochondrial DNA levels;
LUSC	cis	rs3741151	0.656	rs112699563	chr11:73015243	C/T	cg17517138	chr11:73019481	ARHGEF17	0.92	8.39	0.42	1.44e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18588027	chr15:68132741	NA	0.7	6.01	0.31	4.78e-9	Cognitive performance;
LUSC	trans	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg26043149	chr18:55253948	FECH	0.47	6.87	0.35	3.21e-11	Bone mineral density;
LUSC	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg12823233	chr7:2316876	SNX8	-0.34	-5.83	-0.3	1.28e-8	Schizophrenia;
LUSC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg21854759	chr1:92012499	NA	-0.53	-8.99	-0.44	1.89e-17	Breast cancer;
LUSC	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.43	-0.33	4.45e-10	Recombination measurement;
LUSC	cis	rs295140	1.000	rs13026151	chr2:201164570	T/A	cg04283868	chr2:201171347	SPATS2L	0.44	6.63	0.34	1.36e-10	QT interval;
LUSC	cis	rs926392	0.547	rs8118808	chr20:37674996	C/G	cg16355469	chr20:37678765	NA	0.53	7.04	0.36	1.12e-11	Dialysis-related mortality;
LUSC	cis	rs12122100	0.837	rs12742539	chr1:146507845	G/A	cg03526459	chr1:146549940	NA	-0.41	-6.66	-0.34	1.11e-10	HIV-1 control;
LUSC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg22535103	chr8:58192502	C8orf71	-0.73	-9.16	-0.45	5.46e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.88	0.35	3.04e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg23649088	chr2:200775458	C2orf69	0.43	6.36	0.33	6.72e-10	QT interval;
LUSC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg06808227	chr14:105710500	BRF1	-0.64	-9.6	-0.47	1.94e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-9.39	-0.46	9.45e-19	Morning vs. evening chronotype;
LUSC	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.85	-0.47	2.99e-20	Hemoglobin concentration;
LUSC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12524338	chr4:183729343	NA	0.69	9.38	0.46	1.08e-18	Pediatric autoimmune diseases;
LUSC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg24881330	chr22:46731750	TRMU	0.85	7.57	0.38	3.77e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.83	10.81	0.51	1.47e-23	Schizophrenia;
LUSC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg13628971	chr7:2884303	GNA12	0.45	6.38	0.33	6.04e-10	Height;
LUSC	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg10636054	chr15:40330586	SRP14	0.92	9.07	0.44	1.08e-17	Corneal curvature;
LUSC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg22920501	chr2:26401640	FAM59B	0.8	11.94	0.55	1.33e-27	Gut microbiome composition (summer);
LUSC	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg08975724	chr8:8085496	FLJ10661	0.46	6.74	0.35	6.94e-11	Retinal vascular caliber;
LUSC	cis	rs3789045	0.560	rs1107339	chr1:204411942	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.51	-5.77	-0.3	1.77e-8	Educational attainment (college completion);
LUSC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	0.59	9.36	0.46	1.22e-18	Breast cancer;
LUSC	cis	rs9650315	0.929	rs11994717	chr8:57160043	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.48	6.83	0.35	3.91e-11	Height;
LUSC	cis	rs735860	0.726	rs209518	chr6:53208016	C/A	cg10236188	chr6:53219634	NA	0.38	5.66	0.3	3.33e-8	Glaucoma;
LUSC	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.73	11.12	0.52	1.15e-24	Breast cancer;
LUSC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08280861	chr8:58055591	NA	0.57	6.03	0.31	4.4e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg10556349	chr10:835070	NA	0.59	6.48	0.33	3.31e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.71	12.81	0.57	8.06e-31	Platelet distribution width;
LUSC	cis	rs708547	1.000	rs708547	chr4:57821309	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.58	7.22	0.37	3.43e-12	Response to bleomycin (chromatid breaks);
LUSC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg06387496	chr7:2775674	GNA12	-0.36	-5.68	-0.3	2.9e-8	Height;
LUSC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-6.7	-0.34	8.64e-11	Electroencephalogram traits;
LUSC	cis	rs9400467	0.508	rs11153293	chr6:111725899	A/T	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.89	-0.35	2.72e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.36	5.83	0.3	1.28e-8	IgG glycosylation;
LUSC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23158103	chr7:148848205	ZNF398	-0.5	-8.45	-0.42	9.1e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs5758511	0.731	rs12158579	chr22:42351289	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.43	7.18	0.37	4.67e-12	Birth weight;
LUSC	trans	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg04995722	chr7:26192034	NFE2L3	-0.37	-6.0	-0.31	5.25e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg16359550	chr11:109292809	C11orf87	0.32	5.78	0.3	1.67e-8	Schizophrenia;
LUSC	cis	rs7113850	0.541	rs75850541	chr11:24211467	C/G	ch.11.24196551F	chr11:24239977	NA	0.98	7.5	0.38	5.69e-13	Bone fracture in osteoporosis;
LUSC	cis	rs8179	0.761	rs42034	chr7:92239144	A/G	cg15732164	chr7:92237376	CDK6	-0.48	-6.58	-0.34	1.82e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs7215564	0.643	rs59992540	chr17:78658265	G/A	cg09596252	chr17:78655493	RPTOR	0.55	6.04	0.31	4.18e-9	Myopia (pathological);
LUSC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9311676	0.656	rs11918201	chr3:58387777	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.49	0.33	3.05e-10	Systemic lupus erythematosus;
LUSC	trans	rs2392780	0.536	rs400818	chr8:128336546	T/C	cg10195415	chr17:73887371	TRIM65	0.42	6.66	0.34	1.11e-10	Breast cancer (early onset);
LUSC	cis	rs6736093	0.966	rs71414616	chr2:112696684	T/C	cg12686935	chr2:112915763	FBLN7	-0.37	-5.9	-0.31	8.73e-9	Coronary artery disease;
LUSC	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.45	-0.42	8.99e-16	Heart rate;
LUSC	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	6.2	0.32	1.64e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs834603	0.575	rs1799370	chr7:47467864	C/T	cg09696706	chr7:47479511	TNS3	0.32	5.75	0.3	2.01e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg10356904	chr22:49881777	NA	0.33	7.61	0.38	2.85e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg24578937	chr1:2090814	PRKCZ	-0.41	-9.13	-0.45	6.91e-18	Height;
LUSC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg12412775	chr1:25698385	RHCE	-0.29	-5.95	-0.31	6.65e-9	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.32	-0.37	1.84e-12	Bipolar disorder;
LUSC	cis	rs7568458	0.507	rs719023	chr2:85818488	A/G	cg23752985	chr2:85803571	VAMP8	-0.29	-6.03	-0.31	4.36e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.07	14.26	0.62	2.27e-36	Uric acid levels;
LUSC	cis	rs59698941	0.943	rs67460003	chr5:132289501	C/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg05313129	chr8:58192883	C8orf71	-0.53	-6.84	-0.35	3.89e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg26441486	chr22:50317300	CRELD2	0.47	6.54	0.34	2.31e-10	Schizophrenia;
LUSC	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.7	-0.34	9.06e-11	QT interval;
LUSC	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.93	-0.31	7.75e-9	Reticulocyte count;
LUSC	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.93	12.09	0.55	3.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.5	-6.86	-0.35	3.33e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg02972257	chr16:68554789	NA	-0.53	-6.6	-0.34	1.64e-10	Ulcerative colitis;
LUSC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-0.85	-15.6	-0.65	1.32e-41	Gestational age at birth (maternal effect);
LUSC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg03354898	chr7:1950403	MAD1L1	-0.36	-7.05	-0.36	1.05e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg05872129	chr22:39784769	NA	-0.56	-9.51	-0.46	4e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg04017836	chr7:65315216	NA	-0.37	-5.95	-0.31	6.75e-9	Height;
LUSC	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01341218	chr17:43662625	NA	-0.76	-11.05	-0.52	2.07e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.75	0.65	3.58e-42	Morning vs. evening chronotype;
LUSC	cis	rs7106204	0.748	rs11820336	chr11:24219701	G/A	ch.11.24196551F	chr11:24239977	NA	1.14	14.14	0.61	6.98e-36	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg06521331	chr12:34319734	NA	-0.41	-5.96	-0.31	6.36e-9	Resting heart rate;
LUSC	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg12641515	chr19:46296257	DMWD	0.48	7.1	0.36	7.52e-12	Coronary artery disease;
LUSC	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg04998671	chr14:104000505	TRMT61A	-0.4	-6.02	-0.31	4.48e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs710216	0.917	rs900834	chr1:43412343	A/G	cg03128534	chr1:43423976	SLC2A1	-0.48	-6.05	-0.31	3.83e-9	Red cell distribution width;
LUSC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg18305652	chr10:134549665	INPP5A	0.45	6.77	0.35	5.66e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.06e-12	Motion sickness;
LUSC	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg22638593	chr5:131593259	PDLIM4	0.4	5.7	0.3	2.66e-8	Breast cancer;
LUSC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg23262073	chr20:60523788	NA	-0.46	-6.81	-0.35	4.43e-11	Body mass index;
LUSC	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg04450456	chr4:17643702	FAM184B	-0.37	-6.18	-0.32	1.81e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg25036284	chr2:26402008	FAM59B	-0.47	-6.12	-0.32	2.62e-9	Gut microbiome composition (summer);
LUSC	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg13119609	chr19:45449297	APOC2	0.34	5.8	0.3	1.57e-8	Blood protein levels;
LUSC	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-0.82	-12.24	-0.56	1.02e-28	Prostate cancer;
LUSC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.66	-12.3	-0.56	6.3e-29	Type 2 diabetes;
LUSC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg22709100	chr7:91322751	NA	-0.42	-6.11	-0.32	2.72e-9	Breast cancer;
LUSC	cis	rs10186029	0.509	rs10194726	chr2:213936876	G/A	cg08319019	chr2:214017104	IKZF2	-0.43	-6.25	-0.32	1.26e-9	Systemic sclerosis;
LUSC	cis	rs1346	0.552	rs4326800	chr11:65367253	C/T	cg17120908	chr11:65337727	SSSCA1	-0.41	-5.68	-0.3	2.94e-8	Vertical cup-disc ratio;Optic cup area;
LUSC	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg13010199	chr12:38710504	ALG10B	0.65	10.01	0.48	8.37e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7178572	0.625	rs907372	chr15:77844516	G/T	cg22256960	chr15:77711686	NA	-0.43	-6.85	-0.35	3.61e-11	Type 2 diabetes;
LUSC	cis	rs6681460	0.625	rs2872079	chr1:67130071	G/A	cg02459107	chr1:67143332	SGIP1	0.33	5.76	0.3	1.91e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.68	-0.57	2.41e-30	Chronic sinus infection;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08169830	chr7:97822374	LMTK2	-0.39	-6.12	-0.32	2.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.58	-0.46	2.31e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	5.82	0.3	1.36e-8	Breast cancer;
LUSC	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.26	-0.45	2.55e-18	Coronary artery disease;
LUSC	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg05585544	chr11:47624801	NA	-0.41	-7.33	-0.37	1.74e-12	Subjective well-being;
LUSC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg21854759	chr1:92012499	NA	-0.57	-9.85	-0.47	2.93e-20	Breast cancer;
LUSC	cis	rs10100465	0.961	rs10093232	chr8:118679361	A/T	cg09430518	chr8:118662568	NA	0.3	5.69	0.3	2.72e-8	Leprosy;
LUSC	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.45	7.26	0.37	2.66e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9308433	0.643	rs7412913	chr1:214463228	G/A	cg06198575	chr1:214491504	SMYD2	0.45	6.85	0.35	3.5e-11	IgG glycosylation;
LUSC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg24642844	chr7:1081250	C7orf50	-0.45	-7.28	-0.37	2.41e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs34421088	0.506	rs4841519	chr8:11146228	A/T	cg06636001	chr8:8085503	FLJ10661	0.46	7.26	0.37	2.68e-12	Neuroticism;
LUSC	cis	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg01733217	chr16:74700730	RFWD3	0.98	22.58	0.78	3.49e-69	Multiple myeloma;
LUSC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-9.65	-0.47	1.32e-19	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02939508	chr14:21152672	RNASE4;ANG	0.48	6.54	0.34	2.31e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg23985595	chr17:80112537	CCDC57	0.31	5.97	0.31	6.13e-9	Life satisfaction;
LUSC	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg05472934	chr7:22766657	IL6	0.5	7.84	0.39	6.13e-14	Lung cancer;
LUSC	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg11161011	chr14:65562177	MAX	-0.72	-11.07	-0.52	1.85e-24	Obesity-related traits;
LUSC	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.72	-0.35	7.77e-11	Monocyte count;
LUSC	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	1.16	18.4	0.71	1.09e-52	Primary sclerosing cholangitis;
LUSC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	11.47	0.53	6.92e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.74	12.12	0.55	2.8e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg08499158	chr17:42289980	UBTF	0.56	9.12	0.45	7.32e-18	Total body bone mineral density;
LUSC	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg24558204	chr6:135376177	HBS1L	0.68	10.58	0.5	9.61e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs6580649	0.941	rs7963934	chr12:48477086	C/G	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-7.26	-0.37	2.71e-12	Menopause (age at onset);
LUSC	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.42	-0.38	9.53e-13	Glomerular filtration rate (creatinine);
LUSC	trans	rs2905347	0.757	rs2961295	chr7:22696272	C/T	cg09038599	chr8:57233391	SDR16C5	0.28	6.04	0.31	4.1e-9	Major depression and alcohol dependence;
LUSC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.13	-0.41	8.24e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg00255919	chr5:131827918	IRF1	0.43	8.28	0.41	3.11e-15	Asthma (sex interaction);
LUSC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg03929089	chr4:120376271	NA	-0.88	-11.86	-0.54	2.57e-27	Coronary artery disease;
LUSC	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg04310649	chr10:35416472	CREM	0.41	6.34	0.33	7.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg08799069	chr10:126477246	METTL10	0.6	8.24	0.41	3.98e-15	Cocaine dependence;
LUSC	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg15737290	chr11:93063684	CCDC67	-0.59	-7.0	-0.36	1.4e-11	Pulmonary function decline;
LUSC	cis	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.73	-0.3	2.27e-8	Resting heart rate;
LUSC	trans	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.83	0.35	4.01e-11	Monocyte count;
LUSC	cis	rs11214589	0.870	rs10789942	chr11:113236199	C/T	cg14159747	chr11:113255604	NA	-0.28	-7.03	-0.36	1.19e-11	Neuroticism;
LUSC	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.38	4.39e-13	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg08558340	chr7:100472263	SRRT	0.51	6.27	0.32	1.11e-9	Resting heart rate;
LUSC	cis	rs11997175	0.624	rs4355732	chr8:33676920	A/C	ch.8.33884649F	chr8:33765107	NA	0.47	7.11	0.36	7.19e-12	Body mass index;
LUSC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg11663144	chr21:46675770	NA	-0.41	-7.23	-0.37	3.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.32	-0.33	8.38e-10	Dupuytren's disease;
LUSC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	7.5	0.38	5.84e-13	Multiple sclerosis;
LUSC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg25019033	chr10:957182	NA	-0.53	-5.83	-0.3	1.28e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg01416388	chr22:39784598	NA	-0.43	-7.09	-0.36	8.24e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs887829	0.570	rs4553819	chr2:234594083	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.31	-0.33	8.87e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs9649213	0.574	rs17436977	chr7:97883459	T/C	cg21770322	chr7:97807741	LMTK2	0.45	7.57	0.38	3.6e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.77	12.73	0.57	1.55e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg17366294	chr4:99064904	C4orf37	0.54	8.86	0.44	4.93e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11828289	0.660	rs77575887	chr11:23174504	T/A	cg20040320	chr11:23191996	NA	-0.58	-6.09	-0.32	3.05e-9	Cancer;
LUSC	cis	rs4363385	0.747	rs3806219	chr1:152972522	C/T	cg25856811	chr1:152973957	SPRR3	0.34	5.79	0.3	1.58e-8	Inflammatory skin disease;
LUSC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg20887711	chr4:1340912	KIAA1530	0.44	6.67	0.34	1.09e-10	Obesity-related traits;
LUSC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg22907277	chr7:1156413	C7orf50	0.72	7.56	0.38	4.05e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg11941060	chr3:133502564	NA	-0.52	-8.12	-0.41	8.94e-15	Iron status biomarkers;
LUSC	cis	rs710216	0.917	rs1681859	chr1:43411829	G/A	cg22176566	chr1:43424700	SLC2A1	0.49	6.22	0.32	1.53e-9	Red cell distribution width;
LUSC	cis	rs34779708	0.931	rs4934704	chr10:35332164	C/T	cg03585969	chr10:35415529	CREM	0.62	8.91	0.44	3.39e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg08847533	chr14:75593920	NEK9	0.8	13.95	0.61	3.72e-35	Height;
LUSC	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg19875535	chr5:140030758	IK	-0.53	-8.76	-0.43	1.02e-16	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9323205	0.862	rs11629399	chr14:51612814	T/C	cg23942311	chr14:51606299	NA	-0.5	-10.24	-0.49	1.39e-21	Cancer;
LUSC	cis	rs7940866	0.903	rs10750457	chr11:130850277	T/C	cg12179176	chr11:130786555	SNX19	0.57	9.06	0.44	1.09e-17	Schizophrenia;
LUSC	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg05887092	chr17:76393375	PGS1	0.51	9.38	0.46	1.03e-18	HDL cholesterol levels;
LUSC	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	0.87	17.54	0.69	2.79e-49	Metabolite levels;
LUSC	cis	rs12760731	0.623	rs16852708	chr1:178308249	T/G	cg00404053	chr1:178313656	RASAL2	0.47	5.81	0.3	1.48e-8	Obesity-related traits;
LUSC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9581857	0.547	rs9581869	chr13:28082498	G/A	cg22138327	chr13:27999177	GTF3A	0.69	7.16	0.36	5.24e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg12863693	chr15:85201151	NMB	0.36	7.35	0.37	1.56e-12	Schizophrenia;
LUSC	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg11019008	chr10:131425282	MGMT	0.41	6.36	0.33	6.79e-10	Response to temozolomide;
LUSC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg20135002	chr11:47629003	NA	-0.52	-8.08	-0.4	1.17e-14	Subjective well-being;
LUSC	cis	rs7119167	0.686	rs7123298	chr11:73038820	C/T	cg17517138	chr11:73019481	ARHGEF17	0.5	5.85	0.3	1.16e-8	Blood protein levels;
LUSC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg00033643	chr7:134001901	SLC35B4	0.44	6.73	0.35	7.51e-11	Mean platelet volume;
LUSC	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg20701182	chr2:24300061	SF3B14	0.58	6.19	0.32	1.72e-9	Lymphocyte counts;
LUSC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08677398	chr8:58056175	NA	0.44	6.39	0.33	5.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10761482	0.861	rs4948405	chr10:62108419	G/T	cg18175470	chr10:62150864	ANK3	-0.5	-7.1	-0.36	7.67e-12	Schizophrenia;
LUSC	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg07169764	chr2:136633963	MCM6	-0.57	-7.67	-0.39	1.95e-13	Mosquito bite size;
LUSC	cis	rs77741769	0.571	rs61946382	chr12:121344574	A/T	cg02419362	chr12:121203948	SPPL3	0.46	8.64	0.43	2.32e-16	Mean corpuscular volume;
LUSC	cis	rs925255	0.743	rs7600164	chr2:28644862	A/T	cg01273330	chr2:28605224	NA	-0.38	-6.15	-0.32	2.26e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2425143	0.818	rs12481545	chr20:34407698	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-5.99	-0.31	5.47e-9	Blood protein levels;
LUSC	cis	rs62400317	0.762	rs62436411	chr6:44940706	T/G	cg20913747	chr6:44695427	NA	-0.45	-7.1	-0.36	7.39e-12	Total body bone mineral density;
LUSC	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg18105134	chr13:113819100	PROZ	-0.76	-10.64	-0.5	5.78e-23	Platelet distribution width;
LUSC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg09455208	chr3:40491958	NA	0.58	10.22	0.49	1.66e-21	Renal cell carcinoma;
LUSC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06634786	chr22:41940651	POLR3H	0.5	5.89	0.31	9.64e-9	Vitiligo;
LUSC	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg03474202	chr17:45855739	NA	-0.29	-6.67	-0.34	1.07e-10	IgG glycosylation;
LUSC	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.24	0.45	2.88e-18	Red blood cell count;
LUSC	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg08345082	chr10:99160200	RRP12	-0.36	-7.17	-0.37	4.83e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg06238570	chr21:40685208	BRWD1	0.47	7.38	0.37	1.27e-12	Cognitive function;
LUSC	cis	rs7569084	0.566	rs7584295	chr2:65581074	T/C	cg08085232	chr2:65598271	SPRED2	-0.43	-6.75	-0.35	6.74e-11	Sum eosinophil basophil counts;
LUSC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg08601574	chr20:25228251	PYGB	0.55	8.83	0.44	5.91e-17	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-6.99	-0.36	1.53e-11	Menarche (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02310229	chr5:32312285	MTMR12	0.37	5.99	0.31	5.56e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1983170	0.668	rs17131491	chr1:92017649	A/C	cg25838465	chr1:92012736	NA	0.47	5.82	0.3	1.4e-8	Eosinophil percentage of white cells;
LUSC	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.76	-0.39	1.06e-13	Retinal vascular caliber;
LUSC	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-11.24	-0.52	4.52e-25	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg09307838	chr4:120376055	NA	0.73	10.33	0.49	6.88e-22	Corneal astigmatism;
LUSC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.78	0.39	9.22e-14	Colorectal cancer;
LUSC	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-5.77	-0.3	1.79e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7124681	0.546	rs7941399	chr11:47890421	A/T	cg20307385	chr11:47447363	PSMC3	0.47	6.86	0.35	3.42e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.68	13.08	0.58	7.78e-32	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs354225	0.626	rs7608414	chr2:54844995	G/A	cg26097391	chr2:54893211	SPTBN1	0.42	6.28	0.32	1.08e-9	Schizophrenia;
LUSC	cis	rs701145	0.938	rs355773	chr3:154036657	A/G	cg17054900	chr3:154042577	DHX36	-0.8	-8.8	-0.43	7.48e-17	Coronary artery disease;
LUSC	cis	rs2050392	0.858	rs2250569	chr10:30698914	G/C	cg18806716	chr10:30721971	MAP3K8	-0.48	-7.92	-0.4	3.57e-14	Inflammatory bowel disease;
LUSC	cis	rs12541635	0.677	rs2880950	chr8:106983624	C/A	cg10147462	chr8:107024639	NA	0.66	13.52	0.59	1.56e-33	Age of smoking initiation;
LUSC	cis	rs2274273	0.712	rs6572999	chr14:55527374	T/C	cg04306507	chr14:55594613	LGALS3	0.49	10.73	0.51	2.75e-23	Protein biomarker;
LUSC	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.59	8.09	0.4	1.1e-14	Resting heart rate;
LUSC	cis	rs4285028	0.948	rs13089878	chr3:121703895	T/C	cg11130432	chr3:121712080	ILDR1	-0.66	-10.1	-0.48	4.03e-21	Multiple sclerosis;
LUSC	cis	rs13315871	1.000	rs13317835	chr3:58383275	C/T	cg12435725	chr3:58293450	RPP14	-0.73	-7.19	-0.37	4.4e-12	Cholesterol, total;
LUSC	cis	rs10740039	0.810	rs6479720	chr10:62370693	C/T	cg18175470	chr10:62150864	ANK3	-0.44	-6.58	-0.34	1.82e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.99	-0.44	1.88e-17	Response to antipsychotic treatment;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg01373262	chr20:44034880	DBNDD2;SYS1-DBNDD2	0.42	6.09	0.32	3.1e-9	Calcium levels;
LUSC	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg23029597	chr12:123009494	RSRC2	0.72	9.62	0.47	1.64e-19	Body mass index;
LUSC	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg21427119	chr20:30132790	HM13	-0.37	-5.66	-0.3	3.31e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	12.36	0.56	3.86e-29	Lung cancer in ever smokers;
LUSC	cis	rs2652834	0.821	rs7174174	chr15:63372327	A/G	cg05507819	chr15:63340323	TPM1	-0.51	-6.43	-0.33	4.51e-10	HDL cholesterol;
LUSC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg05805236	chr11:65401703	PCNXL3	-0.37	-5.65	-0.3	3.5e-8	Breast cancer;
LUSC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-14.72	-0.63	3.66e-38	Chronic sinus infection;
LUSC	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg09092052	chr15:45571596	NA	-0.43	-6.06	-0.31	3.63e-9	Glomerular filtration rate;
LUSC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06634786	chr22:41940651	POLR3H	-0.56	-6.54	-0.34	2.36e-10	Vitiligo;
LUSC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.52	0.57	9.28e-30	Motion sickness;
LUSC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.89	-0.4	4.34e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	8.83	0.44	5.83e-17	Monocyte count;
LUSC	trans	rs4729127	1.000	rs78697521	chr7:94012938	G/C	cg20086523	chr13:52378287	DHRS12	0.6	6.61	0.34	1.55e-10	Intelligence;
LUSC	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg12002119	chr2:101014098	CHST10	0.35	5.91	0.31	8.66e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs727505	1.000	rs7795943	chr7:124483796	C/A	cg23710748	chr7:124431027	NA	-0.42	-7.67	-0.39	1.93e-13	Lewy body disease;
LUSC	trans	rs71435601	0.574	rs570033	chr2:21399567	C/G	cg20757404	chr19:378427	NA	0.39	6.15	0.32	2.15e-9	Cholesterol, total;
LUSC	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg04362960	chr10:104952993	NT5C2	0.64	9.2	0.45	3.9e-18	Arsenic metabolism;
LUSC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg26335602	chr6:28129616	ZNF389	0.43	5.75	0.3	1.98e-8	Depression;
LUSC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.95	-0.44	2.59e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.88	0.35	2.88e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08109568	chr15:31115862	NA	-0.6	-8.2	-0.41	5.28e-15	Huntington's disease progression;
LUSC	cis	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg21775007	chr8:11205619	TDH	0.47	6.67	0.34	1.05e-10	Myopia (pathological);
LUSC	cis	rs1395	0.961	rs4665965	chr2:27536380	C/T	cg23587288	chr2:27483067	SLC30A3	0.29	5.69	0.3	2.79e-8	Blood metabolite levels;
LUSC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	0.92	16.06	0.66	2.14e-43	Menopause (age at onset);
LUSC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs73416724	1.000	rs77529883	chr6:43364634	C/G	cg26312998	chr6:43337775	ZNF318	0.54	6.29	0.33	1.01e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg01181863	chr3:195395398	SDHAP2	-0.68	-9.28	-0.45	2.26e-18	Pancreatic cancer;
LUSC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.16	15.5	0.65	3.26e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg10247383	chr3:153839028	SGEF	-0.46	-5.72	-0.3	2.33e-8	Coronary artery disease;
LUSC	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.74	-0.3	2.1e-8	Testicular germ cell tumor;
LUSC	trans	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg07211511	chr3:129823064	LOC729375	-1.06	-13.26	-0.59	1.53e-32	Blood pressure (smoking interaction);
LUSC	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-1.14	-17.8	-0.7	2.53e-50	Exhaled nitric oxide output;
LUSC	cis	rs554111	0.593	rs9426660	chr1:21520449	A/G	cg01072550	chr1:21505969	NA	-0.4	-6.0	-0.31	5.22e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.73	-0.43	1.23e-16	Response to antipsychotic treatment;
LUSC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.62	0.5	6.6e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1775715	0.870	rs1615256	chr10:32254101	T/C	cg04359828	chr10:32216031	ARHGAP12	0.38	6.24	0.32	1.33e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6076065	0.723	rs6137905	chr20:23340938	G/A	cg11657817	chr20:23433608	CST11	0.43	8.03	0.4	1.7e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2898681	0.618	rs79471207	chr4:53738524	C/T	cg00791764	chr4:53727839	RASL11B	0.5	6.58	0.34	1.8e-10	Optic nerve measurement (cup area);
LUSC	trans	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.76	-0.35	6.16e-11	Monocyte count;
LUSC	cis	rs662735	0.515	rs535845	chr11:30839228	C/A	cg14844989	chr11:31128820	NA	0.36	5.79	0.3	1.64e-8	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg15423357	chr2:25149977	NA	0.4	7.83	0.39	6.45e-14	Body mass index;
LUSC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg08219700	chr8:58056026	NA	0.45	5.83	0.3	1.28e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs62432291	0.681	rs3003173	chr6:159665692	G/T	cg14500486	chr6:159655392	FNDC1	-0.55	-5.92	-0.31	7.8e-9	Joint mobility (Beighton score);
LUSC	cis	rs9436116	1	rs9436116	chr1:150454724	G/T	cg15654264	chr1:150340011	RPRD2	0.45	7.24	0.37	3.13e-12	Morning vs. evening chronotype;
LUSC	cis	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.4e-10	Ulcerative colitis;
LUSC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg04865166	chr7:105162814	PUS7	0.52	5.92	0.31	7.79e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg06612196	chr6:6737390	NA	0.57	11.22	0.52	5.41e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg20933634	chr6:27740509	NA	0.4	5.87	0.31	1.06e-8	Parkinson's disease;
LUSC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg27588902	chr6:42928151	GNMT	-0.29	-6.28	-0.32	1.07e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7833986	1.000	rs34230678	chr8:57083117	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	9.25	0.45	2.7e-18	Height;
LUSC	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg06784218	chr1:46089804	CCDC17	0.32	5.79	0.3	1.59e-8	Platelet count;
LUSC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.93	-0.35	2.21e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg23985595	chr17:80112537	CCDC57	-0.31	-5.91	-0.31	8.39e-9	Life satisfaction;
LUSC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg12365402	chr11:9010492	NRIP3	0.45	8.29	0.41	2.81e-15	Hemoglobin concentration;
LUSC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.99	0.44	1.87e-17	Motion sickness;
LUSC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg02782426	chr3:40428986	ENTPD3	0.36	7.1	0.36	7.74e-12	Renal cell carcinoma;
LUSC	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.59	-8.52	-0.42	5.59e-16	IgG glycosylation;
LUSC	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.37	5.65	0.3	3.41e-8	Neutrophil percentage of white cells;
LUSC	trans	rs890100	0.644	rs11125631	chr2:56686389	C/A	cg01657744	chr10:88471748	LDB3	0.44	5.97	0.31	6.13e-9	Gut microbiome composition (summer);
LUSC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.49	0.46	4.59e-19	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.51	0.56	1.01e-29	Motion sickness;
LUSC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg00431813	chr7:1051703	C7orf50	-0.47	-8.07	-0.4	1.24e-14	Longevity;Endometriosis;
LUSC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.36	6.44	0.33	4.27e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg13531842	chr10:38383804	ZNF37A	-0.48	-7.44	-0.38	8.5e-13	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.8	-0.35	4.88e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12220238	1.000	rs11000924	chr10:75972311	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.22	0.37	3.42e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg26335602	chr6:28129616	ZNF389	0.46	6.49	0.33	3.18e-10	Parkinson's disease;
LUSC	cis	rs9796	0.835	rs3100807	chr15:41292206	G/A	cg18705301	chr15:41695430	NDUFAF1	0.45	7.89	0.4	4.43e-14	Menopause (age at onset);
LUSC	cis	rs1322639	0.668	rs9766666	chr6:169613541	G/T	cg04662567	chr6:169592167	NA	-0.4	-6.4	-0.33	5.13e-10	Pulse pressure;
LUSC	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg25237894	chr2:233734115	C2orf82	-0.34	-6.29	-0.33	9.71e-10	Coronary artery disease;
LUSC	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg16482183	chr6:26056742	HIST1H1C	0.58	7.98	0.4	2.42e-14	Iron status biomarkers;
LUSC	cis	rs1519814	0.915	rs10808507	chr8:121166429	G/A	cg22335954	chr8:121166405	COL14A1	-0.46	-6.12	-0.32	2.55e-9	Breast cancer;
LUSC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.11	-0.48	3.98e-21	Hemoglobin concentration;
LUSC	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg00383909	chr3:49044727	WDR6	0.57	6.89	0.35	2.73e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs672059	1.000	rs3118181	chr1:183166970	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.56	8.2	0.41	5.21e-15	Hypertriglyceridemia;
LUSC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg25036284	chr2:26402008	FAM59B	0.77	11.34	0.53	1.89e-25	Gut microbiome composition (summer);
LUSC	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.28	-5.75	-0.3	2.06e-8	Schizophrenia;
LUSC	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg26102564	chr10:131424627	MGMT	0.38	5.79	0.3	1.62e-8	Response to temozolomide;
LUSC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg13126279	chr21:47581558	C21orf56	-0.41	-6.02	-0.31	4.72e-9	Testicular germ cell tumor;
LUSC	trans	rs2018683	0.677	rs12540529	chr7:28969384	A/G	cg19402173	chr7:128379420	CALU	-0.45	-6.83	-0.35	4.11e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs10887741	0.646	rs4244979	chr10:89425507	A/C	cg13926569	chr10:89418898	PAPSS2	0.32	6.64	0.34	1.23e-10	Exercise (leisure time);
LUSC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg24690094	chr11:67383802	NA	0.44	8.72	0.43	1.29e-16	Mean corpuscular volume;
LUSC	cis	rs6542838	0.641	rs6760065	chr2:99486318	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.69	-0.3	2.81e-8	Fear of minor pain;
LUSC	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg02569458	chr12:86230093	RASSF9	0.53	8.55	0.42	4.35e-16	Major depressive disorder;
LUSC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.38	0.33	5.87e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2742417	1.000	rs2673025	chr3:45760483	A/G	cg09608765	chr3:45636137	LIMD1	-0.37	-7.43	-0.38	9.37e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7590255	1.000	rs7590255	chr2:37990079	C/T	cg23497611	chr2:37985316	NA	0.41	6.4	0.33	5.2400000000000005e-10	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.77	0.35	5.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-9.12	-0.45	7.15e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.53	-0.46	3.41e-19	Type 2 diabetes;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11820517	chr11:43964150	LOC387763	0.73	6.19	0.32	1.74e-9	Cognitive performance;
LUSC	cis	rs472402	0.540	rs2288445	chr5:6620092	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.41	-6.06	-0.31	3.63e-9	Response to amphetamines;
LUSC	cis	rs4776059	0.550	rs11070906	chr15:52922525	C/G	cg22715398	chr15:52968154	KIAA1370	-0.62	-6.94	-0.35	2.08e-11	Schizophrenia;
LUSC	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg10909506	chr17:38081995	ORMDL3	0.34	6.05	0.31	3.93e-9	Self-reported allergy;
LUSC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.48	-0.46	4.95e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.2	13.62	0.6	6.4e-34	Diabetic kidney disease;
LUSC	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg11965913	chr1:205819406	PM20D1	0.48	6.87	0.35	3.09e-11	Parkinson's disease;
LUSC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg12564285	chr5:131593104	PDLIM4	0.43	7.83	0.39	6.4e-14	Breast cancer;
LUSC	trans	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.6	-10.33	-0.49	6.72e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.71	13.39	0.59	5.22e-33	Height;
LUSC	cis	rs1775715	0.707	rs1541262	chr10:32179771	A/G	cg26784012	chr10:32216390	ARHGAP12	0.46	7.84	0.39	6.15e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.72e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4499344	0.730	rs421607	chr19:33104951	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	13.06	0.58	9.06e-32	Mean platelet volume;
LUSC	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg07148914	chr20:33460835	GGT7	-0.52	-8.13	-0.41	8.68e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg23173402	chr1:227635558	NA	-0.46	-5.73	-0.3	2.2e-8	Major depressive disorder;
LUSC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.73	-14.1	-0.61	9.34e-36	Lung cancer;
LUSC	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	8.08	0.4	1.2e-14	Neuroticism;
LUSC	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.82	0.7	2.19e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	1.03	20.02	0.74	3.9e-59	Menopause (age at onset);
LUSC	cis	rs9467773	0.595	rs4320356	chr6:26423560	C/T	cg05738196	chr6:26577821	NA	-0.51	-7.53	-0.38	4.78e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	0.97	13.49	0.59	2.05e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg02782426	chr3:40428986	ENTPD3	0.38	7.4	0.38	1.15e-12	Renal cell carcinoma;
LUSC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg00701064	chr4:6280414	WFS1	0.59	14.2	0.61	3.93e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	11.32	0.53	2.26e-25	Menarche (age at onset);
LUSC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-9.82	-0.47	3.54e-20	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6869502	0.871	rs13354207	chr5:110151791	C/G	cg07744993	chr5:89705938	CETN3	-0.41	-6.05	-0.31	3.83e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg15103426	chr22:29168792	CCDC117	0.49	6.47	0.33	3.39e-10	Lymphocyte counts;
LUSC	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	10.41	0.5	3.53e-22	Response to antipsychotic treatment;
LUSC	trans	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg25214090	chr10:38739885	LOC399744	0.43	6.53	0.34	2.51e-10	Corneal astigmatism;
LUSC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-14.72	-0.63	3.66e-38	Chronic sinus infection;
LUSC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg17376030	chr22:41985996	PMM1	-0.46	-5.88	-0.31	9.9e-9	Vitiligo;
LUSC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	6.44	0.33	4.16e-10	Mean platelet volume;
LUSC	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.66	-10.28	-0.49	1.02e-21	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg05347473	chr6:146136440	FBXO30	0.65	11.4	0.53	1.16e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg22532475	chr10:104410764	TRIM8	-0.31	-6.05	-0.31	3.83e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg18904891	chr8:8559673	CLDN23	0.58	8.11	0.41	9.67e-15	Obesity-related traits;
LUSC	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg24562669	chr7:97807699	LMTK2	0.38	6.54	0.34	2.37e-10	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs13011075	0.919	rs1542136	chr2:68620930	A/C	cg14221825	chr19:46271408	SIX5	-0.44	-6.2	-0.32	1.7e-9	Mean corpuscular volume;
LUSC	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg03522245	chr20:25566470	NINL	-0.36	-5.77	-0.3	1.85e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06634786	chr22:41940651	POLR3H	0.48	5.71	0.3	2.46e-8	Vitiligo;
LUSC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.59	9.72	0.47	8.16e-20	Aortic root size;
LUSC	trans	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04565464	chr8:145669602	NFKBIL2	0.41	6.58	0.34	1.83e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.7	-0.6	3.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4474465	1.000	rs11602360	chr11:78179336	A/G	cg27205649	chr11:78285834	NARS2	0.48	5.66	0.3	3.18e-8	Alzheimer's disease (survival time);
LUSC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg22800045	chr5:56110881	MAP3K1	-0.79	-9.86	-0.47	2.76e-20	Initial pursuit acceleration;
LUSC	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg06917634	chr15:78832804	PSMA4	-0.8	-14.01	-0.61	2.11e-35	Sudden cardiac arrest;
LUSC	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	7.21	0.37	3.84e-12	Height;
LUSC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs34638657	0.732	rs10514532	chr16:82200337	C/T	cg09439754	chr16:82129088	HSD17B2	0.39	6.62	0.34	1.41e-10	Lung adenocarcinoma;
LUSC	cis	rs3824867	0.920	rs80241400	chr11:47453828	T/C	cg20307385	chr11:47447363	PSMC3	-0.65	-9.65	-0.47	1.35e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg26816564	chr1:7831052	VAMP3	-0.7	-9.71	-0.47	8.22e-20	Inflammatory bowel disease;
LUSC	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg12573674	chr2:1569213	NA	-0.56	-6.18	-0.32	1.86e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.84	-0.54	3.05e-27	Chronic sinus infection;
LUSC	cis	rs6740322	1.000	rs4128209	chr2:43554729	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.46	-6.5	-0.34	2.88e-10	Coronary artery disease;
LUSC	cis	rs939574	0.858	rs2891733	chr2:220135208	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.81	7.05	0.36	1.04e-11	Platelet distribution width;
LUSC	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.7	-11.5	-0.53	5.21e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg26408565	chr15:76604113	ETFA	0.48	7.62	0.38	2.71e-13	Blood metabolite levels;
LUSC	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg03522245	chr20:25566470	NINL	0.35	5.67	0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg24812749	chr6:127587940	RNF146	0.65	9.75	0.47	6.4e-20	Breast cancer;
LUSC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg06238570	chr21:40685208	BRWD1	0.47	7.25	0.37	2.94e-12	Cognitive function;
LUSC	cis	rs1595825	0.891	rs892512	chr2:198905910	C/A	cg10547527	chr2:198650123	BOLL	-0.47	-5.87	-0.31	1.07e-8	Ulcerative colitis;
LUSC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg27170947	chr2:26402098	FAM59B	0.63	8.84	0.44	5.69e-17	Gut microbiome composition (summer);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg00092287	chr2:152146295	NMI	0.41	5.96	0.31	6.58e-9	Mosquito bite size;
LUSC	cis	rs472402	0.580	rs8192186	chr5:6652009	G/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.45	-6.6	-0.34	1.65e-10	Response to amphetamines;
LUSC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg08847533	chr14:75593920	NEK9	0.51	7.46	0.38	7.67e-13	Caffeine consumption;
LUSC	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg06606381	chr12:133084897	FBRSL1	-1.04	-9.08	-0.44	9.35e-18	Depression;
LUSC	cis	rs6967385	0.934	rs2253353	chr7:12370657	A/G	cg06484146	chr7:12443880	VWDE	0.42	6.15	0.32	2.26e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.72	-13.29	-0.59	1.24e-32	Ulcerative colitis;
LUSC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.57	6.14	0.32	2.4e-9	Diabetic retinopathy;
LUSC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg26304593	chr6:42947056	PEX6	-0.49	-7.34	-0.37	1.63e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg05966235	chr16:28915196	ATP2A1	0.33	5.8	0.3	1.54e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2806561	0.929	rs627304	chr1:23537555	A/G	cg19743168	chr1:23544995	NA	0.47	10.15	0.49	2.88e-21	Height;
LUSC	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg01256987	chr12:42539512	GXYLT1	0.46	8.46	0.42	8.77e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs979233	0.502	rs276266	chr5:42068610	G/C	cg07010552	chr17:7358735	CHRNB1	-0.41	-5.98	-0.31	5.65e-9	Systemic lupus erythematosus;
LUSC	cis	rs9644630	0.870	rs4244453	chr8:19359711	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.36	6.92	0.35	2.26e-11	Oropharynx cancer;
LUSC	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.09	15.15	0.64	7.93e-40	Uric acid levels;
LUSC	cis	rs3741151	0.773	rs7934218	chr11:73206729	C/T	cg17517138	chr11:73019481	ARHGEF17	0.83	7.71	0.39	1.48e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg12091567	chr17:66097778	LOC651250	-0.64	-9.16	-0.45	5.35e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg15737290	chr11:93063684	CCDC67	-0.65	-8.16	-0.41	7.04e-15	Pulmonary function decline;
LUSC	cis	rs13242816	1.000	rs13235720	chr7:116113663	T/C	cg16553024	chr7:116138462	CAV2	-0.52	-5.71	-0.3	2.44e-8	P wave duration;
LUSC	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.06	0.36	9.57e-12	Morning vs. evening chronotype;
LUSC	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	6.01	0.31	4.85e-9	Parkinson's disease;
LUSC	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Body mass index;
LUSC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03576123	chr11:487126	PTDSS2	-0.95	-10.54	-0.5	1.29e-22	Body mass index;
LUSC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg18230493	chr5:56204884	C5orf35	-0.55	-8.91	-0.44	3.36e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs4363385	0.574	rs6671520	chr1:152944156	C/T	cg25856811	chr1:152973957	SPRR3	-0.35	-5.76	-0.3	1.87e-8	Inflammatory skin disease;
LUSC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg20608306	chr11:116969690	SIK3	0.36	6.82	0.35	4.26e-11	Blood protein levels;
LUSC	trans	rs11743006	1.000	rs76245514	chr5:136523315	C/A	cg07379741	chr17:7311030	NLGN2	0.42	6.01	0.31	4.9e-9	Mathematical ability;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11635074	chr17:40925442	VPS25	-0.41	-6.14	-0.32	2.29e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4737010	0.570	rs2111804	chr8:41644266	A/T	cg17182837	chr8:41585554	ANK1	-0.36	-6.62	-0.34	1.4e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7586879	0.609	rs7608976	chr2:25075281	G/A	cg01884057	chr2:25150051	NA	0.4	8.99	0.44	1.87e-17	Body mass index;
LUSC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	6.28	0.32	1.08e-9	Bipolar disorder;
LUSC	cis	rs965469	1.000	rs6037526	chr20:3251248	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-6.28	-0.33	1.04e-9	IFN-related cytopenia;
LUSC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.31	0.37	2.03e-12	Motion sickness;
LUSC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.7	-12.66	-0.57	2.88e-30	Aortic root size;
LUSC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg13395646	chr4:1353034	KIAA1530	-0.62	-9.58	-0.46	2.23e-19	Obesity-related traits;
LUSC	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg22875332	chr1:76189707	ACADM	-0.42	-6.26	-0.32	1.16e-9	Daytime sleep phenotypes;
LUSC	cis	rs6714710	0.603	rs13034929	chr2:98402772	G/C	cg26665480	chr2:98280029	ACTR1B	0.63	9.1	0.45	8.41e-18	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs10186029	0.680	rs13007271	chr2:213937767	G/C	cg08319019	chr2:214017104	IKZF2	0.55	8.02	0.4	1.75e-14	Systemic sclerosis;
LUSC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.79	0.6	1.44e-34	Platelet count;
LUSC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07677032	chr17:61819896	STRADA	0.54	9.03	0.44	1.36e-17	Prudent dietary pattern;
LUSC	trans	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg21659725	chr3:3221576	CRBN	-0.71	-7.82	-0.39	7.08e-14	Menarche (age at onset);
LUSC	cis	rs13315871	0.790	rs13071148	chr3:58310838	A/C	cg20936604	chr3:58311152	NA	-0.77	-7.11	-0.36	7.27e-12	Cholesterol, total;
LUSC	cis	rs72792276	1.000	rs72794379	chr5:127464965	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	7.84	0.39	5.98e-14	Red cell distribution width;
LUSC	cis	rs977987	0.806	rs4887823	chr16:75433074	T/A	cg04384234	chr16:75411784	CFDP1	-0.41	-6.77	-0.35	5.95e-11	Dupuytren's disease;
LUSC	cis	rs2625529	0.617	rs11633167	chr15:72179178	C/A	cg16672083	chr15:72433130	SENP8	0.5	8.07	0.4	1.26e-14	Red blood cell count;
LUSC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg09365446	chr1:150670422	GOLPH3L	-0.39	-5.75	-0.3	1.99e-8	Tonsillectomy;
LUSC	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg16898833	chr6:26189333	HIST1H4D	0.69	6.52	0.34	2.55e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9473147	0.543	rs1004173	chr6:47445017	C/T	cg12968598	chr6:47444699	CD2AP	0.54	8.18	0.41	6.18e-15	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg21659725	chr3:3221576	CRBN	-0.68	-7.85	-0.39	5.77e-14	Menarche (age at onset);
LUSC	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg18512352	chr11:47633146	NA	-0.48	-9.64	-0.47	1.49e-19	Subjective well-being;
LUSC	trans	rs61931739	0.635	rs1852224	chr12:33963080	A/C	cg13010199	chr12:38710504	ALG10B	0.4	6.03	0.31	4.34e-9	Morning vs. evening chronotype;
LUSC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg06618935	chr21:46677482	NA	0.38	7.01	0.36	1.33e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4474465	0.833	rs7934912	chr11:78218556	A/T	cg27205649	chr11:78285834	NARS2	0.5	5.77	0.3	1.8e-8	Alzheimer's disease (survival time);
LUSC	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg27433088	chr4:174089019	GALNT7	-0.4	-6.13	-0.32	2.51e-9	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	0.91	17.45	0.69	6.11e-49	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs1983891	0.955	rs4714487	chr6:41547312	T/C	cg20194872	chr6:41519635	FOXP4	0.36	6.37	0.33	6.21e-10	Prostate cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12882476	chr5:114632168	CCDC112	0.7	6.21	0.32	1.59e-9	Cognitive performance;
LUSC	cis	rs1775715	0.677	rs2491272	chr10:32186783	A/G	cg18675610	chr10:32216311	ARHGAP12	0.3	6.65	0.34	1.22e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg27284194	chr4:1044797	NA	0.35	5.78	0.3	1.74e-8	Obesity-related traits;
LUSC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	12.98	0.58	1.77e-31	Hip circumference adjusted for BMI;
LUSC	trans	rs72674100	1.000	rs28575922	chr4:97974891	C/A	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.55	0.46	2.89e-19	Mean platelet volume;
LUSC	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-5.92	-0.31	8.18e-9	IgG glycosylation;
LUSC	cis	rs9326248	0.727	rs4938347	chr11:117021759	T/A	cg26566898	chr11:117069891	TAGLN	0.37	5.87	0.31	1.04e-8	Blood protein levels;
LUSC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.72	-0.39	1.4e-13	Aortic root size;
LUSC	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg19875535	chr5:140030758	IK	0.47	7.52	0.38	5.19e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6494488	0.500	rs72744709	chr15:65013210	T/C	cg08069370	chr15:64387884	SNX1	-0.66	-6.09	-0.32	3.06e-9	Coronary artery disease;
LUSC	trans	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04565464	chr8:145669602	NFKBIL2	0.36	5.96	0.31	6.58e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.71	9.7	0.47	9.15e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg26043149	chr18:55253948	FECH	0.54	8.02	0.4	1.82e-14	Bone mineral density;
LUSC	cis	rs6087990	0.735	rs2424914	chr20:31374520	A/G	cg13636640	chr20:31349939	DNMT3B	0.91	18.44	0.71	7.17e-53	Ulcerative colitis;
LUSC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15369054	chr17:80825471	TBCD	-0.36	-6.01	-0.31	4.8e-9	Breast cancer;
LUSC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-0.84	-14.83	-0.63	1.35e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7216064	1.000	rs7214758	chr17:65880538	T/C	cg12091567	chr17:66097778	LOC651250	-0.76	-9.64	-0.47	1.51e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg22834771	chr12:69754056	YEATS4	-0.53	-8.07	-0.4	1.31e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg24562669	chr7:97807699	LMTK2	0.43	7.32	0.37	1.86e-12	Breast cancer;
LUSC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15369054	chr17:80825471	TBCD	-0.66	-11.0	-0.52	3.09e-24	Breast cancer;
LUSC	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	6.2	0.32	1.71e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs540254	0.619	rs4656932	chr1:160779495	C/T	cg20255094	chr1:160771763	LY9	0.56	7.17	0.37	4.84e-12	Blood protein levels;
LUSC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg05585544	chr11:47624801	NA	0.41	7.24	0.37	3.04e-12	Subjective well-being;
LUSC	trans	rs13011075	0.878	rs13430654	chr2:68587710	C/G	cg14221825	chr19:46271408	SIX5	0.42	5.96	0.31	6.37e-9	Mean corpuscular volume;
LUSC	cis	rs4631830	0.863	rs4935162	chr10:51525699	C/G	cg16070123	chr10:51489643	NA	-0.53	-8.54	-0.42	4.82e-16	Prostate-specific antigen levels;
LUSC	trans	rs9860340	0.690	rs7619452	chr3:87633703	C/G	cg03644585	chr7:884825	UNC84A	0.42	6.09	0.32	3.17e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs4654899	0.897	rs12121807	chr1:21069129	A/C	cg01072550	chr1:21505969	NA	-0.46	-6.92	-0.35	2.25e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs360798	0.553	rs11682530	chr2:63073194	C/T	cg17519650	chr2:63277830	OTX1	-0.52	-7.34	-0.37	1.65e-12	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05935283	chr3:190231667	IL1RAP	-0.44	-6.56	-0.34	2.04e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2363709	0.764	rs9832823	chr3:67418273	C/T	cg23062198	chr2:14774063	FAM84A	-0.54	-5.98	-0.31	5.77e-9	IgE levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10122766	chr19:2977386	TLE6	-0.4	-6.12	-0.32	2.59e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg22681709	chr2:178499509	PDE11A	-0.41	-5.68	-0.3	2.91e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs926938	0.527	rs58658580	chr1:115539726	A/G	cg12756093	chr1:115239321	AMPD1	0.44	6.65	0.34	1.17e-10	Autism;
LUSC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg03676636	chr4:99064102	C4orf37	0.33	7.23	0.37	3.25e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg24110177	chr3:50126178	RBM5	0.4	6.46	0.33	3.73e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs11782517	0.881	rs7845806	chr8:10110188	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.15	0.32	2.2e-9	Nose size;
LUSC	cis	rs136211	0.577	rs9607339	chr22:36768932	G/T	cg16924664	chr22:36878180	TXN2	0.41	6.22	0.32	1.52e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg18904891	chr8:8559673	CLDN23	0.38	5.94	0.31	7.25e-9	Mood instability;
LUSC	cis	rs7818345	0.935	rs6983973	chr8:19287867	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.96	0.36	1.8e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.84e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2307022	0.586	rs3785123	chr16:68386581	C/T	cg02226672	chr16:68398533	SMPD3	0.3	5.82	0.3	1.42e-8	Body mass index;
LUSC	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg20891283	chr12:69753455	YEATS4	0.44	5.82	0.3	1.38e-8	Response to diuretic therapy;
LUSC	cis	rs1712517	0.838	rs6584543	chr10:104997014	G/A	cg05636881	chr10:105038444	INA	-0.4	-6.65	-0.34	1.22e-10	Migraine;
LUSC	cis	rs9487051	0.735	rs1341272	chr6:109507533	C/T	cg01475377	chr6:109611718	NA	0.35	6.04	0.31	4.02e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg11693508	chr17:37793320	STARD3	0.59	7.59	0.38	3.2e-13	Bipolar disorder;
LUSC	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.74	-0.35	6.92e-11	Response to antipsychotic treatment;
LUSC	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg17168535	chr8:21777572	XPO7	0.81	13.03	0.58	1.19e-31	Lung cancer in ever smokers;
LUSC	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	0.57	8.81	0.43	7.14e-17	Breast cancer;
LUSC	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg05340658	chr4:99064831	C4orf37	0.45	7.3	0.37	2.09e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg12016809	chr21:47604291	C21orf56	0.46	6.75	0.35	6.59e-11	Testicular germ cell tumor;
LUSC	cis	rs1124376	1.000	rs9819739	chr3:20140760	G/A	cg05072819	chr3:20081367	KAT2B	0.64	7.37	0.37	1.39e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs9646944	0.501	rs3732127	chr2:103013750	G/C	cg20060108	chr2:102954350	IL1RL1	0.48	6.51	0.34	2.73e-10	Blood protein levels;
LUSC	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg08085267	chr17:45401833	C17orf57	-0.46	-6.96	-0.36	1.82e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.06	-0.4	1.35e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9399401	0.921	rs9373346	chr6:142746992	G/A	cg03128060	chr6:142623767	GPR126	0.34	6.22	0.32	1.51e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg04369109	chr6:150039330	LATS1	-0.55	-8.09	-0.4	1.09e-14	Lung cancer;
LUSC	cis	rs3820928	0.874	rs7423610	chr2:227836262	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.42	-0.38	9.97e-13	Pulmonary function;
LUSC	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg09582351	chr12:29534625	ERGIC2	0.33	6.58	0.34	1.79e-10	QT interval;
LUSC	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.38	7.37	0.37	1.32e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg27446573	chr6:127587934	RNF146	-0.63	-10.23	-0.49	1.55e-21	Breast cancer;
LUSC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.71	10.68	0.5	4.16e-23	Aortic root size;
LUSC	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.02	-0.36	1.24e-11	Schizophrenia;
LUSC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg14582100	chr15:45693742	SPATA5L1	0.6	10.95	0.51	4.7e-24	Homoarginine levels;
LUSC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18876405	chr7:65276391	NA	0.55	8.81	0.43	6.74e-17	Aortic root size;
LUSC	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg20283391	chr11:68216788	NA	-0.57	-8.2	-0.41	5.27e-15	Total body bone mineral density;
LUSC	cis	rs4363385	0.747	rs1577962	chr1:152962013	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.59	-0.38	3.15e-13	Inflammatory skin disease;
LUSC	cis	rs10761482	0.813	rs4948411	chr10:62116075	T/G	cg18175470	chr10:62150864	ANK3	-0.53	-7.5	-0.38	5.65e-13	Schizophrenia;
LUSC	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg27147174	chr7:100797783	AP1S1	-0.63	-10.05	-0.48	6.29e-21	Life satisfaction;
LUSC	cis	rs2742417	1.000	rs2742438	chr3:45743390	G/T	cg04837898	chr3:45731254	SACM1L	-0.35	-5.66	-0.3	3.28e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs3764021	0.870	rs2401395	chr12:9879540	A/C	cg20894963	chr12:9885564	CLECL1	0.34	6.85	0.35	3.58e-11	Type 1 diabetes;
LUSC	cis	rs7582180	0.967	rs7595580	chr2:100896964	A/G	cg08017756	chr2:100939284	LONRF2	-0.36	-5.98	-0.31	5.76e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.95	0.36	1.97e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03399598	chr4:174091002	GALNT7	0.44	6.49	0.33	3.16e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg18815388	chr7:100291905	NA	0.36	6.09	0.32	3.15e-9	Asthma;
LUSC	cis	rs137603	0.602	rs9611146	chr22:39718120	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.52	-8.27	-0.41	3.22e-15	Primary biliary cholangitis;
LUSC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg24562669	chr7:97807699	LMTK2	0.35	6.12	0.32	2.68e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.74	11.98	0.55	9.17e-28	Cognitive function;
LUSC	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg22676075	chr6:135203613	NA	0.59	9.41	0.46	8.46e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.51	-0.34	2.81e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs1953600	0.870	rs2573370	chr10:81951366	C/T	cg00277334	chr10:82204260	NA	0.45	7.08	0.36	8.35e-12	Sarcoidosis;
LUSC	cis	rs2354432	0.556	rs59180647	chr1:146772062	C/T	cg25205988	chr1:146714368	CHD1L	-1.02	-9.56	-0.46	2.71e-19	Mitochondrial DNA levels;
LUSC	cis	rs4776059	1.000	rs62023352	chr15:52889448	T/C	cg22715398	chr15:52968154	KIAA1370	-0.71	-10.09	-0.48	4.56e-21	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.7	0.39	1.61e-13	Prudent dietary pattern;
LUSC	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg26528668	chr16:1614120	IFT140	0.41	7.02	0.36	1.21e-11	Coronary artery disease;
LUSC	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg09184832	chr6:79620586	NA	-0.43	-6.96	-0.36	1.83e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg14664628	chr15:75095509	CSK	0.52	6.82	0.35	4.35e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg18681998	chr4:17616180	MED28	-0.87	-15.39	-0.64	8.93e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00166722	chr3:10149974	C3orf24	0.53	7.59	0.38	3.31e-13	Alzheimer's disease;
LUSC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.64	0.6	5.79e-34	Cognitive test performance;
LUSC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg21251018	chr6:28226885	NKAPL	0.31	5.83	0.3	1.31e-8	Cardiac Troponin-T levels;
LUSC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg21724239	chr8:58056113	NA	0.54	6.86	0.35	3.36e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13911393	chr17:37894944	GRB7	-0.45	-6.38	-0.33	5.78e-10	Hepatitis;
LUSC	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17467752	chr17:38218738	THRA	0.78	12.57	0.57	5.92e-30	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg20744362	chr22:50050164	C22orf34	0.36	6.65	0.34	1.19e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.25	-0.49	1.28e-21	Hemoglobin concentration;
LUSC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg00784671	chr22:46762841	CELSR1	-0.49	-6.7	-0.34	8.75e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08109568	chr15:31115862	NA	-0.74	-11.04	-0.52	2.25e-24	Huntington's disease progression;
LUSC	cis	rs3820928	1.000	rs11686072	chr2:227777493	A/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.96	-0.4	2.8e-14	Pulmonary function;
LUSC	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg11502198	chr6:26597334	ABT1	0.88	10.88	0.51	8.1e-24	Small cell lung carcinoma;
LUSC	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg20734569	chr3:48348370	SPINK8	-0.41	-7.44	-0.38	8.58e-13	Coronary artery disease;
LUSC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg08859206	chr1:53392774	SCP2	0.52	9.02	0.44	1.54e-17	Monocyte count;
LUSC	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg12667521	chr19:29218732	NA	0.53	6.14	0.32	2.32e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.17	-0.32	2.01e-9	Bipolar disorder;
LUSC	trans	rs7939886	0.920	rs11227463	chr11:55955447	C/T	cg03929089	chr4:120376271	NA	0.82	6.22	0.32	1.53e-9	Myopia (pathological);
LUSC	cis	rs2882667	0.690	rs825669	chr5:138066947	A/T	cg04439458	chr5:138467593	SIL1	0.36	6.99	0.36	1.47e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs4722551	0.507	rs10239682	chr7:26019353	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.41	-6.3	-0.33	9.34e-10	LDL cholesterol;Cholesterol, total;Triglycerides;
LUSC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.84	-15.18	-0.64	5.82e-40	Cognitive function;
LUSC	cis	rs6920965	0.507	rs12203025	chr6:126192034	C/T	cg10911889	chr6:126070802	HEY2	0.39	5.65	0.3	3.36e-8	High light scatter reticulocyte count;
LUSC	cis	rs10792830	0.741	rs541674	chr11:85737502	A/G	cg07180834	chr11:85838833	NA	-0.3	-5.7	-0.3	2.63e-8	Psychosis and Alzheimer's disease;
LUSC	cis	rs2273669	0.504	rs77107907	chr6:109436345	C/A	cg05315195	chr6:109294784	ARMC2	-0.55	-5.85	-0.3	1.18e-8	Prostate cancer;
LUSC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg15556689	chr8:8085844	FLJ10661	0.67	10.99	0.52	3.32e-24	Mood instability;
LUSC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.3	-0.33	9.64e-10	Personality dimensions;
LUSC	cis	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg24375607	chr4:120327624	NA	0.51	7.68	0.39	1.8e-13	Corneal astigmatism;
LUSC	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.68	-0.39	1.74e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg10756647	chr7:56101905	PSPH	0.87	8.88	0.44	4.33e-17	Diabetic kidney disease;
LUSC	cis	rs3007168	1.000	rs2999360	chr14:51605429	G/A	cg23942311	chr14:51606299	NA	0.37	6.02	0.31	4.5e-9	Cancer;
LUSC	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg08601574	chr20:25228251	PYGB	0.43	6.57	0.34	1.94e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13126279	chr21:47581558	C21orf56	-0.42	-6.11	-0.32	2.7e-9	Testicular germ cell tumor;
LUSC	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg19743168	chr1:23544995	NA	0.48	10.36	0.49	5.47e-22	Height;
LUSC	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg15485101	chr11:133734466	NA	0.42	7.57	0.38	3.78e-13	Childhood ear infection;
LUSC	cis	rs2273669	0.667	rs11153156	chr6:109365911	C/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	trans	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg10756647	chr7:56101905	PSPH	0.89	8.94	0.44	2.61e-17	Diabetic kidney disease;
LUSC	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg15934090	chr1:100435551	SLC35A3	0.48	8.33	0.41	2.17e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.64	0.34	1.25e-10	IgG glycosylation;
LUSC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12667521	chr19:29218732	NA	0.63	9.05	0.44	1.18e-17	Methadone dose in opioid dependence;
LUSC	cis	rs2219968	1.000	rs28551624	chr8:78957333	A/G	cg00738934	chr8:78996279	NA	0.38	6.97	0.36	1.67e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg00376283	chr12:123451042	ABCB9	-0.68	-10.5	-0.5	1.76e-22	Platelet count;
LUSC	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg19920283	chr7:105172520	RINT1	0.58	6.25	0.32	1.25e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg17127132	chr2:85788382	GGCX	0.47	7.66	0.39	2e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	11.23	0.52	4.9e-25	Mean platelet volume;
LUSC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg23711669	chr6:146136114	FBXO30	0.86	16.1	0.66	1.47e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.77	0.35	5.72e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.38	-0.42	1.54e-15	Longevity;
LUSC	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg26384229	chr12:38710491	ALG10B	0.74	11.9	0.55	1.78e-27	Morning vs. evening chronotype;
LUSC	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg18132916	chr6:79620363	NA	-0.39	-5.98	-0.31	5.66e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.68	-13.03	-0.58	1.13e-31	Monocyte count;
LUSC	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-1.15	-18.3	-0.71	2.71e-52	Exhaled nitric oxide output;
LUSC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26913058	chr16:419975	MRPL28	-0.33	-5.66	-0.3	3.25e-8	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs977987	0.806	rs2161684	chr16:75479153	T/C	cg03315344	chr16:75512273	CHST6	0.5	9.67	0.47	1.17e-19	Dupuytren's disease;
LUSC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs1832871	1.000	rs827857	chr6:158706497	C/T	cg07165851	chr6:158734300	TULP4	0.37	6.47	0.33	3.49e-10	Height;
LUSC	cis	rs2455601	0.786	rs10279	chr11:8969309	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-6.67	-0.34	1.04e-10	Schizophrenia;
LUSC	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg25258033	chr6:167368657	RNASET2	0.43	7.15	0.36	5.49e-12	Crohn's disease;
LUSC	cis	rs2235544	0.565	rs633697	chr1:54468760	A/G	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.76	-0.35	6.24e-11	Total body bone mineral density;
LUSC	cis	rs7903847	0.619	rs10786336	chr10:99134953	A/C	cg06359132	chr10:99160096	RRP12	-0.24	-5.65	-0.3	3.39e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg20734569	chr3:48348370	SPINK8	-0.47	-7.93	-0.4	3.4e-14	Coronary artery disease;
LUSC	cis	rs4409675	0.912	rs11247730	chr1:28270737	A/G	cg23691781	chr1:28212827	C1orf38	-0.28	-5.84	-0.3	1.22e-8	Corneal astigmatism;
LUSC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07677032	chr17:61819896	STRADA	-0.51	-8.49	-0.42	6.65e-16	Prudent dietary pattern;
LUSC	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-10.3	-0.49	8.92e-22	Mood instability;
LUSC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg10360139	chr7:1886902	MAD1L1	-0.46	-7.08	-0.36	8.61e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg04455712	chr21:45112962	RRP1B	0.46	8.88	0.44	4.26e-17	Mean corpuscular volume;
LUSC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg00784671	chr22:46762841	CELSR1	-0.47	-6.31	-0.33	8.66e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg07703079	chr11:430292	ANO9	0.66	6.75	0.35	6.51e-11	Body mass index;
LUSC	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.62	-0.34	1.47e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11997175	0.574	rs4520125	chr8:33648628	C/T	ch.8.33884649F	chr8:33765107	NA	0.51	8.34	0.42	1.94e-15	Body mass index;
LUSC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg16606324	chr3:10149918	C3orf24	0.58	8.28	0.41	2.99e-15	Alzheimer's disease;
LUSC	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg18806716	chr10:30721971	MAP3K8	-0.48	-7.74	-0.39	1.18e-13	Inflammatory bowel disease;
LUSC	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg26384229	chr12:38710491	ALG10B	0.75	11.9	0.55	1.83e-27	Morning vs. evening chronotype;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg03145290	chr16:32857923	NA	0.4	6.62	0.34	1.41e-10	Calcium levels;
LUSC	cis	rs7267979	0.549	rs6138536	chr20:25182648	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.64	11.81	0.54	4.02e-27	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	0.92	16.31	0.67	2.09e-44	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg05347473	chr6:146136440	FBXO30	0.45	7.69	0.39	1.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2688608	1.000	rs2688610	chr10:75654931	A/G	cg17411546	chr10:75410026	SYNPO2L	0.43	6.57	0.34	1.89e-10	Inflammatory bowel disease;
LUSC	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07741184	chr6:167504864	NA	0.39	6.9	0.35	2.56e-11	Crohn's disease;
LUSC	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.77	10.43	0.5	3.16e-22	HIV-1 control;
LUSC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg27494647	chr7:150038898	RARRES2	0.49	7.42	0.38	1.01e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg13206674	chr6:150067644	NUP43	0.56	8.59	0.43	3.41e-16	Lung cancer;
LUSC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg24209194	chr3:40518798	ZNF619	0.41	5.85	0.3	1.18e-8	Renal cell carcinoma;
LUSC	cis	rs7943203	0.568	rs228593	chr11:108141134	G/A	cg04873221	chr11:107992290	ACAT1	-0.4	-5.87	-0.31	1.06e-8	Red blood cell count;Mean corpuscular volume;
LUSC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg21643547	chr1:205240462	TMCC2	-0.42	-7.65	-0.39	2.14e-13	Red blood cell count;
LUSC	cis	rs4730250	0.707	rs3729876	chr7:106786952	T/C	cg02696742	chr7:106810147	HBP1	0.65	9.18	0.45	4.72e-18	Osteoarthritis;
LUSC	cis	rs10493773	0.618	rs17394091	chr1:86075098	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.39	-7.65	-0.39	2.24e-13	Urate levels in overweight individuals;
LUSC	cis	rs2625529	0.824	rs12902006	chr15:72252996	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.44	-0.38	8.62e-13	Red blood cell count;
LUSC	cis	rs10203711	0.901	rs907104	chr2:239564564	T/G	cg14580085	chr2:239553406	NA	0.41	6.99	0.36	1.47e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-7.25	-0.37	2.93e-12	Height;
LUSC	cis	rs1624802	0.841	rs78426981	chr12:130497782	A/G	cg15444478	chr12:130494697	NA	-0.26	-5.95	-0.31	6.81e-9	Obesity-related traits;
LUSC	cis	rs9905704	0.881	rs12942879	chr17:56861253	G/A	cg12560992	chr17:57184187	TRIM37	0.56	8.02	0.4	1.81e-14	Testicular germ cell tumor;
LUSC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20307385	chr11:47447363	PSMC3	-0.44	-5.73	-0.3	2.23e-8	Subjective well-being;
LUSC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.51	-0.42	5.92e-16	Aortic root size;
LUSC	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.23	-0.37	3.37e-12	Mood instability;
LUSC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg18681998	chr4:17616180	MED28	0.89	17.39	0.69	1.05e-48	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg09904177	chr6:26538194	HMGN4	0.75	14.21	0.61	3.52e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	12.97	0.58	1.94e-31	Bipolar disorder;
LUSC	cis	rs9283706	0.608	rs12522430	chr5:66339522	T/C	cg11590213	chr5:66331682	MAST4	0.47	6.93	0.35	2.14e-11	Coronary artery disease;
LUSC	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg01620082	chr3:125678407	NA	-0.8	-7.24	-0.37	3.11e-12	Depression;
LUSC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg23711669	chr6:146136114	FBXO30	0.74	12.72	0.57	1.68e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg06521331	chr12:34319734	NA	-0.38	-6.38	-0.33	6.01e-10	Morning vs. evening chronotype;
LUSC	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.78	11.3	0.53	2.71e-25	Corneal astigmatism;
LUSC	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.55	10.47	0.5	2.33e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg12002119	chr2:101014098	CHST10	0.35	5.81	0.3	1.5e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-12.93	-0.58	2.79e-31	Hemoglobin concentration;
LUSC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg23815491	chr16:72088622	HP	0.34	5.97	0.31	6.12e-9	Fibrinogen levels;
LUSC	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.92	-17.15	-0.68	1.02e-47	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs6681460	0.966	rs10889642	chr1:67143334	T/G	cg02459107	chr1:67143332	SGIP1	0.48	8.88	0.44	4.15e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs7481584	0.962	rs2237905	chr11:2976584	T/C	cg08508325	chr11:3079039	CARS	0.3	5.76	0.3	1.9e-8	Calcium levels;
LUSC	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.2	0.45	3.97e-18	Menarche (age at onset);
LUSC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg11846333	chr4:119757529	SEC24D	0.78	6.68	0.34	9.94e-11	Cannabis dependence symptom count;
LUSC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	9.97	0.48	1.14e-20	Eosinophil percentage of white cells;
LUSC	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg00012203	chr2:219082015	ARPC2	-0.77	-13.8	-0.6	1.38e-34	Colorectal cancer;
LUSC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg01616529	chr11:638424	DRD4	-0.34	-5.8	-0.3	1.58e-8	Systemic lupus erythematosus;
LUSC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.74	-0.3	2.1e-8	Alzheimer's disease (late onset);
LUSC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.56	7.85	0.39	5.86e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg01689657	chr7:91764605	CYP51A1	-0.33	-6.06	-0.31	3.68e-9	Breast cancer;
LUSC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg21770322	chr7:97807741	LMTK2	0.41	7.25	0.37	2.92e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg05805236	chr11:65401703	PCNXL3	-0.66	-10.47	-0.5	2.22e-22	Acne (severe);
LUSC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.39	5.96	0.31	6.31e-9	Lymphocyte counts;
LUSC	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg01884057	chr2:25150051	NA	0.48	11.28	0.53	3.33e-25	Body mass index;
LUSC	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg24692254	chr21:30365293	RNF160	-0.49	-6.23	-0.32	1.41e-9	Cognitive test performance;
LUSC	cis	rs11168618	0.904	rs7135125	chr12:48926268	A/T	cg24011408	chr12:48396354	COL2A1	0.39	6.34	0.33	7.56e-10	Adiponectin levels;
LUSC	cis	rs11229555	0.645	rs11229463	chr11:58210147	A/G	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-0.94	-18.1	-0.7	1.7e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg02018176	chr4:1364513	KIAA1530	0.46	7.67	0.39	1.9e-13	Obesity-related traits;
LUSC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg18190219	chr22:46762943	CELSR1	-0.51	-6.17	-0.32	2e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg26876637	chr1:152193138	HRNR	0.44	6.13	0.32	2.46e-9	Atopic dermatitis;
LUSC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.78	0.35	5.33e-11	Tonsillectomy;
LUSC	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg02275930	chr1:2372054	NA	-0.44	-7.2	-0.37	4.12e-12	Schizophrenia;
LUSC	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg22961513	chr11:14280813	SPON1	0.34	5.85	0.3	1.16e-8	Mitochondrial DNA levels;
LUSC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg06740227	chr12:86229804	RASSF9	-0.37	-5.87	-0.31	1.05e-8	Major depressive disorder;
LUSC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg01125463	chr6:42946178	PEX6	-0.36	-5.97	-0.31	6.19e-9	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg20368463	chr18:77673604	PQLC1	-0.67	-6.95	-0.36	1.94e-11	Opioid sensitivity;
LUSC	cis	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-5.89	-0.31	9.56e-9	Retinal vascular caliber;
LUSC	trans	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Parkinson's disease;
LUSC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	1.03	19.13	0.72	1.36e-55	Menopause (age at onset);
LUSC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.02e-11	Tonsillectomy;
LUSC	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Body mass index;
LUSC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg21724239	chr8:58056113	NA	0.79	9.51	0.46	3.98e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg00677455	chr12:58241039	CTDSP2	0.7	11.0	0.52	3.3e-24	Multiple sclerosis;
LUSC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.77	0.3	1.82e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10186029	0.676	rs10932464	chr2:213968315	T/A	cg08319019	chr2:214017104	IKZF2	0.6	8.76	0.43	9.95e-17	Systemic sclerosis;
LUSC	cis	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg05901451	chr6:126070800	HEY2	0.57	8.58	0.42	3.72e-16	Endometrial cancer;
LUSC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08219700	chr8:58056026	NA	0.64	8.24	0.41	3.88e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg13798780	chr7:105162888	PUS7	0.58	6.32	0.33	8.2e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs1972460	0.506	rs62012050	chr15:82532274	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.55	-8.54	-0.42	4.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg05896524	chr21:47604654	C21orf56	0.53	8.14	0.41	7.98e-15	Testicular germ cell tumor;
LUSC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg15445000	chr17:37608096	MED1	0.4	6.89	0.35	2.83e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.88e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs1941687	0.797	rs8086041	chr18:31402756	G/A	cg27147174	chr7:100797783	AP1S1	-0.43	-6.33	-0.33	7.78e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12484325	chr11:3688985	CHRNA10	-0.85	-6.83	-0.35	4.12e-11	Cognitive performance;
LUSC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg06363034	chr20:62225388	GMEB2	-0.46	-7.75	-0.39	1.11e-13	Glioblastoma;
LUSC	cis	rs4948102	0.642	rs766333	chr7:56126704	T/A	cg17215666	chr7:56131930	SUMF2	0.46	6.34	0.33	7.59e-10	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs12210905	0.688	rs72839471	chr6:27316959	C/T	cg08851530	chr6:28072375	NA	0.9	5.78	0.3	1.75e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs360798	0.532	rs360797	chr2:62942840	C/T	cg17519650	chr2:63277830	OTX1	-0.54	-7.64	-0.39	2.35e-13	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08109568	chr15:31115862	NA	0.49	7.13	0.36	6.39e-12	Huntington's disease progression;
LUSC	trans	rs67539049	1.000	rs77865852	chr8:11303336	A/G	cg26241650	chr22:40417538	FAM83F	0.43	5.99	0.31	5.54e-9	Itch intensity from mosquito bite;
LUSC	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg00105475	chr2:10696890	NA	-0.38	-6.27	-0.32	1.14e-9	Prostate cancer;
LUSC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	0.88	12.29	0.56	7.03e-29	Vitiligo;
LUSC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg03146154	chr1:46216737	IPP	-0.51	-7.46	-0.38	7.41e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	0.89	14.93	0.63	5.8e-39	Schizophrenia;
LUSC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg23791538	chr6:167370224	RNASET2	-0.41	-6.49	-0.33	3.02e-10	Crohn's disease;
LUSC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg27068330	chr11:65405492	SIPA1	-0.45	-5.95	-0.31	6.62e-9	Breast cancer;
LUSC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.12	16.67	0.67	7.63e-46	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg08000102	chr2:233561755	GIGYF2	-0.74	-11.26	-0.52	3.85e-25	Schizophrenia;
LUSC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.06	15.99	0.66	3.89e-43	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg26897989	chr16:1907736	C16orf73	-0.46	-6.81	-0.35	4.67e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.27	-0.37	2.57e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg18350739	chr11:68623251	NA	-0.36	-6.35	-0.33	7.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg18232548	chr7:50535776	DDC	0.52	7.97	0.4	2.49e-14	Malaria;
LUSC	trans	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04565464	chr8:145669602	NFKBIL2	0.39	6.41	0.33	4.9e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg13866156	chr1:1669148	SLC35E2	0.55	9.11	0.45	7.93e-18	Body mass index;
LUSC	cis	rs7180079	1.000	rs7165405	chr15:64662900	C/T	cg02848875	chr15:64387786	SNX1	-0.4	-5.67	-0.3	3.07e-8	Monocyte count;
LUSC	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs1942	1.000	rs1942	chr15:41774423	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.41	-6.45	-0.33	3.99e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs1865721	0.804	rs719179	chr18:73146396	A/G	cg26385618	chr18:73139727	C18orf62	-0.53	-9.74	-0.47	6.68e-20	Intelligence;
LUSC	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg05714579	chr10:131428358	MGMT	0.52	7.9	0.4	4e-14	Response to temozolomide;
LUSC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	16.05	0.66	2.22e-43	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2625529	0.730	rs6494990	chr15:72401074	T/A	cg16672083	chr15:72433130	SENP8	0.5	8.23	0.41	4.26e-15	Red blood cell count;
LUSC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.68	0.3	2.98e-8	Tonsillectomy;
LUSC	cis	rs1595825	0.891	rs57340905	chr2:198565823	C/T	cg00982548	chr2:198649783	BOLL	-0.55	-7.05	-0.36	1.03e-11	Ulcerative colitis;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg21548813	chr6:291882	DUSP22	-0.71	-11.7	-0.54	9.53e-27	Menopause (age at onset);
LUSC	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg05855489	chr10:104503620	C10orf26	0.66	10.06	0.48	5.56e-21	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs12618769	0.543	rs4851132	chr2:99042782	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.64	0.39	2.31e-13	Bipolar disorder;
LUSC	cis	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05901451	chr6:126070800	HEY2	0.57	8.56	0.42	4.25e-16	Endometrial cancer;
LUSC	cis	rs180358	0.568	rs1268353	chr11:116639692	C/T	cg08985259	chr11:116699649	APOC3	0.27	6.02	0.31	4.67e-9	Multiple sclerosis (severity);
LUSC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.79	0.35	5.21e-11	Tonsillectomy;
LUSC	cis	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg20307385	chr11:47447363	PSMC3	0.65	9.46	0.46	5.81e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg12292205	chr6:26970375	C6orf41	-0.52	-8.64	-0.43	2.31e-16	Schizophrenia;
LUSC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg04287289	chr16:89883240	FANCA	0.77	6.23	0.32	1.42e-9	Skin colour saturation;
LUSC	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.84	0.35	3.86e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg15556689	chr8:8085844	FLJ10661	0.42	5.9	0.31	9.05e-9	Recombination measurement;
LUSC	trans	rs12210905	0.925	rs7753123	chr6:26991540	G/C	cg11837749	chr1:55047332	ACOT11	0.55	6.0	0.31	5.25e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs61931739	0.635	rs7138254	chr12:33914422	G/T	cg13010199	chr12:38710504	ALG10B	0.41	6.12	0.32	2.65e-9	Morning vs. evening chronotype;
LUSC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg16228356	chr17:43848958	NA	0.25	5.86	0.31	1.13e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg17294928	chr15:75287854	SCAMP5	-0.76	-10.12	-0.48	3.67e-21	Blood trace element (Zn levels);
LUSC	trans	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.15	-0.32	2.19e-9	Depression;
LUSC	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.99	0.55	8.74e-28	Ileal carcinoids;
LUSC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.69	8.57	0.42	3.83e-16	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs7147624	0.938	rs7151148	chr14:65936665	G/C	cg03016385	chr14:66212404	NA	-0.81	-9.5	-0.46	4.2e-19	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg12463550	chr7:65579703	CRCP	0.47	7.06	0.36	9.86e-12	Aortic root size;
LUSC	cis	rs11645898	0.630	rs72791135	chr16:72259718	G/C	cg14768367	chr16:72042858	DHODH	-0.57	-5.89	-0.31	9.64e-9	Blood protein levels;
LUSC	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-7.93	-0.4	3.32e-14	Glomerular filtration rate (creatinine);
LUSC	trans	rs4662863	0.529	rs17049003	chr2:129766337	A/G	cg05506011	chr3:118864587	C3orf30;IGSF11	0.36	6.08	0.32	3.2e-9	Gut microbiome composition (winter);
LUSC	cis	rs9649213	0.511	rs6950994	chr7:97887872	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.68	-0.3	2.91e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg27266060	chr8:22091797	NA	0.39	7.12	0.36	6.62e-12	Hypertriglyceridemia;
LUSC	cis	rs4499344	0.633	rs259260	chr19:33153261	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	11.42	0.53	1.02e-25	Mean platelet volume;
LUSC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg18350739	chr11:68623251	NA	-0.36	-6.29	-0.33	9.83e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9311676	0.656	rs11130632	chr3:58369324	C/T	cg26110898	chr3:58419937	PDHB	0.42	6.88	0.35	2.97e-11	Systemic lupus erythematosus;
LUSC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg24733560	chr20:60626293	TAF4	0.42	7.58	0.38	3.34e-13	Body mass index;
LUSC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg25036284	chr2:26402008	FAM59B	-0.76	-11.1	-0.52	1.35e-24	Gut microbiome composition (summer);
LUSC	cis	rs911119	1.000	rs6114208	chr20:23621734	C/G	cg16589663	chr20:23618590	CST3	0.59	6.95	0.36	1.96e-11	Chronic kidney disease;
LUSC	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg08847533	chr14:75593920	NEK9	-0.39	-5.68	-0.3	2.98e-8	Caffeine consumption;
LUSC	cis	rs4474465	0.833	rs11606128	chr11:78156960	T/C	cg27205649	chr11:78285834	NARS2	-0.51	-5.97	-0.31	6.15e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7560272	0.538	rs17434655	chr2:73923089	C/T	cg20560298	chr2:73613845	ALMS1	-0.4	-6.12	-0.32	2.66e-9	Schizophrenia;
LUSC	cis	rs12474201	0.832	rs4953419	chr2:46989869	T/G	cg06386533	chr2:46925753	SOCS5	0.66	9.62	0.47	1.66e-19	Height;
LUSC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg12564285	chr5:131593104	PDLIM4	0.56	10.77	0.51	2e-23	Acylcarnitine levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04667467	chr16:90089176	GAS8	-0.47	-6.3	-0.33	9.45e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg14829155	chr15:31115871	NA	0.56	6.95	0.36	1.93e-11	Huntington's disease progression;
LUSC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg02503808	chr4:7069936	GRPEL1	1.0	14.09	0.61	1.01e-35	Monocyte percentage of white cells;
LUSC	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-8.6	-0.43	3.23e-16	Body mass index;
LUSC	cis	rs965469	1.000	rs6037547	chr20:3299228	C/A	cg25506879	chr20:3388711	C20orf194	-0.52	-5.66	-0.3	3.18e-8	IFN-related cytopenia;
LUSC	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.06	12.87	0.58	4.58e-31	Sexual dysfunction (female);
LUSC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.9	17.15	0.68	1.03e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg17971929	chr21:40555470	PSMG1	0.78	13.72	0.6	2.7e-34	Cognitive function;
LUSC	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg24642844	chr7:1081250	C7orf50	-0.69	-6.56	-0.34	2.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	9.74	0.47	6.84e-20	Height;
LUSC	cis	rs6546886	0.912	rs6741544	chr2:74294221	T/C	cg14702570	chr2:74259524	NA	-0.31	-5.85	-0.31	1.15e-8	Dialysis-related mortality;
LUSC	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg06917634	chr15:78832804	PSMA4	0.48	6.18	0.32	1.83e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg27068330	chr11:65405492	SIPA1	-0.76	-10.87	-0.51	9.41e-24	Acne (severe);
LUSC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg08270630	chr22:50330655	NA	-0.43	-6.58	-0.34	1.79e-10	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.44	-6.7	-0.34	8.96e-11	Alzheimer's disease (late onset);
LUSC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-11.33	-0.53	2.16e-25	Schizophrenia;
LUSC	cis	rs208520	0.909	rs9354410	chr6:67018584	C/T	cg07460842	chr6:66804631	NA	0.87	8.76	0.43	1.01e-16	Exhaled nitric oxide output;
LUSC	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg23173402	chr1:227635558	NA	0.56	6.26	0.32	1.2e-9	Major depressive disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02710346	chr3:148805157	HLTF	-0.75	-6.07	-0.32	3.38e-9	Cognitive performance;
LUSC	cis	rs11031096	0.568	rs10767891	chr11:4234524	A/G	cg18678763	chr11:4115507	RRM1	-0.4	-5.65	-0.3	3.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.2e-28	Corneal astigmatism;
LUSC	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg24459738	chr19:57751996	ZNF805	-0.52	-7.68	-0.39	1.83e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg17168535	chr8:21777572	XPO7	0.86	15.72	0.65	4.39e-42	Mean corpuscular volume;
LUSC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08677398	chr8:58056175	NA	0.52	6.29	0.33	9.86e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg11845111	chr2:191398756	TMEM194B	0.54	9.11	0.45	7.98e-18	Pulse pressure;
LUSC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg21770322	chr7:97807741	LMTK2	0.5	8.58	0.43	3.54e-16	Breast cancer;
LUSC	cis	rs11677416	1.000	rs1878320	chr2:113544467	T/C	cg27083787	chr2:113543245	IL1A	0.45	7.13	0.36	6.29e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.14	-0.45	6.37e-18	Monocyte percentage of white cells;
LUSC	trans	rs9401746	0.646	rs693793	chr6:124789269	A/G	cg16857858	chr7:27213984	HOXA10	0.55	6.32	0.33	8.57e-10	Bone mineral density (Ward's triangle area);
LUSC	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.24e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg02711726	chr17:80685570	FN3KRP	-0.41	-6.22	-0.32	1.52e-9	Glycated hemoglobin levels;
LUSC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg22834771	chr12:69754056	YEATS4	-0.5	-7.44	-0.38	8.41e-13	Blood protein levels;
LUSC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg04013166	chr16:89971882	TCF25	-0.68	-8.24	-0.41	3.96e-15	Skin colour saturation;
LUSC	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg03929089	chr4:120376271	NA	0.73	8.86	0.44	4.73e-17	Coronary artery disease;
LUSC	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg26566898	chr11:117069891	TAGLN	0.35	6.69	0.34	9.68e-11	Blood protein levels;
LUSC	cis	rs909341	0.909	rs6122158	chr20:62363096	G/A	cg09650180	chr20:62225654	GMEB2	-0.45	-5.85	-0.31	1.14e-8	Atopic dermatitis;
LUSC	cis	rs2652834	1.000	rs36116701	chr15:63397494	T/C	cg05507819	chr15:63340323	TPM1	0.68	8.27	0.41	3.21e-15	HDL cholesterol;
LUSC	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg26513180	chr16:89883248	FANCA	-0.76	-6.9	-0.35	2.58e-11	Caffeine consumption;
LUSC	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-1.04	-15.6	-0.65	1.29e-41	Exhaled nitric oxide output;
LUSC	cis	rs1953600	0.870	rs2789690	chr10:81938204	G/T	cg00277334	chr10:82204260	NA	0.45	7.12	0.36	6.71e-12	Sarcoidosis;
LUSC	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg07959070	chr22:50026188	C22orf34	-0.31	-6.3	-0.33	9.24e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg08219700	chr8:58056026	NA	0.46	6.02	0.31	4.64e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg16479474	chr6:28041457	NA	-0.33	-5.85	-0.31	1.14e-8	Depression;
LUSC	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg18196295	chr10:418757	DIP2C	0.5	8.32	0.41	2.28e-15	Psychosis in Alzheimer's disease;
LUSC	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg21100191	chr22:23484243	RTDR1	0.89	15.1	0.64	1.26e-39	Bone mineral density;
LUSC	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg17173187	chr15:85201210	NMB	0.37	5.99	0.31	5.29e-9	Schizophrenia;
LUSC	cis	rs10887741	0.690	rs4934358	chr10:89439744	C/A	cg24243914	chr10:89418206	PAPSS2	0.34	6.9	0.35	2.64e-11	Exercise (leisure time);
LUSC	cis	rs7524258	0.868	rs8179413	chr1:7267729	T/G	cg07173049	chr1:7289937	CAMTA1	0.35	7.25	0.37	2.85e-12	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg10518572	chr11:65560635	OVOL1	-0.25	-5.75	-0.3	1.97e-8	Acne (severe);
LUSC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.48	7.02	0.36	1.27e-11	Schizophrenia;
LUSC	cis	rs7267979	0.565	rs13040726	chr20:25559881	T/G	cg03522245	chr20:25566470	NINL	-0.39	-6.06	-0.31	3.64e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg17507749	chr15:85114479	UBE2QP1	0.56	7.14	0.36	5.77e-12	Schizophrenia;
LUSC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg02136620	chr5:178986620	RUFY1	0.51	8.34	0.42	1.91e-15	Lung cancer;
LUSC	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg10167463	chr7:75959203	YWHAG	-0.66	-10.07	-0.48	5.33e-21	Multiple sclerosis;
LUSC	cis	rs3771570	0.792	rs4675970	chr2:242200406	G/A	cg21155796	chr2:242212141	HDLBP	0.6	7.04	0.36	1.1e-11	Prostate cancer;
LUSC	cis	rs1376877	0.519	rs10197623	chr2:204243759	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.48	6.15	0.32	2.16e-9	Subclinical atherosclerosis traits (other);
LUSC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-9.97	-0.48	1.14e-20	Personality dimensions;
LUSC	cis	rs4919694	1.000	rs17881215	chr10:104629236	G/C	cg23093090	chr10:104574429	C10orf26	-0.49	-6.07	-0.32	3.4e-9	Arsenic metabolism;
LUSC	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.69	13.14	0.58	4.41e-32	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg20991723	chr1:152506922	NA	0.48	9.12	0.45	6.99e-18	Hair morphology;
LUSC	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg27661571	chr11:113659931	NA	-0.68	-7.8	-0.39	8.18e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg11130432	chr3:121712080	ILDR1	-0.63	-9.57	-0.46	2.41e-19	Multiple sclerosis;
LUSC	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg03585969	chr10:35415529	CREM	0.6	8.73	0.43	1.27e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs683250	0.730	rs2374424	chr11:83187113	A/G	cg26617787	chr11:123396133	GRAMD1B	0.3	6.06	0.31	3.7e-9	Subcortical brain region volumes;
LUSC	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg02023728	chr11:77925099	USP35	0.4	5.89	0.31	9.23e-9	Testicular germ cell tumor;
LUSC	cis	rs7224314	0.895	rs11654663	chr17:65389305	A/C	cg01507342	chr17:65387096	PITPNC1	-0.44	-7.71	-0.39	1.5e-13	Diisocyanate-induced asthma;
LUSC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.84	-10.95	-0.51	4.73e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg12463550	chr7:65579703	CRCP	0.56	8.38	0.42	1.53e-15	Aortic root size;
LUSC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19346786	chr7:2764209	NA	-0.46	-7.71	-0.39	1.41e-13	Height;
LUSC	cis	rs4704187	0.687	rs13360638	chr5:74433258	G/A	cg03227963	chr5:74354835	NA	0.3	6.51	0.34	2.8e-10	Response to amphetamines;
LUSC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg20203395	chr5:56204925	C5orf35	-0.48	-7.29	-0.37	2.32e-12	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg05025164	chr4:1340916	KIAA1530	0.5	8.05	0.4	1.42e-14	Obesity-related traits;
LUSC	cis	rs12980942	0.872	rs66724427	chr19:41776257	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.59	6.49	0.33	3.13e-10	Coronary artery disease;
LUSC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21171335	chr12:122356390	WDR66	0.64	9.81	0.47	3.96e-20	Mean platelet volume;
LUSC	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14240646	chr10:27532245	ACBD5	-0.66	-7.8	-0.39	8.22e-14	Breast cancer;
LUSC	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.89	15.25	0.64	3.17e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.93	-18.56	-0.71	2.52e-53	Ulcerative colitis;
LUSC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg05347473	chr6:146136440	FBXO30	-0.41	-7.02	-0.36	1.27e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6484504	0.532	rs7116443	chr11:31283170	T/C	cg26647111	chr11:31128758	NA	-0.43	-6.22	-0.32	1.48e-9	Red blood cell count;
LUSC	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg23625390	chr15:77176239	SCAPER	0.54	8.33	0.41	2.18e-15	Blood metabolite levels;
LUSC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg08470875	chr2:26401718	FAM59B	0.74	10.13	0.48	3.38e-21	Gut microbiome composition (summer);
LUSC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	16.58	0.67	1.84e-45	Platelet count;
LUSC	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg22532475	chr10:104410764	TRIM8	0.26	6.14	0.32	2.32e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg22166914	chr1:53195759	ZYG11B	-0.7	-12.19	-0.55	1.63e-28	Monocyte count;
LUSC	cis	rs2130392	0.962	rs35613786	chr4:185625657	A/G	cg04058563	chr4:185651563	MLF1IP	-0.41	-6.67	-0.34	1.06e-10	Kawasaki disease;
LUSC	cis	rs2963155	0.518	rs853178	chr5:142634799	C/T	cg17617527	chr5:142782415	NR3C1	0.7	8.24	0.41	3.96e-15	Breast cancer;
LUSC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg16240275	chr20:61666158	NCRNA00029	0.42	9.29	0.45	1.97e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6494488	0.500	rs72744764	chr15:65076887	G/A	cg08069370	chr15:64387884	SNX1	-0.65	-5.91	-0.31	8.23e-9	Coronary artery disease;
LUSC	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg00792783	chr2:198669748	PLCL1	0.43	5.68	0.3	3.01e-8	Dermatomyositis;
LUSC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.4	-5.89	-0.31	9.42e-9	Platelet count;
LUSC	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg14092571	chr14:90743983	NA	-0.89	-18.83	-0.72	2.03e-54	Gut microbiota (bacterial taxa);
LUSC	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	7.04	0.36	1.07e-11	Schizophrenia;
LUSC	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.93	-0.44	2.85e-17	Monocyte percentage of white cells;
LUSC	cis	rs6076065	1.000	rs2424533	chr20:23375907	C/T	cg11657817	chr20:23433608	CST11	0.44	8.66	0.43	2.12e-16	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg20608306	chr11:116969690	SIK3	0.38	6.33	0.33	8.09e-10	Blood protein levels;
LUSC	cis	rs250677	0.798	rs11168080	chr5:148409821	C/T	cg18129178	chr5:148520854	ABLIM3	-0.64	-9.41	-0.46	8.54e-19	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00556132	chr3:11684351	VGLL4	-0.42	-6.36	-0.33	6.65e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.33	0.56	4.73e-29	Ileal carcinoids;
LUSC	cis	rs9865818	0.791	rs4686955	chr3:188106379	A/G	cg23651889	chr3:188115336	LPP	0.39	5.91	0.31	8.23e-9	Allergic sensitization;
LUSC	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-10.68	-0.5	4.31e-23	Coffee consumption (cups per day);
LUSC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12826209	chr6:26865740	GUSBL1	0.75	9.0	0.44	1.72e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.75	-13.15	-0.58	4.26e-32	Height;
LUSC	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg05110241	chr16:68378359	PRMT7	0.66	7.04	0.36	1.13e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2729354	0.953	rs2649650	chr11:57327567	C/T	cg24343310	chr11:57249947	NA	0.34	6.26	0.32	1.15e-9	Blood protein levels;
LUSC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.39	0.33	5.58e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.74	-12.2	-0.56	1.48e-28	Lymphocyte percentage of white cells;
LUSC	cis	rs983392	0.709	rs11230194	chr11:59980315	C/G	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.16	-0.32	2.1e-9	Alzheimer's disease (late onset);
LUSC	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg24375607	chr4:120327624	NA	0.77	11.13	0.52	1.13e-24	Corneal astigmatism;
LUSC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	29.27	0.85	3.41e-94	Chronic sinus infection;
LUSC	cis	rs7267979	0.528	rs34485039	chr20:25583763	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.7	-12.37	-0.56	3.44e-29	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22438603	chr5:127418940	SLC12A2;FLJ33630	-0.53	-7.07	-0.36	8.83e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.94	0.44	2.8e-17	Menarche (age at onset);
LUSC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg12463550	chr7:65579703	CRCP	0.59	5.73	0.3	2.27e-8	Diabetic kidney disease;
LUSC	cis	rs7106204	0.858	rs2403889	chr11:24210226	T/C	ch.11.24196551F	chr11:24239977	NA	1.13	12.76	0.57	1.21e-30	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2274273	0.592	rs2878174	chr14:55470624	T/C	cg04306507	chr14:55594613	LGALS3	0.42	8.91	0.44	3.47e-17	Protein biomarker;
LUSC	cis	rs9469578	0.901	rs57303110	chr6:33706159	G/A	cg18708504	chr6:33715942	IP6K3	0.73	9.08	0.44	9.9e-18	Phosphorus levels;
LUSC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.53	-8.82	-0.43	6.36e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg06718696	chr17:78121285	EIF4A3	0.44	6.33	0.33	7.81e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg20848291	chr7:100343083	ZAN	-0.59	-7.99	-0.4	2.26e-14	Other erythrocyte phenotypes;
LUSC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg00310523	chr12:86230176	RASSF9	0.49	9.42	0.46	7.56e-19	Major depressive disorder;
LUSC	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.11	0.41	9.98e-15	Axial length;
LUSC	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg05855489	chr10:104503620	C10orf26	0.59	8.99	0.44	1.94e-17	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs926938	0.527	rs2335954	chr1:115534151	C/T	cg01522456	chr1:115632236	TSPAN2	0.43	6.75	0.35	6.72e-11	Autism;
LUSC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.02	0.4	1.82e-14	Lung cancer;
LUSC	trans	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg24247370	chr13:99142703	STK24	0.33	6.17	0.32	1.92e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Alcohol dependence;
LUSC	cis	rs59104589	0.617	rs16843642	chr2:242351379	T/G	cg14842376	chr2:242211374	HDLBP	0.56	6.63	0.34	1.32e-10	Fibrinogen levels;
LUSC	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg05855489	chr10:104503620	C10orf26	-0.68	-10.08	-0.48	4.71e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11543725	chr11:10329292	NA	-0.47	-6.36	-0.33	6.58e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg23791538	chr6:167370224	RNASET2	0.5	8.28	0.41	3.04e-15	Crohn's disease;
LUSC	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	0.95	13.67	0.6	4.25e-34	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs12760731	0.623	rs2300300	chr1:178419387	G/C	cg00404053	chr1:178313656	RASAL2	0.48	5.67	0.3	3.16e-8	Obesity-related traits;
LUSC	cis	rs6469656	0.892	rs10086419	chr8:117744771	C/T	cg24004040	chr8:117650383	NA	-0.43	-6.23	-0.32	1.4e-9	Colorectal cancer;
LUSC	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg05340658	chr4:99064831	C4orf37	0.59	8.83	0.43	6.11e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.82	0.3	1.42e-8	Breast cancer;
LUSC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg25036284	chr2:26402008	FAM59B	0.77	10.92	0.51	5.98e-24	Gut microbiome composition (summer);
LUSC	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg18721089	chr20:30220636	NA	-0.31	-5.67	-0.3	3.02e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg15423357	chr2:25149977	NA	0.44	8.76	0.43	1.03e-16	Body mass index;
LUSC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-9.75	-0.47	6.44e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs7712401	0.569	rs10080185	chr5:122351856	A/G	cg19077854	chr5:122220652	SNX24	-0.27	-6.25	-0.32	1.23e-9	Mean platelet volume;
LUSC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg04414720	chr1:150670196	GOLPH3L	-0.49	-7.76	-0.39	1.07e-13	Tonsillectomy;
LUSC	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	6.48	0.33	3.22e-10	Lung cancer;
LUSC	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg25214090	chr10:38739885	LOC399744	0.54	7.98	0.4	2.39e-14	Corneal astigmatism;
LUSC	cis	rs4702	0.611	rs7177338	chr15:91428636	G/A	cg05469396	chr15:91419421	FURIN	0.46	8.18	0.41	6.19e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg21775007	chr8:11205619	TDH	-0.44	-6.2	-0.32	1.69e-9	Joint mobility (Beighton score);
LUSC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg03146154	chr1:46216737	IPP	-0.57	-8.28	-0.41	2.93e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg26876637	chr1:152193138	HRNR	0.44	6.13	0.32	2.46e-9	Atopic dermatitis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07133894	chr22:32808171	C22orf28	-0.49	-6.39	-0.33	5.5e-10	Hepatitis;
LUSC	cis	rs4474465	0.850	rs11237546	chr11:78266924	T/C	cg27205649	chr11:78285834	NARS2	0.52	6.11	0.32	2.71e-9	Alzheimer's disease (survival time);
LUSC	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg24375607	chr4:120327624	NA	0.66	10.52	0.5	1.48e-22	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg11062466	chr8:58055876	NA	-0.5	-6.92	-0.35	2.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg21361702	chr7:150065534	REPIN1	0.56	8.24	0.41	4.1e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg23630131	chr7:65973040	NA	-0.2	-5.72	-0.3	2.34e-8	Aortic root size;
LUSC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg21770322	chr7:97807741	LMTK2	0.4	7.03	0.36	1.18e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg21211680	chr2:198530	NA	-0.52	-6.32	-0.33	8.23e-10	Blood protein levels;
LUSC	cis	rs3771570	0.901	rs3771587	chr2:242409701	A/G	cg21155796	chr2:242212141	HDLBP	0.61	6.86	0.35	3.35e-11	Prostate cancer;
LUSC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg04414720	chr1:150670196	GOLPH3L	0.49	7.88	0.4	4.66e-14	Tonsillectomy;
LUSC	cis	rs7572644	0.709	rs7607546	chr2:28118662	G/A	cg27432699	chr2:27873401	GPN1	-0.52	-6.44	-0.33	4.27e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg08645402	chr16:4508243	NA	0.49	7.34	0.37	1.66e-12	Schizophrenia;
LUSC	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg06671706	chr8:8559999	CLDN23	0.49	6.36	0.33	6.69e-10	Obesity-related traits;
LUSC	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg19628046	chr18:33552617	C18orf21	0.52	6.36	0.33	6.8e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg22601191	chr20:60968625	CABLES2	0.41	5.95	0.31	6.76e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs4729127	0.908	rs55746023	chr7:94006138	G/A	cg20086523	chr13:52378287	DHRS12	0.54	6.31	0.33	8.9e-10	Intelligence;
LUSC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg08219700	chr8:58056026	NA	-0.45	-5.95	-0.31	6.94e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.11e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg18240062	chr17:79603768	NPLOC4	-0.8	-15.53	-0.65	2.54e-41	Eye color traits;
LUSC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.52	-0.34	2.55e-10	Life satisfaction;
LUSC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg14092988	chr3:52407081	DNAH1	0.32	6.28	0.33	1.05e-9	Bipolar disorder;
LUSC	trans	rs2587949	0.615	rs2600113	chr3:4225734	T/G	cg15139668	chr4:4577005	NA	-0.42	-6.25	-0.32	1.28e-9	Periodontitis (DPAL);
LUSC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg22535103	chr8:58192502	C8orf71	-0.56	-6.74	-0.35	7.17e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg23791538	chr6:167370224	RNASET2	0.42	6.77	0.35	5.78e-11	Crohn's disease;
LUSC	trans	rs7939886	0.920	rs17150095	chr11:55902900	A/G	cg03929089	chr4:120376271	NA	0.77	6.09	0.32	3.03e-9	Myopia (pathological);
LUSC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs11039100	0.850	rs35990969	chr11:5834242	G/A	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg10911889	chr6:126070802	HEY2	0.42	6.44	0.33	4.14e-10	Brugada syndrome;
LUSC	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg10518572	chr11:65560635	OVOL1	-0.25	-5.78	-0.3	1.76e-8	Acne (severe);
LUSC	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg27411982	chr8:10470053	RP1L1	-0.37	-5.9	-0.31	8.72e-9	Neuroticism;
LUSC	cis	rs16854884	0.657	rs6766685	chr3:143736916	C/T	cg06585982	chr3:143692056	C3orf58	0.5	7.93	0.4	3.36e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	9.36	0.46	1.23e-18	Motion sickness;
LUSC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg09455208	chr3:40491958	NA	0.58	10.55	0.5	1.17e-22	Renal cell carcinoma;
LUSC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12292205	chr6:26970375	C6orf41	-0.58	-7.16	-0.36	5.14e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10843647	1.000	rs1586280	chr12:30325540	G/T	cg12718339	chr12:29936407	TMTC1	-0.35	-5.89	-0.31	9.61e-9	Glucose homeostasis traits;
LUSC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.21	0.52	5.93e-25	Prudent dietary pattern;
LUSC	cis	rs2445762	0.584	rs17602588	chr15:51655475	A/T	cg07517944	chr15:51633816	GLDN	0.39	6.5	0.34	2.84e-10	Hormone measurements;
LUSC	cis	rs7772486	0.558	rs2142980	chr6:146080679	G/A	cg23711669	chr6:146136114	FBXO30	-0.7	-9.96	-0.48	1.22e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg22800045	chr5:56110881	MAP3K1	0.79	10.02	0.48	7.68e-21	Initial pursuit acceleration;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg01238044	chr22:24384105	GSTT1	-0.53	-7.79	-0.39	8.77e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg00530320	chr1:46809349	NSUN4	0.56	8.67	0.43	1.91e-16	Menopause (age at onset);
LUSC	cis	rs11997175	0.603	rs11778978	chr8:33804743	G/T	ch.8.33884649F	chr8:33765107	NA	0.42	6.36	0.33	6.55e-10	Body mass index;
LUSC	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg17385448	chr1:15911702	AGMAT	0.35	5.83	0.3	1.33e-8	Systolic blood pressure;
LUSC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.42	6.04	0.31	4.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1499972	0.941	rs62264763	chr3:117637305	G/A	cg07612923	chr3:117604196	NA	0.62	5.64	0.3	3.54e-8	Schizophrenia;
LUSC	trans	rs2229238	0.911	rs111600849	chr1:154487489	G/A	cg25273160	chr11:56955011	LRRC55	0.32	6.23	0.32	1.44e-9	Coronary heart disease;
LUSC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg02018176	chr4:1364513	KIAA1530	0.53	9.24	0.45	2.99e-18	Obesity-related traits;
LUSC	cis	rs2579519	0.547	rs11683523	chr2:96544855	T/C	cg23100626	chr2:96804247	ASTL	0.29	6.83	0.35	4.03e-11	Diastolic blood pressure;
LUSC	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.45	-0.42	8.99e-16	Heart rate;
LUSC	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs9503598	0.714	rs11242859	chr6:3454032	G/A	cg00476032	chr6:3446245	SLC22A23	0.38	7.59	0.38	3.22e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.09e-18	Menopause (age at onset);
LUSC	cis	rs12137294	0.794	rs1172160	chr1:205207015	G/A	cg21643547	chr1:205240462	TMCC2	-0.36	-6.46	-0.33	3.74e-10	Red cell distribution width;
LUSC	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg22601191	chr20:60968625	CABLES2	0.55	9.49	0.46	4.45e-19	Colorectal cancer;
LUSC	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.73e-23	Bladder cancer;
LUSC	cis	rs7760949	0.889	rs9475795	chr6:13931270	A/C	cg27413430	chr6:13925136	RNF182	0.6	9.2	0.45	3.94e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2652822	1.000	rs1126309	chr15:63429062	A/G	cg02713581	chr15:63449717	RPS27L	0.4	6.46	0.33	3.69e-10	Metabolic traits;
LUSC	cis	rs9462027	0.585	rs188190	chr6:34551086	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.03	-0.31	4.43e-9	Systemic lupus erythematosus;
LUSC	cis	rs1018836	0.632	rs7017630	chr8:91482604	A/G	cg16814680	chr8:91681699	NA	-0.66	-9.9	-0.48	1.9e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg06028605	chr16:24865363	SLC5A11	0.5	8.62	0.43	2.69e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg00857998	chr1:205179979	DSTYK	0.61	9.24	0.45	2.97e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg04450456	chr4:17643702	FAM184B	0.4	6.74	0.35	6.84e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-7.06	-0.36	9.86e-12	Monocyte percentage of white cells;
LUSC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg14820908	chr5:178986412	RUFY1	0.56	9.79	0.47	4.73e-20	Lung cancer;
LUSC	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg13319975	chr6:146136371	FBXO30	0.49	7.37	0.37	1.31e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs886126	1.000	rs876027	chr12:111678458	A/T	cg10833066	chr12:111807467	FAM109A	0.4	6.56	0.34	2.05e-10	Coronary heart disease;
LUSC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg17971929	chr21:40555470	PSMG1	0.51	7.96	0.4	2.65e-14	Cognitive function;
LUSC	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg21775007	chr8:11205619	TDH	0.79	13.15	0.58	4.09e-32	Retinal vascular caliber;
LUSC	cis	rs4780401	0.632	rs7192366	chr16:11835209	C/G	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.47	-0.42	8.12e-16	Rheumatoid arthritis;
LUSC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg26897989	chr16:1907736	C16orf73	0.48	7.21	0.37	3.84e-12	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg22437258	chr11:111473054	SIK2	0.48	6.45	0.33	4.01e-10	Primary sclerosing cholangitis;
LUSC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00166722	chr3:10149974	C3orf24	0.53	7.36	0.37	1.41e-12	Alzheimer's disease;
LUSC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.44e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg07936489	chr17:37558343	FBXL20	-0.71	-9.84	-0.47	3.21e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	13.4	0.59	4.48e-33	Alzheimer's disease;
LUSC	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg22089800	chr15:90895588	ZNF774	0.53	7.56	0.38	3.96e-13	Rheumatoid arthritis;
LUSC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg07395648	chr5:131743802	NA	-0.41	-6.45	-0.33	3.85e-10	Breast cancer;Mosquito bite size;
LUSC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	14.89	0.63	8.02e-39	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22980127	chr19:33182716	NUDT19	0.92	12.61	0.57	4.49e-30	Red blood cell traits;
LUSC	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21659725	chr3:3221576	CRBN	0.52	8.17	0.41	6.5e-15	Body mass index;
LUSC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	9.38	0.46	1.02e-18	Menopause (age at onset);
LUSC	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg02423579	chr7:2872169	GNA12	-0.41	-6.41	-0.33	4.97e-10	Height;
LUSC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.52	-8.41	-0.42	1.18e-15	IgG glycosylation;
LUSC	cis	rs13401104	0.686	rs72620812	chr2:237118765	C/T	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs6940638	1.000	rs12215241	chr6:27023081	G/A	cg05738196	chr6:26577821	NA	-0.5	-5.65	-0.3	3.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08280861	chr8:58055591	NA	0.53	5.8	0.3	1.53e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg20203395	chr5:56204925	C5orf35	-0.72	-9.84	-0.47	3.21e-20	Initial pursuit acceleration;
LUSC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg12310025	chr6:25882481	NA	-0.5	-9.07	-0.44	1.03e-17	Blood metabolite levels;
LUSC	cis	rs4654899	1.000	rs4654899	chr1:21410231	G/T	cg01072550	chr1:21505969	NA	-0.54	-8.53	-0.42	5.19e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07988820	chr12:82153109	PPFIA2	-0.42	-6.25	-0.32	1.22e-9	Resting heart rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02916409	chr16:2510063	C16orf59	0.41	6.13	0.32	2.53e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg24130564	chr14:104152367	KLC1	-0.54	-7.82	-0.39	6.77e-14	Body mass index;
LUSC	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.23	-0.32	1.41e-9	Sudden cardiac arrest;
LUSC	cis	rs478607	0.915	rs61884449	chr11:64485193	C/T	cg19131476	chr11:64387923	NRXN2	0.34	5.89	0.31	9.28e-9	Urate levels;
LUSC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-0.9	-16.73	-0.68	4.51e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11958404	0.932	rs72816580	chr5:157432221	A/T	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg07936489	chr17:37558343	FBXL20	0.81	9.95	0.48	1.31e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg18350739	chr11:68623251	NA	-0.37	-6.34	-0.33	7.66e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg11019008	chr10:131425282	MGMT	-0.41	-6.28	-0.32	1.08e-9	Response to temozolomide;
LUSC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg09165964	chr15:75287851	SCAMP5	-1.01	-15.09	-0.64	1.33e-39	Blood trace element (Zn levels);
LUSC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg02038168	chr22:39784481	NA	-0.47	-7.53	-0.38	4.64e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-6.43	-0.33	4.46e-10	Longevity;
LUSC	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-9.73	-0.47	7.28e-20	Morning vs. evening chronotype;
LUSC	trans	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg13565492	chr6:43139072	SRF	-0.74	-10.65	-0.5	5.16e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-9.01	-0.44	1.6e-17	Morning vs. evening chronotype;
LUSC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg00701064	chr4:6280414	WFS1	0.58	14.08	0.61	1.13e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11141652	chr22:24348549	GSTTP1	0.38	5.79	0.3	1.63e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg23590916	chr17:43697445	MGC57346	-0.49	-6.64	-0.34	1.25e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg09436375	chr6:42928200	GNMT	-0.29	-6.82	-0.35	4.33e-11	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs2677744	0.626	rs11207	chr15:91497239	C/T	cg22570213	chr15:91497863	RCCD1	0.39	5.7	0.3	2.57e-8	Attention deficit hyperactivity disorder;
LUSC	trans	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg25214090	chr10:38739885	LOC399744	0.54	8.03	0.4	1.7e-14	Corneal astigmatism;
LUSC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-9.44	-0.46	6.41e-19	Chronic sinus infection;
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg27094323	chr7:1216898	NA	-0.43	-7.47	-0.38	7.24e-13	Longevity;Endometriosis;
LUSC	cis	rs7589342	0.929	rs7562054	chr2:106433513	G/C	cg16077055	chr2:106428750	NCK2	0.38	7.26	0.37	2.75e-12	Addiction;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23016766	chr1:33116697	RBBP4;ZBTB8OS	-0.47	-6.98	-0.36	1.56e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4400599	0.572	rs7516809	chr1:154205501	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.84	-0.3	1.26e-8	Platelet distribution width;
LUSC	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg01884057	chr2:25150051	NA	0.42	8.87	0.44	4.34e-17	Body mass index;
LUSC	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg07959070	chr22:50026188	C22orf34	-0.32	-5.71	-0.3	2.51e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14159747	chr11:113255604	NA	0.32	8.22	0.41	4.5e-15	Neuroticism;
LUSC	cis	rs6500395	1.000	rs9938308	chr16:48607229	A/G	cg04672837	chr16:48644449	N4BP1	0.46	6.89	0.35	2.76e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.48	0.33	3.36e-10	Menarche (age at onset);
LUSC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg18230493	chr5:56204884	C5orf35	-0.87	-12.96	-0.58	2.16e-31	Initial pursuit acceleration;
LUSC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg01657329	chr11:68192670	LRP5	-0.42	-6.36	-0.33	6.68e-10	Total body bone mineral density;
LUSC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.43	-5.66	-0.3	3.28e-8	Menarche (age at onset);
LUSC	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg05182265	chr7:156933206	UBE3C	0.48	7.12	0.36	6.64e-12	Body mass index;
LUSC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg13699009	chr12:122356056	WDR66	0.51	8.15	0.41	7.36e-15	Mean platelet volume;
LUSC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	0.99	14.13	0.61	7.27e-36	Eosinophil percentage of granulocytes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14176475	chr9:135282081	TTF1	0.44	6.33	0.33	8.05e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg04374321	chr14:90722782	PSMC1	0.73	11.56	0.53	3.11e-26	Mortality in heart failure;
LUSC	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs6942756	0.806	rs10248810	chr7:128993806	G/A	cg02491457	chr7:128862824	NA	-0.5	-7.33	-0.37	1.73e-12	White matter hyperintensity burden;
LUSC	trans	rs2039659	0.719	rs1753741	chr13:86250565	A/G	cg22803222	chr6:76636725	IMPG1	0.38	6.06	0.31	3.77e-9	Blood osmolality (transformed sodium);
LUSC	trans	rs62238980	0.614	rs79173736	chr22:32379966	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21545522	chr1:205238299	TMCC2	0.5	9.4	0.46	9.21e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs57046232	0.552	rs6133307	chr20:6333298	C/T	cg21095983	chr6:86352623	SYNCRIP	0.47	7.02	0.36	1.26e-11	Colorectal cancer;
LUSC	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-1.02	-20.42	-0.75	1.04e-60	Dilated cardiomyopathy;
LUSC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg02569458	chr12:86230093	RASSF9	0.57	9.54	0.46	3.09e-19	Major depressive disorder;
LUSC	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18932078	chr1:2524107	MMEL1	0.32	7.12	0.36	6.57e-12	Ulcerative colitis;
LUSC	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg01884057	chr2:25150051	NA	0.44	10.07	0.48	5.3e-21	Body mass index in non-asthmatics;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg16327326	chr16:1662895	IFT140	0.38	6.81	0.35	4.48e-11	Triglycerides;
LUSC	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg09036531	chr10:96991505	NA	-0.62	-10.18	-0.49	2.18e-21	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.69	-0.3	2.8e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs62400317	0.762	rs12214794	chr6:44931465	G/A	cg18551225	chr6:44695536	NA	-0.45	-7.23	-0.37	3.38e-12	Total body bone mineral density;
LUSC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07256732	chr16:621771	PIGQ	-0.36	-6.42	-0.33	4.56e-10	Height;
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18538332	chr22:24372958	LOC391322	-0.49	-8.74	-0.43	1.12e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10979	1.000	rs9376762	chr6:143887248	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-12.01	-0.55	7.28e-28	Hypospadias;
LUSC	cis	rs12760731	0.720	rs12037817	chr1:178261750	A/G	cg00404053	chr1:178313656	RASAL2	0.58	6.29	0.33	1e-9	Obesity-related traits;
LUSC	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg13010199	chr12:38710504	ALG10B	0.7	10.81	0.51	1.48e-23	Bladder cancer;
LUSC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg13798912	chr7:905769	UNC84A	0.59	5.97	0.31	6.05e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs11055008	0.620	rs2111941	chr12:12829404	A/T	cg04607235	chr12:12878440	APOLD1	0.51	7.56	0.38	3.87e-13	Pulse pressure;
LUSC	cis	rs7681440	0.605	rs1372509	chr4:90817311	A/G	cg20003494	chr4:90757398	SNCA	-0.35	-5.87	-0.31	1.07e-8	Dementia with Lewy bodies;
LUSC	cis	rs7681440	0.647	rs11941110	chr4:90819569	T/C	cg15133208	chr4:90757351	SNCA	-0.36	-5.98	-0.31	5.72e-9	Dementia with Lewy bodies;
LUSC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg24920358	chr1:40204285	PPIE	0.6	10.8	0.51	1.64e-23	Blood protein levels;
LUSC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg12963246	chr6:28129442	ZNF389	0.42	6.47	0.33	3.5e-10	Parkinson's disease;
LUSC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg13010199	chr12:38710504	ALG10B	0.7	10.75	0.51	2.4e-23	Bladder cancer;
LUSC	cis	rs28655083	1.000	rs28655083	chr16:77061214	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-6.33	-0.33	7.84e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg04369109	chr6:150039330	LATS1	-0.6	-8.83	-0.43	6.2e-17	Lung cancer;
LUSC	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	23.78	0.79	7.4e-74	Chronic sinus infection;
LUSC	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg04310649	chr10:35416472	CREM	-0.4	-6.27	-0.32	1.13e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg19318889	chr4:1322082	MAEA	0.48	7.69	0.39	1.68e-13	Obesity-related traits;
LUSC	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26314531	chr2:26401878	FAM59B	0.66	8.91	0.44	3.32e-17	Gut microbiome composition (summer);
LUSC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg10909506	chr17:38081995	ORMDL3	0.34	6.03	0.31	4.45e-9	Self-reported allergy;
LUSC	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg19052272	chr2:3704530	ALLC	-0.49	-8.19	-0.41	5.6e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg08888203	chr3:10149979	C3orf24	0.58	7.61	0.38	2.91e-13	Alzheimer's disease;
LUSC	cis	rs1953600	0.687	rs3851054	chr10:81933306	A/G	cg00277334	chr10:82204260	NA	0.36	5.72	0.3	2.4e-8	Sarcoidosis;
LUSC	cis	rs6460942	0.591	rs62448727	chr7:12332362	G/C	cg06484146	chr7:12443880	VWDE	-0.57	-5.98	-0.31	5.79e-9	Coronary artery disease;
LUSC	cis	rs981844	1.000	rs2606328	chr4:154653864	C/T	cg10279832	chr4:154682576	RNF175	-0.38	-5.91	-0.31	8.4e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs1957429	0.901	rs1467571	chr14:65347682	C/T	cg23373153	chr14:65346875	NA	1.07	12.89	0.58	3.85e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs73206853	0.841	rs73191839	chr12:110967652	G/T	cg12870014	chr12:110450643	ANKRD13A	0.67	6.47	0.33	3.57e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg06002616	chr8:101225028	SPAG1	-0.41	-6.83	-0.35	4.11e-11	Atrioventricular conduction;
LUSC	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.92	15.67	0.65	7e-42	Bladder cancer;
LUSC	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg00277334	chr10:82204260	NA	-0.59	-9.81	-0.47	4.05e-20	Post bronchodilator FEV1;
LUSC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.7	-11.17	-0.52	8.08e-25	Monocyte percentage of white cells;
LUSC	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg01990225	chr2:97406019	LMAN2L	-1.09	-7.42	-0.38	9.98e-13	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs13082711	0.911	rs6773733	chr3:27502131	C/A	cg02860705	chr3:27208620	NA	0.5	8.35	0.42	1.86e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.9	12.12	0.55	2.84e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.81	0.54	3.94e-27	Prudent dietary pattern;
LUSC	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg08997352	chr12:9597637	DDX12	-0.71	-11.07	-0.52	1.83e-24	Breast size;
LUSC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	5.83	0.3	1.33e-8	Menopause (age at onset);
LUSC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg15649852	chr7:65879115	NA	-0.4	-5.66	-0.3	3.23e-8	Aortic root size;
LUSC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg23711669	chr6:146136114	FBXO30	0.9	16.79	0.68	2.66e-46	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg06606381	chr12:133084897	FBRSL1	-0.97	-8.2	-0.41	5.16e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1256061	0.646	rs1256059	chr14:64710417	A/G	cg21174375	chr14:64681225	SYNE2	0.32	5.81	0.3	1.45e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-7.96	-0.4	2.65e-14	Schizophrenia;
LUSC	cis	rs9311676	0.656	rs11130634	chr3:58379123	A/C	cg26110898	chr3:58419937	PDHB	0.42	6.83	0.35	4.07e-11	Systemic lupus erythematosus;
LUSC	cis	rs6977660	0.943	rs10225293	chr7:19840636	C/T	cg07541023	chr7:19748670	TWISTNB	-0.52	-6.01	-0.31	4.8e-9	Thyroid stimulating hormone;
LUSC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06481639	chr22:41940642	POLR3H	0.51	5.8	0.3	1.51e-8	Vitiligo;
LUSC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.8	10.48	0.5	2.06e-22	Schizophrenia;
LUSC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.66	-12.01	-0.55	7.21e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.23e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4363385	0.747	rs2339493	chr1:152975277	G/A	cg25856811	chr1:152973957	SPRR3	-0.34	-5.65	-0.3	3.43e-8	Inflammatory skin disease;
LUSC	trans	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg21659725	chr3:3221576	CRBN	-0.46	-7.03	-0.36	1.16e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs68170813	0.523	rs4730241	chr7:107057361	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.06	-0.44	1.15e-17	Coronary artery disease;
LUSC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.75	11.6	0.54	2.29e-26	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6960043	0.743	rs1002061	chr7:15039499	A/T	cg19272540	chr7:15055459	NA	-0.35	-8.39	-0.42	1.35e-15	Type 2 diabetes;
LUSC	cis	rs1595825	0.891	rs892513	chr2:198905874	A/G	cg10547527	chr2:198650123	BOLL	0.49	5.79	0.3	1.63e-8	Ulcerative colitis;
LUSC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg18230493	chr5:56204884	C5orf35	-0.95	-14.05	-0.61	1.46e-35	Type 2 diabetes;
LUSC	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg03060546	chr3:49711283	APEH	0.63	7.35	0.37	1.52e-12	Menarche (age at onset);
LUSC	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg02023728	chr11:77925099	USP35	0.46	6.33	0.33	7.78e-10	Testicular germ cell tumor;
LUSC	cis	rs6942756	1.000	rs7806089	chr7:128972215	C/G	cg02491457	chr7:128862824	NA	-0.48	-6.47	-0.33	3.56e-10	White matter hyperintensity burden;
LUSC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	0.79	13.73	0.6	2.63e-34	Longevity;
LUSC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg13114125	chr14:105738426	BRF1	-0.9	-15.55	-0.65	2.13e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg23283495	chr1:209979779	IRF6	0.56	7.63	0.39	2.55e-13	Cleft lip with or without cleft palate;
LUSC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.83	0.35	3.98e-11	Platelet count;
LUSC	cis	rs7091068	0.721	rs618951	chr10:95404967	A/G	cg20715218	chr10:95462985	C10orf4	-0.62	-7.25	-0.37	2.98e-12	Urinary tract infection frequency;
LUSC	cis	rs7615316	1.000	rs6784089	chr3:142356496	T/C	cg16271453	chr3:142027066	XRN1	-0.34	-5.74	-0.3	2.09e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2625529	0.526	rs7183810	chr15:72560458	A/T	cg16672083	chr15:72433130	SENP8	0.47	7.71	0.39	1.45e-13	Red blood cell count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18417464	chr7:139025179	C7orf55	-0.4	-5.99	-0.31	5.56e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06634786	chr22:41940651	POLR3H	0.49	5.78	0.3	1.74e-8	Vitiligo;
LUSC	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg06937548	chr11:34938143	PDHX;APIP	-0.41	-5.66	-0.3	3.25e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.71	0.54	9.16e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.08	-0.32	3.31e-9	Resting heart rate;
LUSC	cis	rs8099014	1.000	rs4637007	chr18:56126282	G/A	cg12907477	chr18:56117327	MIR122	0.44	6.9	0.35	2.6e-11	Platelet count;
LUSC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg04166393	chr7:2884313	GNA12	0.43	5.66	0.3	3.31e-8	Height;
LUSC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.86	-0.58	4.88e-31	Alzheimer's disease;
LUSC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg18230493	chr5:56204884	C5orf35	-0.92	-13.91	-0.61	5.09e-35	Initial pursuit acceleration;
LUSC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg08859206	chr1:53392774	SCP2	0.46	7.75	0.39	1.1e-13	Monocyte count;
LUSC	cis	rs9646944	0.531	rs17027029	chr2:102990648	G/C	cg20060108	chr2:102954350	IL1RL1	0.48	6.35	0.33	6.92e-10	Blood protein levels;
LUSC	cis	rs3947	0.906	rs709822	chr8:11702313	C/G	cg00262122	chr8:11665843	FDFT1	-0.6	-7.98	-0.4	2.4e-14	Blood protein levels;
LUSC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg06636001	chr8:8085503	FLJ10661	0.74	10.4	0.49	3.89e-22	Red cell distribution width;
LUSC	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg21171335	chr12:122356390	WDR66	0.42	6.04	0.31	4.22e-9	Mean corpuscular volume;
LUSC	cis	rs1461503	0.868	rs7126785	chr11:122839564	C/A	cg27398637	chr11:122830231	C11orf63	-0.4	-6.51	-0.34	2.81e-10	Menarche (age at onset);
LUSC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg17340268	chr14:105411764	AHNAK2	-0.38	-6.07	-0.32	3.45e-9	Rheumatoid arthritis;
LUSC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg07636037	chr3:49044803	WDR6	0.44	6.39	0.33	5.46e-10	Resting heart rate;
LUSC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-6.49	-0.33	3.09e-10	High light scatter reticulocyte count;
LUSC	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg22705602	chr4:152727874	NA	0.35	7.6	0.38	3.1e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-6.49	-0.33	3.07e-10	Longevity;Endometriosis;
LUSC	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.53	0.46	3.29e-19	Coffee consumption (cups per day);
LUSC	cis	rs4474465	1.000	rs10899511	chr11:78170923	T/A	cg27205649	chr11:78285834	NARS2	-0.48	-5.74	-0.3	2.14e-8	Alzheimer's disease (survival time);
LUSC	cis	rs6754311	0.593	rs7355359	chr2:136462441	C/T	cg07169764	chr2:136633963	MCM6	-0.55	-7.3	-0.37	2.16e-12	Mosquito bite size;
LUSC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-7.13	-0.36	6.36e-12	Schizophrenia;
LUSC	trans	rs9944715	0.954	rs8086610	chr18:43844658	A/C	cg01718231	chr17:29326311	RNF135	-0.48	-6.56	-0.34	2.06e-10	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg14784868	chr12:69753453	YEATS4	0.61	8.54	0.42	4.9e-16	Response to diuretic therapy;
LUSC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg18681998	chr4:17616180	MED28	0.85	15.99	0.66	3.99e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08045932	chr20:61659980	NA	0.6	10.57	0.5	1.04e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.06	-0.31	3.64e-9	Coronary artery disease;
LUSC	cis	rs2688608	0.934	rs2675679	chr10:75658581	C/T	cg17411546	chr10:75410026	SYNPO2L	-0.43	-6.37	-0.33	6.36e-10	Inflammatory bowel disease;
LUSC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03264133	chr6:25882463	NA	0.62	10.38	0.49	4.71e-22	Blood metabolite levels;
LUSC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg07741184	chr6:167504864	NA	0.4	7.1	0.36	7.74e-12	Primary biliary cholangitis;
LUSC	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg03676636	chr4:99064102	C4orf37	0.3	5.99	0.31	5.55e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs737008	0.960	rs11640295	chr16:11390728	C/G	cg00044050	chr16:11439710	C16orf75	0.57	8.62	0.43	2.71e-16	Obesity-related traits;
LUSC	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.91	15.42	0.64	7e-41	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13802269	chr4:120133706	USP53	-0.45	-6.68	-0.34	9.99e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.03	0.31	4.3e-9	Schizophrenia;
LUSC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.72	7.21	0.37	3.65e-12	Initial pursuit acceleration;
LUSC	trans	rs208520	0.955	rs208538	chr6:66964492	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-12.26	-0.56	8.59e-29	Exhaled nitric oxide output;
LUSC	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.32	-7.04	-0.36	1.1e-11	Dupuytren's disease;
LUSC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg23262073	chr20:60523788	NA	-0.46	-6.81	-0.35	4.43e-11	Body mass index;
LUSC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg04871131	chr7:94954202	PON1	-0.38	-6.06	-0.31	3.74e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.35e-11	Total body bone mineral density;
LUSC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg12560992	chr17:57184187	TRIM37	0.83	15.26	0.64	2.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg13114125	chr14:105738426	BRF1	-0.94	-15.18	-0.64	5.83e-40	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg01528321	chr10:82214614	TSPAN14	0.83	12.43	0.56	2.11e-29	Post bronchodilator FEV1;
LUSC	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg22709100	chr7:91322751	NA	0.39	5.86	0.31	1.08e-8	Breast cancer;
LUSC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg08975724	chr8:8085496	FLJ10661	0.55	8.03	0.4	1.7e-14	Neuroticism;
LUSC	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg04450456	chr4:17643702	FAM184B	0.35	5.77	0.3	1.81e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg20016023	chr10:99160130	RRP12	-0.34	-7.9	-0.4	4.1e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg14004847	chr7:1930337	MAD1L1	0.47	6.98	0.36	1.59e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4474465	0.850	rs10899549	chr11:78255389	T/C	cg27205649	chr11:78285834	NARS2	0.51	6.17	0.32	2.03e-9	Alzheimer's disease (survival time);
LUSC	cis	rs983392	0.836	rs7946992	chr11:59944810	T/C	cg20284999	chr11:59952153	MS4A6A	-0.38	-6.25	-0.32	1.25e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9612	1.000	rs2277745	chr19:44259077	C/T	cg08581076	chr19:44259116	C19orf61	0.55	6.88	0.35	3.03e-11	Exhaled nitric oxide output;
LUSC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.29	-0.41	2.74e-15	Cystic fibrosis severity;
LUSC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05025164	chr4:1340916	KIAA1530	0.64	9.77	0.47	5.24e-20	Longevity;
LUSC	cis	rs7923609	0.967	rs2393977	chr10:65247609	A/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.44	-0.33	4.1e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.72	6.78	0.35	5.61e-11	Lung cancer in ever smokers;
LUSC	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-6.11	-0.32	2.7e-9	Parkinson's disease;
LUSC	cis	rs1775715	0.811	rs1775741	chr10:32267284	C/T	cg26784012	chr10:32216390	ARHGAP12	-0.43	-6.97	-0.36	1.7e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs11051970	0.918	rs11051969	chr12:32537123	T/C	cg02745156	chr12:32552066	NA	0.44	7.05	0.36	1.05e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg22189786	chr22:42395067	WBP2NL	0.43	5.77	0.3	1.78e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	trans	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg15556689	chr8:8085844	FLJ10661	0.46	6.9	0.35	2.6e-11	Retinal vascular caliber;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25460985	chr2:74055950	STAMBP	0.45	6.12	0.32	2.58e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-1.11	-24.8	-0.81	9.96e-78	Height;
LUSC	cis	rs10266483	0.705	rs599522	chr7:63758482	A/G	cg24201672	chr7:64023550	ZNF680	-0.45	-5.82	-0.3	1.38e-8	Response to statin therapy;
LUSC	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	0.82	11.44	0.53	8.55e-26	Coronary artery disease;
LUSC	cis	rs1662342	1.000	rs7811	chr18:3256112	A/G	cg00760847	chr18:3262519	MYL12B	-0.59	-5.81	-0.3	1.44e-8	QRS duration;
LUSC	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs4654899	0.785	rs7531381	chr1:21403348	A/G	cg01072550	chr1:21505969	NA	-0.51	-7.75	-0.39	1.11e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg23887609	chr12:130822674	PIWIL1	0.48	7.11	0.36	7.08e-12	Menopause (age at onset);
LUSC	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.99	-0.36	1.51e-11	Lung cancer;
LUSC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg23711669	chr6:146136114	FBXO30	-0.88	-17.33	-0.69	1.92e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9463078	0.546	rs10948191	chr6:44947281	G/T	cg25276700	chr6:44698697	NA	0.28	5.69	0.3	2.85e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg16339924	chr4:17578868	LAP3	0.53	8.03	0.4	1.72e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9796	0.870	rs7181816	chr15:41358720	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.98	-0.36	1.55e-11	Menopause (age at onset);
LUSC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.03	20.27	0.74	4.12e-60	Cognitive function;
LUSC	cis	rs540254	0.504	rs11265492	chr1:160799274	C/T	cg20255094	chr1:160771763	LY9	0.54	6.56	0.34	2.04e-10	Blood protein levels;
LUSC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg09904177	chr6:26538194	HMGN4	0.72	12.91	0.58	3.29e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg25407064	chr15:40226267	EIF2AK4	-0.51	-5.67	-0.3	3.09e-8	Response to haloperidol in psychosis;
LUSC	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg12615879	chr12:58013172	SLC26A10	0.36	8.43	0.42	1.07e-15	Multiple sclerosis;
LUSC	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg15997130	chr1:24165203	NA	0.52	8.58	0.43	3.6e-16	Immature fraction of reticulocytes;
LUSC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg20406979	chr6:167373233	NA	-0.26	-6.22	-0.32	1.5e-9	Crohn's disease;
LUSC	cis	rs12519773	0.526	rs4242240	chr5:92517203	A/G	cg18783429	chr5:92414398	NA	0.33	7.03	0.36	1.17e-11	Migraine;
LUSC	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg18105134	chr13:113819100	PROZ	-0.64	-9.35	-0.46	1.26e-18	Platelet distribution width;
LUSC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg08200582	chr11:442649	ANO9	-0.53	-6.13	-0.32	2.49e-9	Body mass index;
LUSC	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg03732007	chr1:2071316	PRKCZ	0.46	7.33	0.37	1.77e-12	Height;
LUSC	cis	rs7605827	0.930	rs6431699	chr2:15540281	A/G	cg19274914	chr2:15703543	NA	0.46	8.98	0.44	2.07e-17	Educational attainment (years of education);
LUSC	cis	rs6977660	1.000	rs6955510	chr7:19821333	G/C	cg07541023	chr7:19748670	TWISTNB	0.51	5.73	0.3	2.3e-8	Thyroid stimulating hormone;
LUSC	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg00383909	chr3:49044727	WDR6	1.03	9.81	0.47	4.11e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs2048656	0.535	rs2014514	chr8:9647196	A/T	cg15556689	chr8:8085844	FLJ10661	0.5	7.44	0.38	8.61e-13	Schizophrenia;
LUSC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.22	0.52	5.34e-25	Prudent dietary pattern;
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10150615	chr22:24372951	LOC391322	-0.42	-6.82	-0.35	4.24e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	1.04	18.16	0.7	9.65e-52	Parkinson's disease;
LUSC	cis	rs12422267	0.536	rs7976530	chr12:132609140	C/T	cg26561844	chr12:132562101	EP400	-0.53	-5.65	-0.3	3.46e-8	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg12963246	chr6:28129442	ZNF389	0.56	7.89	0.4	4.28e-14	Parkinson's disease;
LUSC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg25173405	chr17:45401733	C17orf57	0.39	6.16	0.32	2.03e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg01528321	chr10:82214614	TSPAN14	-0.97	-14.46	-0.62	3.97e-37	Post bronchodilator FEV1;
LUSC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg04518342	chr5:131593106	PDLIM4	-0.32	-5.81	-0.3	1.47e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs4629180	0.586	rs57563359	chr2:102125309	A/G	cg01388757	chr2:102091195	RFX8	-0.36	-6.14	-0.32	2.38e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs16854884	0.632	rs1910691	chr3:143656905	G/A	cg06585982	chr3:143692056	C3orf58	0.52	8.16	0.41	6.68e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.74	-11.41	-0.53	1.14e-25	Menarche (age at onset);
LUSC	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg13114125	chr14:105738426	BRF1	-0.91	-14.94	-0.63	5.2e-39	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.51	7.94	0.4	3.2e-14	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	trans	rs17685	0.535	rs41299460	chr7:75600951	G/A	cg19862616	chr7:65841803	NCRNA00174	0.46	6.2	0.32	1.7e-9	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.57	8.65	0.43	2.14e-16	Alzheimer's disease;
LUSC	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg09904177	chr6:26538194	HMGN4	-0.53	-5.9	-0.31	8.95e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10779751	0.734	rs1130683	chr1:11132217	G/A	cg04508216	chr1:11107452	MASP2	0.31	5.67	0.3	3.17e-8	Body mass index;
LUSC	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg17507749	chr15:85114479	UBE2QP1	0.53	6.57	0.34	1.94e-10	Schizophrenia;
LUSC	cis	rs12776158	0.901	rs61848384	chr10:71215225	T/G	cg12610070	chr10:71211762	TSPAN15	-0.46	-6.04	-0.31	4.07e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs2840044	1.000	rs225295	chr17:33925755	A/G	cg19694781	chr19:47549865	TMEM160	-0.59	-9.38	-0.46	1.07e-18	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs16937	0.711	rs10900471	chr1:205173134	A/G	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.36e-10	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15302128	chr10:104474204	SFXN2;ARL3	-0.42	-6.46	-0.33	3.73e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	14.15	0.61	6.38e-36	Platelet count;
LUSC	cis	rs3741151	0.892	rs7107905	chr11:73061232	A/T	cg17517138	chr11:73019481	ARHGEF17	0.85	8.03	0.4	1.63e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg06636551	chr8:101224915	SPAG1	-0.43	-8.06	-0.4	1.42e-14	Atrioventricular conduction;
LUSC	trans	rs2562456	0.520	rs279793	chr19:21455774	C/T	cg00806126	chr19:22604979	ZNF98	-0.43	-6.14	-0.32	2.37e-9	Pain;
LUSC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs4308124	0.708	rs2137168	chr2:111986509	C/T	cg04571233	chr2:111982156	NA	-0.53	-6.89	-0.35	2.82e-11	Vitiligo;
LUSC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18876405	chr7:65276391	NA	-0.55	-8.77	-0.43	8.95e-17	Aortic root size;
LUSC	cis	rs5758511	0.773	rs1894714	chr22:42349134	T/G	cg00645731	chr22:42541494	CYP2D7P1	-0.44	-7.21	-0.37	3.78e-12	Birth weight;
LUSC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.1	-0.41	1.05e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs601339	0.877	rs2649991	chr12:123179461	A/G	cg11919336	chr12:123188078	GPR109A	0.43	6.52	0.34	2.64e-10	Adiponectin levels;
LUSC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Parkinson's disease;
LUSC	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	6.32	0.33	8.46e-10	Lung cancer;
LUSC	cis	rs11039100	1.000	rs11039110	chr11:5829111	A/G	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.33e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.1	-0.58	6.15e-32	Platelet count;
LUSC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg18230493	chr5:56204884	C5orf35	0.5	7.86	0.4	5.2e-14	Coronary artery disease;
LUSC	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg05163923	chr11:71159392	DHCR7	0.7	10.21	0.49	1.71e-21	Vitamin D levels;
LUSC	cis	rs2219968	1.000	rs7465474	chr8:78959166	C/T	cg00738934	chr8:78996279	NA	0.34	6.19	0.32	1.81e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2479724	0.625	rs9394835	chr6:41818200	A/T	cg17623882	chr6:41773611	USP49	-0.49	-7.15	-0.36	5.63e-12	Menarche (age at onset);
LUSC	cis	rs2857891	0.909	rs56372435	chr11:6938658	T/C	cg04053776	chr11:6947353	ZNF215	0.55	7.89	0.4	4.23e-14	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs9362426	1.000	rs9294377	chr6:88084839	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	6.19	0.32	1.8e-9	Depressive episodes in bipolar disorder;
LUSC	cis	rs8018808	0.875	rs7250	chr14:77935520	G/A	cg20045696	chr14:77926864	AHSA1	0.34	5.76	0.3	1.94e-8	Myeloid white cell count;
LUSC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	0.93	15.89	0.66	1.01e-42	Menopause (age at onset);
LUSC	cis	rs71403859	0.685	rs12444890	chr16:71636026	G/A	cg08717414	chr16:71523259	ZNF19	-0.74	-7.99	-0.4	2.26e-14	Post bronchodilator FEV1;
LUSC	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg02228329	chr11:64053129	BAD;GPR137	-0.41	-5.94	-0.31	7.08e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs6733011	0.500	rs11123754	chr2:99433782	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-6.18	-0.32	1.92e-9	Bipolar disorder;
LUSC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.96	-0.31	6.31e-9	Aortic root size;
LUSC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.17	-0.32	1.95e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1595825	0.838	rs80172713	chr2:198508044	T/C	cg00982548	chr2:198649783	BOLL	-0.52	-6.61	-0.34	1.52e-10	Ulcerative colitis;
LUSC	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg01176363	chr20:62369445	LIME1	-0.46	-6.94	-0.35	2.09e-11	Prostate cancer;
LUSC	cis	rs12464559	0.522	rs6759419	chr2:152549703	G/A	cg01189475	chr2:152685088	ARL5A	0.63	5.65	0.3	3.42e-8	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg05625103	chr10:2543513	NA	0.38	5.83	0.3	1.33e-8	Age-related hearing impairment;
LUSC	cis	rs7577851	0.548	rs59129812	chr2:69656354	T/C	cg10773587	chr2:69614142	GFPT1	0.52	5.71	0.3	2.48e-8	Parkinson's disease (age of onset);
LUSC	cis	rs11051970	0.918	rs12229856	chr12:32531220	C/T	cg24626660	chr12:32551988	NA	0.37	6.12	0.32	2.66e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg13010199	chr12:38710504	ALG10B	0.57	9.09	0.45	9.21e-18	Morning vs. evening chronotype;
LUSC	cis	rs11622475	1.000	rs2269186	chr14:104379912	C/T	cg12183467	chr14:104352244	NA	-0.45	-8.06	-0.4	1.36e-14	Bipolar disorder;
LUSC	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg24375607	chr4:120327624	NA	0.76	11.3	0.53	2.66e-25	Corneal astigmatism;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg15981295	chr2:62081471	FAM161A	0.4	6.15	0.32	2.17e-9	Triglycerides;
LUSC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.62	-7.89	-0.4	4.43e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.91	-0.4	3.77e-14	Blood metabolite levels;
LUSC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24503407	chr1:205819492	PM20D1	-0.8	-15.51	-0.65	2.94e-41	Monocyte percentage of white cells;
LUSC	cis	rs13082711	0.911	rs6789539	chr3:27444076	T/A	cg02860705	chr3:27208620	NA	0.48	8.32	0.41	2.29e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs17255340	0.539	rs3778206	chr6:84058013	G/A	cg08257003	chr6:84140564	ME1	0.34	8.23	0.41	4.23e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg13395646	chr4:1353034	KIAA1530	-0.59	-9.25	-0.45	2.72e-18	Longevity;
LUSC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.6	-0.38	2.95e-13	Subjective well-being;
LUSC	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.91	-0.35	2.41e-11	Coronary artery disease;
LUSC	cis	rs10465746	0.780	rs1871924	chr1:84398466	T/A	cg10977910	chr1:84465055	TTLL7	0.46	6.73	0.35	7.53e-11	Obesity-related traits;
LUSC	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	7.73	0.39	1.31e-13	Neuroticism;
LUSC	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg05340658	chr4:99064831	C4orf37	0.65	10.93	0.51	5.72e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg13736514	chr6:26305472	NA	-0.47	-9.19	-0.45	4.35e-18	Educational attainment;
LUSC	cis	rs55665837	1.000	rs4412729	chr11:14439000	A/G	cg19336497	chr11:14380999	RRAS2	-0.38	-7.5	-0.38	5.91e-13	Vitamin D levels;
LUSC	cis	rs911119	0.913	rs4815222	chr20:23576964	A/G	cg16589663	chr20:23618590	CST3	-0.6	-7.04	-0.36	1.11e-11	Chronic kidney disease;
LUSC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	10.35	0.49	5.72e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7705502	1.000	rs72812832	chr5:173372625	G/A	cg18693985	chr5:173351052	CPEB4	-0.37	-5.83	-0.3	1.3e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg04450456	chr4:17643702	FAM184B	0.39	6.6	0.34	1.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6987853	0.563	rs7004796	chr8:42450170	T/G	cg09913449	chr8:42400586	C8orf40	0.4	6.7	0.34	9.1e-11	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg22800045	chr5:56110881	MAP3K1	0.46	6.17	0.32	1.96e-9	Coronary artery disease;
LUSC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg25204440	chr1:209979598	IRF6	0.49	5.74	0.3	2.14e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg15595755	chr5:1867978	NA	0.47	8.6	0.43	3.12e-16	Cardiovascular disease risk factors;
LUSC	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.68	-0.5	4.34e-23	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs28830936	0.966	rs3743024	chr15:42118971	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.92	-0.31	7.95e-9	Diastolic blood pressure;
LUSC	trans	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg04995722	chr7:26192034	NFE2L3	0.37	6.15	0.32	2.24e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg08601574	chr20:25228251	PYGB	-0.44	-6.79	-0.35	5.29e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-11.08	-0.52	1.61e-24	Alzheimer's disease;
LUSC	cis	rs1524927	1.000	rs12704875	chr7:96341385	G/A	cg03808172	chr7:96339361	SHFM1	0.43	6.66	0.34	1.12e-10	Total body bone mineral density;
LUSC	trans	rs975739	0.868	rs5351	chr13:78475313	C/T	cg15657206	chr11:10772781	CTR9	-0.36	-6.06	-0.31	3.66e-9	Hair color;
LUSC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg06387496	chr7:2775674	GNA12	-0.37	-5.72	-0.3	2.34e-8	Height;
LUSC	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg00484396	chr16:3507460	NAT15	0.86	11.33	0.53	2.21e-25	Tuberculosis;
LUSC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs12289510	0.539	rs3808995	chr11:124955977	A/G	cg03868193	chr11:124958746	SLC37A2	0.59	9.19	0.45	4.22e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg12935359	chr14:103987150	CKB	-0.51	-7.89	-0.4	4.39e-14	Body mass index;
LUSC	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.81	11.79	0.54	4.49e-27	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg21798802	chr22:38057573	PDXP	0.35	7.25	0.37	2.91e-12	Fat distribution (HIV);
LUSC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.71	0.47	8.23e-20	Lung cancer;
LUSC	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg12163867	chr12:51592794	POU6F1	-0.46	-8.4	-0.42	1.27e-15	Cisplatin-induced ototoxicity;
LUSC	cis	rs72634258	0.891	rs404381	chr1:8080745	C/T	cg26816564	chr1:7831052	VAMP3	0.47	6.38	0.33	5.83e-10	Inflammatory bowel disease;
LUSC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.74	0.63	3.2e-38	Platelet count;
LUSC	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.81	0.43	6.73e-17	Lung cancer in ever smokers;
LUSC	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg26384229	chr12:38710491	ALG10B	0.74	12.07	0.55	4.31e-28	Morning vs. evening chronotype;
LUSC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg16606324	chr3:10149918	C3orf24	0.68	9.98	0.48	1.06e-20	Alzheimer's disease;
LUSC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg10862848	chr6:42927986	GNMT	-0.28	-6.58	-0.34	1.83e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.73	-0.3	2.24e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12545109	0.571	rs1370306	chr8:57299137	C/G	cg09654669	chr8:57350985	NA	-0.45	-5.98	-0.31	5.7e-9	Obesity-related traits;
LUSC	cis	rs10193935	0.901	rs6713242	chr2:42470794	C/T	cg27598129	chr2:42591480	NA	-0.63	-7.45	-0.38	8.04e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.62	8.23	0.41	4.34e-15	High light scatter reticulocyte count;
LUSC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg12257692	chr3:49977190	RBM6	0.24	6.43	0.33	4.41e-10	Body mass index;
LUSC	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.46	7.1	0.36	7.47e-12	Response to antipsychotic treatment;
LUSC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg07507251	chr3:52567010	NT5DC2	0.38	7.83	0.39	6.61e-14	Electroencephalogram traits;
LUSC	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg22089800	chr15:90895588	ZNF774	0.65	10.24	0.49	1.41e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg20650035	chr12:29542837	NA	-0.45	-6.01	-0.31	4.85e-9	Thyroid stimulating hormone;
LUSC	cis	rs9815354	0.812	rs55682201	chr3:41848497	A/G	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg21775007	chr8:11205619	TDH	-0.47	-6.72	-0.35	7.66e-11	Morning vs. evening chronotype;
LUSC	cis	rs4664308	0.967	rs7563607	chr2:160910215	C/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-11.33	-0.53	2.16e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg03060546	chr3:49711283	APEH	0.59	8.31	0.41	2.5e-15	Resting heart rate;
LUSC	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg03585969	chr10:35415529	CREM	0.64	9.53	0.46	3.25e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	8.81	0.43	6.86e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs8102476	0.703	rs4803899	chr19:38727640	A/T	cg14131526	chr19:38747285	PPP1R14A	0.33	5.93	0.31	7.39e-9	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg25427524	chr10:38739819	LOC399744	0.56	8.71	0.43	1.48e-16	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.61	-11.76	-0.54	5.82e-27	Pulse pressure;
LUSC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.92	-0.31	8e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.04	-0.4	1.62e-14	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18231159	chr7:99214508	ZNF498	-0.49	-6.27	-0.32	1.15e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-10.52	-0.5	1.46e-22	Morning vs. evening chronotype;
LUSC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08564027	chr20:61660810	NA	0.9	17.32	0.69	2.14e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg02023728	chr11:77925099	USP35	0.48	6.84	0.35	3.87e-11	Testicular germ cell tumor;
LUSC	cis	rs752010	0.574	rs2148636	chr1:42119844	C/T	cg06885757	chr1:42089581	HIVEP3	-0.45	-9.65	-0.47	1.34e-19	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg12419862	chr22:24373484	LOC391322	-1.0	-19.21	-0.72	6.09e-56	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs354225	0.584	rs11898033	chr2:54821518	G/A	cg26097391	chr2:54893211	SPTBN1	0.41	6.27	0.32	1.12e-9	Schizophrenia;
LUSC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	11.6	0.54	2.35e-26	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.83	-0.47	3.42e-20	Chronic sinus infection;
LUSC	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg03929089	chr4:120376271	NA	-0.44	-6.06	-0.31	3.68e-9	Height;
LUSC	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg02750262	chr18:72916776	ZADH2	0.69	7.65	0.39	2.14e-13	Vascular endothelial growth factor levels;
LUSC	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg03733263	chr8:22462867	KIAA1967	0.99	17.75	0.7	4.21e-50	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs9443645	0.507	rs9343814	chr6:79473073	C/G	cg05283184	chr6:79620031	NA	-0.38	-7.02	-0.36	1.25e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.771	rs4888387	chr16:75389755	T/G	cg03315344	chr16:75512273	CHST6	0.51	9.71	0.47	8.39e-20	Dupuytren's disease;
LUSC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg14773178	chr5:1868261	NA	0.33	6.12	0.32	2.56e-9	Cardiovascular disease risk factors;
LUSC	cis	rs4363385	0.693	rs418550	chr1:153048045	A/T	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.18	-0.37	4.6e-12	Inflammatory skin disease;
LUSC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg03538708	chr1:25844672	NA	-0.36	-5.96	-0.31	6.51e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg17173187	chr15:85201210	NMB	0.37	6.4	0.33	5.31e-10	Schizophrenia;
LUSC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.69	-13.09	-0.58	7.01e-32	Bipolar disorder;
LUSC	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg08917208	chr2:24149416	ATAD2B	0.87	9.91	0.48	1.8899999999999998e-20	Lymphocyte counts;
LUSC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg05754148	chr16:3507555	NAT15	0.52	7.82	0.39	6.97e-14	Tuberculosis;
LUSC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg18477163	chr1:228402036	OBSCN	-0.58	-10.89	-0.51	7.96e-24	Diastolic blood pressure;
LUSC	cis	rs3105593	0.575	rs3098174	chr15:50778853	C/T	cg08437265	chr15:50716283	USP8	0.41	5.9	0.31	8.98e-9	QT interval;
LUSC	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg09163369	chr1:210001066	C1orf107	0.57	6.7	0.34	8.8e-11	Orofacial clefts;
LUSC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.7e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg13390004	chr1:15929781	NA	0.44	7.32	0.37	1.87e-12	Systolic blood pressure;
LUSC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.27	-0.32	1.09e-9	Lung cancer;
LUSC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg08888203	chr3:10149979	C3orf24	0.59	8.22	0.41	4.45e-15	Alzheimer's disease;
LUSC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg10755058	chr3:40428713	ENTPD3	0.37	5.99	0.31	5.42e-9	Renal cell carcinoma;
LUSC	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg22089800	chr15:90895588	ZNF774	-0.63	-9.45	-0.46	6.21e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg10857441	chr5:6722123	POLS	-0.44	-8.11	-0.41	9.83e-15	Menopause (age at onset);
LUSC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	13.25	0.59	1.72e-32	Alzheimer's disease;
LUSC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.65	-10.96	-0.51	4.35e-24	Diastolic blood pressure;
LUSC	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg03585969	chr10:35415529	CREM	0.6	8.97	0.44	2.11e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.5	7.73	0.39	1.3e-13	Eosinophil percentage of white cells;
LUSC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg16850897	chr7:100343110	ZAN	-0.6	-8.3	-0.41	2.61e-15	Other erythrocyte phenotypes;
LUSC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg22549504	chr19:17448937	GTPBP3	0.57	7.28	0.37	2.45e-12	Systemic lupus erythematosus;
LUSC	cis	rs6714710	0.535	rs13006932	chr2:98370698	T/A	cg26665480	chr2:98280029	ACTR1B	0.63	9.15	0.45	5.81e-18	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24739457	chr1:205821442	NA	0.36	6.19	0.32	1.72e-9	Menarche (age at onset);
LUSC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.01	-0.36	1.29e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs1595825	0.786	rs77218291	chr2:198565011	A/G	cg00982548	chr2:198649783	BOLL	-0.55	-7.05	-0.36	1.03e-11	Ulcerative colitis;
LUSC	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.27	-17.75	-0.7	4.04e-50	Hip circumference adjusted for BMI;
LUSC	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.54	-0.38	4.51e-13	Retinal vascular caliber;
LUSC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg24011408	chr12:48396354	COL2A1	0.4	5.8	0.3	1.55e-8	Glycated hemoglobin levels;
LUSC	trans	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07923666	chr12:49932857	KCNH3	-0.51	-6.3	-0.33	9.31e-10	Resting heart rate;
LUSC	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg27432699	chr2:27873401	GPN1	-0.89	-17.47	-0.69	5.44e-49	Oral cavity cancer;
LUSC	cis	rs17125944	0.615	rs1998777	chr14:53295706	C/T	cg00686598	chr14:53173677	PSMC6	-0.69	-6.73	-0.35	7.49e-11	Alzheimer's disease (late onset);
LUSC	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg13042288	chr15:90349979	ANPEP	-0.49	-7.08	-0.36	8.35e-12	Uric acid levels;
LUSC	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg17366294	chr4:99064904	C4orf37	0.57	10.1	0.48	4.16e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.59	-9.56	-0.46	2.61e-19	Body mass index;
LUSC	cis	rs72634258	0.945	rs34466510	chr1:8147412	T/C	cg26816564	chr1:7831052	VAMP3	0.48	5.87	0.31	1.08e-8	Inflammatory bowel disease;
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg12419862	chr22:24373484	LOC391322	-0.86	-14.05	-0.61	1.52e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg18880390	chr1:175162128	KIAA0040	0.45	6.13	0.32	2.48e-9	Cognitive function;Information processing speed;
LUSC	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg13010199	chr12:38710504	ALG10B	0.55	7.61	0.38	2.91e-13	Resting heart rate;
LUSC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg13114125	chr14:105738426	BRF1	-0.9	-15.48	-0.65	3.89e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg22980127	chr19:33182716	NUDT19	0.9	13.06	0.58	9.02e-32	Red blood cell traits;
LUSC	cis	rs6541297	0.555	rs910502	chr1:230294185	A/T	cg05784532	chr1:230284198	GALNT2	0.59	6.51	0.34	2.7e-10	Coronary artery disease;
LUSC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.66	11.13	0.52	1.13e-24	Bone mineral density;
LUSC	cis	rs2820315	1.000	rs2494114	chr1:201801011	C/G	cg10061532	chr1:201886748	LMOD1	0.25	5.7	0.3	2.68e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg13683864	chr3:40499215	RPL14	-0.94	-15.82	-0.65	1.87e-42	Renal cell carcinoma;
LUSC	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg16743903	chr16:89593216	SPG7	-0.38	-5.81	-0.3	1.43e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg15468180	chr1:107600409	PRMT6	0.36	5.92	0.31	7.8e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg12667521	chr19:29218732	NA	0.51	6.08	0.32	3.35e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	1.09	17.23	0.69	4.89e-48	Exhaled nitric oxide output;
LUSC	trans	rs272594	0.614	rs420304	chr8:81475569	A/G	cg01004056	chr1:230560318	NA	-0.49	-6.5	-0.34	2.93e-10	Neutrophil count;
LUSC	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.35	-0.37	1.51e-12	Testicular germ cell tumor;
LUSC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.85	0.3	1.2e-8	Tonsillectomy;
LUSC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.4	0.56	2.57e-29	Motion sickness;
LUSC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	0.94	15.65	0.65	8.63e-42	Parkinson's disease;
LUSC	cis	rs62458065	0.850	rs10273165	chr7:32460840	G/A	cg20159608	chr7:32802032	NA	-0.64	-7.57	-0.38	3.72e-13	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg07701084	chr6:150067640	NUP43	0.54	8.15	0.41	7.58e-15	Lung cancer;
LUSC	trans	rs1459104	0.571	rs10459012	chr11:55091574	C/A	cg15704280	chr7:45808275	SEPT13	0.57	6.39	0.33	5.57e-10	Body mass index;
LUSC	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	8.96	0.44	2.34e-17	Iron status biomarkers;
LUSC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg19230755	chr7:65878503	NA	-0.43	-6.02	-0.31	4.48e-9	Aortic root size;
LUSC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	0.98	13.46	0.59	2.73e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.37	-0.46	1.15e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg20701182	chr2:24300061	SF3B14	0.55	5.83	0.3	1.28e-8	Lymphocyte counts;
LUSC	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg22139774	chr2:100720529	AFF3	-0.52	-9.11	-0.45	7.58e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.76	-0.43	9.87e-17	Response to antipsychotic treatment;
LUSC	cis	rs55883249	1.000	rs62119428	chr2:9743332	T/C	cg23886495	chr2:9695866	ADAM17	0.49	5.78	0.3	1.71e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg00933542	chr6:150070202	PCMT1	0.33	6.83	0.35	3.93e-11	Lung cancer;
LUSC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg23283495	chr1:209979779	IRF6	0.64	7.74	0.39	1.2e-13	Cleft lip with or without cleft palate;
LUSC	cis	rs8063160	0.740	rs35850949	chr16:89720724	C/A	cg07984980	chr16:89898383	SPIRE2	0.85	6.4	0.33	5.27e-10	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LUSC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.74	-10.5	-0.5	1.77e-22	Gut microbiome composition (summer);
LUSC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	5.95	0.31	6.6e-9	Cystic fibrosis severity;
LUSC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg18681998	chr4:17616180	MED28	0.85	15.23	0.64	3.79e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.66	11.95	0.55	1.2100000000000001e-27	Birth weight;
LUSC	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-6.8	-0.35	4.83e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	1.03	25.05	0.81	1.11e-78	Multiple system atrophy;
LUSC	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg04362960	chr10:104952993	NT5C2	0.62	9.62	0.47	1.71e-19	Arsenic metabolism;
LUSC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg01475377	chr6:109611718	NA	-0.45	-8.27	-0.41	3.3e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs9921338	0.887	rs7189044	chr16:11442196	G/C	cg00044050	chr16:11439710	C16orf75	-0.5	-6.73	-0.35	7.26e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs13082711	0.911	rs34981505	chr3:27437322	A/T	cg02860705	chr3:27208620	NA	0.46	7.66	0.39	2e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg25894440	chr7:65020034	NA	-0.37	-5.81	-0.3	1.44e-8	Calcium levels;
LUSC	cis	rs9814567	0.712	rs4306900	chr3:134334327	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	12.56	0.57	6.86e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg13256891	chr4:100009986	ADH5	0.49	6.25	0.32	1.27e-9	Alcohol dependence;
LUSC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg18904891	chr8:8559673	CLDN23	0.61	8.43	0.42	1.02e-15	Obesity-related traits;
LUSC	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.91	0.31	8.67e-9	Breast cancer;
LUSC	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg05182265	chr7:156933206	UBE3C	-0.58	-9.02	-0.44	1.46e-17	Body mass index;
LUSC	cis	rs6489882	0.836	rs12322160	chr12:113368505	A/G	cg20102336	chr12:113376681	OAS3	-0.42	-6.13	-0.32	2.44e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.13	0.45	6.89e-18	Coffee consumption (cups per day);
LUSC	trans	rs17507216	0.958	rs28648832	chr15:83236392	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.45	-6.2	-0.32	1.68e-9	Excessive daytime sleepiness;
LUSC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05535760	chr7:792225	HEATR2	-0.73	-7.33	-0.37	1.7e-12	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg01097406	chr16:89675127	NA	-0.47	-9.78	-0.47	4.84e-20	Vitiligo;
LUSC	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.23	-0.69	4.77e-48	Exhaled nitric oxide output;
LUSC	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg00484396	chr16:3507460	NAT15	0.88	11.54	0.53	3.68e-26	Tuberculosis;
LUSC	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	6.98	0.36	1.63e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg13160058	chr8:26243215	BNIP3L	-0.42	-7.53	-0.38	4.82e-13	Red cell distribution width;
LUSC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg11062466	chr8:58055876	NA	0.55	7.63	0.39	2.45e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3126085	0.877	rs4457589	chr1:152247860	T/C	cg26876637	chr1:152193138	HRNR	0.45	6.03	0.31	4.34e-9	Atopic dermatitis;
LUSC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.68	10.99	0.52	3.51e-24	Iron status biomarkers;
LUSC	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg24881330	chr22:46731750	TRMU	0.54	6.17	0.32	1.94e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg00376283	chr12:123451042	ABCB9	0.67	8.44	0.42	9.73e-16	Neutrophil percentage of white cells;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14095692	chr18:8707237	NA	0.4	6.05	0.31	3.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.35	0.33	7.2e-10	Longevity;
LUSC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg23788917	chr6:8435910	SLC35B3	-0.51	-7.49	-0.38	6.2800000000000005e-13	Motion sickness;
LUSC	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg04374321	chr14:90722782	PSMC1	0.73	11.56	0.53	3.22e-26	Mortality in heart failure;
LUSC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7771547	0.519	rs12202691	chr6:36377820	G/A	cg07856975	chr6:36356162	ETV7	0.45	6.53	0.34	2.44e-10	Platelet distribution width;
LUSC	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.41	-0.38	1.04e-12	Retinal vascular caliber;
LUSC	cis	rs2692947	0.695	rs12464148	chr2:96596710	G/C	cg22654517	chr2:96458247	NA	0.34	6.82	0.35	4.29e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.67	9.24	0.45	2.95e-18	High light scatter reticulocyte count;
LUSC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg12365402	chr11:9010492	NRIP3	-0.44	-8.24	-0.41	3.89e-15	Hemoglobin concentration;
LUSC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg11965913	chr1:205819406	PM20D1	0.48	6.84	0.35	3.86e-11	Parkinson's disease;
LUSC	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg22777020	chr22:31556080	RNF185	-0.46	-5.87	-0.31	1.04e-8	Colorectal cancer;
LUSC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12667521	chr19:29218732	NA	0.63	9.05	0.44	1.18e-17	Methadone dose in opioid dependence;
LUSC	cis	rs668210	0.793	rs619701	chr11:65772080	G/A	cg04700828	chr11:65773979	NA	0.4	5.82	0.3	1.41e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6469656	0.892	rs4645587	chr8:117651760	C/T	cg24004040	chr8:117650383	NA	-0.42	-6.12	-0.32	2.69e-9	Colorectal cancer;
LUSC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg16145915	chr7:1198662	ZFAND2A	0.43	6.34	0.33	7.35e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-9.21	-0.45	3.81e-18	Gut microbiome composition (summer);
LUSC	cis	rs7107174	1.000	rs2256051	chr11:77920457	G/A	cg02023728	chr11:77925099	USP35	0.49	7.17	0.37	4.73e-12	Testicular germ cell tumor;
LUSC	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg25801113	chr15:45476975	SHF	-0.32	-6.45	-0.33	3.89e-10	Uric acid levels;
LUSC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg05855489	chr10:104503620	C10orf26	-0.69	-10.18	-0.49	2.31e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg04455712	chr21:45112962	RRP1B	0.45	8.63	0.43	2.55e-16	Mean corpuscular volume;
LUSC	cis	rs2692947	0.727	rs893173	chr2:96789787	T/C	cg23100626	chr2:96804247	ASTL	0.28	7.05	0.36	1.04e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13679077	chr7:22862647	TOMM7	-0.46	-7.05	-0.36	1.06e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg07923666	chr12:49932857	KCNH3	-0.5	-6.26	-0.32	1.16e-9	Resting heart rate;
LUSC	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg05714579	chr10:131428358	MGMT	-0.48	-7.01	-0.36	1.36e-11	Response to temozolomide;
LUSC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	0.93	15.96	0.66	5.28e-43	Menopause (age at onset);
LUSC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	0.98	13.5	0.59	1.87e-33	Cisplatin-induced ototoxicity;
LUSC	cis	rs60015123	0.850	rs58845597	chr12:7120942	T/C	cg26269324	chr12:6977084	TPI1	0.77	5.82	0.3	1.36e-8	Red cell distribution width;
LUSC	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.6	-8.43	-0.42	1.05e-15	Systemic lupus erythematosus;
LUSC	cis	rs9677476	0.863	rs58067379	chr2:232088295	A/T	cg07929768	chr2:232055508	NA	0.34	6.53	0.34	2.5e-10	Food antigen IgG levels;
LUSC	cis	rs1519814	0.876	rs10955954	chr8:121108052	A/G	cg22335954	chr8:121166405	COL14A1	-0.41	-5.65	-0.3	3.44e-8	Breast cancer;
LUSC	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg05874882	chr4:1763078	NA	0.58	9.3	0.45	1.85e-18	Bladder cancer;Urinary bladder cancer;
LUSC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg16393715	chr7:1948819	MAD1L1	0.37	6.34	0.33	7.41e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg02153584	chr22:29168773	CCDC117	0.53	6.79	0.35	5.07e-11	Lymphocyte counts;
LUSC	cis	rs7582720	1.000	rs72934737	chr2:203740798	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.56	0.42	4.25e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	8.92	0.44	3.12e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg16797656	chr11:68205561	LRP5	0.37	6.14	0.32	2.34e-9	Total body bone mineral density;
LUSC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.78	13.04	0.58	1.06e-31	Cognitive function;
LUSC	cis	rs11676348	0.772	rs12471105	chr2:218950209	G/A	cg00012203	chr2:219082015	ARPC2	-0.5	-7.65	-0.39	2.21e-13	Ulcerative colitis;
LUSC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.68	-10.5	-0.5	1.84e-22	Aortic root size;
LUSC	cis	rs17102423	0.559	rs11627382	chr14:65480208	A/G	cg11161011	chr14:65562177	MAX	-0.64	-8.87	-0.44	4.49e-17	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25072359	chr17:41440525	NA	0.66	9.42	0.46	7.64e-19	Menopause (age at onset);
LUSC	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg22705602	chr4:152727874	NA	-0.35	-7.69	-0.39	1.68e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg15309053	chr8:964076	NA	0.42	8.66	0.43	2.11e-16	Schizophrenia;
LUSC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg00101154	chr16:420108	MRPL28	0.52	9.22	0.45	3.43e-18	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg21141812	chr3:48556323	PFKFB4	0.37	6.33	0.33	7.98e-10	Menarche (age at onset);
LUSC	trans	rs2288327	0.673	rs35504893	chr2:179421294	C/T	cg14011486	chr1:26737247	LIN28	0.53	7.02	0.36	1.26e-11	Atrial fibrillation;
LUSC	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.14	-0.32	2.36e-9	Retinal vascular caliber;
LUSC	cis	rs11971779	0.715	rs10954646	chr7:139061069	C/G	cg07862535	chr7:139043722	LUC7L2	-0.54	-7.0	-0.36	1.38e-11	Diisocyanate-induced asthma;
LUSC	trans	rs800082	0.839	rs11714177	chr3:144312862	T/C	cg24215973	chr2:240111563	HDAC4	-0.44	-6.54	-0.34	2.29e-10	Smoking behavior;
LUSC	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.69	10.4	0.49	3.82e-22	Corneal astigmatism;
LUSC	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05901451	chr6:126070800	HEY2	0.58	9.29	0.45	2.09e-18	Endometrial cancer;
LUSC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg13939156	chr17:80058883	NA	-0.33	-6.6	-0.34	1.59e-10	Life satisfaction;
LUSC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg16928487	chr17:17741425	SREBF1	-0.43	-8.55	-0.42	4.5e-16	Total body bone mineral density;
LUSC	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg20734569	chr3:48348370	SPINK8	0.45	7.88	0.4	4.6e-14	Coronary artery disease;
LUSC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.59	-0.46	2.18e-19	Chronic sinus infection;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09555414	chr11:57520668	BTBD18	-0.72	-5.98	-0.31	5.68e-9	Cognitive performance;
LUSC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.06	-0.31	3.74e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3740713	0.669	rs61736803	chr11:18422487	C/A	cg23797887	chr11:18477753	LDHAL6A	-0.49	-5.86	-0.31	1.09e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg15448220	chr1:150897856	SETDB1	0.44	6.49	0.33	3.08e-10	Melanoma;
LUSC	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg04176472	chr15:90893244	GABARAPL3	0.33	5.98	0.31	5.61e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg15997130	chr1:24165203	NA	0.54	8.82	0.43	6.62e-17	Immature fraction of reticulocytes;
LUSC	cis	rs472402	0.580	rs6884552	chr5:6661966	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.55	-7.77	-0.39	9.82e-14	Response to amphetamines;
LUSC	cis	rs6542838	0.583	rs12712040	chr2:99513416	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.18	-0.32	1.86e-9	Fear of minor pain;
LUSC	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg20848291	chr7:100343083	ZAN	0.39	5.99	0.31	5.34e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg27398817	chr8:82754497	SNX16	0.66	8.41	0.42	1.18e-15	Diastolic blood pressure;
LUSC	trans	rs800082	0.516	rs7622736	chr3:144229272	A/G	cg24215973	chr2:240111563	HDAC4	0.46	6.92	0.35	2.37e-11	Smoking behavior;
LUSC	cis	rs7617773	0.925	rs6442105	chr3:48182326	A/G	cg11946769	chr3:48343235	NME6	-0.64	-9.47	-0.46	5.08e-19	Coronary artery disease;
LUSC	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg03258749	chr1:151040405	MLLT11	-0.62	-8.73	-0.43	1.27e-16	Childhood ear infection;
LUSC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.66	-0.43	2.09e-16	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.76	-0.43	1.02e-16	Response to antipsychotic treatment;
LUSC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg02782426	chr3:40428986	ENTPD3	0.41	7.32	0.37	1.82e-12	Renal cell carcinoma;
LUSC	cis	rs6580649	0.941	rs72644841	chr12:48411987	A/G	cg24011408	chr12:48396354	COL2A1	-0.49	-6.62	-0.34	1.43e-10	Lung cancer;
LUSC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.04	-0.4	1.62e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2742234	0.590	rs2435383	chr10:43675671	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.03	-0.36	1.17e-11	Hirschsprung disease;
LUSC	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg26408565	chr15:76604113	ETFA	-0.44	-6.86	-0.35	3.26e-11	Blood metabolite levels;
LUSC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	1.04	14.71	0.63	4.1e-38	Vitiligo;
LUSC	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg06026331	chr20:60912101	LAMA5	-0.43	-5.77	-0.3	1.78e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs4478858	0.735	rs4949384	chr1:31792141	A/G	cg00250761	chr1:31883323	NA	-0.37	-8.97	-0.44	2.17e-17	Alcohol dependence;
LUSC	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg24812749	chr6:127587940	RNF146	0.66	9.92	0.48	1.74e-20	Breast cancer;
LUSC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg23711669	chr6:146136114	FBXO30	-0.92	-18.15	-0.7	1.02e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg21545522	chr1:205238299	TMCC2	-0.48	-9.08	-0.45	9.35e-18	Red blood cell count;
LUSC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg22496339	chr2:162101262	NA	0.73	11.88	0.54	2.26e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg15383120	chr6:291909	DUSP22	0.44	6.91	0.35	2.4e-11	Menopause (age at onset);
LUSC	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg11584989	chr19:19387371	SF4	0.58	7.02	0.36	1.22e-11	Bipolar disorder;
LUSC	cis	rs4899554	0.640	rs4899555	chr14:75719834	T/C	cg18117039	chr14:75741733	NA	0.53	7.11	0.36	7.04e-12	Inflammatory bowel disease;
LUSC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.13	-0.45	6.61e-18	Gut microbiome composition (summer);
LUSC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg05313129	chr8:58192883	C8orf71	-0.5	-6.53	-0.34	2.4e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4776059	1.000	rs1863512	chr15:52959687	C/T	cg22715398	chr15:52968154	KIAA1370	-0.67	-9.6	-0.47	1.92e-19	Schizophrenia;
LUSC	cis	rs4285028	0.948	rs2332033	chr3:121699548	C/T	cg11130432	chr3:121712080	ILDR1	-0.65	-9.87	-0.48	2.52e-20	Multiple sclerosis;
LUSC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg12927641	chr6:109611667	NA	-0.43	-7.58	-0.38	3.41e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.44e-12	Motion sickness;
LUSC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg03790207	chr6:42947109	PEX6	-0.46	-6.98	-0.36	1.57e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg16359550	chr11:109292809	C11orf87	0.37	6.46	0.33	3.71e-10	Schizophrenia;
LUSC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg23262073	chr20:60523788	NA	-0.5	-7.14	-0.36	5.94e-12	Body mass index;
LUSC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg03351412	chr1:154909251	PMVK	0.55	8.7	0.43	1.52e-16	Prostate cancer;
LUSC	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg05791153	chr7:19748676	TWISTNB	0.92	9.51	0.46	4.04e-19	Thyroid stimulating hormone;
LUSC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg16362232	chr11:430036	ANO9	0.71	8.68	0.43	1.82e-16	Body mass index;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	0.99	23.0	0.78	8.03e-71	Menarche (age at onset);
LUSC	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg23649088	chr2:200775458	C2orf69	-0.5	-6.86	-0.35	3.41e-11	Schizophrenia;
LUSC	cis	rs55665837	1.000	rs10832257	chr11:14443316	A/G	cg05501817	chr11:14380813	RRAS2	-0.41	-6.61	-0.34	1.51e-10	Vitamin D levels;
LUSC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.35	0.37	1.56e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02176678	chr2:219576539	TTLL4	0.57	9.93	0.48	1.54e-20	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs9951602	1.000	rs9949784	chr18:76649994	A/G	cg02800362	chr5:177631904	HNRNPAB	1.01	10.99	0.52	3.48e-24	Obesity-related traits;
LUSC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.5	8.37	0.42	1.63e-15	Immature fraction of reticulocytes;
LUSC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-6.93	-0.35	2.12e-11	Bipolar disorder;
LUSC	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.37	-0.62	8.79e-37	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17431860	chr11:118966319	H2AFX	-0.44	-6.83	-0.35	4.07e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4253772	0.530	rs28362161	chr22:46807439	C/T	cg00784671	chr22:46762841	CELSR1	-0.55	-5.9	-0.31	8.78e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	0.99	18.0	0.7	3.97e-51	Cognitive function;
LUSC	cis	rs2303282	0.773	rs12918376	chr16:56558181	G/T	cg00500540	chr16:56394104	NA	0.43	7.02	0.36	1.22e-11	Breast cancer;
LUSC	trans	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.96	-0.31	6.49e-9	Dementia with Lewy bodies;
LUSC	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.87	14.29	0.62	1.83e-36	Bladder cancer;
LUSC	cis	rs911119	0.866	rs4346460	chr20:23569400	C/T	cg16589663	chr20:23618590	CST3	0.63	7.33	0.37	1.74e-12	Chronic kidney disease;
LUSC	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-6.01	-0.31	4.81e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg16339924	chr4:17578868	LAP3	0.55	8.17	0.41	6.53e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg03351412	chr1:154909251	PMVK	0.45	7.0	0.36	1.38e-11	Prostate cancer;
LUSC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-1.19	-12.67	-0.57	2.71e-30	Diabetic kidney disease;
LUSC	cis	rs34421088	0.532	rs2736388	chr8:11159588	T/C	cg21775007	chr8:11205619	TDH	0.48	6.88	0.35	2.97e-11	Neuroticism;
LUSC	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg22800045	chr5:56110881	MAP3K1	0.43	5.83	0.3	1.3e-8	Coronary artery disease;
LUSC	cis	rs1018697	0.518	rs2790914	chr10:104568018	C/T	cg04362960	chr10:104952993	NT5C2	-0.72	-8.51	-0.42	5.89e-16	Colorectal adenoma (advanced);
LUSC	cis	rs4474465	0.850	rs10793330	chr11:78269985	T/C	cg27205649	chr11:78285834	NARS2	0.51	6.08	0.32	3.26e-9	Alzheimer's disease (survival time);
LUSC	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.05	0.4	1.51e-14	Morning vs. evening chronotype;
LUSC	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg05925327	chr15:68127851	NA	-0.38	-5.89	-0.31	9.25e-9	Obesity;
LUSC	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.1	0.48	4.31e-21	Heart rate;
LUSC	cis	rs4356932	0.967	rs10856873	chr4:76972924	T/G	cg00809888	chr4:76862425	NAAA	0.35	5.83	0.3	1.33e-8	Blood protein levels;
LUSC	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.97	-0.31	6.21e-9	IgG glycosylation;
LUSC	cis	rs259282	0.524	rs731674	chr19:33132395	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.75	12.21	0.56	1.3e-28	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg27170947	chr2:26402098	FAM59B	-0.65	-9.52	-0.46	3.75e-19	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08677398	chr8:58056175	NA	0.52	7.15	0.36	5.67e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg22875332	chr1:76189707	ACADM	0.66	8.43	0.42	1.06e-15	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs6549438	1.000	rs6798993	chr3:72161623	A/C	cg14550559	chr2:240039617	HDAC4	0.43	5.95	0.31	6.83e-9	Migraine - clinic-based;
LUSC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08280861	chr8:58055591	NA	0.54	6.39	0.33	5.53e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10802521	chr3:52805072	NEK4	-0.56	-9.11	-0.45	7.82e-18	Bipolar disorder;
LUSC	cis	rs9311676	0.656	rs68021431	chr3:58403136	A/G	cg13750441	chr3:58318267	PXK	0.34	6.55	0.34	2.19e-10	Systemic lupus erythematosus;
LUSC	cis	rs11229555	0.645	rs12786744	chr11:58177549	T/C	cg15696309	chr11:58395628	NA	-0.66	-8.17	-0.41	6.33e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7589342	0.831	rs6731173	chr2:106522928	A/G	cg16077055	chr2:106428750	NCK2	0.35	6.54	0.34	2.36e-10	Addiction;
LUSC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg23034840	chr1:205782522	SLC41A1	-0.74	-12.33	-0.56	4.66e-29	Monocyte percentage of white cells;
LUSC	cis	rs929596	0.517	rs1875263	chr2:234625622	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-8.74	-0.43	1.15e-16	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg20701182	chr2:24300061	SF3B14	0.58	6.19	0.32	1.72e-9	Lymphocyte counts;
LUSC	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg06671706	chr8:8559999	CLDN23	0.49	6.57	0.34	1.94e-10	Obesity-related traits;
LUSC	cis	rs1044826	1.000	rs9834607	chr3:139234184	A/G	cg00490450	chr3:139108681	COPB2	0.52	6.81	0.35	4.58e-11	Obesity-related traits;
LUSC	cis	rs983392	0.679	rs636341	chr11:60019161	A/C	cg24026212	chr11:59952134	MS4A6A	0.37	6.45	0.33	3.95e-10	Alzheimer's disease (late onset);
LUSC	trans	rs705162	0.542	rs845102	chr10:125185442	C/T	cg03174038	chr16:2134317	TSC2	-0.43	-6.06	-0.31	3.63e-9	Migraine;
LUSC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.69	-11.92	-0.55	1.54e-27	Dental caries;
LUSC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.71	10.7	0.51	3.64e-23	Aortic root size;
LUSC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06221963	chr1:154839813	KCNN3	-0.61	-13.83	-0.6	1.03e-34	Prostate cancer;
LUSC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.86	16.48	0.67	4.59e-45	Mean platelet volume;
LUSC	cis	rs36093844	0.605	rs79719453	chr11:85582217	C/A	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs41271473	0.948	rs12144495	chr1:228810937	G/T	cg16512390	chr1:228756714	NA	-0.52	-6.3	-0.33	9.2e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg00634984	chr7:65235879	NA	0.4	5.83	0.3	1.28e-8	Calcium levels;
LUSC	cis	rs4704187	0.663	rs1422697	chr5:74445817	G/A	cg03227963	chr5:74354835	NA	0.31	6.77	0.35	5.96e-11	Response to amphetamines;
LUSC	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.33	-0.33	8.08e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	8.55	0.42	4.56e-16	Motion sickness;
LUSC	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg04450456	chr4:17643702	FAM184B	0.39	6.54	0.34	2.34e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.79	0.57	9.66e-31	Prudent dietary pattern;
LUSC	cis	rs4356932	0.905	rs4859597	chr4:76956630	A/T	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs4919694	1.000	rs74749600	chr10:104732996	T/C	cg04362960	chr10:104952993	NT5C2	1.16	13.56	0.6	1.16e-33	Arsenic metabolism;
LUSC	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg14835575	chr10:16859367	RSU1	0.73	9.57	0.46	2.42e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.97	-17.67	-0.7	8.15e-50	Chronic sinus infection;
LUSC	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg21252483	chr19:49399788	TULP2	-0.48	-6.77	-0.35	5.81e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.78	0.35	5.32e-11	Tonsillectomy;
LUSC	trans	rs62458065	0.850	rs62458100	chr7:32473142	C/G	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.08	-0.32	3.33e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg01416388	chr22:39784598	NA	-0.43	-7.17	-0.37	4.92e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9925964	0.622	rs8046707	chr16:30916233	G/A	cg02466173	chr16:30829666	NA	0.37	6.91	0.35	2.41e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg14664628	chr15:75095509	CSK	-0.58	-9.06	-0.44	1.13e-17	Breast cancer;
LUSC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.4	-0.38	1.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9837602	1.000	rs6790877	chr3:99779658	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.37	5.72	0.3	2.4e-8	Breast cancer;
LUSC	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg19792802	chr11:65647270	CTSW	0.46	6.42	0.33	4.68e-10	Crohn's disease;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg00827380	chr2:118572045	DDX18	0.37	5.97	0.31	6.11e-9	Triglycerides;
LUSC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg12560992	chr17:57184187	TRIM37	-0.84	-15.43	-0.64	6.56e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08704250	chr15:31115839	NA	0.59	9.38	0.46	1.08e-18	Huntington's disease progression;
LUSC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-10.29	-0.49	9.15e-22	Neuroticism;
LUSC	trans	rs12210905	0.925	rs72838238	chr6:26971681	G/A	cg11837749	chr1:55047332	ACOT11	0.57	6.09	0.32	3.07e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg11584989	chr19:19387371	SF4	0.57	6.78	0.35	5.44e-11	Bipolar disorder;
LUSC	trans	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.38e-9	Bladder cancer;
LUSC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg18357645	chr12:58087776	OS9	-0.43	-6.13	-0.32	2.46e-9	Multiple sclerosis;
LUSC	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg12382846	chr20:60892121	LAMA5	0.33	5.92	0.31	8.17e-9	Pelvic organ prolapse;
LUSC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg06600287	chr1:53387719	ECHDC2	0.31	6.24	0.32	1.35e-9	Monocyte count;
LUSC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08677398	chr8:58056175	NA	0.5	5.74	0.3	2.16e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg06207120	chr15:45996521	NA	0.39	6.03	0.31	4.46e-9	Waist circumference;Weight;
LUSC	cis	rs9807989	0.507	rs3755266	chr2:103042712	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.06	0.36	9.92e-12	Asthma;
LUSC	trans	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.22	0.41	4.57e-15	Ulcerative colitis;
LUSC	cis	rs4356932	0.691	rs2242474	chr4:76878982	T/C	cg00809888	chr4:76862425	NAAA	-0.36	-5.72	-0.3	2.31e-8	Blood protein levels;
LUSC	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.42	-5.79	-0.3	1.58e-8	Alzheimer's disease (late onset);
LUSC	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg01966878	chr4:90757139	SNCA	-0.4	-5.7	-0.3	2.7e-8	Neuroticism;
LUSC	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.26	-0.37	2.73e-12	Bipolar disorder;
LUSC	cis	rs7267979	0.844	rs869358	chr20:25374674	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-16.6	-0.67	1.46e-45	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-7.78	-0.39	9.38e-14	Chronic sinus infection;
LUSC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs77741769	0.926	rs61946386	chr12:121364025	T/C	cg02403541	chr12:121454288	C12orf43	0.49	7.25	0.37	2.88e-12	Mean corpuscular volume;
LUSC	cis	rs983392	0.679	rs600064	chr11:60013451	A/G	cg24026212	chr11:59952134	MS4A6A	0.36	6.21	0.32	1.55e-9	Alzheimer's disease (late onset);
LUSC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg21972741	chr5:435613	AHRR	0.34	6.42	0.33	4.6e-10	Cystic fibrosis severity;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg24626850	chr1:36615251	TRAPPC3	0.48	6.18	0.32	1.86e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg08017756	chr2:100939284	LONRF2	-0.42	-7.71	-0.39	1.46e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg08270630	chr22:50330655	NA	-0.41	-6.27	-0.32	1.15e-9	Schizophrenia;
LUSC	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg15133208	chr4:90757351	SNCA	-0.54	-8.45	-0.42	9.03e-16	Neuroticism;
LUSC	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg23093090	chr10:104574429	C10orf26	-0.36	-6.8	-0.35	4.84e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg13385521	chr17:29058706	SUZ12P	0.66	6.31	0.33	8.81e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg18827107	chr12:86230957	RASSF9	-0.41	-6.01	-0.31	4.85e-9	Major depressive disorder;
LUSC	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg22532475	chr10:104410764	TRIM8	-0.33	-6.84	-0.35	3.86e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs208520	0.779	rs208446	chr6:66903515	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-12.9	-0.58	3.55e-31	Exhaled nitric oxide output;
LUSC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23602909	chr7:157956050	PTPRN2	-0.5	-9.68	-0.47	1.06e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg14634687	chr17:47094252	IGF2BP1	0.32	6.75	0.35	6.54e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg26769984	chr7:1090371	C7orf50	0.58	8.12	0.41	9.22e-15	Bronchopulmonary dysplasia;
LUSC	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.44	-6.55	-0.34	2.2e-10	Neuroticism;
LUSC	cis	rs3931020	0.688	rs1051122	chr1:75190452	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.63	8.43	0.42	1.02e-15	Resistin levels;
LUSC	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg15423357	chr2:25149977	NA	0.44	8.97	0.44	2.2e-17	Body mass index;
LUSC	trans	rs17683430	0.702	rs117079807	chr22:32407021	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs2835872	0.758	rs1787395	chr21:39036478	A/C	cg20424643	chr21:39039972	KCNJ6	-0.45	-7.57	-0.38	3.65e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-7.13	-0.36	6.42e-12	Total body bone mineral density;
LUSC	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.9	17.34	0.69	1.8e-48	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.46	-0.33	3.67e-10	Resting heart rate;
LUSC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01632311	chr7:2281785	NUDT1;FTSJ2	-0.44	-6.83	-0.35	4.05e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.21	-0.37	3.86e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.8	-0.35	4.96e-11	Morning vs. evening chronotype;
LUSC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg14440974	chr22:39074834	NA	-0.35	-5.84	-0.3	1.26e-8	Menopause (age at onset);
LUSC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg13395646	chr4:1353034	KIAA1530	-0.78	-13.18	-0.59	3.08e-32	Obesity-related traits;
LUSC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg20476274	chr7:133979776	SLC35B4	0.8	14.19	0.61	4.15e-36	Mean platelet volume;
LUSC	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg04058563	chr4:185651563	MLF1IP	-0.69	-9.63	-0.47	1.52e-19	Systemic lupus erythematosus;
LUSC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05025164	chr4:1340916	KIAA1530	-0.65	-10.15	-0.49	2.87e-21	Obesity-related traits;
LUSC	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg11189052	chr15:85197271	WDR73	0.47	5.76	0.3	1.88e-8	Schizophrenia;
LUSC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-1.22	-13.35	-0.59	7.04e-33	Diabetic kidney disease;
LUSC	cis	rs67696533	1.000	rs6141319	chr20:31144807	A/G	cg13636640	chr20:31349939	DNMT3B	0.46	6.7	0.34	8.67e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs12928939	0.517	rs10852507	chr16:71971900	G/A	cg03805757	chr16:71968109	PKD1L3	-0.64	-9.8	-0.47	4.31e-20	Post bronchodilator FEV1;
LUSC	cis	rs77633900	0.614	rs280030	chr15:77026853	T/C	cg21673338	chr15:77095150	SCAPER	-0.81	-7.96	-0.4	2.63e-14	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	cis	rs5753037	0.809	rs5763512	chr22:30212366	C/T	cg11564601	chr22:30592435	NA	0.32	5.72	0.3	2.39e-8	Type 1 diabetes;
LUSC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg12927641	chr6:109611667	NA	0.44	7.67	0.39	1.95e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg11657440	chr19:46296263	DMWD	-0.68	-10.2	-0.49	1.96e-21	Coronary artery disease;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg25703541	chr22:24373054	LOC391322	-0.98	-18.05	-0.7	2.69e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	0.86	12.58	0.57	5.68e-30	Breast cancer;
LUSC	trans	rs1459104	0.759	rs7939392	chr11:55257285	C/T	cg15704280	chr7:45808275	SEPT13	0.61	6.55	0.34	2.23e-10	Body mass index;
LUSC	cis	rs55882075	0.634	rs11249657	chr5:179111637	G/C	cg14593053	chr5:179126677	CANX	0.39	6.06	0.31	3.69e-9	Monocyte percentage of white cells;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02003818	chr14:58893672	KIAA0586;TIMM9	-0.41	-6.32	-0.33	8.27e-10	Electrocardiographic conduction measures;
LUSC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	0.94	16.46	0.67	5.38e-45	Menopause (age at onset);
LUSC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg14983838	chr19:29218262	NA	0.65	9.87	0.48	2.53e-20	Methadone dose in opioid dependence;
LUSC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg11062466	chr8:58055876	NA	0.7	8.01	0.4	1.91e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg09835421	chr16:68378352	PRMT7	-0.59	-6.32	-0.33	8.14e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg19196401	chr6:110721138	DDO	-0.45	-8.49	-0.42	7.05e-16	Platelet distribution width;
LUSC	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg16482183	chr6:26056742	HIST1H1C	0.88	11.7	0.54	9.71e-27	Iron status biomarkers;
LUSC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg24562669	chr7:97807699	LMTK2	0.35	6.08	0.32	3.26e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2932538	0.922	rs6691917	chr1:113137043	G/C	cg22162597	chr1:113214053	CAPZA1	0.53	7.69	0.39	1.66e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs988712	0.705	rs16917204	chr11:27668355	G/C	cg10635145	chr11:27742435	BDNF	-0.46	-5.96	-0.31	6.27e-9	Obesity;
LUSC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg03146154	chr1:46216737	IPP	0.52	7.74	0.39	1.22e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs834603	0.546	rs1704969	chr7:47467787	A/G	cg09696706	chr7:47479511	TNS3	0.32	5.75	0.3	2.01e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.74	-11.4	-0.53	1.16e-25	Menarche (age at onset);
LUSC	cis	rs2857891	0.817	rs1907611	chr11:6968302	A/G	cg04053776	chr11:6947353	ZNF215	0.41	5.98	0.31	5.69e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs11971779	0.680	rs7785903	chr7:139122643	T/C	cg23387468	chr7:139079360	LUC7L2	0.38	5.73	0.3	2.19e-8	Diisocyanate-induced asthma;
LUSC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg23978390	chr7:1156363	C7orf50	0.5	7.17	0.37	4.98e-12	Longevity;Endometriosis;
LUSC	cis	rs757278	0.552	rs35292549	chr7:117318803	G/A	cg10524701	chr7:117356490	CTTNBP2	0.4	5.68	0.3	2.98e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs3087591	0.708	rs7503922	chr17:29641935	C/A	cg24425628	chr17:29625626	OMG;NF1	0.48	7.23	0.37	3.31e-12	Hip circumference;
LUSC	cis	rs4889855	0.530	rs75398920	chr17:78544540	C/T	cg16591659	chr17:78472290	NA	0.33	5.86	0.31	1.1e-8	Fractional excretion of uric acid;
LUSC	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.62	11.38	0.53	1.43e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg04369109	chr6:150039330	LATS1	-0.58	-8.47	-0.42	8.09e-16	Lung cancer;
LUSC	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg23691781	chr1:28212827	C1orf38	0.32	7.43	0.38	9.44e-13	Corneal astigmatism;
LUSC	cis	rs559928	0.948	rs1198984	chr11:64148420	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.57	-6.21	-0.32	1.61e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg27170947	chr2:26402098	FAM59B	-0.7	-10.49	-0.5	1.87e-22	Gut microbiome composition (summer);
LUSC	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg02527881	chr3:46936655	PTH1R	-0.38	-6.67	-0.34	1.03e-10	Colorectal cancer;
LUSC	cis	rs597583	0.664	rs10892133	chr11:117383694	C/T	cg27161313	chr11:117392002	DSCAML1	-0.48	-7.6	-0.38	3.06e-13	Putamen volume;
LUSC	trans	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg13010199	chr12:38710504	ALG10B	0.44	6.93	0.35	2.21e-11	Morning vs. evening chronotype;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg04015486	chr20:44044769	PIGT	0.44	6.4	0.33	5.25e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg04234412	chr22:24373322	LOC391322	-0.96	-18.07	-0.7	2.23e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg24399712	chr22:39784796	NA	-0.63	-10.75	-0.51	2.44e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg24375607	chr4:120327624	NA	0.76	12.17	0.55	1.85e-28	Corneal astigmatism;
LUSC	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	6.5	0.33	2.98e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg04455712	chr21:45112962	RRP1B	0.45	8.53	0.42	5.06e-16	Mean corpuscular volume;
LUSC	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg21573476	chr21:45109991	RRP1B	-0.4	-6.63	-0.34	1.33e-10	Mean corpuscular volume;
LUSC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg07061783	chr6:25882402	NA	-0.37	-5.81	-0.3	1.42e-8	Blood metabolite levels;
LUSC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.69	-11.18	-0.52	7.13e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg08601574	chr20:25228251	PYGB	0.42	6.41	0.33	4.9e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1712517	0.525	rs7911488	chr10:105154089	A/G	cg04362960	chr10:104952993	NT5C2	-0.52	-6.97	-0.36	1.67e-11	Migraine;
LUSC	cis	rs12618769	1.000	rs72825710	chr2:99239497	G/A	cg10123293	chr2:99228465	UNC50	0.41	5.7	0.3	2.57e-8	Bipolar disorder;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg13094219	chr2:46926190	SOCS5	-0.4	-5.95	-0.31	6.68e-9	Triglycerides;
LUSC	cis	rs56804039	1.000	rs34154295	chr8:8383477	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.41	-0.38	1.03e-12	Cervical cancer;
LUSC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-5.93	-0.31	7.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg04775059	chr7:64541387	NA	0.55	8.07	0.4	1.29e-14	Calcium levels;
LUSC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-6.08	-0.32	3.38e-9	Body mass index;
LUSC	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg24579218	chr15:68104479	NA	-0.38	-6.55	-0.34	2.21e-10	Obesity;
LUSC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	1.1	9.65	0.47	1.34e-19	Skin colour saturation;
LUSC	cis	rs860295	0.812	rs2297775	chr1:155735012	C/T	cg08949192	chr1:155289623	RUSC1;FDPS	0.34	5.68	0.3	2.97e-8	Body mass index;
LUSC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg11645453	chr3:52864694	ITIH4	-0.32	-7.48	-0.38	6.74e-13	Bipolar disorder;
LUSC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg24209194	chr3:40518798	ZNF619	0.49	6.52	0.34	2.64e-10	Renal cell carcinoma;
LUSC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.28	-0.41	3.06e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg08975724	chr8:8085496	FLJ10661	0.46	6.65	0.34	1.22e-10	Neuroticism;
LUSC	cis	rs11608355	0.618	rs7958220	chr12:109830980	T/C	cg19025524	chr12:109796872	NA	-0.47	-8.95	-0.44	2.6e-17	Neuroticism;
LUSC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.64	-0.43	2.4e-16	Aortic root size;
LUSC	cis	rs238295	0.766	rs6038204	chr20:5549071	T/A	cg15842884	chr20:5591925	RP5-1022P6.2	-0.43	-5.87	-0.31	1.07e-8	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs2979489	0.786	rs62508366	chr8:30369499	G/A	cg26383811	chr8:30366931	RBPMS	-0.51	-7.89	-0.4	4.45e-14	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs2637266	0.783	rs12268496	chr10:78487192	G/A	cg18941641	chr10:78392320	NA	0.36	6.58	0.34	1.79e-10	Pulmonary function;
LUSC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	9.93	0.48	1.55e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1044826	0.619	rs7375091	chr3:139090389	T/A	cg00490450	chr3:139108681	COPB2	-0.5	-7.88	-0.4	4.66e-14	Obesity-related traits;
LUSC	cis	rs12208915	0.731	rs9443630	chr6:79661777	G/T	cg05283184	chr6:79620031	NA	0.48	7.25	0.37	2.86e-12	Left atrial antero-posterior diameter;
LUSC	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg07930552	chr6:133119739	C6orf192	-0.79	-10.53	-0.5	1.41e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg05872129	chr22:39784769	NA	-0.61	-11.33	-0.53	2.14e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg18132916	chr6:79620363	NA	-0.4	-6.14	-0.32	2.4e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-12.0	-0.55	7.87e-28	Platelet count;
LUSC	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg17470449	chr10:769945	NA	0.54	7.38	0.37	1.24e-12	Uric acid levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09509035	chr1:235490977	GGPS1;ARID4B	-0.44	-6.49	-0.33	3.1e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	13.25	0.59	1.73e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06360820	chr2:242988706	NA	-0.91	-10.03	-0.48	7.34e-21	Obesity-related traits;
LUSC	cis	rs2279817	0.863	rs12139706	chr1:18026435	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.47	6.86	0.35	3.35e-11	Neuroticism;
LUSC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg18357645	chr12:58087776	OS9	0.58	8.67	0.43	1.94e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg15448220	chr1:150897856	SETDB1	0.42	6.05	0.31	3.98e-9	Melanoma;
LUSC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg02527881	chr3:46936655	PTH1R	0.42	7.53	0.38	4.79e-13	Colorectal cancer;
LUSC	cis	rs7241530	0.662	rs12458336	chr18:75909080	T/A	cg14642773	chr18:75888474	NA	0.39	5.74	0.3	2.17e-8	Educational attainment (years of education);
LUSC	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg07211511	chr3:129823064	LOC729375	-1.27	-20.37	-0.74	1.62e-60	Blood pressure (smoking interaction);
LUSC	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg05855489	chr10:104503620	C10orf26	-0.48	-7.3	-0.37	2.15e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20307385	chr11:47447363	PSMC3	-0.45	-5.78	-0.3	1.71e-8	Subjective well-being;
LUSC	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.48	-8.96	-0.44	2.27e-17	Metabolite levels;
LUSC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg24060327	chr5:131705240	SLC22A5	0.48	8.12	0.41	9.37e-15	Breast cancer;
LUSC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg10351095	chr21:47802916	PCNT	-0.42	-5.85	-0.3	1.18e-8	Testicular germ cell tumor;
LUSC	cis	rs1152591	0.524	rs1255991	chr14:64661642	G/A	cg21174375	chr14:64681225	SYNE2	0.31	5.66	0.3	3.24e-8	Atrial fibrillation;
LUSC	cis	rs500891	0.693	rs1145915	chr6:83989771	A/G	cg08257003	chr6:84140564	ME1	0.33	7.15	0.36	5.67e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12292205	chr6:26970375	C6orf41	0.6	7.53	0.38	4.85e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg01125463	chr6:42946178	PEX6	-0.36	-5.97	-0.31	6.19e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7589342	0.894	rs7557976	chr2:106435061	C/A	cg14210321	chr2:106509881	NCK2	-0.54	-8.12	-0.41	9.28e-15	Addiction;
LUSC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21582582	chr3:182698605	DCUN1D1	0.46	8.27	0.41	3.11e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg20887711	chr4:1340912	KIAA1530	0.56	8.9	0.44	3.54e-17	Longevity;
LUSC	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-10.52	-0.5	1.46e-22	Morning vs. evening chronotype;
LUSC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg02079420	chr8:82753780	SNX16	-0.38	-5.79	-0.3	1.64e-8	Diastolic blood pressure;
LUSC	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg11130432	chr3:121712080	ILDR1	-0.64	-9.64	-0.47	1.48e-19	Multiple sclerosis;
LUSC	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg18478394	chr8:109455254	TTC35	0.42	6.18	0.32	1.85e-9	Dupuytren's disease;
LUSC	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg02269571	chr22:50332266	NA	0.58	7.48	0.38	6.75e-13	Schizophrenia;
LUSC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg18479299	chr3:125709523	NA	-0.51	-5.87	-0.31	1.05e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.47	-0.33	3.53e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg06238570	chr21:40685208	BRWD1	0.53	7.97	0.4	2.47e-14	Cognitive function;
LUSC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-0.64	-13.38	-0.59	5.62e-33	Prudent dietary pattern;
LUSC	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg03859395	chr2:55845619	SMEK2	0.86	15.72	0.65	4.52e-42	Metabolic syndrome;
LUSC	cis	rs56399783	0.901	rs73049327	chr7:2795544	T/G	cg19731401	chr7:2775893	GNA12	0.72	8.62	0.43	2.68e-16	Childhood ear infection;
LUSC	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg17052675	chr2:3827356	NA	-0.58	-11.37	-0.53	1.47e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg22532475	chr10:104410764	TRIM8	0.26	6.11	0.32	2.7e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	7.77	0.39	9.93e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7712401	0.623	rs922140	chr5:122088890	A/G	cg19077854	chr5:122220652	SNX24	0.29	6.39	0.33	5.65e-10	Mean platelet volume;
LUSC	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg05360949	chr19:41903737	BCKDHA;EXOSC5	0.42	5.75	0.3	1.98e-8	Height;
LUSC	cis	rs6723108	0.738	rs10928512	chr2:135451302	A/C	cg12500956	chr2:135428796	TMEM163	0.27	6.38	0.33	5.97e-10	Type 2 diabetes;
LUSC	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg06532163	chr17:45867833	NA	0.34	6.22	0.32	1.49e-9	IgG glycosylation;
LUSC	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17467752	chr17:38218738	THRA	-0.7	-11.27	-0.52	3.54e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	1.06	11.16	0.52	8.87e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg05738196	chr6:26577821	NA	-0.56	-6.16	-0.32	2.12e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg19592336	chr6:28129416	ZNF389	0.53	7.05	0.36	1.02e-11	Parkinson's disease;
LUSC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.79	-14.4	-0.62	6.32e-37	Dental caries;
LUSC	cis	rs559928	1.000	rs559928	chr11:64150370	A/G	cg24687543	chr11:63912206	MACROD1	-0.42	-6.15	-0.32	2.26e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg20016023	chr10:99160130	RRP12	-0.33	-8.07	-0.4	1.26e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-9.49	-0.46	4.45e-19	Gut microbiome composition (summer);
LUSC	cis	rs13385	0.769	rs34994530	chr5:139558669	C/T	cg26211634	chr5:139558579	C5orf32	0.45	6.3	0.33	9.46e-10	Atrial fibrillation;
LUSC	cis	rs17621444	0.522	rs10886579	chr10:121803607	C/T	cg02041677	chr10:121771263	NA	-0.34	-6.37	-0.33	6.24e-10	IgG glycosylation;
LUSC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg22823121	chr1:150693482	HORMAD1	0.6	9.28	0.45	2.21e-18	Tonsillectomy;
LUSC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.7	11.56	0.53	3.06e-26	Gestational age at birth (maternal effect);
LUSC	cis	rs7572644	0.699	rs10194283	chr2:28159079	G/A	cg27432699	chr2:27873401	GPN1	-0.51	-6.86	-0.35	3.39e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs654950	0.841	rs2759247	chr1:41991756	G/C	cg06885757	chr1:42089581	HIVEP3	-0.37	-7.28	-0.37	2.38e-12	Airway imaging phenotypes;
LUSC	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg08000102	chr2:233561755	GIGYF2	0.7	11.71	0.54	9.4e-27	Coronary artery disease;
LUSC	cis	rs11577318	0.579	rs11247936	chr1:26698884	A/G	cg00852783	chr1:26633632	UBXN11	-0.55	-7.49	-0.38	6.33e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg04450456	chr4:17643702	FAM184B	0.39	6.53	0.34	2.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24838063	chr12:130822603	PIWIL1	0.71	11.02	0.52	2.71e-24	Menopause (age at onset);
LUSC	cis	rs7833787	0.832	rs12546229	chr8:18701879	C/T	cg17701159	chr8:18705777	PSD3	-0.37	-5.96	-0.31	6.34e-9	Obesity-related traits;
LUSC	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg27661571	chr11:113659931	NA	-0.69	-7.9	-0.4	4.08e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg25036284	chr2:26402008	FAM59B	0.77	11.29	0.53	2.89e-25	Gut microbiome composition (summer);
LUSC	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg18477163	chr1:228402036	OBSCN	-0.56	-10.27	-0.49	1.1e-21	Diastolic blood pressure;
LUSC	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg21770322	chr7:97807741	LMTK2	0.47	7.93	0.4	3.39e-14	Breast cancer;
LUSC	trans	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg00898013	chr13:113819073	PROZ	-0.57	-8.13	-0.41	8.59e-15	Platelet distribution width;
LUSC	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg27219399	chr15:67835830	MAP2K5	0.36	5.71	0.3	2.56e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs10760279	0.584	rs10760280	chr9:126112812	A/G	cg14503395	chr9:126128745	CRB2	0.33	5.7	0.3	2.59e-8	Body mass index;
LUSC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg22963979	chr7:1858916	MAD1L1	-0.7	-11.64	-0.54	1.62e-26	Bipolar disorder and schizophrenia;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18309895	chr10:105445329	SH3PXD2A	-0.37	-6.07	-0.32	3.52e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6542838	0.641	rs7565510	chr2:99494833	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.33	-0.33	7.77e-10	Fear of minor pain;
LUSC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg25456477	chr12:86230367	RASSF9	-0.32	-5.69	-0.3	2.83e-8	Major depressive disorder;
LUSC	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg21643547	chr1:205240462	TMCC2	-0.38	-6.95	-0.36	1.89e-11	Red blood cell count;
LUSC	cis	rs701145	0.585	rs398512	chr3:153909988	T/C	cg17054900	chr3:154042577	DHX36	0.68	6.76	0.35	5.99e-11	Coronary artery disease;
LUSC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.27	0.52	3.53e-25	Prudent dietary pattern;
LUSC	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg00083206	chr6:110721305	DDO	-0.43	-7.69	-0.39	1.66e-13	Platelet distribution width;
LUSC	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg24375607	chr4:120327624	NA	0.76	11.36	0.53	1.73e-25	Corneal astigmatism;
LUSC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.5	-9.61	-0.47	1.81e-19	Paraoxonase activity;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02047359	chr10:75174015	ANXA7	0.45	7.03	0.36	1.18e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg24006582	chr15:45444508	DUOX1	-0.61	-8.95	-0.44	2.44e-17	Uric acid levels;
LUSC	cis	rs7095944	0.614	rs4962697	chr10:126447545	G/C	cg08799069	chr10:126477246	METTL10	-0.41	-6.3	-0.33	9.46e-10	Asthma;
LUSC	cis	rs1712517	0.873	rs7903004	chr10:105004101	G/A	cg05636881	chr10:105038444	INA	-0.39	-6.44	-0.33	4.18e-10	Migraine;
LUSC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg13206674	chr6:150067644	NUP43	0.58	9.08	0.45	9.37e-18	Lung cancer;
LUSC	cis	rs12891047	0.901	rs2235967	chr14:68249499	C/T	cg20999565	chr14:68265668	ZFYVE26	0.39	5.89	0.31	9.42e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.64	-10.82	-0.51	1.34e-23	Longevity;Endometriosis;
LUSC	trans	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.47	-0.38	7.19e-13	Triglycerides;
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.6	7.62	0.38	2.59e-13	Renal function-related traits (BUN);
LUSC	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg22709100	chr7:91322751	NA	0.41	6.0	0.31	5.02e-9	Breast cancer;
LUSC	cis	rs72781680	0.752	rs55859418	chr2:23904231	C/A	cg20701182	chr2:24300061	SF3B14	0.73	7.06	0.36	9.63e-12	Lymphocyte counts;
LUSC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-6.89	-0.35	2.79e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs4664304	0.629	rs1606117	chr2:160850716	C/T	cg05371993	chr16:1458494	UNKL	0.41	6.01	0.31	4.74e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg27432699	chr2:27873401	GPN1	0.8	14.94	0.63	5.09e-39	Oral cavity cancer;
LUSC	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg20368463	chr18:77673604	PQLC1	-0.68	-7.43	-0.38	9.24e-13	Opioid sensitivity;
LUSC	cis	rs4662945	0.525	rs4662951	chr2:130256272	C/T	cg05962382	chr2:130345044	NA	-0.36	-6.28	-0.32	1.05e-9	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg13010199	chr12:38710504	ALG10B	0.62	9.23	0.45	3.2e-18	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg00024416	chr22:24240387	NA	0.35	6.04	0.31	4.19e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.1	0.41	1.04e-14	Bipolar disorder;
LUSC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg18876405	chr7:65276391	NA	0.49	7.66	0.39	1.98e-13	Calcium levels;
LUSC	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg04545296	chr12:48745243	ZNF641	0.37	6.78	0.35	5.33e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs1160297	0.585	rs12713229	chr2:53090105	T/C	cg07782112	chr2:53107842	NA	0.37	6.22	0.32	1.46e-9	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg24642439	chr20:33292090	TP53INP2	0.59	6.79	0.35	5.13e-11	Protein C levels;
LUSC	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg27539214	chr16:67997921	SLC12A4	-0.54	-7.27	-0.37	2.56e-12	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg14591386	chr6:97345725	NDUFAF4	0.52	6.07	0.32	3.38e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.73	-0.43	1.28e-16	Response to antipsychotic treatment;
LUSC	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07080220	chr10:102295463	HIF1AN	0.67	9.27	0.45	2.29e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11971779	0.648	rs6947309	chr7:139035830	C/T	cg07862535	chr7:139043722	LUC7L2	0.52	6.58	0.34	1.81e-10	Diisocyanate-induced asthma;
LUSC	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg13902645	chr11:5959945	NA	-0.58	-8.23	-0.41	4.32e-15	DNA methylation (variation);
LUSC	cis	rs7584330	0.554	rs13405619	chr2:238445661	C/T	cg14458575	chr2:238380390	NA	0.45	5.72	0.3	2.41e-8	Prostate cancer;
LUSC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg11812906	chr14:75593930	NEK9	0.65	11.1	0.52	1.41e-24	Height;
LUSC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg20608306	chr11:116969690	SIK3	0.38	6.39	0.33	5.59e-10	Blood protein levels;
LUSC	cis	rs1595825	0.891	rs892513	chr2:198905874	A/G	cg00982548	chr2:198649783	BOLL	0.53	6.69	0.34	9.31e-11	Ulcerative colitis;
LUSC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg08477640	chr19:41863820	B9D2	-0.5	-7.81	-0.39	7.6e-14	Migraine;Coronary artery disease;
LUSC	cis	rs9311676	0.632	rs67904096	chr3:58365508	T/A	cg13750441	chr3:58318267	PXK	0.35	6.76	0.35	6.33e-11	Systemic lupus erythematosus;
LUSC	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg01689657	chr7:91764605	CYP51A1	-0.33	-6.06	-0.31	3.68e-9	Breast cancer;
LUSC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.65	8.32	0.41	2.22e-15	Gut microbiome composition (summer);
LUSC	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg13010199	chr12:38710504	ALG10B	0.66	10.21	0.49	1.83e-21	Bladder cancer;
LUSC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	8.55	0.42	4.56e-16	Motion sickness;
LUSC	cis	rs10484885	0.591	rs72912551	chr6:90178347	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.64	-5.95	-0.31	6.77e-9	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-6.96	-0.36	1.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg24324837	chr19:49891574	CCDC155	0.53	7.39	0.37	1.17e-12	Multiple sclerosis;
LUSC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg12564285	chr5:131593104	PDLIM4	0.42	7.7	0.39	1.52e-13	Breast cancer;
LUSC	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.44	0.46	6.85e-19	Coffee consumption (cups per day);
LUSC	cis	rs7188861	0.768	rs12925649	chr16:11390445	T/C	cg00044050	chr16:11439710	C16orf75	0.53	5.99	0.31	5.45e-9	HDL cholesterol;
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg22907277	chr7:1156413	C7orf50	0.6	9.37	0.46	1.16e-18	Longevity;Endometriosis;
LUSC	cis	rs62458065	0.850	rs73096034	chr7:32472048	A/G	cg20159608	chr7:32802032	NA	-0.66	-7.83	-0.39	6.35e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7923609	0.967	rs4486511	chr10:65264266	C/T	cg01631684	chr10:65280961	REEP3	-0.42	-6.44	-0.33	4.07e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.72	-9.87	-0.48	2.59e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.41	-0.38	1.06e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg17366294	chr4:99064904	C4orf37	-0.52	-8.77	-0.43	9.01e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg15595755	chr5:1867978	NA	0.4	6.43	0.33	4.34e-10	Cardiovascular disease risk factors;
LUSC	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.38	0.53	1.44e-25	Coffee consumption (cups per day);
LUSC	cis	rs6740322	0.841	rs10210507	chr2:43556636	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-7.7	-0.39	1.6e-13	Coronary artery disease;
LUSC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg03351412	chr1:154909251	PMVK	0.52	8.08	0.4	1.18e-14	Prostate cancer;
LUSC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.99	0.55	8.55e-28	Chronic sinus infection;
LUSC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg12751644	chr20:60527061	NA	-0.33	-6.14	-0.32	2.4e-9	Body mass index;
LUSC	cis	rs74181299	0.964	rs2540951	chr2:65276736	A/G	cg05010058	chr2:65284262	CEP68	0.31	6.17	0.32	1.97e-9	Pulse pressure;
LUSC	cis	rs12195417	0.574	rs1170459	chr6:84000234	G/T	cg08257003	chr6:84140564	ME1	0.32	7.58	0.38	3.4e-13	Schizophrenia;
LUSC	cis	rs11264213	0.901	rs72661613	chr1:36364781	A/G	cg27506609	chr1:36549197	TEKT2	0.7	8.04	0.4	1.62e-14	Schizophrenia;
LUSC	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg03684893	chr10:554711	DIP2C	-0.38	-6.93	-0.35	2.24e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.09	0.77	2.83e-67	Prudent dietary pattern;
LUSC	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg06917634	chr15:78832804	PSMA4	-0.44	-5.96	-0.31	6.28e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg13736514	chr6:26305472	NA	-0.47	-9.37	-0.46	1.16e-18	Educational attainment;
LUSC	trans	rs7939886	0.920	rs1905069	chr11:55887135	T/C	cg15704280	chr7:45808275	SEPT13	0.82	6.77	0.35	5.73e-11	Myopia (pathological);
LUSC	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg09092052	chr15:45571596	NA	0.47	6.64	0.34	1.24e-10	Glomerular filtration rate;
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.6	10.15	0.49	2.75e-21	Lymphocyte counts;
LUSC	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.91	-0.35	2.52e-11	Response to antipsychotic treatment;
LUSC	cis	rs244293	0.700	rs12939352	chr17:53007655	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.42	-6.25	-0.32	1.28e-9	Menarche (age at onset);
LUSC	cis	rs1957429	0.808	rs1570296	chr14:65332294	T/A	cg23373153	chr14:65346875	NA	0.95	10.83	0.51	1.25e-23	Pediatric areal bone mineral density (radius);
LUSC	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.09	-0.4	1.15e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs9650315	0.866	rs76623919	chr8:57191191	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.54	6.96	0.36	1.75e-11	Height;
LUSC	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg07169764	chr2:136633963	MCM6	-1.04	-14.03	-0.61	1.73e-35	Corneal structure;
LUSC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.55	0.34	2.2e-10	Menopause (age at onset);
LUSC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg20135002	chr11:47629003	NA	-0.51	-8.1	-0.41	1.07e-14	Neuroticism;
LUSC	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg09323728	chr8:95962352	TP53INP1	-0.31	-5.83	-0.3	1.34e-8	Type 2 diabetes;
LUSC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg26373071	chr5:1325741	CLPTM1L	0.43	8.08	0.4	1.18e-14	Lung cancer;
LUSC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg18681998	chr4:17616180	MED28	0.85	15.67	0.65	6.85e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.99	-0.44	1.85e-17	Electroencephalogram traits;
LUSC	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg15133208	chr4:90757351	SNCA	-0.32	-5.66	-0.3	3.22e-8	Dementia with Lewy bodies;
LUSC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg27532560	chr4:187881888	NA	-0.38	-6.27	-0.32	1.1e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6980507	0.523	rs2974294	chr8:42369473	C/T	cg09913449	chr8:42400586	C8orf40	-0.44	-7.71	-0.39	1.44e-13	Glycated hemoglobin levels;
LUSC	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg01966878	chr4:90757139	SNCA	0.35	6.1	0.32	2.9e-9	Dementia with Lewy bodies;
LUSC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg12463550	chr7:65579703	CRCP	0.45	6.76	0.35	6.2e-11	Aortic root size;
LUSC	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.72	-10.12	-0.48	3.48e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9494145	0.838	rs9483788	chr6:135435501	T/C	cg22676075	chr6:135203613	NA	0.57	7.43	0.38	9.09e-13	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs760805	0.932	rs1005734	chr1:25262022	C/A	cg22509179	chr1:25234806	RUNX3	-0.61	-10.16	-0.49	2.58e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg08085267	chr17:45401833	C17orf57	-0.63	-10.73	-0.51	2.9e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07157834	chr1:205819609	PM20D1	-0.73	-13.75	-0.6	2.2e-34	Monocyte percentage of white cells;
LUSC	cis	rs6546537	1.000	rs2048256	chr2:69847357	G/C	cg10773587	chr2:69614142	GFPT1	-0.54	-8.13	-0.41	8.56e-15	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.89	-0.44	3.97e-17	Coffee consumption (cups per day);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09613494	chr21:44846625	SIK1	0.43	5.98	0.31	5.64e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg01973587	chr1:228161476	NA	-0.46	-8.31	-0.41	2.43e-15	Diastolic blood pressure;
LUSC	cis	rs2658782	0.724	rs2248655	chr11:93254612	T/C	cg15737290	chr11:93063684	CCDC67	0.61	7.33	0.37	1.79e-12	Pulmonary function decline;
LUSC	cis	rs10740039	0.842	rs7069157	chr10:62389233	A/G	cg18175470	chr10:62150864	ANK3	-0.48	-7.11	-0.36	7.18e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg04414720	chr1:150670196	GOLPH3L	0.57	9.22	0.45	3.31e-18	Tonsillectomy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10238396	chr2:64067940	UGP2	-0.4	-6.17	-0.32	2e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4499344	0.622	rs73573371	chr19:33047095	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.79	-10.04	-0.48	6.86e-21	Mean platelet volume;
LUSC	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12826209	chr6:26865740	GUSBL1	0.63	8.43	0.42	1.03e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6828523	0.698	rs4695984	chr4:175858796	C/T	cg16870595	chr4:175839423	ADAM29	0.49	6.09	0.32	3.04e-9	Breast cancer;
LUSC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	6.08	0.32	3.27e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs61990749	0.597	rs12896026	chr14:78244436	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	6.69	0.34	9.25e-11	Fibroblast growth factor basic levels;
LUSC	cis	rs7200543	1.000	rs72774845	chr16:15147954	A/C	cg03427771	chr16:15082598	PDXDC1	-0.4	-5.81	-0.3	1.47e-8	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10120925	chr2:223520811	FARSB	-0.41	-6.06	-0.31	3.66e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg07636037	chr3:49044803	WDR6	0.87	11.31	0.53	2.55e-25	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-7.07	-0.36	9.2e-12	Alzheimer's disease (late onset);
LUSC	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-1.0	-23.93	-0.79	2.05e-74	Urate levels in lean individuals;
LUSC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg20243544	chr17:37824526	PNMT	-0.48	-5.84	-0.3	1.22e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs10203711	0.966	rs6716938	chr2:239599283	A/G	cg14580085	chr2:239553406	NA	0.43	7.2	0.37	4.12e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg11984989	chr7:158649758	WDR60	-1.04	-12.33	-0.56	4.97e-29	Height;
LUSC	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg01943577	chr7:158741284	NA	-0.4	-5.74	-0.3	2.15e-8	Height;
LUSC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg05863683	chr7:1912471	MAD1L1	0.3	5.65	0.3	3.39e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.01	-0.4	1.98e-14	Lung cancer;
LUSC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.38	7.62e-13	Bipolar disorder;
LUSC	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg11584989	chr19:19387371	SF4	0.58	6.97	0.36	1.74e-11	Bipolar disorder;
LUSC	trans	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	9.89	0.48	2.13e-20	Coronary artery disease;
LUSC	cis	rs8038465	0.967	rs55868793	chr15:73956856	T/G	cg15420318	chr15:73925796	NPTN	0.42	6.84	0.35	3.82e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs34734847	1.000	rs34734847	chr12:121154221	T/C	cg21892295	chr12:121157589	UNC119B	-0.51	-9.35	-0.46	1.29e-18	Mean corpuscular volume;
LUSC	cis	rs9788682	1.000	rs57064725	chr15:78833036	C/A	cg06917634	chr15:78832804	PSMA4	-0.54	-6.79	-0.35	5.03e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg02017074	chr12:117425053	FBXW8	-0.65	-7.66	-0.39	1.98e-13	Subcortical brain region volumes;Hippocampal volume;
LUSC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg02466173	chr16:30829666	NA	0.69	16.24	0.66	3.88e-44	Dementia with Lewy bodies;
LUSC	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg23029597	chr12:123009494	RSRC2	-0.74	-9.58	-0.46	2.27e-19	Body mass index;
LUSC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg17173187	chr15:85201210	NMB	-0.33	-6.81	-0.35	4.42e-11	P wave terminal force;
LUSC	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.76	-0.3	1.92e-8	Height;
LUSC	cis	rs4285028	0.948	rs12488334	chr3:121702526	T/C	cg11130432	chr3:121712080	ILDR1	-0.65	-9.82	-0.47	3.69e-20	Multiple sclerosis;
LUSC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg17366294	chr4:99064904	C4orf37	0.56	9.91	0.48	1.76e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.21	0.32	1.54e-9	Total body bone mineral density;
LUSC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	6.75	0.35	6.4e-11	Menarche (age at onset);
LUSC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg08888203	chr3:10149979	C3orf24	0.61	8.44	0.42	9.76e-16	Alzheimer's disease;
LUSC	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	5.86	0.31	1.09e-8	Rheumatoid arthritis;
LUSC	cis	rs10746514	1.000	rs10864715	chr1:232243817	G/A	cg09506761	chr1:232265262	NA	0.54	8.72	0.43	1.34e-16	Response to statin therapy;
LUSC	cis	rs1775715	0.737	rs2778672	chr10:32122419	T/C	cg18675610	chr10:32216311	ARHGAP12	0.29	6.23	0.32	1.44e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg05347473	chr6:146136440	FBXO30	0.43	7.05	0.36	1.02e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg12179176	chr11:130786555	SNX19	0.64	9.73	0.47	7.5e-20	Schizophrenia;
LUSC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg14668632	chr7:2872130	GNA12	-0.46	-7.14	-0.36	5.8e-12	Height;
LUSC	trans	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.39	0.33	5.53e-10	Corneal astigmatism;
LUSC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg03060546	chr3:49711283	APEH	0.65	7.28	0.37	2.42e-12	Menarche (age at onset);
LUSC	trans	rs10432489	0.708	rs3922471	chr2:181771937	T/C	cg07312954	chr1:153914453	DENND4B	-0.83	-6.07	-0.32	3.54e-9	QT interval;
LUSC	cis	rs2742234	0.541	rs10793426	chr10:43745280	G/A	cg15436174	chr10:43711423	RASGEF1A	0.42	6.71	0.34	8.14e-11	Hirschsprung disease;
LUSC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg03146154	chr1:46216737	IPP	0.55	8.21	0.41	5.01e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07167872	chr1:205819463	PM20D1	0.54	9.1	0.45	8.19e-18	Menarche (age at onset);
LUSC	cis	rs4253772	0.530	rs11090875	chr22:46785301	C/T	cg18190219	chr22:46762943	CELSR1	-0.58	-5.68	-0.3	2.93e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-8.22	-0.41	4.41e-15	Longevity;Endometriosis;
LUSC	trans	rs4729127	0.901	rs112784431	chr7:94017313	G/A	cg20086523	chr13:52378287	DHRS12	0.62	6.69	0.34	9.44e-11	Intelligence;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06812693	chr4:26323246	RBPJ	0.48	7.19	0.37	4.21e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26314531	chr2:26401878	FAM59B	-0.69	-9.39	-0.46	9.76e-19	Gut microbiome composition (summer);
LUSC	trans	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	8.49	0.42	7.03e-16	Type 2 diabetes;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg11710924	chr2:32503219	YIPF4	0.37	6.21	0.32	1.55e-9	Asthma;
LUSC	cis	rs12824058	0.737	rs2398510	chr12:130816637	G/A	cg26677194	chr12:130822605	PIWIL1	0.6	8.79	0.43	7.95e-17	Menopause (age at onset);
LUSC	cis	rs3916	0.688	rs9204	chr12:121177778	A/G	cg27246729	chr12:121163418	ACADS	0.43	6.41	0.33	4.85e-10	Urinary metabolites (H-NMR features);
LUSC	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.78	-0.35	5.62e-11	Monocyte percentage of white cells;
LUSC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg15556689	chr8:8085844	FLJ10661	-0.7	-11.53	-0.53	4.08e-26	Mood instability;
LUSC	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg13615516	chr5:77269221	NA	0.39	6.62	0.34	1.4e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.72	-11.25	-0.52	4.13e-25	Alcohol dependence;
LUSC	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg13010199	chr12:38710504	ALG10B	0.7	10.59	0.5	8.81e-23	Bladder cancer;
LUSC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	0.91	18.66	0.71	9.36e-54	Dental caries;
LUSC	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg08213375	chr14:104286397	PPP1R13B	0.53	10.33	0.49	6.73e-22	Schizophrenia;
LUSC	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs4664304	0.802	rs62175470	chr2:160858255	G/C	cg03641300	chr2:160917029	PLA2R1	-0.38	-6.1	-0.32	2.98e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.59	8.08	0.4	1.22e-14	Response to diuretic therapy;
LUSC	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg05283184	chr6:79620031	NA	-0.58	-12.17	-0.55	1.82e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg12002119	chr2:101014098	CHST10	0.34	5.74	0.3	2.1e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.46	-0.42	8.29e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg19052272	chr2:3704530	ALLC	-0.46	-7.58	-0.38	3.35e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs524023	0.958	rs2021860	chr11:64361384	G/T	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.76	-0.3	1.91e-8	Urate levels in obese individuals;
LUSC	trans	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg21775007	chr8:11205619	TDH	-0.44	-6.18	-0.32	1.84e-9	Joint mobility (Beighton score);
LUSC	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg18904891	chr8:8559673	CLDN23	0.6	7.82	0.39	7.06e-14	Obesity-related traits;
LUSC	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg04539111	chr16:67997858	SLC12A4	-0.42	-5.87	-0.31	1.04e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LUSC	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.21	0.49	1.8e-21	Birth weight;
LUSC	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg17425144	chr1:10567563	PEX14	0.61	12.82	0.57	6.89e-31	Prostate cancer;
LUSC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.07	-0.44	1.07e-17	Mood instability;
LUSC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.6	0.85	2.14e-95	Chronic sinus infection;
LUSC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.17	-0.52	7.66e-25	Mean corpuscular volume;
LUSC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.0	-12.21	-0.56	1.28e-28	Alzheimer's disease;
LUSC	trans	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs3799379	0.550	rs9467736	chr6:26380032	A/G	cg09904177	chr6:26538194	HMGN4	-0.46	-6.26	-0.32	1.21e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7940866	0.874	rs10894290	chr11:130811049	T/G	cg12179176	chr11:130786555	SNX19	0.62	9.28	0.45	2.22e-18	Schizophrenia;
LUSC	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg19792802	chr11:65647270	CTSW	-0.41	-6.21	-0.32	1.54e-9	Crohn's disease;
LUSC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg11812906	chr14:75593930	NEK9	-0.64	-10.47	-0.5	2.32e-22	Height;
LUSC	cis	rs7220711	1.000	rs8072333	chr17:41793893	C/T	cg26893861	chr17:41843967	DUSP3	0.43	6.04	0.31	4.22e-9	Bone mineral density (spine);Bone mineral density (hip);
LUSC	cis	rs9311676	0.656	rs10866016	chr3:58390844	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.46	0.33	3.74e-10	Systemic lupus erythematosus;
LUSC	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.8	11.28	0.53	3.3e-25	Corneal astigmatism;
LUSC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.61	-0.43	2.96e-16	Breast cancer;
LUSC	trans	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.48	-0.33	3.26e-10	Bladder cancer;
LUSC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg00166722	chr3:10149974	C3orf24	0.39	5.81	0.3	1.43e-8	Alzheimer's disease;
LUSC	cis	rs6714710	0.580	rs6711101	chr2:98379813	G/A	cg26665480	chr2:98280029	ACTR1B	0.58	8.38	0.42	1.51e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs4942242	0.512	rs9533552	chr13:44187194	C/T	cg19169023	chr15:41853346	TYRO3	-0.66	-9.97	-0.48	1.18e-20	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg05855489	chr10:104503620	C10orf26	0.51	7.56	0.38	3.95e-13	Arsenic metabolism;
LUSC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg23711669	chr6:146136114	FBXO30	0.84	14.36	0.62	9.59e-37	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg13615516	chr5:77269221	NA	0.4	6.56	0.34	2.02e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1355223	0.902	rs7121272	chr11:34752562	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.39	-5.65	-0.3	3.4e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	6.88	0.35	2.97e-11	Depressive symptoms;
LUSC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg07701084	chr6:150067640	NUP43	0.55	8.35	0.42	1.78e-15	Lung cancer;
LUSC	trans	rs2363709	0.881	rs73096338	chr3:67387800	C/T	cg23062198	chr2:14774063	FAM84A	0.58	6.21	0.32	1.58e-9	IgE levels;
LUSC	cis	rs7903847	0.620	rs10882904	chr10:99115683	A/G	cg08345082	chr10:99160200	RRP12	-0.35	-6.94	-0.35	2.1e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg15468180	chr1:107600409	PRMT6	-0.39	-6.3	-0.33	9.37e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs870825	0.616	rs6818447	chr4:185650154	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	12.21	0.56	1.35e-28	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15703070	chr1:227128038	CABC1	-0.43	-6.43	-0.33	4.47e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg03929089	chr4:120376271	NA	0.71	6.79	0.35	5.04e-11	Axial length;
LUSC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg06713675	chr4:122721982	EXOSC9	-0.48	-8.41	-0.42	1.2e-15	Type 2 diabetes;
LUSC	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.77	0.35	5.7e-11	Rheumatoid arthritis;
LUSC	cis	rs2969070	0.898	rs2906165	chr7:2508177	T/C	cg03277898	chr7:2518824	NA	-0.27	-5.76	-0.3	1.87e-8	Diastolic blood pressure;
LUSC	cis	rs2224391	0.518	rs116670419	chr6:5261263	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.46	-5.75	-0.3	2.02e-8	Height;
LUSC	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.54	-0.42	4.88e-16	Depression;
LUSC	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg00484396	chr16:3507460	NAT15	-0.46	-6.77	-0.35	5.73e-11	Body mass index (adult);
LUSC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg16447950	chr5:562315	NA	-0.55	-7.1	-0.36	7.47e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-7.01	-0.36	1.33e-11	Chronic sinus infection;
LUSC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg07636037	chr3:49044803	WDR6	0.9	14.5	0.62	2.81e-37	Parkinson's disease;
LUSC	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.12	-0.32	2.67e-9	Height;
LUSC	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg13010199	chr12:38710504	ALG10B	0.53	7.95	0.4	2.82e-14	Morning vs. evening chronotype;
LUSC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg23205692	chr1:25664452	TMEM50A	0.45	6.75	0.35	6.4e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs11603020	0.950	rs11229066	chr11:57374871	C/G	cg23127183	chr11:57508653	C11orf31	-0.45	-6.18	-0.32	1.82e-9	Blood protein levels;
LUSC	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg16102102	chr5:83017553	HAPLN1	-0.94	-14.19	-0.61	4.29e-36	Prostate cancer;
LUSC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg02896835	chr1:92012615	NA	0.64	11.4	0.53	1.22e-25	Breast cancer;
LUSC	cis	rs9420	0.961	rs11570190	chr11:57560452	A/C	cg02958346	chr11:57425731	CLP1	-0.44	-6.43	-0.33	4.54e-10	Schizophrenia;
LUSC	cis	rs9581857	0.547	rs75800999	chr13:28055293	A/G	cg22138327	chr13:27999177	GTF3A	0.77	8.18	0.41	5.84e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	trans	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-9.7	-0.47	9.43e-20	Brugada syndrome;
LUSC	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg04362960	chr10:104952993	NT5C2	0.61	9.57	0.46	2.39e-19	Arsenic metabolism;
LUSC	cis	rs10465746	0.747	rs34155960	chr1:84447539	T/G	cg10977910	chr1:84465055	TTLL7	0.44	6.37	0.33	6.26e-10	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg13560548	chr3:10150139	C3orf24	0.54	7.42	0.38	9.97e-13	Alzheimer's disease;
LUSC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg14196790	chr5:131705035	SLC22A5	0.49	8.32	0.41	2.31e-15	Blood metabolite levels;
LUSC	cis	rs4666002	0.956	rs4665383	chr2:27791555	C/G	cg27432699	chr2:27873401	GPN1	0.43	6.07	0.32	3.43e-9	Phospholipid levels (plasma);
LUSC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg08999081	chr20:33150536	PIGU	0.44	8.13	0.41	8.26e-15	Coronary artery disease;
LUSC	cis	rs12145833	0.596	rs61833906	chr1:243419706	T/C	cg02356786	chr1:243265016	LOC731275	0.68	6.23	0.32	1.41e-9	Obesity (early onset extreme);
LUSC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.61	0.5	7.35e-23	Monocyte percentage of white cells;
LUSC	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.94	0.51	4.97e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.83	14.27	0.62	2.19e-36	Metabolic syndrome;
LUSC	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	1.1	17.21	0.69	5.83e-48	Exhaled nitric oxide output;
LUSC	cis	rs6961069	0.756	rs4731642	chr7:80248001	A/G	cg04458919	chr7:80252533	CD36	0.35	5.97	0.31	6.21e-9	Platelet count;
LUSC	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg24879335	chr3:133465180	TF	0.44	7.51	0.38	5.49e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg24375607	chr4:120327624	NA	0.79	11.67	0.54	1.23e-26	Corneal astigmatism;
LUSC	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg05182265	chr7:156933206	UBE3C	0.45	6.85	0.35	3.58e-11	Body mass index;
LUSC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg09796270	chr17:17721594	SREBF1	-0.42	-7.2	-0.37	3.89e-12	Body mass index;
LUSC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06544989	chr22:39130855	UNC84B	0.33	5.76	0.3	1.86e-8	Menopause (age at onset);
LUSC	cis	rs4363385	0.720	rs6665527	chr1:152967009	C/A	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.32	-0.37	1.85e-12	Inflammatory skin disease;
LUSC	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.86	-0.58	4.9e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22307029	chr19:49891270	CCDC155	0.68	9.57	0.46	2.55e-19	Multiple sclerosis;
LUSC	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg08079166	chr15:68083412	MAP2K5	0.41	7.43	0.38	8.94e-13	Restless legs syndrome;
LUSC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.68	0.54	1.18e-26	Prudent dietary pattern;
LUSC	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.68	-0.43	1.83e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs10740039	0.810	rs2165691	chr10:62371649	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.84	-0.35	3.76e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12292205	chr6:26970375	C6orf41	-0.58	-7.39	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg24375607	chr4:120327624	NA	0.82	11.96	0.55	1.08e-27	Corneal astigmatism;
LUSC	cis	rs9549260	0.755	rs2755214	chr13:41149345	T/G	cg21288729	chr13:41239152	FOXO1	0.6	9.39	0.46	9.46e-19	Red blood cell count;
LUSC	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.66	10.08	0.48	4.84e-21	Colorectal cancer;
LUSC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.3	0.49	8.56e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9943753	0.508	rs11066422	chr12:109807153	A/G	cg19025524	chr12:109796872	NA	-0.39	-7.12	-0.36	6.5e-12	HDL cholesterol;
LUSC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-6.99	-0.36	1.54e-11	Menarche (age at onset);
LUSC	trans	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.53e-10	Corneal astigmatism;
LUSC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg22437258	chr11:111473054	SIK2	-0.49	-6.82	-0.35	4.3e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg16989719	chr2:238392110	NA	-0.38	-6.57	-0.34	1.92e-10	Prostate cancer;
LUSC	cis	rs6700896	0.931	rs2211651	chr1:66156021	G/T	cg04111102	chr1:66153794	NA	0.33	7.33	0.37	1.72e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg22823121	chr1:150693482	HORMAD1	0.59	9.05	0.44	1.17e-17	Urate levels;
LUSC	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg25174290	chr11:3078921	CARS	-0.41	-6.19	-0.32	1.8e-9	Calcium levels;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg25355645	chr19:42873746	MEGF8	-0.41	-6.21	-0.32	1.56e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs600231	0.690	rs1152619	chr11:65255589	C/A	cg21890820	chr11:65308645	LTBP3	0.52	7.05	0.36	1.02e-11	Bone mineral density;
LUSC	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.88	15.03	0.64	2.3e-39	Bladder cancer;
LUSC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg24550644	chr17:30846204	MYO1D	-0.56	-9.64	-0.47	1.46e-19	Schizophrenia;
LUSC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-11.87	-0.54	2.3e-27	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg07930552	chr6:133119739	C6orf192	0.79	10.25	0.49	1.34e-21	Type 2 diabetes nephropathy;
LUSC	cis	rs281408	0.559	rs204248	chr19:49216224	G/C	cg13540341	chr19:49222985	MAMSTR	0.38	6.24	0.32	1.31e-9	Urinary metabolites (H-NMR features);
LUSC	cis	rs62400317	0.826	rs62438867	chr6:45049787	G/A	cg20913747	chr6:44695427	NA	-0.46	-7.45	-0.38	8.3e-13	Total body bone mineral density;
LUSC	cis	rs427941	0.595	rs201477	chr7:101746915	G/A	cg06246474	chr7:101738831	CUX1	0.39	6.42	0.33	4.68e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg22764044	chr5:178986830	RUFY1	-0.6	-10.93	-0.51	5.73e-24	Lung cancer;
LUSC	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.2	-0.49	1.9e-21	Eye color traits;
LUSC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20135002	chr11:47629003	NA	-0.5	-7.86	-0.39	5.43e-14	Subjective well-being;
LUSC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg12560992	chr17:57184187	TRIM37	0.84	15.14	0.64	8.69e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg26116260	chr4:7069785	GRPEL1	-1.0	-12.27	-0.56	7.97e-29	Monocyte percentage of white cells;
LUSC	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg20219074	chr11:18656078	SPTY2D1	0.73	10.97	0.51	4.22e-24	Breast cancer;
LUSC	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg00750074	chr16:89608354	SPG7	-0.47	-8.24	-0.41	4.05e-15	Multiple myeloma (IgH translocation);
LUSC	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg26116260	chr4:7069785	GRPEL1	0.47	6.95	0.36	1.93e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	trans	rs1493916	0.606	rs10432168	chr18:31312106	T/C	cg27147174	chr7:100797783	AP1S1	-0.51	-7.98	-0.4	2.42e-14	Life satisfaction;
LUSC	cis	rs7246967	0.673	rs34682021	chr19:22826728	C/T	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg09904177	chr6:26538194	HMGN4	0.65	11.7	0.54	9.83e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg17143192	chr8:8559678	CLDN23	0.64	9.02	0.44	1.47e-17	Obesity-related traits;
LUSC	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.21	0.64	4.77e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg09034736	chr1:150693464	HORMAD1	0.42	5.85	0.3	1.16e-8	Melanoma;
LUSC	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg05738196	chr6:26577821	NA	-0.47	-7.28	-0.37	2.42e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg10729496	chr3:10149963	C3orf24	0.52	7.11	0.36	7.19e-12	Alzheimer's disease;
LUSC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg04546413	chr19:29218101	NA	0.72	11.5	0.53	5.38e-26	Methadone dose in opioid dependence;
LUSC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg06454157	chr6:167490870	NA	-0.27	-6.67	-0.34	1.07e-10	Primary biliary cholangitis;
LUSC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg07404485	chr7:94953653	PON1	-0.3	-5.88	-0.31	1.02e-8	Paraoxonase activity;
LUSC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	8.94	0.44	2.8e-17	Menopause (age at onset);
LUSC	cis	rs9462027	0.583	rs6937784	chr6:34644276	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.21	-0.32	1.53e-9	Systemic lupus erythematosus;
LUSC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21016266	chr12:122356598	WDR66	0.62	9.27	0.45	2.35e-18	Mean corpuscular volume;
LUSC	cis	rs983392	0.836	rs7935829	chr11:59942815	A/G	cg02771260	chr11:59836817	MS4A3	-0.38	-6.16	-0.32	2.11e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.97	-0.48	1.17e-20	Mood instability;
LUSC	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg03433033	chr1:76189801	ACADM	-0.46	-6.88	-0.35	2.95e-11	Daytime sleep phenotypes;
LUSC	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.38e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg10167378	chr1:228756711	NA	0.76	9.72	0.47	8.12e-20	Chronic lymphocytic leukemia;
LUSC	cis	rs36715	1.000	rs36715	chr5:127562880	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.41	5.87	0.31	1.05e-8	Breast cancer;
LUSC	cis	rs7119	0.717	rs11631274	chr15:77816431	A/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs9341808	0.727	rs1324120	chr6:80976125	G/C	cg08355045	chr6:80787529	NA	0.56	9.76	0.47	5.61e-20	Sitting height ratio;
LUSC	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg18105134	chr13:113819100	PROZ	-0.69	-9.77	-0.47	5.23e-20	Platelet distribution width;
LUSC	cis	rs12973672	1.000	rs10421599	chr19:35767933	G/A	cg12095397	chr19:35769544	USF2	0.44	6.92	0.35	2.37e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg15654264	chr1:150340011	RPRD2	0.62	10.12	0.48	3.62e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	5.67	0.3	3.16e-8	Rheumatoid arthritis;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg17647192	chr12:65563900	LEMD3	0.43	6.34	0.33	7.37e-10	N-glycan levels;
LUSC	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.61	-9.24	-0.45	2.95e-18	Morning vs. evening chronotype;
LUSC	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	1.07	16.47	0.67	5.03e-45	Exhaled nitric oxide output;
LUSC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg12463550	chr7:65579703	CRCP	-0.57	-8.46	-0.42	8.37e-16	Aortic root size;
LUSC	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg12081754	chr8:22256438	SLC39A14	0.99	16.38	0.67	1.08e-44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs7944735	0.507	rs7934659	chr11:48066374	C/T	cg15704280	chr7:45808275	SEPT13	0.61	7.31	0.37	2.04e-12	Intraocular pressure;
LUSC	cis	rs4363385	0.574	rs4845503	chr1:152959939	A/G	cg25856811	chr1:152973957	SPRR3	-0.36	-6.01	-0.31	4.98e-9	Inflammatory skin disease;
LUSC	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg23093090	chr10:104574429	C10orf26	-0.41	-7.81	-0.39	7.36e-14	Waist circumference;Hip circumference;
LUSC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-15.51	-0.65	3.07e-41	Coronary artery disease;
LUSC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.78	-13.64	-0.6	5.72e-34	Cognitive function;
LUSC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg05347473	chr6:146136440	FBXO30	0.54	9.34	0.46	1.36e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.8	12.18	0.55	1.72e-28	Cognitive test performance;
LUSC	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.76	-13.02	-0.58	1.27e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs747782	0.527	rs2270993	chr11:48145166	G/A	cg03929089	chr4:120376271	NA	0.71	6.42	0.33	4.63e-10	Intraocular pressure;
LUSC	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg14664628	chr15:75095509	CSK	-1.02	-18.12	-0.7	1.35e-51	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs11229555	0.574	rs12271501	chr11:58214969	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.83	-0.39	6.55e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs662064	0.962	rs648324	chr1:10556447	G/T	cg20482658	chr1:10539492	PEX14	-0.34	-6.88	-0.35	2.94e-11	Asthma;
LUSC	cis	rs13385	0.728	rs10055141	chr5:139616609	T/C	cg26211634	chr5:139558579	C5orf32	0.46	7.05	0.36	1.04e-11	Atrial fibrillation;
LUSC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.28	-0.32	1.07e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg03713592	chr11:72463424	ARAP1	0.49	6.81	0.35	4.45e-11	Body mass index;
LUSC	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.86	-0.44	4.94e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.21	-0.37	3.86e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-1.19	-12.97	-0.58	2.03e-31	Diabetic kidney disease;
LUSC	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg25457927	chr22:38595422	NA	-0.38	-7.86	-0.4	5.22e-14	Cutaneous nevi;
LUSC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.43	0.38	9.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.5	-6.64	-0.34	1.29e-10	Eosinophil percentage of white cells;
LUSC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.85	-0.44	5.19e-17	Monocyte count;
LUSC	cis	rs9905704	0.846	rs7212271	chr17:56863918	C/T	cg12560992	chr17:57184187	TRIM37	0.58	8.38	0.42	1.5e-15	Testicular germ cell tumor;
LUSC	cis	rs4629180	0.562	rs10198901	chr2:102127937	G/A	cg04415270	chr2:102091202	RFX8	-0.44	-7.76	-0.39	1.05e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-11.1	-0.52	1.43e-24	Bipolar disorder;
LUSC	cis	rs4253772	0.938	rs75977757	chr22:46641525	G/T	cg09491104	chr22:46646882	C22orf40	-0.63	-6.52	-0.34	2.57e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg00191853	chr8:101177733	SPAG1	-0.39	-6.37	-0.33	6.33e-10	Atrioventricular conduction;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00232805	chr2:97779565	ANKRD36	0.44	6.93	0.35	2.21e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg18225595	chr11:63971243	STIP1	0.5	6.32	0.33	8.14e-10	Mean platelet volume;
LUSC	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg09835421	chr16:68378352	PRMT7	-0.44	-5.66	-0.3	3.18e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg22166914	chr1:53195759	ZYG11B	-0.49	-7.76	-0.39	1.04e-13	Monocyte count;
LUSC	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg02073558	chr3:44770973	ZNF501	0.61	10.19	0.49	1.99e-21	Depressive symptoms;
LUSC	cis	rs6500395	1.000	rs9931737	chr16:48623539	C/T	cg04672837	chr16:48644449	N4BP1	0.49	7.28	0.37	2.46e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg12463550	chr7:65579703	CRCP	0.5	7.02	0.36	1.22e-11	Aortic root size;
LUSC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	0.93	13.76	0.6	1.93e-34	Initial pursuit acceleration;
LUSC	cis	rs1639906	1.000	rs1637759	chr7:2220053	C/T	cg18044113	chr7:2236405	MAD1L1	-0.33	-6.2	-0.32	1.66e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7582180	0.838	rs13024601	chr2:100902032	C/T	cg08017756	chr2:100939284	LONRF2	-0.36	-6.16	-0.32	2.12e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg19894588	chr14:64061835	NA	0.49	7.1	0.36	7.68e-12	Glioblastoma;Glioma;
LUSC	trans	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.91	0.51	6.48e-24	Mean corpuscular volume;
LUSC	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg09779027	chr19:7224513	INSR	0.46	9.79	0.47	4.74e-20	Hypothyroidism;
LUSC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg09035930	chr12:129282057	SLC15A4	0.66	13.23	0.59	1.95e-32	Systemic lupus erythematosus;
LUSC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg17279839	chr7:150038598	RARRES2	0.45	6.92	0.35	2.28e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg08975724	chr8:8085496	FLJ10661	0.52	7.68	0.39	1.76e-13	Mood instability;
LUSC	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06002616	chr8:101225028	SPAG1	-0.47	-7.62	-0.38	2.59e-13	Atrioventricular conduction;
LUSC	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-1.02	-12.63	-0.57	3.59e-30	Blood pressure (smoking interaction);
LUSC	cis	rs3007168	0.711	rs10144823	chr14:51640225	T/C	cg23942311	chr14:51606299	NA	-0.35	-6.4	-0.33	5.31e-10	Cancer;
LUSC	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg23840854	chr1:161414152	NA	-0.9	-11.05	-0.52	2.16e-24	Rheumatoid arthritis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25341937	chr6:17706893	NUP153	-0.53	-6.42	-0.33	4.71e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08736216	chr1:53307985	ZYG11A	-0.29	-6.27	-0.32	1.12e-9	Monocyte count;
LUSC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06112835	chr11:68658793	MRPL21	0.51	7.68	0.39	1.84e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg26304593	chr6:42947056	PEX6	-0.52	-8.12	-0.41	9e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg20243544	chr17:37824526	PNMT	0.39	5.82	0.3	1.37e-8	Self-reported allergy;
LUSC	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg03647239	chr10:116582469	FAM160B1	0.47	7.58	0.38	3.35e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg25237894	chr2:233734115	C2orf82	0.34	6.29	0.33	9.81e-10	Coronary artery disease;
LUSC	cis	rs950881	0.932	rs72823646	chr2:102954213	G/A	cg20060108	chr2:102954350	IL1RL1	0.45	5.9	0.31	8.86e-9	Allergy;
LUSC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg05555928	chr11:63887634	MACROD1	-0.48	-6.09	-0.32	3.08e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs17095355	1.000	rs11194923	chr10:111695762	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.56	-6.88	-0.35	3.05e-11	Biliary atresia;
LUSC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg12564285	chr5:131593104	PDLIM4	0.36	6.93	0.35	2.2e-11	Blood metabolite levels;
LUSC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	0.91	13.99	0.61	2.57e-35	Parkinson's disease;
LUSC	cis	rs7180079	0.502	rs6494466	chr15:64508763	A/G	cg02848875	chr15:64387786	SNX1	0.4	7.92	0.4	3.63e-14	Monocyte count;
LUSC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.78	11.23	0.52	4.68e-25	Corneal astigmatism;
LUSC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg24733560	chr20:60626293	TAF4	0.36	5.93	0.31	7.62e-9	Body mass index;
LUSC	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg02825527	chr7:2087843	MAD1L1	-0.46	-5.79	-0.3	1.67e-8	Neuroticism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07237882	chr5:137090689	HNRNPA0	-0.47	-6.25	-0.32	1.25e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg00105475	chr2:10696890	NA	0.37	6.09	0.32	3.03e-9	Prostate cancer;
LUSC	cis	rs76793172	1.000	rs16980059	chr19:46353634	C/T	cg27118825	chr19:46318748	RSPH6A;SYMPK	0.45	5.8	0.3	1.54e-8	Eosinophil counts;
LUSC	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg14036092	chr11:66035641	RAB1B	0.44	6.31	0.33	9.07e-10	Gout;
LUSC	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg00310523	chr12:86230176	RASSF9	0.39	6.99	0.36	1.53e-11	Major depressive disorder;
LUSC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg06784218	chr1:46089804	CCDC17	-0.52	-9.87	-0.48	2.51e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg13939156	chr17:80058883	NA	0.33	6.46	0.33	3.73e-10	Life satisfaction;
LUSC	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg22283653	chr8:49824208	NA	0.32	6.2	0.32	1.62e-9	Sudden cardiac arrest;
LUSC	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg00750074	chr16:89608354	SPG7	-0.46	-7.04	-0.36	1.08e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg06713675	chr4:122721982	EXOSC9	-0.7	-12.04	-0.55	5.88e-28	Type 2 diabetes;
LUSC	cis	rs10465746	0.967	rs12759527	chr1:84434425	T/C	cg10977910	chr1:84465055	TTLL7	0.42	6.23	0.32	1.41e-9	Obesity-related traits;
LUSC	trans	rs12043259	0.502	rs4951111	chr1:204725646	C/T	cg06849515	chr4:13549607	LOC285548	-0.63	-6.29	-0.33	9.95e-10	Addiction;
LUSC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg21856205	chr7:94953877	PON1	-0.36	-5.81	-0.3	1.45e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg17691542	chr6:26056736	HIST1H1C	0.52	7.9	0.4	4.01e-14	Height;
LUSC	cis	rs6690583	0.623	rs12037219	chr1:85505951	G/A	cg11262906	chr1:85462892	MCOLN2	0.63	5.99	0.31	5.34e-9	Serum sulfate level;
LUSC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.19	-13.56	-0.6	1.16e-33	Diabetic kidney disease;
LUSC	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.18e-9	Resting heart rate;
LUSC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-8.18	-0.41	5.92e-15	Blood metabolite levels;
LUSC	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg05373962	chr22:49881684	NA	-0.41	-8.54	-0.42	4.99e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11645898	0.745	rs72787062	chr16:72105844	G/A	cg14768367	chr16:72042858	DHODH	-0.66	-7.3	-0.37	2.18e-12	Blood protein levels;
LUSC	cis	rs10761482	0.861	rs4600155	chr10:62101381	T/A	cg18175470	chr10:62150864	ANK3	-0.52	-7.44	-0.38	8.5e-13	Schizophrenia;
LUSC	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.45	-0.42	8.83e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4903604	0.560	rs4903605	chr14:78035619	C/T	cg18872420	chr14:78023429	SPTLC2	0.38	5.94	0.31	7.06e-9	Gut microbiome composition (winter);
LUSC	cis	rs59698941	0.943	rs67952459	chr5:132297902	C/T	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg12442385	chr7:1034912	NA	-0.36	-6.19	-0.32	1.8e-9	Longevity;Endometriosis;
LUSC	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.92	-18.25	-0.71	4.09e-52	Ulcerative colitis;
LUSC	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg05973401	chr12:123451056	ABCB9	-0.52	-6.51	-0.34	2.69e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7945718	0.934	rs10831905	chr11:12776467	C/T	cg25843174	chr11:12811716	TEAD1	-0.31	-6.83	-0.35	4.01e-11	Educational attainment (years of education);
LUSC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	9.91e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.09	0.58	6.67e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2274273	1.000	rs2075603	chr14:55609955	C/A	cg04306507	chr14:55594613	LGALS3	0.54	11.53	0.53	3.94e-26	Protein biomarker;
LUSC	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg05855489	chr10:104503620	C10orf26	-0.53	-8.21	-0.41	4.73e-15	Arsenic metabolism;
LUSC	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg05110241	chr16:68378359	PRMT7	-0.53	-6.16	-0.32	2.11e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs72781680	0.752	rs7578606	chr2:23902360	T/C	cg08917208	chr2:24149416	ATAD2B	0.98	9.69	0.47	9.64e-20	Lymphocyte counts;
LUSC	cis	rs6084875	0.840	rs2422933	chr20:4720035	T/C	cg26097573	chr20:4721490	PRNT	-0.31	-5.71	-0.3	2.44e-8	Systemic lupus erythematosus;
LUSC	cis	rs4077515	0.806	rs3812564	chr9:139271190	A/G	cg14169450	chr9:139327907	INPP5E	0.42	7.5	0.38	5.93e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg25258033	chr6:167368657	RNASET2	0.37	5.83	0.3	1.28e-8	Primary biliary cholangitis;
LUSC	cis	rs7674212	0.541	rs2045746	chr4:104083578	A/C	cg16532752	chr4:104119610	CENPE	0.47	6.71	0.34	8.55e-11	Type 2 diabetes;
LUSC	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg06740227	chr12:86229804	RASSF9	0.36	5.75	0.3	2.04e-8	Major depressive disorder;
LUSC	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg27446573	chr6:127587934	RNF146	0.57	8.55	0.42	4.54e-16	Breast cancer;
LUSC	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12667521	chr19:29218732	NA	0.62	8.99	0.44	1.87e-17	Methadone dose in opioid dependence;
LUSC	cis	rs4141404	0.851	rs5997893	chr22:31556103	A/G	cg22777020	chr22:31556080	RNF185	-0.49	-6.66	-0.34	1.15e-10	Paclitaxel-induced neuropathy;
LUSC	cis	rs6565180	0.926	rs4787643	chr16:30393660	G/A	cg17640201	chr16:30407289	ZNF48	0.9	15.41	0.64	7.41e-41	Tonsillectomy;
LUSC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.52	8.08	0.4	1.22e-14	Prostate cancer;
LUSC	trans	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg07393940	chr7:158741817	NA	0.37	6.7	0.34	8.88e-11	Life satisfaction;
LUSC	cis	rs1385374	1.000	rs1385374	chr12:129300694	C/T	cg09035930	chr12:129282057	SLC15A4	-0.58	-6.34	-0.33	7.39e-10	Systemic lupus erythematosus;
LUSC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg08798685	chr6:27730294	NA	-0.63	-5.88	-0.31	1.01e-8	Depression;
LUSC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg23711669	chr6:146136114	FBXO30	0.86	15.44	0.65	5.67e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.07e-17	Prudent dietary pattern;
LUSC	trans	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg10756647	chr7:56101905	PSPH	0.88	8.95	0.44	2.46e-17	Diabetic kidney disease;
LUSC	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg26102564	chr10:131424627	MGMT	-0.4	-6.26	-0.32	1.2e-9	Response to temozolomide;
LUSC	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg15704280	chr7:45808275	SEPT13	0.81	7.73	0.39	1.27e-13	Axial length;
LUSC	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.15	-0.45	5.6e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg24879335	chr3:133465180	TF	-0.46	-8.1	-0.41	1.01e-14	Iron status biomarkers (transferrin levels);
LUSC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-1.23	-13.29	-0.59	1.17e-32	Diabetic kidney disease;
LUSC	cis	rs57920188	0.584	rs12068729	chr1:4091650	A/G	cg20703997	chr1:4087676	NA	0.56	8.33	0.41	2.12e-15	Interleukin-17 levels;
LUSC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg07217954	chr7:1067459	C7orf50	0.54	5.71	0.3	2.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg27165867	chr14:105738592	BRF1	-0.53	-7.72	-0.39	1.36e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.76	-0.43	9.63e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.76	-0.35	6.21e-11	Menopause (age at onset);
LUSC	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg24006582	chr15:45444508	DUOX1	0.67	9.67	0.47	1.16e-19	Uric acid levels;
LUSC	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg13609457	chr4:120235615	NA	0.37	5.7	0.3	2.61e-8	Diastolic blood pressure;
LUSC	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.29	0.59	1.2e-32	Blood protein levels;
LUSC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg00800038	chr16:89945340	TCF25	-0.66	-6.82	-0.35	4.41e-11	Skin colour saturation;
LUSC	trans	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg19694781	chr19:47549865	TMEM160	-0.57	-9.41	-0.46	8.09e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.3	-6.03	-0.31	4.23e-9	Schizophrenia;
LUSC	trans	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg00845942	chr12:64062724	DPY19L2	-0.62	-7.97	-0.4	2.45e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-14.2	-0.61	3.99e-36	Hemoglobin concentration;
LUSC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg18904891	chr8:8559673	CLDN23	-0.61	-8.47	-0.42	8.17e-16	Obesity-related traits;
LUSC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg12963246	chr6:28129442	ZNF389	0.48	6.55	0.34	2.12e-10	Depression;
LUSC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15369054	chr17:80825471	TBCD	0.68	11.02	0.52	2.78e-24	Breast cancer;
LUSC	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg11019008	chr10:131425282	MGMT	0.45	6.7	0.34	8.92e-11	Response to temozolomide;
LUSC	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg10255544	chr17:80519551	FOXK2	0.39	6.38	0.33	5.79e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg25457927	chr22:38595422	NA	-0.42	-8.92	-0.44	3.05e-17	Cutaneous nevi;
LUSC	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.63	-11.24	-0.52	4.3e-25	Ulcerative colitis;
LUSC	trans	rs724744	0.772	rs1205913	chr6:22371494	A/G	cg13807341	chr11:118445984	ARCN1	0.35	6.1	0.32	2.88e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.28	0.41	3.03e-15	Tonsillectomy;
LUSC	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg15704280	chr7:45808275	SEPT13	0.79	7.49	0.38	6.36e-13	Axial length;
LUSC	cis	rs8048589	0.515	rs12443524	chr16:12239979	A/G	cg02910054	chr16:12241554	SNX29	-0.49	-7.05	-0.36	1.06e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs8113142	0.651	rs16961698	chr19:29111032	T/C	cg04546413	chr19:29218101	NA	0.42	5.76	0.3	1.96e-8	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.16	0.61	5.72e-36	Platelet count;
LUSC	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg05855489	chr10:104503620	C10orf26	0.59	9.45	0.46	6.25e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg03474202	chr17:45855739	NA	-0.3	-6.93	-0.35	2.14e-11	IgG glycosylation;
LUSC	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg06026331	chr20:60912101	LAMA5	-0.56	-6.78	-0.35	5.63e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg05966235	chr16:28915196	ATP2A1	0.34	5.96	0.31	6.43e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg06917634	chr15:78832804	PSMA4	-0.6	-8.96	-0.44	2.37e-17	Sudden cardiac arrest;
LUSC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg23711669	chr6:146136114	FBXO30	0.92	17.68	0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18802885	chr22:26908376	TFIP11	0.43	6.31	0.33	9.06e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6723108	0.713	rs6728095	chr2:135376072	T/A	cg12500956	chr2:135428796	TMEM163	-0.29	-6.78	-0.35	5.44e-11	Type 2 diabetes;
LUSC	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg12559939	chr2:27858050	GPN1	0.39	5.99	0.31	5.52e-9	Oral cavity cancer;
LUSC	cis	rs6714710	0.627	rs11680883	chr2:98472610	T/C	cg26665480	chr2:98280029	ACTR1B	0.64	9.21	0.45	3.6e-18	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs9886428	1.000	rs34786320	chr8:14115490	G/C	cg19037007	chr20:741798	C20orf54	-0.39	-6.11	-0.32	2.77e-9	IgG glycosylation;
LUSC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.66	0.3	3.26e-8	Menopause (age at onset);
LUSC	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.24	-0.37	3.09e-12	Bipolar disorder;
LUSC	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg03359095	chr20:61002866	C20orf151	-0.3	-5.83	-0.3	1.29e-8	Colorectal cancer;
LUSC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg12751644	chr20:60527061	NA	0.37	6.4	0.33	5.25e-10	Body mass index;
LUSC	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.49	0.46	4.69e-19	Coffee consumption (cups per day);
LUSC	cis	rs4665630	0.522	rs2712100	chr2:23931925	A/T	cg08063864	chr2:24346004	PFN4;LOC375190	-0.81	-7.26	-0.37	2.79e-12	Hypertension;
LUSC	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg15073853	chr19:18549131	ISYNA1	-0.33	-6.16	-0.32	2.13e-9	Breast cancer;
LUSC	cis	rs77633900	0.614	rs280014	chr15:76986890	A/G	cg21673338	chr15:77095150	SCAPER	-0.81	-8.23	-0.41	4.3e-15	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs6977660	0.714	rs2390157	chr7:19786177	G/A	cg07541023	chr7:19748670	TWISTNB	0.67	6.71	0.34	8.19e-11	Thyroid stimulating hormone;
LUSC	cis	rs6686643	1.000	rs6686643	chr1:165616588	T/C	cg16553119	chr1:165599451	MGST3	-0.46	-6.73	-0.35	7.28e-11	Total ventricular volume;
LUSC	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg05163923	chr11:71159392	DHCR7	0.74	10.94	0.51	5.36e-24	Vitamin D levels;
LUSC	cis	rs9653442	0.564	rs11902705	chr2:100795207	A/G	cg07810366	chr2:100720526	AFF3	0.41	6.98	0.36	1.57e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	1.08	14.22	0.61	3.19e-36	Nonalcoholic fatty liver disease;
LUSC	cis	rs2580764	0.566	rs2972075	chr2:55292322	T/G	cg09592903	chr2:55203963	RTN4	0.48	9.85	0.47	2.91e-20	Mean platelet volume;
LUSC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg10729496	chr3:10149963	C3orf24	0.52	6.88	0.35	2.9100000000000002e-11	Alzheimer's disease;
LUSC	cis	rs6725041	0.547	rs17419211	chr2:213207921	C/T	cg16329650	chr2:213403929	ERBB4	-0.43	-6.71	-0.34	8.3e-11	QT interval (ambient particulate matter interaction);
LUSC	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.36e-15	Monocyte count;
LUSC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	10.66	0.5	4.87e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg17968037	chr7:100024898	ZCWPW1	-0.4	-5.99	-0.31	5.28e-9	Platelet count;
LUSC	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg10978503	chr1:24200527	CNR2	0.47	10.39	0.49	4.37e-22	Immature fraction of reticulocytes;
LUSC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.67	0.6	4.39e-34	Alzheimer's disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11251232	chr1:93811340	DR1	0.73	6.38	0.33	5.85e-10	Cognitive performance;
LUSC	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg25319279	chr11:5960081	NA	-0.46	-6.46	-0.33	3.71e-10	DNA methylation (variation);
LUSC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00166722	chr3:10149974	C3orf24	0.55	7.46	0.38	7.77e-13	Alzheimer's disease;
LUSC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.16	0.32	2.11e-9	Menopause (age at onset);
LUSC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02475777	chr4:1388615	CRIPAK	0.62	9.23	0.45	3.15e-18	Longevity;
LUSC	trans	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.41	-0.33	4.96e-10	Blood trace element (Cu levels);
LUSC	cis	rs2742417	0.603	rs13059502	chr3:45781380	A/G	cg04837898	chr3:45731254	SACM1L	-0.45	-7.45	-0.38	8.27e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs72674100	1.000	rs2865776	chr4:97971736	C/T	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg07507251	chr3:52567010	NT5DC2	0.34	6.66	0.34	1.1e-10	Bipolar disorder;
LUSC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg02475777	chr4:1388615	CRIPAK	0.42	6.33	0.33	7.85e-10	Obesity-related traits;
LUSC	cis	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.24	0.52	4.35e-25	Menopause (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg19698570	chr19:3500953	DOHH	0.79	6.51	0.34	2.79e-10	Cognitive performance;
LUSC	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.05	-23.22	-0.79	1.12e-71	Ulcerative colitis;
LUSC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00166722	chr3:10149974	C3orf24	0.6	8.12	0.41	9.32e-15	Alzheimer's disease;
LUSC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg19774624	chr17:42201019	HDAC5	0.7	10.38	0.49	4.71e-22	Total body bone mineral density;
LUSC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg22868518	chr11:507468	RNH1	-0.63	-5.92	-0.31	7.8e-9	Body mass index;
LUSC	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.48	-0.33	3.37e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg13010199	chr12:38710504	ALG10B	0.55	8.36	0.42	1.74e-15	Morning vs. evening chronotype;
LUSC	cis	rs9341808	0.718	rs910266	chr6:80921170	A/T	cg08355045	chr6:80787529	NA	0.58	10.2	0.49	1.97e-21	Sitting height ratio;
LUSC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13126279	chr21:47581558	C21orf56	-0.55	-8.41	-0.42	1.21e-15	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg26384229	chr12:38710491	ALG10B	0.88	15.06	0.64	1.84e-39	Bladder cancer;
LUSC	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	10.93	0.51	5.78e-24	Eye color traits;
LUSC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg03676636	chr4:99064102	C4orf37	0.34	7.44	0.38	8.35e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg26446133	chr18:72167187	CNDP2	-0.81	-9.95	-0.48	1.35e-20	Refractive error;
LUSC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg23630131	chr7:65973040	NA	0.21	5.79	0.3	1.6e-8	Aortic root size;
LUSC	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg03676636	chr4:99064102	C4orf37	0.36	7.94	0.4	3.02e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg17366294	chr4:99064904	C4orf37	0.6	10.71	0.51	3.43e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg03563238	chr19:33554763	RHPN2	-0.4	-6.47	-0.33	3.46e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9467773	0.626	rs9379860	chr6:26370605	T/C	cg05738196	chr6:26577821	NA	-0.49	-7.55	-0.38	4.29e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.68	9.28	0.45	2.19e-18	High light scatter reticulocyte count;
LUSC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.8	0.6	1.3600000000000001e-34	Chronic sinus infection;
LUSC	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg23950597	chr19:37808831	NA	-0.62	-7.63	-0.39	2.54e-13	Coronary artery calcification;
LUSC	trans	rs7259376	0.936	rs55983151	chr19:22552936	T/A	cg08058610	chr19:52674483	ZNF836	0.38	5.95	0.31	6.93e-9	Menopause (age at onset);
LUSC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06873352	chr17:61820015	STRADA	0.56	8.73	0.43	1.25e-16	Height;
LUSC	cis	rs977987	0.843	rs12443834	chr16:75438469	C/T	cg03315344	chr16:75512273	CHST6	0.48	8.94	0.44	2.8e-17	Dupuytren's disease;
LUSC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg02508848	chr16:68573721	ZFP90	-0.43	-5.82	-0.3	1.42e-8	Ulcerative colitis;
LUSC	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.34	0.49	6.17e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg24375607	chr4:120327624	NA	0.77	11.32	0.53	2.32e-25	Corneal astigmatism;
LUSC	cis	rs17095355	0.818	rs12572438	chr10:111769236	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-6.85	-0.35	3.58e-11	Biliary atresia;
LUSC	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	0.99	15.59	0.65	1.45e-41	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg21918786	chr6:109611834	NA	-0.42	-7.29	-0.37	2.21e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg08847533	chr14:75593920	NEK9	0.84	15.46	0.65	4.83e-41	Height;
LUSC	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg24375607	chr4:120327624	NA	0.76	11.14	0.52	1e-24	Corneal astigmatism;
LUSC	trans	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg25214090	chr10:38739885	LOC399744	0.45	6.52	0.34	2.58e-10	Corneal astigmatism;
LUSC	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.75	14.14	0.61	6.59e-36	Multiple sclerosis;
LUSC	cis	rs8179	0.552	rs2888877	chr7:92228400	C/T	cg15732164	chr7:92237376	CDK6	-0.48	-6.54	-0.34	2.25e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs36093844	0.752	rs1445505	chr11:85584722	A/G	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg26384229	chr12:38710491	ALG10B	0.75	11.87	0.54	2.4200000000000002e-27	Morning vs. evening chronotype;
LUSC	cis	rs11030122	0.604	rs10835557	chr11:4083121	A/G	cg18678763	chr11:4115507	RRM1	-0.46	-6.23	-0.32	1.38e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.48	7.46	0.38	7.64e-13	Colorectal cancer;
LUSC	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg08917208	chr2:24149416	ATAD2B	0.89	10.1	0.48	4.26e-21	Lymphocyte counts;
LUSC	cis	rs4285028	0.948	rs34837785	chr3:121657776	G/A	cg11130432	chr3:121712080	ILDR1	-0.64	-9.86	-0.47	2.62e-20	Multiple sclerosis;
LUSC	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg19812747	chr11:111475976	SIK2	0.52	6.93	0.35	2.19e-11	Primary sclerosing cholangitis;
LUSC	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs672059	0.565	rs525410	chr1:183176430	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.41	-6.02	-0.31	4.7e-9	Hypertriglyceridemia;
LUSC	cis	rs17253792	0.732	rs8017891	chr14:56172967	A/G	cg01858014	chr14:56050164	KTN1	0.71	6.28	0.33	1.03e-9	Putamen volume;
LUSC	cis	rs4974559	1.000	rs1882099	chr4:1352685	A/G	cg02980000	chr4:1222292	CTBP1	0.7	7.94	0.4	3.16e-14	Systolic blood pressure;
LUSC	trans	rs8073060	0.586	rs225300	chr17:33922428	C/T	cg19694781	chr19:47549865	TMEM160	-1.12	-17.91	-0.7	9.17e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.38	5.69	0.3	2.85e-8	Lung cancer;
LUSC	trans	rs17039065	1.000	rs16996969	chr4:109382668	A/T	cg07444054	chr2:108107501	NA	0.43	6.27	0.32	1.1e-9	Gut microbiome composition (summer);
LUSC	trans	rs6427908	0.535	rs481298	chr1:201430436	C/T	cg19931106	chr2:37311892	CCDC75;HEATR5B	0.41	6.16	0.32	2.13e-9	Itch intensity from mosquito bite adjusted by bite size;
LUSC	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.81	-0.39	7.56e-14	Neuroticism;
LUSC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.89	15.95	0.66	5.74e-43	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg06454157	chr6:167490870	NA	-0.25	-6.29	-0.33	1.01e-9	Crohn's disease;
LUSC	trans	rs6828577	0.560	rs114938210	chr4:119457257	A/T	cg26518628	chr1:97050305	NA	-0.52	-7.58	-0.38	3.34e-13	Perioperative myocardial infarction in coronary artery bypass surgery;
LUSC	trans	rs11723530	0.512	rs6848359	chr4:170815842	C/T	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.15	-0.32	2.19e-9	Myopia (pathological);
LUSC	cis	rs727505	0.521	rs66787780	chr7:124791849	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.98	-0.36	1.61e-11	Lewy body disease;
LUSC	cis	rs7577851	0.715	rs6759021	chr2:69632620	T/C	cg10773587	chr2:69614142	GFPT1	0.56	6.3	0.33	9.29e-10	Parkinson's disease (age of onset);
LUSC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-12.63	-0.57	3.54e-30	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	8.17	0.41	6.49e-15	Neuroticism;
LUSC	cis	rs2835872	0.965	rs1787331	chr21:39003525	T/G	cg20424643	chr21:39039972	KCNJ6	-0.39	-5.91	-0.31	8.28e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg25922239	chr6:33757077	LEMD2	0.54	8.02	0.4	1.78e-14	Crohn's disease;
LUSC	cis	rs34891900	0.507	rs12167823	chr22:18124362	G/A	cg19898043	chr22:18121309	BCL2L13	0.41	6.26	0.32	1.18e-9	Sum neutrophil eosinophil counts;
LUSC	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18854424	chr1:2615690	NA	-0.52	-10.62	-0.5	6.92e-23	Ulcerative colitis;
LUSC	cis	rs62458065	0.850	rs62458099	chr7:32472395	C/T	cg20159608	chr7:32802032	NA	-0.66	-7.83	-0.39	6.35e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg14061069	chr19:46274453	DMPK	-0.49	-8.32	-0.41	2.34e-15	Coronary artery disease;
LUSC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg02569458	chr12:86230093	RASSF9	0.57	9.47	0.46	5.46e-19	Major depressive disorder;
LUSC	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.75	-0.6	2.1e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg20607287	chr7:12443886	VWDE	-0.65	-6.34	-0.33	7.48e-10	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg07080220	chr10:102295463	HIF1AN	0.61	8.14	0.41	8.11e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg10645314	chr2:3704589	ALLC	-0.49	-7.33	-0.37	1.72e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.81	13.22	0.59	2.12e-32	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg15448220	chr1:150897856	SETDB1	0.42	5.86	0.31	1.09e-8	Urate levels;
LUSC	cis	rs10045504	0.502	rs72746038	chr5:38753999	G/A	cg15396434	chr5:38725168	NA	-0.51	-5.79	-0.3	1.61e-8	Night sleep phenotypes;
LUSC	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg22189786	chr22:42395067	WBP2NL	0.43	5.77	0.3	1.78e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg26876637	chr1:152193138	HRNR	0.44	6.4	0.33	5.27e-10	Atopic dermatitis;
LUSC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	5.8	0.3	1.56e-8	Personality dimensions;
LUSC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg18827107	chr12:86230957	RASSF9	0.46	6.98	0.36	1.65e-11	Major depressive disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18441082	chr5:16466057	ZNF622	0.42	6.27	0.32	1.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs17495987	0.871	rs73061231	chr7:7904396	T/C	cg25844211	chr1:229761456	URB2;TAF5L	0.45	6.05	0.31	3.83e-9	Tonsillectomy;
LUSC	trans	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg06636001	chr8:8085503	FLJ10661	0.43	6.27	0.32	1.11e-9	Retinal vascular caliber;
LUSC	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg00074818	chr8:8560427	CLDN23	0.59	9.92	0.48	1.71e-20	Obesity-related traits;
LUSC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.66	11.38	0.53	1.45e-25	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs554111	0.656	rs10916930	chr1:21395357	C/T	cg01072550	chr1:21505969	NA	-0.37	-5.68	-0.3	2.92e-8	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-6.86	-0.35	3.45e-11	Self-reported allergy;
LUSC	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.69e-11	Response to antipsychotic treatment;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03087852	chr16:30969112	SETD1A	0.78	6.13	0.32	2.47e-9	Cognitive performance;
LUSC	cis	rs6066835	1.000	rs6095272	chr20:47357517	A/G	cg18078177	chr20:47281410	PREX1	0.75	6.44	0.33	4.14e-10	Multiple myeloma;
LUSC	cis	rs6942756	1.000	rs6974155	chr7:128914545	C/G	cg02491457	chr7:128862824	NA	-0.53	-7.63	-0.39	2.4e-13	White matter hyperintensity burden;
LUSC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	trans	rs2302464	1.000	rs111541714	chr4:15730405	C/A	cg17675199	chr6:35436792	RPL10A	-0.88	-6.15	-0.32	2.26e-9	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.32	0.53	2.25e-25	Mean corpuscular volume;
LUSC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.44	0.53	8.79e-26	Prudent dietary pattern;
LUSC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.05e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs488628	1.000	rs487147	chr3:118135310	A/G	cg06621744	chr14:37052470	NKX2-8	-0.29	-6.7	-0.34	8.64e-11	White matter integrity (bipolar disorder risk interaction);
LUSC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg22963979	chr7:1858916	MAD1L1	-0.74	-12.57	-0.57	6.08e-30	Bipolar disorder and schizophrenia;
LUSC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg09035930	chr12:129282057	SLC15A4	0.66	13.35	0.59	7.04e-33	Systemic lupus erythematosus;
LUSC	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	13.51	0.59	1.72e-33	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.64	7.97	0.4	2.5e-14	Lung function (FEV1/FVC);
LUSC	trans	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.76	-0.35	6.16e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	19.83	0.74	2.17e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg15017067	chr4:17643749	FAM184B	0.34	5.75	0.3	2e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2969070	1.000	rs917079	chr7:2514181	C/T	cg03277898	chr7:2518824	NA	-0.26	-5.65	-0.3	3.39e-8	Diastolic blood pressure;
LUSC	cis	rs78579285	0.545	rs79311053	chr16:88785206	C/T	cg01900006	chr16:88814613	FAM38A	0.54	6.13	0.32	2.49e-9	Joint mobility (Beighton score);
LUSC	cis	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg06521331	chr12:34319734	NA	-0.49	-8.14	-0.41	8e-15	Morning vs. evening chronotype;
LUSC	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg04539111	chr16:67997858	SLC12A4	-0.43	-5.74	-0.3	2.09e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.03	-0.44	1.42e-17	Total cholesterol levels;
LUSC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.29	0.49	9.75e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6545883	0.894	rs2177962	chr2:61588070	T/A	cg15711740	chr2:61764176	XPO1	0.44	6.69	0.34	9.36e-11	Tuberculosis;
LUSC	cis	rs7615316	0.934	rs6440094	chr3:142316443	C/T	cg16271453	chr3:142027066	XRN1	-0.36	-6.12	-0.32	2.61e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg03354898	chr7:1950403	MAD1L1	-0.42	-8.36	-0.42	1.72e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.63	-0.43	2.52e-16	Rheumatoid arthritis;
LUSC	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.21	-0.37	3.66e-12	Type 2 diabetes;
LUSC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg05585544	chr11:47624801	NA	-0.41	-7.37	-0.37	1.38e-12	Subjective well-being;
LUSC	cis	rs4356932	1.000	rs6814012	chr4:76950778	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.59e-8	Blood protein levels;
LUSC	cis	rs61612642	0.537	rs6915565	chr6:42192582	G/A	cg01092361	chr6:42185687	MRPS10	0.78	8.49	0.42	6.66e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg20203395	chr5:56204925	C5orf35	-0.45	-6.75	-0.35	6.69e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs2979489	0.591	rs62508371	chr8:30422060	C/T	cg26383811	chr8:30366931	RBPMS	-0.42	-6.65	-0.34	1.18e-10	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.66	-0.34	1.11e-10	Arsenic metabolism;
LUSC	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.6	0.43	3.06e-16	Lung cancer;
LUSC	trans	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg07879474	chr5:139064216	NA	-0.4	-6.05	-0.31	3.83e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg08027265	chr7:2291960	NA	-0.35	-5.67	-0.3	3.08e-8	Schizophrenia;
LUSC	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg24642439	chr20:33292090	TP53INP2	0.5	7.46	0.38	7.71e-13	Height;
LUSC	cis	rs7804356	0.906	rs73069541	chr7:26904928	A/G	cg03456212	chr7:26904342	SKAP2	-0.58	-6.65	-0.34	1.22e-10	Type 1 diabetes;
LUSC	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg04906043	chr13:21280425	IL17D	-0.45	-8.67	-0.43	1.97e-16	Dental caries;
LUSC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg22903657	chr4:1355424	KIAA1530	-0.35	-5.96	-0.31	6.32e-9	Obesity-related traits;
LUSC	cis	rs12900413	0.687	rs28513927	chr15:90304471	T/G	cg24249390	chr15:90295951	MESP1	-0.39	-6.01	-0.31	4.94e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05025164	chr4:1340916	KIAA1530	-0.65	-10.15	-0.49	2.91e-21	Obesity-related traits;
LUSC	cis	rs6700896	0.931	rs7531867	chr1:66107546	A/G	cg04111102	chr1:66153794	NA	-0.33	-7.44	-0.38	8.86e-13	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg23711669	chr6:146136114	FBXO30	0.91	17.88	0.7	1.27e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12667521	chr19:29218732	NA	0.61	8.88	0.44	4.2e-17	Methadone dose in opioid dependence;
LUSC	cis	rs16854884	0.586	rs6795008	chr3:143738421	A/G	cg06585982	chr3:143692056	C3orf58	0.52	8.29	0.41	2.86e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg22777020	chr22:31556080	RNF185	-0.45	-5.76	-0.3	1.95e-8	Colorectal cancer;
LUSC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11764359	chr7:65958608	NA	0.68	10.97	0.51	3.99e-24	Aortic root size;
LUSC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-1.02	-19.42	-0.73	9.06e-57	Height;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00118684	chr18:13726609	RNMT;C18orf19	0.44	5.95	0.31	6.78e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs727505	1.000	rs28622327	chr7:124526213	C/T	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg00684032	chr4:1343700	KIAA1530	0.34	6.1	0.32	2.95e-9	Longevity;
LUSC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-10.92	-0.51	6.32e-24	Schizophrenia;
LUSC	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg04374321	chr14:90722782	PSMC1	-0.68	-10.22	-0.49	1.66e-21	Mortality in heart failure;
LUSC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.88	-0.31	9.74e-9	Neutrophil percentage of white cells;
LUSC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg22834771	chr12:69754056	YEATS4	-0.42	-5.76	-0.3	1.96e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg21782813	chr7:2030301	MAD1L1	-0.43	-7.25	-0.37	2.85e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg00990874	chr7:1149470	C7orf50	-0.51	-6.39	-0.33	5.43e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg13047869	chr3:10149882	C3orf24	0.65	9.2	0.45	3.94e-18	Alzheimer's disease;
LUSC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg11861562	chr11:117069780	TAGLN	0.45	8.02	0.4	1.75e-14	Blood protein levels;
LUSC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg06671706	chr8:8559999	CLDN23	0.51	6.98	0.36	1.6e-11	Obesity-related traits;
LUSC	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.88	10.36	0.49	5.27e-22	Body mass index;
LUSC	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.67	11.14	0.52	9.93e-25	Platelet distribution width;
LUSC	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.84	16.23	0.66	4.22e-44	Itch intensity from mosquito bite;
LUSC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.23	14.1	0.61	9.75e-36	Diabetic kidney disease;
LUSC	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg20744362	chr22:50050164	C22orf34	0.39	7.29	0.37	2.32e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.61	0.69	1.51e-49	Chronic sinus infection;
LUSC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg24296786	chr1:45957014	TESK2	0.52	8.13	0.41	8.45e-15	High light scatter reticulocyte count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01252224	chr16:83841660	HSBP1	0.46	6.34	0.33	7.54e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg17143192	chr8:8559678	CLDN23	0.64	8.85	0.44	5.04e-17	Obesity-related traits;
LUSC	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg03929089	chr4:120376271	NA	0.67	6.3	0.33	9.53e-10	Intraocular pressure;
LUSC	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	0.97	13.53	0.6	1.42e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.14	16.34	0.67	1.63e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9308433	0.529	rs4655243	chr1:214497291	A/G	cg06198575	chr1:214491504	SMYD2	0.45	7.06	0.36	9.75e-12	IgG glycosylation;
LUSC	cis	rs6426558	0.537	rs694740	chr1:227293451	A/G	cg10327440	chr1:227177885	CDC42BPA	0.54	7.26	0.37	2.82e-12	Neutrophil percentage of white cells;
LUSC	cis	rs56804039	1.000	rs59620654	chr8:8382632	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.66	-0.34	1.11e-10	Cervical cancer;
LUSC	trans	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg27411982	chr8:10470053	RP1L1	0.42	6.33	0.33	7.72e-10	Monocyte count;
LUSC	cis	rs4654899	1.000	rs6426656	chr1:21343245	G/C	cg01072550	chr1:21505969	NA	-0.55	-8.41	-0.42	1.23e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.48	0.53	5.96e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	12.0	0.55	7.98e-28	Prudent dietary pattern;
LUSC	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.98	0.58	1.85e-31	White blood cell count;
LUSC	cis	rs4132509	0.895	rs7556516	chr1:243782009	G/A	cg21452805	chr1:244014465	NA	0.49	5.65	0.3	3.37e-8	RR interval (heart rate);
LUSC	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg20503657	chr10:835505	NA	0.7	8.52	0.42	5.57e-16	Eosinophil percentage of granulocytes;
LUSC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg27432699	chr2:27873401	GPN1	-0.63	-9.66	-0.47	1.2e-19	Total body bone mineral density;
LUSC	trans	rs28647808	0.881	rs71483208	chr9:136258824	T/C	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg21775007	chr8:11205619	TDH	-0.56	-8.31	-0.41	2.46e-15	Neuroticism;
LUSC	cis	rs7202877	0.706	rs4993971	chr16:75411634	C/G	cg03315344	chr16:75512273	CHST6	-0.41	-6.22	-0.32	1.5e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg11645453	chr3:52864694	ITIH4	0.35	8.38	0.42	1.53e-15	Bipolar disorder;
LUSC	cis	rs4930561	0.714	rs7126326	chr11:67947275	T/G	cg04465784	chr11:67976953	SUV420H1	-0.28	-5.67	-0.3	3.05e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.65	-9.85	-0.47	2.9e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18758796	chr5:131593413	PDLIM4	0.53	9.17	0.45	4.88e-18	Acylcarnitine levels;
LUSC	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg27661571	chr11:113659931	NA	-0.6	-7.25	-0.37	2.83e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg16359550	chr11:109292809	C11orf87	0.44	7.06	0.36	9.47e-12	Schizophrenia;
LUSC	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg11189052	chr15:85197271	WDR73	0.5	6.26	0.32	1.17e-9	Schizophrenia;
LUSC	cis	rs6537837	1.000	rs11810577	chr1:110138109	C/T	cg05049280	chr1:110155535	GNAT2	0.47	6.55	0.34	2.15e-10	Major depressive disorder;
LUSC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg10636054	chr15:40330586	SRP14	0.88	8.33	0.41	2.17e-15	Corneal curvature;
LUSC	cis	rs9581857	0.685	rs9579084	chr13:28028201	A/G	cg22138327	chr13:27999177	GTF3A	-0.72	-8.57	-0.42	3.95e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg02825527	chr7:2087843	MAD1L1	0.51	5.85	0.3	1.16e-8	Bipolar disorder;
LUSC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg13047869	chr3:10149882	C3orf24	0.42	6.44	0.33	4.21e-10	Alzheimer's disease;
LUSC	cis	rs1163251	0.902	rs511059	chr1:120217081	G/T	cg19096424	chr1:120255104	PHGDH	0.48	6.53	0.34	2.39e-10	Blood metabolite levels;
LUSC	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.66	-10.48	-0.5	2.17e-22	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg06612196	chr6:6737390	NA	0.55	10.39	0.49	4.32e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg03340356	chr1:67600835	NA	0.43	6.64	0.34	1.28e-10	Psoriasis;
LUSC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	7.11	0.36	6.89e-12	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg18827107	chr12:86230957	RASSF9	-0.47	-6.99	-0.36	1.55e-11	Major depressive disorder;
LUSC	cis	rs9399401	0.626	rs4304190	chr6:142778912	A/G	cg04461802	chr6:142623433	GPR126	0.46	5.9	0.31	8.82e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg00579200	chr11:133705235	NA	-0.41	-6.15	-0.32	2.23e-9	Childhood ear infection;
LUSC	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-0.88	-15.47	-0.65	4.51e-41	Height;
LUSC	cis	rs12220238	1.000	rs111704178	chr10:75957251	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.22	0.37	3.42e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-0.95	-17.65	-0.69	1.04e-49	Headache;
LUSC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.04	-0.44	1.26e-17	Monocyte percentage of white cells;
LUSC	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.23e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11764359	chr7:65958608	NA	0.63	9.69	0.47	1.01e-19	Calcium levels;
LUSC	cis	rs4919087	1.000	rs4919087	chr10:99072507	C/T	cg25902810	chr10:99078978	FRAT1	-0.49	-7.19	-0.37	4.17e-12	Monocyte count;
LUSC	cis	rs79149102	0.649	rs1531162	chr15:75111984	C/T	cg09165964	chr15:75287851	SCAMP5	-0.91	-6.49	-0.33	3.08e-10	Lung cancer;
LUSC	cis	rs611744	0.870	rs429315	chr8:109094068	A/G	cg18478394	chr8:109455254	TTC35	-0.39	-5.74	-0.3	2.12e-8	Dupuytren's disease;
LUSC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg21251018	chr6:28226885	NKAPL	-0.32	-6.17	-0.32	1.97e-9	Cardiac Troponin-T levels;
LUSC	cis	rs6489882	0.867	rs6489870	chr12:113363972	G/A	cg20102336	chr12:113376681	OAS3	-0.41	-5.89	-0.31	9.59e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.8	-11.57	-0.53	2.85e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs16910800	0.731	rs1871953	chr11:23192677	G/A	cg20040320	chr11:23191996	NA	-0.6	-7.56	-0.38	4.05e-13	Cancer;
LUSC	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg09835421	chr16:68378352	PRMT7	-0.77	-8.57	-0.42	3.86e-16	Schizophrenia;
LUSC	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg19789473	chr17:27170043	C17orf63	-0.3	-5.68	-0.3	3e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg00531865	chr16:30841666	NA	-0.33	-6.01	-0.31	4.87e-9	Dementia with Lewy bodies;
LUSC	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg07148914	chr20:33460835	GGT7	-0.52	-8.11	-0.41	1e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-18.18	-0.71	7.93e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg01879757	chr17:41196368	BRCA1	-0.48	-7.29	-0.37	2.23e-12	Menopause (age at onset);
LUSC	cis	rs1160297	0.576	rs1451456	chr2:53092604	A/C	cg07782112	chr2:53107842	NA	0.44	7.09	0.36	8.14e-12	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.77	-0.39	1e-13	Morning vs. evening chronotype;
LUSC	trans	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07923666	chr12:49932857	KCNH3	-0.53	-6.59	-0.34	1.74e-10	Resting heart rate;
LUSC	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg17691542	chr6:26056736	HIST1H1C	0.46	6.87	0.35	3.19e-11	Height;
LUSC	cis	rs8114671	0.967	rs2069945	chr20:33761837	C/G	cg24642439	chr20:33292090	TP53INP2	0.45	6.35	0.33	7.14e-10	Height;
LUSC	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg17691542	chr6:26056736	HIST1H1C	0.39	5.85	0.3	1.17e-8	Schizophrenia;
LUSC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00149659	chr3:10157352	C3orf10	0.93	13.6	0.6	7.69e-34	Alzheimer's disease;
LUSC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12379764	chr21:47803548	PCNT	0.45	6.24	0.32	1.34e-9	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08219700	chr8:58056026	NA	0.64	8.26	0.41	3.49e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9815354	0.812	rs17214987	chr3:41810481	C/T	cg03022575	chr3:42003672	ULK4	-0.79	-8.58	-0.42	3.64e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.71	10.66	0.5	5.06e-23	Aortic root size;
LUSC	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.55	11.08	0.52	1.6e-24	Coronary artery disease;
LUSC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-7.59	-0.38	3.19e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg22532475	chr10:104410764	TRIM8	-0.32	-6.94	-0.36	2.03e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg24642439	chr20:33292090	TP53INP2	0.5	7.43	0.38	8.94e-13	Height;
LUSC	cis	rs35995292	0.534	rs2392604	chr7:38918012	C/T	cg19327137	chr7:38886074	VPS41	0.55	10.36	0.49	5.52e-22	Subjective well-being (multi-trait analysis);
LUSC	trans	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-8.47	-0.42	7.94e-16	Obesity-related traits;
LUSC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg03676636	chr4:99064102	C4orf37	0.37	7.91	0.4	3.7e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg22709100	chr7:91322751	NA	0.39	5.86	0.31	1.08e-8	Breast cancer;
LUSC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.8	-14.48	-0.62	3.24e-37	Cognitive function;
LUSC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg18402987	chr7:1209562	NA	0.73	7.84	0.39	5.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg25801113	chr15:45476975	SHF	0.35	7.02	0.36	1.23e-11	Uric acid levels;
LUSC	cis	rs2882667	0.964	rs11958050	chr5:138301828	A/G	cg04439458	chr5:138467593	SIL1	-0.39	-8.0	-0.4	2.05e-14	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg23422044	chr7:1970798	MAD1L1	-0.56	-6.17	-0.32	2.02e-9	Bipolar disorder;
LUSC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.73	11.98	0.55	9.08e-28	Coronary artery disease;
LUSC	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg21643547	chr1:205240462	TMCC2	-0.42	-7.65	-0.39	2.15e-13	Red blood cell count;
LUSC	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg04586622	chr2:25135609	ADCY3	0.4	8.27	0.41	3.29e-15	Body mass index;
LUSC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg05347473	chr6:146136440	FBXO30	-0.55	-9.5	-0.46	4.19e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg06784218	chr1:46089804	CCDC17	0.47	9.35	0.46	1.28e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-16.92	-0.68	7.95e-47	Gut microbiome composition (summer);
LUSC	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg14844989	chr11:31128820	NA	0.36	5.64	0.3	3.56e-8	Red blood cell count;
LUSC	cis	rs698833	0.501	rs35347977	chr2:44506921	C/T	cg04920474	chr2:44395004	PPM1B	0.55	9.05	0.44	1.23e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg16586182	chr3:47516702	SCAP	0.51	8.12	0.41	9.02e-15	Colorectal cancer;
LUSC	cis	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg14019146	chr3:50243930	SLC38A3	-0.44	-10.02	-0.48	7.72e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs7589342	0.791	rs4438504	chr2:106461035	A/C	cg14210321	chr2:106509881	NCK2	-0.52	-7.64	-0.39	2.35e-13	Addiction;
LUSC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-0.6	-9.44	-0.46	6.87e-19	Breast cancer;
LUSC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-5.84	-0.3	1.21e-8	Personality dimensions;
LUSC	cis	rs4561483	0.545	rs9927446	chr16:11957164	A/T	cg08843971	chr16:11963173	GSPT1	0.42	6.4	0.33	5.2e-10	Testicular germ cell tumor;
LUSC	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg08601574	chr20:25228251	PYGB	0.43	6.57	0.34	1.94e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4285028	0.747	rs9817818	chr3:121466826	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-12.86	-0.58	5.27e-31	Multiple sclerosis;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	0.95	19.87	0.74	1.49e-58	Menarche (age at onset);
LUSC	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	16.21	0.66	5.29e-44	Exhaled nitric oxide output;
LUSC	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg13206674	chr6:150067644	NUP43	0.44	6.71	0.34	8.28e-11	Testicular germ cell tumor;
LUSC	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02176678	chr2:219576539	TTLL4	0.64	11.63	0.54	1.77e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2224391	0.628	rs2753231	chr6:5248915	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.47	-6.5	-0.34	2.92e-10	Height;
LUSC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	13.52	0.59	1.58e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg21770322	chr7:97807741	LMTK2	0.4	7.01	0.36	1.31e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg09699651	chr6:150184138	LRP11	0.45	7.08	0.36	8.5e-12	Testicular germ cell tumor;
LUSC	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.37	0.49	5.09e-22	Bladder cancer;
LUSC	cis	rs4713118	0.824	rs13211701	chr6:27750079	T/C	cg20933634	chr6:27740509	NA	0.42	5.92	0.31	8.17e-9	Parkinson's disease;
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04141948	chr7:1023156	CYP2W1	0.29	5.87	0.31	1.05e-8	Longevity;Endometriosis;
LUSC	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg11789530	chr4:8429930	ACOX3	0.57	8.88	0.44	4.27e-17	Response to antineoplastic agents;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18516985	chr5:159846223	SLU7	0.44	6.06	0.31	3.72e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11645453	chr3:52864694	ITIH4	0.33	7.75	0.39	1.11e-13	Bipolar disorder;
LUSC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	14.07	0.61	1.23e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs7900823	0.529	rs10826438	chr10:28556616	C/T	cg06646548	chr10:77152949	NA	-0.44	-5.96	-0.31	6.52e-9	Lung cancer;
LUSC	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg24130564	chr14:104152367	KLC1	-0.51	-7.2	-0.37	4.01e-12	Body mass index;
LUSC	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg08917208	chr2:24149416	ATAD2B	0.99	10.36	0.49	5.38e-22	Lymphocyte percentage of white cells;
LUSC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg22535103	chr8:58192502	C8orf71	-0.69	-7.28	-0.37	2.35e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6714710	0.603	rs11680321	chr2:98379267	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	8.38	0.42	1.51e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs6693567	0.545	rs1260385	chr1:150316385	G/A	cg15654264	chr1:150340011	RPRD2	0.45	7.33	0.37	1.8e-12	Migraine;
LUSC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg08027265	chr7:2291960	NA	-0.38	-6.24	-0.32	1.33e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg05163923	chr11:71159392	DHCR7	0.78	11.49	0.53	5.51e-26	Vitamin D levels;
LUSC	cis	rs3018712	0.532	rs2510397	chr11:68419559	A/G	cg22747802	chr11:68417633	NA	-0.43	-5.81	-0.3	1.48e-8	Total body bone mineral density;
LUSC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg04025307	chr7:1156635	C7orf50	0.46	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9815354	0.812	rs73828283	chr3:41835099	T/C	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs73195822	0.614	rs56259130	chr12:111225650	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	7.14	0.36	5.98e-12	Itch intensity from mosquito bite;
LUSC	cis	rs12986413	0.619	rs1859954	chr19:2145481	G/T	cg09261902	chr19:2140048	AP3D1	-0.37	-7.05	-0.36	1.06e-11	Height;
LUSC	cis	rs2635047	0.811	rs10502880	chr18:44770746	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	6.01	0.31	4.85e-9	Educational attainment;
LUSC	cis	rs9346649	0.967	rs6920748	chr6:168490047	T/G	cg02770688	chr6:168491649	NA	-0.4	-7.65	-0.39	2.23e-13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs3812762	0.912	rs10769954	chr11:8783713	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.36	6.08	0.32	3.38e-9	Hypospadias;
LUSC	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg18721089	chr20:30220636	NA	-0.37	-6.48	-0.33	3.28e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs727505	1.000	rs66665074	chr7:124550526	C/T	cg23710748	chr7:124431027	NA	-0.42	-7.58	-0.38	3.43e-13	Lewy body disease;
LUSC	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg05973401	chr12:123451056	ABCB9	0.52	6.1	0.32	2.87e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg23093090	chr10:104574429	C10orf26	0.39	6.63	0.34	1.34e-10	Arsenic metabolism;
LUSC	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg25797454	chr6:150327115	RAET1K	0.34	7.8	0.39	8.08e-14	Alopecia areata;
LUSC	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg02466173	chr16:30829666	NA	-0.57	-11.52	-0.53	4.32e-26	Dementia with Lewy bodies;
LUSC	trans	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg06521331	chr12:34319734	NA	0.41	6.21	0.32	1.55e-9	Bladder cancer;
LUSC	cis	rs12042938	0.935	rs751229	chr1:231768539	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	6.9	0.35	2.64e-11	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg24879335	chr3:133465180	TF	0.46	8.02	0.4	1.86e-14	Iron status biomarkers (transferrin levels);
LUSC	cis	rs400736	0.602	rs10864330	chr1:8168564	C/T	cg25007680	chr1:8021821	PARK7	-0.44	-6.57	-0.34	1.96e-10	Response to antidepressants and depression;
LUSC	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg01620082	chr3:125678407	NA	-0.78	-7.29	-0.37	2.28e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg13390004	chr1:15929781	NA	0.41	6.91	0.35	2.52e-11	Systolic blood pressure;
LUSC	cis	rs1823874	0.581	rs12910401	chr15:100339897	T/C	cg16400843	chr15:100339927	C15orf51	0.4	7.38	0.37	1.3e-12	IgG glycosylation;
LUSC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.05	-22.08	-0.77	3.04e-67	Ulcerative colitis;
LUSC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	0.77	13.53	0.6	1.44e-33	Cognitive function;
LUSC	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.5	-0.46	4.09e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg04025307	chr7:1156635	C7orf50	0.4	6.35	0.33	7.06e-10	Longevity;Endometriosis;
LUSC	cis	rs2230307	0.536	rs11166409	chr1:100641411	T/C	cg24955406	chr1:100503596	HIAT1	-0.59	-6.52	-0.34	2.52e-10	Carotid intima media thickness;
LUSC	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg17120908	chr11:65337727	SSSCA1	-0.54	-9.54	-0.46	3.19e-19	Bone mineral density;
LUSC	cis	rs7804356	1.000	rs12333525	chr7:26847762	C/T	cg03456212	chr7:26904342	SKAP2	-0.56	-6.54	-0.34	2.38e-10	Type 1 diabetes;
LUSC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	9.11	0.45	7.49e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.6	9.67	0.47	1.14e-19	Aortic root size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12262069	chr3:5028410	NA	0.42	6.11	0.32	2.8e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.37	-0.37	1.36e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18876405	chr7:65276391	NA	0.55	8.73	0.43	1.2e-16	Aortic root size;
LUSC	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-7.59	-0.38	3.15e-13	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07570075	chr5:159343275	ADRA1B	-0.51	-6.41	-0.33	4.96e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg19774624	chr17:42201019	HDAC5	-0.82	-13.73	-0.6	2.43e-34	Total body bone mineral density;
LUSC	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.52	-7.1	-0.36	7.45e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.58	5.67	0.3	3.09e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2413583	0.591	rs12484030	chr22:39712936	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	6.54	0.34	2.37e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.27	0.59	1.45e-32	Chronic sinus infection;
LUSC	cis	rs17604090	0.938	rs73088374	chr7:29654819	C/A	cg19413766	chr7:29689036	LOC646762	-0.58	-6.58	-0.34	1.85e-10	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg07148914	chr20:33460835	GGT7	0.56	8.56	0.42	4.04e-16	Height;
LUSC	cis	rs4663969	0.541	rs11902131	chr2:234594269	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.31	-0.33	8.87e-10	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs9818941	0.824	rs13065628	chr3:157789277	A/G	cg08654915	chr3:157813417	NA	-0.29	-6.61	-0.34	1.49e-10	Height;
LUSC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.75e-10	Crohn's disease;
LUSC	trans	rs4729127	0.708	rs17166230	chr7:94017794	G/C	cg22713327	chr12:120703336	PXN	0.57	6.0	0.31	5.17e-9	Intelligence;
LUSC	cis	rs4423214	0.569	rs4944044	chr11:71120213	G/A	cg05163923	chr11:71159392	DHCR7	0.55	8.08	0.4	1.2e-14	Vitamin D levels;
LUSC	cis	rs4363385	0.818	rs10788852	chr1:153000491	C/G	cg25856811	chr1:152973957	SPRR3	-0.35	-5.68	-0.3	2.94e-8	Inflammatory skin disease;
LUSC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg12927641	chr6:109611667	NA	0.44	7.68	0.39	1.82e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs9392556	0.829	rs7757606	chr6:4119704	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.36	-6.22	-0.32	1.53e-9	Blood metabolite levels;
LUSC	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	0.8	13.2	0.59	2.71e-32	Blood protein levels;
LUSC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg02475777	chr4:1388615	CRIPAK	0.46	6.77	0.35	5.88e-11	Obesity-related traits;
LUSC	cis	rs7582720	0.832	rs114139737	chr2:203721733	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	8.17	0.41	6.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6489882	0.867	rs7972033	chr12:113363283	C/T	cg20102336	chr12:113376681	OAS3	-0.42	-5.92	-0.31	7.96e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.5	0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg20307385	chr11:47447363	PSMC3	0.45	6.52	0.34	2.68e-10	Subjective well-being;
LUSC	cis	rs10497399	0.730	rs73974114	chr2:174116812	C/A	cg22854985	chr2:174082101	ZAK	-0.51	-5.73	-0.3	2.2e-8	Adiponectin levels;
LUSC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg08847533	chr14:75593920	NEK9	-0.81	-14.58	-0.62	1.31e-37	Height;
LUSC	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg01966878	chr4:90757139	SNCA	-0.34	-5.94	-0.31	7.11e-9	Dementia with Lewy bodies;
LUSC	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-7.03	-0.36	1.16e-11	Coronary artery disease;
LUSC	cis	rs7705502	1.000	rs72812826	chr5:173362726	C/T	cg18693985	chr5:173351052	CPEB4	-0.37	-5.83	-0.3	1.3e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg06532163	chr17:45867833	NA	0.34	6.22	0.32	1.5e-9	IgG glycosylation;
LUSC	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg03859395	chr2:55845619	SMEK2	0.86	15.91	0.66	8.28e-43	Metabolic syndrome;
LUSC	cis	rs2230307	0.656	rs1395332	chr1:100503993	A/C	cg24955406	chr1:100503596	HIAT1	0.57	6.15	0.32	2.23e-9	Carotid intima media thickness;
LUSC	cis	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-6.98	-0.36	1.55e-11	Triglycerides;
LUSC	cis	rs10740039	0.810	rs4440977	chr10:62377921	C/G	cg18175470	chr10:62150864	ANK3	-0.45	-6.58	-0.34	1.87e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-9.35	-0.46	1.28e-18	Monocyte percentage of white cells;
LUSC	cis	rs11642862	1.000	rs11642862	chr16:30785824	A/G	cg02466173	chr16:30829666	NA	0.65	7.24	0.37	3.07e-12	Tonsillectomy;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18604876	chr3:5164258	ARL8B	0.41	6.0	0.31	5.16e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11756438	0.572	rs2638551	chr6:118998756	T/C	cg21191810	chr6:118973309	C6orf204	0.35	5.91	0.31	8.34e-9	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4664308	1.000	rs17831161	chr2:160909360	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-11.33	-0.53	2.16e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs4654899	0.931	rs7543140	chr1:21180250	G/A	cg01072550	chr1:21505969	NA	0.47	7.06	0.36	9.68e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	6.35	0.33	6.86e-10	Schizophrenia;
LUSC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg18350739	chr11:68623251	NA	-0.38	-6.67	-0.34	1.04e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.45	-7.12	-0.36	6.52e-12	Alzheimer's disease (late onset);
LUSC	cis	rs7178572	0.568	rs7167794	chr15:77635875	T/C	cg22256960	chr15:77711686	NA	-0.5	-8.04	-0.4	1.57e-14	Type 2 diabetes;
LUSC	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.84	13.08	0.58	7.2e-32	Prostate cancer;
LUSC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.5	0.42	6.19e-16	Prudent dietary pattern;
LUSC	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.8	12.77	0.57	1.06e-30	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs4363385	0.667	rs399550	chr1:153049917	T/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.42e-13	Inflammatory skin disease;
LUSC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg01765077	chr12:122356316	WDR66	0.54	7.58	0.38	3.5e-13	Mean corpuscular volume;
LUSC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.8	12.51	0.56	1.05e-29	Menopause (age at onset);
LUSC	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg23093090	chr10:104574429	C10orf26	-0.4	-6.86	-0.35	3.45e-11	Arsenic metabolism;
LUSC	cis	rs939574	1.000	rs2293078	chr2:220100683	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.09	8.72	0.43	1.31e-16	Platelet distribution width;
LUSC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.8	15.45	0.65	5.01e-41	Dental caries;
LUSC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.83	13.21	0.59	2.41e-32	Cognitive test performance;
LUSC	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg05791153	chr7:19748676	TWISTNB	-0.75	-8.29	-0.41	2.73e-15	Thyroid stimulating hormone;
LUSC	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.14	-14.21	-0.61	3.45e-36	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg05347473	chr6:146136440	FBXO30	0.58	10.14	0.49	3.11e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg08027265	chr7:2291960	NA	-0.64	-11.76	-0.54	5.74e-27	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg22437258	chr11:111473054	SIK2	0.51	6.96	0.36	1.86e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg22508957	chr16:3507546	NAT15	0.44	6.26	0.32	1.18e-9	Body mass index (adult);
LUSC	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs151234	0.565	rs9924471	chr16:28591530	G/A	cg01378222	chr16:28622494	SULT1A1	-0.56	-8.28	-0.41	3.07e-15	Platelet distribution width;
LUSC	cis	rs189798	0.807	rs330909	chr8:8995387	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	6.15	0.32	2.18e-9	Myopia (pathological);
LUSC	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.38e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg04827223	chr11:72435913	ARAP1	-0.66	-8.43	-0.42	1.09e-15	Type 2 diabetes;
LUSC	cis	rs2742417	1.000	rs2742452	chr3:45765708	C/T	cg18779283	chr3:45636154	LIMD1	-0.33	-5.71	-0.3	2.47e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.36	-0.37	1.48e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.44	6.17	0.32	1.96e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18110333	chr6:292329	DUSP22	-0.72	-11.92	-0.55	1.5e-27	Menopause (age at onset);
LUSC	cis	rs10203711	0.933	rs2334025	chr2:239564114	A/G	cg14580085	chr2:239553406	NA	-0.39	-6.62	-0.34	1.42e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2235649	0.753	rs4316755	chr16:1849916	T/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.44	-6.04	-0.31	4.12e-9	Blood metabolite levels;
LUSC	trans	rs9510787	1.000	rs4411364	chr13:24191374	A/C	cg20646490	chr19:45971291	FOSB	0.51	6.06	0.31	3.69e-9	Nasopharyngeal carcinoma;
LUSC	cis	rs7809950	0.599	rs2237658	chr7:106837866	T/G	cg23024343	chr7:107201750	COG5	-0.49	-7.14	-0.36	5.94e-12	Coronary artery disease;
LUSC	trans	rs4650994	0.525	rs11806608	chr1:178511375	T/C	cg05059571	chr16:84539110	KIAA1609	-0.46	-8.67	-0.43	1.87e-16	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs9473147	0.543	rs9349407	chr6:47453378	C/G	cg12968598	chr6:47444699	CD2AP	0.52	7.96	0.4	2.63e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7572644	0.766	rs34483784	chr2:28129391	G/A	cg27432699	chr2:27873401	GPN1	0.52	6.43	0.33	4.31e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6714710	0.603	rs13020776	chr2:98402753	T/A	cg26665480	chr2:98280029	ACTR1B	0.58	8.41	0.42	1.17e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05039488	chr6:79577232	IRAK1BP1	0.44	6.59	0.34	1.74e-10	Endometrial cancer;
LUSC	cis	rs722599	0.683	rs11848876	chr14:75224626	C/G	cg08847533	chr14:75593920	NEK9	0.47	6.56	0.34	2e-10	IgG glycosylation;
LUSC	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg08213375	chr14:104286397	PPP1R13B	0.53	10.28	0.49	1.01e-21	Schizophrenia;
LUSC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg23625390	chr15:77176239	SCAPER	-0.51	-7.75	-0.39	1.11e-13	Blood metabolite levels;
LUSC	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg12292205	chr6:26970375	C6orf41	0.6	7.71	0.39	1.48e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg17173187	chr15:85201210	NMB	0.37	6.7	0.34	8.96e-11	Schizophrenia;
LUSC	cis	rs1865721	1.000	rs8094181	chr18:73193976	T/A	cg26385618	chr18:73139727	C18orf62	-0.48	-8.1	-0.41	1.04e-14	Intelligence;
LUSC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.87	-0.31	1.04e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs737008	0.959	rs11865598	chr16:11403432	T/C	cg00044050	chr16:11439710	C16orf75	0.58	8.83	0.44	5.88e-17	Obesity-related traits;
LUSC	cis	rs174479	0.647	rs174454	chr11:61650747	A/G	cg01500311	chr11:61656094	FADS3	-0.37	-6.43	-0.33	4.29e-10	Sphingolipid levels;
LUSC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg06740227	chr12:86229804	RASSF9	0.4	6.38	0.33	5.89e-10	Major depressive disorder;
LUSC	cis	rs2742234	0.541	rs1879310	chr10:43734775	A/G	cg02780029	chr10:43622663	RET	0.34	5.76	0.3	1.88e-8	Hirschsprung disease;
LUSC	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg01256987	chr12:42539512	GXYLT1	0.34	6.19	0.32	1.77e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6599077	0.724	rs13326962	chr3:40087181	C/T	cg13683864	chr3:40499215	RPL14	-0.47	-6.61	-0.34	1.48e-10	Sleep-related phenotypes;
LUSC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg11645453	chr3:52864694	ITIH4	-0.33	-7.39	-0.37	1.17e-12	Bipolar disorder;
LUSC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.63	9.03	0.44	1.39e-17	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.71	0.39	1.44e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg25173405	chr17:45401733	C17orf57	-0.46	-6.7	-0.34	8.87e-11	Glaucoma (primary open-angle);
LUSC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg22920501	chr2:26401640	FAM59B	0.75	10.05	0.48	6.04e-21	Gut microbiome composition (summer);
LUSC	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.4	-5.67	-0.3	3.09e-8	Bipolar disorder;
LUSC	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg24558204	chr6:135376177	HBS1L	0.58	8.86	0.44	4.81e-17	Red blood cell count;
LUSC	cis	rs4654899	0.802	rs7517642	chr1:21252696	T/C	cg01072550	chr1:21505969	NA	-0.48	-6.99	-0.36	1.48e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02034447	chr16:89574710	SPG7	0.46	7.03	0.36	1.19e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs1034435	0.755	rs6007869	chr22:48894213	A/G	cg05992904	chr22:48892994	FAM19A5	-0.41	-8.18	-0.41	6.13e-15	Late-onset Alzheimer's disease;
LUSC	cis	rs977987	0.751	rs56004344	chr16:75474189	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.38	0.46	1.03e-18	Dupuytren's disease;
LUSC	cis	rs28489187	0.617	rs11161606	chr1:85853902	T/C	cg02862864	chr1:85742044	BCL10	-0.42	-5.79	-0.3	1.62e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LUSC	trans	rs979233	0.502	rs276254	chr5:42063808	T/C	cg07010552	chr17:7358735	CHRNB1	-0.41	-6.02	-0.31	4.72e-9	Systemic lupus erythematosus;
LUSC	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg07423050	chr13:99094983	FARP1	-0.55	-10.68	-0.5	4.25e-23	Longevity;
LUSC	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.83	-0.44	6.04e-17	Total cholesterol levels;
LUSC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg27572855	chr1:25598939	RHD	-0.46	-8.38	-0.42	1.49e-15	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs11971779	0.680	rs6954547	chr7:139054734	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg11887960	chr12:57824829	NA	0.55	7.21	0.37	3.7e-12	Lung disease severity in cystic fibrosis;
LUSC	trans	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg06521331	chr12:34319734	NA	-0.39	-5.95	-0.31	6.95e-9	Morning vs. evening chronotype;
LUSC	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.34	-0.33	7.43e-10	Type 2 diabetes;
LUSC	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.21	0.49	1.77e-21	Lymphocyte counts;
LUSC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.78	0.57	9.99e-31	Prudent dietary pattern;
LUSC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.35	-0.42	1.86e-15	Mean platelet volume;
LUSC	cis	rs12911832	1.000	rs12911961	chr15:58985867	C/T	cg05156742	chr15:59063176	FAM63B	0.51	7.28	0.37	2.45e-12	Schizophrenia;
LUSC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg19912559	chr1:40204330	PPIE	0.5	7.52	0.38	5.17e-13	Blood protein levels;
LUSC	cis	rs12476592	0.602	rs174485	chr2:63857402	G/A	cg10828910	chr2:63850056	LOC388955	0.48	5.69	0.3	2.72e-8	Childhood ear infection;
LUSC	cis	rs12586317	0.531	rs57856432	chr14:35719708	G/T	cg07166546	chr14:35805898	NA	-0.27	-6.22	-0.32	1.45e-9	Psoriasis;
LUSC	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg12310025	chr6:25882481	NA	0.39	6.67	0.34	1.09e-10	Blood metabolite levels;
LUSC	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg25214090	chr10:38739885	LOC399744	0.51	7.82	0.39	7.21e-14	Corneal astigmatism;
LUSC	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-8.18	-0.41	6.1e-15	Axial length;
LUSC	trans	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.51	0.46	3.79e-19	Mean corpuscular volume;
LUSC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18876405	chr7:65276391	NA	-0.53	-8.4	-0.42	1.28e-15	Aortic root size;
LUSC	cis	rs2219968	0.828	rs60036550	chr8:78911936	G/A	cg00738934	chr8:78996279	NA	-0.41	-7.37	-0.37	1.35e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg03146154	chr1:46216737	IPP	0.56	8.37	0.42	1.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.91	-0.48	1.84e-20	Morning vs. evening chronotype;
LUSC	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg18806716	chr10:30721971	MAP3K8	0.72	11.56	0.53	3.13e-26	Inflammatory bowel disease;
LUSC	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg05925327	chr15:68127851	NA	-0.37	-5.76	-0.3	1.92e-8	Obesity;
LUSC	trans	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.7	-0.43	1.5e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg14092988	chr3:52407081	DNAH1	0.31	6.18	0.32	1.82e-9	Bipolar disorder;
LUSC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.11e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg14552801	chr7:65878734	NA	0.39	6.08	0.32	3.37e-9	Aortic root size;
LUSC	cis	rs3087591	1.000	rs9902427	chr17:29625430	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.56	-8.12	-0.41	8.94e-15	Hip circumference;
LUSC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	1.14	17.51	0.69	3.64e-49	Corneal structure;
LUSC	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg05855489	chr10:104503620	C10orf26	0.54	6.39	0.33	5.67e-10	Arsenic metabolism;
LUSC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg02475777	chr4:1388615	CRIPAK	0.45	6.19	0.32	1.74e-9	Obesity-related traits;
LUSC	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.47	7.67	0.39	1.9e-13	Alcohol dependence;
LUSC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.53	0.53	4.18e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg13010199	chr12:38710504	ALG10B	-0.47	-7.25	-0.37	2.94e-12	Morning vs. evening chronotype;
LUSC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.92	12.19	0.55	1.56e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg17330251	chr7:94953956	PON1	-0.37	-5.99	-0.31	5.57e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13980399	chr14:61447827	SLC38A6;TRMT5	-0.43	-6.45	-0.33	4.02e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3790645	1.000	rs3790645	chr1:26884864	G/A	cg17456097	chr1:26900765	RPS6KA1	0.43	6.24	0.32	1.32e-9	Glucose homeostasis traits;
LUSC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.78	0.35	5.32e-11	Tonsillectomy;
LUSC	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.55	8.35	0.42	1.78e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6674970	0.777	rs11204782	chr1:151118035	C/G	cg11822372	chr1:151115635	SEMA6C	-0.84	-13.58	-0.6	9.82e-34	Childhood ear infection;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg12419862	chr22:24373484	LOC391322	-0.87	-14.23	-0.61	2.98e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.9	20.74	0.75	5.35e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-8.07	-0.4	1.32e-14	Height;
LUSC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.25	0.32	1.28e-9	Menopause (age at onset);
LUSC	cis	rs36093844	0.904	rs4631905	chr11:85589418	T/C	cg25872744	chr11:85566296	CCDC83	-0.42	-6.84	-0.35	3.7e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	trans	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg09781936	chr22:19749961	TBX1	-0.34	-6.02	-0.31	4.72e-9	Inflammatory bowel disease;
LUSC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	12.99	0.58	1.65e-31	Personality dimensions;
LUSC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.32	0.45	1.64e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9398803	0.865	rs9398805	chr6:126726295	C/T	cg19875578	chr6:126661172	C6orf173	0.42	6.27	0.32	1.09e-9	Male-pattern baldness;
LUSC	cis	rs4356932	0.967	rs6532159	chr4:76978124	A/G	cg00809888	chr4:76862425	NAAA	0.34	5.69	0.3	2.75e-8	Blood protein levels;
LUSC	cis	rs3764563	0.735	rs62106282	chr19:15727124	T/C	cg20725493	chr19:15740067	CYP4F8	-0.66	-6.83	-0.35	3.91e-11	Inflammatory biomarkers;
LUSC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg23985595	chr17:80112537	CCDC57	0.31	5.88	0.31	9.82e-9	Life satisfaction;
LUSC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg01802117	chr1:53393560	SCP2	0.43	6.89	0.35	2.77e-11	Monocyte count;
LUSC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg16680214	chr1:154839983	KCNN3	-0.44	-7.75	-0.39	1.11e-13	Prostate cancer;
LUSC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.5	-7.59	-0.38	3.24e-13	Personality dimensions;
LUSC	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg08999081	chr20:33150536	PIGU	-0.39	-7.43	-0.38	9.12e-13	Glomerular filtration rate (creatinine);
LUSC	trans	rs12043259	0.685	rs12407417	chr1:204812698	C/T	cg05134015	chr14:36973365	SFTA3	-0.49	-6.01	-0.31	4.77e-9	Addiction;
LUSC	cis	rs9815354	0.812	rs57162396	chr3:41896031	G/A	cg03022575	chr3:42003672	ULK4	0.84	8.74	0.43	1.14e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4974559	0.739	rs28444605	chr4:1290281	C/A	cg02980000	chr4:1222292	CTBP1	1.02	9.35	0.46	1.28e-18	Systolic blood pressure;
LUSC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.64	8.74	0.43	1.15e-16	Multiple sclerosis;
LUSC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg17971929	chr21:40555470	PSMG1	0.79	13.58	0.6	9.54e-34	Cognitive function;
LUSC	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg19116668	chr7:99932089	PMS2L1	0.34	5.76	0.3	1.94e-8	Coronary artery disease;
LUSC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	16.4	0.67	9.02e-45	Platelet count;
LUSC	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.75	0.73	4.73e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03060546	chr3:49711283	APEH	0.67	8.03	0.4	1.64e-14	Menarche (age at onset);
LUSC	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04004882	chr2:215674386	BARD1	-0.6	-9.01	-0.44	1.64e-17	Neuroblastoma (high-risk);
LUSC	cis	rs1506636	1.000	rs684548	chr7:123397102	A/T	cg03229431	chr7:123269106	ASB15	0.65	10.78	0.51	1.82e-23	Plateletcrit;Platelet count;
LUSC	cis	rs1568889	0.838	rs7933991	chr11:28059761	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.92	0.58	3e-31	Bipolar disorder;
LUSC	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg17052675	chr2:3827356	NA	-0.58	-11.38	-0.53	1.42e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg12560992	chr17:57184187	TRIM37	-0.84	-15.34	-0.64	1.38e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-6.81	-0.35	4.6e-11	Alzheimer's disease (late onset);
LUSC	cis	rs11997175	0.603	rs7386384	chr8:33782471	C/T	ch.8.33884649F	chr8:33765107	NA	0.41	6.26	0.32	1.21e-9	Body mass index;
LUSC	trans	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg21659725	chr3:3221576	CRBN	0.69	8.15	0.41	7.46e-15	Menarche (age at onset);
LUSC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg15448220	chr1:150897856	SETDB1	0.39	5.77	0.3	1.79e-8	Tonsillectomy;
LUSC	cis	rs9473147	0.516	rs9367284	chr6:47516369	A/G	cg12968598	chr6:47444699	CD2AP	0.52	7.94	0.4	3.18e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg18302933	chr2:88491318	NA	-0.38	-7.45	-0.38	8.02e-13	Response to metformin (IC50);
LUSC	trans	rs9944715	1.000	rs4890320	chr18:43814124	T/C	cg01718231	chr17:29326311	RNF135	-0.54	-7.71	-0.39	1.45e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg02023728	chr11:77925099	USP35	0.51	7.15	0.36	5.67e-12	Testicular germ cell tumor;
LUSC	cis	rs6545883	0.965	rs12713439	chr2:61752154	G/A	cg15711740	chr2:61764176	XPO1	-0.5	-7.94	-0.4	3.05e-14	Tuberculosis;
LUSC	cis	rs9467773	0.550	rs4712987	chr6:26399615	A/C	cg05738196	chr6:26577821	NA	-0.5	-7.13	-0.36	6.37e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg27494647	chr7:150038898	RARRES2	0.43	6.47	0.33	3.51e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg22823121	chr1:150693482	HORMAD1	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg13010199	chr12:38710504	ALG10B	0.6	9.37	0.46	1.09e-18	Bladder cancer;
LUSC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg13628971	chr7:2884303	GNA12	0.47	6.5	0.34	2.89e-10	Height;
LUSC	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg15395560	chr15:45543142	SLC28A2	0.34	5.72	0.3	2.38e-8	Uric acid levels;
LUSC	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg06002616	chr8:101225028	SPAG1	-0.41	-6.85	-0.35	3.54e-11	Atrioventricular conduction;
LUSC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10802521	chr3:52805072	NEK4	-0.55	-9.0	-0.44	1.75e-17	Electroencephalogram traits;
LUSC	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg27661571	chr11:113659931	NA	-0.62	-7.41	-0.38	1.05e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg07828340	chr4:882639	GAK	1.09	11.48	0.53	5.93e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.86	-0.31	1.09e-8	Height;
LUSC	trans	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg25214090	chr10:38739885	LOC399744	0.53	7.72	0.39	1.36e-13	Corneal astigmatism;
LUSC	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg05182265	chr7:156933206	UBE3C	0.58	9.39	0.46	9.77e-19	Body mass index;
LUSC	trans	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg18187862	chr3:45730750	SACM1L	0.55	7.02	0.36	1.27e-11	Primary sclerosing cholangitis;
LUSC	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg06026331	chr20:60912101	LAMA5	-0.43	-5.77	-0.3	1.78e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs724744	0.772	rs1737236	chr6:22350806	C/G	cg13807341	chr11:118445984	ARCN1	-0.36	-6.18	-0.32	1.89e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.46e-35	Breast cancer;
LUSC	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.97	-0.61	2.98e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg16405210	chr4:1374714	KIAA1530	0.55	8.36	0.42	1.72e-15	Obesity-related traits;
LUSC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg24812749	chr6:127587940	RNF146	0.7	9.92	0.48	1.75e-20	Breast cancer;
LUSC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	0.83	14.07	0.61	1.24e-35	Tonsillectomy;
LUSC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.35	5.99	0.31	5.45e-9	Obesity-related traits;
LUSC	cis	rs7605827	0.897	rs11693457	chr2:15612683	A/C	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.37e-17	Educational attainment (years of education);
LUSC	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05901451	chr6:126070800	HEY2	-0.77	-13.31	-0.59	1.02e-32	Brugada syndrome;
LUSC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs4478137	0.501	rs28477602	chr4:164230477	C/T	cg06758707	chr4:164254230	NPY1R	-0.5	-6.67	-0.34	1.08e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs2742234	0.541	rs10899778	chr10:43718509	G/C	cg02780029	chr10:43622663	RET	0.35	5.82	0.3	1.41e-8	Hirschsprung disease;
LUSC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg12927641	chr6:109611667	NA	-0.37	-6.35	-0.33	6.85e-10	Reticulocyte fraction of red cells;
LUSC	trans	rs28647808	0.786	rs4962136	chr9:136256794	A/G	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg04672769	chr5:140070921	HARS;HARS2	0.53	6.22	0.32	1.46e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.43	6.57	0.34	1.92e-10	Dupuytren's disease;
LUSC	cis	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-5.7	-0.3	2.69e-8	Neuroticism;
LUSC	cis	rs1113500	0.933	rs10785833	chr1:108639082	A/G	cg06207961	chr1:108661230	NA	0.41	7.61	0.38	2.76e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11764359	chr7:65958608	NA	0.52	6.98	0.36	1.61e-11	Aortic root size;
LUSC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.87	0.35	3.2e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24739457	chr1:205821442	NA	0.36	6.2	0.32	1.63e-9	Menarche (age at onset);
LUSC	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg27490568	chr2:178487706	NA	0.45	6.32	0.33	8.19e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg18681998	chr4:17616180	MED28	0.84	15.64	0.65	9.43e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg19539972	chr4:7069911	GRPEL1	0.69	8.68	0.43	1.76e-16	Monocyte percentage of white cells;
LUSC	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg02527881	chr3:46936655	PTH1R	0.4	6.96	0.36	1.78e-11	Colorectal cancer;
LUSC	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	0.57	8.66	0.43	2.03e-16	Breast cancer;
LUSC	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.72	10.24	0.49	1.4e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg23752985	chr2:85803571	VAMP8	0.32	6.7	0.34	9.08e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	7.31	0.37	2.02e-12	Myopia (pathological);
LUSC	cis	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs2109514	0.967	rs55883210	chr7:116160524	G/A	cg12739419	chr7:116140593	CAV2	-0.28	-6.24	-0.32	1.31e-9	Prevalent atrial fibrillation;
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	8.48	0.42	7.26e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.86	0.44	4.97e-17	Motion sickness;
LUSC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg09877947	chr5:131593287	PDLIM4	0.59	10.0	0.48	8.91e-21	Acylcarnitine levels;
LUSC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg19622623	chr12:86230825	RASSF9	-0.43	-6.07	-0.32	3.43e-9	Major depressive disorder;
LUSC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.51	0.59	1.77e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg09904177	chr6:26538194	HMGN4	-0.75	-6.61	-0.34	1.51e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.46	0.33	3.67e-10	Corneal astigmatism;
LUSC	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg15556689	chr8:8085844	FLJ10661	0.7	11.15	0.52	9.54e-25	Mood instability;
LUSC	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg00933542	chr6:150070202	PCMT1	0.28	5.69	0.3	2.72e-8	Lung cancer;
LUSC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg00310523	chr12:86230176	RASSF9	0.52	9.82	0.47	3.74e-20	Major depressive disorder;
LUSC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg19418458	chr7:158789849	NA	-0.5	-8.14	-0.41	8.12e-15	Facial morphology (factor 20);
LUSC	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg23093090	chr10:104574429	C10orf26	-0.47	-5.76	-0.3	1.93e-8	Arsenic metabolism;
LUSC	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg27068330	chr11:65405492	SIPA1	-0.77	-11.03	-0.52	2.43e-24	Acne (severe);
LUSC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg13010199	chr12:38710504	ALG10B	0.67	10.34	0.49	6.19e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.03	-0.31	4.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg02951883	chr7:2050386	MAD1L1	0.45	7.75	0.39	1.11e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg26513180	chr16:89883248	FANCA	0.79	6.37	0.33	6.26e-10	Skin colour saturation;
LUSC	cis	rs859767	0.741	rs6759065	chr2:135389197	A/G	cg12500956	chr2:135428796	TMEM163	-0.28	-6.37	-0.33	6.39e-10	Neuroticism;
LUSC	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg18854424	chr1:2615690	NA	0.51	10.34	0.49	6.36e-22	Ulcerative colitis;
LUSC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	6.35	0.33	7.14e-10	Electroencephalogram traits;
LUSC	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.81	-0.35	4.48e-11	Monocyte percentage of white cells;
LUSC	cis	rs28647808	0.881	rs7029256	chr9:136263655	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08677398	chr8:58056175	NA	0.52	6.07	0.32	3.47e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-7.2	-0.37	3.94e-12	Asthma;
LUSC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.64	-9.04	-0.44	1.3e-17	Schizophrenia;
LUSC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg02569458	chr12:86230093	RASSF9	-0.48	-7.95	-0.4	2.87e-14	Major depressive disorder;
LUSC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg02082929	chr2:109068933	GCC2	0.41	8.68	0.43	1.82e-16	Mean platelet volume;
LUSC	cis	rs72772090	1.000	rs72772092	chr5:96046912	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-6.91	-0.35	2.5e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg02527881	chr3:46936655	PTH1R	0.39	6.85	0.35	3.57e-11	Colorectal cancer;
LUSC	cis	rs2652834	0.904	rs2729827	chr15:63360564	C/T	cg05507819	chr15:63340323	TPM1	0.67	8.89	0.44	3.9e-17	HDL cholesterol;
LUSC	trans	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg14791747	chr16:20752902	THUMPD1	-0.4	-6.16	-0.32	2.09e-9	Dental caries;
LUSC	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg19773385	chr1:10388646	KIF1B	-0.57	-9.86	-0.47	2.77e-20	Hepatocellular carcinoma;
LUSC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.83	-0.35	4.05e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg09509183	chr1:209979624	IRF6	0.44	5.88	0.31	1e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg22920501	chr2:26401640	FAM59B	0.84	12.37	0.56	3.46e-29	Gut microbiome composition (summer);
LUSC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03264133	chr6:25882463	NA	-0.5	-9.15	-0.45	5.74e-18	Blood metabolite levels;
LUSC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg18758796	chr5:131593413	PDLIM4	0.4	7.06	0.36	9.82e-12	Blood metabolite levels;
LUSC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06481639	chr22:41940642	POLR3H	-0.5	-5.71	-0.3	2.56e-8	Vitiligo;
LUSC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05787193	chr1:84543369	PRKACB	0.41	5.98	0.31	5.87e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs3857536	0.776	rs6941904	chr6:66931042	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.44e-9	Blood trace element (Cu levels);
LUSC	cis	rs2932538	0.922	rs12136781	chr1:113090655	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	10.11	0.48	3.74e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	trans	rs10432489	0.708	rs12328545	chr2:181771545	T/A	cg07312954	chr1:153914453	DENND4B	-0.83	-6.07	-0.32	3.54e-9	QT interval;
LUSC	cis	rs2040771	0.804	rs1340958	chr22:19253332	A/G	cg02655711	chr22:19163373	SLC25A1	-0.48	-8.58	-0.42	3.64e-16	Metabolite levels (small molecules and protein measures);
LUSC	trans	rs72674100	1.000	rs28368230	chr4:97970611	G/A	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01295842	chr19:16683254	SLC35E1	-0.39	-5.96	-0.31	6.44e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-0.92	-17.33	-0.69	1.88e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg20406979	chr6:167373233	NA	0.26	6.11	0.32	2.77e-9	Crohn's disease;
LUSC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg06454157	chr6:167490870	NA	-0.25	-6.11	-0.32	2.75e-9	Crohn's disease;
LUSC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg00814883	chr7:100076585	TSC22D4	-0.76	-9.74	-0.47	6.61e-20	Platelet count;
LUSC	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg15896084	chr13:114927664	NA	0.39	7.02	0.36	1.28e-11	Schizophrenia;
LUSC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.37	-0.37	1.34e-12	Electroencephalogram traits;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg09033563	chr22:24373618	LOC391322	-0.48	-6.79	-0.35	5.24e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg26893861	chr17:41843967	DUSP3	1.11	23.99	0.8	1.25e-74	Triglycerides;
LUSC	cis	rs644148	0.836	rs2571111	chr19:45000581	C/A	cg15540054	chr19:45004280	ZNF180	-0.64	-9.41	-0.46	8.26e-19	Personality dimensions;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg16743811	chr6:3752421	C6orf145	0.39	6.13	0.32	2.44e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	13.04	0.58	1.03e-31	Platelet count;
LUSC	cis	rs7264396	0.836	rs6058275	chr20:34186331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-8.05	-0.4	1.48e-14	Total cholesterol levels;
LUSC	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg25828445	chr12:7781288	NA	0.61	6.46	0.33	3.65e-10	HDL cholesterol levels;
LUSC	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	10.69	0.51	3.8e-23	Bone mineral density;
LUSC	cis	rs524281	0.692	rs10791845	chr11:65834340	C/G	cg16950941	chr11:66035639	RAB1B	0.47	5.64	0.3	3.55e-8	Electroencephalogram traits;
LUSC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.73	-10.49	-0.5	1.86e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.61	0.5	7.28e-23	Colorectal cancer;
LUSC	cis	rs354225	0.554	rs4374410	chr2:54819088	G/T	cg01766943	chr2:54829624	SPTBN1	0.48	7.78	0.39	9.33e-14	Schizophrenia;
LUSC	cis	rs7903847	0.642	rs7078004	chr10:99140511	A/G	cg20016023	chr10:99160130	RRP12	-0.33	-8.09	-0.4	1.12e-14	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg25214090	chr10:38739885	LOC399744	0.54	8.06	0.4	1.36e-14	Corneal astigmatism;
LUSC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg25036284	chr2:26402008	FAM59B	0.77	11.38	0.53	1.46e-25	Gut microbiome composition (summer);
LUSC	cis	rs7246657	0.653	rs4805207	chr19:37673733	G/A	cg23950597	chr19:37808831	NA	-0.58	-5.88	-0.31	1.01e-8	Coronary artery calcification;
LUSC	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg01528321	chr10:82214614	TSPAN14	0.84	12.86	0.58	5.03e-31	Post bronchodilator FEV1;
LUSC	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.28	-0.32	1.06e-9	Retinal vascular caliber;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21906728	chr3:138634677	NA	-0.46	-6.14	-0.32	2.3e-9	Hepatitis;
LUSC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg02807482	chr3:125708958	NA	-0.52	-6.4	-0.33	5.2400000000000005e-10	Blood pressure (smoking interaction);
LUSC	cis	rs9650315	0.866	rs13272994	chr8:57183788	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.88	0.35	3.01e-11	Height;
LUSC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg16447950	chr5:562315	NA	-0.57	-6.95	-0.36	1.97e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg12641515	chr19:46296257	DMWD	0.5	7.42	0.38	9.68e-13	Coronary artery disease;
LUSC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.37	-6.4	-0.33	5.39e-10	High light scatter reticulocyte count;
LUSC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg18350739	chr11:68623251	NA	-0.39	-6.78	-0.35	5.47e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.63	-10.68	-0.5	4.31e-23	Mean corpuscular volume;
LUSC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg05738196	chr6:26577821	NA	0.8	14.86	0.63	1.08e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs10186029	0.582	rs2371795	chr2:213994789	C/G	cg08319019	chr2:214017104	IKZF2	0.49	7.48	0.38	6.49e-13	Systemic sclerosis;
LUSC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.4	-0.33	5.3e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7944584	0.502	rs10769256	chr11:47378396	C/T	cg20307385	chr11:47447363	PSMC3	0.89	15.42	0.64	6.82e-41	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.8	12.36	0.56	3.86e-29	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg22625903	chr11:62313283	AHNAK	0.44	5.95	0.31	6.59e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4792901	0.959	rs3826413	chr17:41633645	C/G	cg22562494	chr17:41607896	ETV4	0.28	5.66	0.3	3.22e-8	Dupuytren's disease;
LUSC	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg12091567	chr17:66097778	LOC651250	-0.74	-9.32	-0.45	1.62e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06022373	chr22:39101656	GTPBP1	0.84	13.88	0.6	6.44e-35	Menopause (age at onset);
LUSC	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg04989706	chr14:50066350	PPIL5	-0.46	-6.21	-0.32	1.57e-9	Carotid intima media thickness;
LUSC	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg05163923	chr11:71159392	DHCR7	0.75	11.35	0.53	1.82e-25	Vitamin D levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12107626	chr17:39992626	KLHL10;NT5C3L	0.47	6.58	0.34	1.78e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.12	-0.32	2.56e-9	Retinal vascular caliber;
LUSC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03352830	chr11:487213	PTDSS2	0.73	8.74	0.43	1.18e-16	Body mass index;
LUSC	cis	rs6690583	0.623	rs1371143	chr1:85455532	C/T	cg22153463	chr1:85462885	MCOLN2	0.62	6.2	0.32	1.68e-9	Serum sulfate level;
LUSC	cis	rs501916	0.727	rs12439630	chr15:48035191	C/T	cg16110827	chr15:48056943	SEMA6D	-0.43	-6.79	-0.35	5.18e-11	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg10382835	chr6:42185730	MRPS10	0.7	7.17	0.37	4.92e-12	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg05347473	chr6:146136440	FBXO30	0.54	9.33	0.45	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg06784218	chr1:46089804	CCDC17	-0.4	-7.19	-0.37	4.22e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg00310523	chr12:86230176	RASSF9	0.39	6.95	0.36	1.87e-11	Major depressive disorder;
LUSC	cis	rs2991971	1.000	rs2991970	chr1:46011005	C/T	cg15605315	chr1:45957053	TESK2	0.49	7.8	0.39	7.94e-14	High light scatter reticulocyte count;
LUSC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg08917208	chr2:24149416	ATAD2B	0.84	9.78	0.47	4.84e-20	Lymphocyte counts;
LUSC	cis	rs3818285	1.000	rs3740138	chr10:111630931	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.62	-0.38	2.58e-13	Superior crus of antihelix expression;
LUSC	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-6.13	-0.32	2.49e-9	Fear of minor pain;
LUSC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg23788917	chr6:8435910	SLC35B3	0.51	7.48	0.38	6.83e-13	Motion sickness;
LUSC	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.46	7.36	0.37	1.47e-12	Blood metabolite levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02864875	chr20:36662390	KIAA0406;RPRD1B	-0.48	-6.24	-0.32	1.32e-9	Hepatitis;
LUSC	cis	rs981844	0.796	rs11099904	chr4:154681861	A/G	cg14289246	chr4:154710475	SFRP2	0.52	7.14	0.36	5.7e-12	Response to statins (LDL cholesterol change);
LUSC	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg26647111	chr11:31128758	NA	-0.42	-6.12	-0.32	2.69e-9	Red blood cell count;
LUSC	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg23241863	chr10:102295624	HIF1AN	0.48	5.91	0.31	8.26e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs870825	0.790	rs12513128	chr4:185576729	G/C	cg04058563	chr4:185651563	MLF1IP	0.83	11.33	0.53	2.12e-25	Blood protein levels;
LUSC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.85	0.3	1.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg18190219	chr22:46762943	CELSR1	0.42	5.7	0.3	2.63e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.65	-0.47	1.31e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.32	-0.59	9.43e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.47	-8.19	-0.41	5.67e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg17294928	chr15:75287854	SCAMP5	-0.93	-13.5	-0.59	1.92e-33	Blood trace element (Zn levels);
LUSC	cis	rs4919694	1.000	rs17881215	chr10:104629236	G/C	cg04362960	chr10:104952993	NT5C2	1.11	12.64	0.57	3.43e-30	Arsenic metabolism;
LUSC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg13560548	chr3:10150139	C3orf24	0.49	6.91	0.35	2.43e-11	Alzheimer's disease;
LUSC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	7.34	0.37	1.68e-12	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg08807101	chr21:30365312	RNF160	0.74	13.26	0.59	1.55e-32	Dental caries;
LUSC	cis	rs12928939	0.517	rs12149325	chr16:71968147	G/C	cg03805757	chr16:71968109	PKD1L3	-0.64	-9.8	-0.47	4.31e-20	Post bronchodilator FEV1;
LUSC	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg12927641	chr6:109611667	NA	-0.35	-5.86	-0.31	1.13e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06112835	chr11:68658793	MRPL21	0.49	7.65	0.39	2.19e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.82	-0.47	3.69e-20	Chronic sinus infection;
LUSC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg12963246	chr6:28129442	ZNF389	0.52	7.17	0.37	4.94e-12	Depression;
LUSC	trans	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg20935933	chr6:143382018	AIG1	0.51	7.43	0.38	8.96e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs11785693	0.819	rs6994891	chr8:4989856	T/A	cg26367366	chr8:4980734	NA	0.8	9.32	0.45	1.65e-18	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg07606381	chr6:8435919	SLC35B3	-0.71	-11.8	-0.54	4.33e-27	Motion sickness;
LUSC	cis	rs4751006	0.543	rs9794336	chr10:128777873	C/T	cg05702161	chr10:128779687	DOCK1	0.5	5.78	0.3	1.72e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12413816	0.784	rs35537139	chr10:13768894	G/A	cg16485048	chr10:13749193	FRMD4A	0.45	7.51	0.38	5.54e-13	Red cell distribution width;
LUSC	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.74	-0.39	1.16e-13	Response to antipsychotic treatment;
LUSC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg08219700	chr8:58056026	NA	0.47	5.79	0.3	1.61e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.34	-0.33	7.65e-10	Retinal vascular caliber;
LUSC	cis	rs308403	0.600	rs13135445	chr4:123664457	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.03	0.52	2.39e-24	Blood protein levels;
LUSC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg14092988	chr3:52407081	DNAH1	-0.31	-6.01	-0.31	4.97e-9	Bipolar disorder;
LUSC	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg12615879	chr12:58013172	SLC26A10	-0.31	-6.57	-0.34	1.95e-10	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg05182265	chr7:156933206	UBE3C	0.49	7.4	0.38	1.13e-12	Body mass index;
LUSC	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.94	0.51	5.25e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg16329650	chr2:213403929	ERBB4	0.86	18.45	0.71	6.91e-53	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg06875740	chr19:51307921	C19orf48	-0.52	-7.08	-0.36	8.45e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg07148914	chr20:33460835	GGT7	0.46	6.86	0.35	3.3e-11	Height;
LUSC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.43	6.72	0.35	7.65e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7945718	0.967	rs12417886	chr11:12811731	A/C	cg25843174	chr11:12811716	TEAD1	-0.34	-7.6	-0.38	3.01e-13	Educational attainment (years of education);
LUSC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11039100	0.850	rs12792985	chr11:5833742	A/G	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg02023728	chr11:77925099	USP35	0.43	6.55	0.34	2.17e-10	Testicular germ cell tumor;
LUSC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.49	-7.03	-0.36	1.14e-11	Mean platelet volume;
LUSC	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg14689365	chr7:158441557	NCAPG2	0.52	7.56	0.38	3.97e-13	Height;
LUSC	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg13334819	chr7:99746414	C7orf59	-0.5	-6.73	-0.35	7.41e-11	Coronary artery disease;
LUSC	cis	rs62400317	0.859	rs12205860	chr6:45157323	G/A	cg20913747	chr6:44695427	NA	-0.48	-7.67	-0.39	1.91e-13	Total body bone mineral density;
LUSC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.75	0.35	6.62e-11	Platelet count;
LUSC	trans	rs9409565	0.826	rs9409550	chr9:97223294	C/G	cg05679027	chr9:99775184	HIATL2	-0.49	-6.94	-0.36	2.05e-11	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.56	-0.6	1.12e-33	Chronic sinus infection;
LUSC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg24154853	chr7:158122151	PTPRN2	-0.42	-8.24	-0.41	3.96e-15	Calcium levels;
LUSC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	1.03	17.64	0.69	1.06e-49	Coronary artery disease;
LUSC	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs2742234	1.000	rs1864395	chr10:43655697	G/A	cg02780029	chr10:43622663	RET	-0.35	-6.78	-0.35	5.34e-11	Hirschsprung disease;
LUSC	trans	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg14791747	chr16:20752902	THUMPD1	-0.73	-10.1	-0.48	4.06e-21	Cognitive test performance;
LUSC	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	6.93	0.35	2.15e-11	Schizophrenia;
LUSC	cis	rs9549260	0.755	rs4941987	chr13:41195992	T/C	cg21288729	chr13:41239152	FOXO1	0.6	9.19	0.45	4.44e-18	Red blood cell count;
LUSC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg01206211	chr2:36825736	FEZ2	0.51	10.81	0.51	1.51e-23	Height;
LUSC	cis	rs41271473	0.898	rs17352535	chr1:228822284	C/G	cg10167378	chr1:228756711	NA	0.6	7.15	0.36	5.44e-12	Chronic lymphocytic leukemia;
LUSC	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	8.76	0.43	9.71e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg08824895	chr13:115047677	UPF3A	0.57	8.85	0.44	5.1e-17	Schizophrenia;
LUSC	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg10596483	chr8:143751796	JRK	-0.57	-9.07	-0.44	1.07e-17	Schizophrenia;
LUSC	cis	rs8018808	0.905	rs7142380	chr14:77931231	T/C	cg20045696	chr14:77926864	AHSA1	0.34	5.76	0.3	1.95e-8	Myeloid white cell count;
LUSC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg13722127	chr7:150037890	RARRES2	0.38	5.64	0.3	3.58e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4974559	0.947	rs28649968	chr4:1362913	G/A	cg02980000	chr4:1222292	CTBP1	0.7	6.35	0.33	7.08e-10	Systolic blood pressure;
LUSC	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg03060546	chr3:49711283	APEH	0.65	6.77	0.35	5.86e-11	Menarche (age at onset);
LUSC	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg20848291	chr7:100343083	ZAN	-0.52	-6.33	-0.33	7.73e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg24375607	chr4:120327624	NA	0.53	8.16	0.41	6.95e-15	Diastolic blood pressure;
LUSC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg21733973	chr7:65235735	NA	0.4	5.67	0.3	3.1e-8	Calcium levels;
LUSC	trans	rs9951602	1.000	rs9951602	chr18:76657779	C/T	cg02800362	chr5:177631904	HNRNPAB	0.97	10.55	0.5	1.17e-22	Obesity-related traits;
LUSC	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.64	-9.46	-0.46	5.66e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.0	-0.31	5.02e-9	Recombination rate (females);
LUSC	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg05340658	chr4:99064831	C4orf37	0.43	6.87	0.35	3.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.96	-15.51	-0.65	3.14e-41	Coronary artery disease;
LUSC	cis	rs1808579	0.935	rs6507720	chr18:21119291	A/G	cg14672496	chr18:21087552	C18orf8	0.36	6.13	0.32	2.43e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs9815354	0.812	rs73071328	chr3:41810055	A/C	cg03022575	chr3:42003672	ULK4	0.83	8.34	0.41	2.04e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg13114125	chr14:105738426	BRF1	-0.9	-15.75	-0.65	3.61e-42	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg23649088	chr2:200775458	C2orf69	0.55	7.39	0.38	1.15e-12	Schizophrenia;
LUSC	cis	rs9341808	0.667	rs10943698	chr6:80934301	C/T	cg08355045	chr6:80787529	NA	0.45	7.63	0.39	2.45e-13	Sitting height ratio;
LUSC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg16606324	chr3:10149918	C3orf24	0.55	7.4	0.38	1.11e-12	Alzheimer's disease;
LUSC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg12463550	chr7:65579703	CRCP	0.52	7.54	0.38	4.41e-13	Aortic root size;
LUSC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg06064525	chr11:970664	AP2A2	-0.35	-7.0	-0.36	1.44e-11	Alzheimer's disease (late onset);
LUSC	trans	rs804280	0.662	rs11784764	chr8:11610874	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.25	-0.32	1.27e-9	Myopia (pathological);
LUSC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg15145296	chr3:125709740	NA	-0.56	-6.26	-0.32	1.2e-9	Blood pressure (smoking interaction);
LUSC	trans	rs488628	0.839	rs507279	chr3:118146851	T/C	cg06621744	chr14:37052470	NKX2-8	-0.29	-6.35	-0.33	6.85e-10	White matter integrity (bipolar disorder risk interaction);
LUSC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.7	10.87	0.51	9.12e-24	Breast cancer;
LUSC	cis	rs10100465	0.961	rs34660998	chr8:118679746	T/C	cg09430518	chr8:118662568	NA	0.31	5.91	0.31	8.48e-9	Leprosy;
LUSC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg16339924	chr4:17578868	LAP3	0.59	9.2	0.45	3.85e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg06521331	chr12:34319734	NA	-0.35	-5.93	-0.31	7.61e-9	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg06600287	chr1:53387719	ECHDC2	0.28	5.7	0.3	2.58e-8	Monocyte count;
LUSC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.79	-0.57	9.23e-31	Platelet count;
LUSC	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.91	-0.35	2.45e-11	Response to antipsychotic treatment;
LUSC	cis	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg21775007	chr8:11205619	TDH	0.44	5.76	0.3	1.94e-8	Neuroticism;
LUSC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg20811857	chr17:78079795	GAA	-0.31	-5.82	-0.3	1.36e-8	Yeast infection;
LUSC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg07937631	chr13:79184529	NA	-0.37	-6.37	-0.33	6.12e-10	Large artery stroke;
LUSC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	9.01	0.44	1.56e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs6545883	0.929	rs1900572	chr2:61650715	T/G	cg15711740	chr2:61764176	XPO1	0.43	6.55	0.34	2.13e-10	Tuberculosis;
LUSC	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg27219399	chr15:67835830	MAP2K5	0.37	5.75	0.3	2.05e-8	Obesity;
LUSC	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg18357645	chr12:58087776	OS9	-0.53	-7.84	-0.39	6.03e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9467773	0.595	rs4320356	chr6:26423560	C/T	cg09904177	chr6:26538194	HMGN4	-0.56	-8.54	-0.42	4.88e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg16339924	chr4:17578868	LAP3	0.69	11.25	0.52	4.06e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg06636001	chr8:8085503	FLJ10661	0.68	10.58	0.5	9.08e-23	Neuroticism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04169263	chr16:1756061	MAPK8IP3	-0.4	-6.0	-0.31	5.15e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg07701084	chr6:150067640	NUP43	0.54	8.02	0.4	1.82e-14	Lung cancer;
LUSC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-5.88	-0.31	1e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.89	0.31	9.35e-9	Menopause (age at onset);
LUSC	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg18904891	chr8:8559673	CLDN23	0.6	8.08	0.4	1.2e-14	Obesity-related traits;
LUSC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Parkinson's disease;
LUSC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg07636037	chr3:49044803	WDR6	0.46	6.62	0.34	1.41e-10	Resting heart rate;
LUSC	cis	rs1007190	0.881	rs12941832	chr17:42987482	G/T	cg15406952	chr17:42872593	NA	0.57	5.71	0.3	2.54e-8	DNA methylation (variation);
LUSC	cis	rs7607369	0.500	rs6712856	chr2:219658617	A/T	cg02176678	chr2:219576539	TTLL4	-0.61	-11.37	-0.53	1.57e-25	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15311382	chr11:1404750	NA	0.41	6.2	0.32	1.7e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7621025	0.500	rs16844241	chr3:136635171	A/G	cg15507776	chr3:136538369	TMEM22	-0.6	-8.36	-0.42	1.73e-15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUSC	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg04362960	chr10:104952993	NT5C2	0.57	8.19	0.41	5.56e-15	Arsenic metabolism;
LUSC	cis	rs5167	0.566	rs2075618	chr19:45495668	G/C	cg13119609	chr19:45449297	APOC2	0.34	5.67	0.3	3.01e-8	Blood protein levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27203200	chr16:67193754	TRADD;FBXL8	-0.42	-6.43	-0.33	4.37e-10	Electrocardiographic conduction measures;
LUSC	trans	rs1998174	0.509	rs10798706	chr1:171820018	C/G	cg13482142	chr2:234261155	NA	0.41	5.98	0.31	5.69e-9	Platelet distribution width;
LUSC	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	8.81	0.43	7e-17	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg03351412	chr1:154909251	PMVK	0.55	8.83	0.44	5.92e-17	Prostate cancer;
LUSC	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	1.12	16.22	0.66	5.04e-44	Mitochondrial DNA levels;
LUSC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2019216	0.542	rs12450889	chr17:21889379	A/G	cg22648282	chr17:21454238	C17orf51	-0.53	-7.71	-0.39	1.47e-13	Pelvic organ prolapse;
LUSC	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00631329	chr6:26305371	NA	-0.49	-9.55	-0.46	2.97e-19	Educational attainment;
LUSC	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.86	0.4	5.28e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.09	15.15	0.64	7.93e-40	Uric acid levels;
LUSC	cis	rs9638182	0.638	rs6946689	chr7:72977637	T/A	cg07452164	chr7:72993570	TBL2	0.45	6.36	0.33	6.67e-10	Triglycerides;
LUSC	trans	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.97	0.48	1.14e-20	Mean corpuscular volume;
LUSC	cis	rs751728	1.000	rs6904991	chr6:33732262	T/G	cg25922239	chr6:33757077	LEMD2	0.53	7.83	0.39	6.64e-14	Crohn's disease;
LUSC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg13560548	chr3:10150139	C3orf24	0.52	7.18	0.37	4.69e-12	Alzheimer's disease;
LUSC	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg15595755	chr5:1867978	NA	0.4	6.29	0.33	9.77e-10	Cardiovascular disease risk factors;
LUSC	cis	rs8099014	0.861	rs4940703	chr18:56115386	A/G	cg12907477	chr18:56117327	MIR122	0.45	7.05	0.36	1.01e-11	Platelet count;
LUSC	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg08684580	chr7:98029266	BAIAP2L1	0.38	5.71	0.3	2.48e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11828289	0.660	rs75816907	chr11:23175126	G/A	cg20040320	chr11:23191996	NA	-0.58	-6.09	-0.32	3.05e-9	Cancer;
LUSC	cis	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg17187183	chr4:55093834	PDGFRA	0.39	5.82	0.3	1.41e-8	Corneal astigmatism;
LUSC	cis	rs7809950	0.862	rs12112877	chr7:106941324	T/C	cg23024343	chr7:107201750	COG5	-0.52	-8.26	-0.41	3.36e-15	Coronary artery disease;
LUSC	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg09469691	chr10:81107165	PPIF	0.59	8.91	0.44	3.38e-17	Height;
LUSC	cis	rs57244997	1.000	rs57244997	chr6:162397506	G/A	cg17173639	chr6:162384350	PARK2	-0.66	-6.54	-0.34	2.34e-10	Mosquito bite size;
LUSC	cis	rs273573	0.961	rs158582	chr11:30995033	T/C	cg14844989	chr11:31128820	NA	0.38	5.95	0.31	6.59e-9	Total body bone mineral density;
LUSC	cis	rs12618769	0.652	rs2276603	chr2:99205962	C/T	cg10123293	chr2:99228465	UNC50	-0.49	-7.95	-0.4	2.88e-14	Bipolar disorder;
LUSC	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.82	-13.75	-0.6	2.18e-34	Bladder cancer;
LUSC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg09877947	chr5:131593287	PDLIM4	0.47	7.33	0.37	1.71e-12	Breast cancer;
LUSC	trans	rs11088226	1.000	rs2833889	chr21:33927768	G/T	cg09050820	chr6:167586206	TCP10L2	-0.6	-8.16	-0.41	6.84e-15	Gastritis;
LUSC	trans	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg26043149	chr18:55253948	FECH	-0.54	-7.8	-0.39	7.94e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20783262	chr1:68152310	GADD45A	0.46	7.26	0.37	2.7e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg03342759	chr3:160939853	NMD3	-0.52	-7.45	-0.38	8.2e-13	Parkinson's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05388307	chr4:166248715	SC4MOL	0.43	6.3	0.33	9.52e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg20701182	chr2:24300061	SF3B14	0.59	6.26	0.32	1.21e-9	Lymphocyte counts;
LUSC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.5	0.56	1.12e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6424115	0.708	rs34570472	chr1:24191720	A/G	cg10978503	chr1:24200527	CNR2	-0.46	-9.69	-0.47	9.61e-20	Immature fraction of reticulocytes;
LUSC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg19230755	chr7:65878503	NA	-0.4	-5.77	-0.3	1.79e-8	Aortic root size;
LUSC	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg16235748	chr6:149772707	ZC3H12D	-0.28	-5.8	-0.3	1.5e-8	Dupuytren's disease;
LUSC	trans	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg25815440	chr2:42134162	NA	-0.26	-6.02	-0.31	4.51e-9	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12213003	chr6:10747896	TMEM14B	-0.42	-6.12	-0.32	2.65e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg00990874	chr7:1149470	C7orf50	-0.53	-6.71	-0.34	8.33e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg23625390	chr15:77176239	SCAPER	0.55	8.65	0.43	2.17e-16	Blood metabolite levels;
LUSC	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg03342759	chr3:160939853	NMD3	-0.52	-7.46	-0.38	7.72e-13	Parkinson's disease;
LUSC	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg09223439	chr15:65282374	SPG21	0.37	6.39	0.33	5.61e-10	Triglycerides;
LUSC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg06640241	chr16:89574553	SPG7	0.93	17.31	0.69	2.35e-48	Multiple myeloma (IgH translocation);
LUSC	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	13.38	0.59	5.34e-33	Blood protein levels;
LUSC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg07936489	chr17:37558343	FBXL20	0.7	9.69	0.47	1.02e-19	Glomerular filtration rate (creatinine);
LUSC	trans	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg18187862	chr3:45730750	SACM1L	0.55	6.92	0.35	2.3e-11	Primary sclerosing cholangitis;
LUSC	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg03585969	chr10:35415529	CREM	0.62	9.02	0.44	1.55e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg13010199	chr12:38710504	ALG10B	0.49	7.48	0.38	6.62e-13	Morning vs. evening chronotype;
LUSC	cis	rs7614311	0.681	rs55917937	chr3:63894829	A/C	cg22134162	chr3:63841271	THOC7	-0.43	-5.7	-0.3	2.59e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.87	-0.7	1.34e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.56	9.45	0.46	6.15e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg05925327	chr15:68127851	NA	-0.4	-6.32	-0.33	8.42e-10	Restless legs syndrome;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20355062	chr10:3827618	KLF6	-0.41	-6.37	-0.33	6.33e-10	Electrocardiographic conduction measures;
LUSC	cis	rs61931739	0.591	rs1608907	chr12:33945435	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.86	-0.35	3.29e-11	Morning vs. evening chronotype;
LUSC	cis	rs4730250	0.707	rs257372	chr7:106796977	T/G	cg02696742	chr7:106810147	HBP1	-0.64	-9.1	-0.45	8.66e-18	Osteoarthritis;
LUSC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.56	11.17	0.52	7.79e-25	Asthma (sex interaction);
LUSC	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg06636001	chr8:8085503	FLJ10661	0.56	8.34	0.42	1.92e-15	Retinal vascular caliber;
LUSC	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg25482853	chr8:67687455	SGK3	1.18	18.42	0.71	8.56e-53	Lung disease severity in cystic fibrosis;
LUSC	cis	rs28830936	1.000	rs2412622	chr15:41960311	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.3	-0.33	9.57e-10	Diastolic blood pressure;
LUSC	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg07636037	chr3:49044803	WDR6	0.89	10.8	0.51	1.56e-23	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs9341808	0.558	rs2322635	chr6:80897210	A/G	cg08355045	chr6:80787529	NA	0.48	8.29	0.41	2.72e-15	Sitting height ratio;
LUSC	cis	rs181744922	1	rs181744922	chr3:134974529	T/A	cg07149179	chr3:134978680	EPHB1	-0.35	-5.76	-0.3	1.93e-8	Daytime sleep phenotypes;
LUSC	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg26384229	chr12:38710491	ALG10B	-0.54	-7.93	-0.4	3.38e-14	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.52	7.62	0.39	2.57e-13	Axial length;
LUSC	cis	rs4499344	0.730	rs12460663	chr19:33098238	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	12.47	0.56	1.45e-29	Mean platelet volume;
LUSC	cis	rs34779708	0.733	rs11010146	chr10:35541561	T/A	cg03585969	chr10:35415529	CREM	0.55	7.59	0.38	3.21e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg02269571	chr22:50332266	NA	-0.59	-8.72	-0.43	1.31e-16	Schizophrenia;
LUSC	cis	rs757278	0.552	rs10441245	chr7:117311066	A/G	cg10524701	chr7:117356490	CTTNBP2	0.4	5.75	0.3	1.99e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg09365446	chr1:150670422	GOLPH3L	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg12552261	chr5:112820674	MCC	-0.44	-7.11	-0.36	7.19e-12	Type 2 diabetes;
LUSC	cis	rs7267979	0.789	rs4815400	chr20:25292560	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.77	-16.29	-0.67	2.51e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-0.8	-13.05	-0.58	9.68e-32	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg13175981	chr1:150552382	MCL1	0.45	6.35	0.33	6.95e-10	Tonsillectomy;
LUSC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg04317338	chr11:64019027	PLCB3	0.56	5.91	0.31	8.27e-9	Mean platelet volume;
LUSC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg20283391	chr11:68216788	NA	-0.59	-8.3	-0.41	2.64e-15	Total body bone mineral density;
LUSC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg25456477	chr12:86230367	RASSF9	0.41	7.26	0.37	2.76e-12	Major depressive disorder;
LUSC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg05347473	chr6:146136440	FBXO30	0.46	7.89	0.4	4.31e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06022373	chr22:39101656	GTPBP1	0.79	12.22	0.56	1.2e-28	Menopause (age at onset);
LUSC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg17948913	chr5:572064	NA	0.38	6.27	0.32	1.09e-9	Obesity-related traits;
LUSC	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg12002119	chr2:101014098	CHST10	0.36	5.93	0.31	7.72e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.2	-0.37	4.03e-12	Bipolar disorder;
LUSC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	0.92	15.42	0.64	7.18e-41	Breast cancer;
LUSC	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg14583973	chr4:3374767	RGS12	0.37	7.79	0.39	8.62e-14	Serum sulfate level;
LUSC	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg09953122	chr20:23471693	CST8	-0.67	-5.72	-0.3	2.37e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg03146154	chr1:46216737	IPP	-0.51	-7.14	-0.36	5.86e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg13072238	chr3:49761600	GMPPB	-0.63	-8.19	-0.41	5.63e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg02503808	chr4:7069936	GRPEL1	-1.06	-12.04	-0.55	5.64e-28	Monocyte percentage of white cells;
LUSC	cis	rs920590	0.643	rs6982084	chr8:19669333	G/A	cg03894339	chr8:19674705	INTS10	-0.43	-6.2	-0.32	1.64e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.85	-0.35	3.59e-11	Mood instability;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	1.01	22.85	0.78	3.1e-70	Menarche (age at onset);
LUSC	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.39	0.49	4.16e-22	Bladder cancer;
LUSC	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg03733263	chr8:22462867	KIAA1967	1.01	18.65	0.71	1.11e-53	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg08470875	chr2:26401718	FAM59B	-0.68	-9.29	-0.45	2.07e-18	Gut microbiome composition (summer);
LUSC	cis	rs6012953	1.000	rs6012953	chr20:49123043	A/G	cg13958625	chr20:49123093	NA	0.31	6.63	0.34	1.33e-10	Vitiligo;
LUSC	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg02569458	chr12:86230093	RASSF9	-0.36	-5.78	-0.3	1.69e-8	Major depressive disorder;
LUSC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg21605333	chr4:119757512	SEC24D	1.02	8.31	0.41	2.46e-15	Cannabis dependence symptom count;
LUSC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.48	0.53	5.96e-26	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20318713	chr1:45805724	MUTYH;TOE1	-0.48	-6.11	-0.32	2.74e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Bladder cancer;
LUSC	cis	rs155346	0.901	rs265179	chr5:139365452	C/G	cg01090482	chr5:139365336	NRG2	-0.41	-6.53	-0.34	2.41e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg16797656	chr11:68205561	LRP5	0.42	7.75	0.39	1.09e-13	Total body bone mineral density;
LUSC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg05973401	chr12:123451056	ABCB9	0.55	8.05	0.4	1.5e-14	Platelet count;
LUSC	trans	rs1874124	0.836	rs7549963	chr1:220988260	C/T	cg00338749	chr11:1036677	MUC6	0.4	6.31	0.33	8.8e-10	Cholesterol, total;
LUSC	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg05472934	chr7:22766657	IL6	0.5	7.69	0.39	1.71e-13	Lung cancer;
LUSC	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.69	0.39	1.65e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11039100	0.850	rs34286221	chr11:5834852	G/T	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs116988415	0.584	rs11622171	chr14:65258644	C/G	cg00114569	chr14:65239327	SPTB	0.72	7.48	0.38	6.69e-13	Daytime sleep phenotypes;
LUSC	cis	rs7215564	0.908	rs2316067	chr17:78659720	C/T	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.72	0.39	1.33e-13	Corneal astigmatism;
LUSC	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg15848620	chr12:58087721	OS9	-0.52	-7.47	-0.38	7.21e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg13114125	chr14:105738426	BRF1	-0.92	-15.9	-0.66	9.08e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg10978503	chr1:24200527	CNR2	0.47	11.01	0.52	2.83e-24	Immature fraction of reticulocytes;
LUSC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg06462663	chr19:18546047	ISYNA1	0.49	8.04	0.4	1.59e-14	Breast cancer;
LUSC	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg09918751	chr15:100517450	ADAMTS17	0.53	10.21	0.49	1.74e-21	Height;
LUSC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg15110403	chr19:17392923	ANKLE1	-0.52	-7.17	-0.37	4.89e-12	Systemic lupus erythematosus;
LUSC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg06221963	chr1:154839813	KCNN3	-0.49	-10.02	-0.48	7.84e-21	Prostate cancer;
LUSC	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-6.27	-0.32	1.1e-9	Fear of minor pain;
LUSC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.29	0.37	2.29e-12	Platelet count;
LUSC	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg26384229	chr12:38710491	ALG10B	0.96	17.78	0.7	3.11e-50	Heart rate;
LUSC	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg05714579	chr10:131428358	MGMT	0.47	6.56	0.34	2.03e-10	Response to temozolomide;
LUSC	cis	rs2979489	0.891	rs6982511	chr8:30355513	G/T	cg26383811	chr8:30366931	RBPMS	-0.51	-7.99	-0.4	2.18e-14	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg22800045	chr5:56110881	MAP3K1	-0.42	-5.89	-0.31	9.33e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg18827107	chr12:86230957	RASSF9	-0.38	-5.66	-0.3	3.3e-8	Major depressive disorder;
LUSC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg25036284	chr2:26402008	FAM59B	-0.68	-9.45	-0.46	6.03e-19	Gut microbiome composition (summer);
LUSC	cis	rs12618769	0.597	rs72819996	chr2:99059983	G/A	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.14e-13	Bipolar disorder;
LUSC	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg04896959	chr15:78267971	NA	0.41	6.64	0.34	1.28e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.85	0.39	5.81e-14	Electroencephalogram traits;
LUSC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18131467	chr2:239335373	ASB1	1.05	25.16	0.81	4.26e-79	Multiple system atrophy;
LUSC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.35	0.33	6.89e-10	Bipolar disorder;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg03609292	chr17:4799832	MINK1	-0.42	-6.96	-0.36	1.78e-11	N-glycan levels;
LUSC	cis	rs3740540	0.530	rs10751598	chr10:126290951	A/G	cg04949429	chr10:126290192	LHPP	-0.35	-7.39	-0.37	1.23e-12	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg26043149	chr18:55253948	FECH	0.5	7.39	0.37	1.22e-12	Bone mineral density;
LUSC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg17173187	chr15:85201210	NMB	0.37	6.61	0.34	1.55e-10	Schizophrenia;
LUSC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14240646	chr10:27532245	ACBD5	0.7	8.12	0.41	9.18e-15	Breast cancer;
LUSC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-14.28	-0.62	1.95e-36	Chronic sinus infection;
LUSC	cis	rs9473147	0.516	rs2151975	chr6:47515663	T/C	cg20196966	chr6:47445060	CD2AP	0.41	5.8	0.3	1.57e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg24006582	chr15:45444508	DUOX1	0.67	9.69	0.47	1.01e-19	Uric acid levels;
LUSC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg18512352	chr11:47633146	NA	-0.42	-8.77	-0.43	8.98e-17	Subjective well-being;
LUSC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg13683864	chr3:40499215	RPL14	-0.97	-16.23	-0.66	4.38e-44	Renal cell carcinoma;
LUSC	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg27411982	chr8:10470053	RP1L1	-0.5	-8.09	-0.4	1.11e-14	Neuroticism;
LUSC	cis	rs4629180	0.586	rs2048252	chr2:102138384	C/T	cg04415270	chr2:102091202	RFX8	-0.42	-7.2	-0.37	3.9e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs9837602	1.000	rs62285461	chr3:99767642	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.15	0.32	2.19e-9	Breast cancer;
LUSC	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	8.86	0.44	4.97e-17	Iron status biomarkers;
LUSC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.17	0.58	3.55e-32	Cognitive test performance;
LUSC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg25456477	chr12:86230367	RASSF9	0.44	7.88	0.4	4.75e-14	Major depressive disorder;
LUSC	cis	rs3736594	0.513	rs62138971	chr2:27840754	G/A	cg27432699	chr2:27873401	GPN1	0.64	8.58	0.43	3.6e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs2074585	0.517	rs11637971	chr15:91079863	A/C	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.85	-0.35	3.64e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg08085267	chr17:45401833	C17orf57	-0.5	-8.07	-0.4	1.25e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg08219700	chr8:58056026	NA	0.51	6.41	0.33	5e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg25643088	chr3:52874325	TMEM110	0.39	5.82	0.3	1.4e-8	Schizophrenia;
LUSC	cis	rs9513627	0.920	rs7335315	chr13:100121308	G/A	cg25919922	chr13:100150906	NA	-0.8	-6.96	-0.36	1.83e-11	Obesity-related traits;
LUSC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg07936489	chr17:37558343	FBXL20	-0.7	-9.6	-0.47	1.98e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.48	-0.33	3.36e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg23788917	chr6:8435910	SLC35B3	0.51	7.48	0.38	6.83e-13	Motion sickness;
LUSC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.59	9.12	0.45	7.15e-18	Blood protein levels;
LUSC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg27165867	chr14:105738592	BRF1	-0.55	-7.87	-0.4	4.93e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg05585544	chr11:47624801	NA	-0.37	-6.45	-0.33	3.82e-10	Subjective well-being;
LUSC	trans	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg10840412	chr1:235813424	GNG4	0.54	7.11	0.36	7.15e-12	Bipolar disorder;
LUSC	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg15133208	chr4:90757351	SNCA	-0.55	-8.63	-0.43	2.6e-16	Neuroticism;
LUSC	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg13798780	chr7:105162888	PUS7	0.56	6.08	0.32	3.26e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg10845886	chr2:3471009	TTC15	-0.53	-6.79	-0.35	5.25e-11	Neurofibrillary tangles;
LUSC	cis	rs17125944	0.615	rs2025632	chr14:53294319	T/C	cg00686598	chr14:53173677	PSMC6	-0.75	-6.86	-0.35	3.27e-11	Alzheimer's disease (late onset);
LUSC	trans	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg10756647	chr7:56101905	PSPH	-0.82	-8.21	-0.41	5.01e-15	Diabetic kidney disease;
LUSC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg10729496	chr3:10149963	C3orf24	0.55	7.48	0.38	6.53e-13	Alzheimer's disease;
LUSC	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.42	-0.38	9.53e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg15848620	chr12:58087721	OS9	-0.58	-8.48	-0.42	7.58e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	0.94	18.17	0.71	8.64e-52	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24654547	chr16:68057165	DUS2L;DDX28	0.44	7.54	0.38	4.51e-13	Triglycerides;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12564526	chr7:66767603	PMS2L4;STAG3L4	-0.5	-6.74	-0.35	7.16e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs853679	0.546	rs200996	chr6:27811828	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-7.75	-0.39	1.1e-13	Depression;
LUSC	cis	rs12422267	0.536	rs11831679	chr12:132609960	C/T	cg09764611	chr12:132620959	NA	-0.59	-8.71	-0.43	1.41e-16	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg06521331	chr12:34319734	NA	-0.45	-7.33	-0.37	1.77e-12	Morning vs. evening chronotype;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg15383120	chr6:291909	DUSP22	-0.66	-11.07	-0.52	1.86e-24	Menopause (age at onset);
LUSC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg00033643	chr7:134001901	SLC35B4	0.47	7.27	0.37	2.58e-12	Mean platelet volume;
LUSC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg11235426	chr6:292522	DUSP22	-0.46	-6.96	-0.36	1.86e-11	Menopause (age at onset);
LUSC	cis	rs753274	0.650	rs7257738	chr19:14418921	G/C	cg25450033	chr19:14444658	NA	0.34	5.82	0.3	1.35e-8	Tumor necrosis factor beta levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13620744	chr19:36478289	NA	0.77	6.69	0.34	9.31e-11	Cognitive performance;
LUSC	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg00757033	chr12:89920650	WDR51B	0.6	10.33	0.49	7.01e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01123282	chr2:157189755	NR4A2	-0.4	-6.06	-0.31	3.73e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12541635	0.966	rs7839195	chr8:107020193	G/A	cg10147462	chr8:107024639	NA	0.55	9.84	0.47	3.24e-20	Age of smoking initiation;
LUSC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg07701084	chr6:150067640	NUP43	-0.54	-8.2	-0.41	5.21e-15	Lung cancer;
LUSC	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg16989719	chr2:238392110	NA	-0.42	-6.68	-0.34	1.02e-10	Prostate cancer;
LUSC	cis	rs13089785	1.000	rs2332682	chr3:123654633	C/T	cg02558132	chr3:123411198	MYLK	0.35	6.14	0.32	2.39e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	8.33	0.41	2.06e-15	Lung cancer in ever smokers;
LUSC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg17211192	chr8:82754475	SNX16	0.81	11.11	0.52	1.32e-24	Diastolic blood pressure;
LUSC	trans	rs10432489	0.708	rs4531892	chr2:181746482	T/A	cg04744134	chr19:8408128	KANK3	-0.87	-6.65	-0.34	1.19e-10	QT interval;
LUSC	cis	rs9650315	0.538	rs4075154	chr8:57209246	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.69	0.39	1.65e-13	Height;
LUSC	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.55	-15.02	-0.63	2.6e-39	Urate levels in overweight individuals;
LUSC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg14458575	chr2:238380390	NA	0.67	11.63	0.54	1.77e-26	Prostate cancer;
LUSC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.55	-10.51	-0.5	1.68e-22	Prostate cancer;
LUSC	cis	rs7598759	0.966	rs6754426	chr2:232322779	G/A	cg19187155	chr2:232395269	NMUR1	0.5	7.48	0.38	6.58e-13	Noise-induced hearing loss;
LUSC	cis	rs955333	0.685	rs6924083	chr6:154899155	G/A	cg20019720	chr6:154832845	CNKSR3	0.45	6.35	0.33	6.89e-10	Diabetic kidney disease;
LUSC	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-1.03	-14.29	-0.62	1.74e-36	Exhaled nitric oxide output;
LUSC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg23711669	chr6:146136114	FBXO30	-0.89	-16.79	-0.68	2.69e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg24375607	chr4:120327624	NA	0.75	11.24	0.52	4.35e-25	Corneal astigmatism;
LUSC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.27	-0.32	1.12e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.7	12.66	0.57	2.96e-30	Prudent dietary pattern;
LUSC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg01416388	chr22:39784598	NA	-0.45	-7.6	-0.38	3.11e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg01677386	chr11:118938358	VPS11	-0.48	-6.82	-0.35	4.41e-11	Coronary artery disease;
LUSC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg22535103	chr8:58192502	C8orf71	-0.67	-7.14	-0.36	5.79e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg25024717	chr12:54324583	NA	-0.38	-6.33	-0.33	7.96e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg03788504	chr6:150331562	NA	-0.25	-5.72	-0.3	2.34e-8	Alopecia areata;
LUSC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg06028605	chr16:24865363	SLC5A11	-0.47	-8.49	-0.42	6.75e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg18827107	chr12:86230957	RASSF9	-0.38	-5.65	-0.3	3.52e-8	Major depressive disorder;
LUSC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg13607699	chr17:42295918	UBTF	0.55	8.37	0.42	1.62e-15	Total body bone mineral density;
LUSC	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.25	-27.77	-0.84	8.58e-89	Exhaled nitric oxide output;
LUSC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	0.88	16.21	0.66	5.23e-44	Cognitive function;
LUSC	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.64	-0.43	2.38e-16	Total cholesterol levels;
LUSC	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg23387468	chr7:139079360	LUC7L2	-0.42	-6.28	-0.32	1.05e-9	Diisocyanate-induced asthma;
LUSC	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg00745463	chr17:30367425	LRRC37B	0.64	7.67	0.39	1.9e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.66	-10.08	-0.48	4.86e-21	Hip circumference adjusted for BMI;
LUSC	cis	rs727505	1.000	rs10240673	chr7:124513050	A/G	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs6692729	0.966	rs1150897	chr1:227047249	A/G	cg10327440	chr1:227177885	CDC42BPA	0.51	7.28	0.37	2.44e-12	Electrodermal activity;
LUSC	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	12.42	0.56	2.18e-29	Schizophrenia;
LUSC	cis	rs1355223	1.000	rs1355222	chr11:34758716	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-5.64	-0.3	3.54e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.07	-0.44	1.01e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.25	-0.32	1.23e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg23795048	chr12:9217529	LOC144571	0.33	5.76	0.3	1.94e-8	Sjögren's syndrome;
LUSC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg24642844	chr7:1081250	C7orf50	-0.68	-9.93	-0.48	1.63e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg24375607	chr4:120327624	NA	0.66	10.31	0.49	7.92e-22	Corneal astigmatism;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20060089	chr17:41561319	DHX8	0.42	6.52	0.34	2.65e-10	Triglycerides;
LUSC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.02	0.31	4.49e-9	Menopause (age at onset);
LUSC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.74	10.58	0.5	9.68e-23	Type 2 diabetes;
LUSC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg09021430	chr5:549028	NA	-0.55	-7.37	-0.37	1.35e-12	Obesity-related traits;
LUSC	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg25237894	chr2:233734115	C2orf82	-0.34	-6.22	-0.32	1.52e-9	Coronary artery disease;
LUSC	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.54	0.75	3.49e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.36	-5.85	-0.31	1.15e-8	Breast cancer;
LUSC	trans	rs75804782	0.641	rs59499060	chr2:239341411	C/T	cg01134436	chr17:81009848	B3GNTL1	0.65	6.37	0.33	6.32e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.26	0.52	3.78e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.38	0.69	1.15e-48	Chronic sinus infection;
LUSC	trans	rs11700980	0.515	rs12481795	chr21:30113730	G/A	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg27398817	chr8:82754497	SNX16	-0.48	-6.43	-0.33	4.53e-10	Diastolic blood pressure;
LUSC	cis	rs1957429	0.731	rs10144554	chr14:65321514	T/G	cg23373153	chr14:65346875	NA	0.94	10.5	0.5	1.76e-22	Pediatric areal bone mineral density (radius);
LUSC	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg05738196	chr6:26577821	NA	0.81	15.2	0.64	4.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.28e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg09998033	chr7:158218633	PTPRN2	0.41	6.39	0.33	5.68e-10	Obesity-related traits;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.38	-6.28	-0.32	1.06e-9	Longevity;Endometriosis;
LUSC	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg00129232	chr17:37814104	STARD3	-0.47	-7.03	-0.36	1.18e-11	Asthma;
LUSC	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.92	-0.35	2.35e-11	Retinal vascular caliber;
LUSC	cis	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-7.76	-0.39	1.05e-13	Neuroticism;
LUSC	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	1.13	18.03	0.7	2.99e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs61863818	0.557	rs7895646	chr10:99167436	A/G	cg20016023	chr10:99160130	RRP12	-0.23	-5.69	-0.3	2.72e-8	Monocyte percentage of white cells;
LUSC	cis	rs9326248	0.652	rs7128382	chr11:117023487	A/C	cg26566898	chr11:117069891	TAGLN	0.4	6.41	0.33	4.83e-10	Blood protein levels;
LUSC	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg08601574	chr20:25228251	PYGB	0.41	6.28	0.32	1.06e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg13319975	chr6:146136371	FBXO30	0.46	7.01	0.36	1.33e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg03146154	chr1:46216737	IPP	0.5	7.41	0.38	1.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.72	-10.68	-0.5	4.31e-23	Refractive error;
LUSC	trans	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg07817883	chr1:32538562	TMEM39B	-0.56	-6.75	-0.35	6.65e-11	Monocyte percentage of white cells;
LUSC	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-7.86	-0.39	5.41e-14	Blood metabolite levels;
LUSC	cis	rs10504229	0.516	rs4361758	chr8:57990401	C/T	cg22535103	chr8:58192502	C8orf71	-0.49	-6.43	-0.33	4.5e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.02	-0.4	1.78e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4561483	0.801	rs154148	chr16:11956478	T/C	cg08843971	chr16:11963173	GSPT1	-0.49	-7.39	-0.37	1.22e-12	Testicular germ cell tumor;
LUSC	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg13072238	chr3:49761600	GMPPB	0.69	8.87	0.44	4.43e-17	Menarche (age at onset);
LUSC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg11812906	chr14:75593930	NEK9	0.67	11.71	0.54	8.78e-27	Height;
LUSC	trans	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.14	-0.32	2.39e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg05941027	chr17:61774174	LIMD2	0.22	5.72	0.3	2.4e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg19920283	chr7:105172520	RINT1	0.59	6.08	0.32	3.38e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6545883	0.965	rs10186325	chr2:61757721	G/T	cg15711740	chr2:61764176	XPO1	-0.49	-7.75	-0.39	1.12e-13	Tuberculosis;
LUSC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.08	-0.55	3.94e-28	Type 2 diabetes;
LUSC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg04871131	chr7:94954202	PON1	-0.38	-6.08	-0.32	3.2e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	8.72	0.43	1.35e-16	Monocyte percentage of white cells;
LUSC	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg24634471	chr8:143751801	JRK	0.59	8.99	0.44	1.82e-17	Schizophrenia;
LUSC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg11494091	chr17:61959527	GH2	0.35	5.78	0.3	1.73e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs7849782	0.905	rs10819973	chr9:104422240	C/T	cg22914338	chr19:14376960	NA	0.26	6.36	0.33	6.77e-10	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs2224391	0.534	rs2753228	chr6:5246623	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.49	-6.74	-0.35	7e-11	Height;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22409223	chr3:130465572	PIK3R4	-0.44	-6.04	-0.31	4.13e-9	Hepatitis;
LUSC	cis	rs10504073	0.669	rs818559	chr8:50035806	C/T	cg00325661	chr8:49890786	NA	0.6	9.75	0.47	6.18e-20	Blood metabolite ratios;
LUSC	trans	rs9886428	1.000	rs9886428	chr8:14113816	G/A	cg19037007	chr20:741798	C20orf54	-0.39	-6.11	-0.32	2.77e-9	IgG glycosylation;
LUSC	cis	rs4631830	0.863	rs4486572	chr10:51531805	A/G	cg20129853	chr10:51489980	NA	-0.34	-6.62	-0.34	1.4e-10	Prostate-specific antigen levels;
LUSC	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg10253484	chr15:75165896	SCAMP2	-0.48	-6.69	-0.34	9.15e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs4356932	1.000	rs10014049	chr4:76953532	C/A	cg00809888	chr4:76862425	NAAA	0.34	5.71	0.3	2.44e-8	Blood protein levels;
LUSC	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg02023728	chr11:77925099	USP35	0.45	6.57	0.34	1.98e-10	Testicular germ cell tumor;
LUSC	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17467752	chr17:38218738	THRA	-0.53	-7.87	-0.4	4.97e-14	White blood cell count (basophil);White blood cell count;
LUSC	cis	rs11971779	0.793	rs4728464	chr7:139017670	C/T	cg07862535	chr7:139043722	LUC7L2	-0.58	-7.07	-0.36	8.94e-12	Diisocyanate-induced asthma;
LUSC	cis	rs7197653	0.519	rs55757091	chr16:68323654	G/A	cg05110241	chr16:68378359	PRMT7	-0.64	-7.62	-0.38	2.72e-13	Magnesium levels;
LUSC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.86	0.58	4.99e-31	Prudent dietary pattern;
LUSC	cis	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg05084668	chr3:125655381	ALG1L	-0.91	-11.75	-0.54	6.42e-27	Blood pressure (smoking interaction);
LUSC	cis	rs7709377	0.597	rs6594952	chr5:115488032	A/C	cg23108291	chr5:115420582	COMMD10	0.41	5.79	0.3	1.59e-8	Metabolite levels  (X-11787);
LUSC	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.25	0.52	4.16e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg22029157	chr1:209979665	IRF6	0.54	6.14	0.32	2.35e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg04455712	chr21:45112962	RRP1B	0.43	8.14	0.41	7.98e-15	Mean corpuscular volume;
LUSC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg12365402	chr11:9010492	NRIP3	-0.49	-9.32	-0.45	1.64e-18	Hemoglobin concentration;
LUSC	cis	rs3770081	1.000	rs17026854	chr2:86280496	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.06	-7.07	-0.36	9.17e-12	Facial emotion recognition (sad faces);
LUSC	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg09479241	chr17:27052676	TLCD1	0.41	5.68	0.3	2.93e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs67072384	1.000	rs12289259	chr11:72446731	A/C	cg04827223	chr11:72435913	ARAP1	-0.81	-7.68	-0.39	1.72e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.7	-9.89	-0.48	2.1e-20	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg14552801	chr7:65878734	NA	0.39	5.98	0.31	5.64e-9	Aortic root size;
LUSC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	1.05	20.03	0.74	3.41e-59	Menopause (age at onset);
LUSC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.65	-0.43	2.14e-16	Neuroticism;
LUSC	cis	rs2078087	0.831	rs10911295	chr1:183245285	C/A	cg13843938	chr1:183241246	NMNAT2	0.45	6.09	0.32	3.13e-9	Obesity-related traits;
LUSC	cis	rs1609391	0.543	rs9881139	chr3:136634040	A/G	cg15507776	chr3:136538369	TMEM22	0.52	8.61	0.43	2.84e-16	Neuroticism;
LUSC	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg12559939	chr2:27858050	GPN1	0.4	6.3	0.33	9.22e-10	Oral cavity cancer;
LUSC	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg25011763	chr5:6727354	POLS	-0.35	-5.66	-0.3	3.33e-8	Menopause (age at onset);
LUSC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.9	-0.31	8.73e-9	Platelet count;
LUSC	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg12935359	chr14:103987150	CKB	0.65	10.36	0.49	5.6e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg15423357	chr2:25149977	NA	0.35	6.43	0.33	4.48e-10	Body mass index;
LUSC	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-6.78	-0.35	5.39e-11	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg11062466	chr8:58055876	NA	0.65	8.32	0.41	2.24e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-19.49	-0.73	4.84e-57	Height;
LUSC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.14	-0.45	6.37e-18	Monocyte percentage of white cells;
LUSC	cis	rs3850699	0.683	rs67646802	chr10:104303748	C/T	cg05855489	chr10:104503620	C10orf26	0.6	8.39	0.42	1.4e-15	Prostate cancer;
LUSC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg05313129	chr8:58192883	C8orf71	-0.51	-5.79	-0.3	1.64e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg00191853	chr8:101177733	SPAG1	-0.41	-6.53	-0.34	2.46e-10	Atrioventricular conduction;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03629926	chr19:8438839	ANGPTL4	0.44	6.5	0.34	2.89e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg03395511	chr6:291903	DUSP22	-0.7	-11.7	-0.54	9.52e-27	Menopause (age at onset);
LUSC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg22920501	chr2:26401640	FAM59B	-0.73	-10.61	-0.5	7.14e-23	Gut microbiome composition (summer);
LUSC	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.32	0.53	2.37e-25	Colorectal cancer;
LUSC	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg23260525	chr10:116636907	FAM160B1	-0.44	-9.43	-0.46	7.2e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs11585357	0.843	rs12095095	chr1:17625832	C/G	cg08277548	chr1:17600880	PADI3	-0.6	-6.53	-0.34	2.39e-10	Hair shape;
LUSC	cis	rs12760731	0.565	rs34593395	chr1:178129488	C/T	cg00404053	chr1:178313656	RASAL2	0.68	6.84	0.35	3.78e-11	Obesity-related traits;
LUSC	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg15934090	chr1:100435551	SLC35A3	0.48	8.32	0.41	2.2e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg06008330	chr7:65541103	ASL	-0.4	-6.28	-0.32	1.05e-9	Aortic root size;
LUSC	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.96	-0.48	1.27e-20	Mood instability;
LUSC	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-8.17	-0.41	6.64e-15	Morning vs. evening chronotype;
LUSC	cis	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg26958806	chr6:27640298	NA	0.76	6.31	0.33	8.8e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs4942242	0.602	rs61960076	chr13:44217784	T/C	cg19169023	chr15:41853346	TYRO3	-0.58	-8.85	-0.44	5.15e-17	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4363385	0.510	rs61811902	chr1:153053464	A/G	cg00922841	chr1:152955080	SPRR1A	-0.42	-6.88	-0.35	3.04e-11	Inflammatory skin disease;
LUSC	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg16342193	chr10:102329863	NA	-0.35	-6.24	-0.32	1.32e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-7.28	-0.37	2.39e-12	Mean platelet volume;
LUSC	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.69	10.49	0.5	1.94e-22	Corneal astigmatism;
LUSC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg03929089	chr4:120376271	NA	-0.76	-10.07	-0.48	5.24e-21	Coronary artery disease;
LUSC	cis	rs10193935	0.901	rs10196091	chr2:42541591	T/C	cg27598129	chr2:42591480	NA	-0.56	-7.79	-0.39	8.61e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg16989719	chr2:238392110	NA	-0.41	-6.33	-0.33	7.93e-10	Prostate cancer;
LUSC	trans	rs961253	0.556	rs6054135	chr20:6326654	C/T	cg21095983	chr6:86352623	SYNCRIP	0.45	6.78	0.35	5.62e-11	Colorectal cancer;
LUSC	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg02023728	chr11:77925099	USP35	0.5	7.27	0.37	2.53e-12	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.44e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg15704280	chr7:45808275	SEPT13	0.73	6.87	0.35	3.11e-11	Axial length;
LUSC	cis	rs7809950	1.000	rs2520265	chr7:107181231	A/G	cg23024343	chr7:107201750	COG5	-0.55	-8.55	-0.42	4.56e-16	Coronary artery disease;
LUSC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11645453	chr3:52864694	ITIH4	0.35	8.11	0.41	9.81e-15	Electroencephalogram traits;
LUSC	cis	rs62458065	0.850	rs28677012	chr7:32469811	C/A	cg20159608	chr7:32802032	NA	-0.63	-7.5	-0.38	5.76e-13	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg10174397	chr17:41150394	RPL27	0.41	6.31	0.33	8.68e-10	Mosquito bite size;
LUSC	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.35	-0.42	1.81e-15	Neuroticism;
LUSC	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg01620082	chr3:125678407	NA	-0.77	-6.9	-0.35	2.57e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.69	11.39	0.53	1.28e-25	Heart rate;
LUSC	cis	rs13114435	0.723	rs17331744	chr4:183815561	T/C	cg00486011	chr4:183851557	NA	0.31	5.75	0.3	2.06e-8	Obesity-related traits;
LUSC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg23791538	chr6:167370224	RNASET2	0.41	6.78	0.35	5.51e-11	Crohn's disease;
LUSC	cis	rs10207060	0.500	rs72992164	chr2:240711780	G/A	cg20333904	chr2:240724165	NA	-0.37	-6.25	-0.32	1.25e-9	Obesity-related traits;
LUSC	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.97	0.36	1.7e-11	Rheumatoid arthritis;
LUSC	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg17724175	chr1:150552817	MCL1	-0.33	-5.73	-0.3	2.29e-8	Tonsillectomy;
LUSC	cis	rs4692589	0.802	rs1480542	chr4:170953614	C/T	cg19918862	chr4:170955249	NA	0.32	6.15	0.32	2.22e-9	Anxiety disorder;
LUSC	trans	rs931812	0.691	rs884488	chr8:101898523	C/G	cg20993868	chr7:22813445	NA	0.53	9.76	0.47	5.94e-20	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.35	-5.7	-0.3	2.59e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.13	10.33	0.49	7.02e-22	Alzheimer's disease (late onset);
LUSC	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg17145862	chr1:211918768	LPGAT1	0.23	6.01	0.31	4.76e-9	Leprosy;
LUSC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg27572855	chr1:25598939	RHD	0.42	7.36	0.37	1.45e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg22681709	chr2:178499509	PDE11A	-0.48	-8.92	-0.44	3.19e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2944755	0.959	rs2977491	chr8:141574277	A/G	cg08444833	chr8:141574162	EIF2C2	-0.47	-6.05	-0.31	3.94e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs7086627	0.507	rs7077907	chr10:82017082	A/G	cg01528321	chr10:82214614	TSPAN14	0.59	9.05	0.44	1.22e-17	Post bronchodilator FEV1;
LUSC	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg24375607	chr4:120327624	NA	0.76	11.45	0.53	7.76e-26	Corneal astigmatism;
LUSC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21984481	chr17:79567631	NPLOC4	-0.56	-10.83	-0.51	1.23e-23	Eye color traits;
LUSC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg04287289	chr16:89883240	FANCA	0.78	13.77	0.6	1.85e-34	Vitiligo;
LUSC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg12386194	chr3:101231763	SENP7	0.63	8.73	0.43	1.22e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg26695010	chr11:65641043	EFEMP2	0.46	6.68	0.34	1.02e-10	Eosinophil percentage of white cells;
LUSC	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg23750338	chr8:142222470	SLC45A4	0.58	11.04	0.52	2.3e-24	Immature fraction of reticulocytes;
LUSC	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg14583973	chr4:3374767	RGS12	0.33	7.17	0.37	4.71e-12	Serum sulfate level;
LUSC	cis	rs9807841	0.670	rs2569512	chr19:10790162	A/G	cg17710535	chr19:10819994	QTRT1	0.4	6.43	0.33	4.47e-10	Inflammatory skin disease;
LUSC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.6	9.71	0.47	8.76e-20	Aortic root size;
LUSC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg23982607	chr1:1823379	GNB1	0.72	14.8	0.63	1.78e-38	Body mass index;
LUSC	cis	rs7605827	0.930	rs11893253	chr2:15606618	A/G	cg19274914	chr2:15703543	NA	0.45	8.55	0.42	4.36e-16	Educational attainment (years of education);
LUSC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg27284194	chr4:1044797	NA	0.35	5.98	0.31	5.85e-9	Obesity-related traits;
LUSC	trans	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg26043149	chr18:55253948	FECH	0.48	6.96	0.36	1.8e-11	Bone mineral density;
LUSC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg06494592	chr3:125709126	NA	-0.5	-5.76	-0.3	1.9e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7615316	1.000	rs6775813	chr3:142345623	A/C	cg16271453	chr3:142027066	XRN1	-0.34	-5.82	-0.3	1.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg06521331	chr12:34319734	NA	-0.42	-6.51	-0.34	2.71e-10	Bladder cancer;
LUSC	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg08000102	chr2:233561755	GIGYF2	0.68	11.42	0.53	9.96e-26	Coronary artery disease;
LUSC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg16414030	chr3:133502952	NA	-0.41	-6.47	-0.33	3.45e-10	Iron status biomarkers;
LUSC	cis	rs7615316	0.725	rs7428289	chr3:142008699	A/G	cg16271453	chr3:142027066	XRN1	-0.4	-7.05	-0.36	1.05e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg15147215	chr3:52552868	STAB1	-0.32	-6.26	-0.32	1.19e-9	Bipolar disorder;
LUSC	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg05347473	chr6:146136440	FBXO30	0.51	8.53	0.42	5.01e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9921338	0.961	rs9937269	chr16:11416679	A/G	cg00044050	chr16:11439710	C16orf75	0.49	6.53	0.34	2.38e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg23711669	chr6:146136114	FBXO30	-0.92	-17.68	-0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg03233332	chr7:66118400	NA	-0.43	-6.18	-0.32	1.83e-9	Aortic root size;
LUSC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.28	0.32	1.08e-9	Height;
LUSC	cis	rs74377301	1	rs74377301	chr7:123232495	C/T	cg03229431	chr7:123269106	ASB15	-0.61	-9.19	-0.45	4.18e-18	Left ventricular obstructive tract defect (inherited effect);
LUSC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.83	0.39	6.37e-14	Bipolar disorder;
LUSC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg23985595	chr17:80112537	CCDC57	0.31	5.97	0.31	6.13e-9	Life satisfaction;
LUSC	cis	rs10740039	0.883	rs7902632	chr10:62403569	G/T	cg18175470	chr10:62150864	ANK3	-0.47	-6.96	-0.36	1.77e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6456156	0.774	rs1012656	chr6:167525303	G/C	cg07741184	chr6:167504864	NA	-0.34	-5.91	-0.31	8.59e-9	Primary biliary cholangitis;
LUSC	cis	rs9462027	0.675	rs7755926	chr6:34722574	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.65	-0.3	3.5e-8	Systemic lupus erythematosus;
LUSC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07167872	chr1:205819463	PM20D1	-0.52	-8.3	-0.41	2.61e-15	Menarche (age at onset);
LUSC	cis	rs7589342	0.899	rs879900	chr2:106494347	A/G	cg16077055	chr2:106428750	NCK2	0.32	5.94	0.31	7.17e-9	Addiction;
LUSC	trans	rs4942242	1.000	rs9594987	chr13:44230994	C/T	cg19169023	chr15:41853346	TYRO3	0.48	7.9	0.4	4.13e-14	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-8.04	-0.4	1.57e-14	Lymphocyte counts;
LUSC	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg11584989	chr19:19387371	SF4	0.59	6.99	0.36	1.46e-11	Bipolar disorder;
LUSC	trans	rs1923243	0.546	rs11210226	chr1:73854284	A/G	ch.8.34907260F	chr8:34787718	NA	-0.4	-6.02	-0.31	4.66e-9	Migraine;
LUSC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.1	0.41	1.05e-14	Prudent dietary pattern;
LUSC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs7939886	0.920	rs7107736	chr11:55987980	C/G	cg15704280	chr7:45808275	SEPT13	0.9	6.77	0.35	5.92e-11	Myopia (pathological);
LUSC	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg12573674	chr2:1569213	NA	-0.57	-8.12	-0.41	9.19e-15	IgG glycosylation;
LUSC	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg25801113	chr15:45476975	SHF	-0.36	-7.03	-0.36	1.19e-11	Uric acid levels;
LUSC	cis	rs6599077	1.000	rs4676559	chr3:40090667	C/T	cg13683864	chr3:40499215	RPL14	-0.56	-7.22	-0.37	3.44e-12	Sleep-related phenotypes;
LUSC	cis	rs6066835	1.000	rs3746819	chr20:47307934	A/G	cg18078177	chr20:47281410	PREX1	0.77	6.37	0.33	6.12e-10	Multiple myeloma;
LUSC	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-7.05	-0.36	1.02e-11	Height;
LUSC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg15605315	chr1:45957053	TESK2	0.48	7.94	0.4	3.1e-14	High light scatter reticulocyte count;
LUSC	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg02175503	chr12:58329896	NA	0.61	9.88	0.48	2.39e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg04553112	chr3:125709451	NA	-0.51	-5.67	-0.3	3.12e-8	Blood pressure (smoking interaction);
LUSC	cis	rs9359856	0.564	rs34732313	chr6:90368380	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.88	-8.89	-0.44	3.94e-17	Bipolar disorder;
LUSC	cis	rs10992471	0.603	rs7045572	chr9:95137964	T/C	cg14631576	chr9:95140430	CENPP	-0.37	-6.5	-0.33	3e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	6.99	0.36	1.46e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg02018176	chr4:1364513	KIAA1530	-0.57	-9.9	-0.48	2e-20	Obesity-related traits;
LUSC	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg20811857	chr17:78079795	GAA	-0.32	-6.08	-0.32	3.25e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-6.25	-0.32	1.28e-9	Reticulocyte count;
LUSC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg05973401	chr12:123451056	ABCB9	0.54	6.64	0.34	1.24e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg18132916	chr6:79620363	NA	-0.38	-5.81	-0.3	1.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6961069	0.777	rs4731643	chr7:80248029	A/G	cg04458919	chr7:80252533	CD36	-0.37	-6.59	-0.34	1.7e-10	Platelet count;
LUSC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	ch.11.1652751R	chr11:76171117	C11orf30	0.49	6.28	0.32	1.07e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-5.92	-0.31	8.21e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2219968	1.000	rs13248343	chr8:78975745	A/G	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11209002	0.524	rs982131	chr1:67542360	T/C	cg02640540	chr1:67518911	SLC35D1	0.62	8.56	0.42	4.25e-16	Crohn's disease;
LUSC	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg01966878	chr4:90757139	SNCA	-0.43	-6.26	-0.32	1.22e-9	Neuroticism;
LUSC	cis	rs4664308	0.870	rs1870104	chr2:161032285	A/G	cg03641300	chr2:160917029	PLA2R1	-0.64	-10.9	-0.51	7.12e-24	Idiopathic membranous nephropathy;
LUSC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18854424	chr1:2615690	NA	0.5	10.05	0.48	6.38e-21	Ulcerative colitis;
LUSC	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg24642439	chr20:33292090	TP53INP2	0.48	7.35	0.37	1.51e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.24	0.37	3.11e-12	Bipolar disorder;
LUSC	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg12311346	chr5:56204834	C5orf35	-0.61	-9.34	-0.45	1.44e-18	Coronary artery disease;
LUSC	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg25482853	chr8:67687455	SGK3	-1.09	-15.98	-0.66	4.46e-43	Obesity-related traits;
LUSC	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	15.18	0.64	5.83e-40	Lung cancer in ever smokers;
LUSC	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.7e-32	Blood protein levels;
LUSC	trans	rs3808502	0.534	rs1529858	chr8:11145662	G/T	cg06636001	chr8:8085503	FLJ10661	0.49	7.08	0.36	8.67e-12	Neuroticism;
LUSC	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg13263323	chr15:86062960	AKAP13	-0.36	-5.99	-0.31	5.34e-9	Interstitial lung disease;
LUSC	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg26727032	chr16:67993705	SLC12A4	-0.42	-6.71	-0.34	8.2e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	9.37	0.46	1.13e-18	Motion sickness;
LUSC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.79	0.7	2.73e-50	Chronic sinus infection;
LUSC	cis	rs9815354	0.857	rs9816772	chr3:41872877	C/T	cg03022575	chr3:42003672	ULK4	0.59	6.58	0.34	1.77e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6998277	0.830	rs12543008	chr8:103603747	C/T	cg10187029	chr8:103597600	NA	0.8	12.4	0.56	2.76e-29	Migraine;
LUSC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg02569458	chr12:86230093	RASSF9	0.55	9.38	0.46	1.01e-18	Major depressive disorder;
LUSC	cis	rs6546537	0.910	rs10779953	chr2:69886757	A/G	cg10773587	chr2:69614142	GFPT1	-0.49	-7.48	-0.38	6.62e-13	Serum thyroid-stimulating hormone levels;
LUSC	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg15556689	chr8:8085844	FLJ10661	0.56	8.47	0.42	7.64e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.22	0.88	3.18e-111	Chronic sinus infection;
LUSC	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg05340658	chr4:99064831	C4orf37	0.43	6.79	0.35	5.28e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg20503657	chr10:835505	NA	0.97	12.79	0.57	9.13e-31	Eosinophil percentage of granulocytes;
LUSC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16405210	chr4:1374714	KIAA1530	-0.64	-10.33	-0.49	6.97e-22	Longevity;
LUSC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg25039879	chr17:56429692	SUPT4H1	0.72	9.79	0.47	4.65e-20	Cognitive test performance;
LUSC	cis	rs9534288	0.956	rs2094244	chr13:46605803	T/C	cg15192986	chr13:46630673	CPB2	-0.74	-11.78	-0.54	4.87e-27	Blood protein levels;
LUSC	cis	rs11229555	0.609	rs12273635	chr11:58186327	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.78	-0.39	9.19e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg05393297	chr12:53359155	NA	-0.71	-10.57	-0.5	1.05e-22	Cancer (pleiotropy);
LUSC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg02196655	chr2:10830764	NOL10	0.34	5.76	0.3	1.89e-8	Prostate cancer;
LUSC	cis	rs1113500	0.814	rs1592282	chr1:108601365	T/C	cg06207961	chr1:108661230	NA	0.3	5.65	0.3	3.53e-8	Growth-regulated protein alpha levels;
LUSC	trans	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Parkinson's disease;
LUSC	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg13256891	chr4:100009986	ADH5	-0.43	-6.0	-0.31	5.06e-9	Alcohol dependence;
LUSC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg13770153	chr20:60521292	NA	-0.61	-8.39	-0.42	1.43e-15	Body mass index;
LUSC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.88	-16.87	-0.68	1.31e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4566357	1.000	rs4566357	chr2:227922015	C/T	cg11843606	chr2:227700838	RHBDD1	0.41	5.7	0.3	2.59e-8	Coronary artery disease;
LUSC	cis	rs7759001	0.857	rs6456778	chr6:27370046	T/G	cg18711553	chr6:27366782	ZNF391	0.39	5.73	0.3	2.25e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.59	0.38	3.13e-13	Corneal astigmatism;
LUSC	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg03585969	chr10:35415529	CREM	0.65	9.4	0.46	9.06e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07677032	chr17:61819896	STRADA	0.52	8.78	0.43	8.47e-17	Prudent dietary pattern;
LUSC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.89	12.46	0.56	1.56e-29	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs17152411	1.000	rs17152411	chr10:126649516	A/G	cg07906193	chr10:126599966	NA	0.38	5.7	0.3	2.66e-8	Height;
LUSC	cis	rs8113142	0.614	rs1861173	chr19:29128097	C/A	cg04546413	chr19:29218101	NA	0.45	6.24	0.32	1.29e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg15839431	chr19:19639596	YJEFN3	-0.62	-6.47	-0.33	3.47e-10	Bipolar disorder;
LUSC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg08888203	chr3:10149979	C3orf24	0.66	9.28	0.45	2.15e-18	Alzheimer's disease;
LUSC	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.14	-0.41	8.05e-15	Retinal vascular caliber;
LUSC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07677032	chr17:61819896	STRADA	0.54	8.96	0.44	2.42e-17	Prudent dietary pattern;
LUSC	trans	rs60787346	0.883	rs2838334	chr21:45064961	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.15	0.32	2.16e-9	Coronary artery disease;
LUSC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg02807482	chr3:125708958	NA	-0.53	-7.02	-0.36	1.27e-11	Blood pressure (smoking interaction);
LUSC	cis	rs11958404	0.932	rs111802867	chr5:157424971	G/A	cg05962755	chr5:157440814	NA	0.55	6.44	0.33	4.08e-10	IgG glycosylation;
LUSC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	0.9	16.45	0.67	5.98e-45	Cognitive function;
LUSC	cis	rs60015123	1.000	rs34962575	chr12:7114074	A/C	cg26269324	chr12:6977084	TPI1	0.78	6.16	0.32	2.06e-9	Red cell distribution width;
LUSC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg13319975	chr6:146136371	FBXO30	0.48	7.26	0.37	2.74e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg14092571	chr14:90743983	NA	-0.35	-5.71	-0.3	2.45e-8	Mortality in heart failure;
LUSC	cis	rs9815354	1.000	rs56207540	chr3:41976627	G/C	cg03022575	chr3:42003672	ULK4	0.85	8.85	0.44	5.2e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg02569458	chr12:86230093	RASSF9	0.39	6.26	0.32	1.17e-9	Major depressive disorder;
LUSC	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-1.05	-15.66	-0.65	7.51e-42	Exhaled nitric oxide output;
LUSC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg22868518	chr11:507468	RNH1	-0.59	-5.8	-0.3	1.56e-8	Body mass index;
LUSC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg18099408	chr3:52552593	STAB1	-0.35	-6.01	-0.31	4.88e-9	Electroencephalogram traits;
LUSC	cis	rs12122100	0.651	rs12743228	chr1:146548275	G/A	cg03526459	chr1:146549940	NA	-0.41	-6.56	-0.34	2.04e-10	HIV-1 control;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12862548	chr5:93954431	ANKRD32;C5orf36	0.43	6.17	0.32	1.99e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg05393297	chr12:53359155	NA	-0.36	-6.46	-0.33	3.7e-10	Cancer (pleiotropy);
LUSC	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg24375607	chr4:120327624	NA	0.76	11.9	0.55	1.79e-27	Corneal astigmatism;
LUSC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06850241	chr22:41845214	NA	-0.32	-5.95	-0.31	6.61e-9	Vitiligo;
LUSC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg19774624	chr17:42201019	HDAC5	0.82	14.31	0.62	1.44e-36	Total body bone mineral density;
LUSC	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg24733560	chr20:60626293	TAF4	0.44	8.09	0.4	1.11e-14	Body mass index;
LUSC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	15.14	0.64	8.98e-40	Platelet count;
LUSC	cis	rs9796	0.621	rs2918462	chr15:41481254	A/G	cg18705301	chr15:41695430	NDUFAF1	0.5	8.93	0.44	2.91e-17	Menopause (age at onset);
LUSC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg15448220	chr1:150897856	SETDB1	-0.39	-5.73	-0.3	2.27e-8	Melanoma;
LUSC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg12311346	chr5:56204834	C5orf35	0.65	9.8	0.47	4.4e-20	Type 2 diabetes;
LUSC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.73	10.65	0.5	5.39e-23	Type 2 diabetes;
LUSC	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.9	-18.75	-0.72	4.22e-54	Ulcerative colitis;
LUSC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg17376030	chr22:41985996	PMM1	-0.46	-5.77	-0.3	1.85e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg17052675	chr2:3827356	NA	-0.58	-11.38	-0.53	1.42e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs6733011	0.600	rs1356424	chr2:99425838	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.28	-0.33	1.03e-9	Bipolar disorder;
LUSC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.57	-0.46	2.49e-19	Type 2 diabetes;
LUSC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.92	-0.35	2.31e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg17366294	chr4:99064904	C4orf37	0.58	9.85	0.47	2.87e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg01097406	chr16:89675127	NA	0.33	6.44	0.33	4.24e-10	Vitiligo;
LUSC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg06008330	chr7:65541103	ASL	0.37	5.68	0.3	2.98e-8	Aortic root size;
LUSC	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg03433033	chr1:76189801	ACADM	-0.42	-6.21	-0.32	1.57e-9	Daytime sleep phenotypes;
LUSC	cis	rs295140	1.000	rs55677233	chr2:201168695	T/C	cg04283868	chr2:201171347	SPATS2L	0.44	6.63	0.34	1.36e-10	QT interval;
LUSC	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg05714579	chr10:131428358	MGMT	-0.71	-11.38	-0.53	1.4e-25	Response to temozolomide;
LUSC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg17420585	chr12:42539391	GXYLT1	-0.34	-6.48	-0.33	3.32e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-6.22	-0.32	1.45e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs34421088	0.532	rs2736258	chr8:11170449	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	6.37	0.33	6.1e-10	Neuroticism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12152867	chr6:56708725	DST	-0.48	-6.43	-0.33	4.39e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg06197492	chr11:2016605	H19	0.41	6.71	0.34	8.55e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-9.18	-0.45	4.5e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	0.82	10.53	0.5	1.37e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16680214	chr1:154839983	KCNN3	-0.57	-11.2	-0.52	6.14e-25	Prostate cancer;
LUSC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25072359	chr17:41440525	NA	0.68	9.69	0.47	9.97e-20	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.52	0.38	4.99e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg07460842	chr6:66804631	NA	-0.47	-6.54	-0.34	2.29e-10	Blood trace element (Cu levels);
LUSC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1950500	1.000	rs1950500	chr14:24830850	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	0.48	6.29	0.33	1.02e-9	Height;
LUSC	trans	rs12543645	0.598	rs17767186	chr8:10277494	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	6.17	0.32	2.02e-9	Schizophrenia;
LUSC	cis	rs9467773	0.595	rs3846845	chr6:26444915	G/A	cg09904177	chr6:26538194	HMGN4	-0.57	-8.72	-0.43	1.3e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg09408571	chr1:101003634	GPR88	0.29	5.84	0.3	1.25e-8	Monocyte count;
LUSC	trans	rs12200782	0.769	rs10456329	chr6:26436399	G/A	cg11837749	chr1:55047332	ACOT11	0.52	6.2	0.32	1.67e-9	Small cell lung carcinoma;
LUSC	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07636037	chr3:49044803	WDR6	-0.69	-9.2	-0.45	4.05e-18	Menarche (age at onset);
LUSC	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg14154082	chr13:112174009	NA	0.38	7.76	0.39	1.03e-13	Menarche (age at onset);
LUSC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.29	0.37	2.29e-12	Platelet count;
LUSC	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg06636551	chr8:101224915	SPAG1	-0.4	-7.35	-0.37	1.52e-12	Atrioventricular conduction;
LUSC	cis	rs9392556	0.829	rs659305	chr6:4125655	A/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-6.64	-0.34	1.27e-10	Blood metabolite levels;
LUSC	cis	rs6906287	0.552	rs7740645	chr6:118929208	T/A	cg21191810	chr6:118973309	C6orf204	0.32	5.96	0.31	6.53e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.58	0.34	1.8e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6484504	0.600	rs208063	chr11:31159777	C/T	cg06552810	chr11:31128660	NA	-0.38	-6.86	-0.35	3.42e-11	Red blood cell count;
LUSC	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg24296786	chr1:45957014	TESK2	0.41	5.84	0.3	1.24e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs2398893	0.924	rs7855830	chr9:96798659	A/G	cg14459158	chr9:96720562	NA	0.29	5.71	0.3	2.47e-8	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg16362232	chr11:430036	ANO9	0.68	8.52	0.42	5.61e-16	Body mass index;
LUSC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg11062466	chr8:58055876	NA	0.5	6.45	0.33	3.85e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7715806	0.517	rs34340	chr5:74932099	A/C	cg06933384	chr5:74808293	COL4A3BP;POLK	0.39	5.65	0.3	3.41e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs660498	0.507	rs765700	chr10:27734885	G/A	cg04084786	chr10:27609163	NA	0.39	5.76	0.3	1.96e-8	Asthma (childhood onset);
LUSC	cis	rs11583043	0.708	rs36023027	chr1:101575205	T/C	cg11406453	chr1:101602562	NA	-0.4	-6.94	-0.36	2.03e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	7.96	0.4	2.8e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs61863818	0.557	rs7898743	chr10:99153540	T/G	cg20016023	chr10:99160130	RRP12	-0.27	-6.74	-0.35	6.91e-11	Monocyte percentage of white cells;
LUSC	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.82	-12.52	-0.57	9.1e-30	Body mass index;
LUSC	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg10360139	chr7:1886902	MAD1L1	-0.46	-7.16	-0.36	5.12e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.58	9.4	0.46	8.87e-19	Aortic root size;
LUSC	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg10253484	chr15:75165896	SCAMP2	-0.48	-7.24	-0.37	3.06e-12	Airflow obstruction;
LUSC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg17178900	chr1:205818956	PM20D1	-0.78	-13.36	-0.59	6.3e-33	Menarche (age at onset);
LUSC	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg19622623	chr12:86230825	RASSF9	-0.4	-5.7	-0.3	2.69e-8	Major depressive disorder;
LUSC	cis	rs11168618	0.846	rs11168599	chr12:48879951	A/C	cg24011408	chr12:48396354	COL2A1	0.37	6.02	0.31	4.7e-9	Adiponectin levels;
LUSC	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg07621104	chr11:117668040	DSCAML1	0.51	6.82	0.35	4.18e-11	Myopia;
LUSC	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg00857998	chr1:205179979	DSTYK	0.64	10.11	0.48	3.78e-21	Red blood cell count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04371528	chr3:20081516	KAT2B	0.46	6.53	0.34	2.39e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg24642844	chr7:1081250	C7orf50	-0.64	-9.19	-0.45	4.28e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.87	16.82	0.68	1.96e-46	Body mass index (adult);
LUSC	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg03563238	chr19:33554763	RHPN2	-0.4	-6.43	-0.33	4.3e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.57	10.6	0.5	7.78e-23	Type 2 diabetes;
LUSC	cis	rs9815354	0.761	rs12635286	chr3:42051836	T/C	cg03022575	chr3:42003672	ULK4	0.61	6.44	0.33	4.06e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06002616	chr8:101225028	SPAG1	-0.45	-7.28	-0.37	2.36e-12	Atrioventricular conduction;
LUSC	cis	rs71403859	0.667	rs12920890	chr16:71787588	G/A	cg08717414	chr16:71523259	ZNF19	-0.64	-7.06	-0.36	9.68e-12	Post bronchodilator FEV1;
LUSC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg24920358	chr1:40204285	PPIE	-0.61	-10.93	-0.51	5.64e-24	Blood protein levels;
LUSC	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.7	-0.73	7.16e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.52	0.42	5.63e-16	Prudent dietary pattern;
LUSC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-12.08	-0.55	3.96e-28	Alzheimer's disease;
LUSC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg05347473	chr6:146136440	FBXO30	0.56	9.8	0.47	4.41e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg08859206	chr1:53392774	SCP2	-0.44	-7.56	-0.38	3.88e-13	Monocyte count;
LUSC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	13.17	0.58	3.39e-32	Alzheimer's disease;
LUSC	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg16359550	chr11:109292809	C11orf87	0.35	6.05	0.31	3.96e-9	Schizophrenia;
LUSC	trans	rs629535	0.814	rs549643	chr8:70062884	C/T	cg21567404	chr3:27674614	NA	0.96	15.28	0.64	2.49e-40	Dupuytren's disease;
LUSC	cis	rs17125944	0.686	rs76673112	chr14:53366692	T/C	cg00686598	chr14:53173677	PSMC6	0.86	7.54	0.38	4.57e-13	Alzheimer's disease (late onset);
LUSC	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg21798802	chr22:38057573	PDXP	0.48	10.64	0.5	6.02e-23	Fat distribution (HIV);
LUSC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06634786	chr22:41940651	POLR3H	-0.54	-6.15	-0.32	2.25e-9	Vitiligo;
LUSC	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg25427524	chr10:38739819	LOC399744	-0.39	-6.38	-0.33	5.94e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg15691649	chr6:25882328	NA	-0.38	-6.21	-0.32	1.58e-9	Blood metabolite levels;
LUSC	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg05738196	chr6:26577821	NA	0.79	14.86	0.63	1.05e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23978390	chr7:1156363	C7orf50	0.53	7.48	0.38	6.61e-13	Longevity;Endometriosis;
LUSC	cis	rs7605827	0.897	rs6431694	chr2:15523031	T/C	cg19274914	chr2:15703543	NA	0.47	9.27	0.45	2.39e-18	Educational attainment (years of education);
LUSC	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg23750338	chr8:142222470	SLC45A4	-0.34	-6.39	-0.33	5.46e-10	Birth weight;
LUSC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg04362960	chr10:104952993	NT5C2	0.59	9.47	0.46	5.39e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.21	-0.37	3.66e-12	Type 2 diabetes;
LUSC	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.3	6.18	0.32	1.86e-9	Schizophrenia;
LUSC	cis	rs654950	0.783	rs639298	chr1:42001530	A/G	cg06885757	chr1:42089581	HIVEP3	-0.34	-6.52	-0.34	2.65e-10	Airway imaging phenotypes;
LUSC	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	cis	rs7904985	1.000	rs12358144	chr10:88114486	C/G	cg07322936	chr10:88137208	NA	-0.57	-7.32	-0.37	1.81e-12	Barrett's esophagus;
LUSC	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg19610905	chr11:61596333	FADS2	-0.54	-7.88	-0.4	4.52e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg18681998	chr4:17616180	MED28	0.83	14.9	0.63	7.16e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.29	-0.37	2.29e-12	Monocyte count;
LUSC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg03929089	chr4:120376271	NA	-0.94	-16.31	-0.67	2.11e-44	Height;
LUSC	cis	rs62380364	0.602	rs665324	chr5:88055517	T/C	cg22951263	chr5:87985283	NA	-0.46	-7.53	-0.38	4.89e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.53	-6.0	-0.31	5.25e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9309473	0.519	rs2421583	chr2:73898785	C/G	cg20560298	chr2:73613845	ALMS1	0.48	7.26	0.37	2.76e-12	Metabolite levels;
LUSC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08704250	chr15:31115839	NA	-0.47	-7.03	-0.36	1.17e-11	Huntington's disease progression;
LUSC	cis	rs12928939	0.815	rs8049163	chr16:71719353	C/T	cg03805757	chr16:71968109	PKD1L3	-0.4	-5.74	-0.3	2.13e-8	Post bronchodilator FEV1;
LUSC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg07777115	chr5:623756	CEP72	-0.46	-5.74	-0.3	2.09e-8	Obesity-related traits;
LUSC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-5.79	-0.3	1.66e-8	Mood instability;
LUSC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg12310025	chr6:25882481	NA	-0.41	-7.31	-0.37	1.93e-12	Height;
LUSC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg22676075	chr6:135203613	NA	0.55	8.72	0.43	1.37e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.52	10.01	0.48	8.43e-21	Monocyte count;
LUSC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.41	0.53	1.14e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg01557791	chr16:72042693	DHODH	-0.43	-6.53	-0.34	2.42e-10	Fibrinogen levels;
LUSC	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg10701640	chr17:43249399	NA	0.47	10.0	0.48	8.96e-21	Height;
LUSC	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg07810366	chr2:100720526	AFF3	0.53	9.48	0.46	4.89e-19	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07677032	chr17:61819896	STRADA	0.53	8.91	0.44	3.42e-17	Prudent dietary pattern;
LUSC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11764359	chr7:65958608	NA	0.61	9.21	0.45	3.66e-18	Aortic root size;
LUSC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12545109	0.642	rs2055984	chr8:57418332	A/G	cg09654669	chr8:57350985	NA	-0.52	-6.33	-0.33	7.94e-10	Obesity-related traits;
LUSC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.71	-0.43	1.47e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg00074818	chr8:8560427	CLDN23	0.54	9.39	0.46	9.83e-19	Obesity-related traits;
LUSC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs17433780	0.897	rs17434151	chr1:89500526	G/T	cg09516651	chr1:89888402	LOC400759	0.58	10.0	0.48	8.92e-21	Carotid intima media thickness;
LUSC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.91	-0.35	2.41e-11	Lung cancer;
LUSC	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg25237894	chr2:233734115	C2orf82	0.35	6.5	0.34	2.87e-10	Coronary artery disease;
LUSC	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18932078	chr1:2524107	MMEL1	0.29	6.26	0.32	1.18e-9	Ulcerative colitis;
LUSC	trans	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.47	-0.33	3.53e-10	Endometrial cancer;
LUSC	cis	rs4343996	0.626	rs7791898	chr7:3398325	C/T	cg21248987	chr7:3385318	SDK1	-0.37	-6.21	-0.32	1.61e-9	Motion sickness;
LUSC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.95	0.31	6.66e-9	Lung cancer;
LUSC	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg08917208	chr2:24149416	ATAD2B	0.99	10.09	0.48	4.53e-21	Lymphocyte counts;
LUSC	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg08999081	chr20:33150536	PIGU	0.37	6.81	0.35	4.46e-11	Height;
LUSC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg03354898	chr7:1950403	MAD1L1	0.34	6.67	0.34	1.09e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg18753928	chr3:113234510	CCDC52	-0.53	-8.27	-0.41	3.16e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs977987	0.800	rs3784935	chr16:75336430	T/G	cg04384234	chr16:75411784	CFDP1	-0.36	-5.68	-0.3	2.97e-8	Dupuytren's disease;
LUSC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.68	11.89	0.55	2.03e-27	Height;
LUSC	cis	rs9399401	0.626	rs13198644	chr6:142783233	A/G	cg04461802	chr6:142623433	GPR126	0.46	5.9	0.31	8.97e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs7119	0.717	rs7181283	chr15:77814544	G/A	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.31	-0.91	2.47e-130	Myeloid white cell count;
LUSC	trans	rs11088226	1.000	rs11088226	chr21:33925531	C/G	cg09050820	chr6:167586206	TCP10L2	0.53	7.23	0.37	3.37e-12	Gastritis;
LUSC	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7119038	0.818	rs715412	chr11:118684610	G/A	cg19308663	chr11:118741387	NA	0.36	6.3	0.33	9.39e-10	Sjögren's syndrome;
LUSC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18252515	chr7:66147081	NA	-0.39	-5.66	-0.3	3.22e-8	Aortic root size;
LUSC	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.88	14.94	0.63	5.21e-39	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.92	-0.48	1.72e-20	Mood instability;
LUSC	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg05855489	chr10:104503620	C10orf26	-0.48	-7.4	-0.38	1.09e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	cis	rs1355223	1.000	rs11602909	chr11:34768003	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.85	-0.31	1.14e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs911119	0.913	rs1158167	chr20:23578189	G/A	cg16589663	chr20:23618590	CST3	-0.56	-6.6	-0.34	1.57e-10	Chronic kidney disease;
LUSC	cis	rs524023	0.874	rs506338	chr11:64440920	T/C	cg07220939	chr11:64358617	SLC22A12	-0.21	-5.68	-0.3	2.86e-8	Urate levels in obese individuals;
LUSC	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.4	7.94	0.4	3.05e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.48	-0.38	6.5e-13	Depression;
LUSC	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg11502198	chr6:26597334	ABT1	0.59	9.08	0.44	9.97e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs17604090	1.000	rs67970052	chr7:29655038	C/T	cg19413766	chr7:29689036	LOC646762	-0.59	-6.84	-0.35	3.89e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs7572644	0.640	rs7593136	chr2:28017792	A/G	cg27432699	chr2:27873401	GPN1	0.56	7.26	0.37	2.75e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg13072238	chr3:49761600	GMPPB	-0.39	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg15485101	chr11:133734466	NA	0.39	7.04	0.36	1.08e-11	Childhood ear infection;
LUSC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg20821713	chr7:1055600	C7orf50	-0.47	-7.64	-0.39	2.33e-13	Longevity;Endometriosis;
LUSC	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg09455208	chr3:40491958	NA	0.56	10.12	0.48	3.46e-21	Renal cell carcinoma;
LUSC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg02018176	chr4:1364513	KIAA1530	0.45	7.45	0.38	7.89e-13	Obesity-related traits;
LUSC	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg07423050	chr13:99094983	FARP1	-0.55	-10.19	-0.49	2.04e-21	Longevity;
LUSC	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	7.0	0.36	1.44e-11	Blood metabolite levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21257117	chr11:65029643	POLA2	0.42	6.07	0.32	3.57e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg00409905	chr10:38381863	ZNF37A	-0.35	-5.98	-0.31	5.82e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12220238	1.000	rs12359456	chr10:75937994	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.89	0.35	2.71e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg20818283	chr2:191399100	TMEM194B	-0.42	-6.62	-0.34	1.48e-10	Pulse pressure;
LUSC	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.6	-13.54	-0.6	1.31e-33	Sense of smell;
LUSC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg07716408	chr11:68623521	NA	-0.3	-5.73	-0.3	2.27e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg16447950	chr5:562315	NA	-0.54	-6.69	-0.34	9.21e-11	Obesity-related traits;
LUSC	cis	rs7605827	0.930	rs7588148	chr2:15706392	G/A	cg19274914	chr2:15703543	NA	0.46	8.86	0.44	4.74e-17	Educational attainment (years of education);
LUSC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.22	0.52	5.24e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs7582720	1.000	rs77268589	chr2:203751981	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg15654264	chr1:150340011	RPRD2	0.66	10.96	0.51	4.44e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg13175981	chr1:150552382	MCL1	0.43	6.12	0.32	2.66e-9	Tonsillectomy;
LUSC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16680214	chr1:154839983	KCNN3	-0.55	-10.3	-0.49	8.87e-22	Prostate cancer;
LUSC	cis	rs6982240	0.514	rs10088801	chr8:142275801	T/C	cg00131261	chr8:142287264	NA	-0.36	-6.05	-0.31	3.99e-9	Tonsillectomy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27337868	chr5:139944050	APBB3;SLC35A4	-0.37	-5.95	-0.31	6.78e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4474465	0.850	rs4590904	chr11:78263847	C/T	cg27205649	chr11:78285834	NARS2	0.5	5.87	0.31	1.04e-8	Alzheimer's disease (survival time);
LUSC	cis	rs711245	1.000	rs848602	chr2:36778372	G/A	cg09467607	chr2:36825704	FEZ2	0.4	8.33	0.41	2.06e-15	Height;
LUSC	trans	rs116175374	0.793	rs6709207	chr2:31431064	C/T	cg15543616	chr12:5019024	KCNA1	-0.77	-6.01	-0.31	4.9e-9	Endometriosis;
LUSC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg14196790	chr5:131705035	SLC22A5	0.36	6.0	0.31	5.21e-9	Blood metabolite levels;
LUSC	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.24	-0.37	3.08e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg06521331	chr12:34319734	NA	-0.37	-6.17	-0.32	2.03e-9	Morning vs. evening chronotype;
LUSC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.73	0.35	7.51e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg05347473	chr6:146136440	FBXO30	-0.56	-9.71	-0.47	8.3e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8049040	0.609	rs4258624	chr16:71467951	C/T	cg08717414	chr16:71523259	ZNF19	0.4	5.81	0.3	1.48e-8	Blood protein levels;
LUSC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg12463550	chr7:65579703	CRCP	-0.55	-8.03	-0.4	1.68e-14	Aortic root size;
LUSC	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg02389323	chr16:88786976	FAM38A	1.17	10.58	0.5	9.66e-23	Plateletcrit;
LUSC	trans	rs4912314	1.000	rs4912314	chr1:56968477	A/G	cg13443768	chr11:65084386	CDC42EP2	-0.33	-6.14	-0.32	2.39e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.32	-0.33	8.54e-10	Lung cancer;
LUSC	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg06627628	chr2:24431161	ITSN2	0.52	7.29	0.37	2.29e-12	Asthma;
LUSC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.9	-0.31	8.98e-9	Aortic root size;
LUSC	cis	rs2953174	0.938	rs2975763	chr2:241533845	T/C	cg07929629	chr2:241523174	NA	0.46	5.98	0.31	5.59e-9	Bipolar disorder;
LUSC	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg12940439	chr1:67600707	NA	0.38	6.28	0.33	1.04e-9	Psoriasis;
LUSC	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg10857441	chr5:6722123	POLS	0.46	8.51	0.42	6.12e-16	Menopause (age at onset);
LUSC	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.78	-0.3	1.71e-8	Fear of minor pain;
LUSC	trans	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.11	0.52	1.33e-24	Mean corpuscular volume;
LUSC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg15147215	chr3:52552868	STAB1	-0.31	-6.16	-0.32	2.06e-9	Bipolar disorder;
LUSC	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg03651054	chr13:50194643	NA	0.35	5.9	0.31	8.94e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06635371	chr11:62554837	TMEM179B	0.47	6.33	0.33	8e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4363385	0.818	rs12029168	chr1:152987993	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.61	-0.38	2.91e-13	Inflammatory skin disease;
LUSC	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.87	-0.35	3.13e-11	Response to antipsychotic treatment;
LUSC	cis	rs13006833	0.694	rs291448	chr2:191177216	T/C	cg21644426	chr2:191273491	MFSD6	0.43	6.16	0.32	2.13e-9	Urinary metabolites;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02084808	chr1:172413246	PIGC;C1orf105	0.77	5.97	0.31	5.97e-9	Cognitive performance;
LUSC	cis	rs2742234	0.614	rs3026750	chr10:43607756	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.36	-6.39	-0.33	5.51e-10	Hirschsprung disease;
LUSC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg02423579	chr7:2872169	GNA12	-0.52	-7.15	-0.36	5.68e-12	Height;
LUSC	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.76	-0.39	1.07e-13	Blood metabolite levels;
LUSC	cis	rs17001868	0.568	rs3788578	chr22:40742921	C/T	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	cis	rs117352156	0.943	rs7092115	chr10:29220307	C/T	cg06394621	chr10:29236369	NA	-0.45	-5.91	-0.31	8.29e-9	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg23173402	chr1:227635558	NA	0.56	6.28	0.32	1.07e-9	Major depressive disorder;
LUSC	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg25072359	chr17:41440525	NA	0.62	7.72	0.39	1.38e-13	Menopause (age at onset);
LUSC	cis	rs6469656	1.000	rs13258529	chr8:117797989	G/A	cg24004040	chr8:117650383	NA	0.43	5.88	0.31	1.01e-8	Colorectal cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14546197	chr17:38137043	PSMD3	-0.47	-6.1	-0.32	2.94e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg16606324	chr3:10149918	C3orf24	0.59	8.55	0.42	4.49e-16	Alzheimer's disease;
LUSC	cis	rs9399401	0.667	rs12213892	chr6:142702234	A/G	cg04461802	chr6:142623433	GPR126	0.47	5.87	0.31	1.06e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg06917634	chr15:78832804	PSMA4	0.49	6.05	0.31	3.95e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9392556	0.829	rs643232	chr6:4122249	C/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.35	-5.91	-0.31	8.67e-9	Blood metabolite levels;
LUSC	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.94	9.09	0.45	9.12e-18	Body mass index;
LUSC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-1.19	-12.75	-0.57	1.35e-30	Diabetic kidney disease;
LUSC	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg09953122	chr20:23471693	CST8	-0.66	-5.76	-0.3	1.95e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1595825	0.945	rs73058818	chr2:198862600	C/T	cg10547527	chr2:198650123	BOLL	-0.49	-5.82	-0.3	1.35e-8	Ulcerative colitis;
LUSC	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12826209	chr6:26865740	GUSBL1	0.74	9.08	0.44	9.64e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg22117172	chr7:91764530	CYP51A1	-0.33	-5.93	-0.31	7.65e-9	Breast cancer;
LUSC	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg11502198	chr6:26597334	ABT1	0.59	9.24	0.45	2.86e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07080220	chr10:102295463	HIF1AN	0.65	8.97	0.44	2.25e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs909341	0.678	rs6011018	chr20:62303622	T/G	cg16989086	chr20:62203971	PRIC285	-0.53	-7.31	-0.37	1.95e-12	Atopic dermatitis;
LUSC	cis	rs8040855	0.627	rs12913859	chr15:85638418	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-5.7	-0.3	2.68e-8	Bulimia nervosa;
LUSC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg19046167	chr17:80928561	B3GNTL1	0.47	7.15	0.36	5.61e-12	Breast cancer;
LUSC	trans	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	8.89	0.44	3.78e-17	Mean corpuscular volume;
LUSC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg00074818	chr8:8560427	CLDN23	-0.55	-9.36	-0.46	1.22e-18	Obesity-related traits;
LUSC	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg00757033	chr12:89920650	WDR51B	0.6	10.35	0.49	5.9e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg05110241	chr16:68378359	PRMT7	-0.81	-8.76	-0.43	1.02e-16	Schizophrenia;
LUSC	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg04455712	chr21:45112962	RRP1B	0.46	8.58	0.43	3.51e-16	Mean corpuscular volume;
LUSC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg16647868	chr5:131706066	SLC22A5	-0.38	-5.67	-0.3	3.17e-8	Blood metabolite levels;
LUSC	trans	rs62103177	0.564	rs1864529	chr18:77748975	G/A	cg05926928	chr17:57297772	GDPD1	-0.91	-10.34	-0.49	6.39e-22	Opioid sensitivity;
LUSC	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg08000102	chr2:233561755	GIGYF2	-0.65	-11.07	-0.52	1.78e-24	Coronary artery disease;
LUSC	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg08601574	chr20:25228251	PYGB	-0.42	-6.51	-0.34	2.81e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.92	-0.44	3.02e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs965469	1.000	rs6051703	chr20:3252347	A/T	cg25506879	chr20:3388711	C20orf194	-0.54	-6.31	-0.33	8.79e-10	IFN-related cytopenia;
LUSC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg21433313	chr16:3507492	NAT15	-0.81	-8.94	-0.44	2.7e-17	Tuberculosis;
LUSC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-11.98	-0.55	9.35e-28	Platelet count;
LUSC	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	6.95	0.36	1.93e-11	Colorectal cancer;
LUSC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-0.99	-17.65	-0.69	9.8e-50	Coronary artery disease;
LUSC	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg03806693	chr22:41940476	POLR3H	-0.96	-13.04	-0.58	1.08e-31	Vitiligo;
LUSC	cis	rs10504073	0.669	rs341799	chr8:50036574	A/G	cg00325661	chr8:49890786	NA	0.59	9.63	0.47	1.56e-19	Blood metabolite ratios;
LUSC	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.9	-0.35	2.56e-11	Neuroticism;
LUSC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg15556689	chr8:8085844	FLJ10661	0.8	13.46	0.59	2.74e-33	Systolic blood pressure;
LUSC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	7.67	0.39	1.94e-13	Prudent dietary pattern;
LUSC	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg15839431	chr19:19639596	YJEFN3	0.66	7.27	0.37	2.65e-12	Bipolar disorder;
LUSC	cis	rs6733011	0.628	rs10188156	chr2:99465875	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-5.71	-0.3	2.51e-8	Bipolar disorder;
LUSC	cis	rs1113500	0.862	rs2336129	chr1:108640669	A/G	cg06207961	chr1:108661230	NA	-0.4	-7.51	-0.38	5.44e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.48	-0.67	4.45e-45	Monocyte count;
LUSC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.7	10.7	0.51	3.64e-23	Aortic root size;
LUSC	cis	rs11158026	0.757	rs7159933	chr14:55441641	C/A	cg04306507	chr14:55594613	LGALS3	0.38	7.46	0.38	7.57e-13	Parkinson's disease;
LUSC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23158103	chr7:148848205	ZNF398	-0.49	-7.93	-0.4	3.26e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg00310523	chr12:86230176	RASSF9	0.52	9.81	0.47	3.84e-20	Major depressive disorder;
LUSC	cis	rs3126085	1.000	rs3126092	chr1:152307955	T/A	cg26876637	chr1:152193138	HRNR	-0.44	-5.7	-0.3	2.68e-8	Atopic dermatitis;
LUSC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.09	-0.55	3.78e-28	Mean corpuscular volume;
LUSC	cis	rs662064	0.748	rs2480777	chr1:10597551	C/T	cg20482658	chr1:10539492	PEX14	0.32	6.45	0.33	3.89e-10	Asthma;
LUSC	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg27411982	chr8:10470053	RP1L1	0.4	6.1	0.32	2.91e-9	Myopia (pathological);
LUSC	trans	rs11088226	0.645	rs7281844	chr21:33932435	T/C	cg09050820	chr6:167586206	TCP10L2	0.76	9.85	0.47	2.91e-20	Gastritis;
LUSC	cis	rs273573	1.000	rs175398	chr11:30930393	T/G	cg06552810	chr11:31128660	NA	0.32	5.69	0.3	2.78e-8	Total body bone mineral density;
LUSC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.29	-0.37	2.32e-12	Personality dimensions;
LUSC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.47	7.45	0.38	7.79e-13	Menarche (age at onset);
LUSC	cis	rs2976388	0.647	rs2572898	chr8:143782274	G/C	cg17252645	chr8:143867129	LY6D	0.38	6.68	0.34	9.86e-11	Urinary tract infection frequency;
LUSC	cis	rs12519773	0.526	rs7714485	chr5:92515301	A/C	cg18783429	chr5:92414398	NA	0.33	7.11	0.36	7.23e-12	Migraine;
LUSC	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg10326726	chr10:51549505	MSMB	-0.35	-6.0	-0.31	5.09e-9	Prostate-specific antigen levels;
LUSC	cis	rs6901250	0.523	rs641338	chr6:117086265	C/A	cg12892004	chr6:117198278	RFX6	0.34	6.24	0.32	1.3e-9	C-reactive protein levels;
LUSC	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.68	-0.47	1.07e-19	Multiple sclerosis;
LUSC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg24733560	chr20:60626293	TAF4	0.44	8.11	0.41	9.46e-15	Body mass index;
LUSC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg09092052	chr15:45571596	NA	0.47	6.55	0.34	2.22e-10	Glomerular filtration rate;
LUSC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg23093090	chr10:104574429	C10orf26	-0.36	-6.62	-0.34	1.42e-10	Arsenic metabolism;
LUSC	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-1.45	-17.16	-0.68	9.32e-48	Plateletcrit;
LUSC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs73206853	0.841	rs73191826	chr12:110943001	G/T	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	7.83e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs11039798	1.000	rs6485856	chr11:48556298	G/C	cg15704280	chr7:45808275	SEPT13	0.69	6.56	0.34	2.06e-10	Axial length;
LUSC	cis	rs2637266	0.783	rs846645	chr10:78516000	A/G	cg18941641	chr10:78392320	NA	0.4	7.23	0.37	3.3e-12	Pulmonary function;
LUSC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg22143856	chr6:28129313	ZNF389	0.41	5.8	0.3	1.53e-8	Depression;
LUSC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg11843238	chr5:131593191	PDLIM4	-0.38	-6.07	-0.32	3.54e-9	Breast cancer;
LUSC	trans	rs62238980	0.522	rs117129307	chr22:32519810	A/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.52	-5.98	-0.31	5.76e-9	Childhood ear infection;
LUSC	trans	rs4714291	0.963	rs847777	chr6:40055754	C/T	cg02267698	chr19:7991119	CTXN1	0.53	7.42	0.38	9.76e-13	Strep throat;
LUSC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.46	-6.89	-0.35	2.79e-11	Melanoma;
LUSC	cis	rs12681287	0.517	rs68008113	chr8:87520894	C/A	cg27223183	chr8:87520930	FAM82B	-0.55	-7.23	-0.37	3.3e-12	Caudate activity during reward;
LUSC	cis	rs2294693	0.947	rs9296351	chr6:40988102	T/C	cg14769373	chr6:40998127	UNC5CL	-0.54	-8.03	-0.4	1.71e-14	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-7.47	-0.38	6.85e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg07382826	chr16:28625726	SULT1A1	0.28	5.97	0.31	5.93e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs4499344	0.921	rs12973855	chr19:33085395	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.59	-7.54	-0.38	4.59e-13	Mean platelet volume;
LUSC	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.5e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	10.94	0.51	5.25e-24	Response to antipsychotic treatment;
LUSC	cis	rs983392	0.709	rs56273223	chr11:59984676	A/C	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.16	-0.32	2.1e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-11.89	-0.55	2.01e-27	Body mass index;
LUSC	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	10.74	0.51	2.53e-23	Response to antipsychotic treatment;
LUSC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg14004847	chr7:1930337	MAD1L1	-0.62	-10.19	-0.49	2.1e-21	Schizophrenia;
LUSC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg20821713	chr7:1055600	C7orf50	-0.49	-6.75	-0.35	6.63e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg05283184	chr6:79620031	NA	-0.57	-12.12	-0.55	2.99e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs6714710	0.603	rs12104810	chr2:98443658	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7432375	0.610	rs60574021	chr3:136520281	C/G	cg15507776	chr3:136538369	TMEM22	0.44	7.37	0.37	1.31e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2067615	0.579	rs1922438	chr12:107085171	C/G	cg15890332	chr12:107067104	RFX4	0.33	5.98	0.31	5.83e-9	Heart rate;
LUSC	cis	rs7143963	1.000	rs7153002	chr14:103323915	C/T	cg21920469	chr14:103375193	NA	-0.45	-5.67	-0.3	3.07e-8	Body mass index;
LUSC	cis	rs17001868	0.568	rs6001894	chr22:40779197	T/C	cg07138101	chr22:40742427	ADSL	0.62	7.61	0.38	2.76e-13	Mammographic density (dense area);
LUSC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg15147215	chr3:52552868	STAB1	-0.32	-6.3	-0.33	9.32e-10	Electroencephalogram traits;
LUSC	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.86	13.89	0.61	6e-35	Coronary artery disease;
LUSC	cis	rs113835537	0.529	rs57691879	chr11:66236604	C/T	cg24851651	chr11:66362959	CCS	0.54	8.27	0.41	3.33e-15	Airway imaging phenotypes;
LUSC	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg01689657	chr7:91764605	CYP51A1	0.34	6.09	0.32	3.12e-9	Breast cancer;
LUSC	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg18209359	chr17:80159595	CCDC57	0.38	6.41	0.33	5.03e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg27068330	chr11:65405492	SIPA1	-0.75	-10.33	-0.49	7.02e-22	Acne (severe);
LUSC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.88	0.58	4.32e-31	Platelet count;
LUSC	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	8.87	0.44	4.41e-17	Iron status biomarkers;
LUSC	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg24130564	chr14:104152367	KLC1	0.45	6.25	0.32	1.25e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg22117172	chr7:91764530	CYP51A1	0.33	5.84	0.3	1.24e-8	Breast cancer;
LUSC	cis	rs6740322	0.748	rs6732337	chr2:43462822	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.52	6.91	0.35	2.53e-11	Coronary artery disease;
LUSC	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.07	0.48	5.24e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26695780	chr7:66021476	LOC493754	-0.72	-6.07	-0.32	3.41e-9	Cognitive performance;
LUSC	cis	rs10189230	0.967	rs11692482	chr2:222352405	C/T	cg14652038	chr2:222343519	EPHA4	0.32	5.79	0.3	1.66e-8	Urate levels in lean individuals;
LUSC	cis	rs7809950	0.678	rs62483641	chr7:106901741	T/C	cg23024343	chr7:107201750	COG5	-0.66	-10.06	-0.48	5.78e-21	Coronary artery disease;
LUSC	cis	rs3743266	0.613	rs12442393	chr15:60734460	C/G	cg21667061	chr15:60772094	NARG2	-0.37	-6.13	-0.32	2.55e-9	Menarche (age at onset);
LUSC	cis	rs7072216	0.922	rs4488133	chr10:100159136	A/T	cg26618903	chr10:100175079	PYROXD2	0.31	6.18	0.32	1.85e-9	Metabolite levels;
LUSC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.21e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg20406979	chr6:167373233	NA	0.25	5.81	0.3	1.49e-8	Crohn's disease;
LUSC	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg04586622	chr2:25135609	ADCY3	0.4	8.29	0.41	2.8e-15	Body mass index in non-asthmatics;
LUSC	cis	rs7582720	1.000	rs115810193	chr2:203943168	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.65	0.43	2.2e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg13736514	chr6:26305472	NA	-0.48	-9.49	-0.46	4.46e-19	Educational attainment;
LUSC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg02018176	chr4:1364513	KIAA1530	0.46	7.74	0.39	1.17e-13	Obesity-related traits;
LUSC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2279817	0.780	rs12737453	chr1:18006107	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.2	-0.32	1.71e-9	Neuroticism;
LUSC	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.91	-0.4	3.77e-14	Morning vs. evening chronotype;
LUSC	cis	rs977987	0.788	rs7184525	chr16:75437186	A/G	cg03315344	chr16:75512273	CHST6	0.48	8.94	0.44	2.8e-17	Dupuytren's disease;
LUSC	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.37	-9.13	-0.45	6.74e-18	Diastolic blood pressure;
LUSC	cis	rs1775715	0.966	rs1639132	chr10:32301260	G/A	cg04359828	chr10:32216031	ARHGAP12	-0.36	-6.08	-0.32	3.27e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg05110241	chr16:68378359	PRMT7	-0.54	-6.3	-0.33	9.39e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.48	-0.33	3.28e-10	Platelet count;
LUSC	cis	rs6681460	0.649	rs6691033	chr1:67007429	C/T	cg02459107	chr1:67143332	SGIP1	0.39	6.56	0.34	2.03e-10	Presence of antiphospholipid antibodies;
LUSC	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17691542	chr6:26056736	HIST1H1C	0.84	11.25	0.52	4.11e-25	Iron status biomarkers;
LUSC	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg22153463	chr1:85462885	MCOLN2	-0.62	-8.01	-0.4	1.89e-14	Serum sulfate level;
LUSC	trans	rs9929218	0.954	rs2961	chr16:68818903	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-11.19	-0.52	6.92e-25	Colorectal cancer;
LUSC	cis	rs1376877	0.519	rs113217304	chr2:204281120	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.49	6.29	0.33	9.96e-10	Subclinical atherosclerosis traits (other);
LUSC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg03233332	chr7:66118400	NA	0.42	5.98	0.31	5.61e-9	Aortic root size;
LUSC	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg01884057	chr2:25150051	NA	0.42	9.13	0.45	6.57e-18	Body mass index;
LUSC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.84	-0.3	1.26e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1979679	0.608	rs4931082	chr12:28720020	G/A	cg13890972	chr12:28721907	NA	-0.43	-6.04	-0.31	4.05e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	trans	rs877282	0.842	rs12357963	chr10:757562	C/T	cg22713356	chr15:30763199	NA	1.03	13.61	0.6	7.56e-34	Uric acid levels;
LUSC	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17467752	chr17:38218738	THRA	0.77	12.45	0.56	1.7e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14159672	chr1:205819179	PM20D1	-0.78	-14.79	-0.63	2.07e-38	Monocyte percentage of white cells;
LUSC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg27535305	chr1:53392650	SCP2	-0.41	-8.1	-0.41	1.05e-14	Monocyte count;
LUSC	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg09941381	chr10:64027924	RTKN2	-0.38	-7.04	-0.36	1.11e-11	Rheumatoid arthritis;
LUSC	cis	rs6961069	0.777	rs4545029	chr7:80252518	T/G	cg04458919	chr7:80252533	CD36	0.36	6.47	0.33	3.52e-10	Platelet count;
LUSC	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14169450	chr9:139327907	INPP5E	-0.46	-8.76	-0.43	1.01e-16	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.81	14.53	0.62	2.1e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg05347473	chr6:146136440	FBXO30	0.5	8.39	0.42	1.35e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs870825	0.616	rs56232457	chr4:185628153	T/G	cg04058563	chr4:185651563	MLF1IP	0.88	13.27	0.59	1.4e-32	Blood protein levels;
LUSC	cis	rs73206853	0.841	rs56324794	chr12:111086449	T/A	cg12870014	chr12:110450643	ANKRD13A	0.7	7.29	0.37	2.21e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg01879757	chr17:41196368	BRCA1	0.46	6.96	0.36	1.77e-11	Menopause (age at onset);
LUSC	cis	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.79	-0.3	1.66e-8	Eotaxin levels;
LUSC	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg00540400	chr15:79124168	NA	-0.48	-8.43	-0.42	1.04e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9473147	0.516	rs10948363	chr6:47487762	A/G	cg20196966	chr6:47445060	CD2AP	0.41	5.79	0.3	1.66e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg08000102	chr2:233561755	GIGYF2	-0.69	-11.44	-0.53	8.87e-26	Coronary artery disease;
LUSC	cis	rs7503807	0.967	rs9915162	chr17:78614326	T/C	cg09596252	chr17:78655493	RPTOR	0.44	7.53	0.38	4.77e-13	Obesity;
LUSC	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg04176472	chr15:90893244	GABARAPL3	-0.34	-6.19	-0.32	1.8e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.63	0.47	1.5700000000000001e-19	Coffee consumption (cups per day);
LUSC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg26380479	chr7:97908229	NA	-0.27	-6.06	-0.31	3.67e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg10596483	chr8:143751796	JRK	0.61	9.31	0.45	1.73e-18	Schizophrenia;
LUSC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-11.11	-0.52	1.25e-24	Chronic sinus infection;
LUSC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg21918786	chr6:109611834	NA	-0.42	-7.28	-0.37	2.36e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs6977660	0.714	rs6945753	chr7:19814255	A/G	cg05791153	chr7:19748676	TWISTNB	0.7	7.45	0.38	8.29e-13	Thyroid stimulating hormone;
LUSC	cis	rs4964805	0.657	rs11111783	chr12:104188523	A/G	cg02344784	chr12:104178138	NT5DC3	0.46	8.9	0.44	3.59e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs17095355	0.818	rs61881638	chr10:111863396	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.59	-6.84	-0.35	3.69e-11	Biliary atresia;
LUSC	cis	rs870825	0.929	rs72689265	chr4:185590982	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	11.29	0.53	2.87e-25	Blood protein levels;
LUSC	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg22676075	chr6:135203613	NA	-0.65	-10.27	-0.49	1.13e-21	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg03676636	chr4:99064102	C4orf37	0.3	6.03	0.31	4.28e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg06618935	chr21:46677482	NA	-0.34	-6.53	-0.34	2.49e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs3857536	0.813	rs2040594	chr6:66943966	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.04	-0.31	4.02e-9	Blood trace element (Cu levels);
LUSC	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	trans	rs9409565	0.586	rs9409547	chr9:97212196	A/C	cg05679027	chr9:99775184	HIATL2	-0.46	-6.05	-0.31	3.78e-9	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs155346	1.000	rs265148	chr5:139400779	T/C	cg01090482	chr5:139365336	NRG2	-0.36	-5.93	-0.31	7.65e-9	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg05025164	chr4:1340916	KIAA1530	-0.5	-7.63	-0.39	2.52e-13	Obesity-related traits;
LUSC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg21782813	chr7:2030301	MAD1L1	-0.38	-6.35	-0.33	7.12e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg20573242	chr4:122745356	CCNA2	0.44	6.77	0.35	5.65e-11	Type 2 diabetes;
LUSC	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg05738196	chr6:26577821	NA	-0.46	-5.76	-0.3	1.88e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg01943577	chr7:158741284	NA	-0.4	-5.7	-0.3	2.58e-8	Height;
LUSC	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.24	-0.37	3.14e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-1.05	-15.24	-0.64	3.49e-40	Vitiligo;
LUSC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg21699342	chr2:239360505	ASB1	0.58	10.75	0.51	2.47e-23	Multiple system atrophy;
LUSC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg05768032	chr16:30646687	NA	0.4	5.92	0.31	7.93e-9	Multiple myeloma;
LUSC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.59	-0.38	3.13e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9314323	0.729	rs7007256	chr8:26203081	G/A	cg13160058	chr8:26243215	BNIP3L	-0.37	-6.56	-0.34	2.02e-10	Red cell distribution width;
LUSC	cis	rs860295	0.812	rs10908481	chr1:155713650	T/G	cg08949192	chr1:155289623	RUSC1;FDPS	-0.34	-5.75	-0.3	2.03e-8	Body mass index;
LUSC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg18230493	chr5:56204884	C5orf35	-0.93	-13.72	-0.6	2.66e-34	Initial pursuit acceleration;
LUSC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	6.16	0.32	2.06e-9	Cognitive test performance;
LUSC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-1.11	-24.8	-0.81	9.96e-78	Height;
LUSC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg13531842	chr10:38383804	ZNF37A	-0.46	-7.19	-0.37	4.35e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.69	10.51	0.5	1.65e-22	Corneal astigmatism;
LUSC	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg24642439	chr20:33292090	TP53INP2	0.5	7.5	0.38	5.67e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg24642844	chr7:1081250	C7orf50	-0.69	-9.84	-0.47	3.18e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg14129931	chr18:74513950	NA	0.43	6.24	0.32	1.35e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LUSC	cis	rs7561273	0.609	rs10197527	chr2:24352398	A/C	cg06627628	chr2:24431161	ITSN2	-0.52	-6.99	-0.36	1.55e-11	Quantitative traits;
LUSC	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.63	10.7	0.51	3.73e-23	Blood metabolite ratios;
LUSC	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg18705301	chr15:41695430	NDUFAF1	0.45	7.88	0.4	4.51e-14	Menopause (age at onset);
LUSC	cis	rs11208691	0.513	rs10443260	chr1:66128866	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.93	0.31	7.6e-9	Lymphocyte percentage of white cells;
LUSC	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg14343924	chr8:8086146	FLJ10661	0.45	6.19	0.32	1.77e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg05729581	chr11:3078854	CARS	-0.56	-8.5	-0.42	6.4e-16	Longevity;
LUSC	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg09307838	chr4:120376055	NA	0.67	9.35	0.46	1.28e-18	Corneal astigmatism;
LUSC	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg10434728	chr15:90938212	IQGAP1	0.43	8.66	0.43	1.98e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.44	6.6	0.34	1.66e-10	Endometrial cancer;
LUSC	cis	rs12220238	1.000	rs7907801	chr10:75976638	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.3	0.37	2.12e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg00310523	chr12:86230176	RASSF9	-0.43	-7.91	-0.4	3.85e-14	Major depressive disorder;
LUSC	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg13256891	chr4:100009986	ADH5	0.42	5.98	0.31	5.85e-9	Alcohol dependence;
LUSC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg14552801	chr7:65878734	NA	0.45	6.53	0.34	2.5e-10	Aortic root size;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	0.94	18.97	0.72	5.91e-55	Menarche (age at onset);
LUSC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.96	-13.16	-0.58	3.9e-32	Lung cancer in ever smokers;
LUSC	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11748023	0.531	rs155947	chr5:139520556	C/T	cg26211634	chr5:139558579	C5orf32	0.34	6.17	0.32	2e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs672059	1.000	rs1760624	chr1:183158552	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.98	0.4	2.42e-14	Hypertriglyceridemia;
LUSC	cis	rs2840044	0.534	rs167691	chr17:33885826	G/A	cg05299278	chr17:33885742	SLFN14	0.34	7.77	0.39	9.6e-14	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs9815354	0.812	rs113772069	chr3:41933389	T/C	cg03022575	chr3:42003672	ULK4	0.82	8.55	0.42	4.49e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg22508957	chr16:3507546	NAT15	0.68	11.08	0.52	1.69e-24	Tuberculosis;
LUSC	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg17623882	chr6:41773611	USP49	0.61	10.1	0.48	4.13e-21	Menarche (age at onset);
LUSC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg04756594	chr16:24857601	SLC5A11	-0.38	-6.34	-0.33	7.66e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4285028	0.747	rs3732407	chr3:121416623	G/C	cg11130432	chr3:121712080	ILDR1	-0.59	-8.53	-0.42	5.25e-16	Multiple sclerosis;
LUSC	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.64	-0.39	2.3e-13	Blood metabolite levels;
LUSC	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	6.2	0.32	1.68e-9	Educational attainment;
LUSC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg24562669	chr7:97807699	LMTK2	0.35	6.06	0.31	3.63e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3760982	1.000	rs3760983	chr19:44286660	C/T	cg11993925	chr19:44307056	LYPD5	-0.28	-6.2	-0.32	1.65e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg05855489	chr10:104503620	C10orf26	-0.68	-10.06	-0.48	5.7e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg08017756	chr2:100939284	LONRF2	-0.45	-8.61	-0.43	2.9e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs17150703	0.630	rs12545481	chr8:9747377	G/A	cg06636001	chr8:8085503	FLJ10661	0.51	6.41	0.33	4.89e-10	Obesity (early onset extreme);
LUSC	cis	rs1808579	0.904	rs1618725	chr18:21126952	C/T	cg14672496	chr18:21087552	C18orf8	0.37	6.54	0.34	2.34e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg07777115	chr5:623756	CEP72	-0.46	-5.93	-0.31	7.72e-9	Obesity-related traits;
LUSC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg09796270	chr17:17721594	SREBF1	-0.4	-6.98	-0.36	1.56e-11	Total body bone mineral density;
LUSC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg23719950	chr11:63933701	MACROD1	-0.63	-8.13	-0.41	8.2e-15	Mean platelet volume;
LUSC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg09904177	chr6:26538194	HMGN4	0.42	6.14	0.32	2.41e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg12002119	chr2:101014098	CHST10	0.36	6.13	0.32	2.41e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg15103426	chr22:29168792	CCDC117	0.53	6.47	0.33	3.54e-10	Lymphocyte counts;
LUSC	trans	rs7951105	0.737	rs976909	chr11:39247793	C/G	cg24085930	chr3:21832523	NA	0.49	6.06	0.31	3.58e-9	Free thyroxine concentration;
LUSC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08109568	chr15:31115862	NA	0.48	6.64	0.34	1.3e-10	Huntington's disease progression;
LUSC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.75	-7.22	-0.37	3.53e-12	Cerebrospinal P-tau181p levels;
LUSC	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-8.09	-0.4	1.15e-14	Triglycerides;
LUSC	cis	rs9463078	0.506	rs4714820	chr6:44736737	T/A	cg25276700	chr6:44698697	NA	0.3	6.3	0.33	9.28e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs11677416	1.000	rs2856837	chr2:113541925	G/A	cg27083787	chr2:113543245	IL1A	0.47	7.39	0.37	1.17e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08109568	chr15:31115862	NA	-0.59	-8.22	-0.41	4.55e-15	Huntington's disease progression;
LUSC	cis	rs10266483	0.774	rs642909	chr7:63770321	T/C	cg24201672	chr7:64023550	ZNF680	-0.47	-5.93	-0.31	7.74e-9	Response to statin therapy;
LUSC	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg00432049	chr6:150390894	ULBP3	-0.27	-5.7	-0.3	2.7e-8	Alopecia areata;
LUSC	cis	rs9309473	0.607	rs58962779	chr2:73555801	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-8.24	-0.41	4.1e-15	Metabolite levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05787193	chr1:84543369	PRKACB	-0.41	-6.46	-0.33	3.8e-10	Electrocardiographic conduction measures;
LUSC	cis	rs240764	0.658	rs9322212	chr6:101248474	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-6.65	-0.34	1.18e-10	Neuroticism;
LUSC	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.13	17.23	0.69	4.9e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2997447	0.846	rs3008419	chr1:26402820	A/C	cg19633962	chr1:26362018	EXTL1	-0.49	-5.76	-0.3	1.92e-8	QRS complex (12-leadsum);
LUSC	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg20701182	chr2:24300061	SF3B14	0.74	7.33	0.37	1.77e-12	Lymphocyte counts;
LUSC	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg08085267	chr17:45401833	C17orf57	-0.46	-6.54	-0.34	2.3e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg19683494	chr5:74908142	NA	-0.57	-7.06	-0.36	9.82e-12	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LUSC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs71403859	0.730	rs17355804	chr16:71717214	A/G	cg08717414	chr16:71523259	ZNF19	-0.65	-7.28	-0.37	2.47e-12	Post bronchodilator FEV1;
LUSC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.93	12.86	0.58	5.16e-31	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.72	11.91	0.55	1.68e-27	Monocyte count;
LUSC	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.6	-0.43	3.16e-16	Total cholesterol levels;
LUSC	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.22	0.52	5.39e-25	Morning vs. evening chronotype;
LUSC	cis	rs7760535	0.597	rs9320368	chr6:111904737	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-8.73	-0.43	1.23e-16	Metabolic traits;
LUSC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.89	15.83	0.65	1.73e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg14675211	chr2:100938903	LONRF2	0.37	5.82	0.3	1.4e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs738322	0.511	rs2267371	chr22:38577119	T/G	cg25457927	chr22:38595422	NA	-0.37	-7.11	-0.36	6.88e-12	Cutaneous nevi;
LUSC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.53	-8.37	-0.42	1.58e-15	Platelet count;
LUSC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg08219700	chr8:58056026	NA	0.45	5.84	0.3	1.24e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs59104589	0.617	rs16843671	chr2:242374358	T/C	cg14842376	chr2:242211374	HDLBP	0.53	6.1	0.32	2.97e-9	Fibrinogen levels;
LUSC	cis	rs12472274	0.529	rs11677996	chr2:239118007	A/G	cg17459225	chr2:239074497	NA	0.54	7.32	0.37	1.82e-12	Phospholipid levels (plasma);
LUSC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.9	0.35	2.56e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg02018176	chr4:1364513	KIAA1530	0.45	7.71	0.39	1.42e-13	Obesity-related traits;
LUSC	cis	rs7923609	0.740	rs10761784	chr10:65308750	A/T	cg01631684	chr10:65280961	REEP3	-0.42	-6.44	-0.33	4.27e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg18404041	chr3:52824283	ITIH1	-0.53	-9.01	-0.44	1.63e-17	Schizophrenia;
LUSC	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg23840854	chr1:161414152	NA	-0.9	-11.46	-0.53	7e-26	Rheumatoid arthritis;
LUSC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg07395648	chr5:131743802	NA	-0.43	-7.25	-0.37	2.94e-12	Blood metabolite levels;
LUSC	trans	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg01620082	chr3:125678407	NA	-0.59	-6.38	-0.33	5.96e-10	Depression;
LUSC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg15147215	chr3:52552868	STAB1	-0.35	-6.96	-0.36	1.86e-11	Bipolar disorder;
LUSC	cis	rs3106136	0.967	rs11097409	chr4:95168515	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.11	-0.32	2.76e-9	Capecitabine sensitivity;
LUSC	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg02196655	chr2:10830764	NOL10	0.34	5.79	0.3	1.64e-8	Prostate cancer;
LUSC	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg20026190	chr17:76395443	PGS1	0.46	8.13	0.41	8.42e-15	HDL cholesterol levels;
LUSC	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.71	0.3	2.49e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg13010199	chr12:38710504	ALG10B	0.47	7.03	0.36	1.14e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg05347473	chr6:146136440	FBXO30	0.44	7.57	0.38	3.75e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7804356	0.813	rs76438067	chr7:26911904	C/T	cg03456212	chr7:26904342	SKAP2	-0.6	-6.68	-0.34	9.83e-11	Type 1 diabetes;
LUSC	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	9.08	0.44	9.91e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg23630131	chr7:65973040	NA	0.2	5.73	0.3	2.29e-8	Aortic root size;
LUSC	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg18721089	chr20:30220636	NA	-0.37	-5.76	-0.3	1.86e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg20818283	chr2:191399100	TMEM194B	0.45	6.98	0.36	1.58e-11	Pulse pressure;
LUSC	cis	rs7827545	1.000	rs6578232	chr8:135565690	G/A	cg17885191	chr8:135476712	NA	0.56	8.35	0.42	1.87e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg15395560	chr15:45543142	SLC28A2	0.34	5.9	0.31	9.13e-9	Uric acid levels;
LUSC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.89	-0.31	9.55e-9	Platelet count;
LUSC	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.14	-0.32	2.35e-9	Coronary artery disease;
LUSC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.7	13.16	0.58	3.88e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg22549504	chr19:17448937	GTPBP3	0.55	7.06	0.36	9.83e-12	Systemic lupus erythematosus;
LUSC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-1.17	-16.86	-0.68	1.46e-46	Breast cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg00930347	chr6:110012366	AKD1;FIG4	0.37	6.01	0.31	4.77e-9	Triglycerides;
LUSC	cis	rs6681460	0.966	rs4655646	chr1:67094336	G/A	cg02459107	chr1:67143332	SGIP1	0.46	8.54	0.42	4.73e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg19592336	chr6:28129416	ZNF389	0.51	6.58	0.34	1.8e-10	Parkinson's disease;
LUSC	cis	rs644148	0.693	rs2686772	chr19:44999729	T/C	cg15540054	chr19:45004280	ZNF180	-0.55	-7.79	-0.39	8.35e-14	Personality dimensions;
LUSC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg13319975	chr6:146136371	FBXO30	0.51	7.64	0.39	2.31e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg18225595	chr11:63971243	STIP1	-0.46	-5.92	-0.31	8.04e-9	Mean platelet volume;
LUSC	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg24851651	chr11:66362959	CCS	-0.54	-9.7	-0.47	9.09e-20	HIV-1 susceptibility;
LUSC	trans	rs7849782	0.664	rs1407875	chr9:104391744	A/G	cg22914338	chr19:14376960	NA	0.26	6.41	0.33	4.87e-10	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.48	0.56	1.31e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.9	16.97	0.68	5.1e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.14e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	5.65	0.3	3.5e-8	Menarche (age at onset);
LUSC	cis	rs7572644	0.699	rs1841068	chr2:28191629	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-7.01	-0.36	1.34e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg24459738	chr19:57751996	ZNF805	-0.51	-7.53	-0.38	4.85e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg01503450	chr10:980765	NA	-0.38	-5.7	-0.3	2.68e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs12986413	1.000	rs11882273	chr19:2173836	T/C	cg09261902	chr19:2140048	AP3D1	0.31	5.93	0.31	7.5e-9	Height;
LUSC	cis	rs7771547	0.642	rs628213	chr6:36508646	T/C	cg07856975	chr6:36356162	ETV7	0.37	6.49	0.33	3.18e-10	Platelet distribution width;
LUSC	cis	rs10203711	0.901	rs907101	chr2:239564458	T/A	cg14580085	chr2:239553406	NA	0.4	6.95	0.36	1.95e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg08558340	chr7:100472263	SRRT	0.51	6.33	0.33	8.05e-10	Resting heart rate;
LUSC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg15744005	chr10:104629667	AS3MT	0.31	6.51	0.34	2.77e-10	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg07701084	chr6:150067640	NUP43	0.56	8.63	0.43	2.49e-16	Lung cancer;
LUSC	cis	rs7179456	0.557	rs446126	chr15:59113102	A/G	cg05156742	chr15:59063176	FAM63B	0.55	8.57	0.42	3.76e-16	Asperger disorder;
LUSC	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	0.59	9.25	0.45	2.65e-18	Breast cancer;
LUSC	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg21153622	chr11:89784906	NA	-0.39	-6.0	-0.31	5.21e-9	HDL cholesterol;
LUSC	cis	rs11822910	0.911	rs61886978	chr11:57194848	G/C	cg00522883	chr11:57194120	SLC43A3	0.43	6.95	0.36	1.9e-11	Platelet distribution width;
LUSC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02353165	chr6:42928485	GNMT	0.7	11.99	0.55	8.93e-28	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg12310025	chr6:25882481	NA	-0.5	-8.97	-0.44	2.17e-17	Blood metabolite levels;
LUSC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.38	-5.99	-0.31	5.32e-9	Alzheimer's disease (late onset);
LUSC	cis	rs17572109	0.666	rs4674297	chr2:219229147	A/G	cg00012203	chr2:219082015	ARPC2	0.45	5.84	0.3	1.23e-8	Platelet count;Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.97	0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg02269571	chr22:50332266	NA	-0.55	-8.22	-0.41	4.65e-15	Schizophrenia;
LUSC	cis	rs62400317	0.859	rs10948214	chr6:45170466	T/C	cg18551225	chr6:44695536	NA	-0.45	-7.42	-0.38	9.52e-13	Total body bone mineral density;
LUSC	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.74	-0.3	2.09e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs909674	0.734	rs1005522	chr22:39845898	C/A	cg11247378	chr22:39784982	NA	-0.57	-9.33	-0.45	1.51e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.63	-0.39	2.47e-13	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg00376283	chr12:123451042	ABCB9	0.66	7.74	0.39	1.2e-13	Neutrophil percentage of white cells;
LUSC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.78	0.35	5.38e-11	Tonsillectomy;
LUSC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22968622	chr17:43663579	NA	0.77	11.94	0.55	1.35e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs2742417	0.967	rs2742419	chr3:45731929	G/A	cg09608765	chr3:45636137	LIMD1	-0.37	-7.21	-0.37	3.68e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.48	0.38	6.76e-13	Alzheimer's disease;
LUSC	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	7.43	0.38	8.98e-13	Schizophrenia;
LUSC	trans	rs853679	0.599	rs149949	chr6:28011516	T/C	cg06606381	chr12:133084897	FBRSL1	-0.64	-7.23	-0.37	3.28e-12	Depression;
LUSC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg04352962	chr1:209979756	IRF6	0.5	6.74	0.35	7.02e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-12.29	-0.56	6.68e-29	Body mass index;
LUSC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg12365402	chr11:9010492	NRIP3	-0.49	-9.43	-0.46	7.35e-19	Hemoglobin concentration;
LUSC	cis	rs35883536	0.647	rs55728953	chr1:101046863	T/C	cg06223162	chr1:101003688	GPR88	-0.47	-8.81	-0.43	6.81e-17	Monocyte count;
LUSC	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.35	-0.46	1.28e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.46	6.13	0.32	2.45e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.8	-0.35	4.96e-11	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	0.64	13.71	0.6	2.98e-34	Prudent dietary pattern;
LUSC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg03709012	chr19:19516395	GATAD2A	0.67	9.51	0.46	3.78e-19	Tonsillectomy;
LUSC	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg22676075	chr6:135203613	NA	0.48	7.5	0.38	5.76e-13	Red blood cell count;
LUSC	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg22496339	chr2:162101262	NA	0.5	7.18	0.37	4.47e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1950626	0.833	rs35151884	chr14:101394196	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.4	7.08	0.36	8.68e-12	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	trans	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10493773	0.502	rs12066742	chr1:86081149	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.39	-8.23	-0.41	4.21e-15	Urate levels in overweight individuals;
LUSC	cis	rs2273669	0.667	rs11153148	chr6:109304084	C/T	cg05315195	chr6:109294784	ARMC2	-0.55	-6.19	-0.32	1.76e-9	Prostate cancer;
LUSC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01570182	chr17:44337453	NA	0.62	9.3	0.45	1.83e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.85	14.78	0.63	2.24e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg00277334	chr10:82204260	NA	-0.55	-7.69	-0.39	1.69e-13	Post bronchodilator FEV1;
LUSC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg18135555	chr8:22132992	PIWIL2	0.39	8.06	0.4	1.33e-14	Hypertriglyceridemia;
LUSC	cis	rs10992471	0.603	rs4744141	chr9:95352140	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.75	-0.35	6.38e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg03676636	chr4:99064102	C4orf37	0.35	6.37	0.33	6.18e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg02527881	chr3:46936655	PTH1R	0.34	6.07	0.32	3.45e-9	Colorectal cancer;
LUSC	cis	rs977987	0.843	rs11644741	chr16:75466433	C/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.4e-11	Dupuytren's disease;
LUSC	cis	rs714027	0.585	rs41171	chr22:30422107	C/G	cg11564601	chr22:30592435	NA	-0.36	-6.15	-0.32	2.17e-9	Lymphocyte counts;
LUSC	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.51	7.96	0.4	2.78e-14	Response to antipsychotic treatment;
LUSC	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg19156104	chr2:198669113	PLCL1	-0.48	-5.83	-0.3	1.29e-8	Ulcerative colitis;
LUSC	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg08085267	chr17:45401833	C17orf57	-0.6	-9.93	-0.48	1.6e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02952711	chr10:134145586	LRRC27	-0.44	-6.49	-0.33	3.03e-10	Electrocardiographic conduction measures;
LUSC	cis	rs4891159	0.790	rs11872411	chr18:74132051	C/T	cg24786174	chr18:74118243	ZNF516	-0.83	-15.21	-0.64	4.41e-40	Longevity;
LUSC	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.22	0.71	5.32e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7605827	0.930	rs722327	chr2:15657263	T/A	cg19274914	chr2:15703543	NA	0.46	8.83	0.43	6.22e-17	Educational attainment (years of education);
LUSC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.48	0.33	3.33e-10	Lung cancer;
LUSC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg14552801	chr7:65878734	NA	-0.45	-6.54	-0.34	2.33e-10	Aortic root size;
LUSC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg00857998	chr1:205179979	DSTYK	0.64	9.81	0.47	4.01e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.29	0.33	9.99e-10	Menopause (age at onset);
LUSC	trans	rs6841433	0.615	rs13147106	chr4:115473362	T/C	cg01865118	chr8:29204221	DUSP4	-0.51	-5.97	-0.31	5.93e-9	Hemoglobin concentration;
LUSC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00149659	chr3:10157352	C3orf10	0.9	11.67	0.54	1.28e-26	Alzheimer's disease;
LUSC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	10.63	0.5	6.31e-23	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.61e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7590368	0.961	rs13431852	chr2:10960410	T/C	cg15705551	chr2:10952987	PDIA6	0.58	8.0	0.4	2.11e-14	Educational attainment (years of education);
LUSC	trans	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg25206134	chr2:45395956	NA	0.56	6.14	0.32	2.38e-9	Neuroticism;
LUSC	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.19	-0.41	5.51e-15	Axial length;
LUSC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-5.86	-0.31	1.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9318086	0.901	rs7336730	chr13:24452104	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.39	-5.93	-0.31	7.54e-9	Myopia (pathological);
LUSC	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-17.57	-0.69	2.11e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.28e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4363385	0.626	rs11205179	chr1:153021399	A/G	cg25856811	chr1:152973957	SPRR3	-0.36	-6.03	-0.31	4.41e-9	Inflammatory skin disease;
LUSC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg18402987	chr7:1209562	NA	0.73	7.85	0.39	5.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.66	11.09	0.52	1.47e-24	Colorectal cancer;
LUSC	trans	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	trans	rs7178375	1.000	rs7178375	chr15:31215935	C/T	cg04373760	chr16:53404718	NA	0.65	8.8	0.43	7.59e-17	Hypertriglyceridemia;
LUSC	cis	rs7615316	0.934	rs9683085	chr3:142248498	G/A	cg16271453	chr3:142027066	XRN1	-0.4	-6.83	-0.35	3.93e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.4e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg26043149	chr18:55253948	FECH	0.48	7.31	0.37	2.04e-12	Bone mineral density;
LUSC	trans	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg07211511	chr3:129823064	LOC729375	-0.75	-9.68	-0.47	1.1e-19	Blood pressure (smoking interaction);
LUSC	cis	rs59698941	0.943	rs17691584	chr5:132284251	A/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.53	-0.34	2.52e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.58	10.76	0.51	2.21e-23	Bone mineral density;
LUSC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.66	-10.26	-0.49	1.21e-21	Menarche (age at onset);
LUSC	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg08313168	chr12:7315531	NA	-0.46	-5.98	-0.31	5.67e-9	Obesity-related traits;
LUSC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg03354898	chr7:1950403	MAD1L1	-0.38	-7.18	-0.37	4.63e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg20406979	chr6:167373233	NA	0.27	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs10788264	0.621	rs7907952	chr10:124056774	C/T	cg09507567	chr10:124027408	NA	-0.44	-7.47	-0.38	7.3e-13	Total body bone mineral density;
LUSC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg16624210	chr5:671434	TPPP	0.49	6.05	0.31	3.83e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.71	-11.9	-0.55	1.87e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9648716	0.515	rs38720	chr7:140694458	A/T	cg23214464	chr7:140373596	ADCK2	0.74	6.33	0.33	8.04e-10	Type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.14e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11677416	1.000	rs3783520	chr2:113544339	C/T	cg27083787	chr2:113543245	IL1A	0.47	7.35	0.37	1.56e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	trans	rs683250	1.000	rs505621	chr11:83277927	A/G	cg26617787	chr11:123396133	GRAMD1B	-0.32	-6.13	-0.32	2.46e-9	Subcortical brain region volumes;
LUSC	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.77	11.37	0.53	1.57e-25	Corneal astigmatism;
LUSC	cis	rs9462027	0.583	rs11755420	chr6:34760956	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.11e-8	Systemic lupus erythematosus;
LUSC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg17971929	chr21:40555470	PSMG1	-0.48	-7.2	-0.37	4.1e-12	Menarche (age at onset);
LUSC	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.96	15.46	0.65	4.83e-41	Lymphocyte percentage of white cells;
LUSC	cis	rs61990749	0.597	rs11624101	chr14:78138059	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.6	-6.43	-0.33	4.5e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06873352	chr17:61820015	STRADA	0.56	8.68	0.43	1.83e-16	Height;
LUSC	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg17385448	chr1:15911702	AGMAT	0.36	5.98	0.31	5.86e-9	Systolic blood pressure;
LUSC	cis	rs12200782	1.000	rs72844495	chr6:26610640	T/C	cg11502198	chr6:26597334	ABT1	-0.76	-5.8	-0.3	1.53e-8	Small cell lung carcinoma;
LUSC	cis	rs968451	1.000	rs968451	chr22:39670851	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.72	9.02	0.44	1.5e-17	Primary biliary cholangitis;
LUSC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg21782813	chr7:2030301	MAD1L1	0.46	7.62	0.38	2.72e-13	Schizophrenia;
LUSC	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.84	13.92	0.61	4.87e-35	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12928939	0.954	rs8057568	chr16:71811995	G/A	cg03805757	chr16:71968109	PKD1L3	-0.46	-6.71	-0.34	8.33e-11	Post bronchodilator FEV1;
LUSC	cis	rs944990	0.538	rs10821123	chr9:96169561	G/A	cg13717394	chr9:96054313	WNK2	-0.37	-5.99	-0.31	5.3e-9	Body mass index;
LUSC	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg22482690	chr17:47019901	SNF8	0.39	7.34	0.37	1.64e-12	Type 2 diabetes;
LUSC	cis	rs6546550	0.935	rs4853027	chr2:70039224	A/G	cg02498382	chr2:70120550	SNRNP27	0.29	6.89	0.35	2.8e-11	Prevalent atrial fibrillation;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg18240814	chr5:107718300	FBXL17	0.34	6.42	0.33	4.64e-10	Tuberculosis;
LUSC	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.48	-7.23	-0.37	3.26e-12	Cognitive test performance;
LUSC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.56	9.13	0.45	6.91e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg11657440	chr19:46296263	DMWD	-0.75	-11.94	-0.55	1.29e-27	Coronary artery disease;
LUSC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.83	15.03	0.64	2.24e-39	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg12473912	chr3:136751656	NA	0.39	6.99	0.36	1.48e-11	Neuroticism;
LUSC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg03060546	chr3:49711283	APEH	0.72	12.18	0.55	1.79e-28	Resting heart rate;
LUSC	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg00071950	chr4:10020882	SLC2A9	0.63	10.39	0.49	4.28e-22	Bone mineral density;
LUSC	cis	rs9420	1.000	rs9420	chr11:57510294	A/G	cg02958346	chr11:57425731	CLP1	0.42	6.18	0.32	1.9e-9	Schizophrenia;
LUSC	cis	rs754466	0.651	rs2004382	chr10:79650351	G/C	cg17075019	chr10:79541650	NA	-0.73	-11.76	-0.54	5.75e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg09163369	chr1:210001066	C1orf107	0.58	6.83	0.35	4.08e-11	Orofacial clefts;
LUSC	cis	rs9469578	1.000	rs9469578	chr6:33706479	C/T	cg18708504	chr6:33715942	IP6K3	0.73	9.16	0.45	5.26e-18	Phosphorus levels;
LUSC	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-7.26	-0.37	2.81e-12	Retinal vascular caliber;
LUSC	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg00944433	chr1:107599041	PRMT6	0.37	6.78	0.35	5.37e-11	Facial morphology (factor 21, depth of nasal alae);
LUSC	trans	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg10756647	chr7:56101905	PSPH	0.86	8.85	0.44	5.22e-17	Diabetic kidney disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09559324	chr16:31475905	ARMC5	0.47	6.27	0.32	1.12e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg09904177	chr6:26538194	HMGN4	-0.77	-6.04	-0.31	4.1e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs56399783	0.901	rs73033407	chr7:2878857	G/C	cg19731401	chr7:2775893	GNA12	0.76	9.5	0.46	4.1e-19	Childhood ear infection;
LUSC	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.61	12.37	0.56	3.3e-29	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs4780401	0.655	rs11648550	chr16:11787714	C/G	cg01061890	chr16:11836724	TXNDC11	0.39	5.7	0.3	2.65e-8	Rheumatoid arthritis;
LUSC	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.53	-8.05	-0.4	1.52e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.63	9.94	0.48	1.43e-20	Longevity;
LUSC	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-7.45	-0.38	7.98e-13	Fear of minor pain;
LUSC	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg27068330	chr11:65405492	SIPA1	-0.77	-10.84	-0.51	1.18e-23	Acne (severe);
LUSC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	1.03	20.03	0.74	3.61e-59	Cognitive function;
LUSC	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg21293242	chr8:11204541	TDH	0.31	5.73	0.3	2.21e-8	Retinal vascular caliber;
LUSC	cis	rs11997175	0.536	rs10096323	chr8:33776507	T/C	ch.8.33884649F	chr8:33765107	NA	0.42	6.28	0.33	1.03e-9	Body mass index;
LUSC	trans	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg21775007	chr8:11205619	TDH	-0.44	-6.21	-0.32	1.61e-9	Joint mobility (Beighton score);
LUSC	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.73	-8.94	-0.44	2.67e-17	Breast cancer;
LUSC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg22535103	chr8:58192502	C8orf71	-0.67	-7.57	-0.38	3.68e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg24579218	chr15:68104479	NA	-0.36	-6.45	-0.33	4.01e-10	Restless legs syndrome;
LUSC	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg26162295	chr17:38119207	GSDMA	-0.28	-6.33	-0.33	8.07e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg24375607	chr4:120327624	NA	0.76	11.59	0.54	2.52e-26	Corneal astigmatism;
LUSC	cis	rs6692729	0.933	rs2236915	chr1:227079222	C/G	cg10327440	chr1:227177885	CDC42BPA	0.49	6.99	0.36	1.49e-11	Electrodermal activity;
LUSC	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-39.91	-0.91	3.76e-129	Myeloid white cell count;
LUSC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg11663144	chr21:46675770	NA	-0.35	-5.78	-0.3	1.71e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.08	0.44	9.64e-18	Motion sickness;
LUSC	cis	rs10979	1.000	rs9321923	chr6:143897206	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg17554472	chr22:41940697	POLR3H	0.47	5.84	0.3	1.27e-8	Vitiligo;
LUSC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.17	-0.49	2.5e-21	Hemoglobin concentration;
LUSC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg19230755	chr7:65878503	NA	-0.42	-6.04	-0.31	4.19e-9	Aortic root size;
LUSC	cis	rs4950928	0.823	rs4950882	chr1:203164848	A/G	cg17014757	chr1:203156097	CHI3L1	-0.43	-7.68	-0.39	1.73e-13	YKL-40 levels;
LUSC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.3	0.53	2.82e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs62400317	0.826	rs62400335	chr6:45347782	G/A	cg18551225	chr6:44695536	NA	-0.43	-7.18	-0.37	4.6e-12	Total body bone mineral density;
LUSC	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg20243544	chr17:37824526	PNMT	0.41	6.25	0.32	1.23e-9	Self-reported allergy;
LUSC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg15691649	chr6:25882328	NA	-0.39	-5.73	-0.3	2.25e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.29	0.41	2.71e-15	Ulcerative colitis;
LUSC	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	7.32	0.37	1.87e-12	Height;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg25707994	chr7:157129685	DNAJB6	0.4	7.02	0.36	1.26e-11	Triglycerides;
LUSC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.66	0.3	3.26e-8	Menopause (age at onset);
LUSC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg00814883	chr7:100076585	TSC22D4	-0.67	-9.02	-0.44	1.51e-17	Platelet count;
LUSC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.7	-10.85	-0.51	1.03e-23	Aortic root size;
LUSC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.7	-9.68	-0.47	1.04e-19	Lung function (FEV1);
LUSC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg17724175	chr1:150552817	MCL1	0.32	5.69	0.3	2.73e-8	Melanoma;
LUSC	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs9635231	1	rs9635231	chr14:55887703	C/T	cg04306507	chr14:55594613	LGALS3	-0.32	-6.41	-0.33	5.02e-10	Pediatric bone mineral density (femoral neck);
LUSC	cis	rs1790761	0.505	rs7945035	chr11:67348162	A/G	cg24690094	chr11:67383802	NA	-0.3	-5.75	-0.3	1.98e-8	Mean corpuscular volume;
LUSC	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg26528668	chr16:1614120	IFT140	0.43	7.13	0.36	6.37e-12	Coronary artery disease;
LUSC	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg15839431	chr19:19639596	YJEFN3	0.66	7.17	0.37	4.73e-12	Bipolar disorder;
LUSC	trans	rs72674100	1.000	rs4632666	chr4:97990707	A/T	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg08017756	chr2:100939284	LONRF2	-0.41	-7.66	-0.39	2.1e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg15494558	chr6:150152522	LRP11	0.34	5.81	0.3	1.45e-8	Lung cancer;
LUSC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg22823121	chr1:150693482	HORMAD1	0.48	7.06	0.36	9.78e-12	Melanoma;
LUSC	cis	rs1950626	0.716	rs34158896	chr14:101447373	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.76	0.39	1.03e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs79387448	0.745	rs76720903	chr2:103162826	G/A	cg09003973	chr2:102972529	NA	0.89	8.59	0.43	3.43e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg21890820	chr11:65308645	LTBP3	-0.49	-7.35	-0.37	1.56e-12	Bone mineral density;
LUSC	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg24812749	chr6:127587940	RNF146	0.63	8.95	0.44	2.58e-17	Breast cancer;
LUSC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg06784218	chr1:46089804	CCDC17	0.55	11.2	0.52	6.11e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg12311346	chr5:56204834	C5orf35	-0.61	-9.32	-0.45	1.6e-18	Coronary artery disease;
LUSC	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg15423357	chr2:25149977	NA	0.39	7.57	0.38	3.74e-13	Body mass index in non-asthmatics;
LUSC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg17376030	chr22:41985996	PMM1	0.47	5.99	0.31	5.5e-9	Vitiligo;
LUSC	cis	rs239198	0.602	rs4840157	chr6:101326375	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-6.37	-0.33	6.19e-10	Menarche (age at onset);
LUSC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg23630131	chr7:65973040	NA	0.21	5.93	0.31	7.77e-9	Aortic root size;
LUSC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg22681709	chr2:178499509	PDE11A	-0.6	-12.05	-0.55	5.29e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.94	0.44	2.75e-17	Prudent dietary pattern;
LUSC	cis	rs12545109	0.800	rs2609979	chr8:57390066	G/A	cg09654669	chr8:57350985	NA	-0.51	-7.04	-0.36	1.1e-11	Obesity-related traits;
LUSC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	trans	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg18187862	chr3:45730750	SACM1L	0.55	7.01	0.36	1.35e-11	Primary sclerosing cholangitis;
LUSC	cis	rs36093844	0.800	rs75203358	chr11:85567390	A/G	cg25872744	chr11:85566296	CCDC83	-0.45	-5.85	-0.3	1.16e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg08668510	chr10:1095578	IDI1	0.69	6.23	0.32	1.39e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg26373071	chr5:1325741	CLPTM1L	0.42	7.62	0.39	2.57e-13	Lung cancer;
LUSC	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.38e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-6.41	-0.33	5.09e-10	Response to antipsychotic treatment;
LUSC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs6500395	0.962	rs1564979	chr16:48647017	C/A	cg04672837	chr16:48644449	N4BP1	0.47	6.66	0.34	1.16e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.9	0.61	5.49e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-6.85	-0.35	3.61e-11	Blood metabolite levels;
LUSC	trans	rs7607980	1.000	rs79953491	chr2:165555539	A/G	cg21604450	chr1:66998563	SGIP1	0.53	6.06	0.31	3.6e-9	Fasting blood insulin (BMI interaction);Fasting blood insulin;Type 2 diabetes;
LUSC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg00933542	chr6:150070202	PCMT1	0.33	6.82	0.35	4.37e-11	Lung cancer;
LUSC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg18230493	chr5:56204884	C5orf35	-0.68	-10.47	-0.5	2.23e-22	Coronary artery disease;
LUSC	cis	rs11971779	0.616	rs10269683	chr7:139100868	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.25	0.32	1.25e-9	Diisocyanate-induced asthma;
LUSC	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg03859395	chr2:55845619	SMEK2	0.87	16.02	0.66	2.91e-43	Metabolic syndrome;
LUSC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg08508325	chr11:3079039	CARS	-0.5	-11.54	-0.53	3.81e-26	Longevity;
LUSC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.78	-0.39	9.03e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs56283067	0.578	rs2894641	chr6:45393174	A/G	cg20913747	chr6:44695427	NA	-0.42	-6.07	-0.32	3.56e-9	Total body bone mineral density;
LUSC	cis	rs7127900	0.614	rs11564708	chr11:2206326	C/G	cg25635251	chr11:2234043	NA	0.61	8.36	0.42	1.76e-15	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
LUSC	cis	rs11955175	0.717	rs41271053	chr5:40835393	A/C	cg17351974	chr5:40835760	RPL37	0.68	5.73	0.3	2.23e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs4588572	0.537	rs7702000	chr5:77730556	A/G	cg11547950	chr5:77652471	NA	-0.48	-7.19	-0.37	4.18e-12	Triglycerides;
LUSC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg01097406	chr16:89675127	NA	0.33	6.34	0.33	7.27e-10	Vitiligo;
LUSC	cis	rs4819852	0.958	rs2238792	chr22:19983213	C/T	cg07821417	chr22:19972146	ARVCF	0.31	5.79	0.3	1.65e-8	Pulse pressure;
LUSC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg04455712	chr21:45112962	RRP1B	0.47	9.0	0.44	1.71e-17	Mean corpuscular volume;
LUSC	trans	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg21775007	chr8:11205619	TDH	0.42	6.13	0.32	2.43e-9	Mood instability;
LUSC	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg00484396	chr16:3507460	NAT15	0.49	7.38	0.37	1.28e-12	Body mass index (adult);
LUSC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs6545883	0.929	rs10193666	chr2:61629408	C/T	cg15711740	chr2:61764176	XPO1	0.43	6.53	0.34	2.4e-10	Tuberculosis;
LUSC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	11.25	0.52	4.26e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12627970	0.565	rs5757613	chr22:39715262	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.82	14.48	0.62	3.09e-37	Inflammatory bowel disease;
LUSC	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg23950597	chr19:37808831	NA	-0.64	-7.9	-0.4	4.2e-14	Coronary artery calcification;
LUSC	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-0.89	-12.87	-0.58	4.67e-31	Blood pressure (smoking interaction);
LUSC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg17279839	chr7:150038598	RARRES2	0.49	7.49	0.38	6.19e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21984481	chr17:79567631	NPLOC4	-0.72	-15.12	-0.64	1.07e-39	Eye color traits;
LUSC	cis	rs2236918	0.687	rs2797601	chr1:242029249	C/G	cg17736920	chr1:242011382	EXO1	0.4	6.35	0.33	7.03e-10	Menopause (age at onset);
LUSC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg04398451	chr17:18023971	MYO15A	-0.47	-7.69	-0.39	1.66e-13	Total body bone mineral density;
LUSC	cis	rs17401966	0.540	rs6674949	chr1:10458480	A/G	cg17425144	chr1:10567563	PEX14	-0.32	-5.73	-0.3	2.2e-8	Hepatocellular carcinoma;
LUSC	trans	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg13010199	chr12:38710504	ALG10B	0.43	6.72	0.35	7.83e-11	Morning vs. evening chronotype;
LUSC	cis	rs939658	0.683	rs1474256	chr15:79463847	C/T	cg17916960	chr15:79447300	NA	0.39	7.06	0.36	9.75e-12	Refractive error;
LUSC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg02951883	chr7:2050386	MAD1L1	-0.46	-7.88	-0.4	4.7e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs72829446	0.530	rs7210292	chr17:7380305	G/T	cg02795151	chr17:7402630	POLR2A	0.61	7.43	0.38	9.45e-13	Androgen levels;
LUSC	cis	rs2273669	0.667	rs12208578	chr6:109369745	T/C	cg05315195	chr6:109294784	ARMC2	-0.53	-5.79	-0.3	1.65e-8	Prostate cancer;
LUSC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23158103	chr7:148848205	ZNF398	-0.39	-6.19	-0.32	1.77e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4629710	0.592	rs4310080	chr6:131538377	T/G	cg12700074	chr6:131571435	AKAP7	-0.37	-6.15	-0.32	2.17e-9	Multiple myeloma (IgH translocation);
LUSC	trans	rs1409005	1.000	rs76135795	chr13:79161205	C/T	cg04653021	chr3:122514541	DIRC2	0.47	6.0	0.31	5.25e-9	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg05754148	chr16:3507555	NAT15	-0.83	-8.86	-0.44	4.97e-17	Tuberculosis;
LUSC	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07636037	chr3:49044803	WDR6	0.68	8.81	0.43	6.81e-17	Menarche (age at onset);
LUSC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg11812906	chr14:75593930	NEK9	0.65	11.2	0.52	6.3e-25	Height;
LUSC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg18305652	chr10:134549665	INPP5A	0.44	6.68	0.34	9.79e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg10909506	chr17:38081995	ORMDL3	0.34	6.14	0.32	2.39e-9	Self-reported allergy;
LUSC	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	1.11	19.54	0.73	3.07e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg18904891	chr8:8559673	CLDN23	-0.41	-6.13	-0.32	2.51e-9	Neuroticism;
LUSC	cis	rs7705502	1.000	rs747472	chr5:173353514	T/C	cg18693985	chr5:173351052	CPEB4	-0.38	-5.94	-0.31	7.17e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg17279839	chr7:150038598	RARRES2	0.42	6.57	0.34	1.92e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06028605	chr16:24865363	SLC5A11	0.66	9.73	0.47	7.15e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs2540226	0.816	rs1986876	chr2:39987398	A/G	cg23576258	chr2:39999331	THUMPD2	0.34	5.92	0.31	7.79e-9	Personality dimensions;
LUSC	cis	rs11583043	0.575	rs56403901	chr1:101586047	A/T	cg11406453	chr1:101602562	NA	-0.4	-6.86	-0.35	3.31e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03264133	chr6:25882463	NA	-0.52	-9.48	-0.46	4.99e-19	Blood metabolite levels;
LUSC	trans	rs961253	0.556	rs6054140	chr20:6331643	A/G	cg21095983	chr6:86352623	SYNCRIP	0.45	6.81	0.35	4.68e-11	Colorectal cancer;
LUSC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.74	11.22	0.52	5.1e-25	Type 2 diabetes;
LUSC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-0.92	-13.49	-0.59	2.07e-33	Initial pursuit acceleration;
LUSC	trans	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg25214090	chr10:38739885	LOC399744	0.54	7.83	0.39	6.41e-14	Corneal astigmatism;
LUSC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11764359	chr7:65958608	NA	-0.68	-10.95	-0.51	4.86e-24	Aortic root size;
LUSC	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg21141812	chr3:48556323	PFKFB4	0.35	6.36	0.33	6.81e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg14843632	chr5:14870594	ANKH	-0.38	-7.4	-0.38	1.08e-12	Blood metabolite levels;
LUSC	trans	rs61931739	0.620	rs745608	chr12:33711564	A/G	cg26384229	chr12:38710491	ALG10B	0.42	6.13	0.32	2.41e-9	Morning vs. evening chronotype;
LUSC	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg06547715	chr2:218990976	CXCR2	0.31	5.88	0.31	9.97e-9	Ulcerative colitis;
LUSC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00166722	chr3:10149974	C3orf24	0.62	8.47	0.42	8.07e-16	Alzheimer's disease;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg00817870	chr12:65153201	GNS	0.41	6.35	0.33	6.97e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.75	-0.47	6.29e-20	Gut microbiome composition (summer);
LUSC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg06877462	chr1:205807181	PM20D1	-0.39	-7.02	-0.36	1.21e-11	Menarche (age at onset);
LUSC	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg26566898	chr11:117069891	TAGLN	0.34	6.51	0.34	2.82e-10	Blood protein levels;
LUSC	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg02655711	chr22:19163373	SLC25A1	0.85	16.29	0.67	2.51e-44	Metabolite levels;
LUSC	cis	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg21775007	chr8:11205619	TDH	-0.41	-5.79	-0.3	1.62e-8	Monocyte count;
LUSC	trans	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.97	-0.36	1.71e-11	Neuroticism;
LUSC	cis	rs4834770	1.000	rs6823963	chr4:120242164	A/C	cg24375607	chr4:120327624	NA	0.41	5.84	0.3	1.26e-8	Blood protein levels;
LUSC	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg20908204	chr19:46285434	DMPK	0.41	8.22	0.41	4.62e-15	Coronary artery disease;
LUSC	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg03929089	chr4:120376271	NA	0.74	6.78	0.35	5.58e-11	Axial length;
LUSC	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg00376283	chr12:123451042	ABCB9	0.66	8.35	0.42	1.82e-15	Neutrophil percentage of white cells;
LUSC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06634786	chr22:41940651	POLR3H	0.49	5.99	0.31	5.54e-9	Vitiligo;
LUSC	cis	rs7202877	0.706	rs1074961	chr16:75389484	C/T	cg03315344	chr16:75512273	CHST6	0.44	6.51	0.34	2.74e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs710216	0.718	rs841851	chr1:43401829	A/G	cg03128534	chr1:43423976	SLC2A1	0.46	5.88	0.31	9.93e-9	Red cell distribution width;
LUSC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg04450456	chr4:17643702	FAM184B	0.39	6.6	0.34	1.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.8	-0.3	1.52e-8	Vitiligo;
LUSC	cis	rs2274273	0.682	rs8008134	chr14:55507520	T/C	cg04306507	chr14:55594613	LGALS3	0.5	11.03	0.52	2.44e-24	Protein biomarker;
LUSC	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg13319975	chr6:146136371	FBXO30	0.5	7.48	0.38	6.55e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7771547	0.642	rs605684	chr6:36493265	T/C	cg07856975	chr6:36356162	ETV7	0.36	6.19	0.32	1.72e-9	Platelet distribution width;
LUSC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg03146154	chr1:46216737	IPP	0.56	8.36	0.42	1.75e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.78	-13.78	-0.6	1.62e-34	Age at first birth;
LUSC	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg03128534	chr1:43423976	SLC2A1	0.51	6.54	0.34	2.28e-10	Red cell distribution width;
LUSC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.32	-0.37	1.91e-12	Subjective well-being;
LUSC	cis	rs611744	0.563	rs7815105	chr8:109298794	C/T	cg18478394	chr8:109455254	TTC35	0.46	6.65	0.34	1.21e-10	Dupuytren's disease;
LUSC	cis	rs13394619	1.000	rs4669752	chr2:11727988	G/C	cg07314298	chr2:11723111	GREB1	-0.57	-10.09	-0.48	4.41e-21	Endometriosis;
LUSC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg03146154	chr1:46216737	IPP	0.56	8.37	0.42	1.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs72901758	0.669	rs17641275	chr17:76247796	A/C	cg26068271	chr17:76253126	NA	-0.52	-9.73	-0.47	7.19e-20	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg16989719	chr2:238392110	NA	-0.42	-7.19	-0.37	4.35e-12	Prostate cancer;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04651707	chr7:43622869	STK17A	-0.46	-6.23	-0.32	1.39e-9	Hepatitis;
LUSC	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.7	0.34	8.64e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg03806693	chr22:41940476	POLR3H	0.87	12.97	0.58	2.02e-31	Vitiligo;
LUSC	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	7.02	0.36	1.24e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg05855489	chr10:104503620	C10orf26	0.51	7.75	0.39	1.14e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs859767	0.741	rs6713239	chr2:135434849	C/T	cg12500956	chr2:135428796	TMEM163	-0.28	-6.4	-0.33	5.39e-10	Neuroticism;
LUSC	cis	rs7119	0.635	rs938090	chr15:77879975	A/G	cg27398640	chr15:77910606	LINGO1	0.35	8.28	0.41	3.07e-15	Type 2 diabetes;
LUSC	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg24692254	chr21:30365293	RNF160	0.69	11.35	0.53	1.8e-25	Pancreatic cancer;
LUSC	cis	rs116988415	0.539	rs17180350	chr14:65249066	C/T	cg00114569	chr14:65239327	SPTB	0.63	6.92	0.35	2.28e-11	Daytime sleep phenotypes;
LUSC	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg25206134	chr2:45395956	NA	0.59	6.72	0.35	7.76e-11	Bipolar disorder;
LUSC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.52	-7.38	-0.37	1.27e-12	Renal function-related traits (BUN);
LUSC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08677398	chr8:58056175	NA	0.53	7.05	0.36	1.04e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg23887609	chr12:130822674	PIWIL1	0.48	7.03	0.36	1.19e-11	Menopause (age at onset);
LUSC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg11663144	chr21:46675770	NA	-0.4	-6.81	-0.35	4.49e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.67	0.34	1.09e-10	Obesity-related traits;
LUSC	cis	rs1124376	1.000	rs11712709	chr3:20139777	G/C	cg05072819	chr3:20081367	KAT2B	0.67	7.49	0.38	6.17e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs977987	0.836	rs7199062	chr16:75474827	G/A	cg03315344	chr16:75512273	CHST6	0.53	10.39	0.49	4.26e-22	Dupuytren's disease;
LUSC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg08200582	chr11:442649	ANO9	-0.52	-5.96	-0.31	6.31e-9	Body mass index;
LUSC	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.5	6.59	0.34	1.74e-10	Tuberculosis;
LUSC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.83	-0.35	4.05e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg12292205	chr6:26970375	C6orf41	-0.63	-7.57	-0.38	3.72e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.57	-0.34	1.88e-10	Response to antipsychotic treatment;
LUSC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24549020	chr5:56110836	MAP3K1	0.47	5.66	0.3	3.31e-8	Initial pursuit acceleration;
LUSC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg10729496	chr3:10149963	C3orf24	0.49	6.14	0.32	2.34e-9	Alzheimer's disease;
LUSC	cis	rs8027181	1.000	rs7164727	chr15:73093991	C/T	cg25632853	chr15:73088954	NA	0.33	6.6	0.34	1.57e-10	Triglyceride levels;
LUSC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-14.37	-0.62	9.01e-37	Height;
LUSC	cis	rs3812762	0.833	rs3850933	chr11:8801135	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.39	6.73	0.35	7.57e-11	Hypospadias;
LUSC	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-0.93	-18.52	-0.71	3.49e-53	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11764359	chr7:65958608	NA	0.68	11.06	0.52	2e-24	Aortic root size;
LUSC	cis	rs7212590	0.655	rs34687426	chr17:57997857	A/G	cg10252138	chr17:58120427	NA	-0.73	-7.09	-0.36	7.8e-12	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg15819921	chr19:927150	ARID3A	-0.44	-6.61	-0.34	1.51e-10	Life satisfaction;
LUSC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg11645453	chr3:52864694	ITIH4	0.34	7.82	0.39	6.91e-14	Bipolar disorder;
LUSC	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg08601574	chr20:25228251	PYGB	-0.44	-6.72	-0.35	7.65e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	6.25	0.32	1.22e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs67539049	1.000	rs77865852	chr8:11303336	A/G	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.41	-6.33	-0.33	7.98e-10	Itch intensity from mosquito bite;
LUSC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg05872129	chr22:39784769	NA	-0.59	-10.0	-0.48	9.36e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs6828577	0.695	rs62324878	chr4:119455605	G/A	cg26518628	chr1:97050305	NA	-0.52	-7.61	-0.38	2.77e-13	Perioperative myocardial infarction in coronary artery bypass surgery;
LUSC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg03909863	chr11:638404	DRD4	-0.41	-6.18	-0.32	1.84e-9	Systemic lupus erythematosus;
LUSC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg03188948	chr7:1209495	NA	0.66	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.55	-9.33	-0.45	1.47e-18	Menopause (age at onset);
LUSC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg19318889	chr4:1322082	MAEA	-0.39	-6.41	-0.33	4.82e-10	Obesity-related traits;
LUSC	cis	rs11030122	0.632	rs4910596	chr11:4084604	A/G	cg18678763	chr11:4115507	RRM1	-0.47	-6.32	-0.33	8.53e-10	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg07395648	chr5:131743802	NA	-0.39	-5.85	-0.3	1.2e-8	Acylcarnitine levels;
LUSC	cis	rs6484504	0.652	rs485265	chr11:31407788	G/A	cg06552810	chr11:31128660	NA	0.36	6.16	0.32	2.1e-9	Red blood cell count;
LUSC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg13628971	chr7:2884303	GNA12	0.42	6.25	0.32	1.26e-9	Height;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	1.01	24.37	0.8	4.34e-76	Menarche (age at onset);
LUSC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4474465	1.000	rs10793314	chr11:78174196	G/C	cg27205649	chr11:78285834	NARS2	-0.48	-5.71	-0.3	2.51e-8	Alzheimer's disease (survival time);
LUSC	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg19812747	chr11:111475976	SIK2	-0.45	-6.16	-0.32	2.1e-9	Primary sclerosing cholangitis;
LUSC	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.4	-0.33	5.4e-10	Arsenic metabolism;
LUSC	cis	rs7587476	0.601	rs17489231	chr2:215673739	T/G	cg04004882	chr2:215674386	BARD1	-0.52	-7.28	-0.37	2.42e-12	Neuroblastoma;
LUSC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg03188948	chr7:1209495	NA	0.61	6.38	0.33	5.97e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7560272	0.538	rs11126414	chr2:73932044	G/A	cg20560298	chr2:73613845	ALMS1	0.38	5.72	0.3	2.43e-8	Schizophrenia;
LUSC	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.51	10.12	0.48	3.48e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs9308433	0.798	rs10157166	chr1:214484950	C/T	cg06198575	chr1:214491504	SMYD2	0.45	7.12	0.36	6.86e-12	IgG glycosylation;
LUSC	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg08355456	chr11:67383691	NA	0.38	7.01	0.36	1.35e-11	Mean corpuscular volume;
LUSC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.34	0.59	7.79e-33	Cognitive test performance;
LUSC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.84	-0.57	5.88e-31	Platelet count;
LUSC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.44	-0.33	4.25e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs77741769	0.571	rs1696357	chr12:121348649	A/G	cg02419362	chr12:121203948	SPPL3	0.44	8.47	0.42	8.13e-16	Mean corpuscular volume;
LUSC	cis	rs6543140	0.964	rs4851578	chr2:103028951	T/G	cg09003973	chr2:102972529	NA	0.55	7.19	0.37	4.2e-12	Blood protein levels;
LUSC	cis	rs16867321	0.507	rs2013577	chr2:181370505	C/T	cg23363182	chr2:181467187	NA	-0.45	-7.31	-0.37	1.96e-12	Obesity;
LUSC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.56	0.65	1.98e-41	Platelet count;
LUSC	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg13010199	chr12:38710504	ALG10B	-0.52	-7.85	-0.39	5.58e-14	Morning vs. evening chronotype;
LUSC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg02423579	chr7:2872169	GNA12	-0.46	-6.3	-0.33	9.36e-10	Height;
LUSC	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg23985595	chr17:80112537	CCDC57	-0.31	-6.13	-0.32	2.41e-9	Life satisfaction;
LUSC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00339695	chr16:24857497	SLC5A11	0.61	9.52	0.46	3.52e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg11057378	chr10:81107060	PPIF	0.34	6.04	0.31	4.15e-9	Height;
LUSC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg04733989	chr22:42467013	NAGA	-0.4	-6.58	-0.34	1.77e-10	Cognitive function;
LUSC	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg00334542	chr7:100209784	MOSPD3	-0.48	-5.82	-0.3	1.42e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg23283495	chr1:209979779	IRF6	0.44	7.21	0.37	3.74e-12	Monobrow;
LUSC	cis	rs1451375	0.652	rs10249420	chr7:50623451	C/G	cg18232548	chr7:50535776	DDC	-0.47	-6.52	-0.34	2.56e-10	Malaria;
LUSC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg15595755	chr5:1867978	NA	0.45	8.2	0.41	5.37e-15	Cardiovascular disease risk factors;
LUSC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20307385	chr11:47447363	PSMC3	0.44	5.8	0.3	1.58e-8	Subjective well-being;
LUSC	cis	rs3771570	0.579	rs62190373	chr2:242388685	G/A	cg21155796	chr2:242212141	HDLBP	0.6	6.51	0.34	2.8e-10	Prostate cancer;
LUSC	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg00701064	chr4:6280414	WFS1	0.5	10.42	0.5	3.27e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6594499	0.500	rs10491424	chr5:110453806	T/C	cg04022379	chr5:110408740	TSLP	0.57	8.62	0.43	2.81e-16	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.22	-0.72	5.88e-56	Height;
LUSC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.38	0.42	1.53e-15	Tonsillectomy;
LUSC	cis	rs6537837	0.838	rs6537830	chr1:110107044	A/G	cg05049280	chr1:110155535	GNAT2	0.39	5.74	0.3	2.12e-8	Major depressive disorder;
LUSC	trans	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg18806716	chr10:30721971	MAP3K8	0.44	6.87	0.35	3.11e-11	Inflammatory bowel disease;
LUSC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg02951883	chr7:2050386	MAD1L1	0.55	9.96	0.48	1.21e-20	Bipolar disorder and schizophrenia;
LUSC	cis	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg12435725	chr3:58293450	RPP14	0.67	7.17	0.37	4.88e-12	Cholesterol, total;
LUSC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs16912285	0.748	rs7952223	chr11:24256443	G/C	ch.11.24196551F	chr11:24239977	NA	0.89	9.13	0.45	6.92e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01939664	chr1:33722135	ZNF362	-0.49	-5.96	-0.31	6.56e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.49	-8.07	-0.4	1.27e-14	Bipolar disorder;
LUSC	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg06784218	chr1:46089804	CCDC17	0.32	5.65	0.3	3.43e-8	Platelet count;
LUSC	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.9	-0.4	4.05e-14	Response to antipsychotic treatment;
LUSC	cis	rs1009647	0.583	rs68175860	chr14:55633590	T/C	cg04306507	chr14:55594613	LGALS3	0.46	6.35	0.33	6.89e-10	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs6104690	1.000	rs6078005	chr20:10983151	T/C	cg07172334	chr21:31655261	KRTAP24-1	-0.34	-6.11	-0.32	2.85e-9	Bladder cancer;
LUSC	cis	rs7572644	0.621	rs4462754	chr2:28063994	C/T	cg27432699	chr2:27873401	GPN1	0.51	6.96	0.36	1.78e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.25	0.45	2.66e-18	Prudent dietary pattern;
LUSC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs9462027	0.607	rs205259	chr6:34564066	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.21	-0.32	1.59e-9	Systemic lupus erythematosus;
LUSC	trans	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg26043149	chr18:55253948	FECH	-0.45	-7.09	-0.36	8.09e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.55	-6.87	-0.35	3.23e-11	Body mass index;
LUSC	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.06	-0.31	3.64e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg15147215	chr3:52552868	STAB1	-0.31	-6.09	-0.32	3.15e-9	Bipolar disorder;
LUSC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26818010	chr10:134567672	INPP5A	-0.87	-10.88	-0.51	8.59e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs77216612	0.877	rs66561220	chr12:12878765	T/C	cg09462578	chr12:12878428	APOLD1	-1.0	-17.21	-0.69	5.77e-48	Lymphocyte counts;
LUSC	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg10207240	chr12:122356781	WDR66	0.43	6.0	0.31	5.28e-9	Mean corpuscular volume;
LUSC	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg24375607	chr4:120327624	NA	0.76	12.17	0.55	1.85e-28	Corneal astigmatism;
LUSC	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.59	0.5	8.41e-23	Bladder cancer;
LUSC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg25039879	chr17:56429692	SUPT4H1	0.68	9.14	0.45	6.1e-18	Cognitive test performance;
LUSC	cis	rs11264213	0.901	rs72661636	chr1:36426483	T/C	cg27506609	chr1:36549197	TEKT2	0.7	7.98	0.4	2.39e-14	Schizophrenia;
LUSC	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg07148914	chr20:33460835	GGT7	-0.53	-8.1	-0.41	1.05e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg23625390	chr15:77176239	SCAPER	0.47	7.09	0.36	8.04e-12	Blood metabolite levels;
LUSC	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg26695010	chr11:65641043	EFEMP2	-0.46	-6.92	-0.35	2.32e-11	Eosinophil percentage of white cells;
LUSC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg22532475	chr10:104410764	TRIM8	-0.32	-7.05	-0.36	1.01e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs870825	0.616	rs3184982	chr4:185615768	T/G	cg04058563	chr4:185651563	MLF1IP	0.86	13.29	0.59	1.2e-32	Blood protein levels;
LUSC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg22963979	chr7:1858916	MAD1L1	-0.6	-9.44	-0.46	6.45e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs2086824	0.702	rs3114896	chr16:89393562	C/T	cg06640241	chr16:89574553	SPG7	-0.53	-7.99	-0.4	2.28e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg02549819	chr16:58548995	SETD6	0.94	9.18	0.45	4.63e-18	Schizophrenia;
LUSC	cis	rs4713675	0.584	rs2966	chr6:33689520	C/T	cg14003231	chr6:33640908	ITPR3	0.29	5.7	0.3	2.59e-8	Plateletcrit;
LUSC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.25	-14.23	-0.61	3.05e-36	Diabetic kidney disease;
LUSC	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.59	0.5	8.82e-23	Colorectal cancer;
LUSC	cis	rs11608355	0.545	rs7315846	chr12:109908617	T/C	cg05360138	chr12:110035743	NA	0.89	11.55	0.53	3.47e-26	Neuroticism;
LUSC	cis	rs7178572	1.000	rs12904938	chr15:77721225	A/G	cg22256960	chr15:77711686	NA	-0.54	-9.04	-0.44	1.29e-17	Type 2 diabetes;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg15112475	chr7:1198522	ZFAND2A	-0.29	-5.98	-0.31	5.66e-9	Longevity;Endometriosis;
LUSC	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg05340658	chr4:99064831	C4orf37	0.66	11.23	0.52	4.92e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7605827	0.930	rs10929375	chr2:15684483	A/G	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.77e-16	Educational attainment (years of education);
LUSC	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	8.92	0.44	3.12e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-7.5	-0.38	5.79e-13	Aortic root size;
LUSC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.27	0.41	3.27e-15	Melanoma;
LUSC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg27398817	chr8:82754497	SNX16	-0.64	-8.14	-0.41	7.68e-15	Diastolic blood pressure;
LUSC	cis	rs9640161	0.830	rs1051823	chr7:150070814	G/A	cg17279839	chr7:150038598	RARRES2	0.36	5.86	0.31	1.13e-8	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.75	9.93	0.48	1.54e-20	Gastritis;
LUSC	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg05234568	chr11:5960015	NA	-0.56	-8.15	-0.41	7.16e-15	DNA methylation (variation);
LUSC	trans	rs11935423	0.778	rs11946658	chr4:100491680	C/A	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.1	-0.32	3e-9	Gut microbiome composition (summer);
LUSC	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-10.59	-0.5	8.77e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1775715	0.737	rs55859032	chr10:32213239	C/T	cg18675610	chr10:32216311	ARHGAP12	0.29	6.43	0.33	4.5e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	10.28	0.49	1.02e-21	Lymphocyte counts;
LUSC	cis	rs9472414	0.510	rs3997503	chr6:44708416	G/A	cg20913747	chr6:44695427	NA	0.38	5.77	0.3	1.81e-8	Height;
LUSC	cis	rs11039100	1.000	rs35466594	chr11:5826684	T/G	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg24342717	chr2:85555507	TGOLN2	-0.74	-12.31	-0.56	5.74e-29	Ear protrusion;
LUSC	cis	rs981844	0.753	rs62325149	chr4:154728006	G/C	cg14289246	chr4:154710475	SFRP2	0.44	5.86	0.31	1.09e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg15790184	chr11:494944	RNH1	0.6	6.47	0.33	3.42e-10	Body mass index;
LUSC	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg08462924	chr1:41848221	NA	0.49	8.26	0.41	3.55e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	8.09	0.4	1.15e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg10756647	chr7:56101905	PSPH	-0.86	-8.54	-0.42	4.98e-16	Diabetic kidney disease;
LUSC	trans	rs62103177	0.714	rs12607447	chr18:77605212	A/G	cg05926928	chr17:57297772	GDPD1	1.07	13.14	0.58	4.62e-32	Opioid sensitivity;
LUSC	cis	rs4664304	0.900	rs62176692	chr2:160743463	C/T	cg23995753	chr2:160760732	LY75	-0.32	-5.99	-0.31	5.5e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg27432699	chr2:27873401	GPN1	-0.88	-17.51	-0.69	3.63e-49	Oral cavity cancer;
LUSC	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg05585544	chr11:47624801	NA	-0.33	-5.99	-0.31	5.37e-9	Subjective well-being;
LUSC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg22868518	chr11:507468	RNH1	-0.65	-6.08	-0.32	3.34e-9	Body mass index;
LUSC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg13206674	chr6:150067644	NUP43	0.62	9.92	0.48	1.7e-20	Lung cancer;
LUSC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg22800045	chr5:56110881	MAP3K1	0.45	6.36	0.33	6.68e-10	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.49	-8.47	-0.42	8.09e-16	Lymphocyte counts;
LUSC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Body mass index;
LUSC	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.83	15.05	0.64	1.87e-39	Sudden cardiac arrest;
LUSC	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg08345082	chr10:99160200	RRP12	-0.36	-7.37	-0.37	1.31e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg23241863	chr10:102295624	HIF1AN	0.47	6.0	0.31	5.01e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.0	0.31	5.03e-9	Personality dimensions;
LUSC	cis	rs7923837	0.574	rs2488075	chr10:94490174	T/C	cg25093409	chr10:94429542	NA	-0.35	-5.93	-0.31	7.46e-9	Body mass index;Multiple sclerosis;
LUSC	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg14092571	chr14:90743983	NA	-0.36	-5.99	-0.31	5.35e-9	Mortality in heart failure;
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.41	-6.88	-0.35	3.03e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4664308	0.840	rs1870102	chr2:161070582	A/G	cg03641300	chr2:160917029	PLA2R1	-0.62	-10.55	-0.5	1.21e-22	Idiopathic membranous nephropathy;
LUSC	cis	rs4499344	0.604	rs259275	chr19:33159693	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.75	11.51	0.53	4.84e-26	Mean platelet volume;
LUSC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.18	0.49	2.32e-21	Electroencephalogram traits;
LUSC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg16262614	chr3:133464971	TF	0.42	7.19	0.37	4.19e-12	Iron status biomarkers (transferrin levels);
LUSC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg12386194	chr3:101231763	SENP7	0.56	7.61	0.38	2.8e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg24011408	chr12:48396354	COL2A1	0.41	5.86	0.31	1.13e-8	Glycated hemoglobin levels;
LUSC	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg22508957	chr16:3507546	NAT15	0.42	6.02	0.31	4.59e-9	Body mass index (adult);
LUSC	cis	rs1018836	0.608	rs1033347	chr8:91464137	G/A	cg16814680	chr8:91681699	NA	-0.52	-7.56	-0.38	3.97e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg26338869	chr17:61819248	STRADA	0.41	5.81	0.3	1.49e-8	Prudent dietary pattern;
LUSC	cis	rs113835537	0.529	rs11227515	chr11:66287383	C/T	cg24851651	chr11:66362959	CCS	0.53	8.06	0.4	1.33e-14	Airway imaging phenotypes;
LUSC	cis	rs3820928	0.967	rs16822905	chr2:227770727	G/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.84	-0.39	5.95e-14	Pulmonary function;
LUSC	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg05340658	chr4:99064831	C4orf37	0.44	6.92	0.35	2.25e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg26924012	chr15:45694286	SPATA5L1	1.15	20.56	0.75	2.89e-61	Homoarginine levels;
LUSC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-9.25	-0.45	2.67e-18	Monocyte count;
LUSC	cis	rs75920871	0.528	rs983567	chr11:116783600	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-5.96	-0.31	6.54e-9	Subjective well-being;
LUSC	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg23933602	chr10:16859644	RSU1	0.5	6.01	0.31	4.84e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg02931644	chr1:25747376	RHCE	-0.31	-5.66	-0.3	3.33e-8	Erythrocyte sedimentation rate;
LUSC	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg15704280	chr7:45808275	SEPT13	-0.45	-6.3	-0.33	9.59e-10	Height;
LUSC	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg02466173	chr16:30829666	NA	-0.49	-9.38	-0.46	1.07e-18	Dementia with Lewy bodies;
LUSC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.6	-10.74	-0.51	2.63e-23	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg05347473	chr6:146136440	FBXO30	0.59	10.6	0.5	8.2000000000000006e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg15445000	chr17:37608096	MED1	0.38	6.63	0.34	1.34e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg25767906	chr1:53392781	SCP2	-0.34	-5.69	-0.3	2.72e-8	Monocyte count;
LUSC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	9.24	0.45	2.94e-18	Total body bone mineral density;
LUSC	cis	rs1538970	1.000	rs7417107	chr1:45831915	G/C	cg05343316	chr1:45956843	TESK2	0.58	8.08	0.4	1.22e-14	Platelet count;
LUSC	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg10523679	chr1:76189770	ACADM	-0.49	-7.11	-0.36	6.92e-12	Daytime sleep phenotypes;
LUSC	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg22907277	chr7:1156413	C7orf50	0.38	5.86	0.31	1.11e-8	Longevity;Endometriosis;
LUSC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.27	-0.41	3.23e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg23711669	chr6:146136114	FBXO30	0.78	12.85	0.58	5.36e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs909341	0.859	rs2297441	chr20:62327582	A/G	cg09650180	chr20:62225654	GMEB2	-0.47	-6.15	-0.32	2.19e-9	Atopic dermatitis;
LUSC	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.17	-0.41	6.57e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.4	0.33	5.23e-10	Retinal vascular caliber;
LUSC	cis	rs9311676	0.656	rs11714807	chr3:58405431	A/G	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.1e-10	Systemic lupus erythematosus;
LUSC	cis	rs7572644	0.713	rs11127129	chr2:28076708	C/G	cg27432699	chr2:27873401	GPN1	-0.53	-6.98	-0.36	1.63e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg09201001	chr11:18656081	SPTY2D1	0.92	15.07	0.64	1.57e-39	Breast cancer;
LUSC	cis	rs193541	0.530	rs2045626	chr5:122081253	A/C	cg19077854	chr5:122220652	SNX24	0.34	7.14	0.36	5.93e-12	Glucose homeostasis traits;
LUSC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg11062466	chr8:58055876	NA	0.65	8.33	0.41	2.12e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg10207240	chr12:122356781	WDR66	0.45	6.51	0.34	2.83e-10	Mean corpuscular volume;
LUSC	cis	rs13401104	0.633	rs11679598	chr2:237112451	A/C	cg19324714	chr2:237145437	ASB18	0.43	5.76	0.3	1.94e-8	Educational attainment;
LUSC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg11812906	chr14:75593930	NEK9	0.4	5.91	0.31	8.27e-9	Caffeine consumption;
LUSC	cis	rs11032090	1	rs11032090	chr11:4417129	A/G	cg09983885	chr11:4415245	TRIM21	0.56	9.34	0.46	1.41e-18	Lung cancer;
LUSC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg01097406	chr16:89675127	NA	-0.34	-6.72	-0.34	8.09e-11	Vitiligo;
LUSC	cis	rs4363385	0.818	rs1334848	chr1:153004721	A/T	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.46e-8	Inflammatory skin disease;
LUSC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.61	9.05	0.44	1.18e-17	Blood protein levels;
LUSC	cis	rs7246967	0.611	rs3902164	chr19:22866281	T/A	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-8.29	-0.41	2.77e-15	Blood metabolite levels;
LUSC	cis	rs4478858	0.684	rs10753245	chr1:31731208	A/G	cg00250761	chr1:31883323	NA	-0.34	-8.37	-0.42	1.58e-15	Alcohol dependence;
LUSC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.97	0.31	5.94e-9	Renal function-related traits (BUN);
LUSC	trans	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-8.53	-0.42	5.13e-16	Obesity-related traits;
LUSC	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.19	0.32	1.76e-9	Neuroticism;
LUSC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.59	-0.5	8.72e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg04287289	chr16:89883240	FANCA	-0.41	-5.95	-0.31	6.6e-9	Vitiligo;
LUSC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	3.93e-12	Motion sickness;
LUSC	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg05425664	chr17:57184151	TRIM37	0.48	7.23	0.37	3.4e-12	Testicular germ cell tumor;
LUSC	trans	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	8.58	0.42	3.62e-16	Type 2 diabetes;
LUSC	cis	rs4654899	0.758	rs7530739	chr1:21447480	C/A	cg01072550	chr1:21505969	NA	-0.52	-8.05	-0.4	1.46e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9323205	0.577	rs9672038	chr14:51724856	A/G	cg23942311	chr14:51606299	NA	-0.42	-9.08	-0.44	9.68e-18	Cancer;
LUSC	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg11344533	chr11:111475393	SIK2	-0.49	-6.81	-0.35	4.52e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2694528	0.623	rs1563517	chr5:60063511	A/C	cg11474532	chr5:59995715	DEPDC1B	-0.65	-7.19	-0.37	4.19e-12	Parkinson's disease;
LUSC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg02428538	chr16:24856791	SLC5A11	-0.44	-5.69	-0.3	2.76e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.7	-0.43	1.5e-16	Axial length;
LUSC	trans	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg25214090	chr10:38739885	LOC399744	0.42	6.42	0.33	4.6e-10	Corneal astigmatism;
LUSC	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg04586622	chr2:25135609	ADCY3	0.4	8.45	0.42	9.14e-16	Body mass index;
LUSC	cis	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg27411982	chr8:10470053	RP1L1	-0.47	-7.55	-0.38	4.23e-13	Neuroticism;
LUSC	cis	rs9534288	0.830	rs2897027	chr13:46636235	A/G	cg15192986	chr13:46630673	CPB2	-0.81	-12.51	-0.57	9.9e-30	Blood protein levels;
LUSC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg05973401	chr12:123451056	ABCB9	0.65	9.62	0.47	1.71e-19	Platelet count;
LUSC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg08499158	chr17:42289980	UBTF	0.39	6.1	0.32	2.97e-9	Total body bone mineral density;
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11905131	chr22:24372483	LOC391322	-0.58	-9.61	-0.47	1.78e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.83	14.07	0.61	1.27e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg10523860	chr14:103875565	MARK3	-0.38	-6.03	-0.31	4.44e-9	Body mass index;
LUSC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08280861	chr8:58055591	NA	0.54	6.3	0.33	9.15e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg16482183	chr6:26056742	HIST1H1C	0.44	6.59	0.34	1.72e-10	Height;
LUSC	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg17366294	chr4:99064904	C4orf37	0.54	8.56	0.42	4.08e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg03609598	chr5:56110824	MAP3K1	-0.41	-5.9	-0.31	8.97e-9	Initial pursuit acceleration;
LUSC	cis	rs6696846	0.749	rs7515178	chr1:205084120	G/A	cg00857998	chr1:205179979	DSTYK	0.62	9.92	0.48	1.67e-20	Red blood cell count;
LUSC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.61	9.71	0.47	8.33e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg03060546	chr3:49711283	APEH	0.65	6.99	0.36	1.46e-11	Menarche (age at onset);
LUSC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg16423285	chr20:60520624	NA	-0.46	-5.86	-0.31	1.12e-8	Body mass index;
LUSC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	10.32	0.49	7.69e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg22089800	chr15:90895588	ZNF774	0.67	10.71	0.51	3.27e-23	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs4664304	0.802	rs17830307	chr2:160871799	T/C	cg23995753	chr2:160760732	LY75	-0.34	-6.4	-0.33	5.23e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg13010199	chr12:38710504	ALG10B	0.56	8.46	0.42	8.59e-16	Morning vs. evening chronotype;
LUSC	cis	rs6987853	0.787	rs2923427	chr8:42385748	A/C	cg09913449	chr8:42400586	C8orf40	0.54	9.26	0.45	2.61e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.94	-0.44	2.75e-17	Breast cancer;
LUSC	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg08558340	chr7:100472263	SRRT	0.52	6.49	0.33	3.13e-10	Resting heart rate;
LUSC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs7809950	0.954	rs2520245	chr7:107137428	G/C	cg23024343	chr7:107201750	COG5	-0.55	-8.73	-0.43	1.26e-16	Coronary artery disease;
LUSC	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg05925327	chr15:68127851	NA	-0.4	-6.27	-0.32	1.09e-9	Obesity;
LUSC	cis	rs10904908	1.000	rs7920002	chr10:17259766	T/A	cg01003015	chr10:17271136	VIM	-0.43	-6.17	-0.32	2e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs997295	0.504	rs12905397	chr15:68034150	T/C	cg08079166	chr15:68083412	MAP2K5	-0.38	-7.75	-0.39	1.11e-13	Motion sickness;
LUSC	trans	rs6480314	0.542	rs61854816	chr10:70028808	C/T	cg04882175	chr6:131122610	NA	-0.54	-6.32	-0.33	8.24e-10	Optic nerve measurement (disc area);
LUSC	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg01475377	chr6:109611718	NA	-0.38	-6.75	-0.35	6.74e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-17.88	-0.7	1.27e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.45	-0.42	8.99e-16	Heart rate;
LUSC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg15744005	chr10:104629667	AS3MT	-0.29	-6.28	-0.33	1.04e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg08975724	chr8:8085496	FLJ10661	0.49	6.98	0.36	1.61e-11	Retinal vascular caliber;
LUSC	cis	rs7760535	0.794	rs463860	chr6:111691721	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-7.01	-0.36	1.36e-11	Metabolic traits;
LUSC	cis	rs4474465	0.850	rs7938257	chr11:78224908	A/G	cg27205649	chr11:78285834	NARS2	0.54	6.14	0.32	2.36e-9	Alzheimer's disease (survival time);
LUSC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg13010199	chr12:38710504	ALG10B	0.53	8.24	0.41	4.01e-15	Morning vs. evening chronotype;
LUSC	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-10.08	-0.48	4.76e-21	Migraine;Coronary artery disease;
LUSC	cis	rs7560272	0.538	rs2001436	chr2:73928965	A/T	cg20560298	chr2:73613845	ALMS1	0.38	5.84	0.3	1.22e-8	Schizophrenia;
LUSC	cis	rs708547	0.915	rs28605409	chr4:57766261	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.54	6.5	0.34	2.86e-10	Response to bleomycin (chromatid breaks);
LUSC	trans	rs6600671	1.000	rs2185281	chr1:121179991	A/G	cg00646200	chr1:148855367	NA	0.45	7.09	0.36	8.01e-12	Hip geometry;
LUSC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	9.06	0.44	1.16e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs3857067	0.806	rs9307137	chr4:95135712	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.32	-5.69	-0.3	2.78e-8	QT interval;
LUSC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg14668632	chr7:2872130	GNA12	-0.43	-6.37	-0.33	6.22e-10	Height;
LUSC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06221963	chr1:154839813	KCNN3	-0.66	-15.73	-0.65	4.11e-42	Prostate cancer;
LUSC	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg13010199	chr12:38710504	ALG10B	-0.44	-6.66	-0.34	1.15e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.69	10.35	0.49	5.71e-22	Corneal astigmatism;
LUSC	cis	rs3770081	0.793	rs60719866	chr2:86284378	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.94	-6.99	-0.36	1.51e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs273573	1.000	rs273604	chr11:30966112	G/A	cg14844989	chr11:31128820	NA	0.37	5.89	0.31	9.5e-9	Total body bone mineral density;
LUSC	cis	rs2274459	0.749	rs2281831	chr6:33695815	G/A	cg06253072	chr6:33679850	C6orf125	0.48	5.9	0.31	9.13e-9	Obesity (extreme);
LUSC	cis	rs4478858	0.775	rs6701667	chr1:31707971	A/C	cg00250761	chr1:31883323	NA	-0.35	-9.25	-0.45	2.79e-18	Alcohol dependence;
LUSC	cis	rs146817970	1	rs146817970	chr5:81512947	TA/T	cg15871215	chr5:81402204	ATG10	-0.45	-6.62	-0.34	1.47e-10	Breast cancer;
LUSC	cis	rs2742417	1.000	rs1877932	chr3:45753539	A/G	cg09608765	chr3:45636137	LIMD1	-0.38	-7.53	-0.38	4.87e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2742417	0.967	rs9825559	chr3:45740278	T/C	cg04837898	chr3:45731254	SACM1L	-0.35	-5.66	-0.3	3.31e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.93	0.48	1.52e-20	Bipolar disorder;
LUSC	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-9.41	-0.46	8.22e-19	Neuroticism;
LUSC	cis	rs6545883	0.868	rs2518933	chr2:61797030	C/A	cg15711740	chr2:61764176	XPO1	-0.46	-7.38	-0.37	1.3e-12	Tuberculosis;
LUSC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg05347473	chr6:146136440	FBXO30	-0.59	-10.32	-0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg05528280	chr10:464225	DIP2C	0.39	6.0	0.31	5.23e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg04586622	chr2:25135609	ADCY3	0.43	9.23	0.45	3.12e-18	Body mass index;
LUSC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg25039879	chr17:56429692	SUPT4H1	0.64	8.67	0.43	1.92e-16	Cognitive test performance;
LUSC	cis	rs6977660	1.000	rs13230910	chr7:19806003	A/G	cg07541023	chr7:19748670	TWISTNB	-0.53	-6.08	-0.32	3.3e-9	Thyroid stimulating hormone;
LUSC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07685180	chr8:600429	NA	-0.66	-6.53	-0.34	2.44e-10	IgG glycosylation;
LUSC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07677032	chr17:61819896	STRADA	0.54	8.94	0.44	2.72e-17	Prudent dietary pattern;
LUSC	cis	rs11608355	0.515	rs12831026	chr12:109903651	C/T	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg08355456	chr11:67383691	NA	0.47	9.34	0.46	1.39e-18	Mean corpuscular volume;
LUSC	cis	rs2637266	0.777	rs2637254	chr10:78312002	G/A	cg18941641	chr10:78392320	NA	0.39	7.01	0.36	1.36e-11	Pulmonary function;
LUSC	trans	rs9944715	1.000	rs9944715	chr18:43831259	A/G	cg01718231	chr17:29326311	RNF135	-0.5	-7.12	-0.36	6.79e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.12	0.52	1.19e-24	Colorectal cancer;
LUSC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg14440974	chr22:39074834	NA	-0.4	-6.75	-0.35	6.63e-11	Menopause (age at onset);
LUSC	cis	rs7523050	0.643	rs36052234	chr1:109402943	C/T	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg26061582	chr7:22766209	IL6	0.48	6.91	0.35	2.51e-11	Lung cancer;
LUSC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg20135002	chr11:47629003	NA	-0.53	-8.25	-0.41	3.67e-15	Subjective well-being;
LUSC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg02896835	chr1:92012615	NA	-0.65	-11.83	-0.54	3.3e-27	Breast cancer;
LUSC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.74	11.02	0.52	2.64e-24	Multiple sclerosis;
LUSC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.91	0.61	5.12e-35	Cognitive test performance;
LUSC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg04469686	chr1:162760199	HSD17B7	-0.47	-6.77	-0.35	5.87e-11	Breast cancer;
LUSC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg12615879	chr12:58013172	SLC26A10	-0.28	-5.81	-0.3	1.49e-8	Multiple sclerosis;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg09000178	chr16:67063319	CBFB	0.43	6.77	0.35	5.84e-11	Triglycerides;
LUSC	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg18240062	chr17:79603768	NPLOC4	0.79	15.29	0.64	2.32e-40	Eye color traits;
LUSC	cis	rs4423214	0.592	rs78300366	chr11:71205514	A/G	cg05163923	chr11:71159392	DHCR7	-0.68	-7.11	-0.36	7.22e-12	Vitamin D levels;
LUSC	trans	rs9401746	0.564	rs671820	chr6:124796163	T/A	cg16857858	chr7:27213984	HOXA10	0.55	6.28	0.32	1.08e-9	Bone mineral density (Ward's triangle area);
LUSC	cis	rs2124969	0.522	rs6432608	chr2:161034991	C/T	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.35	-0.37	1.57e-12	Waist circumference adjusted for body mass index;
LUSC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg22823121	chr1:150693482	HORMAD1	0.59	9.05	0.44	1.17e-17	Tonsillectomy;
LUSC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.94	0.36	2.05e-11	Cystic fibrosis severity;
LUSC	trans	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-8.28	-0.41	2.95e-15	Obesity-related traits;
LUSC	cis	rs955333	0.925	rs1533746	chr6:154929308	G/A	cg20019720	chr6:154832845	CNKSR3	0.47	5.84	0.3	1.23e-8	Diabetic kidney disease;
LUSC	cis	rs62400317	0.762	rs12209944	chr6:44788156	G/C	cg20913747	chr6:44695427	NA	-0.48	-7.12	-0.36	6.56e-12	Total body bone mineral density;
LUSC	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	14.75	0.63	2.86e-38	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.69	-11.98	-0.55	9.48e-28	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs714027	0.546	rs5763614	chr22:30331290	A/G	cg11564601	chr22:30592435	NA	0.34	5.77	0.3	1.83e-8	Lymphocyte counts;
LUSC	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.1	-0.32	3.01e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs11209002	0.614	rs4655515	chr1:67566898	T/C	cg02640540	chr1:67518911	SLC35D1	0.63	8.8	0.43	7.73e-17	Crohn's disease;
LUSC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	7.33	0.37	1.78e-12	Personality dimensions;
LUSC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg05082376	chr22:42548792	NA	-0.43	-6.48	-0.33	3.36e-10	Schizophrenia;
LUSC	trans	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg26043149	chr18:55253948	FECH	-0.53	-7.78	-0.39	9.38e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.06	0.31	3.64e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg06238570	chr21:40685208	BRWD1	-0.59	-9.9	-0.48	2.04e-20	Cognitive function;
LUSC	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.7	-0.47	8.88e-20	Coronary artery disease;
LUSC	cis	rs7582180	0.903	rs13031712	chr2:100896512	G/A	cg08017756	chr2:100939284	LONRF2	-0.36	-6.01	-0.31	4.77e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.67	-11.3	-0.53	2.66e-25	Caffeine consumption;
LUSC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11645453	chr3:52864694	ITIH4	0.34	8.14	0.41	7.76e-15	Bipolar disorder;
LUSC	cis	rs9398803	0.965	rs9388490	chr6:126704795	C/T	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	1.96e-9	Male-pattern baldness;
LUSC	cis	rs3820068	0.705	rs4646063	chr1:15829813	G/A	cg17385448	chr1:15911702	AGMAT	0.4	6.11	0.32	2.83e-9	Systolic blood pressure;
LUSC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg04944784	chr2:26401820	FAM59B	0.78	11.21	0.52	5.48e-25	Gut microbiome composition (summer);
LUSC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00166722	chr3:10149974	C3orf24	0.57	7.28	0.37	2.43e-12	Alzheimer's disease;
LUSC	trans	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg06521331	chr12:34319734	NA	0.43	6.7	0.34	8.88e-11	Bladder cancer;
LUSC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg04317338	chr11:64019027	PLCB3	0.64	7.33	0.37	1.77e-12	Mean platelet volume;
LUSC	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg09184832	chr6:79620586	NA	-0.44	-7.09	-0.36	8.02e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7818345	0.967	rs4433156	chr8:19284247	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.36	0.37	1.43e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg02466173	chr16:30829666	NA	-0.59	-10.99	-0.52	3.56e-24	Multiple myeloma;
LUSC	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg15704280	chr7:45808275	SEPT13	-0.58	-7.16	-0.36	5.02e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.97	-17.29	-0.69	2.87e-48	Menopause (age at onset);
LUSC	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg15557168	chr22:42548783	NA	0.35	5.84	0.3	1.25e-8	Cognitive function;
LUSC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg16624210	chr5:671434	TPPP	0.5	6.47	0.33	3.58e-10	Obesity-related traits;
LUSC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.06	-0.36	9.55e-12	Bipolar disorder;
LUSC	cis	rs2979489	0.533	rs62505279	chr8:30447069	C/T	cg26383811	chr8:30366931	RBPMS	-0.46	-7.38	-0.37	1.29e-12	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	0.65	13.71	0.6	3.1e-34	Prudent dietary pattern;
LUSC	cis	rs9467711	0.516	rs1177441	chr6:25859413	A/G	cg08501292	chr6:25962987	TRIM38	0.57	5.8	0.3	1.53e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7561273	0.609	rs2160943	chr2:24288775	G/A	cg06627628	chr2:24431161	ITSN2	-0.51	-6.83	-0.35	3.93e-11	Quantitative traits;
LUSC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.45	0.33	3.96e-10	Obesity-related traits;
LUSC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.39	0.33	5.73e-10	Menopause (age at onset);
LUSC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.18	-0.45	4.76e-18	Type 2 diabetes;
LUSC	trans	rs72674100	1.000	rs28520218	chr4:97966557	T/C	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg01738412	chr7:87505461	SLC25A40;DBF4	0.39	6.01	0.31	4.99e-9	Schizophrenia;
LUSC	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg02176678	chr2:219576539	TTLL4	0.61	11.04	0.52	2.37e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9807989	0.839	rs10204837	chr2:102977730	C/A	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.5e-9	Asthma;
LUSC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.98	0.31	5.66e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg22089800	chr15:90895588	ZNF774	-0.64	-9.53	-0.46	3.44e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs3858145	0.588	rs61854831	chr10:70035837	C/T	cg04882175	chr6:131122610	NA	-0.65	-8.71	-0.43	1.4e-16	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUSC	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg23625390	chr15:77176239	SCAPER	0.53	7.63	0.39	2.41e-13	Blood metabolite levels;
LUSC	cis	rs10186029	0.708	rs4672673	chr2:213981463	A/G	cg08319019	chr2:214017104	IKZF2	0.6	8.62	0.43	2.73e-16	Systemic sclerosis;
LUSC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.86	12.77	0.57	1.13e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs17030434	0.906	rs78436201	chr4:154661755	C/A	cg14289246	chr4:154710475	SFRP2	-0.56	-7.22	-0.37	3.64e-12	Electrocardiographic conduction measures;
LUSC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	5.75	0.3	2.05e-8	Personality dimensions;
LUSC	cis	rs11229555	0.645	rs11229435	chr11:58185796	G/C	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2637266	1.000	rs7474960	chr10:78359021	C/T	cg18941641	chr10:78392320	NA	0.39	7.41	0.38	1.02e-12	Pulmonary function;
LUSC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12756686	chr19:29218302	NA	0.56	6.74	0.35	6.93e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	0.96	15.09	0.64	1.36e-39	Triglycerides;
LUSC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.39	7.05	0.36	1.05e-11	Depressive symptoms;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg20591408	chr2:241516333	RNPEPL1	0.45	6.55	0.34	2.17e-10	Cognitive function;Information processing speed;
LUSC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03264133	chr6:25882463	NA	0.61	10.28	0.49	1.03e-21	Blood metabolite levels;
LUSC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.58	-0.34	1.81e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg18904891	chr8:8559673	CLDN23	0.56	7.71	0.39	1.42e-13	Obesity-related traits;
LUSC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg09877947	chr5:131593287	PDLIM4	0.37	6.23	0.32	1.39e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs6782228	0.585	rs9841161	chr3:128331870	A/G	cg16766828	chr3:128327626	NA	-0.32	-5.84	-0.3	1.25e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg25767906	chr1:53392781	SCP2	-0.48	-8.74	-0.43	1.13e-16	Monocyte count;
LUSC	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21545522	chr1:205238299	TMCC2	0.5	9.45	0.46	5.97e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg25730555	chr22:47059586	GRAMD4	0.45	7.82	0.39	7.06e-14	Urate levels in obese individuals;
LUSC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-1.23	-13.58	-0.6	9.14e-34	Diabetic kidney disease;
LUSC	cis	rs4285028	0.948	rs34478505	chr3:121694071	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.71	-9.34	-0.46	1.36e-18	Multiple sclerosis;
LUSC	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg23992470	chr4:843637	GAK	0.6	6.41	0.33	5.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs72772090	0.539	rs17481759	chr5:96114695	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.87	-0.35	3.07e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.66	0.34	1.15e-10	Menopause (age at onset);
LUSC	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.47	-0.33	3.43e-10	Daytime sleep phenotypes;
LUSC	cis	rs1775715	0.769	rs2799030	chr10:32172935	G/T	cg18675610	chr10:32216311	ARHGAP12	0.3	6.65	0.34	1.19e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg03647239	chr10:116582469	FAM160B1	0.45	7.12	0.36	6.47e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg00432049	chr6:150390894	ULBP3	-0.27	-5.68	-0.3	2.86e-8	Alopecia areata;
LUSC	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.37	-6.4	-0.33	5.18e-10	Breast cancer;
LUSC	trans	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg08975724	chr8:8085496	FLJ10661	0.43	6.2	0.32	1.62e-9	Retinal vascular caliber;
LUSC	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg11984989	chr7:158649758	WDR60	1.04	13.31	0.59	1e-32	Height;
LUSC	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg02023728	chr11:77925099	USP35	0.46	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.08	14.54	0.62	1.89e-37	Gut microbiome composition (summer);
LUSC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-1.0	-19.95	-0.74	7.3e-59	Menopause (age at onset);
LUSC	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02176678	chr2:219576539	TTLL4	0.64	11.82	0.54	3.7e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.6	-0.43	3.26e-16	Obesity-related traits;
LUSC	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg00792783	chr2:198669748	PLCL1	0.45	5.98	0.31	5.69e-9	Intracranial aneurysm;
LUSC	cis	rs701145	0.585	rs1727949	chr3:153875713	A/G	cg17054900	chr3:154042577	DHX36	0.58	5.93	0.31	7.52e-9	Coronary artery disease;
LUSC	trans	rs9944715	1.000	rs12605945	chr18:43834118	A/G	cg01718231	chr17:29326311	RNF135	-0.5	-6.97	-0.36	1.71e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg22875332	chr1:76189707	ACADM	-0.42	-6.24	-0.32	1.35e-9	Daytime sleep phenotypes;
LUSC	cis	rs6845621	0.727	rs10032307	chr4:18911775	T/C	cg12196642	chr4:18937545	NA	-0.34	-6.3	-0.33	9.55e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	6.36	0.33	6.53e-10	Mean platelet volume;
LUSC	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-6.92	-0.35	2.29e-11	Blood metabolite levels;
LUSC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg07741184	chr6:167504864	NA	0.4	6.95	0.36	1.91e-11	Primary biliary cholangitis;
LUSC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg27284194	chr4:1044797	NA	0.35	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg08079166	chr15:68083412	MAP2K5	0.41	7.46	0.38	7.5e-13	Restless legs syndrome;
LUSC	cis	rs4474465	1.000	rs7395344	chr11:78202388	A/G	cg27205649	chr11:78285834	NARS2	-0.5	-5.98	-0.31	5.76e-9	Alzheimer's disease (survival time);
LUSC	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.8	-12.74	-0.57	1.47e-30	Schizophrenia;
LUSC	cis	rs9581857	0.579	rs7332104	chr13:27957831	C/G	cg22138327	chr13:27999177	GTF3A	-0.63	-7.44	-0.38	8.83e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg12927641	chr6:109611667	NA	-0.43	-7.58	-0.38	3.41e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg17264618	chr3:40429014	ENTPD3	0.28	6.08	0.32	3.22e-9	Renal cell carcinoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01525244	chr22:39548611	CBX7	0.57	9.23	0.45	3.17e-18	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg05340658	chr4:99064831	C4orf37	0.6	10.21	0.49	1.82e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg25124228	chr12:125621409	AACS	-0.59	-9.9	-0.48	1.99e-20	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg00033643	chr7:134001901	SLC35B4	0.46	7.11	0.36	7e-12	Mean platelet volume;
LUSC	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg21775007	chr8:11205619	TDH	0.65	10.49	0.5	1.95e-22	Retinal vascular caliber;
LUSC	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg03676636	chr4:99064102	C4orf37	0.36	7.7	0.39	1.5700000000000001e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3015497	0.753	rs12881776	chr14:51136330	T/G	cg26011998	chr14:51135199	SAV1	-0.39	-5.65	-0.3	3.5e-8	Mean platelet volume;
LUSC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12379764	chr21:47803548	PCNT	0.49	7.0	0.36	1.4e-11	Testicular germ cell tumor;
LUSC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg04398451	chr17:18023971	MYO15A	0.57	9.53	0.46	3.41e-19	Total body bone mineral density;
LUSC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.83	0.3	1.31e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg02931644	chr1:25747376	RHCE	0.37	7.0	0.36	1.38e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg16362232	chr11:430036	ANO9	0.6	7.87	0.4	4.86e-14	Body mass index;
LUSC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg12463550	chr7:65579703	CRCP	0.57	8.54	0.42	4.77e-16	Aortic root size;
LUSC	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg16359550	chr11:109292809	C11orf87	0.47	7.88	0.4	4.73e-14	Schizophrenia;
LUSC	cis	rs4629180	1.000	rs11123889	chr2:102107180	G/A	cg04415270	chr2:102091202	RFX8	0.57	9.22	0.45	3.55e-18	Chronic rhinosinusitis with nasal polyps;
LUSC	trans	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs55871839	0.708	rs4738733	chr8:59813760	T/C	cg07426533	chr8:59803705	TOX	-0.36	-5.93	-0.31	7.66e-9	Pneumonia;
LUSC	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.89	15.2	0.64	5.1e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6546550	0.901	rs12232914	chr2:70117176	C/T	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.35	-0.37	1.54e-12	Prevalent atrial fibrillation;
LUSC	cis	rs2273669	0.667	rs11757168	chr6:109301091	A/G	cg05315195	chr6:109294784	ARMC2	-0.56	-6.19	-0.32	1.78e-9	Prostate cancer;
LUSC	cis	rs4953318	0.619	rs10198247	chr2:46362677	C/T	cg12428440	chr2:46370979	PRKCE	-0.47	-7.95	-0.4	2.98e-14	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	cis	rs865483	0.860	rs853228	chr17:35799889	G/T	cg06716730	chr17:35851459	DUSP14	0.27	5.91	0.31	8.66e-9	Monocyte count;
LUSC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.73	-12.51	-0.56	1.07e-29	Height;
LUSC	trans	rs12571093	0.803	rs61854826	chr10:70031558	C/A	cg04882175	chr6:131122610	NA	-0.55	-6.27	-0.32	1.09e-9	Optic nerve measurement (disc area);
LUSC	cis	rs7215564	0.818	rs34760119	chr17:78604583	G/T	cg09596252	chr17:78655493	RPTOR	0.55	6.24	0.32	1.33e-9	Myopia (pathological);
LUSC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18876405	chr7:65276391	NA	0.54	8.33	0.41	2.05e-15	Aortic root size;
LUSC	cis	rs7560272	0.723	rs6729468	chr2:73765253	C/A	cg20560298	chr2:73613845	ALMS1	-0.49	-7.6	-0.38	2.92e-13	Schizophrenia;
LUSC	cis	rs3768617	0.610	rs10911228	chr1:183049792	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.64	0.43	2.3e-16	Fuchs's corneal dystrophy;
LUSC	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg06606381	chr12:133084897	FBRSL1	-0.88	-7.56	-0.38	3.87e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg05283184	chr6:79620031	NA	-0.45	-8.54	-0.42	4.85e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2798269	0.646	rs4770182	chr13:22179186	G/T	cg18095732	chr13:22033692	ZDHHC20	0.38	6.03	0.31	4.31e-9	PR segment;
LUSC	cis	rs1355223	0.872	rs7116409	chr11:34751007	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.39	-5.67	-0.3	3.13e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs10203711	1.000	rs907099	chr2:239559769	G/C	cg14580085	chr2:239553406	NA	0.41	6.96	0.36	1.79e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.97	0.31	6.05e-9	Menopause (age at onset);
LUSC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.51	-8.7	-0.43	1.55e-16	IgG glycosylation;
LUSC	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg20607287	chr7:12443886	VWDE	-0.65	-6.49	-0.33	3.03e-10	Coronary artery disease;
LUSC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg11663144	chr21:46675770	NA	-0.41	-7.12	-0.36	6.49e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg11608241	chr8:8085544	FLJ10661	0.43	6.46	0.33	3.78e-10	Systolic blood pressure;
LUSC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08859206	chr1:53392774	SCP2	-0.54	-9.57	-0.46	2.45e-19	Monocyte count;
LUSC	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg03585969	chr10:35415529	CREM	0.6	8.84	0.44	5.75e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10150615	chr22:24372951	LOC391322	-0.43	-7.07	-0.36	9.39e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7246967	0.673	rs12975767	chr19:22862809	A/C	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs4308124	0.708	rs6727313	chr2:111971540	G/A	cg04571233	chr2:111982156	NA	-0.52	-6.75	-0.35	6.59e-11	Vitiligo;
LUSC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-1.08	-15.78	-0.65	2.71e-42	Initial pursuit acceleration;
LUSC	cis	rs12928939	0.517	rs8050058	chr16:71981374	T/G	cg03805757	chr16:71968109	PKD1L3	-0.62	-9.52	-0.46	3.66e-19	Post bronchodilator FEV1;
LUSC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg17366294	chr4:99064904	C4orf37	-0.54	-8.96	-0.44	2.31e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10740039	0.960	rs10443928	chr10:62405476	A/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.86	-0.35	3.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13082711	0.911	rs57992391	chr3:27511567	A/C	cg02860705	chr3:27208620	NA	0.47	7.96	0.4	2.67e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg07701084	chr6:150067640	NUP43	0.54	8.15	0.41	7.58e-15	Lung cancer;
LUSC	trans	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg07393940	chr7:158741817	NA	0.36	6.41	0.33	5.07e-10	Life satisfaction;
LUSC	cis	rs11640533	1.000	rs11640533	chr16:53412862	A/G	cg08681685	chr16:53407594	NA	-0.38	-5.76	-0.3	1.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg23711669	chr6:146136114	FBXO30	0.73	12.43	0.56	2.1e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg18478394	chr8:109455254	TTC35	0.46	7.13	0.36	6.27e-12	Dupuytren's disease;
LUSC	cis	rs2273669	0.667	rs75671532	chr6:109341298	A/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	8.89e-9	Prostate cancer;
LUSC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.7	-0.3	2.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1832871	0.711	rs9459924	chr6:158703902	G/A	cg07165851	chr6:158734300	TULP4	0.5	7.8	0.39	7.9e-14	Height;
LUSC	cis	rs427941	0.632	rs201478	chr7:101746964	G/C	cg06246474	chr7:101738831	CUX1	0.39	6.42	0.33	4.68e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09820084	chr6:18387507	RNF144B	0.49	7.65	0.39	2.17e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg03806693	chr22:41940476	POLR3H	-0.61	-9.08	-0.44	9.64e-18	Vitiligo;
LUSC	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg17507749	chr15:85114479	UBE2QP1	0.58	7.32	0.37	1.84e-12	Schizophrenia;
LUSC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg22800045	chr5:56110881	MAP3K1	0.43	5.9	0.31	8.91e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-0.81	-9.88	-0.48	2.31e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-1.19	-12.9	-0.58	3.46e-31	Diabetic kidney disease;
LUSC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg07212818	chr11:638076	DRD4	-0.42	-7.15	-0.36	5.65e-12	Systemic lupus erythematosus;
LUSC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.85	0.3	1.2e-8	Tonsillectomy;
LUSC	cis	rs11608355	0.618	rs4486687	chr12:109790741	T/A	cg19025524	chr12:109796872	NA	-0.48	-9.16	-0.45	5.26e-18	Neuroticism;
LUSC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.52	-10.37	-0.49	4.91e-22	Iron status biomarkers;
LUSC	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg13010199	chr12:38710504	ALG10B	0.67	9.61	0.47	1.83e-19	Bladder cancer;
LUSC	cis	rs6693567	0.565	rs1776276	chr1:150293078	A/C	cg15654264	chr1:150340011	RPRD2	0.45	7.27	0.37	2.62e-12	Migraine;
LUSC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.71	0.51	3.24e-23	Menopause (age at onset);
LUSC	cis	rs4919694	1.000	rs4917988	chr10:104752830	T/G	cg04362960	chr10:104952993	NT5C2	1.17	13.66	0.6	4.81e-34	Arsenic metabolism;
LUSC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg04871131	chr7:94954202	PON1	-0.39	-6.11	-0.32	2.7e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.48	-0.46	4.95e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg18827107	chr12:86230957	RASSF9	-0.47	-7.14	-0.36	5.93e-12	Major depressive disorder;
LUSC	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg21798802	chr22:38057573	PDXP	0.35	7.23	0.37	3.32e-12	Fat distribution (HIV);
LUSC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg12432903	chr7:1882776	MAD1L1	-0.37	-5.89	-0.31	9.45e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.69	-0.39	1.71e-13	Depression;
LUSC	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.27	-0.32	1.15e-9	Morning vs. evening chronotype;
LUSC	cis	rs2742234	0.541	rs2742235	chr10:43616325	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.46	-7.51	-0.38	5.29e-13	Hirschsprung disease;
LUSC	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg10130564	chr11:117069849	TAGLN	0.31	5.76	0.3	1.86e-8	Blood protein levels;
LUSC	cis	rs11650494	0.710	rs74619404	chr17:47484445	C/T	cg08112188	chr17:47440006	ZNF652	1.33	9.54	0.46	3.15e-19	Prostate cancer;
LUSC	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg13514129	chr1:39547527	MACF1	0.74	12.07	0.55	4.49e-28	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg05738196	chr6:26577821	NA	0.74	12.18	0.55	1.72e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.02	0.31	4.7e-9	Neuroticism;
LUSC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.79	0.6	1.47e-34	Alzheimer's disease;
LUSC	cis	rs7577851	0.669	rs12464941	chr2:69628089	A/T	cg10773587	chr2:69614142	GFPT1	0.56	6.3	0.33	9.29e-10	Parkinson's disease (age of onset);
LUSC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg07936489	chr17:37558343	FBXL20	-0.7	-9.74	-0.47	6.83e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs12208915	0.848	rs2174740	chr6:79536565	A/G	cg05283184	chr6:79620031	NA	-0.42	-5.78	-0.3	1.68e-8	Left atrial antero-posterior diameter;
LUSC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg20587970	chr11:113659929	NA	-1.03	-13.81	-0.6	1.22e-34	Hip circumference adjusted for BMI;
LUSC	cis	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.42	-0.42	1.14e-15	Morning vs. evening chronotype;
LUSC	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg23173402	chr1:227635558	NA	0.59	7.08	0.36	8.53e-12	Major depressive disorder;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13476336	chr17:38255694	NR1D1	0.42	6.01	0.31	4.83e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg07382826	chr16:28625726	SULT1A1	0.28	5.88	0.31	9.79e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs12776158	0.901	rs61086796	chr10:71216848	T/C	cg12610070	chr10:71211762	TSPAN15	-0.46	-5.93	-0.31	7.46e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs3818285	0.544	rs9787456	chr10:111711822	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.63	-9.08	-0.44	9.95e-18	Superior crus of antihelix expression;
LUSC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg14343924	chr8:8086146	FLJ10661	0.4	5.79	0.3	1.61e-8	Mood instability;
LUSC	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg15556689	chr8:8085844	FLJ10661	-0.59	-9.13	-0.45	6.7e-18	Mood instability;
LUSC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.29	-5.71	-0.3	2.52e-8	Total body bone mineral density;
LUSC	cis	rs9359856	0.564	rs76069351	chr6:90425043	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.88	-8.68	-0.43	1.83e-16	Bipolar disorder;
LUSC	cis	rs4478858	0.611	rs6425721	chr1:31714807	C/T	cg00250761	chr1:31883323	NA	-0.34	-8.29	-0.41	2.72e-15	Alcohol dependence;
LUSC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	18.01	0.7	3.66e-51	Chronic sinus infection;
LUSC	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.0	-0.44	1.72e-17	Monocyte percentage of white cells;
LUSC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg11843238	chr5:131593191	PDLIM4	0.46	7.78	0.39	9.34e-14	Acylcarnitine levels;
LUSC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg11663144	chr21:46675770	NA	-0.4	-6.9	-0.35	2.58e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg02508848	chr16:68573721	ZFP90	-0.43	-5.82	-0.3	1.42e-8	Ulcerative colitis;
LUSC	cis	rs925255	0.747	rs6547851	chr2:28629367	G/C	cg01273330	chr2:28605224	NA	0.41	6.69	0.34	9.19e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs72674100	1.000	rs10016964	chr4:97989089	T/C	cg09670535	chr1:18959427	PAX7	-0.62	-6.34	-0.33	7.58e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg17971929	chr21:40555470	PSMG1	-0.64	-9.73	-0.47	7.26e-20	Cognitive function;
LUSC	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg13010199	chr12:38710504	ALG10B	0.65	10.24	0.49	1.35e-21	Bladder cancer;
LUSC	cis	rs7589342	0.895	rs2033008	chr2:106502585	T/A	cg14210321	chr2:106509881	NCK2	-0.6	-9.09	-0.45	9.21e-18	Addiction;
LUSC	cis	rs1538970	1.000	rs2050884	chr1:45830824	A/G	cg05343316	chr1:45956843	TESK2	0.58	8.08	0.4	1.22e-14	Platelet count;
LUSC	cis	rs59104589	0.535	rs73004374	chr2:242378000	T/C	cg14842376	chr2:242211374	HDLBP	0.5	5.8	0.3	1.57e-8	Fibrinogen levels;
LUSC	cis	rs8099014	1.000	rs17064977	chr18:56107697	C/T	cg12907477	chr18:56117327	MIR122	0.41	6.54	0.34	2.24e-10	Platelet count;
LUSC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.43	-0.5	3.09e-22	Gut microbiome composition (summer);
LUSC	cis	rs911119	1.000	rs5030707	chr20:23618656	C/G	cg16589663	chr20:23618590	CST3	0.6	7.08	0.36	8.36e-12	Chronic kidney disease;
LUSC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg18681998	chr4:17616180	MED28	0.85	16.13	0.66	1.06e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg11632617	chr15:75315747	PPCDC	-0.52	-6.76	-0.35	6.32e-11	Blood trace element (Zn levels);
LUSC	trans	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg26043149	chr18:55253948	FECH	0.43	6.32	0.33	8.57e-10	Bone mineral density;
LUSC	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	0.56	8.69	0.43	1.67e-16	Breast cancer;
LUSC	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg18200150	chr17:30822561	MYO1D	0.52	10.91	0.51	6.73e-24	Schizophrenia;
LUSC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg16339924	chr4:17578868	LAP3	0.58	8.75	0.43	1.1e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg26893861	chr17:41843967	DUSP3	0.96	14.8	0.63	1.86e-38	Triglycerides;
LUSC	cis	rs13315871	1.000	rs9844128	chr3:58391127	C/T	cg12435725	chr3:58293450	RPP14	-0.73	-7.35	-0.37	1.56e-12	Cholesterol, total;
LUSC	cis	rs72781680	0.652	rs72794281	chr2:23893265	G/A	cg08917208	chr2:24149416	ATAD2B	0.98	9.69	0.47	1.02e-19	Lymphocyte counts;
LUSC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg04013166	chr16:89971882	TCF25	0.64	7.33	0.37	1.71e-12	Skin colour saturation;
LUSC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg27541892	chr1:1571801	CDK11B	0.52	8.54	0.42	4.75e-16	Body mass index;
LUSC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg11062466	chr8:58055876	NA	0.72	8.79	0.43	8.28e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs4947962	0.651	rs17586365	chr7:55140786	A/G	cg23757825	chr7:55092271	EGFR	0.61	7.35	0.37	1.51e-12	Subjective response to lithium treatment;
LUSC	trans	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg26043149	chr18:55253948	FECH	0.51	7.59	0.38	3.2e-13	Bone mineral density;
LUSC	cis	rs12618769	0.597	rs10199199	chr2:99061834	T/C	cg10123293	chr2:99228465	UNC50	0.46	7.72	0.39	1.39e-13	Bipolar disorder;
LUSC	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-1.01	-14.28	-0.62	1.98e-36	Exhaled nitric oxide output;
LUSC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.54	-0.34	2.34e-10	Schizophrenia;
LUSC	trans	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.1	-0.36	7.39e-12	Triglycerides;
LUSC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-10.3	-0.49	8.52e-22	Menarche (age at onset);
LUSC	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg04545296	chr12:48745243	ZNF641	0.37	6.68	0.34	1.01e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.07	0.44	1.01e-17	Red blood cell count;
LUSC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg13010199	chr12:38710504	ALG10B	0.69	10.93	0.51	5.83e-24	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.62	-5.94	-0.31	7.17e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	6.79	0.35	5.03e-11	Height;
LUSC	cis	rs7904985	1.000	rs7084928	chr10:88122516	C/T	cg07322936	chr10:88137208	NA	-0.58	-7.4	-0.38	1.1e-12	Barrett's esophagus;
LUSC	cis	rs7577851	0.672	rs60680381	chr2:69533492	A/G	cg10773587	chr2:69614142	GFPT1	0.59	6.38	0.33	6.04e-10	Parkinson's disease (age of onset);
LUSC	trans	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg23094728	chr5:56110263	MAP3K1	0.45	6.02	0.31	4.63e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg08882882	chr6:84937375	KIAA1009	0.45	6.02	0.31	4.59e-9	Cognitive function;Information processing speed;
LUSC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.68	-10.9	-0.51	7.23e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg04450456	chr4:17643702	FAM184B	0.41	6.84	0.35	3.75e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg05896524	chr21:47604654	C21orf56	0.47	7.07	0.36	9.19e-12	Testicular germ cell tumor;
LUSC	cis	rs1198872	0.558	rs10929699	chr2:10918209	C/T	cg15705551	chr2:10952987	PDIA6	0.48	6.29	0.33	9.93e-10	Cardiac Troponin-T levels;
LUSC	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.86	0.54	2.63e-27	Cognitive ability;
LUSC	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.8	-0.3	1.54e-8	Height;
LUSC	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg03929089	chr4:120376271	NA	0.67	7.39	0.37	1.2e-12	Axial length;
LUSC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg15839431	chr19:19639596	YJEFN3	-0.4	-5.69	-0.3	2.76e-8	Tonsillectomy;
LUSC	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg02023728	chr11:77925099	USP35	0.52	7.2	0.37	4.11e-12	Testicular germ cell tumor;
LUSC	cis	rs2235544	0.565	rs665421	chr1:54469883	T/C	cg25741118	chr1:54482237	LDLRAD1	0.28	6.01	0.31	4.76e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs440932	0.798	rs330942	chr8:9020439	A/C	cg15556689	chr8:8085844	FLJ10661	0.42	6.15	0.32	2.17e-9	High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg15556689	chr8:8085844	FLJ10661	0.58	8.88	0.44	4.09e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg13126279	chr21:47581558	C21orf56	-0.4	-5.78	-0.3	1.75e-8	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	trans	rs12210905	0.925	rs12193463	chr6:26961882	T/G	cg11837749	chr1:55047332	ACOT11	0.57	6.09	0.32	3.07e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-8.87	-0.44	4.66e-17	Response to antipsychotic treatment;
LUSC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg03233332	chr7:66118400	NA	0.42	6.12	0.32	2.67e-9	Aortic root size;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg09033563	chr22:24373618	LOC391322	-0.48	-6.74	-0.35	7.08e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9356171	0.572	rs2281407	chr6:164325926	C/T	cg25752492	chr6:164341247	NA	-0.38	-6.54	-0.34	2.25e-10	Diisocyanate-induced asthma;
LUSC	cis	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.74	-0.35	6.92e-11	Morning vs. evening chronotype;
LUSC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-13.36	-0.59	6.46e-33	Chronic sinus infection;
LUSC	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg12179176	chr11:130786555	SNX19	0.62	9.39	0.46	9.86e-19	Schizophrenia;
LUSC	cis	rs2236918	0.710	rs851781	chr1:242034868	C/T	cg17736920	chr1:242011382	EXO1	0.42	6.59	0.34	1.7e-10	Menopause (age at onset);
LUSC	cis	rs4478858	0.735	rs1566963	chr1:31772206	G/A	cg00250761	chr1:31883323	NA	-0.33	-7.82	-0.39	6.82e-14	Alcohol dependence;
LUSC	cis	rs7605827	0.930	rs7605274	chr2:15604269	A/T	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg03233332	chr7:66118400	NA	-0.41	-5.95	-0.31	6.91e-9	Aortic root size;
LUSC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.4	-0.33	5.22e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7408868	0.520	rs10417567	chr19:15308068	C/T	cg14696996	chr19:15285081	NOTCH3	-0.72	-7.17	-0.37	4.71e-12	Pulse pressure;
LUSC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	0.97	13.38	0.59	5.37e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-1.01	-15.01	-0.63	2.75e-39	Initial pursuit acceleration;
LUSC	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg19812747	chr11:111475976	SIK2	-0.55	-8.08	-0.4	1.16e-14	Primary sclerosing cholangitis;
LUSC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg19747945	chr6:42946146	PEX6	-0.35	-5.88	-0.31	9.89e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg07157834	chr1:205819609	PM20D1	-0.44	-5.89	-0.31	9.66e-9	Menarche (age at onset);
LUSC	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.94	-0.31	7.29e-9	Neuroticism;
LUSC	cis	rs1577917	0.839	rs6929514	chr6:86525768	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.35	-0.33	6.87e-10	Response to antipsychotic treatment;
LUSC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg15557168	chr22:42548783	NA	-0.34	-5.65	-0.3	3.39e-8	Cognitive function;
LUSC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.17	0.32	2.03e-9	Height;
LUSC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg23630131	chr7:65973040	NA	-0.21	-5.93	-0.31	7.77e-9	Aortic root size;
LUSC	cis	rs11039100	1.000	rs35466594	chr11:5826684	T/G	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.66	0.34	1.15e-10	Menopause (age at onset);
LUSC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg15445000	chr17:37608096	MED1	-0.38	-6.58	-0.34	1.84e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7091068	0.707	rs829107	chr10:95418102	C/T	cg20715218	chr10:95462985	C10orf4	-0.56	-5.83	-0.3	1.33e-8	Urinary tract infection frequency;
LUSC	cis	rs9807989	0.507	rs10204757	chr2:102998974	A/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.27e-12	Asthma;
LUSC	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg22532475	chr10:104410764	TRIM8	0.26	6.23	0.32	1.39e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1215050	0.791	rs165242	chr4:98686482	A/C	cg05340658	chr4:99064831	C4orf37	-0.37	-5.67	-0.3	3.14e-8	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg12963246	chr6:28129442	ZNF389	0.56	7.89	0.4	4.28e-14	Parkinson's disease;
LUSC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12618769	0.597	rs2278206	chr2:99172244	A/G	cg10123293	chr2:99228465	UNC50	0.46	7.27	0.37	2.57e-12	Bipolar disorder;
LUSC	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg09835421	chr16:68378352	PRMT7	-0.43	-5.74	-0.3	2.16e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.28	-5.74	-0.3	2.09e-8	Dupuytren's disease;
LUSC	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg05110241	chr16:68378359	PRMT7	-0.52	-6.21	-0.32	1.6e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	cis	rs6435862	0.500	rs12477063	chr2:215673664	C/T	cg04004882	chr2:215674386	BARD1	-0.55	-7.99	-0.4	2.27e-14	Neuroblastoma (high-risk);
LUSC	cis	rs12286929	0.687	rs6589485	chr11:115083875	G/A	cg04055981	chr11:115044050	NA	-0.36	-6.28	-0.32	1.07e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg13042288	chr15:90349979	ANPEP	-0.46	-6.67	-0.34	1.07e-10	Uric acid levels;
LUSC	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg23711669	chr6:146136114	FBXO30	0.87	16.03	0.66	2.75e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg15242686	chr22:24348715	GSTTP1	0.42	6.21	0.32	1.53e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4950928	0.887	rs7556099	chr1:203166198	C/G	cg17014757	chr1:203156097	CHI3L1	-0.43	-7.66	-0.39	2.09e-13	YKL-40 levels;
LUSC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg04036182	chr15:45458818	NA	-0.39	-6.35	-0.33	6.96e-10	Glomerular filtration rate;
LUSC	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg17252645	chr8:143867129	LY6D	0.37	6.58	0.34	1.77e-10	Urinary tract infection frequency;
LUSC	trans	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.29	0.41	2.71e-15	Ulcerative colitis;
LUSC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.89	-0.35	2.76e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg23985595	chr17:80112537	CCDC57	0.33	6.49	0.33	3.11e-10	Life satisfaction;
LUSC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg07806771	chr7:64541737	NA	0.44	6.32	0.33	8.38e-10	Calcium levels;
LUSC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	11.15	0.52	9.46e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg06026331	chr20:60912101	LAMA5	-0.42	-5.72	-0.3	2.41e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs7715806	0.500	rs72633985	chr5:75006384	A/G	cg19683494	chr5:74908142	NA	0.57	7.68	0.39	1.83e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	cis	rs3087591	1.000	rs8082020	chr17:29694795	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.58	-8.18	-0.41	6.14e-15	Hip circumference;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00513467	chr9:21335551	KLHL9	-0.38	-6.44	-0.33	4.18e-10	Electrocardiographic conduction measures;
LUSC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.07	15.97	0.66	4.76e-43	Gut microbiome composition (summer);
LUSC	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg02176678	chr2:219576539	TTLL4	-0.58	-10.36	-0.49	5.62e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3126085	0.935	rs12401851	chr1:152259022	T/C	cg26876637	chr1:152193138	HRNR	-0.44	-5.91	-0.31	8.63e-9	Atopic dermatitis;
LUSC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg19748678	chr4:122722346	EXOSC9	0.49	7.57	0.38	3.59e-13	Type 2 diabetes;
LUSC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-1.19	-12.97	-0.58	2.03e-31	Diabetic kidney disease;
LUSC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.49	-7.37	-0.37	1.33e-12	Renal function-related traits (BUN);
LUSC	cis	rs1403694	0.695	rs67173199	chr3:186432858	G/A	cg12454167	chr3:186435060	KNG1	0.34	8.4	0.42	1.26e-15	Blood protein levels;
LUSC	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-12.07	-0.55	4.42e-28	Electrocardiographic conduction measures;
LUSC	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.73	14.19	0.61	4.47e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg06623918	chr6:96969491	KIAA0776	0.73	8.64	0.43	2.33e-16	Migraine;Coronary artery disease;
LUSC	cis	rs12980942	0.935	rs2241718	chr19:41829606	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.14	0.32	2.37e-9	Coronary artery disease;
LUSC	cis	rs2607426	1.000	rs2604877	chr19:41275048	T/C	cg05508168	chr19:41255947	C19orf54;SNRPA	0.63	5.7	0.3	2.68e-8	Blood protein levels;
LUSC	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.6	-8.78	-0.43	8.78e-17	Response to antineoplastic agents;
LUSC	cis	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg00086871	chr4:6988644	TBC1D14	0.89	8.93	0.44	2.86e-17	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4363385	0.747	rs4240866	chr1:152954875	T/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.78	-0.39	9.11e-14	Inflammatory skin disease;
LUSC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.27	0.59	1.45e-32	Chronic sinus infection;
LUSC	cis	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg09307838	chr4:120376055	NA	-0.48	-7.3	-0.37	2.15e-12	Diastolic blood pressure;
LUSC	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg00857998	chr1:205179979	DSTYK	0.66	10.43	0.5	3.11e-22	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg21827317	chr3:136751795	NA	0.39	6.96	0.36	1.83e-11	Neuroticism;
LUSC	cis	rs911119	0.955	rs67997662	chr20:23592864	G/A	cg16589663	chr20:23618590	CST3	0.57	6.79	0.35	5.04e-11	Chronic kidney disease;
LUSC	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg23127183	chr11:57508653	C11orf31	-0.51	-7.7	-0.39	1.55e-13	Schizophrenia;
LUSC	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg25206134	chr2:45395956	NA	0.61	6.92	0.35	2.38e-11	Bipolar disorder;
LUSC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg11062466	chr8:58055876	NA	0.76	9.09	0.45	9.22e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg22166914	chr1:53195759	ZYG11B	-0.49	-7.71	-0.39	1.5e-13	Monocyte count;
LUSC	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg25767906	chr1:53392781	SCP2	0.39	6.64	0.34	1.29e-10	Monocyte count;
LUSC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg04414720	chr1:150670196	GOLPH3L	0.56	8.99	0.44	1.87e-17	Tonsillectomy;
LUSC	cis	rs4499344	0.657	rs4805768	chr19:33049678	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.75	-10.04	-0.48	6.55e-21	Mean platelet volume;
LUSC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-8.46	-0.42	8.34e-16	Bipolar disorder;
LUSC	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.91	15.42	0.64	7e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.14	-0.45	6.37e-18	Monocyte percentage of white cells;
LUSC	cis	rs2816316	0.943	rs2760524	chr1:192530548	C/T	cg02586212	chr1:192544902	RGS1	-0.31	-5.68	-0.3	2.86e-8	Celiac disease;
LUSC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg02018176	chr4:1364513	KIAA1530	-0.54	-9.43	-0.46	7.04e-19	Obesity-related traits;
LUSC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	7.03	0.36	1.17e-11	Motion sickness;
LUSC	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21293242	chr8:11204541	TDH	0.32	6.0	0.31	5.24e-9	Retinal vascular caliber;
LUSC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.53	-8.43	-0.42	1.04e-15	Platelet count;
LUSC	cis	rs7106204	0.748	rs4382909	chr11:24236618	C/T	ch.11.24196551F	chr11:24239977	NA	1.16	14.62	0.62	8.9e-38	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg21770322	chr7:97807741	LMTK2	0.41	7.25	0.37	2.92e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8028182	0.501	rs11072553	chr15:75932777	C/T	cg20655648	chr15:75932815	IMP3	0.46	6.03	0.31	4.31e-9	Sudden cardiac arrest;
LUSC	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.82	-0.43	6.53e-17	Response to antipsychotic treatment;
LUSC	cis	rs12973672	1.000	rs1051995	chr19:35770292	C/T	cg12095397	chr19:35769544	USF2	0.44	6.91	0.35	2.42e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.29	-0.37	2.29e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.63	8.35	0.42	1.8e-15	High light scatter reticulocyte count;
LUSC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg16339924	chr4:17578868	LAP3	0.63	9.83	0.47	3.27e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.34e-10	Corneal astigmatism;
LUSC	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1996152	0.543	rs9906415	chr17:72389282	A/G	cg23221732	chr17:72383708	NA	0.32	6.34	0.33	7.41e-10	Interleukin-12p70 levels;
LUSC	cis	rs12681287	0.640	rs7816629	chr8:87350788	A/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.06	-0.36	9.96e-12	Caudate activity during reward;
LUSC	trans	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg18187862	chr3:45730750	SACM1L	-0.53	-6.66	-0.34	1.14e-10	Primary sclerosing cholangitis;
LUSC	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	11.22	0.52	5.36e-25	Coronary artery disease;
LUSC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg26304593	chr6:42947056	PEX6	-0.52	-8.27	-0.41	3.21e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg25214090	chr10:38739885	LOC399744	0.49	7.53	0.38	4.82e-13	Corneal astigmatism;
LUSC	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg17462356	chr17:80056334	FASN	0.46	6.21	0.32	1.53e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg21427119	chr20:30132790	HM13	-0.38	-5.82	-0.3	1.37e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs2046867	0.628	rs62249880	chr3:72918940	C/T	cg25664220	chr3:72788482	NA	-0.58	-10.29	-0.49	9.51e-22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg03185820	chr7:149158252	ZNF777	0.37	6.1	0.32	3.01e-9	Coronary artery disease;
LUSC	cis	rs6500395	0.775	rs13331298	chr16:48661489	G/A	cg04672837	chr16:48644449	N4BP1	0.46	6.97	0.36	1.7e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.53	-7.11	-0.36	6.97e-12	Longevity;Endometriosis;
LUSC	cis	rs3845702	1.000	rs3845697	chr2:180798553	C/T	cg01881094	chr2:180872142	CWC22	0.81	10.23	0.49	1.49e-21	Schizophrenia;
LUSC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg13498757	chr1:152161927	NA	0.35	5.77	0.3	1.78e-8	Inflammatory skin disease;
LUSC	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21643547	chr1:205240462	TMCC2	0.5	9.5	0.46	4.26e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7107174	1.000	rs2450128	chr11:77940075	G/A	cg02023728	chr11:77925099	USP35	0.54	7.76	0.39	1.08e-13	Testicular germ cell tumor;
LUSC	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.59	-6.38	-0.33	6.06e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.1	26.23	0.82	4.23e-83	Schizophrenia;
LUSC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg19318889	chr4:1322082	MAEA	0.56	9.52	0.46	3.67e-19	Longevity;
LUSC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg19622623	chr12:86230825	RASSF9	-0.43	-6.11	-0.32	2.77e-9	Major depressive disorder;
LUSC	cis	rs73129298	0.551	rs4647958	chr20:48600631	T/C	cg25655593	chr20:48599521	SNAI1	0.6	6.43	0.33	4.49e-10	Inflammatory skin disease;
LUSC	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.13	-0.36	6.41e-12	Menopause (age at onset);
LUSC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-9.39	-0.46	9.84e-19	Gut microbiome composition (summer);
LUSC	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg21466736	chr12:48725269	NA	-0.33	-5.73	-0.3	2.2e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04141948	chr7:1023156	CYP2W1	0.28	5.87	0.31	1.03e-8	Longevity;Endometriosis;
LUSC	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg00225070	chr15:80189496	MTHFS	0.43	6.12	0.32	2.55e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg14458575	chr2:238380390	NA	0.85	14.2	0.61	4.06e-36	Prostate cancer;
LUSC	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg09650180	chr20:62225654	GMEB2	-0.67	-9.6	-0.47	1.9e-19	Glioblastoma;
LUSC	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg24375607	chr4:120327624	NA	0.5	7.46	0.38	7.65e-13	Diastolic blood pressure;
LUSC	cis	rs7923609	0.967	rs7915779	chr10:65244244	G/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.44	-0.33	4.1e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.87	-12.73	-0.57	1.52e-30	Asthma;
LUSC	cis	rs9811920	0.809	rs13059754	chr3:99678490	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.41	-7.79	-0.39	8.44e-14	Axial length;
LUSC	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21545522	chr1:205238299	TMCC2	0.5	9.4	0.46	8.73e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.22	0.88	3.18e-111	Chronic sinus infection;
LUSC	trans	rs7951105	1.000	rs1906684	chr11:39254930	G/A	cg24085930	chr3:21832523	NA	0.48	6.02	0.31	4.72e-9	Free thyroxine concentration;
LUSC	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.89	0.31	9.34e-9	Breast cancer;
LUSC	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg04362960	chr10:104952993	NT5C2	0.58	9.07	0.44	1.03e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg03351412	chr1:154909251	PMVK	0.51	7.84	0.39	6.3e-14	Prostate cancer;
LUSC	trans	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg26043149	chr18:55253948	FECH	-0.46	-6.98	-0.36	1.55e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-9.45	-0.46	6.23e-19	Depression;
LUSC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.65	-0.34	1.21e-10	Total body bone mineral density;
LUSC	cis	rs10193935	0.901	rs59890734	chr2:42595662	G/A	cg27598129	chr2:42591480	NA	-0.66	-8.78	-0.43	8.72e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-6.05	-0.31	3.78e-9	Retinal vascular caliber;
LUSC	cis	rs7809950	0.906	rs62483723	chr7:107186358	A/C	cg23024343	chr7:107201750	COG5	-0.55	-8.7	-0.43	1.53e-16	Coronary artery disease;
LUSC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg21770322	chr7:97807741	LMTK2	0.42	7.51	0.38	5.55e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg07424592	chr7:64974309	NA	-0.64	-5.72	-0.3	2.34e-8	Diabetic kidney disease;
LUSC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg02038168	chr22:39784481	NA	-0.49	-7.85	-0.39	5.62e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7577696	0.554	rs35978916	chr2:32400635	T/C	cg02381751	chr2:32503542	YIPF4	-0.56	-7.26	-0.37	2.68e-12	Inflammatory biomarkers;
LUSC	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg21827317	chr3:136751795	NA	0.39	6.91	0.35	2.41e-11	Neuroticism;
LUSC	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.2	-0.32	1.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs757081	0.667	rs60173525	chr11:17259967	A/G	cg15432903	chr11:17409602	KCNJ11	-0.38	-5.9	-0.31	8.75e-9	Systolic blood pressure;
LUSC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.73	-0.35	7.45e-11	Tonsillectomy;
LUSC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg11663144	chr21:46675770	NA	-0.4	-7.11	-0.36	6.96e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2219968	1.000	rs6473087	chr8:78974859	A/G	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9300255	0.739	rs6633	chr12:123745809	G/T	cg00376283	chr12:123451042	ABCB9	-0.7	-7.81	-0.39	7.42e-14	Neutrophil percentage of white cells;
LUSC	cis	rs7106204	0.614	rs117122818	chr11:24245880	C/T	ch.11.24196551F	chr11:24239977	NA	1.01	9.09	0.45	9.05e-18	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-8.07	-0.4	1.29e-14	Axial length;
LUSC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	0.61	13.02	0.58	1.31e-31	Prudent dietary pattern;
LUSC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7809950	1.000	rs2808	chr7:107260856	A/G	cg23024343	chr7:107201750	COG5	0.54	8.41	0.42	1.2e-15	Coronary artery disease;
LUSC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.86	10.86	0.51	1.01e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg19610905	chr11:61596333	FADS2	-0.54	-8.2	-0.41	5.22e-15	Trans fatty acid levels;
LUSC	cis	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg27411982	chr8:10470053	RP1L1	0.46	6.83	0.35	4.01e-11	Neuroticism;
LUSC	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg01557791	chr16:72042693	DHODH	-0.52	-7.54	-0.38	4.42e-13	Fibrinogen levels;
LUSC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.5	-8.34	-0.42	1.97e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	ch.19.748535F	chr19:17764577	UNC13A	0.38	6.07	0.32	3.48e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.16	-0.36	5.16e-12	Colorectal cancer;
LUSC	cis	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05901451	chr6:126070800	HEY2	-0.58	-8.59	-0.43	3.43e-16	Endometrial cancer;
LUSC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg01652190	chr22:50026171	C22orf34	-0.3	-6.16	-0.32	2.04e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs56399783	0.901	rs17300022	chr7:2808517	C/T	cg19731401	chr7:2775893	GNA12	-0.66	-8.52	-0.42	5.64e-16	Childhood ear infection;
LUSC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg13175981	chr1:150552382	MCL1	0.44	5.74	0.3	2.1e-8	Blood protein levels;
LUSC	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg02487422	chr3:49467188	NICN1	0.44	7.01	0.36	1.33e-11	Resting heart rate;
LUSC	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.71	-0.3	2.5e-8	Bipolar disorder;
LUSC	trans	rs7939886	0.841	rs11227702	chr11:56034774	A/C	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg24324837	chr19:49891574	CCDC155	0.52	7.4	0.38	1.1e-12	Multiple sclerosis;
LUSC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16732880	chr16:791244	NARFL	-0.45	-6.58	-0.34	1.79e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs308403	0.568	rs67050821	chr4:123674383	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.79	9.88	0.48	2.3e-20	Blood protein levels;
LUSC	cis	rs10992471	0.597	rs11789163	chr9:95234973	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.37	-6.58	-0.34	1.78e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg02018176	chr4:1364513	KIAA1530	-0.43	-7.56	-0.38	4.04e-13	Obesity-related traits;
LUSC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	6.37	0.33	6.4e-10	Tonsillectomy;
LUSC	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg15798862	chr7:76129360	DTX2	-0.48	-7.93	-0.4	3.23e-14	Multiple sclerosis;
LUSC	cis	rs4930561	0.714	rs6591335	chr11:67976812	T/C	cg04465784	chr11:67976953	SUV420H1	-0.29	-5.71	-0.3	2.43e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg00757033	chr12:89920650	WDR51B	0.59	10.4	0.49	3.99e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.6	0.38	3.03e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg20608306	chr11:116969690	SIK3	0.38	7.04	0.36	1.09e-11	Blood protein levels;
LUSC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-0.81	-11.04	-0.52	2.2e-24	Breast cancer;
LUSC	cis	rs17828380	1.000	rs71393137	chr15:63505505	G/T	cg05507819	chr15:63340323	TPM1	-0.7	-5.9	-0.31	8.94e-9	Social communication problems;
LUSC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg04310649	chr10:35416472	CREM	-0.44	-6.83	-0.35	3.97e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.04	-0.31	4.21e-9	Resting heart rate;
LUSC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg11812906	chr14:75593930	NEK9	-0.64	-10.99	-0.52	3.49e-24	Height;
LUSC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.29	-0.49	9.04e-22	Electroencephalogram traits;
LUSC	cis	rs12999616	0.817	rs62157581	chr2:98327502	G/T	cg26665480	chr2:98280029	ACTR1B	0.53	6.05	0.31	3.91e-9	Colorectal cancer;
LUSC	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg13072238	chr3:49761600	GMPPB	0.41	6.86	0.35	3.33e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1124376	0.935	rs12490215	chr3:20156185	A/G	cg05072819	chr3:20081367	KAT2B	0.6	7.1	0.36	7.58e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg23752985	chr2:85803571	VAMP8	0.33	6.44	0.33	4.16e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg05340658	chr4:99064831	C4orf37	-0.44	-6.85	-0.35	3.49e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs240764	0.658	rs10457077	chr6:101196767	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-6.27	-0.32	1.11e-9	Neuroticism;
LUSC	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg18105134	chr13:113819100	PROZ	-0.69	-9.94	-0.48	1.48e-20	Platelet distribution width;
LUSC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.58	0.46	2.38e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg06191203	chr2:152266755	RIF1	-0.54	-7.33	-0.37	1.71e-12	Lung cancer;
LUSC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg06454157	chr6:167490870	NA	-0.28	-6.87	-0.35	3.1e-11	Primary biliary cholangitis;
LUSC	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs7818345	0.967	rs12543061	chr8:19286181	G/T	cg11303988	chr8:19266685	CSGALNACT1	-0.38	-7.47	-0.38	6.86e-13	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs4919687	0.577	rs12765459	chr10:104465687	G/C	cg05855489	chr10:104503620	C10orf26	0.75	11.25	0.52	3.97e-25	Colorectal cancer;
LUSC	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg18827107	chr12:86230957	RASSF9	-0.49	-7.15	-0.36	5.47e-12	Major depressive disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17484629	chr4:111119220	ELOVL6	-0.45	-6.62	-0.34	1.41e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs477692	1.000	rs522891	chr10:131430916	T/C	cg11019008	chr10:131425282	MGMT	-0.4	-5.95	-0.31	6.82e-9	Response to temozolomide;
LUSC	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg06784218	chr1:46089804	CCDC17	0.36	6.12	0.32	2.66e-9	Platelet count;
LUSC	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg10596483	chr8:143751796	JRK	0.52	7.57	0.38	3.79e-13	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.79	0.39	8.73e-14	Prudent dietary pattern;
LUSC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.81	-0.51	1.42e-23	Aortic root size;
LUSC	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg12140854	chr5:148520817	ABLIM3	-0.4	-5.94	-0.31	7.27e-9	Breast cancer;
LUSC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg21970626	chr13:21893289	NA	-0.42	-5.67	-0.3	3.12e-8	White matter hyperintensity burden;
LUSC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg15352829	chr14:105391018	PLD4	-0.41	-8.51	-0.42	5.91e-16	Rheumatoid arthritis;
LUSC	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg15557168	chr22:42548783	NA	-0.33	-5.72	-0.3	2.43e-8	Cognitive function;
LUSC	cis	rs6740322	0.696	rs10188539	chr2:43484675	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-6.46	-0.33	3.65e-10	Coronary artery disease;
LUSC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg06454157	chr6:167490870	NA	-0.24	-6.04	-0.31	4.19e-9	Crohn's disease;
LUSC	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-15.58	-0.65	1.68e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.91	13.97	0.61	2.92e-35	Menarche (age at onset);
LUSC	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg06532163	chr17:45867833	NA	0.33	6.06	0.31	3.6e-9	IgG glycosylation;
LUSC	cis	rs4629180	0.544	rs7595274	chr2:102140086	T/C	cg01388757	chr2:102091195	RFX8	-0.36	-6.16	-0.32	2.03e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.92	0.31	8.17e-9	Tonsillectomy;
LUSC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.72	-0.43	1.32e-16	Bipolar disorder;
LUSC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg22920501	chr2:26401640	FAM59B	0.83	12.38	0.56	3.16e-29	Gut microbiome composition (summer);
LUSC	cis	rs7188861	0.768	rs60409583	chr16:11392098	C/T	cg00044050	chr16:11439710	C16orf75	0.57	6.35	0.33	7.17e-10	HDL cholesterol;
LUSC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg12463550	chr7:65579703	CRCP	-0.57	-8.62	-0.43	2.65e-16	Aortic root size;
LUSC	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg25233709	chr10:116636983	FAM160B1	0.39	6.59	0.34	1.7e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	7.9	0.4	4.19e-14	Parkinson's disease;
LUSC	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg12590608	chr7:158785262	NA	-0.37	-6.3	-0.33	9.26e-10	Facial morphology (factor 20);
LUSC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg12463550	chr7:65579703	CRCP	0.55	8.21	0.41	4.85e-15	Aortic root size;
LUSC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg12935359	chr14:103987150	CKB	-0.52	-8.09	-0.4	1.15e-14	Body mass index;
LUSC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg23711669	chr6:146136114	FBXO30	0.82	14.38	0.62	8.11e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg13175981	chr1:150552382	MCL1	0.44	6.13	0.32	2.47e-9	Tonsillectomy;
LUSC	cis	rs500891	0.574	rs13196407	chr6:84120820	G/A	cg08257003	chr6:84140564	ME1	0.34	7.6	0.38	3.06e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.95	-14.71	-0.63	4.02e-38	Initial pursuit acceleration;
LUSC	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.44	-6.28	-0.32	1.08e-9	Corneal astigmatism;
LUSC	cis	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg06521331	chr12:34319734	NA	-0.47	-7.68	-0.39	1.78e-13	Morning vs. evening chronotype;
LUSC	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg27284194	chr4:1044797	NA	0.57	8.39	0.42	1.35e-15	Recombination rate (females);
LUSC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg09640425	chr7:158790006	NA	-0.4	-6.22	-0.32	1.5e-9	Facial morphology (factor 20);
LUSC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.46	0.59	2.79e-33	Platelet count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11559952	chr10:112064744	SMNDC1	-0.52	-6.29	-0.33	1.01e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg24060327	chr5:131705240	SLC22A5	-0.67	-11.47	-0.53	6.44e-26	Acylcarnitine levels;
LUSC	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.5	7.21	0.37	3.75e-12	Coronary heart disease;
LUSC	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg05343316	chr1:45956843	TESK2	0.65	8.88	0.44	4.17e-17	Platelet count;
LUSC	cis	rs12928939	0.769	rs12445161	chr16:71741928	C/T	cg03805757	chr16:71968109	PKD1L3	-0.4	-5.86	-0.31	1.08e-8	Post bronchodilator FEV1;
LUSC	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	12.62	0.57	3.86e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-11.84	-0.54	3.05e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg05714579	chr10:131428358	MGMT	0.52	7.98	0.4	2.44e-14	Response to temozolomide;
LUSC	cis	rs7000551	0.725	rs2449349	chr8:22383284	A/G	cg12081754	chr8:22256438	SLC39A14	0.43	6.47	0.33	3.5e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.38	0.49	4.76e-22	Schizophrenia;
LUSC	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg04608330	chr12:45269318	NELL2	-0.56	-8.95	-0.44	2.49e-17	Gut microbiome composition (summer);
LUSC	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.26	15.61	0.65	1.19e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-7.97	-0.4	2.62e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.62	12.65	0.57	3.08e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg04545296	chr12:48745243	ZNF641	0.34	6.17	0.32	1.98e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.0	0.31	5.17e-9	Platelet count;
LUSC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg11941060	chr3:133502564	NA	-0.56	-8.62	-0.43	2.63e-16	Iron status biomarkers;
LUSC	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg09491104	chr22:46646882	C22orf40	0.58	7.18	0.37	4.48e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11030122	0.702	rs10767713	chr11:3950157	T/C	cg18678763	chr11:4115507	RRM1	-0.43	-5.67	-0.3	3.11e-8	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg20935933	chr6:143382018	AIG1	0.43	6.55	0.34	2.15e-10	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg08085267	chr17:45401833	C17orf57	0.54	8.83	0.44	6.01e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg15556689	chr8:8085844	FLJ10661	0.57	7.82	0.39	6.97e-14	Neuroticism;
LUSC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg20135002	chr11:47629003	NA	-0.51	-8.11	-0.41	9.83e-15	Body mass index;
LUSC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg20821713	chr7:1055600	C7orf50	-0.38	-6.03	-0.31	4.42e-9	Longevity;Endometriosis;
LUSC	cis	rs738322	0.555	rs5750548	chr22:38547016	C/A	cg25457927	chr22:38595422	NA	-0.4	-7.95	-0.4	2.85e-14	Cutaneous nevi;
LUSC	trans	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.73	0.43	1.23e-16	Type 2 diabetes;
LUSC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg22681709	chr2:178499509	PDE11A	-0.61	-12.34	-0.56	4.35e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs983392	0.805	rs7116190	chr11:59964992	G/A	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.17	-0.32	1.95e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.97	0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg14440974	chr22:39074834	NA	-0.35	-5.79	-0.3	1.59e-8	Menopause (age at onset);
LUSC	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg06191203	chr2:152266755	RIF1	-0.42	-5.84	-0.3	1.23e-8	Lung cancer;
LUSC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08280861	chr8:58055591	NA	0.54	6.39	0.33	5.53e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1018836	0.923	rs6988733	chr8:91535686	C/T	cg16814680	chr8:91681699	NA	-0.76	-12.65	-0.57	3.18e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9311676	0.656	rs11130635	chr3:58379143	A/G	cg26110898	chr3:58419937	PDHB	0.42	6.83	0.35	4.07e-11	Systemic lupus erythematosus;
LUSC	cis	rs9467711	0.720	rs7749823	chr6:26158079	A/C	cg12315302	chr6:26189340	HIST1H4D	0.58	5.79	0.3	1.64e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2219968	0.962	rs4565449	chr8:78939877	C/T	cg00738934	chr8:78996279	NA	-0.39	-6.87	-0.35	3.21e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10761482	0.769	rs1417380	chr10:62111286	T/C	cg18175470	chr10:62150864	ANK3	-0.53	-7.5	-0.38	5.65e-13	Schizophrenia;
LUSC	cis	rs9420	0.961	rs682503	chr11:57640994	C/G	cg23127183	chr11:57508653	C11orf31	0.53	7.68	0.39	1.76e-13	Schizophrenia;
LUSC	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.73	-0.35	7.44e-11	Daytime sleep phenotypes;
LUSC	cis	rs9309473	0.660	rs17349321	chr2:73643753	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-5.86	-0.31	1.14e-8	Metabolite levels;
LUSC	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg18876405	chr7:65276391	NA	0.6	9.58	0.46	2.35e-19	Aortic root size;
LUSC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg19592336	chr6:28129416	ZNF389	0.46	6.38	0.33	5.9e-10	Parkinson's disease;
LUSC	trans	rs2490361	0.966	rs2490362	chr1:237325861	C/T	cg15653282	chr18:11689218	GNAL	0.4	6.05	0.31	3.92e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	7.53	0.38	4.68e-13	Cognitive test performance;
LUSC	cis	rs7605827	0.930	rs11689686	chr2:15527659	C/T	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.2	0.41	5.24e-15	Homoarginine levels;
LUSC	cis	rs1113500	0.933	rs2077259	chr1:108629551	T/C	cg11967332	chr1:108735228	SLC25A24	0.38	5.76	0.3	1.92e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg01420254	chr6:26195488	NA	0.69	7.48	0.38	6.55e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14019695	chr9:139328340	INPP5E	-0.51	-10.03	-0.48	7.34e-21	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14558428	chr5:142784982	NR3C1	-0.4	-6.05	-0.31	3.97e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg11502198	chr6:26597334	ABT1	0.72	12.07	0.55	4.23e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg13736514	chr6:26305472	NA	-0.45	-8.94	-0.44	2.72e-17	Educational attainment;
LUSC	trans	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.63	-0.39	2.43e-13	Menarche (age at onset);
LUSC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.6	-0.34	1.58e-10	Lung cancer;
LUSC	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg09835421	chr16:68378352	PRMT7	-0.54	-6.08	-0.32	3.32e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9650315	0.866	rs4576404	chr8:57181155	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.8	0.35	4.85e-11	Height;
LUSC	trans	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg26043149	chr18:55253948	FECH	-0.52	-7.6	-0.38	3e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.11	-0.36	7.15e-12	Bipolar disorder;
LUSC	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg16950941	chr11:66035639	RAB1B	0.53	7.8	0.39	7.78e-14	Gout;
LUSC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg21573476	chr21:45109991	RRP1B	-0.43	-6.97	-0.36	1.75e-11	Mean corpuscular volume;
LUSC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg21361702	chr7:150065534	REPIN1	0.5	6.77	0.35	5.8200000000000003e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11690935	0.655	rs1028127	chr2:172530036	T/C	cg13550731	chr2:172543902	DYNC1I2	0.59	9.42	0.46	7.79e-19	Schizophrenia;
LUSC	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.76	-12.28	-0.56	7.07e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg02569458	chr12:86230093	RASSF9	0.48	7.63	0.39	2.4e-13	Major depressive disorder;
LUSC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.02	-0.44	1.49e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg07424592	chr7:64974309	NA	0.7	6.05	0.31	3.99e-9	Diabetic kidney disease;
LUSC	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17173187	chr15:85201210	NMB	0.48	9.28	0.45	2.17e-18	Schizophrenia;
LUSC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00339695	chr16:24857497	SLC5A11	0.62	9.33	0.45	1.54e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg05855489	chr10:104503620	C10orf26	-0.49	-7.47	-0.38	7.25e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg09904177	chr6:26538194	HMGN4	-0.75	-5.79	-0.3	1.63e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8044995	0.563	rs3785113	chr16:68369213	T/C	cg05110241	chr16:68378359	PRMT7	-0.76	-8.6	-0.43	3.22e-16	Schizophrenia;
LUSC	cis	rs780094	0.500	rs12987055	chr2:27834152	T/C	cg27432699	chr2:27873401	GPN1	0.41	5.82	0.3	1.35e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	trans	rs7916697	0.626	rs3858146	chr10:70013250	C/T	cg04882175	chr6:131122610	NA	-0.51	-6.59	-0.34	1.74e-10	Optic disc area;
LUSC	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg08000102	chr2:233561755	GIGYF2	0.8	13.77	0.6	1.83e-34	Schizophrenia;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg12439834	chr1:1410849	ATAD3B	-0.39	-6.06	-0.31	3.75e-9	Schizophrenia (age at onset);
LUSC	cis	rs193541	0.530	rs9327272	chr5:122073548	T/C	cg19077854	chr5:122220652	SNX24	0.34	7.04	0.36	1.13e-11	Glucose homeostasis traits;
LUSC	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.59	-0.43	3.28e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg03647239	chr10:116582469	FAM160B1	-0.43	-6.84	-0.35	3.71e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs3862435	0.706	rs2601198	chr15:90945443	C/G	cg22089800	chr15:90895588	ZNF774	-0.56	-6.12	-0.32	2.57e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg05985134	chr18:33552581	C18orf21	0.52	7.09	0.36	8.19e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.57	-0.42	4.02e-16	Triglycerides;
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	10.05	0.48	6.22e-21	Lymphocyte counts;
LUSC	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg02176678	chr2:219576539	TTLL4	-0.58	-10.17	-0.49	2.38e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg09238746	chr17:78121135	EIF4A3	-0.43	-6.11	-0.32	2.83e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg26850624	chr5:429559	AHRR	-0.41	-8.0	-0.4	2.1e-14	Cystic fibrosis severity;
LUSC	cis	rs3790645	1.000	rs188158	chr1:26898142	A/G	cg17456097	chr1:26900765	RPS6KA1	0.45	6.6	0.34	1.58e-10	Glucose homeostasis traits;
LUSC	cis	rs11958404	0.932	rs113264420	chr5:157437779	T/C	cg05962755	chr5:157440814	NA	0.53	6.3	0.33	9.34e-10	IgG glycosylation;
LUSC	cis	rs7191700	0.578	rs243327	chr16:11353304	C/T	cg00044050	chr16:11439710	C16orf75	-0.67	-12.16	-0.55	2.04e-28	Multiple sclerosis;
LUSC	cis	rs2692947	0.666	rs10183151	chr2:96774786	T/G	cg23100626	chr2:96804247	ASTL	-0.29	-6.74	-0.35	6.92e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.63	8.41	0.42	1.25e-15	Adiposity;
LUSC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg22800045	chr5:56110881	MAP3K1	0.78	9.7	0.47	9.52e-20	Initial pursuit acceleration;
LUSC	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-10.2	-0.49	1.94e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg21545522	chr1:205238299	TMCC2	-0.46	-8.49	-0.42	6.98e-16	Red blood cell count;
LUSC	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg23093090	chr10:104574429	C10orf26	0.48	9.08	0.44	9.75e-18	Waist circumference;Hip circumference;
LUSC	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-14.05	-0.61	1.51e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg05872129	chr22:39784769	NA	-0.59	-11.12	-0.52	1.21e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg06238570	chr21:40685208	BRWD1	-0.54	-8.4	-0.42	1.28e-15	Menarche (age at onset);
LUSC	cis	rs9650315	0.866	rs34931142	chr8:57186807	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.88	0.35	3.01e-11	Height;
LUSC	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg06885757	chr1:42089581	HIVEP3	0.41	7.69	0.39	1.65e-13	Airway imaging phenotypes;
LUSC	trans	rs75804782	0.520	rs34058921	chr2:239318665	C/T	cg01134436	chr17:81009848	B3GNTL1	0.64	6.08	0.32	3.37e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg05872129	chr22:39784769	NA	-0.59	-10.95	-0.51	4.72e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg13334819	chr7:99746414	C7orf59	0.5	6.79	0.35	5.04e-11	Coronary artery disease;
LUSC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.53	-7.42	-0.38	9.89e-13	Renal function-related traits (BUN);
LUSC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.32	6.25	0.32	1.23e-9	Obesity-related traits;
LUSC	cis	rs10465746	0.846	rs12146038	chr1:84405065	A/T	cg10977910	chr1:84465055	TTLL7	0.41	6.09	0.32	3.06e-9	Obesity-related traits;
LUSC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25880573	chr1:24073129	TCEB3	-0.37	-5.99	-0.31	5.56e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg18825076	chr15:78729989	IREB2	-0.47	-6.49	-0.33	3.1e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs500891	0.574	rs7750443	chr6:84112468	A/G	cg08257003	chr6:84140564	ME1	0.34	8.01	0.4	1.98e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08736216	chr1:53307985	ZYG11A	-0.29	-6.27	-0.32	1.11e-9	Monocyte count;
LUSC	cis	rs6977660	1.000	rs5017191	chr7:19820158	C/A	cg05791153	chr7:19748676	TWISTNB	0.53	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LUSC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11764359	chr7:65958608	NA	-0.58	-8.99	-0.44	1.87e-17	Aortic root size;
LUSC	cis	rs13401104	0.754	rs11687335	chr2:237117233	A/C	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	6.71	0.34	8.3e-11	Response to antipsychotic treatment;
LUSC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.89	0.31	9.52e-9	Menopause (age at onset);
LUSC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.51	0.62	2.44e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg15448220	chr1:150897856	SETDB1	0.43	6.23	0.32	1.43e-9	Melanoma;
LUSC	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg19628046	chr18:33552617	C18orf21	0.52	6.29	0.33	9.87e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg27165867	chr14:105738592	BRF1	-0.49	-7.11	-0.36	7.05e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs796825	0.530	rs2319670	chr3:119996276	T/C	cg21790991	chr3:120137480	FSTL1	-0.33	-6.07	-0.32	3.49e-9	HIV-1 susceptibility;
LUSC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26314531	chr2:26401878	FAM59B	-0.68	-9.23	-0.45	3.17e-18	Gut microbiome composition (summer);
LUSC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg17764715	chr19:33622953	WDR88	0.62	9.16	0.45	5.18e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22857025	chr5:266934	NA	-1.2	-14.11	-0.61	8.51e-36	Breast cancer;
LUSC	cis	rs2625529	0.824	rs12906711	chr15:72215065	A/G	cg16672083	chr15:72433130	SENP8	-0.52	-7.54	-0.38	4.52e-13	Red blood cell count;
LUSC	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg10547527	chr2:198650123	BOLL	-0.51	-5.98	-0.31	5.87e-9	Ulcerative colitis;
LUSC	cis	rs12210905	0.688	rs72839474	chr6:27324757	T/C	cg08851530	chr6:28072375	NA	0.9	5.78	0.3	1.75e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.48	-8.08	-0.4	1.24e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs57466243	1	rs57466243	chr17:27059666	T/A	cg09479241	chr17:27052676	TLCD1	-0.34	-5.96	-0.31	6.38e-9	Reticulocyte count;
LUSC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg23711669	chr6:146136114	FBXO30	0.92	17.69	0.7	7.02e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2075165	0.901	rs1043165	chr1:156220056	T/C	cg20302342	chr1:156215951	PAQR6	0.33	6.3	0.33	9.13e-10	Tonsillectomy;
LUSC	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.63	0.73	1.36e-57	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg23933602	chr10:16859644	RSU1	0.6	7.28	0.37	2.43e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25072359	chr17:41440525	NA	0.66	9.28	0.45	2.14e-18	Menopause (age at onset);
LUSC	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	trans	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg11887960	chr12:57824829	NA	0.53	6.51	0.34	2.81e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.6	13.87	0.6	7.29e-35	Height;
LUSC	cis	rs7615316	1.000	rs1357530	chr3:142350756	C/T	cg16271453	chr3:142027066	XRN1	-0.34	-5.82	-0.3	1.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg12143784	chr7:64541923	NA	-0.38	-6.05	-0.31	3.95e-9	Calcium levels;
LUSC	cis	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.8	0.43	7.65e-17	Endometrial cancer;
LUSC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06850241	chr22:41845214	NA	0.31	5.86	0.31	1.13e-8	Vitiligo;
LUSC	cis	rs2274273	0.840	rs7153110	chr14:55820628	A/G	cg04306507	chr14:55594613	LGALS3	0.57	13.21	0.59	2.46e-32	Protein biomarker;
LUSC	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg10845886	chr2:3471009	TTC15	-0.52	-6.97	-0.36	1.71e-11	Neurofibrillary tangles;
LUSC	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18932078	chr1:2524107	MMEL1	-0.29	-6.44	-0.33	4.14e-10	Ulcerative colitis;
LUSC	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg22906224	chr7:99728672	NA	-0.5	-6.94	-0.35	2.09e-11	Coronary artery disease;
LUSC	cis	rs2976388	0.647	rs13272904	chr8:143782614	T/C	cg17252645	chr8:143867129	LY6D	0.39	6.84	0.35	3.86e-11	Urinary tract infection frequency;
LUSC	cis	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg06521852	chr22:38141419	TRIOBP	0.43	6.56	0.34	2.08e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.94	-0.48	1.47e-20	Mood instability;
LUSC	cis	rs13315871	1.000	rs36097398	chr3:58367330	G/A	cg12435725	chr3:58293450	RPP14	-0.72	-7.16	-0.36	5.13e-12	Cholesterol, total;
LUSC	cis	rs2860975	1.000	rs2226070	chr10:96776721	C/T	cg09036531	chr10:96991505	NA	-0.41	-5.69	-0.3	2.75e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.53	0.46	3.29e-19	Coffee consumption (cups per day);
LUSC	cis	rs7590368	0.715	rs72779452	chr2:10959461	G/T	cg15705551	chr2:10952987	PDIA6	0.58	6.24	0.32	1.31e-9	Educational attainment (years of education);
LUSC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	9.15	0.45	5.74e-18	Mean platelet volume;
LUSC	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg08755490	chr11:65554678	OVOL1	0.4	5.82	0.3	1.4e-8	Acne (severe);
LUSC	trans	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.35	0.49	5.71e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs11858210	1	rs11858210	chr15:79078358	G/A	cg00540400	chr15:79124168	NA	-0.4	-6.97	-0.36	1.71e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.87	-0.31	1.05e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg23795048	chr12:9217529	LOC144571	0.34	5.93	0.31	7.77e-9	Sjögren's syndrome;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg00024416	chr22:24240387	NA	-0.33	-5.68	-0.3	2.96e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.79	11.33	0.53	2.2e-25	Corneal astigmatism;
LUSC	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg15395560	chr15:45543142	SLC28A2	0.34	5.71	0.3	2.5e-8	Uric acid levels;
LUSC	trans	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Depression;
LUSC	trans	rs1459104	0.641	rs12790762	chr11:54933709	T/A	cg15704280	chr7:45808275	SEPT13	0.66	5.96	0.31	6.31e-9	Body mass index;
LUSC	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg06627628	chr2:24431161	ITSN2	0.64	9.57	0.46	2.49e-19	Asthma;
LUSC	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg07382826	chr16:28625726	SULT1A1	0.27	5.82	0.3	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs231513	0.954	rs231479	chr17:41983616	A/G	cg26893861	chr17:41843967	DUSP3	-0.53	-6.06	-0.31	3.64e-9	Cognitive function;
LUSC	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg20243544	chr17:37824526	PNMT	0.45	5.7	0.3	2.69e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.94	0.36	2.05e-11	Cystic fibrosis severity;
LUSC	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg14019695	chr9:139328340	INPP5E	0.45	8.14	0.41	7.67e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg14675211	chr2:100938903	LONRF2	0.37	5.72	0.3	2.35e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21385522	chr1:16154831	NA	0.56	8.91	0.44	3.29e-17	Systolic blood pressure;
LUSC	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.37	-0.33	6.16e-10	Retinal vascular caliber;
LUSC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.11	0.32	2.79e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg03213289	chr20:61660250	NA	0.67	13.61	0.6	7.23e-34	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg05340658	chr4:99064831	C4orf37	0.59	8.88	0.44	4.12e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7215564	0.908	rs2316059	chr17:78663732	C/T	cg23238734	chr17:78661607	RPTOR	0.47	6.1	0.32	2.98e-9	Myopia (pathological);
LUSC	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.22	-0.41	4.54e-15	Neuroticism;
LUSC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg15595755	chr5:1867978	NA	0.47	8.71	0.43	1.4e-16	Cardiovascular disease risk factors;
LUSC	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg27284194	chr4:1044797	NA	-0.57	-8.93	-0.44	2.9e-17	Recombination rate (females);
LUSC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	7.18	0.37	4.48e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg08999081	chr20:33150536	PIGU	0.37	6.69	0.34	9.61e-11	Height;
LUSC	cis	rs17756712	0.527	rs1747586	chr6:614375	A/C	cg14374089	chr6:596013	EXOC2	0.5	6.69	0.34	9.15e-11	Vertical cup-disc ratio;
LUSC	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg15744005	chr10:104629667	AS3MT	-0.32	-5.95	-0.31	6.93e-9	Arsenic metabolism;
LUSC	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg05805236	chr11:65401703	PCNXL3	0.4	6.79	0.35	5.06e-11	Acne (severe);
LUSC	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg05294307	chr14:35346193	BAZ1A	-0.57	-7.05	-0.36	1.03e-11	Psoriasis;
LUSC	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg07148914	chr20:33460835	GGT7	-0.44	-6.57	-0.34	1.98e-10	Height;
LUSC	trans	rs1376359	0.537	rs594441	chr1:103264019	T/G	cg17154563	chr19:40477487	PSMC4	0.47	5.97	0.31	5.92e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg13010199	chr12:38710504	ALG10B	0.71	10.9	0.51	7.24e-24	Bladder cancer;
LUSC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg14784868	chr12:69753453	YEATS4	0.64	9.48	0.46	4.77e-19	Blood protein levels;
LUSC	trans	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.12	0.45	7.26e-18	Mean corpuscular volume;
LUSC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.16	16.28	0.67	2.76e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg19875535	chr5:140030758	IK	-0.55	-8.95	-0.44	2.52e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg06521331	chr12:34319734	NA	-0.41	-6.39	-0.33	5.57e-10	Morning vs. evening chronotype;
LUSC	trans	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-8.56	-0.42	4.22e-16	Obesity-related traits;
LUSC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg23262073	chr20:60523788	NA	-0.5	-7.08	-0.36	8.41e-12	Body mass index;
LUSC	cis	rs9581857	0.547	rs9581870	chr13:28083957	T/G	cg22138327	chr13:27999177	GTF3A	0.65	6.86	0.35	3.45e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.9	13.04	0.58	1.02e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg00427296	chr17:8534932	MYH10	-0.54	-6.03	-0.31	4.38e-9	Blood protein levels;
LUSC	cis	rs30380	0.632	rs26500	chr5:96133712	A/C	cg16492584	chr5:96139282	ERAP1	-0.56	-7.56	-0.38	3.84e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg24733560	chr20:60626293	TAF4	0.41	6.75	0.35	6.46e-11	Body mass index;
LUSC	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg12559939	chr2:27858050	GPN1	0.41	6.41	0.33	5e-10	Oral cavity cancer;
LUSC	trans	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg12856521	chr11:46389249	DGKZ	0.43	6.41	0.33	4.88e-10	Leprosy;
LUSC	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.82	-15.32	-0.64	1.72e-40	Obesity-related traits;
LUSC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg19622623	chr12:86230825	RASSF9	-0.45	-6.22	-0.32	1.53e-9	Major depressive disorder;
LUSC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.17	0.37	4.94e-12	Cognitive ability;
LUSC	trans	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg07211511	chr3:129823064	LOC729375	-0.81	-10.75	-0.51	2.48e-23	Blood pressure (smoking interaction);
LUSC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg08888203	chr3:10149979	C3orf24	0.45	6.83	0.35	4.08e-11	Alzheimer's disease;
LUSC	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.78	11.2	0.52	6.08e-25	Corneal astigmatism;
LUSC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg14552801	chr7:65878734	NA	0.44	6.3	0.33	9.33e-10	Aortic root size;
LUSC	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21293242	chr8:11204541	TDH	0.33	6.32	0.33	8.31e-10	Retinal vascular caliber;
LUSC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg18758796	chr5:131593413	PDLIM4	-0.42	-6.76	-0.35	6.25e-11	Breast cancer;
LUSC	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.65	9.94	0.48	1.5e-20	Schizophrenia;
LUSC	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg21775007	chr8:11205619	TDH	0.54	7.52	0.38	5.09e-13	Monocyte count;
LUSC	cis	rs870825	0.616	rs4615214	chr4:185624129	G/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs76419734	0.510	rs3943980	chr4:106676766	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.57	-6.5	-0.34	2.9e-10	Post bronchodilator FEV1;
LUSC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	0.56	8.6	0.43	3.04e-16	Breast cancer;
LUSC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.19	-0.32	1.79e-9	Initial pursuit acceleration;
LUSC	trans	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg18187862	chr3:45730750	SACM1L	-0.53	-6.54	-0.34	2.33e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg13939156	chr17:80058883	NA	0.34	6.64	0.34	1.27e-10	Life satisfaction;
LUSC	cis	rs6005807	0.719	rs12165893	chr22:29033545	T/C	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg03340356	chr1:67600835	NA	0.39	6.37	0.33	6.14e-10	Psoriasis;
LUSC	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.45	-6.45	-0.33	3.96e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	0.56	8.68	0.43	1.72e-16	Breast cancer;
LUSC	cis	rs17253792	0.822	rs77415412	chr14:56154146	A/G	cg01858014	chr14:56050164	KTN1	-0.82	-6.77	-0.35	5.9e-11	Putamen volume;
LUSC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg09455208	chr3:40491958	NA	0.53	9.59	0.46	2.07e-19	Renal cell carcinoma;
LUSC	cis	rs713587	0.571	rs2438679	chr2:25317653	C/T	cg01884057	chr2:25150051	NA	-0.27	-5.84	-0.3	1.26e-8	Body mass index in non-asthmatics;
LUSC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.43	7.29	0.37	2.2e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg05855489	chr10:104503620	C10orf26	-0.71	-10.35	-0.49	5.72e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-9.99	-0.48	1.01e-20	Neuroticism;
LUSC	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg04362960	chr10:104952993	NT5C2	0.6	9.71	0.47	8.52e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg22563815	chr15:78856949	CHRNA5	-0.25	-6.03	-0.31	4.36e-9	Sudden cardiac arrest;
LUSC	cis	rs16912285	0.688	rs11827298	chr11:24324000	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	9.52	0.46	3.58e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.6	-11.81	-0.54	3.82e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg06784218	chr1:46089804	CCDC17	-0.5	-9.46	-0.46	5.75e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg18904891	chr8:8559673	CLDN23	0.61	8.43	0.42	1.05e-15	Obesity-related traits;
LUSC	cis	rs6546886	0.912	rs6745792	chr2:74284033	G/A	cg14702570	chr2:74259524	NA	-0.31	-5.83	-0.3	1.31e-8	Dialysis-related mortality;
LUSC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg12463550	chr7:65579703	CRCP	0.45	6.73	0.35	7.31e-11	Aortic root size;
LUSC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-7.31	-0.37	1.94e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.67	-11.8	-0.54	4.41e-27	Aortic root size;
LUSC	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	10.76	0.51	2.17e-23	Coffee consumption (cups per day);
LUSC	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg03678062	chr6:149772716	ZC3H12D	-0.32	-6.63	-0.34	1.34e-10	Dupuytren's disease;
LUSC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg01181863	chr3:195395398	SDHAP2	-0.6	-8.15	-0.41	7.43e-15	Pancreatic cancer;
LUSC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg04727924	chr7:799746	HEATR2	-0.55	-6.75	-0.35	6.66e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1595825	0.891	rs16824376	chr2:198684342	C/T	cg10547527	chr2:198650123	BOLL	-0.51	-5.9	-0.31	8.72e-9	Ulcerative colitis;
LUSC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.51	-0.42	5.93e-16	Chronic sinus infection;
LUSC	cis	rs778371	0.630	rs13007579	chr2:233725364	G/A	cg08000102	chr2:233561755	GIGYF2	-0.79	-12.61	-0.57	4.31e-30	Schizophrenia;
LUSC	cis	rs9359856	0.517	rs72919948	chr6:90509389	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.22	-0.41	4.65e-15	Bipolar disorder;
LUSC	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg01028140	chr2:1542097	TPO	-0.6	-8.18	-0.41	5.94e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg08917208	chr2:24149416	ATAD2B	1.01	10.6	0.5	7.75e-23	Lymphocyte counts;
LUSC	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg17623882	chr6:41773611	USP49	-0.64	-10.74	-0.51	2.65e-23	Menarche (age at onset);
LUSC	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.61	-9.71	-0.47	8.36e-20	HDL cholesterol;
LUSC	cis	rs2835872	0.861	rs8126563	chr21:39052624	C/T	cg20424643	chr21:39039972	KCNJ6	0.44	6.84	0.35	3.71e-11	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7202877	0.706	rs247450	chr16:75490017	C/A	cg04384234	chr16:75411784	CFDP1	0.66	8.56	0.42	4.08e-16	Type 2 diabetes;Type 1 diabetes;
LUSC	trans	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg26043149	chr18:55253948	FECH	-0.54	-8.09	-0.4	1.13e-14	Bone mineral density;
LUSC	trans	rs3960554	0.808	rs111714534	chr7:75748896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	9.42	0.46	7.54e-19	Eotaxin levels;
LUSC	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg04310649	chr10:35416472	CREM	-0.43	-6.38	-0.33	5.89e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg02167203	chr6:41068553	NFYA;LOC221442	0.39	5.82	0.3	1.35e-8	Alzheimer's disease (late onset);
LUSC	cis	rs617219	0.819	rs6453434	chr5:78570219	G/T	cg24856658	chr5:78533917	JMY	0.31	6.0	0.31	5.2e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.87	-11.82	-0.54	3.63e-27	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg26924012	chr15:45694286	SPATA5L1	1.14	20.79	0.75	3.36e-62	Homoarginine levels;
LUSC	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg25206134	chr2:45395956	NA	0.59	6.5	0.34	2.95e-10	Bipolar disorder;
LUSC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-5.74	-0.3	2.18e-8	Vitiligo;
LUSC	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25530631	chr11:61100500	DDB1;DAK	-0.41	-6.02	-0.31	4.51e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	13.0	0.58	1.5e-31	Alzheimer's disease;
LUSC	cis	rs2580764	0.566	rs2968794	chr2:55290651	C/G	cg09592903	chr2:55203963	RTN4	-0.48	-9.92	-0.48	1.76e-20	Mean platelet volume;
LUSC	trans	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg06606381	chr12:133084897	FBRSL1	-0.9	-7.7	-0.39	1.51e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg05855489	chr10:104503620	C10orf26	0.58	9.25	0.45	2.73e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	0.81	14.85	0.63	1.19e-38	Ulcerative colitis;
LUSC	cis	rs7267979	0.549	rs6138536	chr20:25182648	A/G	cg08601574	chr20:25228251	PYGB	0.44	6.73	0.35	7.59e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg14696996	chr19:15285081	NOTCH3	0.96	9.25	0.45	2.69e-18	Pulse pressure;
LUSC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg19622623	chr12:86230825	RASSF9	-0.42	-6.01	-0.31	4.85e-9	Major depressive disorder;
LUSC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.53	0.46	3.44e-19	Bipolar disorder;
LUSC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg12257692	chr3:49977190	RBM6	0.24	6.67	0.34	1.06e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.8	-0.43	7.27e-17	Monocyte percentage of white cells;
LUSC	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg18129178	chr5:148520854	ABLIM3	-0.69	-10.61	-0.5	7.34e-23	Breast cancer;
LUSC	cis	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg21775007	chr8:11205619	TDH	-0.47	-6.82	-0.35	4.4e-11	Systolic blood pressure;
LUSC	cis	rs2540226	0.788	rs12623462	chr2:39977265	T/C	cg23576258	chr2:39999331	THUMPD2	0.34	5.79	0.3	1.65e-8	Personality dimensions;
LUSC	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg09307838	chr4:120376055	NA	0.76	11.04	0.52	2.31e-24	Corneal astigmatism;
LUSC	cis	rs12410462	0.581	rs113827839	chr1:227547180	C/T	cg04117972	chr1:227635322	NA	0.6	6.68	0.34	1e-10	Major depressive disorder;
LUSC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06028605	chr16:24865363	SLC5A11	-0.68	-10.88	-0.51	8.33e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.66	11.25	0.52	4.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.56	11.17	0.52	7.79e-25	Asthma (sex interaction);
LUSC	cis	rs2692947	0.673	rs4907279	chr2:96399968	G/C	cg23100626	chr2:96804247	ASTL	0.3	6.96	0.36	1.81e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07626433	chr4:141071632	MAML3	-0.42	-6.26	-0.32	1.16e-9	Hepatitis;
LUSC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.89	0.31	9.61e-9	Menopause (age at onset);
LUSC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg18230493	chr5:56204884	C5orf35	-0.79	-12.49	-0.56	1.27e-29	Initial pursuit acceleration;
LUSC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg17554472	chr22:41940697	POLR3H	0.47	5.72	0.3	2.42e-8	Vitiligo;
LUSC	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.99	-0.31	5.3e-9	Resting heart rate;
LUSC	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg12091567	chr17:66097778	LOC651250	0.88	14.18	0.61	4.62e-36	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.59	9.41	0.46	8.36e-19	Breast cancer;
LUSC	trans	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.64	7.62	0.38	2.61e-13	Menarche (age at onset);
LUSC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs2050392	0.931	rs2265189	chr10:30689316	C/T	cg18806716	chr10:30721971	MAP3K8	0.38	6.23	0.32	1.42e-9	Inflammatory bowel disease;
LUSC	cis	rs1044826	1.000	rs9849578	chr3:139089602	C/T	cg00490450	chr3:139108681	COPB2	0.55	7.37	0.37	1.34e-12	Obesity-related traits;
LUSC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg07395648	chr5:131743802	NA	-0.41	-6.42	-0.33	4.76e-10	Breast cancer;Mosquito bite size;
LUSC	cis	rs868036	1.000	rs4776974	chr15:68095927	G/A	cg08079166	chr15:68083412	MAP2K5	0.4	8.32	0.41	2.2e-15	Restless legs syndrome;
LUSC	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.53	8.35	0.42	1.78e-15	Depressive symptoms;
LUSC	cis	rs6714710	0.603	rs12995673	chr2:98409046	G/A	cg26665480	chr2:98280029	ACTR1B	0.63	9.17	0.45	5.08e-18	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs1941687	0.797	rs2976	chr18:31403254	T/C	cg27147174	chr7:100797783	AP1S1	-0.46	-6.92	-0.35	2.29e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg04310649	chr10:35416472	CREM	-0.41	-6.14	-0.32	2.29e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg16797656	chr11:68205561	LRP5	0.4	7.21	0.37	3.68e-12	Total body bone mineral density;
LUSC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09263875	chr16:632152	PIGQ	0.71	13.18	0.59	3.08e-32	Height;
LUSC	cis	rs75804782	0.521	rs58568091	chr2:239430582	G/A	cg18131467	chr2:239335373	ASB1	-0.66	-5.95	-0.31	6.8e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg16329197	chr12:53359506	NA	-0.63	-8.63	-0.43	2.49e-16	Cancer (pleiotropy);
LUSC	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.08	13.27	0.59	1.47e-32	Sexual dysfunction (female);
LUSC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg14004847	chr7:1930337	MAD1L1	-0.6	-9.11	-0.45	7.68e-18	Schizophrenia;
LUSC	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg21427119	chr20:30132790	HM13	-0.46	-6.65	-0.34	1.23e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs4622329	0.615	rs4764672	chr12:102289215	A/G	cg23541617	chr12:102225335	GNPTAB	0.26	6.07	0.32	3.51e-9	Systemic lupus erythematosus;
LUSC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg13010199	chr12:38710504	ALG10B	0.67	10.36	0.49	5.56e-22	Heart rate;
LUSC	trans	rs62238980	0.614	rs117432936	chr22:32382309	G/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg00495681	chr13:53174319	NA	0.8	15.19	0.64	5.46e-40	Lewy body disease;
LUSC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg03036452	chr22:46663545	TTC38	0.52	5.68	0.3	2.85e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16424519	chr16:21531031	SLC7A5P2	0.44	5.95	0.31	6.75e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg12559939	chr2:27858050	GPN1	0.41	6.48	0.33	3.28e-10	Oral cavity cancer;
LUSC	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.24	0.37	3.07e-12	Morning vs. evening chronotype;
LUSC	cis	rs10875595	0.836	rs6868387	chr5:140660814	G/A	cg24830062	chr5:140700576	TAF7	-0.52	-6.29	-0.33	1e-9	Pulmonary function decline;
LUSC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.61e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.79	0.39	8.73e-14	Prudent dietary pattern;
LUSC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg15147215	chr3:52552868	STAB1	-0.32	-6.49	-0.33	3.07e-10	Electroencephalogram traits;
LUSC	trans	rs2790216	0.526	rs1199093	chr10:59896794	C/G	cg04559609	chr1:101361710	SLC30A7;EXTL2	-0.36	-5.96	-0.31	6.29e-9	Inflammatory bowel disease;
LUSC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg18230493	chr5:56204884	C5orf35	0.9	13.5	0.59	1.85e-33	Initial pursuit acceleration;
LUSC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg27608139	chr16:2294856	DCI	0.33	5.8	0.3	1.53e-8	Height;
LUSC	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg03948781	chr1:205179583	DSTYK	0.32	6.24	0.32	1.33e-9	Red blood cell count;
LUSC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg23711669	chr6:146136114	FBXO30	0.71	12.32	0.56	5.36e-29	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs2692947	0.655	rs4605406	chr2:96583735	A/C	cg22654517	chr2:96458247	NA	0.37	6.82	0.35	4.36e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg08999081	chr20:33150536	PIGU	0.37	6.69	0.34	9.61e-11	Height;
LUSC	cis	rs440932	0.565	rs19334	chr8:9009906	C/T	cg06636001	chr8:8085503	FLJ10661	0.42	6.28	0.32	1.06e-9	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.71	-0.3	2.45e-8	Personality dimensions;
LUSC	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg15819921	chr19:927150	ARID3A	-0.43	-6.36	-0.33	6.54e-10	Life satisfaction;
LUSC	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11645453	chr3:52864694	ITIH4	0.47	10.53	0.5	1.41e-22	Schizophrenia;
LUSC	cis	rs7903847	0.642	rs11189206	chr10:99167802	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.45	-0.38	7.84e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs113835537	0.529	rs11227495	chr11:66263243	C/T	cg24851651	chr11:66362959	CCS	0.54	8.08	0.4	1.17e-14	Airway imaging phenotypes;
LUSC	cis	rs861020	0.563	rs61820640	chr1:210041297	G/T	cg05527609	chr1:210001259	C1orf107	-0.86	-11.31	-0.53	2.55e-25	Orofacial clefts;
LUSC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.59	-0.46	2.18e-19	Chronic sinus infection;
LUSC	cis	rs7615316	0.934	rs6440089	chr3:142279796	T/C	cg16271453	chr3:142027066	XRN1	-0.37	-6.47	-0.33	3.43e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.92	0.44	3.2e-17	Motion sickness;
LUSC	cis	rs7000551	0.751	rs2449338	chr8:22369232	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	6.14	0.32	2.28e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs6500395	0.890	rs3843724	chr16:48618573	C/G	cg04672837	chr16:48644449	N4BP1	0.49	7.09	0.36	7.99e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2224391	0.628	rs2753244	chr6:5257610	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.49	-6.1	-0.32	3.01e-9	Height;
LUSC	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg23093090	chr10:104574429	C10orf26	-0.36	-6.68	-0.34	1e-10	Arsenic metabolism;
LUSC	cis	rs12594515	1.000	rs12185095	chr15:45994635	G/T	cg06207120	chr15:45996521	NA	0.38	5.85	0.3	1.16e-8	Waist circumference;Weight;
LUSC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.25	-0.41	3.75e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9611519	1.000	rs5751069	chr22:41627775	C/G	cg13813247	chr22:41461852	NA	-0.33	-5.84	-0.3	1.26e-8	Neuroticism;
LUSC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg02475777	chr4:1388615	CRIPAK	0.45	6.76	0.35	6.03e-11	Obesity-related traits;
LUSC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg06212747	chr3:49208901	KLHDC8B	0.44	5.98	0.31	5.79e-9	Parkinson's disease;
LUSC	cis	rs1044826	0.642	rs2118981	chr3:139178853	A/G	cg00490450	chr3:139108681	COPB2	0.46	7.11	0.36	6.89e-12	Obesity-related traits;
LUSC	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.62	-0.34	1.44e-10	Fear of minor pain;
LUSC	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg05855489	chr10:104503620	C10orf26	0.48	7.28	0.37	2.41e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs4308124	0.708	rs28871990	chr2:111962441	G/A	cg04571233	chr2:111982156	NA	-0.5	-6.55	-0.34	2.11e-10	Vitiligo;
LUSC	trans	rs890100	0.769	rs1978534	chr2:56716404	G/A	cg01657744	chr10:88471748	LDB3	0.43	5.95	0.31	6.62e-9	Gut microbiome composition (summer);
LUSC	cis	rs7572644	0.713	rs4666021	chr2:28055881	A/G	cg27432699	chr2:27873401	GPN1	0.52	6.73	0.35	7.41e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg05855489	chr10:104503620	C10orf26	-0.69	-9.84	-0.47	3.15e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs2404602	0.684	rs3910756	chr15:76945369	C/T	cg23625390	chr15:77176239	SCAPER	-0.61	-8.98	-0.44	2.03e-17	Blood metabolite levels;
LUSC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg21280719	chr6:42927975	GNMT	-0.32	-7.93	-0.4	3.42e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7215564	0.908	rs74000898	chr17:78653532	A/C	cg09596252	chr17:78655493	RPTOR	0.56	6.05	0.31	3.85e-9	Myopia (pathological);
LUSC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.08	0.32	3.32e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs701145	0.585	rs62276840	chr3:153783622	G/C	cg17054900	chr3:154042577	DHX36	-0.73	-7.44	-0.38	8.72e-13	Coronary artery disease;
LUSC	cis	rs79387448	0.745	rs17027413	chr2:103153667	A/G	cg09003973	chr2:102972529	NA	-0.88	-8.2	-0.41	5.26e-15	Gut microbiota (bacterial taxa);
LUSC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-11.07	-0.52	1.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-10.7	-0.51	3.58e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg09763514	chr7:2298050	SNX8	-0.42	-6.39	-0.33	5.69e-10	Mosquito bite size;
LUSC	trans	rs10221833	0.636	rs355891	chr2:165634983	T/C	cg26993132	chr16:89239499	CDH15	0.31	5.99	0.31	5.47e-9	Response to statin therapy;
LUSC	trans	rs9944715	1.000	rs6507690	chr18:43808597	A/G	cg01718231	chr17:29326311	RNF135	-0.53	-7.33	-0.37	1.76e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg24060327	chr5:131705240	SLC22A5	-0.53	-8.88	-0.44	4.11e-17	Breast cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04422289	chr4:48833305	OCIAD1	-0.44	-6.08	-0.32	3.25e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.33	0.37	1.72e-12	Platelet count;
LUSC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg27165867	chr14:105738592	BRF1	-0.51	-7.21	-0.37	3.77e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2820315	1.000	rs2820312	chr1:201869257	G/A	cg10061532	chr1:201886748	LMOD1	0.28	6.17	0.32	2.03e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg21153622	chr11:89784906	NA	-0.39	-6.13	-0.32	2.5e-9	Coronary artery disease;
LUSC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg09877947	chr5:131593287	PDLIM4	0.46	7.44	0.38	8.87e-13	Breast cancer;
LUSC	cis	rs981844	0.740	rs6858578	chr4:154682058	G/T	cg14289246	chr4:154710475	SFRP2	-0.5	-7.2	-0.37	3.92e-12	Response to statins (LDL cholesterol change);
LUSC	cis	rs2625529	0.761	rs4776582	chr15:72207520	A/T	cg16672083	chr15:72433130	SENP8	-0.5	-7.35	-0.37	1.56e-12	Red blood cell count;
LUSC	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg19678392	chr7:94953810	PON1	-0.35	-5.68	-0.3	2.9e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.53	-0.38	4.8e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg24733560	chr20:60626293	TAF4	0.43	7.85	0.39	5.6e-14	Body mass index;
LUSC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg08742575	chr21:47604166	C21orf56	0.43	6.51	0.34	2.78e-10	Testicular germ cell tumor;
LUSC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg09034736	chr1:150693464	HORMAD1	0.43	6.08	0.32	3.32e-9	Melanoma;
LUSC	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-17.83	-0.7	1.92e-50	Primary sclerosing cholangitis;
LUSC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-6.88	-0.35	3.03e-11	Eosinophil percentage of white cells;
LUSC	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.81	0.43	6.77e-17	Axial length;
LUSC	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg09165964	chr15:75287851	SCAMP5	-0.94	-11.65	-0.54	1.46e-26	Blood trace element (Zn levels);
LUSC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13770153	chr20:60521292	NA	-0.62	-8.16	-0.41	6.68e-15	Body mass index;
LUSC	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg06064525	chr11:970664	AP2A2	-0.31	-6.09	-0.32	3.07e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg05468064	chr22:46423449	NA	-0.43	-6.75	-0.35	6.62e-11	Dupuytren's disease;
LUSC	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.38	-6.66	-0.34	1.15e-10	Primary biliary cholangitis;
LUSC	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-7.72	-0.39	1.33e-13	Morning vs. evening chronotype;
LUSC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.23	-14.09	-0.61	1.07e-35	Diabetic kidney disease;
LUSC	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg19773385	chr1:10388646	KIF1B	-0.54	-8.43	-0.42	1.03e-15	Hepatocellular carcinoma;
LUSC	cis	rs929596	1.000	rs929596	chr2:234674476	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.71	-11.69	-0.54	1.06e-26	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	1.06	22.0	0.77	6.35e-67	Menopause (age at onset);
LUSC	cis	rs926938	0.505	rs360593	chr1:115472265	T/G	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.43	-0.33	4.47e-10	Autism;
LUSC	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	1.14	18.04	0.7	2.84e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs2540226	0.539	rs2716694	chr2:39911336	A/G	cg23576258	chr2:39999331	THUMPD2	0.35	5.76	0.3	1.89e-8	Personality dimensions;
LUSC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg21862992	chr11:68658383	NA	0.5	7.99	0.4	2.28e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg23093090	chr10:104574429	C10orf26	-0.36	-6.61	-0.34	1.51e-10	Arsenic metabolism;
LUSC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg18225595	chr11:63971243	STIP1	0.63	10.91	0.51	6.77e-24	Platelet count;
LUSC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg13902645	chr11:5959945	NA	-0.6	-8.44	-0.42	9.71e-16	DNA methylation (variation);
LUSC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg15212455	chr7:39170539	POU6F2	0.66	11.53	0.53	4.21e-26	IgG glycosylation;
LUSC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-10.93	-0.51	5.62e-24	Bipolar disorder and schizophrenia;
LUSC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg27432699	chr2:27873401	GPN1	-0.58	-8.64	-0.43	2.41e-16	Total body bone mineral density;
LUSC	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.51	-0.34	2.82e-10	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg03929089	chr4:120376271	NA	0.68	7.56	0.38	4.05e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.51	-9.2	-0.45	3.84e-18	Breast cancer;
LUSC	cis	rs8032315	0.965	rs8027450	chr15:91418394	C/T	cg05469396	chr15:91419421	FURIN	-0.42	-6.7	-0.34	8.98e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg15133208	chr4:90757351	SNCA	-0.32	-5.72	-0.3	2.32e-8	Dementia with Lewy bodies;
LUSC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg09034736	chr1:150693464	HORMAD1	0.4	5.72	0.3	2.34e-8	Melanoma;
LUSC	trans	rs80093141	0.575	rs17108513	chr14:39356146	A/G	cg08262584	chr8:54154426	OPRK1	0.44	6.08	0.32	3.21e-9	Common carotid intima-media thickness in HIV infection;
LUSC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-11.07	-0.52	1.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg13010199	chr12:38710504	ALG10B	-0.57	-8.69	-0.43	1.71e-16	Morning vs. evening chronotype;
LUSC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	0.93	18.04	0.7	2.85e-51	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-1.09	-22.46	-0.78	1.02e-68	Height;
LUSC	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg07274523	chr3:49395745	GPX1	0.68	10.63	0.5	6.13e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	0.93	16.17	0.66	7.55e-44	Menopause (age at onset);
LUSC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg05738196	chr6:26577821	NA	0.53	8.32	0.41	2.23e-15	Schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg22658884	chr19:14192470	NA	0.51	6.96	0.36	1.78e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs17125944	0.686	rs2296495	chr14:53379878	G/A	cg00686598	chr14:53173677	PSMC6	0.84	7.57	0.38	3.6e-13	Alzheimer's disease (late onset);
LUSC	trans	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.47	0.53	6.76e-26	Mean corpuscular volume;
LUSC	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg27124370	chr19:33622961	WDR88	0.54	7.16	0.36	5.12e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.64	0.6	5.58e-34	Cognitive test performance;
LUSC	cis	rs1030877	0.515	rs2679893	chr2:105909554	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.65	8.95	0.44	2.53e-17	Obesity-related traits;
LUSC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg23102388	chr7:1867652	MAD1L1	-0.3	-5.68	-0.3	2.97e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-6.79	-0.35	5.01e-11	Bipolar disorder;
LUSC	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	0.88	7.84	0.39	5.96e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg04414720	chr1:150670196	GOLPH3L	0.52	8.27	0.41	3.27e-15	Melanoma;
LUSC	trans	rs11923600	0.793	rs62285823	chr3:175891124	C/G	cg02188190	chr13:112894616	NA	0.45	6.37	0.33	6.1e-10	Height;
LUSC	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg10356904	chr22:49881777	NA	-0.3	-6.19	-0.32	1.74e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg26727032	chr16:67993705	SLC12A4	-0.42	-6.56	-0.34	2.06e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg00750074	chr16:89608354	SPG7	0.42	7.01	0.36	1.31e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs6028335	0.502	rs7265661	chr20:37586842	G/T	cg27552599	chr20:37590471	DHX35	0.45	7.34	0.37	1.68e-12	Alcohol and nicotine co-dependence;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16066221	chr17:28512115	CCDC55	0.44	6.7	0.34	9.01e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.43	6.07	0.32	3.4e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg07741184	chr6:167504864	NA	0.34	6.18	0.32	1.86e-9	Crohn's disease;
LUSC	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-10.73	-0.51	2.72e-23	Morning vs. evening chronotype;
LUSC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.83	-14.73	-0.63	3.56e-38	Cognitive function;
LUSC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg19748678	chr4:122722346	EXOSC9	0.49	7.57	0.38	3.59e-13	Type 2 diabetes;
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg06145435	chr7:1022769	CYP2W1	0.31	6.3	0.33	9.28e-10	Longevity;Endometriosis;
LUSC	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg24634471	chr8:143751801	JRK	0.51	7.21	0.37	3.71e-12	Schizophrenia;
LUSC	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	1.09	18.27	0.71	3.31e-52	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg10326726	chr10:51549505	MSMB	-0.36	-6.16	-0.32	2.09e-9	Prostate-specific antigen levels;
LUSC	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg26395211	chr5:140044315	WDR55	-0.38	-5.76	-0.3	1.87e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-9.82	-0.47	3.77e-20	Bipolar disorder;
LUSC	cis	rs9811920	0.809	rs6440967	chr3:99722396	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.44	6.45	0.33	3.83e-10	Axial length;
LUSC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19717773	chr7:2847554	GNA12	-0.38	-6.13	-0.32	2.51e-9	Height;
LUSC	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	1.12	19.81	0.73	2.72e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05776053	chr2:74358815	NA	0.42	6.27	0.32	1.1e-9	Gestational age at birth (maternal effect);
LUSC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-7.18	-0.37	4.52e-12	Blood metabolite levels;
LUSC	cis	rs7180079	1.000	rs6494477	chr15:64667334	T/C	cg08069370	chr15:64387884	SNX1	0.58	6.2	0.32	1.68e-9	Monocyte count;
LUSC	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg02023728	chr11:77925099	USP35	0.51	7.12	0.36	6.48e-12	Testicular germ cell tumor;
LUSC	cis	rs603446	0.935	rs918143	chr11:116630600	C/T	cg08985259	chr11:116699649	APOC3	-0.25	-5.67	-0.3	3.13e-8	Triglycerides;
LUSC	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.62	9.4	0.46	8.93e-19	Schizophrenia;
LUSC	cis	rs2262909	0.962	rs11673195	chr19:22313814	T/C	cg11619707	chr19:22235551	ZNF257	0.39	5.95	0.31	6.77e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	11.48	0.53	6.12e-26	Menarche (age at onset);
LUSC	trans	rs12200782	0.929	rs72843734	chr6:26448344	C/G	cg11837749	chr1:55047332	ACOT11	0.58	6.23	0.32	1.41e-9	Small cell lung carcinoma;
LUSC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22496380	chr5:211416	CCDC127	0.62	7.31	0.37	2.02e-12	Breast cancer;
LUSC	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	8.69	0.43	1.61e-16	Bipolar disorder;
LUSC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg12560992	chr17:57184187	TRIM37	0.78	13.83	0.6	1.07e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs2952156	0.959	rs11653998	chr17:37877447	C/G	cg20243544	chr17:37824526	PNMT	0.49	6.91	0.35	2.42e-11	Asthma;
LUSC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg03161606	chr19:29218774	NA	0.6	8.75	0.43	1.08e-16	Methadone dose in opioid dependence;
LUSC	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.45	0.53	7.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	trans	rs7903456	0.648	rs6586053	chr10:88829872	G/T	cg16309350	chr10:134983667	KNDC1	0.34	5.97	0.31	6.2e-9	Gout;Renal underexcretion gout;
LUSC	cis	rs4845570	0.749	rs11586446	chr1:151712488	A/G	cg07092448	chr1:151763213	TDRKH	-1.07	-10.77	-0.51	2.03e-23	Coronary artery disease;
LUSC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg15123519	chr2:136567270	LCT	0.39	5.93	0.31	7.56e-9	Mosquito bite size;
LUSC	cis	rs4363385	0.818	rs10788853	chr1:153002231	C/T	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.9	-0.4	4e-14	Inflammatory skin disease;
LUSC	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.71	-0.39	1.42e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs60154123	0.505	rs2206043	chr1:210042983	G/A	cg23283495	chr1:209979779	IRF6	0.63	7.67	0.39	1.85e-13	Coronary artery disease;
LUSC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.53	6.53	0.34	2.46e-10	Renal function-related traits (BUN);
LUSC	cis	rs79387448	0.745	rs59694233	chr2:103116521	G/A	cg09003973	chr2:102972529	NA	0.86	8.49	0.42	6.99e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs1376877	0.519	rs4675332	chr2:204190907	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.47	5.77	0.3	1.82e-8	Subclinical atherosclerosis traits (other);
LUSC	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	1.23	19.55	0.73	2.84e-57	Corneal structure;
LUSC	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg02016764	chr4:38805732	TLR1	-0.54	-5.72	-0.3	2.43e-8	Breast cancer;
LUSC	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg18357645	chr12:58087776	OS9	0.57	8.58	0.42	3.74e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg04025307	chr7:1156635	C7orf50	0.43	6.83	0.35	4.02e-11	Longevity;Endometriosis;
LUSC	cis	rs909002	0.962	rs7537646	chr1:32135495	G/A	cg13919466	chr1:32135498	COL16A1	-0.32	-5.81	-0.3	1.49e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg24060327	chr5:131705240	SLC22A5	0.47	6.72	0.35	7.82e-11	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.6	-0.57	4.72e-30	Chronic sinus infection;
LUSC	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.14	-0.32	2.38e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14240646	chr10:27532245	ACBD5	0.71	8.18	0.41	5.94e-15	Breast cancer;
LUSC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg23711669	chr6:146136114	FBXO30	-0.82	-14.5	-0.62	2.82e-37	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20110780	chr8:109261090	EIF3E	0.38	6.22	0.32	1.49e-9	Triglycerides;
LUSC	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.3	-0.33	9.18e-10	Bipolar disorder;
LUSC	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg17509989	chr5:176798049	RGS14	-0.68	-9.64	-0.47	1.48e-19	Urate levels in lean individuals;
LUSC	trans	rs61931739	0.578	rs61927759	chr12:33713297	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-6.16	-0.32	2.08e-9	Morning vs. evening chronotype;
LUSC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.96	12.45	0.56	1.77e-29	Exhaled nitric oxide output;
LUSC	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg04691961	chr3:161091175	C3orf57	-0.36	-6.12	-0.32	2.6e-9	Morning vs. evening chronotype;
LUSC	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg02176678	chr2:219576539	TTLL4	-0.59	-10.62	-0.5	6.76e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg13319975	chr6:146136371	FBXO30	0.45	6.99	0.36	1.51e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg23649088	chr2:200775458	C2orf69	0.55	7.39	0.38	1.15e-12	Schizophrenia;
LUSC	cis	rs1322512	0.917	rs2623943	chr6:152951141	A/G	cg27316956	chr6:152958899	SYNE1	-0.37	-6.32	-0.33	8.59e-10	Tonometry;
LUSC	cis	rs6546550	0.935	rs11673826	chr2:70041033	G/A	cg02498382	chr2:70120550	SNRNP27	-0.29	-6.95	-0.36	1.89e-11	Prevalent atrial fibrillation;
LUSC	cis	rs6733011	0.582	rs2280256	chr2:99449174	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-6.06	-0.31	3.62e-9	Bipolar disorder;
LUSC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg23281280	chr6:28129359	ZNF389	0.45	5.67	0.3	3.04e-8	Depression;
LUSC	cis	rs2625529	0.761	rs972028	chr15:72173092	C/T	cg16672083	chr15:72433130	SENP8	-0.46	-6.89	-0.35	2.78e-11	Red blood cell count;
LUSC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg02524346	chr8:600233	NA	-0.94	-9.29	-0.45	2.08e-18	IgG glycosylation;
LUSC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	0.93	16.12	0.66	1.16e-43	Menopause (age at onset);
LUSC	cis	rs73129298	0.551	rs16995010	chr20:48602623	C/G	cg25655593	chr20:48599521	SNAI1	-0.56	-6.04	-0.31	4.18e-9	Inflammatory skin disease;
LUSC	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg23625390	chr15:77176239	SCAPER	0.63	9.37	0.46	1.13e-18	Blood metabolite levels;
LUSC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg01125463	chr6:42946178	PEX6	-0.36	-6.06	-0.31	3.74e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg06784218	chr1:46089804	CCDC17	-0.47	-8.92	-0.44	3.06e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11264799	0.669	rs12082378	chr1:157634567	C/A	cg18268488	chr1:157545234	FCRL4	0.33	6.0	0.31	5.27e-9	IgA nephropathy;
LUSC	cis	rs11640533	1.000	rs11640533	chr16:53412862	A/G	cg04653913	chr16:53407753	NA	-0.45	-7.13	-0.36	6.24e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg08200582	chr11:442649	ANO9	-0.52	-6.1	-0.32	3.02e-9	Body mass index;
LUSC	trans	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	2.03e-12	Bone mineral density;
LUSC	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg25457927	chr22:38595422	NA	0.42	8.44	0.42	9.61e-16	Cutaneous nevi;
LUSC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg05082376	chr22:42548792	NA	-0.43	-6.5	-0.33	2.98e-10	Schizophrenia;
LUSC	cis	rs7408868	0.908	rs1044006	chr19:15285052	T/C	cg14696996	chr19:15285081	NOTCH3	0.95	9.06	0.44	1.14e-17	Pulse pressure;
LUSC	trans	rs4800353	0.929	rs899639	chr18:19608112	T/C	cg01841828	chr16:69166849	CHTF8;CIRH1A	-0.58	-6.02	-0.31	4.53e-9	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs2200578	0.841	rs62154623	chr2:99611488	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.62	7.49	0.38	6.26e-13	IgG glycosylation;
LUSC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg02527881	chr3:46936655	PTH1R	0.41	7.47	0.38	6.86e-13	Colorectal cancer;
LUSC	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg14121845	chr20:25566513	NINL	0.31	5.66	0.3	3.21e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4363385	0.567	rs7551791	chr1:153024267	A/T	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.22	-0.32	1.52e-9	Inflammatory skin disease;
LUSC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00684032	chr4:1343700	KIAA1530	0.37	6.47	0.33	3.48e-10	Obesity-related traits;
LUSC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg11062466	chr8:58055876	NA	0.64	7.88	0.4	4.52e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.33	0.56	4.83e-29	Ileal carcinoids;
LUSC	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	8.18	0.41	5.84e-15	Response to antipsychotic treatment;
LUSC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg04362960	chr10:104952993	NT5C2	0.55	8.12	0.41	9.21e-15	Arsenic metabolism;
LUSC	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.3e-11	Uric acid levels;
LUSC	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg27284194	chr4:1044797	NA	0.59	8.86	0.44	4.9e-17	Recombination rate (females);
LUSC	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg22089800	chr15:90895588	ZNF774	-0.57	-8.3	-0.41	2.68e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	7.92	0.4	3.51e-14	Schizophrenia;
LUSC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg11871910	chr12:69753446	YEATS4	0.62	9.27	0.45	2.35e-18	Blood protein levels;
LUSC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.19	0.55	1.64e-28	Prudent dietary pattern;
LUSC	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.72	-0.35	7.96e-11	Bladder cancer;
LUSC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820928	0.874	rs9288618	chr2:227872617	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.64	-0.39	2.35e-13	Pulmonary function;
LUSC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg25767906	chr1:53392781	SCP2	0.46	8.12	0.41	8.86e-15	Monocyte count;
LUSC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.81	0.3	1.44e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg01294253	chr9:136912663	BRD3	0.34	6.07	0.32	3.5e-9	Platelet distribution width;
LUSC	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.37	0.33	6.32e-10	Lung cancer;
LUSC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg04414720	chr1:150670196	GOLPH3L	0.49	7.43	0.38	9.4e-13	Melanoma;
LUSC	trans	rs459571	0.959	rs460888	chr9:136913123	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.76	-12.4	-0.56	2.67e-29	Platelet distribution width;
LUSC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg05347473	chr6:146136440	FBXO30	-0.4	-6.76	-0.35	6.3e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg07810366	chr2:100720526	AFF3	-0.44	-7.36	-0.37	1.4e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-9.26	-0.45	2.58e-18	Gut microbiome composition (summer);
LUSC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg07424592	chr7:64974309	NA	-0.63	-5.65	-0.3	3.53e-8	Diabetic kidney disease;
LUSC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg07701084	chr6:150067640	NUP43	0.57	8.82	0.43	6.43e-17	Lung cancer;
LUSC	trans	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg20587970	chr11:113659929	NA	0.77	9.88	0.48	2.27e-20	Hip circumference adjusted for BMI;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21459921	chr20:60878267	ADRM1	-0.52	-6.25	-0.32	1.23e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg14552801	chr7:65878734	NA	0.38	5.9	0.31	9.1e-9	Aortic root size;
LUSC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg18099408	chr3:52552593	STAB1	0.37	6.19	0.32	1.78e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg21770322	chr7:97807741	LMTK2	0.42	7.2	0.37	4.04e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg06784218	chr1:46089804	CCDC17	-0.47	-9.14	-0.45	6.34e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2282032	1.000	rs75816060	chr14:90759470	C/T	cg14092571	chr14:90743983	NA	0.53	6.83	0.35	4.02e-11	Longevity;
LUSC	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.04	-0.31	4.21e-9	Resting heart rate;
LUSC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.15	-0.32	2.18e-9	Monocyte count;
LUSC	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg22529645	chr1:3704559	LRRC47	0.37	6.23	0.32	1.44e-9	Red cell distribution width;
LUSC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.73	-0.39	1.24e-13	Blood metabolite levels;
LUSC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14829155	chr15:31115871	NA	0.7	10.75	0.51	2.49e-23	Huntington's disease progression;
LUSC	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg16680214	chr1:154839983	KCNN3	-0.55	-10.2	-0.49	1.94e-21	Prostate cancer;
LUSC	cis	rs72792276	1.000	rs56657382	chr5:127387338	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	7.42	0.38	9.76e-13	Red cell distribution width;
LUSC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18876405	chr7:65276391	NA	-0.55	-8.63	-0.43	2.54e-16	Aortic root size;
LUSC	cis	rs45535039	0.506	rs2511856	chr11:119144148	A/C	cg22259797	chr11:118986860	C2CD2L	0.33	6.03	0.31	4.3e-9	Plateletcrit;
LUSC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.85	0.3	1.2e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs427941	0.632	rs201471	chr7:101744145	T/G	cg06246474	chr7:101738831	CUX1	0.39	6.42	0.33	4.68e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg01966878	chr4:90757139	SNCA	-0.42	-5.96	-0.31	6.24e-9	Neuroticism;
LUSC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg00129232	chr17:37814104	STARD3	-0.55	-8.25	-0.41	3.77e-15	Asthma;
LUSC	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg14458575	chr2:238380390	NA	-0.6	-7.76	-0.39	1.05e-13	Prostate cancer;
LUSC	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg06219351	chr7:158114137	PTPRN2	-0.51	-9.22	-0.45	3.39e-18	Calcium levels;
LUSC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-0.91	-19.08	-0.72	2.06e-55	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs17095355	0.818	rs6584970	chr10:111847820	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.54	-5.99	-0.31	5.57e-9	Biliary atresia;
LUSC	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg25233709	chr10:116636983	FAM160B1	0.37	6.59	0.34	1.69e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg06028605	chr16:24865363	SLC5A11	0.44	7.97	0.4	2.6e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	1.07	15.84	0.65	1.52e-42	Uric acid levels;
LUSC	cis	rs3812762	0.912	rs11042058	chr11:8763815	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.37	-5.91	-0.31	8.63e-9	Hypospadias;
LUSC	cis	rs877282	1.000	rs10904552	chr10:774326	A/G	cg17470449	chr10:769945	NA	0.51	7.23	0.37	3.28e-12	Uric acid levels;
LUSC	cis	rs193541	0.632	rs6595413	chr5:122156949	G/A	cg19077854	chr5:122220652	SNX24	0.38	7.9	0.4	4.18e-14	Glucose homeostasis traits;
LUSC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg27170947	chr2:26402098	FAM59B	0.71	11.01	0.52	2.92e-24	Gut microbiome composition (summer);
LUSC	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg06627628	chr2:24431161	ITSN2	-0.68	-9.3	-0.45	1.85e-18	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs877282	0.945	rs10904550	chr10:774177	C/T	cg17470449	chr10:769945	NA	0.51	7.3	0.37	2.06e-12	Uric acid levels;
LUSC	trans	rs747782	0.640	rs11039603	chr11:48256786	G/A	cg03929089	chr4:120376271	NA	0.71	6.03	0.31	4.35e-9	Intraocular pressure;
LUSC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	1.0	13.12	0.58	5.24e-32	Eosinophil percentage of granulocytes;
LUSC	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg02023728	chr11:77925099	USP35	0.47	7.12	0.36	6.7e-12	Testicular germ cell tumor;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg18090447	chr1:165797377	UCK2	0.4	6.48	0.33	3.29e-10	Asthma;
LUSC	cis	rs2742234	0.541	rs10793426	chr10:43745280	G/A	cg02780029	chr10:43622663	RET	0.35	5.72	0.3	2.4e-8	Hirschsprung disease;
LUSC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.67	0.39	1.92e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg23630131	chr7:65973040	NA	0.2	5.74	0.3	2.1e-8	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15226532	chr19:44506876	ZNF230	-0.44	-6.58	-0.34	1.87e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2270927	0.510	rs10942765	chr5:75591324	G/A	cg13563193	chr19:33072644	PDCD5	0.78	6.16	0.32	2.05e-9	Mean corpuscular volume;
LUSC	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.88	-0.31	9.74e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1018697	0.966	rs11191396	chr10:104552865	A/G	cg04362960	chr10:104952993	NT5C2	0.47	6.46	0.33	3.65e-10	Colorectal adenoma (advanced);
LUSC	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.79	-0.43	8.23e-17	Coffee consumption (cups per day);
LUSC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg05347473	chr6:146136440	FBXO30	0.56	9.49	0.46	4.63e-19	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1941687	0.673	rs4427879	chr18:31404751	A/G	cg27147174	chr7:100797783	AP1S1	-0.43	-6.56	-0.34	1.99e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02176678	chr2:219576539	TTLL4	0.64	11.82	0.54	3.7e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9308433	0.529	rs11120298	chr1:214500620	A/G	cg06198575	chr1:214491504	SMYD2	0.45	6.94	0.36	2.02e-11	IgG glycosylation;
LUSC	trans	rs11039798	0.698	rs6485805	chr11:48101723	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.33	0.33	7.86e-10	Axial length;
LUSC	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg23950597	chr19:37808831	NA	-0.63	-7.8	-0.39	8.08e-14	Coronary artery calcification;
LUSC	cis	rs1775715	0.707	rs2808079	chr10:32167385	C/T	cg26784012	chr10:32216390	ARHGAP12	0.44	7.45	0.38	8.2e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7107174	0.688	rs2063725	chr11:78133452	T/G	cg27205649	chr11:78285834	NARS2	-0.5	-5.87	-0.31	1.03e-8	Testicular germ cell tumor;
LUSC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12311346	chr5:56204834	C5orf35	0.85	13.67	0.6	4.36e-34	Initial pursuit acceleration;
LUSC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-8.05	-0.4	1.48e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg12927641	chr6:109611667	NA	0.35	5.74	0.3	2.09e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs77633900	0.614	rs280008	chr15:77011815	T/C	cg21673338	chr15:77095150	SCAPER	-0.82	-8.05	-0.4	1.48e-14	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.1	15.84	0.66	1.47e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7572644	0.699	rs898032	chr2:28202936	C/G	cg27432699	chr2:27873401	GPN1	-0.51	-6.9	-0.35	2.65e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg00546932	chr16:1947055	NA	0.37	5.68	0.3	2.97e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs11700980	1.000	rs77484014	chr21:30125709	G/A	cg05609335	chr17:75789393	NA	0.41	6.21	0.32	1.59e-9	QRS complex (12-leadsum);
LUSC	trans	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg05059571	chr16:84539110	KIAA1609	-0.47	-9.14	-0.45	6.17e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-7.02	-0.36	1.23e-11	Aortic root size;
LUSC	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg12560992	chr17:57184187	TRIM37	-0.64	-10.6	-0.5	7.99e-23	Testicular germ cell tumor;
LUSC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg06740227	chr12:86229804	RASSF9	0.45	7.16	0.36	5.25e-12	Major depressive disorder;
LUSC	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg13010199	chr12:38710504	ALG10B	0.44	6.17	0.32	1.92e-9	Morning vs. evening chronotype;
LUSC	trans	rs2416257	0.673	rs17625012	chr5:110462919	A/T	cg17356964	chr6:106582638	NA	0.7	6.36	0.33	6.51e-10	Eosinophil counts;
LUSC	cis	rs4474465	0.688	rs10501429	chr11:78279790	T/G	cg27205649	chr11:78285834	NARS2	0.54	6.6	0.34	1.63e-10	Alzheimer's disease (survival time);
LUSC	cis	rs62400317	0.859	rs72858511	chr6:45218119	A/G	cg18551225	chr6:44695536	NA	-0.46	-7.58	-0.38	3.53e-13	Total body bone mineral density;
LUSC	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.73	-0.39	1.27e-13	Monocyte count;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25386820	chr18:21242428	ANKRD29	0.43	6.0	0.31	5.25e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg11645453	chr3:52864694	ITIH4	0.35	8.1	0.41	1.07e-14	Bipolar disorder;
LUSC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.23	0.41	4.16e-15	Lung cancer;
LUSC	cis	rs9487051	0.735	rs351756	chr6:109538773	A/G	cg01475377	chr6:109611718	NA	0.35	6.03	0.31	4.42e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18876405	chr7:65276391	NA	0.54	8.47	0.42	8.18e-16	Aortic root size;
LUSC	cis	rs965604	1.000	rs12903295	chr15:78778972	A/G	cg18825076	chr15:78729989	IREB2	-0.43	-6.93	-0.35	2.12e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3857536	0.813	rs9354405	chr6:66948575	G/T	cg07460842	chr6:66804631	NA	-0.45	-6.37	-0.33	6.42e-10	Blood trace element (Cu levels);
LUSC	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg06917634	chr15:78832804	PSMA4	0.5	6.12	0.32	2.55e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7127900	0.583	rs11043147	chr11:2234169	C/G	cg25635251	chr11:2234043	NA	0.87	16.25	0.66	3.75e-44	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
LUSC	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg05887092	chr17:76393375	PGS1	0.55	10.0	0.48	9.01e-21	HDL cholesterol levels;
LUSC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg24733560	chr20:60626293	TAF4	0.36	5.93	0.31	7.49e-9	Body mass index;
LUSC	cis	rs6066835	1.000	rs6066828	chr20:47344233	C/T	cg18078177	chr20:47281410	PREX1	0.69	5.98	0.31	5.66e-9	Multiple myeloma;
LUSC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg25767906	chr1:53392781	SCP2	-0.62	-12.25	-0.56	9.28e-29	Monocyte count;
LUSC	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.78	13.23	0.59	1.98e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg11663144	chr21:46675770	NA	-0.43	-7.55	-0.38	4.24e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-1.42	-12.34	-0.56	4.47e-29	Plateletcrit;
LUSC	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg00898013	chr13:113819073	PROZ	-0.56	-8.11	-0.41	1.01e-14	Platelet distribution width;
LUSC	cis	rs13385	0.769	rs4913075	chr5:139613571	A/G	cg26211634	chr5:139558579	C5orf32	0.45	6.7	0.34	9.06e-11	Atrial fibrillation;
LUSC	cis	rs2857891	0.817	rs2857885	chr11:6967187	G/A	cg04053776	chr11:6947353	ZNF215	0.43	6.16	0.32	2.05e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg08345082	chr10:99160200	RRP12	-0.36	-7.41	-0.38	1.02e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.36	0.33	6.49e-10	Menopause (age at onset);
LUSC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.39	0.59	5.2e-33	Cognitive test performance;
LUSC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg06784218	chr1:46089804	CCDC17	0.55	11.09	0.52	1.53e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg06521331	chr12:34319734	NA	0.4	6.32	0.33	8.45e-10	Morning vs. evening chronotype;
LUSC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg25204440	chr1:209979598	IRF6	0.5	5.72	0.3	2.36e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.28	-5.64	-0.3	3.55e-8	Longevity;Endometriosis;
LUSC	trans	rs710987	0.760	rs710995	chr5:3515519	A/G	cg27629735	chr1:3556483	WDR8	-0.37	-6.18	-0.32	1.9e-9	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
LUSC	cis	rs4843185	0.637	rs4143866	chr16:85716366	A/G	cg05245094	chr16:85669572	KIAA0182	0.43	6.14	0.32	2.41e-9	Platelet distribution width;
LUSC	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.23	0.41	4.34e-15	Corneal astigmatism;
LUSC	trans	rs11696501	0.688	rs714595	chr20:44330591	G/A	cg03272292	chr12:48577362	C12orf68	0.49	6.02	0.31	4.69e-9	Brain structure;
LUSC	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg00520135	chr15:63333846	TPM1	-0.34	-6.78	-0.35	5.42e-11	Platelet count;
LUSC	trans	rs61931739	0.817	rs188588	chr12:34215277	G/A	cg26384229	chr12:38710491	ALG10B	0.54	8.6	0.43	3.09e-16	Morning vs. evening chronotype;
LUSC	cis	rs7572644	0.699	rs2016616	chr2:28134037	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-6.95	-0.36	1.91e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs34734847	0.787	rs695949	chr12:121149736	A/G	cg21892295	chr12:121157589	UNC119B	-0.45	-8.06	-0.4	1.35e-14	Mean corpuscular volume;
LUSC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg03806693	chr22:41940476	POLR3H	0.99	13.85	0.6	9.09e-35	Vitiligo;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08345776	chr10:71993218	PPA1	-0.37	-6.03	-0.31	4.42e-9	Electrocardiographic conduction measures;
LUSC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg17264618	chr3:40429014	ENTPD3	0.35	7.19	0.37	4.15e-12	Renal cell carcinoma;
LUSC	cis	rs17155006	0.711	rs377007	chr7:107750446	T/A	cg05962710	chr7:107745446	LAMB4	-0.36	-6.29	-0.33	9.97e-10	Pneumococcal bacteremia;
LUSC	cis	rs7495211	0.529	rs11247364	chr15:98623984	A/T	cg25404375	chr15:99409942	IGF1R	-0.39	-5.87	-0.31	1.07e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg04362960	chr10:104952993	NT5C2	0.49	6.24	0.32	1.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs4729127	1.000	rs12669501	chr7:93995008	C/T	cg20086523	chr13:52378287	DHRS12	0.57	6.09	0.32	3.07e-9	Intelligence;
LUSC	cis	rs2932538	0.922	rs6671645	chr1:113129128	A/G	cg22162597	chr1:113214053	CAPZA1	0.53	7.69	0.39	1.66e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg24011408	chr12:48396354	COL2A1	-0.46	-7.59	-0.38	3.32e-13	Plateletcrit;
LUSC	cis	rs10193935	0.892	rs12622152	chr2:42482929	C/A	cg27598129	chr2:42591480	NA	-0.61	-8.22	-0.41	4.7e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9807989	0.507	rs4851571	chr2:103019000	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.17e-12	Asthma;
LUSC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg25036284	chr2:26402008	FAM59B	-0.69	-10.17	-0.49	2.34e-21	Gut microbiome composition (summer);
LUSC	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.61	0.62	1.05e-37	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9612	1.000	rs346526	chr19:44259565	A/G	cg08581076	chr19:44259116	C19orf61	0.53	6.66	0.34	1.1e-10	Exhaled nitric oxide output;
LUSC	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs977987	0.843	rs4887820	chr16:75397287	C/T	cg03315344	chr16:75512273	CHST6	0.48	9.18	0.45	4.78e-18	Dupuytren's disease;
LUSC	cis	rs55871839	0.708	rs1448541	chr8:59812938	G/A	cg07426533	chr8:59803705	TOX	-0.36	-5.93	-0.31	7.66e-9	Pneumonia;
LUSC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.89	16.47	0.67	5.01e-45	Menarche (age at onset);
LUSC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg02772935	chr3:125709198	NA	-0.48	-5.78	-0.3	1.7e-8	Blood pressure (smoking interaction);
LUSC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.09	16.29	0.67	2.45e-44	Gut microbiome composition (summer);
LUSC	cis	rs12618769	0.597	rs4851140	chr2:99079339	T/C	cg10123293	chr2:99228465	UNC50	0.46	7.74	0.39	1.21e-13	Bipolar disorder;
LUSC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg10169327	chr19:45448959	APOC2	0.3	6.21	0.32	1.59e-9	Blood protein levels;
LUSC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.22	0.52	5.24e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg12935359	chr14:103987150	CKB	0.66	10.73	0.51	2.73e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	7.84	0.39	6.1e-14	Iron status biomarkers;
LUSC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg11062466	chr8:58055876	NA	0.67	8.14	0.41	7.83e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19717773	chr7:2847554	GNA12	-0.39	-6.16	-0.32	2.12e-9	Height;
LUSC	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg05855489	chr10:104503620	C10orf26	0.55	6.36	0.33	6.81e-10	Arsenic metabolism;
LUSC	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.97	-0.36	1.72e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg06096015	chr1:231504339	EGLN1	0.56	9.8	0.47	4.44e-20	Hemoglobin concentration;
LUSC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg22535103	chr8:58192502	C8orf71	-0.79	-8.22	-0.41	4.44e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9811920	0.809	rs1387647	chr3:99826942	T/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.44	6.39	0.33	5.5e-10	Axial length;
LUSC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg23978390	chr7:1156363	C7orf50	0.46	6.6	0.34	1.6e-10	Longevity;Endometriosis;
LUSC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	15.8	0.65	2.17e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg18335740	chr13:41363409	SLC25A15	-0.45	-6.96	-0.36	1.77e-11	Lewy body disease;
LUSC	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	6.44	0.33	4.24e-10	Menarche (age at onset);
LUSC	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-10.14	-0.48	3.18e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg01448562	chr3:133502909	NA	-0.47	-7.4	-0.38	1.15e-12	Iron status biomarkers;
LUSC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.12	0.41	9.04e-15	Prudent dietary pattern;
LUSC	cis	rs7202877	0.706	rs247423	chr16:75456631	C/A	cg03315344	chr16:75512273	CHST6	-0.42	-5.99	-0.31	5.52e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg05714579	chr10:131428358	MGMT	0.52	7.81	0.39	7.51e-14	Response to temozolomide;
LUSC	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg25011763	chr5:6727354	POLS	-0.36	-6.18	-0.32	1.83e-9	Menopause (age at onset);
LUSC	cis	rs3768617	0.811	rs12563494	chr1:183039698	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.64	0.43	2.29e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10802521	chr3:52805072	NEK4	-0.57	-9.09	-0.45	8.74e-18	Bipolar disorder;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg25703541	chr22:24373054	LOC391322	-1.0	-19.87	-0.74	1.49e-58	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9905704	0.918	rs302880	chr17:56761411	C/T	cg12560992	chr17:57184187	TRIM37	0.54	7.79	0.39	8.77e-14	Testicular germ cell tumor;
LUSC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.69	10.87	0.51	8.84e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.52	-0.57	9.26e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs3755132	0.929	rs976233	chr2:15774115	C/T	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09376238	chr14:96830058	ATG2B	-0.4	-6.02	-0.31	4.61e-9	Electrocardiographic conduction measures;
LUSC	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.83	0.51	1.22e-23	Morning vs. evening chronotype;
LUSC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-5.94	-0.31	7.02e-9	Body mass index;
LUSC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.11	-0.41	9.73e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.03	20.73	0.75	5.92e-62	Cognitive function;
LUSC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg13319975	chr6:146136371	FBXO30	0.71	10.36	0.49	5.35e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13127421	chr17:48202128	SAMD14	-0.55	-9.02	-0.44	1.47e-17	Temporomandibular joint disorder;
LUSC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.35	-0.37	1.5e-12	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.56	0.38	3.83e-13	Prudent dietary pattern;
LUSC	cis	rs55665837	1.000	rs11023216	chr11:14437153	G/A	cg19336497	chr11:14380999	RRAS2	-0.37	-7.54	-0.38	4.53e-13	Vitamin D levels;
LUSC	cis	rs7241530	0.662	rs6506755	chr18:75905002	A/G	cg14642773	chr18:75888474	NA	0.39	6.02	0.31	4.59e-9	Educational attainment (years of education);
LUSC	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.67	-0.34	1.08e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs62481355	0.680	rs2106177	chr7:127072695	T/G	cg25922125	chr7:127225783	GCC1	-0.42	-5.74	-0.3	2.16e-8	Type 2 diabetes;
LUSC	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg01444801	chr10:135216882	MTG1	-0.49	-6.49	-0.33	3.08e-10	Systemic lupus erythematosus;
LUSC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.45	-5.92	-0.31	8.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg05043794	chr9:111880884	C9orf5	-0.35	-7.44	-0.38	8.73e-13	Menarche (age at onset);
LUSC	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg05347473	chr6:146136440	FBXO30	-0.38	-6.3	-0.33	9.2e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg06028605	chr16:24865363	SLC5A11	0.45	7.95	0.4	2.96e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg06145435	chr7:1022769	CYP2W1	0.34	5.8	0.3	1.52e-8	Bronchopulmonary dysplasia;
LUSC	trans	rs57046232	0.552	rs6038449	chr20:6337980	C/T	cg17788362	chr6:86352627	SYNCRIP	0.44	6.21	0.32	1.61e-9	Colorectal cancer;
LUSC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg25456477	chr12:86230367	RASSF9	0.35	6.25	0.32	1.24e-9	Major depressive disorder;
LUSC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-10.18	-0.49	2.29e-21	Monocyte percentage of white cells;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10581632	chr12:56360715	CDK2;SILV	0.41	6.12	0.32	2.63e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs79387448	0.638	rs76255660	chr2:103091028	T/C	cg09003973	chr2:102972529	NA	0.98	9.6	0.47	1.9e-19	Gut microbiota (bacterial taxa);
LUSC	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-5.84	-0.3	1.25e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10504073	0.669	rs341802	chr8:50039313	C/T	cg00325661	chr8:49890786	NA	0.59	9.47	0.46	5.11e-19	Blood metabolite ratios;
LUSC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg26338869	chr17:61819248	STRADA	0.42	5.96	0.31	6.57e-9	Prudent dietary pattern;
LUSC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg27398817	chr8:82754497	SNX16	-0.46	-6.18	-0.32	1.82e-9	Diastolic blood pressure;
LUSC	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg03213289	chr20:61660250	NA	0.66	13.48	0.59	2.21e-33	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9296092	0.517	rs56206922	chr6:33522567	C/T	cg13560919	chr6:33536144	NA	-0.82	-15.86	-0.66	1.26e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	0.8	14.11	0.61	8.94e-36	Cognitive function;
LUSC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg17971929	chr21:40555470	PSMG1	-0.51	-7.69	-0.39	1.67e-13	Menarche (age at onset);
LUSC	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.0	-0.44	1.74e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7084921	0.608	rs2862950	chr10:101844785	A/G	cg02250046	chr10:101825185	CPN1	-0.33	-5.97	-0.31	6.19e-9	Bone mineral density;
LUSC	cis	rs9296092	0.538	rs78061112	chr6:33526587	T/G	cg13560919	chr6:33536144	NA	-0.85	-16.44	-0.67	6.54e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg00277334	chr10:82204260	NA	-0.58	-8.73	-0.43	1.25e-16	Post bronchodilator FEV1;
LUSC	cis	rs870825	0.860	rs72703527	chr4:185605997	C/A	cg04058563	chr4:185651563	MLF1IP	0.77	10.15	0.49	2.77e-21	Blood protein levels;
LUSC	cis	rs4363385	0.818	rs407448	chr1:153007504	C/T	cg25856811	chr1:152973957	SPRR3	-0.35	-5.87	-0.31	1.04e-8	Inflammatory skin disease;
LUSC	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg11502198	chr6:26597334	ABT1	0.59	9.24	0.45	2.86e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs597583	0.806	rs11603340	chr11:117396527	C/G	cg27161313	chr11:117392002	DSCAML1	-0.43	-7.19	-0.37	4.33e-12	Putamen volume;
LUSC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg09034736	chr1:150693464	HORMAD1	0.45	6.46	0.33	3.6e-10	Melanoma;
LUSC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18404041	chr3:52824283	ITIH1	-0.61	-11.74	-0.54	7.31e-27	Bipolar disorder;
LUSC	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg21385522	chr1:16154831	NA	0.51	7.87	0.4	4.91e-14	Dilated cardiomyopathy;
LUSC	cis	rs11051970	0.879	rs2171373	chr12:32575777	C/T	cg24626660	chr12:32551988	NA	0.33	5.7	0.3	2.69e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2625529	0.652	rs2957745	chr15:72288077	T/C	cg16672083	chr15:72433130	SENP8	0.48	8.0	0.4	2.08e-14	Red blood cell count;
LUSC	cis	rs721399	0.583	rs4646267	chr8:18247913	A/G	cg18736775	chr8:18248649	NAT2	-0.57	-6.55	-0.34	2.12e-10	Blood metabolite levels;
LUSC	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg00898013	chr13:113819073	PROZ	-0.53	-7.85	-0.39	5.78e-14	Platelet distribution width;
LUSC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg13770153	chr20:60521292	NA	-1.04	-16.15	-0.66	9.53e-44	Obesity-related traits;
LUSC	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.69	-12.23	-0.56	1.12e-28	Caffeine consumption;
LUSC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.48	0.53	6.04e-26	Prudent dietary pattern;
LUSC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg00684032	chr4:1343700	KIAA1530	-0.37	-6.51	-0.34	2.81e-10	Obesity-related traits;
LUSC	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg05283184	chr6:79620031	NA	-0.46	-8.62	-0.43	2.78e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg13852791	chr20:30311386	BCL2L1	0.84	10.32	0.49	7.33e-22	Mean corpuscular hemoglobin;
LUSC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26818010	chr10:134567672	INPP5A	-0.84	-10.6	-0.5	7.9e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	1.14	15.73	0.65	3.98e-42	Uric acid levels;
LUSC	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.69	-8.69	-0.43	1.6e-16	Schizophrenia;
LUSC	cis	rs8044995	0.563	rs56331745	chr16:68368770	G/T	cg05110241	chr16:68378359	PRMT7	-0.76	-8.6	-0.43	3.22e-16	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.64	-0.34	1.3e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg26408565	chr15:76604113	ETFA	0.48	7.81	0.39	7.41e-14	Blood metabolite levels;
LUSC	cis	rs7503807	0.967	rs4889867	chr17:78593058	C/T	cg09596252	chr17:78655493	RPTOR	0.43	7.44	0.38	8.47e-13	Obesity;
LUSC	cis	rs4343996	0.727	rs4499989	chr7:3371291	T/G	cg21248987	chr7:3385318	SDK1	-0.36	-6.15	-0.32	2.17e-9	Motion sickness;
LUSC	cis	rs12474201	0.963	rs11676737	chr2:46929873	T/C	cg06386533	chr2:46925753	SOCS5	0.77	11.77	0.54	5.58e-27	Height;
LUSC	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg24296786	chr1:45957014	TESK2	-0.41	-5.81	-0.3	1.47e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg09469691	chr10:81107165	PPIF	0.59	8.85	0.44	5.28e-17	Height;
LUSC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	1.05	18.92	0.72	9.37e-55	Parkinson's disease;
LUSC	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg00310523	chr12:86230176	RASSF9	0.39	6.98	0.36	1.58e-11	Major depressive disorder;
LUSC	cis	rs9311676	0.656	rs66793022	chr3:58391565	C/T	cg13750441	chr3:58318267	PXK	0.35	6.77	0.35	5.89e-11	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08677398	chr8:58056175	NA	0.54	6.56	0.34	2.1e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg04865166	chr7:105162814	PUS7	0.52	5.92	0.31	7.79e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg21573476	chr21:45109991	RRP1B	-0.36	-5.68	-0.3	2.96e-8	Mean corpuscular volume;
LUSC	cis	rs11209185	0.545	rs11209184	chr1:68421069	C/T	cg22082780	chr1:68452167	NA	0.38	6.52	0.34	2.67e-10	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06022373	chr22:39101656	GTPBP1	0.83	13.96	0.61	3.27e-35	Menopause (age at onset);
LUSC	cis	rs6736093	1.000	rs79688911	chr2:112657907	C/T	cg12686935	chr2:112915763	FBLN7	-0.39	-6.05	-0.31	3.78e-9	Coronary artery disease;
LUSC	cis	rs8056893	0.714	rs1530643	chr16:68396092	T/C	cg02226672	chr16:68398533	SMPD3	0.33	5.93	0.31	7.59e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs73198271	0.920	rs11781542	chr8:8617181	G/T	cg01851573	chr8:8652454	MFHAS1	0.56	8.51	0.42	6.09e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10761482	0.813	rs3808942	chr10:62150848	C/T	cg18175470	chr10:62150864	ANK3	-0.56	-8.45	-0.42	9.38e-16	Schizophrenia;
LUSC	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg23093090	chr10:104574429	C10orf26	-0.36	-6.61	-0.34	1.48e-10	Arsenic metabolism;
LUSC	cis	rs16910800	1.000	rs7114414	chr11:23201509	A/G	cg20040320	chr11:23191996	NA	-0.44	-6.35	-0.33	6.87e-10	Cancer;
LUSC	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.12	-0.36	6.63e-12	Coronary artery disease;
LUSC	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.13	-0.36	6.09e-12	Blood metabolite levels;
LUSC	cis	rs963731	0.579	rs1454226	chr2:39246862	A/G	cg04010122	chr2:39346883	SOS1	-0.82	-5.74	-0.3	2.11e-8	Corticobasal degeneration;
LUSC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.17	-0.37	4.88e-12	Alzheimer's disease (late onset);
LUSC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg05738196	chr6:26577821	NA	-0.55	-5.96	-0.31	6.48e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3857536	0.813	rs9453639	chr6:66933538	C/T	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.56e-10	Blood trace element (Cu levels);
LUSC	cis	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg05299278	chr17:33885742	SLFN14	0.3	6.46	0.33	3.8e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.44	0.53	8.79e-26	Prudent dietary pattern;
LUSC	trans	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.72	-12.14	-0.55	2.36e-28	Platelet distribution width;
LUSC	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg11584989	chr19:19387371	SF4	0.59	6.99	0.36	1.46e-11	Bipolar disorder;
LUSC	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg18357645	chr12:58087776	OS9	0.55	8.34	0.42	1.95e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg24692254	chr21:30365293	RNF160	-0.68	-11.01	-0.52	3.01e-24	Pancreatic cancer;
LUSC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.66	10.98	0.51	3.84e-24	Bone mineral density;
LUSC	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.75	12.82	0.57	7.34e-31	Metabolic syndrome;
LUSC	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg08079166	chr15:68083412	MAP2K5	0.39	6.96	0.36	1.75e-11	Restless legs syndrome;
LUSC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg10862848	chr6:42927986	GNMT	-0.29	-6.83	-0.35	4.02e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	7.58	0.38	3.53e-13	Obesity-related traits;
LUSC	cis	rs1957429	0.520	rs66511472	chr14:65330330	C/A	cg23373153	chr14:65346875	NA	-0.85	-7.9	-0.4	4.11e-14	Pediatric areal bone mineral density (radius);
LUSC	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.41	6.38	0.33	6.03e-10	Height;
LUSC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg06212747	chr3:49208901	KLHDC8B	0.45	6.13	0.32	2.45e-9	Parkinson's disease;
LUSC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg15557168	chr22:42548783	NA	0.45	6.76	0.35	6.2e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg21361702	chr7:150065534	REPIN1	0.59	8.39	0.42	1.38e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg15896084	chr13:114927664	NA	0.41	7.4	0.38	1.11e-12	Schizophrenia;
LUSC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	7.78	0.39	9.16e-14	Schizophrenia;
LUSC	cis	rs8042849	1	rs8042849	chr15:78817929	C/T	cg06917634	chr15:78832804	PSMA4	0.45	6.33	0.33	7.88e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Parental lifespan;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.53	7.78	0.39	9.38e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	1.08	16.95	0.68	6.24e-47	Exhaled nitric oxide output;
LUSC	cis	rs977987	0.806	rs34996006	chr16:75479434	A/G	cg04384234	chr16:75411784	CFDP1	-0.42	-6.96	-0.36	1.8e-11	Dupuytren's disease;
LUSC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg07959070	chr22:50026188	C22orf34	-0.35	-6.99	-0.36	1.55e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg23172400	chr8:95962367	TP53INP1	-0.41	-8.5	-0.42	6.24e-16	Type 2 diabetes;
LUSC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg16060761	chr17:80687452	NA	-0.41	-6.61	-0.34	1.49e-10	Breast cancer;
LUSC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg03188948	chr7:1209495	NA	0.62	6.56	0.34	2.03e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg19812747	chr11:111475976	SIK2	-0.55	-8.17	-0.41	6.25e-15	Primary sclerosing cholangitis;
LUSC	cis	rs7532866	0.885	rs7520137	chr1:26731035	T/G	cg17456097	chr1:26900765	RPS6KA1	-0.42	-6.11	-0.32	2.85e-9	Height;
LUSC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-13.21	-0.59	2.33e-32	Chronic sinus infection;
LUSC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg11766577	chr21:47581405	C21orf56	-0.54	-8.5	-0.42	6.6e-16	Testicular germ cell tumor;
LUSC	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.19	0.32	1.81e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.73	-10.86	-0.51	9.87e-24	Menarche (age at onset);
LUSC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg00677455	chr12:58241039	CTDSP2	0.61	8.47	0.42	7.68e-16	Multiple sclerosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02533120	chr21:33031840	SOD1	-0.54	-6.46	-0.33	3.71e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg08000102	chr2:233561755	GIGYF2	0.7	11.65	0.54	1.45e-26	Coronary artery disease;
LUSC	cis	rs7553864	0.667	rs7512650	chr1:87609076	T/C	cg17420885	chr1:87600446	LOC339524	-0.49	-6.77	-0.35	5.83e-11	Smoking behavior;
LUSC	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.5	6.73	0.35	7.27e-11	Corneal astigmatism;
LUSC	cis	rs870825	0.520	rs10022842	chr4:185649459	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	trans	rs1275468	0.689	rs1795382	chr12:75979893	A/G	cg04012681	chr10:1511277	ADARB2	0.37	5.98	0.31	5.77e-9	Polycystic ovary syndrome;
LUSC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.57	7.73	0.39	1.29e-13	High light scatter reticulocyte count;
LUSC	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14240646	chr10:27532245	ACBD5	-0.74	-8.23	-0.41	4.36e-15	Breast cancer;
LUSC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.3	-6.03	-0.31	4.44e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg04539111	chr16:67997858	SLC12A4	-0.43	-5.68	-0.3	2.99e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7172677	0.696	rs56262544	chr15:75379471	A/G	cg14664628	chr15:75095509	CSK	0.51	6.53	0.34	2.38e-10	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg24503407	chr1:205819492	PM20D1	-0.44	-6.54	-0.34	2.26e-10	Menarche (age at onset);
LUSC	cis	rs62432291	0.681	rs447637	chr6:159658726	A/G	cg14500486	chr6:159655392	FNDC1	-0.54	-6.06	-0.31	3.76e-9	Joint mobility (Beighton score);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	ch.12.124321348F	chr12:125755395	NA	0.45	6.04	0.31	4.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4729127	1.000	rs17166229	chr7:94017673	A/G	cg22713327	chr12:120703336	PXN	0.57	6.0	0.31	5.17e-9	Intelligence;
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.58	-10.91	-0.51	6.49e-24	Longevity;Endometriosis;
LUSC	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.43	17.45	0.69	6.4e-49	Opioid sensitivity;
LUSC	trans	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg26811252	chr16:29126840	RRN3P2	0.6	9.64	0.47	1.46e-19	Menopause (age at onset);
LUSC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-8.1	-0.41	1.04e-14	Type 2 diabetes;
LUSC	cis	rs12900413	0.687	rs6496599	chr15:90314582	C/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.75	-0.3	2.05e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs554111	0.656	rs12567861	chr1:21395133	C/T	cg01072550	chr1:21505969	NA	0.37	5.71	0.3	2.51e-8	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-0.88	-15.08	-0.64	1.52e-39	Height;
LUSC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.7e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4642101	0.680	rs7626609	chr3:12806080	A/G	cg05775895	chr3:12838266	CAND2	-0.48	-7.68	-0.39	1.75e-13	QRS complex (12-leadsum);
LUSC	cis	rs6594499	0.872	rs1379298	chr5:110435726	T/C	cg04022379	chr5:110408740	TSLP	0.43	6.47	0.33	3.54e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2708377	0.860	rs35318883	chr12:11309750	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg03354898	chr7:1950403	MAD1L1	-0.46	-9.57	-0.46	2.45e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg27165867	chr14:105738592	BRF1	-0.52	-7.45	-0.38	7.91e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	13.16	0.58	3.88e-32	Lung cancer in ever smokers;
LUSC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.33	-0.37	1.75e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg24531977	chr5:56204891	C5orf35	-0.56	-8.16	-0.41	6.79e-15	Coronary artery disease;
LUSC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	8.91	0.44	3.34e-17	Total body bone mineral density;
LUSC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg02951883	chr7:2050386	MAD1L1	-0.44	-7.58	-0.38	3.41e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs3106136	0.934	rs4693004	chr4:95168456	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.11	-0.32	2.76e-9	Capecitabine sensitivity;
LUSC	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg15848620	chr12:58087721	OS9	-0.55	-7.87	-0.4	4.88e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg08213375	chr14:104286397	PPP1R13B	0.48	8.53	0.42	5.03e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7771547	0.519	rs4713972	chr6:36371316	C/A	cg07856975	chr6:36356162	ETV7	0.44	6.49	0.33	3.08e-10	Platelet distribution width;
LUSC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg25767906	chr1:53392781	SCP2	-0.52	-9.52	-0.46	3.62e-19	Monocyte count;
LUSC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg05425664	chr17:57184151	TRIM37	-0.55	-8.05	-0.4	1.47e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg24154853	chr7:158122151	PTPRN2	0.44	8.6	0.43	3.06e-16	Calcium levels;
LUSC	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.16	0.45	5.47e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg17173187	chr15:85201210	NMB	0.37	6.37	0.33	6.23e-10	Schizophrenia;
LUSC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	12.96	0.58	2.08e-31	Hip circumference adjusted for BMI;
LUSC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.12	0.32	2.63e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg06636551	chr8:101224915	SPAG1	0.38	7.02	0.36	1.23e-11	Atrioventricular conduction;
LUSC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg19729930	chr2:74357872	NA	0.88	16.75	0.68	3.82e-46	Gestational age at birth (maternal effect);
LUSC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	0.99	14.04	0.61	1.7000000000000001e-35	Eosinophil percentage of granulocytes;
LUSC	trans	rs7951105	0.867	rs976908	chr11:39247801	C/T	cg24085930	chr3:21832523	NA	0.49	6.06	0.31	3.58e-9	Free thyroxine concentration;
LUSC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg13072238	chr3:49761600	GMPPB	0.37	5.93	0.31	7.36e-9	Body mass index;
LUSC	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.15	-0.36	5.59e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg17366294	chr4:99064904	C4orf37	0.56	9.8	0.47	4.24e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg04990556	chr1:26633338	UBXN11	0.84	11.12	0.52	1.24e-24	Obesity-related traits;
LUSC	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.75	14.7	0.63	4.6e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg21951975	chr1:209979733	IRF6	0.61	7.89	0.4	4.43e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg08508325	chr11:3079039	CARS	0.39	8.3	0.41	2.7e-15	Calcium levels;
LUSC	cis	rs9644630	0.897	rs4921654	chr8:19359974	G/T	cg01280390	chr8:19363452	CSGALNACT1	-0.35	-6.59	-0.34	1.69e-10	Oropharynx cancer;
LUSC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	11.3	0.53	2.7e-25	Tonsillectomy;
LUSC	cis	rs13315871	0.790	rs13066409	chr3:58428444	A/G	cg12435725	chr3:58293450	RPP14	-0.7	-6.89	-0.35	2.75e-11	Cholesterol, total;
LUSC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg05425664	chr17:57184151	TRIM37	-0.55	-8.11	-0.41	9.42e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7131987	0.683	rs12366505	chr12:29474110	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.77	-0.35	5.69e-11	QT interval;
LUSC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg15445000	chr17:37608096	MED1	-0.4	-6.8	-0.35	4.69e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.78	12.42	0.56	2.27e-29	Longevity;
LUSC	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg10018233	chr7:150070692	REPIN1	0.45	9.0	0.44	1.78e-17	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1950500	0.565	rs3181248	chr14:24808168	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.6	9.82	0.47	3.65e-20	Height;
LUSC	cis	rs77741769	0.529	rs2893876	chr12:121245158	T/C	cg02419362	chr12:121203948	SPPL3	0.45	8.29	0.41	2.83e-15	Mean corpuscular volume;
LUSC	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.52	7.68	0.39	1.75e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg20016023	chr10:99160130	RRP12	-0.33	-8.04	-0.4	1.57e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12379764	chr21:47803548	PCNT	-0.43	-5.99	-0.31	5.53e-9	Testicular germ cell tumor;
LUSC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.77	12.84	0.57	5.9e-31	Cognitive function;
LUSC	cis	rs3741798	1.000	rs61922026	chr12:12486428	C/G	cg08615371	chr12:12503544	MANSC1	1.07	10.76	0.51	2.28e-23	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.72	0.51	3.03e-23	Monocyte percentage of white cells;
LUSC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg01657329	chr11:68192670	LRP5	0.45	7.33	0.37	1.71e-12	Total body bone mineral density;
LUSC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.12	0.55	2.82e-28	Prudent dietary pattern;
LUSC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg26924012	chr15:45694286	SPATA5L1	1.14	21.1	0.76	2.08e-63	Homoarginine levels;
LUSC	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg07959070	chr22:50026188	C22orf34	-0.33	-6.83	-0.35	3.92e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	0.87	14.37	0.62	8.48e-37	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg15649852	chr7:65879115	NA	-0.41	-5.76	-0.3	1.96e-8	Aortic root size;
LUSC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg23719950	chr11:63933701	MACROD1	-0.6	-7.9	-0.4	4.11e-14	Mean platelet volume;
LUSC	cis	rs1832871	0.672	rs56115227	chr6:158773884	G/A	cg07165851	chr6:158734300	TULP4	0.47	7.16	0.36	5.04e-12	Height;
LUSC	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg26597838	chr10:835615	NA	0.56	7.33	0.37	1.74e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg03188948	chr7:1209495	NA	0.66	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg23711669	chr6:146136114	FBXO30	0.7	12.24	0.56	1.03e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12286929	0.639	rs4938181	chr11:115041163	A/G	cg04055981	chr11:115044050	NA	0.44	8.05	0.4	1.44e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.51	-8.46	-0.42	8.42e-16	IgG glycosylation;
LUSC	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.31	-0.37	2.01e-12	Bipolar disorder;
LUSC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg11871910	chr12:69753446	YEATS4	0.73	11.28	0.53	3.1e-25	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs36405	0.500	rs8003168	chr14:72363388	A/G	cg23396177	chr14:72358413	NA	-0.34	-6.39	-0.33	5.6e-10	Yang-deficiency constitution;
LUSC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-6.79	-0.35	5.04e-11	Alzheimer's disease (late onset);
LUSC	cis	rs16976116	0.951	rs11857087	chr15:55487181	T/A	cg11288833	chr15:55489084	RSL24D1	0.48	5.69	0.3	2.8e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg04317338	chr11:64019027	PLCB3	0.67	7.69	0.39	1.71e-13	Mean platelet volume;
LUSC	cis	rs9473147	0.602	rs9296567	chr6:47553402	G/A	cg20196966	chr6:47445060	CD2AP	0.43	6.05	0.31	3.86e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.49	7.49	0.38	6.36e-13	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.19	-0.32	1.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3125734	0.633	rs6479791	chr10:63980341	T/C	cg09941381	chr10:64027924	RTKN2	-0.39	-7.36	-0.37	1.43e-12	Rheumatoid arthritis;
LUSC	cis	rs9420	0.528	rs34052104	chr11:57384519	A/C	cg23127183	chr11:57508653	C11orf31	-0.47	-6.57	-0.34	1.95e-10	Schizophrenia;
LUSC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg02079420	chr8:82753780	SNX16	0.41	7.01	0.36	1.29e-11	Diastolic blood pressure;
LUSC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.8	-0.35	4.89e-11	Lung cancer;
LUSC	cis	rs981844	1.000	rs116588966	chr4:154664794	T/C	cg10279832	chr4:154682576	RNF175	-0.4	-5.85	-0.3	1.19e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg07701084	chr6:150067640	NUP43	0.57	8.77	0.43	9.32e-17	Lung cancer;
LUSC	cis	rs2637266	0.935	rs7909808	chr10:78392318	A/G	cg18941641	chr10:78392320	NA	0.4	7.34	0.37	1.66e-12	Pulmonary function;
LUSC	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.92	-0.44	3.05e-17	Joint mobility (Beighton score);
LUSC	cis	rs11997175	0.646	rs4612298	chr8:33713451	G/A	ch.8.33884649F	chr8:33765107	NA	0.46	7.0	0.36	1.44e-11	Body mass index;
LUSC	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg05868516	chr6:26286170	HIST1H4H	0.36	5.8	0.3	1.58e-8	Educational attainment;
LUSC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.17	-0.32	1.97e-9	Lung cancer;
LUSC	cis	rs9815354	0.680	rs73830596	chr3:42028223	G/A	cg03022575	chr3:42003672	ULK4	0.71	7.27	0.37	2.5e-12	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg09085632	chr11:111637200	PPP2R1B	0.5	6.97	0.36	1.67e-11	Primary sclerosing cholangitis;
LUSC	cis	rs13006833	0.668	rs2582770	chr2:191136794	A/C	cg21644426	chr2:191273491	MFSD6	0.45	6.36	0.33	6.83e-10	Urinary metabolites;
LUSC	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg09469691	chr10:81107165	PPIF	0.56	8.33	0.41	2.08e-15	Height;
LUSC	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.12	0.32	2.59e-9	Lymphocyte counts;
LUSC	cis	rs7851660	0.809	rs9299258	chr9:100666543	T/G	cg13688889	chr9:100608707	NA	-0.54	-8.43	-0.42	1.05e-15	Strep throat;
LUSC	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg00105475	chr2:10696890	NA	-0.38	-6.39	-0.33	5.66e-10	Prostate cancer;
LUSC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg03146154	chr1:46216737	IPP	0.54	8.24	0.41	4e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg09904177	chr6:26538194	HMGN4	-0.78	-5.7	-0.3	2.64e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg17252645	chr8:143867129	LY6D	0.38	6.7	0.34	8.75e-11	Urinary tract infection frequency;
LUSC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	0.99	13.99	0.61	2.53e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-0.83	-13.01	-0.58	1.36e-31	Blood protein levels;
LUSC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg00431813	chr7:1051703	C7orf50	-0.37	-5.79	-0.3	1.6e-8	Longevity;Endometriosis;
LUSC	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg05163923	chr11:71159392	DHCR7	0.74	10.94	0.51	5.38e-24	Vitamin D levels;
LUSC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg22963979	chr7:1858916	MAD1L1	-0.74	-12.73	-0.57	1.57e-30	Bipolar disorder and schizophrenia;
LUSC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg00784671	chr22:46762841	CELSR1	-0.48	-5.97	-0.31	6.04e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg03522245	chr20:25566470	NINL	0.36	5.75	0.3	2e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21545522	chr1:205238299	TMCC2	0.49	9.2	0.45	3.93e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs865483	0.895	rs2522965	chr17:35816318	C/G	cg06716730	chr17:35851459	DUSP14	0.27	6.04	0.31	4.13e-9	Monocyte count;
LUSC	cis	rs7945718	0.806	rs7927346	chr11:12835835	C/T	cg25843174	chr11:12811716	TEAD1	0.31	7.12	0.36	6.45e-12	Educational attainment (years of education);
LUSC	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	13.16	0.58	3.88e-32	Lung cancer in ever smokers;
LUSC	cis	rs12620999	0.838	rs7589198	chr2:237967615	C/T	cg23555395	chr2:238036564	NA	0.4	6.85	0.35	3.56e-11	Systemic lupus erythematosus;
LUSC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	0.93	17.88	0.7	1.24e-50	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg12963246	chr6:28129442	ZNF389	0.41	6.35	0.33	6.93e-10	Parkinson's disease;
LUSC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.14	-0.32	2.36e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg01028140	chr2:1542097	TPO	-0.6	-7.99	-0.4	2.16e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg04121214	chr22:50244548	NA	-0.34	-5.69	-0.3	2.79e-8	Schizophrenia;
LUSC	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.86	-0.44	4.84e-17	Monocyte percentage of white cells;
LUSC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.55	-7.7	-0.39	1.54e-13	Tuberculosis;
LUSC	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-8.34	-0.42	2.02e-15	Systolic blood pressure;
LUSC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.53	-6.45	-0.33	3.86e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUSC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.56	0.38	4.05e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg25930673	chr12:123319894	HIP1R	-0.72	-7.24	-0.37	3.14e-12	Schizophrenia;
LUSC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg12463550	chr7:65579703	CRCP	-0.55	-8.23	-0.41	4.3e-15	Aortic root size;
LUSC	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg07080220	chr10:102295463	HIF1AN	0.59	7.61	0.38	2.86e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg21775979	chr11:780331	NA	0.41	6.71	0.34	8.57e-11	Breast cancer;
LUSC	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.24	0.32	1.34e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7189233	0.955	rs72801817	chr16:53474568	C/T	cg04059762	chr16:53544020	NA	-0.32	-5.83	-0.3	1.32e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.59	0.6	9.01e-34	Cognitive test performance;
LUSC	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg08645402	chr16:4508243	NA	-0.48	-7.35	-0.37	1.56e-12	Schizophrenia;
LUSC	cis	rs6489882	0.867	rs4766676	chr12:113365581	A/G	cg20102336	chr12:113376681	OAS3	0.41	5.97	0.31	6.01e-9	Chronic lymphocytic leukemia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18802567	chr5:171433913	FBXW11	0.46	7.2	0.37	4.13e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.39e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2235649	0.828	rs9938694	chr16:1849872	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.18	-0.32	1.84e-9	Blood metabolite levels;
LUSC	cis	rs372883	0.901	rs407463	chr21:30722440	G/A	cg24692254	chr21:30365293	RNF160	-0.41	-5.86	-0.31	1.14e-8	Pancreatic cancer;
LUSC	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg00321850	chr1:175162397	KIAA0040	-0.44	-7.52	-0.38	5.14e-13	Alcohol dependence;
LUSC	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.9	0.35	2.67e-11	Height;
LUSC	cis	rs6669072	0.647	rs698274	chr1:91244177	A/G	cg08895590	chr1:91227319	NA	-0.38	-8.51	-0.42	6.02e-16	Cognitive function;
LUSC	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.86	-0.31	1.11e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg06600287	chr1:53387719	ECHDC2	-0.29	-6.27	-0.32	1.15e-9	Monocyte count;
LUSC	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg09904177	chr6:26538194	HMGN4	-0.47	-7.35	-0.37	1.5e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg15073853	chr19:18549131	ISYNA1	-0.33	-5.97	-0.31	5.91e-9	Breast cancer;
LUSC	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.85	-0.44	5.13e-17	Response to antipsychotic treatment;
LUSC	cis	rs1178127	0.580	rs17139842	chr7:18800697	C/G	cg02370815	chr7:18831390	HDAC9	-0.42	-6.17	-0.32	2.02e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
LUSC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg19592336	chr6:28129416	ZNF389	0.48	6.3	0.33	9.46e-10	Depression;
LUSC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg10253484	chr15:75165896	SCAMP2	-0.46	-6.64	-0.34	1.24e-10	Breast cancer;
LUSC	cis	rs2230307	0.572	rs512999	chr1:100563330	A/G	cg24955406	chr1:100503596	HIAT1	0.59	6.36	0.33	6.62e-10	Carotid intima media thickness;
LUSC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.74	-0.35	6.85e-11	Crohn's disease;
LUSC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	9.15	0.45	5.97e-18	Height;
LUSC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg13206674	chr6:150067644	NUP43	0.6	9.7	0.47	9.47e-20	Lung cancer;
LUSC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	0.65	13.73	0.6	2.53e-34	Prudent dietary pattern;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25266327	chr19:16435660	KLF2	-0.47	-6.48	-0.33	3.23e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg13514129	chr1:39547527	MACF1	0.73	11.88	0.55	2.1e-27	Fractional exhaled nitric oxide (childhood);
LUSC	trans	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg17712092	chr4:129076599	LARP1B	-0.82	-12.09	-0.55	3.78e-28	Eosinophil percentage of white cells;
LUSC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	7.34	0.37	1.6e-12	Obesity-related traits;
LUSC	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg07169764	chr2:136633963	MCM6	1.06	14.11	0.61	8.61e-36	Corneal structure;
LUSC	cis	rs10193935	1.000	rs10173107	chr2:42420302	A/T	cg27598129	chr2:42591480	NA	-0.62	-8.48	-0.42	7.18e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg13319975	chr6:146136371	FBXO30	-0.7	-10.69	-0.5	3.9e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.96	0.55	1.14e-27	Personality dimensions;
LUSC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg21724239	chr8:58056113	NA	0.55	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	15.51	0.65	2.93e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1014246	0.848	rs10749227	chr10:118468631	G/C	cg14919929	chr10:118506882	NA	0.43	6.47	0.33	3.43e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs2742234	0.541	rs7073849	chr10:43740474	G/C	cg07801480	chr10:43725741	RASGEF1A	-0.39	-5.88	-0.31	1.02e-8	Hirschsprung disease;
LUSC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg01879757	chr17:41196368	BRCA1	-0.46	-7.0	-0.36	1.42e-11	Menopause (age at onset);
LUSC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg06640241	chr16:89574553	SPG7	0.85	15.08	0.64	1.43e-39	Multiple myeloma (IgH translocation);
LUSC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24110177	chr3:50126178	RBM5	-0.53	-8.73	-0.43	1.28e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs17401966	0.838	rs9332414	chr1:10326963	C/T	cg19773385	chr1:10388646	KIF1B	-0.5	-8.83	-0.44	5.98e-17	Hepatocellular carcinoma;
LUSC	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs943466	0.513	rs943467	chr6:33731811	A/T	cg25922239	chr6:33757077	LEMD2	0.4	5.65	0.3	3.42e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LUSC	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-8.5	-0.42	6.4e-16	Bladder cancer;
LUSC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg07424592	chr7:64974309	NA	0.69	6.07	0.32	3.41e-9	Diabetic kidney disease;
LUSC	cis	rs416603	0.967	rs7191538	chr16:11363389	C/G	cg00044050	chr16:11439710	C16orf75	-0.68	-12.11	-0.55	3.25e-28	Type 1 diabetes;
LUSC	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg09835421	chr16:68378352	PRMT7	-0.54	-5.91	-0.31	8.4e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg08470875	chr2:26401718	FAM59B	0.62	8.51	0.42	5.98e-16	Gut microbiome composition (summer);
LUSC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-1.0	-16.83	-0.68	1.77e-46	Systemic lupus erythematosus;
LUSC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	5.72	0.3	2.33e-8	Parkinson's disease;
LUSC	cis	rs868036	1.000	rs4776376	chr15:68093435	G/A	cg05925327	chr15:68127851	NA	-0.32	-5.7	-0.3	2.67e-8	Restless legs syndrome;
LUSC	cis	rs10162002	1.000	rs17078796	chr13:24043830	A/G	cg00158254	chr13:24040743	NA	-0.58	-6.5	-0.34	2.94e-10	Hypothyroidism;
LUSC	cis	rs9815354	0.868	rs1716653	chr3:41975598	C/A	cg03022575	chr3:42003672	ULK4	-0.59	-6.52	-0.34	2.53e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1858037	0.867	rs61226353	chr2:65590771	G/A	cg08085232	chr2:65598271	SPRED2	-0.39	-5.73	-0.3	2.3e-8	Rheumatoid arthritis;
LUSC	cis	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg06521331	chr12:34319734	NA	-0.46	-7.55	-0.38	4.16e-13	Morning vs. evening chronotype;
LUSC	cis	rs1018697	1.000	rs7086400	chr10:104562097	G/A	cg04362960	chr10:104952993	NT5C2	0.48	6.59	0.34	1.74e-10	Colorectal adenoma (advanced);
LUSC	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-9.52	-0.46	3.49e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg22508957	chr16:3507546	NAT15	-0.92	-10.64	-0.5	5.74e-23	Tuberculosis;
LUSC	cis	rs7561273	0.565	rs6545275	chr2:24331860	A/G	cg20701182	chr2:24300061	SF3B14	0.51	6.55	0.34	2.19e-10	Quantitative traits;
LUSC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg27535305	chr1:53392650	SCP2	0.37	6.79	0.35	5.29e-11	Monocyte count;
LUSC	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg25512537	chr17:76250053	NA	0.49	8.64	0.43	2.33e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg26811252	chr16:29126840	RRN3P2	0.58	9.33	0.45	1.5e-18	Menopause (age at onset);
LUSC	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg14458575	chr2:238380390	NA	0.77	13.36	0.59	6.69e-33	Prostate cancer;
LUSC	cis	rs75804782	0.520	rs34058921	chr2:239318665	C/T	cg18131467	chr2:239335373	ASB1	-0.74	-6.64	-0.34	1.28e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7605827	0.930	rs3805104	chr2:15535147	C/T	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.31e-17	Educational attainment (years of education);
LUSC	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.56	0.46	2.6e-19	Lung cancer in ever smokers;
LUSC	cis	rs7119	0.604	rs907383	chr15:77870646	A/G	cg27398640	chr15:77910606	LINGO1	0.35	7.71	0.39	1.49e-13	Type 2 diabetes;
LUSC	trans	rs868943	0.582	rs12210252	chr6:116477493	G/T	cg01703780	chr2:192353242	NA	0.34	5.94	0.31	7.01e-9	Total cholesterol levels;
LUSC	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg15605315	chr1:45957053	TESK2	-0.43	-6.59	-0.34	1.73e-10	High light scatter reticulocyte count;
LUSC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	trans	rs2392780	0.536	rs594154	chr8:128334911	G/A	cg10897648	chr18:56338258	MALT1	-0.41	-6.17	-0.32	1.92e-9	Breast cancer (early onset);
LUSC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-7.99	-0.4	2.18e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-7.11	-0.36	7.15e-12	Alzheimer's disease (late onset);
LUSC	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg19116668	chr7:99932089	PMS2L1	-0.33	-5.65	-0.3	3.49e-8	Coronary artery disease;
LUSC	cis	rs4919087	0.962	rs10882891	chr10:99059645	C/A	cg25902810	chr10:99078978	FRAT1	0.49	7.18	0.37	4.51e-12	Monocyte count;
LUSC	trans	rs9380880	0.826	rs2273062	chr6:39550935	C/A	cg14673904	chr12:46609063	SLC38A1	0.54	5.99	0.31	5.41e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg00898013	chr13:113819073	PROZ	0.55	8.22	0.41	4.58e-15	Platelet distribution width;
LUSC	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg07148914	chr20:33460835	GGT7	0.54	8.25	0.41	3.63e-15	Height;
LUSC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg09165964	chr15:75287851	SCAMP5	-1.15	-19.33	-0.73	2.1e-56	Blood trace element (Zn levels);
LUSC	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg26318627	chr11:63887540	MACROD1	-0.32	-6.11	-0.32	2.71e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7246967	0.673	rs2361245	chr19:22834530	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs6565180	1.000	rs6565180	chr16:30361341	G/T	cg17640201	chr16:30407289	ZNF48	-0.87	-15.27	-0.64	2.6e-40	Tonsillectomy;
LUSC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg13010344	chr12:123464640	ARL6IP4	-0.5	-8.18	-0.41	6e-15	Platelet count;
LUSC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg15103426	chr22:29168792	CCDC117	0.45	5.77	0.3	1.81e-8	Lymphocyte counts;
LUSC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg16447950	chr5:562315	NA	-0.53	-6.97	-0.36	1.69e-11	Obesity-related traits;
LUSC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.65	-10.02	-0.48	7.56e-21	Menarche (age at onset);
LUSC	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg13319975	chr6:146136371	FBXO30	-0.45	-6.76	-0.35	6.04e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg00884529	chr7:16685823	BZW2;ANKMY2	0.51	6.13	0.32	2.52e-9	Cognitive function;Information processing speed;
LUSC	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.13	-0.36	6.22e-12	Major depressive disorder;
LUSC	cis	rs11992162	0.569	rs35283519	chr8:11831661	C/T	cg20542592	chr8:11973495	FAM66D	0.45	5.82	0.3	1.41e-8	Monocyte count;
LUSC	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg06937882	chr20:24974362	C20orf3	0.42	7.0	0.36	1.43e-11	Blood protein levels;
LUSC	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg17470723	chr8:74884337	TCEB1	0.52	8.2	0.41	5.26e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg23590916	chr17:43697445	MGC57346	0.5	6.67	0.34	1.08e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-11.98	-0.55	9.35e-28	Platelet count;
LUSC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01755729	chr8:146012904	ZNF34	0.68	6.18	0.32	1.82e-9	Cognitive performance;
LUSC	trans	rs57046232	0.531	rs6054146	chr20:6335865	G/T	cg17788362	chr6:86352627	SYNCRIP	0.42	6.1	0.32	2.95e-9	Colorectal cancer;
LUSC	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg03342759	chr3:160939853	NMD3	-0.5	-8.44	-0.42	9.95e-16	Morning vs. evening chronotype;
LUSC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg12963246	chr6:28129442	ZNF389	0.48	5.88	0.31	1.01e-8	Depression;
LUSC	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg22862634	chr11:62369728	EML3;MTA2	-0.5	-8.3	-0.41	2.53e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg18512352	chr11:47633146	NA	-0.41	-8.15	-0.41	7.45e-15	Neuroticism;
LUSC	cis	rs11997175	0.549	rs4357253	chr8:33652458	G/A	ch.8.33884649F	chr8:33765107	NA	0.52	8.57	0.42	3.9e-16	Body mass index;
LUSC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.4	-8.0	-0.4	2.04e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.22	-0.32	1.48e-9	Response to antipsychotic treatment;
LUSC	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs4363385	0.647	rs7548977	chr1:152987365	T/G	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.18	-0.32	1.83e-9	Inflammatory skin disease;
LUSC	cis	rs10905065	0.827	rs10752111	chr10:5837286	T/C	cg11519256	chr10:5708881	ASB13	0.4	5.78	0.3	1.7e-8	Menopause (age at onset);
LUSC	cis	rs12980942	0.630	rs11881940	chr19:41808432	A/T	cg25627403	chr19:41769009	HNRNPUL1	0.61	6.59	0.34	1.68e-10	Coronary artery disease;
LUSC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.51	-0.34	2.8e-10	Monocyte count;
LUSC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.25	-0.41	3.64e-15	Joint mobility (Beighton score);
LUSC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg23711669	chr6:146136114	FBXO30	-0.74	-13.05	-0.58	1.02e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg13939156	chr17:80058883	NA	0.33	6.51	0.34	2.73e-10	Life satisfaction;
LUSC	cis	rs9359856	0.564	rs6914142	chr6:90398903	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.86	-8.75	-0.43	1.09e-16	Bipolar disorder;
LUSC	cis	rs2573652	0.722	rs12595247	chr15:100541689	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.39	-7.0	-0.36	1.38e-11	Height;
LUSC	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg01989461	chr14:81687754	GTF2A1	0.74	13.33	0.59	8.29e-33	Schizophrenia;
LUSC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg04871131	chr7:94954202	PON1	-0.4	-6.2	-0.32	1.67e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs497273	0.517	rs580240	chr12:121199903	T/G	cg02419362	chr12:121203948	SPPL3	0.43	7.9	0.4	3.94e-14	Systemic lupus erythematosus;
LUSC	cis	rs73198271	0.740	rs10105690	chr8:8649232	G/T	cg01851573	chr8:8652454	MFHAS1	0.55	9.18	0.45	4.78e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs74181299	0.964	rs2723065	chr2:65279414	A/G	cg05010058	chr2:65284262	CEP68	0.31	6.2	0.32	1.67e-9	Pulse pressure;
LUSC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg14092988	chr3:52407081	DNAH1	0.31	6.18	0.32	1.82e-9	Bipolar disorder;
LUSC	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg17385448	chr1:15911702	AGMAT	0.37	5.81	0.3	1.45e-8	Systolic blood pressure;
LUSC	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2637266	0.935	rs2579720	chr10:78399918	T/C	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.94e-13	Pulmonary function;
LUSC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg20203395	chr5:56204925	C5orf35	-0.78	-10.4	-0.49	4.07e-22	Initial pursuit acceleration;
LUSC	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.87	-0.35	3.12e-11	Response to antipsychotic treatment;
LUSC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg11752832	chr7:134001865	SLC35B4	0.55	8.65	0.43	2.28e-16	Mean platelet volume;
LUSC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg27494647	chr7:150038898	RARRES2	0.49	7.47	0.38	6.9e-13	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-21.89	-0.77	1.67e-66	Height;
LUSC	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg18232548	chr7:50535776	DDC	-0.53	-7.47	-0.38	6.91e-13	Malaria;
LUSC	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.57	-7.76	-0.39	1.01e-13	Colorectal cancer;
LUSC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg26335602	chr6:28129616	ZNF389	0.46	6.13	0.32	2.5e-9	Depression;
LUSC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg24375607	chr4:120327624	NA	0.77	11.27	0.53	3.36e-25	Corneal astigmatism;
LUSC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg19592336	chr6:28129416	ZNF389	0.54	7.05	0.36	1.02e-11	Parkinson's disease;
LUSC	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07169764	chr2:136633963	MCM6	-0.72	-9.84	-0.47	3.19e-20	Mosquito bite size;
LUSC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg02915803	chr1:1606292	LOC728661;CDK11B	0.37	5.78	0.3	1.76e-8	Body mass index;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg10163222	chr19:45004637	ZNF180	0.77	6.1	0.32	2.95e-9	Cognitive performance;
LUSC	trans	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	23.53	0.79	6.92e-73	Colorectal cancer;
LUSC	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg03676636	chr4:99064102	C4orf37	-0.33	-7.12	-0.36	6.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.27	0.71	3.52e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg03859395	chr2:55845619	SMEK2	-0.8	-13.47	-0.59	2.51e-33	Metabolic syndrome;
LUSC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg15103426	chr22:29168792	CCDC117	0.45	5.98	0.31	5.88e-9	Lymphocyte counts;
LUSC	cis	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg04414720	chr1:150670196	GOLPH3L	0.51	7.82	0.39	6.77e-14	Melanoma;
LUSC	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg01849466	chr14:104193079	ZFYVE21	0.45	6.78	0.35	5.31e-11	Reticulocyte count;
LUSC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	1.04	19.29	0.73	2.97e-56	Menopause (age at onset);
LUSC	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg00999904	chr2:3704751	ALLC	0.32	5.73	0.3	2.25e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs11645898	0.683	rs72787038	chr16:72066102	A/C	cg14768367	chr16:72042858	DHODH	-0.59	-6.74	-0.35	7.12e-11	Blood protein levels;
LUSC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19717773	chr7:2847554	GNA12	-0.39	-6.0	-0.31	5.14e-9	Height;
LUSC	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg05163923	chr11:71159392	DHCR7	-0.78	-9.97	-0.48	1.18e-20	Vitamin D levels;
LUSC	cis	rs4631830	0.863	rs2843550	chr10:51521452	C/T	cg16070123	chr10:51489643	NA	-0.51	-8.08	-0.4	1.23e-14	Prostate-specific antigen levels;
LUSC	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-8.1	-0.41	1.02e-14	Longevity;Endometriosis;
LUSC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg13390004	chr1:15929781	NA	0.42	7.01	0.36	1.31e-11	Systolic blood pressure;
LUSC	cis	rs4343996	0.686	rs4722654	chr7:3336778	A/C	cg21248987	chr7:3385318	SDK1	0.36	6.2	0.32	1.67e-9	Motion sickness;
LUSC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg09165964	chr15:75287851	SCAMP5	-1.16	-19.7	-0.73	7.33e-58	Blood trace element (Zn levels);
LUSC	trans	rs10792665	0.575	rs4625493	chr11:82540975	C/T	cg05721830	chr1:37980522	MEAF6	-0.35	-6.21	-0.32	1.55e-9	Obesity-related traits;
LUSC	cis	rs72949976	0.934	rs1922794	chr2:214026181	G/A	cg08319019	chr2:214017104	IKZF2	-0.64	-9.94	-0.48	1.48e-20	Lung cancer;Squamous cell lung carcinoma;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg23420005	chr9:34957718	KIAA1045	0.72	6.14	0.32	2.39e-9	Body mass index;
LUSC	cis	rs7512552	0.809	rs828783	chr1:150376977	C/T	cg15654264	chr1:150340011	RPRD2	0.66	10.96	0.51	4.44e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg19743168	chr1:23544995	NA	0.39	7.26	0.37	2.8e-12	Height;
LUSC	cis	rs2445762	0.518	rs6493496	chr15:51628119	A/T	cg07517944	chr15:51633816	GLDN	0.37	6.89	0.35	2.83e-11	Hormone measurements;
LUSC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg00750074	chr16:89608354	SPG7	-0.45	-7.9	-0.4	4.21e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.54	-10.56	-0.5	1.1e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.65	0.34	1.22e-10	Corneal astigmatism;
LUSC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.99	-0.31	5.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg03060546	chr3:49711283	APEH	0.72	12.22	0.56	1.2e-28	Resting heart rate;
LUSC	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg23229984	chr5:148520753	ABLIM3	0.41	6.48	0.33	3.22e-10	Breast cancer;
LUSC	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.89	16.03	0.66	2.76e-43	Metabolic syndrome;
LUSC	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg06713675	chr4:122721982	EXOSC9	0.37	6.06	0.31	3.77e-9	Type 2 diabetes;
LUSC	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg11019008	chr10:131425282	MGMT	0.43	6.22	0.32	1.46e-9	Response to temozolomide;
LUSC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.69	-12.08	-0.55	3.97e-28	Dental caries;
LUSC	cis	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg26958806	chr6:27640298	NA	0.72	5.79	0.3	1.65e-8	Breast cancer;
LUSC	cis	rs922692	0.744	rs11072806	chr15:79079074	G/A	cg00540400	chr15:79124168	NA	-0.4	-7.02	-0.36	1.22e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08470875	chr2:26401718	FAM59B	0.73	10.0	0.48	9.08e-21	Gut microbiome composition (summer);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02047577	chr20:62587702	UCKL1AS;UCKL1	0.5	6.83	0.35	4e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4786125	0.587	rs1473515	chr16:6923092	T/G	cg03623568	chr16:6915990	A2BP1	-0.51	-8.43	-0.42	1.04e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs1178968	1.000	rs6460041	chr7:72757671	A/G	cg25889504	chr7:72793014	NA	0.58	7.54	0.38	4.5e-13	Triglyceride levels;
LUSC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg23887609	chr12:130822674	PIWIL1	0.48	7.08	0.36	8.43e-12	Menopause (age at onset);
LUSC	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	10.71	0.51	3.28e-23	Nonalcoholic fatty liver disease;
LUSC	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg04998671	chr14:104000505	TRMT61A	0.47	7.36	0.37	1.43e-12	Coronary artery disease;
LUSC	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg10978503	chr1:24200527	CNR2	0.49	11.52	0.53	4.34e-26	Immature fraction of reticulocytes;
LUSC	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.64	10.77	0.51	2.06e-23	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.32	7.48	0.38	6.78e-13	Coronary artery disease;
LUSC	cis	rs7215564	0.558	rs4889876	chr17:78657071	T/G	cg23238734	chr17:78661607	RPTOR	0.48	6.16	0.32	2.07e-9	Myopia (pathological);
LUSC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg10729496	chr3:10149963	C3orf24	0.58	7.69	0.39	1.61e-13	Alzheimer's disease;
LUSC	cis	rs6847149	0.714	rs6850377	chr4:110814115	T/C	cg07850274	chr4:110748770	RRH	0.52	7.2	0.37	3.95e-12	Exercise treadmill test traits;
LUSC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg13560548	chr3:10150139	C3orf24	0.47	6.6	0.34	1.64e-10	Alzheimer's disease;
LUSC	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.8	12.1	0.55	3.4e-28	Lymphocyte counts;
LUSC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg09626299	chr10:82213104	TSPAN14	-0.2	-5.92	-0.31	8.16e-9	Post bronchodilator FEV1;
LUSC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-6.09	-0.32	3.1e-9	Personality dimensions;
LUSC	cis	rs7572644	0.699	rs937812	chr2:28255302	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-7.07	-0.36	9.22e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs500891	0.525	rs6940284	chr6:84063926	T/G	cg08257003	chr6:84140564	ME1	0.34	8.4	0.42	1.3e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg21427119	chr20:30132790	HM13	-0.42	-6.28	-0.32	1.07e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs34421088	0.623	rs2572433	chr8:11101041	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.98	0.36	1.63e-11	Neuroticism;
LUSC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg24250549	chr1:154909240	PMVK	0.58	9.35	0.46	1.28e-18	Prostate cancer;
LUSC	cis	rs10203711	0.966	rs4663939	chr2:239569867	C/A	cg14580085	chr2:239553406	NA	0.43	7.39	0.37	1.21e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg00066239	chr17:78472159	NA	-0.42	-7.0	-0.36	1.41e-11	Fractional excretion of uric acid;
LUSC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg08773314	chr2:239334832	ASB1	0.42	9.03	0.44	1.38e-17	Multiple system atrophy;
LUSC	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg21211680	chr2:198530	NA	0.74	7.5	0.38	5.85e-13	Blood protein levels;
LUSC	cis	rs6005807	0.668	rs9620808	chr22:28993331	A/C	cg12565055	chr22:29076175	TTC28	0.56	5.97	0.31	6.06e-9	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs9473147	0.516	rs6931478	chr6:47461913	C/A	cg12968598	chr6:47444699	CD2AP	0.53	8.0	0.4	2.1e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08677398	chr8:58056175	NA	0.58	7.13	0.36	6.42e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs8113142	0.614	rs60001754	chr19:29190250	C/T	cg04546413	chr19:29218101	NA	0.44	5.93	0.31	7.76e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs11214589	0.747	rs11214582	chr11:113218050	C/T	cg14159747	chr11:113255604	NA	0.24	5.96	0.31	6.4e-9	Neuroticism;
LUSC	cis	rs11997175	0.838	rs7836762	chr8:33667153	A/G	ch.8.33884649F	chr8:33765107	NA	0.45	6.97	0.36	1.74e-11	Body mass index;
LUSC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.68	-10.37	-0.49	5.14e-22	Platelet count;
LUSC	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg25233709	chr10:116636983	FAM160B1	-0.37	-6.64	-0.34	1.3e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-10.45	-0.5	2.63e-22	Morning vs. evening chronotype;
LUSC	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg15571903	chr15:79123663	NA	-0.33	-6.13	-0.32	2.47e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg15704280	chr7:45808275	SEPT13	0.7	8.12	0.41	9.08e-15	Axial length;
LUSC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg25258033	chr6:167368657	RNASET2	0.47	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6494488	0.500	rs72744788	chr15:65095235	C/T	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg03929089	chr4:120376271	NA	-0.44	-6.1	-0.32	2.87e-9	Height;
LUSC	cis	rs137603	0.562	rs137644	chr22:39728139	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.51	-8.25	-0.41	3.83e-15	Primary biliary cholangitis;
LUSC	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg12165864	chr7:66369176	NA	-0.56	-7.37	-0.37	1.37e-12	Corneal structure;
LUSC	cis	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg07988820	chr12:82153109	PPFIA2	-0.42	-6.12	-0.32	2.62e-9	Resting heart rate;
LUSC	cis	rs955333	0.641	rs73003010	chr6:154903170	T/C	cg20019720	chr6:154832845	CNKSR3	0.49	6.51	0.34	2.7e-10	Diabetic kidney disease;
LUSC	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg03585969	chr10:35415529	CREM	-0.63	-9.46	-0.46	5.54e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23158103	chr7:148848205	ZNF398	-0.42	-6.62	-0.34	1.46e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg24642844	chr7:1081250	C7orf50	-0.45	-7.21	-0.37	3.68e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7512552	0.839	rs4581308	chr1:150276872	A/G	cg15654264	chr1:150340011	RPRD2	-0.66	-11.21	-0.52	5.91e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs72960926	0.744	rs55792900	chr6:74924010	C/A	cg03266952	chr6:74778945	NA	-0.77	-6.79	-0.35	5.1e-11	Metabolite levels (MHPG);
LUSC	cis	rs653178	0.501	rs17696736	chr12:112486818	C/T	cg10833066	chr12:111807467	FAM109A	0.31	6.0	0.31	5.09e-9	Tonsillectomy;Monocyte count;Eosinophil percentage of white cells;Myocardial infarction;Crohn's disease;Inflammatory bowel disease;Eosinophil counts;Chronic kidney disease;Diastolic blood pressure;Celiac disease;Thyroid peroxidase antibody positivity;Sum eosinophil basophil counts;Blood pressure;Peripheral artery disease;Alopecia areata;Celiac disease or Rheumatoid arthritis;Urate levels;Thyroid peroxidase antibody levels;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg26856596	chr11:1961893	NA	0.33	6.08	0.32	3.25e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs250677	0.798	rs11168080	chr5:148409821	C/T	cg23229984	chr5:148520753	ABLIM3	0.39	6.0	0.31	5.22e-9	Breast cancer;
LUSC	cis	rs6060717	0.610	rs1891151	chr20:34612726	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.25	-0.32	1.22e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg10645314	chr2:3704589	ALLC	0.48	7.22	0.37	3.64e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg24687543	chr11:63912206	MACROD1	0.47	5.82	0.3	1.4e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg09365446	chr1:150670422	GOLPH3L	-0.54	-8.25	-0.41	3.61e-15	Tonsillectomy;
LUSC	trans	rs9372498	0.505	rs9489493	chr6:118992323	T/C	cg07666134	chr16:1331609	NA	0.37	6.18	0.32	1.83e-9	Diastolic blood pressure;
LUSC	cis	rs6845621	0.901	rs7436965	chr4:18917774	G/A	cg12196642	chr4:18937545	NA	-0.34	-6.43	-0.33	4.3e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs80130819	0.515	rs1793917	chr12:48384944	A/T	cg05342945	chr12:48394962	COL2A1	-0.45	-5.69	-0.3	2.74e-8	Prostate cancer;
LUSC	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg02016764	chr4:38805732	TLR1	-0.54	-5.71	-0.3	2.55e-8	Breast cancer;
LUSC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg08048268	chr3:133502702	NA	-0.38	-6.82	-0.35	4.23e-11	Iron status biomarkers;
LUSC	cis	rs2637266	0.739	rs2395404	chr10:78380513	G/T	cg18941641	chr10:78392320	NA	0.37	6.65	0.34	1.21e-10	Pulmonary function;
LUSC	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	trans	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg02113368	chr10:135107346	TUBGCP2	-0.34	-6.08	-0.32	3.28e-9	Dementia with Lewy bodies;
LUSC	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	6.88	0.35	2.95e-11	Height;
LUSC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.49	0.69	4.31e-49	Chronic sinus infection;
LUSC	cis	rs7575217	0.697	rs34429055	chr2:101703696	G/C	cg23907051	chr2:101730305	TBC1D8	0.28	7.5	0.38	5.98e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg05347473	chr6:146136440	FBXO30	0.56	9.79	0.47	4.57e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg00990874	chr7:1149470	C7orf50	-0.5	-6.32	-0.33	8.61e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs7809950	0.817	rs3779495	chr7:107250260	G/A	cg23024343	chr7:107201750	COG5	0.67	9.92	0.48	1.73e-20	Coronary artery disease;
LUSC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg13877915	chr19:58951672	ZNF132	0.49	7.73	0.39	1.32e-13	Uric acid clearance;
LUSC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08859206	chr1:53392774	SCP2	0.5	8.51	0.42	6.03e-16	Monocyte count;
LUSC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25072359	chr17:41440525	NA	0.66	9.47	0.46	5.09e-19	Menopause (age at onset);
LUSC	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg22681709	chr2:178499509	PDE11A	0.42	5.95	0.31	6.93e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg05872129	chr22:39784769	NA	-0.59	-10.78	-0.51	1.82e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg16359550	chr11:109292809	C11orf87	0.38	6.51	0.34	2.8e-10	Schizophrenia;
LUSC	trans	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg21775007	chr8:11205619	TDH	0.43	6.13	0.32	2.51e-9	Mood instability;
LUSC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	11.11	0.52	1.28e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12905574	chr5:134181527	C5orf24	0.37	6.05	0.31	3.85e-9	Asthma;
LUSC	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-8.42	-0.42	1.12e-15	Coffee consumption (cups per day);
LUSC	cis	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg17469321	chr7:55412551	NA	0.65	10.58	0.5	9.39e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.84	-13.67	-0.6	4.33e-34	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg00701064	chr4:6280414	WFS1	0.59	14.2	0.61	3.93e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg06637938	chr14:75390232	RPS6KL1	0.52	8.32	0.41	2.23e-15	Height;
LUSC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg08847533	chr14:75593920	NEK9	-0.81	-13.97	-0.61	3.03e-35	Height;
LUSC	trans	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg14227996	chr4:17616232	MED28	0.65	7.06	0.36	9.85e-12	Opioid sensitivity;
LUSC	cis	rs9473147	0.516	rs10948367	chr6:47585615	A/G	cg20196966	chr6:47445060	CD2AP	0.43	6.12	0.32	2.62e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs9359856	0.564	rs34766278	chr6:90397132	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.83	-8.49	-0.42	7e-16	Bipolar disorder;
LUSC	cis	rs11039100	0.850	rs35746872	chr11:5834335	T/A	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	11.45	0.53	7.9e-26	Colorectal cancer;
LUSC	cis	rs3820068	0.608	rs10927831	chr1:16028373	T/G	cg13390004	chr1:15929781	NA	0.41	6.79	0.35	5.02e-11	Systolic blood pressure;
LUSC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg19622623	chr12:86230825	RASSF9	-0.42	-6.01	-0.31	4.85e-9	Major depressive disorder;
LUSC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg18225595	chr11:63971243	STIP1	0.51	6.39	0.33	5.51e-10	Mean platelet volume;
LUSC	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg16586182	chr3:47516702	SCAP	0.55	8.64	0.43	2.39e-16	Colorectal cancer;
LUSC	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-10.7	-0.51	3.58e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg23711669	chr6:146136114	FBXO30	-0.93	-17.64	-0.69	1.1e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	0.94	13.19	0.59	2.77e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg00310523	chr12:86230176	RASSF9	0.45	8.0	0.4	2.1e-14	Major depressive disorder;
LUSC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-8.15	-0.41	7.44e-15	Obesity-related traits;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20781819	chr1:173837197	SNORD76;SNORD74;SNORD75;GAS5;ZBTB37	0.36	5.97	0.31	6.14e-9	Asthma;
LUSC	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.07	-0.32	3.44e-9	Systolic blood pressure;
LUSC	cis	rs4363385	0.747	rs2339496	chr1:152970719	C/T	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.59	-0.38	3.32e-13	Inflammatory skin disease;
LUSC	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg16070123	chr10:51489643	NA	-0.52	-8.38	-0.42	1.5e-15	Prostate-specific antigen levels;
LUSC	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg12292205	chr6:26970375	C6orf41	-0.62	-7.57	-0.38	3.56e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg00814883	chr7:100076585	TSC22D4	0.67	8.73	0.43	1.24e-16	Platelet count;
LUSC	cis	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-7.07	-0.36	9.26e-12	Bladder cancer;
LUSC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.61	0.43	3.03e-16	Prudent dietary pattern;
LUSC	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg20026190	chr17:76395443	PGS1	0.35	6.0	0.31	5.17e-9	HDL cholesterol;
LUSC	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg02017074	chr12:117425053	FBXW8	0.69	7.93	0.4	3.28e-14	Subcortical brain region volumes;Hippocampal volume;
LUSC	cis	rs72772090	0.539	rs11750464	chr5:96113031	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.76	7.47	0.38	7.02e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.72	-10.83	-0.51	1.28e-23	Menarche (age at onset);
LUSC	cis	rs62158211	1.000	rs4618068	chr2:114109355	C/T	cg17784749	chr2:114082611	LOC440839	0.52	6.19	0.32	1.74e-9	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LUSC	cis	rs4363385	0.782	rs2152993	chr1:152991695	C/A	cg25856811	chr1:152973957	SPRR3	-0.34	-5.67	-0.3	3.14e-8	Inflammatory skin disease;
LUSC	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.52	8.14	0.41	7.67e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.07	-0.4	1.31e-14	Bipolar disorder and schizophrenia;
LUSC	trans	rs72674100	0.867	rs72880579	chr4:97979244	T/A	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs4714291	0.832	rs9471244	chr6:40092331	A/G	cg02267698	chr19:7991119	CTXN1	0.54	8.31	0.41	2.44e-15	Strep throat;
LUSC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg24675056	chr1:15929824	NA	0.48	8.27	0.41	3.15e-15	Systolic blood pressure;
LUSC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-6.79	-0.35	5.04e-11	Alzheimer's disease (late onset);
LUSC	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-6.1	-0.32	2.87e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-0.87	-11.58	-0.54	2.75e-26	Cisplatin-induced ototoxicity;
LUSC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg21724239	chr8:58056113	NA	0.62	7.07	0.36	9.3e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg09359103	chr1:154839909	KCNN3	-0.72	-17.45	-0.69	6.51e-49	Prostate cancer;
LUSC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg04850211	chr1:228464232	OBSCN	0.32	5.83	0.3	1.28e-8	Diastolic blood pressure;
LUSC	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-5.77	-0.3	1.82e-8	Ulcerative colitis;
LUSC	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.83	-0.39	6.41e-14	Neuroticism;
LUSC	cis	rs9921192	1.000	rs251733	chr16:4321605	A/T	cg00021532	chr16:4324280	TFAP4	0.76	13.72	0.6	2.88e-34	Prostate-specific antigen levels;
LUSC	trans	rs61931739	0.529	rs1525900	chr12:33976652	T/G	cg13010199	chr12:38710504	ALG10B	0.4	6.05	0.31	3.86e-9	Morning vs. evening chronotype;
LUSC	cis	rs13720	0.722	rs163795	chr20:57577505	C/G	cg23907860	chr20:57583709	CTSZ	-0.42	-5.75	-0.3	2.02e-8	Platelet distribution width;
LUSC	cis	rs6669072	0.835	rs12046172	chr1:91325323	T/G	cg08895590	chr1:91227319	NA	-0.32	-6.78	-0.35	5.51e-11	Cognitive function;
LUSC	trans	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg04995722	chr7:26192034	NFE2L3	0.36	5.95	0.31	6.93e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13057196	chr4:8442503	ACOX3	-0.42	-6.22	-0.32	1.53e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.66	-0.34	1.15e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg27068330	chr11:65405492	SIPA1	-0.46	-5.96	-0.31	6.51e-9	Breast cancer;
LUSC	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg19052272	chr2:3704530	ALLC	-0.43	-6.12	-0.32	2.56e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs2262909	0.853	rs56207853	chr19:22292357	C/T	cg05197062	chr11:11642011	GALNTL4	0.52	7.29	0.37	2.22e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg05926928	chr17:57297772	GDPD1	1.21	14.34	0.62	1.11e-36	Opioid sensitivity;
LUSC	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg22681709	chr2:178499509	PDE11A	-0.42	-5.76	-0.3	1.91e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg09904177	chr6:26538194	HMGN4	-0.39	-5.69	-0.3	2.76e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg17807903	chr1:86174739	ZNHIT6	0.43	10.64	0.5	6.01e-23	Urate levels in overweight individuals;
LUSC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg10729496	chr3:10149963	C3orf24	0.56	7.51	0.38	5.4e-13	Alzheimer's disease;
LUSC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.42	-6.47	-0.33	3.51e-10	Tonsillectomy;
LUSC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	0.94	17.87	0.7	1.34e-50	Heart rate;
LUSC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg20821713	chr7:1055600	C7orf50	-0.5	-7.31	-0.37	1.99e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg13852791	chr20:30311386	BCL2L1	0.77	8.74	0.43	1.15e-16	Mean corpuscular hemoglobin;
LUSC	trans	rs76248362	0.881	rs7328209	chr13:24434624	G/A	cg26511321	chr7:27196790	HOXA7	0.54	6.24	0.32	1.35e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg03929089	chr4:120376271	NA	-0.44	-6.03	-0.31	4.27e-9	HDL cholesterol;
LUSC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.81	0.35	4.51e-11	Menarche (age at onset);
LUSC	cis	rs4629710	0.568	rs9492883	chr6:131573872	A/T	cg12700074	chr6:131571435	AKAP7	-0.35	-5.9	-0.31	8.89e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.82	-0.47	3.69e-20	Chronic sinus infection;
LUSC	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg05805236	chr11:65401703	PCNXL3	-0.56	-9.1	-0.45	8.47e-18	Acne (severe);
LUSC	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg27171569	chr16:83987465	OSGIN1	0.64	13.57	0.6	9.94e-34	Pursuit maintenance gain;
LUSC	cis	rs9583531	0.891	rs61969072	chr13:111380701	T/G	cg24331049	chr13:111365604	ING1	-0.65	-7.42	-0.38	9.53e-13	Coronary artery disease;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg20260663	chr12:56211576	ORMDL2;SARNP	0.37	5.97	0.31	6.2e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.85	-15.07	-0.64	1.55e-39	Cognitive function;
LUSC	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg14092571	chr14:90743983	NA	-0.36	-5.86	-0.31	1.11e-8	Mortality in heart failure;
LUSC	cis	rs60154123	0.772	rs628908	chr1:210428002	C/T	cg22029157	chr1:209979665	IRF6	0.58	5.96	0.31	6.51e-9	Coronary artery disease;
LUSC	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07169764	chr2:136633963	MCM6	1.15	18.77	0.72	3.45e-54	Corneal structure;
LUSC	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-5.82	-0.3	1.39e-8	Fear of minor pain;
LUSC	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg13072238	chr3:49761600	GMPPB	-0.39	-6.43	-0.33	4.5e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.48	-6.95	-0.36	1.97e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10979	0.557	rs9390117	chr6:143907590	C/T	cg25407410	chr6:143891975	LOC285740	-0.65	-8.19	-0.41	5.6e-15	Hypospadias;
LUSC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg03790207	chr6:42947109	PEX6	-0.46	-7.06	-0.36	9.53e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7215564	0.818	rs35638109	chr17:78657367	C/T	cg23238734	chr17:78661607	RPTOR	0.48	6.16	0.32	2.07e-9	Myopia (pathological);
LUSC	cis	rs4730250	0.707	rs6960148	chr7:106786142	A/G	cg02696742	chr7:106810147	HBP1	0.65	9.18	0.45	4.72e-18	Osteoarthritis;
LUSC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg11663144	chr21:46675770	NA	0.38	6.64	0.34	1.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7659604	0.521	rs6822155	chr4:122673274	C/A	cg19748678	chr4:122722346	EXOSC9	-0.41	-6.06	-0.31	3.7e-9	Type 2 diabetes;
LUSC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg16414030	chr3:133502952	NA	-0.48	-7.6	-0.38	3.02e-13	Iron status biomarkers;
LUSC	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.45	-0.42	8.92e-16	Schizophrenia;
LUSC	cis	rs60154123	0.614	rs661190	chr1:210458697	G/T	cg22029157	chr1:209979665	IRF6	0.51	5.92	0.31	7.78e-9	Coronary artery disease;
LUSC	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg11161011	chr14:65562177	MAX	-0.72	-11.23	-0.52	4.71e-25	Obesity-related traits;
LUSC	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg23202291	chr11:1979235	NA	0.41	6.34	0.33	7.46e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	trans	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg06521331	chr12:34319734	NA	-0.4	-6.13	-0.32	2.51e-9	Bladder cancer;
LUSC	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.57	-0.46	2.51e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08677398	chr8:58056175	NA	0.54	7.01	0.36	1.34e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg18478394	chr8:109455254	TTC35	0.42	6.53	0.34	2.38e-10	Dupuytren's disease;
LUSC	cis	rs9625935	0.843	rs41172	chr22:30422865	T/C	cg11564601	chr22:30592435	NA	-0.37	-5.84	-0.3	1.21e-8	Tonsillectomy;
LUSC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.8	0.35	4.77e-11	Lung cancer;
LUSC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.74	-0.39	1.18e-13	Aortic root size;
LUSC	cis	rs4363385	0.647	rs7548977	chr1:152987365	T/G	cg25856811	chr1:152973957	SPRR3	-0.38	-6.13	-0.32	2.54e-9	Inflammatory skin disease;
LUSC	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-7.47	-0.38	7.11e-13	Atrioventricular conduction;
LUSC	cis	rs11971779	0.666	rs7786851	chr7:139007020	C/G	cg07862535	chr7:139043722	LUC7L2	-0.56	-6.27	-0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7804356	1.000	rs12539719	chr7:26844852	A/T	cg03456212	chr7:26904342	SKAP2	-0.56	-6.55	-0.34	2.2e-10	Type 1 diabetes;
LUSC	cis	rs73206853	0.563	rs80044246	chr12:111133535	C/A	cg12870014	chr12:110450643	ANKRD13A	0.67	7.36	0.37	1.45e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.37	0.53	1.58e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg02972257	chr16:68554789	NA	-0.53	-6.37	-0.33	6.25e-10	Ulcerative colitis;
LUSC	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.0	-0.31	5.02e-9	Recombination rate (females);
LUSC	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.66	11.28	0.53	3.13e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg17425144	chr1:10567563	PEX14	0.6	11.67	0.54	1.29e-26	Hand grip strength;
LUSC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.17	-0.37	4.9e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg22800045	chr5:56110881	MAP3K1	0.8	10.13	0.48	3.29e-21	Initial pursuit acceleration;
LUSC	cis	rs35771425	0.509	rs3120782	chr1:211419700	A/T	cg25617285	chr1:211431773	RCOR3	-0.38	-5.74	-0.3	2.08e-8	Educational attainment (years of education);
LUSC	cis	rs9905704	0.633	rs2680697	chr17:56478711	T/A	cg12560992	chr17:57184187	TRIM37	-0.46	-5.65	-0.3	3.52e-8	Testicular germ cell tumor;
LUSC	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg13010199	chr12:38710504	ALG10B	-0.52	-7.91	-0.4	3.77e-14	Morning vs. evening chronotype;
LUSC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	7.09	0.36	7.84e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg04369109	chr6:150039330	LATS1	-0.52	-7.5	-0.38	5.95e-13	Lung cancer;
LUSC	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg03522245	chr20:25566470	NINL	0.37	5.96	0.31	6.45e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg12463550	chr7:65579703	CRCP	0.5	7.03	0.36	1.17e-11	Aortic root size;
LUSC	cis	rs9905704	0.846	rs35082135	chr17:56939694	A/G	cg12560992	chr17:57184187	TRIM37	0.6	8.56	0.42	4.06e-16	Testicular germ cell tumor;
LUSC	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg22961513	chr11:14280813	SPON1	0.34	5.73	0.3	2.29e-8	Mitochondrial DNA levels;
LUSC	cis	rs2479724	1.000	rs1536703	chr6:41852755	C/T	cg17623882	chr6:41773611	USP49	-0.59	-9.81	-0.47	4.11e-20	Menarche (age at onset);
LUSC	cis	rs4700695	0.841	rs153367	chr5:65419170	G/A	cg21114390	chr5:65439923	SFRS12	-0.47	-5.7	-0.3	2.6e-8	Facial morphology (factor 19);
LUSC	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg26597838	chr10:835615	NA	0.64	8.08	0.4	1.21e-14	Eosinophil percentage of granulocytes;
LUSC	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg01028140	chr2:1542097	TPO	-0.61	-8.28	-0.41	2.96e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg11266682	chr4:10021025	SLC2A9	0.46	8.18	0.41	6.14e-15	Bone mineral density;
LUSC	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.85	14.85	0.63	1.22e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26918957	chr8:22926800	TNFRSF10B	0.38	5.94	0.31	7.02e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg00784671	chr22:46762841	CELSR1	-0.49	-6.67	-0.34	1.04e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1185460	0.967	rs3825061	chr11:118944675	C/T	cg01677386	chr11:118938358	VPS11	-0.48	-6.46	-0.33	3.62e-10	Coronary artery disease;
LUSC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg02018176	chr4:1364513	KIAA1530	0.51	8.73	0.43	1.2e-16	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg08888203	chr3:10149979	C3orf24	0.69	9.25	0.45	2.66e-18	Alzheimer's disease;
LUSC	trans	rs7944735	0.517	rs11039520	chr11:48130794	A/G	cg03929089	chr4:120376271	NA	0.67	6.13	0.32	2.52e-9	Intraocular pressure;
LUSC	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-8.2	-0.41	5.16e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.61	-0.57	4.44e-30	Type 2 diabetes;
LUSC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.78	11.23	0.52	4.68e-25	Corneal astigmatism;
LUSC	cis	rs834603	0.575	rs834592	chr7:47474328	T/C	cg09696706	chr7:47479511	TNS3	0.33	6.01	0.31	4.93e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-7.03	-0.36	1.19e-11	Electroencephalogram traits;
LUSC	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	cis	rs55665837	1.000	rs10832256	chr11:14442875	G/A	cg19336497	chr11:14380999	RRAS2	-0.37	-7.53	-0.38	4.9e-13	Vitamin D levels;
LUSC	cis	rs9902453	0.967	rs17825877	chr17:28515188	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.79	0.43	8.12e-17	Coffee consumption (cups per day);
LUSC	trans	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg02800362	chr5:177631904	HNRNPAB	0.83	12.44	0.56	1.95e-29	Obesity-related traits;
LUSC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg07424592	chr7:64974309	NA	-0.64	-5.72	-0.3	2.34e-8	Diabetic kidney disease;
LUSC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02018176	chr4:1364513	KIAA1530	0.72	13.9	0.61	5.85e-35	Longevity;
LUSC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.68	-11.25	-0.52	4.15e-25	Blood protein levels;
LUSC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg04455712	chr21:45112962	RRP1B	0.43	8.13	0.41	8.46e-15	Mean corpuscular volume;
LUSC	cis	rs17253792	0.822	rs118027213	chr14:56039076	T/C	cg01858014	chr14:56050164	KTN1	-0.89	-7.04	-0.36	1.1e-11	Putamen volume;
LUSC	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg13390004	chr1:15929781	NA	0.41	7.12	0.36	6.8e-12	Systolic blood pressure;
LUSC	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg06784218	chr1:46089804	CCDC17	0.32	5.8	0.3	1.52e-8	Platelet count;
LUSC	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	16.76	0.68	3.52e-46	Exhaled nitric oxide output;
LUSC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg13206674	chr6:150067644	NUP43	0.6	9.5	0.46	4.09e-19	Lung cancer;
LUSC	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.02	-0.36	1.23e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs17253792	0.822	rs78615025	chr14:56168012	G/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.09	-0.36	8.09e-12	Putamen volume;
LUSC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	8.07	0.4	1.32e-14	Personality dimensions;
LUSC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.06	-0.48	5.69e-21	Hemoglobin concentration;
LUSC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00149659	chr3:10157352	C3orf10	0.99	14.53	0.62	2.01e-37	Alzheimer's disease;
LUSC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg13683864	chr3:40499215	RPL14	-1.05	-18.25	-0.71	4.01e-52	Renal cell carcinoma;
LUSC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg13395646	chr4:1353034	KIAA1530	-0.6	-9.51	-0.46	3.89e-19	Longevity;
LUSC	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.84	-0.39	6.1e-14	Blood metabolite levels;
LUSC	cis	rs6963495	0.818	rs1721500	chr7:105219233	T/G	cg19920283	chr7:105172520	RINT1	0.61	6.48	0.33	3.26e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.88	-0.35	2.94e-11	Monocyte percentage of white cells;
LUSC	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg09479241	chr17:27052676	TLCD1	0.42	5.79	0.3	1.64e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs662064	0.926	rs589400	chr1:10561282	A/G	cg20482658	chr1:10539492	PEX14	0.34	6.85	0.35	3.47e-11	Asthma;
LUSC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg25258033	chr6:167368657	RNASET2	0.44	7.02	0.36	1.25e-11	Crohn's disease;
LUSC	cis	rs2219968	0.669	rs10099742	chr8:78871804	C/G	cg00738934	chr8:78996279	NA	-0.38	-6.74	-0.35	7.11e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg05985134	chr18:33552581	C18orf21	0.5	6.73	0.35	7.56e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg24531977	chr5:56204891	C5orf35	0.62	9.3	0.45	1.94e-18	Coronary artery disease;
LUSC	trans	rs747782	0.527	rs2270993	chr11:48145166	G/A	cg15704280	chr7:45808275	SEPT13	0.71	6.42	0.33	4.6e-10	Intraocular pressure;
LUSC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.75	-0.35	6.52e-11	Lung cancer;
LUSC	cis	rs2274273	1.000	rs6573006	chr14:55610432	T/C	cg04306507	chr14:55594613	LGALS3	0.57	13.17	0.58	3.46e-32	Protein biomarker;
LUSC	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg04374321	chr14:90722782	PSMC1	0.75	12.12	0.55	2.92e-28	Mortality in heart failure;
LUSC	cis	rs6690583	0.573	rs75119114	chr1:85451385	A/C	cg22153463	chr1:85462885	MCOLN2	0.63	6.02	0.31	4.49e-9	Serum sulfate level;
LUSC	cis	rs4660531	1.000	rs4660532	chr1:41840197	C/T	cg08462924	chr1:41848221	NA	0.43	6.6	0.34	1.61e-10	Bipolar disorder;
LUSC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	6.96	0.36	1.85e-11	Calcium levels;
LUSC	trans	rs1325195	0.920	rs2636280	chr1:179156375	A/C	cg11624085	chr17:8464688	MYH10	0.4	6.53	0.34	2.44e-10	IgE grass sensitization;
LUSC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.54	-0.34	2.34e-10	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18404041	chr3:52824283	ITIH1	0.57	10.92	0.51	6.02e-24	Bipolar disorder;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02397499	chr11:61891354	INCENP	-0.5	-6.81	-0.35	4.61e-11	Hepatitis;
LUSC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg04871131	chr7:94954202	PON1	-0.38	-6.05	-0.31	3.93e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9906944	0.585	rs11650936	chr17:47072261	C/G	cg14634687	chr17:47094252	IGF2BP1	-0.26	-6.0	-0.31	5.1e-9	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs7927771	0.524	rs7111576	chr11:47787445	G/A	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.18e-10	Subjective well-being;
LUSC	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg01652190	chr22:50026171	C22orf34	-0.31	-6.39	-0.33	5.6e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.62	0.43	2.78e-16	Coffee consumption (cups per day);
LUSC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22590775	chr19:49891494	CCDC155	0.49	6.8	0.35	4.87e-11	Multiple sclerosis;
LUSC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.46	-8.84	-0.44	5.57e-17	Colorectal cancer;
LUSC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.73	11.86	0.54	2.48e-27	Coronary artery disease;
LUSC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	7.05	0.36	1.03e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.1	0.52	1.35e-24	Eye color traits;
LUSC	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.9	15.55	0.65	2.12e-41	Bladder cancer;
LUSC	cis	rs738321	0.711	rs5995541	chr22:38553411	C/T	cg25457927	chr22:38595422	NA	-0.39	-7.35	-0.37	1.54e-12	Breast cancer;
LUSC	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	7.58	0.38	3.46e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg06618935	chr21:46677482	NA	-0.37	-7.59	-0.38	3.25e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.73	-0.35	7.53e-11	Neuroticism;
LUSC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.74	-9.73	-0.47	7.14e-20	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg23422044	chr7:1970798	MAD1L1	-0.54	-5.79	-0.3	1.63e-8	Bipolar disorder;
LUSC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg05347473	chr6:146136440	FBXO30	-0.57	-9.79	-0.47	4.46e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10740039	0.768	rs10761549	chr10:62461660	A/G	cg18175470	chr10:62150864	ANK3	-0.43	-6.64	-0.34	1.28e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg21724239	chr8:58056113	NA	0.82	9.61	0.47	1.8e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.31	0.41	2.49e-15	Homoarginine levels;
LUSC	cis	rs16937	0.662	rs10900464	chr1:205157100	T/C	cg00857998	chr1:205179979	DSTYK	0.46	6.45	0.33	4e-10	Schizophrenia;
LUSC	cis	rs909341	0.710	rs6010998	chr20:62294402	A/T	cg16989086	chr20:62203971	PRIC285	-0.53	-7.38	-0.37	1.26e-12	Atopic dermatitis;
LUSC	cis	rs4766646	0.757	rs4766641	chr12:110301492	T/A	cg10794374	chr12:110278745	NA	-0.31	-6.47	-0.33	3.45e-10	Metabolite levels (MHPG);
LUSC	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg13813247	chr22:41461852	NA	-0.36	-6.51	-0.34	2.83e-10	Neuroticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17665931	chr19:38894173	FAM98C	0.39	6.01	0.31	4.82e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg25036284	chr2:26402008	FAM59B	-0.73	-10.66	-0.5	4.85e-23	Gut microbiome composition (summer);
LUSC	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.15	-0.36	5.48e-12	Bipolar disorder;
LUSC	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg14830002	chr1:247616686	OR2B11	-0.53	-8.1	-0.41	1.07e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs17789174	0.903	rs12597107	chr16:85070381	G/T	cg01715842	chr16:85045600	ZDHHC7	-0.42	-5.8	-0.3	1.53e-8	Dysphagia;
LUSC	trans	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.33	0.33	7.77e-10	Monocyte count;
LUSC	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.26	0.32	1.21e-9	Corneal astigmatism;
LUSC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg06454157	chr6:167490870	NA	-0.28	-6.85	-0.35	3.67e-11	Primary biliary cholangitis;
LUSC	cis	rs1775715	0.870	rs1775737	chr10:32256871	T/C	cg03015672	chr10:32216066	ARHGAP12	0.33	5.7	0.3	2.58e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-7.27	-0.37	2.61e-12	Height;
LUSC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25072359	chr17:41440525	NA	-0.62	-9.23	-0.45	3.21e-18	Menopause (age at onset);
LUSC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.45	6.59	0.34	1.69e-10	Systemic lupus erythematosus;
LUSC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26314531	chr2:26401878	FAM59B	-0.68	-8.97	-0.44	2.21e-17	Gut microbiome composition (summer);
LUSC	cis	rs27434	0.607	rs34753	chr5:96150911	C/T	cg16492584	chr5:96139282	ERAP1	-0.56	-7.67	-0.39	1.88e-13	Ankylosing spondylitis;
LUSC	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.69	-10.09	-0.48	4.37e-21	Systemic lupus erythematosus;
LUSC	cis	rs2147959	0.825	rs12746910	chr1:228658133	G/A	cg18477163	chr1:228402036	OBSCN	0.41	5.65	0.3	3.39e-8	Adult asthma;
LUSC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg13918804	chr1:2043761	PRKCZ	0.27	5.82	0.3	1.41e-8	Height;
LUSC	cis	rs7084921	0.608	rs7474634	chr10:101863410	A/C	cg02250046	chr10:101825185	CPN1	0.34	6.31	0.33	8.61e-10	Bone mineral density;
LUSC	cis	rs1472147	1.000	rs3736609	chr7:128509319	G/A	cg00260937	chr7:128520193	KCP	0.46	6.04	0.31	4.15e-9	Calcium levels;
LUSC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg13918804	chr1:2043761	PRKCZ	0.27	5.74	0.3	2.12e-8	Height;
LUSC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg18225595	chr11:63971243	STIP1	0.63	10.83	0.51	1.23e-23	Platelet count;
LUSC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg08684580	chr7:98029266	BAIAP2L1	0.44	8.04	0.4	1.62e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg00745463	chr17:30367425	LRRC37B	0.79	8.83	0.44	5.9e-17	Hip circumference adjusted for BMI;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07630649	chr16:75600717	GABARAPL2	-0.38	-5.94	-0.31	7.06e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9888739	0.800	rs7200615	chr16:31337155	G/A	cg15817542	chr16:31343056	ITGAM	-0.52	-7.01	-0.36	1.34e-11	Systemic lupus erythematosus;
LUSC	cis	rs59698941	0.943	rs997633	chr5:132219304	A/T	cg02081065	chr5:132209139	LEAP2	-0.65	-6.76	-0.35	6.04e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs2637266	1.000	rs2637270	chr10:78336901	C/T	cg18941641	chr10:78392320	NA	0.37	6.91	0.35	2.4e-11	Pulmonary function;
LUSC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03517284	chr6:25882590	NA	-0.52	-9.69	-0.47	9.99e-20	Blood metabolite levels;
LUSC	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.47	-6.43	-0.33	4.42e-10	Neutrophil percentage of white cells;
LUSC	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg01420254	chr6:26195488	NA	0.65	7.24	0.37	3.03e-12	Gout;Renal underexcretion gout;
LUSC	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg27661571	chr11:113659931	NA	-0.64	-7.53	-0.38	4.66e-13	Hip circumference adjusted for BMI;
LUSC	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.05	-25.92	-0.82	6.1e-82	Colorectal cancer;
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.68	15.09	0.64	1.4e-39	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6684514	1.000	rs12045339	chr1:156294211	C/T	cg16558208	chr1:156270281	VHLL	0.36	5.8	0.3	1.58e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUSC	cis	rs3736594	0.513	rs76013440	chr2:27816315	G/A	cg27432699	chr2:27873401	GPN1	0.66	8.64	0.43	2.45e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg15556689	chr8:8085844	FLJ10661	0.68	10.6	0.5	8.19e-23	Mood instability;
LUSC	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg19789473	chr17:27170043	C17orf63	-0.29	-5.65	-0.3	3.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg18305652	chr10:134549665	INPP5A	0.39	6.78	0.35	5.58e-11	Migraine;
LUSC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg08470875	chr2:26401718	FAM59B	0.69	8.48	0.42	7.18e-16	Gut microbiome composition (summer);
LUSC	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg12292205	chr6:26970375	C6orf41	-0.62	-7.57	-0.38	3.56e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg15556689	chr8:8085844	FLJ10661	0.48	7.34	0.37	1.65e-12	Triglycerides;
LUSC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg00684032	chr4:1343700	KIAA1530	-0.36	-6.29	-0.33	1e-9	Obesity-related traits;
LUSC	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg16576597	chr16:28551801	NUPR1	0.34	6.8	0.35	4.9e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1775715	0.870	rs1755072	chr10:32266642	A/G	cg03015672	chr10:32216066	ARHGAP12	-0.33	-5.81	-0.3	1.44e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg08085267	chr17:45401833	C17orf57	0.58	9.56	0.46	2.63e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	0.98	14.97	0.63	4.11e-39	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.79	11.58	0.54	2.77e-26	Corneal astigmatism;
LUSC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.66	-0.34	1.15e-10	Monocyte percentage of white cells;
LUSC	cis	rs2637266	0.783	rs846585	chr10:78494466	T/G	cg18941641	chr10:78392320	NA	0.39	7.1	0.36	7.32e-12	Pulmonary function;
LUSC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.62	10.72	0.51	3.07e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs61931739	0.635	rs1405025	chr12:33908491	C/T	cg13010199	chr12:38710504	ALG10B	0.41	6.12	0.32	2.65e-9	Morning vs. evening chronotype;
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg00024416	chr22:24240387	NA	-0.34	-5.91	-0.31	8.55e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg05110241	chr16:68378359	PRMT7	-0.45	-6.05	-0.31	3.96e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.1e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.23e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg09021430	chr5:549028	NA	-0.55	-7.25	-0.37	2.95e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.11	0.45	7.69e-18	Prudent dietary pattern;
LUSC	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg23241863	chr10:102295624	HIF1AN	0.47	5.65	0.3	3.41e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.68	11.02	0.52	2.8e-24	Heart rate;
LUSC	cis	rs8040855	0.599	rs6496792	chr15:85725745	T/A	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.87	0.35	3.1e-11	Bulimia nervosa;
LUSC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg03233332	chr7:66118400	NA	-0.44	-6.28	-0.33	1.05e-9	Aortic root size;
LUSC	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg17252645	chr8:143867129	LY6D	-0.55	-10.43	-0.5	3.02e-22	Urinary tract infection frequency;
LUSC	trans	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg26513180	chr16:89883248	FANCA	0.9	16.51	0.67	3.45e-45	Vitiligo;
LUSC	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.36	-6.13	-0.32	2.42e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg06784218	chr1:46089804	CCDC17	0.5	10.14	0.49	3.03e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7512552	0.809	rs2794685	chr1:150312268	C/T	cg15654264	chr1:150340011	RPRD2	0.68	11.51	0.53	4.95e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.52	-0.38	5.26e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.9	0.77	1.58e-66	Prudent dietary pattern;
LUSC	cis	rs2677744	0.688	rs7183098	chr15:91452294	A/G	cg23684204	chr15:91497937	RCCD1	0.44	6.13	0.32	2.47e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg21724239	chr8:58056113	NA	0.77	8.37	0.42	1.55e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg13390004	chr1:15929781	NA	0.42	6.86	0.35	3.25e-11	Systolic blood pressure;
LUSC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg17892150	chr10:133769511	PPP2R2D	0.64	9.27	0.45	2.42e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.47	6.15	0.32	2.21e-9	Renal function-related traits (BUN);
LUSC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.92	0.44	3.2e-17	Motion sickness;
LUSC	cis	rs6542838	0.646	rs17756034	chr2:99382810	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-6.49	-0.33	3.01e-10	Fear of minor pain;
LUSC	cis	rs1506636	0.962	rs2456551	chr7:123394610	C/G	cg03229431	chr7:123269106	ASB15	0.65	10.78	0.51	1.82e-23	Plateletcrit;Platelet count;
LUSC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg20203395	chr5:56204925	C5orf35	-0.78	-10.61	-0.5	7.52e-23	Initial pursuit acceleration;
LUSC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg06287003	chr12:125626642	AACS	-0.39	-6.39	-0.33	5.71e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg15448220	chr1:150897856	SETDB1	0.41	5.91	0.31	8.67e-9	Melanoma;
LUSC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	10.69	0.5	4.01e-23	Homoarginine levels;
LUSC	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.36	0.37	1.42e-12	Morning vs. evening chronotype;
LUSC	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg23758822	chr17:41437982	NA	1.01	15.0	0.63	3.04e-39	Menopause (age at onset);
LUSC	trans	rs12692738	0.526	rs355869	chr2:165631397	C/T	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg01028140	chr2:1542097	TPO	-0.48	-6.8	-0.35	4.94e-11	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06544989	chr22:39130855	UNC84B	0.36	6.59	0.34	1.67e-10	Menopause (age at onset);
LUSC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.88	0.6	6.55e-35	Cognitive test performance;
LUSC	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg24011408	chr12:48396354	COL2A1	0.52	8.64	0.43	2.3e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg03146154	chr1:46216737	IPP	-0.55	-8.13	-0.41	8.57e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6484504	0.779	rs16921914	chr11:31210771	G/A	cg14844989	chr11:31128820	NA	-0.47	-6.74	-0.35	7.15e-11	Red blood cell count;
LUSC	cis	rs11997175	0.603	rs7464072	chr8:33776973	G/A	ch.8.33884649F	chr8:33765107	NA	0.48	7.29	0.37	2.23e-12	Body mass index;
LUSC	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg12002119	chr2:101014098	CHST10	0.35	5.94	0.31	6.99e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg09060275	chr22:27053596	MIAT	-0.4	-6.03	-0.31	4.45e-9	Height;
LUSC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg22907277	chr7:1156413	C7orf50	0.45	6.9	0.35	2.7e-11	Longevity;Endometriosis;
LUSC	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg03465714	chr1:152285911	FLG	-0.4	-5.75	-0.3	2.05e-8	Atopic dermatitis;
LUSC	cis	rs738321	0.757	rs4820314	chr22:38518538	G/A	cg25457927	chr22:38595422	NA	-0.37	-7.11	-0.36	7.29e-12	Breast cancer;
LUSC	cis	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg05084668	chr3:125655381	ALG1L	-0.74	-11.37	-0.53	1.55e-25	Blood pressure (smoking interaction);
LUSC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg12257692	chr3:49977190	RBM6	-0.25	-6.79	-0.35	5.24e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7719624	1.000	rs2282791	chr5:135377730	T/G	cg12897067	chr5:135418308	NA	0.42	6.11	0.32	2.72e-9	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs4815879	0.509	rs4815883	chr20:6040283	C/T	cg25325723	chr20:6104886	FERMT1	-0.52	-6.17	-0.32	1.94e-9	Preeclampsia;
LUSC	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.87	-12.73	-0.57	1.52e-30	Asthma;
LUSC	trans	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg07211511	chr3:129823064	LOC729375	-0.75	-9.7	-0.47	9.15e-20	Blood pressure (smoking interaction);
LUSC	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg17127132	chr2:85788382	GGCX	-0.47	-7.57	-0.38	3.71e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg10224037	chr5:178157518	ZNF354A	0.64	8.58	0.43	3.59e-16	Neutrophil percentage of white cells;
LUSC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg04455712	chr21:45112962	RRP1B	-0.51	-9.87	-0.48	2.53e-20	Mean corpuscular volume;
LUSC	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg09092052	chr15:45571596	NA	0.47	6.67	0.34	1.09e-10	Glomerular filtration rate;
LUSC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg06494592	chr3:125709126	NA	-0.5	-5.73	-0.3	2.24e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2963155	0.518	rs864355	chr5:142633229	A/G	cg17617527	chr5:142782415	NR3C1	0.71	8.42	0.42	1.14e-15	Breast cancer;
LUSC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg08392591	chr16:89556376	ANKRD11	0.45	6.69	0.34	9.38e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs3740713	1.000	rs73440625	chr11:18470800	A/G	cg23797887	chr11:18477753	LDHAL6A	-0.56	-6.77	-0.35	5.8e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg20283391	chr11:68216788	NA	-0.61	-8.55	-0.42	4.43e-16	Total body bone mineral density;
LUSC	cis	rs11168618	0.875	rs11458	chr12:48888594	C/T	cg24011408	chr12:48396354	COL2A1	0.4	6.28	0.33	1.04e-9	Adiponectin levels;
LUSC	cis	rs9403521	0.580	rs9376772	chr6:143960454	T/C	cg18240653	chr6:144019428	PHACTR2	-0.51	-5.75	-0.3	2.06e-8	Obesity-related traits;
LUSC	cis	rs908922	0.887	rs1415432	chr1:152480654	G/A	cg20991723	chr1:152506922	NA	0.53	8.84	0.44	5.62e-17	Hair morphology;
LUSC	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19717773	chr7:2847554	GNA12	-0.35	-6.0	-0.31	5.27e-9	Height;
LUSC	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.27	0.45	2.34e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg19875535	chr5:140030758	IK	-0.47	-7.79	-0.39	8.34e-14	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21659725	chr3:3221576	CRBN	-0.65	-10.79	-0.51	1.73e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg22349387	chr12:9600060	DDX12	-0.43	-6.99	-0.36	1.49e-11	Breast size;
LUSC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7589342	0.831	rs11124062	chr2:106455967	G/A	cg14210321	chr2:106509881	NCK2	-0.54	-8.06	-0.4	1.35e-14	Addiction;
LUSC	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg18904891	chr8:8559673	CLDN23	0.55	7.67	0.39	1.85e-13	Obesity-related traits;
LUSC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg09092052	chr15:45571596	NA	0.43	5.96	0.31	6.56e-9	Glomerular filtration rate;
LUSC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg08088566	chr11:430123	ANO9	0.73	8.04	0.4	1.55e-14	Body mass index;
LUSC	cis	rs8114671	0.967	rs6142323	chr20:33788983	A/G	cg07148914	chr20:33460835	GGT7	-0.44	-6.51	-0.34	2.74e-10	Height;
LUSC	cis	rs6076065	0.723	rs2424548	chr20:23394456	A/C	cg11657817	chr20:23433608	CST11	0.43	8.16	0.41	6.81e-15	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12187437	chr12:66524584	LLPH	0.43	6.19	0.32	1.76e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs17095355	1.000	rs13377046	chr10:111729228	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.42	-0.38	1.01e-12	Biliary atresia;
LUSC	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.74	0.35	6.77e-11	Aortic root size;
LUSC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg15145296	chr3:125709740	NA	-0.56	-6.65	-0.34	1.22e-10	Blood pressure (smoking interaction);
LUSC	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg24375607	chr4:120327624	NA	0.76	11.14	0.52	1e-24	Corneal astigmatism;
LUSC	cis	rs9815354	0.812	rs17217536	chr3:41923300	A/C	cg03022575	chr3:42003672	ULK4	0.83	8.57	0.42	3.85e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg14004847	chr7:1930337	MAD1L1	0.54	8.46	0.42	8.35e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg05714579	chr10:131428358	MGMT	0.46	6.56	0.34	2e-10	Response to temozolomide;
LUSC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-1.11	-15.3	-0.64	1.99e-40	Hip circumference adjusted for BMI;
LUSC	cis	rs12940923	0.872	rs59775965	chr17:56370439	T/C	cg19466818	chr17:56409534	MIR142	-0.38	-6.76	-0.35	6.25e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs62400317	0.821	rs12206568	chr6:45152747	C/T	cg18551225	chr6:44695536	NA	-0.42	-6.89	-0.35	2.85e-11	Total body bone mineral density;
LUSC	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg15839431	chr19:19639596	YJEFN3	0.64	6.99	0.36	1.5e-11	Bipolar disorder;
LUSC	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg21138405	chr5:131827807	IRF1	-0.35	-6.24	-0.32	1.31e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg11843238	chr5:131593191	PDLIM4	-0.35	-6.14	-0.32	2.41e-9	Breast cancer;
LUSC	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.08	0.52	1.71e-24	Colorectal cancer;
LUSC	cis	rs2742417	1.000	rs2742389	chr3:45756683	G/C	cg18779283	chr3:45636154	LIMD1	-0.34	-5.9	-0.31	8.79e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs4604732	0.642	rs4489599	chr1:247635213	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.34	-5.74	-0.3	2.17e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs524023	0.874	rs7102344	chr11:64396569	A/T	cg19131476	chr11:64387923	NRXN2	-0.38	-10.37	-0.49	4.89e-22	Urate levels in obese individuals;
LUSC	cis	rs4595586	0.655	rs11170269	chr12:39387077	G/A	cg26384229	chr12:38710491	ALG10B	0.42	5.8	0.3	1.56e-8	Morning vs. evening chronotype;
LUSC	cis	rs6692729	0.933	rs1794038	chr1:227073712	T/G	cg10327440	chr1:227177885	CDC42BPA	-0.49	-6.9	-0.35	2.57e-11	Electrodermal activity;
LUSC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22442454	chr1:209979470	IRF6	0.43	5.88	0.31	9.86e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg27170947	chr2:26402098	FAM59B	-0.64	-9.34	-0.46	1.35e-18	Gut microbiome composition (summer);
LUSC	trans	rs2151145	0.823	rs1930259	chr9:82314409	A/G	cg21119293	chr14:104621601	KIF26A	-0.3	-5.98	-0.31	5.6e-9	Menopause (age at onset);
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05670192	chr19:56154902	ZNF581	0.4	6.26	0.32	1.2e-9	Calcium levels;
LUSC	cis	rs7953508	0.750	rs7310512	chr12:93976703	C/T	cg18151635	chr12:93972918	NA	-0.56	-7.98	-0.4	2.32e-14	Pubertal anthropometrics;
LUSC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs9581857	0.685	rs9319371	chr13:28042564	A/G	cg22138327	chr13:27999177	GTF3A	0.74	8.04	0.4	1.53e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg15848620	chr12:58087721	OS9	0.47	6.89	0.35	2.86e-11	Multiple sclerosis;
LUSC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg05347473	chr6:146136440	FBXO30	-0.58	-10.02	-0.48	7.55e-21	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.52	8.01	0.4	1.99e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg15423357	chr2:25149977	NA	0.44	8.97	0.44	2.13e-17	Body mass index;
LUSC	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-6.99	-0.36	1.5e-11	Bipolar disorder;
LUSC	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg20129853	chr10:51489980	NA	-0.34	-6.91	-0.35	2.45e-11	Prostate-specific antigen levels;
LUSC	cis	rs10170310	0.938	rs11680891	chr2:139264454	T/G	cg03782584	chr2:139258740	SPOPL	0.34	5.92	0.31	7.97e-9	Response to antipsychotic treatment;
LUSC	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg20003494	chr4:90757398	SNCA	-0.34	-5.86	-0.31	1.13e-8	Dementia with Lewy bodies;
LUSC	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg02569458	chr12:86230093	RASSF9	0.48	7.64	0.39	2.37e-13	Major depressive disorder;
LUSC	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg16558253	chr16:72132732	DHX38	-0.37	-5.92	-0.31	8.15e-9	Fibrinogen levels;
LUSC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg25767906	chr1:53392781	SCP2	-0.54	-10.54	-0.5	1.27e-22	Monocyte count;
LUSC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg06784218	chr1:46089804	CCDC17	0.53	10.49	0.5	1.9e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg14773178	chr5:1868261	NA	0.33	6.03	0.31	4.33e-9	Cardiovascular disease risk factors;
LUSC	cis	rs12973672	0.812	rs2280745	chr19:35756178	T/C	cg12095397	chr19:35769544	USF2	0.41	6.1	0.32	3.01e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs4478858	0.684	rs4949372	chr1:31738857	G/A	cg00250761	chr1:31883323	NA	-0.34	-8.19	-0.41	5.53e-15	Alcohol dependence;
LUSC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.76	12.01	0.55	7.33e-28	Platelet count;
LUSC	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-8.42	-0.42	1.09e-15	Schizophrenia;
LUSC	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg16586182	chr3:47516702	SCAP	-0.51	-7.91	-0.4	3.91e-14	Colorectal cancer;
LUSC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg09365446	chr1:150670422	GOLPH3L	0.54	7.82	0.39	7.08e-14	Melanoma;
LUSC	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg21427119	chr20:30132790	HM13	-0.42	-6.28	-0.33	1.05e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs1163251	0.902	rs639761	chr1:120217558	G/A	cg19096424	chr1:120255104	PHGDH	0.48	6.53	0.34	2.39e-10	Blood metabolite levels;
LUSC	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg21132104	chr15:45694354	SPATA5L1	0.42	6.13	0.32	2.45e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.54	-7.59	-0.38	3.25e-13	Adiposity;
LUSC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg21699342	chr2:239360505	ASB1	0.56	10.41	0.49	3.78e-22	Multiple system atrophy;
LUSC	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg12863693	chr15:85201151	NMB	0.39	8.08	0.4	1.19e-14	Schizophrenia;
LUSC	trans	rs6561151	0.681	rs10507521	chr13:44441834	C/G	cg12856521	chr11:46389249	DGKZ	-0.76	-10.12	-0.48	3.6e-21	Crohn's disease;
LUSC	cis	rs1983170	0.808	rs2893176	chr1:92017684	A/C	cg25838465	chr1:92012736	NA	0.42	5.82	0.3	1.4e-8	Eosinophil percentage of white cells;
LUSC	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.97	-0.31	6.16e-9	IgG glycosylation;
LUSC	cis	rs11583043	0.708	rs12754497	chr1:101571888	A/G	cg11406453	chr1:101602562	NA	0.4	6.91	0.35	2.5e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg21724239	chr8:58056113	NA	0.55	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.95	0.36	1.88e-11	Endometrial cancer;
LUSC	trans	rs564343	0.545	rs576836	chr11:65823569	G/C	cg26701943	chr11:108369231	KDELC2	-0.44	-6.02	-0.31	4.66e-9	Obesity (early onset extreme);
LUSC	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg06207120	chr15:45996521	NA	0.39	5.99	0.31	5.51e-9	Waist circumference;Weight;
LUSC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-6.95	-0.36	1.98e-11	Neutrophil percentage of white cells;
LUSC	cis	rs6460942	0.822	rs13340498	chr7:12233877	G/T	cg06484146	chr7:12443880	VWDE	-0.58	-6.09	-0.32	3.08e-9	Coronary artery disease;
LUSC	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg27398640	chr15:77910606	LINGO1	-0.28	-5.91	-0.31	8.58e-9	Type 2 diabetes;
LUSC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.37	0.37	1.34e-12	Prudent dietary pattern;
LUSC	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg21918786	chr6:109611834	NA	-0.4	-6.91	-0.35	2.49e-11	Reticulocyte fraction of red cells;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27451230	chr4:77870891	SEPT11	-0.48	-6.26	-0.32	1.18e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg01881094	chr2:180872142	CWC22	0.8	10.29	0.49	9.18e-22	Schizophrenia;
LUSC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg05585544	chr11:47624801	NA	-0.43	-7.51	-0.38	5.31e-13	Subjective well-being;
LUSC	cis	rs2029213	0.523	rs4687715	chr3:53269904	G/A	cg16894138	chr3:53270350	TKT	0.34	7.3	0.37	2.12e-12	Heart rate;
LUSC	cis	rs2067615	0.579	rs11113119	chr12:107200056	C/A	cg15890332	chr12:107067104	RFX4	0.34	6.26	0.32	1.21e-9	Heart rate;
LUSC	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.68	0.34	9.88e-11	Corneal astigmatism;
LUSC	cis	rs2108225	0.837	rs7810937	chr7:107447500	A/G	cg18560240	chr7:107437656	SLC26A3	-0.45	-6.67	-0.34	1.06e-10	Ulcerative colitis;
LUSC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg24733560	chr20:60626293	TAF4	0.39	6.31	0.33	8.99e-10	Body mass index;
LUSC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg23788917	chr6:8435910	SLC35B3	0.48	7.11	0.36	7.03e-12	Motion sickness;
LUSC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.49	-6.83	-0.35	3.92e-11	Tonsillectomy;
LUSC	cis	rs6504249	0.893	rs2521827	chr17:62692728	T/G	cg02598441	chr17:62777298	LOC146880	-0.56	-7.28	-0.37	2.48e-12	Joint mobility (Beighton score);
LUSC	trans	rs75804782	0.641	rs6715311	chr2:239363321	A/G	cg01134436	chr17:81009848	B3GNTL1	0.61	5.96	0.31	6.34e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg09034736	chr1:150693464	HORMAD1	0.49	7.16	0.36	5.33e-12	Tonsillectomy;
LUSC	cis	rs13315871	0.929	rs1045115	chr3:58305199	C/T	cg20936604	chr3:58311152	NA	-0.65	-6.78	-0.35	5.4e-11	Cholesterol, total;
LUSC	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg19773385	chr1:10388646	KIF1B	-0.5	-7.57	-0.38	3.73e-13	Hepatocellular carcinoma;
LUSC	cis	rs6840360	1.000	rs17360475	chr4:152671640	C/G	cg22705602	chr4:152727874	NA	0.34	6.83	0.35	4.01e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg11752832	chr7:134001865	SLC35B4	0.59	9.06	0.44	1.1e-17	Mean platelet volume;
LUSC	trans	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	8.21	0.41	4.86e-15	Ulcerative colitis;
LUSC	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	19.06	0.72	2.56e-55	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs72674100	0.867	rs75247520	chr4:97980121	C/T	cg16405019	chr1:18959625	PAX7	-0.61	-6.0	-0.31	5.27e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg23262073	chr20:60523788	NA	-0.42	-6.0	-0.31	5.03e-9	Body mass index;
LUSC	cis	rs2413583	0.591	rs79605405	chr22:39696638	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	6.54	0.34	2.36e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs11971779	0.680	rs17691238	chr7:139052284	A/G	cg23387468	chr7:139079360	LUC7L2	-0.39	-6.01	-0.31	4.84e-9	Diisocyanate-induced asthma;
LUSC	cis	rs4363385	0.510	rs11590835	chr1:153047166	T/C	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.35	-0.33	6.9e-10	Inflammatory skin disease;
LUSC	cis	rs7523050	0.643	rs35885176	chr1:109401868	G/A	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg00376283	chr12:123451042	ABCB9	0.67	9.37	0.46	1.12e-18	Neutrophil percentage of white cells;
LUSC	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg03522245	chr20:25566470	NINL	-0.35	-5.74	-0.3	2.18e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.76	-11.95	-0.55	1.18e-27	Tonsillectomy;
LUSC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.44	6.62	0.34	1.47e-10	Systemic lupus erythematosus;
LUSC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12016809	chr21:47604291	C21orf56	-0.46	-6.97	-0.36	1.69e-11	Testicular germ cell tumor;
LUSC	cis	rs317689	1.000	rs317689	chr12:69727190	G/A	cg11871910	chr12:69753446	YEATS4	0.55	7.12	0.36	6.71e-12	Response to diuretic therapy;
LUSC	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.16	-0.32	2.1e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-1.02	-11.15	-0.52	9.24e-25	Diabetic kidney disease;
LUSC	cis	rs1568889	0.641	rs34857148	chr11:28481976	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.53	6.64	0.34	1.28e-10	Bipolar disorder;
LUSC	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg03289416	chr15:75166202	SCAMP2	0.46	7.02	0.36	1.23e-11	Breast cancer;
LUSC	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	14.76	0.63	2.59e-38	Post bronchodilator FEV1;
LUSC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg23630131	chr7:65973040	NA	0.2	5.72	0.3	2.4e-8	Aortic root size;
LUSC	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg18904891	chr8:8559673	CLDN23	0.42	6.05	0.31	3.9e-9	Neuroticism;
LUSC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg00033643	chr7:134001901	SLC35B4	0.47	7.42	0.38	9.63e-13	Mean platelet volume;
LUSC	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg01884057	chr2:25150051	NA	0.48	11.39	0.53	1.29e-25	Body mass index;
LUSC	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg22705602	chr4:152727874	NA	-0.32	-6.49	-0.33	3.07e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	8.12e-16	Aortic root size;
LUSC	cis	rs7605827	0.930	rs7578126	chr2:15522772	C/T	cg19274914	chr2:15703543	NA	0.45	8.93	0.44	2.91e-17	Educational attainment (years of education);
LUSC	cis	rs17253792	0.749	rs79713967	chr14:56124186	T/C	cg01858014	chr14:56050164	KTN1	-0.8	-6.58	-0.34	1.79e-10	Putamen volume;
LUSC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg22823121	chr1:150693482	HORMAD1	0.5	7.44	0.38	8.47e-13	Melanoma;
LUSC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg22823121	chr1:150693482	HORMAD1	0.6	9.28	0.45	2.21e-18	Tonsillectomy;
LUSC	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.11	-0.48	3.72e-21	Monocyte count;
LUSC	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg01620082	chr3:125678407	NA	-0.78	-7.29	-0.37	2.28e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg21665744	chr7:39171113	POU6F2	0.43	6.51	0.34	2.82e-10	IgG glycosylation;
LUSC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg13560548	chr3:10150139	C3orf24	0.54	7.11	0.36	7.09e-12	Alzheimer's disease;
LUSC	cis	rs11168618	0.904	rs12371700	chr12:48919213	G/T	cg24011408	chr12:48396354	COL2A1	-0.39	-6.22	-0.32	1.46e-9	Adiponectin levels;
LUSC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg06238570	chr21:40685208	BRWD1	-0.56	-9.03	-0.44	1.37e-17	Menarche (age at onset);
LUSC	cis	rs1113500	0.636	rs3853493	chr1:108637193	G/A	cg06207961	chr1:108661230	NA	0.31	5.78	0.3	1.69e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg26924012	chr15:45694286	SPATA5L1	1.14	20.94	0.75	9e-63	Homoarginine levels;
LUSC	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.84	-0.3	1.24e-8	IgG glycosylation;
LUSC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg08601574	chr20:25228251	PYGB	0.48	7.37	0.37	1.33e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2324229	0.789	rs1180197	chr6:83959124	C/T	cg08257003	chr6:84140564	ME1	0.3	6.96	0.36	1.76e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs7605827	0.930	rs2287263	chr2:15637366	C/T	cg19274914	chr2:15703543	NA	0.45	8.51	0.42	5.89e-16	Educational attainment (years of education);
LUSC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg15704280	chr7:45808275	SEPT13	-1.09	-22.35	-0.77	2.54e-68	Height;
LUSC	cis	rs7712401	0.601	rs36180885	chr5:122356403	C/A	cg19077854	chr5:122220652	SNX24	-0.37	-7.58	-0.38	3.54e-13	Mean platelet volume;
LUSC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg22166914	chr1:53195759	ZYG11B	-0.49	-7.7	-0.39	1.5700000000000001e-13	Monocyte count;
LUSC	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg15445000	chr17:37608096	MED1	0.38	6.69	0.34	9.58e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg18209359	chr17:80159595	CCDC57	-0.39	-6.66	-0.34	1.15e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-9.83	-0.47	3.5e-20	Joint mobility (Beighton score);
LUSC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg17264618	chr3:40429014	ENTPD3	0.32	6.83	0.35	3.96e-11	Renal cell carcinoma;
LUSC	cis	rs11971779	0.638	rs77668044	chr7:139111085	T/A	cg07862535	chr7:139043722	LUC7L2	0.7	7.58	0.38	3.5e-13	Diisocyanate-induced asthma;
LUSC	cis	rs36093844	0.706	rs79814326	chr11:85585573	A/G	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg24375607	chr4:120327624	NA	0.81	12.0	0.55	8.02e-28	Corneal astigmatism;
LUSC	cis	rs4654899	1.000	rs3767248	chr1:21276854	A/G	cg01072550	chr1:21505969	NA	-0.56	-8.63	-0.43	2.5e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	9.67	0.47	1.12e-19	Height;
LUSC	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.85	-12.72	-0.57	1.7e-30	Asthma;
LUSC	cis	rs9309473	0.904	rs62149783	chr2:73821384	T/A	cg20560298	chr2:73613845	ALMS1	-0.44	-6.33	-0.33	7.94e-10	Metabolite levels;
LUSC	cis	rs7000551	0.675	rs2443503	chr8:22381850	A/G	cg12081754	chr8:22256438	SLC39A14	0.45	6.66	0.34	1.14e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.52	-7.77	-0.39	9.57e-14	Platelet distribution width;
LUSC	cis	rs4812048	0.793	rs62205397	chr20:57597011	C/T	cg14073986	chr20:57617431	SLMO2	0.71	7.26	0.37	2.68e-12	Mean platelet volume;
LUSC	cis	rs9581857	0.512	rs9581866	chr13:28063176	G/A	cg22138327	chr13:27999177	GTF3A	0.81	8.37	0.42	1.61e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs965469	1.000	rs6037554	chr20:3315613	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-5.68	-0.3	2.97e-8	IFN-related cytopenia;
LUSC	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.19e-14	Retinal vascular caliber;
LUSC	trans	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg01620082	chr3:125678407	NA	-0.69	-7.05	-0.36	1.06e-11	Breast cancer;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg05095774	chr18:52495848	RAB27B	0.49	6.07	0.32	3.52e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg08859206	chr1:53392774	SCP2	-0.7	-13.19	-0.59	3.01e-32	Monocyte count;
LUSC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.13	0.45	6.72e-18	Motion sickness;
LUSC	cis	rs897984	0.762	rs4889599	chr16:30968589	C/T	cg02466173	chr16:30829666	NA	0.56	11.1	0.52	1.39e-24	Dementia with Lewy bodies;
LUSC	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg23029597	chr12:123009494	RSRC2	-0.73	-9.1	-0.45	8.29e-18	Body mass index;
LUSC	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg02018176	chr4:1364513	KIAA1530	0.43	5.85	0.3	1.16e-8	Recombination rate (females);
LUSC	cis	rs7106204	0.686	rs12803800	chr11:24258319	A/G	ch.11.24196551F	chr11:24239977	NA	0.73	6.22	0.32	1.49e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg15133208	chr4:90757351	SNCA	-0.55	-8.63	-0.43	2.6e-16	Neuroticism;
LUSC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg00933542	chr6:150070202	PCMT1	0.29	5.93	0.31	7.45e-9	Lung cancer;
LUSC	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg01989461	chr14:81687754	GTF2A1	-0.67	-11.79	-0.54	4.58e-27	Schizophrenia;
LUSC	cis	rs11166629	1.000	rs6992668	chr8:135645129	T/C	cg27224718	chr8:135614730	ZFAT	0.66	10.9	0.51	6.87e-24	Smoking quantity;
LUSC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08859206	chr1:53392774	SCP2	-0.57	-10.68	-0.5	4.36e-23	Monocyte count;
LUSC	cis	rs4774899	0.837	rs12899904	chr15:57416843	A/T	cg21617494	chr15:57618479	NA	-0.36	-6.0	-0.31	5.18e-9	Urinary tract infection frequency;
LUSC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg15556689	chr8:8085844	FLJ10661	0.68	11.09	0.52	1.56e-24	Neuroticism;
LUSC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg11608241	chr8:8085544	FLJ10661	-0.4	-5.67	-0.3	3.11e-8	Mean corpuscular volume;
LUSC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg05855489	chr10:104503620	C10orf26	-0.7	-10.43	-0.5	3.12e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg06521331	chr12:34319734	NA	-0.38	-6.21	-0.32	1.57e-9	Morning vs. evening chronotype;
LUSC	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07636037	chr3:49044803	WDR6	0.64	8.29	0.41	2.8e-15	Menarche (age at onset);
LUSC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08677398	chr8:58056175	NA	0.58	7.13	0.36	6.42e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg24675658	chr1:53192096	ZYG11B	0.59	9.22	0.45	3.51e-18	Monocyte count;
LUSC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26314531	chr2:26401878	FAM59B	0.72	10.16	0.49	2.55e-21	Gut microbiome composition (summer);
LUSC	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg04691961	chr3:161091175	C3orf57	-0.35	-5.94	-0.31	7.23e-9	Morning vs. evening chronotype;
LUSC	cis	rs6980507	0.524	rs4568607	chr8:42364354	T/C	cg09913449	chr8:42400586	C8orf40	-0.44	-7.67	-0.39	1.84e-13	Glycated hemoglobin levels;
LUSC	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg12365402	chr11:9010492	NRIP3	0.4	6.83	0.35	4.06e-11	Hematocrit;
LUSC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.92	0.35	2.25e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.31	0.64	1.87e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs10740039	1.000	rs10761545	chr10:62418569	C/T	cg18175470	chr10:62150864	ANK3	-0.43	-6.8	-0.35	4.8e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs10432489	0.708	rs10189224	chr2:181764318	A/C	cg11196870	chr8:41386826	GINS4	-0.91	-6.37	-0.33	6.21e-10	QT interval;
LUSC	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg13798780	chr7:105162888	PUS7	0.57	5.99	0.31	5.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1009647	0.583	rs72715746	chr14:55741370	G/A	cg04306507	chr14:55594613	LGALS3	0.43	5.82	0.3	1.37e-8	Testicular germ cell tumor;
LUSC	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg27539214	chr16:67997921	SLC12A4	-0.46	-5.93	-0.31	7.38e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.71	-9.96	-0.48	1.21e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.8	13.36	0.59	6.6e-33	Bladder cancer;
LUSC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg20295408	chr7:1910781	MAD1L1	-0.49	-6.82	-0.35	4.23e-11	Schizophrenia;
LUSC	cis	rs977987	0.806	rs35552529	chr16:75405879	G/C	cg04384234	chr16:75411784	CFDP1	-0.42	-6.85	-0.35	3.49e-11	Dupuytren's disease;
LUSC	trans	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	8.32	0.41	2.23e-15	Type 2 diabetes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg20566420	chr12:122327043	PSMD9	0.45	6.28	0.32	1.05e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.23	0.49	1.56e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7264396	0.887	rs6120954	chr20:34059536	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-5.85	-0.3	1.17e-8	Total cholesterol levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16689800	chr10:122216376	PPAPDC1A	-0.5	-6.06	-0.31	3.63e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3849570	0.615	rs6766011	chr3:81986136	G/A	cg07356753	chr3:81810745	GBE1	-0.42	-6.19	-0.32	1.73e-9	Waist circumference;Body mass index;
LUSC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	11.47	0.53	6.92e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg02775129	chr4:119771670	NA	-0.79	-6.58	-0.34	1.85e-10	Cannabis dependence symptom count;
LUSC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg10207240	chr12:122356781	WDR66	-0.46	-6.82	-0.35	4.18e-11	Mean corpuscular volume;
LUSC	cis	rs231513	0.871	rs231522	chr17:41954602	A/G	cg26893861	chr17:41843967	DUSP3	-0.53	-5.84	-0.3	1.26e-8	Cognitive function;
LUSC	cis	rs4851254	0.550	rs13402289	chr2:100659389	C/T	cg07810366	chr2:100720526	AFF3	-0.46	-5.95	-0.31	6.87e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9549260	0.564	rs4943805	chr13:41270080	A/G	cg21288729	chr13:41239152	FOXO1	0.53	8.01	0.4	1.99e-14	Red blood cell count;
LUSC	cis	rs4144027	0.967	rs12879686	chr14:104360741	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.37	-5.67	-0.3	3.04e-8	Blood metabolite levels;
LUSC	cis	rs2387326	0.671	rs12256275	chr10:129947139	T/C	cg16087940	chr10:129947807	NA	-0.39	-5.89	-0.31	9.25e-9	Select biomarker traits;
LUSC	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg23262073	chr20:60523788	NA	-0.44	-6.23	-0.32	1.4e-9	Body mass index;
LUSC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25072359	chr17:41440525	NA	0.68	9.69	0.47	9.97e-20	Menopause (age at onset);
LUSC	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg23625390	chr15:77176239	SCAPER	0.53	8.27	0.41	3.11e-15	Blood metabolite levels;
LUSC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08704250	chr15:31115839	NA	-0.48	-7.12	-0.36	6.63e-12	Huntington's disease progression;
LUSC	cis	rs6120849	0.754	rs6119560	chr20:33606977	G/C	cg24642439	chr20:33292090	TP53INP2	0.62	6.82	0.35	4.29e-11	Protein C levels;
LUSC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	1.08	19.15	0.72	1.09e-55	Parkinson's disease;
LUSC	cis	rs11191205	0.686	rs10883676	chr10:103445325	A/C	cg15320455	chr10:103880129	LDB1	-0.46	-5.65	-0.3	3.43e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs983392	0.679	rs7930318	chr11:60033371	C/T	cg24026212	chr11:59952134	MS4A6A	0.36	6.32	0.33	8.42e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg13206674	chr6:150067644	NUP43	0.53	8.03	0.4	1.65e-14	Lung cancer;
LUSC	cis	rs3772130	0.962	rs9812228	chr3:121495682	C/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.23	0.49	1.48e-21	Cognitive performance;
LUSC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg19774624	chr17:42201019	HDAC5	0.72	10.55	0.5	1.22e-22	Total body bone mineral density;
LUSC	cis	rs7818345	0.967	rs17479099	chr8:19277144	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.35	0.37	1.57e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs453301	0.562	rs1038248	chr8:9040858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.1	-0.32	2.86e-9	Joint mobility (Beighton score);
LUSC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg05347473	chr6:146136440	FBXO30	0.56	9.76	0.47	6e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	6.54	0.34	2.27e-10	Tonsillectomy;
LUSC	trans	rs9860340	0.690	rs67833493	chr3:87635809	C/T	cg03644585	chr7:884825	UNC84A	0.42	6.09	0.32	3.17e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	6.38	0.33	5.75e-10	Calcium levels;
LUSC	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg08270630	chr22:50330655	NA	0.4	5.94	0.31	7.32e-9	Schizophrenia;
LUSC	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg11057378	chr10:81107060	PPIF	0.34	5.73	0.3	2.3e-8	Height;
LUSC	cis	rs7147624	1.000	rs11848209	chr14:66022832	T/A	cg03016385	chr14:66212404	NA	-0.85	-9.58	-0.46	2.21e-19	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.17	-0.41	6.51e-15	Chronic sinus infection;
LUSC	cis	rs4494114	0.967	rs9439083	chr1:39344766	C/T	cg25970120	chr1:39325951	RRAGC	-0.41	-6.47	-0.33	3.56e-10	Blood protein levels;
LUSC	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.59	-0.34	1.73e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-1.12	-21.84	-0.77	2.7e-66	Total cholesterol levels;
LUSC	trans	rs12210905	0.920	rs72839453	chr6:27265761	A/G	cg11837749	chr1:55047332	ACOT11	0.66	6.32	0.33	8.31e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19346786	chr7:2764209	NA	-0.44	-7.56	-0.38	3.82e-13	Height;
LUSC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg18758796	chr5:131593413	PDLIM4	0.41	6.79	0.35	5.11e-11	Breast cancer;
LUSC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10802521	chr3:52805072	NEK4	-0.49	-7.86	-0.4	5.4e-14	Bipolar disorder;
LUSC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.48	7.68	0.39	1.75e-13	Menarche (age at onset);
LUSC	cis	rs7072216	0.763	rs7091709	chr10:100167605	G/A	cg26618903	chr10:100175079	PYROXD2	-0.44	-8.37	-0.42	1.56e-15	Metabolite levels;
LUSC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14829155	chr15:31115871	NA	-0.57	-7.93	-0.4	3.23e-14	Huntington's disease progression;
LUSC	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.47	-0.38	7.04e-13	Morning vs. evening chronotype;
LUSC	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg21906852	chr1:75198582	TYW3;CRYZ	0.45	6.45	0.33	4.02e-10	Resistin levels;
LUSC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg10792982	chr14:105748885	BRF1	0.5	9.13	0.45	6.94e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6499755	0.965	rs2042448	chr16:55352063	G/A	cg02859129	chr16:55357253	IRX6	0.35	5.91	0.31	8.5e-9	Hypospadias;
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg27094323	chr7:1216898	NA	-0.43	-7.32	-0.37	1.92e-12	Longevity;Endometriosis;
LUSC	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.84	-0.44	5.48e-17	Response to antipsychotic treatment;
LUSC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg27608139	chr16:2294856	DCI	0.42	7.98	0.4	2.44e-14	Height;
LUSC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg03146154	chr1:46216737	IPP	0.5	7.43	0.38	9.1e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12826209	chr6:26865740	GUSBL1	0.74	9.08	0.44	9.64e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg21770322	chr7:97807741	LMTK2	0.5	8.59	0.43	3.5e-16	Breast cancer;
LUSC	cis	rs116139393	0.611	rs62439722	chr7:6764940	G/A	cg09896999	chr7:6746977	ZNF12	-0.51	-6.91	-0.35	2.46e-11	Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	1.0	16.07	0.66	1.81e-43	Parkinson's disease;
LUSC	cis	rs6722750	0.683	rs2901647	chr2:64418097	G/C	cg22352474	chr2:64371530	PELI1	-0.51	-7.67	-0.39	1.89e-13	Neuroticism;
LUSC	cis	rs11229555	0.645	rs1986404	chr11:58194614	T/C	cg15696309	chr11:58395628	NA	-0.67	-8.13	-0.41	8.64e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg13939156	chr17:80058883	NA	-0.32	-6.29	-0.33	1.01e-9	Life satisfaction;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16322581	chr12:70636648	CNOT2	-0.52	-6.48	-0.33	3.32e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.14	0.32	2.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg14416269	chr4:6271139	WFS1	0.5	10.55	0.5	1.2e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg06521331	chr12:34319734	NA	0.4	6.55	0.34	2.17e-10	Morning vs. evening chronotype;
LUSC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg12863693	chr15:85201151	NMB	0.35	6.97	0.36	1.68e-11	Schizophrenia;
LUSC	cis	rs2625529	0.713	rs16956634	chr15:72552243	C/G	cg16672083	chr15:72433130	SENP8	0.49	7.29	0.37	2.32e-12	Red blood cell count;
LUSC	trans	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	7.71	0.39	1.41e-13	Neuroticism;
LUSC	cis	rs17102423	0.755	rs8009714	chr14:65573446	G/T	cg11161011	chr14:65562177	MAX	-0.81	-12.19	-0.55	1.57e-28	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg12826209	chr6:26865740	GUSBL1	0.64	5.72	0.3	2.32e-8	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg05896524	chr21:47604654	C21orf56	0.4	5.91	0.31	8.52e-9	Testicular germ cell tumor;
LUSC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg14552801	chr7:65878734	NA	0.38	5.79	0.3	1.65e-8	Aortic root size;
LUSC	cis	rs9517320	0.967	rs9517317	chr13:99125711	G/C	cg07423050	chr13:99094983	FARP1	0.33	6.35	0.33	6.94e-10	Longevity;
LUSC	cis	rs10465746	0.935	rs4907189	chr1:84374982	G/T	cg10977910	chr1:84465055	TTLL7	0.43	6.14	0.32	2.33e-9	Obesity-related traits;
LUSC	cis	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg06521331	chr12:34319734	NA	0.4	6.61	0.34	1.48e-10	Morning vs. evening chronotype;
LUSC	cis	rs73198271	0.628	rs11783457	chr8:8588842	G/C	cg01851573	chr8:8652454	MFHAS1	0.48	6.05	0.31	3.9e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg03733263	chr8:22462867	KIAA1967	1.02	19.27	0.73	3.62e-56	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg15557168	chr22:42548783	NA	0.48	7.39	0.38	1.16e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.32	0.45	1.66e-18	Bipolar disorder;
LUSC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg01181863	chr3:195395398	SDHAP2	-0.6	-8.15	-0.41	7.43e-15	Pancreatic cancer;
LUSC	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg11845111	chr2:191398756	TMEM194B	-0.87	-11.29	-0.53	2.84e-25	Diastolic blood pressure;
LUSC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg25258033	chr6:167368657	RNASET2	0.44	7.05	0.36	1.02e-11	Crohn's disease;
LUSC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	0.81	14.27	0.62	2.16e-36	Blood protein levels;
LUSC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg20476274	chr7:133979776	SLC35B4	0.87	17.01	0.68	3.43e-47	Mean platelet volume;
LUSC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-7.93	-0.4	3.43e-14	Total body bone mineral density;
LUSC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	0.77	13.37	0.59	5.99e-33	Cognitive function;
LUSC	trans	rs867371	0.502	rs3759800	chr15:82532963	A/C	cg04831495	chr15:85060580	GOLGA6L5	0.38	6.39	0.33	5.49e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs34779708	0.733	rs7070778	chr10:35541688	T/C	cg03585969	chr10:35415529	CREM	0.54	7.56	0.38	4.03e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg11887960	chr12:57824829	NA	0.54	6.65	0.34	1.18e-10	Obesity-related traits;
LUSC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08109568	chr15:31115862	NA	0.49	6.98	0.36	1.56e-11	Huntington's disease progression;
LUSC	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg04851639	chr8:1020857	NA	-0.41	-8.71	-0.43	1.39e-16	Schizophrenia;
LUSC	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg24558204	chr6:135376177	HBS1L	0.67	10.49	0.5	2e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg13319975	chr6:146136371	FBXO30	0.5	7.48	0.38	6.8e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg08132940	chr7:1081526	C7orf50	-0.48	-5.95	-0.31	6.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg17168535	chr8:21777572	XPO7	0.69	11.68	0.54	1.16e-26	Lung cancer in ever smokers;
LUSC	cis	rs62400317	0.859	rs72870950	chr6:45154779	A/G	cg20913747	chr6:44695427	NA	-0.47	-7.46	-0.38	7.32e-13	Total body bone mineral density;
LUSC	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	6.25	0.32	1.22e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs17286411	1.000	rs17286411	chr16:71968701	C/G	cg03805757	chr16:71968109	PKD1L3	0.37	5.96	0.31	6.38e-9	Blood protein levels;
LUSC	cis	rs554111	0.660	rs12042978	chr1:21170811	T/C	cg01072550	chr1:21505969	NA	0.39	5.96	0.31	6.44e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg02574844	chr11:5959923	NA	-0.5	-7.94	-0.4	3.11e-14	DNA methylation (variation);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12698784	chr3:119813316	GSK3B	-0.4	-5.95	-0.31	6.8e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08859206	chr1:53392774	SCP2	0.51	8.74	0.43	1.18e-16	Monocyte count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16491909	chr1:154193730	C1orf43;UBAP2L	0.46	6.45	0.33	4.03e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg08470875	chr2:26401718	FAM59B	0.75	9.99	0.48	1e-20	Gut microbiome composition (summer);
LUSC	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.94	-8.7	-0.43	1.5e-16	Lung cancer in ever smokers;
LUSC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg06096015	chr1:231504339	EGLN1	-0.52	-9.38	-0.46	1.02e-18	Hemoglobin concentration;
LUSC	cis	rs9914988	1.000	rs901975	chr17:27189774	A/G	cg09479241	chr17:27052676	TLCD1	-0.43	-5.79	-0.3	1.65e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg24851651	chr11:66362959	CCS	0.37	5.89	0.31	9.66e-9	Educational attainment (years of education);
LUSC	cis	rs3744061	0.557	rs9889902	chr17:74648034	T/C	cg27546012	chr17:74684504	MXRA7	-0.39	-6.47	-0.33	3.43e-10	Retinal arteriolar caliber;
LUSC	cis	rs56399783	0.901	rs6964740	chr7:2819656	C/G	cg19731401	chr7:2775893	GNA12	0.6	8.04	0.4	1.6e-14	Childhood ear infection;
LUSC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg23262073	chr20:60523788	NA	-0.42	-5.87	-0.31	1.05e-8	Body mass index;
LUSC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg11871910	chr12:69753446	YEATS4	0.62	9.83	0.47	3.37e-20	Response to diuretic therapy;
LUSC	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg20583945	chr8:144636462	GSDMD	0.42	5.65	0.3	3.37e-8	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg01191920	chr7:158217561	PTPRN2	-0.58	-11.9	-0.55	1.78e-27	Obesity-related traits;
LUSC	cis	rs2625529	0.824	rs12439900	chr15:72373640	A/G	cg16672083	chr15:72433130	SENP8	-0.52	-7.64	-0.39	2.38e-13	Red blood cell count;
LUSC	trans	rs7309687	1.000	rs4288814	chr12:43067451	A/G	cg05280148	chr16:30134882	MAPK3	-0.43	-6.21	-0.32	1.61e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9473147	0.543	rs13211285	chr6:47479618	C/T	cg20196966	chr6:47445060	CD2AP	0.42	5.83	0.3	1.31e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.8	14.23	0.61	2.9e-36	Morning vs. evening chronotype;
LUSC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.74	-0.39	1.17e-13	Bipolar disorder;
LUSC	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg10523679	chr1:76189770	ACADM	-0.48	-7.11	-0.36	7.25e-12	Daytime sleep phenotypes;
LUSC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg13206674	chr6:150067644	NUP43	0.59	9.36	0.46	1.24e-18	Lung cancer;
LUSC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg05623727	chr3:50126028	RBM5	-0.32	-6.1	-0.32	2.86e-9	Body mass index;
LUSC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24531977	chr5:56204891	C5orf35	0.86	13.99	0.61	2.45e-35	Initial pursuit acceleration;
LUSC	trans	rs3857536	0.813	rs6904511	chr6:66939102	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg02696742	chr7:106810147	HBP1	-0.63	-9.54	-0.46	3.16e-19	Coronary artery disease;
LUSC	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	-0.37	-5.74	-0.3	2.13e-8	Cystic fibrosis severity;
LUSC	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.64	9.34	0.46	1.38e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs9309473	1.000	rs13431267	chr2:73782200	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.45	-0.33	4.02e-10	Metabolite levels;
LUSC	cis	rs250677	0.522	rs10050928	chr5:148353463	C/A	cg18129178	chr5:148520854	ABLIM3	0.53	7.56	0.38	3.89e-13	Breast cancer;
LUSC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg16928487	chr17:17741425	SREBF1	0.36	6.77	0.35	5.75e-11	Total body bone mineral density;
LUSC	trans	rs61931739	0.649	rs12426686	chr12:33714473	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-6.17	-0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.1	0.41	1.07e-14	Bipolar disorder;
LUSC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.54	-9.26	-0.45	2.57e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg07828340	chr4:882639	GAK	0.97	9.94	0.48	1.5e-20	Parkinson's disease;
LUSC	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.06	-22.34	-0.77	2.99e-68	Ulcerative colitis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16025584	chr9:139887217	C9orf142	0.41	6.14	0.32	2.3e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg03188948	chr7:1209495	NA	0.63	6.64	0.34	1.3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg08677398	chr8:58056175	NA	0.47	5.98	0.31	5.86e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg13560548	chr3:10150139	C3orf24	-0.53	-7.72	-0.39	1.4e-13	Alzheimer's disease;
LUSC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs7192380	0.965	rs7205551	chr16:69605968	G/A	cg26679644	chr16:69762563	NA	0.34	6.04	0.31	4.02e-9	Sjögren's syndrome;
LUSC	trans	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg04995722	chr7:26192034	NFE2L3	-0.43	-6.67	-0.34	1.05e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7119	0.678	rs12914098	chr15:77823013	C/T	cg27398640	chr15:77910606	LINGO1	-0.3	-6.32	-0.33	8.13e-10	Type 2 diabetes;
LUSC	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.47	-0.38	7e-13	Retinal vascular caliber;
LUSC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.13	0.41	8.64e-15	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg04865166	chr7:105162814	PUS7	0.53	5.87	0.31	1.06e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg16558253	chr16:72132732	DHX38	-0.37	-5.76	-0.3	1.86e-8	Fibrinogen levels;
LUSC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg01579765	chr21:45077557	HSF2BP	-0.48	-10.11	-0.48	3.97e-21	Mean corpuscular volume;
LUSC	cis	rs6690583	0.623	rs2028304	chr1:85488030	G/A	cg22153463	chr1:85462885	MCOLN2	-0.58	-5.73	-0.3	2.3e-8	Serum sulfate level;
LUSC	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-7.23	-0.37	3.28e-12	Retinal vascular caliber;
LUSC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.69	0.6	3.45e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00166722	chr3:10149974	C3orf24	0.54	7.45	0.38	7.83e-13	Alzheimer's disease;
LUSC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08677398	chr8:58056175	NA	0.52	7.04	0.36	1.09e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	6.22	0.32	1.46e-9	IgG glycosylation;
LUSC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg16393715	chr7:1948819	MAD1L1	-0.36	-6.28	-0.32	1.05e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg14843632	chr5:14870594	ANKH	0.42	7.89	0.4	4.29e-14	Blood metabolite levels;
LUSC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.95	0.36	1.96e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg14343924	chr8:8086146	FLJ10661	0.44	6.11	0.32	2.74e-9	Myopia (pathological);
LUSC	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.46	-0.33	3.61e-10	Mood instability;
LUSC	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg21775007	chr8:11205619	TDH	-0.55	-7.97	-0.4	2.54e-14	Neuroticism;
LUSC	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.92	-0.35	2.28e-11	Menopause (age at onset);
LUSC	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg27432699	chr2:27873401	GPN1	0.83	15.85	0.66	1.4e-42	Oral cavity cancer;
LUSC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg22868518	chr11:507468	RNH1	-0.65	-5.92	-0.31	8.03e-9	Body mass index;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18538332	chr22:24372958	LOC391322	-0.47	-8.47	-0.42	8.05e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.46	-0.33	3.67e-10	Menopause (age at onset);
LUSC	cis	rs9341808	0.628	rs2490245	chr6:80892427	A/G	cg08355045	chr6:80787529	NA	0.48	8.2	0.41	5.06e-15	Sitting height ratio;
LUSC	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-10.5	-0.5	1.72e-22	Migraine;Coronary artery disease;
LUSC	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.55	9.48	0.46	4.97e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs72949976	0.584	rs13001511	chr2:214025262	G/A	cg08319019	chr2:214017104	IKZF2	0.68	11.62	0.54	1.9e-26	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.26	-0.37	2.69e-12	Major depressive disorder;
LUSC	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg23533926	chr12:111358616	MYL2	0.34	6.12	0.32	2.64e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs753274	0.650	rs28497965	chr19:14417402	T/G	cg25450033	chr19:14444658	NA	0.36	5.99	0.31	5.3300000000000004e-09	Tumor necrosis factor beta levels;
LUSC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg26441486	chr22:50317300	CRELD2	-0.54	-8.2	-0.41	5.14e-15	Schizophrenia;
LUSC	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg20019720	chr6:154832845	CNKSR3	0.58	8.67	0.43	1.91e-16	Lipoprotein (a) levels;
LUSC	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.54	0.75	3.49e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg24296786	chr1:45957014	TESK2	-0.41	-5.81	-0.3	1.47e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-11.85	-0.54	2.83e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	0.89	15.67	0.65	7.27e-42	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg18854424	chr1:2615690	NA	0.46	9.58	0.46	2.38e-19	Ulcerative colitis;
LUSC	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	10.02	0.48	7.83e-21	Lymphocyte counts;
LUSC	cis	rs7572733	0.534	rs13026569	chr2:198783330	C/G	cg00792783	chr2:198669748	PLCL1	-0.44	-5.96	-0.31	6.57e-9	Dermatomyositis;
LUSC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	13.58	0.6	9.08e-34	Chronic sinus infection;
LUSC	cis	rs6733011	0.500	rs7560696	chr2:99405800	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-5.96	-0.31	6.58e-9	Bipolar disorder;
LUSC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.66	0.39	2.07e-13	Vitiligo;
LUSC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg01256987	chr12:42539512	GXYLT1	0.45	8.58	0.42	3.75e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg16203607	chr17:62500946	DDX5	0.35	6.26	0.32	1.18e-9	Triglycerides;
LUSC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg26408565	chr15:76604113	ETFA	-0.5	-8.05	-0.4	1.45e-14	Blood metabolite levels;
LUSC	cis	rs17661538	0.504	rs11591660	chr10:18432750	C/G	cg03634479	chr10:18430412	CACNB2	0.67	6.29	0.33	9.7e-10	Response to antipsychotic treatment;
LUSC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg18681998	chr4:17616180	MED28	0.86	15.62	0.65	1.1e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg10840412	chr1:235813424	GNG4	0.6	7.72	0.39	1.38e-13	Bipolar disorder;
LUSC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	7.28	0.37	2.34e-12	Cognitive ability;
LUSC	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-6.85	-0.35	3.66e-11	Colorectal cancer;
LUSC	cis	rs975210	0.656	rs16954106	chr15:70357918	C/T	cg12349571	chr15:70364359	TLE3	-0.6	-7.11	-0.36	7.28e-12	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LUSC	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg01528321	chr10:82214614	TSPAN14	0.87	13.3	0.59	1.1e-32	Post bronchodilator FEV1;
LUSC	cis	rs4285028	0.948	rs12497349	chr3:121708517	T/C	cg11130432	chr3:121712080	ILDR1	-0.65	-10.09	-0.48	4.39e-21	Multiple sclerosis;
LUSC	cis	rs68170813	0.641	rs79328953	chr7:106901557	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.92	-0.48	1.74e-20	Coronary artery disease;
LUSC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg15147215	chr3:52552868	STAB1	-0.33	-6.45	-0.33	3.88e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.68	-10.47	-0.5	2.3e-22	Aortic root size;
LUSC	cis	rs10162002	0.872	rs3764067	chr13:24042897	T/C	cg00158254	chr13:24040743	NA	0.54	6.03	0.31	4.46e-9	Hypothyroidism;
LUSC	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-6.78	-0.35	5.47e-11	Total cholesterol levels;
LUSC	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg15501526	chr10:2543763	NA	0.56	9.92	0.48	1.64e-20	Age-related hearing impairment;
LUSC	cis	rs7582720	1.000	rs76890136	chr2:203850011	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.35	0.42	1.88e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg04362960	chr10:104952993	NT5C2	0.61	9.4	0.46	8.7e-19	Arsenic metabolism;
LUSC	trans	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg25214090	chr10:38739885	LOC399744	0.39	5.96	0.31	6.43e-9	Corneal astigmatism;
LUSC	cis	rs977987	0.843	rs62062568	chr16:75445324	T/C	cg03315344	chr16:75512273	CHST6	0.53	10.2	0.49	1.89e-21	Dupuytren's disease;
LUSC	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg24631222	chr15:78858424	CHRNA5	0.64	8.42	0.42	1.09e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7712401	0.601	rs13155907	chr5:122334633	C/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.22	-0.45	3.4e-18	Mean platelet volume;
LUSC	cis	rs6599077	1.000	rs2068977	chr3:40095152	A/T	cg13683864	chr3:40499215	RPL14	-0.6	-7.66	-0.39	2.06e-13	Sleep-related phenotypes;
LUSC	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg27411982	chr8:10470053	RP1L1	0.4	6.26	0.32	1.19e-9	Myopia (pathological);
LUSC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg25019033	chr10:957182	NA	0.5	6.26	0.32	1.2e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs3741798	1.000	rs55865572	chr12:12497333	T/C	cg08615371	chr12:12503544	MANSC1	1.08	11.07	0.52	1.79e-24	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs7181230	0.885	rs28826672	chr15:40360366	G/T	cg22705835	chr10:65332833	REEP3	-0.39	-6.27	-0.32	1.12e-9	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs73206853	0.841	rs73191808	chr12:110904685	T/C	cg12870014	chr12:110450643	ANKRD13A	0.67	6.46	0.33	3.72e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs672059	1.000	rs674343	chr1:183162052	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.55	7.96	0.4	2.78e-14	Hypertriglyceridemia;
LUSC	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.37	1.18e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.42	6.11	0.32	2.83e-9	Lung cancer;
LUSC	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-14.05	-0.61	1.51e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg13206674	chr6:150067644	NUP43	0.63	10.38	0.49	4.6e-22	Lung cancer;
LUSC	cis	rs28795989	0.795	rs4696778	chr4:7919308	C/G	cg24250820	chr4:7887609	AFAP1	-0.48	-8.92	-0.44	3.13e-17	Intraocular pressure;
LUSC	trans	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs7577696	0.597	rs11691939	chr2:32339561	A/G	cg02381751	chr2:32503542	YIPF4	0.51	7.01	0.36	1.31e-11	Inflammatory biomarkers;
LUSC	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.69	-0.65	6e-42	Height;
LUSC	cis	rs6669008	1.000	rs55912359	chr1:114167099	C/T	cg13572289	chr1:114447746	DCLRE1B;AP4B1	-0.36	-5.73	-0.3	2.21e-8	Bacteremia;
LUSC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.12	0.41	9.01e-15	Homoarginine levels;
LUSC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg15782153	chr7:917662	C7orf20	0.43	6.52	0.34	2.54e-10	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg16928487	chr17:17741425	SREBF1	0.37	7.13	0.36	6.28e-12	Total body bone mineral density;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg02723225	chr16:3019192	PAQR4	0.38	6.04	0.31	4.1e-9	Schizophrenia (age at onset);
LUSC	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21659725	chr3:3221576	CRBN	-0.58	-8.06	-0.4	1.35e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.68	-13.31	-0.59	9.73e-33	Bipolar disorder;
LUSC	cis	rs4363385	0.818	rs423692	chr1:153005681	T/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.43e-12	Inflammatory skin disease;
LUSC	trans	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.64	-10.83	-0.51	1.27e-23	Mean corpuscular volume;
LUSC	cis	rs9807989	0.801	rs72823663	chr2:102968738	G/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.91	0.31	8.63e-9	Asthma;
LUSC	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg23093090	chr10:104574429	C10orf26	-0.36	-6.61	-0.34	1.54e-10	Arsenic metabolism;
LUSC	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg17691542	chr6:26056736	HIST1H1C	0.4	5.99	0.31	5.45e-9	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg06784218	chr1:46089804	CCDC17	0.48	9.57	0.46	2.47e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg18196295	chr10:418757	DIP2C	0.5	8.29	0.41	2.88e-15	Psychosis in Alzheimer's disease;
LUSC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.86	0.35	3.29e-11	Platelet count;
LUSC	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg18681998	chr4:17616180	MED28	0.77	13.81	0.6	1.24e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs654950	0.806	rs2759251	chr1:42041749	C/G	cg06885757	chr1:42089581	HIVEP3	-0.44	-9.01	-0.44	1.57e-17	Airway imaging phenotypes;
LUSC	cis	rs5771242	0.518	rs6010216	chr22:50679471	C/T	cg16473166	chr22:50639996	SELO	0.72	10.06	0.48	5.85e-21	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LUSC	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg20790798	chr5:1857306	NA	-0.38	-5.66	-0.3	3.27e-8	Cardiovascular disease risk factors;
LUSC	cis	rs7241530	0.662	rs55634452	chr18:75902067	A/G	cg14642773	chr18:75888474	NA	0.4	5.86	0.31	1.11e-8	Educational attainment (years of education);
LUSC	cis	rs9311676	0.632	rs11130630	chr3:58360800	A/G	cg26110898	chr3:58419937	PDHB	0.41	6.64	0.34	1.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs78572108	0.858	rs13397360	chr2:42265162	T/A	cg00607755	chr2:42274082	PKDCC	0.36	6.52	0.34	2.61e-10	Total body bone mineral density;
LUSC	trans	rs7980799	0.905	rs4244865	chr12:33511917	C/T	cg26384229	chr12:38710491	ALG10B	-0.41	-5.96	-0.31	6.41e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg08807101	chr21:30365312	RNF160	-0.54	-6.85	-0.35	3.48e-11	Cognitive test performance;
LUSC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs3764021	0.933	rs2268146	chr12:9869271	A/G	cg20894963	chr12:9885564	CLECL1	0.35	7.02	0.36	1.23e-11	Type 1 diabetes;
LUSC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.74	-0.35	6.77e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg13010199	chr12:38710504	ALG10B	0.64	9.79	0.47	4.49e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg26769984	chr7:1090371	C7orf50	0.59	8.17	0.41	6.32e-15	Bronchopulmonary dysplasia;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.56	-9.4	-0.46	9.24e-19	Lymphocyte counts;
LUSC	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg03929089	chr4:120376271	NA	-0.49	-6.91	-0.35	2.47e-11	HDL cholesterol;
LUSC	cis	rs7809950	0.731	rs4730238	chr7:107054787	G/A	cg23024343	chr7:107201750	COG5	-0.7	-10.09	-0.48	4.47e-21	Coronary artery disease;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg00510360	chr3:108308232	KIAA1524;DZIP3	0.49	6.23	0.32	1.44e-9	Cognitive function;Information processing speed;
LUSC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg12311346	chr5:56204834	C5orf35	-0.55	-8.5	-0.42	6.48e-16	Coronary artery disease;
LUSC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg20295408	chr7:1910781	MAD1L1	0.42	6.06	0.31	3.61e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg05868516	chr6:26286170	HIST1H4H	0.37	6.1	0.32	2.86e-9	Educational attainment;
LUSC	cis	rs9807989	0.507	rs2310300	chr2:103049074	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.06	0.36	9.98e-12	Asthma;
LUSC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg14983838	chr19:29218262	NA	0.55	6.21	0.32	1.53e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.52	3.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg24812749	chr6:127587940	RNF146	-0.62	-8.84	-0.44	5.43e-17	Breast cancer;
LUSC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.36	0.37	1.48e-12	Prudent dietary pattern;
LUSC	cis	rs4917300	0.549	rs902819	chr8:143098548	C/T	cg25363559	chr8:143086065	NA	-0.32	-7.15	-0.36	5.52e-12	Amyotrophic lateral sclerosis;
LUSC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05025164	chr4:1340916	KIAA1530	-0.64	-10.07	-0.48	5.35e-21	Obesity-related traits;
LUSC	cis	rs73071352	0.577	rs73075228	chr3:42049629	T/G	cg03022575	chr3:42003672	ULK4	0.79	7.96	0.4	2.75e-14	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
LUSC	trans	rs2797160	1.000	rs78602343	chr6:126019768	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.94	0.36	2.04e-11	Endometrial cancer;
LUSC	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg15704280	chr7:45808275	SEPT13	-0.83	-11.71	-0.54	8.72e-27	Coronary artery disease;
LUSC	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg18230493	chr5:56204884	C5orf35	-0.64	-9.93	-0.48	1.53e-20	Coronary artery disease;
LUSC	cis	rs10097731	0.901	rs9298344	chr8:82043063	C/T	cg25230327	chr8:82042993	NA	-0.48	-7.06	-0.36	9.8e-12	Serum total protein level;
LUSC	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg06917634	chr15:78832804	PSMA4	-0.56	-6.95	-0.36	1.97e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg11050988	chr7:1952600	MAD1L1	-0.31	-5.89	-0.31	9.17e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg04315214	chr1:2043799	PRKCZ	0.49	10.42	0.5	3.37e-22	Height;
LUSC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg27572855	chr1:25598939	RHD	0.43	7.5	0.38	5.96e-13	Erythrocyte sedimentation rate;
LUSC	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg08270630	chr22:50330655	NA	-0.46	-6.85	-0.35	3.56e-11	Schizophrenia;
LUSC	cis	rs41271473	0.948	rs17437060	chr1:228822374	C/T	cg16512390	chr1:228756714	NA	0.55	6.53	0.34	2.42e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.45	0.46	5.94e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12681287	0.547	rs6998303	chr8:87510185	T/C	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	cis	rs7315438	0.785	rs10850518	chr12:115898565	C/A	cg24172291	chr12:115889509	NA	-0.34	-5.72	-0.3	2.33e-8	Colorectal cancer;
LUSC	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg10547527	chr2:198650123	BOLL	-0.49	-5.72	-0.3	2.32e-8	Ulcerative colitis;
LUSC	cis	rs259282	0.628	rs35946544	chr19:33109983	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.67	10.01	0.48	8.13e-21	Schizophrenia;
LUSC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	0.91	15.04	0.64	2.2e-39	Breast cancer;
LUSC	cis	rs11051970	0.655	rs7298381	chr12:32530257	G/T	cg02745156	chr12:32552066	NA	0.39	7.0	0.36	1.44e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04565464	chr8:145669602	NFKBIL2	0.37	6.13	0.32	2.44e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7106204	1.000	rs7106204	chr11:24236096	C/T	ch.11.24196551F	chr11:24239977	NA	-1.04	-10.17	-0.49	2.5e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.39	0.33	5.46e-10	Renal cell carcinoma;
LUSC	cis	rs617219	0.890	rs72764981	chr5:78494003	C/T	cg24856658	chr5:78533917	JMY	-0.3	-5.86	-0.31	1.13e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs1185460	0.967	rs1307145	chr11:118950217	C/G	cg01677386	chr11:118938358	VPS11	-0.49	-6.9	-0.35	2.61e-11	Coronary artery disease;
LUSC	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg15704280	chr7:45808275	SEPT13	0.73	8.29	0.41	2.88e-15	Axial length;
LUSC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	14.92	0.63	6.36e-39	Platelet count;
LUSC	cis	rs7568458	0.704	rs10176176	chr2:85762048	A/T	cg17127132	chr2:85788382	GGCX	0.45	6.94	0.36	2e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg23752985	chr2:85803571	VAMP8	0.32	6.26	0.32	1.19e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg03732007	chr1:2071316	PRKCZ	0.48	7.77	0.39	9.67e-14	Height;
LUSC	trans	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.27	0.32	1.09e-9	Corneal astigmatism;
LUSC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-17.76	-0.7	3.74e-50	Primary sclerosing cholangitis;
LUSC	cis	rs4925114	0.568	rs941448	chr17:17654542	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-6.97	-0.36	1.73e-11	Body mass index;
LUSC	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg23752985	chr2:85803571	VAMP8	0.38	8.17	0.41	6.53e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg17553881	chr5:443987	EXOC3;C5orf55	0.3	6.65	0.34	1.18e-10	Cystic fibrosis severity;
LUSC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg21775007	chr8:11205619	TDH	0.44	6.27	0.32	1.13e-9	Neuroticism;
LUSC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg26898376	chr11:64110657	CCDC88B	-0.36	-6.95	-0.36	1.88e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs11997175	0.766	rs4733176	chr8:33685334	A/T	ch.8.33884649F	chr8:33765107	NA	0.39	6.1	0.32	3e-9	Body mass index;
LUSC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg17554472	chr22:41940697	POLR3H	0.47	5.84	0.3	1.27e-8	Vitiligo;
LUSC	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg24459738	chr19:57751996	ZNF805	-0.51	-7.54	-0.38	4.41e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.24e-19	Prudent dietary pattern;
LUSC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg14668632	chr7:2872130	GNA12	-0.43	-6.07	-0.32	3.53e-9	Height;
LUSC	cis	rs3931020	0.657	rs10890142	chr1:75179129	G/A	cg21906852	chr1:75198582	TYW3;CRYZ	0.45	5.86	0.31	1.08e-8	Resistin levels;
LUSC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg06454157	chr6:167490870	NA	0.27	6.58	0.34	1.82e-10	Primary biliary cholangitis;
LUSC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg25767906	chr1:53392781	SCP2	0.47	8.55	0.42	4.37e-16	Monocyte count;
LUSC	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg09165964	chr15:75287851	SCAMP5	-0.73	-6.73	-0.35	7.21e-11	Lung cancer;
LUSC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg03188948	chr7:1209495	NA	0.62	6.56	0.34	2.03e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17102423	0.963	rs11626496	chr14:65600981	C/G	cg11161011	chr14:65562177	MAX	-0.62	-9.61	-0.47	1.88e-19	Obesity-related traits;
LUSC	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	8.12e-16	Aortic root size;
LUSC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg20302533	chr7:39170763	POU6F2	0.57	9.49	0.46	4.54e-19	IgG glycosylation;
LUSC	trans	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg26043149	chr18:55253948	FECH	-0.45	-6.93	-0.35	2.15e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg05347473	chr6:146136440	FBXO30	0.38	6.42	0.33	4.67e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6599077	1.000	rs6599077	chr3:40096618	G/A	cg13683864	chr3:40499215	RPL14	-0.6	-7.64	-0.39	2.38e-13	Sleep-related phenotypes;
LUSC	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg06713675	chr4:122721982	EXOSC9	-0.66	-11.62	-0.54	1.92e-26	Type 2 diabetes;
LUSC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg27266027	chr21:40555129	PSMG1	-0.41	-5.92	-0.31	7.8e-9	Cognitive function;
LUSC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg04553112	chr3:125709451	NA	-0.5	-5.66	-0.3	3.27e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg07389463	chr12:132296394	NA	0.41	7.41	0.38	1.02e-12	Migraine;
LUSC	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg02569458	chr12:86230093	RASSF9	0.41	6.65	0.34	1.23e-10	Major depressive disorder;
LUSC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.09	-19.88	-0.74	1.39e-58	Homoarginine levels;
LUSC	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg08213375	chr14:104286397	PPP1R13B	0.47	9.32	0.45	1.63e-18	Schizophrenia;
LUSC	cis	rs12931792	0.682	rs12373113	chr16:30187513	C/T	cg17640201	chr16:30407289	ZNF48	0.61	9.82	0.47	3.61e-20	Tonsillectomy;
LUSC	trans	rs78049276	0.512	rs6820938	chr4:148395903	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.55	-6.35	-0.33	6.92e-10	Pulse pressure;
LUSC	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg15704280	chr7:45808275	SEPT13	0.66	7.22	0.37	3.45e-12	Axial length;
LUSC	trans	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg25206134	chr2:45395956	NA	0.59	6.06	0.31	3.66e-9	Neuroticism;
LUSC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg03060546	chr3:49711283	APEH	0.72	11.81	0.54	3.94e-27	Resting heart rate;
LUSC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg09165964	chr15:75287851	SCAMP5	-1.15	-19.33	-0.73	2.1e-56	Blood trace element (Zn levels);
LUSC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	6.35	0.33	6.99e-10	Tonsillectomy;
LUSC	cis	rs7577696	0.785	rs7572964	chr2:32372096	A/T	cg02381751	chr2:32503542	YIPF4	-0.43	-6.07	-0.32	3.38e-9	Inflammatory biomarkers;
LUSC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.42	0.38	9.68e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	12.95	0.58	2.35e-31	Cognitive test performance;
LUSC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.03	0.4	1.67e-14	Parkinson's disease;
LUSC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.65	-0.43	2.14e-16	Breast cancer;
LUSC	trans	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg06521331	chr12:34319734	NA	-0.39	-5.98	-0.31	5.82e-9	Bladder cancer;
LUSC	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg08270630	chr22:50330655	NA	-0.4	-5.76	-0.3	1.93e-8	Schizophrenia;
LUSC	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg23176889	chr5:176863531	GRK6	0.66	13.78	0.6	1.56e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg06207120	chr15:45996521	NA	0.4	6.14	0.32	2.33e-9	Waist circumference;Weight;
LUSC	cis	rs2067615	0.524	rs4275715	chr12:107062246	C/T	cg15890332	chr12:107067104	RFX4	0.34	6.06	0.31	3.72e-9	Heart rate;
LUSC	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2279817	0.863	rs6586569	chr1:18027377	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.48	6.8	0.35	4.82e-11	Neuroticism;
LUSC	trans	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg03185820	chr7:149158252	ZNF777	0.4	6.47	0.33	3.51e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs2186369	0.681	rs5760020	chr22:24133092	G/A	cg16317291	chr12:7076865	SCARNA12;PHB2	-0.4	-5.99	-0.31	5.48e-9	IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;
LUSC	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg09526685	chr4:187126073	CYP4V2	0.62	5.91	0.31	8.56e-9	Blood protein levels;
LUSC	cis	rs4654899	0.571	rs34530426	chr1:21085204	C/T	cg01072550	chr1:21505969	NA	-0.47	-7.04	-0.36	1.07e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.58	-11.31	-0.53	2.6e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg04518342	chr5:131593106	PDLIM4	0.36	6.69	0.34	9.4e-11	Blood metabolite levels;
LUSC	cis	rs1957429	0.614	rs66883381	chr14:65334773	C/T	cg23373153	chr14:65346875	NA	-0.88	-8.1	-0.41	1.06e-14	Pediatric areal bone mineral density (radius);
LUSC	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg06612196	chr6:6737390	NA	0.56	11.11	0.52	1.32e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.55	0.46	2.95e-19	Prudent dietary pattern;
LUSC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg07587117	chr16:2239488	CASKIN1	0.39	7.56	0.38	3.98e-13	Height;
LUSC	cis	rs968451	1.000	rs971964	chr22:39702473	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.69	8.9	0.44	3.55e-17	Primary biliary cholangitis;
LUSC	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-1.14	-18.07	-0.7	2.26e-51	Exhaled nitric oxide output;
LUSC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.76	-0.39	1.03e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg25428297	chr7:1022841	CYP2W1	0.3	6.4	0.33	5.32e-10	Longevity;Endometriosis;
LUSC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg26876637	chr1:152193138	HRNR	0.43	6.24	0.32	1.34e-9	Atopic dermatitis;
LUSC	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg20016023	chr10:99160130	RRP12	-0.33	-8.04	-0.4	1.57e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg02023728	chr11:77925099	USP35	0.47	6.76	0.35	6.01e-11	Testicular germ cell tumor;
LUSC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18099408	chr3:52552593	STAB1	0.44	7.77	0.39	9.83e-14	Bipolar disorder;
LUSC	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg04455712	chr21:45112962	RRP1B	0.48	8.77	0.43	9.22e-17	Mean corpuscular volume;
LUSC	cis	rs7851660	0.874	rs1443436	chr9:100631298	T/A	cg13688889	chr9:100608707	NA	-0.56	-8.91	-0.44	3.48e-17	Strep throat;
LUSC	trans	rs1267813	1	rs1267813	chr11:133981075	G/C	cg13056653	chr4:141538969	NA	0.28	6.17	0.32	1.92e-9	Schizophrenia;
LUSC	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08645402	chr16:4508243	NA	0.52	8.77	0.43	9.04e-17	Schizophrenia;
LUSC	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.85	14.53	0.62	2.07e-37	Morning vs. evening chronotype;
LUSC	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg02389323	chr16:88786976	FAM38A	1.17	10.06	0.48	5.79e-21	Plateletcrit;
LUSC	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg22089800	chr15:90895588	ZNF774	-0.64	-9.66	-0.47	1.27e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs259282	0.524	rs1559180	chr19:33127443	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.79	12.84	0.57	6e-31	Schizophrenia;
LUSC	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.14	14.2	0.61	3.95e-36	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.63	9.89	0.48	2.11e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg03929089	chr4:120376271	NA	0.87	12.01	0.55	7.53e-28	Coronary artery disease;
LUSC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.16	0.77	1.43e-67	Prudent dietary pattern;
LUSC	trans	rs72792513	1.000	rs7602014	chr2:22920499	G/T	cg05844895	chr16:88969569	CBFA2T3	0.5	6.2	0.32	1.69e-9	Hepatitis B;
LUSC	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.31	-0.33	8.73e-10	Resting heart rate;
LUSC	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg11189052	chr15:85197271	WDR73	0.51	6.41	0.33	5.07e-10	Schizophrenia;
LUSC	cis	rs7927771	0.524	rs12226431	chr11:47805856	G/A	cg20307385	chr11:47447363	PSMC3	0.44	6.43	0.33	4.36e-10	Subjective well-being;
LUSC	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg17644776	chr2:200775616	C2orf69	-0.51	-6.63	-0.34	1.34e-10	Chickenpox;
LUSC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg13047869	chr3:10149882	C3orf24	0.56	7.72	0.39	1.37e-13	Alzheimer's disease;
LUSC	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-8.25	-0.41	3.63e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg16482183	chr6:26056742	HIST1H1C	0.58	8.02	0.4	1.86e-14	Iron status biomarkers;
LUSC	cis	rs4851254	0.961	rs11691486	chr2:100796182	T/C	cg07810366	chr2:100720526	AFF3	-0.36	-5.75	-0.3	2.06e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.85	14.85	0.63	1.22e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs4072705	0.646	rs7037254	chr9:127245412	C/T	cg13476313	chr9:127244764	NR5A1	-0.36	-6.78	-0.35	5.4e-11	Menarche (age at onset);
LUSC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-7.86	-0.4	5.18e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	0.64	13.4	0.59	4.47e-33	Prudent dietary pattern;
LUSC	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg00105475	chr2:10696890	NA	0.38	6.36	0.33	6.75e-10	Prostate cancer;
LUSC	cis	rs4692589	0.556	rs13133562	chr4:170965709	C/T	cg19918862	chr4:170955249	NA	0.36	6.6	0.34	1.57e-10	Anxiety disorder;
LUSC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg21880101	chr17:80066754	CCDC57	-0.31	-5.91	-0.31	8.52e-9	Life satisfaction;
LUSC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg24324837	chr19:49891574	CCDC155	0.53	7.32	0.37	1.89e-12	Multiple sclerosis;
LUSC	cis	rs2953145	0.617	rs7557192	chr2:241541274	T/C	cg03371404	chr2:241525653	CAPN10	-0.41	-5.71	-0.3	2.45e-8	Bipolar disorder;
LUSC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06656553	chr16:89960601	TCF25	-0.63	-5.7	-0.3	2.68e-8	Skin colour saturation;
LUSC	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	0.94	13.31	0.59	1.05e-32	Primary sclerosing cholangitis;
LUSC	cis	rs13401104	0.796	rs10929170	chr2:237115591	A/G	cg19324714	chr2:237145437	ASB18	0.43	5.65	0.3	3.43e-8	Educational attainment;
LUSC	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg08213375	chr14:104286397	PPP1R13B	0.44	8.56	0.42	4.21e-16	Schizophrenia;
LUSC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg17554472	chr22:41940697	POLR3H	0.48	5.91	0.31	8.32e-9	Cannabis dependence symptom count;
LUSC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg08888203	chr3:10149979	C3orf24	0.46	6.81	0.35	4.62e-11	Alzheimer's disease;
LUSC	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg03806693	chr22:41940476	POLR3H	0.8	11.19	0.52	6.91e-25	Vitiligo;
LUSC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs9287719	0.649	rs2160258	chr2:10717221	T/A	cg00105475	chr2:10696890	NA	0.34	5.66	0.3	3.24e-8	Prostate cancer;
LUSC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg03146154	chr1:46216737	IPP	-0.51	-7.35	-0.37	1.59e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg24060327	chr5:131705240	SLC22A5	-0.42	-6.79	-0.35	5.22e-11	Blood metabolite levels;
LUSC	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg06623918	chr6:96969491	KIAA0776	0.77	9.83	0.47	3.42e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.78	10.89	0.51	7.61e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	12.99	0.58	1.6e-31	Platelet count;
LUSC	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg08079166	chr15:68083412	MAP2K5	-0.42	-8.62	-0.43	2.79e-16	Restless legs syndrome;
LUSC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg05025164	chr4:1340916	KIAA1530	-0.43	-6.53	-0.34	2.51e-10	Obesity-related traits;
LUSC	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg15654264	chr1:150340011	RPRD2	0.61	10.13	0.48	3.39e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg16989719	chr2:238392110	NA	-0.45	-7.12	-0.36	6.79e-12	Prostate cancer;
LUSC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.38	0.46	1.04e-18	Monocyte percentage of white cells;
LUSC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg12927641	chr6:109611667	NA	-0.4	-6.92	-0.35	2.37e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs9311676	0.609	rs55646457	chr3:58415263	T/A	cg13750441	chr3:58318267	PXK	0.35	6.86	0.35	3.38e-11	Systemic lupus erythematosus;
LUSC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg11247378	chr22:39784982	NA	-0.68	-13.63	-0.6	6.14e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.9	0.31	9.02e-9	Menopause (age at onset);
LUSC	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg09877947	chr5:131593287	PDLIM4	0.41	6.67	0.34	1.05e-10	Blood metabolite levels;
LUSC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg00750074	chr16:89608354	SPG7	-0.45	-7.36	-0.37	1.47e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg07424592	chr7:64974309	NA	-0.64	-5.72	-0.3	2.34e-8	Diabetic kidney disease;
LUSC	cis	rs9549260	0.755	rs2721066	chr13:41156188	C/T	cg21288729	chr13:41239152	FOXO1	-0.61	-9.64	-0.47	1.44e-19	Red blood cell count;
LUSC	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg19875535	chr5:140030758	IK	0.47	7.68	0.39	1.78e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg02972257	chr16:68554789	NA	-0.53	-6.6	-0.34	1.64e-10	Ulcerative colitis;
LUSC	trans	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.63	-0.34	1.33e-10	Endometrial cancer;
LUSC	trans	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.75e-10	Corneal astigmatism;
LUSC	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg08601574	chr20:25228251	PYGB	0.43	6.51	0.34	2.77e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg12963246	chr6:28129442	ZNF389	0.48	6.63	0.34	1.34e-10	Depression;
LUSC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg04756594	chr16:24857601	SLC5A11	-0.49	-6.88	-0.35	2.92e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06850241	chr22:41845214	NA	-0.31	-5.66	-0.3	3.27e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9650315	0.714	rs7463962	chr8:57195932	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	7.13	0.36	6.25e-12	Height;
LUSC	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg03433033	chr1:76189801	ACADM	-0.43	-6.39	-0.33	5.51e-10	Daytime sleep phenotypes;
LUSC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08704250	chr15:31115839	NA	-0.47	-7.07	-0.36	9.16e-12	Huntington's disease progression;
LUSC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.14	0.41	7.83e-15	Prudent dietary pattern;
LUSC	cis	rs1983170	0.808	rs6685254	chr1:92018415	T/C	cg25838465	chr1:92012736	NA	0.42	5.86	0.31	1.09e-8	Eosinophil percentage of white cells;
LUSC	cis	rs231513	0.954	rs425135	chr17:41984517	A/C	cg26893861	chr17:41843967	DUSP3	-0.5	-5.82	-0.3	1.42e-8	Cognitive function;
LUSC	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg06092702	chr1:163392909	NA	-0.45	-7.43	-0.38	9.13e-13	Motion sickness;
LUSC	cis	rs9815354	0.904	rs9848992	chr3:41875297	C/T	cg03022575	chr3:42003672	ULK4	0.64	7.02	0.36	1.21e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.57	-0.38	3.57e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10489525	0.599	rs11102879	chr1:115603504	C/T	cg01522456	chr1:115632236	TSPAN2	0.5	7.33	0.37	1.8e-12	Autism;
LUSC	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg00864171	chr11:67383662	NA	0.34	5.97	0.31	5.93e-9	Mean corpuscular volume;
LUSC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg24642439	chr20:33292090	TP53INP2	0.64	10.01	0.48	8.11e-21	Coronary artery disease;
LUSC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg09365446	chr1:150670422	GOLPH3L	0.52	7.56	0.38	3.81e-13	Melanoma;
LUSC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-1.08	-16.08	-0.66	1.79e-43	Initial pursuit acceleration;
LUSC	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg03983476	chr2:10830698	NOL10	0.38	5.94	0.31	7.17e-9	Prostate cancer;
LUSC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.97	0.36	1.66e-11	Platelet count;
LUSC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.39	-6.36	-0.33	6.75e-10	IgG glycosylation;
LUSC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.73	0.54	7.69e-27	Alzheimer's disease;
LUSC	cis	rs4699052	0.787	rs2169508	chr4:104066890	T/A	cg16532752	chr4:104119610	CENPE	-0.5	-7.09	-0.36	8.02e-12	Testicular germ cell tumor;
LUSC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.46	-5.99	-0.31	5.49e-9	Longevity;Endometriosis;
LUSC	cis	rs3931020	0.657	rs277369	chr1:75234661	T/C	cg10128416	chr1:75198403	TYW3;CRYZ	-0.63	-8.39	-0.42	1.38e-15	Resistin levels;
LUSC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.32	-0.37	1.89e-12	Bipolar disorder;
LUSC	cis	rs72949976	0.646	rs11681232	chr2:214033002	G/A	cg08319019	chr2:214017104	IKZF2	0.67	11.13	0.52	1.13e-24	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	0.81	15.07	0.64	1.65e-39	Gut microbiome composition (winter);
LUSC	cis	rs9807841	0.592	rs1053007	chr19:10754400	A/G	cg09936142	chr19:10668400	KRI1	-0.4	-6.47	-0.33	3.57e-10	Inflammatory skin disease;
LUSC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg06521331	chr12:34319734	NA	-0.37	-6.31	-0.33	8.65e-10	Morning vs. evening chronotype;
LUSC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg26924012	chr15:45694286	SPATA5L1	1.14	20.79	0.75	3.36e-62	Homoarginine levels;
LUSC	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg00012203	chr2:219082015	ARPC2	0.7	11.53	0.53	3.91e-26	Colorectal cancer;
LUSC	cis	rs7608623	0.773	rs17507628	chr2:23921287	T/C	cg08917208	chr2:24149416	ATAD2B	-0.42	-5.74	-0.3	2.12e-8	Obesity-related traits;
LUSC	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg06740227	chr12:86229804	RASSF9	0.36	5.75	0.3	2.04e-8	Major depressive disorder;
LUSC	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg01528321	chr10:82214614	TSPAN14	0.87	13.27	0.59	1.39e-32	Post bronchodilator FEV1;
LUSC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg15448220	chr1:150897856	SETDB1	0.41	6.18	0.32	1.84e-9	Melanoma;
LUSC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06873352	chr17:61820015	STRADA	0.56	8.67	0.43	1.94e-16	Height;
LUSC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg12463550	chr7:65579703	CRCP	-0.55	-8.3	-0.41	2.62e-15	Aortic root size;
LUSC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03934478	chr11:495069	RNH1	0.82	9.84	0.47	3.08e-20	Body mass index;
LUSC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18876405	chr7:65276391	NA	-0.55	-8.79	-0.43	8.32e-17	Aortic root size;
LUSC	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs6457821	1.000	rs73415611	chr6:35437630	T/C	cg06087101	chr6:35551932	FKBP5	0.62	5.71	0.3	2.51e-8	Height;
LUSC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.99	0.4	2.24e-14	Bipolar disorder;
LUSC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08736216	chr1:53307985	ZYG11A	0.29	6.03	0.31	4.36e-9	Monocyte count;
LUSC	cis	rs9815354	0.680	rs73075219	chr3:42038429	A/C	cg03022575	chr3:42003672	ULK4	0.78	7.87	0.4	5.1e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-0.75	-18.0	-0.7	4.07e-51	Prudent dietary pattern;
LUSC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07677032	chr17:61819896	STRADA	-0.54	-8.99	-0.44	1.89e-17	Prudent dietary pattern;
LUSC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	9.8	0.47	4.32e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg22431228	chr1:16359049	CLCNKA	0.37	7.86	0.4	5.22e-14	Systolic blood pressure;
LUSC	cis	rs9378688	1.000	rs3800184	chr6:2211690	A/T	cg12303981	chr6:2244766	GMDS	0.56	6.83	0.35	4.12e-11	Caudate nucleus volume;
LUSC	cis	rs9297145	0.565	rs56132062	chr7:98778198	C/T	cg05967295	chr7:98741636	SMURF1	-0.63	-9.7	-0.47	9.17e-20	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg03060546	chr3:49711283	APEH	0.56	8.06	0.4	1.36e-14	Resting heart rate;
LUSC	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	10.37	0.49	4.94e-22	Response to antipsychotic treatment;
LUSC	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.51	9.35	0.46	1.35e-18	Bone mineral density;
LUSC	cis	rs73198271	0.515	rs113524005	chr8:8634672	C/A	cg01851573	chr8:8652454	MFHAS1	0.58	6.53	0.34	2.49e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg22467129	chr15:76604101	ETFA	-0.44	-6.89	-0.35	2.82e-11	Blood metabolite levels;
LUSC	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg13010199	chr12:38710504	ALG10B	0.53	7.95	0.4	2.88e-14	Morning vs. evening chronotype;
LUSC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg23625390	chr15:77176239	SCAPER	0.5	7.75	0.39	1.11e-13	Blood metabolite levels;
LUSC	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg27284194	chr4:1044797	NA	0.6	8.8	0.43	7.32e-17	Recombination rate (females);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12145289	chr11:65385911	PCNXL3	0.47	6.09	0.32	3.19e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4622329	0.615	rs7137913	chr12:102291377	C/T	cg23541617	chr12:102225335	GNPTAB	0.27	6.21	0.32	1.55e-9	Systemic lupus erythematosus;
LUSC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg06784218	chr1:46089804	CCDC17	0.55	11.01	0.52	2.99e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.13	0.55	2.67e-28	Motion sickness;
LUSC	cis	rs7106204	0.748	rs6484028	chr11:24222438	A/G	ch.11.24196551F	chr11:24239977	NA	1.14	14.29	0.62	1.8e-36	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs11671005	0.737	rs11671033	chr19:58963669	G/T	cg13877915	chr19:58951672	ZNF132	0.47	5.73	0.3	2.29e-8	Mean platelet volume;
LUSC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg17971929	chr21:40555470	PSMG1	0.75	11.63	0.54	1.7e-26	Cognitive function;
LUSC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.95	-10.9	-0.51	7.15e-24	Type 2 diabetes;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02750587	chr1:85156370	SSX2IP	0.4	6.92	0.35	2.39e-11	Triglycerides;
LUSC	cis	rs977987	0.771	rs8048527	chr16:75422054	C/A	cg03315344	chr16:75512273	CHST6	0.47	8.98	0.44	1.95e-17	Dupuytren's disease;
LUSC	cis	rs3087591	0.708	rs4794887	chr17:29649696	G/A	cg24425628	chr17:29625626	OMG;NF1	0.46	6.87	0.35	3.09e-11	Hip circumference;
LUSC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.75	-0.47	6.29e-20	Gut microbiome composition (summer);
LUSC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08704250	chr15:31115839	NA	-0.47	-7.03	-0.36	1.19e-11	Huntington's disease progression;
LUSC	cis	rs3733418	0.929	rs12512234	chr4:165908865	C/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-5.92	-0.31	7.89e-9	Obesity-related traits;
LUSC	cis	rs9790314	0.690	rs1599389	chr3:160836006	G/A	cg03342759	chr3:160939853	NMD3	-0.41	-6.78	-0.35	5.57e-11	Morning vs. evening chronotype;
LUSC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25072359	chr17:41440525	NA	0.66	9.42	0.46	7.64e-19	Menopause (age at onset);
LUSC	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg09307838	chr4:120376055	NA	0.7	9.88	0.48	2.23e-20	Corneal astigmatism;
LUSC	cis	rs9788721	0.868	rs17486278	chr15:78867482	A/C	cg18825076	chr15:78729989	IREB2	-0.47	-7.28	-0.37	2.37e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.31	-0.37	2.01e-12	Bipolar disorder;
LUSC	cis	rs75804782	0.521	rs72982590	chr2:239451826	T/C	cg18131467	chr2:239335373	ASB1	-0.65	-6.01	-0.31	4.81e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg04287289	chr16:89883240	FANCA	-0.64	-5.69	-0.3	2.82e-8	Caffeine consumption;
LUSC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.71	0.7	5.89e-50	Chronic sinus infection;
LUSC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg16339924	chr4:17578868	LAP3	0.63	9.88	0.48	2.3e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.69e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2235649	0.592	rs11647980	chr16:1959753	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-5.95	-0.31	6.66e-9	Blood metabolite levels;
LUSC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg02527881	chr3:46936655	PTH1R	-0.45	-8.13	-0.41	8.66e-15	Colorectal cancer;
LUSC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.98	-0.52	3.66e-24	Alzheimer's disease;
LUSC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg18402987	chr7:1209562	NA	0.73	7.84	0.39	5.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg25358565	chr5:93447407	FAM172A	-0.58	-8.26	-0.41	3.48e-15	Diabetic retinopathy;
LUSC	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg08017756	chr2:100939284	LONRF2	-0.43	-8.06	-0.4	1.41e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs11051970	0.879	rs950079	chr12:32588620	A/G	cg24626660	chr12:32551988	NA	0.33	5.66	0.3	3.2e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg06484146	chr7:12443880	VWDE	-0.72	-7.25	-0.37	2.84e-12	Coronary artery disease;
LUSC	cis	rs17490626	0.533	rs12771890	chr10:71189483	T/A	cg14388049	chr10:71211838	TSPAN15	-0.32	-5.87	-0.31	1.04e-8	Thrombosis;
LUSC	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg02023728	chr11:77925099	USP35	0.47	7.11	0.36	7.28e-12	Testicular germ cell tumor;
LUSC	cis	rs11971779	0.680	rs10242419	chr7:139089380	A/G	cg07862535	chr7:139043722	LUC7L2	-0.58	-7.32	-0.37	1.86e-12	Diisocyanate-induced asthma;
LUSC	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg03929089	chr4:120376271	NA	-0.79	-10.53	-0.5	1.35e-22	Coronary artery disease;
LUSC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg22815214	chr1:201083145	CACNA1S	0.56	9.82	0.47	3.69e-20	Permanent tooth development;
LUSC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg00310523	chr12:86230176	RASSF9	0.51	9.61	0.47	1.8e-19	Major depressive disorder;
LUSC	trans	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	1.13	17.57	0.69	2.12e-49	Corneal structure;
LUSC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg25258033	chr6:167368657	RNASET2	0.47	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	12.03	0.55	6.07e-28	Chronic sinus infection;
LUSC	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg01733217	chr16:74700730	RFWD3	0.8	13.42	0.59	3.86e-33	Testicular germ cell tumor;
LUSC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.22	-0.32	1.46e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg04369109	chr6:150039330	LATS1	-0.51	-7.32	-0.37	1.81e-12	Lung cancer;
LUSC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-8.57	-0.42	3.99e-16	Personality dimensions;
LUSC	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg09184832	chr6:79620586	NA	-0.44	-6.95	-0.36	1.89e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11764359	chr7:65958608	NA	0.69	11.09	0.52	1.48e-24	Aortic root size;
LUSC	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg07930552	chr6:133119739	C6orf192	0.84	10.54	0.5	1.29e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.9	0.31	8.84e-9	Rheumatoid arthritis;
LUSC	cis	rs4474633	1	rs4474633	chr15:49260601	A/G	cg19135536	chr15:49267992	NA	-0.45	-6.61	-0.34	1.54e-10	Major depressive disorder;
LUSC	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg15445000	chr17:37608096	MED1	-0.39	-6.7	-0.34	8.93e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg25208724	chr1:156163844	SLC25A44	0.79	6.57	0.34	1.94e-10	Paclitaxel disposition in epithelial ovarian cancer;
LUSC	cis	rs7799006	0.582	rs7781284	chr7:2339405	G/T	cg08027265	chr7:2291960	NA	-0.47	-8.12	-0.41	9.28e-15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg27631724	chr1:11040367	C1orf127	0.54	9.4	0.46	8.69e-19	Ewing sarcoma;
LUSC	cis	rs1775715	0.769	rs2799030	chr10:32172935	G/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.66	0.34	1.14e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs11625487	0.609	rs78677337	chr14:77966223	G/A	cg16049707	chr14:77965284	ISM2	-0.64	-6.78	-0.35	5.31e-11	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	14.24	0.61	2.72e-36	Platelet count;
LUSC	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg09904177	chr6:26538194	HMGN4	0.64	11.07	0.52	1.85e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg14092571	chr14:90743983	NA	-0.36	-5.9	-0.31	8.76e-9	Mortality in heart failure;
LUSC	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-12.64	-0.57	3.34e-30	Colorectal cancer;
LUSC	cis	rs2303282	0.716	rs1478478	chr16:56402531	C/A	cg00500540	chr16:56394104	NA	-0.44	-7.55	-0.38	4.1e-13	Breast cancer;
LUSC	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.94	0.31	7.08e-9	Morning vs. evening chronotype;
LUSC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg09359103	chr1:154839909	KCNN3	-0.43	-8.18	-0.41	6.13e-15	Schizophrenia;
LUSC	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg08645402	chr16:4508243	NA	-0.46	-7.26	-0.37	2.66e-12	Schizophrenia;
LUSC	cis	rs13006833	0.765	rs291431	chr2:191199530	G/A	cg21644426	chr2:191273491	MFSD6	0.46	6.47	0.33	3.45e-10	Urinary metabolites;
LUSC	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg05973401	chr12:123451056	ABCB9	0.52	6.43	0.33	4.29e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18404041	chr3:52824283	ITIH1	-0.63	-12.21	-0.56	1.38e-28	Bipolar disorder;
LUSC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg11663144	chr21:46675770	NA	-0.43	-7.65	-0.39	2.21e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg19729930	chr2:74357872	NA	0.94	18.09	0.7	1.76e-51	Gestational age at birth (maternal effect);
LUSC	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.23	-0.32	1.43e-9	Response to antipsychotic treatment;
LUSC	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg21775007	chr8:11205619	TDH	0.44	6.26	0.32	1.19e-9	Neuroticism;
LUSC	cis	rs9807989	0.811	rs4485585	chr2:102970759	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.88	0.31	9.76e-9	Asthma;
LUSC	cis	rs4666002	0.956	rs10179872	chr2:27778572	G/A	cg27432699	chr2:27873401	GPN1	0.41	5.7	0.3	2.69e-8	Phospholipid levels (plasma);
LUSC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg04369109	chr6:150039330	LATS1	-0.56	-8.25	-0.41	3.68e-15	Lung cancer;
LUSC	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg22834771	chr12:69754056	YEATS4	-0.49	-7.41	-0.38	1.02e-12	Blood protein levels;
LUSC	cis	rs1775715	0.678	rs2778649	chr10:32146803	C/G	cg26784012	chr10:32216390	ARHGAP12	0.45	7.51	0.38	5.36e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.43	6.59	0.34	1.68e-10	Dupuytren's disease;
LUSC	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-7.23	-0.37	3.37e-12	Morning vs. evening chronotype;
LUSC	cis	rs7911264	0.739	rs10882091	chr10:94374377	C/T	cg25093409	chr10:94429542	NA	0.36	6.21	0.32	1.59e-9	Inflammatory bowel disease;
LUSC	cis	rs2835872	0.828	rs73220494	chr21:38989276	C/T	cg20424643	chr21:39039972	KCNJ6	0.36	5.69	0.3	2.84e-8	Electroencephalographic traits in alcoholism;
LUSC	trans	rs72674100	1.000	rs7694339	chr4:97968342	C/T	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.82	-14.41	-0.62	6.05e-37	Cognitive function;
LUSC	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg04998671	chr14:104000505	TRMT61A	-0.49	-7.76	-0.39	1.07e-13	Coronary artery disease;
LUSC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18131467	chr2:239335373	ASB1	1.05	25.01	0.81	1.55e-78	Multiple system atrophy;
LUSC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg02038168	chr22:39784481	NA	0.41	6.16	0.32	2.1e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg22638593	chr5:131593259	PDLIM4	0.39	5.76	0.3	1.9e-8	Breast cancer;
LUSC	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg12863693	chr15:85201151	NMB	-0.27	-5.9	-0.31	9e-9	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07080220	chr10:102295463	HIF1AN	0.7	9.4	0.46	8.73e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.08	-0.32	3.28e-9	Bipolar disorder;
LUSC	cis	rs887829	0.641	rs10167119	chr2:234589312	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-6.55	-0.34	2.23e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs12541635	0.677	rs6997487	chr8:106965511	A/C	cg10147462	chr8:107024639	NA	0.64	12.92	0.58	3.03e-31	Age of smoking initiation;
LUSC	cis	rs6840360	0.642	rs1470281	chr4:152431552	A/G	cg20465933	chr4:152376761	FAM160A1	0.33	5.91	0.31	8.36e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg07424592	chr7:64974309	NA	0.69	6.07	0.32	3.41e-9	Diabetic kidney disease;
LUSC	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg08807101	chr21:30365312	RNF160	-0.51	-6.44	-0.33	4.27e-10	Cognitive test performance;
LUSC	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.6	-0.38	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2898681	0.581	rs731073	chr4:53680090	A/G	cg00338735	chr4:53728038	RASL11B	0.42	5.77	0.3	1.78e-8	Optic nerve measurement (cup area);
LUSC	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg21775007	chr8:11205619	TDH	0.43	6.2	0.32	1.69e-9	Mood instability;
LUSC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.83	-0.39	6.51e-14	Bipolar disorder and schizophrenia;
LUSC	trans	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg27600084	chr12:12264075	NA	0.49	7.18	0.37	4.46e-12	Breast size;
LUSC	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg12935359	chr14:103987150	CKB	0.65	10.54	0.5	1.31e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg00033643	chr7:134001901	SLC35B4	0.46	7.25	0.37	2.87e-12	Mean platelet volume;
LUSC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-0.91	-16.52	-0.67	3.02e-45	Cognitive function;
LUSC	cis	rs2573652	0.722	rs11636047	chr15:100543341	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.35	-6.27	-0.32	1.09e-9	Height;
LUSC	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg22681709	chr2:178499509	PDE11A	-0.47	-8.43	-0.42	1.02e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs6681460	0.546	rs10889648	chr1:67168182	T/C	cg02459107	chr1:67143332	SGIP1	0.33	5.88	0.31	9.9e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs1524927	0.966	rs7812179	chr7:96354770	A/G	cg03808172	chr7:96339361	SHFM1	0.43	6.53	0.34	2.48e-10	Total body bone mineral density;
LUSC	cis	rs662064	0.962	rs622623	chr1:10555257	C/T	cg20482658	chr1:10539492	PEX14	-0.32	-6.61	-0.34	1.54e-10	Asthma;
LUSC	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-0.96	-16.5	-0.67	3.73e-45	Height;
LUSC	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg11764359	chr7:65958608	NA	0.44	6.29	0.33	9.94e-10	Corneal structure;
LUSC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg20887711	chr4:1340912	KIAA1530	-0.5	-7.5	-0.38	5.93e-13	Obesity-related traits;
LUSC	cis	rs3820928	0.874	rs7605032	chr2:227847630	T/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.58	-0.38	3.4e-13	Pulmonary function;
LUSC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-13.41	-0.59	4.27e-33	Hemoglobin concentration;
LUSC	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg17294928	chr15:75287854	SCAMP5	-0.72	-8.16	-0.41	6.7e-15	Blood trace element (Zn levels);
LUSC	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-8.98	-0.44	1.99e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs17604090	0.793	rs17136535	chr7:29689158	C/T	cg19413766	chr7:29689036	LOC646762	-0.56	-7.01	-0.36	1.36e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg00677455	chr12:58241039	CTDSP2	0.71	10.73	0.51	2.77e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.86	-13.72	-0.6	2.77e-34	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg01733217	chr16:74700730	RFWD3	0.8	13.43	0.59	3.48e-33	Testicular germ cell tumor;
LUSC	cis	rs7180079	0.563	rs2733381	chr15:64857043	T/C	cg08069370	chr15:64387884	SNX1	0.51	5.71	0.3	2.47e-8	Monocyte count;
LUSC	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg26875233	chr11:93583750	C11orf90	-0.31	-6.04	-0.31	4.07e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs11158026	0.757	rs56164809	chr14:55400212	A/G	cg04306507	chr14:55594613	LGALS3	0.34	6.43	0.33	4.48e-10	Parkinson's disease;
LUSC	cis	rs3099143	1.000	rs35645941	chr15:77140302	C/T	cg21673338	chr15:77095150	SCAPER	-0.8	-7.36	-0.37	1.41e-12	Recalcitrant atopic dermatitis;
LUSC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg04414720	chr1:150670196	GOLPH3L	0.56	9.09	0.45	8.97e-18	Tonsillectomy;
LUSC	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg25019033	chr10:957182	NA	-0.51	-6.36	-0.33	6.76e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg07274523	chr3:49395745	GPX1	-0.62	-8.83	-0.43	6.23e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg18478394	chr8:109455254	TTC35	0.43	6.65	0.34	1.22e-10	Dupuytren's disease;
LUSC	trans	rs895636	0.898	rs10205310	chr2:45188646	A/G	cg01331992	chr9:19379118	RPS6	0.48	5.98	0.31	5.67e-9	Metabolite levels;Fasting plasma glucose;
LUSC	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.56	-8.45	-0.42	8.99e-16	Heart rate;
LUSC	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg24558204	chr6:135376177	HBS1L	0.68	10.65	0.5	5.52e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs9815354	0.767	rs73069245	chr3:41951452	G/A	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.55e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.87	-11.31	-0.53	2.45e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.53	-8.87	-0.44	4.42e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7589342	0.839	rs7589790	chr2:106433909	C/G	cg16077055	chr2:106428750	NCK2	-0.35	-6.44	-0.33	4.18e-10	Addiction;
LUSC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.53e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg21699342	chr2:239360505	ASB1	0.55	10.14	0.48	3.17e-21	Multiple system atrophy;
LUSC	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg25801113	chr15:45476975	SHF	0.35	7.08	0.36	8.74e-12	Uric acid levels;
LUSC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.45e-9	Menopause (age at onset);
LUSC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.84	-0.3	1.22e-8	Platelet count;
LUSC	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg09184832	chr6:79620586	NA	-0.41	-6.32	-0.33	8.39e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg23241863	chr10:102295624	HIF1AN	0.49	5.98	0.31	5.84e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg16339924	chr4:17578868	LAP3	0.47	7.37	0.37	1.34e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg05855489	chr10:104503620	C10orf26	-0.53	-7.28	-0.37	2.44e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2742234	0.541	rs11238481	chr10:43719286	A/G	cg15436174	chr10:43711423	RASGEF1A	0.44	7.06	0.36	9.75e-12	Hirschsprung disease;
LUSC	cis	rs9549260	0.604	rs9532587	chr13:41302694	A/T	cg21288729	chr13:41239152	FOXO1	0.56	6.37	0.33	6.19e-10	Red blood cell count;
LUSC	cis	rs7674212	0.512	rs2720462	chr4:104056210	T/G	cg16532752	chr4:104119610	CENPE	-0.47	-6.66	-0.34	1.1e-10	Type 2 diabetes;
LUSC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.9	-0.51	6.89e-24	Hemoglobin concentration;
LUSC	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg22601191	chr20:60968625	CABLES2	-0.45	-6.29	-0.33	9.93e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg13683864	chr3:40499215	RPL14	-0.93	-15.94	-0.66	5.93e-43	Renal cell carcinoma;
LUSC	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg01528321	chr10:82214614	TSPAN14	0.62	9.31	0.45	1.74e-18	Post bronchodilator FEV1;
LUSC	trans	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.58	-0.34	1.78e-10	Mood instability;
LUSC	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg09839279	chr12:125627357	AACS	-0.33	-6.01	-0.31	4.96e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs17407555	0.738	rs55731306	chr4:10067885	G/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-6.26	-0.32	1.19e-9	Schizophrenia (age at onset);
LUSC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg13114125	chr14:105738426	BRF1	-0.93	-16.05	-0.66	2.23e-43	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg13010199	chr12:38710504	ALG10B	0.52	8.0	0.4	2.01e-14	Morning vs. evening chronotype;
LUSC	cis	rs7903847	0.642	rs7088410	chr10:99135539	G/T	cg06359132	chr10:99160096	RRP12	-0.24	-5.66	-0.3	3.33e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg24375607	chr4:120327624	NA	-0.77	-11.67	-0.54	1.25e-26	Corneal astigmatism;
LUSC	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg17143192	chr8:8559678	CLDN23	0.55	8.03	0.4	1.65e-14	Obesity-related traits;
LUSC	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.8	-0.39	7.79e-14	Glomerular filtration rate;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17720231	chr1:159915374	IGSF9	-0.37	-6.42	-0.33	4.56e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2637266	0.935	rs7393727	chr10:78365977	T/A	cg18941641	chr10:78392320	NA	0.39	7.22	0.37	3.61e-12	Pulmonary function;
LUSC	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.78	0.3	1.76e-8	Breast cancer;
LUSC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.27	0.52	3.49e-25	Menopause (age at onset);
LUSC	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg18825076	chr15:78729989	IREB2	0.44	6.06	0.31	3.7e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg21141812	chr3:48556323	PFKFB4	0.34	6.2	0.32	1.68e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg21782813	chr7:2030301	MAD1L1	-0.54	-9.16	-0.45	5.26e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs7493	0.950	rs11977702	chr7:95029767	C/T	cg04871131	chr7:94954202	PON1	-0.37	-5.9	-0.31	8.9e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.33	-5.82	-0.3	1.4e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.51	0.34	2.7e-10	Aortic root size;
LUSC	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg05163923	chr11:71159392	DHCR7	0.74	11.07	0.52	1.79e-24	Vitamin D levels;
LUSC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg06671706	chr8:8559999	CLDN23	0.5	6.68	0.34	9.98e-11	Obesity-related traits;
LUSC	trans	rs1927790	0.759	rs12583996	chr13:96991702	G/A	cg03198741	chr6:1003969	LOC285768	-0.4	-5.99	-0.31	5.57e-9	Body mass index;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17608500	chr1:154955711	FLAD1	0.42	6.35	0.33	7.18e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg03585969	chr10:35415529	CREM	0.6	8.88	0.44	4.32e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs16976116	0.901	rs73409851	chr15:55502516	G/A	cg11288833	chr15:55489084	RSL24D1	0.51	6.13	0.32	2.5e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg04362960	chr10:104952993	NT5C2	0.65	9.45	0.46	6.2e-19	Arsenic metabolism;
LUSC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg16647868	chr5:131706066	SLC22A5	0.35	5.87	0.31	1.03e-8	Blood metabolite levels;
LUSC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg16325326	chr1:53192061	ZYG11B	0.75	12.8	0.57	8.33e-31	Monocyte count;
LUSC	cis	rs13006833	0.668	rs291447	chr2:191177005	A/C	cg21644426	chr2:191273491	MFSD6	0.43	6.14	0.32	2.39e-9	Urinary metabolites;
LUSC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.38	5.84	0.3	1.22e-8	Longevity;Endometriosis;
LUSC	trans	rs236907	0.859	rs36080557	chr1:171764003	A/G	cg13482142	chr2:234261155	NA	0.49	6.17	0.32	1.95e-9	Mean platelet volume;
LUSC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg15605315	chr1:45957053	TESK2	0.46	7.33	0.37	1.78e-12	High light scatter reticulocyte count;
LUSC	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.6	8.57	0.42	3.94e-16	Inhibitory control;
LUSC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.97	0.36	1.66e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6982240	0.514	rs10088801	chr8:142275801	T/C	cg27411547	chr8:142287226	NA	-0.47	-8.02	-0.4	1.77e-14	Tonsillectomy;
LUSC	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.68	11.58	0.54	2.61e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12760731	0.623	rs71628283	chr1:178458450	G/A	cg00404053	chr1:178313656	RASAL2	0.63	6.67	0.34	1.09e-10	Obesity-related traits;
LUSC	cis	rs16937	0.711	rs3851289	chr1:205149657	G/T	cg00857998	chr1:205179979	DSTYK	0.46	6.47	0.33	3.46e-10	Schizophrenia;
LUSC	cis	rs611744	0.870	rs2212703	chr8:109198401	G/C	cg18478394	chr8:109455254	TTC35	0.4	5.95	0.31	6.61e-9	Dupuytren's disease;
LUSC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04155289	chr7:94953770	PON1	-0.47	-9.47	-0.46	5.37e-19	Paraoxonase activity;
LUSC	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.68	-0.7	7.51e-50	Exhaled nitric oxide output;
LUSC	cis	rs6732160	0.691	rs11886257	chr2:73416873	C/T	cg24220031	chr2:73402428	NA	-0.23	-5.76	-0.3	1.9e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7119	0.717	rs7180732	chr15:77829921	G/A	cg27398640	chr15:77910606	LINGO1	-0.32	-6.8	-0.35	4.98e-11	Type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.35	0.42	1.82e-15	Prudent dietary pattern;
LUSC	cis	rs1044826	1.000	rs13092935	chr3:139175464	C/T	cg00490450	chr3:139108681	COPB2	0.5	6.67	0.34	1.04e-10	Obesity-related traits;
LUSC	cis	rs422421	1.000	rs422421	chr5:176517326	A/G	cg00618323	chr5:176515533	FGFR4	0.37	5.69	0.3	2.74e-8	Height;
LUSC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.7	-13.11	-0.58	6.02e-32	Bipolar disorder;
LUSC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.58	9.03	0.44	1.42e-17	Longevity;
LUSC	cis	rs5770917	1.000	rs2073604	chr22:51008925	G/A	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.61	-5.89	-0.31	9.54e-9	Narcolepsy;
LUSC	trans	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg13565492	chr6:43139072	SRF	-0.57	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-9.24	-0.45	3.04e-18	Gut microbiome composition (summer);
LUSC	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg01420254	chr6:26195488	NA	0.67	7.5	0.38	5.77e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs71403859	0.554	rs12920245	chr16:72029069	C/A	cg08717414	chr16:71523259	ZNF19	-0.7	-5.84	-0.3	1.21e-8	Post bronchodilator FEV1;
LUSC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg26338869	chr17:61819248	STRADA	0.42	6.06	0.31	3.7e-9	Prudent dietary pattern;
LUSC	trans	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg19694781	chr19:47549865	TMEM160	-0.58	-9.38	-0.46	1.03e-18	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs295140	1.000	rs10931899	chr2:201176901	A/G	cg04283868	chr2:201171347	SPATS2L	-0.42	-6.29	-0.33	9.83e-10	QT interval;
LUSC	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg22532475	chr10:104410764	TRIM8	0.25	5.96	0.31	6.52e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg06521331	chr12:34319734	NA	-0.52	-9.1	-0.45	8.63e-18	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg25767906	chr1:53392781	SCP2	0.71	14.08	0.61	1.12e-35	Monocyte count;
LUSC	cis	rs4654899	1.000	rs2271115	chr1:21295864	C/T	cg01072550	chr1:21505969	NA	-0.55	-8.41	-0.42	1.23e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg12334488	chr2:20871173	GDF7	-0.34	-6.18	-0.32	1.82e-9	Abdominal aortic aneurysm;
LUSC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.92	0.44	3.2e-17	Motion sickness;
LUSC	cis	rs9039	0.959	rs4985101	chr16:9194963	T/C	cg08831531	chr16:9218945	NA	-0.56	-8.76	-0.43	1.01e-16	Menopause (age at onset);
LUSC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs6736093	0.796	rs4848971	chr2:112790446	C/T	cg12686935	chr2:112915763	FBLN7	-0.39	-6.28	-0.32	1.08e-9	Coronary artery disease;
LUSC	cis	rs1957429	0.808	rs11158564	chr14:65335082	G/A	cg23373153	chr14:65346875	NA	0.97	11.0	0.52	3.19e-24	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7119	0.651	rs8025968	chr15:77839616	C/T	cg27398640	chr15:77910606	LINGO1	-0.33	-6.63	-0.34	1.32e-10	Type 2 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21902160	chr7:29689075	LOC646762	0.49	6.17	0.32	1.93e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg16928487	chr17:17741425	SREBF1	0.48	9.72	0.47	7.76e-20	Total body bone mineral density;
LUSC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg08742575	chr21:47604166	C21orf56	0.48	7.27	0.37	2.5e-12	Testicular germ cell tumor;
LUSC	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.57	-0.46	2.49e-19	Joint mobility (Beighton score);
LUSC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	11.67	0.54	1.26e-26	Hip circumference adjusted for BMI;
LUSC	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg26528668	chr16:1614120	IFT140	0.41	6.77	0.35	5.98e-11	Coronary artery disease;
LUSC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg27572855	chr1:25598939	RHD	0.45	8.23	0.41	4.38e-15	Erythrocyte sedimentation rate;
LUSC	cis	rs9796	0.621	rs2899013	chr15:41492283	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.51	-8.99	-0.44	1.88e-17	Menopause (age at onset);
LUSC	trans	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	10.79	0.51	1.78e-23	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg06096015	chr1:231504339	EGLN1	0.58	10.45	0.5	2.68e-22	Hemoglobin concentration;
LUSC	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.1	-27.19	-0.83	1.14e-86	Myeloid white cell count;
LUSC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg04025307	chr7:1156635	C7orf50	0.43	5.8	0.3	1.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg18230493	chr5:56204884	C5orf35	0.62	9.15	0.45	5.73e-18	Coronary artery disease;
LUSC	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg16482183	chr6:26056742	HIST1H1C	0.64	9.18	0.45	4.59e-18	Iron status biomarkers;
LUSC	trans	rs6601327	0.575	rs6994574	chr8:9578255	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.6	-0.34	1.66e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs28655083	1.000	rs8045658	chr16:77056343	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-6.27	-0.32	1.12e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs56804039	1.000	rs58361948	chr8:8380995	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.27	-0.32	1.12e-9	Cervical cancer;
LUSC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg10792982	chr14:105748885	BRF1	0.49	8.88	0.44	4.19e-17	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg25206134	chr2:45395956	NA	0.51	5.98	0.31	5.87e-9	Bipolar disorder;
LUSC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.71	-0.34	8.52e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1950626	0.827	rs35829821	chr14:101409763	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.46	0.38	7.73e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs6961069	0.743	rs1054517	chr7:80285003	C/T	cg04458919	chr7:80252533	CD36	-0.35	-6.14	-0.32	2.28e-9	Platelet count;
LUSC	cis	rs4664308	1.000	rs6719686	chr2:160908292	T/G	cg03641300	chr2:160917029	PLA2R1	-0.66	-11.25	-0.52	4.06e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg00701064	chr4:6280414	WFS1	0.58	13.96	0.61	3.27e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6084875	0.840	rs2065705	chr20:4719407	A/G	cg07258627	chr20:4721683	PRNT	0.34	6.21	0.32	1.6e-9	Systemic lupus erythematosus;
LUSC	cis	rs6546537	0.911	rs62133968	chr2:69891910	C/T	cg10773587	chr2:69614142	GFPT1	-0.53	-8.12	-0.41	9.2e-15	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs73416724	0.858	rs4466248	chr6:43279652	T/C	cg26312998	chr6:43337775	ZNF318	-0.53	-6.14	-0.32	2.38e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg10792982	chr14:105748885	BRF1	0.52	9.29	0.45	2.08e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2652834	0.808	rs11071723	chr15:63355275	A/T	cg05507819	chr15:63340323	TPM1	0.69	8.66	0.43	2.05e-16	HDL cholesterol;
LUSC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg04518342	chr5:131593106	PDLIM4	0.34	6.18	0.32	1.92e-9	Blood metabolite levels;
LUSC	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg19792802	chr11:65647270	CTSW	-0.41	-6.23	-0.32	1.38e-9	Crohn's disease;
LUSC	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg18753928	chr3:113234510	CCDC52	-0.44	-6.76	-0.35	6.31e-11	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.22	-13.8	-0.6	1.31e-34	Diabetic kidney disease;
LUSC	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.58	-0.6	9.26e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1018836	0.798	rs4735295	chr8:91671608	C/A	cg16814680	chr8:91681699	NA	-0.98	-18.51	-0.71	3.7e-53	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs617219	0.819	rs10074882	chr5:78602863	C/T	cg24856658	chr5:78533917	JMY	-0.31	-6.23	-0.32	1.39e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg21016266	chr12:122356598	WDR66	0.54	7.68	0.39	1.82e-13	Mean corpuscular volume;
LUSC	trans	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg25214090	chr10:38739885	LOC399744	0.45	6.49	0.33	3.1e-10	Corneal astigmatism;
LUSC	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	7.68	0.39	1.82e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-1.07	-25.74	-0.82	2.75e-81	Testicular germ cell tumor;
LUSC	trans	rs11700980	0.551	rs2251445	chr21:30109148	G/A	cg14791747	chr16:20752902	THUMPD1	0.56	6.1	0.32	2.88e-9	QRS complex (12-leadsum);
LUSC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.74	0.84	1.09e-88	Chronic sinus infection;
LUSC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg16586182	chr3:47516702	SCAP	0.5	7.81	0.39	7.26e-14	Colorectal cancer;
LUSC	cis	rs12940923	1.000	rs12452417	chr17:56367202	G/A	cg19466818	chr17:56409534	MIR142	-0.39	-6.87	-0.35	3.19e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg19774624	chr17:42201019	HDAC5	-0.8	-13.44	-0.59	3.23e-33	Total body bone mineral density;
LUSC	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg17517138	chr11:73019481	ARHGEF17	1.09	9.0	0.44	1.69e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg19230755	chr7:65878503	NA	-0.41	-5.75	-0.3	2e-8	Aortic root size;
LUSC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.96	0.51	4.51e-24	Menopause (age at onset);
LUSC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14893161	chr1:205819251	PM20D1	0.58	10.01	0.48	8.11e-21	Menarche (age at onset);
LUSC	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-11.9	-0.55	1.89e-27	Mean corpuscular volume;
LUSC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg16558253	chr16:72132732	DHX38	-0.41	-6.32	-0.33	8.5e-10	Fibrinogen levels;
LUSC	cis	rs2932538	0.922	rs12143068	chr1:113138110	A/G	cg22162597	chr1:113214053	CAPZA1	0.7	10.1	0.48	4.1e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.62	10.04	0.48	6.47e-21	Blood metabolite ratios;
LUSC	trans	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg10756647	chr7:56101905	PSPH	0.88	8.43	0.42	1.02e-15	Diabetic kidney disease;
LUSC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18404041	chr3:52824283	ITIH1	-0.63	-11.65	-0.54	1.45e-26	Bipolar disorder;
LUSC	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg20991723	chr1:152506922	NA	0.49	8.97	0.44	2.19e-17	Hair morphology;
LUSC	cis	rs6733011	0.628	rs4851163	chr2:99466664	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.71	-0.34	8.42e-11	Bipolar disorder;
LUSC	cis	rs17155006	0.655	rs426812	chr7:107728512	T/C	cg05962710	chr7:107745446	LAMB4	-0.33	-5.83	-0.3	1.31e-8	Pneumococcal bacteremia;
LUSC	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.55	0.34	2.17e-10	Corneal astigmatism;
LUSC	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg16342193	chr10:102329863	NA	-0.35	-6.39	-0.33	5.63e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs666930	0.519	rs662602	chr1:120266903	C/G	cg19096424	chr1:120255104	PHGDH	0.59	8.28	0.41	3.02e-15	Breast cancer;
LUSC	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg18190219	chr22:46762943	CELSR1	-0.55	-6.02	-0.31	4.66e-9	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg26384229	chr12:38710491	ALG10B	0.77	13.05	0.58	1e-31	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	14.01	0.61	2.15e-35	Platelet count;
LUSC	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg20701182	chr2:24300061	SF3B14	0.57	6.02	0.31	4.55e-9	Lymphocyte counts;
LUSC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.01	0.44	1.57e-17	Motion sickness;
LUSC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg22823121	chr1:150693482	HORMAD1	0.59	9.05	0.44	1.17e-17	Tonsillectomy;
LUSC	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg23280166	chr11:118938394	VPS11	0.48	7.57	0.38	3.62e-13	Coronary artery disease;
LUSC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.06	-17.67	-0.7	8.51e-50	Primary sclerosing cholangitis;
LUSC	cis	rs17253792	0.822	rs75936910	chr14:56149351	T/C	cg01858014	chr14:56050164	KTN1	-0.81	-6.96	-0.36	1.84e-11	Putamen volume;
LUSC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.06	0.31	3.77e-9	Menopause (age at onset);
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	1.01	23.16	0.79	1.86e-71	Menarche (age at onset);
LUSC	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	0.81	11.34	0.53	2e-25	Coronary artery disease;
LUSC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	5.86	0.31	1.13e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg00220769	chr6:153305382	FBXO5	-0.43	-5.94	-0.31	7.04e-9	Neuroticism;
LUSC	cis	rs9807989	0.507	rs6749014	chr2:103006448	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.29e-12	Asthma;
LUSC	cis	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg02972257	chr16:68554789	NA	-0.52	-6.48	-0.33	3.26e-10	Ulcerative colitis;
LUSC	cis	rs2279817	1.000	rs2279815	chr1:18022066	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.48	6.7	0.34	8.91e-11	Neuroticism;
LUSC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg02891314	chr5:179741120	GFPT2	-0.58	-9.12	-0.45	6.99e-18	Height;
LUSC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg25258033	chr6:167368657	RNASET2	0.47	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	cis	rs10740039	0.883	rs7093573	chr10:62394369	C/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1506636	0.927	rs11983604	chr7:123329754	T/G	cg03229431	chr7:123269106	ASB15	-0.64	-10.57	-0.5	1.05e-22	Plateletcrit;Platelet count;
LUSC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.83	0.3	1.3e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg08824895	chr13:115047677	UPF3A	0.55	8.53	0.42	5.28e-16	Schizophrenia;
LUSC	cis	rs631288	0.793	rs11239952	chr1:146715204	A/G	cg25205988	chr1:146714368	CHD1L	1.08	7.41	0.38	1.02e-12	PR interval in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.9	12.12	0.55	2.84e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.6	8.66	0.43	2.06e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg02503808	chr4:7069936	GRPEL1	1.04	14.8	0.63	1.77e-38	Monocyte percentage of white cells;
LUSC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg05729581	chr11:3078854	CARS	-0.54	-8.34	-0.42	1.97e-15	Longevity;
LUSC	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.72	-0.35	7.72e-11	Response to antipsychotic treatment;
LUSC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08677398	chr8:58056175	NA	0.5	5.85	0.3	1.17e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1185460	0.967	rs11217133	chr11:118928249	G/A	cg23280166	chr11:118938394	VPS11	0.44	6.39	0.33	5.73e-10	Coronary artery disease;
LUSC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21545522	chr1:205238299	TMCC2	0.5	9.64	0.47	1.48e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18404041	chr3:52824283	ITIH1	-0.53	-10.11	-0.48	3.79e-21	Electroencephalogram traits;
LUSC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.1	0.32	2.86e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	8.58	0.43	3.53e-16	Response to bleomycin (chromatid breaks);
LUSC	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg09455208	chr3:40491958	NA	-0.47	-8.91	-0.44	3.28e-17	Renal cell carcinoma;
LUSC	cis	rs6815814	0.861	rs7658651	chr4:38786002	A/C	cg06935464	chr4:38784597	TLR10	0.45	5.81	0.3	1.42e-8	Breast cancer;
LUSC	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg27205649	chr11:78285834	NARS2	-0.49	-5.79	-0.3	1.6e-8	Alzheimer's disease (survival time);
LUSC	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg27219399	chr15:67835830	MAP2K5	0.37	5.95	0.31	6.81e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg13072238	chr3:49761600	GMPPB	0.68	8.75	0.43	1.04e-16	Menarche (age at onset);
LUSC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg23262073	chr20:60523788	NA	-0.4	-5.93	-0.31	7.71e-9	Body mass index;
LUSC	cis	rs4654899	0.965	rs4654898	chr1:21376383	T/C	cg01072550	chr1:21505969	NA	-0.53	-8.04	-0.4	1.55e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg16230307	chr14:35515116	FAM177A1	0.77	10.07	0.48	5.28e-21	Psoriasis;
LUSC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg05313129	chr8:58192883	C8orf71	-0.51	-6.64	-0.34	1.26e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1256061	0.654	rs1256031	chr14:64746179	C/T	cg21174375	chr14:64681225	SYNE2	0.34	6.27	0.32	1.09e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs710216	0.752	rs841845	chr1:43404713	C/T	cg03128534	chr1:43423976	SLC2A1	-0.46	-5.92	-0.31	8.03e-9	Red cell distribution width;
LUSC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg23649088	chr2:200775458	C2orf69	0.55	7.42	0.38	9.66e-13	Schizophrenia;
LUSC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.27	0.37	2.54e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg27535305	chr1:53392650	SCP2	-0.48	-9.47	-0.46	5.31e-19	Monocyte count;
LUSC	trans	rs3932549	1	rs3932549	chr9:97073588	A/C	cg05679027	chr9:99775184	HIATL2	0.43	6.0	0.31	5.25e-9	Body mass index;
LUSC	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.86	-0.31	1.08e-8	Resting heart rate;
LUSC	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg23711669	chr6:146136114	FBXO30	-0.83	-14.84	-0.63	1.25e-38	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs979233	0.502	rs276259	chr5:42066323	C/T	cg07010552	chr17:7358735	CHRNB1	-0.41	-6.02	-0.31	4.72e-9	Systemic lupus erythematosus;
LUSC	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg01171360	chr6:293285	DUSP22	0.48	7.3	0.37	2.17e-12	Menopause (age at onset);
LUSC	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.32	-0.41	2.27e-15	Retinal vascular caliber;
LUSC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	7.75	0.39	1.11e-13	Prudent dietary pattern;
LUSC	cis	rs722599	0.683	rs10139016	chr14:75274288	T/C	cg08847533	chr14:75593920	NEK9	0.45	6.33	0.33	7.74e-10	IgG glycosylation;
LUSC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg10057126	chr4:77819792	ANKRD56	0.53	7.88	0.4	4.75e-14	Emphysema distribution in smoking;
LUSC	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.51	8.7	0.43	1.49e-16	Bone mineral density;
LUSC	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg00310523	chr12:86230176	RASSF9	0.44	7.75	0.39	1.12e-13	Major depressive disorder;
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg18538332	chr22:24372958	LOC391322	-0.47	-8.25	-0.41	3.64e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg00310523	chr12:86230176	RASSF9	-0.36	-6.5	-0.33	2.98e-10	Major depressive disorder;
LUSC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.31	0.37	1.96e-12	Motion sickness;
LUSC	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg11019008	chr10:131425282	MGMT	0.41	6.28	0.32	1.08e-9	Response to temozolomide;
LUSC	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg22906224	chr7:99728672	NA	-0.47	-6.52	-0.34	2.56e-10	Coronary artery disease;
LUSC	cis	rs4953318	0.619	rs13406773	chr2:46362868	T/C	cg12428440	chr2:46370979	PRKCE	0.46	7.74	0.39	1.18e-13	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06873352	chr17:61820015	STRADA	0.57	8.78	0.43	8.9e-17	Height;
LUSC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg23625390	chr15:77176239	SCAPER	0.46	7.05	0.36	1.05e-11	Blood metabolite levels;
LUSC	cis	rs10822145	1	rs10822145	chr10:64934548	C/T	cg01631684	chr10:65280961	REEP3	-0.4	-6.27	-0.32	1.1e-9	Triglycerides;
LUSC	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg20476159	chr18:77451067	CTDP1	-0.31	-5.76	-0.3	1.95e-8	Monocyte count;
LUSC	cis	rs427941	0.703	rs201453	chr7:101739788	T/C	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	trans	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg17712092	chr4:129076599	LARP1B	-0.73	-10.31	-0.49	7.87e-22	Breast cancer;
LUSC	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg15556689	chr8:8085844	FLJ10661	0.58	8.79	0.43	7.75e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-7.47	-0.38	7.11e-13	Atrioventricular conduction;
LUSC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.91	-0.51	6.33e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.5	0.46	4.24e-19	Mean corpuscular volume;
LUSC	cis	rs10905065	0.735	rs10795347	chr10:5742077	C/G	cg11519256	chr10:5708881	ASB13	-0.45	-6.56	-0.34	2.07e-10	Menopause (age at onset);
LUSC	cis	rs1983170	0.808	rs10874788	chr1:92017941	C/T	cg25838465	chr1:92012736	NA	0.41	5.8	0.3	1.57e-8	Eosinophil percentage of white cells;
LUSC	cis	rs612683	0.694	rs6688166	chr1:101000717	G/C	cg09408571	chr1:101003634	GPR88	0.32	5.95	0.31	6.87e-9	Breast cancer;
LUSC	cis	rs10979	0.557	rs9376767	chr6:143909380	G/A	cg25407410	chr6:143891975	LOC285740	-0.65	-8.11	-0.41	9.93e-15	Hypospadias;
LUSC	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg14458575	chr2:238380390	NA	0.61	10.83	0.51	1.22e-23	Prostate cancer;
LUSC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg03146154	chr1:46216737	IPP	0.56	8.36	0.42	1.75e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg24692254	chr21:30365293	RNF160	0.68	10.73	0.51	2.77e-23	Pancreatic cancer;
LUSC	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg17764715	chr19:33622953	WDR88	0.6	8.29	0.41	2.72e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg04944784	chr2:26401820	FAM59B	0.78	11.34	0.53	1.94e-25	Gut microbiome composition (summer);
LUSC	cis	rs9815354	0.680	rs61646756	chr3:42029352	A/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs977987	0.806	rs72787160	chr16:75445162	G/C	cg04384234	chr16:75411784	CFDP1	-0.41	-6.63	-0.34	1.3100000000000001e-10	Dupuytren's disease;
LUSC	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.74	-0.35	7.16e-11	Blood metabolite levels;
LUSC	cis	rs62400317	0.859	rs62438864	chr6:45041787	G/A	cg20913747	chr6:44695427	NA	-0.46	-7.43	-0.38	9.41e-13	Total body bone mineral density;
LUSC	trans	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07923666	chr12:49932857	KCNH3	-0.52	-6.4	-0.33	5.15e-10	Resting heart rate;
LUSC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg00074818	chr8:8560427	CLDN23	-0.51	-8.75	-0.43	1.07e-16	Obesity-related traits;
LUSC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg09877947	chr5:131593287	PDLIM4	0.51	7.88	0.4	4.63e-14	Acylcarnitine levels;
LUSC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg23719950	chr11:63933701	MACROD1	0.41	6.36	0.33	6.75e-10	Platelet count;
LUSC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg06784218	chr1:46089804	CCDC17	0.48	9.33	0.45	1.47e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	8.96	0.44	2.3e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04004882	chr2:215674386	BARD1	0.49	6.38	0.33	5.93e-10	Neuroblastoma;
LUSC	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg05925327	chr15:68127851	NA	-0.41	-6.62	-0.34	1.46e-10	Restless legs syndrome;
LUSC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	7.67	0.39	1.86e-13	Parkinson's disease;
LUSC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.6	-9.9	-0.48	2e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg17385448	chr1:15911702	AGMAT	0.37	6.15	0.32	2.19e-9	Systolic blood pressure;
LUSC	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg04733989	chr22:42467013	NAGA	0.49	6.66	0.34	1.12e-10	Schizophrenia;
LUSC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg09455208	chr3:40491958	NA	0.58	9.77	0.47	5.57e-20	Renal cell carcinoma;
LUSC	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg00310523	chr12:86230176	RASSF9	0.4	7.33	0.37	1.8e-12	Major depressive disorder;
LUSC	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.53	-10.53	-0.5	1.36e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg15423357	chr2:25149977	NA	-0.37	-7.35	-0.37	1.55e-12	Body mass index in non-asthmatics;
LUSC	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg00677455	chr12:58241039	CTDSP2	0.59	8.39	0.42	1.35e-15	Multiple sclerosis;
LUSC	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12292205	chr6:26970375	C6orf41	-0.58	-7.39	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7818345	0.967	rs4617172	chr8:19273362	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.4	7.63	0.39	2.52e-13	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg22875332	chr1:76189707	ACADM	-0.42	-6.24	-0.32	1.35e-9	Daytime sleep phenotypes;
LUSC	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00631329	chr6:26305371	NA	-0.45	-8.86	-0.44	4.68e-17	Educational attainment;
LUSC	cis	rs12474201	0.894	rs34401107	chr2:46972768	A/C	cg06386533	chr2:46925753	SOCS5	0.72	10.74	0.51	2.66e-23	Height;
LUSC	trans	rs7939886	0.920	rs11227158	chr11:55843795	A/G	cg03929089	chr4:120376271	NA	0.73	6.06	0.31	3.74e-9	Myopia (pathological);
LUSC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	0.92	17.56	0.69	2.35e-49	Heart rate;
LUSC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.14e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.68	11.57	0.53	2.84e-26	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg25214090	chr10:38739885	LOC399744	0.53	7.72	0.39	1.33e-13	Corneal astigmatism;
LUSC	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg06096015	chr1:231504339	EGLN1	0.56	9.88	0.48	2.27e-20	Hemoglobin concentration;
LUSC	cis	rs1550582	0.548	rs7828645	chr8:135497385	A/G	cg17885191	chr8:135476712	NA	-0.91	-14.09	-0.61	1.07e-35	Educational attainment;
LUSC	cis	rs10779751	1.000	rs4845858	chr1:11304720	C/T	cg08854313	chr1:11322531	MTOR	0.9	16.01	0.66	3.38e-43	Body mass index;
LUSC	cis	rs10779751	0.690	rs2791659	chr1:11126569	C/A	cg04508216	chr1:11107452	MASP2	0.33	5.87	0.31	1.03e-8	Body mass index;
LUSC	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-10.02	-0.48	7.54e-21	Total cholesterol levels;
LUSC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg07424592	chr7:64974309	NA	0.69	6.18	0.32	1.88e-9	Diabetic kidney disease;
LUSC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.8	-0.35	4.76e-11	Schizophrenia;
LUSC	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08045932	chr20:61659980	NA	0.55	9.23	0.45	3.17e-18	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04198698	chr15:62515913	NA	0.34	6.43	0.33	4.48e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs12681287	0.547	rs35871312	chr8:87543219	T/C	cg27223183	chr8:87520930	FAM82B	0.53	6.99	0.36	1.54e-11	Caudate activity during reward;
LUSC	cis	rs965469	1.000	rs6037590	chr20:3374085	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-5.76	-0.3	1.93e-8	IFN-related cytopenia;
LUSC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg10792982	chr14:105748885	BRF1	0.48	8.77	0.43	9.27e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs13082711	0.595	rs17317435	chr3:27339326	A/G	cg02860705	chr3:27208620	NA	0.75	11.94	0.55	1.31e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	trans	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg14343924	chr8:8086146	FLJ10661	-0.45	-6.23	-0.32	1.43e-9	Monocyte count;
LUSC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg14061069	chr19:46274453	DMPK	0.68	14.06	0.61	1.34e-35	Coronary artery disease;
LUSC	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg18404041	chr3:52824283	ITIH1	0.39	6.73	0.35	7.52e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11209002	0.524	rs2815386	chr1:67541996	A/G	cg02640540	chr1:67518911	SLC35D1	0.62	8.53	0.42	5.27e-16	Crohn's disease;
LUSC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg24060327	chr5:131705240	SLC22A5	-0.47	-8.21	-0.41	4.91e-15	Blood metabolite levels;
LUSC	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg09034736	chr1:150693464	HORMAD1	-0.43	-5.84	-0.3	1.24e-8	Urate levels;
LUSC	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg21051086	chr3:73046214	PPP4R2	-0.52	-7.96	-0.4	2.63e-14	Pancreatic cancer;
LUSC	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg06191203	chr2:152266755	RIF1	-0.55	-7.29	-0.37	2.21e-12	Lung cancer;
LUSC	trans	rs11782517	0.883	rs13258235	chr8:10106503	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.05	-0.31	3.99e-9	Nose size;
LUSC	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg27284194	chr4:1044797	NA	0.45	7.34	0.37	1.67e-12	Recombination rate (males);
LUSC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	0.96	9.14	0.45	6.02e-18	Plasma clusterin levels;
LUSC	cis	rs9650315	0.530	rs7830138	chr8:57084125	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.54	8.36	0.42	1.72e-15	Height;
LUSC	trans	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg13010199	chr12:38710504	ALG10B	0.51	7.0	0.36	1.4e-11	Resting heart rate;
LUSC	cis	rs4363385	0.747	rs6665575	chr1:152960506	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.49	-0.38	6.08e-13	Inflammatory skin disease;
LUSC	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg19812747	chr11:111475976	SIK2	-0.49	-6.99	-0.36	1.51e-11	Primary sclerosing cholangitis;
LUSC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.35	-0.42	1.79e-15	Height;
LUSC	cis	rs10892173	0.765	rs7125694	chr11:117670657	C/T	cg21640587	chr11:117668038	DSCAML1	0.35	5.72	0.3	2.35e-8	Myopia;
LUSC	cis	rs11716531	0.512	rs7612312	chr3:27230230	C/A	cg02860705	chr3:27208620	NA	0.43	7.82	0.39	6.87e-14	Diastolic blood pressure;
LUSC	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	0.71	11.19	0.52	6.77e-25	Blood metabolite ratios;
LUSC	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg00750074	chr16:89608354	SPG7	-0.46	-7.0	-0.36	1.41e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg27094323	chr7:1216898	NA	-0.42	-7.08	-0.36	8.7e-12	Longevity;Endometriosis;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg01628140	chr12:102590990	C12orf48;PMCH	-0.4	-6.15	-0.32	2.24e-9	Calcium levels;
LUSC	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.74	-12.51	-0.56	9.93e-30	White blood cell count (basophil);
LUSC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg21724239	chr8:58056113	NA	0.55	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.49	6.24	0.32	1.29e-9	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg23505145	chr19:12996616	KLF1	0.64	10.87	0.51	8.87e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18252515	chr7:66147081	NA	-0.57	-7.85	-0.39	5.71e-14	Corneal structure;
LUSC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.26	0.56	8.73e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg02079420	chr8:82753780	SNX16	0.42	7.19	0.37	4.24e-12	Diastolic blood pressure;
LUSC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg11843238	chr5:131593191	PDLIM4	0.5	9.01	0.44	1.63e-17	Acylcarnitine levels;
LUSC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg06096015	chr1:231504339	EGLN1	0.57	10.12	0.48	3.69e-21	Hemoglobin concentration;
LUSC	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg24690094	chr11:67383802	NA	0.42	8.24	0.41	4.1e-15	Mean corpuscular volume;
LUSC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg13319975	chr6:146136371	FBXO30	-0.42	-6.26	-0.32	1.16e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07167872	chr1:205819463	PM20D1	0.84	15.52	0.65	2.81e-41	Menarche (age at onset);
LUSC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg22903657	chr4:1355424	KIAA1530	-0.35	-5.78	-0.3	1.68e-8	Obesity-related traits;
LUSC	cis	rs12776158	1.000	rs34618077	chr10:71216134	T/C	cg12610070	chr10:71211762	TSPAN15	-0.46	-6.05	-0.31	3.9e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06634786	chr22:41940651	POLR3H	-0.46	-5.9	-0.31	8.9e-9	Vitiligo;
LUSC	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.32	-5.78	-0.3	1.7e-8	Social autistic-like traits;
LUSC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.89	0.35	2.77e-11	Menarche (age at onset);
LUSC	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg00290607	chr11:67383545	NA	0.36	6.7	0.34	9.12e-11	Mean corpuscular volume;
LUSC	cis	rs911119	1.000	rs911119	chr20:23612737	C/T	cg16589663	chr20:23618590	CST3	-0.53	-6.4	-0.33	5.13e-10	Chronic kidney disease;
LUSC	cis	rs4851254	0.920	rs4850920	chr2:100757308	C/A	cg07810366	chr2:100720526	AFF3	-0.36	-5.66	-0.3	3.19e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.44	-5.97	-0.31	5.99e-9	Renal function-related traits (BUN);
LUSC	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg22532475	chr10:104410764	TRIM8	0.26	6.27	0.32	1.15e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs34779708	0.702	rs4244995	chr10:35547175	A/G	cg03585969	chr10:35415529	CREM	0.53	7.38	0.37	1.3e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs13401104	0.796	rs12464503	chr2:237113007	C/T	cg19324714	chr2:237145437	ASB18	0.43	5.79	0.3	1.67e-8	Educational attainment;
LUSC	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	9.61	0.47	1.89e-19	Response to bleomycin (chromatid breaks);
LUSC	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg18240062	chr17:79603768	NPLOC4	0.58	10.09	0.48	4.35e-21	Eye color traits;
LUSC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg09455208	chr3:40491958	NA	0.52	9.54	0.46	3.11e-19	Renal cell carcinoma;
LUSC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.57	10.8	0.51	1.61e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg05294307	chr14:35346193	BAZ1A	-0.56	-6.62	-0.34	1.39e-10	Psoriasis;
LUSC	cis	rs1395	0.778	rs2580761	chr2:27426362	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.27	0.37	2.64e-12	Blood metabolite levels;
LUSC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg23711669	chr6:146136114	FBXO30	0.82	14.02	0.61	2e-35	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-1.18	-17.99	-0.7	4.68e-51	Blood pressure (smoking interaction);
LUSC	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg06917634	chr15:78832804	PSMA4	0.74	12.35	0.56	4.13e-29	Sudden cardiac arrest;
LUSC	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.44	8.21	0.41	5e-15	Breast cancer;
LUSC	cis	rs6076065	0.723	rs761726	chr20:23401481	G/C	cg11657817	chr20:23433608	CST11	0.41	7.38	0.37	1.29e-12	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.67	-0.39	1.9e-13	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.95	-16.18	-0.66	6.84e-44	Coronary artery disease;
LUSC	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg01191920	chr7:158217561	PTPRN2	0.42	8.39	0.42	1.41e-15	Obesity-related traits;
LUSC	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.66	-9.63	-0.47	1.61e-19	Corneal astigmatism;
LUSC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.62	8.02	0.4	1.82e-14	Schizophrenia;
LUSC	cis	rs6484504	0.576	rs2150213	chr11:31244634	A/G	cg14844989	chr11:31128820	NA	-0.37	-5.86	-0.31	1.13e-8	Red blood cell count;
LUSC	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.76	-0.35	5.99e-11	Uric acid levels;
LUSC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg16447950	chr5:562315	NA	-0.57	-6.95	-0.36	1.97e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-6.66	-0.34	1.13e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	0.58	9.73	0.47	7.14e-20	Breast cancer;
LUSC	cis	rs859767	0.741	rs883964	chr2:135436200	G/C	cg12500956	chr2:135428796	TMEM163	-0.29	-6.47	-0.33	3.55e-10	Neuroticism;
LUSC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18099408	chr3:52552593	STAB1	-0.4	-6.79	-0.35	5.01e-11	Bipolar disorder;
LUSC	cis	rs9341808	0.754	rs1015158	chr6:80945745	C/T	cg08355045	chr6:80787529	NA	0.56	9.62	0.47	1.7e-19	Sitting height ratio;
LUSC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg09085632	chr11:111637200	PPP2R1B	0.52	7.43	0.38	9.4e-13	Primary sclerosing cholangitis;
LUSC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	16.51	0.67	3.47e-45	Gut microbiome composition (summer);
LUSC	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg20283391	chr11:68216788	NA	-0.61	-8.53	-0.42	5e-16	Total body bone mineral density;
LUSC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	10.78	0.51	1.84e-23	Hip circumference adjusted for BMI;
LUSC	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg26647111	chr11:31128758	NA	-0.42	-6.05	-0.31	3.81e-9	Red blood cell count;
LUSC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg13114125	chr14:105738426	BRF1	-0.92	-15.57	-0.65	1.81e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg23791538	chr6:167370224	RNASET2	0.42	6.82	0.35	4.24e-11	Crohn's disease;
LUSC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg12143784	chr7:64541923	NA	-0.38	-6.02	-0.31	4.68e-9	Calcium levels;
LUSC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.54	0.46	3.18e-19	Mean platelet volume;
LUSC	trans	rs9944715	0.954	rs8098751	chr18:43850587	G/A	cg01718231	chr17:29326311	RNF135	-0.5	-7.07	-0.36	9.02e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15505349	chr1:246670199	SMYD3	0.51	6.9	0.35	2.63e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg13010199	chr12:38710504	ALG10B	0.7	10.74	0.51	2.64e-23	Bladder cancer;
LUSC	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-10.84	-0.51	1.16e-23	Coffee consumption (cups per day);
LUSC	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.66	0.57	2.87e-30	Bipolar disorder;
LUSC	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg02269571	chr22:50332266	NA	-0.64	-9.46	-0.46	5.77e-19	Schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06459454	chr8:146033798	ZNF517	-0.79	-6.5	-0.34	2.87e-10	Cognitive performance;
LUSC	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg13798780	chr7:105162888	PUS7	0.53	5.96	0.31	6.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-10.02	-0.48	7.58e-21	Gut microbiome composition (summer);
LUSC	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.63	6.79	0.35	5e-11	Schizophrenia;
LUSC	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-6.62	-0.34	1.41e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11608355	0.515	rs1045582	chr12:109915727	G/T	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-8.71	-0.43	1.43e-16	Bipolar disorder;
LUSC	cis	rs2857891	0.817	rs2857903	chr11:6979378	G/A	cg14883916	chr11:6947541	ZNF215	0.45	5.79	0.3	1.59e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs17401966	0.540	rs10864452	chr1:10395683	G/T	cg19773385	chr1:10388646	KIF1B	-0.39	-6.82	-0.35	4.2e-11	Hepatocellular carcinoma;
LUSC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6542838	0.641	rs12467189	chr2:99495820	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.39	-0.33	5.73e-10	Fear of minor pain;
LUSC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-1.03	-20.07	-0.74	2.43e-59	Height;
LUSC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg13126279	chr21:47581558	C21orf56	-0.42	-6.17	-0.32	1.93e-9	Testicular germ cell tumor;
LUSC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg21573476	chr21:45109991	RRP1B	-0.42	-6.82	-0.35	4.16e-11	Mean corpuscular volume;
LUSC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg15145296	chr3:125709740	NA	-0.57	-6.36	-0.33	6.67e-10	Blood pressure (smoking interaction);
LUSC	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.45	0.33	4.01e-10	Corneal astigmatism;
LUSC	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	8.38	0.42	1.49e-15	Response to bleomycin (chromatid breaks);
LUSC	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	1.18	13.92	0.61	4.83e-35	Arsenic metabolism;
LUSC	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg24675056	chr1:15929824	NA	0.45	7.76	0.39	1.02e-13	Systolic blood pressure;
LUSC	cis	rs1322512	0.713	rs1631244	chr6:152939865	C/T	cg27316956	chr6:152958899	SYNE1	-0.35	-5.8	-0.3	1.58e-8	Tonometry;
LUSC	trans	rs62458065	0.713	rs3801329	chr7:32496956	A/C	cg00845942	chr12:64062724	DPY19L2	-0.55	-6.59	-0.34	1.74e-10	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-9.13	-0.45	6.72e-18	Gut microbiome composition (summer);
LUSC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.36e-10	Menopause (age at onset);
LUSC	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.8	-0.73	2.78e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg25019033	chr10:957182	NA	-0.53	-6.74	-0.35	6.97e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs6120849	0.707	rs3746444	chr20:33578251	A/G	cg24642439	chr20:33292090	TP53INP2	0.62	6.81	0.35	4.68e-11	Protein C levels;
LUSC	cis	rs6494488	0.500	rs72742966	chr15:64919179	G/A	cg08069370	chr15:64387884	SNX1	-0.65	-5.78	-0.3	1.75e-8	Coronary artery disease;
LUSC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.03	0.55	6.17e-28	Cognitive test performance;
LUSC	cis	rs6714710	0.603	rs55776387	chr2:98405034	T/C	cg26665480	chr2:98280029	ACTR1B	0.6	8.75	0.43	1.06e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg08755490	chr11:65554678	OVOL1	-0.4	-5.76	-0.3	1.9e-8	Acne (severe);
LUSC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg16447950	chr5:562315	NA	-0.51	-6.51	-0.34	2.71e-10	Obesity-related traits;
LUSC	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg09092052	chr15:45571596	NA	0.46	6.56	0.34	2.1e-10	Glomerular filtration rate;
LUSC	cis	rs80282103	0.764	rs12247779	chr10:1107957	T/G	cg18964960	chr10:1102726	WDR37	0.69	6.33	0.33	8e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.58	8.71	0.43	1.48e-16	Blood protein levels;
LUSC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg05941027	chr17:61774174	LIMD2	0.22	5.8	0.3	1.56e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg02423579	chr7:2872169	GNA12	-0.43	-6.26	-0.32	1.21e-9	Height;
LUSC	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.81	12.23	0.56	1.17e-28	Eosinophil percentage of white cells;
LUSC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg01181863	chr3:195395398	SDHAP2	0.6	8.1	0.41	1.02e-14	Pancreatic cancer;
LUSC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.93	0.31	7.71e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs113352275	1	rs113352275	chr15:78840567	C/T	cg24631222	chr15:78858424	CHRNA5	0.87	11.71	0.54	9.44e-27	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg05855489	chr10:104503620	C10orf26	0.59	9.39	0.46	9.82e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg27165867	chr14:105738592	BRF1	-0.52	-7.54	-0.38	4.4e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg22963979	chr7:1858916	MAD1L1	-0.7	-11.43	-0.53	8.94e-26	Bipolar disorder and schizophrenia;
LUSC	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.12	0.45	7.4e-18	Red blood cell count;
LUSC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.29	6.17	0.32	2e-9	Electroencephalogram traits;
LUSC	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg20608306	chr11:116969690	SIK3	0.36	6.75	0.35	6.56e-11	Blood protein levels;
LUSC	cis	rs4478037	1.000	rs58864038	chr3:33161355	G/A	cg19404215	chr3:33155277	CRTAP	0.96	9.76	0.47	5.72e-20	Major depressive disorder;
LUSC	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg20991723	chr1:152506922	NA	0.51	9.74	0.47	6.76e-20	Hair morphology;
LUSC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	11.91	0.55	1.72e-27	Mean corpuscular hemoglobin;
LUSC	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs4843185	0.669	rs889502	chr16:85716832	A/G	cg05245094	chr16:85669572	KIAA0182	0.43	6.2	0.32	1.64e-9	Platelet distribution width;
LUSC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.59	9.16	0.45	5.33e-18	Mood instability;
LUSC	cis	rs9487051	0.768	rs1269172	chr6:109522080	G/C	cg00509249	chr6:109615579	CCDC162	-0.33	-5.79	-0.3	1.66e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs17001868	0.568	rs9607699	chr22:40737036	G/A	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg06784218	chr1:46089804	CCDC17	-0.3	-5.89	-0.31	9.63e-9	Red blood cell count;Reticulocyte count;
LUSC	trans	rs2018683	0.707	rs10279870	chr7:28968935	A/G	cg19402173	chr7:128379420	CALU	-0.45	-6.87	-0.35	3.06e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg24562669	chr7:97807699	LMTK2	0.35	6.27	0.32	1.13e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.76	-0.35	6.16e-11	Morning vs. evening chronotype;
LUSC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg11663144	chr21:46675770	NA	-0.42	-7.34	-0.37	1.59e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.35	0.42	1.88e-15	Hemoglobin concentration;
LUSC	cis	rs791888	1.000	rs791888	chr10:89412575	G/T	cg13926569	chr10:89418898	PAPSS2	-0.3	-5.7	-0.3	2.6e-8	Magnesium levels;
LUSC	cis	rs2625529	0.526	rs10851850	chr15:72486509	A/G	cg16672083	chr15:72433130	SENP8	0.47	7.72	0.39	1.34e-13	Red blood cell count;
LUSC	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg02807482	chr3:125708958	NA	-0.49	-5.73	-0.3	2.21e-8	Blood pressure (smoking interaction);
LUSC	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg25801113	chr15:45476975	SHF	-0.33	-6.44	-0.33	4.06e-10	Uric acid levels;
LUSC	cis	rs6088813	1.000	rs2425066	chr20:33927006	A/C	cg14752227	chr20:34000481	UQCC	0.36	5.65	0.3	3.4e-8	Height;
LUSC	cis	rs12681287	0.640	rs13264364	chr8:87466385	G/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs12210905	0.925	rs12192502	chr6:26995720	A/C	cg23155468	chr6:27110703	HIST1H2BK	0.6	5.74	0.3	2.1e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs983392	0.679	rs4938932	chr11:60033448	C/T	cg02771260	chr11:59836817	MS4A3	0.37	6.08	0.32	3.31e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	12.6	0.57	4.77e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs988712	0.705	rs4923460	chr11:27656789	A/C	cg10635145	chr11:27742435	BDNF	0.45	6.07	0.32	3.5e-9	Obesity;
LUSC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.76	-0.35	6.22e-11	Lung cancer;
LUSC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.59	9.61	0.47	1.82e-19	Aortic root size;
LUSC	cis	rs308403	0.568	rs13135778	chr4:123664446	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.79	10.18	0.49	2.16e-21	Blood protein levels;
LUSC	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg11130432	chr3:121712080	ILDR1	0.71	11.85	0.54	2.72e-27	Multiple sclerosis;
LUSC	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg22852734	chr6:133119734	C6orf192	1.28	10.95	0.51	4.58e-24	Type 2 diabetes nephropathy;
LUSC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.72	0.43	1.34e-16	Prudent dietary pattern;
LUSC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs72949976	1.000	rs62186568	chr2:214033955	G/A	cg08319019	chr2:214017104	IKZF2	-0.61	-9.37	-0.46	1.15e-18	Lung cancer;Squamous cell lung carcinoma;
LUSC	trans	rs3960554	0.569	rs11973658	chr7:75882026	A/C	cg19862616	chr7:65841803	NCRNA00174	0.65	8.14	0.41	7.96e-15	Eotaxin levels;
LUSC	cis	rs988712	0.622	rs4922793	chr11:27729505	A/G	cg10635145	chr11:27742435	BDNF	-0.48	-6.46	-0.33	3.66e-10	Obesity;
LUSC	trans	rs1864729	0.892	rs1821134	chr8:98266824	C/T	cg08679828	chr8:102218111	ZNF706	0.79	7.12	0.36	6.56e-12	Estradiol plasma levels (breast cancer);
LUSC	cis	rs12986413	1.000	rs12983458	chr19:2168612	A/G	cg09261902	chr19:2140048	AP3D1	0.31	5.93	0.31	7.51e-9	Height;
LUSC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08109568	chr15:31115862	NA	-0.74	-11.03	-0.52	2.51e-24	Huntington's disease progression;
LUSC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.32	-0.33	8.19e-10	Lung cancer;
LUSC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	10.18	0.49	2.24e-21	Hip circumference adjusted for BMI;
LUSC	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.67	-11.16	-0.52	8.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.24	0.52	4.29e-25	Eye color traits;
LUSC	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg01849466	chr14:104193079	ZFYVE21	0.53	8.12	0.41	8.99e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2708377	0.799	rs7296270	chr12:11311590	A/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs7216064	0.911	rs6504551	chr17:65903326	T/G	cg12091567	chr17:66097778	LOC651250	-0.64	-9.14	-0.45	6.26e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs10892173	0.765	rs7125693	chr11:117670651	C/T	cg21640587	chr11:117668038	DSCAML1	0.35	5.72	0.3	2.35e-8	Myopia;
LUSC	cis	rs4363385	0.617	rs5010885	chr1:152973141	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.67	-0.3	3.09e-8	Inflammatory skin disease;
LUSC	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg05855489	chr10:104503620	C10orf26	0.59	9.5	0.46	4.35e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg24558204	chr6:135376177	HBS1L	0.68	10.65	0.5	5.53e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs3764021	0.933	rs10492165	chr12:9885961	A/G	cg20894963	chr12:9885564	CLECL1	0.35	7.05	0.36	1.06e-11	Type 1 diabetes;
LUSC	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg27102117	chr16:15229624	NA	0.49	7.55	0.38	4.18e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs10511400	0.867	rs6438569	chr3:119953272	C/T	cg02809009	chr19:50354510	PTOV1	-0.69	-6.04	-0.31	4.15e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs4629710	0.645	rs34601891	chr6:131551238	C/T	cg12700074	chr6:131571435	AKAP7	-0.36	-5.96	-0.31	6.33e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03517284	chr6:25882590	NA	0.35	6.14	0.32	2.35e-9	Blood metabolite levels;
LUSC	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	9.39	0.46	9.47e-19	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-6.69	-0.34	9.51e-11	Mean corpuscular volume;
LUSC	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg26395211	chr5:140044315	WDR55	0.37	5.72	0.3	2.32e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.43	-6.46	-0.33	3.73e-10	Neuroticism;
LUSC	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.31	6.17	0.32	1.96e-9	Hemoglobin concentration;
LUSC	cis	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.34	0.42	1.98e-15	Hemoglobin concentration;
LUSC	cis	rs9494145	0.667	rs1331309	chr6:135406178	T/G	cg22676075	chr6:135203613	NA	0.68	9.47	0.46	5.29e-19	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs9359856	0.510	rs78649003	chr6:90454644	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.91	-10.67	-0.5	4.44e-23	Bipolar disorder;
LUSC	cis	rs16854884	0.584	rs34372603	chr3:143738249	T/C	cg06585982	chr3:143692056	C3orf58	0.5	7.93	0.4	3.36e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.17	-0.32	1.95e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs617219	0.927	rs949644	chr5:78442351	A/G	cg24856658	chr5:78533917	JMY	-0.3	-5.7	-0.3	2.69e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.94	-0.48	1.47e-20	Mood instability;
LUSC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.43	6.42	0.33	4.69e-10	Systemic lupus erythematosus;
LUSC	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg00531865	chr16:30841666	NA	0.34	6.14	0.32	2.31e-9	Dementia with Lewy bodies;
LUSC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg13206674	chr6:150067644	NUP43	0.59	9.6	0.47	1.94e-19	Lung cancer;
LUSC	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	8.04	0.4	1.57e-14	Neuroticism;
LUSC	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-9.44	-0.46	6.56e-19	Response to antipsychotic treatment;
LUSC	cis	rs9653442	0.564	rs4851261	chr2:100786717	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-7.12	-0.36	6.51e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg08079166	chr15:68083412	MAP2K5	0.41	7.35	0.37	1.51e-12	Restless legs syndrome;
LUSC	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg07173049	chr1:7289937	CAMTA1	0.32	6.71	0.34	8.32e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs11229555	0.645	rs12802960	chr11:58174775	T/C	cg15696309	chr11:58395628	NA	-0.63	-7.8	-0.39	8.25e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs12579753	0.917	rs11612874	chr12:82212649	A/C	cg07923666	chr12:49932857	KCNH3	0.51	6.04	0.31	4.1e-9	Resting heart rate;
LUSC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	15.51	0.65	3.02e-41	Platelet count;
LUSC	cis	rs73416724	1.000	rs70953686	chr6:43269516	G/A	cg26312998	chr6:43337775	ZNF318	0.56	6.34	0.33	7.59e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.0	-0.31	5.24e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4903604	0.581	rs4903607	chr14:78038462	G/A	cg18872420	chr14:78023429	SPTLC2	0.39	6.09	0.32	3.17e-9	Gut microbiome composition (winter);
LUSC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	cis	rs5758511	0.573	rs4501042	chr22:42245763	C/T	cg03131358	chr22:42195972	CCDC134	-0.32	-5.73	-0.3	2.24e-8	Birth weight;
LUSC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg04398451	chr17:18023971	MYO15A	-0.56	-9.16	-0.45	5.29e-18	Total body bone mineral density;
LUSC	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	6.27	0.32	1.1e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs8027181	0.839	rs998021	chr15:72999825	T/C	cg25632853	chr15:73088954	NA	0.32	6.62	0.34	1.47e-10	Triglyceride levels;
LUSC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg11871910	chr12:69753446	YEATS4	-0.68	-10.48	-0.5	2.1e-22	Blood protein levels;
LUSC	cis	rs11051970	1.000	rs6488051	chr12:32532733	G/C	cg02745156	chr12:32552066	NA	0.44	7.24	0.37	3.07e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg09365446	chr1:150670422	GOLPH3L	0.46	6.93	0.35	2.16e-11	Melanoma;
LUSC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.24	-0.49	1.4e-21	Monocyte count;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.62	13.2	0.59	2.61e-32	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.5	-8.11	-0.41	9.76e-15	IgG glycosylation;
LUSC	cis	rs66679842	1	rs66679842	chr6:88171407	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-6.15	-0.32	2.2e-9	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.21	0.32	1.54e-9	Personality dimensions;
LUSC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg20243544	chr17:37824526	PNMT	0.39	5.76	0.3	1.96e-8	Self-reported allergy;
LUSC	cis	rs4664308	0.618	rs62175488	chr2:160892758	T/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-7.9	-0.4	4.1e-14	Idiopathic membranous nephropathy;
LUSC	cis	rs1957429	0.520	rs17102258	chr14:65332369	G/A	cg23373153	chr14:65346875	NA	-0.85	-7.9	-0.4	4.11e-14	Pediatric areal bone mineral density (radius);
LUSC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg27535305	chr1:53392650	SCP2	-0.4	-7.44	-0.38	8.64e-13	Monocyte count;
LUSC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	trans	rs12692738	0.526	rs355871	chr2:165632068	A/G	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.4	6.3	0.33	9.6e-10	Response to antipsychotic treatment;
LUSC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg22166914	chr1:53195759	ZYG11B	-0.5	-7.92	-0.4	3.64e-14	Monocyte count;
LUSC	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	10.03	0.48	7.03e-21	Coffee consumption (cups per day);
LUSC	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg08017756	chr2:100939284	LONRF2	-0.47	-8.65	-0.43	2.25e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs621559	0.540	rs583116	chr1:43548257	C/G	cg17613259	chr2:105484139	NA	-0.49	-6.21	-0.32	1.58e-9	Telomere length;
LUSC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.94	0.44	2.61e-17	Prudent dietary pattern;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg21548813	chr6:291882	DUSP22	-0.7	-11.71	-0.54	9.09e-27	Menopause (age at onset);
LUSC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08677398	chr8:58056175	NA	0.56	7.07	0.36	9.1e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9308433	0.529	rs867445	chr1:214502230	C/G	cg06198575	chr1:214491504	SMYD2	0.45	7.11	0.36	7.28e-12	IgG glycosylation;
LUSC	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.65	-0.39	2.24e-13	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.516	rs9376932	chr6:145729490	T/C	cg23711669	chr6:146136114	FBXO30	0.47	7.3	0.37	2.18e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-5.83	-0.3	1.33e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg04450456	chr4:17643702	FAM184B	0.37	6.21	0.32	1.53e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.66	-10.75	-0.51	2.45e-23	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-7.93	-0.4	3.26e-14	Morning vs. evening chronotype;
LUSC	cis	rs3740713	1.000	rs35593189	chr11:18468378	C/T	cg07915343	chr11:18477680	LDHAL6A	-0.56	-7.06	-0.36	9.87e-12	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs2926702	0.810	rs16936749	chr8:71046183	G/A	cg16517358	chr11:46164796	NA	0.37	5.97	0.31	6.03e-9	Non-small cell lung cancer;
LUSC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19346786	chr7:2764209	NA	-0.5	-8.56	-0.42	4.06e-16	Height;
LUSC	trans	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.25	-0.32	1.27e-9	Triglycerides;
LUSC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.59	10.66	0.5	4.93e-23	Bone mineral density;
LUSC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg23625390	chr15:77176239	SCAPER	0.46	6.85	0.35	3.54e-11	Blood metabolite levels;
LUSC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9323205	0.765	rs2999387	chr14:51652986	C/G	cg23942311	chr14:51606299	NA	-0.33	-6.85	-0.35	3.62e-11	Cancer;
LUSC	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-7.55	-0.38	4.16e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15369054	chr17:80825471	TBCD	0.7	11.95	0.55	1.16e-27	Breast cancer;
LUSC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.24	-0.8	1.33e-75	Height;
LUSC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.48	-0.42	7.37e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs4594175	0.926	rs4349056	chr14:51625819	A/G	cg23942311	chr14:51606299	NA	0.31	5.88	0.31	1.01e-8	Cancer;
LUSC	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg11846333	chr4:119757529	SEC24D	0.86	6.35	0.33	6.97e-10	Cannabis dependence symptom count;
LUSC	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg18404041	chr3:52824283	ITIH1	0.4	6.94	0.35	2.07e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg06212747	chr3:49208901	KLHDC8B	0.43	5.86	0.31	1.1e-8	Parkinson's disease;
LUSC	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg11130432	chr3:121712080	ILDR1	-0.64	-9.78	-0.47	4.84e-20	Multiple sclerosis;
LUSC	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg15704280	chr7:45808275	SEPT13	0.69	6.48	0.33	3.28e-10	Intraocular pressure;
LUSC	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg12756686	chr19:29218302	NA	0.56	6.32	0.33	8.42e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg22244940	chr12:132335942	MMP17	0.4	6.03	0.31	4.37e-9	Migraine;
LUSC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg00049323	chr5:472564	LOC25845	-0.44	-6.8	-0.35	4.79e-11	Cystic fibrosis severity;
LUSC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg16447950	chr5:562315	NA	-0.55	-7.1	-0.36	7.47e-12	Lung disease severity in cystic fibrosis;
LUSC	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg27411982	chr8:10470053	RP1L1	-0.49	-7.94	-0.4	3.08e-14	Neuroticism;
LUSC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.74	-0.3	2.1e-8	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs931812	0.825	rs35472498	chr8:101894167	G/A	cg20993868	chr7:22813445	NA	0.59	10.22	0.49	1.62e-21	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.69	0.34	9.42e-11	IgG glycosylation;
LUSC	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.94	-0.36	1.99e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.27e-27	Menopause (age at onset);
LUSC	trans	rs3857536	0.813	rs6903411	chr6:66938288	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg01881094	chr2:180872142	CWC22	0.81	10.37	0.49	4.91e-22	Schizophrenia;
LUSC	cis	rs2970818	0.731	rs11063199	chr12:4591854	C/T	cg11146114	chr12:4671731	NA	0.57	6.17	0.32	1.99e-9	Phosphorus levels;
LUSC	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00321850	chr1:175162397	KIAA0040	0.45	7.79	0.39	8.55e-14	Alcohol dependence;
LUSC	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.13e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs11605924	0.766	rs12419690	chr11:45858584	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.5	-7.38	-0.37	1.28e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg06287003	chr12:125626642	AACS	-0.43	-7.49	-0.38	6.15e-13	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2247341	1.000	rs13124276	chr4:1700368	C/T	cg07465881	chr4:1713556	SLBP	-0.37	-5.69	-0.3	2.73e-8	Hip circumference adjusted for BMI;Height;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg26921846	chr21:30671131	BACH1	-0.45	-6.22	-0.32	1.49e-9	Cognitive function;Information processing speed;
LUSC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg27121462	chr16:89883253	FANCA	0.55	8.8	0.43	7.59e-17	Vitiligo;
LUSC	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg23625390	chr15:77176239	SCAPER	-0.61	-9.7	-0.47	9.55e-20	Blood metabolite levels;
LUSC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg20283391	chr11:68216788	NA	-0.59	-8.4	-0.42	1.26e-15	Total body bone mineral density;
LUSC	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg05585544	chr11:47624801	NA	0.41	7.34	0.37	1.64e-12	Subjective well-being;
LUSC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.25	-0.37	2.89e-12	Menarche (age at onset);
LUSC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg00945038	chr17:61921165	SMARCD2	0.4	6.02	0.31	4.69e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2274273	0.600	rs10131730	chr14:55840092	C/T	cg04306507	chr14:55594613	LGALS3	0.49	9.94	0.48	1.47e-20	Protein biomarker;
LUSC	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg15212455	chr7:39170539	POU6F2	-0.51	-7.62	-0.38	2.63e-13	IgG glycosylation;
LUSC	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg21211680	chr2:198530	NA	-0.76	-8.15	-0.41	7.15e-15	Blood protein levels;
LUSC	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg13902645	chr11:5959945	NA	-0.56	-8.03	-0.4	1.7e-14	DNA methylation (variation);
LUSC	cis	rs1062746	0.528	rs12149622	chr16:87340235	A/G	cg02258303	chr16:87377426	FBXO31	-0.52	-7.84	-0.39	6.23e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg12564285	chr5:131593104	PDLIM4	-0.46	-7.86	-0.4	5.35e-14	Breast cancer;
LUSC	cis	rs7215564	0.908	rs35844609	chr17:78664850	T/C	cg09596252	chr17:78655493	RPTOR	0.53	5.78	0.3	1.71e-8	Myopia (pathological);
LUSC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.75	13.48	0.59	2.18e-33	Aortic root size;
LUSC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25072359	chr17:41440525	NA	-0.62	-9.09	-0.45	8.9e-18	Menopause (age at onset);
LUSC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg08219700	chr8:58056026	NA	0.46	5.88	0.31	1e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg12756686	chr19:29218302	NA	-0.5	-5.78	-0.3	1.74e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg03146154	chr1:46216737	IPP	-0.5	-7.52	-0.38	5.04e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg06060754	chr5:176797920	RGS14	-0.62	-8.96	-0.44	2.3e-17	Urate levels in lean individuals;
LUSC	cis	rs12210905	0.925	rs72838243	chr6:26984198	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg24375607	chr4:120327624	NA	0.73	10.64	0.5	5.66e-23	Corneal astigmatism;
LUSC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20307385	chr11:47447363	PSMC3	-0.47	-6.05	-0.31	3.8e-9	Subjective well-being;
LUSC	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg03340356	chr1:67600835	NA	0.4	6.38	0.33	5.74e-10	Psoriasis;
LUSC	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg03806693	chr22:41940476	POLR3H	-0.54	-7.37	-0.37	1.33e-12	Neuroticism;
LUSC	trans	rs13219787	0.915	rs13214703	chr6:27941387	A/G	cg12734449	chr6:30038004	PPP1R11	0.78	7.03	0.36	1.18e-11	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;
LUSC	cis	rs3772130	1.000	rs3732408	chr3:121421179	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.64	9.28	0.45	2.14e-18	Cognitive performance;
LUSC	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.68	17.6	0.69	1.6e-49	Anterior chamber depth;
LUSC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg05709478	chr1:6581295	PLEKHG5	0.56	6.92	0.35	2.28e-11	Body mass index;
LUSC	cis	rs10992471	0.603	rs7045572	chr9:95137964	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-8.08	-0.4	1.17e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs727505	0.954	rs1009450	chr7:124628723	C/G	cg23710748	chr7:124431027	NA	-0.37	-6.25	-0.32	1.27e-9	Lewy body disease;
LUSC	cis	rs1451375	0.698	rs1839740	chr7:50646280	C/T	cg18232548	chr7:50535776	DDC	0.5	7.58	0.38	3.49e-13	Malaria;
LUSC	cis	rs8114671	0.967	rs4911478	chr20:33782625	A/C	cg07148914	chr20:33460835	GGT7	-0.44	-6.55	-0.34	2.12e-10	Height;
LUSC	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg15423357	chr2:25149977	NA	0.47	9.5	0.46	4.11e-19	Body mass index in non-asthmatics;
LUSC	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	7.16	0.36	5.24e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs12618769	0.597	rs72819972	chr2:99035113	A/C	cg10123293	chr2:99228465	UNC50	0.47	7.9	0.4	3.99e-14	Bipolar disorder;
LUSC	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg09092052	chr15:45571596	NA	0.46	6.36	0.33	6.52e-10	Glomerular filtration rate;
LUSC	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg03929089	chr4:120376271	NA	0.72	6.87	0.35	3.08e-11	Axial length;
LUSC	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg05110241	chr16:68378359	PRMT7	-0.5	-6.45	-0.33	3.95e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs791888	0.929	rs791887	chr10:89411554	A/G	cg10377144	chr10:89419177	PAPSS2	-0.27	-5.92	-0.31	8.13e-9	Magnesium levels;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.66	10.01	0.48	8.59e-21	Lymphocyte counts;
LUSC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg16414030	chr3:133502952	NA	-0.43	-6.68	-0.34	1.02e-10	Iron status biomarkers;
LUSC	cis	rs698813	0.572	rs4953076	chr2:44480950	G/C	cg00619915	chr2:44497795	NA	-0.52	-7.34	-0.37	1.61e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.48	-7.46	-0.38	7.61e-13	Height;
LUSC	cis	rs372883	0.901	rs733610	chr21:30656199	G/A	cg24692254	chr21:30365293	RNF160	-0.41	-5.77	-0.3	1.76e-8	Pancreatic cancer;
LUSC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg21699342	chr2:239360505	ASB1	0.55	10.46	0.5	2.51e-22	Multiple system atrophy;
LUSC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02034447	chr16:89574710	SPG7	0.43	6.39	0.33	5.63e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs12421382	0.683	rs10789735	chr11:109431361	A/T	cg27471124	chr11:109292789	C11orf87	0.47	7.82	0.39	6.91e-14	Schizophrenia;
LUSC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg16384552	chr7:74938386	SPDYE8P	-0.61	-9.39	-0.46	9.4e-19	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg07424592	chr7:64974309	NA	-0.63	-5.7	-0.3	2.63e-8	Diabetic kidney disease;
LUSC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.86	0.44	4.97e-17	Motion sickness;
LUSC	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg27068330	chr11:65405492	SIPA1	-0.69	-9.73	-0.47	7.13e-20	Acne (severe);
LUSC	cis	rs983392	0.617	rs667897	chr11:59936979	C/T	cg20284999	chr11:59952153	MS4A6A	0.36	6.53	0.34	2.44e-10	Alzheimer's disease (late onset);
LUSC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-1.1	-22.35	-0.77	2.55e-68	Coronary artery disease;
LUSC	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg04545296	chr12:48745243	ZNF641	0.37	6.79	0.35	5e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.03	-0.44	1.39e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg06494592	chr3:125709126	NA	-0.52	-5.82	-0.3	1.35e-8	Blood pressure (smoking interaction);
LUSC	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg23649088	chr2:200775458	C2orf69	-0.54	-6.89	-0.35	2.72e-11	Schizophrenia;
LUSC	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg06191203	chr2:152266755	RIF1	-0.57	-8.05	-0.4	1.49e-14	Lung cancer;
LUSC	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.52	-0.42	5.45e-16	Hip circumference adjusted for BMI;
LUSC	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg17830980	chr10:43048298	ZNF37B	0.46	7.21	0.37	3.81e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg17718321	chr1:152188247	HRNR	-0.38	-6.81	-0.35	4.52e-11	Inflammatory skin disease;
LUSC	cis	rs7833787	0.965	rs7830045	chr8:18700282	A/C	cg17701159	chr8:18705777	PSD3	-0.37	-5.96	-0.31	6.32e-9	Obesity-related traits;
LUSC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg11344533	chr11:111475393	SIK2	-0.49	-6.89	-0.35	2.86e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00631329	chr6:26305371	NA	-0.48	-9.6	-0.47	1.98e-19	Educational attainment;
LUSC	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg26898376	chr11:64110657	CCDC88B	-0.32	-6.11	-0.32	2.82e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs2067615	0.579	rs10861657	chr12:107131314	A/G	cg15890332	chr12:107067104	RFX4	0.33	6.09	0.32	3.14e-9	Heart rate;
LUSC	cis	rs17828380	1.000	rs35612331	chr15:63494964	T/C	cg05507819	chr15:63340323	TPM1	-0.7	-5.89	-0.31	9.42e-9	Social communication problems;
LUSC	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg03465714	chr1:152285911	FLG	-0.4	-5.71	-0.3	2.53e-8	Atopic dermatitis;
LUSC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg23625390	chr15:77176239	SCAPER	0.5	7.73	0.39	1.31e-13	Blood metabolite levels;
LUSC	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg05925327	chr15:68127851	NA	-0.38	-6.01	-0.31	4.92e-9	Restless legs syndrome;
LUSC	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg24690094	chr11:67383802	NA	0.43	8.51	0.42	5.91e-16	Mean corpuscular volume;
LUSC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06481639	chr22:41940642	POLR3H	-0.53	-6.18	-0.32	1.88e-9	Vitiligo;
LUSC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg04369109	chr6:150039330	LATS1	-0.58	-8.5	-0.42	6.24e-16	Lung cancer;
LUSC	trans	rs11039798	0.920	rs61448762	chr11:48923756	G/A	cg03929089	chr4:120376271	NA	0.73	6.3	0.33	9.27e-10	Axial length;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00472393	chr6:97730957	C6orf167;MIR548H3	-0.55	-6.71	-0.34	8.17e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg02153584	chr22:29168773	CCDC117	0.6	9.05	0.44	1.17e-17	Lymphocyte counts;
LUSC	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg17462356	chr17:80056334	FASN	0.44	5.95	0.31	6.92e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs41271951	0.512	rs77306500	chr1:151080096	G/C	cg11822372	chr1:151115635	SEMA6C	-0.78	-7.18	-0.37	4.51e-12	Blood protein levels;
LUSC	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg21427119	chr20:30132790	HM13	-0.39	-5.73	-0.3	2.19e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg06627628	chr2:24431161	ITSN2	-0.78	-11.39	-0.53	1.28e-25	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg21770322	chr7:97807741	LMTK2	0.44	7.53	0.38	4.65e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg03342759	chr3:160939853	NMD3	-0.52	-7.42	-0.38	9.59e-13	Parkinson's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24951396	chr12:125473687	DHX37	0.52	7.43	0.38	8.92e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg20283391	chr11:68216788	NA	0.58	8.19	0.41	5.8e-15	Total body bone mineral density;
LUSC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg25428297	chr7:1022841	CYP2W1	0.28	5.82	0.3	1.37e-8	Longevity;Endometriosis;
LUSC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg06212747	chr3:49208901	KLHDC8B	0.44	5.93	0.31	7.49e-9	Parkinson's disease;
LUSC	cis	rs9469578	1.000	rs16869458	chr6:33714639	C/T	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	cis	rs2274273	0.624	rs72717738	chr14:55842761	C/G	cg04306507	chr14:55594613	LGALS3	0.48	9.63	0.47	1.6e-19	Protein biomarker;
LUSC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.58	-8.69	-0.43	1.61e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00166722	chr3:10149974	C3orf24	0.55	7.51	0.38	5.38e-13	Alzheimer's disease;
LUSC	cis	rs2963155	0.518	rs853177	chr5:142635460	A/G	cg17617527	chr5:142782415	NR3C1	0.7	8.24	0.41	3.96e-15	Breast cancer;
LUSC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg08270630	chr22:50330655	NA	0.55	7.1	0.36	7.49e-12	Schizophrenia;
LUSC	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg04374321	chr14:90722782	PSMC1	0.76	12.04	0.55	5.82e-28	Mortality in heart failure;
LUSC	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg19052272	chr2:3704530	ALLC	-0.35	-6.68	-0.34	1.02e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg18230493	chr5:56204884	C5orf35	-0.93	-13.72	-0.6	2.66e-34	Initial pursuit acceleration;
LUSC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg04414720	chr1:150670196	GOLPH3L	0.51	8.18	0.41	5.89e-15	Melanoma;
LUSC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg03804128	chr16:635623	NA	0.3	5.83	0.3	1.28e-8	Height;
LUSC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg20283391	chr11:68216788	NA	-0.53	-7.78	-0.39	9.29e-14	Total body bone mineral density;
LUSC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	9.03	0.44	1.4e-17	Prudent dietary pattern;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20912066	chr11:107436729	ALKBH8	0.39	6.04	0.31	4.06e-9	Triglycerides;
LUSC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg02569458	chr12:86230093	RASSF9	0.58	9.82	0.47	3.54e-20	Major depressive disorder;
LUSC	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg06238570	chr21:40685208	BRWD1	0.47	7.11	0.36	7.08e-12	Cognitive function;
LUSC	trans	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg25214090	chr10:38739885	LOC399744	0.47	6.77	0.35	5.73e-11	Corneal astigmatism;
LUSC	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.53	7.74	0.39	1.19e-13	Night sleep phenotypes;
LUSC	cis	rs36093844	0.898	rs11234457	chr11:85591041	C/T	cg25872744	chr11:85566296	CCDC83	-0.42	-6.2	-0.32	1.64e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	trans	rs1451882	0.698	rs1376786	chr8:1061074	A/G	cg25830660	chr3:197026096	DLG1	0.59	6.96	0.36	1.84e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs11214589	0.807	rs2155463	chr11:113242301	T/C	cg14159747	chr11:113255604	NA	0.26	6.48	0.33	3.21e-10	Neuroticism;
LUSC	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.49	-12.22	-0.56	1.18e-28	Urate levels in overweight individuals;
LUSC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.79	-0.57	9.28e-31	Platelet count;
LUSC	cis	rs780094	0.500	rs12995461	chr2:27778167	A/C	cg27432699	chr2:27873401	GPN1	0.4	5.65	0.3	3.43e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg00701064	chr4:6280414	WFS1	0.41	7.5	0.38	5.64e-13	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg03146154	chr1:46216737	IPP	0.51	7.66	0.39	2.08e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-10.69	-0.5	3.96e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs9644630	0.870	rs10888165	chr8:19358961	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.38	7.24	0.37	3.09e-12	Oropharynx cancer;
LUSC	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg15704280	chr7:45808275	SEPT13	0.81	7.57	0.38	3.71e-13	Axial length;
LUSC	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg24011408	chr12:48396354	COL2A1	-0.39	-5.65	-0.3	3.45e-8	Glycated hemoglobin levels;
LUSC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg07424592	chr7:64974309	NA	0.69	6.07	0.32	3.4e-9	Diabetic kidney disease;
LUSC	trans	rs2790216	0.526	rs1199093	chr10:59896794	C/G	cg04544938	chr11:76092429	PRKRIR	-0.39	-6.25	-0.32	1.25e-9	Inflammatory bowel disease;
LUSC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.73	-11.03	-0.52	2.4e-24	Menarche (age at onset);
LUSC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	14.53	0.62	2.03e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2580764	0.517	rs2972070	chr2:55301691	G/A	cg09592903	chr2:55203963	RTN4	0.45	8.87	0.44	4.58e-17	Mean platelet volume;
LUSC	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg01966878	chr4:90757139	SNCA	-0.36	-6.11	-0.32	2.77e-9	Dementia with Lewy bodies;
LUSC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg23711669	chr6:146136114	FBXO30	0.71	12.44	0.56	1.93e-29	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06307169	chr17:38296698	CASC3	0.54	8.11	0.41	9.49e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg25767906	chr1:53392781	SCP2	0.45	8.08	0.4	1.2e-14	Monocyte count;
LUSC	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-11.12	-0.52	1.16e-24	Morning vs. evening chronotype;
LUSC	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21659725	chr3:3221576	CRBN	0.57	9.0	0.44	1.7e-17	Body mass index;
LUSC	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.8	-11.68	-0.54	1.21e-26	Blood pressure (smoking interaction);
LUSC	cis	rs17685	0.925	rs1057868	chr7:75615006	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.39	-5.82	-0.3	1.35e-8	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg00677455	chr12:58241039	CTDSP2	0.7	11.11	0.52	1.29e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg26752888	chr8:11627280	NEIL2	0.52	7.27	0.37	2.57e-12	Myopia (pathological);
LUSC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.41	-5.87	-0.31	1.05e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs858239	0.601	rs73272048	chr7:23152653	C/G	cg23682824	chr7:23144976	KLHL7	0.4	5.88	0.31	9.71e-9	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg11965913	chr1:205819406	PM20D1	0.51	7.64	0.39	2.27e-13	Menarche (age at onset);
LUSC	cis	rs7188861	0.681	rs12922409	chr16:11415289	C/T	cg00044050	chr16:11439710	C16orf75	0.6	6.3	0.33	9.51e-10	HDL cholesterol;
LUSC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg09035930	chr12:129282057	SLC15A4	0.73	16.11	0.66	1.27e-43	Systemic lupus erythematosus;
LUSC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg02569458	chr12:86230093	RASSF9	-0.57	-9.75	-0.47	6.41e-20	Major depressive disorder;
LUSC	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg13010199	chr12:38710504	ALG10B	0.69	10.8	0.51	1.59e-23	Bladder cancer;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg25860314	chr4:119757220	SEC24D	0.43	6.02	0.31	4.64e-9	Mosquito bite size;
LUSC	trans	rs1493916	0.837	rs9952002	chr18:31414314	C/G	cg13755796	chr4:20253514	NA	-0.39	-6.04	-0.31	4.22e-9	Life satisfaction;
LUSC	trans	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg02030672	chr11:45687055	CHST1	-0.43	-6.62	-0.34	1.42e-10	Obesity-related traits;
LUSC	trans	rs2786098	0.656	rs12731480	chr1:197529264	T/C	cg16005942	chr6:160526640	IGF2R	0.51	6.03	0.31	4.34e-9	Asthma;
LUSC	cis	rs2073300	0.793	rs75758241	chr20:23434696	A/G	cg09953122	chr20:23471693	CST8	-0.71	-6.44	-0.33	4.11e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.52	-0.5	1.57e-22	Glomerular filtration rate;
LUSC	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05731713	chr7:157510257	PTPRN2	0.48	9.12	0.45	7.23e-18	Bipolar disorder and schizophrenia;
LUSC	trans	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg21659725	chr3:3221576	CRBN	-0.68	-7.67	-0.39	1.89e-13	Menarche (age at onset);
LUSC	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg07423050	chr13:99094983	FARP1	-0.52	-9.83	-0.47	3.38e-20	Longevity;
LUSC	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg04117972	chr1:227635322	NA	0.57	6.58	0.34	1.78e-10	Major depressive disorder;
LUSC	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg09941381	chr10:64027924	RTKN2	0.4	7.35	0.37	1.56e-12	Rheumatoid arthritis;
LUSC	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg05110241	chr16:68378359	PRMT7	-0.51	-6.12	-0.32	2.69e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg09835421	chr16:68378352	PRMT7	-0.54	-6.12	-0.32	2.56e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.71	-12.52	-0.57	9.8e-30	Obesity-related traits;
LUSC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg22532475	chr10:104410764	TRIM8	0.33	6.92	0.35	2.26e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.36	-0.46	1.25e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6460942	0.908	rs59410610	chr7:12282847	A/G	cg06484146	chr7:12443880	VWDE	-0.54	-5.82	-0.3	1.41e-8	Coronary artery disease;
LUSC	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg02016764	chr4:38805732	TLR1	-0.53	-6.01	-0.31	4.98e-9	Breast cancer;
LUSC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	12.77	0.57	1.1e-30	Cognitive test performance;
LUSC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.78	-13.72	-0.6	2.75e-34	Total body bone mineral density;
LUSC	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.83	-0.39	6.35e-14	Chronic sinus infection;
LUSC	trans	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg12856521	chr11:46389249	DGKZ	0.39	6.35	0.33	7.19e-10	Leprosy;
LUSC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	12.81	0.57	7.56e-31	Cognitive test performance;
LUSC	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg09184832	chr6:79620586	NA	-0.44	-7.24	-0.37	3.16e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg19116668	chr7:99932089	PMS2L1	-0.33	-5.67	-0.3	3.17e-8	Coronary artery disease;
LUSC	cis	rs13385	0.769	rs13353859	chr5:139620455	A/G	cg26211634	chr5:139558579	C5orf32	0.46	7.08	0.36	8.79e-12	Atrial fibrillation;
LUSC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg24503407	chr1:205819492	PM20D1	-0.4	-5.85	-0.3	1.19e-8	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg10074409	chr1:209979377	IRF6	0.33	6.63	0.34	1.36e-10	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06481639	chr22:41940642	POLR3H	-0.46	-5.67	-0.3	3.09e-8	Vitiligo;
LUSC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-7.31	-0.37	1.95e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg24130564	chr14:104152367	KLC1	0.44	6.33	0.33	8.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.96	0.55	1.14e-27	Personality dimensions;
LUSC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.47	5.81	0.3	1.45e-8	Renal function-related traits (BUN);
LUSC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-7.1	-0.36	7.4e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26975351	chr11:10315761	SBF2	-0.41	-6.28	-0.32	1.06e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1808579	0.935	rs4800488	chr18:21117571	C/A	cg14672496	chr18:21087552	C18orf8	0.37	6.28	0.33	1.05e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.44	-6.12	-0.32	2.64e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-0.85	-12.48	-0.56	1.3e-29	Migraine;Coronary artery disease;
LUSC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg13683864	chr3:40499215	RPL14	0.95	15.51	0.65	3.17e-41	Renal cell carcinoma;
LUSC	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg14690467	chr7:148917905	ZNF282	-0.25	-5.66	-0.3	3.19e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2274273	0.522	rs2251366	chr14:55518156	A/G	cg04306507	chr14:55594613	LGALS3	0.49	10.52	0.5	1.55e-22	Protein biomarker;
LUSC	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg09904177	chr6:26538194	HMGN4	-0.46	-6.58	-0.34	1.84e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.59	0.38	3.23e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg02569458	chr12:86230093	RASSF9	0.55	9.43	0.46	7.16e-19	Major depressive disorder;
LUSC	cis	rs4629710	0.592	rs749375	chr6:131553692	C/G	cg12700074	chr6:131571435	AKAP7	-0.35	-5.76	-0.3	1.91e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg05844789	chr1:228464394	OBSCN	-0.3	-5.76	-0.3	1.89e-8	Diastolic blood pressure;
LUSC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.75	-10.35	-0.49	5.93e-22	Body mass index;
LUSC	trans	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg25206134	chr2:45395956	NA	0.56	6.14	0.32	2.38e-9	Neuroticism;
LUSC	trans	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg25214090	chr10:38739885	LOC399744	0.52	7.7	0.39	1.5700000000000001e-13	Corneal astigmatism;
LUSC	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg11189052	chr15:85197271	WDR73	-0.39	-5.67	-0.3	3.16e-8	P wave terminal force;
LUSC	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg00083206	chr6:110721305	DDO	-0.43	-7.6	-0.38	2.97e-13	Platelet distribution width;
LUSC	cis	rs7582180	0.934	rs2309817	chr2:100897674	T/A	cg08017756	chr2:100939284	LONRF2	-0.34	-5.74	-0.3	2.15e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg21775007	chr8:11205619	TDH	-0.45	-6.34	-0.33	7.46e-10	Myopia (pathological);
LUSC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg20203395	chr5:56204925	C5orf35	-0.78	-10.48	-0.5	2.01e-22	Initial pursuit acceleration;
LUSC	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4285028	0.747	rs7648343	chr3:121426195	G/A	cg11130432	chr3:121712080	ILDR1	-0.59	-8.53	-0.42	5.25e-16	Multiple sclerosis;
LUSC	cis	rs1355223	0.833	rs11032804	chr11:34680598	C/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.75	-0.3	2.07e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg21775007	chr8:11205619	TDH	0.44	5.96	0.31	6.26e-9	Monocyte count;
LUSC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg10729496	chr3:10149963	C3orf24	0.54	7.1	0.36	7.41e-12	Alzheimer's disease;
LUSC	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg09003973	chr2:102972529	NA	0.55	7.15	0.36	5.37e-12	Blood protein levels;
LUSC	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg22815214	chr1:201083145	CACNA1S	0.52	8.79	0.43	8.33e-17	Permanent tooth development;
LUSC	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23544223	chr18:12777786	NA	0.59	6.27	0.32	1.15e-9	Inflammatory skin disease;
LUSC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg02772935	chr3:125709198	NA	-0.48	-5.78	-0.3	1.7e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg15556689	chr8:8085844	FLJ10661	0.68	10.85	0.51	1.06e-23	Mood instability;
LUSC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.52	10.42	0.5	3.46e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs2279817	0.863	rs28481933	chr1:18026277	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.46	6.72	0.35	7.76e-11	Neuroticism;
LUSC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.57	-9.3	-0.45	1.96e-18	Neurofibrillary tangles;
LUSC	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg05926928	chr17:57297772	GDPD1	1.26	14.89	0.63	7.86e-39	Opioid sensitivity;
LUSC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	0.97	13.55	0.6	1.23e-33	Eosinophil percentage of granulocytes;
LUSC	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg25482853	chr8:67687455	SGK3	1.19	19.12	0.72	1.43e-55	Lung disease severity in cystic fibrosis;
LUSC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08219700	chr8:58056026	NA	0.64	8.1	0.41	1.03e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg22709100	chr7:91322751	NA	0.4	5.85	0.3	1.17e-8	Breast cancer;
LUSC	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg03929089	chr4:120376271	NA	0.66	6.25	0.32	1.23e-9	Intraocular pressure;
LUSC	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg13010344	chr12:123464640	ARL6IP4	-0.48	-5.84	-0.3	1.23e-8	Platelet count;
LUSC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.74	-0.65	3.74e-42	Gut microbiome composition (summer);
LUSC	cis	rs1376877	0.519	rs13416670	chr2:204285774	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.51	6.53	0.34	2.46e-10	Subclinical atherosclerosis traits (other);
LUSC	trans	rs1325195	0.920	rs2816170	chr1:179214726	G/A	cg11624085	chr17:8464688	MYH10	0.41	6.82	0.35	4.27e-11	IgE grass sensitization;
LUSC	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg22732515	chr19:44031385	ETHE1	0.62	10.32	0.49	7.17e-22	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.69	10.47	0.5	2.2e-22	Corneal astigmatism;
LUSC	cis	rs7605827	0.930	rs6732252	chr2:15595473	T/C	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.26e-17	Educational attainment (years of education);
LUSC	cis	rs9311676	0.656	rs55692656	chr3:58383174	A/T	cg26110898	chr3:58419937	PDHB	0.39	6.32	0.33	8.19e-10	Systemic lupus erythematosus;
LUSC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.9	-0.4	4.2e-14	Height;
LUSC	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg09479241	chr17:27052676	TLCD1	0.43	5.78	0.3	1.74e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9549260	0.564	rs9549271	chr13:41295477	T/C	cg21288729	chr13:41239152	FOXO1	0.54	7.96	0.4	2.75e-14	Red blood cell count;
LUSC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg17173187	chr15:85201210	NMB	0.37	6.45	0.33	3.94e-10	Schizophrenia;
LUSC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.67	-11.73	-0.54	7.83e-27	Lung cancer;
LUSC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.37	1.18e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg10621924	chr7:39171070	POU6F2	0.44	6.82	0.35	4.26e-11	IgG glycosylation;
LUSC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg08847533	chr14:75593920	NEK9	0.86	16.21	0.66	5.23e-44	Height;
LUSC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	7.17	0.37	4.96e-12	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.65	0.43	2.26e-16	Prudent dietary pattern;
LUSC	cis	rs17828380	0.844	rs34568831	chr15:63444365	C/T	cg05507819	chr15:63340323	TPM1	-0.78	-5.91	-0.31	8.37e-9	Social communication problems;
LUSC	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	7.79	0.39	8.71e-14	Iron status biomarkers;
LUSC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18932078	chr1:2524107	MMEL1	-0.3	-6.47	-0.33	3.48e-10	Ulcerative colitis;
LUSC	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg15556689	chr8:8085844	FLJ10661	0.7	11.34	0.53	1.91e-25	Mood instability;
LUSC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg21053147	chr12:120880522	NA	0.5	6.01	0.31	4.82e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg00933542	chr6:150070202	PCMT1	0.33	6.89	0.35	2.85e-11	Lung cancer;
LUSC	cis	rs4654899	0.758	rs1609558	chr1:21525228	C/T	cg01072550	chr1:21505969	NA	0.55	8.53	0.42	5.1e-16	Superior frontal gyrus grey matter volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18767321	chr22:39096505	JOSD1	-0.49	-5.97	-0.31	6.07e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg17173187	chr15:85201210	NMB	0.51	9.44	0.46	6.57e-19	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg03599575	chr15:90893182	GABARAPL3	-0.34	-5.71	-0.3	2.48e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg20628663	chr10:43360327	NA	0.76	11.26	0.52	3.79e-25	Blood protein levels;
LUSC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg04025307	chr7:1156635	C7orf50	0.45	6.47	0.33	3.52e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs10992471	0.603	rs10820968	chr9:95106443	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-7.92	-0.4	3.56e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg11189052	chr15:85197271	WDR73	0.48	5.86	0.31	1.14e-8	Schizophrenia;
LUSC	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.57	-6.79	-0.35	5.23e-11	Neutrophil percentage of white cells;
LUSC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24110177	chr3:50126178	RBM5	0.56	9.27	0.45	2.36e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs897984	0.806	rs10782001	chr16:30942625	G/A	cg02466173	chr16:30829666	NA	0.56	11.3	0.53	2.68e-25	Dementia with Lewy bodies;
LUSC	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg23093090	chr10:104574429	C10orf26	0.33	5.78	0.3	1.75e-8	Arsenic metabolism;
LUSC	cis	rs9309473	0.519	rs2178154	chr2:73661738	C/T	cg20560298	chr2:73613845	ALMS1	0.46	7.18	0.37	4.44e-12	Metabolite levels;
LUSC	cis	rs7712401	0.715	rs401226	chr5:122347726	G/A	cg19077854	chr5:122220652	SNX24	-0.41	-8.85	-0.44	5.29e-17	Mean platelet volume;
LUSC	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg19920283	chr7:105172520	RINT1	0.6	6.23	0.32	1.38e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg02018176	chr4:1364513	KIAA1530	0.49	8.27	0.41	3.33e-15	Obesity-related traits;
LUSC	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg06627628	chr2:24431161	ITSN2	-0.77	-11.54	-0.53	3.75e-26	Asthma;
LUSC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.27	-0.32	1.11e-9	Menopause (age at onset);
LUSC	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg10523679	chr1:76189770	ACADM	-0.45	-6.55	-0.34	2.23e-10	Daytime sleep phenotypes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03397389	chr1:36397003	EIF2C3	0.47	6.86	0.35	3.38e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.62	-0.47	1.71e-19	Coronary artery disease;
LUSC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15369054	chr17:80825471	TBCD	0.38	6.4	0.33	5.19e-10	Breast cancer;
LUSC	cis	rs16937	0.662	rs10900472	chr1:205181526	A/G	cg00857998	chr1:205179979	DSTYK	0.4	5.86	0.31	1.09e-8	Schizophrenia;
LUSC	cis	rs7173743	0.756	rs12903668	chr15:79129320	A/G	cg00540400	chr15:79124168	NA	0.36	6.36	0.33	6.71e-10	Coronary artery disease;
LUSC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg14668632	chr7:2872130	GNA12	-0.48	-7.02	-0.36	1.27e-11	Height;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03289602	chr19:11708437	ZNF627	-0.44	-6.0	-0.31	5.16e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.52	0.38	4.99e-13	Obesity-related traits;
LUSC	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg04362960	chr10:104952993	NT5C2	0.45	6.65	0.34	1.17e-10	Waist circumference;Hip circumference;
LUSC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs12429206	0.520	rs75594262	chr13:51474385	T/C	cg00778807	chr1:43524347	NA	-0.36	-5.95	-0.31	6.91e-9	Prostate-specific antigen levels (conditioned on lead SNPs);
LUSC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg18350739	chr11:68623251	NA	-0.36	-6.45	-0.33	3.97e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20279784	chr6:112408575	TUBE1;C6orf225	0.65	6.04	0.31	4.16e-9	Cognitive performance;
LUSC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg05896524	chr21:47604654	C21orf56	0.42	6.2	0.32	1.69e-9	Testicular germ cell tumor;
LUSC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00149659	chr3:10157352	C3orf10	0.9	11.67	0.54	1.28e-26	Alzheimer's disease;
LUSC	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg04362960	chr10:104952993	NT5C2	0.61	9.82	0.47	3.72e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg05585544	chr11:47624801	NA	-0.41	-7.17	-0.37	4.95e-12	Subjective well-being;
LUSC	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg01765077	chr12:122356316	WDR66	0.54	7.5	0.38	5.86e-13	Mean corpuscular volume;
LUSC	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.54	10.52	0.5	1.48e-22	Monocyte percentage of white cells;
LUSC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg20701182	chr2:24300061	SF3B14	0.89	11.43	0.53	9.08e-26	Lymphocyte counts;
LUSC	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.43	0.53	9.1e-26	Eye color traits;
LUSC	trans	rs12614435	0.512	rs36113194	chr2:179490785	C/T	cg14011486	chr1:26737247	LIN28	0.48	6.65	0.34	1.19e-10	Atrial fibrillation;
LUSC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20307385	chr11:47447363	PSMC3	-0.44	-5.8	-0.3	1.5e-8	Subjective well-being;
LUSC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.75	0.43	1.09e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg03351412	chr1:154909251	PMVK	-0.42	-6.28	-0.33	1.05e-9	Prostate cancer;
LUSC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	12.81	0.57	8.15e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.29	-0.41	2.72e-15	Coronary artery disease;
LUSC	cis	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg24375607	chr4:120327624	NA	-0.47	-7.24	-0.37	3.1e-12	Diastolic blood pressure;
LUSC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03576123	chr11:487126	PTDSS2	-0.94	-10.06	-0.48	5.76e-21	Body mass index;
LUSC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg24399712	chr22:39784796	NA	0.63	11.42	0.53	9.75e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg14196790	chr5:131705035	SLC22A5	0.45	7.38	0.37	1.27e-12	Breast cancer;Mosquito bite size;
LUSC	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.72	-0.3	2.42e-8	Alzheimer's disease (survival time);
LUSC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.03	0.31	4.3e-9	Schizophrenia;
LUSC	cis	rs10754283	0.967	rs7523046	chr1:90109499	G/A	cg21401794	chr1:90099060	LRRC8C	0.64	9.65	0.47	1.33e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg19052272	chr2:3704530	ALLC	-0.36	-6.85	-0.35	3.49e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.28	-0.41	2.9e-15	Response to antipsychotic treatment;
LUSC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg07507251	chr3:52567010	NT5DC2	0.34	6.72	0.35	7.76e-11	Bipolar disorder;
LUSC	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg05855489	chr10:104503620	C10orf26	0.52	8.0	0.4	2.12e-14	Arsenic metabolism;
LUSC	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg01475377	chr6:109611718	NA	-0.44	-7.84	-0.39	6.06e-14	Reticulocyte fraction of red cells;
LUSC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg12935359	chr14:103987150	CKB	-0.51	-7.98	-0.4	2.31e-14	Body mass index;
LUSC	cis	rs6906287	0.647	rs11153734	chr6:118726220	A/G	cg21191810	chr6:118973309	C6orf204	0.33	6.06	0.31	3.77e-9	Electrocardiographic conduction measures;
LUSC	trans	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg18187862	chr3:45730750	SACM1L	0.55	7.1	0.36	7.64e-12	Primary sclerosing cholangitis;
LUSC	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.67	11.02	0.52	2.71e-24	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg07507251	chr3:52567010	NT5DC2	-0.34	-6.67	-0.34	1.04e-10	Bipolar disorder;
LUSC	cis	rs6977660	0.660	rs10269891	chr7:19816063	T/C	cg05791153	chr7:19748676	TWISTNB	0.69	7.36	0.37	1.48e-12	Thyroid stimulating hormone;
LUSC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg06640241	chr16:89574553	SPG7	0.7	11.11	0.52	1.31e-24	Multiple myeloma (IgH translocation);
LUSC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg06740227	chr12:86229804	RASSF9	0.45	7.14	0.36	5.83e-12	Major depressive disorder;
LUSC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg07777115	chr5:623756	CEP72	-0.45	-5.65	-0.3	3.48e-8	Obesity-related traits;
LUSC	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg08917208	chr2:24149416	ATAD2B	0.96	9.92	0.48	1.69e-20	Lymphocyte counts;
LUSC	cis	rs10892173	0.846	rs7943887	chr11:117670282	C/G	cg21640587	chr11:117668038	DSCAML1	0.36	5.82	0.3	1.35e-8	Myopia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22949040	chr2:204399512	RAPH1	0.43	6.28	0.32	1.05e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.39	0.59	5.01e-33	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-8.53	-0.42	5.12e-16	Body mass index;
LUSC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg01765077	chr12:122356316	WDR66	0.54	7.6	0.38	2.96e-13	Mean corpuscular volume;
LUSC	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg17173187	chr15:85201210	NMB	-0.37	-6.7	-0.34	8.96e-11	Schizophrenia;
LUSC	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg26727032	chr16:67993705	SLC12A4	-0.38	-5.76	-0.3	1.88e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.51	-10.41	-0.5	3.5e-22	Schizophrenia;
LUSC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14159672	chr1:205819179	PM20D1	-0.5	-7.58	-0.38	3.45e-13	Menarche (age at onset);
LUSC	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg08508325	chr11:3079039	CARS	0.37	8.27	0.41	3.15e-15	Calcium levels;
LUSC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg27494647	chr7:150038898	RARRES2	-0.48	-7.37	-0.37	1.34e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	7.41	0.38	1.05e-12	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07134292	chr1:51702069	RNF11	0.43	6.01	0.31	4.88e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.66	-0.34	1.11e-10	Arsenic metabolism;
LUSC	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.57	-0.34	1.94e-10	Response to antipsychotic treatment;
LUSC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	5.8	0.3	1.56e-8	Personality dimensions;
LUSC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-8.43	-0.42	1.02e-15	Alzheimer's disease;
LUSC	cis	rs10489202	1.000	rs1060041	chr1:167973976	C/T	cg24449463	chr1:168025552	DCAF6	-0.54	-6.92	-0.35	2.34e-11	Schizophrenia;
LUSC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.62	9.91	0.48	1.86e-20	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs7923609	1.000	rs10761727	chr10:64995493	C/T	cg01631684	chr10:65280961	REEP3	-0.4	-6.26	-0.32	1.19e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.61	-7.9	-0.4	4.15e-14	Body mass index (adult);
LUSC	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg25554036	chr4:6271136	WFS1	0.41	6.53	0.34	2.41e-10	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg06637938	chr14:75390232	RPS6KL1	0.53	8.61	0.43	2.95e-16	Height;
LUSC	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg08999081	chr20:33150536	PIGU	-0.38	-6.88	-0.35	3.03e-11	Coronary artery disease;
LUSC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg04352962	chr1:209979756	IRF6	0.5	6.75	0.35	6.6e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg24642439	chr20:33292090	TP53INP2	0.5	7.58	0.38	3.43e-13	Height;
LUSC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg04450456	chr4:17643702	FAM184B	0.37	6.42	0.33	4.74e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1018836	0.851	rs7007129	chr8:91629790	T/G	cg16814680	chr8:91681699	NA	-0.79	-13.33	-0.59	8.69e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10743315	0.643	rs12579951	chr12:19331186	C/T	cg02471346	chr12:19282374	PLEKHA5	0.6	6.05	0.31	3.94e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg07148914	chr20:33460835	GGT7	-0.56	-8.54	-0.42	4.68e-16	Glomerular filtration rate (creatinine);
LUSC	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg25482853	chr8:67687455	SGK3	-1.1	-15.86	-0.66	1.25e-42	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg06484146	chr7:12443880	VWDE	-0.62	-7.21	-0.37	3.69e-12	Coronary artery disease;
LUSC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg25811766	chr13:21894605	NA	0.62	9.61	0.47	1.83e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg00225070	chr15:80189496	MTHFS	0.43	6.18	0.32	1.84e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4474465	0.688	rs4944210	chr11:78282878	C/T	cg27205649	chr11:78285834	NARS2	0.56	6.79	0.35	5.06e-11	Alzheimer's disease (survival time);
LUSC	cis	rs180358	0.588	rs2542062	chr11:116680449	G/A	cg08985259	chr11:116699649	APOC3	0.3	5.93	0.31	7.39e-9	Multiple sclerosis (severity);
LUSC	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg24812749	chr6:127587940	RNF146	0.71	10.21	0.49	1.76e-21	Breast cancer;
LUSC	cis	rs16949788	0.793	rs12439705	chr15:66668003	C/A	cg08120210	chr15:66682733	MAP2K1	-0.58	-5.82	-0.3	1.41e-8	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs965469	1.000	rs6051705	chr20:3253143	G/A	cg25506879	chr20:3388711	C20orf194	-0.54	-6.31	-0.33	8.79e-10	IFN-related cytopenia;
LUSC	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg18753928	chr3:113234510	CCDC52	-0.54	-8.23	-0.41	4.16e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg23029597	chr12:123009494	RSRC2	-0.7	-9.23	-0.45	3.12e-18	Body mass index;
LUSC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24110177	chr3:50126178	RBM5	-0.57	-9.4	-0.46	8.81e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs2108225	1.000	rs2108226	chr7:107453279	A/C	cg18560240	chr7:107437656	SLC26A3	-0.44	-6.54	-0.34	2.36e-10	Ulcerative colitis;
LUSC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg06096015	chr1:231504339	EGLN1	0.57	10.02	0.48	7.85e-21	Hemoglobin concentration;
LUSC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.11	16.38	0.67	1.12e-44	Gut microbiome composition (summer);
LUSC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-5.83	-0.3	1.34e-8	Tonsillectomy;
LUSC	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg18681998	chr4:17616180	MED28	-0.76	-13.35	-0.59	7.4e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs727505	0.909	rs1031957	chr7:124627301	T/C	cg23710748	chr7:124431027	NA	-0.37	-6.43	-0.33	4.42e-10	Lewy body disease;
LUSC	cis	rs4474465	0.850	rs4944205	chr11:78227790	T/A	cg27205649	chr11:78285834	NARS2	0.5	5.75	0.3	2.03e-8	Alzheimer's disease (survival time);
LUSC	cis	rs9473147	0.516	rs9296564	chr6:47494759	A/G	cg20196966	chr6:47445060	CD2AP	0.42	5.83	0.3	1.31e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs4343996	0.967	rs6958390	chr7:3353005	T/C	cg21248987	chr7:3385318	SDK1	-0.39	-6.53	-0.34	2.47e-10	Motion sickness;
LUSC	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.5	-5.74	-0.3	2.15e-8	Schizophrenia;
LUSC	cis	rs2742234	0.541	rs10899782	chr10:43736361	A/T	cg15436174	chr10:43711423	RASGEF1A	0.43	7.01	0.36	1.33e-11	Hirschsprung disease;
LUSC	cis	rs77741769	0.571	rs7969140	chr12:121303626	T/C	cg02419362	chr12:121203948	SPPL3	0.46	8.64	0.43	2.42e-16	Mean corpuscular volume;
LUSC	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg27247225	chr6:26970382	C6orf41	-0.47	-5.81	-0.3	1.44e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18099408	chr3:52552593	STAB1	0.39	6.71	0.34	8.57e-11	Bipolar disorder;
LUSC	cis	rs9865818	0.626	rs12485704	chr3:188109766	C/T	cg23651889	chr3:188115336	LPP	-0.4	-5.91	-0.31	8.44e-9	Allergic sensitization;
LUSC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg11645453	chr3:52864694	ITIH4	0.36	8.63	0.43	2.5e-16	Bipolar disorder;
LUSC	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg01579765	chr21:45077557	HSF2BP	0.54	11.46	0.53	7.23e-26	Mean corpuscular volume;
LUSC	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg08975724	chr8:8085496	FLJ10661	0.48	7.0	0.36	1.44e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.26	0.52	3.78e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9944715	0.911	rs7230154	chr18:43835793	C/T	cg01718231	chr17:29326311	RNF135	-0.54	-7.49	-0.38	6.16e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs7582720	1.000	rs79539678	chr2:203740938	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.56	0.42	4.25e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	8.5	0.42	6.47e-16	Ulcerative colitis;
LUSC	cis	rs73198271	0.960	rs17154702	chr8:8609880	C/T	cg01851573	chr8:8652454	MFHAS1	0.6	8.17	0.41	6.27e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4144743	1.000	rs67615769	chr17:45325478	A/G	cg18085866	chr17:45331354	ITGB3	-0.73	-7.75	-0.39	1.12e-13	Body mass index;
LUSC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg15445000	chr17:37608096	MED1	-0.38	-6.62	-0.34	1.42e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.65	-11.36	-0.53	1.59e-25	Menopause (age at onset);
LUSC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11764359	chr7:65958608	NA	0.58	8.91	0.44	3.25e-17	Aortic root size;
LUSC	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg10046767	chr12:53297693	KRT8	0.46	6.46	0.33	3.61e-10	Cancer (pleiotropy);
LUSC	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.43	-0.38	9.21e-13	Myopia (pathological);
LUSC	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg17467752	chr17:38218738	THRA	0.41	5.69	0.3	2.73e-8	Myeloid white cell count;
LUSC	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg00376283	chr12:123451042	ABCB9	0.8	12.14	0.55	2.4e-28	Platelet count;
LUSC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.33	0.53	2.21e-25	Menopause (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17840061	chr6:70577478	COL19A1	-0.52	-6.82	-0.35	4.34e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9807989	0.801	rs6752482	chr2:102967858	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.9	0.31	9.04e-9	Asthma;
LUSC	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg19784903	chr17:45786737	TBKBP1	-0.43	-6.15	-0.32	2.18e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg07211511	chr3:129823064	LOC729375	-0.63	-8.24	-0.41	3.95e-15	Blood pressure (smoking interaction);
LUSC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg23985595	chr17:80112537	CCDC57	-0.31	-5.98	-0.31	5.8e-9	Life satisfaction;
LUSC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg10360139	chr7:1886902	MAD1L1	-0.39	-5.81	-0.3	1.44e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	0.86	16.22	0.66	5e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-19.49	-0.73	4.84e-57	Height;
LUSC	trans	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg21659725	chr3:3221576	CRBN	-0.67	-7.97	-0.4	2.5e-14	Menarche (age at onset);
LUSC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg23649088	chr2:200775458	C2orf69	0.53	7.23	0.37	3.26e-12	Schizophrenia;
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg18538332	chr22:24372958	LOC391322	-0.47	-8.07	-0.4	1.31e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg20573242	chr4:122745356	CCNA2	0.65	9.59	0.46	2.18e-19	Type 2 diabetes;
LUSC	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-0.68	-6.8	-0.35	4.89e-11	Prostate cancer;
LUSC	trans	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.26	-0.32	1.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg08859206	chr1:53392774	SCP2	0.53	9.22	0.45	3.44e-18	Monocyte count;
LUSC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg05973401	chr12:123451056	ABCB9	0.52	6.56	0.34	2e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.45	-7.56	-0.38	3.94e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.78	14.27	0.62	2.1e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-12.67	-0.57	2.58e-30	Hemoglobin concentration;
LUSC	cis	rs12200782	1.000	rs12204145	chr6:26600156	C/T	cg11502198	chr6:26597334	ABT1	-0.76	-5.73	-0.3	2.24e-8	Small cell lung carcinoma;
LUSC	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	0.6	9.71	0.47	8.83e-20	Breast cancer;
LUSC	cis	rs73200209	0.744	rs7136498	chr12:116483993	T/G	cg01776926	chr12:116560359	MED13L	-0.5	-5.97	-0.31	6.1e-9	Total body bone mineral density;
LUSC	cis	rs7000551	0.778	rs2469760	chr8:22365945	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	6.4	0.33	5.13e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs897080	0.552	rs1067365	chr2:44655398	G/A	cg00619915	chr2:44497795	NA	-0.43	-6.37	-0.33	6.39e-10	Height;
LUSC	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg17252645	chr8:143867129	LY6D	0.38	6.78	0.35	5.63e-11	Urinary tract infection frequency;
LUSC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg18681998	chr4:17616180	MED28	0.84	15.71	0.65	5.11e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12618769	0.652	rs17034171	chr2:99221095	A/G	cg10123293	chr2:99228465	UNC50	0.47	7.6	0.38	2.98e-13	Bipolar disorder;
LUSC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.5	-0.46	4.24e-19	Chronic sinus infection;
LUSC	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg20991723	chr1:152506922	NA	0.53	10.17	0.49	2.39e-21	Hair morphology;
LUSC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	10.41	0.5	3.59e-22	Hip circumference adjusted for BMI;
LUSC	cis	rs7534801	0.579	rs10803244	chr1:244908049	G/A	cg20597013	chr1:244894274	NA	-0.4	-6.06	-0.31	3.67e-9	Longitudinal change in brain amyloid plaque burden;
LUSC	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg01420254	chr6:26195488	NA	-0.63	-7.06	-0.36	9.94e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs9653442	0.564	rs10185510	chr2:100790581	C/T	cg07810366	chr2:100720526	AFF3	-0.44	-7.49	-0.38	6.14e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4423214	0.592	rs10898223	chr11:71219264	G/A	cg05163923	chr11:71159392	DHCR7	-0.7	-7.3	-0.37	2.12e-12	Vitamin D levels;
LUSC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg15352829	chr14:105391018	PLD4	-0.42	-8.9	-0.44	3.73e-17	Rheumatoid arthritis;
LUSC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.7	-0.43	1.56e-16	Lung cancer;
LUSC	cis	rs2692947	0.711	rs34639392	chr2:96508976	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.31	0.33	8.96e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6545883	0.929	rs1186707	chr2:61673520	C/A	cg15711740	chr2:61764176	XPO1	-0.45	-6.87	-0.35	3.09e-11	Tuberculosis;
LUSC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg03146154	chr1:46216737	IPP	0.52	7.62	0.38	2.68e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg12559939	chr2:27858050	GPN1	0.41	6.45	0.33	3.94e-10	Oral cavity cancer;
LUSC	cis	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg07460842	chr6:66804631	NA	-0.62	-8.95	-0.44	2.44e-17	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs2219968	0.701	rs34965401	chr8:78991957	C/G	cg00738934	chr8:78996279	NA	0.42	7.61	0.38	2.9e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs747782	0.527	rs7113857	chr11:48141859	G/T	cg03929089	chr4:120376271	NA	0.69	6.32	0.33	8.25e-10	Intraocular pressure;
LUSC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg24789503	chr3:195384528	SDHAP2	-0.61	-6.98	-0.36	1.59e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs3925075	0.966	rs12935192	chr16:31359330	G/A	cg02846316	chr16:31340340	ITGAM	0.33	6.0	0.31	5e-9	IgA nephropathy;
LUSC	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.6	0.38	2.93e-13	Schizophrenia;
LUSC	cis	rs1419980	0.643	rs10743997	chr12:7798565	A/C	cg10578777	chr12:7781093	NA	0.61	5.73	0.3	2.19e-8	HDL cholesterol levels;
LUSC	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21984481	chr17:79567631	NPLOC4	-0.72	-15.07	-0.64	1.65e-39	Eye color traits;
LUSC	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg18196295	chr10:418757	DIP2C	0.49	8.06	0.4	1.38e-14	Psychosis in Alzheimer's disease;
LUSC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg16647868	chr5:131706066	SLC22A5	0.34	5.71	0.3	2.51e-8	Blood metabolite levels;
LUSC	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg10701640	chr17:43249399	NA	0.45	9.47	0.46	5.36e-19	Height;
LUSC	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.07	-22.54	-0.78	4.9e-69	Ulcerative colitis;
LUSC	cis	rs73206853	0.841	rs7961345	chr12:111081598	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	6.51	0.34	2.76e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg00792783	chr2:198669748	PLCL1	0.46	6.19	0.32	1.79e-9	Dermatomyositis;
LUSC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg08888203	chr3:10149979	C3orf24	0.59	8.2	0.41	5.23e-15	Alzheimer's disease;
LUSC	cis	rs4654899	1.000	rs6426668	chr1:21396596	T/C	cg01072550	chr1:21505969	NA	-0.53	-8.02	-0.4	1.78e-14	Superior frontal gyrus grey matter volume;
LUSC	trans	rs643955	0.609	rs13259465	chr8:9982953	C/G	cg21775007	chr8:11205619	TDH	-0.48	-6.47	-0.33	3.44e-10	Systemic lupus erythematosus;
LUSC	cis	rs17818399	0.533	rs4384837	chr2:46789514	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-7.68	-0.39	1.76e-13	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27277848	chr15:40575356	NA	-0.41	-6.09	-0.32	3.11e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7605827	0.930	rs4668911	chr2:15610650	A/C	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg08807101	chr21:30365312	RNF160	0.68	11.44	0.53	8.68e-26	Dental caries;
LUSC	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg05082376	chr22:42548792	NA	-0.4	-6.6	-0.34	1.61e-10	Cognitive function;
LUSC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg17554472	chr22:41940697	POLR3H	-0.47	-5.75	-0.3	1.97e-8	Vitiligo;
LUSC	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg18932078	chr1:2524107	MMEL1	0.29	6.43	0.33	4.29e-10	Ulcerative colitis;
LUSC	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg03585969	chr10:35415529	CREM	0.62	9.27	0.45	2.43e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.68	11.51	0.53	4.9e-26	Prudent dietary pattern;
LUSC	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg05163923	chr11:71159392	DHCR7	0.69	10.49	0.5	1.88e-22	Vitamin D levels;
LUSC	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg17470723	chr8:74884337	TCEB1	0.52	8.06	0.4	1.33e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72627509	0.951	rs72606404	chr4:57841213	G/C	cg26694713	chr4:57773883	REST	0.49	5.68	0.3	2.93e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg10609677	chr17:41278573	BRCA1;NBR2	0.36	5.86	0.31	1.09e-8	Menopause (age at onset);
LUSC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.47	-0.33	3.45e-10	Longevity;Endometriosis;
LUSC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-1.03	-20.11	-0.74	1.74e-59	Height;
LUSC	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	7.4	0.38	1.09e-12	Neuroticism;
LUSC	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.58	8.27	0.41	3.16e-15	Bipolar disorder;
LUSC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg07701084	chr6:150067640	NUP43	0.57	8.69	0.43	1.6e-16	Lung cancer;
LUSC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg01483505	chr11:975446	AP2A2	0.43	6.0	0.31	5.08e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg03060546	chr3:49711283	APEH	0.65	7.67	0.39	1.84e-13	Menarche (age at onset);
LUSC	trans	rs116175374	0.793	rs77354826	chr2:31431980	C/T	cg15543616	chr12:5019024	KCNA1	-0.77	-6.01	-0.31	4.9e-9	Endometriosis;
LUSC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05564831	chr3:52568323	NT5DC2	0.37	6.63	0.34	1.33e-10	Electroencephalogram traits;
LUSC	cis	rs11971779	0.555	rs6950143	chr7:139054418	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs9283706	0.594	rs7735834	chr5:66337444	A/G	cg11590213	chr5:66331682	MAST4	-0.45	-6.73	-0.35	7.4e-11	Coronary artery disease;
LUSC	trans	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	cis	rs7173743	0.518	rs12899452	chr15:79112550	T/A	cg15571903	chr15:79123663	NA	0.31	5.76	0.3	1.86e-8	Coronary artery disease;
LUSC	cis	rs4363385	0.531	rs11205188	chr1:153053645	A/T	cg00922841	chr1:152955080	SPRR1A	-0.4	-6.67	-0.34	1.04e-10	Inflammatory skin disease;
LUSC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.44	6.64	0.34	1.25e-10	Cognitive test performance;
LUSC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg13607699	chr17:42295918	UBTF	0.7	11.02	0.52	2.73e-24	Total body bone mineral density;
LUSC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-7.97	-0.4	2.58e-14	Bipolar disorder;
LUSC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-17.68	-0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.53	-8.35	-0.42	1.89e-15	Height;
LUSC	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg06873352	chr17:61820015	STRADA	-0.6	-10.29	-0.49	9.13e-22	Prudent dietary pattern;
LUSC	cis	rs17286411	0.750	rs2288030	chr16:71914107	G/A	cg03805757	chr16:71968109	PKD1L3	0.42	6.89	0.35	2.72e-11	Blood protein levels;
LUSC	trans	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg04995722	chr7:26192034	NFE2L3	0.42	6.59	0.34	1.7e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.79	-0.43	7.94e-17	Response to antipsychotic treatment;
LUSC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg22484793	chr3:52261325	TLR9	0.26	6.04	0.31	4.13e-9	Electroencephalogram traits;
LUSC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21016266	chr12:122356598	WDR66	0.57	8.62	0.43	2.82e-16	Mean corpuscular volume;
LUSC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg04398451	chr17:18023971	MYO15A	-0.49	-8.18	-0.41	6.05e-15	Total body bone mineral density;
LUSC	cis	rs10788264	0.544	rs10788269	chr10:124022870	A/G	cg09507567	chr10:124027408	NA	0.53	9.3	0.45	1.84e-18	Total body bone mineral density;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	1.02	24.42	0.8	2.7e-76	Menarche (age at onset);
LUSC	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.52	-0.46	3.57e-19	Total cholesterol levels;
LUSC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg17554472	chr22:41940697	POLR3H	-0.46	-5.78	-0.3	1.67e-8	Vitiligo;
LUSC	trans	rs12692738	0.526	rs355866	chr2:165630823	G/A	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2274273	0.840	rs7144737	chr14:55822946	C/T	cg04306507	chr14:55594613	LGALS3	0.55	11.98	0.55	9.68e-28	Protein biomarker;
LUSC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg15110403	chr19:17392923	ANKLE1	0.52	7.3	0.37	2.12e-12	Systemic lupus erythematosus;
LUSC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.72	10.01	0.48	8.24e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs6993770	0.813	rs4734875	chr8:106554737	A/G	cg03716822	chr8:38126029	PPAPDC1B	0.46	5.97	0.31	5.95e-9	Interleukin-12p70 levels;Plateletcrit;Vascular endothelial growth factor levels;Platelet distribution width;Platelet count;Mean platelet volume;
LUSC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg04586622	chr2:25135609	ADCY3	0.43	9.11	0.45	7.9e-18	Body mass index;
LUSC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg04013166	chr16:89971882	TCF25	0.54	6.03	0.31	4.38e-9	Skin colour saturation;
LUSC	cis	rs11209002	0.614	rs7544189	chr1:67568351	C/T	cg02640540	chr1:67518911	SLC35D1	0.63	8.8	0.43	7.73e-17	Crohn's disease;
LUSC	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg12412775	chr1:25698385	RHCE	-0.3	-6.17	-0.32	1.94e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.48	-0.33	3.28e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13315871	0.929	rs4560319	chr3:58386274	C/T	cg20936604	chr3:58311152	NA	-0.67	-6.29	-0.33	9.73e-10	Cholesterol, total;
LUSC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg13939156	chr17:80058883	NA	0.34	6.69	0.34	9.5e-11	Life satisfaction;
LUSC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg17948913	chr5:572064	NA	0.37	5.65	0.3	3.4e-8	Obesity-related traits;
LUSC	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg06060754	chr5:176797920	RGS14	0.58	7.83	0.39	6.58e-14	Urate levels in lean individuals;
LUSC	cis	rs2932538	0.922	rs3790612	chr1:113084146	G/A	cg22162597	chr1:113214053	CAPZA1	0.71	10.22	0.49	1.66e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs9309473	0.519	rs12618600	chr2:73890682	T/C	cg20560298	chr2:73613845	ALMS1	0.48	7.31	0.37	1.99e-12	Metabolite levels;
LUSC	cis	rs9638182	0.666	rs12531645	chr7:73023881	G/A	cg07452164	chr7:72993570	TBL2	0.48	6.7	0.34	9.01e-11	Triglycerides;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04498971	chr17:56084468	SFRS1	0.46	6.35	0.33	7.14e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	14.7	0.63	4.49e-38	Platelet count;
LUSC	cis	rs11153730	0.503	rs12212582	chr6:118626480	A/G	cg21191810	chr6:118973309	C6orf204	0.34	5.87	0.31	1.04e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUSC	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg06191203	chr2:152266755	RIF1	0.52	7.13	0.36	6.27e-12	Lung cancer;
LUSC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg03929089	chr4:120376271	NA	-0.93	-16.02	-0.66	2.85e-43	Height;
LUSC	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg08085267	chr17:45401833	C17orf57	0.54	8.87	0.44	4.44e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg10792982	chr14:105748885	BRF1	0.47	8.3	0.41	2.56e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg18827107	chr12:86230957	RASSF9	-0.5	-7.46	-0.38	7.62e-13	Major depressive disorder;
LUSC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg18479299	chr3:125709523	NA	-0.5	-5.7	-0.3	2.7e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg23711669	chr6:146136114	FBXO30	-0.79	-13.87	-0.6	7.6e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg26513180	chr16:89883248	FANCA	-0.57	-8.83	-0.43	6.19e-17	Vitiligo;
LUSC	trans	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.63	-0.39	2.48e-13	Morning vs. evening chronotype;
LUSC	cis	rs1461503	0.780	rs75981430	chr11:122842469	A/C	cg27398637	chr11:122830231	C11orf63	-0.4	-6.46	-0.33	3.72e-10	Menarche (age at onset);
LUSC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg10018233	chr7:150070692	REPIN1	0.37	6.45	0.33	3.98e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6541297	0.645	rs4846918	chr1:230300586	A/G	cg05784532	chr1:230284198	GALNT2	-0.57	-6.88	-0.35	2.98e-11	Coronary artery disease;
LUSC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-17.29	-0.69	2.65e-48	Body mass index;
LUSC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg16510040	chr1:40042432	PABPC4	-0.56	-6.02	-0.31	4.62e-9	Schizophrenia;
LUSC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg19912559	chr1:40204330	PPIE	-0.53	-8.03	-0.4	1.68e-14	Blood protein levels;
LUSC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg14552801	chr7:65878734	NA	0.45	6.33	0.33	8.04e-10	Aortic root size;
LUSC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.91	-0.35	2.41e-11	Lung cancer;
LUSC	cis	rs225245	0.782	rs225293	chr17:33925906	A/G	cg05299278	chr17:33885742	SLFN14	0.31	6.82	0.35	4.37e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs10763170	0.669	rs11004721	chr10:56824909	C/G	cg10538533	chr12:53074328	KRT1	0.3	5.97	0.31	6e-9	Sporadic pituitary adenoma;
LUSC	cis	rs10779751	0.734	rs2791658	chr1:11127871	A/G	cg04508216	chr1:11107452	MASP2	0.33	5.87	0.31	1.03e-8	Body mass index;
LUSC	cis	rs7131987	0.868	rs10771508	chr12:29414211	G/A	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.25	-0.32	1.28e-9	QT interval;
LUSC	cis	rs354225	0.544	rs4641979	chr2:54811917	G/A	cg01766943	chr2:54829624	SPTBN1	0.48	7.95	0.4	2.85e-14	Schizophrenia;
LUSC	trans	rs4650994	0.507	rs2811312	chr1:178617603	A/G	cg05059571	chr16:84539110	KIAA1609	0.47	8.83	0.44	6.21e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs9462027	0.583	rs9469862	chr6:34729848	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.93	-0.31	7.62e-9	Systemic lupus erythematosus;
LUSC	cis	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg02972257	chr16:68554789	NA	-0.43	-5.74	-0.3	2.12e-8	Colorectal cancer;
LUSC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg09165964	chr15:75287851	SCAMP5	-1.16	-19.39	-0.73	1.27e-56	Blood trace element (Zn levels);
LUSC	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg06636001	chr8:8085503	FLJ10661	0.51	7.67	0.39	1.84e-13	Retinal vascular caliber;
LUSC	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.42	6.5	0.34	2.88e-10	Colorectal cancer;
LUSC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.39	0.33	5.59e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg05347473	chr6:146136440	FBXO30	0.46	7.97	0.4	2.55e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.88	15.03	0.64	2.3e-39	Bladder cancer;
LUSC	cis	rs603424	0.551	rs646767	chr10:102084897	A/G	cg10365880	chr10:102089681	PKD2L1	-0.55	-7.04	-0.36	1.08e-11	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
LUSC	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg13010199	chr12:38710504	ALG10B	0.45	6.4	0.33	5.12e-10	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10802521	chr3:52805072	NEK4	-0.52	-8.38	-0.42	1.51e-15	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.92	0.31	7.86e-9	Menopause (age at onset);
LUSC	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg04287289	chr16:89883240	FANCA	-0.48	-7.18	-0.37	4.64e-12	Vitiligo;
LUSC	cis	rs9646944	0.501	rs13030642	chr2:103091585	C/A	cg20060108	chr2:102954350	IL1RL1	0.47	6.25	0.32	1.24e-9	Blood protein levels;
LUSC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.2	13.62	0.6	6.4e-34	Diabetic kidney disease;
LUSC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg21435336	chr19:17392852	ANKLE1	-0.47	-6.49	-0.33	3.15e-10	Systemic lupus erythematosus;
LUSC	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg11189052	chr15:85197271	WDR73	-0.45	-6.48	-0.33	3.35e-10	P wave terminal force;
LUSC	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg16576597	chr16:28551801	NUPR1	0.29	5.75	0.3	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.55	9.33	0.45	1.53e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg12257692	chr3:49977190	RBM6	0.25	6.82	0.35	4.34e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg06636001	chr8:8085503	FLJ10661	0.68	11.49	0.53	5.44e-26	Mood instability;
LUSC	cis	rs7119038	0.865	rs10892299	chr11:118726843	C/T	cg19308663	chr11:118741387	NA	0.34	5.65	0.3	3.47e-8	Sjögren's syndrome;
LUSC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg05025164	chr4:1340916	KIAA1530	0.47	7.32	0.37	1.89e-12	Obesity-related traits;
LUSC	cis	rs4280164	0.551	rs3212242	chr14:24810401	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.55	-6.86	-0.35	3.38e-11	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg25036284	chr2:26402008	FAM59B	-0.68	-9.64	-0.47	1.49e-19	Gut microbiome composition (summer);
LUSC	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg17507749	chr15:85114479	UBE2QP1	0.54	6.73	0.35	7.18e-11	Schizophrenia;
LUSC	cis	rs394563	0.534	rs388335	chr6:149791986	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.35	-6.24	-0.32	1.3e-9	Dupuytren's disease;
LUSC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg01657329	chr11:68192670	LRP5	-0.43	-6.35	-0.33	7.09e-10	Total body bone mineral density;
LUSC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg06795559	chr20:5931181	MCM8;TRMT6	0.62	6.41	0.33	4.98e-10	Myocardial infarction;
LUSC	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg13010199	chr12:38710504	ALG10B	-0.6	-9.31	-0.45	1.8e-18	Morning vs. evening chronotype;
LUSC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg21385522	chr1:16154831	NA	0.54	8.28	0.41	2.99e-15	Dilated cardiomyopathy;
LUSC	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg13010199	chr12:38710504	ALG10B	-0.54	-8.16	-0.41	6.81e-15	Morning vs. evening chronotype;
LUSC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.5	-0.38	5.66e-13	Neuroticism;
LUSC	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg04310649	chr10:35416472	CREM	-0.41	-6.54	-0.34	2.32e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg09307838	chr4:120376055	NA	0.72	10.36	0.49	5.25e-22	Corneal astigmatism;
LUSC	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg13256891	chr4:100009986	ADH5	0.47	6.46	0.33	3.62e-10	Alcohol dependence;
LUSC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	7.27	0.37	2.56e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs2514895	0.660	rs56297939	chr11:127112010	G/A	cg22738642	chr12:43137977	NA	0.5	6.26	0.32	1.17e-9	IgG glycosylation;
LUSC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg18230493	chr5:56204884	C5orf35	-0.79	-12.52	-0.57	9.14e-30	Initial pursuit acceleration;
LUSC	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24838063	chr12:130822603	PIWIL1	0.69	10.79	0.51	1.69e-23	Menopause (age at onset);
LUSC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg21016266	chr12:122356598	WDR66	0.6	9.11	0.45	7.92e-18	Mean corpuscular volume;
LUSC	trans	rs12200782	1.000	rs12205909	chr6:26630999	G/A	cg11837749	chr1:55047332	ACOT11	0.57	5.98	0.31	5.64e-9	Small cell lung carcinoma;
LUSC	cis	rs472402	0.580	rs7720479	chr5:6640049	A/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.53	-7.7	-0.39	1.54e-13	Response to amphetamines;
LUSC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg13319975	chr6:146136371	FBXO30	0.71	11.26	0.52	3.93e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28647808	0.786	rs28649804	chr9:136257709	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg26408565	chr15:76604113	ETFA	-0.48	-7.63	-0.39	2.4e-13	Blood metabolite levels;
LUSC	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg14583973	chr4:3374767	RGS12	0.35	7.27	0.37	2.6e-12	Serum sulfate level;
LUSC	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg10483660	chr13:112241077	NA	-0.31	-5.68	-0.3	3e-8	Hepatitis;
LUSC	cis	rs11642862	0.901	rs11647243	chr16:30965308	G/A	cg02466173	chr16:30829666	NA	-0.63	-6.45	-0.33	3.9e-10	Tonsillectomy;
LUSC	cis	rs2398893	0.960	rs34849895	chr9:96751069	T/C	cg14459158	chr9:96720562	NA	0.31	5.87	0.31	1.06e-8	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg15605315	chr1:45957053	TESK2	0.47	7.57	0.38	3.68e-13	High light scatter reticulocyte count;
LUSC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg26380479	chr7:97908229	NA	-0.28	-6.26	-0.32	1.19e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.69	0.54	1.07e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1062746	0.520	rs67174101	chr16:87328817	G/A	cg02258303	chr16:87377426	FBXO31	-0.53	-7.88	-0.4	4.52e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg05283184	chr6:79620031	NA	-0.57	-11.83	-0.54	3.38e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg13798780	chr7:105162888	PUS7	0.56	6.15	0.32	2.23e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1351164	0.688	rs34587525	chr2:218253689	G/A	cg15335768	chr2:218268053	DIRC3	-0.33	-5.88	-0.31	1.01e-8	Height;
LUSC	cis	rs9535307	0.745	rs1407440	chr13:50286218	T/C	cg04663916	chr13:50265991	EBPL	0.49	5.71	0.3	2.44e-8	Obesity-related traits;
LUSC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.41	0.42	1.18e-15	Tonsillectomy;
LUSC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	10.89	0.51	7.85e-24	Hip circumference adjusted for BMI;
LUSC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2692947	0.770	rs72823920	chr2:96430876	G/A	cg23100626	chr2:96804247	ASTL	0.29	6.86	0.35	3.31e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg26220528	chr12:57623348	SHMT2	0.37	6.39	0.33	5.58e-10	Tuberculosis;
LUSC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	1.15	10.52	0.5	1.54e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	trans	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg01620082	chr3:125678407	NA	-0.59	-6.55	-0.34	2.21e-10	Depression;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02619805	chr19:5623015	SAFB2;SAFB	-0.42	-6.27	-0.32	1.14e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.73	0.35	7.39e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs1547374	0.960	rs4920090	chr21:43777897	A/G	cg09521743	chr10:75415752	SYNPO2L	-0.44	-7.24	-0.37	3.2e-12	Pancreatic cancer;
LUSC	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg04310649	chr10:35416472	CREM	-0.43	-6.64	-0.34	1.29e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	9.04	0.44	1.3e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs870825	0.860	rs72703518	chr4:185602109	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	10.68	0.5	4.15e-23	Blood protein levels;
LUSC	trans	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg07923666	chr12:49932857	KCNH3	-0.5	-6.18	-0.32	1.9e-9	Resting heart rate;
LUSC	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg08085267	chr17:45401833	C17orf57	-0.63	-10.63	-0.5	6.32e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	0.7	11.11	0.52	1.32e-24	Blood metabolite ratios;
LUSC	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg21775007	chr8:11205619	TDH	-0.73	-11.4	-0.53	1.21e-25	Retinal vascular caliber;
LUSC	cis	rs231513	0.906	rs11657450	chr17:42002464	C/T	cg26893861	chr17:41843967	DUSP3	0.55	5.74	0.3	2.11e-8	Cognitive function;
LUSC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg06454157	chr6:167490870	NA	-0.28	-6.87	-0.35	3.1e-11	Primary biliary cholangitis;
LUSC	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02176678	chr2:219576539	TTLL4	0.55	9.51	0.46	3.97e-19	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg00509249	chr6:109615579	CCDC162	-0.33	-5.97	-0.31	5.98e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs360798	0.512	rs17027429	chr2:63079983	C/T	cg17519650	chr2:63277830	OTX1	0.48	6.75	0.35	6.5e-11	Coronary artery disease;
LUSC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg24130564	chr14:104152367	KLC1	-0.4	-5.7	-0.3	2.66e-8	Body mass index;
LUSC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg06134567	chr22:46658398	PKDREJ	-0.53	-6.0	-0.31	5.15e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08470875	chr2:26401718	FAM59B	0.71	9.86	0.47	2.71e-20	Gut microbiome composition (summer);
LUSC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg16339924	chr4:17578868	LAP3	0.51	7.85	0.39	5.82e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.55	-0.34	2.2e-10	Alzheimer's disease (late onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15740054	chr19:41221099	ADCK4	-0.39	-5.94	-0.31	7.03e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.63	-10.22	-0.49	1.62e-21	Iron status biomarkers;
LUSC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-11.28	-0.53	3.12e-25	Monocyte count;
LUSC	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg21053147	chr12:120880522	NA	0.5	6.08	0.32	3.37e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	9.42	0.46	7.9e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg03886242	chr7:26192032	NFE2L3	0.36	5.96	0.31	6.58e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-1.01	-24.69	-0.8	2.52e-77	Urate levels in lean individuals;
LUSC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.74	-17.87	-0.7	1.33e-50	Prostate cancer;
LUSC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg02018176	chr4:1364513	KIAA1530	-0.46	-8.16	-0.41	7.05e-15	Obesity-related traits;
LUSC	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg08601574	chr20:25228251	PYGB	-0.44	-6.78	-0.35	5.45e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg24579218	chr15:68104479	NA	-0.34	-5.79	-0.3	1.63e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg12559939	chr2:27858050	GPN1	0.4	6.13	0.32	2.52e-9	Oral cavity cancer;
LUSC	trans	rs2587949	0.615	rs2629241	chr3:4208798	A/G	cg15139668	chr4:4577005	NA	-0.41	-6.03	-0.31	4.44e-9	Periodontitis (DPAL);
LUSC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg11494091	chr17:61959527	GH2	0.4	6.91	0.35	2.47e-11	Height;
LUSC	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg04310649	chr10:35416472	CREM	-0.41	-6.47	-0.33	3.43e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-5.75	-0.3	2.03e-8	Retinal vascular caliber;
LUSC	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg09877947	chr5:131593287	PDLIM4	-0.39	-6.65	-0.34	1.23e-10	Blood metabolite levels;
LUSC	cis	rs9811920	0.809	rs6806323	chr3:99722564	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-7.14	-0.36	5.79e-12	Axial length;
LUSC	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	trans	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.4	0.42	1.31e-15	Diabetic kidney disease;
LUSC	cis	rs4474465	1.000	rs7943673	chr11:78172986	A/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.71	-0.3	2.51e-8	Alzheimer's disease (survival time);
LUSC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.26	0.37	2.75e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7523273	0.606	rs2724382	chr1:207928635	G/C	cg22525895	chr1:207977042	MIR29B2	0.4	6.43	0.33	4.3e-10	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.63	0.5	6.24e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-1.12	-25.14	-0.81	4.96e-79	Height;
LUSC	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg12935359	chr14:103987150	CKB	0.66	10.73	0.51	2.73e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg20476274	chr7:133979776	SLC35B4	0.86	16.01	0.66	3.35e-43	Mean platelet volume;
LUSC	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg03713592	chr11:72463424	ARAP1	0.59	7.75	0.39	1.09e-13	Body mass index;
LUSC	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.76	-13.13	-0.58	5.03e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.09	-0.48	4.43e-21	Obesity-related traits;
LUSC	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.56	-0.34	2.05e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00543196	chr1:147142741	ACP6	-0.42	-6.1	-0.32	2.93e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6782228	0.606	rs9828893	chr3:128332925	T/C	cg16766828	chr3:128327626	NA	-0.32	-5.85	-0.3	1.19e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs11971779	0.680	rs4728467	chr7:139120562	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	7.16	0.36	5.33e-12	Diisocyanate-induced asthma;
LUSC	cis	rs9341808	0.718	rs2874829	chr6:80856097	A/G	cg08355045	chr6:80787529	NA	0.57	9.9	0.48	1.96e-20	Sitting height ratio;
LUSC	cis	rs6840360	0.642	rs7666571	chr4:152443273	C/T	cg20465933	chr4:152376761	FAM160A1	0.32	5.84	0.3	1.22e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12493885	0.818	rs1521324	chr3:153758863	G/T	cg17054900	chr3:154042577	DHX36	-0.75	-7.65	-0.39	2.18e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9420	0.961	rs12804972	chr11:57463767	T/C	cg23127183	chr11:57508653	C11orf31	-0.58	-9.06	-0.44	1.08e-17	Schizophrenia;
LUSC	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg18002602	chr11:66138449	SLC29A2	0.45	8.16	0.41	6.95e-15	Educational attainment (years of education);
LUSC	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg03433033	chr1:76189801	ACADM	0.53	7.42	0.38	9.88e-13	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg14552801	chr7:65878734	NA	0.37	5.85	0.3	1.18e-8	Aortic root size;
LUSC	cis	rs10761482	0.813	rs4948407	chr10:62110199	T/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.05	-0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-7.85	-0.39	5.74e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03878208	chr11:72483293	STARD10	0.57	7.28	0.37	2.33e-12	Type 2 diabetes;
LUSC	cis	rs1003719	0.667	rs28666643	chr21:38455999	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	9.49	0.46	4.57e-19	Eye color traits;
LUSC	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg03806693	chr22:41940476	POLR3H	-0.97	-13.08	-0.58	7.85e-32	Vitiligo;
LUSC	trans	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg10756647	chr7:56101905	PSPH	-0.84	-8.42	-0.42	1.14e-15	Diabetic kidney disease;
LUSC	cis	rs9283706	0.608	rs10060497	chr5:66332406	A/G	cg11590213	chr5:66331682	MAST4	0.47	7.17	0.37	4.71e-12	Coronary artery disease;
LUSC	trans	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg04995722	chr7:26192034	NFE2L3	0.37	6.06	0.31	3.67e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.5	-0.42	6.44e-16	Heart rate;
LUSC	cis	rs12681287	0.604	rs71502657	chr8:87478781	T/A	cg27223183	chr8:87520930	FAM82B	-0.51	-6.81	-0.35	4.59e-11	Caudate activity during reward;
LUSC	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.61	-7.32	-0.37	1.87e-12	Mammographic density (dense area);
LUSC	trans	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.56	0.34	2.1e-10	Resting heart rate;
LUSC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1256061	0.603	rs1269056	chr14:64743890	T/C	cg23250157	chr14:64679961	SYNE2	0.32	5.71	0.3	2.56e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs6429422	0.725	rs2787232	chr1:243306475	G/C	cg01826367	chr1:224180288	NA	0.43	6.36	0.33	6.77e-10	Cognitive ability (multi-trait analysis);
LUSC	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Bladder cancer;
LUSC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	10.0	0.48	9.35e-21	Eosinophil percentage of white cells;
LUSC	cis	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg27411982	chr8:10470053	RP1L1	0.38	5.81	0.3	1.43e-8	Neuroticism;
LUSC	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg04546413	chr19:29218101	NA	0.58	7.23	0.37	3.31e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg22089800	chr15:90895588	ZNF774	0.51	7.43	0.38	9.16e-13	Rheumatoid arthritis;
LUSC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs1018836	0.544	rs2063978	chr8:91459525	C/T	cg16814680	chr8:91681699	NA	-0.48	-6.89	-0.35	2.85e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg05163923	chr11:71159392	DHCR7	-0.77	-10.04	-0.48	6.5e-21	Vitamin D levels;
LUSC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg23711669	chr6:146136114	FBXO30	0.82	14.54	0.62	1.91e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.58	-9.75	-0.47	6.24e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-8.58	-0.43	3.54e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12711979	0.875	rs11686157	chr2:3855020	C/G	cg17052675	chr2:3827356	NA	-0.45	-8.16	-0.41	6.98e-15	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.37	0.49	4.95e-22	Bladder cancer;
LUSC	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg14061069	chr19:46274453	DMPK	-0.49	-8.35	-0.42	1.89e-15	Coronary artery disease;
LUSC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg22823121	chr1:150693482	HORMAD1	-0.6	-9.43	-0.46	7.2e-19	Tonsillectomy;
LUSC	cis	rs2637266	0.935	rs751770	chr10:78393956	A/G	cg18941641	chr10:78392320	NA	0.38	6.74	0.35	7.15e-11	Pulmonary function;
LUSC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.92	14.5	0.62	2.79e-37	Height;
LUSC	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg18681998	chr4:17616180	MED28	-0.76	-13.48	-0.59	2.2e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg11214544	chr1:2391121	NA	-0.36	-6.14	-0.32	2.29e-9	Schizophrenia;
LUSC	cis	rs7246967	0.611	rs60021625	chr19:22829554	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs1865721	0.771	rs8093397	chr18:73136217	C/G	cg26385618	chr18:73139727	C18orf62	-0.55	-10.1	-0.48	4.25e-21	Intelligence;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23336486	chr4:1341064	KIAA1530	0.39	6.31	0.33	8.62e-10	Asthma;
LUSC	cis	rs62400317	0.762	rs62436376	chr6:44885817	C/T	cg18551225	chr6:44695536	NA	-0.48	-7.86	-0.4	5.3e-14	Total body bone mineral density;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07336999	chr16:89939803	TCF25	0.41	6.36	0.33	6.65e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg06484146	chr7:12443880	VWDE	-0.68	-8.42	-0.42	1.16e-15	Coronary artery disease;
LUSC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg00290607	chr11:67383545	NA	0.35	6.59	0.34	1.67e-10	Mean corpuscular volume;
LUSC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.82	13.93	0.61	4.42e-35	Monocyte count;
LUSC	trans	rs61931739	0.592	rs815042	chr12:33724221	C/A	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-0.79	-10.97	-0.51	4.1e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg23985595	chr17:80112537	CCDC57	-0.3	-5.71	-0.3	2.52e-8	Life satisfaction;
LUSC	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg25427524	chr10:38739819	LOC399744	-0.51	-6.47	-0.33	3.52e-10	Obesity (extreme);
LUSC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	0.91	17.85	0.7	1.61e-50	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.67	-10.26	-0.49	1.18e-21	Fuchs's corneal dystrophy;
LUSC	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg07936489	chr17:37558343	FBXL20	0.78	9.89	0.48	2.15e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.13	0.58	4.89e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg13042288	chr15:90349979	ANPEP	0.39	6.1	0.32	2.99e-9	Uric acid levels;
LUSC	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg25482853	chr8:67687455	SGK3	1.12	16.14	0.66	1.01e-43	Obesity-related traits;
LUSC	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg24634471	chr8:143751801	JRK	-0.5	-7.15	-0.36	5.65e-12	Schizophrenia;
LUSC	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.94	0.51	4.97e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg10253484	chr15:75165896	SCAMP2	-0.48	-7.36	-0.37	1.42e-12	Breast cancer;
LUSC	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg08847533	chr14:75593920	NEK9	0.83	14.44	0.62	4.55e-37	Height;
LUSC	cis	rs3741151	0.881	rs10898917	chr11:73065979	G/A	cg17517138	chr11:73019481	ARHGEF17	0.89	8.11	0.41	9.44e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	12.75	0.57	1.34e-30	Cognitive test performance;
LUSC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	0.93	15.69	0.65	5.75e-42	Menopause (age at onset);
LUSC	cis	rs7809950	1.000	rs10267907	chr7:107184466	C/T	cg23024343	chr7:107201750	COG5	-0.55	-8.66	-0.43	2.12e-16	Coronary artery disease;
LUSC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg13628971	chr7:2884303	GNA12	0.5	6.87	0.35	3.08e-11	Height;
LUSC	cis	rs1113500	0.933	rs10881498	chr1:108634984	C/A	cg06207961	chr1:108661230	NA	0.41	7.61	0.38	2.89e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg03909863	chr11:638404	DRD4	-0.41	-6.19	-0.32	1.81e-9	Systemic lupus erythematosus;
LUSC	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg04989706	chr14:50066350	PPIL5	-0.44	-5.81	-0.3	1.42e-8	Carotid intima media thickness;
LUSC	cis	rs6545883	0.794	rs12053388	chr2:61532320	G/A	cg15711740	chr2:61764176	XPO1	0.46	6.99	0.36	1.46e-11	Tuberculosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25445977	chr19:2061242	NA	-0.51	-5.98	-0.31	5.81e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg08017756	chr2:100939284	LONRF2	-0.45	-8.32	-0.41	2.31e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg02753203	chr1:228287806	NA	-0.68	-11.8	-0.54	4.37e-27	Diastolic blood pressure;
LUSC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg12442385	chr7:1034912	NA	-0.37	-6.38	-0.33	5.88e-10	Longevity;Endometriosis;
LUSC	cis	rs7542375	0.930	rs6680690	chr1:221063684	T/A	cg16008148	chr1:221062819	NA	0.37	6.61	0.34	1.49e-10	Obesity-related traits;
LUSC	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	6.26	0.32	1.18e-9	Response to antipsychotic treatment;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08089031	chr6:139456240	HECA	-0.46	-6.22	-0.32	1.47e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7291412	0.540	rs9627391	chr22:46447097	C/T	cg23691090	chr22:46449981	C22orf26;LOC150381	0.37	6.45	0.33	3.88e-10	Dupuytren's disease;Subjective well-being;
LUSC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg03146154	chr1:46216737	IPP	-0.53	-7.64	-0.39	2.39e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs17401966	0.558	rs12128374	chr1:10426417	G/A	cg19773385	chr1:10388646	KIF1B	-0.37	-6.41	-0.33	4.88e-10	Hepatocellular carcinoma;
LUSC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg05425664	chr17:57184151	TRIM37	0.55	8.57	0.42	3.81e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg06917634	chr15:78832804	PSMA4	0.68	10.78	0.51	1.93e-23	Sudden cardiac arrest;
LUSC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg12317470	chr15:67143691	NA	-0.62	-8.06	-0.4	1.4e-14	Lung cancer (smoking interaction);
LUSC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg09165964	chr15:75287851	SCAMP5	0.52	7.59	0.38	3.32e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg04851639	chr8:1020857	NA	-0.38	-7.76	-0.39	1.02e-13	Schizophrenia;
LUSC	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg19700328	chr14:106028568	NA	-0.37	-6.22	-0.32	1.45e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg07080220	chr10:102295463	HIF1AN	0.66	8.51	0.42	5.81e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg03340356	chr1:67600835	NA	0.42	6.51	0.34	2.8e-10	Psoriasis;
LUSC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg12963246	chr6:28129442	ZNF389	0.4	6.25	0.32	1.27e-9	Parkinson's disease;
LUSC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg04455712	chr21:45112962	RRP1B	0.47	8.82	0.43	6.3e-17	Mean corpuscular volume;
LUSC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg16325326	chr1:53192061	ZYG11B	0.89	16.36	0.67	1.39e-44	Monocyte count;
LUSC	cis	rs56283067	0.847	rs56172130	chr6:44696262	G/A	cg18551225	chr6:44695536	NA	-0.48	-8.15	-0.41	7.32e-15	Total body bone mineral density;
LUSC	trans	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.08	-0.32	3.31e-9	Depression;
LUSC	cis	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.21	-0.32	1.56e-9	Ulcerative colitis;
LUSC	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg09699651	chr6:150184138	LRP11	0.45	7.21	0.37	3.88e-12	Lung cancer;
LUSC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg13319975	chr6:146136371	FBXO30	0.48	7.28	0.37	2.41e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2262909	0.962	rs2017521	chr19:22126138	T/C	cg05197062	chr11:11642011	GALNTL4	-0.51	-7.02	-0.36	1.27e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.3	0.33	9.28e-10	Platelet count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04246999	chr16:71930048	KIAA0174	-0.43	-6.68	-0.34	1.01e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7119	0.651	rs35577135	chr15:77840074	C/T	cg27398640	chr15:77910606	LINGO1	-0.33	-6.66	-0.34	1.15e-10	Type 2 diabetes;
LUSC	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg25237894	chr2:233734115	C2orf82	0.34	6.24	0.32	1.3e-9	Coronary artery disease;
LUSC	cis	rs2857891	0.817	rs1491829	chr11:6968941	T/A	cg04053776	chr11:6947353	ZNF215	0.42	5.86	0.31	1.14e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12760731	0.668	rs72482621	chr1:178410442	C/T	cg00404053	chr1:178313656	RASAL2	0.59	6.22	0.32	1.46e-9	Obesity-related traits;
LUSC	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg08085267	chr17:45401833	C17orf57	0.55	8.96	0.44	2.32e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg27411982	chr8:10470053	RP1L1	-0.46	-7.16	-0.36	5.17e-12	Monocyte count;
LUSC	cis	rs7809950	1.000	rs2395883	chr7:107089670	T/C	cg23024343	chr7:107201750	COG5	-0.56	-8.85	-0.44	5.32e-17	Coronary artery disease;
LUSC	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.64	-0.3	3.56e-8	Coronary artery disease;
LUSC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg08847533	chr14:75593920	NEK9	-0.82	-15.13	-0.64	9.25e-40	Height;
LUSC	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs10754283	0.967	rs7513928	chr1:90104834	A/G	cg21401794	chr1:90099060	LRRC8C	0.66	9.93	0.48	1.55e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg06718696	chr17:78121285	EIF4A3	-0.79	-11.69	-0.54	1.09e-26	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.55	0.34	2.2e-10	Menopause (age at onset);
LUSC	cis	rs9549260	0.755	rs2721069	chr13:41143720	C/T	cg21288729	chr13:41239152	FOXO1	0.58	8.69	0.43	1.62e-16	Red blood cell count;
LUSC	cis	rs8078723	0.510	rs9898547	chr17:38136026	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.58	9.9	0.48	1.97e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.4	0.59	4.75e-33	Blood protein levels;
LUSC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg27494647	chr7:150038898	RARRES2	0.49	7.42	0.38	1.01e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs834811	0.829	rs834818	chr7:135895070	A/G	cg01726295	chr7:135938950	NA	0.41	7.17	0.37	4.72e-12	Post-traumatic stress disorder;
LUSC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08704250	chr15:31115839	NA	-0.47	-7.09	-0.36	8.12e-12	Huntington's disease progression;
LUSC	trans	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg10756647	chr7:56101905	PSPH	-0.87	-8.68	-0.43	1.81e-16	Diabetic kidney disease;
LUSC	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg15744005	chr10:104629667	AS3MT	-0.27	-5.71	-0.3	2.44e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.08	-0.4	1.17e-14	Bone mineral density;
LUSC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg01616529	chr11:638424	DRD4	-0.33	-5.73	-0.3	2.3e-8	Systemic lupus erythematosus;
LUSC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	11.77	0.54	5.6e-27	Menopause (age at onset);
LUSC	cis	rs6594499	0.843	rs1993465	chr5:110433098	A/G	cg04022379	chr5:110408740	TSLP	0.45	6.78	0.35	5.51e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs250677	0.522	rs1007400	chr5:148382635	C/T	cg18129178	chr5:148520854	ABLIM3	0.49	7.25	0.37	2.97e-12	Breast cancer;
LUSC	cis	rs62400317	0.826	rs12213735	chr6:45152848	C/T	cg18551225	chr6:44695536	NA	0.42	6.96	0.36	1.83e-11	Total body bone mineral density;
LUSC	trans	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg26043149	chr18:55253948	FECH	-0.45	-6.89	-0.35	2.86e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.02	-0.31	4.56e-9	Breast cancer;
LUSC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.8	0.6	1.3600000000000001e-34	Chronic sinus infection;
LUSC	cis	rs2282300	0.739	rs34224414	chr11:30251041	T/G	cg25418670	chr11:30344373	C11orf46	-0.66	-9.53	-0.46	3.4e-19	Morning vs. evening chronotype;
LUSC	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.58	8.85	0.44	5.08e-17	Blood protein levels;
LUSC	trans	rs11671005	0.610	rs4756	chr19:59074653	T/C	cg22037779	chr5:139682734	PFDN1	-0.57	-7.4	-0.38	1.08e-12	Mean platelet volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11192808	chr8:101170185	SPAG1	-0.49	-6.39	-0.33	5.67e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09746031	chr17:40336180	HCRT	0.43	6.34	0.33	7.29e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.55	-0.34	2.22e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg00310523	chr12:86230176	RASSF9	0.44	7.91	0.4	3.74e-14	Major depressive disorder;
LUSC	cis	rs668210	0.793	rs507672	chr11:65767153	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.58	-7.72	-0.39	1.34e-13	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.91	-0.4	3.82e-14	Retinal vascular caliber;
LUSC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02018176	chr4:1364513	KIAA1530	0.72	13.96	0.61	3.36e-35	Longevity;
LUSC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg11812906	chr14:75593930	NEK9	-0.65	-11.23	-0.52	4.73e-25	Height;
LUSC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-8.78	-0.43	8.37e-17	Bipolar disorder;
LUSC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg27284194	chr4:1044797	NA	0.35	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs9650657	0.644	rs7012206	chr8:10697015	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.32	-0.33	8.37e-10	Neuroticism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20477929	chr11:70116563	PPFIA1	-0.44	-6.68	-0.34	1.02e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4619890	0.528	rs28417050	chr4:7883077	T/C	cg24250820	chr4:7887609	AFAP1	0.36	6.19	0.32	1.73e-9	Glaucoma (primary open-angle);
LUSC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24531977	chr5:56204891	C5orf35	-0.83	-12.98	-0.58	1.72e-31	Coronary artery disease;
LUSC	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg05110241	chr16:68378359	PRMT7	-0.46	-6.12	-0.32	2.59e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	0.94	17.96	0.7	5.88e-51	Heart rate;
LUSC	cis	rs4604732	0.631	rs12080860	chr1:247623053	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.45	6.69	0.34	9.48e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs4629710	0.592	rs10484763	chr6:131549060	T/C	cg12700074	chr6:131571435	AKAP7	-0.37	-6.11	-0.32	2.84e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.34	-5.79	-0.3	1.62e-8	Longevity;Endometriosis;
LUSC	cis	rs4343996	0.934	rs6959232	chr7:3376530	A/G	cg21248987	chr7:3385318	SDK1	-0.4	-6.8	-0.35	4.75e-11	Motion sickness;
LUSC	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg00745463	chr17:30367425	LRRC37B	-0.56	-7.16	-0.36	5.04e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg08213375	chr14:104286397	PPP1R13B	0.4	6.94	0.35	2.08e-11	Reticulocyte count;
LUSC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg01557791	chr16:72042693	DHODH	-0.54	-7.84	-0.39	6.29e-14	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LUSC	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.54	9.91	0.48	1.78e-20	Metabolite levels;
LUSC	cis	rs4363385	0.667	rs11803197	chr1:152934420	G/A	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.09	-0.32	3.1e-9	Inflammatory skin disease;
LUSC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg21724239	chr8:58056113	NA	0.69	7.53	0.38	4.92e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg20887711	chr4:1340912	KIAA1530	0.44	6.76	0.35	6.26e-11	Obesity-related traits;
LUSC	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg23711669	chr6:146136114	FBXO30	0.84	15.12	0.64	9.9e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg24642844	chr7:1081250	C7orf50	-0.71	-6.69	-0.34	9.41e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12516959	chr21:47718080	NA	-0.39	-6.32	-0.33	8.37e-10	Testicular germ cell tumor;
LUSC	cis	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg17469321	chr7:55412551	NA	0.62	10.13	0.48	3.24e-21	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg03433033	chr1:76189801	ACADM	-0.46	-6.97	-0.36	1.73e-11	Daytime sleep phenotypes;
LUSC	cis	rs7315438	0.600	rs7962892	chr12:115877766	T/A	cg24172291	chr12:115889509	NA	-0.35	-5.96	-0.31	6.3e-9	Colorectal cancer;
LUSC	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg02176678	chr2:219576539	TTLL4	-0.57	-10.19	-0.49	2.02e-21	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg15235185	chr1:193028809	TROVE2;UCHL5	0.41	6.04	0.31	4.04e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21659725	chr3:3221576	CRBN	0.63	10.24	0.49	1.43e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.8	0.39	7.87e-14	Gut microbiome composition (summer);
LUSC	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg02153584	chr22:29168773	CCDC117	0.5	6.53	0.34	2.45e-10	Lymphocyte counts;
LUSC	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	0.73	11.49	0.53	5.69e-26	Bone mineral density;
LUSC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg07936489	chr17:37558343	FBXL20	0.72	10.11	0.48	3.74e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.7	-0.39	1.53e-13	Joint mobility (Beighton score);
LUSC	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg13263323	chr15:86062960	AKAP13	-0.35	-5.72	-0.3	2.38e-8	Coronary artery disease;
LUSC	cis	rs7119	0.679	rs34075648	chr15:77847802	G/C	cg27398640	chr15:77910606	LINGO1	-0.33	-7.04	-0.36	1.12e-11	Type 2 diabetes;
LUSC	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.55	9.31	0.45	1.8e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.86	14.38	0.62	7.74e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18876405	chr7:65276391	NA	-0.56	-8.93	-0.44	2.86e-17	Aortic root size;
LUSC	cis	rs79387448	0.745	rs6709719	chr2:103144953	G/A	cg09003973	chr2:102972529	NA	0.89	8.68	0.43	1.76e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs4665630	0.522	rs75866363	chr2:24046426	G/A	cg08063864	chr2:24346004	PFN4;LOC375190	0.94	8.03	0.4	1.74e-14	Hypertension;
LUSC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24531977	chr5:56204891	C5orf35	-0.78	-11.46	-0.53	7.52e-26	Type 2 diabetes;
LUSC	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.58	-11.12	-0.52	1.17e-24	Monocyte percentage of white cells;
LUSC	cis	rs887829	0.570	rs11680450	chr2:234597483	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.28	-0.33	1.04e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	3.96e-12	Motion sickness;
LUSC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.46	0.59	2.79e-33	Platelet count;
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.48	-7.81	-0.39	7.47e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2479724	0.805	rs11756454	chr6:41798578	T/A	cg17623882	chr6:41773611	USP49	0.65	10.61	0.5	7.42e-23	Menarche (age at onset);
LUSC	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg05855489	chr10:104503620	C10orf26	0.6	8.7	0.43	1.55e-16	Arsenic metabolism;
LUSC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg23788917	chr6:8435910	SLC35B3	0.51	7.58	0.38	3.38e-13	Motion sickness;
LUSC	cis	rs12425451	0.544	rs3741951	chr12:3147080	A/G	cg05389053	chr12:3131226	TEAD4	0.43	5.75	0.3	1.96e-8	Narcolepsy with cataplexy;
LUSC	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg00376283	chr12:123451042	ABCB9	0.68	8.44	0.42	1.01e-15	Neutrophil percentage of white cells;
LUSC	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-9.8	-0.47	4.44e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.65	11.09	0.52	1.47e-24	Myeloid white cell count;
LUSC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg06238570	chr21:40685208	BRWD1	0.47	7.27	0.37	2.56e-12	Cognitive function;
LUSC	cis	rs16976116	0.951	rs12385963	chr15:55482851	A/G	cg11288833	chr15:55489084	RSL24D1	0.53	6.35	0.33	7.21e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg21856205	chr7:94953877	PON1	-0.36	-5.77	-0.3	1.77e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg21141812	chr3:48556323	PFKFB4	0.33	5.68	0.3	2.96e-8	Menarche (age at onset);
LUSC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg26304593	chr6:42947056	PEX6	-0.54	-8.39	-0.42	1.35e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg24130564	chr14:104152367	KLC1	-0.39	-5.69	-0.3	2.71e-8	Body mass index;
LUSC	cis	rs56283067	0.578	rs12201563	chr6:45359394	T/C	cg18551225	chr6:44695536	NA	-0.44	-6.58	-0.34	1.86e-10	Total body bone mineral density;
LUSC	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.89	-0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg10018233	chr7:150070692	REPIN1	0.39	7.08	0.36	8.46e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.63	13.32	0.59	9.24e-33	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs4862307	0.836	rs6829678	chr4:185001631	C/T	cg06737308	chr4:185021514	ENPP6	-0.46	-7.14	-0.36	5.87e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUSC	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg24011408	chr12:48396354	COL2A1	-0.53	-8.72	-0.43	1.34e-16	Plateletcrit;
LUSC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg00944433	chr1:107599041	PRMT6	-0.38	-6.97	-0.36	1.69e-11	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg03806693	chr22:41940476	POLR3H	-0.75	-10.71	-0.51	3.31e-23	Vitiligo;
LUSC	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg06026331	chr20:60912101	LAMA5	0.58	6.9	0.35	2.65e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg13685833	chr1:53393034	SCP2	0.39	5.93	0.31	7.74e-9	Monocyte count;
LUSC	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg13010344	chr12:123464640	ARL6IP4	0.47	5.85	0.3	1.18e-8	Neutrophil percentage of white cells;
LUSC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg10862848	chr6:42927986	GNMT	-0.29	-7.04	-0.36	1.08e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg19901468	chr14:105411992	AHNAK2	-0.7	-12.14	-0.55	2.36e-28	Rheumatoid arthritis;
LUSC	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.7	0.75	7.91e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.42	-0.42	1.12e-15	Type 2 diabetes;
LUSC	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.7	-0.34	8.66e-11	Response to antipsychotic treatment;
LUSC	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg03522245	chr20:25566470	NINL	-0.36	-5.88	-0.31	1.02e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg13628971	chr7:2884303	GNA12	0.47	6.64	0.34	1.27e-10	Height;
LUSC	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg16482183	chr6:26056742	HIST1H1C	0.78	9.84	0.47	3.11e-20	Iron status biomarkers;
LUSC	trans	rs10090774	0.965	rs13264974	chr8:141918720	C/A	cg16477744	chr7:157367142	PTPRN2;MIR153-2	0.28	5.96	0.31	6.36e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25878452	chr7:6746558	ZNF12	-0.47	-6.95	-0.36	1.91e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2901656	0.677	rs2301455	chr1:172418268	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.35	7.03	0.36	1.15e-11	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs2273669	0.585	rs6900472	chr6:109372120	G/A	cg05315195	chr6:109294784	ARMC2	-0.51	-5.71	-0.3	2.53e-8	Prostate cancer;
LUSC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg14668632	chr7:2872130	GNA12	-0.43	-6.01	-0.31	4.78e-9	Height;
LUSC	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.61	9.29	0.45	2.02e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg15534755	chr11:117069859	TAGLN	0.36	6.3	0.33	9.54e-10	Blood protein levels;
LUSC	cis	rs10821973	0.558	rs6479799	chr10:64023166	A/G	cg19640130	chr10:64028056	RTKN2	-0.39	-6.31	-0.33	8.72e-10	Hypothyroidism;
LUSC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg11663144	chr21:46675770	NA	-0.41	-7.09	-0.36	7.96e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg04398451	chr17:18023971	MYO15A	-0.46	-7.29	-0.37	2.3e-12	Total body bone mineral density;
LUSC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.18	0.37	4.54e-12	Bipolar disorder;
LUSC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg06453172	chr10:134556979	INPP5A	-0.49	-6.11	-0.32	2.78e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs57046232	0.552	rs4402836	chr20:6338026	G/A	cg21095983	chr6:86352623	SYNCRIP	0.46	6.91	0.35	2.45e-11	Colorectal cancer;
LUSC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg20243544	chr17:37824526	PNMT	0.38	5.78	0.3	1.7e-8	Self-reported allergy;
LUSC	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.44	6.23	0.32	1.43e-9	Lung cancer;
LUSC	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg07382826	chr16:28625726	SULT1A1	-0.28	-6.08	-0.32	3.29e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg09307838	chr4:120376055	NA	0.75	10.89	0.51	7.5e-24	Corneal astigmatism;
LUSC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-11.7	-0.54	1.02e-26	Colorectal cancer;
LUSC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-1.11	-22.0	-0.77	6.18e-67	Height;
LUSC	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.39	-5.73	-0.3	2.23e-8	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06395280	chr2:242295608	FARP2	-0.42	-6.2	-0.32	1.65e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.05	20.0	0.74	4.7e-59	Cognitive ability;
LUSC	cis	rs907683	0.570	rs2666104	chr2:220281010	C/T	cg15015639	chr2:220282977	DES	-0.31	-7.05	-0.36	1.03e-11	Resting heart rate;
LUSC	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg05973401	chr12:123451056	ABCB9	0.52	6.46	0.33	3.79e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18876405	chr7:65276391	NA	0.55	5.87	0.31	1.06e-8	Diabetic kidney disease;
LUSC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg06636001	chr8:8085503	FLJ10661	0.65	10.52	0.5	1.58e-22	Mood instability;
LUSC	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg26162295	chr17:38119207	GSDMA	-0.28	-6.33	-0.33	8.07e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	1.05	20.23	0.74	5.91e-60	Menopause (age at onset);
LUSC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19717773	chr7:2847554	GNA12	-0.37	-6.05	-0.31	3.98e-9	Height;
LUSC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg20203395	chr5:56204925	C5orf35	-0.72	-9.94	-0.48	1.41e-20	Initial pursuit acceleration;
LUSC	cis	rs2294693	0.786	rs10456497	chr6:40989057	T/C	cg14769373	chr6:40998127	UNC5CL	-0.57	-7.32	-0.37	1.86e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg09455208	chr3:40491958	NA	0.58	10.15	0.49	2.74e-21	Renal cell carcinoma;
LUSC	cis	rs977987	0.836	rs7199062	chr16:75474827	G/A	cg04384234	chr16:75411784	CFDP1	-0.45	-7.5	-0.38	5.93e-13	Dupuytren's disease;
LUSC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.78	12.42	0.56	2.27e-29	Longevity;
LUSC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg15468180	chr1:107600409	PRMT6	-0.36	-5.83	-0.3	1.31e-8	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.48	7.36	0.37	1.45e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg08847533	chr14:75593920	NEK9	0.86	16.21	0.66	5.23e-44	Height;
LUSC	cis	rs28595532	0.748	rs67928655	chr4:119336525	C/A	cg21605333	chr4:119757512	SEC24D	0.97	8.07	0.4	1.26e-14	Cannabis dependence symptom count;
LUSC	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg15556689	chr8:8085844	FLJ10661	0.57	8.34	0.42	1.98e-15	Retinal vascular caliber;
LUSC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-1.12	-25.08	-0.81	8.21e-79	Height;
LUSC	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.55	-7.88	-0.4	4.53e-14	Reticulocyte count;
LUSC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	0.77	11.41	0.53	1.12e-25	Gut microbiome composition (summer);
LUSC	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.47	6.7	0.34	8.83e-11	Monocyte percentage of white cells;
LUSC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg23985595	chr17:80112537	CCDC57	-0.31	-5.94	-0.31	7.02e-9	Life satisfaction;
LUSC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg21573476	chr21:45109991	RRP1B	-0.36	-6.04	-0.31	4.04e-9	Mean corpuscular volume;
LUSC	cis	rs7215564	0.818	rs35459747	chr17:78661475	T/C	cg23238734	chr17:78661607	RPTOR	0.47	6.09	0.32	3.13e-9	Myopia (pathological);
LUSC	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg21016266	chr12:122356598	WDR66	0.57	8.48	0.42	7.25e-16	Mean corpuscular volume;
LUSC	cis	rs9905704	0.918	rs12949138	chr17:56934865	A/C	cg12560992	chr17:57184187	TRIM37	0.54	7.75	0.39	1.15e-13	Testicular germ cell tumor;
LUSC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	13.09	0.58	7.12e-32	Cognitive test performance;
LUSC	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg21775007	chr8:11205619	TDH	0.81	13.85	0.6	8.77e-35	Retinal vascular caliber;
LUSC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg12751644	chr20:60527061	NA	-0.33	-5.91	-0.31	8.33e-9	Body mass index;
LUSC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg24399712	chr22:39784796	NA	-0.63	-10.47	-0.5	2.18e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg26727032	chr16:67993705	SLC12A4	-0.44	-6.2	-0.32	1.65e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg03676636	chr4:99064102	C4orf37	0.38	8.0	0.4	2.02e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.17	-0.52	8.01e-25	Mean corpuscular volume;
LUSC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-14.06	-0.61	1.38e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3744061	0.557	rs2098091	chr17:74646817	A/G	cg27546012	chr17:74684504	MXRA7	-0.37	-6.37	-0.33	6.19e-10	Retinal arteriolar caliber;
LUSC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg22800045	chr5:56110881	MAP3K1	-0.48	-6.35	-0.33	7.05e-10	Coronary artery disease;
LUSC	cis	rs3771570	1.000	rs73004382	chr2:242382192	C/T	cg21155796	chr2:242212141	HDLBP	0.6	6.54	0.34	2.28e-10	Prostate cancer;
LUSC	trans	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg10756647	chr7:56101905	PSPH	0.87	8.5	0.42	6.62e-16	Diabetic kidney disease;
LUSC	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg27284194	chr4:1044797	NA	0.51	8.48	0.42	7.14e-16	Recombination rate (males);
LUSC	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.39	6.9	0.35	2.56e-11	Crohn's disease;
LUSC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg17143192	chr8:8559678	CLDN23	0.66	9.26	0.45	2.46e-18	Obesity-related traits;
LUSC	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.19	-0.32	1.79e-9	IgG glycosylation;
LUSC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-9.96	-0.48	1.24e-20	Mood instability;
LUSC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.72	-10.77	-0.51	2.11e-23	Vitiligo;
LUSC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg06784218	chr1:46089804	CCDC17	-0.57	-11.28	-0.53	3.09e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	7.17	0.37	4.86e-12	Cognitive test performance;
LUSC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.64	8.05	0.4	1.45e-14	Lung function (FEV1/FVC);
LUSC	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg21798802	chr22:38057573	PDXP	0.34	7.17	0.37	4.89e-12	Fat distribution (HIV);
LUSC	trans	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg05926928	chr17:57297772	GDPD1	-0.46	-6.46	-0.33	3.76e-10	Schizophrenia;
LUSC	cis	rs77633900	0.614	rs203753	chr15:76946195	A/T	cg21673338	chr15:77095150	SCAPER	-0.74	-7.39	-0.37	1.19e-12	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg27284194	chr4:1044797	NA	0.6	9.01	0.44	1.62e-17	Recombination rate (females);
LUSC	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg01191920	chr7:158217561	PTPRN2	-0.51	-10.71	-0.51	3.3e-23	Obesity-related traits;
LUSC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20541753	chr11:34938014	PDHX;APIP	-0.45	-6.75	-0.35	6.43e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21211367	chr2:162094118	NA	0.44	7.13	0.36	6.38e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg24829409	chr8:58192753	C8orf71	0.54	6.01	0.31	4.95e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs500891	0.553	rs9449623	chr6:84180355	A/T	cg08257003	chr6:84140564	ME1	-0.32	-7.79	-0.39	8.71e-14	Platelet-derived growth factor BB levels;
LUSC	trans	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg18187862	chr3:45730750	SACM1L	-0.52	-6.33	-0.33	7.7e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg11344533	chr11:111475393	SIK2	-0.49	-6.89	-0.35	2.86e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg09307838	chr4:120376055	NA	0.7	10.17	0.49	2.4e-21	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg07424592	chr7:64974309	NA	0.66	5.83	0.3	1.32e-8	Diabetic kidney disease;
LUSC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg22823121	chr1:150693482	HORMAD1	0.5	7.24	0.37	3.11e-12	Melanoma;
LUSC	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg16339924	chr4:17578868	LAP3	0.55	8.37	0.42	1.57e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6700896	0.931	rs4655585	chr1:66155627	T/C	cg04111102	chr1:66153794	NA	0.33	7.4	0.38	1.14e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2860975	1.000	rs7899746	chr10:96787859	T/C	cg09036531	chr10:96991505	NA	-0.42	-5.71	-0.3	2.46e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg06623918	chr6:96969491	KIAA0776	-0.82	-10.0	-0.48	9.04e-21	Migraine;Coronary artery disease;
LUSC	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg03929089	chr4:120376271	NA	0.58	6.49	0.33	3.04e-10	Axial length;
LUSC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg17986701	chr20:44574422	PCIF1	0.37	6.64	0.34	1.26e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9650657	0.655	rs4841434	chr8:10586123	T/C	cg14992524	chr8:10586135	SOX7	-0.33	-5.94	-0.31	7.03e-9	Neuroticism;
LUSC	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg17986701	chr20:44574422	PCIF1	0.4	7.12	0.36	6.79e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9648716	0.515	rs38730	chr7:140704638	C/T	cg23214464	chr7:140373596	ADCK2	0.72	6.24	0.32	1.34e-9	Type 2 diabetes;
LUSC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15664640	chr17:80829946	TBCD	-0.72	-12.55	-0.57	7.43e-30	Breast cancer;
LUSC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg23630131	chr7:65973040	NA	0.21	5.78	0.3	1.74e-8	Aortic root size;
LUSC	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg18478394	chr8:109455254	TTC35	0.42	6.41	0.33	5.04e-10	Dupuytren's disease;
LUSC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg26513180	chr16:89883248	FANCA	0.92	17.48	0.69	4.71e-49	Vitiligo;
LUSC	trans	rs6480314	0.542	rs17297383	chr10:70028863	C/T	cg04882175	chr6:131122610	NA	-0.54	-6.26	-0.32	1.18e-9	Optic nerve measurement (disc area);
LUSC	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg03342759	chr3:160939853	NMD3	-0.41	-5.98	-0.31	5.71e-9	Morning vs. evening chronotype;
LUSC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.79	14.92	0.63	6.05e-39	Dental caries;
LUSC	cis	rs7827545	0.545	rs1867062	chr8:135559079	G/A	cg17885191	chr8:135476712	NA	0.62	7.91	0.4	3.76e-14	Hypertension (SNP x SNP interaction);
LUSC	cis	rs6496044	0.568	rs12708554	chr15:86074297	C/G	cg13263323	chr15:86062960	AKAP13	-0.35	-5.73	-0.3	2.25e-8	Interstitial lung disease;
LUSC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg23590916	chr17:43697445	MGC57346	-0.49	-6.59	-0.34	1.7e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.95	-0.48	1.37e-20	Morning vs. evening chronotype;
LUSC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24549020	chr5:56110836	MAP3K1	0.48	5.71	0.3	2.46e-8	Initial pursuit acceleration;
LUSC	cis	rs1957429	0.614	rs73279823	chr14:65351315	A/G	cg23373153	chr14:65346875	NA	-0.99	-8.98	-0.44	1.97e-17	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.65	-8.92	-0.44	3.2e-17	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs724744	0.935	rs707871	chr6:22335048	T/C	cg13807341	chr11:118445984	ARCN1	-0.35	-6.02	-0.31	4.72e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.78	7.41	0.38	1.08e-12	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg05855489	chr10:104503620	C10orf26	0.52	8.0	0.4	2.13e-14	Arsenic metabolism;
LUSC	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.73	0.43	1.22e-16	Lung cancer in ever smokers;
LUSC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.85	15.67	0.65	6.91e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.23	-14.09	-0.61	1.07e-35	Diabetic kidney disease;
LUSC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg19257562	chr1:2043853	PRKCZ	0.31	6.25	0.32	1.23e-9	Height;
LUSC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.44	-0.38	8.49e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3847687	1.000	rs3847688	chr12:131525310	C/T	cg25772418	chr12:131519998	GPR133	-0.26	-5.74	-0.3	2.11e-8	Longevity;
LUSC	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg27284194	chr4:1044797	NA	0.59	8.7	0.43	1.49e-16	Recombination rate (females);
LUSC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg18904891	chr8:8559673	CLDN23	0.56	7.8	0.39	7.89e-14	Obesity-related traits;
LUSC	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs7578035	0.500	rs17021941	chr2:99384299	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.29	-0.33	9.72e-10	Bipolar disorder;
LUSC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg18350739	chr11:68623251	NA	-0.37	-6.36	-0.33	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.9	0.31	9.03e-9	Menopause (age at onset);
LUSC	trans	rs2229238	0.911	rs6674171	chr1:154491683	A/G	cg25273160	chr11:56955011	LRRC55	0.31	5.96	0.31	6.37e-9	Coronary heart disease;
LUSC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.85	13.81	0.6	1.22e-34	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg11344533	chr11:111475393	SIK2	-0.47	-6.31	-0.33	8.66e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6961069	0.745	rs1953298	chr7:80265451	C/T	cg04458919	chr7:80252533	CD36	-0.37	-6.69	-0.34	9.65e-11	Platelet count;
LUSC	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg24558204	chr6:135376177	HBS1L	0.59	9.12	0.45	7.4e-18	Red blood cell count;
LUSC	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.6	9.35	0.46	1.34e-18	Morning vs. evening chronotype;
LUSC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.91	-13.29	-0.59	1.22e-32	Alzheimer's disease;
LUSC	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg04455712	chr21:45112962	RRP1B	0.49	9.23	0.45	3.25e-18	Mean corpuscular volume;
LUSC	cis	rs2274273	0.588	rs11158037	chr14:55832152	C/A	cg04306507	chr14:55594613	LGALS3	0.49	9.82	0.47	3.79e-20	Protein biomarker;
LUSC	cis	rs1784581	0.588	rs1784606	chr6:162405992	A/T	cg17173639	chr6:162384350	PARK2	-0.54	-9.26	-0.45	2.55e-18	Itch intensity from mosquito bite;
LUSC	cis	rs2455601	0.671	rs2568091	chr11:8986048	C/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.43	-7.09	-0.36	8.27e-12	Schizophrenia;
LUSC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg08975724	chr8:8085496	FLJ10661	0.59	8.85	0.44	5.37e-17	Systolic blood pressure;
LUSC	cis	rs367943	0.712	rs7714734	chr5:112691261	G/A	cg12552261	chr5:112820674	MCC	0.41	6.69	0.34	9.64e-11	Type 2 diabetes;
LUSC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg09877947	chr5:131593287	PDLIM4	0.49	8.45	0.42	9.13e-16	Blood metabolite levels;
LUSC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg16423285	chr20:60520624	NA	-0.46	-5.76	-0.3	1.94e-8	Body mass index;
LUSC	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg20701182	chr2:24300061	SF3B14	0.89	11.69	0.54	1.08e-26	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.6	0.38	3.03e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg20398880	chr6:41068722	NFYA;LOC221442	-0.36	-5.86	-0.31	1.11e-8	Alzheimer's disease (late onset);
LUSC	cis	rs11051970	0.879	rs2651378	chr12:32581794	A/G	cg02745156	chr12:32552066	NA	0.43	7.32	0.37	1.88e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg06784218	chr1:46089804	CCDC17	0.56	11.25	0.52	4.04e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg16339924	chr4:17578868	LAP3	0.67	10.72	0.51	2.97e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg18105134	chr13:113819100	PROZ	0.66	9.57	0.46	2.46e-19	Platelet distribution width;
LUSC	cis	rs2652834	1.000	rs68088462	chr15:63397617	T/C	cg05507819	chr15:63340323	TPM1	0.67	8.13	0.41	8.72e-15	HDL cholesterol;
LUSC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.87	0.4	4.98e-14	Major depressive disorder;
LUSC	cis	rs3126085	0.935	rs3126094	chr1:152308243	T/C	cg26876637	chr1:152193138	HRNR	-0.45	-6.32	-0.33	8.44e-10	Atopic dermatitis;
LUSC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg11645453	chr3:52864694	ITIH4	0.35	8.06	0.4	1.36e-14	Bipolar disorder;
LUSC	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg04362960	chr10:104952993	NT5C2	0.58	9.19	0.45	4.29e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.41	-6.15	-0.32	2.23e-9	Tonsillectomy;
LUSC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg23719950	chr11:63933701	MACROD1	-0.6	-7.48	-0.38	6.57e-13	Mean platelet volume;
LUSC	cis	rs2235649	0.552	rs8056773	chr16:1959432	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.47	-5.69	-0.3	2.76e-8	Blood metabolite levels;
LUSC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg07424592	chr7:64974309	NA	0.63	5.69	0.3	2.81e-8	Diabetic kidney disease;
LUSC	cis	rs6977660	1.000	rs6959591	chr7:19821824	A/G	cg07541023	chr7:19748670	TWISTNB	0.51	5.73	0.3	2.3e-8	Thyroid stimulating hormone;
LUSC	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12292205	chr6:26970375	C6orf41	0.57	7.34	0.37	1.62e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg15704280	chr7:45808275	SEPT13	-0.65	-7.06	-0.36	9.8e-12	Axial length;
LUSC	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg00105475	chr2:10696890	NA	0.36	6.0	0.31	5.25e-9	Prostate cancer;
LUSC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.05	0.55	5.3e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19627864	chr1:16940181	NBPF1	-0.4	-5.99	-0.31	5.51e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs4073416	0.595	rs11158598	chr14:65923738	A/G	cg03016385	chr14:66212404	NA	-0.38	-5.89	-0.31	9.65e-9	N-glycan levels;
LUSC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.53	-8.35	-0.42	1.8e-15	Platelet count;
LUSC	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-0.69	-9.9	-0.48	2.01e-20	Platelet distribution width;
LUSC	cis	rs12425451	0.544	rs7961302	chr12:3146436	G/C	cg05389053	chr12:3131226	TEAD4	-0.43	-5.73	-0.3	2.26e-8	Narcolepsy with cataplexy;
LUSC	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg09479241	chr17:27052676	TLCD1	0.43	5.78	0.3	1.74e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg21827317	chr3:136751795	NA	0.37	6.57	0.34	1.9e-10	Neuroticism;
LUSC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.86	-0.81	6.04e-78	Height;
LUSC	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg23387468	chr7:139079360	LUC7L2	0.42	6.34	0.33	7.52e-10	Diisocyanate-induced asthma;
LUSC	cis	rs11264213	0.901	rs72661643	chr1:36451599	A/G	cg27506609	chr1:36549197	TEKT2	0.7	7.98	0.4	2.33e-14	Schizophrenia;
LUSC	cis	rs10484885	0.759	rs56230212	chr6:90234654	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.71	-6.47	-0.33	3.49e-10	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs34779708	0.733	rs4444023	chr10:35548354	G/A	cg03585969	chr10:35415529	CREM	0.53	7.38	0.37	1.3e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg06951627	chr6:26196580	NA	0.53	5.72	0.3	2.39e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg16576597	chr16:28551801	NUPR1	0.31	6.24	0.32	1.29e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-9.71	-0.47	8.3e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg25173405	chr17:45401733	C17orf57	-0.42	-6.8	-0.35	4.96e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.58	0.34	1.81e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs11030122	0.673	rs11030660	chr11:4043268	T/C	cg08557956	chr11:4115526	RRM1	-0.46	-5.99	-0.31	5.54e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg09455208	chr3:40491958	NA	0.57	10.09	0.48	4.35e-21	Renal cell carcinoma;
LUSC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.25	0.41	3.79e-15	Melanoma;
LUSC	trans	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.95	-0.36	1.96e-11	Neuroticism;
LUSC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06634786	chr22:41940651	POLR3H	-0.55	-6.53	-0.34	2.49e-10	Vitiligo;
LUSC	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg02782426	chr3:40428986	ENTPD3	0.3	5.7	0.3	2.64e-8	Renal cell carcinoma;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg24081974	chr4:78784263	MRPL1	0.41	6.52	0.34	2.63e-10	Schizophrenia;
LUSC	cis	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05901451	chr6:126070800	HEY2	-0.58	-8.7	-0.43	1.5e-16	Endometrial cancer;
LUSC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.08	-0.44	9.9e-18	Gut microbiome composition (summer);
LUSC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.59	9.19	0.45	4.42e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	0.94	18.18	0.71	7.7e-52	Cognitive function;
LUSC	cis	rs7715806	0.500	rs72633984	chr5:75005899	A/G	cg19683494	chr5:74908142	NA	0.57	7.68	0.39	1.83e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7818345	0.967	rs7004435	chr8:19282732	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.41	0.38	1.05e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.29	-5.81	-0.3	1.49e-8	Total body bone mineral density;
LUSC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg11764359	chr7:65958608	NA	-0.52	-6.71	-0.34	8.17e-11	Aortic root size;
LUSC	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.71	-12.23	-0.56	1.13e-28	White blood cell count (basophil);
LUSC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg21672276	chr3:44754072	ZNF502	-0.37	-5.73	-0.3	2.24e-8	Depressive symptoms;
LUSC	cis	rs4954585	0.708	rs10200263	chr2:137007429	C/T	cg05194412	chr2:137003533	NA	0.39	7.11	0.36	7.1e-12	Colorectal cancer;
LUSC	trans	rs9951602	0.833	rs9953548	chr18:76640601	C/T	cg02800362	chr5:177631904	HNRNPAB	0.95	10.32	0.49	7.21e-22	Obesity-related traits;
LUSC	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg27284194	chr4:1044797	NA	0.61	8.92	0.44	3.08e-17	Recombination rate (females);
LUSC	cis	rs2262909	0.962	rs73019842	chr19:22249909	T/G	cg11619707	chr19:22235551	ZNF257	0.39	5.83	0.3	1.29e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg24558204	chr6:135376177	HBS1L	0.59	9.26	0.45	2.63e-18	Red blood cell count;
LUSC	cis	rs6967385	0.560	rs7790370	chr7:12353523	G/C	cg20607287	chr7:12443886	VWDE	0.5	7.5	0.38	5.88e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg18477163	chr1:228402036	OBSCN	0.63	12.0	0.55	8e-28	Diastolic blood pressure;
LUSC	cis	rs1595825	1.000	rs1304165	chr2:198877300	G/A	cg00982548	chr2:198649783	BOLL	-0.49	-6.15	-0.32	2.15e-9	Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00376283	chr12:123451042	ABCB9	0.68	8.65	0.43	2.18e-16	Neutrophil percentage of white cells;
LUSC	cis	rs7537052	0.564	rs6669395	chr1:36653717	A/G	cg24686825	chr1:36642396	MAP7D1	-0.74	-12.93	-0.58	2.66e-31	Schizophrenia;
LUSC	cis	rs6977660	0.943	rs9639334	chr7:19838810	G/A	cg05791153	chr7:19748676	TWISTNB	0.58	6.46	0.33	3.6e-10	Thyroid stimulating hormone;
LUSC	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.77	-0.47	5.22e-20	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11051970	0.918	rs73084101	chr12:32544339	A/C	cg24626660	chr12:32551988	NA	0.37	6.13	0.32	2.46e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2348418	0.864	rs7314984	chr12:28710869	C/T	cg13890972	chr12:28721907	NA	-0.36	-6.31	-0.33	8.63e-10	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg12564285	chr5:131593104	PDLIM4	0.44	7.92	0.4	3.63e-14	Blood metabolite levels;
LUSC	cis	rs7809950	0.954	rs2520243	chr7:107136973	T/C	cg23024343	chr7:107201750	COG5	-0.54	-8.69	-0.43	1.71e-16	Coronary artery disease;
LUSC	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.7	13.56	0.6	1.08e-33	Ulcerative colitis;
LUSC	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg00852783	chr1:26633632	UBXN11	-0.48	-5.67	-0.3	3.16e-8	Obesity-related traits;
LUSC	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.46	-6.36	-0.33	6.57e-10	Neutrophil percentage of white cells;
LUSC	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg10326726	chr10:51549505	MSMB	-0.36	-6.3	-0.33	9.6e-10	Prostate-specific antigen levels;
LUSC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg03465714	chr1:152285911	FLG	0.43	6.06	0.31	3.58e-9	Atopic dermatitis;
LUSC	cis	rs11055008	0.620	rs10845608	chr12:12836088	C/T	cg04607235	chr12:12878440	APOLD1	0.5	7.5	0.38	5.94e-13	Pulse pressure;
LUSC	trans	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04565464	chr8:145669602	NFKBIL2	0.39	6.41	0.33	4.9e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg12311346	chr5:56204834	C5orf35	0.5	7.68	0.39	1.83e-13	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	11.3	0.53	2.7e-25	Tonsillectomy;
LUSC	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg10167378	chr1:228756711	NA	0.75	9.65	0.47	1.37e-19	Chronic lymphocytic leukemia;
LUSC	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	11.7	0.54	9.93e-27	Ileal carcinoids;
LUSC	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-6.57	-0.34	1.96e-10	Colorectal cancer;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg16769688	chr16:1823307	MRPS34;EME2	0.45	6.12	0.32	2.69e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg26668828	chr6:292823	DUSP22	-0.5	-7.34	-0.37	1.68e-12	Menopause (age at onset);
LUSC	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-1.12	-19.49	-0.73	4.76e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6545883	0.894	rs2694649	chr2:61573826	G/A	cg15711740	chr2:61764176	XPO1	0.43	6.59	0.34	1.73e-10	Tuberculosis;
LUSC	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg19682013	chr15:45996608	NA	0.39	5.99	0.31	5.4e-9	Waist circumference;Weight;
LUSC	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg22496339	chr2:162101262	NA	0.45	6.54	0.34	2.32e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg08888203	chr3:10149979	C3orf24	0.65	8.29	0.41	2.78e-15	Alzheimer's disease;
LUSC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs72634258	0.786	rs9434993	chr1:8179744	G/C	cg26816564	chr1:7831052	VAMP3	0.46	6.13	0.32	2.51e-9	Inflammatory bowel disease;
LUSC	trans	rs67133203	0.796	rs1005559	chr12:51414232	T/A	cg17484237	chr5:156536107	HAVCR2	0.44	5.97	0.31	6.1e-9	Urinary tract infection frequency;
LUSC	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg26408565	chr15:76604113	ETFA	-0.48	-7.68	-0.39	1.84e-13	Blood metabolite levels;
LUSC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg12365402	chr11:9010492	NRIP3	0.42	7.69	0.39	1.7e-13	Hemoglobin concentration;
LUSC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg00800038	chr16:89945340	TCF25	-0.63	-6.68	-0.34	1.02e-10	Skin colour saturation;
LUSC	cis	rs9326248	0.652	rs7128382	chr11:117023487	A/C	cg11861562	chr11:117069780	TAGLN	0.36	5.87	0.31	1.06e-8	Blood protein levels;
LUSC	cis	rs714027	0.565	rs9614099	chr22:30288338	A/T	cg11564601	chr22:30592435	NA	0.33	5.84	0.3	1.21e-8	Lymphocyte counts;
LUSC	cis	rs9796	0.870	rs8023345	chr15:41338348	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.41	-7.08	-0.36	8.46e-12	Menopause (age at onset);
LUSC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.77	-12.8	-0.57	8.5e-31	Age at first birth;
LUSC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg09323728	chr8:95962352	TP53INP1	-0.4	-7.92	-0.4	3.56e-14	Type 2 diabetes;
LUSC	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg11861562	chr11:117069780	TAGLN	0.33	6.32	0.33	8.42e-10	Blood protein levels;
LUSC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg05623727	chr3:50126028	RBM5	0.31	5.73	0.3	2.21e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg03859395	chr2:55845619	SMEK2	0.85	14.99	0.63	3.24e-39	Metabolic syndrome;
LUSC	cis	rs7084921	0.608	rs2862948	chr10:101864173	A/G	cg11888571	chr10:102027403	CWF19L1	-0.42	-5.9	-0.31	8.71e-9	Bone mineral density;
LUSC	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg00745463	chr17:30367425	LRRC37B	0.87	8.55	0.42	4.49e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg12288994	chr5:1860383	NA	0.28	6.18	0.32	1.9e-9	Cardiovascular disease risk factors;
LUSC	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.61	8.41	0.42	1.24e-15	Resting heart rate;
LUSC	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.63	-0.43	2.59e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg13126279	chr21:47581558	C21orf56	-0.41	-5.83	-0.3	1.31e-8	Testicular germ cell tumor;
LUSC	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg18806716	chr10:30721971	MAP3K8	-0.58	-9.18	-0.45	4.62e-18	Inflammatory bowel disease;
LUSC	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.46	-0.33	3.6e-10	Breast cancer;
LUSC	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg13126279	chr21:47581558	C21orf56	-0.41	-6.03	-0.31	4.29e-9	Testicular germ cell tumor;
LUSC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg00343986	chr7:65444356	GUSB	0.43	6.56	0.34	2.07e-10	Aortic root size;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg15242686	chr22:24348715	GSTTP1	0.54	8.56	0.42	4.05e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.9	12.12	0.55	2.84e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs834603	0.546	rs1704973	chr7:47483705	T/C	cg09696706	chr7:47479511	TNS3	0.34	6.06	0.31	3.65e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs367943	0.712	rs27567	chr5:112741798	C/T	cg12552261	chr5:112820674	MCC	0.36	6.05	0.31	3.85e-9	Type 2 diabetes;
LUSC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg04775059	chr7:64541387	NA	0.48	6.97	0.36	1.7e-11	Calcium levels;
LUSC	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.46	-0.33	3.7e-10	Resting heart rate;
LUSC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13732083	chr21:47605072	C21orf56	-0.43	-6.24	-0.32	1.32e-9	Testicular germ cell tumor;
LUSC	cis	rs8040855	0.627	rs3816105	chr15:85640911	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-5.81	-0.3	1.45e-8	Bulimia nervosa;
LUSC	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	1.17	13.66	0.6	4.72e-34	Arsenic metabolism;
LUSC	cis	rs983392	0.679	rs72920867	chr11:60005424	T/C	cg24026212	chr11:59952134	MS4A6A	-0.35	-5.93	-0.31	7.37e-9	Alzheimer's disease (late onset);
LUSC	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg09307838	chr4:120376055	NA	0.78	11.42	0.53	9.85e-26	Corneal astigmatism;
LUSC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.71	-12.2	-0.56	1.46e-28	Dental caries;
LUSC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-11.66	-0.54	1.32e-26	Chronic sinus infection;
LUSC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.91	-0.4	3.78e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg16797656	chr11:68205561	LRP5	0.36	5.94	0.31	7.09e-9	Total body bone mineral density;
LUSC	trans	rs12914656	0.556	rs34347645	chr15:86659428	C/A	cg27136844	chr3:147142355	NA	-0.41	-6.23	-0.32	1.42e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs12220238	1.000	rs4745740	chr10:75942469	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	7.22	0.37	3.49e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.41	6.3	0.33	9.28e-10	Platelet count;
LUSC	cis	rs7759001	0.817	rs4339442	chr6:27372127	A/T	cg18711553	chr6:27366782	ZNF391	0.39	5.73	0.3	2.25e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg15994321	chr1:161736098	ATF6	0.38	6.14	0.32	2.37e-9	Asthma;
LUSC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.52	0.38	5.14e-13	Electroencephalogram traits;
LUSC	cis	rs11608355	0.545	rs2302703	chr12:109898832	G/A	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.88	13.67	0.6	4.25e-34	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg00495681	chr13:53174319	NA	-0.42	-6.36	-0.33	6.58e-10	Lewy body disease;
LUSC	cis	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg19274914	chr2:15703543	NA	-0.42	-8.5	-0.42	6.36e-16	Educational attainment (years of education);
LUSC	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg09469691	chr10:81107165	PPIF	0.63	9.94	0.48	1.47e-20	Height;
LUSC	cis	rs62400317	0.826	rs12216308	chr6:45342305	T/G	cg18551225	chr6:44695536	NA	-0.44	-7.3	-0.37	2.06e-12	Total body bone mineral density;
LUSC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg01879757	chr17:41196368	BRCA1	-0.47	-7.58	-0.38	3.45e-13	Menopause (age at onset);
LUSC	cis	rs9462027	0.606	rs2235569	chr6:34570070	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.15	-0.32	2.19e-9	Systemic lupus erythematosus;
LUSC	trans	rs800082	0.516	rs4511940	chr3:144219392	T/C	cg24215973	chr2:240111563	HDAC4	0.44	6.64	0.34	1.27e-10	Smoking behavior;
LUSC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.47	-0.33	3.41e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg06784218	chr1:46089804	CCDC17	-0.58	-11.55	-0.53	3.58e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs748404	0.697	rs530188	chr15:43545314	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	7.79	0.39	8.69e-14	Lung cancer;
LUSC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg24060327	chr5:131705240	SLC22A5	0.48	7.45	0.38	8.06e-13	Acylcarnitine levels;
LUSC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg04733989	chr22:42467013	NAGA	0.6	9.35	0.46	1.26e-18	Schizophrenia;
LUSC	trans	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	10.34	0.49	6.5600000000000005e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg06612196	chr6:6737390	NA	0.56	11.14	0.52	9.79e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	trans	rs7951105	0.867	rs11035162	chr11:39251033	A/C	cg24085930	chr3:21832523	NA	0.49	6.05	0.31	3.94e-9	Free thyroxine concentration;
LUSC	trans	rs4252134	0.959	rs4252096	chr6:161134273	C/G	cg15416064	chr12:49209402	NA	-0.43	-6.01	-0.31	4.86e-9	Giant cell arteritis;
LUSC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08219700	chr8:58056026	NA	0.68	7.97	0.4	2.49e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-6.22	-0.32	1.5e-9	Vitiligo;
LUSC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.39	0.33	5.66e-10	Renal cell carcinoma;
LUSC	cis	rs9309473	0.687	rs6546827	chr2:73606493	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-7.45	-0.38	7.99e-13	Metabolite levels;
LUSC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12016809	chr21:47604291	C21orf56	-0.45	-6.71	-0.34	8.23e-11	Testicular germ cell tumor;
LUSC	cis	rs877282	1.000	rs11253367	chr10:773389	G/A	cg17470449	chr10:769945	NA	0.52	7.29	0.37	2.32e-12	Uric acid levels;
LUSC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.78	-12.27	-0.56	8.07e-29	Pancreatic cancer;
LUSC	cis	rs5770917	1.000	rs2269385	chr22:51010939	G/A	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.65	-5.7	-0.3	2.65e-8	Narcolepsy;
LUSC	cis	rs4363385	0.509	rs11576882	chr1:152918785	T/G	cg00922841	chr1:152955080	SPRR1A	-0.36	-5.94	-0.31	7.09e-9	Inflammatory skin disease;
LUSC	cis	rs3857536	0.776	rs9342535	chr6:66932963	C/T	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.56e-10	Blood trace element (Cu levels);
LUSC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg18240062	chr17:79603768	NPLOC4	0.59	10.07	0.48	5.3e-21	Eye color traits;
LUSC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg18827107	chr12:86230957	RASSF9	-0.44	-6.56	-0.34	2.07e-10	Major depressive disorder;
LUSC	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21659725	chr3:3221576	CRBN	0.64	10.59	0.5	8.53e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg17691542	chr6:26056736	HIST1H1C	0.59	8.19	0.41	5.46e-15	Iron status biomarkers;
LUSC	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg01294253	chr9:136912663	BRD3	0.34	5.99	0.31	5.41e-9	Platelet distribution width;
LUSC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10802521	chr3:52805072	NEK4	0.58	9.33	0.45	1.56e-18	Bipolar disorder;
LUSC	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg14696996	chr19:15285081	NOTCH3	0.93	8.77	0.43	9.25e-17	Pulse pressure;
LUSC	cis	rs2274273	0.624	rs8014477	chr14:55841477	A/G	cg04306507	chr14:55594613	LGALS3	-0.46	-9.55	-0.46	2.88e-19	Protein biomarker;
LUSC	cis	rs6500395	0.962	rs9922356	chr16:48640025	C/T	cg04672837	chr16:48644449	N4BP1	0.47	6.66	0.34	1.16e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg05941027	chr17:61774174	LIMD2	0.21	5.77	0.3	1.83e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.64e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.87	-14.74	-0.63	3.17e-38	Tonsillectomy;
LUSC	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.94	-0.44	2.7e-17	Total cholesterol levels;
LUSC	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg11502198	chr6:26597334	ABT1	0.72	12.12	0.55	2.76e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.8	13.48	0.59	2.24e-33	Menarche (age at onset);
LUSC	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.65	-11.02	-0.52	2.77e-24	Diastolic blood pressure;
LUSC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.92	12.18	0.55	1.78e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs4363385	0.571	rs387930	chr1:153050058	A/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-6.84	-0.35	3.9e-11	Inflammatory skin disease;
LUSC	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	0.89	16.7	0.67	5.82e-46	Heart rate;
LUSC	trans	rs2806864	1.000	rs2250865	chr1:117462691	A/G	cg04557197	chr17:77764992	NA	0.65	6.01	0.31	4.75e-9	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.45	-7.15	-0.36	5.4e-12	Systemic lupus erythematosus;
LUSC	cis	rs143985986	1	rs143985986	chr3:58399886	TC/T	cg26110898	chr3:58419937	PDHB	0.39	6.29	0.33	9.72e-10	Hematocrit;
LUSC	cis	rs701145	0.529	rs355759	chr3:154008078	G/C	cg10247383	chr3:153839028	SGEF	-0.47	-5.79	-0.3	1.61e-8	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09077966	chr16:89724782	C16orf55;CHMP1A	0.42	6.21	0.32	1.53e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.95	-0.44	2.43e-17	Total cholesterol levels;
LUSC	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	6.15	0.32	2.16e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7605827	0.930	rs13024118	chr2:15494640	A/T	cg19274914	chr2:15703543	NA	0.44	8.31	0.41	2.47e-15	Educational attainment (years of education);
LUSC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg02454025	chr1:11042201	C1orf127	1.03	18.59	0.71	1.91e-53	Ewing sarcoma;
LUSC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13126279	chr21:47581558	C21orf56	0.47	7.05	0.36	1e-11	Testicular germ cell tumor;
LUSC	cis	rs12900413	0.687	rs13343248	chr15:90311226	A/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.91	-0.31	8.6e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg13256891	chr4:100009986	ADH5	0.4	5.66	0.3	3.23e-8	Alcohol dependence;
LUSC	cis	rs11690935	0.802	rs34636594	chr2:172911094	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.82	-12.85	-0.58	5.62e-31	Schizophrenia;
LUSC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg14552801	chr7:65878734	NA	-0.43	-5.89	-0.31	9.49e-9	Aortic root size;
LUSC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	6.28	0.33	1.04e-9	Menopause (age at onset);
LUSC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	0.83	13.76	0.6	1.89e-34	Tonsillectomy;
LUSC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.39	7.65	0.39	2.13e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg02023728	chr11:77925099	USP35	0.42	6.26	0.32	1.19e-9	Testicular germ cell tumor;
LUSC	cis	rs9463078	0.764	rs1576382	chr6:44957553	G/A	cg25276700	chr6:44698697	NA	-0.28	-5.72	-0.3	2.43e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg23711669	chr6:146136114	FBXO30	0.74	13.07	0.58	7.88e-32	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14757344	chr21:45209507	RRP1	-0.45	-6.59	-0.34	1.7e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.7	12.3	0.56	6.32e-29	Aortic root size;
LUSC	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.05	-0.31	3.97e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1865721	0.682	rs7242637	chr18:73147492	A/C	cg26385618	chr18:73139727	C18orf62	-0.47	-8.78	-0.43	8.7e-17	Intelligence;
LUSC	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg24562669	chr7:97807699	LMTK2	0.4	6.78	0.35	5.32e-11	Breast cancer;
LUSC	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.55	11.62	0.54	1.95e-26	Vitamin D levels;
LUSC	cis	rs6076065	0.723	rs2253924	chr20:23388020	G/A	cg11657817	chr20:23433608	CST11	0.42	8.01	0.4	1.94e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs909341	0.909	rs2427532	chr20:62363817	G/A	cg09650180	chr20:62225654	GMEB2	-0.45	-5.81	-0.3	1.48e-8	Atopic dermatitis;
LUSC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg21918786	chr6:109611834	NA	0.42	7.32	0.37	1.92e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs2115630	0.764	rs11073716	chr15:85335774	C/T	cg09876464	chr15:85330779	ZNF592	0.37	6.78	0.35	5.36e-11	P wave terminal force;
LUSC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-0.78	-12.51	-0.56	1.03e-29	Longevity;
LUSC	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.85	-0.35	3.54e-11	Neuroticism;
LUSC	cis	rs6469656	1.000	rs4335153	chr8:117651448	A/T	cg24004040	chr8:117650383	NA	-0.43	-6.22	-0.32	1.46e-9	Colorectal cancer;
LUSC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg17264618	chr3:40429014	ENTPD3	-0.32	-6.43	-0.33	4.37e-10	Renal cell carcinoma;
LUSC	cis	rs965469	0.947	rs965468	chr20:3381443	C/T	cg25506879	chr20:3388711	C20orf194	-0.53	-5.74	-0.3	2.17e-8	IFN-related cytopenia;
LUSC	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.74	-14.38	-0.62	8.23e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.71	-11.91	-0.55	1.71e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg11887960	chr12:57824829	NA	0.59	7.66	0.39	2.07e-13	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.95	0.36	1.93e-11	Morning vs. evening chronotype;
LUSC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg24733560	chr20:60626293	TAF4	0.42	7.59	0.38	3.15e-13	Body mass index;
LUSC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg02176678	chr2:219576539	TTLL4	0.61	11.03	0.52	2.41e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.18	0.37	4.6e-12	Bipolar disorder;
LUSC	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg16797656	chr11:68205561	LRP5	-0.36	-5.86	-0.31	1.12e-8	Bone mineral density (spine);
LUSC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg19774624	chr17:42201019	HDAC5	0.83	14.44	0.62	4.62e-37	Total body bone mineral density;
LUSC	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.47	0.38	6.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg02023728	chr11:77925099	USP35	0.46	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	cis	rs9398803	0.865	rs9385399	chr6:126759033	A/C	cg19875578	chr6:126661172	C6orf173	-0.43	-6.42	-0.33	4.55e-10	Male-pattern baldness;
LUSC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.56e-10	Menopause (age at onset);
LUSC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12200782	1.000	rs4515370	chr6:26625319	T/C	cg11502198	chr6:26597334	ABT1	-0.76	-5.8	-0.3	1.53e-8	Small cell lung carcinoma;
LUSC	cis	rs524023	0.874	rs519090	chr11:64456240	G/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.5	-0.5	1.75e-22	Urate levels in obese individuals;
LUSC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg12751644	chr20:60527061	NA	-0.34	-6.16	-0.32	2.07e-9	Body mass index;
LUSC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg20887711	chr4:1340912	KIAA1530	0.42	6.33	0.33	7.96e-10	Obesity-related traits;
LUSC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.16	-0.32	2.12e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-8.43	-0.42	1.09e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg16482183	chr6:26056742	HIST1H1C	0.58	8.02	0.4	1.86e-14	Iron status biomarkers;
LUSC	cis	rs193541	0.626	rs10079456	chr5:122090442	G/A	cg19077854	chr5:122220652	SNX24	0.28	6.26	0.32	1.18e-9	Glucose homeostasis traits;
LUSC	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg11861562	chr11:117069780	TAGLN	0.33	6.36	0.33	6.48e-10	Blood protein levels;
LUSC	cis	rs7833787	0.832	rs7827258	chr8:18698295	G/C	cg17701159	chr8:18705777	PSD3	-0.36	-5.88	-0.31	1.02e-8	Obesity-related traits;
LUSC	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg03433033	chr1:76189801	ACADM	-0.43	-6.24	-0.32	1.33e-9	Daytime sleep phenotypes;
LUSC	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.9	15.7	0.65	5.49e-42	Morning vs. evening chronotype;
LUSC	cis	rs6684514	0.506	rs3762281	chr1:156304782	A/G	cg20302342	chr1:156215951	PAQR6	0.31	5.82	0.3	1.39e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUSC	cis	rs11997175	0.583	rs17780571	chr8:33817821	G/C	ch.8.33884649F	chr8:33765107	NA	0.45	6.47	0.33	3.56e-10	Body mass index;
LUSC	cis	rs2281558	0.837	rs56238023	chr20:25516947	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.62	9.33	0.45	1.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg22563815	chr15:78856949	CHRNA5	0.27	6.41	0.33	4.82e-10	Sudden cardiac arrest;
LUSC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg17333051	chr19:2783644	SGTA	0.51	7.59	0.38	3.32e-13	Total cholesterol levels;
LUSC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg00343986	chr7:65444356	GUSB	-0.43	-6.42	-0.33	4.74e-10	Aortic root size;
LUSC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg26554054	chr8:600488	NA	-0.61	-6.32	-0.33	8.37e-10	IgG glycosylation;
LUSC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.09	14.43	0.62	5.1e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.5	-0.38	5.71e-13	Retinal vascular caliber;
LUSC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg18190219	chr22:46762943	CELSR1	-0.48	-6.0	-0.31	5.03e-9	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg04282206	chr17:62833786	PLEKHM1P	-0.42	-6.18	-0.32	1.83e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg22437258	chr11:111473054	SIK2	0.52	7.01	0.36	1.33e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg22467129	chr15:76604101	ETFA	0.4	5.65	0.3	3.41e-8	Blood metabolite levels;
LUSC	cis	rs7605827	0.930	rs11896745	chr2:15515373	C/T	cg19274914	chr2:15703543	NA	0.46	8.77	0.43	9.32e-17	Educational attainment (years of education);
LUSC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg03146154	chr1:46216737	IPP	-0.58	-8.34	-0.41	2.04e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2729354	0.768	rs2584856	chr11:57267312	C/A	cg24343310	chr11:57249947	NA	0.43	8.32	0.41	2.19e-15	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.24	0.37	3.18e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg20307385	chr11:47447363	PSMC3	0.45	6.62	0.34	1.48e-10	Subjective well-being;
LUSC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg00409905	chr10:38381863	ZNF37A	0.4	6.8	0.35	4.88e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs2274273	0.870	rs8021583	chr14:55749607	G/A	cg04306507	chr14:55594613	LGALS3	0.54	12.06	0.55	4.93e-28	Protein biomarker;
LUSC	cis	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg06521331	chr12:34319734	NA	0.42	6.85	0.35	3.6e-11	Morning vs. evening chronotype;
LUSC	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg13334819	chr7:99746414	C7orf59	0.49	6.5	0.34	2.96e-10	Coronary artery disease;
LUSC	cis	rs9905704	0.846	rs304267	chr17:56799380	A/G	cg12560992	chr17:57184187	TRIM37	0.58	8.4	0.42	1.34e-15	Testicular germ cell tumor;
LUSC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-7.99	-0.4	2.25e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.94	13.01	0.58	1.35e-31	Gut microbiome composition (summer);
LUSC	trans	rs941408	0.515	rs759067	chr19:2775668	C/T	cg19676328	chr12:49525230	TUBA1B	-0.52	-7.39	-0.37	1.19e-12	Total cholesterol levels;
LUSC	cis	rs12210905	1.000	rs1102557	chr6:27149794	C/A	cg11502198	chr6:26597334	ABT1	0.79	5.66	0.3	3.22e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.56	5.7	0.3	2.67e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg09034736	chr1:150693464	HORMAD1	0.42	5.92	0.31	7.92e-9	Melanoma;
LUSC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg07636037	chr3:49044803	WDR6	0.44	6.29	0.33	1.01e-9	Resting heart rate;
LUSC	cis	rs4919087	0.851	rs2297987	chr10:98989454	C/T	cg25902810	chr10:99078978	FRAT1	-0.4	-5.8	-0.3	1.57e-8	Monocyte count;
LUSC	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg05340658	chr4:99064831	C4orf37	0.65	10.82	0.51	1.34e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg05283184	chr6:79620031	NA	-0.57	-12.12	-0.55	2.96e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg22482690	chr17:47019901	SNF8	0.37	7.0	0.36	1.43e-11	Type 2 diabetes;
LUSC	cis	rs6542838	0.646	rs17756034	chr2:99382810	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-5.81	-0.3	1.44e-8	Fear of minor pain;
LUSC	cis	rs2274273	0.837	rs7146748	chr14:55747086	G/A	cg04306507	chr14:55594613	LGALS3	0.57	13.34	0.59	7.78e-33	Protein biomarker;
LUSC	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-0.53	-8.18	-0.41	6.04e-15	Breast cancer;
LUSC	trans	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	9.98	0.48	1.09e-20	Mean corpuscular volume;
LUSC	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg09307838	chr4:120376055	NA	0.55	8.26	0.41	3.56e-15	Diastolic blood pressure;
LUSC	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg23231163	chr10:75533350	FUT11	-0.43	-6.86	-0.35	3.39e-11	Inflammatory bowel disease;
LUSC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-1.01	-14.58	-0.62	1.33e-37	Initial pursuit acceleration;
LUSC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-12.84	-0.57	5.91e-31	Alzheimer's disease;
LUSC	trans	rs73019876	0.901	rs2666440	chr19:22139345	G/T	cg16204205	chr18:19753432	GATA6	0.31	5.94	0.31	7.01e-9	Testicular germ cell tumor;
LUSC	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.4	0.49	4.04e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.97	-0.36	1.72e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg26897989	chr16:1907736	C16orf73	-0.45	-7.02	-0.36	1.28e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-6.59	-0.34	1.69e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg15556689	chr8:8085844	FLJ10661	0.45	6.04	0.31	4.15e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-9.4	-0.46	8.68e-19	Eye color traits;
LUSC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg17971929	chr21:40555470	PSMG1	-0.47	-7.13	-0.36	6.12e-12	Menarche (age at onset);
LUSC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg20302342	chr1:156215951	PAQR6	0.32	6.09	0.32	3.11e-9	Tonsillectomy;
LUSC	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg05855489	chr10:104503620	C10orf26	-0.49	-7.47	-0.38	7.25e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg15445000	chr17:37608096	MED1	0.37	6.72	0.35	7.63e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg05084668	chr3:125655381	ALG1L	-0.68	-10.22	-0.49	1.67e-21	Blood pressure (smoking interaction);
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg15673029	chr19:46234190	FBXO46	0.41	6.05	0.31	3.95e-9	Schizophrenia (age at onset);
LUSC	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg11161011	chr14:65562177	MAX	-0.71	-10.82	-0.51	1.33e-23	Obesity-related traits;
LUSC	cis	rs6500395	0.925	rs16946342	chr16:48668542	G/A	cg04672837	chr16:48644449	N4BP1	0.45	6.74	0.35	6.83e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg15819921	chr19:927150	ARID3A	-0.43	-6.41	-0.33	5.02e-10	Life satisfaction;
LUSC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg05738196	chr6:26577821	NA	-0.48	-7.06	-0.36	9.54e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	8.24	0.41	3.99e-15	Response to antipsychotic treatment;
LUSC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.42	-0.33	4.79e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg23649088	chr2:200775458	C2orf69	-0.47	-6.31	-0.33	8.98e-10	Schizophrenia;
LUSC	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg12940439	chr1:67600707	NA	0.37	5.92	0.31	7.98e-9	Psoriasis;
LUSC	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22442454	chr1:209979470	IRF6	0.43	5.9	0.31	9.14e-9	Cleft lip with or without cleft palate;
LUSC	trans	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.57	0.46	2.43e-19	Resting heart rate;
LUSC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21782813	chr7:2030301	MAD1L1	-0.51	-9.08	-0.44	9.66e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs6840360	1.000	rs6535818	chr4:152650882	T/G	cg22705602	chr4:152727874	NA	-0.28	-6.05	-0.31	3.8e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg07332563	chr6:291687	DUSP22	-0.46	-6.75	-0.35	6.71e-11	Menopause (age at onset);
LUSC	trans	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg24247370	chr13:99142703	STK24	-0.35	-6.46	-0.33	3.62e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs870825	0.616	rs6844588	chr4:185644517	T/G	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.87	-0.44	4.47e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322817	0.653	rs2400051	chr6:105169478	A/C	cg02098413	chr6:105308735	HACE1	-0.28	-5.66	-0.3	3.18e-8	Thyroid stimulating hormone;
LUSC	cis	rs7804356	1.000	rs3801843	chr7:26830201	A/G	cg03456212	chr7:26904342	SKAP2	-0.55	-6.56	-0.34	2.08e-10	Type 1 diabetes;
LUSC	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg24675056	chr1:15929824	NA	0.46	7.92	0.4	3.44e-14	Systolic blood pressure;
LUSC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.63	-0.57	3.85e-30	Type 2 diabetes;
LUSC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg20243544	chr17:37824526	PNMT	0.39	5.93	0.31	7.49e-9	Self-reported allergy;
LUSC	cis	rs4654899	0.865	rs6658526	chr1:21391314	A/G	cg01072550	chr1:21505969	NA	0.48	6.97	0.36	1.69e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg02660097	chr11:68866761	NA	0.43	6.1	0.32	2.9e-9	Blond vs. brown hair color;
LUSC	trans	rs12200782	1.000	rs12195971	chr6:26460424	G/A	cg11837749	chr1:55047332	ACOT11	0.57	5.97	0.31	6.19e-9	Small cell lung carcinoma;
LUSC	cis	rs1014246	0.848	rs11197798	chr10:118457277	C/T	cg14919929	chr10:118506882	NA	0.45	7.16	0.36	5.33e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9513627	1.000	rs7321269	chr13:100126271	C/T	cg25919922	chr13:100150906	NA	-0.74	-6.55	-0.34	2.2e-10	Obesity-related traits;
LUSC	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg03258749	chr1:151040405	MLLT11	-0.44	-6.62	-0.34	1.44e-10	Childhood ear infection;
LUSC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.72	12.96	0.58	2.1e-31	Prudent dietary pattern;
LUSC	cis	rs17401966	1.000	rs4348727	chr1:10265606	G/A	cg19773385	chr1:10388646	KIF1B	-0.52	-8.05	-0.4	1.44e-14	Hepatocellular carcinoma;
LUSC	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg15839431	chr19:19639596	YJEFN3	0.61	6.6	0.34	1.63e-10	Bipolar disorder;
LUSC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg25258033	chr6:167368657	RNASET2	0.46	7.67	0.39	1.91e-13	Crohn's disease;
LUSC	cis	rs2236918	0.710	rs1776174	chr1:242031839	G/T	cg17736920	chr1:242011382	EXO1	0.41	6.48	0.33	3.25e-10	Menopause (age at onset);
LUSC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.81	13.3	0.59	1.06e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg03973167	chr4:185394988	IRF2	0.42	6.06	0.31	3.6e-9	Schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10350352	chr3:169487235	ARPM1	-0.43	-6.59	-0.34	1.67e-10	Triglycerides;
LUSC	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg07148914	chr20:33460835	GGT7	-0.51	-8.04	-0.4	1.53e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs3099143	1.000	rs7172639	chr15:77165288	G/A	cg21673338	chr15:77095150	SCAPER	0.81	7.7	0.39	1.56e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.94	0.31	7.16e-9	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.1	0.41	1.05e-14	Prudent dietary pattern;
LUSC	cis	rs806215	0.950	rs3735644	chr7:127222157	G/A	cg25922125	chr7:127225783	GCC1	-0.61	-7.37	-0.37	1.31e-12	Type 2 diabetes;
LUSC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg21770322	chr7:97807741	LMTK2	0.41	7.12	0.36	6.82e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.75	12.01	0.55	7.57e-28	Cognitive function;
LUSC	cis	rs3743266	0.613	rs7180766	chr15:60774493	C/T	cg21667061	chr15:60772094	NARG2	-0.38	-6.34	-0.33	7.53e-10	Menarche (age at onset);
LUSC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg04450456	chr4:17643702	FAM184B	0.39	6.67	0.34	1.09e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11866815	0.901	rs9938786	chr16:399054	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.4	6.18	0.32	1.83e-9	Body mass index;
LUSC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg16606324	chr3:10149918	C3orf24	0.58	8.28	0.41	2.99e-15	Alzheimer's disease;
LUSC	cis	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg07460842	chr6:66804631	NA	-0.47	-6.54	-0.34	2.29e-10	Blood trace element (Cu levels);
LUSC	cis	rs1451375	0.698	rs7797131	chr7:50647934	A/G	cg18232548	chr7:50535776	DDC	0.5	7.58	0.38	3.49e-13	Malaria;
LUSC	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.68	-0.47	1.09e-19	Total cholesterol levels;
LUSC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg05805236	chr11:65401703	PCNXL3	-0.38	-5.8	-0.3	1.54e-8	Breast cancer;
LUSC	cis	rs2692947	0.759	rs11687113	chr2:96658588	A/G	cg23100626	chr2:96804247	ASTL	0.25	6.07	0.32	3.4e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.61	-0.43	2.97e-16	Total cholesterol levels;
LUSC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-6.84	-0.35	3.75e-11	Renal function-related traits (BUN);
LUSC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	12.02	0.55	6.69e-28	Prudent dietary pattern;
LUSC	cis	rs6546537	0.550	rs7568057	chr2:69877783	T/G	cg10773587	chr2:69614142	GFPT1	-0.36	-5.89	-0.31	9.61e-9	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg12560992	chr17:57184187	TRIM37	-0.66	-11.67	-0.54	1.26e-26	Primary tooth development (time to first tooth eruption);
LUSC	cis	rs10140922	0.931	rs4982258	chr14:35821891	G/A	cg07166546	chr14:35805898	NA	-0.24	-5.89	-0.31	9.53e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg02569458	chr12:86230093	RASSF9	0.58	9.93	0.48	1.6e-20	Major depressive disorder;
LUSC	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg06238570	chr21:40685208	BRWD1	-0.48	-7.47	-0.38	6.85e-13	Cognitive function;
LUSC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg25767906	chr1:53392781	SCP2	0.48	8.69	0.43	1.67e-16	Monocyte count;
LUSC	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-8.79	-0.43	8.04e-17	Monocyte percentage of white cells;
LUSC	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg08017756	chr2:100939284	LONRF2	-0.44	-8.33	-0.41	2.09e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.71	-12.26	-0.56	8.96e-29	White blood cell count (basophil);
LUSC	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg10253484	chr15:75165896	SCAMP2	0.43	5.8	0.3	1.56e-8	Systemic lupus erythematosus;
LUSC	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.21	0.52	5.75e-25	Colorectal cancer;
LUSC	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-11.26	-0.52	3.85e-25	Schizophrenia;
LUSC	cis	rs6681460	1.000	rs10789210	chr1:67066030	G/A	cg02459107	chr1:67143332	SGIP1	0.48	8.85	0.44	5.02e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs231513	0.954	rs170766	chr17:41963407	C/G	cg26893861	chr17:41843967	DUSP3	-0.52	-6.29	-0.33	1e-9	Cognitive function;
LUSC	cis	rs10887741	0.646	rs1358864	chr10:89426630	A/C	cg13926569	chr10:89418898	PAPSS2	0.32	6.72	0.35	7.85e-11	Exercise (leisure time);
LUSC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.69	0.6	3.61e-34	Platelet count;
LUSC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-12.33	-0.56	4.89e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.17	-0.49	2.38e-21	Obesity-related traits;
LUSC	cis	rs5009270	0.512	rs1024410	chr7:112247542	A/T	cg23628563	chr7:112262597	NA	0.43	5.97	0.31	6.01e-9	Osteoarthritis (hip);
LUSC	cis	rs460214	0.576	rs2836604	chr21:40041295	A/C	cg12884169	chr21:40033163	ERG	-0.35	-5.68	-0.3	2.96e-8	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg04756594	chr16:24857601	SLC5A11	-0.5	-7.42	-0.38	9.8e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs11039100	1.000	rs11039100	chr11:5827003	C/T	cg05234568	chr11:5960015	NA	0.52	5.87	0.31	1.07e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7107174	1.000	rs58235466	chr11:78030886	T/C	cg02023728	chr11:77925099	USP35	0.45	6.83	0.35	3.99e-11	Testicular germ cell tumor;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.84	15.23	0.64	3.78e-40	Menarche (age at onset);
LUSC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.26	0.37	2.77e-12	Motion sickness;
LUSC	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg25174290	chr11:3078921	CARS	-0.42	-6.19	-0.32	1.75e-9	Calcium levels;
LUSC	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg15445000	chr17:37608096	MED1	0.39	6.62	0.34	1.44e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg24848339	chr3:12840334	CAND2	0.33	6.41	0.33	4.95e-10	QRS complex (12-leadsum);
LUSC	cis	rs2235649	0.753	rs7200472	chr16:1849669	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-6.01	-0.31	4.89e-9	Blood metabolite levels;
LUSC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.32	0.33	8.29e-10	Menopause (age at onset);
LUSC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg06808227	chr14:105710500	BRF1	-0.6	-8.4	-0.42	1.26e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4919694	1.000	rs17727044	chr10:104821256	A/T	cg04362960	chr10:104952993	NT5C2	1.2	14.03	0.61	1.84e-35	Arsenic metabolism;
LUSC	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-9.64	-0.47	1.45e-19	Coffee consumption (cups per day);
LUSC	cis	rs3790645	1.000	rs396997	chr1:26893067	T/C	cg17456097	chr1:26900765	RPS6KA1	0.42	6.03	0.31	4.23e-9	Glucose homeostasis traits;
LUSC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.19	-0.52	6.61e-25	Alzheimer's disease;
LUSC	cis	rs17253792	0.915	rs77161327	chr14:56178565	A/G	cg01858014	chr14:56050164	KTN1	-0.85	-6.86	-0.35	3.35e-11	Putamen volume;
LUSC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	7.78	0.39	8.98e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg00898013	chr13:113819073	PROZ	-0.57	-8.06	-0.4	1.38e-14	Platelet distribution width;
LUSC	cis	rs11971779	0.680	rs1862879	chr7:139019951	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.22	0.32	1.45e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7106204	0.514	rs7118022	chr11:24253352	C/T	ch.11.24196551F	chr11:24239977	NA	0.92	10.2	0.49	1.98e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg13010199	chr12:38710504	ALG10B	0.39	6.26	0.32	1.2e-9	Morning vs. evening chronotype;
LUSC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.9	-0.35	2.59e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-10.9	-0.51	7.2e-24	Mean corpuscular volume;
LUSC	cis	rs897984	0.762	rs4889604	chr16:30985994	G/T	cg02466173	chr16:30829666	NA	0.55	10.88	0.51	8.73e-24	Dementia with Lewy bodies;
LUSC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.24	0.41	3.84e-15	Melanoma;
LUSC	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg11502198	chr6:26597334	ABT1	0.59	9.38	0.46	1.06e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs2562456	0.520	rs250001	chr19:21408189	A/G	cg00806126	chr19:22604979	ZNF98	-0.43	-6.06	-0.31	3.64e-9	Pain;
LUSC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.76	-17.37	-0.69	1.31e-48	Longevity;Endometriosis;
LUSC	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg07936489	chr17:37558343	FBXL20	0.71	9.74	0.47	6.96e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.87	-12.65	-0.57	3.21e-30	Alzheimer's disease;
LUSC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg25258033	chr6:167368657	RNASET2	-0.49	-8.17	-0.41	6.37e-15	Lung cancer;
LUSC	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.85	-0.3	1.19e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg07701084	chr6:150067640	NUP43	0.57	8.71	0.43	1.47e-16	Lung cancer;
LUSC	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.04	-0.44	1.25e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg09034736	chr1:150693464	HORMAD1	-0.48	-7.02	-0.36	1.22e-11	Tonsillectomy;
LUSC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg11062466	chr8:58055876	NA	0.52	6.76	0.35	6.25e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg05805236	chr11:65401703	PCNXL3	0.4	6.84	0.35	3.82e-11	Acne (severe);
LUSC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg03233332	chr7:66118400	NA	0.42	6.07	0.32	3.46e-9	Aortic root size;
LUSC	cis	rs7043114	0.525	rs10116241	chr9:95240546	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.33	-0.33	8.05e-10	Height;
LUSC	cis	rs7084921	0.608	rs11597390	chr10:101861435	A/G	cg02250046	chr10:101825185	CPN1	0.35	6.39	0.33	5.64e-10	Bone mineral density;
LUSC	cis	rs11583043	0.575	rs12727971	chr1:101589175	A/G	cg11406453	chr1:101602562	NA	-0.4	-6.64	-0.34	1.24e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs911119	0.955	rs8115417	chr20:23605223	T/A	cg16589663	chr20:23618590	CST3	0.57	6.82	0.35	4.18e-11	Chronic kidney disease;
LUSC	cis	rs72781680	0.699	rs72794291	chr2:23897935	C/T	cg20701182	chr2:24300061	SF3B14	0.75	7.32	0.37	1.87e-12	Lymphocyte counts;
LUSC	trans	rs1864585	0.520	rs17776622	chr8:10676497	T/C	cg26278703	chr11:58910052	FAM111A	0.54	6.13	0.32	2.53e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUSC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg07703079	chr11:430292	ANO9	0.6	6.52	0.34	2.66e-10	Body mass index;
LUSC	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-5.84	-0.3	1.23e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg03354898	chr7:1950403	MAD1L1	-0.42	-8.43	-0.42	1.02e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18404041	chr3:52824283	ITIH1	-0.6	-11.57	-0.53	3.03e-26	Bipolar disorder;
LUSC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.19	-0.52	6.61e-25	Alzheimer's disease;
LUSC	cis	rs7241530	0.662	rs55752151	chr18:75901986	T/C	cg14642773	chr18:75888474	NA	0.41	6.27	0.32	1.14e-9	Educational attainment (years of education);
LUSC	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.42	-6.19	-0.32	1.81e-9	IgG glycosylation;
LUSC	cis	rs7586879	0.861	rs10164466	chr2:25114069	T/C	cg01884057	chr2:25150051	NA	0.43	8.98	0.44	1.98e-17	Body mass index;
LUSC	cis	rs4845570	0.920	rs1521185	chr1:151764049	A/G	cg07092448	chr1:151763213	TDRKH	1.26	16.49	0.67	4.2e-45	Coronary artery disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15234297	chr19:50143472	RRAS	-0.43	-6.39	-0.33	5.42e-10	Electrocardiographic conduction measures;
LUSC	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg11244672	chr19:19639970	YJEFN3	-0.53	-6.65	-0.34	1.19e-10	Bipolar disorder;
LUSC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.03	20.65	0.75	1.23e-61	Cognitive function;
LUSC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg12564285	chr5:131593104	PDLIM4	0.5	9.02	0.44	1.47e-17	Acylcarnitine levels;
LUSC	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg22532475	chr10:104410764	TRIM8	-0.32	-7.13	-0.36	6.24e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	0.84	14.34	0.62	1.1e-36	Tonsillectomy;
LUSC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.18	-0.41	6.08e-15	Platelet count;
LUSC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg08888203	chr3:10149979	C3orf24	-0.66	-7.91	-0.4	3.8e-14	Alzheimer's disease;
LUSC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg14019146	chr3:50243930	SLC38A3	0.32	7.05	0.36	1.04e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6580649	0.657	rs57863747	chr12:48470425	G/T	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	cis	rs35883536	0.626	rs34752753	chr1:101045193	T/G	cg06223162	chr1:101003688	GPR88	-0.48	-9.01	-0.44	1.6e-17	Monocyte count;
LUSC	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg17252645	chr8:143867129	LY6D	0.38	6.67	0.34	1.06e-10	Urinary tract infection frequency;
LUSC	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg18681998	chr4:17616180	MED28	0.83	14.53	0.62	2.08e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.71	-12.7	-0.57	2.07e-30	Aortic root size;
LUSC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00152838	chr16:24741724	TNRC6A	0.48	6.11	0.32	2.71e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.92	0.4	3.53e-14	Bipolar disorder;
LUSC	cis	rs7923609	1.000	rs10822163	chr10:65124098	C/G	cg01631684	chr10:65280961	REEP3	-0.38	-5.93	-0.31	7.44e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1322512	0.760	rs2758806	chr6:152960141	A/G	cg27316956	chr6:152958899	SYNE1	-0.38	-6.33	-0.33	7.73e-10	Tonometry;
LUSC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.58	0.5	9.76e-23	Schizophrenia;
LUSC	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg26102564	chr10:131424627	MGMT	0.37	5.79	0.3	1.59e-8	Response to temozolomide;
LUSC	cis	rs30380	0.587	rs469674	chr5:96130015	G/C	cg16492584	chr5:96139282	ERAP1	-0.53	-7.2	-0.37	4.07e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.01	-0.36	1.31e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7106204	0.514	rs1443044	chr11:24255575	C/G	ch.11.24196551F	chr11:24239977	NA	-0.89	-10.16	-0.49	2.59e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs10484885	0.824	rs11967579	chr6:90540008	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.85	-7.99	-0.4	2.26e-14	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs11958404	0.932	rs72816563	chr5:157427447	C/T	cg05962755	chr5:157440814	NA	0.52	6.22	0.32	1.52e-9	IgG glycosylation;
LUSC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg00684032	chr4:1343700	KIAA1530	-0.38	-6.52	-0.34	2.66e-10	Obesity-related traits;
LUSC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.66	-0.3	3.23e-8	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs564343	0.563	rs570760	chr11:65833631	C/T	cg26701943	chr11:108369231	KDELC2	-0.45	-6.25	-0.32	1.28e-9	Obesity (early onset extreme);
LUSC	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.93	-0.35	2.24e-11	Body mass index;
LUSC	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22455342	chr2:225449267	CUL3	0.46	6.16	0.32	2.14e-9	IgE levels in asthmatics (D.p. specific);
LUSC	trans	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.41	-0.33	5.05e-10	Monocyte count;
LUSC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.43	0.5	3.19e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-7.35	-0.37	1.58e-12	Schizophrenia;
LUSC	cis	rs12210905	0.688	rs12374607	chr6:27343620	A/G	cg08851530	chr6:28072375	NA	0.9	5.78	0.3	1.75e-8	Hip circumference adjusted for BMI;
LUSC	trans	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.35	0.53	1.8e-25	Alzheimer's disease;
LUSC	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg09904177	chr6:26538194	HMGN4	-0.72	-6.68	-0.34	1e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.34	0.56	4.44e-29	Prudent dietary pattern;
LUSC	cis	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg26958806	chr6:27640298	NA	0.59	5.79	0.3	1.63e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.29	-0.45	2.04e-18	Morning vs. evening chronotype;
LUSC	cis	rs977987	0.645	rs10871311	chr16:75450912	T/A	cg03315344	chr16:75512273	CHST6	0.48	8.91	0.44	3.28e-17	Dupuytren's disease;
LUSC	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg25902810	chr10:99078978	FRAT1	0.53	7.42	0.38	9.65e-13	Monocyte count;
LUSC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg10729496	chr3:10149963	C3orf24	0.58	7.68	0.39	1.75e-13	Alzheimer's disease;
LUSC	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg05738196	chr6:26577821	NA	0.78	14.76	0.63	2.72e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg23029597	chr12:123009494	RSRC2	0.74	9.36	0.46	1.24e-18	Body mass index;
LUSC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs2067615	0.579	rs4964486	chr12:107140790	A/G	cg15890332	chr12:107067104	RFX4	0.34	6.27	0.32	1.1e-9	Heart rate;
LUSC	cis	rs9463078	0.547	rs116177834	chr6:44738548	C/A	cg25276700	chr6:44698697	NA	0.3	6.3	0.33	9.28e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg08888203	chr3:10149979	C3orf24	0.66	9.33	0.45	1.48e-18	Alzheimer's disease;
LUSC	cis	rs8014204	0.762	rs12889665	chr14:75234830	T/G	cg06637938	chr14:75390232	RPS6KL1	0.51	8.01	0.4	1.95e-14	Caffeine consumption;
LUSC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.57	10.82	0.51	1.36e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs735539	0.645	rs6490600	chr13:21208189	G/T	cg04906043	chr13:21280425	IL17D	-0.43	-6.83	-0.35	4.07e-11	Dental caries;
LUSC	trans	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.34	-0.33	7.31e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs76878669	0.561	rs7125752	chr11:66162419	C/T	cg24851651	chr11:66362959	CCS	0.37	5.86	0.31	1.08e-8	Educational attainment (years of education);
LUSC	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.36	-5.99	-0.31	5.53e-9	Rheumatoid arthritis;
LUSC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg13282195	chr8:144660772	NAPRT1	-0.68	-7.77	-0.39	9.81e-14	Attention deficit hyperactivity disorder;
LUSC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg01802117	chr1:53393560	SCP2	0.39	6.41	0.33	5.03e-10	Monocyte count;
LUSC	cis	rs6714710	0.580	rs11692470	chr2:98520564	T/C	cg26665480	chr2:98280029	ACTR1B	0.61	8.9	0.44	3.72e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg25237894	chr2:233734115	C2orf82	-0.34	-6.35	-0.33	6.91e-10	Coronary artery disease;
LUSC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg16405210	chr4:1374714	KIAA1530	-0.52	-8.13	-0.41	8.57e-15	Obesity-related traits;
LUSC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06481639	chr22:41940642	POLR3H	0.5	5.72	0.3	2.42e-8	Vitiligo;
LUSC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.28	-0.49	9.98e-22	Platelet count;
LUSC	cis	rs1009647	0.656	rs10147254	chr14:55850315	C/A	cg04306507	chr14:55594613	LGALS3	0.48	9.5	0.46	4.36e-19	Testicular germ cell tumor;
LUSC	cis	rs887829	0.569	rs4124874	chr2:234665659	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-7.33	-0.37	1.77e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg00757033	chr12:89920650	WDR51B	0.59	10.19	0.49	2.14e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.14	0.32	2.31e-9	Corneal astigmatism;
LUSC	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg21890820	chr11:65308645	LTBP3	0.5	7.38	0.37	1.27e-12	Bone mineral density;
LUSC	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	0.89	12.81	0.57	8e-31	Uric acid levels;
LUSC	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg03684893	chr10:554711	DIP2C	-0.37	-6.67	-0.34	1.07e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs2235649	0.833	rs9939694	chr16:1852760	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.44	-6.02	-0.31	4.57e-9	Blood metabolite levels;
LUSC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg14092988	chr3:52407081	DNAH1	0.3	5.92	0.31	7.78e-9	Bipolar disorder;
LUSC	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg09654669	chr8:57350985	NA	-0.58	-7.79	-0.39	8.28e-14	Obesity-related traits;
LUSC	cis	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.13	-0.41	8.57e-15	Coronary artery disease;
LUSC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg06636001	chr8:8085503	FLJ10661	0.69	11.54	0.53	3.78e-26	Mood instability;
LUSC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00339695	chr16:24857497	SLC5A11	-0.61	-9.61	-0.47	1.76e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.51	-0.91	6.17e-131	Myeloid white cell count;
LUSC	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg14530993	chr4:882597	GAK	0.72	7.42	0.38	1e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.747	rs1415959	chr1:152973690	C/T	cg25856811	chr1:152973957	SPRR3	0.34	5.78	0.3	1.67e-8	Inflammatory skin disease;
LUSC	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg23711669	chr6:146136114	FBXO30	0.85	15.09	0.64	1.38e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7945718	0.935	rs11022501	chr11:12809314	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.61	0.38	2.9e-13	Educational attainment (years of education);
LUSC	cis	rs11169552	0.510	rs10876063	chr12:50972085	C/T	cg12884762	chr12:50931848	DIP2B	-0.32	-5.67	-0.3	3.11e-8	Colorectal cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21086891	chr3:192635035	C3orf59	0.45	6.4	0.33	5.22e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9462027	0.628	rs7774697	chr6:34791027	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.32	5.65	0.3	3.45e-8	Systemic lupus erythematosus;
LUSC	cis	rs701145	0.585	rs1713798	chr3:153807407	G/A	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg20848291	chr7:100343083	ZAN	0.4	6.08	0.32	3.24e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	9.19	0.45	4.39e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-6.05	-0.31	3.99e-9	Morning vs. evening chronotype;
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	0.96	20.06	0.74	2.79e-59	Menarche (age at onset);
LUSC	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg14830002	chr1:247616686	OR2B11	0.49	7.05	0.36	1.05e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10761482	0.861	rs719095	chr10:62110949	T/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.01	-0.36	1.36e-11	Schizophrenia;
LUSC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	8.2	0.41	5.37e-15	Cognitive test performance;
LUSC	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg09092052	chr15:45571596	NA	0.45	6.26	0.32	1.18e-9	Glomerular filtration rate;
LUSC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-5.95	-0.31	6.64e-9	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4820792	1.000	rs4820792	chr22:29161007	C/T	cg22827864	chr6:72298424	NA	-0.47	-6.31	-0.33	9.11e-10	Breast size;
LUSC	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-8.64	-0.43	2.43e-16	Schizophrenia;
LUSC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg13319975	chr6:146136371	FBXO30	0.49	7.48	0.38	6.77e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg12463550	chr7:65579703	CRCP	0.45	6.76	0.35	6.2e-11	Aortic root size;
LUSC	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg11584989	chr19:19387371	SF4	0.57	6.82	0.35	4.18e-11	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.82	0.78	3.9e-70	Prudent dietary pattern;
LUSC	trans	rs13390641	0.614	rs72818308	chr2:104082460	A/T	cg03260781	chr1:16346299	HSPB7	-0.46	-6.09	-0.32	3.14e-9	Blood pressure;Blood pressure (anthropometric measures interaction);
LUSC	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	10.05	0.48	6.26e-21	Coffee consumption (cups per day);
LUSC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg03790207	chr6:42947109	PEX6	-0.45	-6.83	-0.35	4.01e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.12	0.55	2.92e-28	Motion sickness;
LUSC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.65	0.47	1.38e-19	Bipolar disorder;
LUSC	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg19812747	chr11:111475976	SIK2	-0.49	-7.0	-0.36	1.4e-11	Primary sclerosing cholangitis;
LUSC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.66	-11.6	-0.54	2.26e-26	Aortic root size;
LUSC	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg10596483	chr8:143751796	JRK	0.51	7.31	0.37	1.94e-12	Schizophrenia;
LUSC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg16647868	chr5:131706066	SLC22A5	-0.34	-5.72	-0.3	2.36e-8	Blood metabolite levels;
LUSC	cis	rs6546550	0.901	rs10496174	chr2:70153436	T/G	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.31	-0.37	1.98e-12	Prevalent atrial fibrillation;
LUSC	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg05187965	chr10:45406764	TMEM72	0.39	9.01	0.44	1.62e-17	Mean corpuscular volume;
LUSC	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg09904177	chr6:26538194	HMGN4	-0.75	-5.79	-0.3	1.63e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.89	-0.31	9.46e-9	Tonsillectomy;
LUSC	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg18196295	chr10:418757	DIP2C	0.48	7.37	0.37	1.33e-12	Psychosis in Alzheimer's disease;
LUSC	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-15.38	-0.64	9.97e-41	Exhaled nitric oxide output;
LUSC	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg27411982	chr8:10470053	RP1L1	-0.37	-5.89	-0.31	9.23e-9	Retinal vascular caliber;
LUSC	cis	rs9815354	0.761	rs12186051	chr3:41836919	G/A	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21862992	chr11:68658383	NA	0.51	8.4	0.42	1.34e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg26195577	chr20:24973756	C20orf3	-1.12	-18.25	-0.71	4.21e-52	Blood protein levels;
LUSC	trans	rs877282	0.898	rs12358513	chr10:757571	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.51	-0.34	2.71e-10	Uric acid levels;
LUSC	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg17252645	chr8:143867129	LY6D	0.37	6.58	0.34	1.77e-10	Urinary tract infection frequency;
LUSC	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg24313572	chr1:56050060	NA	-0.29	-5.96	-0.31	6.34e-9	Morning vs. evening chronotype;
LUSC	cis	rs72781680	0.752	rs56343114	chr2:23900629	C/G	cg20701182	chr2:24300061	SF3B14	0.57	5.84	0.3	1.23e-8	Lymphocyte counts;
LUSC	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.72	9.81	0.47	4.02e-20	Platelet count;
LUSC	cis	rs10193935	0.792	rs2053349	chr2:42516205	G/A	cg27598129	chr2:42591480	NA	-0.58	-8.03	-0.4	1.72e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg11502198	chr6:26597334	ABT1	0.63	9.95	0.48	1.3e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs887829	0.569	rs3755319	chr2:234667582	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.41	-6.8	-0.35	4.7e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs4631830	0.828	rs10763567	chr10:51538169	C/A	cg16070123	chr10:51489643	NA	0.47	7.38	0.37	1.25e-12	Prostate-specific antigen levels;
LUSC	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.42	-0.53	9.82e-26	Mean corpuscular volume;
LUSC	cis	rs11625487	0.609	rs45493395	chr14:77976468	T/C	cg16049707	chr14:77965284	ISM2	-0.61	-6.55	-0.34	2.12e-10	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs28830936	1.000	rs28830936	chr15:41906408	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.31	-0.33	8.69e-10	Diastolic blood pressure;
LUSC	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.96	-0.44	2.42e-17	Neuroticism;
LUSC	cis	rs6967385	0.560	rs55794302	chr7:12351495	C/A	cg06484146	chr7:12443880	VWDE	0.49	7.34	0.37	1.63e-12	Response to taxane treatment (placlitaxel);
LUSC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10053473	chr17:62856997	LRRC37A3	0.65	10.27	0.49	1.13e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg17063962	chr7:91808500	NA	0.42	6.78	0.35	5.35e-11	Breast cancer;
LUSC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-8.39	-0.42	1.43e-15	Height;
LUSC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	0.96	18.39	0.71	1.14e-52	Heart rate;
LUSC	trans	rs1493916	0.592	rs1389068	chr18:31312738	G/T	cg27147174	chr7:100797783	AP1S1	-0.45	-6.91	-0.35	2.4e-11	Life satisfaction;
LUSC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-12.22	-0.56	1.23e-28	Chronic sinus infection;
LUSC	cis	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	0.91	12.35	0.56	3.99e-29	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	5.99	0.31	5.53e-9	Breast cancer;
LUSC	trans	rs1038903	0.849	rs1038905	chr4:28739878	C/T	cg08616269	chr10:70480892	CCAR1	0.49	6.0	0.31	5.16e-9	Menarche (age at onset);
LUSC	cis	rs6460942	0.591	rs62448733	chr7:12350526	C/T	cg06484146	chr7:12443880	VWDE	-0.59	-6.28	-0.32	1.05e-9	Coronary artery disease;
LUSC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg17330251	chr7:94953956	PON1	-0.37	-5.99	-0.31	5.57e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	7.57	0.38	3.58e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg09953122	chr20:23471693	CST8	0.87	7.32	0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6012953	0.874	rs1885177	chr20:49191228	A/C	cg13958625	chr20:49123093	NA	-0.27	-5.94	-0.31	7.2e-9	Vitiligo;
LUSC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.58	8.56	0.42	4.29e-16	IgG glycosylation;
LUSC	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg21573476	chr21:45109991	RRP1B	-0.4	-6.66	-0.34	1.11e-10	Mean corpuscular volume;
LUSC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg00343986	chr7:65444356	GUSB	0.45	6.92	0.35	2.33e-11	Aortic root size;
LUSC	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg06484146	chr7:12443880	VWDE	-0.62	-6.24	-0.32	1.36e-9	Coronary artery disease;
LUSC	cis	rs7011049	1.000	rs11997538	chr8:53832663	A/C	cg26025543	chr8:53854495	NA	0.48	5.97	0.31	6.03e-9	Systolic blood pressure;
LUSC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg06784218	chr1:46089804	CCDC17	-0.51	-9.84	-0.47	3.24e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg25039879	chr17:56429692	SUPT4H1	0.68	9.14	0.45	6.1e-18	Cognitive test performance;
LUSC	cis	rs6084875	0.840	rs2422934	chr20:4720146	G/A	cg26097573	chr20:4721490	PRNT	-0.31	-5.75	-0.3	2.03e-8	Systemic lupus erythematosus;
LUSC	cis	rs9837602	1.000	rs6799379	chr3:99762840	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	6.17	0.32	2.01e-9	Breast cancer;
LUSC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg03351412	chr1:154909251	PMVK	0.49	7.48	0.38	6.69e-13	Prostate cancer;
LUSC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08109568	chr15:31115862	NA	-0.57	-7.95	-0.4	2.99e-14	Huntington's disease progression;
LUSC	trans	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg18187862	chr3:45730750	SACM1L	-0.52	-6.32	-0.33	8.33e-10	Primary sclerosing cholangitis;
LUSC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg00484396	chr16:3507460	NAT15	-0.91	-10.62	-0.5	6.98e-23	Tuberculosis;
LUSC	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.0	-0.36	1.44e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg15309053	chr8:964076	NA	0.3	6.3	0.33	9.24e-10	Schizophrenia;
LUSC	cis	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg06521331	chr12:34319734	NA	-0.51	-8.37	-0.42	1.55e-15	Morning vs. evening chronotype;
LUSC	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.78	0.35	5.42e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs7605827	0.857	rs10185835	chr2:15495763	A/G	cg19274914	chr2:15703543	NA	0.44	8.54	0.42	4.75e-16	Educational attainment (years of education);
LUSC	trans	rs236907	0.859	rs7522582	chr1:171770111	G/C	cg13482142	chr2:234261155	NA	0.5	6.16	0.32	2.07e-9	Mean platelet volume;
LUSC	cis	rs1267303	1.000	rs1267303	chr1:46990457	A/G	cg25110126	chr1:46999211	NA	0.51	7.74	0.39	1.17e-13	Monobrow;
LUSC	cis	rs9653442	0.564	rs12712071	chr2:100793876	G/A	cg07810366	chr2:100720526	AFF3	-0.45	-7.64	-0.39	2.34e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg09877947	chr5:131593287	PDLIM4	0.37	6.0	0.31	5.04e-9	Breast cancer;Mosquito bite size;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg01287788	chr2:86362935	SNORD94;PTCD3	0.48	7.53	0.38	4.81e-13	Cognitive function;Information processing speed;
LUSC	cis	rs983392	0.709	rs1820428	chr11:59986333	A/T	cg02771260	chr11:59836817	MS4A3	-0.36	-5.93	-0.31	7.71e-9	Alzheimer's disease (late onset);
LUSC	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg27661571	chr11:113659931	NA	-0.6	-7.29	-0.37	2.25e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg08085267	chr17:45401833	C17orf57	0.45	6.63	0.34	1.36e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7605827	0.930	rs4668921	chr2:15672071	T/C	cg19274914	chr2:15703543	NA	0.46	8.81	0.43	7.12e-17	Educational attainment (years of education);
LUSC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.66	-0.3	3.31e-8	Life satisfaction;
LUSC	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg08755490	chr11:65554678	OVOL1	0.41	5.87	0.31	1.05e-8	Acne (severe);
LUSC	trans	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18876405	chr7:65276391	NA	0.49	6.64	0.34	1.24e-10	Corneal structure;
LUSC	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.98	0.36	1.58e-11	Menarche (age at onset);
LUSC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg17173187	chr15:85201210	NMB	0.37	6.57	0.34	1.96e-10	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.47	0.38	7.01e-13	Motion sickness;
LUSC	trans	rs7567288	0.636	rs6726369	chr2:134464994	G/A	cg12381416	chr3:14359266	NA	0.53	5.99	0.31	5.3e-9	Height;
LUSC	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg08508325	chr11:3079039	CARS	0.35	7.65	0.39	2.1e-13	Calcium levels;
LUSC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.34	-0.42	1.91e-15	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04334417	chr11:32112457	RCN1	-0.43	-6.39	-0.33	5.44e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg20203395	chr5:56204925	C5orf35	0.77	10.05	0.48	6.16e-21	Initial pursuit acceleration;
LUSC	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.57	10.0	0.48	8.88e-21	Birth weight;
LUSC	trans	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	0.83	13.98	0.61	2.73e-35	Menopause (age at onset);
LUSC	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.04	-0.4	1.6e-14	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	14.01	0.61	2.15e-35	Platelet count;
LUSC	cis	rs7246657	0.551	rs4806414	chr19:37638788	T/C	cg23950597	chr19:37808831	NA	-0.56	-5.81	-0.3	1.46e-8	Coronary artery calcification;
LUSC	cis	rs7712401	0.592	rs154515	chr5:122191145	G/T	cg19077854	chr5:122220652	SNX24	0.35	8.11	0.41	9.49e-15	Mean platelet volume;
LUSC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.45	7.12	0.36	6.81e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.73	-11.31	-0.53	2.45e-25	Alcohol dependence;
LUSC	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.44	6.23	0.32	1.37e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18876405	chr7:65276391	NA	-0.55	-8.76	-0.43	9.78e-17	Aortic root size;
LUSC	cis	rs16854884	0.633	rs6779321	chr3:143736676	T/C	cg06585982	chr3:143692056	C3orf58	0.5	7.93	0.4	3.36e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg03806693	chr22:41940476	POLR3H	-0.74	-10.94	-0.51	5.05e-24	Vitiligo;
LUSC	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg20701182	chr2:24300061	SF3B14	0.46	5.64	0.3	3.55e-8	Asthma;
LUSC	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg12365402	chr11:9010492	NRIP3	-0.46	-8.17	-0.41	6.36e-15	Hematocrit;
LUSC	cis	rs11608355	0.515	rs11614551	chr12:109931630	G/A	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-6.02	-0.31	4.65e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs131777	0.576	rs131758	chr22:51017082	T/A	cg00047287	chr22:51016899	CPT1B;CHKB-CPT1B	0.36	5.96	0.31	6.32e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21545522	chr1:205238299	TMCC2	0.49	9.47	0.46	5.26e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg05347473	chr6:146136440	FBXO30	-0.59	-10.46	-0.5	2.46e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	0.59	8.39	0.42	1.36e-15	Platelet distribution width;
LUSC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg11663144	chr21:46675770	NA	-0.42	-7.57	-0.38	3.72e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10170310	1.000	rs12691947	chr2:139264471	A/G	cg10095539	chr2:139258744	SPOPL	0.33	5.89	0.31	9.45e-9	Response to antipsychotic treatment;
LUSC	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.78	-0.43	8.67e-17	Bone mineral density;
LUSC	cis	rs7538876	0.903	rs730153	chr1:17749504	A/G	cg07965774	chr1:17746286	RCC2	-0.33	-6.22	-0.32	1.46e-9	Basal cell carcinoma;
LUSC	cis	rs11039100	0.850	rs12363853	chr11:5830163	G/A	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg05855489	chr10:104503620	C10orf26	-0.57	-7.6	-0.38	2.98e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	7.12	0.36	6.66e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg23601095	chr6:26197514	HIST1H3D	0.7	7.44	0.38	8.35e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs12136530	0.774	rs12409301	chr1:19774715	G/A	cg01832549	chr1:19774989	CAPZB	-0.32	-5.94	-0.31	7.33e-9	Lead levels in blood;
LUSC	cis	rs4253772	0.550	rs9615347	chr22:46728153	A/G	cg09491104	chr22:46646882	C22orf40	-0.71	-7.03	-0.36	1.13e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs5758511	0.573	rs1569451	chr22:42232291	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-7.52	-0.38	5.01e-13	Birth weight;
LUSC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.93	-0.44	2.88e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.83	-0.3	1.32e-8	Tonsillectomy;
LUSC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-8.27	-0.41	3.19e-15	Systemic lupus erythematosus;
LUSC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg24399712	chr22:39784796	NA	-0.64	-11.92	-0.55	1.53e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.99	-15.41	-0.64	7.63e-41	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-7.54	-0.38	4.33e-13	Blood metabolite levels;
LUSC	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg14227996	chr4:17616232	MED28	0.77	7.8	0.39	8.18e-14	Opioid sensitivity;
LUSC	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg07661805	chr8:143867942	LY6D	-0.26	-6.08	-0.32	3.25e-9	Urinary tract infection frequency;
LUSC	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.39	-0.33	5.51e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg06530960	chr19:49140787	SEC1;DBP	0.73	9.29	0.45	2.05e-18	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg22089800	chr15:90895588	ZNF774	-0.6	-9.17	-0.45	4.87e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg05347473	chr6:146136440	FBXO30	0.52	8.68	0.43	1.82e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg24642439	chr20:33292090	TP53INP2	0.59	8.73	0.43	1.25e-16	Coronary artery disease;
LUSC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg02475777	chr4:1388615	CRIPAK	0.43	6.39	0.33	5.68e-10	Obesity-related traits;
LUSC	cis	rs10740039	0.729	rs6479721	chr10:62373122	A/C	cg18175470	chr10:62150864	ANK3	-0.43	-6.45	-0.33	3.87e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.88	15.02	0.63	2.46e-39	Morning vs. evening chronotype;
LUSC	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	6.56	0.34	2.01e-10	Response to antipsychotic treatment;
LUSC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12292205	chr6:26970375	C6orf41	-0.58	-7.15	-0.36	5.62e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	ch.11.42038R	chr11:967971	AP2A2	0.43	6.42	0.33	4.65e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs711244	0.777	rs12476515	chr2:37102620	T/C	cg14987922	chr2:37194071	STRN	-0.44	-6.36	-0.33	6.83e-10	Mean platelet volume;
LUSC	trans	rs1927790	0.616	rs1925119	chr13:96939586	C/A	cg03198741	chr6:1003969	LOC285768	-0.41	-6.26	-0.32	1.21e-9	Body mass index;
LUSC	cis	rs7572644	0.656	rs4666016	chr2:28037140	T/A	cg27432699	chr2:27873401	GPN1	0.58	7.37	0.37	1.36e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg05585544	chr11:47624801	NA	-0.33	-6.04	-0.31	4.11e-9	Subjective well-being;
LUSC	cis	rs7147624	0.572	rs2411813	chr14:66023906	G/A	cg03016385	chr14:66212404	NA	-0.82	-7.76	-0.39	1.02e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7953508	0.506	rs930316	chr12:93967035	A/G	cg18151635	chr12:93972918	NA	-0.62	-8.96	-0.44	2.35e-17	Pubertal anthropometrics;
LUSC	cis	rs7267979	0.527	rs6083891	chr20:25574272	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-12.76	-0.57	1.17e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9612	1.000	rs28373139	chr19:44246706	A/G	cg08581076	chr19:44259116	C19orf61	0.53	6.57	0.34	1.88e-10	Exhaled nitric oxide output;
LUSC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	10.73	0.51	2.75e-23	Cognitive test performance;
LUSC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg13683864	chr3:40499215	RPL14	-1.14	-21.17	-0.76	1.15e-63	Renal cell carcinoma;
LUSC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13126279	chr21:47581558	C21orf56	0.54	8.39	0.42	1.41e-15	Testicular germ cell tumor;
LUSC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg19468946	chr17:37922297	IKZF3	-0.44	-6.99	-0.36	1.5e-11	Self-reported allergy;
LUSC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg06558623	chr16:89946397	TCF25	0.83	7.39	0.38	1.15e-12	Skin colour saturation;
LUSC	trans	rs89107	0.651	rs2356080	chr6:118609174	G/T	cg11574620	chr4:80246899	NAA11	-0.37	-6.1	-0.32	2.94e-9	Cardiac structure and function;
LUSC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-7.95	-0.4	2.96e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2731664	0.792	rs335467	chr5:176890642	A/G	cg23176889	chr5:176863531	GRK6	-0.71	-14.74	-0.63	3.07e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.57	-8.93	-0.44	2.8e-17	Lung cancer;
LUSC	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.13	0.55	2.73e-28	Colorectal cancer;
LUSC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.76	0.43	1.03e-16	Lung cancer;
LUSC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.73	0.54	7.69e-27	Alzheimer's disease;
LUSC	cis	rs7605827	1.000	rs7605827	chr2:15598740	A/T	cg19274914	chr2:15703543	NA	0.47	9.08	0.45	9.55e-18	Educational attainment (years of education);
LUSC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg05084668	chr3:125655381	ALG1L	-0.5	-7.01	-0.36	1.28e-11	Blood pressure (smoking interaction);
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18337363	chr3:52569053	NT5DC2	0.25	5.77	0.3	1.81e-8	Electroencephalogram traits;
LUSC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg04166393	chr7:2884313	GNA12	0.4	5.74	0.3	2.13e-8	Height;
LUSC	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	9.79	0.47	4.78e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg25428297	chr7:1022841	CYP2W1	0.29	5.77	0.3	1.8e-8	Longevity;Endometriosis;
LUSC	trans	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg27411982	chr8:10470053	RP1L1	0.38	6.12	0.32	2.59e-9	Mood instability;
LUSC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg14993813	chr1:46806288	NSUN4	0.49	6.88	0.35	3.01e-11	Menopause (age at onset);
LUSC	cis	rs11690935	0.550	rs6746701	chr2:172869255	G/A	cg13550731	chr2:172543902	DYNC1I2	0.52	7.93	0.4	3.22e-14	Schizophrenia;
LUSC	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.47	-0.42	8.08e-16	Response to antipsychotic treatment;
LUSC	trans	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.6	0.38	3.08e-13	Ulcerative colitis;
LUSC	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg23950597	chr19:37808831	NA	-0.64	-7.74	-0.39	1.16e-13	Coronary artery calcification;
LUSC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg13114125	chr14:105738426	BRF1	-0.92	-16.0	-0.66	3.5e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.94	0.51	5.25e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg18827107	chr12:86230957	RASSF9	0.43	6.46	0.33	3.78e-10	Major depressive disorder;
LUSC	cis	rs7815909	0.610	rs4077819	chr8:57210682	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	-0.61	-7.75	-0.39	1.12e-13	Height;
LUSC	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg03585969	chr10:35415529	CREM	0.6	8.81	0.43	6.71e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg08601574	chr20:25228251	PYGB	0.43	6.57	0.34	1.98e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg26408565	chr15:76604113	ETFA	-0.49	-7.96	-0.4	2.66e-14	Blood metabolite levels;
LUSC	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg27661571	chr11:113659931	NA	0.65	6.51	0.34	2.83e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs649057	1.000	rs649057	chr9:102234323	G/T	cg11260715	chr7:22602834	NA	-0.63	-6.01	-0.31	4.76e-9	Smooth-surface caries;Dental caries;Otitis media;Otitis media (chronic);
LUSC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	0.94	13.54	0.6	1.34e-33	Vitiligo;
LUSC	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	8.86	0.44	4.85e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08219700	chr8:58056026	NA	0.66	8.37	0.42	1.58e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.26	-0.41	3.35e-15	Total cholesterol levels;
LUSC	trans	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg20935933	chr6:143382018	AIG1	0.5	7.32	0.37	1.92e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.05	0.48	6.07e-21	Lung cancer in ever smokers;
LUSC	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.9	20.74	0.75	5.32e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.63	7.96	0.4	2.63e-14	Schizophrenia;
LUSC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	10.42	0.5	3.45e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.5	6.16	0.32	2.15e-9	Multiple sclerosis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06419771	chr15:42264912	EHD4	0.45	6.46	0.33	3.61e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg03522245	chr20:25566470	NINL	-0.35	-5.78	-0.3	1.68e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7605827	0.930	rs12692262	chr2:15539084	A/G	cg19274914	chr2:15703543	NA	0.46	8.96	0.44	2.28e-17	Educational attainment (years of education);
LUSC	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg23950597	chr19:37808831	NA	0.58	7.15	0.36	5.63e-12	Coronary artery calcification;
LUSC	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg23625390	chr15:77176239	SCAPER	0.47	7.23	0.37	3.23e-12	Blood metabolite levels;
LUSC	cis	rs13082711	0.871	rs13061912	chr3:27495586	A/G	cg02860705	chr3:27208620	NA	0.47	7.8	0.39	8.1e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg07460842	chr6:66804631	NA	0.49	5.97	0.31	6.2e-9	Metabolite levels;
LUSC	cis	rs981844	1.000	rs17298985	chr4:154664261	C/T	cg14289246	chr4:154710475	SFRP2	0.52	6.76	0.35	6.25e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs73206853	0.925	rs12318836	chr12:110642190	A/C	cg12870014	chr12:110450643	ANKRD13A	0.46	5.87	0.31	1.07e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9517320	1.000	rs12864890	chr13:99126457	T/C	cg07423050	chr13:99094983	FARP1	0.34	6.41	0.33	5.07e-10	Longevity;
LUSC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg07636037	chr3:49044803	WDR6	0.59	6.25	0.32	1.28e-9	Menarche (age at onset);
LUSC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg16339924	chr4:17578868	LAP3	0.49	7.4	0.38	1.12e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg18404041	chr3:52824283	ITIH1	0.61	10.3	0.49	8.6e-22	Schizophrenia;
LUSC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.86	16.48	0.67	4.59e-45	Mean platelet volume;
LUSC	cis	rs3771570	0.901	rs4075818	chr2:242432142	T/C	cg21155796	chr2:242212141	HDLBP	0.61	6.84	0.35	3.83e-11	Prostate cancer;
LUSC	cis	rs7000551	0.715	rs12544074	chr8:22338378	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	6.37	0.33	6.33e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg27572855	chr1:25598939	RHD	0.42	7.3	0.37	2.14e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs67072384	1.000	rs2365442	chr11:72450218	G/A	cg04827223	chr11:72435913	ARAP1	-0.78	-6.71	-0.34	8.4e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg14440974	chr22:39074834	NA	0.36	5.8	0.3	1.5e-8	Menopause (age at onset);
LUSC	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.58	8.59	0.43	3.41e-16	Menopause (age at onset);
LUSC	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg14835575	chr10:16859367	RSU1	0.76	9.47	0.46	5.44e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs2625529	0.775	rs16956273	chr15:72117102	C/T	cg16672083	chr15:72433130	SENP8	-0.48	-7.52	-0.38	5.09e-13	Red blood cell count;
LUSC	cis	rs7851660	0.844	rs12343182	chr9:100624259	G/C	cg13688889	chr9:100608707	NA	-0.57	-9.08	-0.44	9.65e-18	Strep throat;
LUSC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg07395648	chr5:131743802	NA	0.39	6.12	0.32	2.55e-9	Asthma (sex interaction);
LUSC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg07952391	chr2:88470173	THNSL2	0.76	6.7	0.34	8.69e-11	Plasma clusterin levels;
LUSC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-5.89	-0.31	9.49e-9	Major depressive disorder;
LUSC	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg04455712	chr21:45112962	RRP1B	0.46	8.69	0.43	1.61e-16	Mean corpuscular volume;
LUSC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	14.52	0.62	2.24e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.44	6.44	0.33	4.05e-10	Breast cancer;
LUSC	cis	rs273573	1.000	rs156399	chr11:30955947	A/G	cg14844989	chr11:31128820	NA	0.36	5.71	0.3	2.51e-8	Total body bone mineral density;
LUSC	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.66	0.5	5e-23	Colorectal cancer;
LUSC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg03188948	chr7:1209495	NA	0.6	7.04	0.36	1.09e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-8.69	-0.43	1.65e-16	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.88	0.66	1.1e-42	Bladder cancer;
LUSC	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.9e-20	Migraine;Coronary artery disease;
LUSC	cis	rs2455601	1.000	rs11042108	chr11:8906021	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.56	-0.34	2e-10	Schizophrenia;
LUSC	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg23649088	chr2:200775458	C2orf69	-0.53	-6.82	-0.35	4.37e-11	Schizophrenia;
LUSC	cis	rs698813	0.604	rs12712917	chr2:44482190	A/G	cg00619915	chr2:44497795	NA	-0.52	-7.41	-0.38	1.06e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg10845886	chr2:3471009	TTC15	-0.48	-6.35	-0.33	6.97e-10	Neurofibrillary tangles;
LUSC	cis	rs751728	0.588	rs7774620	chr6:33736285	T/A	cg25922239	chr6:33757077	LEMD2	0.42	6.25	0.32	1.25e-9	Crohn's disease;
LUSC	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.6	10.05	0.48	6.31e-21	Birth weight;
LUSC	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.92	-0.44	3.08e-17	Bone mineral density;
LUSC	cis	rs12911832	0.701	rs452698	chr15:59105571	A/G	cg05156742	chr15:59063176	FAM63B	0.55	8.57	0.42	3.76e-16	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26801646	chr10:76970496	VDAC2	0.45	7.44	0.38	8.45e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg25482853	chr8:67687455	SGK3	1.03	15.45	0.65	5.41e-41	Obesity-related traits;
LUSC	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-0.86	-9.87	-0.48	2.48e-20	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg16359550	chr11:109292809	C11orf87	0.32	5.78	0.3	1.74e-8	Schizophrenia;
LUSC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg24011408	chr12:48396354	COL2A1	-0.53	-8.72	-0.43	1.35e-16	Plateletcrit;
LUSC	cis	rs3106136	0.967	rs4693377	chr4:95157256	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.93	-0.31	7.72e-9	Capecitabine sensitivity;
LUSC	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg17507749	chr15:85114479	UBE2QP1	0.7	9.24	0.45	3.03e-18	Schizophrenia;
LUSC	cis	rs12519773	1.000	rs4470752	chr5:92460541	C/T	cg18783429	chr5:92414398	NA	0.29	6.48	0.33	3.2e-10	Migraine;
LUSC	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg22532475	chr10:104410764	TRIM8	-0.29	-5.9	-0.31	8.72e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.82	11.36	0.53	1.69e-25	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg11344533	chr11:111475393	SIK2	-0.46	-6.31	-0.33	8.96e-10	Primary sclerosing cholangitis;
LUSC	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg24375607	chr4:120327624	NA	0.79	11.91	0.55	1.72e-27	Corneal astigmatism;
LUSC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg12437481	chr16:420112	MRPL28	-0.54	-9.45	-0.46	6.32e-19	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.53	-11.24	-0.52	4.64e-25	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.73	-10.0	-0.48	8.94e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg06112835	chr11:68658793	MRPL21	0.38	6.42	0.33	4.78e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg14809332	chr8:144654887	C8orf73	0.54	6.51	0.34	2.78e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs4409675	0.576	rs7533918	chr1:28230667	G/A	cg23691781	chr1:28212827	C1orf38	0.32	7.65	0.39	2.21e-13	Corneal astigmatism;
LUSC	trans	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.59	-0.34	1.71e-10	Endometrial cancer;
LUSC	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg09085632	chr11:111637200	PPP2R1B	0.97	13.91	0.61	5.25e-35	Primary sclerosing cholangitis;
LUSC	cis	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05901451	chr6:126070800	HEY2	-0.58	-8.59	-0.43	3.43e-16	Endometrial cancer;
LUSC	cis	rs9473147	0.543	rs9473126	chr6:47481833	C/G	cg12968598	chr6:47444699	CD2AP	0.53	8.07	0.4	1.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg15556689	chr8:8085844	FLJ10661	0.63	9.09	0.45	9.32e-18	Neuroticism;
LUSC	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg18806716	chr10:30721971	MAP3K8	-0.65	-9.73	-0.47	7.45e-20	Inflammatory bowel disease;
LUSC	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg09307838	chr4:120376055	NA	0.72	10.4	0.49	3.85e-22	Corneal astigmatism;
LUSC	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg25301532	chr20:43378953	KCNK15	-0.34	-5.97	-0.31	6.01e-9	Obesity-related traits;
LUSC	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	8.76	0.43	1.03e-16	Lung cancer;
LUSC	cis	rs11958404	0.615	rs7724696	chr5:157450852	A/C	cg05962755	chr5:157440814	NA	0.39	5.71	0.3	2.53e-8	IgG glycosylation;
LUSC	cis	rs887829	0.569	rs4148326	chr2:234673462	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.63	-0.39	2.53e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.77	7.55	0.38	4.1e-13	Initial pursuit acceleration;
LUSC	cis	rs6546550	0.901	rs6546559	chr2:70145833	G/A	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.29	-0.37	2.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.96	-0.44	2.36e-17	Gut microbiome composition (summer);
LUSC	cis	rs2286503	0.780	rs981792	chr7:22861639	C/A	cg11367502	chr7:22862612	TOMM7	0.46	6.17	0.32	1.96e-9	Fibrinogen;
LUSC	cis	rs6722750	0.682	rs1866048	chr2:64416837	A/G	cg22352474	chr2:64371530	PELI1	-0.53	-7.96	-0.4	2.76e-14	Neuroticism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19082003	chr1:231004179	C1orf198	-0.43	-6.25	-0.32	1.28e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg26587870	chr6:27730563	NA	-0.64	-6.15	-0.32	2.16e-9	Depression;
LUSC	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg06532163	chr17:45867833	NA	0.35	6.53	0.34	2.51e-10	IgG glycosylation;
LUSC	trans	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg02269571	chr22:50332266	NA	-0.59	-8.72	-0.43	1.31e-16	Schizophrenia;
LUSC	cis	rs440932	0.798	rs330942	chr8:9020439	A/C	cg06636001	chr8:8085503	FLJ10661	0.42	6.19	0.32	1.73e-9	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs6977660	1.000	rs6959889	chr7:19822024	A/C	cg07541023	chr7:19748670	TWISTNB	0.51	5.73	0.3	2.3e-8	Thyroid stimulating hormone;
LUSC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg23625390	chr15:77176239	SCAPER	-0.67	-10.08	-0.48	5.01e-21	Blood metabolite levels;
LUSC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.77	0.47	5.19e-20	Bipolar disorder;
LUSC	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg13010199	chr12:38710504	ALG10B	0.69	11.78	0.54	5.17e-27	Heart rate;
LUSC	cis	rs12122100	0.774	rs12723253	chr1:146523303	C/T	cg03526459	chr1:146549940	NA	-0.41	-6.59	-0.34	1.72e-10	HIV-1 control;
LUSC	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.28	-0.41	3.08e-15	Neuroticism;
LUSC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	12.37	0.56	3.42e-29	Cognitive test performance;
LUSC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-9.62	-0.47	1.67e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs58749629	1.000	rs58749629	chr20:44571317	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.54	-6.04	-0.31	4.08e-9	Abdominal aortic aneurysm;
LUSC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg21951975	chr1:209979733	IRF6	0.55	8.22	0.41	4.41e-15	Cleft lip with or without cleft palate;
LUSC	cis	rs11955175	1.000	rs11960585	chr5:40662007	C/A	cg05478818	chr5:40835740	RPL37	0.7	5.69	0.3	2.74e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1127311	0.905	rs6699729	chr1:154582896	A/T	cg17218026	chr1:154582156	ADAR	0.56	10.06	0.48	5.92e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.69	-10.13	-0.48	3.24e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs4704187	0.663	rs12523187	chr5:74379625	A/T	cg03227963	chr5:74354835	NA	0.31	6.73	0.35	7.4e-11	Response to amphetamines;
LUSC	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg06096015	chr1:231504339	EGLN1	0.57	10.33	0.49	6.72e-22	Hemoglobin concentration;
LUSC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg00784671	chr22:46762841	CELSR1	-0.48	-6.24	-0.32	1.32e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08219700	chr8:58056026	NA	0.69	8.22	0.41	4.58e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg24675658	chr1:53192096	ZYG11B	0.62	9.86	0.47	2.63e-20	Monocyte count;
LUSC	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg24692254	chr21:30365293	RNF160	-0.56	-8.2	-0.41	5.35e-15	Pancreatic cancer;
LUSC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03352830	chr11:487213	PTDSS2	0.71	8.65	0.43	2.24e-16	Body mass index;
LUSC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg08499158	chr17:42289980	UBTF	-0.48	-7.79	-0.39	8.46e-14	Total body bone mineral density;
LUSC	cis	rs672059	1.000	rs546183	chr1:183157753	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.55	7.98	0.4	2.3e-14	Hypertriglyceridemia;
LUSC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	22.2	0.77	9.81e-68	Prudent dietary pattern;
LUSC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg02038168	chr22:39784481	NA	-0.49	-7.85	-0.39	5.76e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.64	-0.43	2.34e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21171335	chr12:122356390	WDR66	0.61	9.22	0.45	3.37e-18	Mean corpuscular volume;
LUSC	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg05714579	chr10:131428358	MGMT	-0.76	-12.27	-0.56	8.04e-29	Response to temozolomide;
LUSC	cis	rs6469656	1.000	rs1347626	chr8:117656781	T/C	cg24004040	chr8:117650383	NA	-0.45	-6.48	-0.33	3.3e-10	Colorectal cancer;
LUSC	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg13010199	chr12:38710504	ALG10B	0.45	6.97	0.36	1.68e-11	Morning vs. evening chronotype;
LUSC	cis	rs4356932	1.000	rs6850515	chr4:76973751	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.83	0.3	1.33e-8	Blood protein levels;
LUSC	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg01973587	chr1:228161476	NA	0.47	8.47	0.42	7.96e-16	Diastolic blood pressure;
LUSC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.47	7.13	0.36	6.42e-12	Testicular germ cell tumor;
LUSC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	7.5	0.38	5.63e-13	Multiple sclerosis;
LUSC	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg23711669	chr6:146136114	FBXO30	-0.82	-14.58	-0.62	1.32e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg21141812	chr3:48556323	PFKFB4	-0.34	-6.23	-0.32	1.43e-9	Menarche (age at onset);
LUSC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg02782426	chr3:40428986	ENTPD3	0.35	6.6	0.34	1.66e-10	Renal cell carcinoma;
LUSC	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg22139774	chr2:100720529	AFF3	-0.54	-9.6	-0.47	1.93e-19	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg14322403	chr8:57123418	PLAG1;CHCHD7	0.37	5.97	0.31	6.05e-9	Mosquito bite size;
LUSC	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg05425664	chr17:57184151	TRIM37	0.41	6.2	0.32	1.71e-9	Testicular germ cell tumor;
LUSC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg16928487	chr17:17741425	SREBF1	-0.43	-8.45	-0.42	8.85e-16	Total body bone mineral density;
LUSC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg06713675	chr4:122721982	EXOSC9	-0.46	-8.14	-0.41	7.83e-15	Type 2 diabetes;
LUSC	cis	rs698813	0.604	rs7606004	chr2:44479983	G/A	cg00619915	chr2:44497795	NA	-0.53	-7.42	-0.38	9.62e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	trans	rs208520	1.000	rs208521	chr6:66953625	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-12.34	-0.56	4.42e-29	Exhaled nitric oxide output;
LUSC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.72	-11.16	-0.52	8.52e-25	Body mass index;
LUSC	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.81	11.74	0.54	7.02e-27	Corneal astigmatism;
LUSC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	7.43	0.38	9.23e-13	Blood metabolite levels;
LUSC	cis	rs11229555	0.609	rs7927730	chr11:58187906	G/A	cg15696309	chr11:58395628	NA	-0.64	-7.77	-0.39	9.83e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6693567	0.565	rs8006	chr1:150280801	G/C	cg15654264	chr1:150340011	RPRD2	-0.45	-7.39	-0.37	1.22e-12	Migraine;
LUSC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.34	-6.56	-0.34	2.09e-10	Total body bone mineral density;
LUSC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26850624	chr5:429559	AHRR	-0.41	-8.0	-0.4	2.1e-14	Cystic fibrosis severity;
LUSC	cis	rs7923609	0.967	rs10509186	chr10:65207018	C/T	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.03e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8092503	1.000	rs12960467	chr18:52492951	C/G	cg12377874	chr18:52495404	RAB27B	0.33	5.79	0.3	1.59e-8	Childhood body mass index;
LUSC	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-10.31	-0.49	7.76e-22	Morning vs. evening chronotype;
LUSC	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.67e-24	Hypertriglyceridemia;
LUSC	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg04850211	chr1:228464232	OBSCN	-0.33	-5.7	-0.3	2.69e-8	Diastolic blood pressure;
LUSC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg20135002	chr11:47629003	NA	-0.51	-8.11	-0.41	9.83e-15	Subjective well-being;
LUSC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.91	0.48	1.78e-20	Bipolar disorder;
LUSC	cis	rs2303282	0.716	rs4620948	chr16:56439776	A/G	cg00500540	chr16:56394104	NA	-0.43	-7.32	-0.37	1.88e-12	Breast cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23260190	chr10:101419318	ENTPD7	-0.47	-6.05	-0.31	3.9e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11030122	0.673	rs10835601	chr11:4106416	G/A	cg08557956	chr11:4115526	RRM1	-0.47	-6.03	-0.31	4.31e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs701145	0.585	rs4680125	chr3:153784698	G/A	cg17054900	chr3:154042577	DHX36	-0.73	-7.44	-0.38	8.72e-13	Coronary artery disease;
LUSC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg12403142	chr1:92012408	NA	-0.38	-6.12	-0.32	2.7e-9	Breast cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23121547	chr11:1593657	HCCA2;LOC338651;DUSP8	-0.53	-6.28	-0.32	1.03e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-8.43	-0.42	1.06e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg18129178	chr5:148520854	ABLIM3	-0.73	-10.05	-0.48	6.34e-21	Breast cancer;
LUSC	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg00540400	chr15:79124168	NA	0.45	7.94	0.4	3.18e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs1865721	0.804	rs7243462	chr18:73147998	A/T	cg26385618	chr18:73139727	C18orf62	-0.52	-9.51	-0.46	3.94e-19	Intelligence;
LUSC	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18252515	chr7:66147081	NA	-0.57	-7.89	-0.4	4.26e-14	Corneal structure;
LUSC	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.51	-0.46	3.89e-19	Extrinsic epigenetic age acceleration;
LUSC	trans	rs12637928	0.580	rs13078633	chr3:110253113	A/G	cg17371621	chr15:61264283	RORA	0.36	5.96	0.31	6.51e-9	Neuroticism;
LUSC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08280861	chr8:58055591	NA	0.57	6.2	0.32	1.67e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg27411982	chr8:10470053	RP1L1	-0.43	-6.98	-0.36	1.62e-11	Systolic blood pressure;
LUSC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-1.13	-24.99	-0.81	1.8e-78	Height;
LUSC	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	7.02	0.36	1.23e-11	Cognitive test performance;
LUSC	cis	rs2580764	0.566	rs2972075	chr2:55292322	T/G	cg20993754	chr2:55226987	RTN4	-0.36	-6.06	-0.31	3.73e-9	Mean platelet volume;
LUSC	cis	rs501916	0.634	rs3803349	chr15:48064867	T/A	cg16110827	chr15:48056943	SEMA6D	-0.39	-6.16	-0.32	2.1e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.88	0.58	4.42e-31	Prudent dietary pattern;
LUSC	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg12615879	chr12:58013172	SLC26A10	-0.29	-5.94	-0.31	7.18e-9	Multiple sclerosis;
LUSC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg05585544	chr11:47624801	NA	-0.42	-7.35	-0.37	1.5e-12	Subjective well-being;
LUSC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-18.06	-0.7	2.45e-51	Coronary artery disease;
LUSC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg20734569	chr3:48348370	SPINK8	-0.47	-7.93	-0.4	3.4e-14	Coronary artery disease;
LUSC	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02176678	chr2:219576539	TTLL4	0.64	11.63	0.54	1.77e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9303542	0.625	rs4239209	chr17:46574317	T/A	cg09704116	chr17:46666958	LOC404266	0.31	5.81	0.3	1.44e-8	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg13798780	chr7:105162888	PUS7	0.52	6.56	0.34	2.11e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg03806693	chr22:41940476	POLR3H	-0.54	-7.3	-0.37	2.11e-12	Neuroticism;
LUSC	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg20991723	chr1:152506922	NA	0.49	9.21	0.45	3.74e-18	Hair morphology;
LUSC	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-6.0	-0.31	5.1e-9	Reticulocyte count;
LUSC	cis	rs9462027	0.628	rs9469863	chr6:34739649	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.74	-0.3	2.08e-8	Systemic lupus erythematosus;
LUSC	trans	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg12856521	chr11:46389249	DGKZ	0.4	6.19	0.32	1.73e-9	Leprosy;
LUSC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg00431813	chr7:1051703	C7orf50	-0.38	-5.97	-0.31	6.08e-9	Longevity;Endometriosis;
LUSC	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.73	-13.36	-0.59	6.47e-33	Ulcerative colitis;
LUSC	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.65	-0.43	2.26e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.54	-10.6	-0.5	8.12e-23	Educational attainment;
LUSC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs4655582	0.527	rs4655794	chr1:66159301	T/C	cg04111102	chr1:66153794	NA	0.27	5.69	0.3	2.74e-8	Fibrinogen levels;
LUSC	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg01884057	chr2:25150051	NA	0.49	11.42	0.53	9.77e-26	Body mass index;
LUSC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.76	-13.74	-0.6	2.24e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg18681998	chr4:17616180	MED28	0.85	15.11	0.64	1.17e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-7.39	-0.38	1.15e-12	Alzheimer's disease (late onset);
LUSC	trans	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg10756647	chr7:56101905	PSPH	-0.81	-8.22	-0.41	4.4e-15	Diabetic kidney disease;
LUSC	cis	rs17828380	1.000	rs34119905	chr15:63490547	C/T	cg05507819	chr15:63340323	TPM1	-0.7	-5.9	-0.31	9.09e-9	Social communication problems;
LUSC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg12560992	chr17:57184187	TRIM37	-0.82	-14.75	-0.63	2.92e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.75	12.72	0.57	1.74e-30	Motion sickness;
LUSC	cis	rs11828289	0.660	rs79045664	chr11:23238737	G/A	cg20040320	chr11:23191996	NA	-0.63	-6.19	-0.32	1.79e-9	Cancer;
LUSC	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg00999904	chr2:3704751	ALLC	-0.44	-6.77	-0.35	5.73e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.94	-16.07	-0.66	1.96e-43	Coronary artery disease;
LUSC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs3820928	0.874	rs2177593	chr2:227833869	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.39	-0.37	1.18e-12	Pulmonary function;
LUSC	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg24687543	chr11:63912206	MACROD1	0.46	5.93	0.31	7.47e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.66	-7.07	-0.36	9.01e-12	Birth weight;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg26253258	chr20:60697513	LSM14B	-0.46	-6.0	-0.31	5.19e-9	Cognitive function;Information processing speed;
LUSC	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.9	14.93	0.63	5.72e-39	Bladder cancer;
LUSC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg22920501	chr2:26401640	FAM59B	-0.79	-11.59	-0.54	2.53e-26	Gut microbiome composition (summer);
LUSC	cis	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.3	-0.41	2.67e-15	Coronary artery disease;
LUSC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	0.86	14.42	0.62	5.3e-37	Tonsillectomy;
LUSC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg12432903	chr7:1882776	MAD1L1	0.51	8.65	0.43	2.25e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg05738196	chr6:26577821	NA	0.81	15.72	0.65	4.7e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs1160297	0.633	rs12477231	chr2:53084648	T/G	cg07782112	chr2:53107842	NA	0.4	6.41	0.33	4.89e-10	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.79	-0.39	8.77e-14	Retinal vascular caliber;
LUSC	cis	rs9644630	0.841	rs4292704	chr8:19329303	G/C	cg06562184	chr8:19319451	CSGALNACT1	0.41	6.04	0.31	4.22e-9	Oropharynx cancer;
LUSC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg18306943	chr3:40428807	ENTPD3	0.39	6.09	0.32	3.13e-9	Renal cell carcinoma;
LUSC	cis	rs2274273	0.773	rs8006525	chr14:55813394	T/G	cg04306507	chr14:55594613	LGALS3	0.56	12.81	0.57	7.72e-31	Protein biomarker;
LUSC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg02807482	chr3:125708958	NA	-0.54	-6.68	-0.34	1.02e-10	Blood pressure (smoking interaction);
LUSC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs193541	0.632	rs4835896	chr5:122121240	C/T	cg19077854	chr5:122220652	SNX24	-0.39	-8.24	-0.41	3.85e-15	Glucose homeostasis traits;
LUSC	cis	rs12900413	0.840	rs28700196	chr15:90297238	G/T	cg24249390	chr15:90295951	MESP1	-0.48	-7.33	-0.37	1.71e-12	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg15133208	chr4:90757351	SNCA	-0.55	-8.63	-0.43	2.6e-16	Neuroticism;
LUSC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg16624210	chr5:671434	TPPP	0.49	6.05	0.31	3.83e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7119	0.671	rs10152850	chr15:77904426	G/A	cg27398640	chr15:77910606	LINGO1	0.39	8.97	0.44	2.16e-17	Type 2 diabetes;
LUSC	cis	rs11229555	0.645	rs10896814	chr11:58430699	T/C	cg15696309	chr11:58395628	NA	-0.63	-6.7	-0.34	8.8e-11	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg04117972	chr1:227635322	NA	0.62	6.59	0.34	1.73e-10	Major depressive disorder;
LUSC	cis	rs10100465	0.855	rs1396351	chr8:118689728	A/G	cg09430518	chr8:118662568	NA	0.32	5.87	0.31	1.05e-8	Leprosy;
LUSC	cis	rs9309711	0.736	rs9678647	chr2:3497036	A/G	cg10845886	chr2:3471009	TTC15	0.45	5.85	0.3	1.19e-8	Neurofibrillary tangles;
LUSC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg16624210	chr5:671434	TPPP	0.47	5.92	0.31	8.21e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg07936489	chr17:37558343	FBXL20	0.72	9.92	0.48	1.64e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs4356932	1.000	rs6532157	chr4:76974373	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.83	0.3	1.33e-8	Blood protein levels;
LUSC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg27121462	chr16:89883253	FANCA	0.54	8.65	0.43	2.27e-16	Vitiligo;
LUSC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg06212747	chr3:49208901	KLHDC8B	0.43	5.84	0.3	1.24e-8	Parkinson's disease;
LUSC	cis	rs7605827	0.897	rs763355	chr2:15518838	A/G	cg19274914	chr2:15703543	NA	0.47	9.2	0.45	4.07e-18	Educational attainment (years of education);
LUSC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13732083	chr21:47605072	C21orf56	-0.45	-6.7	-0.34	8.72e-11	Testicular germ cell tumor;
LUSC	cis	rs10392	0.571	rs4812350	chr20:37631192	C/T	cg27552599	chr20:37590471	DHX35	0.47	7.84	0.39	6.16e-14	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg21775007	chr8:11205619	TDH	0.47	6.33	0.33	8.03e-10	Neuroticism;
LUSC	cis	rs77633900	0.772	rs284898	chr15:76750695	A/G	cg21673338	chr15:77095150	SCAPER	-0.7	-5.95	-0.31	6.83e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-0.66	-9.53	-0.46	3.35e-19	Platelet distribution width;
LUSC	cis	rs7809950	0.678	rs7790080	chr7:107031322	G/A	cg23024343	chr7:107201750	COG5	-0.68	-9.97	-0.48	1.12e-20	Coronary artery disease;
LUSC	cis	rs11039100	0.850	rs12363855	chr11:5830186	G/C	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11439475	chr15:52821378	MYO5A	-0.48	-5.97	-0.31	5.9e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4664308	0.806	rs4665162	chr2:161060184	A/G	cg03641300	chr2:160917029	PLA2R1	-0.62	-10.69	-0.51	3.8e-23	Idiopathic membranous nephropathy;
LUSC	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.94	-0.31	7.31e-9	Neutrophil percentage of white cells;
LUSC	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg16359550	chr11:109292809	C11orf87	0.41	6.84	0.35	3.69e-11	Schizophrenia;
LUSC	cis	rs7173743	1.000	rs4567668	chr15:79140692	T/C	cg00540400	chr15:79124168	NA	-0.33	-5.72	-0.3	2.39e-8	Coronary artery disease;
LUSC	cis	rs8114671	0.935	rs35193912	chr20:33785050	C/T	cg07148914	chr20:33460835	GGT7	-0.44	-6.58	-0.34	1.82e-10	Height;
LUSC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.77	16.77	0.68	3.29e-46	Birth weight;
LUSC	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	5.68	0.3	2.94e-8	Rheumatoid arthritis;
LUSC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg04455712	chr21:45112962	RRP1B	-0.45	-8.72	-0.43	1.38e-16	Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08677398	chr8:58056175	NA	0.53	6.98	0.36	1.61e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	10.01	0.48	8.14e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.84	-0.44	5.55e-17	Monocyte percentage of white cells;
LUSC	cis	rs7091068	0.671	rs1764322	chr10:95406276	T/G	cg20715218	chr10:95462985	C10orf4	-0.62	-7.29	-0.37	2.29e-12	Urinary tract infection frequency;
LUSC	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.42	6.72	0.34	8.07e-11	Response to antipsychotic treatment;
LUSC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg07169764	chr2:136633963	MCM6	-0.58	-7.55	-0.38	4.27e-13	Mosquito bite size;
LUSC	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg08773314	chr2:239334832	ASB1	0.44	9.54	0.46	3.16e-19	Multiple system atrophy;
LUSC	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg23625390	chr15:77176239	SCAPER	-0.64	-9.67	-0.47	1.12e-19	Blood metabolite levels;
LUSC	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg26195577	chr20:24973756	C20orf3	1.11	18.48	0.71	5e-53	Blood protein levels;
LUSC	cis	rs3960554	0.740	rs10216079	chr7:75690988	A/C	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.65	-0.3	3.52e-8	Eotaxin levels;
LUSC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg12463550	chr7:65579703	CRCP	-0.53	-7.72	-0.39	1.4e-13	Aortic root size;
LUSC	cis	rs6545883	0.929	rs55806663	chr2:61740487	G/T	cg15711740	chr2:61764176	XPO1	-0.5	-7.94	-0.4	3.03e-14	Tuberculosis;
LUSC	cis	rs9341808	0.529	rs9350851	chr6:81059188	A/G	cg08355045	chr6:80787529	NA	0.47	7.86	0.4	5.35e-14	Sitting height ratio;
LUSC	cis	rs965604	1.000	rs12904234	chr15:78779384	C/T	cg18825076	chr15:78729989	IREB2	-0.43	-6.93	-0.35	2.12e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg07701084	chr6:150067640	NUP43	0.55	8.15	0.41	7.52e-15	Lung cancer;
LUSC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.61	-0.6	7.35e-34	Chronic sinus infection;
LUSC	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.84	0.51	1.15e-23	Fuchs's corneal dystrophy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19941170	chr5:172067912	NEURL1B	0.43	6.68	0.34	1.02e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg24011408	chr12:48396354	COL2A1	-0.53	-7.35	-0.37	1.49e-12	Lung cancer;
LUSC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.44	6.24	0.32	1.33e-9	Osteoporosis;
LUSC	trans	rs2018683	0.707	rs1021691	chr7:28974496	C/T	cg19402173	chr7:128379420	CALU	-0.47	-7.23	-0.37	3.36e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	trans	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg13010199	chr12:38710504	ALG10B	0.45	6.92	0.35	2.25e-11	Morning vs. evening chronotype;
LUSC	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	0.56	8.51	0.42	5.95e-16	Breast cancer;
LUSC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg03351412	chr1:154909251	PMVK	0.49	7.48	0.38	6.61e-13	Prostate cancer;
LUSC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.83	13.25	0.59	1.78e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs62400317	0.859	rs62436780	chr6:45128261	A/T	cg20913747	chr6:44695427	NA	-0.46	-7.49	-0.38	6.22e-13	Total body bone mineral density;
LUSC	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg12863693	chr15:85201151	NMB	-0.35	-7.24	-0.37	3.1e-12	Schizophrenia;
LUSC	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.69	0.34	9.51e-11	Intraocular pressure;
LUSC	trans	rs72674100	1.000	rs28630925	chr4:97991385	G/T	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg06784218	chr1:46089804	CCDC17	0.55	11.09	0.52	1.53e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13372927	chr11:111896293	DLAT	-0.41	-6.1	-0.32	2.97e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13315871	0.929	rs7635697	chr3:58313706	G/A	cg12435725	chr3:58293450	RPP14	-0.76	-7.39	-0.37	1.23e-12	Cholesterol, total;
LUSC	cis	rs9902453	0.967	rs7222685	chr17:28496430	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.18	0.41	5.84e-15	Coffee consumption (cups per day);
LUSC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg24812749	chr6:127587940	RNF146	0.73	10.44	0.5	2.79e-22	Breast cancer;
LUSC	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg03248196	chr12:48214108	HDAC7	-0.49	-6.06	-0.31	3.67e-9	Neuroticism;
LUSC	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg23093090	chr10:104574429	C10orf26	-0.42	-6.86	-0.35	3.32e-11	Arsenic metabolism;
LUSC	cis	rs295140	0.903	rs56326533	chr2:201168758	T/C	cg04283868	chr2:201171347	SPATS2L	0.43	6.45	0.33	3.85e-10	QT interval;
LUSC	cis	rs7241530	0.662	rs67266500	chr18:75907596	C/T	cg14642773	chr18:75888474	NA	0.38	5.64	0.3	3.56e-8	Educational attainment (years of education);
LUSC	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	10.78	0.51	1.92e-23	Response to antipsychotic treatment;
LUSC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg06028605	chr16:24865363	SLC5A11	-0.5	-8.94	-0.44	2.66e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02788857	chr8:22132959	PIWIL2	0.39	7.52	0.38	5.14e-13	Hypertriglyceridemia;
LUSC	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.06	0.31	3.75e-9	Height;
LUSC	cis	rs897080	0.515	rs1067402	chr2:44676226	C/T	cg00619915	chr2:44497795	NA	0.41	5.67	0.3	3.13e-8	Height;
LUSC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg26769984	chr7:1090371	C7orf50	0.7	10.59	0.5	8.55e-23	Bronchopulmonary dysplasia;
LUSC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.8	-12.74	-0.57	1.44e-30	Tonsillectomy;
LUSC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Parkinson's disease;
LUSC	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.56	10.19	0.49	2.04e-21	Endometriosis;
LUSC	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.82	-14.22	-0.61	3.17e-36	Ulcerative colitis;
LUSC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg13699009	chr12:122356056	WDR66	0.45	6.81	0.35	4.68e-11	Mean corpuscular volume;
LUSC	cis	rs4845570	0.920	rs6694952	chr1:151760131	T/C	cg07092448	chr1:151763213	TDRKH	1.27	14.77	0.63	2.37e-38	Coronary artery disease;
LUSC	cis	rs12989701	1.000	rs13009551	chr2:127889118	C/T	cg08168897	chr2:127865431	BIN1	0.72	8.24	0.41	4.06e-15	Alzheimer's disease (late onset);
LUSC	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	6.97	0.36	1.66e-11	Mean platelet volume;
LUSC	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg11189052	chr15:85197271	WDR73	-0.44	-6.48	-0.33	3.35e-10	P wave terminal force;
LUSC	cis	rs7572644	0.941	rs2337700	chr2:28306943	G/A	cg27432699	chr2:27873401	GPN1	0.52	6.22	0.32	1.52e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.57	-8.77	-0.43	9.07e-17	Neurofibrillary tangles;
LUSC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg10207240	chr12:122356781	WDR66	0.43	6.27	0.32	1.11e-9	Mean corpuscular volume;
LUSC	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg24342717	chr2:85555507	TGOLN2	-0.74	-11.94	-0.55	1.31e-27	Ear protrusion;
LUSC	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.82	-0.3	1.41e-8	Bipolar disorder;
LUSC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	7.23	0.37	3.29e-12	Personality dimensions;
LUSC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-5.87	-0.31	1.05e-8	Major depressive disorder;
LUSC	cis	rs7605827	0.930	rs2287260	chr2:15624810	T/C	cg19274914	chr2:15703543	NA	0.45	8.57	0.42	3.81e-16	Educational attainment (years of education);
LUSC	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg13736514	chr6:26305472	NA	-0.47	-9.33	-0.45	1.55e-18	Educational attainment;
LUSC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg27588902	chr6:42928151	GNMT	-0.28	-6.04	-0.31	4.22e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.95	-0.36	1.98e-11	Menopause (age at onset);
LUSC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg04414720	chr1:150670196	GOLPH3L	0.51	7.91	0.4	3.9e-14	Melanoma;
LUSC	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	6.84	0.35	3.77e-11	Schizophrenia;
LUSC	cis	rs78579285	0.545	rs113385327	chr16:88785242	A/C	cg01900006	chr16:88814613	FAM38A	0.54	6.13	0.32	2.49e-9	Joint mobility (Beighton score);
LUSC	cis	rs9650315	0.714	rs28447646	chr8:57183102	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.88	0.35	3.01e-11	Height;
LUSC	cis	rs7215564	0.818	rs34929663	chr17:78617212	C/T	cg09596252	chr17:78655493	RPTOR	0.55	6.05	0.31	3.91e-9	Myopia (pathological);
LUSC	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg12935359	chr14:103987150	CKB	-0.55	-8.49	-0.42	7e-16	Body mass index;
LUSC	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.27	0.37	2.49e-12	Diisocyanate-induced asthma;
LUSC	cis	rs859767	0.741	rs7602801	chr2:135363870	A/G	cg12500956	chr2:135428796	TMEM163	-0.28	-6.23	-0.32	1.42e-9	Neuroticism;
LUSC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.58	-9.44	-0.46	6.72e-19	Aortic root size;
LUSC	trans	rs2392780	0.638	rs283704	chr8:128315582	A/G	cg10897648	chr18:56338258	MALT1	-0.43	-6.45	-0.33	3.87e-10	Breast cancer (early onset);
LUSC	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg12559939	chr2:27858050	GPN1	0.41	6.38	0.33	5.85e-10	Oral cavity cancer;
LUSC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg12560992	chr17:57184187	TRIM37	0.83	15.26	0.64	2.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg13010199	chr12:38710504	ALG10B	-0.58	-9.17	-0.45	4.95e-18	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg19774624	chr17:42201019	HDAC5	-0.55	-8.68	-0.43	1.76e-16	Bone mineral density (hip);Bone mineral density;
LUSC	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg19812747	chr11:111475976	SIK2	-0.45	-6.24	-0.32	1.31e-9	Primary sclerosing cholangitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21859597	chr1:115323395	SIKE1	-0.39	-5.99	-0.31	5.29e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg11608241	chr8:8085544	FLJ10661	-0.4	-5.86	-0.31	1.09e-8	Joint mobility (Beighton score);
LUSC	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	1.1	15.68	0.65	6.69e-42	Uric acid levels;
LUSC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg20684491	chr1:25596433	NA	0.36	5.69	0.3	2.73e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs2692947	0.526	rs4907225	chr2:96576670	C/T	cg22654517	chr2:96458247	NA	0.37	6.97	0.36	1.66e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg09085632	chr11:111637200	PPP2R1B	0.98	14.46	0.62	3.84e-37	Primary sclerosing cholangitis;
LUSC	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg13010199	chr12:38710504	ALG10B	0.56	8.45	0.42	9.2e-16	Morning vs. evening chronotype;
LUSC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.82	13.98	0.61	2.89e-35	Blood protein levels;
LUSC	cis	rs9399401	0.925	rs6929442	chr6:142742659	T/C	cg03128060	chr6:142623767	GPR126	0.33	6.05	0.31	3.91e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.56	-0.34	2.11e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10740039	0.842	rs1442541	chr10:62386043	C/T	cg18175470	chr10:62150864	ANK3	-0.47	-7.0	-0.36	1.42e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7937890	0.681	rs4756784	chr11:14270904	G/A	cg19336497	chr11:14380999	RRAS2	0.41	7.23	0.37	3.27e-12	Mitochondrial DNA levels;
LUSC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg16339924	chr4:17578868	LAP3	0.62	9.39	0.46	9.43e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg10018233	chr7:150070692	REPIN1	0.34	6.01	0.31	4.93e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.68	-10.39	-0.49	4.22e-22	Aortic root size;
LUSC	cis	rs259282	0.583	rs12981373	chr19:33108189	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.66	9.93	0.48	1.58e-20	Schizophrenia;
LUSC	cis	rs11252926	0.673	rs553326	chr10:749238	G/T	cg18196295	chr10:418757	DIP2C	-0.41	-6.4	-0.33	5.27e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg20476274	chr7:133979776	SLC35B4	0.82	14.95	0.63	4.64e-39	Mean platelet volume;
LUSC	cis	rs12474201	0.862	rs7562173	chr2:46976217	C/G	cg06386533	chr2:46925753	SOCS5	-0.66	-9.7	-0.47	9.07e-20	Height;
LUSC	trans	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	11.06	0.52	1.94e-24	Mean corpuscular volume;
LUSC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg11663144	chr21:46675770	NA	-0.42	-7.25	-0.37	3.01e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4889855	0.556	rs11150863	chr17:78532321	A/G	cg16591659	chr17:78472290	NA	-0.32	-5.9	-0.31	8.98e-9	Fractional excretion of uric acid;
LUSC	trans	rs3889199	0.779	rs12746759	chr1:59667150	G/A	cg24327262	chr19:46929907	NA	-0.39	-6.09	-0.32	3.09e-9	Pulse pressure;
LUSC	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg05110241	chr16:68378359	PRMT7	-0.53	-6.16	-0.32	2.11e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs1532331	0.966	rs6870418	chr5:43111526	C/T	cg02477305	chr13:23993013	SACS	0.35	5.98	0.31	5.68e-9	Menarche (age at onset);
LUSC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.58	7.81	0.39	7.23e-14	High light scatter reticulocyte count;
LUSC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg00409905	chr10:38381863	ZNF37A	0.35	6.07	0.32	3.56e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg26061582	chr7:22766209	IL6	0.41	5.92	0.31	8.09e-9	Lung cancer;
LUSC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg06740227	chr12:86229804	RASSF9	-0.37	-5.87	-0.31	1.05e-8	Major depressive disorder;
LUSC	cis	rs16867321	0.588	rs1919156	chr2:181456978	C/T	cg23363182	chr2:181467187	NA	-0.6	-9.72	-0.47	8.06e-20	Obesity;
LUSC	cis	rs61931739	0.635	rs1525895	chr12:33966496	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.87	-0.35	3.07e-11	Morning vs. evening chronotype;
LUSC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg16524733	chr11:117070046	TAGLN	-0.44	-7.67	-0.39	1.93e-13	Blood protein levels;
LUSC	trans	rs208520	0.874	rs208512	chr6:66943869	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.87	-0.6	7.31e-35	Exhaled nitric oxide output;
LUSC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-7.26	-0.37	2.75e-12	Longevity;
LUSC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.3	-0.41	2.63e-15	Obesity-related traits;
LUSC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg07701084	chr6:150067640	NUP43	0.53	7.99	0.4	2.25e-14	Lung cancer;
LUSC	cis	rs73206853	0.764	rs56127909	chr12:110833763	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16755598	chr14:50100815	C14orf104	-0.45	-6.02	-0.31	4.55e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg01097406	chr16:89675127	NA	0.41	7.83	0.39	6.4e-14	Vitiligo;
LUSC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg22920501	chr2:26401640	FAM59B	0.77	11.26	0.52	3.73e-25	Gut microbiome composition (summer);
LUSC	cis	rs1697139	0.935	rs1627990	chr5:66513326	C/T	cg11553311	chr5:66541588	NA	0.32	6.14	0.32	2.33e-9	Breast cancer;
LUSC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg03060546	chr3:49711283	APEH	0.71	12.0	0.55	7.94e-28	Resting heart rate;
LUSC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg08499158	chr17:42289980	UBTF	-0.39	-6.15	-0.32	2.21e-9	Total body bone mineral density;
LUSC	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg15556689	chr8:8085844	FLJ10661	0.57	8.54	0.42	4.71e-16	Retinal vascular caliber;
LUSC	cis	rs6558174	0.965	rs2009212	chr8:22491496	G/A	cg03733263	chr8:22462867	KIAA1967	0.47	6.31	0.33	8.94e-10	Breast cancer;
LUSC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg06808227	chr14:105710500	BRF1	-0.68	-10.38	-0.49	4.68e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs858239	0.539	rs10270695	chr7:23188988	C/T	cg23682824	chr7:23144976	KLHL7	-0.42	-5.88	-0.31	1.01e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs12208915	0.945	rs12201183	chr6:79570120	A/G	cg05283184	chr6:79620031	NA	0.46	6.0	0.31	5.19e-9	Left atrial antero-posterior diameter;
LUSC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs9398803	0.865	rs2326451	chr6:126811928	A/T	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	2.01e-9	Male-pattern baldness;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg25461163	chr5:72112466	TNPO1	0.56	6.68	0.34	9.84e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.68	-0.39	1.74e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10072221	0.771	rs28386181	chr5:75703952	T/C	cg03132911	chr5:75698732	IQGAP2	0.35	5.95	0.31	6.96e-9	Mean platelet volume;
LUSC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.42	5.76	0.3	1.9e-8	Gut microbiome composition (summer);
LUSC	cis	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05901451	chr6:126070800	HEY2	0.57	8.48	0.42	7.3e-16	Endometrial cancer;
LUSC	cis	rs7589342	0.839	rs35812588	chr2:106432201	C/T	cg14210321	chr2:106509881	NCK2	-0.53	-7.92	-0.4	3.47e-14	Addiction;
LUSC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg02423579	chr7:2872169	GNA12	-0.44	-6.43	-0.33	4.29e-10	Height;
LUSC	cis	rs2455601	0.638	rs11042148	chr11:9008674	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-6.81	-0.35	4.57e-11	Schizophrenia;
LUSC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg11344533	chr11:111475393	SIK2	-0.49	-6.8	-0.35	4.8e-11	Primary sclerosing cholangitis;
LUSC	cis	rs240764	0.658	rs11155659	chr6:101222568	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.48	-0.33	3.29e-10	Neuroticism;
LUSC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.61	0.54	2.12e-26	Alzheimer's disease;
LUSC	cis	rs7605827	0.930	rs6431707	chr2:15638165	A/T	cg19274914	chr2:15703543	NA	0.47	9.08	0.45	9.34e-18	Educational attainment (years of education);
LUSC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg05347473	chr6:146136440	FBXO30	-0.41	-6.94	-0.36	2.01e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-7.74	-0.39	1.21e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10789491	0.767	rs1816730	chr1:47207346	T/C	cg15501359	chr1:47185051	KIAA0494	0.78	10.13	0.48	3.24e-21	Response to hepatitis C treatment;
LUSC	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg26898376	chr11:64110657	CCDC88B	0.33	6.2	0.32	1.67e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7911264	0.739	rs7914814	chr10:94382950	A/G	cg25093409	chr10:94429542	NA	0.35	6.06	0.31	3.61e-9	Inflammatory bowel disease;
LUSC	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs7945718	0.781	rs11022513	chr11:12840986	C/T	cg25843174	chr11:12811716	TEAD1	-0.32	-7.41	-0.38	1.08e-12	Educational attainment (years of education);
LUSC	cis	rs3857536	0.776	rs2040593	chr6:66944076	G/A	cg07460842	chr6:66804631	NA	-0.46	-6.41	-0.33	4.93e-10	Blood trace element (Cu levels);
LUSC	trans	rs6601327	0.571	rs7820675	chr8:9647748	C/G	cg08975724	chr8:8085496	FLJ10661	0.45	6.5	0.34	2.97e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg11965913	chr1:205819406	PM20D1	-0.47	-7.15	-0.36	5.38e-12	Parkinson's disease;
LUSC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	1.02	20.24	0.74	5.16e-60	Menopause (age at onset);
LUSC	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg05791153	chr7:19748676	TWISTNB	0.79	8.39	0.42	1.38e-15	Thyroid stimulating hormone;
LUSC	cis	rs4843185	0.731	rs3815795	chr16:85712105	A/G	cg26571870	chr16:85723150	GINS2	0.31	5.73	0.3	2.23e-8	Platelet distribution width;
LUSC	cis	rs17021463	0.726	rs62320444	chr4:95261251	C/T	cg11021082	chr4:95130006	SMARCAD1	0.37	6.9	0.35	2.59e-11	Testicular germ cell tumor;
LUSC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg27094323	chr7:1216898	NA	-0.39	-6.66	-0.34	1.13e-10	Longevity;Endometriosis;
LUSC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg12257692	chr3:49977190	RBM6	-0.25	-6.64	-0.34	1.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.23	-14.27	-0.62	2.16e-36	Diabetic kidney disease;
LUSC	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg18477163	chr1:228402036	OBSCN	0.57	9.52	0.46	3.7e-19	Diastolic blood pressure;
LUSC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.14	-0.32	2.38e-9	Neutrophil percentage of white cells;
LUSC	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.4	-6.2	-0.32	1.64e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.4	-5.67	-0.3	3.07e-8	Eosinophil percentage of white cells;
LUSC	cis	rs9341808	0.690	rs9343970	chr6:80881289	C/G	cg08355045	chr6:80787529	NA	0.58	10.07	0.48	5.31e-21	Sitting height ratio;
LUSC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg14433983	chr11:636460	DRD4	-0.35	-5.85	-0.31	1.15e-8	Systemic lupus erythematosus;
LUSC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg17376030	chr22:41985996	PMM1	-0.47	-5.84	-0.3	1.25e-8	Cannabis dependence symptom count;
LUSC	cis	rs10788972	0.510	rs665817	chr1:54469948	T/G	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Parkinson disease and lewy body pathology;
LUSC	cis	rs1971762	0.542	rs12303370	chr12:54091807	A/C	cg23533419	chr12:54090519	NA	-0.36	-5.92	-0.31	8.13e-9	Height;
LUSC	cis	rs2050392	1.000	rs2250714	chr10:30697396	G/C	cg18806716	chr10:30721971	MAP3K8	-0.46	-7.44	-0.38	8.6e-13	Inflammatory bowel disease;
LUSC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg01657329	chr11:68192670	LRP5	-0.44	-6.59	-0.34	1.73e-10	Total body bone mineral density;
LUSC	cis	rs9341808	0.754	rs6918172	chr6:81019242	A/G	cg08355045	chr6:80787529	NA	0.55	9.73	0.47	7.16e-20	Sitting height ratio;
LUSC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-12.16	-0.55	2.04e-28	Platelet count;
LUSC	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07080220	chr10:102295463	HIF1AN	0.65	8.72	0.43	1.3e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7712401	1.000	rs7712401	chr5:122374459	C/T	cg19077854	chr5:122220652	SNX24	0.32	7.03	0.36	1.14e-11	Mean platelet volume;
LUSC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.96	-15.51	-0.65	3.14e-41	Coronary artery disease;
LUSC	cis	rs11229555	0.645	rs12291551	chr11:58176915	T/A	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.5	7.91	0.4	3.76e-14	Resistin levels;
LUSC	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.42	5.72	0.3	2.41e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs13223928	0.511	rs11773338	chr7:3144508	T/C	cg19214707	chr7:3157722	NA	-0.46	-9.11	-0.45	7.85e-18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg24130564	chr14:104152367	KLC1	0.44	6.25	0.32	1.24e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	6.19	0.32	1.76e-9	Response to antipsychotic treatment;
LUSC	cis	rs12681287	0.752	rs10435564	chr8:87266239	T/C	cg27223183	chr8:87520930	FAM82B	-0.45	-5.72	-0.3	2.33e-8	Caudate activity during reward;
LUSC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg06740227	chr12:86229804	RASSF9	0.39	6.25	0.32	1.23e-9	Major depressive disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10109876	chr10:61122470	FAM13C	-0.45	-6.0	-0.31	5.02e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4356932	0.715	rs9992952	chr4:76898174	A/C	cg00809888	chr4:76862425	NAAA	0.37	5.91	0.31	8.4e-9	Blood protein levels;
LUSC	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg24558204	chr6:135376177	HBS1L	0.46	6.78	0.35	5.52e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.47	6.3	0.33	9.33e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg17052675	chr2:3827356	NA	-0.57	-11.28	-0.53	3.18e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg22729335	chr19:2427816	TIMM13	1.04	18.49	0.71	4.53e-53	Cortisol levels (saliva);
LUSC	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg20129853	chr10:51489980	NA	-0.37	-7.67	-0.39	1.93e-13	Prostate-specific antigen levels;
LUSC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg18904891	chr8:8559673	CLDN23	0.61	8.13	0.41	8.56e-15	Obesity-related traits;
LUSC	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg09044154	chr16:88155775	NA	-0.56	-7.59	-0.38	3.22e-13	Menopause (age at onset);
LUSC	cis	rs4792901	0.765	rs9894019	chr17:41565505	T/G	cg22562494	chr17:41607896	ETV4	-0.34	-6.53	-0.34	2.45e-10	Dupuytren's disease;
LUSC	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg26647111	chr11:31128758	NA	-0.41	-5.89	-0.31	9.29e-9	Red blood cell count;
LUSC	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-7.94	-0.4	3.08e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs68170813	0.559	rs6964798	chr7:106933013	C/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.82	-0.47	3.55e-20	Coronary artery disease;
LUSC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	11.08	0.52	1.71e-24	Alzheimer's disease;
LUSC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg21724239	chr8:58056113	NA	0.75	8.01	0.4	1.93e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg05347473	chr6:146136440	FBXO30	0.53	9.0	0.44	1.73e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9534288	0.797	rs7996875	chr13:46612836	C/T	cg15192986	chr13:46630673	CPB2	0.65	10.74	0.51	2.67e-23	Blood protein levels;
LUSC	cis	rs72901758	0.661	rs56683270	chr17:76247827	T/C	cg26068271	chr17:76253126	NA	0.52	9.44	0.46	6.54e-19	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg03526776	chr6:41159608	TREML2	0.33	6.33	0.33	7.97e-10	Alzheimer's disease (late onset);
LUSC	trans	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg07211511	chr3:129823064	LOC729375	-0.8	-10.65	-0.5	5.31e-23	Blood pressure (smoking interaction);
LUSC	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.72	-11.85	-0.54	2.73e-27	Breast size;
LUSC	cis	rs4704187	0.617	rs2035192	chr5:74407231	T/A	cg03227963	chr5:74354835	NA	0.32	6.87	0.35	3.09e-11	Response to amphetamines;
LUSC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg20203395	chr5:56204925	C5orf35	-0.51	-7.46	-0.38	7.62e-13	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.35	0.53	1.79e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs12200782	0.872	rs59438701	chr6:26412527	C/T	cg11837749	chr1:55047332	ACOT11	0.52	6.28	0.32	1.06e-9	Small cell lung carcinoma;
LUSC	cis	rs2274273	0.662	rs67588230	chr14:55667030	C/T	cg04306507	chr14:55594613	LGALS3	0.48	9.56	0.46	2.77e-19	Protein biomarker;
LUSC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg27124370	chr19:33622961	WDR88	0.59	8.26	0.41	3.36e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs17685	0.740	rs2286821	chr7:75611355	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.94	-15.25	-0.64	3.13e-40	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg18721089	chr20:30220636	NA	-0.41	-6.08	-0.32	3.29e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg10609677	chr17:41278573	BRCA1;NBR2	-0.36	-5.87	-0.31	1.05e-8	Menopause (age at onset);
LUSC	cis	rs9517302	0.615	rs2274053	chr13:99098318	C/T	cg22223119	chr13:99095684	FARP1	-0.71	-9.85	-0.47	2.88e-20	Obesity-related traits;
LUSC	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.63	-0.34	1.32e-10	Fear of minor pain;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07920148	chr11:33397821	NA	-0.37	-6.46	-0.33	3.76e-10	Electrocardiographic conduction measures;
LUSC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg02466173	chr16:30829666	NA	-0.68	-16.26	-0.66	3.38e-44	Dementia with Lewy bodies;
LUSC	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg18135206	chr14:102964638	TECPR2	0.58	8.96	0.44	2.29e-17	Plateletcrit;
LUSC	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg26061582	chr7:22766209	IL6	0.48	6.91	0.35	2.51e-11	Lung cancer;
LUSC	cis	rs73206853	0.764	rs60027620	chr12:111103669	T/G	cg12870014	chr12:110450643	ANKRD13A	0.7	7.54	0.38	4.44e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg26338869	chr17:61819248	STRADA	0.41	5.94	0.31	7.15e-9	Prudent dietary pattern;
LUSC	cis	rs9309473	1.000	rs11899902	chr2:73631564	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-6.83	-0.35	3.95e-11	Metabolite levels;
LUSC	cis	rs78707713	0.560	rs12784882	chr10:71230334	C/G	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.58	-0.46	2.31e-19	Venous thromboembolism;
LUSC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	9.36	0.46	1.23e-18	Motion sickness;
LUSC	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg17127132	chr2:85788382	GGCX	-0.47	-7.53	-0.38	4.68e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.13	-0.32	2.54e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg09479241	chr17:27052676	TLCD1	0.43	5.96	0.31	6.29e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7178572	1.000	rs965480	chr15:77781926	A/G	cg22256960	chr15:77711686	NA	-0.55	-9.25	-0.45	2.74e-18	Type 2 diabetes;
LUSC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.19	15.61	0.65	1.22e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.73	0.35	7.44e-11	Tonsillectomy;
LUSC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg02475777	chr4:1388615	CRIPAK	0.44	6.61	0.34	1.55e-10	Obesity-related traits;
LUSC	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.3	5.77	0.3	1.78e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg21951975	chr1:209979733	IRF6	0.4	6.67	0.34	1.08e-10	Monobrow;
LUSC	cis	rs3764563	0.935	rs4807958	chr19:15718042	T/C	cg20725493	chr19:15740067	CYP4F8	-0.67	-6.58	-0.34	1.85e-10	Inflammatory biomarkers;
LUSC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs7202877	0.706	rs247437	chr16:75431275	T/G	cg03315344	chr16:75512273	CHST6	-0.41	-5.98	-0.31	5.76e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg17507749	chr15:85114479	UBE2QP1	0.58	7.38	0.37	1.28e-12	Schizophrenia;
LUSC	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg24130564	chr14:104152367	KLC1	-0.47	-6.82	-0.35	4.31e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg01849466	chr14:104193079	ZFYVE21	0.58	9.49	0.46	4.59e-19	Schizophrenia;
LUSC	cis	rs4631830	0.900	rs7920517	chr10:51532621	G/A	cg16070123	chr10:51489643	NA	-0.51	-8.18	-0.41	6.22e-15	Prostate-specific antigen levels;
LUSC	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.13e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2652834	0.718	rs2652836	chr15:63396301	A/G	cg05507819	chr15:63340323	TPM1	-0.51	-6.65	-0.34	1.18e-10	HDL cholesterol;
LUSC	cis	rs2191566	0.576	rs381759	chr19:44495145	A/G	cg18700516	chr19:44507157	ZNF230	-0.4	-5.65	-0.3	3.42e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg02175503	chr12:58329896	NA	0.47	6.8	0.35	4.86e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg18190219	chr22:46762943	CELSR1	-0.56	-6.45	-0.33	3.83e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.83	0.43	6.09e-17	Lung cancer in ever smokers;
LUSC	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg21951975	chr1:209979733	IRF6	-0.54	-6.99	-0.36	1.47e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00166722	chr3:10149974	C3orf24	0.62	7.77	0.39	1e-13	Alzheimer's disease;
LUSC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg00106254	chr7:1943704	MAD1L1	-0.4	-5.77	-0.3	1.81e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg27284194	chr4:1044797	NA	0.58	8.71	0.43	1.4e-16	Recombination rate (females);
LUSC	cis	rs4654899	0.785	rs9426736	chr1:21505931	T/G	cg01072550	chr1:21505969	NA	-0.54	-8.22	-0.41	4.67e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg00792783	chr2:198669748	PLCL1	0.43	5.7	0.3	2.6e-8	Dermatomyositis;
LUSC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2562456	0.833	rs2968076	chr19:21637101	C/T	cg00806126	chr19:22604979	ZNF98	0.38	5.94	0.31	7.34e-9	Pain;
LUSC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg05347473	chr6:146136440	FBXO30	0.59	10.32	0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs836788	0.570	rs26783	chr5:80050103	T/A	cg27031367	chr8:145510315	BOP1	-0.37	-6.07	-0.32	3.42e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs1950626	0.699	rs12880855	chr14:101468382	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.35	5.69	0.3	2.72e-8	Pelvic organ prolapse (moderate/severe);
LUSC	trans	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg03886242	chr7:26192032	NFE2L3	0.4	6.34	0.33	7.37e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs727505	0.754	rs56012154	chr7:124781250	A/G	cg23710748	chr7:124431027	NA	-0.4	-7.02	-0.36	1.24e-11	Lewy body disease;
LUSC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08280861	chr8:58055591	NA	0.54	5.87	0.31	1.04e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.65	-0.3	3.35e-8	Life satisfaction;
LUSC	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.48	0.38	6.74e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg04352962	chr1:209979756	IRF6	0.54	6.3	0.33	9.64e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs11997175	0.545	rs4428637	chr8:33666944	T/G	ch.8.33884649F	chr8:33765107	NA	0.51	7.33	0.37	1.79e-12	Body mass index;
LUSC	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg26594503	chr5:96210394	ERAP2	0.4	6.03	0.31	4.44e-9	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs9860340	0.730	rs57108523	chr3:87643655	A/G	cg03644585	chr7:884825	UNC84A	0.42	6.05	0.31	3.9e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	0.95	17.74	0.7	4.5e-50	Headache;
LUSC	cis	rs740160	0.510	rs6973408	chr7:98900853	A/G	cg24650262	chr7:98904301	NA	0.61	6.8	0.35	4.93e-11	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.23	0.32	1.4e-9	Total body bone mineral density;
LUSC	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.58	0.34	1.81e-10	Corneal astigmatism;
LUSC	cis	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.98	-0.36	1.6e-11	Morning vs. evening chronotype;
LUSC	trans	rs979233	0.502	rs276247	chr5:42062298	A/G	cg07010552	chr17:7358735	CHRNB1	-0.41	-6.02	-0.31	4.72e-9	Systemic lupus erythematosus;
LUSC	cis	rs12999616	1.000	rs12999616	chr2:98324381	C/T	cg26665480	chr2:98280029	ACTR1B	0.65	6.96	0.36	1.8e-11	Colorectal cancer;
LUSC	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg01966878	chr4:90757139	SNCA	-0.36	-6.22	-0.32	1.52e-9	Dementia with Lewy bodies;
LUSC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg27124370	chr19:33622961	WDR88	0.61	8.6	0.43	3.19e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.63	-8.81	-0.43	7.13e-17	Multiple sclerosis;
LUSC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-6.65	-0.34	1.17e-10	Mean platelet volume;
LUSC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg02117656	chr17:79614917	TSPAN10	0.3	5.67	0.3	3.16e-8	Eye color traits;
LUSC	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.77	12.06	0.55	4.9e-28	Heart rate;
LUSC	cis	rs1178968	0.818	rs2262777	chr7:72786490	A/T	cg25889504	chr7:72793014	NA	0.61	7.83	0.39	6.55e-14	Triglyceride levels;
LUSC	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg22782873	chr19:19639568	YJEFN3	-0.53	-6.45	-0.33	3.94e-10	Bipolar disorder;
LUSC	cis	rs10761482	0.813	rs10740026	chr10:62112842	G/A	cg18175470	chr10:62150864	ANK3	-0.51	-7.25	-0.37	2.99e-12	Schizophrenia;
LUSC	cis	rs2230307	0.536	rs12733952	chr1:100611571	A/G	cg24955406	chr1:100503596	HIAT1	0.59	6.42	0.33	4.65e-10	Carotid intima media thickness;
LUSC	cis	rs9650315	0.733	rs13251457	chr8:57202902	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.34	0.37	1.64e-12	Height;
LUSC	cis	rs8056893	0.714	rs1465470	chr16:68397909	A/G	cg02226672	chr16:68398533	SMPD3	0.32	5.75	0.3	2.03e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg03342759	chr3:160939853	NMD3	-0.45	-6.03	-0.31	4.41e-9	Parkinson's disease;
LUSC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03517284	chr6:25882590	NA	-0.47	-8.98	-0.44	1.97e-17	Blood metabolite levels;
LUSC	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25427524	chr10:38739819	LOC399744	-0.78	-14.67	-0.63	5.73e-38	Breast cancer;
LUSC	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg00530320	chr1:46809349	NSUN4	0.56	8.37	0.42	1.6e-15	Menopause (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04570466	chr21:40752046	WRB	0.74	6.0	0.31	5.25e-9	Cognitive performance;
LUSC	cis	rs17125944	0.615	rs8003334	chr14:53374967	C/T	cg00686598	chr14:53173677	PSMC6	0.7	6.37	0.33	6.18e-10	Alzheimer's disease (late onset);
LUSC	cis	rs12545109	0.800	rs2582401	chr8:57401656	A/G	cg09654669	chr8:57350985	NA	-0.52	-6.66	-0.34	1.16e-10	Obesity-related traits;
LUSC	cis	rs12190007	0.547	rs1018559	chr6:169854176	A/G	cg15038512	chr6:170123185	PHF10	-0.44	-7.0	-0.36	1.41e-11	Obesity-related traits;
LUSC	trans	rs17266958	1.000	rs62574474	chr9:83265810	C/T	cg01905489	chr1:26616534	UBXN11	-0.61	-6.27	-0.32	1.15e-9	Preschool internalizing problems;
LUSC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg11663144	chr21:46675770	NA	-0.42	-7.25	-0.37	2.94e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-6.98	-0.36	1.55e-11	Blood metabolite levels;
LUSC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.31	-0.45	1.71e-18	Platelet count;
LUSC	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg08807101	chr21:30365312	RNF160	0.64	9.87	0.48	2.51e-20	Selective IgA deficiency;
LUSC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08736216	chr1:53307985	ZYG11A	-0.29	-5.98	-0.31	5.85e-9	Monocyte count;
LUSC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg11645453	chr3:52864694	ITIH4	0.35	8.19	0.41	5.54e-15	Electroencephalogram traits;
LUSC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.05	0.4	1.52e-14	Parkinson's disease;
LUSC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg16228356	chr17:43848958	NA	0.28	6.42	0.33	4.57e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11636714	chr8:42128950	IKBKB	-0.47	-6.4	-0.33	5.29e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2224391	0.628	rs2773309	chr6:5248916	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.47	-6.5	-0.34	2.92e-10	Height;
LUSC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02463440	chr8:22132932	PIWIL2	0.44	8.32	0.41	2.32e-15	Hypertriglyceridemia;
LUSC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11645453	chr3:52864694	ITIH4	0.37	8.57	0.42	3.91e-16	Bipolar disorder;
LUSC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26314531	chr2:26401878	FAM59B	-0.65	-9.19	-0.45	4.33e-18	Gut microbiome composition (summer);
LUSC	cis	rs12760731	0.565	rs16828608	chr1:178129899	C/T	cg00404053	chr1:178313656	RASAL2	0.61	6.45	0.33	3.9e-10	Obesity-related traits;
LUSC	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.77	0.51	2.03e-23	Heart rate;
LUSC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg27535305	chr1:53392650	SCP2	0.36	6.73	0.35	7.3e-11	Monocyte count;
LUSC	cis	rs9309473	1.000	rs11903916	chr2:73815328	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-6.95	-0.36	1.97e-11	Metabolite levels;
LUSC	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg17261708	chr5:176794207	RGS14	-0.34	-5.91	-0.31	8.55e-9	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg02018176	chr4:1364513	KIAA1530	0.44	6.03	0.31	4.23e-9	Recombination rate (females);
LUSC	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg03599575	chr15:90893182	GABARAPL3	-0.34	-5.82	-0.3	1.36e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.85	-12.84	-0.57	6.18e-31	Asthma;
LUSC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.67	0.39	1.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg18678763	chr11:4115507	RRM1	0.46	6.03	0.31	4.3e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.47	7.3	0.37	2.13e-12	Colorectal cancer;
LUSC	cis	rs8058578	0.945	rs34480360	chr16:30798689	G/A	cg02466173	chr16:30829666	NA	-0.6	-10.81	-0.51	1.49e-23	Multiple myeloma;
LUSC	cis	rs6066835	0.867	rs6095271	chr20:47356176	C/G	cg18078177	chr20:47281410	PREX1	0.76	6.72	0.35	7.74e-11	Multiple myeloma;
LUSC	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.46	-0.33	3.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg02136620	chr5:178986620	RUFY1	-0.47	-7.62	-0.38	2.58e-13	Lung cancer;
LUSC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg03609598	chr5:56110824	MAP3K1	-0.4	-5.86	-0.31	1.1e-8	Initial pursuit acceleration;
LUSC	trans	rs7939886	0.764	rs7113688	chr11:55946865	C/T	cg15704280	chr7:45808275	SEPT13	0.89	6.88	0.35	3e-11	Myopia (pathological);
LUSC	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg21775007	chr8:11205619	TDH	0.61	9.7	0.47	9.49e-20	Retinal vascular caliber;
LUSC	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.67	11.27	0.52	3.58e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg16606324	chr3:10149918	C3orf24	0.58	8.38	0.42	1.54e-15	Alzheimer's disease;
LUSC	trans	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg07393940	chr7:158741817	NA	0.36	6.43	0.33	4.41e-10	Life satisfaction;
LUSC	cis	rs3740713	1.000	rs76599129	chr11:18471627	T/A	cg07915343	chr11:18477680	LDHAL6A	-0.54	-6.71	-0.34	8.43e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7202877	0.656	rs977986	chr16:75506696	T/G	cg04384234	chr16:75411784	CFDP1	-0.65	-9.01	-0.44	1.61e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg11584989	chr19:19387371	SF4	0.59	7.07	0.36	8.9e-12	Bipolar disorder;
LUSC	cis	rs11971779	0.648	rs4732367	chr7:139028102	A/C	cg07862535	chr7:139043722	LUC7L2	0.53	6.55	0.34	2.17e-10	Diisocyanate-induced asthma;
LUSC	cis	rs9807989	0.839	rs6749114	chr2:102967587	A/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.87	0.31	1.03e-8	Asthma;
LUSC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg22823121	chr1:150693482	HORMAD1	0.56	8.47	0.42	8.01e-16	Melanoma;
LUSC	cis	rs116139393	0.611	rs7792579	chr7:6765593	C/T	cg09896999	chr7:6746977	ZNF12	-0.51	-7.05	-0.36	1.02e-11	Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg07741184	chr6:167504864	NA	0.4	7.13	0.36	6.36e-12	Crohn's disease;
LUSC	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.42	-0.38	1.01e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg10434728	chr15:90938212	IQGAP1	-0.46	-9.23	-0.45	3.16e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg21699342	chr2:239360505	ASB1	-0.58	-10.79	-0.51	1.7e-23	Multiple system atrophy;
LUSC	cis	rs6456156	0.742	rs1331299	chr6:167533467	A/G	cg07741184	chr6:167504864	NA	0.36	6.62	0.34	1.43e-10	Primary biliary cholangitis;
LUSC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg11871910	chr12:69753446	YEATS4	0.93	17.32	0.69	2.16e-48	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg16989719	chr2:238392110	NA	-0.35	-5.98	-0.31	5.66e-9	Prostate cancer;
LUSC	cis	rs16910800	0.953	rs73481422	chr11:23205174	T/C	cg20040320	chr11:23191996	NA	-0.44	-6.45	-0.33	3.85e-10	Cancer;
LUSC	cis	rs701145	0.585	rs357482	chr3:153889855	A/G	cg17054900	chr3:154042577	DHX36	0.7	6.82	0.35	4.38e-11	Coronary artery disease;
LUSC	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg24397884	chr7:158709396	WDR60	-0.78	-9.15	-0.45	5.58e-18	Height;
LUSC	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg14530993	chr4:882597	GAK	0.66	6.59	0.34	1.76e-10	Parkinson's disease;
LUSC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg24130564	chr14:104152367	KLC1	-0.41	-5.87	-0.31	1.06e-8	Body mass index;
LUSC	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg22681709	chr2:178499509	PDE11A	-0.48	-8.7	-0.43	1.49e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg20887711	chr4:1340912	KIAA1530	-0.45	-6.91	-0.35	2.54e-11	Obesity-related traits;
LUSC	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg18105134	chr13:113819100	PROZ	-0.64	-9.42	-0.46	7.72e-19	Platelet distribution width;
LUSC	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.55	8.41	0.42	1.2e-15	Schizophrenia;
LUSC	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.71	10.76	0.51	2.23e-23	Alcohol dependence;
LUSC	cis	rs7615316	0.751	rs1825522	chr3:142003664	A/G	cg16271453	chr3:142027066	XRN1	-0.41	-7.33	-0.37	1.76e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03264133	chr6:25882463	NA	-0.44	-7.63	-0.39	2.44e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.2	25.23	0.81	2.31e-79	Exhaled nitric oxide output;
LUSC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.64	8.74	0.43	1.15e-16	Multiple sclerosis;
LUSC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg20406979	chr6:167373233	NA	-0.25	-5.96	-0.31	6.31e-9	Crohn's disease;
LUSC	cis	rs897080	0.515	rs1085450	chr2:44650698	A/T	cg00619915	chr2:44497795	NA	-0.39	-5.66	-0.3	3.26e-8	Height;
LUSC	cis	rs8020912	0.504	rs3759577	chr14:103850963	C/T	cg12935359	chr14:103987150	CKB	0.64	8.77	0.43	9.58e-17	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg05347473	chr6:146136440	FBXO30	-0.6	-10.6	-0.5	7.93e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg24851651	chr11:66362959	CCS	-0.36	-5.73	-0.3	2.25e-8	Educational attainment (years of education);
LUSC	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg04920474	chr2:44395004	PPM1B	0.65	8.5	0.42	6.5e-16	Height;
LUSC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.7	-12.57	-0.57	6.28e-30	Aortic root size;
LUSC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.75	-0.47	6.42e-20	Myopia;Myopia (pathological);
LUSC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.88	-16.59	-0.67	1.69e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9653442	0.527	rs11123812	chr2:100761548	T/C	cg22139774	chr2:100720529	AFF3	-0.42	-7.26	-0.37	2.8e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs12286929	0.609	rs11602686	chr11:115100638	G/A	cg04055981	chr11:115044050	NA	0.35	6.21	0.32	1.57e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg06207120	chr15:45996521	NA	0.38	5.9	0.31	8.97e-9	Waist circumference;Weight;
LUSC	cis	rs4834770	1.000	rs4336213	chr4:120236469	G/T	cg24375607	chr4:120327624	NA	0.41	5.85	0.3	1.19e-8	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg17366294	chr4:99064904	C4orf37	0.6	10.77	0.51	2.0500000000000001e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg26441486	chr22:50317300	CRELD2	0.47	7.07	0.36	9.01e-12	Schizophrenia;
LUSC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg03526776	chr6:41159608	TREML2	0.32	6.37	0.33	6.32e-10	Alzheimer's disease (late onset);
LUSC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.35	5.99	0.31	5.45e-9	Obesity-related traits;
LUSC	cis	rs12145833	0.538	rs12026408	chr1:243366805	G/A	cg02356786	chr1:243265016	LOC731275	0.72	6.62	0.34	1.46e-10	Obesity (early onset extreme);
LUSC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg17515076	chr17:73810948	UNK	-0.4	-6.7	-0.34	8.97e-11	White matter hyperintensity burden;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg25942691	chr19:36705733	ZNF565;ZNF146	0.46	6.53	0.34	2.4e-10	Mosquito bite size;
LUSC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-10.36	-0.49	5.35e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs240764	0.658	rs10223467	chr6:101207589	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.24	-0.32	1.3e-9	Neuroticism;
LUSC	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg01420254	chr6:26195488	NA	0.65	7.16	0.36	5.29e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-1.14	-17.77	-0.7	3.45e-50	Exhaled nitric oxide output;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg01916446	chr16:87425777	FBXO31;MAP1LC3B	0.38	6.18	0.32	1.84e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.61	8.34	0.41	2.03e-15	Adiposity;
LUSC	trans	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	6.3	0.33	9.55e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg25427524	chr10:38739819	LOC399744	-0.43	-5.73	-0.3	2.25e-8	Obesity (extreme);
LUSC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	0.92	12.56	0.57	6.67e-30	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	6.3	0.33	9.43e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.62	0.34	1.45e-10	Height;
LUSC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.48	-7.46	-0.38	7.61e-13	Height;
LUSC	cis	rs2607426	0.681	rs79361456	chr19:41240363	A/C	cg05508168	chr19:41255947	C19orf54;SNRPA	0.89	6.71	0.34	8.5e-11	Blood protein levels;
LUSC	cis	rs870825	0.932	rs28594349	chr4:185574415	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	11.24	0.52	4.52e-25	Blood protein levels;
LUSC	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg22529645	chr1:3704559	LRRC47	-0.36	-6.42	-0.33	4.59e-10	Red cell distribution width;
LUSC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.74	-0.3	2.1e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg08676812	chr11:65308423	LTBP3	1.07	6.74	0.35	7.15e-11	Height;
LUSC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-1.03	-20.48	-0.75	5.94e-61	Height;
LUSC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg23172400	chr8:95962367	TP53INP1	-0.41	-8.19	-0.41	5.46e-15	Type 2 diabetes;
LUSC	cis	rs1143633	0.615	rs4364030	chr2:113664409	C/G	cg06156847	chr2:113672199	IL1F7	0.28	5.76	0.3	1.96e-8	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg00310523	chr12:86230176	RASSF9	0.51	9.82	0.47	3.65e-20	Major depressive disorder;
LUSC	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.53	-0.42	5.25e-16	Total cholesterol levels;
LUSC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg16447950	chr5:562315	NA	-0.55	-7.1	-0.36	7.78e-12	Lung disease severity in cystic fibrosis;
LUSC	trans	rs7939886	0.920	rs61742348	chr11:55905078	C/T	cg03929089	chr4:120376271	NA	0.77	6.09	0.32	3.03e-9	Myopia (pathological);
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.33	-0.41	2.17e-15	Lymphocyte counts;
LUSC	cis	rs16949788	1.000	rs41306345	chr15:66782048	C/T	cg08120210	chr15:66682733	MAP2K1	-0.6	-6.3	-0.33	9.41e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06634786	chr22:41940651	POLR3H	-0.53	-6.44	-0.33	4.05e-10	Vitiligo;
LUSC	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs12266014	0.965	rs10828722	chr10:25199951	A/G	cg16316141	chr10:25305874	ENKUR;THNSL1	0.4	5.74	0.3	2.09e-8	Monocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg23601095	chr6:26197514	HIST1H3D	0.72	7.37	0.37	1.35e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs6084875	0.840	rs2104143	chr20:4723157	G/A	cg07258627	chr20:4721683	PRNT	-0.35	-6.21	-0.32	1.57e-9	Systemic lupus erythematosus;
LUSC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg12863693	chr15:85201151	NMB	-0.27	-6.18	-0.32	1.89e-9	P wave terminal force;
LUSC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19346786	chr7:2764209	NA	0.41	7.12	0.36	6.5e-12	Height;
LUSC	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg06917634	chr15:78832804	PSMA4	-0.78	-13.66	-0.6	4.74e-34	Sudden cardiac arrest;
LUSC	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs9653442	0.527	rs11690905	chr2:100761473	C/T	cg22139774	chr2:100720529	AFF3	0.41	7.09	0.36	8.12e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg15448220	chr1:150897856	SETDB1	0.4	5.82	0.3	1.36e-8	Melanoma;
LUSC	cis	rs3820928	1.000	rs9288617	chr2:227762815	G/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.74	-0.39	1.21e-13	Pulmonary function;
LUSC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.09	-0.36	8.22e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg05368731	chr17:41323189	NBR1	0.78	12.52	0.57	9.52e-30	Menopause (age at onset);
LUSC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg00857998	chr1:205179979	DSTYK	0.64	9.83	0.47	3.41e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs72934535	0.722	rs16839813	chr2:204324094	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.59	5.84	0.3	1.25e-8	Coronary artery disease;
LUSC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg27535305	chr1:53392650	SCP2	0.38	7.08	0.36	8.63e-12	Monocyte count;
LUSC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg08999081	chr20:33150536	PIGU	0.43	7.58	0.38	3.53e-13	Coronary artery disease;
LUSC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg23625390	chr15:77176239	SCAPER	0.46	6.95	0.36	1.96e-11	Blood metabolite levels;
LUSC	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg00784671	chr22:46762841	CELSR1	-0.55	-6.01	-0.31	4.84e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.56	10.29	0.49	9.65e-22	Homoarginine levels;
LUSC	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg24397884	chr7:158709396	WDR60	0.61	9.29	0.45	2.09e-18	Height;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25789511	chr20:60757919	GTPBP5	-0.5	-6.11	-0.32	2.82e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs72792513	1.000	rs3843863	chr2:22912149	C/T	cg05844895	chr16:88969569	CBFA2T3	0.53	6.22	0.32	1.5e-9	Hepatitis B;
LUSC	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.96	0.66	5.01e-43	Bladder cancer;
LUSC	cis	rs4654899	0.932	rs10916943	chr1:21472429	T/C	cg01072550	chr1:21505969	NA	0.53	8.17	0.41	6.25e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4786125	0.665	rs8060329	chr16:6908864	G/A	cg03623568	chr16:6915990	A2BP1	-0.5	-8.12	-0.41	8.94e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.59	0.38	3.18e-13	Vitiligo;
LUSC	cis	rs3736594	0.546	rs6734059	chr2:27808154	C/T	cg27432699	chr2:27873401	GPN1	-0.65	-8.89	-0.44	3.77e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs7264396	0.887	rs4281980	chr20:34096581	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.39	-0.33	5.72e-10	Total cholesterol levels;
LUSC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.47	-7.29	-0.37	2.27e-12	Alzheimer's disease (late onset);
LUSC	cis	rs6545883	0.859	rs13004855	chr2:61505072	C/T	cg15711740	chr2:61764176	XPO1	0.47	7.15	0.36	5.45e-12	Tuberculosis;
LUSC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.2	13.84	0.6	9.22e-35	Diabetic kidney disease;
LUSC	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg04310649	chr10:35416472	CREM	-0.42	-6.35	-0.33	7.09e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg04369109	chr6:150039330	LATS1	-0.54	-7.86	-0.39	5.47e-14	Lung cancer;
LUSC	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg09796270	chr17:17721594	SREBF1	-0.45	-8.03	-0.4	1.68e-14	Total body bone mineral density;
LUSC	trans	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg21659725	chr3:3221576	CRBN	-0.43	-6.44	-0.33	4.06e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg22676075	chr6:135203613	NA	0.47	7.43	0.38	9.18e-13	Red blood cell count;
LUSC	cis	rs2274273	1.000	rs2274273	chr14:55614636	A/G	cg04306507	chr14:55594613	LGALS3	-0.53	-11.39	-0.53	1.27e-25	Protein biomarker;
LUSC	trans	rs12145833	0.596	rs1060643	chr1:243429976	G/C	cg01826367	chr1:224180288	NA	0.66	5.96	0.31	6.34e-9	Obesity (early onset extreme);
LUSC	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18932078	chr1:2524107	MMEL1	0.32	6.98	0.36	1.64e-11	Multiple sclerosis;
LUSC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.83	-0.39	6.45e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg03146154	chr1:46216737	IPP	-0.57	-8.24	-0.41	4.04e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11609545	chr12:57024192	BAZ2A	-0.48	-6.36	-0.33	6.67e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.03	-0.44	1.39e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	0.71	12.18	0.55	1.72e-28	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg15571903	chr15:79123663	NA	-0.33	-6.13	-0.32	2.47e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	0.93	18.31	0.71	2.44e-52	Cognitive function;
LUSC	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.83	-0.3	1.32e-8	Coronary artery disease;
LUSC	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.24	0.45	3.04e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7315438	0.517	rs11067597	chr12:115873888	C/G	cg24172291	chr12:115889509	NA	-0.35	-5.93	-0.31	7.38e-9	Colorectal cancer;
LUSC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg21643547	chr1:205240462	TMCC2	-0.42	-7.67	-0.39	1.93e-13	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09502511	chr6:30539237	ABCF1	0.77	6.82	0.35	4.36e-11	Cognitive performance;
LUSC	cis	rs7577696	0.568	rs462878	chr2:32438655	A/G	cg02381751	chr2:32503542	YIPF4	0.52	6.75	0.35	6.47e-11	Inflammatory biomarkers;
LUSC	trans	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg00074818	chr8:8560427	CLDN23	-0.53	-8.55	-0.42	4.57e-16	Obesity-related traits;
LUSC	cis	rs17030434	0.911	rs75822357	chr4:154738258	T/C	cg14289246	chr4:154710475	SFRP2	-0.57	-7.49	-0.38	6.29e-13	Electrocardiographic conduction measures;
LUSC	cis	rs67539049	1.000	rs67350204	chr8:11300293	A/G	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.39	-5.71	-0.3	2.51e-8	Itch intensity from mosquito bite;
LUSC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg06238570	chr21:40685208	BRWD1	-0.56	-9.03	-0.44	1.37e-17	Menarche (age at onset);
LUSC	cis	rs2233152	0.611	rs28660501	chr19:41300277	G/T	cg21869046	chr19:41225005	ITPKC	0.45	6.46	0.33	3.6e-10	Kawasaki disease;
LUSC	cis	rs9682041	0.627	rs6786374	chr3:170105233	A/G	cg11886554	chr3:170076028	SKIL	-0.68	-9.39	-0.46	9.57e-19	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LUSC	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg01966878	chr4:90757139	SNCA	-0.35	-6.12	-0.32	2.56e-9	Dementia with Lewy bodies;
LUSC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg23205692	chr1:25664452	TMEM50A	-0.38	-5.66	-0.3	3.27e-8	Erythrocyte sedimentation rate;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24545250	chr17:43025328	KIF18B	-0.4	-6.0	-0.31	5.16e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg24449463	chr1:168025552	DCAF6	-0.63	-9.51	-0.46	3.96e-19	Schizophrenia;
LUSC	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03878208	chr11:72483293	STARD10	0.5	5.76	0.3	1.94e-8	Type 2 diabetes;
LUSC	cis	rs12760731	0.720	rs12048459	chr1:178412702	T/C	cg00404053	chr1:178313656	RASAL2	0.59	6.19	0.32	1.72e-9	Obesity-related traits;
LUSC	cis	rs1443512	0.947	rs9804784	chr12:54343472	A/C	cg17410650	chr12:54324560	NA	-0.43	-6.97	-0.36	1.73e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg00376283	chr12:123451042	ABCB9	-0.71	-10.93	-0.51	5.4e-24	Platelet count;
LUSC	cis	rs9296095	1.000	rs9296095	chr6:33542523	A/G	cg14003231	chr6:33640908	ITPR3	0.43	6.91	0.35	2.51e-11	Platelet count;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13310671	chr20:48553087	RNF114	0.73	6.13	0.32	2.43e-9	Cognitive performance;
LUSC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg06677660	chr19:49140777	SEC1;DBP	-0.45	-5.94	-0.31	6.98e-9	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs450533	0.540	rs419764	chr4:107844157	C/T	cg19546012	chr19:752860	C19orf21	-0.3	-6.11	-0.32	2.76e-9	Cancer;
LUSC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	5.87	0.31	1.06e-8	Personality dimensions;
LUSC	cis	rs12618769	0.652	rs4851146	chr2:99237439	A/G	cg10123293	chr2:99228465	UNC50	0.47	7.59	0.38	3.26e-13	Bipolar disorder;
LUSC	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.63	-9.73	-0.47	7.42e-20	Response to antineoplastic agents;
LUSC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg23711669	chr6:146136114	FBXO30	0.81	15.02	0.64	2.48e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs57244997	1.000	rs73026551	chr6:162393642	A/C	cg17173639	chr6:162384350	PARK2	-0.56	-5.72	-0.3	2.43e-8	Mosquito bite size;
LUSC	cis	rs4654899	0.758	rs12402486	chr1:21447935	A/G	cg01072550	chr1:21505969	NA	0.51	7.92	0.4	3.54e-14	Superior frontal gyrus grey matter volume;
LUSC	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg10840412	chr1:235813424	GNG4	0.7	9.55	0.46	2.83e-19	Bipolar disorder;
LUSC	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.76	-12.87	-0.58	4.47e-31	Schizophrenia;
LUSC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg07741184	chr6:167504864	NA	0.34	6.3	0.33	9.61e-10	Crohn's disease;
LUSC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg12454169	chr2:30669597	LCLAT1	1.02	10.57	0.5	1.01e-22	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUSC	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	11.0	0.52	3.09e-24	Response to antipsychotic treatment;
LUSC	trans	rs2679649	0.655	rs2679641	chr6:122355637	T/G	cg00167820	chr8:131663355	NA	0.54	6.3	0.33	9.21e-10	Subcutaneous adipose tissue;
LUSC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg08270630	chr22:50330655	NA	-0.43	-6.58	-0.34	1.79e-10	Schizophrenia;
LUSC	cis	rs742132	0.527	rs12526321	chr6:25494503	A/G	cg03517284	chr6:25882590	NA	0.46	6.34	0.33	7.3e-10	Uric acid levels;
LUSC	cis	rs3824867	0.920	rs7108143	chr11:47453722	T/G	cg20307385	chr11:47447363	PSMC3	-0.65	-9.65	-0.47	1.35e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs9796	0.870	rs2412574	chr15:41259707	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.92	-0.35	2.37e-11	Menopause (age at onset);
LUSC	trans	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg08975724	chr8:8085496	FLJ10661	0.45	6.0	0.31	5.13e-9	Neuroticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15581235	chr15:41708917	RTF1	0.44	6.35	0.33	7.24e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg21775007	chr8:11205619	TDH	-0.44	-6.19	-0.32	1.76e-9	Joint mobility (Beighton score);
LUSC	cis	rs6906287	0.647	rs13219555	chr6:118816364	G/A	cg21191810	chr6:118973309	C6orf204	0.34	6.26	0.32	1.18e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.45	-0.46	6.07e-19	Morning vs. evening chronotype;
LUSC	cis	rs4953076	0.573	rs7595470	chr2:44402467	A/G	cg04920474	chr2:44395004	PPM1B	0.63	8.15	0.41	7.41e-15	Height;
LUSC	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.2	-0.49	1.86e-21	Eye color traits;
LUSC	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.9	-0.35	2.55e-11	Alcohol dependence;
LUSC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg27427491	chr17:78079615	GAA	0.31	5.95	0.31	6.88e-9	Yeast infection;
LUSC	cis	rs6845621	0.901	rs1377146	chr4:18917384	T/C	cg12196642	chr4:18937545	NA	-0.34	-6.44	-0.33	4.14e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7463659	1.000	rs7836944	chr8:135436202	A/G	cg17885191	chr8:135476712	NA	0.43	6.05	0.31	3.89e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg07169764	chr2:136633963	MCM6	1.18	17.48	0.69	4.99e-49	Corneal structure;
LUSC	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg17173187	chr15:85201210	NMB	0.51	9.69	0.47	9.71e-20	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg26043149	chr18:55253948	FECH	0.46	7.05	0.36	1.05e-11	Bone mineral density;
LUSC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-11.64	-0.54	1.58e-26	Bipolar disorder;
LUSC	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg23750338	chr8:142222470	SLC45A4	0.48	9.38	0.46	1.02e-18	Immature fraction of reticulocytes;
LUSC	cis	rs80130819	0.688	rs6580660	chr12:48588112	T/C	cg24011408	chr12:48396354	COL2A1	0.45	5.89	0.31	9.18e-9	Prostate cancer;
LUSC	cis	rs6545883	0.894	rs2600672	chr2:61536740	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.67	-0.34	1.09e-10	Tuberculosis;
LUSC	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg24675056	chr1:15929824	NA	0.46	8.02	0.4	1.83e-14	Systolic blood pressure;
LUSC	cis	rs4363385	0.510	rs11205182	chr1:153045748	C/T	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.5	-0.34	2.92e-10	Inflammatory skin disease;
LUSC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg08917208	chr2:24149416	ATAD2B	0.53	5.87	0.31	1.03e-8	Lymphocyte counts;
LUSC	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg15744005	chr10:104629667	AS3MT	-0.28	-5.89	-0.31	9.39e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16553447	chr15:77197883	NA	0.46	6.29	0.33	9.76e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg08523384	chr5:141488047	NDFIP1	-0.5	-7.16	-0.36	5.25e-12	Crohn's disease;
LUSC	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg26384229	chr12:38710491	ALG10B	0.74	12.07	0.55	4.31e-28	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	14.73	0.63	3.3e-38	Platelet count;
LUSC	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10754283	0.967	rs10922685	chr1:90118320	A/G	cg21401794	chr1:90099060	LRRC8C	0.61	8.78	0.43	8.72e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg26335602	chr6:28129616	ZNF389	-0.47	-6.36	-0.33	6.55e-10	Parkinson's disease;
LUSC	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.78	0.51	1.94e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg24060327	chr5:131705240	SLC22A5	-0.35	-5.91	-0.31	8.49e-9	Blood metabolite levels;
LUSC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	0.63	13.38	0.59	5.59e-33	Prudent dietary pattern;
LUSC	cis	rs7804356	1.000	rs10227231	chr7:26888074	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg21427119	chr20:30132790	HM13	-0.38	-5.86	-0.31	1.14e-8	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg19743168	chr1:23544995	NA	0.39	7.19	0.37	4.23e-12	Height;
LUSC	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg15644404	chr18:77186268	NFATC1	-0.68	-7.62	-0.38	2.63e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg00684032	chr4:1343700	KIAA1530	0.35	6.07	0.32	3.41e-9	Obesity-related traits;
LUSC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs10465746	0.780	rs1324486	chr1:84384825	A/G	cg10977910	chr1:84465055	TTLL7	-0.49	-6.95	-0.36	1.92e-11	Obesity-related traits;
LUSC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-1.24	-13.73	-0.6	2.53e-34	Diabetic kidney disease;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg05191729	chr10:74856975	P4HA1	0.41	6.5	0.34	2.9e-10	Mosquito bite size;
LUSC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg16339924	chr4:17578868	LAP3	0.55	8.16	0.41	7.09e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg22535103	chr8:58192502	C8orf71	-0.72	-7.55	-0.38	4.13e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	8.94	0.44	2.77e-17	Height;
LUSC	cis	rs2607426	1.000	rs2607422	chr19:41276990	A/G	cg05508168	chr19:41255947	C19orf54;SNRPA	0.63	5.71	0.3	2.48e-8	Blood protein levels;
LUSC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg11062466	chr8:58055876	NA	0.52	6.76	0.35	6.25e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg02023728	chr11:77925099	USP35	0.49	7.07	0.36	9.01e-12	Testicular germ cell tumor;
LUSC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.5	0.59	1.89e-33	Cognitive test performance;
LUSC	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	9.38	0.46	1.06e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg05283184	chr6:79620031	NA	0.57	11.93	0.55	1.46e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg04865166	chr7:105162814	PUS7	0.51	5.84	0.3	1.25e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6693567	0.586	rs12031973	chr1:150485566	T/G	cg15654264	chr1:150340011	RPRD2	0.44	6.89	0.35	2.87e-11	Migraine;
LUSC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg07701084	chr6:150067640	NUP43	0.57	8.87	0.44	4.47e-17	Lung cancer;
LUSC	trans	rs9944715	0.911	rs718513	chr18:43856267	C/G	cg01718231	chr17:29326311	RNF135	-0.5	-7.08	-0.36	8.46e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg04586622	chr2:25135609	ADCY3	0.37	7.65	0.39	2.2e-13	Body mass index in non-asthmatics;
LUSC	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg05925327	chr15:68127851	NA	0.43	6.32	0.33	8.14e-10	Restless legs syndrome;
LUSC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.65	-9.15	-0.45	5.77e-18	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2944591	0.505	rs2592127	chr2:233791648	G/T	cg11972305	chr2:233791962	NGEF	-0.34	-6.4	-0.33	5.18e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.77	-0.3	1.77e-8	Resting heart rate;
LUSC	cis	rs11776272	0.927	rs11135789	chr8:21878607	C/T	cg17168535	chr8:21777572	XPO7	-0.46	-6.7	-0.34	8.86e-11	Obesity-related traits;
LUSC	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.89	-0.31	9.23e-9	Height;
LUSC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg09904177	chr6:26538194	HMGN4	-0.77	-14.49	-0.62	2.83e-37	Intelligence (multi-trait analysis);
LUSC	cis	rs12220238	0.841	rs10824161	chr10:76133762	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.51	-5.84	-0.3	1.26e-8	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs3099143	1.000	rs7174048	chr15:77165416	T/C	cg21673338	chr15:77095150	SCAPER	0.81	7.7	0.39	1.56e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg11161011	chr14:65562177	MAX	-0.81	-12.51	-0.56	1.01e-29	Obesity-related traits;
LUSC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg23281280	chr6:28129359	ZNF389	0.49	6.24	0.32	1.34e-9	Parkinson's disease;
LUSC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg17376030	chr22:41985996	PMM1	-0.48	-6.02	-0.31	4.57e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg05623727	chr3:50126028	RBM5	0.32	5.93	0.31	7.61e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.67	-0.3	3.03e-8	Total body bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27158523	chr6:149867355	PPIL4	-0.43	-6.29	-0.33	1.02e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg13319975	chr6:146136371	FBXO30	0.47	6.83	0.35	4.05e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg12863693	chr15:85201151	NMB	0.36	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg05347473	chr6:146136440	FBXO30	-0.39	-6.57	-0.34	1.88e-10	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.44	-0.33	4.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg23093090	chr10:104574429	C10orf26	0.45	8.53	0.42	5.03e-16	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.93	0.35	2.16e-11	Educational attainment;
LUSC	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg18512352	chr11:47633146	NA	-0.48	-9.87	-0.48	2.52e-20	Subjective well-being;
LUSC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg02423579	chr7:2872169	GNA12	-0.45	-6.89	-0.35	2.85e-11	Height;
LUSC	cis	rs3087591	0.708	rs9894648	chr17:29653293	T/C	cg24425628	chr17:29625626	OMG;NF1	0.49	7.3	0.37	2.17e-12	Hip circumference;
LUSC	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg08916839	chr5:415575	AHRR	0.83	7.78	0.39	8.85e-14	Fat distribution (HIV);
LUSC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.24	-0.49	1.4e-21	Hemoglobin concentration;
LUSC	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	6.57	0.34	1.94e-10	Fibroblast growth factor basic levels;
LUSC	trans	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.81e-10	Life satisfaction;
LUSC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg05025164	chr4:1340916	KIAA1530	0.42	6.59	0.34	1.74e-10	Obesity-related traits;
LUSC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg10018233	chr7:150070692	REPIN1	-0.46	-9.42	-0.46	7.73e-19	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4812048	0.895	rs236691	chr20:57583536	G/C	cg14073986	chr20:57617431	SLMO2	0.58	6.17	0.32	1.99e-9	Mean platelet volume;
LUSC	cis	rs7168353	0.519	rs11074140	chr15:93635244	C/G	cg12595281	chr15:93633172	RGMA	-0.31	-5.77	-0.3	1.81e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg09365446	chr1:150670422	GOLPH3L	0.47	6.94	0.36	2.04e-11	Melanoma;
LUSC	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg05768032	chr16:30646687	NA	0.38	5.75	0.3	2.02e-8	Multiple myeloma;
LUSC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-1.01	-14.56	-0.62	1.62e-37	Initial pursuit acceleration;
LUSC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg09021430	chr5:549028	NA	-0.55	-7.27	-0.37	2.64e-12	Obesity-related traits;
LUSC	cis	rs7705502	1.000	rs17763772	chr5:173380934	A/G	cg18693985	chr5:173351052	CPEB4	-0.4	-6.17	-0.32	2.01e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg04117972	chr1:227635322	NA	0.6	6.37	0.33	6.36e-10	Major depressive disorder;
LUSC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.6	8.45	0.42	9.09e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg04998671	chr14:104000505	TRMT61A	-0.43	-6.28	-0.33	1.04e-9	Reticulocyte count;
LUSC	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg05163923	chr11:71159392	DHCR7	0.74	10.95	0.51	4.74e-24	Vitamin D levels;
LUSC	cis	rs4629180	0.675	rs908132	chr2:102093096	A/G	cg01388757	chr2:102091195	RFX8	-0.36	-6.13	-0.32	2.43e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg08975724	chr8:8085496	FLJ10661	0.66	9.97	0.48	1.15e-20	Neuroticism;
LUSC	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg07541023	chr7:19748670	TWISTNB	-0.68	-7.26	-0.37	2.73e-12	Thyroid stimulating hormone;
LUSC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.52e-25	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-6.21	-0.32	1.61e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	6.88	0.35	2.89e-11	Menarche (age at onset);
LUSC	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg19683494	chr5:74908142	NA	-0.53	-6.79	-0.35	5.09e-11	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LUSC	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg05784532	chr1:230284198	GALNT2	0.64	8.84	0.44	5.65e-17	Coronary artery disease;
LUSC	cis	rs3862260	0.967	rs3862261	chr1:120160822	G/A	cg16322792	chr1:120165303	ZNF697	0.5	9.59	0.46	2.2e-19	Systemic lupus erythematosus;
LUSC	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg03474202	chr17:45855739	NA	-0.29	-6.74	-0.35	7.09e-11	IgG glycosylation;
LUSC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12311346	chr5:56204834	C5orf35	-0.83	-13.46	-0.59	2.82e-33	Initial pursuit acceleration;
LUSC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg04166393	chr7:2884313	GNA12	0.42	5.72	0.3	2.43e-8	Height;
LUSC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.61	0.34	1.5e-10	Tonsillectomy;
LUSC	cis	rs2046867	0.628	rs7617996	chr3:72915315	C/T	cg25664220	chr3:72788482	NA	-0.54	-9.77	-0.47	5.54e-20	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg06784218	chr1:46089804	CCDC17	-0.48	-9.21	-0.45	3.67e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3771570	1.000	rs62193208	chr2:242322430	G/A	cg21155796	chr2:242212141	HDLBP	0.63	6.92	0.35	2.29e-11	Prostate cancer;
LUSC	cis	rs7523273	0.526	rs2724394	chr1:208017072	T/A	cg22525895	chr1:207977042	MIR29B2	-0.41	-6.83	-0.35	3.95e-11	Schizophrenia;
LUSC	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.58	9.54	0.46	3.05e-19	Breast cancer;
LUSC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg19418458	chr7:158789849	NA	-0.65	-11.06	-0.52	1.93e-24	Facial morphology (factor 20);
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.51	-7.43	-0.38	9.43e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	0.94	13.42	0.59	4e-33	Inflammatory bowel disease;
LUSC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg19468946	chr17:37922297	IKZF3	0.47	7.75	0.39	1.08e-13	Self-reported allergy;
LUSC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	1.05	19.65	0.73	1.16e-57	Menopause (age at onset);
LUSC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg17376030	chr22:41985996	PMM1	-0.46	-5.77	-0.3	1.85e-8	Vitiligo;
LUSC	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg01073479	chr16:3509474	NAT15	0.39	5.65	0.3	3.46e-8	Tuberculosis;
LUSC	cis	rs554111	0.634	rs4654875	chr1:21165176	A/G	cg01072550	chr1:21505969	NA	0.39	5.92	0.31	8.17e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs3125734	0.671	rs3852406	chr10:64015162	T/C	cg19640130	chr10:64028056	RTKN2	-0.4	-7.02	-0.36	1.23e-11	Rheumatoid arthritis;
LUSC	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.44	0.75	8.46e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13067593	1.000	rs66966540	chr3:188573196	A/C	cg17809494	chr3:188572244	LPP	0.42	5.73	0.3	2.22e-8	Immune reponse to smallpox (secreted IFN-alpha);
LUSC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg25036284	chr2:26402008	FAM59B	0.72	10.2	0.49	1.88e-21	Gut microbiome composition (summer);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg10164686	chr6:2971950	SERPINB6	0.39	6.18	0.32	1.88e-9	Schizophrenia;
LUSC	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	1.1	15.68	0.65	6.69e-42	Uric acid levels;
LUSC	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg04733989	chr22:42467013	NAGA	0.37	6.14	0.32	2.33e-9	Cognitive function;
LUSC	cis	rs34375054	0.573	rs12581813	chr12:125656402	A/G	cg25124228	chr12:125621409	AACS	-0.5	-6.36	-0.33	6.59e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs905938	0.559	rs76306191	chr1:155006451	C/G	cg16256492	chr1:154989843	ZBTB7B	0.63	7.23	0.37	3.24e-12	Waist-to-hip ratio adjusted for body mass index;Birth length;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg02038168	chr22:39784481	NA	-0.48	-7.79	-0.39	8.53e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7589342	0.895	rs11901644	chr2:106432113	T/G	cg14210321	chr2:106509881	NCK2	-0.55	-8.12	-0.41	8.83e-15	Addiction;
LUSC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg01579765	chr21:45077557	HSF2BP	-0.58	-12.69	-0.57	2.29e-30	Mean corpuscular volume;
LUSC	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.7	10.49	0.5	1.92e-22	Alcohol dependence;
LUSC	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.94	-0.44	2.75e-17	Breast cancer;
LUSC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-1.04	-20.32	-0.74	2.46e-60	Height;
LUSC	cis	rs6987853	0.686	rs10087350	chr8:42359484	G/A	cg09913449	chr8:42400586	C8orf40	-0.44	-7.45	-0.38	8.03e-13	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24980700	chr20:30410739	MYLK2	0.41	6.12	0.32	2.67e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11031096	0.782	rs4910888	chr11:4152915	G/A	cg18678763	chr11:4115507	RRM1	-0.52	-7.56	-0.38	4.06e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4594175	0.926	rs12432356	chr14:51631223	T/G	cg23942311	chr14:51606299	NA	0.3	5.68	0.3	2.86e-8	Cancer;
LUSC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg14196790	chr5:131705035	SLC22A5	0.48	7.96	0.4	2.65e-14	Blood metabolite levels;
LUSC	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg15423357	chr2:25149977	NA	0.47	9.67	0.47	1.17e-19	Body mass index in non-asthmatics;
LUSC	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.17	0.37	4.9e-12	Red cell distribution width;
LUSC	cis	rs7914558	0.646	rs12768205	chr10:104647849	C/T	cg05855489	chr10:104503620	C10orf26	0.43	5.82	0.3	1.42e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs12210905	1.000	rs3800310	chr6:27206843	C/G	cg11837749	chr1:55047332	ACOT11	0.58	6.19	0.32	1.76e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg12419862	chr22:24373484	LOC391322	-0.89	-14.8	-0.63	1.88e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.6	-8.95	-0.44	2.45e-17	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7809950	0.817	rs17154091	chr7:107084790	T/C	cg23024343	chr7:107201750	COG5	-0.7	-10.34	-0.49	6.27e-22	Coronary artery disease;
LUSC	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.98	0.44	2e-17	Lung cancer in ever smokers;
LUSC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg07507251	chr3:52567010	NT5DC2	0.36	6.91	0.35	2.39e-11	Bipolar disorder;
LUSC	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg18827107	chr12:86230957	RASSF9	-0.4	-5.87	-0.31	1.04e-8	Major depressive disorder;
LUSC	cis	rs2692947	0.644	rs1030864	chr2:96822373	A/G	cg22654517	chr2:96458247	NA	0.32	5.87	0.31	1.06e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.89	-0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg09998033	chr7:158218633	PTPRN2	-0.51	-8.2	-0.41	5.11e-15	Obesity-related traits;
LUSC	trans	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.57	-8.05	-0.4	1.48e-14	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs2710642	0.861	rs2710644	chr2:63248968	A/C	cg17519650	chr2:63277830	OTX1	0.57	7.89	0.4	4.46e-14	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.85	0.39	5.6e-14	Parkinson's disease;
LUSC	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg25019033	chr10:957182	NA	-0.52	-7.22	-0.37	3.55e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs9646944	0.501	rs3771158	chr2:103009894	A/G	cg20060108	chr2:102954350	IL1RL1	0.49	6.91	0.35	2.5e-11	Blood protein levels;
LUSC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs79387448	0.701	rs76943877	chr2:102970677	T/C	cg09003973	chr2:102972529	NA	1.21	12.75	0.57	1.31e-30	Gut microbiota (bacterial taxa);
LUSC	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.58	-9.69	-0.47	9.99e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg03676636	chr4:99064102	C4orf37	0.35	7.76	0.39	1.04e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	10.83	0.51	1.23e-23	Menopause (age at onset);
LUSC	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg06484146	chr7:12443880	VWDE	-0.68	-7.08	-0.36	8.67e-12	Coronary artery disease;
LUSC	trans	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.82	0.54	3.63e-27	Mean corpuscular volume;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10445487	chr16:75599896	GABARAPL2	0.44	6.84	0.35	3.78e-11	Triglycerides;
LUSC	trans	rs12210905	0.925	rs114172511	chr6:26964301	G/A	cg11837749	chr1:55047332	ACOT11	0.57	6.09	0.32	3.07e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7264396	0.943	rs11167267	chr20:34109273	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.22	-0.32	1.48e-9	Total cholesterol levels;
LUSC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.36	-0.56	3.84e-29	Rheumatoid arthritis;
LUSC	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg19743168	chr1:23544995	NA	-0.38	-7.56	-0.38	3.93e-13	Height;
LUSC	cis	rs77633900	0.614	rs2468123	chr15:76931345	T/C	cg21673338	chr15:77095150	SCAPER	-0.76	-7.65	-0.39	2.13e-13	Non-glioblastoma glioma;Glioma;
LUSC	trans	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg01620082	chr3:125678407	NA	-0.8	-7.02	-0.36	1.28e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17051395	chr17:78644292	RPTOR	0.44	6.41	0.33	5e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9399401	0.667	rs6900233	chr6:142717283	C/G	cg03128060	chr6:142623767	GPR126	0.58	9.64	0.47	1.45e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg02176678	chr2:219576539	TTLL4	0.59	10.5	0.5	1.72e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.59	8.11	0.41	1e-14	High light scatter reticulocyte count;
LUSC	trans	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg24247370	chr13:99142703	STK24	-0.33	-6.01	-0.31	4.74e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg14264380	chr17:79651103	ARL16;HGS	0.44	5.95	0.31	6.64e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg13736514	chr6:26305472	NA	-0.45	-8.95	-0.44	2.55e-17	Educational attainment;
LUSC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg18512352	chr11:47633146	NA	-0.46	-9.19	-0.45	4.42e-18	Subjective well-being;
LUSC	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.73	-0.43	1.28e-16	Coffee consumption (cups per day);
LUSC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg00409905	chr10:38381863	ZNF37A	-0.35	-5.98	-0.31	5.62e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg12257692	chr3:49977190	RBM6	0.24	6.57	0.34	1.93e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg13010199	chr12:38710504	ALG10B	-0.44	-6.55	-0.34	2.12e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.81	-0.43	6.9e-17	Mood instability;
LUSC	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07080220	chr10:102295463	HIF1AN	0.67	9.15	0.45	5.81e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg26513180	chr16:89883248	FANCA	-0.49	-7.71	-0.39	1.49e-13	Vitiligo;
LUSC	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg20487152	chr13:99095054	FARP1	-0.35	-6.19	-0.32	1.73e-9	Longevity;
LUSC	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg11019008	chr10:131425282	MGMT	-0.39	-5.84	-0.3	1.21e-8	Response to temozolomide;
LUSC	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.39	-5.99	-0.31	5.52e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg05973401	chr12:123451056	ABCB9	0.54	6.64	0.34	1.24e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg05738196	chr6:26577821	NA	-0.52	-8.06	-0.4	1.41e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	6.54	0.34	2.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.27	0.59	1.45e-32	Chronic sinus infection;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24442661	chr7:36192818	EEPD1	-0.41	-6.11	-0.32	2.73e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.77	12.08	0.55	3.87e-28	Squamous cell carcinoma;
LUSC	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg02466173	chr16:30829666	NA	-0.59	-11.02	-0.52	2.66e-24	Multiple myeloma;
LUSC	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg06637938	chr14:75390232	RPS6KL1	0.51	8.18	0.41	6.13e-15	Height;
LUSC	cis	rs17193922	0.798	rs7203644	chr16:53547209	C/T	cg09728985	chr16:53543985	NA	-0.39	-6.37	-0.33	6.31e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	8.76	0.43	9.74e-17	Exhaled nitric oxide output;
LUSC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg00509249	chr6:109615579	CCDC162	-0.32	-5.81	-0.3	1.49e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.47	-6.82	-0.35	4.35e-11	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs9815354	0.812	rs73071304	chr3:41797504	G/C	cg03022575	chr3:42003672	ULK4	0.85	8.73	0.43	1.26e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs977987	0.843	rs4888372	chr16:75313485	G/A	cg03315344	chr16:75512273	CHST6	0.46	8.64	0.43	2.38e-16	Dupuytren's disease;
LUSC	cis	rs2734839	0.964	rs2734833	chr11:113292920	G/A	cg14159747	chr11:113255604	NA	0.23	5.71	0.3	2.55e-8	Information processing speed;
LUSC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg18827107	chr12:86230957	RASSF9	-0.43	-6.48	-0.33	3.22e-10	Major depressive disorder;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05454237	chr11:14913849	CYP2R1	-0.47	-6.07	-0.32	3.48e-9	Hepatitis;
LUSC	cis	rs4481887	0.617	rs28719164	chr1:248543802	T/G	cg26353448	chr1:248524236	OR2T4	-0.33	-6.2	-0.32	1.64e-9	Common traits (Other);
LUSC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs4722585	0.605	rs10268883	chr7:26200417	C/T	cg07876897	chr7:26191696	NFE2L3	0.48	7.24	0.37	3.21e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUSC	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg22431228	chr1:16359049	CLCNKA	0.41	7.48	0.38	6.66e-13	Dilated cardiomyopathy;
LUSC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg05132306	chr1:1846340	CALML6	-0.34	-8.55	-0.42	4.61e-16	Body mass index;
LUSC	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg15083037	chr5:83017644	HAPLN1	-0.6	-7.71	-0.39	1.5e-13	Prostate cancer;
LUSC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.48	-7.35	-0.37	1.57e-12	Total body bone mineral density;
LUSC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg25767906	chr1:53392781	SCP2	0.71	14.14	0.61	6.86e-36	Monocyte count;
LUSC	cis	rs2348418	0.966	rs4144964	chr12:28684182	C/T	cg13890972	chr12:28721907	NA	-0.34	-5.76	-0.3	1.93e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs983392	1.000	rs4939311	chr11:59877967	C/T	cg24026212	chr11:59952134	MS4A6A	-0.33	-5.79	-0.3	1.64e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg15448220	chr1:150897856	SETDB1	0.39	5.87	0.31	1.04e-8	Melanoma;
LUSC	cis	rs868036	0.918	rs4238411	chr15:68079424	A/T	cg08079166	chr15:68083412	MAP2K5	0.4	8.16	0.41	7.05e-15	Restless legs syndrome;
LUSC	cis	rs1953600	0.837	rs3098105	chr10:81953266	C/T	cg00277334	chr10:82204260	NA	0.45	7.08	0.36	8.35e-12	Sarcoidosis;
LUSC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	0.98	21.78	0.77	4.56e-66	Testicular germ cell tumor;
LUSC	trans	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.73	0.43	1.23e-16	Type 2 diabetes;
LUSC	cis	rs7759001	0.857	rs980963	chr6:27360937	C/T	cg18711553	chr6:27366782	ZNF391	0.39	5.69	0.3	2.77e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg05110241	chr16:68378359	PRMT7	-0.56	-6.38	-0.33	5.96e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg05340658	chr4:99064831	C4orf37	0.64	10.17	0.49	2.45e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4664308	0.935	rs6731260	chr2:160977769	A/G	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.63	-0.54	1.73e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs3820928	0.874	rs12105952	chr2:227864521	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.65	-0.39	2.18e-13	Pulmonary function;
LUSC	cis	rs7828089	0.935	rs896375	chr8:22262098	A/G	cg12081754	chr8:22256438	SLC39A14	0.53	8.28	0.41	2.96e-15	Verbal declarative memory;
LUSC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.69	10.75	0.51	2.38e-23	Longevity;
LUSC	trans	rs6011368	0.654	rs1570521	chr20:62911019	G/T	cg13869341	chr1:15865	WASH5P	0.39	6.08	0.32	3.28e-9	Clozapine-induced cytotoxicity;
LUSC	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs9937943	0.667	rs11862508	chr16:74598688	T/C	cg01733217	chr16:74700730	RFWD3	0.61	6.93	0.35	2.13e-11	Neutrophil percentage of white cells;
LUSC	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg20203395	chr5:56204925	C5orf35	-0.53	-7.67	-0.39	1.85e-13	Coronary artery disease;
LUSC	trans	rs12439619	0.846	rs62010071	chr15:82581783	G/C	cg04831495	chr15:85060580	GOLGA6L5	-0.48	-6.37	-0.33	6.15e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg07636037	chr3:49044803	WDR6	0.44	6.38	0.33	5.9e-10	Resting heart rate;
LUSC	trans	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg07393940	chr7:158741817	NA	-0.55	-8.51	-0.42	5.85e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.85	0.44	5.37e-17	Coffee consumption (cups per day);
LUSC	trans	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg13010199	chr12:38710504	ALG10B	0.45	6.9	0.35	2.67e-11	Morning vs. evening chronotype;
LUSC	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg12081754	chr8:22256438	SLC39A14	0.79	12.61	0.57	4.49e-30	Verbal declarative memory;
LUSC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.88	-0.35	3.01e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11764359	chr7:65958608	NA	0.68	10.85	0.51	1.06e-23	Aortic root size;
LUSC	cis	rs7577696	0.962	rs6738349	chr2:32314131	G/C	cg02381751	chr2:32503542	YIPF4	-0.4	-5.78	-0.3	1.72e-8	Inflammatory biomarkers;
LUSC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.01e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06636551	chr8:101224915	SPAG1	-0.39	-7.23	-0.37	3.35e-12	Atrioventricular conduction;
LUSC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg09626299	chr10:82213104	TSPAN14	-0.2	-6.01	-0.31	4.78e-9	Post bronchodilator FEV1;
LUSC	cis	rs28785552	0.800	rs1971063	chr19:53232854	G/C	cg10871876	chr19:53194124	ZNF83	0.55	8.17	0.41	6.31e-15	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg15556689	chr8:8085844	FLJ10661	0.63	9.92	0.48	1.68e-20	Mood instability;
LUSC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26314531	chr2:26401878	FAM59B	-0.68	-9.29	-0.45	2.1e-18	Gut microbiome composition (summer);
LUSC	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.08	-0.4	1.17e-14	Neuroticism;
LUSC	cis	rs8032315	0.965	rs7497304	chr15:91429176	G/T	cg04510874	chr15:91427884	FES	0.32	6.33	0.33	8.06e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg05896524	chr21:47604654	C21orf56	0.4	5.91	0.31	8.52e-9	Testicular germ cell tumor;
LUSC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg13939156	chr17:80058883	NA	0.33	6.44	0.33	4.21e-10	Life satisfaction;
LUSC	cis	rs1784581	0.588	rs4131681	chr6:162422167	T/G	cg17173639	chr6:162384350	PARK2	0.57	9.98	0.48	1.06e-20	Itch intensity from mosquito bite;
LUSC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.29	-5.69	-0.3	2.74e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg19187155	chr2:232395269	NMUR1	0.8	13.65	0.6	5.01e-34	Height;
LUSC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.8	12.78	0.57	1.04e-30	Breast cancer;
LUSC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg23281280	chr6:28129359	ZNF389	0.45	5.67	0.3	3.04e-8	Depression;
LUSC	cis	rs9811920	0.965	rs9837131	chr3:99854514	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.33	-5.75	-0.3	2.03e-8	Axial length;
LUSC	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.7	-0.43	1.49e-16	Response to antipsychotic treatment;
LUSC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.93	0.48	1.54e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg10729496	chr3:10149963	C3orf24	0.52	6.98	0.36	1.56e-11	Alzheimer's disease;
LUSC	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.56	-0.67	2.25e-45	Monocyte count;
LUSC	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg09915433	chr19:53449742	NA	-0.61	-9.67	-0.47	1.14e-19	Psoriasis;
LUSC	cis	rs72960926	0.744	rs6914400	chr6:75018941	G/A	cg03266952	chr6:74778945	NA	-0.8	-6.98	-0.36	1.58e-11	Metabolite levels (MHPG);
LUSC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg20503657	chr10:835505	NA	0.87	12.23	0.56	1.12e-28	Eosinophil percentage of granulocytes;
LUSC	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg13010199	chr12:38710504	ALG10B	0.69	10.61	0.5	7.62e-23	Bladder cancer;
LUSC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg11764359	chr7:65958608	NA	0.49	6.1	0.32	2.93e-9	Aortic root size;
LUSC	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg00074818	chr8:8560427	CLDN23	0.56	9.55	0.46	2.94e-19	Obesity-related traits;
LUSC	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg04851639	chr8:1020857	NA	-0.37	-7.66	-0.39	1.99e-13	Schizophrenia;
LUSC	cis	rs1113500	0.933	rs12035689	chr1:108636756	T/C	cg06207961	chr1:108661230	NA	0.41	7.57	0.38	3.61e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg15485101	chr11:133734466	NA	0.41	7.73	0.39	1.28e-13	Childhood ear infection;
LUSC	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-9.44	-0.46	6.82e-19	Morning vs. evening chronotype;
LUSC	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2.04e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg12091567	chr17:66097778	LOC651250	0.88	14.09	0.61	9.98e-36	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg09650180	chr20:62225654	GMEB2	-0.66	-9.66	-0.47	1.22e-19	Glioblastoma;
LUSC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.05	20.0	0.74	4.44e-59	Cognitive ability;
LUSC	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg23289794	chr7:2394357	EIF3B	-0.71	-9.81	-0.47	3.9e-20	Multiple sclerosis;
LUSC	cis	rs13315871	0.929	rs4560319	chr3:58386274	C/T	cg12435725	chr3:58293450	RPP14	-0.73	-7.35	-0.37	1.56e-12	Cholesterol, total;
LUSC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg02569458	chr12:86230093	RASSF9	0.55	9.43	0.46	7.16e-19	Major depressive disorder;
LUSC	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg14462750	chr9:136913113	BRD3	-0.41	-6.22	-0.32	1.46e-9	Platelet distribution width;
LUSC	cis	rs12618769	0.597	rs72819987	chr2:99046253	A/G	cg10123293	chr2:99228465	UNC50	0.47	7.77	0.39	9.91e-14	Bipolar disorder;
LUSC	cis	rs79387448	0.745	rs72993720	chr2:103121269	A/T	cg09003973	chr2:102972529	NA	0.87	8.56	0.42	4.28e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.4	-5.84	-0.3	1.21e-8	Tonsillectomy;
LUSC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.45	6.74	0.35	7.05e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg18827107	chr12:86230957	RASSF9	-0.49	-7.16	-0.36	5.22e-12	Major depressive disorder;
LUSC	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.66	11.99	0.55	8.87e-28	Birth weight;
LUSC	cis	rs9914988	0.559	rs1109024	chr17:27189971	C/T	cg09479241	chr17:27052676	TLCD1	-0.43	-5.79	-0.3	1.65e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg13385521	chr17:29058706	SUZ12P	0.59	5.7	0.3	2.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs11650494	0.710	rs73987293	chr17:47474728	A/G	cg08112188	chr17:47440006	ZNF652	0.93	7.93	0.4	3.3e-14	Prostate cancer;
LUSC	cis	rs877282	0.898	rs2004478	chr10:770709	C/A	cg17470449	chr10:769945	NA	0.51	7.25	0.37	3.01e-12	Uric acid levels;
LUSC	trans	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg00857998	chr1:205179979	DSTYK	0.61	9.17	0.45	4.95e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.76	-13.71	-0.6	3e-34	Ulcerative colitis;
LUSC	trans	rs61931739	0.635	rs1852225	chr12:33963004	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.62	0.38	2.61e-13	Morning vs. evening chronotype;
LUSC	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg05973401	chr12:123451056	ABCB9	0.55	7.9	0.4	4.02e-14	Platelet count;
LUSC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg16743903	chr16:89593216	SPG7	-0.4	-5.97	-0.31	6.19e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07080220	chr10:102295463	HIF1AN	0.63	8.42	0.42	1.14e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg03146154	chr1:46216737	IPP	0.56	8.32	0.41	2.35e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg14092571	chr14:90743983	NA	-0.36	-5.84	-0.3	1.24e-8	Mortality in heart failure;
LUSC	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.72	-0.3	2.42e-8	Alzheimer's disease (survival time);
LUSC	trans	rs7980799	0.565	rs2200159	chr12:33648544	G/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.92	-0.4	3.67e-14	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.7	-0.39	1.5700000000000001e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.38	-5.81	-0.3	1.43e-8	Tonsillectomy;
LUSC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	9.28	0.45	2.22e-18	Menopause (age at onset);
LUSC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg22508957	chr16:3507546	NAT15	-0.91	-10.51	-0.5	1.7e-22	Tuberculosis;
LUSC	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	0.94	8.24	0.41	3.94e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12016809	chr21:47604291	C21orf56	-0.45	-6.71	-0.34	8.23e-11	Testicular germ cell tumor;
LUSC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	4.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7264396	1.000	rs224415	chr20:34135629	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-6.66	-0.34	1.1e-10	Total cholesterol levels;
LUSC	cis	rs10865397	0.506	rs60764301	chr2:73384850	G/A	cg24220031	chr2:73402428	NA	-0.26	-6.05	-0.31	3.89e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs954108	0.522	rs7983818	chr13:29383182	A/C	cg11788234	chr13:29393811	NA	-0.51	-10.18	-0.49	2.17e-21	Obesity-related traits;
LUSC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg11871910	chr12:69753446	YEATS4	0.91	16.98	0.68	4.65e-47	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg16339924	chr4:17578868	LAP3	-0.5	-7.3	-0.37	2.15e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg21280719	chr6:42927975	GNMT	-0.26	-5.71	-0.3	2.49e-8	Blood protein levels;
LUSC	cis	rs889312	0.924	rs1910020	chr5:56026500	T/C	cg18230493	chr5:56204884	C5orf35	-0.41	-5.9	-0.31	8.69e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-10.9	-0.51	6.92e-24	Chronic sinus infection;
LUSC	cis	rs2303282	0.716	rs2617849	chr16:56404703	C/T	cg00500540	chr16:56394104	NA	-0.44	-7.55	-0.38	4.1e-13	Breast cancer;
LUSC	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg27411982	chr8:10470053	RP1L1	-0.37	-5.75	-0.3	2e-8	Retinal vascular caliber;
LUSC	cis	rs240764	0.658	rs9322213	chr6:101248480	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-6.63	-0.34	1.33e-10	Neuroticism;
LUSC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.16	0.49	2.71e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6087990	0.806	rs4911108	chr20:31375311	A/G	cg13636640	chr20:31349939	DNMT3B	0.89	17.85	0.7	1.67e-50	Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14893161	chr1:205819251	PM20D1	0.44	6.07	0.32	3.44e-9	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs72960926	0.744	rs11752920	chr6:75000195	C/T	cg03266952	chr6:74778945	NA	-0.76	-6.65	-0.34	1.21e-10	Metabolite levels (MHPG);
LUSC	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07080220	chr10:102295463	HIF1AN	0.64	8.67	0.43	1.95e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6961069	0.777	rs6961024	chr7:80249671	G/T	cg04458919	chr7:80252533	CD36	0.37	6.58	0.34	1.78e-10	Platelet count;
LUSC	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg15133208	chr4:90757351	SNCA	-0.32	-5.66	-0.3	3.18e-8	Dementia with Lewy bodies;
LUSC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.7	12.64	0.57	3.53e-30	Prudent dietary pattern;
LUSC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg07424592	chr7:64974309	NA	-0.64	-5.71	-0.3	2.46e-8	Diabetic kidney disease;
LUSC	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-6.05	-0.31	3.92e-9	Mean corpuscular volume;
LUSC	cis	rs9650657	0.771	rs6601513	chr8:10594843	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.11	-0.32	2.71e-9	Neuroticism;
LUSC	cis	rs16854884	0.657	rs16854819	chr3:143736126	C/T	cg06585982	chr3:143692056	C3orf58	-0.49	-7.81	-0.39	7.48e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg15556689	chr8:8085844	FLJ10661	0.58	8.68	0.43	1.73e-16	Neuroticism;
LUSC	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg27539214	chr16:67997921	SLC12A4	-0.5	-6.72	-0.35	7.83e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9549260	0.816	rs9532582	chr13:41251207	A/G	cg21288729	chr13:41239152	FOXO1	0.57	8.6	0.43	3.04e-16	Red blood cell count;
LUSC	cis	rs6545883	0.894	rs12620105	chr2:61512321	A/T	cg15711740	chr2:61764176	XPO1	0.46	6.93	0.35	2.16e-11	Tuberculosis;
LUSC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg21856205	chr7:94953877	PON1	-0.35	-5.71	-0.3	2.51e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg15242686	chr22:24348715	GSTTP1	0.55	9.14	0.45	6.06e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.35	-0.37	1.53e-12	Bipolar disorder;
LUSC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg13010199	chr12:38710504	ALG10B	0.64	9.79	0.47	4.45e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg23649088	chr2:200775458	C2orf69	-0.57	-7.01	-0.36	1.33e-11	Schizophrenia;
LUSC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6496044	0.548	rs7163032	chr15:86072419	T/A	cg13263323	chr15:86062960	AKAP13	-0.37	-6.16	-0.32	2.06e-9	Interstitial lung disease;
LUSC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	9.69	0.47	9.58e-20	Cognitive test performance;
LUSC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg19077165	chr18:44547161	KATNAL2	0.44	6.67	0.34	1.04e-10	Personality dimensions;
LUSC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg26566898	chr11:117069891	TAGLN	-0.48	-8.46	-0.42	8.42e-16	Blood protein levels;
LUSC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg27165867	chr14:105738592	BRF1	-0.54	-7.77	-0.39	9.99e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs78572108	0.858	rs13384309	chr2:42265288	G/A	cg00607755	chr2:42274082	PKDCC	0.36	6.52	0.34	2.61e-10	Total body bone mineral density;
LUSC	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg06606381	chr12:133084897	FBRSL1	-0.97	-8.98	-0.44	1.96e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg10560079	chr2:191398806	TMEM194B	-0.67	-7.59	-0.38	3.33e-13	Diastolic blood pressure;
LUSC	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg03676636	chr4:99064102	C4orf37	0.36	8.05	0.4	1.44e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg13385521	chr17:29058706	SUZ12P	0.59	5.7	0.3	2.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.48	0.53	5.99e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4561483	0.771	rs12924398	chr16:11972948	T/A	cg08843971	chr16:11963173	GSPT1	-0.44	-6.12	-0.32	2.62e-9	Testicular germ cell tumor;
LUSC	cis	rs1256061	0.630	rs1256030	chr14:64747170	A/G	cg21174375	chr14:64681225	SYNE2	0.35	6.46	0.33	3.77e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-7.41	-0.38	1.03e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1403694	0.515	rs822362	chr3:186453065	A/C	cg12454167	chr3:186435060	KNG1	0.29	7.6	0.38	3.1e-13	Blood protein levels;
LUSC	cis	rs11690935	0.531	rs4280428	chr2:172813219	G/A	cg13550731	chr2:172543902	DYNC1I2	0.49	7.27	0.37	2.52e-12	Schizophrenia;
LUSC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg27170947	chr2:26402098	FAM59B	-0.69	-10.59	-0.5	8.47e-23	Gut microbiome composition (summer);
LUSC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg11247378	chr22:39784982	NA	-0.63	-11.01	-0.52	2.83e-24	Post bronchodilator FEV1;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04688917	chr3:179040469	ZNF639	0.4	6.18	0.32	1.88e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg04871131	chr7:94954202	PON1	-0.35	-5.65	-0.3	3.52e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1178968	1.000	rs7793764	chr7:72759953	G/T	cg25889504	chr7:72793014	NA	0.52	6.81	0.35	4.42e-11	Triglyceride levels;
LUSC	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	13.38	0.59	5.34e-33	Blood protein levels;
LUSC	cis	rs12413816	0.784	rs11258560	chr10:13770137	A/G	cg16485048	chr10:13749193	FRMD4A	0.44	7.35	0.37	1.55e-12	Red cell distribution width;
LUSC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg14668632	chr7:2872130	GNA12	-0.48	-7.19	-0.37	4.21e-12	Height;
LUSC	cis	rs62458065	0.513	rs10268803	chr7:32547835	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.55	-5.92	-0.31	7.77e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs66731853	0.769	rs657624	chr1:20888348	C/T	cg04087271	chr1:20915334	CDA	-0.51	-8.86	-0.44	4.73e-17	Mean corpuscular volume;
LUSC	cis	rs4499344	0.730	rs453804	chr19:33105612	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.87	13.17	0.58	3.36e-32	Mean platelet volume;
LUSC	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg05855489	chr10:104503620	C10orf26	0.59	8.14	0.41	7.93e-15	Arsenic metabolism;
LUSC	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg00484396	chr16:3507460	NAT15	-0.43	-7.01	-0.36	1.29e-11	Body mass index (adult);
LUSC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.78	-0.39	9.11e-14	Type 2 diabetes;
LUSC	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg23260525	chr10:116636907	FAM160B1	-0.42	-8.61	-0.43	2.9e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs11601602	0.531	rs35031414	chr11:28545563	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	5.99	0.31	5.4e-9	Obesity-related traits;
LUSC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg08088566	chr11:430123	ANO9	0.62	7.21	0.37	3.77e-12	Body mass index;
LUSC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	0.92	15.61	0.65	1.22e-41	Menopause (age at onset);
LUSC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07167872	chr1:205819463	PM20D1	0.76	13.51	0.59	1.81e-33	Menarche (age at onset);
LUSC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12826209	chr6:26865740	GUSBL1	0.74	8.95	0.44	2.43e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg09904177	chr6:26538194	HMGN4	-0.51	-8.05	-0.4	1.45e-14	Schizophrenia;
LUSC	trans	rs6076960	0.598	rs3905168	chr20:6226752	C/T	cg17788362	chr6:86352627	SYNCRIP	0.42	6.11	0.32	2.8e-9	Smooth-surface caries;
LUSC	trans	rs853679	1.000	rs853685	chr6:28288785	C/T	cg01620082	chr3:125678407	NA	-0.57	-6.43	-0.33	4.42e-10	Depression;
LUSC	cis	rs427941	0.632	rs201470	chr7:101744045	G/A	cg06246474	chr7:101738831	CUX1	0.39	6.42	0.33	4.68e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs2692947	0.770	rs6719831	chr2:96502590	A/C	cg22654517	chr2:96458247	NA	0.38	7.48	0.38	6.83e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs668210	0.793	rs677350	chr11:65761967	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.59	7.78	0.39	9.13e-14	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg10840412	chr1:235813424	GNG4	0.67	8.99	0.44	1.9e-17	Bipolar disorder;
LUSC	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg27129171	chr3:47204927	SETD2	0.7	11.75	0.54	6.42e-27	Colorectal cancer;
LUSC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.45	-6.37	-0.33	6.32e-10	Osteoporosis;
LUSC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg18404041	chr3:52824283	ITIH1	-0.39	-6.93	-0.35	2.13e-11	Electroencephalogram traits;
LUSC	trans	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg12856521	chr11:46389249	DGKZ	0.42	6.75	0.35	6.53e-11	Leprosy;
LUSC	cis	rs11039100	0.920	rs11039075	chr11:5820917	C/A	cg05234568	chr11:5960015	NA	-0.51	-5.76	-0.3	1.87e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg19743168	chr1:23544995	NA	-0.53	-10.64	-0.5	5.92e-23	Height;
LUSC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg24296786	chr1:45957014	TESK2	0.47	6.91	0.35	2.51e-11	High light scatter reticulocyte count;
LUSC	cis	rs870825	0.698	rs7673203	chr4:185625397	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.77e-32	Blood protein levels;
LUSC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg19592336	chr6:28129416	ZNF389	0.5	6.82	0.35	4.3e-11	Parkinson's disease;
LUSC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.44	-7.05	-0.36	1.05e-11	Tonsillectomy;
LUSC	cis	rs4363385	0.667	rs2066004	chr1:152922896	A/G	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.03	-0.36	1.2e-11	Inflammatory skin disease;
LUSC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg04586622	chr2:25135609	ADCY3	0.39	8.05	0.4	1.43e-14	Body mass index;
LUSC	cis	rs907612	0.638	rs11041476	chr11:1875067	C/T	cg07277017	chr11:1874093	LSP1	0.33	5.83	0.3	1.31e-8	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg01528321	chr10:82214614	TSPAN14	0.62	9.17	0.45	5.01e-18	Post bronchodilator FEV1;
LUSC	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	12.65	0.57	3.2e-30	Total body bone mineral density;
LUSC	cis	rs34638657	0.732	rs62045962	chr16:82200604	T/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.33	-0.33	7.89e-10	Lung adenocarcinoma;
LUSC	cis	rs1044826	1.000	rs9860201	chr3:139091444	G/C	cg00490450	chr3:139108681	COPB2	0.55	7.37	0.37	1.34e-12	Obesity-related traits;
LUSC	trans	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg13565492	chr6:43139072	SRF	-0.56	-6.0	-0.31	5.03e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6692729	0.897	rs7518926	chr1:227000011	C/G	cg10327440	chr1:227177885	CDC42BPA	0.47	6.72	0.35	7.93e-11	Electrodermal activity;
LUSC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.25	-0.41	3.75e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4588572	0.643	rs10063742	chr5:77759362	A/G	cg11547950	chr5:77652471	NA	-0.56	-7.9	-0.4	4.03e-14	Triglycerides;
LUSC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg23788917	chr6:8435910	SLC35B3	-0.5	-7.42	-0.38	9.8e-13	Motion sickness;
LUSC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18402987	chr7:1209562	NA	0.47	6.13	0.32	2.54e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4308124	0.708	rs6747657	chr2:112003163	C/T	cg04571233	chr2:111982156	NA	-0.48	-6.37	-0.33	6.14e-10	Vitiligo;
LUSC	cis	rs9311676	0.656	rs62258140	chr3:58407083	C/T	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.3e-10	Systemic lupus erythematosus;
LUSC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg06046430	chr4:77819534	ANKRD56	0.49	7.16	0.36	5.01e-12	Emphysema distribution in smoking;
LUSC	cis	rs7572644	0.766	rs10495761	chr2:28235955	T/C	cg27432699	chr2:27873401	GPN1	0.52	6.44	0.33	4.19e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	1.07	20.32	0.74	2.41e-60	Cognitive ability;
LUSC	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg24449463	chr1:168025552	DCAF6	-0.64	-9.52	-0.46	3.62e-19	Schizophrenia;
LUSC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg02569458	chr12:86230093	RASSF9	0.58	9.82	0.47	3.54e-20	Major depressive disorder;
LUSC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg13385521	chr17:29058706	SUZ12P	0.65	6.32	0.33	8.37e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs11650494	0.908	rs75092916	chr17:47412578	T/C	cg08112188	chr17:47440006	ZNF652	1.22	10.07	0.48	5.39e-21	Prostate cancer;
LUSC	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg18721089	chr20:30220636	NA	-0.41	-6.57	-0.34	1.93e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs6426558	0.515	rs7412928	chr1:227332148	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.53	-7.25	-0.37	2.98e-12	Neutrophil percentage of white cells;
LUSC	cis	rs2153904	1.000	rs2153904	chr1:205642790	A/C	cg23034840	chr1:205782522	SLC41A1	0.56	6.38	0.33	5.87e-10	Prostate-specific antigen levels;
LUSC	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg20476274	chr7:133979776	SLC35B4	0.87	17.01	0.68	3.4e-47	Mean platelet volume;
LUSC	cis	rs59698941	0.709	rs58237345	chr5:132266351	T/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.36	-0.33	6.75e-10	Apolipoprotein A-IV levels;
LUSC	trans	rs10221833	1.000	rs441414	chr2:165675693	A/G	cg10323433	chr13:47471562	HTR2A	0.62	6.54	0.34	2.32e-10	Response to statin therapy;
LUSC	cis	rs4356932	0.967	rs13113632	chr4:76972516	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.86	0.31	1.14e-8	Blood protein levels;
LUSC	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.91	0.31	8.42e-9	Rheumatoid arthritis;
LUSC	cis	rs12618769	0.597	rs56197140	chr2:99113740	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.48	0.38	6.81e-13	Bipolar disorder;
LUSC	cis	rs9469578	1.000	rs73743326	chr6:33709980	C/A	cg18708504	chr6:33715942	IP6K3	0.72	9.23	0.45	3.08e-18	Phosphorus levels;
LUSC	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg19920283	chr7:105172520	RINT1	0.63	7.0	0.36	1.42e-11	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7264396	0.836	rs6120995	chr20:34185726	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-7.65	-0.39	2.17e-13	Total cholesterol levels;
LUSC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg10729496	chr3:10149963	C3orf24	0.49	6.14	0.32	2.34e-9	Alzheimer's disease;
LUSC	cis	rs1007190	0.570	rs7224712	chr17:42874218	G/T	cg15406952	chr17:42872593	NA	-0.59	-6.13	-0.32	2.45e-9	DNA methylation (variation);
LUSC	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg10840412	chr1:235813424	GNG4	0.63	8.71	0.43	1.4e-16	Bipolar disorder;
LUSC	cis	rs7570971	0.583	rs1375132	chr2:135954405	A/G	cg07169764	chr2:136633963	MCM6	0.51	6.73	0.35	7.42e-11	Blood metabolite levels;Body mass index;Cholesterol, total;
LUSC	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg02016764	chr4:38805732	TLR1	-0.53	-5.74	-0.3	2.16e-8	Breast cancer;
LUSC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	0.97	17.61	0.69	1.44e-49	Cognitive function;
LUSC	cis	rs11051970	0.679	rs2651377	chr12:32556919	A/C	cg02745156	chr12:32552066	NA	0.37	6.81	0.35	4.42e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2479724	0.870	rs7766960	chr6:41918190	T/G	cg17623882	chr6:41773611	USP49	-0.58	-9.45	-0.46	5.97e-19	Menarche (age at onset);
LUSC	cis	rs9303542	0.559	rs12602539	chr17:46617459	T/A	cg09704116	chr17:46666958	LOC404266	-0.38	-6.69	-0.34	9.51e-11	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs8077889	0.750	rs231533	chr17:41945588	A/G	cg26893861	chr17:41843967	DUSP3	-0.88	-11.11	-0.52	1.31e-24	Triglycerides;
LUSC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.38	6.32	0.33	8.5e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs909002	0.800	rs3753612	chr1:32082410	C/G	cg01639898	chr1:32083012	HCRTR1	0.3	7.42	0.38	1.01e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg19792802	chr11:65647270	CTSW	0.4	6.24	0.32	1.35e-9	Crohn's disease;
LUSC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg00945038	chr17:61921165	SMARCD2	0.4	6.1	0.32	2.88e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs478304	0.718	rs1144789	chr11:65389631	A/G	cg05805236	chr11:65401703	PCNXL3	0.48	7.88	0.4	4.69e-14	Acne (severe);
LUSC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	13.2	0.59	2.56e-32	Monocyte percentage of white cells;
LUSC	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.62	9.91	0.48	1.8899999999999998e-20	Blood metabolite ratios;
LUSC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg03676636	chr4:99064102	C4orf37	0.35	7.54	0.38	4.56e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.8	10.54	0.5	1.34e-22	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.49	0.5	1.86e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2274273	0.870	rs67514154	chr14:55767382	T/C	cg04306507	chr14:55594613	LGALS3	0.54	11.92	0.55	1.5e-27	Protein biomarker;
LUSC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg27494647	chr7:150038898	RARRES2	0.48	7.41	0.38	1.06e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg11965913	chr1:205819406	PM20D1	0.5	7.16	0.36	5.26e-12	Parkinson's disease;
LUSC	cis	rs4400599	1.000	rs3001363	chr1:154125067	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.36	5.86	0.31	1.09e-8	Platelet distribution width;
LUSC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg13395646	chr4:1353034	KIAA1530	-0.57	-8.6	-0.43	3.06e-16	Longevity;
LUSC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg08680598	chr22:49984980	NA	-0.34	-6.54	-0.34	2.31e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg08684580	chr7:98029266	BAIAP2L1	0.38	5.65	0.3	3.38e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.46	-8.0	-0.4	2.13e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.45	9.46	0.46	5.61e-19	Lymphocyte counts;
LUSC	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg22089800	chr15:90895588	ZNF774	0.55	8.02	0.4	1.79e-14	Rheumatoid arthritis;
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg27094323	chr7:1216898	NA	-0.44	-7.44	-0.38	8.32e-13	Longevity;Endometriosis;
LUSC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.75	-13.36	-0.59	6.48e-33	Cognitive function;
LUSC	cis	rs4974559	0.501	rs900013	chr4:1240450	G/A	cg02980000	chr4:1222292	CTBP1	-1.04	-10.42	-0.5	3.44e-22	Systolic blood pressure;
LUSC	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.11	-0.64	1.09e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs259282	0.605	rs8101007	chr19:33109557	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	9.58	0.46	2.27e-19	Schizophrenia;
LUSC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg02951883	chr7:2050386	MAD1L1	-0.59	-11.17	-0.52	8.06e-25	Bipolar disorder and schizophrenia;
LUSC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	10.83	0.51	1.25e-23	Homoarginine levels;
LUSC	cis	rs61990749	0.597	rs59848135	chr14:78129000	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.58	-6.17	-0.32	1.97e-9	Fibroblast growth factor basic levels;
LUSC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg03806693	chr22:41940476	POLR3H	0.99	13.49	0.59	2e-33	Vitiligo;
LUSC	cis	rs34638657	0.872	rs2967355	chr16:82200103	G/T	cg09439754	chr16:82129088	HSD17B2	0.39	6.07	0.32	3.4e-9	Lung adenocarcinoma;
LUSC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg21918786	chr6:109611834	NA	-0.42	-7.34	-0.37	1.6e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg02475777	chr4:1388615	CRIPAK	0.45	6.76	0.35	6.33e-11	Obesity-related traits;
LUSC	cis	rs7760535	0.656	rs1883136	chr6:111907023	G/T	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-8.77	-0.43	9.43e-17	Metabolic traits;
LUSC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-15.57	-0.65	1.75e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	8.86	0.44	4.77e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.75	14.7	0.63	4.6e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg11344533	chr11:111475393	SIK2	-0.49	-6.6	-0.34	1.59e-10	Primary sclerosing cholangitis;
LUSC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.78	0.57	1.04e-30	Prudent dietary pattern;
LUSC	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.63	9.83	0.47	3.32e-20	Morning vs. evening chronotype;
LUSC	cis	rs61869271	0.797	rs6585313	chr10:116745558	T/A	cg23260525	chr10:116636907	FAM160B1	0.3	5.79	0.3	1.61e-8	Tonsillectomy;
LUSC	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.79	0.3	1.6e-8	Breast cancer;
LUSC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	16.84	0.68	1.64e-46	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07677032	chr17:61819896	STRADA	0.53	8.99	0.44	1.89e-17	Prudent dietary pattern;
LUSC	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg23173402	chr1:227635558	NA	0.6	7.19	0.37	4.24e-12	Major depressive disorder;
LUSC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg18681998	chr4:17616180	MED28	-0.81	-14.11	-0.61	8.73e-36	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg02073558	chr3:44770973	ZNF501	-0.46	-7.27	-0.37	2.54e-12	Depressive symptoms;
LUSC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg13607699	chr17:42295918	UBTF	0.5	7.75	0.39	1.09e-13	Total body bone mineral density;
LUSC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg14416269	chr4:6271139	WFS1	0.54	11.38	0.53	1.35e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg21573476	chr21:45109991	RRP1B	0.4	6.67	0.34	1.09e-10	Mean corpuscular volume;
LUSC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.61	-0.43	2.98e-16	Lung cancer;
LUSC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.54	-8.18	-0.41	5.91e-15	IgG glycosylation;
LUSC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg27432699	chr2:27873401	GPN1	-0.58	-8.46	-0.42	8.46e-16	Total body bone mineral density;
LUSC	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-6.42	-0.33	4.73e-10	Red blood cell count;Reticulocyte count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25291941	chr8:99129319	POP1;HRSP12	-0.5	-6.49	-0.33	3.16e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg09359103	chr1:154839909	KCNN3	-0.7	-16.23	-0.66	4.49e-44	Prostate cancer;
LUSC	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg05754148	chr16:3507555	NAT15	0.43	5.68	0.3	2.94e-8	Body mass index (adult);
LUSC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	0.9	16.36	0.67	1.37e-44	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs35883536	0.626	rs80052576	chr1:101039229	A/G	cg06223162	chr1:101003688	GPR88	-0.47	-8.99	-0.44	1.89e-17	Monocyte count;
LUSC	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg17366294	chr4:99064904	C4orf37	0.55	9.03	0.44	1.42e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4889855	0.614	rs9892081	chr17:78484484	A/C	cg16591659	chr17:78472290	NA	0.45	7.58	0.38	3.53e-13	Fractional excretion of uric acid;
LUSC	trans	rs6445975	0.666	rs6767291	chr3:58408910	C/T	cg18950693	chr14:70346909	SMOC1	-0.4	-6.06	-0.31	3.75e-9	Systemic lupus erythematosus;
LUSC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	8.98	0.44	2.09e-17	Post bronchodilator FEV1;
LUSC	cis	rs9473147	0.843	rs7772202	chr6:47621579	G/A	cg12968598	chr6:47444699	CD2AP	0.39	5.88	0.31	9.81e-9	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg26043149	chr18:55253948	FECH	0.48	7.32	0.37	1.85e-12	Bone mineral density;
LUSC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg26408565	chr15:76604113	ETFA	-0.52	-8.47	-0.42	7.93e-16	Blood metabolite levels;
LUSC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg20203395	chr5:56204925	C5orf35	0.57	8.17	0.41	6.39e-15	Initial pursuit acceleration;
LUSC	cis	rs7106204	0.514	rs7126508	chr11:24255147	G/A	ch.11.24196551F	chr11:24239977	NA	0.92	10.2	0.49	1.98e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs6087990	0.735	rs1855350	chr20:31387525	C/T	cg13636640	chr20:31349939	DNMT3B	0.93	18.92	0.72	8.99e-55	Ulcerative colitis;
LUSC	cis	rs1957429	0.901	rs8009996	chr14:65351582	A/G	cg23373153	chr14:65346875	NA	1.05	12.67	0.57	2.53e-30	Pediatric areal bone mineral density (radius);
LUSC	cis	rs6076065	0.707	rs12349	chr20:23352480	A/G	cg11657817	chr20:23433608	CST11	0.54	11.13	0.52	1.05e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs11030122	0.645	rs11493482	chr11:4034772	A/G	cg18678763	chr11:4115507	RRM1	-0.47	-6.12	-0.32	2.58e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg24060327	chr5:131705240	SLC22A5	0.66	11.0	0.52	3.24e-24	Breast cancer;
LUSC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg11632617	chr15:75315747	PPCDC	-0.51	-6.68	-0.34	9.77e-11	Blood trace element (Zn levels);
LUSC	cis	rs3862435	0.764	rs79900358	chr15:90993295	A/G	cg22089800	chr15:90895588	ZNF774	0.57	5.97	0.31	5.95e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg12463550	chr7:65579703	CRCP	-0.42	-6.12	-0.32	2.63e-9	Aortic root size;
LUSC	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg00277334	chr10:82204260	NA	-0.95	-20.77	-0.75	4.31e-62	Post bronchodilator FEV1;
LUSC	trans	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	6.81	0.35	4.48e-11	Systemic lupus erythematosus;
LUSC	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.56	9.03	0.44	1.42e-17	Schizophrenia;
LUSC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23158103	chr7:148848205	ZNF398	-0.45	-7.31	-0.37	1.97e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26314531	chr2:26401878	FAM59B	-0.66	-9.25	-0.45	2.84e-18	Gut microbiome composition (summer);
LUSC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.92	0.35	2.31e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg04775059	chr7:64541387	NA	0.47	6.83	0.35	4.05e-11	Calcium levels;
LUSC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg03128945	chr5:622914	CEP72	0.34	5.83	0.3	1.29e-8	Obesity-related traits;
LUSC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.2	0.32	1.68e-9	Platelet count;
LUSC	cis	rs11650494	0.808	rs76366926	chr17:47396628	T/C	cg08112188	chr17:47440006	ZNF652	1.25	10.63	0.5	6.24e-23	Prostate cancer;
LUSC	trans	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg04565464	chr8:145669602	NFKBIL2	0.39	6.42	0.33	4.75e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.65e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.37e-9	Life satisfaction;
LUSC	cis	rs35883536	0.588	rs955338	chr1:101108794	G/C	cg06223162	chr1:101003688	GPR88	0.35	6.3	0.33	9.2e-10	Monocyte count;
LUSC	cis	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg06521331	chr12:34319734	NA	-0.43	-7.13	-0.36	6.1e-12	Morning vs. evening chronotype;
LUSC	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.53	-10.12	-0.48	3.59e-21	Schizophrenia;
LUSC	cis	rs1044826	0.667	rs295471	chr3:139213922	G/C	cg15131784	chr3:139108705	COPB2	0.39	6.36	0.33	6.82e-10	Obesity-related traits;
LUSC	cis	rs72829446	0.530	rs9646411	chr17:7398909	A/G	cg02795151	chr17:7402630	POLR2A	-0.58	-7.04	-0.36	1.08e-11	Androgen levels;
LUSC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.31	-5.81	-0.3	1.47e-8	IgG glycosylation;
LUSC	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.93	15.94	0.66	5.93e-43	Bladder cancer;
LUSC	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	0.98	19.49	0.73	4.9e-57	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs354225	0.553	rs7564719	chr2:54829731	A/C	cg26097391	chr2:54893211	SPTBN1	0.43	6.54	0.34	2.35e-10	Schizophrenia;
LUSC	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg03474202	chr17:45855739	NA	-0.29	-6.52	-0.34	2.58e-10	IgG glycosylation;
LUSC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg17143192	chr8:8559678	CLDN23	0.59	8.43	0.42	1.07e-15	Obesity-related traits;
LUSC	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg11871910	chr12:69753446	YEATS4	0.44	5.82	0.3	1.37e-8	Response to diuretic therapy;
LUSC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.33	0.37	1.78e-12	Motion sickness;
LUSC	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-9.68	-0.47	1.09e-19	Hemoglobin concentration;
LUSC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg04369109	chr6:150039330	LATS1	-0.58	-8.44	-0.42	9.96e-16	Lung cancer;
LUSC	cis	rs2273669	0.588	rs111773102	chr6:109306480	C/T	cg05315195	chr6:109294784	ARMC2	-0.55	-6.21	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs72781680	0.752	rs72796114	chr2:23906133	C/G	cg20701182	chr2:24300061	SF3B14	0.73	7.06	0.36	9.63e-12	Lymphocyte counts;
LUSC	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg26395211	chr5:140044315	WDR55	-0.37	-5.7	-0.3	2.69e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg06636001	chr8:8085503	FLJ10661	0.55	8.04	0.4	1.6e-14	Neuroticism;
LUSC	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg09491104	chr22:46646882	C22orf40	-0.61	-8.56	-0.42	4.16e-16	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06481639	chr22:41940642	POLR3H	0.48	5.72	0.3	2.37e-8	Vitiligo;
LUSC	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg16346588	chr10:242978	ZMYND11	-0.44	-5.88	-0.31	9.73e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg08000102	chr2:233561755	GIGYF2	-0.49	-7.67	-0.39	1.92e-13	Coronary artery disease;
LUSC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg23262073	chr20:60523788	NA	-0.39	-5.77	-0.3	1.79e-8	Body mass index;
LUSC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg02187348	chr16:89574699	SPG7	0.51	6.91	0.35	2.39e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg09163369	chr1:210001066	C1orf107	-0.56	-6.19	-0.32	1.8e-9	Orofacial clefts;
LUSC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg06618935	chr21:46677482	NA	-0.4	-7.68	-0.39	1.74e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11630290	0.592	rs11071769	chr15:64156842	G/C	cg12036633	chr15:63758958	NA	0.53	6.74	0.35	7.13e-11	Iris characteristics;
LUSC	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.67	-0.5	4.42e-23	Glomerular filtration rate;
LUSC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03517284	chr6:25882590	NA	-0.52	-9.66	-0.47	1.21e-19	Blood metabolite levels;
LUSC	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg00757033	chr12:89920650	WDR51B	0.6	10.33	0.49	7.01e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs77972916	0.505	rs3851318	chr2:43532808	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.46	-5.91	-0.31	8.43e-9	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.75	-0.35	6.58e-11	Triglycerides;
LUSC	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.08	23.28	0.79	6.73e-72	Colorectal cancer;
LUSC	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg11887960	chr12:57824829	NA	0.58	7.05	0.36	1.05e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs909002	0.800	rs4949454	chr1:32099041	A/G	cg01639898	chr1:32083012	HCRTR1	-0.31	-7.61	-0.38	2.74e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg04450456	chr4:17643702	FAM184B	0.39	6.51	0.34	2.77e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1998174	0.509	rs6657315	chr1:171827283	G/T	cg13482142	chr2:234261155	NA	0.42	6.09	0.32	3.11e-9	Platelet distribution width;
LUSC	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg02187348	chr16:89574699	SPG7	0.51	7.12	0.36	6.76e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg01879757	chr17:41196368	BRCA1	0.5	8.11	0.41	9.96e-15	Menopause (age at onset);
LUSC	cis	rs16949788	0.793	rs78483581	chr15:66769365	C/T	cg08120210	chr15:66682733	MAP2K1	-0.63	-6.52	-0.34	2.56e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg06784218	chr1:46089804	CCDC17	-0.57	-11.23	-0.52	4.96e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg10792982	chr14:105748885	BRF1	0.49	9.0	0.44	1.75e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg24375607	chr4:120327624	NA	0.77	11.46	0.53	7.47e-26	Corneal astigmatism;
LUSC	trans	rs75763843	0.941	rs12456054	chr18:42077425	A/G	cg12620806	chr12:5602045	NTF3	0.51	6.07	0.32	3.39e-9	Mean platelet volume;
LUSC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg21918786	chr6:109611834	NA	-0.41	-7.21	-0.37	3.87e-12	Reticulocyte fraction of red cells;
LUSC	trans	rs1268789	0.545	rs753752	chr4:79372930	C/T	cg06112894	chr8:141469983	TRAPPC9	0.23	6.2	0.32	1.71e-9	Hair shape;Hair morphology;
LUSC	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg23422044	chr7:1970798	MAD1L1	-0.55	-6.07	-0.32	3.53e-9	Bipolar disorder;
LUSC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-1.03	-20.07	-0.74	2.43e-59	Height;
LUSC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg00484396	chr16:3507460	NAT15	0.88	11.59	0.54	2.45e-26	Tuberculosis;
LUSC	cis	rs1858037	0.867	rs1553675	chr2:65570307	C/T	cg08085232	chr2:65598271	SPRED2	0.39	5.91	0.31	8.43e-9	Rheumatoid arthritis;
LUSC	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.13	0.32	2.49e-9	Corneal astigmatism;
LUSC	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-9.33	-0.45	1.55e-18	Retinal vascular caliber;
LUSC	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.6	-8.16	-0.41	7.03e-15	Body mass index (adult);
LUSC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg03579872	chr1:53393473	SCP2	-0.39	-5.77	-0.3	1.86e-8	Monocyte count;
LUSC	cis	rs7215564	0.908	rs4889783	chr17:78667160	C/T	cg23238734	chr17:78661607	RPTOR	0.49	6.43	0.33	4.46e-10	Myopia (pathological);
LUSC	cis	rs2357013	0.752	rs12474925	chr2:53176117	C/A	cg07782112	chr2:53107842	NA	-0.39	-6.25	-0.32	1.23e-9	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs354225	0.565	rs2971880	chr2:54885640	A/T	cg26097391	chr2:54893211	SPTBN1	0.4	6.65	0.34	1.22e-10	Schizophrenia;
LUSC	cis	rs4664304	0.903	rs72957576	chr2:160754132	A/C	cg03641300	chr2:160917029	PLA2R1	-0.4	-6.48	-0.33	3.26e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.69	10.11	0.48	3.78e-21	Menopause (age at onset);
LUSC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg24209194	chr3:40518798	ZNF619	0.46	6.17	0.32	1.95e-9	Renal cell carcinoma;
LUSC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg25456477	chr12:86230367	RASSF9	0.33	5.71	0.3	2.53e-8	Major depressive disorder;
LUSC	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg18811423	chr2:55921094	PNPT1	-0.64	-9.03	-0.44	1.38e-17	Metabolic syndrome;
LUSC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg19046167	chr17:80928561	B3GNTL1	-0.37	-6.02	-0.31	4.52e-9	Glycated hemoglobin levels;
LUSC	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.88	0.31	9.75e-9	Rheumatoid arthritis;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg15687138	chr1:151138326	SCNM1;LYSMD1	0.4	6.29	0.33	9.77e-10	Triglycerides;
LUSC	cis	rs7575217	0.670	rs2592392	chr2:101723343	A/G	cg23907051	chr2:101730305	TBC1D8	0.28	7.5	0.38	5.79e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg13798780	chr7:105162888	PUS7	0.56	6.04	0.31	4.06e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg13798780	chr7:105162888	PUS7	0.56	6.15	0.32	2.23e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg16989719	chr2:238392110	NA	-0.5	-6.3	-0.33	9.42e-10	Prostate cancer;
LUSC	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.18e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06022373	chr22:39101656	GTPBP1	0.71	10.27	0.49	1.1e-21	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07362569	chr17:61921086	SMARCD2	0.37	7.61	0.38	2.87e-13	Prudent dietary pattern;
LUSC	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.64	0.39	2.3e-13	Corneal astigmatism;
LUSC	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	7.08	0.36	8.51e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg04374321	chr14:90722782	PSMC1	0.75	12.1	0.55	3.52e-28	Mortality in heart failure;
LUSC	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg25344623	chr2:136566232	LCT	0.38	5.69	0.3	2.76e-8	Mosquito bite size;
LUSC	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg00376283	chr12:123451042	ABCB9	0.7	7.92	0.4	3.67e-14	Neutrophil percentage of white cells;
LUSC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg25019033	chr10:957182	NA	-0.51	-7.0	-0.36	1.38e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg03806693	chr22:41940476	POLR3H	-0.87	-12.53	-0.57	8.73e-30	Vitiligo;
LUSC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg13535736	chr9:111863775	C9orf5	0.38	6.02	0.31	4.5e-9	Menarche (age at onset);
LUSC	cis	rs9400467	0.528	rs459403	chr6:111653877	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.69	-0.34	9.43e-11	Blood metabolite levels;Amino acid levels;
LUSC	trans	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.57	-8.89	-0.44	3.92e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs75920871	0.748	rs61905689	chr11:116869217	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.91	-0.31	8.23e-9	Subjective well-being;
LUSC	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.61	-0.69	1.49e-49	Exhaled nitric oxide output;
LUSC	cis	rs2667011	0.512	rs10929960	chr2:160815141	A/C	cg06573604	chr2:160760825	LY75	0.45	6.27	0.32	1.14e-9	Bilirubin levels;
LUSC	cis	rs273573	1.000	rs158505	chr11:30981248	T/C	cg14844989	chr11:31128820	NA	0.38	6.11	0.32	2.84e-9	Total body bone mineral density;
LUSC	trans	rs9380880	0.826	rs12198307	chr6:39550197	C/T	cg09045552	chr2:169506620	LASS6	0.73	6.56	0.34	2.11e-10	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.45	6.62	0.34	1.44e-10	Systemic lupus erythematosus;
LUSC	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.98	-0.31	5.86e-9	IgG glycosylation;
LUSC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	12.6	0.57	4.85e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg25011763	chr5:6727354	POLS	-0.37	-6.43	-0.33	4.3e-10	Menopause (age at onset);
LUSC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg14004847	chr7:1930337	MAD1L1	0.5	7.68	0.39	1.83e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg26513180	chr16:89883248	FANCA	0.79	6.37	0.33	6.26e-10	Skin colour saturation;
LUSC	cis	rs9473147	0.516	rs9349416	chr6:47551938	G/A	cg12968598	chr6:47444699	CD2AP	0.52	7.93	0.4	3.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg13852791	chr20:30311386	BCL2L1	0.94	14.43	0.62	5.13e-37	Mean corpuscular hemoglobin;
LUSC	trans	rs6601327	0.573	rs13278824	chr8:9646119	T/A	cg06636001	chr8:8085503	FLJ10661	0.51	7.52	0.38	5.26e-13	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg03651054	chr13:50194643	NA	0.36	6.2	0.32	1.71e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg17470449	chr10:769945	NA	0.53	7.13	0.36	6.24e-12	Uric acid levels;
LUSC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg12292205	chr6:26970375	C6orf41	0.51	8.56	0.42	4.13e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg05805236	chr11:65401703	PCNXL3	-0.38	-6.39	-0.33	5.47e-10	Acne (severe);
LUSC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.51	-0.34	2.8e-10	Monocyte count;
LUSC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11890956	chr21:40555474	PSMG1	1.0	18.39	0.71	1.19e-52	Cognitive function;
LUSC	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg25124228	chr12:125621409	AACS	-0.55	-8.34	-0.42	1.97e-15	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg06521331	chr12:34319734	NA	-0.45	-7.21	-0.37	3.74e-12	Morning vs. evening chronotype;
LUSC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg21573476	chr21:45109991	RRP1B	0.39	6.31	0.33	9.08e-10	Mean corpuscular volume;
LUSC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.2	22.43	0.78	1.32e-68	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	1.13	19.75	0.73	4.46e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg00745463	chr17:30367425	LRRC37B	-0.64	-8.13	-0.41	8.64e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg00310523	chr12:86230176	RASSF9	0.4	7.15	0.36	5.35e-12	Major depressive disorder;
LUSC	cis	rs7923609	0.935	rs10995477	chr10:65010672	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.59	-0.34	1.72e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg07211511	chr3:129823064	LOC729375	-0.75	-9.75	-0.47	6.42e-20	Blood pressure (smoking interaction);
LUSC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.81	0.47	4.05e-20	Bipolar disorder;
LUSC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg17330251	chr7:94953956	PON1	-0.38	-5.92	-0.31	7.8e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs10465746	0.935	rs4258241	chr1:84437929	G/A	cg10977910	chr1:84465055	TTLL7	0.41	6.05	0.31	3.81e-9	Obesity-related traits;
LUSC	cis	rs12900413	0.687	rs8035472	chr15:90313432	T/C	cg24249390	chr15:90295951	MESP1	-0.37	-5.9	-0.31	8.74e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.83	0.35	4.05e-11	Height;
LUSC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg24642844	chr7:1081250	C7orf50	-0.76	-10.03	-0.48	7.28e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg26304593	chr6:42947056	PEX6	-0.49	-7.33	-0.37	1.74e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6496667	0.600	rs28674812	chr15:91077809	G/T	cg04176472	chr15:90893244	GABARAPL3	0.39	5.7	0.3	2.65e-8	Rheumatoid arthritis;
LUSC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.1	0.55	3.33e-28	Cognitive test performance;
LUSC	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg11645453	chr3:52864694	ITIH4	0.39	9.35	0.46	1.31e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg21724239	chr8:58056113	NA	0.76	8.17	0.41	6.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg23260525	chr10:116636907	FAM160B1	0.44	9.43	0.46	7.04e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.74	12.09	0.55	3.59e-28	Lymphocyte percentage of white cells;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13155599	chr4:120221765	C4orf3	-0.48	-5.95	-0.31	6.62e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.67	0.6	4.32e-34	Alzheimer's disease;
LUSC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.37	0.37	1.32e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	0.92	15.84	0.66	1.49e-42	Menopause (age at onset);
LUSC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg03433033	chr1:76189801	ACADM	-0.4	-6.05	-0.31	3.89e-9	Daytime sleep phenotypes;
LUSC	cis	rs7084921	0.608	rs2862950	chr10:101844785	A/G	cg11888571	chr10:102027403	CWF19L1	-0.45	-6.23	-0.32	1.44e-9	Bone mineral density;
LUSC	cis	rs8064299	0.597	rs3785539	chr17:72775099	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.91	17.9	0.7	1.06e-50	Monocyte count;
LUSC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.42	7.96	0.4	2.79e-14	Monocyte percentage of white cells;
LUSC	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.61	-0.43	2.97e-16	Total cholesterol levels;
LUSC	cis	rs7193541	0.673	rs12716769	chr16:74652537	T/C	cg01733217	chr16:74700730	RFWD3	1.02	23.17	0.79	1.77e-71	Multiple myeloma;
LUSC	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.92	15.76	0.65	3.19e-42	Bladder cancer;
LUSC	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg03060546	chr3:49711283	APEH	-0.62	-7.29	-0.37	2.32e-12	Menarche (age at onset);
LUSC	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg22117172	chr7:91764530	CYP51A1	0.31	5.7	0.3	2.7e-8	Breast cancer;
LUSC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20307385	chr11:47447363	PSMC3	-0.45	-5.9	-0.31	8.95e-9	Subjective well-being;
LUSC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20135002	chr11:47629003	NA	-0.51	-8.1	-0.41	1.06e-14	Subjective well-being;
LUSC	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	8.69	0.43	1.71e-16	Monocyte percentage of white cells;
LUSC	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg12940439	chr1:67600707	NA	0.35	6.12	0.32	2.56e-9	Psoriasis;
LUSC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg05861140	chr6:150128134	PCMT1	-0.4	-6.41	-0.33	4.86e-10	Lung cancer;
LUSC	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.32	-5.76	-0.3	1.88e-8	IgG glycosylation;
LUSC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7818345	1.000	rs6984145	chr8:19294111	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.17	0.37	4.73e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs2637266	0.626	rs2583067	chr10:78555804	A/G	cg18941641	chr10:78392320	NA	0.38	7.03	0.36	1.19e-11	Pulmonary function;
LUSC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg06808227	chr14:105710500	BRF1	0.66	10.17	0.49	2.49e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	11.86	0.54	2.68e-27	Prudent dietary pattern;
LUSC	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09307838	chr4:120376055	NA	0.76	10.41	0.49	3.77e-22	Corneal astigmatism;
LUSC	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.14	-0.45	6.2e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.74e-15	Neuroticism;
LUSC	cis	rs3106136	0.527	rs2632411	chr4:95149434	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.54	-0.42	4.89e-16	Capecitabine sensitivity;
LUSC	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.16	0.32	2.1e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg10018233	chr7:150070692	REPIN1	0.39	6.42	0.33	4.81e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.72	9.75	0.47	6.34e-20	Platelet count;
LUSC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg04546413	chr19:29218101	NA	0.62	8.12	0.41	8.94e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs7615316	0.844	rs13069307	chr3:142315074	G/A	cg16271453	chr3:142027066	XRN1	-0.36	-6.03	-0.31	4.41e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg15147215	chr3:52552868	STAB1	-0.29	-5.74	-0.3	2.09e-8	Electroencephalogram traits;
LUSC	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.53	0.46	3.28e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg12432903	chr7:1882776	MAD1L1	-0.39	-6.2	-0.32	1.66e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6714710	0.603	rs7583868	chr2:98588372	C/A	cg26665480	chr2:98280029	ACTR1B	0.56	8.1	0.41	1.06e-14	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs11671005	0.735	rs12977592	chr19:58961056	C/G	cg13877915	chr19:58951672	ZNF132	0.44	5.83	0.3	1.32e-8	Mean platelet volume;
LUSC	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg25173405	chr17:45401733	C17orf57	-0.4	-5.97	-0.31	5.91e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs7830057	0.786	rs28444271	chr8:101438231	C/T	cg18795127	chr10:135212911	MTG1	-0.41	-6.06	-0.31	3.76e-9	Asthma;
LUSC	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg26647111	chr11:31128758	NA	0.41	6.04	0.31	4.07e-9	Red blood cell count;
LUSC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-1.04	-20.3	-0.74	2.97e-60	Height;
LUSC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg14895029	chr7:2775587	GNA12	-0.4	-6.08	-0.32	3.24e-9	Height;
LUSC	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.53	7.59	0.38	3.19e-13	Breast cancer;
LUSC	trans	rs1927790	0.727	rs4771932	chr13:96950542	G/A	cg03198741	chr6:1003969	LOC285768	-0.4	-5.99	-0.31	5.52e-9	Body mass index;
LUSC	cis	rs10761482	0.701	rs12411733	chr10:62123046	A/G	cg18175470	chr10:62150864	ANK3	-0.42	-6.3	-0.33	9.19e-10	Schizophrenia;
LUSC	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg05855489	chr10:104503620	C10orf26	0.52	8.08	0.4	1.19e-14	Arsenic metabolism;
LUSC	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg17173187	chr15:85201210	NMB	0.5	8.75	0.43	1.09e-16	Schizophrenia;
LUSC	cis	rs2425143	1.000	rs6060639	chr20:34438183	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.11	-0.32	2.85e-9	Blood protein levels;
LUSC	trans	rs12571093	0.803	rs61854829	chr10:70033043	A/G	cg04882175	chr6:131122610	NA	-0.57	-6.55	-0.34	2.23e-10	Optic nerve measurement (disc area);
LUSC	cis	rs34526934	0.608	rs2857539	chr2:177024863	G/A	cg26754761	chr2:177040938	NA	-0.39	-7.64	-0.39	2.34e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg14895029	chr7:2775587	GNA12	-0.36	-5.67	-0.3	3.05e-8	Height;
LUSC	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg21918786	chr6:109611834	NA	-0.36	-6.25	-0.32	1.25e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs597583	1.000	rs521609	chr11:117407301	C/T	cg27161313	chr11:117392002	DSCAML1	-0.39	-6.63	-0.34	1.33e-10	Putamen volume;
LUSC	cis	rs12760731	0.565	rs11580064	chr1:178226520	A/G	cg00404053	chr1:178313656	RASAL2	0.65	6.66	0.34	1.12e-10	Obesity-related traits;
LUSC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg18230493	chr5:56204884	C5orf35	0.77	12.52	0.57	9.66e-30	Initial pursuit acceleration;
LUSC	cis	rs9503598	0.714	rs7758776	chr6:3452245	C/T	cg00476032	chr6:3446245	SLC22A23	0.39	8.31	0.41	2.52e-15	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg17509989	chr5:176798049	RGS14	-0.68	-9.35	-0.46	1.26e-18	Urate levels in lean individuals;
LUSC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.3	0.69	2.6e-48	Chronic sinus infection;
LUSC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg26752003	chr8:145688521	CYHR1	-0.68	-11.68	-0.54	1.14e-26	Age at first birth;
LUSC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.83	14.05	0.61	1.51e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg06713675	chr4:122721982	EXOSC9	-0.57	-9.88	-0.48	2.29e-20	Type 2 diabetes;
LUSC	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg01448562	chr3:133502909	NA	-0.58	-9.11	-0.45	7.96e-18	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg02466173	chr16:30829666	NA	-0.53	-8.69	-0.43	1.69e-16	Dementia with Lewy bodies;
LUSC	cis	rs4766646	0.542	rs7963600	chr12:110276689	A/C	cg10794374	chr12:110278745	NA	-0.29	-6.25	-0.32	1.26e-9	Metabolite levels (MHPG);
LUSC	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg07167872	chr1:205819463	PM20D1	0.43	5.92	0.31	7.89e-9	Menarche (age at onset);
LUSC	cis	rs59698941	0.882	rs56353702	chr5:132248575	A/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.82	-0.3	1.35e-8	Type 2 diabetes;
LUSC	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg00074818	chr8:8560427	CLDN23	0.59	9.95	0.48	1.32e-20	Obesity-related traits;
LUSC	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.2e-28	Corneal astigmatism;
LUSC	cis	rs738321	0.757	rs3788535	chr22:38534045	T/C	cg25457927	chr22:38595422	NA	-0.38	-7.18	-0.37	4.69e-12	Breast cancer;
LUSC	cis	rs1256061	0.603	rs1256037	chr14:64743301	G/A	cg21174375	chr14:64681225	SYNE2	0.35	6.26	0.32	1.18e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg14092571	chr14:90743983	NA	0.35	5.65	0.3	3.37e-8	Mortality in heart failure;
LUSC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.14	13.35	0.59	6.87e-33	Diabetic kidney disease;
LUSC	cis	rs9361491	0.508	rs9343787	chr6:79415606	A/C	cg05283184	chr6:79620031	NA	-0.39	-6.9	-0.35	2.66e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg04310649	chr10:35416472	CREM	-0.42	-6.43	-0.33	4.42e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-10.49	-0.5	1.97e-22	Gut microbiome composition (summer);
LUSC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg10253484	chr15:75165896	SCAMP2	-0.44	-6.19	-0.32	1.73e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.4	5.92	0.31	8.08e-9	Longevity;Endometriosis;
LUSC	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg18721089	chr20:30220636	NA	-0.35	-5.94	-0.31	7.31e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6500395	0.890	rs11861666	chr16:48679914	G/T	cg04672837	chr16:48644449	N4BP1	0.44	6.35	0.33	6.99e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg21573476	chr21:45109991	RRP1B	-0.4	-6.42	-0.33	4.78e-10	Mean corpuscular volume;
LUSC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	1.04	20.08	0.74	2.21e-59	Menopause (age at onset);
LUSC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg17724175	chr1:150552817	MCL1	0.36	6.53	0.34	2.45e-10	Tonsillectomy;
LUSC	cis	rs11603020	0.950	rs11229063	chr11:57369730	G/A	cg23127183	chr11:57508653	C11orf31	-0.46	-6.37	-0.33	6.21e-10	Blood protein levels;
LUSC	cis	rs59104589	0.535	rs73002160	chr2:242321707	A/C	cg14842376	chr2:242211374	HDLBP	0.56	6.53	0.34	2.48e-10	Fibrinogen levels;
LUSC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg27170947	chr2:26402098	FAM59B	0.64	8.95	0.44	2.53e-17	Gut microbiome composition (summer);
LUSC	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg03465714	chr1:152285911	FLG	-0.42	-5.85	-0.3	1.17e-8	Atopic dermatitis;
LUSC	cis	rs6942756	0.956	rs7792317	chr7:128963971	G/A	cg02491457	chr7:128862824	NA	-0.48	-6.47	-0.33	3.56e-10	White matter hyperintensity burden;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23441208	chr19:49314192	BCAT2	-0.39	-5.98	-0.31	5.8e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs698813	0.604	rs7565928	chr2:44489956	T/C	cg00619915	chr2:44497795	NA	-0.54	-7.49	-0.38	6.35e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg02187348	chr16:89574699	SPG7	0.52	7.08	0.36	8.72e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg16228356	chr17:43848958	NA	-0.29	-6.21	-0.32	1.55e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs4343996	0.840	rs4131987	chr7:3380895	C/T	cg21248987	chr7:3385318	SDK1	-0.42	-6.94	-0.36	2e-11	Motion sickness;
LUSC	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg24558204	chr6:135376177	HBS1L	0.58	8.82	0.43	6.45e-17	Red blood cell count;
LUSC	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg05347473	chr6:146136440	FBXO30	0.51	8.45	0.42	9.3e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.97	-0.4	2.62e-14	Lymphocyte counts;
LUSC	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.47e-8	Breast cancer;
LUSC	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg13390004	chr1:15929781	NA	0.42	7.04	0.36	1.07e-11	Systolic blood pressure;
LUSC	cis	rs977987	0.806	rs4146809	chr16:75415775	A/G	cg03315344	chr16:75512273	CHST6	-0.47	-8.8	-0.43	7.48e-17	Dupuytren's disease;
LUSC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06544989	chr22:39130855	UNC84B	0.33	5.87	0.31	1.07e-8	Menopause (age at onset);
LUSC	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg15819921	chr19:927150	ARID3A	-0.44	-6.42	-0.33	4.77e-10	Life satisfaction;
LUSC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg09904177	chr6:26538194	HMGN4	-0.44	-6.51	-0.34	2.7e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg12620499	chr2:216877984	MREG	0.9	13.84	0.6	9.37e-35	Alcohol dependence;
LUSC	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg03894339	chr8:19674705	INTS10	0.5	6.77	0.35	5.76e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4144743	1.000	rs4144743	chr17:45323125	A/G	cg18085866	chr17:45331354	ITGB3	-0.68	-7.6	-0.38	3.03e-13	Body mass index;
LUSC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	trans	rs72742734	0.731	rs2302955	chr5:32735532	T/A	cg16345559	chr2:213933386	IKZF2	-0.66	-6.01	-0.31	4.84e-9	Height;
LUSC	cis	rs8141797	0.901	rs76376425	chr22:24523177	C/T	cg00411358	chr22:24577142	SUSD2	-0.58	-5.75	-0.3	1.97e-8	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-11.57	-0.53	2.96e-26	Monocyte count;
LUSC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.83	14.58	0.62	1.35e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.76e-12	Type 2 diabetes;
LUSC	trans	rs459571	0.920	rs417142	chr9:136891370	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-12.39	-0.56	2.77e-29	Platelet distribution width;
LUSC	cis	rs754466	0.914	rs4595491	chr10:79685833	G/A	cg17075019	chr10:79541650	NA	-0.63	-8.23	-0.41	4.17e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg02772935	chr3:125709198	NA	-0.49	-5.88	-0.31	9.95e-9	Blood pressure (smoking interaction);
LUSC	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg13010199	chr12:38710504	ALG10B	0.41	6.03	0.31	4.46e-9	Morning vs. evening chronotype;
LUSC	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg09835421	chr16:68378352	PRMT7	-0.76	-8.71	-0.43	1.47e-16	Schizophrenia;
LUSC	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg11812906	chr14:75593930	NEK9	0.64	10.47	0.5	2.28e-22	Height;
LUSC	trans	rs11671005	0.504	rs2305119	chr19:59067623	C/T	cg22037779	chr5:139682734	PFDN1	-0.56	-7.31	-0.37	1.96e-12	Mean platelet volume;
LUSC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	ch.11.42038R	chr11:967971	AP2A2	0.41	6.01	0.31	4.97e-9	Alzheimer's disease (late onset);
LUSC	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg11473876	chr11:109292803	C11orf87	0.41	6.58	0.34	1.78e-10	Schizophrenia;
LUSC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg08807101	chr21:30365312	RNF160	0.71	11.66	0.54	1.4e-26	Selective IgA deficiency;
LUSC	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg20307385	chr11:47447363	PSMC3	-0.47	-7.02	-0.36	1.24e-11	Subjective well-being;
LUSC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06634786	chr22:41940651	POLR3H	-0.57	-6.44	-0.33	4.11e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg25214090	chr10:38739885	LOC399744	0.5	7.32	0.37	1.88e-12	Corneal astigmatism;
LUSC	cis	rs7572733	0.534	rs6434943	chr2:198762192	T/G	cg00792783	chr2:198669748	PLCL1	0.46	6.13	0.32	2.47e-9	Dermatomyositis;
LUSC	cis	rs4343996	1.000	rs10238520	chr7:3341615	G/A	cg21248987	chr7:3385318	SDK1	0.4	6.83	0.35	4.07e-11	Motion sickness;
LUSC	cis	rs2200578	1.000	rs72961173	chr2:99886868	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.61	7.16	0.36	5.11e-12	IgG glycosylation;
LUSC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.75	-10.27	-0.49	1.06e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.42	5.97	0.31	5.95e-9	Schizophrenia;
LUSC	cis	rs72960926	0.744	rs72952275	chr6:74926492	A/G	cg03266952	chr6:74778945	NA	-0.84	-7.01	-0.36	1.34e-11	Metabolite levels (MHPG);
LUSC	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg13390004	chr1:15929781	NA	0.36	6.09	0.32	3.05e-9	Systolic blood pressure;
LUSC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg22903471	chr2:27725779	GCKR	-0.4	-6.79	-0.35	5.14e-11	Total body bone mineral density;
LUSC	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.84	-0.3	1.21e-8	Ileal carcinoids;
LUSC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03517284	chr6:25882590	NA	-0.43	-7.39	-0.38	1.16e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6489785	0.687	rs3213567	chr12:121222556	T/C	cg02403541	chr12:121454288	C12orf43	0.39	5.75	0.3	2.03e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs240764	0.853	rs10457808	chr6:100979506	A/T	cg09795085	chr6:101329169	ASCC3	-0.43	-6.32	-0.33	8.47e-10	Neuroticism;
LUSC	cis	rs11264799	0.554	rs59424684	chr1:157586990	G/A	cg18268488	chr1:157545234	FCRL4	0.36	6.21	0.32	1.61e-9	IgA nephropathy;
LUSC	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg00383909	chr3:49044727	WDR6	1.14	10.58	0.5	9.36e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.06e-12	Motion sickness;
LUSC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg06008330	chr7:65541103	ASL	-0.41	-6.39	-0.33	5.74e-10	Aortic root size;
LUSC	cis	rs2637266	0.655	rs861744	chr10:78519132	T/G	cg18941641	chr10:78392320	NA	0.39	7.12	0.36	6.8e-12	Pulmonary function;
LUSC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg14773178	chr5:1868261	NA	0.33	6.26	0.32	1.19e-9	Cardiovascular disease risk factors;
LUSC	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.78	13.42	0.59	3.95e-33	Height;
LUSC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg09877947	chr5:131593287	PDLIM4	0.4	6.89	0.35	2.72e-11	Blood metabolite levels;
LUSC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg05868516	chr6:26286170	HIST1H4H	0.37	6.09	0.32	3.03e-9	Educational attainment;
LUSC	cis	rs9309473	1.000	rs7576245	chr2:73829678	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.57	-0.34	1.9e-10	Metabolite levels;
LUSC	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg10483660	chr13:112241077	NA	-0.31	-5.77	-0.3	1.8e-8	Hepatitis;
LUSC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03934478	chr11:495069	RNH1	0.84	10.03	0.48	7.17e-21	Body mass index;
LUSC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg02807482	chr3:125708958	NA	-0.52	-6.54	-0.34	2.26e-10	Blood pressure (smoking interaction);
LUSC	cis	rs9549260	0.709	rs9549240	chr13:41186644	T/G	cg21288729	chr13:41239152	FOXO1	0.59	9.07	0.44	1.07e-17	Red blood cell count;
LUSC	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-9.31	-0.45	1.78e-18	Retinal vascular caliber;
LUSC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.34	0.67	1.6e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	9.9	0.48	1.96e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg05347473	chr6:146136440	FBXO30	0.57	9.96	0.48	1.23e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-0.9	-17.19	-0.69	7.1e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.62	-6.31	-0.33	8.99e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17691542	chr6:26056736	HIST1H1C	0.99	12.8	0.57	8.78e-31	Iron status biomarkers;
LUSC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	7.51	0.38	5.38e-13	Personality dimensions;
LUSC	cis	rs13242816	1.000	rs13247987	chr7:116113344	A/C	cg16553024	chr7:116138462	CAV2	-0.52	-5.71	-0.3	2.44e-8	P wave duration;
LUSC	cis	rs1891275	0.515	rs10881957	chr10:93501876	C/T	cg07889827	chr10:93443413	NA	-0.39	-8.93	-0.44	2.87e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg03585969	chr10:35415529	CREM	-0.63	-9.29	-0.45	2.04e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	7.81	0.39	7.29e-14	Calcium levels;
LUSC	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg26597838	chr10:835615	NA	0.74	8.84	0.44	5.41e-17	Eosinophil percentage of granulocytes;
LUSC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg16606324	chr3:10149918	C3orf24	0.61	8.02	0.4	1.8e-14	Alzheimer's disease;
LUSC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.73	-0.57	1.62e-30	Alzheimer's disease;
LUSC	trans	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg21856205	chr7:94953877	PON1	-0.36	-5.94	-0.31	7.32e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg05115182	chr10:99496889	ZFYVE27	0.46	6.11	0.32	2.82e-9	Thyroid stimulating hormone;
LUSC	cis	rs7264396	0.887	rs224351	chr20:34052273	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.66	-0.34	1.1e-10	Total cholesterol levels;
LUSC	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg14196790	chr5:131705035	SLC22A5	-0.46	-7.93	-0.4	3.37e-14	Blood metabolite levels;
LUSC	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg16077055	chr2:106428750	NCK2	0.32	5.98	0.31	5.61e-9	Addiction;
LUSC	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-10.15	-0.49	2.88e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg09044154	chr16:88155775	NA	-0.56	-7.54	-0.38	4.39e-13	Menopause (age at onset);
LUSC	cis	rs1712517	0.844	rs1163075	chr10:105021263	A/G	cg05636881	chr10:105038444	INA	-0.37	-6.16	-0.32	2.03e-9	Migraine;
LUSC	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg05738196	chr6:26577821	NA	0.56	6.94	0.36	1.99e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.09	0.32	3.02e-9	Menopause (age at onset);
LUSC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg03146154	chr1:46216737	IPP	0.53	7.74	0.39	1.21e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg09469691	chr10:81107165	PPIF	0.64	10.27	0.49	1.06e-21	Height;
LUSC	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-10.89	-0.51	7.99e-24	Heart rate;
LUSC	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.87	13.93	0.61	4.29e-35	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.78	0.39	9.21e-14	Electroencephalogram traits;
LUSC	cis	rs796825	0.530	rs6771116	chr3:120001314	A/G	cg21790991	chr3:120137480	FSTL1	-0.33	-6.05	-0.31	3.78e-9	HIV-1 susceptibility;
LUSC	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.48	6.58	0.34	1.84e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs911555	0.504	rs4906340	chr14:104076645	G/A	cg12935359	chr14:103987150	CKB	0.47	7.03	0.36	1.15e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs78366141	0.649	rs76884708	chr4:89692043	G/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.86	7.14	0.36	5.92e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg05855489	chr10:104503620	C10orf26	-0.68	-9.77	-0.47	5.43e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg06008330	chr7:65541103	ASL	0.4	6.17	0.32	1.96e-9	Aortic root size;
LUSC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.41	0.33	5.09e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg03433033	chr1:76189801	ACADM	-0.45	-6.84	-0.35	3.86e-11	Daytime sleep phenotypes;
LUSC	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg14530993	chr4:882597	GAK	0.7	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg10018233	chr7:150070692	REPIN1	0.34	5.66	0.3	3.19e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg22676075	chr6:135203613	NA	0.48	7.51	0.38	5.47e-13	Red blood cell count;
LUSC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24023847	chr6:119256284	MCM9	-0.47	-7.15	-0.36	5.63e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg20821713	chr7:1055600	C7orf50	-0.52	-6.75	-0.35	6.39e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	1.06	16.05	0.66	2.25e-43	Corneal structure;
LUSC	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg25457927	chr22:38595422	NA	-0.42	-8.92	-0.44	3.05e-17	Cutaneous nevi;
LUSC	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg02023728	chr11:77925099	USP35	0.46	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg05874882	chr4:1763078	NA	0.53	8.76	0.43	1.03e-16	Bladder cancer;Urinary bladder cancer;
LUSC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg01879757	chr17:41196368	BRCA1	-0.47	-7.07	-0.36	8.95e-12	Menopause (age at onset);
LUSC	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg07169764	chr2:136633963	MCM6	1.05	14.07	0.61	1.21e-35	Corneal structure;
LUSC	cis	rs7582180	0.874	rs7601442	chr2:100897351	T/A	cg08017756	chr2:100939284	LONRF2	-0.37	-6.18	-0.32	1.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.78	9.61	0.47	1.8e-19	White matter hyperintensity burden;
LUSC	cis	rs5769707	0.681	rs6009803	chr22:50051007	A/G	cg20744362	chr22:50050164	C22orf34	0.38	7.01	0.36	1.36e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.52	-0.34	2.55e-10	Life satisfaction;
LUSC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.62	-9.89	-0.48	2.21e-20	Cognitive test performance;
LUSC	cis	rs7929679	0.521	rs10768094	chr11:34792189	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.91	0.31	8.29e-9	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	cis	rs4919694	0.901	rs74376228	chr10:104677662	G/C	cg04362960	chr10:104952993	NT5C2	1.17	13.48	0.59	2.36e-33	Arsenic metabolism;
LUSC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.72	-9.95	-0.48	1.35e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs72960926	0.744	rs67280742	chr6:75004753	T/C	cg03266952	chr6:74778945	NA	-0.75	-6.61	-0.34	1.48e-10	Metabolite levels (MHPG);
LUSC	trans	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg14791747	chr16:20752902	THUMPD1	-0.41	-5.96	-0.31	6.3e-9	Pancreatic cancer;
LUSC	trans	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07923666	chr12:49932857	KCNH3	-0.53	-6.57	-0.34	1.88e-10	Resting heart rate;
LUSC	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg17366294	chr4:99064904	C4orf37	0.53	8.64	0.43	2.32e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg00024416	chr22:24240387	NA	-0.36	-6.02	-0.31	4.71e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg05564831	chr3:52568323	NT5DC2	0.35	6.44	0.33	4.05e-10	Electroencephalogram traits;
LUSC	cis	rs2387326	0.717	rs12254442	chr10:129945793	C/T	cg16087940	chr10:129947807	NA	-0.4	-6.12	-0.32	2.59e-9	Select biomarker traits;
LUSC	cis	rs6942756	0.737	rs61570833	chr7:128933492	C/A	cg02491457	chr7:128862824	NA	-0.48	-6.64	-0.34	1.28e-10	White matter hyperintensity burden;
LUSC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg25258033	chr6:167368657	RNASET2	0.49	8.1	0.41	1.04e-14	Crohn's disease;
LUSC	cis	rs7119167	0.901	rs7952686	chr11:73128503	C/T	cg17517138	chr11:73019481	ARHGEF17	0.54	6.07	0.32	3.45e-9	Blood protein levels;
LUSC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.95	0.36	1.97e-11	Platelet count;
LUSC	cis	rs7582720	1.000	rs72934767	chr2:203766563	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.66	0.43	2.06e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg22823121	chr1:150693482	HORMAD1	-0.49	-6.82	-0.35	4.25e-11	Blood protein levels;
LUSC	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg02389323	chr16:88786976	FAM38A	1.11	11.41	0.53	1.14e-25	Plateletcrit;
LUSC	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.76	-0.3	1.96e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg26384229	chr12:38710491	ALG10B	0.59	9.42	0.46	7.54e-19	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06573718	chr12:99038766	APAF1;IKBIP	-0.46	-6.98	-0.36	1.56e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11924390	0.800	rs1648698	chr3:186449582	G/C	cg12454167	chr3:186435060	KNG1	0.28	7.6	0.38	2.98e-13	Adiponectin levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10954665	chr17:36453009	MRPL45	-0.46	-6.84	-0.35	3.76e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg26335602	chr6:28129616	ZNF389	0.43	5.77	0.3	1.79e-8	Depression;
LUSC	cis	rs360798	0.532	rs2136737	chr2:62969310	G/C	cg17519650	chr2:63277830	OTX1	-0.5	-7.02	-0.36	1.21e-11	Coronary artery disease;
LUSC	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg27411982	chr8:10470053	RP1L1	0.42	6.14	0.32	2.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg24562669	chr7:97807699	LMTK2	0.35	6.16	0.32	2.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3916	1.000	rs34708625	chr12:121180019	T/C	cg27246729	chr12:121163418	ACADS	0.46	6.59	0.34	1.7e-10	Urinary metabolites (H-NMR features);
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg18538332	chr22:24372958	LOC391322	0.46	8.13	0.41	8.45e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.47	-0.33	3.41e-10	High light scatter reticulocyte count;
LUSC	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg10434728	chr15:90938212	IQGAP1	0.43	8.72	0.43	1.35e-16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg26893861	chr17:41843967	DUSP3	0.87	13.5	0.59	1.99e-33	Triglycerides;
LUSC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg16606324	chr3:10149918	C3orf24	0.62	9.06	0.44	1.15e-17	Alzheimer's disease;
LUSC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.51	-0.38	5.35e-13	Aortic root size;
LUSC	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.16	-0.36	5.25e-12	Neuroticism;
LUSC	cis	rs7572644	0.699	rs2337373	chr2:28092922	T/C	cg27432699	chr2:27873401	GPN1	-0.51	-6.97	-0.36	1.75e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs57994353	0.568	rs10747044	chr9:139319129	G/T	cg14019695	chr9:139328340	INPP5E	0.36	5.94	0.31	7.22e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUSC	cis	rs2639990	1.000	rs2639990	chr18:72915551	T/C	cg11568697	chr18:72916393	ZADH2	0.62	6.84	0.35	3.9e-11	Vascular endothelial growth factor levels;
LUSC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.93	-0.44	3.01e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs12912251	0.948	rs34141940	chr15:38989657	G/A	cg01338139	chr15:38987640	C15orf53	-0.51	-7.11	-0.36	7.04e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg23260525	chr10:116636907	FAM160B1	-0.46	-9.65	-0.47	1.38e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6580649	0.941	rs72644844	chr12:48465425	A/C	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	cis	rs6429082	0.608	rs4659836	chr1:235564412	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.5	-6.87	-0.35	3.14e-11	Adiposity;
LUSC	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.02	-0.31	4.6e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9815354	1.000	rs1612124	chr3:41967893	C/A	cg03022575	chr3:42003672	ULK4	-0.58	-6.4	-0.33	5.41e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs427941	0.703	rs201443	chr7:101737688	A/T	cg06246474	chr7:101738831	CUX1	0.41	6.71	0.34	8.21e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.15	-0.36	5.68e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03264133	chr6:25882463	NA	0.42	7.23	0.37	3.36e-12	Blood metabolite levels;
LUSC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06022373	chr22:39101656	GTPBP1	0.81	12.63	0.57	3.64e-30	Menopause (age at onset);
LUSC	cis	rs308403	0.600	rs376131	chr4:123629225	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.77	10.15	0.49	2.75e-21	Blood protein levels;
LUSC	cis	rs6785206	0.892	rs6793907	chr3:128391626	A/G	cg16766828	chr3:128327626	NA	0.64	7.44	0.38	8.86e-13	Lymphocyte percentage of white cells;
LUSC	trans	rs10098647	0.632	rs11778794	chr8:61108773	A/C	cg09970348	chr3:183978600	ECE2;CAMK2N2	0.46	6.15	0.32	2.26e-9	Obesity-related traits;
LUSC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	0.93	16.12	0.66	1.16e-43	Menopause (age at onset);
LUSC	cis	rs9733	0.681	rs7412746	chr1:150860471	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.45	-6.97	-0.36	1.68e-11	Tonsillectomy;
LUSC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.5	-0.34	2.95e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.36	-0.33	6.82e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg24375607	chr4:120327624	NA	0.49	7.53	0.38	4.7e-13	Diastolic blood pressure;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06956805	chr11:485055	PTDSS2	-0.81	-6.62	-0.34	1.43e-10	Cognitive performance;
LUSC	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.89	0.31	9.61e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10710896	chr2:202645397	ALS2	-0.44	-6.41	-0.33	4.92e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg09479241	chr17:27052676	TLCD1	0.43	5.75	0.3	2.06e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	6.85	0.35	3.59e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg02487422	chr3:49467188	NICN1	0.45	7.08	0.36	8.74e-12	Resting heart rate;
LUSC	trans	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.29	0.41	2.71e-15	Ulcerative colitis;
LUSC	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg16850897	chr7:100343110	ZAN	-0.6	-8.3	-0.41	2.61e-15	Other erythrocyte phenotypes;
LUSC	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.49	0.5	1.89e-22	Schizophrenia;
LUSC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg14668632	chr7:2872130	GNA12	-0.42	-6.14	-0.32	2.37e-9	Height;
LUSC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg09904177	chr6:26538194	HMGN4	0.76	14.14	0.61	6.79e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.59	-0.34	1.71e-10	Schizophrenia;
LUSC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00339695	chr16:24857497	SLC5A11	0.61	9.26	0.45	2.53e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.68	-10.39	-0.49	4.22e-22	Aortic root size;
LUSC	cis	rs10992471	0.603	rs12336415	chr9:95195458	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-7.95	-0.4	2.84e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	1.11	16.05	0.66	2.18e-43	Primary sclerosing cholangitis;
LUSC	cis	rs7799006	0.606	rs12535174	chr7:2310974	C/T	cg12823233	chr7:2316876	SNX8	-0.45	-7.58	-0.38	3.52e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg22823121	chr1:150693482	HORMAD1	0.52	8.05	0.4	1.5e-14	Melanoma;
LUSC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg16423285	chr20:60520624	NA	-0.46	-5.75	-0.3	1.98e-8	Body mass index;
LUSC	cis	rs4834770	0.765	rs1511016	chr4:120170355	A/T	cg24375607	chr4:120327624	NA	0.4	5.69	0.3	2.84e-8	Blood protein levels;
LUSC	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg03060546	chr3:49711283	APEH	0.55	7.7	0.39	1.53e-13	Resting heart rate;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24972377	chr12:122326574	PSMD9	-0.52	-6.9	-0.35	2.6e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10761482	0.861	rs10733763	chr10:62109280	T/C	cg18175470	chr10:62150864	ANK3	-0.5	-7.05	-0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06636551	chr8:101224915	SPAG1	0.41	7.22	0.37	3.51e-12	Atrioventricular conduction;
LUSC	cis	rs367943	0.712	rs6594709	chr5:112700714	T/C	cg12552261	chr5:112820674	MCC	0.39	6.5	0.34	2.96e-10	Type 2 diabetes;
LUSC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg15352829	chr14:105391018	PLD4	-0.4	-8.41	-0.42	1.18e-15	Rheumatoid arthritis;
LUSC	cis	rs9341808	0.538	rs623048	chr6:80981916	C/T	cg08355045	chr6:80787529	NA	-0.39	-6.68	-0.34	9.8e-11	Sitting height ratio;
LUSC	cis	rs7215564	0.908	rs34199628	chr17:78661675	A/G	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02034563	chr2:179060011	OSBPL6	0.44	6.03	0.31	4.31e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.78	0.3	1.74e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12618769	0.597	rs2278212	chr2:99136266	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	trans	rs6076960	0.622	rs6054063	chr20:6262992	C/A	cg21095983	chr6:86352623	SYNCRIP	0.52	8.28	0.41	2.98e-15	Smooth-surface caries;
LUSC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.19	-0.8	2.06e-75	Height;
LUSC	cis	rs6695223	1.000	rs4907130	chr1:85536879	T/C	cg22153463	chr1:85462885	MCOLN2	-0.59	-5.65	-0.3	3.46e-8	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg20243544	chr17:37824526	PNMT	-0.47	-5.9	-0.31	9.11e-9	Glomerular filtration rate (creatinine);
LUSC	trans	rs1417205	1.000	rs9316278	chr13:47841469	A/G	cg21511415	chr3:126034448	NA	-0.49	-6.18	-0.32	1.83e-9	Cannabis use (initiation);
LUSC	cis	rs7799006	0.895	rs3757437	chr7:2271980	C/T	cg02951883	chr7:2050386	MAD1L1	-0.37	-6.21	-0.32	1.58e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.86	14.03	0.61	1.75e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg17469321	chr7:55412551	NA	0.66	10.46	0.5	2.51e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg05729581	chr11:3078854	CARS	-0.53	-8.13	-0.41	8.39e-15	Longevity;
LUSC	trans	rs7822058	0.722	rs7460309	chr8:53693490	A/G	cg16864198	chr12:26340863	NA	0.45	6.15	0.32	2.22e-9	Obesity-related traits;
LUSC	cis	rs3744061	0.569	rs2240769	chr17:74718155	C/T	cg02128979	chr17:74682217	MXRA7	0.43	6.52	0.34	2.63e-10	Retinal arteriolar caliber;
LUSC	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.59	-11.22	-0.52	5.44e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-7.79	-0.39	8.65e-14	Mood instability;
LUSC	cis	rs1971762	0.563	rs3897117	chr12:54077407	T/G	cg23533419	chr12:54090519	NA	-0.37	-6.02	-0.31	4.6e-9	Height;
LUSC	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.49	6.91	0.35	2.43e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6977660	0.660	rs12531296	chr7:19816450	A/C	cg07541023	chr7:19748670	TWISTNB	0.63	6.84	0.35	3.87e-11	Thyroid stimulating hormone;
LUSC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg01579765	chr21:45077557	HSF2BP	0.51	10.86	0.51	9.57e-24	Mean corpuscular volume;
LUSC	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.47	7.5	0.38	5.97e-13	Asthma (sex interaction);
LUSC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9815354	0.812	rs73073326	chr3:41834195	G/T	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg22920501	chr2:26401640	FAM59B	0.82	11.99	0.55	8.49e-28	Gut microbiome composition (summer);
LUSC	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.67	-0.34	1.08e-10	Monocyte percentage of white cells;
LUSC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg09904177	chr6:26538194	HMGN4	0.76	14.14	0.61	6.79e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg12963246	chr6:28129442	ZNF389	0.51	6.17	0.32	1.99e-9	Depression;
LUSC	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg15704280	chr7:45808275	SEPT13	-0.6	-7.38	-0.37	1.29e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.46	9.67	0.47	1.13e-19	Airflow obstruction;
LUSC	cis	rs4363385	0.765	rs11205165	chr1:152986928	G/T	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.37	-0.37	1.33e-12	Inflammatory skin disease;
LUSC	cis	rs55665837	1.000	rs7121171	chr11:14446420	A/G	cg19336497	chr11:14380999	RRAS2	-0.36	-7.21	-0.37	3.69e-12	Vitamin D levels;
LUSC	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg16576597	chr16:28551801	NUPR1	0.31	6.3	0.33	9.58e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	0.99	19.5	0.73	4.42e-57	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg17173187	chr15:85201210	NMB	0.35	6.29	0.33	1e-9	Schizophrenia;
LUSC	cis	rs6489785	0.509	rs4767937	chr12:121223244	G/C	cg02419362	chr12:121203948	SPPL3	0.46	8.62	0.43	2.8e-16	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.38	7.47	0.38	7.06e-13	Hemoglobin concentration;
LUSC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg15103426	chr22:29168792	CCDC117	0.58	7.95	0.4	2.83e-14	Lymphocyte counts;
LUSC	trans	rs6445975	0.666	rs4390943	chr3:58376639	A/C	cg18950693	chr14:70346909	SMOC1	0.38	6.05	0.31	3.97e-9	Systemic lupus erythematosus;
LUSC	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-8.17	-0.41	6.41e-15	Body mass index;
LUSC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg11871910	chr12:69753446	YEATS4	0.92	17.3	0.69	2.46e-48	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.9	15.61	0.65	1.27e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs911555	0.504	rs4906340	chr14:104076645	G/A	cg24130564	chr14:104152367	KLC1	0.68	10.63	0.5	6.39e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg20684491	chr1:25596433	NA	-0.38	-5.92	-0.31	7.88e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg21951975	chr1:209979733	IRF6	0.56	7.34	0.37	1.63e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.94	-15.12	-0.64	1e-39	Menarche (age at onset);
LUSC	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.26e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.3	-7.63	-0.39	2.56e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg17143192	chr8:8559678	CLDN23	-0.37	-5.74	-0.3	2.11e-8	Mood instability;
LUSC	trans	rs4948088	1.000	rs2329568	chr7:51018103	C/G	cg26816907	chr1:197890812	LHX9	0.56	6.21	0.32	1.62e-9	Type 1 diabetes;
LUSC	cis	rs941898	0.957	rs7159195	chr14:100583330	G/A	cg26002632	chr14:100625216	DEGS2	-0.31	-5.69	-0.3	2.71e-8	White matter hyperintensity burden;
LUSC	cis	rs6076065	0.723	rs4813495	chr20:23391617	A/G	cg11657817	chr20:23433608	CST11	0.42	8.01	0.4	1.94e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.9	-0.35	2.61e-11	Joint mobility (Beighton score);
LUSC	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg09876464	chr15:85330779	ZNF592	0.36	6.67	0.34	1.05e-10	P wave terminal force;
LUSC	cis	rs7107174	0.901	rs4945275	chr11:78119822	G/A	cg02023728	chr11:77925099	USP35	0.41	6.3	0.33	9.43e-10	Testicular germ cell tumor;
LUSC	cis	rs3087591	1.000	rs6505235	chr17:29688603	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.55	-7.78	-0.39	8.96e-14	Hip circumference;
LUSC	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg25281562	chr12:121454272	C12orf43	-0.43	-5.67	-0.3	3.04e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg05110241	chr16:68378359	PRMT7	-0.44	-5.77	-0.3	1.77e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs983392	0.678	rs7108663	chr11:60028142	C/T	cg20284999	chr11:59952153	MS4A6A	0.38	6.44	0.33	4.09e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg06917634	chr15:78832804	PSMA4	-0.48	-5.94	-0.31	7.15e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.16	-0.36	5.06e-12	Blood protein levels;
LUSC	cis	rs4253772	1.000	rs11705483	chr22:46630544	C/A	cg09491104	chr22:46646882	C22orf40	-0.62	-6.55	-0.34	2.16e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg20203395	chr5:56204925	C5orf35	-0.45	-6.67	-0.34	1.03e-10	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg09491104	chr22:46646882	C22orf40	-0.58	-7.98	-0.4	2.34e-14	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9513627	0.749	rs73556149	chr13:100117012	G/A	cg25919922	chr13:100150906	NA	-0.74	-6.22	-0.32	1.52e-9	Obesity-related traits;
LUSC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.06	-17.07	-0.68	2.15e-47	Homoarginine levels;
LUSC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25072359	chr17:41440525	NA	0.66	9.25	0.45	2.8e-18	Menopause (age at onset);
LUSC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	1.05	18.88	0.72	1.28e-54	Parkinson's disease;
LUSC	cis	rs1506636	1.000	rs2215554	chr7:123347063	A/C	cg03229431	chr7:123269106	ASB15	-0.63	-10.1	-0.48	4.09e-21	Plateletcrit;Platelet count;
LUSC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.16	0.32	2.13e-9	Bipolar disorder;
LUSC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg03351412	chr1:154909251	PMVK	0.53	8.19	0.41	5.74e-15	Prostate cancer;
LUSC	cis	rs4494114	0.967	rs9438980	chr1:39355371	A/G	cg25970120	chr1:39325951	RRAGC	-0.38	-5.96	-0.31	6.24e-9	Blood protein levels;
LUSC	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg03676636	chr4:99064102	C4orf37	0.33	6.07	0.32	3.55e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6733011	0.578	rs11893888	chr2:99495239	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.19	-0.32	1.73e-9	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08470185	chr1:1334798	CCNL2;LOC148413	0.42	6.31	0.33	8.88e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg00071950	chr4:10020882	SLC2A9	-0.62	-10.15	-0.49	2.9e-21	Bone mineral density;
LUSC	cis	rs4494114	1.000	rs3790442	chr1:39357646	C/A	cg25970120	chr1:39325951	RRAGC	-0.4	-6.21	-0.32	1.58e-9	Blood protein levels;
LUSC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.5	-10.92	-0.51	6.08e-24	Type 2 diabetes;
LUSC	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.76	-0.43	9.87e-17	Response to antipsychotic treatment;
LUSC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg06636001	chr8:8085503	FLJ10661	0.49	7.11	0.36	7.17e-12	Myopia (pathological);
LUSC	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg02175503	chr12:58329896	NA	0.61	10.06	0.48	5.74e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.86	-0.31	1.13e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4474465	0.703	rs10899547	chr11:78254720	C/T	cg27205649	chr11:78285834	NARS2	0.53	6.36	0.33	6.57e-10	Alzheimer's disease (survival time);
LUSC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05165339	chr4:1420672	NA	-0.3	-6.62	-0.34	1.42e-10	Longevity;
LUSC	trans	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.63	9.79	0.47	4.6e-20	Endometrial cancer;
LUSC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg01802117	chr1:53393560	SCP2	0.37	6.11	0.32	2.83e-9	Monocyte count;
LUSC	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.53	-0.34	2.44e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg21573476	chr21:45109991	RRP1B	-0.36	-5.88	-0.31	1.02e-8	Mean corpuscular volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23486179	chr3:49466665	NICN1	-0.51	-6.34	-0.33	7.64e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg17328964	chr8:145687451	CYHR1	-0.4	-6.13	-0.32	2.48e-9	Age at first birth;
LUSC	cis	rs61990749	0.597	rs6574402	chr14:78267950	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	6.34	0.33	7.34e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs1775715	0.707	rs2808094	chr10:32133756	T/C	cg04359828	chr10:32216031	ARHGAP12	0.41	7.07	0.36	9.07e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1030877	0.557	rs2576752	chr2:105978761	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.53	9.05	0.44	1.23e-17	Obesity-related traits;
LUSC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg10207240	chr12:122356781	WDR66	0.46	6.46	0.33	3.61e-10	Mean corpuscular volume;
LUSC	cis	rs1014246	0.848	rs58568639	chr10:118456886	C/G	cg14919929	chr10:118506882	NA	0.47	7.29	0.37	2.31e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg18187862	chr3:45730750	SACM1L	0.56	7.06	0.36	9.52e-12	Primary sclerosing cholangitis;
LUSC	cis	rs2236918	0.901	rs1776135	chr1:242025530	A/G	cg17736920	chr1:242011382	EXO1	0.44	6.86	0.35	3.3e-11	Menopause (age at onset);
LUSC	cis	rs4499344	0.730	rs259286	chr19:33164759	C/T	cg22980127	chr19:33182716	NUDT19	-0.44	-6.64	-0.34	1.3100000000000001e-10	Mean platelet volume;
LUSC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	7.55	0.38	4.28e-13	Resistin levels;
LUSC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg26304593	chr6:42947056	PEX6	-0.53	-8.48	-0.42	7.42e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg12463550	chr7:65579703	CRCP	0.42	6.0	0.31	5.11e-9	Calcium levels;
LUSC	trans	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg26384229	chr12:38710491	ALG10B	0.57	8.84	0.44	5.71e-17	Morning vs. evening chronotype;
LUSC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg05623727	chr3:50126028	RBM5	0.31	5.81	0.3	1.43e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9399401	0.710	rs12197866	chr6:142706063	C/T	cg04461802	chr6:142623433	GPR126	0.47	5.87	0.31	1.06e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg12927641	chr6:109611667	NA	-0.43	-7.5	-0.38	5.64e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs7215564	0.730	rs4889877	chr17:78662459	A/C	cg23238734	chr17:78661607	RPTOR	0.45	5.81	0.3	1.49e-8	Myopia (pathological);
LUSC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg06454157	chr6:167490870	NA	-0.28	-6.87	-0.35	3.1e-11	Primary biliary cholangitis;
LUSC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07092213	chr7:1199455	ZFAND2A	0.42	6.49	0.33	3.11e-10	Longevity;Endometriosis;
LUSC	cis	rs56283067	0.886	rs56110323	chr6:44679934	G/A	cg20913747	chr6:44695427	NA	-0.47	-7.83	-0.39	6.54e-14	Total body bone mineral density;
LUSC	trans	rs800082	0.668	rs9876975	chr3:144292255	G/A	cg24215973	chr2:240111563	HDAC4	-0.62	-9.89	-0.48	2.08e-20	Smoking behavior;
LUSC	cis	rs4290604	0.748	rs10754942	chr2:238075187	T/C	cg23555395	chr2:238036564	NA	-0.47	-6.41	-0.33	4.85e-10	Asthma;
LUSC	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg13256891	chr4:100009986	ADH5	-0.44	-6.11	-0.32	2.83e-9	Alcohol dependence;
LUSC	cis	rs9905704	0.587	rs2003537	chr17:56611871	C/G	cg19466818	chr17:56409534	MIR142	0.35	6.53	0.34	2.48e-10	Testicular germ cell tumor;
LUSC	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-1.11	-17.7	-0.7	6.23e-50	Exhaled nitric oxide output;
LUSC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.75e-14	Melanoma;
LUSC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg23758822	chr17:41437982	NA	1.0	19.79	0.73	3.27e-58	Menopause (age at onset);
LUSC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg27535305	chr1:53392650	SCP2	0.33	6.01	0.31	4.85e-9	Monocyte count;
LUSC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06481639	chr22:41940642	POLR3H	-0.49	-5.69	-0.3	2.79e-8	Vitiligo;
LUSC	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-6.83	-0.35	4.12e-11	Morning vs. evening chronotype;
LUSC	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg19875535	chr5:140030758	IK	-0.48	-7.72	-0.39	1.34e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg12924262	chr12:102091054	CHPT1	0.45	6.26	0.32	1.2e-9	Blood protein levels;
LUSC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.92	0.31	7.86e-9	Menopause (age at onset);
LUSC	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.14e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg12639453	chr1:2035780	PRKCZ	0.32	6.87	0.35	3.18e-11	Height;
LUSC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.97	-14.0	-0.61	2.41e-35	Initial pursuit acceleration;
LUSC	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	6.29	0.33	9.72e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg13531842	chr10:38383804	ZNF37A	-0.43	-6.71	-0.34	8.54e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12618769	0.597	rs3769737	chr2:99088873	C/G	cg10123293	chr2:99228465	UNC50	-0.46	-7.7	-0.39	1.5700000000000001e-13	Bipolar disorder;
LUSC	trans	rs12145833	0.596	rs61833913	chr1:243440028	C/G	cg01826367	chr1:224180288	NA	0.63	5.95	0.31	6.62e-9	Obesity (early onset extreme);
LUSC	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg25173405	chr17:45401733	C17orf57	-0.37	-5.73	-0.3	2.2e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2573652	0.722	rs12898366	chr15:100543067	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.38	-6.88	-0.35	3.01e-11	Height;
LUSC	cis	rs7246967	0.673	rs597906	chr19:22868205	T/C	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg12573674	chr2:1569213	NA	-0.53	-5.72	-0.3	2.41e-8	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs1981331	1.000	rs118078026	chr21:48012129	T/C	cg23283320	chr21:48055893	PRMT2	1.12	8.14	0.41	7.72e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg25319279	chr11:5960081	NA	-0.4	-5.79	-0.3	1.63e-8	DNA methylation (variation);
LUSC	cis	rs4751006	0.543	rs17692028	chr10:128783983	C/T	cg05702161	chr10:128779687	DOCK1	-0.77	-6.22	-0.32	1.51e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	11.78	0.54	4.92e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg14169450	chr9:139327907	INPP5E	0.41	6.98	0.36	1.57e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-7.28	-0.37	2.35e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg14552801	chr7:65878734	NA	-0.44	-6.19	-0.32	1.75e-9	Aortic root size;
LUSC	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.64	9.79	0.47	4.53e-20	Corneal astigmatism;
LUSC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg16624210	chr5:671434	TPPP	0.5	6.38	0.33	6.07e-10	Obesity-related traits;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg16983211	chr12:54427636	HOXC4;HOXC5	0.46	6.33	0.33	8.06e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg04455712	chr21:45112962	RRP1B	0.45	8.87	0.44	4.61e-17	Mean corpuscular volume;
LUSC	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.85	-0.47	2.92e-20	Total cholesterol levels;
LUSC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg24399712	chr22:39784796	NA	-0.62	-11.12	-0.52	1.19e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg22681709	chr2:178499509	PDE11A	-0.6	-12.05	-0.55	5.29e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg10018233	chr7:150070692	REPIN1	0.39	6.79	0.35	5.11e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11822910	1.000	rs2439448	chr11:57199211	T/C	cg00522883	chr11:57194120	SLC43A3	0.42	6.62	0.34	1.45e-10	Platelet distribution width;
LUSC	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.04	0.36	1.13e-11	Lung cancer in ever smokers;
LUSC	cis	rs2386661	0.547	rs11259540	chr10:5646706	A/T	cg17085576	chr10:5658249	NA	-0.43	-6.37	-0.33	6.09e-10	Breast cancer;
LUSC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg17211192	chr8:82754475	SNX16	0.81	11.11	0.52	1.32e-24	Diastolic blood pressure;
LUSC	cis	rs868036	1.000	rs1026735	chr15:68101700	A/G	cg08079166	chr15:68083412	MAP2K5	0.4	8.28	0.41	3.04e-15	Restless legs syndrome;
LUSC	cis	rs58785573	0.504	rs11947292	chr4:38634749	A/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.59	8.95	0.44	2.54e-17	Lymphocyte percentage of white cells;
LUSC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg01802117	chr1:53393560	SCP2	-0.39	-6.5	-0.33	2.99e-10	Monocyte count;
LUSC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06656553	chr16:89960601	TCF25	-0.64	-5.66	-0.3	3.2e-8	Skin colour saturation;
LUSC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.2	0.32	1.7e-9	Menopause (age at onset);
LUSC	cis	rs55986470	0.646	rs112559043	chr2:239446187	A/G	cg18131467	chr2:239335373	ASB1	-0.73	-5.79	-0.3	1.62e-8	Chronotype;
LUSC	cis	rs365132	0.875	rs2940521	chr5:176339209	A/C	cg25401027	chr5:176370377	UIMC1	0.35	5.74	0.3	2.11e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg02423579	chr7:2872169	GNA12	-0.5	-7.05	-0.36	1.03e-11	Height;
LUSC	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg05805236	chr11:65401703	PCNXL3	-0.5	-8.13	-0.41	8.52e-15	Acne (severe);
LUSC	cis	rs6076065	0.723	rs743022	chr20:23401129	G/C	cg11657817	chr20:23433608	CST11	0.42	7.5	0.38	5.87e-13	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.72	12.03	0.55	6.32e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05972308	chr16:31476161	ARMC5	-0.73	-6.12	-0.32	2.66e-9	Cognitive performance;
LUSC	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg14675211	chr2:100938903	LONRF2	0.37	5.76	0.3	1.89e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2692947	1.000	rs2692947	chr2:96674116	T/C	cg23100626	chr2:96804247	ASTL	0.23	5.67	0.3	3.14e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg01851573	chr8:8652454	MFHAS1	0.53	8.71	0.43	1.48e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs243505	0.624	rs6975291	chr7:148548393	C/G	cg09806900	chr7:148480153	CUL1	0.48	6.39	0.33	5.5e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg06002616	chr8:101225028	SPAG1	0.39	6.65	0.34	1.23e-10	Atrioventricular conduction;
LUSC	cis	rs73206853	0.841	rs57821814	chr12:110829254	A/C	cg12870014	chr12:110450643	ANKRD13A	0.67	6.46	0.33	3.72e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg09436375	chr6:42928200	GNMT	-0.3	-7.03	-0.36	1.18e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.27	-0.37	2.58e-12	Monocyte count;
LUSC	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.03e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6565189	1.000	rs6565189	chr16:30507265	A/C	cg17640201	chr16:30407289	ZNF48	0.45	6.08	0.32	3.2e-9	Tonsillectomy;
LUSC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg09509183	chr1:209979624	IRF6	0.43	5.73	0.3	2.25e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg04352962	chr1:209979756	IRF6	0.58	6.66	0.34	1.1e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg21775007	chr8:11205619	TDH	-0.67	-10.48	-0.5	2.06e-22	Retinal vascular caliber;
LUSC	cis	rs710216	0.957	rs841570	chr1:43435571	C/G	cg22176566	chr1:43424700	SLC2A1	0.46	5.89	0.31	9.22e-9	Red cell distribution width;
LUSC	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg13010199	chr12:38710504	ALG10B	-0.63	-9.72	-0.47	7.93e-20	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg00945038	chr17:61921165	SMARCD2	0.51	8.63	0.43	2.48e-16	Prudent dietary pattern;
LUSC	cis	rs2651899	0.902	rs1798246	chr1:3080855	A/C	cg22674798	chr1:3096360	PRDM16	0.28	6.46	0.33	3.72e-10	Migraine;
LUSC	cis	rs9326248	0.768	rs4936366	chr11:117026885	G/A	cg26566898	chr11:117069891	TAGLN	0.38	6.06	0.31	3.6e-9	Blood protein levels;
LUSC	cis	rs4561483	0.556	rs11570136	chr16:12058832	T/A	cg08843971	chr16:11963173	GSPT1	-0.42	-6.02	-0.31	4.68e-9	Testicular germ cell tumor;
LUSC	cis	rs9359856	0.564	rs11961752	chr6:90481896	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.51	-0.42	5.78e-16	Bipolar disorder;
LUSC	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg00033643	chr7:134001901	SLC35B4	0.43	6.3	0.33	9.64e-10	Mean platelet volume;
LUSC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00864171	chr11:67383662	NA	0.35	6.32	0.33	8.55e-10	Mean corpuscular volume;
LUSC	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg10523679	chr1:76189770	ACADM	-0.43	-6.21	-0.32	1.53e-9	Daytime sleep phenotypes;
LUSC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg27284194	chr4:1044797	NA	0.35	5.83	0.3	1.32e-8	Obesity-related traits;
LUSC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14008834	chr4:24472254	NA	0.36	5.99	0.31	5.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg16606324	chr3:10149918	C3orf24	0.44	6.78	0.35	5.34e-11	Alzheimer's disease;
LUSC	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg24375607	chr4:120327624	NA	0.76	11.54	0.53	3.82e-26	Corneal astigmatism;
LUSC	cis	rs8038465	0.592	rs1542579	chr15:73935897	A/G	cg15420318	chr15:73925796	NPTN	0.58	10.11	0.48	3.77e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.68	11.42	0.53	1.02e-25	Heart rate;
LUSC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.59	-0.38	3.19e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	0.92	13.97	0.61	3.03e-35	Breast cancer;
LUSC	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg05283184	chr6:79620031	NA	-0.57	-12.14	-0.55	2.5e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg14784868	chr12:69753453	YEATS4	0.61	8.85	0.44	5.16e-17	Response to diuretic therapy;
LUSC	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	12.57	0.57	6.01e-30	Cognitive test performance;
LUSC	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.31	-0.41	2.43e-15	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.95	0.36	1.97e-11	Cystic fibrosis severity;
LUSC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.2	-0.37	3.92e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs3741151	0.686	rs12291233	chr11:73272946	T/G	cg17517138	chr11:73019481	ARHGEF17	0.82	7.65	0.39	2.15e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg18305652	chr10:134549665	INPP5A	0.44	6.68	0.34	9.79e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.96	-12.97	-0.58	1.97e-31	Gut microbiome composition (summer);
LUSC	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-9.25	-0.45	2.79e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs3087591	0.708	rs12940802	chr17:29643564	C/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.09	0.36	8.2e-12	Hip circumference;
LUSC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.38	-0.37	1.29e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.65	-9.73	-0.47	7.55e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1178968	0.818	rs2108235	chr7:72783383	A/G	cg25889504	chr7:72793014	NA	0.61	8.21	0.41	4.75e-15	Triglyceride levels;
LUSC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg24642844	chr7:1081250	C7orf50	-0.79	-10.39	-0.49	4.39e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs2278907	0.898	rs4073959	chr11:68481490	C/T	cg10806483	chr12:102459329	NA	0.32	6.09	0.32	3.08e-9	Total body bone mineral density;
LUSC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg03146154	chr1:46216737	IPP	0.56	8.32	0.41	2.35e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg02475777	chr4:1388615	CRIPAK	0.44	6.58	0.34	1.84e-10	Obesity-related traits;
LUSC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg25767906	chr1:53392781	SCP2	-0.53	-9.61	-0.47	1.84e-19	Monocyte count;
LUSC	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.32	-0.41	2.25e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9611519	1.000	rs5758267	chr22:41619350	A/T	cg03806693	chr22:41940476	POLR3H	0.47	6.56	0.34	2.04e-10	Neuroticism;
LUSC	cis	rs12823128	1.000	rs12823128	chr12:26872730	C/T	cg19407459	chr12:26986763	ITPR2	-0.42	-5.8	-0.3	1.55e-8	Birth weight;
LUSC	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg15605315	chr1:45957053	TESK2	0.43	6.6	0.34	1.63e-10	High light scatter reticulocyte count;
LUSC	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg05625103	chr10:2543513	NA	0.5	7.33	0.37	1.74e-12	Age-related hearing impairment;
LUSC	cis	rs977987	0.778	rs4887821	chr16:75398574	G/A	cg04384234	chr16:75411784	CFDP1	-0.42	-6.95	-0.36	1.94e-11	Dupuytren's disease;
LUSC	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg03929089	chr4:120376271	NA	0.66	6.25	0.32	1.23e-9	Axial length;
LUSC	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg13010199	chr12:38710504	ALG10B	0.55	8.36	0.42	1.74e-15	Morning vs. evening chronotype;
LUSC	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg16482183	chr6:26056742	HIST1H1C	0.44	6.46	0.33	3.77e-10	Height;
LUSC	cis	rs7246967	0.611	rs16999598	chr19:22943125	A/G	cg23217946	chr19:22817039	ZNF492	0.43	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg04998671	chr14:104000505	TRMT61A	-0.58	-7.82	-0.39	7.1e-14	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg06096015	chr1:231504339	EGLN1	0.56	9.85	0.47	2.87e-20	Hemoglobin concentration;
LUSC	cis	rs6005807	0.719	rs12166245	chr22:28999890	C/T	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg19626725	chr5:178986131	RUFY1	0.52	9.06	0.44	1.13e-17	Lung cancer;
LUSC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg01616529	chr11:638424	DRD4	-0.34	-5.66	-0.3	3.33e-8	Systemic lupus erythematosus;
LUSC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg02423579	chr7:2872169	GNA12	-0.45	-6.29	-0.33	9.8e-10	Height;
LUSC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.71	10.99	0.52	3.36e-24	Monocyte percentage of white cells;
LUSC	cis	rs2625529	0.938	rs2723343	chr15:72108269	C/T	cg16672083	chr15:72433130	SENP8	-0.52	-7.25	-0.37	2.94e-12	Red blood cell count;
LUSC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.42	0.46	7.67e-19	Prudent dietary pattern;
LUSC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.82	12.57	0.57	6.09e-30	IgG glycosylation;
LUSC	trans	rs6076960	0.681	rs4487157	chr20:6249581	G/A	cg21095983	chr6:86352623	SYNCRIP	0.49	7.39	0.37	1.16e-12	Smooth-surface caries;
LUSC	cis	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg07460842	chr6:66804631	NA	0.47	5.83	0.3	1.33e-8	Metabolite levels;
LUSC	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg00383909	chr3:49044727	WDR6	-0.87	-8.42	-0.42	1.12e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2348418	0.715	rs1581076	chr12:28723657	A/G	cg13890972	chr12:28721907	NA	-0.39	-6.86	-0.35	3.39e-11	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs870825	0.616	rs4264873	chr4:185624336	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.82	-0.35	4.27e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6601450	0.540	rs7824231	chr8:10273958	G/A	cg21775007	chr8:11205619	TDH	-0.45	-6.28	-0.32	1.07e-9	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.8	0.54	4.39e-27	Exhaled nitric oxide output;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05779081	chr10:93683588	BTAF1	0.7	6.05	0.31	3.93e-9	Cognitive performance;
LUSC	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg24375607	chr4:120327624	NA	-0.75	-11.62	-0.54	1.93e-26	Corneal astigmatism;
LUSC	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg00376283	chr12:123451042	ABCB9	0.66	8.34	0.42	2e-15	Neutrophil percentage of white cells;
LUSC	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg16791601	chr12:66731901	HELB	-0.57	-9.4	-0.46	8.98e-19	White blood cell count (basophil);
LUSC	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg05855489	chr10:104503620	C10orf26	-0.6	-8.05	-0.4	1.48e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3743162	0.553	rs12915656	chr15:85415580	G/C	cg12863693	chr15:85201151	NMB	0.31	5.96	0.31	6.29e-9	Alzheimer's disease (age of onset);
LUSC	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg09904177	chr6:26538194	HMGN4	0.76	14.42	0.62	5.75e-37	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.29	-0.33	1.01e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs727505	1.000	rs6971909	chr7:124525517	C/T	cg23710748	chr7:124431027	NA	-0.4	-7.18	-0.37	4.56e-12	Lewy body disease;
LUSC	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg09491104	chr22:46646882	C22orf40	-0.71	-7.24	-0.37	3.2e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg26876637	chr1:152193138	HRNR	0.46	6.57	0.34	1.96e-10	Atopic dermatitis;
LUSC	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg01579765	chr21:45077557	HSF2BP	-0.48	-10.07	-0.48	5.18e-21	Mean corpuscular volume;
LUSC	trans	rs1146849	0.836	rs495677	chr13:72864140	A/G	cg23661343	chr18:616707	CLUL1	-0.41	-5.97	-0.31	6.23e-9	Facial emotion recognition (sad faces);
LUSC	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg00852783	chr1:26633632	UBXN11	-0.49	-5.8	-0.3	1.52e-8	Obesity-related traits;
LUSC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg24977027	chr2:88469347	THNSL2	0.56	5.84	0.3	1.21e-8	Plasma clusterin levels;
LUSC	trans	rs9860340	0.730	rs12108006	chr3:87636588	A/G	cg03644585	chr7:884825	UNC84A	0.42	6.09	0.32	3.17e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg20406979	chr6:167373233	NA	0.26	6.13	0.32	2.5e-9	Crohn's disease;
LUSC	trans	rs1015291	0.708	rs1565591	chr12:19997707	A/G	cg01501474	chr7:55323552	NA	-0.45	-5.97	-0.31	6.09e-9	Diastolic blood pressure;
LUSC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.03	21.12	0.76	1.7e-63	Cognitive function;
LUSC	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg24562669	chr7:97807699	LMTK2	0.36	6.32	0.33	8.56e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23158103	chr7:148848205	ZNF398	-0.43	-6.72	-0.35	7.94e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	0.57	8.75	0.43	1.1e-16	Breast cancer;
LUSC	cis	rs668210	0.793	rs534201	chr11:65776728	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.59	7.89	0.4	4.27e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg20476274	chr7:133979776	SLC35B4	0.83	15.25	0.64	3.17e-40	Mean platelet volume;
LUSC	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg09876464	chr15:85330779	ZNF592	0.36	6.57	0.34	1.94e-10	P wave terminal force;
LUSC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	cis	rs12911832	0.958	rs12912003	chr15:58986001	A/T	cg05156742	chr15:59063176	FAM63B	0.5	7.14	0.36	5.8e-12	Schizophrenia;
LUSC	cis	rs1832871	0.711	rs9459877	chr6:158692331	G/A	cg07165851	chr6:158734300	TULP4	0.5	7.8	0.39	7.87e-14	Height;
LUSC	cis	rs9807841	0.617	rs2229383	chr19:10794630	G/T	cg09936142	chr19:10668400	KRI1	-0.4	-6.43	-0.33	4.34e-10	Inflammatory skin disease;
LUSC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2658782	0.547	rs4344448	chr11:93047047	T/C	cg15737290	chr11:93063684	CCDC67	0.9	13.72	0.6	2.69e-34	Pulmonary function decline;
LUSC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg10729496	chr3:10149963	C3orf24	0.52	7.11	0.36	7.19e-12	Alzheimer's disease;
LUSC	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07169764	chr2:136633963	MCM6	1.15	18.77	0.72	3.45e-54	Corneal structure;
LUSC	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg20283391	chr11:68216788	NA	-0.51	-7.34	-0.37	1.67e-12	Total body bone mineral density;
LUSC	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg20701182	chr2:24300061	SF3B14	0.77	7.69	0.39	1.67e-13	Lymphocyte counts;
LUSC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg15445000	chr17:37608096	MED1	0.39	6.77	0.35	5.9e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-7.81	-0.39	7.68e-14	Blood metabolite levels;
LUSC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.73	-0.35	7.19e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-1.02	-17.33	-0.69	1.93e-48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1784581	0.588	rs9355971	chr6:162421242	A/G	cg17173639	chr6:162384350	PARK2	0.57	9.91	0.48	1.8e-20	Itch intensity from mosquito bite;
LUSC	trans	rs1268789	0.545	rs10026662	chr4:79372856	A/C	cg06112894	chr8:141469983	TRAPPC9	0.23	6.26	0.32	1.19e-9	Hair shape;Hair morphology;
LUSC	cis	rs6906287	0.647	rs12203006	chr6:118917086	C/T	cg21191810	chr6:118973309	C6orf204	0.32	5.92	0.31	7.82e-9	Electrocardiographic conduction measures;
LUSC	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-1.13	-17.82	-0.7	2.14e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg04844267	chr4:1394941	NA	0.3	5.95	0.31	6.6e-9	Obesity-related traits;
LUSC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg00343986	chr7:65444356	GUSB	0.47	6.99	0.36	1.47e-11	Aortic root size;
LUSC	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.76	-12.82	-0.57	7.37e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg13813247	chr22:41461852	NA	-0.38	-6.82	-0.35	4.38e-11	Neuroticism;
LUSC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-6.13	-0.32	2.45e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1784581	0.588	rs7453474	chr6:162421736	C/T	cg17173639	chr6:162384350	PARK2	0.57	9.98	0.48	1.06e-20	Itch intensity from mosquito bite;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18373944	chr11:33722333	C11orf91	0.44	6.56	0.34	2.11e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03364193	chr7:100167564	NA	0.71	6.4	0.33	5.29e-10	Cognitive performance;
LUSC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg27572855	chr1:25598939	RHD	0.49	8.88	0.44	4.31e-17	Erythrocyte sedimentation rate;
LUSC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg04518342	chr5:131593106	PDLIM4	0.42	7.47	0.38	7.28e-13	Breast cancer;
LUSC	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg15711740	chr2:61764176	XPO1	-0.5	-7.94	-0.4	3.21e-14	Tuberculosis;
LUSC	cis	rs7177699	0.581	rs7165081	chr15:79123396	C/G	cg15571903	chr15:79123663	NA	0.34	6.34	0.33	7.41e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg13010199	chr12:38710504	ALG10B	0.49	7.37	0.37	1.32e-12	Morning vs. evening chronotype;
LUSC	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	13.56	0.6	1.14e-33	Multiple sclerosis;
LUSC	cis	rs308403	0.509	rs309357	chr4:123653576	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.97	18.22	0.71	5.31e-52	Blood protein levels;
LUSC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg14949292	chr17:78079608	GAA	-0.31	-5.87	-0.31	1.06e-8	Yeast infection;
LUSC	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg04691961	chr3:161091175	C3orf57	-0.35	-5.9	-0.31	8.87e-9	Morning vs. evening chronotype;
LUSC	cis	rs4285028	0.580	rs2293611	chr3:121643163	G/C	cg20356878	chr3:121714668	ILDR1	-0.45	-6.81	-0.35	4.63e-11	Multiple sclerosis;
LUSC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg22166914	chr1:53195759	ZYG11B	0.47	7.67	0.39	1.93e-13	Monocyte count;
LUSC	cis	rs2109514	0.774	rs6954077	chr7:116129153	G/A	cg12739419	chr7:116140593	CAV2	-0.27	-5.77	-0.3	1.77e-8	Prevalent atrial fibrillation;
LUSC	cis	rs4786125	0.581	rs1473519	chr16:6921533	G/A	cg03623568	chr16:6915990	A2BP1	-0.45	-7.56	-0.38	4.05e-13	Heart rate variability traits (SDNN);
LUSC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	0.79	13.97	0.61	3.04e-35	Cognitive function;
LUSC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg19592336	chr6:28129416	ZNF389	-0.52	-6.78	-0.35	5.56e-11	Parkinson's disease;
LUSC	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06002616	chr8:101225028	SPAG1	0.45	7.36	0.37	1.45e-12	Atrioventricular conduction;
LUSC	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg05425664	chr17:57184151	TRIM37	-0.51	-7.64	-0.39	2.27e-13	Testicular germ cell tumor;
LUSC	cis	rs6840360	1.000	rs10019048	chr4:152603615	A/G	cg22705602	chr4:152727874	NA	-0.29	-6.24	-0.32	1.36e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg20503657	chr10:835505	NA	0.79	9.87	0.48	2.49e-20	Eosinophil percentage of granulocytes;
LUSC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg14004847	chr7:1930337	MAD1L1	-0.58	-9.01	-0.44	1.64e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03517284	chr6:25882590	NA	-0.39	-6.86	-0.35	3.33e-11	Height;
LUSC	cis	rs2652834	0.718	rs2652813	chr15:63405366	G/A	cg05507819	chr15:63340323	TPM1	0.56	7.17	0.37	4.99e-12	HDL cholesterol;
LUSC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg25767906	chr1:53392781	SCP2	0.48	8.56	0.42	4.16e-16	Monocyte count;
LUSC	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.47	0.38	6.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.79	0.43	8.33e-17	Prudent dietary pattern;
LUSC	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg13852791	chr20:30311386	BCL2L1	-0.89	-13.3	-0.59	1.11e-32	Mean corpuscular hemoglobin;
LUSC	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg22906224	chr7:99728672	NA	-0.47	-6.52	-0.34	2.56e-10	Coronary artery disease;
LUSC	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.3	-0.33	9.56e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg00339695	chr16:24857497	SLC5A11	0.4	7.3	0.37	2.11e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs6725041	0.805	rs6745249	chr2:213130571	A/G	cg26962342	chr5:153418526	MFAP3;FAM114A2	-0.45	-6.58	-0.34	1.83e-10	QT interval (ambient particulate matter interaction);
LUSC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg18827107	chr12:86230957	RASSF9	0.46	6.96	0.36	1.86e-11	Major depressive disorder;
LUSC	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg24558204	chr6:135376177	HBS1L	0.67	10.54	0.5	1.27e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	0.92	13.86	0.6	7.98e-35	Breast cancer;
LUSC	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg24642439	chr20:33292090	TP53INP2	-0.5	-7.5	-0.38	5.92e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs1044826	0.642	rs2071388	chr3:139236683	C/T	cg15131784	chr3:139108705	COPB2	-0.41	-6.52	-0.34	2.58e-10	Obesity-related traits;
LUSC	cis	rs4660306	0.677	rs781060	chr1:45934166	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.42	5.88	0.31	1.01e-8	Homocysteine levels;
LUSC	cis	rs9549260	0.651	rs57735994	chr13:41226561	C/G	cg21288729	chr13:41239152	FOXO1	0.65	10.04	0.48	6.48e-21	Red blood cell count;
LUSC	cis	rs62400317	0.859	rs12193812	chr6:45140761	C/T	cg18551225	chr6:44695536	NA	-0.42	-6.9	-0.35	2.69e-11	Total body bone mineral density;
LUSC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg15103426	chr22:29168792	CCDC117	0.5	6.87	0.35	3.17e-11	Lymphocyte counts;
LUSC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg03538708	chr1:25844672	NA	-0.36	-5.95	-0.31	6.74e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.2e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.84	0.35	3.76e-11	Educational attainment;
LUSC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg22601191	chr20:60968625	CABLES2	0.57	9.8	0.47	4.23e-20	Colorectal cancer;
LUSC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01570182	chr17:44337453	NA	-0.69	-10.4	-0.49	4.08e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.6	0.38	2.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.97	-0.44	2.18e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg06784218	chr1:46089804	CCDC17	0.3	5.95	0.31	6.92e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg26513180	chr16:89883248	FANCA	-0.75	-6.34	-0.33	7.54e-10	Skin colour saturation;
LUSC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-1.07	-25.94	-0.82	4.9e-82	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg06713675	chr4:122721982	EXOSC9	-0.72	-12.31	-0.56	5.85e-29	Type 2 diabetes;
LUSC	cis	rs3744061	0.557	rs9909137	chr17:74648029	G/A	cg27546012	chr17:74684504	MXRA7	-0.37	-6.33	-0.33	8.13e-10	Retinal arteriolar caliber;
LUSC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg11812906	chr14:75593930	NEK9	0.39	5.77	0.3	1.85e-8	Caffeine consumption;
LUSC	cis	rs4654899	1.000	rs10799686	chr1:21486445	A/T	cg01072550	chr1:21505969	NA	0.53	8.11	0.41	9.91e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	1.04	19.77	0.73	3.88e-58	Menopause (age at onset);
LUSC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-8.05	-0.4	1.5e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7903847	0.642	rs10882909	chr10:99137998	G/C	cg20016023	chr10:99160130	RRP12	-0.34	-8.41	-0.42	1.22e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg23887609	chr12:130822674	PIWIL1	0.49	7.34	0.37	1.64e-12	Menopause (age at onset);
LUSC	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg12454169	chr2:30669597	LCLAT1	-0.57	-7.66	-0.39	2.04e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs17034641	1.000	rs10495929	chr2:46372174	A/G	cg12428440	chr2:46370979	PRKCE	-0.47	-6.42	-0.33	4.57e-10	Hemoglobin;Hematocrit;
LUSC	cis	rs4919687	0.550	rs7904252	chr10:104456725	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.4	5.85	0.3	1.16e-8	Colorectal cancer;
LUSC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg16228356	chr17:43848958	NA	-0.27	-6.29	-0.33	1e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.9	15.11	0.64	1.13e-39	Bladder cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04047827	chr16:24740859	TNRC6A	0.41	5.94	0.31	6.97e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg22532475	chr10:104410764	TRIM8	0.28	5.7	0.3	2.65e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg20406979	chr6:167373233	NA	-0.26	-6.16	-0.32	2.1e-9	Crohn's disease;
LUSC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-0.82	-9.92	-0.48	1.67e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg00310523	chr12:86230176	RASSF9	0.4	7.18	0.37	4.67e-12	Major depressive disorder;
LUSC	cis	rs597583	0.715	rs11216437	chr11:117394685	A/G	cg27161313	chr11:117392002	DSCAML1	0.46	7.79	0.39	8.49e-14	Putamen volume;
LUSC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11764359	chr7:65958608	NA	0.61	9.15	0.45	5.77e-18	Aortic root size;
LUSC	cis	rs11971779	0.680	rs10274480	chr7:139052428	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.06	0.36	9.47e-12	Diisocyanate-induced asthma;
LUSC	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg06197492	chr11:2016605	H19	0.43	6.95	0.36	1.92e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.56	-0.46	2.75e-19	Coronary artery disease;
LUSC	cis	rs4950928	0.700	rs946263	chr1:203165381	A/G	cg17014757	chr1:203156097	CHI3L1	0.39	6.31	0.33	8.84e-10	YKL-40 levels;
LUSC	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg15819921	chr19:927150	ARID3A	-0.44	-6.54	-0.34	2.26e-10	Life satisfaction;
LUSC	trans	rs9650657	0.593	rs1968401	chr8:10615383	C/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.23	-0.32	1.36e-9	Neuroticism;
LUSC	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg22676075	chr6:135203613	NA	0.46	7.27	0.37	2.56e-12	Red blood cell count;
LUSC	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-6.41	-0.33	4.93e-10	Menarche (age at onset);
LUSC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	9.02	0.44	1.52e-17	Prudent dietary pattern;
LUSC	cis	rs1113500	0.836	rs1618973	chr1:108586767	T/C	cg06207961	chr1:108661230	NA	-0.37	-6.82	-0.35	4.18e-11	Growth-regulated protein alpha levels;
LUSC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg00012203	chr2:219082015	ARPC2	0.86	16.31	0.67	2.15e-44	Colorectal cancer;
LUSC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.22	-13.8	-0.6	1.31e-34	Diabetic kidney disease;
LUSC	trans	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.34e-10	Corneal astigmatism;
LUSC	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.44	-0.33	4.26e-10	Arsenic metabolism;
LUSC	cis	rs9462027	0.651	rs9469870	chr6:34744349	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.73	-0.3	2.27e-8	Systemic lupus erythematosus;
LUSC	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	1.08	14.6	0.62	1.08e-37	Exhaled nitric oxide levels;
LUSC	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg20243544	chr17:37824526	PNMT	0.51	7.42	0.38	9.72e-13	Asthma;
LUSC	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-1.04	-16.3	-0.67	2.24e-44	Exhaled nitric oxide output;
LUSC	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.75	0.51	2.35e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.74	10.31	0.49	7.79e-22	Corneal astigmatism;
LUSC	cis	rs4561483	0.583	rs1019813	chr16:11940829	C/T	cg08843971	chr16:11963173	GSPT1	0.38	5.79	0.3	1.62e-8	Testicular germ cell tumor;
LUSC	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.77	-12.29	-0.56	6.75e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.82	14.63	0.62	8.81e-38	Sudden cardiac arrest;
LUSC	cis	rs71444571	1	rs71444571	chr12:123771015	G/A	cg00376283	chr12:123451042	ABCB9	-0.72	-7.84	-0.39	5.96e-14	Lymphocyte percentage of white cells;
LUSC	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg18002602	chr11:66138449	SLC29A2	0.34	6.07	0.32	3.52e-9	HIV-1 susceptibility;
LUSC	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.16	0.45	5.19e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7580658	0.963	rs10803585	chr2:128130108	G/A	cg09760422	chr2:128146352	NA	-0.33	-7.25	-0.37	2.91e-12	Protein C levels;
LUSC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg05623727	chr3:50126028	RBM5	-0.33	-6.2	-0.32	1.65e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.54	0.38	4.62e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg00750074	chr16:89608354	SPG7	-0.55	-9.88	-0.48	2.29e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00149659	chr3:10157352	C3orf10	0.89	12.15	0.55	2.18e-28	Alzheimer's disease;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg02181963	chr13:111358803	CARS2	-0.43	-5.95	-0.31	6.78e-9	Cognitive function;Information processing speed;
LUSC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.9	-0.48	1.99e-20	Platelet count;
LUSC	cis	rs9362426	0.895	rs242292	chr6:88078074	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	6.1	0.32	2.97e-9	Depressive episodes in bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09184467	chr10:14995699	DCLRE1C	0.46	7.45	0.38	8.17e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs61774743	0.557	rs4660192	chr1:41842350	C/T	cg08462924	chr1:41848221	NA	0.5	8.55	0.42	4.46e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg18477163	chr1:228402036	OBSCN	-0.61	-11.64	-0.54	1.68e-26	Diastolic blood pressure;
LUSC	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.28	0.53	3.13e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg01620082	chr3:125678407	NA	-0.6	-6.8	-0.35	4.77e-11	Depression;
LUSC	cis	rs6545883	0.894	rs2463102	chr2:61571295	G/C	cg15711740	chr2:61764176	XPO1	0.42	6.5	0.34	2.87e-10	Tuberculosis;
LUSC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.94	-19.27	-0.73	3.78e-56	Post bronchodilator FEV1;
LUSC	trans	rs2786098	0.656	rs4915552	chr1:197512778	G/A	cg16005942	chr6:160526640	IGF2R	0.5	6.04	0.31	4.13e-9	Asthma;
LUSC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg15839431	chr19:19639596	YJEFN3	0.42	5.73	0.3	2.3e-8	Tonsillectomy;
LUSC	cis	rs4776059	0.916	rs2414161	chr15:52883285	T/C	cg25063058	chr15:52860530	ARPP19	0.47	6.48	0.33	3.27e-10	Schizophrenia;
LUSC	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.84	-0.39	6.14e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7119167	0.686	rs6592520	chr11:73048267	T/G	cg17517138	chr11:73019481	ARHGEF17	0.48	5.64	0.3	3.56e-8	Blood protein levels;
LUSC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg06532163	chr17:45867833	NA	-0.35	-6.5	-0.34	2.9e-10	IgG glycosylation;
LUSC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg15335139	chr3:50242325	SLC38A3	0.25	5.71	0.3	2.49e-8	Body mass index;
LUSC	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg26668713	chr11:65405903	SIPA1	0.63	7.57	0.38	3.75e-13	Blood pressure (age interaction);
LUSC	trans	rs2700987	0.692	rs1986567	chr7:37386650	C/G	cg26076750	chr5:98105150	RGMB	0.37	6.53	0.34	2.39e-10	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg06008330	chr7:65541103	ASL	-0.41	-6.39	-0.33	5.68e-10	Aortic root size;
LUSC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg23625390	chr15:77176239	SCAPER	-0.62	-8.9	-0.44	3.53e-17	Blood metabolite levels;
LUSC	trans	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Bladder cancer;
LUSC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg21138405	chr5:131827807	IRF1	0.35	6.4	0.33	5.2e-10	Breast cancer;Mosquito bite size;
LUSC	cis	rs9463078	0.585	rs1521355	chr6:44932755	T/C	cg25276700	chr6:44698697	NA	-0.28	-5.74	-0.3	2.17e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.63	-5.93	-0.31	7.39e-9	Major depressive disorder;
LUSC	cis	rs740160	0.510	rs11771702	chr7:98904300	C/G	cg24650262	chr7:98904301	NA	0.62	6.85	0.35	3.54e-11	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg26394196	chr10:1453818	ADARB2	-0.37	-6.36	-0.33	6.48e-10	Radiation response;
LUSC	cis	rs7408868	0.563	rs10423702	chr19:15300069	T/C	cg14696996	chr19:15285081	NOTCH3	0.77	7.83	0.39	6.51e-14	Pulse pressure;
LUSC	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg01579765	chr21:45077557	HSF2BP	-0.49	-10.18	-0.49	2.16e-21	Mean corpuscular volume;
LUSC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.52e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.39e-22	Alzheimer's disease (late onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg20539690	chr10:101190675	GOT1	0.48	6.49	0.33	3.09e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg05299278	chr17:33885742	SLFN14	0.3	6.23	0.32	1.39e-9	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14019695	chr9:139328340	INPP5E	0.52	10.05	0.48	6.06e-21	Monocyte percentage of white cells;
LUSC	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.83	-0.35	4.14e-11	Response to antipsychotic treatment;
LUSC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg05132306	chr1:1846340	CALML6	0.26	6.25	0.32	1.25e-9	Body mass index;
LUSC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.46	-7.26	-0.37	2.68e-12	Schizophrenia;
LUSC	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg02569458	chr12:86230093	RASSF9	0.39	6.33	0.33	8.03e-10	Major depressive disorder;
LUSC	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg09307838	chr4:120376055	NA	0.51	7.55	0.38	4.27e-13	Diastolic blood pressure;
LUSC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-0.88	-16.83	-0.68	1.92e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7804356	1.000	rs12534899	chr7:26877189	C/T	cg03456212	chr7:26904342	SKAP2	0.5	5.99	0.31	5.3e-9	Type 1 diabetes;
LUSC	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg24550644	chr17:30846204	MYO1D	-0.44	-7.03	-0.36	1.14e-11	Schizophrenia;
LUSC	trans	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg01620082	chr3:125678407	NA	-0.86	-7.42	-0.38	9.7e-13	Depression;
LUSC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg10862848	chr6:42927986	GNMT	-0.29	-7.04	-0.36	1.08e-11	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg16372103	chr5:203701	NA	-0.42	-5.81	-0.3	1.49e-8	Breast cancer;
LUSC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15664640	chr17:80829946	TBCD	-0.74	-13.23	-0.59	2.12e-32	Breast cancer;
LUSC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg12463550	chr7:65579703	CRCP	-0.48	-7.17	-0.37	4.76e-12	Aortic root size;
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.53	-8.13	-0.41	8.36e-15	Lymphocyte counts;
LUSC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-1.0	-13.86	-0.6	8.31e-35	Vitiligo;
LUSC	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg15819921	chr19:927150	ARID3A	0.42	6.0	0.31	5.2e-9	Life satisfaction;
LUSC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16405210	chr4:1374714	KIAA1530	-0.59	-9.37	-0.46	1.08e-18	Longevity;
LUSC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg00784671	chr22:46762841	CELSR1	-0.48	-5.97	-0.31	6.22e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-7.83	-0.39	6.58e-14	Menarche (age at onset);
LUSC	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg07936489	chr17:37558343	FBXL20	-0.71	-9.74	-0.47	6.9e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg17541715	chr7:1216824	NA	-0.39	-6.18	-0.32	1.92e-9	Longevity;Endometriosis;
LUSC	cis	rs870825	0.860	rs72703519	chr4:185602707	G/A	cg04058563	chr4:185651563	MLF1IP	0.77	10.26	0.49	1.17e-21	Blood protein levels;
LUSC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	11.98	0.55	9.49e-28	Colorectal cancer;
LUSC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	0.93	13.01	0.58	1.34e-31	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1865721	0.771	rs724764	chr18:73139742	C/T	cg26385618	chr18:73139727	C18orf62	-0.55	-10.12	-0.48	3.64e-21	Intelligence;
LUSC	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	0.93	17.58	0.69	1.94e-49	Headache;
LUSC	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg27286337	chr10:134555280	INPP5A	0.6	9.41	0.46	8.4e-19	Gait speed in old age;
LUSC	cis	rs977987	0.835	rs11641532	chr16:75329480	T/C	cg03315344	chr16:75512273	CHST6	0.51	9.66	0.47	1.21e-19	Dupuytren's disease;
LUSC	cis	rs7200543	1.000	rs1121	chr16:15131076	G/A	cg03427771	chr16:15082598	PDXDC1	-0.42	-5.88	-0.31	9.86e-9	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg06191203	chr2:152266755	RIF1	-0.56	-7.41	-0.38	1.05e-12	Lung cancer;
LUSC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg23625390	chr15:77176239	SCAPER	0.52	8.01	0.4	1.99e-14	Blood metabolite levels;
LUSC	trans	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17712092	chr4:129076599	LARP1B	-0.97	-15.95	-0.66	5.71e-43	Eosinophil percentage of white cells;
LUSC	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12826209	chr6:26865740	GUSBL1	0.74	9.08	0.44	9.64e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg03351412	chr1:154909251	PMVK	0.52	7.94	0.4	3.18e-14	Prostate cancer;
LUSC	cis	rs909341	0.903	rs1291205	chr20:62328829	C/G	cg09650180	chr20:62225654	GMEB2	-0.45	-5.94	-0.31	7.04e-9	Atopic dermatitis;
LUSC	cis	rs4343996	0.869	rs10232431	chr7:3511115	G/A	cg21248987	chr7:3385318	SDK1	0.35	5.73	0.3	2.25e-8	Motion sickness;
LUSC	trans	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	9.49	0.46	4.38e-19	Eotaxin levels;
LUSC	cis	rs9900062	0.519	rs2676293	chr17:62710461	T/C	cg02598441	chr17:62777298	LOC146880	-0.56	-7.29	-0.37	2.22e-12	QT interval;
LUSC	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.91	0.31	8.5e-9	Rheumatoid arthritis;
LUSC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.88	16.91	0.68	9.02e-47	Mean platelet volume;
LUSC	cis	rs72781680	0.821	rs12623521	chr2:24181670	C/T	cg08917208	chr2:24149416	ATAD2B	0.6	6.94	0.35	2.07e-11	Lymphocyte counts;
LUSC	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	7.16	0.36	5.24e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg11663144	chr21:46675770	NA	-0.41	-7.14	-0.36	5.99e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11971779	0.680	rs2355787	chr7:139089928	G/T	cg07862535	chr7:139043722	LUC7L2	-0.59	-7.54	-0.38	4.45e-13	Diisocyanate-induced asthma;
LUSC	cis	rs11622475	1.000	rs2236247	chr14:104378087	C/T	cg12183467	chr14:104352244	NA	-0.36	-6.58	-0.34	1.79e-10	Bipolar disorder;
LUSC	cis	rs4499344	0.633	rs259239	chr19:33141090	C/T	cg22980127	chr19:33182716	NUDT19	-0.39	-5.92	-0.31	7.99e-9	Mean platelet volume;
LUSC	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg11062466	chr8:58055876	NA	0.66	8.74	0.43	1.15e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.69	11.39	0.53	1.28e-25	Heart rate;
LUSC	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg17145862	chr1:211918768	LPGAT1	0.23	6.1	0.32	2.97e-9	Leprosy;
LUSC	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.71	-0.3	2.44e-8	Recombination rate (females);
LUSC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	13.01	0.58	1.33e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg17264618	chr3:40429014	ENTPD3	0.32	7.01	0.36	1.3e-11	Renal cell carcinoma;
LUSC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.28	-0.45	2.26e-18	Gut microbiome composition (summer);
LUSC	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg04455712	chr21:45112962	RRP1B	0.46	8.62	0.43	2.73e-16	Mean corpuscular volume;
LUSC	cis	rs12986413	1.000	rs12982593	chr19:2175891	C/A	cg09261902	chr19:2140048	AP3D1	0.31	5.93	0.31	7.5e-9	Height;
LUSC	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg13755796	chr4:20253514	NA	-0.44	-6.9	-0.35	2.56e-11	Life satisfaction;
LUSC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg21699342	chr2:239360505	ASB1	0.43	6.66	0.34	1.14e-10	Multiple system atrophy;
LUSC	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	13.86	0.6	7.72e-35	Blood protein levels;
LUSC	cis	rs642803	0.591	rs620088	chr11:65508986	G/A	cg02870584	chr11:65547924	DKFZp761E198	0.44	5.96	0.31	6.3e-9	Urate levels;
LUSC	trans	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg06606381	chr12:133084897	FBRSL1	-0.58	-8.76	-0.43	9.71e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs508618	0.697	rs7534248	chr1:231554531	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.58	7.08	0.36	8.71e-12	Red blood cell count;
LUSC	cis	rs2742234	0.541	rs4648313	chr10:43716739	G/A	cg02780029	chr10:43622663	RET	0.35	5.82	0.3	1.41e-8	Hirschsprung disease;
LUSC	cis	rs7605827	0.930	rs1019360	chr2:15524741	C/T	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs9463078	0.764	rs9395051	chr6:44825715	C/A	cg25276700	chr6:44698697	NA	-0.28	-5.72	-0.3	2.38e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.81	-12.24	-0.56	1e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg05623727	chr3:50126028	RBM5	0.32	5.98	0.31	5.61e-9	Body mass index;
LUSC	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg15556689	chr8:8085844	FLJ10661	0.54	7.78	0.39	9.28e-14	Neuroticism;
LUSC	cis	rs4908769	0.624	rs2708630	chr1:8447404	C/T	cg00546117	chr1:8445545	RERE	0.3	6.04	0.31	4.09e-9	Allergy;
LUSC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg20607287	chr7:12443886	VWDE	-0.6	-7.29	-0.37	2.31e-12	Coronary artery disease;
LUSC	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.4	-0.42	1.27e-15	Response to antipsychotic treatment;
LUSC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	0.79	13.88	0.6	6.93e-35	Cognitive function;
LUSC	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg24459738	chr19:57751996	ZNF805	-0.51	-7.67	-0.39	1.87e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg06454157	chr6:167490870	NA	-0.29	-6.77	-0.35	5.66e-11	Rheumatoid arthritis;
LUSC	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg23229984	chr5:148520753	ABLIM3	0.41	6.48	0.33	3.22e-10	Breast cancer;
LUSC	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	8.62	0.43	2.72e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs12618769	0.597	rs4851138	chr2:99065464	A/C	cg10123293	chr2:99228465	UNC50	0.45	7.71	0.39	1.46e-13	Bipolar disorder;
LUSC	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.93	15.97	0.66	4.9e-43	Morning vs. evening chronotype;
LUSC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg19539972	chr4:7069911	GRPEL1	-0.69	-7.13	-0.36	6.07e-12	Monocyte percentage of white cells;
LUSC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg22903471	chr2:27725779	GCKR	-0.41	-7.07	-0.36	8.93e-12	Total body bone mineral density;
LUSC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg11965913	chr1:205819406	PM20D1	0.59	10.28	0.49	1.02e-21	Menarche (age at onset);
LUSC	cis	rs3736594	0.513	rs6547735	chr2:27831607	T/C	cg27432699	chr2:27873401	GPN1	0.62	8.48	0.42	7.18e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs17255340	0.539	rs10455140	chr6:84059498	G/A	cg08257003	chr6:84140564	ME1	0.34	8.26	0.41	3.45e-15	Platelet-derived growth factor BB levels;
LUSC	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg11887960	chr12:57824829	NA	0.54	6.8	0.35	4.89e-11	Obesity-related traits;
LUSC	cis	rs897080	0.552	rs1067397	chr2:44679285	A/T	cg00619915	chr2:44497795	NA	-0.45	-6.51	-0.34	2.82e-10	Height;
LUSC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg16060761	chr17:80687452	NA	-0.52	-8.03	-0.4	1.73e-14	Glycated hemoglobin levels;
LUSC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg11871910	chr12:69753446	YEATS4	0.64	9.51	0.46	3.95e-19	Blood protein levels;
LUSC	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.6	10.55	0.5	1.19e-22	Weight;
LUSC	cis	rs27434	0.583	rs34756	chr5:96152383	C/T	cg16492584	chr5:96139282	ERAP1	0.46	6.49	0.33	3.06e-10	Ankylosing spondylitis;
LUSC	cis	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg26958806	chr6:27640298	NA	0.81	6.28	0.32	1.05e-9	Lung cancer in ever smokers;
LUSC	cis	rs7408868	1.000	rs7254269	chr19:15277429	A/T	cg14696996	chr19:15285081	NOTCH3	-0.91	-9.16	-0.45	5.24e-18	Pulse pressure;
LUSC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg23711669	chr6:146136114	FBXO30	-0.82	-14.93	-0.63	5.87e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg27572855	chr1:25598939	RHD	-0.41	-7.29	-0.37	2.26e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs2030746	0.521	rs13415147	chr2:121329768	A/G	cg03661458	chr2:121334411	NA	-0.3	-5.78	-0.3	1.71e-8	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LUSC	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg22563815	chr15:78856949	CHRNA5	0.24	5.75	0.3	1.96e-8	Sudden cardiac arrest;
LUSC	trans	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg25214090	chr10:38739885	LOC399744	-0.52	-7.47	-0.38	7.16e-13	Corneal astigmatism;
LUSC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	7.12	0.36	6.47e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg05855489	chr10:104503620	C10orf26	-0.59	-9.73	-0.47	7.31e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21963583	chr11:68658836	MRPL21	0.56	8.54	0.42	4.94e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg20503657	chr10:835505	NA	-0.51	-7.03	-0.36	1.16e-11	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg26380479	chr7:97908229	NA	-0.27	-6.14	-0.32	2.37e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.7	0.47	9.46e-20	Lymphocyte counts;
LUSC	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg09307838	chr4:120376055	NA	-0.72	-10.52	-0.5	1.53e-22	Corneal astigmatism;
LUSC	cis	rs7572644	0.620	rs6547816	chr2:28169597	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-6.51	-0.34	2.83e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg27165867	chr14:105738592	BRF1	-0.52	-7.25	-0.37	2.89e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.55	-8.42	-0.42	1.13e-15	Longevity;
LUSC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg11608241	chr8:8085544	FLJ10661	0.43	6.47	0.33	3.57e-10	Mood instability;
LUSC	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.69	-11.11	-0.52	1.28e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.76	-12.16	-0.55	1.96e-28	Height;
LUSC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg11062466	chr8:58055876	NA	0.66	8.52	0.42	5.58e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs253664	1.000	rs4346503	chr3:138107597	A/G	cg25188949	chr3:137893707	DBR1	-0.49	-5.88	-0.31	9.73e-9	Body mass index;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01906555	chr2:74776410	LOXL3	-0.47	-6.25	-0.32	1.24e-9	Hepatitis;
LUSC	cis	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.76	0.43	1.03e-16	Endometrial cancer;
LUSC	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.51	6.62	0.34	1.4e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs983392	0.678	rs4938931	chr11:60026613	G/T	cg24026212	chr11:59952134	MS4A6A	0.35	6.09	0.32	3.12e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.51	-7.79	-0.39	8.61e-14	Lymphocyte counts;
LUSC	trans	rs370763	0.660	rs264776	chr5:64395452	C/T	cg26054548	chr3:62802561	CADPS	0.37	5.97	0.31	6.03e-9	Inguinal hernia;
LUSC	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg00191853	chr8:101177733	SPAG1	-0.41	-6.59	-0.34	1.68e-10	Atrioventricular conduction;
LUSC	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg10434728	chr15:90938212	IQGAP1	0.46	9.17	0.45	4.94e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg20744362	chr22:50050164	C22orf34	0.36	6.66	0.34	1.1e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg14895029	chr7:2775587	GNA12	-0.4	-6.11	-0.32	2.8e-9	Height;
LUSC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.17	0.58	3.41e-32	Cognitive test performance;
LUSC	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.43	0.56	1.99e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14495033	chr9:140707378	EHMT1	-0.41	-6.64	-0.34	1.29e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9811920	0.809	rs766778	chr3:99751480	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.36	-6.79	-0.35	5.03e-11	Axial length;
LUSC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.58e-8	Life satisfaction;
LUSC	trans	rs62055045	0.528	rs62056191	chr16:71533831	C/T	cg09088153	chr15:96890598	NA	-0.47	-6.42	-0.33	4.68e-10	Schizophrenia;
LUSC	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg00191853	chr8:101177733	SPAG1	-0.41	-6.53	-0.34	2.46e-10	Atrioventricular conduction;
LUSC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg14552801	chr7:65878734	NA	0.38	5.83	0.3	1.33e-8	Aortic root size;
LUSC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.38	-0.33	6e-10	Longevity;Endometriosis;
LUSC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21171335	chr12:122356390	WDR66	0.65	9.79	0.47	4.74e-20	Mean corpuscular volume;
LUSC	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	trans	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg06521331	chr12:34319734	NA	0.4	6.32	0.33	8.45e-10	Morning vs. evening chronotype;
LUSC	cis	rs4947962	0.564	rs2330948	chr7:55080356	A/G	cg23757825	chr7:55092271	EGFR	0.69	8.77	0.43	9.39e-17	Subjective response to lithium treatment;
LUSC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	0.97	14.15	0.61	6.21e-36	Vitiligo;
LUSC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.58	-9.46	-0.46	5.63e-19	Aortic root size;
LUSC	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.06	-0.36	9.76e-12	Triglycerides;
LUSC	cis	rs2282300	0.739	rs1222210	chr11:30362125	A/G	cg25418670	chr11:30344373	C11orf46	0.61	8.86	0.44	4.67e-17	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg09021430	chr5:549028	NA	-0.54	-7.46	-0.38	7.38e-13	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.27	0.45	2.41e-18	Red blood cell count;
LUSC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg15649852	chr7:65879115	NA	-0.4	-5.65	-0.3	3.44e-8	Aortic root size;
LUSC	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	7.5	0.38	5.7e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs948562	0.647	rs71486418	chr11:58240133	C/T	cg15696309	chr11:58395628	NA	-0.42	-5.96	-0.31	6.47e-9	Lymphoma;
LUSC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg06363034	chr20:62225388	GMEB2	0.46	7.86	0.4	5.4e-14	Glioblastoma;
LUSC	cis	rs7224314	1.000	rs8066725	chr17:65387326	G/A	cg01507342	chr17:65387096	PITPNC1	-0.44	-7.79	-0.39	8.5e-14	Diisocyanate-induced asthma;
LUSC	cis	rs6543140	0.964	rs6748390	chr2:103062175	A/G	cg09003973	chr2:102972529	NA	0.53	6.91	0.35	2.45e-11	Blood protein levels;
LUSC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	6.55	0.34	2.17e-10	Mean platelet volume;
LUSC	cis	rs516243	0.871	rs3748687	chr1:10736216	G/A	cg02903756	chr1:10750680	CASZ1	-0.46	-8.12	-0.41	9.35e-15	Migraine - clinic-based;
LUSC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg23262073	chr20:60523788	NA	-0.4	-5.93	-0.31	7.71e-9	Body mass index;
LUSC	cis	rs28655083	0.956	rs11863953	chr16:77065710	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.41	-6.08	-0.32	3.2e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg05855489	chr10:104503620	C10orf26	0.55	8.05	0.4	1.47e-14	Arsenic metabolism;
LUSC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-6.09	-0.32	3.16e-9	Tonsillectomy;
LUSC	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg11244672	chr19:19639970	YJEFN3	-0.57	-6.94	-0.35	2.06e-11	Bipolar disorder;
LUSC	cis	rs12801636	0.512	rs7119750	chr11:65422591	C/T	cg24147428	chr11:65409760	SIPA1	-0.5	-5.81	-0.3	1.45e-8	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18051889	chr17:53046101	COX11;STXBP4	0.43	6.25	0.32	1.24e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.65	-12.57	-0.57	6.15e-30	Longevity;Endometriosis;
LUSC	cis	rs2425143	1.000	rs73902914	chr20:34432882	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.89	-0.31	9.2e-9	Blood protein levels;
LUSC	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg01884057	chr2:25150051	NA	0.43	9.99	0.48	9.54e-21	Body mass index;
LUSC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg01881094	chr2:180872142	CWC22	-0.8	-10.28	-0.49	1.03e-21	Schizophrenia;
LUSC	trans	rs2018683	0.933	rs12536127	chr7:28985967	T/C	cg19402173	chr7:128379420	CALU	-0.54	-8.6	-0.43	3.22e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg20701182	chr2:24300061	SF3B14	0.58	6.16	0.32	2.1e-9	Lymphocyte counts;
LUSC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg00933542	chr6:150070202	PCMT1	0.32	6.8	0.35	4.8e-11	Lung cancer;
LUSC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg02187348	chr16:89574699	SPG7	0.48	7.09	0.36	8.07e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg23791538	chr6:167370224	RNASET2	-0.42	-6.74	-0.35	6.85e-11	Crohn's disease;
LUSC	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg11502198	chr6:26597334	ABT1	0.59	9.24	0.45	2.88e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg25206134	chr2:45395956	NA	0.6	6.33	0.33	7.71e-10	Bipolar disorder;
LUSC	trans	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg19676328	chr12:49525230	TUBA1B	-0.53	-8.12	-0.41	9.28e-15	Total cholesterol levels;
LUSC	trans	rs931812	0.757	rs4734015	chr8:101909258	C/G	cg20993868	chr7:22813445	NA	0.53	9.99	0.48	9.81e-21	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs6076065	0.723	rs2275788	chr20:23338694	G/A	cg11657817	chr20:23433608	CST11	0.43	8.03	0.4	1.7e-14	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs6445975	0.617	rs13071422	chr3:58398813	A/G	cg18950693	chr14:70346909	SMOC1	-0.4	-6.05	-0.31	3.87e-9	Systemic lupus erythematosus;
LUSC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08109568	chr15:31115862	NA	-0.74	-11.04	-0.52	2.25e-24	Huntington's disease progression;
LUSC	cis	rs4343996	1.000	rs4343996	chr7:3362642	G/A	cg21248987	chr7:3385318	SDK1	-0.38	-6.42	-0.33	4.75e-10	Motion sickness;
LUSC	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg07169764	chr2:136633963	MCM6	0.52	7.2	0.37	4.1e-12	Mosquito bite size;
LUSC	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg09184832	chr6:79620586	NA	-0.43	-6.96	-0.36	1.83e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg01528321	chr10:82214614	TSPAN14	1.12	18.04	0.7	2.77e-51	Post bronchodilator FEV1;
LUSC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg24562669	chr7:97807699	LMTK2	0.36	6.31	0.33	8.61e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11650494	0.901	rs117087923	chr17:47364913	G/A	cg08112188	chr17:47440006	ZNF652	1.22	10.33	0.49	6.95e-22	Prostate cancer;
LUSC	cis	rs6545883	0.894	rs10177303	chr2:61594459	G/A	cg15711740	chr2:61764176	XPO1	0.42	6.34	0.33	7.38e-10	Tuberculosis;
LUSC	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg15133208	chr4:90757351	SNCA	-0.32	-5.66	-0.3	3.23e-8	Dementia with Lewy bodies;
LUSC	cis	rs2011503	0.739	rs10412176	chr19:19689164	T/C	cg11244672	chr19:19639970	YJEFN3	0.47	6.16	0.32	2.12e-9	Bipolar disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16326998	chr7:5553266	FBXL18	-0.51	-6.41	-0.33	4.82e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs238295	0.805	rs6038214	chr20:5569822	C/G	cg15842884	chr20:5591925	RP5-1022P6.2	0.43	5.95	0.31	6.92e-9	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg01802117	chr1:53393560	SCP2	-0.39	-6.45	-0.33	3.94e-10	Monocyte count;
LUSC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg15605315	chr1:45957053	TESK2	0.47	7.49	0.38	6.26e-13	High light scatter reticulocyte count;
LUSC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.67	0.6	4.46e-34	Cognitive test performance;
LUSC	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg01966878	chr4:90757139	SNCA	-0.34	-5.85	-0.31	1.15e-8	Dementia with Lewy bodies;
LUSC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg13047869	chr3:10149882	C3orf24	0.66	9.53	0.46	3.37e-19	Alzheimer's disease;
LUSC	trans	rs10486158	0.843	rs2191818	chr7:7381902	C/A	cg01895333	chr3:109035405	DPPA2	-0.37	-6.01	-0.31	4.76e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09827037	chr3:5028674	NA	0.37	6.1	0.32	2.96e-9	Asthma;
LUSC	trans	rs11743006	0.589	rs11750026	chr5:136499798	T/C	cg07379741	chr17:7311030	NLGN2	0.4	6.01	0.31	4.78e-9	Mathematical ability;
LUSC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg27170947	chr2:26402098	FAM59B	0.6	8.53	0.42	5.22e-16	Gut microbiome composition (summer);
LUSC	cis	rs2625529	0.556	rs11630611	chr15:72466312	C/T	cg16672083	chr15:72433130	SENP8	0.5	8.0	0.4	2.14e-14	Red blood cell count;
LUSC	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg23093090	chr10:104574429	C10orf26	-0.45	-7.93	-0.4	3.35e-14	Arsenic metabolism;
LUSC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg02079420	chr8:82753780	SNX16	0.41	6.97	0.36	1.69e-11	Diastolic blood pressure;
LUSC	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg12826209	chr6:26865740	GUSBL1	0.68	7.67	0.39	1.85e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs17039065	1.000	rs17039065	chr4:109385403	C/T	cg07444054	chr2:108107501	NA	0.44	6.41	0.33	5e-10	Gut microbiome composition (summer);
LUSC	cis	rs10109025	0.701	rs10101292	chr8:10856474	T/C	cg21775007	chr8:11205619	TDH	-0.42	-5.86	-0.31	1.1e-8	Joint mobility (Beighton score);
LUSC	cis	rs9399401	0.884	rs6570510	chr6:142755024	C/T	cg03128060	chr6:142623767	GPR126	0.31	5.79	0.3	1.61e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.6	-12.56	-0.57	6.52e-30	Monocyte percentage of white cells;
LUSC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.4	0.62	6.35e-37	Platelet count;
LUSC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.82	-0.35	4.24e-11	Menopause (age at onset);
LUSC	trans	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.59	-9.57	-0.46	2.41e-19	Mean corpuscular volume;
LUSC	cis	rs1595825	0.735	rs113834557	chr2:198611624	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-5.99	-0.31	5.45e-9	Ulcerative colitis;
LUSC	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.26	0.52	3.73e-25	Hypertriglyceridemia;
LUSC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.7	0.39	1.61e-13	Prudent dietary pattern;
LUSC	cis	rs4655582	0.510	rs11208700	chr1:66133443	A/T	cg04111102	chr1:66153794	NA	0.26	5.64	0.3	3.56e-8	Fibrinogen levels;
LUSC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg15557168	chr22:42548783	NA	0.48	7.39	0.38	1.16e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs138918	0.772	rs138933	chr22:43565855	C/T	cg08909806	chr22:43548696	TSPO	0.36	6.18	0.32	1.82e-9	Monocyte count;
LUSC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26314531	chr2:26401878	FAM59B	-0.66	-9.44	-0.46	6.86e-19	Gut microbiome composition (summer);
LUSC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.17	-0.41	6.37e-15	Lymphocyte counts;
LUSC	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.45	-0.42	8.88e-16	Body mass index;
LUSC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg03929089	chr4:120376271	NA	-0.88	-13.69	-0.6	3.54e-34	Height;
LUSC	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.15	-0.36	5.68e-12	Joint mobility (Beighton score);
LUSC	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.71	-0.3	2.47e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04741861	chr19:3531604	FZR1	0.49	7.3	0.37	2.18e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10992471	0.528	rs3739606	chr9:95237222	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.19	-0.32	1.75e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg18721089	chr20:30220636	NA	-0.34	-5.89	-0.31	9.62e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs28655083	0.912	rs2171097	chr16:77085037	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.45	-6.93	-0.35	2.2e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg16325326	chr1:53192061	ZYG11B	-0.83	-14.56	-0.62	1.63e-37	Monocyte count;
LUSC	trans	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg20587970	chr11:113659929	NA	-0.98	-12.21	-0.56	1.38e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs55675132	0.620	rs2335722	chr1:115635991	G/A	cg01522456	chr1:115632236	TSPAN2	0.47	6.54	0.34	2.31e-10	Schizophrenia;
LUSC	cis	rs422421	1.000	rs2456173	chr5:176514595	T/C	cg00618323	chr5:176515533	FGFR4	0.36	5.83	0.3	1.34e-8	Height;
LUSC	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg22815214	chr1:201083145	CACNA1S	0.51	8.77	0.43	9.09e-17	Permanent tooth development;
LUSC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg03146154	chr1:46216737	IPP	0.54	8.17	0.41	6.65e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg08213375	chr14:104286397	PPP1R13B	0.46	9.05	0.44	1.17e-17	Schizophrenia;
LUSC	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg00191853	chr8:101177733	SPAG1	-0.4	-6.45	-0.33	3.86e-10	Atrioventricular conduction;
LUSC	cis	rs7264396	0.887	rs1886696	chr20:34055706	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.46	-0.33	3.78e-10	Total cholesterol levels;
LUSC	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg21361702	chr7:150065534	REPIN1	0.57	8.03	0.4	1.65e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-6.25	-0.32	1.23e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg04553112	chr3:125709451	NA	-0.5	-5.67	-0.3	3.08e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7903847	0.620	rs954149	chr10:99122936	G/A	cg08345082	chr10:99160200	RRP12	-0.36	-7.17	-0.37	5.01e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs10875746	0.903	rs11168420	chr12:48515896	C/T	cg13454099	chr12:49076203	C12orf41	-0.49	-5.68	-0.3	2.95e-8	Longevity (90 years and older);
LUSC	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	10.09	0.48	4.34e-21	Lymphocyte counts;
LUSC	cis	rs55883249	0.957	rs10495572	chr2:9734859	C/G	cg23886495	chr2:9695866	ADAM17	-0.49	-5.75	-0.3	1.98e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-0.99	-22.74	-0.78	8.19e-70	Urate levels in lean individuals;
LUSC	trans	rs6590322	0.610	rs4937321	chr11:128216466	G/T	cg19073447	chr10:134024191	STK32C	0.35	6.12	0.32	2.63e-9	Hippocampal atrophy;
LUSC	trans	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.83	-0.35	4.02e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs12439619	0.508	rs8023960	chr15:82499045	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.47	-7.46	-0.38	7.3e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs10465746	0.780	rs12145258	chr1:84401211	G/A	cg10977910	chr1:84465055	TTLL7	0.43	6.25	0.32	1.23e-9	Obesity-related traits;
LUSC	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg08558340	chr7:100472263	SRRT	0.51	6.37	0.33	6.41e-10	Resting heart rate;
LUSC	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.51e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg12560992	chr17:57184187	TRIM37	0.86	15.43	0.65	6.22e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg07148914	chr20:33460835	GGT7	0.48	7.14	0.36	5.69e-12	Height;
LUSC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	14.46	0.62	3.7e-37	Platelet count;
LUSC	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	1.02	15.35	0.64	1.24e-40	Corneal structure;
LUSC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	12.53	0.57	8.87e-30	Monocyte percentage of white cells;
LUSC	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg05343316	chr1:45956843	TESK2	0.68	9.4	0.46	9.28e-19	Platelet count;
LUSC	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg26850624	chr5:429559	AHRR	-0.33	-5.82	-0.3	1.41e-8	Cystic fibrosis severity;
LUSC	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg25482853	chr8:67687455	SGK3	1.12	15.85	0.66	1.36e-42	Obesity-related traits;
LUSC	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	10.11	0.48	3.75e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06850241	chr22:41845214	NA	0.31	5.8	0.3	1.56e-8	Vitiligo;
LUSC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg07148914	chr20:33460835	GGT7	-0.44	-6.53	-0.34	2.4e-10	Height;
LUSC	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg15556689	chr8:8085844	FLJ10661	0.7	11.63	0.54	1.83e-26	Systolic blood pressure;
LUSC	cis	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-6.8	-0.35	4.86e-11	Systolic blood pressure;
LUSC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.46	6.77	0.35	5.7e-11	Alzheimer's disease (late onset);
LUSC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg05785598	chr3:49045655	WDR6	0.33	5.85	0.3	1.17e-8	Parkinson's disease;
LUSC	trans	rs9401746	0.564	rs582822	chr6:124800907	T/C	cg16857858	chr7:27213984	HOXA10	0.55	6.14	0.32	2.3e-9	Bone mineral density (Ward's triangle area);
LUSC	cis	rs668210	0.793	rs540584	chr11:65765866	C/G	cg04700828	chr11:65773979	NA	0.39	5.64	0.3	3.55e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg19678392	chr7:94953810	PON1	-0.38	-6.09	-0.32	3.07e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs10779751	0.770	rs2258621	chr1:11141187	C/G	cg08854313	chr1:11322531	MTOR	0.83	12.37	0.56	3.3e-29	Body mass index;
LUSC	cis	rs950881	0.866	rs72823628	chr2:102928617	G/A	cg20060108	chr2:102954350	IL1RL1	0.48	6.36	0.33	6.7e-10	Allergy;
LUSC	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg13010199	chr12:38710504	ALG10B	0.52	7.71	0.39	1.43e-13	Morning vs. evening chronotype;
LUSC	cis	rs2580764	0.565	rs6760429	chr2:55228499	C/T	cg09592903	chr2:55203963	RTN4	-0.49	-10.05	-0.48	6.22e-21	Mean platelet volume;
LUSC	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg21775007	chr8:11205619	TDH	-0.57	-8.49	-0.42	6.72e-16	Neuroticism;
LUSC	cis	rs10392	0.543	rs6015981	chr20:37533958	A/G	cg27552599	chr20:37590471	DHX35	0.44	6.98	0.36	1.6e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs7577696	0.962	rs212745	chr2:32412832	C/G	cg02381751	chr2:32503542	YIPF4	0.41	5.84	0.3	1.21e-8	Inflammatory biomarkers;
LUSC	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg20976159	chr1:228193529	WNT3A	0.28	5.71	0.3	2.54e-8	Diastolic blood pressure;
LUSC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg10729496	chr3:10149963	C3orf24	-0.5	-7.01	-0.36	1.33e-11	Alzheimer's disease;
LUSC	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg09904177	chr6:26538194	HMGN4	0.75	14.04	0.61	1.66e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs3820928	0.874	rs6728239	chr2:227856552	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.39	-0.37	1.19e-12	Pulmonary function;
LUSC	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg01881094	chr2:180872142	CWC22	-0.82	-10.71	-0.51	3.19e-23	Schizophrenia;
LUSC	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.16	-0.32	2.08e-9	Morning vs. evening chronotype;
LUSC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12310025	chr6:25882481	NA	-0.47	-8.01	-0.4	1.93e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg00750074	chr16:89608354	SPG7	-0.47	-8.06	-0.4	1.38e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg11965913	chr1:205819406	PM20D1	0.49	6.77	0.35	5.98e-11	Menarche (age at onset);
LUSC	trans	rs7980799	0.682	rs1351682	chr12:33598775	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.43	-0.33	4.37e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs6681460	0.549	rs11208908	chr1:67036636	C/T	cg02459107	chr1:67143332	SGIP1	0.31	5.66	0.3	3.25e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs3743266	0.507	rs9630426	chr15:60739053	C/T	cg21667061	chr15:60772094	NARG2	0.51	6.92	0.35	2.33e-11	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg17366294	chr4:99064904	C4orf37	0.57	9.91	0.48	1.76e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg03188948	chr7:1209495	NA	0.66	6.91	0.35	2.44e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.11	14.84	0.63	1.26e-38	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7147624	1.000	rs10873192	chr14:66110653	A/G	cg03016385	chr14:66212404	NA	-0.82	-9.13	-0.45	6.88e-18	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs829883	0.616	rs249832	chr12:98832387	C/T	cg25150519	chr12:98850993	NA	0.8	13.45	0.59	3.01e-33	Colorectal adenoma (advanced);
LUSC	cis	rs870825	0.616	rs28620459	chr4:185627132	G/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.77e-32	Blood protein levels;
LUSC	cis	rs593982	0.920	rs4930298	chr11:65448108	T/A	cg08755490	chr11:65554678	OVOL1	-1.54	-12.26	-0.56	8.83e-29	Atopic dermatitis;
LUSC	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg15997130	chr1:24165203	NA	-0.53	-8.82	-0.43	6.68e-17	Immature fraction of reticulocytes;
LUSC	cis	rs12493885	0.769	rs61791508	chr3:153750816	A/G	cg17054900	chr3:154042577	DHX36	-0.57	-6.14	-0.32	2.39e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4691139	0.903	rs10434177	chr4:165915531	A/T	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.5	-5.92	-0.31	7.95e-9	Ovarian cancer in BRCA1 mutation carriers;
LUSC	cis	rs9905704	0.846	rs2567894	chr17:56794115	G/A	cg12560992	chr17:57184187	TRIM37	0.58	8.4	0.42	1.34e-15	Testicular germ cell tumor;
LUSC	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs72949976	0.678	rs7573232	chr2:214040425	C/T	cg08319019	chr2:214017104	IKZF2	-0.53	-7.12	-0.36	6.76e-12	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg27205649	chr11:78285834	NARS2	-0.51	-5.77	-0.3	1.77e-8	Testicular germ cell tumor;
LUSC	cis	rs6961069	0.574	rs7784648	chr7:80232655	T/C	cg04458919	chr7:80252533	CD36	-0.41	-7.17	-0.37	4.95e-12	Platelet count;
LUSC	cis	rs10193935	1.000	rs4494804	chr2:42395946	A/T	cg27598129	chr2:42591480	NA	-0.59	-7.96	-0.4	2.75e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.1	-0.45	8.3e-18	Neuroticism;
LUSC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg23758822	chr17:41437982	NA	1.0	18.94	0.72	7.62e-55	Menopause (age at onset);
LUSC	cis	rs722599	0.683	rs8011071	chr14:75286705	T/C	cg08847533	chr14:75593920	NEK9	0.44	6.18	0.32	1.84e-9	IgG glycosylation;
LUSC	cis	rs5770917	1.000	rs2073604	chr22:51008925	G/A	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.57	-5.72	-0.3	2.31e-8	Narcolepsy;
LUSC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg24578937	chr1:2090814	PRKCZ	0.43	9.46	0.46	5.5e-19	Height;
LUSC	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg00277334	chr10:82204260	NA	-0.55	-7.63	-0.39	2.52e-13	Post bronchodilator FEV1;
LUSC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.14	-0.45	6.39e-18	Gut microbiome composition (summer);
LUSC	trans	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.14	-0.36	5.95e-12	Triglycerides;
LUSC	cis	rs8038465	0.615	rs62004618	chr15:73962164	A/G	cg15420318	chr15:73925796	NPTN	0.6	10.34	0.49	6.3e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9473147	0.543	rs9367279	chr6:47448336	A/G	cg20196966	chr6:47445060	CD2AP	0.42	5.92	0.31	7.99e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7072216	0.770	rs7896828	chr10:100170507	A/T	cg26618903	chr10:100175079	PYROXD2	-0.34	-6.8	-0.35	4.85e-11	Metabolite levels;
LUSC	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg18002602	chr11:66138449	SLC29A2	-0.46	-8.08	-0.4	1.17e-14	Educational attainment (years of education);
LUSC	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.75	13.1	0.58	6.18e-32	Sudden cardiac arrest;
LUSC	cis	rs2274273	0.653	rs1209087	chr14:55493220	C/T	cg04306507	chr14:55594613	LGALS3	-0.5	-11.04	-0.52	2.21e-24	Protein biomarker;
LUSC	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg02176678	chr2:219576539	TTLL4	0.59	10.62	0.5	6.58e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.7	12.59	0.57	5.27e-30	Aortic root size;
LUSC	trans	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg07817883	chr1:32538562	TMEM39B	-0.57	-6.88	-0.35	2.89e-11	Monocyte percentage of white cells;
LUSC	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg25233709	chr10:116636983	FAM160B1	0.44	7.93	0.4	3.39e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg18190219	chr22:46762943	CELSR1	-0.48	-6.0	-0.31	5.01e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-17.0	-0.68	3.84e-47	Gut microbiome composition (summer);
LUSC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.2	0.32	1.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg12463550	chr7:65579703	CRCP	-0.43	-6.36	-0.33	6.61e-10	Aortic root size;
LUSC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg12963246	chr6:28129442	ZNF389	0.52	7.18	0.37	4.53e-12	Depression;
LUSC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.17	0.58	3.43e-32	Chronic sinus infection;
LUSC	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg01884057	chr2:25150051	NA	0.42	9.8	0.47	4.44e-20	Body mass index in non-asthmatics;
LUSC	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg09904177	chr6:26538194	HMGN4	0.51	5.77	0.3	1.8e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg00262122	chr8:11665843	FDFT1	-0.44	-6.59	-0.34	1.68e-10	Morning vs. evening chronotype;
LUSC	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	6.85	0.35	3.49e-11	Blood metabolite levels;
LUSC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	1.03	18.04	0.7	2.76e-51	Parkinson's disease;
LUSC	trans	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg02800362	chr5:177631904	HNRNPAB	0.88	13.12	0.58	5.45e-32	Obesity-related traits;
LUSC	cis	rs61990749	0.597	rs2032781	chr14:78214875	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	6.59	0.34	1.76e-10	Fibroblast growth factor basic levels;
LUSC	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.05	0.31	3.84e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs79387448	0.745	rs1523197	chr2:103163732	A/G	cg09003973	chr2:102972529	NA	0.89	8.62	0.43	2.69e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06028605	chr16:24865363	SLC5A11	-0.69	-10.81	-0.51	1.49e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.15	-0.52	9.55e-25	Coronary artery disease;
LUSC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg20203395	chr5:56204925	C5orf35	-0.54	-7.86	-0.39	5.47e-14	Coronary artery disease;
LUSC	cis	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg17411546	chr10:75410026	SYNPO2L	-0.41	-5.92	-0.31	8.04e-9	Inflammatory bowel disease;
LUSC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.42	-0.38	9.96e-13	Blood metabolite levels;
LUSC	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg01065977	chr19:18549689	ISYNA1	-0.23	-5.93	-0.31	7.54e-9	Breast cancer;
LUSC	trans	rs629535	0.767	rs62513418	chr8:70114376	G/T	cg21567404	chr3:27674614	NA	-0.97	-15.83	-0.65	1.73e-42	Dupuytren's disease;
LUSC	cis	rs9472414	0.510	rs227844	chr6:44692212	A/C	cg20913747	chr6:44695427	NA	0.42	6.15	0.32	2.27e-9	Height;
LUSC	trans	rs10511400	0.618	rs9289143	chr3:119918661	A/C	cg02809009	chr19:50354510	PTOV1	0.64	6.05	0.31	3.97e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs4654899	0.865	rs72973154	chr1:21459125	G/T	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.61	-0.34	1.56e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg00944433	chr1:107599041	PRMT6	-0.38	-7.07	-0.36	9.07e-12	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.38	-0.37	1.29e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.82	14.39	0.62	7.5e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.43	-0.33	4.36e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg20283391	chr11:68216788	NA	-0.54	-8.15	-0.41	7.55e-15	Total body bone mineral density;
LUSC	cis	rs17095355	1.000	rs12570423	chr10:111690942	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.56	-6.81	-0.35	4.65e-11	Biliary atresia;
LUSC	cis	rs96067	0.772	rs2231318	chr1:36602943	C/T	cg24686825	chr1:36642396	MAP7D1	-0.56	-7.57	-0.38	3.57e-13	Corneal structure;
LUSC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.67	10.68	0.5	4.2e-23	Blood protein levels;
LUSC	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-8.38	-0.42	1.5e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg16405210	chr4:1374714	KIAA1530	-0.85	-14.01	-0.61	2.07e-35	Longevity;
LUSC	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg25237894	chr2:233734115	C2orf82	0.35	6.42	0.33	4.67e-10	Coronary artery disease;
LUSC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg03929089	chr4:120376271	NA	-0.85	-12.03	-0.55	6.29e-28	Height;
LUSC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg10729496	chr3:10149963	C3orf24	0.59	7.89	0.4	4.31e-14	Alzheimer's disease;
LUSC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg09455208	chr3:40491958	NA	-0.53	-9.73	-0.47	7.45e-20	Renal cell carcinoma;
LUSC	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.41	-5.91	-0.31	8.26e-9	Monocyte percentage of white cells;
LUSC	trans	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.31	-0.33	9.04e-10	Joint mobility (Beighton score);
LUSC	cis	rs68170813	0.559	rs78440378	chr7:106962782	C/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.46	-0.46	5.6e-19	Coronary artery disease;
LUSC	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg18705301	chr15:41695430	NDUFAF1	0.44	7.18	0.37	4.64e-12	Menopause (age at onset);
LUSC	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg21775007	chr8:11205619	TDH	-0.54	-8.04	-0.4	1.52e-14	Neuroticism;
LUSC	cis	rs4380275	0.965	rs4315562	chr2:772723	A/G	cg21665850	chr2:731073	NA	0.42	6.81	0.35	4.58e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg20891558	chr2:74357851	NA	0.83	15.12	0.64	1.01e-39	Gestational age at birth (maternal effect);
LUSC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg25019033	chr10:957182	NA	-0.51	-6.35	-0.33	7.09e-10	Eosinophil percentage of granulocytes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05210937	chr4:185655043	MLF1IP	-0.43	-6.38	-0.33	6.07e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11645453	chr3:52864694	ITIH4	0.56	13.65	0.6	5.3e-34	Schizophrenia;
LUSC	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg16797656	chr11:68205561	LRP5	0.38	6.22	0.32	1.52e-9	Total body bone mineral density;
LUSC	cis	rs11585357	0.793	rs11588418	chr1:17616445	A/G	cg08277548	chr1:17600880	PADI3	-0.63	-6.51	-0.34	2.7e-10	Hair shape;
LUSC	cis	rs240764	0.817	rs11155606	chr6:101163915	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-6.26	-0.32	1.19e-9	Neuroticism;
LUSC	cis	rs10489525	0.556	rs11102882	chr1:115612222	T/A	cg01522456	chr1:115632236	TSPAN2	0.4	5.69	0.3	2.83e-8	Autism;
LUSC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg03909863	chr11:638404	DRD4	-0.41	-5.69	-0.3	2.74e-8	Systemic lupus erythematosus;
LUSC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg10729496	chr3:10149963	C3orf24	0.57	7.48	0.38	6.62e-13	Alzheimer's disease;
LUSC	cis	rs28374715	0.787	rs11856169	chr15:41547938	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.83	-14.19	-0.61	4.39e-36	Ulcerative colitis;
LUSC	cis	rs793571	0.669	rs714696	chr15:58962987	C/G	cg05156742	chr15:59063176	FAM63B	0.56	7.87	0.4	4.92e-14	Schizophrenia;
LUSC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg23649088	chr2:200775458	C2orf69	0.54	7.39	0.37	1.2e-12	Schizophrenia;
LUSC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.63	0.47	1.61e-19	Bipolar disorder;
LUSC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg24813613	chr7:1882135	MAD1L1	-0.38	-6.21	-0.32	1.56e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2236918	0.710	rs2488470	chr1:242019580	A/G	cg17736920	chr1:242011382	EXO1	0.41	6.48	0.33	3.39e-10	Menopause (age at onset);
LUSC	cis	rs9928842	0.771	rs2870471	chr16:75274282	A/G	cg09066997	chr16:75300724	BCAR1	-0.46	-6.05	-0.31	3.91e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs9837602	1.000	rs1021103	chr3:99603230	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	5.76	0.3	1.87e-8	Breast cancer;
LUSC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.89	-12.92	-0.58	2.98e-31	Initial pursuit acceleration;
LUSC	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg12615879	chr12:58013172	SLC26A10	0.28	5.81	0.3	1.49e-8	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg22906224	chr7:99728672	NA	0.48	6.68	0.34	1.03e-10	Coronary artery disease;
LUSC	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.38	0.59	5.61e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg06606381	chr12:133084897	FBRSL1	-0.45	-5.97	-0.31	6.07e-9	Depression;
LUSC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.27	-0.49	1.06e-21	Hemoglobin concentration;
LUSC	cis	rs617219	0.853	rs13355606	chr5:78522359	T/C	cg24856658	chr5:78533917	JMY	-0.3	-5.87	-0.31	1.05e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs3960554	0.674	rs113848658	chr7:75791858	G/A	cg17325771	chr7:75508891	RHBDD2	-0.42	-5.89	-0.31	9.52e-9	Eotaxin levels;
LUSC	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21028142	chr17:79581711	NPLOC4	0.34	8.0	0.4	2e-14	Eye color traits;
LUSC	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.9	-0.35	2.55e-11	Alcohol dependence;
LUSC	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg17120908	chr11:65337727	SSSCA1	-0.53	-9.44	-0.46	6.76e-19	Bone mineral density;
LUSC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg21724239	chr8:58056113	NA	0.77	8.29	0.41	2.73e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg06223162	chr1:101003688	GPR88	0.57	11.47	0.53	6.65e-26	Breast cancer;
LUSC	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg05110241	chr16:68378359	PRMT7	-0.6	-6.75	-0.35	6.44e-11	HDL cholesterol;
LUSC	cis	rs977987	0.778	rs35214308	chr16:75476088	C/T	cg03315344	chr16:75512273	CHST6	0.49	9.5	0.46	4.32e-19	Dupuytren's disease;
LUSC	cis	rs4654899	0.758	rs12078457	chr1:21397071	C/T	cg01072550	chr1:21505969	NA	-0.5	-7.69	-0.39	1.68e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg08079166	chr15:68083412	MAP2K5	-0.42	-8.69	-0.43	1.68e-16	Restless legs syndrome;
LUSC	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.94	0.51	4.97e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.78	8.11	0.41	9.99e-15	Initial pursuit acceleration;
LUSC	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg20307385	chr11:47447363	PSMC3	0.45	6.5	0.34	2.87e-10	Subjective well-being;
LUSC	trans	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg07211511	chr3:129823064	LOC729375	-0.53	-6.08	-0.32	3.25e-9	Blood pressure (smoking interaction);
LUSC	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.1	0.64	1.26e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.43	6.94	0.36	2.04e-11	Platelet count;
LUSC	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg20307385	chr11:47447363	PSMC3	-0.45	-6.69	-0.34	9.64e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.03	0.4	1.66e-14	Melanoma;
LUSC	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg01294253	chr9:136912663	BRD3	0.36	6.34	0.33	7.25e-10	Platelet distribution width;
LUSC	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg15997130	chr1:24165203	NA	0.52	8.58	0.42	3.67e-16	Immature fraction of reticulocytes;
LUSC	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05901451	chr6:126070800	HEY2	-0.96	-18.94	-0.72	7.19e-55	Brugada syndrome;
LUSC	cis	rs11032090	1	rs11032090	chr11:4417129	A/G	cg07244098	chr11:4415203	TRIM21	0.35	5.8	0.3	1.57e-8	Lung cancer;
LUSC	cis	rs3820928	0.804	rs4675125	chr2:227802499	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.75	-0.39	1.14e-13	Pulmonary function;
LUSC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg23791538	chr6:167370224	RNASET2	0.41	6.45	0.33	4.03e-10	Crohn's disease;
LUSC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg08470875	chr2:26401718	FAM59B	-0.67	-9.08	-0.44	9.81e-18	Gut microbiome composition (summer);
LUSC	trans	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg24313572	chr1:56050060	NA	-0.31	-6.43	-0.33	4.53e-10	Morning vs. evening chronotype;
LUSC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg14983838	chr19:29218262	NA	0.66	9.79	0.47	4.71e-20	Methadone dose in opioid dependence;
LUSC	cis	rs4319547	0.688	rs10847415	chr12:123144293	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.29	-0.37	2.27e-12	Body mass index;
LUSC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	0.8	14.34	0.62	1.08e-36	Cognitive function;
LUSC	cis	rs7903847	0.642	rs10882908	chr10:99134970	T/C	cg08345082	chr10:99160200	RRP12	-0.38	-7.76	-0.39	1.06e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg01689657	chr7:91764605	CYP51A1	-0.32	-5.66	-0.3	3.18e-8	Breast cancer;
LUSC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06112835	chr11:68658793	MRPL21	0.51	7.81	0.39	7.24e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg22868518	chr11:507468	RNH1	-0.65	-6.1	-0.32	2.87e-9	Body mass index;
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.38	-0.42	1.45e-15	Lymphocyte counts;
LUSC	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg20016023	chr10:99160130	RRP12	-0.32	-7.95	-0.4	2.92e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.5e-8	Breast cancer;
LUSC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.6	-8.65	-0.43	2.24e-16	Mean platelet volume;
LUSC	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.47	10.27	0.49	1.11e-21	Airflow obstruction;
LUSC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg08742575	chr21:47604166	C21orf56	0.41	6.13	0.32	2.41e-9	Testicular germ cell tumor;
LUSC	cis	rs7923609	0.967	rs10761751	chr10:65154885	A/G	cg01631684	chr10:65280961	REEP3	-0.4	-6.21	-0.32	1.56e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1595825	1.000	rs73058832	chr2:198873214	G/T	cg19156104	chr2:198669113	PLCL1	-0.47	-5.73	-0.3	2.22e-8	Ulcerative colitis;
LUSC	cis	rs4919687	0.550	rs12784517	chr10:104464970	T/C	cg05855489	chr10:104503620	C10orf26	0.71	11.51	0.53	4.8e-26	Colorectal cancer;
LUSC	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg25809561	chr17:30822961	MYO1D	0.38	6.3	0.33	9.22e-10	Schizophrenia;
LUSC	cis	rs4947962	0.617	rs112317270	chr7:55126160	T/C	cg23757825	chr7:55092271	EGFR	-0.53	-6.41	-0.33	4.9e-10	Subjective response to lithium treatment;
LUSC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg16362232	chr11:430036	ANO9	0.63	8.24	0.41	3.85e-15	Body mass index;
LUSC	trans	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg05926928	chr17:57297772	GDPD1	-1.05	-11.85	-0.54	2.72e-27	Opioid sensitivity;
LUSC	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg20026190	chr17:76395443	PGS1	-0.42	-7.53	-0.38	4.89e-13	HDL cholesterol levels;
LUSC	cis	rs2274273	0.686	rs28631821	chr14:55845987	T/C	cg04306507	chr14:55594613	LGALS3	0.56	12.97	0.58	1.97e-31	Protein biomarker;
LUSC	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg15704280	chr7:45808275	SEPT13	-0.6	-6.45	-0.33	4.02e-10	Axial length;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	1.05	28.06	0.84	7.22e-90	Menarche (age at onset);
LUSC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	7.32	0.37	1.83e-12	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg10207240	chr12:122356781	WDR66	0.44	6.19	0.32	1.72e-9	Mean corpuscular volume;
LUSC	cis	rs16958440	0.708	rs1434528	chr18:44632323	G/A	cg17192377	chr18:44677553	HDHD2	0.43	5.67	0.3	3.02e-8	Sitting height ratio;
LUSC	cis	rs4713675	0.565	rs4711341	chr6:33690797	A/G	cg14003231	chr6:33640908	ITPR3	0.29	5.7	0.3	2.59e-8	Plateletcrit;
LUSC	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg04865166	chr7:105162814	PUS7	0.51	5.74	0.3	2.15e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7553864	0.667	rs4656143	chr1:87605208	G/A	cg17420885	chr1:87600446	LOC339524	-0.46	-6.37	-0.33	6.24e-10	Smoking behavior;
LUSC	cis	rs12711979	0.509	rs882418	chr2:3820113	A/G	cg17052675	chr2:3827356	NA	-0.83	-17.72	-0.7	5.16e-50	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.56	-0.42	4.16e-16	Bipolar disorder;
LUSC	cis	rs7241530	0.662	rs7230384	chr18:75908189	A/G	cg14642773	chr18:75888474	NA	0.38	5.66	0.3	3.27e-8	Educational attainment (years of education);
LUSC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.56	0.53	3.14e-26	Menopause (age at onset);
LUSC	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg01733217	chr16:74700730	RFWD3	0.8	13.43	0.59	3.48e-33	Testicular germ cell tumor;
LUSC	trans	rs6601327	0.641	rs7014663	chr8:9587275	G/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.47	-0.33	3.57e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg17173187	chr15:85201210	NMB	0.37	6.37	0.33	6.23e-10	Schizophrenia;
LUSC	cis	rs3733631	0.948	rs3733632	chr4:104640935	A/G	cg24090629	chr4:104641072	TACR3	-0.5	-6.44	-0.33	4.17e-10	Menarche (age at onset);
LUSC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg13114125	chr14:105738426	BRF1	-0.92	-15.77	-0.65	2.85e-42	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.44	7.76	0.39	1.06e-13	Obesity-related traits;
LUSC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg11247378	chr22:39784982	NA	-0.67	-13.64	-0.6	5.67e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.47	-6.4	-0.33	5.14e-10	Renal function-related traits (BUN);
LUSC	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	0.87	14.37	0.62	8.48e-37	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs7202877	0.706	rs37605	chr16:75506572	G/C	cg04384234	chr16:75411784	CFDP1	0.66	9.01	0.44	1.61e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs6087990	0.899	rs6087999	chr20:31363774	A/G	cg13636640	chr20:31349939	DNMT3B	0.99	22.58	0.78	3.34e-69	Ulcerative colitis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12035827	chr1:10855226	CASZ1	-0.51	-6.7	-0.34	8.78e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4356932	1.000	rs3921	chr4:76942943	C/G	cg00809888	chr4:76862425	NAAA	0.35	5.83	0.3	1.29e-8	Blood protein levels;
LUSC	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg26876637	chr1:152193138	HRNR	0.47	6.62	0.34	1.47e-10	Atopic dermatitis;
LUSC	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7633770	0.710	rs4683259	chr3:46698538	A/G	cg11219411	chr3:46661640	NA	-0.29	-5.72	-0.3	2.31e-8	Coronary artery disease;
LUSC	trans	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg13010199	chr12:38710504	ALG10B	0.43	6.85	0.35	3.59e-11	Morning vs. evening chronotype;
LUSC	cis	rs3737883	1.000	rs2270543	chr1:203030685	T/C	cg00805880	chr1:203045044	PPFIA4	-0.28	-5.76	-0.3	1.88e-8	Early onset atrial fibrillation;
LUSC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg09650180	chr20:62225654	GMEB2	-0.67	-9.74	-0.47	6.68e-20	Glioblastoma;
LUSC	cis	rs4481887	0.676	rs946764	chr1:248522033	A/C	cg26353448	chr1:248524236	OR2T4	-0.33	-6.27	-0.32	1.12e-9	Common traits (Other);
LUSC	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg23649088	chr2:200775458	C2orf69	0.53	8.18	0.41	5.92e-15	Osteoporosis;
LUSC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg21918786	chr6:109611834	NA	-0.4	-7.07	-0.36	9.06e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg08330031	chr10:104623503	C10orf32	0.31	5.64	0.3	3.54e-8	Arsenic metabolism;
LUSC	cis	rs6066835	1.000	rs6063311	chr20:47325315	C/T	cg18078177	chr20:47281410	PREX1	0.75	6.1	0.32	2.87e-9	Multiple myeloma;
LUSC	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg22089800	chr15:90895588	ZNF774	-0.63	-9.47	-0.46	5.25e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg15242686	chr22:24348715	GSTTP1	0.44	6.52	0.34	2.61e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg25214090	chr10:38739885	LOC399744	0.53	7.85	0.39	5.88e-14	Corneal astigmatism;
LUSC	trans	rs911555	0.504	rs745079	chr14:104073551	G/A	cg03785828	chr5:81573306	RPS23	-0.37	-6.02	-0.31	4.56e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7000551	0.689	rs6993341	chr8:22310933	T/C	cg12081754	chr8:22256438	SLC39A14	0.45	6.89	0.35	2.72e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg24812749	chr6:127587940	RNF146	0.73	11.04	0.52	2.24e-24	Breast cancer;
LUSC	cis	rs10761482	0.564	rs10733765	chr10:62237399	T/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.38	-0.33	5.9e-10	Schizophrenia;
LUSC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.43	-7.06	-0.36	9.49e-12	Mean platelet volume;
LUSC	cis	rs61931739	0.635	rs1486883	chr12:33908740	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.54	-0.34	2.29e-10	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.78	13.32	0.59	8.93e-33	Developmental language disorder (linguistic errors);
LUSC	trans	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-12.08	-0.55	3.88e-28	Colorectal cancer;
LUSC	cis	rs11971779	0.793	rs11764426	chr7:139024050	C/G	cg07862535	chr7:139043722	LUC7L2	0.59	7.12	0.36	6.49e-12	Diisocyanate-induced asthma;
LUSC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.45	0.42	8.8e-16	Prudent dietary pattern;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01949902	chr22:40440554	TNRC6B	0.71	5.97	0.31	6.04e-9	Cognitive performance;
LUSC	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-7.67	-0.39	1.87e-13	Morning vs. evening chronotype;
LUSC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg27094323	chr7:1216898	NA	-0.44	-7.43	-0.38	9.04e-13	Longevity;Endometriosis;
LUSC	cis	rs56283067	0.887	rs12198016	chr6:44771708	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.23	-0.37	3.35e-12	Total body bone mineral density;
LUSC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg20607287	chr7:12443886	VWDE	-0.61	-6.43	-0.33	4.45e-10	Coronary artery disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17619082	chr7:43768796	C7orf44	-0.54	-7.17	-0.37	4.85e-12	Bipolar disorder and schizophrenia;
LUSC	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.62	-0.43	2.68e-16	Systolic blood pressure;
LUSC	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg22875332	chr1:76189707	ACADM	-0.39	-5.86	-0.31	1.1e-8	Daytime sleep phenotypes;
LUSC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg16586182	chr3:47516702	SCAP	-0.48	-7.46	-0.38	7.78e-13	Colorectal cancer;
LUSC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg12463550	chr7:65579703	CRCP	0.44	6.5	0.33	3.01e-10	Aortic root size;
LUSC	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg00484396	chr16:3507460	NAT15	0.41	6.62	0.34	1.4e-10	Body mass index (adult);
LUSC	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.68	9.95	0.48	1.33e-20	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.67	-11.48	-0.53	6.14e-26	Diastolic blood pressure;
LUSC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg14983838	chr19:29218262	NA	0.65	8.85	0.44	5.33e-17	Methadone dose in opioid dependence;
LUSC	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22980127	chr19:33182716	NUDT19	0.9	12.86	0.58	5.17e-31	Red blood cell traits;
LUSC	cis	rs1322512	1.000	rs2758780	chr6:153008108	A/G	cg27316956	chr6:152958899	SYNE1	0.35	6.06	0.31	3.59e-9	Tonometry;
LUSC	cis	rs3741151	0.686	rs12276892	chr11:73283990	A/T	cg17517138	chr11:73019481	ARHGEF17	0.78	7.43	0.38	9.07e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1185460	0.967	rs1168568	chr11:118949799	G/A	cg01677386	chr11:118938358	VPS11	-0.49	-6.9	-0.35	2.61e-11	Coronary artery disease;
LUSC	cis	rs2275620	1.000	rs7910936	chr10:96804451	C/T	cg09036531	chr10:96991505	NA	-0.39	-5.68	-0.3	2.95e-8	Gout;
LUSC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.54	-6.9	-0.35	2.62e-11	Schizophrenia;
LUSC	cis	rs73416724	1.000	rs70953670	chr6:43264895	C/A	cg26312998	chr6:43337775	ZNF318	0.56	6.32	0.33	8.29e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-7.11	-0.36	7.15e-12	Daytime sleep phenotypes;
LUSC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg10978503	chr1:24200527	CNR2	-0.47	-11.21	-0.52	5.48e-25	Immature fraction of reticulocytes;
LUSC	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.87	-0.31	1.05e-8	Testicular germ cell tumor;
LUSC	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg03522245	chr20:25566470	NINL	0.35	5.79	0.3	1.59e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3925075	1.000	rs4506917	chr16:31347350	T/G	cg02846316	chr16:31340340	ITGAM	0.36	6.66	0.34	1.11e-10	IgA nephropathy;
LUSC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg26116260	chr4:7069785	GRPEL1	1.16	18.16	0.7	9.53e-52	Monocyte percentage of white cells;
LUSC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg19622623	chr12:86230825	RASSF9	-0.44	-6.33	-0.33	7.94e-10	Major depressive disorder;
LUSC	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg13175981	chr1:150552382	MCL1	0.48	6.55	0.34	2.16e-10	Tonsillectomy;
LUSC	cis	rs12464559	0.522	rs4664498	chr2:152575417	A/G	cg01189475	chr2:152685088	ARL5A	0.64	6.79	0.35	5.27e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg01884057	chr2:25150051	NA	0.48	11.43	0.53	9.67e-26	Body mass index;
LUSC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg18479299	chr3:125709523	NA	-0.51	-5.92	-0.31	8.12e-9	Blood pressure (smoking interaction);
LUSC	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	7.98	0.4	2.41e-14	Body mass index;
LUSC	cis	rs2625529	0.590	rs2856929	chr15:72496762	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-7.29	-0.37	2.31e-12	Red blood cell count;
LUSC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg16797656	chr11:68205561	LRP5	-0.4	-7.06	-0.36	9.87e-12	Total body bone mineral density;
LUSC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg06618935	chr21:46677482	NA	0.38	7.65	0.39	2.17e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs367615	0.550	rs10060801	chr5:108881782	A/G	cg17395555	chr5:108820864	NA	0.43	8.04	0.4	1.54e-14	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg26924012	chr15:45694286	SPATA5L1	1.14	20.79	0.75	3.36e-62	Homoarginine levels;
LUSC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg17211192	chr8:82754475	SNX16	0.77	10.41	0.49	3.7e-22	Diastolic blood pressure;
LUSC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.48	-7.64	-0.39	2.24e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2625529	0.824	rs12916694	chr15:72298140	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.44	-0.38	8.7e-13	Red blood cell count;
LUSC	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg10434728	chr15:90938212	IQGAP1	0.33	6.2	0.32	1.63e-9	Rheumatoid arthritis;
LUSC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.97	-16.69	-0.67	6.59e-46	Coronary artery disease;
LUSC	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg27129171	chr3:47204927	SETD2	-0.67	-10.94	-0.51	4.98e-24	Colorectal cancer;
LUSC	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.88	0.6	6.88e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2479724	0.591	rs2479723	chr6:41890835	G/A	cg17623882	chr6:41773611	USP49	-0.48	-6.33	-0.33	7.87e-10	Menarche (age at onset);
LUSC	cis	rs2692947	0.770	rs2579552	chr2:96737083	A/G	cg23100626	chr2:96804247	ASTL	0.32	7.58	0.38	3.5e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg05163923	chr11:71159392	DHCR7	-0.77	-10.28	-0.49	1e-21	Vitamin D levels;
LUSC	cis	rs9341808	0.727	rs9352809	chr6:80999316	C/T	cg08355045	chr6:80787529	NA	0.56	9.8	0.47	4.14e-20	Sitting height ratio;
LUSC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg17747265	chr1:1875780	NA	0.64	13.6	0.6	8.03e-34	Body mass index;
LUSC	cis	rs10992471	0.603	rs10820974	chr9:95211876	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.24	-0.32	1.35e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4363385	0.818	rs451939	chr1:153006877	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.65	-0.3	3.44e-8	Inflammatory skin disease;
LUSC	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.32	-0.33	8.29e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg02569458	chr12:86230093	RASSF9	0.58	9.96	0.48	1.26e-20	Major depressive disorder;
LUSC	trans	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs7107174	0.748	rs2063730	chr11:78048524	A/C	cg02023728	chr11:77925099	USP35	0.39	5.93	0.31	7.42e-9	Testicular germ cell tumor;
LUSC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.64	-0.34	1.24e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg12935359	chr14:103987150	CKB	-0.57	-8.83	-0.44	5.97e-17	Body mass index;
LUSC	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg18404041	chr3:52824283	ITIH1	0.41	6.92	0.35	2.38e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg03396347	chr1:1875803	NA	0.54	12.15	0.55	2.31e-28	Body mass index;
LUSC	cis	rs59698941	0.943	rs67268447	chr5:132303194	G/A	cg02081065	chr5:132209139	LEAP2	-0.61	-5.87	-0.31	1.03e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.61	9.31	0.45	1.71e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs13006833	0.635	rs2664251	chr2:191147667	C/T	cg21644426	chr2:191273491	MFSD6	0.47	6.76	0.35	6.15e-11	Urinary metabolites;
LUSC	cis	rs921665	0.831	rs4337500	chr2:3190786	T/C	cg16434511	chr2:3151078	NA	-0.63	-6.82	-0.35	4.22e-11	World class endurance athleticism;
LUSC	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg11473876	chr11:109292803	C11orf87	0.34	5.72	0.3	2.4e-8	Schizophrenia;
LUSC	cis	rs10979	1.000	rs10979	chr6:143890039	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.3	5.94	0.31	7.34e-9	Lymphocyte counts;
LUSC	cis	rs7106204	0.764	rs4508205	chr11:24218850	C/T	ch.11.24196551F	chr11:24239977	NA	0.93	9.49	0.46	4.68e-19	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04267008	chr7:1944627	MAD1L1	0.42	6.17	0.32	1.93e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-14.05	-0.61	1.5e-35	Hemoglobin concentration;
LUSC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg06784218	chr1:46089804	CCDC17	0.55	11.22	0.52	5.24e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg09165964	chr15:75287851	SCAMP5	0.5	7.37	0.37	1.31e-12	Breast cancer;
LUSC	cis	rs13082711	0.871	rs7624790	chr3:27468601	C/A	cg02860705	chr3:27208620	NA	0.5	8.41	0.42	1.2e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.72	-7.39	-0.37	1.21e-12	Initial pursuit acceleration;
LUSC	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg22906224	chr7:99728672	NA	-0.47	-6.55	-0.34	2.15e-10	Coronary artery disease;
LUSC	trans	rs1325195	0.920	rs2793803	chr1:179201438	A/C	cg11624085	chr17:8464688	MYH10	0.41	6.69	0.34	9.35e-11	IgE grass sensitization;
LUSC	trans	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg20935933	chr6:143382018	AIG1	0.5	7.33	0.37	1.71e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg13939156	chr17:80058883	NA	0.33	6.52	0.34	2.59e-10	Life satisfaction;
LUSC	cis	rs2274273	0.870	rs4597235	chr14:55851987	A/G	cg04306507	chr14:55594613	LGALS3	0.56	12.83	0.57	6.51e-31	Protein biomarker;
LUSC	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg01629716	chr15:45996671	NA	0.4	5.96	0.31	6.25e-9	Waist circumference;Weight;
LUSC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.68	-10.39	-0.49	4.22e-22	Aortic root size;
LUSC	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg24579218	chr15:68104479	NA	-0.37	-6.16	-0.32	2.1e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs4919694	1.000	rs17787717	chr10:104695699	T/G	cg04362960	chr10:104952993	NT5C2	1.17	13.94	0.61	4.04e-35	Arsenic metabolism;
LUSC	cis	rs73198271	0.641	rs34473848	chr8:8649837	C/T	cg01851573	chr8:8652454	MFHAS1	0.53	8.51	0.42	5.95e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg05347473	chr6:146136440	FBXO30	-0.56	-9.78	-0.47	4.91e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.71	-0.39	1.42e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12190007	0.547	rs2981945	chr6:169819839	G/A	cg15038512	chr6:170123185	PHF10	-0.38	-6.18	-0.32	1.84e-9	Obesity-related traits;
LUSC	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg16230307	chr14:35515116	FAM177A1	0.79	10.04	0.48	6.44e-21	Psoriasis;
LUSC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg24829409	chr8:58192753	C8orf71	-0.48	-5.78	-0.3	1.73e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.16	-0.32	2.04e-9	Alzheimer's disease (late onset);
LUSC	cis	rs921665	0.831	rs12476669	chr2:3195428	A/T	cg16434511	chr2:3151078	NA	-0.74	-7.56	-0.38	3.87e-13	World class endurance athleticism;
LUSC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06022373	chr22:39101656	GTPBP1	0.84	14.01	0.61	2.07e-35	Menopause (age at onset);
LUSC	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.62	-11.64	-0.54	1.63e-26	Congenital heart disease (maternal effect);
LUSC	cis	rs921968	1.000	rs921968	chr2:219272294	G/T	cg02176678	chr2:219576539	TTLL4	0.5	8.43	0.42	1.03e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	10.06	0.48	5.89e-21	Coffee consumption (cups per day);
LUSC	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-13.91	-0.61	5.22e-35	Exhaled nitric oxide output;
LUSC	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.93	-0.63	5.62e-39	Schizophrenia;
LUSC	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.87	13.93	0.61	4.29e-35	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-7.39	-0.37	1.22e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg15445000	chr17:37608096	MED1	-0.38	-6.55	-0.34	2.15e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs3784262	1.000	rs12908953	chr15:58277812	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.78	-0.3	1.68e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	trans	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg13565492	chr6:43139072	SRF	-0.61	-7.02	-0.36	1.25e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6484504	0.576	rs2447671	chr11:31334323	A/G	cg06552810	chr11:31128660	NA	-0.36	-6.33	-0.33	7.88e-10	Red blood cell count;
LUSC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.61	7.54	0.38	4.61e-13	Lung function (FEV1/FVC);
LUSC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-8.26	-0.41	3.51e-15	Personality dimensions;
LUSC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	0.93	17.88	0.7	1.24e-50	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs12122100	0.913	rs35811591	chr1:146515238	C/T	cg03526459	chr1:146549940	NA	-0.4	-6.47	-0.33	3.56e-10	HIV-1 control;
LUSC	trans	rs71435601	0.628	rs494465	chr2:21401010	C/T	cg20757404	chr19:378427	NA	0.37	5.96	0.31	6.28e-9	Cholesterol, total;
LUSC	cis	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg21775007	chr8:11205619	TDH	-0.49	-6.81	-0.35	4.65e-11	Triglycerides;
LUSC	cis	rs3743266	0.613	rs4775273	chr15:60738566	T/G	cg21667061	chr15:60772094	NARG2	-0.37	-6.2	-0.32	1.63e-9	Menarche (age at onset);
LUSC	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg00277334	chr10:82204260	NA	-0.5	-7.26	-0.37	2.8e-12	Post bronchodilator FEV1;
LUSC	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-17.98	-0.7	4.8e-51	Primary sclerosing cholangitis;
LUSC	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg26536354	chr8:144654954	C8orf73	0.64	7.34	0.37	1.63e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg05925327	chr15:68127851	NA	-0.41	-6.46	-0.33	3.79e-10	Restless legs syndrome;
LUSC	cis	rs7659604	0.540	rs116452657	chr4:122674147	A/G	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.91	-0.31	8.47e-9	Type 2 diabetes;
LUSC	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.25	0.37	2.93e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg17173187	chr15:85201210	NMB	-0.32	-6.37	-0.33	6.2e-10	P wave terminal force;
LUSC	cis	rs11642862	0.792	rs75586365	chr16:30996363	C/T	cg02466173	chr16:30829666	NA	-0.61	-6.47	-0.33	3.42e-10	Tonsillectomy;
LUSC	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.93	-0.35	2.14e-11	Triglycerides;
LUSC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg26335602	chr6:28129616	ZNF389	0.43	5.75	0.3	1.98e-8	Depression;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18404009	chr19:33667550	NA	0.77	6.13	0.32	2.51e-9	Cognitive performance;
LUSC	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.31	0.33	9.12e-10	Corneal astigmatism;
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg12419862	chr22:24373484	LOC391322	-0.87	-14.22	-0.61	3.27e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg04352962	chr1:209979756	IRF6	0.55	6.46	0.33	3.73e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs12220238	0.908	rs11000937	chr10:75998785	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.03	0.36	1.17e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg14829155	chr15:31115871	NA	-0.64	-8.72	-0.43	1.29e-16	Huntington's disease progression;
LUSC	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.4	-6.84	-0.35	3.75e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg11584989	chr19:19387371	SF4	-0.55	-6.31	-0.33	8.61e-10	Bipolar disorder;
LUSC	cis	rs909341	0.868	rs6089961	chr20:62349491	G/A	cg09650180	chr20:62225654	GMEB2	-0.46	-6.09	-0.32	3.09e-9	Atopic dermatitis;
LUSC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.78	0.3	1.7e-8	Menopause (age at onset);
LUSC	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg04990556	chr1:26633338	UBXN11	-0.87	-11.52	-0.53	4.55e-26	Obesity-related traits;
LUSC	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg21951975	chr1:209979733	IRF6	0.41	6.8	0.35	4.89e-11	Monobrow;
LUSC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs6961069	0.743	rs1358337	chr7:80288385	C/T	cg04458919	chr7:80252533	CD36	-0.34	-6.06	-0.31	3.59e-9	Platelet count;
LUSC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-1.04	-19.93	-0.74	9.13e-59	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09181473	chr12:93836052	UBE2N	-0.42	-6.35	-0.33	7.05e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18061532	chr13:25086879	PARP4	0.72	6.48	0.33	3.3e-10	Cognitive performance;
LUSC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg06637938	chr14:75390232	RPS6KL1	0.51	8.33	0.41	2.07e-15	Height;
LUSC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg20283391	chr11:68216788	NA	-0.57	-8.05	-0.4	1.44e-14	Total body bone mineral density;
LUSC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.19	0.76	9.28e-64	Prudent dietary pattern;
LUSC	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg04362960	chr10:104952993	NT5C2	0.58	9.3	0.45	1.9e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs4596713	0.538	rs7865373	chr9:71765105	T/C	cg25283916	chr1:242222868	NA	-0.32	-6.57	-0.34	1.89e-10	Headache;
LUSC	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.71	0.51	3.22e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg16049864	chr8:95962084	TP53INP1	-0.51	-9.22	-0.45	3.54e-18	Type 2 diabetes;
LUSC	cis	rs8077577	0.895	rs1563373	chr17:18114228	G/A	cg16794390	chr17:18148240	FLII	0.41	5.75	0.3	2.01e-8	Obesity-related traits;
LUSC	cis	rs8018808	0.935	rs17824034	chr14:77878683	A/G	cg20045696	chr14:77926864	AHSA1	0.35	5.75	0.3	1.99e-8	Myeloid white cell count;
LUSC	trans	rs7818345	0.624	rs12682196	chr8:19332963	A/C	cg07611933	chr16:2773245	NA	0.23	6.03	0.31	4.43e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg26597838	chr10:835615	NA	0.8	10.92	0.51	6.11e-24	Eosinophil percentage of granulocytes;
LUSC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg11062466	chr8:58055876	NA	0.71	8.73	0.43	1.27e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg27121462	chr16:89883253	FANCA	0.56	8.95	0.44	2.48e-17	Vitiligo;
LUSC	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.57	-0.46	2.51e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg12560992	chr17:57184187	TRIM37	0.84	15.48	0.65	3.82e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg23289794	chr7:2394357	EIF3B	-0.7	-9.39	-0.46	9.64e-19	Multiple sclerosis;
LUSC	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.47	-6.98	-0.36	1.56e-11	Immature fraction of reticulocytes;
LUSC	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg24675056	chr1:15929824	NA	0.43	7.41	0.38	1.03e-12	Systolic blood pressure;
LUSC	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.53	-10.52	-0.5	1.52e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.48	-5.89	-0.31	9.51e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs12145833	0.596	rs12134228	chr1:243447618	C/T	cg01826367	chr1:224180288	NA	0.63	5.95	0.31	6.62e-9	Obesity (early onset extreme);
LUSC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06634786	chr22:41940651	POLR3H	0.52	6.04	0.31	4.17e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.71	12.54	0.57	7.86e-30	Superior crus of antihelix expression;
LUSC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	0.97	9.55	0.46	2.87e-19	Plasma clusterin levels;
LUSC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	10.24	0.49	1.4e-21	Colorectal cancer;
LUSC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg14558114	chr2:88469736	THNSL2	0.76	6.66	0.34	1.15e-10	Plasma clusterin levels;
LUSC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg05665937	chr4:1216051	CTBP1	-0.37	-5.78	-0.3	1.69e-8	Obesity-related traits;
LUSC	cis	rs2637266	0.783	rs4980006	chr10:78477993	G/C	cg18941641	chr10:78392320	NA	0.34	6.21	0.32	1.56e-9	Pulmonary function;
LUSC	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg10018233	chr7:150070692	REPIN1	0.41	7.2	0.37	3.99e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05901451	chr6:126070800	HEY2	-0.93	-18.12	-0.7	1.34e-51	Brugada syndrome;
LUSC	cis	rs1982963	1.000	rs2029975	chr14:52506070	C/T	cg10843707	chr14:52510701	NID2	-0.4	-6.45	-0.33	3.99e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg25258033	chr6:167368657	RNASET2	-0.36	-5.68	-0.3	2.99e-8	Crohn's disease;
LUSC	cis	rs8060686	0.668	rs9932414	chr16:68219969	A/G	cg05110241	chr16:68378359	PRMT7	-0.44	-5.78	-0.3	1.72e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg05373962	chr22:49881684	NA	-0.41	-8.59	-0.43	3.46e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg10645314	chr2:3704589	ALLC	-0.37	-6.64	-0.34	1.27e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2658782	0.789	rs2605574	chr11:93136444	T/G	cg15737290	chr11:93063684	CCDC67	0.64	8.15	0.41	7.32e-15	Pulmonary function decline;
LUSC	cis	rs11229555	0.609	rs34782543	chr11:58187398	G/A	cg15696309	chr11:58395628	NA	-0.64	-7.78	-0.39	9.19e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs597583	0.806	rs11605509	chr11:117396433	T/C	cg27161313	chr11:117392002	DSCAML1	-0.43	-7.19	-0.37	4.33e-12	Putamen volume;
LUSC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg07701084	chr6:150067640	NUP43	0.5	7.43	0.38	8.98e-13	Lung cancer;
LUSC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg02569458	chr12:86230093	RASSF9	0.54	9.21	0.45	3.78e-18	Major depressive disorder;
LUSC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg25039879	chr17:56429692	SUPT4H1	0.42	6.0	0.31	5.16e-9	Cognitive test performance;
LUSC	cis	rs78523330	0.614	rs78443405	chr17:37072073	G/A	cg21637561	chr17:37074902	LASP1	-0.62	-5.9	-0.31	8.92e-9	Multiple system atrophy;
LUSC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg07701084	chr6:150067640	NUP43	0.56	8.38	0.42	1.47e-15	Lung cancer;
LUSC	cis	rs701145	0.556	rs357502	chr3:153955950	C/T	cg10247383	chr3:153839028	SGEF	-0.51	-6.19	-0.32	1.74e-9	Coronary artery disease;
LUSC	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg22508957	chr16:3507546	NAT15	-0.41	-5.8	-0.3	1.54e-8	Body mass index (adult);
LUSC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	ch.11.42038R	chr11:967971	AP2A2	-0.42	-6.34	-0.33	7.35e-10	Alzheimer's disease (late onset);
LUSC	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.3	-6.16	-0.32	2.11e-9	Dupuytren's disease;
LUSC	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07636037	chr3:49044803	WDR6	0.67	8.78	0.43	8.93e-17	Menarche (age at onset);
LUSC	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.18	-0.32	1.84e-9	Breast cancer;
LUSC	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg09876464	chr15:85330779	ZNF592	0.36	6.66	0.34	1.14e-10	P wave terminal force;
LUSC	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg05343316	chr1:45956843	TESK2	0.63	8.73	0.43	1.2e-16	Platelet count;
LUSC	cis	rs6088813	0.922	rs6088800	chr20:33934437	T/A	cg14752227	chr20:34000481	UQCC	-0.36	-5.65	-0.3	3.4e-8	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22077701	chr4:144434441	SMARCA5	-0.46	-6.73	-0.35	7.28e-11	Electrocardiographic conduction measures;
LUSC	cis	rs12760731	0.565	rs116253445	chr1:178216962	C/T	cg00404053	chr1:178313656	RASAL2	0.67	6.92	0.35	2.33e-11	Obesity-related traits;
LUSC	cis	rs1322512	0.883	rs2758814	chr6:152966367	C/T	cg27316956	chr6:152958899	SYNE1	-0.34	-5.87	-0.31	1.04e-8	Tonometry;
LUSC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.03	20.49	0.75	5.09e-61	Cognitive function;
LUSC	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg21772509	chr8:41503840	NKX6-3	0.67	11.22	0.52	5.34e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs2599510	0.807	rs176416	chr2:32652223	A/G	cg02381751	chr2:32503542	YIPF4	-0.4	-5.83	-0.3	1.27e-8	Interleukin-18 levels;
LUSC	cis	rs68170813	0.652	rs4730250	chr7:107207695	A/G	cg24556660	chr7:106842632	COG5;HBP1	-0.48	-5.89	-0.31	9.58e-9	Coronary artery disease;
LUSC	cis	rs4654899	0.601	rs6668094	chr1:21464387	C/T	cg01072550	chr1:21505969	NA	0.5	7.51	0.38	5.5e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10754283	0.557	rs1215511	chr1:90087543	C/A	cg21401794	chr1:90099060	LRRC8C	0.53	7.39	0.37	1.21e-12	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg24692254	chr21:30365293	RNF160	-0.63	-8.6	-0.43	3.16e-16	Cognitive test performance;
LUSC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg02018176	chr4:1364513	KIAA1530	0.52	8.83	0.43	6.21e-17	Obesity-related traits;
LUSC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg10169327	chr19:45448959	APOC2	-0.29	-6.03	-0.31	4.42e-9	Blood protein levels;
LUSC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.47	-7.35	-0.37	1.56e-12	Height;
LUSC	cis	rs3791556	0.842	rs55840142	chr2:240106884	G/A	cg03281426	chr2:240109471	HDAC4	0.52	7.15	0.36	5.53e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs2629540	1.000	rs2629540	chr10:126426148	G/C	cg08799069	chr10:126477246	METTL10	0.67	9.18	0.45	4.74e-18	Cocaine dependence;
LUSC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg00049323	chr5:472564	LOC25845	0.49	7.72	0.39	1.33e-13	Cystic fibrosis severity;
LUSC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg11742103	chr11:62369870	EML3;MTA2	-0.48	-7.3	-0.37	2.18e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs698813	0.851	rs698807	chr2:44701659	G/C	cg00619915	chr2:44497795	NA	-0.41	-5.92	-0.31	8.12e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs6001027	0.517	rs2284060	chr22:38543453	A/G	cg25457927	chr22:38595422	NA	-0.3	-6.01	-0.31	4.94e-9	Melanoma;
LUSC	trans	rs4650994	0.525	rs2811295	chr1:178551267	C/T	cg05059571	chr16:84539110	KIAA1609	0.48	9.35	0.46	1.35e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg24375607	chr4:120327624	NA	0.8	12.13	0.55	2.66e-28	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21450137	chr2:25016479	C2orf79;CENPO	-0.42	-6.27	-0.32	1.09e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg21918786	chr6:109611834	NA	-0.42	-7.29	-0.37	2.33e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.9	13.68	0.6	3.95e-34	Alzheimer's disease;
LUSC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	6.73	0.35	7.22e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg06454157	chr6:167490870	NA	-0.25	-5.68	-0.3	2.97e-8	Crohn's disease;
LUSC	trans	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg03415429	chr6:28048723	ZNF165	0.41	6.12	0.32	2.64e-9	Lymphocyte percentage of white cells;
LUSC	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg24634471	chr8:143751801	JRK	0.59	8.88	0.44	4.24e-17	Schizophrenia;
LUSC	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-9.02	-0.44	1.52e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	0.65	9.43	0.46	7.38e-19	Methadone dose in opioid dependence;
LUSC	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.41	-0.42	1.23e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg27165867	chr14:105738592	BRF1	-0.56	-8.49	-0.42	6.7e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2273669	0.667	rs7759014	chr6:109351125	A/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.05	-0.4	1.45e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2236918	0.710	rs2526698	chr1:242029101	T/C	cg17736920	chr1:242011382	EXO1	0.4	6.35	0.33	7.03e-10	Menopause (age at onset);
LUSC	cis	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg07460842	chr6:66804631	NA	0.46	5.66	0.3	3.2e-8	Metabolite levels;
LUSC	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg14895029	chr7:2775587	GNA12	-0.35	-5.94	-0.31	7.05e-9	Height;
LUSC	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	0.83	13.06	0.58	9.08e-32	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs2324229	0.730	rs1738632	chr6:83952189	T/G	cg08257003	chr6:84140564	ME1	0.32	7.59	0.38	3.33e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg21280719	chr6:42927975	GNMT	-0.32	-7.98	-0.4	2.35e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9905704	0.914	rs2643117	chr17:56829516	G/A	cg12560992	chr17:57184187	TRIM37	0.55	7.78	0.39	9.28e-14	Testicular germ cell tumor;
LUSC	cis	rs8141797	0.748	rs6004050	chr22:24461944	A/G	cg00411358	chr22:24577142	SUSD2	0.61	6.32	0.33	8.56e-10	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs6496044	0.527	rs7163068	chr15:86072466	T/C	cg13263323	chr15:86062960	AKAP13	-0.37	-6.16	-0.32	2.06e-9	Interstitial lung disease;
LUSC	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg06484146	chr7:12443880	VWDE	-0.63	-7.41	-0.38	1.07e-12	Coronary artery disease;
LUSC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.38e-12	Motion sickness;
LUSC	cis	rs1018836	0.923	rs6999898	chr8:91650549	G/A	cg16814680	chr8:91681699	NA	-0.82	-13.97	-0.61	3.06e-35	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg08601574	chr20:25228251	PYGB	0.41	6.25	0.32	1.22e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg00579484	chr14:23475993	C14orf93	0.39	5.74	0.3	2.12e-8	Cognitive ability (multi-trait analysis);
LUSC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg24296786	chr1:45957014	TESK2	0.53	8.22	0.41	4.52e-15	High light scatter reticulocyte count;
LUSC	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg03465714	chr1:152285911	FLG	-0.42	-5.88	-0.31	9.75e-9	Atopic dermatitis;
LUSC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg08888203	chr3:10149979	C3orf24	0.59	8.21	0.41	4.83e-15	Alzheimer's disease;
LUSC	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg02176678	chr2:219576539	TTLL4	0.6	10.88	0.51	8.48e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg24642844	chr7:1081250	C7orf50	-0.48	-7.59	-0.38	3.3e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg22139774	chr2:100720529	AFF3	-0.47	-8.06	-0.4	1.34e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg09092052	chr15:45571596	NA	0.47	6.54	0.34	2.26e-10	Glomerular filtration rate;
LUSC	cis	rs17255340	0.539	rs1170500	chr6:83991710	T/C	cg08257003	chr6:84140564	ME1	0.32	7.89	0.4	4.39e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.77	11.37	0.53	1.54e-25	Corneal astigmatism;
LUSC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs12681287	0.752	rs13255058	chr8:87287445	G/A	cg27223183	chr8:87520930	FAM82B	-0.45	-5.7	-0.3	2.69e-8	Caudate activity during reward;
LUSC	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg19743168	chr1:23544995	NA	0.47	10.22	0.49	1.67e-21	Height;
LUSC	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	5.96	0.31	6.32e-9	Rheumatoid arthritis;
LUSC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	11.36	0.53	1.69e-25	Tonsillectomy;
LUSC	cis	rs2898681	0.561	rs58577680	chr4:53734294	C/T	cg00791764	chr4:53727839	RASL11B	0.56	7.68	0.39	1.82e-13	Optic nerve measurement (cup area);
LUSC	cis	rs2652834	0.718	rs2414811	chr15:63397725	C/T	cg05507819	chr15:63340323	TPM1	0.56	7.13	0.36	6.22e-12	HDL cholesterol;
LUSC	cis	rs3087591	0.960	rs1013947	chr17:29530362	C/T	cg24425628	chr17:29625626	OMG;NF1	0.55	8.22	0.41	4.45e-15	Hip circumference;
LUSC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg11859384	chr17:80120422	CCDC57	0.36	5.69	0.3	2.71e-8	Life satisfaction;
LUSC	cis	rs6120849	0.754	rs752448	chr20:33592248	C/T	cg24642439	chr20:33292090	TP53INP2	0.62	6.85	0.35	3.65e-11	Protein C levels;
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.59	10.07	0.48	5.09e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26102683	chr11:82904715	ANKRD42	0.78	6.01	0.31	4.83e-9	Cognitive performance;
LUSC	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg09904177	chr6:26538194	HMGN4	-0.47	-6.79	-0.35	5.03e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg22166914	chr1:53195759	ZYG11B	0.68	11.49	0.53	5.62e-26	Monocyte count;
LUSC	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-9.17	-0.45	4.92e-18	Schizophrenia;
LUSC	trans	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg21659725	chr3:3221576	CRBN	0.7	8.41	0.42	1.24e-15	Menarche (age at onset);
LUSC	trans	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg07211511	chr3:129823064	LOC729375	-0.8	-10.65	-0.5	5.31e-23	Blood pressure (smoking interaction);
LUSC	cis	rs4478858	0.684	rs3753374	chr1:31740668	C/T	cg00250761	chr1:31883323	NA	-0.35	-8.37	-0.42	1.61e-15	Alcohol dependence;
LUSC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg20607798	chr8:58055168	NA	0.51	5.65	0.3	3.44e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.27e-31	Prudent dietary pattern;
LUSC	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07636037	chr3:49044803	WDR6	0.64	8.47	0.42	7.76e-16	Menarche (age at onset);
LUSC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.57	-0.34	1.98e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6693567	0.545	rs5011187	chr1:150422761	T/C	cg15654264	chr1:150340011	RPRD2	0.44	7.1	0.36	7.33e-12	Migraine;
LUSC	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg07169764	chr2:136633963	MCM6	0.87	12.05	0.55	4.98e-28	Mosquito bite size;
LUSC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	11.39	0.53	1.33e-25	Tonsillectomy;
LUSC	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-10.84	-0.51	1.16e-23	Coffee consumption (cups per day);
LUSC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18876405	chr7:65276391	NA	0.54	8.47	0.42	8.1e-16	Aortic root size;
LUSC	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.45	-0.33	3.82e-10	Recombination measurement;
LUSC	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.95	-0.4	2.98e-14	Chronic sinus infection;
LUSC	cis	rs1595825	0.891	rs73058867	chr2:198891568	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-6.3	-0.33	9.56e-10	Ulcerative colitis;
LUSC	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg06207120	chr15:45996521	NA	0.39	5.99	0.31	5.51e-9	Waist circumference;Weight;
LUSC	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg11502198	chr6:26597334	ABT1	0.89	10.63	0.5	6.06e-23	Small cell lung carcinoma;
LUSC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.31	6.07	0.31	3.56e-9	Obesity-related traits;
LUSC	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg10596483	chr8:143751796	JRK	0.61	9.4	0.46	9.11e-19	Schizophrenia;
LUSC	cis	rs6005807	0.719	rs58542867	chr22:28988260	A/G	cg12565055	chr22:29076175	TTC28	0.56	5.97	0.31	6.06e-9	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs9341808	0.690	rs2505932	chr6:80839252	G/T	cg08355045	chr6:80787529	NA	0.47	8.21	0.41	4.88e-15	Sitting height ratio;
LUSC	cis	rs1018836	0.545	rs4236827	chr8:91688943	A/T	cg16814680	chr8:91681699	NA	-1.05	-24.21	-0.8	1.77e-75	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.13	0.64	9.04e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	7.47	0.38	6.89e-13	Initial pursuit acceleration;
LUSC	cis	rs9311676	0.656	rs6773193	chr3:58385960	C/T	cg13750441	chr3:58318267	PXK	0.35	6.72	0.35	7.86e-11	Systemic lupus erythematosus;
LUSC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg09165964	chr15:75287851	SCAMP5	0.45	6.71	0.34	8.34e-11	Breast cancer;
LUSC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg05887092	chr17:76393375	PGS1	0.52	9.34	0.46	1.41e-18	HDL cholesterol levels;
LUSC	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg00129232	chr17:37814104	STARD3	-0.42	-6.16	-0.32	2.13e-9	Asthma;
LUSC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06112835	chr11:68658793	MRPL21	0.51	7.54	0.38	4.53e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg14664628	chr15:75095509	CSK	0.43	6.07	0.32	3.43e-9	Systemic lupus erythematosus;
LUSC	cis	rs1572072	0.545	rs1572073	chr13:24127240	C/T	cg24350296	chr13:24144486	TNFRSF19	-0.31	-5.7	-0.3	2.57e-8	Nasopharyngeal carcinoma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19557340	chr13:35516445	NBEA	-0.47	-6.18	-0.32	1.84e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg11901034	chr3:128598214	ACAD9	-0.4	-6.21	-0.32	1.57e-9	IgG glycosylation;
LUSC	trans	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg06627628	chr2:24431161	ITSN2	0.61	7.39	0.37	1.21e-12	Lymphocyte counts;
LUSC	cis	rs7572644	0.766	rs13016573	chr2:28094270	C/G	cg27432699	chr2:27873401	GPN1	-0.51	-6.6	-0.34	1.62e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg12310025	chr6:25882481	NA	-0.35	-5.78	-0.3	1.74e-8	Height;
LUSC	cis	rs9283706	0.594	rs10515036	chr5:66343787	A/G	cg11590213	chr5:66331682	MAST4	-0.48	-7.27	-0.37	2.5e-12	Coronary artery disease;
LUSC	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg12884169	chr21:40033163	ERG	-0.55	-10.82	-0.51	1.38e-23	Coronary artery disease;
LUSC	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg26647111	chr11:31128758	NA	0.4	5.65	0.3	3.36e-8	Red blood cell count;
LUSC	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.58	-8.84	-0.44	5.49e-17	Vitiligo;
LUSC	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg16576597	chr16:28551801	NUPR1	0.3	6.01	0.31	4.79e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg05043794	chr9:111880884	C9orf5	-0.35	-7.43	-0.38	9.16e-13	Menarche (age at onset);
LUSC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg04871131	chr7:94954202	PON1	0.38	6.05	0.31	3.87e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03517284	chr6:25882590	NA	-0.45	-7.73	-0.39	1.3e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg08854313	chr1:11322531	MTOR	0.8	12.45	0.56	1.6800000000000001e-29	Body mass index;
LUSC	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-9.94	-0.48	1.49e-20	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.8	10.69	0.5	3.87e-23	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs1385374	0.858	rs11059933	chr12:129303593	T/C	cg09035930	chr12:129282057	SLC15A4	-0.61	-6.56	-0.34	2.11e-10	Systemic lupus erythematosus;
LUSC	cis	rs62400317	0.859	rs12214749	chr6:45307906	A/G	cg18551225	chr6:44695536	NA	-0.45	-7.44	-0.38	8.38e-13	Total body bone mineral density;
LUSC	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24903225	chr12:108956097	SART3;ISCU	0.36	6.05	0.31	3.87e-9	Triglycerides;
LUSC	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg20628663	chr10:43360327	NA	-0.76	-11.3	-0.53	2.76e-25	Blood protein levels;
LUSC	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg05343316	chr1:45956843	TESK2	0.72	9.75	0.47	6.34e-20	Platelet count;
LUSC	cis	rs7560272	0.538	rs11126415	chr2:73936500	C/T	cg20560298	chr2:73613845	ALMS1	0.4	6.11	0.32	2.8e-9	Schizophrenia;
LUSC	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08736216	chr1:53307985	ZYG11A	-0.29	-6.07	-0.32	3.5e-9	Monocyte count;
LUSC	cis	rs2267137	0.574	rs5752910	chr22:29803493	A/G	cg07256473	chr22:29710276	RASL10A	0.38	7.34	0.37	1.69e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg09509183	chr1:209979624	IRF6	-0.45	-7.06	-0.36	9.7e-12	Orofacial clefts;
LUSC	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg08484992	chr16:88977278	CBFA2T3	0.35	6.13	0.32	2.41e-9	Social autistic-like traits;
LUSC	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.26	-0.32	1.17e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg11244672	chr19:19639970	YJEFN3	0.58	7.26	0.37	2.73e-12	Bipolar disorder;
LUSC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg18758796	chr5:131593413	PDLIM4	0.4	7.07	0.36	9.38e-12	Blood metabolite levels;
LUSC	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.4	-7.75	-0.39	1.14e-13	Caffeine consumption;
LUSC	cis	rs7527798	0.592	rs6667238	chr1:207822856	G/A	cg09232269	chr1:207846808	CR1L	-0.3	-6.46	-0.33	3.78e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.29	0.53	3e-25	Eye color traits;
LUSC	cis	rs2842992	0.747	rs4709379	chr6:160227530	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	8.87	0.44	4.4e-17	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg11887960	chr12:57824829	NA	0.58	7.05	0.36	1.05e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.49	0.38	6.07e-13	Motion sickness;
LUSC	cis	rs1322512	0.837	rs2758786	chr6:153013644	G/A	cg27316956	chr6:152958899	SYNE1	0.36	6.19	0.32	1.81e-9	Tonometry;
LUSC	cis	rs9311676	0.656	rs55783924	chr3:58403610	C/T	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.11e-10	Systemic lupus erythematosus;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11141652	chr22:24348549	GSTTP1	0.42	6.51	0.34	2.69e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg00343986	chr7:65444356	GUSB	-0.42	-6.44	-0.33	4.05e-10	Aortic root size;
LUSC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26314531	chr2:26401878	FAM59B	-0.68	-9.1	-0.45	8.35e-18	Gut microbiome composition (summer);
LUSC	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg20701182	chr2:24300061	SF3B14	0.82	8.15	0.41	7.36e-15	Lymphocyte counts;
LUSC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.09	0.4	1.09e-14	Lung cancer;
LUSC	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg17366294	chr4:99064904	C4orf37	0.52	8.35	0.42	1.82e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.45	0.38	8.3e-13	Bipolar disorder;
LUSC	cis	rs2274273	0.623	rs1187877	chr14:55495161	T/C	cg04306507	chr14:55594613	LGALS3	-0.5	-11.01	-0.52	2.94e-24	Protein biomarker;
LUSC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13770153	chr20:60521292	NA	-0.64	-8.62	-0.43	2.74e-16	Body mass index;
LUSC	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg14227996	chr4:17616232	MED28	0.8	8.14	0.41	7.99e-15	Opioid sensitivity;
LUSC	trans	rs2392780	0.512	rs594076	chr8:128334966	G/C	cg10897648	chr18:56338258	MALT1	-0.41	-6.17	-0.32	1.92e-9	Breast cancer (early onset);
LUSC	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg01579765	chr21:45077557	HSF2BP	-0.47	-9.78	-0.47	5.04e-20	Mean corpuscular volume;
LUSC	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg08975724	chr8:8085496	FLJ10661	0.45	6.69	0.34	9.62e-11	Retinal vascular caliber;
LUSC	cis	rs6504340	0.739	rs4793943	chr17:46666937	C/G	cg09704116	chr17:46666958	LOC404266	-0.37	-5.67	-0.3	3.13e-8	Primary tooth development (number of teeth);
LUSC	cis	rs67981189	0.593	rs2877714	chr14:71568215	G/T	cg15816911	chr14:71606274	NA	0.34	5.98	0.31	5.8e-9	Schizophrenia;
LUSC	cis	rs3741798	1.000	rs73277486	chr12:12494761	T/C	cg08615371	chr12:12503544	MANSC1	1.08	11.05	0.52	2.07e-24	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg19610905	chr11:61596333	FADS2	-0.55	-8.27	-0.41	3.13e-15	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUSC	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg16405210	chr4:1374714	KIAA1530	0.47	5.79	0.3	1.66e-8	Recombination rate (females);
LUSC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.27	0.32	1.11e-9	Menopause (age at onset);
LUSC	cis	rs68170813	0.559	rs12538769	chr7:106984288	C/T	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.66	-0.3	3.23e-8	Coronary artery disease;
LUSC	trans	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.51	-0.34	2.81e-10	Triglycerides;
LUSC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg18681998	chr4:17616180	MED28	0.87	16.39	0.67	9.86e-45	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs708547	0.671	rs1718863	chr4:57887586	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	7.64	0.39	2.25e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg05501817	chr11:14380813	RRAS2	-0.56	-8.68	-0.43	1.79e-16	Sense of smell;
LUSC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg14668632	chr7:2872130	GNA12	-0.45	-6.44	-0.33	4.05e-10	Height;
LUSC	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.48	0.38	6.51e-13	Morning vs. evening chronotype;
LUSC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.82	-13.3	-0.59	1.14e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	13.69	0.6	3.59e-34	Exhaled nitric oxide levels;
LUSC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg08219700	chr8:58056026	NA	0.5	6.4	0.33	5.22e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.61	10.21	0.49	1.71e-21	Blood metabolite levels;
LUSC	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg24375607	chr4:120327624	NA	0.75	11.05	0.52	2.18e-24	Corneal astigmatism;
LUSC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg04414720	chr1:150670196	GOLPH3L	0.5	7.83	0.39	6.59e-14	Melanoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17599186	chr17:3572162	TMEM93;TAX1BP3	-0.42	-6.35	-0.33	7e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.92	15.52	0.65	2.71e-41	Bladder cancer;
LUSC	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	7.9	0.4	3.97e-14	Retinal vascular caliber;
LUSC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg25204440	chr1:209979598	IRF6	0.5	5.72	0.3	2.4e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg04518342	chr5:131593106	PDLIM4	0.52	9.49	0.46	4.59e-19	Acylcarnitine levels;
LUSC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg26335602	chr6:28129616	ZNF389	0.46	6.34	0.33	7.57e-10	Parkinson's disease;
LUSC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.85	-0.35	3.59e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs8030485	0.536	rs12595749	chr15:79432359	A/G	cg17916960	chr15:79447300	NA	0.4	7.38	0.37	1.29e-12	Left ventricle wall thickness;
LUSC	cis	rs11756438	0.572	rs1857312	chr6:119001526	A/C	cg21191810	chr6:118973309	C6orf204	0.35	5.92	0.31	8.2e-9	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.84	13.26	0.59	1.52e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg02574844	chr11:5959923	NA	-0.5	-6.81	-0.35	4.66e-11	DNA methylation (variation);
LUSC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	0.9	15.57	0.65	1.82e-41	Height;
LUSC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg12442385	chr7:1034912	NA	-0.35	-6.1	-0.32	2.9e-9	Longevity;Endometriosis;
LUSC	trans	rs7939886	0.844	rs2512784	chr11:55894186	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-6.07	-0.32	3.47e-9	Myopia (pathological);
LUSC	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-5.82	-0.3	1.36e-8	Recombination measurement;
LUSC	cis	rs16866061	0.517	rs7580488	chr2:225473263	C/T	cg12698349	chr2:225449008	CUL3	0.47	7.12	0.36	6.56e-12	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg16797656	chr11:68205561	LRP5	0.47	8.37	0.42	1.56e-15	Total body bone mineral density;
LUSC	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg04374321	chr14:90722782	PSMC1	0.73	11.32	0.53	2.29e-25	Mortality in heart failure;
LUSC	cis	rs2219968	1.000	rs7003597	chr8:78976117	A/G	cg00738934	chr8:78996279	NA	0.35	6.34	0.33	7.41e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg05347473	chr6:146136440	FBXO30	-0.61	-9.47	-0.46	5.47e-19	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg26384229	chr12:38710491	ALG10B	0.71	11.12	0.52	1.24e-24	Morning vs. evening chronotype;
LUSC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg08392591	chr16:89556376	ANKRD11	0.46	7.19	0.37	4.39e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg19318889	chr4:1322082	MAEA	0.57	9.71	0.47	8.22e-20	Longevity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14792983	chr20:18447909	C20orf12;POLR3F	0.47	6.78	0.35	5.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs17155006	0.746	rs401066	chr7:107747937	G/A	cg05962710	chr7:107745446	LAMB4	-0.36	-6.52	-0.34	2.57e-10	Pneumococcal bacteremia;
LUSC	cis	rs10216189	0.785	rs4623325	chr7:5526807	C/T	cg11800390	chr7:5515995	FBXL18	-0.32	-6.71	-0.34	8.33e-11	Relative hand skill in reading disability;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09689279	chr15:49169965	SHC4;EID1	0.44	6.1	0.32	2.95e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-8.59	-0.43	3.48e-16	Chronic sinus infection;
LUSC	cis	rs6681460	0.549	rs7547794	chr1:67031878	A/G	cg02459107	chr1:67143332	SGIP1	0.31	5.69	0.3	2.85e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg09307838	chr4:120376055	NA	0.74	10.61	0.5	7.28e-23	Corneal astigmatism;
LUSC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg21770322	chr7:97807741	LMTK2	0.41	7.11	0.36	7.23e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.61	-12.65	-0.57	3.14e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-0.81	-9.95	-0.48	1.35e-20	Refractive error;
LUSC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg08088566	chr11:430123	ANO9	0.72	7.77	0.39	9.65e-14	Body mass index;
LUSC	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg27219399	chr15:67835830	MAP2K5	0.36	5.86	0.31	1.14e-8	Obesity;
LUSC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	15.65	0.65	8.56e-42	Platelet count;
LUSC	cis	rs2236918	0.687	rs851778	chr1:242037110	A/G	cg17736920	chr1:242011382	EXO1	0.42	6.63	0.34	1.32e-10	Menopause (age at onset);
LUSC	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07636037	chr3:49044803	WDR6	0.69	8.83	0.44	5.99e-17	Menarche (age at onset);
LUSC	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.13e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg05373962	chr22:49881684	NA	-0.4	-8.97	-0.44	2.25e-17	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg04998671	chr14:104000505	TRMT61A	-0.48	-6.71	-0.34	8.58e-11	Reticulocyte count;
LUSC	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg11130432	chr3:121712080	ILDR1	-0.61	-9.18	-0.45	4.74e-18	Multiple sclerosis;
LUSC	cis	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg21775007	chr8:11205619	TDH	-0.5	-7.54	-0.38	4.51e-13	Systolic blood pressure;
LUSC	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg01657329	chr11:68192670	LRP5	-0.4	-5.76	-0.3	1.92e-8	Total body bone mineral density;
LUSC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg23711669	chr6:146136114	FBXO30	0.72	12.82	0.57	7.47e-31	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08802696	chr7:44240534	YKT6	0.44	6.49	0.33	3.05e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-11.93	-0.55	1.41e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg08355456	chr11:67383691	NA	0.46	8.67	0.43	1.89e-16	Mean corpuscular volume;
LUSC	cis	rs240764	0.817	rs11155610	chr6:101170233	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.12	-0.32	2.61e-9	Neuroticism;
LUSC	cis	rs16976116	0.851	rs28784096	chr15:55503312	C/T	cg11288833	chr15:55489084	RSL24D1	0.51	6.16	0.32	2.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9399401	0.601	rs262113	chr6:142824950	T/G	cg03128060	chr6:142623767	GPR126	0.55	8.92	0.44	3.16e-17	Chronic obstructive pulmonary disease;
LUSC	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg08079166	chr15:68083412	MAP2K5	0.41	7.46	0.38	7.5e-13	Restless legs syndrome;
LUSC	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg16989719	chr2:238392110	NA	-0.38	-6.57	-0.34	1.92e-10	Prostate cancer;
LUSC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg09650180	chr20:62225654	GMEB2	-0.67	-9.77	-0.47	5.56e-20	Glioblastoma;
LUSC	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg01238044	chr22:24384105	GSTT1	-0.62	-9.65	-0.47	1.38e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-20.32	-0.74	2.4e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg02997394	chr19:33096574	ANKRD27	0.82	9.32	0.45	1.68e-18	Eosinophilic esophagitis;
LUSC	cis	rs6076065	0.723	rs2275787	chr20:23338486	A/G	cg11657817	chr20:23433608	CST11	0.43	8.09	0.4	1.15e-14	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.1	-0.45	8.46e-18	Depression;
LUSC	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg27411982	chr8:10470053	RP1L1	0.41	6.27	0.32	1.14e-9	Mood instability;
LUSC	cis	rs2398893	0.960	rs7849645	chr9:96744232	A/T	cg14459158	chr9:96720562	NA	0.32	5.89	0.31	9.33e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	8.78	0.43	8.88e-17	Motion sickness;
LUSC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.03	21.08	0.76	2.6e-63	Cognitive function;
LUSC	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.5	0.34	2.86e-10	Schizophrenia;
LUSC	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg08601574	chr20:25228251	PYGB	0.42	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg04944784	chr2:26401820	FAM59B	0.78	11.21	0.52	5.54e-25	Gut microbiome composition (summer);
LUSC	cis	rs243505	0.660	rs7785022	chr7:148533384	C/T	cg09806900	chr7:148480153	CUL1	0.48	6.49	0.33	3.19e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg14004847	chr7:1930337	MAD1L1	0.55	8.28	0.41	3.07e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14584159	chr10:134351371	INPP5A	-0.53	-6.05	-0.31	3.81e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg10370574	chr19:1840461	REXO1	-0.55	-7.92	-0.4	3.54e-14	Bipolar disorder;
LUSC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-1.04	-20.3	-0.74	2.97e-60	Height;
LUSC	cis	rs12681287	0.752	rs10103229	chr8:87248954	C/T	cg27223183	chr8:87520930	FAM82B	0.47	6.03	0.31	4.36e-9	Caudate activity during reward;
LUSC	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg22089800	chr15:90895588	ZNF774	-0.64	-9.63	-0.47	1.52e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg24011408	chr12:48396354	COL2A1	-0.53	-8.72	-0.43	1.38e-16	Plateletcrit;
LUSC	cis	rs9494145	0.680	rs4895441	chr6:135426573	C/T	cg22676075	chr6:135203613	NA	-0.61	-9.0	-0.44	1.73e-17	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	7.2	0.37	3.94e-12	Resting heart rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00821098	chr10:101419190	ENTPD7	0.42	6.59	0.34	1.7e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7567389	0.740	rs1604817	chr2:127999921	C/T	cg09760422	chr2:128146352	NA	-0.31	-6.53	-0.34	2.39e-10	Self-rated health;
LUSC	cis	rs7575217	0.552	rs13032971	chr2:101689726	T/G	cg23907051	chr2:101730305	TBC1D8	0.26	6.49	0.33	3.17e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-18.18	-0.71	7.93e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg11247378	chr22:39784982	NA	-0.66	-13.0	-0.58	1.52e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-11.76	-0.54	5.89e-27	Extrinsic epigenetic age acceleration;
LUSC	trans	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg09050820	chr6:167586206	TCP10L2	0.74	9.55	0.46	2.82e-19	Gastritis;
LUSC	cis	rs2692947	0.644	rs1168975	chr2:96814075	G/A	cg23100626	chr2:96804247	ASTL	0.3	7.17	0.37	4.93e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4141404	0.757	rs5749272	chr22:31830351	C/T	cg22777020	chr22:31556080	RNF185	-0.41	-5.8	-0.3	1.57e-8	Paclitaxel-induced neuropathy;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03066081	chr17:77784036	NA	0.42	6.05	0.31	3.95e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06445916	chr8:42268472	NA	-0.4	-6.04	-0.31	4.11e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs11608355	0.545	rs9943764	chr12:109905720	G/A	cg05360138	chr12:110035743	NA	0.89	11.55	0.53	3.47e-26	Neuroticism;
LUSC	cis	rs7561273	0.609	rs6720226	chr2:24295853	A/G	cg06627628	chr2:24431161	ITSN2	-0.51	-6.83	-0.35	4.03e-11	Quantitative traits;
LUSC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg27432699	chr2:27873401	GPN1	-0.56	-8.21	-0.41	5.03e-15	Total body bone mineral density;
LUSC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	9.32	0.45	1.58e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg07701084	chr6:150067640	NUP43	0.58	9.06	0.44	1.15e-17	Lung cancer;
LUSC	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg17764715	chr19:33622953	WDR88	0.54	7.4	0.38	1.12e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.26	34.13	0.88	6.59e-111	Chronic sinus infection;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03911494	chr16:71660463	MARVELD3	0.73	5.96	0.31	6.46e-9	Cognitive performance;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14460708	chr3:172428874	NCEH1	0.52	7.68	0.39	1.78e-13	Triglycerides;
LUSC	trans	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg04146151	chr16:2155961	PKD1	-0.45	-7.56	-0.38	3.8e-13	Triglycerides;
LUSC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg06454157	chr6:167490870	NA	-0.29	-6.78	-0.35	5.52e-11	Crohn's disease;
LUSC	cis	rs10779751	0.881	rs2744815	chr1:11360957	C/T	cg08854313	chr1:11322531	MTOR	0.73	12.03	0.55	6.36e-28	Body mass index;
LUSC	trans	rs6601327	0.607	rs13276086	chr8:9578982	T/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.58	-0.34	1.83e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.73	-0.35	7.21e-11	Total cholesterol levels;
LUSC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg10130564	chr11:117069849	TAGLN	0.37	6.32	0.33	8.21e-10	Blood protein levels;
LUSC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	10.84	0.51	1.21e-23	Prudent dietary pattern;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg12897942	chr3:170626357	EIF5A2	0.39	6.28	0.32	1.03e-9	Schizophrenia;
LUSC	cis	rs7621025	0.500	rs12629000	chr3:136643571	T/A	cg15507776	chr3:136538369	TMEM22	0.61	8.42	0.42	1.13e-15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUSC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9815354	0.723	rs61182696	chr3:42032511	C/T	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg05729581	chr11:3078854	CARS	-0.58	-8.91	-0.44	3.37e-17	Longevity;
LUSC	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg06627628	chr2:24431161	ITSN2	-0.52	-7.43	-0.38	9.23e-13	Asthma;
LUSC	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg11189052	chr15:85197271	WDR73	0.48	6.08	0.32	3.22e-9	Schizophrenia;
LUSC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg27398817	chr8:82754497	SNX16	-0.65	-8.24	-0.41	4e-15	Diastolic blood pressure;
LUSC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.46	-0.38	7.74e-13	Personality dimensions;
LUSC	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg05283184	chr6:79620031	NA	-0.57	-12.03	-0.55	6.01e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg23450324	chr2:170551086	KLHL23;C2orf77;PHOSPHO2	0.4	5.99	0.31	5.53e-9	Mosquito bite size;
LUSC	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg05738196	chr6:26577821	NA	-0.52	-8.21	-0.41	5.04e-15	Schizophrenia;
LUSC	cis	rs1003719	0.843	rs1003721	chr21:38492657	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.61	9.69	0.47	1.03e-19	Eye color traits;
LUSC	trans	rs6601327	0.571	rs7838571	chr8:9647796	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	6.54	0.34	2.36e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	5.96	0.31	6.56e-9	Schizophrenia;
LUSC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg02423579	chr7:2872169	GNA12	-0.44	-5.98	-0.31	5.78e-9	Height;
LUSC	cis	rs7149337	0.837	rs10132658	chr14:51677599	C/T	cg23942311	chr14:51606299	NA	0.47	10.31	0.49	7.99e-22	Cancer;
LUSC	trans	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7923609	0.846	rs7073753	chr10:65062820	C/T	cg01631684	chr10:65280961	REEP3	-0.38	-5.65	-0.3	3.44e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8032315	0.965	rs8027450	chr15:91418394	C/T	cg04510874	chr15:91427884	FES	0.3	5.89	0.31	9.25e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg22535103	chr8:58192502	C8orf71	-0.67	-7.55	-0.38	4.15e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg20607287	chr7:12443886	VWDE	-0.65	-6.44	-0.33	4.17e-10	Coronary artery disease;
LUSC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg02569458	chr12:86230093	RASSF9	0.55	9.37	0.46	1.12e-18	Major depressive disorder;
LUSC	cis	rs2274273	0.624	rs11158034	chr14:55753560	C/T	cg04306507	chr14:55594613	LGALS3	0.48	9.85	0.47	2.9e-20	Protein biomarker;
LUSC	cis	rs73200209	0.744	rs17498872	chr12:116669888	A/T	cg01776926	chr12:116560359	MED13L	-0.49	-5.98	-0.31	5.8e-9	Total body bone mineral density;
LUSC	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.59	-0.43	3.43e-16	Mood instability;
LUSC	cis	rs4417855	0.794	rs3868898	chr3:187425632	A/T	cg19198148	chr3:187451818	BCL6	0.57	10.3	0.49	8.38e-22	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.53	-0.46	3.44e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg02569458	chr12:86230093	RASSF9	0.47	7.47	0.38	6.9e-13	Major depressive disorder;
LUSC	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg09462578	chr12:12878428	APOLD1	0.64	7.54	0.38	4.62e-13	Systemic lupus erythematosus;
LUSC	cis	rs9473147	0.516	rs9296564	chr6:47494759	A/G	cg12968598	chr6:47444699	CD2AP	0.53	7.97	0.4	2.49e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.38	-0.42	1.47e-15	Schizophrenia;
LUSC	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.69	-11.28	-0.53	3.19e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg08859206	chr1:53392774	SCP2	-0.42	-6.74	-0.35	7.06e-11	Monocyte count;
LUSC	cis	rs62400317	0.859	rs72858517	chr6:45223467	A/C	cg18551225	chr6:44695536	NA	-0.44	-7.34	-0.37	1.63e-12	Total body bone mineral density;
LUSC	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg19610905	chr11:61596333	FADS2	-0.42	-5.91	-0.31	8.55e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg05868516	chr6:26286170	HIST1H4H	0.37	6.09	0.32	3.03e-9	Educational attainment;
LUSC	cis	rs72772090	0.710	rs17479052	chr5:96065636	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-7.43	-0.38	9.39e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.34	-0.37	1.62e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg03929089	chr4:120376271	NA	-0.54	-6.73	-0.35	7.51e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg05283184	chr6:79620031	NA	-0.55	-11.32	-0.53	2.38e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg19622623	chr12:86230825	RASSF9	0.4	5.92	0.31	7.89e-9	Major depressive disorder;
LUSC	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.69	-10.98	-0.52	3.69e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	10.08	0.48	5.02e-21	Bone mineral density;
LUSC	cis	rs2625529	0.617	rs2929509	chr15:72239272	T/C	cg16672083	chr15:72433130	SENP8	0.48	8.08	0.4	1.17e-14	Red blood cell count;
LUSC	cis	rs6982240	0.514	rs10093988	chr8:142260995	T/C	cg00131261	chr8:142287264	NA	-0.36	-6.0	-0.31	5.17e-9	Tonsillectomy;
LUSC	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.7	0.75	7.61e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg06703304	chr16:68057150	DUS2L;DDX28	0.39	5.95	0.31	6.83e-9	N-glycan levels;
LUSC	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg03929089	chr4:120376271	NA	0.7	6.48	0.33	3.37e-10	Intraocular pressure;
LUSC	cis	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg26958806	chr6:27640298	NA	0.81	6.28	0.32	1.05e-9	Depression;
LUSC	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.23	0.49	1.56e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.05	0.36	1.01e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg01596870	chr19:55963115	NA	0.56	7.43	0.38	9.05e-13	Obesity-related traits;
LUSC	cis	rs9534288	0.912	rs4942468	chr13:46618290	C/A	cg15192986	chr13:46630673	CPB2	-0.73	-11.27	-0.52	3.51e-25	Blood protein levels;
LUSC	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg16512390	chr1:228756714	NA	0.5	7.31	0.37	1.97e-12	Chronic lymphocytic leukemia;
LUSC	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg06917634	chr15:78832804	PSMA4	-0.7	-11.63	-0.54	1.76e-26	Sudden cardiac arrest;
LUSC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg02782426	chr3:40428986	ENTPD3	0.33	6.67	0.34	1.09e-10	Renal cell carcinoma;
LUSC	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg08345082	chr10:99160200	RRP12	-0.35	-7.2	-0.37	3.91e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg25174290	chr11:3078921	CARS	0.6	9.58	0.46	2.28e-19	Longevity;
LUSC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg05425664	chr17:57184151	TRIM37	-0.57	-8.45	-0.42	9.38e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs500891	0.620	rs3812144	chr6:84141253	T/G	cg08257003	chr6:84140564	ME1	0.37	9.19	0.45	4.23e-18	Platelet-derived growth factor BB levels;
LUSC	trans	rs2392780	0.536	rs631845	chr8:128338760	G/A	cg10195415	chr17:73887371	TRIM65	0.41	6.64	0.34	1.3100000000000001e-10	Breast cancer (early onset);
LUSC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg07507251	chr3:52567010	NT5DC2	0.36	7.01	0.36	1.29e-11	Bipolar disorder;
LUSC	cis	rs4253772	0.938	rs41371446	chr22:46637272	T/C	cg09491104	chr22:46646882	C22orf40	-0.62	-6.62	-0.34	1.47e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7615316	0.902	rs6440091	chr3:142313515	C/T	cg16271453	chr3:142027066	XRN1	-0.36	-6.12	-0.32	2.61e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4561483	0.645	rs2192645	chr16:11928019	C/T	cg08843971	chr16:11963173	GSPT1	-0.38	-5.79	-0.3	1.63e-8	Testicular germ cell tumor;
LUSC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg16606324	chr3:10149918	C3orf24	0.44	6.83	0.35	4.05e-11	Alzheimer's disease;
LUSC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.86	-0.31	1.13e-8	Alzheimer's disease (late onset);
LUSC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg01802117	chr1:53393560	SCP2	-0.4	-6.75	-0.35	6.51e-11	Monocyte count;
LUSC	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.67	-11.16	-0.52	8.79e-25	Caffeine consumption;
LUSC	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg04719120	chr6:96025338	MANEA	0.46	5.81	0.3	1.45e-8	Behavioural disinhibition (generation interaction);
LUSC	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg07828340	chr4:882639	GAK	0.97	9.67	0.47	1.14e-19	Parkinson's disease;
LUSC	cis	rs1322512	0.677	rs1727040	chr6:152937509	G/A	cg27316956	chr6:152958899	SYNE1	-0.36	-5.94	-0.31	7.06e-9	Tonometry;
LUSC	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	1.0	9.75	0.47	6.2e-20	Diabetic kidney disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03150409	chr4:1892317	WHSC1	-0.44	-7.72	-0.39	1.38e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	12.59	0.57	5.23e-30	Cognitive test performance;
LUSC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg02503808	chr4:7069936	GRPEL1	-1.03	-11.28	-0.53	3.09e-25	Monocyte percentage of white cells;
LUSC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg04287289	chr16:89883240	FANCA	0.78	6.24	0.32	1.3e-9	Skin colour saturation;
LUSC	trans	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.9	0.35	2.57e-11	Endometrial cancer;
LUSC	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg17757837	chr7:157058334	UBE3C	-0.82	-13.31	-0.59	1.01e-32	Body mass index;
LUSC	cis	rs1178968	0.901	rs7779909	chr7:72751966	G/T	cg25889504	chr7:72793014	NA	0.57	7.85	0.39	5.62e-14	Triglyceride levels;
LUSC	cis	rs240764	0.817	rs239207	chr6:101137765	A/C	cg09795085	chr6:101329169	ASCC3	0.42	6.17	0.32	2.01e-9	Neuroticism;
LUSC	cis	rs28493229	0.881	rs10404911	chr19:41174903	A/T	cg21869046	chr19:41225005	ITPKC	0.54	7.23	0.37	3.38e-12	Kawasaki disease;
LUSC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg08219700	chr8:58056026	NA	0.43	5.68	0.3	2.99e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg12826209	chr6:26865740	GUSBL1	0.45	6.39	0.33	5.61e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.83	-0.3	1.32e-8	Coronary artery disease;
LUSC	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg16482183	chr6:26056742	HIST1H1C	0.65	9.37	0.46	1.15e-18	Height;
LUSC	cis	rs7617773	0.963	rs12495221	chr3:48179178	C/T	cg11946769	chr3:48343235	NME6	-0.63	-9.41	-0.46	8.57e-19	Coronary artery disease;
LUSC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.08	-0.4	1.19e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg02153584	chr22:29168773	CCDC117	0.65	10.52	0.5	1.52e-22	Lymphocyte counts;
LUSC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg21724239	chr8:58056113	NA	0.56	6.66	0.34	1.13e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09608387	chr6:150464020	PPP1R14C	-0.51	-6.18	-0.32	1.84e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14442939	chr10:27389572	ANKRD26	0.83	9.47	0.46	5.11e-19	Breast cancer;
LUSC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg16262614	chr3:133464971	TF	0.43	7.56	0.38	3.85e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg14004847	chr7:1930337	MAD1L1	0.61	9.66	0.47	1.22e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-0.94	-13.88	-0.6	6.62e-35	Initial pursuit acceleration;
LUSC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.92	-13.66	-0.6	4.74e-34	Initial pursuit acceleration;
LUSC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-1.19	-12.75	-0.57	1.35e-30	Diabetic kidney disease;
LUSC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg23985595	chr17:80112537	CCDC57	0.32	6.16	0.32	2.15e-9	Life satisfaction;
LUSC	cis	rs2637266	0.783	rs846597	chr10:78529114	A/G	cg18941641	chr10:78392320	NA	0.38	6.79	0.35	5.11e-11	Pulmonary function;
LUSC	cis	rs3867498	0.550	rs12901127	chr15:25074586	A/C	cg02919448	chr15:24122782	NA	-0.33	-6.14	-0.32	2.29e-9	Pulmonary function;
LUSC	trans	rs890448	0.796	rs2471673	chr4:102353587	C/T	cg05120309	chr14:100485494	NA	-0.36	-6.02	-0.31	4.67e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg03453431	chr7:157225567	NA	-0.58	-10.37	-0.49	4.84e-22	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg17385448	chr1:15911702	AGMAT	0.36	5.86	0.31	1.12e-8	Systolic blood pressure;
LUSC	cis	rs9341835	0.518	rs6942342	chr6:64176447	T/C	cg03326410	chr6:64151739	NA	-0.37	-6.01	-0.31	4.8e-9	Schizophrenia;
LUSC	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-8.2	-0.41	5.24e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4566357	0.615	rs10178260	chr2:227914458	G/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.2	-0.41	5.4e-15	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg03188948	chr7:1209495	NA	0.66	6.93	0.35	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	12.21	0.56	1.31e-28	Colorectal cancer;
LUSC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg03676636	chr4:99064102	C4orf37	0.34	7.46	0.38	7.44e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4629710	0.534	rs6916881	chr6:131565153	C/T	cg12606694	chr6:131520996	AKAP7	0.6	9.27	0.45	2.39e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.45	-0.46	6.19e-19	Body mass index;
LUSC	trans	rs57046232	0.552	rs6038443	chr20:6328844	A/G	cg17788362	chr6:86352627	SYNCRIP	0.45	6.23	0.32	1.38e-9	Colorectal cancer;
LUSC	trans	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.52	-0.38	5.05e-13	Depression;
LUSC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	9.15	0.45	5.74e-18	Height;
LUSC	trans	rs747782	0.640	rs11039603	chr11:48256786	G/A	cg15704280	chr7:45808275	SEPT13	0.77	6.64	0.34	1.27e-10	Intraocular pressure;
LUSC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg08088566	chr11:430123	ANO9	0.61	7.07	0.36	8.89e-12	Body mass index;
LUSC	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.94	-0.36	1.99e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs968451	0.865	rs5757611	chr22:39708357	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	8.89	0.44	3.81e-17	Primary biliary cholangitis;
LUSC	cis	rs2708377	0.929	rs2600337	chr12:11293130	G/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.8	-7.8	-0.39	7.98e-14	Bitter taste perception;
LUSC	cis	rs2970818	0.764	rs61909578	chr12:4570303	G/C	cg11146114	chr12:4671731	NA	-0.64	-6.14	-0.32	2.31e-9	Phosphorus levels;
LUSC	cis	rs926392	0.965	rs6129167	chr20:37689228	C/T	cg27552599	chr20:37590471	DHX35	-0.34	-5.94	-0.31	7.04e-9	Dialysis-related mortality;
LUSC	trans	rs3960554	0.932	rs4728597	chr7:75821062	C/T	cg19862616	chr7:65841803	NCRNA00174	0.89	9.72	0.47	8.08e-20	Eotaxin levels;
LUSC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.4	6.05	0.31	3.93e-9	Calcium levels;
LUSC	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.62	-9.25	-0.45	2.76e-18	Bipolar disorder;
LUSC	cis	rs7674212	0.541	rs2251322	chr4:104079424	C/T	cg16532752	chr4:104119610	CENPE	-0.5	-7.4	-0.38	1.11e-12	Type 2 diabetes;
LUSC	cis	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg21775007	chr8:11205619	TDH	0.44	5.95	0.31	6.85e-9	Neuroticism;
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg04025307	chr7:1156635	C7orf50	0.42	6.37	0.33	6.36e-10	Longevity;Endometriosis;
LUSC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.05	0.31	3.95e-9	Menopause (age at onset);
LUSC	cis	rs12155623	0.834	rs6472110	chr8:49784810	T/C	cg22283653	chr8:49824208	NA	-0.39	-7.51	-0.38	5.61e-13	Sudden cardiac arrest;
LUSC	cis	rs6982240	0.514	rs28588820	chr8:142285342	C/T	cg27411547	chr8:142287226	NA	-0.47	-7.61	-0.38	2.85e-13	Tonsillectomy;
LUSC	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg01475377	chr6:109611718	NA	0.41	7.16	0.36	5.08e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg07636037	chr3:49044803	WDR6	0.44	6.41	0.33	4.89e-10	Resting heart rate;
LUSC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg09365446	chr1:150670422	GOLPH3L	0.52	7.9	0.4	4.17e-14	Tonsillectomy;
LUSC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.58	10.63	0.5	6.51e-23	Bone mineral density;
LUSC	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03878208	chr11:72483293	STARD10	0.59	7.58	0.38	3.54e-13	Type 2 diabetes;
LUSC	cis	rs1005224	0.963	rs2303345	chr14:76156609	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	0.61	8.4	0.42	1.32e-15	Large artery stroke;
LUSC	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg19812747	chr11:111475976	SIK2	-0.55	-8.08	-0.4	1.16e-14	Primary sclerosing cholangitis;
LUSC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg05785598	chr3:49045655	WDR6	0.37	6.52	0.34	2.54e-10	Parkinson's disease;
LUSC	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-0.95	-17.57	-0.69	2.17e-49	Bone mineral density;
LUSC	cis	rs10203711	1.000	rs10207724	chr2:239566705	G/C	cg14580085	chr2:239553406	NA	0.41	6.93	0.35	2.24e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg05313129	chr8:58192883	C8orf71	-0.5	-6.52	-0.34	2.58e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	10.8	0.51	1.58e-23	Response to antipsychotic treatment;
LUSC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.35	-5.71	-0.3	2.45e-8	Total body bone mineral density;
LUSC	cis	rs55910451	0.525	rs17143628	chr10:5832205	C/T	cg11519256	chr10:5708881	ASB13	-0.46	-6.04	-0.31	4.15e-9	Breast cancer;
LUSC	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg22705602	chr4:152727874	NA	-0.3	-5.94	-0.31	7.11e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4964805	0.954	rs10861105	chr12:104189999	C/T	cg02344784	chr12:104178138	NT5DC3	0.45	7.15	0.36	5.34e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs4595586	1.000	rs4595586	chr12:39225991	A/T	cg26384229	chr12:38710491	ALG10B	-0.4	-5.66	-0.3	3.34e-8	Morning vs. evening chronotype;
LUSC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.49	-6.88	-0.35	3.04e-11	Mean platelet volume;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18881962	chr6:1604697	NA	0.72	6.24	0.32	1.34e-9	Cognitive performance;
LUSC	cis	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.26	-0.32	1.15e-9	Resting heart rate;
LUSC	cis	rs7804356	1.000	rs58760954	chr7:26850776	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg26384229	chr12:38710491	ALG10B	0.49	6.99	0.36	1.51e-11	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26314531	chr2:26401878	FAM59B	0.75	10.1	0.48	4.27e-21	Gut microbiome composition (summer);
LUSC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg23262073	chr20:60523788	NA	-0.42	-6.0	-0.31	5.03e-9	Body mass index;
LUSC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-14.08	-0.61	1.14e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg01802117	chr1:53393560	SCP2	0.37	6.0	0.31	5.15e-9	Monocyte count;
LUSC	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg10518543	chr12:38710700	ALG10B	0.41	5.79	0.3	1.61e-8	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9296092	0.500	rs4376348	chr6:33521097	A/G	cg13560919	chr6:33536144	NA	-0.82	-15.68	-0.65	6.77e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg20368463	chr18:77673604	PQLC1	-0.71	-10.84	-0.51	1.13e-23	Schizophrenia;
LUSC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg25767906	chr1:53392781	SCP2	0.48	8.71	0.43	1.47e-16	Monocyte count;
LUSC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg22535103	chr8:58192502	C8orf71	-0.72	-7.18	-0.37	4.53e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.35	0.49	5.93e-22	Morning vs. evening chronotype;
LUSC	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.5	8.16	0.41	6.86e-15	IgG glycosylation;
LUSC	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg24459738	chr19:57751996	ZNF805	-0.52	-7.61	-0.38	2.91e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg18350739	chr11:68623251	NA	-0.36	-6.43	-0.33	4.41e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-7.14	-0.36	6.03e-12	Mood instability;
LUSC	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.72	12.87	0.58	4.72e-31	White blood cell count;
LUSC	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.89	9.68	0.47	1.04e-19	Body mass index;
LUSC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg21862992	chr11:68658383	NA	-0.48	-7.81	-0.39	7.55e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.16	-0.32	2.06e-9	Bipolar disorder;
LUSC	trans	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.21	-0.32	1.57e-9	Depression;
LUSC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg11060661	chr22:24314208	DDT;DDTL	-0.48	-6.4	-0.33	5.41e-10	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg18477163	chr1:228402036	OBSCN	-0.56	-10.26	-0.49	1.21e-21	Diastolic blood pressure;
LUSC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.82	13.08	0.58	7.77e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg14092988	chr3:52407081	DNAH1	0.31	6.04	0.31	4.15e-9	Bipolar disorder;
LUSC	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg03168497	chr17:48586147	MYCBPAP	0.47	6.31	0.33	8.66e-10	Visceral fat;
LUSC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.4	-6.1	-0.32	2.96e-9	Tonsillectomy;
LUSC	cis	rs4499344	0.633	rs259251	chr19:33149768	G/A	cg22980127	chr19:33182716	NUDT19	-0.44	-6.45	-0.33	3.88e-10	Mean platelet volume;
LUSC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg10792982	chr14:105748885	BRF1	0.48	8.71	0.43	1.44e-16	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	6.11	0.32	2.7e-9	Neuroticism;
LUSC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg26924012	chr15:45694286	SPATA5L1	1.12	20.31	0.74	2.75e-60	Homoarginine levels;
LUSC	trans	rs953492	0.644	rs4634890	chr1:243390825	A/C	cg25284624	chr1:224180302	NA	-0.41	-6.19	-0.32	1.72e-9	Diastolic blood pressure;
LUSC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg16928487	chr17:17741425	SREBF1	-0.42	-8.21	-0.41	4.86e-15	Total body bone mineral density;
LUSC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05165339	chr4:1420672	NA	-0.29	-6.46	-0.33	3.77e-10	Longevity;
LUSC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.49	-7.01	-0.36	1.34e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs72634258	0.842	rs6668846	chr1:8152102	C/G	cg26816564	chr1:7831052	VAMP3	-0.43	-5.69	-0.3	2.82e-8	Inflammatory bowel disease;
LUSC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	1.02	19.7	0.73	7.26e-58	Menopause (age at onset);
LUSC	cis	rs17286411	0.750	rs4788450	chr16:71955400	T/G	cg03805757	chr16:71968109	PKD1L3	0.43	7.02	0.36	1.23e-11	Blood protein levels;
LUSC	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.46	-7.61	-0.38	2.75e-13	Schizophrenia;
LUSC	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg11764359	chr7:65958608	NA	0.44	6.3	0.33	9.25e-10	Corneal structure;
LUSC	trans	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg26043149	chr18:55253948	FECH	-0.45	-6.87	-0.35	3.23e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	0.86	18.99	0.72	4.68e-55	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg03647239	chr10:116582469	FAM160B1	0.47	7.58	0.38	3.42e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2559856	0.935	rs7970952	chr12:102081577	C/T	cg12924262	chr12:102091054	CHPT1	0.42	5.7	0.3	2.67e-8	Blood protein levels;
LUSC	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.41	-6.42	-0.33	4.6e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14442939	chr10:27389572	ANKRD26	0.9	9.51	0.46	3.81e-19	Breast cancer;
LUSC	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.75	7.6	0.38	2.93e-13	Yeast infection;
LUSC	cis	rs56399783	0.901	rs73051444	chr7:2866529	G/A	cg19731401	chr7:2775893	GNA12	0.69	9.87	0.48	2.45e-20	Childhood ear infection;
LUSC	cis	rs11247915	0.561	rs12750420	chr1:26608649	G/A	cg15628303	chr1:26608928	UBXN11	0.49	8.0	0.4	2.01e-14	Obesity-related traits;
LUSC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06634786	chr22:41940651	POLR3H	0.52	6.04	0.31	4.17e-9	Vitiligo;
LUSC	cis	rs7523050	0.643	rs67091034	chr1:109402567	C/G	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg25482853	chr8:67687455	SGK3	1.12	16.14	0.66	1.01e-43	Obesity-related traits;
LUSC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.52	-7.15	-0.36	5.45e-12	Mean platelet volume;
LUSC	cis	rs11637445	0.677	rs3784713	chr15:68073013	C/T	cg08079166	chr15:68083412	MAP2K5	0.36	7.39	0.37	1.17e-12	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg07777115	chr5:623756	CEP72	-0.47	-5.86	-0.31	1.11e-8	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07677032	chr17:61819896	STRADA	-0.51	-8.6	-0.43	3.12e-16	Prudent dietary pattern;
LUSC	cis	rs117623576	0.941	rs16932939	chr10:32407862	T/C	cg03047570	chr10:32398778	NA	-0.64	-6.8	-0.35	4.8e-11	Anti-saccade response;
LUSC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	11.97	0.55	1.01e-27	Cognitive test performance;
LUSC	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg24375607	chr4:120327624	NA	0.7	11.14	0.52	9.78e-25	Corneal astigmatism;
LUSC	trans	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg09060275	chr22:27053596	MIAT	-0.4	-6.03	-0.31	4.45e-9	Height;
LUSC	trans	rs1864729	0.901	rs1348184	chr8:98276912	C/G	cg08679828	chr8:102218111	ZNF706	-0.87	-7.83	-0.39	6.43e-14	Estradiol plasma levels (breast cancer);
LUSC	cis	rs727505	1.000	rs2402751	chr7:124434760	C/T	cg23710748	chr7:124431027	NA	-0.41	-6.98	-0.36	1.62e-11	Lewy body disease;
LUSC	cis	rs6460942	0.591	rs75804221	chr7:12364319	C/T	cg06484146	chr7:12443880	VWDE	-0.6	-6.37	-0.33	6.2e-10	Coronary artery disease;
LUSC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg19812747	chr11:111475976	SIK2	-0.55	-8.18	-0.41	5.92e-15	Primary sclerosing cholangitis;
LUSC	cis	rs7095944	0.614	rs10901817	chr10:126443404	A/T	cg08799069	chr10:126477246	METTL10	-0.41	-6.31	-0.33	9.12e-10	Asthma;
LUSC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12826209	chr6:26865740	GUSBL1	0.77	8.94	0.44	2.74e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.35	-0.37	1.53e-12	Triglycerides;
LUSC	trans	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs4865169	0.871	rs9918067	chr4:57870544	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.38	-5.76	-0.3	1.93e-8	Breast cancer;
LUSC	cis	rs9581857	0.547	rs9319374	chr13:28047587	A/C	cg22138327	chr13:27999177	GTF3A	0.73	7.89	0.4	4.26e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	trans	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg26043149	chr18:55253948	FECH	-0.45	-6.86	-0.35	3.42e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7216064	1.000	rs8079754	chr17:65887896	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-8.97	-0.44	2.1e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg00254258	chr1:3105189	PRDM16	-0.29	-5.7	-0.3	2.66e-8	Migraine;
LUSC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg09359103	chr1:154839909	KCNN3	-0.69	-15.99	-0.66	3.74e-43	Prostate cancer;
LUSC	cis	rs3741798	1.000	rs61922028	chr12:12487096	A/C	cg08615371	chr12:12503544	MANSC1	1.09	11.13	0.52	1.13e-24	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs73198271	0.515	rs11774722	chr8:8642448	T/C	cg01851573	chr8:8652454	MFHAS1	0.62	6.84	0.35	3.78e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg15448220	chr1:150897856	SETDB1	0.39	5.76	0.3	1.95e-8	Melanoma;
LUSC	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.98	-0.4	2.44e-14	Schizophrenia;
LUSC	cis	rs68092024	0.731	rs792841	chr3:99471308	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.35	-6.85	-0.35	3.5e-11	Cleft lip with or without cleft palate;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23704733	chr4:84031142	PLAC8	-0.42	-6.23	-0.32	1.42e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6460942	0.524	rs6948366	chr7:12369905	A/G	cg06484146	chr7:12443880	VWDE	-0.51	-6.29	-0.33	1.01e-9	Coronary artery disease;
LUSC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06634786	chr22:41940651	POLR3H	0.51	6.05	0.31	3.96e-9	Vitiligo;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13980399	chr14:61447827	SLC38A6;TRMT5	0.76	6.1	0.32	2.92e-9	Cognitive performance;
LUSC	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg14830002	chr1:247616686	OR2B11	0.45	6.86	0.35	3.32e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.7	-12.78	-0.57	1.0500000000000001e-30	Ulcerative colitis;
LUSC	cis	rs4478858	0.735	rs12734617	chr1:31823446	G/T	cg00250761	chr1:31883323	NA	-0.38	-9.14	-0.45	6.41e-18	Alcohol dependence;
LUSC	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.42	-0.42	1.09e-15	Bipolar disorder;
LUSC	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg23985595	chr17:80112537	CCDC57	-0.31	-6.13	-0.32	2.41e-9	Life satisfaction;
LUSC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.84	0.51	1.17e-23	Menopause (age at onset);
LUSC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg02018176	chr4:1364513	KIAA1530	0.51	8.78	0.43	8.6e-17	Obesity-related traits;
LUSC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg01616529	chr11:638424	DRD4	-0.34	-5.8	-0.3	1.58e-8	Systemic lupus erythematosus;
LUSC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.73	-0.3	2.19e-8	Aortic root size;
LUSC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg08847533	chr14:75593920	NEK9	0.84	15.64	0.65	9.26e-42	Height;
LUSC	trans	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg21659725	chr3:3221576	CRBN	-0.71	-7.82	-0.39	7.08e-14	Menarche (age at onset);
LUSC	cis	rs9905704	0.846	rs304268	chr17:56799907	T/C	cg12560992	chr17:57184187	TRIM37	0.58	8.4	0.42	1.34e-15	Testicular germ cell tumor;
LUSC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.82	0.3	1.39e-8	Breast cancer;
LUSC	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	10.5	0.5	1.84e-22	Coffee consumption (cups per day);
LUSC	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg13072238	chr3:49761600	GMPPB	-0.38	-6.25	-0.32	1.28e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs1998174	0.509	rs4916403	chr1:171815963	T/C	cg13482142	chr2:234261155	NA	0.41	6.05	0.31	3.83e-9	Platelet distribution width;
LUSC	cis	rs10838532	0.506	rs11038739	chr11:46017895	A/T	cg24204282	chr11:45944920	GYLTL1B	0.44	5.82	0.3	1.35e-8	Axial length;
LUSC	trans	rs75804782	0.520	rs72987319	chr2:239351143	C/T	cg01134436	chr17:81009848	B3GNTL1	0.66	6.28	0.32	1.02e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg20283391	chr11:68216788	NA	-0.6	-8.38	-0.42	1.53e-15	Total body bone mineral density;
LUSC	cis	rs829883	0.622	rs7302630	chr12:98959577	C/A	cg25150519	chr12:98850993	NA	-0.62	-8.53	-0.42	5.13e-16	Colorectal adenoma (advanced);
LUSC	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-7.44	-0.38	8.44e-13	Atrioventricular conduction;
LUSC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg05084668	chr3:125655381	ALG1L	-0.49	-6.86	-0.35	3.26e-11	Blood pressure (smoking interaction);
LUSC	cis	rs6537837	0.793	rs12023963	chr1:110084827	A/G	cg05049280	chr1:110155535	GNAT2	-0.37	-5.69	-0.3	2.83e-8	Major depressive disorder;
LUSC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg04546413	chr19:29218101	NA	0.71	11.42	0.53	1.02e-25	Methadone dose in opioid dependence;
LUSC	cis	rs6977660	0.714	rs28605851	chr7:19815219	G/A	cg05791153	chr7:19748676	TWISTNB	0.7	7.45	0.38	8.29e-13	Thyroid stimulating hormone;
LUSC	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.67	12.06	0.55	4.76e-28	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg23601095	chr6:26197514	HIST1H3D	0.68	7.42	0.38	9.69e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	8.75	0.43	1.09e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs10754283	0.967	rs7546518	chr1:90109956	C/T	cg21401794	chr1:90099060	LRRC8C	0.64	9.49	0.46	4.38e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg03474202	chr17:45855739	NA	-0.29	-6.62	-0.34	1.44e-10	IgG glycosylation;
LUSC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg09359103	chr1:154839909	KCNN3	-0.69	-15.99	-0.66	3.74e-43	Prostate cancer;
LUSC	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.77	9.72	0.47	7.81e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg01982873	chr5:490308	SLC9A3	-0.35	-6.2	-0.32	1.69e-9	Cystic fibrosis severity;
LUSC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg22467129	chr15:76604101	ETFA	-0.52	-8.38	-0.42	1.46e-15	Blood metabolite levels;
LUSC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg11764359	chr7:65958608	NA	-0.51	-6.51	-0.34	2.74e-10	Aortic root size;
LUSC	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg24558204	chr6:135376177	HBS1L	0.58	9.03	0.44	1.38e-17	Red blood cell count;
LUSC	cis	rs62400317	0.859	rs11965520	chr6:45259431	T/A	cg20913747	chr6:44695427	NA	-0.46	-7.49	-0.38	6.09e-13	Total body bone mineral density;
LUSC	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.5	-0.46	4.09e-19	Extrinsic epigenetic age acceleration;
LUSC	trans	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg27411982	chr8:10470053	RP1L1	0.45	7.51	0.38	5.53e-13	Mood instability;
LUSC	trans	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg26043149	chr18:55253948	FECH	0.51	7.56	0.38	3.8e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg23719950	chr11:63933701	MACROD1	-0.38	-5.93	-0.31	7.6e-9	Platelet count;
LUSC	trans	rs9380880	0.826	rs12198307	chr6:39550197	C/T	cg12580580	chr10:74544059	CCDC109A	0.59	6.68	0.34	9.96e-11	Immune response to smallpox vaccine (IL-6);
LUSC	trans	rs6725041	0.805	rs6745249	chr2:213130571	A/G	cg08517562	chr20:49126905	PTPN1	-0.4	-6.0	-0.31	5.14e-9	QT interval (ambient particulate matter interaction);
LUSC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05535760	chr7:792225	HEATR2	0.75	9.04	0.44	1.27e-17	Cerebrospinal P-tau181p levels;
LUSC	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	1.02	14.11	0.61	8.54e-36	Exhaled nitric oxide levels;
LUSC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg01802117	chr1:53393560	SCP2	0.39	6.31	0.33	8.82e-10	Monocyte count;
LUSC	trans	rs4596713	0.508	rs4745650	chr9:71777892	G/A	cg25283916	chr1:242222868	NA	-0.29	-6.0	-0.31	5.05e-9	Headache;
LUSC	cis	rs62400317	0.762	rs3997499	chr6:44864552	G/T	cg20913747	chr6:44695427	NA	-0.48	-7.44	-0.38	8.79e-13	Total body bone mineral density;
LUSC	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	1.15	18.27	0.71	3.51e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg21251018	chr6:28226885	NKAPL	0.3	5.72	0.3	2.4e-8	Pubertal anthropometrics;
LUSC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.12	0.58	5.34e-32	Cognitive test performance;
LUSC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6929568	0.966	rs537368	chr6:8213872	A/G	cg05398487	chr6:8064678	MUTED	0.42	5.92	0.31	7.94e-9	Coronary artery calcification;
LUSC	cis	rs10886558	0.619	rs10886564	chr10:121762869	C/T	cg02041677	chr10:121771263	NA	-0.34	-5.72	-0.3	2.31e-8	Shingles;
LUSC	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg19683494	chr5:74908142	NA	0.59	8.05	0.4	1.48e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg13010199	chr12:38710504	ALG10B	0.53	7.91	0.4	3.75e-14	Morning vs. evening chronotype;
LUSC	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg12091567	chr17:66097778	LOC651250	-0.72	-9.53	-0.46	3.46e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.03	-0.31	4.24e-9	Bipolar disorder;
LUSC	cis	rs66716358	0.744	rs10769036	chr11:44321508	C/A	cg16977035	chr11:44330474	ALX4	0.35	5.8	0.3	1.52e-8	Monobrow;
LUSC	trans	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg17712092	chr4:129076599	LARP1B	-0.71	-10.22	-0.49	1.65e-21	Eosinophil percentage of white cells;
LUSC	cis	rs7759001	0.857	rs9461378	chr6:27360245	A/G	cg18711553	chr6:27366782	ZNF391	0.39	5.69	0.3	2.77e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs6961069	0.742	rs1722502	chr7:80241874	A/C	cg04458919	chr7:80252533	CD36	-0.36	-6.63	-0.34	1.32e-10	Platelet count;
LUSC	cis	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg06521331	chr12:34319734	NA	-0.45	-7.33	-0.37	1.77e-12	Morning vs. evening chronotype;
LUSC	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.69	-0.34	9.33e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7180079	1.000	rs11855072	chr15:64538524	C/T	cg08069370	chr15:64387884	SNX1	-0.56	-5.87	-0.31	1.02e-8	Monocyte count;
LUSC	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg27124370	chr19:33622961	WDR88	-0.5	-6.62	-0.34	1.42e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg20933634	chr6:27740509	NA	-0.44	-5.79	-0.3	1.61e-8	Parkinson's disease;
LUSC	trans	rs3857536	0.730	rs7761295	chr6:66932532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.44e-9	Blood trace element (Cu levels);
LUSC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg23795048	chr12:9217529	LOC144571	0.34	5.88	0.31	1.02e-8	Sjögren's syndrome;
LUSC	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg08601574	chr20:25228251	PYGB	0.43	6.53	0.34	2.4e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10207060	0.500	rs11884577	chr2:240702216	C/G	cg07506560	chr2:240697449	NA	0.45	6.92	0.35	2.25e-11	Obesity-related traits;
LUSC	trans	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg26043149	chr18:55253948	FECH	-0.46	-7.11	-0.36	7.02e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12681287	0.640	rs13261901	chr8:87478717	G/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.36	6.24e-12	Caudate activity during reward;
LUSC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg08470875	chr2:26401718	FAM59B	-0.65	-8.6	-0.43	3.12e-16	Gut microbiome composition (summer);
LUSC	cis	rs4631830	0.896	rs7077830	chr10:51522276	C/G	cg10326726	chr10:51549505	MSMB	0.33	5.7	0.3	2.66e-8	Prostate-specific antigen levels;
LUSC	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg05738196	chr6:26577821	NA	0.82	15.82	0.65	1.9e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs9815354	0.812	rs76966288	chr3:41825055	G/A	cg03022575	chr3:42003672	ULK4	0.85	8.67	0.43	1.9e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs17102423	0.826	rs10873182	chr14:65605408	C/T	cg11161011	chr14:65562177	MAX	-0.71	-10.96	-0.51	4.27e-24	Obesity-related traits;
LUSC	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	12.35	0.56	4.15e-29	Electrocardiographic conduction measures;
LUSC	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg17623882	chr6:41773611	USP49	0.65	10.72	0.51	2.94e-23	Menarche (age at onset);
LUSC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-1.07	-20.42	-0.75	9.87e-61	Coronary artery disease;
LUSC	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg00012203	chr2:219082015	ARPC2	-0.78	-13.95	-0.61	3.62e-35	Colorectal cancer;
LUSC	cis	rs2274273	0.840	rs6573020	chr14:55871452	C/T	cg04306507	chr14:55594613	LGALS3	0.56	12.74	0.57	1.44e-30	Protein biomarker;
LUSC	cis	rs174479	0.677	rs1000778	chr11:61655305	A/G	cg01500311	chr11:61656094	FADS3	0.39	6.7	0.34	8.66e-11	Sphingolipid levels;
LUSC	cis	rs12410462	0.581	rs73102371	chr1:227554880	G/A	cg23173402	chr1:227635558	NA	0.52	6.08	0.32	3.26e-9	Major depressive disorder;
LUSC	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg07828340	chr4:882639	GAK	0.98	10.03	0.48	7.38e-21	Parkinson's disease;
LUSC	cis	rs10208940	0.920	rs10164780	chr2:68766250	A/T	cg12452813	chr2:68675892	NA	0.58	5.96	0.31	6.45e-9	Urate levels in lean individuals;
LUSC	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.69	-0.43	1.66e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg11645453	chr3:52864694	ITIH4	0.28	6.58	0.34	1.82e-10	Electroencephalogram traits;
LUSC	cis	rs11997175	0.574	rs4733456	chr8:33656359	C/T	ch.8.33884649F	chr8:33765107	NA	0.53	8.65	0.43	2.18e-16	Body mass index;
LUSC	cis	rs2677744	0.688	rs3784779	chr15:91453131	C/T	cg23684204	chr15:91497937	RCCD1	0.46	6.53	0.34	2.45e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.24	0.45	3.04e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.74	-0.35	7.07e-11	QT interval;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22366698	chr11:3400543	ZNF195	0.52	7.83	0.39	6.33e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs17039065	1.000	rs12502981	chr4:109392960	G/A	cg07444054	chr2:108107501	NA	0.43	6.3	0.33	9.24e-10	Gut microbiome composition (summer);
LUSC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg21535247	chr6:8435926	SLC35B3	0.6	9.37	0.46	1.13e-18	Motion sickness;
LUSC	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg13902645	chr11:5959945	NA	-0.59	-8.28	-0.41	3.1e-15	DNA methylation (variation);
LUSC	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.09	24.72	0.8	2.06e-77	Colorectal cancer;
LUSC	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg21775007	chr8:11205619	TDH	-0.46	-6.91	-0.35	2.4e-11	Neuroticism;
LUSC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg11247378	chr22:39784982	NA	-0.63	-12.21	-0.56	1.34e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	0.89	17.81	0.7	2.27e-50	Metabolite levels;
LUSC	cis	rs1609391	0.561	rs6439675	chr3:136625436	G/A	cg15507776	chr3:136538369	TMEM22	0.51	8.39	0.42	1.37e-15	Neuroticism;
LUSC	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg23283495	chr1:209979779	IRF6	-0.65	-7.98	-0.4	2.4e-14	Coronary artery disease;
LUSC	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg16576597	chr16:28551801	NUPR1	0.29	5.9	0.31	8.68e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg13010199	chr12:38710504	ALG10B	0.39	5.76	0.3	1.93e-8	Morning vs. evening chronotype;
LUSC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.35	5.66	0.3	3.2e-8	Menopause (age at onset);
LUSC	cis	rs6977660	0.652	rs4721826	chr7:19823804	T/C	cg05791153	chr7:19748676	TWISTNB	0.67	6.98	0.36	1.55e-11	Thyroid stimulating hormone;
LUSC	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg02696742	chr7:106810147	HBP1	-0.64	-9.58	-0.46	2.35e-19	Coronary artery disease;
LUSC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.73	11.86	0.54	2.56e-27	Cognitive function;
LUSC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	7.93	0.4	3.38e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg20887711	chr4:1340912	KIAA1530	0.44	6.57	0.34	1.97e-10	Obesity-related traits;
LUSC	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	7.22	0.37	3.48e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs654950	0.807	rs61773660	chr1:41993298	C/T	cg06885757	chr1:42089581	HIVEP3	-0.4	-7.76	-0.39	1.05e-13	Airway imaging phenotypes;
LUSC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	12.98	0.58	1.82e-31	Personality dimensions;
LUSC	cis	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg20368463	chr18:77673604	PQLC1	-0.55	-7.78	-0.39	9.16e-14	Schizophrenia;
LUSC	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg01420254	chr6:26195488	NA	0.7	7.46	0.38	7.56e-13	Gout;Renal underexcretion gout;
LUSC	trans	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17712092	chr4:129076599	LARP1B	0.74	11.32	0.53	2.39e-25	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.35	0.37	1.57e-12	Bipolar disorder;
LUSC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg20283391	chr11:68216788	NA	-0.52	-7.74	-0.39	1.18e-13	Total body bone mineral density;
LUSC	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg03453431	chr7:157225567	NA	0.51	8.77	0.43	9.45e-17	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg17143192	chr8:8559678	CLDN23	0.63	9.0	0.44	1.72e-17	Obesity-related traits;
LUSC	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.14	-0.36	5.8e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.84	-0.44	5.55e-17	Monocyte percentage of white cells;
LUSC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	1.08	9.33	0.45	1.49e-18	Skin colour saturation;
LUSC	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.1	0.41	1.02e-14	Lung cancer in ever smokers;
LUSC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.05	-0.31	3.99e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	1.22	20.96	0.75	7.24e-63	Blood pressure (smoking interaction);
LUSC	cis	rs12618769	0.597	rs3769723	chr2:99105988	A/G	cg10123293	chr2:99228465	UNC50	0.45	7.48	0.38	6.81e-13	Bipolar disorder;
LUSC	trans	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg18187862	chr3:45730750	SACM1L	0.55	7.09	0.36	8.01e-12	Primary sclerosing cholangitis;
LUSC	cis	rs4953318	0.577	rs67087783	chr2:46363544	C/T	cg12428440	chr2:46370979	PRKCE	0.46	7.61	0.38	2.86e-13	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg16325326	chr1:53192061	ZYG11B	0.97	18.75	0.72	4.37e-54	Monocyte count;
LUSC	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg08601574	chr20:25228251	PYGB	0.55	8.76	0.43	9.9900000000000006e-17	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7043114	0.507	rs10992291	chr9:95033009	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.32	-0.33	8.32e-10	Height;
LUSC	cis	rs1595825	0.627	rs78002594	chr2:198467113	A/T	cg00982548	chr2:198649783	BOLL	-0.51	-5.96	-0.31	6.33e-9	Ulcerative colitis;
LUSC	cis	rs2625529	0.824	rs16953769	chr15:72463325	G/A	cg16672083	chr15:72433130	SENP8	-0.52	-7.49	-0.38	6.36e-13	Red blood cell count;
LUSC	cis	rs3820928	0.900	rs6754155	chr2:227784961	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.01	-0.4	1.99e-14	Pulmonary function;
LUSC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.8	-0.35	4.84e-11	Total body bone mineral density;
LUSC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.72	-0.3	2.37e-8	Tonsillectomy;
LUSC	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-5.7	-0.3	2.62e-8	Arsenic metabolism;
LUSC	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg13852791	chr20:30311386	BCL2L1	0.97	15.03	0.64	2.25e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg24375607	chr4:120327624	NA	0.74	11.02	0.52	2.59e-24	Corneal astigmatism;
LUSC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.66	14.48	0.62	3.29e-37	Hemoglobin concentration;
LUSC	cis	rs3767633	0.528	rs6671373	chr1:161890796	C/G	cg27519958	chr1:161735129	ATF6	-0.43	-7.09	-0.36	8.08e-12	IgG glycosylation;
LUSC	cis	rs4786125	0.769	rs4129042	chr16:6901398	G/T	cg03623568	chr16:6915990	A2BP1	0.4	6.24	0.32	1.3e-9	Heart rate variability traits (SDNN);
LUSC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	9.77	0.47	5.33e-20	Eosinophil percentage of white cells;
LUSC	cis	rs75229567	0.618	rs11177849	chr12:70182473	C/T	cg10114359	chr12:70132523	RAB3IP	-1.31	-12.14	-0.55	2.48e-28	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs7771547	0.519	rs2057351	chr6:36361682	G/A	cg07856975	chr6:36356162	ETV7	0.44	6.66	0.34	1.13e-10	Platelet distribution width;
LUSC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg06784218	chr1:46089804	CCDC17	0.53	10.32	0.49	7.66e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.6	8.84	0.44	5.69e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.6	9.27	0.45	2.29e-18	Morning vs. evening chronotype;
LUSC	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg15704280	chr7:45808275	SEPT13	0.66	7.28	0.37	2.46e-12	Axial length;
LUSC	trans	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg07393940	chr7:158741817	NA	-0.37	-6.54	-0.34	2.29e-10	Life satisfaction;
LUSC	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg00101154	chr16:420108	MRPL28	-0.4	-6.37	-0.33	6.43e-10	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22618164	chr12:122356400	WDR66	0.57	8.61	0.43	2.93e-16	Mean corpuscular volume;
LUSC	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg08508325	chr11:3079039	CARS	0.38	8.66	0.43	2.05e-16	Calcium levels;
LUSC	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg13010344	chr12:123464640	ARL6IP4	0.49	7.94	0.4	3.05e-14	Platelet count;
LUSC	cis	rs28785552	0.931	rs10406850	chr19:53240807	A/C	cg10871876	chr19:53194124	ZNF83	0.57	8.81	0.43	7.07e-17	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg04362960	chr10:104952993	NT5C2	0.62	9.62	0.47	1.71e-19	Arsenic metabolism;
LUSC	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	11.94	0.55	1.27e-27	Menopause (age at onset);
LUSC	cis	rs6961069	0.585	rs1722506	chr7:80238852	A/G	cg04458919	chr7:80252533	CD36	-0.4	-7.32	-0.37	1.91e-12	Platelet count;
LUSC	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg27411982	chr8:10470053	RP1L1	0.38	5.96	0.31	6.51e-9	Retinal vascular caliber;
LUSC	cis	rs7804356	1.000	rs3823938	chr7:26853741	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.16	-0.32	2.1e-9	Type 1 diabetes;
LUSC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.87	-16.71	-0.67	5.33e-46	Colorectal cancer;
LUSC	cis	rs13315871	1.000	rs11713214	chr3:58445991	C/T	cg12435725	chr3:58293450	RPP14	-0.7	-6.93	-0.35	2.21e-11	Cholesterol, total;
LUSC	cis	rs1808579	0.904	rs891387	chr18:21103909	A/G	cg14672496	chr18:21087552	C18orf8	0.4	6.62	0.34	1.42e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs12780046	0.505	rs2862553	chr10:101048492	C/T	cg27143070	chr10:101087766	CNNM1	0.37	5.67	0.3	3.13e-8	Non-glioblastoma glioma;
LUSC	cis	rs11264799	0.539	rs849825	chr1:157546762	C/T	cg18268488	chr1:157545234	FCRL4	0.39	7.67	0.39	1.92e-13	IgA nephropathy;
LUSC	cis	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg21775007	chr8:11205619	TDH	0.47	6.72	0.34	8.08e-11	Myopia (pathological);
LUSC	cis	rs16854884	0.657	rs35959290	chr3:143725566	T/A	cg06585982	chr3:143692056	C3orf58	0.45	6.97	0.36	1.67e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs7192380	0.965	rs4633710	chr16:69632961	A/G	cg26679644	chr16:69762563	NA	0.35	6.2	0.32	1.7e-9	Sjögren's syndrome;
LUSC	cis	rs72772090	0.634	rs72773912	chr5:96107801	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-8.58	-0.42	3.65e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs983392	0.680	rs7929589	chr11:59975078	C/T	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.24	-0.32	1.3e-9	Alzheimer's disease (late onset);
LUSC	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.82	-0.3	1.34e-8	Resting heart rate;
LUSC	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-0.96	-10.41	-0.49	3.72e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9311676	0.609	rs11921259	chr3:58368646	A/G	cg13750441	chr3:58318267	PXK	0.36	6.91	0.35	2.51e-11	Systemic lupus erythematosus;
LUSC	cis	rs9815354	0.812	rs73073371	chr3:41843443	A/G	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.6	0.54	2.25e-26	Cognitive ability;
LUSC	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg13813247	chr22:41461852	NA	-0.38	-6.73	-0.35	7.55e-11	Neuroticism;
LUSC	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.51	8.21	0.41	4.74e-15	Immature fraction of reticulocytes;
LUSC	cis	rs9837602	1.000	rs62285461	chr3:99767642	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	5.64	0.3	3.56e-8	Breast cancer;
LUSC	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	9.26	0.45	2.54e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg26441486	chr22:50317300	CRELD2	0.5	7.66	0.39	2.08e-13	Schizophrenia;
LUSC	cis	rs886126	0.950	rs2097658	chr12:111690466	C/T	cg10833066	chr12:111807467	FAM109A	0.4	6.09	0.32	3.06e-9	Coronary heart disease;
LUSC	cis	rs9403521	0.898	rs10872562	chr6:143974930	A/G	cg18240653	chr6:144019428	PHACTR2	-0.48	-5.78	-0.3	1.72e-8	Obesity-related traits;
LUSC	cis	rs12286929	0.644	rs7942036	chr11:115078356	G/C	cg04055981	chr11:115044050	NA	0.45	8.03	0.4	1.7e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.81	-12.54	-0.57	8.07e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs7726839	0.540	rs7558	chr5:660491	C/T	cg11887960	chr12:57824829	NA	0.51	6.43	0.33	4.46e-10	Obesity-related traits;
LUSC	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.21	0.32	1.59e-9	Schizophrenia;
LUSC	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg18477163	chr1:228402036	OBSCN	0.63	12.02	0.55	6.94e-28	Diastolic blood pressure;
LUSC	cis	rs4664304	0.802	rs3792175	chr2:160862804	T/A	cg03641300	chr2:160917029	PLA2R1	-0.37	-5.97	-0.31	5.92e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg01475377	chr6:109611718	NA	-0.4	-7.08	-0.36	8.58e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg01528321	chr10:82214614	TSPAN14	0.6	9.02	0.44	1.51e-17	Post bronchodilator FEV1;
LUSC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg05844789	chr1:228464394	OBSCN	-0.3	-5.71	-0.3	2.54e-8	Diastolic blood pressure;
LUSC	trans	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg26384229	chr12:38710491	ALG10B	0.55	8.73	0.43	1.24e-16	Morning vs. evening chronotype;
LUSC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg14789911	chr21:47582049	C21orf56	-0.39	-6.13	-0.32	2.45e-9	Testicular germ cell tumor;
LUSC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg15691649	chr6:25882328	NA	0.47	7.06	0.36	9.59e-12	Blood metabolite levels;
LUSC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3741798	1.000	rs61922052	chr12:12497620	A/G	cg08615371	chr12:12503544	MANSC1	1.08	11.07	0.52	1.79e-24	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2274273	0.686	rs66531545	chr14:55587460	T/C	cg04306507	chr14:55594613	LGALS3	0.48	9.54	0.46	3.03e-19	Protein biomarker;
LUSC	cis	rs17092148	1.000	rs2425003	chr20:33403584	G/T	cg16810054	chr20:33298113	TP53INP2	0.42	6.48	0.33	3.21e-10	Neuroticism;
LUSC	cis	rs6542838	0.641	rs4499468	chr2:99475204	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.49	-0.33	3.19e-10	Fear of minor pain;
LUSC	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg09904177	chr6:26538194	HMGN4	-0.76	-6.89	-0.35	2.83e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.55	0.53	3.44e-26	Hip circumference adjusted for BMI;
LUSC	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg19717773	chr7:2847554	GNA12	-0.41	-7.32	-0.37	1.89e-12	Height;
LUSC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-7.87	-0.4	5.08e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.38	-5.8	-0.3	1.5e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10823500	0.777	rs10509321	chr10:71985733	A/G	cg02100629	chr10:71892760	AIFM2	0.37	6.14	0.32	2.39e-9	Blood protein levels;
LUSC	cis	rs13266463	0.858	rs13255588	chr8:143384727	C/G	cg16886403	chr8:143471632	TSNARE1	0.64	8.98	0.44	1.98e-17	Schizophrenia;
LUSC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg12463550	chr7:65579703	CRCP	0.49	7.11	0.36	6.92e-12	Aortic root size;
LUSC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.17	-0.41	6.24e-15	Chronic sinus infection;
LUSC	cis	rs240764	0.621	rs10457844	chr6:101196532	T/A	cg09795085	chr6:101329169	ASCC3	-0.44	-6.46	-0.33	3.65e-10	Neuroticism;
LUSC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.19	-0.32	1.79e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	17.96	0.7	6.16e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs2048656	0.605	rs7814507	chr8:9646560	G/A	cg06636001	chr8:8085503	FLJ10661	0.45	6.3	0.33	9.56e-10	Schizophrenia;
LUSC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-0.73	-10.68	-0.5	4.23e-23	Gut microbiome composition (summer);
LUSC	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg20908204	chr19:46285434	DMPK	-0.46	-8.75	-0.43	1.09e-16	Coronary artery disease;
LUSC	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	7.16	0.36	5.32e-12	Personality dimensions;
LUSC	cis	rs7705502	1.000	rs17695555	chr5:173351081	C/T	cg18693985	chr5:173351052	CPEB4	-0.38	-5.97	-0.31	6.06e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg11244672	chr19:19639970	YJEFN3	-0.55	-6.7	-0.34	9.01e-11	Bipolar disorder;
LUSC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg01416388	chr22:39784598	NA	-0.43	-7.17	-0.37	4.92e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg00990874	chr7:1149470	C7orf50	-0.5	-6.34	-0.33	7.54e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs9467773	0.526	rs9348710	chr6:26360486	A/C	cg09904177	chr6:26538194	HMGN4	-0.52	-8.16	-0.41	6.82e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg00484396	chr16:3507460	NAT15	-0.45	-6.67	-0.34	1.06e-10	Body mass index (adult);
LUSC	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg05868516	chr6:26286170	HIST1H4H	0.36	5.99	0.31	5.35e-9	Educational attainment;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.73	-15.32	-0.64	1.65e-40	Longevity;Endometriosis;
LUSC	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-0.93	-17.6	-0.69	1.57e-49	Headache;
LUSC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.11	-0.48	3.74e-21	Monocyte count;
LUSC	cis	rs6076065	0.723	rs6132604	chr20:23342226	G/A	cg11657817	chr20:23433608	CST11	0.44	8.18	0.41	6.2e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7759001	0.857	rs9468079	chr6:27346905	A/G	cg18711553	chr6:27366782	ZNF391	0.41	5.95	0.31	6.67e-9	Glomerular filtration rate (creatinine);
LUSC	trans	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg22328901	chr2:86333256	PTCD3;POLR1A	0.41	6.05	0.31	3.88e-9	Metabolic syndrome;
LUSC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6541297	0.699	rs1555290	chr1:230294989	A/C	cg05784532	chr1:230284198	GALNT2	-0.56	-6.53	-0.34	2.5e-10	Coronary artery disease;
LUSC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.95	-0.44	2.56e-17	Platelet count;
LUSC	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg14825688	chr5:132208181	LEAP2	-0.43	-6.41	-0.33	4.95e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.25	-0.32	1.22e-9	Sudden cardiac arrest;
LUSC	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg08085267	chr17:45401833	C17orf57	-0.41	-6.2	-0.32	1.62e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg18681998	chr4:17616180	MED28	0.85	16.06	0.66	2e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.43	0.33	4.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg10411590	chr13:21900810	NA	0.3	5.76	0.3	1.91e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-6.91	-0.35	2.41e-11	Lung cancer;
LUSC	trans	rs4714291	0.963	rs1721412	chr6:40100606	T/G	cg02267698	chr19:7991119	CTXN1	0.5	7.01	0.36	1.31e-11	Strep throat;
LUSC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16744531	chr19:17905626	B3GNT3	0.44	6.54	0.34	2.35e-10	Tumor biomarkers;
LUSC	cis	rs6545883	0.525	rs1621048	chr2:61364216	C/G	cg15711740	chr2:61764176	XPO1	0.37	5.8	0.3	1.5e-8	Tuberculosis;
LUSC	cis	rs2274273	0.623	rs1187881	chr14:55489197	G/A	cg04306507	chr14:55594613	LGALS3	-0.5	-10.62	-0.5	6.77e-23	Protein biomarker;
LUSC	cis	rs4654899	0.865	rs6671056	chr1:21488610	G/A	cg02927042	chr1:21476669	EIF4G3	-0.36	-5.69	-0.3	2.82e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs926938	0.527	rs360670	chr1:115482386	G/A	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.41	-0.33	5.03e-10	Autism;
LUSC	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg04362960	chr10:104952993	NT5C2	0.59	9.34	0.46	1.36e-18	Arsenic metabolism;
LUSC	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg07936489	chr17:37558343	FBXL20	-0.67	-8.89	-0.44	3.8e-17	Glomerular filtration rate (creatinine);
LUSC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.82	-15.72	-0.65	4.35e-42	Colorectal cancer;
LUSC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00149659	chr3:10157352	C3orf10	0.91	12.92	0.58	3.1e-31	Alzheimer's disease;
LUSC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	cis	rs711245	0.702	rs1110127	chr2:36768456	G/C	cg01206211	chr2:36825736	FEZ2	0.48	9.47	0.46	5.3e-19	Height;
LUSC	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg08048268	chr3:133502702	NA	0.35	6.26	0.32	1.19e-9	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14442939	chr10:27389572	ANKRD26	0.92	10.89	0.51	7.59e-24	Breast cancer;
LUSC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg17279839	chr7:150038598	RARRES2	0.4	6.27	0.32	1.14e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg13385521	chr17:29058706	SUZ12P	0.7	7.08	0.36	8.63e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg05738196	chr6:26577821	NA	-0.6	-7.21	-0.37	3.78e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg17173187	chr15:85201210	NMB	0.35	6.3	0.33	9.27e-10	Schizophrenia;
LUSC	cis	rs11997175	0.568	rs4733169	chr8:33581855	T/C	ch.8.33884649F	chr8:33765107	NA	0.39	6.06	0.31	3.59e-9	Body mass index;
LUSC	trans	rs7939886	0.920	rs12223014	chr11:55878290	G/A	cg03929089	chr4:120376271	NA	0.72	6.03	0.31	4.43e-9	Myopia (pathological);
LUSC	cis	rs10484885	0.571	rs76955220	chr6:90252030	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.57	-5.84	-0.3	1.23e-8	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg10596483	chr8:143751796	JRK	0.6	9.28	0.45	2.21e-18	Schizophrenia;
LUSC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg02428538	chr16:24856791	SLC5A11	-0.56	-6.19	-0.32	1.79e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg09307838	chr4:120376055	NA	0.75	10.87	0.51	9.01e-24	Corneal astigmatism;
LUSC	cis	rs9467773	0.587	rs3208733	chr6:26414425	C/T	cg09904177	chr6:26538194	HMGN4	-0.55	-8.41	-0.42	1.2e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	12.1	0.55	3.37e-28	Colorectal cancer;
LUSC	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.51e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.23	-0.32	1.41e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	13.27	0.59	1.39e-32	Post bronchodilator FEV1;
LUSC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg09035930	chr12:129282057	SLC15A4	0.66	13.35	0.59	7.04e-33	Systemic lupus erythematosus;
LUSC	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg27471124	chr11:109292789	C11orf87	-0.43	-7.74	-0.39	1.17e-13	Schizophrenia;
LUSC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.72	13.04	0.58	1.11e-31	Prudent dietary pattern;
LUSC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg17279839	chr7:150038598	RARRES2	0.45	6.92	0.35	2.28e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.73	0.35	7.58e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.08	-0.36	8.53e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs911119	0.955	rs8116859	chr20:23590703	A/T	cg16589663	chr20:23618590	CST3	0.57	6.79	0.35	5.12e-11	Chronic kidney disease;
LUSC	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg26566898	chr11:117069891	TAGLN	0.38	7.22	0.37	3.44e-12	Blood protein levels;
LUSC	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg12365402	chr11:9010492	NRIP3	-0.37	-5.95	-0.31	6.74e-9	Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24278218	chr17:62207299	ERN1	-0.5	-6.06	-0.31	3.71e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs1015291	0.708	rs2731614	chr12:19999688	T/C	cg01501474	chr7:55323552	NA	-0.46	-6.18	-0.32	1.85e-9	Diastolic blood pressure;
LUSC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg22868518	chr11:507468	RNH1	-0.59	-5.8	-0.3	1.56e-8	Body mass index;
LUSC	cis	rs9323205	0.953	rs11623710	chr14:51694261	C/T	cg23942311	chr14:51606299	NA	-0.47	-9.75	-0.47	6.34e-20	Cancer;
LUSC	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	19.81	0.73	2.69e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg15133208	chr4:90757351	SNCA	-0.54	-8.34	-0.42	1.92e-15	Neuroticism;
LUSC	trans	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg07211511	chr3:129823064	LOC729375	-0.8	-10.65	-0.5	5.31e-23	Blood pressure (smoking interaction);
LUSC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.92	0.31	7.86e-9	Menopause (age at onset);
LUSC	cis	rs7119	0.745	rs12911649	chr15:77807127	C/T	cg27398640	chr15:77910606	LINGO1	-0.29	-6.12	-0.32	2.58e-9	Type 2 diabetes;
LUSC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg00310523	chr12:86230176	RASSF9	0.52	9.81	0.47	3.84e-20	Major depressive disorder;
LUSC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg06046430	chr4:77819534	ANKRD56	0.45	6.29	0.33	1e-9	Emphysema distribution in smoking;
LUSC	cis	rs11568819	1.000	rs11568819	chr11:102401633	C/T	cg01813071	chr11:102401616	MMP7	1.07	9.44	0.46	6.39e-19	Blood protein levels;
LUSC	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg03342759	chr3:160939853	NMD3	0.42	5.94	0.31	7.16e-9	Parkinson's disease;
LUSC	cis	rs17253792	0.822	rs17685102	chr14:56129214	A/G	cg01858014	chr14:56050164	KTN1	-0.79	-6.68	-0.34	9.73e-11	Putamen volume;
LUSC	cis	rs2580764	0.565	rs6760429	chr2:55228499	C/T	cg20993754	chr2:55226987	RTN4	0.35	5.86	0.31	1.12e-8	Mean platelet volume;
LUSC	trans	rs9929218	0.954	rs7199991	chr16:68818245	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-11.19	-0.52	6.92e-25	Colorectal cancer;
LUSC	cis	rs9311676	0.656	rs55668308	chr3:58388453	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.49	0.33	3.05e-10	Systemic lupus erythematosus;
LUSC	cis	rs7539542	0.556	rs2275734	chr1:202887295	C/T	cg19681188	chr1:202830198	LOC148709	0.43	6.31	0.33	8.73e-10	Mean platelet volume;
LUSC	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg20734569	chr3:48348370	SPINK8	-0.47	-8.05	-0.4	1.42e-14	Coronary artery disease;
LUSC	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg23711669	chr6:146136114	FBXO30	0.89	16.36	0.67	1.39e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg16339924	chr4:17578868	LAP3	0.49	7.53	0.38	4.83e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-0.83	-15.33	-0.64	1.49e-40	Longevity;
LUSC	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg23422044	chr7:1970798	MAD1L1	-0.65	-7.36	-0.37	1.46e-12	Bipolar disorder;
LUSC	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg25173405	chr17:45401733	C17orf57	-0.39	-6.13	-0.32	2.46e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg03733263	chr8:22462867	KIAA1967	0.84	14.19	0.61	4.2500000000000003e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg26408565	chr15:76604113	ETFA	-0.49	-7.92	-0.4	3.55e-14	Blood metabolite levels;
LUSC	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg09365446	chr1:150670422	GOLPH3L	-0.42	-6.12	-0.32	2.6e-9	Tonsillectomy;
LUSC	cis	rs1865721	1.000	rs7236756	chr18:73175689	T/C	cg26385618	chr18:73139727	C18orf62	-0.49	-8.38	-0.42	1.5e-15	Intelligence;
LUSC	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg04310649	chr10:35416472	CREM	-0.39	-6.05	-0.31	3.84e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg06521331	chr12:34319734	NA	-0.41	-6.48	-0.33	3.3e-10	Morning vs. evening chronotype;
LUSC	cis	rs679087	0.606	rs302347	chr12:29944246	G/A	cg14258853	chr12:29935411	TMTC1	-0.68	-8.18	-0.41	5.89e-15	Schizophrenia;
LUSC	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg12292205	chr6:26970375	C6orf41	-0.63	-7.6	-0.38	3.04e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6700896	0.864	rs7515766	chr1:66167452	G/A	cg04111102	chr1:66153794	NA	-0.32	-6.95	-0.36	1.98e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg06484146	chr7:12443880	VWDE	-0.63	-7.41	-0.38	1.07e-12	Coronary artery disease;
LUSC	cis	rs500891	0.525	rs1170347	chr6:84021294	G/A	cg08257003	chr6:84140564	ME1	0.33	7.11	0.36	6.96e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg20283391	chr11:68216788	NA	-0.61	-8.51	-0.42	5.97e-16	Total body bone mineral density;
LUSC	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg13531842	chr10:38383804	ZNF37A	-0.46	-7.23	-0.37	3.4e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.8	-0.39	8.02e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-6.66	-0.34	1.1e-10	Major depressive disorder;
LUSC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg24209194	chr3:40518798	ZNF619	-0.47	-6.23	-0.32	1.37e-9	Renal cell carcinoma;
LUSC	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg01884057	chr2:25150051	NA	0.47	11.28	0.53	3.15e-25	Body mass index in non-asthmatics;
LUSC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg05294307	chr14:35346193	BAZ1A	-0.52	-6.93	-0.35	2.16e-11	Psoriasis;
LUSC	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg08807101	chr21:30365312	RNF160	-0.51	-6.52	-0.34	2.63e-10	Cognitive test performance;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12046629	chr8:59466299	SDCBP	0.44	6.33	0.33	7.95e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg11861562	chr11:117069780	TAGLN	0.36	7.15	0.36	5.49e-12	Blood protein levels;
LUSC	cis	rs7827545	1.000	rs7823948	chr8:135566580	G/A	cg17885191	chr8:135476712	NA	0.57	8.5	0.42	6.26e-16	Hypertension (SNP x SNP interaction);
LUSC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg03790207	chr6:42947109	PEX6	-0.47	-6.95	-0.36	1.91e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg21770322	chr7:97807741	LMTK2	-0.44	-7.35	-0.37	1.55e-12	Breast cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02662155	chr11:46639265	KIAA0652;HARBI1	0.43	6.51	0.34	2.78e-10	Triglycerides;
LUSC	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg12923728	chr3:195709715	SDHAP1	-0.78	-11.86	-0.54	2.49e-27	Pancreatic cancer;
LUSC	cis	rs4622329	0.615	rs7136688	chr12:102294494	T/A	cg23541617	chr12:102225335	GNPTAB	0.25	5.97	0.31	6.17e-9	Systemic lupus erythematosus;
LUSC	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg09904177	chr6:26538194	HMGN4	0.68	12.18	0.55	1.72e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs61869271	0.805	rs7086663	chr10:116766336	A/T	cg23260525	chr10:116636907	FAM160B1	0.3	6.13	0.32	2.52e-9	Tonsillectomy;
LUSC	trans	rs8073060	0.855	rs12150450	chr17:33868896	A/T	cg19694781	chr19:47549865	TMEM160	0.7	10.43	0.5	3.08e-22	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg26384229	chr12:38710491	ALG10B	0.66	10.8	0.51	1.67e-23	Morning vs. evening chronotype;
LUSC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	0.91	16.4	0.67	9.5e-45	Cognitive function;
LUSC	cis	rs7192380	0.964	rs8055756	chr16:69648653	A/G	cg26679644	chr16:69762563	NA	-0.35	-6.25	-0.32	1.26e-9	Sjögren's syndrome;
LUSC	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg25206134	chr2:45395956	NA	0.62	7.22	0.37	3.47e-12	Bipolar disorder;
LUSC	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg02423579	chr7:2872169	GNA12	-0.39	-5.83	-0.3	1.3e-8	Height;
LUSC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00166722	chr3:10149974	C3orf24	0.56	7.57	0.38	3.75e-13	Alzheimer's disease;
LUSC	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg05768032	chr16:30646687	NA	0.39	5.86	0.31	1.1e-8	Multiple myeloma;
LUSC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg25204440	chr1:209979598	IRF6	-0.5	-5.76	-0.3	1.95e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg05025164	chr4:1340916	KIAA1530	0.42	6.43	0.33	4.38e-10	Obesity-related traits;
LUSC	cis	rs7119	0.717	rs8040702	chr15:77803615	G/A	cg27398640	chr15:77910606	LINGO1	-0.28	-6.02	-0.31	4.56e-9	Type 2 diabetes;
LUSC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg22681709	chr2:178499509	PDE11A	-0.56	-10.66	-0.5	4.9e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg00310523	chr12:86230176	RASSF9	0.45	8.0	0.4	2.1e-14	Major depressive disorder;
LUSC	cis	rs6487679	1.000	rs1017302	chr12:9367402	A/G	cg00504896	chr12:9437009	LOC642846	-0.44	-5.77	-0.3	1.85e-8	Non-alcoholic fatty liver disease histology (AST);
LUSC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg07741184	chr6:167504864	NA	-0.35	-6.39	-0.33	5.46e-10	Crohn's disease;
LUSC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg13206674	chr6:150067644	NUP43	0.59	9.24	0.45	2.87e-18	Lung cancer;
LUSC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.61e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.71	-13.26	-0.59	1.53e-32	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg18005901	chr6:33739558	LEMD2	-0.39	-5.74	-0.3	2.07e-8	Schizophrenia;
LUSC	trans	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg25214090	chr10:38739885	LOC399744	-0.37	-6.06	-0.31	3.74e-9	Diastolic blood pressure;
LUSC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg09436375	chr6:42928200	GNMT	-0.3	-6.82	-0.35	4.31e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg23262073	chr20:60523788	NA	-0.4	-5.93	-0.31	7.71e-9	Body mass index;
LUSC	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg00129232	chr17:37814104	STARD3	-0.44	-6.32	-0.33	8.34e-10	Asthma;
LUSC	cis	rs7119	0.689	rs12916833	chr15:77819778	G/A	cg27398640	chr15:77910606	LINGO1	-0.31	-6.59	-0.34	1.73e-10	Type 2 diabetes;
LUSC	cis	rs62432291	0.764	rs433256	chr6:159660105	C/T	cg14500486	chr6:159655392	FNDC1	-0.54	-6.06	-0.31	3.76e-9	Joint mobility (Beighton score);
LUSC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07677032	chr17:61819896	STRADA	0.53	8.93	0.44	2.87e-17	Prudent dietary pattern;
LUSC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9937943	0.667	rs12934000	chr16:74623420	T/G	cg01733217	chr16:74700730	RFWD3	0.61	6.47	0.33	3.59e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg08742575	chr21:47604166	C21orf56	0.48	7.38	0.37	1.3e-12	Testicular germ cell tumor;
LUSC	cis	rs7640424	0.819	rs34154497	chr3:107824222	T/C	cg09227934	chr3:107805635	CD47	-0.44	-6.94	-0.36	2.01e-11	Body mass index;
LUSC	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.85	0.44	5.15e-17	Coffee consumption (cups per day);
LUSC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.44	-6.37	-0.33	6.31e-10	Schizophrenia;
LUSC	trans	rs11039798	0.764	rs11039771	chr11:48513273	C/T	cg03929089	chr4:120376271	NA	0.65	6.07	0.32	3.39e-9	Axial length;
LUSC	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg11693508	chr17:37793320	STARD3	0.65	7.95	0.4	2.93e-14	Bipolar disorder;
LUSC	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg09904177	chr6:26538194	HMGN4	-0.71	-6.38	-0.33	5.84e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.63	-0.39	2.46e-13	Blood metabolite levels;
LUSC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg03060546	chr3:49711283	APEH	0.72	12.18	0.55	1.79e-28	Resting heart rate;
LUSC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.24	-0.37	3.09e-12	Bipolar disorder;
LUSC	trans	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.39	0.49	4.17e-22	Mean corpuscular volume;
LUSC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.01	-0.4	1.87e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg06600287	chr1:53387719	ECHDC2	-0.3	-6.26	-0.32	1.19e-9	Monocyte count;
LUSC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg25204440	chr1:209979598	IRF6	0.5	5.72	0.3	2.4e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg02782426	chr3:40428986	ENTPD3	0.33	6.28	0.32	1.05e-9	Renal cell carcinoma;
LUSC	cis	rs722599	0.748	rs2300599	chr14:75359441	A/G	cg08847533	chr14:75593920	NEK9	-0.47	-6.74	-0.35	7.04e-11	IgG glycosylation;
LUSC	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg18512352	chr11:47633146	NA	-0.43	-9.06	-0.44	1.12e-17	Subjective well-being;
LUSC	cis	rs7246657	0.653	rs10425441	chr19:37670648	T/C	cg23950597	chr19:37808831	NA	-0.58	-5.88	-0.31	1.01e-8	Coronary artery calcification;
LUSC	cis	rs5758511	0.773	rs62240999	chr22:42355563	C/G	cg12850546	chr22:42539477	CYP2D7P1	-0.49	-6.05	-0.31	3.84e-9	Birth weight;
LUSC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12311346	chr5:56204834	C5orf35	0.84	13.52	0.59	1.56e-33	Initial pursuit acceleration;
LUSC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg01017244	chr2:74357527	NA	0.72	13.61	0.6	7.46e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg13319975	chr6:146136371	FBXO30	0.52	7.82	0.39	7.03e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7178572	0.539	rs16968809	chr15:77672118	C/T	cg22256960	chr15:77711686	NA	0.52	7.54	0.38	4.49e-13	Type 2 diabetes;
LUSC	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg13160058	chr8:26243215	BNIP3L	-0.41	-7.43	-0.38	9.2e-13	Red cell distribution width;
LUSC	cis	rs76419734	0.510	rs2216515	chr4:106750214	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.52	-5.94	-0.31	7.22e-9	Post bronchodilator FEV1;
LUSC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg16362232	chr11:430036	ANO9	0.6	7.87	0.4	4.86e-14	Body mass index;
LUSC	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg23649088	chr2:200775458	C2orf69	-0.56	-6.45	-0.33	3.82e-10	Schizophrenia;
LUSC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03576123	chr11:487126	PTDSS2	-1.05	-11.18	-0.52	7.13e-25	Body mass index;
LUSC	cis	rs2019216	0.500	rs7502283	chr17:21878561	G/C	cg22648282	chr17:21454238	C17orf51	-0.54	-7.82	-0.39	6.97e-14	Pelvic organ prolapse;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14787155	chr3:108308533	DZIP3;KIAA1524	-0.36	-6.11	-0.32	2.72e-9	Electrocardiographic conduction measures;
LUSC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg16325326	chr1:53192061	ZYG11B	0.83	14.59	0.62	1.17e-37	Monocyte count;
LUSC	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg23262351	chr6:79576851	IRAK1BP1	-0.39	-5.94	-0.31	7.16e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.902	rs4888430	chr16:75494424	T/C	cg03315344	chr16:75512273	CHST6	0.58	11.34	0.53	1.95e-25	Dupuytren's disease;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10667969	chr3:149181941	NA	-0.4	-6.39	-0.33	5.54e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.84	-0.35	3.73e-11	Response to antipsychotic treatment;
LUSC	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg15083037	chr5:83017644	HAPLN1	-0.59	-7.78	-0.39	9.16e-14	Prostate cancer;
LUSC	cis	rs10761482	1.000	rs10761482	chr10:62085337	C/T	cg18175470	chr10:62150864	ANK3	0.44	6.23	0.32	1.39e-9	Schizophrenia;
LUSC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg21573476	chr21:45109991	RRP1B	-0.4	-6.37	-0.33	6.25e-10	Mean corpuscular volume;
LUSC	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg23752985	chr2:85803571	VAMP8	-0.35	-7.63	-0.39	2.56e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg25418670	chr11:30344373	C11orf46	-0.63	-9.11	-0.45	8.01e-18	Morning vs. evening chronotype;
LUSC	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg11130432	chr3:121712080	ILDR1	-0.63	-9.57	-0.46	2.41e-19	Multiple sclerosis;
LUSC	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg11984989	chr7:158649758	WDR60	1.08	22.43	0.78	1.26e-68	Height;
LUSC	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg17845761	chr1:175162550	KIAA0040	-0.31	-5.95	-0.31	6.59e-9	Alcohol dependence;
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.43	7.0	0.36	1.39e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.7	11.79	0.54	4.52e-27	Menarche (age at onset);
LUSC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg02018176	chr4:1364513	KIAA1530	0.54	9.68	0.47	1.03e-19	Longevity;
LUSC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg14403583	chr14:105418241	AHNAK2	-0.58	-9.66	-0.47	1.29e-19	Rheumatoid arthritis;
LUSC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg11766577	chr21:47581405	C21orf56	-0.52	-7.94	-0.4	3.05e-14	Testicular germ cell tumor;
LUSC	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg07828340	chr4:882639	GAK	1.07	10.8	0.51	1.67e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs6005807	0.719	rs9625512	chr22:29020756	G/C	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	0.79	13.76	0.6	2.01e-34	Cognitive function;
LUSC	cis	rs17407555	0.520	rs4292327	chr4:9943700	G/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.12	-0.32	2.68e-9	Schizophrenia (age at onset);
LUSC	cis	rs62027291	0.950	rs17465482	chr15:77262489	A/G	cg26408565	chr15:76604113	ETFA	0.56	6.45	0.33	4.01e-10	Plateletcrit;
LUSC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg03188948	chr7:1209495	NA	0.66	6.93	0.35	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg00701064	chr4:6280414	WFS1	0.59	14.34	0.62	1.11e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg21132104	chr15:45694354	SPATA5L1	0.55	7.26	0.37	2.73e-12	Homoarginine levels;
LUSC	cis	rs16854884	0.657	rs7610378	chr3:143711298	G/A	cg06585982	chr3:143692056	C3orf58	0.48	7.33	0.37	1.76e-12	Economic and political preferences (feminism/equality);
LUSC	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.81	-0.39	7.27e-14	Joint mobility (Beighton score);
LUSC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg13206674	chr6:150067644	NUP43	0.6	9.36	0.46	1.17e-18	Lung cancer;
LUSC	cis	rs9905704	0.718	rs758377	chr17:56607124	T/C	cg19466818	chr17:56409534	MIR142	0.35	6.47	0.33	3.4e-10	Testicular germ cell tumor;
LUSC	cis	rs4594175	0.926	rs66625118	chr14:51631062	T/C	cg23942311	chr14:51606299	NA	0.3	5.68	0.3	2.86e-8	Cancer;
LUSC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.67	0.34	1.07e-10	Menopause (age at onset);
LUSC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg20891283	chr12:69753455	YEATS4	0.44	5.82	0.3	1.36e-8	Response to diuretic therapy;
LUSC	cis	rs7809950	1.000	rs7782057	chr7:107098877	T/A	cg23024343	chr7:107201750	COG5	-0.55	-8.75	-0.43	1.06e-16	Coronary artery disease;
LUSC	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg06552810	chr11:31128660	NA	-0.42	-7.4	-0.38	1.09e-12	Red blood cell count;
LUSC	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-9.2	-0.45	3.87e-18	Neuroticism;
LUSC	cis	rs10140922	0.966	rs8003074	chr14:35821692	A/C	cg07166546	chr14:35805898	NA	-0.24	-5.95	-0.31	6.7e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg18357645	chr12:58087776	OS9	-0.5	-6.54	-0.34	2.32e-10	Multiple sclerosis;
LUSC	cis	rs17604090	1.000	rs17603986	chr7:29690489	C/T	cg19413766	chr7:29689036	LOC646762	-0.63	-7.48	-0.38	6.73e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	trans	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg20935933	chr6:143382018	AIG1	0.5	7.33	0.37	1.71e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10489202	0.686	rs11585936	chr1:167847069	G/T	cg24449463	chr1:168025552	DCAF6	-0.56	-6.4	-0.33	5.38e-10	Schizophrenia;
LUSC	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg24449463	chr1:168025552	DCAF6	-0.66	-9.13	-0.45	6.8e-18	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00944502	chr5:64858997	PPWD1;CENPK	0.46	6.2	0.32	1.68e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg05985134	chr18:33552581	C18orf21	0.51	6.73	0.35	7.4e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs9650315	0.810	rs35845576	chr8:57202652	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.31	0.37	1.93e-12	Height;
LUSC	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21385522	chr1:16154831	NA	-0.57	-9.15	-0.45	5.61e-18	Systolic blood pressure;
LUSC	cis	rs7615316	0.528	rs13074172	chr3:142352978	A/G	cg16271453	chr3:142027066	XRN1	-0.45	-7.92	-0.4	3.56e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7605827	0.930	rs10929373	chr2:15663317	T/C	cg19274914	chr2:15703543	NA	0.45	8.55	0.42	4.62e-16	Educational attainment (years of education);
LUSC	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg04218760	chr10:45406644	TMEM72	-0.28	-6.94	-0.35	2.08e-11	Mean corpuscular volume;
LUSC	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg18404041	chr3:52824283	ITIH1	0.44	7.72	0.39	1.37e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg00191853	chr8:101177733	SPAG1	-0.37	-5.95	-0.31	6.76e-9	Atrioventricular conduction;
LUSC	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	ch.11.42038R	chr11:967971	AP2A2	0.54	8.06	0.4	1.41e-14	Alzheimer's disease (late onset);
LUSC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-0.92	-15.23	-0.64	3.94e-40	Breast cancer;
LUSC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02034447	chr16:89574710	SPG7	0.43	6.4	0.33	5.18e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs13082711	0.911	rs13075550	chr3:27427618	A/G	cg02860705	chr3:27208620	NA	0.5	8.64	0.43	2.34e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg17830980	chr10:43048298	ZNF37B	0.43	6.71	0.34	8.21e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg16339924	chr4:17578868	LAP3	0.47	7.0	0.36	1.38e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg02023728	chr11:77925099	USP35	0.47	7.11	0.36	7.26e-12	Testicular germ cell tumor;
LUSC	cis	rs983392	0.679	rs1026255	chr11:60029949	A/G	cg24026212	chr11:59952134	MS4A6A	-0.37	-6.39	-0.33	5.58e-10	Alzheimer's disease (late onset);
LUSC	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg17411546	chr10:75410026	SYNPO2L	-0.53	-8.07	-0.4	1.26e-14	Inflammatory bowel disease;
LUSC	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg23719950	chr11:63933701	MACROD1	-0.62	-7.41	-0.38	1.05e-12	Mean platelet volume;
LUSC	cis	rs2346177	0.806	rs56048837	chr2:46656647	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-7.96	-0.4	2.76e-14	HDL cholesterol;
LUSC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.33e-21	Lymphocyte counts;
LUSC	cis	rs6565180	0.791	rs4247355	chr16:30392099	A/G	cg17640201	chr16:30407289	ZNF48	0.9	15.41	0.64	7.41e-41	Tonsillectomy;
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.57	-8.86	-0.44	5e-17	Lymphocyte counts;
LUSC	cis	rs28830936	1.000	rs12441300	chr15:42102845	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.98	-0.31	5.63e-9	Diastolic blood pressure;
LUSC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg27165867	chr14:105738592	BRF1	-0.53	-7.8	-0.39	8.2e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.02	0.44	1.46e-17	Motion sickness;
LUSC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.48e-28	Motion sickness;
LUSC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg03146154	chr1:46216737	IPP	0.52	7.58	0.38	3.4e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs62458065	1.000	rs10246687	chr7:32465183	T/A	cg20159608	chr7:32802032	NA	-0.57	-7.01	-0.36	1.34e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs16976116	0.901	rs28489312	chr15:55494048	A/C	cg11288833	chr15:55489084	RSL24D1	0.5	6.0	0.31	5.19e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.7	10.85	0.51	1.04e-23	Aortic root size;
LUSC	trans	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg02800362	chr5:177631904	HNRNPAB	0.88	13.11	0.58	5.56e-32	Obesity-related traits;
LUSC	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.58	-11.49	-0.53	5.62e-26	Prostate cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27098574	chr16:75285489	BCAR1	-0.48	-6.65	-0.34	1.19e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs72781680	0.821	rs2339887	chr2:24198376	G/A	cg08917208	chr2:24149416	ATAD2B	0.6	6.9	0.35	2.66e-11	Lymphocyte counts;
LUSC	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg00083937	chr22:51039805	MAPK8IP2	0.51	8.63	0.43	2.53e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10982590	chr2:27579041	GTF3C2	-0.44	-5.98	-0.31	5.67e-9	Hepatitis;
LUSC	trans	rs7726558	0.731	rs80063787	chr5:118831460	G/A	cg14402224	chr7:50570049	DDC	-0.48	-6.12	-0.32	2.55e-9	QT interval (sulfonylurea treatment interaction);
LUSC	cis	rs28829049	0.508	rs4578242	chr1:19391565	G/C	cg13387374	chr1:19411106	UBR4	0.43	5.88	0.31	9.72e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg26384229	chr12:38710491	ALG10B	0.61	8.52	0.42	5.63e-16	Resting heart rate;
LUSC	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.69	-11.11	-0.52	1.28e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3764563	1.000	rs4239617	chr19:15741537	C/T	cg20725493	chr19:15740067	CYP4F8	-0.64	-6.62	-0.34	1.44e-10	Inflammatory biomarkers;
LUSC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	6.56	0.34	2.07e-10	Bipolar disorder;
LUSC	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg23029597	chr12:123009494	RSRC2	0.75	9.5	0.46	4.15e-19	Body mass index;
LUSC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg00316803	chr15:76480434	C15orf27	-0.41	-6.99	-0.36	1.5e-11	Blood metabolite levels;
LUSC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.7	0.3	2.6e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg13393036	chr8:95962371	TP53INP1	0.38	7.91	0.4	3.75e-14	Type 2 diabetes;
LUSC	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.84	-0.35	3.81e-11	Monocyte percentage of white cells;
LUSC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.23	-0.37	3.37e-12	Blood metabolite levels;
LUSC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg18904891	chr8:8559673	CLDN23	-0.41	-6.35	-0.33	6.96e-10	Mood instability;
LUSC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg12560992	chr17:57184187	TRIM37	0.83	15.25	0.64	3.12e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg18850127	chr7:39170497	POU6F2	0.49	7.06	0.36	9.94e-12	IgG glycosylation;
LUSC	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg10645314	chr2:3704589	ALLC	-0.47	-7.18	-0.37	4.47e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg21775979	chr11:780331	NA	0.46	7.77	0.39	9.6e-14	Breast cancer;
LUSC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg12311346	chr5:56204834	C5orf35	-0.8	-9.17	-0.45	4.89e-18	Type 2 diabetes;
LUSC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.9	15.7	0.65	5.45e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg26769984	chr7:1090371	C7orf50	0.58	8.97	0.44	2.17e-17	Bronchopulmonary dysplasia;
LUSC	cis	rs12900413	0.687	rs12903462	chr15:90304075	C/T	cg24249390	chr15:90295951	MESP1	-0.36	-5.69	-0.3	2.82e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	5.89	0.31	9.41e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06636551	chr8:101224915	SPAG1	-0.45	-8.26	-0.41	3.35e-15	Atrioventricular conduction;
LUSC	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg12823233	chr7:2316876	SNX8	-0.46	-7.8	-0.39	7.86e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs5758265	1	rs5758265	chr22:41617897	G/A	cg13813247	chr22:41461852	NA	-0.36	-6.55	-0.34	2.17e-10	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7172677	0.961	rs12102035	chr15:75418871	A/G	cg14664628	chr15:75095509	CSK	-0.44	-5.77	-0.3	1.85e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg17252645	chr8:143867129	LY6D	-0.36	-6.31	-0.33	9.04e-10	Urinary tract infection frequency;
LUSC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg06740227	chr12:86229804	RASSF9	-0.37	-5.87	-0.31	1.05e-8	Major depressive disorder;
LUSC	trans	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg21659725	chr3:3221576	CRBN	0.68	8.24	0.41	3.83e-15	Menarche (age at onset);
LUSC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg06454157	chr6:167490870	NA	-0.27	-6.64	-0.34	1.28e-10	Primary biliary cholangitis;
LUSC	cis	rs4268898	0.760	rs7597919	chr2:24563646	A/G	cg06627628	chr2:24431161	ITSN2	0.58	8.35	0.42	1.8e-15	Asthma;
LUSC	cis	rs12594515	1.000	rs7162201	chr15:45992658	A/C	cg06207120	chr15:45996521	NA	0.38	5.86	0.31	1.14e-8	Waist circumference;Weight;
LUSC	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg05340658	chr4:99064831	C4orf37	0.58	8.63	0.43	2.47e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4474465	0.850	rs10793329	chr11:78265655	G/C	cg27205649	chr11:78285834	NARS2	0.51	6.05	0.31	3.99e-9	Alzheimer's disease (survival time);
LUSC	cis	rs17401966	0.518	rs10864453	chr1:10407169	T/G	cg17425144	chr1:10567563	PEX14	-0.35	-6.25	-0.32	1.27e-9	Hepatocellular carcinoma;
LUSC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg07777115	chr5:623756	CEP72	-0.47	-5.77	-0.3	1.78e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs79911532	0.515	rs10226745	chr7:75843603	C/T	cg03592824	chr7:75666768	STYXL1	0.67	6.64	0.34	1.25e-10	Mononucleosis;
LUSC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs7172677	0.732	rs55922358	chr15:75313967	G/C	cg09165964	chr15:75287851	SCAMP5	0.46	5.74	0.3	2.16e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2737618	0.630	rs2821328	chr1:200082051	G/A	cg21825944	chr1:200113062	NR5A2	-0.3	-5.72	-0.3	2.41e-8	Uric acid levels;
LUSC	cis	rs6690583	0.524	rs12030837	chr1:85519383	A/G	cg11262906	chr1:85462892	MCOLN2	-0.64	-6.09	-0.32	3.13e-9	Serum sulfate level;
LUSC	cis	rs7818345	0.967	rs4412390	chr8:19270143	A/T	cg11303988	chr8:19266685	CSGALNACT1	-0.37	-7.12	-0.36	6.74e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg00310523	chr12:86230176	RASSF9	0.37	6.54	0.34	2.26e-10	Major depressive disorder;
LUSC	cis	rs55883249	0.957	rs17453675	chr2:9754407	A/G	cg23886495	chr2:9695866	ADAM17	0.48	5.75	0.3	2.07e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg22823121	chr1:150693482	HORMAD1	0.57	8.85	0.44	5.08e-17	Tonsillectomy;
LUSC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg15001381	chr16:403314	AXIN1	0.34	6.37	0.33	6.28e-10	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs2857891	0.695	rs2346002	chr11:6987741	T/C	cg04053776	chr11:6947353	ZNF215	0.42	6.18	0.32	1.86e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	8.98	0.44	1.99e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12220238	1.000	rs11000936	chr10:75992383	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.3	0.37	2.18e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.79	-14.4	-0.62	6.32e-37	Dental caries;
LUSC	cis	rs3925075	1.000	rs11859274	chr16:31361059	C/T	cg02846316	chr16:31340340	ITGAM	0.36	6.73	0.35	7.2e-11	IgA nephropathy;
LUSC	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.39	5.75	0.3	2.01e-8	Height;
LUSC	trans	rs867371	0.762	rs1846910	chr15:82571780	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.49	-7.17	-0.37	4.76e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	trans	rs2975734	0.680	rs1052453	chr8:10108325	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.38	-0.33	5.8e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs13401104	0.754	rs11902623	chr2:237117624	G/A	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	trans	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg10840412	chr1:235813424	GNG4	0.53	6.33	0.33	8.1e-10	Neuroticism;
LUSC	cis	rs1178127	0.580	rs1178178	chr7:18799718	G/A	cg02370815	chr7:18831390	HDAC9	-0.39	-5.86	-0.31	1.13e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
LUSC	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg05555928	chr11:63887634	MACROD1	-0.49	-6.18	-0.32	1.87e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7674212	0.541	rs2720458	chr4:104052963	C/G	cg16532752	chr4:104119610	CENPE	-0.46	-6.33	-0.33	7.87e-10	Type 2 diabetes;
LUSC	cis	rs6700896	0.931	rs17127849	chr1:66105512	A/G	cg04111102	chr1:66153794	NA	0.32	7.06	0.36	9.67e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11764359	chr7:65958608	NA	-0.62	-9.33	-0.45	1.47e-18	Calcium levels;
LUSC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg12463550	chr7:65579703	CRCP	0.57	8.47	0.42	7.7e-16	Aortic root size;
LUSC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.37	-6.58	-0.34	1.77e-10	Longevity;Endometriosis;
LUSC	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10489525	1.000	rs10489525	chr1:115263685	A/G	cg01522456	chr1:115632236	TSPAN2	-0.43	-6.06	-0.31	3.72e-9	Autism;
LUSC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg13206674	chr6:150067644	NUP43	0.56	8.69	0.43	1.67e-16	Lung cancer;
LUSC	cis	rs10743315	0.557	rs10505840	chr12:19403729	G/T	cg02471346	chr12:19282374	PLEKHA5	0.82	6.42	0.33	4.72e-10	Gut microbiota (bacterial taxa);
LUSC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg04414720	chr1:150670196	GOLPH3L	0.57	9.22	0.45	3.31e-18	Tonsillectomy;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12655452	chr1:77685094	PIGK	-0.44	-6.03	-0.31	4.34e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.69e-9	Aortic root size;
LUSC	cis	rs4363385	0.747	rs1933383	chr1:152963468	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.6	-0.38	2.97e-13	Inflammatory skin disease;
LUSC	trans	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg11663144	chr21:46675770	NA	-0.41	-7.14	-0.36	6.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3771570	1.000	rs60604866	chr2:242352257	A/G	cg21155796	chr2:242212141	HDLBP	0.61	6.76	0.35	6.18e-11	Prostate cancer;
LUSC	trans	rs11700980	1.000	rs2832049	chr21:30129277	T/C	cg05609335	chr17:75789393	NA	0.4	6.19	0.32	1.76e-9	QRS complex (12-leadsum);
LUSC	cis	rs9650657	0.675	rs2409658	chr8:10668965	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.31	-0.33	8.62e-10	Neuroticism;
LUSC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs2235649	0.552	rs8056773	chr16:1959432	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-6.16	-0.32	2.09e-9	Blood metabolite levels;
LUSC	cis	rs2970818	0.731	rs61909580	chr12:4595291	C/T	cg11146114	chr12:4671731	NA	-0.6	-5.71	-0.3	2.54e-8	Phosphorus levels;
LUSC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.18	0.52	7.04e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg18811423	chr2:55921094	PNPT1	0.85	14.56	0.62	1.58e-37	Metabolic syndrome;
LUSC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-8.89	-0.44	3.94e-17	Personality dimensions;
LUSC	cis	rs6496044	0.568	rs2880764	chr15:86056408	A/G	cg13263323	chr15:86062960	AKAP13	-0.36	-5.95	-0.31	6.73e-9	Interstitial lung disease;
LUSC	cis	rs1185460	0.565	rs10892325	chr11:118912702	T/C	cg01677386	chr11:118938358	VPS11	0.42	5.8	0.3	1.56e-8	Coronary artery disease;
LUSC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.72	-0.39	1.34e-13	Height;
LUSC	cis	rs3106136	0.546	rs4693003	chr4:95145469	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.46	-0.42	8.25e-16	Capecitabine sensitivity;
LUSC	cis	rs9473147	0.516	rs10948363	chr6:47487762	A/G	cg12968598	chr6:47444699	CD2AP	0.53	8.07	0.4	1.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.86	0.44	4.97e-17	Motion sickness;
LUSC	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	-0.4	-6.3	-0.33	9.27e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg15556689	chr8:8085844	FLJ10661	0.5	7.23	0.37	3.26e-12	Retinal vascular caliber;
LUSC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg14552801	chr7:65878734	NA	0.38	5.93	0.31	7.69e-9	Aortic root size;
LUSC	cis	rs6429082	0.608	rs4469707	chr1:235570634	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.5	-6.86	-0.35	3.36e-11	Adiposity;
LUSC	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.35	0.53	1.79e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg00074818	chr8:8560427	CLDN23	0.58	9.43	0.46	7.04e-19	Obesity-related traits;
LUSC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg26408565	chr15:76604113	ETFA	-0.52	-8.3	-0.41	2.6e-15	Blood metabolite levels;
LUSC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg24829409	chr8:58192753	C8orf71	-0.53	-6.17	-0.32	1.98e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7493	0.950	rs11981299	chr7:95029701	T/A	cg04871131	chr7:94954202	PON1	-0.38	-6.05	-0.31	3.79e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.8	-13.48	-0.59	2.21e-33	Metabolic syndrome;
LUSC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.64	-5.99	-0.31	5.32e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.68	-9.46	-0.46	5.56e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg02030672	chr11:45687055	CHST1	0.52	8.33	0.41	2.17e-15	Obesity-related traits;
LUSC	trans	rs1493916	0.777	rs1941685	chr18:31304318	G/T	cg27147174	chr7:100797783	AP1S1	-0.56	-8.76	-0.43	9.68e-17	Life satisfaction;
LUSC	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-1.02	-20.46	-0.75	6.88e-61	Dilated cardiomyopathy;
LUSC	cis	rs7903847	0.596	rs10882934	chr10:99170995	T/G	cg08345082	chr10:99160200	RRP12	-0.37	-7.51	-0.38	5.39e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	12.09	0.55	3.7e-28	Personality dimensions;
LUSC	cis	rs6545883	0.929	rs1186711	chr2:61688505	T/C	cg15711740	chr2:61764176	XPO1	-0.44	-6.67	-0.34	1.05e-10	Tuberculosis;
LUSC	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg18232548	chr7:50535776	DDC	0.53	8.21	0.41	5.02e-15	Malaria;
LUSC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-0.88	-18.2	-0.71	6.32e-52	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6580649	0.941	rs1859441	chr12:48423233	C/T	cg24011408	chr12:48396354	COL2A1	-0.52	-6.86	-0.35	3.35e-11	Lung cancer;
LUSC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.4	0.53	1.16e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg06462663	chr19:18546047	ISYNA1	0.5	8.52	0.42	5.69e-16	Breast cancer;
LUSC	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg10909506	chr17:38081995	ORMDL3	0.32	5.75	0.3	2.06e-8	Self-reported allergy;
LUSC	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg13852791	chr20:30311386	BCL2L1	0.62	7.1	0.36	7.77e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg27219399	chr15:67835830	MAP2K5	0.35	5.69	0.3	2.71e-8	Restless legs syndrome;
LUSC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	14.05	0.61	1.44e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs13315871	0.929	rs35376204	chr3:58325563	T/C	cg12435725	chr3:58293450	RPP14	-0.72	-7.15	-0.36	5.35e-12	Cholesterol, total;
LUSC	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg00852783	chr1:26633632	UBXN11	0.49	8.77	0.43	9.1e-17	Obesity-related traits;
LUSC	cis	rs2688608	0.967	rs9971038	chr10:75661149	C/T	cg17411546	chr10:75410026	SYNPO2L	-0.42	-6.16	-0.32	2.05e-9	Inflammatory bowel disease;
LUSC	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	6.49	0.33	3.11e-10	Height;
LUSC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg25039879	chr17:56429692	SUPT4H1	0.5	7.04	0.36	1.07e-11	Cognitive test performance;
LUSC	cis	rs6736093	0.966	rs3811634	chr2:112754943	C/T	cg12686935	chr2:112915763	FBLN7	-0.37	-6.06	-0.31	3.65e-9	Coronary artery disease;
LUSC	cis	rs7605827	0.897	rs13010658	chr2:15668468	A/G	cg19274914	chr2:15703543	NA	0.45	8.5	0.42	6.45e-16	Educational attainment (years of education);
LUSC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.71	-9.84	-0.47	3.12e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg12615879	chr12:58013172	SLC26A10	0.27	5.84	0.3	1.21e-8	Rheumatoid arthritis;
LUSC	cis	rs11608355	0.515	rs12826754	chr12:109923244	A/G	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.08	0.32	3.32e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg17279839	chr7:150038598	RARRES2	0.41	6.31	0.33	8.98e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-7.26	-0.37	2.71e-12	Menopause (age at onset);
LUSC	cis	rs6076065	0.723	rs2224074	chr20:23360171	G/C	cg11657817	chr20:23433608	CST11	0.43	8.07	0.4	1.25e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg15556689	chr8:8085844	FLJ10661	-0.63	-9.78	-0.47	5.12e-20	Joint mobility (Beighton score);
LUSC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg13206674	chr6:150067644	NUP43	0.55	8.59	0.43	3.41e-16	Lung cancer;
LUSC	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg25206134	chr2:45395956	NA	0.61	7.1	0.36	7.39e-12	Bipolar disorder;
LUSC	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg09904177	chr6:26538194	HMGN4	0.73	13.27	0.59	1.45e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.65	-0.34	1.23e-10	Lung cancer;
LUSC	trans	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg10756647	chr7:56101905	PSPH	0.85	8.47	0.42	7.94e-16	Gout;
LUSC	cis	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg13647721	chr17:30228624	UTP6	-0.6	-7.29	-0.37	2.27e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg02423579	chr7:2872169	GNA12	-0.41	-6.13	-0.32	2.43e-9	Height;
LUSC	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg13010199	chr12:38710504	ALG10B	0.68	10.77	0.51	1.98e-23	Morning vs. evening chronotype;
LUSC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg24733560	chr20:60626293	TAF4	0.41	6.77	0.35	5.69e-11	Body mass index;
LUSC	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-14.01	-0.61	2.11e-35	Exhaled nitric oxide output;
LUSC	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg25251562	chr2:3704773	ALLC	0.48	8.37	0.42	1.58e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs12928939	0.815	rs7185575	chr16:71672569	A/G	cg03805757	chr16:71968109	PKD1L3	-0.39	-5.66	-0.3	3.2e-8	Post bronchodilator FEV1;
LUSC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	6.47	0.33	3.5e-10	Obesity-related traits;
LUSC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg05729581	chr11:3078854	CARS	-0.57	-8.86	-0.44	4.74e-17	Longevity;
LUSC	cis	rs472402	0.580	rs6884552	chr5:6661966	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.44	-6.29	-0.33	9.9e-10	Response to amphetamines;
LUSC	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.47	7.24	0.37	3.03e-12	Cognitive test performance;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07029396	chr17:79650519	HGS;ARL16	-0.43	-6.31	-0.33	9.01e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.03	-20.95	-0.75	8.07e-63	Ulcerative colitis;
LUSC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.68	-0.43	1.73e-16	Bipolar disorder;
LUSC	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg07169764	chr2:136633963	MCM6	1.04	13.93	0.61	4.22e-35	Corneal structure;
LUSC	cis	rs6087990	0.769	rs17123658	chr20:31390840	C/A	cg13636640	chr20:31349939	DNMT3B	0.88	17.72	0.7	5.2e-50	Ulcerative colitis;
LUSC	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg15704280	chr7:45808275	SEPT13	0.78	7.55	0.38	4.31e-13	Axial length;
LUSC	cis	rs10740039	0.804	rs7094818	chr10:62411971	G/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.85	-0.35	3.61e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg10503236	chr1:231470652	EXOC8	-0.35	-5.71	-0.3	2.49e-8	Hemoglobin concentration;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05762101	chr4:1857817	LETM1	-0.41	-5.95	-0.31	6.78e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9905704	0.918	rs11650343	chr17:56919549	G/A	cg12560992	chr17:57184187	TRIM37	0.56	7.86	0.4	5.16e-14	Testicular germ cell tumor;
LUSC	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.21	0.61	3.68e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg14582100	chr15:45693742	SPATA5L1	0.46	8.62	0.43	2.7e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg16584290	chr5:462447	EXOC3	-0.37	-6.43	-0.33	4.39e-10	Cystic fibrosis severity;
LUSC	cis	rs9341808	0.667	rs3828753	chr6:80912746	C/T	cg08355045	chr6:80787529	NA	0.46	7.96	0.4	2.73e-14	Sitting height ratio;
LUSC	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.86	0.54	2.63e-27	Cognitive ability;
LUSC	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.7	11.21	0.52	5.5e-25	Corneal astigmatism;
LUSC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg10862848	chr6:42927986	GNMT	-0.25	-5.83	-0.3	1.31e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg12935359	chr14:103987150	CKB	-0.55	-8.52	-0.42	5.69e-16	Body mass index;
LUSC	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg06784218	chr1:46089804	CCDC17	0.32	5.68	0.3	2.96e-8	Platelet count;
LUSC	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg04310649	chr10:35416472	CREM	-0.41	-6.43	-0.33	4.53e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.85	-0.51	1.07e-23	Aortic root size;
LUSC	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg10604040	chr11:65559109	OVOL1	0.31	5.78	0.3	1.72e-8	Eosinophil percentage of white cells;
LUSC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg03351412	chr1:154909251	PMVK	-0.55	-8.89	-0.44	3.75e-17	Prostate cancer;
LUSC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg00982548	chr2:198649783	BOLL	-0.58	-7.29	-0.37	2.32e-12	Ulcerative colitis;
LUSC	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.84	-8.43	-0.42	1.01e-15	Lung cancer in ever smokers;
LUSC	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.68	11.58	0.54	2.71e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg07703079	chr11:430292	ANO9	0.62	6.49	0.33	3.04e-10	Body mass index;
LUSC	cis	rs5770917	1.000	rs12627787	chr22:51012381	C/T	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.62	-5.74	-0.3	2.07e-8	Narcolepsy;
LUSC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.76	-0.3	1.94e-8	Personality dimensions;
LUSC	cis	rs4285028	0.948	rs76593525	chr3:121690477	G/A	cg11130432	chr3:121712080	ILDR1	-0.63	-9.5	-0.46	4.26e-19	Multiple sclerosis;
LUSC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg24324837	chr19:49891574	CCDC155	0.53	7.39	0.37	1.17e-12	Multiple sclerosis;
LUSC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21659725	chr3:3221576	CRBN	-0.53	-8.4	-0.42	1.32e-15	Body mass index;
LUSC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-5.79	-0.3	1.62e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg01879757	chr17:41196368	BRCA1	-0.46	-7.33	-0.37	1.71e-12	Menopause (age at onset);
LUSC	cis	rs983392	0.709	rs1426250	chr11:60001325	A/G	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.16	-0.32	2.12e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg08499158	chr17:42289980	UBTF	-0.49	-8.31	-0.41	2.46e-15	Total body bone mineral density;
LUSC	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg04218760	chr10:45406644	TMEM72	-0.29	-7.05	-0.36	1.04e-11	Mean corpuscular volume;
LUSC	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	1.03	15.82	0.65	1.87e-42	Corneal structure;
LUSC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg15556689	chr8:8085844	FLJ10661	0.68	11.54	0.53	3.84e-26	Mood instability;
LUSC	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg24459738	chr19:57751996	ZNF805	-0.51	-7.54	-0.38	4.56e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg01973587	chr1:228161476	NA	-0.36	-6.02	-0.31	4.61e-9	Diastolic blood pressure;
LUSC	cis	rs2692947	0.655	rs4605406	chr2:96583735	A/C	cg23100626	chr2:96804247	ASTL	0.3	6.9	0.35	2.7e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg21951975	chr1:209979733	IRF6	0.56	7.0	0.36	1.4e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs6546550	0.867	rs4401231	chr2:70063563	G/C	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.16	-0.36	5.13e-12	Prevalent atrial fibrillation;
LUSC	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg20628663	chr10:43360327	NA	0.55	8.13	0.41	8.27e-15	Blood protein levels;
LUSC	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg05283184	chr6:79620031	NA	-0.58	-12.25	-0.56	9.76e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg06623918	chr6:96969491	KIAA0776	0.79	11.74	0.54	6.98e-27	Migraine;Coronary artery disease;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg15572146	chr11:695533	TMEM80;DEAF1	0.39	5.94	0.31	7e-9	N-glycan levels;
LUSC	cis	rs7107174	1.000	rs10899451	chr11:77991222	A/C	cg02023728	chr11:77925099	USP35	0.49	6.8	0.35	4.83e-11	Testicular germ cell tumor;
LUSC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.67	10.99	0.52	3.34e-24	Heart rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00783759	chr4:128983441	LARP1B	0.43	6.05	0.31	3.92e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg00945038	chr17:61921165	SMARCD2	0.52	9.22	0.45	3.39e-18	Prudent dietary pattern;
LUSC	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg00579200	chr11:133705235	NA	-0.39	-5.97	-0.31	6.21e-9	Childhood ear infection;
LUSC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg17264618	chr3:40429014	ENTPD3	0.31	6.79	0.35	5.01e-11	Renal cell carcinoma;
LUSC	cis	rs1904096	0.506	rs6532476	chr4:95192461	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.45	-0.42	8.99e-16	Type 2 diabetes;
LUSC	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg26384229	chr12:38710491	ALG10B	0.74	11.9	0.55	1.78e-27	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.83	0.63	1.46e-38	Platelet count;
LUSC	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg04310649	chr10:35416472	CREM	-0.42	-6.41	-0.33	5.11e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-6.53	-0.34	2.5e-10	Renal function-related traits (BUN);
LUSC	cis	rs2979489	0.891	rs2915590	chr8:30393334	A/G	cg26383811	chr8:30366931	RBPMS	-0.51	-8.44	-0.42	9.64e-16	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg00579484	chr14:23475993	C14orf93	0.39	5.66	0.3	3.23e-8	Cognitive ability (multi-trait analysis);
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg00024416	chr22:24240387	NA	-0.33	-5.77	-0.3	1.8e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg19318889	chr4:1322082	MAEA	0.43	5.66	0.3	3.22e-8	Recombination rate (females);
LUSC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg26380479	chr7:97908229	NA	-0.27	-6.0	-0.31	5e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg23172400	chr8:95962367	TP53INP1	0.35	6.7	0.34	8.71e-11	Type 2 diabetes;
LUSC	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.82	-14.11	-0.61	8.58e-36	Bladder cancer;
LUSC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg22535103	chr8:58192502	C8orf71	0.77	8.37	0.42	1.55e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs983392	0.868	rs7926954	chr11:59932579	G/A	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.11	-0.32	2.82e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.82	-15.9	-0.66	8.61e-43	Inflammatory bowel disease;
LUSC	trans	rs953492	0.624	rs4469702	chr1:243365196	T/C	cg01826367	chr1:224180288	NA	-0.43	-6.33	-0.33	8.08e-10	Diastolic blood pressure;
LUSC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg23795048	chr12:9217529	LOC144571	0.33	5.64	0.3	3.56e-8	Sjögren's syndrome;
LUSC	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-6.38	-0.33	6.06e-10	Fibrinogen levels;
LUSC	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg21211680	chr2:198530	NA	-0.53	-6.81	-0.35	4.66e-11	Blood protein levels;
LUSC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg12639453	chr1:2035780	PRKCZ	-0.32	-6.86	-0.35	3.35e-11	Height;
LUSC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg22705602	chr4:152727874	NA	-0.39	-8.52	-0.42	5.42e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.7	12.64	0.57	3.53e-30	Prudent dietary pattern;
LUSC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg15790184	chr11:494944	RNH1	0.55	6.2	0.32	1.67e-9	Body mass index;
LUSC	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg09307838	chr4:120376055	NA	0.7	9.88	0.48	2.23e-20	Corneal astigmatism;
LUSC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg04398451	chr17:18023971	MYO15A	0.45	7.02	0.36	1.22e-11	Total body bone mineral density;
LUSC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg16586182	chr3:47516702	SCAP	-0.48	-7.46	-0.38	7.78e-13	Colorectal cancer;
LUSC	trans	rs72674100	1.000	rs6830382	chr4:97977606	G/A	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg12751644	chr20:60527061	NA	0.43	7.45	0.38	7.94e-13	Obesity-related traits;
LUSC	cis	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg06521331	chr12:34319734	NA	-0.35	-5.78	-0.3	1.67e-8	Morning vs. evening chronotype;
LUSC	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg15704280	chr7:45808275	SEPT13	-0.62	-6.78	-0.35	5.33e-11	Axial length;
LUSC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-1.02	-11.22	-0.52	5.21e-25	Monocyte percentage of white cells;
LUSC	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg10130564	chr11:117069849	TAGLN	0.37	6.05	0.31	3.94e-9	Blood protein levels;
LUSC	cis	rs1957429	0.522	rs57319601	chr14:65415743	C/T	cg23373153	chr14:65346875	NA	-0.78	-6.53	-0.34	2.4e-10	Pediatric areal bone mineral density (radius);
LUSC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg24060327	chr5:131705240	SLC22A5	-0.51	-8.18	-0.41	6.15e-15	Acylcarnitine levels;
LUSC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	trans	rs61931739	0.686	rs708145	chr12:33731580	G/A	cg26384229	chr12:38710491	ALG10B	0.43	6.18	0.32	1.9e-9	Morning vs. evening chronotype;
LUSC	cis	rs28647808	0.881	rs4962139	chr9:136267869	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	0.56	5.67	0.3	3.04e-8	Blood protein levels;
LUSC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg26441486	chr22:50317300	CRELD2	0.5	7.3	0.37	2.06e-12	Schizophrenia;
LUSC	cis	rs7000551	0.505	rs4872499	chr8:22293306	A/G	cg12081754	chr8:22256438	SLC39A14	-0.86	-11.84	-0.54	3.11e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg20991723	chr1:152506922	NA	-0.48	-9.09	-0.45	8.99e-18	Hair morphology;
LUSC	cis	rs2976388	0.967	rs2976393	chr8:143763618	C/G	cg17252645	chr8:143867129	LY6D	-0.37	-6.34	-0.33	7.38e-10	Urinary tract infection frequency;
LUSC	cis	rs6696846	0.515	rs6593924	chr1:205110452	A/G	cg00857998	chr1:205179979	DSTYK	0.45	6.31	0.33	9.09e-10	Red blood cell count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08902025	chr16:85646717	KIAA0182	-0.41	-6.28	-0.32	1.07e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.14	-0.41	7.8e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12595990	chr12:49351331	ARF3	-0.42	-6.52	-0.34	2.63e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7119	0.604	rs2682921	chr15:77865459	C/T	cg27398640	chr15:77910606	LINGO1	0.35	7.85	0.39	5.57e-14	Type 2 diabetes;
LUSC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.13	16.52	0.67	3.08e-45	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg02958346	chr11:57425731	CLP1	-0.43	-6.28	-0.32	1.06e-9	Schizophrenia;
LUSC	cis	rs35424364	1	rs35424364	chr6:109643605	A/AT	cg12927641	chr6:109611667	NA	-0.54	-6.23	-0.32	1.41e-9	Obstructive sleep apnea trait (average respiratory event duration);
LUSC	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg19539972	chr4:7069911	GRPEL1	0.72	9.06	0.44	1.13e-17	Monocyte percentage of white cells;
LUSC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg03929089	chr4:120376271	NA	-0.94	-16.31	-0.67	2.11e-44	Height;
LUSC	cis	rs662064	0.962	rs596537	chr1:10554709	G/T	cg17425144	chr1:10567563	PEX14	0.36	5.79	0.3	1.59e-8	Asthma;
LUSC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg16797656	chr11:68205561	LRP5	0.35	5.83	0.3	1.28e-8	Total body bone mineral density;
LUSC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg16339924	chr4:17578868	LAP3	0.6	8.95	0.44	2.44e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs56804039	1.000	rs59620654	chr8:8382632	A/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.38	-0.37	1.27e-12	Cervical cancer;
LUSC	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs71017072	1	rs71017072	chr7:19794295	G/GA	cg05791153	chr7:19748676	TWISTNB	0.66	7.1	0.36	7.62e-12	Rubella;
LUSC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg23281280	chr6:28129359	ZNF389	0.44	5.74	0.3	2.17e-8	Depression;
LUSC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg02896835	chr1:92012615	NA	-0.65	-11.7	-0.54	9.9e-27	Breast cancer;
LUSC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg24733560	chr20:60626293	TAF4	-0.43	-7.98	-0.4	2.35e-14	Body mass index;
LUSC	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg10840412	chr1:235813424	GNG4	0.67	8.37	0.42	1.64e-15	Bipolar disorder;
LUSC	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg21849932	chr20:62369462	LIME1	-0.41	-6.1	-0.32	2.94e-9	Prostate cancer;
LUSC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg24209194	chr3:40518798	ZNF619	0.47	6.35	0.33	7.19e-10	Renal cell carcinoma;
LUSC	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg02454025	chr1:11042201	C1orf127	1.02	18.51	0.71	3.88e-53	Ewing sarcoma;
LUSC	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	6.37	0.33	6.14e-10	Recombination rate (females);
LUSC	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.22	-0.41	4.54e-15	Response to antipsychotic treatment;
LUSC	cis	rs10908458	0.808	rs10908456	chr1:155086148	A/G	cg23973274	chr1:155060172	NA	0.3	5.74	0.3	2.09e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08280861	chr8:58055591	NA	0.56	5.98	0.31	5.87e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08736216	chr1:53307985	ZYG11A	-0.31	-6.39	-0.33	5.68e-10	Monocyte count;
LUSC	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.53	-7.14	-0.36	5.85e-12	Renal function-related traits (BUN);
LUSC	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg17173187	chr15:85201210	NMB	0.37	6.4	0.33	5.31e-10	Schizophrenia;
LUSC	cis	rs30380	0.587	rs30185	chr5:96125465	G/A	cg16492584	chr5:96139282	ERAP1	-0.52	-7.05	-0.36	1e-11	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs12519773	0.576	rs55971857	chr5:92441594	A/C	cg18783429	chr5:92414398	NA	0.31	6.08	0.32	3.23e-9	Migraine;
LUSC	cis	rs240764	0.658	rs9377214	chr6:101212146	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-6.26	-0.32	1.21e-9	Neuroticism;
LUSC	cis	rs4919087	0.892	rs10786319	chr10:99008951	T/C	cg25902810	chr10:99078978	FRAT1	0.44	6.45	0.33	3.97e-10	Monocyte count;
LUSC	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	7.98	0.4	2.44e-14	Neuroticism;
LUSC	trans	rs208520	0.802	rs208499	chr6:66932146	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.71	-0.6	2.88e-34	Exhaled nitric oxide output;
LUSC	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg13010199	chr12:38710504	ALG10B	0.4	6.38	0.33	5.88e-10	Morning vs. evening chronotype;
LUSC	cis	rs6546550	0.901	rs11126251	chr2:70163434	A/C	cg02498382	chr2:70120550	SNRNP27	-0.32	-8.2	-0.41	5.12e-15	Prevalent atrial fibrillation;
LUSC	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg06640241	chr16:89574553	SPG7	0.82	13.87	0.6	7.35e-35	Multiple myeloma (IgH translocation);
LUSC	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg14227996	chr4:17616232	MED28	0.67	7.12	0.36	6.76e-12	Opioid sensitivity;
LUSC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.14	-0.49	3.12e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.87	-12.56	-0.57	6.5e-30	Ileal carcinoids;
LUSC	cis	rs3743266	0.613	rs8027901	chr15:60733464	A/C	cg21667061	chr15:60772094	NARG2	-0.38	-6.3	-0.33	9.15e-10	Menarche (age at onset);
LUSC	cis	rs9463078	0.739	rs1041333	chr6:44945206	A/T	cg25276700	chr6:44698697	NA	-0.29	-5.87	-0.31	1.06e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs367943	0.712	rs7734061	chr5:112700175	A/G	cg12552261	chr5:112820674	MCC	0.4	6.54	0.34	2.31e-10	Type 2 diabetes;
LUSC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-1.12	-24.77	-0.8	1.22e-77	Height;
LUSC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg06600287	chr1:53387719	ECHDC2	-0.3	-6.18	-0.32	1.91e-9	Monocyte count;
LUSC	cis	rs9341808	0.754	rs10806185	chr6:80954511	G/A	cg08355045	chr6:80787529	NA	0.56	9.62	0.47	1.7e-19	Sitting height ratio;
LUSC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.27	-0.49	1.14e-21	Hemoglobin concentration;
LUSC	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg10255544	chr17:80519551	FOXK2	0.41	6.69	0.34	9.59e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg01444801	chr10:135216882	MTG1	-0.48	-6.4	-0.33	5.18e-10	Systemic lupus erythematosus;
LUSC	cis	rs7590368	0.715	rs56162318	chr2:10958936	A/C	cg15705551	chr2:10952987	PDIA6	0.58	6.24	0.32	1.31e-9	Educational attainment (years of education);
LUSC	cis	rs9309473	0.748	rs2421552	chr2:73758803	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.53	-0.34	2.45e-10	Metabolite levels;
LUSC	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg25457927	chr22:38595422	NA	-0.41	-8.73	-0.43	1.24e-16	Cutaneous nevi;
LUSC	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg24399712	chr22:39784796	NA	-0.58	-9.38	-0.46	1.02e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg01017244	chr2:74357527	NA	0.74	14.39	0.62	7.35e-37	Gestational age at birth (maternal effect);
LUSC	trans	rs4650994	0.544	rs2761469	chr1:178590638	A/C	cg05059571	chr16:84539110	KIAA1609	0.46	8.76	0.43	9.66e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-1.14	-17.81	-0.7	2.27e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.72	-12.81	-0.57	7.8e-31	Dental caries;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04105453	chr2:27440337	CAD	-0.52	-6.2	-0.32	1.68e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg23172400	chr8:95962367	TP53INP1	-0.41	-8.19	-0.41	5.46e-15	Type 2 diabetes;
LUSC	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg24675056	chr1:15929824	NA	0.46	8.03	0.4	1.69e-14	Systolic blood pressure;
LUSC	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.19	0.32	1.76e-9	Neuroticism;
LUSC	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-8.58	-0.42	3.69e-16	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.21	-0.32	1.6e-9	Bladder cancer;
LUSC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27286337	chr10:134555280	INPP5A	0.81	10.76	0.51	2.19e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs656319	0.580	rs13252589	chr8:10005526	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-6.58	-0.34	1.8e-10	Myopia (pathological);
LUSC	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg20744362	chr22:50050164	C22orf34	0.38	7.87	0.4	4.97e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg06462663	chr19:18546047	ISYNA1	0.44	7.47	0.38	6.97e-13	Breast cancer;
LUSC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg11764359	chr7:65958608	NA	0.52	6.85	0.35	3.5e-11	Aortic root size;
LUSC	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg23752985	chr2:85803571	VAMP8	0.32	6.27	0.32	1.11e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.05	13.17	0.58	3.32e-32	Sexual dysfunction (female);
LUSC	cis	rs77372450	0.636	rs10057597	chr5:157012870	A/G	cg25387487	chr5:157003181	ADAM19	-0.47	-5.67	-0.3	3.13e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg07661805	chr8:143867942	LY6D	-0.26	-5.91	-0.31	8.23e-9	Urinary tract infection frequency;
LUSC	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg03676636	chr4:99064102	C4orf37	0.31	6.23	0.32	1.44e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg02972257	chr16:68554789	NA	-0.54	-6.73	-0.35	7.29e-11	Ulcerative colitis;
LUSC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.69	0.83	1.71e-88	Chronic sinus infection;
LUSC	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg22906224	chr7:99728672	NA	0.54	7.25	0.37	2.96e-12	Coronary artery disease;
LUSC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-9.71	-0.47	8.69e-20	Rheumatoid arthritis;
LUSC	cis	rs17095355	1.000	rs72828241	chr10:111744704	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.65	-7.58	-0.38	3.53e-13	Biliary atresia;
LUSC	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg15145296	chr3:125709740	NA	-0.59	-5.96	-0.31	6.41e-9	Blood pressure (smoking interaction);
LUSC	cis	rs1953600	0.870	rs2245168	chr10:81921918	T/C	cg00277334	chr10:82204260	NA	-0.44	-6.85	-0.35	3.5e-11	Sarcoidosis;
LUSC	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg26876637	chr1:152193138	HRNR	0.42	5.96	0.31	6.41e-9	Atopic dermatitis;
LUSC	cis	rs6060717	0.698	rs8123175	chr20:34609872	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.57	-0.34	1.98e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg09835421	chr16:68378352	PRMT7	-0.54	-6.09	-0.32	3.03e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg11189052	chr15:85197271	WDR73	0.47	5.93	0.31	7.41e-9	Schizophrenia;
LUSC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05165339	chr4:1420672	NA	-0.29	-6.83	-0.35	3.94e-11	Longevity;
LUSC	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg00310523	chr12:86230176	RASSF9	0.4	7.31	0.37	1.94e-12	Major depressive disorder;
LUSC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg26441486	chr22:50317300	CRELD2	-0.52	-7.81	-0.39	7.65e-14	Schizophrenia;
LUSC	cis	rs7561273	0.586	rs7580772	chr2:24357657	T/C	cg06627628	chr2:24431161	ITSN2	-0.51	-6.8	-0.35	4.71e-11	Quantitative traits;
LUSC	cis	rs2625529	0.730	rs7403191	chr15:72160964	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-7.86	-0.4	5.4e-14	Red blood cell count;
LUSC	trans	rs1998174	0.509	rs742510	chr1:171828070	C/T	cg13482142	chr2:234261155	NA	-0.42	-6.12	-0.32	2.66e-9	Platelet distribution width;
LUSC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-1.03	-20.07	-0.74	2.43e-59	Height;
LUSC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-9.18	-0.45	4.77e-18	Gut microbiome composition (summer);
LUSC	cis	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg20368463	chr18:77673604	PQLC1	0.48	6.81	0.35	4.64e-11	Schizophrenia;
LUSC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg14829360	chr17:73884958	NA	-0.36	-5.93	-0.31	7.59e-9	White matter hyperintensity burden;
LUSC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg09650180	chr20:62225654	GMEB2	-0.67	-9.59	-0.46	2.11e-19	Glioblastoma;
LUSC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg08219700	chr8:58056026	NA	0.45	5.78	0.3	1.71e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.14	0.32	2.4e-9	Corneal astigmatism;
LUSC	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg13319975	chr6:146136371	FBXO30	-0.45	-6.68	-0.34	9.95e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg12310025	chr6:25882481	NA	-0.45	-7.82	-0.39	7.19e-14	Blood metabolite levels;
LUSC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg05234568	chr11:5960015	NA	-0.68	-11.36	-0.53	1.72e-25	DNA methylation (variation);
LUSC	cis	rs13006833	0.668	rs291453	chr2:191160196	G/A	cg21644426	chr2:191273491	MFSD6	0.47	6.76	0.35	6.15e-11	Urinary metabolites;
LUSC	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg01851573	chr8:8652454	MFHAS1	0.55	7.74	0.39	1.18e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs2267681	0.544	rs4726838	chr7:139516964	T/C	cg14116596	chr7:139528673	TBXAS1	0.37	6.42	0.33	4.77e-10	Cervical cancer;
LUSC	cis	rs9534288	0.699	rs2146886	chr13:46646711	C/T	cg15192986	chr13:46630673	CPB2	-0.77	-11.48	-0.53	6.23e-26	Blood protein levels;
LUSC	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg02574844	chr11:5959923	NA	-0.42	-5.88	-0.31	1.01e-8	DNA methylation (variation);
LUSC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.47	-0.38	7.29e-13	Retinal vascular caliber;
LUSC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg21724239	chr8:58056113	NA	0.54	6.26	0.32	1.19e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.95	0.51	4.95e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg12292205	chr6:26970375	C6orf41	-0.39	-5.83	-0.3	1.29e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.64	8.35	0.42	1.78e-15	Schizophrenia;
LUSC	cis	rs2219968	0.828	rs13265358	chr8:78930198	T/C	cg00738934	chr8:78996279	NA	-0.42	-7.56	-0.38	4.05e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7712401	0.607	rs246270	chr5:122258649	T/C	cg19077854	chr5:122220652	SNX24	0.42	9.25	0.45	2.81e-18	Mean platelet volume;
LUSC	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg23260525	chr10:116636907	FAM160B1	-0.4	-8.34	-0.42	1.94e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg16339924	chr4:17578868	LAP3	-0.52	-7.66	-0.39	2.03e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg02339015	chr20:62561062	DNAJC5	-0.41	-6.23	-0.32	1.39e-9	N-glycan levels;
LUSC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.86	15.74	0.65	3.91e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs73198271	0.562	rs113730597	chr8:8651573	G/A	cg01851573	chr8:8652454	MFHAS1	0.59	8.03	0.4	1.69e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs983392	0.679	rs7930318	chr11:60033371	C/T	cg02771260	chr11:59836817	MS4A3	0.37	6.11	0.32	2.83e-9	Alzheimer's disease (late onset);
LUSC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-0.83	-13.92	-0.61	4.6e-35	Tonsillectomy;
LUSC	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg02018176	chr4:1364513	KIAA1530	0.46	6.49	0.33	3.12e-10	Recombination rate (females);
LUSC	cis	rs7524258	0.868	rs2412152	chr1:7303213	C/T	cg07173049	chr1:7289937	CAMTA1	0.35	7.2	0.37	3.98e-12	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.14	-0.32	2.36e-9	Life satisfaction;
LUSC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.58	12.08	0.55	3.96e-28	Hemoglobin concentration;
LUSC	cis	rs9359856	0.673	rs1179901	chr6:90321196	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-8.2	-0.41	5.22e-15	Bipolar disorder;
LUSC	cis	rs6690583	0.524	rs6680422	chr1:85451945	C/T	cg22153463	chr1:85462885	MCOLN2	0.63	6.04	0.31	4.1e-9	Serum sulfate level;
LUSC	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.76	-0.3	1.92e-8	Total body bone mineral density;
LUSC	cis	rs5758511	0.731	rs58302269	chr22:42351309	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.29	0.37	2.19e-12	Birth weight;
LUSC	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg25258033	chr6:167368657	RNASET2	-0.36	-5.69	-0.3	2.79e-8	Graves' disease;
LUSC	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.61	-0.43	2.88e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs73198271	0.515	rs76653757	chr8:8624901	C/A	cg01851573	chr8:8652454	MFHAS1	0.62	7.15	0.36	5.52e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg24399712	chr22:39784796	NA	-0.63	-11.44	-0.53	8.66e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg06026331	chr20:60912101	LAMA5	0.59	6.98	0.36	1.55e-11	Colorectal cancer;
LUSC	cis	rs9653442	0.564	rs4850924	chr2:100782273	A/G	cg07810366	chr2:100720526	AFF3	-0.43	-7.26	-0.37	2.68e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4851254	0.660	rs10209201	chr2:100672808	C/T	cg07810366	chr2:100720526	AFF3	-0.45	-6.04	-0.31	4.06e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg08470875	chr2:26401718	FAM59B	0.67	8.65	0.43	2.26e-16	Gut microbiome composition (summer);
LUSC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg22549504	chr19:17448937	GTPBP3	0.56	7.3	0.37	2.1e-12	Systemic lupus erythematosus;
LUSC	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.47	-0.38	7.29e-13	Retinal vascular caliber;
LUSC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21724239	chr8:58056113	NA	0.79	9.43	0.46	7.13e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs926938	0.618	rs1286555	chr1:115361896	C/T	cg12756093	chr1:115239321	AMPD1	-0.5	-7.15	-0.36	5.59e-12	Autism;
LUSC	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg05855489	chr10:104503620	C10orf26	0.69	10.15	0.49	2.93e-21	Arsenic metabolism;
LUSC	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg22709100	chr7:91322751	NA	0.39	5.8	0.3	1.56e-8	Breast cancer;
LUSC	cis	rs548181	0.545	rs4486648	chr11:125610589	T/A	cg03464685	chr11:125439445	EI24	-0.92	-11.03	-0.52	2.57e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg26061582	chr7:22766209	IL6	0.51	7.4	0.38	1.12e-12	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
LUSC	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.97	-0.36	1.74e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg19592336	chr6:28129416	ZNF389	0.46	6.14	0.32	2.37e-9	Depression;
LUSC	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-6.68	-0.34	9.79e-11	Monocyte percentage of white cells;
LUSC	cis	rs77633900	0.772	rs284884	chr15:76828289	A/G	cg21673338	chr15:77095150	SCAPER	-0.67	-5.71	-0.3	2.53e-8	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	9.51	0.46	3.93e-19	Lung cancer in ever smokers;
LUSC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg07741184	chr6:167504864	NA	-0.37	-6.73	-0.35	7.26e-11	Crohn's disease;
LUSC	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg20503657	chr10:835505	NA	0.63	7.93	0.4	3.38e-14	Eosinophil percentage of granulocytes;
LUSC	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg05360949	chr19:41903737	BCKDHA;EXOSC5	0.42	5.75	0.3	1.98e-8	Height;
LUSC	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.89	15.2	0.64	5.05e-40	Bladder cancer;
LUSC	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg22491629	chr6:157744540	C6orf35	-0.91	-10.89	-0.51	7.95e-24	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs886126	0.901	rs10744770	chr12:111662578	G/A	cg10833066	chr12:111807467	FAM109A	0.39	6.1	0.32	2.99e-9	Coronary heart disease;
LUSC	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg21433313	chr16:3507492	NAT15	0.41	6.34	0.33	7.29e-10	Body mass index (adult);
LUSC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.42	-0.38	9.56e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11637445	0.603	rs7183168	chr15:68121483	A/C	cg08079166	chr15:68083412	MAP2K5	0.35	7.33	0.37	1.76e-12	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg10909506	chr17:38081995	ORMDL3	0.33	5.77	0.3	1.86e-8	Self-reported allergy;
LUSC	cis	rs2235649	0.833	rs9929262	chr16:1851928	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.42	-6.02	-0.31	4.48e-9	Blood metabolite levels;
LUSC	trans	rs7939886	0.623	rs77065109	chr11:55906843	G/A	cg15704280	chr7:45808275	SEPT13	0.83	6.68	0.34	9.8e-11	Myopia (pathological);
LUSC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg18135555	chr8:22132992	PIWIL2	-0.38	-7.73	-0.39	1.29e-13	Hypertriglyceridemia;
LUSC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.87	-0.31	1.07e-8	Platelet count;
LUSC	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.77	0.35	5.97e-11	Tonsillectomy;
LUSC	cis	rs2286503	0.809	rs4719716	chr7:22861369	G/A	cg11367502	chr7:22862612	TOMM7	0.46	6.17	0.32	1.96e-9	Fibrinogen;
LUSC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.47	0.42	7.64e-16	Prudent dietary pattern;
LUSC	cis	rs921665	0.831	rs11688404	chr2:3188755	C/T	cg02624386	chr2:3182749	NA	0.51	5.79	0.3	1.6e-8	World class endurance athleticism;
LUSC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg01802117	chr1:53393560	SCP2	-0.38	-6.51	-0.34	2.71e-10	Monocyte count;
LUSC	cis	rs6960043	0.818	rs1558318	chr7:15065612	A/T	cg19272540	chr7:15055459	NA	-0.28	-6.84	-0.35	3.8e-11	Type 2 diabetes;
LUSC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg07952391	chr2:88470173	THNSL2	0.75	6.49	0.33	3.06e-10	Plasma clusterin levels;
LUSC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.54	-9.34	-0.46	1.4e-18	Bipolar disorder;
LUSC	cis	rs12618769	0.597	rs72820002	chr2:99075259	T/A	cg10123293	chr2:99228465	UNC50	0.45	7.65	0.39	2.17e-13	Bipolar disorder;
LUSC	trans	rs9630182	0.561	rs11022810	chr11:13438245	T/C	cg00234616	chr2:74740572	TLX2	0.3	5.96	0.31	6.25e-9	Bone mineral density;
LUSC	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg20307385	chr11:47447363	PSMC3	-0.43	-6.25	-0.32	1.22e-9	Subjective well-being;
LUSC	cis	rs2625529	0.627	rs12898585	chr15:72473928	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-7.54	-0.38	4.44e-13	Red blood cell count;
LUSC	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg10167378	chr1:228756711	NA	0.76	9.78	0.47	5.16e-20	Chronic lymphocytic leukemia;
LUSC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	trans	rs7395662	1.000	rs4929903	chr11:48913332	T/G	cg00717180	chr2:96193071	NA	-0.38	-6.02	-0.31	4.55e-9	HDL cholesterol;
LUSC	trans	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.6	0.38	3.08e-13	Ulcerative colitis;
LUSC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg06784218	chr1:46089804	CCDC17	0.54	10.91	0.51	6.6e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	6.2	0.32	1.65e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.85	14.99	0.63	3.21e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.69	-0.3	2.73e-8	Bipolar disorder;
LUSC	cis	rs2227564	0.597	rs2633305	chr10:75652123	A/G	cg23231163	chr10:75533350	FUT11	-0.42	-5.89	-0.31	9.32e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg09092052	chr15:45571596	NA	0.45	6.3	0.33	9.44e-10	Glomerular filtration rate;
LUSC	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg13939156	chr17:80058883	NA	-0.34	-6.76	-0.35	6.08e-11	Life satisfaction;
LUSC	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.89	15.26	0.64	2.9e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg06784218	chr1:46089804	CCDC17	0.56	11.33	0.53	2.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg12564285	chr5:131593104	PDLIM4	0.47	8.25	0.41	3.63e-15	Breast cancer;
LUSC	cis	rs7264396	0.887	rs224364	chr20:34063865	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.44	-0.33	4.26e-10	Total cholesterol levels;
LUSC	trans	rs1997103	0.822	rs940878	chr7:55419663	A/G	cg20935933	chr6:143382018	AIG1	0.48	6.44	0.33	4.19e-10	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6076065	1.000	rs2424553	chr20:23403939	A/G	cg11657817	chr20:23433608	CST11	0.38	7.12	0.36	6.67e-12	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.32	0.56	5.06e-29	Height;
LUSC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.83	-0.54	3.3699999999999996e-27	Type 2 diabetes;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg08305872	chr2:210867207	RPE	0.43	6.0	0.31	5.12e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-9.6	-0.47	1.91e-19	Longevity;Endometriosis;
LUSC	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-10.3	-0.49	8.92e-22	Mood instability;
LUSC	cis	rs4588572	0.606	rs4290994	chr5:77742253	C/T	cg11547950	chr5:77652471	NA	-0.46	-6.74	-0.35	7.08e-11	Triglycerides;
LUSC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	9.28	0.45	2.17e-18	Total body bone mineral density;
LUSC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg16060761	chr17:80687452	NA	-0.53	-8.03	-0.4	1.63e-14	Glycated hemoglobin levels;
LUSC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26314531	chr2:26401878	FAM59B	0.69	9.49	0.46	4.66e-19	Gut microbiome composition (summer);
LUSC	cis	rs6906287	0.647	rs3951042	chr6:118722495	C/T	cg21191810	chr6:118973309	C6orf204	0.34	6.12	0.32	2.64e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.53	-5.74	-0.3	2.09e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs4853525	0.522	rs6744420	chr2:191589082	A/G	cg11845111	chr2:191398756	TMEM194B	0.43	5.82	0.3	1.39e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22307029	chr19:49891270	CCDC155	0.67	9.53	0.46	3.3e-19	Multiple sclerosis;
LUSC	trans	rs1508086	0.935	rs12676415	chr8:57813418	A/G	cg01310875	chr8:27938995	C8orf80	-0.31	-6.75	-0.35	6.62e-11	Hand grip strength;
LUSC	cis	rs829883	1.000	rs829883	chr12:98879606	G/A	cg25150519	chr12:98850993	NA	0.64	10.02	0.48	7.74e-21	Colorectal adenoma (advanced);
LUSC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg03929089	chr4:120376271	NA	-0.93	-16.15	-0.66	9.42e-44	Height;
LUSC	cis	rs113835537	0.529	rs11227511	chr11:66281244	A/C	cg24851651	chr11:66362959	CCS	0.54	8.12	0.41	8.9e-15	Airway imaging phenotypes;
LUSC	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.45	-0.33	3.95e-10	Uric acid levels;
LUSC	cis	rs11677416	0.961	rs1894399	chr2:113540177	C/T	cg27083787	chr2:113543245	IL1A	0.45	7.16	0.36	5.05e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs870825	0.616	rs4616798	chr4:185634144	C/T	cg04058563	chr4:185651563	MLF1IP	-0.81	-12.68	-0.57	2.49e-30	Blood protein levels;
LUSC	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg08355456	chr11:67383691	NA	0.37	6.88	0.35	2.97e-11	Mean corpuscular volume;
LUSC	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg00310523	chr12:86230176	RASSF9	0.36	6.47	0.33	3.4e-10	Major depressive disorder;
LUSC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.61	-9.59	-0.46	2.2e-19	Cognitive test performance;
LUSC	cis	rs4664308	0.692	rs13009231	chr2:160964057	G/T	cg03641300	chr2:160917029	PLA2R1	-0.62	-10.2	-0.49	1.9e-21	Idiopathic membranous nephropathy;
LUSC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.72	14.09	0.61	1e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg18512352	chr11:47633146	NA	-0.45	-9.03	-0.44	1.44e-17	Subjective well-being;
LUSC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.47	-8.29	-0.41	2.8e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1044826	0.619	rs6439856	chr3:139134868	A/T	cg15131784	chr3:139108705	COPB2	-0.42	-6.95	-0.36	1.89e-11	Obesity-related traits;
LUSC	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg19116668	chr7:99932089	PMS2L1	-0.33	-5.67	-0.3	3.17e-8	Coronary artery disease;
LUSC	cis	rs4664304	0.966	rs7601374	chr2:160754050	T/C	cg03641300	chr2:160917029	PLA2R1	-0.4	-6.48	-0.33	3.26e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg26811252	chr16:29126840	RRN3P2	0.58	9.29	0.45	2.02e-18	Menopause (age at onset);
LUSC	cis	rs7584330	0.554	rs4420668	chr2:238444793	G/A	cg16989719	chr2:238392110	NA	-0.41	-5.88	-0.31	1.01e-8	Prostate cancer;
LUSC	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg22681709	chr2:178499509	PDE11A	-0.56	-11.25	-0.52	3.95e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12210905	0.688	rs12215386	chr6:27406877	G/T	cg08851530	chr6:28072375	NA	0.93	5.77	0.3	1.77e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.51	7.75	0.39	1.09e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9362426	0.708	rs6907825	chr6:88102822	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.11	0.32	2.82e-9	Depressive episodes in bipolar disorder;
LUSC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.36	5.65	0.3	3.41e-8	Platelet count;
LUSC	cis	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05901451	chr6:126070800	HEY2	0.76	12.4	0.56	2.57e-29	Endometrial cancer;
LUSC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.08	-0.36	8.53e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg22875332	chr1:76189707	ACADM	-0.41	-6.18	-0.32	1.89e-9	Daytime sleep phenotypes;
LUSC	cis	rs2932538	0.922	rs12758377	chr1:113137221	C/A	cg22162597	chr1:113214053	CAPZA1	0.7	10.1	0.48	4.1e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.03	0.4	1.66e-14	Axial length;
LUSC	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.61	-0.34	1.57e-10	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs800082	0.799	rs1949954	chr3:144227977	A/C	cg24215973	chr2:240111563	HDAC4	0.4	5.96	0.31	6.41e-9	Smoking behavior;
LUSC	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-8.39	-0.42	1.43e-15	Morning vs. evening chronotype;
LUSC	cis	rs6496044	0.568	rs1982743	chr15:86068759	A/T	cg13263323	chr15:86062960	AKAP13	-0.37	-6.04	-0.31	4.14e-9	Interstitial lung disease;
LUSC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg00343986	chr7:65444356	GUSB	-0.43	-6.55	-0.34	2.17e-10	Aortic root size;
LUSC	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.32	-0.33	8.53e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg07212818	chr11:638076	DRD4	-0.45	-7.46	-0.38	7.78e-13	Systemic lupus erythematosus;
LUSC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg16647868	chr5:131706066	SLC22A5	0.4	6.27	0.32	1.13e-9	Breast cancer;
LUSC	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.56	-0.34	2.11e-10	Menarche (age at onset);
LUSC	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg12826209	chr6:26865740	GUSBL1	0.52	7.51	0.38	5.31e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08677398	chr8:58056175	NA	0.58	7.01	0.36	1.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.48	-0.42	7.37e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg08755490	chr11:65554678	OVOL1	0.4	5.82	0.3	1.4e-8	Acne (severe);
LUSC	cis	rs925255	0.713	rs9309662	chr2:28629892	A/G	cg01273330	chr2:28605224	NA	0.41	6.7	0.34	8.86e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.7	11.0	0.52	3.29e-24	Aortic root size;
LUSC	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-7.13	-0.36	6.36e-12	Triglycerides;
LUSC	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs4343996	0.536	rs10270365	chr7:3417373	C/T	cg21248987	chr7:3385318	SDK1	0.35	5.95	0.31	6.88e-9	Motion sickness;
LUSC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg07636037	chr3:49044803	WDR6	0.46	6.81	0.35	4.56e-11	Resting heart rate;
LUSC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-8.78	-0.43	8.85e-17	Breast cancer;
LUSC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg06618935	chr21:46677482	NA	-0.37	-7.5	-0.38	5.78e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.13	0.55	2.73e-28	Colorectal cancer;
LUSC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.04	-0.31	4.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg16339924	chr4:17578868	LAP3	0.63	9.23	0.45	3.22e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.34	-0.37	1.65e-12	Psoriasis;
LUSC	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.24	0.32	1.32e-9	Corneal astigmatism;
LUSC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg06454157	chr6:167490870	NA	-0.3	-7.03	-0.36	1.19e-11	Crohn's disease;
LUSC	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg22906224	chr7:99728672	NA	-0.47	-6.52	-0.34	2.56e-10	Coronary artery disease;
LUSC	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.93	-0.35	2.15e-11	Bipolar disorder;
LUSC	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	8.72	0.43	1.37e-16	Lung cancer in ever smokers;
LUSC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg13531842	chr10:38383804	ZNF37A	-0.46	-7.19	-0.37	4.37e-12	Extrinsic epigenetic age acceleration;
LUSC	trans	rs61931739	0.649	rs2263218	chr12:33729679	C/G	cg26384229	chr12:38710491	ALG10B	0.42	6.07	0.32	3.54e-9	Morning vs. evening chronotype;
LUSC	cis	rs9653442	0.545	rs12987212	chr2:100761156	C/T	cg22139774	chr2:100720529	AFF3	-0.42	-7.26	-0.37	2.8e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg03146154	chr1:46216737	IPP	0.58	8.69	0.43	1.69e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg17330251	chr7:94953956	PON1	0.39	5.93	0.31	7.37e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02149884	chr3:123680462	CCDC14	-0.49	-7.24	-0.37	3.15e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20787340	chr1:59250966	JUN	0.77	6.2	0.32	1.68e-9	Cognitive performance;
LUSC	trans	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg26384229	chr12:38710491	ALG10B	0.58	9.44	0.46	6.47e-19	Morning vs. evening chronotype;
LUSC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg24642439	chr20:33292090	TP53INP2	0.64	9.96	0.48	1.19e-20	Coronary artery disease;
LUSC	cis	rs9420	0.925	rs10896636	chr11:57448032	C/G	cg23127183	chr11:57508653	C11orf31	-0.59	-9.02	-0.44	1.53e-17	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.62	-9.01	-0.44	1.57e-17	Blood trace element (Cu levels);
LUSC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.02	20.38	0.74	1.44e-60	Cognitive function;
LUSC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg07414643	chr4:187882934	NA	0.51	8.93	0.44	2.98e-17	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.59	-0.34	1.71e-10	Endometrial cancer;
LUSC	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.93	15.74	0.65	3.8e-42	Bladder cancer;
LUSC	trans	rs72834455	0.858	rs72834468	chr2:119518483	G/A	cg02397686	chr17:73851076	WBP2	-0.65	-6.09	-0.32	3.19e-9	Tonsillectomy;
LUSC	cis	rs9837602	0.935	rs9875640	chr3:99729091	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.93	-0.31	7.76e-9	Breast cancer;
LUSC	cis	rs1957429	0.901	rs60979440	chr14:65390231	A/G	cg23373153	chr14:65346875	NA	-1.04	-11.35	-0.53	1.85e-25	Pediatric areal bone mineral density (radius);
LUSC	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg13010199	chr12:38710504	ALG10B	-0.49	-7.33	-0.37	1.74e-12	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9905704	0.709	rs758378	chr17:56607746	G/C	cg19466818	chr17:56409534	MIR142	0.31	6.01	0.31	4.75e-9	Testicular germ cell tumor;
LUSC	cis	rs6906287	0.647	rs3734381	chr6:118887303	A/G	cg21191810	chr6:118973309	C6orf204	0.34	6.21	0.32	1.54e-9	Electrocardiographic conduction measures;
LUSC	trans	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg05926928	chr17:57297772	GDPD1	0.52	7.36	0.37	1.46e-12	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20062097	chr7:45808644	SEPT13	-0.4	-5.96	-0.31	6.5e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.67	-11.82	-0.54	3.73e-27	Lung cancer;
LUSC	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg23840854	chr1:161414152	NA	-0.92	-11.2	-0.52	6.13e-25	Rheumatoid arthritis;
LUSC	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg05283184	chr6:79620031	NA	-0.57	-12.13	-0.55	2.57e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.806	rs7188604	chr16:75451170	T/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.64	-0.34	1.27e-10	Dupuytren's disease;
LUSC	cis	rs4499344	0.623	rs11670818	chr19:33099854	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.96	13.55	0.6	1.2e-33	Mean platelet volume;
LUSC	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.58e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg14844989	chr11:31128820	NA	-0.37	-5.79	-0.3	1.67e-8	Red blood cell count;
LUSC	trans	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.49	-6.21	-0.32	1.59e-9	Multiple sclerosis;
LUSC	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg22153745	chr1:153894579	GATAD2B	-0.55	-8.54	-0.42	4.68e-16	Total cholesterol levels;
LUSC	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.85	-0.44	5.09e-17	Response to antipsychotic treatment;
LUSC	cis	rs9815354	1.000	rs2272006	chr3:41997059	C/T	cg03022575	chr3:42003672	ULK4	-0.51	-5.79	-0.3	1.65e-8	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs79527984	0.742	rs1949395	chr7:71836708	T/A	cg12001078	chr4:100790361	DAPP1	0.33	6.1	0.32	2.9e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs981844	0.712	rs4292309	chr4:154745178	C/A	cg14289246	chr4:154710475	SFRP2	-0.44	-6.05	-0.31	3.86e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg18479299	chr3:125709523	NA	-0.51	-5.87	-0.31	1.05e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg01879757	chr17:41196368	BRCA1	-0.47	-7.16	-0.36	5.11e-12	Menopause (age at onset);
LUSC	cis	rs877282	0.898	rs12358513	chr10:757571	A/G	cg17470449	chr10:769945	NA	0.52	6.97	0.36	1.72e-11	Uric acid levels;
LUSC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg13628971	chr7:2884303	GNA12	0.49	6.93	0.35	2.17e-11	Height;
LUSC	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg04989706	chr14:50066350	PPIL5	-0.46	-6.09	-0.32	3.17e-9	Carotid intima media thickness;
LUSC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg08847533	chr14:75593920	NEK9	-0.78	-13.52	-0.59	1.59e-33	Height;
LUSC	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg07173049	chr1:7289937	CAMTA1	0.32	6.55	0.34	2.22e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-9.1	-0.45	8.27e-18	Eye color traits;
LUSC	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg12091567	chr17:66097778	LOC651250	-0.76	-9.6	-0.46	2e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs4631830	0.900	rs7920517	chr10:51532621	G/A	cg10326726	chr10:51549505	MSMB	-0.37	-6.39	-0.33	5.56e-10	Prostate-specific antigen levels;
LUSC	cis	rs27434	0.583	rs26653	chr5:96139250	C/G	cg16492584	chr5:96139282	ERAP1	-0.56	-7.8	-0.39	7.82e-14	Ankylosing spondylitis;
LUSC	cis	rs9427116	0.702	rs9427109	chr1:154609009	A/G	cg17218026	chr1:154582156	ADAR	0.56	9.92	0.48	1.69e-20	Blood protein levels;
LUSC	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.98	-0.36	1.58e-11	Menopause (age at onset);
LUSC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg05738196	chr6:26577821	NA	-0.59	-6.85	-0.35	3.53e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg20607798	chr8:58055168	NA	0.51	5.98	0.31	5.58e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.3e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9399401	0.710	rs7765770	chr6:142687305	C/T	cg04461802	chr6:142623433	GPR126	0.48	5.96	0.31	6.25e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg17340268	chr14:105411764	AHNAK2	-0.39	-6.2	-0.32	1.62e-9	Rheumatoid arthritis;
LUSC	trans	rs1325195	0.881	rs2066279	chr1:179172856	T/A	cg11624085	chr17:8464688	MYH10	0.41	6.64	0.34	1.29e-10	IgE grass sensitization;
LUSC	cis	rs870825	0.860	rs72703526	chr4:185605676	A/T	cg04058563	chr4:185651563	MLF1IP	0.77	10.15	0.49	2.77e-21	Blood protein levels;
LUSC	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg07828340	chr4:882639	GAK	1.09	11.58	0.54	2.65e-26	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg25214090	chr10:38739885	LOC399744	0.6	8.84	0.44	5.75e-17	Corneal astigmatism;
LUSC	cis	rs7833787	1.000	rs17468166	chr8:18705047	C/T	cg17701159	chr8:18705777	PSD3	-0.39	-6.42	-0.33	4.71e-10	Obesity-related traits;
LUSC	cis	rs380904	0.517	rs11775744	chr8:144649192	A/G	cg13399544	chr8:144649678	C8orf73	-0.43	-6.72	-0.35	7.9e-11	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.84	-20.22	-0.74	6.49e-60	Itch intensity from mosquito bite adjusted by bite size;
LUSC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg03929089	chr4:120376271	NA	-0.65	-9.46	-0.46	5.78e-19	Coronary artery disease;
LUSC	cis	rs11051970	0.636	rs188978	chr12:32570627	T/C	cg02745156	chr12:32552066	NA	0.4	7.11	0.36	7.3e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2963155	0.518	rs2963151	chr5:142734151	T/C	cg17617527	chr5:142782415	NR3C1	0.68	8.42	0.42	1.14e-15	Breast cancer;
LUSC	cis	rs926938	0.584	rs1286561	chr1:115375428	T/C	cg12756093	chr1:115239321	AMPD1	-0.53	-7.97	-0.4	2.59e-14	Autism;
LUSC	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg16989719	chr2:238392110	NA	-0.42	-7.23	-0.37	3.27e-12	Prostate cancer;
LUSC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18404041	chr3:52824283	ITIH1	-0.62	-11.94	-0.55	1.32e-27	Bipolar disorder;
LUSC	trans	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.7	0.47	8.99e-20	Mean corpuscular volume;
LUSC	cis	rs983392	0.709	rs11826180	chr11:59991333	T/C	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.08	-0.32	3.22e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-9.58	-0.46	2.38e-19	Gut microbiome composition (summer);
LUSC	cis	rs240993	0.595	rs4947127	chr6:111902798	T/G	cg22127309	chr6:111907043	TRAF3IP2	0.34	6.12	0.32	2.69e-9	Inflammatory skin disease;Psoriasis;
LUSC	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.92	12.04	0.55	5.76e-28	Exhaled nitric oxide output;
LUSC	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.77	10.81	0.51	1.49e-23	Corneal astigmatism;
LUSC	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	11.07	0.52	1.84e-24	Height;
LUSC	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg08601574	chr20:25228251	PYGB	0.49	7.55	0.38	4.12e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg26061582	chr7:22766209	IL6	0.52	7.48	0.38	6.8e-13	Lung cancer;
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg06877462	chr1:205807181	PM20D1	0.53	10.13	0.48	3.36e-21	Menarche (age at onset);
LUSC	trans	rs9987353	0.830	rs4841117	chr8:9130132	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.21	-0.32	1.61e-9	Recombination measurement;
LUSC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg06494592	chr3:125709126	NA	-0.53	-5.92	-0.31	8.19e-9	Blood pressure (smoking interaction);
LUSC	trans	rs1941687	0.831	rs12957087	chr18:31328519	C/T	cg27147174	chr7:100797783	AP1S1	-0.46	-6.82	-0.35	4.38e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg27129171	chr3:47204927	SETD2	0.56	8.99	0.44	1.91e-17	Colorectal cancer;
LUSC	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg26876637	chr1:152193138	HRNR	-0.45	-6.34	-0.33	7.32e-10	Atopic dermatitis;
LUSC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	0.79	13.99	0.61	2.56e-35	Cognitive function;
LUSC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg12560992	chr17:57184187	TRIM37	0.85	15.41	0.64	7.59e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	1.93e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26384229	chr12:38710491	ALG10B	-0.86	-14.5	-0.62	2.66e-37	Morning vs. evening chronotype;
LUSC	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg08213375	chr14:104286397	PPP1R13B	0.44	7.58	0.38	3.4e-13	Reticulocyte count;
LUSC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.18	-0.72	8.14e-56	Height;
LUSC	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg00376283	chr12:123451042	ABCB9	-0.66	-8.36	-0.42	1.74e-15	Neutrophil percentage of white cells;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00557709	chr1:82268801	LPHN2	-0.44	-6.34	-0.33	7.51e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.56	10.98	0.52	3.71e-24	Asthma (sex interaction);
LUSC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.47	-7.99	-0.4	2.25e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.65	-0.34	1.21e-10	Lung cancer;
LUSC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg23711669	chr6:146136114	FBXO30	0.88	16.44	0.67	6.52e-45	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2455601	0.638	rs3815991	chr11:9007669	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.45	6.45	0.33	3.83e-10	Schizophrenia;
LUSC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-6.87	-0.35	3.15e-11	Aortic root size;
LUSC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18357526	chr6:26021779	HIST1H4A	0.4	6.22	0.32	1.47e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6815814	0.861	rs10034903	chr4:38784678	C/G	cg06935464	chr4:38784597	TLR10	0.46	5.94	0.31	7.29e-9	Breast cancer;
LUSC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg13902645	chr11:5959945	NA	-0.63	-10.31	-0.49	8.35e-22	DNA methylation (variation);
LUSC	cis	rs17014483	1.000	rs3017903	chr4:89657776	A/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.68	5.76	0.3	1.93e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg06640241	chr16:89574553	SPG7	0.75	12.27	0.56	7.99e-29	Multiple myeloma (IgH translocation);
LUSC	cis	rs295140	0.605	rs3739119	chr2:201194279	C/A	cg04283868	chr2:201171347	SPATS2L	0.41	6.03	0.31	4.41e-9	QT interval;
LUSC	cis	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg21775007	chr8:11205619	TDH	-0.47	-6.35	-0.33	7.06e-10	Triglycerides;
LUSC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	6.45	0.33	3.97e-10	Schizophrenia;
LUSC	cis	rs116139393	0.540	rs12539942	chr7:6776585	C/T	cg09896999	chr7:6746977	ZNF12	-0.47	-6.86	-0.35	3.43e-11	Alzheimer's disease (APOE e4 interaction);
LUSC	trans	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg18335740	chr13:41363409	SLC25A15	0.6	8.87	0.44	4.43e-17	Lewy body disease;
LUSC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg00945038	chr17:61921165	SMARCD2	0.37	5.66	0.3	3.21e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg20243544	chr17:37824526	PNMT	0.46	5.66	0.3	3.19e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	1e-64	Prudent dietary pattern;
LUSC	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg19789473	chr17:27170043	C17orf63	0.3	5.72	0.3	2.39e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7651511	0.674	rs11916906	chr3:141314133	A/T	cg00789793	chr3:141329863	RASA2	0.38	5.74	0.3	2.1e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg16506815	chr2:162101123	NA	0.42	6.28	0.32	1.06e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg04374321	chr14:90722782	PSMC1	0.76	12.11	0.55	3.19e-28	Mortality in heart failure;
LUSC	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg14154082	chr13:112174009	NA	0.37	7.7	0.39	1.6e-13	Menarche (age at onset);
LUSC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07343612	chr16:622815	PIGQ	-0.77	-13.11	-0.58	5.63e-32	Height;
LUSC	cis	rs34779708	0.766	rs7913451	chr10:35551525	T/C	cg03585969	chr10:35415529	CREM	0.51	6.99	0.36	1.54e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg04287289	chr16:89883240	FANCA	0.51	7.71	0.39	1.5e-13	Vitiligo;
LUSC	trans	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg10756647	chr7:56101905	PSPH	-0.84	-8.42	-0.42	1.14e-15	Diabetic kidney disease;
LUSC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.63	-14.45	-0.62	4.29e-37	Prostate cancer;
LUSC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.66	8.52	0.42	5.43e-16	Schizophrenia;
LUSC	trans	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.85	-0.39	5.57e-14	Morning vs. evening chronotype;
LUSC	cis	rs3829109	0.534	rs563	chr9:139296485	C/T	cg14019695	chr9:139328340	INPP5E	-0.37	-5.86	-0.31	1.11e-8	Peak insulin response;Acute insulin response;
LUSC	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg11019008	chr10:131425282	MGMT	0.45	6.8	0.35	4.85e-11	Response to temozolomide;
LUSC	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg04492858	chr10:133558786	NA	0.38	6.29	0.33	9.82e-10	Survival in rectal cancer;
LUSC	cis	rs7605827	0.930	rs6710456	chr2:15669939	C/T	cg19274914	chr2:15703543	NA	-0.45	-8.57	-0.42	3.82e-16	Educational attainment (years of education);
LUSC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg06008330	chr7:65541103	ASL	-0.36	-5.71	-0.3	2.54e-8	Aortic root size;
LUSC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg24675658	chr1:53192096	ZYG11B	-0.6	-9.92	-0.48	1.75e-20	Monocyte count;
LUSC	cis	rs6487679	1.000	rs10734765	chr12:9369385	G/A	cg00504896	chr12:9437009	LOC642846	-0.44	-5.77	-0.3	1.85e-8	Non-alcoholic fatty liver disease histology (AST);
LUSC	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-0.51	-7.8	-0.39	7.79e-14	Breast cancer;
LUSC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.28e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs193541	0.617	rs2045628	chr5:122095154	C/T	cg19077854	chr5:122220652	SNX24	0.39	7.91	0.4	3.85e-14	Glucose homeostasis traits;
LUSC	cis	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg08000102	chr2:233561755	GIGYF2	0.72	12.67	0.57	2.71e-30	Schizophrenia;
LUSC	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg13010199	chr12:38710504	ALG10B	0.56	8.57	0.42	3.99e-16	Morning vs. evening chronotype;
LUSC	cis	rs926938	0.527	rs360678	chr1:115493902	T/A	cg12756093	chr1:115239321	AMPD1	0.46	7.01	0.36	1.33e-11	Autism;
LUSC	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg19682013	chr15:45996608	NA	-0.4	-6.1	-0.32	2.95e-9	Waist circumference;Weight;
LUSC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.45	7.95	0.4	2.82e-14	Obesity-related traits;
LUSC	cis	rs9378357	0.702	rs4385351	chr6:3280591	A/C	cg08754725	chr6:3293098	SLC22A23	0.52	5.79	0.3	1.66e-8	Obesity-related traits;
LUSC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg27170947	chr2:26402098	FAM59B	-0.7	-10.69	-0.5	3.92e-23	Gut microbiome composition (summer);
LUSC	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.76	14.85	0.63	1.13e-38	Obesity-related traits;
LUSC	cis	rs73206853	0.841	rs73206894	chr12:110876328	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg18479299	chr3:125709523	NA	-0.51	-5.77	-0.3	1.76e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1358748	0.555	rs2815340	chr1:67533623	G/C	cg02640540	chr1:67518911	SLC35D1	0.66	6.69	0.34	9.24e-11	Tuberculosis;
LUSC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg08088566	chr11:430123	ANO9	0.6	6.76	0.35	6.23e-11	Body mass index;
LUSC	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.67	10.78	0.51	1.95e-23	Body mass index (adult);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg14310890	chr6:108881016	FOXO3	0.52	6.38	0.33	5.85e-10	Cognitive function;Information processing speed;
LUSC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	0.61	12.44	0.56	1.96e-29	Prudent dietary pattern;
LUSC	cis	rs11031096	0.711	rs61899755	chr11:4201317	G/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.77	-0.3	1.85e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.43	-0.33	4.4e-10	Electroencephalogram traits;
LUSC	cis	rs6785206	0.772	rs2811493	chr3:128357299	C/G	cg16766828	chr3:128327626	NA	-0.71	-7.69	-0.39	1.68e-13	Lymphocyte percentage of white cells;
LUSC	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg12386194	chr3:101231763	SENP7	-0.64	-8.59	-0.43	3.46e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10416265	0.528	rs10420258	chr19:33602757	C/T	cg17764715	chr19:33622953	WDR88	0.54	5.86	0.31	1.09e-8	Bone properties (heel);
LUSC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg21951975	chr1:209979733	IRF6	0.54	7.86	0.39	5.45e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs7582720	0.836	rs72938315	chr2:204121063	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	8.04	0.4	1.62e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-5.91	-0.31	8.47e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23158103	chr7:148848205	ZNF398	-0.46	-7.62	-0.38	2.72e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg23950597	chr19:37808831	NA	-0.64	-6.97	-0.36	1.65e-11	Coronary artery calcification;
LUSC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg22907277	chr7:1156413	C7orf50	0.72	7.57	0.38	3.61e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg11050988	chr7:1952600	MAD1L1	-0.32	-6.04	-0.31	4.14e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs72674100	0.881	rs10016957	chr4:97989074	T/C	cg16405019	chr1:18959625	PAX7	-0.61	-6.44	-0.33	4.04e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	6.47	0.33	3.56e-10	Schizophrenia;
LUSC	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg25566285	chr7:158114605	PTPRN2	0.36	6.69	0.34	9.34e-11	Calcium levels;
LUSC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.82	-0.35	4.29e-11	Total body bone mineral density;
LUSC	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg05714579	chr10:131428358	MGMT	0.52	7.9	0.4	4e-14	Response to temozolomide;
LUSC	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg24634471	chr8:143751801	JRK	0.51	7.34	0.37	1.59e-12	Schizophrenia;
LUSC	cis	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg09650180	chr20:62225654	GMEB2	-0.46	-5.97	-0.31	6.1e-9	Atopic dermatitis;
LUSC	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.67	-10.45	-0.5	2.64e-22	Morning vs. evening chronotype;
LUSC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.82	13.83	0.6	1.02e-34	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11039100	0.920	rs11038963	chr11:5781361	A/G	cg13902645	chr11:5959945	NA	-0.55	-6.06	-0.31	3.7e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.93	19.36	0.73	1.53e-56	Monocyte count;
LUSC	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg08999081	chr20:33150536	PIGU	0.45	8.29	0.41	2.78e-15	Coronary artery disease;
LUSC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg07507251	chr3:52567010	NT5DC2	0.35	6.94	0.35	2.1e-11	Bipolar disorder;
LUSC	cis	rs2073300	1.000	rs112057098	chr20:23448901	C/T	cg09953122	chr20:23471693	CST8	-0.72	-6.6	-0.34	1.62e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg23283495	chr1:209979779	IRF6	0.63	9.24	0.45	3e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.37	5.85	0.3	1.16e-8	Total body bone mineral density;
LUSC	cis	rs7215564	0.908	rs55886624	chr17:78658657	G/A	cg09596252	chr17:78655493	RPTOR	0.55	6.04	0.31	4.18e-9	Myopia (pathological);
LUSC	cis	rs8141797	0.685	rs732811	chr22:24587818	T/C	cg00411358	chr22:24577142	SUSD2	-0.58	-6.1	-0.32	3.02e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.17	-0.45	5.08e-18	Platelet count;
LUSC	cis	rs2179367	0.600	rs58747890	chr6:149780505	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.37	-6.13	-0.32	2.53e-9	Dupuytren's disease;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg24542852	chr12:569111	B4GALNT3	0.42	6.04	0.31	4.22e-9	Mosquito bite size;
LUSC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg10253484	chr15:75165896	SCAMP2	-0.43	-6.09	-0.32	3.17e-9	Caffeine consumption;
LUSC	cis	rs243505	1.000	rs1019059	chr7:148424247	A/G	cg09806900	chr7:148480153	CUL1	-0.48	-6.84	-0.35	3.81e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg00376283	chr12:123451042	ABCB9	0.65	8.22	0.41	4.63e-15	Neutrophil percentage of white cells;
LUSC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg07936489	chr17:37558343	FBXL20	0.7	9.69	0.47	1.02e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	6.28	0.33	1.03e-9	Personality dimensions;
LUSC	cis	rs9517320	0.967	rs7997785	chr13:99127985	T/A	cg20487152	chr13:99095054	FARP1	0.35	6.44	0.33	4.08e-10	Longevity;
LUSC	cis	rs4423214	0.840	rs1790328	chr11:71148038	G/A	cg05163923	chr11:71159392	DHCR7	-0.7	-9.2	-0.45	4.07e-18	Vitamin D levels;
LUSC	cis	rs4253772	0.872	rs11704508	chr22:46638540	A/G	cg18190219	chr22:46762943	CELSR1	-0.52	-6.02	-0.31	4.71e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9314323	0.767	rs7012604	chr8:26204089	G/A	cg11498726	chr8:26250323	BNIP3L	-0.42	-5.88	-0.31	1.02e-8	Red cell distribution width;
LUSC	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg26850624	chr5:429559	AHRR	-0.37	-7.03	-0.36	1.19e-11	Cystic fibrosis severity;
LUSC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg07741184	chr6:167504864	NA	0.38	6.76	0.35	6.07e-11	Primary biliary cholangitis;
LUSC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg17252645	chr8:143867129	LY6D	-0.53	-10.25	-0.49	1.3e-21	Urinary tract infection frequency;
LUSC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg21724239	chr8:58056113	NA	0.59	7.2	0.37	3.98e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-6.03	-0.31	4.31e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg03522245	chr20:25566470	NINL	-0.36	-5.83	-0.3	1.33e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg17764715	chr19:33622953	WDR88	-0.6	-8.66	-0.43	2.11e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg11189052	chr15:85197271	WDR73	0.47	5.76	0.3	1.94e-8	Schizophrenia;
LUSC	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg18240062	chr17:79603768	NPLOC4	-0.78	-15.34	-0.64	1.45e-40	Eye color traits;
LUSC	cis	rs11648785	0.590	rs4324129	chr16:90099061	C/T	cg16611967	chr16:90144006	NA	0.4	5.69	0.3	2.82e-8	Tanning;
LUSC	cis	rs12210905	0.688	rs72843191	chr6:27383301	G/C	cg08851530	chr6:28072375	NA	0.95	5.85	0.3	1.2e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08677398	chr8:58056175	NA	0.52	6.29	0.33	9.86e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4954585	0.683	rs10221893	chr2:137013606	C/T	cg05194412	chr2:137003533	NA	0.41	7.57	0.38	3.79e-13	Colorectal cancer;
LUSC	cis	rs4363385	0.597	rs6679201	chr1:152976840	C/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.82	-0.39	6.89e-14	Inflammatory skin disease;
LUSC	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg00376283	chr12:123451042	ABCB9	0.7	7.93	0.4	3.22e-14	Neutrophil percentage of white cells;
LUSC	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-6.74	-0.35	6.84e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.09	-17.73	-0.7	4.82e-50	Primary sclerosing cholangitis;
LUSC	cis	rs7580658	0.864	rs1566823	chr2:128018192	A/G	cg09760422	chr2:128146352	NA	-0.28	-5.89	-0.31	9.32e-9	Protein C levels;
LUSC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg11663144	chr21:46675770	NA	-0.41	-7.22	-0.37	3.46e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9359856	0.517	rs11962350	chr6:90592406	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.88	-8.37	-0.42	1.58e-15	Bipolar disorder;
LUSC	trans	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-9.57	-0.46	2.41e-19	Morning vs. evening chronotype;
LUSC	cis	rs7520050	0.902	rs7514192	chr1:46248977	A/G	cg24296786	chr1:45957014	TESK2	0.42	5.88	0.31	9.75e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1018836	0.544	rs2339154	chr8:91459316	T/C	cg16814680	chr8:91681699	NA	-0.48	-6.91	-0.35	2.51e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.93	15.77	0.65	2.91e-42	Bladder cancer;
LUSC	cis	rs9517302	0.847	rs9517300	chr13:99095057	T/C	cg22223119	chr13:99095684	FARP1	-0.77	-11.92	-0.55	1.51e-27	Obesity-related traits;
LUSC	cis	rs2302729	0.625	rs10848693	chr12:2833013	A/T	cg19945202	chr12:2788847	CACNA1C	0.39	5.66	0.3	3.28e-8	Sleep quality;
LUSC	cis	rs2273669	0.504	rs77608624	chr6:109442854	A/G	cg05315195	chr6:109294784	ARMC2	-0.55	-5.85	-0.3	1.18e-8	Prostate cancer;
LUSC	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg10857441	chr5:6722123	POLS	-0.45	-8.05	-0.4	1.51e-14	Menopause (age at onset);
LUSC	trans	rs13300663	0.626	rs7865442	chr9:4772328	C/G	cg09381805	chr19:42932508	LIPE	0.42	5.94	0.31	7.04e-9	Platelet count;
LUSC	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg17467752	chr17:38218738	THRA	0.41	5.69	0.3	2.73e-8	Myeloid white cell count;
LUSC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	1.05	20.2	0.74	7.77e-60	Menopause (age at onset);
LUSC	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.05	-22.83	-0.78	3.76e-70	Ulcerative colitis;
LUSC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	6.17	0.32	1.93e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	10.39	0.49	4.38e-22	Lymphocyte counts;
LUSC	cis	rs8030485	0.756	rs1521624	chr15:79412399	C/A	cg17916960	chr15:79447300	NA	0.35	6.43	0.33	4.41e-10	Left ventricle wall thickness;
LUSC	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.47	-6.9	-0.35	2.66e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6076065	0.707	rs1419007	chr20:23336895	T/C	cg11657817	chr20:23433608	CST11	0.55	11.08	0.52	1.7e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg16797656	chr11:68205561	LRP5	-0.42	-7.81	-0.39	7.67e-14	Total body bone mineral density;
LUSC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	6.16	0.32	2.14e-9	Tonsillectomy;
LUSC	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg17385448	chr1:15911702	AGMAT	0.36	6.12	0.32	2.57e-9	Systolic blood pressure;
LUSC	cis	rs2224391	0.628	rs2753245	chr6:5258092	G/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.49	-6.03	-0.31	4.42e-9	Height;
LUSC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg19230755	chr7:65878503	NA	0.44	5.87	0.31	1.03e-8	Aortic root size;
LUSC	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg09365446	chr1:150670422	GOLPH3L	-0.44	-6.37	-0.33	6.43e-10	Tonsillectomy;
LUSC	trans	rs208520	0.586	rs208442	chr6:66900618	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.8	-11.46	-0.53	7.4e-26	Exhaled nitric oxide output;
LUSC	cis	rs7712401	0.601	rs442427	chr5:122322265	T/C	cg19077854	chr5:122220652	SNX24	-0.43	-9.48	-0.46	4.83e-19	Mean platelet volume;
LUSC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	14.42	0.62	5.36e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11822910	0.871	rs2581928	chr11:57202790	A/G	cg00522883	chr11:57194120	SLC43A3	-0.42	-6.47	-0.33	3.52e-10	Platelet distribution width;
LUSC	cis	rs4654899	0.833	rs10127757	chr1:21490045	A/G	cg01072550	chr1:21505969	NA	-0.53	-7.9	-0.4	4.08e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg17143192	chr8:8559678	CLDN23	0.39	5.81	0.3	1.46e-8	Mood instability;
LUSC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg11062466	chr8:58055876	NA	0.75	9.1	0.45	8.12e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-11.84	-0.54	3.05e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18404041	chr3:52824283	ITIH1	-0.56	-10.62	-0.5	6.62e-23	Bipolar disorder;
LUSC	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	15.33	0.64	1.55e-40	Lung cancer in ever smokers;
LUSC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg04287289	chr16:89883240	FANCA	0.79	13.78	0.6	1.64e-34	Vitiligo;
LUSC	trans	rs72674100	1.000	rs1987173	chr4:97973574	G/C	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs62400317	0.859	rs17209741	chr6:45292438	A/T	cg20913747	chr6:44695427	NA	-0.45	-7.36	-0.37	1.48e-12	Total body bone mineral density;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05141026	chr8:145064874	GRINA	-0.49	-6.66	-0.34	1.16e-10	Hepatitis;
LUSC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg05861140	chr6:150128134	PCMT1	-0.4	-6.31	-0.33	9.11e-10	Lung cancer;
LUSC	trans	rs7556950	0.572	rs7566733	chr2:41942989	C/T	cg13792581	chr20:43590115	TOMM34	-0.82	-6.62	-0.34	1.46e-10	Major depression and alcohol dependence;
LUSC	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.07	14.17	0.61	5.24e-36	Uric acid levels;
LUSC	cis	rs710216	0.797	rs841854	chr1:43400485	C/T	cg22176566	chr1:43424700	SLC2A1	0.49	6.02	0.31	4.67e-9	Red cell distribution width;
LUSC	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg01528321	chr10:82214614	TSPAN14	0.95	14.55	0.62	1.68e-37	Post bronchodilator FEV1;
LUSC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.35e-30	Motion sickness;
LUSC	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-9.74	-0.47	6.68e-20	Migraine;Coronary artery disease;
LUSC	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg27446573	chr6:127587934	RNF146	0.72	10.98	0.51	3.87e-24	Breast cancer;
LUSC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg10360139	chr7:1886902	MAD1L1	-0.44	-6.82	-0.35	4.21e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg16447950	chr5:562315	NA	-0.55	-7.1	-0.36	7.78e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6977660	0.714	rs10232870	chr7:19818040	A/G	cg07541023	chr7:19748670	TWISTNB	0.6	6.51	0.34	2.7e-10	Thyroid stimulating hormone;
LUSC	cis	rs12541635	0.934	rs57715289	chr8:106967124	A/T	cg10147462	chr8:107024639	NA	0.55	9.54	0.46	3.08e-19	Age of smoking initiation;
LUSC	cis	rs17818399	0.502	rs1451152	chr2:46800150	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-7.81	-0.39	7.46e-14	Height;
LUSC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.45	-7.68	-0.39	1.83e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4604732	0.588	rs6677477	chr1:247629411	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.78	0.35	5.42e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs13315871	0.929	rs76226186	chr3:58318499	C/T	cg12435725	chr3:58293450	RPP14	-0.74	-7.16	-0.36	5.15e-12	Cholesterol, total;
LUSC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg24562669	chr7:97807699	LMTK2	0.33	5.75	0.3	1.99e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg19784903	chr17:45786737	TBKBP1	-0.42	-6.04	-0.31	4.05e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1595825	0.732	rs4589750	chr2:198426003	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.2	-0.32	1.69e-9	Ulcerative colitis;
LUSC	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	1.17	17.75	0.7	4.18e-50	Corneal structure;
LUSC	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-10.37	-0.49	4.97e-22	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs4343996	0.967	rs34735349	chr7:3344115	C/G	cg21248987	chr7:3385318	SDK1	0.4	6.88	0.35	3.04e-11	Motion sickness;
LUSC	cis	rs7705502	0.962	rs56245789	chr5:173365310	T/C	cg18693985	chr5:173351052	CPEB4	-0.37	-5.83	-0.3	1.3e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs897984	0.721	rs2305884	chr16:30970741	G/A	cg02466173	chr16:30829666	NA	0.56	11.1	0.52	1.39e-24	Dementia with Lewy bodies;
LUSC	cis	rs9399401	1.000	rs9399401	chr6:142668901	T/C	cg03128060	chr6:142623767	GPR126	0.32	5.9	0.31	8.7e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg03233332	chr7:66118400	NA	-0.42	-6.08	-0.32	3.3e-9	Aortic root size;
LUSC	cis	rs886126	0.684	rs3858704	chr12:111705893	A/G	cg10833066	chr12:111807467	FAM109A	0.49	8.41	0.42	1.21e-15	Coronary heart disease;
LUSC	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg23283495	chr1:209979779	IRF6	0.64	7.61	0.38	2.91e-13	Coronary artery disease;
LUSC	trans	rs4729127	1.000	rs60238694	chr7:94008118	C/T	cg14660007	chr13:78271894	SLAIN1	0.5	6.45	0.33	3.88e-10	Intelligence;
LUSC	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg05373962	chr22:49881684	NA	-0.44	-10.6	-0.5	7.78e-23	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6489882	0.867	rs6489867	chr12:113363550	C/T	cg20102336	chr12:113376681	OAS3	-0.43	-6.21	-0.32	1.62e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.9e-20	Migraine;Coronary artery disease;
LUSC	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg24692254	chr21:30365293	RNF160	0.78	13.63	0.6	6.17e-34	Dental caries;
LUSC	cis	rs9314323	1.000	rs9314323	chr8:26243136	A/G	cg11498726	chr8:26250323	BNIP3L	-0.47	-6.94	-0.35	2.06e-11	Red cell distribution width;
LUSC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.98	0.58	1.83e-31	Prudent dietary pattern;
LUSC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg02423579	chr7:2872169	GNA12	-0.48	-7.14	-0.36	6e-12	Height;
LUSC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	0.59	9.36	0.46	1.22e-18	Breast cancer;
LUSC	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.71	0.39	1.41e-13	Lung cancer in ever smokers;
LUSC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	9.12	0.45	7.4e-18	Menopause (age at onset);
LUSC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.37	-0.42	1.6e-15	Height;
LUSC	cis	rs80282103	0.764	rs10047382	chr10:1102868	T/C	cg08668510	chr10:1095578	IDI1	0.67	5.91	0.31	8.35e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs7072216	0.881	rs10883084	chr10:100151189	T/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-5.64	-0.3	3.57e-8	Metabolite levels;
LUSC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7520050	0.966	rs1707336	chr1:46493460	T/G	cg06784218	chr1:46089804	CCDC17	-0.29	-5.64	-0.3	3.56e-8	Red blood cell count;Reticulocyte count;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20069020	chr7:108166782	PNPLA8	-0.45	-6.74	-0.35	6.97e-11	Electrocardiographic conduction measures;
LUSC	cis	rs12959570	1	rs12959570	chr18:54333584	G/A	cg00152799	chr18:54306261	TXNL1	0.36	5.89	0.31	9.43e-9	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg01884057	chr2:25150051	NA	-0.38	-8.57	-0.42	4.02e-16	Body mass index in non-asthmatics;
LUSC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.28	0.32	1.08e-9	Height;
LUSC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00376283	chr12:123451042	ABCB9	0.68	8.54	0.42	4.8e-16	Neutrophil percentage of white cells;
LUSC	cis	rs1395	0.778	rs6709602	chr2:27405497	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.2	0.37	4.12e-12	Blood metabolite levels;
LUSC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.72	-12.08	-0.55	4.14e-28	Motion sickness;
LUSC	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-19.94	-0.74	8.05e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.31	-5.87	-0.31	1.02e-8	Total body bone mineral density;
LUSC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	0.95	19.19	0.72	7.57e-56	Cognitive function;
LUSC	cis	rs7615316	0.934	rs6782400	chr3:142295368	C/A	cg16271453	chr3:142027066	XRN1	-0.36	-6.19	-0.32	1.8e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6722750	0.846	rs34923691	chr2:64395183	C/T	cg22352474	chr2:64371530	PELI1	0.65	10.33	0.49	6.92e-22	Neuroticism;
LUSC	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg12826209	chr6:26865740	GUSBL1	0.67	7.49	0.38	6.06e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg13397359	chr6:42928475	GNMT	0.58	9.53	0.46	3.4e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg24375607	chr4:120327624	NA	-0.52	-8.16	-0.41	6.8e-15	Diastolic blood pressure;
LUSC	cis	rs7605827	0.930	rs6719652	chr2:15571679	T/G	cg19274914	chr2:15703543	NA	0.46	8.61	0.43	2.84e-16	Educational attainment (years of education);
LUSC	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg20848291	chr7:100343083	ZAN	-0.68	-9.4	-0.46	9.08e-19	Other erythrocyte phenotypes;
LUSC	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg09184832	chr6:79620586	NA	-0.44	-7.24	-0.37	3.16e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs708547	0.647	rs12621	chr4:57897570	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.4	-5.74	-0.3	2.08e-8	Response to bleomycin (chromatid breaks);
LUSC	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg03929089	chr4:120376271	NA	-0.84	-11.51	-0.53	4.83e-26	Coronary artery disease;
LUSC	cis	rs4072705	1.000	rs4836991	chr9:127512040	A/G	cg13476313	chr9:127244764	NR5A1	-0.31	-5.99	-0.31	5.42e-9	Menarche (age at onset);
LUSC	cis	rs9309473	1.000	rs6755217	chr2:73641285	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-7.12	-0.36	6.54e-12	Metabolite levels;
LUSC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg10356904	chr22:49881777	NA	-0.32	-7.3	-0.37	2.15e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg05347473	chr6:146136440	FBXO30	0.43	7.47	0.38	6.89e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15820397	chr19:17622945	PGLS	0.44	6.36	0.33	6.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs2700987	0.545	rs2700984	chr7:37391820	C/T	cg26076750	chr5:98105150	RGMB	0.34	6.06	0.31	3.65e-9	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs12681287	0.609	rs13279850	chr8:87477800	C/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.16	-0.36	5.04e-12	Caudate activity during reward;
LUSC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg27147174	chr7:100797783	AP1S1	0.53	8.04	0.4	1.58e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	7.83	0.39	6.58e-14	Coffee consumption (cups per day);
LUSC	cis	rs13006833	0.703	rs291459	chr2:191181527	T/C	cg21644426	chr2:191273491	MFSD6	0.43	6.16	0.32	2.13e-9	Urinary metabolites;
LUSC	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.74	0.35	6.88e-11	Rheumatoid arthritis;
LUSC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg03146154	chr1:46216737	IPP	0.54	7.73	0.39	1.27e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg15432903	chr11:17409602	KCNJ11	0.62	11.13	0.52	1.09e-24	Type 2 diabetes;
LUSC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-17.32	-0.69	2.06e-48	Primary sclerosing cholangitis;
LUSC	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg27631724	chr1:11040367	C1orf127	0.55	9.55	0.46	2.88e-19	Male-pattern baldness;
LUSC	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg00603274	chr11:61596626	FADS2	-0.58	-7.98	-0.4	2.36e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs6722750	0.716	rs6546057	chr2:64414165	A/G	cg22352474	chr2:64371530	PELI1	-0.49	-7.28	-0.37	2.48e-12	Neuroticism;
LUSC	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg16482183	chr6:26056742	HIST1H1C	0.87	11.6	0.54	2.22e-26	Iron status biomarkers;
LUSC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.99	-0.36	1.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2455601	0.786	rs2568070	chr11:8976893	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.52	-0.34	2.55e-10	Schizophrenia;
LUSC	cis	rs4356932	1.000	rs4401475	chr4:76975924	T/C	cg00809888	chr4:76862425	NAAA	0.34	5.7	0.3	2.6e-8	Blood protein levels;
LUSC	trans	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	7.04	0.36	1.09e-11	Corneal astigmatism;
LUSC	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg18512352	chr11:47633146	NA	0.28	5.79	0.3	1.63e-8	Subjective well-being;
LUSC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg05347473	chr6:146136440	FBXO30	-0.6	-10.71	-0.51	3.44e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg08680598	chr22:49984980	NA	-0.32	-5.97	-0.31	6.16e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg25258033	chr6:167368657	RNASET2	0.39	6.27	0.32	1.12e-9	Crohn's disease;
LUSC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg21782813	chr7:2030301	MAD1L1	0.5	8.38	0.42	1.52e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08045932	chr20:61659980	NA	0.57	9.7	0.47	9.37e-20	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg19680485	chr15:31195859	MTMR15	0.48	6.41	0.33	5.06e-10	Huntington's disease progression;
LUSC	cis	rs4499344	0.576	rs259280	chr19:33161452	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.75	11.51	0.53	4.77e-26	Mean platelet volume;
LUSC	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg02023728	chr11:77925099	USP35	0.48	6.97	0.36	1.69e-11	Testicular germ cell tumor;
LUSC	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg17507749	chr15:85114479	UBE2QP1	0.44	5.95	0.31	6.93e-9	Schizophrenia;
LUSC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.16	-0.36	5.04e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs16976116	0.806	rs28466870	chr15:55495113	C/T	cg11288833	chr15:55489084	RSL24D1	0.49	5.8	0.3	1.53e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg23711669	chr6:146136114	FBXO30	-0.7	-12.1	-0.55	3.5e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg19812747	chr11:111475976	SIK2	0.54	8.0	0.4	2e-14	Primary sclerosing cholangitis;
LUSC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg06454157	chr6:167490870	NA	-0.28	-6.71	-0.34	8.57e-11	Primary biliary cholangitis;
LUSC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg09021430	chr5:549028	NA	-0.53	-6.97	-0.36	1.7e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs11756438	0.572	rs2638541	chr6:119003743	A/T	cg21191810	chr6:118973309	C6orf204	0.35	5.91	0.31	8.23e-9	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg24006582	chr15:45444508	DUOX1	-0.62	-8.85	-0.44	5.25e-17	Uric acid levels;
LUSC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	0.89	15.68	0.65	6.48e-42	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs55675132	0.704	rs7553371	chr1:115591053	T/G	cg01522456	chr1:115632236	TSPAN2	-0.47	-5.7	-0.3	2.63e-8	Schizophrenia;
LUSC	cis	rs524023	0.957	rs528211	chr11:64351721	C/T	cg07220939	chr11:64358617	SLC22A12	0.23	5.9	0.31	9.15e-9	Urate levels in obese individuals;
LUSC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.12	0.55	2.98e-28	Motion sickness;
LUSC	trans	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg06521331	chr12:34319734	NA	0.38	6.04	0.31	4.21e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.34	-0.42	2.01e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg26418507	chr12:54121361	CALCOCO1	0.43	6.07	0.32	3.44e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.28	0.62	1.92e-36	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg05347473	chr6:146136440	FBXO30	0.48	7.9	0.4	4.04e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg15571903	chr15:79123663	NA	0.31	5.86	0.31	1.13e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg16680214	chr1:154839983	KCNN3	-0.51	-9.68	-0.47	1.08e-19	Prostate cancer;
LUSC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg13385521	chr17:29058706	SUZ12P	0.63	7.04	0.36	1.13e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg11764359	chr7:65958608	NA	0.69	6.99	0.36	1.51e-11	Diabetic kidney disease;
LUSC	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07362569	chr17:61921086	SMARCD2	0.36	7.27	0.37	2.63e-12	Prudent dietary pattern;
LUSC	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.46	0.46	5.81e-19	Blood protein levels;
LUSC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg11871910	chr12:69753446	YEATS4	0.63	9.26	0.45	2.61e-18	Response to diuretic therapy;
LUSC	cis	rs10489202	1.000	rs7535138	chr1:167931462	T/G	cg24449463	chr1:168025552	DCAF6	-0.58	-7.37	-0.37	1.32e-12	Schizophrenia;
LUSC	cis	rs2652834	0.904	rs34786874	chr15:63397504	A/G	cg05507819	chr15:63340323	TPM1	0.68	8.27	0.41	3.21e-15	HDL cholesterol;
LUSC	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg06917634	chr15:78832804	PSMA4	-0.58	-7.15	-0.36	5.64e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg16342193	chr10:102329863	NA	-0.38	-6.74	-0.35	7.13e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg27121462	chr16:89883253	FANCA	0.42	6.41	0.33	4.93e-10	Vitiligo;
LUSC	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-8.24	-0.41	3.96e-15	Morning vs. evening chronotype;
LUSC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg23791538	chr6:167370224	RNASET2	-0.35	-5.65	-0.3	3.46e-8	Crohn's disease;
LUSC	cis	rs7241530	0.717	rs28612511	chr18:75889196	T/G	cg14642773	chr18:75888474	NA	0.36	6.01	0.31	4.91e-9	Educational attainment (years of education);
LUSC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg07741184	chr6:167504864	NA	0.35	6.23	0.32	1.41e-9	Crohn's disease;
LUSC	cis	rs7179456	0.545	rs605928	chr15:59046163	C/G	cg05156742	chr15:59063176	FAM63B	0.52	7.87	0.4	4.88e-14	Asperger disorder;
LUSC	cis	rs929596	0.564	rs2741042	chr2:234565917	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-5.97	-0.31	5.94e-9	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	7.73	0.39	1.26e-13	Reticulocyte count;
LUSC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.44	-6.27	-0.32	1.13e-9	Platelet count;
LUSC	cis	rs13315871	0.929	rs13080398	chr3:58300282	A/G	cg12435725	chr3:58293450	RPP14	-0.74	-7.47	-0.38	7.23e-13	Cholesterol, total;
LUSC	trans	rs12210905	0.920	rs9348759	chr6:27290888	C/T	cg11837749	chr1:55047332	ACOT11	0.66	6.3	0.33	9.13e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04565464	chr8:145669602	NFKBIL2	0.38	6.39	0.33	5.72e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg00277334	chr10:82204260	NA	-0.49	-6.77	-0.35	5.89e-11	Post bronchodilator FEV1;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg20682991	chr2:74981952	NA	-0.4	-6.27	-0.32	1.09e-9	Educational attainment (years of education);
LUSC	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.32e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7605827	0.930	rs7590340	chr2:15601441	C/T	cg19274914	chr2:15703543	NA	0.46	9.1	0.45	8.11e-18	Educational attainment (years of education);
LUSC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg06671706	chr8:8559999	CLDN23	0.49	6.61	0.34	1.52e-10	Obesity-related traits;
LUSC	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.73	9.11	0.45	7.89e-18	Type 2 diabetes;
LUSC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg11632617	chr15:75315747	PPCDC	0.5	6.09	0.32	3.05e-9	Blood trace element (Zn levels);
LUSC	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg05805236	chr11:65401703	PCNXL3	0.4	6.79	0.35	5.06e-11	Acne (severe);
LUSC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg01097406	chr16:89675127	NA	0.46	9.24	0.45	3e-18	Vitiligo;
LUSC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.47	-8.24	-0.41	3.87e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.53	-0.38	4.75e-13	Height;
LUSC	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.22e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs6693567	0.507	rs4970964	chr1:150458029	A/G	cg15654264	chr1:150340011	RPRD2	0.43	6.85	0.35	3.57e-11	Migraine;
LUSC	cis	rs56399783	0.614	rs11772508	chr7:2771504	A/C	cg19731401	chr7:2775893	GNA12	-0.62	-7.88	-0.4	4.64e-14	Childhood ear infection;
LUSC	trans	rs4596713	0.538	rs7030146	chr9:71756390	T/G	cg25283916	chr1:242222868	NA	-0.32	-6.59	-0.34	1.69e-10	Headache;
LUSC	cis	rs7599312	0.586	rs4404217	chr2:213385817	G/A	cg16329650	chr2:213403929	ERBB4	0.52	7.54	0.38	4.42e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg03579872	chr1:53393473	SCP2	-0.4	-5.76	-0.3	1.94e-8	Monocyte count;
LUSC	cis	rs9837602	1.000	rs35844878	chr3:99796626	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.51	6.29	0.33	1.01e-9	Breast cancer;
LUSC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.67	-11.33	-0.53	2.19e-25	Intelligence (multi-trait analysis);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg05922972	chr15:77362853	TSPAN3	0.48	6.11	0.32	2.76e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9341808	0.754	rs3805885	chr6:80996751	C/G	cg08355045	chr6:80787529	NA	-0.55	-9.64	-0.47	1.51e-19	Sitting height ratio;
LUSC	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg08854313	chr1:11322531	MTOR	0.86	14.41	0.62	6.16e-37	Body mass index;
LUSC	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg05163923	chr11:71159392	DHCR7	-0.77	-10.02	-0.48	7.56e-21	Vitamin D levels;
LUSC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs7119	0.717	rs11635567	chr15:77819515	A/G	cg27398640	chr15:77910606	LINGO1	-0.31	-6.63	-0.34	1.34e-10	Type 2 diabetes;
LUSC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05165339	chr4:1420672	NA	0.28	6.2	0.32	1.66e-9	Obesity-related traits;
LUSC	cis	rs965469	0.652	rs4507156	chr20:3228460	A/G	cg25506879	chr20:3388711	C20orf194	0.45	6.13	0.32	2.44e-9	IFN-related cytopenia;
LUSC	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg24579218	chr15:68104479	NA	-0.39	-6.81	-0.35	4.68e-11	Restless legs syndrome;
LUSC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg26695010	chr11:65641043	EFEMP2	0.46	6.79	0.35	5.08e-11	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10862848	chr6:42927986	GNMT	-0.28	-6.78	-0.35	5.49e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg06784218	chr1:46089804	CCDC17	0.33	5.91	0.31	8.22e-9	Platelet count;
LUSC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.3	-0.41	2.54e-15	Platelet count;
LUSC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg06096015	chr1:231504339	EGLN1	0.56	10.03	0.48	7.06e-21	Hemoglobin concentration;
LUSC	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg24631222	chr15:78858424	CHRNA5	-0.55	-6.36	-0.33	6.82e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs12681287	0.640	rs4587306	chr8:87385511	T/C	cg00550725	chr8:87521180	FAM82B	-0.43	-5.73	-0.3	2.21e-8	Caudate activity during reward;
LUSC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03517284	chr6:25882590	NA	-0.52	-9.71	-0.47	8.33e-20	Blood metabolite levels;
LUSC	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.31	0.53	2.56e-25	Coffee consumption (cups per day);
LUSC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg12463550	chr7:65579703	CRCP	0.63	5.7	0.3	2.58e-8	Gout;
LUSC	cis	rs41271473	0.750	rs17352829	chr1:228889664	A/G	cg10167378	chr1:228756711	NA	0.53	6.26	0.32	1.17e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.67e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	0.81	11.2	0.52	6.18e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.41	-6.11	-0.32	2.81e-9	Renal function-related traits (BUN);
LUSC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg00945038	chr17:61921165	SMARCD2	-0.53	-9.32	-0.45	1.57e-18	Prudent dietary pattern;
LUSC	cis	rs7799006	0.929	rs6461233	chr7:2261468	G/A	cg08027265	chr7:2291960	NA	-0.43	-7.37	-0.37	1.38e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2236918	1.000	rs1635511	chr1:242026172	C/T	cg17736920	chr1:242011382	EXO1	0.44	6.86	0.35	3.34e-11	Menopause (age at onset);
LUSC	cis	rs13385	0.769	rs17118781	chr5:139642929	C/T	cg26211634	chr5:139558579	C5orf32	0.47	6.7	0.34	9.01e-11	Atrial fibrillation;
LUSC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.71	-0.43	1.38e-16	Lung cancer;
LUSC	cis	rs9653442	0.593	rs6737502	chr2:100862903	C/T	cg07810366	chr2:100720526	AFF3	-0.4	-6.43	-0.33	4.29e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg03929089	chr4:120376271	NA	-0.79	-10.1	-0.48	4.02e-21	Coronary artery disease;
LUSC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	0.93	18.07	0.7	2.16e-51	Cognitive function;
LUSC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg13047869	chr3:10149882	C3orf24	0.59	7.71	0.39	1.49e-13	Alzheimer's disease;
LUSC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.6	8.08	0.4	1.2e-14	High light scatter reticulocyte count;
LUSC	trans	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.42	0.33	4.57e-10	Retinal vascular caliber;
LUSC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg26677194	chr12:130822605	PIWIL1	0.57	8.59	0.43	3.4e-16	Menopause (age at onset);
LUSC	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg04362960	chr10:104952993	NT5C2	0.62	9.7	0.47	9.07e-20	Arsenic metabolism;
LUSC	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg24006582	chr15:45444508	DUOX1	0.67	9.7	0.47	9.32e-20	Uric acid levels;
LUSC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	cis	rs12928939	0.769	rs34680964	chr16:71658594	G/A	cg08717414	chr16:71523259	ZNF19	-0.43	-5.96	-0.31	6.32e-9	Post bronchodilator FEV1;
LUSC	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg01528321	chr10:82214614	TSPAN14	0.87	13.27	0.59	1.39e-32	Post bronchodilator FEV1;
LUSC	cis	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs936229	0.906	rs9210	chr15:75128501	T/C	cg10253484	chr15:75165896	SCAMP2	-0.5	-6.44	-0.33	4.2e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg27539214	chr16:67997921	SLC12A4	-0.55	-6.89	-0.35	2.85e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg07424592	chr7:64974309	NA	0.66	5.83	0.3	1.32e-8	Diabetic kidney disease;
LUSC	cis	rs3099143	1.000	rs3102709	chr15:77072260	C/T	cg21673338	chr15:77095150	SCAPER	-0.84	-8.22	-0.41	4.7e-15	Recalcitrant atopic dermatitis;
LUSC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg05347473	chr6:146136440	FBXO30	-0.49	-8.24	-0.41	4.04e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9309473	1.000	rs3813227	chr2:73651967	A/G	cg20560298	chr2:73613845	ALMS1	0.52	7.31	0.37	1.97e-12	Metabolite levels;
LUSC	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg09307838	chr4:120376055	NA	-0.58	-8.86	-0.44	4.9e-17	Corneal astigmatism;
LUSC	cis	rs7582720	1.000	rs72934732	chr2:203739856	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.56	0.42	4.25e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg18753928	chr3:113234510	CCDC52	-0.49	-7.34	-0.37	1.62e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg24675658	chr1:53192096	ZYG11B	0.59	9.22	0.45	3.51e-18	Monocyte count;
LUSC	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg08917208	chr2:24149416	ATAD2B	0.97	10.29	0.49	9.41e-22	Lymphocyte counts;
LUSC	cis	rs9309473	1.000	rs6740223	chr2:73653332	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-6.54	-0.34	2.34e-10	Metabolite levels;
LUSC	cis	rs7106204	0.748	rs2403891	chr11:24213130	C/T	ch.11.24196551F	chr11:24239977	NA	1.13	12.76	0.57	1.21e-30	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg18187862	chr3:45730750	SACM1L	-0.5	-6.35	-0.33	7.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-0.89	-13.24	-0.59	1.81e-32	Asthma;
LUSC	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg02176678	chr2:219576539	TTLL4	0.61	11.1	0.52	1.41e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs909002	0.703	rs4949460	chr1:32143138	A/G	cg01639898	chr1:32083012	HCRTR1	-0.25	-5.81	-0.3	1.45e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs524023	1.000	rs11602903	chr11:64358241	A/T	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.67	-0.3	3.12e-8	Urate levels in obese individuals;
LUSC	cis	rs10193935	0.901	rs12619348	chr2:42625586	C/T	cg27598129	chr2:42591480	NA	-0.61	-8.15	-0.41	7.4e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg19622623	chr12:86230825	RASSF9	0.4	5.8	0.3	1.51e-8	Major depressive disorder;
LUSC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.34	-0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg04673462	chr1:38461896	NA	0.4	6.49	0.33	3.18e-10	Coronary artery disease;
LUSC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg00376283	chr12:123451042	ABCB9	0.67	8.44	0.42	9.73e-16	Neutrophil percentage of white cells;
LUSC	cis	rs7605827	0.930	rs12692266	chr2:15572380	T/C	cg19274914	chr2:15703543	NA	0.48	9.18	0.45	4.52e-18	Educational attainment (years of education);
LUSC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg05863683	chr7:1912471	MAD1L1	0.3	5.73	0.3	2.22e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1124376	0.748	rs67713322	chr3:20148258	G/T	cg05072819	chr3:20081367	KAT2B	0.67	7.82	0.39	6.8e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs965604	0.965	rs12899351	chr15:78792398	T/C	cg18825076	chr15:78729989	IREB2	-0.43	-6.82	-0.35	4.31e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs8040855	0.826	rs6496771	chr15:85705328	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.04	0.31	4.02e-9	Bulimia nervosa;
LUSC	cis	rs4654899	1.000	rs61117207	chr1:21394374	A/C	cg01072550	chr1:21505969	NA	-0.53	-8.05	-0.4	1.44e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7224314	1.000	rs62085808	chr17:65357692	G/A	cg01507342	chr17:65387096	PITPNC1	-0.39	-6.91	-0.35	2.4e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg23711669	chr6:146136114	FBXO30	0.92	17.7	0.7	6.72e-50	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11700980	0.591	rs2832025	chr21:30114322	C/G	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	trans	rs2975734	0.674	rs6983870	chr8:10111294	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.06	-0.31	3.62e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.45	10.18	0.49	2.22e-21	Schizophrenia;
LUSC	cis	rs6714710	0.603	rs35424768	chr2:98395653	A/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.41	0.42	1.18e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg11812906	chr14:75593930	NEK9	-0.62	-10.08	-0.48	4.95e-21	Height;
LUSC	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg22189786	chr22:42395067	WBP2NL	-0.44	-5.97	-0.31	6.12e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg07148914	chr20:33460835	GGT7	0.46	6.73	0.35	7.48e-11	Height;
LUSC	cis	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg06521331	chr12:34319734	NA	-0.34	-5.84	-0.3	1.24e-8	Morning vs. evening chronotype;
LUSC	cis	rs55883249	1.000	rs11676903	chr2:9763201	G/C	cg23886495	chr2:9695866	ADAM17	0.49	5.84	0.3	1.24e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg06671706	chr8:8559999	CLDN23	0.5	6.83	0.35	3.98e-11	Obesity-related traits;
LUSC	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg13010199	chr12:38710504	ALG10B	0.54	8.41	0.42	1.21e-15	Morning vs. evening chronotype;
LUSC	cis	rs16867321	0.950	rs12477283	chr2:181501355	G/T	cg23363182	chr2:181467187	NA	-0.45	-5.85	-0.3	1.2e-8	Obesity;
LUSC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.96	-0.51	4.26e-24	Schizophrenia;
LUSC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg05347473	chr6:146136440	FBXO30	0.59	9.67	0.47	1.16e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7615316	0.934	rs2227928	chr3:142281612	A/G	cg16271453	chr3:142027066	XRN1	-0.37	-6.47	-0.33	3.43e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9309473	0.607	rs2421489	chr2:73593448	A/G	cg20560298	chr2:73613845	ALMS1	-0.59	-9.11	-0.45	7.73e-18	Metabolite levels;
LUSC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26354017	chr1:205819088	PM20D1	-0.79	-15.27	-0.64	2.65e-40	Monocyte percentage of white cells;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.3	-5.74	-0.3	2.09e-8	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg17366294	chr4:99064904	C4orf37	0.56	9.77	0.47	5.22e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17253792	0.558	rs10083353	chr14:56066370	G/T	cg01858014	chr14:56050164	KTN1	-0.9	-7.33	-0.37	1.71e-12	Putamen volume;
LUSC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.18	0.88	4.53e-111	Chronic sinus infection;
LUSC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-10.92	-0.51	6.32e-24	Schizophrenia;
LUSC	cis	rs7577851	0.672	rs111506194	chr2:69631579	G/A	cg10773587	chr2:69614142	GFPT1	0.52	5.85	0.3	1.19e-8	Parkinson's disease (age of onset);
LUSC	trans	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg13565492	chr6:43139072	SRF	-0.56	-6.01	-0.31	4.81e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.53	-0.42	5.2e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18404041	chr3:52824283	ITIH1	-0.62	-12.3	-0.56	6.21e-29	Bipolar disorder;
LUSC	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg24375607	chr4:120327624	NA	0.76	12.23	0.56	1.14e-28	Corneal astigmatism;
LUSC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08677398	chr8:58056175	NA	0.51	6.87	0.35	3.25e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs75804782	0.641	rs72987309	chr2:239348025	A/G	cg18131467	chr2:239335373	ASB1	-0.75	-6.89	-0.35	2.71e-11	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs80264589	1	rs80264589	chr6:26927602	G/A	cg06606381	chr12:133084897	FBRSL1	-0.87	-7.83	-0.39	6.68e-14	Lung cancer;Intelligence (multi-trait analysis);
LUSC	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg00579200	chr11:133705235	NA	-0.39	-5.86	-0.31	1.12e-8	Childhood ear infection;
LUSC	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg16989719	chr2:238392110	NA	0.38	6.73	0.35	7.24e-11	Prostate cancer;
LUSC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.81	13.64	0.6	5.83e-34	Aortic root size;
LUSC	cis	rs1560104	0.709	rs9806858	chr16:12704421	T/C	cg02946846	chr16:12632861	SNX29	0.33	6.14	0.32	2.28e-9	Obesity-related traits;
LUSC	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.6	0.69	1.59e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-6.86	-0.35	3.31e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2455601	0.882	rs11042116	chr11:8928472	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-7.81	-0.39	7.35e-14	Schizophrenia;
LUSC	cis	rs12760731	0.720	rs12022646	chr1:178355821	A/G	cg00404053	chr1:178313656	RASAL2	0.6	6.28	0.33	1.03e-9	Obesity-related traits;
LUSC	cis	rs7177699	0.557	rs7164479	chr15:79123054	C/T	cg15571903	chr15:79123663	NA	0.33	6.28	0.32	1.07e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.89e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg19468946	chr17:37922297	IKZF3	-0.44	-6.95	-0.36	1.97e-11	Self-reported allergy;
LUSC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.05e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg19628046	chr18:33552617	C18orf21	0.49	6.03	0.31	4.36e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.54	-11.51	-0.53	4.79e-26	Vitamin D levels;
LUSC	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.26	-0.37	2.81e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8092503	1.000	rs12457718	chr18:52499626	T/C	cg12377874	chr18:52495404	RAB27B	0.32	5.67	0.3	3.12e-8	Childhood body mass index;
LUSC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-10.26	-0.49	1.19e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg06784218	chr1:46089804	CCDC17	0.48	9.5	0.46	4.33e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22618350	chr1:91487603	ZNF644	0.45	6.26	0.32	1.21e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.23	0.49	1.55e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23505970	chr6:90529759	MDN1	0.45	6.48	0.33	3.32e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.9	-0.4	4.01e-14	Joint mobility (Beighton score);
LUSC	cis	rs4474465	0.790	rs10899554	chr11:78265667	T/G	cg27205649	chr11:78285834	NARS2	0.52	6.12	0.32	2.64e-9	Alzheimer's disease (survival time);
LUSC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg09035930	chr12:129282057	SLC15A4	0.65	12.97	0.58	1.88e-31	Systemic lupus erythematosus;
LUSC	cis	rs35000415	0.873	rs62478615	chr7:128684316	G/C	cg19972273	chr7:128594194	NA	0.67	6.75	0.35	6.46e-11	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-6.43	-0.33	4.39e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg11584989	chr19:19387371	SF4	0.57	6.77	0.35	5.94e-11	Bipolar disorder;
LUSC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg00033643	chr7:134001901	SLC35B4	0.45	7.16	0.36	5.28e-12	Mean platelet volume;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg22153345	chr8:651449	ERICH1	-0.74	-5.99	-0.31	5.44e-9	Cognitive performance;
LUSC	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.24	-11.41	-0.53	1.14e-25	Reticulocyte fraction of red cells;Reticulocyte count;
LUSC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg13206674	chr6:150067644	NUP43	0.62	9.96	0.48	1.21e-20	Lung cancer;
LUSC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg12257692	chr3:49977190	RBM6	0.24	6.57	0.34	1.93e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2191566	0.959	rs7255623	chr19:44510906	G/C	cg03039196	chr19:44506973	ZNF230	0.36	5.93	0.31	7.69e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-9.43	-0.46	7.05e-19	Type 2 diabetes;
LUSC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.0	0.36	1.39e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs7495211	0.529	rs12594533	chr15:98624254	A/G	cg08901157	chr15:56033728	PRTG	0.35	6.21	0.32	1.6e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg26727032	chr16:67993705	SLC12A4	-0.45	-5.94	-0.31	7.32e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3772130	0.962	rs6768621	chr3:121530274	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.22	0.49	1.66e-21	Cognitive performance;
LUSC	cis	rs3820928	1.000	rs3731593	chr2:227773924	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.13	-0.41	8.52e-15	Pulmonary function;
LUSC	cis	rs7759001	0.857	rs10080567	chr6:27363058	G/C	cg18711553	chr6:27366782	ZNF391	0.39	5.69	0.3	2.73e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.28e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs73206853	0.841	rs73206886	chr12:110851190	T/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg07414643	chr4:187882934	NA	0.56	10.6	0.5	7.74e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg00898013	chr13:113819073	PROZ	0.55	7.93	0.4	3.28e-14	Platelet distribution width;
LUSC	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-8.69	-0.43	1.7e-16	Response to antipsychotic treatment;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg19902918	chr1:28586105	SESN2	0.42	6.71	0.34	8.31e-11	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg10664184	chr19:17420304	DDA1	0.53	6.73	0.35	7.44e-11	Systemic lupus erythematosus;
LUSC	cis	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg20368463	chr18:77673604	PQLC1	-0.53	-7.56	-0.38	3.96e-13	Schizophrenia;
LUSC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg04267008	chr7:1944627	MAD1L1	-0.48	-6.92	-0.35	2.27e-11	Schizophrenia;
LUSC	cis	rs3849570	0.615	rs1851918	chr3:81980557	C/T	cg07356753	chr3:81810745	GBE1	-0.43	-6.38	-0.33	5.92e-10	Waist circumference;Body mass index;
LUSC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.06	-0.4	1.35e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg26727032	chr16:67993705	SLC12A4	-0.45	-5.96	-0.31	6.44e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2932538	0.961	rs1238	chr1:113214097	G/A	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.7	-0.47	9.01e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.43	0.59	3.62e-33	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-6.81	-0.35	4.61e-11	Coronary artery disease;
LUSC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg22800045	chr5:56110881	MAP3K1	0.72	9.08	0.45	9.41e-18	Initial pursuit acceleration;
LUSC	trans	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg12884169	chr21:40033163	ERG	0.61	12.26	0.56	8.41e-29	Coronary artery disease;
LUSC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg23711669	chr6:146136114	FBXO30	0.86	16.1	0.66	1.47e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg09455208	chr3:40491958	NA	0.54	9.78	0.47	5.15e-20	Renal cell carcinoma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19826439	chr1:226297528	NA	-0.54	-6.68	-0.34	1.02e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3772130	0.583	rs11710169	chr3:121426655	A/G	cg20356878	chr3:121714668	ILDR1	0.51	8.2	0.41	5.35e-15	Cognitive performance;
LUSC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg17747265	chr1:1875780	NA	-0.75	-17.71	-0.7	5.82e-50	Body mass index;
LUSC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.75	9.81	0.47	4.09e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg16230307	chr14:35515116	FAM177A1	0.78	10.01	0.48	8.33e-21	Psoriasis;
LUSC	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-7.28	-0.37	2.43e-12	Mood instability;
LUSC	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg07701084	chr6:150067640	NUP43	0.47	7.03	0.36	1.15e-11	Testicular germ cell tumor;
LUSC	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg24375607	chr4:120327624	NA	0.73	10.93	0.51	5.82e-24	Corneal astigmatism;
LUSC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg20573242	chr4:122745356	CCNA2	0.64	9.03	0.44	1.36e-17	Type 2 diabetes;
LUSC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.54	-7.62	-0.38	2.6e-13	Alzheimer's disease (late onset);
LUSC	cis	rs11608355	0.960	rs3742021	chr12:109883117	T/C	cg05360138	chr12:110035743	NA	0.45	6.2	0.32	1.62e-9	Neuroticism;
LUSC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg16680214	chr1:154839983	KCNN3	-0.51	-9.7	-0.47	9.21e-20	Prostate cancer;
LUSC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.45	0.33	3.87e-10	Lung cancer;
LUSC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg05347473	chr6:146136440	FBXO30	0.46	7.97	0.4	2.52e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg26380479	chr7:97908229	NA	-0.27	-6.07	-0.32	3.46e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg12856521	chr11:46389249	DGKZ	0.43	6.44	0.33	4.28e-10	Leprosy;
LUSC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.38	-7.37	-0.37	1.34e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg19812747	chr11:111475976	SIK2	0.56	8.2	0.41	5.38e-15	Primary sclerosing cholangitis;
LUSC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.44	-7.1	-0.36	7.57e-12	Bipolar disorder;
LUSC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg00684032	chr4:1343700	KIAA1530	0.33	5.69	0.3	2.72e-8	Obesity-related traits;
LUSC	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg22676075	chr6:135203613	NA	0.48	7.54	0.38	4.48e-13	Red blood cell count;
LUSC	cis	rs3736594	0.840	rs57238885	chr2:27974260	C/G	cg27432699	chr2:27873401	GPN1	0.65	9.07	0.44	1.03e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg08824895	chr13:115047677	UPF3A	0.59	9.04	0.44	1.32e-17	Schizophrenia;
LUSC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg03354898	chr7:1950403	MAD1L1	-0.42	-8.28	-0.41	3.03e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg12419862	chr22:24373484	LOC391322	-0.88	-14.3	-0.62	1.55e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg27165867	chr14:105738592	BRF1	-0.55	-7.81	-0.39	7.43e-14	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg07923666	chr12:49932857	KCNH3	-0.52	-6.51	-0.34	2.74e-10	Resting heart rate;
LUSC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.89	-0.48	2.15e-20	Joint mobility (Beighton score);
LUSC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg06108461	chr20:60628389	TAF4	-0.71	-9.35	-0.46	1.31e-18	Obesity-related traits;
LUSC	cis	rs6460942	0.591	rs62451461	chr7:12355480	G/A	cg06484146	chr7:12443880	VWDE	-0.57	-5.85	-0.3	1.17e-8	Coronary artery disease;
LUSC	trans	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg10756647	chr7:56101905	PSPH	0.86	8.41	0.42	1.18e-15	Diabetic kidney disease;
LUSC	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08109568	chr15:31115862	NA	-0.6	-8.29	-0.41	2.79e-15	Huntington's disease progression;
LUSC	cis	rs16976116	0.901	rs28630909	chr15:55500102	G/A	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg13319975	chr6:146136371	FBXO30	0.51	7.71	0.39	1.44e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311676	0.656	rs56198078	chr3:58392224	G/C	cg13750441	chr3:58318267	PXK	0.35	6.78	0.35	5.47e-11	Systemic lupus erythematosus;
LUSC	trans	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg26043149	chr18:55253948	FECH	0.49	7.18	0.37	4.68e-12	Bone mineral density;
LUSC	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg17366294	chr4:99064904	C4orf37	0.6	10.73	0.51	2.76e-23	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.6	0.38	2.99e-13	Neuroticism;
LUSC	cis	rs4588572	0.643	rs10044028	chr5:77794750	C/T	cg11547950	chr5:77652471	NA	0.58	8.42	0.42	1.12e-15	Triglycerides;
LUSC	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg17691542	chr6:26056736	HIST1H1C	-0.38	-5.67	-0.3	3.02e-8	Schizophrenia;
LUSC	cis	rs939574	0.722	rs115402093	chr2:220096128	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.85	5.96	0.31	6.42e-9	Platelet distribution width;
LUSC	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg11901034	chr3:128598214	ACAD9	-0.42	-6.68	-0.34	9.84e-11	IgG glycosylation;
LUSC	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.05	-0.31	3.78e-9	Bipolar disorder;
LUSC	cis	rs12618769	0.625	rs4850880	chr2:99212417	C/T	cg10123293	chr2:99228465	UNC50	0.47	7.6	0.38	2.98e-13	Bipolar disorder;
LUSC	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.49	-6.81	-0.35	4.55e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06634786	chr22:41940651	POLR3H	-0.53	-6.43	-0.33	4.33e-10	Vitiligo;
LUSC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.6	-9.75	-0.47	6.36e-20	Aortic root size;
LUSC	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs2050392	0.928	rs6481677	chr10:30701816	A/G	cg18806716	chr10:30721971	MAP3K8	-0.48	-7.81	-0.39	7.65e-14	Inflammatory bowel disease;
LUSC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.07	20.49	0.75	5.48e-61	Cognitive ability;
LUSC	cis	rs10887741	0.646	rs12413510	chr10:89436979	T/C	cg13926569	chr10:89418898	PAPSS2	0.32	6.92	0.35	2.27e-11	Exercise (leisure time);
LUSC	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg11244672	chr19:19639970	YJEFN3	0.64	7.68	0.39	1.76e-13	Bipolar disorder;
LUSC	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.49	-0.42	6.69e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13090731	chr18:54305960	TXNL1	0.67	6.09	0.32	3.13e-9	Cognitive performance;
LUSC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg09034736	chr1:150693464	HORMAD1	-0.46	-6.53	-0.34	2.39e-10	Melanoma;
LUSC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	0.9	15.14	0.64	8.55e-40	Breast cancer;
LUSC	trans	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.15	-0.32	2.16e-9	Depression;
LUSC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg13319975	chr6:146136371	FBXO30	-0.45	-6.78	-0.35	5.51e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg00310523	chr12:86230176	RASSF9	0.52	9.83	0.47	3.52e-20	Major depressive disorder;
LUSC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg22437258	chr11:111473054	SIK2	0.53	7.5	0.38	5.65e-13	Primary sclerosing cholangitis;
LUSC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg07606381	chr6:8435919	SLC35B3	0.76	12.82	0.57	6.89e-31	Motion sickness;
LUSC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.41	5.94	0.31	7.03e-9	Lung cancer;
LUSC	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg00531865	chr16:30841666	NA	0.33	5.71	0.3	2.54e-8	Dementia with Lewy bodies;
LUSC	cis	rs113835537	0.877	rs2229455	chr11:66328055	A/G	cg24851651	chr11:66362959	CCS	0.46	5.9	0.31	8.71e-9	Airway imaging phenotypes;
LUSC	cis	rs7119	0.623	rs11637932	chr15:77847353	T/G	cg27398640	chr15:77910606	LINGO1	-0.33	-7.04	-0.36	1.12e-11	Type 2 diabetes;
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.4	5.95	0.31	6.88e-9	Longevity;Endometriosis;
LUSC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg05043794	chr9:111880884	C9orf5	-0.38	-8.11	-0.41	9.63e-15	Menarche (age at onset);
LUSC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg01657329	chr11:68192670	LRP5	-0.44	-6.61	-0.34	1.55e-10	Total body bone mineral density;
LUSC	cis	rs4073416	0.518	rs2184601	chr14:65897368	T/A	cg03016385	chr14:66212404	NA	-0.39	-5.87	-0.31	1.05e-8	N-glycan levels;
LUSC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg06238570	chr21:40685208	BRWD1	-0.57	-8.9	-0.44	3.65e-17	Menarche (age at onset);
LUSC	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg24642439	chr20:33292090	TP53INP2	-0.48	-7.32	-0.37	1.86e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs934734	0.563	rs1858036	chr2:65598241	A/G	cg08085232	chr2:65598271	SPRED2	-0.44	-6.9	-0.35	2.56e-11	Rheumatoid arthritis;
LUSC	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg16797656	chr11:68205561	LRP5	-0.36	-5.86	-0.31	1.12e-8	Bone mineral density (spine);
LUSC	trans	rs11088226	0.581	rs1967870	chr21:33882858	A/G	cg09050820	chr6:167586206	TCP10L2	0.47	7.1	0.36	7.49e-12	Gastritis;
LUSC	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg16414030	chr3:133502952	NA	-0.39	-5.65	-0.3	3.52e-8	Iron status biomarkers;
LUSC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.46	-0.33	3.7e-10	Total body bone mineral density;
LUSC	cis	rs10207060	0.500	rs56346503	chr2:240719409	T/C	cg07506560	chr2:240697449	NA	0.44	6.78	0.35	5.5e-11	Obesity-related traits;
LUSC	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg03806693	chr22:41940476	POLR3H	1.01	14.37	0.62	8.38e-37	Vitiligo;
LUSC	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.61	0.34	1.48e-10	Corneal astigmatism;
LUSC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.82	0.43	6.31e-17	Menopause (age at onset);
LUSC	trans	rs656319	0.513	rs6985941	chr8:9983179	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.86	-0.35	3.39e-11	Myopia (pathological);
LUSC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-17.68	-0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg15445000	chr17:37608096	MED1	0.38	6.5	0.34	2.95e-10	Glomerular filtration rate (creatinine);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15248989	chr19:14682900	NDUFB7	0.43	6.26	0.32	1.19e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg23711669	chr6:146136114	FBXO30	0.83	14.5	0.62	2.61e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg24110177	chr3:50126178	RBM5	0.43	6.71	0.34	8.5e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.33	5.83	0.3	1.33e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg20307385	chr11:47447363	PSMC3	-0.45	-6.69	-0.34	9.64e-11	Subjective well-being;
LUSC	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg02493740	chr2:85810744	VAMP5	0.39	7.16	0.36	5.13e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs28647808	1.000	rs28591209	chr9:136259668	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs7043114	0.525	rs7045409	chr9:95201540	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.31	-0.33	8.98e-10	Height;
LUSC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.13	0.41	8.33e-15	Bipolar disorder;
LUSC	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg23942311	chr14:51606299	NA	0.49	11.44	0.53	8.92e-26	Cancer;
LUSC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg18402987	chr7:1209562	NA	0.7	7.64	0.39	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.54	-10.71	-0.51	3.27e-23	Paraoxonase activity;
LUSC	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.65	9.98	0.48	1.03e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	6.01	0.31	4.84e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9400467	0.528	rs56827	chr6:111623203	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.42	-0.33	4.58e-10	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.35	-0.33	7e-10	Neuroticism;
LUSC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg09323728	chr8:95962352	TP53INP1	-0.36	-7.45	-0.38	8.24e-13	Type 2 diabetes;
LUSC	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg08027265	chr7:2291960	NA	-0.42	-7.12	-0.36	6.82e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs1949829	0.826	rs4947598	chr7:51537440	A/G	cg20941110	chr15:83953819	BNC1	0.55	6.01	0.31	4.98e-9	Wegener's granulomatosis;
LUSC	cis	rs977987	0.872	rs10781976	chr16:75314838	G/T	cg03315344	chr16:75512273	CHST6	0.42	7.73	0.39	1.3e-13	Dupuytren's disease;
LUSC	cis	rs7605827	0.866	rs13014988	chr2:15498404	C/T	cg19274914	chr2:15703543	NA	0.45	8.51	0.42	6.15e-16	Educational attainment (years of education);
LUSC	trans	rs9831754	1.000	rs3946823	chr3:78353052	G/A	cg06695833	chr19:18220682	MAST3	0.48	6.06	0.31	3.76e-9	Calcium levels;
LUSC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06022373	chr22:39101656	GTPBP1	0.79	12.2	0.56	1.48e-28	Menopause (age at onset);
LUSC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03517284	chr6:25882590	NA	0.38	6.5	0.33	2.97e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg14154082	chr13:112174009	NA	0.38	7.95	0.4	2.92e-14	Menarche (age at onset);
LUSC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.76	-0.47	5.88e-20	Platelet count;
LUSC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.05	-0.4	1.45e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.3	0.45	1.9e-18	Prudent dietary pattern;
LUSC	cis	rs9649465	0.561	rs603060	chr7:123427568	A/G	cg03229431	chr7:123269106	ASB15	-0.47	-7.7	-0.39	1.5700000000000001e-13	Migraine;
LUSC	cis	rs4356932	1.000	rs4619915	chr4:76955201	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.83	-15.41	-0.64	7.33e-41	Itch intensity from mosquito bite;
LUSC	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg02228329	chr11:64053129	BAD;GPR137	0.53	7.76	0.39	1.04e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14906687	chr6:157099894	ARID1B	0.45	6.05	0.31	3.87e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.65	-10.36	-0.49	5.43e-22	Endometrial cancer;
LUSC	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg22117172	chr7:91764530	CYP51A1	0.32	5.75	0.3	1.99e-8	Breast cancer;
LUSC	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg10596483	chr8:143751796	JRK	0.61	9.39	0.46	9.97e-19	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg03146154	chr1:46216737	IPP	0.52	7.7	0.39	1.58e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg08968635	chr6:28129556	ZNF389	-0.45	-5.95	-0.31	6.69e-9	Depression;
LUSC	cis	rs4566357	0.615	rs10177528	chr2:227913706	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.23	-0.41	4.2e-15	Coronary artery disease;
LUSC	cis	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg24375607	chr4:120327624	NA	0.42	6.37	0.33	6.33e-10	Diastolic blood pressure;
LUSC	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg03676636	chr4:99064102	C4orf37	0.36	8.0	0.4	2.1e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg15073853	chr19:18549131	ISYNA1	-0.33	-6.16	-0.32	2.13e-9	Breast cancer;
LUSC	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.79	-0.39	8.31e-14	Glomerular filtration rate;
LUSC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg04450456	chr4:17643702	FAM184B	0.41	6.86	0.35	3.29e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.57	-0.46	2.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs11229555	1.000	rs12799215	chr11:58405674	C/T	cg15696309	chr11:58395628	NA	-0.68	-8.98	-0.44	2.08e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs13315871	1.000	rs4362735	chr3:58429893	C/G	cg12435725	chr3:58293450	RPP14	-0.69	-7.33	-0.37	1.77e-12	Cholesterol, total;
LUSC	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg21605333	chr4:119757512	SEC24D	1.14	9.16	0.45	5.52e-18	Cannabis dependence symptom count;
LUSC	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.29	6.54	0.34	2.27e-10	Coronary artery disease;
LUSC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg04756594	chr16:24857601	SLC5A11	0.37	6.15	0.32	2.24e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4663866	0.901	rs76312449	chr2:239190906	A/G	cg16914508	chr2:239161102	PER2	0.69	7.48	0.38	6.62e-13	Irritable bowel syndrome;
LUSC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.6	8.96	0.44	2.25e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg08916839	chr5:415575	AHRR	0.76	7.1	0.36	7.48e-12	Fat distribution (HIV);
LUSC	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg06363034	chr20:62225388	GMEB2	-0.45	-7.5	-0.38	5.91e-13	Glioblastoma;
LUSC	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-6.81	-0.35	4.67e-11	Coronary artery disease;
LUSC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.65	0.34	1.21e-10	Parkinson's disease;
LUSC	cis	rs1568889	1.000	rs7937778	chr11:28104605	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.51	0.46	3.95e-19	Bipolar disorder;
LUSC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-1.06	-20.14	-0.74	1.34e-59	Coronary artery disease;
LUSC	cis	rs9303280	0.901	rs2290400	chr17:38066240	A/G	cg19468946	chr17:37922297	IKZF3	-0.39	-6.26	-0.32	1.2e-9	Self-reported allergy;
LUSC	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-1.06	-12.75	-0.57	1.28e-30	Schizophrenia;
LUSC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg00310523	chr12:86230176	RASSF9	0.45	8.28	0.41	2.97e-15	Major depressive disorder;
LUSC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg00343986	chr7:65444356	GUSB	0.44	6.68	0.34	9.96e-11	Aortic root size;
LUSC	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg26876637	chr1:152193138	HRNR	0.46	6.57	0.34	1.89e-10	Atopic dermatitis;
LUSC	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg15848620	chr12:58087721	OS9	-0.4	-5.68	-0.3	2.99e-8	Multiple sclerosis;
LUSC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg24060327	chr5:131705240	SLC22A5	-0.54	-9.05	-0.44	1.2e-17	Breast cancer;
LUSC	trans	rs72674100	0.737	rs2865756	chr4:97992626	C/T	cg09670535	chr1:18959427	PAX7	-0.61	-6.23	-0.32	1.41e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg14186256	chr22:23484241	RTDR1	0.63	8.28	0.41	2.98e-15	Serum parathyroid hormone levels;
LUSC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	1.0	15.3	0.64	1.97e-40	Primary sclerosing cholangitis;
LUSC	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg00129232	chr17:37814104	STARD3	-0.45	-6.49	-0.33	3.15e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg02527881	chr3:46936655	PTH1R	0.37	6.57	0.34	1.99e-10	Colorectal cancer;
LUSC	cis	rs4290604	1.000	rs4290604	chr2:238070885	A/G	cg23555395	chr2:238036564	NA	-0.44	-6.48	-0.33	3.36e-10	Asthma;
LUSC	cis	rs7659604	0.502	rs13104233	chr4:122672473	T/C	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.92	-0.31	7.78e-9	Type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-7.57	-0.38	3.6e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs10426930	0.700	rs10407399	chr19:5009466	A/C	cg25246084	chr19:4971487	KDM4B	0.34	6.28	0.32	1.06e-9	Monocyte percentage of white cells;
LUSC	cis	rs2425143	1.000	rs6060643	chr20:34449851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.9	-0.31	9.06e-9	Blood protein levels;
LUSC	cis	rs6426558	0.515	rs7521110	chr1:227384459	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.52	-7.08	-0.36	8.4e-12	Neutrophil percentage of white cells;
LUSC	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg19628046	chr18:33552617	C18orf21	0.5	5.98	0.31	5.58e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs62400317	0.762	rs10948176	chr6:44833913	A/G	cg18551225	chr6:44695536	NA	-0.46	-7.46	-0.38	7.6e-13	Total body bone mineral density;
LUSC	cis	rs977987	0.866	rs17696831	chr16:75493298	C/G	cg03315344	chr16:75512273	CHST6	0.53	9.97	0.48	1.13e-20	Dupuytren's disease;
LUSC	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg22029157	chr1:209979665	IRF6	0.51	8.27	0.41	3.33e-15	Monobrow;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	0.91	18.01	0.7	3.64e-51	Menarche (age at onset);
LUSC	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg27147174	chr7:100797783	AP1S1	-0.63	-10.2	-0.49	1.86e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-0.85	-13.41	-0.59	4.32e-33	Refractive error;
LUSC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg17971929	chr21:40555470	PSMG1	0.8	14.24	0.61	2.79e-36	Cognitive function;
LUSC	cis	rs7929679	0.551	rs10836302	chr11:34791897	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.91	0.31	8.29e-9	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg24687543	chr11:63912206	MACROD1	0.44	5.81	0.3	1.45e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg15242686	chr22:24348715	GSTTP1	0.48	7.75	0.39	1.09e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg13206674	chr6:150067644	NUP43	0.58	9.14	0.45	6.43e-18	Lung cancer;
LUSC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg21132104	chr15:45694354	SPATA5L1	0.57	7.97	0.4	2.54e-14	Homoarginine levels;
LUSC	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg11473876	chr11:109292803	C11orf87	0.39	6.32	0.33	8.41e-10	Schizophrenia;
LUSC	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg21095983	chr6:86352623	SYNCRIP	-0.52	-8.27	-0.41	3.31e-15	Smooth-surface caries;
LUSC	trans	rs2694917	0.680	rs1043011	chr12:56865040	G/T	cg19051015	chr17:46697414	NA	0.39	6.06	0.31	3.67e-9	Blood metabolite ratios;
LUSC	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg13010199	chr12:38710504	ALG10B	0.64	9.54	0.46	3.17e-19	Bladder cancer;
LUSC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg11344533	chr11:111475393	SIK2	0.47	6.6	0.34	1.6e-10	Primary sclerosing cholangitis;
LUSC	cis	rs79220007	1.000	rs79220007	chr6:26098474	T/C	cg16482183	chr6:26056742	HIST1H1C	0.99	6.26	0.32	1.19e-9	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	0.79	13.68	0.6	4.05e-34	Cognitive function;
LUSC	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg21681030	chr2:46777652	RHOQ	0.46	6.35	0.33	7.24e-10	Height;
LUSC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-11.3	-0.53	2.68e-25	Extrinsic epigenetic age acceleration;
LUSC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg04455712	chr21:45112962	RRP1B	0.45	8.71	0.43	1.47e-16	Mean corpuscular volume;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02899788	chr1:47133675	ATPAF1	0.44	5.95	0.31	6.95e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.19	0.41	5.48e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1113500	0.614	rs61797342	chr1:108608385	G/A	cg06207961	chr1:108661230	NA	0.35	5.7	0.3	2.69e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg16342193	chr10:102329863	NA	-0.34	-6.21	-0.32	1.59e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.51	6.67	0.34	1.04e-10	Huntington's disease progression;
LUSC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg05535760	chr7:792225	HEATR2	-0.73	-7.52	-0.38	5.18e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs10186029	0.676	rs10932465	chr2:213968389	T/C	cg08319019	chr2:214017104	IKZF2	0.6	8.76	0.43	9.95e-17	Systemic sclerosis;
LUSC	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg01973587	chr1:228161476	NA	0.47	8.49	0.42	6.91e-16	Diastolic blood pressure;
LUSC	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg21918786	chr6:109611834	NA	-0.4	-6.88	-0.35	2.97e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs7043114	0.525	rs6479419	chr9:95110002	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.72	-0.35	7.86e-11	Height;
LUSC	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg04025307	chr7:1156635	C7orf50	0.46	6.83	0.35	4e-11	Longevity;Endometriosis;
LUSC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.88	-10.99	-0.52	3.5e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs9378688	0.654	rs2479004	chr6:2326765	A/G	cg12303981	chr6:2244766	GMDS	-0.4	-5.76	-0.3	1.87e-8	Caudate nucleus volume;
LUSC	cis	rs6076065	0.723	rs2051093	chr20:23371349	G/A	cg11657817	chr20:23433608	CST11	0.43	8.07	0.4	1.25e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2652834	0.851	rs12902237	chr15:63418188	C/T	cg05507819	chr15:63340323	TPM1	0.45	5.82	0.3	1.4e-8	HDL cholesterol;
LUSC	cis	rs886126	1.000	rs7969686	chr12:111665388	G/A	cg10833066	chr12:111807467	FAM109A	0.41	6.54	0.34	2.28e-10	Coronary heart disease;
LUSC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg07741184	chr6:167504864	NA	0.39	6.95	0.36	1.96e-11	Primary biliary cholangitis;
LUSC	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg19318889	chr4:1322082	MAEA	0.45	5.67	0.3	3.09e-8	Recombination rate (females);
LUSC	cis	rs240764	0.817	rs239246	chr6:101089134	G/A	cg09795085	chr6:101329169	ASCC3	0.42	6.12	0.32	2.68e-9	Neuroticism;
LUSC	trans	rs853679	1.000	rs853694	chr6:28279100	A/T	cg01620082	chr3:125678407	NA	-0.57	-6.79	-0.35	5.18e-11	Depression;
LUSC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.65	-0.39	2.18e-13	Personality dimensions;
LUSC	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg09904177	chr6:26538194	HMGN4	-0.78	-5.94	-0.31	6.98e-9	Depression;
LUSC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17554472	chr22:41940697	POLR3H	-0.5	-6.22	-0.32	1.51e-9	Vitiligo;
LUSC	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Colorectal cancer;
LUSC	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.14	0.41	7.79e-15	Coffee consumption (cups per day);
LUSC	cis	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg17174613	chr18:77631625	KCNG2	0.39	5.84	0.3	1.26e-8	Opioid sensitivity;
LUSC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-1.21	-13.41	-0.59	4.35e-33	Diabetic kidney disease;
LUSC	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10266483	0.656	rs670966	chr7:63762899	A/T	cg24201672	chr7:64023550	ZNF680	-0.5	-6.6	-0.34	1.63e-10	Response to statin therapy;
LUSC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg09436375	chr6:42928200	GNMT	-0.28	-6.64	-0.34	1.28e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs710216	0.752	rs841849	chr1:43402205	G/A	cg22176566	chr1:43424700	SLC2A1	0.48	5.94	0.31	7.3e-9	Red cell distribution width;
LUSC	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.6	-0.38	3.07e-13	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LUSC	cis	rs4400599	0.618	rs1194600	chr1:154236009	G/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.9	-0.31	8.84e-9	Platelet distribution width;
LUSC	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.61	10.29	0.49	9.22e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.72	14.14	0.61	6.92e-36	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08422181	chr19:4909468	UHRF1	-0.49	-6.1	-0.32	2.97e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg18721089	chr20:30220636	NA	-0.41	-6.85	-0.35	3.62e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg26441486	chr22:50317300	CRELD2	-0.53	-8.01	-0.4	1.93e-14	Schizophrenia;
LUSC	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg21211680	chr2:198530	NA	-0.78	-8.35	-0.42	1.84e-15	Blood protein levels;
LUSC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg15448220	chr1:150897856	SETDB1	0.41	6.17	0.32	2.02e-9	Melanoma;
LUSC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg11645453	chr3:52864694	ITIH4	0.36	8.22	0.41	4.47e-15	Bipolar disorder;
LUSC	cis	rs6982240	0.514	rs7002268	chr8:142277340	A/G	cg00131261	chr8:142287264	NA	-0.38	-6.32	-0.33	8.31e-10	Tonsillectomy;
LUSC	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg12310025	chr6:25882481	NA	-0.35	-5.77	-0.3	1.79e-8	Height;
LUSC	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg23625390	chr15:77176239	SCAPER	0.63	9.86	0.47	2.74e-20	Blood metabolite levels;
LUSC	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg02415014	chr8:143852576	LYNX1	0.34	7.88	0.4	4.74e-14	Urinary tract infection frequency;
LUSC	cis	rs4343996	0.719	rs7803004	chr7:3474084	A/G	cg21248987	chr7:3385318	SDK1	0.35	5.78	0.3	1.71e-8	Motion sickness;
LUSC	cis	rs1014246	1.000	rs1014244	chr10:118466150	C/T	cg14919929	chr10:118506882	NA	0.38	5.88	0.31	9.98e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.8	-0.3	1.51e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs4654899	0.743	rs17409373	chr1:21188871	C/A	cg01072550	chr1:21505969	NA	-0.48	-7.23	-0.37	3.26e-12	Superior frontal gyrus grey matter volume;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg27477148	chr19:3360463	NFIC	0.37	6.34	0.33	7.59e-10	Asthma;
LUSC	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-14.73	-0.63	3.35e-38	Lymphocyte percentage of white cells;
LUSC	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg17470723	chr8:74884337	TCEB1	0.52	8.19	0.41	5.44e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg26856596	chr11:1961893	NA	0.33	6.18	0.32	1.9e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	trans	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg18187862	chr3:45730750	SACM1L	-0.56	-6.79	-0.35	5.17e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7202877	0.706	rs8055609	chr16:75402088	C/T	cg04384234	chr16:75411784	CFDP1	-0.65	-9.28	-0.45	2.15e-18	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg10755058	chr3:40428713	ENTPD3	0.36	5.93	0.31	7.74e-9	Renal cell carcinoma;
LUSC	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg24634471	chr8:143751801	JRK	0.51	7.21	0.37	3.71e-12	Schizophrenia;
LUSC	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-0.75	-11.17	-0.52	8.07e-25	Refractive error;
LUSC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg05043794	chr9:111880884	C9orf5	-0.34	-7.23	-0.37	3.33e-12	Menarche (age at onset);
LUSC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	1.03	15.97	0.66	4.58e-43	Parkinson's disease;
LUSC	cis	rs9807989	0.507	rs6726985	chr2:103048580	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.06	0.36	9.98e-12	Asthma;
LUSC	cis	rs7589342	0.598	rs7602442	chr2:106402795	C/T	cg09152813	chr2:106391379	NCK2	0.37	5.8	0.3	1.53e-8	Addiction;
LUSC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg15556689	chr8:8085844	FLJ10661	0.74	11.96	0.55	1.14e-27	Neuroticism;
LUSC	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg00898013	chr13:113819073	PROZ	-0.63	-8.81	-0.43	6.9e-17	Platelet distribution width;
LUSC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	10.35	0.49	6.06e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs12542260	0.953	rs5004281	chr8:125477134	C/T	cg10355837	chr17:64961440	CACNG4	0.44	6.05	0.31	3.8e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72781680	0.821	rs72796361	chr2:24160689	A/T	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	cis	rs2286885	1.000	rs10733678	chr9:129242280	G/A	cg15282417	chr9:129245246	FAM125B	0.35	5.83	0.3	1.34e-8	Intraocular pressure;
LUSC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg22868518	chr11:507468	RNH1	-0.6	-5.98	-0.31	5.74e-9	Body mass index;
LUSC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.42	-0.38	9.8e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12712073	0.845	rs1370353	chr2:100764824	G/C	cg07810366	chr2:100720526	AFF3	-0.45	-7.68	-0.39	1.83e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-6.02	-0.31	4.71e-9	Alzheimer's disease (survival time);
LUSC	cis	rs6489785	0.687	rs3213567	chr12:121222556	T/C	cg02419362	chr12:121203948	SPPL3	0.41	7.34	0.37	1.6e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg19729930	chr2:74357872	NA	0.9	16.75	0.68	4.01e-46	Gestational age at birth (maternal effect);
LUSC	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg13072238	chr3:49761600	GMPPB	-0.69	-8.19	-0.41	5.44e-15	Menarche (age at onset);
LUSC	trans	rs1325195	0.537	rs2793804	chr1:179201000	C/T	cg11624085	chr17:8464688	MYH10	0.43	6.38	0.33	5.94e-10	IgE grass sensitization;
LUSC	trans	rs1998174	0.509	rs10798702	chr1:171815452	A/T	cg13482142	chr2:234261155	NA	0.41	6.03	0.31	4.32e-9	Platelet distribution width;
LUSC	cis	rs1784581	0.588	rs7758559	chr6:162438635	G/T	cg17173639	chr6:162384350	PARK2	0.53	9.13	0.45	6.52e-18	Itch intensity from mosquito bite;
LUSC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg22166914	chr1:53195759	ZYG11B	-0.53	-8.56	-0.42	4.13e-16	Monocyte count;
LUSC	cis	rs8099014	1.000	rs7243073	chr18:56130293	A/C	cg12907477	chr18:56117327	MIR122	0.42	6.63	0.34	1.38e-10	Platelet count;
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.36	-7.61	-0.38	2.85e-13	Longevity;Endometriosis;
LUSC	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg07959070	chr22:50026188	C22orf34	-0.34	-7.01	-0.36	1.32e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg08219700	chr8:58056026	NA	0.47	5.92	0.31	7.98e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	15.88	0.66	1.08e-42	Platelet count;
LUSC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg22920501	chr2:26401640	FAM59B	-0.79	-11.76	-0.54	5.97e-27	Gut microbiome composition (summer);
LUSC	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg27471124	chr11:109292789	C11orf87	-0.42	-7.41	-0.38	1.03e-12	Schizophrenia;
LUSC	cis	rs13089785	1.000	rs13071800	chr3:123626813	C/A	cg02558132	chr3:123411198	MYLK	0.36	6.22	0.32	1.52e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg08999081	chr20:33150536	PIGU	-0.41	-7.68	-0.39	1.79e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg24342717	chr2:85555507	TGOLN2	0.74	12.31	0.56	5.7e-29	Ear protrusion;
LUSC	cis	rs6429082	0.689	rs4659923	chr1:235709519	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.43	-5.79	-0.3	1.66e-8	Adiposity;
LUSC	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg24803719	chr17:45855879	NA	-0.29	-5.67	-0.3	3.12e-8	IgG glycosylation;
LUSC	cis	rs983392	0.805	rs10897011	chr11:59961427	G/A	cg24026212	chr11:59952134	MS4A6A	-0.38	-6.43	-0.33	4.41e-10	Alzheimer's disease (late onset);
LUSC	trans	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.57	0.38	3.58e-13	Ulcerative colitis;
LUSC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg24881330	chr22:46731750	TRMU	0.88	8.87	0.44	4.44e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6469656	0.803	rs4289847	chr8:117683201	C/G	cg24004040	chr8:117650383	NA	-0.45	-6.48	-0.33	3.3e-10	Colorectal cancer;
LUSC	cis	rs2267681	0.583	rs10256282	chr7:139528444	C/T	cg14116596	chr7:139528673	TBXAS1	0.36	6.23	0.32	1.42e-9	Cervical cancer;
LUSC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg25039879	chr17:56429692	SUPT4H1	0.67	9.01	0.44	1.65e-17	Cognitive test performance;
LUSC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.37	-6.29	-0.33	9.74e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg08508325	chr11:3079039	CARS	-0.52	-12.2	-0.56	1.46e-28	Longevity;
LUSC	cis	rs9921338	0.961	rs7200667	chr16:11440404	C/A	cg00044050	chr16:11439710	C16orf75	-0.51	-6.68	-0.34	9.91e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs273573	0.890	rs273606	chr11:30945167	A/T	cg14844989	chr11:31128820	NA	0.36	5.76	0.3	1.96e-8	Total body bone mineral density;
LUSC	cis	rs2235649	0.833	rs2011088	chr16:1850091	T/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-6.07	-0.32	3.44e-9	Blood metabolite levels;
LUSC	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.61	-0.43	2.97e-16	Blood protein levels;
LUSC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg21782813	chr7:2030301	MAD1L1	0.53	9.27	0.45	2.38e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg01176363	chr20:62369445	LIME1	-0.46	-6.85	-0.35	3.62e-11	Prostate cancer;
LUSC	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg27411982	chr8:10470053	RP1L1	0.39	6.03	0.31	4.29e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	0.81	11.42	0.53	1.01e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg05802129	chr4:122689817	NA	-0.52	-8.67	-0.43	1.96e-16	Type 2 diabetes;
LUSC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	0.78	13.53	0.59	1.5e-33	Cognitive function;
LUSC	cis	rs2455601	0.638	rs2742484	chr11:8988083	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-5.94	-0.31	7.28e-9	Schizophrenia;
LUSC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg04267008	chr7:1944627	MAD1L1	-0.45	-6.81	-0.35	4.64e-11	Schizophrenia;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg26436829	chr16:86588937	MTHFSD;FLJ30679	0.38	5.94	0.31	7e-9	Schizophrenia;
LUSC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg04287289	chr16:89883240	FANCA	0.76	6.26	0.32	1.19e-9	Skin colour saturation;
LUSC	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg05855489	chr10:104503620	C10orf26	0.6	9.7	0.47	9.42e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-8.04	-0.4	1.56e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg05802129	chr4:122689817	NA	-0.37	-6.64	-0.34	1.26e-10	Type 2 diabetes;
LUSC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg11657440	chr19:46296263	DMWD	0.88	16.75	0.68	3.86e-46	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12963096	chr13:39612675	NHLRC3;C13orf23	0.42	6.51	0.34	2.83e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-0.8	-14.08	-0.61	1.15e-35	Cognitive function;
LUSC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.52	8.61	0.43	2.88e-16	Immature fraction of reticulocytes;
LUSC	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	7.56	0.38	3.88e-13	Retinal vascular caliber;
LUSC	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg20607287	chr7:12443886	VWDE	-0.59	-6.14	-0.32	2.35e-9	Coronary artery disease;
LUSC	trans	rs12000445	1.000	rs12000445	chr9:23426271	A/G	cg26130488	chr17:59530104	NA	-0.44	-6.05	-0.31	3.91e-9	Response to platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg04518342	chr5:131593106	PDLIM4	0.35	6.37	0.33	6.33e-10	Blood metabolite levels;
LUSC	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg18721089	chr20:30220636	NA	-0.41	-6.08	-0.32	3.29e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg03585969	chr10:35415529	CREM	0.64	9.53	0.46	3.25e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg18357645	chr12:58087776	OS9	0.5	7.49	0.38	6.23e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg05283184	chr6:79620031	NA	-0.54	-10.8	-0.51	1.64e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06636551	chr8:101224915	SPAG1	-0.45	-8.26	-0.41	3.35e-15	Atrioventricular conduction;
LUSC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06558623	chr16:89946397	TCF25	0.95	10.21	0.49	1.82e-21	Skin colour saturation;
LUSC	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg07211511	chr3:129823064	LOC729375	-0.62	-8.21	-0.41	4.72e-15	Blood pressure (smoking interaction);
LUSC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03517284	chr6:25882590	NA	0.43	7.64	0.39	2.36e-13	Blood metabolite levels;
LUSC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg09877947	chr5:131593287	PDLIM4	0.48	7.87	0.4	5e-14	Blood metabolite levels;
LUSC	cis	rs6500395	0.890	rs9936271	chr16:48601291	A/G	cg04672837	chr16:48644449	N4BP1	0.43	6.31	0.33	8.66e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs34375054	0.525	rs12316499	chr12:125593318	G/A	cg25124228	chr12:125621409	AACS	-0.57	-9.44	-0.46	6.67e-19	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs7681440	0.606	rs2736998	chr4:90754336	A/C	cg16902087	chr1:2220497	SKI	-0.3	-6.02	-0.31	4.69e-9	Dementia with Lewy bodies;
LUSC	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg07169764	chr2:136633963	MCM6	1.06	14.11	0.61	8.61e-36	Corneal structure;
LUSC	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.54	-7.98	-0.4	2.3e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg23795048	chr12:9217529	LOC144571	0.34	5.88	0.31	1.02e-8	Sjögren's syndrome;
LUSC	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg16482183	chr6:26056742	HIST1H1C	0.85	11.52	0.53	4.45e-26	Iron status biomarkers;
LUSC	cis	rs529866	0.519	rs4451969	chr16:11383519	A/G	cg00044050	chr16:11439710	C16orf75	-0.63	-9.85	-0.47	2.94e-20	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2273669	0.667	rs75675305	chr6:109324353	T/C	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs72700829	0.593	rs80350997	chr1:150992010	G/A	cg11822372	chr1:151115635	SEMA6C	-0.74	-6.77	-0.35	5.98e-11	Schizophrenia;
LUSC	cis	rs7712401	0.623	rs30043	chr5:122272293	G/C	cg19077854	chr5:122220652	SNX24	0.42	9.32	0.45	1.68e-18	Mean platelet volume;
LUSC	cis	rs1009647	0.614	rs17253702	chr14:55583883	C/T	cg04306507	chr14:55594613	LGALS3	0.43	6.1	0.32	2.89e-9	Testicular germ cell tumor;
LUSC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg13072238	chr3:49761600	GMPPB	-0.36	-5.84	-0.3	1.23e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg26441486	chr22:50317300	CRELD2	0.48	7.21	0.37	3.88e-12	Schizophrenia;
LUSC	cis	rs78366141	0.649	rs78179026	chr4:89657456	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.93	7.0	0.36	1.37e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg01017244	chr2:74357527	NA	0.67	12.03	0.55	6.03e-28	Gestational age at birth (maternal effect);
LUSC	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg13206674	chr6:150067644	NUP43	0.53	8.05	0.4	1.44e-14	Lung cancer;
LUSC	cis	rs11583043	0.708	rs11590358	chr1:101560214	C/A	cg11406453	chr1:101602562	NA	-0.4	-6.69	-0.34	9.45e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs4631830	0.932	rs4581397	chr10:51532367	A/G	cg20129853	chr10:51489980	NA	-0.33	-6.66	-0.34	1.11e-10	Prostate-specific antigen levels;
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.65	-10.77	-0.51	2.08e-23	Lymphocyte counts;
LUSC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg02807482	chr3:125708958	NA	-0.52	-7.02	-0.36	1.28e-11	Blood pressure (smoking interaction);
LUSC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg23978390	chr7:1156363	C7orf50	0.44	6.31	0.33	8.65e-10	Longevity;Endometriosis;
LUSC	cis	rs2637266	1.000	rs2637267	chr10:78331803	A/G	cg18941641	chr10:78392320	NA	0.37	6.58	0.34	1.83e-10	Pulmonary function;
LUSC	cis	rs17373728	0.710	rs2221810	chr8:76221468	C/G	cg07016329	chr8:76221503	NA	-0.48	-6.96	-0.36	1.86e-11	Diabetic kidney disease;
LUSC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	7.86	0.39	5.5e-14	Eosinophil percentage of white cells;
LUSC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg03806693	chr22:41940476	POLR3H	-0.87	-12.62	-0.57	3.99e-30	Vitiligo;
LUSC	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg16576597	chr16:28551801	NUPR1	0.34	6.91	0.35	2.46e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs4343996	0.558	rs10273728	chr7:3414854	A/G	cg21248987	chr7:3385318	SDK1	0.34	5.71	0.3	2.44e-8	Motion sickness;
LUSC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.95	0.44	2.52e-17	Prudent dietary pattern;
LUSC	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg05855489	chr10:104503620	C10orf26	0.48	7.35	0.37	1.53e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs4356932	0.967	rs9999755	chr4:76961802	G/A	cg00809888	chr4:76862425	NAAA	0.36	5.92	0.31	7.79e-9	Blood protein levels;
LUSC	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg10560079	chr2:191398806	TMEM194B	-0.71	-7.95	-0.4	2.98e-14	Diastolic blood pressure;
LUSC	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg25319279	chr11:5960081	NA	0.44	6.37	0.33	6.19e-10	DNA methylation (variation);
LUSC	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	7.18	0.37	4.57e-12	Iron status biomarkers;
LUSC	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg24006582	chr15:45444508	DUOX1	0.66	9.48	0.46	4.73e-19	Uric acid levels;
LUSC	cis	rs1775715	0.707	rs2808094	chr10:32133756	T/C	cg18675610	chr10:32216311	ARHGAP12	0.31	6.75	0.35	6.67e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.23	-0.32	1.41e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs10090774	0.965	rs11785430	chr8:142009527	A/G	cg10310310	chr7:157367150	PTPRN2;MIR153-2	0.29	6.11	0.32	2.72e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg04369109	chr6:150039330	LATS1	0.53	7.67	0.39	1.92e-13	Lung cancer;
LUSC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.3	-6.23	-0.32	1.38e-9	Longevity;Endometriosis;
LUSC	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg14696996	chr19:15285081	NOTCH3	1.02	9.37	0.46	1.1e-18	Pulse pressure;
LUSC	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.32	-0.41	2.21e-15	Schizophrenia;
LUSC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg24399712	chr22:39784796	NA	0.62	10.7	0.51	3.59e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs2219968	0.923	rs11779013	chr8:78930177	T/C	cg00738934	chr8:78996279	NA	0.39	7.1	0.36	7.4e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4654899	0.629	rs2320590	chr1:21155195	C/T	cg01072550	chr1:21505969	NA	0.42	6.42	0.33	4.81e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4343996	0.701	rs4722709	chr7:3388206	G/A	cg21248987	chr7:3385318	SDK1	-0.36	-6.04	-0.31	4.08e-9	Motion sickness;
LUSC	cis	rs4731207	0.741	rs1557969	chr7:124405738	A/G	cg14311320	chr7:124405732	GPR37	0.32	6.18	0.32	1.84e-9	Cutaneous malignant melanoma;
LUSC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.6	-0.34	1.59e-10	Life satisfaction;
LUSC	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg05555928	chr11:63887634	MACROD1	-0.46	-6.08	-0.32	3.36e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg08999081	chr20:33150536	PIGU	0.36	6.51	0.34	2.82e-10	Glomerular filtration rate (creatinine);
LUSC	trans	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.47	6.99	0.36	1.53e-11	Endometrial cancer;
LUSC	cis	rs12541635	0.966	rs6469023	chr8:106989558	T/C	cg10147462	chr8:107024639	NA	0.56	9.86	0.47	2.76e-20	Age of smoking initiation;
LUSC	trans	rs236907	0.812	rs17657363	chr1:171801416	C/T	cg13482142	chr2:234261155	NA	-0.51	-6.32	-0.33	8.52e-10	Mean platelet volume;
LUSC	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.79	11.65	0.54	1.5e-26	Corneal astigmatism;
LUSC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg14558114	chr2:88469736	THNSL2	0.8	7.13	0.36	6.19e-12	Plasma clusterin levels;
LUSC	trans	rs2262909	0.962	rs401424	chr19:22232023	A/G	cg17074339	chr11:11642133	GALNTL4	-0.4	-6.13	-0.32	2.53e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23158103	chr7:148848205	ZNF398	0.5	8.6	0.43	3.06e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg08999081	chr20:33150536	PIGU	0.44	8.15	0.41	7.3e-15	Coronary artery disease;
LUSC	cis	rs6494488	0.500	rs55990268	chr15:64854304	A/G	cg08069370	chr15:64387884	SNX1	-0.64	-5.73	-0.3	2.24e-8	Coronary artery disease;
LUSC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-1.13	-12.82	-0.57	7.23e-31	Diabetic kidney disease;
LUSC	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg10253484	chr15:75165896	SCAMP2	-0.4	-5.7	-0.3	2.63e-8	Systemic lupus erythematosus;
LUSC	cis	rs240764	0.817	rs6938440	chr6:101152009	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.17	-0.32	2.03e-9	Neuroticism;
LUSC	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg00310523	chr12:86230176	RASSF9	0.44	7.85	0.39	5.84e-14	Major depressive disorder;
LUSC	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg12560992	chr17:57184187	TRIM37	0.6	9.77	0.47	5.35e-20	Testicular germ cell tumor;
LUSC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	7.76	0.39	1.06e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17467752	chr17:38218738	THRA	-0.71	-11.39	-0.53	1.31e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	trans	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg13010199	chr12:38710504	ALG10B	0.48	6.62	0.34	1.39e-10	Resting heart rate;
LUSC	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg04058563	chr4:185651563	MLF1IP	0.41	6.58	0.34	1.84e-10	Kawasaki disease;
LUSC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg16325326	chr1:53192061	ZYG11B	-0.81	-14.54	-0.62	1.97e-37	Monocyte count;
LUSC	cis	rs7432375	0.641	rs835649	chr3:136671890	G/A	cg15507776	chr3:136538369	TMEM22	0.44	7.27	0.37	2.53e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21862992	chr11:68658383	NA	0.52	8.03	0.4	1.64e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg04374321	chr14:90722782	PSMC1	-0.69	-10.4	-0.49	3.84e-22	Mortality in heart failure;
LUSC	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg16928487	chr17:17741425	SREBF1	0.46	9.06	0.44	1.1e-17	Total body bone mineral density;
LUSC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg12310025	chr6:25882481	NA	0.42	6.9	0.35	2.57e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.32	-6.47	-0.33	3.42e-10	Dupuytren's disease;
LUSC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.08	-0.52	1.68e-24	Chronic sinus infection;
LUSC	trans	rs7944735	0.938	rs59185955	chr11:47961566	G/C	cg15704280	chr7:45808275	SEPT13	0.63	6.57	0.34	1.98e-10	Intraocular pressure;
LUSC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg06263672	chr7:65235340	NA	-0.4	-5.8	-0.3	1.5e-8	Calcium levels;
LUSC	trans	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07923666	chr12:49932857	KCNH3	-0.5	-6.25	-0.32	1.28e-9	Resting heart rate;
LUSC	cis	rs7705502	0.962	rs55850761	chr5:173373488	A/C	cg18693985	chr5:173351052	CPEB4	-0.37	-5.87	-0.31	1.06e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg13010199	chr12:38710504	ALG10B	-0.62	-10.53	-0.5	1.44e-22	Heart rate;
LUSC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg14552801	chr7:65878734	NA	-0.46	-6.54	-0.34	2.37e-10	Aortic root size;
LUSC	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg10911889	chr6:126070802	HEY2	0.43	6.63	0.34	1.38e-10	Brugada syndrome;
LUSC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25072359	chr17:41440525	NA	0.66	9.5	0.46	4.09e-19	Menopause (age at onset);
LUSC	trans	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg27631724	chr1:11040367	C1orf127	0.51	9.05	0.44	1.23e-17	Ewing sarcoma;
LUSC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.52	-7.38	-0.37	1.27e-12	Tuberculosis;
LUSC	cis	rs96067	0.805	rs2231317	chr1:36603290	C/T	cg24686825	chr1:36642396	MAP7D1	-0.43	-6.03	-0.31	4.28e-9	Corneal structure;
LUSC	cis	rs11971779	0.680	rs2355786	chr7:139065622	A/C	cg23387468	chr7:139079360	LUC7L2	-0.41	-6.18	-0.32	1.88e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg14196790	chr5:131705035	SLC22A5	0.45	7.57	0.38	3.68e-13	Blood metabolite levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23296058	chr5:86708877	CCNH	-0.36	-5.95	-0.31	6.81e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg26380479	chr7:97908229	NA	-0.26	-5.77	-0.3	1.82e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg07507251	chr3:52567010	NT5DC2	0.38	7.59	0.38	3.18e-13	Electroencephalogram traits;
LUSC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-7.58	-0.38	3.33e-13	Alzheimer's disease (late onset);
LUSC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.79	0.63	2.05e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.71	13.09	0.58	6.8e-32	Height;
LUSC	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg11244672	chr19:19639970	YJEFN3	-0.49	-6.08	-0.32	3.25e-9	Bipolar disorder;
LUSC	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.23	0.41	4.2e-15	Coffee consumption (cups per day);
LUSC	cis	rs559928	1.000	rs471584	chr11:64149252	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.6	-6.36	-0.33	6.76e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg07157834	chr1:205819609	PM20D1	-0.44	-5.83	-0.3	1.33e-8	Menarche (age at onset);
LUSC	cis	rs4363385	0.818	rs1334850	chr1:153004519	G/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.23	-0.37	3.4e-12	Inflammatory skin disease;
LUSC	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.0	-0.36	1.39e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg21132104	chr15:45694354	SPATA5L1	0.55	7.81	0.39	7.71e-14	Homoarginine levels;
LUSC	trans	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg01620082	chr3:125678407	NA	-0.83	-7.16	-0.36	5.24e-12	Depression;
LUSC	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg07080220	chr10:102295463	HIF1AN	0.65	8.57	0.42	3.96e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9311676	0.656	rs7620012	chr3:58373716	G/A	cg13750441	chr3:58318267	PXK	0.36	6.93	0.35	2.12e-11	Systemic lupus erythematosus;
LUSC	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg14500267	chr11:67383377	NA	0.34	6.51	0.34	2.75e-10	Mean corpuscular volume;
LUSC	cis	rs72772090	0.539	rs72773947	chr5:96125533	T/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-6.96	-0.36	1.82e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-8.22	-0.41	4.62e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08439880	chr3:133502540	NA	-0.34	-6.07	-0.32	3.48e-9	Iron status biomarkers;
LUSC	cis	rs4499344	0.696	rs2868154	chr19:33099305	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	12.92	0.58	3.09e-31	Mean platelet volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00914462	chr1:245027772	HNRNPU	-0.41	-6.18	-0.32	1.87e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg15423357	chr2:25149977	NA	0.42	8.41	0.42	1.17e-15	Body mass index;
LUSC	cis	rs9807989	0.507	rs6706002	chr2:103006104	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.29e-12	Asthma;
LUSC	cis	rs7246967	0.673	rs35731237	chr19:22820510	G/T	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	trans	rs4800353	0.929	rs7243005	chr18:19612287	A/C	cg01841828	chr16:69166849	CHTF8;CIRH1A	-0.55	-5.95	-0.31	6.73e-9	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs6733011	0.560	rs7579189	chr2:99464718	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-6.38	-0.33	5.77e-10	Bipolar disorder;
LUSC	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.46	-0.33	3.73e-10	Retinal vascular caliber;
LUSC	trans	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs28493229	0.708	rs4803352	chr19:41159193	C/T	cg21869046	chr19:41225005	ITPKC	-0.4	-5.79	-0.3	1.66e-8	Kawasaki disease;
LUSC	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg16386425	chr10:429943	DIP2C	-0.37	-5.85	-0.31	1.14e-8	Psychosis in Alzheimer's disease;
LUSC	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.74	-0.39	1.17e-13	Neuroticism;
LUSC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg09323728	chr8:95962352	TP53INP1	-0.42	-8.81	-0.43	7.18e-17	Type 2 diabetes;
LUSC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	12.32	0.56	5.15e-29	Platelet count;
LUSC	cis	rs7178572	0.633	rs7162637	chr15:77843365	A/G	cg22256960	chr15:77711686	NA	-0.47	-6.92	-0.35	2.35e-11	Type 2 diabetes;
LUSC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08048268	chr3:133502702	NA	-0.4	-7.31	-0.37	2.03e-12	Iron status biomarkers;
LUSC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.24	0.32	1.33e-9	Menopause (age at onset);
LUSC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg22800045	chr5:56110881	MAP3K1	0.78	9.7	0.47	9.52e-20	Initial pursuit acceleration;
LUSC	cis	rs7095944	0.613	rs11245366	chr10:126482849	C/T	cg08799069	chr10:126477246	METTL10	-0.43	-6.57	-0.34	1.97e-10	Asthma;
LUSC	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg06002616	chr8:101225028	SPAG1	0.45	7.37	0.37	1.39e-12	Atrioventricular conduction;
LUSC	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg26924012	chr15:45694286	SPATA5L1	1.09	18.53	0.71	3.27e-53	Homoarginine levels;
LUSC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.56	-9.19	-0.45	4.31e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2315504	1.000	rs2315504	chr17:39046881	A/C	cg17985300	chr17:38952333	KRT28	0.35	7.36	0.37	1.4e-12	Height;
LUSC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg27121462	chr16:89883253	FANCA	0.55	8.89	0.44	3.93e-17	Vitiligo;
LUSC	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg25173405	chr17:45401733	C17orf57	-0.38	-5.66	-0.3	3.3e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.76	-12.73	-0.57	1.56e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg18302933	chr2:88491318	NA	-0.39	-7.57	-0.38	3.66e-13	Response to metformin (IC50);
LUSC	trans	rs62238980	0.614	rs77886759	chr22:32390956	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs796825	0.530	rs1907683	chr3:119950617	A/C	cg21790991	chr3:120137480	FSTL1	-0.33	-6.04	-0.31	4.05e-9	HIV-1 susceptibility;
LUSC	cis	rs965469	0.724	rs2007022	chr20:3237674	C/A	cg25506879	chr20:3388711	C20orf194	-0.49	-5.67	-0.3	3.17e-8	IFN-related cytopenia;
LUSC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13732083	chr21:47605072	C21orf56	0.41	5.93	0.31	7.77e-9	Testicular germ cell tumor;
LUSC	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.79	-11.57	-0.54	2.84e-26	Blood pressure (smoking interaction);
LUSC	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.19	0.52	6.75e-25	Coffee consumption (cups per day);
LUSC	cis	rs11608355	0.545	rs11613021	chr12:109897998	T/G	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	trans	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg21775007	chr8:11205619	TDH	-0.44	-6.28	-0.32	1.04e-9	Mood instability;
LUSC	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.72	0.34	7.98e-11	Cognitive test performance;
LUSC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	7.88	0.4	4.67e-14	Colorectal cancer;
LUSC	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg23711669	chr6:146136114	FBXO30	0.84	14.9	0.63	7.77e-39	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2269241	0.636	rs61765292	chr1:64113459	A/G	cg15664323	chr6:4427110	NA	0.35	5.96	0.31	6.41e-9	Type 1 diabetes;
LUSC	cis	rs16867321	0.694	rs4666853	chr2:181439671	C/T	cg23363182	chr2:181467187	NA	0.57	9.27	0.45	2.34e-18	Obesity;
LUSC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg21665744	chr7:39171113	POU6F2	0.43	6.55	0.34	2.2e-10	IgG glycosylation;
LUSC	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg12435725	chr3:58293450	RPP14	-0.72	-7.38	-0.37	1.3e-12	Cholesterol, total;
LUSC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08219700	chr8:58056026	NA	0.64	8.1	0.41	1.03e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	0.81	11.47	0.53	6.7e-26	Response to hepatitis C treatment;
LUSC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.68	-0.57	2.41e-30	Chronic sinus infection;
LUSC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06481639	chr22:41940642	POLR3H	-0.49	-5.71	-0.3	2.55e-8	Vitiligo;
LUSC	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.59	-0.43	3.42e-16	Coffee consumption (cups per day);
LUSC	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg16342193	chr10:102329863	NA	-0.4	-6.51	-0.34	2.75e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg05585544	chr11:47624801	NA	-0.4	-7.02	-0.36	1.28e-11	Subjective well-being;
LUSC	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg23029597	chr12:123009494	RSRC2	0.75	9.48	0.46	5.05e-19	Body mass index;
LUSC	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg15556689	chr8:8085844	FLJ10661	0.54	8.44	0.42	9.84e-16	Retinal vascular caliber;
LUSC	trans	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg18187862	chr3:45730750	SACM1L	0.52	6.83	0.35	4e-11	Primary sclerosing cholangitis;
LUSC	cis	rs10743315	0.557	rs17505005	chr12:19296294	C/T	cg02471346	chr12:19282374	PLEKHA5	0.76	6.23	0.32	1.36e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs7799006	0.929	rs7781856	chr7:2257199	C/T	cg08027265	chr7:2291960	NA	-0.42	-7.02	-0.36	1.23e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs10761482	0.813	rs4948402	chr10:62107452	T/C	cg18175470	chr10:62150864	ANK3	-0.51	-7.24	-0.37	3.06e-12	Schizophrenia;
LUSC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg20283391	chr11:68216788	NA	-0.51	-7.39	-0.37	1.17e-12	Total body bone mineral density;
LUSC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-6.65	-0.34	1.17e-10	Total body bone mineral density;
LUSC	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg00191853	chr8:101177733	SPAG1	-0.4	-6.42	-0.33	4.77e-10	Atrioventricular conduction;
LUSC	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg13010199	chr12:38710504	ALG10B	0.46	7.15	0.36	5.43e-12	Morning vs. evening chronotype;
LUSC	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg13010199	chr12:38710504	ALG10B	0.63	9.3	0.45	1.84e-18	Morning vs. evening chronotype;
LUSC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg07741184	chr6:167504864	NA	-0.38	-6.97	-0.36	1.75e-11	Crohn's disease;
LUSC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg08859206	chr1:53392774	SCP2	0.52	9.03	0.44	1.39e-17	Monocyte count;
LUSC	cis	rs654950	0.934	rs654220	chr1:42002556	A/T	cg06885757	chr1:42089581	HIVEP3	-0.43	-8.07	-0.4	1.26e-14	Airway imaging phenotypes;
LUSC	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg24562669	chr7:97807699	LMTK2	0.47	8.27	0.41	3.2e-15	Breast cancer;
LUSC	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	7.3	0.37	2.1e-12	Response to antipsychotic treatment;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16203330	chr2:65658524	SPRED2	-0.41	-6.12	-0.32	2.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.9	0.48	2e-20	Migraine;Coronary artery disease;
LUSC	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.76	-0.43	9.87e-17	Response to antipsychotic treatment;
LUSC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.29	0.33	9.92e-10	Menopause (age at onset);
LUSC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg11941060	chr3:133502564	NA	-0.53	-8.17	-0.41	6.64e-15	Iron status biomarkers;
LUSC	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg14830002	chr1:247616686	OR2B11	0.51	7.0	0.36	1.42e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg06145435	chr7:1022769	CYP2W1	0.29	6.11	0.32	2.74e-9	Longevity;Endometriosis;
LUSC	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.69	-0.34	9.14e-11	Monocyte percentage of white cells;
LUSC	trans	rs12476592	0.602	rs2028887	chr2:63716223	A/G	cg11186405	chr13:112728206	NA	-0.37	-5.94	-0.31	7.06e-9	Childhood ear infection;
LUSC	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg21132104	chr15:45694354	SPATA5L1	0.41	6.02	0.31	4.69e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg04990556	chr1:26633338	UBXN11	-0.78	-14.42	-0.62	5.7e-37	Obesity-related traits;
LUSC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs9311676	0.632	rs11130643	chr3:58423288	G/A	cg26110898	chr3:58419937	PDHB	0.39	6.42	0.33	4.71e-10	Systemic lupus erythematosus;
LUSC	trans	rs2487048	0.725	rs2246293	chr9:107690838	C/G	cg17444859	chr7:41543664	NA	-0.26	-6.18	-0.32	1.88e-9	Intraocular pressure;
LUSC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg26408565	chr15:76604113	ETFA	-0.52	-8.3	-0.41	2.62e-15	Blood metabolite levels;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg19725989	chr11:67007604	KDM2A	0.49	6.04	0.31	4.2e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg27661571	chr11:113659931	NA	-0.55	-6.73	-0.35	7.54e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg25039879	chr17:56429692	SUPT4H1	0.68	9.03	0.44	1.41e-17	Cognitive test performance;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25220428	chr6:19144084	NA	0.48	6.06	0.31	3.61e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7178572	0.524	rs7163503	chr15:77493505	C/A	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06221963	chr1:154839813	KCNN3	-0.61	-13.87	-0.6	7.21e-35	Prostate cancer;
LUSC	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg08000102	chr2:233561755	GIGYF2	-0.69	-11.5	-0.53	5.13e-26	Coronary artery disease;
LUSC	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg06346307	chr22:19949965	COMT	-0.35	-7.2	-0.37	3.91e-12	Blood metabolite levels;
LUSC	trans	rs7951105	1.000	rs1906682	chr11:39254780	A/G	cg24085930	chr3:21832523	NA	0.49	6.06	0.31	3.64e-9	Free thyroxine concentration;
LUSC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg22920501	chr2:26401640	FAM59B	0.81	12.01	0.55	7.35e-28	Gut microbiome composition (summer);
LUSC	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg18854424	chr1:2615690	NA	-0.52	-10.6	-0.5	8.29e-23	Ulcerative colitis;
LUSC	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg01191920	chr7:158217561	PTPRN2	-0.58	-12.14	-0.55	2.36e-28	Obesity-related traits;
LUSC	cis	rs10208940	0.764	rs6741037	chr2:68787042	C/T	cg12452813	chr2:68675892	NA	0.57	5.92	0.31	7.99e-9	Urate levels in lean individuals;
LUSC	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg05283184	chr6:79620031	NA	-0.57	-12.18	-0.55	1.73e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.49	-7.26	-0.37	2.68e-12	Renal function-related traits (BUN);
LUSC	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.65	-10.49	-0.5	1.91e-22	Colorectal cancer;
LUSC	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.72	-9.9	-0.48	2e-20	Systemic sclerosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23732384	chr19:7968566	MAP2K7	-0.39	-5.95	-0.31	6.75e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-9.02	-0.44	1.46e-17	Brugada syndrome;
LUSC	cis	rs977987	0.806	rs11865004	chr16:75395777	C/T	cg04384234	chr16:75411784	CFDP1	-0.42	-6.95	-0.36	1.94e-11	Dupuytren's disease;
LUSC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg22906224	chr7:99728672	NA	0.6	8.89	0.44	3.91e-17	Coronary artery disease;
LUSC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg13607699	chr17:42295918	UBTF	-0.47	-7.52	-0.38	5.14e-13	Total body bone mineral density;
LUSC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg26850624	chr5:429559	AHRR	-0.41	-8.0	-0.4	2.1e-14	Cystic fibrosis severity;
LUSC	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg19508488	chr2:152266495	RIF1	0.46	6.65	0.34	1.2e-10	Lung cancer;
LUSC	cis	rs9815354	0.638	rs56194645	chr3:41843593	T/C	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08859206	chr1:53392774	SCP2	-0.5	-8.66	-0.43	2.02e-16	Monocyte count;
LUSC	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg11502198	chr6:26597334	ABT1	0.63	9.95	0.48	1.31e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-9.64	-0.47	1.42e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg03342759	chr3:160939853	NMD3	0.47	7.84	0.39	6.12e-14	Morning vs. evening chronotype;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg20829379	chr3:45838083	SLC6A20	0.36	6.07	0.32	3.44e-9	Metabolite levels (Pyroglutamine);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08984023	chr10:64133896	ZNF365	-0.49	-6.36	-0.33	6.6e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg00857998	chr1:205179979	DSTYK	0.61	9.85	0.47	2.83e-20	Red blood cell count;
LUSC	cis	rs7246967	0.673	rs9677019	chr19:22912659	T/C	cg23217946	chr19:22817039	ZNF492	0.46	6.22	0.32	1.48e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg18876405	chr7:65276391	NA	-0.55	-8.56	-0.42	4.3e-16	Aortic root size;
LUSC	cis	rs6967385	0.560	rs4301352	chr7:12356481	T/G	cg20607287	chr7:12443886	VWDE	0.51	7.63	0.39	2.52e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs35264875	0.851	rs72930631	chr11:68867835	T/C	cg02660097	chr11:68866761	NA	0.42	6.44	0.33	4.18e-10	Blond vs. brown hair color;
LUSC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-8.29	-0.41	2.87e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9283706	0.623	rs10041624	chr5:66314861	T/A	cg11590213	chr5:66331682	MAST4	0.43	6.29	0.33	9.67e-10	Coronary artery disease;
LUSC	cis	rs17014483	0.822	rs3017895	chr4:89649491	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	-0.58	-5.69	-0.3	2.83e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg11502198	chr6:26597334	ABT1	0.68	10.7	0.51	3.65e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg05754148	chr16:3507555	NAT15	-0.83	-8.87	-0.44	4.51e-17	Tuberculosis;
LUSC	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg22681709	chr2:178499509	PDE11A	0.49	7.01	0.36	1.32e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg13256891	chr4:100009986	ADH5	0.52	6.95	0.36	1.88e-11	Smoking initiation;
LUSC	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.31	-0.64	1.87e-40	Height;
LUSC	cis	rs28829049	0.536	rs2073106	chr1:19549343	G/C	cg13387374	chr1:19411106	UBR4	0.44	5.69	0.3	2.85e-8	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg02023728	chr11:77925099	USP35	0.46	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27223758	chr11:64491106	NRXN2	-0.51	-6.14	-0.32	2.32e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg22496339	chr2:162101262	NA	0.73	11.88	0.54	2.23e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.73	12.14	0.55	2.45e-28	Alcohol dependence;
LUSC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05776053	chr2:74358815	NA	0.45	7.19	0.37	4.38e-12	Gestational age at birth (maternal effect);
LUSC	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg03929089	chr4:120376271	NA	-0.86	-12.04	-0.55	5.53e-28	Height;
LUSC	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg26061582	chr7:22766209	IL6	0.42	6.25	0.32	1.26e-9	Lung cancer;
LUSC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg21770322	chr7:97807741	LMTK2	0.4	6.99	0.36	1.47e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg15704280	chr7:45808275	SEPT13	-0.83	-11.71	-0.54	8.72e-27	Coronary artery disease;
LUSC	cis	rs12543645	0.598	rs17767186	chr8:10277494	C/T	cg12940923	chr8:10282607	MSRA	0.38	6.85	0.35	3.62e-11	Schizophrenia;
LUSC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.69	-10.07	-0.48	5.42e-21	Glomerular filtration rate;
LUSC	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.31	-6.07	-0.31	3.57e-9	Schizophrenia;
LUSC	trans	rs1325195	0.920	rs411266	chr1:179224861	A/G	cg11624085	chr17:8464688	MYH10	0.43	6.92	0.35	2.28e-11	IgE grass sensitization;
LUSC	cis	rs9473147	0.798	rs4711895	chr6:47627027	C/T	cg12968598	chr6:47444699	CD2AP	-0.37	-5.75	-0.3	2.01e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg12257692	chr3:49977190	RBM6	-0.25	-6.95	-0.36	1.96e-11	Body mass index;
LUSC	cis	rs9356171	0.539	rs11755754	chr6:164325492	A/G	cg25752492	chr6:164341247	NA	-0.39	-6.68	-0.34	9.82e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.57	11.02	0.52	2.7e-24	Hemoglobin concentration;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19963747	chr17:79633496	C17orf90;CCDC137	-0.45	-6.79	-0.35	5.1e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg23625390	chr15:77176239	SCAPER	0.55	8.65	0.43	2.26e-16	Blood metabolite levels;
LUSC	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg00277334	chr10:82204260	NA	-0.51	-7.41	-0.38	1.05e-12	Post bronchodilator FEV1;
LUSC	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg03676636	chr4:99064102	C4orf37	0.33	6.42	0.33	4.7e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg25258033	chr6:167368657	RNASET2	0.38	5.82	0.3	1.38e-8	Primary biliary cholangitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10944437	chr8:56686135	TMEM68;TGS1	-0.4	-5.96	-0.31	6.36e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg00745463	chr17:30367425	LRRC37B	-0.78	-9.0	-0.44	1.7e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	6.33	0.33	7.72e-10	Response to antipsychotic treatment;
LUSC	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg11645453	chr3:52864694	ITIH4	-0.38	-8.69	-0.43	1.68e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.63	8.37	0.42	1.59e-15	High light scatter reticulocyte count;
LUSC	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg11244672	chr19:19639970	YJEFN3	-0.63	-7.39	-0.38	1.16e-12	Bipolar disorder;
LUSC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg11494091	chr17:61959527	GH2	0.4	6.82	0.35	4.31e-11	Height;
LUSC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg17077180	chr1:38461687	NA	0.55	9.63	0.47	1.6e-19	Coronary artery disease;
LUSC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12748703	chr10:97453984	TCTN3	-0.43	-6.25	-0.32	1.28e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg16797656	chr11:68205561	LRP5	0.36	5.97	0.31	6.15e-9	Total body bone mineral density;
LUSC	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.59	-0.38	3.27e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	9.51	0.46	4.03e-19	Lung cancer in ever smokers;
LUSC	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.77	-12.99	-0.58	1.66e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg05861140	chr6:150128134	PCMT1	0.41	5.98	0.31	5.8e-9	Lung cancer;
LUSC	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg14664628	chr15:75095509	CSK	0.42	6.07	0.31	3.56e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg05527609	chr1:210001259	C1orf107	0.67	9.63	0.47	1.5700000000000001e-19	Orofacial clefts;
LUSC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.6	0.65	1.41e-41	Bladder cancer;
LUSC	cis	rs8040855	0.644	rs2342120	chr15:85728820	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.4	6.54	0.34	2.33e-10	Bulimia nervosa;
LUSC	cis	rs12824058	0.737	rs2398508	chr12:130816460	G/A	cg23887609	chr12:130822674	PIWIL1	0.45	6.35	0.33	6.92e-10	Menopause (age at onset);
LUSC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18876405	chr7:65276391	NA	0.54	8.47	0.42	8.18e-16	Aortic root size;
LUSC	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg25214090	chr10:38739885	LOC399744	0.54	8.02	0.4	1.78e-14	Corneal astigmatism;
LUSC	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	6.91	0.35	2.39e-11	Lung cancer in ever smokers;
LUSC	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg02023728	chr11:77925099	USP35	0.48	6.76	0.35	6.33e-11	Testicular germ cell tumor;
LUSC	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg04865166	chr7:105162814	PUS7	0.51	5.7	0.3	2.65e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9905704	0.633	rs2018966	chr17:56477565	C/T	cg12560992	chr17:57184187	TRIM37	-0.46	-5.65	-0.3	3.52e-8	Testicular germ cell tumor;
LUSC	trans	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg25214090	chr10:38739885	LOC399744	0.46	6.71	0.34	8.23e-11	Corneal astigmatism;
LUSC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg12963246	chr6:28129442	ZNF389	0.48	6.55	0.34	2.12e-10	Depression;
LUSC	cis	rs56146971	0.763	rs77450079	chr14:91863924	A/C	cg10511902	chr14:91842949	CCDC88C	0.43	5.71	0.3	2.55e-8	Alzheimer disease and age of onset;
LUSC	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.65	-7.42	-0.38	9.95e-13	Iron status biomarkers;
LUSC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg16545954	chr1:2118288	C1orf86	-0.3	-5.95	-0.31	6.89e-9	Height;
LUSC	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.1	0.32	2.95e-9	Rheumatoid arthritis;
LUSC	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg23598886	chr18:12777645	NA	0.65	6.47	0.33	3.49e-10	Inflammatory skin disease;
LUSC	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg24130564	chr14:104152367	KLC1	-0.43	-6.1	-0.32	2.87e-9	Body mass index;
LUSC	cis	rs4654899	0.802	rs12137203	chr1:21109088	T/A	cg01072550	chr1:21505969	NA	-0.48	-7.04	-0.36	1.12e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2637266	1.000	rs2395386	chr10:78341623	C/T	cg18941641	chr10:78392320	NA	0.36	6.69	0.34	9.6e-11	Pulmonary function;
LUSC	cis	rs228769	0.792	rs454192	chr17:42171206	T/C	cg19774624	chr17:42201019	HDAC5	0.7	8.95	0.44	2.45e-17	Bone mineral density (hip);Bone mineral density (spine);
LUSC	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15506890	chr2:3487001	NA	-0.54	-8.6	-0.43	3.07e-16	Neurofibrillary tangles;
LUSC	cis	rs36093844	0.559	rs10898403	chr11:85498451	A/G	cg25872744	chr11:85566296	CCDC83	-0.43	-6.61	-0.34	1.53e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg12560992	chr17:57184187	TRIM37	0.84	14.89	0.63	8.26e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg15147215	chr3:52552868	STAB1	-0.32	-6.25	-0.32	1.24e-9	Bipolar disorder;
LUSC	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg26924012	chr15:45694286	SPATA5L1	0.78	12.36	0.56	3.65e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg21880101	chr17:80066754	CCDC57	-0.31	-5.8	-0.3	1.54e-8	Life satisfaction;
LUSC	trans	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.59e-15	Diabetic kidney disease;
LUSC	cis	rs7189233	0.531	rs17800577	chr16:53476804	G/A	cg09728985	chr16:53543985	NA	-0.31	-5.69	-0.3	2.78e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.33	-6.94	-0.36	1.99e-11	Longevity;Endometriosis;
LUSC	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg26875233	chr11:93583750	C11orf90	-0.31	-6.06	-0.31	3.76e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg04455712	chr21:45112962	RRP1B	0.4	7.51	0.38	5.49e-13	Mean corpuscular volume;
LUSC	cis	rs983392	0.591	rs3132886	chr11:60016387	T/A	cg20284999	chr11:59952153	MS4A6A	0.39	6.46	0.33	3.75e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1018836	0.886	rs10112242	chr8:91642631	G/C	cg16814680	chr8:91681699	NA	-0.78	-12.9	-0.58	3.74e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.98	0.4	2.45e-14	Prudent dietary pattern;
LUSC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg12863693	chr15:85201151	NMB	0.38	7.77	0.39	1e-13	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10358630	chr2:130820810	NA	0.36	6.12	0.32	2.58e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs55871839	0.708	rs10098750	chr8:59813205	T/G	cg07426533	chr8:59803705	TOX	-0.36	-5.93	-0.31	7.66e-9	Pneumonia;
LUSC	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg05738196	chr6:26577821	NA	0.8	15.37	0.64	1.07e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg08975724	chr8:8085496	FLJ10661	0.53	7.64	0.39	2.33e-13	Neuroticism;
LUSC	trans	rs6445525	0.967	rs7648741	chr3:65996570	T/C	cg12639933	chr12:57626296	SHMT2	0.34	6.18	0.32	1.87e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7532866	1.000	rs17163904	chr1:26741106	C/T	cg17456097	chr1:26900765	RPS6KA1	0.41	6.41	0.33	4.91e-10	Height;
LUSC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg12751644	chr20:60527061	NA	-0.32	-5.71	-0.3	2.44e-8	Body mass index;
LUSC	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg06917634	chr15:78832804	PSMA4	-0.48	-5.98	-0.31	5.88e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3824867	0.920	rs7105907	chr11:47450318	A/T	cg20307385	chr11:47447363	PSMC3	-0.64	-9.52	-0.46	3.67e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg17366294	chr4:99064904	C4orf37	0.53	7.43	0.38	8.9e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs981844	0.767	rs6857738	chr4:154689140	A/C	cg14289246	chr4:154710475	SFRP2	-0.52	-7.33	-0.37	1.76e-12	Response to statins (LDL cholesterol change);
LUSC	cis	rs3820928	0.967	rs4675113	chr2:227766339	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.73	-0.39	1.3e-13	Pulmonary function;
LUSC	cis	rs9807989	0.811	rs11688559	chr2:102969913	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	5.79	0.3	1.58e-8	Asthma;
LUSC	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.93	0.66	6.63e-43	Bladder cancer;
LUSC	cis	rs62344088	1.000	rs10065373	chr5:106819	C/T	cg22857025	chr5:266934	NA	-0.95	-6.99	-0.36	1.53e-11	Asthma (childhood onset);
LUSC	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg06462663	chr19:18546047	ISYNA1	0.49	8.44	0.42	9.79e-16	Breast cancer;
LUSC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14957430	chr2:64995219	NA	0.46	6.6	0.34	1.65e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	0.81	11.42	0.53	1.05e-25	Response to hepatitis C treatment;
LUSC	cis	rs12493885	0.818	rs6800048	chr3:153766181	T/C	cg17054900	chr3:154042577	DHX36	-0.57	-6.07	-0.32	3.42e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.18	0.52	7.28e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.05	-0.36	1.06e-11	Blood metabolite levels;
LUSC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg09165964	chr15:75287851	SCAMP5	-1.01	-15.29	-0.64	2.16e-40	Blood trace element (Zn levels);
LUSC	cis	rs2078087	0.568	rs498993	chr1:183240470	C/T	cg13843938	chr1:183241246	NMNAT2	-0.42	-6.82	-0.35	4.2e-11	Obesity-related traits;
LUSC	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg04691961	chr3:161091175	C3orf57	-0.34	-5.9	-0.31	8.92e-9	Morning vs. evening chronotype;
LUSC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg05805236	chr11:65401703	PCNXL3	-0.37	-5.73	-0.3	2.29e-8	Breast cancer;
LUSC	cis	rs17401966	0.838	rs35257796	chr1:10267390	T/A	cg19773385	chr1:10388646	KIF1B	-0.51	-8.65	-0.43	2.17e-16	Hepatocellular carcinoma;
LUSC	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-0.85	-12.43	-0.56	2.07e-29	Migraine;Coronary artery disease;
LUSC	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10035650	0.510	rs6898585	chr5:93896128	A/G	cg21051031	chr5:93905482	C5orf36;MIR1974	0.37	6.02	0.31	4.49e-9	Cancer;
LUSC	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg05868516	chr6:26286170	HIST1H4H	0.37	6.05	0.31	3.94e-9	Educational attainment;
LUSC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg08219700	chr8:58056026	NA	0.5	6.27	0.32	1.11e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg24154853	chr7:158122151	PTPRN2	0.45	8.8	0.43	7.55e-17	Calcium levels;
LUSC	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg04827223	chr11:72435913	ARAP1	-0.77	-9.04	-0.44	1.31e-17	Type 2 diabetes;
LUSC	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-8.49	-0.42	6.88e-16	Morning vs. evening chronotype;
LUSC	cis	rs9660992	0.626	rs9326600	chr1:205245268	G/A	cg21643547	chr1:205240462	TMCC2	-0.45	-8.87	-0.44	4.45e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.49	6.48	0.33	3.38e-10	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6693567	0.565	rs834243	chr1:150339290	C/A	cg15654264	chr1:150340011	RPRD2	0.44	7.04	0.36	1.11e-11	Migraine;
LUSC	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg24558204	chr6:135376177	HBS1L	0.57	8.66	0.43	2.1e-16	Red blood cell count;
LUSC	cis	rs983392	0.679	rs7121656	chr11:60024008	C/T	cg20284999	chr11:59952153	MS4A6A	0.4	6.82	0.35	4.22e-11	Alzheimer's disease (late onset);
LUSC	cis	rs11031096	0.702	rs34356743	chr11:4153891	T/C	cg18678763	chr11:4115507	RRM1	0.38	5.77	0.3	1.83e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6546550	0.901	rs6721891	chr2:70146121	A/G	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.26	-0.37	2.67e-12	Prevalent atrial fibrillation;
LUSC	cis	rs9905704	0.813	rs304269	chr17:56802059	A/G	cg12560992	chr17:57184187	TRIM37	-0.58	-8.46	-0.42	8.33e-16	Testicular germ cell tumor;
LUSC	cis	rs7771547	0.573	rs9470278	chr6:36399239	G/A	cg07856975	chr6:36356162	ETV7	-0.35	-6.3	-0.33	9.53e-10	Platelet distribution width;
LUSC	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg20976159	chr1:228193529	WNT3A	0.29	5.86	0.31	1.11e-8	Diastolic blood pressure;
LUSC	cis	rs9296092	0.517	rs7775914	chr6:33518110	T/C	cg13560919	chr6:33536144	NA	-0.82	-15.79	-0.65	2.45e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg13126279	chr21:47581558	C21orf56	-0.42	-6.15	-0.32	2.19e-9	Testicular germ cell tumor;
LUSC	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.82	13.73	0.6	2.54e-34	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg07169764	chr2:136633963	MCM6	-0.59	-7.64	-0.39	2.34e-13	Mosquito bite size;
LUSC	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg10167378	chr1:228756711	NA	0.47	6.49	0.33	3.04e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	10.89	0.51	7.63e-24	Lymphocyte counts;
LUSC	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.53	-0.42	5.06e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg16695835	chr1:90460886	LOC492303;ZNF326	0.76	6.02	0.31	4.54e-9	Cognitive performance;
LUSC	trans	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg13010199	chr12:38710504	ALG10B	-0.39	-5.95	-0.31	6.67e-9	Morning vs. evening chronotype;
LUSC	cis	rs9811920	0.555	rs9850382	chr3:99915939	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.33	6.26	0.32	1.18e-9	Axial length;
LUSC	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.24	-11.38	-0.53	1.46e-25	Reticulocyte fraction of red cells;Reticulocyte count;
LUSC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg11317459	chr13:21872234	NA	1.26	19.59	0.73	1.93e-57	White matter hyperintensity burden;
LUSC	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.64	-0.43	2.32e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg14895029	chr7:2775587	GNA12	-0.42	-6.21	-0.32	1.54e-9	Height;
LUSC	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.86	-13.65	-0.6	5.05e-34	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7605827	0.930	rs11676198	chr2:15603097	G/A	cg19274914	chr2:15703543	NA	0.46	8.74	0.43	1.16e-16	Educational attainment (years of education);
LUSC	cis	rs7582720	1.000	rs114079739	chr2:203825106	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs11785693	0.862	rs7007542	chr8:4996718	G/A	cg26367366	chr8:4980734	NA	0.73	8.61	0.43	2.9e-16	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.72	-11.69	-0.54	1.1e-26	Colorectal cancer;
LUSC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg11344533	chr11:111475393	SIK2	-0.49	-6.85	-0.35	3.5e-11	Primary sclerosing cholangitis;
LUSC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg06008330	chr7:65541103	ASL	-0.4	-6.23	-0.32	1.43e-9	Aortic root size;
LUSC	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg18232548	chr7:50535776	DDC	-0.53	-7.42	-0.38	9.56e-13	Malaria;
LUSC	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg18200150	chr17:30822561	MYO1D	0.52	10.48	0.5	2.14e-22	Schizophrenia;
LUSC	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg13256891	chr4:100009986	ADH5	0.46	6.32	0.33	8.54e-10	Alcohol dependence;
LUSC	cis	rs708547	0.647	rs1718831	chr4:57886946	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	7.64	0.39	2.25e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-0.83	-14.48	-0.62	3.14e-37	Longevity;
LUSC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.68	-0.43	1.72e-16	Bipolar disorder;
LUSC	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg18478394	chr8:109455254	TTC35	0.42	6.54	0.34	2.35e-10	Dupuytren's disease;
LUSC	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg24375607	chr4:120327624	NA	0.7	11.14	0.52	1.03e-24	Corneal astigmatism;
LUSC	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg07080220	chr10:102295463	HIF1AN	0.61	8.14	0.41	8.11e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg00106254	chr7:1943704	MAD1L1	-0.4	-5.97	-0.31	6.11e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg03146154	chr1:46216737	IPP	-0.57	-8.23	-0.41	4.16e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.16	0.32	2.13e-9	Neuroticism;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg24060136	chr17:18162181	FLII	0.39	6.08	0.32	3.2e-9	Schizophrenia;
LUSC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08564027	chr20:61660810	NA	0.91	17.47	0.69	5.29e-49	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg15556689	chr8:8085844	FLJ10661	0.56	8.47	0.42	7.67e-16	Neuroticism;
LUSC	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06544989	chr22:39130855	UNC84B	0.34	6.19	0.32	1.81e-9	Menopause (age at onset);
LUSC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.1e-30	Aortic root size;
LUSC	trans	rs8060598	0.866	rs3135499	chr16:50766127	G/T	cg11505180	chr12:75724112	CAPS2	-0.44	-6.53	-0.34	2.49e-10	Leprosy;
LUSC	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg25427524	chr10:38739819	LOC399744	-0.51	-6.29	-0.33	9.74e-10	Obesity (extreme);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03311064	chr5:139781280	ANKHD1;ANKHD1-EIF4EBP3	-0.44	-6.6	-0.34	1.62e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg10523860	chr14:103875565	MARK3	-0.38	-6.23	-0.32	1.44e-9	Body mass index;
LUSC	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg25182066	chr10:30743637	MAP3K8	-0.44	-6.68	-0.34	9.75e-11	Inflammatory bowel disease;
LUSC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg02569458	chr12:86230093	RASSF9	0.52	8.64	0.43	2.3e-16	Major depressive disorder;
LUSC	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg00191853	chr8:101177733	SPAG1	-0.39	-6.35	-0.33	7.09e-10	Atrioventricular conduction;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19424343	chr3:16306684	OXNAD1;DPH3	-0.45	-6.73	-0.35	7.28e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg07959070	chr22:50026188	C22orf34	-0.31	-5.65	-0.3	3.45e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.69	-11.53	-0.53	4.06e-26	Cognitive function;
LUSC	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.82	14.37	0.62	8.34e-37	Metabolic syndrome;
LUSC	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg08523384	chr5:141488047	NDFIP1	-0.49	-6.93	-0.35	2.21e-11	Crohn's disease;
LUSC	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.75	0.43	1.1e-16	Axial length;
LUSC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg26335602	chr6:28129616	ZNF389	0.46	6.06	0.31	3.64e-9	Depression;
LUSC	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg12615879	chr12:58013172	SLC26A10	-0.31	-6.55	-0.34	2.18e-10	Multiple sclerosis;
LUSC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.05	-0.36	1.02e-11	Colorectal cancer;
LUSC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg12463550	chr7:65579703	CRCP	0.52	7.46	0.38	7.59e-13	Aortic root size;
LUSC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.38	0.33	5.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg22089800	chr15:90895588	ZNF774	-0.64	-9.65	-0.47	1.3e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg13852791	chr20:30311386	BCL2L1	0.76	8.67	0.43	1.92e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs4629710	0.545	rs2077490	chr6:131554184	C/T	cg12606694	chr6:131520996	AKAP7	0.58	8.85	0.44	5.12e-17	Multiple myeloma (IgH translocation);
LUSC	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21643547	chr1:205240462	TMCC2	-0.53	-10.15	-0.49	2.88e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11700980	0.551	rs12481819	chr21:30113901	G/T	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg02176678	chr2:219576539	TTLL4	0.62	11.11	0.52	1.28e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg12365402	chr11:9010492	NRIP3	-0.51	-9.7	-0.47	9.39e-20	Hemoglobin concentration;
LUSC	cis	rs6750047	0.566	rs1157185	chr2:38285735	C/T	cg07380506	chr2:38303506	CYP1B1	0.44	6.19	0.32	1.73e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	8.56	0.42	4.04e-16	Height;
LUSC	cis	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg27411982	chr8:10470053	RP1L1	-0.37	-5.77	-0.3	1.79e-8	Systolic blood pressure;
LUSC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg01765077	chr12:122356316	WDR66	-0.51	-7.33	-0.37	1.78e-12	Mean corpuscular volume;
LUSC	cis	rs13315871	1.000	rs9864325	chr3:58336846	A/C	cg20936604	chr3:58311152	NA	-0.66	-6.72	-0.35	7.73e-11	Cholesterol, total;
LUSC	cis	rs934734	1.000	rs934734	chr2:65595586	A/G	cg08085232	chr2:65598271	SPRED2	0.37	5.84	0.3	1.26e-8	Rheumatoid arthritis;
LUSC	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg16070123	chr10:51489643	NA	-0.57	-9.46	-0.46	5.83e-19	Prostate-specific antigen levels;
LUSC	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg06454157	chr6:167490870	NA	-0.29	-6.58	-0.34	1.77e-10	Crohn's disease;
LUSC	cis	rs2425143	1.000	rs7264414	chr20:34446826	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.09	-0.32	3.08e-9	Blood protein levels;
LUSC	cis	rs9399401	0.601	rs262130	chr6:142853486	C/T	cg03128060	chr6:142623767	GPR126	0.51	8.51	0.42	6.12e-16	Chronic obstructive pulmonary disease;
LUSC	cis	rs75920871	0.588	rs10892054	chr11:116868221	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-6.76	-0.35	6.07e-11	Subjective well-being;
LUSC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg07741184	chr6:167504864	NA	0.43	7.63	0.39	2.43e-13	Crohn's disease;
LUSC	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.42	-0.42	1.12e-15	Body mass index;
LUSC	cis	rs7011049	1.000	rs72640868	chr8:53843812	C/A	cg26025543	chr8:53854495	NA	0.53	6.35	0.33	7.13e-10	Systolic blood pressure;
LUSC	cis	rs6546550	0.867	rs4852349	chr2:70076954	A/T	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.36	-0.37	1.4e-12	Prevalent atrial fibrillation;
LUSC	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	cis	rs7189233	0.531	rs11859538	chr16:53497045	A/G	cg09728985	chr16:53543985	NA	-0.33	-6.13	-0.32	2.46e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg27094323	chr7:1216898	NA	-0.35	-6.14	-0.32	2.32e-9	Longevity;Endometriosis;
LUSC	cis	rs4443100	0.916	rs6003495	chr22:23399743	A/G	cg21100191	chr22:23484243	RTDR1	0.46	5.68	0.3	2.97e-8	Serum parathyroid hormone levels;
LUSC	cis	rs4499344	0.633	rs259262	chr19:33153951	G/A	cg22980127	chr19:33182716	NUDT19	-0.44	-6.45	-0.33	3.88e-10	Mean platelet volume;
LUSC	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg24397884	chr7:158709396	WDR60	-0.79	-9.07	-0.44	1.05e-17	Height;
LUSC	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg21466736	chr12:48725269	NA	-0.33	-5.75	-0.3	2.06e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.69	11.49	0.53	5.55e-26	Colorectal cancer;
LUSC	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	5.95	0.31	6.81e-9	Breast cancer;
LUSC	trans	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg15556689	chr8:8085844	FLJ10661	0.63	8.76	0.43	9.86e-17	Neuroticism;
LUSC	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	11.57	0.53	3e-26	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9534288	0.619	rs2146881	chr13:46679598	T/C	cg15192986	chr13:46630673	CPB2	-0.76	-11.19	-0.52	6.93e-25	Blood protein levels;
LUSC	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg22089800	chr15:90895588	ZNF774	-0.45	-7.05	-0.36	1.02e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs34638657	0.732	rs4889477	chr16:82201302	C/T	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.33	-0.33	7.89e-10	Lung adenocarcinoma;
LUSC	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg27124370	chr19:33622961	WDR88	0.56	7.38	0.37	1.27e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg16339924	chr4:17578868	LAP3	0.52	8.0	0.4	2.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg00343986	chr7:65444356	GUSB	-0.42	-6.07	-0.32	3.41e-9	Aortic root size;
LUSC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg06640241	chr16:89574553	SPG7	0.88	15.87	0.66	1.12e-42	Multiple myeloma (IgH translocation);
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg00024416	chr22:24240387	NA	0.34	5.86	0.31	1.14e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-13.96	-0.61	3.17e-35	Hemoglobin concentration;
LUSC	trans	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.14	-0.36	6.05e-12	Triglycerides;
LUSC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg19622623	chr12:86230825	RASSF9	0.4	5.75	0.3	2.02e-8	Major depressive disorder;
LUSC	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg09238746	chr17:78121135	EIF4A3	-0.69	-10.21	-0.49	1.75e-21	Yeast infection;
LUSC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-11.76	-0.54	6.18e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg09021430	chr5:549028	NA	-0.56	-7.67	-0.39	1.96e-13	Obesity-related traits;
LUSC	cis	rs62158211	0.955	rs1823125	chr2:114090412	C/T	cg17784749	chr2:114082611	LOC440839	-0.47	-5.82	-0.3	1.4e-8	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LUSC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16473166	chr22:50639996	SELO	0.65	9.27	0.45	2.45e-18	Obesity-related traits;
LUSC	cis	rs9467603	0.566	rs10214468	chr6:25789390	T/A	cg08501292	chr6:25962987	TRIM38	0.6	6.13	0.32	2.51e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.11	-0.41	9.67e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg12062639	chr20:23401060	NAPB	0.92	6.76	0.35	6.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg10645314	chr2:3704589	ALLC	-0.48	-7.25	-0.37	2.92e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07677032	chr17:61819896	STRADA	0.53	8.91	0.44	3.42e-17	Prudent dietary pattern;
LUSC	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg05791153	chr7:19748676	TWISTNB	0.79	8.56	0.42	4.24e-16	Thyroid stimulating hormone;
LUSC	cis	rs193541	0.565	rs4836224	chr5:122092875	A/C	cg19077854	chr5:122220652	SNX24	0.28	6.25	0.32	1.29e-9	Glucose homeostasis traits;
LUSC	cis	rs7809950	0.871	rs11771278	chr7:107285925	C/T	cg23024343	chr7:107201750	COG5	0.4	6.03	0.31	4.38e-9	Coronary artery disease;
LUSC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	7.77e-16	Aortic root size;
LUSC	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.95	0.31	6.61e-9	Rheumatoid arthritis;
LUSC	trans	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg07393940	chr7:158741817	NA	0.36	6.48	0.33	3.33e-10	Life satisfaction;
LUSC	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg09165964	chr15:75287851	SCAMP5	-0.89	-8.41	-0.42	1.22e-15	Lung cancer;
LUSC	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14893161	chr1:205819251	PM20D1	0.45	5.99	0.31	5.44e-9	Parkinson's disease;
LUSC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg07636037	chr3:49044803	WDR6	-0.44	-6.34	-0.33	7.64e-10	Resting heart rate;
LUSC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg13560548	chr3:10150139	C3orf24	0.48	6.6	0.34	1.6e-10	Alzheimer's disease;
LUSC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg22143856	chr6:28129313	ZNF389	0.41	5.68	0.3	2.98e-8	Parkinson's disease;
LUSC	cis	rs1775715	0.513	rs2808089	chr10:32145112	A/T	cg26784012	chr10:32216390	ARHGAP12	0.46	7.82	0.39	6.89e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.64	-0.34	1.3100000000000001e-10	Lung cancer;
LUSC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-9.7	-0.47	9.47e-20	Gut microbiome composition (summer);
LUSC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.47	-6.98	-0.36	1.56e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg00825309	chr19:58991885	ZNF446	-0.5	-7.19	-0.37	4.36e-12	Uric acid clearance;
LUSC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.56	0.34	2.11e-10	Personality dimensions;
LUSC	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg09998033	chr7:158218633	PTPRN2	0.44	7.05	0.36	1.04e-11	Obesity-related traits;
LUSC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs10743315	0.557	rs78983750	chr12:19284967	C/T	cg02471346	chr12:19282374	PLEKHA5	0.94	6.81	0.35	4.67e-11	Gut microbiota (bacterial taxa);
LUSC	cis	rs6942756	0.747	rs598412	chr7:129127736	C/T	cg02491457	chr7:128862824	NA	0.4	5.65	0.3	3.42e-8	White matter hyperintensity burden;
LUSC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06221963	chr1:154839813	KCNN3	-0.59	-12.98	-0.58	1.77e-31	Prostate cancer;
LUSC	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg13010199	chr12:38710504	ALG10B	0.49	7.66	0.39	2.08e-13	Morning vs. evening chronotype;
LUSC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg03146154	chr1:46216737	IPP	0.56	8.34	0.42	2e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.78	-0.3	1.7e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1506636	0.924	rs4370458	chr7:123260968	G/A	cg03229431	chr7:123269106	ASB15	-0.67	-11.13	-0.52	1.11e-24	Plateletcrit;Platelet count;
LUSC	trans	rs12210905	0.925	rs4541737	chr6:27002821	C/T	cg11837749	chr1:55047332	ACOT11	0.59	6.3	0.33	9.16e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg00531865	chr16:30841666	NA	0.34	5.94	0.31	6.99e-9	Dementia with Lewy bodies;
LUSC	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.75	-0.35	6.53e-11	Monocyte percentage of white cells;
LUSC	cis	rs727505	1.000	rs1541416	chr7:124450345	T/C	cg23710748	chr7:124431027	NA	-0.41	-7.32	-0.37	1.88e-12	Lewy body disease;
LUSC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.87	0.63	9.77e-39	Platelet count;
LUSC	cis	rs1005224	0.895	rs6574252	chr14:76141834	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.63	-8.71	-0.43	1.42e-16	Large artery stroke;
LUSC	cis	rs4631830	0.869	rs7896437	chr10:51529593	A/C	cg10326726	chr10:51549505	MSMB	-0.36	-6.07	-0.32	3.54e-9	Prostate-specific antigen levels;
LUSC	cis	rs599083	0.590	rs10791984	chr11:68407835	T/G	cg20283391	chr11:68216788	NA	0.53	7.79	0.39	8.3e-14	Bone mineral density (spine);
LUSC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.0	-0.31	5.02e-9	Bipolar disorder;
LUSC	trans	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg26384229	chr12:38710491	ALG10B	0.55	8.73	0.43	1.24e-16	Morning vs. evening chronotype;
LUSC	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.53	8.18	0.41	6.18e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg20026190	chr17:76395443	PGS1	0.34	5.79	0.3	1.66e-8	HDL cholesterol levels;
LUSC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06544989	chr22:39130855	UNC84B	0.32	5.72	0.3	2.31e-8	Menopause (age at onset);
LUSC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	6.71	0.34	8.58e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10904908	0.829	rs359282	chr10:17325281	G/A	cg01003015	chr10:17271136	VIM	0.41	6.05	0.31	3.86e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.22	-14.19	-0.61	4.12e-36	Diabetic kidney disease;
LUSC	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.7	-0.39	1.58e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9463078	0.764	rs1854547	chr6:44912366	G/A	cg25276700	chr6:44698697	NA	-0.29	-5.9	-0.31	8.73e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7202877	0.706	rs247436	chr16:75445971	T/G	cg04384234	chr16:75411784	CFDP1	0.65	8.88	0.44	4.14e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	trans	rs16930685	1.000	rs292784	chr11:37869212	C/T	cg14690467	chr7:148917905	ZNF282	-0.41	-5.97	-0.31	6.1e-9	Cutaneous nevi;
LUSC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg14092988	chr3:52407081	DNAH1	0.33	6.33	0.33	7.77e-10	Bipolar disorder;
LUSC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg08088566	chr11:430123	ANO9	0.6	7.04	0.36	1.09e-11	Body mass index;
LUSC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.54	-10.37	-0.49	4.99e-22	Asthma (sex interaction);
LUSC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg00484396	chr16:3507460	NAT15	-0.74	-9.39	-0.46	9.62e-19	Tuberculosis;
LUSC	cis	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg20307385	chr11:47447363	PSMC3	0.52	6.22	0.32	1.52e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.48	-6.44	-0.33	4.09e-10	Tonsillectomy;
LUSC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg09365446	chr1:150670422	GOLPH3L	0.55	8.44	0.42	9.59e-16	Tonsillectomy;
LUSC	cis	rs7408868	0.831	rs7249115	chr19:15280765	A/G	cg14696996	chr19:15285081	NOTCH3	0.82	8.3	0.41	2.59e-15	Pulse pressure;
LUSC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg22655196	chr4:3374909	RGS12	0.32	6.42	0.33	4.61e-10	Serum sulfate level;
LUSC	cis	rs2463822	0.583	rs11600383	chr11:62060451	A/G	cg06239285	chr11:62104954	ASRGL1	0.55	5.83	0.3	1.3e-8	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13315871	0.929	rs7635697	chr3:58313706	G/A	cg20936604	chr3:58311152	NA	-0.77	-7.11	-0.36	7.27e-12	Cholesterol, total;
LUSC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg16240275	chr20:61666158	NCRNA00029	0.42	9.23	0.45	3.14e-18	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg25206134	chr2:45395956	NA	0.61	7.08	0.36	8.57e-12	Neuroticism;
LUSC	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.2	0.41	5.25e-15	Corneal astigmatism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05910615	chr19:36248877	HSPB6;C19orf55	-0.52	-6.91	-0.35	2.51e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	ch.11.42038R	chr11:967971	AP2A2	0.42	6.23	0.32	1.37e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg10729496	chr3:10149963	C3orf24	0.51	6.89	0.35	2.74e-11	Alzheimer's disease;
LUSC	cis	rs2692947	0.644	rs1168976	chr2:96813480	G/A	cg22654517	chr2:96458247	NA	0.32	5.88	0.31	9.97e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg25036284	chr2:26402008	FAM59B	0.75	9.21	0.45	3.77e-18	Gut microbiome composition (summer);
LUSC	cis	rs7508679	1.000	rs4804411	chr19:7222377	G/C	cg00428638	chr19:7224713	INSR	0.35	7.6	0.38	2.98e-13	Hypothyroidism;
LUSC	trans	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.54	-8.42	-0.42	1.15e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg16724585	chr3:197361211	NA	-0.62	-8.71	-0.43	1.45e-16	Pancreatic cancer;
LUSC	trans	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg13010199	chr12:38710504	ALG10B	0.46	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs713477	1.000	rs713477	chr14:55904426	C/A	cg13175173	chr14:55914753	NA	-0.31	-6.39	-0.33	5.64e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg05855489	chr10:104503620	C10orf26	-0.68	-10.15	-0.49	2.8e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg24829409	chr8:58192753	C8orf71	-0.47	-5.91	-0.31	8.56e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg27102117	chr16:15229624	NA	-0.48	-7.63	-0.39	2.42e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg19592336	chr6:28129416	ZNF389	0.45	6.0	0.31	5.12e-9	Depression;
LUSC	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg18825076	chr15:78729989	IREB2	-0.51	-7.91	-0.4	3.77e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg13852791	chr20:30311386	BCL2L1	0.72	8.29	0.41	2.73e-15	Mean corpuscular hemoglobin;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25007487	chr6:74079672	OOEP	0.43	6.05	0.31	3.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.55	0.34	2.2e-10	Menopause (age at onset);
LUSC	trans	rs2894969	0.664	rs11252703	chr10:4795125	A/T	cg26872149	chr2:157191396	NA	0.4	6.1	0.32	2.9e-9	Major depressive disorder;
LUSC	cis	rs2274273	0.638	rs67416413	chr14:55702263	A/G	cg04306507	chr14:55594613	LGALS3	0.48	9.5	0.46	4.1e-19	Protein biomarker;
LUSC	cis	rs939658	0.967	rs11629665	chr15:79457133	C/T	cg17916960	chr15:79447300	NA	0.46	9.41	0.46	8.45e-19	Refractive error;
LUSC	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg24342717	chr2:85555507	TGOLN2	-0.74	-11.93	-0.55	1.44e-27	Ear protrusion;
LUSC	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg16359550	chr11:109292809	C11orf87	0.37	6.37	0.33	6.08e-10	Schizophrenia;
LUSC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03517284	chr6:25882590	NA	-0.52	-9.67	-0.47	1.16e-19	Blood metabolite levels;
LUSC	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-6.78	-0.35	5.57e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg02117656	chr17:79614917	TSPAN10	0.31	5.7	0.3	2.63e-8	Eye color traits;
LUSC	trans	rs979233	0.522	rs593256	chr5:42085687	T/C	cg07010552	chr17:7358735	CHRNB1	-0.42	-6.11	-0.32	2.7e-9	Systemic lupus erythematosus;
LUSC	cis	rs7760535	0.931	rs466923	chr6:111662977	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.85	-0.35	3.51e-11	Metabolic traits;
LUSC	cis	rs4478858	0.735	rs68008576	chr1:31805905	T/C	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-6.0	-0.31	5.01e-9	IgG glycosylation;
LUSC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg01416388	chr22:39784598	NA	0.43	6.56	0.34	2.06e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.33	-0.37	1.75e-12	Testicular germ cell tumor;
LUSC	trans	rs10911902	0.913	rs80040530	chr1:186572184	T/C	cg03946955	chr1:156096301	LMNA	-0.43	-6.04	-0.31	4.22e-9	Schizophrenia;
LUSC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.24	-14.64	-0.63	7.55e-38	Diabetic kidney disease;
LUSC	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg15848620	chr12:58087721	OS9	-0.41	-5.92	-0.31	8.09e-9	Multiple sclerosis;
LUSC	trans	rs1325195	0.920	rs9728480	chr1:179089491	A/C	cg11624085	chr17:8464688	MYH10	-0.44	-7.38	-0.37	1.25e-12	IgE grass sensitization;
LUSC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.89	0.31	9.52e-9	Menopause (age at onset);
LUSC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.91	0.31	8.67e-9	Menopause (age at onset);
LUSC	cis	rs12928939	0.774	rs7192860	chr16:71643622	G/A	cg08717414	chr16:71523259	ZNF19	-0.44	-6.13	-0.32	2.53e-9	Post bronchodilator FEV1;
LUSC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg00343986	chr7:65444356	GUSB	-0.47	-7.01	-0.36	1.3e-11	Calcium levels;
LUSC	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg17633681	chr16:88106987	BANP	0.53	10.12	0.48	3.63e-21	Menopause (age at onset);
LUSC	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg22681709	chr2:178499509	PDE11A	-0.35	-6.26	-0.32	1.2e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11958404	0.932	rs72816595	chr5:157435957	A/G	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg11050988	chr7:1952600	MAD1L1	-0.32	-6.11	-0.32	2.84e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6740322	1.000	rs6756736	chr2:43558743	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.46	-6.4	-0.33	5.12e-10	Coronary artery disease;
LUSC	trans	rs9929218	0.954	rs7198799	chr16:68818390	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.55	-0.53	3.33e-26	Colorectal cancer;
LUSC	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg13660082	chr14:53194042	PSMC6	-0.8	-6.96	-0.36	1.78e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.66	-11.34	-0.53	1.95e-25	Diastolic blood pressure;
LUSC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.78	-0.39	9.28e-14	Personality dimensions;
LUSC	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg02886208	chr11:14281011	SPON1	0.33	5.94	0.31	7.07e-9	Mitochondrial DNA levels;
LUSC	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg05294307	chr14:35346193	BAZ1A	-0.58	-6.38	-0.33	5.78e-10	Psoriasis;
LUSC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs9811920	0.683	rs793502	chr3:99588417	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.34	6.56	0.34	2.11e-10	Axial length;
LUSC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	0.63	13.63	0.6	6.26e-34	Prudent dietary pattern;
LUSC	cis	rs7215564	0.908	rs74000898	chr17:78653532	A/C	cg23238734	chr17:78661607	RPTOR	0.49	6.28	0.32	1.08e-9	Myopia (pathological);
LUSC	cis	rs2898681	0.614	rs4864680	chr4:53708421	T/G	cg00338735	chr4:53728038	RASL11B	0.43	5.86	0.31	1.11e-8	Optic nerve measurement (cup area);
LUSC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg21132104	chr15:45694354	SPATA5L1	0.57	7.96	0.4	2.63e-14	Homoarginine levels;
LUSC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.78	-0.35	5.63e-11	Alzheimer's disease (late onset);
LUSC	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg02574844	chr11:5959923	NA	-0.45	-6.36	-0.33	6.66e-10	DNA methylation (variation);
LUSC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg05043794	chr9:111880884	C9orf5	0.35	7.5	0.38	5.66e-13	Menarche (age at onset);
LUSC	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	5.71	0.3	2.56e-8	Schizophrenia;
LUSC	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg01579765	chr21:45077557	HSF2BP	-0.47	-9.72	-0.47	7.86e-20	Mean corpuscular volume;
LUSC	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.26	-0.37	2.65e-12	Bipolar disorder;
LUSC	cis	rs1178968	1.000	rs2353062	chr7:72740048	C/T	cg25889504	chr7:72793014	NA	0.58	7.53	0.38	4.84e-13	Triglyceride levels;
LUSC	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-6.91	-0.35	2.48e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	8.62	0.43	2.68e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.96	0.36	1.85e-11	Platelet count;
LUSC	cis	rs4786125	0.587	rs6500861	chr16:6923966	A/G	cg03623568	chr16:6915990	A2BP1	-0.5	-8.41	-0.42	1.22e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg08668510	chr10:1095578	IDI1	0.64	6.1	0.32	2.97e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg14004847	chr7:1930337	MAD1L1	0.5	6.79	0.35	5.06e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-9.64	-0.47	1.4e-19	Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14967899	chr8:26434689	DPYSL2	0.47	7.0	0.36	1.44e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.12	0.32	2.59e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs983392	0.679	rs1026253	chr11:60030556	G/A	cg20284999	chr11:59952153	MS4A6A	0.37	6.09	0.32	3.02e-9	Alzheimer's disease (late onset);
LUSC	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg27471124	chr11:109292789	C11orf87	0.42	7.37	0.37	1.31e-12	Schizophrenia;
LUSC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26354017	chr1:205819088	PM20D1	0.8	13.78	0.6	1.56e-34	Menarche (age at onset);
LUSC	cis	rs983392	0.709	rs1349667	chr11:59993346	T/A	cg02771260	chr11:59836817	MS4A3	-0.35	-5.69	-0.3	2.83e-8	Alzheimer's disease (late onset);
LUSC	cis	rs8112211	0.911	rs2286476	chr19:38850759	G/A	cg14299480	chr19:38876666	GGN	-0.36	-6.13	-0.32	2.48e-9	Blood protein levels;
LUSC	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg08601574	chr20:25228251	PYGB	0.42	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg18479299	chr3:125709523	NA	-0.5	-5.68	-0.3	2.86e-8	Blood pressure (smoking interaction);
LUSC	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg00677455	chr12:58241039	CTDSP2	0.61	9.13	0.45	6.64e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg17376030	chr22:41985996	PMM1	-0.47	-5.99	-0.31	5.44e-9	Vitiligo;
LUSC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03517284	chr6:25882590	NA	-0.52	-9.66	-0.47	1.25e-19	Blood metabolite levels;
LUSC	cis	rs9811920	0.809	rs793475	chr3:99543764	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-7.25	-0.37	2.94e-12	Axial length;
LUSC	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.57	9.0	0.44	1.7e-17	Menopause (age at onset);
LUSC	cis	rs2219968	1.000	rs33987699	chr8:78953437	A/C	cg00738934	chr8:78996279	NA	0.37	6.67	0.34	1.05e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg23127183	chr11:57508653	C11orf31	-0.58	-8.91	-0.44	3.41e-17	Schizophrenia;
LUSC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.59	0.38	3.23e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11153147	0.649	rs11153145	chr6:109300799	C/T	cg05315195	chr6:109294784	ARMC2	-0.56	-6.19	-0.32	1.78e-9	Mean corpuscular volume;
LUSC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.36e-10	Menopause (age at onset);
LUSC	cis	rs62408225	1.000	rs905670	chr6:90958502	G/A	cg06866423	chr6:90926672	BACH2	0.41	5.86	0.31	1.08e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg08085267	chr17:45401833	C17orf57	-0.45	-6.63	-0.34	1.36e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3740713	1.000	rs2643872	chr11:18450444	A/T	cg15463284	chr11:18477534	LDHAL6A	-0.5	-5.87	-0.31	1.04e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg05861140	chr6:150128134	PCMT1	-0.39	-6.13	-0.32	2.49e-9	Lung cancer;
LUSC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg16606324	chr3:10149918	C3orf24	0.57	8.34	0.42	1.98e-15	Alzheimer's disease;
LUSC	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg01858014	chr14:56050164	KTN1	-0.86	-7.18	-0.37	4.47e-12	Putamen volume;
LUSC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg08392591	chr16:89556376	ANKRD11	0.47	7.11	0.36	6.9e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg02503808	chr4:7069936	GRPEL1	0.44	6.51	0.34	2.72e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg06627628	chr2:24431161	ITSN2	-0.86	-12.07	-0.55	4.48e-28	Asthma;
LUSC	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.48	-9.27	-0.45	2.38e-18	Glomerular filtration rate (creatinine);
LUSC	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg10255544	chr17:80519551	FOXK2	0.38	6.25	0.32	1.23e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.28	-0.41	2.99e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg18681998	chr4:17616180	MED28	0.86	15.64	0.65	9.61e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg24642439	chr20:33292090	TP53INP2	0.62	7.08	0.36	8.79e-12	Protein C levels;
LUSC	cis	rs7572644	0.656	rs34096628	chr2:28060990	A/C	cg27432699	chr2:27873401	GPN1	0.52	6.95	0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg05791153	chr7:19748676	TWISTNB	0.61	6.55	0.34	2.12e-10	Thyroid stimulating hormone;
LUSC	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg05791153	chr7:19748676	TWISTNB	0.78	8.3	0.41	2.53e-15	Thyroid stimulating hormone;
LUSC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18357526	chr6:26021779	HIST1H4A	0.4	6.42	0.33	4.64e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg10556349	chr10:835070	NA	0.58	6.27	0.32	1.14e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs7923609	0.846	rs10761739	chr10:65062008	C/G	cg01631684	chr10:65280961	REEP3	0.38	5.64	0.3	3.56e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.77e-22	Eye color traits;
LUSC	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg18232548	chr7:50535776	DDC	-0.64	-9.74	-0.47	6.91e-20	Systemic sclerosis;
LUSC	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg10523860	chr14:103875565	MARK3	-0.38	-6.16	-0.32	2.1e-9	Body mass index;
LUSC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	5.71	0.3	2.52e-8	Menarche (age at onset);
LUSC	cis	rs17253792	0.822	rs78261053	chr14:56061784	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.96	-0.36	1.81e-11	Putamen volume;
LUSC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg04317338	chr11:64019027	PLCB3	0.69	7.79	0.39	8.29e-14	Mean platelet volume;
LUSC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13126279	chr21:47581558	C21orf56	-0.56	-8.56	-0.42	4.09e-16	Testicular germ cell tumor;
LUSC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg10360139	chr7:1886902	MAD1L1	-0.39	-5.96	-0.31	6.51e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.72	-0.3	2.31e-8	Bipolar disorder;
LUSC	trans	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg07923666	chr12:49932857	KCNH3	-0.49	-6.09	-0.32	3.03e-9	Resting heart rate;
LUSC	cis	rs9837602	1.000	rs9878931	chr3:99712634	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.17	0.32	1.96e-9	Breast cancer;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04903157	chr22:35795952	MCM5	-0.42	-6.41	-0.33	4.9e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	0.94	18.84	0.72	1.87e-54	Menarche (age at onset);
LUSC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg26441486	chr22:50317300	CRELD2	-0.54	-8.25	-0.41	3.75e-15	Schizophrenia;
LUSC	cis	rs72772090	0.908	rs6864233	chr5:96044681	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.58	7.03	0.36	1.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9549260	0.753	rs61963264	chr13:41154792	G/A	cg21288729	chr13:41239152	FOXO1	0.54	6.19	0.32	1.72e-9	Red blood cell count;
LUSC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05535760	chr7:792225	HEATR2	0.89	9.42	0.46	7.79e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg04851639	chr8:1020857	NA	-0.4	-8.05	-0.4	1.45e-14	Schizophrenia;
LUSC	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg16099169	chr2:106886729	NA	-0.43	-6.32	-0.33	8.29e-10	Facial morphology (factor 23);
LUSC	cis	rs7178375	0.607	rs34178381	chr15:31222585	G/C	cg15020726	chr15:31196382	MTMR15	0.91	7.64	0.39	2.3e-13	Hypertriglyceridemia;
LUSC	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	1.12	13.36	0.59	6.58e-33	Arsenic metabolism;
LUSC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg04450456	chr4:17643702	FAM184B	0.39	6.55	0.34	2.21e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg00857998	chr1:205179979	DSTYK	0.65	10.27	0.49	1.09e-21	Red blood cell count;
LUSC	trans	rs9944715	1.000	rs4890633	chr18:43833278	C/T	cg01718231	chr17:29326311	RNF135	-0.48	-6.87	-0.35	3.1e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-1.15	-18.3	-0.71	2.71e-52	Exhaled nitric oxide output;
LUSC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg08975724	chr8:8085496	FLJ10661	0.62	9.24	0.45	2.86e-18	Neuroticism;
LUSC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.78	0.3	1.76e-8	Personality dimensions;
LUSC	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg02825527	chr7:2087843	MAD1L1	-0.45	-5.85	-0.3	1.17e-8	Neuroticism;
LUSC	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.17	-0.32	1.99e-9	Retinal vascular caliber;
LUSC	cis	rs2708377	0.858	rs117212341	chr12:11282556	C/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.81	7.9	0.4	4.08e-14	Bitter taste perception;
LUSC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg24829409	chr8:58192753	C8orf71	-0.57	-7.24	-0.37	3.11e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs6011368	0.678	rs6089801	chr20:62911391	T/G	cg13869341	chr1:15865	WASH5P	0.39	6.03	0.31	4.34e-9	Clozapine-induced cytotoxicity;
LUSC	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.53	-0.42	5.31e-16	Retinal vascular caliber;
LUSC	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg02423579	chr7:2872169	GNA12	-0.38	-5.91	-0.31	8.49e-9	Height;
LUSC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	0.66	10.29	0.49	9.09e-22	Height;
LUSC	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg04362960	chr10:104952993	NT5C2	0.59	9.34	0.46	1.42e-18	Arsenic metabolism;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02603192	chr20:25677290	ZNF337	-0.4	-6.12	-0.32	2.58e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg20129853	chr10:51489980	NA	-0.34	-6.82	-0.35	4.29e-11	Prostate-specific antigen levels;
LUSC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.52	-0.42	5.65e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg16339924	chr4:17578868	LAP3	0.63	9.23	0.45	3.22e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg00750074	chr16:89608354	SPG7	-0.56	-10.16	-0.49	2.61e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.81	-13.11	-0.58	5.9e-32	Morning vs. evening chronotype;
LUSC	trans	rs9944715	0.859	rs73425119	chr18:43753831	G/C	cg01718231	chr17:29326311	RNF135	0.53	7.58	0.38	3.52e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	1.09	15.49	0.65	3.65e-41	Uric acid levels;
LUSC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg17279839	chr7:150038598	RARRES2	0.36	5.87	0.31	1.06e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.67e-24	Hypertriglyceridemia;
LUSC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg08132940	chr7:1081526	C7orf50	-0.49	-6.16	-0.32	2.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg06558623	chr16:89946397	TCF25	0.85	9.17	0.45	4.82e-18	Skin colour saturation;
LUSC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	15.92	0.66	7.26e-43	Platelet count;
LUSC	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07080220	chr10:102295463	HIF1AN	0.66	9.22	0.45	3.46e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.5	10.02	0.48	7.63e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.59	-9.77	-0.47	5.31e-20	Dilated cardiomyopathy;
LUSC	cis	rs1322512	0.752	rs1407489	chr6:152941182	G/T	cg27316956	chr6:152958899	SYNE1	-0.36	-5.89	-0.31	9.48e-9	Tonometry;
LUSC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg13319975	chr6:146136371	FBXO30	0.48	7.33	0.37	1.76e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg09877947	chr5:131593287	PDLIM4	0.38	6.25	0.32	1.27e-9	Blood metabolite levels;
LUSC	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg17509989	chr5:176798049	RGS14	0.66	8.72	0.43	1.3e-16	Urate levels in lean individuals;
LUSC	cis	rs752010	0.695	rs12134166	chr1:42105867	C/T	cg06885757	chr1:42089581	HIVEP3	0.44	8.48	0.42	7.29e-16	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg05855489	chr10:104503620	C10orf26	0.52	8.09	0.4	1.13e-14	Arsenic metabolism;
LUSC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-1.19	-12.67	-0.57	2.71e-30	Diabetic kidney disease;
LUSC	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.11	-17.83	-0.7	1.92e-50	Primary sclerosing cholangitis;
LUSC	cis	rs7712401	0.755	rs1545696	chr5:122102442	A/G	cg19077854	chr5:122220652	SNX24	0.32	7.02	0.36	1.27e-11	Mean platelet volume;
LUSC	trans	rs459571	0.959	rs410876	chr9:136893867	C/A	cg10765909	chr12:53715428	AAAS	-0.43	-6.21	-0.32	1.54e-9	Platelet distribution width;
LUSC	cis	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.36	-0.33	6.57e-10	Retinal vascular caliber;
LUSC	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg27219399	chr15:67835830	MAP2K5	0.34	5.66	0.3	3.33e-8	Restless legs syndrome;
LUSC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg02423579	chr7:2872169	GNA12	-0.45	-6.59	-0.34	1.75e-10	Height;
LUSC	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg05805236	chr11:65401703	PCNXL3	0.63	10.91	0.51	6.47e-24	Systemic lupus erythematosus;
LUSC	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg05738196	chr6:26577821	NA	-0.75	-13.48	-0.59	2.37e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.82	0.43	6.43e-17	Motion sickness;
LUSC	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg03563238	chr19:33554763	RHPN2	-0.39	-6.25	-0.32	1.22e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.27	0.64	2.6e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06022373	chr22:39101656	GTPBP1	-0.74	-11.63	-0.54	1.75e-26	Menopause (age at onset);
LUSC	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-1.06	-16.01	-0.66	3.32e-43	Exhaled nitric oxide output;
LUSC	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg08999081	chr20:33150536	PIGU	-0.42	-7.82	-0.39	6.91e-14	Glomerular filtration rate (creatinine);
LUSC	trans	rs12145833	0.538	rs10926977	chr1:243411367	T/G	cg01826367	chr1:224180288	NA	0.67	6.01	0.31	4.96e-9	Obesity (early onset extreme);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05261336	chr7:1032904	NA	-0.4	-6.0	-0.31	5.17e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3125734	0.633	rs7100297	chr10:63985100	T/C	cg09941381	chr10:64027924	RTKN2	-0.37	-6.93	-0.35	2.17e-11	Rheumatoid arthritis;
LUSC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.62	8.36	0.42	1.68e-15	Response to diuretic therapy;
LUSC	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg23950597	chr19:37808831	NA	-0.63	-7.68	-0.39	1.82e-13	Coronary artery calcification;
LUSC	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.14	0.52	1.03e-24	Hypertriglyceridemia;
LUSC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg01416388	chr22:39784598	NA	-0.44	-7.21	-0.37	3.73e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.93	16.59	0.67	1.63e-45	Chronic sinus infection;
LUSC	trans	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.79	0.54	4.45e-27	Exhaled nitric oxide output;
LUSC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg06212747	chr3:49208901	KLHDC8B	0.45	6.08	0.32	3.37e-9	Parkinson's disease;
LUSC	cis	rs4129585	1.000	rs4129585	chr8:143312933	A/C	cg16886403	chr8:143471632	TSNARE1	0.45	6.4	0.33	5.2e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6961069	0.645	rs10275699	chr7:80224709	G/A	cg04458919	chr7:80252533	CD36	-0.41	-7.32	-0.37	1.91e-12	Platelet count;
LUSC	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg02017074	chr12:117425053	FBXW8	0.67	7.71	0.39	1.47e-13	Subcortical brain region volumes;Hippocampal volume;
LUSC	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg23029597	chr12:123009494	RSRC2	-0.73	-9.17	-0.45	4.89e-18	Body mass index;
LUSC	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg23505145	chr19:12996616	KLF1	0.63	10.56	0.5	1.14e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg00484396	chr16:3507460	NAT15	0.7	11.93	0.55	1.38e-27	Tuberculosis;
LUSC	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	12.35	0.56	4.1e-29	Electrocardiographic conduction measures;
LUSC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22029157	chr1:209979665	IRF6	-0.71	-10.57	-0.5	1.03e-22	Cleft lip with or without cleft palate;
LUSC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg27068330	chr11:65405492	SIPA1	-0.79	-11.42	-0.53	1.03e-25	Acne (severe);
LUSC	cis	rs1113500	0.933	rs11185260	chr1:108635079	A/T	cg06207961	chr1:108661230	NA	-0.4	-7.49	-0.38	6.09e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg25703541	chr22:24373054	LOC391322	-0.9	-16.1	-0.66	1.38e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08645402	chr16:4508243	NA	0.46	7.08	0.36	8.43e-12	Schizophrenia;
LUSC	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg23422044	chr7:1970798	MAD1L1	-0.59	-6.66	-0.34	1.11e-10	Bipolar disorder;
LUSC	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg07211511	chr3:129823064	LOC729375	-0.59	-7.98	-0.4	2.38e-14	Blood pressure (smoking interaction);
LUSC	cis	rs72700829	0.576	rs6695311	chr1:151002758	G/A	cg11822372	chr1:151115635	SEMA6C	-0.75	-6.69	-0.34	9.53e-11	Schizophrenia;
LUSC	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg12560992	chr17:57184187	TRIM37	0.59	9.51	0.46	4e-19	Testicular germ cell tumor;
LUSC	cis	rs6494488	0.500	rs80142506	chr15:64995147	G/C	cg08069370	chr15:64387884	SNX1	-0.68	-5.9	-0.31	8.97e-9	Coronary artery disease;
LUSC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	7.48	0.38	6.69e-13	Personality dimensions;
LUSC	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg21775007	chr8:11205619	TDH	-0.64	-9.97	-0.48	1.12e-20	Retinal vascular caliber;
LUSC	cis	rs4363385	0.510	rs1500937	chr1:153045483	G/C	cg25856811	chr1:152973957	SPRR3	-0.39	-6.37	-0.33	6.39e-10	Inflammatory skin disease;
LUSC	cis	rs7851660	0.874	rs1955145	chr9:100634751	A/C	cg13688889	chr9:100608707	NA	0.55	8.62	0.43	2.68e-16	Strep throat;
LUSC	cis	rs870825	0.616	rs28497285	chr4:185629169	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.77e-32	Blood protein levels;
LUSC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07362569	chr17:61921086	SMARCD2	-0.37	-7.54	-0.38	4.45e-13	Prudent dietary pattern;
LUSC	trans	rs12043259	0.730	rs2208843	chr1:204789624	A/G	cg05134015	chr14:36973365	SFTA3	0.5	5.97	0.31	5.99e-9	Addiction;
LUSC	cis	rs2050392	0.931	rs2265187	chr10:30690844	C/T	cg18806716	chr10:30721971	MAP3K8	-0.44	-7.14	-0.36	5.8e-12	Inflammatory bowel disease;
LUSC	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg13615516	chr5:77269221	NA	0.4	6.72	0.35	7.73e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.57	0.53	3.01e-26	Mean corpuscular volume;
LUSC	cis	rs6939532	0.648	rs9379862	chr6:26370707	T/C	cg14345882	chr6:26364793	BTN3A2	0.44	6.09	0.32	3.08e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg13560548	chr3:10150139	C3orf24	0.52	7.47	0.38	6.96e-13	Alzheimer's disease;
LUSC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25072359	chr17:41440525	NA	0.66	9.5	0.46	4.09e-19	Menopause (age at onset);
LUSC	cis	rs7246967	0.673	rs2082445	chr19:22834587	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs17253792	0.915	rs28663681	chr14:56178820	A/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.86	-0.35	3.35e-11	Putamen volume;
LUSC	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg06623918	chr6:96969491	KIAA0776	0.8	11.59	0.54	2.38e-26	Migraine;Coronary artery disease;
LUSC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg02569458	chr12:86230093	RASSF9	-0.48	-7.91	-0.4	3.71e-14	Major depressive disorder;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg13003239	chr3:49044627	WDR6	-0.48	-6.43	-0.33	4.42e-10	Cognitive function;Information processing speed;
LUSC	cis	rs1419980	0.673	rs4883421	chr12:7774028	A/G	cg10578777	chr12:7781093	NA	0.54	6.0	0.31	5.13e-9	HDL cholesterol levels;
LUSC	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg12311346	chr5:56204834	C5orf35	-0.65	-9.57	-0.46	2.49e-19	Coronary artery disease;
LUSC	cis	rs7911264	1.000	rs7911264	chr10:94436851	C/T	cg25093409	chr10:94429542	NA	-0.39	-6.62	-0.34	1.41e-10	Inflammatory bowel disease;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg06037631	chr2:74942369	NA	0.35	6.25	0.32	1.23e-9	Triglycerides;
LUSC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg06287003	chr12:125626642	AACS	-0.4	-6.13	-0.32	2.41e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg07148914	chr20:33460835	GGT7	-0.53	-8.1	-0.41	1.05e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.72	14.08	0.61	1.13e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs981844	0.735	rs111822747	chr4:154734629	G/C	cg14289246	chr4:154710475	SFRP2	0.46	6.17	0.32	1.93e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs9473147	0.516	rs7767350	chr6:47485126	C/T	cg12968598	chr6:47444699	CD2AP	0.53	8.07	0.4	1.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs9886651	0.806	rs13280865	chr8:128781333	A/G	cg07795030	chr8:128802207	NA	-0.34	-6.27	-0.32	1.14e-9	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LUSC	cis	rs859767	0.540	rs13424016	chr2:135406395	A/G	cg12500956	chr2:135428796	TMEM163	-0.26	-5.99	-0.31	5.58e-9	Neuroticism;
LUSC	cis	rs2688608	0.904	rs2675669	chr10:75653872	C/T	cg23231163	chr10:75533350	FUT11	-0.36	-5.99	-0.31	5.42e-9	Inflammatory bowel disease;
LUSC	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg04727924	chr7:799746	HEATR2	-0.53	-6.31	-0.33	8.76e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.84	-0.44	5.41e-17	Bipolar disorder;
LUSC	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg15704280	chr7:45808275	SEPT13	0.78	7.55	0.38	4.31e-13	Axial length;
LUSC	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	cis	rs77633900	0.772	rs284905	chr15:76743345	C/T	cg21673338	chr15:77095150	SCAPER	-0.68	-5.94	-0.31	7.22e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	10.41	0.49	3.7e-22	Lymphocyte counts;
LUSC	cis	rs11264799	0.603	rs7520627	chr1:157568371	A/T	cg18268488	chr1:157545234	FCRL4	0.34	6.21	0.32	1.54e-9	IgA nephropathy;
LUSC	cis	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg06521331	chr12:34319734	NA	-0.37	-6.19	-0.32	1.81e-9	Morning vs. evening chronotype;
LUSC	cis	rs9653442	0.527	rs2164712	chr2:100745404	C/G	cg22139774	chr2:100720529	AFF3	-0.41	-6.93	-0.35	2.14e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg00530320	chr1:46809349	NSUN4	0.55	8.46	0.42	8.29e-16	Menopause (age at onset);
LUSC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg23791538	chr6:167370224	RNASET2	-0.41	-6.62	-0.34	1.44e-10	Crohn's disease;
LUSC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg13854012	chr2:162103682	NA	-0.45	-7.97	-0.4	2.58e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	trans	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	7.69	0.39	1.69e-13	Neuroticism;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg06096824	chr1:51443952	NA	0.34	6.11	0.32	2.7e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg13575925	chr12:9217583	LOC144571	0.35	6.41	0.33	4.95e-10	Sjögren's syndrome;
LUSC	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg19508488	chr2:152266495	RIF1	0.56	8.6	0.43	3.16e-16	Lung cancer;
LUSC	cis	rs1865721	0.917	rs62089506	chr18:73178913	A/G	cg26385618	chr18:73139727	C18orf62	-0.48	-8.19	-0.41	5.65e-15	Intelligence;
LUSC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg21951975	chr1:209979733	IRF6	-0.56	-7.23	-0.37	3.4e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg13126279	chr21:47581558	C21orf56	-0.43	-6.34	-0.33	7.48e-10	Testicular germ cell tumor;
LUSC	cis	rs2279817	0.743	rs12023874	chr1:18025612	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.49	6.97	0.36	1.74e-11	Neuroticism;
LUSC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg12292205	chr6:26970375	C6orf41	0.36	5.72	0.3	2.38e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs2963482	0.691	rs2963440	chr5:157942696	G/T	cg04221764	chr5:177410766	NA	0.33	6.41	0.33	4.83e-10	Nonsyndromic cleft lip with or without cleft palate;
LUSC	cis	rs9653442	0.545	rs11681966	chr2:100759457	A/C	cg07810366	chr2:100720526	AFF3	0.44	7.46	0.38	7.36e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg27432699	chr2:27873401	GPN1	-0.58	-8.46	-0.42	8.46e-16	Total body bone mineral density;
LUSC	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.81	-14.09	-0.61	9.99e-36	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg15423357	chr2:25149977	NA	0.45	9.13	0.45	6.59e-18	Body mass index;
LUSC	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg23625390	chr15:77176239	SCAPER	0.46	7.13	0.36	6.07e-12	Blood metabolite levels;
LUSC	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg10792982	chr14:105748885	BRF1	0.49	8.48	0.42	7.31e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg26513180	chr16:89883248	FANCA	0.92	17.5	0.69	3.99e-49	Vitiligo;
LUSC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	7.19	0.37	4.39e-12	Platelet count;
LUSC	trans	rs12709013	0.636	rs1646269	chr16:58777316	T/C	cg19313373	chr1:162694184	DDR2	-0.35	-5.96	-0.31	6.55e-9	Blood metabolite ratios;
LUSC	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.77	15.99	0.66	4.06e-43	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg21573476	chr21:45109991	RRP1B	-0.43	-6.94	-0.36	2.04e-11	Mean corpuscular volume;
LUSC	cis	rs1143633	0.566	rs2708932	chr2:113690675	C/A	cg06156847	chr2:113672199	IL1F7	0.3	6.34	0.33	7.45e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-25.6	-0.81	9.6e-81	Exhaled nitric oxide output;
LUSC	cis	rs888194	0.544	rs2196612	chr12:109849535	A/G	cg05360138	chr12:110035743	NA	0.4	5.88	0.31	9.84e-9	Neuroticism;
LUSC	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg08000102	chr2:233561755	GIGYF2	-0.64	-8.4	-0.42	1.27e-15	Schizophrenia;
LUSC	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.02	0.4	1.84e-14	Axial length;
LUSC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.95	-0.51	4.95e-24	Aortic root size;
LUSC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-6.52	-0.34	2.57e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2573652	0.722	rs8034841	chr15:100541593	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.3	-5.65	-0.3	3.52e-8	Height;
LUSC	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-6.67	-0.34	1.06e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg02569458	chr12:86230093	RASSF9	0.47	7.41	0.38	1.05e-12	Major depressive disorder;
LUSC	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs8038465	0.638	rs12591473	chr15:73967485	A/T	cg15420318	chr15:73925796	NPTN	0.54	9.63	0.47	1.56e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10754283	0.967	rs6428559	chr1:90099036	C/T	cg21401794	chr1:90099060	LRRC8C	0.65	9.76	0.47	5.75e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs11677416	1.000	rs4848304	chr2:113552737	T/C	cg27083787	chr2:113543245	IL1A	0.47	7.33	0.37	1.79e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.6	10.11	0.48	4.01e-21	Bone mineral density;
LUSC	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.7	-0.3	2.67e-8	Recombination rate (females);
LUSC	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.8	-0.35	4.82e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.22	0.32	1.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.41e-28	Motion sickness;
LUSC	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg20701182	chr2:24300061	SF3B14	0.56	6.05	0.31	3.84e-9	Lymphocyte counts;
LUSC	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.68	-10.99	-0.52	3.42e-24	Sudden cardiac arrest;
LUSC	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg16342193	chr10:102329863	NA	-0.35	-6.48	-0.33	3.28e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	0.8	14.07	0.61	1.2e-35	Cognitive function;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21767207	chr19:36236454	PSENEN;U2AF1L4	-0.5	-6.82	-0.35	4.29e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.64	0.34	1.26e-10	Lung cancer;
LUSC	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg15556689	chr8:8085844	FLJ10661	-0.59	-9.91	-0.48	1.88e-20	Mood instability;
LUSC	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg17168535	chr8:21777572	XPO7	-0.65	-9.93	-0.48	1.53e-20	Mean corpuscular volume;
LUSC	cis	rs1395	0.922	rs11898114	chr2:27515527	C/T	cg23587288	chr2:27483067	SLC30A3	-0.3	-5.81	-0.3	1.46e-8	Blood metabolite levels;
LUSC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.86	0.6	8.34e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg08557956	chr11:4115526	RRM1	0.47	6.04	0.31	4.07e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.41	-0.49	3.71e-22	Eye color traits;
LUSC	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg25019033	chr10:957182	NA	-0.5	-6.2	-0.32	1.69e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg24399712	chr22:39784796	NA	-0.63	-11.31	-0.53	2.41e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs9434723	0.844	rs9435148	chr1:9300962	G/C	cg04199779	chr1:9294473	H6PD	0.51	5.97	0.31	6.12e-9	Height;
LUSC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	8.5	0.42	6.52e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs739496	0.542	rs7312913	chr12:111793552	A/G	cg10833066	chr12:111807467	FAM109A	0.62	12.05	0.55	5.06e-28	Platelet count;
LUSC	cis	rs11264799	0.520	rs849817	chr1:157542045	G/A	cg18268488	chr1:157545234	FCRL4	0.38	7.53	0.38	4.67e-13	IgA nephropathy;
LUSC	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.37	-6.12	-0.32	2.57e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg08213375	chr14:104286397	PPP1R13B	0.53	10.39	0.49	4.15e-22	Schizophrenia;
LUSC	trans	rs12080794	1.000	rs11121322	chr1:9155410	G/A	cg11315153	chr6:62996299	KHDRBS2	-0.52	-6.11	-0.32	2.76e-9	Response to antidepressant treatment (citalopram);
LUSC	cis	rs10746514	1.000	rs9724948	chr1:232248244	C/T	cg09506761	chr1:232265262	NA	0.47	7.64	0.39	2.25e-13	Response to statin therapy;
LUSC	cis	rs9463078	0.547	rs720576	chr6:44729974	A/T	cg25276700	chr6:44698697	NA	0.3	6.3	0.33	9.28e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs11247915	0.561	rs12750420	chr1:26608649	G/A	cg04990556	chr1:26633338	UBXN11	-0.53	-7.24	-0.37	3.15e-12	Obesity-related traits;
LUSC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg21435336	chr19:17392852	ANKLE1	0.45	6.33	0.33	7.76e-10	Systemic lupus erythematosus;
LUSC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg24324837	chr19:49891574	CCDC155	0.5	7.08	0.36	8.33e-12	Multiple sclerosis;
LUSC	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.77	-11.0	-0.52	3.19e-24	Breast cancer;
LUSC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.66	-11.66	-0.54	1.34e-26	Aortic root size;
LUSC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.25	0.37	2.83e-12	Bipolar disorder;
LUSC	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg06026331	chr20:60912101	LAMA5	0.59	6.32	0.33	8.17e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg20243544	chr17:37824526	PNMT	0.49	6.95	0.36	1.92e-11	Asthma;
LUSC	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg13010199	chr12:38710504	ALG10B	0.57	8.94	0.44	2.68e-17	Morning vs. evening chronotype;
LUSC	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg14634687	chr17:47094252	IGF2BP1	0.31	6.54	0.34	2.26e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg02807482	chr3:125708958	NA	-0.54	-6.74	-0.35	6.88e-11	Blood pressure (smoking interaction);
LUSC	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg08807101	chr21:30365312	RNF160	0.58	8.84	0.44	5.47e-17	Selective IgA deficiency;
LUSC	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs57994353	0.568	rs10870151	chr9:139309584	G/A	cg14019695	chr9:139328340	INPP5E	0.37	5.79	0.3	1.67e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUSC	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg00105475	chr2:10696890	NA	-0.38	-6.4	-0.33	5.4e-10	Prostate cancer;
LUSC	cis	rs9359856	0.564	rs17584108	chr6:90458209	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.2	-0.41	5.08e-15	Bipolar disorder;
LUSC	cis	rs500891	0.525	rs12213724	chr6:84078990	A/C	cg08257003	chr6:84140564	ME1	0.35	8.63	0.43	2.58e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12292205	chr6:26970375	C6orf41	-0.55	-6.71	-0.34	8.34e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg25214090	chr10:38739885	LOC399744	0.55	8.04	0.4	1.62e-14	Corneal astigmatism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	ch.20.661824R	chr20:32868459	AHCY	0.45	6.23	0.32	1.41e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00032686	chr4:1005072	FGFRL1	-0.42	-6.62	-0.34	1.45e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.46	0.38	7.77e-13	Motion sickness;
LUSC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.5	-0.5	1.79e-22	Bipolar disorder;
LUSC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg00310523	chr12:86230176	RASSF9	0.44	8.25	0.41	3.7e-15	Major depressive disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg08532152	chr11:10772778	CTR9	0.78	6.09	0.32	3.05e-9	Cognitive performance;
LUSC	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg08508325	chr11:3079039	CARS	0.35	7.85	0.39	5.9e-14	Calcium levels;
LUSC	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg25173405	chr17:45401733	C17orf57	-0.48	-7.13	-0.36	6.14e-12	Glaucoma (primary open-angle);
LUSC	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg15839431	chr19:19639596	YJEFN3	0.6	6.75	0.35	6.71e-11	Bipolar disorder;
LUSC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg26695010	chr11:65641043	EFEMP2	-0.44	-6.65	-0.34	1.2e-10	Eosinophil percentage of white cells;
LUSC	cis	rs4423214	0.559	rs10898203	chr11:71203436	C/T	cg05163923	chr11:71159392	DHCR7	-0.7	-7.23	-0.37	3.32e-12	Vitamin D levels;
LUSC	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg24110177	chr3:50126178	RBM5	0.43	6.83	0.35	4.05e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	0.98	18.79	0.72	3e-54	Cognitive function;
LUSC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg15691649	chr6:25882328	NA	-0.5	-7.45	-0.38	7.99e-13	Blood metabolite levels;
LUSC	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.91	-0.44	3.36e-17	Breast cancer;
LUSC	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg13010199	chr12:38710504	ALG10B	0.66	10.17	0.49	2.5e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs61332075	0.518	rs112649209	chr2:239422814	C/G	cg18131467	chr2:239335373	ASB1	-0.68	-6.47	-0.33	3.41e-10	Lung function (FEV1/FVC);
LUSC	cis	rs597583	0.950	rs473343	chr11:117408156	G/C	cg27161313	chr11:117392002	DSCAML1	-0.38	-6.55	-0.34	2.11e-10	Putamen volume;
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg05863683	chr7:1912471	MAD1L1	0.31	5.99	0.31	5.34e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg13575925	chr12:9217583	LOC144571	0.32	5.75	0.3	2.03e-8	Sjögren's syndrome;
LUSC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg18402987	chr7:1209562	NA	0.73	7.84	0.39	5.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg27129171	chr3:47204927	SETD2	-0.68	-11.27	-0.52	3.58e-25	Colorectal cancer;
LUSC	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg14458575	chr2:238380390	NA	0.74	13.37	0.59	6.16e-33	Prostate cancer;
LUSC	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.22	-15.44	-0.65	5.73e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.93	-18.16	-0.7	9.41e-52	Prudent dietary pattern;
LUSC	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.41	-0.33	5.01e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.52	-8.51	-0.42	6.12e-16	Prudent dietary pattern;
LUSC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-9.5	-0.46	4.09e-19	Mood instability;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16236679	chr11:96123321	JRKL;CCDC82	0.42	6.08	0.32	3.34e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg25344623	chr2:136566232	LCT	0.38	5.72	0.3	2.41e-8	Mosquito bite size;
LUSC	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg17644776	chr2:200775616	C2orf69	0.4	6.14	0.32	2.37e-9	Schizophrenia;
LUSC	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg25214090	chr10:38739885	LOC399744	0.53	7.62	0.38	2.71e-13	Corneal astigmatism;
LUSC	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg03859395	chr2:55845619	SMEK2	0.88	16.63	0.67	1.14e-45	Metabolic syndrome;
LUSC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg17971929	chr21:40555470	PSMG1	-0.68	-11.11	-0.52	1.31e-24	Cognitive function;
LUSC	cis	rs8005677	0.828	rs2295680	chr14:23374435	A/G	cg25600027	chr14:23388339	RBM23	0.4	6.24	0.32	1.36e-9	Cognitive ability (multi-trait analysis);
LUSC	cis	rs73206853	0.563	rs1973505	chr12:111160003	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.7	-9.08	-0.44	9.68e-18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.7	-0.57	2.02e-30	Chronic sinus infection;
LUSC	cis	rs6977660	0.607	rs7357321	chr7:19817636	C/T	cg05791153	chr7:19748676	TWISTNB	0.65	7.0	0.36	1.39e-11	Thyroid stimulating hormone;
LUSC	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.54	0.5	1.25e-22	Morning vs. evening chronotype;
LUSC	cis	rs62158211	0.691	rs1964463	chr2:114069021	C/T	cg17784749	chr2:114082611	LOC440839	-0.45	-5.89	-0.31	9.18e-9	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LUSC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.83	0.3	1.32e-8	Breast cancer;
LUSC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg05802129	chr4:122689817	NA	-0.34	-6.0	-0.31	5.17e-9	Type 2 diabetes;
LUSC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.57	8.41	0.42	1.17e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.67	0.34	1.06e-10	Menopause (age at onset);
LUSC	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.59	0.43	3.48e-16	Response to antipsychotic treatment;
LUSC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg18190219	chr22:46762943	CELSR1	-0.49	-6.08	-0.32	3.2e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10779751	0.734	rs2259886	chr1:11137778	C/T	cg08854313	chr1:11322531	MTOR	0.81	12.51	0.57	9.9e-30	Body mass index;
LUSC	cis	rs1950626	0.833	rs67456801	chr14:101399169	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.39	6.84	0.35	3.71e-11	Pelvic organ prolapse (moderate/severe);
LUSC	trans	rs3929778	0.848	rs2326793	chr20:6541381	C/G	cg26955290	chr17:7015607	ASGR2	-0.41	-6.19	-0.32	1.73e-9	QRS complex (Cornell);
LUSC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11645453	chr3:52864694	ITIH4	0.35	8.05	0.4	1.43e-14	Bipolar disorder;
LUSC	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.31	-5.77	-0.3	1.84e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	0.83	13.66	0.6	4.78e-34	Menopause (age at onset);
LUSC	cis	rs11997175	0.646	rs7464237	chr8:33716596	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	7.0	0.36	1.44e-11	Body mass index;
LUSC	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-0.97	-15.16	-0.64	6.95e-40	Triglycerides;
LUSC	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.17	-0.32	1.96e-9	Response to antipsychotic treatment;
LUSC	cis	rs2635047	0.811	rs12958943	chr18:44786818	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	5.7	0.3	2.68e-8	Educational attainment;
LUSC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg26762873	chr11:5879799	OR52E8	-0.3	-5.94	-0.31	7.25e-9	DNA methylation (variation);
LUSC	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-6.89	-0.35	2.82e-11	Breast cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00658016	chr3:178865678	PIK3CA	-0.4	-5.94	-0.31	7.01e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg20935933	chr6:143382018	AIG1	0.48	7.19	0.37	4.23e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.22	-0.41	4.54e-15	Response to antipsychotic treatment;
LUSC	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg02574844	chr11:5959923	NA	-0.4	-5.96	-0.31	6.27e-9	DNA methylation (variation);
LUSC	cis	rs7760949	0.925	rs9464420	chr6:13925892	C/T	cg27413430	chr6:13925136	RNF182	0.61	9.04	0.44	1.33e-17	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg06637938	chr14:75390232	RPS6KL1	0.5	7.74	0.39	1.2e-13	Height;
LUSC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06657462	chr10:94608040	EXOC6	0.5	6.67	0.34	1.05e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.78	-0.3	1.73e-8	Alzheimer's disease (late onset);
LUSC	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	10.16	0.49	2.67e-21	Lymphocyte counts;
LUSC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg26441486	chr22:50317300	CRELD2	-0.54	-8.21	-0.41	4.86e-15	Schizophrenia;
LUSC	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.51	0.34	2.77e-10	Schizophrenia;
LUSC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs4363385	0.747	rs10494285	chr1:152982285	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.33e-13	Inflammatory skin disease;
LUSC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg08200582	chr11:442649	ANO9	-0.57	-6.07	-0.32	3.53e-9	Body mass index;
LUSC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg25456477	chr12:86230367	RASSF9	0.35	6.25	0.32	1.24e-9	Major depressive disorder;
LUSC	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.62	-0.34	1.44e-10	Breast cancer;
LUSC	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg09184832	chr6:79620586	NA	-0.41	-6.32	-0.33	8.39e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.44	0.38	8.39e-13	Schizophrenia;
LUSC	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg00277334	chr10:82204260	NA	-0.41	-5.76	-0.3	1.89e-8	Post bronchodilator FEV1;
LUSC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg24733560	chr20:60626293	TAF4	0.42	7.75	0.39	1.11e-13	Body mass index;
LUSC	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg19418458	chr7:158789849	NA	0.49	6.44	0.33	4.24e-10	Facial morphology (factor 20);
LUSC	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.01	-0.36	1.31e-11	Response to antipsychotic treatment;
LUSC	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg10434728	chr15:90938212	IQGAP1	0.4	8.36	0.42	1.7e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg16325326	chr1:53192061	ZYG11B	0.69	11.22	0.52	5.1e-25	Monocyte count;
LUSC	cis	rs13072153	0.793	rs9841477	chr3:123157477	A/C	cg04138502	chr3:123167522	ADCY5	0.28	5.72	0.3	2.39e-8	Chronic kidney disease;
LUSC	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19346786	chr7:2764209	NA	-0.52	-8.63	-0.43	2.5e-16	Height;
LUSC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg16060761	chr17:80687452	NA	0.42	7.07	0.36	8.83e-12	Breast cancer;
LUSC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	11.28	0.53	3.31e-25	Prudent dietary pattern;
LUSC	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.71	-12.51	-0.56	1.04e-29	White blood cell count (basophil);
LUSC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg16606324	chr3:10149918	C3orf24	0.44	6.83	0.35	4.05e-11	Alzheimer's disease;
LUSC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05901451	chr6:126070800	HEY2	-0.77	-12.61	-0.57	4.37e-30	Endometrial cancer;
LUSC	cis	rs61897795	0.657	rs174590	chr11:61616977	G/C	cg19610905	chr11:61596333	FADS2	-0.44	-5.76	-0.3	1.88e-8	Neutrophil count;Sum basophil neutrophil counts;
LUSC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	1.03	17.92	0.7	8.94e-51	Coronary artery disease;
LUSC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg08999081	chr20:33150536	PIGU	0.45	8.29	0.41	2.85e-15	Coronary artery disease;
LUSC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg05313129	chr8:58192883	C8orf71	-0.5	-6.5	-0.34	2.9e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.64	-10.93	-0.51	5.69e-24	Caffeine consumption;
LUSC	cis	rs2249625	0.526	rs17781511	chr6:72845455	C/T	cg18830697	chr6:72922368	RIMS1	0.38	7.59	0.38	3.25e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg19508488	chr2:152266495	RIF1	0.54	7.72	0.39	1.36e-13	Lung cancer;
LUSC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg10360139	chr7:1886902	MAD1L1	0.44	6.94	0.35	2.1e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6545883	0.929	rs3732170	chr2:61749716	C/T	cg15711740	chr2:61764176	XPO1	-0.5	-7.92	-0.4	3.51e-14	Tuberculosis;
LUSC	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg17652424	chr22:38574118	PLA2G6	-0.31	-6.66	-0.34	1.15e-10	Cutaneous nevi;
LUSC	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	20.83	0.75	2.5e-62	Homoarginine levels;
LUSC	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg05855489	chr10:104503620	C10orf26	-0.65	-8.29	-0.41	2.8e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.03	-0.31	4.46e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg08742575	chr21:47604166	C21orf56	-0.42	-6.26	-0.32	1.2e-9	Testicular germ cell tumor;
LUSC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.92	0.7	8.72e-51	Chronic sinus infection;
LUSC	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.88	0.31	1e-8	Breast cancer;
LUSC	cis	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg02972257	chr16:68554789	NA	-0.5	-6.18	-0.32	1.91e-9	Ulcerative colitis;
LUSC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg15448220	chr1:150897856	SETDB1	0.4	5.89	0.31	9.64e-9	Melanoma;
LUSC	trans	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.11	-0.36	7.29e-12	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.54	-0.34	2.27e-10	Retinal vascular caliber;
LUSC	cis	rs4964805	0.657	rs11111781	chr12:104187440	C/T	cg02344784	chr12:104178138	NT5DC3	0.46	8.9	0.44	3.55e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.74	13.07	0.58	8.13e-32	Prostate cancer;
LUSC	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg12884169	chr21:40033163	ERG	-0.61	-12.66	-0.57	2.97e-30	Coronary artery disease;
LUSC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg23711669	chr6:146136114	FBXO30	0.92	17.68	0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11971779	0.680	rs73154134	chr7:139039951	G/A	cg07862535	chr7:139043722	LUC7L2	0.58	7.07	0.36	9.11e-12	Diisocyanate-induced asthma;
LUSC	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-9.19	-0.45	4.25e-18	Myeloid white cell count;
LUSC	cis	rs1881396	0.891	rs2141372	chr2:27827196	G/T	cg27432699	chr2:27873401	GPN1	0.63	8.61	0.43	2.91e-16	Nonalcoholic fatty liver disease;
LUSC	trans	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg16487237	chr3:137487248	NA	0.36	6.02	0.31	4.69e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg04455712	chr21:45112962	RRP1B	0.42	7.96	0.4	2.77e-14	Mean corpuscular volume;
LUSC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg22117172	chr7:91764530	CYP51A1	0.32	5.68	0.3	2.88e-8	Breast cancer;
LUSC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.53	0.57	8.85e-30	Motion sickness;
LUSC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg17330251	chr7:94953956	PON1	-0.39	-6.45	-0.33	3.93e-10	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg05973401	chr12:123451056	ABCB9	0.52	6.45	0.33	4.04e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg27398817	chr8:82754497	SNX16	0.47	6.36	0.33	6.61e-10	Diastolic blood pressure;
LUSC	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg21231944	chr12:82153410	PPFIA2	-0.36	-5.75	-0.3	2.04e-8	Resting heart rate;
LUSC	trans	rs17607347	0.542	rs17609808	chr16:72568186	A/T	cg12945194	chr11:64703312	GPHA2	0.38	5.95	0.31	6.73e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg17633681	chr16:88106987	BANP	0.53	10.16	0.49	2.64e-21	Menopause (age at onset);
LUSC	cis	rs11039100	0.850	rs34930440	chr11:5834157	A/T	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs778371	0.722	rs778348	chr2:233802635	G/A	cg08000102	chr2:233561755	GIGYF2	-0.52	-6.94	-0.36	2.03e-11	Schizophrenia;
LUSC	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg08601574	chr20:25228251	PYGB	0.42	6.52	0.34	2.66e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.43	0.67	7.13e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg07817648	chr10:79422355	NA	-0.56	-7.68	-0.39	1.77e-13	Bone mineral density;
LUSC	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	0.87	14.02	0.61	1.97e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.67	10.75	0.51	2.42e-23	Mood instability;
LUSC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg18240062	chr17:79603768	NPLOC4	0.69	12.86	0.58	4.96e-31	Eye color traits;
LUSC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg06008330	chr7:65541103	ASL	-0.4	-6.23	-0.32	1.43e-9	Aortic root size;
LUSC	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17467752	chr17:38218738	THRA	-0.52	-7.44	-0.38	8.46e-13	White blood cell count;
LUSC	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg15557168	chr22:42548783	NA	-0.42	-6.39	-0.33	5.57e-10	Schizophrenia;
LUSC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg16325326	chr1:53192061	ZYG11B	0.69	11.17	0.52	7.98e-25	Monocyte count;
LUSC	trans	rs12677056	0.739	rs62514398	chr8:113312090	G/T	cg12159992	chr12:102059490	MYBPC1	0.36	6.01	0.31	4.84e-9	Peripheral artery disease;
LUSC	cis	rs10740039	0.671	rs7913549	chr10:62418232	C/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.55e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs965604	1.000	rs12593229	chr15:78765290	T/G	cg18825076	chr15:78729989	IREB2	-0.42	-6.78	-0.35	5.38e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6969780	0.908	rs6461987	chr7:27166956	G/C	cg26364809	chr7:27145159	NA	-0.58	-5.86	-0.31	1.09e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg26384229	chr12:38710491	ALG10B	0.57	7.98	0.4	2.43e-14	Morning vs. evening chronotype;
LUSC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg26429629	chr5:169758391	LOC257358	0.43	7.3	0.37	2.16e-12	Schizophrenia;
LUSC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.42	6.51	0.34	2.73e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg18681998	chr4:17616180	MED28	0.9	17.84	0.7	1.85e-50	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg18478394	chr8:109455254	TTC35	0.47	7.28	0.37	2.38e-12	Dupuytren's disease;
LUSC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg00815214	chr21:47717953	NA	0.39	6.07	0.32	3.45e-9	Testicular germ cell tumor;
LUSC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg20135002	chr11:47629003	NA	-0.51	-8.02	-0.4	1.83e-14	Subjective well-being;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20530339	chr18:21594203	TTC39C	0.39	7.08	0.36	8.5e-12	Asthma;
LUSC	cis	rs7598759	0.712	rs6740474	chr2:232331831	A/G	cg19187155	chr2:232395269	NMUR1	0.49	7.2	0.37	3.96e-12	Noise-induced hearing loss;
LUSC	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg07936489	chr17:37558343	FBXL20	0.78	9.96	0.48	1.27e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9816226	0.587	rs9863591	chr3:185841624	C/G	cg00760338	chr3:185826511	ETV5	-0.66	-10.63	-0.5	6.54e-23	Obesity;Body mass index;
LUSC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg14583973	chr4:3374767	RGS12	-0.36	-7.85	-0.39	5.76e-14	Serum sulfate level;
LUSC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg27124370	chr19:33622961	WDR88	0.51	6.68	0.34	1e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12379764	chr21:47803548	PCNT	-0.42	-5.91	-0.31	8.56e-9	Testicular germ cell tumor;
LUSC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-1.07	-15.83	-0.65	1.64e-42	Initial pursuit acceleration;
LUSC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.53	-6.7	-0.34	8.73e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.88	10.54	0.5	1.31e-22	Body mass index;
LUSC	trans	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg07923666	chr12:49932857	KCNH3	-0.48	-5.96	-0.31	6.29e-9	Resting heart rate;
LUSC	cis	rs500891	0.525	rs1535588	chr6:84051050	A/C	cg08257003	chr6:84140564	ME1	0.33	7.98	0.4	2.44e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg15145296	chr3:125709740	NA	-0.57	-6.45	-0.33	3.94e-10	Blood pressure (smoking interaction);
LUSC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs3812762	0.912	rs4929936	chr11:8792622	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.37	-6.14	-0.32	2.37e-9	Hypospadias;
LUSC	cis	rs4631830	0.863	rs10826125	chr10:51530505	G/A	cg20129853	chr10:51489980	NA	-0.34	-6.86	-0.35	3.36e-11	Prostate-specific antigen levels;
LUSC	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00631329	chr6:26305371	NA	-0.49	-9.57	-0.46	2.41e-19	Educational attainment;
LUSC	cis	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.71	9.96	0.48	1.21e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg17366294	chr4:99064904	C4orf37	0.54	9.7	0.47	9.28e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-7.59	-0.38	3.18e-13	Total body bone mineral density;
LUSC	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg15704280	chr7:45808275	SEPT13	0.72	6.85	0.35	3.54e-11	Axial length;
LUSC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg11062466	chr8:58055876	NA	0.64	8.41	0.42	1.21e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg25019033	chr10:957182	NA	-0.52	-7.22	-0.37	3.55e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs10504073	0.647	rs56057508	chr8:49982793	G/T	cg00325661	chr8:49890786	NA	0.63	10.09	0.48	4.51e-21	Blood metabolite ratios;
LUSC	cis	rs7267979	0.844	rs6083824	chr20:25363057	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-16.94	-0.68	6.65e-47	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02018176	chr4:1364513	KIAA1530	0.57	10.3	0.49	8.48e-22	Longevity;
LUSC	cis	rs7246967	0.611	rs62120457	chr19:22958519	A/G	cg23217946	chr19:22817039	ZNF492	0.43	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.41	-0.38	1.03e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg15744005	chr10:104629667	AS3MT	-0.28	-5.92	-0.31	7.82e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg14847009	chr1:175162515	KIAA0040	-0.31	-5.96	-0.31	6.47e-9	Diastolic blood pressure;
LUSC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg05863683	chr7:1912471	MAD1L1	0.31	5.96	0.31	6.31e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.77	-0.39	1.01e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg08270630	chr22:50330655	NA	-0.43	-6.43	-0.33	4.35e-10	Schizophrenia;
LUSC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg00784671	chr22:46762841	CELSR1	-0.49	-6.7	-0.34	8.75e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg23161317	chr6:28129485	ZNF389	0.44	5.67	0.3	3.05e-8	Parkinson's disease;
LUSC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg14552801	chr7:65878734	NA	0.38	5.93	0.31	7.76e-9	Aortic root size;
LUSC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg13683864	chr3:40499215	RPL14	-0.97	-16.36	-0.67	1.39e-44	Renal cell carcinoma;
LUSC	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg01134436	chr17:81009848	B3GNTL1	0.66	6.41	0.33	4.82e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Smoking initiation;
LUSC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	12.04	0.55	5.76e-28	Chronic sinus infection;
LUSC	trans	rs7939886	0.920	rs80232778	chr11:55970655	G/A	cg15704280	chr7:45808275	SEPT13	0.9	6.87	0.35	3.14e-11	Myopia (pathological);
LUSC	cis	rs3862435	0.518	rs2601166	chr15:90911179	G/A	cg22089800	chr15:90895588	ZNF774	0.58	6.35	0.33	6.93e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg06636001	chr8:8085503	FLJ10661	0.67	10.88	0.51	8.14e-24	Systolic blood pressure;
LUSC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.28	-0.53	3.08e-25	Schizophrenia;
LUSC	cis	rs56804039	1.000	rs67180327	chr8:8380754	G/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.96	-0.36	1.84e-11	Cervical cancer;
LUSC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25072359	chr17:41440525	NA	0.66	9.27	0.45	2.4e-18	Menopause (age at onset);
LUSC	trans	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg15556689	chr8:8085844	FLJ10661	0.43	6.39	0.33	5.61e-10	Neuroticism;
LUSC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg06637938	chr14:75390232	RPS6KL1	0.52	8.33	0.41	2.18e-15	Height;
LUSC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	8.4	0.42	1.29e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg09034736	chr1:150693464	HORMAD1	0.5	7.17	0.37	4.82e-12	Tonsillectomy;
LUSC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg11344533	chr11:111475393	SIK2	-0.49	-6.87	-0.35	3.18e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg18232548	chr7:50535776	DDC	0.51	7.79	0.39	8.37e-14	Malaria;
LUSC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg13175981	chr1:150552382	MCL1	-0.41	-5.65	-0.3	3.53e-8	Melanoma;
LUSC	cis	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05901451	chr6:126070800	HEY2	-0.58	-8.78	-0.43	8.6e-17	Endometrial cancer;
LUSC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.86	-14.77	-0.63	2.42e-38	Height;
LUSC	cis	rs17092148	1.000	rs3787220	chr20:33337751	T/C	cg16810054	chr20:33298113	TP53INP2	-0.41	-6.42	-0.33	4.77e-10	Neuroticism;
LUSC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg18904891	chr8:8559673	CLDN23	0.61	8.43	0.42	1.05e-15	Obesity-related traits;
LUSC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg00677455	chr12:58241039	CTDSP2	0.63	8.89	0.44	3.99e-17	Multiple sclerosis;
LUSC	trans	rs11700980	0.551	rs2832013	chr21:30110940	C/T	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.41e-9	QRS complex (12-leadsum);
LUSC	cis	rs735539	0.645	rs9552253	chr13:21202350	T/C	cg04906043	chr13:21280425	IL17D	-0.41	-6.53	-0.34	2.5e-10	Dental caries;
LUSC	cis	rs2898681	0.561	rs2200225	chr4:53738411	A/G	cg21521518	chr4:53727714	RASL11B	0.41	5.81	0.3	1.43e-8	Optic nerve measurement (cup area);
LUSC	trans	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg26043149	chr18:55253948	FECH	0.71	11.26	0.52	3.82e-25	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.51	0.38	5.59e-13	Motion sickness;
LUSC	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg01966878	chr4:90757139	SNCA	-0.34	-5.85	-0.31	1.15e-8	Dementia with Lewy bodies;
LUSC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.95	-0.31	6.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg10978503	chr1:24200527	CNR2	-0.51	-11.65	-0.54	1.44e-26	Immature fraction of reticulocytes;
LUSC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg15448220	chr1:150897856	SETDB1	0.42	6.11	0.32	2.8e-9	Melanoma;
LUSC	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg04310649	chr10:35416472	CREM	-0.4	-6.24	-0.32	1.35e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7215564	0.908	rs35821645	chr17:78652479	G/A	cg09596252	chr17:78655493	RPTOR	0.56	6.05	0.31	3.85e-9	Myopia (pathological);
LUSC	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.41	-0.42	1.17e-15	Axial length;
LUSC	cis	rs1461503	0.900	rs10892935	chr11:122838590	C/T	cg27398637	chr11:122830231	C11orf63	-0.4	-6.37	-0.33	6.12e-10	Menarche (age at onset);
LUSC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9549260	0.609	rs9315780	chr13:41263960	C/T	cg21288729	chr13:41239152	FOXO1	0.56	8.31	0.41	2.36e-15	Red blood cell count;
LUSC	cis	rs1775715	0.707	rs2808088	chr10:32146150	A/G	cg26784012	chr10:32216390	ARHGAP12	0.46	7.9	0.4	3.96e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs72772090	0.539	rs72773932	chr5:96118148	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.58	-0.34	1.83e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1595825	1.000	rs73058834	chr2:198873779	T/G	cg19156104	chr2:198669113	PLCL1	-0.46	-5.68	-0.3	2.91e-8	Ulcerative colitis;
LUSC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26769984	chr7:1090371	C7orf50	0.72	10.41	0.49	3.66e-22	Bronchopulmonary dysplasia;
LUSC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg13560548	chr3:10150139	C3orf24	0.53	7.43	0.38	9.1e-13	Alzheimer's disease;
LUSC	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.58	-0.42	3.7e-16	Total cholesterol levels;
LUSC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg23711669	chr6:146136114	FBXO30	-0.89	-16.71	-0.67	5.59e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg24060327	chr5:131705240	SLC22A5	-0.66	-11.6	-0.54	2.26e-26	Breast cancer;
LUSC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg11494091	chr17:61959527	GH2	0.38	6.24	0.32	1.31e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.5	-0.34	2.9e-10	Retinal vascular caliber;
LUSC	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg24634471	chr8:143751801	JRK	0.51	7.16	0.36	5.14e-12	Schizophrenia;
LUSC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg11317459	chr13:21872234	NA	1.25	19.52	0.73	3.81e-57	White matter hyperintensity burden;
LUSC	cis	rs6060717	0.536	rs7271036	chr20:34467215	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.55	5.67	0.3	3.14e-8	Hip circumference adjusted for BMI;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24538372	chr2:105953882	C2orf49	-0.52	-6.74	-0.35	6.82e-11	Hepatitis;
LUSC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.67	11.04	0.52	2.21e-24	Gestational age at birth (maternal effect);
LUSC	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg15103426	chr22:29168792	CCDC117	0.45	5.8	0.3	1.52e-8	Lymphocyte counts;
LUSC	cis	rs911119	0.913	rs3004139	chr20:23578674	C/T	cg16589663	chr20:23618590	CST3	-0.56	-6.67	-0.34	1.08e-10	Chronic kidney disease;
LUSC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg10755058	chr3:40428713	ENTPD3	0.38	6.29	0.33	1e-9	Renal cell carcinoma;
LUSC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs2294693	0.530	rs9381034	chr6:41049508	T/C	cg14769373	chr6:40998127	UNC5CL	-0.46	-5.81	-0.3	1.49e-8	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg05025164	chr4:1340916	KIAA1530	0.41	6.12	0.32	2.59e-9	Obesity-related traits;
LUSC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg08088566	chr11:430123	ANO9	0.66	7.18	0.37	4.57e-12	Body mass index;
LUSC	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg16482183	chr6:26056742	HIST1H1C	0.56	8.49	0.42	6.98e-16	Iron status biomarkers;
LUSC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.47e-12	Motion sickness;
LUSC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.62	-0.73	1.47e-57	Height;
LUSC	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-10.55	-0.5	1.15e-22	Mean corpuscular volume;
LUSC	cis	rs1034435	0.962	rs1894542	chr22:48890335	G/C	cg05992904	chr22:48892994	FAM19A5	-0.38	-7.4	-0.38	1.14e-12	Late-onset Alzheimer's disease;
LUSC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg26695010	chr11:65641043	EFEMP2	-0.48	-7.23	-0.37	3.32e-12	Eosinophil percentage of white cells;
LUSC	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg05163923	chr11:71159392	DHCR7	0.74	11.07	0.52	1.79e-24	Vitamin D levels;
LUSC	cis	rs2281558	0.583	rs11087526	chr20:25648016	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.53	6.34	0.33	7.33e-10	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs3770081	0.826	rs1019591	chr2:86298599	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.85	-6.07	-0.32	3.48e-9	Facial emotion recognition (sad faces);
LUSC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg16339924	chr4:17578868	LAP3	0.59	9.1	0.45	8.66e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4363385	0.747	rs1984198	chr1:152958584	T/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.78	-0.39	9.33e-14	Inflammatory skin disease;
LUSC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	16.09	0.66	1.53e-43	Platelet count;
LUSC	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21643547	chr1:205240462	TMCC2	-0.51	-9.54	-0.46	3.08e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.55	8.92	0.44	3.22e-17	Longevity;Endometriosis;
LUSC	cis	rs4776059	0.798	rs11855616	chr15:52874833	C/T	cg25063058	chr15:52860530	ARPP19	-0.48	-5.95	-0.31	6.7e-9	Schizophrenia;
LUSC	cis	rs4786125	0.587	rs9938245	chr16:6926744	T/G	cg03623568	chr16:6915990	A2BP1	-0.5	-8.34	-0.42	1.94e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg22906224	chr7:99728672	NA	0.55	8.13	0.41	8.36e-15	Coronary artery disease;
LUSC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.94	-14.58	-0.62	1.34e-37	Alzheimer's disease;
LUSC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg16447950	chr5:562315	NA	-0.58	-7.11	-0.36	7.26e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg06784218	chr1:46089804	CCDC17	0.53	10.22	0.49	1.67e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.28	0.59	1.28e-32	Cognitive test performance;
LUSC	trans	rs2039659	0.719	rs1764953	chr13:86253145	C/A	cg22803222	chr6:76636725	IMPG1	0.37	5.99	0.31	5.56e-9	Blood osmolality (transformed sodium);
LUSC	cis	rs7605827	0.930	rs7598196	chr2:15596662	A/G	cg19274914	chr2:15703543	NA	0.46	8.69	0.43	1.62e-16	Educational attainment (years of education);
LUSC	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg26816564	chr1:7831052	VAMP3	0.5	5.97	0.31	6.12e-9	Inflammatory bowel disease;
LUSC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03264133	chr6:25882463	NA	0.39	6.46	0.33	3.62e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg19230755	chr7:65878503	NA	-0.43	-6.02	-0.31	4.48e-9	Aortic root size;
LUSC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg04871131	chr7:94954202	PON1	-0.39	-6.19	-0.32	1.72e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.68	-10.47	-0.5	2.3e-22	Aortic root size;
LUSC	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-16.09	-0.66	1.58e-43	Height;
LUSC	cis	rs9653442	0.545	rs2009095	chr2:100765081	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-7.06	-0.36	9.45e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg06484146	chr7:12443880	VWDE	-0.73	-7.31	-0.37	1.98e-12	Coronary artery disease;
LUSC	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.16	-0.45	5.33e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4478858	0.611	rs10914338	chr1:31733782	T/A	cg00250761	chr1:31883323	NA	-0.33	-8.06	-0.4	1.35e-14	Alcohol dependence;
LUSC	cis	rs7131987	0.903	rs11050163	chr12:29420398	C/T	cg09582351	chr12:29534625	ERGIC2	-0.31	-6.39	-0.33	5.44e-10	QT interval;
LUSC	trans	rs800082	0.668	rs9821986	chr3:144292701	T/G	cg24215973	chr2:240111563	HDAC4	-0.61	-9.81	-0.47	3.99e-20	Smoking behavior;
LUSC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	13.98	0.61	2.7e-35	Platelet count;
LUSC	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg22676075	chr6:135203613	NA	0.47	7.4	0.38	1.08e-12	Red blood cell count;
LUSC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.67	-11.68	-0.54	1.15e-26	Breast cancer;
LUSC	trans	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg26043149	chr18:55253948	FECH	0.45	6.85	0.35	3.51e-11	Bone mineral density;
LUSC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg20203395	chr5:56204925	C5orf35	-0.78	-10.2	-0.49	1.93e-21	Initial pursuit acceleration;
LUSC	cis	rs79387448	0.745	rs2310294	chr2:103165706	A/G	cg09003973	chr2:102972529	NA	0.89	8.62	0.43	2.69e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg18512352	chr11:47633146	NA	-0.48	-10.05	-0.48	6.4e-21	Subjective well-being;
LUSC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg10729496	chr3:10149963	C3orf24	0.56	7.62	0.38	2.62e-13	Alzheimer's disease;
LUSC	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.01	0.36	1.33e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19074533	chr20:25604700	NANP	-0.41	-6.02	-0.31	4.64e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.7	0.3	2.59e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs17092148	0.945	rs6060009	chr20:33303974	T/G	cg16810054	chr20:33298113	TP53INP2	-0.39	-6.21	-0.32	1.53e-9	Neuroticism;
LUSC	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-8.37	-0.42	1.56e-15	Prudent dietary pattern;
LUSC	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.47	-6.81	-0.35	4.64e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.73	0.43	1.24e-16	Cognitive test performance;
LUSC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.2	0.45	4.11e-18	Monocyte percentage of white cells;
LUSC	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-0.56	-9.27	-0.45	2.33e-18	Breast cancer;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg13665263	chr7:135662016	MTPN;LUZP6	0.38	6.39	0.33	5.65e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	trans	rs62238980	0.614	rs17683310	chr22:32477445	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	0.51	6.04	0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs42235	0.683	rs60814640	chr7:92286918	A/G	cg15732164	chr7:92237376	CDK6	-0.37	-5.86	-0.31	1.12e-8	Hip circumference adjusted for BMI;Height;
LUSC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg01879757	chr17:41196368	BRCA1	-0.47	-7.09	-0.36	7.95e-12	Menopause (age at onset);
LUSC	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg27471124	chr11:109292789	C11orf87	0.38	6.94	0.35	2.08e-11	Schizophrenia;
LUSC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg27094323	chr7:1216898	NA	-0.47	-8.4	-0.42	1.32e-15	Longevity;Endometriosis;
LUSC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg00933542	chr6:150070202	PCMT1	0.33	6.76	0.35	6.34e-11	Lung cancer;
LUSC	cis	rs4356932	1.000	rs4859600	chr4:76959967	C/G	cg00809888	chr4:76862425	NAAA	0.35	5.8	0.3	1.53e-8	Blood protein levels;
LUSC	cis	rs17001868	0.568	rs2280790	chr22:40745181	T/C	cg07138101	chr22:40742427	ADSL	0.62	7.45	0.38	8.07e-13	Mammographic density (dense area);
LUSC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	13.71	0.6	2.98e-34	Platelet count;
LUSC	cis	rs11997175	0.625	rs4733171	chr8:33615617	C/G	ch.8.33884649F	chr8:33765107	NA	-0.4	-6.36	-0.33	6.65e-10	Body mass index;
LUSC	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.19	-0.41	5.51e-15	Axial length;
LUSC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg03146154	chr1:46216737	IPP	0.5	7.38	0.37	1.28e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg03563238	chr19:33554763	RHPN2	-0.37	-5.92	-0.31	7.79e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg16342193	chr10:102329863	NA	-0.4	-6.51	-0.34	2.75e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg24642439	chr20:33292090	TP53INP2	0.5	7.5	0.38	5.77e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08280861	chr8:58055591	NA	0.54	6.3	0.33	9.15e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg07169764	chr2:136633963	MCM6	-1.13	-16.48	-0.67	4.61e-45	Corneal structure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23311531	chr8:94712629	FAM92A1	-0.39	-6.08	-0.32	3.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs36096196	0.891	rs12081179	chr1:2251119	A/G	cg17974515	chr1:2252516	NA	0.39	7.3	0.37	2.18e-12	Coronary artery disease;
LUSC	cis	rs11025523	0.904	rs10833311	chr11:20379638	C/T	cg19653624	chr11:20408972	PRMT3	-0.51	-5.95	-0.31	6.77e-9	Obesity-related traits;
LUSC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg08219700	chr8:58056026	NA	0.47	6.26	0.32	1.21e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg04733989	chr22:42467013	NAGA	0.4	6.49	0.33	3.19e-10	Cognitive function;
LUSC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.36	0.53	1.63e-25	Prudent dietary pattern;
LUSC	cis	rs8099014	1.000	rs4940698	chr18:56108914	G/A	cg12907477	chr18:56117327	MIR122	0.44	7.02	0.36	1.28e-11	Platelet count;
LUSC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	6.28	0.32	1.08e-9	Tonsillectomy;
LUSC	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg10596483	chr8:143751796	JRK	0.62	9.29	0.45	2.06e-18	Schizophrenia;
LUSC	cis	rs7408868	0.572	rs2074616	chr19:15294991	C/T	cg14696996	chr19:15285081	NOTCH3	0.67	6.99	0.36	1.48e-11	Pulse pressure;
LUSC	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg22089800	chr15:90895588	ZNF774	-0.59	-9.06	-0.44	1.11e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18960028	chr11:75526075	UVRAG	-0.49	-6.28	-0.32	1.08e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg21361702	chr7:150065534	REPIN1	0.5	6.84	0.35	3.79e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg07061783	chr6:25882402	NA	-0.38	-5.94	-0.31	7.17e-9	Blood metabolite levels;
LUSC	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	6.13	0.32	2.42e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs7215564	0.908	rs7501544	chr17:78660946	T/A	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg12071656	chr20:44642570	MMP9	0.41	6.82	0.35	4.2e-11	Metabolite levels (Pyroglutamine);
LUSC	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg21100191	chr22:23484243	RTDR1	-0.91	-15.99	-0.66	3.86e-43	Bone mineral density;
LUSC	cis	rs34779708	0.733	rs4934740	chr10:35547141	C/T	cg03585969	chr10:35415529	CREM	0.53	7.38	0.37	1.3e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6500395	1.000	rs7197732	chr16:48575878	G/A	cg04672837	chr16:48644449	N4BP1	0.45	6.53	0.34	2.52e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs751728	1.000	rs747695	chr6:33736672	G/A	cg25922239	chr6:33757077	LEMD2	0.55	8.1	0.41	1.02e-14	Crohn's disease;
LUSC	cis	rs4474465	1.000	rs11237520	chr11:78201201	G/C	cg27205649	chr11:78285834	NARS2	-0.52	-6.01	-0.31	4.99e-9	Alzheimer's disease (survival time);
LUSC	cis	rs701145	0.617	rs7426835	chr3:154049539	C/T	cg17054900	chr3:154042577	DHX36	0.48	6.92	0.35	2.36e-11	Coronary artery disease;
LUSC	cis	rs7582720	1.000	rs72932590	chr2:203884308	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.64	0.43	2.32e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg20701182	chr2:24300061	SF3B14	0.74	7.28	0.37	2.4e-12	Lymphocyte counts;
LUSC	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg21171335	chr12:122356390	WDR66	0.42	5.89	0.31	9.23e-9	Mean corpuscular volume;
LUSC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs79387448	0.745	rs17027496	chr2:103178223	T/A	cg09003973	chr2:102972529	NA	0.87	8.35	0.42	1.8e-15	Gut microbiota (bacterial taxa);
LUSC	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg06060754	chr5:176797920	RGS14	-0.61	-8.88	-0.44	4.16e-17	Urate levels in lean individuals;
LUSC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.95	-14.95	-0.63	4.79e-39	Body mass index;
LUSC	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg02153584	chr22:29168773	CCDC117	0.55	7.61	0.38	2.9e-13	Lymphocyte counts;
LUSC	cis	rs2637266	1.000	rs12414151	chr10:78359041	T/G	cg18941641	chr10:78392320	NA	0.38	7.08	0.36	8.29e-12	Pulmonary function;
LUSC	cis	rs2224391	0.590	rs2753235	chr6:5252182	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.49	7.0	0.36	1.42e-11	Height;
LUSC	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg05234568	chr11:5960015	NA	-0.6	-8.64	-0.43	2.43e-16	DNA methylation (variation);
LUSC	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.71	-0.34	8.55e-11	Reticulocyte count;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13265914	chr8:21999630	REEP4	0.43	6.24	0.32	1.36e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.52	-0.38	4.97e-13	Hemoglobin concentration;
LUSC	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.75	-0.39	1.14e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.23	26.78	0.83	3.63e-85	Exhaled nitric oxide output;
LUSC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.02	20.37	0.74	1.57e-60	Cognitive function;
LUSC	cis	rs77633900	0.772	rs284901	chr15:76747761	C/T	cg21673338	chr15:77095150	SCAPER	-0.69	-5.68	-0.3	2.87e-8	Non-glioblastoma glioma;Glioma;
LUSC	trans	rs1486139	1.000	rs7779727	chr7:46267566	G/A	cg17534202	chr9:96721102	NA	-0.35	-6.15	-0.32	2.26e-9	Select biomarker traits;
LUSC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.25	-33.12	-0.88	1.52e-107	Chronic sinus infection;
LUSC	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg05738196	chr6:26577821	NA	0.81	15.88	0.66	1.04e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs2692947	0.832	rs62153679	chr2:96558400	C/T	cg22654517	chr2:96458247	NA	0.38	7.58	0.38	3.45e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg23241863	chr10:102295624	HIF1AN	0.49	5.98	0.31	5.84e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg04545296	chr12:48745243	ZNF641	0.33	6.14	0.32	2.4e-9	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs1395	0.925	rs1659676	chr2:27399294	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.41	-6.91	-0.35	2.45e-11	Blood metabolite levels;
LUSC	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06634786	chr22:41940651	POLR3H	-0.56	-6.56	-0.34	2.05e-10	Vitiligo;
LUSC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1728785	0.681	rs4783649	chr16:68558467	G/A	cg02972257	chr16:68554789	NA	0.58	7.15	0.36	5.59e-12	Ulcerative colitis;
LUSC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg25258033	chr6:167368657	RNASET2	0.44	7.05	0.36	1.06e-11	Crohn's disease;
LUSC	cis	rs939658	0.805	rs35318825	chr15:79447098	C/A	cg17916960	chr15:79447300	NA	-0.55	-11.07	-0.52	1.86e-24	Refractive error;
LUSC	cis	rs12956009	0.583	rs12327454	chr18:44863964	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.34	0.33	7.55e-10	Educational attainment (years of education);
LUSC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.13	15.2	0.64	5.07e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.12	-0.45	7.21e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6908843	0.582	rs7758118	chr6:166663862	T/G	cg06878426	chr6:166666287	NA	0.46	6.3	0.33	9.19e-10	Macrophage inflammatory protein 1b levels;
LUSC	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg04450456	chr4:17643702	FAM184B	0.36	6.02	0.31	4.52e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7953508	0.506	rs2200160	chr12:93963873	C/T	cg18151635	chr12:93972918	NA	-0.61	-8.83	-0.44	5.91e-17	Pubertal anthropometrics;
LUSC	trans	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg13010199	chr12:38710504	ALG10B	0.44	6.95	0.36	1.93e-11	Morning vs. evening chronotype;
LUSC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25072359	chr17:41440525	NA	0.62	9.05	0.44	1.2e-17	Menopause (age at onset);
LUSC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg19622623	chr12:86230825	RASSF9	0.4	5.75	0.3	2.02e-8	Major depressive disorder;
LUSC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-0.92	-12.84	-0.57	5.9e-31	Blood trace element (Zn levels);
LUSC	cis	rs243505	1.000	rs243505	chr7:148435339	A/G	cg09806900	chr7:148480153	CUL1	-0.47	-6.73	-0.35	7.44e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg18200150	chr17:30822561	MYO1D	0.52	10.65	0.5	5.37e-23	Schizophrenia;
LUSC	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.65	-0.43	2.13e-16	Morning vs. evening chronotype;
LUSC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.73	12.61	0.57	4.3e-30	Colorectal cancer;
LUSC	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	1.06	15.63	0.65	1.06e-41	Primary sclerosing cholangitis;
LUSC	cis	rs6681460	0.932	rs523956	chr1:67188276	A/G	cg02459107	chr1:67143332	SGIP1	-0.45	-8.19	-0.41	5.5e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs10769945	0.679	rs2137322	chr11:1917354	A/G	cg26856596	chr11:1961893	NA	-0.32	-6.36	-0.33	6.73e-10	DNA methylation (variation);
LUSC	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg23093090	chr10:104574429	C10orf26	-0.35	-6.39	-0.33	5.57e-10	Arsenic metabolism;
LUSC	cis	rs9649465	0.561	rs2429620	chr7:123430012	A/G	cg03229431	chr7:123269106	ASB15	0.48	7.71	0.39	1.49e-13	Migraine;
LUSC	cis	rs7200543	1.000	rs4500751	chr16:15140211	C/T	cg03427771	chr16:15082598	PDXDC1	-0.4	-5.7	-0.3	2.61e-8	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07220488	chr17:77006061	CANT1	-0.52	-6.04	-0.31	4.03e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3126085	0.735	rs4845752	chr1:152226576	C/A	cg26876637	chr1:152193138	HRNR	0.44	6.21	0.32	1.62e-9	Atopic dermatitis;
LUSC	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.23	16.53	0.67	2.82e-45	Hip circumference adjusted for BMI;
LUSC	cis	rs17095355	1.000	rs55897175	chr10:111699190	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.6	-0.38	2.95e-13	Biliary atresia;
LUSC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.7	-12.3	-0.56	5.96e-29	Aortic root size;
LUSC	trans	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg17567195	chr5:167378696	ODZ2	-0.39	-6.01	-0.31	4.78e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.48	-6.44	-0.33	4.27e-10	Tonsillectomy;
LUSC	cis	rs62400317	0.859	rs12201555	chr6:45294400	T/A	cg20913747	chr6:44695427	NA	-0.47	-7.62	-0.38	2.63e-13	Total body bone mineral density;
LUSC	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-6.74	-0.35	7.11e-11	Schizophrenia;
LUSC	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.61	7.82	0.39	7.19e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg05347473	chr6:146136440	FBXO30	0.49	8.24	0.41	3.93e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs713477	0.712	rs72717779	chr14:55893440	A/G	cg04306507	chr14:55594613	LGALS3	-0.32	-6.45	-0.33	3.85e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.31	-6.49	-0.33	3.09e-10	Cystic fibrosis severity;
LUSC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	ch.11.42038R	chr11:967971	AP2A2	0.54	8.23	0.41	4.38e-15	Alzheimer's disease (late onset);
LUSC	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg03934865	chr2:198174659	NA	0.35	5.87	0.31	1.07e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	0.88	16.86	0.68	1.41e-46	Intelligence (multi-trait analysis);
LUSC	cis	rs9921338	0.961	rs7626	chr16:11445596	C/T	cg00044050	chr16:11439710	C16orf75	-0.51	-6.7	-0.34	9e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg27494647	chr7:150038898	RARRES2	0.36	5.8	0.3	1.55e-8	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-13.89	-0.61	6.19e-35	Coronary artery disease;
LUSC	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg23173402	chr1:227635558	NA	0.58	7.0	0.36	1.45e-11	Major depressive disorder;
LUSC	cis	rs72781680	0.716	rs2712061	chr2:24026411	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	7.13	0.36	6.07e-12	Lymphocyte counts;
LUSC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg02018176	chr4:1364513	KIAA1530	0.47	8.01	0.4	1.93e-14	Obesity-related traits;
LUSC	cis	rs887829	0.569	rs4399719	chr2:234666461	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.53	-0.38	4.68e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.66	-0.34	1.13e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	cis	rs17286411	0.669	rs4788809	chr16:71615820	G/A	cg10085824	chr16:71800315	AP1G1	0.35	5.66	0.3	3.24e-8	Blood protein levels;
LUSC	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg17507749	chr15:85114479	UBE2QP1	0.72	9.39	0.46	9.61e-19	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg24562669	chr7:97807699	LMTK2	0.35	6.16	0.32	2.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3947	1.000	rs2645425	chr8:11701278	G/A	cg00262122	chr8:11665843	FDFT1	-0.51	-6.13	-0.32	2.45e-9	Blood protein levels;
LUSC	cis	rs2742234	0.541	rs11238481	chr10:43719286	A/G	cg02780029	chr10:43622663	RET	0.35	5.82	0.3	1.41e-8	Hirschsprung disease;
LUSC	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.52	8.03	0.4	1.73e-14	Cognitive test performance;
LUSC	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg10645314	chr2:3704589	ALLC	-0.48	-7.18	-0.37	4.44e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg19773385	chr1:10388646	KIF1B	-0.52	-8.98	-0.44	2.08e-17	Hepatocellular carcinoma;
LUSC	cis	rs8099014	1.000	rs7238962	chr18:56130112	A/G	cg12907477	chr18:56117327	MIR122	0.44	7.04	0.36	1.11e-11	Platelet count;
LUSC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.49	-0.42	7.05e-16	Aortic root size;
LUSC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.66e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg14689365	chr7:158441557	NCAPG2	-0.47	-6.33	-0.33	8.12e-10	Height;
LUSC	trans	rs11696501	0.637	rs3746596	chr20:44312028	C/T	cg03272292	chr12:48577362	C12orf68	0.53	6.33	0.33	7.83e-10	Brain structure;
LUSC	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg24692254	chr21:30365293	RNF160	-0.56	-6.86	-0.35	3.34e-11	Cognitive test performance;
LUSC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg22601191	chr20:60968625	CABLES2	-0.37	-6.03	-0.31	4.33e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs10511400	0.850	rs9289142	chr3:119892779	G/T	cg02809009	chr19:50354510	PTOV1	0.64	5.99	0.31	5.37e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.48	7.64	0.39	2.35e-13	IgG glycosylation;
LUSC	trans	rs1376359	0.537	rs486226	chr1:103269537	G/A	cg17154563	chr19:40477487	PSMC4	0.48	6.1	0.32	2.97e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03060546	chr3:49711283	APEH	0.66	7.6	0.38	3.07e-13	Menarche (age at onset);
LUSC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.27	0.52	3.49e-25	Menopause (age at onset);
LUSC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg24881330	chr22:46731750	TRMU	0.88	8.87	0.44	4.55e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7605827	0.930	rs2052438	chr2:15701951	G/A	cg19274914	chr2:15703543	NA	0.46	8.64	0.43	2.43e-16	Educational attainment (years of education);
LUSC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg17264618	chr3:40429014	ENTPD3	0.33	6.98	0.36	1.64e-11	Renal cell carcinoma;
LUSC	trans	rs6601327	0.700	rs12114661	chr8:9573154	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.29	-0.33	1e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg27121462	chr16:89883253	FANCA	-0.54	-8.74	-0.43	1.18e-16	Vitiligo;
LUSC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg17366294	chr4:99064904	C4orf37	0.6	10.55	0.5	1.19e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.6	-0.43	3.1e-16	Bladder cancer;
LUSC	cis	rs6998277	1.000	rs62523306	chr8:103640752	C/A	cg10187029	chr8:103597600	NA	0.69	8.81	0.43	6.86e-17	Migraine;
LUSC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg18904891	chr8:8559673	CLDN23	-0.43	-6.46	-0.33	3.63e-10	Mood instability;
LUSC	cis	rs977987	0.778	rs12930452	chr16:75462055	A/G	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.39e-11	Dupuytren's disease;
LUSC	cis	rs7336332	0.598	rs9581852	chr13:28013748	A/G	cg22138327	chr13:27999177	GTF3A	0.82	9.91	0.48	1.83e-20	Weight;
LUSC	trans	rs71435601	0.628	rs504091	chr2:21403481	T/G	cg20757404	chr19:378427	NA	0.38	6.02	0.31	4.71e-9	Cholesterol, total;
LUSC	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg08085267	chr17:45401833	C17orf57	-0.55	-8.32	-0.41	2.24e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7424096	0.613	rs17332671	chr2:37244124	C/G	cg14987922	chr2:37194071	STRN	0.61	8.2	0.41	5.41e-15	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg09655341	chr17:79618100	PDE6G	-0.27	-6.1	-0.32	3e-9	Eye color traits;
LUSC	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21643547	chr1:205240462	TMCC2	-0.49	-9.54	-0.46	3.16e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg11752832	chr7:134001865	SLC35B4	0.49	7.32	0.37	1.84e-12	Mean platelet volume;
LUSC	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.59	0.6	8.62e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-9.13	-0.45	6.82e-18	Developmental language disorder (linguistic errors);
LUSC	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.37	-0.42	1.6e-15	Systolic blood pressure;
LUSC	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg10167463	chr7:75959203	YWHAG	0.58	8.58	0.42	3.66e-16	Multiple sclerosis;
LUSC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg03233332	chr7:66118400	NA	-0.43	-6.15	-0.32	2.22e-9	Aortic root size;
LUSC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg07507251	chr3:52567010	NT5DC2	0.35	6.8	0.35	4.82e-11	Bipolar disorder;
LUSC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	0.91	12.24	0.56	1.04e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9815354	0.812	rs73077373	chr3:41852887	C/T	cg03022575	chr3:42003672	ULK4	0.85	8.74	0.43	1.19e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg27124370	chr19:33622961	WDR88	0.52	6.65	0.34	1.22e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.64	7.73	0.39	1.24e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg15704280	chr7:45808275	SEPT13	0.67	7.35	0.37	1.51e-12	Axial length;
LUSC	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg25344623	chr2:136566232	LCT	0.37	5.69	0.3	2.84e-8	Mosquito bite size;
LUSC	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg00277334	chr10:82204260	NA	-0.54	-7.3	-0.37	2.12e-12	Post bronchodilator FEV1;
LUSC	cis	rs253664	1.000	rs1720825	chr3:138108083	A/G	cg25188949	chr3:137893707	DBR1	-0.49	-5.88	-0.31	9.73e-9	Body mass index;
LUSC	cis	rs7000551	0.715	rs34649162	chr8:22314730	T/C	cg12081754	chr8:22256438	SLC39A14	0.47	7.03	0.36	1.15e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7804356	0.906	rs10266759	chr7:26855282	G/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg26338869	chr17:61819248	STRADA	0.41	5.89	0.31	9.19e-9	Prudent dietary pattern;
LUSC	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg03526459	chr1:146549940	NA	-0.4	-7.15	-0.36	5.35e-12	HIV-1 control;
LUSC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19717773	chr7:2847554	GNA12	-0.38	-6.24	-0.32	1.31e-9	Height;
LUSC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.76	0.65	3.06e-42	Platelet count;
LUSC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg04450456	chr4:17643702	FAM184B	0.39	6.77	0.35	5.88e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg21775007	chr8:11205619	TDH	-0.53	-7.96	-0.4	2.72e-14	Neuroticism;
LUSC	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg00898013	chr13:113819073	PROZ	0.51	7.46	0.38	7.56e-13	Platelet distribution width;
LUSC	cis	rs10740039	0.729	rs7091383	chr10:62436177	C/T	cg18175470	chr10:62150864	ANK3	-0.45	-6.73	-0.35	7.58e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11608355	0.545	rs12823587	chr12:109896390	A/G	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs3750965	0.920	rs10896420	chr11:68863047	G/A	cg06818126	chr11:68850279	TPCN2	-0.43	-6.37	-0.33	6.24e-10	Hair color;
LUSC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg11344533	chr11:111475393	SIK2	-0.49	-6.87	-0.35	3.18e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg16558253	chr16:72132732	DHX38	-0.37	-5.76	-0.3	1.86e-8	Fibrinogen levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03043160	chr13:76056444	TBC1D4	-0.58	-8.13	-0.41	8.43e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs981844	1.000	rs17299041	chr4:154673127	T/C	cg14289246	chr4:154710475	SFRP2	0.51	6.57	0.34	1.98e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg13770153	chr20:60521292	NA	-0.64	-8.89	-0.44	3.86e-17	Body mass index;
LUSC	cis	rs34891900	0.507	rs5992088	chr22:18135912	C/T	cg19898043	chr22:18121309	BCL2L13	-0.36	-5.64	-0.3	3.55e-8	Sum neutrophil eosinophil counts;
LUSC	cis	rs7552167	0.925	rs78312791	chr1:24513613	C/A	cg01960748	chr1:24522592	NA	0.68	10.21	0.49	1.8e-21	Psoriasis vulgaris;
LUSC	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg21427119	chr20:30132790	HM13	-0.36	-5.67	-0.3	3.14e-8	Mean corpuscular volume;
LUSC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	9.14	0.45	6.21e-18	Prudent dietary pattern;
LUSC	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg16482183	chr6:26056742	HIST1H1C	0.58	7.95	0.4	2.87e-14	Iron status biomarkers;
LUSC	cis	rs4683142	0.518	rs4682811	chr3:46164795	A/G	cg08033130	chr3:45983597	CXCR6;FYCO1	0.39	5.69	0.3	2.75e-8	Methadone dose in opioid dependence;
LUSC	cis	rs6545883	0.525	rs1177274	chr2:61368532	T/G	cg15711740	chr2:61764176	XPO1	-0.4	-6.29	-0.33	9.74e-10	Tuberculosis;
LUSC	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg00310523	chr12:86230176	RASSF9	0.45	8.0	0.4	2.1e-14	Major depressive disorder;
LUSC	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg18209359	chr17:80159595	CCDC57	0.39	6.44	0.33	4.06e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs68170813	0.559	rs76859341	chr7:107070146	C/G	cg02696742	chr7:106810147	HBP1	-0.61	-8.85	-0.44	5.36e-17	Coronary artery disease;
LUSC	trans	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg26384229	chr12:38710491	ALG10B	0.66	10.26	0.49	1.19e-21	Morning vs. evening chronotype;
LUSC	cis	rs9811920	0.535	rs792831	chr3:99473720	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.31	-6.0	-0.31	5.01e-9	Axial length;
LUSC	cis	rs7043114	0.507	rs2007837	chr9:95189767	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.9	-0.35	2.67e-11	Height;
LUSC	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg05887092	chr17:76393375	PGS1	0.55	9.8	0.47	4.39e-20	HDL cholesterol levels;
LUSC	cis	rs11676348	0.838	rs17844697	chr2:218999255	G/A	cg00012203	chr2:219082015	ARPC2	-0.54	-8.24	-0.41	3.88e-15	Ulcerative colitis;
LUSC	cis	rs7709377	0.574	rs11241372	chr5:115502656	T/C	cg23108291	chr5:115420582	COMMD10	0.42	5.97	0.31	5.96e-9	Metabolite levels  (X-11787);
LUSC	trans	rs72674100	1.000	rs6830465	chr4:97977822	C/T	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg07716408	chr11:68623521	NA	-0.35	-6.75	-0.35	6.38e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.36	0.37	1.47e-12	Blood metabolite levels;
LUSC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-6.4	-0.33	5.27e-10	Eosinophil percentage of white cells;
LUSC	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg00071950	chr4:10020882	SLC2A9	-0.58	-9.43	-0.46	7.32e-19	Bone mineral density;
LUSC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-1.01	-20.01	-0.74	4.1e-59	Menopause (age at onset);
LUSC	trans	rs7980799	0.649	rs11559754	chr12:33649229	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.95	-0.31	6.71e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg27411982	chr8:10470053	RP1L1	-0.38	-5.99	-0.31	5.55e-9	Retinal vascular caliber;
LUSC	cis	rs9653442	0.564	rs10197987	chr2:100790783	A/T	cg22139774	chr2:100720529	AFF3	-0.4	-6.91	-0.35	2.54e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg07169764	chr2:136633963	MCM6	1.03	15.73	0.65	4.08e-42	Corneal structure;
LUSC	cis	rs11958404	0.860	rs6868830	chr5:157442187	T/C	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs9649465	0.542	rs616297	chr7:123426949	A/G	cg03229431	chr7:123269106	ASB15	0.48	7.81	0.39	7.37e-14	Migraine;
LUSC	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.61	8.56	0.42	4.1e-16	Schizophrenia;
LUSC	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg26536354	chr8:144654954	C8orf73	0.65	7.1	0.36	7.37e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs6005807	0.719	rs7293232	chr22:29015590	T/G	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg27124370	chr19:33622961	WDR88	0.56	7.21	0.37	3.86e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.35	5.68	0.3	2.99e-8	Systemic lupus erythematosus;
LUSC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-1.1	-22.22	-0.77	8.57e-68	Coronary artery disease;
LUSC	cis	rs4919687	0.550	rs11191371	chr10:104459897	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-5.68	-0.3	2.87e-8	Colorectal cancer;
LUSC	trans	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg19641455	chr1:111506798	C1orf103	0.4	5.95	0.31	6.68e-9	Neuroticism;
LUSC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.56	8.64	0.43	2.38e-16	Menopause (age at onset);
LUSC	trans	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs10876993	0.893	rs7979246	chr12:58092554	A/G	cg15848620	chr12:58087721	OS9	-0.57	-7.99	-0.4	2.17e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.62	9.97	0.48	1.13e-20	Blood metabolite ratios;
LUSC	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-7.98	-0.4	2.39e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg25039879	chr17:56429692	SUPT4H1	0.74	10.28	0.49	1.03e-21	Cognitive test performance;
LUSC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg17971929	chr21:40555470	PSMG1	0.51	7.91	0.4	3.85e-14	Cognitive function;
LUSC	cis	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg09904177	chr6:26538194	HMGN4	-0.77	-5.97	-0.31	6.22e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg18479299	chr3:125709523	NA	-0.5	-5.79	-0.3	1.66e-8	Blood pressure (smoking interaction);
LUSC	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg26380479	chr7:97908229	NA	-0.27	-5.77	-0.3	1.8e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs790123	1.000	rs810976	chr3:122381683	T/C	cg17380795	chr3:122379686	NA	0.39	6.59	0.34	1.7e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs735860	0.572	rs186003	chr6:53185124	A/C	cg10236188	chr6:53219634	NA	0.4	6.31	0.33	8.75e-10	Glaucoma;
LUSC	cis	rs11166629	1.000	rs1867059	chr8:135647019	A/G	cg27224718	chr8:135614730	ZFAT	0.62	10.25	0.49	1.28e-21	Smoking quantity;
LUSC	cis	rs1044826	1.000	rs9812192	chr3:139177597	C/T	cg00490450	chr3:139108681	COPB2	0.5	6.61	0.34	1.5e-10	Obesity-related traits;
LUSC	cis	rs2580764	0.515	rs7570629	chr2:55255935	A/T	cg20993754	chr2:55226987	RTN4	0.35	5.86	0.31	1.13e-8	Mean platelet volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13170934	chr1:156722147	HDGF	0.41	6.21	0.32	1.62e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-0.83	-15.28	-0.64	2.37e-40	Dental caries;
LUSC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg06145435	chr7:1022769	CYP2W1	0.3	6.22	0.32	1.5e-9	Longevity;Endometriosis;
LUSC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg19592336	chr6:28129416	ZNF389	0.5	6.82	0.35	4.41e-11	Parkinson's disease;
LUSC	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.79	0.51	1.7e-23	Coffee consumption (cups per day);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20095036	chr4:153456176	FBXW7	0.36	5.99	0.31	5.28e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.99	-0.31	5.47e-9	Dementia with Lewy bodies;
LUSC	cis	rs61990749	0.597	rs2267758	chr14:78147429	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.6	-6.43	-0.33	4.5e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs79911532	0.515	rs78085898	chr7:75703215	T/C	cg03592824	chr7:75666768	STYXL1	0.67	6.42	0.33	4.79e-10	Mononucleosis;
LUSC	cis	rs4499344	0.881	rs35447302	chr19:33068499	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.62	-7.92	-0.4	3.47e-14	Mean platelet volume;
LUSC	cis	rs926938	0.527	rs11084	chr1:115537933	A/G	cg12756093	chr1:115239321	AMPD1	0.45	6.73	0.35	7.54e-11	Autism;
LUSC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.35	0.46	1.3e-18	Prudent dietary pattern;
LUSC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg25039879	chr17:56429692	SUPT4H1	0.67	8.85	0.44	5.03e-17	Cognitive test performance;
LUSC	cis	rs2522056	1.000	rs2706395	chr5:131796803	A/T	cg24060327	chr5:131705240	SLC22A5	0.45	5.96	0.31	6.39e-9	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.75	10.82	0.51	1.32e-23	Corneal astigmatism;
LUSC	cis	rs722599	0.748	rs11623342	chr14:75347937	A/C	cg08847533	chr14:75593920	NEK9	-0.49	-7.02	-0.36	1.26e-11	IgG glycosylation;
LUSC	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.39	-0.56	2.9e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.49	-0.33	3.12e-10	Life satisfaction;
LUSC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg06951627	chr6:26196580	NA	0.55	5.88	0.31	1e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs7789940	0.857	rs12532935	chr7:75939698	G/C	cg10167463	chr7:75959203	YWHAG	-0.58	-8.36	-0.42	1.74e-15	Multiple sclerosis;
LUSC	cis	rs16854884	0.837	rs13083068	chr3:143801642	G/T	cg06585982	chr3:143692056	C3orf58	0.43	6.39	0.33	5.48e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg11344533	chr11:111475393	SIK2	-0.49	-6.87	-0.35	3.18e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.39	-5.95	-0.31	6.81e-9	Renal function-related traits (BUN);
LUSC	cis	rs10743315	0.778	rs7397459	chr12:19377578	C/G	cg02471346	chr12:19282374	PLEKHA5	0.5	6.38	0.33	5.87e-10	Gut microbiota (bacterial taxa);
LUSC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.49	9.55	0.46	2.87e-19	Eosinophil percentage of white cells;
LUSC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11764359	chr7:65958608	NA	0.62	9.41	0.46	8.33e-19	Aortic root size;
LUSC	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg04851639	chr8:1020857	NA	-0.4	-8.3	-0.41	2.6e-15	Schizophrenia;
LUSC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.02	0.31	4.51e-9	Schizophrenia;
LUSC	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg21775007	chr8:11205619	TDH	0.46	6.61	0.34	1.57e-10	Myopia (pathological);
LUSC	cis	rs4478037	1.000	rs4074415	chr3:33161745	A/G	cg19404215	chr3:33155277	CRTAP	0.83	8.85	0.44	5.15e-17	Major depressive disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19156104	chr2:198669113	PLCL1	-0.39	-5.99	-0.31	5.29e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9300255	0.664	rs28636834	chr12:123871070	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.4	6.04	0.31	4.01e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg03351412	chr1:154909251	PMVK	0.53	8.35	0.42	1.9e-15	Prostate cancer;
LUSC	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.15	0.32	2.16e-9	Recombination rate (females);
LUSC	cis	rs3806843	0.569	rs753279	chr5:140023818	A/G	cg19875535	chr5:140030758	IK	-0.42	-6.96	-0.36	1.81e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7119	0.717	rs12916822	chr15:77818548	G/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.61	-0.34	1.53e-10	Type 2 diabetes;
LUSC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg09491104	chr22:46646882	C22orf40	-0.66	-7.26	-0.37	2.69e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg24562669	chr7:97807699	LMTK2	0.39	6.67	0.34	1.08e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.4	5.79	0.3	1.62e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.95	0.51	4.59e-24	Hypertriglyceridemia;
LUSC	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg17757837	chr7:157058334	UBE3C	0.82	13.01	0.58	1.35e-31	Body mass index;
LUSC	cis	rs7827545	0.545	rs4909477	chr8:135562976	A/G	cg17885191	chr8:135476712	NA	0.61	7.82	0.39	6.87e-14	Hypertension (SNP x SNP interaction);
LUSC	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg18005901	chr6:33739558	LEMD2	-0.39	-5.65	-0.3	3.38e-8	Schizophrenia;
LUSC	trans	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg20935933	chr6:143382018	AIG1	0.5	7.18	0.37	4.55e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg06627628	chr2:24431161	ITSN2	-0.6	-7.21	-0.37	3.78e-12	Lymphocyte counts;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg04102586	chr1:100435512	SLC35A3	0.66	6.04	0.31	4.21e-9	Body mass index;
LUSC	cis	rs500891	0.553	rs2000375	chr6:84169965	A/G	cg08257003	chr6:84140564	ME1	0.36	8.79	0.43	7.82e-17	Platelet-derived growth factor BB levels;
LUSC	trans	rs156299	0.526	rs34942629	chr7:24193160	C/T	cg06529468	chr19:10676722	KRI1	0.38	6.2	0.32	1.7e-9	Vitamin D levels;
LUSC	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.95	0.51	4.59e-24	Hypertriglyceridemia;
LUSC	cis	rs2625529	0.627	rs11858015	chr15:72552492	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-7.23	-0.37	3.32e-12	Red blood cell count;
LUSC	cis	rs2625529	0.824	rs35167572	chr15:72378960	A/G	cg16672083	chr15:72433130	SENP8	-0.52	-7.63	-0.39	2.45e-13	Red blood cell count;
LUSC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg12963246	chr6:28129442	ZNF389	0.39	6.03	0.31	4.29e-9	Parkinson's disease;
LUSC	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	0.84	11.99	0.55	8.48e-28	Blood protein levels;
LUSC	cis	rs12208915	0.945	rs116984077	chr6:79583325	A/G	cg05283184	chr6:79620031	NA	0.46	6.0	0.31	5.19e-9	Left atrial antero-posterior diameter;
LUSC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	1.06	19.1	0.72	1.68e-55	Parkinson's disease;
LUSC	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg19773385	chr1:10388646	KIF1B	-0.57	-9.86	-0.47	2.77e-20	Hepatocellular carcinoma;
LUSC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.17	0.32	2.03e-9	Height;
LUSC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-10.44	-0.5	2.96e-22	Alzheimer's disease (late onset);
LUSC	cis	rs6714788	0.546	rs12712062	chr2:100654307	A/T	cg22139774	chr2:100720529	AFF3	-0.38	-6.04	-0.31	4.2e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	7.14	0.36	5.98e-12	Neuroticism;
LUSC	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.57	0.38	3.75e-13	Blood metabolite levels;
LUSC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	10.95	0.51	4.59e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.59	0.43	3.5e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12711979	0.513	rs1454241	chr2:3851675	A/G	cg17052675	chr2:3827356	NA	0.37	6.24	0.32	1.35e-9	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg00750074	chr16:89608354	SPG7	0.38	6.29	0.33	9.86e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg01802117	chr1:53393560	SCP2	0.39	6.36	0.33	6.52e-10	Monocyte count;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg00108277	chr3:49840710	C3orf54	0.45	6.22	0.32	1.52e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg16342193	chr10:102329863	NA	-0.33	-5.85	-0.3	1.17e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg27426351	chr10:43362370	NA	-0.42	-5.8	-0.3	1.51e-8	Blood protein levels;
LUSC	cis	rs6545883	0.894	rs2600660	chr2:61549600	G/T	cg15711740	chr2:61764176	XPO1	0.46	6.85	0.35	3.54e-11	Tuberculosis;
LUSC	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg20159608	chr7:32802032	NA	-0.7	-9.12	-0.45	7.4e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs6977660	0.714	rs9969171	chr7:19827328	T/C	cg07541023	chr7:19748670	TWISTNB	0.59	6.14	0.32	2.39e-9	Thyroid stimulating hormone;
LUSC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg11764359	chr7:65958608	NA	-0.69	-10.46	-0.5	2.43e-22	Aortic root size;
LUSC	cis	rs9296092	0.538	rs9469487	chr6:33516943	G/T	cg13560919	chr6:33536144	NA	-0.82	-15.73	-0.65	4.29e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.76	-0.43	1.01e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03517284	chr6:25882590	NA	-0.4	-7.06	-0.36	9.88e-12	Height;
LUSC	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg15744005	chr10:104629667	AS3MT	-0.28	-6.05	-0.31	3.84e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs96067	0.805	rs3767705	chr1:36602044	A/T	cg24686825	chr1:36642396	MAP7D1	-0.54	-7.33	-0.37	1.76e-12	Corneal structure;
LUSC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.11	-0.32	2.78e-9	Total body bone mineral density;
LUSC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.38	0.69	1.15e-48	Chronic sinus infection;
LUSC	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg08807101	chr21:30365312	RNF160	-0.69	-10.87	-0.51	8.77e-24	Pancreatic cancer;
LUSC	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg17376030	chr22:41985996	PMM1	-0.44	-5.85	-0.3	1.19e-8	Vitiligo;
LUSC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.79	-14.22	-0.61	3.17e-36	Dental caries;
LUSC	cis	rs10740039	0.883	rs10761542	chr10:62415223	T/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.96	-0.36	1.83e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.36	-5.91	-0.31	8.54e-9	Total body bone mineral density;
LUSC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg08677398	chr8:58056175	NA	0.41	5.73	0.3	2.19e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.76	-0.47	5.93e-20	Hemoglobin concentration;
LUSC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg07936489	chr17:37558343	FBXL20	-0.72	-10.04	-0.48	6.9e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.0	-0.36	1.38e-11	Bipolar disorder;
LUSC	cis	rs6960043	0.714	rs7784091	chr7:15047637	A/G	cg19272540	chr7:15055459	NA	-0.34	-8.66	-0.43	1.99e-16	Type 2 diabetes;
LUSC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg04450456	chr4:17643702	FAM184B	0.38	6.28	0.32	1.05e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	0.92	15.42	0.64	6.99e-41	Breast cancer;
LUSC	cis	rs2932538	0.922	rs6690169	chr1:113114974	A/G	cg22162597	chr1:113214053	CAPZA1	0.7	10.0	0.48	9.16e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19862838	chr3:101396008	ZBTB11;LOC100009676	-0.38	-5.97	-0.31	5.92e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg09307838	chr4:120376055	NA	0.7	9.88	0.48	2.23e-20	Corneal astigmatism;
LUSC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg04450456	chr4:17643702	FAM184B	0.38	6.41	0.33	5.02e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg16359550	chr11:109292809	C11orf87	0.37	6.33	0.33	7.74e-10	Schizophrenia;
LUSC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03264133	chr6:25882463	NA	-0.5	-9.04	-0.44	1.33e-17	Blood metabolite levels;
LUSC	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg24503407	chr1:205819492	PM20D1	0.48	6.42	0.33	4.56e-10	Menarche (age at onset);
LUSC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.85	0.3	1.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2050392	0.965	rs2265371	chr10:30690840	C/T	cg18806716	chr10:30721971	MAP3K8	-0.44	-7.14	-0.36	5.8e-12	Inflammatory bowel disease;
LUSC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg13206674	chr6:150067644	NUP43	0.57	8.94	0.44	2.75e-17	Lung cancer;
LUSC	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg21798802	chr22:38057573	PDXP	0.48	10.64	0.5	6.02e-23	Fat distribution (HIV);
LUSC	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg01966878	chr4:90757139	SNCA	-0.42	-5.96	-0.31	6.24e-9	Neuroticism;
LUSC	cis	rs4812048	0.793	rs6070693	chr20:57589516	C/T	cg14073986	chr20:57617431	SLMO2	0.66	6.3	0.33	9.41e-10	Mean platelet volume;
LUSC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.82	13.97	0.61	2.99e-35	Blood protein levels;
LUSC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.19	21.53	0.76	4.41e-65	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9398803	0.865	rs9401883	chr6:126797111	A/G	cg19875578	chr6:126661172	C6orf173	0.43	6.37	0.33	6.18e-10	Male-pattern baldness;
LUSC	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.74	12.09	0.55	3.59e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg24450063	chr1:156163899	SLC25A44	1.17	24.47	0.8	1.76e-76	Testicular germ cell tumor;
LUSC	trans	rs870142	0.922	rs4689908	chr4:4637516	T/A	cg04017672	chr1:182359056	GLUL	0.41	6.12	0.32	2.59e-9	Congenital heart disease;
LUSC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg18681998	chr4:17616180	MED28	0.9	17.84	0.7	1.85e-50	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	1.22	16.41	0.67	8.56e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs865483	0.895	rs853229	chr17:35800919	A/G	cg06716730	chr17:35851459	DUSP14	0.27	5.91	0.31	8.66e-9	Monocyte count;
LUSC	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg21918786	chr6:109611834	NA	-0.36	-6.25	-0.32	1.25e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg00343986	chr7:65444356	GUSB	-0.38	-5.71	-0.3	2.46e-8	Aortic root size;
LUSC	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.6	9.75	0.47	6.13e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg24296786	chr1:45957014	TESK2	-0.51	-7.58	-0.38	3.46e-13	High light scatter reticulocyte count;
LUSC	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-8.03	-0.4	1.66e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-7.19	-0.37	4.24e-12	Alzheimer's disease (late onset);
LUSC	cis	rs983392	0.805	rs1834550	chr11:59959843	T/C	cg20284999	chr11:59952153	MS4A6A	-0.39	-6.35	-0.33	7.23e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg00944433	chr1:107599041	PRMT6	-0.34	-6.24	-0.32	1.35e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.69	-10.44	-0.5	2.78e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05756109	chr10:103347662	POLL;RP11-529I10.4	-0.41	-6.24	-0.32	1.32e-9	Hepatitis;
LUSC	trans	rs4714291	0.775	rs2949019	chr6:40051200	C/T	cg02267698	chr19:7991119	CTXN1	-0.55	-8.26	-0.41	3.4e-15	Strep throat;
LUSC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-9.63	-0.47	1.59e-19	Gut microbiome composition (summer);
LUSC	cis	rs10186029	0.680	rs4673726	chr2:213981115	T/C	cg08319019	chr2:214017104	IKZF2	0.6	8.66	0.43	1.99e-16	Systemic sclerosis;
LUSC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-7.34	-0.37	1.61e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs4774899	0.837	rs10518894	chr15:57403598	C/T	cg21617494	chr15:57618479	NA	-0.35	-5.9	-0.31	9.06e-9	Urinary tract infection frequency;
LUSC	cis	rs17661538	0.504	rs35769984	chr10:18436542	A/G	cg03634479	chr10:18430412	CACNB2	0.69	6.61	0.34	1.53e-10	Response to antipsychotic treatment;
LUSC	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg21775007	chr8:11205619	TDH	0.51	7.0	0.36	1.42e-11	Neuroticism;
LUSC	cis	rs79911532	0.515	rs115332207	chr7:75635405	G/A	cg03592824	chr7:75666768	STYXL1	0.7	7.04	0.36	1.12e-11	Mononucleosis;
LUSC	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg15445000	chr17:37608096	MED1	-0.41	-6.87	-0.35	3.18e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.83	12.24	0.56	1.07e-28	Coronary artery disease;
LUSC	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg03733263	chr8:22462867	KIAA1967	1.0	18.93	0.72	8.06e-55	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg00042356	chr1:8021962	PARK7	0.72	9.19	0.45	4.15e-18	Inflammatory bowel disease;
LUSC	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg24375607	chr4:120327624	NA	0.76	11.48	0.53	6.02e-26	Corneal astigmatism;
LUSC	cis	rs9341808	0.600	rs590641	chr6:80966483	A/G	cg08355045	chr6:80787529	NA	0.41	6.84	0.35	3.73e-11	Sitting height ratio;
LUSC	cis	rs12042938	0.905	rs823160	chr1:231776636	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	5.97	0.31	5.94e-9	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs2733201	1.000	rs1426658	chr15:44338919	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.75	-5.71	-0.3	2.49e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
LUSC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	0.77	13.53	0.6	1.44e-33	Cognitive function;
LUSC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.64	0.6	5.58e-34	Cognitive test performance;
LUSC	cis	rs870825	0.616	rs2090590	chr4:185647850	A/C	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.54	-14.71	-0.63	3.96e-38	Urate levels in overweight individuals;
LUSC	cis	rs11168618	0.846	rs11168586	chr12:48854012	C/T	cg24011408	chr12:48396354	COL2A1	0.37	5.78	0.3	1.7e-8	Adiponectin levels;
LUSC	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg17173187	chr15:85201210	NMB	0.39	6.94	0.35	2.07e-11	Schizophrenia;
LUSC	cis	rs2354432	0.607	rs9661159	chr1:146757923	G/A	cg25205988	chr1:146714368	CHD1L	-1.04	-9.45	-0.46	6.22e-19	Mitochondrial DNA levels;
LUSC	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg08079166	chr15:68083412	MAP2K5	-0.35	-7.01	-0.36	1.29e-11	Motion sickness;
LUSC	cis	rs911119	0.818	rs67862677	chr20:23591086	A/C	cg16589663	chr20:23618590	CST3	0.61	7.29	0.37	2.32e-12	Chronic kidney disease;
LUSC	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg20811857	chr17:78079795	GAA	-0.32	-6.0	-0.31	5.16e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg05925327	chr15:68127851	NA	-0.43	-6.54	-0.34	2.26e-10	Obesity;
LUSC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg16393715	chr7:1948819	MAD1L1	0.34	5.82	0.3	1.35e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7246967	0.611	rs2361022	chr19:22816533	A/G	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	trans	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.42	0.33	4.57e-10	Retinal vascular caliber;
LUSC	cis	rs3771570	1.000	rs56156035	chr2:242205955	T/A	cg21155796	chr2:242212141	HDLBP	0.68	7.52	0.38	5.12e-13	Prostate cancer;
LUSC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.48	8.13	0.41	8.59e-15	Vitiligo;
LUSC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.43e-12	Body mass index;
LUSC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.95	12.12	0.55	2.92e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.57	9.52	0.46	3.59e-19	DNA methylation (variation);
LUSC	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg16743903	chr16:89593216	SPG7	-0.44	-6.09	-0.32	3.09e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg02569458	chr12:86230093	RASSF9	0.52	8.64	0.43	2.3e-16	Major depressive disorder;
LUSC	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.92	15.81	0.65	1.92e-42	Bladder cancer;
LUSC	cis	rs6005807	0.719	rs134547	chr22:28801009	A/G	cg12565055	chr22:29076175	TTC28	0.52	5.82	0.3	1.38e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	trans	rs12571093	0.803	rs61854814	chr10:70027396	A/G	cg04882175	chr6:131122610	NA	-0.55	-6.36	-0.33	6.49e-10	Optic nerve measurement (disc area);
LUSC	cis	rs10740039	0.516	rs10761526	chr10:62354419	T/C	cg18175470	chr10:62150864	ANK3	-0.47	-6.94	-0.36	2.04e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.55	-8.27	-0.41	3.3e-15	Bladder cancer;
LUSC	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg03161606	chr19:29218774	NA	0.52	6.76	0.35	6.23e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.43	0.5	3.18e-22	Ileal carcinoids;
LUSC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-1.24	-13.69	-0.6	3.59e-34	Diabetic kidney disease;
LUSC	cis	rs34779708	0.733	rs7914468	chr10:35548071	G/A	cg03585969	chr10:35415529	CREM	0.53	7.38	0.37	1.3e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13770153	chr20:60521292	NA	-0.62	-8.39	-0.42	1.36e-15	Body mass index;
LUSC	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.82	-15.64	-0.65	9.6e-42	Itch intensity from mosquito bite;
LUSC	cis	rs7523050	0.643	rs34367763	chr1:109400805	C/T	cg08274380	chr1:109419600	GPSM2	1.1	10.69	0.51	3.76e-23	Fat distribution (HIV);
LUSC	cis	rs12973672	0.812	rs10419959	chr19:35764705	G/A	cg12095397	chr19:35769544	USF2	0.45	6.77	0.35	5.92e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs4780355	0.843	rs413024	chr16:11354091	A/G	cg00044050	chr16:11439710	C16orf75	0.59	8.71	0.43	1.42e-16	Crohn's disease and psoriasis;
LUSC	trans	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg21659725	chr3:3221576	CRBN	-0.72	-7.62	-0.38	2.66e-13	Menarche (age at onset);
LUSC	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg01528321	chr10:82214614	TSPAN14	0.87	13.03	0.58	1.14e-31	Post bronchodilator FEV1;
LUSC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.15	0.32	2.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg02423579	chr7:2872169	GNA12	-0.37	-5.75	-0.3	2.03e-8	Height;
LUSC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg14582100	chr15:45693742	SPATA5L1	0.59	10.83	0.51	1.25e-23	Homoarginine levels;
LUSC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.33	0.69	1.95e-48	Chronic sinus infection;
LUSC	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-7.65	-0.39	2.12e-13	Menarche (age at onset);
LUSC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.11	0.32	2.79e-9	Schizophrenia;
LUSC	cis	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.86	12.36	0.56	3.64e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs10411161	0.752	rs10402107	chr19:52384600	A/G	cg22319618	chr22:45562946	NUP50	-0.49	-5.94	-0.31	6.97e-9	Breast cancer;
LUSC	cis	rs8014204	0.533	rs12434646	chr14:75178693	C/T	cg06637938	chr14:75390232	RPS6KL1	0.53	8.28	0.41	3.1e-15	Caffeine consumption;
LUSC	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-7.04	-0.36	1.1e-11	Fear of minor pain;
LUSC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-12.67	-0.57	2.58e-30	Hemoglobin concentration;
LUSC	cis	rs9341835	0.681	rs9352960	chr6:64150426	C/G	cg03326410	chr6:64151739	NA	-0.37	-6.13	-0.32	2.53e-9	Schizophrenia;
LUSC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg20203395	chr5:56204925	C5orf35	-0.75	-10.33	-0.49	6.65e-22	Initial pursuit acceleration;
LUSC	cis	rs11640436	0.565	rs1594051	chr16:77307040	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.37	5.71	0.3	2.51e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg04865166	chr7:105162814	PUS7	0.51	5.67	0.3	3.06e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2274273	0.688	rs6573001	chr14:55556502	A/G	cg04306507	chr14:55594613	LGALS3	0.52	11.31	0.53	2.49e-25	Protein biomarker;
LUSC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.11	-0.32	2.84e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg05501817	chr11:14380813	RRAS2	0.56	9.23	0.45	3.27e-18	Sense of smell;
LUSC	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	1.14	19.67	0.73	9.55e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs727505	0.607	rs67680878	chr7:124787381	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.92	-0.35	2.31e-11	Lewy body disease;
LUSC	cis	rs791888	0.858	rs2180968	chr10:89418730	A/C	cg10377144	chr10:89419177	PAPSS2	0.25	5.66	0.3	3.32e-8	Magnesium levels;
LUSC	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg17279839	chr7:150038598	RARRES2	0.51	7.82	0.39	7.21e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg12559939	chr2:27858050	GPN1	0.41	6.33	0.33	8.01e-10	Oral cavity cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08608532	chr13:100741163	PCCA	-0.39	-5.98	-0.31	5.7e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg20818283	chr2:191399100	TMEM194B	-0.42	-6.54	-0.34	2.25e-10	Pulse pressure;
LUSC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg00012203	chr2:219082015	ARPC2	-0.69	-11.26	-0.52	3.77e-25	Colorectal cancer;
LUSC	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.18	29.21	0.85	5.44e-94	Testicular germ cell tumor;
LUSC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg15468180	chr1:107600409	PRMT6	0.41	6.54	0.34	2.32e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.7	-12.54	-0.57	8.25e-30	Prudent dietary pattern;
LUSC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg08847533	chr14:75593920	NEK9	0.85	15.6	0.65	1.32e-41	Height;
LUSC	cis	rs6489882	0.902	rs3759375	chr12:113373588	A/G	cg20102336	chr12:113376681	OAS3	-0.42	-6.03	-0.31	4.29e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg26769984	chr7:1090371	C7orf50	0.59	7.93	0.4	3.43e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs12760731	0.565	rs34303391	chr1:178178126	T/A	cg00404053	chr1:178313656	RASAL2	0.66	6.82	0.35	4.26e-11	Obesity-related traits;
LUSC	trans	rs7939886	0.920	rs7936219	chr11:55977335	C/T	cg15704280	chr7:45808275	SEPT13	0.91	6.86	0.35	3.36e-11	Myopia (pathological);
LUSC	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg17810781	chr1:201082982	CACNA1S	0.3	5.69	0.3	2.77e-8	Permanent tooth development;
LUSC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.38	0.69	1.15e-48	Chronic sinus infection;
LUSC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	18.34	0.71	1.9e-52	Chronic sinus infection;
LUSC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg04369109	chr6:150039330	LATS1	-0.54	-8.05	-0.4	1.51e-14	Lung cancer;
LUSC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	7.24	0.37	3.14e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg16339924	chr4:17578868	LAP3	0.52	7.78	0.39	9.09e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	10.76	0.51	2.15e-23	Coronary artery disease;
LUSC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.11	-0.41	9.95e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg17366294	chr4:99064904	C4orf37	0.59	8.61	0.43	2.83e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs500891	0.574	rs1112482	chr6:84112019	G/C	cg08257003	chr6:84140564	ME1	0.34	7.6	0.38	3.06e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg07701084	chr6:150067640	NUP43	0.49	7.34	0.37	1.68e-12	Lung cancer;
LUSC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.75	-0.51	2.45e-23	Chronic sinus infection;
LUSC	cis	rs17152411	1.000	rs12355869	chr10:126645231	G/T	cg07906193	chr10:126599966	NA	0.42	5.83	0.3	1.29e-8	Height;
LUSC	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.23e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg23711669	chr6:146136114	FBXO30	0.85	15.37	0.64	1.06e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg13256891	chr4:100009986	ADH5	-0.43	-5.94	-0.31	7.28e-9	Alcohol dependence;
LUSC	cis	rs1030877	0.515	rs17030766	chr2:105911905	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.52	-6.77	-0.35	5.88e-11	Obesity-related traits;
LUSC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.49	-7.68	-0.39	1.81e-13	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11051970	0.594	rs325418	chr12:32572517	T/C	cg02745156	chr12:32552066	NA	0.38	6.9	0.35	2.67e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs10097731	0.901	rs10464932	chr8:82042901	T/G	cg25230327	chr8:82042993	NA	-0.48	-6.78	-0.35	5.55e-11	Serum total protein level;
LUSC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18932078	chr1:2524107	MMEL1	-0.31	-6.76	-0.35	6.14e-11	Multiple sclerosis;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg14387532	chr2:232571819	PTMA	0.75	5.95	0.31	6.87e-9	Cognitive performance;
LUSC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.83	0.63	1.46e-38	Platelet count;
LUSC	cis	rs1322512	0.713	rs1744387	chr6:152939439	A/G	cg27316956	chr6:152958899	SYNE1	-0.35	-5.8	-0.3	1.58e-8	Tonometry;
LUSC	cis	rs9648716	0.515	rs71645993	chr7:140434845	T/C	cg23214464	chr7:140373596	ADCK2	0.78	6.26	0.32	1.17e-9	Type 2 diabetes;
LUSC	trans	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	22.58	0.78	3.49e-69	Colorectal cancer;
LUSC	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg04155231	chr12:9217510	LOC144571	0.31	5.68	0.3	3e-8	Sjögren's syndrome;
LUSC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg11645453	chr3:52864694	ITIH4	0.31	7.31	0.37	2.04e-12	Electroencephalogram traits;
LUSC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs12210905	1.000	rs10946906	chr6:27252780	G/A	cg18180407	chr1:55047736	ACOT11	0.54	5.98	0.31	5.71e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.26	-0.37	2.81e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.3	-0.37	2.1e-12	Bipolar disorder;
LUSC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06112835	chr11:68658793	MRPL21	0.51	8.09	0.4	1.1e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.4	-0.33	5.22e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs8113142	0.690	rs4805256	chr19:29109359	T/C	cg04546413	chr19:29218101	NA	0.43	5.91	0.31	8.43e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	trans	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	5.96	0.31	6.26e-9	Neuroticism;
LUSC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg07703079	chr11:430292	ANO9	0.67	7.08	0.36	8.45e-12	Body mass index;
LUSC	cis	rs2227564	0.620	rs10740418	chr10:75519322	T/C	cg23231163	chr10:75533350	FUT11	-0.44	-6.56	-0.34	2.11e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg14844989	chr11:31128820	NA	-0.36	-5.68	-0.3	2.95e-8	Red blood cell count;
LUSC	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.98	0.44	1.97e-17	Neuroticism;
LUSC	cis	rs3761218	0.738	rs4815604	chr20:3772913	C/T	cg02737268	chr20:3780182	CDC25B	0.35	6.93	0.35	2.19e-11	Bipolar disorder;
LUSC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02034447	chr16:89574710	SPG7	0.4	5.97	0.31	5.9e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg00255919	chr5:131827918	IRF1	0.41	7.93	0.4	3.36e-14	Asthma (sex interaction);
LUSC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg08847533	chr14:75593920	NEK9	-0.79	-13.57	-0.6	1e-33	Height;
LUSC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08219700	chr8:58056026	NA	0.66	7.44	0.38	8.4e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2625529	0.824	rs55854204	chr15:72433182	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.47	-0.38	7.17e-13	Red blood cell count;
LUSC	cis	rs12541635	0.966	rs12680670	chr8:107006811	T/G	cg10147462	chr8:107024639	NA	0.55	9.97	0.48	1.16e-20	Age of smoking initiation;
LUSC	cis	rs2625529	0.824	rs4238449	chr15:72421603	G/A	cg16672083	chr15:72433130	SENP8	-0.52	-7.54	-0.38	4.48e-13	Red blood cell count;
LUSC	cis	rs6489785	0.521	rs668622	chr12:121198299	G/A	cg02419362	chr12:121203948	SPPL3	0.38	6.8	0.35	4.84e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg24631222	chr15:78858424	CHRNA5	0.83	11.64	0.54	1.6e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3730682	0.901	rs59788851	chr18:51778362	G/A	cg04730925	chr18:51795821	POLI	0.43	5.8	0.3	1.54e-8	Psoriasis;
LUSC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3862435	0.764	rs28545005	chr15:90954131	A/G	cg22089800	chr15:90895588	ZNF774	0.58	6.32	0.33	8.53e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg20283391	chr11:68216788	NA	-0.54	-8.23	-0.41	4.33e-15	Total body bone mineral density;
LUSC	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg00074818	chr8:8560427	CLDN23	0.57	8.95	0.44	2.57e-17	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13999099	chr5:55290899	IL6ST	0.42	5.95	0.31	6.95e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs67539049	1.000	rs7832089	chr8:11306003	C/A	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.42	-6.47	-0.33	3.48e-10	Itch intensity from mosquito bite;
LUSC	cis	rs12760731	0.623	rs10913556	chr1:178436678	C/T	cg00404053	chr1:178313656	RASAL2	0.43	5.65	0.3	3.52e-8	Obesity-related traits;
LUSC	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg20487152	chr13:99095054	FARP1	0.44	7.96	0.4	2.8e-14	Neuroticism;
LUSC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg08470875	chr2:26401718	FAM59B	0.67	8.34	0.42	1.99e-15	Gut microbiome composition (summer);
LUSC	cis	rs2236918	0.710	rs2797603	chr1:242029027	T/G	cg17736920	chr1:242011382	EXO1	0.42	6.61	0.34	1.52e-10	Menopause (age at onset);
LUSC	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg19196401	chr6:110721138	DDO	-0.45	-8.46	-0.42	8.59e-16	Platelet distribution width;
LUSC	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg18196295	chr10:418757	DIP2C	-0.47	-7.78	-0.39	8.91e-14	Psychosis in Alzheimer's disease;
LUSC	cis	rs12122100	0.955	rs12141289	chr1:146509468	A/G	cg03526459	chr1:146549940	NA	-0.41	-6.71	-0.34	8.23e-11	HIV-1 control;
LUSC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg11766577	chr21:47581405	C21orf56	0.47	7.09	0.36	8.02e-12	Testicular germ cell tumor;
LUSC	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21293242	chr8:11204541	TDH	0.32	5.96	0.31	6.38e-9	Retinal vascular caliber;
LUSC	cis	rs9902453	0.904	rs12951836	chr17:28410277	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-10.89	-0.51	7.72e-24	Coffee consumption (cups per day);
LUSC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg05025164	chr4:1340916	KIAA1530	0.56	8.99	0.44	1.91e-17	Longevity;
LUSC	cis	rs806215	0.950	rs3735642	chr7:127224286	A/G	cg25922125	chr7:127225783	GCC1	-0.6	-7.38	-0.37	1.24e-12	Type 2 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16280946	chr22:20716554	NA	0.51	6.11	0.32	2.74e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	0.89	14.93	0.63	5.8e-39	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6060717	0.536	rs6060669	chr20:34480557	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.39	-0.33	5.45e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg24375607	chr4:120327624	NA	0.78	11.49	0.53	5.51e-26	Corneal astigmatism;
LUSC	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg16342193	chr10:102329863	NA	-0.36	-6.56	-0.34	2.08e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-7.22	-0.37	3.6e-12	Homocysteine levels;
LUSC	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg25801113	chr15:45476975	SHF	0.33	6.9	0.35	2.62e-11	Uric acid levels;
LUSC	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg23435118	chr5:141488016	NDFIP1	-0.56	-7.93	-0.4	3.4e-14	Crohn's disease;
LUSC	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	1.18	13.93	0.61	4.45e-35	Arsenic metabolism;
LUSC	cis	rs68170813	0.559	rs76167266	chr7:106900664	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.92e-20	Coronary artery disease;
LUSC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	15.92	0.66	7.33e-43	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg26384229	chr12:38710491	ALG10B	0.7	10.9	0.51	7.43e-24	Morning vs. evening chronotype;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00226754	chr12:124068984	TMED2	-0.51	-6.32	-0.33	8.51e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg26576206	chr19:1064938	ABCA7	0.44	6.7	0.34	9.06e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-14.29	-0.62	1.69e-36	Headache;
LUSC	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-8.01	-0.4	1.92e-14	Major depressive disorder;
LUSC	trans	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs6545883	0.894	rs4672431	chr2:61519922	C/A	cg15711740	chr2:61764176	XPO1	0.44	6.78	0.35	5.44e-11	Tuberculosis;
LUSC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.4	0.38	1.11e-12	Lung cancer in ever smokers;
LUSC	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.67	-11.89	-0.55	2.01e-27	Electrocardiographic conduction measures;
LUSC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-1.04	-20.21	-0.74	7.12e-60	Height;
LUSC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.53	0.57	8.85e-30	Motion sickness;
LUSC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.35	5.77	0.3	1.85e-8	Vitiligo;
LUSC	cis	rs11997175	0.646	rs6993892	chr8:33729200	T/C	ch.8.33884649F	chr8:33765107	NA	0.49	7.32	0.37	1.89e-12	Body mass index;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00419759	chr1:114301964	PHTF1	0.41	6.18	0.32	1.82e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7119	0.635	rs2667764	chr15:77881239	C/T	cg27398640	chr15:77910606	LINGO1	0.35	8.2	0.41	5.1e-15	Type 2 diabetes;
LUSC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.89	-0.51	7.77e-24	Alzheimer's disease (late onset);
LUSC	cis	rs7937682	0.593	rs1944121	chr11:111347223	T/C	cg09085632	chr11:111637200	PPP2R1B	0.44	5.82	0.3	1.35e-8	Primary sclerosing cholangitis;
LUSC	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg07959070	chr22:50026188	C22orf34	-0.36	-7.25	-0.37	2.87e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9902453	1.000	rs9906340	chr17:28398977	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-9.01	-0.44	1.63e-17	Coffee consumption (cups per day);
LUSC	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg09835421	chr16:68378352	PRMT7	-0.45	-5.95	-0.31	6.8e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs981844	0.767	rs6857738	chr4:154689140	A/C	cg10279832	chr4:154682576	RNF175	0.37	5.91	0.31	8.67e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs727505	0.563	rs73227531	chr7:124800221	T/A	cg23710748	chr7:124431027	NA	-0.38	-6.6	-0.34	1.64e-10	Lewy body disease;
LUSC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg02153584	chr22:29168773	CCDC117	0.55	7.94	0.4	3.01e-14	Lymphocyte counts;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04661747	chr11:46264818	NA	0.47	6.54	0.34	2.28e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs36093844	0.800	rs79349553	chr11:85567836	G/T	cg25872744	chr11:85566296	CCDC83	-0.45	-5.78	-0.3	1.74e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.69	-0.39	1.68e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.87	15.49	0.65	3.75e-41	Metabolic syndrome;
LUSC	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg17252645	chr8:143867129	LY6D	0.38	6.79	0.35	5.28e-11	Urinary tract infection frequency;
LUSC	trans	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg01620082	chr3:125678407	NA	-0.62	-6.83	-0.35	3.98e-11	Depression;
LUSC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13126279	chr21:47581558	C21orf56	-0.47	-7.07	-0.36	9.17e-12	Testicular germ cell tumor;
LUSC	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg20587970	chr11:113659929	NA	-0.99	-13.28	-0.59	1.27e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg27494647	chr7:150038898	RARRES2	0.45	6.84	0.35	3.88e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7523050	0.730	rs11102650	chr1:109464228	C/G	cg08274380	chr1:109419600	GPSM2	1.03	10.3	0.49	8.35e-22	Fat distribution (HIV);
LUSC	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.15	-0.32	2.26e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.09	-0.36	8.22e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg22963979	chr7:1858916	MAD1L1	-0.57	-8.84	-0.44	5.78e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg27124370	chr19:33622961	WDR88	0.53	7.65	0.39	2.13e-13	Colorectal cancer;
LUSC	trans	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg21775007	chr8:11205619	TDH	0.42	6.01	0.31	4.83e-9	Neuroticism;
LUSC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.46	-7.18	-0.37	4.6e-12	Systemic lupus erythematosus;
LUSC	cis	rs7000551	0.751	rs2469755	chr8:22360212	G/A	cg12081754	chr8:22256438	SLC39A14	0.45	6.8	0.35	4.83e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg16230307	chr14:35515116	FAM177A1	0.78	10.0	0.48	8.96e-21	Psoriasis;
LUSC	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg15896084	chr13:114927664	NA	0.4	7.18	0.37	4.42e-12	Schizophrenia;
LUSC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg00074818	chr8:8560427	CLDN23	0.58	9.66	0.47	1.23e-19	Obesity-related traits;
LUSC	cis	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg27411982	chr8:10470053	RP1L1	0.54	9.13	0.45	6.6e-18	Neuroticism;
LUSC	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg05872129	chr22:39784769	NA	0.36	6.15	0.32	2.21e-9	IgG glycosylation;
LUSC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg12559939	chr2:27858050	GPN1	0.38	5.91	0.31	8.6e-9	Oral cavity cancer;
LUSC	cis	rs6736093	1.000	rs6736093	chr2:112655242	C/T	cg12686935	chr2:112915763	FBLN7	0.39	6.05	0.31	3.95e-9	Coronary artery disease;
LUSC	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.74	15.64	0.65	9.03e-42	Systemic lupus erythematosus;
LUSC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg25767906	chr1:53392781	SCP2	-0.53	-10.33	-0.49	7.07e-22	Monocyte count;
LUSC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.67	-11.54	-0.53	3.59e-26	Dental caries;
LUSC	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.59	-9.44	-0.46	6.62e-19	Body mass index;
LUSC	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.51	8.57	0.42	4.01e-16	Schizophrenia;
LUSC	cis	rs2742234	0.541	rs61268333	chr10:43721370	G/A	cg02780029	chr10:43622663	RET	0.35	5.82	0.3	1.41e-8	Hirschsprung disease;
LUSC	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18932078	chr1:2524107	MMEL1	0.28	6.15	0.32	2.18e-9	Ulcerative colitis;
LUSC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg12292205	chr6:26970375	C6orf41	-0.7	-12.22	-0.56	1.23e-28	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs13314892	1.000	rs13314892	chr3:69795052	A/G	cg14672293	chr2:48542674	FOXN2	0.48	6.01	0.31	4.78e-9	QRS complex (12-leadsum);
LUSC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg06008330	chr7:65541103	ASL	0.4	6.24	0.32	1.32e-9	Aortic root size;
LUSC	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg26597838	chr10:835615	NA	-0.5	-6.75	-0.35	6.65e-11	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.66	-0.43	2.03e-16	Glomerular filtration rate (creatinine);
LUSC	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg22482690	chr17:47019901	SNF8	0.34	6.35	0.33	6.85e-10	Type 2 diabetes;
LUSC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg14092988	chr3:52407081	DNAH1	0.32	5.94	0.31	7.16e-9	Bipolar disorder;
LUSC	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg23093090	chr10:104574429	C10orf26	-0.38	-7.06	-0.36	9.84e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg11861562	chr11:117069780	TAGLN	0.35	6.73	0.35	7.59e-11	Blood protein levels;
LUSC	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07080220	chr10:102295463	HIF1AN	0.7	9.3	0.45	1.88e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	15.37	0.64	1.09e-40	Platelet count;
LUSC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	12.95	0.58	2.27e-31	Cognitive test performance;
LUSC	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	0.59	9.11	0.45	7.8e-18	Breast cancer;
LUSC	cis	rs789294	1	rs789294	chr3:154057741	C/G	cg17054900	chr3:154042577	DHX36	0.81	8.69	0.43	1.7e-16	Coronary artery disease;
LUSC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	8.07	0.4	1.32e-14	Personality dimensions;
LUSC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.31	0.49	8.09e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.71	12.79	0.57	9.66e-31	Prudent dietary pattern;
LUSC	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg13042288	chr15:90349979	ANPEP	-0.49	-6.82	-0.35	4.39e-11	Uric acid levels;
LUSC	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg02248941	chr16:2239361	CASKIN1	-0.44	-7.94	-0.4	3.05e-14	Height;
LUSC	cis	rs11030122	0.673	rs10835596	chr11:4099666	C/T	cg08557956	chr11:4115526	RRM1	-0.46	-5.96	-0.31	6.57e-9	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.54	-0.34	2.26e-10	Retinal vascular caliber;
LUSC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26801646	chr10:76970496	VDAC2	-0.41	-7.17	-0.37	4.95e-12	Electrocardiographic conduction measures;
LUSC	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg15654264	chr1:150340011	RPRD2	0.61	10.09	0.48	4.38e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg11161011	chr14:65562177	MAX	0.7	10.98	0.51	3.87e-24	Obesity-related traits;
LUSC	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg09092052	chr15:45571596	NA	0.47	6.53	0.34	2.42e-10	Glomerular filtration rate;
LUSC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2282802	0.660	rs4463213	chr5:139545748	G/A	cg26211634	chr5:139558579	C5orf32	-0.41	-7.59	-0.38	3.12e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.65	10.16	0.49	2.58e-21	Endometrial cancer;
LUSC	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.59	9.48	0.46	4.74e-19	Body mass index;
LUSC	trans	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg04539111	chr16:67997858	SLC12A4	-0.42	-5.88	-0.31	1.01e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg08209724	chr17:30677138	MIR632;ZNF207	0.4	7.06	0.36	9.58e-12	Triglycerides;
LUSC	cis	rs9807989	0.839	rs10192036	chr2:102968211	C/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.91	0.31	8.63e-9	Asthma;
LUSC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg26304593	chr6:42947056	PEX6	-0.54	-8.56	-0.42	4.07e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs3857536	0.813	rs9363554	chr6:66930183	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.23	-0.32	1.4e-9	Blood trace element (Cu levels);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03438904	chr3:197518158	LRCH3	-0.44	-6.53	-0.34	2.43e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg25233709	chr10:116636983	FAM160B1	0.44	7.83	0.39	6.41e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.72	10.69	0.5	4.02e-23	Smoking initiation;
LUSC	trans	rs890100	0.902	rs13422571	chr2:56740231	C/T	cg08299783	chr2:48920986	GTF2A1L;LHCGR	-0.31	-6.09	-0.32	3.15e-9	Gut microbiome composition (summer);
LUSC	trans	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg07393940	chr7:158741817	NA	-0.37	-6.76	-0.35	6.27e-11	Life satisfaction;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04048411	chr12:94541943	PLXNC1	-0.49	-6.42	-0.33	4.78e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg05925327	chr15:68127851	NA	0.41	6.48	0.33	3.28e-10	Motion sickness;
LUSC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg10862848	chr6:42927986	GNMT	-0.28	-6.57	-0.34	1.97e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7605827	0.930	rs2049719	chr2:15515058	A/G	cg19274914	chr2:15703543	NA	0.46	8.86	0.44	4.71e-17	Educational attainment (years of education);
LUSC	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg12856521	chr11:46389249	DGKZ	0.41	6.38	0.33	6.02e-10	Leprosy;
LUSC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.37	-0.42	1.66e-15	Height;
LUSC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg02580895	chr19:2754563	NA	-0.46	-6.97	-0.36	1.67e-11	Total cholesterol levels;
LUSC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg19592336	chr6:28129416	ZNF389	0.53	7.05	0.36	1.02e-11	Parkinson's disease;
LUSC	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg05868516	chr6:26286170	HIST1H4H	0.37	6.09	0.32	3.03e-9	Educational attainment;
LUSC	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09909775	chr12:45610071	ANO6;PLEKHA9	0.46	5.96	0.31	6.4e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.67e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs62408225	1.000	rs62408225	chr6:90956409	A/G	cg06866423	chr6:90926672	BACH2	0.4	5.83	0.3	1.33e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.62	0.47	1.7e-19	Personality dimensions;
LUSC	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg12935359	chr14:103987150	CKB	0.66	10.45	0.5	2.64e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7315438	0.758	rs3858648	chr12:115894913	C/A	cg24172291	chr12:115889509	NA	-0.34	-5.7	-0.3	2.59e-8	Colorectal cancer;
LUSC	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg12292205	chr6:26970375	C6orf41	-0.42	-6.29	-0.33	1.02e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00166722	chr3:10149974	C3orf24	0.63	8.47	0.42	7.65e-16	Alzheimer's disease;
LUSC	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg04719120	chr6:96025338	MANEA	0.48	5.93	0.31	7.59e-9	Behavioural disinhibition (generation interaction);
LUSC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg02951883	chr7:2050386	MAD1L1	-0.38	-6.56	-0.34	2.01e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg24675056	chr1:15929824	NA	0.48	8.27	0.41	3.15e-15	Systolic blood pressure;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09379601	chr19:12992224	DNASE2	0.49	7.23	0.37	3.28e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg10172584	chr19:19639581	YJEFN3	-0.46	-5.65	-0.3	3.42e-8	Bipolar disorder;
LUSC	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg21724239	chr8:58056113	NA	0.56	6.8	0.35	4.94e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.8	0.35	4.73e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7605827	0.930	rs2287274	chr2:15658577	T/C	cg19274914	chr2:15703543	NA	0.45	8.69	0.43	1.69e-16	Educational attainment (years of education);
LUSC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg14829155	chr15:31115871	NA	-0.53	-7.67	-0.39	1.85e-13	Huntington's disease progression;
LUSC	cis	rs500891	0.533	rs583637	chr6:84196263	G/T	cg08257003	chr6:84140564	ME1	-0.34	-8.35	-0.42	1.87e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.25	0.52	4.02e-25	Prudent dietary pattern;
LUSC	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-6.86	-0.35	3.26e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg25664220	chr3:72788482	NA	-0.71	-11.88	-0.55	2.09e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.57	-8.63	-0.43	2.6e-16	Ulcerative colitis;
LUSC	trans	rs8181588	1.000	rs2074197	chr11:2825279	C/T	cg23136573	chr6:52230573	PAQR8	0.74	5.97	0.31	5.95e-9	Type 2 diabetes;
LUSC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-14.85	-0.63	1.22e-38	Total body bone mineral density;
LUSC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05665937	chr4:1216051	CTBP1	0.38	6.01	0.31	4.74e-9	Obesity-related traits;
LUSC	cis	rs708547	0.957	rs2458552	chr4:57773442	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.69	-0.3	2.83e-8	Response to bleomycin (chromatid breaks);
LUSC	cis	rs9902453	0.817	rs12941382	chr17:28410124	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-10.65	-0.5	5.42e-23	Coffee consumption (cups per day);
LUSC	cis	rs11153306	0.552	rs12196381	chr6:111939400	A/C	cg22127309	chr6:111907043	TRAF3IP2	0.36	7.16	0.36	5.3e-12	Tonsillectomy;
LUSC	cis	rs4474465	0.850	rs4945287	chr11:78226521	C/T	cg27205649	chr11:78285834	NARS2	0.54	6.27	0.32	1.13e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg18512352	chr11:47633146	NA	-0.46	-9.19	-0.45	4.42e-18	Subjective well-being;
LUSC	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg05738196	chr6:26577821	NA	-0.5	-7.68	-0.39	1.82e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2073300	1.000	rs6137984	chr20:23469864	T/A	cg09953122	chr20:23471693	CST8	-0.87	-6.99	-0.36	1.54e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg21433313	chr16:3507492	NAT15	0.39	6.23	0.32	1.42e-9	Body mass index (adult);
LUSC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg26924012	chr15:45694286	SPATA5L1	1.14	21.1	0.76	2.08e-63	Homoarginine levels;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg15365588	chr7:7681016	RPA3	0.36	6.14	0.32	2.35e-9	Schizophrenia;
LUSC	cis	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg21775007	chr8:11205619	TDH	-0.43	-6.03	-0.31	4.36e-9	Monocyte count;
LUSC	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg10172584	chr19:19639581	YJEFN3	-0.5	-5.99	-0.31	5.3e-9	Bipolar disorder;
LUSC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg22638593	chr5:131593259	PDLIM4	0.41	5.95	0.31	6.73e-9	Breast cancer;
LUSC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.76	13.62	0.6	6.8e-34	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg22823121	chr1:150693482	HORMAD1	0.45	6.47	0.33	3.47e-10	Melanoma;
LUSC	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg19743168	chr1:23544995	NA	-0.45	-9.74	-0.47	6.75e-20	Height;
LUSC	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg08684580	chr7:98029266	BAIAP2L1	0.38	5.8	0.3	1.52e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3768617	0.782	rs12146099	chr1:182968079	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.49	0.42	6.66e-16	Fuchs's corneal dystrophy;
LUSC	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.76	-0.43	9.86e-17	Neuroticism;
LUSC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.08	-0.4	1.17e-14	Type 2 diabetes;
LUSC	cis	rs539096	0.692	rs7549094	chr1:44213178	C/A	cg15962314	chr1:44399869	ARTN	0.24	5.73	0.3	2.28e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.33	0.53	2.09e-25	Coffee consumption (cups per day);
LUSC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.13	-0.41	8.71e-15	Chronic sinus infection;
LUSC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.62	0.47	1.65e-19	Bipolar disorder;
LUSC	cis	rs8027181	0.804	rs34661924	chr15:72994564	A/G	cg25632853	chr15:73088954	NA	0.33	6.73	0.35	7.22e-11	Triglyceride levels;
LUSC	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.12	0.41	9.19e-15	Homoarginine levels;
LUSC	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	9.91	0.48	1.88e-20	Lymphocyte counts;
LUSC	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg24375607	chr4:120327624	NA	0.8	11.96	0.55	1.1e-27	Corneal astigmatism;
LUSC	cis	rs11785693	0.862	rs6995565	chr8:4990461	C/T	cg26367366	chr8:4980734	NA	-0.72	-8.44	-0.42	9.45e-16	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.21	0.32	1.55e-9	Total body bone mineral density;
LUSC	cis	rs9420	0.961	rs11601320	chr11:57642617	T/C	cg02958346	chr11:57425731	CLP1	-0.46	-6.56	-0.34	2.08e-10	Schizophrenia;
LUSC	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg11161846	chr1:160990452	F11R	-0.31	-5.69	-0.3	2.8e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg26695010	chr11:65641043	EFEMP2	0.42	6.01	0.31	4.9e-9	Breast cancer;
LUSC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	8.32	0.41	2.3e-15	Prudent dietary pattern;
LUSC	cis	rs2324229	0.828	rs1180203	chr6:83957225	A/G	cg08257003	chr6:84140564	ME1	0.29	6.75	0.35	6.5e-11	Platelet-derived growth factor BB levels;
LUSC	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	1.08	17.88	0.7	1.23e-50	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6494488	0.500	rs72743002	chr15:65011195	G/A	cg08069370	chr15:64387884	SNX1	-0.66	-5.78	-0.3	1.71e-8	Coronary artery disease;
LUSC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.4	0.33	5.39e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4363385	0.818	rs572821	chr1:153008276	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	trans	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.56	0.34	2.1e-10	Resting heart rate;
LUSC	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.4	0.38	1.08e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg18478394	chr8:109455254	TTC35	0.44	6.81	0.35	4.63e-11	Dupuytren's disease;
LUSC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg25258033	chr6:167368657	RNASET2	-0.49	-8.09	-0.4	1.13e-14	Crohn's disease;
LUSC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg09626299	chr10:82213104	TSPAN14	-0.2	-5.92	-0.31	8.16e-9	Post bronchodilator FEV1;
LUSC	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-8.46	-0.42	8.76e-16	Coffee consumption (cups per day);
LUSC	trans	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg07211511	chr3:129823064	LOC729375	-0.53	-6.1	-0.32	2.86e-9	Blood pressure (smoking interaction);
LUSC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg14895029	chr7:2775587	GNA12	-0.38	-5.97	-0.31	6.06e-9	Height;
LUSC	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg11189052	chr15:85197271	WDR73	0.47	5.81	0.3	1.44e-8	Schizophrenia;
LUSC	cis	rs60015123	0.850	rs73264674	chr12:7131014	C/T	cg26269324	chr12:6977084	TPI1	0.77	5.93	0.31	7.39e-9	Red cell distribution width;
LUSC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg12963246	chr6:28129442	ZNF389	0.38	5.84	0.3	1.21e-8	Cardiac Troponin-T levels;
LUSC	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg17366294	chr4:99064904	C4orf37	0.58	10.46	0.5	2.44e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg06096015	chr1:231504339	EGLN1	0.56	9.86	0.47	2.61e-20	Hemoglobin concentration;
LUSC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg05941027	chr17:61774174	LIMD2	0.22	5.69	0.3	2.75e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg02023728	chr11:77925099	USP35	0.46	6.56	0.34	2.03e-10	Testicular germ cell tumor;
LUSC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs9487051	0.702	rs368467	chr6:109519451	T/C	cg01475377	chr6:109611718	NA	-0.36	-6.11	-0.32	2.7e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.87	0.35	3.11e-11	Height;
LUSC	trans	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs1044826	0.642	rs7624321	chr3:139220159	C/A	cg15131784	chr3:139108705	COPB2	0.39	6.34	0.33	7.33e-10	Obesity-related traits;
LUSC	trans	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17712092	chr4:129076599	LARP1B	0.74	10.99	0.52	3.53e-24	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg11764359	chr7:65958608	NA	0.54	6.97	0.36	1.75e-11	Aortic root size;
LUSC	cis	rs2267137	0.747	rs1963292	chr22:29805867	T/C	cg07256473	chr22:29710276	RASL10A	0.38	7.33	0.37	1.75e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.7	-0.3	2.63e-8	Resting heart rate;
LUSC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.63	0.85	1.69e-95	Chronic sinus infection;
LUSC	cis	rs62400317	0.859	rs10948213	chr6:45158515	T/C	cg18551225	chr6:44695536	NA	-0.45	-7.22	-0.37	3.47e-12	Total body bone mineral density;
LUSC	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.24	0.37	3.16e-12	Morning vs. evening chronotype;
LUSC	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-0.52	-8.06	-0.4	1.34e-14	Breast cancer;
LUSC	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg08079166	chr15:68083412	MAP2K5	0.49	8.12	0.41	8.9e-15	Restless legs syndrome;
LUSC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg16928487	chr17:17741425	SREBF1	0.37	7.13	0.36	6.28e-12	Total body bone mineral density;
LUSC	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.59	-6.41	-0.33	4.99e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg15654264	chr1:150340011	RPRD2	0.66	11.15	0.52	9.34e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg03788504	chr6:150331562	NA	-0.27	-6.01	-0.31	4.88e-9	Alopecia areata;
LUSC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg07703079	chr11:430292	ANO9	0.64	6.7	0.34	8.87e-11	Body mass index;
LUSC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg13560548	chr3:10150139	C3orf24	0.51	7.22	0.37	3.61e-12	Alzheimer's disease;
LUSC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	8.3	0.41	2.62e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09184467	chr10:14995699	DCLRE1C	-0.38	-6.28	-0.32	1.03e-9	Electrocardiographic conduction measures;
LUSC	trans	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg16724585	chr3:197361211	NA	-0.59	-8.51	-0.42	6.03e-16	Pancreatic cancer;
LUSC	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg25427524	chr10:38739819	LOC399744	0.45	5.95	0.31	6.81e-9	Obesity (extreme);
LUSC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.11	-0.48	3.98e-21	Hemoglobin concentration;
LUSC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.71	7.16	0.36	5.14e-12	Initial pursuit acceleration;
LUSC	cis	rs912057	0.671	rs1294433	chr6:6745163	G/A	cg06612196	chr6:6737390	NA	0.55	10.78	0.51	1.91e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg03929089	chr4:120376271	NA	0.69	7.79	0.39	8.71e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg18132916	chr6:79620363	NA	-0.4	-6.08	-0.32	3.29e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg02403541	chr12:121454288	C12orf43	0.59	8.45	0.42	8.98e-16	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	0.65	13.75	0.6	2.03e-34	Prudent dietary pattern;
LUSC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-0.81	-11.07	-0.52	1.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg00852783	chr1:26633632	UBXN11	-0.49	-8.76	-0.43	1.02e-16	Obesity-related traits;
LUSC	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg00784671	chr22:46762841	CELSR1	-0.54	-6.79	-0.35	5.18e-11	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.62	-10.91	-0.51	6.48e-24	Mean corpuscular volume;
LUSC	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg13390004	chr1:15929781	NA	0.41	6.54	0.34	2.28e-10	Systolic blood pressure;
LUSC	cis	rs7202877	0.706	rs1540	chr16:75481185	G/C	cg03315344	chr16:75512273	CHST6	-0.45	-6.22	-0.32	1.48e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg26408565	chr15:76604113	ETFA	-0.36	-5.64	-0.3	3.53e-8	Blood metabolite levels;
LUSC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg16989086	chr20:62203971	PRIC285	0.46	6.42	0.33	4.69e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUSC	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg04362960	chr10:104952993	NT5C2	0.57	8.83	0.44	5.99e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs72781680	0.768	rs112139157	chr2:24150783	A/C	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.8	0.47	4.17e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg06808227	chr14:105710500	BRF1	-0.66	-9.9	-0.48	1.9e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.94	0.48	1.47e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2502731	0.539	rs3003608	chr9:130984430	C/A	cg09976142	chr9:130955436	CIZ1	0.39	6.52	0.34	2.65e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	0.97	21.42	0.76	1.16e-64	Longevity;
LUSC	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.83	0.35	4.02e-11	Educational attainment;
LUSC	trans	rs72674100	1.000	rs28612505	chr4:97992338	G/T	cg09670535	chr1:18959427	PAX7	-0.63	-6.52	-0.34	2.63e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3849570	0.555	rs4452351	chr3:82007977	C/T	cg07356753	chr3:81810745	GBE1	-0.42	-6.04	-0.31	4.12e-9	Waist circumference;Body mass index;
LUSC	cis	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg17469321	chr7:55412551	NA	-0.67	-10.79	-0.51	1.73e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg26102564	chr10:131424627	MGMT	0.41	6.38	0.33	5.9e-10	Response to temozolomide;
LUSC	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.45	-9.9	-0.48	1.91e-20	Airflow obstruction;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg27524515	chr8:38239417	WHSC1L1	-0.53	-7.21	-0.37	3.85e-12	Cognitive function;Information processing speed;
LUSC	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg10596483	chr8:143751796	JRK	0.53	7.66	0.39	1.98e-13	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg21724239	chr8:58056113	NA	0.57	6.58	0.34	1.87e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs17818399	0.501	rs13413254	chr2:46802934	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-6.93	-0.35	2.14e-11	Height;
LUSC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	0.93	15.69	0.65	5.75e-42	Menopause (age at onset);
LUSC	trans	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Bladder cancer;
LUSC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg16393715	chr7:1948819	MAD1L1	0.39	6.75	0.35	6.43e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.99	-0.31	5.52e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg07700843	chr1:2391317	NA	-0.44	-6.81	-0.35	4.43e-11	Non-obstructive azoospermia;
LUSC	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.94	0.51	4.97e-24	Colorectal cancer;
LUSC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.52	0.59	1.57e-33	Platelet count;
LUSC	cis	rs593982	0.920	rs563427	chr11:65484569	A/G	cg08755490	chr11:65554678	OVOL1	1.51	13.45	0.59	3.1e-33	Atopic dermatitis;
LUSC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.21	-0.37	3.74e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12541635	0.966	rs4734894	chr8:106995313	G/A	cg10147462	chr8:107024639	NA	0.55	9.77	0.47	5.52e-20	Age of smoking initiation;
LUSC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg03146154	chr1:46216737	IPP	-0.51	-7.36	-0.37	1.47e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	11.21	0.52	5.73e-25	Electrocardiographic conduction measures;
LUSC	cis	rs204247	0.565	rs411094	chr6:13718264	C/A	cg02206980	chr6:13574034	SIRT5	-0.43	-8.73	-0.43	1.21e-16	Breast cancer;
LUSC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	9.15	0.45	5.96e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs977987	0.778	rs35415181	chr16:75403124	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.33	0.45	1.48e-18	Dupuytren's disease;
LUSC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg01448562	chr3:133502909	NA	-0.77	-13.41	-0.59	4.15e-33	Iron status biomarkers;
LUSC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg14552801	chr7:65878734	NA	0.45	6.34	0.33	7.34e-10	Aortic root size;
LUSC	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.61	7.88	0.4	4.73e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12220238	1.000	rs11000930	chr10:75982982	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.64	-6.75	-0.35	6.57e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs193541	0.632	rs39821	chr5:122295472	T/C	cg19077854	chr5:122220652	SNX24	0.39	8.38	0.42	1.48e-15	Glucose homeostasis traits;
LUSC	cis	rs713477	0.845	rs4898863	chr14:55910284	T/A	cg13175173	chr14:55914753	NA	-0.3	-6.19	-0.32	1.76e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs10740039	0.516	rs2893840	chr10:62314015	T/C	cg18175470	chr10:62150864	ANK3	-0.47	-6.91	-0.35	2.44e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.79	10.06	0.48	5.75e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2274459	0.841	rs2281919	chr6:33663171	A/C	cg06253072	chr6:33679850	C6orf125	0.48	5.76	0.3	1.94e-8	Obesity (extreme);
LUSC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.44	6.21	0.32	1.59e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs11971779	1.000	rs11971779	chr7:139040258	A/G	cg07862535	chr7:139043722	LUC7L2	-0.71	-8.09	-0.4	1.1e-14	Diisocyanate-induced asthma;
LUSC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	12.88	0.58	4.26e-31	Cognitive test performance;
LUSC	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg03929089	chr4:120376271	NA	0.72	6.86	0.35	3.37e-11	Axial length;
LUSC	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	cis	rs9687065	1.000	rs10078963	chr5:148400424	G/A	cg23229984	chr5:148520753	ABLIM3	-0.38	-5.67	-0.3	3.16e-8	Diastolic blood pressure;
LUSC	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg27471124	chr11:109292789	C11orf87	0.41	7.22	0.37	3.44e-12	Schizophrenia;
LUSC	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg20933634	chr6:27740509	NA	0.43	5.93	0.31	7.46e-9	Parkinson's disease;
LUSC	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.79	11.49	0.53	5.74e-26	Corneal astigmatism;
LUSC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	18.78	0.72	3.31e-54	Chronic sinus infection;
LUSC	cis	rs4474465	0.790	rs10751295	chr11:78266047	T/A	cg27205649	chr11:78285834	NARS2	0.51	6.05	0.31	3.99e-9	Alzheimer's disease (survival time);
LUSC	cis	rs757278	0.591	rs1042180	chr7:117308413	C/T	cg10524701	chr7:117356490	CTTNBP2	0.4	5.76	0.3	1.9e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs2692947	0.550	rs12623771	chr2:96633504	A/G	cg22654517	chr2:96458247	NA	0.34	6.87	0.35	3.23e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.99	-0.36	1.53e-11	Coronary artery calcification;
LUSC	cis	rs4450131	0.522	rs11245327	chr10:126358174	T/C	cg20435097	chr10:126320824	FAM53B	0.24	6.25	0.32	1.27e-9	White blood cell count (basophil);
LUSC	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg17279839	chr7:150038598	RARRES2	0.4	6.15	0.32	2.2e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg12751644	chr20:60527061	NA	-0.32	-5.78	-0.3	1.74e-8	Body mass index;
LUSC	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg12884169	chr21:40033163	ERG	0.61	12.27	0.56	7.69e-29	Coronary artery disease;
LUSC	cis	rs17092148	1.000	rs910871	chr20:33333208	C/A	cg16810054	chr20:33298113	TP53INP2	-0.41	-6.42	-0.33	4.77e-10	Neuroticism;
LUSC	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg03522245	chr20:25566470	NINL	0.35	5.68	0.3	2.99e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.86	0.4	5.28e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg19418458	chr7:158789849	NA	-0.57	-9.13	-0.45	6.68e-18	Facial morphology (factor 20);
LUSC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg08270630	chr22:50330655	NA	0.41	6.09	0.32	3.03e-9	Schizophrenia;
LUSC	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.12	-0.32	2.66e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2692947	0.637	rs72492201	chr2:96630201	G/A	cg22654517	chr2:96458247	NA	0.32	6.22	0.32	1.52e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg20476274	chr7:133979776	SLC35B4	0.7	12.0	0.55	7.87e-28	Mean platelet volume;
LUSC	cis	rs1113500	0.933	rs745795	chr1:108629345	C/T	cg06207961	chr1:108661230	NA	0.4	7.45	0.38	8.2e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs1451375	0.959	rs6962356	chr7:50621941	T/C	cg18232548	chr7:50535776	DDC	0.51	7.84	0.39	6.19e-14	Malaria;
LUSC	cis	rs6494488	0.500	rs72744740	chr15:65050491	C/G	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	trans	rs7939886	0.920	rs74962317	chr11:56036589	C/T	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	21.75	0.77	5.93e-66	Height;
LUSC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg23711669	chr6:146136114	FBXO30	0.88	16.13	0.66	1.12e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg04450456	chr4:17643702	FAM184B	0.36	5.9	0.31	8.88e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	25.2	0.81	2.88e-79	Chronic sinus infection;
LUSC	cis	rs4964805	0.594	rs4964830	chr12:104168908	A/G	cg02344784	chr12:104178138	NT5DC3	-0.36	-5.73	-0.3	2.21e-8	Attention deficit hyperactivity disorder;
LUSC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg25767906	chr1:53392781	SCP2	-0.65	-12.85	-0.58	5.69e-31	Monocyte count;
LUSC	trans	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg02030672	chr11:45687055	CHST1	-0.43	-6.85	-0.35	3.46e-11	Obesity-related traits;
LUSC	trans	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg06521331	chr12:34319734	NA	-0.4	-6.19	-0.32	1.74e-9	Bladder cancer;
LUSC	cis	rs68170813	0.559	rs1989814	chr7:107045076	A/G	cg24556660	chr7:106842632	COG5;HBP1	-0.43	-5.65	-0.3	3.4e-8	Coronary artery disease;
LUSC	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg26850624	chr5:429559	AHRR	-0.37	-7.04	-0.36	1.08e-11	Cystic fibrosis severity;
LUSC	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg25309564	chr22:51001381	C22orf41	0.43	6.06	0.31	3.67e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg11211951	chr8:145729740	GPT	0.57	11.13	0.52	1.09e-24	Age at first birth;
LUSC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg09640425	chr7:158790006	NA	-0.46	-7.08	-0.36	8.43e-12	Facial morphology (factor 20);
LUSC	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.33	-7.09	-0.36	7.79e-12	Dupuytren's disease;
LUSC	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.82	-0.43	6.68e-17	Response to antipsychotic treatment;
LUSC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg18240062	chr17:79603768	NPLOC4	0.71	13.16	0.58	3.7e-32	Eye color traits;
LUSC	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.94	12.35	0.56	4.02e-29	Exhaled nitric oxide output;
LUSC	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg25214090	chr10:38739885	LOC399744	0.51	7.43	0.38	9.11e-13	Corneal astigmatism;
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg25428297	chr7:1022841	CYP2W1	0.28	5.66	0.3	3.32e-8	Longevity;Endometriosis;
LUSC	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg26384229	chr12:38710491	ALG10B	0.52	7.41	0.38	1.06e-12	Morning vs. evening chronotype;
LUSC	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.24	-0.37	3.14e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg06784218	chr1:46089804	CCDC17	0.54	11.06	0.52	1.88e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg04310649	chr10:35416472	CREM	-0.41	-6.52	-0.34	2.6e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12900413	0.687	rs12906905	chr15:90315399	A/G	cg24249390	chr15:90295951	MESP1	-0.37	-5.75	-0.3	2.05e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg21782813	chr7:2030301	MAD1L1	-0.44	-7.33	-0.37	1.76e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.83	12.78	0.57	9.76e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.61	-11.82	-0.54	3.68e-27	Pulse pressure;
LUSC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg16743903	chr16:89593216	SPG7	-0.38	-5.92	-0.31	7.84e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg01503450	chr10:980765	NA	-0.36	-5.84	-0.3	1.26e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg01884057	chr2:25150051	NA	0.47	10.68	0.5	4.18e-23	Body mass index in non-asthmatics;
LUSC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22968622	chr17:43663579	NA	-0.79	-12.21	-0.56	1.33e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.61	-0.43	2.98e-16	Lung cancer;
LUSC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg09858108	chr8:58055024	NA	0.52	7.02	0.36	1.24e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.81	-0.39	7.69e-14	Joint mobility (Beighton score);
LUSC	cis	rs11158026	0.576	rs56013432	chr14:55351179	T/C	cg04306507	chr14:55594613	LGALS3	0.4	6.43	0.33	4.45e-10	Parkinson's disease;
LUSC	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg19743168	chr1:23544995	NA	-0.44	-9.37	-0.46	1.09e-18	Height;
LUSC	cis	rs36093844	1.000	rs36093844	chr11:85576127	A/G	cg16165120	chr11:85566439	CCDC83	0.35	5.84	0.3	1.24e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg01416388	chr22:39784598	NA	-0.45	-7.03	-0.36	1.13e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.3	0.41	2.67e-15	Prudent dietary pattern;
LUSC	cis	rs9865818	0.545	rs12634152	chr3:188121019	C/T	cg23651889	chr3:188115336	LPP	0.38	5.94	0.31	7.11e-9	Allergic sensitization;
LUSC	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg21132104	chr15:45694354	SPATA5L1	0.42	6.1	0.32	2.96e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg10596483	chr8:143751796	JRK	0.6	9.28	0.45	2.23e-18	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg13010199	chr12:38710504	ALG10B	-0.4	-6.01	-0.31	4.99e-9	Morning vs. evening chronotype;
LUSC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg18305652	chr10:134549665	INPP5A	0.46	6.83	0.35	4.01e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg07701084	chr6:150067640	NUP43	0.58	9.19	0.45	4.31e-18	Lung cancer;
LUSC	cis	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.53	-0.46	3.44e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg24675056	chr1:15929824	NA	0.46	8.02	0.4	1.83e-14	Systolic blood pressure;
LUSC	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.92	12.13	0.55	2.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs6690583	0.623	rs61768853	chr1:85455707	T/C	cg11262906	chr1:85462892	MCOLN2	0.68	6.56	0.34	2.03e-10	Serum sulfate level;
LUSC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11945232	1.000	rs28630962	chr4:88336386	C/T	cg23841344	chr4:88312519	HSD17B11	-0.67	-10.15	-0.49	2.86e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	6.15	0.32	2.21e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07973146	chr20:18488185	SEC23B	-0.44	-5.94	-0.31	6.98e-9	Hepatitis;
LUSC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07677032	chr17:61819896	STRADA	0.54	9.03	0.44	1.36e-17	Prudent dietary pattern;
LUSC	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24531977	chr5:56204891	C5orf35	-1.17	-18.44	-0.71	7.36e-53	Initial pursuit acceleration;
LUSC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg18225595	chr11:63971243	STIP1	0.66	11.27	0.52	3.61e-25	Platelet count;
LUSC	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg02780029	chr10:43622663	RET	0.32	6.14	0.32	2.37e-9	Hirschsprung disease;
LUSC	trans	rs12200782	1.000	rs4515370	chr6:26625319	T/C	cg11837749	chr1:55047332	ACOT11	0.57	5.98	0.31	5.64e-9	Small cell lung carcinoma;
LUSC	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg23231163	chr10:75533350	FUT11	0.43	7.12	0.36	6.71e-12	Inflammatory bowel disease;
LUSC	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.28	-0.37	2.44e-12	Bipolar disorder;
LUSC	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg22676075	chr6:135203613	NA	0.47	7.26	0.37	2.7e-12	Red blood cell count;
LUSC	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.51	1.26e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1413885	0.504	rs9436287	chr1:65863302	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.39	-5.78	-0.3	1.71e-8	Anticoagulant levels;
LUSC	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg02018176	chr4:1364513	KIAA1530	0.44	6.05	0.31	3.91e-9	Recombination rate (females);
LUSC	cis	rs9815354	0.680	rs73073239	chr3:42014597	G/C	cg03022575	chr3:42003672	ULK4	0.78	7.52	0.38	4.94e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg07080220	chr10:102295463	HIF1AN	0.59	7.86	0.4	5.23e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs921665	0.831	rs6751452	chr2:3183930	T/G	cg02624386	chr2:3182749	NA	0.58	6.54	0.34	2.35e-10	World class endurance athleticism;
LUSC	cis	rs548181	0.621	rs2912098	chr11:125528569	C/T	cg03464685	chr11:125439445	EI24	1.15	13.9	0.61	5.42e-35	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7589342	0.536	rs10177914	chr2:106386693	G/T	cg09152813	chr2:106391379	NCK2	-0.37	-6.07	-0.32	3.43e-9	Addiction;
LUSC	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-6.15	-0.32	2.25e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg25214090	chr10:38739885	LOC399744	-0.51	-7.52	-0.38	5e-13	Corneal astigmatism;
LUSC	cis	rs4654899	1.000	rs6659152	chr1:21355841	C/G	cg01072550	chr1:21505969	NA	-0.49	-7.61	-0.38	2.85e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2219968	0.828	rs10808823	chr8:78903013	C/T	cg00738934	chr8:78996279	NA	-0.38	-6.76	-0.35	6.09e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs814295	0.866	rs74928908	chr2:27744089	A/G	cg27432699	chr2:27873401	GPN1	0.5	6.02	0.31	4.55e-9	Triglyceride levels;
LUSC	cis	rs2979489	0.533	rs62505280	chr8:30448124	C/T	cg26383811	chr8:30366931	RBPMS	-0.45	-7.35	-0.37	1.57e-12	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	trans	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg26043149	chr18:55253948	FECH	0.48	7.39	0.37	1.22e-12	Bone mineral density;
LUSC	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg04851639	chr8:1020857	NA	-0.4	-8.37	-0.42	1.63e-15	Schizophrenia;
LUSC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00149659	chr3:10157352	C3orf10	1.01	14.57	0.62	1.42e-37	Alzheimer's disease;
LUSC	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.03	0.31	4.27e-9	Morning vs. evening chronotype;
LUSC	cis	rs7615316	0.934	rs9808914	chr3:142241058	T/G	cg16271453	chr3:142027066	XRN1	-0.4	-6.83	-0.35	3.93e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs877282	0.533	rs10904565	chr10:819991	G/T	cg13042288	chr15:90349979	ANPEP	-0.42	-6.34	-0.33	7.48e-10	Uric acid levels;
LUSC	trans	rs8073060	0.586	rs226090	chr17:34034059	C/T	cg19694781	chr19:47549865	TMEM160	-1.14	-18.04	-0.7	2.84e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12681287	0.570	rs4961188	chr8:87383033	T/C	cg27223183	chr8:87520930	FAM82B	0.55	7.37	0.37	1.37e-12	Caudate activity during reward;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15804432	chr15:64454965	PPIB	0.44	6.34	0.33	7.61e-10	Neuroticism;
LUSC	trans	rs3824488	0.920	rs80155616	chr9:98243868	C/T	cg23555120	chr12:106533863	NUAK1	0.57	6.19	0.32	1.81e-9	Neuroticism;
LUSC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg16606324	chr3:10149918	C3orf24	0.59	8.53	0.42	5.1e-16	Alzheimer's disease;
LUSC	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg24011408	chr12:48396354	COL2A1	0.58	7.66	0.39	1.99e-13	Lung cancer;
LUSC	trans	rs12310956	0.532	rs2171534	chr12:33838998	C/T	cg26384229	chr12:38710491	ALG10B	0.53	8.05	0.4	1.46e-14	Morning vs. evening chronotype;
LUSC	cis	rs2708377	0.858	rs55748583	chr12:11139712	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.82	8.01	0.4	1.92e-14	Bitter taste perception;
LUSC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg00132208	chr4:10120780	NA	0.35	5.71	0.3	2.49e-8	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg04374321	chr14:90722782	PSMC1	-0.71	-11.58	-0.54	2.58e-26	Mortality in heart failure;
LUSC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg00012203	chr2:219082015	ARPC2	0.81	14.2	0.61	3.83e-36	Colorectal cancer;
LUSC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-7.89	-0.4	4.4e-14	Prudent dietary pattern;
LUSC	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	8.86e-24	Morning vs. evening chronotype;
LUSC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg03188948	chr7:1209495	NA	0.66	7.06	0.36	9.67e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg17143192	chr8:8559678	CLDN23	0.61	8.71	0.43	1.39e-16	Obesity-related traits;
LUSC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-6.85	-0.35	3.62e-11	Bipolar disorder;
LUSC	cis	rs10746514	0.768	rs11122427	chr1:232261085	C/T	cg09506761	chr1:232265262	NA	-0.56	-9.56	-0.46	2.57e-19	Response to statin therapy;
LUSC	cis	rs6546550	0.868	rs12713682	chr2:70154134	G/A	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.31	-0.37	2.02e-12	Prevalent atrial fibrillation;
LUSC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg00033643	chr7:134001901	SLC35B4	0.47	7.35	0.37	1.53e-12	Mean platelet volume;
LUSC	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg14530993	chr4:882597	GAK	0.73	7.48	0.38	6.78e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.36	-0.42	1.68e-15	Lung cancer;
LUSC	cis	rs894344	0.650	rs56411737	chr8:135582243	C/T	cg17885191	chr8:135476712	NA	0.4	5.65	0.3	3.45e-8	Systolic blood pressure;
LUSC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg04369109	chr6:150039330	LATS1	-0.58	-8.43	-0.42	1.02e-15	Lung cancer;
LUSC	cis	rs4343996	0.967	rs10228723	chr7:3348120	A/G	cg21248987	chr7:3385318	SDK1	0.4	6.66	0.34	1.1e-10	Motion sickness;
LUSC	cis	rs2286503	0.839	rs2270107	chr7:22862183	G/A	cg11367502	chr7:22862612	TOMM7	0.46	6.22	0.32	1.51e-9	Fibrinogen;
LUSC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg03146154	chr1:46216737	IPP	-0.51	-7.73	-0.39	1.3e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg17764715	chr19:33622953	WDR88	0.57	8.36	0.42	1.74e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg07701084	chr6:150067640	NUP43	-0.5	-7.44	-0.38	8.38e-13	Lung cancer;
LUSC	cis	rs75804782	0.641	rs56396448	chr2:239335234	C/T	cg18131467	chr2:239335373	ASB1	-0.74	-6.62	-0.34	1.45e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.32	-0.37	1.9e-12	Putamen volume;
LUSC	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg09835421	chr16:68378352	PRMT7	-0.76	-8.49	-0.42	7.06e-16	Schizophrenia;
LUSC	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg04374321	chr14:90722782	PSMC1	-0.68	-10.35	-0.49	5.96e-22	Mortality in heart failure;
LUSC	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg24337881	chr12:102091387	CHPT1	-0.43	-6.29	-0.33	9.74e-10	Blood protein levels;
LUSC	cis	rs7804356	1.000	rs3823931	chr7:26854026	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.6	11.62	0.54	1.88e-26	Pulse pressure;
LUSC	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg24375607	chr4:120327624	NA	0.78	11.51	0.53	4.8e-26	Corneal astigmatism;
LUSC	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg17252645	chr8:143867129	LY6D	0.38	6.74	0.35	6.83e-11	Urinary tract infection frequency;
LUSC	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg08048268	chr3:133502702	NA	-0.33	-6.25	-0.32	1.23e-9	Iron status biomarkers;
LUSC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg17376030	chr22:41985996	PMM1	0.47	5.91	0.31	8.36e-9	Vitiligo;
LUSC	cis	rs2798269	0.668	rs1199950	chr13:22091153	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.38	-5.97	-0.31	5.96e-9	PR segment;
LUSC	cis	rs13242816	1.000	rs56298491	chr7:116116687	C/T	cg16553024	chr7:116138462	CAV2	-0.52	-5.72	-0.3	2.37e-8	P wave duration;
LUSC	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg09904177	chr6:26538194	HMGN4	-0.47	-6.88	-0.35	2.99e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg02958346	chr11:57425731	CLP1	-0.39	-5.71	-0.3	2.47e-8	Schizophrenia;
LUSC	cis	rs9616064	0.889	rs7284276	chr22:46996137	G/C	cg05621596	chr22:47072043	GRAMD4	-0.44	-6.63	-0.34	1.33e-10	Urate levels in obese individuals;
LUSC	cis	rs36096196	0.891	rs12082516	chr1:2251160	C/T	cg17974515	chr1:2252516	NA	-0.39	-7.45	-0.38	8.15e-13	Coronary artery disease;
LUSC	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-7.58	-0.38	3.46e-13	Fear of minor pain;
LUSC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.47	0.56	1.48e-29	Motion sickness;
LUSC	cis	rs7084921	0.521	rs12782269	chr10:101875210	T/C	cg02250046	chr10:101825185	CPN1	-0.31	-5.89	-0.31	9.4e-9	Bone mineral density;
LUSC	cis	rs9581857	1.000	rs9581857	chr13:28027714	A/C	cg22138327	chr13:27999177	GTF3A	0.8	9.06	0.44	1.08e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg05872129	chr22:39784769	NA	-0.51	-8.26	-0.41	3.37e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs11603020	0.950	rs28362951	chr11:57372526	A/G	cg23127183	chr11:57508653	C11orf31	-0.45	-6.28	-0.32	1.08e-9	Blood protein levels;
LUSC	cis	rs11031096	0.536	rs894459	chr11:4213590	A/G	cg08557956	chr11:4115526	RRM1	-0.42	-5.72	-0.3	2.37e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9403521	1.000	rs12208927	chr6:143993634	A/G	cg18240653	chr6:144019428	PHACTR2	-0.48	-5.84	-0.3	1.25e-8	Obesity-related traits;
LUSC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg25036284	chr2:26402008	FAM59B	-0.68	-9.47	-0.46	5.29e-19	Gut microbiome composition (summer);
LUSC	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg22532475	chr10:104410764	TRIM8	-0.32	-7.11	-0.36	6.97e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg11584989	chr19:19387371	SF4	0.58	7.02	0.36	1.22e-11	Bipolar disorder;
LUSC	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.65	-9.55	-0.46	2.8e-19	Metabolic syndrome;
LUSC	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg27165867	chr14:105738592	BRF1	-0.53	-7.68	-0.39	1.79e-13	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs7170930	0.618	rs67243507	chr15:66547088	C/T	cg06396762	chr16:3202609	NA	-0.72	-5.98	-0.31	5.75e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg08213375	chr14:104286397	PPP1R13B	0.52	10.24	0.49	1.38e-21	Schizophrenia;
LUSC	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg02176678	chr2:219576539	TTLL4	0.61	10.95	0.51	4.76e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg06917634	chr15:78832804	PSMA4	-0.44	-5.98	-0.31	5.8e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	8.97	0.44	2.24e-17	Total body bone mineral density;
LUSC	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg13256891	chr4:100009986	ADH5	0.51	7.03	0.36	1.21e-11	Smoking initiation;
LUSC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	0.99	13.85	0.6	9.05e-35	Eosinophil percentage of granulocytes;
LUSC	trans	rs800082	0.507	rs2575183	chr3:144260523	C/T	cg24215973	chr2:240111563	HDAC4	0.48	7.48	0.38	6.74e-13	Smoking behavior;
LUSC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-8.71	-0.43	1.45e-16	Hemoglobin concentration;
LUSC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg22638593	chr5:131593259	PDLIM4	0.49	7.48	0.38	6.76e-13	Acylcarnitine levels;
LUSC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg03188948	chr7:1209495	NA	0.46	6.07	0.32	3.41e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg05082376	chr22:42548792	NA	-0.43	-6.53	-0.34	2.43e-10	Schizophrenia;
LUSC	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg25828445	chr12:7781288	NA	0.57	5.97	0.31	5.96e-9	HDL cholesterol levels;
LUSC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.66	-12.3	-0.56	6.3e-29	Type 2 diabetes;
LUSC	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg02807482	chr3:125708958	NA	-0.48	-5.66	-0.3	3.18e-8	Blood pressure (smoking interaction);
LUSC	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg12856521	chr11:46389249	DGKZ	0.43	6.44	0.33	4.28e-10	Leprosy;
LUSC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	6.17	0.32	1.93e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs113835537	0.502	rs7104378	chr11:66216675	A/G	cg24851651	chr11:66362959	CCS	0.54	8.35	0.42	1.89e-15	Airway imaging phenotypes;
LUSC	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.02	0.36	1.22e-11	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.68	11.58	0.54	2.71e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg06637938	chr14:75390232	RPS6KL1	0.49	7.72	0.39	1.33e-13	Caffeine consumption;
LUSC	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg14154082	chr13:112174009	NA	0.38	7.88	0.4	4.53e-14	Menarche (age at onset);
LUSC	cis	rs11756438	0.572	rs2798328	chr6:119005378	C/T	cg21191810	chr6:118973309	C6orf204	0.34	5.76	0.3	1.94e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs10193935	1.000	rs10180528	chr2:42436723	T/A	cg27598129	chr2:42591480	NA	-0.62	-8.47	-0.42	7.97e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.54	6.82	0.35	4.15e-11	Renal function-related traits (BUN);
LUSC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	cis	rs7923609	0.936	rs4405189	chr10:65013935	A/G	cg01631684	chr10:65280961	REEP3	-0.43	-6.65	-0.34	1.18e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg22638593	chr5:131593259	PDLIM4	0.41	6.54	0.34	2.35e-10	Blood metabolite levels;
LUSC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.3	-0.33	9.36e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg13010199	chr12:38710504	ALG10B	0.7	10.88	0.51	8.7e-24	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg22166914	chr1:53195759	ZYG11B	0.64	10.35	0.49	6.08e-22	Monocyte count;
LUSC	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	6.6	0.34	1.57e-10	Resting heart rate;
LUSC	cis	rs7605827	0.930	rs7580672	chr2:15586646	A/G	cg19274914	chr2:15703543	NA	0.48	9.21	0.45	3.65e-18	Educational attainment (years of education);
LUSC	trans	rs57046232	0.552	rs1887412	chr20:6340856	A/G	cg21095983	chr6:86352623	SYNCRIP	0.48	7.14	0.36	5.84e-12	Colorectal cancer;
LUSC	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg04362960	chr10:104952993	NT5C2	0.59	9.23	0.45	3.21e-18	Arsenic metabolism;
LUSC	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg18478394	chr8:109455254	TTC35	0.41	6.33	0.33	7.89e-10	Dupuytren's disease;
LUSC	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg15423357	chr2:25149977	NA	0.46	9.19	0.45	4.21e-18	Body mass index;
LUSC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg22705602	chr4:152727874	NA	-0.35	-7.63	-0.39	2.47e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg04155231	chr12:9217510	LOC144571	0.3	5.66	0.3	3.26e-8	Sjögren's syndrome;
LUSC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg22963979	chr7:1858916	MAD1L1	-0.7	-11.66	-0.54	1.43e-26	Bipolar disorder and schizophrenia;
LUSC	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.68	-10.94	-0.51	5.22e-24	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs17336368	1.000	rs17336368	chr6:44751668	G/A	cg20913747	chr6:44695427	NA	-0.5	-8.36	-0.42	1.7e-15	Chin dimples;
LUSC	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.77	0.51	1.98e-23	Fuchs's corneal dystrophy;
LUSC	trans	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg15556689	chr8:8085844	FLJ10661	0.48	6.83	0.35	4.01e-11	Monocyte count;
LUSC	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg06636001	chr8:8085503	FLJ10661	0.53	7.84	0.39	5.94e-14	Neuroticism;
LUSC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg12463550	chr7:65579703	CRCP	0.51	7.38	0.37	1.26e-12	Aortic root size;
LUSC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-9.38	-0.46	1.04e-18	Gut microbiome composition (summer);
LUSC	cis	rs4601821	0.895	rs7130431	chr11:113238223	A/C	cg14159747	chr11:113255604	NA	0.25	5.86	0.31	1.11e-8	Alcoholic chronic pancreatitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18576635	chr6:137540623	IFNGR1	-0.46	-6.92	-0.35	2.25e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg18827107	chr12:86230957	RASSF9	-0.39	-5.74	-0.3	2.1e-8	Major depressive disorder;
LUSC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg25237894	chr2:233734115	C2orf82	0.34	5.82	0.3	1.39e-8	Coronary artery disease;
LUSC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.33	0.49	6.71e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg01475377	chr6:109611718	NA	-0.4	-7.25	-0.37	2.89e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs2425143	0.818	rs2378414	chr20:34534374	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-5.8	-0.3	1.53e-8	Blood protein levels;
LUSC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg17971929	chr21:40555470	PSMG1	0.78	13.52	0.59	1.56e-33	Cognitive function;
LUSC	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg07936489	chr17:37558343	FBXL20	-0.8	-9.89	-0.48	2.18e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.29	-0.37	2.33e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs7589342	0.929	rs2060036	chr2:106436101	G/A	cg16077055	chr2:106428750	NCK2	0.38	7.3	0.37	2.15e-12	Addiction;
LUSC	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg16576597	chr16:28551801	NUPR1	0.28	5.65	0.3	3.52e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs12620999	0.774	rs2875726	chr2:237954576	T/C	cg23555395	chr2:238036564	NA	0.41	6.92	0.35	2.25e-11	Systemic lupus erythematosus;
LUSC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	7.18	0.37	4.69e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg18876405	chr7:65276391	NA	-0.5	-7.85	-0.39	5.78e-14	Calcium levels;
LUSC	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg16070123	chr10:51489643	NA	-0.5	-8.01	-0.4	1.94e-14	Prostate-specific antigen levels;
LUSC	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg15556689	chr8:8085844	FLJ10661	0.57	8.64	0.43	2.35e-16	Neuroticism;
LUSC	trans	rs62238980	0.614	rs117535757	chr22:32373437	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg18357645	chr12:58087776	OS9	-0.53	-7.72	-0.39	1.37e-13	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg03929089	chr4:120376271	NA	0.7	7.63	0.39	2.45e-13	Axial length;
LUSC	cis	rs6840360	0.967	rs6535815	chr4:152609700	A/C	cg22705602	chr4:152727874	NA	-0.31	-6.6	-0.34	1.58e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg13010199	chr12:38710504	ALG10B	0.61	10.1	0.48	4.06e-21	Heart rate;
LUSC	cis	rs35883536	0.588	rs955337	chr1:101108834	A/T	cg06223162	chr1:101003688	GPR88	0.36	6.41	0.33	4.83e-10	Monocyte count;
LUSC	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg01620082	chr3:125678407	NA	-0.83	-7.11	-0.36	7.11e-12	Depression;
LUSC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.93	-0.4	3.36e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg04733989	chr22:42467013	NAGA	0.62	9.7	0.47	8.94e-20	Schizophrenia;
LUSC	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg06636001	chr8:8085503	FLJ10661	0.62	9.35	0.46	1.26e-18	Joint mobility (Beighton score);
LUSC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg12365402	chr11:9010492	NRIP3	-0.49	-9.36	-0.46	1.18e-18	Hemoglobin concentration;
LUSC	trans	rs9898058	0.943	rs17645899	chr17:47829551	C/T	cg07356555	chr10:1284242	ADARB2	0.4	5.96	0.31	6.32e-9	Milk allergy;
LUSC	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg26816564	chr1:7831052	VAMP3	0.93	13.06	0.58	9.01e-32	Inflammatory bowel disease;
LUSC	cis	rs4919694	1.000	rs112240253	chr10:104753726	C/T	cg04362960	chr10:104952993	NT5C2	1.18	13.62	0.6	6.87e-34	Arsenic metabolism;
LUSC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg04455712	chr21:45112962	RRP1B	-0.47	-8.75	-0.43	1.11e-16	Mean corpuscular volume;
LUSC	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.05	-0.36	1.03e-11	Menopause (age at onset);
LUSC	cis	rs10743315	0.557	rs77782809	chr12:19364138	T/C	cg02471346	chr12:19282374	PLEKHA5	0.78	6.28	0.33	1.03e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	9.28	0.45	2.25e-18	Total body bone mineral density;
LUSC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg07395648	chr5:131743802	NA	0.4	5.83	0.3	1.32e-8	Breast cancer;
LUSC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs12681287	0.640	rs7832493	chr8:87371533	A/C	cg27223183	chr8:87520930	FAM82B	0.55	7.38	0.37	1.27e-12	Caudate activity during reward;
LUSC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	9.91	0.48	1.84e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11051970	0.659	rs950082	chr12:32588414	G/T	cg02745156	chr12:32552066	NA	0.37	5.82	0.3	1.37e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14435695	chr11:71950660	PHOX2A	0.41	6.35	0.33	7.18e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.38	0.37	1.3e-12	Motion sickness;
LUSC	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.44	0.33	4.04e-10	Corneal astigmatism;
LUSC	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg00757033	chr12:89920650	WDR51B	0.6	10.33	0.49	7.01e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11764359	chr7:65958608	NA	-0.6	-8.9	-0.44	3.62e-17	Aortic root size;
LUSC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg02423579	chr7:2872169	GNA12	0.48	7.28	0.37	2.42e-12	Height;
LUSC	cis	rs3733418	1.000	rs3733419	chr4:165878170	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.49	-5.71	-0.3	2.44e-8	Obesity-related traits;
LUSC	cis	rs9359856	0.600	rs17584763	chr6:90502088	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.83	-8.28	-0.41	3.05e-15	Bipolar disorder;
LUSC	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.16	0.49	2.55e-21	Lymphocyte counts;
LUSC	cis	rs400736	0.894	rs226253	chr1:8027706	T/C	cg25007680	chr1:8021821	PARK7	0.61	9.54	0.46	3.1e-19	Response to antidepressants and depression;
LUSC	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.67e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg05805236	chr11:65401703	PCNXL3	-0.53	-8.9	-0.44	3.72e-17	Non-alcoholic fatty liver disease histology (lobular);
LUSC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg12463550	chr7:65579703	CRCP	-0.57	-8.62	-0.43	2.65e-16	Aortic root size;
LUSC	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg09835421	chr16:68378352	PRMT7	-0.52	-6.26	-0.32	1.16e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs34421088	0.532	rs2736385	chr8:11148613	T/C	cg21775007	chr8:11205619	TDH	0.51	7.43	0.38	9.28e-13	Neuroticism;
LUSC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg24642439	chr20:33292090	TP53INP2	-0.48	-7.2	-0.37	4.05e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg16797656	chr11:68205561	LRP5	0.39	7.14	0.36	5.87e-12	Total body bone mineral density;
LUSC	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg23093090	chr10:104574429	C10orf26	-0.34	-6.15	-0.32	2.2e-9	Arsenic metabolism;
LUSC	trans	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	10.76	0.51	2.28e-23	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9359856	0.510	rs6937789	chr6:90468775	C/G	cg13799429	chr6:90582589	CASP8AP2	0.92	11.01	0.52	3.02e-24	Bipolar disorder;
LUSC	cis	rs4700695	0.719	rs27046	chr5:65439964	G/C	cg21114390	chr5:65439923	SFRS12	-0.62	-8.74	-0.43	1.19e-16	Facial morphology (factor 19);
LUSC	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg13010199	chr12:38710504	ALG10B	0.48	7.39	0.38	1.16e-12	Morning vs. evening chronotype;
LUSC	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.66	9.92	0.48	1.65e-20	Total cholesterol levels;
LUSC	trans	rs2729385	1.000	rs2729385	chr11:57262993	C/T	cg08276543	chr12:124856791	NCOR2	-0.45	-6.04	-0.31	4.15e-9	Interleukin-18 levels;
LUSC	trans	rs1973993	0.689	rs17115225	chr1:96884330	C/T	cg10631902	chr5:14652156	NA	-0.54	-8.07	-0.4	1.29e-14	Weight;
LUSC	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg00898013	chr13:113819073	PROZ	-0.57	-8.12	-0.41	9.33e-15	Platelet distribution width;
LUSC	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21659725	chr3:3221576	CRBN	0.64	10.6	0.5	7.9e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23158103	chr7:148848205	ZNF398	-0.45	-7.32	-0.37	1.89e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg04310649	chr10:35416472	CREM	-0.42	-6.45	-0.33	3.9e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4947962	0.585	rs17172432	chr7:55141317	C/T	cg23757825	chr7:55092271	EGFR	0.46	6.34	0.33	7.3e-10	Subjective response to lithium treatment;
LUSC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.53	-8.35	-0.42	1.8e-15	Platelet count;
LUSC	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-14.16	-0.61	5.71e-36	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4704187	0.687	rs4621537	chr5:74362222	A/G	cg03227963	chr5:74354835	NA	0.33	7.02	0.36	1.28e-11	Response to amphetamines;
LUSC	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg17294928	chr15:75287854	SCAMP5	-0.76	-6.61	-0.34	1.49e-10	Lung cancer;
LUSC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg12564285	chr5:131593104	PDLIM4	-0.56	-10.62	-0.5	7.09e-23	Acylcarnitine levels;
LUSC	cis	rs7577851	0.585	rs67347664	chr2:69664921	A/T	cg10773587	chr2:69614142	GFPT1	0.53	5.86	0.31	1.11e-8	Parkinson's disease (age of onset);
LUSC	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg01557791	chr16:72042693	DHODH	-0.47	-6.92	-0.35	2.28e-11	Fibrinogen levels;
LUSC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg06238570	chr21:40685208	BRWD1	0.49	7.46	0.38	7.78e-13	Cognitive function;
LUSC	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg00310523	chr12:86230176	RASSF9	0.47	8.47	0.42	7.74e-16	Major depressive disorder;
LUSC	cis	rs6076065	0.723	rs743024	chr20:23342476	C/T	cg11657817	chr20:23433608	CST11	-0.43	-8.2	-0.41	5.21e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg18402987	chr7:1209562	NA	0.73	7.85	0.39	5.7e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	1.11	9.74	0.47	6.79e-20	Skin colour saturation;
LUSC	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-24.39	-0.8	3.65e-76	Ulcerative colitis;
LUSC	cis	rs17001868	0.568	rs9611325	chr22:40782490	G/A	cg07138101	chr22:40742427	ADSL	0.62	7.59	0.38	3.22e-13	Mammographic density (dense area);
LUSC	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg19508488	chr2:152266495	RIF1	0.53	7.6	0.38	3.08e-13	Lung cancer;
LUSC	cis	rs62400317	0.859	rs10948211	chr6:45156767	G/A	cg20913747	chr6:44695427	NA	-0.48	-7.69	-0.39	1.63e-13	Total body bone mineral density;
LUSC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.3	-0.53	2.78e-25	Mean corpuscular volume;
LUSC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg26513180	chr16:89883248	FANCA	0.79	6.38	0.33	5.88e-10	Skin colour saturation;
LUSC	trans	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg06521331	chr12:34319734	NA	0.4	6.42	0.33	4.7e-10	Morning vs. evening chronotype;
LUSC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg03161606	chr19:29218774	NA	0.63	9.79	0.47	4.79e-20	Methadone dose in opioid dependence;
LUSC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg14552801	chr7:65878734	NA	-0.48	-6.67	-0.34	1.06e-10	Aortic root size;
LUSC	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.76	12.16	0.55	2.07e-28	Selective IgA deficiency;
LUSC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg08736216	chr1:53307985	ZYG11A	0.28	5.74	0.3	2.12e-8	Monocyte count;
LUSC	cis	rs11168618	1.000	rs11168621	chr12:48938971	G/A	cg24011408	chr12:48396354	COL2A1	0.4	6.37	0.33	6.34e-10	Adiponectin levels;
LUSC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg04733989	chr22:42467013	NAGA	0.41	6.68	0.34	1.02e-10	Cognitive function;
LUSC	cis	rs372883	0.935	rs1153295	chr21:30704080	T/G	cg08807101	chr21:30365312	RNF160	-0.41	-5.89	-0.31	9.54e-9	Pancreatic cancer;
LUSC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg10523679	chr1:76189770	ACADM	0.86	11.39	0.53	1.29e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg21573476	chr21:45109991	RRP1B	0.39	6.36	0.33	6.74e-10	Mean corpuscular volume;
LUSC	cis	rs4663866	0.803	rs71426511	chr2:239180200	G/A	cg16914508	chr2:239161102	PER2	0.68	7.25	0.37	3.01e-12	Irritable bowel syndrome;
LUSC	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg01528321	chr10:82214614	TSPAN14	0.83	12.44	0.56	1.93e-29	Post bronchodilator FEV1;
LUSC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.51	0.78	6.17e-69	Prudent dietary pattern;
LUSC	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg16339924	chr4:17578868	LAP3	0.55	8.51	0.42	6.11e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg24558204	chr6:135376177	HBS1L	0.68	10.65	0.5	5.52e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.69	0.83	1.71e-88	Chronic sinus infection;
LUSC	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg25182066	chr10:30743637	MAP3K8	0.43	6.07	0.32	3.41e-9	Inflammatory bowel disease;
LUSC	cis	rs116988415	0.584	rs2269305	chr14:65245650	C/G	cg00114569	chr14:65239327	SPTB	0.61	6.62	0.34	1.4e-10	Daytime sleep phenotypes;
LUSC	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg19920283	chr7:105172520	RINT1	0.59	6.32	0.33	8.44e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4400599	0.618	rs4393149	chr1:154195753	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-6.02	-0.31	4.47e-9	Platelet distribution width;
LUSC	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-6.56	-0.34	2.05e-10	Morning vs. evening chronotype;
LUSC	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.17	-0.45	4.9e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.53	-0.34	2.44e-10	Platelet count;
LUSC	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.62	-8.9	-0.44	3.6e-17	Hip circumference;
LUSC	trans	rs34421088	0.506	rs2572426	chr8:11147123	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	7.43	0.38	9.47e-13	Neuroticism;
LUSC	cis	rs1451375	0.652	rs7803903	chr7:50625945	C/T	cg18232548	chr7:50535776	DDC	0.48	6.53	0.34	2.49e-10	Malaria;
LUSC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-10.82	-0.51	1.33e-23	Schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08871383	chr2:46524363	EPAS1	-0.42	-6.15	-0.32	2.23e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10819733	chr22:24237672	NA	-0.4	-6.02	-0.31	4.59e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg10057126	chr4:77819792	ANKRD56	0.51	7.63	0.39	2.51e-13	Emphysema distribution in smoking;
LUSC	cis	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg20368463	chr18:77673604	PQLC1	-0.71	-10.99	-0.52	3.54e-24	Schizophrenia;
LUSC	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	0.83	15.28	0.64	2.51e-40	Longevity;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03001875	chr1:234614834	TARBP1	0.76	5.99	0.31	5.36e-9	Cognitive performance;
LUSC	cis	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg04362960	chr10:104952993	NT5C2	-0.47	-6.11	-0.32	2.76e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2853333	0.935	rs1894232	chr19:35754511	C/G	cg12287945	chr19:35758300	LSR	-0.39	-6.06	-0.31	3.73e-9	Red blood cell count;
LUSC	cis	rs7432375	0.610	rs6793936	chr3:136509793	A/C	cg21827317	chr3:136751795	NA	0.32	5.65	0.3	3.35e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs59698941	0.943	rs67656232	chr5:132254426	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.55	5.8	0.3	1.5e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-9.18	-0.45	4.78e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.14	0.45	6.25e-18	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6120849	0.754	rs17319032	chr20:33643296	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.58	0.34	1.8e-10	Protein C levels;
LUSC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg13114125	chr14:105738426	BRF1	-0.95	-15.95	-0.66	5.69e-43	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs724744	0.741	rs1737226	chr6:22352868	C/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.2	-0.32	1.71e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16863872	chr21:45526972	PWP2	-0.43	-6.19	-0.32	1.72e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg21435336	chr19:17392852	ANKLE1	-0.47	-6.22	-0.32	1.52e-9	Systemic lupus erythematosus;
LUSC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg09365446	chr1:150670422	GOLPH3L	0.49	7.17	0.37	4.77e-12	Melanoma;
LUSC	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg04374321	chr14:90722782	PSMC1	-0.68	-10.35	-0.49	5.96e-22	Mortality in heart failure;
LUSC	cis	rs4073416	0.508	rs11844682	chr14:65910844	G/C	cg03016385	chr14:66212404	NA	-0.38	-5.66	-0.3	3.35e-8	N-glycan levels;
LUSC	cis	rs7572733	0.534	rs10211202	chr2:198771941	A/G	cg00792783	chr2:198669748	PLCL1	0.45	6.03	0.31	4.26e-9	Dermatomyositis;
LUSC	cis	rs988712	0.705	rs4244531	chr11:27657250	A/G	cg10635145	chr11:27742435	BDNF	-0.47	-6.16	-0.32	2.09e-9	Obesity;
LUSC	trans	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.1	0.48	4.12e-21	Mean corpuscular volume;
LUSC	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.91	-15.7	-0.65	5.6e-42	Schizophrenia;
LUSC	trans	rs9944715	0.954	rs6507680	chr18:43766986	A/C	cg01718231	chr17:29326311	RNF135	-0.49	-7.06	-0.36	9.55e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg06718696	chr17:78121285	EIF4A3	0.78	11.61	0.54	2.07e-26	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07677032	chr17:61819896	STRADA	0.55	9.2	0.45	4.08e-18	Prudent dietary pattern;
LUSC	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg18721089	chr20:30220636	NA	-0.32	-5.7	-0.3	2.66e-8	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg19230755	chr7:65878503	NA	-0.41	-5.82	-0.3	1.36e-8	Aortic root size;
LUSC	cis	rs6960043	0.782	rs4721401	chr7:15064896	T/G	cg19272540	chr7:15055459	NA	-0.32	-7.88	-0.4	4.75e-14	Type 2 diabetes;
LUSC	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.42	6.72	0.35	7.9e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg23796481	chr11:64053134	BAD;GPR137	-0.4	-6.64	-0.34	1.25e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs12541635	0.771	rs12155864	chr8:107105491	C/T	cg10147462	chr8:107024639	NA	-0.45	-7.99	-0.4	2.18e-14	Age of smoking initiation;
LUSC	trans	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.9	0.35	2.57e-11	Endometrial cancer;
LUSC	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg17252645	chr8:143867129	LY6D	-0.56	-10.6	-0.5	7.81e-23	Urinary tract infection frequency;
LUSC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.08	0.55	4.01e-28	Prudent dietary pattern;
LUSC	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.99	0.36	1.5e-11	Bladder cancer;
LUSC	cis	rs9311676	0.656	rs6445977	chr3:58379560	T/C	cg26110898	chr3:58419937	PDHB	0.42	6.83	0.35	4.07e-11	Systemic lupus erythematosus;
LUSC	cis	rs9287719	0.625	rs12473787	chr2:10717194	G/C	cg00105475	chr2:10696890	NA	0.34	5.7	0.3	2.67e-8	Prostate cancer;
LUSC	cis	rs4730250	0.634	rs11767623	chr7:106792332	C/T	cg02696742	chr7:106810147	HBP1	0.64	9.04	0.44	1.32e-17	Osteoarthritis;
LUSC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.7	-10.85	-0.51	1.07e-23	Aortic root size;
LUSC	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.92	0.51	5.92e-24	Bladder cancer;
LUSC	cis	rs6961069	0.585	rs13225492	chr7:80240837	A/G	cg04458919	chr7:80252533	CD36	-0.39	-6.91	-0.35	2.41e-11	Platelet count;
LUSC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.91	-0.35	2.41e-11	Morning vs. evening chronotype;
LUSC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg01770232	chr7:22766155	IL6	0.4	5.76	0.3	1.89e-8	Lung cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06755612	chr14:45603778	FKBP3;FANCM	-0.48	-6.35	-0.33	7.23e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.73	0.54	7.69e-27	Alzheimer's disease;
LUSC	trans	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-9.01	-0.44	1.64e-17	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.15	0.52	9.13e-25	Hypertriglyceridemia;
LUSC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg18758796	chr5:131593413	PDLIM4	0.35	6.27	0.32	1.11e-9	Blood metabolite levels;
LUSC	cis	rs1160297	0.576	rs13003962	chr2:53110176	C/T	cg07782112	chr2:53107842	NA	0.43	7.12	0.36	6.85e-12	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs4356932	1.000	rs6848603	chr4:76973521	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.82	0.3	1.39e-8	Blood protein levels;
LUSC	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg15133208	chr4:90757351	SNCA	-0.32	-5.66	-0.3	3.18e-8	Dementia with Lewy bodies;
LUSC	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg03733263	chr8:22462867	KIAA1967	-0.78	-12.84	-0.58	5.77e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.67	6.42	0.33	4.63e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9473147	0.543	rs4715019	chr6:47447041	T/A	cg02130027	chr6:47444894	CD2AP	0.35	5.67	0.3	3.01e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	0.92	19.45	0.73	6.89e-57	Dental caries;
LUSC	cis	rs710865	0.966	rs709683	chr1:19565344	C/G	cg13387374	chr1:19411106	UBR4	0.44	6.33	0.33	8.06e-10	Brain structure;
LUSC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11001216	chr19:58859029	A1BG	0.44	5.77	0.3	1.86e-8	Mean platelet volume;
LUSC	cis	rs7771547	0.519	rs7773253	chr6:36373451	T/A	cg07856975	chr6:36356162	ETV7	0.44	6.43	0.33	4.32e-10	Platelet distribution width;
LUSC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18301423	chr5:131593218	PDLIM4	0.46	7.01	0.36	1.34e-11	Acylcarnitine levels;
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg24846343	chr22:24311635	DDTL	0.68	14.47	0.62	3.43e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg08999081	chr20:33150536	PIGU	0.44	8.19	0.41	5.6e-15	Coronary artery disease;
LUSC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg16434002	chr17:42200994	HDAC5	-0.46	-6.57	-0.34	1.98e-10	Total body bone mineral density;
LUSC	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	8.74	0.43	1.15e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.6	-13.48	-0.59	2.3e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.72	0.43	1.38e-16	Lung cancer;
LUSC	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg13010199	chr12:38710504	ALG10B	0.51	8.16	0.41	6.87e-15	Morning vs. evening chronotype;
LUSC	cis	rs4664308	0.935	rs4637057	chr2:160950161	G/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.62	-0.54	1.97e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg05347473	chr6:146136440	FBXO30	0.52	9.05	0.44	1.23e-17	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs62103177	0.584	rs9956207	chr18:77968392	A/G	cg05926928	chr17:57297772	GDPD1	-0.69	-7.15	-0.36	5.36e-12	Opioid sensitivity;
LUSC	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg12062639	chr20:23401060	NAPB	0.77	5.99	0.31	5.55e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.75	-10.33	-0.49	6.69e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg16060761	chr17:80687452	NA	-0.5	-7.89	-0.4	4.42e-14	Glycated hemoglobin levels;
LUSC	cis	rs7119167	0.901	rs880317	chr11:73108276	A/G	cg17517138	chr11:73019481	ARHGEF17	0.56	6.35	0.33	7.22e-10	Blood protein levels;
LUSC	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06022373	chr22:39101656	GTPBP1	0.79	12.83	0.57	6.52e-31	Menopause (age at onset);
LUSC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg24130564	chr14:104152367	KLC1	-0.43	-6.12	-0.32	2.66e-9	Body mass index;
LUSC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg08219700	chr8:58056026	NA	0.49	6.27	0.32	1.14e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg11901034	chr3:128598214	ACAD9	-0.41	-6.47	-0.33	3.54e-10	IgG glycosylation;
LUSC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg22618164	chr12:122356400	WDR66	0.55	7.8	0.39	8.09e-14	Mean corpuscular volume;
LUSC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.11	0.32	2.78e-9	Mean platelet volume;
LUSC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg16586182	chr3:47516702	SCAP	-0.5	-7.73	-0.39	1.31e-13	Colorectal cancer;
LUSC	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.95	17.5	0.69	4.06e-49	Bone mineral density;
LUSC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg06454157	chr6:167490870	NA	-0.29	-6.78	-0.35	5.52e-11	Crohn's disease;
LUSC	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-10.81	-0.51	1.53e-23	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs1568889	0.877	rs17310076	chr11:28147590	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.57	6.78	0.35	5.43e-11	Bipolar disorder;
LUSC	cis	rs394563	0.534	rs388335	chr6:149791986	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.41	-7.85	-0.39	5.82e-14	Dupuytren's disease;
LUSC	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.97	-0.36	1.75e-11	Menopause (age at onset);
LUSC	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.43	-6.11	-0.32	2.72e-9	Lung cancer;
LUSC	cis	rs2455826	0.874	rs2455853	chr3:15690025	C/T	cg09340198	chr3:15902540	ANKRD28	-0.37	-5.79	-0.3	1.66e-8	Inflammatory skin disease;
LUSC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg24154853	chr7:158122151	PTPRN2	0.45	8.88	0.44	4.06e-17	Calcium levels;
LUSC	cis	rs6845621	0.901	rs11725033	chr4:18929234	G/A	cg12196642	chr4:18937545	NA	-0.37	-6.81	-0.35	4.59e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg24069376	chr3:38537580	EXOG	-0.4	-7.8	-0.39	7.78e-14	Electrocardiographic conduction measures;
LUSC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg00343986	chr7:65444356	GUSB	0.44	6.72	0.35	7.92e-11	Aortic root size;
LUSC	cis	rs981844	1.000	rs2579916	chr4:154659972	G/T	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg06060754	chr5:176797920	RGS14	0.6	9.61	0.47	1.78e-19	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg13607699	chr17:42295918	UBTF	0.47	7.56	0.38	3.83e-13	Total body bone mineral density;
LUSC	cis	rs8032315	0.965	rs7497304	chr15:91429176	G/T	cg05469396	chr15:91419421	FURIN	-0.42	-6.67	-0.34	1.05e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg22681709	chr2:178499509	PDE11A	-0.34	-6.36	-0.33	6.47e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.14	0.41	8.18e-15	Prudent dietary pattern;
LUSC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg04166393	chr7:2884313	GNA12	0.45	5.93	0.31	7.55e-9	Height;
LUSC	cis	rs57590327	0.503	rs6802480	chr3:81906671	G/A	cg07356753	chr3:81810745	GBE1	-0.66	-10.49	-0.5	2e-22	Extraversion;
LUSC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.46	-6.72	-0.35	7.85e-11	Menarche (age at onset);
LUSC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.86	14.15	0.61	6.09e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg10756647	chr7:56101905	PSPH	0.89	8.61	0.43	2.86e-16	Diabetic kidney disease;
LUSC	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg23093090	chr10:104574429	C10orf26	-0.36	-6.75	-0.35	6.36e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg09904177	chr6:26538194	HMGN4	0.75	14.0	0.61	2.38e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.13	0.36	6.29e-12	Morning vs. evening chronotype;
LUSC	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg16230307	chr14:35515116	FAM177A1	0.8	10.11	0.48	3.96e-21	Psoriasis;
LUSC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.78	-10.7	-0.51	3.54e-23	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.48	0.42	7.53e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3087591	0.960	rs2071009	chr17:29558082	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.58	-8.42	-0.42	1.1e-15	Hip circumference;
LUSC	cis	rs11229555	0.574	rs12272096	chr11:58186118	A/G	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6545883	1.000	rs778763	chr2:61785639	C/G	cg15711740	chr2:61764176	XPO1	-0.5	-7.99	-0.4	2.23e-14	Tuberculosis;
LUSC	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.88	0.35	2.9e-11	IgG glycosylation;
LUSC	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.67	-0.39	1.87e-13	Morning vs. evening chronotype;
LUSC	cis	rs9715521	0.677	rs6822690	chr4:59853530	A/G	cg11281224	chr4:60001000	NA	-0.51	-7.06	-0.36	9.42e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.22	0.52	5.24e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.09	0.32	3.07e-9	Height;
LUSC	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg05861140	chr6:150128134	PCMT1	-0.45	-7.17	-0.37	4.83e-12	Lung cancer;
LUSC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25072359	chr17:41440525	NA	0.69	9.81	0.47	4.02e-20	Menopause (age at onset);
LUSC	cis	rs17125944	0.615	rs1998779	chr14:53295950	T/A	cg00686598	chr14:53173677	PSMC6	-0.67	-6.4	-0.33	5.36e-10	Alzheimer's disease (late onset);
LUSC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg26695010	chr11:65641043	EFEMP2	-0.48	-6.84	-0.35	3.78e-11	Eosinophil percentage of white cells;
LUSC	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg25482853	chr8:67687455	SGK3	1.2	17.23	0.69	4.62e-48	Lung disease severity in cystic fibrosis;
LUSC	cis	rs17253792	0.822	rs77741349	chr14:56097462	C/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.9	0.4	3.97e-14	Prudent dietary pattern;
LUSC	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg05343316	chr1:45956843	TESK2	0.61	8.49	0.42	6.97e-16	Platelet count;
LUSC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg22535103	chr8:58192502	C8orf71	-0.56	-6.65	-0.34	1.18e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg22823121	chr1:150693482	HORMAD1	0.51	7.47	0.38	7.01e-13	Melanoma;
LUSC	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.38	5.73	0.3	2.21e-8	Educational attainment;
LUSC	cis	rs7119	0.700	rs57471224	chr15:77888169	A/G	cg27398640	chr15:77910606	LINGO1	0.37	8.59	0.43	3.27e-16	Type 2 diabetes;
LUSC	trans	rs3942852	0.955	rs7117386	chr11:48125371	G/A	cg03929089	chr4:120376271	NA	-0.55	-6.33	-0.33	8.09e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9503598	0.636	rs6596974	chr6:3465833	C/T	cg00476032	chr6:3446245	SLC22A23	0.31	6.02	0.31	4.71e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs9308433	1.000	rs9308433	chr1:214457009	T/C	cg06198575	chr1:214491504	SMYD2	0.44	6.85	0.35	3.47e-11	IgG glycosylation;
LUSC	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.62	-7.71	-0.39	1.46e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.88	-14.59	-0.62	1.23e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg23029597	chr12:123009494	RSRC2	-0.74	-9.42	-0.46	7.52e-19	Body mass index;
LUSC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	10.24	0.49	1.35e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg08470875	chr2:26401718	FAM59B	-0.66	-8.78	-0.43	8.93e-17	Gut microbiome composition (summer);
LUSC	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	0.81	14.85	0.63	1.19e-38	Ulcerative colitis;
LUSC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02034447	chr16:89574710	SPG7	0.44	6.46	0.33	3.73e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.49	0.53	5.51e-26	Prudent dietary pattern;
LUSC	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17916960	chr15:79447300	NA	-0.53	-10.59	-0.5	8.48e-23	Refractive error;
LUSC	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.44	0.46	6.68e-19	Bipolar disorder;
LUSC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg17845761	chr1:175162550	KIAA0040	0.31	5.98	0.31	5.7e-9	Alcohol dependence;
LUSC	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.58	8.25	0.41	3.71e-15	Night sleep phenotypes;
LUSC	trans	rs2018683	0.707	rs1874974	chr7:28967647	G/C	cg19402173	chr7:128379420	CALU	-0.45	-6.78	-0.35	5.46e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs9807989	0.839	rs11695627	chr2:102970105	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.88	0.31	9.76e-9	Asthma;
LUSC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg07701084	chr6:150067640	NUP43	0.57	8.82	0.43	6.43e-17	Lung cancer;
LUSC	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg22705602	chr4:152727874	NA	-0.37	-7.89	-0.4	4.32e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7572644	0.760	rs9309659	chr2:28326258	C/G	cg27432699	chr2:27873401	GPN1	0.48	6.72	0.35	7.92e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg02269571	chr22:50332266	NA	-0.57	-8.69	-0.43	1.68e-16	Schizophrenia;
LUSC	cis	rs554111	0.634	rs1453265	chr1:21277711	C/T	cg01072550	chr1:21505969	NA	0.41	6.23	0.32	1.39e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.26	-0.32	1.17e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg02018176	chr4:1364513	KIAA1530	0.43	6.0	0.31	5.18e-9	Recombination rate (females);
LUSC	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg11244672	chr19:19639970	YJEFN3	-0.61	-7.24	-0.37	3.03e-12	Bipolar disorder;
LUSC	cis	rs16854884	0.657	rs2099543	chr3:143742164	C/T	cg06585982	chr3:143692056	C3orf58	0.5	7.93	0.4	3.36e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg11859384	chr17:80120422	CCDC57	0.36	5.69	0.3	2.71e-8	Life satisfaction;
LUSC	cis	rs6494488	0.500	rs72744725	chr15:65023953	T/C	cg08069370	chr15:64387884	SNX1	-0.58	-5.66	-0.3	3.23e-8	Coronary artery disease;
LUSC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg03146154	chr1:46216737	IPP	0.55	8.27	0.41	3.11e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs73206853	0.563	rs17682444	chr12:111154626	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	6.74	0.35	7.01e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.26	-0.37	2.65e-12	Bipolar disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15238519	chr22:50683529	TUBGCP6	-0.55	-6.82	-0.35	4.24e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.55	-5.7	-0.3	2.61e-8	Menarche (age at onset);
LUSC	cis	rs77633900	0.772	rs4886492	chr15:76672817	T/A	cg21673338	chr15:77095150	SCAPER	0.68	6.12	0.32	2.67e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs10276303	0.502	rs11768500	chr7:3396320	A/G	cg21248987	chr7:3385318	SDK1	-0.4	-6.67	-0.34	1.05e-10	Dupuytren's disease;
LUSC	cis	rs6674970	1.000	rs7546304	chr1:151114484	C/G	cg11822372	chr1:151115635	SEMA6C	0.55	8.45	0.42	9.26e-16	Childhood ear infection;
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	6.87	0.35	3.24e-11	Renal function-related traits (BUN);
LUSC	cis	rs9323205	0.723	rs12147193	chr14:51748063	A/G	cg23942311	chr14:51606299	NA	-0.43	-8.03	-0.4	1.72e-14	Cancer;
LUSC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.52	0.38	5.09e-13	Prudent dietary pattern;
LUSC	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg13575925	chr12:9217583	LOC144571	0.34	6.28	0.32	1.07e-9	Sjögren's syndrome;
LUSC	cis	rs17286411	0.806	rs952159	chr16:71965915	G/A	cg03805757	chr16:71968109	PKD1L3	0.39	5.68	0.3	2.91e-8	Blood protein levels;
LUSC	cis	rs68092024	0.731	rs792840	chr3:99471251	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	7.13	0.36	6.11e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg13319975	chr6:146136371	FBXO30	-0.42	-6.2	-0.32	1.63e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg27094323	chr7:1216898	NA	-0.43	-7.19	-0.37	4.2e-12	Longevity;Endometriosis;
LUSC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg03146154	chr1:46216737	IPP	0.54	7.8	0.39	7.79e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg01973587	chr1:228161476	NA	0.46	8.45	0.42	9.2e-16	Diastolic blood pressure;
LUSC	cis	rs4690686	0.500	rs7657249	chr4:177275198	A/G	cg17059388	chr4:177262070	NA	0.48	8.81	0.43	6.95e-17	Essential tremor;
LUSC	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg02158880	chr13:53174818	NA	0.58	10.42	0.5	3.39e-22	Lewy body disease;
LUSC	cis	rs4604732	0.603	rs4546958	chr1:247639478	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.36	5.82	0.3	1.38e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg21775007	chr8:11205619	TDH	0.69	10.79	0.51	1.78e-23	Retinal vascular caliber;
LUSC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.62	0.43	2.78e-16	Prudent dietary pattern;
LUSC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg07395648	chr5:131743802	NA	-0.4	-5.88	-0.31	1e-8	Breast cancer;
LUSC	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.54	-7.87	-0.4	4.88e-14	Reticulocyte count;
LUSC	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.62	11.39	0.53	1.32e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs17621444	0.505	rs10886578	chr10:121797264	G/A	cg02041677	chr10:121771263	NA	-0.36	-6.59	-0.34	1.69e-10	IgG glycosylation;
LUSC	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.36	6.32	0.33	8.45e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg08000102	chr2:233561755	GIGYF2	0.75	11.7	0.54	9.96e-27	Coronary artery disease;
LUSC	cis	rs10995240	1	rs10995240	chr10:64388631	G/C	cg03961010	chr10:64397487	ZNF365	-0.43	-6.69	-0.34	9.6e-11	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg08219700	chr8:58056026	NA	0.5	6.57	0.34	1.98e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9976767	0.608	rs3746923	chr21:43826344	C/T	cg23042151	chr21:43824109	UBASH3A	-0.33	-6.48	-0.33	3.21e-10	Type 1 diabetes;
LUSC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.34	6.13	0.32	2.49e-9	Obesity-related traits;
LUSC	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg03806693	chr22:41940476	POLR3H	-0.83	-11.85	-0.54	2.87e-27	Vitiligo;
LUSC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg26335602	chr6:28129616	ZNF389	0.43	5.77	0.3	1.79e-8	Depression;
LUSC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg13560548	chr3:10150139	C3orf24	0.54	7.12	0.36	6.45e-12	Alzheimer's disease;
LUSC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.08	-0.36	8.61e-12	Total body bone mineral density;
LUSC	cis	rs12137294	0.794	rs1172160	chr1:205207015	G/A	cg00857998	chr1:205179979	DSTYK	0.4	5.77	0.3	1.77e-8	Red cell distribution width;
LUSC	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.41	-0.42	1.23e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs17401966	0.518	rs10864453	chr1:10407169	T/G	cg19773385	chr1:10388646	KIF1B	-0.36	-6.24	-0.32	1.31e-9	Hepatocellular carcinoma;
LUSC	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07080220	chr10:102295463	HIF1AN	0.65	8.72	0.43	1.34e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6696846	0.630	rs11240373	chr1:205135600	A/C	cg21545522	chr1:205238299	TMCC2	0.49	8.86	0.44	4.69e-17	Red blood cell count;
LUSC	cis	rs7580658	0.857	rs17015199	chr2:128094053	A/G	cg09760422	chr2:128146352	NA	-0.3	-6.4	-0.33	5.19e-10	Protein C levels;
LUSC	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg15556689	chr8:8085844	FLJ10661	0.56	8.36	0.42	1.76e-15	Neuroticism;
LUSC	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg00042356	chr1:8021962	PARK7	0.6	7.0	0.36	1.41e-11	Inflammatory bowel disease;
LUSC	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.56	-8.45	-0.42	8.99e-16	Heart rate;
LUSC	cis	rs2273669	0.667	rs9688496	chr6:109364825	G/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.17	0.32	2.03e-9	Height;
LUSC	cis	rs7804356	1.000	rs73067437	chr7:26850313	T/C	cg03456212	chr7:26904342	SKAP2	-0.54	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09763514	chr7:2298050	SNX8	-0.41	-5.95	-0.31	6.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs56804039	1.000	rs6986470	chr8:8381430	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.01	-0.36	1.29e-11	Cervical cancer;
LUSC	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg22676075	chr6:135203613	NA	0.58	9.32	0.45	1.61e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg01858014	chr14:56050164	KTN1	-0.89	-7.32	-0.37	1.9e-12	Putamen volume;
LUSC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg11645453	chr3:52864694	ITIH4	0.36	8.63	0.43	2.5e-16	Bipolar disorder;
LUSC	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.46	-0.5	2.51e-22	Eye color traits;
LUSC	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg12165864	chr7:66369176	NA	-0.53	-7.2	-0.37	4.13e-12	Corneal structure;
LUSC	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg22676075	chr6:135203613	NA	0.48	7.47	0.38	6.97e-13	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs965513	1.000	rs965513	chr9:100556109	A/G	cg13688889	chr9:100608707	NA	-0.54	-8.16	-0.41	6.68e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg01802117	chr1:53393560	SCP2	0.36	5.84	0.3	1.23e-8	Monocyte count;
LUSC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-10.63	-0.5	6.41e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg02487331	chr1:146550467	NA	-0.43	-7.51	-0.38	5.28e-13	HIV-1 control;
LUSC	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg20991723	chr1:152506922	NA	0.53	9.87	0.48	2.41e-20	Hair morphology;
LUSC	cis	rs6700896	0.931	rs11208717	chr1:66158994	T/C	cg04111102	chr1:66153794	NA	0.34	7.42	0.38	1e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg26380479	chr7:97908229	NA	-0.28	-6.26	-0.32	1.16e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	0.9	12.97	0.58	1.87e-31	Uric acid levels;
LUSC	cis	rs240768	1.000	rs33988845	chr6:100964158	G/A	cg12253828	chr6:101329408	ASCC3	0.93	6.4	0.33	5.13e-10	Economic and political preferences (immigration/crime);
LUSC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg03676636	chr4:99064102	C4orf37	0.33	7.11	0.36	6.98e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg22431228	chr1:16359049	CLCNKA	0.34	6.41	0.33	5.1e-10	Dilated cardiomyopathy;
LUSC	cis	rs7809950	0.906	rs2395907	chr7:107253304	A/G	cg23024343	chr7:107201750	COG5	0.56	8.55	0.42	4.45e-16	Coronary artery disease;
LUSC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg05802129	chr4:122689817	NA	-0.37	-6.69	-0.34	9.46e-11	Type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03315476	chr1:40915606	ZNF643	0.44	6.23	0.32	1.4e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.9	16.03	0.66	2.76e-43	Metabolic syndrome;
LUSC	cis	rs1113500	0.548	rs17020971	chr1:108655288	C/A	cg06207961	chr1:108661230	NA	0.34	5.82	0.3	1.4e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg23711669	chr6:146136114	FBXO30	-0.73	-12.87	-0.58	4.55e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.74	-0.35	7e-11	Personality dimensions;
LUSC	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg00191853	chr8:101177733	SPAG1	0.41	6.64	0.34	1.3100000000000001e-10	Atrioventricular conduction;
LUSC	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-1.13	-17.64	-0.69	1.06e-49	Exhaled nitric oxide output;
LUSC	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02176678	chr2:219576539	TTLL4	-0.74	-14.04	-0.61	1.64e-35	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2625529	0.586	rs11639282	chr15:72435260	G/A	cg16672083	chr15:72433130	SENP8	0.5	8.27	0.41	3.29e-15	Red blood cell count;
LUSC	cis	rs4722585	0.533	rs2049843	chr7:26196963	G/A	cg07876897	chr7:26191696	NFE2L3	0.46	6.85	0.35	3.65e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUSC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg07212818	chr11:638076	DRD4	-0.42	-7.15	-0.36	5.65e-12	Systemic lupus erythematosus;
LUSC	cis	rs738321	0.725	rs5756926	chr22:38542613	T/C	cg25457927	chr22:38595422	NA	-0.42	-8.01	-0.4	1.93e-14	Breast cancer;
LUSC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.8	-12.88	-0.58	4.22e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg09835421	chr16:68378352	PRMT7	-0.55	-6.16	-0.32	2.09e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg08859206	chr1:53392774	SCP2	-0.68	-12.93	-0.58	2.87e-31	Monocyte count;
LUSC	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.54	-6.51	-0.34	2.82e-10	Neutrophil percentage of white cells;
LUSC	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg04310649	chr10:35416472	CREM	-0.42	-6.47	-0.33	3.4e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs12145833	0.596	rs12123491	chr1:243297924	C/G	cg01826367	chr1:224180288	NA	0.69	6.44	0.33	4.06e-10	Obesity (early onset extreme);
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg23131131	chr22:24373011	LOC391322	-0.41	-5.99	-0.31	5.46e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg13319975	chr6:146136371	FBXO30	0.48	7.25	0.37	2.88e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg13334819	chr7:99746414	C7orf59	-0.44	-5.87	-0.31	1.05e-8	Coronary artery disease;
LUSC	cis	rs1113500	0.932	rs1343205	chr1:108597873	C/G	cg11967332	chr1:108735228	SLC25A24	0.38	5.72	0.3	2.41e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg09367891	chr1:107599246	PRMT6	0.51	7.85	0.39	5.71e-14	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-8.18	-0.41	5.91e-15	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs72772090	0.539	rs72773923	chr5:96117579	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.55	-0.34	2.18e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg05484376	chr2:27715224	FNDC4	0.3	5.67	0.3	3.01e-8	Total body bone mineral density;
LUSC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.57	-0.5	1.04e-22	Alzheimer's disease;
LUSC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg09877947	chr5:131593287	PDLIM4	0.43	6.7	0.34	8.76e-11	Breast cancer;
LUSC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-6.88	-0.35	3.01e-11	Blood metabolite levels;
LUSC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.37	6.53	0.34	2.38e-10	Obesity-related traits;
LUSC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.55	-0.42	4.52e-16	Joint mobility (Beighton score);
LUSC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.9	15.64	0.65	9.37e-42	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.4	5.75	0.3	2.01e-8	Tonsillectomy;
LUSC	cis	rs9534288	0.699	rs4280137	chr13:46664008	G/A	cg15192986	chr13:46630673	CPB2	-0.72	-10.54	-0.5	1.28e-22	Blood protein levels;
LUSC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg12927641	chr6:109611667	NA	-0.43	-7.5	-0.38	5.89e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	cis	rs9398803	0.865	rs9375439	chr6:126758540	C/G	cg19875578	chr6:126661172	C6orf173	0.41	6.09	0.32	3.18e-9	Male-pattern baldness;
LUSC	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.58	-7.63	-0.39	2.43e-13	Red cell distribution width;
LUSC	cis	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.61	0.43	2.85e-16	Endometrial cancer;
LUSC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg23711669	chr6:146136114	FBXO30	0.88	16.07	0.66	1.92e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4363385	0.818	rs684305	chr1:153006242	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.43e-12	Inflammatory skin disease;
LUSC	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.9	-0.35	2.6e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.72	-14.8	-0.63	1.82e-38	Longevity;Endometriosis;
LUSC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.88	11.15	0.52	9.46e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg13114125	chr14:105738426	BRF1	-0.91	-15.96	-0.66	5.14e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.6	0.38	2.95e-13	Obesity-related traits;
LUSC	cis	rs75804782	0.521	rs72993044	chr2:239397949	C/T	cg18131467	chr2:239335373	ASB1	-0.67	-6.17	-0.32	2e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs710216	0.957	rs12041787	chr1:43432275	G/C	cg22176566	chr1:43424700	SLC2A1	0.48	6.01	0.31	4.79e-9	Red cell distribution width;
LUSC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg15103426	chr22:29168792	CCDC117	0.45	5.87	0.31	1.06e-8	Lymphocyte counts;
LUSC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg06697600	chr4:7070879	GRPEL1	-0.4	-6.61	-0.34	1.49e-10	Monocyte percentage of white cells;
LUSC	cis	rs10203711	0.966	rs10187949	chr2:239558408	T/C	cg14580085	chr2:239553406	NA	0.4	6.8	0.35	4.78e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9905704	0.633	rs917016	chr17:56454156	C/T	cg19466818	chr17:56409534	MIR142	0.32	5.91	0.31	8.36e-9	Testicular germ cell tumor;
LUSC	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg06623918	chr6:96969491	KIAA0776	0.73	8.64	0.43	2.33e-16	Migraine;Coronary artery disease;
LUSC	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg18132916	chr6:79620363	NA	-0.41	-6.2	-0.32	1.63e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7336332	0.598	rs1885988	chr13:28010262	C/T	cg22138327	chr13:27999177	GTF3A	-0.76	-9.87	-0.48	2.58e-20	Weight;
LUSC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.27	-0.32	1.11e-9	Menopause (age at onset);
LUSC	cis	rs13315871	1.000	rs13060489	chr3:58339287	G/A	cg12435725	chr3:58293450	RPP14	-0.75	-7.83	-0.39	6.63e-14	Cholesterol, total;
LUSC	cis	rs921665	0.831	rs11690724	chr2:3188333	T/G	cg16434511	chr2:3151078	NA	-0.63	-6.78	-0.35	5.3e-11	World class endurance athleticism;
LUSC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.06e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	8.63	0.43	2.62e-16	Bipolar disorder;
LUSC	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg00277334	chr10:82204260	NA	-0.53	-7.8	-0.39	7.93e-14	Post bronchodilator FEV1;
LUSC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg11608241	chr8:8085544	FLJ10661	0.43	6.32	0.33	8.46e-10	Systolic blood pressure;
LUSC	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg23950597	chr19:37808831	NA	-0.63	-7.63	-0.39	2.43e-13	Coronary artery calcification;
LUSC	cis	rs3087591	0.960	rs9896041	chr17:29571326	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.56	-8.19	-0.41	5.62e-15	Hip circumference;
LUSC	cis	rs12618769	0.597	rs72821907	chr2:99085296	A/G	cg10123293	chr2:99228465	UNC50	0.45	7.38	0.37	1.25e-12	Bipolar disorder;
LUSC	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.03	-0.44	1.44e-17	Triglycerides;
LUSC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg01879757	chr17:41196368	BRCA1	-0.45	-6.99	-0.36	1.54e-11	Menopause (age at onset);
LUSC	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.59	0.5	8.69e-23	Colorectal cancer;
LUSC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25072359	chr17:41440525	NA	0.63	9.22	0.45	3.35e-18	Menopause (age at onset);
LUSC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg22823121	chr1:150693482	HORMAD1	0.55	7.94	0.4	3.09e-14	Melanoma;
LUSC	cis	rs2742417	0.603	rs2673055	chr3:45772772	G/A	cg10512202	chr3:45649293	LIMD1	0.36	5.94	0.31	7.3e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9462027	0.675	rs34657938	chr6:34801631	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.03	-0.31	4.26e-9	Systemic lupus erythematosus;
LUSC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg27572855	chr1:25598939	RHD	-0.43	-7.6	-0.38	3.1e-13	Erythrocyte sedimentation rate;
LUSC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg16989719	chr2:238392110	NA	-0.42	-7.14	-0.36	5.97e-12	Prostate cancer;
LUSC	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg10326726	chr10:51549505	MSMB	-0.33	-5.66	-0.3	3.32e-8	Prostate-specific antigen levels;
LUSC	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.29	-0.37	2.27e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs6580649	0.941	rs11613485	chr12:48462455	T/C	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.87	-12.96	-0.58	2.05e-31	Alcohol dependence;
LUSC	cis	rs79387448	0.745	rs1523196	chr2:103163700	T/G	cg09003973	chr2:102972529	NA	0.89	8.62	0.43	2.69e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg25019033	chr10:957182	NA	-0.53	-6.1	-0.32	2.91e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg03806693	chr22:41940476	POLR3H	0.91	12.73	0.57	1.53e-30	Vitiligo;
LUSC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg20608306	chr11:116969690	SIK3	0.39	6.51	0.34	2.69e-10	Blood protein levels;
LUSC	cis	rs500891	0.533	rs6454331	chr6:84175632	G/A	cg08257003	chr6:84140564	ME1	0.33	8.11	0.41	9.92e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs977987	0.931	rs8057084	chr16:75492706	G/T	cg04384234	chr16:75411784	CFDP1	0.45	7.28	0.37	2.45e-12	Dupuytren's disease;
LUSC	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg20991723	chr1:152506922	NA	-0.48	-8.86	-0.44	4.99e-17	Hair morphology;
LUSC	cis	rs6076065	0.723	rs2144381	chr20:23369940	C/T	cg11657817	chr20:23433608	CST11	0.42	7.99	0.4	2.19e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs68170813	0.559	rs76646886	chr7:107034328	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.26	-0.45	2.51e-18	Coronary artery disease;
LUSC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07677032	chr17:61819896	STRADA	0.53	8.91	0.44	3.42e-17	Prudent dietary pattern;
LUSC	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg24450063	chr1:156163899	SLC25A44	1.06	20.26	0.74	4.47e-60	Testicular germ cell tumor;
LUSC	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg27411982	chr8:10470053	RP1L1	0.42	6.49	0.33	3.02e-10	Neuroticism;
LUSC	cis	rs9398803	0.605	rs112166936	chr6:126733140	A/C	cg19875578	chr6:126661172	C6orf173	0.43	6.26	0.32	1.15e-9	Male-pattern baldness;
LUSC	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.4	-0.33	5.26e-10	Ulcerative colitis;
LUSC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg12365402	chr11:9010492	NRIP3	0.46	8.95	0.44	2.46e-17	Tonsillectomy;
LUSC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.16	-14.37	-0.62	8.82e-37	Breast cancer;
LUSC	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	11.15	0.52	9.51e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg08917208	chr2:24149416	ATAD2B	1.01	10.61	0.5	7.29e-23	Lymphocyte counts;
LUSC	cis	rs8114671	0.967	rs6142320	chr20:33788193	A/G	cg07148914	chr20:33460835	GGT7	-0.44	-6.52	-0.34	2.66e-10	Height;
LUSC	cis	rs3736594	0.513	rs62141278	chr2:27768381	C/T	cg27432699	chr2:27873401	GPN1	0.67	8.86	0.44	4.69e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05918473	chr13:32885580	ZAR1L	0.48	5.99	0.31	5.42e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg13660082	chr14:53194042	PSMC6	-0.78	-6.82	-0.35	4.38e-11	Alzheimer's disease (late onset);
LUSC	cis	rs10489202	1.000	rs7538581	chr1:167979347	A/G	cg24449463	chr1:168025552	DCAF6	-0.58	-7.31	-0.37	1.98e-12	Schizophrenia;
LUSC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg19257562	chr1:2043853	PRKCZ	0.31	6.12	0.32	2.65e-9	Height;
LUSC	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.69	-10.09	-0.48	4.37e-21	Systemic lupus erythematosus;
LUSC	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-7.28	-0.37	2.35e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2692947	0.644	rs1724125	chr2:96831355	G/A	cg22654517	chr2:96458247	NA	0.32	5.84	0.3	1.21e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg05658215	chr7:157211628	NA	0.31	5.74	0.3	2.15e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-5.85	-0.3	1.17e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg03806693	chr22:41940476	POLR3H	-0.51	-6.93	-0.35	2.17e-11	Neuroticism;
LUSC	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg11502198	chr6:26597334	ABT1	0.54	8.01	0.4	1.93e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21862992	chr11:68658383	NA	0.51	7.75	0.39	1.09e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg20476274	chr7:133979776	SLC35B4	0.84	15.5	0.65	3.46e-41	Mean platelet volume;
LUSC	cis	rs9309473	0.660	rs79370894	chr2:73683515	C/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.51	-0.34	2.69e-10	Metabolite levels;
LUSC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg08270630	chr22:50330655	NA	-0.43	-6.58	-0.34	1.79e-10	Schizophrenia;
LUSC	trans	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg20935933	chr6:143382018	AIG1	0.5	7.32	0.37	1.92e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg02269571	chr22:50332266	NA	-0.44	-6.89	-0.35	2.74e-11	Schizophrenia;
LUSC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg11871910	chr12:69753446	YEATS4	0.91	17.0	0.68	3.9e-47	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg14809332	chr8:144654887	C8orf73	0.46	5.95	0.31	6.77e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg15352829	chr14:105391018	PLD4	-0.43	-8.99	-0.44	1.9e-17	Rheumatoid arthritis;
LUSC	cis	rs11018904	0.906	rs7925507	chr11:89940146	T/C	cg26834418	chr11:89957033	CHORDC1	-0.51	-6.08	-0.32	3.28e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg18132916	chr6:79620363	NA	-0.39	-6.02	-0.31	4.69e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg25237894	chr2:233734115	C2orf82	-0.36	-6.63	-0.34	1.35e-10	Coronary artery disease;
LUSC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.51	6.2	0.32	1.69e-9	Multiple sclerosis;
LUSC	cis	rs9503598	0.636	rs6596977	chr6:3466254	G/A	cg00476032	chr6:3446245	SLC22A23	0.3	5.99	0.31	5.5e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03647317	chr4:187891568	NA	-0.34	-5.75	-0.3	1.96e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12136530	0.774	rs58952060	chr1:19774582	G/A	cg01832549	chr1:19774989	CAPZB	-0.32	-5.94	-0.31	7.33e-9	Lead levels in blood;
LUSC	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.67	10.12	0.48	3.54e-21	Breast cancer;
LUSC	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg15704280	chr7:45808275	SEPT13	0.77	7.41	0.38	1.01e-12	Axial length;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08081407	chr3:57583693	ARF4	-0.36	-6.09	-0.32	3.09e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg14019146	chr3:50243930	SLC38A3	0.29	6.42	0.33	4.63e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.97	-0.44	2.14e-17	Neuroticism;
LUSC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg11608241	chr8:8085544	FLJ10661	0.4	5.8	0.3	1.58e-8	Mood instability;
LUSC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg27535305	chr1:53392650	SCP2	0.33	5.98	0.31	5.85e-9	Monocyte count;
LUSC	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg19773385	chr1:10388646	KIF1B	-0.58	-9.39	-0.46	9.87e-19	Hepatocellular carcinoma;
LUSC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.37	0.33	6.28e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2279817	0.735	rs12075624	chr1:17991573	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.47	-6.15	-0.32	2.27e-9	Neuroticism;
LUSC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg13628971	chr7:2884303	GNA12	0.43	6.56	0.34	2.02e-10	Height;
LUSC	trans	rs208520	1.000	rs208536	chr6:66963440	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-12.34	-0.56	4.42e-29	Exhaled nitric oxide output;
LUSC	cis	rs67072384	1.000	rs56693670	chr11:72445143	G/T	cg04827223	chr11:72435913	ARAP1	-0.82	-7.76	-0.39	1.04e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg24375607	chr4:120327624	NA	-0.77	-11.08	-0.52	1.7e-24	Corneal astigmatism;
LUSC	cis	rs12210905	0.925	rs72838236	chr6:26971202	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06544989	chr22:39130855	UNC84B	0.39	7.03	0.36	1.15e-11	Menopause (age at onset);
LUSC	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg08798685	chr6:27730294	NA	-0.66	-6.01	-0.31	4.77e-9	Depression;
LUSC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg01765077	chr12:122356316	WDR66	0.53	7.66	0.39	2.03e-13	Mean corpuscular volume;
LUSC	cis	rs2573652	1.000	rs12440866	chr15:100517010	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.46	-8.67	-0.43	1.84e-16	Height;
LUSC	cis	rs13401104	0.740	rs12475284	chr2:237118586	A/C	cg19324714	chr2:237145437	ASB18	0.43	5.73	0.3	2.25e-8	Educational attainment;
LUSC	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.28	-0.32	1.03e-9	Myopia (pathological);
LUSC	cis	rs34658409	1	rs34658409	chr8:42433985	TC/T	cg09913449	chr8:42400586	C8orf40	0.5	8.26	0.41	3.35e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg03806693	chr22:41940476	POLR3H	0.85	12.3	0.56	6.36e-29	Vitiligo;
LUSC	trans	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg24643429	chr1:3562429	WDR8	0.33	6.05	0.31	3.88e-9	Monocyte count;
LUSC	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg12552261	chr5:112820674	MCC	0.44	7.11	0.36	7.19e-12	Type 2 diabetes;
LUSC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg07777115	chr5:623756	CEP72	-0.45	-5.65	-0.3	3.48e-8	Obesity-related traits;
LUSC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02475777	chr4:1388615	CRIPAK	0.62	9.3	0.45	1.88e-18	Longevity;
LUSC	cis	rs1865721	1.000	rs72977890	chr18:73198776	C/A	cg26385618	chr18:73139727	C18orf62	-0.47	-7.9	-0.4	3.94e-14	Intelligence;
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.46	7.8	0.39	7.91e-14	Lymphocyte counts;
LUSC	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg12615879	chr12:58013172	SLC26A10	-0.42	-10.45	-0.5	2.67e-22	Multiple sclerosis;
LUSC	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg10018233	chr7:150070692	REPIN1	0.37	6.51	0.34	2.78e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.95	-0.44	2.42e-17	Response to antipsychotic treatment;
LUSC	trans	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-6.09	-0.32	3.06e-9	Morning vs. evening chronotype;
LUSC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg06740227	chr12:86229804	RASSF9	0.44	6.96	0.36	1.84e-11	Major depressive disorder;
LUSC	trans	rs877282	0.583	rs10904562	chr10:819058	T/C	cg13042288	chr15:90349979	ANPEP	-0.43	-6.39	-0.33	5.44e-10	Uric acid levels;
LUSC	cis	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg21775007	chr8:11205619	TDH	-0.45	-6.12	-0.32	2.6e-9	Triglycerides;
LUSC	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg16576597	chr16:28551801	NUPR1	0.33	6.72	0.35	7.96e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7106204	0.513	rs7131144	chr11:24249486	A/G	ch.11.24196551F	chr11:24239977	NA	0.9	9.58	0.46	2.36e-19	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs11779988	0.545	rs208759	chr8:17807929	G/C	cg01800426	chr8:17659068	MTUS1	-0.47	-5.91	-0.31	8.31e-9	Breast cancer;
LUSC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-6.61	-0.34	1.52e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg21856205	chr7:94953877	PON1	-0.38	-6.18	-0.32	1.82e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	0.78	11.63	0.54	1.74e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20135002	chr11:47629003	NA	-0.49	-7.49	-0.38	6.26e-13	Subjective well-being;
LUSC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg27398817	chr8:82754497	SNX16	-0.51	-6.79	-0.35	5.01e-11	Diastolic blood pressure;
LUSC	trans	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg26043149	chr18:55253948	FECH	-0.46	-7.14	-0.36	5.88e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9378688	0.654	rs2505657	chr6:2331510	T/C	cg12303981	chr6:2244766	GMDS	-0.44	-6.12	-0.32	2.64e-9	Caudate nucleus volume;
LUSC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg22903471	chr2:27725779	GCKR	-0.42	-7.2	-0.37	3.91e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs981844	0.683	rs1037647	chr4:154737991	A/G	cg14289246	chr4:154710475	SFRP2	-0.44	-6.13	-0.32	2.46e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21862992	chr11:68658383	NA	0.5	7.9	0.4	3.97e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg06697600	chr4:7070879	GRPEL1	0.45	6.43	0.33	4.31e-10	Monocyte percentage of white cells;
LUSC	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg15133208	chr4:90757351	SNCA	-0.53	-8.21	-0.41	4.76e-15	Neuroticism;
LUSC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg04414720	chr1:150670196	GOLPH3L	0.53	8.53	0.42	5e-16	Tonsillectomy;
LUSC	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg05082376	chr22:42548792	NA	-0.4	-6.62	-0.34	1.45e-10	Cognitive function;
LUSC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.81	14.5	0.62	2.68e-37	Mean platelet volume;
LUSC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg22800045	chr5:56110881	MAP3K1	0.77	9.42	0.46	7.46e-19	Initial pursuit acceleration;
LUSC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg27535305	chr1:53392650	SCP2	0.36	6.8	0.35	4.92e-11	Monocyte count;
LUSC	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.43	-0.33	4.31e-10	Bipolar disorder;
LUSC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg08742575	chr21:47604166	C21orf56	0.46	6.92	0.35	2.27e-11	Testicular germ cell tumor;
LUSC	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg23815491	chr16:72088622	HP	0.36	6.37	0.33	6.29e-10	Fibrinogen levels;
LUSC	cis	rs73206853	0.841	rs7956963	chr12:110947783	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.06	0.36	9.69e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg11901034	chr3:128598214	ACAD9	-0.41	-6.47	-0.33	3.54e-10	IgG glycosylation;
LUSC	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg19554555	chr3:13937349	NA	-0.49	-7.69	-0.39	1.71e-13	Ovarian reserve;
LUSC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.78	12.05	0.55	5.37e-28	Tonsillectomy;
LUSC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg20295408	chr7:1910781	MAD1L1	-0.54	-7.84	-0.39	5.98e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.79	-13.09	-0.58	7.18e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg15744005	chr10:104629667	AS3MT	-0.33	-6.07	-0.32	3.51e-9	Arsenic metabolism;
LUSC	cis	rs2233152	0.656	rs10405633	chr19:41291703	G/A	cg21869046	chr19:41225005	ITPKC	0.44	6.15	0.32	2.16e-9	Kawasaki disease;
LUSC	cis	rs66887589	0.934	rs4834792	chr4:120555696	T/A	cg09307838	chr4:120376055	NA	-0.49	-7.4	-0.38	1.13e-12	Diastolic blood pressure;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14631462	chr10:31607925	ZEB1;LOC220930	-0.39	-6.32	-0.33	8.16e-10	Triglycerides;
LUSC	cis	rs9326248	0.861	rs4938352	chr11:117027481	G/A	cg11861562	chr11:117069780	TAGLN	0.35	5.65	0.3	3.4e-8	Blood protein levels;
LUSC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05535760	chr7:792225	HEATR2	0.78	9.14	0.45	6.04e-18	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg01884057	chr2:25150051	NA	0.4	8.99	0.44	1.9e-17	Body mass index;
LUSC	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	0.95	19.8	0.73	2.85e-58	Menarche (age at onset);
LUSC	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg09184832	chr6:79620586	NA	-0.44	-7.1	-0.36	7.62e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg05552183	chr6:42928497	GNMT	0.55	9.43	0.46	7.36e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg05973401	chr12:123451056	ABCB9	0.62	9.24	0.45	2.94e-18	Platelet count;
LUSC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg14196790	chr5:131705035	SLC22A5	0.37	6.23	0.32	1.39e-9	Blood metabolite levels;
LUSC	cis	rs4631830	0.737	rs7071471	chr10:51503335	C/T	cg16070123	chr10:51489643	NA	0.53	8.34	0.41	2.04e-15	Prostate-specific antigen levels;
LUSC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg05082376	chr22:42548792	NA	-0.43	-6.41	-0.33	5.03e-10	Schizophrenia;
LUSC	cis	rs9560113	0.960	rs9560101	chr13:112173798	G/A	cg14154082	chr13:112174009	NA	0.38	7.95	0.4	2.97e-14	Menarche (age at onset);
LUSC	cis	rs11209185	0.545	rs1926284	chr1:68446291	T/C	cg22082780	chr1:68452167	NA	0.44	7.31	0.37	2.05e-12	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs929596	0.556	rs10168416	chr2:234597087	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-7.78	-0.39	9.19e-14	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.81	-0.51	1.5e-23	Alzheimer's disease (late onset);
LUSC	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.41	0.42	1.18e-15	Fuchs's corneal dystrophy;
LUSC	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg13535736	chr9:111863775	C9orf5	-0.43	-6.96	-0.36	1.76e-11	Menarche (age at onset);
LUSC	cis	rs10392	0.543	rs6028200	chr20:37540615	C/T	cg27552599	chr20:37590471	DHX35	0.42	6.77	0.35	5.65e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg09998033	chr7:158218633	PTPRN2	-0.6	-9.74	-0.47	6.8e-20	Obesity-related traits;
LUSC	cis	rs977987	0.778	rs4888412	chr16:75443196	A/G	cg03315344	chr16:75512273	CHST6	0.48	8.98	0.44	2.08e-17	Dupuytren's disease;
LUSC	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg25182066	chr10:30743637	MAP3K8	-0.39	-5.92	-0.31	8.02e-9	Inflammatory bowel disease;
LUSC	cis	rs7424096	0.527	rs4670637	chr2:37164857	T/G	cg14987922	chr2:37194071	STRN	0.63	9.64	0.47	1.47e-19	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs3770081	1.000	rs79152960	chr2:86290661	A/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.84	-0.35	3.84e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.51	0.34	2.8e-10	Schizophrenia;
LUSC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.59	8.08	0.4	1.22e-14	Response to diuretic therapy;
LUSC	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg06640241	chr16:89574553	SPG7	0.49	7.0	0.36	1.44e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg07460842	chr6:66804631	NA	0.47	5.8	0.3	1.53e-8	Metabolite levels;
LUSC	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.28	-0.37	2.44e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9309473	0.898	rs6546852	chr2:73833431	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.63	-0.34	1.37e-10	Metabolite levels;
LUSC	trans	rs7980799	0.682	rs1351682	chr12:33598775	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.85	-0.44	5.37e-17	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08045932	chr20:61659980	NA	0.58	10.07	0.48	5.3e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.78	0.39	8.95e-14	Electroencephalogram traits;
LUSC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg19077165	chr18:44547161	KATNAL2	0.46	6.76	0.35	6.36e-11	Personality dimensions;
LUSC	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg08975724	chr8:8085496	FLJ10661	0.5	7.08	0.36	8.66e-12	Retinal vascular caliber;
LUSC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.59	9.61	0.47	1.82e-19	Aortic root size;
LUSC	cis	rs1775715	0.737	rs2778672	chr10:32122419	T/C	cg03015672	chr10:32216066	ARHGAP12	0.33	5.85	0.3	1.18e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg22681709	chr2:178499509	PDE11A	-0.57	-11.54	-0.53	3.85e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-10.53	-0.5	1.44e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg04871131	chr7:94954202	PON1	-0.37	-5.97	-0.31	6.14e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.83	0.47	3.46e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs73200209	0.744	rs11614867	chr12:116658916	A/C	cg01776926	chr12:116560359	MED13L	-0.49	-6.05	-0.31	3.97e-9	Total body bone mineral density;
LUSC	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg15549821	chr19:49342101	PLEKHA4	-0.58	-7.63	-0.39	2.43e-13	Red cell distribution width;
LUSC	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.52	-0.34	2.53e-10	High light scatter reticulocyte count;
LUSC	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg09835421	chr16:68378352	PRMT7	-0.54	-6.04	-0.31	4.2e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg10018233	chr7:150070692	REPIN1	0.4	7.23	0.37	3.3e-12	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	18.97	0.72	5.86e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg14092988	chr3:52407081	DNAH1	0.32	6.22	0.32	1.51e-9	Bipolar disorder;
LUSC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.37	-0.49	5.14e-22	Gut microbiome composition (summer);
LUSC	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg05890377	chr2:74357713	NA	0.68	11.96	0.55	1.1e-27	Gestational age at birth (maternal effect);
LUSC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Depression;
LUSC	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.62	10.3	0.49	8.96e-22	Blood metabolite ratios;
LUSC	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg10560079	chr2:191398806	TMEM194B	0.71	9.02	0.44	1.54e-17	Diastolic blood pressure;
LUSC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg24531977	chr5:56204891	C5orf35	-0.61	-9.04	-0.44	1.26e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.92	17.06	0.68	2.34e-47	Tonsillectomy;
LUSC	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg00530320	chr1:46809349	NSUN4	0.55	8.49	0.42	6.91e-16	Menopause (age at onset);
LUSC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	1.05	19.18	0.72	8.03e-56	Parkinson's disease;
LUSC	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg02176678	chr2:219576539	TTLL4	-0.57	-10.08	-0.48	5.06e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12493885	0.585	rs696869	chr3:153630341	A/C	cg17054900	chr3:154042577	DHX36	-0.59	-6.01	-0.31	4.73e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg03733263	chr8:22462867	KIAA1967	0.99	18.5	0.71	4.35e-53	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg21095983	chr6:86352623	SYNCRIP	0.51	8.08	0.4	1.19e-14	Smooth-surface caries;
LUSC	cis	rs6489882	0.807	rs10774677	chr12:113362421	G/A	cg20102336	chr12:113376681	OAS3	-0.41	-5.88	-0.31	9.9e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs7215564	0.822	rs2340769	chr17:78755271	C/T	cg23238734	chr17:78661607	RPTOR	-0.51	-6.14	-0.32	2.31e-9	Myopia (pathological);
LUSC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg00745463	chr17:30367425	LRRC37B	-0.85	-9.92	-0.48	1.72e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	0.65	13.92	0.61	4.91e-35	Prudent dietary pattern;
LUSC	cis	rs17286411	0.701	rs4788812	chr16:71625467	A/G	cg10085824	chr16:71800315	AP1G1	0.37	5.97	0.31	5.94e-9	Blood protein levels;
LUSC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	8.16	0.41	6.87e-15	Bipolar disorder;
LUSC	cis	rs4363385	0.553	rs61813181	chr1:152942177	T/C	cg00922841	chr1:152955080	SPRR1A	-0.36	-6.06	-0.31	3.63e-9	Inflammatory skin disease;
LUSC	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.32e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg17807903	chr1:86174739	ZNHIT6	-0.44	-9.42	-0.46	7.59e-19	Urate levels in overweight individuals;
LUSC	cis	rs2742234	0.504	rs10899780	chr10:43725796	T/C	cg02780029	chr10:43622663	RET	0.34	5.7	0.3	2.58e-8	Hirschsprung disease;
LUSC	cis	rs2067615	0.579	rs4385986	chr12:107133775	C/T	cg15890332	chr12:107067104	RFX4	0.33	6.01	0.31	4.92e-9	Heart rate;
LUSC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg08847533	chr14:75593920	NEK9	-0.81	-13.05	-0.58	9.79e-32	Height;
LUSC	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg04352962	chr1:209979756	IRF6	0.58	6.3	0.33	9.3e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs62400317	0.826	rs11970496	chr6:45125833	A/G	cg20913747	chr6:44695427	NA	-0.47	-7.55	-0.38	4.27e-13	Total body bone mineral density;
LUSC	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg18512352	chr11:47633146	NA	-0.47	-9.48	-0.46	4.78e-19	Subjective well-being;
LUSC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	1.04	16.32	0.67	1.96e-44	Parkinson's disease;
LUSC	trans	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg07211511	chr3:129823064	LOC729375	-0.57	-6.3	-0.33	9.48e-10	Blood pressure (smoking interaction);
LUSC	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg27068330	chr11:65405492	SIPA1	-0.75	-10.31	-0.49	7.88e-22	Acne (severe);
LUSC	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg04850211	chr1:228464232	OBSCN	-0.32	-5.75	-0.3	1.98e-8	Diastolic blood pressure;
LUSC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11645453	chr3:52864694	ITIH4	0.28	6.32	0.33	8.2e-10	Bipolar disorder;
LUSC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.58	0.46	2.25e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg02038168	chr22:39784481	NA	0.5	8.34	0.42	1.94e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24110177	chr3:50126178	RBM5	0.63	10.93	0.51	5.59e-24	Body mass index;
LUSC	cis	rs308403	0.568	rs13102440	chr4:123664919	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.79	10.18	0.49	2.16e-21	Blood protein levels;
LUSC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg15103426	chr22:29168792	CCDC117	0.45	5.76	0.3	1.87e-8	Lymphocyte counts;
LUSC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10802521	chr3:52805072	NEK4	-0.49	-7.76	-0.39	1.02e-13	Electroencephalogram traits;
LUSC	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg00677455	chr12:58241039	CTDSP2	0.54	7.74	0.39	1.21e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs13315871	1.000	rs35621601	chr3:58323174	A/G	cg12435725	chr3:58293450	RPP14	-0.72	-7.15	-0.36	5.35e-12	Cholesterol, total;
LUSC	trans	rs1268789	0.545	rs753751	chr4:79373254	A/G	cg06112894	chr8:141469983	TRAPPC9	0.22	6.05	0.31	3.96e-9	Hair shape;Hair morphology;
LUSC	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.41	-6.01	-0.31	4.86e-9	Response to antipsychotic treatment;
LUSC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.28	-0.33	1.05e-9	Monocyte count;
LUSC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.5	-0.34	2.94e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg02773041	chr1:40204384	PPIE	0.54	8.26	0.41	3.35e-15	Blood protein levels;
LUSC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.6	-0.57	4.72e-30	Chronic sinus infection;
LUSC	cis	rs11577318	0.579	rs12131370	chr1:26698430	G/A	cg00852783	chr1:26633632	UBXN11	-0.54	-7.45	-0.38	7.88e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9638182	0.560	rs67644909	chr7:72995954	C/T	cg07452164	chr7:72993570	TBL2	0.45	6.33	0.33	7.79e-10	Triglycerides;
LUSC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.45	-7.14	-0.36	5.87e-12	Blood metabolite levels;
LUSC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg06808227	chr14:105710500	BRF1	-0.73	-11.76	-0.54	5.74e-27	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg17633681	chr16:88106987	BANP	0.5	9.29	0.45	2.01e-18	Menopause (age at onset);
LUSC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.96	0.51	4.51e-24	Menopause (age at onset);
LUSC	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg16586182	chr3:47516702	SCAP	-0.56	-9.08	-0.44	9.89e-18	Colorectal cancer;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg23131131	chr22:24373011	LOC391322	-0.5	-7.13	-0.36	6.42e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.99	-0.31	5.39e-9	Monocyte count;
LUSC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg15445000	chr17:37608096	MED1	0.4	6.79	0.35	5.09e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs4919087	0.923	rs11189038	chr10:98974765	A/T	cg25902810	chr10:99078978	FRAT1	0.46	6.55	0.34	2.24e-10	Monocyte count;
LUSC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.9	-0.31	9.08e-9	Platelet count;
LUSC	cis	rs6012564	0.963	rs6125551	chr20:47720386	C/G	cg03212862	chr20:47662828	CSE1L	0.46	6.58	0.34	1.85e-10	Anger;
LUSC	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg06606381	chr12:133084897	FBRSL1	-0.92	-8.91	-0.44	3.3e-17	Urinary tract infection frequency;
LUSC	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.1	-16.79	-0.68	2.73e-46	Primary sclerosing cholangitis;
LUSC	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	7.61	0.38	2.92e-13	Colorectal cancer;
LUSC	cis	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg24375607	chr4:120327624	NA	-0.46	-7.43	-0.38	8.93e-13	Diastolic blood pressure;
LUSC	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.77	11.23	0.52	4.66e-25	Corneal astigmatism;
LUSC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg16647868	chr5:131706066	SLC22A5	0.38	5.97	0.31	6.22e-9	Breast cancer;
LUSC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.58	0.42	3.71e-16	Bipolar disorder;
LUSC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs7614311	0.636	rs73117059	chr3:63916028	A/G	cg22134162	chr3:63841271	THOC7	-0.49	-6.2	-0.32	1.71e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg13010199	chr12:38710504	ALG10B	-0.65	-11.12	-0.52	1.19e-24	Heart rate;
LUSC	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.09	-0.32	3.13e-9	Neutrophil percentage of white cells;
LUSC	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.16	-0.32	2.09e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg17948913	chr5:572064	NA	0.36	6.08	0.32	3.32e-9	Obesity-related traits;
LUSC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	6.03	0.31	4.44e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02788857	chr8:22132959	PIWIL2	0.39	7.48	0.38	6.82e-13	Hypertriglyceridemia;
LUSC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg16240275	chr20:61666158	NCRNA00029	0.42	9.25	0.45	2.82e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.67	0.3	3.06e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6714788	0.565	rs7599083	chr2:100658077	G/A	cg07810366	chr2:100720526	AFF3	-0.39	-6.22	-0.32	1.51e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08045932	chr20:61659980	NA	0.59	10.33	0.49	6.74e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-17.36	-0.69	1.44e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.86	-0.44	5.01e-17	Response to antipsychotic treatment;
LUSC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.38	0.69	1.15e-48	Chronic sinus infection;
LUSC	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.55	8.74	0.43	1.18e-16	Birth weight;
LUSC	trans	rs4724055	0.557	rs2118679	chr7:41636787	T/C	cg23476065	chr7:151106043	WDR86	0.71	6.1	0.32	2.95e-9	Non-substance related behavioral disinhibition;
LUSC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg12288994	chr5:1860383	NA	0.28	6.16	0.32	2.12e-9	Cardiovascular disease risk factors;
LUSC	cis	rs8054556	0.647	rs11863174	chr16:30019375	A/C	cg06326092	chr16:30034487	C16orf92	0.23	5.68	0.3	3.01e-8	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg11084020	chr7:27779567	TAX1BP1	0.32	6.32	0.33	8.26e-10	Tuberculosis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09857708	chr16:66586376	CKLF	0.46	6.29	0.33	1e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg19628046	chr18:33552617	C18orf21	0.51	6.11	0.32	2.73e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs17095355	0.605	rs3740140	chr10:111632937	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.55	-6.51	-0.34	2.81e-10	Biliary atresia;
LUSC	trans	rs10432489	0.708	rs12328545	chr2:181771545	T/A	cg04744134	chr19:8408128	KANK3	0.83	6.27	0.32	1.13e-9	QT interval;
LUSC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.75	-0.3	1.97e-8	Tonsillectomy;
LUSC	cis	rs2028299	1.000	rs1371135	chr15:90391270	T/C	cg23731826	chr15:90371692	NA	0.29	5.65	0.3	3.45e-8	Type 2 diabetes;
LUSC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	0.95	18.75	0.72	4.32e-54	Cognitive function;
LUSC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.72	12.12	0.55	2.87e-28	Motion sickness;
LUSC	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg09699651	chr6:150184138	LRP11	0.38	5.72	0.3	2.42e-8	Lung cancer;
LUSC	cis	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.39	-0.33	5.57e-10	Morning vs. evening chronotype;
LUSC	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg24675056	chr1:15929824	NA	0.45	7.76	0.39	1.03e-13	Systolic blood pressure;
LUSC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.09	-0.4	1.12e-14	Type 2 diabetes;
LUSC	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg03647239	chr10:116582469	FAM160B1	0.44	7.02	0.36	1.24e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg13535736	chr9:111863775	C9orf5	-0.41	-6.56	-0.34	2.03e-10	Menarche (age at onset);
LUSC	cis	rs7739264	0.564	rs760794	chr6:19790560	C/T	cg02404759	chr6:19790362	NA	-0.44	-7.02	-0.36	1.22e-11	Endometriosis;
LUSC	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg13852791	chr20:30311386	BCL2L1	-0.91	-13.97	-0.61	3.14e-35	Mean corpuscular hemoglobin;
LUSC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg06238570	chr21:40685208	BRWD1	-0.57	-8.76	-0.43	9.9900000000000006e-17	Menarche (age at onset);
LUSC	cis	rs13064411	0.597	rs2291905	chr3:113010466	C/T	cg18753928	chr3:113234510	CCDC52	-0.36	-5.79	-0.3	1.61e-8	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg00310523	chr12:86230176	RASSF9	-0.51	-9.67	-0.47	1.2e-19	Major depressive disorder;
LUSC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg06028605	chr16:24865363	SLC5A11	-0.38	-6.15	-0.32	2.18e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg21770322	chr7:97807741	LMTK2	0.5	8.81	0.43	7.01e-17	Breast cancer;
LUSC	trans	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg06636001	chr8:8085503	FLJ10661	0.43	6.26	0.32	1.17e-9	Retinal vascular caliber;
LUSC	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.39	-0.33	5.47e-10	Resting heart rate;
LUSC	cis	rs12594515	1.000	rs11854554	chr15:45994546	C/G	cg01629716	chr15:45996671	NA	0.39	5.87	0.31	1.08e-8	Waist circumference;Weight;
LUSC	cis	rs662064	0.962	rs622623	chr1:10555257	C/T	cg17425144	chr1:10567563	PEX14	0.36	5.76	0.3	1.89e-8	Asthma;
LUSC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg15212455	chr7:39170539	POU6F2	0.6	9.87	0.48	2.41e-20	IgG glycosylation;
LUSC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg04518342	chr5:131593106	PDLIM4	0.44	7.61	0.38	2.87e-13	Breast cancer;
LUSC	cis	rs9512730	0.527	rs11619784	chr13:27999643	A/G	cg08193333	chr13:27998609	GTF3A	0.46	5.77	0.3	1.76e-8	Schizophrenia;
LUSC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg10729496	chr3:10149963	C3orf24	0.55	7.21	0.37	3.79e-12	Alzheimer's disease;
LUSC	cis	rs977987	0.806	rs1109342	chr16:75445675	A/G	cg03315344	chr16:75512273	CHST6	-0.47	-8.76	-0.43	9.76e-17	Dupuytren's disease;
LUSC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.94	-0.31	6.96e-9	Longevity;
LUSC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.54	8.42	0.42	1.1e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.7	10.54	0.5	1.25e-22	Corneal astigmatism;
LUSC	cis	rs2074585	0.517	rs11638010	chr15:91079920	A/G	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.85	-0.35	3.64e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs977987	0.843	rs60730309	chr16:75431769	C/G	cg04384234	chr16:75411784	CFDP1	-0.44	-7.2	-0.37	4.03e-12	Dupuytren's disease;
LUSC	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg20243544	chr17:37824526	PNMT	0.49	6.88	0.35	2.98e-11	Asthma;
LUSC	cis	rs12594515	1.000	rs11855562	chr15:45995659	C/T	cg01629716	chr15:45996671	NA	0.39	5.87	0.31	1.08e-8	Waist circumference;Weight;
LUSC	cis	rs2019216	0.521	rs12449447	chr17:21888786	C/T	cg22648282	chr17:21454238	C17orf51	-0.52	-7.58	-0.38	3.37e-13	Pelvic organ prolapse;
LUSC	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg05738196	chr6:26577821	NA	0.83	16.11	0.66	1.29e-43	Intelligence (multi-trait analysis);
LUSC	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-0.82	-15.35	-0.64	1.32e-40	Longevity;
LUSC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg05855489	chr10:104503620	C10orf26	0.58	9.2	0.45	4.02e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg06784218	chr1:46089804	CCDC17	0.53	10.22	0.49	1.67e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg13010199	chr12:38710504	ALG10B	0.68	11.24	0.52	4.28e-25	Heart rate;
LUSC	cis	rs10203711	1.000	rs4994756	chr2:239567125	T/C	cg14580085	chr2:239553406	NA	0.41	6.99	0.36	1.53e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg27432699	chr2:27873401	GPN1	-0.59	-8.84	-0.44	5.51e-17	Total body bone mineral density;
LUSC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.08	0.58	7.59e-32	Cognitive test performance;
LUSC	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg02176678	chr2:219576539	TTLL4	-0.57	-9.99	-0.48	1.02e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg09184832	chr6:79620586	NA	-0.44	-7.01	-0.36	1.34e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs722599	0.715	rs11851433	chr14:75339450	C/T	cg08847533	chr14:75593920	NEK9	0.45	6.38	0.33	5.83e-10	IgG glycosylation;
LUSC	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.97	0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6500395	1.000	rs2354578	chr16:48593298	T/C	cg04672837	chr16:48644449	N4BP1	0.43	6.34	0.33	7.56e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08564027	chr20:61660810	NA	0.9	17.01	0.68	3.71e-47	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs56283067	0.671	rs1028608	chr6:44681721	C/T	cg20913747	chr6:44695427	NA	-0.43	-7.16	-0.36	5.05e-12	Total body bone mineral density;
LUSC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	0.92	18.06	0.7	2.35e-51	Cognitive function;
LUSC	cis	rs6558174	0.930	rs1038311	chr8:22489247	T/C	cg03733263	chr8:22462867	KIAA1967	0.48	6.45	0.33	3.81e-10	Breast cancer;
LUSC	cis	rs9886651	0.776	rs4733560	chr8:128779001	G/A	cg07795030	chr8:128802207	NA	-0.36	-6.61	-0.34	1.54e-10	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LUSC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06112835	chr11:68658793	MRPL21	0.52	7.95	0.4	2.84e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg27494647	chr7:150038898	RARRES2	0.56	8.22	0.41	4.61e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2455601	0.608	rs1368017	chr11:8867070	A/C	cg12365402	chr11:9010492	NRIP3	-0.36	-5.75	-0.3	2.04e-8	Schizophrenia;
LUSC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg26647111	chr11:31128758	NA	-0.43	-6.12	-0.32	2.58e-9	Red blood cell count;
LUSC	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg08000102	chr2:233561755	GIGYF2	-0.71	-11.74	-0.54	6.86e-27	Coronary artery disease;
LUSC	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.05	0.36	1.05e-11	Neuroticism;
LUSC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg24060327	chr5:131705240	SLC22A5	-0.52	-8.62	-0.43	2.72e-16	Breast cancer;
LUSC	cis	rs727505	0.721	rs67607629	chr7:124765867	C/T	cg23710748	chr7:124431027	NA	-0.39	-6.96	-0.36	1.76e-11	Lewy body disease;
LUSC	cis	rs9925964	0.933	rs2303223	chr16:31075175	G/A	cg02466173	chr16:30829666	NA	0.36	6.49	0.33	3.09e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg19610905	chr11:61596333	FADS2	-0.54	-7.88	-0.4	4.52e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	trans	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04565464	chr8:145669602	NFKBIL2	0.43	7.14	0.36	5.92e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7605827	0.930	rs6431704	chr2:15592061	G/T	cg19274914	chr2:15703543	NA	0.47	8.96	0.44	2.36e-17	Educational attainment (years of education);
LUSC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05564831	chr3:52568323	NT5DC2	0.36	6.51	0.34	2.69e-10	Electroencephalogram traits;
LUSC	cis	rs11779988	0.528	rs208029	chr8:17840987	A/C	cg01800426	chr8:17659068	MTUS1	-0.55	-6.89	-0.35	2.81e-11	Breast cancer;
LUSC	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg01990225	chr2:97406019	LMAN2L	-1.05	-7.21	-0.37	3.67e-12	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg01802117	chr1:53393560	SCP2	0.4	6.6	0.34	1.64e-10	Monocyte count;
LUSC	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.44	-6.07	-0.32	3.49e-9	Neutrophil percentage of white cells;
LUSC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg05347473	chr6:146136440	FBXO30	0.64	10.89	0.51	7.72e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	11.75	0.54	6.72e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg06784218	chr1:46089804	CCDC17	0.55	11.18	0.52	7.53e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg03894339	chr8:19674705	INTS10	0.58	7.84	0.39	5.95e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg11645453	chr3:52864694	ITIH4	0.37	8.7	0.43	1.52e-16	Bipolar disorder;
LUSC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg22834771	chr12:69754056	YEATS4	-0.55	-8.28	-0.41	3.04e-15	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg21724239	chr8:58056113	NA	0.85	8.52	0.42	5.38e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.86	-11.07	-0.52	1.83e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg14092988	chr3:52407081	DNAH1	0.31	6.03	0.31	4.33e-9	Bipolar disorder;
LUSC	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-9.4	-0.46	9.02e-19	Morning vs. evening chronotype;
LUSC	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg06636551	chr8:101224915	SPAG1	0.38	7.02	0.36	1.23e-11	Atrioventricular conduction;
LUSC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-11.84	-0.54	3.05e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg14552801	chr7:65878734	NA	-0.43	-6.23	-0.32	1.43e-9	Aortic root size;
LUSC	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg14395844	chr9:139980277	LOC100289341;MAN1B1	-0.42	-6.48	-0.33	3.22e-10	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	0.56	8.69	0.43	1.63e-16	Breast cancer;
LUSC	cis	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg09904177	chr6:26538194	HMGN4	-0.74	-5.65	-0.3	3.43e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9815354	0.812	rs59138513	chr3:41908611	T/G	cg03022575	chr3:42003672	ULK4	0.83	8.67	0.43	1.88e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg24375607	chr4:120327624	NA	0.74	11.22	0.52	5.36e-25	Corneal astigmatism;
LUSC	trans	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.94	0.55	1.29e-27	Exhaled nitric oxide output;
LUSC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.57	0.34	1.98e-10	Lung cancer;
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.59	-8.33	-0.41	2.14e-15	Longevity;Endometriosis;
LUSC	cis	rs926938	0.563	rs360652	chr1:115445478	C/T	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.28	-0.32	1.05e-9	Autism;
LUSC	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg24675056	chr1:15929824	NA	0.44	7.77	0.39	1.01e-13	Systolic blood pressure;
LUSC	cis	rs34734847	0.842	rs556001	chr12:121152967	A/G	cg27246729	chr12:121163418	ACADS	0.42	6.62	0.34	1.4e-10	Mean corpuscular volume;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg23145915	chr12:58146234	CDK4	-0.4	-6.04	-0.31	4e-9	Hepatitis;
LUSC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg27284194	chr4:1044797	NA	-0.36	-5.81	-0.3	1.47e-8	Obesity-related traits;
LUSC	cis	rs7605827	0.930	rs2058867	chr2:15520153	T/C	cg19274914	chr2:15703543	NA	0.45	8.78	0.43	8.82e-17	Educational attainment (years of education);
LUSC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.71	10.02	0.48	7.57e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs6733011	0.518	rs12992214	chr2:99466337	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.66	-0.34	1.15e-10	Bipolar disorder;
LUSC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.32	-0.41	2.32e-15	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7527798	0.592	rs6684643	chr1:207846242	A/T	cg09232269	chr1:207846808	CR1L	-0.29	-6.16	-0.32	2.11e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg14830002	chr1:247616686	OR2B11	0.5	6.91	0.35	2.45e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg24399712	chr22:39784796	NA	-0.65	-12.1	-0.55	3.5e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs10266483	0.881	rs636242	chr7:63744755	A/T	cg24201672	chr7:64023550	ZNF680	-0.43	-5.66	-0.3	3.2e-8	Response to statin therapy;
LUSC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg27398817	chr8:82754497	SNX16	0.59	7.4	0.38	1.15e-12	Diastolic blood pressure;
LUSC	trans	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.12	-0.36	6.69e-12	Triglycerides;
LUSC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg25767906	chr1:53392781	SCP2	0.4	6.91	0.35	2.48e-11	Monocyte count;
LUSC	cis	rs4409675	0.556	rs2064710	chr1:28231154	G/A	cg23691781	chr1:28212827	C1orf38	0.31	7.48	0.38	6.53e-13	Corneal astigmatism;
LUSC	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg22029157	chr1:209979665	IRF6	0.76	9.85	0.47	2.97e-20	Cleft lip with or without cleft palate;
LUSC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg24503407	chr1:205819492	PM20D1	-0.54	-8.48	-0.42	7.63e-16	Menarche (age at onset);
LUSC	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.62	-0.57	4.01e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg13010199	chr12:38710504	ALG10B	-0.6	-10.25	-0.49	1.29e-21	Heart rate;
LUSC	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg27284194	chr4:1044797	NA	0.57	8.42	0.42	1.12e-15	Recombination rate (females);
LUSC	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17173187	chr15:85201210	NMB	0.48	9.16	0.45	5.35e-18	Schizophrenia;
LUSC	cis	rs72634258	0.945	rs67717282	chr1:8041290	C/T	cg26816564	chr1:7831052	VAMP3	0.47	5.98	0.31	5.67e-9	Inflammatory bowel disease;
LUSC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03517284	chr6:25882590	NA	-0.52	-9.7	-0.47	9.32e-20	Blood metabolite levels;
LUSC	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg03128534	chr1:43423976	SLC2A1	0.48	6.21	0.32	1.56e-9	Red cell distribution width;
LUSC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.24	-0.37	3.21e-12	Blood metabolite levels;
LUSC	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg02753203	chr1:228287806	NA	0.71	12.53	0.57	8.91e-30	Diastolic blood pressure;
LUSC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg06784218	chr1:46089804	CCDC17	0.48	9.49	0.46	4.5e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg24829409	chr8:58192753	C8orf71	-0.61	-7.49	-0.38	6.09e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.3	6.63	0.34	1.37e-10	Coronary artery disease;
LUSC	cis	rs6599077	0.802	rs17075542	chr3:40128458	A/G	cg13683864	chr3:40499215	RPL14	0.54	7.45	0.38	7.88e-13	Sleep-related phenotypes;
LUSC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg18904891	chr8:8559673	CLDN23	0.59	8.15	0.41	7.49e-15	Obesity-related traits;
LUSC	trans	rs1555543	0.538	rs7416802	chr1:96909292	G/C	cg10631902	chr5:14652156	NA	-0.49	-6.74	-0.35	6.84e-11	Body mass index;
LUSC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg16447950	chr5:562315	NA	-0.57	-7.04	-0.36	1.12e-11	Obesity-related traits;
LUSC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.83	0.63	1.37e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06850241	chr22:41845214	NA	0.31	5.73	0.3	2.23e-8	Vitiligo;
LUSC	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg00579200	chr11:133705235	NA	-0.39	-5.96	-0.31	6.35e-9	Childhood ear infection;
LUSC	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg12863693	chr15:85201151	NMB	0.33	6.83	0.35	4.06e-11	Schizophrenia;
LUSC	cis	rs55675132	0.596	rs1627205	chr1:115643166	A/G	cg01522456	chr1:115632236	TSPAN2	0.45	6.28	0.32	1.05e-9	Schizophrenia;
LUSC	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg23950597	chr19:37808831	NA	-0.65	-7.78	-0.39	8.97e-14	Coronary artery calcification;
LUSC	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.77	11.15	0.52	9.05e-25	Corneal astigmatism;
LUSC	cis	rs9322817	0.691	rs2034821	chr6:105219537	C/T	cg02098413	chr6:105308735	HACE1	-0.28	-5.7	-0.3	2.59e-8	Thyroid stimulating hormone;
LUSC	cis	rs10992471	0.580	rs1535756	chr9:95202032	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-7.89	-0.4	4.36e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.2	-0.37	3.94e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3847687	1.000	rs11061303	chr12:131526322	A/G	cg25772418	chr12:131519998	GPR133	-0.26	-5.76	-0.3	1.93e-8	Longevity;
LUSC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	5.97	0.31	6.12e-9	Breast cancer;
LUSC	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg21951975	chr1:209979733	IRF6	0.55	6.99	0.36	1.53e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs73206853	0.764	rs16940935	chr12:111107470	A/G	cg12870014	chr12:110450643	ANKRD13A	0.7	7.43	0.38	9.41e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.93	15.83	0.65	1.69e-42	Bladder cancer;
LUSC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.87	0.4	5.13e-14	Parkinson's disease;
LUSC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg20135002	chr11:47629003	NA	-0.48	-7.55	-0.38	4.19e-13	Subjective well-being;
LUSC	cis	rs10170310	0.938	rs11680891	chr2:139264454	T/G	cg10095539	chr2:139258744	SPOPL	0.34	5.92	0.31	8.17e-9	Response to antipsychotic treatment;
LUSC	cis	rs11166629	1.000	rs894349	chr8:135638055	T/C	cg27224718	chr8:135614730	ZFAT	0.67	11.29	0.53	3.03e-25	Smoking quantity;
LUSC	cis	rs16854884	0.657	rs13086088	chr3:143723942	G/A	cg06585982	chr3:143692056	C3orf58	0.5	8.1	0.41	1.06e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.51	-7.79	-0.39	8.27e-14	Lymphocyte counts;
LUSC	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.79	-0.43	8.21e-17	Response to antipsychotic treatment;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.86	15.57	0.65	1.7e-41	Menarche (age at onset);
LUSC	cis	rs4363385	0.818	rs11205164	chr1:152986023	A/T	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.09	-0.36	7.87e-12	Inflammatory skin disease;
LUSC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13770153	chr20:60521292	NA	0.73	9.83	0.47	3.36e-20	Body mass index;
LUSC	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg20503657	chr10:835505	NA	0.92	12.57	0.57	6.3e-30	Eosinophil percentage of granulocytes;
LUSC	cis	rs6736093	0.933	rs4848238	chr2:112754720	A/C	cg12686935	chr2:112915763	FBLN7	-0.37	-6.06	-0.31	3.73e-9	Coronary artery disease;
LUSC	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	6.29	0.33	9.9e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg26441486	chr22:50317300	CRELD2	0.42	6.67	0.34	1.09e-10	Schizophrenia;
LUSC	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-7.31	-0.37	1.97e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg21053147	chr12:120880522	NA	-0.53	-6.5	-0.33	2.96e-10	Type 1 diabetes nephropathy;
LUSC	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg01528321	chr10:82214614	TSPAN14	-0.88	-13.39	-0.59	5.17e-33	Post bronchodilator FEV1;
LUSC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg04622731	chr7:157956161	PTPRN2	-0.48	-8.54	-0.42	4.73e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.87	0.6	7.37e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg18402987	chr7:1209562	NA	0.71	7.88	0.4	4.57e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06858599	chr2:70520566	SNRPG	-0.45	-6.7	-0.34	8.82e-11	Electrocardiographic conduction measures;
LUSC	cis	rs6500395	1.000	rs1386040	chr16:48631207	A/G	cg04672837	chr16:48644449	N4BP1	0.49	7.34	0.37	1.65e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg05941027	chr17:61774174	LIMD2	0.23	6.37	0.33	6.34e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.33	0.33	7.87e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs500891	0.525	rs12198419	chr6:84105865	A/T	cg08257003	chr6:84140564	ME1	0.34	8.35	0.42	1.83e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg10253484	chr15:75165896	SCAMP2	-0.49	-7.29	-0.37	2.33e-12	Breast cancer;
LUSC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.69	-0.34	9.56e-11	Lung cancer;
LUSC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.66	8.97	0.44	2.22e-17	High light scatter reticulocyte count;
LUSC	trans	rs1973993	0.691	rs1980683	chr1:96890379	A/G	cg10631902	chr5:14652156	NA	0.6	10.73	0.51	2.8e-23	Weight;
LUSC	cis	rs4792901	0.765	rs12600416	chr17:41546558	A/G	cg22562494	chr17:41607896	ETV4	-0.34	-6.35	-0.33	7.12e-10	Dupuytren's disease;
LUSC	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.79	-0.39	8.63e-14	Blood metabolite levels;
LUSC	cis	rs7712401	0.601	rs398142	chr5:122345576	C/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.25	-0.45	2.68e-18	Mean platelet volume;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02576345	chr2:37311098	CCDC75;HEATR5B	-0.42	-6.04	-0.31	4.08e-9	Hepatitis;
LUSC	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg27247225	chr6:26970382	C6orf41	-0.46	-5.76	-0.3	1.91e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg15309053	chr8:964076	NA	0.4	7.97	0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-13.02	-0.58	1.23e-31	Platelet count;
LUSC	cis	rs3820928	0.874	rs4234063	chr2:227828335	A/T	cg11843606	chr2:227700838	RHBDD1	0.54	7.91	0.4	3.85e-14	Pulmonary function;
LUSC	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg05283184	chr6:79620031	NA	-0.57	-12.2	-0.56	1.41e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21659725	chr3:3221576	CRBN	0.63	10.37	0.49	5.03e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg21775007	chr8:11205619	TDH	0.6	9.2	0.45	3.93e-18	Retinal vascular caliber;
LUSC	trans	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg07393940	chr7:158741817	NA	0.36	6.43	0.33	4.41e-10	Life satisfaction;
LUSC	trans	rs6450176	0.633	rs10054623	chr5:53343821	A/G	cg12559925	chr2:235863365	SH3BP4	0.36	5.95	0.31	6.64e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LUSC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg19773385	chr1:10388646	KIF1B	-0.57	-9.79	-0.47	4.78e-20	Hepatocellular carcinoma;
LUSC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16405210	chr4:1374714	KIAA1530	-0.58	-9.57	-0.46	2.46e-19	Longevity;
LUSC	cis	rs2540226	0.874	rs11124691	chr2:39967768	T/A	cg23576258	chr2:39999331	THUMPD2	0.35	6.01	0.31	4.76e-9	Personality dimensions;
LUSC	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg05527609	chr1:210001259	C1orf107	0.9	11.69	0.54	1.04e-26	Orofacial clefts;
LUSC	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.49	-8.39	-0.42	1.37e-15	Coronary artery disease;
LUSC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.22	0.88	3.18e-111	Chronic sinus infection;
LUSC	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.8	-0.39	7.75e-14	Schizophrenia;
LUSC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg11502198	chr6:26597334	ABT1	0.64	10.07	0.48	5.3e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.35	6.95	0.36	1.98e-11	Hemoglobin concentration;
LUSC	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.48	-0.38	6.57e-13	Retinal vascular caliber;
LUSC	trans	rs62458065	0.713	rs921406	chr7:32486205	G/C	cg00845942	chr12:64062724	DPY19L2	-0.56	-6.74	-0.35	7.03e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7560272	0.723	rs6722867	chr2:73816285	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-7.33	-0.37	1.76e-12	Schizophrenia;
LUSC	cis	rs10838532	0.591	rs11038743	chr11:46029826	T/A	cg24204282	chr11:45944920	GYLTL1B	0.43	5.8	0.3	1.53e-8	Axial length;
LUSC	cis	rs11209002	0.614	rs4655673	chr1:67555018	T/C	cg02640540	chr1:67518911	SLC35D1	0.65	9.18	0.45	4.77e-18	Crohn's disease;
LUSC	cis	rs722599	1.000	rs722599	chr14:75327443	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.48	-7.57	-0.38	3.77e-13	IgG glycosylation;
LUSC	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg25206134	chr2:45395956	NA	0.57	6.52	0.34	2.6200000000000003e-10	Bipolar disorder;
LUSC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	28.75	0.84	2.4e-92	Chronic sinus infection;
LUSC	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.69	-12.08	-0.55	4.07e-28	White blood cell count (basophil);
LUSC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	11.4	0.53	1.17e-25	Colorectal cancer;
LUSC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.97	0.4	2.6e-14	Prudent dietary pattern;
LUSC	cis	rs669446	0.533	rs11210913	chr1:44222597	G/A	cg15962314	chr1:44399869	ARTN	0.24	5.7	0.3	2.57e-8	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs3087591	1.000	rs12600974	chr17:29589360	A/G	cg24425628	chr17:29625626	OMG;NF1	0.56	8.05	0.4	1.48e-14	Hip circumference;
LUSC	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg00129232	chr17:37814104	STARD3	-0.43	-6.32	-0.33	8.52e-10	Asthma;
LUSC	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.4	0.33	5.15e-10	IgG glycosylation;
LUSC	cis	rs4253772	0.938	rs77378083	chr22:46639386	G/A	cg09491104	chr22:46646882	C22orf40	-0.63	-6.55	-0.34	2.18e-10	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	11.93	0.55	1.4e-27	Exhaled nitric oxide output;
LUSC	cis	rs77633900	0.614	rs1905694	chr15:76951772	T/C	cg21673338	chr15:77095150	SCAPER	-0.78	-7.76	-0.39	1.06e-13	Non-glioblastoma glioma;Glioma;
LUSC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	0.91	14.91	0.63	6.85e-39	IgG glycosylation;
LUSC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.07	0.4	1.27e-14	Prudent dietary pattern;
LUSC	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg12365402	chr11:9010492	NRIP3	-0.46	-8.45	-0.42	9.12e-16	Hemoglobin concentration;
LUSC	cis	rs965469	0.901	rs6037563	chr20:3326568	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-5.65	-0.3	3.48e-8	IFN-related cytopenia;
LUSC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg19748678	chr4:122722346	EXOSC9	0.65	9.79	0.47	4.47e-20	Type 2 diabetes;
LUSC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg07061783	chr6:25882402	NA	-0.37	-5.87	-0.31	1.02e-8	Blood metabolite levels;
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.53	8.38	0.42	1.47e-15	Longevity;Endometriosis;
LUSC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	0.92	15.42	0.64	7.18e-41	Breast cancer;
LUSC	cis	rs72949976	0.707	rs10932473	chr2:214039057	C/T	cg08319019	chr2:214017104	IKZF2	-0.54	-7.29	-0.37	2.22e-12	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.26	0.32	1.17e-9	Lung cancer;
LUSC	cis	rs7589342	0.660	rs1897169	chr2:106397624	C/T	cg09152813	chr2:106391379	NCK2	0.42	6.71	0.34	8.55e-11	Addiction;
LUSC	cis	rs9323205	0.798	rs4465517	chr14:51673715	C/A	cg23942311	chr14:51606299	NA	0.38	7.65	0.39	2.15e-13	Cancer;
LUSC	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.67	11.24	0.52	4.42e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg07424592	chr7:64974309	NA	0.67	5.96	0.31	6.37e-9	Diabetic kidney disease;
LUSC	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.3	-6.25	-0.32	1.26e-9	Dupuytren's disease;
LUSC	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg00579200	chr11:133705235	NA	-0.39	-5.97	-0.31	6.21e-9	Childhood ear infection;
LUSC	cis	rs8017423	0.607	rs10142482	chr14:90848280	G/T	cg04374321	chr14:90722782	PSMC1	-0.4	-6.03	-0.31	4.25e-9	Mortality in heart failure;
LUSC	cis	rs4789693	0.518	rs6502117	chr17:80452592	G/C	cg04308225	chr17:80449738	NA	0.4	6.65	0.34	1.21e-10	Glucocorticoid-induced osteonecrosis;
LUSC	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg23649088	chr2:200775458	C2orf69	-0.54	-6.53	-0.34	2.39e-10	Schizophrenia;
LUSC	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-6.85	-0.35	3.67e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18187865	chr6:34857018	ANKS1A;TAF11	0.5	7.36	0.37	1.41e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10761482	0.861	rs2061491	chr10:62103675	T/C	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg17330251	chr7:94953956	PON1	0.54	10.63	0.5	6.41e-23	Paraoxonase activity;
LUSC	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	15.37	0.64	1.09e-40	Platelet count;
LUSC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg08888203	chr3:10149979	C3orf24	0.62	8.05	0.4	1.45e-14	Alzheimer's disease;
LUSC	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg01528321	chr10:82214614	TSPAN14	0.84	13.07	0.58	8.17e-32	Post bronchodilator FEV1;
LUSC	cis	rs2629540	0.882	rs10901813	chr10:126429875	G/A	cg08799069	chr10:126477246	METTL10	-0.68	-9.81	-0.47	3.92e-20	Cocaine dependence;
LUSC	cis	rs9326248	0.813	rs4938350	chr11:117022276	A/G	cg26566898	chr11:117069891	TAGLN	0.37	5.98	0.31	5.75e-9	Blood protein levels;
LUSC	cis	rs8077577	0.945	rs11656035	chr17:18086025	T/C	cg16794390	chr17:18148240	FLII	0.44	6.19	0.32	1.72e-9	Obesity-related traits;
LUSC	cis	rs2970818	0.831	rs2909380	chr12:4607342	A/T	cg11146114	chr12:4671731	NA	-0.59	-5.99	-0.31	5.58e-9	Phosphorus levels;
LUSC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.44	-0.5	2.98e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-7.22	-0.37	3.55e-12	Response to antipsychotic treatment;
LUSC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg03948781	chr1:205179583	DSTYK	0.3	5.65	0.3	3.5e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.54	-6.87	-0.35	3.15e-11	Allergy;
LUSC	cis	rs9463078	0.809	rs9369515	chr6:44812515	T/G	cg25276700	chr6:44698697	NA	-0.3	-5.85	-0.3	1.19e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.62	10.3	0.49	8.92e-22	Lymphocyte counts;
LUSC	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg03433033	chr1:76189801	ACADM	-0.4	-6.01	-0.31	4.82e-9	Daytime sleep phenotypes;
LUSC	cis	rs1506636	1.000	rs659416	chr7:123401764	A/G	cg03229431	chr7:123269106	ASB15	-0.65	-10.73	-0.51	2.86e-23	Plateletcrit;Platelet count;
LUSC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.68	0.3	2.88e-8	Menopause (age at onset);
LUSC	cis	rs6690583	1.000	rs2304641	chr1:85513398	C/T	cg22153463	chr1:85462885	MCOLN2	0.68	7.46	0.38	7.72e-13	Serum sulfate level;
LUSC	cis	rs7809950	0.954	rs12673675	chr7:107113220	T/C	cg23024343	chr7:107201750	COG5	-0.54	-8.73	-0.43	1.23e-16	Coronary artery disease;
LUSC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg23711669	chr6:146136114	FBXO30	0.9	17.22	0.69	5.08e-48	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.570	rs7315655	chr12:33912869	G/A	cg26384229	chr12:38710491	ALG10B	0.52	7.78	0.39	8.87e-14	Morning vs. evening chronotype;
LUSC	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg03264133	chr6:25882463	NA	0.35	5.91	0.31	8.64e-9	Blood metabolite levels;
LUSC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01341218	chr17:43662625	NA	-0.73	-10.48	-0.5	2.06e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs3916	0.911	rs2239758	chr12:121162637	A/G	cg27246729	chr12:121163418	ACADS	0.5	7.27	0.37	2.65e-12	Urinary metabolites (H-NMR features);
LUSC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg02079420	chr8:82753780	SNX16	-0.38	-5.79	-0.3	1.64e-8	Diastolic blood pressure;
LUSC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	9.37	0.46	1.13e-18	Motion sickness;
LUSC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg08859206	chr1:53392774	SCP2	0.52	9.02	0.44	1.49e-17	Monocyte count;
LUSC	cis	rs735860	0.737	rs2397139	chr6:53150804	C/G	cg10236188	chr6:53219634	NA	-0.38	-5.89	-0.31	9.37e-9	Glaucoma;
LUSC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06544989	chr22:39130855	UNC84B	0.33	5.81	0.3	1.46e-8	Menopause (age at onset);
LUSC	cis	rs6747952	0.899	rs2880132	chr2:239082976	G/A	cg17459225	chr2:239074497	NA	0.33	5.68	0.3	2.88e-8	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs17253792	0.822	rs75049893	chr14:56089158	A/G	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.72	-9.95	-0.48	1.38e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg00310523	chr12:86230176	RASSF9	0.45	8.27	0.41	3.14e-15	Major depressive disorder;
LUSC	trans	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg07393940	chr7:158741817	NA	-0.53	-8.68	-0.43	1.78e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg11752832	chr7:134001865	SLC35B4	0.6	9.38	0.46	1.04e-18	Mean platelet volume;
LUSC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg03188948	chr7:1209495	NA	0.67	7.1	0.36	7.38e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg21963583	chr11:68658836	MRPL21	0.57	8.5	0.42	6.54e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9487051	0.768	rs461487	chr6:109525504	A/G	cg00509249	chr6:109615579	CCDC162	-0.33	-5.73	-0.3	2.23e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.63	-8.64	-0.43	2.42e-16	Body mass index (adult);
LUSC	trans	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.72	0.54	8.02e-27	Mean corpuscular volume;
LUSC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg02153584	chr22:29168773	CCDC117	0.6	9.07	0.44	1.03e-17	Lymphocyte counts;
LUSC	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-6.0	-0.31	5.01e-9	Alzheimer's disease (survival time);
LUSC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00166722	chr3:10149974	C3orf24	0.61	8.47	0.42	7.9e-16	Alzheimer's disease;
LUSC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg21535247	chr6:8435926	SLC35B3	0.57	8.91	0.44	3.35e-17	Motion sickness;
LUSC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.27	0.45	2.34e-18	Prudent dietary pattern;
LUSC	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg22138327	chr13:27999177	GTF3A	0.7	9.58	0.46	2.23e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg02896835	chr1:92012615	NA	-0.53	-8.93	-0.44	2.88e-17	Breast cancer;
LUSC	cis	rs9395066	0.545	rs12209076	chr6:44833423	G/A	cg25276700	chr6:44698697	NA	0.3	6.05	0.31	3.87e-9	Height;
LUSC	cis	rs10979	0.603	rs9321920	chr6:143883588	C/G	cg25407410	chr6:143891975	LOC285740	-0.67	-8.99	-0.44	1.93e-17	Hypospadias;
LUSC	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	7.13	0.36	6.3e-12	Iron status biomarkers;
LUSC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.5	0.46	4.05e-19	Bipolar disorder;
LUSC	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.77	13.27	0.59	1.41e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg00810483	chr4:3375144	RGS12	0.31	5.95	0.31	6.64e-9	Serum sulfate level;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17322163	chr12:51632344	DAZAP2	-0.53	-6.88	-0.35	3.01e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg11693508	chr17:37793320	STARD3	0.65	7.95	0.4	2.86e-14	Bipolar disorder;
LUSC	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg20744362	chr22:50050164	C22orf34	0.37	6.93	0.35	2.19e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg11871910	chr12:69753446	YEATS4	0.44	5.69	0.3	2.81e-8	Response to diuretic therapy;
LUSC	cis	rs10934753	0.560	rs73859048	chr3:125931603	G/A	cg01346077	chr3:125931526	NA	0.53	10.13	0.48	3.35e-21	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg09238746	chr17:78121135	EIF4A3	0.56	8.39	0.42	1.4e-15	Yeast infection;
LUSC	cis	rs13401104	0.796	rs1530956	chr2:237111086	T/C	cg19324714	chr2:237145437	ASB18	0.43	5.79	0.3	1.6e-8	Educational attainment;
LUSC	cis	rs4474465	0.850	rs4565922	chr11:78260699	A/G	cg27205649	chr11:78285834	NARS2	0.52	6.2	0.32	1.7e-9	Alzheimer's disease (survival time);
LUSC	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg11901034	chr3:128598214	ACAD9	-0.4	-6.21	-0.32	1.57e-9	IgG glycosylation;
LUSC	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg12615879	chr12:58013172	SLC26A10	0.37	8.8	0.43	7.34e-17	Multiple sclerosis;
LUSC	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg05110241	chr16:68378359	PRMT7	-0.64	-7.0	-0.36	1.41e-11	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs5756813	1.000	rs1074407	chr22:38156183	T/A	cg19894588	chr14:64061835	NA	0.6	8.73	0.43	1.24e-16	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg22681709	chr2:178499509	PDE11A	-0.39	-5.66	-0.3	3.25e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg13319975	chr6:146136371	FBXO30	-0.51	-7.71	-0.39	1.42e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg04511125	chr2:88470314	THNSL2	-0.43	-6.48	-0.33	3.34e-10	Response to metformin (IC50);
LUSC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10802521	chr3:52805072	NEK4	-0.5	-7.75	-0.39	1.09e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.61	8.11	0.41	9.99e-15	High light scatter reticulocyte count;
LUSC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs921665	0.831	rs11690724	chr2:3188333	T/G	cg02624386	chr2:3182749	NA	0.59	6.59	0.34	1.68e-10	World class endurance athleticism;
LUSC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.74	-0.39	1.2e-13	Blood metabolite levels;
LUSC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg03859395	chr2:55845619	SMEK2	0.85	15.18	0.64	5.99e-40	Metabolic syndrome;
LUSC	cis	rs7075426	0.669	rs3858279	chr10:88257602	A/G	cg07322936	chr10:88137208	NA	0.45	6.45	0.33	3.84e-10	Migraine without aura;
LUSC	cis	rs6982240	0.514	rs1865247	chr8:142274654	A/T	cg00131261	chr8:142287264	NA	-0.36	-6.11	-0.32	2.84e-9	Tonsillectomy;
LUSC	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs41271473	0.950	rs72750042	chr1:228854138	T/C	cg10167378	chr1:228756711	NA	0.6	7.26	0.37	2.8e-12	Chronic lymphocytic leukemia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08436942	chr4:4249992	TMEM128	0.4	6.06	0.31	3.66e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.19	-0.37	4.35e-12	Bipolar disorder;
LUSC	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	0.97	10.96	0.51	4.58e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg03464685	chr11:125439445	EI24	1.26	15.45	0.65	5.01e-41	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12530845	0.945	rs73725433	chr7:135313251	C/T	cg23117316	chr7:135346802	PL-5283	-0.57	-9.93	-0.48	1.61e-20	Red blood cell traits;
LUSC	cis	rs4654899	0.865	rs72975078	chr1:21476196	A/G	cg01072550	chr1:21505969	NA	-0.51	-7.55	-0.38	4.19e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg11608241	chr8:8085544	FLJ10661	0.43	6.11	0.32	2.81e-9	Systolic blood pressure;
LUSC	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.54	0.57	8.04e-30	Lymphocyte percentage of white cells;
LUSC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg16606324	chr3:10149918	C3orf24	0.68	9.9	0.48	2.05e-20	Alzheimer's disease;
LUSC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06634786	chr22:41940651	POLR3H	-0.55	-6.39	-0.33	5.42e-10	Vitiligo;
LUSC	cis	rs367943	0.635	rs2222144	chr5:112712208	G/T	cg12552261	chr5:112820674	MCC	0.35	5.71	0.3	2.46e-8	Type 2 diabetes;
LUSC	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-6.19	-0.32	1.78e-9	Self-reported allergy;
LUSC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.81	-0.35	4.6e-11	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.65	10.81	0.51	1.44e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg11766577	chr21:47581405	C21orf56	0.5	7.62	0.38	2.61e-13	Testicular germ cell tumor;
LUSC	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg17517138	chr11:73019481	ARHGEF17	1.14	9.61	0.47	1.78e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs11229555	0.645	rs12802819	chr11:58174747	T/G	cg15696309	chr11:58395628	NA	-0.64	-7.96	-0.4	2.69e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs73200209	0.744	rs3214009	chr12:116486852	C/T	cg01776926	chr12:116560359	MED13L	0.49	5.68	0.3	2.97e-8	Total body bone mineral density;
LUSC	trans	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg07923666	chr12:49932857	KCNH3	-0.49	-6.12	-0.32	2.58e-9	Resting heart rate;
LUSC	cis	rs62577244	0.645	rs12001733	chr9:138431675	G/T	cg14097499	chr9:138441348	OBP2A	0.3	6.19	0.32	1.77e-9	Subcutaneous adipose tissue (sex interaction);Subcutaneous adipose tissue;
LUSC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg18721089	chr20:30220636	NA	-0.31	-5.69	-0.3	2.77e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs2692947	0.826	rs7423942	chr2:96645257	G/A	cg22654517	chr2:96458247	NA	0.33	6.83	0.35	4.07e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg20790798	chr5:1857306	NA	-0.46	-7.84	-0.39	6.2e-14	Cardiovascular disease risk factors;
LUSC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.39	0.37	1.21e-12	Schizophrenia;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg06603828	chr5:149829668	RPS14	0.43	6.06	0.31	3.64e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26314531	chr2:26401878	FAM59B	-0.66	-9.12	-0.45	7.39e-18	Gut microbiome composition (summer);
LUSC	trans	rs6600671	0.934	rs11249429	chr1:121291080	C/T	cg00646200	chr1:148855367	NA	-0.49	-7.75	-0.39	1.12e-13	Hip geometry;
LUSC	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg18132916	chr6:79620363	NA	-0.4	-6.08	-0.32	3.29e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg03676636	chr4:99064102	C4orf37	0.32	7.05	0.36	1.06e-11	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg13010199	chr12:38710504	ALG10B	0.55	8.36	0.42	1.74e-15	Morning vs. evening chronotype;
LUSC	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	1.18	14.03	0.61	1.78e-35	Arsenic metabolism;
LUSC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg03354898	chr7:1950403	MAD1L1	-0.37	-7.21	-0.37	3.84e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs9311676	1.000	rs9311676	chr3:58470351	A/G	cg26110898	chr3:58419937	PDHB	-0.39	-6.16	-0.32	2.08e-9	Systemic lupus erythematosus;
LUSC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg27170947	chr2:26402098	FAM59B	0.72	11.0	0.52	3.29e-24	Gut microbiome composition (summer);
LUSC	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg15628303	chr1:26608928	UBXN11	0.48	7.98	0.4	2.4e-14	Obesity-related traits;
LUSC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs3857536	0.740	rs9354392	chr6:66894555	G/T	cg07460842	chr6:66804631	NA	-0.47	-6.62	-0.34	1.41e-10	Blood trace element (Cu levels);
LUSC	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-6.06	-0.31	3.68e-9	Breast cancer;
LUSC	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg09092052	chr15:45571596	NA	-0.43	-6.03	-0.31	4.27e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg06552810	chr11:31128660	NA	0.41	7.3	0.37	2.08e-12	Red blood cell count;
LUSC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.46	6.9	0.35	2.65e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg16339924	chr4:17578868	LAP3	0.47	7.33	0.37	1.74e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Depression;
LUSC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg26039829	chr8:22132926	PIWIL2	0.42	7.58	0.38	3.4e-13	Hypertriglyceridemia;
LUSC	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Smoking initiation;
LUSC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg15103426	chr22:29168792	CCDC117	0.58	7.85	0.39	5.64e-14	Lymphocyte counts;
LUSC	cis	rs3736594	1.000	rs13013484	chr2:27988821	G/A	cg27432699	chr2:27873401	GPN1	-0.61	-8.77	-0.43	9.2e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg19052272	chr2:3704530	ALLC	-0.33	-6.37	-0.33	6.31e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg04920474	chr2:44395004	PPM1B	0.66	8.58	0.43	3.55e-16	Height;
LUSC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18932078	chr1:2524107	MMEL1	-0.31	-6.84	-0.35	3.79e-11	Ulcerative colitis;
LUSC	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22980127	chr19:33182716	NUDT19	0.9	13.02	0.58	1.21e-31	Red blood cell traits;
LUSC	trans	rs890100	0.673	rs11687295	chr2:56658548	T/C	cg01657744	chr10:88471748	LDB3	0.43	5.95	0.31	6.75e-9	Gut microbiome composition (summer);
LUSC	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	6.85	0.35	3.58e-11	Menarche (age at onset);
LUSC	cis	rs981844	0.740	rs6841173	chr4:154682563	A/G	cg14289246	chr4:154710475	SFRP2	-0.48	-6.93	-0.35	2.17e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg13722127	chr7:150037890	RARRES2	0.38	5.8	0.3	1.58e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.6	-0.43	3.16e-16	Total cholesterol levels;
LUSC	cis	rs1595825	0.891	rs6751690	chr2:198574523	G/A	cg00982548	chr2:198649783	BOLL	-0.53	-6.71	-0.34	8.13e-11	Ulcerative colitis;
LUSC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg24634471	chr8:143751801	JRK	0.59	9.01	0.44	1.66e-17	Schizophrenia;
LUSC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04267008	chr7:1944627	MAD1L1	0.57	8.76	0.43	1.03e-16	Bipolar disorder and schizophrenia;
LUSC	trans	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg25214090	chr10:38739885	LOC399744	0.49	7.17	0.37	4.76e-12	Corneal astigmatism;
LUSC	cis	rs9326248	0.520	rs10892060	chr11:116881662	C/A	cg26566898	chr11:117069891	TAGLN	0.33	6.25	0.32	1.29e-9	Blood protein levels;
LUSC	trans	rs1486139	0.967	rs10252585	chr7:46281477	A/G	cg17534202	chr9:96721102	NA	-0.34	-5.96	-0.31	6.36e-9	Select biomarker traits;
LUSC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg20887711	chr4:1340912	KIAA1530	-0.43	-6.47	-0.33	3.47e-10	Obesity-related traits;
LUSC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-8.35	-0.42	1.78e-15	Alzheimer's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24973791	chr3:136471376	STAG1	-0.46	-6.74	-0.35	6.87e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12940923	0.529	rs2240261	chr17:56381389	C/T	cg19466818	chr17:56409534	MIR142	0.3	5.88	0.31	1.02e-8	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg20891283	chr12:69753455	YEATS4	0.45	6.13	0.32	2.48e-9	Response to diuretic therapy;
LUSC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18404041	chr3:52824283	ITIH1	-0.58	-11.15	-0.52	9.39e-25	Bipolar disorder;
LUSC	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.43	-0.38	9.03e-13	Retinal vascular caliber;
LUSC	trans	rs6600671	0.934	rs11249348	chr1:121188302	T/C	cg00646200	chr1:148855367	NA	0.48	7.78	0.39	9.35e-14	Hip geometry;
LUSC	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08109568	chr15:31115862	NA	-0.59	-8.24	-0.41	3.89e-15	Huntington's disease progression;
LUSC	cis	rs2742417	1.000	rs2742421	chr3:45732515	G/T	cg04837898	chr3:45731254	SACM1L	0.38	6.17	0.32	1.93e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg03676636	chr4:99064102	C4orf37	0.34	7.56	0.38	3.98e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05165339	chr4:1420672	NA	0.28	6.24	0.32	1.34e-9	Longevity;
LUSC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg05896524	chr21:47604654	C21orf56	0.51	7.64	0.39	2.38e-13	Testicular germ cell tumor;
LUSC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg06008330	chr7:65541103	ASL	-0.41	-6.4	-0.33	5.13e-10	Aortic root size;
LUSC	cis	rs2354432	0.607	rs12404113	chr1:146750343	C/A	cg25205988	chr1:146714368	CHD1L	-0.99	-9.33	-0.45	1.49e-18	Mitochondrial DNA levels;
LUSC	cis	rs2282300	0.739	rs12577729	chr11:30257377	C/T	cg25418670	chr11:30344373	C11orf46	-0.65	-9.32	-0.45	1.69e-18	Morning vs. evening chronotype;
LUSC	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg11189052	chr15:85197271	WDR73	0.47	5.93	0.31	7.49e-9	Schizophrenia;
LUSC	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg03576123	chr11:487126	PTDSS2	-0.45	-5.81	-0.3	1.45e-8	Systemic lupus erythematosus;
LUSC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	0.64	13.28	0.59	1.29e-32	Prudent dietary pattern;
LUSC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10802521	chr3:52805072	NEK4	-0.49	-7.74	-0.39	1.2e-13	Electroencephalogram traits;
LUSC	cis	rs6728642	0.803	rs11891457	chr2:97632449	G/T	cg26665480	chr2:98280029	ACTR1B	-0.65	-5.77	-0.3	1.76e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs12681287	0.752	rs7822268	chr8:87306440	G/T	cg27223183	chr8:87520930	FAM82B	-0.47	-5.9	-0.31	8.75e-9	Caudate activity during reward;
LUSC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg05084668	chr3:125655381	ALG1L	-0.65	-9.92	-0.48	1.64e-20	Blood pressure (smoking interaction);
LUSC	trans	rs12614435	0.512	rs12693162	chr2:179488194	C/T	cg14011486	chr1:26737247	LIN28	0.44	5.95	0.31	6.61e-9	Atrial fibrillation;
LUSC	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg18190219	chr22:46762943	CELSR1	-0.55	-6.38	-0.33	5.88e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg13902645	chr11:5959945	NA	-0.59	-8.04	-0.4	1.59e-14	DNA methylation (variation);
LUSC	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.78	11.14	0.52	1.05e-24	Corneal astigmatism;
LUSC	cis	rs2540226	0.684	rs35761077	chr2:40006442	C/T	cg23576258	chr2:39999331	THUMPD2	0.34	5.82	0.3	1.4e-8	Personality dimensions;
LUSC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg13206674	chr6:150067644	NUP43	0.59	9.21	0.45	3.8e-18	Lung cancer;
LUSC	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg27411982	chr8:10470053	RP1L1	0.37	5.99	0.31	5.36e-9	Retinal vascular caliber;
LUSC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-9.75	-0.47	6.44e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.53	-0.38	4.89e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg04058563	chr4:185651563	MLF1IP	0.81	10.69	0.5	3.94e-23	Blood protein levels;
LUSC	cis	rs6005807	0.719	rs12169880	chr22:29054875	G/C	cg12565055	chr22:29076175	TTC28	0.54	5.86	0.31	1.12e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg08000102	chr2:233561755	GIGYF2	0.68	11.26	0.52	3.82e-25	Coronary artery disease;
LUSC	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg22709100	chr7:91322751	NA	0.47	6.87	0.35	3.1e-11	Breast cancer;
LUSC	cis	rs4478858	0.647	rs12752761	chr1:31710888	T/C	cg00250761	chr1:31883323	NA	-0.35	-8.36	-0.42	1.76e-15	Alcohol dependence;
LUSC	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-1.0	-14.11	-0.61	8.91e-36	Exhaled nitric oxide output;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg26745402	chr7:95402189	DYNC1I1	0.33	6.21	0.32	1.59e-9	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	0.63	13.44	0.59	3.14e-33	Prudent dietary pattern;
LUSC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg21545522	chr1:205238299	TMCC2	0.46	8.4	0.42	1.33e-15	Red blood cell count;
LUSC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.35	0.56	3.96e-29	Prudent dietary pattern;
LUSC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.33	0.53	2.21e-25	Menopause (age at onset);
LUSC	cis	rs10740039	0.883	rs1442540	chr10:62413306	C/T	cg18175470	chr10:62150864	ANK3	0.44	6.66	0.34	1.16e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg07936489	chr17:37558343	FBXL20	0.72	10.11	0.48	3.74e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs7119	0.604	rs1055691	chr15:77864625	G/C	cg27398640	chr15:77910606	LINGO1	0.35	7.85	0.39	5.86e-14	Type 2 diabetes;
LUSC	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg23711669	chr6:146136114	FBXO30	0.88	16.36	0.67	1.31e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11648785	0.810	rs4354938	chr16:90098828	G/C	cg16611967	chr16:90144006	NA	0.48	6.22	0.32	1.45e-9	Tanning;
LUSC	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	-0.47	-7.53	-0.38	4.63e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.28	0.59	1.28e-32	Cognitive test performance;
LUSC	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	11.94	0.55	1.3e-27	Mean corpuscular hemoglobin;
LUSC	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg26395211	chr5:140044315	WDR55	-0.37	-5.7	-0.3	2.69e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs343496	0.756	rs376690	chr9:6134926	C/T	cg15581944	chr11:35551852	NA	-0.33	-6.02	-0.31	4.52e-9	Asthma and hay fever;
LUSC	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.45	6.87	0.35	3.16e-11	Colorectal cancer;
LUSC	cis	rs7843479	1.000	rs727694	chr8:21849962	T/C	cg17168535	chr8:21777572	XPO7	0.65	9.66	0.47	1.23e-19	Mean corpuscular volume;
LUSC	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17691542	chr6:26056736	HIST1H1C	0.83	11.18	0.52	7.24e-25	Iron status biomarkers;
LUSC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.37	5.65	0.3	3.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15557168	chr22:42548783	NA	-0.45	-7.58	-0.38	3.38e-13	Cognitive function;
LUSC	trans	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg05267876	chr1:229644265	NUP133	-0.56	-6.08	-0.32	3.25e-9	Lung cancer in ever smokers;
LUSC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08677398	chr8:58056175	NA	0.58	7.13	0.36	6.42e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.47	-5.91	-0.31	8.29e-9	Neutrophil percentage of white cells;
LUSC	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg07169764	chr2:136633963	MCM6	-0.73	-9.84	-0.47	3.16e-20	Mosquito bite size;
LUSC	cis	rs13315871	0.929	rs35004361	chr3:58313394	T/C	cg20936604	chr3:58311152	NA	-0.73	-7.09	-0.36	7.97e-12	Cholesterol, total;
LUSC	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07080220	chr10:102295463	HIF1AN	0.67	8.77	0.43	8.99e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg07393940	chr7:158741817	NA	-0.36	-6.46	-0.33	3.76e-10	Life satisfaction;
LUSC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.61	0.38	2.74e-13	Bipolar disorder;
LUSC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg13319975	chr6:146136371	FBXO30	0.5	7.59	0.38	3.24e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2692947	0.760	rs2438924	chr2:96645069	A/G	cg22654517	chr2:96458247	NA	0.33	6.83	0.35	4.07e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs12155623	0.603	rs2203065	chr8:49881987	A/G	cg22283653	chr8:49824208	NA	-0.3	-6.16	-0.32	2.06e-9	Sudden cardiac arrest;
LUSC	cis	rs243505	1.000	rs243521	chr7:148421571	T/C	cg09806900	chr7:148480153	CUL1	-0.48	-6.88	-0.35	3.02e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs17253792	0.822	rs17253716	chr14:56153661	G/C	cg01858014	chr14:56050164	KTN1	-0.82	-6.77	-0.35	5.9e-11	Putamen volume;
LUSC	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	0.59	9.29	0.45	2.06e-18	Breast cancer;
LUSC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg27068330	chr11:65405492	SIPA1	-0.46	-5.96	-0.31	6.51e-9	Breast cancer;
LUSC	cis	rs6580649	0.941	rs7310579	chr12:48427523	G/A	cg24011408	chr12:48396354	COL2A1	-0.52	-6.9	-0.35	2.59e-11	Lung cancer;
LUSC	cis	rs2286503	0.839	rs4722188	chr7:22860211	C/G	cg11367502	chr7:22862612	TOMM7	0.44	6.01	0.31	4.83e-9	Fibrinogen;
LUSC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg20573242	chr4:122745356	CCNA2	0.64	9.22	0.45	3.55e-18	Type 2 diabetes;
LUSC	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg09654669	chr8:57350985	NA	-0.56	-7.78	-0.39	9.24e-14	Obesity-related traits;
LUSC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg06212747	chr3:49208901	KLHDC8B	0.42	5.73	0.3	2.2e-8	Parkinson's disease;
LUSC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg24110177	chr3:50126178	RBM5	0.53	8.57	0.42	3.91e-16	Menarche (age at onset);
LUSC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg08847533	chr14:75593920	NEK9	0.85	16.21	0.66	5.49e-44	Height;
LUSC	cis	rs2359239	0.519	rs8007145	chr14:75185748	T/A	cg06637938	chr14:75390232	RPS6KL1	0.42	6.22	0.32	1.47e-9	Neuroticism (multi-trait analysis);
LUSC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	9.64	0.47	1.43e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg09904177	chr6:26538194	HMGN4	-0.63	-5.8	-0.3	1.53e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	8.08	0.4	1.22e-14	Lung cancer;
LUSC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg11663144	chr21:46675770	NA	-0.4	-6.9	-0.35	2.55e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.65	0.34	1.18e-10	Height;
LUSC	cis	rs78572108	0.858	rs13409333	chr2:42265073	A/G	cg00607755	chr2:42274082	PKDCC	0.37	6.56	0.34	2.03e-10	Total body bone mineral density;
LUSC	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg06145435	chr7:1022769	CYP2W1	0.35	5.75	0.3	1.99e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.61	10.07	0.48	5.1e-21	Age at first birth;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19345165	chr11:47600677	NDUFS3;KBTBD4	-0.42	-6.11	-0.32	2.81e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg23625390	chr15:77176239	SCAPER	-0.62	-9.51	-0.46	3.79e-19	Blood metabolite levels;
LUSC	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg24881330	chr22:46731750	TRMU	0.83	7.49	0.38	6.37e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.5	9.29	0.45	2.1e-18	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs721399	0.539	rs12676857	chr8:18266572	T/C	cg18736775	chr8:18248649	NAT2	-0.6	-7.09	-0.36	7.9e-12	Blood metabolite levels;
LUSC	cis	rs1595825	0.891	rs1992313	chr2:198896766	T/C	cg00982548	chr2:198649783	BOLL	-0.54	-6.89	-0.35	2.72e-11	Ulcerative colitis;
LUSC	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg13683864	chr3:40499215	RPL14	0.73	12.36	0.56	3.58e-29	Renal cell carcinoma;
LUSC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	16.23	0.66	4.25e-44	Homoarginine levels;
LUSC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03934478	chr11:495069	RNH1	0.9	10.5	0.5	1.76e-22	Body mass index;
LUSC	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg13010199	chr12:38710504	ALG10B	0.7	10.77	0.51	1.97e-23	Bladder cancer;
LUSC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg00750074	chr16:89608354	SPG7	0.44	7.66	0.39	1.99e-13	Multiple myeloma (IgH translocation);
LUSC	trans	rs10885582	0.846	rs4752016	chr10:116348539	C/T	cg01002288	chr1:43166549	YBX1	-0.36	-6.09	-0.32	3.15e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs73416724	1.000	rs111882537	chr6:43366075	C/A	cg26312998	chr6:43337775	ZNF318	0.53	6.24	0.32	1.35e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2294693	0.945	rs9349175	chr6:40982401	T/C	cg14769373	chr6:40998127	UNC5CL	-0.55	-7.59	-0.38	3.28e-13	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.3e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-1.0	-14.65	-0.63	7.31e-38	Initial pursuit acceleration;
LUSC	cis	rs7712401	0.601	rs35334805	chr5:122335261	G/A	cg19077854	chr5:122220652	SNX24	-0.43	-9.27	-0.45	2.29e-18	Mean platelet volume;
LUSC	cis	rs9616064	0.889	rs5767287	chr22:46996179	G/A	cg25730555	chr22:47059586	GRAMD4	0.43	6.53	0.34	2.47e-10	Urate levels in obese individuals;
LUSC	cis	rs4356932	1.000	rs6532111	chr4:76955914	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs7091068	0.616	rs7084701	chr10:95482249	A/G	cg20715218	chr10:95462985	C10orf4	0.63	7.03	0.36	1.14e-11	Urinary tract infection frequency;
LUSC	cis	rs12464559	0.522	rs7583060	chr2:152620943	C/A	cg01189475	chr2:152685088	ARL5A	0.64	6.99	0.36	1.49e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg10840412	chr1:235813424	GNG4	0.6	7.74	0.39	1.21e-13	Bipolar disorder;
LUSC	cis	rs965513	1.000	rs7020976	chr9:100547972	T/C	cg13688889	chr9:100608707	NA	-0.54	-8.05	-0.4	1.45e-14	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.98	0.44	2e-17	Lung cancer in ever smokers;
LUSC	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg08085267	chr17:45401833	C17orf57	0.46	6.71	0.34	8.42e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs367615	0.552	rs3828603	chr5:108712068	G/C	cg17395555	chr5:108820864	NA	-0.47	-8.25	-0.41	3.76e-15	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs4363385	0.693	rs1933384	chr1:152959488	A/T	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.44	-0.38	8.86e-13	Inflammatory skin disease;
LUSC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg12310025	chr6:25882481	NA	0.4	6.84	0.35	3.75e-11	Blood metabolite levels;
LUSC	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg26384229	chr12:38710491	ALG10B	-0.56	-8.33	-0.41	2.11e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4792901	0.765	rs9892162	chr17:41600800	T/C	cg22562494	chr17:41607896	ETV4	-0.33	-6.05	-0.31	3.8e-9	Dupuytren's disease;
LUSC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23158103	chr7:148848205	ZNF398	-0.42	-6.38	-0.33	5.75e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg19468946	chr17:37922297	IKZF3	-0.38	-6.07	-0.32	3.47e-9	Self-reported allergy;
LUSC	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg12257692	chr3:49977190	RBM6	-0.21	-5.68	-0.3	2.99e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg13451222	chr11:65405525	SIPA1	0.46	5.75	0.3	2.02e-8	Blood pressure (age interaction);
LUSC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg13119609	chr19:45449297	APOC2	0.47	9.46	0.46	5.65e-19	Blood protein levels;
LUSC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.24	14.24	0.61	2.72e-36	Diabetic kidney disease;
LUSC	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.73	10.5	0.5	1.72e-22	Corneal astigmatism;
LUSC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg00376283	chr12:123451042	ABCB9	0.8	12.54	0.57	8.08e-30	Platelet count;
LUSC	cis	rs7177699	0.557	rs4389113	chr15:79121739	G/A	cg00540400	chr15:79124168	NA	-0.48	-8.23	-0.41	4.2e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg19792802	chr11:65647270	CTSW	0.41	6.23	0.32	1.38e-9	Crohn's disease;
LUSC	cis	rs56283067	0.886	rs2023311	chr6:44678306	A/T	cg20913747	chr6:44695427	NA	-0.45	-7.54	-0.38	4.5e-13	Total body bone mineral density;
LUSC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg12963246	chr6:28129442	ZNF389	0.48	6.63	0.34	1.34e-10	Depression;
LUSC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg16606324	chr3:10149918	C3orf24	0.68	9.9	0.48	2.05e-20	Alzheimer's disease;
LUSC	cis	rs7246967	0.673	rs6511374	chr19:22866370	T/A	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	trans	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg18335740	chr13:41363409	SLC25A15	0.54	8.86	0.44	5e-17	Lewy body disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04226401	chr1:100818170	CDC14A	0.45	6.71	0.34	8.22e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg04727924	chr7:799746	HEATR2	-0.58	-6.23	-0.32	1.42e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg09626299	chr10:82213104	TSPAN14	-0.2	-5.92	-0.31	8.16e-9	Post bronchodilator FEV1;
LUSC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.77	10.99	0.52	3.55e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs62238980	0.614	rs117002438	chr22:32371395	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg00310523	chr12:86230176	RASSF9	0.52	9.54	0.46	3e-19	Major depressive disorder;
LUSC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg02153584	chr22:29168773	CCDC117	0.66	10.6	0.5	8.09e-23	Lymphocyte counts;
LUSC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg02038168	chr22:39784481	NA	-0.45	-6.83	-0.35	4.02e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg06060754	chr5:176797920	RGS14	-0.54	-8.72	-0.43	1.33e-16	Urinary electrolytes (magnesium/calcium ratio);
LUSC	cis	rs7804356	0.954	rs3801808	chr7:26896555	T/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.23	-0.32	1.41e-9	Type 1 diabetes;
LUSC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.48e-24	Aortic root size;
LUSC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.53	-0.38	4.89e-13	Aortic root size;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14956593	chr14:24685421	MDP1	-0.45	-6.02	-0.31	4.54e-9	Hepatitis;
LUSC	cis	rs4363385	0.791	rs3120744	chr1:153010330	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.2	-0.37	4.14e-12	Inflammatory skin disease;
LUSC	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg11812906	chr14:75593930	NEK9	0.65	10.77	0.51	2.06e-23	Height;
LUSC	cis	rs9811920	0.809	rs6802817	chr3:99779264	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.44	-6.53	-0.34	2.46e-10	Axial length;
LUSC	cis	rs6496044	0.568	rs6496040	chr15:86064129	C/G	cg13263323	chr15:86062960	AKAP13	-0.38	-6.24	-0.32	1.36e-9	Interstitial lung disease;
LUSC	cis	rs897984	0.609	rs72800847	chr16:31022639	G/A	cg02466173	chr16:30829666	NA	-0.55	-10.14	-0.49	2.99e-21	Dementia with Lewy bodies;
LUSC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03526776	chr6:41159608	TREML2	-0.51	-10.63	-0.5	6.47e-23	Alzheimer's disease (late onset);
LUSC	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg09184832	chr6:79620586	NA	-0.36	-5.72	-0.3	2.35e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2200578	1.000	rs12053519	chr2:99875018	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	6.48	0.33	3.26e-10	IgG glycosylation;
LUSC	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.64	-0.34	1.25e-10	Reticulocyte count;
LUSC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg16989719	chr2:238392110	NA	-0.42	-7.1	-0.36	7.39e-12	Prostate cancer;
LUSC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-7.93	-0.4	3.38e-14	Chronic sinus infection;
LUSC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg04756594	chr16:24857601	SLC5A11	0.47	7.02	0.36	1.21e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg08079166	chr15:68083412	MAP2K5	0.41	7.5	0.38	5.85e-13	Restless legs syndrome;
LUSC	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg13902645	chr11:5959945	NA	-0.53	-7.45	-0.38	8.17e-13	DNA methylation (variation);
LUSC	cis	rs7727544	0.582	rs3805681	chr5:131537860	T/G	cg24060327	chr5:131705240	SLC22A5	-0.35	-5.69	-0.3	2.8e-8	Blood metabolite levels;
LUSC	cis	rs16854884	0.632	rs10513234	chr3:143670957	A/G	cg06585982	chr3:143692056	C3orf58	-0.49	-7.55	-0.38	4.09e-13	Economic and political preferences (feminism/equality);
LUSC	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg03342759	chr3:160939853	NMD3	-0.48	-8.03	-0.4	1.68e-14	Morning vs. evening chronotype;
LUSC	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	6.5	0.33	2.99e-10	Height;
LUSC	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg08558340	chr7:100472263	SRRT	0.5	6.23	0.32	1.37e-9	Resting heart rate;
LUSC	cis	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg06521331	chr12:34319734	NA	-0.39	-6.71	-0.34	8.55e-11	Morning vs. evening chronotype;
LUSC	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs477692	0.967	rs496692	chr10:131429100	C/T	cg11019008	chr10:131425282	MGMT	0.4	6.0	0.31	5.17e-9	Response to temozolomide;
LUSC	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.73	12.11	0.55	3.07e-28	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.76	-0.68	3.56e-46	Monocyte count;
LUSC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.37	5.92	0.31	7.78e-9	Electroencephalogram traits;
LUSC	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg18477163	chr1:228402036	OBSCN	0.63	12.0	0.55	8e-28	Diastolic blood pressure;
LUSC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg12257692	chr3:49977190	RBM6	-0.25	-6.77	-0.35	5.69e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs11971779	0.680	rs6965212	chr7:139026465	G/T	cg23387468	chr7:139079360	LUC7L2	0.42	6.13	0.32	2.53e-9	Diisocyanate-induced asthma;
LUSC	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg07148914	chr20:33460835	GGT7	0.56	8.53	0.42	5.25e-16	Height;
LUSC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg22535103	chr8:58192502	C8orf71	-0.78	-7.98	-0.4	2.41e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg21433313	chr16:3507492	NAT15	0.41	5.75	0.3	2.02e-8	Body mass index (adult);
LUSC	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs6977660	0.714	rs728156	chr7:19826309	G/C	cg05791153	chr7:19748676	TWISTNB	0.67	6.93	0.35	2.24e-11	Thyroid stimulating hormone;
LUSC	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg09307838	chr4:120376055	NA	0.5	7.53	0.38	4.84e-13	Diastolic blood pressure;
LUSC	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg17173187	chr15:85201210	NMB	0.5	9.39	0.46	9.74e-19	Schizophrenia;
LUSC	cis	rs174775	0.513	rs3788411	chr22:29728783	T/C	cg07256473	chr22:29710276	RASL10A	-0.44	-8.1	-0.41	1.02e-14	Immature fraction of reticulocytes;
LUSC	trans	rs2864527	0.522	rs8098544	chr18:9219317	C/T	cg19809734	chr13:112772980	NA	-0.58	-6.0	-0.31	5.04e-9	Dental caries;
LUSC	cis	rs9534288	0.830	rs1126365	chr13:46633196	T/A	cg15192986	chr13:46630673	CPB2	-0.8	-12.69	-0.57	2.14e-30	Blood protein levels;
LUSC	trans	rs2679649	1.000	rs2816121	chr6:122362907	C/T	cg00167820	chr8:131663355	NA	0.53	6.2	0.32	1.68e-9	Subcutaneous adipose tissue;
LUSC	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.02	-21.37	-0.76	1.74e-64	Ulcerative colitis;
LUSC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07677032	chr17:61819896	STRADA	0.53	8.93	0.44	2.87e-17	Prudent dietary pattern;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01778114	chr2:216877947	MREG	-0.44	-6.44	-0.33	4.24e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg08999081	chr20:33150536	PIGU	0.51	9.82	0.47	3.67e-20	Coronary artery disease;
LUSC	trans	rs72674100	1.000	rs72874648	chr4:97964979	A/G	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg21573476	chr21:45109991	RRP1B	-0.36	-5.74	-0.3	2.14e-8	Mean corpuscular volume;
LUSC	cis	rs6674176	0.518	rs917294	chr1:44249485	A/G	cg12908607	chr1:44402522	ARTN	-0.4	-6.08	-0.32	3.33e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg27432699	chr2:27873401	GPN1	0.83	15.76	0.65	3.06e-42	Oral cavity cancer;
LUSC	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg26924012	chr15:45694286	SPATA5L1	0.78	12.31	0.56	5.66e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2219968	0.923	rs35703732	chr8:78953269	C/T	cg00738934	chr8:78996279	NA	0.34	6.08	0.32	3.2e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg23625390	chr15:77176239	SCAPER	0.46	7.02	0.36	1.22e-11	Blood metabolite levels;
LUSC	cis	rs12286929	0.644	rs9645660	chr11:115081563	C/T	cg04055981	chr11:115044050	NA	0.39	6.96	0.36	1.77e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg02023728	chr11:77925099	USP35	0.49	7.07	0.36	9.23e-12	Testicular germ cell tumor;
LUSC	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg18132916	chr6:79620363	NA	-0.38	-5.84	-0.3	1.23e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-6.06	-0.31	3.59e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11955175	1.000	rs75929994	chr5:40821816	T/C	cg04002187	chr5:40835754	RPL37	0.71	5.84	0.3	1.27e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg08499158	chr17:42289980	UBTF	0.5	7.95	0.4	2.81e-14	Total body bone mineral density;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg15783272	chr19:50980145	C19orf63;FAM71E1	0.39	6.15	0.32	2.17e-9	Mosquito bite size;
LUSC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-13.7	-0.6	3.38e-34	Coronary artery disease;
LUSC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg17261708	chr5:176794207	RGS14	0.34	6.05	0.31	3.79e-9	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.7	11.44	0.53	8.42e-26	Blood protein levels;
LUSC	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg13010344	chr12:123464640	ARL6IP4	0.4	5.93	0.31	7.51e-9	Neutrophil percentage of white cells;
LUSC	trans	rs2288327	1.000	rs890578	chr2:179414633	G/T	cg14011486	chr1:26737247	LIN28	0.47	6.13	0.32	2.47e-9	Atrial fibrillation;
LUSC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.15	16.21	0.66	5.28e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs7680126	0.596	rs10805364	chr4:10275518	A/G	cg26043149	chr18:55253948	FECH	-0.49	-6.24	-0.32	1.3e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUSC	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg16230307	chr14:35515116	FAM177A1	-0.8	-10.12	-0.48	3.56e-21	Psoriasis;
LUSC	cis	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg24375607	chr4:120327624	NA	-0.47	-7.24	-0.37	3.13e-12	Diastolic blood pressure;
LUSC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg09359103	chr1:154839909	KCNN3	-0.43	-8.18	-0.41	5.91e-15	Schizophrenia;
LUSC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08045932	chr20:61659980	NA	0.58	10.21	0.49	1.78e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs909341	0.909	rs1291207	chr20:62329412	G/A	cg09650180	chr20:62225654	GMEB2	-0.46	-5.98	-0.31	5.88e-9	Atopic dermatitis;
LUSC	cis	rs2346177	0.875	rs12986585	chr2:46644121	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-8.59	-0.43	3.29e-16	HDL cholesterol;
LUSC	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg24675056	chr1:15929824	NA	0.43	7.41	0.38	1.02e-12	Systolic blood pressure;
LUSC	cis	rs4704187	0.663	rs4704189	chr5:74487375	A/C	cg03227963	chr5:74354835	NA	0.3	6.54	0.34	2.32e-10	Response to amphetamines;
LUSC	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg04374321	chr14:90722782	PSMC1	-0.42	-6.39	-0.33	5.65e-10	Mortality in heart failure;
LUSC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22433210	chr17:43662623	NA	-0.72	-10.47	-0.5	2.31e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg13565492	chr6:43139072	SRF	-0.57	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12900413	0.603	rs12905689	chr15:90301343	G/A	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.56e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.91e-9	Menopause (age at onset);
LUSC	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg17173187	chr15:85201210	NMB	0.51	9.66	0.47	1.24e-19	Schizophrenia;
LUSC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg22638593	chr5:131593259	PDLIM4	0.49	7.33	0.37	1.69e-12	Acylcarnitine levels;
LUSC	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg23992470	chr4:843637	GAK	0.62	6.16	0.32	2.11e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs7584330	0.554	rs74001383	chr2:238424418	T/C	cg14458575	chr2:238380390	NA	0.45	5.86	0.31	1.1e-8	Prostate cancer;
LUSC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	12.37	0.56	3.34e-29	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6931421	0.800	rs12662365	chr6:80905389	T/A	cg08355045	chr6:80787529	NA	0.58	9.13	0.45	6.74e-18	Sitting height ratio;
LUSC	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-0.56	-8.65	-0.43	2.28e-16	Breast cancer;
LUSC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-0.7	-11.14	-0.52	1.03e-24	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg23691781	chr1:28212827	C1orf38	0.32	7.6	0.38	3.06e-13	Corneal astigmatism;
LUSC	cis	rs34375054	0.573	rs12579211	chr12:125647752	C/T	cg25124228	chr12:125621409	AACS	-0.52	-6.75	-0.35	6.75e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7605827	0.626	rs2031011	chr2:15548390	A/G	cg19274914	chr2:15703543	NA	0.42	7.51	0.38	5.6e-13	Educational attainment (years of education);
LUSC	trans	rs11696501	0.739	rs2235600	chr20:44238299	T/G	cg03272292	chr12:48577362	C12orf68	0.53	6.29	0.33	1.01e-9	Brain structure;
LUSC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg13010199	chr12:38710504	ALG10B	0.68	11.24	0.52	4.28e-25	Heart rate;
LUSC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08859206	chr1:53392774	SCP2	-0.67	-12.74	-0.57	1.4e-30	Monocyte count;
LUSC	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg22823121	chr1:150693482	HORMAD1	0.6	9.28	0.45	2.21e-18	Tonsillectomy;
LUSC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	10.93	0.51	5.65e-24	Bone mineral density;
LUSC	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg23172400	chr8:95962367	TP53INP1	-0.35	-6.5	-0.34	2.85e-10	Type 2 diabetes;
LUSC	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg23029597	chr12:123009494	RSRC2	0.76	9.32	0.45	1.64e-18	Body mass index;
LUSC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11764359	chr7:65958608	NA	0.62	9.47	0.46	5.16e-19	Calcium levels;
LUSC	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg22676075	chr6:135203613	NA	0.47	7.31	0.37	1.95e-12	Red blood cell count;
LUSC	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg08917208	chr2:24149416	ATAD2B	1.01	10.61	0.5	7.29e-23	Lymphocyte counts;
LUSC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.6	10.9	0.51	7.13e-24	Bone mineral density;
LUSC	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg07169764	chr2:136633963	MCM6	1.04	13.69	0.6	3.6e-34	Corneal structure;
LUSC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03352830	chr11:487213	PTDSS2	0.69	8.67	0.43	1.9e-16	Body mass index;
LUSC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg20821713	chr7:1055600	C7orf50	-0.38	-5.83	-0.3	1.29e-8	Longevity;Endometriosis;
LUSC	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.81	-13.69	-0.6	3.55e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11077998	0.840	rs9910991	chr17:80481193	G/A	cg10255544	chr17:80519551	FOXK2	0.41	6.57	0.34	1.92e-10	Reticulocyte fraction of red cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11276198	chr12:25404189	KRAS	-0.42	-6.37	-0.33	6.13e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg02176678	chr2:219576539	TTLL4	0.6	10.75	0.51	2.5e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg02079420	chr8:82753780	SNX16	-0.42	-7.2	-0.37	4.14e-12	Diastolic blood pressure;
LUSC	cis	rs7572644	0.766	rs11902158	chr2:28086765	A/G	cg27432699	chr2:27873401	GPN1	0.51	6.42	0.33	4.57e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18357526	chr6:26021779	HIST1H4A	0.41	6.65	0.34	1.2e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4776059	1.000	rs4776068	chr15:52947401	G/A	cg22715398	chr15:52968154	KIAA1370	-0.69	-9.99	-0.48	9.68e-21	Schizophrenia;
LUSC	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg10978503	chr1:24200527	CNR2	0.54	13.3	0.59	1.11e-32	Immature fraction of reticulocytes;
LUSC	cis	rs500891	0.533	rs6903322	chr6:84168968	C/T	cg08257003	chr6:84140564	ME1	0.35	8.63	0.43	2.58e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs7246967	0.673	rs28649847	chr19:22811540	G/T	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg15997130	chr1:24165203	NA	-0.5	-8.21	-0.41	4.77e-15	Immature fraction of reticulocytes;
LUSC	cis	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg08112188	chr17:47440006	ZNF652	1.39	11.33	0.53	2.06e-25	Prostate cancer;
LUSC	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.9	-0.35	2.55e-11	Alcohol dependence;
LUSC	cis	rs258324	0.790	rs258318	chr16:89732050	T/C	cg26513180	chr16:89883248	FANCA	-0.75	-6.74	-0.35	7.13e-11	Height;
LUSC	cis	rs2564921	0.570	rs3821831	chr3:52853401	C/T	cg11645453	chr3:52864694	ITIH4	-0.27	-6.08	-0.32	3.35e-9	Height;
LUSC	cis	rs11264799	0.520	rs849828	chr1:157545047	A/G	cg18268488	chr1:157545234	FCRL4	0.39	7.69	0.39	1.62e-13	IgA nephropathy;
LUSC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg21724239	chr8:58056113	NA	0.78	8.56	0.42	4.04e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.74	0.35	7.12e-11	Platelet count;
LUSC	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.73	0.35	7.39e-11	Corneal astigmatism;
LUSC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg08807101	chr21:30365312	RNF160	0.65	9.74	0.47	6.74e-20	Selective IgA deficiency;
LUSC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	cis	rs806215	1.000	rs806216	chr7:127237862	C/A	cg25922125	chr7:127225783	GCC1	-0.58	-7.05	-0.36	1.03e-11	Type 2 diabetes;
LUSC	trans	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg04995722	chr7:26192034	NFE2L3	-0.38	-6.28	-0.32	1.06e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs13233308	0.868	rs7779623	chr7:87391761	A/G	cg22633988	chr4:77610603	SHROOM3	-0.42	-6.26	-0.32	1.18e-9	Schizophrenia;
LUSC	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg17252645	chr8:143867129	LY6D	0.37	6.49	0.33	3.08e-10	Urinary tract infection frequency;
LUSC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.61	0.43	2.84e-16	Prudent dietary pattern;
LUSC	trans	rs573521	0.584	rs1144397	chr11:102682285	T/G	cg19721115	chr12:70759665	KCNMB4	-0.41	-5.99	-0.31	5.3300000000000004e-09	Cerebrospinal fluid levels of Alzheimer's disease-related proteins;
LUSC	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.09	15.27	0.64	2.72e-40	Lung cancer in ever smokers;
LUSC	cis	rs9653442	0.527	rs4850923	chr2:100782256	A/C	cg07810366	chr2:100720526	AFF3	-0.45	-7.63	-0.39	2.44e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2637266	1.000	rs12251543	chr10:78345465	G/A	cg18941641	chr10:78392320	NA	0.38	7.07	0.36	8.85e-12	Pulmonary function;
LUSC	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg04455712	chr21:45112962	RRP1B	0.47	9.12	0.45	7.06e-18	Mean corpuscular volume;
LUSC	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	7.47	0.38	6.86e-13	Coffee consumption (cups per day);
LUSC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.86	9.88	0.48	2.32e-20	Gut microbiome composition (summer);
LUSC	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.44	0.5	2.94e-22	Colorectal cancer;
LUSC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.56	0.42	4.21e-16	Motion sickness;
LUSC	cis	rs950881	0.932	rs13408569	chr2:102955056	G/C	cg20060108	chr2:102954350	IL1RL1	0.45	5.9	0.31	8.86e-9	Allergy;
LUSC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg18479299	chr3:125709523	NA	-0.5	-5.77	-0.3	1.82e-8	Blood pressure (smoking interaction);
LUSC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg14668632	chr7:2872130	GNA12	-0.46	-6.96	-0.36	1.85e-11	Height;
LUSC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	0.93	13.08	0.58	7.66e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg12463550	chr7:65579703	CRCP	0.51	7.33	0.37	1.74e-12	Aortic root size;
LUSC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.94	-0.31	6.98e-9	Tonsillectomy;
LUSC	cis	rs7739264	0.602	rs1121384	chr6:19771507	A/G	cg02404759	chr6:19790362	NA	-0.43	-6.7	-0.34	9.02e-11	Endometriosis;
LUSC	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg00677455	chr12:58241039	CTDSP2	0.61	9.06	0.44	1.15e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-13.38	-0.59	5.32e-33	Extrinsic epigenetic age acceleration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12958836	chr12:8185024	FOXJ2	0.39	6.29	0.33	9.74e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg16359550	chr11:109292809	C11orf87	0.37	6.33	0.33	7.89e-10	Schizophrenia;
LUSC	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg04362960	chr10:104952993	NT5C2	0.62	9.83	0.47	3.51e-20	Arsenic metabolism;
LUSC	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg02660097	chr11:68866761	NA	0.44	6.27	0.32	1.11e-9	Blond vs. brown hair color;
LUSC	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg24692254	chr21:30365293	RNF160	0.55	7.04	0.36	1.08e-11	Cognitive test performance;
LUSC	cis	rs7119	0.667	rs1058129	chr15:77905661	A/G	cg27398640	chr15:77910606	LINGO1	0.38	8.79	0.43	7.98e-17	Type 2 diabetes;
LUSC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	0.86	11.2	0.52	6.15e-25	Coronary artery disease;
LUSC	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.67	10.12	0.48	3.54e-21	Breast cancer;
LUSC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg27121462	chr16:89883253	FANCA	-0.38	-5.97	-0.31	5.97e-9	Vitiligo;
LUSC	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg26384229	chr12:38710491	ALG10B	-0.55	-8.22	-0.41	4.49e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6542838	0.641	rs11123756	chr2:99508012	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.45	6.08	0.32	3.33e-9	Fear of minor pain;
LUSC	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg12935359	chr14:103987150	CKB	-0.62	-10.17	-0.49	2.46e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg13683864	chr3:40499215	RPL14	-1.13	-21.27	-0.76	4.37e-64	Renal cell carcinoma;
LUSC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg06238570	chr21:40685208	BRWD1	0.56	8.49	0.42	7.07e-16	Cognitive function;
LUSC	cis	rs12545109	0.876	rs1992120	chr8:57337112	G/A	cg09654669	chr8:57350985	NA	-0.59	-7.86	-0.4	5.21e-14	Obesity-related traits;
LUSC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg06808227	chr14:105710500	BRF1	0.67	10.78	0.51	1.94e-23	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9976767	0.608	rs9784208	chr21:43824986	A/G	cg23042151	chr21:43824109	UBASH3A	-0.34	-6.74	-0.35	7.01e-11	Type 1 diabetes;
LUSC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-1.17	-19.43	-0.73	8.65e-57	Blood trace element (Zn levels);
LUSC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg21970626	chr13:21893289	NA	-0.53	-9.75	-0.47	6.47e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg12081754	chr8:22256438	SLC39A14	0.79	12.61	0.57	4.49e-30	Verbal declarative memory;
LUSC	cis	rs7804356	1.000	rs17315775	chr7:26860134	A/G	cg03456212	chr7:26904342	SKAP2	-0.52	-6.0	-0.31	5.12e-9	Type 1 diabetes;
LUSC	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.52	-0.38	5.11e-13	Retinal vascular caliber;
LUSC	cis	rs12681287	0.640	rs10086340	chr8:87446789	G/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.16	-0.36	5.17e-12	Caudate activity during reward;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16401290	chr5:79950120	MSH3;DHFR	-0.43	-6.42	-0.33	4.75e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4908769	0.624	rs2120461	chr1:8447722	C/T	cg00546117	chr1:8445545	RERE	0.3	6.13	0.32	2.51e-9	Allergy;
LUSC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg12927641	chr6:109611667	NA	-0.42	-7.33	-0.37	1.7e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.35	0.33	7.01e-10	Schizophrenia;
LUSC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	6.05	0.31	3.92e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11166629	1.000	rs935119	chr8:135638353	C/T	cg27224718	chr8:135614730	ZFAT	-0.66	-11.24	-0.52	4.58e-25	Smoking quantity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19442730	chr13:73634476	KLF5	0.44	6.87	0.35	3.19e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg06877462	chr1:205807181	PM20D1	0.5	9.01	0.44	1.67e-17	Menarche (age at onset);
LUSC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.16	-0.36	5.18e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg03806693	chr22:41940476	POLR3H	1.0	14.45	0.62	4.19e-37	Vitiligo;
LUSC	cis	rs889512	0.642	rs13337017	chr16:75272367	C/T	cg04987608	chr16:75300043	BCAR1	-0.5	-5.72	-0.3	2.41e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.59	8.18	0.41	5.92e-15	Body mass index (adult);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17772535	chr12:65153236	GNS	-0.41	-6.12	-0.32	2.56e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.73	-11.47	-0.53	6.55e-26	Dilated cardiomyopathy;
LUSC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg06784218	chr1:46089804	CCDC17	-0.57	-11.33	-0.53	2.14e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg06784218	chr1:46089804	CCDC17	0.49	9.61	0.47	1.83e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7903847	0.642	rs7088410	chr10:99135539	G/T	cg08345082	chr10:99160200	RRP12	-0.38	-7.74	-0.39	1.16e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.8	11.84	0.54	3.08e-27	Corneal astigmatism;
LUSC	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg24558204	chr6:135376177	HBS1L	0.58	8.7	0.43	1.58e-16	Red blood cell count;
LUSC	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg11584989	chr19:19387371	SF4	0.56	6.53	0.34	2.46e-10	Bipolar disorder;
LUSC	cis	rs4499344	0.730	rs8103269	chr19:33097503	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	12.66	0.57	2.92e-30	Mean platelet volume;
LUSC	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg21775007	chr8:11205619	TDH	0.71	11.81	0.54	3.78e-27	Retinal vascular caliber;
LUSC	cis	rs7091068	0.671	rs588912	chr10:95402929	T/C	cg20715218	chr10:95462985	C10orf4	-0.63	-7.4	-0.38	1.1e-12	Urinary tract infection frequency;
LUSC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24531977	chr5:56204891	C5orf35	0.89	14.21	0.61	3.61e-36	Initial pursuit acceleration;
LUSC	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	1.05	14.32	0.62	1.33e-36	Exhaled nitric oxide levels;
LUSC	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.77e-22	Eye color traits;
LUSC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.85	-0.35	3.59e-11	Mood instability;
LUSC	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg15704280	chr7:45808275	SEPT13	0.58	7.33	0.37	1.78e-12	Intraocular pressure;
LUSC	cis	rs11971779	0.648	rs59791374	chr7:139116962	C/T	cg07862535	chr7:139043722	LUC7L2	0.6	7.62	0.39	2.56e-13	Diisocyanate-induced asthma;
LUSC	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg12552261	chr5:112820674	MCC	-0.43	-6.95	-0.36	1.98e-11	Type 2 diabetes;
LUSC	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg11984989	chr7:158649758	WDR60	1.12	13.38	0.59	5.4e-33	Height;
LUSC	cis	rs8014204	0.747	rs2070598	chr14:75360906	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-9.1	-0.45	8.48e-18	Caffeine consumption;
LUSC	cis	rs10761482	0.813	rs4336985	chr10:62101374	C/A	cg18175470	chr10:62150864	ANK3	-0.52	-7.44	-0.38	8.5e-13	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg07701084	chr6:150067640	NUP43	0.56	8.84	0.44	5.69e-17	Lung cancer;
LUSC	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.47	-5.65	-0.3	3.42e-8	Cognitive ability;
LUSC	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.58	0.57	5.44e-30	Motion sickness;
LUSC	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg23029597	chr12:123009494	RSRC2	-0.73	-9.02	-0.44	1.52e-17	Body mass index;
LUSC	cis	rs10450586	0.863	rs7125719	chr11:27288359	G/C	cg08958251	chr11:27270390	NA	0.34	5.65	0.3	3.4e-8	Total body bone mineral density;
LUSC	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	0.84	14.04	0.61	1.57e-35	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.74	-0.3	2.12e-8	Ileal carcinoids;
LUSC	cis	rs4730250	0.707	rs1981696	chr7:106794100	C/T	cg02696742	chr7:106810147	HBP1	0.61	8.93	0.44	2.87e-17	Osteoarthritis;
LUSC	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg13010199	chr12:38710504	ALG10B	0.61	9.36	0.46	1.25e-18	Morning vs. evening chronotype;
LUSC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg19748678	chr4:122722346	EXOSC9	0.5	7.58	0.38	3.54e-13	Type 2 diabetes;
LUSC	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg04539111	chr16:67997858	SLC12A4	-0.42	-5.86	-0.31	1.09e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg00310523	chr12:86230176	RASSF9	0.55	10.26	0.49	1.21e-21	Major depressive disorder;
LUSC	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg22508957	chr16:3507546	NAT15	-0.4	-5.74	-0.3	2.14e-8	Body mass index (adult);
LUSC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg03233332	chr7:66118400	NA	-0.4	-6.02	-0.31	4.58e-9	Aortic root size;
LUSC	trans	rs10221833	0.602	rs355881	chr2:165633716	C/G	cg26993132	chr16:89239499	CDH15	0.31	5.97	0.31	6.09e-9	Response to statin therapy;
LUSC	cis	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg27411982	chr8:10470053	RP1L1	0.38	5.81	0.3	1.48e-8	Systolic blood pressure;
LUSC	trans	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.54	-8.39	-0.42	1.43e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs950893	0.597	rs2942219	chr8:23439308	A/G	cg20845639	chr8:23430886	NA	0.3	5.67	0.3	3.09e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs4363385	0.747	rs6678107	chr1:152966818	T/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.66	-0.39	2.03e-13	Inflammatory skin disease;
LUSC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg25036284	chr2:26402008	FAM59B	0.78	11.06	0.52	1.94e-24	Gut microbiome composition (summer);
LUSC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg08859206	chr1:53392774	SCP2	0.46	7.75	0.39	1.1e-13	Monocyte count;
LUSC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg12365402	chr11:9010492	NRIP3	-0.52	-10.03	-0.48	7.49e-21	Hemoglobin concentration;
LUSC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg05585544	chr11:47624801	NA	0.41	7.25	0.37	2.92e-12	Subjective well-being;
LUSC	cis	rs1355223	0.902	rs11605785	chr11:34751387	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-5.65	-0.3	3.38e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg18479299	chr3:125709523	NA	-0.5	-6.11	-0.32	2.72e-9	Blood pressure (smoking interaction);
LUSC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	0.68	10.85	0.51	1.11e-23	Height;
LUSC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg18904891	chr8:8559673	CLDN23	0.56	7.69	0.39	1.68e-13	Obesity-related traits;
LUSC	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg05163923	chr11:71159392	DHCR7	-0.76	-9.95	-0.48	1.32e-20	Vitamin D levels;
LUSC	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg18196295	chr10:418757	DIP2C	0.49	8.06	0.4	1.38e-14	Psychosis in Alzheimer's disease;
LUSC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg03146154	chr1:46216737	IPP	-0.56	-8.39	-0.42	1.39e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs11264213	0.901	rs72661623	chr1:36398368	G/A	cg05872835	chr6:75796125	COL12A1	0.51	5.97	0.31	5.97e-9	Schizophrenia;
LUSC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.37	-6.38	-0.33	5.74e-10	Breast cancer;
LUSC	cis	rs10979	0.964	rs12526234	chr6:143898680	A/T	cg25407410	chr6:143891975	LOC285740	-0.74	-11.79	-0.54	4.66e-27	Hypospadias;
LUSC	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg22356347	chr1:167427500	CD247	-0.34	-7.73	-0.39	1.3e-13	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18099408	chr3:52552593	STAB1	0.37	6.57	0.34	1.96e-10	Electroencephalogram traits;
LUSC	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.74e-19	Body mass index;
LUSC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg19678392	chr7:94953810	PON1	-0.37	-5.98	-0.31	5.89e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.88	-14.16	-0.61	5.75e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.47	-0.42	8.08e-16	Response to antipsychotic treatment;
LUSC	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.44	-6.53	-0.34	2.4e-10	Axial length;
LUSC	cis	rs2607426	0.579	rs2644917	chr19:41287007	G/T	cg05508168	chr19:41255947	C19orf54;SNRPA	0.92	7.26	0.37	2.8e-12	Blood protein levels;
LUSC	cis	rs713477	0.967	rs4898865	chr14:55910998	G/A	cg13175173	chr14:55914753	NA	-0.32	-6.74	-0.35	7.01e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg06238570	chr21:40685208	BRWD1	0.52	7.96	0.4	2.75e-14	Cognitive function;
LUSC	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.42	-6.74	-0.35	6.92e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.75	-11.65	-0.54	1.47e-26	Menarche (age at onset);
LUSC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg14004847	chr7:1930337	MAD1L1	-0.58	-8.83	-0.44	5.93e-17	Schizophrenia;
LUSC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-17.6	-0.69	1.62e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	0.59	9.16	0.45	5.16e-18	Breast cancer;
LUSC	cis	rs10979	0.597	rs9403515	chr6:143908013	A/G	cg25407410	chr6:143891975	LOC285740	-0.65	-8.19	-0.41	5.6e-15	Hypospadias;
LUSC	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg09021430	chr5:549028	NA	-0.6	-9.41	-0.46	8.29e-19	Obesity-related traits;
LUSC	cis	rs10746514	0.841	rs9725652	chr1:232245997	T/A	cg09506761	chr1:232265262	NA	0.52	8.41	0.42	1.23e-15	Response to statin therapy;
LUSC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg07701084	chr6:150067640	NUP43	0.55	8.34	0.42	1.96e-15	Lung cancer;
LUSC	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg03806693	chr22:41940476	POLR3H	0.85	12.55	0.57	7.53e-30	Vitiligo;
LUSC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	0.92	15.33	0.64	1.58e-40	Breast cancer;
LUSC	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg01884057	chr2:25150051	NA	0.44	10.18	0.49	2.23e-21	Body mass index;
LUSC	cis	rs9323205	0.861	rs56137183	chr14:51693463	C/A	cg23942311	chr14:51606299	NA	-0.47	-9.35	-0.46	1.33e-18	Cancer;
LUSC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg06096015	chr1:231504339	EGLN1	-0.53	-9.18	-0.45	4.66e-18	Hemoglobin concentration;
LUSC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg12463550	chr7:65579703	CRCP	0.45	6.76	0.35	6.19e-11	Aortic root size;
LUSC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg02569458	chr12:86230093	RASSF9	0.58	9.8	0.47	4.13e-20	Major depressive disorder;
LUSC	cis	rs4919694	0.611	rs77328741	chr10:105066314	T/C	cg04362960	chr10:104952993	NT5C2	1.04	10.73	0.51	2.73e-23	Arsenic metabolism;
LUSC	cis	rs2658782	0.547	rs10765602	chr11:93048165	G/T	cg15737290	chr11:93063684	CCDC67	0.9	13.88	0.6	6.67e-35	Pulmonary function decline;
LUSC	cis	rs2737618	0.651	rs2249156	chr1:200083541	A/G	cg21825944	chr1:200113062	NR5A2	0.3	5.66	0.3	3.24e-8	Uric acid levels;
LUSC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg11941060	chr3:133502564	NA	-0.41	-5.88	-0.31	1.02e-8	Iron status biomarkers;
LUSC	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg26195577	chr20:24973756	C20orf3	1.1	17.95	0.7	6.25e-51	Blood protein levels;
LUSC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg04775059	chr7:64541387	NA	-0.49	-7.39	-0.38	1.15e-12	Calcium levels;
LUSC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.7	10.85	0.51	1.03e-23	Aortic root size;
LUSC	cis	rs6942756	1.000	rs11769045	chr7:128895335	A/G	cg02491457	chr7:128862824	NA	-0.52	-7.48	-0.38	6.68e-13	White matter hyperintensity burden;
LUSC	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg24634471	chr8:143751801	JRK	0.5	7.17	0.37	4.9e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.5	0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.51	6.93	0.35	2.19e-11	Body mass index (adult);
LUSC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg06008330	chr7:65541103	ASL	0.4	6.19	0.32	1.77e-9	Aortic root size;
LUSC	cis	rs62400317	0.826	rs12213735	chr6:45152848	C/T	cg20913747	chr6:44695427	NA	0.46	7.44	0.38	8.72e-13	Total body bone mineral density;
LUSC	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg21573476	chr21:45109991	RRP1B	-0.42	-6.63	-0.34	1.39e-10	Mean corpuscular volume;
LUSC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16680214	chr1:154839983	KCNN3	0.58	11.37	0.53	1.5e-25	Prostate cancer;
LUSC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg01657329	chr11:68192670	LRP5	-0.45	-7.23	-0.37	3.34e-12	Total body bone mineral density;
LUSC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg02033258	chr5:131593261	PDLIM4	0.4	5.74	0.3	2.11e-8	Acylcarnitine levels;
LUSC	cis	rs75804782	0.521	rs55713398	chr2:239419933	A/G	cg18131467	chr2:239335373	ASB1	-0.72	-6.3	-0.33	9.19e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg14844989	chr11:31128820	NA	-0.38	-5.88	-0.31	9.81e-9	Red blood cell count;
LUSC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg22437258	chr11:111473054	SIK2	0.47	6.25	0.32	1.22e-9	Primary sclerosing cholangitis;
LUSC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg27165867	chr14:105738592	BRF1	-0.53	-7.76	-0.39	1.06e-13	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.3e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs858239	0.601	rs10255228	chr7:23158863	G/T	cg23682824	chr7:23144976	KLHL7	0.4	5.88	0.31	1.02e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg16386425	chr10:429943	DIP2C	0.39	5.75	0.3	2.05e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg20701182	chr2:24300061	SF3B14	0.74	7.28	0.37	2.48e-12	Lymphocyte counts;
LUSC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.43	-6.57	-0.34	1.98e-10	Tonsillectomy;
LUSC	cis	rs4478858	0.746	rs7520468	chr1:31688812	G/A	cg00250761	chr1:31883323	NA	0.36	9.37	0.46	1.1e-18	Alcohol dependence;
LUSC	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg06462663	chr19:18546047	ISYNA1	0.45	7.88	0.4	4.81e-14	Breast cancer;
LUSC	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg01528321	chr10:82214614	TSPAN14	1.15	18.5	0.71	4.1e-53	Post bronchodilator FEV1;
LUSC	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg10018233	chr7:150070692	REPIN1	0.37	6.49	0.33	3.07e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg01483505	chr11:975446	AP2A2	0.42	5.9	0.31	9.14e-9	Alzheimer's disease (late onset);
LUSC	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg15557168	chr22:42548783	NA	-0.43	-7.26	-0.37	2.79e-12	Cognitive function;
LUSC	trans	rs7939886	0.920	rs12417606	chr11:55750479	C/T	cg03929089	chr4:120376271	NA	0.79	6.5	0.34	2.94e-10	Myopia (pathological);
LUSC	cis	rs2354432	0.505	rs3737845	chr1:146724408	A/G	cg25205988	chr1:146714368	CHD1L	0.99	9.19	0.45	4.16e-18	Mitochondrial DNA levels;
LUSC	trans	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg26513180	chr16:89883248	FANCA	0.9	17.39	0.69	1.13e-48	Vitiligo;
LUSC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00934597	chr7:893267	UNC84A	-0.48	-7.18	-0.37	4.55e-12	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg00745463	chr17:30367425	LRRC37B	-0.87	-10.23	-0.49	1.46e-21	Hip circumference adjusted for BMI;
LUSC	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg17507749	chr15:85114479	UBE2QP1	0.71	9.37	0.46	1.13e-18	Schizophrenia;
LUSC	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg09044154	chr16:88155775	NA	-0.51	-6.97	-0.36	1.74e-11	Menopause (age at onset);
LUSC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg23630131	chr7:65973040	NA	0.2	5.73	0.3	2.29e-8	Aortic root size;
LUSC	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg21775007	chr8:11205619	TDH	0.8	13.52	0.59	1.64e-33	Retinal vascular caliber;
LUSC	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg24397884	chr7:158709396	WDR60	0.73	8.48	0.42	7.27e-16	Height;
LUSC	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg14121845	chr20:25566513	NINL	0.31	5.78	0.3	1.76e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	22.65	0.78	1.88e-69	Colorectal cancer;
LUSC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg06238570	chr21:40685208	BRWD1	0.48	7.54	0.38	4.41e-13	Cognitive function;
LUSC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg24881330	chr22:46731750	TRMU	0.87	10.08	0.48	4.76e-21	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-10.08	-0.48	4.94e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.92	0.44	3.19e-17	Prudent dietary pattern;
LUSC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg15557168	chr22:42548783	NA	-0.43	-6.5	-0.33	3.01e-10	Schizophrenia;
LUSC	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.77	-10.41	-0.49	3.56e-22	Coronary artery disease;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	0.94	18.78	0.72	3.35e-54	Menarche (age at onset);
LUSC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03934478	chr11:495069	RNH1	0.84	9.12	0.45	7.17e-18	Body mass index;
LUSC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg16393715	chr7:1948819	MAD1L1	0.39	6.51	0.34	2.82e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg11494091	chr17:61959527	GH2	0.39	6.77	0.35	5.85e-11	Height;
LUSC	trans	rs853679	0.546	rs200981	chr6:27833174	A/G	cg01620082	chr3:125678407	NA	-0.69	-7.08	-0.36	8.45e-12	Depression;
LUSC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg04369109	chr6:150039330	LATS1	-0.57	-8.45	-0.42	9.43e-16	Lung cancer;
LUSC	trans	rs12571093	0.803	rs36103935	chr10:70032928	A/G	cg04882175	chr6:131122610	NA	-0.58	-6.6	-0.34	1.65e-10	Optic nerve measurement (disc area);
LUSC	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg27432699	chr2:27873401	GPN1	0.83	15.71	0.65	4.95e-42	Oral cavity cancer;
LUSC	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.81	-0.35	4.48e-11	Monocyte percentage of white cells;
LUSC	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg04586622	chr2:25135609	ADCY3	0.32	6.18	0.32	1.92e-9	Body mass index;
LUSC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08677398	chr8:58056175	NA	0.57	6.93	0.35	2.12e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg17252645	chr8:143867129	LY6D	0.38	6.79	0.35	5.28e-11	Urinary tract infection frequency;
LUSC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.8	0.3	1.5e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg24675658	chr1:53192096	ZYG11B	0.62	9.91	0.48	1.78e-20	Monocyte count;
LUSC	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06022373	chr22:39101656	GTPBP1	0.73	12.0	0.55	8.2e-28	Menopause (age at onset);
LUSC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg25019033	chr10:957182	NA	-0.53	-6.0	-0.31	5.01e-9	Eosinophil percentage of granulocytes;
LUSC	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.27	-17.75	-0.7	4.04e-50	Hip circumference adjusted for BMI;
LUSC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.25	-0.32	1.22e-9	Initial pursuit acceleration;
LUSC	cis	rs12545109	0.800	rs2576602	chr8:57394495	C/T	cg09654669	chr8:57350985	NA	-0.51	-6.87	-0.35	3.1e-11	Obesity-related traits;
LUSC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.71	-0.3	2.47e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg26441486	chr22:50317300	CRELD2	0.48	7.21	0.37	3.88e-12	Schizophrenia;
LUSC	cis	rs6142102	0.961	rs6119447	chr20:32668576	A/G	cg08999081	chr20:33150536	PIGU	0.35	5.88	0.31	9.75e-9	Skin pigmentation;
LUSC	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg00745463	chr17:30367425	LRRC37B	-0.72	-8.79	-0.43	8.04e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.57	11.18	0.52	7.15e-25	Hemoglobin concentration;
LUSC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.56	0.34	2.06e-10	Lung cancer;
LUSC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06634786	chr22:41940651	POLR3H	-0.53	-6.44	-0.33	4.05e-10	Vitiligo;
LUSC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.78	0.3	1.74e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg10018233	chr7:150070692	REPIN1	0.38	6.73	0.35	7.52e-11	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs9886428	0.967	rs10087038	chr8:14115672	A/G	cg11959399	chr20:741723	C20orf54	-0.4	-6.42	-0.33	4.67e-10	IgG glycosylation;
LUSC	cis	rs3820928	0.874	rs1054413	chr2:227867719	A/G	cg11843606	chr2:227700838	RHBDD1	0.51	7.51	0.38	5.56e-13	Pulmonary function;
LUSC	cis	rs9653442	0.900	rs6740838	chr2:100813499	T/G	cg07810366	chr2:100720526	AFF3	-0.46	-7.93	-0.4	3.32e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg03388025	chr16:89894329	SPIRE2	-0.3	-6.32	-0.33	8.48e-10	Vitiligo;
LUSC	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg24130564	chr14:104152367	KLC1	-0.46	-6.55	-0.34	2.13e-10	Body mass index;
LUSC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.94	-0.31	7.19e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg22823121	chr1:150693482	HORMAD1	0.5	7.24	0.37	3.2e-12	Melanoma;
LUSC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg25258033	chr6:167368657	RNASET2	0.49	8.12	0.41	8.86e-15	Crohn's disease;
LUSC	cis	rs6693567	0.565	rs11205355	chr1:150252329	G/A	cg15654264	chr1:150340011	RPRD2	-0.45	-7.2	-0.37	4.02e-12	Migraine;
LUSC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.08	0.32	3.34e-9	Menopause (age at onset);
LUSC	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg14092571	chr14:90743983	NA	-0.36	-5.89	-0.31	9.58e-9	Mortality in heart failure;
LUSC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.74	12.84	0.57	6.03e-31	Prudent dietary pattern;
LUSC	cis	rs1595825	0.730	rs1902248	chr2:198492598	C/T	cg00982548	chr2:198649783	BOLL	-0.53	-6.74	-0.35	6.92e-11	Ulcerative colitis;
LUSC	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg05425664	chr17:57184151	TRIM37	0.5	7.56	0.38	3.92e-13	Testicular germ cell tumor;
LUSC	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-7.06	-0.36	9.51e-12	Height;
LUSC	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg08270630	chr22:50330655	NA	-0.37	-5.65	-0.3	3.4e-8	Schizophrenia;
LUSC	cis	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg17469321	chr7:55412551	NA	0.64	10.19	0.49	2.02e-21	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs877282	0.898	rs11253347	chr10:765769	A/G	cg17470449	chr10:769945	NA	0.53	7.09	0.36	8.21e-12	Uric acid levels;
LUSC	cis	rs9394438	0.529	rs10947681	chr6:37547073	C/A	cg00985040	chr6:37553208	NA	-0.44	-9.64	-0.47	1.44e-19	IgG glycosylation;
LUSC	cis	rs11867934	0.731	rs9908767	chr17:17005086	C/T	cg26176665	chr17:16994978	MPRIP	-0.45	-5.82	-0.3	1.42e-8	Diabetic retinopathy;
LUSC	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg13057898	chr1:3703894	LRRC47	0.5	8.97	0.44	2.17e-17	Red cell distribution width;
LUSC	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.53	-0.5	1.46e-22	Coffee consumption (cups per day);
LUSC	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-9.94	-0.48	1.47e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07677032	chr17:61819896	STRADA	0.53	8.91	0.44	3.42e-17	Prudent dietary pattern;
LUSC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg13535736	chr9:111863775	C9orf5	-0.42	-6.69	-0.34	9.51e-11	Menarche (age at onset);
LUSC	trans	rs1027479	0.842	rs2935794	chr8:109723537	G/C	cg14904725	chr13:113777045	F10	-0.25	-6.12	-0.32	2.58e-9	Facial morphology (factor 6, height of vermillion lower lip);
LUSC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06221963	chr1:154839813	KCNN3	-0.61	-13.72	-0.6	2.81e-34	Prostate cancer;
LUSC	cis	rs9815354	1.000	rs9867627	chr3:41795841	G/T	cg03022575	chr3:42003672	ULK4	-0.56	-6.31	-0.33	8.82e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg05340658	chr4:99064831	C4orf37	0.59	9.67	0.47	1.15e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4654899	0.865	rs10916910	chr1:21283192	G/T	cg01072550	chr1:21505969	NA	-0.53	-7.79	-0.39	8.52e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.7	-11.77	-0.54	5.32e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.98	-0.31	5.71e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg07703079	chr11:430292	ANO9	0.58	6.35	0.33	6.89e-10	Body mass index;
LUSC	cis	rs4144743	1.000	rs34182248	chr17:45321359	T/C	cg18085866	chr17:45331354	ITGB3	-0.79	-8.33	-0.41	2.06e-15	Body mass index;
LUSC	cis	rs4974559	0.947	rs58750335	chr4:1364764	G/A	cg02980000	chr4:1222292	CTBP1	0.73	6.45	0.33	3.92e-10	Systolic blood pressure;
LUSC	cis	rs62458065	0.640	rs10241303	chr7:32534203	T/G	cg20159608	chr7:32802032	NA	-0.74	-9.51	-0.46	4.04e-19	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.47	-6.97	-0.36	1.71e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg16850897	chr7:100343110	ZAN	0.37	5.89	0.31	9.66e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg24596788	chr1:163392923	NA	-0.44	-7.28	-0.37	2.38e-12	Motion sickness;
LUSC	cis	rs2230307	0.536	rs640030	chr1:100574992	C/T	cg24955406	chr1:100503596	HIAT1	-0.63	-6.68	-0.34	1.01e-10	Carotid intima media thickness;
LUSC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.71	0.3	2.49e-8	Self-reported allergy;
LUSC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg12002119	chr2:101014098	CHST10	0.35	5.81	0.3	1.5e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2625529	0.824	rs4411469	chr15:72421689	A/G	cg16672083	chr15:72433130	SENP8	-0.52	-7.55	-0.38	4.15e-13	Red blood cell count;
LUSC	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg07173049	chr1:7289937	CAMTA1	-0.32	-6.56	-0.34	2.09e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13012494	chr21:47604986	C21orf56	0.51	7.72	0.39	1.38e-13	Testicular germ cell tumor;
LUSC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg08888203	chr3:10149979	C3orf24	0.66	9.07	0.44	1.06e-17	Alzheimer's disease;
LUSC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg17294928	chr15:75287854	SCAMP5	-0.76	-10.2	-0.49	1.97e-21	Blood trace element (Zn levels);
LUSC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.11	0.32	2.74e-9	Personality dimensions;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20979926	chr12:112546623	NAA25	-0.47	-6.01	-0.31	4.73e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs12692738	0.526	rs355857	chr2:165629214	A/G	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg04998671	chr14:104000505	TRMT61A	0.44	6.9	0.35	2.64e-11	Coronary artery disease;
LUSC	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg08213375	chr14:104286397	PPP1R13B	0.47	9.18	0.45	4.76e-18	Schizophrenia;
LUSC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.57	-8.25	-0.41	3.77e-15	Obesity-related traits;
LUSC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-7.4	-0.38	1.08e-12	Renal function-related traits (BUN);
LUSC	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg13256891	chr4:100009986	ADH5	0.51	6.95	0.36	1.91e-11	Smoking initiation;
LUSC	cis	rs7759001	0.857	rs10080555	chr6:27362866	C/T	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg04310649	chr10:35416472	CREM	-0.42	-6.39	-0.33	5.7e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4478137	0.931	rs11100488	chr4:164237660	C/A	cg06758707	chr4:164254230	NPY1R	0.66	10.1	0.48	4.13e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	trans	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg15556689	chr8:8085844	FLJ10661	0.49	7.18	0.37	4.43e-12	Retinal vascular caliber;
LUSC	cis	rs6494488	0.500	rs72742921	chr15:64855556	G/A	cg08069370	chr15:64387884	SNX1	-0.64	-5.73	-0.3	2.24e-8	Coronary artery disease;
LUSC	cis	rs2898681	0.580	rs41279517	chr4:53729771	T/C	cg21521518	chr4:53727714	RASL11B	0.49	6.05	0.31	3.97e-9	Optic nerve measurement (cup area);
LUSC	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.69	-10.24	-0.49	1.42e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg11984989	chr7:158649758	WDR60	1.08	23.07	0.78	4.28e-71	Height;
LUSC	cis	rs4285028	0.747	rs1574133	chr3:121468794	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-12.97	-0.58	2.02e-31	Multiple sclerosis;
LUSC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.55	7.78	0.39	8.93e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs73001065	0.551	rs56397647	chr19:19642795	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	7.9	0.4	4.09e-14	LDL cholesterol;
LUSC	cis	rs4363385	0.510	rs6693927	chr1:153044009	G/A	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.39	-0.33	5.43e-10	Inflammatory skin disease;
LUSC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg06521331	chr12:34319734	NA	-0.39	-6.37	-0.33	6.35e-10	Morning vs. evening chronotype;
LUSC	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg07741184	chr6:167504864	NA	0.51	8.74	0.43	1.15e-16	Crohn's disease;
LUSC	cis	rs2742417	0.603	rs2673062	chr3:45763635	A/G	cg10512202	chr3:45649293	LIMD1	0.35	5.89	0.31	9.61e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs193541	0.593	rs1035372	chr5:122169448	C/A	cg19077854	chr5:122220652	SNX24	0.37	7.83	0.39	6.46e-14	Glucose homeostasis traits;
LUSC	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg05855489	chr10:104503620	C10orf26	0.57	9.18	0.45	4.51e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg19435381	chr5:41870796	OXCT1	-0.46	-6.02	-0.31	4.63e-9	Cognitive function;Information processing speed;
LUSC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg21856205	chr7:94953877	PON1	-0.36	-5.85	-0.3	1.19e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg17507749	chr15:85114479	UBE2QP1	0.53	6.58	0.34	1.87e-10	Schizophrenia;
LUSC	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.6	-0.43	3.16e-16	Total cholesterol levels;
LUSC	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg22875332	chr1:76189707	ACADM	-0.41	-6.1	-0.32	2.9e-9	Daytime sleep phenotypes;
LUSC	cis	rs3755132	0.929	rs60269778	chr2:15753604	A/G	cg12888861	chr2:15731646	DDX1	0.52	7.48	0.38	6.45e-13	Wilms tumor;
LUSC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg14893161	chr1:205819251	PM20D1	-0.48	-6.48	-0.33	3.38e-10	Menarche (age at onset);
LUSC	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg27124370	chr19:33622961	WDR88	-0.54	-7.13	-0.36	6.26e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg19694781	chr19:47549865	TMEM160	0.58	9.39	0.46	9.66e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs1035144	0.506	rs2371416	chr14:81275672	A/T	cg06600135	chr14:81408086	NA	-0.53	-7.72	-0.39	1.33e-13	Male sexual orientation;
LUSC	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg20219074	chr11:18656078	SPTY2D1	0.73	10.98	0.51	3.79e-24	Breast cancer;
LUSC	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg18825076	chr15:78729989	IREB2	-0.49	-7.64	-0.39	2.28e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.69	0.47	1.02e-19	Bipolar disorder;
LUSC	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg00999904	chr2:3704751	ALLC	-0.42	-6.53	-0.34	2.44e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	9.15	0.45	5.78e-18	Lung cancer in ever smokers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08486583	chr10:94333347	IDE	-0.42	-6.32	-0.33	8.33e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11997175	0.545	rs4733457	chr8:33661236	G/A	ch.8.33884649F	chr8:33765107	NA	0.49	7.29	0.37	2.2e-12	Body mass index;
LUSC	trans	rs800082	0.516	rs1182797	chr3:144241495	T/C	cg24215973	chr2:240111563	HDAC4	0.44	6.81	0.35	4.55e-11	Smoking behavior;
LUSC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg03128945	chr5:622914	CEP72	-0.46	-6.64	-0.34	1.27e-10	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg03676636	chr4:99064102	C4orf37	0.32	7.05	0.36	1.06e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg04315214	chr1:2043799	PRKCZ	0.46	9.38	0.46	1.01e-18	Height;
LUSC	trans	rs1376359	0.577	rs648505	chr1:103284892	G/T	cg17154563	chr19:40477487	PSMC4	0.47	5.96	0.31	6.52e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.54	-0.34	2.27e-10	Retinal vascular caliber;
LUSC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg14440974	chr22:39074834	NA	-0.35	-5.72	-0.3	2.37e-8	Menopause (age at onset);
LUSC	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg00852783	chr1:26633632	UBXN11	-0.48	-5.73	-0.3	2.25e-8	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.66	0.3	3.26e-8	Menopause (age at onset);
LUSC	cis	rs7605827	0.930	rs7577130	chr2:15527859	G/A	cg19274914	chr2:15703543	NA	0.45	8.78	0.43	8.59e-17	Educational attainment (years of education);
LUSC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg13685833	chr1:53393034	SCP2	0.4	6.0	0.31	5.27e-9	Monocyte count;
LUSC	cis	rs3818285	0.504	rs7100154	chr10:111650150	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-8.56	-0.42	4.31e-16	Superior crus of antihelix expression;
LUSC	cis	rs8032315	0.965	rs35346340	chr15:91427872	G/C	cg06330618	chr15:91428456	FES	0.29	5.76	0.3	1.89e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg11861562	chr11:117069780	TAGLN	0.33	6.57	0.34	1.91e-10	Blood protein levels;
LUSC	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg18850929	chr19:1828978	REXO1	0.42	6.23	0.32	1.4e-9	Bipolar disorder;
LUSC	cis	rs72781680	0.821	rs116583405	chr2:24208221	T/C	cg08917208	chr2:24149416	ATAD2B	0.6	6.84	0.35	3.68e-11	Lymphocyte counts;
LUSC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg16624210	chr5:671434	TPPP	0.49	6.39	0.33	5.59e-10	Obesity-related traits;
LUSC	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.56	-10.31	-0.49	8.11e-22	Homoarginine levels;
LUSC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg08923669	chr16:420230	MRPL28	0.46	8.02	0.4	1.81e-14	Bone mineral density (spine);Bone mineral density;
LUSC	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.39	-0.42	1.4e-15	Neuroticism;
LUSC	cis	rs11168618	0.904	rs7978948	chr12:48930023	A/G	cg24011408	chr12:48396354	COL2A1	0.4	6.42	0.33	4.67e-10	Adiponectin levels;
LUSC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg18479299	chr3:125709523	NA	-0.51	-5.87	-0.31	1.05e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.8	13.81	0.6	1.29e-34	Blood protein levels;
LUSC	trans	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg24247370	chr13:99142703	STK24	-0.35	-6.2	-0.32	1.63e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg26924012	chr15:45694286	SPATA5L1	1.12	20.32	0.74	2.51e-60	Homoarginine levels;
LUSC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7123876	0.587	rs61895588	chr11:72360986	A/G	cg03713592	chr11:72463424	ARAP1	0.69	7.18	0.37	4.5e-12	Body mass index;
LUSC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg05729581	chr11:3078854	CARS	-0.54	-8.06	-0.4	1.36e-14	Longevity;
LUSC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg05855489	chr10:104503620	C10orf26	0.58	9.32	0.45	1.66e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg13010199	chr12:38710504	ALG10B	0.57	8.64	0.43	2.29e-16	Bladder cancer;
LUSC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.79	11.78	0.54	5.12e-27	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6500395	1.000	rs3743779	chr16:48574040	T/G	cg04672837	chr16:48644449	N4BP1	0.46	6.82	0.35	4.17e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18854424	chr1:2615690	NA	-0.5	-10.0	-0.48	8.88e-21	Ulcerative colitis;
LUSC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg06784218	chr1:46089804	CCDC17	0.54	10.59	0.5	8.43e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg07211511	chr3:129823064	LOC729375	-0.81	-10.67	-0.5	4.41e-23	Blood pressure (smoking interaction);
LUSC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.69	-12.57	-0.57	6.41e-30	Extrinsic epigenetic age acceleration;
LUSC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg08999081	chr20:33150536	PIGU	0.37	6.74	0.35	6.97e-11	Height;
LUSC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.58	7.42	0.38	1e-12	Multiple sclerosis;
LUSC	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.39	-0.42	1.35e-15	Coffee consumption (cups per day);
LUSC	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg16070123	chr10:51489643	NA	0.55	9.14	0.45	6.23e-18	Prostate-specific antigen levels;
LUSC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.19	0.45	4.35e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg22437258	chr11:111473054	SIK2	0.51	6.99	0.36	1.53e-11	Primary sclerosing cholangitis;
LUSC	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.59	0.5	8.45e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg25767906	chr1:53392781	SCP2	0.38	6.45	0.33	3.96e-10	Monocyte count;
LUSC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg22875332	chr1:76189707	ACADM	0.77	10.32	0.49	7.56e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.73	-10.2	-0.49	1.98e-21	Bronchopulmonary dysplasia;
LUSC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg14582100	chr15:45693742	SPATA5L1	0.6	10.95	0.51	4.7e-24	Homoarginine levels;
LUSC	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.64	11.41	0.53	1.07e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.99	-0.31	5.47e-9	Dementia with Lewy bodies;
LUSC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg01879757	chr17:41196368	BRCA1	-0.52	-8.46	-0.42	8.48e-16	Menopause (age at onset);
LUSC	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg07148914	chr20:33460835	GGT7	0.56	8.53	0.42	5.09e-16	Height;
LUSC	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg04998671	chr14:104000505	TRMT61A	-0.48	-6.8	-0.35	4.86e-11	Reticulocyte count;
LUSC	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg08601574	chr20:25228251	PYGB	0.39	6.12	0.32	2.59e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.26	0.52	3.68e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg15445000	chr17:37608096	MED1	0.38	6.5	0.34	2.95e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg23791538	chr6:167370224	RNASET2	-0.36	-5.71	-0.3	2.52e-8	Crohn's disease;
LUSC	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg08085267	chr17:45401833	C17orf57	0.43	6.52	0.34	2.52e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4947962	0.585	rs10245472	chr7:55147478	G/A	cg23757825	chr7:55092271	EGFR	-0.46	-5.78	-0.3	1.7e-8	Subjective response to lithium treatment;
LUSC	cis	rs62400317	0.723	rs755	chr6:44795790	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.27	-0.37	2.55e-12	Total body bone mineral density;
LUSC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08280861	chr8:58055591	NA	0.53	6.27	0.32	1.1e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.45	0.85	7.39e-95	Chronic sinus infection;
LUSC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	1.08	25.59	0.81	9.83e-81	Testicular germ cell tumor;
LUSC	cis	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg02508848	chr16:68573721	ZFP90	-0.42	-5.72	-0.3	2.31e-8	Ulcerative colitis;
LUSC	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg05347473	chr6:146136440	FBXO30	0.48	7.89	0.4	4.3e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	10.15	0.49	2.9e-21	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	11.43	0.53	9.07e-26	Menarche (age at onset);
LUSC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.29	0.37	2.24e-12	Platelet count;
LUSC	trans	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.16	0.32	2.03e-9	Corneal astigmatism;
LUSC	trans	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg25214090	chr10:38739885	LOC399744	0.46	6.71	0.34	8.56e-11	Corneal astigmatism;
LUSC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg05347473	chr6:146136440	FBXO30	0.46	7.91	0.4	3.77e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg26384229	chr12:38710491	ALG10B	0.63	8.87	0.44	4.57e-17	Resting heart rate;
LUSC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.88	0.63	8.88e-39	Platelet count;
LUSC	trans	rs17683430	0.702	rs117303909	chr22:32377614	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.07	0.52	1.8e-24	Mean corpuscular volume;
LUSC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.17	-0.41	6.24e-15	Chronic sinus infection;
LUSC	cis	rs35146811	0.589	rs1727142	chr7:99816179	T/C	cg13334819	chr7:99746414	C7orf59	0.51	6.61	0.34	1.53e-10	Coronary artery disease;
LUSC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg27535305	chr1:53392650	SCP2	0.33	5.97	0.31	6e-9	Monocyte count;
LUSC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg00933542	chr6:150070202	PCMT1	0.33	6.7	0.34	8.84e-11	Lung cancer;
LUSC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.85	15.29	0.64	2.22e-40	Menarche (age at onset);
LUSC	trans	rs13314892	1.000	rs13314892	chr3:69795052	A/G	cg27026831	chr7:72971748	BCL7B	0.46	5.97	0.31	6.23e-9	QRS complex (12-leadsum);
LUSC	trans	rs9630182	0.599	rs11600996	chr11:13396166	T/C	cg00234616	chr2:74740572	TLX2	0.3	5.98	0.31	5.71e-9	Bone mineral density;
LUSC	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg07636037	chr3:49044803	WDR6	0.88	11.75	0.54	6.73e-27	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs4499344	0.921	rs752718	chr19:33086262	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.6	-7.86	-0.4	5.19e-14	Mean platelet volume;
LUSC	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg06627628	chr2:24431161	ITSN2	-0.74	-9.98	-0.48	1.08e-20	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg22601191	chr20:60968625	CABLES2	0.55	7.18	0.37	4.51e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg03886242	chr7:26192032	NFE2L3	-0.37	-6.14	-0.32	2.4e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9311676	0.656	rs55783924	chr3:58403610	C/T	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg04362960	chr10:104952993	NT5C2	0.6	9.21	0.45	3.82e-18	Arsenic metabolism;
LUSC	cis	rs3764563	1.000	rs2031061	chr19:15721961	T/C	cg20725493	chr19:15740067	CYP4F8	-0.71	-6.97	-0.36	1.75e-11	Inflammatory biomarkers;
LUSC	cis	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg09307838	chr4:120376055	NA	-0.48	-7.25	-0.37	2.84e-12	Diastolic blood pressure;
LUSC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.43	-7.14	-0.36	5.85e-12	Alzheimer's disease (late onset);
LUSC	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg24110177	chr3:50126178	RBM5	-0.41	-6.6	-0.34	1.6e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.45	-7.5	-0.38	5.65e-13	Pulse pressure;
LUSC	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg23093090	chr10:104574429	C10orf26	-0.35	-6.4	-0.33	5.4e-10	Arsenic metabolism;
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10150615	chr22:24372951	LOC391322	-0.36	-6.17	-0.32	1.97e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg07895657	chr22:50616420	PANX2	-0.35	-5.9	-0.31	8.75e-9	Obesity-related traits;
LUSC	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-7.79	-0.39	8.69e-14	Schizophrenia;
LUSC	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.32	0.45	1.64e-18	Lung cancer in ever smokers;
LUSC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg18305652	chr10:134549665	INPP5A	0.45	6.54	0.34	2.36e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg08017756	chr2:100939284	LONRF2	-0.45	-8.47	-0.42	8.15e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11997175	0.625	rs2882300	chr8:33585323	G/A	ch.8.33884649F	chr8:33765107	NA	0.4	6.38	0.33	5.78e-10	Body mass index;
LUSC	trans	rs2587949	0.593	rs2629248	chr3:4238859	A/G	cg15139668	chr4:4577005	NA	-0.41	-6.22	-0.32	1.51e-9	Periodontitis (DPAL);
LUSC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg04450456	chr4:17643702	FAM184B	0.4	6.92	0.35	2.25e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.85	-0.3	1.17e-8	Bipolar disorder;
LUSC	cis	rs7681440	0.560	rs2619371	chr4:90736678	A/G	cg06632027	chr4:90757378	SNCA	-0.36	-5.73	-0.3	2.24e-8	Dementia with Lewy bodies;
LUSC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg17971929	chr21:40555470	PSMG1	-0.63	-10.28	-0.49	9.88e-22	Cognitive function;
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.34	-7.07	-0.36	9.21e-12	Longevity;Endometriosis;
LUSC	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	11.21	0.52	5.56e-25	Lung cancer in ever smokers;
LUSC	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg18196295	chr10:418757	DIP2C	0.48	7.49	0.38	6.3e-13	Psychosis in Alzheimer's disease;
LUSC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg22508957	chr16:3507546	NAT15	0.68	11.11	0.52	1.28e-24	Tuberculosis;
LUSC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg08508325	chr11:3079039	CARS	-0.4	-9.04	-0.44	1.27e-17	Longevity;
LUSC	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23158103	chr7:148848205	ZNF398	-0.49	-8.22	-0.41	4.69e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.83	14.86	0.63	1.11e-38	Age at first birth;
LUSC	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.78	0.39	9.12e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.47	-0.42	7.81e-16	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg26384229	chr12:38710491	ALG10B	0.72	10.1	0.48	4.28e-21	Resting heart rate;
LUSC	cis	rs9403521	0.898	rs12198291	chr6:143975600	G/A	cg18240653	chr6:144019428	PHACTR2	-0.5	-6.07	-0.32	3.51e-9	Obesity-related traits;
LUSC	cis	rs7771547	0.507	rs6457918	chr6:36414308	A/T	cg07856975	chr6:36356162	ETV7	-0.35	-6.14	-0.32	2.35e-9	Platelet distribution width;
LUSC	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg19338460	chr6:170058176	WDR27	-1.01	-8.52	-0.42	5.37e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	1.02	19.34	0.73	1.88e-56	Cognitive function;
LUSC	cis	rs3806933	0.522	rs12522383	chr5:110455266	C/T	cg04022379	chr5:110408740	TSLP	0.61	9.3	0.45	1.89e-18	Eosinophilic esophagitis;
LUSC	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg01557791	chr16:72042693	DHODH	-0.54	-7.88	-0.4	4.73e-14	Fibrinogen levels;
LUSC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg05754148	chr16:3507555	NAT15	0.55	8.27	0.41	3.14e-15	Tuberculosis;
LUSC	cis	rs2625529	0.689	rs8178	chr15:72114747	G/A	cg16672083	chr15:72433130	SENP8	-0.47	-7.61	-0.38	2.79e-13	Red blood cell count;
LUSC	cis	rs11209185	0.527	rs11209186	chr1:68434340	A/G	cg22082780	chr1:68452167	NA	-0.44	-7.16	-0.36	5.29e-12	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg15423357	chr2:25149977	NA	0.46	9.29	0.45	2.04e-18	Body mass index in non-asthmatics;
LUSC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg03233332	chr7:66118400	NA	-0.42	-5.96	-0.31	6.28e-9	Aortic root size;
LUSC	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg06995285	chr7:2418615	EIF3B	0.38	5.75	0.3	2e-8	Multiple sclerosis;
LUSC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg05294307	chr14:35346193	BAZ1A	-0.57	-6.73	-0.35	7.5e-11	Psoriasis;
LUSC	trans	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg25214090	chr10:38739885	LOC399744	0.46	6.71	0.34	8.56e-11	Corneal astigmatism;
LUSC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg02475777	chr4:1388615	CRIPAK	0.4	6.07	0.32	3.53e-9	Obesity-related traits;
LUSC	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg09904177	chr6:26538194	HMGN4	-0.48	-7.64	-0.39	2.29e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg04727924	chr7:799746	HEATR2	-0.59	-6.27	-0.32	1.09e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25072359	chr17:41440525	NA	0.65	9.22	0.45	3.32e-18	Menopause (age at onset);
LUSC	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg20701182	chr2:24300061	SF3B14	0.6	6.32	0.33	8.22e-10	Lymphocyte counts;
LUSC	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg09835421	chr16:68378352	PRMT7	-0.67	-7.03	-0.36	1.17e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg02951883	chr7:2050386	MAD1L1	0.59	10.76	0.51	2.2e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.08	0.32	3.32e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.7	10.9	0.51	7.07e-24	Aortic root size;
LUSC	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg13319975	chr6:146136371	FBXO30	0.72	11.07	0.52	1.73e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg01097406	chr16:89675127	NA	0.31	6.31	0.33	8.81e-10	Vitiligo;
LUSC	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg23796481	chr11:64053134	BAD;GPR137	-0.5	-7.89	-0.4	4.4e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7605827	0.930	rs12692268	chr2:15595519	A/G	cg19274914	chr2:15703543	NA	0.46	8.76	0.43	1e-16	Educational attainment (years of education);
LUSC	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg09184832	chr6:79620586	NA	0.44	7.06	0.36	9.41e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg11752832	chr7:134001865	SLC35B4	0.55	8.66	0.43	2.09e-16	Mean platelet volume;
LUSC	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg23933602	chr10:16859644	RSU1	0.61	9.8	0.47	4.39e-20	Platelet distribution width;
LUSC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.15	17.41	0.69	9.13e-49	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg04362960	chr10:104952993	NT5C2	0.5	6.29	0.33	9.94e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.2	-0.32	1.65e-9	Sudden cardiac arrest;
LUSC	trans	rs6445975	0.578	rs6772652	chr3:58406693	A/G	cg18950693	chr14:70346909	SMOC1	-0.39	-5.96	-0.31	6.27e-9	Systemic lupus erythematosus;
LUSC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.7	0.3	2.64e-8	Menopause (age at onset);
LUSC	cis	rs977987	0.806	rs2865531	chr16:75390316	T/A	cg04384234	chr16:75411784	CFDP1	-0.4	-6.6	-0.34	1.64e-10	Dupuytren's disease;
LUSC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg14668632	chr7:2872130	GNA12	-0.42	-6.53	-0.34	2.47e-10	Height;
LUSC	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg19812747	chr11:111475976	SIK2	0.49	6.93	0.35	2.22e-11	Primary sclerosing cholangitis;
LUSC	cis	rs8099014	0.814	rs4245272	chr18:56115145	T/A	cg12907477	chr18:56117327	MIR122	0.45	7.05	0.36	1.01e-11	Platelet count;
LUSC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg03804128	chr16:635623	NA	0.31	6.06	0.31	3.74e-9	Height;
LUSC	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg11189052	chr15:85197271	WDR73	-0.46	-6.66	-0.34	1.16e-10	P wave terminal force;
LUSC	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg18232548	chr7:50535776	DDC	-0.52	-7.2	-0.37	4.03e-12	Systemic sclerosis;
LUSC	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg10547527	chr2:198650123	BOLL	-0.5	-5.85	-0.3	1.16e-8	Ulcerative colitis;
LUSC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	7.82	0.39	7.08e-14	Bipolar disorder;
LUSC	cis	rs7605827	0.964	rs10929367	chr2:15564718	T/C	cg19274914	chr2:15703543	NA	0.49	9.41	0.46	8.59e-19	Educational attainment (years of education);
LUSC	cis	rs9650315	0.929	rs7815788	chr8:57179020	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	6.82	0.35	4.17e-11	Height;
LUSC	cis	rs7615316	0.934	rs6780250	chr3:142179497	T/C	cg16271453	chr3:142027066	XRN1	-0.39	-6.67	-0.34	1.06e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg00540400	chr15:79124168	NA	-0.48	-8.43	-0.42	1.04e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.19e-30	Aortic root size;
LUSC	cis	rs977987	0.806	rs11862684	chr16:75461746	T/G	cg04384234	chr16:75411784	CFDP1	-0.43	-7.01	-0.36	1.35e-11	Dupuytren's disease;
LUSC	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg00277334	chr10:82204260	NA	-0.51	-7.34	-0.37	1.64e-12	Post bronchodilator FEV1;
LUSC	cis	rs7572644	0.699	rs1458396	chr2:28136351	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-6.95	-0.36	1.91e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg25036284	chr2:26402008	FAM59B	-0.74	-10.11	-0.48	3.89e-21	Gut microbiome composition (summer);
LUSC	cis	rs140410685	1	rs140410685	chr1:66118329	GCCT/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	6.36	0.33	6.62e-10	Age at voice drop;
LUSC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	9.27	0.45	2.37e-18	Motion sickness;
LUSC	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg01966878	chr4:90757139	SNCA	-0.41	-5.89	-0.31	9.29e-9	Neuroticism;
LUSC	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg23587288	chr2:27483067	SLC30A3	-0.29	-5.7	-0.3	2.61e-8	Blood metabolite levels;
LUSC	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg26068271	chr17:76253126	NA	0.58	10.03	0.48	7.13e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg22089800	chr15:90895588	ZNF774	-0.63	-9.53	-0.46	3.26e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.84	14.92	0.63	6.4e-39	Menarche (age at onset);
LUSC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg12560992	chr17:57184187	TRIM37	0.64	10.91	0.51	6.55e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05535760	chr7:792225	HEATR2	0.79	9.53	0.46	3.23e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.91	0.31	8.61e-9	Menopause (age at onset);
LUSC	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg06917634	chr15:78832804	PSMA4	-0.43	-5.75	-0.3	2e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg24375607	chr4:120327624	NA	0.76	12.23	0.56	1.14e-28	Corneal astigmatism;
LUSC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg04871131	chr7:94954202	PON1	-0.38	-6.06	-0.31	3.62e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.81	-15.08	-0.64	1.53e-39	Dental caries;
LUSC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.57	10.8	0.51	1.61e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.84	-0.35	3.89e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg13636640	chr20:31349939	DNMT3B	-0.81	-15.5	-0.65	3.33e-41	Inflammatory bowel disease;
LUSC	cis	rs6733011	0.559	rs6711022	chr2:99449536	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-6.38	-0.33	5.81e-10	Bipolar disorder;
LUSC	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg04586622	chr2:25135609	ADCY3	0.43	9.09	0.45	9.3e-18	Body mass index;
LUSC	cis	rs10504229	0.516	rs11776524	chr8:57983246	A/G	cg22535103	chr8:58192502	C8orf71	-0.46	-6.22	-0.32	1.48e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs240764	0.658	rs7740783	chr6:101263516	C/T	cg09795085	chr6:101329169	ASCC3	0.46	6.64	0.34	1.29e-10	Neuroticism;
LUSC	cis	rs11039100	1.000	rs12362696	chr11:5828034	G/A	cg05234568	chr11:5960015	NA	-0.51	-5.73	-0.3	2.27e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12681287	0.752	rs10092651	chr8:87247678	A/C	cg27223183	chr8:87520930	FAM82B	-0.46	-5.75	-0.3	2.06e-8	Caudate activity during reward;
LUSC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg23711669	chr6:146136114	FBXO30	-0.89	-16.79	-0.68	2.69e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4654899	0.714	rs12123093	chr1:21114416	C/T	cg01072550	chr1:21505969	NA	-0.41	-6.02	-0.31	4.49e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg08601574	chr20:25228251	PYGB	0.39	5.94	0.31	7.13e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.8	-0.43	7.69e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg19875535	chr5:140030758	IK	0.5	8.21	0.41	4.85e-15	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-1.14	-18.19	-0.71	7.14e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs3125734	0.572	rs7896627	chr10:64046354	T/G	cg19640130	chr10:64028056	RTKN2	-0.4	-6.92	-0.35	2.37e-11	Rheumatoid arthritis;
LUSC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.51	0.38	5.59e-13	Motion sickness;
LUSC	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.64	-0.3	3.56e-8	Recombination rate (females);
LUSC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	7.12	0.36	6.47e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg02569458	chr12:86230093	RASSF9	0.58	9.9	0.48	1.96e-20	Major depressive disorder;
LUSC	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg24631222	chr15:78858424	CHRNA5	-0.69	-9.46	-0.46	5.59e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg24375607	chr4:120327624	NA	-0.73	-10.94	-0.51	4.98e-24	Corneal astigmatism;
LUSC	cis	rs6469656	1.000	rs10505282	chr8:117676559	T/C	cg24004040	chr8:117650383	NA	-0.45	-6.48	-0.33	3.3e-10	Colorectal cancer;
LUSC	cis	rs793571	0.518	rs12906705	chr15:58955036	C/T	cg05156742	chr15:59063176	FAM63B	0.59	6.11	0.32	2.75e-9	Schizophrenia;
LUSC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00166722	chr3:10149974	C3orf24	0.63	8.3	0.41	2.6e-15	Alzheimer's disease;
LUSC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg10729496	chr3:10149963	C3orf24	0.51	7.06	0.36	9.87e-12	Alzheimer's disease;
LUSC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg17971929	chr21:40555470	PSMG1	0.78	13.76	0.6	1.94e-34	Cognitive function;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16438291	chr17:1945154	OVCA2;DPH1	-0.42	-6.25	-0.32	1.23e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28735056	1.000	rs28865701	chr18:77620911	A/G	cg20368463	chr18:77673604	PQLC1	-0.53	-7.7	-0.39	1.56e-13	Schizophrenia;
LUSC	cis	rs59104589	0.583	rs12624195	chr2:242254734	G/C	cg14842376	chr2:242211374	HDLBP	0.59	6.56	0.34	2.05e-10	Fibrinogen levels;
LUSC	trans	rs9324380	0.735	rs4322261	chr1:98405856	G/A	cg13344961	chr6:165341241	NA	0.58	6.01	0.31	4.97e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2979489	0.891	rs2979508	chr8:30388444	C/T	cg26383811	chr8:30366931	RBPMS	-0.51	-8.18	-0.41	6e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg11871910	chr12:69753446	YEATS4	0.6	8.04	0.4	1.6e-14	Response to diuretic therapy;
LUSC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg10909506	chr17:38081995	ORMDL3	0.33	5.94	0.31	6.99e-9	Self-reported allergy;
LUSC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-1.13	-17.64	-0.69	1.06e-49	Exhaled nitric oxide output;
LUSC	cis	rs4792901	0.722	rs12601849	chr17:41546288	G/T	cg22562494	chr17:41607896	ETV4	-0.33	-6.31	-0.33	8.79e-10	Dupuytren's disease;
LUSC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg11645453	chr3:52864694	ITIH4	0.35	7.93	0.4	3.28e-14	Bipolar disorder;
LUSC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-8.58	-0.43	3.55e-16	Chronic sinus infection;
LUSC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.96	0.58	2.1e-31	Prudent dietary pattern;
LUSC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25072359	chr17:41440525	NA	0.65	9.22	0.45	3.32e-18	Menopause (age at onset);
LUSC	cis	rs1865721	1.000	rs8091890	chr18:73197242	T/C	cg26385618	chr18:73139727	C18orf62	-0.47	-7.9	-0.4	3.94e-14	Intelligence;
LUSC	cis	rs983392	0.805	rs2081545	chr11:59958380	C/A	cg02771260	chr11:59836817	MS4A3	-0.36	-5.78	-0.3	1.74e-8	Alzheimer's disease (late onset);
LUSC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg16339924	chr4:17578868	LAP3	0.56	8.53	0.42	5.17e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs17767294	0.708	rs72848753	chr6:27878269	C/G	cg19566879	chr6:16334128	ATXN1	0.66	5.98	0.31	5.71e-9	Parkinson's disease;
LUSC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg26924012	chr15:45694286	SPATA5L1	1.12	20.85	0.75	2.06e-62	Homoarginine levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04517374	chr20:60981909	CABLES2	0.43	5.94	0.31	7e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg02423579	chr7:2872169	GNA12	-0.44	-6.22	-0.32	1.52e-9	Height;
LUSC	trans	rs11723530	0.538	rs4692759	chr4:170806538	G/A	cg14385325	chr17:74564821	ST6GALNAC2	-0.31	-6.01	-0.31	4.8e-9	Myopia (pathological);
LUSC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg00750074	chr16:89608354	SPG7	-0.52	-9.6	-0.47	1.95e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	13.21	0.59	2.51e-32	Monocyte percentage of white cells;
LUSC	cis	rs55665837	1.000	rs12792120	chr11:14469443	G/T	cg05501817	chr11:14380813	RRAS2	-0.4	-6.5	-0.34	2.85e-10	Vitamin D levels;
LUSC	cis	rs7804356	1.000	rs10248500	chr7:26863294	A/C	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.05e-9	Type 1 diabetes;
LUSC	cis	rs7605827	0.930	rs1528622	chr2:15557535	A/T	cg19274914	chr2:15703543	NA	0.45	8.56	0.42	4.19e-16	Educational attainment (years of education);
LUSC	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg19920283	chr7:105172520	RINT1	0.59	6.02	0.31	4.72e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07080220	chr10:102295463	HIF1AN	0.7	9.4	0.46	8.73e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg07148914	chr20:33460835	GGT7	0.49	7.35	0.37	1.55e-12	Height;
LUSC	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg16342193	chr10:102329863	NA	-0.36	-6.2	-0.32	1.64e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg03060546	chr3:49711283	APEH	0.67	9.14	0.45	6.17e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs227833	1.000	rs227833	chr6:44681840	G/C	cg20913747	chr6:44695427	NA	0.37	5.72	0.3	2.36e-8	Monobrow;
LUSC	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg02549819	chr16:58548995	SETD6	0.96	9.03	0.44	1.35e-17	Schizophrenia;
LUSC	cis	rs2742417	0.935	rs2742442	chr3:45748599	T/A	cg09608765	chr3:45636137	LIMD1	-0.38	-7.51	-0.38	5.48e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	1.1	17.9	0.7	1.04e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg25206134	chr2:45395956	NA	0.49	5.99	0.31	5.3e-9	Bipolar disorder;
LUSC	cis	rs12594515	1.000	rs11855509	chr15:45995474	C/T	cg06207120	chr15:45996521	NA	0.39	5.86	0.31	1.11e-8	Waist circumference;Weight;
LUSC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg24675056	chr1:15929824	NA	-0.47	-8.33	-0.41	2.15e-15	Systolic blood pressure;
LUSC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6554196	0.525	rs3819391	chr4:55526702	A/G	cg18836493	chr4:55524333	KIT	-0.44	-7.51	-0.38	5.51e-13	Monocyte count;
LUSC	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg21100191	chr22:23484243	RTDR1	0.92	16.16	0.66	8.69e-44	Bone mineral density;
LUSC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg21361702	chr7:150065534	REPIN1	0.58	9.16	0.45	5.54e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4631830	0.900	rs10763576	chr10:51538813	A/T	cg10326726	chr10:51549505	MSMB	-0.34	-5.74	-0.3	2.14e-8	Prostate-specific antigen levels;
LUSC	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg20307385	chr11:47447363	PSMC3	-0.89	-15.08	-0.64	1.48e-39	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs8077577	0.895	rs16960996	chr17:18110559	A/G	cg16794390	chr17:18148240	FLII	0.41	5.75	0.3	2.01e-8	Obesity-related traits;
LUSC	cis	rs5771069	0.896	rs137862	chr22:50446550	C/A	cg27068297	chr22:50451975	IL17REL	0.29	5.84	0.3	1.21e-8	Ulcerative colitis;
LUSC	cis	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05901451	chr6:126070800	HEY2	-0.58	-8.7	-0.43	1.5e-16	Endometrial cancer;
LUSC	cis	rs9811920	0.965	rs10222474	chr3:99862551	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	6.8	0.35	4.75e-11	Axial length;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10981275	chr2:3381760	TSSC1	0.43	6.9	0.35	2.58e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	7.23	0.37	3.21e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg02153584	chr22:29168773	CCDC117	0.66	10.6	0.5	8e-23	Lymphocyte counts;
LUSC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg05347473	chr6:146136440	FBXO30	0.53	8.95	0.44	2.59e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg16132339	chr22:24313637	DDTL;DDT	-0.39	-6.25	-0.32	1.29e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg12560992	chr17:57184187	TRIM37	-0.84	-15.49	-0.65	3.54e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg05084668	chr3:125655381	ALG1L	-0.5	-7.08	-0.36	8.76e-12	Blood pressure (smoking interaction);
LUSC	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.44	-0.42	9.51e-16	Neuroticism;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg03095379	chr16:31106146	VKORC1	0.4	5.98	0.31	5.68e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	8.13	0.41	8.21e-15	Homoarginine levels;
LUSC	trans	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg25214090	chr10:38739885	LOC399744	0.41	6.32	0.33	8.21e-10	Corneal astigmatism;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02999463	chr8:37707322	BRF2	0.77	6.01	0.31	4.81e-9	Cognitive performance;
LUSC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg12288994	chr5:1860383	NA	0.31	6.98	0.36	1.62e-11	Cardiovascular disease risk factors;
LUSC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg21361702	chr7:150065534	REPIN1	-0.49	-6.73	-0.35	7.19e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.61	0.6	7.09e-34	Cognitive test performance;
LUSC	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg12432903	chr7:1882776	MAD1L1	0.51	6.19	0.32	1.81e-9	Bipolar disorder;
LUSC	trans	rs7567288	0.636	rs34454875	chr2:134460268	G/A	cg12381416	chr3:14359266	NA	0.6	6.46	0.33	3.7e-10	Height;
LUSC	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg26441486	chr22:50317300	CRELD2	0.48	7.31	0.37	1.97e-12	Schizophrenia;
LUSC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg04362960	chr10:104952993	NT5C2	0.52	6.56	0.34	2.07e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6987853	0.563	rs2923408	chr8:42451526	A/G	cg09913449	chr8:42400586	C8orf40	0.43	7.27	0.37	2.5e-12	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg05343316	chr1:45956843	TESK2	0.67	8.88	0.44	4.32e-17	Platelet count;
LUSC	cis	rs6543140	0.601	rs7558013	chr2:102992806	G/T	cg09003973	chr2:102972529	NA	0.73	8.7	0.43	1.54e-16	Blood protein levels;
LUSC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg12365402	chr11:9010492	NRIP3	-0.5	-9.44	-0.46	6.52e-19	Hemoglobin concentration;
LUSC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg03036452	chr22:46663545	TTC38	0.58	5.76	0.3	1.88e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg13615516	chr5:77269221	NA	0.39	6.67	0.34	1.07e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7575217	0.670	rs796061	chr2:101727327	T/C	cg23907051	chr2:101730305	TBC1D8	-0.29	-7.7	-0.39	1.52e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs662735	0.515	rs532202	chr11:30839635	C/T	cg14844989	chr11:31128820	NA	0.37	5.81	0.3	1.45e-8	Hemoglobin concentration;Hematocrit;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06297571	chr12:132270829	SFRS8	0.41	6.52	0.34	2.59e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs131777	0.577	rs131748	chr22:51024837	A/G	cg00083937	chr22:51039805	MAPK8IP2	-0.5	-8.91	-0.44	3.38e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.78	-0.51	1.94e-23	Alzheimer's disease (late onset);
LUSC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg22903471	chr2:27725779	GCKR	-0.41	-7.07	-0.36	8.93e-12	Total body bone mineral density;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg12410154	chr3:57261551	APPL1	0.4	6.08	0.32	3.21e-9	Triglycerides;
LUSC	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-8.58	-0.42	3.7e-16	Joint mobility (Beighton score);
LUSC	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg05373962	chr22:49881684	NA	-0.44	-10.77	-0.51	2.12e-23	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-5.74	-0.3	2.14e-8	Neuroticism;
LUSC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg01448562	chr3:133502909	NA	-0.71	-11.96	-0.55	1.11e-27	Iron status biomarkers;
LUSC	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg00074818	chr8:8560427	CLDN23	0.56	9.55	0.46	2.93e-19	Obesity-related traits;
LUSC	cis	rs35079168	0.735	rs1887309	chr9:137308242	A/G	cg14344989	chr9:137329237	RXRA	0.41	6.81	0.35	4.47e-11	Intelligence;
LUSC	cis	rs10875746	0.951	rs10875748	chr12:48526360	A/G	cg13454099	chr12:49076203	C12orf41	-0.52	-6.11	-0.32	2.81e-9	Longevity (90 years and older);
LUSC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg05623727	chr3:50126028	RBM5	-0.34	-6.54	-0.34	2.26e-10	Body mass index;
LUSC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7605827	0.930	rs1861768	chr2:15625186	C/A	cg19274914	chr2:15703543	NA	0.46	8.87	0.44	4.51e-17	Educational attainment (years of education);
LUSC	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg13010199	chr12:38710504	ALG10B	0.43	6.07	0.32	3.39e-9	Morning vs. evening chronotype;
LUSC	trans	rs72674100	1.000	rs28655295	chr4:97990984	T/G	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12618769	1.000	rs72825704	chr2:99239164	T/C	cg10123293	chr2:99228465	UNC50	0.41	5.7	0.3	2.57e-8	Bipolar disorder;
LUSC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg04398451	chr17:18023971	MYO15A	-0.53	-8.94	-0.44	2.79e-17	Total body bone mineral density;
LUSC	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg22676075	chr6:135203613	NA	0.48	7.61	0.38	2.9e-13	Red blood cell count;
LUSC	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.33	-0.33	8.06e-10	Response to antipsychotic treatment;
LUSC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08439880	chr3:133502540	NA	-0.39	-7.2	-0.37	4.13e-12	Iron status biomarkers;
LUSC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg08917208	chr2:24149416	ATAD2B	0.53	5.97	0.31	6e-9	Lymphocyte counts;
LUSC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.72	11.62	0.54	1.86e-26	Coronary artery disease;
LUSC	cis	rs9549260	0.755	rs7333037	chr13:41215256	A/T	cg21288729	chr13:41239152	FOXO1	0.63	9.88	0.48	2.33e-20	Red blood cell count;
LUSC	cis	rs2455601	0.608	rs59025804	chr11:8870301	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-7.35	-0.37	1.53e-12	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs56283067	0.578	rs12197755	chr6:45387495	T/G	cg18551225	chr6:44695536	NA	-0.39	-5.78	-0.3	1.7e-8	Total body bone mineral density;
LUSC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.74	12.2	0.56	1.43e-28	Cognitive function;
LUSC	cis	rs793571	0.568	rs6494029	chr15:58923206	T/C	cg05156742	chr15:59063176	FAM63B	0.57	8.6	0.43	3.18e-16	Schizophrenia;
LUSC	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg05966235	chr16:28915196	ATP2A1	0.34	6.04	0.31	4.01e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs11723530	0.538	rs6848018	chr4:170809088	G/A	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.18	-0.32	1.87e-9	Myopia (pathological);
LUSC	cis	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg07460842	chr6:66804631	NA	0.7	8.69	0.43	1.68e-16	Type 2 diabetes;
LUSC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.79	0.63	2.05e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg01689657	chr7:91764605	CYP51A1	0.31	5.73	0.3	2.22e-8	Breast cancer;
LUSC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg23281280	chr6:28129359	ZNF389	0.44	5.8	0.3	1.52e-8	Parkinson's disease;
LUSC	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg14582100	chr15:45693742	SPATA5L1	0.41	7.59	0.38	3.33e-13	Glomerular filtration rate;
LUSC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	10.1	0.48	4.09e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.11	0.45	7.89e-18	Motion sickness;
LUSC	cis	rs17001868	0.527	rs9611324	chr22:40781162	T/C	cg07138101	chr22:40742427	ADSL	0.53	6.51	0.34	2.69e-10	Mammographic density (dense area);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg12107626	chr17:39992626	KLHL10;NT5C3L	0.49	6.2	0.32	1.71e-9	Cognitive function;Information processing speed;
LUSC	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg24375607	chr4:120327624	NA	0.75	12.14	0.55	2.34e-28	Corneal astigmatism;
LUSC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19717773	chr7:2847554	GNA12	-0.36	-5.95	-0.31	6.63e-9	Height;
LUSC	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg00191853	chr8:101177733	SPAG1	-0.41	-6.53	-0.34	2.46e-10	Atrioventricular conduction;
LUSC	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg20933634	chr6:27740509	NA	0.43	6.16	0.32	2.12e-9	Parkinson's disease;
LUSC	cis	rs7177699	0.557	rs8035093	chr15:79120670	T/C	cg15571903	chr15:79123663	NA	0.32	5.91	0.31	8.39e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2692947	0.526	rs4907225	chr2:96576670	C/T	cg23100626	chr2:96804247	ASTL	0.3	7.08	0.36	8.71e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	1.06	12.67	0.57	2.59e-30	Schizophrenia;
LUSC	cis	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg06521331	chr12:34319734	NA	-0.48	-7.77	-0.39	9.54e-14	Morning vs. evening chronotype;
LUSC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg24531977	chr5:56204891	C5orf35	-0.64	-9.57	-0.46	2.52e-19	Coronary artery disease;
LUSC	trans	rs11014632	0.509	rs4747531	chr10:25865513	G/A	cg07132650	chr16:83659882	CDH13	0.37	5.99	0.31	5.32e-9	Intraocular pressure;
LUSC	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg02569458	chr12:86230093	RASSF9	0.48	7.64	0.39	2.37e-13	Major depressive disorder;
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.6	-11.6	-0.54	2.32e-26	Longevity;Endometriosis;
LUSC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.57	-8.38	-0.42	1.51e-15	Obesity-related traits;
LUSC	cis	rs908922	0.887	rs6587688	chr1:152529622	C/T	cg20991723	chr1:152506922	NA	-0.51	-8.74	-0.43	1.16e-16	Hair morphology;
LUSC	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg11245181	chr6:149772854	ZC3H12D	0.29	6.22	0.32	1.45e-9	Dupuytren's disease;
LUSC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg13939156	chr17:80058883	NA	0.34	6.54	0.34	2.35e-10	Life satisfaction;
LUSC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Parkinson's disease;
LUSC	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.62	-0.38	2.62e-13	Bone mineral density;
LUSC	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg09904177	chr6:26538194	HMGN4	-0.47	-7.51	-0.38	5.45e-13	Schizophrenia;
LUSC	trans	rs72674100	1.000	rs28461859	chr4:97988033	T/A	cg16405019	chr1:18959625	PAX7	-0.58	-6.33	-0.33	7.76e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg06917634	chr15:78832804	PSMA4	0.46	6.36	0.33	6.6e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05871582	chr8:648014	ERICH1	0.42	6.16	0.32	2.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05226292	chr8:71520850	TRAM1	-0.51	-6.32	-0.33	8.27e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.81	13.56	0.6	1.09e-33	Bladder cancer;
LUSC	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg05283184	chr6:79620031	NA	-0.45	-8.59	-0.43	3.35e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs516243	0.703	rs284313	chr1:10736434	A/G	cg02903756	chr1:10750680	CASZ1	-0.47	-8.44	-0.42	9.76e-16	Migraine - clinic-based;
LUSC	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg01557791	chr16:72042693	DHODH	-0.57	-8.57	-0.42	4e-16	Fibrinogen levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01423147	chr1:89458345	RBMXL1;CCBL2	-0.43	-6.47	-0.33	3.51e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08808811	chr3:184079573	CLCN2	-0.51	-6.51	-0.34	2.73e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6669072	0.679	rs1766162	chr1:91313066	C/T	cg08895590	chr1:91227319	NA	0.33	7.05	0.36	1.03e-11	Cognitive function;
LUSC	cis	rs12681287	0.752	rs4534114	chr8:87271956	A/G	cg27223183	chr8:87520930	FAM82B	-0.46	-5.92	-0.31	7.82e-9	Caudate activity during reward;
LUSC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg04944784	chr2:26401820	FAM59B	0.79	11.29	0.53	2.95e-25	Gut microbiome composition (summer);
LUSC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg17143192	chr8:8559678	CLDN23	0.38	5.92	0.31	7.81e-9	Mood instability;
LUSC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg16797656	chr11:68205561	LRP5	-0.39	-7.13	-0.36	6.15e-12	Total body bone mineral density;
LUSC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs225245	0.782	rs161183	chr17:33919475	G/C	cg19694781	chr19:47549865	TMEM160	-0.41	-6.61	-0.34	1.51e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9807989	0.507	rs6758936	chr2:102991369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.36	-6.89	-0.35	2.77e-11	Asthma;
LUSC	cis	rs6700896	0.500	rs12025906	chr1:66101384	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	6.36	0.33	6.49e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg24375607	chr4:120327624	NA	0.79	12.03	0.55	6.08e-28	Corneal astigmatism;
LUSC	cis	rs13315871	0.929	rs2056120	chr3:58309436	A/T	cg20936604	chr3:58311152	NA	-0.72	-6.98	-0.36	1.63e-11	Cholesterol, total;
LUSC	cis	rs790123	0.692	rs790118	chr3:122380614	C/A	cg00926285	chr3:122398533	PARP14	-0.42	-5.97	-0.31	6.04e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs7903847	0.642	rs11817875	chr10:99158414	G/A	cg20016023	chr10:99160130	RRP12	-0.33	-8.04	-0.4	1.59e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs607541	0.764	rs629880	chr15:45934810	A/T	cg26924012	chr15:45694286	SPATA5L1	0.55	5.86	0.31	1.1e-8	Obesity-related traits;
LUSC	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg00310523	chr12:86230176	RASSF9	-0.35	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs7000551	0.725	rs2249102	chr8:22400193	C/G	cg12081754	chr8:22256438	SLC39A14	0.4	5.78	0.3	1.74e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.52	-10.4	-0.49	3.92e-22	Schizophrenia;
LUSC	trans	rs953492	0.672	rs1766030	chr1:243314577	C/T	cg27113374	chr10:38692187	CDC10L	-0.4	-5.97	-0.31	6.14e-9	Diastolic blood pressure;
LUSC	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg10909506	chr17:38081995	ORMDL3	0.32	5.78	0.3	1.7e-8	Self-reported allergy;
LUSC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg20302533	chr7:39170763	POU6F2	0.55	8.92	0.44	3.18e-17	IgG glycosylation;
LUSC	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg13319975	chr6:146136371	FBXO30	0.49	7.37	0.37	1.31e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05167392	chr10:103874593	LDB1	0.42	6.17	0.32	1.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg07741184	chr6:167504864	NA	0.51	8.94	0.44	2.77e-17	Crohn's disease;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08269986	chr1:35735167	ZMYM4	-0.42	-6.14	-0.32	2.33e-9	Hepatitis;
LUSC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.57	-6.79	-0.35	5.23e-11	Neutrophil percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05482832	chr17:74734106	MIR636;SFRS2;MFSD11	-0.43	-6.39	-0.33	5.54e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-8.71	-0.43	1.43e-16	Bipolar disorder;
LUSC	cis	rs7771547	0.519	rs67313027	chr6:36363487	G/C	cg07856975	chr6:36356162	ETV7	0.43	6.21	0.32	1.59e-9	Platelet distribution width;
LUSC	cis	rs4474465	1.000	rs11237522	chr11:78209879	A/G	cg27205649	chr11:78285834	NARS2	-0.54	-6.23	-0.32	1.41e-9	Alzheimer's disease (survival time);
LUSC	cis	rs501916	0.634	rs3743286	chr15:48065792	A/G	cg16110827	chr15:48056943	SEMA6D	-0.39	-6.0	-0.31	5.18e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg06917634	chr15:78832804	PSMA4	-0.58	-7.24	-0.37	3.03e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg11262906	chr1:85462892	MCOLN2	0.69	6.63	0.34	1.37e-10	Serum sulfate level;
LUSC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg27094323	chr7:1216898	NA	-0.35	-6.11	-0.32	2.84e-9	Longevity;Endometriosis;
LUSC	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg22705602	chr4:152727874	NA	-0.31	-6.17	-0.32	1.98e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg05283184	chr6:79620031	NA	0.56	11.42	0.53	1.03e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg09165964	chr15:75287851	SCAMP5	-0.87	-7.77	-0.39	9.65e-14	Lung cancer;
LUSC	cis	rs4974559	0.739	rs28412861	chr4:1320092	A/G	cg02980000	chr4:1222292	CTBP1	0.97	9.1	0.45	8.62e-18	Systolic blood pressure;
LUSC	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg13010199	chr12:38710504	ALG10B	0.66	10.22	0.49	1.61e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	15.19	0.64	5.33e-40	Platelet count;
LUSC	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg08601574	chr20:25228251	PYGB	0.43	6.57	0.34	1.94e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14829155	chr15:31115871	NA	0.6	9.08	0.45	9.48e-18	Huntington's disease progression;
LUSC	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg19743168	chr1:23544995	NA	0.4	7.86	0.39	5.44e-14	Height;
LUSC	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg13010199	chr12:38710504	ALG10B	0.65	10.14	0.49	2.97e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.24	-0.37	3.13e-12	Height;
LUSC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	14.38	0.62	8.07e-37	Platelet count;
LUSC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs4478858	0.735	rs4949389	chr1:31824023	A/G	cg00250761	chr1:31883323	NA	0.36	8.4	0.42	1.34e-15	Alcohol dependence;
LUSC	cis	rs7818345	0.967	rs11204039	chr8:19280442	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.19	0.37	4.25e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	trans	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs4776059	1.000	rs62023352	chr15:52889448	T/C	cg25063058	chr15:52860530	ARPP19	0.46	6.29	0.33	1.01e-9	Schizophrenia;
LUSC	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg20988073	chr3:125900093	ALDH1L1	-0.32	-6.36	-0.33	6.51e-10	Metabolite levels;
LUSC	cis	rs2835872	0.759	rs4816567	chr21:38988155	T/C	cg20424643	chr21:39039972	KCNJ6	0.36	5.68	0.3	2.91e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg11663144	chr21:46675770	NA	-0.42	-7.3	-0.37	2.18e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg07148914	chr20:33460835	GGT7	-0.45	-6.67	-0.34	1.07e-10	Height;
LUSC	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg25208724	chr1:156163844	SLC25A44	1.08	22.41	0.78	1.51e-68	Testicular germ cell tumor;
LUSC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg04455712	chr21:45112962	RRP1B	0.46	8.67	0.43	1.94e-16	Mean corpuscular volume;
LUSC	cis	rs9311676	0.632	rs6445978	chr3:58379586	T/A	cg26110898	chr3:58419937	PDHB	0.42	6.83	0.35	4.07e-11	Systemic lupus erythematosus;
LUSC	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg14582100	chr15:45693742	SPATA5L1	0.44	8.44	0.42	1.01e-15	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs1005224	1.000	rs1005224	chr14:76173860	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.51	-6.72	-0.35	7.75e-11	Large artery stroke;
LUSC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16405210	chr4:1374714	KIAA1530	-0.57	-9.05	-0.44	1.24e-17	Obesity-related traits;
LUSC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg06028605	chr16:24865363	SLC5A11	0.46	8.1	0.41	1.02e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.24	0.52	4.63e-25	Prudent dietary pattern;
LUSC	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg16586182	chr3:47516702	SCAP	-0.51	-8.04	-0.4	1.62e-14	Colorectal cancer;
LUSC	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg12002119	chr2:101014098	CHST10	0.34	5.74	0.3	2.11e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-0.99	-19.49	-0.73	4.99e-57	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg03563238	chr19:33554763	RHPN2	-0.37	-5.97	-0.31	6.18e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	7.27	0.37	2.55e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs16912285	0.688	rs12279442	chr11:24317174	C/G	ch.11.24196551F	chr11:24239977	NA	0.9	9.64	0.47	1.45e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.61	-0.69	1.49e-49	Exhaled nitric oxide output;
LUSC	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg07080220	chr10:102295463	HIF1AN	0.59	8.0	0.4	2.03e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs1941687	0.797	rs12607190	chr18:31394699	G/A	cg27147174	chr7:100797783	AP1S1	-0.44	-6.46	-0.33	3.71e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.61	0.34	1.48e-10	Corneal astigmatism;
LUSC	trans	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg26384229	chr12:38710491	ALG10B	0.65	10.24	0.49	1.37e-21	Morning vs. evening chronotype;
LUSC	trans	rs11088226	0.681	rs2833895	chr21:33929802	G/A	cg09050820	chr6:167586206	TCP10L2	0.75	9.74	0.47	6.57e-20	Gastritis;
LUSC	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.77	-0.43	9.17e-17	Response to antipsychotic treatment;
LUSC	cis	rs35883536	0.551	rs6666607	chr1:101032368	A/G	cg09408571	chr1:101003634	GPR88	-0.3	-5.71	-0.3	2.46e-8	Monocyte count;
LUSC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.7	12.21	0.56	1.32e-28	Prudent dietary pattern;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05981015	chr17:27717136	TAOK1	0.42	5.99	0.31	5.37e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg00945038	chr17:61921165	SMARCD2	0.38	5.65	0.3	3.45e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg22601191	chr20:60968625	CABLES2	-0.37	-5.92	-0.31	7.96e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg16558253	chr16:72132732	DHX38	-0.4	-6.16	-0.32	2.06e-9	Fibrinogen levels;
LUSC	cis	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg20368463	chr18:77673604	PQLC1	0.62	5.73	0.3	2.19e-8	Opioid sensitivity;
LUSC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg05872129	chr22:39784769	NA	-0.59	-10.78	-0.51	1.82e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.67	-0.54	1.26e-26	Coffee consumption (cups per day);
LUSC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08677398	chr8:58056175	NA	0.53	7.05	0.36	1.04e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg06697600	chr4:7070879	GRPEL1	-0.42	-7.19	-0.37	4.34e-12	Monocyte percentage of white cells;
LUSC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg24733560	chr20:60626293	TAF4	0.41	6.73	0.35	7.47e-11	Body mass index;
LUSC	trans	rs953492	0.701	rs1796846	chr1:243306924	A/G	cg01826367	chr1:224180288	NA	-0.42	-6.43	-0.33	4.29e-10	Diastolic blood pressure;
LUSC	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg08807101	chr21:30365312	RNF160	0.47	6.37	0.33	6.12e-10	Cognitive test performance;
LUSC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21582582	chr3:182698605	DCUN1D1	0.45	8.15	0.41	7.46e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	1.09	15.49	0.65	3.65e-41	Uric acid levels;
LUSC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.37	5.88	0.31	9.88e-9	Total body bone mineral density;
LUSC	cis	rs432925	0.600	rs385862	chr16:344659	A/G	cg08823186	chr16:347294	AXIN1	0.34	5.97	0.31	6.06e-9	Morning vs. evening chronotype;
LUSC	cis	rs2996428	0.667	rs113120570	chr1:3770450	G/C	cg22529645	chr1:3704559	LRRC47	0.35	6.12	0.32	2.63e-9	Red cell distribution width;
LUSC	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg03676636	chr4:99064102	C4orf37	0.37	7.91	0.4	3.7e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg02772935	chr3:125709198	NA	-0.48	-5.78	-0.3	1.67e-8	Blood pressure (smoking interaction);
LUSC	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.17	0.52	7.99e-25	Colorectal cancer;
LUSC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg04121214	chr22:50244548	NA	-0.34	-5.69	-0.3	2.79e-8	Schizophrenia;
LUSC	cis	rs921665	0.505	rs1037467	chr2:3200948	A/C	cg02624386	chr2:3182749	NA	-0.58	-6.45	-0.33	3.96e-10	World class endurance athleticism;
LUSC	cis	rs4343996	1.000	rs7794279	chr7:3341806	A/G	cg21248987	chr7:3385318	SDK1	0.4	6.83	0.35	4.07e-11	Motion sickness;
LUSC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg16325326	chr1:53192061	ZYG11B	0.7	11.29	0.53	3.04e-25	Monocyte count;
LUSC	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.56	0.34	2.01e-10	Testicular germ cell tumor;
LUSC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.95	0.36	1.97e-11	Cystic fibrosis severity;
LUSC	cis	rs72634258	0.945	rs225132	chr1:8095500	A/C	cg00042356	chr1:8021962	PARK7	0.63	7.8	0.39	8.15e-14	Inflammatory bowel disease;
LUSC	cis	rs62400317	0.859	rs10948201	chr6:45093494	A/C	cg18551225	chr6:44695536	NA	0.42	6.73	0.35	7.45e-11	Total body bone mineral density;
LUSC	cis	rs1124376	1.000	rs12488369	chr3:20154059	G/T	cg05072819	chr3:20081367	KAT2B	-0.65	-7.56	-0.38	3.83e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs7804356	0.906	rs10225904	chr7:26869888	G/A	cg03456212	chr7:26904342	SKAP2	-0.56	-6.44	-0.33	4.06e-10	Type 1 diabetes;
LUSC	cis	rs9660992	1.000	rs1779410	chr1:205248759	A/G	cg21545522	chr1:205238299	TMCC2	0.42	7.94	0.4	3.01e-14	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06112727	chr8:22102711	POLR3D;MIR320A	-0.43	-6.37	-0.33	6.14e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg15448220	chr1:150897856	SETDB1	0.4	5.87	0.31	1.02e-8	Melanoma;
LUSC	trans	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg09050820	chr6:167586206	TCP10L2	0.73	9.47	0.46	5.31e-19	Gastritis;
LUSC	cis	rs3812762	0.843	rs10732515	chr11:8801790	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.4	6.97	0.36	1.69e-11	Hypospadias;
LUSC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg02018176	chr4:1364513	KIAA1530	0.52	8.87	0.44	4.63e-17	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04807856	chr11:73685776	UCP2	0.37	6.25	0.32	1.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg27535305	chr1:53392650	SCP2	0.39	7.26	0.37	2.82e-12	Monocyte count;
LUSC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	0.93	17.86	0.7	1.45e-50	Heart rate;
LUSC	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg08975724	chr8:8085496	FLJ10661	0.51	7.78	0.39	9.06e-14	Parkinson's disease;
LUSC	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.69	10.16	0.49	2.54e-21	Corneal astigmatism;
LUSC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.07	-0.48	5.45e-21	Hemoglobin concentration;
LUSC	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.22	-0.32	1.46e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20456258	chr4:962124	DGKQ	0.33	6.18	0.32	1.89e-9	Sjögren's syndrome;
LUSC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg06637938	chr14:75390232	RPS6KL1	0.52	8.36	0.42	1.68e-15	Height;
LUSC	trans	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04565464	chr8:145669602	NFKBIL2	0.39	6.41	0.33	4.9e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg20307385	chr11:47447363	PSMC3	0.43	6.32	0.33	8.29e-10	Subjective well-being;
LUSC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg17971929	chr21:40555470	PSMG1	-0.63	-10.39	-0.49	4.14e-22	Cognitive function;
LUSC	cis	rs3820928	0.934	rs4675117	chr2:227769794	A/G	cg11843606	chr2:227700838	RHBDD1	0.54	7.64	0.39	2.28e-13	Pulmonary function;
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg00431813	chr7:1051703	C7orf50	-0.38	-5.97	-0.31	6.1e-9	Longevity;Endometriosis;
LUSC	cis	rs9815354	1.000	rs1717006	chr3:41940448	A/C	cg03022575	chr3:42003672	ULK4	0.53	5.96	0.31	6.27e-9	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	5.89	0.31	9.27e-9	Schizophrenia;
LUSC	cis	rs9653442	0.564	rs7601892	chr2:100789490	G/A	cg22139774	chr2:100720529	AFF3	-0.41	-7.04	-0.36	1.09e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	trans	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.85	0.39	5.61e-14	Ulcerative colitis;
LUSC	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg17366294	chr4:99064904	C4orf37	0.59	10.39	0.49	4.12e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.5	-8.42	-0.42	1.13e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg17366294	chr4:99064904	C4orf37	0.55	9.51	0.46	3.91e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg09479241	chr17:27052676	TLCD1	0.46	6.23	0.32	1.44e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-0.83	-16.18	-0.66	6.79e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg09877947	chr5:131593287	PDLIM4	0.59	10.0	0.48	8.91e-21	Acylcarnitine levels;
LUSC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg23985595	chr17:80112537	CCDC57	0.31	5.88	0.31	9.8e-9	Life satisfaction;
LUSC	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg26893861	chr17:41843967	DUSP3	0.88	13.77	0.6	1.79e-34	Triglycerides;
LUSC	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg27471124	chr11:109292789	C11orf87	0.37	6.74	0.35	6.83e-11	Schizophrenia;
LUSC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	14.01	0.61	2.15e-35	Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25509121	chr17:61851092	DDX42;CCDC47	0.47	6.49	0.33	3.06e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2708977	0.933	rs2464914	chr2:97179828	A/G	cg01950434	chr2:97203154	ARID5A	-0.54	-8.05	-0.4	1.46e-14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg07424592	chr7:64974309	NA	-0.64	-5.73	-0.3	2.24e-8	Diabetic kidney disease;
LUSC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18876405	chr7:65276391	NA	0.55	8.81	0.43	6.74e-17	Aortic root size;
LUSC	cis	rs10887741	0.646	rs7903568	chr10:89433931	T/A	cg13926569	chr10:89418898	PAPSS2	0.32	6.87	0.35	3.19e-11	Exercise (leisure time);
LUSC	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg08997352	chr12:9597637	DDX12	-0.6	-9.5	-0.46	4.24e-19	Breast size;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01720705	chr1:231175557	FAM89A	-0.43	-5.99	-0.31	5.45e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7202877	0.656	rs247427	chr16:75439132	T/C	cg04384234	chr16:75411784	CFDP1	0.63	8.18	0.41	5.87e-15	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg08017756	chr2:100939284	LONRF2	-0.47	-8.78	-0.43	8.83e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.49	7.69	0.39	1.7e-13	Colorectal cancer;
LUSC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg09238746	chr17:78121135	EIF4A3	0.97	14.88	0.63	8.88e-39	Yeast infection;
LUSC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25072359	chr17:41440525	NA	0.66	9.42	0.46	7.64e-19	Menopause (age at onset);
LUSC	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg22437258	chr11:111473054	SIK2	0.52	7.29	0.37	2.29e-12	Primary sclerosing cholangitis;
LUSC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg13385521	chr17:29058706	SUZ12P	0.66	6.43	0.33	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-1.02	-12.72	-0.57	1.71e-30	Blood pressure (smoking interaction);
LUSC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg01238044	chr22:24384105	GSTT1	-0.56	-8.83	-0.43	6.13e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg21724239	chr8:58056113	NA	0.77	7.97	0.4	2.61e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs497273	0.534	rs608394	chr12:121194053	C/T	cg02419362	chr12:121203948	SPPL3	0.43	7.8	0.39	8.14e-14	Systemic lupus erythematosus;
LUSC	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.67	-0.43	1.92e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg00343986	chr7:65444356	GUSB	-0.4	-6.13	-0.32	2.46e-9	Aortic root size;
LUSC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg03579872	chr1:53393473	SCP2	-0.39	-5.97	-0.31	6.13e-9	Monocyte count;
LUSC	cis	rs4919087	0.962	rs3814164	chr10:98982749	G/A	cg25902810	chr10:99078978	FRAT1	0.5	7.1	0.36	7.66e-12	Monocyte count;
LUSC	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.74	14.33	0.62	1.24e-36	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg06636001	chr8:8085503	FLJ10661	0.48	7.13	0.36	6.42e-12	Neuroticism;
LUSC	cis	rs4604732	0.588	rs4925552	chr1:247631749	C/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.42	6.58	0.34	1.78e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg08125733	chr17:73851984	WBP2	0.49	7.0	0.36	1.38e-11	White matter hyperintensity burden;
LUSC	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-0.86	-16.62	-0.67	1.25e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.15	-0.32	2.16e-9	Total body bone mineral density;
LUSC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6906287	0.625	rs7453914	chr6:118692981	A/T	cg21191810	chr6:118973309	C6orf204	0.38	6.97	0.36	1.66e-11	Electrocardiographic conduction measures;
LUSC	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	0.77	11.36	0.53	1.68e-25	Gut microbiome composition (summer);
LUSC	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.46	-0.42	8.36e-16	Retinal vascular caliber;
LUSC	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-8.01	-0.4	1.97e-14	Morning vs. evening chronotype;
LUSC	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg08645402	chr16:4508243	NA	0.54	9.09	0.45	8.97e-18	Schizophrenia;
LUSC	cis	rs55675132	0.704	rs57276179	chr1:115606491	A/G	cg01522456	chr1:115632236	TSPAN2	-0.45	-5.7	-0.3	2.65e-8	Schizophrenia;
LUSC	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg06623918	chr6:96969491	KIAA0776	0.77	9.23	0.45	3.28e-18	Migraine;Coronary artery disease;
LUSC	cis	rs6540559	0.546	rs75308488	chr1:210030639	T/C	cg22029157	chr1:209979665	IRF6	0.78	8.93	0.44	2.98e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs9677476	0.863	rs10181630	chr2:232091757	C/T	cg07929768	chr2:232055508	NA	0.35	6.5	0.34	2.88e-10	Food antigen IgG levels;
LUSC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00149659	chr3:10157352	C3orf10	0.99	14.46	0.62	3.71e-37	Alzheimer's disease;
LUSC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.71	10.6	0.5	7.97e-23	Cognitive test performance;
LUSC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.07	-17.76	-0.7	3.74e-50	Primary sclerosing cholangitis;
LUSC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg15445000	chr17:37608096	MED1	0.4	6.76	0.35	6.29e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg24399712	chr22:39784796	NA	-0.63	-10.43	-0.5	3e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs67981189	0.634	rs221900	chr14:71604354	C/T	cg15816911	chr14:71606274	NA	0.37	6.61	0.34	1.51e-10	Schizophrenia;
LUSC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.84	-0.54	3.05e-27	Chronic sinus infection;
LUSC	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.54	7.13	0.36	6.42e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg25214090	chr10:38739885	LOC399744	0.52	7.54	0.38	4.52e-13	Corneal astigmatism;
LUSC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg24642844	chr7:1081250	C7orf50	-0.46	-7.4	-0.38	1.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1163251	0.902	rs514491	chr1:120216743	C/T	cg19096424	chr1:120255104	PHGDH	0.48	6.53	0.34	2.39e-10	Blood metabolite levels;
LUSC	trans	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.14	0.32	2.31e-9	Corneal astigmatism;
LUSC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg07167872	chr1:205819463	PM20D1	0.48	6.88	0.35	3.05e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs62408225	1.000	rs2325291	chr6:90986686	G/A	cg06866423	chr6:90926672	BACH2	0.42	5.92	0.31	8.02e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6543140	0.964	rs10169192	chr2:103072211	A/G	cg09003973	chr2:102972529	NA	0.54	7.02	0.36	1.25e-11	Blood protein levels;
LUSC	cis	rs2637266	0.783	rs11001866	chr10:78486774	C/T	cg18941641	chr10:78392320	NA	0.36	6.61	0.34	1.53e-10	Pulmonary function;
LUSC	cis	rs1385374	0.563	rs12299194	chr12:129264838	A/G	cg09035930	chr12:129282057	SLC15A4	-0.61	-6.53	-0.34	2.44e-10	Systemic lupus erythematosus;
LUSC	cis	rs6469656	1.000	rs13262725	chr8:117661566	C/T	cg24004040	chr8:117650383	NA	-0.45	-6.48	-0.33	3.3e-10	Colorectal cancer;
LUSC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.1	-19.16	-0.72	1e-55	Homoarginine levels;
LUSC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	20.32	0.74	2.48e-60	Prudent dietary pattern;
LUSC	cis	rs6669072	0.565	rs4658085	chr1:91266786	T/C	cg08895590	chr1:91227319	NA	-0.27	-5.75	-0.3	1.99e-8	Cognitive function;
LUSC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg08470875	chr2:26401718	FAM59B	-0.67	-8.9	-0.44	3.72e-17	Gut microbiome composition (summer);
LUSC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.54	9.55	0.46	2.9e-19	Osteoporosis;
LUSC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg14668632	chr7:2872130	GNA12	-0.46	-7.22	-0.37	3.54e-12	Height;
LUSC	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg09904177	chr6:26538194	HMGN4	0.51	6.96	0.36	1.85e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg26384229	chr12:38710491	ALG10B	0.7	10.77	0.51	2.06e-23	Morning vs. evening chronotype;
LUSC	cis	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg16576597	chr16:28551801	NUPR1	0.3	5.99	0.31	5.56e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs10754283	0.935	rs10801756	chr1:90101832	C/T	cg21401794	chr1:90099060	LRRC8C	0.65	9.79	0.47	4.51e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.44	-0.38	8.82e-13	Blood metabolite levels;
LUSC	cis	rs2130392	0.926	rs7679215	chr4:185635311	C/T	cg04058563	chr4:185651563	MLF1IP	-0.39	-6.56	-0.34	2.04e-10	Kawasaki disease;
LUSC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg18350739	chr11:68623251	NA	-0.39	-6.84	-0.35	3.88e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1971762	0.563	rs10747678	chr12:54077687	A/C	cg23533419	chr12:54090519	NA	0.36	5.88	0.31	9.8e-9	Height;
LUSC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg18681998	chr4:17616180	MED28	0.89	17.19	0.69	7.03e-48	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg06618935	chr21:46677482	NA	-0.39	-7.95	-0.4	2.83e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg07169764	chr2:136633963	MCM6	0.95	12.81	0.57	7.61e-31	Corneal structure;
LUSC	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.73	-13.36	-0.59	6.61e-33	Pulse pressure;
LUSC	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.92	-0.35	2.35e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg11502198	chr6:26597334	ABT1	0.91	11.21	0.52	5.77e-25	Small cell lung carcinoma;
LUSC	cis	rs7178375	0.607	rs71474639	chr15:31213257	A/G	cg03767031	chr15:31195708	MTMR15	0.77	6.8	0.35	4.81e-11	Hypertriglyceridemia;
LUSC	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg09839279	chr12:125627357	AACS	-0.33	-5.89	-0.31	9.51e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-10.0	-0.48	9.04e-21	Migraine;Coronary artery disease;
LUSC	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg09092052	chr15:45571596	NA	0.46	6.34	0.33	7.51e-10	Glomerular filtration rate;
LUSC	cis	rs10743315	0.557	rs1552750	chr12:19356505	A/T	cg02471346	chr12:19282374	PLEKHA5	0.74	5.99	0.31	5.43e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.87	-15.4	-0.64	8.03e-41	Cognitive function;
LUSC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg07936489	chr17:37558343	FBXL20	0.72	9.97	0.48	1.12e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg07148914	chr20:33460835	GGT7	0.52	7.53	0.38	4.77e-13	Height;
LUSC	cis	rs9311676	0.632	rs11705721	chr3:58400414	T/C	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.11e-10	Systemic lupus erythematosus;
LUSC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg13393036	chr8:95962371	TP53INP1	0.39	7.4	0.38	1.12e-12	Type 2 diabetes;
LUSC	trans	rs459571	0.959	rs410876	chr9:136893867	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.76	-12.5	-0.56	1.13e-29	Platelet distribution width;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg04319218	chr19:11307663	KANK2	0.63	6.21	0.32	1.56e-9	Body mass index;
LUSC	cis	rs10501293	0.529	rs2902301	chr11:43093159	A/T	cg03447554	chr11:43094025	NA	-0.37	-7.01	-0.36	1.36e-11	Cognitive performance;
LUSC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.6	-11.13	-0.52	1.12e-24	Longevity;Endometriosis;
LUSC	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21659725	chr3:3221576	CRBN	-0.64	-10.71	-0.51	3.44e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg08470875	chr2:26401718	FAM59B	-0.7	-9.38	-0.46	1.07e-18	Gut microbiome composition (summer);
LUSC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg00509249	chr6:109615579	CCDC162	-0.33	-5.9	-0.31	9.08e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs979233	0.502	rs276277	chr5:42076852	T/A	cg07010552	chr17:7358735	CHRNB1	-0.41	-6.09	-0.32	3.06e-9	Systemic lupus erythematosus;
LUSC	cis	rs11158026	0.603	rs8020545	chr14:55409070	T/A	cg04306507	chr14:55594613	LGALS3	0.36	6.47	0.33	3.44e-10	Parkinson's disease;
LUSC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg01879757	chr17:41196368	BRCA1	0.45	7.32	0.37	1.84e-12	Menopause (age at onset);
LUSC	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg25482853	chr8:67687455	SGK3	1.19	16.05	0.66	2.21e-43	Lung disease severity in cystic fibrosis;
LUSC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07343612	chr16:622815	PIGQ	-0.72	-12.16	-0.55	2e-28	Height;
LUSC	cis	rs7712401	0.655	rs6884312	chr5:122103977	A/C	cg19077854	chr5:122220652	SNX24	0.31	6.97	0.36	1.75e-11	Mean platelet volume;
LUSC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg20887711	chr4:1340912	KIAA1530	0.41	6.26	0.32	1.16e-9	Obesity-related traits;
LUSC	cis	rs9807989	0.507	rs3213732	chr2:102998279	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.27e-12	Asthma;
LUSC	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg17633681	chr16:88106987	BANP	0.5	9.19	0.45	4.32e-18	Menopause (age at onset);
LUSC	cis	rs7815909	0.604	rs73679807	chr8:57202782	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	6.86	0.35	3.39e-11	Height;
LUSC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg14552801	chr7:65878734	NA	-0.45	-6.52	-0.34	2.6e-10	Aortic root size;
LUSC	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.69e-11	Response to antipsychotic treatment;
LUSC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg15445000	chr17:37608096	MED1	-0.39	-6.69	-0.34	9.29e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2853333	1.000	rs2853336	chr19:35746799	G/A	cg12287945	chr19:35758300	LSR	-0.37	-5.87	-0.31	1.05e-8	Red blood cell count;
LUSC	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.83	14.37	0.62	8.77e-37	Metabolic syndrome;
LUSC	trans	rs41419946	1.000	rs12072131	chr1:165397025	G/A	cg06650914	chr18:74208293	NA	0.66	6.21	0.32	1.55e-9	Gut microbiome composition (winter);
LUSC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.88e-11	Primary biliary cholangitis;
LUSC	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-10.07	-0.48	5.39e-21	Morning vs. evening chronotype;
LUSC	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18854424	chr1:2615690	NA	0.51	10.14	0.49	3e-21	Ulcerative colitis;
LUSC	cis	rs4478137	0.501	rs7657483	chr4:164232102	T/C	cg06758707	chr4:164254230	NPY1R	-0.51	-6.79	-0.35	5.2e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg22532475	chr10:104410764	TRIM8	0.24	5.64	0.3	3.58e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21171335	chr12:122356390	WDR66	0.63	9.31	0.45	1.82e-18	Mean corpuscular volume;
LUSC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.44	0.38	8.79e-13	Motion sickness;
LUSC	cis	rs9329289	0.510	rs35854428	chr10:2554280	T/C	cg15501526	chr10:2543763	NA	0.53	9.3	0.45	1.89e-18	Age-related hearing impairment;
LUSC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4285028	0.747	rs4048699	chr3:121404483	A/G	cg11130432	chr3:121712080	ILDR1	0.53	8.06	0.4	1.37e-14	Multiple sclerosis;
LUSC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg18230493	chr5:56204884	C5orf35	-0.66	-10.15	-0.49	2.81e-21	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg07701084	chr6:150067640	NUP43	0.57	8.92	0.44	3.05e-17	Lung cancer;
LUSC	cis	rs244293	1.000	rs244286	chr17:53232594	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.7	-0.3	2.68e-8	Menarche (age at onset);
LUSC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg02187348	chr16:89574699	SPG7	0.49	7.59	0.38	3.22e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg16447950	chr5:562315	NA	-0.57	-6.95	-0.36	1.97e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg22089800	chr15:90895588	ZNF774	0.63	9.42	0.46	7.97e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs56283067	0.847	rs62435998	chr6:44695206	C/T	cg20913747	chr6:44695427	NA	-0.48	-7.75	-0.39	1.12e-13	Total body bone mineral density;
LUSC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-0.77	-15.04	-0.64	2.04e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg09034736	chr1:150693464	HORMAD1	0.43	6.3	0.33	9.53e-10	Melanoma;
LUSC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.34	-0.42	1.95e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs925255	0.810	rs2048240	chr2:28640327	C/T	cg01273330	chr2:28605224	NA	-0.38	-6.15	-0.32	2.27e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg16228356	chr17:43848958	NA	0.28	6.42	0.33	4.67e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7851660	0.967	rs7847126	chr9:100600635	A/C	cg13688889	chr9:100608707	NA	-0.61	-10.55	-0.5	1.19e-22	Strep throat;
LUSC	cis	rs12200560	0.524	rs1413525	chr6:97073096	C/T	cg06623918	chr6:96969491	KIAA0776	0.5	7.06	0.36	9.85e-12	Coronary heart disease;
LUSC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-9.27	-0.45	2.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.14	0.41	8.18e-15	Prudent dietary pattern;
LUSC	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg26102564	chr10:131424627	MGMT	0.37	5.79	0.3	1.59e-8	Response to temozolomide;
LUSC	trans	rs62238980	0.614	rs78680556	chr22:32395329	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg03929089	chr4:120376271	NA	0.74	6.95	0.36	1.87e-11	Axial length;
LUSC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.56e-24	Aortic root size;
LUSC	trans	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07923666	chr12:49932857	KCNH3	-0.51	-6.33	-0.33	7.74e-10	Resting heart rate;
LUSC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg04518342	chr5:131593106	PDLIM4	0.45	7.93	0.4	3.23e-14	Breast cancer;
LUSC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg12963246	chr6:28129442	ZNF389	0.51	7.35	0.37	1.52e-12	Parkinson's disease;
LUSC	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.56	-9.25	-0.45	2.75e-18	Breast cancer;
LUSC	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg06360820	chr2:242988706	NA	0.72	8.4	0.42	1.29e-15	Obesity-related traits;
LUSC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg16524733	chr11:117070046	TAGLN	0.41	6.63	0.34	1.37e-10	Blood protein levels;
LUSC	cis	rs6142102	0.923	rs6059635	chr20:32613493	A/T	cg08999081	chr20:33150536	PIGU	0.36	6.39	0.33	5.58e-10	Skin pigmentation;
LUSC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11644478	chr21:40555479	PSMG1	-0.64	-9.81	-0.47	3.84e-20	Menarche (age at onset);
LUSC	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	6.85	0.35	3.59e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg23711669	chr6:146136114	FBXO30	0.83	14.81	0.63	1.69e-38	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg02800362	chr5:177631904	HNRNPAB	0.85	12.83	0.57	6.81e-31	Obesity-related traits;
LUSC	cis	rs727505	1.000	rs66513837	chr7:124492763	A/G	cg23710748	chr7:124431027	NA	-0.42	-7.47	-0.38	6.9e-13	Lewy body disease;
LUSC	cis	rs6500395	0.962	rs1386042	chr16:48600332	G/A	cg04672837	chr16:48644449	N4BP1	0.43	6.17	0.32	1.94e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.29	0.53	3.03e-25	Eye color traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24283186	chr10:49514530	NA	-0.4	-6.08	-0.32	3.2e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg00031303	chr3:195681400	NA	0.69	9.87	0.48	2.5e-20	Pancreatic cancer;
LUSC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg18681998	chr4:17616180	MED28	0.79	14.0	0.61	2.26e-35	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg21862992	chr11:68658383	NA	-0.47	-7.58	-0.38	3.47e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg16606324	chr3:10149918	C3orf24	0.59	7.91	0.4	3.85e-14	Alzheimer's disease;
LUSC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg21775007	chr8:11205619	TDH	0.47	6.81	0.35	4.56e-11	Mood instability;
LUSC	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg02527881	chr3:46936655	PTH1R	-0.41	-7.41	-0.38	1.04e-12	Colorectal cancer;
LUSC	cis	rs7428	0.545	rs9248	chr2:85537312	G/A	cg24342717	chr2:85555507	TGOLN2	-0.73	-11.65	-0.54	1.44e-26	Ear protrusion;
LUSC	trans	rs11039798	0.841	rs11039783	chr11:48526828	G/C	cg03929089	chr4:120376271	NA	0.65	6.05	0.31	3.79e-9	Axial length;
LUSC	cis	rs2289328	0.943	rs3803360	chr15:40662669	C/T	cg13931752	chr15:40660718	DISP2	0.45	6.33	0.33	7.84e-10	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg06784218	chr1:46089804	CCDC17	-0.46	-8.78	-0.43	8.85e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-11.57	-0.53	2.96e-26	Monocyte count;
LUSC	trans	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-9.0	-0.44	1.7e-17	Obesity-related traits;
LUSC	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	0.89	15.53	0.65	2.62e-41	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg08779649	chr13:50194554	NA	-0.37	-6.28	-0.33	1.04e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg26373071	chr5:1325741	CLPTM1L	0.43	8.01	0.4	1.93e-14	Lung cancer;
LUSC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg10523679	chr1:76189770	ACADM	-0.81	-10.99	-0.52	3.55e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg04539111	chr16:67997858	SLC12A4	-0.47	-6.3	-0.33	9.58e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3818285	0.504	rs4917547	chr10:111652285	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.59	-8.27	-0.41	3.13e-15	Superior crus of antihelix expression;
LUSC	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.14	-19.47	-0.73	5.97e-57	Primary sclerosing cholangitis;
LUSC	cis	rs977987	0.843	rs10459859	chr16:75381950	T/C	cg03315344	chr16:75512273	CHST6	0.55	10.61	0.5	7.14e-23	Dupuytren's disease;
LUSC	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg08017756	chr2:100939284	LONRF2	-0.45	-8.35	-0.42	1.82e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg00933542	chr6:150070202	PCMT1	0.3	6.07	0.32	3.39e-9	Lung cancer;
LUSC	cis	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.3	-0.41	2.61e-15	Morning vs. evening chronotype;
LUSC	trans	rs8073060	0.963	rs4795082	chr17:33873501	C/T	cg19694781	chr19:47549865	TMEM160	0.68	10.42	0.5	3.42e-22	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.6	0.5	8.01e-23	Mean corpuscular volume;
LUSC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg23711669	chr6:146136114	FBXO30	0.79	14.43	0.62	4.95e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg15654264	chr1:150340011	RPRD2	0.65	10.76	0.51	2.24e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-7.55	-0.38	4.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg05802129	chr4:122689817	NA	-0.52	-8.96	-0.44	2.26e-17	Type 2 diabetes;
LUSC	cis	rs6484504	0.576	rs208067	chr11:31153578	C/T	cg26647111	chr11:31128758	NA	-0.42	-6.19	-0.32	1.77e-9	Red blood cell count;
LUSC	cis	rs17102423	0.654	rs8008095	chr14:65525794	A/G	cg11161011	chr14:65562177	MAX	-0.58	-9.02	-0.44	1.46e-17	Obesity-related traits;
LUSC	trans	rs4734806	0.579	rs72677050	chr8:105872590	T/G	cg19267248	chr12:98849532	NA	0.39	6.08	0.32	3.37e-9	Periodontitis (DPAL);
LUSC	trans	rs12571093	0.803	rs61854839	chr10:70044616	T/C	cg04882175	chr6:131122610	NA	-0.56	-6.22	-0.32	1.46e-9	Optic nerve measurement (disc area);
LUSC	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg13073564	chr4:8508604	NA	0.44	8.32	0.41	2.25e-15	Response to antineoplastic agents;
LUSC	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-6.3	-0.33	9.65e-10	Hemoglobin concentration;
LUSC	cis	rs117623576	0.941	rs211423	chr10:32398777	A/G	cg03047570	chr10:32398778	NA	0.73	7.86	0.4	5.39e-14	Anti-saccade response;
LUSC	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.62	-0.34	1.47e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg17385448	chr1:15911702	AGMAT	0.37	5.81	0.3	1.45e-8	Systolic blood pressure;
LUSC	cis	rs67072384	1.000	rs12272109	chr11:72453850	G/A	cg04827223	chr11:72435913	ARAP1	-0.78	-6.8	-0.35	4.98e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs9303542	0.625	rs8072250	chr17:46569216	C/T	cg09704116	chr17:46666958	LOC404266	-0.32	-5.84	-0.3	1.22e-8	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg06521331	chr12:34319734	NA	0.38	6.62	0.34	1.47e-10	Morning vs. evening chronotype;
LUSC	trans	rs1927790	0.727	rs9556551	chr13:96947223	T/A	cg03198741	chr6:1003969	LOC285768	-0.4	-6.09	-0.32	3.08e-9	Body mass index;
LUSC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	0.78	13.94	0.61	4.02e-35	Cognitive function;
LUSC	cis	rs240764	0.817	rs240115	chr6:101053069	T/C	cg09795085	chr6:101329169	ASCC3	0.41	6.01	0.31	4.84e-9	Neuroticism;
LUSC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg12334488	chr2:20871173	GDF7	-0.34	-6.12	-0.32	2.64e-9	Abdominal aortic aneurysm;
LUSC	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg24733560	chr20:60626293	TAF4	0.42	7.65	0.39	2.11e-13	Body mass index;
LUSC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg05425664	chr17:57184151	TRIM37	-0.55	-8.21	-0.41	4.91e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-6.8	-0.35	4.87e-11	Blood metabolite levels;
LUSC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg25428297	chr7:1022841	CYP2W1	0.27	5.68	0.3	3e-8	Longevity;Endometriosis;
LUSC	cis	rs7973719	0.865	rs12830671	chr12:7347278	T/G	cg07052231	chr12:7363540	PEX5	0.53	9.07	0.44	1.05e-17	IgG glycosylation;
LUSC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	10.78	0.51	1.84e-23	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs10761482	0.817	rs2061484	chr10:62105498	A/C	cg18175470	chr10:62150864	ANK3	-0.5	-7.12	-0.36	6.69e-12	Schizophrenia;
LUSC	cis	rs10865050	1	rs10865050	chr2:102941311	G/A	cg20060108	chr2:102954350	IL1RL1	0.48	6.37	0.33	6.4e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9534288	0.659	rs1581846	chr13:46650686	G/A	cg15192986	chr13:46630673	CPB2	-0.76	-11.6	-0.54	2.26e-26	Blood protein levels;
LUSC	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg23705487	chr8:91013396	DECR1	-0.49	-6.16	-0.32	2.09e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
LUSC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.74	-0.51	2.59e-23	Chronic sinus infection;
LUSC	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.83	13.91	0.61	5.01e-35	Bladder cancer;
LUSC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg11062466	chr8:58055876	NA	0.49	6.34	0.33	7.38e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg13535736	chr9:111863775	C9orf5	-0.41	-6.8	-0.35	4.87e-11	Menarche (age at onset);
LUSC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg07701084	chr6:150067640	NUP43	0.57	8.68	0.43	1.74e-16	Lung cancer;
LUSC	cis	rs4862307	0.688	rs6552741	chr4:184990335	A/G	cg06737308	chr4:185021514	ENPP6	-0.44	-6.65	-0.34	1.17e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUSC	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg05925327	chr15:68127851	NA	-0.34	-6.05	-0.31	3.8e-9	Restless legs syndrome;
LUSC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.19	0.32	1.8e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg18681998	chr4:17616180	MED28	-0.74	-10.7	-0.51	3.69e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg08999081	chr20:33150536	PIGU	0.44	8.2	0.41	5.25e-15	Coronary artery disease;
LUSC	cis	rs988712	0.672	rs925947	chr11:27667367	G/T	cg10635145	chr11:27742435	BDNF	-0.46	-5.96	-0.31	6.27e-9	Obesity;
LUSC	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-7.94	-0.4	3.15e-14	Bladder cancer;
LUSC	cis	rs10979	0.679	rs35914889	chr6:143886392	A/T	cg25407410	chr6:143891975	LOC285740	-0.69	-9.45	-0.46	5.92e-19	Hypospadias;
LUSC	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg08975724	chr8:8085496	FLJ10661	0.47	6.14	0.32	2.36e-9	Neuroticism;
LUSC	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg20701182	chr2:24300061	SF3B14	0.73	7.33	0.37	1.74e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg14844989	chr11:31128820	NA	-0.37	-5.79	-0.3	1.67e-8	Red blood cell count;
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg15242686	chr22:24348715	GSTTP1	-0.42	-6.37	-0.33	6.16e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22450460	chr6:7389544	CAGE1;RIOK1	-0.46	-6.36	-0.33	6.74e-10	Hepatitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26776742	chr6:117002360	KPNA5	-0.44	-6.58	-0.34	1.87e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4356932	0.691	rs10008757	chr4:76903036	A/G	cg00809888	chr4:76862425	NAAA	0.37	5.88	0.31	9.75e-9	Blood protein levels;
LUSC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	9.26	0.45	2.61e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-8.33	-0.41	2.14e-15	Aortic root size;
LUSC	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.35	-0.46	1.28e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06002616	chr8:101225028	SPAG1	0.45	7.39	0.37	1.23e-12	Atrioventricular conduction;
LUSC	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg25797454	chr6:150327115	RAET1K	0.36	8.18	0.41	5.97e-15	Alopecia areata;
LUSC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg27494647	chr7:150038898	RARRES2	0.44	6.75	0.35	6.37e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg18306943	chr3:40428807	ENTPD3	0.4	5.96	0.31	6.5e-9	Renal cell carcinoma;
LUSC	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg03732007	chr1:2071316	PRKCZ	0.47	7.61	0.38	2.8e-13	Height;
LUSC	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg04450456	chr4:17643702	FAM184B	0.38	6.24	0.32	1.29e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs912057	0.901	rs744056	chr6:6733540	A/G	cg06612196	chr6:6737390	NA	0.51	9.71	0.47	8.55e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg01973587	chr1:228161476	NA	-0.4	-7.03	-0.36	1.18e-11	Diastolic blood pressure;
LUSC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.63	0.47	1.61e-19	Bipolar disorder;
LUSC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.98	-16.38	-0.67	1.14e-44	Coronary artery disease;
LUSC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg12564285	chr5:131593104	PDLIM4	-0.47	-8.21	-0.41	4.79e-15	Breast cancer;
LUSC	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	6.96	0.36	1.77e-11	Menarche (age at onset);
LUSC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg13560548	chr3:10150139	C3orf24	0.54	7.74	0.39	1.17e-13	Alzheimer's disease;
LUSC	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	8.24	0.41	4.06e-15	Neuroticism;
LUSC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg15448220	chr1:150897856	SETDB1	0.42	6.06	0.31	3.68e-9	Melanoma;
LUSC	cis	rs9649465	0.561	rs631445	chr7:123413707	C/T	cg03229431	chr7:123269106	ASB15	-0.48	-7.79	-0.39	8.65e-14	Migraine;
LUSC	cis	rs10761482	0.515	rs2393642	chr10:62282490	G/A	cg18175470	chr10:62150864	ANK3	-0.51	-7.25	-0.37	2.95e-12	Schizophrenia;
LUSC	trans	rs7939886	0.920	rs17150117	chr11:55941186	T/C	cg03929089	chr4:120376271	NA	0.8	6.07	0.32	3.54e-9	Myopia (pathological);
LUSC	cis	rs62400317	0.859	rs12211519	chr6:45160530	C/A	cg18551225	chr6:44695536	NA	-0.45	-7.22	-0.37	3.47e-12	Total body bone mineral density;
LUSC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	0.46	6.88	0.35	2.9e-11	Menarche (age at onset);
LUSC	cis	rs7202877	0.706	rs42472	chr16:75473320	T/A	cg04384234	chr16:75411784	CFDP1	0.67	9.18	0.45	4.7e-18	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg13010199	chr12:38710504	ALG10B	0.47	7.27	0.37	2.56e-12	Morning vs. evening chronotype;
LUSC	trans	rs11123259	0.794	rs11691241	chr2:115690810	T/C	cg00844339	chr9:138873417	NA	0.3	6.0	0.31	5.15e-9	Gut microbiome composition (winter);
LUSC	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	7.9	0.4	4.09e-14	Lung cancer in ever smokers;
LUSC	cis	rs6087990	0.965	rs742630	chr20:31350664	C/G	cg13636640	chr20:31349939	DNMT3B	1.05	24.37	0.8	4.18e-76	Ulcerative colitis;
LUSC	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg19682013	chr15:45996608	NA	0.38	5.88	0.31	1.02e-8	Waist circumference;Weight;
LUSC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	0.79	13.89	0.61	6.06e-35	Cognitive function;
LUSC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	13.13	0.58	4.69e-32	Chronic sinus infection;
LUSC	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.08	-0.91	1.14e-129	Myeloid white cell count;
LUSC	cis	rs17621444	0.522	rs10788024	chr10:121817172	C/T	cg02041677	chr10:121771263	NA	-0.32	-6.22	-0.32	1.52e-9	IgG glycosylation;
LUSC	cis	rs7527798	0.592	rs4097398	chr1:207857760	C/T	cg09232269	chr1:207846808	CR1L	-0.31	-6.71	-0.34	8.55e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs12980942	0.810	rs12974323	chr19:41807071	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.62	6.77	0.35	5.89e-11	Coronary artery disease;
LUSC	cis	rs76793172	1.000	rs28433213	chr19:46341168	C/T	cg00442267	chr19:46317840	RSPH6A	-0.5	-5.7	-0.3	2.66e-8	Eosinophil counts;
LUSC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg05855489	chr10:104503620	C10orf26	-0.76	-12.87	-0.58	4.64e-31	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs662064	0.962	rs648399	chr1:10556485	T/C	cg17425144	chr1:10567563	PEX14	0.35	5.66	0.3	3.25e-8	Asthma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04977610	chr16:30366665	CD2BP2	-0.45	-6.04	-0.31	4.06e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	1.12	17.82	0.7	2.09e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-0.9	-16.31	-0.67	2.2e-44	Cognitive function;
LUSC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06022373	chr22:39101656	GTPBP1	0.85	14.22	0.61	3.23e-36	Menopause (age at onset);
LUSC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.46	0.75	6.72e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg14895029	chr7:2775587	GNA12	-0.41	-6.06	-0.31	3.58e-9	Height;
LUSC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg24642844	chr7:1081250	C7orf50	-0.79	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4792901	0.802	rs12602059	chr17:41573730	A/G	cg22562494	chr17:41607896	ETV4	-0.33	-6.06	-0.31	3.59e-9	Dupuytren's disease;
LUSC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg24562669	chr7:97807699	LMTK2	0.35	6.22	0.32	1.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	8.08	0.4	1.17e-14	Coffee consumption (cups per day);
LUSC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg08392591	chr16:89556376	ANKRD11	0.47	7.19	0.37	4.28e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg26373071	chr5:1325741	CLPTM1L	0.43	8.09	0.4	1.14e-14	Lung cancer;
LUSC	cis	rs4629710	0.568	rs67021539	chr6:131552900	A/G	cg12700074	chr6:131571435	AKAP7	-0.36	-5.95	-0.31	6.86e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.89	-0.4	4.49e-14	Chronic sinus infection;
LUSC	cis	rs2273669	0.667	rs7761290	chr6:109326621	T/G	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs7923609	0.967	rs7909269	chr10:65177766	G/A	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.01e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg08999081	chr20:33150536	PIGU	0.37	6.69	0.34	9.61e-11	Height;
LUSC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg17143192	chr8:8559678	CLDN23	0.63	9.14	0.45	6.03e-18	Obesity-related traits;
LUSC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg17724175	chr1:150552817	MCL1	0.37	6.7	0.34	8.92e-11	Tonsillectomy;
LUSC	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg00376283	chr12:123451042	ABCB9	0.72	10.87	0.51	9.46e-24	Platelet count;
LUSC	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg01528321	chr10:82214614	TSPAN14	0.83	12.44	0.56	1.93e-29	Post bronchodilator FEV1;
LUSC	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg24558204	chr6:135376177	HBS1L	0.59	9.11	0.45	7.57e-18	Red blood cell count;
LUSC	cis	rs4363385	0.647	rs56158137	chr1:152994380	A/T	cg00922841	chr1:152955080	SPRR1A	-0.4	-6.54	-0.34	2.3e-10	Inflammatory skin disease;
LUSC	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.77	-0.39	1e-13	Pulmonary function;
LUSC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg00033643	chr7:134001901	SLC35B4	0.43	6.81	0.35	4.42e-11	Mean platelet volume;
LUSC	trans	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.03	-0.31	4.26e-9	Bladder cancer;
LUSC	trans	rs7726558	0.731	rs3756513	chr5:118832965	C/G	cg14402224	chr7:50570049	DDC	-0.48	-6.12	-0.32	2.57e-9	QT interval (sulfonylurea treatment interaction);
LUSC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg00166722	chr3:10149974	C3orf24	0.39	5.84	0.3	1.24e-8	Alzheimer's disease;
LUSC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.72	9.55	0.46	2.8e-19	Schizophrenia;
LUSC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg26408565	chr15:76604113	ETFA	-0.5	-8.02	-0.4	1.82e-14	Blood metabolite levels;
LUSC	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.76	-12.59	-0.57	5.34e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs113835537	0.597	rs10896129	chr11:66338300	T/C	cg24851651	chr11:66362959	CCS	0.58	9.04	0.44	1.28e-17	Airway imaging phenotypes;
LUSC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg21770322	chr7:97807741	LMTK2	0.41	7.06	0.36	9.5e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg13010199	chr12:38710504	ALG10B	0.56	8.37	0.42	1.56e-15	Morning vs. evening chronotype;
LUSC	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.43	6.6	0.34	1.58e-10	Dupuytren's disease;
LUSC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg04369109	chr6:150039330	LATS1	-0.56	-8.17	-0.41	6.41e-15	Lung cancer;
LUSC	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.63	13.9	0.61	5.42e-35	Hemoglobin concentration;
LUSC	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg02931644	chr1:25747376	RHCE	0.34	6.2	0.32	1.65e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	9.81	0.47	3.81e-20	Lymphocyte counts;
LUSC	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.59e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	15.02	0.64	2.48e-39	Platelet count;
LUSC	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg21672276	chr3:44754072	ZNF502	-0.39	-6.33	-0.33	7.75e-10	Depressive symptoms;
LUSC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg08773314	chr2:239334832	ASB1	0.38	6.92	0.35	2.28e-11	Multiple system atrophy;
LUSC	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg08601574	chr20:25228251	PYGB	-0.43	-6.51	-0.34	2.68e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-10.24	-0.49	1.43e-21	Platelet distribution width;
LUSC	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg05110241	chr16:68378359	PRMT7	-0.58	-6.68	-0.34	1.02e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg03676636	chr4:99064102	C4orf37	0.3	6.11	0.32	2.75e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg10483660	chr13:112241077	NA	-0.31	-5.7	-0.3	2.68e-8	Hepatitis;
LUSC	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.76	9.92	0.48	1.75e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1499972	0.941	rs62264782	chr3:117655445	C/A	cg07612923	chr3:117604196	NA	0.65	5.85	0.3	1.18e-8	Schizophrenia;
LUSC	cis	rs13223928	0.516	rs11763949	chr7:3150279	A/C	cg19214707	chr7:3157722	NA	-0.46	-8.79	-0.43	8.3e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg05347473	chr6:146136440	FBXO30	-0.6	-10.6	-0.5	7.93e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.86	-15.31	-0.64	1.79e-40	Metabolic syndrome;
LUSC	cis	rs62400317	0.859	rs58769170	chr6:45298531	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.72	-0.39	1.35e-13	Total body bone mineral density;
LUSC	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.47	-5.83	-0.3	1.31e-8	Birth weight;
LUSC	cis	rs9326248	0.530	rs11216171	chr11:116749113	T/A	cg26566898	chr11:117069891	TAGLN	0.4	6.85	0.35	3.67e-11	Blood protein levels;
LUSC	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg02753203	chr1:228287806	NA	0.71	12.42	0.56	2.25e-29	Diastolic blood pressure;
LUSC	trans	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg25214090	chr10:38739885	LOC399744	-0.41	-6.22	-0.32	1.52e-9	Corneal astigmatism;
LUSC	cis	rs6961069	0.708	rs2030711	chr7:80219942	A/G	cg04458919	chr7:80252533	CD36	-0.38	-6.74	-0.35	6.84e-11	Platelet count;
LUSC	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	12.44	0.56	1.93e-29	Ileal carcinoids;
LUSC	cis	rs9650315	0.866	rs13270709	chr8:57182507	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.8	0.35	4.85e-11	Height;
LUSC	trans	rs8022206	0.659	rs34050208	chr14:68330633	C/T	cg15809352	chr2:121748218	GLI2	0.45	6.58	0.34	1.8e-10	Platelet count;Mean platelet volume;
LUSC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.93	0.48	1.54e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-9.82	-0.47	3.54e-20	Gut microbiome composition (summer);
LUSC	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23583168	chr7:148888333	NA	-0.92	-17.27	-0.69	3.23e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2798269	0.902	rs2476637	chr13:22112927	G/A	cg18095732	chr13:22033692	ZDHHC20	-0.41	-6.31	-0.33	8.81e-10	PR segment;
LUSC	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	7.13	0.36	6.3e-12	IgG glycosylation;
LUSC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.31	0.33	8.94e-10	Menopause (age at onset);
LUSC	cis	rs68170813	0.559	rs10953532	chr7:106881808	C/T	cg02696742	chr7:106810147	HBP1	-0.64	-9.65	-0.47	1.31e-19	Coronary artery disease;
LUSC	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	9.23	0.45	3.27e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.3	-0.33	9.58e-10	Dupuytren's disease;
LUSC	cis	rs7659604	0.540	rs28394772	chr4:122678543	C/T	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.89	-0.31	9.28e-9	Type 2 diabetes;
LUSC	cis	rs3768617	0.546	rs2296296	chr1:183105399	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.98	0.52	3.72e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg22166914	chr1:53195759	ZYG11B	0.63	10.59	0.5	8.96e-23	Monocyte count;
LUSC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg07395648	chr5:131743802	NA	-0.4	-5.92	-0.31	8.19e-9	Acylcarnitine levels;
LUSC	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg17470723	chr8:74884337	TCEB1	0.52	8.11	0.41	9.95e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6460942	1.000	rs6944134	chr7:12418036	T/C	cg20607287	chr7:12443886	VWDE	-0.65	-6.47	-0.33	3.53e-10	Coronary artery disease;
LUSC	cis	rs4144743	1.000	rs11871407	chr17:45331358	C/G	cg18085866	chr17:45331354	ITGB3	-0.75	-7.95	-0.4	2.83e-14	Body mass index;
LUSC	cis	rs10887741	0.646	rs1358863	chr10:89426508	T/G	cg13926569	chr10:89418898	PAPSS2	0.33	7.08	0.36	8.39e-12	Exercise (leisure time);
LUSC	cis	rs11779988	0.543	rs379066	chr8:17881835	T/C	cg01800426	chr8:17659068	MTUS1	-0.45	-5.9	-0.31	8.81e-9	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14039463	chr1:212004169	LPGAT1	-0.43	-6.54	-0.34	2.27e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg09455208	chr3:40491958	NA	0.51	9.31	0.45	1.79e-18	Renal cell carcinoma;
LUSC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1858037	0.765	rs67404371	chr2:65597271	C/A	cg08085232	chr2:65598271	SPRED2	-0.4	-5.93	-0.31	7.6e-9	Rheumatoid arthritis;
LUSC	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg24505687	chr6:33548425	BAK1	0.45	6.56	0.34	2.04e-10	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUSC	trans	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg26043149	chr18:55253948	FECH	-0.48	-7.46	-0.38	7.31e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg02423579	chr7:2872169	GNA12	-0.38	-5.99	-0.31	5.55e-9	Height;
LUSC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.82	0.39	7.14e-14	Prudent dietary pattern;
LUSC	cis	rs1572438	0.811	rs6916756	chr6:880467	G/A	cg13447295	chr6:887704	NA	0.4	6.34	0.33	7.45e-10	Aging;
LUSC	cis	rs6087990	0.966	rs2377667	chr20:31346925	A/G	cg13636640	chr20:31349939	DNMT3B	1.04	23.39	0.79	2.56e-72	Ulcerative colitis;
LUSC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg15212455	chr7:39170539	POU6F2	0.65	11.29	0.53	2.84e-25	IgG glycosylation;
LUSC	cis	rs4356932	0.691	rs2273	chr4:76889388	C/T	cg00809888	chr4:76862425	NAAA	-0.36	-5.85	-0.3	1.19e-8	Blood protein levels;
LUSC	cis	rs9807989	0.765	rs13424006	chr2:102967236	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.85	0.3	1.19e-8	Asthma;
LUSC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.08	15.3	0.64	2.06e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05863534	chr17:34948351	DHRS11	-0.46	-6.11	-0.32	2.77e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3847687	1.000	rs34853396	chr12:131519265	G/T	cg25772418	chr12:131519998	GPR133	-0.27	-5.99	-0.31	5.37e-9	Longevity;
LUSC	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg02403541	chr12:121454288	C12orf43	0.74	11.51	0.53	4.95e-26	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg23711669	chr6:146136114	FBXO30	0.73	12.89	0.58	3.92e-31	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.94	-0.68	7.04e-47	Exhaled nitric oxide output;
LUSC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06022373	chr22:39101656	GTPBP1	-0.71	-10.83	-0.51	1.22e-23	Menopause (age at onset);
LUSC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg17971929	chr21:40555470	PSMG1	-0.51	-7.63	-0.39	2.48e-13	Menarche (age at onset);
LUSC	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.57	8.2	0.41	5.11e-15	Night sleep phenotypes;
LUSC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg05025164	chr4:1340916	KIAA1530	0.42	6.59	0.34	1.74e-10	Obesity-related traits;
LUSC	cis	rs7799006	0.527	rs6967286	chr7:2212758	C/A	cg03354898	chr7:1950403	MAD1L1	-0.29	-5.71	-0.3	2.44e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg07211511	chr3:129823064	LOC729375	-1.17	-18.57	-0.71	2.26e-53	Blood pressure (smoking interaction);
LUSC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.49	-0.33	3.17e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	14.49	0.62	2.84e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg01528321	chr10:82214614	TSPAN14	1.03	15.98	0.66	4.45e-43	Post bronchodilator FEV1;
LUSC	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg22676075	chr6:135203613	NA	0.47	7.33	0.37	1.72e-12	Red blood cell count;
LUSC	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg26395211	chr5:140044315	WDR55	-0.48	-7.51	-0.38	5.38e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	9.51	0.46	3.95e-19	Bipolar disorder;
LUSC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24549020	chr5:56110836	MAP3K1	0.5	5.7	0.3	2.58e-8	Initial pursuit acceleration;
LUSC	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.46	6.86	0.35	3.42e-11	Schizophrenia;
LUSC	trans	rs2894969	0.664	rs11252703	chr10:4795125	A/T	cg18036248	chr18:55712422	NEDD4L	0.39	6.07	0.32	3.39e-9	Major depressive disorder;
LUSC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.61	-0.43	2.96e-16	Breast cancer;
LUSC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.83	-0.39	6.57e-14	Height;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg17558973	chr5:37249223	C5orf42	0.32	6.06	0.31	3.72e-9	Metabolite levels (Pyroglutamine);
LUSC	trans	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg07393940	chr7:158741817	NA	-0.37	-6.62	-0.34	1.46e-10	Life satisfaction;
LUSC	cis	rs4285028	0.747	rs3732410	chr3:121415720	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-13.07	-0.58	7.96e-32	Multiple sclerosis;
LUSC	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg16342193	chr10:102329863	NA	-0.34	-6.39	-0.33	5.67e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.38	6.6	0.34	1.62e-10	Obesity-related traits;
LUSC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg06008330	chr7:65541103	ASL	-0.4	-6.31	-0.33	8.86e-10	Aortic root size;
LUSC	cis	rs6840360	1.000	rs10023298	chr4:152666768	A/C	cg22705602	chr4:152727874	NA	-0.27	-5.89	-0.31	9.43e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg06636001	chr8:8085503	FLJ10661	0.51	7.95	0.4	2.94e-14	Retinal vascular caliber;
LUSC	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg24375607	chr4:120327624	NA	0.72	11.5	0.53	5.4e-26	Corneal astigmatism;
LUSC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg27588902	chr6:42928151	GNMT	-0.3	-6.6	-0.34	1.59e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg03188948	chr7:1209495	NA	0.71	7.56	0.38	3.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7759001	0.857	rs4579353	chr6:27372490	A/G	cg18711553	chr6:27366782	ZNF391	0.39	5.72	0.3	2.31e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7575217	0.767	rs796064	chr2:101729682	G/A	cg23907051	chr2:101730305	TBC1D8	-0.3	-8.19	-0.41	5.75e-15	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs35306767	0.623	rs56201968	chr10:1141666	A/G	cg26597838	chr10:835615	NA	0.5	6.49	0.33	3.05e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.59	-8.36	-0.42	1.66e-15	Diastolic blood pressure;
LUSC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg23985595	chr17:80112537	CCDC57	-0.33	-6.39	-0.33	5.61e-10	Life satisfaction;
LUSC	cis	rs9341808	0.690	rs9448909	chr6:80909031	G/A	cg08355045	chr6:80787529	NA	0.59	10.22	0.49	1.64e-21	Sitting height ratio;
LUSC	cis	rs12989701	0.877	rs35860453	chr2:127866047	C/T	cg08168897	chr2:127865431	BIN1	0.73	9.5	0.46	4.08e-19	Alzheimer's disease (late onset);
LUSC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21963583	chr11:68658836	MRPL21	0.54	8.26	0.41	3.36e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg05234568	chr11:5960015	NA	-0.62	-8.87	-0.44	4.61e-17	DNA methylation (variation);
LUSC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg18681998	chr4:17616180	MED28	0.83	15.52	0.65	2.83e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-1.13	-17.82	-0.7	2.14e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg03859395	chr2:55845619	SMEK2	0.81	14.18	0.61	4.63e-36	Metabolic syndrome;
LUSC	cis	rs11645898	0.935	rs4788614	chr16:72188828	C/T	cg14768367	chr16:72042858	DHODH	0.67	7.5	0.38	5.85e-13	Blood protein levels;
LUSC	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg09173681	chr1:183549694	NCF2	0.64	11.45	0.53	7.79e-26	Systemic lupus erythematosus;
LUSC	cis	rs2324229	0.861	rs1180184	chr6:83970665	A/C	cg08257003	chr6:84140564	ME1	0.27	5.87	0.31	1.03e-8	Platelet-derived growth factor BB levels;
LUSC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg15445000	chr17:37608096	MED1	0.41	6.89	0.35	2.81e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg01191920	chr7:158217561	PTPRN2	-0.52	-10.8	-0.51	1.64e-23	Obesity-related traits;
LUSC	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg22676075	chr6:135203613	NA	0.46	7.28	0.37	2.39e-12	Red blood cell count;
LUSC	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg12062639	chr20:23401060	NAPB	-0.96	-8.09	-0.4	1.12e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg23093090	chr10:104574429	C10orf26	-0.38	-7.12	-0.36	6.8e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg24579218	chr15:68104479	NA	-0.4	-6.42	-0.33	4.7e-10	Restless legs syndrome;
LUSC	trans	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	1.93e-12	Bone mineral density;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13171016	chr1:40219054	PPIE	0.5	6.15	0.32	2.19e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.46	-0.33	3.61e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.74	-11.69	-0.54	1.07e-26	Schizophrenia;
LUSC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg20243544	chr17:37824526	PNMT	0.5	7.2	0.37	4.09e-12	Asthma;
LUSC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.17	-0.49	2.5e-21	Hemoglobin concentration;
LUSC	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.64	-0.5	5.89e-23	Coffee consumption (cups per day);
LUSC	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.58	0.46	2.24e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg02569458	chr12:86230093	RASSF9	-0.48	-7.95	-0.4	2.87e-14	Major depressive disorder;
LUSC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg23630131	chr7:65973040	NA	0.21	5.78	0.3	1.76e-8	Aortic root size;
LUSC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.91	11.96	0.55	1.07e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg13010199	chr12:38710504	ALG10B	0.55	8.38	0.42	1.44e-15	Morning vs. evening chronotype;
LUSC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg15073853	chr19:18549131	ISYNA1	-0.33	-6.03	-0.31	4.42e-9	Breast cancer;
LUSC	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg11965913	chr1:205819406	PM20D1	0.48	6.6	0.34	1.61e-10	Parkinson's disease;
LUSC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg07701084	chr6:150067640	NUP43	0.45	6.79	0.35	5.06e-11	Testicular germ cell tumor;
LUSC	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16386425	chr10:429943	DIP2C	-0.45	-7.23	-0.37	3.3e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs11264213	0.579	rs7523017	chr1:36015011	C/T	cg27506609	chr1:36549197	TEKT2	0.54	6.08	0.32	3.27e-9	Schizophrenia;
LUSC	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg25182066	chr10:30743637	MAP3K8	0.41	6.41	0.33	5.07e-10	Inflammatory bowel disease;
LUSC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	7.91	0.4	3.81e-14	Eosinophil percentage of white cells;
LUSC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.93	-0.51	5.65e-24	Aortic root size;
LUSC	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg08085267	chr17:45401833	C17orf57	-0.65	-10.88	-0.51	8.49e-24	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg16339924	chr4:17578868	LAP3	0.5	7.35	0.37	1.5e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.77	-0.39	9.67e-14	Glomerular filtration rate;
LUSC	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.64	-10.32	-0.49	7.48e-22	Retinal vascular caliber;
LUSC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.63	-0.34	1.38e-10	Schizophrenia;
LUSC	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg01528321	chr10:82214614	TSPAN14	0.86	13.12	0.58	5.51e-32	Post bronchodilator FEV1;
LUSC	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg11887960	chr12:57824829	NA	0.56	6.84	0.35	3.75e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg12310025	chr6:25882481	NA	-0.5	-9.09	-0.45	9.27e-18	Blood metabolite levels;
LUSC	trans	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17712092	chr4:129076599	LARP1B	0.73	10.86	0.51	1.02e-23	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg05855489	chr10:104503620	C10orf26	0.53	8.19	0.41	5.77e-15	Arsenic metabolism;
LUSC	trans	rs72674100	1.000	rs10010759	chr4:97987227	T/C	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.24	0.32	1.29e-9	Personality dimensions;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06446895	chr17:79829189	ARHGDIA	0.41	6.41	0.33	4.84e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg22166914	chr1:53195759	ZYG11B	0.57	9.29	0.45	2.08e-18	Monocyte count;
LUSC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg12463550	chr7:65579703	CRCP	0.56	8.35	0.42	1.79e-15	Aortic root size;
LUSC	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.42	6.26	0.32	1.2e-9	Response to antipsychotic treatment;
LUSC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.69	0.43	1.65e-16	Prudent dietary pattern;
LUSC	cis	rs28595532	0.702	rs72670250	chr4:119337134	T/C	cg02775129	chr4:119771670	NA	-0.76	-6.32	-0.33	8.59e-10	Cannabis dependence symptom count;
LUSC	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg27489772	chr12:121021490	NA	-0.58	-7.7	-0.39	1.54e-13	Type 1 diabetes nephropathy;
LUSC	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.78	0.43	8.37e-17	Axial length;
LUSC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg15691649	chr6:25882328	NA	-0.38	-6.22	-0.32	1.49e-9	Blood metabolite levels;
LUSC	cis	rs9650657	0.707	rs2005309	chr8:10652170	T/C	cg27411982	chr8:10470053	RP1L1	-0.4	-6.55	-0.34	2.15e-10	Neuroticism;
LUSC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg18681998	chr4:17616180	MED28	0.85	14.78	0.63	2.15e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg07382826	chr16:28625726	SULT1A1	0.28	5.81	0.3	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs11031096	0.678	rs12223062	chr11:4180178	G/T	cg18678763	chr11:4115507	RRM1	-0.4	-5.67	-0.3	3.07e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg18681998	chr4:17616180	MED28	0.83	15.27	0.64	2.61e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg01802117	chr1:53393560	SCP2	0.38	6.14	0.32	2.4e-9	Monocyte count;
LUSC	cis	rs4343996	0.967	rs4722663	chr7:3350567	C/T	cg21248987	chr7:3385318	SDK1	-0.37	-6.37	-0.33	6.2e-10	Motion sickness;
LUSC	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg24313572	chr1:56050060	NA	-0.29	-5.95	-0.31	6.66e-9	Morning vs. evening chronotype;
LUSC	cis	rs9447004	0.583	rs28360541	chr6:74432427	T/G	cg03006477	chr6:74432658	CD109	0.29	6.04	0.31	4e-9	Blood protein levels;Calcium levels;
LUSC	trans	rs1351696	1	rs1351696	chr11:48382471	A/G	cg03929089	chr4:120376271	NA	-0.64	-5.98	-0.31	5.65e-9	D-dimer levels;
LUSC	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg13010199	chr12:38710504	ALG10B	0.62	9.23	0.45	3.3e-18	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.74	-0.51	2.64e-23	Chronic sinus infection;
LUSC	cis	rs11971779	0.838	rs58074268	chr7:139108925	C/T	cg07862535	chr7:139043722	LUC7L2	0.7	8.37	0.42	1.57e-15	Diisocyanate-induced asthma;
LUSC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg04865166	chr7:105162814	PUS7	0.52	5.71	0.3	2.51e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2235649	0.833	rs7190337	chr16:1850469	A/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-6.0	-0.31	5.27e-9	Blood metabolite levels;
LUSC	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg06191203	chr2:152266755	RIF1	-0.55	-7.27	-0.37	2.51e-12	Lung cancer;
LUSC	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg05738196	chr6:26577821	NA	0.81	15.7	0.65	5.45e-42	Intelligence (multi-trait analysis);
LUSC	trans	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg14791747	chr16:20752902	THUMPD1	0.74	10.51	0.5	1.6400000000000001e-22	Cognitive test performance;
LUSC	cis	rs147120681	1	rs147120681	chr1:101239293	CT/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.49	-7.0	-0.36	1.41e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUSC	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg18105134	chr13:113819100	PROZ	-0.67	-9.45	-0.46	6.04e-19	Platelet distribution width;
LUSC	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg02580895	chr19:2754563	NA	-0.46	-6.79	-0.35	5.13e-11	Total cholesterol levels;
LUSC	cis	rs2625529	0.824	rs4777480	chr15:72328997	A/C	cg16672083	chr15:72433130	SENP8	-0.52	-7.57	-0.38	3.79e-13	Red blood cell count;
LUSC	cis	rs1044826	0.913	rs12488939	chr3:139050831	C/T	cg00490450	chr3:139108681	COPB2	0.55	7.31	0.37	1.99e-12	Obesity-related traits;
LUSC	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-5.73	-0.3	2.26e-8	IgG glycosylation;
LUSC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg11812906	chr14:75593930	NEK9	-0.66	-11.23	-0.52	4.83e-25	Height;
LUSC	cis	rs500891	0.693	rs1144190	chr6:83981858	C/T	cg08257003	chr6:84140564	ME1	0.33	7.35	0.37	1.56e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg08499158	chr17:42289980	UBTF	-0.47	-8.04	-0.4	1.61e-14	Total body bone mineral density;
LUSC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	6.31	0.33	8.82e-10	Electroencephalogram traits;
LUSC	cis	rs7246967	0.673	rs59567211	chr19:22829882	G/A	cg23217946	chr19:22817039	ZNF492	0.47	6.55	0.34	2.19e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	0.88	13.37	0.59	6.01e-33	Triglycerides;
LUSC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg09034736	chr1:150693464	HORMAD1	0.41	5.72	0.3	2.38e-8	Melanoma;
LUSC	cis	rs7809950	0.768	rs62482493	chr7:106951579	T/C	cg23024343	chr7:107201750	COG5	-0.68	-9.57	-0.46	2.45e-19	Coronary artery disease;
LUSC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg17507749	chr15:85114479	UBE2QP1	0.69	8.63	0.43	2.5e-16	Schizophrenia;
LUSC	cis	rs7945718	0.781	rs10741604	chr11:12840940	C/A	cg25843174	chr11:12811716	TEAD1	0.32	7.35	0.37	1.49e-12	Educational attainment (years of education);
LUSC	cis	rs2219968	1.000	rs12056577	chr8:78961915	A/C	cg00738934	chr8:78996279	NA	0.34	6.18	0.32	1.89e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg20476274	chr7:133979776	SLC35B4	0.8	14.12	0.61	8.01e-36	Mean platelet volume;
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.37	5.75	0.3	1.99e-8	Lymphocyte counts;
LUSC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg07701084	chr6:150067640	NUP43	0.44	6.74	0.35	7.05e-11	Testicular germ cell tumor;
LUSC	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg22709100	chr7:91322751	NA	-0.39	-5.83	-0.3	1.32e-8	Breast cancer;
LUSC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.66	0.57	2.79e-30	Prudent dietary pattern;
LUSC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg06008330	chr7:65541103	ASL	-0.38	-5.76	-0.3	1.94e-8	Aortic root size;
LUSC	cis	rs1568889	0.838	rs10835283	chr11:28214985	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	12.8	0.57	8.38e-31	Bipolar disorder;
LUSC	cis	rs6543140	0.964	rs1523205	chr2:103070176	G/T	cg09003973	chr2:102972529	NA	0.54	6.87	0.35	3.08e-11	Blood protein levels;
LUSC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00149659	chr3:10157352	C3orf10	0.91	12.66	0.57	2.94e-30	Alzheimer's disease;
LUSC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg20406979	chr6:167373233	NA	-0.26	-6.29	-0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs11039100	0.607	rs35916605	chr11:5782844	T/G	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs909341	0.909	rs1048665	chr20:62331989	T/G	cg09650180	chr20:62225654	GMEB2	-0.46	-6.01	-0.31	4.87e-9	Atopic dermatitis;
LUSC	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Smoking initiation;
LUSC	cis	rs68170813	0.652	rs763386	chr7:107196723	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-8.59	-0.43	3.37e-16	Coronary artery disease;
LUSC	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.81	-0.43	6.75e-17	Total cholesterol levels;
LUSC	cis	rs4494114	1.000	rs12037982	chr1:39358600	G/A	cg25970120	chr1:39325951	RRAGC	-0.39	-6.2	-0.32	1.7e-9	Blood protein levels;
LUSC	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.68	11.57	0.53	2.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg11473876	chr11:109292803	C11orf87	0.41	6.87	0.35	3.13e-11	Schizophrenia;
LUSC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12516959	chr21:47718080	NA	0.39	6.32	0.33	8.44e-10	Testicular germ cell tumor;
LUSC	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg06484146	chr7:12443880	VWDE	-0.68	-7.08	-0.36	8.67e-12	Coronary artery disease;
LUSC	cis	rs2282802	0.685	rs6580473	chr5:139646962	C/T	cg26211634	chr5:139558579	C5orf32	-0.36	-6.51	-0.34	2.74e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg15557168	chr22:42548783	NA	-0.41	-6.07	-0.32	3.43e-9	Schizophrenia;
LUSC	cis	rs6700896	0.500	rs72641129	chr1:66075123	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.35	0.33	6.99e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.23e-10	Extrinsic epigenetic age acceleration;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17157516	chr1:35332203	DLGAP3	0.46	6.68	0.34	9.8e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg17420585	chr12:42539391	GXYLT1	-0.36	-7.14	-0.36	5.99e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs656319	0.580	rs13252589	chr8:10005526	A/G	cg21775007	chr8:11205619	TDH	-0.44	-6.1	-0.32	2.88e-9	Myopia (pathological);
LUSC	cis	rs4654899	0.758	rs6426667	chr1:21396216	C/A	cg01072550	chr1:21505969	NA	-0.5	-7.64	-0.39	2.31e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7215564	0.908	rs7501544	chr17:78660946	T/A	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs8014204	0.781	rs10143492	chr14:75212114	G/C	cg06637938	chr14:75390232	RPS6KL1	0.56	8.74	0.43	1.16e-16	Caffeine consumption;
LUSC	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.55	-0.34	2.19e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs354225	0.544	rs10170355	chr2:54808322	G/A	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg05082376	chr22:42548792	NA	-0.4	-6.74	-0.35	6.87e-11	Cognitive function;
LUSC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11764359	chr7:65958608	NA	0.63	9.51	0.46	3.92e-19	Aortic root size;
LUSC	trans	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg13010199	chr12:38710504	ALG10B	0.38	6.09	0.32	3.17e-9	Morning vs. evening chronotype;
LUSC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg25204440	chr1:209979598	IRF6	0.49	5.73	0.3	2.29e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23158103	chr7:148848205	ZNF398	-0.48	-8.03	-0.4	1.63e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg17252645	chr8:143867129	LY6D	-0.36	-6.31	-0.33	9.04e-10	Urinary tract infection frequency;
LUSC	cis	rs1983170	0.736	rs11164909	chr1:92002506	T/C	cg25838465	chr1:92012736	NA	0.47	5.77	0.3	1.77e-8	Eosinophil percentage of white cells;
LUSC	cis	rs1572072	0.686	rs4770462	chr13:24129056	C/G	cg24350296	chr13:24144486	TNFRSF19	-0.31	-5.91	-0.31	8.64e-9	Nasopharyngeal carcinoma;
LUSC	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg21293242	chr8:11204541	TDH	-0.31	-5.93	-0.31	7.59e-9	Retinal vascular caliber;
LUSC	cis	rs9309473	0.519	rs13009035	chr2:73845709	T/C	cg20560298	chr2:73613845	ALMS1	0.46	7.08	0.36	8.43e-12	Metabolite levels;
LUSC	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg13514129	chr1:39547527	MACF1	0.71	11.79	0.54	4.48e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs2290159	0.800	rs55762590	chr3:12689451	C/T	cg23032965	chr3:12705835	RAF1	0.74	9.1	0.45	8.33e-18	Cholesterol, total;
LUSC	cis	rs6076065	1.000	rs6083105	chr20:23368475	C/A	cg11657817	chr20:23433608	CST11	0.44	8.66	0.43	2.12e-16	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg06627628	chr2:24431161	ITSN2	0.61	9.09	0.45	9.2e-18	Asthma;
LUSC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg05855489	chr10:104503620	C10orf26	-0.7	-10.22	-0.49	1.59e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg04995722	chr7:26192034	NFE2L3	-0.41	-6.48	-0.33	3.31e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg07274523	chr3:49395745	GPX1	-0.47	-5.93	-0.31	7.66e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19346786	chr7:2764209	NA	-0.45	-7.56	-0.38	3.99e-13	Height;
LUSC	cis	rs3772130	0.564	rs28760466	chr3:121601510	A/G	cg11130432	chr3:121712080	ILDR1	0.37	5.87	0.31	1.04e-8	Cognitive performance;
LUSC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg19230755	chr7:65878503	NA	-0.41	-5.74	-0.3	2.17e-8	Aortic root size;
LUSC	cis	rs4285028	0.747	rs10049060	chr3:121358448	C/T	cg11130432	chr3:121712080	ILDR1	0.57	8.55	0.42	4.41e-16	Multiple sclerosis;
LUSC	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg01420254	chr6:26195488	NA	0.7	7.46	0.38	7.56e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.8	12.53	0.57	8.45e-30	Menopause (age at onset);
LUSC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg03579872	chr1:53393473	SCP2	-0.39	-5.78	-0.3	1.74e-8	Monocyte count;
LUSC	cis	rs13394619	0.875	rs9287734	chr2:11724475	A/G	cg07314298	chr2:11723111	GREB1	-0.58	-10.46	-0.5	2.37e-22	Endometriosis;
LUSC	cis	rs4363385	0.747	rs10399896	chr1:152975083	T/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.67	-0.39	1.85e-13	Inflammatory skin disease;
LUSC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08736216	chr1:53307985	ZYG11A	-0.29	-5.76	-0.3	1.92e-8	Monocyte count;
LUSC	cis	rs6942756	1.000	rs7803052	chr7:128959427	A/G	cg02491457	chr7:128862824	NA	-0.48	-6.51	-0.34	2.75e-10	White matter hyperintensity burden;
LUSC	cis	rs2227564	0.620	rs3911887	chr10:75548026	A/G	cg23231163	chr10:75533350	FUT11	-0.46	-6.79	-0.35	5.08e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg25039879	chr17:56429692	SUPT4H1	0.67	8.76	0.43	1.01e-16	Cognitive test performance;
LUSC	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg00745463	chr17:30367425	LRRC37B	0.63	7.58	0.38	3.37e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs1691799	0.799	rs10784525	chr12:66772766	G/A	cg16791601	chr12:66731901	HELB	-0.73	-12.47	-0.56	1.45e-29	White blood cell count (basophil);
LUSC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg27588902	chr6:42928151	GNMT	-0.3	-6.65	-0.34	1.17e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24110177	chr3:50126178	RBM5	-0.63	-10.82	-0.51	1.41e-23	Body mass index;
LUSC	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg25237894	chr2:233734115	C2orf82	0.35	6.51	0.34	2.83e-10	Coronary artery disease;
LUSC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg08847533	chr14:75593920	NEK9	-0.81	-13.83	-0.6	1.08e-34	Height;
LUSC	cis	rs4343996	0.837	rs10215256	chr7:3484884	T/C	cg21248987	chr7:3385318	SDK1	0.36	6.11	0.32	2.84e-9	Motion sickness;
LUSC	cis	rs4766566	0.651	rs933307	chr12:111735537	A/C	cg10833066	chr12:111807467	FAM109A	-0.54	-9.98	-0.48	1.05e-20	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUSC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02018176	chr4:1364513	KIAA1530	0.53	9.3	0.45	1.84e-18	Longevity;
LUSC	cis	rs7799006	0.606	rs4721527	chr7:2306655	G/A	cg12823233	chr7:2316876	SNX8	-0.45	-7.54	-0.38	4.38e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg16325326	chr1:53192061	ZYG11B	-1.0	-20.61	-0.75	1.82e-61	Monocyte count;
LUSC	trans	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg26384229	chr12:38710491	ALG10B	0.56	8.69	0.43	1.66e-16	Morning vs. evening chronotype;
LUSC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	12.0	0.55	7.98e-28	Prudent dietary pattern;
LUSC	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.6	0.43	3.2e-16	Response to antipsychotic treatment;
LUSC	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg20701182	chr2:24300061	SF3B14	0.75	7.34	0.37	1.61e-12	Lymphocyte counts;
LUSC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg17971929	chr21:40555470	PSMG1	0.78	13.24	0.59	1.8e-32	Cognitive function;
LUSC	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg13334819	chr7:99746414	C7orf59	-0.42	-5.68	-0.3	2.91e-8	Coronary artery disease;
LUSC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13126279	chr21:47581558	C21orf56	-0.43	-6.18	-0.32	1.82e-9	Testicular germ cell tumor;
LUSC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg27284194	chr4:1044797	NA	0.34	5.68	0.3	2.86e-8	Obesity-related traits;
LUSC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.72	9.13	0.45	6.54e-18	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21028142	chr17:79581711	NPLOC4	0.33	7.88	0.4	4.82e-14	Eye color traits;
LUSC	cis	rs422421	0.951	rs31777	chr5:176523562	C/A	cg00618323	chr5:176515533	FGFR4	0.38	6.07	0.32	3.52e-9	Height;
LUSC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.03e-17	Prudent dietary pattern;
LUSC	cis	rs273573	0.925	rs163883	chr11:30947248	A/G	cg14844989	chr11:31128820	NA	0.38	6.0	0.31	5.07e-9	Total body bone mineral density;
LUSC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg10596483	chr8:143751796	JRK	0.61	9.41	0.46	8.19e-19	Schizophrenia;
LUSC	cis	rs500891	0.533	rs10943931	chr6:84146803	T/C	cg08257003	chr6:84140564	ME1	0.36	8.73	0.43	1.27e-16	Platelet-derived growth factor BB levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03784882	chr7:2758244	NA	-0.39	-6.03	-0.31	4.33e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.45	8.06	0.4	1.38e-14	Axial length;
LUSC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg18230493	chr5:56204884	C5orf35	-0.88	-13.39	-0.59	4.99e-33	Initial pursuit acceleration;
LUSC	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg26769984	chr7:1090371	C7orf50	0.58	7.62	0.38	2.6e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg22618164	chr12:122356400	WDR66	0.63	9.57	0.46	2.42e-19	Mean platelet volume;
LUSC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	0.92	13.82	0.6	1.14e-34	Breast cancer;
LUSC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg27398817	chr8:82754497	SNX16	0.47	6.3	0.33	9.56e-10	Diastolic blood pressure;
LUSC	cis	rs12980942	0.810	rs8103839	chr19:41781493	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.59	6.44	0.33	4.28e-10	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg01879757	chr17:41196368	BRCA1	-0.47	-7.28	-0.37	2.36e-12	Menopause (age at onset);
LUSC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg22800045	chr5:56110881	MAP3K1	0.8	10.0	0.48	9.12e-21	Initial pursuit acceleration;
LUSC	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	19.66	0.73	1.04e-57	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg21880101	chr17:80066754	CCDC57	-0.32	-5.93	-0.31	7.63e-9	Life satisfaction;
LUSC	cis	rs2219968	0.961	rs35174414	chr8:78977693	C/T	cg00738934	chr8:78996279	NA	0.35	6.33	0.33	7.89e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.36	0.69	1.51e-48	Chronic sinus infection;
LUSC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.8	-0.39	7.95e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg13042288	chr15:90349979	ANPEP	-0.44	-6.31	-0.33	8.93e-10	Uric acid levels;
LUSC	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg07169764	chr2:136633963	MCM6	1.08	14.51	0.62	2.58e-37	Corneal structure;
LUSC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg11843238	chr5:131593191	PDLIM4	-0.38	-6.18	-0.32	1.87e-9	Breast cancer;
LUSC	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg12002119	chr2:101014098	CHST10	0.36	6.09	0.32	3.15e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.38	-0.42	1.49e-15	Response to antipsychotic treatment;
LUSC	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg00677455	chr12:58241039	CTDSP2	0.73	11.33	0.53	2.08e-25	Multiple sclerosis;
LUSC	cis	rs2692947	0.770	rs4527246	chr2:96560303	T/C	cg22654517	chr2:96458247	NA	0.38	7.62	0.38	2.72e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg27661571	chr11:113659931	NA	-0.67	-7.74	-0.39	1.16e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg20701182	chr2:24300061	SF3B14	0.9	11.53	0.53	4.11e-26	Lymphocyte counts;
LUSC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg06484146	chr7:12443880	VWDE	-0.69	-7.35	-0.37	1.53e-12	Coronary artery disease;
LUSC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg24296786	chr1:45957014	TESK2	0.47	6.91	0.35	2.51e-11	High light scatter reticulocyte count;
LUSC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	14.15	0.61	6.21e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05901451	chr6:126070800	HEY2	0.57	8.53	0.42	5.32e-16	Endometrial cancer;
LUSC	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	8.86e-24	Morning vs. evening chronotype;
LUSC	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	6.48	0.33	3.38e-10	Height;
LUSC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg05738196	chr6:26577821	NA	-0.48	-7.12	-0.36	6.61e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg01119278	chr6:110721349	DDO	-0.48	-8.71	-0.43	1.45e-16	Platelet distribution width;
LUSC	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-8.13	-0.41	8.56e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg07929629	chr2:241523174	NA	0.55	8.82	0.43	6.44e-17	Bipolar disorder;
LUSC	trans	rs1941687	0.831	rs12954615	chr18:31384449	G/T	cg27147174	chr7:100797783	AP1S1	-0.45	-6.94	-0.36	2.05e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs61774743	0.557	rs4660192	chr1:41842350	C/T	cg01193554	chr1:41846683	NA	-0.29	-6.18	-0.32	1.86e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-1.02	-16.53	-0.67	2.81e-45	Systemic lupus erythematosus;
LUSC	cis	rs7674212	0.541	rs2720448	chr4:104030589	C/T	cg16532752	chr4:104119610	CENPE	-0.49	-6.82	-0.35	4.2e-11	Type 2 diabetes;
LUSC	cis	rs17125944	0.506	rs7151491	chr14:53313711	C/G	cg00686598	chr14:53173677	PSMC6	-0.62	-5.82	-0.3	1.36e-8	Alzheimer's disease (late onset);
LUSC	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg05791153	chr7:19748676	TWISTNB	0.75	7.9	0.4	3.96e-14	Thyroid stimulating hormone;
LUSC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg04398451	chr17:18023971	MYO15A	0.5	7.97	0.4	2.45e-14	Total body bone mineral density;
LUSC	cis	rs1904096	0.506	rs4693378	chr4:95168552	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.36	-0.42	1.73e-15	Type 2 diabetes;
LUSC	cis	rs2617583	0.530	rs905201	chr5:1457986	C/T	cg13982541	chr5:1466431	LPCAT1	0.41	5.92	0.31	7.84e-9	Breast cancer;
LUSC	cis	rs877282	0.853	rs7092805	chr10:756246	G/A	cg17470449	chr10:769945	NA	0.52	7.14	0.36	6e-12	Uric acid levels;
LUSC	cis	rs2625529	0.652	rs8030815	chr15:72403001	T/C	cg16672083	chr15:72433130	SENP8	0.48	8.08	0.4	1.21e-14	Red blood cell count;
LUSC	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg03585969	chr10:35415529	CREM	0.6	8.84	0.44	5.75e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg26924012	chr15:45694286	SPATA5L1	1.1	19.11	0.72	1.62e-55	Homoarginine levels;
LUSC	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.36	-0.42	1.68e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2625529	0.586	rs7175197	chr15:72461648	G/A	cg16672083	chr15:72433130	SENP8	0.48	7.92	0.4	3.5e-14	Red blood cell count;
LUSC	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg15744005	chr10:104629667	AS3MT	-0.28	-6.0	-0.31	5.09e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.38	0.46	1.03e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.58	0.38	3.35e-13	Parkinson's disease;
LUSC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg08088566	chr11:430123	ANO9	0.67	7.39	0.37	1.22e-12	Body mass index;
LUSC	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.71e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.64	8.42	0.42	1.09e-15	Response to bleomycin (chromatid breaks);
LUSC	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg12140854	chr5:148520817	ABLIM3	-0.39	-6.15	-0.32	2.27e-9	Breast cancer;
LUSC	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg08017756	chr2:100939284	LONRF2	-0.48	-8.9	-0.44	3.73e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg27284194	chr4:1044797	NA	0.6	8.85	0.44	5.26e-17	Recombination rate (females);
LUSC	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg08000102	chr2:233561755	GIGYF2	-0.63	-8.39	-0.42	1.43e-15	Schizophrenia;
LUSC	cis	rs7202877	0.610	rs11149814	chr16:75332981	T/C	cg03315344	chr16:75512273	CHST6	0.4	5.84	0.3	1.23e-8	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg07936489	chr17:37558343	FBXL20	-0.81	-10.51	-0.5	1.6400000000000001e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02018176	chr4:1364513	KIAA1530	0.71	12.62	0.57	3.91e-30	Longevity;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg16558319	chr12:97301661	NEDD1	0.33	6.04	0.31	4.14e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.27	0.56	8.01e-29	Prudent dietary pattern;
LUSC	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg09469691	chr10:81107165	PPIF	0.65	9.72	0.47	7.73e-20	Height;
LUSC	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg03859395	chr2:55845619	SMEK2	0.91	16.85	0.68	1.56e-46	Metabolic syndrome;
LUSC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.42	0.85	9.58e-95	Chronic sinus infection;
LUSC	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.92	-0.44	3.04e-17	Axial length;
LUSC	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg20476159	chr18:77451067	CTDP1	-0.32	-5.8	-0.3	1.58e-8	Monocyte count;
LUSC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg06212747	chr3:49208901	KLHDC8B	0.45	6.06	0.31	3.63e-9	Parkinson's disease;
LUSC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.78	0.3	1.67e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg02569458	chr12:86230093	RASSF9	0.6	10.08	0.48	4.97e-21	Major depressive disorder;
LUSC	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.64	-0.34	1.24e-10	Response to antipsychotic treatment;
LUSC	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.5	6.83	0.35	3.91e-11	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08219700	chr8:58056026	NA	0.66	8.37	0.42	1.58e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs539514	0.690	rs528783	chr13:76319460	T/C	cg05302441	chr11:125157402	PKNOX2	0.27	6.25	0.32	1.25e-9	Type 1 diabetes;
LUSC	cis	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-8.23	-0.41	4.13e-15	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7215564	0.908	rs56078934	chr17:78658849	A/C	cg09596252	chr17:78655493	RPTOR	0.55	6.04	0.31	4.18e-9	Myopia (pathological);
LUSC	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.44e-8	Breast cancer;
LUSC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.71	-0.39	1.43e-13	Type 2 diabetes;
LUSC	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg16049707	chr14:77965284	ISM2	-0.55	-7.68	-0.39	1.84e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-39.14	-0.91	8.08e-127	Myeloid white cell count;
LUSC	cis	rs7084921	0.608	rs7474634	chr10:101863410	A/C	cg11888571	chr10:102027403	CWF19L1	0.45	6.3	0.33	9.47e-10	Bone mineral density;
LUSC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21984481	chr17:79567631	NPLOC4	-0.57	-10.9	-0.51	7.17e-24	Eye color traits;
LUSC	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.51	-6.63	-0.34	1.39e-10	Response to bleomycin (chromatid breaks);
LUSC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16346588	chr10:242978	ZMYND11	0.4	5.72	0.3	2.38e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg08975724	chr8:8085496	FLJ10661	0.51	7.93	0.4	3.27e-14	Mood instability;
LUSC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg04398451	chr17:18023971	MYO15A	-0.46	-7.35	-0.37	1.59e-12	Total body bone mineral density;
LUSC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg06600287	chr1:53387719	ECHDC2	-0.3	-6.18	-0.32	1.91e-9	Monocyte count;
LUSC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.79	0.39	8.44e-14	Parkinson's disease;
LUSC	cis	rs600231	0.508	rs34582634	chr11:65220206	G/A	cg17120908	chr11:65337727	SSSCA1	-0.64	-9.34	-0.46	1.41e-18	Bone mineral density;
LUSC	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.37	-0.33	6.31e-10	Retinal vascular caliber;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg11728497	chr12:12871887	CDKN1B	0.54	6.31	0.33	9.03e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg12560992	chr17:57184187	TRIM37	-0.78	-13.61	-0.6	7.3e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.53	-8.4	-0.42	1.32e-15	Platelet count;
LUSC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	1.12	17.82	0.7	2.17e-50	Monocyte percentage of white cells;
LUSC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg06618935	chr21:46677482	NA	-0.37	-7.2	-0.37	4.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs243505	0.667	rs10249029	chr7:148576042	C/T	cg09806900	chr7:148480153	CUL1	0.53	7.44	0.38	8.44e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg02176678	chr2:219576539	TTLL4	0.59	10.61	0.5	7.4e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08109568	chr15:31115862	NA	0.73	11.38	0.53	1.39e-25	Huntington's disease progression;
LUSC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.64	0.47	1.49e-19	Bipolar disorder;
LUSC	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.28	-0.33	1.04e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02047577	chr20:62587702	UCKL1AS;UCKL1	-0.45	-6.54	-0.34	2.27e-10	Electrocardiographic conduction measures;
LUSC	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg11473876	chr11:109292803	C11orf87	0.41	6.76	0.35	6.24e-11	Schizophrenia;
LUSC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg23978390	chr7:1156363	C7orf50	0.46	5.98	0.31	5.59e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs75920871	0.702	rs59511712	chr11:116945762	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-5.92	-0.31	8.02e-9	Subjective well-being;
LUSC	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg12473912	chr3:136751656	NA	0.38	6.68	0.34	9.74e-11	Neuroticism;
LUSC	trans	rs2562456	0.793	rs627522	chr19:21495804	C/T	cg00806126	chr19:22604979	ZNF98	-0.39	-6.28	-0.32	1.07e-9	Pain;
LUSC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg00310523	chr12:86230176	RASSF9	-0.42	-7.84	-0.39	6.02e-14	Major depressive disorder;
LUSC	cis	rs9815354	0.812	rs73073337	chr3:41837497	T/C	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg20019720	chr6:154832845	CNKSR3	0.62	8.69	0.43	1.63e-16	Lipoprotein (a) levels;
LUSC	cis	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.51	7.79	0.39	8.75e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg20849893	chr7:64541193	NA	0.5	7.11	0.36	7.26e-12	Calcium levels;
LUSC	cis	rs6598955	0.543	rs57564009	chr1:26557618	A/T	cg04990556	chr1:26633338	UBXN11	0.88	11.67	0.54	1.3e-26	Obesity-related traits;
LUSC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.93	-0.31	7.59e-9	Tonsillectomy;
LUSC	trans	rs1508086	0.935	rs7829576	chr8:57826398	A/G	cg01310875	chr8:27938995	C8orf80	0.28	6.2	0.32	1.67e-9	Hand grip strength;
LUSC	trans	rs62238980	0.614	rs4821005	chr22:32369804	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs6496667	0.683	rs2589973	chr15:90892293	C/T	cg22089800	chr15:90895588	ZNF774	0.58	8.26	0.41	3.45e-15	Rheumatoid arthritis;
LUSC	trans	rs236907	0.859	rs12753043	chr1:171761821	G/A	cg13482142	chr2:234261155	NA	0.48	6.05	0.31	3.8e-9	Mean platelet volume;
LUSC	cis	rs654351	0.572	rs813274	chr6:10387731	C/T	cg04978078	chr6:10383147	NA	-0.31	-5.77	-0.3	1.82e-8	Squamous cell lung carcinoma;
LUSC	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg25482853	chr8:67687455	SGK3	1.18	16.97	0.68	5.1e-47	Lung disease severity in cystic fibrosis;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07667813	chr19:7985168	SNAPC2	0.37	6.43	0.33	4.39e-10	Calcium levels;
LUSC	cis	rs62400317	0.762	rs12208332	chr6:44903221	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.31	-0.37	1.96e-12	Total body bone mineral density;
LUSC	cis	rs9309473	0.500	rs6757996	chr2:73772251	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-7.76	-0.39	1.05e-13	Metabolite levels;
LUSC	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.15	0.55	2.14e-28	Height;
LUSC	cis	rs10266483	0.705	rs660228	chr7:63756245	T/C	cg24201672	chr7:64023550	ZNF680	-0.45	-5.75	-0.3	1.97e-8	Response to statin therapy;
LUSC	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg09754948	chr16:28834200	ATXN2L	0.41	6.13	0.32	2.5e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg03938978	chr2:103052716	IL18RAP	0.36	6.93	0.35	2.2e-11	Asthma;
LUSC	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg04310649	chr10:35416472	CREM	-0.41	-6.54	-0.34	2.32e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.83	0.39	6.53e-14	Prudent dietary pattern;
LUSC	cis	rs7119	0.635	rs867916	chr15:77882860	A/G	cg27398640	chr15:77910606	LINGO1	0.36	8.45	0.42	8.95e-16	Type 2 diabetes;
LUSC	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg18357645	chr12:58087776	OS9	0.51	7.68	0.39	1.74e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs11039100	0.850	rs12792985	chr11:5833742	A/G	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.78	-10.87	-0.51	9.06e-24	Refractive error;
LUSC	cis	rs983392	0.678	rs7108663	chr11:60028142	C/T	cg24026212	chr11:59952134	MS4A6A	0.36	6.33	0.33	7.73e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.53	-0.38	4.76e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg07169764	chr2:136633963	MCM6	-0.61	-8.02	-0.4	1.81e-14	Mosquito bite size;
LUSC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11645453	chr3:52864694	ITIH4	0.37	8.48	0.42	7.18e-16	Bipolar disorder;
LUSC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg18230493	chr5:56204884	C5orf35	0.76	12.29	0.56	6.94e-29	Initial pursuit acceleration;
LUSC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg12311346	chr5:56204834	C5orf35	-0.63	-9.02	-0.44	1.47e-17	Coronary artery disease;
LUSC	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg24375607	chr4:120327624	NA	0.69	10.34	0.49	6.59e-22	Corneal astigmatism;
LUSC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06634786	chr22:41940651	POLR3H	0.51	5.95	0.31	6.94e-9	Vitiligo;
LUSC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg01238044	chr22:24384105	GSTT1	0.59	7.42	0.38	9.77e-13	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg00033643	chr7:134001901	SLC35B4	0.42	6.61	0.34	1.56e-10	Mean platelet volume;
LUSC	cis	rs9788721	1.000	rs8034191	chr15:78806023	A/G	cg18825076	chr15:78729989	IREB2	-0.48	-7.85	-0.39	5.75e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg25036284	chr2:26402008	FAM59B	0.77	11.38	0.53	1.46e-25	Gut microbiome composition (summer);
LUSC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21984481	chr17:79567631	NPLOC4	-0.72	-15.08	-0.64	1.53e-39	Eye color traits;
LUSC	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg04036182	chr15:45458818	NA	-0.36	-6.08	-0.32	3.26e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2274273	0.684	rs2340921	chr14:55563705	A/G	cg04306507	chr14:55594613	LGALS3	0.5	10.94	0.51	5.1e-24	Protein biomarker;
LUSC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03576123	chr11:487126	PTDSS2	-1.05	-11.18	-0.52	7.13e-25	Body mass index;
LUSC	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg19743168	chr1:23544995	NA	-0.48	-9.17	-0.45	5.08e-18	Height;
LUSC	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-6.88	-0.35	3.01e-11	Fear of minor pain;
LUSC	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg26384229	chr12:38710491	ALG10B	0.61	9.68	0.47	1.11e-19	Morning vs. evening chronotype;
LUSC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18932078	chr1:2524107	MMEL1	0.3	6.4	0.33	5.25e-10	Ulcerative colitis;
LUSC	cis	rs4776059	0.798	rs58018557	chr15:52901284	T/C	cg24008177	chr15:52972085	KIAA1370	-0.33	-5.86	-0.31	1.1e-8	Schizophrenia;
LUSC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18876405	chr7:65276391	NA	0.56	8.78	0.43	8.71e-17	Aortic root size;
LUSC	trans	rs895636	0.519	rs4953155	chr2:45189496	A/T	cg09302903	chr17:46801314	C17orf93;PRAC	0.3	6.01	0.31	4.82e-9	Metabolite levels;Fasting plasma glucose;
LUSC	cis	rs2236918	0.710	rs1635507	chr1:242028358	G/T	cg17736920	chr1:242011382	EXO1	0.44	6.9	0.35	2.61e-11	Menopause (age at onset);
LUSC	cis	rs4974559	0.739	rs59810282	chr4:1320968	A/G	cg02980000	chr4:1222292	CTBP1	0.98	9.13	0.45	6.68e-18	Systolic blood pressure;
LUSC	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg00376283	chr12:123451042	ABCB9	0.7	7.83	0.39	6.5e-14	Platelet count;
LUSC	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.37	-0.42	1.6e-15	Systolic blood pressure;
LUSC	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	7.12	0.36	6.68e-12	Ovarian reserve;
LUSC	cis	rs738322	0.810	rs4820325	chr22:38599978	G/A	cg25457927	chr22:38595422	NA	0.48	10.04	0.48	6.43e-21	Cutaneous nevi;
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18404041	chr3:52824283	ITIH1	-0.46	-8.51	-0.42	5.91e-16	Electroencephalogram traits;
LUSC	cis	rs4988958	0.525	rs3771159	chr2:103004958	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.29e-12	Asthma (childhood onset);
LUSC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg13560548	chr3:10150139	C3orf24	0.53	7.37	0.37	1.39e-12	Alzheimer's disease;
LUSC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.67	0.39	1.93e-13	Obesity-related traits;
LUSC	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg19318889	chr4:1322082	MAEA	0.47	5.69	0.3	2.85e-8	Recombination rate (females);
LUSC	trans	rs12902680	0.607	rs12440533	chr15:46585492	A/T	cg04321580	chr8:143696133	ARC	0.4	6.16	0.32	2.11e-9	Neuroticism;
LUSC	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.32	0.33	8.2e-10	IgG glycosylation;
LUSC	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-0.58	-9.19	-0.45	4.34e-18	Breast cancer;
LUSC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg09877947	chr5:131593287	PDLIM4	0.48	7.83	0.39	6.63e-14	Breast cancer;
LUSC	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg19784903	chr17:45786737	TBKBP1	-0.42	-6.04	-0.31	4.11e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	15.19	0.64	5.47e-40	Platelet count;
LUSC	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg04362960	chr10:104952993	NT5C2	0.6	8.79	0.43	7.81e-17	Arsenic metabolism;
LUSC	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg05855489	chr10:104503620	C10orf26	0.51	7.85	0.39	5.58e-14	Arsenic metabolism;
LUSC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg20887711	chr4:1340912	KIAA1530	0.44	6.61	0.34	1.48e-10	Obesity-related traits;
LUSC	cis	rs793571	0.544	rs11638244	chr15:58907151	A/T	cg05156742	chr15:59063176	FAM63B	0.54	8.2	0.41	5.1e-15	Schizophrenia;
LUSC	cis	rs17604090	1.000	rs17604090	chr7:29691438	C/T	cg19413766	chr7:29689036	LOC646762	-0.58	-6.81	-0.35	4.46e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg13390004	chr1:15929781	NA	0.45	7.78	0.39	9.35e-14	Systolic blood pressure;
LUSC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.51	6.2	0.32	1.69e-9	Multiple sclerosis;
LUSC	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.78	0.35	5.5e-11	Platelet count;
LUSC	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg16576597	chr16:28551801	NUPR1	0.3	6.0	0.31	5.12e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg09626299	chr10:82213104	TSPAN14	-0.2	-5.92	-0.31	8.16e-9	Post bronchodilator FEV1;
LUSC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg06238570	chr21:40685208	BRWD1	-0.56	-8.7	-0.43	1.59e-16	Menarche (age at onset);
LUSC	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.83	9.26	0.45	2.58e-18	Yeast infection;
LUSC	cis	rs1499972	0.941	rs1456182	chr3:117659680	C/T	cg07612923	chr3:117604196	NA	0.64	5.75	0.3	1.97e-8	Schizophrenia;
LUSC	trans	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg04995722	chr7:26192034	NFE2L3	-0.43	-6.74	-0.35	7.14e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg01557791	chr16:72042693	DHODH	-0.58	-8.57	-0.42	3.84e-16	Fibrinogen levels;
LUSC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.47	-0.33	3.42e-10	Resting heart rate;
LUSC	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg23034840	chr1:205782522	SLC41A1	-0.66	-6.98	-0.36	1.64e-11	Prostate-specific antigen levels;
LUSC	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg24342717	chr2:85555507	TGOLN2	-0.74	-12.31	-0.56	5.74e-29	Ear protrusion;
LUSC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.85	-0.35	3.53e-11	Lung cancer;
LUSC	cis	rs6076065	0.723	rs2424546	chr20:23391751	G/T	cg11657817	chr20:23433608	CST11	0.42	7.97	0.4	2.62e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg11861562	chr11:117069780	TAGLN	0.32	6.2	0.32	1.64e-9	Blood protein levels;
LUSC	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.56	-6.72	-0.35	7.9e-11	Body mass index;
LUSC	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg18753928	chr3:113234510	CCDC52	-0.52	-7.84	-0.39	6.31e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	19.72	0.73	5.93e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs149163995	1	rs149163995	chr2:203777226	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.38	0.42	1.49e-15	Migraine;
LUSC	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.62	9.96	0.48	1.27e-20	Blood metabolite ratios;
LUSC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg15445000	chr17:37608096	MED1	-0.41	-6.97	-0.36	1.65e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01722185	chr2:20550205	NA	-0.39	-5.97	-0.31	5.99e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg03806693	chr22:41940476	POLR3H	0.98	14.25	0.61	2.56e-36	Vitiligo;
LUSC	trans	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg06606381	chr12:133084897	FBRSL1	-0.71	-7.15	-0.36	5.34e-12	Breast cancer;
LUSC	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-5.88	-0.31	9.78e-9	Bipolar disorder;
LUSC	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg26876637	chr1:152193138	HRNR	0.47	6.61	0.34	1.48e-10	Atopic dermatitis;
LUSC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.64	0.39	2.27e-13	Prudent dietary pattern;
LUSC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg11861562	chr11:117069780	TAGLN	0.45	8.25	0.41	3.7e-15	Blood protein levels;
LUSC	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg24675056	chr1:15929824	NA	0.45	7.78	0.39	9.02e-14	Systolic blood pressure;
LUSC	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.66e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Bladder cancer;
LUSC	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg24375607	chr4:120327624	NA	0.75	11.42	0.53	9.94e-26	Corneal astigmatism;
LUSC	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.45	-6.71	-0.34	8.14e-11	Schizophrenia;
LUSC	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg05343316	chr1:45956843	TESK2	0.59	8.17	0.41	6.24e-15	Platelet count;
LUSC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.3	0.45	1.9e-18	Prudent dietary pattern;
LUSC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg15147215	chr3:52552868	STAB1	-0.29	-5.76	-0.3	1.93e-8	Electroencephalogram traits;
LUSC	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg07895657	chr22:50616420	PANX2	-0.36	-6.18	-0.32	1.9e-9	Obesity-related traits;
LUSC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.89	0.61	6.05e-35	Breast cancer;
LUSC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.87	-0.31	1.08e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs354225	0.597	rs10176445	chr2:54845776	G/C	cg26097391	chr2:54893211	SPTBN1	0.42	6.23	0.32	1.39e-9	Schizophrenia;
LUSC	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.75	-0.39	1.12e-13	Mood instability;
LUSC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg07395648	chr5:131743802	NA	-0.44	-7.43	-0.38	8.89e-13	Blood metabolite levels;
LUSC	cis	rs7949030	0.780	rs3017666	chr11:62404417	A/T	cg22862634	chr11:62369728	EML3;MTA2	-0.49	-8.05	-0.4	1.47e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7084921	0.548	rs12776483	chr10:101828600	C/A	cg02250046	chr10:101825185	CPN1	-0.34	-6.13	-0.32	2.45e-9	Bone mineral density;
LUSC	cis	rs2979489	0.773	rs2915617	chr8:30272310	C/G	cg26383811	chr8:30366931	RBPMS	0.38	5.96	0.31	6.58e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs11924390	0.749	rs822363	chr3:186452991	C/G	cg12454167	chr3:186435060	KNG1	0.29	7.56	0.38	3.97e-13	Adiponectin levels;
LUSC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg12463550	chr7:65579703	CRCP	0.51	7.37	0.37	1.33e-12	Aortic root size;
LUSC	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.81	0.35	4.67e-11	Height;
LUSC	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.71	0.39	1.48e-13	Schizophrenia;
LUSC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.19	-0.52	6.61e-25	Bipolar disorder;
LUSC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg05872129	chr22:39784769	NA	-0.61	-11.35	-0.53	1.82e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.82	-0.35	4.34e-11	Response to antipsychotic treatment;
LUSC	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-9.3	-0.45	1.95e-18	Morning vs. evening chronotype;
LUSC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.24	14.21	0.61	3.56e-36	Diabetic kidney disease;
LUSC	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg03929089	chr4:120376271	NA	-0.44	-6.15	-0.32	2.24e-9	HDL cholesterol;
LUSC	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg20307385	chr11:47447363	PSMC3	0.45	6.57	0.34	1.88e-10	Subjective well-being;
LUSC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.42	-6.37	-0.33	6.13e-10	Menarche (age at onset);
LUSC	cis	rs6489882	0.867	rs1154970	chr12:113370427	A/C	cg20102336	chr12:113376681	OAS3	-0.42	-6.37	-0.33	6.43e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg06484146	chr7:12443880	VWDE	-0.61	-6.07	-0.32	3.47e-9	Coronary artery disease;
LUSC	trans	rs9473924	1.000	rs6923215	chr6:50889848	G/A	cg22375689	chr19:34175036	CHST8	0.38	6.15	0.32	2.2e-9	Body mass index;
LUSC	trans	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg20935933	chr6:143382018	AIG1	0.49	7.16	0.36	5.08e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.54	-0.38	4.51e-13	Neuroticism;
LUSC	trans	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	9.0	0.44	1.77e-17	Type 2 diabetes;
LUSC	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.9	-0.4	4.2e-14	Triglycerides;
LUSC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg12963246	chr6:28129442	ZNF389	0.41	6.5	0.33	3e-10	Parkinson's disease;
LUSC	cis	rs10779751	0.959	rs2092642	chr1:11317320	C/T	cg08854313	chr1:11322531	MTOR	0.92	16.17	0.66	7.91e-44	Body mass index;
LUSC	cis	rs2230307	0.536	rs631977	chr1:100544564	C/G	cg24955406	chr1:100503596	HIAT1	0.59	6.42	0.33	4.63e-10	Carotid intima media thickness;
LUSC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg18827107	chr12:86230957	RASSF9	-0.48	-7.15	-0.36	5.47e-12	Major depressive disorder;
LUSC	cis	rs934734	0.967	rs702875	chr2:65614197	T/C	cg08085232	chr2:65598271	SPRED2	-0.39	-6.05	-0.31	3.9e-9	Rheumatoid arthritis;
LUSC	trans	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg27411982	chr8:10470053	RP1L1	0.45	7.43	0.38	9.32e-13	Mood instability;
LUSC	cis	rs354225	0.544	rs12713268	chr2:54808845	C/G	cg01766943	chr2:54829624	SPTBN1	-0.46	-7.51	-0.38	5.34e-13	Schizophrenia;
LUSC	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	7.97	0.4	2.45e-14	Body mass index;
LUSC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg04369109	chr6:150039330	LATS1	-0.54	-7.94	-0.4	3.06e-14	Lung cancer;
LUSC	cis	rs886126	0.950	rs2078851	chr12:111690579	C/T	cg10833066	chr12:111807467	FAM109A	-0.4	-6.15	-0.32	2.16e-9	Coronary heart disease;
LUSC	cis	rs925255	0.817	rs7606480	chr2:28632377	G/A	cg01273330	chr2:28605224	NA	0.46	7.64	0.39	2.36e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs642803	0.613	rs565427	chr11:65532825	G/A	cg02870584	chr11:65547924	DKFZp761E198	0.43	5.93	0.31	7.37e-9	Urate levels;
LUSC	trans	rs459571	0.606	rs457420	chr9:136909261	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.51	7.93	0.4	3.36e-14	Platelet distribution width;
LUSC	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21775007	chr8:11205619	TDH	0.73	11.84	0.54	3.02e-27	Retinal vascular caliber;
LUSC	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.58	8.23	0.41	4.29e-15	Breast cancer;
LUSC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.3	-0.41	2.63e-15	Obesity-related traits;
LUSC	trans	rs12200782	0.872	rs41266837	chr6:26409729	G/A	cg18180407	chr1:55047736	ACOT11	0.44	6.01	0.31	4.8e-9	Small cell lung carcinoma;
LUSC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	6.23	0.32	1.43e-9	Renal cell carcinoma;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg11081185	chr11:208423	RIC8A;BET1L	0.39	6.32	0.33	8.43e-10	Triglycerides;
LUSC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg14668632	chr7:2872130	GNA12	-0.43	-6.1	-0.32	2.95e-9	Height;
LUSC	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg04111992	chr7:158790115	NA	0.36	5.85	0.3	1.19e-8	Facial morphology (factor 20);
LUSC	cis	rs2857891	0.817	rs2857902	chr11:6980256	C/G	cg14883916	chr11:6947541	ZNF215	0.45	5.83	0.3	1.29e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05025164	chr4:1340916	KIAA1530	0.64	9.86	0.48	2.59e-20	Longevity;
LUSC	cis	rs2219968	1.000	rs6982487	chr8:78972260	C/A	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17125944	0.556	rs1952088	chr14:53319832	A/C	cg00686598	chr14:53173677	PSMC6	-0.62	-5.82	-0.3	1.36e-8	Alzheimer's disease (late onset);
LUSC	cis	rs295140	0.803	rs4516415	chr2:201129608	C/G	cg04283868	chr2:201171347	SPATS2L	0.41	5.95	0.31	6.78e-9	QT interval;
LUSC	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-7.15	-0.36	5.48e-12	Homocysteine levels;
LUSC	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.41	6.53	0.34	2.43e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg19468946	chr17:37922297	IKZF3	-0.38	-5.91	-0.31	8.66e-9	Self-reported allergy;
LUSC	cis	rs2652834	0.950	rs2729789	chr15:63400345	G/A	cg05507819	chr15:63340323	TPM1	0.67	8.15	0.41	7.6e-15	HDL cholesterol;
LUSC	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg05043794	chr9:111880884	C9orf5	-0.26	-6.0	-0.31	5.07e-9	Menarche (age at onset);
LUSC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg04121214	chr22:50244548	NA	-0.34	-5.66	-0.3	3.2e-8	Schizophrenia;
LUSC	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg21427119	chr20:30132790	HM13	-0.44	-5.77	-0.3	1.82e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs6840360	1.000	rs6535813	chr4:152599652	A/T	cg22705602	chr4:152727874	NA	-0.27	-5.7	-0.3	2.66e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.78	13.14	0.58	4.31e-32	Metabolic syndrome;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22450693	chr17:48624483	SPATA20	-0.41	-6.19	-0.32	1.73e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4144743	0.759	rs67972765	chr17:45318326	G/A	cg18085866	chr17:45331354	ITGB3	-0.77	-7.51	-0.38	5.29e-13	Body mass index;
LUSC	cis	rs36051895	0.632	rs7850484	chr9:5147817	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-7.22	-0.37	3.47e-12	Pediatric autoimmune diseases;
LUSC	cis	rs7940866	0.809	rs2324317	chr11:130877142	T/C	cg12179176	chr11:130786555	SNX19	0.6	9.51	0.46	3.76e-19	Schizophrenia;
LUSC	cis	rs4356932	1.000	rs7684889	chr4:76963264	T/A	cg00809888	chr4:76862425	NAAA	0.36	6.0	0.31	5.07e-9	Blood protein levels;
LUSC	cis	rs2667011	0.654	rs2465668	chr2:160838391	T/C	cg06573604	chr2:160760825	LY75	-0.5	-6.36	-0.33	6.7e-10	Bilirubin levels;
LUSC	cis	rs11955175	1.000	rs11951044	chr5:40671189	G/A	cg04002187	chr5:40835754	RPL37	0.67	5.87	0.31	1.04e-8	Bipolar disorder and schizophrenia;
LUSC	trans	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg25214090	chr10:38739885	LOC399744	0.47	6.86	0.35	3.32e-11	Corneal astigmatism;
LUSC	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.54	0.42	4.93e-16	Lung cancer in ever smokers;
LUSC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg18827107	chr12:86230957	RASSF9	-0.46	-6.87	-0.35	3.16e-11	Major depressive disorder;
LUSC	cis	rs2652834	0.718	rs2729829	chr15:63395484	C/T	cg05507819	chr15:63340323	TPM1	0.54	6.96	0.36	1.82e-11	HDL cholesterol;
LUSC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg11247378	chr22:39784982	NA	0.61	11.83	0.54	3.34e-27	IgG glycosylation;
LUSC	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.2e-28	Corneal astigmatism;
LUSC	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg25214090	chr10:38739885	LOC399744	0.57	8.42	0.42	1.1e-15	Corneal astigmatism;
LUSC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg07741184	chr6:167504864	NA	0.43	7.49	0.38	6.4e-13	Primary biliary cholangitis;
LUSC	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg25797454	chr6:150327115	RAET1K	0.32	7.62	0.38	2.62e-13	Alopecia areata;
LUSC	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg27411982	chr8:10470053	RP1L1	0.37	5.73	0.3	2.27e-8	Neuroticism;
LUSC	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg24375607	chr4:120327624	NA	0.73	11.24	0.52	4.6e-25	Corneal astigmatism;
LUSC	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21775007	chr8:11205619	TDH	0.7	11.29	0.53	2.85e-25	Retinal vascular caliber;
LUSC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg08949735	chr16:89699720	DPEP1	-0.23	-5.76	-0.3	1.89e-8	Vitiligo;
LUSC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-8.54	-0.42	4.67e-16	Hemoglobin concentration;
LUSC	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg02466173	chr16:30829666	NA	-0.5	-9.55	-0.46	2.91e-19	Dementia with Lewy bodies;
LUSC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03517284	chr6:25882590	NA	-0.37	-6.07	-0.32	3.46e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	6.81	0.35	4.68e-11	Multiple sclerosis;
LUSC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.51	10.02	0.48	7.88e-21	Monocyte percentage of white cells;
LUSC	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg16230307	chr14:35515116	FAM177A1	0.79	10.05	0.48	6.13e-21	Psoriasis;
LUSC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg16624210	chr5:671434	TPPP	0.46	5.94	0.31	7.33e-9	Obesity-related traits;
LUSC	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.58	8.79	0.43	7.97e-17	Blood protein levels;
LUSC	cis	rs72772090	0.539	rs3333	chr5:96115111	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-6.55	-0.34	2.11e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11645898	0.935	rs72787078	chr16:72158493	C/T	cg14768367	chr16:72042858	DHODH	-0.66	-7.41	-0.38	1.05e-12	Blood protein levels;
LUSC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06634786	chr22:41940651	POLR3H	-0.51	-5.92	-0.31	8.1e-9	Vitiligo;
LUSC	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg18449964	chr18:72917101	ZADH2	0.46	5.77	0.3	1.79e-8	Vascular endothelial growth factor levels;
LUSC	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg07936489	chr17:37558343	FBXL20	-0.81	-9.86	-0.47	2.7e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs10746514	0.833	rs2026302	chr1:232264047	A/G	cg09506761	chr1:232265262	NA	-0.56	-9.74	-0.47	6.56e-20	Response to statin therapy;
LUSC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg00255919	chr5:131827918	IRF1	0.43	8.27	0.41	3.31e-15	Asthma (sex interaction);
LUSC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08736216	chr1:53307985	ZYG11A	0.3	6.24	0.32	1.34e-9	Monocyte count;
LUSC	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg03676636	chr4:99064102	C4orf37	0.36	7.83	0.39	6.75e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg13072238	chr3:49761600	GMPPB	-0.4	-6.52	-0.34	2.6e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.51	0.86	1.3e-98	Chronic sinus infection;
LUSC	cis	rs1044826	0.642	rs432387	chr3:139231853	T/G	cg00490450	chr3:139108681	COPB2	-0.46	-7.08	-0.36	8.58e-12	Obesity-related traits;
LUSC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg09034736	chr1:150693464	HORMAD1	0.44	6.59	0.34	1.68e-10	Tonsillectomy;
LUSC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.82	0.68	1.93e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11630290	0.736	rs6494440	chr15:64145709	C/T	cg12036633	chr15:63758958	NA	0.59	6.59	0.34	1.69e-10	Iris characteristics;
LUSC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg19748678	chr4:122722346	EXOSC9	0.5	7.67	0.39	1.86e-13	Type 2 diabetes;
LUSC	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg19875535	chr5:140030758	IK	-0.5	-8.29	-0.41	2.89e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg13560548	chr3:10150139	C3orf24	0.5	7.09	0.36	8.1e-12	Alzheimer's disease;
LUSC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg26727032	chr16:67993705	SLC12A4	-0.45	-5.94	-0.31	7.32e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6669072	0.585	rs1025961	chr1:91264048	T/C	cg08895590	chr1:91227319	NA	-0.27	-5.8	-0.3	1.54e-8	Cognitive function;
LUSC	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg18131467	chr2:239335373	ASB1	0.96	20.73	0.75	6.01e-62	Multiple system atrophy;
LUSC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg01475377	chr6:109611718	NA	-0.46	-8.37	-0.42	1.59e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-7.07	-0.36	9.07e-12	Monocyte percentage of white cells;
LUSC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12292205	chr6:26970375	C6orf41	-0.56	-7.39	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2041895	0.509	rs2024518	chr12:107296902	G/A	cg13944111	chr12:107296891	NA	0.36	6.27	0.32	1.15e-9	Glaucoma (low intraocular pressure);
LUSC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.6	10.06	0.48	5.68e-21	Lymphocyte counts;
LUSC	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.35	-6.6	-0.34	1.62e-10	Coronary artery disease;
LUSC	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg03983476	chr2:10830698	NOL10	-0.37	-5.66	-0.3	3.31e-8	Prostate cancer;
LUSC	cis	rs7615316	0.779	rs4608715	chr3:142051147	T/C	cg16271453	chr3:142027066	XRN1	-0.4	-6.98	-0.36	1.55e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6906287	0.647	rs3890198	chr6:118706447	T/C	cg21191810	chr6:118973309	C6orf204	0.33	5.86	0.31	1.1e-8	Electrocardiographic conduction measures;
LUSC	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg00105475	chr2:10696890	NA	-0.35	-5.77	-0.3	1.8e-8	Prostate cancer;
LUSC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg15595755	chr5:1867978	NA	0.46	8.49	0.42	6.64e-16	Cardiovascular disease risk factors;
LUSC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg02153584	chr22:29168773	CCDC117	-0.58	-8.66	-0.43	2.01e-16	Lymphocyte counts;
LUSC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03264133	chr6:25882463	NA	-0.5	-9.11	-0.45	7.57e-18	Blood metabolite levels;
LUSC	cis	rs838147	0.563	rs281379	chr19:49214274	C/T	cg21064579	chr19:49206444	FUT2	0.35	6.41	0.33	4.89e-10	Dietary macronutrient intake;
LUSC	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg16482183	chr6:26056742	HIST1H1C	0.63	8.97	0.44	2.11e-17	Iron status biomarkers;
LUSC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg16339924	chr4:17578868	LAP3	0.52	7.99	0.4	2.15e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg00431813	chr7:1051703	C7orf50	-0.46	-7.69	-0.39	1.66e-13	Longevity;Endometriosis;
LUSC	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg07211511	chr3:129823064	LOC729375	-0.6	-8.03	-0.4	1.69e-14	Blood pressure (smoking interaction);
LUSC	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs12365397	0.526	rs11037263	chr11:43161203	A/C	cg03447554	chr11:43094025	NA	0.35	5.79	0.3	1.59e-8	Migraine;
LUSC	cis	rs8014204	0.816	rs28426374	chr14:75346740	C/T	cg08847533	chr14:75593920	NEK9	-0.41	-6.03	-0.31	4.32e-9	Caffeine consumption;
LUSC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.71	13.45	0.59	2.88e-33	Height;
LUSC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg18240062	chr17:79603768	NPLOC4	0.58	9.87	0.48	2.58e-20	Eye color traits;
LUSC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg22535103	chr8:58192502	C8orf71	0.74	7.66	0.39	2.09e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg13683864	chr3:40499215	RPL14	-0.97	-16.04	-0.66	2.37e-43	Renal cell carcinoma;
LUSC	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg10729496	chr3:10149963	C3orf24	0.47	6.11	0.32	2.83e-9	Alzheimer's disease;
LUSC	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg08601574	chr20:25228251	PYGB	0.42	6.41	0.33	4.9e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs62458065	0.513	rs7788809	chr7:32552622	T/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.55	-5.92	-0.31	7.8e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg11584989	chr19:19387371	SF4	0.57	6.78	0.35	5.44e-11	Bipolar disorder;
LUSC	cis	rs4713675	0.584	rs4711339	chr6:33667199	A/G	cg14003231	chr6:33640908	ITPR3	0.31	5.99	0.31	5.39e-9	Plateletcrit;
LUSC	trans	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg07393940	chr7:158741817	NA	0.51	8.24	0.41	3.97e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg27037943	chr1:84972490	SPATA1;GNG5	-0.47	-6.38	-0.33	5.98e-10	Hepatitis;
LUSC	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.77	0.35	5.96e-11	Educational attainment;
LUSC	cis	rs11031096	0.678	rs11031184	chr11:4186192	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-6.33	-0.33	7.81e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-7.94	-0.4	3.14e-14	Chronic sinus infection;
LUSC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg00945038	chr17:61921165	SMARCD2	-0.38	-5.8	-0.3	1.53e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs17253792	0.822	rs79398217	chr14:56067350	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.96	-0.36	1.81e-11	Putamen volume;
LUSC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg07741184	chr6:167504864	NA	0.36	6.53	0.34	2.52e-10	Crohn's disease;
LUSC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg22800045	chr5:56110881	MAP3K1	0.79	10.51	0.5	1.59e-22	Initial pursuit acceleration;
LUSC	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	7.52	0.38	5.26e-13	Response to antipsychotic treatment;
LUSC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.66	0.57	2.9e-30	Motion sickness;
LUSC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg12463550	chr7:65579703	CRCP	-0.52	-7.5	-0.38	5.79e-13	Aortic root size;
LUSC	trans	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg24675658	chr1:53192096	ZYG11B	-0.65	-10.22	-0.49	1.63e-21	Monocyte count;
LUSC	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg16576597	chr16:28551801	NUPR1	0.28	5.68	0.3	2.93e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.39	-0.33	5.45e-10	Daytime sleep phenotypes;
LUSC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.09	-0.32	3.04e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs16910800	1.000	rs1531809	chr11:23194373	A/T	cg20040320	chr11:23191996	NA	-0.45	-6.52	-0.34	2.6e-10	Cancer;
LUSC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	cis	rs1215050	0.655	rs6842706	chr4:98499037	A/T	cg05340658	chr4:99064831	C4orf37	-0.39	-5.81	-0.3	1.45e-8	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg22907277	chr7:1156413	C7orf50	0.61	9.6	0.47	1.97e-19	Longevity;Endometriosis;
LUSC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg06008330	chr7:65541103	ASL	-0.41	-6.31	-0.33	8.66e-10	Aortic root size;
LUSC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg03233332	chr7:66118400	NA	-0.41	-6.05	-0.31	3.99e-9	Aortic root size;
LUSC	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17467752	chr17:38218738	THRA	-0.48	-6.65	-0.34	1.21e-10	Myeloid white cell count;
LUSC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg05347473	chr6:146136440	FBXO30	0.57	10.04	0.48	6.65e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.43	7.11	0.36	7.11e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.18	0.32	1.88e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.97	0.36	1.72e-11	Cystic fibrosis severity;
LUSC	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg27284194	chr4:1044797	NA	0.46	7.2	0.37	4.05e-12	Recombination rate (males);
LUSC	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg20307385	chr11:47447363	PSMC3	0.45	6.52	0.34	2.68e-10	Subjective well-being;
LUSC	cis	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg06521331	chr12:34319734	NA	-0.37	-5.98	-0.31	5.7e-9	Morning vs. evening chronotype;
LUSC	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-35.46	-0.89	2.82e-115	Myeloid white cell count;
LUSC	cis	rs3857536	0.813	rs1029400	chr6:66952385	A/G	cg07460842	chr6:66804631	NA	-0.46	-6.36	-0.33	6.75e-10	Blood trace element (Cu levels);
LUSC	cis	rs2798269	0.966	rs2798272	chr13:22136766	C/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.04	-0.31	4.15e-9	PR segment;
LUSC	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg22906224	chr7:99728672	NA	0.47	6.54	0.34	2.36e-10	Coronary artery disease;
LUSC	cis	rs55728055	0.661	rs56411340	chr22:31984476	G/T	cg01338084	chr22:32026380	PISD	0.93	6.78	0.35	5.4e-11	Age-related hearing impairment;
LUSC	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg24631222	chr15:78858424	CHRNA5	-0.44	-5.94	-0.31	7.25e-9	Coronary artery disease or large artery stroke;
LUSC	cis	rs737337	0.623	rs4804155	chr19:11334295	C/G	cg00586551	chr19:11347513	LOC55908;DOCK6	0.63	8.64	0.43	2.38e-16	HDL cholesterol;HDL cholesterol levels;
LUSC	trans	rs6852435	1.000	rs62335857	chr4:175309122	C/T	cg23753247	chr11:8615842	STK33	-0.53	-5.97	-0.31	5.91e-9	Response to acetaminophen (hepatotoxicity);
LUSC	cis	rs977987	0.806	rs11641587	chr16:75464419	G/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.42e-11	Dupuytren's disease;
LUSC	cis	rs73206853	0.841	rs11065663	chr12:110988886	G/T	cg12870014	chr12:110450643	ANKRD13A	0.66	7.29	0.37	2.25e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.93	15.81	0.65	1.96e-42	Morning vs. evening chronotype;
LUSC	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.34	-0.33	7.25e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg21775007	chr8:11205619	TDH	-0.49	-7.35	-0.37	1.55e-12	Triglycerides;
LUSC	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg25214090	chr10:38739885	LOC399744	0.57	8.42	0.42	1.1e-15	Corneal astigmatism;
LUSC	cis	rs524023	0.957	rs893006	chr11:64365796	C/A	cg07220939	chr11:64358617	SLC22A12	-0.23	-6.1	-0.32	2.99e-9	Urate levels in obese individuals;
LUSC	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg27068330	chr11:65405492	SIPA1	0.61	9.03	0.44	1.39e-17	Acne (severe);
LUSC	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg00334542	chr7:100209784	MOSPD3	-0.67	-7.52	-0.38	5.23e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs17818399	0.926	rs7590693	chr2:46823992	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.43	6.66	0.34	1.15e-10	Height;
LUSC	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg22782873	chr19:19639568	YJEFN3	-0.48	-6.11	-0.32	2.7e-9	Bipolar disorder;
LUSC	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.9e-23	Bladder cancer;
LUSC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg26769984	chr7:1090371	C7orf50	0.57	7.69	0.39	1.69e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	0.7	11.22	0.52	5.35e-25	Blood metabolite ratios;
LUSC	trans	rs9944715	0.954	rs9675387	chr18:43798023	G/A	cg01718231	chr17:29326311	RNF135	-0.53	-7.34	-0.37	1.68e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs12760731	0.623	rs61520802	chr1:178428494	G/A	cg00404053	chr1:178313656	RASAL2	0.48	5.84	0.3	1.27e-8	Obesity-related traits;
LUSC	cis	rs76419734	0.510	rs2193856	chr4:106742958	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.54	-6.06	-0.31	3.71e-9	Post bronchodilator FEV1;
LUSC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	1.1	9.65	0.47	1.34e-19	Skin colour saturation;
LUSC	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg15557168	chr22:42548783	NA	-0.41	-6.18	-0.32	1.88e-9	Schizophrenia;
LUSC	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.84	0.44	5.47e-17	Coffee consumption (cups per day);
LUSC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg08200582	chr11:442649	ANO9	-0.52	-6.04	-0.31	4.09e-9	Body mass index;
LUSC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs977987	0.806	rs4888404	chr16:75428097	G/A	cg03315344	chr16:75512273	CHST6	0.48	9.05	0.44	1.17e-17	Dupuytren's disease;
LUSC	cis	rs7904985	0.924	rs2217223	chr10:88111630	A/G	cg07322936	chr10:88137208	NA	0.6	8.05	0.4	1.44e-14	Barrett's esophagus;
LUSC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03264133	chr6:25882463	NA	-0.42	-7.26	-0.37	2.76e-12	Blood metabolite levels;
LUSC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs13082711	0.513	rs66472045	chr3:27242887	G/A	cg02860705	chr3:27208620	NA	0.64	11.15	0.52	9.46e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.98	0.48	1.08e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4450131	0.522	rs4962680	chr10:126358833	C/T	cg20435097	chr10:126320824	FAM53B	0.24	6.07	0.32	3.41e-9	White blood cell count (basophil);
LUSC	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg21433313	chr16:3507492	NAT15	-0.39	-6.14	-0.32	2.34e-9	Body mass index (adult);
LUSC	cis	rs6709815	0.902	rs13020432	chr2:219668211	C/T	cg02176678	chr2:219576539	TTLL4	-0.52	-9.13	-0.45	6.64e-18	Reticulocyte count;High light scatter reticulocyte count;
LUSC	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg03647239	chr10:116582469	FAM160B1	0.45	7.19	0.37	4.19e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg08807101	chr21:30365312	RNF160	0.67	10.59	0.5	8.53e-23	Selective IgA deficiency;
LUSC	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg05347473	chr6:146136440	FBXO30	0.42	6.95	0.36	1.92e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg25587211	chr3:43663662	ANO10	0.44	6.67	0.34	1.04e-10	Triglycerides;
LUSC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg04518342	chr5:131593106	PDLIM4	0.45	7.88	0.4	4.52e-14	Acylcarnitine levels;
LUSC	cis	rs7561273	0.609	rs10189243	chr2:24293756	C/T	cg06627628	chr2:24431161	ITSN2	-0.51	-6.83	-0.35	3.93e-11	Quantitative traits;
LUSC	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.68	11.38	0.53	1.42e-25	Schizophrenia;
LUSC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.13	-0.41	8.39e-15	Lung cancer;
LUSC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg19678392	chr7:94953810	PON1	-0.36	-5.65	-0.3	3.48e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7523050	0.730	rs12729728	chr1:109431110	C/A	cg08274380	chr1:109419600	GPSM2	1.12	10.87	0.51	8.87e-24	Fat distribution (HIV);
LUSC	trans	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg18187862	chr3:45730750	SACM1L	-0.51	-6.27	-0.32	1.1e-9	Primary sclerosing cholangitis;
LUSC	cis	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg06521331	chr12:34319734	NA	-0.37	-6.16	-0.32	2.07e-9	Morning vs. evening chronotype;
LUSC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg06618935	chr21:46677482	NA	-0.4	-8.12	-0.41	9.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06002616	chr8:101225028	SPAG1	-0.43	-6.97	-0.36	1.68e-11	Atrioventricular conduction;
LUSC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg27068330	chr11:65405492	SIPA1	0.52	6.03	0.31	4.3e-9	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs4363385	0.747	rs1015996	chr1:152976108	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.65	-0.3	3.43e-8	Inflammatory skin disease;
LUSC	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg05163923	chr11:71159392	DHCR7	-0.77	-10.11	-0.48	3.81e-21	Vitamin D levels;
LUSC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg24250549	chr1:154909240	PMVK	0.66	11.06	0.52	2.01e-24	Prostate cancer;
LUSC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg02807482	chr3:125708958	NA	-0.52	-6.5	-0.33	2.98e-10	Blood pressure (smoking interaction);
LUSC	cis	rs7119	0.604	rs2458035	chr15:77862806	G/A	cg27398640	chr15:77910606	LINGO1	0.36	7.92	0.4	3.62e-14	Type 2 diabetes;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00698688	chr19:49055432	SULT2B1	-0.24	-6.26	-0.32	1.21e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.94e-9	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg22823121	chr1:150693482	HORMAD1	0.61	9.35	0.46	1.34e-18	Tonsillectomy;
LUSC	trans	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg13565492	chr6:43139072	SRF	-0.58	-6.57	-0.34	1.97e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-7.14	-0.36	5.99e-12	Daytime sleep phenotypes;
LUSC	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg13334819	chr7:99746414	C7orf59	-0.44	-6.04	-0.31	4.18e-9	Coronary artery disease;
LUSC	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg21385522	chr1:16154831	NA	-0.98	-18.47	-0.71	5.65e-53	Dilated cardiomyopathy;
LUSC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg00750074	chr16:89608354	SPG7	-0.56	-10.09	-0.48	4.63e-21	Multiple myeloma (IgH translocation);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21497602	chr12:12715811	DUSP16	0.76	6.05	0.31	3.9e-9	Cognitive performance;
LUSC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg06618935	chr21:46677482	NA	-0.34	-7.02	-0.36	1.24e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg11693508	chr17:37793320	STARD3	0.65	7.9	0.4	4.19e-14	Bipolar disorder;
LUSC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg19748678	chr4:122722346	EXOSC9	0.49	7.55	0.38	4.29e-13	Type 2 diabetes;
LUSC	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg18002602	chr11:66138449	SLC29A2	0.47	8.33	0.41	2.16e-15	Educational attainment (years of education);
LUSC	cis	rs6076065	0.748	rs4142246	chr20:23388975	A/G	cg11657817	chr20:23433608	CST11	0.54	11.1	0.52	1.37e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.55	-5.95	-0.31	6.86e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg03465714	chr1:152285911	FLG	-0.41	-5.89	-0.31	9.28e-9	Atopic dermatitis;
LUSC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg20302533	chr7:39170763	POU6F2	0.54	9.08	0.44	9.88e-18	IgG glycosylation;
LUSC	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg16482183	chr6:26056742	HIST1H1C	0.64	9.14	0.45	6.03e-18	Iron status biomarkers;
LUSC	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg03676636	chr4:99064102	C4orf37	0.38	8.07	0.4	1.3e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg08470875	chr2:26401718	FAM59B	-0.71	-9.6	-0.47	1.92e-19	Gut microbiome composition (summer);
LUSC	cis	rs9318086	0.712	rs9510916	chr13:24442789	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.42	6.23	0.32	1.39e-9	Myopia (pathological);
LUSC	cis	rs2050392	0.771	rs303446	chr10:30728489	C/T	cg18806716	chr10:30721971	MAP3K8	-0.48	-8.01	-0.4	1.93e-14	Inflammatory bowel disease;
LUSC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-8.92	-0.44	3.11e-17	Gut microbiome composition (summer);
LUSC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	11.96	0.55	1.11e-27	Colorectal cancer;
LUSC	cis	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.36	-0.33	6.81e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs953492	0.591	rs10803128	chr1:243393842	T/C	cg25284624	chr1:224180302	NA	-0.42	-6.34	-0.33	7.64e-10	Diastolic blood pressure;
LUSC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg03909863	chr11:638404	DRD4	-0.39	-5.74	-0.3	2.17e-8	Systemic lupus erythematosus;
LUSC	cis	rs9837602	0.507	rs1059905	chr3:99516879	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-7.26	-0.37	2.69e-12	Breast cancer;
LUSC	cis	rs10740039	0.842	rs7915540	chr10:62406296	G/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.86	-0.35	3.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.78	0.35	5.46e-11	Tonsillectomy;
LUSC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.39	6.05	0.31	3.87e-9	Height;
LUSC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg09455208	chr3:40491958	NA	0.59	10.39	0.49	4.39e-22	Renal cell carcinoma;
LUSC	cis	rs4363385	0.818	rs4845522	chr1:153011099	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs10740039	0.804	rs7900848	chr10:62415651	C/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.92	-0.35	2.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg00074818	chr8:8560427	CLDN23	0.59	9.8	0.47	4.21e-20	Obesity-related traits;
LUSC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.85	0.44	5.14e-17	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-6.67	-0.34	1.06e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg18002602	chr11:66138449	SLC29A2	0.35	6.22	0.32	1.53e-9	HIV-1 susceptibility;
LUSC	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.56	9.36	0.46	1.23e-18	Breast cancer;
LUSC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg02079420	chr8:82753780	SNX16	0.43	7.47	0.38	7.14e-13	Diastolic blood pressure;
LUSC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg26597838	chr10:835615	NA	1.21	15.68	0.65	6.59e-42	Eosinophil percentage of granulocytes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05663418	chr16:3451086	ZNF174;ZNF434	0.46	6.15	0.32	2.25e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg02158880	chr13:53174818	NA	-0.39	-6.73	-0.35	7.6e-11	Lewy body disease;
LUSC	cis	rs9323205	0.954	rs4898682	chr14:51639577	C/T	cg23942311	chr14:51606299	NA	-0.38	-7.81	-0.39	7.48e-14	Cancer;
LUSC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.69	0.5	3.96e-23	Schizophrenia;
LUSC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg18758796	chr5:131593413	PDLIM4	-0.42	-6.76	-0.35	6.25e-11	Breast cancer;
LUSC	cis	rs977987	0.800	rs12935787	chr16:75332335	C/T	cg03315344	chr16:75512273	CHST6	0.47	8.82	0.43	6.26e-17	Dupuytren's disease;
LUSC	cis	rs10193935	1.000	rs10193935	chr2:42419829	C/T	cg27598129	chr2:42591480	NA	-0.61	-8.57	-0.42	4.01e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-6.47	-0.33	3.42e-10	Electroencephalogram traits;
LUSC	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg08000102	chr2:233561755	GIGYF2	-0.8	-13.76	-0.6	1.95e-34	Schizophrenia;
LUSC	trans	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg04995722	chr7:26192034	NFE2L3	0.41	6.47	0.33	3.49e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg16482183	chr6:26056742	HIST1H1C	0.65	9.13	0.45	6.68e-18	Iron status biomarkers;
LUSC	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg16579770	chr16:72058938	DHODH	0.34	5.77	0.3	1.85e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg02269571	chr22:50332266	NA	-0.57	-8.59	-0.43	3.41e-16	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg06618935	chr21:46677482	NA	-0.38	-7.67	-0.39	1.94e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15929228	chr2:240323491	HDAC4	-0.47	-6.32	-0.33	8.58e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg24644049	chr4:85504048	CDS1	-0.64	-6.69	-0.34	9.38e-11	Skin colour saturation;
LUSC	cis	rs6429082	0.683	rs2131920	chr1:235579912	T/A	cg26050004	chr1:235667680	B3GALNT2	-0.56	-7.95	-0.4	2.89e-14	Adiposity;
LUSC	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21659725	chr3:3221576	CRBN	0.6	8.77	0.43	9.54e-17	Resting heart rate;
LUSC	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.46	7.88	0.4	4.8e-14	Alcohol dependence;
LUSC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.86	-0.35	3.41e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg23649088	chr2:200775458	C2orf69	-0.55	-6.98	-0.36	1.64e-11	Schizophrenia;
LUSC	cis	rs2219968	0.923	rs7004112	chr8:78941331	G/T	cg00738934	chr8:78996279	NA	0.39	6.97	0.36	1.66e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg07393940	chr7:158741817	NA	0.38	6.74	0.35	6.87e-11	Life satisfaction;
LUSC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.36	-6.38	-0.33	6.02e-10	Longevity;Endometriosis;
LUSC	cis	rs7903847	0.642	rs7092350	chr10:99140218	A/T	cg20016023	chr10:99160130	RRP12	-0.33	-8.19	-0.41	5.76e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs240764	0.658	rs4571568	chr6:101223955	T/A	cg09795085	chr6:101329169	ASCC3	-0.42	-6.11	-0.32	2.74e-9	Neuroticism;
LUSC	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg09877947	chr5:131593287	PDLIM4	-0.37	-6.0	-0.31	5.25e-9	Blood metabolite levels;
LUSC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.3	-0.33	9.58e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg02153584	chr22:29168773	CCDC117	0.54	8.12	0.41	9.23e-15	Lymphocyte counts;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00619347	chr3:149688574	PFN2	-0.46	-6.01	-0.31	4.96e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07080220	chr10:102295463	HIF1AN	0.67	8.6	0.43	3.17e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06022373	chr22:39101656	GTPBP1	0.89	14.68	0.63	5.52e-38	Menopause (age at onset);
LUSC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.46	-0.46	5.68e-19	Electroencephalogram traits;
LUSC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18099408	chr3:52552593	STAB1	-0.37	-6.48	-0.33	3.33e-10	Electroencephalogram traits;
LUSC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.76	-11.27	-0.53	3.37e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4474465	0.850	rs4945289	chr11:78245334	G/T	cg27205649	chr11:78285834	NARS2	0.48	5.84	0.3	1.24e-8	Alzheimer's disease (survival time);
LUSC	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg24851651	chr11:66362959	CCS	-0.38	-6.08	-0.32	3.37e-9	Educational attainment (years of education);
LUSC	cis	rs7804356	0.906	rs73069540	chr7:26904770	C/T	cg03456212	chr7:26904342	SKAP2	-0.58	-6.65	-0.34	1.22e-10	Type 1 diabetes;
LUSC	trans	rs12317459	0.591	rs11830781	chr12:83205083	G/A	cg10237817	chr1:154519846	TDRD10	0.31	6.14	0.32	2.28e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12989701	0.877	rs13029812	chr2:127872622	A/G	cg08168897	chr2:127865431	BIN1	0.71	9.36	0.46	1.2e-18	Alzheimer's disease (late onset);
LUSC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.67e-12	Motion sickness;
LUSC	trans	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg25214090	chr10:38739885	LOC399744	0.46	6.74	0.35	7.06e-11	Corneal astigmatism;
LUSC	cis	rs17102423	0.589	rs4899162	chr14:65614126	G/T	cg11161011	chr14:65562177	MAX	-0.62	-8.39	-0.42	1.39e-15	Obesity-related traits;
LUSC	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg00277334	chr10:82204260	NA	-0.51	-7.41	-0.38	1.05e-12	Post bronchodilator FEV1;
LUSC	trans	rs72674100	1.000	rs28656993	chr4:97965682	C/T	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	9.82	0.47	3.67e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06544989	chr22:39130855	UNC84B	0.37	6.41	0.33	5.04e-10	Menopause (age at onset);
LUSC	cis	rs877282	1.000	rs2004479	chr10:770854	G/A	cg17470449	chr10:769945	NA	0.53	7.53	0.38	4.63e-13	Uric acid levels;
LUSC	trans	rs3960554	0.674	rs113848658	chr7:75791858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.9	10.07	0.48	5.19e-21	Eotaxin levels;
LUSC	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13126279	chr21:47581558	C21orf56	0.49	7.46	0.38	7.5e-13	Testicular germ cell tumor;
LUSC	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg05738196	chr6:26577821	NA	-0.54	-5.93	-0.31	7.52e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg18993701	chr15:65715356	IGDCC4	0.48	6.06	0.31	3.71e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg14196790	chr5:131705035	SLC22A5	0.48	8.18	0.41	6.2e-15	Blood metabolite levels;
LUSC	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg21100191	chr22:23484243	RTDR1	0.91	16.02	0.66	2.88e-43	Bone mineral density;
LUSC	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-7.93	-0.4	3.36e-14	Depression;
LUSC	cis	rs76793172	1.000	rs60283385	chr19:46329079	T/C	cg27118825	chr19:46318748	RSPH6A;SYMPK	0.46	5.69	0.3	2.75e-8	Eosinophil counts;
LUSC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg18230493	chr5:56204884	C5orf35	-0.94	-14.41	-0.62	6.18e-37	Initial pursuit acceleration;
LUSC	cis	rs9341808	0.683	rs7771449	chr6:80919977	C/T	cg08355045	chr6:80787529	NA	0.58	10.2	0.49	1.97e-21	Sitting height ratio;
LUSC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg04352962	chr1:209979756	IRF6	-0.5	-5.91	-0.31	8.51e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.71	0.51	3.28e-23	Bladder cancer;
LUSC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg18350739	chr11:68623251	NA	0.32	5.65	0.3	3.38e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg08807101	chr21:30365312	RNF160	0.68	11.44	0.53	8.68e-26	Dental caries;
LUSC	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.39	-0.42	1.35e-15	Coffee consumption (cups per day);
LUSC	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	9.02	0.44	1.45e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg21775007	chr8:11205619	TDH	0.46	6.63	0.34	1.33e-10	Myopia (pathological);
LUSC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg16586182	chr3:47516702	SCAP	0.54	8.37	0.42	1.61e-15	Colorectal cancer;
LUSC	cis	rs6977660	1.000	rs13237667	chr7:19820288	G/C	cg05791153	chr7:19748676	TWISTNB	0.53	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LUSC	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg03465714	chr1:152285911	FLG	-0.41	-5.89	-0.31	9.28e-9	Atopic dermatitis;
LUSC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg24154853	chr7:158122151	PTPRN2	-0.42	-8.24	-0.41	3.89e-15	Calcium levels;
LUSC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.4	-0.42	1.26e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06035161	chr3:53915801	ACTR8	0.8	6.43	0.33	4.52e-10	Cognitive performance;
LUSC	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg10356904	chr22:49881777	NA	-0.29	-5.77	-0.3	1.78e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.34	0.67	1.6e-44	Platelet count;
LUSC	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg06223162	chr1:101003688	GPR88	0.45	8.37	0.42	1.56e-15	Monocyte count;
LUSC	cis	rs701145	0.617	rs355775	chr3:154036129	A/G	cg10247383	chr3:153839028	SGEF	-0.47	-5.68	-0.3	2.87e-8	Coronary artery disease;
LUSC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.17	-0.41	6.51e-15	Chronic sinus infection;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26933736	chr6:83902998	RWDD2A;PGM3	-0.38	-6.02	-0.31	4.54e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	9.27	0.45	2.39e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4589502	0.841	rs75991095	chr15:67123224	C/G	cg12317470	chr15:67143691	NA	0.7	5.92	0.31	7.9e-9	Lung cancer (smoking interaction);
LUSC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-10.77	-0.51	2.07e-23	Heart rate;
LUSC	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.4	-8.0	-0.4	2e-14	Late-onset Alzheimer's disease;
LUSC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	9.8e-65	Prudent dietary pattern;
LUSC	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.23	0.49	1.45e-21	Birth weight;
LUSC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.76	13.55	0.6	1.2e-33	Colorectal cancer;
LUSC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	0.92	16.06	0.66	2.14e-43	Menopause (age at onset);
LUSC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00290607	chr11:67383545	NA	-0.36	-6.43	-0.33	4.3e-10	Mean corpuscular volume;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg06789412	chr3:101405552	RPL24	0.4	7.1	0.36	7.34e-12	Triglycerides;
LUSC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.16	0.32	2.11e-9	Menopause (age at onset);
LUSC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg05754148	chr16:3507555	NAT15	0.84	8.81	0.43	7.11e-17	Tuberculosis;
LUSC	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg17376030	chr22:41985996	PMM1	-0.42	-5.75	-0.3	2.05e-8	Vitiligo;
LUSC	cis	rs11158026	0.603	rs8022049	chr14:55462869	C/T	cg04306507	chr14:55594613	LGALS3	-0.4	-7.41	-0.38	1.03e-12	Parkinson's disease;
LUSC	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg20701182	chr2:24300061	SF3B14	0.77	7.73	0.39	1.25e-13	Immature fraction of reticulocytes;
LUSC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-1.0	-18.3	-0.71	2.56e-52	Height;
LUSC	cis	rs67539049	1.000	rs3021512	chr8:11301601	G/C	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.39	-5.99	-0.31	5.36e-9	Itch intensity from mosquito bite;
LUSC	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg05855489	chr10:104503620	C10orf26	0.67	9.06	0.44	1.15e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg15147215	chr3:52552868	STAB1	-0.31	-6.11	-0.32	2.7e-9	Bipolar disorder;
LUSC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	10.83	0.51	1.29e-23	Hip circumference adjusted for BMI;
LUSC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg18230493	chr5:56204884	C5orf35	-0.55	-8.81	-0.43	6.91e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg08392591	chr16:89556376	ANKRD11	0.39	5.75	0.3	2.03e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18404041	chr3:52824283	ITIH1	-0.61	-11.76	-0.54	5.97e-27	Bipolar disorder;
LUSC	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg00405596	chr8:11794950	NA	-0.36	-6.01	-0.31	4.92e-9	Myopia (pathological);
LUSC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg18301423	chr5:131593218	PDLIM4	0.47	7.36	0.37	1.41e-12	Acylcarnitine levels;
LUSC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg13047869	chr3:10149882	C3orf24	0.57	7.9	0.4	4.11e-14	Alzheimer's disease;
LUSC	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg23231163	chr10:75533350	FUT11	-0.4	-6.55	-0.34	2.11e-10	Inflammatory bowel disease;
LUSC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.64	9.84	0.47	3.11e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg08798685	chr6:27730294	NA	-0.62	-5.94	-0.31	7.19e-9	Breast cancer;
LUSC	cis	rs2835872	0.759	rs2835896	chr21:39066640	A/G	cg20424643	chr21:39039972	KCNJ6	-0.37	-5.72	-0.3	2.43e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.45	-6.41	-0.33	4.89e-10	Reticulocyte count;
LUSC	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg23093090	chr10:104574429	C10orf26	-0.36	-6.66	-0.34	1.15e-10	Arsenic metabolism;
LUSC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg17211192	chr8:82754475	SNX16	0.81	11.11	0.52	1.32e-24	Diastolic blood pressure;
LUSC	cis	rs72960926	0.744	rs2351778	chr6:74866814	T/G	cg03266952	chr6:74778945	NA	-0.83	-7.31	-0.37	2.05e-12	Metabolite levels (MHPG);
LUSC	cis	rs4072705	0.646	rs915034	chr9:127244955	G/A	cg13476313	chr9:127244764	NR5A1	0.35	6.78	0.35	5.37e-11	Menarche (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14965979	chr2:44588995	PREPL;C2orf34	-0.49	-6.38	-0.33	6.02e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg14092988	chr3:52407081	DNAH1	0.31	6.01	0.31	4.93e-9	Bipolar disorder;
LUSC	cis	rs9612	1.000	rs8105041	chr19:44258458	A/G	cg08581076	chr19:44259116	C19orf61	0.53	6.71	0.34	8.22e-11	Exhaled nitric oxide output;
LUSC	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg05673287	chr15:77411982	SGK269	-0.44	-6.98	-0.36	1.59e-11	Type 2 diabetes;
LUSC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.51	0.46	3.94e-19	Bipolar disorder;
LUSC	cis	rs12220238	1.000	rs10824113	chr10:75969018	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.3	0.37	2.12e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs11958404	0.932	rs72816552	chr5:157422376	G/A	cg05962755	chr5:157440814	NA	0.49	6.09	0.32	3.09e-9	IgG glycosylation;
LUSC	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg05340658	chr4:99064831	C4orf37	0.61	9.62	0.47	1.72e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg09796270	chr17:17721594	SREBF1	-0.45	-7.98	-0.4	2.32e-14	Total body bone mineral density;
LUSC	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg15819921	chr19:927150	ARID3A	-0.43	-6.25	-0.32	1.28e-9	Life satisfaction;
LUSC	cis	rs6690583	0.623	rs12042910	chr1:85452580	G/A	cg11262906	chr1:85462892	MCOLN2	0.68	6.56	0.34	2.02e-10	Serum sulfate level;
LUSC	cis	rs5753618	0.539	rs2106294	chr22:31645759	C/T	cg22777020	chr22:31556080	RNF185	-0.45	-5.88	-0.31	9.79e-9	Colorectal cancer;
LUSC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26850624	chr5:429559	AHRR	-0.41	-7.92	-0.4	3.58e-14	Cystic fibrosis severity;
LUSC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg07507251	chr3:52567010	NT5DC2	0.32	5.91	0.31	8.59e-9	Bipolar disorder;
LUSC	cis	rs9463078	0.547	rs4714822	chr6:44742290	T/C	cg25276700	chr6:44698697	NA	0.3	6.33	0.33	7.67e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2398893	0.960	rs2153791	chr9:96744928	G/A	cg14459158	chr9:96720562	NA	0.32	5.84	0.3	1.21e-8	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg04998671	chr14:104000505	TRMT61A	-0.41	-6.03	-0.31	4.41e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg23711669	chr6:146136114	FBXO30	0.89	16.78	0.68	2.88e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8113142	0.651	rs58606095	chr19:29096004	C/T	cg04546413	chr19:29218101	NA	0.43	5.87	0.31	1.05e-8	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-6.55	-0.34	2.14e-10	Monocyte percentage of white cells;
LUSC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	0.87	13.42	0.59	3.78e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg11062466	chr8:58055876	NA	0.65	8.33	0.41	2.12e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs829883	0.659	rs11109528	chr12:98951362	G/A	cg25150519	chr12:98850993	NA	-0.64	-8.84	-0.44	5.54e-17	Colorectal adenoma (advanced);
LUSC	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg15103426	chr22:29168792	CCDC117	0.55	7.18	0.37	4.47e-12	Lymphocyte counts;
LUSC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg23630131	chr7:65973040	NA	-0.2	-5.66	-0.3	3.22e-8	Aortic root size;
LUSC	cis	rs66731853	0.769	rs530104	chr1:20895721	A/G	cg04087271	chr1:20915334	CDA	-0.46	-6.44	-0.33	4.26e-10	Mean corpuscular volume;
LUSC	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-7.79	-0.39	8.41e-14	Monocyte percentage of white cells;
LUSC	cis	rs6580649	0.941	rs1018973	chr12:48441692	C/G	cg24011408	chr12:48396354	COL2A1	0.46	6.09	0.32	3.16e-9	Lung cancer;
LUSC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg21770322	chr7:97807741	LMTK2	0.4	7.03	0.36	1.19e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg07741184	chr6:167504864	NA	0.39	6.98	0.36	1.64e-11	Crohn's disease;
LUSC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24110177	chr3:50126178	RBM5	0.57	9.24	0.45	3e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.07	0.52	1.76e-24	Alzheimer's disease;
LUSC	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.13	0.55	2.73e-28	Colorectal cancer;
LUSC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg13256891	chr4:100009986	ADH5	-0.54	-8.69	-0.43	1.7e-16	Alcohol dependence;
LUSC	cis	rs2742417	0.603	rs2742370	chr3:45782098	T/C	cg10512202	chr3:45649293	LIMD1	0.35	5.88	0.31	1.01e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07080220	chr10:102295463	HIF1AN	-0.59	-8.11	-0.41	9.48e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs36715	0.951	rs36698	chr5:127549749	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.93	0.35	2.18e-11	Breast cancer;
LUSC	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.66	0.34	1.16e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg27411982	chr8:10470053	RP1L1	0.38	5.89	0.31	9.35e-9	Retinal vascular caliber;
LUSC	trans	rs12637928	0.580	rs35156093	chr3:110209637	C/T	cg17371621	chr15:61264283	RORA	0.36	5.96	0.31	6.29e-9	Neuroticism;
LUSC	cis	rs240764	0.541	rs9390693	chr6:101239935	T/C	cg09795085	chr6:101329169	ASCC3	0.44	6.27	0.32	1.13e-9	Neuroticism;
LUSC	cis	rs7584330	0.554	rs74001383	chr2:238424418	T/C	cg16989719	chr2:238392110	NA	-0.41	-5.86	-0.31	1.13e-8	Prostate cancer;
LUSC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg03526776	chr6:41159608	TREML2	-0.32	-6.1	-0.32	2.96e-9	Alzheimer's disease (late onset);
LUSC	cis	rs11214589	1.000	rs11214589	chr11:113245048	C/T	cg14159747	chr11:113255604	NA	0.27	6.63	0.34	1.39e-10	Neuroticism;
LUSC	cis	rs3771570	1.000	rs62193205	chr2:242316512	C/T	cg21155796	chr2:242212141	HDLBP	0.62	6.67	0.34	1.07e-10	Prostate cancer;
LUSC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg04166393	chr7:2884313	GNA12	0.43	5.68	0.3	2.99e-8	Height;
LUSC	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg03929089	chr4:120376271	NA	0.66	6.09	0.32	3.09e-9	Axial length;
LUSC	cis	rs6546550	0.935	rs10865380	chr2:70091246	T/C	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.08	-0.36	8.57e-12	Prevalent atrial fibrillation;
LUSC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg06096015	chr1:231504339	EGLN1	0.57	9.98	0.48	1.08e-20	Hemoglobin concentration;
LUSC	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg12552261	chr5:112820674	MCC	-0.44	-7.02	-0.36	1.25e-11	Type 2 diabetes;
LUSC	cis	rs4664304	0.802	rs62175470	chr2:160858255	G/C	cg23995753	chr2:160760732	LY75	-0.33	-6.14	-0.32	2.37e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs8044995	0.563	rs61602448	chr16:68377520	C/T	cg05110241	chr16:68378359	PRMT7	-0.76	-8.7	-0.43	1.59e-16	Schizophrenia;
LUSC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg18357645	chr12:58087776	OS9	0.55	8.31	0.41	2.38e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-0.9	-13.02	-0.58	1.22e-31	Initial pursuit acceleration;
LUSC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg06618935	chr21:46677482	NA	-0.39	-7.99	-0.4	2.21e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg02353165	chr6:42928485	GNMT	0.5	6.45	0.33	3.84e-10	Blood protein levels;
LUSC	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg26195577	chr20:24973756	C20orf3	1.12	18.1	0.7	1.58e-51	Blood protein levels;
LUSC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-5.94	-0.31	7.02e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg25036284	chr2:26402008	FAM59B	0.67	8.03	0.4	1.72e-14	Gut microbiome composition (summer);
LUSC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08859206	chr1:53392774	SCP2	-0.54	-9.61	-0.47	1.89e-19	Monocyte count;
LUSC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs760794	0.765	rs7759616	chr6:19794585	G/A	cg02404759	chr6:19790362	NA	-0.4	-6.37	-0.33	6.13e-10	Endometriosis;
LUSC	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06544989	chr22:39130855	UNC84B	0.32	5.87	0.31	1.08e-8	Menopause (age at onset);
LUSC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg11494091	chr17:61959527	GH2	0.4	6.85	0.35	3.62e-11	Height;
LUSC	cis	rs7107174	0.901	rs2450140	chr11:77924388	T/C	cg02023728	chr11:77925099	USP35	0.49	6.78	0.35	5.48e-11	Testicular germ cell tumor;
LUSC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg23711669	chr6:146136114	FBXO30	-0.79	-13.87	-0.6	7.57e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4363385	0.693	rs2339487	chr1:152983528	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.43	-0.38	9.1e-13	Inflammatory skin disease;
LUSC	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7707921	1.000	rs79616997	chr5:81504600	G/T	cg15871215	chr5:81402204	ATG10	-0.45	-6.62	-0.34	1.47e-10	Breast cancer;
LUSC	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg25319279	chr11:5960081	NA	-0.46	-6.51	-0.34	2.74e-10	DNA methylation (variation);
LUSC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg15448220	chr1:150897856	SETDB1	0.42	6.06	0.31	3.68e-9	Melanoma;
LUSC	cis	rs754466	0.580	rs17516020	chr10:79538734	C/T	cg17075019	chr10:79541650	NA	-0.69	-9.74	-0.47	6.72e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2262909	0.962	rs12609368	chr19:22263996	T/C	cg11619707	chr19:22235551	ZNF257	0.39	5.84	0.3	1.25e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg26102564	chr10:131424627	MGMT	0.41	6.05	0.31	3.88e-9	Response to temozolomide;
LUSC	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg11342453	chr6:26196699	NA	0.55	5.78	0.3	1.7e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg18904891	chr8:8559673	CLDN23	0.61	8.45	0.42	9.12e-16	Obesity-related traits;
LUSC	cis	rs7575217	0.767	rs28371411	chr2:101754723	C/T	cg23907051	chr2:101730305	TBC1D8	-0.28	-7.33	-0.37	1.8e-12	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg09796270	chr17:17721594	SREBF1	-0.43	-7.76	-0.39	1.02e-13	Total body bone mineral density;
LUSC	cis	rs7809950	1.000	rs2712189	chr7:107195747	G/A	cg23024343	chr7:107201750	COG5	-0.56	-8.87	-0.44	4.54e-17	Coronary artery disease;
LUSC	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg18753928	chr3:113234510	CCDC52	-0.52	-8.01	-0.4	1.99e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg24375607	chr4:120327624	NA	-0.67	-10.29	-0.49	9.22e-22	Corneal astigmatism;
LUSC	cis	rs887829	0.570	rs13015720	chr2:234600999	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.3	-0.33	9.47e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg15744005	chr10:104629667	AS3MT	-0.36	-7.42	-0.38	9.87e-13	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.58	-9.19	-0.45	4.45e-18	Lymphocyte counts;
LUSC	trans	rs722208	0.724	rs7757956	chr6:152317140	T/A	cg01002891	chr10:82363434	SH2D4B	0.48	5.95	0.31	6.75e-9	Developmental language disorder;
LUSC	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg05507819	chr15:63340323	TPM1	-0.97	-12.62	-0.57	4.12e-30	Platelet count;
LUSC	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg17691542	chr6:26056736	HIST1H1C	0.47	7.04	0.36	1.08e-11	Height;
LUSC	cis	rs367615	0.512	rs814153	chr5:108667829	A/C	cg17395555	chr5:108820864	NA	0.56	9.71	0.47	8.57e-20	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg24558204	chr6:135376177	HBS1L	0.66	10.19	0.49	2.06e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	6.91	0.35	2.39e-11	Bipolar disorder;
LUSC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs68170813	0.523	rs111590023	chr7:107055323	T/C	cg02696742	chr7:106810147	HBP1	-0.62	-9.05	-0.44	1.24e-17	Coronary artery disease;
LUSC	trans	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04565464	chr8:145669602	NFKBIL2	0.37	6.1	0.32	2.96e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg06060754	chr5:176797920	RGS14	0.59	9.45	0.46	6.37e-19	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs295140	1.000	rs67190025	chr2:201172086	C/T	cg04283868	chr2:201171347	SPATS2L	0.44	6.63	0.34	1.36e-10	QT interval;
LUSC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.8	11.7	0.54	9.87e-27	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg24692254	chr21:30365293	RNF160	-0.55	-7.94	-0.4	3.18e-14	Pancreatic cancer;
LUSC	cis	rs1865721	0.771	rs7228890	chr18:73137492	C/A	cg26385618	chr18:73139727	C18orf62	-0.54	-9.91	-0.48	1.84e-20	Intelligence;
LUSC	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.32	-0.33	8.27e-10	Dupuytren's disease;
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg23034840	chr1:205782522	SLC41A1	0.59	8.28	0.41	2.93e-15	Menarche (age at onset);
LUSC	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg08917208	chr2:24149416	ATAD2B	0.96	9.92	0.48	1.69e-20	Lymphocyte counts;
LUSC	trans	rs7586604	0.748	rs7578433	chr2:100384141	T/C	cg26466323	chr19:19729535	PBX4	-0.86	-6.05	-0.31	3.9e-9	Cannabis dependence symptom count;
LUSC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg06074448	chr4:187884817	NA	-0.38	-6.41	-0.33	4.99e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg24375607	chr4:120327624	NA	0.77	12.51	0.56	1.08e-29	Corneal astigmatism;
LUSC	cis	rs28785552	0.769	rs11669363	chr19:53232321	C/A	cg10871876	chr19:53194124	ZNF83	0.55	8.52	0.42	5.59e-16	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs3087591	1.000	rs6505234	chr17:29688299	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.55	-7.78	-0.39	8.96e-14	Hip circumference;
LUSC	trans	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.59e-15	Diabetic kidney disease;
LUSC	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg06002616	chr8:101225028	SPAG1	-0.41	-6.82	-0.35	4.37e-11	Atrioventricular conduction;
LUSC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.62	8.31	0.41	2.42e-15	High light scatter reticulocyte count;
LUSC	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.66	-14.98	-0.63	3.5e-39	Neuroticism;
LUSC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg17986701	chr20:44574422	PCIF1	0.37	6.63	0.34	1.35e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs73206853	0.563	rs73194047	chr12:111191926	G/A	cg12870014	chr12:110450643	ANKRD13A	0.66	6.91	0.35	2.49e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs13089785	1.000	rs34159794	chr3:123645893	A/G	cg02012769	chr3:123398346	MYLK	0.31	5.72	0.3	2.35e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4919687	0.550	rs4264100	chr10:104454113	C/G	cg05855489	chr10:104503620	C10orf26	0.7	11.37	0.53	1.58e-25	Colorectal cancer;
LUSC	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg26597838	chr10:835615	NA	0.78	9.46	0.46	5.75e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs6782228	0.606	rs2811489	chr3:128337371	A/G	cg16766828	chr3:128327626	NA	0.32	5.78	0.3	1.69e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg27121462	chr16:89883253	FANCA	0.59	9.42	0.46	7.52e-19	Vitiligo;
LUSC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	9.51	0.46	3.94e-19	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9549260	0.755	rs9549244	chr13:41218685	C/T	cg21288729	chr13:41239152	FOXO1	0.63	9.59	0.46	2.05e-19	Red blood cell count;
LUSC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg15839431	chr19:19639596	YJEFN3	0.44	6.1	0.32	2.87e-9	Tonsillectomy;
LUSC	cis	rs7927771	0.507	rs10838759	chr11:47785347	T/C	cg20307385	chr11:47447363	PSMC3	0.44	6.47	0.33	3.4e-10	Subjective well-being;
LUSC	cis	rs13088645	0.729	rs7620040	chr3:134163082	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.52	-7.49	-0.38	6.02e-13	Coronary artery disease;
LUSC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg02136620	chr5:178986620	RUFY1	0.39	6.02	0.31	4.5e-9	Lung cancer;
LUSC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg05082376	chr22:42548792	NA	-0.4	-6.69	-0.34	9.34e-11	Cognitive function;
LUSC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06558623	chr16:89946397	TCF25	1.11	9.73	0.47	7.08e-20	Skin colour saturation;
LUSC	cis	rs9638182	0.560	rs66506038	chr7:72995943	T/C	cg07452164	chr7:72993570	TBL2	0.45	6.33	0.33	7.79e-10	Triglycerides;
LUSC	cis	rs2859741	0.528	rs6686296	chr1:37489380	G/T	cg09363841	chr1:37513479	NA	0.4	7.85	0.39	5.9e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs4666002	0.564	rs13030345	chr2:28003174	A/C	cg27432699	chr2:27873401	GPN1	-0.48	-5.73	-0.3	2.26e-8	Phospholipid levels (plasma);
LUSC	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg05026186	chr5:148520876	ABLIM3	-0.37	-6.03	-0.31	4.41e-9	Breast cancer;
LUSC	cis	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg13636640	chr20:31349939	DNMT3B	-0.81	-15.5	-0.65	3.33e-41	Inflammatory bowel disease;
LUSC	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.8	-0.39	7.96e-14	Blood metabolite levels;
LUSC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg00310523	chr12:86230176	RASSF9	0.52	9.89	0.48	2.12e-20	Major depressive disorder;
LUSC	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg26876637	chr1:152193138	HRNR	-0.41	-5.77	-0.3	1.84e-8	Atopic dermatitis;
LUSC	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg05043794	chr9:111880884	C9orf5	-0.33	-6.93	-0.35	2.21e-11	Menarche (age at onset);
LUSC	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.74	-15.77	-0.65	3.01e-42	Longevity;Endometriosis;
LUSC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg04450456	chr4:17643702	FAM184B	0.42	7.19	0.37	4.19e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7943203	0.568	rs61913891	chr11:108335075	A/G	cg04873221	chr11:107992290	ACAT1	-0.39	-5.79	-0.3	1.63e-8	Red blood cell count;Mean corpuscular volume;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16944820	chr13:45492071	NA	0.46	6.04	0.31	4.07e-9	Neuroticism;
LUSC	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg16482183	chr6:26056742	HIST1H1C	0.63	8.97	0.44	2.11e-17	Iron status biomarkers;
LUSC	cis	rs9326248	0.861	rs1871757	chr11:117030581	A/T	cg11861562	chr11:117069780	TAGLN	0.36	5.91	0.31	8.66e-9	Blood protein levels;
LUSC	cis	rs2455601	0.608	rs59025804	chr11:8870301	T/C	cg12365402	chr11:9010492	NRIP3	-0.37	-5.86	-0.31	1.12e-8	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.48	0.33	3.28e-10	Lung cancer;
LUSC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.59	0.38	3.18e-13	Vitiligo;
LUSC	cis	rs4363385	0.818	rs6587719	chr1:152993409	G/C	cg25856811	chr1:152973957	SPRR3	-0.35	-5.79	-0.3	1.63e-8	Inflammatory skin disease;
LUSC	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.7	10.41	0.5	3.52e-22	Corneal astigmatism;
LUSC	trans	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07923666	chr12:49932857	KCNH3	-0.54	-6.67	-0.34	1.05e-10	Resting heart rate;
LUSC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-1.01	-18.94	-0.72	7.37e-55	Height;
LUSC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Depression;
LUSC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg17376030	chr22:41985996	PMM1	0.45	5.77	0.3	1.77e-8	Vitiligo;
LUSC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg09365446	chr1:150670422	GOLPH3L	0.49	7.23	0.37	3.36e-12	Melanoma;
LUSC	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.21	-0.32	1.57e-9	Retinal vascular caliber;
LUSC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg25767906	chr1:53392781	SCP2	-0.36	-6.18	-0.32	1.88e-9	Monocyte count;
LUSC	cis	rs12912251	1.000	rs34356257	chr15:38989605	T/C	cg01338139	chr15:38987640	C15orf53	-0.51	-7.11	-0.36	7.04e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs9309473	1.000	rs1534471	chr2:73647508	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-6.33	-0.33	7.93e-10	Metabolite levels;
LUSC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.47	-7.89	-0.4	4.25e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.35	-0.42	1.79e-15	Body mass index;
LUSC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg05043794	chr9:111880884	C9orf5	-0.35	-7.46	-0.38	7.48e-13	Menarche (age at onset);
LUSC	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg20701182	chr2:24300061	SF3B14	0.73	7.42	0.38	9.58e-13	Lymphocyte counts;
LUSC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	12.31	0.56	5.87e-29	Cognitive test performance;
LUSC	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg12863693	chr15:85201151	NMB	0.41	8.61	0.43	2.99e-16	Schizophrenia;
LUSC	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg11984989	chr7:158649758	WDR60	1.13	13.48	0.59	2.25e-33	Height;
LUSC	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg08508325	chr11:3079039	CARS	0.38	8.58	0.42	3.75e-16	Calcium levels;
LUSC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	0.86	12.23	0.56	1.15e-28	Vitiligo;
LUSC	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg18854424	chr1:2615690	NA	0.46	9.59	0.46	2.09e-19	Ulcerative colitis;
LUSC	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg03433033	chr1:76189801	ACADM	-0.48	-7.27	-0.37	2.63e-12	Daytime sleep phenotypes;
LUSC	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg13256891	chr4:100009986	ADH5	-0.45	-6.16	-0.32	2.05e-9	Alcohol dependence;
LUSC	trans	rs236907	0.679	rs12750330	chr1:171803556	G/A	cg13482142	chr2:234261155	NA	0.52	6.29	0.33	9.75e-10	Mean platelet volume;
LUSC	cis	rs500891	0.574	rs12197649	chr6:84123548	C/T	cg08257003	chr6:84140564	ME1	0.34	7.72	0.39	1.4e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs9326248	0.861	rs4938343	chr11:117003528	G/C	cg26566898	chr11:117069891	TAGLN	0.4	6.17	0.32	1.99e-9	Blood protein levels;
LUSC	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg19875535	chr5:140030758	IK	-0.54	-8.71	-0.43	1.43e-16	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.8	-0.43	7.35e-17	Obesity-related traits;
LUSC	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg05347473	chr6:146136440	FBXO30	0.48	7.81	0.39	7.56e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg11584989	chr19:19387371	SF4	0.59	6.99	0.36	1.46e-11	Bipolar disorder;
LUSC	cis	rs9303542	0.559	rs35621842	chr17:46606222	C/T	cg09704116	chr17:46666958	LOC404266	-0.39	-6.97	-0.36	1.75e-11	Ovarian cancer;Epithelial ovarian cancer;
LUSC	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	0.94	14.09	0.61	1.08e-35	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs6545883	0.791	rs4672445	chr2:61655008	T/C	cg15711740	chr2:61764176	XPO1	0.45	6.94	0.36	2.04e-11	Tuberculosis;
LUSC	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg23241863	chr10:102295624	HIF1AN	0.48	5.78	0.3	1.68e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.17	0.52	7.73e-25	Prudent dietary pattern;
LUSC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.87	0.54	2.36e-27	Prudent dietary pattern;
LUSC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg11812906	chr14:75593930	NEK9	-0.63	-10.35	-0.49	5.99e-22	Height;
LUSC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg16584290	chr5:462447	EXOC3	-0.37	-6.38	-0.33	5.96e-10	Cystic fibrosis severity;
LUSC	cis	rs9612	1.000	rs1059	chr19:44268348	C/T	cg08581076	chr19:44259116	C19orf61	0.49	5.94	0.31	7.29e-9	Exhaled nitric oxide output;
LUSC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg11843238	chr5:131593191	PDLIM4	-0.37	-6.26	-0.32	1.17e-9	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21875080	chr1:46598774	PIK3R3	-0.38	-6.0	-0.31	5e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg15117754	chr3:10150083	C3orf24	0.44	5.66	0.3	3.32e-8	Alzheimer's disease;
LUSC	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg08975724	chr8:8085496	FLJ10661	0.47	6.73	0.35	7.34e-11	Neuroticism;
LUSC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg26566898	chr11:117069891	TAGLN	-0.32	-6.11	-0.32	2.84e-9	Blood protein levels;
LUSC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.62	-13.21	-0.59	2.42e-32	Monocyte percentage of white cells;
LUSC	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg20701182	chr2:24300061	SF3B14	0.54	5.8	0.3	1.56e-8	Lymphocyte counts;
LUSC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg10729496	chr3:10149963	C3orf24	-0.55	-7.54	-0.38	4.42e-13	Alzheimer's disease;
LUSC	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg05110241	chr16:68378359	PRMT7	-0.71	-7.36	-0.37	1.42e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg16342193	chr10:102329863	NA	-0.37	-6.49	-0.33	3.16e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.44	-0.33	4.18e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2072499	0.833	rs2842873	chr1:156204653	C/T	cg25208724	chr1:156163844	SLC25A44	1.03	22.67	0.78	1.45e-69	Testicular germ cell tumor;
LUSC	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg22676075	chr6:135203613	NA	0.47	7.27	0.37	2.62e-12	Red blood cell count;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg04703749	chr11:64809102	SAC3D1	0.51	6.47	0.33	3.45e-10	Cognitive function;Information processing speed;
LUSC	cis	rs9535307	0.929	rs9526593	chr13:50288777	T/C	cg04663916	chr13:50265991	EBPL	0.49	5.71	0.3	2.44e-8	Obesity-related traits;
LUSC	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg00121533	chr1:75199117	CRYZ;TYW3	0.42	5.72	0.3	2.34e-8	Resistin levels;
LUSC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg18230493	chr5:56204884	C5orf35	-0.85	-13.2	-0.59	2.74e-32	Initial pursuit acceleration;
LUSC	trans	rs7710178	0.652	rs2656894	chr5:155949781	G/C	cg00803088	chr10:43600706	RET	-0.48	-6.05	-0.31	3.88e-9	Airway responsiveness in chronic obstructive pulmonary disease;
LUSC	cis	rs7818345	0.935	rs7016259	chr8:19277530	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	7.42	0.38	9.75e-13	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs7605827	0.930	rs7568459	chr2:15691026	C/T	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.82e-16	Educational attainment (years of education);
LUSC	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg13010199	chr12:38710504	ALG10B	0.65	10.2	0.49	1.93e-21	Morning vs. evening chronotype;
LUSC	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg00012203	chr2:219082015	ARPC2	0.55	8.83	0.43	6.09e-17	Ulcerative colitis;
LUSC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg12935359	chr14:103987150	CKB	-0.52	-8.1	-0.41	1.02e-14	Body mass index;
LUSC	cis	rs72781680	0.752	rs7578606	chr2:23902360	T/C	cg20701182	chr2:24300061	SF3B14	0.73	7.06	0.36	9.63e-12	Lymphocyte counts;
LUSC	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg02493740	chr2:85810744	VAMP5	-0.33	-5.83	-0.3	1.34e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs11168618	0.904	rs4359253	chr12:48927708	G/A	cg24011408	chr12:48396354	COL2A1	0.39	6.27	0.32	1.1e-9	Adiponectin levels;
LUSC	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg26695010	chr11:65641043	EFEMP2	0.5	7.21	0.37	3.73e-12	Eosinophil percentage of white cells;
LUSC	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	11.59	0.54	2.57e-26	Coronary artery disease;
LUSC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg17971929	chr21:40555470	PSMG1	-0.61	-9.78	-0.47	5.09e-20	Cognitive function;
LUSC	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg26876637	chr1:152193138	HRNR	0.45	6.44	0.33	4.15e-10	Atopic dermatitis;
LUSC	trans	rs330071	0.549	rs11785593	chr8:9256324	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.22	0.32	1.47e-9	Acne (severe);
LUSC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24531977	chr5:56204891	C5orf35	-0.72	-10.46	-0.5	2.37e-22	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg04369109	chr6:150039330	LATS1	-0.53	-7.86	-0.39	5.51e-14	Lung cancer;
LUSC	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg17470449	chr10:769945	NA	0.53	7.12	0.36	6.81e-12	Uric acid levels;
LUSC	cis	rs7589342	0.839	rs7589790	chr2:106433909	C/G	cg14210321	chr2:106509881	NCK2	0.44	6.32	0.33	8.24e-10	Addiction;
LUSC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.63	-10.72	-0.51	2.98e-23	Schizophrenia;
LUSC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.75	-11.65	-0.54	1.47e-26	Menarche (age at onset);
LUSC	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.91	-0.35	2.41e-11	Lung cancer;
LUSC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.81	0.51	1.51e-23	Monocyte percentage of white cells;
LUSC	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg11019008	chr10:131425282	MGMT	0.42	6.39	0.33	5.57e-10	Response to temozolomide;
LUSC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg14541582	chr5:601475	NA	-0.38	-5.93	-0.31	7.36e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg00750074	chr16:89608354	SPG7	0.45	7.65	0.39	2.21e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.86	-0.47	2.63e-20	Migraine;Coronary artery disease;
LUSC	cis	rs12295403	0.691	rs9705036	chr11:18686916	A/G	cg20219074	chr11:18656078	SPTY2D1	-0.41	-5.83	-0.3	1.34e-8	Ovarian reserve;
LUSC	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg21573476	chr21:45109991	RRP1B	-0.38	-6.08	-0.32	3.37e-9	Mean corpuscular volume;
LUSC	cis	rs6060717	0.536	rs3787173	chr20:34472105	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.69	-0.3	2.73e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs73200209	0.744	rs73200226	chr12:116637861	G/A	cg01776926	chr12:116560359	MED13L	-0.49	-6.02	-0.31	4.47e-9	Total body bone mineral density;
LUSC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.7	10.47	0.5	2.28e-22	IgG glycosylation;
LUSC	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg14036092	chr11:66035641	RAB1B	0.42	6.04	0.31	4.2e-9	Gout;
LUSC	cis	rs7000551	0.681	rs2461488	chr8:22371858	G/A	cg12081754	chr8:22256438	SLC39A14	0.43	6.51	0.34	2.72e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg18825076	chr15:78729989	IREB2	0.44	6.06	0.31	3.7e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7799006	0.755	rs2256545	chr7:2291943	G/A	cg02951883	chr7:2050386	MAD1L1	-0.38	-6.27	-0.32	1.12e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06634786	chr22:41940651	POLR3H	0.52	6.07	0.32	3.53e-9	Vitiligo;
LUSC	cis	rs62103177	0.564	rs3930043	chr18:77723832	G/A	cg20368463	chr18:77673604	PQLC1	0.73	7.46	0.38	7.45e-13	Opioid sensitivity;
LUSC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22496380	chr5:211416	CCDC127	-0.74	-8.57	-0.42	3.87e-16	Breast cancer;
LUSC	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00166722	chr3:10149974	C3orf24	0.62	8.47	0.42	8.07e-16	Alzheimer's disease;
LUSC	trans	rs13394458	0.643	rs116576020	chr2:142225421	A/T	cg22060041	chr2:1796155	MYT1L	0.45	6.23	0.32	1.41e-9	Night sleep phenotypes;
LUSC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.18	0.52	7.4e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg12419862	chr22:24373484	LOC391322	-0.82	-12.36	-0.56	3.57e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10072221	0.836	rs6895725	chr5:75696657	A/G	cg03132911	chr5:75698732	IQGAP2	0.39	6.5	0.34	2.92e-10	Mean platelet volume;
LUSC	cis	rs16949788	1.000	rs11071894	chr15:66773733	A/C	cg08120210	chr15:66682733	MAP2K1	0.55	5.8	0.3	1.57e-8	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs829883	0.724	rs3168521	chr12:98908547	C/T	cg25150519	chr12:98850993	NA	-0.64	-8.67	-0.43	1.94e-16	Colorectal adenoma (advanced);
LUSC	trans	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.72e-10	Life satisfaction;
LUSC	cis	rs273573	0.925	rs273569	chr11:30914035	G/A	cg14844989	chr11:31128820	NA	0.35	5.68	0.3	2.98e-8	Total body bone mineral density;
LUSC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg24209194	chr3:40518798	ZNF619	0.47	6.51	0.34	2.75e-10	Renal cell carcinoma;
LUSC	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.99	-0.36	1.5e-11	Monocyte percentage of white cells;
LUSC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg24675658	chr1:53192096	ZYG11B	0.73	12.2	0.56	1.44e-28	Monocyte count;
LUSC	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.67	-0.39	1.9e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2235649	0.833	rs4335769	chr16:1849376	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-6.06	-0.31	3.74e-9	Blood metabolite levels;
LUSC	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg06627628	chr2:24431161	ITSN2	-0.74	-10.35	-0.49	5.96e-22	Venous thromboembolism (SNP x SNP interaction);
LUSC	trans	rs1922233	1.000	rs2204874	chr4:92367486	A/G	cg24250684	chr1:219729030	NA	-0.36	-6.37	-0.33	6.33e-10	Gut microbiome composition (summer and winter);
LUSC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg06713675	chr4:122721982	EXOSC9	-0.46	-8.07	-0.4	1.27e-14	Type 2 diabetes;
LUSC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg03233332	chr7:66118400	NA	0.42	6.09	0.32	3.02e-9	Aortic root size;
LUSC	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg26876637	chr1:152193138	HRNR	0.47	6.62	0.34	1.47e-10	Atopic dermatitis;
LUSC	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg02951883	chr7:2050386	MAD1L1	-0.36	-6.14	-0.32	2.36e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-11.86	-0.54	2.49e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4704187	0.687	rs9763362	chr5:74406316	T/C	cg03227963	chr5:74354835	NA	0.32	6.87	0.35	3.09e-11	Response to amphetamines;
LUSC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00149659	chr3:10157352	C3orf10	-1.02	-13.7	-0.6	3.18e-34	Alzheimer's disease;
LUSC	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg17411546	chr10:75410026	SYNPO2L	-0.53	-7.81	-0.39	7.29e-14	Inflammatory bowel disease;
LUSC	cis	rs11051970	0.918	rs7309115	chr12:32541241	A/G	cg02745156	chr12:32552066	NA	0.44	6.92	0.35	2.36e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg11812906	chr14:75593930	NEK9	0.66	11.39	0.53	1.26e-25	Height;
LUSC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-0.97	-16.53	-0.67	2.89e-45	Body mass index;
LUSC	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg26384229	chr12:38710491	ALG10B	-0.72	-11.69	-0.54	1.03e-26	Morning vs. evening chronotype;
LUSC	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg11161011	chr14:65562177	MAX	-0.71	-10.82	-0.51	1.37e-23	Obesity-related traits;
LUSC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg06238570	chr21:40685208	BRWD1	0.46	7.14	0.36	5.73e-12	Cognitive function;
LUSC	cis	rs977987	0.843	rs10871312	chr16:75486202	C/T	cg03315344	chr16:75512273	CHST6	0.49	9.41	0.46	8.39e-19	Dupuytren's disease;
LUSC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg17971929	chr21:40555470	PSMG1	0.76	12.75	0.57	1.29e-30	Cognitive function;
LUSC	cis	rs9815354	0.680	rs73073263	chr3:42018666	C/A	cg03022575	chr3:42003672	ULK4	0.76	7.6	0.38	3e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9677476	0.863	rs60953838	chr2:232065864	G/C	cg07929768	chr2:232055508	NA	0.36	6.79	0.35	5.22e-11	Food antigen IgG levels;
LUSC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg14343924	chr8:8086146	FLJ10661	0.42	6.11	0.32	2.77e-9	Mood instability;
LUSC	cis	rs10792830	0.714	rs501505	chr11:85667916	C/A	cg07180834	chr11:85838833	NA	-0.3	-5.77	-0.3	1.79e-8	Psychosis and Alzheimer's disease;
LUSC	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14442939	chr10:27389572	ANKRD26	-0.88	-9.9	-0.48	1.97e-20	Breast cancer;
LUSC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg18827107	chr12:86230957	RASSF9	-0.43	-6.37	-0.33	6.35e-10	Major depressive disorder;
LUSC	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.86	-0.35	3.4e-11	Monocyte percentage of white cells;
LUSC	cis	rs1322512	0.874	rs1727048	chr6:152942842	A/G	cg27316956	chr6:152958899	SYNE1	-0.35	-5.8	-0.3	1.54e-8	Tonometry;
LUSC	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg19875535	chr5:140030758	IK	0.51	8.25	0.41	3.64e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2742417	0.603	rs2064064	chr3:45759995	C/T	cg04837898	chr3:45731254	SACM1L	-0.44	-7.19	-0.37	4.38e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg01475377	chr6:109611718	NA	-0.4	-7.0	-0.36	1.44e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.05	12.84	0.57	6.06e-31	Sexual dysfunction (female);
LUSC	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg06096015	chr1:231504339	EGLN1	0.56	10.02	0.48	7.84e-21	Hemoglobin concentration;
LUSC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.52	7.23	0.37	3.27e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7178375	1.000	rs35162264	chr15:31200683	T/A	cg04373760	chr16:53404718	NA	0.65	8.72	0.43	1.36e-16	Hypertriglyceridemia;
LUSC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.84	15.31	0.64	1.93e-40	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9650657	0.615	rs12541110	chr8:10695125	A/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.25	-0.32	1.28e-9	Neuroticism;
LUSC	cis	rs7577696	0.513	rs212685	chr2:32434701	A/G	cg02381751	chr2:32503542	YIPF4	0.53	7.08	0.36	8.5e-12	Inflammatory biomarkers;
LUSC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-12.69	-0.57	2.29e-30	Body mass index;
LUSC	cis	rs3755132	0.929	rs4668942	chr2:15750443	A/G	cg12888861	chr2:15731646	DDX1	0.5	7.51	0.38	5.48e-13	Wilms tumor;
LUSC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg09877947	chr5:131593287	PDLIM4	0.49	8.04	0.4	1.52e-14	Blood metabolite levels;
LUSC	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	17.41	0.69	9.46e-49	Headache;
LUSC	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.05	-0.31	3.81e-9	Resting heart rate;
LUSC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg05802129	chr4:122689817	NA	-0.37	-6.56	-0.34	2.06e-10	Type 2 diabetes;
LUSC	cis	rs12681287	0.640	rs72606633	chr8:87476236	T/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.16	-0.36	5.04e-12	Caudate activity during reward;
LUSC	cis	rs722599	0.639	rs12882676	chr14:75272433	A/G	cg08847533	chr14:75593920	NEK9	0.44	6.15	0.32	2.23e-9	IgG glycosylation;
LUSC	cis	rs7508679	1.000	rs10401485	chr19:7222234	T/C	cg00428638	chr19:7224713	INSR	0.36	7.74	0.39	1.21e-13	Hypothyroidism;
LUSC	cis	rs11209185	0.509	rs12130147	chr1:68446944	G/A	cg22082780	chr1:68452167	NA	0.44	7.26	0.37	2.7e-12	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg07424592	chr7:64974309	NA	0.7	6.15	0.32	2.24e-9	Diabetic kidney disease;
LUSC	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	11.78	0.54	5.24e-27	Mean corpuscular hemoglobin;
LUSC	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg17691542	chr6:26056736	HIST1H1C	0.47	6.93	0.35	2.18e-11	Height;
LUSC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.78	0.63	2.13e-38	Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25289973	chr4:41362397	LIMCH1	0.41	6.11	0.32	2.72e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.76	0.35	6.34e-11	Tonsillectomy;
LUSC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.78	-0.3	1.75e-8	Tonsillectomy;
LUSC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-7.74	-0.39	1.2e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg09796270	chr17:17721594	SREBF1	-0.4	-6.98	-0.36	1.56e-11	Total body bone mineral density;
LUSC	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg23992470	chr4:843637	GAK	0.61	6.52	0.34	2.55e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg25664220	chr3:72788482	NA	0.56	10.72	0.51	3.16e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs113835537	0.529	rs75683511	chr11:66275026	A/G	cg24851651	chr11:66362959	CCS	0.52	7.55	0.38	4.16e-13	Airway imaging phenotypes;
LUSC	cis	rs11785693	0.862	rs11781233	chr8:4993653	C/G	cg26367366	chr8:4980734	NA	-0.74	-8.97	-0.44	2.23e-17	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.76	16.98	0.68	4.84e-47	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg06197492	chr11:2016605	H19	0.43	7.0	0.36	1.42e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg01097406	chr16:89675127	NA	0.48	9.88	0.48	2.31e-20	Vitiligo;
LUSC	trans	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg15704280	chr7:45808275	SEPT13	0.72	6.8	0.35	4.71e-11	Axial length;
LUSC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg26769984	chr7:1090371	C7orf50	0.55	7.44	0.38	8.76e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs6494488	0.500	rs951721	chr15:65044435	C/T	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg10792982	chr14:105748885	BRF1	0.48	8.7	0.43	1.52e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg01879757	chr17:41196368	BRCA1	-0.45	-6.99	-0.36	1.54e-11	Menopause (age at onset);
LUSC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg10356904	chr22:49881777	NA	-0.33	-7.52	-0.38	5.24e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs5771069	0.931	rs137864	chr22:50446988	C/T	cg03721641	chr22:50451245	IL17REL	0.28	5.71	0.3	2.56e-8	Ulcerative colitis;
LUSC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	0.96	16.31	0.67	2.17e-44	Menopause (age at onset);
LUSC	cis	rs4947962	0.590	rs759171	chr7:55086212	A/C	cg23757825	chr7:55092271	EGFR	0.65	8.44	0.42	9.59e-16	Subjective response to lithium treatment;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12311644	chr22:31687046	PIK3IP1	0.44	6.03	0.31	4.25e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7818345	0.624	rs12682196	chr8:19332963	A/C	cg11303988	chr8:19266685	CSGALNACT1	-0.33	-5.98	-0.31	5.83e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18252515	chr7:66147081	NA	-0.4	-5.72	-0.3	2.32e-8	Aortic root size;
LUSC	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	1.15	13.83	0.6	1.01e-34	Arsenic metabolism;
LUSC	cis	rs7640424	0.659	rs7639774	chr3:107816216	T/G	cg09227934	chr3:107805635	CD47	-0.54	-7.83	-0.39	6.71e-14	Body mass index;
LUSC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs259282	0.605	rs36107586	chr19:33109674	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.66	9.97	0.48	1.11e-20	Schizophrenia;
LUSC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.07e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.52	-0.42	5.55e-16	Body mass index;
LUSC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20135002	chr11:47629003	NA	-0.48	-7.52	-0.38	5.13e-13	Subjective well-being;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.3	-7.5	-0.38	5.75e-13	Lymphocyte counts;
LUSC	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs981844	0.857	rs72731698	chr4:154716353	T/C	cg14289246	chr4:154710475	SFRP2	0.48	6.23	0.32	1.38e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg11245181	chr6:149772854	ZC3H12D	0.29	6.33	0.33	7.8e-10	Dupuytren's disease;
LUSC	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg14092571	chr14:90743983	NA	0.36	5.97	0.31	6.1e-9	Mortality in heart failure;
LUSC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.48	0.33	3.32e-10	Menarche (age at onset);
LUSC	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg11102782	chr19:18549136	ISYNA1	-0.36	-6.78	-0.35	5.34e-11	Breast cancer;
LUSC	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.55	0.38	4.06e-13	Iron status biomarkers;
LUSC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.39	-6.34	-0.33	7.64e-10	Longevity;Endometriosis;
LUSC	trans	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg07393940	chr7:158741817	NA	0.36	6.48	0.33	3.19e-10	Life satisfaction;
LUSC	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.33	0.45	1.54e-18	Bipolar disorder;
LUSC	cis	rs7589342	0.745	rs933793	chr2:106511846	C/T	cg14210321	chr2:106509881	NCK2	0.59	9.27	0.45	2.42e-18	Addiction;
LUSC	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg02574844	chr11:5959923	NA	-0.43	-6.14	-0.32	2.34e-9	DNA methylation (variation);
LUSC	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	5.71	0.3	2.47e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-7.44	-0.38	8.78e-13	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg02423579	chr7:2872169	GNA12	-0.46	-6.43	-0.33	4.41e-10	Height;
LUSC	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg25237894	chr2:233734115	C2orf82	0.34	6.33	0.33	7.76e-10	Coronary artery disease;
LUSC	cis	rs360798	0.553	rs7562734	chr2:63047973	G/C	cg17519650	chr2:63277830	OTX1	-0.51	-7.25	-0.37	2.91e-12	Coronary artery disease;
LUSC	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg04989706	chr14:50066350	PPIL5	-0.48	-6.32	-0.33	8.2e-10	Carotid intima media thickness;
LUSC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg09034736	chr1:150693464	HORMAD1	0.42	5.88	0.31	9.72e-9	Melanoma;
LUSC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg11062466	chr8:58055876	NA	0.5	6.39	0.33	5.51e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11971779	0.680	rs6467837	chr7:139023575	A/G	cg23387468	chr7:139079360	LUC7L2	0.42	6.29	0.33	9.94e-10	Diisocyanate-induced asthma;
LUSC	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg06197492	chr11:2016605	H19	0.42	6.87	0.35	3.22e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs12210905	0.688	rs12213533	chr6:27346021	C/T	cg08851530	chr6:28072375	NA	0.9	5.84	0.3	1.21e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg22709100	chr7:91322751	NA	0.4	5.79	0.3	1.59e-8	Breast cancer;
LUSC	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg05501817	chr11:14380813	RRAS2	-0.43	-6.33	-0.33	7.87e-10	Sense of smell;
LUSC	cis	rs73206853	0.764	rs9737665	chr12:111031847	A/C	cg12870014	chr12:110450643	ANKRD13A	0.7	7.81	0.39	7.23e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	14.83	0.63	1.39e-38	Lymphocyte percentage of white cells;
LUSC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.71	0.6	3.09e-34	Cognitive test performance;
LUSC	cis	rs10193935	0.901	rs1496329	chr2:42688797	T/C	cg27598129	chr2:42591480	NA	0.62	7.98	0.4	2.33e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs62432291	0.614	rs420339	chr6:159657195	G/T	cg14500486	chr6:159655392	FNDC1	-0.54	-6.06	-0.31	3.64e-9	Joint mobility (Beighton score);
LUSC	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.44	6.21	0.32	1.59e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.49	-0.38	6.4e-13	Blood metabolite levels;
LUSC	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.67	-0.5	4.68e-23	Migraine;Coronary artery disease;
LUSC	cis	rs11622475	1.000	rs2236246	chr14:104379206	A/C	cg12183467	chr14:104352244	NA	0.47	8.25	0.41	3.59e-15	Bipolar disorder;
LUSC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	6.8	0.35	4.82e-11	Schizophrenia;
LUSC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg25019033	chr10:957182	NA	-0.47	-5.83	-0.3	1.31e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.67	-12.21	-0.56	1.34e-28	Birth weight;
LUSC	cis	rs34091558	1	rs34091558	chr1:201886769	TA/T	cg10061532	chr1:201886748	LMOD1	0.29	6.63	0.34	1.32e-10	Breast size;
LUSC	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg14458575	chr2:238380390	NA	0.67	11.78	0.54	5.12e-27	Prostate cancer;
LUSC	cis	rs6669072	0.605	rs11586930	chr1:91255296	T/G	cg08895590	chr1:91227319	NA	-0.28	-6.05	-0.31	3.97e-9	Cognitive function;
LUSC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.47	0.53	6.83e-26	Alzheimer's disease;
LUSC	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.81	-13.48	-0.59	2.33e-33	Bladder cancer;
LUSC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.13	-0.41	8.48e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg24733560	chr20:60626293	TAF4	0.41	6.7	0.34	8.82e-11	Body mass index;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg25428297	chr7:1022841	CYP2W1	0.28	5.67	0.3	3.01e-8	Longevity;Endometriosis;
LUSC	cis	rs814295	0.932	rs780092	chr2:27743154	A/G	cg27432699	chr2:27873401	GPN1	0.48	5.74	0.3	2.16e-8	Triglyceride levels;
LUSC	trans	rs4650994	0.524	rs1998544	chr1:178605276	T/C	cg05059571	chr16:84539110	KIAA1609	0.47	8.85	0.44	5.35e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg01475377	chr6:109611718	NA	-0.41	-7.4	-0.38	1.15e-12	Reticulocyte fraction of red cells;
LUSC	trans	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg26043149	chr18:55253948	FECH	0.45	7.02	0.36	1.21e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs8027181	0.839	rs998020	chr15:72999635	C/T	cg25632853	chr15:73088954	NA	0.32	6.59	0.34	1.68e-10	Triglyceride levels;
LUSC	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-0.87	-14.93	-0.63	5.53e-39	Headache;
LUSC	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	8.1	0.41	1.04e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs983392	0.679	rs10736700	chr11:60031399	T/C	cg02771260	chr11:59836817	MS4A3	0.37	6.08	0.32	3.31e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs6484504	0.576	rs176373	chr11:31136026	G/T	cg06552810	chr11:31128660	NA	-0.4	-7.24	-0.37	3.05e-12	Red blood cell count;
LUSC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	0.65	13.97	0.61	2.98e-35	Prudent dietary pattern;
LUSC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg19774624	chr17:42201019	HDAC5	0.73	10.76	0.51	2.18e-23	Total body bone mineral density;
LUSC	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg17366294	chr4:99064904	C4orf37	0.54	8.83	0.43	6.14e-17	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs877282	0.583	rs11253429	chr10:823234	A/C	cg22713356	chr15:30763199	NA	0.75	9.37	0.46	1.12e-18	Uric acid levels;
LUSC	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg04989706	chr14:50066350	PPIL5	0.47	6.43	0.33	4.29e-10	Carotid intima media thickness;
LUSC	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg02493740	chr2:85810744	VAMP5	-0.53	-9.26	-0.45	2.59e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg18232548	chr7:50535776	DDC	0.51	7.69	0.39	1.65e-13	Malaria;
LUSC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.73	-0.43	1.25e-16	Monocyte count;
LUSC	cis	rs8099014	1.000	rs7234602	chr18:56111593	G/T	cg12907477	chr18:56117327	MIR122	0.44	7.08	0.36	8.82e-12	Platelet count;
LUSC	cis	rs1832871	0.616	rs55675950	chr6:158773994	T/A	cg07165851	chr6:158734300	TULP4	0.48	7.32	0.37	1.87e-12	Height;
LUSC	cis	rs4478858	0.746	rs10798831	chr1:31688385	A/C	cg00250761	chr1:31883323	NA	0.36	9.37	0.46	1.15e-18	Alcohol dependence;
LUSC	cis	rs8022179	0.580	rs8013228	chr14:103842650	A/G	cg12935359	chr14:103987150	CKB	-0.62	-8.42	-0.42	1.11e-15	Monocyte count;
LUSC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.14e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.8	-0.43	7.56e-17	Obesity-related traits;
LUSC	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg19682013	chr15:45996608	NA	0.39	5.95	0.31	6.77e-9	Waist circumference;Weight;
LUSC	trans	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg25214090	chr10:38739885	LOC399744	0.46	6.71	0.34	8.23e-11	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08280861	chr8:58055591	NA	0.55	6.26	0.32	1.19e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11677416	1.000	rs3783514	chr2:113547425	A/G	cg27083787	chr2:113543245	IL1A	0.47	7.39	0.37	1.17e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg14346243	chr4:90757452	SNCA	-0.39	-5.7	-0.3	2.58e-8	Neuroticism;
LUSC	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.39	0.37	1.21e-12	Corneal astigmatism;
LUSC	cis	rs7927771	0.507	rs7111606	chr11:47787538	G/A	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.18e-10	Subjective well-being;
LUSC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg04369109	chr6:150039330	LATS1	-0.6	-8.81	-0.43	7.08e-17	Lung cancer;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.87	-14.0	-0.61	2.27e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.39	-0.33	5.58e-10	Triglycerides;
LUSC	cis	rs354225	0.597	rs4347868	chr2:54830616	G/A	cg01766943	chr2:54829624	SPTBN1	0.46	7.28	0.37	2.45e-12	Schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10743145	chr19:45927001	ERCC1	-0.43	-6.13	-0.32	2.51e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg15997130	chr1:24165203	NA	0.55	8.93	0.44	2.82e-17	Immature fraction of reticulocytes;
LUSC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg07636037	chr3:49044803	WDR6	0.6	6.35	0.33	6.98e-10	Menarche (age at onset);
LUSC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg25456477	chr12:86230367	RASSF9	0.4	6.9	0.35	2.62e-11	Major depressive disorder;
LUSC	cis	rs13006833	0.739	rs291468	chr2:191188119	A/G	cg21644426	chr2:191273491	MFSD6	0.43	6.16	0.32	2.1e-9	Urinary metabolites;
LUSC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg15445000	chr17:37608096	MED1	0.38	6.64	0.34	1.24e-10	Glomerular filtration rate (creatinine);
LUSC	trans	rs629535	0.814	rs652483	chr8:70055083	G/A	cg21567404	chr3:27674614	NA	0.98	15.62	0.65	1.15e-41	Dupuytren's disease;
LUSC	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs2625529	0.878	rs2929511	chr15:72231682	C/T	cg16672083	chr15:72433130	SENP8	0.49	8.15	0.41	7.45e-15	Red blood cell count;
LUSC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg13531842	chr10:38383804	ZNF37A	-0.48	-7.42	-0.38	9.51e-13	Extrinsic epigenetic age acceleration;
LUSC	trans	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	trans	rs9929218	0.954	rs57688464	chr16:68826109	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.14	-0.52	1e-24	Colorectal cancer;
LUSC	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg22029157	chr1:209979665	IRF6	0.51	8.12	0.41	9e-15	Monobrow;
LUSC	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4629180	0.586	rs1509497	chr2:102138184	C/T	cg04415270	chr2:102091202	RFX8	-0.42	-7.23	-0.37	3.24e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg13683864	chr3:40499215	RPL14	-0.91	-16.07	-0.66	1.81e-43	Renal cell carcinoma;
LUSC	cis	rs1595825	0.891	rs1851779	chr2:198647108	C/T	cg00982548	chr2:198649783	BOLL	-0.58	-7.21	-0.37	3.87e-12	Ulcerative colitis;
LUSC	cis	rs3750082	0.582	rs7800883	chr7:32971282	G/A	cg08946731	chr7:32981826	RP9P	0.42	6.8	0.35	4.81e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.72	9.81	0.47	4.02e-20	Platelet count;
LUSC	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg00277334	chr10:82204260	NA	-0.5	-7.28	-0.37	2.37e-12	Post bronchodilator FEV1;
LUSC	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg05340658	chr4:99064831	C4orf37	0.68	11.4	0.53	1.19e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.63	-6.73	-0.35	7.2e-11	Lung cancer in ever smokers;
LUSC	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg24692254	chr21:30365293	RNF160	0.72	11.42	0.53	1.02e-25	Pancreatic cancer;
LUSC	cis	rs9467160	0.651	rs7755403	chr6:24453447	C/G	cg20631270	chr6:24437470	GPLD1	0.41	6.34	0.33	7.43e-10	Liver enzyme levels;
LUSC	cis	rs174479	0.743	rs174464	chr11:61657926	A/G	cg01500311	chr11:61656094	FADS3	0.4	6.96	0.36	1.8e-11	Sphingolipid levels;
LUSC	cis	rs7903847	0.620	rs17112676	chr10:99122288	G/A	cg08345082	chr10:99160200	RRP12	-0.35	-6.9	-0.35	2.62e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.73e-23	Bladder cancer;
LUSC	cis	rs13385	0.769	rs3822739	chr5:139625743	A/G	cg26211634	chr5:139558579	C5orf32	0.46	7.05	0.36	1.01e-11	Atrial fibrillation;
LUSC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg04944784	chr2:26401820	FAM59B	-0.68	-9.83	-0.47	3.44e-20	Gut microbiome composition (summer);
LUSC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-6.68	-0.34	1e-10	Mean platelet volume;
LUSC	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.73	-0.43	1.23e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg17691542	chr6:26056736	HIST1H1C	-0.4	-6.03	-0.31	4.41e-9	Schizophrenia;
LUSC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg08499158	chr17:42289980	UBTF	-0.54	-8.78	-0.43	8.69e-17	Total body bone mineral density;
LUSC	cis	rs3820068	0.562	rs10927841	chr1:16045261	T/C	cg24675056	chr1:15929824	NA	0.43	6.87	0.35	3.12e-11	Systolic blood pressure;
LUSC	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg21545522	chr1:205238299	TMCC2	0.43	8.15	0.41	7.46e-15	Red blood cell count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27255459	chr8:37962652	ASH2L	0.44	6.05	0.31	3.99e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg13902645	chr11:5959945	NA	-0.54	-8.03	-0.4	1.73e-14	DNA methylation (variation);
LUSC	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg15423357	chr2:25149977	NA	0.43	8.73	0.43	1.25e-16	Body mass index;
LUSC	cis	rs12413816	0.517	rs4750400	chr10:13765923	A/G	cg16485048	chr10:13749193	FRMD4A	0.37	6.11	0.32	2.77e-9	Red cell distribution width;
LUSC	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg08345082	chr10:99160200	RRP12	-0.34	-6.7	-0.34	8.94e-11	Monocyte percentage of white cells;
LUSC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-9.88	-0.48	2.23e-20	Chronic sinus infection;
LUSC	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg00898013	chr13:113819073	PROZ	-0.56	-8.08	-0.4	1.21e-14	Platelet distribution width;
LUSC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.0	0.58	1.55e-31	Chronic sinus infection;
LUSC	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg17120908	chr11:65337727	SSSCA1	-0.53	-9.22	-0.45	3.31e-18	Bone mineral density;
LUSC	cis	rs113835537	0.529	rs11821155	chr11:66246337	C/T	cg24851651	chr11:66362959	CCS	-0.53	-7.87	-0.4	5.14e-14	Airway imaging phenotypes;
LUSC	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg26727032	chr16:67993705	SLC12A4	-0.39	-6.01	-0.31	4.8e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg22431228	chr1:16359049	CLCNKA	0.34	6.42	0.33	4.7e-10	Dilated cardiomyopathy;
LUSC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg13114125	chr14:105738426	BRF1	0.88	14.98	0.63	3.49e-39	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-8.86	-0.44	4.99e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-8.42	-0.42	1.12e-15	Coffee consumption (cups per day);
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.63	9.73	0.47	7.25e-20	Lymphocyte counts;
LUSC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg03233332	chr7:66118400	NA	0.42	6.09	0.32	3.02e-9	Aortic root size;
LUSC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg27432699	chr2:27873401	GPN1	-0.47	-6.98	-0.36	1.55e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg00757033	chr12:89920650	WDR51B	0.61	10.76	0.51	2.3e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00864171	chr11:67383662	NA	0.34	5.96	0.31	6.34e-9	Mean corpuscular volume;
LUSC	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg02466173	chr16:30829666	NA	-0.58	-10.9	-0.51	7.11e-24	Multiple myeloma;
LUSC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg24399712	chr22:39784796	NA	-0.61	-10.28	-0.49	9.79e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.68	-0.39	1.75e-13	Joint mobility (Beighton score);
LUSC	cis	rs6681460	0.528	rs4655498	chr1:67039245	T/G	cg02459107	chr1:67143332	SGIP1	0.32	5.71	0.3	2.53e-8	Presence of antiphospholipid antibodies;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07286436	chr15:43425883	TMEM62	-0.42	-6.26	-0.32	1.21e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11674863	chr7:107531486	DLD	-0.4	-5.97	-0.31	6.13e-9	Electrocardiographic conduction measures;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24922631	chr19:19303269	RFXANK;LOC729991;LOC729991-MEF2B	0.43	6.02	0.31	4.68e-9	Triglycerides;
LUSC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg05805236	chr11:65401703	PCNXL3	0.36	5.75	0.3	1.96e-8	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs140884840	1	rs140884840	chr10:25200805	AAAAC/A	cg16316141	chr10:25305874	ENKUR;THNSL1	0.39	5.69	0.3	2.82e-8	Platelet count;Plateletcrit;
LUSC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs440932	1.000	rs365309	chr8:9026940	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-6.16	-0.32	2.08e-9	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.35	0.37	1.5e-12	Motion sickness;
LUSC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg21433313	chr16:3507492	NAT15	-0.61	-9.64	-0.47	1.42e-19	Tuberculosis;
LUSC	trans	rs3858145	0.588	rs731063	chr10:70043190	A/G	cg04882175	chr6:131122610	NA	0.62	8.4	0.42	1.25e-15	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23896311	chr4:122791762	BBS7	-0.46	-6.75	-0.35	6.41e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg12412775	chr1:25698385	RHCE	-0.31	-6.32	-0.33	8.46e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg10604040	chr11:65559109	OVOL1	0.32	5.85	0.3	1.18e-8	Acne (severe);
LUSC	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg05360138	chr12:110035743	NA	0.87	10.34	0.49	6.22e-22	Neuroticism;
LUSC	cis	rs13253111	0.624	rs1979329	chr8:28096772	C/G	cg26534493	chr8:28060551	NA	0.38	6.91	0.35	2.47e-11	Childhood body mass index;
LUSC	cis	rs2637266	0.627	rs2013238	chr10:78476272	A/C	cg18941641	chr10:78392320	NA	0.33	6.02	0.31	4.51e-9	Pulmonary function;
LUSC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.54	7.48	0.38	6.5e-13	Gut microbiome composition (summer);
LUSC	cis	rs611744	0.816	rs626211	chr8:109189448	A/C	cg18478394	chr8:109455254	TTC35	0.4	5.95	0.31	6.61e-9	Dupuytren's disease;
LUSC	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg24558204	chr6:135376177	HBS1L	0.57	8.99	0.44	1.85e-17	Red blood cell count;
LUSC	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg05973401	chr12:123451056	ABCB9	0.55	7.89	0.4	4.32e-14	Platelet count;
LUSC	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg11161011	chr14:65562177	MAX	-0.8	-12.14	-0.55	2.48e-28	Obesity-related traits;
LUSC	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg26876637	chr1:152193138	HRNR	-0.44	-6.12	-0.32	2.68e-9	Atopic dermatitis;
LUSC	cis	rs722599	0.748	rs7145173	chr14:75351647	G/A	cg08847533	chr14:75593920	NEK9	-0.48	-6.88	-0.35	3e-11	IgG glycosylation;
LUSC	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg21775007	chr8:11205619	TDH	-0.5	-7.54	-0.38	4.51e-13	Systolic blood pressure;
LUSC	cis	rs6460942	0.591	rs6945587	chr7:12356992	G/A	cg06484146	chr7:12443880	VWDE	-0.57	-5.96	-0.31	6.56e-9	Coronary artery disease;
LUSC	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg05738196	chr6:26577821	NA	-0.65	-10.32	-0.49	7.71e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.82e-24	Hypertriglyceridemia;
LUSC	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-5.91	-0.31	8.61e-9	Bipolar disorder;
LUSC	cis	rs501916	0.833	rs11855134	chr15:48047676	A/G	cg16110827	chr15:48056943	SEMA6D	-0.47	-7.16	-0.36	5.04e-12	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs13385	0.769	rs67836595	chr5:139603615	G/A	cg26211634	chr5:139558579	C5orf32	0.45	6.56	0.34	2.05e-10	Atrial fibrillation;
LUSC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	0.99	13.94	0.61	3.95e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg11584989	chr19:19387371	SF4	-0.59	-7.12	-0.36	6.62e-12	Bipolar disorder;
LUSC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6076960	0.652	rs3843045	chr20:6264593	C/T	cg21095983	chr6:86352623	SYNCRIP	-0.5	-8.13	-0.41	8.29e-15	Smooth-surface caries;
LUSC	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg15848620	chr12:58087721	OS9	-0.53	-7.69	-0.39	1.68e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.32	-0.33	8.56e-10	Total body bone mineral density;
LUSC	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg01256987	chr12:42539512	GXYLT1	-0.34	-6.21	-0.32	1.6e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg05163923	chr11:71159392	DHCR7	0.74	11.04	0.52	2.34e-24	Vitamin D levels;
LUSC	cis	rs9400467	0.528	rs6913769	chr6:111792897	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.92	-0.35	2.29e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.9	-12.47	-0.56	1.48e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg13246856	chr1:44399776	ARTN	-0.35	-7.08	-0.36	8.77e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg23262073	chr20:60523788	NA	-0.38	-6.09	-0.32	3.13e-9	Body mass index;
LUSC	trans	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-7.8	-0.39	7.78e-14	Menarche (age at onset);
LUSC	cis	rs1160297	0.544	rs10173886	chr2:53094788	T/C	cg07782112	chr2:53107842	NA	0.39	6.45	0.33	3.82e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs61931739	0.529	rs1525900	chr12:33976652	T/G	cg06521331	chr12:34319734	NA	-0.41	-6.94	-0.36	2.04e-11	Morning vs. evening chronotype;
LUSC	cis	rs9837602	0.872	rs4928234	chr3:99704861	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-6.17	-0.32	1.96e-9	Breast cancer;
LUSC	trans	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg06521331	chr12:34319734	NA	0.41	6.49	0.33	3.19e-10	Bladder cancer;
LUSC	cis	rs28595532	0.748	rs72670249	chr4:119336823	G/T	cg02775129	chr4:119771670	NA	-0.76	-6.32	-0.33	8.59e-10	Cannabis dependence symptom count;
LUSC	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg07701084	chr6:150067640	NUP43	0.53	7.89	0.4	4.41e-14	Lung cancer;
LUSC	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.57	-0.34	1.93e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg05973401	chr12:123451056	ABCB9	-0.51	-6.37	-0.33	6.13e-10	Neutrophil percentage of white cells;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg25511237	chr20:57978889	NA	0.41	6.34	0.33	7.62e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg24642439	chr20:33292090	TP53INP2	0.41	5.93	0.31	7.42e-9	Height;
LUSC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.55	0.57	7.07e-30	Motion sickness;
LUSC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg00814883	chr7:100076585	TSC22D4	-0.66	-8.53	-0.42	5.25e-16	Platelet count;
LUSC	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-13.06	-0.58	9.2e-32	Platelet distribution width;
LUSC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	6.43	0.33	4.42e-10	Electroencephalogram traits;
LUSC	cis	rs4363385	0.747	rs6670614	chr1:152964338	A/G	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.97	-0.4	2.61e-14	Inflammatory skin disease;
LUSC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg03605463	chr16:89740564	NA	0.38	5.75	0.3	2.05e-8	Vitiligo;
LUSC	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg05163923	chr11:71159392	DHCR7	-0.76	-9.95	-0.48	1.32e-20	Vitamin D levels;
LUSC	cis	rs7572644	0.699	rs12466717	chr2:28096792	A/G	cg27432699	chr2:27873401	GPN1	-0.51	-6.89	-0.35	2.86e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs17095355	0.605	rs7916801	chr10:111632445	A/G	cg00817464	chr10:111662876	XPNPEP1	0.55	6.49	0.33	3.04e-10	Biliary atresia;
LUSC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg17911788	chr17:44343683	NA	0.3	5.82	0.3	1.39e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg11843238	chr5:131593191	PDLIM4	0.39	6.54	0.34	2.28e-10	Breast cancer;
LUSC	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.73	-0.43	1.22e-16	Response to antipsychotic treatment;
LUSC	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg12564285	chr5:131593104	PDLIM4	0.33	6.01	0.31	4.76e-9	Blood metabolite levels;
LUSC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg03060546	chr3:49711283	APEH	0.71	11.94	0.55	1.29e-27	Resting heart rate;
LUSC	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg14458575	chr2:238380390	NA	0.67	11.98	0.55	9.09e-28	Prostate cancer;
LUSC	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg17366294	chr4:99064904	C4orf37	0.61	10.91	0.51	6.72e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1595825	0.891	rs76308665	chr2:198518062	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.63	-0.34	1.32e-10	Ulcerative colitis;
LUSC	cis	rs1152591	0.543	rs1152594	chr14:64675044	C/T	cg21174375	chr14:64681225	SYNE2	-0.34	-6.22	-0.32	1.45e-9	Atrial fibrillation;
LUSC	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.63	-13.05	-0.58	9.81e-32	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs4947962	0.585	rs7785013	chr7:55152667	A/G	cg23757825	chr7:55092271	EGFR	0.46	5.78	0.3	1.74e-8	Subjective response to lithium treatment;
LUSC	cis	rs9395066	0.545	rs17424547	chr6:44988970	A/G	cg25276700	chr6:44698697	NA	0.29	5.97	0.31	6.21e-9	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18662566	chr2:128643056	AMMECR1L	-0.38	-6.08	-0.32	3.3e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.73	-12.08	-0.55	4.1e-28	Motion sickness;
LUSC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg02569458	chr12:86230093	RASSF9	0.59	10.0	0.48	8.85e-21	Major depressive disorder;
LUSC	cis	rs259282	0.652	rs2161458	chr19:33129038	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.79	12.8	0.57	8.2e-31	Schizophrenia;
LUSC	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg22508957	chr16:3507546	NAT15	0.42	6.7	0.34	9.01e-11	Body mass index (adult);
LUSC	trans	rs225245	0.817	rs225302	chr17:33922396	C/T	cg19694781	chr19:47549865	TMEM160	-0.41	-6.55	-0.34	2.17e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs11039100	0.607	rs11038940	chr11:5777739	T/C	cg05234568	chr11:5960015	NA	-0.42	-5.68	-0.3	2.97e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6977660	0.714	rs10249477	chr7:19805388	T/A	cg05791153	chr7:19748676	TWISTNB	0.69	7.43	0.38	9.12e-13	Thyroid stimulating hormone;
LUSC	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg06484146	chr7:12443880	VWDE	-0.68	-7.18	-0.37	4.69e-12	Coronary artery disease;
LUSC	trans	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.3	0.33	9.6e-10	Corneal astigmatism;
LUSC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.58	8.85	0.44	5.19e-17	Longevity;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04974121	chr4:20701990	PACRGL	-0.39	-6.42	-0.33	4.55e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7215564	0.908	rs2316061	chr17:78663660	A/G	cg23238734	chr17:78661607	RPTOR	0.47	6.11	0.32	2.82e-9	Myopia (pathological);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24321774	chr2:27193835	MAPRE3	-0.45	-6.35	-0.33	7.01e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg17757837	chr7:157058334	UBE3C	0.9	14.71	0.63	4.2e-38	Body mass index;
LUSC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg23815491	chr16:72088622	HP	-0.35	-6.04	-0.31	4.19e-9	Fibrinogen levels;
LUSC	cis	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg07460842	chr6:66804631	NA	0.71	8.75	0.43	1.07e-16	Type 2 diabetes;
LUSC	cis	rs9341808	0.500	rs2223873	chr6:81048288	A/G	cg08355045	chr6:80787529	NA	0.48	8.3	0.41	2.69e-15	Sitting height ratio;
LUSC	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg17075019	chr10:79541650	NA	-0.76	-12.18	-0.55	1.73e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7599312	0.963	rs6735267	chr2:213403863	C/T	cg16329650	chr2:213403929	ERBB4	0.65	9.03	0.44	1.42e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4474465	0.790	rs6592785	chr11:78235095	C/T	cg27205649	chr11:78285834	NARS2	0.52	6.09	0.32	3.17e-9	Alzheimer's disease (survival time);
LUSC	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg02018176	chr4:1364513	KIAA1530	0.43	6.15	0.32	2.24e-9	Recombination rate (females);
LUSC	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg25214090	chr10:38739885	LOC399744	0.51	7.51	0.38	5.54e-13	Corneal astigmatism;
LUSC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.43	0.46	7e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2354432	0.556	rs7516165	chr1:146866418	G/T	cg25205988	chr1:146714368	CHD1L	0.86	7.6	0.38	2.98e-13	Mitochondrial DNA levels;
LUSC	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg22676075	chr6:135203613	NA	0.48	7.42	0.38	9.61e-13	Red blood cell count;
LUSC	cis	rs2324229	0.828	rs1180194	chr6:83962421	C/T	cg08257003	chr6:84140564	ME1	0.32	7.52	0.38	5.02e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg02079420	chr8:82753780	SNX16	0.41	6.97	0.36	1.69e-11	Diastolic blood pressure;
LUSC	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	8.13	0.41	8.51e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg03396347	chr1:1875803	NA	0.48	10.32	0.49	7.56e-22	Body mass index;
LUSC	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg17143192	chr8:8559678	CLDN23	0.63	9.07	0.44	1.02e-17	Obesity-related traits;
LUSC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg06238570	chr21:40685208	BRWD1	0.53	7.87	0.4	5.12e-14	Cognitive function;
LUSC	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.06	13.11	0.58	5.81e-32	Sexual dysfunction (female);
LUSC	cis	rs12989701	0.877	rs7557280	chr2:127873161	T/A	cg08168897	chr2:127865431	BIN1	0.73	9.32	0.45	1.65e-18	Alzheimer's disease (late onset);
LUSC	cis	rs981844	0.807	rs56053818	chr4:154638126	T/A	cg14289246	chr4:154710475	SFRP2	0.43	5.82	0.3	1.4e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs12286929	0.679	rs11601041	chr11:115083348	A/G	cg04055981	chr11:115044050	NA	0.36	6.33	0.33	7.78e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-10.81	-0.51	1.47e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg06937882	chr20:24974362	C20orf3	-0.44	-7.67	-0.39	1.89e-13	Blood protein levels;
LUSC	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.62	-0.43	2.63e-16	Mood instability;
LUSC	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-8.31	-0.41	2.52e-15	Prudent dietary pattern;
LUSC	cis	rs3829109	0.534	rs563	chr9:139296485	C/T	cg14169450	chr9:139327907	INPP5E	-0.4	-6.07	-0.32	3.49e-9	Peak insulin response;Acute insulin response;
LUSC	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.08	0.32	3.29e-9	Morning vs. evening chronotype;
LUSC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg20608306	chr11:116969690	SIK3	-0.38	-6.35	-0.33	6.84e-10	Blood protein levels;
LUSC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00339695	chr16:24857497	SLC5A11	-0.61	-9.23	-0.45	3.25e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.77	-0.8	1.22e-77	Height;
LUSC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.06e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg03146154	chr1:46216737	IPP	0.54	8.22	0.41	4.47e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg15448220	chr1:150897856	SETDB1	0.38	5.69	0.3	2.84e-8	Tonsillectomy;
LUSC	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.99	-21.34	-0.76	2.39e-64	Schizophrenia;
LUSC	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg10523679	chr1:76189770	ACADM	-0.51	-7.04	-0.36	1.13e-11	Daytime sleep phenotypes;
LUSC	cis	rs6541297	0.699	rs4846915	chr1:230296470	C/A	cg05784532	chr1:230284198	GALNT2	0.58	6.68	0.34	9.94e-11	Coronary artery disease;
LUSC	cis	rs587080	0.624	rs512715	chr11:65191208	C/G	cg21890820	chr11:65308645	LTBP3	-0.48	-6.7	-0.34	8.68e-11	Plateletcrit;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14633757	chr17:80231324	CSNK1D	-0.53	-6.46	-0.33	3.69e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	1.04	20.17	0.74	1.03e-59	Menopause (age at onset);
LUSC	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14159747	chr11:113255604	NA	-0.29	-7.65	-0.39	2.13e-13	Neuroticism;
LUSC	cis	rs7586879	0.789	rs13382979	chr2:25131736	G/A	cg01884057	chr2:25150051	NA	0.41	8.4	0.42	1.26e-15	Body mass index;
LUSC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg11366901	chr6:160182831	ACAT2	0.97	13.07	0.58	8.27e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	0.86	14.62	0.62	9.31e-38	Height;
LUSC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg08968635	chr6:28129556	ZNF389	0.45	5.67	0.3	3.06e-8	Parkinson's disease;
LUSC	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg22437258	chr11:111473054	SIK2	0.5	6.89	0.35	2.78e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg06552810	chr11:31128660	NA	0.4	6.89	0.35	2.71e-11	Red blood cell count;
LUSC	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg26061582	chr7:22766209	IL6	0.45	6.54	0.34	2.26e-10	Lung cancer;
LUSC	cis	rs2742234	0.541	rs10899778	chr10:43718509	G/C	cg15436174	chr10:43711423	RASGEF1A	0.44	7.06	0.36	9.75e-12	Hirschsprung disease;
LUSC	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg13010199	chr12:38710504	ALG10B	0.62	9.03	0.44	1.39e-17	Morning vs. evening chronotype;
LUSC	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg02018176	chr4:1364513	KIAA1530	0.48	6.59	0.34	1.74e-10	Recombination rate (females);
LUSC	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg20503657	chr10:835505	NA	-0.49	-6.86	-0.35	3.31e-11	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg20991723	chr1:152506922	NA	0.52	9.8	0.47	4.38e-20	Hair morphology;
LUSC	trans	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.02	-0.31	4.47e-9	Monocyte count;
LUSC	cis	rs807669	0.770	rs807458	chr22:19220648	G/A	cg26795923	chr22:19165960	SLC25A1	0.82	6.45	0.33	4.01e-10	Metabolite levels;
LUSC	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.64	-0.3	3.56e-8	Coronary artery disease;
LUSC	cis	rs950881	0.799	rs72823669	chr2:102982033	G/T	cg20060108	chr2:102954350	IL1RL1	0.49	6.2	0.32	1.63e-9	Allergy;
LUSC	cis	rs7113850	0.551	rs4365050	chr11:24245730	G/A	ch.11.24196551F	chr11:24239977	NA	1.01	9.09	0.45	9.05e-18	Bone fracture in osteoporosis;
LUSC	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg03342759	chr3:160939853	NMD3	-0.44	-7.37	-0.37	1.34e-12	Morning vs. evening chronotype;
LUSC	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg14664628	chr15:75095509	CSK	0.49	6.43	0.33	4.34e-10	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18402987	chr7:1209562	NA	0.45	5.86	0.31	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2455601	0.574	rs2568094	chr11:8992218	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.32	-0.33	8.16e-10	Schizophrenia;
LUSC	cis	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg24375607	chr4:120327624	NA	-0.46	-7.03	-0.36	1.17e-11	Diastolic blood pressure;
LUSC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg02574844	chr11:5959923	NA	0.5	7.56	0.38	4.04e-13	DNA methylation (variation);
LUSC	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg12826209	chr6:26865740	GUSBL1	0.64	5.65	0.3	3.37e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.65	11.28	0.53	3.11e-25	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs899997	0.731	rs58717592	chr15:79030417	T/C	cg04896959	chr15:78267971	NA	-0.53	-10.06	-0.48	5.87e-21	Coronary artery disease or large artery stroke;
LUSC	cis	rs6546537	1.000	rs6727435	chr2:69864236	C/A	cg10773587	chr2:69614142	GFPT1	-0.53	-7.85	-0.39	5.77e-14	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg11344533	chr11:111475393	SIK2	-0.44	-5.74	-0.3	2.14e-8	Primary sclerosing cholangitis;
LUSC	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg02023728	chr11:77925099	USP35	0.49	7.15	0.36	5.56e-12	Testicular germ cell tumor;
LUSC	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg04310649	chr10:35416472	CREM	-0.4	-6.24	-0.32	1.3e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg07741184	chr6:167504864	NA	0.35	6.41	0.33	4.97e-10	Crohn's disease;
LUSC	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg01689657	chr7:91764605	CYP51A1	0.33	6.03	0.31	4.39e-9	Breast cancer;
LUSC	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	6.42	0.33	4.68e-10	Recombination rate (females);
LUSC	trans	rs5760842	0.517	rs2076930	chr22:25495138	T/C	cg16733866	chr21:42792609	MX1	0.5	7.0	0.36	1.39e-11	Recurrent major depressive disorder;
LUSC	cis	rs4664308	1.000	rs10929966	chr2:160908341	C/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-11.38	-0.53	1.42e-25	Idiopathic membranous nephropathy;
LUSC	trans	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	8.5	0.42	6.47e-16	Ulcerative colitis;
LUSC	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg17127132	chr2:85788382	GGCX	0.41	5.93	0.31	7.66e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg11502198	chr6:26597334	ABT1	0.59	9.08	0.44	9.95e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18099408	chr3:52552593	STAB1	-0.48	-8.56	-0.42	4.15e-16	Bipolar disorder;
LUSC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg24634471	chr8:143751801	JRK	-0.51	-7.12	-0.36	6.67e-12	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.57	0.5	1.02e-22	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg08975724	chr8:8085496	FLJ10661	0.45	6.66	0.34	1.1e-10	Retinal vascular caliber;
LUSC	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	10.62	0.5	6.6e-23	Coffee consumption (cups per day);
LUSC	cis	rs6882046	0.513	rs679232	chr5:88054763	A/C	cg22951263	chr5:87985283	NA	0.45	7.38	0.37	1.29e-12	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LUSC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs10779751	0.734	rs2486920	chr1:11125050	T/C	cg08854313	chr1:11322531	MTOR	0.79	11.58	0.54	2.78e-26	Body mass index;
LUSC	cis	rs7903847	0.620	rs17112674	chr10:99122178	C/T	cg20016023	chr10:99160130	RRP12	0.31	7.48	0.38	6.46e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-0.91	-15.86	-0.66	1.23e-42	Height;
LUSC	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg19812747	chr11:111475976	SIK2	0.52	7.17	0.37	4.78e-12	Primary sclerosing cholangitis;
LUSC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg21280719	chr6:42927975	GNMT	-0.32	-7.96	-0.4	2.77e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7586879	0.828	rs11675013	chr2:25107208	G/A	cg01884057	chr2:25150051	NA	0.41	8.61	0.43	3.02e-16	Body mass index;
LUSC	cis	rs954108	0.809	rs715704	chr13:29369317	C/T	cg11788234	chr13:29393811	NA	-0.39	-6.75	-0.35	6.41e-11	Obesity-related traits;
LUSC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	6.39	0.33	5.42e-10	Renal function-related traits (BUN);
LUSC	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-5.99	-0.31	5.43e-9	IgG glycosylation;
LUSC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21702128	chr5:142784721	NR3C1	0.42	6.11	0.32	2.84e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.34	-6.35	-0.33	7.05e-10	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg06028605	chr16:24865363	SLC5A11	0.47	8.52	0.42	5.36e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2124969	0.548	rs72979963	chr2:161014483	A/G	cg03641300	chr2:160917029	PLA2R1	-0.47	-5.7	-0.3	2.7e-8	Waist circumference adjusted for body mass index;
LUSC	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg01444801	chr10:135216882	MTG1	-0.5	-6.55	-0.34	2.15e-10	Systemic lupus erythematosus;
LUSC	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg21775007	chr8:11205619	TDH	0.46	6.65	0.34	1.19e-10	Neuroticism;
LUSC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg09365446	chr1:150670422	GOLPH3L	0.46	6.74	0.35	7.09e-11	Melanoma;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21872393	chr18:3247654	MYL12A	0.49	7.04	0.36	1.12e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg00383909	chr3:49044727	WDR6	1.1	9.65	0.47	1.36e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2274273	0.901	rs8011288	chr14:55735112	C/T	cg04306507	chr14:55594613	LGALS3	0.57	13.76	0.6	1.98e-34	Protein biomarker;
LUSC	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-0.53	-8.18	-0.41	6.04e-15	Breast cancer;
LUSC	trans	rs539514	0.690	rs607095	chr13:76316165	A/T	cg05302441	chr11:125157402	PKNOX2	0.26	6.0	0.31	5.12e-9	Type 1 diabetes;
LUSC	cis	rs7582720	1.000	rs114123510	chr2:203831212	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg20219074	chr11:18656078	SPTY2D1	0.72	10.81	0.51	1.49e-23	Breast cancer;
LUSC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg08132940	chr7:1081526	C7orf50	-0.51	-5.99	-0.31	5.3300000000000004e-09	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg27432699	chr2:27873401	GPN1	-0.58	-8.69	-0.43	1.62e-16	Total body bone mineral density;
LUSC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg22920501	chr2:26401640	FAM59B	-0.75	-10.64	-0.5	5.79e-23	Gut microbiome composition (summer);
LUSC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.59	-0.46	2.1e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs977987	0.902	rs4888430	chr16:75494424	T/C	cg04384234	chr16:75411784	CFDP1	-0.48	-8.01	-0.4	1.93e-14	Dupuytren's disease;
LUSC	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg15704280	chr7:45808275	SEPT13	-0.44	-6.1	-0.32	3e-9	HDL cholesterol;
LUSC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	4.85e-15	Homoarginine levels;
LUSC	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg27284194	chr4:1044797	NA	0.57	8.39	0.42	1.35e-15	Recombination rate (females);
LUSC	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg21548813	chr6:291882	DUSP22	0.47	7.2	0.37	4.07e-12	Menopause (age at onset);
LUSC	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	0.91	16.1	0.66	1.43e-43	Height;
LUSC	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-0.95	-16.21	-0.66	5.44e-44	Dilated cardiomyopathy;
LUSC	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg16743903	chr16:89593216	SPG7	-0.38	-5.85	-0.3	1.19e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs7166081	0.738	rs2286664	chr15:67701495	A/G	cg05925327	chr15:68127851	NA	-0.36	-5.78	-0.3	1.72e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg18827107	chr12:86230957	RASSF9	-0.49	-7.11	-0.36	7.04e-12	Major depressive disorder;
LUSC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg05234568	chr11:5960015	NA	-0.58	-9.21	-0.45	3.72e-18	DNA methylation (variation);
LUSC	cis	rs7527798	1.000	rs36001492	chr1:207841745	A/T	cg09232269	chr1:207846808	CR1L	-0.32	-5.8	-0.3	1.56e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg01256987	chr12:42539512	GXYLT1	-0.4	-7.31	-0.37	2.03e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg21856205	chr7:94953877	PON1	-0.36	-5.8	-0.3	1.56e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg06640241	chr16:89574553	SPG7	0.69	10.83	0.51	1.23e-23	Multiple myeloma (IgH translocation);
LUSC	cis	rs9399401	0.845	rs263188	chr6:142860028	C/T	cg03128060	chr6:142623767	GPR126	0.32	6.05	0.31	3.86e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21028142	chr17:79581711	NPLOC4	-0.33	-7.56	-0.38	4.01e-13	Eye color traits;
LUSC	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.87	0.35	3.22e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.09	-0.36	8e-12	Major depressive disorder;
LUSC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg12758973	chr1:247694275	LOC148824;OR2C3	0.37	5.69	0.3	2.73e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.2	0.45	3.91e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.16	0.36	5.3e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11645453	chr3:52864694	ITIH4	0.4	8.73	0.43	1.23e-16	Bipolar disorder;
LUSC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06850241	chr22:41845214	NA	-0.3	-5.75	-0.3	2e-8	Vitiligo;
LUSC	cis	rs6977660	0.619	rs10231972	chr7:19789354	C/G	cg05791153	chr7:19748676	TWISTNB	0.63	7.17	0.37	4.86e-12	Thyroid stimulating hormone;
LUSC	cis	rs16976116	0.901	rs2899580	chr15:55491571	A/G	cg11288833	chr15:55489084	RSL24D1	0.49	5.9	0.31	9.16e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4588572	0.643	rs10063319	chr5:77758425	T/C	cg11547950	chr5:77652471	NA	-0.56	-7.9	-0.4	4.04e-14	Triglycerides;
LUSC	cis	rs12310956	0.510	rs4931759	chr12:33871969	T/C	cg06521331	chr12:34319734	NA	-0.36	-5.95	-0.31	6.73e-9	Morning vs. evening chronotype;
LUSC	cis	rs17125944	0.686	rs77625717	chr14:53336544	T/C	cg00686598	chr14:53173677	PSMC6	0.84	6.89	0.35	2.81e-11	Alzheimer's disease (late onset);
LUSC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.86	-0.81	6.04e-78	Height;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg23845507	chr1:91966731	CDC7	0.37	6.04	0.31	4e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs17253792	0.822	rs79807559	chr14:56108117	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.28e-10	Putamen volume;
LUSC	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg11502198	chr6:26597334	ABT1	0.7	11.83	0.54	3.39e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg01097406	chr16:89675127	NA	-0.29	-5.71	-0.3	2.51e-8	Hemoglobin concentration;
LUSC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	10.66	0.5	4.78e-23	Homoarginine levels;
LUSC	cis	rs1729407	0.695	rs1263176	chr11:116690123	T/C	cg08985259	chr11:116699649	APOC3	-0.25	-5.71	-0.3	2.52e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg23795048	chr12:9217529	LOC144571	0.34	5.94	0.31	7.26e-9	Sjögren's syndrome;
LUSC	trans	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.63	-0.34	1.36e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs11587400	0.679	rs6537834	chr1:115108870	T/C	cg12756093	chr1:115239321	AMPD1	0.4	5.93	0.31	7.76e-9	Autism;
LUSC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.19e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4363385	0.818	rs10788853	chr1:153002231	C/T	cg25856811	chr1:152973957	SPRR3	-0.36	-5.94	-0.31	6.97e-9	Inflammatory skin disease;
LUSC	cis	rs13315871	1.000	rs4362735	chr3:58429893	C/G	cg20936604	chr3:58311152	NA	-0.66	-6.58	-0.34	1.79e-10	Cholesterol, total;
LUSC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.65	0.34	1.2e-10	Lung cancer;
LUSC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.68	-0.39	1.75e-13	Aortic root size;
LUSC	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg25237894	chr2:233734115	C2orf82	0.36	6.21	0.32	1.59e-9	Coronary artery disease;
LUSC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg16586182	chr3:47516702	SCAP	0.52	8.26	0.41	3.35e-15	Colorectal cancer;
LUSC	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-1.13	-17.71	-0.7	6.06e-50	Exhaled nitric oxide output;
LUSC	trans	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-12.74	-0.57	1.48e-30	Colorectal cancer;
LUSC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg12751644	chr20:60527061	NA	-0.36	-6.47	-0.33	3.45e-10	Body mass index;
LUSC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg05025164	chr4:1340916	KIAA1530	-0.5	-7.65	-0.39	2.21e-13	Obesity-related traits;
LUSC	trans	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg13010199	chr12:38710504	ALG10B	0.38	6.05	0.31	3.91e-9	Morning vs. evening chronotype;
LUSC	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.38	-0.73	1.37e-56	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg13175981	chr1:150552382	MCL1	0.53	7.56	0.38	4.01e-13	Tonsillectomy;
LUSC	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.83	-12.62	-0.57	3.88e-30	Body mass index;
LUSC	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg18105134	chr13:113819100	PROZ	-0.76	-11.03	-0.52	2.42e-24	Platelet distribution width;
LUSC	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.57	8.19	0.41	5.73e-15	Systemic lupus erythematosus;
LUSC	cis	rs2282802	0.685	rs10077671	chr5:139689505	C/T	cg26211634	chr5:139558579	C5orf32	0.42	8.11	0.41	9.79e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.16	0.36	5.16e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7605827	0.893	rs741437	chr2:15626327	A/G	cg19274914	chr2:15703543	NA	0.46	8.87	0.44	4.51e-17	Educational attainment (years of education);
LUSC	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.46	9.58	0.46	2.26e-19	Airflow obstruction;
LUSC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.68	-0.39	1.81e-13	Height;
LUSC	trans	rs17039065	0.920	rs1562973	chr4:109408138	G/T	cg07444054	chr2:108107501	NA	0.43	6.25	0.32	1.23e-9	Gut microbiome composition (summer);
LUSC	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg02574844	chr11:5959923	NA	-0.47	-6.75	-0.35	6.74e-11	DNA methylation (variation);
LUSC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg26380479	chr7:97908229	NA	-0.26	-5.84	-0.3	1.24e-8	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.58	-7.31	-0.37	1.98e-12	Ulcerative colitis;
LUSC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.96	-0.31	6.28e-9	Longevity;
LUSC	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg07701084	chr6:150067640	NUP43	0.47	7.03	0.36	1.15e-11	Testicular germ cell tumor;
LUSC	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg11244672	chr19:19639970	YJEFN3	-0.58	-6.97	-0.36	1.72e-11	Bipolar disorder;
LUSC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg03563238	chr19:33554763	RHPN2	-0.39	-6.36	-0.33	6.68e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4478858	0.735	rs12126725	chr1:31805853	G/T	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg15798862	chr7:76129360	DTX2	-0.51	-8.54	-0.42	4.77e-16	Multiple sclerosis;
LUSC	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg11584989	chr19:19387371	SF4	0.51	6.41	0.33	4.89e-10	Bipolar disorder;
LUSC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16680214	chr1:154839983	KCNN3	-0.53	-10.03	-0.48	6.96e-21	Prostate cancer;
LUSC	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg15212455	chr7:39170539	POU6F2	0.66	11.52	0.53	4.51e-26	IgG glycosylation;
LUSC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	1.04	20.11	0.74	1.65e-59	Menopause (age at onset);
LUSC	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg17830980	chr10:43048298	ZNF37B	0.6	9.71	0.47	8.35e-20	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg22571038	chr17:48585470	MYCBPAP	0.46	5.85	0.3	1.18e-8	Visceral fat;
LUSC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg20476274	chr7:133979776	SLC35B4	0.84	15.04	0.64	2.21e-39	Mean platelet volume;
LUSC	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg01503450	chr10:980765	NA	-0.39	-5.79	-0.3	1.59e-8	Eosinophil percentage of granulocytes;
LUSC	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-8.38	-0.42	1.52e-15	Systolic blood pressure;
LUSC	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg05234568	chr11:5960015	NA	-0.57	-8.29	-0.41	2.82e-15	DNA methylation (variation);
LUSC	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg05973401	chr12:123451056	ABCB9	-0.42	-5.65	-0.3	3.49e-8	Neutrophil percentage of white cells;
LUSC	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg19052272	chr2:3704530	ALLC	0.42	7.86	0.4	5.33e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg15017067	chr4:17643749	FAM184B	0.35	5.72	0.3	2.41e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs11637445	0.677	rs1564278	chr15:68107388	G/C	cg08079166	chr15:68083412	MAP2K5	0.36	7.38	0.37	1.25e-12	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg00129232	chr17:37814104	STARD3	-0.49	-7.28	-0.37	2.37e-12	Asthma;
LUSC	cis	rs737337	0.623	rs4804154	chr19:11334179	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.55	6.84	0.35	3.75e-11	HDL cholesterol;HDL cholesterol levels;
LUSC	trans	rs11696501	0.688	rs2072974	chr20:44313401	G/A	cg03272292	chr12:48577362	C12orf68	0.5	6.01	0.31	4.88e-9	Brain structure;
LUSC	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg21775007	chr8:11205619	TDH	0.46	6.57	0.34	1.93e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg11965913	chr1:205819406	PM20D1	-0.5	-7.12	-0.36	6.81e-12	Parkinson's disease;
LUSC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg19592336	chr6:28129416	ZNF389	0.48	6.27	0.32	1.11e-9	Parkinson's disease;
LUSC	cis	rs896543	0.702	rs12692188	chr2:237495929	A/G	cg25295825	chr2:237489920	CXCR7	0.51	6.2	0.32	1.62e-9	Alcohol dependence (age at onset);
LUSC	cis	rs2667011	0.818	rs2667000	chr2:160850354	A/T	cg06573604	chr2:160760825	LY75	-0.5	-6.42	-0.33	4.78e-10	Bilirubin levels;
LUSC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.36	5.76	0.3	1.9e-8	Menopause (age at onset);
LUSC	cis	rs952623	0.649	rs6462886	chr7:39066567	A/T	cg15212455	chr7:39170539	POU6F2	-0.35	-5.77	-0.3	1.8e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4664308	0.618	rs62175487	chr2:160892521	C/T	cg03641300	chr2:160917029	PLA2R1	-0.48	-7.9	-0.4	4.1e-14	Idiopathic membranous nephropathy;
LUSC	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.21	-0.32	1.6e-9	Neuroticism;
LUSC	trans	rs2229238	0.868	rs73018293	chr1:154465577	C/T	cg25273160	chr11:56955011	LRRC55	0.31	6.05	0.31	3.81e-9	Coronary heart disease;
LUSC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	14.09	0.61	1.09e-35	Platelet count;
LUSC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21643547	chr1:205240462	TMCC2	-0.46	-8.63	-0.43	2.52e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01570182	chr17:44337453	NA	0.69	10.39	0.49	4.39e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg21854759	chr1:92012499	NA	-0.41	-6.56	-0.34	2.02e-10	Breast cancer;
LUSC	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	11.43	0.53	9.1e-26	Coronary artery disease;
LUSC	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg13010199	chr12:38710504	ALG10B	0.45	6.38	0.33	5.74e-10	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14487680	chr2:3381855	TSSC1	0.47	6.37	0.33	6.36e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg08888203	chr3:10149979	C3orf24	0.66	8.6	0.43	3.06e-16	Alzheimer's disease;
LUSC	cis	rs6987853	0.814	rs2167338	chr8:42455079	A/G	cg09913449	chr8:42400586	C8orf40	0.42	7.06	0.36	9.67e-12	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg17971929	chr21:40555470	PSMG1	-0.66	-10.79	-0.51	1.8e-23	Cognitive function;
LUSC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.1	0.41	1.06e-14	Prudent dietary pattern;
LUSC	cis	rs76793172	1.000	rs10420834	chr19:46347542	G/T	cg00442267	chr19:46317840	RSPH6A	-0.49	-5.74	-0.3	2.17e-8	Eosinophil counts;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22320231	chr17:28903436	LRRC37B2	0.39	5.99	0.31	5.39e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08859206	chr1:53392774	SCP2	-0.54	-9.41	-0.46	8.07e-19	Monocyte count;
LUSC	cis	rs1030877	0.515	rs1020064	chr2:105897740	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.67	9.22	0.45	3.35e-18	Obesity-related traits;
LUSC	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	8.84	0.44	5.58e-17	Bipolar disorder;
LUSC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.47	-8.29	-0.41	2.78e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2274273	0.743	rs13379159	chr14:55540801	C/T	cg04306507	chr14:55594613	LGALS3	0.5	10.72	0.51	3.17e-23	Protein biomarker;
LUSC	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.69	-10.93	-0.51	5.6e-24	Systemic lupus erythematosus;
LUSC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg08027265	chr7:2291960	NA	-0.38	-6.29	-0.33	9.98e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.26	-0.37	2.66e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18404974	chr22:18560667	PEX26	-0.42	-6.34	-0.33	7.34e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.14	-0.45	5.99e-18	Schizophrenia;
LUSC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg07424592	chr7:64974309	NA	0.66	5.8	0.3	1.55e-8	Diabetic kidney disease;
LUSC	cis	rs231513	0.954	rs231504	chr17:41970906	C/G	cg26893861	chr17:41843967	DUSP3	-0.51	-6.17	-0.32	1.97e-9	Cognitive function;
LUSC	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.29	5.79	0.3	1.65e-8	Cognitive function;
LUSC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg11764359	chr7:65958608	NA	-0.79	-12.87	-0.58	4.64e-31	Aortic root size;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14986359	chr19:59085030	MZF1;LOC100131691	0.41	6.79	0.35	5.24e-11	Triglycerides;
LUSC	trans	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg13010199	chr12:38710504	ALG10B	0.4	6.33	0.33	7.75e-10	Morning vs. evening chronotype;
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.92	16.5	0.67	3.83e-45	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg19336497	chr11:14380999	RRAS2	0.45	8.13	0.41	8.49e-15	Mitochondrial DNA levels;
LUSC	cis	rs1355223	1.000	rs11601205	chr11:34768479	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.94	-0.31	7.22e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.03	-0.52	2.41e-24	Bipolar disorder;
LUSC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.81	0.43	6.92e-17	Prudent dietary pattern;
LUSC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg16325326	chr1:53192061	ZYG11B	-0.92	-17.21	-0.69	5.71e-48	Monocyte count;
LUSC	cis	rs6545883	0.868	rs6752938	chr2:61841588	C/T	cg15711740	chr2:61764176	XPO1	-0.43	-6.78	-0.35	5.57e-11	Tuberculosis;
LUSC	cis	rs55986470	0.763	rs6739251	chr2:239419603	A/G	cg18131467	chr2:239335373	ASB1	-0.61	-7.05	-0.36	1.01e-11	Chronotype;
LUSC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg20976159	chr1:228193529	WNT3A	0.28	5.79	0.3	1.59e-8	Diastolic blood pressure;
LUSC	cis	rs17253792	0.822	rs74653073	chr14:56079528	T/C	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.56	0.42	4.3e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	7.78	0.39	8.94e-14	Mean platelet volume;
LUSC	cis	rs1335645	0.570	rs2278578	chr1:111659792	G/T	cg00321911	chr1:111669324	DRAM2	-0.6	-6.84	-0.35	3.88e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg04450456	chr4:17643702	FAM184B	-0.39	-6.44	-0.33	4.26e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs61990749	0.597	rs176943	chr14:78175797	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.61	-6.48	-0.33	3.33e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs554111	0.613	rs1567128	chr1:21404653	G/A	cg01072550	chr1:21505969	NA	0.38	5.79	0.3	1.58e-8	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg12744634	chr1:26560303	CCDC21	0.39	5.84	0.3	1.25e-8	Obesity-related traits;
LUSC	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg01884057	chr2:25150051	NA	0.48	11.49	0.53	5.56e-26	Body mass index;
LUSC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg19077165	chr18:44547161	KATNAL2	0.38	5.8	0.3	1.55e-8	Personality dimensions;
LUSC	cis	rs460214	0.564	rs9979888	chr21:40022099	A/G	cg21578987	chr21:40029669	ERG	-0.42	-6.67	-0.34	1.09e-10	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs654950	0.875	rs687766	chr1:41998849	C/G	cg06885757	chr1:42089581	HIVEP3	0.34	6.44	0.33	4.14e-10	Airway imaging phenotypes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24378597	chr1:179263242	SOAT1	-0.43	-6.3	-0.33	9.52e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg23896874	chr8:21924512	EPB49	0.68	5.95	0.31	6.89e-9	Cognitive performance;
LUSC	cis	rs9473147	0.543	rs9473122	chr6:47474962	C/T	cg20196966	chr6:47445060	CD2AP	0.42	5.83	0.3	1.31e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs10887741	0.690	rs12781358	chr10:89444367	C/T	cg13926569	chr10:89418898	PAPSS2	0.28	5.91	0.31	8.62e-9	Exercise (leisure time);
LUSC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.42e-19	Prudent dietary pattern;
LUSC	cis	rs2540226	0.935	rs2373689	chr2:39987287	C/T	cg23576258	chr2:39999331	THUMPD2	0.35	5.97	0.31	6.04e-9	Personality dimensions;
LUSC	cis	rs7605827	0.897	rs34191114	chr2:15670691	C/A	cg19274914	chr2:15703543	NA	0.47	9.22	0.45	3.46e-18	Educational attainment (years of education);
LUSC	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1007190	0.881	rs34854300	chr17:42969013	T/C	cg15406952	chr17:42872593	NA	0.56	5.76	0.3	1.88e-8	DNA methylation (variation);
LUSC	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg04287289	chr16:89883240	FANCA	-0.42	-6.02	-0.31	4.61e-9	Vitiligo;
LUSC	cis	rs4971059	0.629	rs12904	chr1:155106697	G/A	cg22049894	chr1:155113146	DPM3	0.39	6.19	0.32	1.79e-9	Breast cancer;
LUSC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg02117656	chr17:79614917	TSPAN10	0.3	5.67	0.3	3.16e-8	Eye color traits;
LUSC	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.21	25.35	0.81	8.33e-80	Exhaled nitric oxide output;
LUSC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21862992	chr11:68658383	NA	0.51	8.3	0.41	2.58e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg01557791	chr16:72042693	DHODH	-0.45	-6.67	-0.34	1.07e-10	Fibrinogen levels;
LUSC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10053473	chr17:62856997	LRRC37A3	0.67	10.61	0.5	7.58e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9462027	0.606	rs412392	chr6:34549699	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.97	-0.31	6.08e-9	Systemic lupus erythematosus;
LUSC	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg13813247	chr22:41461852	NA	-0.38	-6.77	-0.35	5.83e-11	Neuroticism;
LUSC	cis	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg06521331	chr12:34319734	NA	-0.48	-7.86	-0.4	5.33e-14	Morning vs. evening chronotype;
LUSC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg21665744	chr7:39171113	POU6F2	0.47	7.56	0.38	3.96e-13	IgG glycosylation;
LUSC	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg08213375	chr14:104286397	PPP1R13B	0.35	5.99	0.31	5.55e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg09085632	chr11:111637200	PPP2R1B	0.97	13.84	0.6	9.19e-35	Primary sclerosing cholangitis;
LUSC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14893161	chr1:205819251	PM20D1	-0.56	-8.93	-0.44	2.85e-17	Menarche (age at onset);
LUSC	cis	rs3815700	1.000	rs10404211	chr19:33093565	C/T	cg02997394	chr19:33096574	ANKRD27	0.71	7.11	0.36	7e-12	Eosinophilic esophagitis;
LUSC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg24209194	chr3:40518798	ZNF619	0.48	6.2	0.32	1.64e-9	Renal cell carcinoma;
LUSC	trans	rs6869502	0.871	rs13354207	chr5:110151791	C/G	cg00576301	chr13:36920965	SPG20	-0.46	-6.23	-0.32	1.4e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg22676075	chr6:135203613	NA	0.59	9.41	0.46	8.46e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-0.78	-12.39	-0.56	2.86e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	12.79	0.57	9.56e-31	Lung cancer in ever smokers;
LUSC	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.58	-7.83	-0.39	6.38e-14	Red cell distribution width;
LUSC	cis	rs2274273	0.901	rs12050099	chr14:55764331	G/C	cg04306507	chr14:55594613	LGALS3	0.54	12.17	0.55	1.88e-28	Protein biomarker;
LUSC	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg12165864	chr7:66369176	NA	-0.51	-6.94	-0.35	2.06e-11	Corneal structure;
LUSC	trans	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07923666	chr12:49932857	KCNH3	-0.51	-6.41	-0.33	4.85e-10	Resting heart rate;
LUSC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg09436375	chr6:42928200	GNMT	-0.27	-6.16	-0.32	2.14e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg06521331	chr12:34319734	NA	-0.47	-7.79	-0.39	8.31e-14	Morning vs. evening chronotype;
LUSC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.56	0.65	2.01e-41	Platelet count;
LUSC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.34	-0.42	1.94e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg22782873	chr19:19639568	YJEFN3	-0.43	-6.01	-0.31	4.87e-9	Bipolar disorder;
LUSC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg18305652	chr10:134549665	INPP5A	0.45	6.55	0.34	2.2e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	0.85	14.6	0.62	1.09e-37	Menopause (age at onset);
LUSC	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg05163923	chr11:71159392	DHCR7	-0.67	-9.44	-0.46	6.53e-19	Vitamin D levels;
LUSC	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.52	-13.84	-0.6	9.31e-35	Urate levels in overweight individuals;
LUSC	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.9	20.74	0.75	5.32e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg26127166	chr9:116812388	ZNF618	-0.36	-6.11	-0.32	2.72e-9	Breast cancer;
LUSC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg25072359	chr17:41440525	NA	0.61	8.64	0.43	2.34e-16	Menopause (age at onset);
LUSC	cis	rs62344088	1.000	rs13436694	chr5:122882	A/T	cg22857025	chr5:266934	NA	-0.99	-7.12	-0.36	6.61e-12	Asthma (childhood onset);
LUSC	cis	rs7605827	0.930	rs1035246	chr2:15512891	G/A	cg19274914	chr2:15703543	NA	0.46	8.89	0.44	3.98e-17	Educational attainment (years of education);
LUSC	cis	rs3820928	0.648	rs1997484	chr2:227898962	T/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.8	-0.39	7.86e-14	Pulmonary function;
LUSC	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg05973401	chr12:123451056	ABCB9	0.52	6.43	0.33	4.36e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2120243	0.874	rs2316706	chr3:157160061	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.38	6.18	0.32	1.86e-9	Hepatocellular carcinoma in hepatitis B infection;
LUSC	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg26384229	chr12:38710491	ALG10B	0.74	11.5	0.53	5.04e-26	Morning vs. evening chronotype;
LUSC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg27266060	chr8:22091797	NA	0.39	7.15	0.36	5.38e-12	Hypertriglyceridemia;
LUSC	cis	rs7539409	0.651	rs6696140	chr1:84317468	C/T	cg10977910	chr1:84465055	TTLL7	-0.74	-7.89	-0.4	4.24e-14	Alzheimer's disease;
LUSC	trans	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg06606381	chr12:133084897	FBRSL1	0.44	6.06	0.31	3.71e-9	Depression;
LUSC	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg03684893	chr10:554711	DIP2C	-0.39	-7.09	-0.36	7.89e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg09509183	chr1:209979624	IRF6	0.5	6.02	0.31	4.57e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.73	-0.39	1.26e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs2562456	0.755	rs2650773	chr19:21644088	A/G	cg00806126	chr19:22604979	ZNF98	0.39	6.02	0.31	4.47e-9	Pain;
LUSC	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-0.57	-8.98	-0.44	2.05e-17	Breast cancer;
LUSC	cis	rs2274273	0.967	rs17832359	chr14:55615941	T/C	cg04306507	chr14:55594613	LGALS3	0.55	12.09	0.55	3.69e-28	Protein biomarker;
LUSC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18099408	chr3:52552593	STAB1	-0.44	-6.97	-0.36	1.74e-11	Bipolar disorder;
LUSC	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg05973401	chr12:123451056	ABCB9	0.52	6.49	0.33	3.19e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2230307	0.536	rs482466	chr1:100488177	C/T	cg24955406	chr1:100503596	HIAT1	0.57	6.17	0.32	1.95e-9	Carotid intima media thickness;
LUSC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg23752985	chr2:85803571	VAMP8	0.33	6.36	0.33	6.62e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.71	0.47	8.46e-20	Bipolar disorder;
LUSC	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg12140854	chr5:148520817	ABLIM3	-0.36	-5.88	-0.31	9.93e-9	Breast cancer;
LUSC	cis	rs9905704	0.627	rs1267543	chr17:56656624	A/G	cg12560992	chr17:57184187	TRIM37	-0.53	-6.34	-0.33	7.56e-10	Testicular germ cell tumor;
LUSC	cis	rs56283067	0.847	rs10456536	chr6:44692995	G/C	cg18551225	chr6:44695536	NA	-0.49	-8.27	-0.41	3.22e-15	Total body bone mineral density;
LUSC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs73198271	0.531	rs17154758	chr8:8653343	G/A	cg01851573	chr8:8652454	MFHAS1	0.59	7.77	0.39	9.84e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.0	0.31	5.14e-9	Corneal astigmatism;
LUSC	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.49	7.03	0.36	1.2e-11	Coronary heart disease;
LUSC	trans	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.88	0.35	2.9e-11	Endometrial cancer;
LUSC	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg07169764	chr2:136633963	MCM6	0.68	9.86	0.47	2.7e-20	Mosquito bite size;
LUSC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg26513180	chr16:89883248	FANCA	0.76	5.99	0.31	5.4e-9	Skin colour saturation;
LUSC	cis	rs7264396	0.623	rs6060507	chr20:34198334	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.16	-0.36	5.13e-12	Total cholesterol levels;
LUSC	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg24375607	chr4:120327624	NA	0.72	10.67	0.5	4.5e-23	Corneal astigmatism;
LUSC	cis	rs4948102	0.732	rs6951810	chr7:56076598	T/C	cg17215666	chr7:56131930	SUMF2	0.46	5.85	0.31	1.15e-8	Plasma homocysteine levels (post-methionine load test);
LUSC	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg03929089	chr4:120376271	NA	0.64	5.98	0.31	5.65e-9	Axial length;
LUSC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg13175981	chr1:150552382	MCL1	0.43	6.13	0.32	2.49e-9	Tonsillectomy;
LUSC	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.45	-0.5	2.56e-22	Eye color traits;
LUSC	cis	rs7833986	0.818	rs79824205	chr8:57093233	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.63	9.35	0.46	1.28e-18	Height;
LUSC	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.13	0.41	8.45e-15	Axial length;
LUSC	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg03929089	chr4:120376271	NA	0.74	6.95	0.36	1.87e-11	Axial length;
LUSC	cis	rs4812048	0.649	rs3761255	chr20:57618802	T/C	cg14073986	chr20:57617431	SLMO2	0.88	9.51	0.46	3.89e-19	Mean platelet volume;
LUSC	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg01256987	chr12:42539512	GXYLT1	-0.39	-7.15	-0.36	5.43e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg03713592	chr11:72463424	ARAP1	-0.45	-6.12	-0.32	2.56e-9	Body mass index;
LUSC	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.66	11.48	0.53	6.18e-26	Myeloid white cell count;
LUSC	cis	rs3768617	0.811	rs6424883	chr1:183037695	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.64	0.43	2.29e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg12826209	chr6:26865740	GUSBL1	0.53	7.56	0.38	4.03e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg25736982	chr6:160182554	ACAT2	0.67	9.45	0.46	6.17e-19	Iron status biomarkers;
LUSC	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg25664220	chr3:72788482	NA	0.68	12.12	0.55	2.79e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.06	-0.31	3.67e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.84	-14.63	-0.63	8.26e-38	Cognitive function;
LUSC	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg20587970	chr11:113659929	NA	-1.04	-13.97	-0.61	3.13e-35	Hip circumference adjusted for BMI;
LUSC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg06212747	chr3:49208901	KLHDC8B	0.44	6.1	0.32	2.92e-9	Parkinson's disease;
LUSC	cis	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg01251360	chr16:68772225	CDH1	0.25	6.07	0.32	3.46e-9	Colorectal cancer;
LUSC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg17507749	chr15:85114479	UBE2QP1	0.69	8.7	0.43	1.56e-16	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16761131	chr22:38142377	TRIOBP	-0.42	-6.27	-0.32	1.11e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06112835	chr11:68658793	MRPL21	0.52	8.0	0.4	2.08e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.52	10.42	0.5	3.46e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs2777491	0.874	rs13379756	chr15:41663896	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.71	-12.65	-0.57	3.15e-30	Ulcerative colitis;
LUSC	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.96	0.4	2.72e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2658782	0.724	rs2658769	chr11:93252030	T/C	cg15737290	chr11:93063684	CCDC67	0.6	7.2	0.37	4.13e-12	Pulmonary function decline;
LUSC	cis	rs1784581	1.000	rs1784581	chr6:162401127	A/C	cg17173639	chr6:162384350	PARK2	-0.81	-14.73	-0.63	3.48e-38	Itch intensity from mosquito bite;
LUSC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg25036284	chr2:26402008	FAM59B	0.72	10.36	0.49	5.33e-22	Gut microbiome composition (summer);
LUSC	trans	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg06521331	chr12:34319734	NA	0.4	6.34	0.33	7.28e-10	Bladder cancer;
LUSC	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.69	-0.47	9.75e-20	Total cholesterol levels;
LUSC	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg22139774	chr2:100720529	AFF3	-0.48	-8.28	-0.41	2.96e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.86	0.6	7.72e-35	Blood protein levels;
LUSC	cis	rs554111	0.634	rs7551785	chr1:21524297	C/G	cg01072550	chr1:21505969	NA	-0.4	-6.0	-0.31	5.25e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-7.45	-0.38	8.04e-13	Axial length;
LUSC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg16797656	chr11:68205561	LRP5	0.35	5.87	0.31	1.08e-8	Total body bone mineral density;
LUSC	cis	rs6736093	1.000	rs17779482	chr2:112665677	C/T	cg12686935	chr2:112915763	FBLN7	-0.35	-5.74	-0.3	2.1e-8	Coronary artery disease;
LUSC	cis	rs11608355	1.000	rs2075439	chr12:109859374	A/G	cg19025524	chr12:109796872	NA	-0.38	-6.01	-0.31	4.76e-9	Neuroticism;
LUSC	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.7	0.75	7.91e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg13256891	chr4:100009986	ADH5	0.52	7.21	0.37	3.67e-12	Smoking initiation;
LUSC	cis	rs7106204	0.514	rs10834307	chr11:24272516	G/A	ch.11.24196551F	chr11:24239977	NA	-0.9	-9.82	-0.47	3.71e-20	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2348418	0.864	rs11609924	chr12:28716130	G/A	cg13890972	chr12:28721907	NA	-0.34	-5.81	-0.3	1.49e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg26380479	chr7:97908229	NA	-0.27	-5.86	-0.31	1.13e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2050392	0.965	rs2265370	chr10:30690581	C/T	cg18806716	chr10:30721971	MAP3K8	-0.44	-7.15	-0.36	5.54e-12	Inflammatory bowel disease;
LUSC	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg06112835	chr11:68658793	MRPL21	-0.38	-6.29	-0.33	9.85e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg13628971	chr7:2884303	GNA12	0.39	5.94	0.31	7.19e-9	Height;
LUSC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.84	-0.3	1.21e-8	Personality dimensions;
LUSC	trans	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg25206134	chr2:45395956	NA	0.6	6.51	0.34	2.73e-10	Neuroticism;
LUSC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg17554472	chr22:41940697	POLR3H	-0.48	-5.94	-0.31	7.14e-9	Vitiligo;
LUSC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg00129232	chr17:37814104	STARD3	-0.53	-7.96	-0.4	2.75e-14	Asthma;
LUSC	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg11812906	chr14:75593930	NEK9	-0.63	-10.63	-0.5	6.15e-23	Height;
LUSC	cis	rs17253792	0.822	rs80328469	chr14:56067701	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-6.96	-0.36	1.81e-11	Putamen volume;
LUSC	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg18132916	chr6:79620363	NA	-0.4	-6.13	-0.32	2.43e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.86	-0.35	3.35e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07362569	chr17:61921086	SMARCD2	0.36	7.13	0.36	6.16e-12	Prudent dietary pattern;
LUSC	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg08017756	chr2:100939284	LONRF2	-0.48	-9.06	-0.44	1.09e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08280861	chr8:58055591	NA	0.54	6.14	0.32	2.31e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg16339924	chr4:17578868	LAP3	0.58	8.68	0.43	1.74e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg12559939	chr2:27858050	GPN1	-0.4	-6.13	-0.32	2.48e-9	Oral cavity cancer;
LUSC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg04727924	chr7:799746	HEATR2	-0.51	-6.04	-0.31	4.11e-9	Cerebrospinal P-tau181p levels;
LUSC	trans	rs6601327	0.602	rs7820917	chr8:9647868	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	7.53	0.38	4.64e-13	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-0.89	-17.77	-0.7	3.37e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs13221852	0.659	rs1554502	chr7:3418411	C/T	cg21248987	chr7:3385318	SDK1	0.36	6.03	0.31	4.36e-9	Acute graft versus host disease in bone marrow transplantation (donor effect);
LUSC	cis	rs7539542	0.577	rs6662398	chr1:202888456	T/G	cg19681188	chr1:202830198	LOC148709	0.41	6.08	0.32	3.21e-9	Mean platelet volume;
LUSC	cis	rs4622329	0.572	rs7956803	chr12:102293862	T/G	cg23541617	chr12:102225335	GNPTAB	0.26	6.07	0.32	3.51e-9	Systemic lupus erythematosus;
LUSC	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg13334819	chr7:99746414	C7orf59	-0.51	-6.9	-0.35	2.61e-11	Coronary artery disease;
LUSC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg09796270	chr17:17721594	SREBF1	-0.4	-6.98	-0.36	1.56e-11	Total body bone mineral density;
LUSC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	0.93	15.91	0.66	8.22e-43	Menopause (age at onset);
LUSC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg14004847	chr7:1930337	MAD1L1	0.52	7.66	0.39	2.02e-13	Bipolar disorder and schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02767470	chr2:152663031	ARL5A	-0.43	-6.16	-0.32	2.03e-9	Triglycerides;
LUSC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg07424592	chr7:64974309	NA	-0.63	-5.68	-0.3	2.9e-8	Diabetic kidney disease;
LUSC	trans	rs17039065	0.834	rs12499196	chr4:109425988	T/C	cg07444054	chr2:108107501	NA	0.45	6.29	0.33	1.01e-9	Gut microbiome composition (summer);
LUSC	cis	rs4704187	0.687	rs10051572	chr5:74502797	G/A	cg03227963	chr5:74354835	NA	0.3	6.64	0.34	1.24e-10	Response to amphetamines;
LUSC	cis	rs2294693	0.898	rs6458195	chr6:40972498	A/T	cg14418226	chr6:40996092	UNC5CL	-0.4	-5.82	-0.3	1.4e-8	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg25173405	chr17:45401733	C17orf57	-0.37	-5.72	-0.3	2.37e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg27494647	chr7:150038898	RARRES2	0.51	7.44	0.38	8.79e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9473147	0.543	rs4715025	chr6:47483653	C/G	cg20196966	chr6:47445060	CD2AP	0.41	5.79	0.3	1.66e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg26647111	chr11:31128758	NA	-0.4	-5.79	-0.3	1.6e-8	Red blood cell count;
LUSC	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg08824895	chr13:115047677	UPF3A	0.56	8.8	0.43	7.46e-17	Schizophrenia;
LUSC	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.78	-12.51	-0.56	1.02e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs701145	0.529	rs355746	chr3:153961627	C/G	cg10247383	chr3:153839028	SGEF	-0.5	-6.11	-0.32	2.79e-9	Coronary artery disease;
LUSC	cis	rs9796	0.840	rs1009913	chr15:41331050	C/T	cg18705301	chr15:41695430	NDUFAF1	0.44	7.83	0.39	6.54e-14	Menopause (age at onset);
LUSC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg11247378	chr22:39784982	NA	-0.65	-13.16	-0.58	3.8e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg26513180	chr16:89883248	FANCA	0.51	7.69	0.39	1.65e-13	Vitiligo;
LUSC	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg22496339	chr2:162101262	NA	0.52	7.56	0.38	3.9e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg05347473	chr6:146136440	FBXO30	0.46	7.99	0.4	2.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.77	0.35	5.79e-11	Lung cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09419983	chr3:148847273	HPS3	0.75	6.37	0.33	6.12e-10	Cognitive performance;
LUSC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg05585544	chr11:47624801	NA	0.41	7.19	0.37	4.39e-12	Subjective well-being;
LUSC	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg10909506	chr17:38081995	ORMDL3	0.35	6.16	0.32	2.11e-9	Self-reported allergy;
LUSC	cis	rs9921338	0.961	rs12934968	chr16:11414066	C/A	cg00044050	chr16:11439710	C16orf75	0.5	6.71	0.34	8.3e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg03433033	chr1:76189801	ACADM	0.73	9.65	0.47	1.39e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs2018683	0.677	rs2057956	chr7:28973460	G/A	cg19402173	chr7:128379420	CALU	-0.47	-7.08	-0.36	8.32e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	0.96	13.34	0.59	8.01e-33	Primary sclerosing cholangitis;
LUSC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg02782426	chr3:40428986	ENTPD3	0.32	6.04	0.31	4.03e-9	Renal cell carcinoma;
LUSC	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg01557791	chr16:72042693	DHODH	-0.56	-8.49	-0.42	6.84e-16	Fibrinogen levels;
LUSC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	6.33	0.33	7.68e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg14675211	chr2:100938903	LONRF2	0.37	5.76	0.3	1.89e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9341808	0.754	rs10733162	chr6:81023389	G/A	cg08355045	chr6:80787529	NA	0.56	9.73	0.47	7.43e-20	Sitting height ratio;
LUSC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.7	0.39	1.61e-13	Prudent dietary pattern;
LUSC	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.38	0.59	5.5e-33	Platelet count;
LUSC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs6977660	0.660	rs10253753	chr7:19823032	A/G	cg07541023	chr7:19748670	TWISTNB	0.58	6.24	0.32	1.34e-9	Thyroid stimulating hormone;
LUSC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.22	0.61	3.35e-36	Platelet count;
LUSC	cis	rs1957429	0.614	rs76809238	chr14:65380579	C/T	cg23373153	chr14:65346875	NA	-0.98	-7.73	-0.39	1.3e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20135002	chr11:47629003	NA	-0.48	-7.51	-0.38	5.38e-13	Subjective well-being;
LUSC	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.28	0.45	2.14e-18	Coffee consumption (cups per day);
LUSC	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs17155006	0.638	rs2074747	chr7:107744735	G/A	cg05962710	chr7:107745446	LAMB4	-0.35	-6.13	-0.32	2.52e-9	Pneumococcal bacteremia;
LUSC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg15839431	chr19:19639596	YJEFN3	-0.43	-6.13	-0.32	2.5e-9	Tonsillectomy;
LUSC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg07677032	chr17:61819896	STRADA	0.55	8.97	0.44	2.24e-17	Prudent dietary pattern;
LUSC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg19729930	chr2:74357872	NA	0.93	17.57	0.69	2.03e-49	Gestational age at birth (maternal effect);
LUSC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg16405210	chr4:1374714	KIAA1530	0.55	8.35	0.42	1.81e-15	Obesity-related traits;
LUSC	cis	rs3857536	0.813	rs6455090	chr6:66948909	G/A	cg07460842	chr6:66804631	NA	-0.46	-6.41	-0.33	5.04e-10	Blood trace element (Cu levels);
LUSC	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg27432699	chr2:27873401	GPN1	0.8	14.94	0.63	5.09e-39	Oral cavity cancer;
LUSC	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.66	11.84	0.54	3.02e-27	Itch intensity from mosquito bite;
LUSC	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg27102117	chr16:15229624	NA	0.52	8.12	0.41	8.86e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg13175981	chr1:150552382	MCL1	0.48	6.55	0.34	2.12e-10	Tonsillectomy;
LUSC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg22907277	chr7:1156413	C7orf50	0.49	7.43	0.38	9.12e-13	Longevity;Endometriosis;
LUSC	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg23587288	chr2:27483067	SLC30A3	-0.29	-5.7	-0.3	2.61e-8	Blood metabolite levels;
LUSC	cis	rs2731664	0.792	rs335466	chr5:176889530	C/A	cg23176889	chr5:176863531	GRK6	-0.66	-13.43	-0.59	3.5e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.52	-0.57	9.7e-30	Rheumatoid arthritis;
LUSC	cis	rs4629180	0.675	rs6707298	chr2:102089738	A/G	cg01388757	chr2:102091195	RFX8	0.36	6.26	0.32	1.16e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg26195577	chr20:24973756	C20orf3	-1.12	-18.25	-0.71	4.21e-52	Blood protein levels;
LUSC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg00815214	chr21:47717953	NA	0.42	6.62	0.34	1.45e-10	Testicular germ cell tumor;
LUSC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg08200582	chr11:442649	ANO9	-0.52	-6.02	-0.31	4.59e-9	Body mass index;
LUSC	cis	rs9420	1.000	rs543725	chr11:57483039	A/T	cg02958346	chr11:57425731	CLP1	-0.41	-6.04	-0.31	4.19e-9	Schizophrenia;
LUSC	trans	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg21775007	chr8:11205619	TDH	-0.41	-6.22	-0.32	1.49e-9	Mood instability;
LUSC	trans	rs71435601	0.600	rs502323	chr2:21403297	A/C	cg20757404	chr19:378427	NA	0.38	6.02	0.31	4.71e-9	Cholesterol, total;
LUSC	trans	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.57	0.5	1.01e-22	Mean corpuscular volume;
LUSC	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.04	0.4	1.62e-14	Retinal vascular caliber;
LUSC	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg14690467	chr7:148917905	ZNF282	-0.26	-5.74	-0.3	2.1e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg22709100	chr7:91322751	NA	0.43	6.25	0.32	1.26e-9	Breast cancer;
LUSC	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.46	6.87	0.35	3.24e-11	Schizophrenia;
LUSC	cis	rs7818345	0.935	rs4333618	chr8:19283442	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.39	7.48	0.38	6.81e-13	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg24642439	chr20:33292090	TP53INP2	-0.64	-10.2	-0.49	1.95e-21	Coronary artery disease;
LUSC	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg13010199	chr12:38710504	ALG10B	0.41	5.92	0.31	7.89e-9	Morning vs. evening chronotype;
LUSC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.5	-7.59	-0.38	3.2e-13	Menarche (age at onset);
LUSC	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg11693508	chr17:37793320	STARD3	0.64	7.76	0.39	1.05e-13	Bipolar disorder;
LUSC	cis	rs12421382	0.659	rs1439511	chr11:109392839	G/T	cg27471124	chr11:109292789	C11orf87	-0.49	-8.0	-0.4	2.06e-14	Schizophrenia;
LUSC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg00343986	chr7:65444356	GUSB	-0.43	-6.55	-0.34	2.22e-10	Aortic root size;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27067269	chr10:48355070	ZNF488	0.45	5.98	0.31	5.85e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4954585	0.708	rs13034241	chr2:137021263	G/A	cg05194412	chr2:137003533	NA	0.41	7.57	0.38	3.67e-13	Colorectal cancer;
LUSC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.82	-0.47	3.8e-20	Gut microbiome composition (summer);
LUSC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg16339924	chr4:17578868	LAP3	0.51	7.86	0.4	5.4e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg10729496	chr3:10149963	C3orf24	0.54	7.06	0.36	9.62e-12	Alzheimer's disease;
LUSC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg16362232	chr11:430036	ANO9	0.66	8.29	0.41	2.74e-15	Body mass index;
LUSC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg15001381	chr16:403314	AXIN1	0.33	5.96	0.31	6.56e-9	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs1832871	0.711	rs62439861	chr6:158700531	A/G	cg07165851	chr6:158734300	TULP4	0.5	7.78	0.39	9.42e-14	Height;
LUSC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg00255919	chr5:131827918	IRF1	-0.41	-7.71	-0.39	1.41e-13	Asthma (sex interaction);
LUSC	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-1.13	-18.17	-0.71	8.74e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg11663144	chr21:46675770	NA	-0.32	-5.66	-0.3	3.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg15448220	chr1:150897856	SETDB1	0.42	6.1	0.32	2.93e-9	Melanoma;
LUSC	cis	rs3099143	1.000	rs3110381	chr15:77099665	A/T	cg21673338	chr15:77095150	SCAPER	-0.8	-7.78	-0.39	9.39e-14	Recalcitrant atopic dermatitis;
LUSC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg05187965	chr10:45406764	TMEM72	-0.37	-8.71	-0.43	1.42e-16	Mean corpuscular volume;
LUSC	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05901451	chr6:126070800	HEY2	-0.59	-9.15	-0.45	5.68e-18	Endometrial cancer;
LUSC	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg04369109	chr6:150039330	LATS1	-0.53	-7.3	-0.37	2.15e-12	Lung cancer;
LUSC	cis	rs62458065	1.000	rs979355	chr7:32463933	A/G	cg20159608	chr7:32802032	NA	0.55	6.81	0.35	4.59e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg10207240	chr12:122356781	WDR66	0.46	6.45	0.33	3.84e-10	Mean corpuscular volume;
LUSC	trans	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg25214090	chr10:38739885	LOC399744	0.46	6.63	0.34	1.34e-10	Corneal astigmatism;
LUSC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg14552801	chr7:65878734	NA	-0.36	-5.68	-0.3	2.91e-8	Aortic root size;
LUSC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.86	-0.35	3.27e-11	Lung cancer;
LUSC	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg00042356	chr1:8021962	PARK7	0.77	9.26	0.45	2.61e-18	Inflammatory bowel disease;
LUSC	cis	rs554111	0.571	rs4537519	chr1:21461370	T/C	cg01072550	chr1:21505969	NA	0.39	5.87	0.31	1.07e-8	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	trans	rs694739	0.628	rs645078	chr11:64135298	A/C	cg20325517	chr11:96123557	JRKL;CCDC82	-0.43	-6.03	-0.31	4.34e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs2224391	0.955	rs2773322	chr6:5263065	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.46	-6.61	-0.34	1.55e-10	Height;
LUSC	cis	rs7246967	0.673	rs35335083	chr19:22869592	A/C	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg09699651	chr6:150184138	LRP11	0.45	7.07	0.36	9.31e-12	Lung cancer;
LUSC	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11676348	0.772	rs6738953	chr2:218950036	C/A	cg18102446	chr2:218934044	RUFY4	0.35	5.66	0.3	3.31e-8	Ulcerative colitis;
LUSC	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.19	-0.41	5.56e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	11.91	0.55	1.74e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg11502198	chr6:26597334	ABT1	0.63	9.95	0.48	1.31e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs11608355	0.846	rs12581637	chr12:109855429	G/A	cg19025524	chr12:109796872	NA	-0.39	-5.66	-0.3	3.33e-8	Neuroticism;
LUSC	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg05234568	chr11:5960015	NA	-0.53	-7.4	-0.38	1.13e-12	DNA methylation (variation);
LUSC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-11.18	-0.52	7.15e-25	Chronic sinus infection;
LUSC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.58	7.78	0.39	9.35e-14	High light scatter reticulocyte count;
LUSC	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.92	15.81	0.65	1.92e-42	Bladder cancer;
LUSC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg06740227	chr12:86229804	RASSF9	0.4	6.38	0.33	5.89e-10	Major depressive disorder;
LUSC	cis	rs12681287	0.608	rs13272148	chr8:87481853	T/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.36	6.24e-12	Caudate activity during reward;
LUSC	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg03894339	chr8:19674705	INTS10	0.51	6.83	0.35	4.07e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-9.1	-0.45	8.18e-18	Gut microbiome composition (summer);
LUSC	trans	rs890100	0.642	rs1157475	chr2:56685562	G/C	cg01657744	chr10:88471748	LDB3	0.44	5.97	0.31	6.13e-9	Gut microbiome composition (summer);
LUSC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg12257692	chr3:49977190	RBM6	-0.26	-7.41	-0.38	1.03e-12	Body mass index;
LUSC	cis	rs4423214	0.879	rs1630498	chr11:71150785	A/C	cg05163923	chr11:71159392	DHCR7	-0.67	-9.0	-0.44	1.74e-17	Vitamin D levels;
LUSC	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg11693508	chr17:37793320	STARD3	-0.63	-7.88	-0.4	4.56e-14	Bipolar disorder;
LUSC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-8.82	-0.43	6.4e-17	Personality dimensions;
LUSC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	11.63	0.54	1.71e-26	Personality dimensions;
LUSC	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg16624210	chr5:671434	TPPP	0.5	6.2	0.32	1.63e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg00999904	chr2:3704751	ALLC	0.46	7.52	0.38	5.01e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7336332	0.527	rs1475219	chr13:28037415	A/G	cg22138327	chr13:27999177	GTF3A	0.66	8.69	0.43	1.62e-16	Weight;
LUSC	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18932078	chr1:2524107	MMEL1	0.32	7.08	0.36	8.45e-12	Ulcerative colitis;
LUSC	cis	rs73206853	0.620	rs112599609	chr12:111147643	C/T	cg12870014	chr12:110450643	ANKRD13A	0.67	6.52	0.34	2.64e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2446066	0.520	rs34649330	chr12:53893031	C/T	cg20730629	chr12:53886622	MAP3K12	-0.46	-5.99	-0.31	5.39e-9	Red blood cell count;
LUSC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg25258033	chr6:167368657	RNASET2	-0.47	-7.78	-0.39	9.43e-14	Crohn's disease;
LUSC	cis	rs714027	0.585	rs41157	chr22:30405151	T/C	cg11564601	chr22:30592435	NA	-0.35	-5.92	-0.31	7.84e-9	Lymphocyte counts;
LUSC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs67072384	1.000	rs67075228	chr11:72450775	C/T	cg04827223	chr11:72435913	ARAP1	-0.78	-6.71	-0.34	8.4e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg20203395	chr5:56204925	C5orf35	0.57	8.24	0.41	4.09e-15	Initial pursuit acceleration;
LUSC	cis	rs62432291	0.681	rs402388	chr6:159654994	A/C	cg14500486	chr6:159655392	FNDC1	-0.52	-5.84	-0.3	1.22e-8	Joint mobility (Beighton score);
LUSC	trans	rs61931739	0.546	rs61927758	chr12:33712017	T/C	cg26384229	chr12:38710491	ALG10B	-0.42	-6.12	-0.32	2.68e-9	Morning vs. evening chronotype;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13608629	chr2:70531203	NA	0.44	6.18	0.32	1.87e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg26924012	chr15:45694286	SPATA5L1	0.78	12.28	0.56	7.55e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs73001065	0.818	rs73004975	chr19:19727152	A/G	cg03709012	chr19:19516395	GATAD2A	0.89	7.2	0.37	4.1e-12	LDL cholesterol;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10130860	chr1:43124230	PPIH	0.44	6.82	0.35	4.29e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	8.86	0.44	4.77e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg00520135	chr15:63333846	TPM1	-0.34	-6.84	-0.35	3.88e-11	Platelet count;
LUSC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25072359	chr17:41440525	NA	0.64	9.06	0.44	1.15e-17	Menopause (age at onset);
LUSC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.2	-0.45	3.89e-18	Platelet count;
LUSC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg10802521	chr3:52805072	NEK4	-0.38	-5.77	-0.3	1.76e-8	Electroencephalogram traits;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg13986881	chr7:73669141	RFC2	0.4	6.31	0.33	8.81e-10	Schizophrenia;
LUSC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	6.64	0.34	1.28e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.73	-0.57	1.58e-30	Alzheimer's disease;
LUSC	cis	rs79149102	0.737	rs7163332	chr15:75193623	C/T	cg09165964	chr15:75287851	SCAMP5	-0.79	-6.39	-0.33	5.6e-10	Lung cancer;
LUSC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.69	0.47	1.01e-19	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs62400317	0.859	rs10948214	chr6:45170466	T/C	cg20913747	chr6:44695427	NA	-0.48	-7.69	-0.39	1.66e-13	Total body bone mineral density;
LUSC	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.75	-14.52	-0.62	2.21e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12379764	chr21:47803548	PCNT	-0.42	-5.96	-0.31	6.38e-9	Testicular germ cell tumor;
LUSC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg24881330	chr22:46731750	TRMU	0.85	8.39	0.42	1.38e-15	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg15133208	chr4:90757351	SNCA	-0.32	-5.66	-0.3	3.23e-8	Dementia with Lewy bodies;
LUSC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg14784868	chr12:69753453	YEATS4	0.64	9.59	0.46	2.07e-19	Blood protein levels;
LUSC	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-5.95	-0.31	6.82e-9	Schizophrenia;
LUSC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.69	-10.74	-0.51	2.71e-23	Aortic root size;
LUSC	cis	rs6977660	1.000	rs1468288	chr7:19810580	C/G	cg05791153	chr7:19748676	TWISTNB	0.63	6.85	0.35	3.55e-11	Thyroid stimulating hormone;
LUSC	cis	rs8056893	0.550	rs9923188	chr16:68311867	G/T	cg02226672	chr16:68398533	SMPD3	0.29	5.67	0.3	3.06e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	13.27	0.59	1.48e-32	Electrocardiographic conduction measures;
LUSC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13126279	chr21:47581558	C21orf56	-0.46	-6.89	-0.35	2.85e-11	Testicular germ cell tumor;
LUSC	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg10253484	chr15:75165896	SCAMP2	0.41	5.84	0.3	1.22e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs3754214	0.823	rs496203	chr1:150270025	A/G	cg15654264	chr1:150340011	RPRD2	-0.45	-7.4	-0.38	1.09e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg14530993	chr4:882597	GAK	0.66	6.67	0.34	1.09e-10	Parkinson's disease;
LUSC	cis	rs7830933	0.955	rs57220043	chr8:23602763	A/T	cg04349084	chr8:23602677	NA	0.38	6.02	0.31	4.7e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUSC	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg04352962	chr1:209979756	IRF6	0.55	6.37	0.33	6.41e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	1.04	19.64	0.73	1.23e-57	Menopause (age at onset);
LUSC	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg09998033	chr7:158218633	PTPRN2	-0.53	-8.58	-0.42	3.63e-16	Obesity-related traits;
LUSC	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.64	-0.43	2.38e-16	Total cholesterol levels;
LUSC	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg02655711	chr22:19163373	SLC25A1	0.56	10.24	0.49	1.42e-21	Metabolite levels;
LUSC	cis	rs6977660	0.714	rs10950753	chr7:19817302	G/A	cg07541023	chr7:19748670	TWISTNB	0.61	6.57	0.34	1.91e-10	Thyroid stimulating hormone;
LUSC	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg21427119	chr20:30132790	HM13	-0.41	-6.07	-0.32	3.47e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg08470875	chr2:26401718	FAM59B	-0.69	-9.34	-0.46	1.39e-18	Gut microbiome composition (summer);
LUSC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg03146154	chr1:46216737	IPP	-0.56	-8.13	-0.41	8.36e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1451375	0.729	rs6593017	chr7:50644812	G/A	cg18232548	chr7:50535776	DDC	0.5	7.58	0.38	3.49e-13	Malaria;
LUSC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	0.88	15.87	0.66	1.19e-42	Cognitive function;
LUSC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg19468946	chr17:37922297	IKZF3	-0.44	-6.92	-0.35	2.33e-11	Self-reported allergy;
LUSC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00166722	chr3:10149974	C3orf24	0.6	7.91	0.4	3.74e-14	Alzheimer's disease;
LUSC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	12.56	0.57	6.47e-30	Alzheimer's disease;
LUSC	cis	rs9341808	0.622	rs684283	chr6:80967317	T/G	cg08355045	chr6:80787529	NA	-0.41	-6.87	-0.35	3.16e-11	Sitting height ratio;
LUSC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg18758796	chr5:131593413	PDLIM4	-0.4	-6.53	-0.34	2.45e-10	Breast cancer;
LUSC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	13.63	0.6	6.19e-34	Platelet count;
LUSC	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.19	0.32	1.74e-9	Neuroticism;
LUSC	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg12564285	chr5:131593104	PDLIM4	0.46	8.53	0.42	5.28e-16	Blood metabolite levels;
LUSC	cis	rs1018697	1.000	rs7911528	chr10:104551567	A/G	cg04362960	chr10:104952993	NT5C2	0.47	6.43	0.33	4.37e-10	Colorectal adenoma (advanced);
LUSC	cis	rs12620999	0.774	rs6711726	chr2:238101795	C/T	cg23555395	chr2:238036564	NA	-0.32	-5.69	-0.3	2.72e-8	Systemic lupus erythematosus;
LUSC	cis	rs1335645	0.570	rs56200127	chr1:111628519	G/A	cg00321911	chr1:111669324	DRAM2	-0.62	-6.49	-0.33	3.04e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg23630131	chr7:65973040	NA	-0.21	-5.79	-0.3	1.66e-8	Aortic root size;
LUSC	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg18721089	chr20:30220636	NA	-0.38	-6.13	-0.32	2.54e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	15.06	0.64	1.8e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.06	-0.31	3.71e-9	Total body bone mineral density;
LUSC	cis	rs7903847	0.642	rs11189204	chr10:99164394	C/T	cg08345082	chr10:99160200	RRP12	-0.35	-7.25	-0.37	2.93e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.45	0.86	2.28e-98	Chronic sinus infection;
LUSC	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg17644776	chr2:200775616	C2orf69	0.36	5.68	0.3	2.89e-8	Osteoporosis;
LUSC	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.63	-9.13	-0.45	6.82e-18	HIV-1 control;
LUSC	trans	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.09	-0.36	8.24e-12	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg07727134	chr12:120222632	CIT	-0.42	-6.55	-0.34	2.21e-10	N-glycan levels;
LUSC	cis	rs3106136	0.933	rs35718240	chr4:95164030	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.1	-0.32	2.9e-9	Capecitabine sensitivity;
LUSC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg12863693	chr15:85201151	NMB	-0.26	-5.98	-0.31	5.71e-9	P wave terminal force;
LUSC	cis	rs3136441	0.901	rs11039002	chr11:46857279	T/C	cg01183595	chr11:46746236	F2	0.38	5.72	0.3	2.33e-8	HDL cholesterol;
LUSC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.49	-0.33	3.03e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs977987	0.806	rs7204984	chr16:75475520	G/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.16	-0.36	5.2e-12	Dupuytren's disease;
LUSC	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg21775007	chr8:11205619	TDH	0.44	6.28	0.32	1.06e-9	Mood instability;
LUSC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg13393036	chr8:95962371	TP53INP1	-0.45	-9.35	-0.46	1.28e-18	Type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21871394	chr19:50380797	AKT1S1;TBC1D17	0.43	6.26	0.32	1.19e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7804356	1.000	rs3801820	chr7:26861353	A/G	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.05e-9	Type 1 diabetes;
LUSC	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.96	-0.44	2.36e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg14092571	chr14:90743983	NA	-0.35	-5.71	-0.3	2.45e-8	Mortality in heart failure;
LUSC	cis	rs9920506	0.536	rs12441998	chr15:78929372	G/A	cg04896959	chr15:78267971	NA	0.38	6.84	0.35	3.75e-11	Post bronchodilator FEV1;
LUSC	cis	rs2046867	0.818	rs1502754	chr3:72895345	G/T	cg25664220	chr3:72788482	NA	-0.6	-10.35	-0.49	5.89e-22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9311676	0.609	rs11921259	chr3:58368646	A/G	cg26110898	chr3:58419937	PDHB	0.44	7.18	0.37	4.67e-12	Systemic lupus erythematosus;
LUSC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	7.72	0.39	1.36e-13	Bipolar disorder;
LUSC	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.95	0.51	4.59e-24	Hypertriglyceridemia;
LUSC	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg01629716	chr15:45996671	NA	0.4	6.12	0.32	2.57e-9	Waist circumference;Weight;
LUSC	cis	rs11792861	0.566	rs67780641	chr9:111850710	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	7.08	0.36	8.49e-12	Menarche (age at onset);
LUSC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg17294928	chr15:75287854	SCAMP5	-0.76	-10.12	-0.48	3.67e-21	Blood trace element (Zn levels);
LUSC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.08	-0.4	1.21e-14	Chronic sinus infection;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22470056	chr3:49947811	MON1A	0.39	5.96	0.31	6.45e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04039784	chr16:68877714	TMCO7	0.68	6.0	0.31	5.27e-9	Cognitive performance;
LUSC	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg24812749	chr6:127587940	RNF146	0.73	10.31	0.49	8.33e-22	Breast cancer;
LUSC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	7.23	0.37	3.41e-12	Rheumatoid arthritis;
LUSC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg05585544	chr11:47624801	NA	-0.42	-7.18	-0.37	4.55e-12	Subjective well-being;
LUSC	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg08999081	chr20:33150536	PIGU	0.32	5.65	0.3	3.51e-8	Height;
LUSC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	6.43	0.33	4.39e-10	Obesity-related traits;
LUSC	cis	rs2979489	0.891	rs16877096	chr8:30364388	T/C	cg26383811	chr8:30366931	RBPMS	-0.49	-7.66	-0.39	2.03e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.95	0.31	6.94e-9	Lung cancer;
LUSC	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg14458575	chr2:238380390	NA	0.68	11.98	0.55	9.46e-28	Prostate cancer;
LUSC	cis	rs400736	0.602	rs4573544	chr1:8165247	C/T	cg25007680	chr1:8021821	PARK7	-0.46	-6.82	-0.35	4.36e-11	Response to antidepressants and depression;
LUSC	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.53	-8.05	-0.4	1.5e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	9.09	0.45	8.83e-18	Total body bone mineral density;
LUSC	cis	rs3771570	0.901	rs9052	chr2:242434809	G/T	cg21155796	chr2:242212141	HDLBP	0.53	6.17	0.32	1.98e-9	Prostate cancer;
LUSC	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.58	0.34	1.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-8.3	-0.41	2.7e-15	Obesity-related traits;
LUSC	cis	rs6977660	1.000	rs10249989	chr7:19822296	A/G	cg05791153	chr7:19748676	TWISTNB	0.53	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LUSC	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg20283391	chr11:68216788	NA	-0.61	-8.55	-0.42	4.43e-16	Total body bone mineral density;
LUSC	cis	rs12620999	0.941	rs10929215	chr2:238037456	G/A	cg23555395	chr2:238036564	NA	-0.53	-8.91	-0.44	3.32e-17	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08677398	chr8:58056175	NA	0.58	6.95	0.36	1.96e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg02605672	chr17:80854741	TBCD	-0.41	-6.5	-0.34	3.01e-10	N-glycan levels;
LUSC	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg16512390	chr1:228756714	NA	0.67	8.42	0.42	1.09e-15	Chronic lymphocytic leukemia;
LUSC	cis	rs12136530	0.774	rs10442634	chr1:19775246	C/T	cg01832549	chr1:19774989	CAPZB	-0.32	-5.94	-0.31	7.33e-9	Lead levels in blood;
LUSC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg15691649	chr6:25882328	NA	-0.48	-6.53	-0.34	2.51e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg21827317	chr3:136751795	NA	0.39	6.95	0.36	1.97e-11	Neuroticism;
LUSC	cis	rs9443189	0.526	rs6902898	chr6:76201856	G/A	cg01950844	chr6:76311363	SENP6	0.68	6.81	0.35	4.62e-11	Prostate cancer;
LUSC	cis	rs12956009	0.583	rs9653016	chr18:44894189	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.14	0.32	2.36e-9	Educational attainment (years of education);
LUSC	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.46	-5.65	-0.3	3.44e-8	Menarche (age at onset);
LUSC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg13047869	chr3:10149882	C3orf24	0.63	8.73	0.43	1.21e-16	Alzheimer's disease;
LUSC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	7.71	0.39	1.41e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20068463	chr7:148725962	PDIA4	0.39	6.13	0.32	2.52e-9	Asthma;
LUSC	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.54	-0.34	2.27e-10	Retinal vascular caliber;
LUSC	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg05163923	chr11:71159392	DHCR7	0.74	11.05	0.52	2.15e-24	Vitamin D levels;
LUSC	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg21545522	chr1:205238299	TMCC2	0.46	8.69	0.43	1.7e-16	Red blood cell count;
LUSC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	0.87	16.76	0.68	3.62e-46	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg03929089	chr4:120376271	NA	-0.63	-9.02	-0.44	1.49e-17	Coronary artery disease;
LUSC	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg07080220	chr10:102295463	HIF1AN	0.59	7.61	0.38	2.86e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.7	11.66	0.54	1.34e-26	Heart rate;
LUSC	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg05714579	chr10:131428358	MGMT	-0.43	-6.19	-0.32	1.81e-9	Response to temozolomide;
LUSC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26314531	chr2:26401878	FAM59B	-0.7	-9.76	-0.47	5.69e-20	Gut microbiome composition (summer);
LUSC	cis	rs714027	1.000	rs1003342	chr22:30570022	A/G	cg11564601	chr22:30592435	NA	0.37	6.86	0.35	3.33e-11	Lymphocyte counts;
LUSC	cis	rs72781680	0.752	rs55859418	chr2:23904231	C/A	cg08917208	chr2:24149416	ATAD2B	0.98	9.69	0.47	9.64e-20	Lymphocyte counts;
LUSC	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg09904177	chr6:26538194	HMGN4	-0.48	-7.42	-0.38	9.66e-13	Schizophrenia;
LUSC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg10792982	chr14:105748885	BRF1	0.51	9.42	0.46	7.53e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg23752985	chr2:85803571	VAMP8	0.32	6.59	0.34	1.71e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2013441	0.866	rs2526492	chr17:20095615	C/A	cg04132472	chr17:19861366	AKAP10	-0.35	-5.69	-0.3	2.83e-8	Obesity-related traits;
LUSC	cis	rs16986825	0.570	rs5752822	chr22:29266025	A/G	cg02153584	chr22:29168773	CCDC117	0.54	6.3	0.33	9.2e-10	Pancreatic cancer;
LUSC	cis	rs12286929	0.699	rs1048932	chr11:115044850	C/A	cg04055981	chr11:115044050	NA	-0.38	-6.59	-0.34	1.67e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6906287	0.647	rs12660455	chr6:118717382	C/T	cg21191810	chr6:118973309	C6orf204	0.34	6.12	0.32	2.69e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg11632617	chr15:75315747	PPCDC	-0.52	-6.8	-0.35	4.83e-11	Blood trace element (Zn levels);
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg11965913	chr1:205819406	PM20D1	0.92	18.96	0.72	6.41e-55	Menarche (age at onset);
LUSC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg00310523	chr12:86230176	RASSF9	-0.43	-7.91	-0.4	3.85e-14	Major depressive disorder;
LUSC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg27266027	chr21:40555129	PSMG1	-0.39	-5.68	-0.3	2.97e-8	Cognitive function;
LUSC	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg19700328	chr14:106028568	NA	0.37	6.37	0.33	6.43e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg17178900	chr1:205818956	PM20D1	0.44	6.23	0.32	1.44e-9	Prostate-specific antigen levels;
LUSC	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg16989719	chr2:238392110	NA	-0.45	-7.32	-0.37	1.9e-12	Prostate cancer;
LUSC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg11062466	chr8:58055876	NA	0.68	9.07	0.44	1.05e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg06134567	chr22:46658398	PKDREJ	-0.46	-5.65	-0.3	3.37e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg05472934	chr7:22766657	IL6	0.51	8.28	0.41	2.92e-15	Lung cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17105206	chr16:67211972	KIAA0895L	-0.49	-6.14	-0.32	2.38e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11645453	chr3:52864694	ITIH4	0.38	8.65	0.43	2.25e-16	Bipolar disorder;
LUSC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.14	-0.41	7.98e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg26647111	chr11:31128758	NA	-0.42	-6.0	-0.31	5.03e-9	Red blood cell count;
LUSC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg15557168	chr22:42548783	NA	-0.37	-6.24	-0.32	1.31e-9	Cognitive function;
LUSC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.28	-5.7	-0.3	2.64e-8	Crohn's disease;
LUSC	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.63	8.33	0.41	2.13e-15	High light scatter reticulocyte count;
LUSC	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.92	0.35	2.34e-11	Educational attainment;
LUSC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05535760	chr7:792225	HEATR2	0.78	9.17	0.45	5.01e-18	Cerebrospinal P-tau181p levels;
LUSC	trans	rs10432489	0.572	rs4346342	chr2:181706206	G/A	cg01101058	chr14:70235157	SFRS5;LOC100289511	0.54	6.02	0.31	4.55e-9	QT interval;
LUSC	cis	rs73198271	0.545	rs78352360	chr8:8627831	G/A	cg01851573	chr8:8652454	MFHAS1	0.63	7.36	0.37	1.45e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg04944784	chr2:26401820	FAM59B	-0.74	-10.43	-0.5	3.01e-22	Gut microbiome composition (summer);
LUSC	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg25173405	chr17:45401733	C17orf57	0.4	6.42	0.33	4.81e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7923609	0.902	rs7897379	chr10:65301725	T/C	cg01631684	chr10:65280961	REEP3	-0.41	-6.37	-0.33	6.16e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.42	0.69	8.19e-49	Chronic sinus infection;
LUSC	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg00083206	chr6:110721305	DDO	-0.47	-8.55	-0.42	4.63e-16	Platelet distribution width;
LUSC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg27535305	chr1:53392650	SCP2	0.36	6.78	0.35	5.43e-11	Monocyte count;
LUSC	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.8	-0.39	8.25e-14	Neuroticism;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg01125463	chr6:42946178	PEX6	-0.38	-6.23	-0.32	1.44e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00166722	chr3:10149974	C3orf24	0.58	7.81	0.39	7.42e-14	Alzheimer's disease;
LUSC	cis	rs10186029	0.509	rs10203749	chr2:213935855	T/A	cg08319019	chr2:214017104	IKZF2	-0.41	-6.03	-0.31	4.3e-9	Systemic sclerosis;
LUSC	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.65	-0.43	2.25e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs965469	0.779	rs6139048	chr20:3239753	T/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.68	-0.3	2.88e-8	IFN-related cytopenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16919317	chr8:120868184	DSCC1	-0.39	-6.19	-0.32	1.74e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg17366294	chr4:99064904	C4orf37	0.56	8.86	0.44	4.88e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg21251018	chr6:28226885	NKAPL	0.33	6.21	0.32	1.55e-9	Cardiac Troponin-T levels;
LUSC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg26695010	chr11:65641043	EFEMP2	-0.46	-7.03	-0.36	1.17e-11	Eosinophil percentage of white cells;
LUSC	cis	rs5771069	0.931	rs5771222	chr22:50445704	C/T	cg27068297	chr22:50451975	IL17REL	-0.29	-5.97	-0.31	6.05e-9	Ulcerative colitis;
LUSC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	0.67	11.88	0.55	2.12e-27	Gestational age at birth (maternal effect);
LUSC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.68	9.18	0.45	4.58e-18	Menarche (age at onset);
LUSC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg00343986	chr7:65444356	GUSB	-0.42	-6.38	-0.33	6.07e-10	Aortic root size;
LUSC	cis	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05901451	chr6:126070800	HEY2	0.57	8.61	0.43	2.85e-16	Endometrial cancer;
LUSC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg04369109	chr6:150039330	LATS1	-0.59	-8.65	-0.43	2.27e-16	Lung cancer;
LUSC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg09509183	chr1:209979624	IRF6	-0.45	-6.75	-0.35	6.63e-11	Monobrow;
LUSC	cis	rs775227	0.574	rs13067967	chr3:113265215	C/G	cg18753928	chr3:113234510	CCDC52	-0.46	-6.43	-0.33	4.38e-10	Dental caries;
LUSC	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	7.11	0.36	6.9e-12	Protein C levels;
LUSC	cis	rs662064	0.962	rs648399	chr1:10556485	T/C	cg20482658	chr1:10539492	PEX14	-0.31	-6.57	-0.34	1.96e-10	Asthma;
LUSC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.4	0.56	2.61e-29	Prudent dietary pattern;
LUSC	cis	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg06521331	chr12:34319734	NA	-0.48	-7.69	-0.39	1.65e-13	Morning vs. evening chronotype;
LUSC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg12564285	chr5:131593104	PDLIM4	-0.35	-6.58	-0.34	1.83e-10	Blood metabolite levels;
LUSC	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg25237894	chr2:233734115	C2orf82	-0.32	-5.91	-0.31	8.41e-9	Coronary artery disease;
LUSC	cis	rs11608355	0.515	rs2287184	chr12:109970251	T/C	cg05360138	chr12:110035743	NA	0.92	12.2	0.56	1.48e-28	Neuroticism;
LUSC	trans	rs72674100	1.000	rs28504129	chr4:97990879	G/A	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs16976116	0.855	rs28522816	chr15:55495114	C/G	cg11288833	chr15:55489084	RSL24D1	0.49	5.8	0.3	1.53e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7149337	0.809	rs10134478	chr14:51693708	G/C	cg23942311	chr14:51606299	NA	0.48	10.51	0.5	1.59e-22	Cancer;
LUSC	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg02023728	chr11:77925099	USP35	0.53	7.55	0.38	4.11e-13	Testicular germ cell tumor;
LUSC	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg17691542	chr6:26056736	HIST1H1C	0.47	7.03	0.36	1.19e-11	Height;
LUSC	cis	rs7707921	1.000	rs749402	chr5:81561325	C/T	cg15871215	chr5:81402204	ATG10	-0.43	-6.25	-0.32	1.29e-9	Breast cancer;
LUSC	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.92	-0.44	3.02e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg12744634	chr1:26560303	CCDC21	0.39	5.88	0.31	1.01e-8	Obesity-related traits;
LUSC	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	8.53	0.42	5.05e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03264133	chr6:25882463	NA	-0.4	-7.02	-0.36	1.25e-11	Height;
LUSC	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg27219399	chr15:67835830	MAP2K5	0.34	5.66	0.3	3.33e-8	Restless legs syndrome;
LUSC	cis	rs4588572	0.643	rs1159929	chr5:77768820	A/G	cg11547950	chr5:77652471	NA	0.48	6.88	0.35	2.92e-11	Triglycerides;
LUSC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg10360139	chr7:1886902	MAD1L1	-0.44	-6.77	-0.35	5.8e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs17092148	0.945	rs6058115	chr20:33358397	T/G	cg16810054	chr20:33298113	TP53INP2	-0.43	-6.81	-0.35	4.68e-11	Neuroticism;
LUSC	cis	rs4654899	0.865	rs3856173	chr1:21114833	C/T	cg01072550	chr1:21505969	NA	-0.47	-7.0	-0.36	1.43e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.11	0.36	7.29e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs483069	0.933	rs487638	chr1:34422278	C/T	cg03916189	chr9:132360049	NA	0.39	6.48	0.33	3.26e-10	Depressive symptoms (SSRI exposure interaction);
LUSC	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg20701182	chr2:24300061	SF3B14	0.76	7.73	0.39	1.26e-13	Lymphocyte counts;
LUSC	cis	rs7590368	0.673	rs17365181	chr2:10937980	T/C	cg15705551	chr2:10952987	PDIA6	0.52	5.78	0.3	1.7e-8	Educational attainment (years of education);
LUSC	cis	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg11548914	chr2:179343871	FKBP7;PLEKHA3;MIR548N	-0.55	-6.87	-0.35	3.07e-11	Atrial fibrillation;
LUSC	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg00310523	chr12:86230176	RASSF9	0.44	8.2	0.41	5.3e-15	Major depressive disorder;
LUSC	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg03563238	chr19:33554763	RHPN2	-0.4	-6.23	-0.32	1.43e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg24399712	chr22:39784796	NA	0.63	11.93	0.55	1.49e-27	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg25258033	chr6:167368657	RNASET2	0.44	6.69	0.34	9.54e-11	Crohn's disease;
LUSC	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.75	14.7	0.63	4.6e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6987853	0.830	rs12542919	chr8:42356035	C/T	cg09913449	chr8:42400586	C8orf40	-0.41	-6.76	-0.35	6.35e-11	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9807989	0.524	rs4851576	chr2:103028895	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.14e-12	Asthma;
LUSC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg12412775	chr1:25698385	RHCE	-0.29	-5.86	-0.31	1.1e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs2901656	0.546	rs9425598	chr1:172371922	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.36	7.11	0.36	7.21e-12	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg24558204	chr6:135376177	HBS1L	0.6	9.41	0.46	8.48e-19	Red blood cell count;
LUSC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-9.33	-0.45	1.48e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg12826209	chr6:26865740	GUSBL1	0.64	5.69	0.3	2.74e-8	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.74	-0.35	7.03e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06505273	chr16:24850292	NA	0.4	5.76	0.3	1.94e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg00933542	chr6:150070202	PCMT1	0.34	7.02	0.36	1.25e-11	Lung cancer;
LUSC	cis	rs7789940	0.817	rs6946310	chr7:75936099	T/C	cg15798862	chr7:76129360	DTX2	-0.43	-6.91	-0.35	2.39e-11	Multiple sclerosis;
LUSC	cis	rs3770081	1.000	rs76297018	chr2:86227007	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.0	-6.48	-0.33	3.38e-10	Facial emotion recognition (sad faces);
LUSC	trans	rs417096	0.893	rs302602	chr6:39732663	T/C	cg17457912	chr17:1617102	C17orf91	-0.33	-6.4	-0.33	5.3e-10	Hypospadias;
LUSC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.9	0.61	5.49e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9549260	0.755	rs2721071	chr13:41144507	G/A	cg21288729	chr13:41239152	FOXO1	0.57	8.75	0.43	1.05e-16	Red blood cell count;
LUSC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg00750074	chr16:89608354	SPG7	-0.46	-8.05	-0.4	1.46e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg15423357	chr2:25149977	NA	0.43	8.54	0.42	4.92e-16	Body mass index;
LUSC	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg06784218	chr1:46089804	CCDC17	0.35	6.04	0.31	4.14e-9	Platelet count;
LUSC	cis	rs11650494	0.908	rs57390430	chr17:47374886	G/A	cg08112188	chr17:47440006	ZNF652	1.18	10.16	0.49	2.53e-21	Prostate cancer;
LUSC	trans	rs459571	0.959	rs460888	chr9:136913123	C/G	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.43	-6.13	-0.32	2.48e-9	Platelet distribution width;
LUSC	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17467752	chr17:38218738	THRA	-0.7	-11.29	-0.53	2.96e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg03522245	chr20:25566470	NINL	-0.35	-5.71	-0.3	2.45e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.92	-0.35	2.28e-11	Menopause (age at onset);
LUSC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18932078	chr1:2524107	MMEL1	0.28	6.07	0.32	3.54e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg25019777	chr4:53525403	USP46	0.39	6.25	0.32	1.27e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg04315214	chr1:2043799	PRKCZ	0.46	9.51	0.46	3.79e-19	Height;
LUSC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg18681998	chr4:17616180	MED28	-0.86	-16.14	-0.66	1.03e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg20476274	chr7:133979776	SLC35B4	0.84	15.6	0.65	1.33e-41	Mean platelet volume;
LUSC	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg05360138	chr12:110035743	NA	0.38	5.77	0.3	1.84e-8	Neuroticism;
LUSC	cis	rs12422267	0.536	rs11831679	chr12:132609960	C/T	cg26561844	chr12:132562101	EP400	-0.54	-5.71	-0.3	2.54e-8	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg08807101	chr21:30365312	RNF160	-0.53	-6.68	-0.34	9.85e-11	Cognitive test performance;
LUSC	cis	rs11031096	0.727	rs12290828	chr11:4144867	C/G	cg18678763	chr11:4115507	RRM1	-0.49	-7.25	-0.37	2.98e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-0.63	-13.3	-0.59	1.08e-32	Prudent dietary pattern;
LUSC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.94	0.31	7.29e-9	Personality dimensions;
LUSC	cis	rs8038465	0.592	rs1542580	chr15:73935834	C/G	cg15420318	chr15:73925796	NPTN	0.58	10.11	0.48	3.77e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10875746	0.903	rs10875738	chr12:48473739	T/A	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	trans	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg05267876	chr1:229644265	NUP133	-0.49	-6.2	-0.32	1.67e-9	Parkinson's disease;
LUSC	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg02018176	chr4:1364513	KIAA1530	-0.46	-6.4	-0.33	5.39e-10	Recombination rate (females);
LUSC	trans	rs6076960	0.629	rs6054024	chr20:6229282	A/C	cg17788362	chr6:86352627	SYNCRIP	0.42	6.13	0.32	2.51e-9	Smooth-surface caries;
LUSC	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19717773	chr7:2847554	GNA12	-0.36	-6.18	-0.32	1.9e-9	Height;
LUSC	cis	rs12210905	0.688	rs10456051	chr6:27463436	T/C	cg08851530	chr6:28072375	NA	0.93	5.71	0.3	2.47e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs9921338	0.961	rs4356497	chr16:11414196	C/G	cg00044050	chr16:11439710	C16orf75	0.49	6.58	0.34	1.77e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg05110241	chr16:68378359	PRMT7	-0.53	-6.54	-0.34	2.25e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg07606381	chr6:8435919	SLC35B3	-0.51	-7.83	-0.39	6.41e-14	Motion sickness;
LUSC	cis	rs72634258	0.842	rs7545745	chr1:8165667	T/A	cg00042356	chr1:8021962	PARK7	-0.54	-6.8	-0.35	4.87e-11	Inflammatory bowel disease;
LUSC	cis	rs13089785	1.000	rs13089785	chr3:123653909	A/C	cg02558132	chr3:123411198	MYLK	0.35	6.11	0.32	2.78e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2625529	0.824	rs7172309	chr15:72384483	C/T	cg16672083	chr15:72433130	SENP8	-0.52	-7.59	-0.38	3.22e-13	Red blood cell count;
LUSC	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg04511125	chr2:88470314	THNSL2	-0.43	-6.49	-0.33	3.15e-10	Response to metformin (IC50);
LUSC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg24733560	chr20:60626293	TAF4	0.35	5.75	0.3	1.98e-8	Body mass index;
LUSC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg03161606	chr19:29218774	NA	0.62	8.83	0.44	6.02e-17	Methadone dose in opioid dependence;
LUSC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg18904891	chr8:8559673	CLDN23	0.59	8.07	0.4	1.25e-14	Obesity-related traits;
LUSC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg18402987	chr7:1209562	NA	0.69	7.41	0.38	1.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg07148914	chr20:33460835	GGT7	0.55	8.42	0.42	1.16e-15	Height;
LUSC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg23758822	chr17:41437982	NA	1.0	19.2	0.72	7.15e-56	Menopause (age at onset);
LUSC	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg13073564	chr4:8508604	NA	-0.49	-9.23	-0.45	3.23e-18	Response to antineoplastic agents;
LUSC	cis	rs11637445	0.677	rs10152422	chr15:68102929	C/T	cg08079166	chr15:68083412	MAP2K5	-0.38	-7.81	-0.39	7.45e-14	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg13206674	chr6:150067644	NUP43	0.59	9.28	0.45	2.26e-18	Lung cancer;
LUSC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg09640425	chr7:158790006	NA	0.4	6.46	0.33	3.8e-10	Facial morphology (factor 20);
LUSC	cis	rs36093844	0.800	rs112468922	chr11:85576694	A/G	cg25872744	chr11:85566296	CCDC83	-0.46	-6.15	-0.32	2.26e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.48	-6.4	-0.33	5.17e-10	Tonsillectomy;
LUSC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg00509249	chr6:109615579	CCDC162	-0.32	-5.85	-0.3	1.19e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs12545109	0.613	rs10958480	chr8:57278717	A/T	cg09654669	chr8:57350985	NA	-0.44	-5.93	-0.31	7.46e-9	Obesity-related traits;
LUSC	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.44	6.68	0.34	1.02e-10	Breast cancer;
LUSC	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21659725	chr3:3221576	CRBN	0.62	10.41	0.49	3.63e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg23229984	chr5:148520753	ABLIM3	0.41	6.45	0.33	3.99e-10	Breast cancer;
LUSC	cis	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg26958806	chr6:27640298	NA	0.74	6.04	0.31	4.02e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4290604	0.748	rs7594554	chr2:238065981	A/G	cg23555395	chr2:238036564	NA	-0.47	-6.34	-0.33	7.5e-10	Asthma;
LUSC	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg24579218	chr15:68104479	NA	-0.39	-6.31	-0.33	9.08e-10	Restless legs syndrome;
LUSC	trans	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.66	-11.59	-0.54	2.39e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg23630131	chr7:65973040	NA	-0.21	-5.93	-0.31	7.77e-9	Aortic root size;
LUSC	cis	rs11945232	1.000	rs6854710	chr4:88334640	A/G	cg23841344	chr4:88312519	HSD17B11	-0.69	-10.72	-0.51	3.14e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21171335	chr12:122356390	WDR66	0.58	8.84	0.44	5.4e-17	Mean corpuscular volume;
LUSC	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg03806693	chr22:41940476	POLR3H	0.92	13.27	0.59	1.42e-32	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06544989	chr22:39130855	UNC84B	0.32	5.72	0.3	2.39e-8	Menopause (age at onset);
LUSC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3771570	0.901	rs3821285	chr2:242421314	A/G	cg21155796	chr2:242212141	HDLBP	-0.49	-5.96	-0.31	6.46e-9	Prostate cancer;
LUSC	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.47	0.59	2.57e-33	Morning vs. evening chronotype;
LUSC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg12639453	chr1:2035780	PRKCZ	-0.34	-7.17	-0.37	4.97e-12	Height;
LUSC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.67	8.12	0.41	9.05e-15	Lung function (FEV1/FVC);
LUSC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg02534363	chr3:47050950	NBEAL2	0.38	6.16	0.32	2.09e-9	Colorectal cancer;
LUSC	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.19	0.32	1.73e-9	Diisocyanate-induced asthma;
LUSC	trans	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg18187862	chr3:45730750	SACM1L	-0.51	-6.17	-0.32	1.99e-9	Primary sclerosing cholangitis;
LUSC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg26338869	chr17:61819248	STRADA	0.4	5.77	0.3	1.81e-8	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg17366294	chr4:99064904	C4orf37	0.57	9.91	0.48	1.88e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-9.54	-0.46	3.07e-19	Eye color traits;
LUSC	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg18230493	chr5:56204884	C5orf35	-0.55	-8.84	-0.44	5.44e-17	Breast cancer;Breast cancer (early onset);
LUSC	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.07	14.17	0.61	5.24e-36	Uric acid levels;
LUSC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.36e-12	Motion sickness;
LUSC	cis	rs2652834	0.851	rs4775625	chr15:63410577	G/A	cg05507819	chr15:63340323	TPM1	0.45	5.68	0.3	2.9e-8	HDL cholesterol;
LUSC	cis	rs317865	0.737	rs28483204	chr4:16205098	A/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.61	5.79	0.3	1.6e-8	Kidney disease (early stage) in type 1 diabetes;
LUSC	cis	rs6700896	0.897	rs1938494	chr1:66117691	G/T	cg04111102	chr1:66153794	NA	0.32	7.1	0.36	7.54e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg27284194	chr4:1044797	NA	0.36	5.91	0.31	8.46e-9	Longevity;
LUSC	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg01557791	chr16:72042693	DHODH	-0.56	-8.1	-0.41	1.03e-14	Fibrinogen levels;
LUSC	cis	rs2235649	0.798	rs78540053	chr16:1853275	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-6.01	-0.31	4.92e-9	Blood metabolite levels;
LUSC	cis	rs748404	0.697	rs530188	chr15:43545314	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.42	6.04	0.31	4.03e-9	Lung cancer;
LUSC	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.39	0.46	9.94e-19	Coffee consumption (cups per day);
LUSC	cis	rs12195417	0.603	rs9350981	chr6:84200221	C/T	cg08257003	chr6:84140564	ME1	0.3	7.01	0.36	1.33e-11	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.65	0.34	1.19e-10	Lung cancer;
LUSC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.79	0.43	7.99e-17	Schizophrenia;
LUSC	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg21951975	chr1:209979733	IRF6	0.56	6.8	0.35	4.91e-11	Coronary artery disease;
LUSC	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-10.6	-0.5	7.74e-23	Monocyte percentage of white cells;
LUSC	cis	rs7523050	0.643	rs35438081	chr1:109402831	G/T	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg22491629	chr6:157744540	C6orf35	-0.62	-7.86	-0.4	5.48e-14	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.32	-0.33	8.21e-10	Bipolar disorder;
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg04234412	chr22:24373322	LOC391322	-0.86	-13.97	-0.61	3.02e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg00376283	chr12:123451042	ABCB9	0.69	10.67	0.5	4.56e-23	Platelet count;
LUSC	cis	rs952623	0.649	rs17171519	chr7:39060312	T/C	cg15212455	chr7:39170539	POU6F2	0.37	6.03	0.31	4.45e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.34	-0.46	1.38e-18	Brugada syndrome;
LUSC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs7929679	0.521	rs10768097	chr11:34792902	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.91	0.31	8.29e-9	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04228274	chr13:21751145	MRP63;SKA3	-0.51	-6.07	-0.32	3.57e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs6600671	1.000	rs11249350	chr1:121178446	C/T	cg00646200	chr1:148855367	NA	0.45	7.09	0.36	8.01e-12	Hip geometry;
LUSC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06221963	chr1:154839813	KCNN3	-0.61	-13.83	-0.6	1.06e-34	Prostate cancer;
LUSC	cis	rs2463822	0.925	rs1528730	chr11:62081181	A/C	cg06239285	chr11:62104954	ASRGL1	0.95	10.47	0.5	2.18e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.71	0.3	2.47e-8	Tonsillectomy;
LUSC	cis	rs12900413	0.687	rs28653538	chr15:90304964	T/C	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.4e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg11645453	chr3:52864694	ITIH4	0.32	7.34	0.37	1.6e-12	Electroencephalogram traits;
LUSC	cis	rs10426930	0.700	rs7253212	chr19:5021391	G/A	cg25246084	chr19:4971487	KDM4B	-0.34	-6.2	-0.32	1.65e-9	Monocyte percentage of white cells;
LUSC	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg18105134	chr13:113819100	PROZ	-0.68	-9.6	-0.47	1.9e-19	Platelet distribution width;
LUSC	trans	rs8026898	0.961	rs7170107	chr15:70010647	C/T	cg27385734	chr18:15003734	NA	0.31	6.15	0.32	2.17e-9	Rheumatoid arthritis;
LUSC	cis	rs1453414	1	rs1453414	chr11:5829084	G/C	cg13902645	chr11:5959945	NA	-0.54	-6.03	-0.31	4.37e-9	Oral cavity and pharyngeal cancer;Oropharynx cancer;
LUSC	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg04036182	chr15:45458818	NA	0.35	5.74	0.3	2.13e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg07460842	chr6:66804631	NA	0.89	9.06	0.44	1.1e-17	Exhaled nitric oxide output;
LUSC	cis	rs500891	0.574	rs10455419	chr6:84154242	T/G	cg08257003	chr6:84140564	ME1	0.37	9.09	0.45	8.78e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg09034736	chr1:150693464	HORMAD1	0.44	6.16	0.32	2.05e-9	Melanoma;
LUSC	cis	rs9314323	0.964	rs3808576	chr8:26266834	G/A	cg13160058	chr8:26243215	BNIP3L	-0.41	-7.46	-0.38	7.53e-13	Red cell distribution width;
LUSC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24110177	chr3:50126178	RBM5	-0.55	-8.85	-0.44	5.15e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs6489882	0.867	rs2384072	chr12:113367422	T/C	cg20102336	chr12:113376681	OAS3	-0.4	-5.74	-0.3	2.17e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg08508325	chr11:3079039	CARS	0.39	8.73	0.43	1.2e-16	Calcium levels;
LUSC	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.69	-0.34	9.56e-11	Retinal vascular caliber;
LUSC	cis	rs12464559	0.522	rs4316939	chr2:152525120	C/T	cg01189475	chr2:152685088	ARL5A	-0.59	-6.37	-0.33	6.31e-10	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg12935359	chr14:103987150	CKB	-0.51	-7.82	-0.39	6.85e-14	Body mass index;
LUSC	cis	rs7572644	0.766	rs1350481	chr2:28185808	G/C	cg27432699	chr2:27873401	GPN1	-0.52	-6.46	-0.33	3.72e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-6.18	-0.32	1.82e-9	Total body bone mineral density;
LUSC	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.72	0.39	1.33e-13	Corneal astigmatism;
LUSC	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.33e-21	Lymphocyte counts;
LUSC	cis	rs2282300	0.739	rs2225909	chr11:30329744	T/C	cg25418670	chr11:30344373	C11orf46	0.64	9.23	0.45	3.29e-18	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg05340658	chr4:99064831	C4orf37	0.65	10.9	0.51	7.24e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2573652	1.000	rs2573651	chr15:100514109	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.42	-7.74	-0.39	1.19e-13	Height;
LUSC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00149659	chr3:10157352	C3orf10	1.0	13.2	0.59	2.59e-32	Alzheimer's disease;
LUSC	cis	rs6076065	0.548	rs6048740	chr20:23325047	G/A	cg11657817	chr20:23433608	CST11	0.49	9.74	0.47	6.78e-20	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg11247378	chr22:39784982	NA	-0.62	-11.22	-0.52	5.2e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg01770232	chr7:22766155	IL6	0.4	5.66	0.3	3.24e-8	Lung cancer;
LUSC	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg22906224	chr7:99728672	NA	-0.47	-6.52	-0.34	2.56e-10	Coronary artery disease;
LUSC	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg23625390	chr15:77176239	SCAPER	0.48	7.24	0.37	3.12e-12	Blood metabolite levels;
LUSC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg02423579	chr7:2872169	GNA12	-0.47	-6.73	-0.35	7.52e-11	Height;
LUSC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.7	12.62	0.57	3.9e-30	Prudent dietary pattern;
LUSC	cis	rs28595532	0.748	rs115651241	chr4:119363509	C/T	cg02775129	chr4:119771670	NA	-0.79	-6.58	-0.34	1.81e-10	Cannabis dependence symptom count;
LUSC	cis	rs4845459	0.933	rs6700181	chr1:152593087	A/G	cg08895932	chr1:152778580	LCE1C	-0.38	-6.53	-0.34	2.46e-10	Psoriasis;
LUSC	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg21153622	chr11:89784906	NA	-0.39	-5.98	-0.31	5.58e-9	HDL cholesterol;
LUSC	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg00677455	chr12:58241039	CTDSP2	-0.38	-5.75	-0.3	2.07e-8	Multiple sclerosis;
LUSC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	19.1	0.72	1.79e-55	Chronic sinus infection;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01809437	chr16:84695622	KLHL36	0.45	6.07	0.32	3.44e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg00852783	chr1:26633632	UBXN11	0.48	5.87	0.31	1.06e-8	Obesity-related traits;
LUSC	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	6.6	0.34	1.57e-10	Resting heart rate;
LUSC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21963583	chr11:68658836	MRPL21	0.54	8.26	0.41	3.37e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08736216	chr1:53307985	ZYG11A	0.3	6.19	0.32	1.73e-9	Monocyte count;
LUSC	trans	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg26384229	chr12:38710491	ALG10B	0.56	8.69	0.43	1.66e-16	Morning vs. evening chronotype;
LUSC	cis	rs9359856	0.564	rs913425	chr6:90256934	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.47	-5.76	-0.3	1.93e-8	Bipolar disorder;
LUSC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg05064044	chr6:292385	DUSP22	-0.5	-7.1	-0.36	7.77e-12	Menopause (age at onset);
LUSC	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg24634471	chr8:143751801	JRK	0.5	7.18	0.37	4.56e-12	Schizophrenia;
LUSC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12756686	chr19:29218302	NA	0.67	9.61	0.47	1.85e-19	Methadone dose in opioid dependence;
LUSC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg05025164	chr4:1340916	KIAA1530	0.51	8.3	0.41	2.61e-15	Obesity-related traits;
LUSC	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg04865166	chr7:105162814	PUS7	0.51	5.7	0.3	2.65e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg17366294	chr4:99064904	C4orf37	0.59	10.56	0.5	1.13e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg01879757	chr17:41196368	BRCA1	-0.46	-7.1	-0.36	7.49e-12	Menopause (age at onset);
LUSC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg21972741	chr5:435613	AHRR	0.36	6.84	0.35	3.82e-11	Cystic fibrosis severity;
LUSC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg18904891	chr8:8559673	CLDN23	0.6	8.13	0.41	8.6e-15	Obesity-related traits;
LUSC	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg16342193	chr10:102329863	NA	-0.35	-6.22	-0.32	1.53e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.42	0.33	4.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg03146154	chr1:46216737	IPP	0.5	7.46	0.38	7.53e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg00191853	chr8:101177733	SPAG1	0.35	5.73	0.3	2.23e-8	Atrioventricular conduction;
LUSC	cis	rs9341808	0.718	rs9361584	chr6:80819946	G/C	cg08355045	chr6:80787529	NA	0.56	9.6	0.46	2.04e-19	Sitting height ratio;
LUSC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06505273	chr16:24850292	NA	0.39	5.76	0.3	1.91e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1062746	0.711	rs8056833	chr16:87378388	G/C	cg02258303	chr16:87377426	FBXO31	-0.57	-9.29	-0.45	2.07e-18	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs2348418	0.864	rs7304776	chr12:28713567	C/A	cg13890972	chr12:28721907	NA	-0.34	-5.81	-0.3	1.48e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs6942756	0.876	rs822040	chr7:129065922	C/G	cg02491457	chr7:128862824	NA	0.39	5.76	0.3	1.91e-8	White matter hyperintensity burden;
LUSC	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg06552810	chr11:31128660	NA	-0.42	-7.35	-0.37	1.5e-12	Red blood cell count;
LUSC	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	cg07049167	chr1:166818506	POGK	0.54	8.16	0.41	6.71e-15	Refractive astigmatism;
LUSC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg04450456	chr4:17643702	FAM184B	0.38	6.55	0.34	2.12e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12220238	1.000	rs7096553	chr10:75957835	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.14	0.36	5.87e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg01191920	chr7:158217561	PTPRN2	0.46	9.14	0.45	6.05e-18	Obesity-related traits;
LUSC	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg20243544	chr17:37824526	PNMT	0.5	7.06	0.36	9.93e-12	Asthma;
LUSC	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg04455712	chr21:45112962	RRP1B	0.43	8.08	0.4	1.17e-14	Mean corpuscular volume;
LUSC	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg04362960	chr10:104952993	NT5C2	0.57	8.26	0.41	3.53e-15	Arsenic metabolism;
LUSC	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg22676075	chr6:135203613	NA	0.47	7.35	0.37	1.52e-12	Red blood cell count;
LUSC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg12564285	chr5:131593104	PDLIM4	0.47	8.25	0.41	3.63e-15	Breast cancer;
LUSC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.19e-10	Alzheimer's disease (late onset);
LUSC	trans	rs2262909	0.925	rs73019838	chr19:22247732	T/A	cg05197062	chr11:11642011	GALNTL4	0.57	7.89	0.4	4.43e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9398803	0.865	rs9375442	chr6:126803137	A/C	cg19875578	chr6:126661172	C6orf173	0.41	5.93	0.31	7.66e-9	Male-pattern baldness;
LUSC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.18	30.08	0.85	4.31e-97	Testicular germ cell tumor;
LUSC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.79	14.23	0.61	2.92e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs6469656	1.000	rs4422805	chr8:117651299	C/T	cg24004040	chr8:117650383	NA	-0.43	-6.22	-0.32	1.46e-9	Colorectal cancer;
LUSC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-9.86	-0.47	2.64e-20	Gut microbiome composition (summer);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07564088	chr5:95170684	NA	0.72	5.96	0.31	6.45e-9	Cognitive performance;
LUSC	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.59	-0.34	1.72e-10	Breast cancer;
LUSC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg24578937	chr1:2090814	PRKCZ	0.43	9.42	0.46	7.54e-19	Height;
LUSC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg11062466	chr8:58055876	NA	0.46	6.51	0.34	2.76e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7589342	0.792	rs13426321	chr2:106500280	G/A	cg16077055	chr2:106428750	NCK2	0.34	6.29	0.33	1.02e-9	Addiction;
LUSC	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.35	-0.46	1.34e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg09650180	chr20:62225654	GMEB2	-0.68	-9.73	-0.47	7.21e-20	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUSC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg16606324	chr3:10149918	C3orf24	0.64	9.55	0.46	2.89e-19	Alzheimer's disease;
LUSC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg13683864	chr3:40499215	RPL14	-1.11	-21.85	-0.77	2.39e-66	Renal cell carcinoma;
LUSC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg05552183	chr6:42928497	GNMT	0.48	8.13	0.41	8.59e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg00950971	chr10:72015325	NPFFR1	-0.37	-5.96	-0.31	6.51e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-9.7	-0.47	9.52e-20	Morning vs. evening chronotype;
LUSC	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.67	-11.89	-0.55	2.05e-27	Electrocardiographic conduction measures;
LUSC	cis	rs4682868	0.581	rs13068366	chr3:42922020	G/A	cg21365077	chr3:42922735	NA	0.42	5.91	0.31	8.52e-9	Monocyte percentage of white cells;
LUSC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.34	0.59	7.79e-33	Cognitive test performance;
LUSC	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	1.12	19.09	0.72	1.96e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs113835537	0.529	rs2277302	chr11:66240882	T/C	cg24851651	chr11:66362959	CCS	0.56	8.68	0.43	1.76e-16	Airway imaging phenotypes;
LUSC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-8.15	-0.41	7.15e-15	Hemoglobin concentration;
LUSC	cis	rs2658782	0.654	rs2248531	chr11:93255363	G/T	cg15737290	chr11:93063684	CCDC67	0.59	7.67	0.39	1.89e-13	Pulmonary function decline;
LUSC	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.24	-0.41	3.96e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	7.05	0.36	1.05e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg02153584	chr22:29168773	CCDC117	0.65	10.25	0.49	1.24e-21	Lymphocyte counts;
LUSC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg15147215	chr3:52552868	STAB1	-0.33	-6.62	-0.34	1.45e-10	Bipolar disorder;
LUSC	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg25382214	chr1:3105252	PRDM16	-0.3	-5.85	-0.3	1.18e-8	Migraine;
LUSC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.58	8.21	0.41	4.83e-15	Diastolic blood pressure;
LUSC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg12639453	chr1:2035780	PRKCZ	0.29	6.05	0.31	3.9e-9	Height;
LUSC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.63	0.85	1.69e-95	Chronic sinus infection;
LUSC	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg00277334	chr10:82204260	NA	-0.49	-7.15	-0.36	5.4e-12	Post bronchodilator FEV1;
LUSC	cis	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg01251360	chr16:68772225	CDH1	-0.26	-6.2	-0.32	1.62e-9	Colorectal cancer;
LUSC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-1.1	-22.22	-0.77	8.57e-68	Coronary artery disease;
LUSC	trans	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.63	10.48	0.5	2.11e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23158103	chr7:148848205	ZNF398	-0.49	-8.02	-0.4	1.74e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg13010199	chr12:38710504	ALG10B	0.54	8.5	0.42	6.35e-16	Morning vs. evening chronotype;
LUSC	trans	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg17675199	chr6:35436792	RPL10A	-0.41	-6.01	-0.31	4.89e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-12.95	-0.58	2.27e-31	Platelet count;
LUSC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg21724239	chr8:58056113	NA	0.8	8.44	0.42	9.52e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7577851	0.625	rs67560216	chr2:69584616	C/A	cg10773587	chr2:69614142	GFPT1	0.57	6.24	0.32	1.29e-9	Parkinson's disease (age of onset);
LUSC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg22601191	chr20:60968625	CABLES2	0.56	9.67	0.47	1.11e-19	Colorectal cancer;
LUSC	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-7.1	-0.36	7.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg22903657	chr4:1355424	KIAA1530	-0.48	-8.05	-0.4	1.42e-14	Obesity-related traits;
LUSC	cis	rs2637266	0.967	rs12244619	chr10:78352502	C/T	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg13010199	chr12:38710504	ALG10B	0.59	9.1	0.45	8.57e-18	Bladder cancer;
LUSC	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.97	-0.4	2.56e-14	Morning vs. evening chronotype;
LUSC	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg12091567	chr17:66097778	LOC651250	0.92	14.26	0.62	2.34e-36	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg01884057	chr2:25150051	NA	0.46	10.95	0.51	4.75e-24	Body mass index;
LUSC	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.34	-0.33	7.63e-10	Lung cancer;
LUSC	cis	rs13223928	0.565	rs10240820	chr7:3154415	T/C	cg19214707	chr7:3157722	NA	-0.49	-9.38	-0.46	1.05e-18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.47	0.42	7.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs12406019	0.510	rs2025614	chr1:78618151	G/A	cg20826526	chr3:156266748	SSR3	-0.44	-6.61	-0.34	1.52e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg22535103	chr8:58192502	C8orf71	-0.79	-8.4	-0.42	1.28e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.52	-8.31	-0.41	2.39e-15	Facial morphology (factor 20);
LUSC	cis	rs6845621	0.782	rs1377149	chr4:18917722	A/G	cg12196642	chr4:18937545	NA	-0.34	-6.46	-0.33	3.75e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg04362960	chr10:104952993	NT5C2	0.6	9.63	0.47	1.5700000000000001e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg21466736	chr12:48725269	NA	-0.32	-5.71	-0.3	2.56e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs983392	0.836	rs12453	chr11:59945745	T/C	cg20284999	chr11:59952153	MS4A6A	-0.38	-6.36	-0.33	6.59e-10	Alzheimer's disease (late onset);
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-0.43	-7.18	-0.37	4.58e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg23711669	chr6:146136114	FBXO30	0.88	16.07	0.66	1.92e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg00509249	chr6:109615579	CCDC162	-0.34	-6.12	-0.32	2.55e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg15352829	chr14:105391018	PLD4	-0.42	-8.71	-0.43	1.42e-16	Rheumatoid arthritis;
LUSC	cis	rs7945718	0.967	rs10741602	chr11:12761699	A/T	cg25843174	chr11:12811716	TEAD1	0.32	7.07	0.36	9.39e-12	Educational attainment (years of education);
LUSC	cis	rs7110373	1	rs7110373	chr11:122813224	C/T	cg27398637	chr11:122830231	C11orf63	-0.39	-6.44	-0.33	4.05e-10	Age at voice drop;
LUSC	trans	rs2392780	0.536	rs400818	chr8:128336546	T/C	cg10897648	chr18:56338258	MALT1	-0.42	-6.38	-0.33	5.94e-10	Breast cancer (early onset);
LUSC	cis	rs9815354	0.767	rs73071337	chr3:41822518	G/C	cg03022575	chr3:42003672	ULK4	0.85	8.65	0.43	2.27e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg09455208	chr3:40491958	NA	0.54	9.48	0.46	4.72e-19	Renal cell carcinoma;
LUSC	cis	rs7264396	0.573	rs55969606	chr20:34075688	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.32	-0.33	8.54e-10	Total cholesterol levels;
LUSC	cis	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs9341808	0.754	rs9361591	chr6:80953255	C/A	cg08355045	chr6:80787529	NA	0.56	9.66	0.47	1.22e-19	Sitting height ratio;
LUSC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg23985595	chr17:80112537	CCDC57	0.3	5.79	0.3	1.66e-8	Life satisfaction;
LUSC	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg04989706	chr14:50066350	PPIL5	-0.45	-6.03	-0.31	4.36e-9	Carotid intima media thickness;
LUSC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg06238570	chr21:40685208	BRWD1	0.46	7.05	0.36	1.04e-11	Cognitive function;
LUSC	cis	rs2742417	0.603	rs2742453	chr3:45765858	G/A	cg04837898	chr3:45731254	SACM1L	-0.45	-7.21	-0.37	3.71e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	1.19	16.22	0.66	5.02e-44	Eosinophil percentage of granulocytes;
LUSC	trans	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg07393940	chr7:158741817	NA	0.38	6.88	0.35	2.93e-11	Life satisfaction;
LUSC	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg16482183	chr6:26056742	HIST1H1C	0.43	6.45	0.33	3.96e-10	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22429776	chr1:113162371	ST7L;CAPZA1	-0.39	-6.28	-0.32	1.06e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg26395211	chr5:140044315	WDR55	-0.38	-5.84	-0.3	1.27e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.64	0.39	2.27e-13	Prudent dietary pattern;
LUSC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg13206674	chr6:150067644	NUP43	0.63	10.24	0.49	1.38e-21	Lung cancer;
LUSC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg01097406	chr16:89675127	NA	-0.35	-7.04	-0.36	1.09e-11	Vitiligo;
LUSC	cis	rs12801636	0.512	rs11227247	chr11:65422853	A/C	cg24147428	chr11:65409760	SIPA1	-0.51	-6.03	-0.31	4.3e-9	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	7.9	0.4	4.01e-14	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17189058	chr2:70418126	C2orf42	-0.42	-6.06	-0.31	3.68e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1044826	0.642	rs295473	chr3:139215585	T/C	cg15131784	chr3:139108705	COPB2	0.39	6.36	0.33	6.82e-10	Obesity-related traits;
LUSC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg08470875	chr2:26401718	FAM59B	-0.65	-8.68	-0.43	1.74e-16	Gut microbiome composition (summer);
LUSC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.42	-0.33	4.76e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg00277334	chr10:82204260	NA	-0.6	-9.94	-0.48	1.5e-20	Post bronchodilator FEV1;
LUSC	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	13.38	0.59	5.34e-33	Blood protein levels;
LUSC	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg27529037	chr20:44575021	PCIF1	0.41	7.12	0.36	6.68e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg16384552	chr7:74938386	SPDYE8P	-0.49	-7.07	-0.36	8.87e-12	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.51	0.46	3.83e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg01097406	chr16:89675127	NA	0.33	6.84	0.35	3.71e-11	Vitiligo;
LUSC	trans	rs941408	0.515	rs759067	chr19:2775668	C/T	cg22153745	chr1:153894579	GATAD2B	-0.51	-6.94	-0.36	2.09e-11	Total cholesterol levels;
LUSC	cis	rs2652834	1.000	rs34575783	chr15:63397686	G/C	cg05507819	chr15:63340323	TPM1	0.69	8.32	0.41	2.22e-15	HDL cholesterol;
LUSC	cis	rs240764	0.817	rs239206	chr6:101137332	T/G	cg09795085	chr6:101329169	ASCC3	0.42	6.17	0.32	2.01e-9	Neuroticism;
LUSC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg21918786	chr6:109611834	NA	0.4	7.08	0.36	8.81e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	12.63	0.57	3.6e-30	Bipolar disorder;
LUSC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg11752832	chr7:134001865	SLC35B4	0.54	7.92	0.4	3.61e-14	Mean platelet volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00840257	chr16:8963031	CARHSP1	-0.49	-6.37	-0.33	6.24e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.28	-0.45	2.14e-18	Schizophrenia;
LUSC	cis	rs4947962	0.648	rs76692262	chr7:55089831	A/G	cg23757825	chr7:55092271	EGFR	-0.66	-8.4	-0.42	1.25e-15	Subjective response to lithium treatment;
LUSC	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17916960	chr15:79447300	NA	-0.53	-10.55	-0.5	1.24e-22	Refractive error;
LUSC	cis	rs16895831	0.519	rs16895856	chr6:42564921	A/C	cg10605015	chr6:42532144	UBR2	-0.49	-5.98	-0.31	5.69e-9	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg13010199	chr12:38710504	ALG10B	-0.53	-8.18	-0.41	6.13e-15	Morning vs. evening chronotype;
LUSC	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg18964960	chr10:1102726	WDR37	-0.43	-5.84	-0.3	1.27e-8	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs7582720	1.000	rs72926787	chr2:203818299	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.55	0.53	3.4e-26	Coffee consumption (cups per day);
LUSC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg17507749	chr15:85114479	UBE2QP1	0.68	8.57	0.42	3.92e-16	Schizophrenia;
LUSC	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg13010199	chr12:38710504	ALG10B	0.54	8.3	0.41	2.53e-15	Morning vs. evening chronotype;
LUSC	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg08392591	chr16:89556376	ANKRD11	0.39	5.75	0.3	1.97e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12379764	chr21:47803548	PCNT	-0.47	-6.79	-0.35	5.12e-11	Testicular germ cell tumor;
LUSC	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg03522245	chr20:25566470	NINL	0.35	5.69	0.3	2.82e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg13736514	chr6:26305472	NA	-0.49	-9.53	-0.46	3.35e-19	Educational attainment;
LUSC	cis	rs73416724	1.000	rs17209407	chr6:43358362	A/G	cg26312998	chr6:43337775	ZNF318	0.57	6.72	0.34	8.1e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.64	10.28	0.49	1.03e-21	Morning vs. evening chronotype;
LUSC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg09034736	chr1:150693464	HORMAD1	0.4	5.72	0.3	2.34e-8	Melanoma;
LUSC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg13047869	chr3:10149882	C3orf24	-0.42	-6.66	-0.34	1.11e-10	Alzheimer's disease;
LUSC	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg22529645	chr1:3704559	LRRC47	0.35	6.54	0.34	2.25e-10	Red cell distribution width;
LUSC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.36e-8	Lung cancer;
LUSC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.87	13.7	0.6	3.27e-34	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11158026	0.546	rs8011446	chr14:55425913	C/G	cg04306507	chr14:55594613	LGALS3	0.35	6.15	0.32	2.17e-9	Parkinson's disease;
LUSC	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg18681998	chr4:17616180	MED28	-0.88	-15.29	-0.64	2.29e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs11743006	0.626	rs56352214	chr5:136506500	G/A	cg07379741	chr17:7311030	NLGN2	0.41	6.11	0.32	2.82e-9	Mathematical ability;
LUSC	cis	rs6942756	1.000	rs2103232	chr7:128951232	G/T	cg02491457	chr7:128862824	NA	-0.48	-6.57	-0.34	1.92e-10	White matter hyperintensity burden;
LUSC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.03	0.44	1.37e-17	Motion sickness;
LUSC	cis	rs62400317	0.762	rs12209944	chr6:44788156	G/C	cg18551225	chr6:44695536	NA	-0.47	-7.21	-0.37	3.74e-12	Total body bone mineral density;
LUSC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21724239	chr8:58056113	NA	0.85	9.53	0.46	3.26e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	0.96	16.31	0.67	2.17e-44	Menopause (age at onset);
LUSC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.6	0.57	4.77e-30	Motion sickness;
LUSC	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg05855489	chr10:104503620	C10orf26	0.47	7.2	0.37	4.12e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg02466173	chr16:30829666	NA	-0.53	-10.22	-0.49	1.58e-21	Dementia with Lewy bodies;
LUSC	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	1.06	14.42	0.62	5.65e-37	Exhaled nitric oxide levels;
LUSC	cis	rs9815354	0.812	rs73071315	chr3:41805887	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.52	0.42	5.39e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg20936604	chr3:58311152	NA	-0.72	-6.92	-0.35	2.36e-11	Cholesterol, total;
LUSC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg26116260	chr4:7069785	GRPEL1	1.1	15.44	0.65	5.63e-41	Monocyte percentage of white cells;
LUSC	cis	rs400736	0.729	rs9434948	chr1:8004963	A/C	cg25007680	chr1:8021821	PARK7	-0.49	-7.21	-0.37	3.83e-12	Response to antidepressants and depression;
LUSC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.57	-8.56	-0.42	4.16e-16	Gut microbiome composition (summer);
LUSC	cis	rs1358748	0.522	rs1885276	chr1:67568824	G/T	cg02640540	chr1:67518911	SLC35D1	0.58	5.97	0.31	6.09e-9	Tuberculosis;
LUSC	cis	rs10276303	0.519	rs6462035	chr7:3397101	G/A	cg21248987	chr7:3385318	SDK1	-0.39	-6.6	-0.34	1.66e-10	Dupuytren's disease;
LUSC	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg14092571	chr14:90743983	NA	-0.35	-5.83	-0.3	1.29e-8	Mortality in heart failure;
LUSC	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg15485101	chr11:133734466	NA	0.4	7.23	0.37	3.23e-12	Childhood ear infection;
LUSC	cis	rs4654899	0.758	rs6668370	chr1:21369568	C/T	cg01072550	chr1:21505969	NA	-0.53	-8.14	-0.41	8.09e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.57	0.38	3.58e-13	Prudent dietary pattern;
LUSC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg10556349	chr10:835070	NA	0.56	6.19	0.32	1.72e-9	Eosinophil percentage of granulocytes;
LUSC	trans	rs236907	0.859	rs17650310	chr1:171757204	A/G	cg13482142	chr2:234261155	NA	0.48	5.95	0.31	6.7e-9	Mean platelet volume;
LUSC	cis	rs4974559	0.790	rs11933855	chr4:1315183	C/T	cg02980000	chr4:1222292	CTBP1	0.77	8.91	0.44	3.38e-17	Systolic blood pressure;
LUSC	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg11845111	chr2:191398756	TMEM194B	-0.84	-10.9	-0.51	6.99e-24	Diastolic blood pressure;
LUSC	cis	rs17767294	0.541	rs72845051	chr6:27610545	G/A	cg08851530	chr6:28072375	NA	0.9	6.3	0.33	9.55e-10	Parkinson's disease;
LUSC	cis	rs1507153	0.847	rs9361422	chr6:79377738	C/G	cg05283184	chr6:79620031	NA	-0.42	-7.09	-0.36	7.92e-12	Sjögren's syndrome;
LUSC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg22800045	chr5:56110881	MAP3K1	0.71	7.59	0.38	3.32e-13	Type 2 diabetes;
LUSC	cis	rs7215564	0.818	rs4889878	chr17:78662479	G/T	cg09596252	chr17:78655493	RPTOR	0.54	5.86	0.31	1.13e-8	Myopia (pathological);
LUSC	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg23093090	chr10:104574429	C10orf26	-0.38	-7.12	-0.36	6.8e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08470875	chr2:26401718	FAM59B	0.68	9.16	0.45	5.31e-18	Gut microbiome composition (summer);
LUSC	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg22491629	chr6:157744540	C6orf35	-0.92	-10.95	-0.51	4.68e-24	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg23306229	chr2:178417860	TTC30B	-0.55	-5.74	-0.3	2.1e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg21770322	chr7:97807741	LMTK2	0.4	7.03	0.36	1.19e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06748231	chr5:1112251	SLC12A7	-0.51	-6.23	-0.32	1.42e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.58	-9.16	-0.45	5.28e-18	Lymphocyte counts;
LUSC	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.95	-0.31	6.64e-9	Alcohol dependence;
LUSC	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg24011408	chr12:48396354	COL2A1	-0.39	-5.67	-0.3	3.01e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7560272	0.513	rs7558546	chr2:73937732	A/T	cg20560298	chr2:73613845	ALMS1	0.42	6.31	0.33	9.04e-10	Schizophrenia;
LUSC	cis	rs11030122	0.604	rs10835557	chr11:4083121	A/G	cg08557956	chr11:4115526	RRM1	-0.45	-5.94	-0.31	7.02e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.68	9.59	0.46	2.11e-19	Methadone dose in opioid dependence;
LUSC	cis	rs2688608	0.967	rs2688609	chr10:75658181	A/G	cg17411546	chr10:75410026	SYNPO2L	0.43	6.43	0.33	4.44e-10	Inflammatory bowel disease;
LUSC	cis	rs3770081	1.000	rs1561328	chr2:86272758	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.8	-5.95	-0.31	6.7e-9	Facial emotion recognition (sad faces);
LUSC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg04287289	chr16:89883240	FANCA	0.76	6.26	0.32	1.19e-9	Skin colour saturation;
LUSC	cis	rs189798	0.738	rs330908	chr8:8995166	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	6.53	0.34	2.47e-10	Myopia (pathological);
LUSC	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	5.74	0.3	2.15e-8	Breast cancer;
LUSC	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg04539111	chr16:67997858	SLC12A4	-0.45	-6.03	-0.31	4.27e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs953492	0.644	rs12145759	chr1:243411405	G/C	cg25284624	chr1:224180302	NA	-0.43	-6.54	-0.34	2.3e-10	Diastolic blood pressure;
LUSC	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg27411982	chr8:10470053	RP1L1	0.38	5.75	0.3	1.96e-8	Retinal vascular caliber;
LUSC	cis	rs1775715	0.769	rs2808102	chr10:32117749	A/T	cg04359828	chr10:32216031	ARHGAP12	0.41	6.95	0.36	1.95e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg01733217	chr16:74700730	RFWD3	0.8	13.44	0.59	3.38e-33	Testicular germ cell tumor;
LUSC	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg09998033	chr7:158218633	PTPRN2	-0.51	-8.23	-0.41	4.13e-15	Obesity-related traits;
LUSC	cis	rs4253772	0.872	rs45528736	chr22:46638312	A/G	cg09491104	chr22:46646882	C22orf40	-0.59	-6.48	-0.33	3.23e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg22920501	chr2:26401640	FAM59B	-0.8	-11.67	-0.54	1.27e-26	Gut microbiome composition (summer);
LUSC	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg16060761	chr17:80687452	NA	-0.42	-6.79	-0.35	5.12e-11	Breast cancer;
LUSC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg21535247	chr6:8435926	SLC35B3	0.6	9.22	0.45	3.32e-18	Motion sickness;
LUSC	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg11584989	chr19:19387371	SF4	0.56	6.81	0.35	4.64e-11	Bipolar disorder;
LUSC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg11752832	chr7:134001865	SLC35B4	0.59	9.29	0.45	2.08e-18	Mean platelet volume;
LUSC	trans	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg19894588	chr14:64061835	NA	0.49	7.07	0.36	9.02e-12	Glioblastoma;Glioma;
LUSC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg16524733	chr11:117070046	TAGLN	0.43	7.62	0.38	2.64e-13	Blood protein levels;
LUSC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg23711669	chr6:146136114	FBXO30	0.92	17.7	0.7	6.44e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs137603	0.644	rs137619	chr22:39706360	A/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.54	-8.51	-0.42	5.83e-16	Primary biliary cholangitis;
LUSC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	7.5	0.38	5.84e-13	Multiple sclerosis;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09068169	chr17:952071	ABR	0.48	6.31	0.33	9.06e-10	Neuroticism;
LUSC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.5	-0.38	5.8e-13	Morning vs. evening chronotype;
LUSC	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg20991723	chr1:152506922	NA	0.51	9.51	0.46	3.98e-19	Hair morphology;
LUSC	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-0.53	-8.18	-0.41	6.04e-15	Breast cancer;
LUSC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.06	-0.4	1.36e-14	Lung cancer;
LUSC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg05082376	chr22:42548792	NA	-0.41	-6.38	-0.33	5.84e-10	Schizophrenia;
LUSC	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg09754948	chr16:28834200	ATXN2L	0.41	5.86	0.31	1.13e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7000551	0.725	rs2443496	chr8:22365788	G/A	cg12081754	chr8:22256438	SLC39A14	0.42	6.38	0.33	5.76e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg21770322	chr7:97807741	LMTK2	0.51	9.1	0.45	8.4e-18	Breast cancer;
LUSC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg13256891	chr4:100009986	ADH5	-0.44	-5.89	-0.31	9.49e-9	Alcohol dependence;
LUSC	cis	rs34779708	0.702	rs7087150	chr10:35542138	A/T	cg03585969	chr10:35415529	CREM	0.55	7.59	0.38	3.21e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg04287289	chr16:89883240	FANCA	-0.5	-7.6	-0.38	3.07e-13	Vitiligo;
LUSC	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.69	-0.34	9.52e-11	Axial length;
LUSC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.49	7.69	0.39	1.71e-13	Colorectal cancer;
LUSC	cis	rs2742417	1.000	rs2742386	chr3:45756310	A/C	cg18779283	chr3:45636154	LIMD1	-0.34	-5.9	-0.31	8.79e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs8179	0.645	rs17766836	chr7:92258961	C/T	cg15732164	chr7:92237376	CDK6	-0.43	-5.91	-0.31	8.45e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg06618935	chr21:46677482	NA	-0.4	-7.66	-0.39	2.02e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7759001	0.857	rs3734575	chr6:27371011	C/T	cg18711553	chr6:27366782	ZNF391	0.39	5.73	0.3	2.25e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg15704280	chr7:45808275	SEPT13	0.61	7.98	0.4	2.4e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg04155231	chr12:9217510	LOC144571	0.3	5.66	0.3	3.26e-8	Sjögren's syndrome;
LUSC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18301423	chr5:131593218	PDLIM4	0.46	7.01	0.36	1.34e-11	Acylcarnitine levels;
LUSC	cis	rs10193935	1.000	rs12618105	chr2:42414146	T/G	cg27598129	chr2:42591480	NA	-0.61	-8.05	-0.4	1.48e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	0.9	13.63	0.6	6.33e-34	Height;
LUSC	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.71	-0.39	1.44e-13	Neuroticism;
LUSC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.62	12.65	0.57	3.08e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-0.93	-14.22	-0.61	3.28e-36	Prostate cancer;
LUSC	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg07636037	chr3:49044803	WDR6	0.9	10.52	0.5	1.55e-22	Menarche (age at onset);
LUSC	cis	rs4356932	1.000	rs7699624	chr4:76962631	G/T	cg00809888	chr4:76862425	NAAA	0.36	6.14	0.32	2.38e-9	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg03676636	chr4:99064102	C4orf37	0.35	7.47	0.38	6.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26314531	chr2:26401878	FAM59B	0.66	8.48	0.42	7.57e-16	Gut microbiome composition (summer);
LUSC	cis	rs10986311	0.802	rs1323761	chr9:127116942	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.46	7.37	0.37	1.33e-12	Vitiligo;
LUSC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	8.33	0.41	2.08e-15	Bipolar disorder;
LUSC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.78	-0.3	1.73e-8	Alzheimer's disease (late onset);
LUSC	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg23029597	chr12:123009494	RSRC2	-0.73	-9.88	-0.48	2.32e-20	Body mass index;
LUSC	trans	rs9944715	0.954	rs4890317	chr18:43770510	A/G	cg01718231	chr17:29326311	RNF135	-0.52	-7.59	-0.38	3.19e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg09408571	chr1:101003634	GPR88	0.29	5.7	0.3	2.62e-8	Monocyte count;
LUSC	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg19789473	chr17:27170043	C17orf63	0.3	5.8	0.3	1.51e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg00603274	chr11:61596626	FADS2	-0.58	-8.05	-0.4	1.49e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg20821713	chr7:1055600	C7orf50	-0.55	-7.07	-0.36	9.18e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs2285947	1.000	rs2285946	chr7:21583329	T/C	cg04471919	chr7:21584483	DNAH11	0.35	7.75	0.39	1.1e-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.75	-0.39	1.09e-13	Body mass index;
LUSC	cis	rs68170813	0.559	rs17429146	chr7:106964281	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.85	-0.47	3e-20	Coronary artery disease;
LUSC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg13047869	chr3:10149882	C3orf24	0.6	8.27	0.41	3.15e-15	Alzheimer's disease;
LUSC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg03709012	chr19:19516395	GATAD2A	0.85	14.47	0.62	3.69e-37	Tonsillectomy;
LUSC	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.8	11.56	0.53	3.14e-26	Corneal astigmatism;
LUSC	cis	rs708547	1.000	rs10003229	chr4:57809598	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.57	-7.11	-0.36	6.87e-12	Response to bleomycin (chromatid breaks);
LUSC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.17	-0.32	1.92e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg23942311	chr14:51606299	NA	0.47	10.33	0.49	6.91e-22	Cancer;
LUSC	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-6.91	-0.35	2.4e-11	Menopause (age at onset);
LUSC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.47	-0.42	7.72e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.04	-0.31	4.14e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12995849	0.905	rs7565757	chr2:106452408	T/A	cg14210321	chr2:106509881	NCK2	-0.39	-5.81	-0.3	1.42e-8	Addiction;
LUSC	cis	rs9341808	0.935	rs9448894	chr6:80837253	G/T	cg08355045	chr6:80787529	NA	0.53	9.39	0.46	9.98e-19	Sitting height ratio;
LUSC	cis	rs4132509	1.000	rs1458024	chr1:243937445	G/C	cg21452805	chr1:244014465	NA	0.5	5.71	0.3	2.49e-8	RR interval (heart rate);
LUSC	cis	rs965604	1.000	rs8042260	chr15:78774374	A/G	cg18825076	chr15:78729989	IREB2	-0.43	-6.88	-0.35	3.03e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.81	0.3	1.43e-8	Menopause (age at onset);
LUSC	cis	rs231513	0.906	rs11653808	chr17:42005366	A/T	cg26893861	chr17:41843967	DUSP3	0.56	5.76	0.3	1.91e-8	Cognitive function;
LUSC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg02423579	chr7:2872169	GNA12	0.39	6.14	0.32	2.3e-9	Height;
LUSC	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	0.82	11.66	0.54	1.34e-26	Response to hepatitis C treatment;
LUSC	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg03585969	chr10:35415529	CREM	0.63	9.25	0.45	2.73e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4481887	0.676	rs7527991	chr1:248527649	T/A	cg26353448	chr1:248524236	OR2T4	-0.31	-6.06	-0.31	3.63e-9	Common traits (Other);
LUSC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6696846	0.630	rs11240373	chr1:205135600	A/C	cg03948781	chr1:205179583	DSTYK	0.31	5.73	0.3	2.23e-8	Red blood cell count;
LUSC	cis	rs6690583	0.623	rs6700723	chr1:85514234	C/T	cg11262906	chr1:85462892	MCOLN2	0.67	6.1	0.32	2.99e-9	Serum sulfate level;
LUSC	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14019695	chr9:139328340	INPP5E	0.52	10.05	0.48	6.06e-21	Monocyte percentage of white cells;
LUSC	cis	rs7923609	0.967	rs3740331	chr10:65192288	G/A	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.01e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9560113	1.000	rs9560104	chr13:112174389	A/G	cg14154082	chr13:112174009	NA	0.39	7.97	0.4	2.56e-14	Menarche (age at onset);
LUSC	cis	rs9359856	0.564	rs41273329	chr6:90393483	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.36	-0.42	1.77e-15	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25072359	chr17:41440525	NA	0.65	9.38	0.46	1.06e-18	Menopause (age at onset);
LUSC	cis	rs1461503	0.932	rs11218909	chr11:122842613	C/T	cg27398637	chr11:122830231	C11orf63	-0.41	-6.54	-0.34	2.29e-10	Menarche (age at onset);
LUSC	cis	rs7659604	0.540	rs4240264	chr4:122683818	A/G	cg19748678	chr4:122722346	EXOSC9	-0.39	-5.79	-0.3	1.6e-8	Type 2 diabetes;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg09423085	chr2:68478351	PPP3R1	0.38	6.29	0.33	9.73e-10	Schizophrenia;
LUSC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.35	-6.07	-0.32	3.4e-9	Longevity;Endometriosis;
LUSC	trans	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg25815440	chr2:42134162	NA	-0.25	-5.96	-0.31	6.49e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	1.01	18.81	0.72	2.46e-54	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	1.04	18.83	0.72	2.12e-54	Parkinson's disease;
LUSC	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg27411982	chr8:10470053	RP1L1	-0.5	-7.83	-0.39	6.74e-14	Neuroticism;
LUSC	cis	rs17092148	0.616	rs6059908	chr20:33132159	T/C	cg16810054	chr20:33298113	TP53INP2	-0.38	-5.95	-0.31	6.73e-9	Neuroticism;
LUSC	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.36	-0.37	1.49e-12	Mood instability;
LUSC	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg00579200	chr11:133705235	NA	-0.39	-5.97	-0.31	6.21e-9	Childhood ear infection;
LUSC	cis	rs28647808	0.748	rs28721280	chr9:136267318	C/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg06096015	chr1:231504339	EGLN1	-0.41	-6.08	-0.32	3.29e-9	Red blood cell count;
LUSC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05776053	chr2:74358815	NA	0.4	5.75	0.3	2.01e-8	Gestational age at birth (maternal effect);
LUSC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02475777	chr4:1388615	CRIPAK	0.62	9.0	0.44	1.69e-17	Longevity;
LUSC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg19626725	chr5:178986131	RUFY1	0.52	8.99	0.44	1.83e-17	Lung cancer;
LUSC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg06784218	chr1:46089804	CCDC17	0.46	8.85	0.44	5.26e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs59698941	0.943	rs10900812	chr5:132268567	G/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs3947	0.688	rs1293326	chr8:11694765	G/C	cg00262122	chr8:11665843	FDFT1	-0.5	-6.29	-0.33	9.82e-10	Blood protein levels;
LUSC	cis	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg21775007	chr8:11205619	TDH	-0.41	-5.79	-0.3	1.62e-8	Monocyte count;
LUSC	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.43	5.8	0.3	1.53e-8	Lung disease severity in cystic fibrosis;
LUSC	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.01	-0.4	1.97e-14	Morning vs. evening chronotype;
LUSC	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg24006582	chr15:45444508	DUOX1	-0.61	-8.85	-0.44	5.04e-17	Uric acid levels;
LUSC	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.85	-0.68	1.58e-46	Exhaled nitric oxide output;
LUSC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22433210	chr17:43662623	NA	0.75	10.84	0.51	1.13e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg01191920	chr7:158217561	PTPRN2	0.49	10.07	0.48	5.27e-21	Obesity-related traits;
LUSC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg01879757	chr17:41196368	BRCA1	-0.46	-6.94	-0.36	2e-11	Menopause (age at onset);
LUSC	cis	rs17030434	0.906	rs5020754	chr4:154670444	T/C	cg14289246	chr4:154710475	SFRP2	-0.49	-6.46	-0.33	3.8e-10	Electrocardiographic conduction measures;
LUSC	cis	rs17255340	0.520	rs6914164	chr6:84116252	C/T	cg08257003	chr6:84140564	ME1	0.36	8.88	0.44	4.2e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs72772090	0.634	rs17402639	chr5:96107005	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-8.58	-0.42	3.65e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg13535736	chr9:111863775	C9orf5	-0.4	-6.6	-0.34	1.59e-10	Menarche (age at onset);
LUSC	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg27529037	chr20:44575021	PCIF1	0.38	6.71	0.34	8.42e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.15	-18.41	-0.71	9.52e-53	Primary sclerosing cholangitis;
LUSC	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg15704280	chr7:45808275	SEPT13	0.64	7.22	0.37	3.58e-12	Axial length;
LUSC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.58	-9.5	-0.46	4.35e-19	Aortic root size;
LUSC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg23791538	chr6:167370224	RNASET2	-0.39	-6.02	-0.31	4.72e-9	Crohn's disease;
LUSC	cis	rs2242663	0.798	rs607736	chr11:66328877	G/A	cg24851651	chr11:66362959	CCS	0.39	6.34	0.33	7.35e-10	Bipolar disorder;
LUSC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19717773	chr7:2847554	GNA12	-0.4	-6.3	-0.33	9.45e-10	Height;
LUSC	cis	rs10875746	0.903	rs12315625	chr12:48472453	G/A	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs11051970	1.000	rs11051970	chr12:32537488	G/T	cg02745156	chr12:32552066	NA	0.44	7.27	0.37	2.59e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6961069	0.585	rs13244883	chr7:80248336	G/T	cg04458919	chr7:80252533	CD36	-0.4	-7.02	-0.36	1.25e-11	Platelet count;
LUSC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11644478	chr21:40555479	PSMG1	-0.53	-7.83	-0.39	6.32e-14	Menarche (age at onset);
LUSC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg24829409	chr8:58192753	C8orf71	0.49	5.72	0.3	2.37e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg01733217	chr16:74700730	RFWD3	0.8	13.44	0.59	3.38e-33	Testicular germ cell tumor;
LUSC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.89	13.93	0.61	4.41e-35	Coronary artery disease;
LUSC	cis	rs6500395	0.926	rs11076570	chr16:48597915	G/A	cg04672837	chr16:48644449	N4BP1	0.43	6.17	0.32	1.94e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg06637938	chr14:75390232	RPS6KL1	0.52	8.41	0.42	1.21e-15	Height;
LUSC	trans	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg07211511	chr3:129823064	LOC729375	-0.77	-10.01	-0.48	8.21e-21	Blood pressure (smoking interaction);
LUSC	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg09092052	chr15:45571596	NA	-0.46	-6.48	-0.33	3.23e-10	Glomerular filtration rate;
LUSC	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg05714579	chr10:131428358	MGMT	0.47	6.73	0.35	7.53e-11	Response to temozolomide;
LUSC	cis	rs71403859	0.502	rs12919417	chr16:71579711	A/G	cg08717414	chr16:71523259	ZNF19	0.68	7.8	0.39	8.17e-14	Post bronchodilator FEV1;
LUSC	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg00012203	chr2:219082015	ARPC2	-0.6	-9.77	-0.47	5.39e-20	Ulcerative colitis;
LUSC	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg23241863	chr10:102295624	HIF1AN	0.48	5.9	0.31	9.04e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24597927	chr20:45317651	TP53RK	-0.41	-5.99	-0.31	5.51e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg26897989	chr16:1907736	C16orf73	0.4	6.72	0.35	7.69e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs11229555	0.645	rs12794534	chr11:58179568	C/A	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg03676636	chr4:99064102	C4orf37	0.29	6.37	0.33	6.31e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-11.91	-0.55	1.64e-27	Hemoglobin concentration;
LUSC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg12463550	chr7:65579703	CRCP	-0.57	-8.54	-0.42	4.88e-16	Aortic root size;
LUSC	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg13010199	chr12:38710504	ALG10B	-0.5	-7.5	-0.38	5.89e-13	Morning vs. evening chronotype;
LUSC	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg04310649	chr10:35416472	CREM	-0.42	-6.39	-0.33	5.6e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg11050988	chr7:1952600	MAD1L1	-0.3	-5.68	-0.3	2.88e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg16989719	chr2:238392110	NA	0.49	7.92	0.4	3.64e-14	Prostate cancer;
LUSC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-6.79	-0.35	5.04e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2274273	0.624	rs10143136	chr14:55743528	G/A	cg04306507	chr14:55594613	LGALS3	0.48	9.72	0.47	7.65e-20	Protein biomarker;
LUSC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	0.98	13.46	0.59	2.82e-33	Vitiligo;
LUSC	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg26384229	chr12:38710491	ALG10B	0.72	11.36	0.53	1.66e-25	Morning vs. evening chronotype;
LUSC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.76	13.58	0.6	9.13e-34	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg14552801	chr7:65878734	NA	0.45	6.4	0.33	5.4e-10	Aortic root size;
LUSC	cis	rs12618769	0.597	rs4850876	chr2:99112069	C/T	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg05738196	chr6:26577821	NA	0.78	14.95	0.63	4.82e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg07507251	chr3:52567010	NT5DC2	0.33	6.38	0.33	5.76e-10	Bipolar disorder;
LUSC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.6	8.43	0.42	1.05e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.16	0.32	2.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11764359	chr7:65958608	NA	-0.68	-10.93	-0.51	5.62e-24	Aortic root size;
LUSC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg06740227	chr12:86229804	RASSF9	0.37	5.84	0.3	1.27e-8	Major depressive disorder;
LUSC	cis	rs231513	0.954	rs231498	chr17:41975251	C/G	cg26893861	chr17:41843967	DUSP3	-0.53	-6.39	-0.33	5.53e-10	Cognitive function;
LUSC	cis	rs7589342	0.517	rs6726571	chr2:106390251	T/C	cg09152813	chr2:106391379	NCK2	-0.37	-5.91	-0.31	8.29e-9	Addiction;
LUSC	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg18721089	chr20:30220636	NA	-0.39	-6.09	-0.32	3.12e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs1832871	0.711	rs9459887	chr6:158696479	C/T	cg07165851	chr6:158734300	TULP4	0.5	7.8	0.39	7.87e-14	Height;
LUSC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg08132940	chr7:1081526	C7orf50	-0.52	-6.22	-0.32	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7903847	0.642	rs11189167	chr10:99125722	A/G	cg20016023	chr10:99160130	RRP12	-0.3	-6.33	-0.33	7.68e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.81	-0.43	6.75e-17	Platelet count;
LUSC	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg18825119	chr6:163149453	PACRG;PARK2	-0.34	-6.02	-0.31	4.62e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg04998671	chr14:104000505	TRMT61A	-0.46	-7.2	-0.37	4.12e-12	Coronary artery disease;
LUSC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.35	-6.96	-0.36	1.78e-11	Schizophrenia;
LUSC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg12863693	chr15:85201151	NMB	0.35	6.87	0.35	3.09e-11	Schizophrenia;
LUSC	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg05283184	chr6:79620031	NA	-0.57	-12.12	-0.55	2.99e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.17e-12	Asthma;
LUSC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.46	0.59	2.81e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg18404041	chr3:52824283	ITIH1	0.4	6.84	0.35	3.77e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg08270630	chr22:50330655	NA	0.43	6.44	0.33	4.22e-10	Schizophrenia;
LUSC	cis	rs4776059	0.724	rs8030141	chr15:52937689	G/A	cg24008177	chr15:52972085	KIAA1370	-0.36	-6.45	-0.33	3.89e-10	Schizophrenia;
LUSC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.98	-0.4	2.44e-14	Schizophrenia;
LUSC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg06637938	chr14:75390232	RPS6KL1	0.54	8.7	0.43	1.53e-16	Height;
LUSC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg22709100	chr7:91322751	NA	-0.4	-5.82	-0.3	1.41e-8	Breast cancer;
LUSC	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg04362960	chr10:104952993	NT5C2	0.59	9.31	0.45	1.7e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	-1.2	-20.58	-0.75	2.26e-61	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg15383120	chr6:291909	DUSP22	-0.47	-7.22	-0.37	3.44e-12	Menopause (age at onset);
LUSC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg03146154	chr1:46216737	IPP	0.51	7.6	0.38	2.94e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg25233709	chr10:116636983	FAM160B1	0.45	8.11	0.41	9.82e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	5.79	0.3	1.63e-8	Breast cancer;
LUSC	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg13256891	chr4:100009986	ADH5	-0.44	-6.02	-0.31	4.68e-9	Alcohol dependence;
LUSC	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg15744005	chr10:104629667	AS3MT	-0.4	-8.3	-0.41	2.7e-15	Arsenic metabolism;
LUSC	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg10327440	chr1:227177885	CDC42BPA	-0.74	-6.1	-0.32	2.86e-9	Major depressive disorder;
LUSC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-6.03	-0.31	4.32e-9	Lung cancer;
LUSC	cis	rs6690583	0.524	rs6680422	chr1:85451945	C/T	cg11262906	chr1:85462892	MCOLN2	0.68	6.6	0.34	1.63e-10	Serum sulfate level;
LUSC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs2029213	0.523	rs3773745	chr3:53270424	A/G	cg16894138	chr3:53270350	TKT	-0.33	-6.98	-0.36	1.55e-11	Heart rate;
LUSC	cis	rs12286929	0.609	rs12791813	chr11:115091510	G/A	cg04055981	chr11:115044050	NA	0.37	6.72	0.34	7.98e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg10621924	chr7:39171070	POU6F2	0.49	7.68	0.39	1.75e-13	IgG glycosylation;
LUSC	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg27205649	chr11:78285834	NARS2	-0.51	-5.77	-0.3	1.77e-8	Testicular germ cell tumor;
LUSC	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg20848291	chr7:100343083	ZAN	0.39	6.05	0.31	3.89e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.61	0.65	1.25e-41	Platelet count;
LUSC	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.81	13.44	0.59	3.28e-33	Bladder cancer;
LUSC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg18678763	chr11:4115507	RRM1	-0.46	-6.0	-0.31	5.13e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-7.03	-0.36	1.18e-11	Aortic root size;
LUSC	cis	rs860295	0.812	rs12024257	chr1:155780536	G/A	cg08949192	chr1:155289623	RUSC1;FDPS	-0.36	-5.87	-0.31	1.06e-8	Body mass index;
LUSC	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg25828334	chr19:18545568	ISYNA1	-0.37	-6.18	-0.32	1.9e-9	Breast cancer;
LUSC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg02269571	chr22:50332266	NA	-0.57	-8.4	-0.42	1.26e-15	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06761793	chr1:1550770	MIB2	-0.43	-6.39	-0.33	5.42e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03264133	chr6:25882463	NA	-0.39	-6.82	-0.35	4.24e-11	Height;
LUSC	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg17385448	chr1:15911702	AGMAT	0.37	5.86	0.31	1.08e-8	Systolic blood pressure;
LUSC	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg08807101	chr21:30365312	RNF160	0.65	10.48	0.5	2.04e-22	Pancreatic cancer;
LUSC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.54	-0.5	1.29e-22	Chronic sinus infection;
LUSC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg12564285	chr5:131593104	PDLIM4	0.45	8.72	0.43	1.31e-16	Blood metabolite levels;
LUSC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.43	-0.33	4.29e-10	Total body bone mineral density;
LUSC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg05313129	chr8:58192883	C8orf71	-0.53	-6.84	-0.35	3.89e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg22681709	chr2:178499509	PDE11A	-0.57	-11.33	-0.53	2.19e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.06e-17	Prudent dietary pattern;
LUSC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg20821713	chr7:1055600	C7orf50	-0.38	-5.92	-0.31	7.85e-9	Longevity;Endometriosis;
LUSC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg03388025	chr16:89894329	SPIRE2	0.33	6.9	0.35	2.65e-11	Vitiligo;
LUSC	cis	rs10779751	0.960	rs4845988	chr1:11319587	A/G	cg08854313	chr1:11322531	MTOR	0.91	15.94	0.66	6.12e-43	Body mass index;
LUSC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg18350739	chr11:68623251	NA	-0.38	-6.79	-0.35	5.16e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11971779	0.680	rs2355787	chr7:139089928	G/T	cg23387468	chr7:139079360	LUC7L2	-0.39	-5.99	-0.31	5.43e-9	Diisocyanate-induced asthma;
LUSC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg24675658	chr1:53192096	ZYG11B	0.73	12.09	0.55	3.83e-28	Monocyte count;
LUSC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg09365446	chr1:150670422	GOLPH3L	0.56	8.55	0.42	4.33e-16	Tonsillectomy;
LUSC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg18512352	chr11:47633146	NA	-0.48	-9.69	-0.47	9.85e-20	Subjective well-being;
LUSC	cis	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg06521331	chr12:34319734	NA	-0.47	-7.57	-0.38	3.56e-13	Morning vs. evening chronotype;
LUSC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	4.85e-15	Homoarginine levels;
LUSC	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg03599575	chr15:90893182	GABARAPL3	-0.34	-5.69	-0.3	2.8e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg11473876	chr11:109292803	C11orf87	0.4	6.46	0.33	3.7e-10	Schizophrenia;
LUSC	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.67	-10.24	-0.49	1.42e-21	Fuchs's corneal dystrophy;
LUSC	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg27432699	chr2:27873401	GPN1	0.81	15.14	0.64	8.6e-40	Oral cavity cancer;
LUSC	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg26597838	chr10:835615	NA	0.53	6.42	0.33	4.6e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg18200150	chr17:30822561	MYO1D	-0.43	-8.6	-0.43	3.09e-16	Schizophrenia;
LUSC	cis	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg26384229	chr12:38710491	ALG10B	-0.78	-12.61	-0.57	4.4e-30	Morning vs. evening chronotype;
LUSC	cis	rs12760731	0.565	rs12037429	chr1:178224741	C/T	cg00404053	chr1:178313656	RASAL2	0.67	6.92	0.35	2.33e-11	Obesity-related traits;
LUSC	cis	rs7267979	0.740	rs2259961	chr20:25282626	T/G	cg14121845	chr20:25566513	NINL	0.31	5.77	0.3	1.81e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg13319975	chr6:146136371	FBXO30	0.49	7.36	0.37	1.42e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08470875	chr2:26401718	FAM59B	-0.72	-9.94	-0.48	1.43e-20	Gut microbiome composition (summer);
LUSC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-11.23	-0.52	4.84e-25	Total body bone mineral density;
LUSC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg20090143	chr19:45452003	APOC2	0.47	9.14	0.45	6.27e-18	Blood protein levels;
LUSC	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg14458575	chr2:238380390	NA	0.76	13.63	0.6	5.84e-34	Prostate cancer;
LUSC	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg08854313	chr1:11322531	MTOR	-0.9	-15.72	-0.65	4.54e-42	Body mass index;
LUSC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	10.83	0.51	1.24e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs17095355	0.901	rs10884919	chr10:111757791	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.35	-0.37	1.53e-12	Biliary atresia;
LUSC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.95	-0.36	1.96e-11	Blood metabolite levels;
LUSC	cis	rs78663649	0.708	rs115656720	chr19:16622921	C/A	cg05286348	chr19:16641544	CHERP	-1.34	-10.78	-0.51	1.88e-23	White blood cell count;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg08206623	chr11:2907334	CDKN1C	-0.45	-6.75	-0.35	6.59e-11	Cognitive function;Information processing speed;
LUSC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18876405	chr7:65276391	NA	-0.56	-8.96	-0.44	2.27e-17	Aortic root size;
LUSC	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg06917634	chr15:78832804	PSMA4	-0.44	-5.93	-0.31	7.39e-9	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.76	-0.35	6.18e-11	Reticulocyte count;
LUSC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg21724239	chr8:58056113	NA	0.57	6.83	0.35	3.97e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg09033563	chr22:24373618	LOC391322	-0.47	-6.59	-0.34	1.75e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.67	8.39	0.42	1.37e-15	Type 2 diabetes;
LUSC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	trans	rs12439619	0.774	rs2867649	chr15:82554672	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.48	-6.48	-0.33	3.35e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	0.95	16.07	0.66	1.92e-43	Menopause (age at onset);
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.52	-0.46	3.74e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg21045802	chr8:109455806	TTC35	0.42	6.58	0.34	1.77e-10	Dupuytren's disease;
LUSC	cis	rs116988415	0.584	rs78707026	chr14:65249283	A/G	cg25083366	chr14:65239357	SPTB	0.62	6.65	0.34	1.21e-10	Daytime sleep phenotypes;
LUSC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg03732007	chr1:2071316	PRKCZ	0.59	10.81	0.51	1.54e-23	Height;
LUSC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.23e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg05585544	chr11:47624801	NA	-0.41	-7.39	-0.37	1.22e-12	Subjective well-being;
LUSC	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21545522	chr1:205238299	TMCC2	0.48	9.04	0.44	1.26e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs12760731	0.565	rs12040475	chr1:178185651	G/A	cg00404053	chr1:178313656	RASAL2	0.68	6.9	0.35	2.55e-11	Obesity-related traits;
LUSC	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg06219351	chr7:158114137	PTPRN2	-0.54	-9.91	-0.48	1.84e-20	Calcium levels;
LUSC	cis	rs4343996	0.537	rs7791343	chr7:3416780	A/C	cg21248987	chr7:3385318	SDK1	0.35	5.79	0.3	1.59e-8	Motion sickness;
LUSC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg04450456	chr4:17643702	FAM184B	0.39	6.52	0.34	2.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg04362960	chr10:104952993	NT5C2	1.1	12.99	0.58	1.63e-31	Arsenic metabolism;
LUSC	cis	rs4654899	0.629	rs7515279	chr1:21172774	C/T	cg01072550	chr1:21505969	NA	0.47	7.1	0.36	7.55e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.75	-0.3	2.04e-8	Type 2 diabetes;
LUSC	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.55	8.29	0.41	2.72e-15	Colorectal cancer;
LUSC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg09365446	chr1:150670422	GOLPH3L	0.52	7.47	0.38	6.89e-13	Melanoma;
LUSC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg03732007	chr1:2071316	PRKCZ	0.47	7.62	0.38	2.68e-13	Height;
LUSC	cis	rs612683	0.518	rs565590	chr1:100846956	T/C	cg06223162	chr1:101003688	GPR88	0.37	6.88	0.35	3.02e-11	Breast cancer;
LUSC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg16624210	chr5:671434	TPPP	0.48	6.05	0.31	3.96e-9	Obesity-related traits;
LUSC	cis	rs16854884	0.770	rs7621079	chr3:143814500	G/C	cg06585982	chr3:143692056	C3orf58	0.41	6.14	0.32	2.3e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg24011408	chr12:48396354	COL2A1	0.55	7.61	0.38	2.78e-13	Lung cancer;
LUSC	cis	rs8016982	0.963	rs7149672	chr14:81657336	A/G	cg01989461	chr14:81687754	GTF2A1	0.57	8.47	0.42	7.73e-16	Schizophrenia;
LUSC	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg23950597	chr19:37808831	NA	-0.63	-7.68	-0.39	1.82e-13	Coronary artery calcification;
LUSC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	14.07	0.61	1.21e-35	Tonsillectomy;
LUSC	cis	rs3754214	0.857	rs488271	chr1:150284534	A/G	cg15654264	chr1:150340011	RPRD2	-0.45	-7.39	-0.37	1.22e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs10419226	0.511	rs7246437	chr19:18786784	A/G	cg22001208	chr19:18782374	NA	-0.37	-6.07	-0.32	3.54e-9	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg22997252	chr11:11643842	GALNTL4	0.49	6.04	0.31	4.02e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	7.12	0.36	6.66e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg04518342	chr5:131593106	PDLIM4	0.41	7.26	0.37	2.7e-12	Breast cancer;
LUSC	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-7.35	-0.37	1.53e-12	Total cholesterol levels;
LUSC	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg23241863	chr10:102295624	HIF1AN	0.48	5.74	0.3	2.18e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs72772090	0.539	rs35898772	chr5:96179685	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.45	-0.33	3.87e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs752010	0.695	rs11210508	chr1:42106935	A/G	cg06885757	chr1:42089581	HIVEP3	0.44	8.54	0.42	4.78e-16	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg02187348	chr16:89574699	SPG7	0.49	7.68	0.39	1.73e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.23	-0.49	1.51e-21	Monocyte count;
LUSC	cis	rs4319547	0.688	rs10847242	chr12:123079020	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.48	-6.56	-0.34	2.05e-10	Body mass index;
LUSC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.79	-0.39	8.44e-14	Type 2 diabetes;
LUSC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13012494	chr21:47604986	C21orf56	0.38	5.66	0.3	3.29e-8	Testicular germ cell tumor;
LUSC	cis	rs926938	0.527	rs360594	chr1:115472401	G/A	cg12756093	chr1:115239321	AMPD1	0.46	7.04	0.36	1.13e-11	Autism;
LUSC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg18827107	chr12:86230957	RASSF9	-0.46	-6.96	-0.36	1.81e-11	Major depressive disorder;
LUSC	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg13615516	chr5:77269221	NA	0.4	6.66	0.34	1.15e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg18721089	chr20:30220636	NA	-0.33	-6.09	-0.32	3.02e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs6967385	0.560	rs4554369	chr7:12356511	C/T	cg20607287	chr7:12443886	VWDE	0.49	7.37	0.37	1.37e-12	Response to taxane treatment (placlitaxel);
LUSC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg03146154	chr1:46216737	IPP	0.57	8.51	0.42	6.03e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	0.98	15.54	0.65	2.35e-41	Dupuytren's disease;
LUSC	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.73	0.47	7.46e-20	Coffee consumption (cups per day);
LUSC	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg18200150	chr17:30822561	MYO1D	0.31	5.91	0.31	8.66e-9	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01357409	chr2:178128772	NFE2L2	-0.43	-6.36	-0.33	6.48e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9905704	0.681	rs2680710	chr17:56552902	A/G	cg19466818	chr17:56409534	MIR142	0.36	6.61	0.34	1.53e-10	Testicular germ cell tumor;
LUSC	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	6.49	0.33	3.07e-10	Menarche (age at onset);
LUSC	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg03878208	chr11:72483293	STARD10	0.46	6.88	0.35	2.9100000000000002e-11	Body mass index;
LUSC	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg17173187	chr15:85201210	NMB	0.4	6.53	0.34	2.43e-10	Schizophrenia;
LUSC	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg06713675	chr4:122721982	EXOSC9	-0.47	-7.28	-0.37	2.47e-12	Type 2 diabetes;
LUSC	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg16230307	chr14:35515116	FAM177A1	0.78	10.03	0.48	7.34e-21	Psoriasis;
LUSC	trans	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.47	7.0	0.36	1.41e-11	Endometrial cancer;
LUSC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg05872129	chr22:39784769	NA	-0.6	-11.3	-0.53	2.82e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg24881330	chr22:46731750	TRMU	0.93	10.62	0.5	6.64e-23	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg24558204	chr6:135376177	HBS1L	0.59	9.12	0.45	7.4e-18	Red blood cell count;
LUSC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.22	-0.61	3.15e-36	Eye color traits;
LUSC	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.25	0.45	2.77e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg21226059	chr5:178986404	RUFY1	-0.67	-12.77	-0.57	1.06e-30	Lung cancer;
LUSC	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg10356904	chr22:49881777	NA	-0.32	-7.21	-0.37	3.79e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	22.9	0.78	1.85e-70	Height;
LUSC	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg06877462	chr1:205807181	PM20D1	-0.41	-7.11	-0.36	6.98e-12	Menarche (age at onset);
LUSC	cis	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-6.03	-0.31	4.46e-9	Neuroticism;
LUSC	cis	rs9473147	0.516	rs9349415	chr6:47551861	T/C	cg20196966	chr6:47445060	CD2AP	0.41	5.75	0.3	2.07e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg14668632	chr7:2872130	GNA12	-0.47	-6.58	-0.34	1.85e-10	Height;
LUSC	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg08798685	chr6:27730294	NA	-0.64	-6.01	-0.31	4.93e-9	Breast cancer;
LUSC	cis	rs2274273	1.000	rs7142704	chr14:55630603	C/A	cg04306507	chr14:55594613	LGALS3	0.57	13.27	0.59	1.44e-32	Protein biomarker;
LUSC	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.45	-0.33	3.95e-10	Uric acid levels;
LUSC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.08	-0.36	8.62e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4499344	0.521	rs1862214	chr19:33035849	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.75	10.16	0.49	2.55e-21	Mean platelet volume;
LUSC	cis	rs500891	0.533	rs1171102	chr6:84198015	C/T	cg08257003	chr6:84140564	ME1	0.34	8.36	0.42	1.69e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg22029157	chr1:209979665	IRF6	0.51	8.12	0.41	9e-15	Monobrow;
LUSC	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg27068330	chr11:65405492	SIPA1	0.52	6.39	0.33	5.51e-10	Blood pressure (age interaction);
LUSC	cis	rs963731	0.649	rs2888585	chr2:39246683	C/T	cg04010122	chr2:39346883	SOS1	-0.82	-5.74	-0.3	2.11e-8	Corticobasal degeneration;
LUSC	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg16329197	chr12:53359506	NA	-0.63	-8.63	-0.43	2.58e-16	Cancer (pleiotropy);
LUSC	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.96	-13.74	-0.6	2.31e-34	Primary sclerosing cholangitis;
LUSC	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg02023728	chr11:77925099	USP35	0.46	6.93	0.35	2.19e-11	Testicular germ cell tumor;
LUSC	cis	rs9469578	0.892	rs73743334	chr6:33714094	G/C	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	cis	rs5769707	0.681	rs739240	chr22:50052607	C/A	cg20744362	chr22:50050164	C22orf34	0.39	7.28	0.37	2.41e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.1	-0.36	7.5e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10140922	0.931	rs4982262	chr14:35822193	C/T	cg07166546	chr14:35805898	NA	-0.24	-5.89	-0.31	9.42e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-14.89	-0.63	7.94e-39	Total body bone mineral density;
LUSC	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg22117172	chr7:91764530	CYP51A1	-0.33	-5.87	-0.31	1.04e-8	Breast cancer;
LUSC	cis	rs7605827	0.893	rs7575722	chr2:15597551	G/A	cg19274914	chr2:15703543	NA	0.47	9.08	0.45	9.55e-18	Educational attainment (years of education);
LUSC	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-7.77	-0.39	9.86e-14	Height;
LUSC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.86	-0.81	6.04e-78	Height;
LUSC	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg18352616	chr4:3374830	RGS12	0.31	6.27	0.32	1.12e-9	Serum sulfate level;
LUSC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21724239	chr8:58056113	NA	0.82	8.89	0.44	4.02e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs12681287	0.752	rs4463401	chr8:87250309	C/T	cg27223183	chr8:87520930	FAM82B	-0.45	-5.76	-0.3	1.87e-8	Caudate activity during reward;
LUSC	cis	rs4363385	0.719	rs6664823	chr1:152933424	A/C	cg00922841	chr1:152955080	SPRR1A	-0.42	-6.92	-0.35	2.26e-11	Inflammatory skin disease;
LUSC	cis	rs2835872	0.930	rs857974	chr21:39005741	A/G	cg20424643	chr21:39039972	KCNJ6	-0.4	-6.09	-0.32	3.15e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg05340658	chr4:99064831	C4orf37	0.63	9.8	0.47	4.15e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg04450456	chr4:17643702	FAM184B	0.37	5.97	0.31	6.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7106204	0.513	rs7131112	chr11:24249402	A/G	ch.11.24196551F	chr11:24239977	NA	0.98	11.41	0.53	1.13e-25	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg05585544	chr11:47624801	NA	-0.41	-7.26	-0.37	2.75e-12	Subjective well-being;
LUSC	cis	rs3750965	0.920	rs896978	chr11:68828929	G/A	cg06818126	chr11:68850279	TPCN2	-0.44	-6.24	-0.32	1.3e-9	Hair color;
LUSC	cis	rs4654899	0.931	rs935917	chr1:21167102	A/T	cg01072550	chr1:21505969	NA	-0.46	-7.06	-0.36	9.84e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19346786	chr7:2764209	NA	-0.46	-7.85	-0.39	5.68e-14	Height;
LUSC	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg05805236	chr11:65401703	PCNXL3	-0.39	-6.55	-0.34	2.21e-10	Acne (severe);
LUSC	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg17691542	chr6:26056736	HIST1H1C	0.5	6.82	0.35	4.31e-11	Iron status biomarkers;
LUSC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.76	-0.47	5.98e-20	Bipolar disorder;
LUSC	cis	rs4766566	0.609	rs6490042	chr12:111719060	T/A	cg10833066	chr12:111807467	FAM109A	0.52	9.16	0.45	5.27e-18	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUSC	cis	rs13089785	1.000	rs13081955	chr3:123600144	A/G	cg01860459	chr3:123419554	MYLK	0.34	5.66	0.3	3.22e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg05913197	chr6:166796386	BRP44L	0.48	5.96	0.31	6.34e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg11663144	chr21:46675770	NA	-0.41	-7.18	-0.37	4.59e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg24006582	chr15:45444508	DUOX1	-0.61	-8.96	-0.44	2.41e-17	Uric acid levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11499772	chr17:79818530	P4HB	-0.39	-6.04	-0.31	4e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7607369	0.536	rs13013510	chr2:219667227	A/G	cg02176678	chr2:219576539	TTLL4	-0.52	-9.15	-0.45	5.72e-18	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs2051211	1.000	rs2051211	chr3:38559749	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.55	-7.73	-0.39	1.29e-13	QRS duration;
LUSC	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg16070123	chr10:51489643	NA	-0.5	-7.95	-0.4	3e-14	Prostate-specific antigen levels;
LUSC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.73	11.55	0.53	3.31e-26	Coronary artery disease;
LUSC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg12963246	chr6:28129442	ZNF389	0.52	7.18	0.37	4.53e-12	Depression;
LUSC	cis	rs500891	0.547	rs1170480	chr6:84036345	A/G	cg08257003	chr6:84140564	ME1	0.34	8.05	0.4	1.43e-14	Platelet-derived growth factor BB levels;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg02517558	chr12:53473207	SPRYD3	0.4	6.3	0.33	9.51e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg20607287	chr7:12443886	VWDE	-0.59	-6.13	-0.32	2.54e-9	Coronary artery disease;
LUSC	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2835872	0.965	rs73222307	chr21:39012225	G/A	cg20424643	chr21:39039972	KCNJ6	0.39	6.05	0.31	3.87e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.92	0.35	2.38e-11	IgG glycosylation;
LUSC	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg23711669	chr6:146136114	FBXO30	0.76	13.09	0.58	6.62e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7267979	0.604	rs242130	chr20:25594020	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.66	-11.69	-0.54	1.05e-26	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg01528321	chr10:82214614	TSPAN14	0.62	9.08	0.45	9.41e-18	Post bronchodilator FEV1;
LUSC	cis	rs477692	1.000	rs479478	chr10:131428959	G/A	cg05714579	chr10:131428358	MGMT	0.51	7.57	0.38	3.65e-13	Response to temozolomide;
LUSC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.73	0.54	7.69e-27	Alzheimer's disease;
LUSC	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg20701182	chr2:24300061	SF3B14	0.73	7.42	0.38	9.58e-13	Lymphocyte counts;
LUSC	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-5.74	-0.3	2.1e-8	Testicular germ cell tumor;
LUSC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-7.92	-0.4	3.51e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg05163923	chr11:71159392	DHCR7	-0.77	-10.02	-0.48	7.56e-21	Vitamin D levels;
LUSC	cis	rs138918	0.776	rs138938	chr22:43569608	C/A	cg08909806	chr22:43548696	TSPO	0.36	6.04	0.31	4.06e-9	Monocyte count;
LUSC	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg08601574	chr20:25228251	PYGB	0.42	6.41	0.33	4.9e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg02187348	chr16:89574699	SPG7	0.48	7.33	0.37	1.79e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg11645453	chr3:52864694	ITIH4	0.33	7.62	0.38	2.63e-13	Bipolar disorder;
LUSC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03264133	chr6:25882463	NA	-0.52	-9.51	-0.46	4.03e-19	Blood metabolite levels;
LUSC	cis	rs2652834	0.718	rs12912721	chr15:63397385	T/C	cg05507819	chr15:63340323	TPM1	0.55	7.07	0.36	8.99e-12	HDL cholesterol;
LUSC	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.71	-0.3	2.56e-8	Obesity-related traits;
LUSC	trans	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-12.41	-0.56	2.38e-29	Platelet distribution width;
LUSC	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14442939	chr10:27389572	ANKRD26	-0.81	-8.97	-0.44	2.24e-17	Breast cancer;
LUSC	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg08807101	chr21:30365312	RNF160	0.65	10.32	0.49	7.47e-22	Pancreatic cancer;
LUSC	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg04310649	chr10:35416472	CREM	-0.41	-6.52	-0.34	2.61e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg15556689	chr8:8085844	FLJ10661	0.69	11.03	0.52	2.39e-24	Mean corpuscular hemoglobin;
LUSC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg23711669	chr6:146136114	FBXO30	0.86	15.66	0.65	7.86e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.54	-8.12	-0.41	9.05e-15	Lymphocyte counts;
LUSC	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.45	-0.46	6.32e-19	Body mass index;
LUSC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	0.66	13.94	0.61	3.9e-35	Prudent dietary pattern;
LUSC	cis	rs9420	0.925	rs488769	chr11:57450720	A/C	cg23127183	chr11:57508653	C11orf31	-0.53	-8.04	-0.4	1.59e-14	Schizophrenia;
LUSC	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg20019720	chr6:154832845	CNKSR3	0.62	9.33	0.45	1.56e-18	Lipoprotein (a) levels;
LUSC	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg23093090	chr10:104574429	C10orf26	-0.37	-6.31	-0.33	9.04e-10	Waist circumference;Hip circumference;
LUSC	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg01097406	chr16:89675127	NA	-0.31	-5.97	-0.31	5.94e-9	Hemoglobin concentration;
LUSC	cis	rs9378688	0.654	rs2505658	chr6:2329626	C/T	cg12303981	chr6:2244766	GMDS	-0.44	-6.12	-0.32	2.61e-9	Caudate nucleus volume;
LUSC	cis	rs2249625	0.523	rs2496501	chr6:72885364	A/G	cg18830697	chr6:72922368	RIMS1	-0.37	-7.38	-0.37	1.25e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg09034736	chr1:150693464	HORMAD1	0.44	6.32	0.33	8.16e-10	Melanoma;
LUSC	cis	rs668210	0.793	rs1786172	chr11:65770658	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.58	7.69	0.39	1.66e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-1.09	-25.02	-0.81	1.41e-78	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg26924012	chr15:45694286	SPATA5L1	1.12	20.31	0.74	2.75e-60	Homoarginine levels;
LUSC	trans	rs9393777	0.778	rs67457459	chr6:27198343	T/G	cg06606381	chr12:133084897	FBRSL1	-0.62	-6.42	-0.33	4.69e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs12681287	0.785	rs13263353	chr8:87244582	C/T	cg27223183	chr8:87520930	FAM82B	-0.46	-5.98	-0.31	5.76e-9	Caudate activity during reward;
LUSC	cis	rs10186029	0.509	rs6733869	chr2:213949073	T/C	cg08319019	chr2:214017104	IKZF2	-0.43	-6.25	-0.32	1.28e-9	Systemic sclerosis;
LUSC	trans	rs931812	0.829	rs13266662	chr8:101916156	C/T	cg20993868	chr7:22813445	NA	0.5	9.34	0.46	1.43e-18	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs12210905	0.925	rs6920115	chr6:26988417	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.98	-0.31	5.84e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs870825	0.616	rs7660064	chr4:185617529	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.42	0.59	3.9e-33	Blood protein levels;
LUSC	cis	rs6733011	0.628	rs4850888	chr2:99456946	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.57	-0.34	1.88e-10	Bipolar disorder;
LUSC	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg20991723	chr1:152506922	NA	0.49	9.36	0.46	1.17e-18	Hair morphology;
LUSC	cis	rs16912285	0.688	rs12805482	chr11:24346955	C/A	ch.11.24196551F	chr11:24239977	NA	0.87	8.38	0.42	1.5e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs11018904	0.861	rs4589254	chr11:89963355	A/C	cg26138821	chr11:89956704	CHORDC1	0.55	6.69	0.34	9.62e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs3812762	0.879	rs1079452	chr11:8779172	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.37	-6.48	-0.33	3.22e-10	Hypospadias;
LUSC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21862992	chr11:68658383	NA	0.5	8.08	0.4	1.19e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08736216	chr1:53307985	ZYG11A	-0.3	-5.96	-0.31	6.42e-9	Monocyte count;
LUSC	cis	rs7577696	0.719	rs3752916	chr2:32354558	C/T	cg02381751	chr2:32503542	YIPF4	-0.44	-6.22	-0.32	1.46e-9	Inflammatory biomarkers;
LUSC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg18357526	chr6:26021779	HIST1H4A	0.43	6.41	0.33	5.01e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21984481	chr17:79567631	NPLOC4	0.72	15.49	0.65	3.61e-41	Eye color traits;
LUSC	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg23093090	chr10:104574429	C10orf26	-0.36	-6.85	-0.35	3.49e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.51	-8.02	-0.4	1.79e-14	Height;
LUSC	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-13.7	-0.6	3.26e-34	Lymphocyte percentage of white cells;
LUSC	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg15704280	chr7:45808275	SEPT13	0.78	7.46	0.38	7.71e-13	Axial length;
LUSC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg13206674	chr6:150067644	NUP43	0.59	9.24	0.45	2.87e-18	Lung cancer;
LUSC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.4	-0.38	1.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4622329	0.636	rs7976377	chr12:102313507	G/C	cg23541617	chr12:102225335	GNPTAB	0.26	5.82	0.3	1.38e-8	Systemic lupus erythematosus;
LUSC	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg09307838	chr4:120376055	NA	-0.58	-8.86	-0.44	4.9e-17	Corneal astigmatism;
LUSC	cis	rs9837602	1.000	rs2291495	chr3:99782227	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.37	5.68	0.3	2.98e-8	Breast cancer;
LUSC	cis	rs7180079	0.620	rs3935716	chr15:65035979	A/G	cg08069370	chr15:64387884	SNX1	0.52	5.77	0.3	1.83e-8	Monocyte count;
LUSC	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg05472934	chr7:22766657	IL6	0.44	6.95	0.36	1.93e-11	Lung cancer;
LUSC	cis	rs9361491	0.657	rs9352625	chr6:79454754	G/A	cg05283184	chr6:79620031	NA	-0.32	-5.91	-0.31	8.65e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg00745463	chr17:30367425	LRRC37B	-0.71	-8.64	-0.43	2.39e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08018356	chr19:36706053	ZNF146;ZNF565	0.41	6.48	0.33	3.21e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14240646	chr10:27532245	ACBD5	-0.65	-7.75	-0.39	1.15e-13	Breast cancer;
LUSC	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg24690094	chr11:67383802	NA	-0.34	-6.42	-0.33	4.6e-10	Mean corpuscular volume;
LUSC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg11812906	chr14:75593930	NEK9	0.65	11.16	0.52	8.81e-25	Height;
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg00024416	chr22:24240387	NA	0.33	5.7	0.3	2.63e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs68170813	0.563	rs6979198	chr7:107197694	T/G	cg24556660	chr7:106842632	COG5;HBP1	-0.43	-5.7	-0.3	2.7e-8	Coronary artery disease;
LUSC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-0.92	-17.33	-0.69	1.88e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg23260525	chr10:116636907	FAM160B1	0.44	9.34	0.46	1.38e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg04565464	chr8:145669602	NFKBIL2	-0.38	-6.27	-0.32	1.11e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg02475777	chr4:1388615	CRIPAK	0.45	6.69	0.34	9.62e-11	Obesity-related traits;
LUSC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.38	-6.83	-0.35	3.96e-11	Longevity;Endometriosis;
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	0.43	7.3	0.37	2.13e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg23630131	chr7:65973040	NA	-0.21	-5.91	-0.31	8.39e-9	Aortic root size;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11179286	chr13:115047994	UPF3A	-0.45	-6.01	-0.31	4.93e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg05340658	chr4:99064831	C4orf37	-0.47	-7.44	-0.38	8.76e-13	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg01528321	chr10:82214614	TSPAN14	0.97	14.76	0.63	2.7e-38	Post bronchodilator FEV1;
LUSC	cis	rs7123876	0.541	rs61895574	chr11:72347988	A/T	cg03713592	chr11:72463424	ARAP1	0.69	6.9	0.35	2.69e-11	Body mass index;
LUSC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg06238570	chr21:40685208	BRWD1	-0.55	-8.58	-0.42	3.69e-16	Menarche (age at onset);
LUSC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg13628971	chr7:2884303	GNA12	0.46	6.33	0.33	8.02e-10	Height;
LUSC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg25767906	chr1:53392781	SCP2	-0.63	-12.44	-0.56	1.82e-29	Monocyte count;
LUSC	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg21466736	chr12:48725269	NA	-0.33	-5.76	-0.3	1.92e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg12379764	chr21:47803548	PCNT	-0.41	-5.73	-0.3	2.26e-8	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.62	0.43	2.79e-16	Coffee consumption (cups per day);
LUSC	cis	rs754133	0.891	rs12426399	chr12:54419910	G/T	cg10005224	chr12:54424964	HOXC4;HOXC5	0.42	8.28	0.41	2.94e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
LUSC	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg09165964	chr15:75287851	SCAMP5	-0.91	-10.98	-0.51	3.82e-24	Blood trace element (Zn levels);
LUSC	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg22875332	chr1:76189707	ACADM	-0.41	-6.18	-0.32	1.91e-9	Daytime sleep phenotypes;
LUSC	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg23280166	chr11:118938394	VPS11	0.48	7.64	0.39	2.27e-13	Coronary artery disease;
LUSC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg22834771	chr12:69754056	YEATS4	-0.49	-7.37	-0.37	1.31e-12	Blood protein levels;
LUSC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg05347473	chr6:146136440	FBXO30	0.5	8.69	0.43	1.61e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg20701182	chr2:24300061	SF3B14	0.87	11.4	0.53	1.19e-25	Lymphocyte counts;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20332866	chr1:100678932	DBT	0.58	8.49	0.42	7.03e-16	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.3	-0.37	2.19e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg06454157	chr6:167490870	NA	0.25	6.17	0.32	1.96e-9	Crohn's disease;
LUSC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg03526776	chr6:41159608	TREML2	0.33	6.19	0.32	1.74e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg12560992	chr17:57184187	TRIM37	0.59	9.47	0.46	5.35e-19	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg17366294	chr4:99064904	C4orf37	0.59	10.39	0.49	4.24e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg02269571	chr22:50332266	NA	-0.58	-8.67	-0.43	1.97e-16	Schizophrenia;
LUSC	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.64	10.05	0.48	5.93e-21	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.51	0.42	6.04e-16	Lung cancer;
LUSC	cis	rs138229	0.506	rs9628282	chr22:50534952	G/T	cg16473166	chr22:50639996	SELO	0.51	6.55	0.34	2.14e-10	Behavioural disinhibition (generation interaction);
LUSC	cis	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg06521331	chr12:34319734	NA	-0.47	-7.82	-0.39	7.04e-14	Morning vs. evening chronotype;
LUSC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg15212455	chr7:39170539	POU6F2	0.65	11.47	0.53	6.57e-26	IgG glycosylation;
LUSC	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg06885757	chr1:42089581	HIVEP3	-0.44	-8.22	-0.41	4.47e-15	Airway imaging phenotypes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18903719	chr5:133340536	VDAC1	-0.4	-6.01	-0.31	4.99e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg25039879	chr17:56429692	SUPT4H1	0.75	10.42	0.5	3.2800000000000002e-22	Cognitive test performance;
LUSC	cis	rs7189233	0.513	rs8044091	chr16:53520998	T/C	cg09728985	chr16:53543985	NA	-0.31	-5.84	-0.3	1.26e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.82	0.68	2.11e-46	Exhaled nitric oxide output;
LUSC	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.09	-0.32	3.03e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9653442	0.527	rs2164712	chr2:100745404	C/G	cg07810366	chr2:100720526	AFF3	-0.43	-7.2	-0.37	3.95e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7605827	0.897	rs13022830	chr2:15696542	T/C	cg19274914	chr2:15703543	NA	0.45	8.6	0.43	3.1e-16	Educational attainment (years of education);
LUSC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg00310523	chr12:86230176	RASSF9	0.52	9.89	0.48	2.12e-20	Major depressive disorder;
LUSC	cis	rs12618769	0.597	rs3754879	chr2:99164541	G/T	cg10123293	chr2:99228465	UNC50	0.5	8.21	0.41	4.78e-15	Bipolar disorder;
LUSC	cis	rs8092503	0.903	rs12970424	chr18:52472982	G/A	cg12377874	chr18:52495404	RAB27B	0.33	5.97	0.31	6.2e-9	Childhood body mass index;
LUSC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg03351412	chr1:154909251	PMVK	-0.48	-7.45	-0.38	7.95e-13	Prostate cancer;
LUSC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg01503450	chr10:980765	NA	-0.39	-6.04	-0.31	4.12e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg25456477	chr12:86230367	RASSF9	0.4	6.87	0.35	3.2e-11	Major depressive disorder;
LUSC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11764359	chr7:65958608	NA	0.69	11.16	0.52	8.79e-25	Aortic root size;
LUSC	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.7	-9.99	-0.48	9.74e-21	Glomerular filtration rate;
LUSC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.96	0.31	6.4e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg07080220	chr10:102295463	HIF1AN	0.61	8.14	0.41	8.11e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg18305652	chr10:134549665	INPP5A	0.44	6.68	0.34	9.79e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-7.73	-0.39	1.31e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-0.9	-16.73	-0.68	4.51e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7264396	0.943	rs1810742	chr20:34109718	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.47	-0.33	3.57e-10	Total cholesterol levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01153979	chr6:79577195	IRAK1BP1	-0.47	-6.15	-0.32	2.25e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg11822372	chr1:151115635	SEMA6C	0.54	8.28	0.41	3.01e-15	Childhood ear infection;
LUSC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg15556689	chr8:8085844	FLJ10661	0.52	8.09	0.4	1.12e-14	Retinal vascular caliber;
LUSC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg08847533	chr14:75593920	NEK9	-0.8	-13.94	-0.61	4e-35	Height;
LUSC	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg26395211	chr5:140044315	WDR55	-0.38	-5.78	-0.3	1.76e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-7.09	-0.36	8.19e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs11229555	0.609	rs12575080	chr11:58224917	A/G	cg15696309	chr11:58395628	NA	-0.68	-8.26	-0.41	3.34e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg08017756	chr2:100939284	LONRF2	-0.45	-8.49	-0.42	6.65e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.05	0.44	1.22e-17	Motion sickness;
LUSC	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02176678	chr2:219576539	TTLL4	0.6	10.94	0.51	5.22e-24	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg27147174	chr7:100797783	AP1S1	-0.63	-10.28	-0.49	1.01e-21	Life satisfaction;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03802069	chr3:137482593	SOX14	0.44	6.98	0.36	1.57e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg20703242	chr1:230279135	GALNT2	-0.63	-9.14	-0.45	5.99e-18	Coronary artery disease;
LUSC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2262909	0.849	rs2666447	chr19:22132868	T/A	cg11619707	chr19:22235551	ZNF257	-0.38	-5.66	-0.3	3.3e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4566357	1.000	rs3820926	chr2:227926621	G/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.89	-0.31	9.43e-9	Coronary artery disease;
LUSC	cis	rs6120849	0.754	rs3818253	chr20:33596876	C/T	cg24642439	chr20:33292090	TP53INP2	0.58	6.44	0.33	4.11e-10	Protein C levels;
LUSC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.0	0.58	1.44e-31	Cognitive test performance;
LUSC	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg00277334	chr10:82204260	NA	-0.54	-8.02	-0.4	1.81e-14	Post bronchodilator FEV1;
LUSC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg16362232	chr11:430036	ANO9	0.66	8.29	0.41	2.74e-15	Body mass index;
LUSC	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg06627628	chr2:24431161	ITSN2	0.79	11.53	0.53	4.1e-26	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg20848291	chr7:100343083	ZAN	0.4	6.37	0.33	6.35e-10	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg00012203	chr2:219082015	ARPC2	0.6	9.81	0.47	3.91e-20	Ulcerative colitis;
LUSC	cis	rs7671900	0.965	rs9996312	chr4:88285222	T/A	cg23841344	chr4:88312519	HSD17B11	-0.42	-6.19	-0.32	1.72e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg14583973	chr4:3374767	RGS12	0.37	8.05	0.4	1.48e-14	Serum sulfate level;
LUSC	cis	rs9420	0.528	rs73480556	chr11:57400462	G/C	cg23127183	chr11:57508653	C11orf31	-0.45	-6.25	-0.32	1.28e-9	Schizophrenia;
LUSC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg11843238	chr5:131593191	PDLIM4	0.5	8.81	0.43	6.71e-17	Acylcarnitine levels;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg26419426	chr5:110074663	SLC25A46	0.36	6.18	0.32	1.86e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17916960	chr15:79447300	NA	-0.53	-10.65	-0.5	5.21e-23	Refractive error;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg04085039	chr16:1712707	CRAMP1L	-0.41	-6.6	-0.34	1.66e-10	N-glycan levels;
LUSC	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02176678	chr2:219576539	TTLL4	-0.55	-9.83	-0.47	3.42e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.7	10.88	0.51	8.72e-24	Menopause (age at onset);
LUSC	cis	rs6977660	0.714	rs6945533	chr7:19813913	G/C	cg05791153	chr7:19748676	TWISTNB	0.7	7.45	0.38	8.29e-13	Thyroid stimulating hormone;
LUSC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.48	6.9	0.35	2.64e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs3849570	0.643	rs6548779	chr3:81968512	A/G	cg07356753	chr3:81810745	GBE1	-0.49	-7.23	-0.37	3.34e-12	Waist circumference;Body mass index;
LUSC	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg08917208	chr2:24149416	ATAD2B	0.89	9.65	0.47	1.31e-19	Lymphocyte counts;
LUSC	cis	rs748404	0.723	rs11853991	chr15:43557549	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.41	5.66	0.3	3.31e-8	Lung cancer;
LUSC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg12927641	chr6:109611667	NA	-0.43	-7.59	-0.38	3.15e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg22800045	chr5:56110881	MAP3K1	0.79	10.33	0.49	6.92e-22	Initial pursuit acceleration;
LUSC	trans	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.11	0.32	2.82e-9	Corneal astigmatism;
LUSC	trans	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs6496044	0.568	rs7166642	chr15:86061271	A/G	cg13263323	chr15:86062960	AKAP13	-0.38	-6.23	-0.32	1.38e-9	Interstitial lung disease;
LUSC	trans	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg01620082	chr3:125678407	NA	-0.86	-7.5	-0.38	5.97e-13	Depression;
LUSC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg21285383	chr16:89894308	SPIRE2	0.35	7.55	0.38	4.22e-13	Vitiligo;
LUSC	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg03878208	chr11:72483293	STARD10	0.49	7.23	0.37	3.4e-12	Type 2 diabetes;
LUSC	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg03806693	chr22:41940476	POLR3H	-0.59	-8.62	-0.43	2.81e-16	Neuroticism;
LUSC	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg22705602	chr4:152727874	NA	-0.33	-6.61	-0.34	1.53e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg13395646	chr4:1353034	KIAA1530	-0.65	-10.74	-0.51	2.5e-23	Obesity-related traits;
LUSC	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg00701064	chr4:6280414	WFS1	0.5	10.51	0.5	1.58e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs4252134	0.959	rs4252096	chr6:161134273	C/G	cg07697006	chr5:132202367	UQCRQ	-0.43	-6.03	-0.31	4.34e-9	Giant cell arteritis;
LUSC	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.54	0.5	1.27e-22	Colorectal cancer;
LUSC	cis	rs67981189	0.513	rs7154395	chr14:71566300	G/A	cg15816911	chr14:71606274	NA	0.33	5.78	0.3	1.68e-8	Schizophrenia;
LUSC	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg17517138	chr11:73019481	ARHGEF17	1.07	9.19	0.45	4.24e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs8179	0.645	rs66939011	chr7:92265798	T/C	cg15732164	chr7:92237376	CDK6	-0.4	-5.67	-0.3	3.06e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs9494145	1.000	rs9494145	chr6:135432552	T/C	cg22676075	chr6:135203613	NA	0.62	8.15	0.41	7.39e-15	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg10253484	chr15:75165896	SCAMP2	-0.47	-6.61	-0.34	1.52e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg15790184	chr11:494944	RNH1	0.58	6.26	0.32	1.18e-9	Body mass index;
LUSC	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg00277334	chr10:82204260	NA	-0.51	-7.56	-0.38	3.83e-13	Post bronchodilator FEV1;
LUSC	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg22709100	chr7:91322751	NA	0.39	5.75	0.3	1.98e-8	Breast cancer;
LUSC	cis	rs9807989	0.801	rs7558339	chr2:102970243	T/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.88	0.31	9.76e-9	Asthma;
LUSC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg18827107	chr12:86230957	RASSF9	-0.47	-7.05	-0.36	1.05e-11	Major depressive disorder;
LUSC	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.75	-11.11	-0.52	1.3e-24	Glomerular filtration rate;
LUSC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-6.57	-0.34	1.93e-10	Aortic root size;
LUSC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-8.2	-0.41	5.17e-15	Lymphocyte counts;
LUSC	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg22029157	chr1:209979665	IRF6	0.75	9.2	0.45	4e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.72	0.3	2.4e-8	Life satisfaction;
LUSC	cis	rs11997175	0.740	rs4467902	chr8:33693415	G/T	ch.8.33884649F	chr8:33765107	NA	0.37	5.8	0.3	1.5e-8	Body mass index;
LUSC	cis	rs870825	0.587	rs6826883	chr4:185616167	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.5	0.59	1.86e-33	Blood protein levels;
LUSC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg10523860	chr14:103875565	MARK3	-0.4	-6.38	-0.33	6.08e-10	Body mass index;
LUSC	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	12.0	0.55	7.98e-28	Prudent dietary pattern;
LUSC	cis	rs12618769	0.597	rs3754885	chr2:99121708	G/T	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.82	0.35	4.17e-11	Platelet count;
LUSC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg09021430	chr5:549028	NA	-0.42	-7.49	-0.38	6.29e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg12310025	chr6:25882481	NA	0.41	6.82	0.35	4.18e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09687332	chr3:49977370	RBM6	0.84	6.62	0.34	1.46e-10	Cognitive performance;
LUSC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg22535103	chr8:58192502	C8orf71	-0.67	-7.55	-0.38	4.15e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg08270630	chr22:50330655	NA	-0.42	-6.29	-0.33	1e-9	Schizophrenia;
LUSC	cis	rs16937	0.711	rs12129162	chr1:205164650	A/G	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.36e-10	Schizophrenia;
LUSC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg03477792	chr4:77819574	ANKRD56	0.56	7.66	0.39	2.09e-13	Emphysema distribution in smoking;
LUSC	cis	rs7617773	0.963	rs12495221	chr3:48179178	C/T	cg20734569	chr3:48348370	SPINK8	0.44	7.93	0.4	3.25e-14	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17105604	chr19:10764573	ILF3;LOC147727	-0.41	-6.09	-0.32	3.17e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg14582100	chr15:45693742	SPATA5L1	0.56	10.09	0.48	4.45e-21	Homoarginine levels;
LUSC	trans	rs10098647	0.632	rs10091445	chr8:61106834	G/C	cg09970348	chr3:183978600	ECE2;CAMK2N2	0.46	6.33	0.33	7.92e-10	Obesity-related traits;
LUSC	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21643547	chr1:205240462	TMCC2	-0.51	-9.61	-0.47	1.82e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg23625390	chr15:77176239	SCAPER	-0.66	-9.86	-0.47	2.61e-20	Blood metabolite levels;
LUSC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg22535103	chr8:58192502	C8orf71	-0.75	-9.49	-0.46	4.42e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.4	-6.41	-0.33	5.01e-10	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg11062466	chr8:58055876	NA	0.43	5.77	0.3	1.81e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.79	12.05	0.55	5.1e-28	Lymphocyte counts;
LUSC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-7.83	-0.39	6.56e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg24838063	chr12:130822603	PIWIL1	0.67	10.45	0.5	2.57e-22	Menopause (age at onset);
LUSC	cis	rs9815354	0.857	rs1474219	chr3:42000913	G/A	cg03022575	chr3:42003672	ULK4	-0.51	-5.72	-0.3	2.37e-8	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	7.22	0.37	3.64e-12	Cognitive ability;
LUSC	cis	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg20368463	chr18:77673604	PQLC1	0.69	5.93	0.31	7.62e-9	Opioid sensitivity;
LUSC	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg21643547	chr1:205240462	TMCC2	-0.36	-6.74	-0.35	7.08e-11	Red blood cell count;
LUSC	cis	rs9815354	0.812	rs17215183	chr3:41812334	T/C	cg03022575	chr3:42003672	ULK4	0.85	8.67	0.43	1.87e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7267979	0.527	rs6076369	chr20:25576783	G/A	cg03522245	chr20:25566470	NINL	-0.39	-6.09	-0.32	3.1e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6845621	0.717	rs4696962	chr4:18873031	T/C	cg12196642	chr4:18937545	NA	-0.32	-6.04	-0.31	4.06e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg14893161	chr1:205819251	PM20D1	-0.47	-6.41	-0.33	4.93e-10	Menarche (age at onset);
LUSC	cis	rs9309473	0.948	rs7607892	chr2:73818707	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.76	-0.35	6.28e-11	Metabolite levels;
LUSC	cis	rs4499344	0.730	rs614370	chr19:33106390	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	12.93	0.58	2.86e-31	Mean platelet volume;
LUSC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03576123	chr11:487126	PTDSS2	-0.95	-10.4	-0.49	3.94e-22	Body mass index;
LUSC	cis	rs9362426	0.708	rs4707365	chr6:88100912	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.15	0.32	2.16e-9	Depressive episodes in bipolar disorder;
LUSC	cis	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg09307838	chr4:120376055	NA	-0.49	-7.48	-0.38	6.83e-13	Diastolic blood pressure;
LUSC	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg27087555	chr16:88793112	FAM38A	-1.27	-12.67	-0.57	2.56e-30	Plateletcrit;
LUSC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg25258033	chr6:167368657	RNASET2	0.39	6.39	0.33	5.72e-10	Crohn's disease;
LUSC	cis	rs13385	0.769	rs10477333	chr5:139617885	T/C	cg26211634	chr5:139558579	C5orf32	0.45	7.02	0.36	1.21e-11	Atrial fibrillation;
LUSC	cis	rs2274273	0.870	rs3825616	chr14:55853288	G/C	cg04306507	chr14:55594613	LGALS3	0.56	12.76	0.57	1.24e-30	Protein biomarker;
LUSC	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg00129232	chr17:37814104	STARD3	-0.45	-6.57	-0.34	1.93e-10	Asthma;
LUSC	cis	rs240993	0.595	rs3777910	chr6:111902451	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.34	6.09	0.32	3.07e-9	Inflammatory skin disease;Psoriasis;
LUSC	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg21153622	chr11:89784906	NA	-0.39	-6.0	-0.31	5.21e-9	HDL cholesterol;
LUSC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.13	0.32	2.52e-9	Menopause (age at onset);
LUSC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06634786	chr22:41940651	POLR3H	0.56	6.5	0.34	2.87e-10	Vitiligo;
LUSC	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-6.67	-0.34	1.03e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs16976116	0.901	rs9920219	chr15:55503964	T/C	cg11288833	chr15:55489084	RSL24D1	0.5	5.92	0.31	7.84e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-0.88	-15.47	-0.65	4.51e-41	Height;
LUSC	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	8.91	0.44	3.32e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4478858	0.735	rs10798845	chr1:31822636	A/G	cg00250761	chr1:31883323	NA	0.37	9.26	0.45	2.57e-18	Alcohol dependence;
LUSC	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg11621586	chr10:70884670	VPS26A	1.12	14.08	0.61	1.17e-35	Left atrial antero-posterior diameter;
LUSC	cis	rs6012953	0.874	rs2426159	chr20:49173179	C/T	cg13958625	chr20:49123093	NA	-0.27	-6.08	-0.32	3.22e-9	Vitiligo;
LUSC	cis	rs6987853	0.830	rs4737048	chr8:42359035	G/T	cg09913449	chr8:42400586	C8orf40	-0.41	-6.78	-0.35	5.36e-11	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9341808	0.718	rs10080237	chr6:80854470	T/C	cg08355045	chr6:80787529	NA	0.57	9.9	0.48	1.96e-20	Sitting height ratio;
LUSC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.41	7.0	0.36	1.39e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.73	-13.36	-0.59	6.47e-33	Ulcerative colitis;
LUSC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.77	0.3	1.81e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg16447950	chr5:562315	NA	-0.47	-6.36	-0.33	6.8e-10	Obesity-related traits;
LUSC	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg02527881	chr3:46936655	PTH1R	-0.39	-6.79	-0.35	5.04e-11	Colorectal cancer;
LUSC	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg24375607	chr4:120327624	NA	0.69	10.92	0.51	6.06e-24	Corneal astigmatism;
LUSC	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg13206674	chr6:150067644	NUP43	0.55	8.28	0.41	3.02e-15	Lung cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03577460	chr14:24836084	NFATC4	0.41	5.99	0.31	5.34e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg09955084	chr16:413813	NA	0.29	6.32	0.33	8.32e-10	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.45	-6.54	-0.34	2.34e-10	Menarche (age at onset);
LUSC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg26441486	chr22:50317300	CRELD2	0.53	7.75	0.39	1.1e-13	Schizophrenia;
LUSC	cis	rs983392	0.667	rs632185	chr11:59951433	A/G	cg20284999	chr11:59952153	MS4A6A	0.35	6.21	0.32	1.58e-9	Alzheimer's disease (late onset);
LUSC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	11.21	0.52	5.84e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg09491104	chr22:46646882	C22orf40	-0.64	-7.28	-0.37	2.46e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg22782873	chr19:19639568	YJEFN3	-0.54	-6.58	-0.34	1.82e-10	Bipolar disorder;
LUSC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg27572855	chr1:25598939	RHD	0.41	7.26	0.37	2.7e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs12318506	0.826	rs35933860	chr12:75731821	A/G	cg04728562	chr12:75699417	CAPS2	-0.84	-5.91	-0.31	8.43e-9	Coronary artery calcification;
LUSC	cis	rs4343996	0.566	rs6971287	chr7:3396180	T/G	cg21248987	chr7:3385318	SDK1	-0.35	-5.79	-0.3	1.67e-8	Motion sickness;
LUSC	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg04362960	chr10:104952993	NT5C2	0.61	9.52	0.46	3.52e-19	Arsenic metabolism;
LUSC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg13683864	chr3:40499215	RPL14	-0.94	-16.74	-0.68	4.21e-46	Renal cell carcinoma;
LUSC	cis	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg24375607	chr4:120327624	NA	0.49	7.55	0.38	4.15e-13	Diastolic blood pressure;
LUSC	cis	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg21775007	chr8:11205619	TDH	0.47	6.66	0.34	1.11e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg11793168	chr2:37415747	SULT6B1	0.42	6.18	0.32	1.89e-9	Cognitive function;Information processing speed;
LUSC	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg10518543	chr12:38710700	ALG10B	0.44	6.12	0.32	2.58e-9	Morning vs. evening chronotype;
LUSC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg22800045	chr5:56110881	MAP3K1	0.48	6.19	0.32	1.73e-9	Coronary artery disease;
LUSC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.7	0.3	2.64e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg14664628	chr15:75095509	CSK	0.44	6.25	0.32	1.23e-9	Systemic lupus erythematosus;
LUSC	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.94	-15.9	-0.66	8.97e-43	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg27284194	chr4:1044797	NA	-0.54	-7.94	-0.4	3.03e-14	Recombination rate (females);
LUSC	trans	rs13390641	0.614	rs67467351	chr2:104084844	C/T	cg03260781	chr1:16346299	HSPB7	-0.46	-6.09	-0.32	3.14e-9	Blood pressure;Blood pressure (anthropometric measures interaction);
LUSC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg14440974	chr22:39074834	NA	-0.39	-6.44	-0.33	4.23e-10	Menopause (age at onset);
LUSC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg15448220	chr1:150897856	SETDB1	0.42	6.13	0.32	2.47e-9	Melanoma;
LUSC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	trans	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg18187862	chr3:45730750	SACM1L	-0.51	-6.17	-0.32	1.99e-9	Primary sclerosing cholangitis;
LUSC	cis	rs68170813	0.605	rs2299428	chr7:107134384	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.51	-0.46	3.85e-19	Coronary artery disease;
LUSC	cis	rs1568889	0.592	rs7110074	chr11:28469325	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.54	6.72	0.35	7.75e-11	Bipolar disorder;
LUSC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg00484396	chr16:3507460	NAT15	0.69	12.07	0.55	4.48e-28	Tuberculosis;
LUSC	cis	rs2274273	0.600	rs35112084	chr14:55781100	T/A	cg04306507	chr14:55594613	LGALS3	0.48	9.7	0.47	9.23e-20	Protein biomarker;
LUSC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.45	-6.23	-0.32	1.42e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06873352	chr17:61820015	STRADA	0.56	8.62	0.43	2.81e-16	Height;
LUSC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.42	-5.89	-0.31	9.49e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.54	-10.28	-0.49	1.05e-21	Prostate cancer;
LUSC	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.82	-0.65	1.76e-42	Height;
LUSC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg12463550	chr7:65579703	CRCP	0.45	6.65	0.34	1.23e-10	Aortic root size;
LUSC	trans	rs11949289	0.933	rs58515706	chr5:28344653	A/T	cg18220921	chr1:242687527	PLD5	0.35	5.96	0.31	6.57e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.86	16.3	0.67	2.31e-44	Mean platelet volume;
LUSC	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.21	0.45	3.72e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg22705602	chr4:152727874	NA	-0.32	-6.39	-0.33	5.71e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9818941	0.910	rs9825122	chr3:157672947	T/C	cg08654915	chr3:157813417	NA	-0.24	-5.88	-0.31	9.89e-9	Height;
LUSC	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg07741184	chr6:167504864	NA	0.5	8.44	0.42	1.01e-15	Crohn's disease;
LUSC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	13.48	0.59	2.36e-33	Monocyte percentage of white cells;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04520396	chr17:1585312	PRPF8	0.4	6.31	0.33	8.63e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03517284	chr6:25882590	NA	-0.38	-6.8	-0.35	4.95e-11	Height;
LUSC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg08677398	chr8:58056175	NA	0.41	5.65	0.3	3.37e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg06877462	chr1:205807181	PM20D1	0.36	5.9	0.31	8.7e-9	Menarche (age at onset);
LUSC	cis	rs7572644	0.639	rs74429612	chr2:27993843	C/T	cg27432699	chr2:27873401	GPN1	0.58	7.36	0.37	1.45e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs911119	1.000	rs34374560	chr20:23609462	C/T	cg16589663	chr20:23618590	CST3	0.59	6.96	0.36	1.8e-11	Chronic kidney disease;
LUSC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.59	10.67	0.5	4.56e-23	Bone mineral density;
LUSC	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg04362960	chr10:104952993	NT5C2	0.59	9.31	0.45	1.8e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2708977	0.698	rs772161	chr2:97043803	C/A	cg01950434	chr2:97203154	ARID5A	-0.45	-5.98	-0.31	5.67e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg04310649	chr10:35416472	CREM	-0.43	-6.59	-0.34	1.73e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	0.91	13.16	0.58	3.71e-32	Uric acid levels;
LUSC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg24250549	chr1:154909240	PMVK	0.66	11.05	0.52	2.07e-24	Prostate cancer;
LUSC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg27165867	chr14:105738592	BRF1	-0.55	-7.86	-0.39	5.46e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2905347	0.520	rs1858936	chr7:22647553	G/C	cg23521230	chr7:22704884	NA	0.43	5.7	0.3	2.64e-8	Major depression and alcohol dependence;
LUSC	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg01733217	chr16:74700730	RFWD3	0.78	12.75	0.57	1.33e-30	Testicular germ cell tumor;
LUSC	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg18681998	chr4:17616180	MED28	0.78	13.71	0.6	3.02e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg22782873	chr19:19639568	YJEFN3	-0.46	-5.82	-0.3	1.39e-8	Bipolar disorder;
LUSC	cis	rs7705502	1.000	rs6861681	chr5:173362458	G/A	cg18693985	chr5:173351052	CPEB4	-0.37	-5.83	-0.3	1.3e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg18827107	chr12:86230957	RASSF9	-0.5	-7.29	-0.37	2.3e-12	Major depressive disorder;
LUSC	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg00857998	chr1:205179979	DSTYK	0.53	8.12	0.41	9.08e-15	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg02167203	chr6:41068553	NFYA;LOC221442	-0.43	-6.08	-0.32	3.32e-9	Alzheimer's disease (late onset);
LUSC	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.25	-11.61	-0.54	2.06e-26	Reticulocyte fraction of red cells;Reticulocyte count;
LUSC	cis	rs16854884	0.657	rs4611822	chr3:143735544	C/T	cg06585982	chr3:143692056	C3orf58	0.5	8.13	0.41	8.55e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg06784218	chr1:46089804	CCDC17	0.51	10.38	0.49	4.73e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7781370	1.000	rs4727338	chr7:96120675	G/C	cg00604640	chr7:96133485	NA	-0.33	-5.82	-0.3	1.36e-8	Bone mineral density (hip);
LUSC	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg17470723	chr8:74884337	TCEB1	0.51	7.91	0.4	3.71e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7582720	1.000	rs114155121	chr2:203718682	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	8.17	0.41	6.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.42	-0.33	4.69e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.38	-0.37	1.25e-12	Electroencephalogram traits;
LUSC	cis	rs4363385	0.818	rs382292	chr1:153006641	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.45e-8	Inflammatory skin disease;
LUSC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg22029157	chr1:209979665	IRF6	0.82	10.35	0.49	5.72e-22	Cleft lip with or without cleft palate;
LUSC	cis	rs7112043	1.000	rs7112043	chr11:34789386	A/T	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.87	0.31	1.03e-8	Lung disease severity in cystic fibrosis;
LUSC	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg22491629	chr6:157744540	C6orf35	-0.9	-10.88	-0.51	8.12e-24	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg25643088	chr3:52874325	TMEM110	0.38	5.86	0.31	1.1e-8	Schizophrenia;
LUSC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg07777115	chr5:623756	CEP72	0.45	5.78	0.3	1.75e-8	Obesity-related traits;
LUSC	trans	rs7939886	0.920	rs11227321	chr11:55904828	A/G	cg03929089	chr4:120376271	NA	0.77	6.09	0.32	3.03e-9	Myopia (pathological);
LUSC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	0.9	17.22	0.69	5.31e-48	Heart rate;
LUSC	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg23950597	chr19:37808831	NA	-0.63	-7.51	-0.38	5.51e-13	Coronary artery calcification;
LUSC	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.6	0.34	1.62e-10	Joint mobility (Beighton score);
LUSC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-7.1	-0.36	7.69e-12	Platelet count;
LUSC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.83	0.65	1.69e-42	Bladder cancer;
LUSC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	0.94	13.78	0.6	1.62e-34	Vitiligo;
LUSC	cis	rs10843647	1.000	rs1114770	chr12:30330231	T/C	cg12718339	chr12:29936407	TMTC1	-0.34	-5.77	-0.3	1.77e-8	Glucose homeostasis traits;
LUSC	cis	rs2652834	0.718	rs2729834	chr15:63397047	G/C	cg05507819	chr15:63340323	TPM1	0.55	6.98	0.36	1.55e-11	HDL cholesterol;
LUSC	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-0.9	-16.33	-0.67	1.83e-44	Tonsillectomy;
LUSC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg12463550	chr7:65579703	CRCP	0.56	8.35	0.42	1.8e-15	Aortic root size;
LUSC	cis	rs12318506	0.623	rs12313311	chr12:75768327	A/T	cg04728562	chr12:75699417	CAPS2	-0.82	-5.82	-0.3	1.36e-8	Coronary artery calcification;
LUSC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg22907277	chr7:1156413	C7orf50	0.71	7.42	0.38	9.47e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg14534967	chr7:73153139	ABHD11	0.41	5.97	0.31	6.13e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs977987	0.806	rs12051326	chr16:75437887	G/A	cg03315344	chr16:75512273	CHST6	0.48	8.94	0.44	2.8e-17	Dupuytren's disease;
LUSC	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg13042288	chr15:90349979	ANPEP	-0.48	-6.93	-0.35	2.24e-11	Uric acid levels;
LUSC	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg05925327	chr15:68127851	NA	-0.41	-6.6	-0.34	1.6e-10	Restless legs syndrome;
LUSC	cis	rs4423214	0.840	rs1790340	chr11:71182589	T/C	cg05163923	chr11:71159392	DHCR7	-0.8	-10.2	-0.49	1.88e-21	Vitamin D levels;
LUSC	cis	rs4132509	0.744	rs12021907	chr1:243995640	A/G	cg21452805	chr1:244014465	NA	-0.58	-5.96	-0.31	6.25e-9	RR interval (heart rate);
LUSC	cis	rs13401104	0.796	rs10929166	chr2:237111201	C/T	cg19324714	chr2:237145437	ASB18	0.43	5.79	0.3	1.6e-8	Educational attainment;
LUSC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.42	-0.46	7.83e-19	Type 2 diabetes;
LUSC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25072359	chr17:41440525	NA	0.65	9.08	0.44	9.83e-18	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.4	0.33	5.28e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs13233308	0.868	rs1029421	chr7:87418861	T/C	cg22633988	chr4:77610603	SHROOM3	-0.43	-6.35	-0.33	7.13e-10	Schizophrenia;
LUSC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.46	-6.27	-0.32	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg20243544	chr17:37824526	PNMT	0.48	6.87	0.35	3.2e-11	Asthma;
LUSC	cis	rs6138458	0.701	rs6050255	chr20:25007089	A/G	cg26195577	chr20:24973756	C20orf3	0.79	12.11	0.55	3.07e-28	Blood protein levels;
LUSC	cis	rs1009647	1.000	rs1890256	chr14:55881276	C/T	cg04306507	chr14:55594613	LGALS3	0.43	7.27	0.37	2.58e-12	Testicular germ cell tumor;
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	1.0	19.21	0.72	6.3e-56	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.93	15.74	0.65	3.8e-42	Bladder cancer;
LUSC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.52	0.34	2.54e-10	Schizophrenia;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg09702105	chr4:108910794	HADH	0.38	5.94	0.31	7.04e-9	Mosquito bite size;
LUSC	cis	rs3007168	0.951	rs3007074	chr14:51604731	T/A	cg23942311	chr14:51606299	NA	0.37	6.02	0.31	4.5e-9	Cancer;
LUSC	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.55	0.34	2.23e-10	IgG glycosylation;
LUSC	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg17063962	chr7:91808500	NA	0.57	8.62	0.43	2.67e-16	Breast cancer;
LUSC	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.11	-0.36	7.29e-12	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs2070433	0.904	rs8130209	chr21:47925984	T/C	cg12379764	chr21:47803548	PCNT	0.7	9.21	0.45	3.71e-18	Lymphocyte counts;
LUSC	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg17470449	chr10:769945	NA	0.53	7.31	0.37	1.98e-12	Uric acid levels;
LUSC	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg02176678	chr2:219576539	TTLL4	0.58	10.49	0.5	1.91e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.47	-6.85	-0.35	3.62e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.26	-0.41	3.38e-15	Response to antipsychotic treatment;
LUSC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06544989	chr22:39130855	UNC84B	0.33	5.76	0.3	1.86e-8	Menopause (age at onset);
LUSC	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg21905437	chr5:178450457	ZNF879	0.46	5.98	0.31	5.62e-9	Pubertal anthropometrics;
LUSC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.85	0.51	1.06e-23	Monocyte percentage of white cells;
LUSC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.16	-0.36	5.25e-12	Blood metabolite levels;
LUSC	cis	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg06521331	chr12:34319734	NA	0.37	6.3	0.33	9.33e-10	Morning vs. evening chronotype;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg06212498	chr3:49045151	WDR6	0.42	7.07	0.36	8.96e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg05738196	chr6:26577821	NA	-0.6	-7.21	-0.37	3.78e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4845459	0.967	rs6700160	chr1:152593024	A/C	cg08895932	chr1:152778580	LCE1C	-0.38	-6.46	-0.33	3.68e-10	Psoriasis;
LUSC	trans	rs783147	0.500	rs9456578	chr6:161147368	A/T	cg15416064	chr12:49209402	NA	-0.43	-6.06	-0.31	3.58e-9	Lp (a) levels;
LUSC	trans	rs1043099	0.912	rs4820831	chr22:30711443	C/T	cg10543363	chr10:11784253	ECHDC3	-0.51	-6.06	-0.31	3.73e-9	Rheumatoid arthritis;
LUSC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-1.09	-21.84	-0.77	2.65e-66	Height;
LUSC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.85	-15.07	-0.64	1.55e-39	Cognitive function;
LUSC	cis	rs7511006	1.000	rs7290710	chr22:50677454	C/T	cg07895657	chr22:50616420	PANX2	-0.35	-5.79	-0.3	1.58e-8	Obesity-related traits;
LUSC	cis	rs12618769	0.597	rs3769715	chr2:99146855	C/T	cg10123293	chr2:99228465	UNC50	0.46	7.47	0.38	7.09e-13	Bipolar disorder;
LUSC	cis	rs73195822	0.614	rs73194056	chr12:111216325	A/G	cg12870014	chr12:110450643	ANKRD13A	0.69	7.06	0.36	9.82e-12	Itch intensity from mosquito bite;
LUSC	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg05373962	chr22:49881684	NA	-0.4	-8.49	-0.42	7.08e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21887597	chr15:83419354	NA	0.53	7.85	0.39	5.76e-14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11997175	0.595	rs6468204	chr8:33774748	T/C	ch.8.33884649F	chr8:33765107	NA	0.43	6.31	0.33	8.78e-10	Body mass index;
LUSC	cis	rs290268	0.647	rs1333637	chr9:93557066	C/T	cg02608019	chr9:93564028	SYK	-0.54	-8.89	-0.44	3.87e-17	Platelet count;
LUSC	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.49	0.38	6.36e-13	Iron status biomarkers;
LUSC	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg18200150	chr17:30822561	MYO1D	-0.31	-5.99	-0.31	5.43e-9	Schizophrenia;
LUSC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg19539972	chr4:7069911	GRPEL1	-0.65	-7.21	-0.37	3.85e-12	Monocyte percentage of white cells;
LUSC	cis	rs10100465	0.961	rs1508555	chr8:118638344	T/C	cg09430518	chr8:118662568	NA	-0.29	-5.66	-0.3	3.2e-8	Leprosy;
LUSC	cis	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg00262122	chr8:11665843	FDFT1	0.39	5.7	0.3	2.66e-8	Neuroticism;
LUSC	cis	rs710216	0.957	rs841563	chr1:43429520	C/T	cg22176566	chr1:43424700	SLC2A1	0.48	5.98	0.31	5.71e-9	Red cell distribution width;
LUSC	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg07080220	chr10:102295463	HIF1AN	0.59	7.61	0.38	2.86e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4930561	0.690	rs6591334	chr11:67924559	A/G	cg04465784	chr11:67976953	SUV420H1	-0.29	-5.73	-0.3	2.19e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg10755058	chr3:40428713	ENTPD3	0.35	5.79	0.3	1.64e-8	Renal cell carcinoma;
LUSC	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	13.17	0.58	3.35e-32	Blood protein levels;
LUSC	cis	rs3755132	0.929	rs4668950	chr2:15780191	T/C	cg12888861	chr2:15731646	DDX1	0.52	7.43	0.38	9.29e-13	Wilms tumor;
LUSC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg08493051	chr2:3487164	NA	-0.56	-8.81	-0.43	6.76e-17	Neurofibrillary tangles;
LUSC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.32	-0.37	1.84e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg21643860	chr11:62358814	TUT1	0.37	6.32	0.33	8.45e-10	Triglycerides;
LUSC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg24733560	chr20:60626293	TAF4	0.41	6.73	0.35	7.6e-11	Body mass index;
LUSC	cis	rs4959270	0.869	rs55776749	chr6:452732	A/G	cg09757644	chr6:447497	NA	0.28	5.79	0.3	1.66e-8	Limited cutaneous systemic scleroderma;
LUSC	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg16339924	chr4:17578868	LAP3	0.54	7.98	0.4	2.38e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-7.67	-0.39	1.87e-13	Retinal vascular caliber;
LUSC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg03060546	chr3:49711283	APEH	0.71	11.99	0.55	8.86e-28	Resting heart rate;
LUSC	cis	rs8141797	0.901	rs4822472	chr22:24468123	C/A	cg00411358	chr22:24577142	SUSD2	0.61	6.32	0.33	8.56e-10	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs7903847	0.620	rs17112674	chr10:99122178	C/T	cg08345082	chr10:99160200	RRP12	0.34	6.81	0.35	4.68e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2282300	0.956	rs2685286	chr11:30381588	G/A	cg25418670	chr11:30344373	C11orf46	-0.52	-7.25	-0.37	2.91e-12	Morning vs. evening chronotype;
LUSC	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.06	0.55	4.92e-28	Ileal carcinoids;
LUSC	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-9.77	-0.47	5.22e-20	Extrinsic epigenetic age acceleration;
LUSC	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-9.02	-0.44	1.49e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs6977940	0.512	rs11765726	chr7:2850878	A/G	cg14895029	chr7:2775587	GNA12	0.5	6.35	0.33	7.16e-10	White matter integrity;
LUSC	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.88	14.49	0.62	2.95e-37	Bladder cancer;
LUSC	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg12698349	chr2:225449008	CUL3	0.84	13.81	0.6	1.21e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs892961	0.932	rs9646396	chr17:75416755	G/A	cg05865280	chr17:75406074	SEPT9	0.45	9.24	0.45	3.05e-18	Airflow obstruction;
LUSC	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg26875233	chr11:93583750	C11orf90	-0.31	-6.05	-0.31	3.91e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-8.44	-0.42	9.59e-16	Breast cancer;
LUSC	cis	rs79387448	0.745	rs7601773	chr2:103120483	G/T	cg09003973	chr2:102972529	NA	0.86	8.61	0.43	3.03e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg21132104	chr15:45694354	SPATA5L1	0.57	8.01	0.4	1.93e-14	Homoarginine levels;
LUSC	cis	rs34375054	0.558	rs67041765	chr12:125672913	T/G	cg06287003	chr12:125626642	AACS	-0.38	-6.29	-0.33	9.95e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.62	-8.82	-0.43	6.69e-17	Iron status biomarkers;
LUSC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.84	-0.3	1.21e-8	Neutrophil percentage of white cells;
LUSC	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg25427524	chr10:38739819	LOC399744	0.45	5.9	0.31	8.86e-9	Obesity (extreme);
LUSC	cis	rs62400317	0.859	rs6920046	chr6:45159431	A/C	cg20913747	chr6:44695427	NA	-0.48	-7.7	-0.39	1.56e-13	Total body bone mineral density;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07496106	chr16:46918160	GPT2	0.76	6.09	0.32	3.15e-9	Cognitive performance;
LUSC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg14024328	chr4:719362	PCGF3	-0.51	-8.29	-0.41	2.77e-15	White blood cell count;
LUSC	cis	rs7178572	0.524	rs11853287	chr15:77399371	A/G	cg22256960	chr15:77711686	NA	-0.5	-7.71	-0.39	1.46e-13	Type 2 diabetes;
LUSC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg02269571	chr22:50332266	NA	-0.6	-9.04	-0.44	1.3e-17	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	9.55	0.46	2.94e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.16	0.32	2.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg03465714	chr1:152285911	FLG	-0.4	-5.67	-0.3	3.07e-8	Atopic dermatitis;
LUSC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06544989	chr22:39130855	UNC84B	-0.33	-5.84	-0.3	1.21e-8	Menopause (age at onset);
LUSC	trans	rs800082	1.000	rs62275526	chr3:144291707	G/A	cg24215973	chr2:240111563	HDAC4	-0.46	-6.93	-0.35	2.19e-11	Smoking behavior;
LUSC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg04398451	chr17:18023971	MYO15A	-0.47	-7.67	-0.39	1.94e-13	Total body bone mineral density;
LUSC	cis	rs2625529	0.938	rs9120	chr15:72115763	G/A	cg16672083	chr15:72433130	SENP8	-0.51	-7.22	-0.37	3.59e-12	Red blood cell count;
LUSC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg14844989	chr11:31128820	NA	0.39	5.93	0.31	7.53e-9	Red blood cell count;
LUSC	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg25643088	chr3:52874325	TMEM110	0.39	5.97	0.31	6.09e-9	Schizophrenia;
LUSC	cis	rs7575217	0.767	rs10207371	chr2:101763227	C/T	cg23907051	chr2:101730305	TBC1D8	-0.29	-7.68	-0.39	1.76e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs12815613	1.000	rs12815613	chr12:121407256	A/G	cg02403541	chr12:121454288	C12orf43	-0.48	-6.04	-0.31	4.06e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg11812906	chr14:75593930	NEK9	0.66	11.38	0.53	1.35e-25	Height;
LUSC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	6.97	0.36	1.65e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-7.59	-0.38	3.28e-13	Adiposity;
LUSC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg03579872	chr1:53393473	SCP2	0.38	5.64	0.3	3.54e-8	Monocyte count;
LUSC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08704250	chr15:31115839	NA	0.4	6.14	0.32	2.37e-9	Huntington's disease progression;
LUSC	cis	rs7582180	0.652	rs11687864	chr2:100946993	T/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.59	-0.43	3.35e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg10356904	chr22:49881777	NA	-0.33	-7.52	-0.38	5.26e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.42	6.11	0.32	2.84e-9	Response to antipsychotic treatment;
LUSC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	0.59	9.35	0.46	1.32e-18	Breast cancer;
LUSC	cis	rs113835537	0.529	rs11227509	chr11:66281194	T/C	cg24851651	chr11:66362959	CCS	0.53	7.93	0.4	3.42e-14	Airway imaging phenotypes;
LUSC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg15448220	chr1:150897856	SETDB1	0.43	6.29	0.33	1.02e-9	Melanoma;
LUSC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg06238570	chr21:40685208	BRWD1	-0.66	-10.47	-0.5	2.29e-22	Cognitive function;
LUSC	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	14.84	0.63	1.26e-38	Lymphocyte percentage of white cells;
LUSC	cis	rs1160297	0.601	rs1828337	chr2:53096942	G/T	cg07782112	chr2:53107842	NA	0.39	6.43	0.33	4.3e-10	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg26384229	chr12:38710491	ALG10B	0.56	9.04	0.44	1.29e-17	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg03676636	chr4:99064102	C4orf37	0.31	6.68	0.34	9.74e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg06671706	chr8:8559999	CLDN23	-0.42	-5.81	-0.3	1.46e-8	Obesity-related traits;
LUSC	cis	rs7851660	0.844	rs4743139	chr9:100638420	A/G	cg13688889	chr9:100608707	NA	-0.55	-8.34	-0.42	1.91e-15	Strep throat;
LUSC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg17376030	chr22:41985996	PMM1	-0.47	-5.73	-0.3	2.19e-8	Vitiligo;
LUSC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.09	0.4	1.14e-14	Prudent dietary pattern;
LUSC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg06494592	chr3:125709126	NA	-0.52	-6.01	-0.31	4.85e-9	Blood pressure (smoking interaction);
LUSC	cis	rs4595586	0.566	rs7307174	chr12:39368862	A/G	cg26384229	chr12:38710491	ALG10B	0.45	6.3	0.33	9.47e-10	Morning vs. evening chronotype;
LUSC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.51	-8.86	-0.44	4.92e-17	Menopause (age at onset);
LUSC	cis	rs11209185	0.563	rs10889733	chr1:68424136	G/A	cg22082780	chr1:68452167	NA	-0.38	-6.32	-0.33	8.59e-10	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg22800045	chr5:56110881	MAP3K1	0.46	6.5	0.34	2.9e-10	Breast cancer;Breast cancer (early onset);
LUSC	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.47	-0.46	5.22e-19	Neuroticism;
LUSC	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg05966235	chr16:28915196	ATP2A1	0.33	5.81	0.3	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg27398817	chr8:82754497	SNX16	-0.64	-8.01	-0.4	1.9e-14	Diastolic blood pressure;
LUSC	trans	rs6856616	0.614	rs1487630	chr4:38335823	A/G	cg06902698	chr1:151137676	SCNM1;LYSMD1	-0.46	-6.77	-0.35	5.65e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs35000415	0.938	rs34725944	chr7:128641653	T/C	cg19972273	chr7:128594194	NA	0.68	6.79	0.35	5.04e-11	Systemic lupus erythematosus;
LUSC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg18850127	chr7:39170497	POU6F2	0.66	10.7	0.51	3.71e-23	IgG glycosylation;
LUSC	cis	rs28655083	0.529	rs1485794	chr16:77101977	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.39	6.19	0.32	1.72e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.68	-6.43	-0.33	4.4e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg01879757	chr17:41196368	BRCA1	-0.45	-6.83	-0.35	4.07e-11	Menopause (age at onset);
LUSC	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg21064579	chr19:49206444	FUT2	0.44	8.42	0.42	1.12e-15	Dietary macronutrient intake;
LUSC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	1.05	18.39	0.71	1.18e-52	Parkinson's disease;
LUSC	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg23093090	chr10:104574429	C10orf26	-0.35	-6.44	-0.33	4.15e-10	Arsenic metabolism;
LUSC	cis	rs6005807	0.563	rs7288792	chr22:29015603	C/T	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs2860975	1.000	rs10159983	chr10:96774437	C/T	cg09036531	chr10:96991505	NA	-0.41	-5.66	-0.3	3.26e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg10729496	chr3:10149963	C3orf24	-0.48	-6.68	-0.34	1e-10	Alzheimer's disease;
LUSC	cis	rs28655083	1.000	rs1843457	chr16:77072400	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.38	-5.76	-0.3	1.93e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs834603	0.575	rs1799371	chr7:47467436	C/T	cg09696706	chr7:47479511	TNS3	0.32	5.87	0.31	1.03e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	trans	rs67539049	1.000	rs7832089	chr8:11306003	C/A	cg26241650	chr22:40417538	FAM83F	0.45	6.04	0.31	4.03e-9	Itch intensity from mosquito bite;
LUSC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.22	0.37	3.56e-12	Mean platelet volume;
LUSC	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.3	6.68	0.34	9.74e-11	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14047339	chr6:45345544	RUNX2;SUPT3H	0.4	5.99	0.31	5.54e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19590674	chr17:25783100	NA	0.4	6.2	0.32	1.7e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs17092148	1.000	rs6088603	chr20:33370945	A/G	cg16810054	chr20:33298113	TP53INP2	-0.43	-6.81	-0.35	4.68e-11	Neuroticism;
LUSC	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.22	-0.32	1.45e-9	Response to antipsychotic treatment;
LUSC	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg26408565	chr15:76604113	ETFA	-0.5	-7.82	-0.39	6.94e-14	Blood metabolite levels;
LUSC	cis	rs981844	0.689	rs6835372	chr4:154682056	T/C	cg14289246	chr4:154710475	SFRP2	-0.5	-7.2	-0.37	3.92e-12	Response to statins (LDL cholesterol change);
LUSC	cis	rs2932538	0.922	rs12750621	chr1:113206502	G/C	cg22162597	chr1:113214053	CAPZA1	0.7	9.8	0.47	4.23e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg23172400	chr8:95962367	TP53INP1	0.34	6.82	0.35	4.24e-11	Type 2 diabetes;
LUSC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.78	12.64	0.57	3.42e-30	Colorectal cancer;
LUSC	cis	rs193541	0.632	rs1363200	chr5:122163802	G/T	cg19077854	chr5:122220652	SNX24	0.38	7.9	0.4	4.18e-14	Glucose homeostasis traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27006027	chr19:33165562	ANKRD27;RGS9BP	-0.42	-6.13	-0.32	2.42e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg24642439	chr20:33292090	TP53INP2	0.62	7.08	0.36	8.79e-12	Protein C levels;
LUSC	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg10547527	chr2:198650123	BOLL	-0.51	-5.97	-0.31	5.92e-9	Ulcerative colitis;
LUSC	cis	rs965469	1.000	rs965469	chr20:3381549	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-5.77	-0.3	1.82e-8	IFN-related cytopenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27261837	chr1:146714163	CHD1L	0.47	7.0	0.36	1.41e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg04691961	chr3:161091175	C3orf57	-0.34	-5.87	-0.31	1.02e-8	Morning vs. evening chronotype;
LUSC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-11.0	-0.52	3.3e-24	Mean corpuscular volume;
LUSC	trans	rs2679649	1.000	rs2684270	chr6:122352450	C/A	cg00167820	chr8:131663355	NA	0.54	6.35	0.33	6.96e-10	Subcutaneous adipose tissue;
LUSC	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg19875535	chr5:140030758	IK	0.47	7.56	0.38	4.05e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.33	0.53	2.21e-25	Eye color traits;
LUSC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.43	-0.38	9.43e-13	Bipolar disorder;
LUSC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg20203395	chr5:56204925	C5orf35	-0.56	-8.14	-0.41	7.99e-15	Coronary artery disease;
LUSC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg24296786	chr1:45957014	TESK2	0.53	8.36	0.42	1.73e-15	High light scatter reticulocyte count;
LUSC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg16928487	chr17:17741425	SREBF1	-0.42	-8.26	-0.41	3.35e-15	Total body bone mineral density;
LUSC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.49	-8.92	-0.44	3.03e-17	Electroencephalogram traits;
LUSC	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg19682013	chr15:45996608	NA	0.39	6.0	0.31	5.09e-9	Waist circumference;Weight;
LUSC	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg15711740	chr2:61764176	XPO1	-0.5	-7.93	-0.4	3.24e-14	Tuberculosis;
LUSC	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-7.63	-0.39	2.54e-13	Schizophrenia;
LUSC	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11645453	chr3:52864694	ITIH4	-0.47	-10.43	-0.5	3.06e-22	Schizophrenia;
LUSC	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.9	15.73	0.65	4.14e-42	Morning vs. evening chronotype;
LUSC	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg25482853	chr8:67687455	SGK3	1.1	15.7	0.65	5.5e-42	Obesity-related traits;
LUSC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg01483505	chr11:975446	AP2A2	0.44	6.1	0.32	2.94e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.7	-7.36	-0.37	1.43e-12	Yeast infection;
LUSC	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg16482183	chr6:26056742	HIST1H1C	0.63	8.96	0.44	2.34e-17	Iron status biomarkers;
LUSC	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg04998671	chr14:104000505	TRMT61A	0.57	7.92	0.4	3.61e-14	Coronary artery disease;
LUSC	cis	rs372883	0.967	rs1153287	chr21:30685611	C/T	cg08807101	chr21:30365312	RNF160	-0.4	-5.82	-0.3	1.41e-8	Pancreatic cancer;
LUSC	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg19920283	chr7:105172520	RINT1	0.59	6.16	0.32	2.14e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2637266	1.000	rs7905033	chr10:78368212	A/C	cg18941641	chr10:78392320	NA	0.39	7.06	0.36	9.56e-12	Pulmonary function;
LUSC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-7.73	-0.39	1.25e-13	Renal function-related traits (BUN);
LUSC	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg27411982	chr8:10470053	RP1L1	0.38	5.89	0.31	9.35e-9	Retinal vascular caliber;
LUSC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26314531	chr2:26401878	FAM59B	-0.65	-9.05	-0.44	1.21e-17	Gut microbiome composition (summer);
LUSC	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg05805236	chr11:65401703	PCNXL3	-0.65	-10.78	-0.51	1.91e-23	Acne (severe);
LUSC	trans	rs12200782	1.000	rs72845509	chr6:26639865	T/C	cg11837749	chr1:55047332	ACOT11	0.57	5.98	0.31	5.64e-9	Small cell lung carcinoma;
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg15383120	chr6:291909	DUSP22	-0.66	-11.04	-0.52	2.32e-24	Menopause (age at onset);
LUSC	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.15	-0.36	5.59e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05901451	chr6:126070800	HEY2	0.57	8.56	0.42	4.29e-16	Endometrial cancer;
LUSC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg11861562	chr11:117069780	TAGLN	0.3	5.76	0.3	1.95e-8	Blood protein levels;
LUSC	cis	rs9517320	1.000	rs9517322	chr13:99126338	C/G	cg07423050	chr13:99094983	FARP1	0.33	6.29	0.33	1.02e-9	Longevity;
LUSC	cis	rs12681287	0.547	rs10956873	chr8:87547028	T/C	cg27223183	chr8:87520930	FAM82B	0.53	6.99	0.36	1.54e-11	Caudate activity during reward;
LUSC	cis	rs8114671	0.967	rs6142320	chr20:33788193	A/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.93	-0.31	7.56e-9	Height;
LUSC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.56e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg05283184	chr6:79620031	NA	0.58	12.3	0.56	6.3e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg26408565	chr15:76604113	ETFA	-0.5	-7.98	-0.4	2.42e-14	Blood metabolite levels;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	1.02	24.42	0.8	2.7e-76	Menarche (age at onset);
LUSC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg18477163	chr1:228402036	OBSCN	-0.55	-10.16	-0.49	2.62e-21	Diastolic blood pressure;
LUSC	cis	rs740160	0.510	rs733991	chr7:98895250	C/T	cg24650262	chr7:98904301	NA	0.62	6.9	0.35	2.68e-11	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.65	0.57	3.22e-30	Prudent dietary pattern;
LUSC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg15445000	chr17:37608096	MED1	0.39	6.72	0.34	8e-11	Lung function (FEV1);
LUSC	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.59	-0.43	3.46e-16	Body mass index;
LUSC	trans	rs72674100	1.000	rs9993686	chr4:97974447	C/T	cg09670535	chr1:18959427	PAX7	-0.55	-6.26	-0.32	1.18e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg11416102	chr8:651193	ERICH1	0.63	5.83	0.3	1.32e-8	IgG glycosylation;
LUSC	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs7759001	0.857	rs4713090	chr6:27350847	C/T	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	2.04e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05901451	chr6:126070800	HEY2	-0.58	-8.7	-0.43	1.5e-16	Endometrial cancer;
LUSC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21984481	chr17:79567631	NPLOC4	-0.56	-10.83	-0.51	1.23e-23	Eye color traits;
LUSC	cis	rs3771570	0.901	rs3771585	chr2:242400723	G/A	cg21155796	chr2:242212141	HDLBP	0.51	6.25	0.32	1.23e-9	Prostate cancer;
LUSC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg12463550	chr7:65579703	CRCP	-0.48	-7.13	-0.36	6.16e-12	Aortic root size;
LUSC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg21699342	chr2:239360505	ASB1	0.43	6.66	0.34	1.14e-10	Multiple system atrophy;
LUSC	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg26395211	chr5:140044315	WDR55	0.46	7.11	0.36	6.88e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg01851573	chr8:8652454	MFHAS1	0.53	8.45	0.42	8.97e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.96	0.4	2.66e-14	Iron status biomarkers;
LUSC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.15	-0.45	5.86e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs7188861	0.681	rs2216763	chr16:11404428	G/A	cg00044050	chr16:11439710	C16orf75	0.56	5.94	0.31	7.05e-9	HDL cholesterol;
LUSC	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.94	-0.31	7.34e-9	IgG glycosylation;
LUSC	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg20848291	chr7:100343083	ZAN	0.38	5.93	0.31	7.71e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg24562669	chr7:97807699	LMTK2	-0.39	-6.38	-0.33	5.92e-10	Breast cancer;
LUSC	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg06636001	chr8:8085503	FLJ10661	0.6	9.09	0.45	8.84e-18	Mood instability;
LUSC	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.35	-5.65	-0.3	3.45e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00149659	chr3:10157352	C3orf10	0.97	13.75	0.6	2.17e-34	Alzheimer's disease;
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.75	-16.2	-0.66	5.8e-44	Longevity;Endometriosis;
LUSC	cis	rs12912251	1.000	rs2132157	chr15:38992547	A/G	cg01338139	chr15:38987640	C15orf53	-0.49	-6.74	-0.35	6.86e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg00825309	chr19:58991885	ZNF446	-0.5	-7.23	-0.37	3.27e-12	Uric acid clearance;
LUSC	trans	rs1922233	1.000	rs6858278	chr4:92378742	T/G	cg24250684	chr1:219729030	NA	-0.34	-6.17	-0.32	1.93e-9	Gut microbiome composition (summer and winter);
LUSC	trans	rs1347297	0.526	rs2276617	chr2:179250397	A/G	cg14011486	chr1:26737247	LIN28	0.41	6.5	0.34	3e-10	Alzheimer disease and age of onset;
LUSC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs10465746	0.780	rs6703493	chr1:84435812	G/A	cg10977910	chr1:84465055	TTLL7	0.44	6.43	0.33	4.44e-10	Obesity-related traits;
LUSC	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	6.87	0.35	3.07e-11	Lung cancer in ever smokers;
LUSC	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.56	-0.42	4.2e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg02503808	chr4:7069936	GRPEL1	-0.95	-10.96	-0.51	4.39e-24	Monocyte percentage of white cells;
LUSC	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs3755132	1.000	rs56253741	chr2:15730773	A/G	cg12888861	chr2:15731646	DDX1	0.5	7.15	0.36	5.5e-12	Wilms tumor;
LUSC	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.9	0.4	4.02e-14	Colorectal cancer;
LUSC	trans	rs11165623	0.715	rs1980769	chr1:96888201	A/T	cg10631902	chr5:14652156	NA	-0.54	-8.76	-0.43	1.03e-16	Hip circumference;Waist circumference;
LUSC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg20607798	chr8:58055168	NA	0.57	5.78	0.3	1.7e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg08508325	chr11:3079039	CARS	0.37	8.27	0.41	3.15e-15	Calcium levels;
LUSC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25072359	chr17:41440525	NA	0.65	9.39	0.46	9.33e-19	Menopause (age at onset);
LUSC	cis	rs6693567	0.565	rs1260374	chr1:150331593	G/A	cg15654264	chr1:150340011	RPRD2	0.45	7.33	0.37	1.8e-12	Migraine;
LUSC	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg22467129	chr15:76604101	ETFA	-0.43	-6.85	-0.35	3.54e-11	Blood metabolite levels;
LUSC	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg21827317	chr3:136751795	NA	0.38	7.02	0.36	1.27e-11	Neuroticism;
LUSC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg12463550	chr7:65579703	CRCP	0.63	5.7	0.3	2.7e-8	Diabetic kidney disease;
LUSC	cis	rs2637266	0.783	rs846647	chr10:78515508	C/G	cg18941641	chr10:78392320	NA	0.4	7.23	0.37	3.3e-12	Pulmonary function;
LUSC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08219700	chr8:58056026	NA	0.64	8.18	0.41	6.2e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg04701473	chr1:161359506	NA	0.41	6.24	0.32	1.35e-9	Educational attainment (years of education);
LUSC	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg11657440	chr19:46296263	DMWD	-0.64	-9.49	-0.46	4.48e-19	Coronary artery disease;
LUSC	cis	rs1595825	0.891	rs41468149	chr2:198910107	C/G	cg10547527	chr2:198650123	BOLL	0.52	6.16	0.32	2.07e-9	Ulcerative colitis;
LUSC	trans	rs9409565	0.762	rs55877910	chr9:97234213	G/C	cg05679027	chr9:99775184	HIATL2	-0.5	-7.09	-0.36	8.17e-12	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs17125944	0.505	rs17125762	chr14:53289288	A/G	cg00686598	chr14:53173677	PSMC6	1.09	9.26	0.45	2.56e-18	Alzheimer's disease (late onset);
LUSC	cis	rs16912285	0.535	rs7109619	chr11:24251339	G/A	ch.11.24196551F	chr11:24239977	NA	0.89	9.79	0.47	4.54e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7267979	0.586	rs1007708	chr20:25190959	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	12.31	0.56	5.81e-29	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.38	-0.33	5.89e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06544989	chr22:39130855	UNC84B	0.34	5.8	0.3	1.53e-8	Menopause (age at onset);
LUSC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.75	-0.47	6.29e-20	Gut microbiome composition (summer);
LUSC	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.33	5.97	0.31	6.08e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.16	0.32	2.05e-9	Corneal astigmatism;
LUSC	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg11344533	chr11:111475393	SIK2	-0.49	-6.81	-0.35	4.52e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg21141812	chr3:48556323	PFKFB4	0.36	6.12	0.32	2.67e-9	Menarche (age at onset);
LUSC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06634786	chr22:41940651	POLR3H	-0.57	-6.93	-0.35	2.14e-11	Vitiligo;
LUSC	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg13395646	chr4:1353034	KIAA1530	-0.65	-10.68	-0.5	4.28e-23	Longevity;
LUSC	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.14	0.36	5.95e-12	Asthma;
LUSC	cis	rs12980942	0.872	rs3816052	chr19:41773797	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.58	6.28	0.33	1.03e-9	Coronary artery disease;
LUSC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-14.7	-0.63	4.64e-38	Hemoglobin concentration;
LUSC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01570182	chr17:44337453	NA	-0.67	-10.11	-0.48	3.77e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-25.77	-0.82	2.2e-81	Exhaled nitric oxide output;
LUSC	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg25019033	chr10:957182	NA	-0.52	-7.06	-0.36	9.93e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.51	-6.55	-0.34	2.14e-10	Response to bleomycin (chromatid breaks);
LUSC	cis	rs28785552	0.589	rs7257371	chr19:53243910	A/G	cg22067481	chr19:53234126	ZNF611	-0.5	-6.63	-0.34	1.34e-10	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs2262909	0.962	rs409835	chr19:22230671	T/C	cg11619707	chr19:22235551	ZNF257	-0.38	-5.7	-0.3	2.7e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg03146154	chr1:46216737	IPP	0.51	7.65	0.39	2.12e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg16515820	chr3:114866447	ZBTB20	0.48	6.62	0.34	1.44e-10	Cognitive function;Information processing speed;
LUSC	cis	rs1577917	0.917	rs2084293	chr6:86566002	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg21132104	chr15:45694354	SPATA5L1	0.57	8.14	0.41	7.67e-15	Homoarginine levels;
LUSC	trans	rs4596713	0.603	rs9314854	chr9:71686181	T/C	cg04349162	chr17:62464701	C17orf60	-0.35	-6.05	-0.31	3.92e-9	Headache;
LUSC	cis	rs1044826	0.642	rs6784684	chr3:139177634	T/C	cg00490450	chr3:139108681	COPB2	0.45	7.05	0.36	1.05e-11	Obesity-related traits;
LUSC	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.61	9.49	0.46	4.41e-19	Morning vs. evening chronotype;
LUSC	cis	rs7607369	0.536	rs7566656	chr2:219664519	A/G	cg02176678	chr2:219576539	TTLL4	-0.51	-9.02	-0.44	1.53e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.26	-0.41	3.39e-15	Neuroticism;
LUSC	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.48	9.78	0.47	4.88e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg03354898	chr7:1950403	MAD1L1	0.32	6.35	0.33	6.93e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg16325326	chr1:53192061	ZYG11B	-1.0	-20.14	-0.74	1.24e-59	Monocyte count;
LUSC	cis	rs722599	0.748	rs731952	chr14:75366447	A/G	cg06637938	chr14:75390232	RPS6KL1	0.41	6.02	0.31	4.66e-9	IgG glycosylation;
LUSC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg19622623	chr12:86230825	RASSF9	-0.43	-6.15	-0.32	2.16e-9	Major depressive disorder;
LUSC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg09365446	chr1:150670422	GOLPH3L	0.54	8.28	0.41	2.91e-15	Tonsillectomy;
LUSC	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg08847533	chr14:75593920	NEK9	0.39	5.77	0.3	1.81e-8	Caffeine consumption;
LUSC	cis	rs1395	1.000	rs1395	chr2:27424636	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.38	-6.23	-0.32	1.4e-9	Blood metabolite levels;
LUSC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-0.84	-14.83	-0.63	1.35e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs12541635	0.801	rs12155862	chr8:107105243	G/A	cg10147462	chr8:107024639	NA	-0.45	-7.99	-0.4	2.18e-14	Age of smoking initiation;
LUSC	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg09307838	chr4:120376055	NA	0.75	10.72	0.51	3.04e-23	Corneal astigmatism;
LUSC	cis	rs911119	0.913	rs13037490	chr20:23583725	T/C	cg16589663	chr20:23618590	CST3	0.65	7.8	0.39	8.05e-14	Chronic kidney disease;
LUSC	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg07828340	chr4:882639	GAK	1.1	11.94	0.55	1.33e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.35	-5.98	-0.31	5.87e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7903847	0.642	rs12258560	chr10:99137048	T/C	cg08345082	chr10:99160200	RRP12	-0.38	-7.68	-0.39	1.72e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg07460842	chr6:66804631	NA	0.47	5.8	0.3	1.53e-8	Metabolite levels;
LUSC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg09877947	chr5:131593287	PDLIM4	-0.37	-5.89	-0.31	9.18e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg08017756	chr2:100939284	LONRF2	-0.45	-8.42	-0.42	1.15e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg24579218	chr15:68104479	NA	-0.39	-6.81	-0.35	4.68e-11	Restless legs syndrome;
LUSC	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg15798862	chr7:76129360	DTX2	-0.51	-8.57	-0.42	3.77e-16	Multiple sclerosis;
LUSC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg16624210	chr5:671434	TPPP	0.5	6.47	0.33	3.58e-10	Obesity-related traits;
LUSC	cis	rs11676348	0.808	rs4674267	chr2:219046437	C/T	cg06547715	chr2:218990976	CXCR2	0.31	5.87	0.31	1.07e-8	Ulcerative colitis;
LUSC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3771570	1.000	rs62193197	chr2:242294301	G/A	cg21155796	chr2:242212141	HDLBP	0.63	6.76	0.35	6.25e-11	Prostate cancer;
LUSC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg17971929	chr21:40555470	PSMG1	0.48	7.37	0.37	1.37e-12	Cognitive function;
LUSC	cis	rs6845621	0.745	rs1517989	chr4:18854961	T/C	cg12196642	chr4:18937545	NA	-0.31	-5.84	-0.3	1.23e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7212590	0.748	rs8074843	chr17:57935935	C/G	cg10252138	chr17:58120427	NA	-0.73	-7.06	-0.36	9.79e-12	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg06521331	chr12:34319734	NA	-0.39	-6.12	-0.32	2.68e-9	Bladder cancer;
LUSC	cis	rs73200209	0.704	rs17498131	chr12:116436185	C/G	cg01776926	chr12:116560359	MED13L	-0.51	-6.01	-0.31	4.9e-9	Total body bone mineral density;
LUSC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg14004847	chr7:1930337	MAD1L1	-0.57	-8.78	-0.43	8.63e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.56	8.04	0.4	1.62e-14	Night sleep phenotypes;
LUSC	cis	rs2625529	0.504	rs11072349	chr15:72464471	T/C	cg16672083	chr15:72433130	SENP8	0.48	7.88	0.4	4.61e-14	Red blood cell count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02806352	chr6:36410757	PXT1;KCTD20	0.49	7.18	0.37	4.64e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg10729496	chr3:10149963	C3orf24	0.54	7.18	0.37	4.45e-12	Alzheimer's disease;
LUSC	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg08645402	chr16:4508243	NA	-0.42	-6.43	-0.33	4.4e-10	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.65	-0.39	2.16e-13	Bipolar disorder;
LUSC	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.83	-20.1	-0.74	1.83e-59	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs672059	0.966	rs492228	chr1:183156476	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.99	0.4	2.15e-14	Hypertriglyceridemia;
LUSC	trans	rs12165098	0.636	rs11873983	chr18:36748849	A/G	cg23858286	chr9:138135095	NA	-0.42	-6.18	-0.32	1.84e-9	Sleep duration;
LUSC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.93	0.35	2.24e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.18	-0.49	2.18e-21	Eye color traits;
LUSC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.06e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01859739	chr19:58739986	ZNF544	-0.41	-6.06	-0.31	3.61e-9	Electrocardiographic conduction measures;
LUSC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg25767906	chr1:53392781	SCP2	0.46	8.16	0.41	7.03e-15	Monocyte count;
LUSC	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.69	-0.6	3.65e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs3820068	0.608	rs10927840	chr1:16045250	A/G	cg13390004	chr1:15929781	NA	0.41	6.51	0.34	2.71e-10	Systolic blood pressure;
LUSC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-0.96	-13.54	-0.6	1.34e-33	Vitiligo;
LUSC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.76	0.39	1.01e-13	Prudent dietary pattern;
LUSC	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg14343924	chr8:8086146	FLJ10661	0.47	6.55	0.34	2.18e-10	Myopia (pathological);
LUSC	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg16558253	chr16:72132732	DHX38	-0.38	-6.07	-0.32	3.45e-9	Fibrinogen levels;
LUSC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg25767906	chr1:53392781	SCP2	0.48	8.63	0.43	2.55e-16	Monocyte count;
LUSC	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg09904177	chr6:26538194	HMGN4	-0.75	-7.02	-0.36	1.25e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg22143856	chr6:28129313	ZNF389	0.41	5.68	0.3	2.98e-8	Parkinson's disease;
LUSC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.37	0.33	6.13e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg20701182	chr2:24300061	SF3B14	0.73	7.4	0.38	1.12e-12	Lymphocyte counts;
LUSC	trans	rs11696501	0.739	rs6104252	chr20:44254323	G/A	cg03272292	chr12:48577362	C12orf68	0.49	5.99	0.31	5.29e-9	Brain structure;
LUSC	trans	rs1864729	0.748	rs2635165	chr8:98296209	T/C	cg08679828	chr8:102218111	ZNF706	-0.71	-6.28	-0.32	1.04e-9	Estradiol plasma levels (breast cancer);
LUSC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs4253772	0.938	rs10154348	chr22:46638159	C/A	cg24881330	chr22:46731750	TRMU	0.63	5.85	0.31	1.15e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg06784218	chr1:46089804	CCDC17	-0.55	-11.21	-0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs1486139	1.000	rs1385934	chr7:46268072	A/C	cg17534202	chr9:96721102	NA	-0.35	-6.15	-0.32	2.26e-9	Select biomarker traits;
LUSC	cis	rs500891	0.525	rs35281711	chr6:84093177	G/A	cg08257003	chr6:84140564	ME1	0.32	7.29	0.37	2.29e-12	Platelet-derived growth factor BB levels;
LUSC	trans	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-13.91	-0.61	5.27e-35	Colorectal cancer;
LUSC	cis	rs921665	0.831	rs4497900	chr2:3190754	A/G	cg02624386	chr2:3182749	NA	0.59	6.58	0.34	1.8e-10	World class endurance athleticism;
LUSC	cis	rs3770081	1.000	rs3770082	chr2:86280922	T/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.84	-0.35	3.84e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg07395648	chr5:131743802	NA	-0.46	-7.23	-0.37	3.33e-12	Breast cancer;Mosquito bite size;
LUSC	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.38e-20	Coronary artery disease;
LUSC	cis	rs9487051	0.703	rs351755	chr6:109538073	G/A	cg12927641	chr6:109611667	NA	0.35	5.79	0.3	1.61e-8	Reticulocyte fraction of red cells;
LUSC	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg03929089	chr4:120376271	NA	0.6	6.43	0.33	4.33e-10	Axial length;
LUSC	cis	rs73198271	0.515	rs78890841	chr8:8637018	G/A	cg01851573	chr8:8652454	MFHAS1	0.56	6.24	0.32	1.32e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4280164	0.945	rs4374085	chr14:24771080	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.57	-6.75	-0.35	6.52e-11	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs7527798	0.592	rs12022909	chr1:207859743	T/C	cg09232269	chr1:207846808	CR1L	-0.3	-6.33	-0.33	7.79e-10	Erythrocyte sedimentation rate;
LUSC	trans	rs979233	0.502	rs276241	chr5:42060180	T/C	cg07010552	chr17:7358735	CHRNB1	-0.42	-6.06	-0.31	3.71e-9	Systemic lupus erythematosus;
LUSC	cis	rs7827545	0.545	rs6988000	chr8:135559534	C/T	cg17885191	chr8:135476712	NA	0.64	8.38	0.42	1.45e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs6693567	0.565	rs1694379	chr1:150292417	C/A	cg09579323	chr1:150459698	TARS2	0.4	5.66	0.3	3.27e-8	Migraine;
LUSC	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg27171569	chr16:83987465	OSGIN1	-0.54	-9.61	-0.47	1.8e-19	Pursuit maintenance gain;
LUSC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18876405	chr7:65276391	NA	0.55	8.79	0.43	8.1e-17	Aortic root size;
LUSC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.31	-0.37	2.04e-12	Subjective well-being;
LUSC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12516959	chr21:47718080	NA	-0.48	-7.48	-0.38	6.78e-13	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08677398	chr8:58056175	NA	0.54	6.39	0.33	5.43e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg12463550	chr7:65579703	CRCP	0.53	7.73	0.39	1.29e-13	Aortic root size;
LUSC	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-1.14	-17.81	-0.7	2.27e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg07211511	chr3:129823064	LOC729375	-1.26	-21.01	-0.75	4.84e-63	Blood pressure (smoking interaction);
LUSC	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg05973401	chr12:123451056	ABCB9	0.54	6.67	0.34	1.06e-10	Neutrophil percentage of white cells;
LUSC	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg04374321	chr14:90722782	PSMC1	-0.42	-6.39	-0.33	5.65e-10	Mortality in heart failure;
LUSC	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg02023728	chr11:77925099	USP35	0.46	6.65	0.34	1.23e-10	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08280861	chr8:58055591	NA	0.53	5.83	0.3	1.31e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.28	0.53	3.33e-25	Menopause (age at onset);
LUSC	trans	rs8073060	0.544	rs225287	chr17:33929487	G/T	cg19694781	chr19:47549865	TMEM160	-1.12	-17.8	-0.7	2.55e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg04827223	chr11:72435913	ARAP1	-0.75	-13.06	-0.58	8.57e-32	Body mass index;
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14159672	chr1:205819179	PM20D1	0.86	15.4	0.64	8.29e-41	Menarche (age at onset);
LUSC	cis	rs17756712	0.527	rs1193742	chr6:635629	T/C	cg14374089	chr6:596013	EXOC2	0.51	7.21	0.37	3.8e-12	Vertical cup-disc ratio;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20994084	chr17:79269488	SLC38A10	0.37	6.19	0.32	1.75e-9	Triglycerides;
LUSC	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg26677194	chr12:130822605	PIWIL1	0.59	8.73	0.43	1.22e-16	Menopause (age at onset);
LUSC	trans	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg07817883	chr1:32538562	TMEM39B	-0.61	-7.45	-0.38	7.97e-13	Monocyte percentage of white cells;
LUSC	cis	rs6489882	0.867	rs7132404	chr12:113368605	A/G	cg20102336	chr12:113376681	OAS3	-0.42	-6.13	-0.32	2.44e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg01802117	chr1:53393560	SCP2	-0.39	-6.67	-0.34	1.05e-10	Monocyte count;
LUSC	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.97	-0.36	1.73e-11	Neuroticism;
LUSC	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg24110177	chr3:50126178	RBM5	0.42	6.73	0.35	7.18e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg16928487	chr17:17741425	SREBF1	0.46	9.01	0.44	1.59e-17	Total body bone mineral density;
LUSC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.05	-0.36	1.02e-11	Colorectal cancer;
LUSC	cis	rs16976116	0.855	rs28649719	chr15:55500211	C/T	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21963583	chr11:68658836	MRPL21	0.56	8.32	0.41	2.29e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs17490626	0.568	rs2033371	chr10:71212310	G/A	cg12610070	chr10:71211762	TSPAN15	-0.48	-9.25	-0.45	2.74e-18	Thrombosis;
LUSC	cis	rs6546886	0.912	rs4853006	chr2:74263419	A/G	cg14702570	chr2:74259524	NA	-0.31	-5.78	-0.3	1.67e-8	Dialysis-related mortality;
LUSC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg18402987	chr7:1209562	NA	0.69	8.0	0.4	2.02e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06634786	chr22:41940651	POLR3H	-0.48	-5.65	-0.3	3.4e-8	Vitiligo;
LUSC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.68	0.39	1.74e-13	Prudent dietary pattern;
LUSC	cis	rs17401966	0.540	rs3748581	chr1:10441664	T/C	cg19773385	chr1:10388646	KIF1B	-0.37	-6.49	-0.33	3.08e-10	Hepatocellular carcinoma;
LUSC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg00933542	chr6:150070202	PCMT1	0.31	6.48	0.33	3.33e-10	Lung cancer;
LUSC	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg05283184	chr6:79620031	NA	-0.57	-12.03	-0.55	6.25e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg22705602	chr4:152727874	NA	-0.34	-7.57	-0.38	3.77e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9879311	0.643	rs1473183	chr3:10411827	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.45	7.08	0.36	8.56e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.2	-0.32	1.71e-9	Coronary artery disease;
LUSC	trans	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.4	0.42	1.29e-15	Ulcerative colitis;
LUSC	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg26384229	chr12:38710491	ALG10B	0.5	7.17	0.37	4.71e-12	Morning vs. evening chronotype;
LUSC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20887711	chr4:1340912	KIAA1530	0.55	8.59	0.43	3.43e-16	Longevity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00330502	chr2:219264282	CTDSP1	-0.41	-6.01	-0.31	4.89e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-7.9	-0.4	3.99e-14	Electroencephalogram traits;
LUSC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg06096015	chr1:231504339	EGLN1	0.58	10.45	0.5	2.68e-22	Hemoglobin concentration;
LUSC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg11663144	chr21:46675770	NA	-0.41	-7.1	-0.36	7.43e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs714027	1.000	rs2412973	chr22:30529631	C/A	cg11564601	chr22:30592435	NA	-0.37	-6.82	-0.35	4.38e-11	Lymphocyte counts;
LUSC	trans	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg18335740	chr13:41363409	SLC25A15	-0.47	-6.92	-0.35	2.28e-11	Lewy body disease;
LUSC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg10556349	chr10:835070	NA	0.55	6.21	0.32	1.53e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg02660097	chr11:68866761	NA	0.42	5.78	0.3	1.68e-8	Blond vs. brown hair color;
LUSC	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg05187965	chr10:45406764	TMEM72	-0.38	-9.04	-0.44	1.3e-17	Mean corpuscular volume;
LUSC	cis	rs9473147	0.516	rs2151974	chr6:47515630	G/A	cg12968598	chr6:47444699	CD2AP	0.52	7.94	0.4	3.18e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.24	0.52	4.48e-25	Eye color traits;
LUSC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg01475377	chr6:109611718	NA	-0.46	-8.44	-0.42	1e-15	Reticulocyte fraction of red cells;
LUSC	trans	rs7951105	1.000	rs7932010	chr11:39243705	C/G	cg24085930	chr3:21832523	NA	0.49	6.06	0.31	3.58e-9	Free thyroxine concentration;
LUSC	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg14582100	chr15:45693742	SPATA5L1	0.57	9.69	0.47	9.56e-20	Homoarginine levels;
LUSC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-0.82	-13.52	-0.59	1.67e-33	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs4789693	0.546	rs7220204	chr17:80376130	T/A	cg04308225	chr17:80449738	NA	0.39	6.12	0.32	2.6e-9	Glucocorticoid-induced osteonecrosis;
LUSC	cis	rs7043114	0.525	rs1133908	chr9:95068046	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.46	-0.33	3.63e-10	Height;
LUSC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg20701182	chr2:24300061	SF3B14	0.9	11.53	0.53	4.11e-26	Lymphocyte counts;
LUSC	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg20026190	chr17:76395443	PGS1	0.45	8.01	0.4	1.93e-14	HDL cholesterol levels;
LUSC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg13918804	chr1:2043761	PRKCZ	0.27	5.8	0.3	1.58e-8	Height;
LUSC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08048268	chr3:133502702	NA	-0.51	-9.84	-0.47	3.14e-20	Iron status biomarkers;
LUSC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10802521	chr3:52805072	NEK4	0.5	7.74	0.39	1.2e-13	Bipolar disorder;
LUSC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07157834	chr1:205819609	PM20D1	0.75	12.54	0.57	8.23e-30	Menarche (age at onset);
LUSC	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg27205649	chr11:78285834	NARS2	-0.51	-6.02	-0.31	4.71e-9	Alzheimer's disease (survival time);
LUSC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg02896835	chr1:92012615	NA	-0.65	-11.81	-0.54	4.04e-27	Breast cancer;
LUSC	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg16482183	chr6:26056742	HIST1H1C	0.65	9.2	0.45	4.03e-18	Iron status biomarkers;
LUSC	trans	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg04995722	chr7:26192034	NFE2L3	0.42	6.62	0.34	1.44e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-7.5	-0.38	5.67e-13	Total cholesterol levels;
LUSC	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg18132916	chr6:79620363	NA	-0.42	-6.57	-0.34	1.93e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg02569458	chr12:86230093	RASSF9	0.54	8.82	0.43	6.7e-17	Major depressive disorder;
LUSC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg08027265	chr7:2291960	NA	-0.38	-6.22	-0.32	1.52e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg05805236	chr11:65401703	PCNXL3	0.36	5.84	0.3	1.23e-8	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg06092702	chr1:163392909	NA	-0.39	-6.43	-0.33	4.5e-10	Motion sickness;
LUSC	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15557168	chr22:42548783	NA	-0.43	-7.25	-0.37	2.98e-12	Cognitive function;
LUSC	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.26	0.32	1.18e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg26924012	chr15:45694286	SPATA5L1	-1.07	-16.89	-0.68	1.06e-46	Homoarginine levels;
LUSC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg06454157	chr6:167490870	NA	-0.26	-6.08	-0.32	3.25e-9	Crohn's disease;
LUSC	cis	rs10193935	0.901	rs62142639	chr2:42600019	C/G	cg27598129	chr2:42591480	NA	-0.65	-8.7	-0.43	1.5e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg17971929	chr21:40555470	PSMG1	-0.61	-9.82	-0.47	3.79e-20	Cognitive function;
LUSC	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.1	-0.61	9.35e-36	Exhaled nitric oxide output;
LUSC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22442454	chr1:209979470	IRF6	0.43	5.89	0.31	9.29e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs4363385	0.747	rs1413848	chr1:152970210	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.79	-0.39	8.81e-14	Inflammatory skin disease;
LUSC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg22823121	chr1:150693482	HORMAD1	0.51	7.47	0.38	7.01e-13	Tonsillectomy;
LUSC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs7582180	0.903	rs2309819	chr2:100899665	C/T	cg08017756	chr2:100939284	LONRF2	-0.35	-5.92	-0.31	7.88e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs13011075	0.919	rs2902068	chr2:68614918	T/G	cg14221825	chr19:46271408	SIX5	0.43	6.22	0.32	1.51e-9	Mean corpuscular volume;
LUSC	cis	rs757110	0.590	rs7484027	chr11:17368381	T/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-7.82	-0.39	6.99e-14	Type 2 diabetes;
LUSC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg06238570	chr21:40685208	BRWD1	-0.57	-8.96	-0.44	2.41e-17	Menarche (age at onset);
LUSC	cis	rs1322512	0.792	rs2623952	chr6:152965132	A/G	cg27316956	chr6:152958899	SYNE1	-0.37	-6.32	-0.33	8.6e-10	Tonometry;
LUSC	cis	rs1979679	0.659	rs11049461	chr12:28360621	C/A	cg13890972	chr12:28721907	NA	0.45	6.18	0.32	1.91e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.98	-16.38	-0.67	1.14e-44	Coronary artery disease;
LUSC	cis	rs2239815	0.515	rs5752810	chr22:29225523	G/A	cg02153584	chr22:29168773	CCDC117	0.52	6.22	0.32	1.48e-9	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.78	14.67	0.63	6.05e-38	Longevity;
LUSC	cis	rs7945718	0.967	rs11022496	chr11:12789561	G/A	cg25843174	chr11:12811716	TEAD1	0.31	7.03	0.36	1.16e-11	Educational attainment (years of education);
LUSC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-5.75	-0.3	1.99e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg24110177	chr3:50126178	RBM5	-0.42	-6.6	-0.34	1.63e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6733011	0.628	rs4263159	chr2:99456151	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.61	-0.34	1.53e-10	Bipolar disorder;
LUSC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.46	-0.38	7.78e-13	Aortic root size;
LUSC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg02574844	chr11:5959923	NA	-0.41	-6.4	-0.33	5.33e-10	DNA methylation (variation);
LUSC	cis	rs56283067	0.847	rs10807302	chr6:44710152	G/C	cg18551225	chr6:44695536	NA	-0.49	-8.39	-0.42	1.41e-15	Total body bone mineral density;
LUSC	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg08847533	chr14:75593920	NEK9	0.84	15.57	0.65	1.85e-41	Height;
LUSC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4242434	0.927	rs3735894	chr8:22454826	A/G	cg03733263	chr8:22462867	KIAA1967	1.02	18.33	0.71	1.97e-52	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs116988415	0.584	rs2269306	chr14:65245417	A/G	cg00114569	chr14:65239327	SPTB	-0.59	-6.41	-0.33	5.08e-10	Daytime sleep phenotypes;
LUSC	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg26384229	chr12:38710491	ALG10B	0.78	13.36	0.59	6.3e-33	Morning vs. evening chronotype;
LUSC	cis	rs62408225	0.962	rs58521088	chr6:90985198	A/T	cg06866423	chr6:90926672	BACH2	0.41	5.87	0.31	1.03e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg26727032	chr16:67993705	SLC12A4	-0.43	-6.14	-0.32	2.31e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.16	0.32	2.14e-9	Corneal astigmatism;
LUSC	trans	rs1459104	0.714	rs67321261	chr11:54911368	A/G	cg03929089	chr4:120376271	NA	0.74	6.24	0.32	1.36e-9	Body mass index;
LUSC	trans	rs961253	0.556	rs6038442	chr20:6325523	G/T	cg21095983	chr6:86352623	SYNCRIP	0.45	6.78	0.35	5.62e-11	Colorectal cancer;
LUSC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.03	-0.52	2.51e-24	Bipolar disorder;
LUSC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg01616529	chr11:638424	DRD4	-0.37	-6.08	-0.32	3.22e-9	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.59	-0.38	3.27e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg19875535	chr5:140030758	IK	0.37	5.66	0.3	3.3e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.62	0.54	1.97e-26	Ileal carcinoids;
LUSC	cis	rs7615316	0.934	rs6792259	chr3:142301439	A/T	cg16271453	chr3:142027066	XRN1	-0.36	-6.12	-0.32	2.58e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs1555543	0.517	rs2391766	chr1:96909240	T/C	cg10631902	chr5:14652156	NA	-0.49	-6.74	-0.35	6.84e-11	Body mass index;
LUSC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	6.3	0.33	9.38e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.47	0.33	3.44e-10	Platelet count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02865447	chr6:90062469	UBE2J1	-0.44	-6.68	-0.34	1.02e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17253792	0.822	rs17747083	chr14:56110594	T/C	cg01858014	chr14:56050164	KTN1	-0.84	-6.78	-0.35	5.6e-11	Putamen volume;
LUSC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg05973401	chr12:123451056	ABCB9	0.54	6.64	0.34	1.24e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg05187965	chr10:45406764	TMEM72	-0.36	-8.38	-0.42	1.49e-15	Mean corpuscular volume;
LUSC	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-14.01	-0.61	2.13e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg27446573	chr6:127587934	RNF146	0.61	9.71	0.47	8.39e-20	Breast cancer;
LUSC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.81	-0.35	4.6e-11	Menopause (age at onset);
LUSC	cis	rs7216064	1.000	rs2052187	chr17:65834737	T/C	cg12091567	chr17:66097778	LOC651250	-0.74	-9.57	-0.46	2.47e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs6496667	0.683	rs1869180	chr15:90895467	T/C	cg10434728	chr15:90938212	IQGAP1	0.35	6.53	0.34	2.39e-10	Rheumatoid arthritis;
LUSC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4776059	0.550	rs8030871	chr15:52938101	G/A	cg22715398	chr15:52968154	KIAA1370	-0.61	-6.81	-0.35	4.44e-11	Schizophrenia;
LUSC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.89	-0.4	4.26e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14019695	chr9:139328340	INPP5E	0.52	10.09	0.48	4.57e-21	Monocyte percentage of white cells;
LUSC	cis	rs4478858	0.647	rs4949380	chr1:31764160	A/G	cg00250761	chr1:31883323	NA	-0.34	-8.15	-0.41	7.26e-15	Alcohol dependence;
LUSC	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17467752	chr17:38218738	THRA	0.77	12.47	0.56	1.47e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg16928487	chr17:17741425	SREBF1	0.37	7.13	0.36	6.28e-12	Total body bone mineral density;
LUSC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.2	0.52	6.11e-25	Prudent dietary pattern;
LUSC	trans	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs9658691	0.607	rs9325604	chr10:90775756	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-6.25	-0.32	1.23e-9	Mosquito bite size;
LUSC	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg15704280	chr7:45808275	SEPT13	0.78	7.55	0.38	4.31e-13	Axial length;
LUSC	cis	rs7180079	0.920	rs11071790	chr15:64601979	G/A	cg08069370	chr15:64387884	SNX1	0.53	5.72	0.3	2.32e-8	Monocyte count;
LUSC	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg03676636	chr4:99064102	C4orf37	0.3	6.51	0.34	2.82e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs714027	0.585	rs9306468	chr22:30374281	T/C	cg11564601	chr22:30592435	NA	0.34	5.69	0.3	2.8e-8	Lymphocyte counts;
LUSC	cis	rs4474465	0.736	rs4945291	chr11:78254413	C/T	cg27205649	chr11:78285834	NARS2	0.51	6.17	0.32	2.03e-9	Alzheimer's disease (survival time);
LUSC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg04944784	chr2:26401820	FAM59B	-0.7	-9.69	-0.47	9.59e-20	Gut microbiome composition (summer);
LUSC	cis	rs4285028	0.747	rs9817818	chr3:121466826	C/A	cg11130432	chr3:121712080	ILDR1	-0.53	-7.76	-0.39	1.02e-13	Multiple sclerosis;
LUSC	trans	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg24644049	chr4:85504048	CDS1	0.74	7.45	0.38	7.81e-13	Skin colour saturation;
LUSC	cis	rs6977660	1.000	rs6943114	chr7:19818354	G/T	cg05791153	chr7:19748676	TWISTNB	0.52	5.89	0.31	9.55e-9	Thyroid stimulating hormone;
LUSC	cis	rs977987	0.898	rs12918974	chr16:75493943	T/A	cg04384234	chr16:75411784	CFDP1	-0.48	-7.89	-0.4	4.26e-14	Dupuytren's disease;
LUSC	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22455342	chr2:225449267	CUL3	0.47	6.41	0.33	4.92e-10	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs4561483	0.832	rs33645	chr16:11985201	T/C	cg08843971	chr16:11963173	GSPT1	-0.48	-7.13	-0.36	6.11e-12	Testicular germ cell tumor;
LUSC	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg04398451	chr17:18023971	MYO15A	-0.46	-7.4	-0.38	1.1e-12	Total body bone mineral density;
LUSC	cis	rs7523050	0.643	rs35665867	chr1:109395436	G/A	cg08274380	chr1:109419600	GPSM2	1.11	10.57	0.5	1.04e-22	Fat distribution (HIV);
LUSC	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-10.42	-0.5	3.24e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg12573674	chr2:1569213	NA	-0.55	-6.03	-0.31	4.38e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	trans	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg10756647	chr7:56101905	PSPH	0.88	8.45	0.42	8.8e-16	Diabetic kidney disease;
LUSC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg03806693	chr22:41940476	POLR3H	1.0	14.25	0.62	2.41e-36	Vitiligo;
LUSC	cis	rs1982963	0.906	rs2029976	chr14:52505811	C/T	cg10843707	chr14:52510701	NID2	-0.4	-6.48	-0.33	3.2e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg02951883	chr7:2050386	MAD1L1	-0.34	-5.88	-0.31	9.99e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7113850	0.541	rs7129839	chr11:24208606	C/T	ch.11.24196551F	chr11:24239977	NA	0.96	7.47	0.38	7.26e-13	Bone fracture in osteoporosis;
LUSC	cis	rs9837602	0.938	rs9823908	chr3:99795507	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.28	0.32	1.07e-9	Breast cancer;
LUSC	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg03676636	chr4:99064102	C4orf37	0.31	6.25	0.32	1.26e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg05340658	chr4:99064831	C4orf37	-0.47	-7.44	-0.38	8.44e-13	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg12751644	chr20:60527061	NA	0.36	6.22	0.32	1.51e-9	Body mass index;
LUSC	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg17470449	chr10:769945	NA	0.54	7.43	0.38	8.91e-13	Uric acid levels;
LUSC	cis	rs8040855	0.627	rs11632899	chr15:85600840	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-5.71	-0.3	2.51e-8	Bulimia nervosa;
LUSC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg21433313	chr16:3507492	NAT15	0.7	11.47	0.53	6.94e-26	Tuberculosis;
LUSC	cis	rs2637266	1.000	rs2579747	chr10:78327759	C/T	cg18941641	chr10:78392320	NA	0.37	6.66	0.34	1.14e-10	Pulmonary function;
LUSC	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.96	0.36	1.8e-11	Testicular germ cell tumor;
LUSC	cis	rs17001868	0.568	rs9611318	chr22:40739414	C/G	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	cis	rs4144743	1.000	rs3809861	chr17:45330066	A/G	cg18085866	chr17:45331354	ITGB3	-0.74	-7.72	-0.39	1.38e-13	Body mass index;
LUSC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg06784218	chr1:46089804	CCDC17	0.55	11.17	0.52	7.69e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg06223162	chr1:101003688	GPR88	0.45	8.47	0.42	7.85e-16	Monocyte count;
LUSC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg21918786	chr6:109611834	NA	-0.4	-6.88	-0.35	2.97e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg17652424	chr22:38574118	PLA2G6	-0.31	-6.9	-0.35	2.57e-11	Cutaneous nevi;
LUSC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08645402	chr16:4508243	NA	0.53	9.12	0.45	7.36e-18	Schizophrenia;
LUSC	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg25251562	chr2:3704773	ALLC	0.34	6.0	0.31	5.15e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs62103177	0.564	rs3930042	chr18:77723843	G/A	cg02751453	chr18:77725136	HSBP1L1	-0.47	-6.14	-0.32	2.3e-9	Opioid sensitivity;
LUSC	cis	rs12980942	0.591	rs2304232	chr19:41762525	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.69	7.34	0.37	1.69e-12	Coronary artery disease;
LUSC	cis	rs2274273	0.662	rs60445539	chr14:55624245	C/T	cg04306507	chr14:55594613	LGALS3	0.48	9.7	0.47	9.24e-20	Protein biomarker;
LUSC	trans	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg04995722	chr7:26192034	NFE2L3	-0.4	-6.51	-0.34	2.7e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg27284194	chr4:1044797	NA	0.56	8.17	0.41	6.61e-15	Recombination rate (females);
LUSC	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg04362960	chr10:104952993	NT5C2	0.6	9.43	0.46	7.29e-19	Arsenic metabolism;
LUSC	cis	rs7091068	0.616	rs1409336	chr10:95479674	T/G	cg20715218	chr10:95462985	C10orf4	0.61	6.79	0.35	5.14e-11	Urinary tract infection frequency;
LUSC	cis	rs6963495	0.818	rs73192144	chr7:105203535	C/T	cg13798780	chr7:105162888	PUS7	0.55	5.8	0.3	1.53e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6681460	0.549	rs7547866	chr1:67031924	A/G	cg02459107	chr1:67143332	SGIP1	0.31	5.69	0.3	2.85e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs2302729	0.929	rs7306298	chr12:2777311	G/A	cg19945202	chr12:2788847	CACNA1C	-0.39	-5.83	-0.3	1.33e-8	Sleep quality;
LUSC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg16325326	chr1:53192061	ZYG11B	0.96	18.44	0.71	7.09e-53	Monocyte count;
LUSC	cis	rs4786125	0.665	rs6500858	chr16:6906111	T/C	cg03623568	chr16:6915990	A2BP1	-0.5	-8.0	-0.4	2.02e-14	Heart rate variability traits (SDNN);
LUSC	cis	rs61990749	0.597	rs7147516	chr14:78153980	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.61	-6.49	-0.33	3.14e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg15468180	chr1:107600409	PRMT6	0.42	6.67	0.34	1.06e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg10911889	chr6:126070802	HEY2	0.43	6.54	0.34	2.28e-10	Brugada syndrome;
LUSC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg06784218	chr1:46089804	CCDC17	0.55	11.09	0.52	1.49e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7264396	1.000	rs7264396	chr20:34154741	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.47	6.85	0.35	3.49e-11	Total cholesterol levels;
LUSC	trans	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	6.51	0.34	2.73e-10	Retinal vascular caliber;
LUSC	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	12.48	0.56	1.37e-29	Electrocardiographic conduction measures;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.56	-9.35	-0.46	1.35e-18	Lymphocyte counts;
LUSC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.66	10.64	0.5	6.01e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg07817648	chr10:79422355	NA	-0.54	-7.41	-0.38	1.06e-12	Bone mineral density;
LUSC	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg02269571	chr22:50332266	NA	0.59	7.57	0.38	3.67e-13	Schizophrenia;
LUSC	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.33	0.62	1.18e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7481584	0.847	rs1468102	chr11:3004526	C/G	cg08508325	chr11:3079039	CARS	0.31	5.97	0.31	6.05e-9	Calcium levels;
LUSC	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.71	-12.65	-0.57	3.03e-30	White blood cell count (basophil);
LUSC	cis	rs9346649	0.630	rs4708641	chr6:168491416	G/A	cg02770688	chr6:168491649	NA	0.48	9.01	0.44	1.59e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg13010199	chr12:38710504	ALG10B	0.49	7.48	0.38	6.62e-13	Morning vs. evening chronotype;
LUSC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.85	0.3	1.17e-8	Personality dimensions;
LUSC	cis	rs6700559	0.740	rs10919999	chr1:200649759	G/A	cg07804481	chr1:200639085	DDX59	0.41	5.77	0.3	1.85e-8	Coronary artery disease;
LUSC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.97	0.31	6.23e-9	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07677032	chr17:61819896	STRADA	0.55	9.2	0.45	4.08e-18	Prudent dietary pattern;
LUSC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg00409905	chr10:38381863	ZNF37A	0.35	5.97	0.31	6.21e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs981844	1.000	rs2606335	chr4:154656536	T/C	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	7.16	0.36	5.02e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg10896623	chr1:19923370	C1orf151	0.42	6.3	0.33	9.24e-10	Educational attainment (years of education);
LUSC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.99	0.44	1.91e-17	Lung cancer;
LUSC	trans	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg24313572	chr1:56050060	NA	-0.31	-6.32	-0.33	8.32e-10	Morning vs. evening chronotype;
LUSC	cis	rs2235649	0.789	rs4567715	chr16:1849363	G/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-6.09	-0.32	3.19e-9	Blood metabolite levels;
LUSC	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg24692254	chr21:30365293	RNF160	-0.58	-7.22	-0.37	3.57e-12	Cognitive test performance;
LUSC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg00701064	chr4:6280414	WFS1	0.58	14.12	0.61	8.04e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-0.59	-9.31	-0.45	1.74e-18	Breast cancer;
LUSC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg13628971	chr7:2884303	GNA12	0.48	6.82	0.35	4.2e-11	Height;
LUSC	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.5	-9.18	-0.45	4.72e-18	Urinary metabolites;
LUSC	cis	rs35883536	0.611	rs72977390	chr1:101107147	C/T	cg06223162	chr1:101003688	GPR88	0.34	6.16	0.32	2.05e-9	Monocyte count;
LUSC	cis	rs7264396	0.887	rs2236160	chr20:34101821	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.69	-0.34	9.21e-11	Total cholesterol levels;
LUSC	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.2	0.49	1.95e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	0.85	14.57	0.62	1.41e-37	Cognitive function;
LUSC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.31	0.53	2.45e-25	Menopause (age at onset);
LUSC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg21963583	chr11:68658836	MRPL21	-0.5	-7.59	-0.38	3.32e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1113500	0.548	rs6583062	chr1:108656463	G/A	cg06207961	chr1:108661230	NA	0.37	6.13	0.32	2.45e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg24375607	chr4:120327624	NA	0.77	11.22	0.52	5.07e-25	Corneal astigmatism;
LUSC	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg09754948	chr16:28834200	ATXN2L	0.41	5.96	0.31	6.27e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg24375607	chr4:120327624	NA	0.77	11.32	0.53	2.32e-25	Corneal astigmatism;
LUSC	cis	rs239198	0.568	rs9404059	chr6:101331497	T/C	cg09795085	chr6:101329169	ASCC3	0.42	6.01	0.31	4.77e-9	Menarche (age at onset);
LUSC	cis	rs360798	0.512	rs4671050	chr2:62988169	G/T	cg17519650	chr2:63277830	OTX1	-0.51	-7.08	-0.36	8.37e-12	Coronary artery disease;
LUSC	cis	rs911119	0.954	rs2405367	chr20:23622880	A/G	cg16589663	chr20:23618590	CST3	-0.64	-7.84	-0.39	6.27e-14	Chronic kidney disease;
LUSC	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg05855489	chr10:104503620	C10orf26	0.52	8.02	0.4	1.85e-14	Arsenic metabolism;
LUSC	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg23093090	chr10:104574429	C10orf26	-0.36	-6.61	-0.34	1.54e-10	Arsenic metabolism;
LUSC	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg15423357	chr2:25149977	NA	0.39	7.5	0.38	5.99e-13	Body mass index in non-asthmatics;
LUSC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08280861	chr8:58055591	NA	0.54	6.43	0.33	4.34e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20196129	chr10:31609347	ZEB1;LOC220930	-0.51	-6.23	-0.32	1.38e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg14664628	chr15:75095509	CSK	-0.9	-14.11	-0.61	8.46e-36	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg10560079	chr2:191398806	TMEM194B	-0.52	-6.67	-0.34	1.03e-10	Diastolic blood pressure;
LUSC	cis	rs7074356	0.569	rs7090863	chr10:82021393	C/A	cg27171509	chr10:82033454	MAT1A	-0.32	-5.85	-0.3	1.18e-8	Borderline personality disorder;
LUSC	cis	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg17187183	chr4:55093834	PDGFRA	0.39	5.89	0.31	9.61e-9	Corneal astigmatism;
LUSC	trans	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.53	-0.53	4.11e-26	Colorectal cancer;
LUSC	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg16342193	chr10:102329863	NA	-0.36	-7.14	-0.36	6.03e-12	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	11.09	0.52	1.56e-24	Hypertriglyceridemia;
LUSC	cis	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.59	7.82	0.39	6.97e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.11	-0.36	7.28e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs727505	0.954	rs68102397	chr7:124685315	C/T	cg23710748	chr7:124431027	NA	-0.41	-7.15	-0.36	5.37e-12	Lewy body disease;
LUSC	cis	rs10465746	0.752	rs10874426	chr1:84451820	A/G	cg10977910	chr1:84465055	TTLL7	0.5	7.35	0.37	1.54e-12	Obesity-related traits;
LUSC	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg26876637	chr1:152193138	HRNR	0.39	5.65	0.3	3.48e-8	Atopic dermatitis;
LUSC	cis	rs5758511	0.773	rs73165164	chr22:42355549	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.93	-0.31	7.54e-9	Birth weight;
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg27094323	chr7:1216898	NA	-0.45	-7.8	-0.39	8.07e-14	Longevity;Endometriosis;
LUSC	cis	rs3931020	0.657	rs277376	chr1:75242246	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.6	-8.02	-0.4	1.78e-14	Resistin levels;
LUSC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.36	5.85	0.3	1.18e-8	Menopause (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23381116	chr14:24616413	PSME2;RNF31	0.44	6.27	0.32	1.12e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4654899	0.802	rs2290381	chr1:21213271	C/A	cg01072550	chr1:21505969	NA	-0.48	-7.06	-0.36	9.83e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg05855489	chr10:104503620	C10orf26	0.59	9.19	0.45	4.16e-18	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21724239	chr8:58056113	NA	0.75	8.54	0.42	4.93e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg07460842	chr6:66804631	NA	0.89	9.68	0.47	1.1e-19	Exhaled nitric oxide output;
LUSC	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg04362960	chr10:104952993	NT5C2	0.69	9.42	0.46	7.98e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1865721	1.000	rs1865721	chr18:73192446	C/T	cg26385618	chr18:73139727	C18orf62	-0.48	-8.1	-0.41	1.04e-14	Intelligence;
LUSC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg13319975	chr6:146136371	FBXO30	-0.42	-6.34	-0.33	7.64e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg03676636	chr4:99064102	C4orf37	0.36	8.07	0.4	1.24e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.5	8.68	0.43	1.82e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg05855489	chr10:104503620	C10orf26	-0.68	-9.85	-0.47	2.9e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	0.94	18.7	0.72	6.71e-54	Menarche (age at onset);
LUSC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-7.95	-0.4	2.83e-14	Monocyte percentage of white cells;
LUSC	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg22705602	chr4:152727874	NA	-0.32	-6.37	-0.33	6.24e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg10018233	chr7:150070692	REPIN1	0.4	7.16	0.36	5.1e-12	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-8.0	-0.4	2.12e-14	Neuroticism;
LUSC	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg12292205	chr6:26970375	C6orf41	0.37	5.78	0.3	1.7e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.49	0.33	3.13e-10	Lung cancer;
LUSC	cis	rs4234798	0.500	rs7661066	chr4:7219878	C/T	cg18431297	chr4:7219810	SORCS2	0.33	6.21	0.32	1.55e-9	Insulin-like growth factors;
LUSC	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg05373962	chr22:49881684	NA	-0.4	-8.63	-0.43	2.63e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-12.37	-0.56	3.29e-29	Platelet count;
LUSC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg11645453	chr3:52864694	ITIH4	0.35	8.13	0.41	8.73e-15	Bipolar disorder;
LUSC	trans	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg13010199	chr12:38710504	ALG10B	0.44	6.95	0.36	1.93e-11	Morning vs. evening chronotype;
LUSC	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg23029597	chr12:123009494	RSRC2	-0.63	-7.38	-0.37	1.28e-12	Body mass index;
LUSC	cis	rs1595825	1.000	rs79508374	chr2:198864568	G/A	cg00982548	chr2:198649783	BOLL	-0.5	-6.22	-0.32	1.46e-9	Ulcerative colitis;
LUSC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg04398451	chr17:18023971	MYO15A	-0.46	-7.38	-0.37	1.31e-12	Total body bone mineral density;
LUSC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00166722	chr3:10149974	C3orf24	0.63	8.77	0.43	9.36e-17	Alzheimer's disease;
LUSC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg16339924	chr4:17578868	LAP3	0.56	8.54	0.42	4.9e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.77	0.3	1.82e-8	Personality dimensions;
LUSC	cis	rs701145	0.585	rs357477	chr3:153892717	A/G	cg17054900	chr3:154042577	DHX36	0.69	6.76	0.35	6.12e-11	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01469421	chr19:57999034	ZNF419	0.42	6.68	0.34	1.03e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg06521331	chr12:34319734	NA	-0.45	-7.59	-0.38	3.32e-13	Morning vs. evening chronotype;
LUSC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.83	13.11	0.58	5.75e-32	Cognitive test performance;
LUSC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	0.77	13.48	0.59	2.3e-33	Cognitive function;
LUSC	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg20991723	chr1:152506922	NA	0.53	9.8	0.47	4.42e-20	Hair morphology;
LUSC	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08645402	chr16:4508243	NA	0.49	8.11	0.41	9.77e-15	Schizophrenia;
LUSC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg05872129	chr22:39784769	NA	-0.54	-8.93	-0.44	2.91e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg00074818	chr8:8560427	CLDN23	0.53	9.16	0.45	5.19e-18	Obesity-related traits;
LUSC	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg15711740	chr2:61764176	XPO1	0.45	6.87	0.35	3.24e-11	Tuberculosis;
LUSC	cis	rs4481887	0.512	rs1538702	chr1:248519665	A/T	cg26353448	chr1:248524236	OR2T4	-0.42	-9.48	-0.46	4.87e-19	Common traits (Other);
LUSC	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-14.01	-0.61	2.11e-35	Exhaled nitric oxide output;
LUSC	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg07148914	chr20:33460835	GGT7	0.46	6.74	0.35	6.97e-11	Height;
LUSC	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.52	10.01	0.48	8.64e-21	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-7.88	-0.4	4.69e-14	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-11.57	-0.53	2.91e-26	Bipolar disorder;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07157834	chr1:205819609	PM20D1	-0.81	-14.5	-0.62	2.79e-37	Menarche (age at onset);
LUSC	cis	rs2708977	0.933	rs2579502	chr2:97198800	A/G	cg01950434	chr2:97203154	ARID5A	-0.57	-8.49	-0.42	6.68e-16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg23034840	chr1:205782522	SLC41A1	0.59	8.29	0.41	2.81e-15	Menarche (age at onset);
LUSC	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	1.08	9.74	0.47	6.73e-20	Skin colour saturation;
LUSC	cis	rs7945718	0.967	rs11022490	chr11:12773526	C/G	cg25843174	chr11:12811716	TEAD1	-0.3	-6.83	-0.35	4.11e-11	Educational attainment (years of education);
LUSC	cis	rs9469578	0.579	rs73743310	chr6:33689299	A/G	cg18708504	chr6:33715942	IP6K3	0.67	6.33	0.33	7.75e-10	Phosphorus levels;
LUSC	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg15744005	chr10:104629667	AS3MT	-0.38	-7.8	-0.39	8.23e-14	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs7264396	0.775	rs2296402	chr20:34054729	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.23	-0.32	1.4e-9	Total cholesterol levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02725935	chr1:120612404	NOTCH2	0.48	6.66	0.34	1.13e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg10857441	chr5:6722123	POLS	-0.45	-8.31	-0.41	2.44e-15	Menopause (age at onset);
LUSC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.94	-0.31	7.19e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg18002602	chr11:66138449	SLC29A2	0.45	8.1	0.41	1.06e-14	Educational attainment (years of education);
LUSC	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg21681030	chr2:46777652	RHOQ	0.42	5.92	0.31	7.79e-9	Height;
LUSC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg05313129	chr8:58192883	C8orf71	-0.53	-6.86	-0.35	3.31e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg20607287	chr7:12443886	VWDE	-0.57	-6.03	-0.31	4.43e-9	Coronary artery disease;
LUSC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72627509	0.904	rs3796529	chr4:57797414	C/T	cg26694713	chr4:57773883	REST	0.49	6.06	0.31	3.76e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.91	0.35	2.53e-11	Platelet count;
LUSC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg09165964	chr15:75287851	SCAMP5	0.47	7.11	0.36	6.9e-12	Breast cancer;
LUSC	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg24375607	chr4:120327624	NA	0.77	11.46	0.53	7.47e-26	Corneal astigmatism;
LUSC	cis	rs6939532	0.522	rs9379870	chr6:26374410	A/G	cg09904177	chr6:26538194	HMGN4	-0.45	-6.44	-0.33	4.09e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs559928	1.000	rs11601872	chr11:64147627	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	6.61	0.34	1.52e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2742234	0.554	rs1254963	chr10:43696086	C/T	cg02780029	chr10:43622663	RET	0.34	5.65	0.3	3.37e-8	Hirschsprung disease;
LUSC	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg23029597	chr12:123009494	RSRC2	-0.71	-9.45	-0.46	6.22e-19	Body mass index;
LUSC	cis	rs3857536	0.776	rs4710583	chr6:66940101	A/C	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	9.43	0.46	7.3e-19	Response to antipsychotic treatment;
LUSC	cis	rs113835537	0.529	rs2305535	chr11:66272237	A/G	cg24851651	chr11:66362959	CCS	-0.49	-7.37	-0.37	1.39e-12	Airway imaging phenotypes;
LUSC	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg15212455	chr7:39170539	POU6F2	-0.37	-5.67	-0.3	3.11e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.68	-10.39	-0.49	4.2e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg00074818	chr8:8560427	CLDN23	0.59	9.54	0.46	3.07e-19	Obesity-related traits;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg25135922	chr1:226497286	LIN9	0.4	6.11	0.32	2.77e-9	Schizophrenia (age at onset);
LUSC	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	7.05	0.36	1.02e-11	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs7605827	0.930	rs2111453	chr2:15673248	C/T	cg19274914	chr2:15703543	NA	0.45	8.7	0.43	1.49e-16	Educational attainment (years of education);
LUSC	trans	rs459571	0.920	rs433402	chr9:136898627	A/G	cg10765909	chr12:53715428	AAAS	-0.43	-6.15	-0.32	2.17e-9	Platelet distribution width;
LUSC	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	7.0	0.36	1.45e-11	Ovarian reserve;
LUSC	cis	rs4478137	0.931	rs7687423	chr4:164250797	C/T	cg06758707	chr4:164254230	NPY1R	-0.6	-9.7	-0.47	9.41e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg03146154	chr1:46216737	IPP	0.53	7.72	0.39	1.33e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.13	0.64	9.65e-40	Lymphocyte percentage of white cells;
LUSC	trans	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg26043149	chr18:55253948	FECH	0.47	7.16	0.36	5.05e-12	Bone mineral density;
LUSC	cis	rs6845621	0.717	rs2222192	chr4:18844340	G/A	cg12196642	chr4:18937545	NA	-0.32	-5.8	-0.3	1.53e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg16339924	chr4:17578868	LAP3	0.6	9.22	0.45	3.34e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg16482183	chr6:26056742	HIST1H1C	1.0	12.85	0.58	5.41e-31	Iron status biomarkers;
LUSC	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.78	13.35	0.59	6.83e-33	Metabolic syndrome;
LUSC	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.44	-0.46	6.8e-19	Neuroticism;
LUSC	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg27411982	chr8:10470053	RP1L1	0.4	6.23	0.32	1.37e-9	Myopia (pathological);
LUSC	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg24375607	chr4:120327624	NA	0.69	10.92	0.51	6.06e-24	Corneal astigmatism;
LUSC	cis	rs10779751	0.770	rs2486922	chr1:11124885	T/C	cg08854313	chr1:11322531	MTOR	0.81	12.1	0.55	3.52e-28	Body mass index;
LUSC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg06600287	chr1:53387719	ECHDC2	-0.3	-6.28	-0.33	1.04e-9	Monocyte count;
LUSC	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg22532475	chr10:104410764	TRIM8	-0.26	-6.06	-0.31	3.64e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg05234568	chr11:5960015	NA	-0.57	-8.48	-0.42	7.41e-16	DNA methylation (variation);
LUSC	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg05855489	chr10:104503620	C10orf26	-0.68	-10.21	-0.49	1.74e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6087990	0.735	rs2424921	chr20:31385814	C/T	cg13636640	chr20:31349939	DNMT3B	0.92	18.85	0.72	1.63e-54	Ulcerative colitis;
LUSC	cis	rs6828523	0.698	rs56004315	chr4:175859382	C/T	cg16870595	chr4:175839423	ADAM29	0.5	5.67	0.3	3.09e-8	Breast cancer;
LUSC	cis	rs9326248	0.731	rs90192	chr11:117059347	C/T	cg26566898	chr11:117069891	TAGLN	0.39	5.84	0.3	1.26e-8	Blood protein levels;
LUSC	cis	rs12545109	0.842	rs2670050	chr8:57402914	T/G	cg09654669	chr8:57350985	NA	-0.5	-6.54	-0.34	2.34e-10	Obesity-related traits;
LUSC	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg04374321	chr14:90722782	PSMC1	-0.68	-10.22	-0.49	1.66e-21	Mortality in heart failure;
LUSC	cis	rs7568498	0.564	rs9287807	chr2:161915361	T/C	cg22496339	chr2:162101262	NA	-0.57	-7.41	-0.38	1.03e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LUSC	cis	rs2970818	0.831	rs11063205	chr12:4597745	G/A	cg11146114	chr12:4671731	NA	-0.62	-5.99	-0.31	5.57e-9	Phosphorus levels;
LUSC	cis	rs793571	0.650	rs12899638	chr15:58920275	G/A	cg05156742	chr15:59063176	FAM63B	0.56	8.53	0.42	5.14e-16	Schizophrenia;
LUSC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg09796270	chr17:17721594	SREBF1	0.43	7.6	0.38	2.97e-13	Total body bone mineral density;
LUSC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.56	0.46	2.6e-19	Lung cancer in ever smokers;
LUSC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg13939156	chr17:80058883	NA	-0.34	-6.73	-0.35	7.53e-11	Life satisfaction;
LUSC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg17077180	chr1:38461687	NA	0.4	6.09	0.32	3.18e-9	Coronary artery disease;
LUSC	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.07	14.26	0.62	2.27e-36	Uric acid levels;
LUSC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg09658497	chr7:2847517	GNA12	-0.32	-5.72	-0.3	2.42e-8	Height;
LUSC	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg10636054	chr15:40330586	SRP14	0.91	9.01	0.44	1.63e-17	Corneal curvature;
LUSC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg04369109	chr6:150039330	LATS1	-0.58	-8.44	-0.42	9.96e-16	Lung cancer;
LUSC	cis	rs2625529	0.824	rs7170754	chr15:72218594	G/A	cg16672083	chr15:72433130	SENP8	-0.52	-7.51	-0.38	5.28e-13	Red blood cell count;
LUSC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg24324837	chr19:49891574	CCDC155	0.51	6.94	0.35	2.05e-11	Multiple sclerosis;
LUSC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg10130564	chr11:117069849	TAGLN	0.33	6.31	0.33	9.01e-10	Blood protein levels;
LUSC	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg04121214	chr22:50244548	NA	-0.35	-5.77	-0.3	1.82e-8	Schizophrenia;
LUSC	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.38	-0.33	5.93e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10492096	0.947	rs11064227	chr12:6598043	A/G	cg13857086	chr12:6580257	VAMP1	0.59	7.11	0.36	7.22e-12	Hip geometry;
LUSC	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.75	10.36	0.49	5.28e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4704187	0.687	rs1422696	chr5:74464415	T/C	cg03227963	chr5:74354835	NA	0.32	6.83	0.35	4.02e-11	Response to amphetamines;
LUSC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg18240062	chr17:79603768	NPLOC4	-0.57	-9.84	-0.47	3.25e-20	Eye color traits;
LUSC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg24531977	chr5:56204891	C5orf35	-0.55	-8.16	-0.41	7.13e-15	Coronary artery disease;
LUSC	trans	rs62238980	0.614	rs75386630	chr22:32380975	G/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs3784262	1.000	rs4646629	chr15:58255215	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.8	-0.3	1.51e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg02018176	chr4:1364513	KIAA1530	-0.45	-6.25	-0.32	1.22e-9	Recombination rate (females);
LUSC	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg24375607	chr4:120327624	NA	0.72	10.44	0.5	2.84e-22	Corneal astigmatism;
LUSC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg09359103	chr1:154839909	KCNN3	0.43	8.34	0.42	1.97e-15	Schizophrenia;
LUSC	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.94	-0.44	2.7e-17	Total cholesterol levels;
LUSC	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.18	0.32	1.85e-9	Corneal astigmatism;
LUSC	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.54	-6.34	-0.33	7.27e-10	Birth weight;
LUSC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg15494558	chr6:150152522	LRP11	0.34	5.77	0.3	1.77e-8	Lung cancer;
LUSC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-7.58	-0.38	3.35e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg06618935	chr21:46677482	NA	-0.39	-7.95	-0.4	3e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg15445000	chr17:37608096	MED1	0.41	6.91	0.35	2.41e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg25174290	chr11:3078921	CARS	0.61	9.47	0.46	5.11e-19	Longevity;
LUSC	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg08236123	chr12:132219811	SFRS8	-0.43	-6.54	-0.34	2.36e-10	Migraine;
LUSC	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg16482183	chr6:26056742	HIST1H1C	0.61	8.39	0.42	1.36e-15	Height;
LUSC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg09197432	chr4:183729176	NA	0.69	9.8	0.47	4.33e-20	Pediatric autoimmune diseases;
LUSC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg09365446	chr1:150670422	GOLPH3L	0.54	8.41	0.42	1.24e-15	Tonsillectomy;
LUSC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg26335602	chr6:28129616	ZNF389	0.43	5.75	0.3	1.98e-8	Parkinson's disease;
LUSC	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg26384229	chr12:38710491	ALG10B	0.73	11.84	0.54	3.15e-27	Morning vs. evening chronotype;
LUSC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.79	0.6	1.52e-34	Alzheimer's disease;
LUSC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs1113500	0.897	rs4628530	chr1:108638708	T/G	cg06207961	chr1:108661230	NA	0.41	7.64	0.39	2.29e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs3126085	0.877	rs1969019	chr1:152211502	A/C	cg26876637	chr1:152193138	HRNR	0.45	6.27	0.32	1.12e-9	Atopic dermatitis;
LUSC	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg23750338	chr8:142222470	SLC45A4	-0.54	-10.21	-0.49	1.82e-21	Immature fraction of reticulocytes;
LUSC	cis	rs6596100	0.538	rs55976357	chr5:132194565	C/A	cg02081065	chr5:132209139	LEAP2	-0.62	-5.9	-0.31	9.1e-9	Breast cancer;
LUSC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-8.2	-0.41	5.39e-15	Chronic sinus infection;
LUSC	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.59	-7.97	-0.4	2.51e-14	Body mass index (adult);
LUSC	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg03806693	chr22:41940476	POLR3H	-0.54	-7.91	-0.4	3.76e-14	Neuroticism;
LUSC	cis	rs4588572	0.537	rs7705718	chr5:77730349	T/C	cg11547950	chr5:77652471	NA	-0.48	-7.19	-0.37	4.18e-12	Triglycerides;
LUSC	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	7.96	0.4	2.68e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg07080220	chr10:102295463	HIF1AN	0.6	7.75	0.39	1.1e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3820928	0.934	rs16822890	chr2:227761477	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.74	-0.39	1.21e-13	Pulmonary function;
LUSC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg11645453	chr3:52864694	ITIH4	0.34	7.78	0.39	8.92e-14	Bipolar disorder;
LUSC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg00033643	chr7:134001901	SLC35B4	0.42	6.71	0.34	8.2e-11	Mean platelet volume;
LUSC	cis	rs151349	1.000	rs151345	chr20:57586849	G/C	cg23907860	chr20:57583709	CTSZ	-0.46	-7.47	-0.38	6.97e-13	Platelet distribution width;
LUSC	cis	rs4363385	0.934	rs4240865	chr1:152954839	G/T	cg08895932	chr1:152778580	LCE1C	0.34	5.8	0.3	1.52e-8	Inflammatory skin disease;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg06303282	chr4:154266565	MND1	0.53	6.18	0.32	1.86e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08109568	chr15:31115862	NA	0.48	6.64	0.34	1.3e-10	Huntington's disease progression;
LUSC	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg00129232	chr17:37814104	STARD3	-0.47	-7.03	-0.36	1.18e-11	Asthma;
LUSC	cis	rs8038465	0.762	rs35149321	chr15:73962728	G/A	cg15420318	chr15:73925796	NPTN	0.52	8.68	0.43	1.79e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-6.64	-0.34	1.26e-10	Extrinsic epigenetic age acceleration;
LUSC	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg26384229	chr12:38710491	ALG10B	0.71	11.0	0.52	3.29e-24	Morning vs. evening chronotype;
LUSC	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg08558340	chr7:100472263	SRRT	0.5	6.23	0.32	1.37e-9	Resting heart rate;
LUSC	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg23229984	chr5:148520753	ABLIM3	0.37	5.97	0.31	6.15e-9	Breast cancer;
LUSC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs11645898	0.687	rs72787058	chr16:72105084	C/T	cg14768367	chr16:72042858	DHODH	-0.53	-6.15	-0.32	2.16e-9	Blood protein levels;
LUSC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg19622623	chr12:86230825	RASSF9	-0.46	-6.39	-0.33	5.57e-10	Major depressive disorder;
LUSC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg05785598	chr3:49045655	WDR6	0.37	6.61	0.34	1.52e-10	Parkinson's disease;
LUSC	cis	rs12891047	0.901	rs1040598	chr14:68258982	C/A	cg20999565	chr14:68265668	ZFYVE26	-0.39	-6.03	-0.31	4.34e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs3764563	1.000	rs3764563	chr19:15724203	A/G	cg20725493	chr19:15740067	CYP4F8	-0.56	-6.56	-0.34	2.05e-10	Inflammatory biomarkers;
LUSC	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg21775007	chr8:11205619	TDH	0.46	6.48	0.33	3.26e-10	Neuroticism;
LUSC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg22244940	chr12:132335942	MMP17	-0.44	-6.77	-0.35	5.83e-11	Migraine;
LUSC	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg04362960	chr10:104952993	NT5C2	0.9	11.69	0.54	1.06e-26	Arsenic metabolism;
LUSC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg24733560	chr20:60626293	TAF4	0.4	6.39	0.33	5.49e-10	Body mass index;
LUSC	cis	rs9677476	1.000	rs12470450	chr2:232113888	T/A	cg07929768	chr2:232055508	NA	0.3	5.78	0.3	1.7e-8	Food antigen IgG levels;
LUSC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs3106136	0.967	rs7435106	chr4:95169772	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.36	-6.32	-0.33	8.37e-10	Capecitabine sensitivity;
LUSC	cis	rs4478858	0.735	rs2271072	chr1:31840426	C/G	cg00250761	chr1:31883323	NA	-0.36	-8.67	-0.43	1.97e-16	Alcohol dependence;
LUSC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.22	13.75	0.6	2.15e-34	Diabetic kidney disease;
LUSC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg00343986	chr7:65444356	GUSB	-0.43	-6.55	-0.34	2.17e-10	Aortic root size;
LUSC	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg27411982	chr8:10470053	RP1L1	-0.36	-5.8	-0.3	1.56e-8	Retinal vascular caliber;
LUSC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.71	-0.34	8.42e-11	Longevity;Endometriosis;
LUSC	cis	rs17685	0.767	rs10954732	chr7:75611149	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.44	6.92	0.35	2.28e-11	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg27539214	chr16:67997921	SLC12A4	-0.52	-7.06	-0.36	9.75e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7615316	0.779	rs13061823	chr3:142120786	C/T	cg16271453	chr3:142027066	XRN1	-0.41	-7.19	-0.37	4.17e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg19592336	chr6:28129416	ZNF389	0.53	6.95	0.36	1.87e-11	Parkinson's disease;
LUSC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg13175981	chr1:150552382	MCL1	-0.41	-5.65	-0.3	3.53e-8	Melanoma;
LUSC	cis	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg24375607	chr4:120327624	NA	0.51	7.87	0.4	4.87e-14	Diastolic blood pressure;
LUSC	cis	rs2594714	1.000	rs2594714	chr19:13954571	G/A	cg18576835	chr19:13944261	NA	-0.39	-5.67	-0.3	3.11e-8	Breast cancer;
LUSC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg07212818	chr11:638076	DRD4	-0.44	-7.37	-0.37	1.36e-12	Systemic lupus erythematosus;
LUSC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg11645453	chr3:52864694	ITIH4	0.35	8.23	0.41	4.18e-15	Bipolar disorder;
LUSC	cis	rs4964805	0.657	rs73192049	chr12:104187993	T/C	cg02344784	chr12:104178138	NT5DC3	0.46	8.87	0.44	4.61e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs1832871	0.672	rs9456285	chr6:158732819	T/G	cg07165851	chr6:158734300	TULP4	0.46	6.89	0.35	2.81e-11	Height;
LUSC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg24642844	chr7:1081250	C7orf50	-0.77	-10.29	-0.49	9.04e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11246602	1	rs11246602	chr11:51512090	T/C	cg03929089	chr4:120376271	NA	0.79	6.7	0.34	8.71e-11	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14240646	chr10:27532245	ACBD5	-0.74	-8.14	-0.41	8.13e-15	Breast cancer;
LUSC	cis	rs728616	0.558	rs12772945	chr10:82154496	C/T	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.8	-0.3	1.57e-8	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	11.22	0.52	5.3e-25	Bone mineral density;
LUSC	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg00083206	chr6:110721305	DDO	-0.44	-7.91	-0.4	3.8e-14	Platelet distribution width;
LUSC	cis	rs3820928	0.874	rs13403281	chr2:227880769	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.71	-0.39	1.49e-13	Pulmonary function;
LUSC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.42	0.76	1.15e-64	Prudent dietary pattern;
LUSC	cis	rs4478137	0.501	rs4146926	chr4:164230788	C/G	cg06758707	chr4:164254230	NPY1R	-0.52	-6.93	-0.35	2.13e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg16414030	chr3:133502952	NA	0.35	5.67	0.3	3.06e-8	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.86	12.59	0.57	5.41e-30	Chronic sinus infection;
LUSC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg01802117	chr1:53393560	SCP2	-0.36	-5.79	-0.3	1.62e-8	Monocyte count;
LUSC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	0.92	13.86	0.6	7.98e-35	Breast cancer;
LUSC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.9	0.44	3.49e-17	Prudent dietary pattern;
LUSC	trans	rs1459104	0.866	rs12787024	chr11:54883667	C/T	cg03929089	chr4:120376271	NA	0.68	6.03	0.31	4.28e-9	Body mass index;
LUSC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg09491104	chr22:46646882	C22orf40	-0.64	-7.38	-0.37	1.3e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg01097406	chr16:89675127	NA	0.31	6.06	0.31	3.71e-9	Vitiligo;
LUSC	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg01884057	chr2:25150051	NA	0.48	11.31	0.53	2.52e-25	Body mass index;
LUSC	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg10018233	chr7:150070692	REPIN1	0.4	7.11	0.36	6.9e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg12963246	chr6:28129442	ZNF389	0.53	7.5	0.38	5.9e-13	Depression;
LUSC	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	0.97	21.02	0.75	4.14e-63	Longevity;
LUSC	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg08000102	chr2:233561755	GIGYF2	-0.51	-8.11	-0.41	9.53e-15	Coronary artery disease;
LUSC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg13393036	chr8:95962371	TP53INP1	-0.44	-9.15	-0.45	5.61e-18	Type 2 diabetes;
LUSC	cis	rs662064	0.925	rs597438	chr1:10554505	A/G	cg20482658	chr1:10539492	PEX14	-0.34	-6.9	-0.35	2.6e-11	Asthma;
LUSC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.24	-0.32	1.32e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg06521331	chr12:34319734	NA	-0.41	-6.69	-0.34	9.21e-11	Morning vs. evening chronotype;
LUSC	cis	rs2573652	0.722	rs968412	chr15:100544512	C/G	cg00587665	chr15:100533223	ADAMTS17	-0.34	-5.94	-0.31	7.24e-9	Height;
LUSC	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.63	-0.43	2.59e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg15445000	chr17:37608096	MED1	-0.4	-6.81	-0.35	4.56e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg21293242	chr8:11204541	TDH	0.32	5.91	0.31	8.42e-9	Retinal vascular caliber;
LUSC	cis	rs1997103	0.954	rs7811098	chr7:55413012	A/G	cg17469321	chr7:55412551	NA	0.65	10.53	0.5	1.45e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.67	-0.5	4.42e-23	Glomerular filtration rate;
LUSC	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg23750338	chr8:142222470	SLC45A4	-0.56	-10.95	-0.51	4.79e-24	Immature fraction of reticulocytes;
LUSC	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg12744634	chr1:26560303	CCDC21	0.4	5.92	0.31	8.03e-9	Obesity-related traits;
LUSC	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.02	-20.84	-0.75	2.3e-62	Ulcerative colitis;
LUSC	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.44	-0.42	1.01e-15	Menopause (age at onset);
LUSC	cis	rs1256061	0.603	rs1256039	chr14:64738979	G/C	cg23250157	chr14:64679961	SYNE2	0.32	5.7	0.3	2.68e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg01851573	chr8:8652454	MFHAS1	0.54	8.86	0.44	4.92e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4494114	1.000	rs3790441	chr1:39352492	G/A	cg25970120	chr1:39325951	RRAGC	-0.39	-6.05	-0.31	3.81e-9	Blood protein levels;
LUSC	cis	rs6977660	1.000	rs10275322	chr7:19821220	C/T	cg07541023	chr7:19748670	TWISTNB	0.51	5.73	0.3	2.3e-8	Thyroid stimulating hormone;
LUSC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.57	-9.33	-0.45	1.56e-18	Aortic root size;
LUSC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.37	-6.41	-0.33	4.99e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.78	0.39	9.3e-14	Prudent dietary pattern;
LUSC	cis	rs983392	0.709	rs7928895	chr11:59975165	G/A	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.22	-0.32	1.53e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.17	0.45	4.98e-18	Monocyte percentage of white cells;
LUSC	trans	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg26384229	chr12:38710491	ALG10B	0.53	8.49	0.42	7.1e-16	Morning vs. evening chronotype;
LUSC	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg04450456	chr4:17643702	FAM184B	0.36	5.87	0.31	1.04e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs75804782	0.521	rs55988884	chr2:239396930	G/A	cg18131467	chr2:239335373	ASB1	-0.67	-6.23	-0.32	1.43e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg08085267	chr17:45401833	C17orf57	0.59	8.59	0.43	3.34e-16	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.52	0.42	5.49e-16	Neutrophil percentage of white cells;
LUSC	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg06885757	chr1:42089581	HIVEP3	0.41	8.18	0.41	5.81e-15	Lupus nephritis in systemic lupus erythematosus;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16656864	chr17:27718261	TAOK1	0.48	6.33	0.33	7.81e-10	Neuroticism;
LUSC	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg24399712	chr22:39784796	NA	-0.54	-7.86	-0.4	5.25e-14	IgG glycosylation;
LUSC	trans	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.63	-0.39	2.43e-13	Menarche (age at onset);
LUSC	cis	rs593982	1.000	rs593982	chr11:65513107	T/C	cg08755490	chr11:65554678	OVOL1	1.41	17.72	0.7	5.44e-50	Atopic dermatitis;
LUSC	cis	rs894344	0.584	rs2028556	chr8:135648040	T/C	cg27224718	chr8:135614730	ZFAT	0.35	5.68	0.3	2.98e-8	Systolic blood pressure;
LUSC	cis	rs8062405	0.756	rs151301	chr16:28497059	T/A	cg16576597	chr16:28551801	NUPR1	0.29	5.85	0.3	1.18e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg03929089	chr4:120376271	NA	-0.77	-12.25	-0.56	9.36e-29	Height;
LUSC	cis	rs11264799	0.603	rs12134075	chr1:157586516	C/T	cg18268488	chr1:157545234	FCRL4	0.33	6.03	0.31	4.34e-9	IgA nephropathy;
LUSC	cis	rs7189233	0.955	rs72801853	chr16:53516824	A/G	cg09728985	chr16:53543985	NA	-0.34	-6.05	-0.31	3.91e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.59e-9	Menopause (age at onset);
LUSC	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg22431228	chr1:16359049	CLCNKA	-0.44	-8.53	-0.42	5.02e-16	Dilated cardiomyopathy;
LUSC	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-0.89	-14.35	-0.62	1.04e-36	Headache;
LUSC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	5.92	0.31	7.79e-9	Personality dimensions;
LUSC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	8.34	0.42	1.99e-15	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.7	-10.34	-0.49	6.33e-22	Chronic sinus infection;
LUSC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg00012203	chr2:219082015	ARPC2	0.88	16.79	0.68	2.75e-46	Colorectal cancer;
LUSC	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg10818794	chr15:86012489	AKAP13	-0.42	-6.55	-0.34	2.23e-10	Coronary artery disease;
LUSC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg13683864	chr3:40499215	RPL14	-1.11	-21.81	-0.77	3.53e-66	Renal cell carcinoma;
LUSC	cis	rs7605827	0.930	rs6431705	chr2:15599988	C/G	cg19274914	chr2:15703543	NA	-0.47	-9.15	-0.45	5.78e-18	Educational attainment (years of education);
LUSC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg08917208	chr2:24149416	ATAD2B	-0.52	-5.78	-0.3	1.75e-8	Lymphocyte counts;
LUSC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	6.91	0.35	2.39e-11	Bipolar disorder;
LUSC	cis	rs2455799	0.574	rs2470534	chr3:15701054	C/G	cg16303742	chr3:15540471	COLQ	0.33	6.57	0.34	1.96e-10	Mean platelet volume;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.63	-9.35	-0.46	1.28e-18	Longevity;Endometriosis;
LUSC	cis	rs3126085	0.935	rs4595369	chr1:152248193	G/A	cg26876637	chr1:152193138	HRNR	0.46	6.33	0.33	8e-10	Atopic dermatitis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03182158	chr8:125487804	RNF139	-0.49	-5.98	-0.31	5.59e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.54	8.63	0.43	2.48e-16	Menopause (age at onset);
LUSC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg19230755	chr7:65878503	NA	-0.43	-5.96	-0.31	6.34e-9	Aortic root size;
LUSC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg06640241	chr16:89574553	SPG7	-0.86	-15.6	-0.65	1.33e-41	Multiple myeloma (IgH translocation);
LUSC	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.44	6.6	0.34	1.63e-10	Axial length;
LUSC	trans	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg00845942	chr12:64062724	DPY19L2	-0.62	-7.97	-0.4	2.45e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs2637266	0.655	rs846584	chr10:78495419	G/A	cg18941641	chr10:78392320	NA	0.38	6.91	0.35	2.49e-11	Pulmonary function;
LUSC	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg17507749	chr15:85114479	UBE2QP1	0.56	7.18	0.37	4.53e-12	Schizophrenia;
LUSC	cis	rs17604090	0.938	rs68158127	chr7:29684698	A/G	cg19413766	chr7:29689036	LOC646762	-0.57	-6.66	-0.34	1.1e-10	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs713477	0.967	rs4901568	chr14:55912789	T/A	cg13175173	chr14:55914753	NA	-0.32	-6.79	-0.35	5.12e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26314531	chr2:26401878	FAM59B	0.68	8.82	0.43	6.6e-17	Gut microbiome composition (summer);
LUSC	cis	rs9309473	0.500	rs10189578	chr2:73728609	C/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.25	-0.37	2.91e-12	Metabolite levels;
LUSC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg20135002	chr11:47629003	NA	0.51	7.99	0.4	2.26e-14	Subjective well-being;
LUSC	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg20701182	chr2:24300061	SF3B14	0.84	10.43	0.5	3.11e-22	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.23	0.52	4.8e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg00898013	chr13:113819073	PROZ	-0.6	-8.55	-0.42	4.63e-16	Platelet distribution width;
LUSC	cis	rs9443645	0.588	rs1415310	chr6:79822314	C/T	cg05283184	chr6:79620031	NA	-0.46	-8.69	-0.43	1.6e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg03684893	chr10:554711	DIP2C	0.36	6.5	0.34	2.96e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg25039879	chr17:56429692	SUPT4H1	0.66	8.86	0.44	4.86e-17	Cognitive test performance;
LUSC	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg06627628	chr2:24431161	ITSN2	-0.58	-7.15	-0.36	5.66e-12	Lymphocyte counts;
LUSC	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-7.9	-0.4	4.17e-14	Glomerular filtration rate (creatinine);
LUSC	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.5	6.83	0.35	3.91e-11	Corneal astigmatism;
LUSC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg07741184	chr6:167504864	NA	0.39	6.88	0.35	2.9e-11	Primary biliary cholangitis;
LUSC	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21385522	chr1:16154831	NA	0.56	8.89	0.44	3.78e-17	Systolic blood pressure;
LUSC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg02187348	chr16:89574699	SPG7	0.49	7.55	0.38	4.1e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.75	13.4	0.59	4.65e-33	Aortic root size;
LUSC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.86	-11.29	-0.53	2.9e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs8063160	0.740	rs71396950	chr16:89726550	G/A	cg07984980	chr16:89898383	SPIRE2	0.87	6.78	0.35	5.44e-11	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LUSC	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.89	-0.4	4.34e-14	Glomerular filtration rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20703375	chr7:98957328	ARPC1A	0.44	6.23	0.32	1.4e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg18230493	chr5:56204884	C5orf35	-0.93	-13.74	-0.6	2.25e-34	Initial pursuit acceleration;
LUSC	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	7.46	0.38	7.51e-13	Colorectal cancer;
LUSC	cis	rs6977660	1.000	rs10279601	chr7:19822171	G/A	cg07541023	chr7:19748670	TWISTNB	0.51	5.73	0.3	2.3e-8	Thyroid stimulating hormone;
LUSC	cis	rs2276314	0.857	rs28540805	chr18:33641975	T/G	cg19628046	chr18:33552617	C18orf21	0.5	6.05	0.31	3.79e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg15556689	chr8:8085844	FLJ10661	0.54	8.33	0.41	2.19e-15	Systolic blood pressure;
LUSC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-8.53	-0.42	5.26e-16	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg11062466	chr8:58055876	NA	0.5	6.43	0.33	4.37e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg05110241	chr16:68378359	PRMT7	-0.57	-6.55	-0.34	2.11e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg25214090	chr10:38739885	LOC399744	0.44	6.63	0.34	1.38e-10	Corneal astigmatism;
LUSC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg27398817	chr8:82754497	SNX16	-0.51	-6.79	-0.35	5.01e-11	Diastolic blood pressure;
LUSC	trans	rs890100	0.768	rs13410457	chr2:56695046	A/G	cg01657744	chr10:88471748	LDB3	0.44	6.05	0.31	3.99e-9	Gut microbiome composition (summer);
LUSC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg17330251	chr7:94953956	PON1	-0.37	-5.99	-0.31	5.43e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.29	-5.83	-0.3	1.3e-8	Cognitive function;
LUSC	cis	rs4363385	0.530	rs58298199	chr1:152908814	A/C	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.28	-0.32	1.08e-9	Inflammatory skin disease;
LUSC	cis	rs10754283	0.871	rs72712569	chr1:90125657	G/C	cg21401794	chr1:90099060	LRRC8C	-0.55	-7.58	-0.38	3.43e-13	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs10992471	0.605	rs7872375	chr9:95064843	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.46	-0.33	3.63e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg09877947	chr5:131593287	PDLIM4	-0.46	-7.06	-0.36	9.71e-12	Breast cancer;
LUSC	trans	rs417096	0.895	rs57021432	chr6:39734042	T/C	cg17457912	chr17:1617102	C17orf91	-0.33	-6.38	-0.33	5.84e-10	Hypospadias;
LUSC	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.44	0.5	2.79e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.2	16.31	0.67	2.22e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs983392	0.805	rs7926354	chr11:59962189	G/A	cg24026212	chr11:59952134	MS4A6A	-0.38	-6.58	-0.34	1.86e-10	Alzheimer's disease (late onset);
LUSC	trans	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg27411982	chr8:10470053	RP1L1	-0.41	-6.21	-0.32	1.62e-9	Monocyte count;
LUSC	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg26618903	chr10:100175079	PYROXD2	-0.46	-8.6	-0.43	3.19e-16	Metabolite levels;
LUSC	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg21605333	chr4:119757512	SEC24D	1.27	10.11	0.48	3.98e-21	Cannabis dependence symptom count;
LUSC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg17724175	chr1:150552817	MCL1	0.37	6.53	0.34	2.49e-10	Tonsillectomy;
LUSC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg16624210	chr5:671434	TPPP	0.49	6.16	0.32	2.14e-9	Obesity-related traits;
LUSC	cis	rs497273	0.530	rs2701185	chr12:121352974	A/G	cg02403541	chr12:121454288	C12orf43	0.41	5.84	0.3	1.26e-8	Systemic lupus erythematosus;
LUSC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg13319975	chr6:146136371	FBXO30	-0.71	-11.44	-0.53	8.48e-26	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11997175	0.574	rs12156280	chr8:33650277	C/T	ch.8.33884649F	chr8:33765107	NA	0.52	8.46	0.42	8.64e-16	Body mass index;
LUSC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg18225595	chr11:63971243	STIP1	-0.43	-7.07	-0.36	9.2e-12	Platelet count;
LUSC	cis	rs11785693	0.865	rs11784227	chr8:4970485	A/C	cg26367366	chr8:4980734	NA	0.84	9.14	0.45	6.24e-18	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg10360139	chr7:1886902	MAD1L1	-0.39	-6.06	-0.31	3.65e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6901004	0.596	rs411604	chr6:111565847	A/G	cg15721981	chr6:111408429	SLC16A10	-0.55	-7.88	-0.4	4.61e-14	Blood metabolite levels;
LUSC	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	7.04	0.36	1.1e-11	Neuroticism;
LUSC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg02782426	chr3:40428986	ENTPD3	0.33	6.28	0.32	1.05e-9	Renal cell carcinoma;
LUSC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg22823121	chr1:150693482	HORMAD1	0.62	9.47	0.46	5.19e-19	Tonsillectomy;
LUSC	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.72	-12.12	-0.55	2.91e-28	Retinal vascular caliber;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg13472656	chr22:25960710	ADRBK2	-0.48	-5.96	-0.31	6.29e-9	Height;
LUSC	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg25922239	chr6:33757077	LEMD2	0.53	7.87	0.4	4.93e-14	Crohn's disease;
LUSC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-9.15	-0.45	5.98e-18	Gut microbiome composition (summer);
LUSC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.33	-0.33	7.76e-10	Personality dimensions;
LUSC	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.5	6.15	0.32	2.15e-9	Crohn's disease;
LUSC	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.38	-5.92	-0.31	8.15e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11971779	0.941	rs7802779	chr7:139122579	G/T	cg07862535	chr7:139043722	LUC7L2	0.73	8.73	0.43	1.24e-16	Diisocyanate-induced asthma;
LUSC	cis	rs1577917	0.958	rs36035797	chr6:86562880	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg11802864	chr11:65308245	LTBP3	0.84	5.81	0.3	1.42e-8	Height;
LUSC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Schizophrenia;
LUSC	cis	rs981844	0.712	rs3925717	chr4:154750917	C/G	cg14289246	chr4:154710475	SFRP2	-0.46	-6.3	-0.33	9.19e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg13010199	chr12:38710504	ALG10B	0.48	7.49	0.38	6.31e-13	Morning vs. evening chronotype;
LUSC	cis	rs2742417	1.000	rs2742386	chr3:45756310	A/C	cg09608765	chr3:45636137	LIMD1	-0.39	-7.81	-0.39	7.4e-14	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	13.47	0.59	2.39e-33	Platelet count;
LUSC	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.21	-0.32	1.56e-9	Alcohol dependence;
LUSC	cis	rs62400317	0.859	rs12193030	chr6:45175210	G/A	cg18551225	chr6:44695536	NA	-0.45	-7.38	-0.37	1.27e-12	Total body bone mineral density;
LUSC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-1.01	-17.91	-0.7	9.77e-51	Height;
LUSC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.54	-0.46	3.12e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs17828380	0.920	rs71393133	chr15:63459591	C/T	cg05507819	chr15:63340323	TPM1	-0.75	-6.16	-0.32	2.1e-9	Social communication problems;
LUSC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg24642844	chr7:1081250	C7orf50	-0.71	-9.88	-0.48	2.22e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg05082376	chr22:42548792	NA	-0.43	-6.48	-0.33	3.36e-10	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	0.58	9.25	0.45	2.75e-18	Breast cancer;
LUSC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg03806693	chr22:41940476	POLR3H	-0.79	-11.59	-0.54	2.37e-26	Vitiligo;
LUSC	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	6.01	0.31	4.91e-9	Rheumatoid arthritis;
LUSC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg22834771	chr12:69754056	YEATS4	-0.43	-5.66	-0.3	3.25e-8	Response to diuretic therapy;
LUSC	cis	rs4604732	0.588	rs4356092	chr1:247632668	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.41	6.46	0.33	3.71e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	trans	rs4794665	0.874	rs1467246	chr17:54845117	C/T	cg18503679	chr3:21792543	ZNF385D	0.36	5.96	0.31	6.48e-9	Height;
LUSC	cis	rs11039100	1.000	rs4474469	chr11:5828849	T/C	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs12043259	0.502	rs6593907	chr1:204746302	A/G	cg06849515	chr4:13549607	LOC285548	0.54	5.95	0.31	6.81e-9	Addiction;
LUSC	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg08917208	chr2:24149416	ATAD2B	0.87	9.69	0.47	9.99e-20	Lymphocyte counts;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06494227	chr22:30752758	CCDC157;SF3A1	-0.51	-6.47	-0.33	3.54e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg15704280	chr7:45808275	SEPT13	0.68	6.43	0.33	4.36e-10	Intraocular pressure;
LUSC	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07169764	chr2:136633963	MCM6	0.76	10.14	0.49	2.94e-21	Mosquito bite size;
LUSC	cis	rs713477	0.817	rs55868790	chr14:55913275	T/C	cg13175173	chr14:55914753	NA	-0.3	-6.21	-0.32	1.57e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg07810366	chr2:100720526	AFF3	-0.51	-8.86	-0.44	4.76e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.85	-0.3	1.17e-8	Bipolar disorder;
LUSC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.3	-0.37	2.14e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs1113500	0.933	rs11185256	chr1:108633957	C/T	cg11967332	chr1:108735228	SLC25A24	0.39	5.92	0.31	7.86e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06634786	chr22:41940651	POLR3H	0.49	5.75	0.3	2.01e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.73	-12.92	-0.58	2.91e-31	Prudent dietary pattern;
LUSC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24838063	chr12:130822603	PIWIL1	0.69	10.79	0.51	1.69e-23	Menopause (age at onset);
LUSC	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg11789530	chr4:8429930	ACOX3	0.55	8.82	0.43	6.42e-17	Response to antineoplastic agents;
LUSC	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg10560079	chr2:191398806	TMEM194B	-0.76	-9.52	-0.46	3.75e-19	Diastolic blood pressure;
LUSC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.1	-0.32	2.85e-9	Initial pursuit acceleration;
LUSC	cis	rs2425143	0.558	rs7274724	chr20:34539466	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.68	-0.3	2.89e-8	Blood protein levels;
LUSC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg01171360	chr6:293285	DUSP22	-0.51	-7.68	-0.39	1.74e-13	Menopause (age at onset);
LUSC	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg19539972	chr4:7069911	GRPEL1	0.73	9.0	0.44	1.72e-17	Monocyte percentage of white cells;
LUSC	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	12.54	0.57	7.8e-30	Blood protein levels;
LUSC	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg17173187	chr15:85201210	NMB	-0.28	-5.73	-0.3	2.2e-8	P wave terminal force;
LUSC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	trans	rs2144940	0.920	rs2567617	chr20:23049547	G/A	cg01465325	chr10:50747588	ERCC6	0.79	6.06	0.31	3.78e-9	Venous thromboembolism;
LUSC	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg11019008	chr10:131425282	MGMT	0.4	6.2	0.32	1.68e-9	Response to temozolomide;
LUSC	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg03929089	chr4:120376271	NA	0.61	6.6	0.34	1.65e-10	Axial length;
LUSC	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.55	9.8	0.47	4.25e-20	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUSC	cis	rs2540226	0.935	rs3732121	chr2:39988804	C/T	cg23576258	chr2:39999331	THUMPD2	0.35	5.85	0.3	1.19e-8	Personality dimensions;
LUSC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.58	0.34	1.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg21252483	chr19:49399788	TULP2	-0.48	-6.77	-0.35	5.81e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg23711669	chr6:146136114	FBXO30	-0.83	-15.28	-0.64	2.37e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.53	6.99	0.36	1.54e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.74	12.24	0.56	1e-28	Coronary artery disease;
LUSC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg22903657	chr4:1355424	KIAA1530	-0.39	-6.55	-0.34	2.13e-10	Longevity;
LUSC	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg23173402	chr1:227635558	NA	0.71	7.32	0.37	1.85e-12	Major depressive disorder;
LUSC	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg13390004	chr1:15929781	NA	0.41	6.75	0.35	6.57e-11	Systolic blood pressure;
LUSC	cis	rs8027181	1.000	rs2162269	chr15:73090262	C/T	cg25632853	chr15:73088954	NA	0.34	6.61	0.34	1.55e-10	Triglyceride levels;
LUSC	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-6.87	-0.35	3.2e-11	Colorectal cancer;
LUSC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7589342	0.536	rs17201484	chr2:106394809	C/G	cg09152813	chr2:106391379	NCK2	-0.39	-6.26	-0.32	1.16e-9	Addiction;
LUSC	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg16346588	chr10:242978	ZMYND11	-0.45	-6.14	-0.32	2.31e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05890377	chr2:74357713	NA	0.72	13.68	0.6	3.83e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.05e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg22709100	chr7:91322751	NA	-0.39	-5.72	-0.3	2.42e-8	Breast cancer;
LUSC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	0.97	13.55	0.6	1.23e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg22709100	chr7:91322751	NA	-0.4	-5.78	-0.3	1.67e-8	Breast cancer;
LUSC	trans	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.35	-0.33	7.23e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg04450456	chr4:17643702	FAM184B	0.37	6.34	0.33	7.37e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg11752832	chr7:134001865	SLC35B4	0.54	8.12	0.41	9.29e-15	Mean platelet volume;
LUSC	cis	rs56283067	0.578	rs10948233	chr6:45364096	A/T	cg18551225	chr6:44695536	NA	0.43	6.56	0.34	2.05e-10	Total body bone mineral density;
LUSC	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs4409675	0.576	rs6598912	chr1:28233289	C/T	cg23691781	chr1:28212827	C1orf38	0.3	7.34	0.37	1.67e-12	Corneal astigmatism;
LUSC	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg08557956	chr11:4115526	RRM1	-0.42	-5.7	-0.3	2.62e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.7	-9.79	-0.47	4.49e-20	Gut microbiome composition (summer);
LUSC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg13319975	chr6:146136371	FBXO30	0.53	7.84	0.39	6.04e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg16405210	chr4:1374714	KIAA1530	0.58	8.82	0.43	6.51e-17	Obesity-related traits;
LUSC	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg06064525	chr11:970664	AP2A2	0.35	6.99	0.36	1.46e-11	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg20307385	chr11:47447363	PSMC3	0.64	9.37	0.46	1.13e-18	Mean corpuscular hemoglobin;
LUSC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.62	8.06	0.4	1.4e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg23791538	chr6:167370224	RNASET2	0.5	8.4	0.42	1.34e-15	Crohn's disease;
LUSC	cis	rs2235649	0.746	rs35104579	chr16:1848657	A/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.46	-6.12	-0.32	2.65e-9	Blood metabolite levels;
LUSC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.56	-0.34	2.06e-10	Schizophrenia;
LUSC	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17467752	chr17:38218738	THRA	0.77	12.47	0.56	1.47e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-6.42	-0.33	4.67e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg25456477	chr12:86230367	RASSF9	0.43	7.73	0.39	1.25e-13	Major depressive disorder;
LUSC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg06238570	chr21:40685208	BRWD1	-0.58	-9.13	-0.45	6.88e-18	Menarche (age at onset);
LUSC	cis	rs16976116	0.901	rs3759861	chr15:55473192	C/T	cg11288833	chr15:55489084	RSL24D1	0.48	5.77	0.3	1.77e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg21211680	chr2:198530	NA	0.7	7.27	0.37	2.54e-12	Blood protein levels;
LUSC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	1.01	18.96	0.72	6.39e-55	Cognitive function;
LUSC	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12776158	0.901	rs57028689	chr10:71216345	G/A	cg12610070	chr10:71211762	TSPAN15	-0.46	-6.05	-0.31	3.9e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.62	-7.79	-0.39	8.39e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs1506636	1.000	rs2429617	chr7:123418027	A/G	cg03229431	chr7:123269106	ASB15	0.65	10.68	0.5	4.29e-23	Plateletcrit;Platelet count;
LUSC	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-1.04	-16.36	-0.67	1.35e-44	Exhaled nitric oxide output;
LUSC	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	8.26	0.41	3.48e-15	Myopia (pathological);
LUSC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	0.99	13.72	0.6	2.7200000000000002e-34	Vitiligo;
LUSC	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg09835421	chr16:68378352	PRMT7	-0.75	-7.87	-0.4	5.06e-14	Schizophrenia;
LUSC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg11812906	chr14:75593930	NEK9	-0.63	-10.43	-0.5	3.18e-22	Height;
LUSC	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg02807482	chr3:125708958	NA	-0.49	-5.73	-0.3	2.21e-8	Blood pressure (smoking interaction);
LUSC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	7.95	0.4	2.88e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-7.02	-0.36	1.28e-11	Fear of minor pain;
LUSC	cis	rs12618769	0.652	rs1139829	chr2:99225168	C/T	cg10123293	chr2:99228465	UNC50	0.47	7.7	0.39	1.59e-13	Bipolar disorder;
LUSC	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg00012203	chr2:219082015	ARPC2	-0.77	-13.72	-0.6	2.88e-34	Colorectal cancer;
LUSC	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21545522	chr1:205238299	TMCC2	0.51	9.46	0.46	5.7e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs11597390	0.867	rs11596837	chr10:101850079	C/A	cg02250046	chr10:101825185	CPN1	-0.34	-6.06	-0.31	3.7e-9	Liver enzyme levels;
LUSC	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg16342193	chr10:102329863	NA	-0.34	-6.12	-0.32	2.68e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg17757837	chr7:157058334	UBE3C	-0.93	-15.88	-0.66	1.09e-42	Body mass index;
LUSC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg20283391	chr11:68216788	NA	-0.59	-8.34	-0.41	2.03e-15	Total body bone mineral density;
LUSC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-0.8	-13.29	-0.59	1.19e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1044826	0.642	rs4683464	chr3:139196961	C/T	cg15131784	chr3:139108705	COPB2	0.37	5.78	0.3	1.69e-8	Obesity-related traits;
LUSC	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg20701182	chr2:24300061	SF3B14	0.55	5.85	0.3	1.2e-8	Lymphocyte counts;
LUSC	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg25838465	chr1:92012736	NA	-0.52	-7.68	-0.39	1.81e-13	Eosinophil percentage of white cells;
LUSC	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.32	0.45	1.64e-18	Coffee consumption (cups per day);
LUSC	trans	rs800082	0.698	rs800073	chr3:144347599	G/A	cg24215973	chr2:240111563	HDAC4	-0.7	-10.34	-0.49	6.26e-22	Smoking behavior;
LUSC	cis	rs4478137	0.931	rs56233753	chr4:164249023	A/G	cg06758707	chr4:164254230	NPY1R	0.62	9.8	0.47	4.19e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg18230493	chr5:56204884	C5orf35	-0.86	-12.9	-0.58	3.52e-31	Initial pursuit acceleration;
LUSC	cis	rs240764	0.782	rs239231	chr6:101105022	G/A	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.69e-9	Neuroticism;
LUSC	cis	rs7598759	0.679	rs6437019	chr2:232327707	T/C	cg19187155	chr2:232395269	NMUR1	0.49	7.16	0.36	5.13e-12	Noise-induced hearing loss;
LUSC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg04166393	chr7:2884313	GNA12	0.42	5.91	0.31	8.66e-9	Height;
LUSC	cis	rs6977660	0.714	rs6970798	chr7:19816741	G/C	cg05791153	chr7:19748676	TWISTNB	0.68	7.22	0.37	3.49e-12	Thyroid stimulating hormone;
LUSC	cis	rs3772130	0.583	rs9819530	chr3:121387784	T/G	cg20356878	chr3:121714668	ILDR1	0.55	8.86	0.44	4.95e-17	Cognitive performance;
LUSC	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-8.52	-0.42	5.68e-16	Axial length;
LUSC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg24578937	chr1:2090814	PRKCZ	-0.41	-9.04	-0.44	1.32e-17	Height;
LUSC	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.77	11.37	0.53	1.54e-25	Corneal astigmatism;
LUSC	cis	rs41271951	0.512	rs41266632	chr1:151042980	C/T	cg11822372	chr1:151115635	SEMA6C	-0.78	-7.18	-0.37	4.51e-12	Blood protein levels;
LUSC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.3	6.55	0.34	2.18e-10	Electroencephalogram traits;
LUSC	cis	rs7580658	0.724	rs12623948	chr2:128001342	G/A	cg09760422	chr2:128146352	NA	-0.31	-6.88	-0.35	2.88e-11	Protein C levels;
LUSC	cis	rs10140922	0.966	rs10135277	chr14:35823231	A/G	cg07166546	chr14:35805898	NA	0.26	6.34	0.33	7.3e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.36	-0.33	6.65e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg08270630	chr22:50330655	NA	-0.44	-6.61	-0.34	1.48e-10	Schizophrenia;
LUSC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg15921436	chr17:44337874	NA	-0.71	-10.88	-0.51	8.17e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9517320	1.000	rs9517320	chr13:99126303	G/T	cg07423050	chr13:99094983	FARP1	-0.36	-7.0	-0.36	1.43e-11	Longevity;
LUSC	cis	rs1775715	0.737	rs2808090	chr10:32143208	A/C	cg18675610	chr10:32216311	ARHGAP12	0.31	6.67	0.34	1.05e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4072705	0.646	rs4838187	chr9:127242076	G/C	cg13476313	chr9:127244764	NR5A1	0.34	6.53	0.34	2.43e-10	Menarche (age at onset);
LUSC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg22823121	chr1:150693482	HORMAD1	0.51	7.89	0.4	4.49e-14	Melanoma;
LUSC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	trans	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg27661571	chr11:113659931	NA	-0.63	-6.11	-0.32	2.73e-9	Height;
LUSC	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg14689365	chr7:158441557	NCAPG2	-0.46	-6.33	-0.33	8.02e-10	Height;
LUSC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	14.4	0.62	6.36e-37	Platelet count;
LUSC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.67	6.87	0.35	3.2e-11	Initial pursuit acceleration;
LUSC	cis	rs6785206	0.527	rs9844706	chr3:128380781	G/A	cg16766828	chr3:128327626	NA	-0.61	-7.23	-0.37	3.27e-12	Lymphocyte percentage of white cells;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06112727	chr8:22102711	POLR3D;MIR320A	0.49	6.81	0.35	4.44e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg10573190	chr2:85843190	USP39	-0.43	-6.13	-0.32	2.54e-9	Mean corpuscular volume;
LUSC	cis	rs1113500	0.862	rs2336128	chr1:108640739	G/T	cg11967332	chr1:108735228	SLC25A24	0.39	5.92	0.31	7.99e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg02018176	chr4:1364513	KIAA1530	0.5	8.54	0.42	4.76e-16	Obesity-related traits;
LUSC	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg21427119	chr20:30132790	HM13	-0.44	-6.3	-0.33	9.21e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg05738196	chr6:26577821	NA	-0.47	-6.68	-0.34	9.71e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.79	-13.02	-0.58	1.31e-31	Aortic root size;
LUSC	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg27432699	chr2:27873401	GPN1	-0.59	-8.82	-0.43	6.57e-17	Total body bone mineral density;
LUSC	cis	rs11650494	0.908	rs9891264	chr17:47407342	T/A	cg08112188	chr17:47440006	ZNF652	1.15	10.51	0.5	1.61e-22	Prostate cancer;
LUSC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg21856205	chr7:94953877	PON1	-0.35	-5.71	-0.3	2.51e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.16	-0.36	5.08e-12	Coronary artery disease;
LUSC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.94	-19.27	-0.73	3.78e-56	Post bronchodilator FEV1;
LUSC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg13535736	chr9:111863775	C9orf5	-0.42	-6.84	-0.35	3.78e-11	Menarche (age at onset);
LUSC	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg27661571	chr11:113659931	NA	-0.55	-6.51	-0.34	2.7e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg05234568	chr11:5960015	NA	-0.65	-9.02	-0.44	1.53e-17	DNA methylation (variation);
LUSC	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.65	-11.31	-0.53	2.44e-25	Monocyte count;
LUSC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg17507749	chr15:85114479	UBE2QP1	0.69	8.7	0.43	1.56e-16	Schizophrenia;
LUSC	cis	rs11785693	0.862	rs62491191	chr8:4993460	G/A	cg26367366	chr8:4980734	NA	0.77	9.11	0.45	7.7e-18	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg16339924	chr4:17578868	LAP3	0.62	9.71	0.47	8.61e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2652822	0.935	rs7162825	chr15:63439186	A/G	cg02713581	chr15:63449717	RPS27L	-0.39	-5.88	-0.31	9.83e-9	Metabolic traits;
LUSC	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg09754948	chr16:28834200	ATXN2L	0.44	6.46	0.33	3.73e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-7.1	-0.36	7.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2236918	0.710	rs1776159	chr1:242018583	C/G	cg17736920	chr1:242011382	EXO1	0.43	6.81	0.35	4.47e-11	Menopause (age at onset);
LUSC	cis	rs41271473	1.000	rs11578216	chr1:228880098	A/T	cg16512390	chr1:228756714	NA	-0.48	-5.84	-0.3	1.21e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs11696845	0.787	rs13043441	chr20:43364308	A/G	cg25301532	chr20:43378953	KCNK15	0.34	6.2	0.32	1.66e-9	Obesity-related traits;
LUSC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg24101359	chr6:42928495	GNMT	0.39	6.41	0.33	5.09e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3820928	0.967	rs4675114	chr2:227768362	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.66	-0.39	2.06e-13	Pulmonary function;
LUSC	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.42	0.64	6.71e-41	Bladder cancer;
LUSC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	14.32	0.62	1.4e-36	Platelet count;
LUSC	cis	rs6961069	0.585	rs10216184	chr7:80262830	A/G	cg04458919	chr7:80252533	CD36	-0.41	-7.16	-0.36	5.11e-12	Platelet count;
LUSC	cis	rs675828	1.000	rs675828	chr13:103350733	A/G	cg19359983	chr13:103346900	C13orf39	0.34	5.82	0.3	1.36e-8	Borderline personality disorder;
LUSC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg11663144	chr21:46675770	NA	0.41	7.21	0.37	3.68e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs477692	1.000	rs522891	chr10:131430916	T/C	cg05714579	chr10:131428358	MGMT	-0.51	-7.47	-0.38	7.2e-13	Response to temozolomide;
LUSC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg20476274	chr7:133979776	SLC35B4	-0.81	-14.39	-0.62	7.29e-37	Mean platelet volume;
LUSC	cis	rs7818345	0.637	rs4599829	chr8:19358434	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.31	5.86	0.31	1.12e-8	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg14298792	chr15:30685198	CHRFAM7A	0.48	5.99	0.31	5.47e-9	Huntington's disease progression;
LUSC	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg09173681	chr1:183549694	NCF2	0.66	12.21	0.56	1.38e-28	Systemic lupus erythematosus;
LUSC	cis	rs1044826	0.692	rs188420	chr3:139233865	G/A	cg00490450	chr3:139108681	COPB2	-0.46	-7.05	-0.36	1.06e-11	Obesity-related traits;
LUSC	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg08917208	chr2:24149416	ATAD2B	0.98	10.23	0.49	1.51e-21	Lymphocyte counts;
LUSC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg22903471	chr2:27725779	GCKR	-0.41	-7.09	-0.36	8.05e-12	Total body bone mineral density;
LUSC	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg22482690	chr17:47019901	SNF8	0.39	7.38	0.37	1.3e-12	Type 2 diabetes;
LUSC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.92	-0.31	8e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs56283067	0.578	rs1321078	chr6:45368214	G/T	cg20913747	chr6:44695427	NA	-0.46	-6.69	-0.34	9.19e-11	Total body bone mineral density;
LUSC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg14552801	chr7:65878734	NA	0.38	5.9	0.31	9e-9	Aortic root size;
LUSC	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg21433313	chr16:3507492	NAT15	-0.39	-6.15	-0.32	2.22e-9	Body mass index (adult);
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg06877462	chr1:205807181	PM20D1	0.5	8.99	0.44	1.94e-17	Menarche (age at onset);
LUSC	cis	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg23950597	chr19:37808831	NA	-0.61	-7.32	-0.37	1.84e-12	Coronary artery calcification;
LUSC	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg23649088	chr2:200775458	C2orf69	-0.51	-6.94	-0.36	2.01e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg15711740	chr2:61764176	XPO1	-0.5	-7.99	-0.4	2.19e-14	Tuberculosis;
LUSC	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21385522	chr1:16154831	NA	0.7	10.64	0.5	6.02e-23	Dilated cardiomyopathy;
LUSC	cis	rs17655565	0.533	rs12825729	chr12:52706854	G/A	cg08257133	chr12:52711352	KRT83	0.41	9.03	0.44	1.44e-17	Plasma amyloid beta peptide concentrations (ABx-42);
LUSC	cis	rs7760949	0.852	rs9475801	chr6:13933115	G/A	cg27413430	chr6:13925136	RNF182	0.61	8.94	0.44	2.64e-17	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg03929089	chr4:120376271	NA	-0.49	-6.83	-0.35	4.06e-11	HDL cholesterol;
LUSC	cis	rs9653442	0.527	rs10185059	chr2:100790172	C/T	cg07810366	chr2:100720526	AFF3	-0.44	-7.5	-0.38	5.75e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.67	10.8	0.51	1.61e-23	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs68170813	0.617	rs117884147	chr7:107177593	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.45	-5.65	-0.3	3.52e-8	Coronary artery disease;
LUSC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg12310025	chr6:25882481	NA	-0.35	-5.68	-0.3	2.93e-8	Height;
LUSC	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.44	0.5	2.81e-22	Schizophrenia;
LUSC	cis	rs17433780	1.000	rs17433780	chr1:89474818	C/T	cg09516651	chr1:89888402	LOC400759	-0.48	-8.3	-0.41	2.6e-15	Carotid intima media thickness;
LUSC	cis	rs57920188	0.568	rs10915665	chr1:4093717	G/T	cg20703997	chr1:4087676	NA	0.59	8.24	0.41	3.85e-15	Interleukin-17 levels;
LUSC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.37	0.56	3.34e-29	Prudent dietary pattern;
LUSC	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg01689657	chr7:91764605	CYP51A1	-0.33	-6.06	-0.31	3.68e-9	Breast cancer;
LUSC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14829155	chr15:31115871	NA	-0.56	-7.81	-0.39	7.44e-14	Huntington's disease progression;
LUSC	cis	rs2625529	0.652	rs2929517	chr15:72332917	T/G	cg16672083	chr15:72433130	SENP8	0.49	7.93	0.4	3.34e-14	Red blood cell count;
LUSC	cis	rs13082711	0.834	rs2840088	chr3:27428371	G/A	cg02860705	chr3:27208620	NA	0.5	8.64	0.43	2.34e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.66	-0.43	2.06e-16	Bipolar disorder;
LUSC	cis	rs17604090	0.938	rs10253264	chr7:29692543	T/C	cg19413766	chr7:29689036	LOC646762	-0.62	-7.46	-0.38	7.31e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs1595825	0.891	rs10497810	chr2:198895732	C/T	cg10547527	chr2:198650123	BOLL	-0.52	-6.25	-0.32	1.23e-9	Ulcerative colitis;
LUSC	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg19773385	chr1:10388646	KIF1B	-0.58	-10.23	-0.49	1.56e-21	Hepatocellular carcinoma;
LUSC	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.93	15.97	0.66	4.9e-43	Morning vs. evening chronotype;
LUSC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg20243544	chr17:37824526	PNMT	0.39	5.88	0.31	9.84e-9	Self-reported allergy;
LUSC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.98	0.31	5.68e-9	Menopause (age at onset);
LUSC	cis	rs155346	1.000	rs645898	chr5:139404852	C/T	cg01090482	chr5:139365336	NRG2	-0.35	-5.71	-0.3	2.51e-8	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.84	14.54	0.62	1.97e-37	Menarche (age at onset);
LUSC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.86	0.44	4.97e-17	Motion sickness;
LUSC	cis	rs11657217	1.000	rs8081537	chr17:77708264	A/G	cg06901238	chr17:77706717	ENPP7	0.54	10.33	0.49	6.83e-22	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LUSC	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.73	14.19	0.61	4.47e-36	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg14895029	chr7:2775587	GNA12	-0.4	-6.42	-0.33	4.55e-10	Height;
LUSC	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs231513	0.906	rs179586	chr17:41999094	T/C	cg26893861	chr17:41843967	DUSP3	-0.59	-6.28	-0.33	1.02e-9	Cognitive function;
LUSC	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg18196295	chr10:418757	DIP2C	-0.44	-6.52	-0.34	2.61e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-7.62	-0.38	2.65e-13	Morning vs. evening chronotype;
LUSC	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.74	15.5	0.65	3.38e-41	Systemic lupus erythematosus;
LUSC	cis	rs10740039	0.883	rs1442546	chr10:62409998	G/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.85	-0.35	3.61e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1163251	0.902	rs487081	chr1:120217389	G/A	cg19096424	chr1:120255104	PHGDH	0.48	6.53	0.34	2.39e-10	Blood metabolite levels;
LUSC	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg17788362	chr6:86352627	SYNCRIP	0.46	6.93	0.35	2.12e-11	Smooth-surface caries;
LUSC	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	13.38	0.59	5.34e-33	Blood protein levels;
LUSC	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.81	15.24	0.64	3.52e-40	Ulcerative colitis;
LUSC	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg20573242	chr4:122745356	CCNA2	-0.45	-6.76	-0.35	6.17e-11	Type 2 diabetes;
LUSC	cis	rs57920188	0.640	rs4311852	chr1:4085353	C/A	cg20703997	chr1:4087676	NA	0.59	8.52	0.42	5.66e-16	Interleukin-17 levels;
LUSC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg02931644	chr1:25747376	RHCE	0.33	5.95	0.31	6.84e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.84	0.35	3.83e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg01251360	chr16:68772225	CDH1	-0.26	-6.09	-0.32	3.15e-9	Colorectal cancer;
LUSC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg05425664	chr17:57184151	TRIM37	0.54	8.04	0.4	1.53e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg18827107	chr12:86230957	RASSF9	0.45	6.87	0.35	3.17e-11	Major depressive disorder;
LUSC	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg15704280	chr7:45808275	SEPT13	-0.45	-5.98	-0.31	5.77e-9	HDL cholesterol;
LUSC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg05425664	chr17:57184151	TRIM37	-0.55	-8.2	-0.41	5.31e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1080500	1.000	rs1080500	chr3:53175017	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-6.42	-0.33	4.62e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg06521331	chr12:34319734	NA	-0.39	-5.95	-0.31	6.77e-9	Bladder cancer;
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.73	-0.39	1.31e-13	Lymphocyte counts;
LUSC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg05340658	chr4:99064831	C4orf37	0.58	9.37	0.46	1.14e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-8.99	-0.44	1.83e-17	Monocyte percentage of white cells;
LUSC	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	1.16	10.58	0.5	9.4e-23	Alzheimer's disease (late onset);
LUSC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.05	0.4	1.43e-14	Bipolar disorder;
LUSC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	6.82	0.35	4.29e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg05501817	chr11:14380813	RRAS2	-0.39	-6.28	-0.33	1.03e-9	Vitamin D levels;
LUSC	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.78	0.39	9.05e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.94	-13.05	-0.58	9.74e-32	Type 2 diabetes;
LUSC	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-11.39	-0.53	1.28e-25	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg22705602	chr4:152727874	NA	-0.34	-7.58	-0.38	3.36e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1624802	0.638	rs1696431	chr12:130498408	C/T	cg15444478	chr12:130494697	NA	0.25	5.75	0.3	1.97e-8	Obesity-related traits;
LUSC	cis	rs3761218	0.714	rs1968648	chr20:3763349	C/T	cg02737268	chr20:3780182	CDC25B	-0.33	-6.69	-0.34	9.25e-11	Bipolar disorder;
LUSC	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.89	12.16	0.55	2.05e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs11039100	0.765	rs1032648	chr11:5782756	A/G	cg13902645	chr11:5959945	NA	-0.55	-6.05	-0.31	3.83e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.68	-11.7	-0.54	9.55e-27	Lung cancer;
LUSC	cis	rs8179	1.000	rs42031	chr7:92237396	A/T	cg15732164	chr7:92237376	CDK6	-0.55	-7.41	-0.38	1.01e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs970548	0.730	rs61854093	chr10:45934881	C/A	cg15590007	chr10:45870220	ALOX5	0.5	5.7	0.3	2.62e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs7180079	0.620	rs686634	chr15:64854511	A/G	cg08069370	chr15:64387884	SNX1	0.51	5.74	0.3	2.13e-8	Monocyte count;
LUSC	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg16512390	chr1:228756714	NA	0.7	8.89	0.44	4.03e-17	Chronic lymphocytic leukemia;
LUSC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02034447	chr16:89574710	SPG7	0.42	6.14	0.32	2.34e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg04352962	chr1:209979756	IRF6	0.53	6.32	0.33	8.42e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs80130819	0.515	rs1793912	chr12:48387052	A/C	cg24011408	chr12:48396354	COL2A1	0.5	6.36	0.33	6.75e-10	Prostate cancer;
LUSC	cis	rs71403859	0.502	rs12708914	chr16:71470636	G/A	cg08717414	chr16:71523259	ZNF19	-0.65	-7.91	-0.4	3.69e-14	Post bronchodilator FEV1;
LUSC	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg23093090	chr10:104574429	C10orf26	-0.45	-8.43	-0.42	1.02e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg09491104	chr22:46646882	C22orf40	-0.67	-7.0	-0.36	1.42e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg07507251	chr3:52567010	NT5DC2	-0.3	-5.95	-0.31	6.77e-9	Bipolar disorder;
LUSC	cis	rs3740540	0.530	rs4297414	chr10:126292116	T/G	cg04949429	chr10:126290192	LHPP	0.36	7.7	0.39	1.58e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs11112613	0.609	rs7350593	chr12:106038119	C/T	cg03607813	chr12:105948248	NA	0.63	8.01	0.4	1.95e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs11018904	0.817	rs11601793	chr11:89946354	T/G	cg26138821	chr11:89956704	CHORDC1	-0.58	-6.66	-0.34	1.1e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2067615	0.524	rs7309351	chr12:107077432	C/T	cg15890332	chr12:107067104	RFX4	-0.35	-6.15	-0.32	2.22e-9	Heart rate;
LUSC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg13395646	chr4:1353034	KIAA1530	0.49	6.93	0.35	2.19e-11	Obesity-related traits;
LUSC	cis	rs600626	0.636	rs10899110	chr11:75452342	C/G	cg24262691	chr11:75473276	NA	0.5	6.77	0.35	5.8200000000000003e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg06092702	chr1:163392909	NA	-0.44	-7.33	-0.37	1.75e-12	Motion sickness;
LUSC	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg22532475	chr10:104410764	TRIM8	-0.31	-6.96	-0.36	1.81e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg03146154	chr1:46216737	IPP	-0.58	-8.36	-0.42	1.7e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg24558204	chr6:135376177	HBS1L	0.59	9.22	0.45	3.55e-18	Red blood cell count;
LUSC	cis	rs2857891	0.817	rs2239733	chr11:6976666	T/C	cg14883916	chr11:6947541	ZNF215	0.45	5.87	0.31	1.06e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs262150	0.659	rs73167293	chr7:158772638	C/T	cg19418458	chr7:158789849	NA	0.47	5.94	0.31	7.3e-9	Facial morphology (factor 20);
LUSC	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg13010199	chr12:38710504	ALG10B	0.67	10.38	0.49	4.53e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.33	0.53	2.21e-25	Menopause (age at onset);
LUSC	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg06092702	chr1:163392909	NA	-0.47	-7.84	-0.39	6.13e-14	Motion sickness;
LUSC	cis	rs10887741	0.966	rs7085195	chr10:89429897	T/C	cg24243914	chr10:89418206	PAPSS2	0.32	5.98	0.31	5.79e-9	Exercise (leisure time);
LUSC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.67	-0.39	1.84e-13	Schizophrenia;
LUSC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg08499158	chr17:42289980	UBTF	0.42	6.38	0.33	5.78e-10	Total body bone mineral density;
LUSC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg07701084	chr6:150067640	NUP43	0.58	9.03	0.44	1.36e-17	Lung cancer;
LUSC	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg08854313	chr1:11322531	MTOR	0.87	14.45	0.62	4.15e-37	Body mass index;
LUSC	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg10523860	chr14:103875565	MARK3	-0.4	-6.44	-0.33	4.18e-10	Body mass index;
LUSC	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg13072238	chr3:49761600	GMPPB	-0.63	-8.19	-0.41	5.63e-15	Menarche (age at onset);
LUSC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg06636001	chr8:8085503	FLJ10661	0.71	11.66	0.54	1.43e-26	Mood instability;
LUSC	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07226813	chr3:49044374	P4HTM;WDR6	0.46	6.72	0.35	7.75e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg08088566	chr11:430123	ANO9	0.65	7.24	0.37	3.08e-12	Body mass index;
LUSC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg07404485	chr7:94953653	PON1	-0.31	-5.98	-0.31	5.78e-9	Paraoxonase activity;
LUSC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.57	0.34	1.97e-10	Personality dimensions;
LUSC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18854424	chr1:2615690	NA	0.48	9.3	0.45	1.85e-18	Multiple sclerosis;
LUSC	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg15790184	chr11:494944	RNH1	0.42	6.21	0.32	1.61e-9	Systemic lupus erythematosus;
LUSC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00339695	chr16:24857497	SLC5A11	-0.61	-9.23	-0.45	3.25e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg08601574	chr20:25228251	PYGB	-0.42	-6.43	-0.33	4.39e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.74	-14.08	-0.61	1.14e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg00431813	chr7:1051703	C7orf50	-0.4	-6.24	-0.32	1.31e-9	Longevity;Endometriosis;
LUSC	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg08999081	chr20:33150536	PIGU	0.38	6.82	0.35	4.36e-11	Height;
LUSC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26314531	chr2:26401878	FAM59B	0.73	9.71	0.47	8.38e-20	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg13114125	chr14:105738426	BRF1	-0.92	-15.77	-0.65	2.85e-42	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg20503657	chr10:835505	NA	0.77	8.96	0.44	2.39e-17	Eosinophil percentage of granulocytes;
LUSC	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg08213375	chr14:104286397	PPP1R13B	0.44	7.61	0.38	2.78e-13	Reticulocyte count;
LUSC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	6.93	0.35	2.16e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs708547	0.647	rs1277308	chr4:57897864	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.5	7.45	0.38	7.8e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg02221750	chr19:17393354	ANKLE1	-0.92	-14.22	-0.61	3.42e-36	Systemic lupus erythematosus;
LUSC	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg21132104	chr15:45694354	SPATA5L1	0.4	5.94	0.31	7.32e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg25767906	chr1:53392781	SCP2	-0.48	-8.62	-0.43	2.76e-16	Monocyte count;
LUSC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12667521	chr19:29218732	NA	0.57	6.96	0.36	1.77e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg23630131	chr7:65973040	NA	0.2	5.73	0.3	2.29e-8	Aortic root size;
LUSC	cis	rs3820928	0.874	rs2229812	chr2:227896886	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.72	-0.39	1.4e-13	Pulmonary function;
LUSC	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg05738196	chr6:26577821	NA	-0.52	-5.76	-0.3	1.92e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg16587794	chr15:69706675	KIF23	0.78	6.28	0.32	1.07e-9	Cognitive performance;
LUSC	cis	rs10186029	0.676	rs1025820	chr2:213933778	T/G	cg08319019	chr2:214017104	IKZF2	0.61	8.99	0.44	1.9e-17	Systemic sclerosis;
LUSC	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.3	0.56	6.01e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs12618769	0.597	rs2278214	chr2:99135738	A/G	cg10123293	chr2:99228465	UNC50	-0.45	-7.42	-0.38	9.52e-13	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22924838	chr2:200715629	NA	0.42	6.33	0.33	7.77e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.37	-7.02	-0.36	1.22e-11	Coronary artery disease;
LUSC	cis	rs9463078	0.605	rs3799981	chr6:44882380	T/A	cg25276700	chr6:44698697	NA	0.29	5.95	0.31	6.88e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg21573476	chr21:45109991	RRP1B	-0.36	-5.93	-0.31	7.63e-9	Mean corpuscular volume;
LUSC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.99	-0.4	2.27e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	0.69	13.32	0.59	9.32e-33	Gestational age at birth (maternal effect);
LUSC	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	5.97	0.31	5.93e-9	Rheumatoid arthritis;
LUSC	cis	rs2274273	0.624	rs3783651	chr14:55850973	G/C	cg04306507	chr14:55594613	LGALS3	0.48	9.52	0.46	3.69e-19	Protein biomarker;
LUSC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg05861140	chr6:150128134	PCMT1	0.4	6.37	0.33	6.22e-10	Lung cancer;
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg24846343	chr22:24311635	DDTL	0.66	14.14	0.61	6.41e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.77	-0.35	5.87e-11	Response to antipsychotic treatment;
LUSC	cis	rs13315871	0.929	rs7628038	chr3:58313813	T/C	cg20936604	chr3:58311152	NA	-0.72	-6.95	-0.36	1.94e-11	Cholesterol, total;
LUSC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06505273	chr16:24850292	NA	-0.4	-5.75	-0.3	1.98e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg24851651	chr11:66362959	CCS	-0.52	-8.35	-0.42	1.87e-15	Bipolar disorder;
LUSC	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	13.38	0.59	5.28e-33	Blood protein levels;
LUSC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.92	11.6	0.54	2.24e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2731664	0.792	rs179809	chr5:176865329	T/G	cg23176889	chr5:176863531	GRK6	-0.68	-13.83	-0.6	1.02e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs28785552	0.796	rs8112908	chr19:53248041	C/T	cg10871876	chr19:53194124	ZNF83	0.57	8.76	0.43	9.76e-17	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72781680	0.566	rs72796106	chr2:23901362	A/C	cg20701182	chr2:24300061	SF3B14	0.72	7.88	0.4	4.55e-14	Lymphocyte counts;
LUSC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.33e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg13683864	chr3:40499215	RPL14	-0.94	-15.93	-0.66	6.81e-43	Renal cell carcinoma;
LUSC	cis	rs3784262	1.000	rs7170896	chr15:58252393	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.83	-0.3	1.3e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg00579200	chr11:133705235	NA	-0.41	-5.82	-0.3	1.38e-8	Childhood ear infection;
LUSC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg11752832	chr7:134001865	SLC35B4	0.61	9.65	0.47	1.35e-19	Mean platelet volume;
LUSC	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg22732515	chr19:44031385	ETHE1	0.63	10.27	0.49	1.1e-21	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs4631830	0.812	rs11593361	chr10:51539156	A/G	cg10326726	chr10:51549505	MSMB	-0.36	-6.07	-0.32	3.55e-9	Prostate-specific antigen levels;
LUSC	cis	rs354225	0.584	rs7586311	chr2:54810762	A/G	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	trans	rs11700980	0.551	rs2832040	chr21:30115840	C/T	cg14791747	chr16:20752902	THUMPD1	0.55	6.01	0.31	4.94e-9	QRS complex (12-leadsum);
LUSC	cis	rs9395066	0.527	rs55893720	chr6:44955716	G/T	cg25276700	chr6:44698697	NA	0.29	5.8	0.3	1.53e-8	Height;
LUSC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	9.28e-24	Bladder cancer;
LUSC	cis	rs34779708	0.868	rs2384352	chr10:35492832	A/G	cg03585969	chr10:35415529	CREM	0.63	9.19	0.45	4.4e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs17401966	0.522	rs2027330	chr1:10275592	C/T	cg19773385	chr1:10388646	KIF1B	-0.37	-6.46	-0.33	3.61e-10	Hepatocellular carcinoma;
LUSC	cis	rs1712517	0.771	rs11191672	chr10:105138961	C/T	cg05636881	chr10:105038444	INA	0.4	6.59	0.34	1.67e-10	Migraine;
LUSC	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg03690763	chr11:133734501	NA	-0.32	-5.68	-0.3	2.98e-8	Childhood ear infection;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22308382	chr13:28194838	POLR1D;LNX2	-0.42	-6.17	-0.32	1.99e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10189230	0.967	rs1367241	chr2:222353413	G/A	cg14652038	chr2:222343519	EPHA4	0.32	5.73	0.3	2.29e-8	Urate levels in lean individuals;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14783646	chr7:4800873	FOXK1	0.47	6.33	0.33	7.95e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg02269571	chr22:50332266	NA	0.56	8.27	0.41	3.33e-15	Schizophrenia;
LUSC	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg26384229	chr12:38710491	ALG10B	0.79	13.58	0.6	9.51e-34	Morning vs. evening chronotype;
LUSC	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg09699651	chr6:150184138	LRP11	0.45	7.17	0.37	4.98e-12	Testicular germ cell tumor;
LUSC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.84	-10.95	-0.51	4.73e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.25	14.23	0.61	3.05e-36	Diabetic kidney disease;
LUSC	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg21100191	chr22:23484243	RTDR1	0.91	15.35	0.64	1.27e-40	Bone mineral density;
LUSC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.97	0.44	2.22e-17	Motion sickness;
LUSC	trans	rs34421088	0.586	rs2272594	chr8:11142625	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	7.4	0.38	1.15e-12	Neuroticism;
LUSC	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg06917634	chr15:78832804	PSMA4	0.47	5.95	0.31	6.95e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg06138931	chr13:21896616	NA	0.4	6.74	0.35	6.78e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg23587288	chr2:27483067	SLC30A3	-0.29	-5.7	-0.3	2.61e-8	Blood metabolite levels;
LUSC	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg04362960	chr10:104952993	NT5C2	0.6	9.56	0.46	2.61e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg06877462	chr1:205807181	PM20D1	0.5	9.03	0.44	1.43e-17	Menarche (age at onset);
LUSC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.61	12.6	0.57	4.91e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.93	0.48	1.55e-20	Bipolar disorder;
LUSC	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.54	0.42	4.66e-16	Menopause (age at onset);
LUSC	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg01657329	chr11:68192670	LRP5	-0.4	-5.77	-0.3	1.85e-8	Total body bone mineral density;
LUSC	trans	rs7939886	0.841	rs1905053	chr11:56011848	C/T	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs243505	0.762	rs10225300	chr7:148502007	G/C	cg09806900	chr7:148480153	CUL1	0.58	8.53	0.42	5.2e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg26924012	chr15:45694286	SPATA5L1	1.13	20.71	0.75	7.34e-62	Homoarginine levels;
LUSC	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	0.9	13.19	0.59	2.88e-32	Triglycerides;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05061393	chr2:220043337	FAM134A	-0.39	-6.84	-0.35	3.8e-11	Electrocardiographic conduction measures;
LUSC	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg10247383	chr3:153839028	SGEF	-0.48	-5.85	-0.3	1.18e-8	Coronary artery disease;
LUSC	cis	rs2742417	0.603	rs2742372	chr3:45783472	T/C	cg10512202	chr3:45649293	LIMD1	0.36	6.09	0.32	3.17e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.49	-7.33	-0.37	1.8e-12	Immature fraction of reticulocytes;
LUSC	cis	rs7215564	0.730	rs76584516	chr17:78549237	A/G	cg23238734	chr17:78661607	RPTOR	0.53	6.24	0.32	1.35e-9	Myopia (pathological);
LUSC	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.63	-0.34	1.37e-10	Response to antipsychotic treatment;
LUSC	cis	rs5758511	0.573	rs139558	chr22:42189551	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-7.41	-0.38	1.03e-12	Birth weight;
LUSC	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.45	0.42	8.88e-16	Motion sickness;
LUSC	trans	rs1864729	1.000	rs1864729	chr8:98282189	G/A	cg08679828	chr8:102218111	ZNF706	-0.87	-7.9	-0.4	3.95e-14	Estradiol plasma levels (breast cancer);
LUSC	cis	rs10905065	0.759	rs1533215	chr10:5869767	T/C	cg25171089	chr10:5708825	ASB13	0.4	5.7	0.3	2.7e-8	Menopause (age at onset);
LUSC	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg24879335	chr3:133465180	TF	0.44	7.53	0.38	4.8e-13	Iron status biomarkers (transferrin levels);
LUSC	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.2e-15	Neuroticism;
LUSC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-6.7	-0.34	8.97e-11	Colorectal cancer;
LUSC	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg13263323	chr15:86062960	AKAP13	-0.35	-5.72	-0.3	2.38e-8	Coronary artery disease;
LUSC	cis	rs6840360	0.967	rs10049728	chr4:152672121	C/G	cg22705602	chr4:152727874	NA	-0.26	-5.7	-0.3	2.62e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs977987	0.806	rs35937717	chr16:75331567	C/A	cg03315344	chr16:75512273	CHST6	0.5	9.61	0.47	1.77e-19	Dupuytren's disease;
LUSC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs427941	0.632	rs201497	chr7:101755928	A/C	cg06246474	chr7:101738831	CUX1	0.39	6.32	0.33	8.14e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7215564	0.908	rs34135683	chr17:78652903	G/T	cg23238734	chr17:78661607	RPTOR	0.48	6.13	0.32	2.5e-9	Myopia (pathological);
LUSC	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg21251018	chr6:28226885	NKAPL	-0.31	-5.77	-0.3	1.82e-8	Pubertal anthropometrics;
LUSC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg00857998	chr1:205179979	DSTYK	0.67	10.68	0.5	4.31e-23	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg01448562	chr3:133502909	NA	0.49	7.61	0.38	2.75e-13	Alcohol consumption (transferrin glycosylation);
LUSC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg03929089	chr4:120376271	NA	-0.84	-11.51	-0.53	4.83e-26	Coronary artery disease;
LUSC	cis	rs7590368	0.715	rs72779453	chr2:10959475	G/C	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	cis	rs17030434	1.000	rs12651051	chr4:154722114	A/G	cg14289246	chr4:154710475	SFRP2	-0.51	-6.54	-0.34	2.35e-10	Electrocardiographic conduction measures;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04141459	chr3:183852329	EIF2B5	0.44	6.0	0.31	5e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.16	-0.41	6.92e-15	Lung cancer;
LUSC	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg26784012	chr10:32216390	ARHGAP12	0.44	7.32	0.37	1.9e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.17	-0.52	7.69e-25	Coffee consumption (cups per day);
LUSC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.65	-0.39	2.19e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg13010199	chr12:38710504	ALG10B	0.7	10.93	0.51	5.81e-24	Bladder cancer;
LUSC	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.5	-0.34	2.85e-10	Triglycerides;
LUSC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06221963	chr1:154839813	KCNN3	-0.6	-13.38	-0.59	5.65e-33	Prostate cancer;
LUSC	cis	rs3857536	0.813	rs7771569	chr6:66946717	C/T	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg06637938	chr14:75390232	RPS6KL1	0.65	10.87	0.51	9.27e-24	Caffeine consumption;
LUSC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg10169327	chr19:45448959	APOC2	0.31	6.66	0.34	1.15e-10	Blood protein levels;
LUSC	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg09307838	chr4:120376055	NA	0.64	9.62	0.47	1.69e-19	Corneal astigmatism;
LUSC	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg23711669	chr6:146136114	FBXO30	0.76	12.23	0.56	1.09e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.67	0.47	1.16e-19	Coffee consumption (cups per day);
LUSC	cis	rs713477	0.967	rs6573032	chr14:55913776	A/G	cg13175173	chr14:55914753	NA	-0.31	-6.49	-0.33	3.05e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg12463550	chr7:65579703	CRCP	-0.52	-7.63	-0.39	2.48e-13	Aortic root size;
LUSC	cis	rs2180341	0.594	rs7738385	chr6:127777516	T/C	cg27446573	chr6:127587934	RNF146	0.57	8.48	0.42	7.37e-16	Breast cancer;
LUSC	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	0.96	8.09	0.4	1.12e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg04733989	chr22:42467013	NAGA	0.4	6.46	0.33	3.69e-10	Cognitive function;
LUSC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.6	0.57	4.81e-30	Motion sickness;
LUSC	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg02018176	chr4:1364513	KIAA1530	0.43	6.15	0.32	2.24e-9	Recombination rate (females);
LUSC	cis	rs9837602	1.000	rs793496	chr3:99507254	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-5.73	-0.3	2.26e-8	Breast cancer;
LUSC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg24375607	chr4:120327624	NA	0.77	11.22	0.52	5.19e-25	Corneal astigmatism;
LUSC	cis	rs1113500	1.000	rs1113500	chr1:108595442	G/T	cg06207961	chr1:108661230	NA	-0.41	-7.55	-0.38	4.06e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs6484504	0.625	rs672396	chr11:31386165	A/G	cg06552810	chr11:31128660	NA	0.39	6.77	0.35	5.87e-11	Red blood cell count;
LUSC	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg03859395	chr2:55845619	SMEK2	0.86	15.55	0.65	2.13e-41	Metabolic syndrome;
LUSC	cis	rs17001868	0.568	rs9611311	chr22:40733951	T/C	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg08917208	chr2:24149416	ATAD2B	0.54	6.01	0.31	4.87e-9	Lymphocyte counts;
LUSC	cis	rs874628	0.686	rs11666906	chr19:18241898	A/G	cg00493341	chr19:18228948	MAST3	0.45	6.28	0.32	1.06e-9	Multiple sclerosis;
LUSC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg01802117	chr1:53393560	SCP2	-0.39	-6.38	-0.33	5.85e-10	Monocyte count;
LUSC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.95	-16.2	-0.66	5.7e-44	Coronary artery disease;
LUSC	trans	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg13565492	chr6:43139072	SRF	-0.57	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg13047869	chr3:10149882	C3orf24	0.63	9.07	0.44	1.02e-17	Alzheimer's disease;
LUSC	cis	rs12541635	0.966	rs62527363	chr8:107024258	A/G	cg10147462	chr8:107024639	NA	0.56	10.1	0.48	4.08e-21	Age of smoking initiation;
LUSC	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg13385521	chr17:29058706	SUZ12P	0.58	5.97	0.31	6.22e-9	Body mass index;
LUSC	cis	rs7804356	0.954	rs6948584	chr7:26855732	G/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.2	-0.32	1.66e-9	Type 1 diabetes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19670317	chr17:8093380	C17orf59	-0.46	-6.32	-0.33	8.13e-10	Hepatitis;
LUSC	cis	rs12824058	0.737	rs2398510	chr12:130816637	G/A	cg24838063	chr12:130822603	PIWIL1	0.69	10.6	0.5	7.8e-23	Menopause (age at onset);
LUSC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-10.21	-0.49	1.75e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg23262073	chr20:60523788	NA	-0.4	-5.93	-0.31	7.71e-9	Body mass index;
LUSC	cis	rs2742417	0.603	rs2742395	chr3:45758595	A/G	cg04837898	chr3:45731254	SACM1L	-0.46	-7.36	-0.37	1.42e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18876405	chr7:65276391	NA	0.54	8.47	0.42	8.18e-16	Aortic root size;
LUSC	cis	rs136211	0.662	rs9607338	chr22:36759026	C/T	cg10790723	chr22:36903033	FOXRED2	0.4	5.83	0.3	1.29e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg24733560	chr20:60626293	TAF4	0.45	8.15	0.41	7.2e-15	Body mass index;
LUSC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.45	-8.0	-0.4	2.01e-14	Colorectal cancer;
LUSC	cis	rs7615316	0.902	rs9825207	chr3:142304543	T/C	cg16271453	chr3:142027066	XRN1	-0.35	-5.9	-0.31	8.83e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.34	-0.46	1.38e-18	Acne (severe);
LUSC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg05043794	chr9:111880884	C9orf5	-0.35	-7.46	-0.38	7.48e-13	Menarche (age at onset);
LUSC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg09365446	chr1:150670422	GOLPH3L	0.54	8.28	0.41	2.91e-15	Tonsillectomy;
LUSC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg13047869	chr3:10149882	C3orf24	-0.56	-8.03	-0.4	1.73e-14	Alzheimer's disease;
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24739457	chr1:205821442	NA	0.36	6.2	0.32	1.63e-9	Menarche (age at onset);
LUSC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs6009527	0.963	rs6009532	chr22:49572757	C/G	cg12746016	chr22:49560550	NA	0.37	6.22	0.32	1.51e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs8113142	0.651	rs10500236	chr19:29091594	C/T	cg04546413	chr19:29218101	NA	0.44	6.05	0.31	3.89e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.0	-0.36	1.43e-11	Blood metabolite levels;
LUSC	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg12463550	chr7:65579703	CRCP	0.45	6.18	0.32	1.84e-9	Aortic root size;
LUSC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg25039879	chr17:56429692	SUPT4H1	0.67	9.01	0.44	1.65e-17	Cognitive test performance;
LUSC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg11789530	chr4:8429930	ACOX3	0.59	9.02	0.44	1.53e-17	Response to antineoplastic agents;
LUSC	cis	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg21775007	chr8:11205619	TDH	-0.47	-6.63	-0.34	1.34e-10	Morning vs. evening chronotype;
LUSC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg16362232	chr11:430036	ANO9	0.6	7.87	0.4	4.86e-14	Body mass index;
LUSC	cis	rs4903214	0.895	rs7157482	chr14:74712696	C/T	cg08255017	chr14:74727001	VSX2	-0.52	-7.1	-0.36	7.44e-12	Inflammatory bowel disease;
LUSC	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg17127132	chr2:85788382	GGCX	0.47	7.66	0.39	1.99e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg12016809	chr21:47604291	C21orf56	0.46	7.07	0.36	8.84e-12	Testicular germ cell tumor;
LUSC	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg01475377	chr6:109611718	NA	-0.37	-6.46	-0.33	3.61e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs10416265	0.528	rs3826906	chr19:33620897	C/T	cg17764715	chr19:33622953	WDR88	0.56	6.33	0.33	7.93e-10	Bone properties (heel);
LUSC	cis	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg06305312	chr1:19638330	AKR7A2;PQLC2	0.41	6.2	0.32	1.69e-9	Schizophrenia;
LUSC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg10018233	chr7:150070692	REPIN1	0.39	6.43	0.33	4.37e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.16	-0.41	7.12e-15	Morning vs. evening chronotype;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg06877462	chr1:205807181	PM20D1	-0.5	-9.07	-0.44	1.07e-17	Menarche (age at onset);
LUSC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.49	-7.44	-0.38	8.34e-13	Menarche (age at onset);
LUSC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg12560992	chr17:57184187	TRIM37	0.82	14.75	0.63	2.92e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg02493740	chr2:85810744	VAMP5	-0.32	-5.78	-0.3	1.72e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg17830980	chr10:43048298	ZNF37B	-0.39	-6.09	-0.32	3.12e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg22907277	chr7:1156413	C7orf50	0.45	6.8	0.35	4.95e-11	Longevity;Endometriosis;
LUSC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	0.85	14.75	0.63	2.79e-38	Cognitive function;
LUSC	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg17470449	chr10:769945	NA	0.51	7.02	0.36	1.24e-11	Uric acid levels;
LUSC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg22800045	chr5:56110881	MAP3K1	0.44	6.07	0.31	3.57e-9	Coronary artery disease;
LUSC	cis	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg06636551	chr8:101224915	SPAG1	-0.39	-7.37	-0.37	1.38e-12	Atrioventricular conduction;
LUSC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg08949735	chr16:89699720	DPEP1	-0.24	-5.76	-0.3	1.96e-8	Vitiligo;
LUSC	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg13256891	chr4:100009986	ADH5	-0.49	-6.43	-0.33	4.41e-10	Alcohol dependence;
LUSC	cis	rs877282	0.853	rs11593836	chr10:756715	G/A	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs7605827	0.930	rs2052439	chr2:15702029	C/G	cg19274914	chr2:15703543	NA	0.48	9.24	0.45	2.91e-18	Educational attainment (years of education);
LUSC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.91	-14.3	-0.62	1.59e-36	Multiple sclerosis;
LUSC	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	7.06	0.36	9.64e-12	Blood metabolite levels;
LUSC	cis	rs2806561	0.780	rs12135629	chr1:23338899	A/G	cg19743168	chr1:23544995	NA	-0.37	-7.74	-0.39	1.16e-13	Height;
LUSC	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg19875535	chr5:140030758	IK	0.47	7.57	0.38	3.58e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg01657329	chr11:68192670	LRP5	-0.39	-5.67	-0.3	3.17e-8	Total body bone mineral density;
LUSC	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg24851651	chr11:66362959	CCS	-0.38	-6.06	-0.31	3.72e-9	Educational attainment (years of education);
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11905131	chr22:24372483	LOC391322	-0.5	-7.71	-0.39	1.47e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs601339	1.000	rs509548	chr12:123181855	T/A	cg11919336	chr12:123188078	GPR109A	0.44	6.58	0.34	1.87e-10	Adiponectin levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15441230	chr15:44069583	ELL3	-0.49	-6.01	-0.31	4.81e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg17470449	chr10:769945	NA	0.53	7.12	0.36	6.81e-12	Uric acid levels;
LUSC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-9.49	-0.46	4.48e-19	Schizophrenia;
LUSC	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg26162295	chr17:38119207	GSDMA	-0.29	-6.96	-0.36	1.85e-11	Asthma;
LUSC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg09365446	chr1:150670422	GOLPH3L	-0.41	-5.94	-0.31	7.12e-9	Tonsillectomy;
LUSC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg08677398	chr8:58056175	NA	0.47	5.94	0.31	7.29e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	1.09	15.3	0.64	2.06e-40	Uric acid levels;
LUSC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.74	-12.67	-0.57	2.64e-30	Sudden cardiac arrest;
LUSC	cis	rs7598759	0.548	rs11686485	chr2:232360697	C/T	cg19187155	chr2:232395269	NMUR1	0.92	15.91	0.66	7.75e-43	Noise-induced hearing loss;
LUSC	trans	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	10.15	0.49	2.74e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg07507251	chr3:52567010	NT5DC2	0.33	6.61	0.34	1.49e-10	Bipolar disorder;
LUSC	cis	rs4948275	0.550	rs7082786	chr10:63176990	C/A	cg03237606	chr10:63212265	TMEM26	-0.39	-5.99	-0.31	5.3e-9	Night sleep phenotypes;
LUSC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg24675658	chr1:53192096	ZYG11B	0.79	14.06	0.61	1.4e-35	Monocyte count;
LUSC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg18230493	chr5:56204884	C5orf35	-0.61	-9.5	-0.46	4.27e-19	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.52	3.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg08742575	chr21:47604166	C21orf56	-0.44	-6.78	-0.35	5.39e-11	Testicular germ cell tumor;
LUSC	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg14438399	chr17:27053147	TLCD1	-0.53	-5.96	-0.31	6.37e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1957429	0.901	rs3813422	chr14:65347404	G/A	cg23373153	chr14:65346875	NA	1.07	12.89	0.58	3.85e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs460214	0.564	rs9979888	chr21:40022099	A/G	cg05519781	chr21:40033154	ERG	0.41	5.69	0.3	2.82e-8	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg16342193	chr10:102329863	NA	-0.36	-6.56	-0.34	2.08e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23237634	chr1:154976031	ZBTB7B	0.43	6.33	0.33	7.71e-10	Triglycerides;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23000811	chr4:2464397	NA	0.4	6.0	0.31	5.04e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	0.92	16.06	0.66	2.14e-43	Menopause (age at onset);
LUSC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg17507749	chr15:85114479	UBE2QP1	0.68	8.55	0.42	4.36e-16	Schizophrenia;
LUSC	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg18357645	chr12:58087776	OS9	0.51	7.64	0.39	2.33e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.88	-0.35	2.89e-11	Total body bone mineral density;
LUSC	cis	rs7572644	0.640	rs12617113	chr2:28059937	A/G	cg27432699	chr2:27873401	GPN1	0.51	6.96	0.36	1.78e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs701145	0.537	rs357471	chr3:153896403	C/T	cg17054900	chr3:154042577	DHX36	0.7	7.21	0.37	3.87e-12	Coronary artery disease;
LUSC	cis	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg02972257	chr16:68554789	NA	0.43	5.65	0.3	3.43e-8	Colorectal cancer;
LUSC	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg27068330	chr11:65405492	SIPA1	-0.61	-8.97	-0.44	2.16e-17	Acne (severe);
LUSC	cis	rs12543645	0.609	rs35112858	chr8:10277269	C/T	cg12940923	chr8:10282607	MSRA	0.41	7.11	0.36	6.87e-12	Schizophrenia;
LUSC	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg17330251	chr7:94953956	PON1	-0.38	-6.17	-0.32	1.92e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.75e-10	Crohn's disease;
LUSC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg12310025	chr6:25882481	NA	-0.5	-9.02	-0.44	1.46e-17	Blood metabolite levels;
LUSC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.46	5.94	0.31	7.02e-9	Schizophrenia;
LUSC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.44	-0.46	6.87e-19	Chronic sinus infection;
LUSC	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg17507749	chr15:85114479	UBE2QP1	0.7	8.77	0.43	8.99e-17	Schizophrenia;
LUSC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08859206	chr1:53392774	SCP2	-0.54	-9.67	-0.47	1.17e-19	Monocyte count;
LUSC	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-7.17	-0.37	4.97e-12	Blood metabolite levels;
LUSC	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg06026331	chr20:60912101	LAMA5	0.56	6.73	0.35	7.56e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9323205	0.906	rs11629336	chr14:51686620	A/C	cg23942311	chr14:51606299	NA	0.48	9.6	0.47	1.94e-19	Cancer;
LUSC	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.77	-13.26	-0.59	1.58e-32	Schizophrenia;
LUSC	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg26528668	chr16:1614120	IFT140	0.47	7.95	0.4	2.83e-14	Coronary artery disease;
LUSC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg03395511	chr6:291903	DUSP22	-0.5	-7.53	-0.38	4.73e-13	Menopause (age at onset);
LUSC	cis	rs7804356	1.000	rs73069533	chr7:26892325	G/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.11e-9	Type 1 diabetes;
LUSC	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg22782873	chr19:19639568	YJEFN3	-0.48	-6.11	-0.32	2.7e-9	Bipolar disorder;
LUSC	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.54	0.5	1.34e-22	Bladder cancer;
LUSC	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg07930552	chr6:133119739	C6orf192	0.84	10.61	0.5	7.57e-23	Type 2 diabetes nephropathy;
LUSC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.75	-11.36	-0.53	1.6e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-6.14	-0.32	2.29e-9	Schizophrenia;
LUSC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.63	-8.22	-0.41	4.61e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg04362960	chr10:104952993	NT5C2	0.62	9.75	0.47	6.07e-20	Arsenic metabolism;
LUSC	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg03929089	chr4:120376271	NA	-0.52	-7.25	-0.37	2.87e-12	HDL cholesterol;
LUSC	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg04865166	chr7:105162814	PUS7	0.53	5.69	0.3	2.82e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg10434728	chr15:90938212	IQGAP1	0.33	6.2	0.32	1.63e-9	Rheumatoid arthritis;
LUSC	cis	rs2274273	0.840	rs28493647	chr14:55824463	T/C	cg04306507	chr14:55594613	LGALS3	0.53	11.91	0.55	1.69e-27	Protein biomarker;
LUSC	cis	rs12540874	0.895	rs4245556	chr7:50661661	C/T	cg18232548	chr7:50535776	DDC	-0.47	-6.6	-0.34	1.64e-10	Systemic sclerosis;
LUSC	cis	rs11997175	0.766	rs60855034	chr8:33684732	G/A	ch.8.33884649F	chr8:33765107	NA	0.39	6.09	0.32	3.09e-9	Body mass index;
LUSC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.47	-8.24	-0.41	3.87e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg24733560	chr20:60626293	TAF4	0.46	8.36	0.42	1.67e-15	Body mass index;
LUSC	cis	rs977987	0.835	rs8057535	chr16:75347941	C/T	cg03315344	chr16:75512273	CHST6	0.53	10.12	0.48	3.61e-21	Dupuytren's disease;
LUSC	trans	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07923666	chr12:49932857	KCNH3	-0.52	-6.37	-0.33	6.32e-10	Resting heart rate;
LUSC	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.4	7.5	0.38	5.71e-13	Axial length;
LUSC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.21	0.37	3.85e-12	Platelet count;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg04432617	chr1:154976216	ZBTB7B	0.45	6.31	0.33	9.06e-10	Mosquito bite size;
LUSC	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg24130564	chr14:104152367	KLC1	0.45	6.46	0.33	3.78e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg15556689	chr8:8085844	FLJ10661	0.66	10.74	0.51	2.62e-23	Neuroticism;
LUSC	trans	rs7618314	0.571	rs1597077	chr3:108506820	T/A	cg05749855	chr16:89472771	ANKRD11	0.59	6.0	0.31	5.2e-9	Airway responsiveness in chronic obstructive pulmonary disease;
LUSC	cis	rs12980942	0.872	rs2304230	chr19:41774064	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.59	6.49	0.33	3.13e-10	Coronary artery disease;
LUSC	cis	rs9837602	1.000	rs704582	chr3:99571926	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.38	6.12	0.32	2.62e-9	Breast cancer;
LUSC	cis	rs13315871	1.000	rs9862969	chr3:58341917	A/G	cg12435725	chr3:58293450	RPP14	-0.74	-7.81	-0.39	7.27e-14	Cholesterol, total;
LUSC	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg13318129	chr22:45737514	FAM118A	-0.69	-8.45	-0.42	9.25e-16	Tonsillectomy;
LUSC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg16060761	chr17:80687452	NA	0.41	6.26	0.32	1.21e-9	Breast cancer;
LUSC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg18350739	chr11:68623251	NA	-0.35	-6.38	-0.33	5.83e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.58	0.6	9.51e-34	Morning vs. evening chronotype;
LUSC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs12760731	0.565	rs34041572	chr1:178184493	T/C	cg00404053	chr1:178313656	RASAL2	0.68	6.89	0.35	2.73e-11	Obesity-related traits;
LUSC	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg11498726	chr8:26250323	BNIP3L	-0.46	-6.81	-0.35	4.59e-11	Red cell distribution width;
LUSC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg14092988	chr3:52407081	DNAH1	0.3	5.92	0.31	8.12e-9	Bipolar disorder;
LUSC	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg06028605	chr16:24865363	SLC5A11	0.46	8.38	0.42	1.45e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs11209002	0.567	rs983111	chr1:67539356	T/C	cg02640540	chr1:67518911	SLC35D1	0.62	8.53	0.42	5.27e-16	Crohn's disease;
LUSC	cis	rs7927771	0.507	rs12366244	chr11:47882130	C/A	cg20307385	chr11:47447363	PSMC3	0.47	6.86	0.35	3.42e-11	Subjective well-being;
LUSC	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg06360820	chr2:242988706	NA	-0.82	-9.54	-0.46	3.17e-19	Obesity-related traits;
LUSC	cis	rs362296	0.698	rs3135172	chr4:3258735	A/G	cg14583973	chr4:3374767	RGS12	-0.31	-5.91	-0.31	8.59e-9	Parental longevity (mother's age at death);
LUSC	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17467752	chr17:38218738	THRA	0.78	12.57	0.57	5.92e-30	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.59	0.46	2.05e-19	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01704976	chr3:52273381	TWF2	0.41	6.28	0.32	1.04e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg24209194	chr3:40518798	ZNF619	0.47	6.58	0.34	1.84e-10	Renal cell carcinoma;
LUSC	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	9.5	0.46	4.37e-19	Menarche (age at onset);
LUSC	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg14634687	chr17:47094252	IGF2BP1	0.32	6.69	0.34	9.15e-11	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg07701084	chr6:150067640	NUP43	0.46	6.93	0.35	2.23e-11	Testicular germ cell tumor;
LUSC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	7.98	0.4	2.41e-14	Lymphocyte counts;
LUSC	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg03161606	chr19:29218774	NA	0.51	5.98	0.31	5.58e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	trans	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg26043149	chr18:55253948	FECH	-0.53	-7.78	-0.39	9e-14	Bone mineral density;
LUSC	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg04317338	chr11:64019027	PLCB3	0.71	8.0	0.4	2.1e-14	Mean platelet volume;
LUSC	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg08975724	chr8:8085496	FLJ10661	0.65	10.06	0.48	5.65e-21	Mood instability;
LUSC	cis	rs7914558	0.646	rs7100709	chr10:104649729	A/C	cg05855489	chr10:104503620	C10orf26	0.43	5.82	0.3	1.42e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-9.45	-0.46	6.09e-19	Electroencephalogram traits;
LUSC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg27398640	chr15:77910606	LINGO1	-0.28	-5.73	-0.3	2.19e-8	Type 2 diabetes;
LUSC	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.47	0.42	8.05e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	7.46	0.38	7.44e-13	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg18827107	chr12:86230957	RASSF9	-0.48	-7.13	-0.36	6.22e-12	Major depressive disorder;
LUSC	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg22852734	chr6:133119734	C6orf192	1.34	10.6	0.5	8.1e-23	Type 2 diabetes nephropathy;
LUSC	cis	rs865483	1.000	rs865483	chr17:35851177	A/C	cg06716730	chr17:35851459	DUSP14	0.29	6.33	0.33	7.77e-10	Monocyte count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04709120	chr10:74451858	CCDC109A	-0.58	-6.97	-0.36	1.68e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg11632617	chr15:75315747	PPCDC	-0.51	-6.69	-0.34	9.31e-11	Blood trace element (Zn levels);
LUSC	cis	rs939658	0.935	rs4778651	chr15:79447810	G/A	cg17916960	chr15:79447300	NA	-0.53	-10.56	-0.5	1.09e-22	Refractive error;
LUSC	cis	rs722599	0.748	rs61978932	chr14:75342954	C/T	cg08847533	chr14:75593920	NEK9	-0.46	-6.64	-0.34	1.28e-10	IgG glycosylation;
LUSC	cis	rs7980687	0.678	rs7132277	chr12:123593382	C/T	cg00376283	chr12:123451042	ABCB9	-0.71	-7.67	-0.39	1.95e-13	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.03	-0.36	1.15e-11	Bipolar disorder;
LUSC	cis	rs28619038	1	rs28619038	chr15:64642517	C/A	cg02848875	chr15:64387786	SNX1	-0.41	-5.92	-0.31	7.78e-9	Myeloid white cell count;
LUSC	cis	rs8067545	0.750	rs4924803	chr17:19991806	C/T	cg13482628	chr17:19912719	NA	0.47	7.75	0.39	1.09e-13	Schizophrenia;
LUSC	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg15133208	chr4:90757351	SNCA	-0.57	-8.73	-0.43	1.22e-16	Neuroticism;
LUSC	cis	rs722599	0.748	rs731165	chr14:75352555	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.42	-6.15	-0.32	2.18e-9	IgG glycosylation;
LUSC	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg12940923	chr8:10282607	MSRA	-0.32	-5.66	-0.3	3.34e-8	Retinal vascular caliber;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg21829265	chr6:56911139	KIAA1586	0.36	6.41	0.33	5.09e-10	Tuberculosis;
LUSC	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg07148914	chr20:33460835	GGT7	0.56	8.53	0.42	5.25e-16	Height;
LUSC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.84	0.35	3.83e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4077515	0.967	rs11794847	chr9:139271747	G/A	cg14169450	chr9:139327907	INPP5E	0.43	7.55	0.38	4.28e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs500891	0.525	rs12190282	chr6:84056328	A/G	cg08257003	chr6:84140564	ME1	0.34	8.09	0.4	1.08e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg19812747	chr11:111475976	SIK2	-0.52	-7.34	-0.37	1.67e-12	Primary sclerosing cholangitis;
LUSC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg09367891	chr1:107599246	PRMT6	0.52	8.15	0.41	7.44e-15	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg14668632	chr7:2872130	GNA12	-0.45	-6.79	-0.35	5.1e-11	Height;
LUSC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.46	-0.53	7.13e-26	Mean corpuscular volume;
LUSC	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs2046867	0.818	rs7637138	chr3:72910886	A/G	cg25664220	chr3:72788482	NA	-0.61	-10.13	-0.48	3.31e-21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1595825	1.000	rs1440087	chr2:198871476	G/C	cg00982548	chr2:198649783	BOLL	-0.51	-6.31	-0.33	8.95e-10	Ulcerative colitis;
LUSC	cis	rs6693567	0.565	rs1313570	chr1:150342642	T/C	cg15654264	chr1:150340011	RPRD2	0.44	7.04	0.36	1.11e-11	Migraine;
LUSC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08219700	chr8:58056026	NA	0.72	8.29	0.41	2.9e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.94	0.55	1.29e-27	Exhaled nitric oxide output;
LUSC	cis	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg21775007	chr8:11205619	TDH	-0.54	-7.23	-0.37	3.21e-12	Triglycerides;
LUSC	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg15395560	chr15:45543142	SLC28A2	0.33	5.66	0.3	3.25e-8	Uric acid levels;
LUSC	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg00999904	chr2:3704751	ALLC	-0.34	-6.26	-0.32	1.18e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg21775007	chr8:11205619	TDH	0.44	6.26	0.32	1.18e-9	Mood instability;
LUSC	cis	rs6690583	0.562	rs12024977	chr1:85531051	A/C	cg11262906	chr1:85462892	MCOLN2	0.67	6.43	0.33	4.45e-10	Serum sulfate level;
LUSC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.26e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	10.42	0.5	3.3e-22	Bone mineral density;
LUSC	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.55	-9.81	-0.47	4.02e-20	Platelet distribution width;
LUSC	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.96	18.01	0.7	3.76e-51	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4499344	0.519	rs259226	chr19:33134965	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	13.74	0.6	2.35e-34	Mean platelet volume;
LUSC	cis	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg06521331	chr12:34319734	NA	-0.35	-6.01	-0.31	4.82e-9	Morning vs. evening chronotype;
LUSC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg24733560	chr20:60626293	TAF4	0.44	8.16	0.41	6.76e-15	Body mass index;
LUSC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg09365446	chr1:150670422	GOLPH3L	-0.54	-8.45	-0.42	9.05e-16	Tonsillectomy;
LUSC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg23719950	chr11:63933701	MACROD1	-0.62	-8.07	-0.4	1.24e-14	Mean platelet volume;
LUSC	cis	rs11039100	0.527	rs2047460	chr11:5781159	A/G	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs62400317	0.826	rs11963924	chr6:45306562	C/T	cg18551225	chr6:44695536	NA	-0.45	-7.44	-0.38	8.38e-13	Total body bone mineral density;
LUSC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg04111992	chr7:158790115	NA	-0.44	-6.99	-0.36	1.46e-11	Facial morphology (factor 20);
LUSC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.55	11.18	0.52	7.08e-25	Asthma (sex interaction);
LUSC	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.85	15.22	0.64	4.04e-40	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs56399783	0.901	rs11761804	chr7:2792524	C/T	cg14895029	chr7:2775587	GNA12	0.55	5.72	0.3	2.41e-8	Childhood ear infection;
LUSC	cis	rs62400317	0.859	rs10948212	chr6:45156933	A/C	cg20913747	chr6:44695427	NA	-0.48	-7.63	-0.39	2.56e-13	Total body bone mineral density;
LUSC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg03806693	chr22:41940476	POLR3H	-0.96	-12.95	-0.58	2.42e-31	Vitiligo;
LUSC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg08999081	chr20:33150536	PIGU	0.44	8.2	0.41	5.32e-15	Coronary artery disease;
LUSC	cis	rs72781680	0.716	rs2712050	chr2:24059408	A/C	cg08917208	chr2:24149416	ATAD2B	0.6	6.89	0.35	2.84e-11	Lymphocyte counts;
LUSC	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg22676075	chr6:135203613	NA	0.48	7.48	0.38	6.5e-13	Red blood cell count;
LUSC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.25	-0.37	2.9e-12	Obesity-related traits;
LUSC	cis	rs859767	0.501	rs4954160	chr2:135431692	A/C	cg12500956	chr2:135428796	TMEM163	-0.29	-6.98	-0.36	1.6e-11	Neuroticism;
LUSC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg18196295	chr10:418757	DIP2C	0.42	6.82	0.35	4.32e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg14458575	chr2:238380390	NA	0.73	12.59	0.57	5.23e-30	Prostate cancer;
LUSC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg14440974	chr22:39074834	NA	-0.36	-6.07	-0.32	3.43e-9	Menopause (age at onset);
LUSC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.77	-0.3	1.77e-8	Depression;
LUSC	cis	rs10871290	0.881	rs7498574	chr16:74472661	A/G	cg01733217	chr16:74700730	RFWD3	-0.62	-8.95	-0.44	2.47e-17	Breast cancer;
LUSC	cis	rs6460942	0.908	rs117451929	chr7:12265149	A/T	cg06484146	chr7:12443880	VWDE	-0.61	-6.47	-0.33	3.48e-10	Coronary artery disease;
LUSC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.45	6.7	0.34	8.95e-11	Platelet count;
LUSC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg05425664	chr17:57184151	TRIM37	0.56	9.05	0.44	1.24e-17	Primary tooth development (time to first tooth eruption);
LUSC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.43	-0.38	9e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.65	8.46	0.42	8.6e-16	Migraine;
LUSC	cis	rs9469578	0.681	rs78748610	chr6:33714412	T/C	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.45e-9	Menopause (age at onset);
LUSC	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg21775007	chr8:11205619	TDH	-0.66	-10.23	-0.49	1.46e-21	Retinal vascular caliber;
LUSC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00149659	chr3:10157352	C3orf10	0.91	13.04	0.58	1.03e-31	Alzheimer's disease;
LUSC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg16680214	chr1:154839983	KCNN3	-0.45	-8.19	-0.41	5.67e-15	Prostate cancer;
LUSC	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-7.63	-0.39	2.54e-13	Schizophrenia;
LUSC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg16414030	chr3:133502952	NA	-0.45	-7.0	-0.36	1.42e-11	Iron status biomarkers;
LUSC	cis	rs4363385	0.747	rs4845507	chr1:152968414	T/G	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.9	-0.4	3.97e-14	Inflammatory skin disease;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg23034840	chr1:205782522	SLC41A1	0.67	10.04	0.48	6.73e-21	Menarche (age at onset);
LUSC	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.52	8.14	0.41	7.67e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18206459	chr2:208030726	KLF7	-0.39	-6.26	-0.32	1.19e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.55	0.34	2.13e-10	Rheumatoid arthritis;
LUSC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	20.42	0.75	1.03e-60	Prudent dietary pattern;
LUSC	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg08017756	chr2:100939284	LONRF2	-0.43	-8.03	-0.4	1.69e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg08470875	chr2:26401718	FAM59B	0.69	8.08	0.4	1.19e-14	Gut microbiome composition (summer);
LUSC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20887711	chr4:1340912	KIAA1530	0.54	8.65	0.43	2.24e-16	Longevity;
LUSC	cis	rs1127311	0.901	rs11264223	chr1:154565519	G/A	cg17218026	chr1:154582156	ADAR	0.57	10.15	0.49	2.89e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.02	-0.4	1.86e-14	Monocyte count;
LUSC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.84	0.39	5.97e-14	Bipolar disorder;
LUSC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg01657329	chr11:68192670	LRP5	0.45	7.2	0.37	4.04e-12	Total body bone mineral density;
LUSC	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg08085267	chr17:45401833	C17orf57	-0.51	-7.95	-0.4	2.86e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg14552801	chr7:65878734	NA	0.38	5.93	0.31	7.76e-9	Aortic root size;
LUSC	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg18721089	chr20:30220636	NA	-0.33	-5.81	-0.3	1.44e-8	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.56	8.37	0.42	1.63e-15	Lymphocyte counts;
LUSC	cis	rs11051970	0.636	rs325424	chr12:32570193	C/T	cg02745156	chr12:32552066	NA	0.39	7.08	0.36	8.63e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	6.82	0.35	4.2e-11	Resting heart rate;
LUSC	cis	rs6426558	0.537	rs6682642	chr1:227244600	G/T	cg10327440	chr1:227177885	CDC42BPA	0.57	8.24	0.41	4e-15	Neutrophil percentage of white cells;
LUSC	cis	rs238295	0.805	rs6053486	chr20:5530767	T/G	cg15842884	chr20:5591925	RP5-1022P6.2	-0.43	-5.84	-0.3	1.25e-8	Occipital cortical area (total cortical area interaction);
LUSC	trans	rs7893279	0.822	rs11014185	chr10:18714347	T/A	cg01840055	chr3:141338555	NA	0.5	6.04	0.31	4.02e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg04362960	chr10:104952993	NT5C2	0.61	9.76	0.47	5.68e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg09904177	chr6:26538194	HMGN4	0.66	11.7	0.54	1.01e-26	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20583797	chr15:86338184	KLHL25	0.42	5.98	0.31	5.72e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2742234	0.955	rs2435385	chr10:43665750	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.37	-6.35	-0.33	7.06e-10	Hirschsprung disease;
LUSC	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	1.16	17.2	0.69	6.54e-48	Corneal structure;
LUSC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.78	0.3	1.74e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg22903471	chr2:27725779	GCKR	-0.41	-7.07	-0.36	9.02e-12	Total body bone mineral density;
LUSC	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-6.69	-0.34	9.39e-11	Mean platelet volume;
LUSC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.78	0.47	5.09e-20	Bipolar disorder;
LUSC	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.78	10.21	0.49	1.8e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-0.98	-10.73	-0.51	2.8e-23	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg03806693	chr22:41940476	POLR3H	-0.63	-9.25	-0.45	2.75e-18	Neuroticism;
LUSC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg09796270	chr17:17721594	SREBF1	-0.4	-7.1	-0.36	7.57e-12	Total body bone mineral density;
LUSC	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg14343924	chr8:8086146	FLJ10661	0.46	6.38	0.33	6.04e-10	Mood instability;
LUSC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg04025307	chr7:1156635	C7orf50	0.45	5.98	0.31	5.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7178572	0.889	rs7171448	chr15:77832316	C/G	cg22256960	chr15:77711686	NA	-0.52	-8.43	-0.42	1.04e-15	Type 2 diabetes;
LUSC	cis	rs12980942	1.000	rs7257742	chr19:41827352	G/T	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.15	0.32	2.17e-9	Coronary artery disease;
LUSC	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	11.19	0.52	6.82e-25	Coffee consumption (cups per day);
LUSC	cis	rs1941023	0.584	rs2233252	chr11:60157107	T/G	cg08716584	chr11:60157161	MS4A7	-0.65	-12.23	-0.56	1.11e-28	Congenital heart disease (maternal effect);
LUSC	trans	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg01620082	chr3:125678407	NA	-0.78	-7.29	-0.37	2.28e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg06740227	chr12:86229804	RASSF9	0.44	7.12	0.36	6.82e-12	Major depressive disorder;
LUSC	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	9.65	0.47	1.37e-19	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg20988073	chr3:125900093	ALDH1L1	-0.31	-6.25	-0.32	1.26e-9	Metabolite levels;
LUSC	cis	rs9929218	0.817	rs3114405	chr16:68722377	G/A	cg02972257	chr16:68554789	NA	0.44	5.67	0.3	3.14e-8	Colorectal cancer;
LUSC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-5.87	-0.31	1.04e-8	Vitiligo;
LUSC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.61	-11.13	-0.52	1.07e-24	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18876405	chr7:65276391	NA	0.56	8.96	0.44	2.33e-17	Aortic root size;
LUSC	cis	rs7818345	1.000	rs7823194	chr8:19292528	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.26	0.37	2.72e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	0.84	15.5	0.65	3.28e-41	Height;
LUSC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-0.83	-15.38	-0.64	9.88e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9296092	0.560	rs3846853	chr6:33528194	C/G	cg13560919	chr6:33536144	NA	-0.85	-16.44	-0.67	6.54e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg16724585	chr3:197361211	NA	-0.6	-8.43	-0.42	1.02e-15	Pancreatic cancer;
LUSC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.84	-0.44	5.43e-17	Monocyte count;
LUSC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg20406979	chr6:167373233	NA	-0.26	-6.16	-0.32	2.1e-9	Crohn's disease;
LUSC	cis	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg07988820	chr12:82153109	PPFIA2	-0.4	-5.72	-0.3	2.32e-8	Resting heart rate;
LUSC	cis	rs28619038	1	rs28619038	chr15:64642517	C/A	cg08069370	chr15:64387884	SNX1	-0.56	-6.23	-0.32	1.44e-9	Myeloid white cell count;
LUSC	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg13010199	chr12:38710504	ALG10B	0.41	6.62	0.34	1.46e-10	Morning vs. evening chronotype;
LUSC	cis	rs7715806	0.500	rs10515213	chr5:74980572	C/T	cg19683494	chr5:74908142	NA	-0.57	-7.83	-0.39	6.34e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2200578	0.786	rs57656020	chr2:99799378	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	6.4	0.33	5.21e-10	IgG glycosylation;
LUSC	cis	rs10463316	0.894	rs13357969	chr5:150751557	A/G	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.09	-0.36	8.25e-12	Metabolite levels (Pyroglutamine);
LUSC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-0.84	-14.33	-0.62	1.19e-36	Menopause (age at onset);
LUSC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.63e-16	Lung cancer;
LUSC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg25258033	chr6:167368657	RNASET2	-0.47	-7.82	-0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs9942416	0.660	rs4704234	chr5:75001432	A/G	cg19683494	chr5:74908142	NA	0.41	6.4	0.33	5.28e-10	Age-related disease endophenotypes;
LUSC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11644478	chr21:40555479	PSMG1	-0.61	-9.61	-0.47	1.88e-19	Menarche (age at onset);
LUSC	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg05234568	chr11:5960015	NA	-0.6	-8.72	-0.43	1.35e-16	DNA methylation (variation);
LUSC	cis	rs3820928	0.874	rs13393894	chr2:227880543	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.8	-0.39	7.97e-14	Pulmonary function;
LUSC	trans	rs4800353	0.929	rs899640	chr18:19607986	T/G	cg01841828	chr16:69166849	CHTF8;CIRH1A	-0.58	-6.02	-0.31	4.53e-9	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs2414856	0.510	rs72756997	chr15:64608662	G/C	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg11905131	chr22:24372483	LOC391322	-0.54	-8.54	-0.42	4.83e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6961069	0.774	rs1054516	chr7:80284942	T/C	cg04458919	chr7:80252533	CD36	0.34	6.04	0.31	4.21e-9	Platelet count;
LUSC	cis	rs2120019	0.507	rs4886642	chr15:75228846	T/C	cg17294928	chr15:75287854	SCAMP5	-0.76	-8.79	-0.43	7.81e-17	Blood trace element (Zn levels);
LUSC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg16584290	chr5:462447	EXOC3	-0.42	-7.53	-0.38	4.92e-13	Cystic fibrosis severity;
LUSC	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg13072238	chr3:49761600	GMPPB	-0.69	-8.19	-0.41	5.44e-15	Menarche (age at onset);
LUSC	cis	rs926938	0.527	rs58658580	chr1:115539726	A/G	cg01522456	chr1:115632236	TSPAN2	-0.4	-6.21	-0.32	1.57e-9	Autism;
LUSC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.87	-0.35	3.19e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs12554020	0.892	rs6479494	chr9:96330499	C/T	cg06165706	chr14:101347143	RTL1;MIR431;MIR433	-0.38	-6.01	-0.31	4.76e-9	Schizophrenia;
LUSC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg06808227	chr14:105710500	BRF1	-0.65	-9.9	-0.48	1.97e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs78572108	0.858	rs4952580	chr2:42266740	G/C	cg00607755	chr2:42274082	PKDCC	0.35	6.11	0.32	2.79e-9	Total body bone mineral density;
LUSC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.53	-8.08	-0.4	1.18e-14	Lymphocyte counts;
LUSC	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg23298862	chr7:158159286	PTPRN2	-0.32	-5.79	-0.3	1.59e-8	Response to amphetamines;
LUSC	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg23950597	chr19:37808831	NA	-0.63	-7.8	-0.39	8.08e-14	Coronary artery calcification;
LUSC	cis	rs11585357	0.895	rs72633828	chr1:17632251	G/A	cg08277548	chr1:17600880	PADI3	-0.59	-6.17	-0.32	1.92e-9	Hair shape;
LUSC	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg14809332	chr8:144654887	C8orf73	0.54	6.51	0.34	2.83e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.79	0.65	2.34e-42	Platelet count;
LUSC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg10523860	chr14:103875565	MARK3	-0.37	-5.9	-0.31	9.07e-9	Body mass index;
LUSC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg17264618	chr3:40429014	ENTPD3	0.33	7.02	0.36	1.28e-11	Renal cell carcinoma;
LUSC	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.59	-0.43	3.42e-16	Coffee consumption (cups per day);
LUSC	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg21775007	chr8:11205619	TDH	0.82	13.79	0.6	1.53e-34	Retinal vascular caliber;
LUSC	cis	rs9359856	0.913	rs9362665	chr6:90309844	C/T	cg13799429	chr6:90582589	CASP8AP2	0.58	6.48	0.33	3.2e-10	Bipolar disorder;
LUSC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg19418458	chr7:158789849	NA	-0.5	-8.14	-0.41	8.12e-15	Facial morphology (factor 20);
LUSC	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	8.44	0.42	9.54e-16	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.13	0.32	2.44e-9	Bipolar disorder;
LUSC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22968622	chr17:43663579	NA	-0.78	-12.08	-0.55	3.97e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs6601327	0.606	rs4841203	chr8:9582730	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.58	-0.34	1.83e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg16850897	chr7:100343110	ZAN	-0.52	-7.84	-0.39	5.94e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.31	-0.45	1.78e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg04513422	chr13:111522314	C13orf29	-0.52	-6.33	-0.33	7.75e-10	Sitting height ratio;
LUSC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg20406979	chr6:167373233	NA	-0.26	-6.09	-0.32	3.18e-9	Crohn's disease;
LUSC	cis	rs4285028	0.699	rs1920298	chr3:121597888	T/C	cg11130432	chr3:121712080	ILDR1	-0.62	-9.4	-0.46	9.2e-19	Multiple sclerosis;
LUSC	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg09835421	chr16:68378352	PRMT7	-0.54	-5.94	-0.31	7.01e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg04518342	chr5:131593106	PDLIM4	0.44	8.13	0.41	8.44e-15	Breast cancer;
LUSC	trans	rs67133203	0.851	rs11169667	chr12:51403088	G/A	cg17484237	chr5:156536107	HAVCR2	0.44	6.02	0.31	4.52e-9	Urinary tract infection frequency;
LUSC	trans	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.76	-13.43	-0.59	3.44e-33	Cognitive function;
LUSC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg06145435	chr7:1022769	CYP2W1	0.3	6.43	0.33	4.31e-10	Longevity;Endometriosis;
LUSC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	6.08	0.32	3.27e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-9.0	-0.44	1.77e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.47	7.75	0.39	1.15e-13	Vitiligo;
LUSC	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg00376283	chr12:123451042	ABCB9	0.7	9.19	0.45	4.24e-18	Neutrophil percentage of white cells;
LUSC	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg10523860	chr14:103875565	MARK3	-0.37	-5.82	-0.3	1.4e-8	Body mass index;
LUSC	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg13010199	chr12:38710504	ALG10B	0.45	6.4	0.33	5.12e-10	Morning vs. evening chronotype;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg23131131	chr22:24373011	LOC391322	-0.41	-6.05	-0.31	3.84e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg14154082	chr13:112174009	NA	0.39	8.01	0.4	1.89e-14	Menarche (age at onset);
LUSC	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg04117972	chr1:227635322	NA	0.61	6.56	0.34	2e-10	Major depressive disorder;
LUSC	cis	rs1550582	0.548	rs11538239	chr8:135490539	A/G	cg17885191	chr8:135476712	NA	-0.94	-13.8	-0.6	1.31e-34	Educational attainment;
LUSC	cis	rs2742417	0.565	rs2673031	chr3:45756986	A/G	cg04837898	chr3:45731254	SACM1L	-0.43	-7.01	-0.36	1.34e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs57590327	0.527	rs9845467	chr3:81614473	G/A	cg07356753	chr3:81810745	GBE1	-0.47	-6.31	-0.33	8.95e-10	Extraversion;
LUSC	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-7.82	-0.39	6.9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.92	0.51	6.12e-24	Hypertriglyceridemia;
LUSC	cis	rs80130819	0.748	rs1387255	chr12:48648943	C/T	cg24011408	chr12:48396354	COL2A1	0.47	5.89	0.31	9.22e-9	Prostate cancer;
LUSC	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg24006582	chr15:45444508	DUOX1	-0.6	-8.77	-0.43	9.28e-17	Uric acid levels;
LUSC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg12310025	chr6:25882481	NA	0.41	6.84	0.35	3.69e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs970548	0.606	rs12355888	chr10:45931564	G/T	cg14222797	chr10:16859974	RSU1	-0.65	-6.21	-0.32	1.56e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs593982	1.000	rs118030231	chr11:65501905	G/A	cg08755490	chr11:65554678	OVOL1	-1.46	-15.35	-0.64	1.35e-40	Atopic dermatitis;
LUSC	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg05347473	chr6:146136440	FBXO30	0.63	10.52	0.5	1.52e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg25730555	chr22:47059586	GRAMD4	0.45	7.07	0.36	9.04e-12	Urate levels in obese individuals;
LUSC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg07636037	chr3:49044803	WDR6	0.44	6.36	0.33	6.58e-10	Resting heart rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06445916	chr8:42268472	NA	0.51	6.96	0.36	1.85e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs193541	0.632	rs154512	chr5:122195040	T/C	cg19077854	chr5:122220652	SNX24	0.37	7.84	0.39	5.91e-14	Glucose homeostasis traits;
LUSC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	11.26	0.52	3.93e-25	Menarche (age at onset);
LUSC	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.97	0.66	4.9e-43	Morning vs. evening chronotype;
LUSC	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg24397884	chr7:158709396	WDR60	0.77	8.58	0.43	3.56e-16	Height;
LUSC	cis	rs9341835	0.740	rs10755410	chr6:64150689	G/A	cg03326410	chr6:64151739	NA	-0.37	-6.13	-0.32	2.53e-9	Schizophrenia;
LUSC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg13010199	chr12:38710504	ALG10B	0.68	10.87	0.51	9.2e-24	Heart rate;
LUSC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21862992	chr11:68658383	NA	0.5	8.13	0.41	8.64e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg25214090	chr10:38739885	LOC399744	0.54	7.92	0.4	3.59e-14	Corneal astigmatism;
LUSC	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg04374321	chr14:90722782	PSMC1	-0.43	-6.6	-0.34	1.65e-10	Mortality in heart failure;
LUSC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg12639453	chr1:2035780	PRKCZ	0.29	6.05	0.31	3.9e-9	Height;
LUSC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.32	0.56	5.39e-29	Prudent dietary pattern;
LUSC	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-7.55	-0.38	4.24e-13	Retinal vascular caliber;
LUSC	trans	rs2910490	1.000	rs2910490	chr5:56922085	A/G	cg24648061	chr7:107114615	COG5;GPR22	-0.34	-6.08	-0.32	3.34e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4363385	0.818	rs1415966	chr1:153002864	A/G	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.9	-0.4	4e-14	Inflammatory skin disease;
LUSC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg24829409	chr8:58192753	C8orf71	-0.51	-6.06	-0.31	3.7e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11679564	0.714	rs4389320	chr2:37172531	T/C	cg14987922	chr2:37194071	STRN	0.63	9.57	0.46	2.57e-19	Immature fraction of reticulocytes;
LUSC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg25767906	chr1:53392781	SCP2	-0.39	-6.85	-0.35	3.62e-11	Monocyte count;
LUSC	cis	rs9467773	0.595	rs3846845	chr6:26444915	G/A	cg05738196	chr6:26577821	NA	-0.52	-7.73	-0.39	1.28e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2282032	1.000	rs75722521	chr14:90760478	T/C	cg14092571	chr14:90743983	NA	0.53	6.81	0.35	4.52e-11	Longevity;
LUSC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg22907277	chr7:1156413	C7orf50	0.7	10.29	0.49	9.45e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg21100191	chr22:23484243	RTDR1	0.92	16.16	0.66	8.69e-44	Bone mineral density;
LUSC	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg18132916	chr6:79620363	NA	0.37	5.65	0.3	3.4e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4144743	1.000	rs66738981	chr17:45325538	T/A	cg18085866	chr17:45331354	ITGB3	-0.73	-7.75	-0.39	1.12e-13	Body mass index;
LUSC	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.71	-11.79	-0.54	4.5e-27	Retinal vascular caliber;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg05621195	chr12:123237031	DENR	0.39	6.04	0.31	4e-9	Triglycerides;
LUSC	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg26384229	chr12:38710491	ALG10B	-0.66	-10.52	-0.5	1.5e-22	Morning vs. evening chronotype;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg03853227	chr12:107487365	CRY1	0.62	5.98	0.31	5.84e-9	Body mass index;
LUSC	cis	rs56283067	0.887	rs10948171	chr6:44761028	C/T	cg18551225	chr6:44695536	NA	-0.48	-7.65	-0.39	2.13e-13	Total body bone mineral density;
LUSC	cis	rs10992471	0.528	rs10761158	chr9:95205322	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.24	-0.32	1.36e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7572644	0.699	rs13411592	chr2:28098724	G/A	cg27432699	chr2:27873401	GPN1	-0.51	-6.94	-0.36	2.04e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg25036284	chr2:26402008	FAM59B	-0.68	-10.03	-0.48	7.02e-21	Gut microbiome composition (summer);
LUSC	cis	rs7119038	0.865	rs11217044	chr11:118696022	T/C	cg19308663	chr11:118741387	NA	0.35	6.18	0.32	1.83e-9	Sjögren's syndrome;
LUSC	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.6	-0.5	8.24e-23	Glomerular filtration rate;
LUSC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg16647868	chr5:131706066	SLC22A5	0.38	5.89	0.31	9.29e-9	Breast cancer;
LUSC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.8	10.13	0.48	3.2e-21	Cognitive function;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24655899	chr17:79519568	C17orf70	-0.4	-6.0	-0.31	5.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6076065	0.723	rs2251145	chr20:23399998	G/A	cg11657817	chr20:23433608	CST11	0.43	7.92	0.4	3.54e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	7.71	0.39	1.41e-13	Menarche (age at onset);
LUSC	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg18209359	chr17:80159595	CCDC57	0.39	6.38	0.33	6.04e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10992471	0.603	rs7868013	chr9:95240173	G/A	cg14631576	chr9:95140430	CENPP	-0.34	-6.17	-0.32	1.97e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12810548	chr4:53579237	SNORA26;KIAA0114	0.44	6.93	0.35	2.14e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7759001	0.857	rs4713092	chr6:27363898	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs977987	0.671	rs9922008	chr16:75335406	T/C	cg04384234	chr16:75411784	CFDP1	-0.41	-6.45	-0.33	3.91e-10	Dupuytren's disease;
LUSC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.17	-0.32	2.03e-9	Menopause (age at onset);
LUSC	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-7.18	-0.37	4.47e-12	Putamen volume;
LUSC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-6.6	-0.34	1.61e-10	Alzheimer's disease (late onset);
LUSC	cis	rs155346	1.000	rs265156	chr5:139386659	C/T	cg01090482	chr5:139365336	NRG2	-0.38	-6.24	-0.32	1.34e-9	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg09436375	chr6:42928200	GNMT	0.28	6.28	0.32	1.08e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg14683138	chr19:10781796	ILF3	-0.63	-6.06	-0.31	3.64e-9	Cognitive performance;
LUSC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg27165867	chr14:105738592	BRF1	-0.55	-8.25	-0.41	3.72e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg23711669	chr6:146136114	FBXO30	0.75	11.93	0.55	1.44e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.23	-39.56	-0.91	4.37e-128	Myeloid white cell count;
LUSC	cis	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.35	-0.42	1.85e-15	Morning vs. evening chronotype;
LUSC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg18681998	chr4:17616180	MED28	0.86	16.36	0.67	1.31e-44	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg05729581	chr11:3078854	CARS	0.42	6.25	0.32	1.28e-9	Calcium levels;
LUSC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	0.92	15.38	0.64	1.02e-40	Breast cancer;
LUSC	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg19875535	chr5:140030758	IK	-0.54	-8.91	-0.44	3.39e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg24631222	chr15:78858424	CHRNA5	0.71	8.95	0.44	2.46e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg04315214	chr1:2043799	PRKCZ	0.47	9.93	0.48	1.51e-20	Height;
LUSC	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	0.88	13.29	0.59	1.19e-32	Blood protein levels;
LUSC	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.61	-0.34	1.52e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1459104	0.641	rs4454742	chr11:54840592	A/T	cg03929089	chr4:120376271	NA	0.74	6.42	0.33	4.54e-10	Body mass index;
LUSC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23158103	chr7:148848205	ZNF398	0.5	8.23	0.41	4.25e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs137603	0.644	rs470082	chr22:39715140	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.5	-8.03	-0.4	1.72e-14	Primary biliary cholangitis;
LUSC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.69	-10.39	-0.49	4.28e-22	Aortic root size;
LUSC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	0.88	15.87	0.66	1.19e-42	Cognitive function;
LUSC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg20891283	chr12:69753455	YEATS4	0.45	6.01	0.31	4.96e-9	Response to diuretic therapy;
LUSC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg06521331	chr12:34319734	NA	-0.52	-8.62	-0.43	2.69e-16	Morning vs. evening chronotype;
LUSC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	22.66	0.78	1.69e-69	Height;
LUSC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg18350739	chr11:68623251	NA	-0.35	-6.15	-0.32	2.18e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6541297	0.699	rs4846915	chr1:230296470	C/A	cg20703242	chr1:230279135	GALNT2	0.5	5.72	0.3	2.33e-8	Coronary artery disease;
LUSC	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg13852791	chr20:30311386	BCL2L1	0.71	8.05	0.4	1.49e-14	Mean corpuscular hemoglobin;
LUSC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg25767906	chr1:53392781	SCP2	-0.52	-9.61	-0.47	1.79e-19	Monocyte count;
LUSC	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.54	0.5	1.25e-22	Morning vs. evening chronotype;
LUSC	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.6	-0.43	3.22e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg18904891	chr8:8559673	CLDN23	0.59	8.15	0.41	7.49e-15	Obesity-related traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01669482	chr16:25043131	NA	0.47	6.58	0.34	1.84e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs12367572	0.965	rs11182706	chr12:45223339	T/C	cg04608330	chr12:45269318	NELL2	-0.54	-8.37	-0.42	1.58e-15	Gut microbiome composition (summer);
LUSC	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.6	13.87	0.6	7.21e-35	Height;
LUSC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg08200582	chr11:442649	ANO9	-0.58	-6.56	-0.34	2e-10	Body mass index;
LUSC	cis	rs9921338	0.961	rs4390613	chr16:11422836	T/C	cg00044050	chr16:11439710	C16orf75	0.47	6.19	0.32	1.78e-9	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs11650494	0.710	rs8066722	chr17:47475007	A/G	cg08112188	chr17:47440006	ZNF652	-0.88	-7.83	-0.39	6.49e-14	Prostate cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05364412	chr19:2136934	AP3D1	0.48	7.22	0.37	3.62e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg00982548	chr2:198649783	BOLL	-0.6	-7.35	-0.37	1.55e-12	Ulcerative colitis;
LUSC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	1.01	14.57	0.62	1.49e-37	Vitiligo;
LUSC	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg21496419	chr19:44306685	LYPD5	0.33	6.51	0.34	2.76e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg15704280	chr7:45808275	SEPT13	-1.13	-24.46	-0.8	2.01e-76	Height;
LUSC	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03878208	chr11:72483293	STARD10	0.59	7.72	0.39	1.37e-13	Type 2 diabetes;
LUSC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg20684491	chr1:25596433	NA	0.39	6.24	0.32	1.32e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs273573	0.925	rs163882	chr11:30947681	C/G	cg06552810	chr11:31128660	NA	0.33	5.73	0.3	2.26e-8	Total body bone mineral density;
LUSC	cis	rs72960926	0.744	rs72954354	chr6:74949552	C/G	cg03266952	chr6:74778945	NA	-0.77	-6.77	-0.35	5.96e-11	Metabolite levels (MHPG);
LUSC	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-1.02	-18.29	-0.71	3e-52	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7712401	0.601	rs246328	chr5:122287628	G/A	cg19077854	chr5:122220652	SNX24	0.44	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.38	-6.14	-0.32	2.34e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11229555	0.645	rs7946522	chr11:58197905	G/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg08219700	chr8:58056026	NA	0.47	6.24	0.32	1.29e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg20135002	chr11:47629003	NA	0.51	7.88	0.4	4.57e-14	Subjective well-being;
LUSC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg05717871	chr11:638507	DRD4	-0.33	-5.84	-0.3	1.26e-8	Systemic lupus erythematosus;
LUSC	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg22437258	chr11:111473054	SIK2	0.51	7.05	0.36	1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6967385	0.934	rs17165850	chr7:12366064	G/C	cg06484146	chr7:12443880	VWDE	0.42	6.15	0.32	2.26e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs9311676	0.618	rs11130639	chr3:58406004	G/T	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.1e-10	Systemic lupus erythematosus;
LUSC	cis	rs2652834	0.851	rs4238372	chr15:63351488	G/A	cg05507819	chr15:63340323	TPM1	0.69	8.66	0.43	2.05e-16	HDL cholesterol;
LUSC	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg17173187	chr15:85201210	NMB	0.37	6.53	0.34	2.41e-10	Schizophrenia;
LUSC	cis	rs7923609	0.936	rs10761778	chr10:65273782	A/G	cg01631684	chr10:65280961	REEP3	-0.42	-6.43	-0.33	4.38e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg09526685	chr4:187126073	CYP4V2	0.55	5.92	0.31	7.86e-9	Blood protein levels;
LUSC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg03146154	chr1:46216737	IPP	0.51	7.62	0.38	2.61e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg26695010	chr11:65641043	EFEMP2	-0.45	-6.57	-0.34	1.91e-10	Eosinophil percentage of white cells;
LUSC	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg00495681	chr13:53174319	NA	0.52	7.58	0.38	3.43e-13	Lewy body disease;
LUSC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.27	0.45	2.43e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	8.02	0.4	1.86e-14	Bipolar disorder;
LUSC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00149659	chr3:10157352	C3orf10	0.95	13.69	0.6	3.67e-34	Alzheimer's disease;
LUSC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.12	0.41	9.16e-15	Prudent dietary pattern;
LUSC	cis	rs2637266	1.000	rs1907305	chr10:78339512	C/G	cg18941641	chr10:78392320	NA	0.36	6.51	0.34	2.69e-10	Pulmonary function;
LUSC	cis	rs36051895	0.589	rs7874785	chr9:5196695	C/T	cg02405213	chr9:5042618	JAK2	0.5	7.33	0.37	1.77e-12	Pediatric autoimmune diseases;
LUSC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.67	9.56	0.46	2.68e-19	Methadone dose in opioid dependence;
LUSC	cis	rs2191566	1.000	rs10418363	chr19:44525463	A/G	cg03039196	chr19:44506973	ZNF230	0.36	5.83	0.3	1.29e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs12928939	0.815	rs34731378	chr16:71745748	C/T	cg08717414	chr16:71523259	ZNF19	-0.42	-5.93	-0.31	7.68e-9	Post bronchodilator FEV1;
LUSC	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	1.05	12.98	0.58	1.79e-31	Sexual dysfunction (female);
LUSC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.64	0.47	1.44e-19	Personality dimensions;
LUSC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18099408	chr3:52552593	STAB1	-0.4	-6.85	-0.35	3.62e-11	Bipolar disorder;
LUSC	trans	rs2048656	0.570	rs7814635	chr8:9646620	G/A	cg08975724	chr8:8085496	FLJ10661	0.43	5.97	0.31	5.96e-9	Schizophrenia;
LUSC	trans	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	0.96	11.89	0.55	1.93e-27	Menarche (age at onset);
LUSC	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-7.82	-0.39	6.78e-14	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4499344	0.730	rs28402742	chr19:33099734	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-16.39	-0.67	1.03e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg06145435	chr7:1022769	CYP2W1	0.33	7.2	0.37	4.07e-12	Longevity;Endometriosis;
LUSC	cis	rs7590368	1.000	rs17456225	chr2:10963238	C/G	cg15705551	chr2:10952987	PDIA6	0.57	7.8	0.39	8.2e-14	Educational attainment (years of education);
LUSC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg26304593	chr6:42947056	PEX6	-0.53	-8.31	-0.41	2.44e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4363385	0.553	rs61813181	chr1:152942177	T/C	cg25856811	chr1:152973957	SPRR3	-0.35	-5.77	-0.3	1.77e-8	Inflammatory skin disease;
LUSC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg13206674	chr6:150067644	NUP43	-0.59	-9.25	-0.45	2.79e-18	Lung cancer;
LUSC	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg14343924	chr8:8086146	FLJ10661	0.43	5.77	0.3	1.77e-8	Neuroticism;
LUSC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	0.93	16.0	0.66	3.59e-43	Menopause (age at onset);
LUSC	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.12e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-1.04	-20.3	-0.74	2.97e-60	Height;
LUSC	trans	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17712092	chr4:129076599	LARP1B	0.74	11.11	0.52	1.25e-24	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs4594175	0.926	rs7160948	chr14:51612537	T/A	cg23942311	chr14:51606299	NA	0.3	5.79	0.3	1.6e-8	Cancer;
LUSC	cis	rs6977660	1.000	rs6955510	chr7:19821333	G/C	cg05791153	chr7:19748676	TWISTNB	0.53	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LUSC	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	7.23	0.37	3.42e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg21951975	chr1:209979733	IRF6	0.42	6.97	0.36	1.67e-11	Monobrow;
LUSC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg23711669	chr6:146136114	FBXO30	-0.86	-15.9	-0.66	8.91e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg03465714	chr1:152285911	FLG	-0.41	-5.74	-0.3	2.09e-8	Atopic dermatitis;
LUSC	cis	rs6542838	0.646	rs2008648	chr2:99408323	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-6.37	-0.33	6.22e-10	Fear of minor pain;
LUSC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.38	6.04	0.31	4.07e-9	Electroencephalogram traits;
LUSC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg15445000	chr17:37608096	MED1	0.4	6.77	0.35	5.76e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs12651329	1.000	rs12651329	chr4:36079594	A/G	cg11770404	chr20:60962048	RPS21	-0.36	-5.94	-0.31	7.02e-9	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs6577655	0.561	rs6577654	chr8:135593610	G/A	cg17885191	chr8:135476712	NA	0.59	7.4	0.38	1.09e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.73	9.35	0.46	1.33e-18	IgE levels in asthmatics (D.p. specific);
LUSC	trans	rs911555	0.504	rs4906340	chr14:104076645	G/A	cg03785828	chr5:81573306	RPS23	0.43	6.99	0.36	1.53e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15362955	chr3:187463294	BCL6	-0.46	-6.98	-0.36	1.61e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs1350666	0.608	rs1017735	chr4:75253136	G/T	cg12453539	chr20:6033866	LRRN4	-0.28	-5.99	-0.31	5.38e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg20503657	chr10:835505	NA	1.19	15.42	0.64	7.03e-41	Eosinophil percentage of granulocytes;
LUSC	cis	rs30380	0.632	rs26495	chr5:96137840	A/G	cg16492584	chr5:96139282	ERAP1	-0.57	-7.71	-0.39	1.5e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg14092571	chr14:90743983	NA	-0.35	-5.83	-0.3	1.29e-8	Mortality in heart failure;
LUSC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-8.44	-0.42	1e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03934478	chr11:495069	RNH1	0.85	9.73	0.47	7.4e-20	Body mass index;
LUSC	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.88	-0.44	4.24e-17	Response to antipsychotic treatment;
LUSC	cis	rs506338	0.517	rs1207179	chr11:64450795	C/T	cg19131476	chr11:64387923	NRXN2	0.36	7.9	0.4	4.15e-14	Body mass index;Urate levels;
LUSC	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.34	5.64	0.3	3.54e-8	Hematocrit;
LUSC	cis	rs886126	0.650	rs4766566	chr12:111706877	C/T	cg10833066	chr12:111807467	FAM109A	0.49	8.32	0.41	2.3e-15	Coronary heart disease;
LUSC	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg05340658	chr4:99064831	C4orf37	0.57	9.22	0.45	3.46e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg15649852	chr7:65879115	NA	-0.41	-5.78	-0.3	1.74e-8	Aortic root size;
LUSC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6967385	0.538	rs10275154	chr7:12355002	T/C	cg20607287	chr7:12443886	VWDE	0.5	7.52	0.38	5.06e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.9	15.66	0.65	7.56e-42	Bladder cancer;
LUSC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg03351412	chr1:154909251	PMVK	0.52	8.08	0.4	1.18e-14	Prostate cancer;
LUSC	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg07895657	chr22:50616420	PANX2	0.34	5.91	0.31	8.52e-9	Obesity-related traits;
LUSC	cis	rs4919087	1.000	rs10786330	chr10:99074959	C/A	cg25902810	chr10:99078978	FRAT1	0.5	7.33	0.37	1.8e-12	Monocyte count;
LUSC	cis	rs4285028	0.699	rs4676758	chr3:121583415	T/C	cg11130432	chr3:121712080	ILDR1	0.63	9.66	0.47	1.28e-19	Multiple sclerosis;
LUSC	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg05527609	chr1:210001259	C1orf107	0.67	9.63	0.47	1.5700000000000001e-19	Orofacial clefts;
LUSC	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.4	-0.33	5.19e-10	Mood instability;
LUSC	cis	rs3125734	0.633	rs4561099	chr10:64041163	T/C	cg19640130	chr10:64028056	RTKN2	-0.39	-6.84	-0.35	3.69e-11	Rheumatoid arthritis;
LUSC	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg05163923	chr11:71159392	DHCR7	0.74	11.07	0.52	1.79e-24	Vitamin D levels;
LUSC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.59	0.38	3.26e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs7000551	0.638	rs2469771	chr8:22376627	T/C	cg12081754	chr8:22256438	SLC39A14	0.45	6.72	0.35	7.95e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg26043149	chr18:55253948	FECH	-0.46	-7.11	-0.36	7.3e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9658691	0.607	rs9658786	chr10:90776349	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.58	5.92	0.31	8.13e-9	Mosquito bite size;
LUSC	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg13010199	chr12:38710504	ALG10B	-0.53	-8.07	-0.4	1.3e-14	Morning vs. evening chronotype;
LUSC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05165339	chr4:1420672	NA	-0.29	-6.86	-0.35	3.31e-11	Longevity;
LUSC	cis	rs12989701	1.000	rs6710467	chr2:127889932	C/T	cg08168897	chr2:127865431	BIN1	0.62	8.1	0.41	1.01e-14	Alzheimer's disease (late onset);
LUSC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg05347473	chr6:146136440	FBXO30	0.57	9.99	0.48	9.56e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg23711669	chr6:146136114	FBXO30	0.8	14.44	0.62	4.65e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7523050	0.643	rs7519293	chr1:109399543	A/G	cg08274380	chr1:109419600	GPSM2	1.1	10.69	0.51	3.76e-23	Fat distribution (HIV);
LUSC	trans	rs8029989	1.000	rs8029989	chr15:38733847	A/G	cg26796815	chr5:134094372	DDX46	-0.42	-6.02	-0.31	4.51e-9	Psychosis (atypical);
LUSC	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	9.7	0.47	9.12e-20	Bone mineral density;
LUSC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.62	-8.35	-0.42	1.84e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg13047869	chr3:10149882	C3orf24	0.42	6.22	0.32	1.48e-9	Alzheimer's disease;
LUSC	cis	rs1775715	0.707	rs2808087	chr10:32146444	C/G	cg26784012	chr10:32216390	ARHGAP12	0.46	7.9	0.4	3.96e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14193481	chr6:105850839	PREP	-0.43	-6.39	-0.33	5.42e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg13685833	chr1:53393034	SCP2	-0.37	-5.81	-0.3	1.43e-8	Monocyte count;
LUSC	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg15744005	chr10:104629667	AS3MT	-0.32	-6.3	-0.33	9.55e-10	Arsenic metabolism;
LUSC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	1.03	15.27	0.64	2.63e-40	Primary sclerosing cholangitis;
LUSC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6982240	0.514	rs11785274	chr8:142261541	G/A	cg27411547	chr8:142287226	NA	-0.47	-8.05	-0.4	1.45e-14	Tonsillectomy;
LUSC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19346786	chr7:2764209	NA	-0.42	-7.36	-0.37	1.48e-12	Height;
LUSC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.17	0.41	6.44e-15	Prudent dietary pattern;
LUSC	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.16	0.49	2.55e-21	Lymphocyte counts;
LUSC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	0.96	12.87	0.58	4.67e-31	Eosinophil percentage of granulocytes;
LUSC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.09	0.32	3.1e-9	Personality dimensions;
LUSC	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg05555928	chr11:63887634	MACROD1	-0.48	-6.09	-0.32	3.08e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.82	-0.43	6.56e-17	Bipolar disorder;
LUSC	cis	rs2153904	0.793	rs71633563	chr1:205735854	C/T	cg23034840	chr1:205782522	SLC41A1	-0.65	-6.87	-0.35	3.22e-11	Prostate-specific antigen levels;
LUSC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	6.8	0.35	4.78e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg11062466	chr8:58055876	NA	0.53	6.97	0.36	1.72e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.94	-0.36	2.09e-11	Systemic lupus erythematosus;
LUSC	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.8	-12.92	-0.58	3.06e-31	Schizophrenia;
LUSC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.69	0.54	1.11e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9549260	0.755	rs2701863	chr13:41170140	C/T	cg21288729	chr13:41239152	FOXO1	0.59	8.84	0.44	5.79e-17	Red blood cell count;
LUSC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg06637938	chr14:75390232	RPS6KL1	0.57	9.43	0.46	7.26e-19	Coronary artery disease;
LUSC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg05802129	chr4:122689817	NA	-0.37	-6.56	-0.34	2.06e-10	Type 2 diabetes;
LUSC	cis	rs7582720	0.945	rs72934601	chr2:204031137	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.47	0.42	8.07e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg25251562	chr2:3704773	ALLC	-0.52	-7.87	-0.4	4.86e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg21770322	chr7:97807741	LMTK2	0.56	9.85	0.47	2.85e-20	Breast cancer;
LUSC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg12615879	chr12:58013172	SLC26A10	-0.27	-5.77	-0.3	1.78e-8	Multiple sclerosis;
LUSC	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08109568	chr15:31115862	NA	-0.57	-7.53	-0.38	4.71e-13	Huntington's disease progression;
LUSC	trans	rs629535	0.814	rs62513381	chr8:70110991	T/C	cg21567404	chr3:27674614	NA	-0.98	-15.88	-0.66	1.02e-42	Dupuytren's disease;
LUSC	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.53	-0.42	5.25e-16	Total cholesterol levels;
LUSC	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg11845111	chr2:191398756	TMEM194B	-0.9	-11.5	-0.53	5.27e-26	Diastolic blood pressure;
LUSC	trans	rs6834483	1.000	rs1655083	chr4:35975257	A/G	cg26559689	chr6:4905329	CDYL	0.69	5.95	0.31	6.76e-9	Obesity-related traits;
LUSC	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg00857998	chr1:205179979	DSTYK	0.63	9.74	0.47	6.69e-20	Red blood cell count;
LUSC	cis	rs6977660	0.891	rs10226962	chr7:19819464	T/C	cg05791153	chr7:19748676	TWISTNB	0.55	6.11	0.32	2.81e-9	Thyroid stimulating hormone;
LUSC	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.66	0.3	3.22e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.57	10.0	0.48	8.88e-21	Birth weight;
LUSC	cis	rs59698941	0.943	rs12515752	chr5:132312960	C/G	cg14825688	chr5:132208181	LEAP2	-0.54	-5.77	-0.3	1.77e-8	Apolipoprotein A-IV levels;
LUSC	trans	rs4083578	0.732	rs9572894	chr13:72702312	C/T	cg14305763	chr2:28114016	BRE;RBKS;LOC100302650	0.43	6.08	0.32	3.2e-9	Cognitive performance;
LUSC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg03146154	chr1:46216737	IPP	0.51	7.5	0.38	5.68e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7605827	0.930	rs4668925	chr2:15703576	C/T	cg19274914	chr2:15703543	NA	0.47	9.09	0.45	8.76e-18	Educational attainment (years of education);
LUSC	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	6.75	0.35	6.39e-11	Coronary artery disease;
LUSC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19346786	chr7:2764209	NA	-0.43	-7.41	-0.38	1.07e-12	Height;
LUSC	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.71	0.39	1.46e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs17767294	0.708	rs72848752	chr6:27878268	A/C	cg08851530	chr6:28072375	NA	1.24	8.4	0.42	1.32e-15	Parkinson's disease;
LUSC	trans	rs7838490	0.780	rs35642681	chr8:89685209	A/G	cg24558378	chr1:183589673	NA	0.34	6.25	0.32	1.28e-9	Body mass index and cholesterol (psychopharmacological treatment);
LUSC	cis	rs2979489	0.945	rs2979472	chr8:30291704	G/C	cg26383811	chr8:30366931	RBPMS	0.48	7.36	0.37	1.46e-12	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-17.87	-0.7	1.36e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.52	-0.38	5.21e-13	Type 2 diabetes;
LUSC	cis	rs6977940	0.643	rs73033417	chr7:2882855	C/G	cg19731401	chr7:2775893	GNA12	0.7	7.68	0.39	1.78e-13	White matter integrity;
LUSC	cis	rs9818941	1.000	rs4507209	chr3:157710946	T/A	cg08654915	chr3:157813417	NA	-0.25	-6.21	-0.32	1.57e-9	Height;
LUSC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg07507251	chr3:52567010	NT5DC2	0.34	6.67	0.34	1.06e-10	Bipolar disorder;
LUSC	trans	rs2262909	0.962	rs11667209	chr19:22259467	A/G	cg05197062	chr11:11642011	GALNTL4	0.56	7.88	0.4	4.75e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08280861	chr8:58055591	NA	0.52	6.81	0.35	4.68e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg26441486	chr22:50317300	CRELD2	0.53	7.93	0.4	3.43e-14	Schizophrenia;
LUSC	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg07810366	chr2:100720526	AFF3	-0.51	-8.81	-0.43	6.75e-17	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7189233	0.956	rs62048478	chr16:53429180	C/T	cg09728985	chr16:53543985	NA	-0.32	-5.73	-0.3	2.22e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4654899	0.865	rs6426674	chr1:21483906	C/T	cg01072550	chr1:21505969	NA	-0.49	-7.36	-0.37	1.47e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.44	-0.38	8.81e-13	Height;
LUSC	cis	rs2637266	1.000	rs34483246	chr10:78342790	G/A	cg18941641	chr10:78392320	NA	0.4	7.41	0.38	1.04e-12	Pulmonary function;
LUSC	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg09479241	chr17:27052676	TLCD1	0.43	5.82	0.3	1.35e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg25019033	chr10:957182	NA	-0.51	-6.35	-0.33	7.22e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs12249377	0.519	rs12259401	chr10:92594121	T/G	cg14313238	chr10:92632228	RPP30	0.43	5.79	0.3	1.64e-8	White matter microstructure (global fractional anisotropy);
LUSC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg24829409	chr8:58192753	C8orf71	-0.57	-7.24	-0.37	3.11e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.06	-0.36	9.65e-12	Alzheimer's disease (late onset);
LUSC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.4	-0.33	5.22e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	13.19	0.59	2.77e-32	Lung cancer in ever smokers;
LUSC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.75	-13.52	-0.59	1.64e-33	Corneal structure;
LUSC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.55	-0.53	3.31e-26	Mean corpuscular volume;
LUSC	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.01	0.31	4.84e-9	Retinal vascular caliber;
LUSC	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg09904177	chr6:26538194	HMGN4	0.49	7.85	0.39	5.6e-14	Schizophrenia;
LUSC	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	15.44	0.65	5.93e-41	Lung cancer in ever smokers;
LUSC	cis	rs11039100	0.681	rs11039120	chr11:5833096	A/G	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.99	-0.36	1.53e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg23630131	chr7:65973040	NA	-0.21	-6.01	-0.31	4.93e-9	Aortic root size;
LUSC	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg17830980	chr10:43048298	ZNF37B	-0.43	-6.73	-0.35	7.2e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg15744005	chr10:104629667	AS3MT	-0.35	-7.44	-0.38	8.33e-13	Immature fraction of reticulocytes;Schizophrenia;
LUSC	trans	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.25	-0.41	3.73e-15	Ulcerative colitis;
LUSC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.79	11.32	0.53	2.24e-25	Multiple sclerosis;
LUSC	cis	rs7945705	0.875	rs10769955	chr11:8784647	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.57	11.25	0.52	4.21e-25	Hemoglobin concentration;
LUSC	cis	rs9296092	0.538	rs62407566	chr6:33535786	C/T	cg13560919	chr6:33536144	NA	-0.88	-15.98	-0.66	4.2e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg26380479	chr7:97908229	NA	-0.26	-5.94	-0.31	7.3e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7833787	1.000	rs6993404	chr8:18705723	C/T	cg17701159	chr8:18705777	PSD3	0.38	6.14	0.32	2.28e-9	Obesity-related traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13904199	chr9:86594091	HNRNPK	0.44	6.01	0.31	4.88e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg11494091	chr17:61959527	GH2	0.36	6.04	0.31	4.21e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.09	-17.41	-0.69	9.58e-49	Primary sclerosing cholangitis;
LUSC	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.86	-0.4	5.34e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg00343986	chr7:65444356	GUSB	0.48	7.13	0.36	6.14e-12	Aortic root size;
LUSC	cis	rs4642101	0.561	rs7638333	chr3:12806142	T/C	cg24848339	chr3:12840334	CAND2	0.32	6.35	0.33	6.95e-10	QRS complex (12-leadsum);
LUSC	cis	rs858239	0.601	rs10278776	chr7:23169759	C/T	cg23682824	chr7:23144976	KLHL7	0.41	5.94	0.31	7.13e-9	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg18758796	chr5:131593413	PDLIM4	0.39	6.63	0.34	1.39e-10	Breast cancer;
LUSC	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg04362960	chr10:104952993	NT5C2	0.55	7.94	0.4	3.08e-14	Arsenic metabolism;
LUSC	trans	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.57e-15	Diabetic kidney disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26159030	chr19:36214806	MLL4	-0.73	-5.97	-0.31	6.06e-9	Cognitive performance;
LUSC	cis	rs17540621	1.000	rs115394889	chr2:47250076	A/T	cg23978866	chr2:47230407	TTC7A	-0.88	-6.22	-0.32	1.45e-9	Response to statin therapy;
LUSC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg09034736	chr1:150693464	HORMAD1	0.43	5.95	0.31	6.8e-9	Melanoma;
LUSC	cis	rs34638657	0.656	rs2911429	chr16:82203443	T/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-5.97	-0.31	6.18e-9	Lung adenocarcinoma;
LUSC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg03188948	chr7:1209495	NA	0.66	6.91	0.35	2.44e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg18402987	chr7:1209562	NA	0.71	7.85	0.39	5.89e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	0.47	8.07	0.4	1.26e-14	Lymphocyte counts;
LUSC	cis	rs4654899	1.000	rs6681064	chr1:21339644	A/G	cg01072550	chr1:21505969	NA	-0.53	-8.1	-0.41	1.02e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg23205692	chr1:25664452	TMEM50A	0.38	5.69	0.3	2.85e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg17330251	chr7:94953956	PON1	-0.37	-5.99	-0.31	5.57e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs600231	0.508	rs17146964	chr11:65249145	C/T	cg17120908	chr11:65337727	SSSCA1	0.6	8.82	0.43	6.48e-17	Bone mineral density;
LUSC	cis	rs722599	0.748	rs929579	chr14:75330697	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.43	-6.34	-0.33	7.64e-10	IgG glycosylation;
LUSC	cis	rs4363385	0.818	rs2070964	chr1:153004213	C/T	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.34	-0.37	1.64e-12	Inflammatory skin disease;
LUSC	cis	rs6987853	0.563	rs2974301	chr8:42442238	A/G	cg09913449	chr8:42400586	C8orf40	0.4	6.67	0.34	1.05e-10	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.42	6.43	0.33	4.48e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg15145296	chr3:125709740	NA	-0.55	-6.6	-0.34	1.66e-10	Blood pressure (smoking interaction);
LUSC	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.68	11.91	0.55	1.76e-27	Endometriosis;
LUSC	trans	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg21775007	chr8:11205619	TDH	-0.43	-6.01	-0.31	4.74e-9	Mood instability;
LUSC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.44	-7.25	-0.37	2.98e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs4474465	0.920	rs7947852	chr11:78198030	T/C	cg27205649	chr11:78285834	NARS2	-0.53	-6.19	-0.32	1.8e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg02023728	chr11:77925099	USP35	0.52	7.26	0.37	2.76e-12	Testicular germ cell tumor;
LUSC	cis	rs10823500	0.604	rs10762345	chr10:71939374	A/G	cg02100629	chr10:71892760	AIFM2	-0.39	-6.84	-0.35	3.85e-11	Blood protein levels;
LUSC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	14.15	0.61	6.21e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg16423285	chr20:60520624	NA	-0.45	-5.71	-0.3	2.48e-8	Body mass index;
LUSC	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg24692254	chr21:30365293	RNF160	-0.69	-10.55	-0.5	1.23e-22	Pancreatic cancer;
LUSC	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.85	-0.68	1.53e-46	Exhaled nitric oxide output;
LUSC	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg24531977	chr5:56204891	C5orf35	-0.6	-8.73	-0.43	1.22e-16	Coronary artery disease;
LUSC	trans	rs1015213	0.609	rs117144627	chr8:52823157	A/C	cg26618441	chr5:140213825	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA5;PCDHA3;PCDHA4	-0.87	-6.09	-0.32	3.14e-9	Glaucoma (primary angle closure);
LUSC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg25894440	chr7:65020034	NA	0.37	5.72	0.3	2.37e-8	Calcium levels;
LUSC	cis	rs1395	0.778	rs56364136	chr2:27451429	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.38	6.34	0.33	7.53e-10	Blood metabolite levels;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg12350185	chr22:32150051	DEPDC5	0.46	6.25	0.32	1.22e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg05738196	chr6:26577821	NA	0.82	15.85	0.66	1.46e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs2274459	1.000	rs729376	chr6:33704823	C/T	cg06253072	chr6:33679850	C6orf125	0.52	5.98	0.31	5.85e-9	Obesity (extreme);
LUSC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg19468946	chr17:37922297	IKZF3	-0.43	-6.8	-0.35	4.72e-11	Self-reported allergy;
LUSC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.51	-11.17	-0.52	8.18e-25	Type 2 diabetes;
LUSC	cis	rs11051970	0.611	rs56146365	chr12:32529634	A/G	cg02745156	chr12:32552066	NA	0.39	6.95	0.36	1.94e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg27275811	chr11:74457193	NA	-0.64	-6.22	-0.32	1.51e-9	Type 2 diabetes nephropathy;
LUSC	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg00852783	chr1:26633632	UBXN11	-0.51	-6.06	-0.31	3.72e-9	Obesity-related traits;
LUSC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg14829155	chr15:31115871	NA	0.47	6.55	0.34	2.11e-10	Huntington's disease progression;
LUSC	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg15704280	chr7:45808275	SEPT13	0.77	7.43	0.38	9.41e-13	Axial length;
LUSC	cis	rs6725041	0.547	rs6753945	chr2:213204574	T/C	cg16329650	chr2:213403929	ERBB4	-0.42	-6.67	-0.34	1.09e-10	QT interval (ambient particulate matter interaction);
LUSC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg14668632	chr7:2872130	GNA12	-0.45	-6.61	-0.34	1.49e-10	Height;
LUSC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg02772935	chr3:125709198	NA	-0.48	-5.84	-0.3	1.23e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg07395648	chr5:131743802	NA	0.37	5.8	0.3	1.52e-8	Asthma (sex interaction);
LUSC	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg15133208	chr4:90757351	SNCA	-0.55	-8.63	-0.43	2.6e-16	Neuroticism;
LUSC	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	1.04	16.65	0.67	9.21e-46	Corneal structure;
LUSC	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.16	-0.45	5.38e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6426558	0.502	rs2813965	chr1:227445733	A/G	cg10327440	chr1:227177885	CDC42BPA	0.56	7.54	0.38	4.46e-13	Neutrophil percentage of white cells;
LUSC	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.22e-13	Corneal astigmatism;
LUSC	cis	rs10186029	0.509	rs6435755	chr2:213941131	C/T	cg08319019	chr2:214017104	IKZF2	-0.41	-5.99	-0.31	5.48e-9	Systemic sclerosis;
LUSC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg06637938	chr14:75390232	RPS6KL1	0.51	8.05	0.4	1.48e-14	Height;
LUSC	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21643547	chr1:205240462	TMCC2	-0.49	-9.3	-0.45	1.88e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	6.01	0.31	4.84e-9	Neuroticism;
LUSC	cis	rs17092148	0.945	rs17092080	chr20:33335657	A/G	cg16810054	chr20:33298113	TP53INP2	-0.41	-6.42	-0.33	4.77e-10	Neuroticism;
LUSC	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg20587970	chr11:113659929	NA	-0.75	-9.75	-0.47	6.09e-20	Hip circumference adjusted for BMI;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11172286	chr11:47600544	KBTBD4;NDUFS3	0.39	6.03	0.31	4.45e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7216064	1.000	rs7209675	chr17:65831258	A/T	cg12091567	chr17:66097778	LOC651250	-0.73	-9.11	-0.45	7.71e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	trans	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.48	-6.92	-0.35	2.28e-11	Monocyte count;
LUSC	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg23625390	chr15:77176239	SCAPER	-0.61	-8.63	-0.43	2.59e-16	Blood metabolite levels;
LUSC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06850241	chr22:41845214	NA	0.34	6.33	0.33	7.95e-10	Vitiligo;
LUSC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg23711669	chr6:146136114	FBXO30	0.72	12.67	0.57	2.53e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg01579765	chr21:45077557	HSF2BP	0.48	9.69	0.47	9.92e-20	Mean corpuscular volume;
LUSC	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg15485101	chr11:133734466	NA	0.37	7.06	0.36	9.8e-12	Childhood ear infection;
LUSC	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.35	-0.33	7.06e-10	Systolic blood pressure;
LUSC	cis	rs7712401	0.755	rs10900759	chr5:122105080	T/A	cg19077854	chr5:122220652	SNX24	0.31	6.78	0.35	5.48e-11	Mean platelet volume;
LUSC	cis	rs806215	1.000	rs712703	chr7:127257498	C/T	cg25922125	chr7:127225783	GCC1	-0.57	-7.29	-0.37	2.23e-12	Type 2 diabetes;
LUSC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg04851639	chr8:1020857	NA	0.37	7.62	0.38	2.69e-13	Schizophrenia;
LUSC	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.8	12.92	0.58	2.91e-31	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.19	15.39	0.64	8.99e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10762132	chr2:113403533	SLC20A1	-0.43	-6.79	-0.35	5.19e-11	Electrocardiographic conduction measures;
LUSC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26314531	chr2:26401878	FAM59B	-0.73	-10.17	-0.49	2.34e-21	Gut microbiome composition (summer);
LUSC	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.99	0.31	5.45e-9	Schizophrenia;
LUSC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-10.19	-0.49	2.08e-21	Bipolar disorder;
LUSC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg04450456	chr4:17643702	FAM184B	0.38	6.46	0.33	3.77e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6545883	0.931	rs778768	chr2:61790289	C/G	cg15711740	chr2:61764176	XPO1	-0.5	-8.01	-0.4	1.93e-14	Tuberculosis;
LUSC	cis	rs11645898	0.687	rs6499558	chr16:72102813	G/C	cg14768367	chr16:72042858	DHODH	-0.53	-6.27	-0.32	1.14e-9	Blood protein levels;
LUSC	cis	rs7681440	0.715	rs17016305	chr4:90791381	A/G	cg20003494	chr4:90757398	SNCA	-0.37	-6.08	-0.32	3.35e-9	Dementia with Lewy bodies;
LUSC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.76	-0.35	6.16e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04230589	chr11:61735144	FTH1	-0.45	-6.85	-0.35	3.59e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg06815965	chr1:205818668	PM20D1	0.39	6.08	0.32	3.28e-9	Menarche (age at onset);
LUSC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg13319975	chr6:146136371	FBXO30	0.51	7.62	0.39	2.57e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg11764359	chr7:65958608	NA	-0.5	-6.26	-0.32	1.19e-9	Aortic root size;
LUSC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	1.04	20.81	0.75	2.95e-62	Cognitive function;
LUSC	cis	rs9925964	0.591	rs11649653	chr16:30918487	C/G	cg02466173	chr16:30829666	NA	0.37	6.79	0.35	5.07e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	trans	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg25214090	chr10:38739885	LOC399744	0.41	6.32	0.33	8.21e-10	Corneal astigmatism;
LUSC	trans	rs587847	0.507	rs1379348	chr15:37809303	A/G	cg18296784	chr11:116147929	NA	-0.35	-6.64	-0.34	1.28e-10	Intraocular pressure;
LUSC	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg06532163	chr17:45867833	NA	0.34	6.41	0.33	4.93e-10	IgG glycosylation;
LUSC	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-8.27	-0.41	3.2e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg01073479	chr16:3509474	NAT15	0.4	5.76	0.3	1.88e-8	Tuberculosis;
LUSC	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg18196295	chr10:418757	DIP2C	0.49	8.12	0.41	8.96e-15	Psychosis in Alzheimer's disease;
LUSC	cis	rs10823500	0.604	rs10740329	chr10:71941253	A/T	cg02100629	chr10:71892760	AIFM2	0.38	6.44	0.33	4.17e-10	Blood protein levels;
LUSC	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.34	-7.3	-0.37	2.16e-12	Dupuytren's disease;
LUSC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22496380	chr5:211416	CCDC127	-0.79	-9.1	-0.45	8.39e-18	Breast cancer;
LUSC	cis	rs12220238	1.000	rs11000902	chr10:75920483	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	6.94	0.35	2.07e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs68092024	0.704	rs704576	chr3:99487154	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-6.14	-0.32	2.31e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.21	-0.52	5.73e-25	Mean corpuscular volume;
LUSC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.72	12.12	0.55	2.79e-28	Motion sickness;
LUSC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.58	-0.38	3.4e-13	Caffeine consumption;
LUSC	cis	rs6939532	0.522	rs2073528	chr6:26375143	G/C	cg09904177	chr6:26538194	HMGN4	-0.45	-6.42	-0.33	4.73e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7572733	0.555	rs2341778	chr2:198776546	G/A	cg00792783	chr2:198669748	PLCL1	-0.45	-6.03	-0.31	4.26e-9	Dermatomyositis;
LUSC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg19774624	chr17:42201019	HDAC5	-0.81	-13.53	-0.6	1.46e-33	Total body bone mineral density;
LUSC	cis	rs6960043	0.846	rs7781710	chr7:15056045	T/A	cg19272540	chr7:15055459	NA	0.33	8.04	0.4	1.57e-14	Type 2 diabetes;
LUSC	cis	rs7084402	1.000	rs1346301	chr10:60267310	G/A	cg07615347	chr10:60278583	BICC1	-0.36	-5.85	-0.3	1.18e-8	Refractive error;
LUSC	cis	rs8051149	0.688	rs12444533	chr16:87869711	C/T	cg01412419	chr16:87856264	NA	0.47	7.35	0.37	1.55e-12	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.82e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.06	0.58	8.72e-32	Cognitive test performance;
LUSC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	1.17	13.76	0.6	2.02e-34	Arsenic metabolism;
LUSC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg05234568	chr11:5960015	NA	-0.56	-8.99	-0.44	1.82e-17	DNA methylation (variation);
LUSC	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	6.39	0.33	5.53e-10	Rheumatoid arthritis;
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.93	19.27	0.73	3.8e-56	Menarche (age at onset);
LUSC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.67	-0.39	1.91e-13	Mood instability;
LUSC	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg24851651	chr11:66362959	CCS	0.55	9.98	0.48	1.07e-20	HIV-1 susceptibility;
LUSC	trans	rs72674100	1.000	rs72882317	chr4:97991290	C/G	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg27572855	chr1:25598939	RHD	-0.41	-7.29	-0.37	2.26e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.66	-11.9	-0.55	1.84e-27	Birth weight;
LUSC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg04369109	chr6:150039330	LATS1	-0.57	-8.34	-0.42	1.91e-15	Lung cancer;
LUSC	cis	rs7192380	0.639	rs7186296	chr16:69808998	A/G	cg00738113	chr16:70207722	CLEC18C	0.32	6.65	0.34	1.19e-10	Sjögren's syndrome;
LUSC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-0.83	-14.19	-0.61	4.23e-36	Longevity;
LUSC	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg19767477	chr5:127420684	SLC12A2	0.41	5.75	0.3	1.99e-8	Ileal carcinoids;
LUSC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.47	-8.41	-0.42	1.17e-15	Longevity;Endometriosis;
LUSC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06112835	chr11:68658793	MRPL21	0.51	7.82	0.39	7.13e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2667011	0.759	rs2715931	chr2:160847638	A/C	cg06573604	chr2:160760825	LY75	-0.49	-6.48	-0.33	3.29e-10	Bilirubin levels;
LUSC	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg02655711	chr22:19163373	SLC25A1	0.66	12.03	0.55	6.18e-28	Metabolite levels;
LUSC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg04267008	chr7:1944627	MAD1L1	-0.51	-7.63	-0.39	2.55e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg12560992	chr17:57184187	TRIM37	-0.89	-17.46	-0.69	6.05e-49	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg08499158	chr17:42289980	UBTF	-0.48	-8.26	-0.41	3.46e-15	Total body bone mineral density;
LUSC	cis	rs6480314	0.831	rs6480318	chr10:69984105	T/C	cg06988349	chr10:69991859	ATOH7	0.34	5.67	0.3	3.02e-8	Optic nerve measurement (disc area);
LUSC	cis	rs6693567	0.565	rs35784258	chr1:150405882	T/C	cg15654264	chr1:150340011	RPRD2	0.44	7.09	0.36	8.16e-12	Migraine;
LUSC	cis	rs9937943	0.667	rs35253850	chr16:74599103	T/C	cg01733217	chr16:74700730	RFWD3	0.62	7.21	0.37	3.74e-12	Neutrophil percentage of white cells;
LUSC	cis	rs4843185	0.576	rs381624	chr16:85728679	G/A	cg26571870	chr16:85723150	GINS2	-0.35	-6.51	-0.34	2.68e-10	Platelet distribution width;
LUSC	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg13010199	chr12:38710504	ALG10B	0.69	11.81	0.54	3.94e-27	Heart rate;
LUSC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg19346786	chr7:2764209	NA	0.36	6.3	0.33	9.64e-10	Height;
LUSC	cis	rs4481887	0.676	rs7520659	chr1:248527586	C/A	cg26353448	chr1:248524236	OR2T4	-0.31	-6.06	-0.31	3.63e-9	Common traits (Other);
LUSC	trans	rs17261688	0.556	rs6843218	chr4:160997303	T/G	cg06105778	chr5:176830667	F12	-0.53	-6.04	-0.31	4.21e-9	DNA methylation (variation);
LUSC	cis	rs9318086	0.753	rs9553094	chr13:24474613	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.39	-5.96	-0.31	6.5e-9	Myopia (pathological);
LUSC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg26924012	chr15:45694286	SPATA5L1	1.12	19.82	0.74	2.37e-58	Homoarginine levels;
LUSC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-6.8	-0.35	4.8e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.54	8.81	0.43	6.9e-17	Age at first birth;
LUSC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	0.95	12.63	0.57	3.77e-30	Eosinophil percentage of granulocytes;
LUSC	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg04586622	chr2:25135609	ADCY3	0.32	6.18	0.32	1.92e-9	Body mass index;
LUSC	cis	rs9473147	0.516	rs9367284	chr6:47516369	A/G	cg20196966	chr6:47445060	CD2AP	0.41	5.8	0.3	1.57e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.33	-5.66	-0.3	3.21e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg20637307	chr2:213403960	ERBB4	0.45	7.66	0.39	2.09e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9796	0.870	rs3214068	chr15:41313064	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-7.0	-0.36	1.42e-11	Menopause (age at onset);
LUSC	trans	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg01620082	chr3:125678407	NA	-0.48	-6.13	-0.32	2.49e-9	Depression;
LUSC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.58	-9.41	-0.46	8.44e-19	Aortic root size;
LUSC	cis	rs7615316	0.934	rs9816736	chr3:142172780	T/C	cg16271453	chr3:142027066	XRN1	-0.41	-7.19	-0.37	4.26e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.38	-0.46	1.01e-18	Morning vs. evening chronotype;
LUSC	cis	rs7851660	0.809	rs3824495	chr9:100663700	A/C	cg13688889	chr9:100608707	NA	0.54	8.43	0.42	1.05e-15	Strep throat;
LUSC	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.66	-10.95	-0.51	4.65e-24	Caffeine consumption;
LUSC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg06454157	chr6:167490870	NA	-0.28	-6.71	-0.34	8.57e-11	Primary biliary cholangitis;
LUSC	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	7.19	0.37	4.21e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg06627628	chr2:24431161	ITSN2	-0.74	-10.35	-0.49	5.96e-22	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs2281558	0.876	rs12625157	chr20:25345549	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.63	9.64	0.47	1.44e-19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg13628971	chr7:2884303	GNA12	0.44	6.4	0.33	5.34e-10	Height;
LUSC	cis	rs7827545	0.961	rs4909482	chr8:135564786	G/T	cg17885191	chr8:135476712	NA	0.56	8.32	0.41	2.34e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg22356347	chr1:167427500	CD247	-0.31	-7.08	-0.36	8.34e-12	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg15448220	chr1:150897856	SETDB1	0.42	6.09	0.32	3.05e-9	Melanoma;
LUSC	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg05784532	chr1:230284198	GALNT2	0.54	8.05	0.4	1.46e-14	Coronary artery disease;
LUSC	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.63	-0.57	3.84e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg08755490	chr11:65554678	OVOL1	0.4	5.72	0.3	2.37e-8	Acne (severe);
LUSC	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg20476274	chr7:133979776	SLC35B4	0.79	13.11	0.58	5.59e-32	Mean platelet volume;
LUSC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg19622623	chr12:86230825	RASSF9	0.4	5.75	0.3	2.02e-8	Major depressive disorder;
LUSC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg24209194	chr3:40518798	ZNF619	-0.5	-7.07	-0.36	9.21e-12	Renal cell carcinoma;
LUSC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg27094323	chr7:1216898	NA	-0.35	-6.06	-0.31	3.58e-9	Longevity;Endometriosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16882097	chr18:21166899	NPC1	-0.42	-6.35	-0.33	6.9e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	14.7	0.63	4.49e-38	Platelet count;
LUSC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	8.0	0.4	2.01e-14	Bipolar disorder;
LUSC	cis	rs7851660	0.809	rs7048255	chr9:100665698	A/G	cg13688889	chr9:100608707	NA	-0.54	-8.43	-0.42	1.05e-15	Strep throat;
LUSC	cis	rs722599	0.748	rs731952	chr14:75366447	A/G	cg08847533	chr14:75593920	NEK9	0.47	6.75	0.35	6.5500000000000006e-11	IgG glycosylation;
LUSC	trans	rs7939886	0.920	rs10431119	chr11:55977069	C/T	cg03929089	chr4:120376271	NA	0.83	6.2	0.32	1.71e-9	Myopia (pathological);
LUSC	trans	rs2894969	0.664	rs11252703	chr10:4795125	A/T	cg21477170	chr4:3418713	RGS12	-0.34	-6.14	-0.32	2.33e-9	Major depressive disorder;
LUSC	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.89	15.52	0.65	2.78e-41	Morning vs. evening chronotype;
LUSC	cis	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.8	-0.51	1.62e-23	Glomerular filtration rate;
LUSC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg04398451	chr17:18023971	MYO15A	-0.67	-11.53	-0.53	4.16e-26	Total body bone mineral density;
LUSC	cis	rs9469578	0.579	rs59957785	chr6:33704601	C/T	cg18708504	chr6:33715942	IP6K3	0.68	6.29	0.33	9.87e-10	Phosphorus levels;
LUSC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.88	-0.35	2.89e-11	Total body bone mineral density;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg27310827	chr1:1163671	SDF4	-0.41	-6.49	-0.33	3.05e-10	N-glycan levels;
LUSC	cis	rs2692947	0.759	rs2692937	chr2:96751871	G/A	cg22654517	chr2:96458247	NA	0.33	6.13	0.32	2.54e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg12219531	chr12:120966889	COQ5	0.58	7.61	0.38	2.78e-13	High light scatter reticulocyte count;
LUSC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2742234	1.000	rs1864399	chr10:43610455	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.37	-6.52	-0.34	2.6e-10	Hirschsprung disease;
LUSC	trans	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg17675199	chr6:35436792	RPL10A	-0.43	-6.31	-0.33	8.84e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg00484396	chr16:3507460	NAT15	-0.45	-6.81	-0.35	4.65e-11	Body mass index (adult);
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.29	5.72	0.3	2.33e-8	Lymphocyte counts;
LUSC	cis	rs28647808	0.786	rs28590601	chr9:136256224	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs72781680	0.799	rs2712084	chr2:24003051	A/G	cg08917208	chr2:24149416	ATAD2B	0.6	6.91	0.35	2.44e-11	Lymphocyte counts;
LUSC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	14.15	0.61	5.9e-36	Platelet count;
LUSC	cis	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg08798685	chr6:27730294	NA	-0.63	-5.74	-0.3	2.08e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.01	-0.4	1.99e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.64	10.05	0.48	6.14e-21	Morning vs. evening chronotype;
LUSC	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.98	0.44	2e-17	Lung cancer in ever smokers;
LUSC	cis	rs997295	0.713	rs12904982	chr15:68006279	T/C	cg08079166	chr15:68083412	MAP2K5	-0.33	-6.51	-0.34	2.68e-10	Motion sickness;
LUSC	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg12062639	chr20:23401060	NAPB	0.9	6.64	0.34	1.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	6.29	0.33	1.01e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg24579218	chr15:68104479	NA	-0.39	-6.78	-0.35	5.39e-11	Restless legs syndrome;
LUSC	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg08997352	chr12:9597637	DDX12	-0.71	-11.07	-0.52	1.83e-24	Breast size;
LUSC	cis	rs12530845	1.000	rs12540325	chr7:135334111	T/C	cg23117316	chr7:135346802	PL-5283	-0.58	-10.01	-0.48	8.1e-21	Red blood cell traits;
LUSC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	0.78	9.96	0.48	1.27e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs4654899	0.680	rs6704421	chr1:21220674	A/C	cg01072550	chr1:21505969	NA	0.5	7.62	0.39	2.58e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.69	-0.34	9.51e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20667211	chr5:89770600	MBLAC2;POLR3G	-0.43	-6.33	-0.33	7.81e-10	Electrocardiographic conduction measures;
LUSC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg11766577	chr21:47581405	C21orf56	-0.4	-5.77	-0.3	1.86e-8	Testicular germ cell tumor;
LUSC	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.9	0.48	2e-20	Migraine;Coronary artery disease;
LUSC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg24642844	chr7:1081250	C7orf50	-0.8	-10.72	-0.51	3.14e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	1.04	19.9	0.74	1.14e-58	Menopause (age at onset);
LUSC	trans	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.34	-0.46	1.42e-18	Brugada syndrome;
LUSC	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.64	-11.14	-0.52	1.01e-24	Monocyte count;
LUSC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23158103	chr7:148848205	ZNF398	-0.44	-7.22	-0.37	3.6e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg18811423	chr2:55921094	PNPT1	0.79	13.13	0.58	4.87e-32	Metabolic syndrome;
LUSC	trans	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg01620082	chr3:125678407	NA	-0.79	-6.86	-0.35	3.26e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg09491104	chr22:46646882	C22orf40	-0.72	-9.22	-0.45	3.47e-18	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs78572108	0.858	rs12328618	chr2:42271261	G/A	cg00607755	chr2:42274082	PKDCC	0.35	5.89	0.31	9.25e-9	Total body bone mineral density;
LUSC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.67	-9.26	-0.45	2.5e-18	Other erythrocyte phenotypes;
LUSC	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg27411982	chr8:10470053	RP1L1	0.4	6.39	0.33	5.59e-10	Retinal vascular caliber;
LUSC	cis	rs4343996	0.558	rs1915984	chr7:3409328	T/C	cg21248987	chr7:3385318	SDK1	0.36	6.12	0.32	2.68e-9	Motion sickness;
LUSC	cis	rs4766566	0.704	rs10774617	chr12:111755178	T/C	cg10833066	chr12:111807467	FAM109A	0.54	9.35	0.46	1.34e-18	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUSC	cis	rs4974559	0.790	rs2293631	chr4:1315917	C/A	cg02980000	chr4:1222292	CTBP1	0.84	9.45	0.46	6.36e-19	Systolic blood pressure;
LUSC	cis	rs4474465	0.850	rs10899538	chr11:78237749	C/T	cg27205649	chr11:78285834	NARS2	0.51	6.0	0.31	5.07e-9	Alzheimer's disease (survival time);
LUSC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-9.99	-0.48	9.79e-21	Bipolar disorder;
LUSC	trans	rs3857536	0.813	rs9453639	chr6:66933538	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.44e-9	Blood trace element (Cu levels);
LUSC	cis	rs7903847	0.667	rs10882931	chr10:99165794	C/A	cg08345082	chr10:99160200	RRP12	-0.35	-7.22	-0.37	3.46e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg20848291	chr7:100343083	ZAN	-0.62	-8.66	-0.43	2.1e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.51	0.56	1e-29	Motion sickness;
LUSC	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg24881330	chr22:46731750	TRMU	0.84	7.53	0.38	4.69e-13	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg22153745	chr1:153894579	GATAD2B	-0.54	-8.7	-0.43	1.52e-16	Total cholesterol levels;
LUSC	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg27661571	chr11:113659931	NA	0.59	6.41	0.33	4.92e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs3790645	1.000	rs3127013	chr1:26891360	T/G	cg17456097	chr1:26900765	RPS6KA1	0.41	5.93	0.31	7.6e-9	Glucose homeostasis traits;
LUSC	cis	rs3126085	0.877	rs11204968	chr1:152250211	A/T	cg26876637	chr1:152193138	HRNR	0.45	6.08	0.32	3.31e-9	Atopic dermatitis;
LUSC	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg19610905	chr11:61596333	FADS2	-0.55	-8.26	-0.41	3.54e-15	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUSC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg13609457	chr4:120235615	NA	0.41	5.69	0.3	2.74e-8	Corneal astigmatism;
LUSC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg07507251	chr3:52567010	NT5DC2	0.34	6.55	0.34	2.15e-10	Bipolar disorder;
LUSC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09307838	chr4:120376055	NA	0.69	9.32	0.45	1.65e-18	Corneal astigmatism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24630566	chr15:41187168	VPS18	0.45	6.74	0.35	7.09e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2235649	0.753	rs4316755	chr16:1849916	T/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.1	-0.32	2.96e-9	Blood metabolite levels;
LUSC	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg08610935	chr16:1836813	NUBP2	-0.56	-8.94	-0.44	2.7e-17	Insulin-like growth factors;
LUSC	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg16482183	chr6:26056742	HIST1H1C	0.83	10.2	0.49	1.89e-21	Iron status biomarkers;
LUSC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.73	-9.93	-0.48	1.6e-20	Refractive error;
LUSC	trans	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg16928487	chr17:17741425	SREBF1	0.45	8.78	0.43	8.74e-17	Total body bone mineral density;
LUSC	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.61	8.77	0.43	9.5e-17	Inhibitory control;
LUSC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg13206674	chr6:150067644	NUP43	0.61	9.77	0.47	5.32e-20	Lung cancer;
LUSC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg13628971	chr7:2884303	GNA12	0.51	6.98	0.36	1.56e-11	Height;
LUSC	cis	rs6469656	0.881	rs10096134	chr8:117663998	C/A	cg24004040	chr8:117650383	NA	-0.45	-6.48	-0.33	3.3e-10	Colorectal cancer;
LUSC	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg08558340	chr7:100472263	SRRT	0.46	5.95	0.31	6.59e-9	Resting heart rate;
LUSC	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg06623918	chr6:96969491	KIAA0776	-0.83	-10.35	-0.49	5.8e-22	Migraine;Coronary artery disease;
LUSC	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	0.69	11.2	0.52	6.06e-25	Blood metabolite ratios;
LUSC	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg18806716	chr10:30721971	MAP3K8	-0.48	-7.9	-0.4	4.07e-14	Inflammatory bowel disease;
LUSC	cis	rs12711979	0.513	rs7566217	chr2:3851381	A/C	cg17052675	chr2:3827356	NA	-0.33	-5.73	-0.3	2.2e-8	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs10992471	0.528	rs2296666	chr9:95274261	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.34	5.9	0.31	8.8e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg27535305	chr1:53392650	SCP2	-0.43	-8.48	-0.42	7.17e-16	Monocyte count;
LUSC	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg24675056	chr1:15929824	NA	0.44	7.65	0.39	2.11e-13	Systolic blood pressure;
LUSC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg04369109	chr6:150039330	LATS1	-0.55	-7.94	-0.4	3.13e-14	Lung cancer;
LUSC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.56	10.49	0.5	1.91e-22	Bone mineral density;
LUSC	trans	rs72792513	1.000	rs2879511	chr2:22920687	G/A	cg05844895	chr16:88969569	CBFA2T3	0.5	6.2	0.32	1.69e-9	Hepatitis B;
LUSC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.72	-12.56	-0.57	6.93e-30	White blood cell count (basophil);
LUSC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg12564285	chr5:131593104	PDLIM4	-0.41	-7.54	-0.38	4.59e-13	Breast cancer;
LUSC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg07507251	chr3:52567010	NT5DC2	0.32	6.15	0.32	2.21e-9	Bipolar disorder;
LUSC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg20848291	chr7:100343083	ZAN	-0.51	-6.26	-0.32	1.17e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg26897989	chr16:1907736	C16orf73	-0.43	-6.73	-0.35	7.42e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9815354	1.000	rs9874513	chr3:41909508	G/A	cg03022575	chr3:42003672	ULK4	0.61	6.69	0.34	9.3e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.92	-0.35	2.35e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs10203711	1.000	rs10187717	chr2:239558168	T/C	cg14580085	chr2:239553406	NA	0.4	6.74	0.35	6.97e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.69	12.71	0.57	1.82e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg00321850	chr1:175162397	KIAA0040	-0.49	-8.3	-0.41	2.63e-15	Diastolic blood pressure;
LUSC	cis	rs72634258	0.945	rs36016881	chr1:8051241	A/G	cg26816564	chr1:7831052	VAMP3	0.48	6.21	0.32	1.55e-9	Inflammatory bowel disease;
LUSC	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.73	-0.3	2.28e-8	Total body bone mineral density;
LUSC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg24768116	chr2:27665128	KRTCAP3	0.35	7.01	0.36	1.34e-11	Total body bone mineral density;
LUSC	cis	rs4654899	0.796	rs77366434	chr1:21520069	C/T	cg01072550	chr1:21505969	NA	-0.5	-7.45	-0.38	8e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.99	0.4	2.22e-14	Bipolar disorder;
LUSC	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07080220	chr10:102295463	HIF1AN	0.65	8.83	0.44	6.01e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22029157	chr1:209979665	IRF6	0.69	9.9	0.48	1.96e-20	Cleft lip with or without cleft palate;
LUSC	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg22437258	chr11:111473054	SIK2	-0.45	-5.7	-0.3	2.58e-8	Primary sclerosing cholangitis;
LUSC	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg25258033	chr6:167368657	RNASET2	-0.47	-7.88	-0.4	4.58e-14	Crohn's disease;
LUSC	cis	rs617219	0.889	rs1622238	chr5:78437340	A/G	cg24856658	chr5:78533917	JMY	-0.3	-5.66	-0.3	3.29e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs11158026	0.757	rs8019220	chr14:55453469	C/T	cg04306507	chr14:55594613	LGALS3	0.37	7.4	0.38	1.14e-12	Parkinson's disease;
LUSC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg16339924	chr4:17578868	LAP3	0.6	9.43	0.46	7.3e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg22834771	chr12:69754056	YEATS4	-0.49	-7.26	-0.37	2.81e-12	Blood protein levels;
LUSC	cis	rs34779708	0.741	rs34397613	chr10:35550313	A/G	cg03585969	chr10:35415529	CREM	0.52	7.18	0.37	4.44e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4356932	1.000	rs10003382	chr4:76955473	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.85	0.3	1.2e-8	Blood protein levels;
LUSC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	10.83	0.51	1.25e-23	Homoarginine levels;
LUSC	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg00898013	chr13:113819073	PROZ	0.54	8.02	0.4	1.76e-14	Platelet distribution width;
LUSC	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg06363034	chr20:62225388	GMEB2	-0.46	-7.68	-0.39	1.79e-13	Glioblastoma;
LUSC	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg22139774	chr2:100720529	AFF3	-0.49	-8.35	-0.42	1.8e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4631830	0.863	rs6481329	chr10:51529746	G/A	cg10326726	chr10:51549505	MSMB	-0.37	-6.31	-0.33	8.67e-10	Prostate-specific antigen levels;
LUSC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg01879757	chr17:41196368	BRCA1	-0.46	-7.0	-0.36	1.42e-11	Menopause (age at onset);
LUSC	trans	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg07211511	chr3:129823064	LOC729375	-0.75	-7.17	-0.37	4.92e-12	Blood pressure (smoking interaction);
LUSC	cis	rs13385	0.769	rs11538394	chr5:139574050	G/A	cg26211634	chr5:139558579	C5orf32	0.44	6.31	0.33	8.82e-10	Atrial fibrillation;
LUSC	trans	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.87	0.51	9.28e-24	Mean corpuscular volume;
LUSC	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg27489772	chr12:121021490	NA	-0.55	-7.29	-0.37	2.21e-12	Type 1 diabetes nephropathy;
LUSC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg20821713	chr7:1055600	C7orf50	-0.46	-6.09	-0.32	3.13e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg07636037	chr3:49044803	WDR6	0.55	5.69	0.3	2.82e-8	Menarche (age at onset);
LUSC	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.65	-5.7	-0.3	2.66e-8	Narcolepsy;
LUSC	cis	rs6977660	0.714	rs10244210	chr7:19823972	T/C	cg05791153	chr7:19748676	TWISTNB	0.67	6.93	0.35	2.24e-11	Thyroid stimulating hormone;
LUSC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg27535305	chr1:53392650	SCP2	0.32	5.9	0.31	8.7e-9	Monocyte count;
LUSC	trans	rs1486139	1.000	rs7779479	chr7:46267620	A/G	cg17534202	chr9:96721102	NA	-0.35	-6.15	-0.32	2.26e-9	Select biomarker traits;
LUSC	cis	rs75920871	0.512	rs6589583	chr11:116863766	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-6.52	-0.34	2.59e-10	Subjective well-being;
LUSC	cis	rs713477	1.000	rs12888361	chr14:55906187	A/G	cg13175173	chr14:55914753	NA	-0.32	-6.77	-0.35	5.7e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg25237894	chr2:233734115	C2orf82	0.35	6.43	0.33	4.36e-10	Coronary artery disease;
LUSC	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg23950597	chr19:37808831	NA	-0.63	-7.5	-0.38	5.65e-13	Coronary artery calcification;
LUSC	cis	rs259282	0.605	rs8100423	chr19:33109003	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	9.66	0.47	1.3e-19	Schizophrenia;
LUSC	cis	rs8051149	0.793	rs34831152	chr16:87870607	A/G	cg01412419	chr16:87856264	NA	0.44	6.48	0.33	3.2e-10	Blood metabolite levels;
LUSC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg17376030	chr22:41985996	PMM1	-0.48	-5.99	-0.31	5.37e-9	Vitiligo;
LUSC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg13047869	chr3:10149882	C3orf24	0.54	7.03	0.36	1.18e-11	Alzheimer's disease;
LUSC	cis	rs9800506	0.584	rs12203632	chr6:35518738	T/C	cg03566752	chr6:35512600	NA	0.35	7.87	0.4	4.87e-14	Neutrophil percentage of granulocytes;
LUSC	cis	rs10754283	0.967	rs10801763	chr1:90120822	C/T	cg21401794	chr1:90099060	LRRC8C	0.61	8.78	0.43	8.66e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2625529	0.652	rs8028115	chr15:72339503	C/T	cg16672083	chr15:72433130	SENP8	0.48	8.05	0.4	1.44e-14	Red blood cell count;
LUSC	cis	rs10203711	1.000	rs10191070	chr2:239565413	A/G	cg14580085	chr2:239553406	NA	0.41	6.97	0.36	1.71e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1784581	0.588	rs7451121	chr6:162412344	A/G	cg17173639	chr6:162384350	PARK2	0.57	9.94	0.48	1.44e-20	Itch intensity from mosquito bite;
LUSC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.12	0.58	5.41e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg26384229	chr12:38710491	ALG10B	-0.58	-9.3	-0.45	1.89e-18	Morning vs. evening chronotype;
LUSC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg09640425	chr7:158790006	NA	-0.41	-6.47	-0.33	3.53e-10	Facial morphology (factor 20);
LUSC	cis	rs4919694	0.611	rs2271750	chr10:105174869	A/G	cg04362960	chr10:104952993	NT5C2	-0.95	-10.57	-0.5	9.97e-23	Arsenic metabolism;
LUSC	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg12884169	chr21:40033163	ERG	-0.59	-11.77	-0.54	5.32e-27	Coronary artery disease;
LUSC	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg08798685	chr6:27730294	NA	-0.63	-6.01	-0.31	4.99e-9	Breast cancer;
LUSC	cis	rs11645898	0.935	rs8047881	chr16:72193906	A/G	cg14768367	chr16:72042858	DHODH	-0.6	-6.74	-0.35	6.93e-11	Blood protein levels;
LUSC	trans	rs7939886	0.920	rs10792448	chr11:55804542	C/G	cg03929089	chr4:120376271	NA	0.74	6.28	0.32	1.07e-9	Myopia (pathological);
LUSC	cis	rs981844	1.000	rs2606328	chr4:154653864	C/T	cg14289246	chr4:154710475	SFRP2	0.5	6.59	0.34	1.69e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00166722	chr3:10149974	C3orf24	-0.49	-6.44	-0.33	4.13e-10	Alzheimer's disease;
LUSC	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg00852783	chr1:26633632	UBXN11	-0.5	-5.86	-0.31	1.13e-8	Obesity-related traits;
LUSC	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg04362960	chr10:104952993	NT5C2	0.62	9.48	0.46	4.79e-19	Arsenic metabolism;
LUSC	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg24558204	chr6:135376177	HBS1L	0.59	9.26	0.45	2.63e-18	Red blood cell count;
LUSC	cis	rs6138458	0.620	rs914314	chr20:24897355	C/T	cg22963164	chr20:24940490	CST7	0.58	5.73	0.3	2.19e-8	Blood protein levels;
LUSC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg15744005	chr10:104629667	AS3MT	0.31	6.51	0.34	2.84e-10	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.67	-9.09	-0.45	9.1e-18	Schizophrenia;
LUSC	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.22	-0.37	3.45e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06096994	chr13:41635664	WBP4	-0.55	-6.49	-0.33	3.11e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.58	8.21	0.41	4.83e-15	Diastolic blood pressure;
LUSC	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg10820045	chr2:198174542	NA	-0.33	-6.02	-0.31	4.49e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	trans	rs4596713	0.568	rs7850547	chr9:71747208	G/A	cg25283916	chr1:242222868	NA	-0.3	-6.25	-0.32	1.28e-9	Headache;
LUSC	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg07169764	chr2:136633963	MCM6	-0.59	-7.78	-0.39	9.31e-14	Mosquito bite size;
LUSC	cis	rs68092024	0.704	rs704576	chr3:99487154	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	6.34	0.33	7.66e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg05187965	chr10:45406764	TMEM72	-0.36	-8.43	-0.42	1.06e-15	Mean corpuscular volume;
LUSC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.73	-0.39	1.25e-13	Type 2 diabetes;
LUSC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg01017244	chr2:74357527	NA	0.69	13.25	0.59	1.7e-32	Gestational age at birth (maternal effect);
LUSC	cis	rs4363385	0.693	rs4845331	chr1:152982623	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.33e-13	Inflammatory skin disease;
LUSC	cis	rs34638657	0.833	rs7200628	chr16:82200747	C/T	cg09439754	chr16:82129088	HSD17B2	-0.4	-6.44	-0.33	4.26e-10	Lung adenocarcinoma;
LUSC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.76	-11.99	-0.55	8.98e-28	Tonsillectomy;
LUSC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.19	0.37	4.31e-12	Motion sickness;
LUSC	trans	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg07393940	chr7:158741817	NA	0.38	7.06	0.36	9.57e-12	Life satisfaction;
LUSC	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	1.13	19.47	0.73	5.91e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg07741184	chr6:167504864	NA	-0.36	-6.59	-0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.73	-0.7	4.95e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11487532	chr11:44586968	CD82	-0.47	-5.99	-0.31	5.32e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.39	0.46	9.85e-19	Prudent dietary pattern;
LUSC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg12963246	chr6:28129442	ZNF389	0.52	7.47	0.38	6.9e-13	Parkinson's disease;
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg23131131	chr22:24373011	LOC391322	-0.49	-7.1	-0.36	7.67e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.97	20.82	0.75	2.64e-62	Subjective well-being;
LUSC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg03388025	chr16:89894329	SPIRE2	0.34	6.94	0.35	2.1e-11	Vitiligo;
LUSC	cis	rs9644630	0.965	rs10105097	chr8:19364883	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.37	-7.09	-0.36	7.91e-12	Oropharynx cancer;
LUSC	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-11.85	-0.54	2.84e-27	Colorectal cancer;
LUSC	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg08085267	chr17:45401833	C17orf57	0.62	10.31	0.49	8.19e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7582720	0.945	rs72936875	chr2:203791912	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg08000102	chr2:233561755	GIGYF2	-0.72	-10.3	-0.49	8.93e-22	Schizophrenia;
LUSC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00149659	chr3:10157352	C3orf10	0.89	12.11	0.55	3.04e-28	Alzheimer's disease;
LUSC	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	6.96	0.36	1.79e-11	Neuroticism;
LUSC	cis	rs6741892	0.590	rs12469534	chr2:38912029	G/A	cg23643435	chr2:38893251	GALM	-0.71	-5.69	-0.3	2.8e-8	5-HTT brain serotonin transporter levels;
LUSC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.7	12.65	0.57	3.11e-30	Prudent dietary pattern;
LUSC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg11062466	chr8:58055876	NA	0.71	8.53	0.42	5.07e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.84	-0.3	1.22e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg22823121	chr1:150693482	HORMAD1	-0.5	-7.37	-0.37	1.38e-12	Melanoma;
LUSC	cis	rs34734847	0.933	rs998727	chr12:121149064	T/G	cg27246729	chr12:121163418	ACADS	0.46	7.3	0.37	2.14e-12	Mean corpuscular volume;
LUSC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg23625390	chr15:77176239	SCAPER	0.5	7.68	0.39	1.77e-13	Blood metabolite levels;
LUSC	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg08999081	chr20:33150536	PIGU	0.37	6.87	0.35	3.09e-11	Height;
LUSC	cis	rs9815354	0.638	rs73069277	chr3:41967521	C/T	cg03022575	chr3:42003672	ULK4	0.85	8.85	0.44	5.2e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg22496339	chr2:162101262	NA	-0.4	-5.64	-0.3	3.55e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs9427116	0.967	rs7547072	chr1:154639255	A/G	cg17218026	chr1:154582156	ADAR	-0.36	-6.3	-0.33	9.13e-10	Blood protein levels;
LUSC	cis	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg02972257	chr16:68554789	NA	0.44	6.01	0.31	4.89e-9	Colorectal cancer;
LUSC	cis	rs12286929	0.839	rs11215375	chr11:115014002	C/T	cg04055981	chr11:115044050	NA	0.36	6.16	0.32	2.07e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg06784218	chr1:46089804	CCDC17	0.54	10.59	0.5	8.43e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg23359895	chr10:1095482	IDI1	0.63	5.73	0.3	2.25e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18099408	chr3:52552593	STAB1	0.42	7.57	0.38	3.78e-13	Bipolar disorder;
LUSC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	6.49	0.33	3.02e-10	Menarche (age at onset);
LUSC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9811920	0.965	rs9289981	chr3:99868104	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.34	6.49	0.33	3.03e-10	Axial length;
LUSC	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg03929089	chr4:120376271	NA	-0.53	-6.46	-0.33	3.67e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.39	-0.33	5.59e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs13401104	0.686	rs1530954	chr2:237110960	C/G	cg19324714	chr2:237145437	ASB18	0.43	5.79	0.3	1.6e-8	Educational attainment;
LUSC	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg21293242	chr8:11204541	TDH	0.31	5.89	0.31	9.28e-9	Retinal vascular caliber;
LUSC	cis	rs6674176	0.542	rs803675	chr1:44353237	G/A	cg12908607	chr1:44402522	ARTN	-0.4	-5.74	-0.3	2.17e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06636551	chr8:101224915	SPAG1	-0.44	-8.03	-0.4	1.63e-14	Atrioventricular conduction;
LUSC	cis	rs6546537	0.503	rs13433043	chr2:69906658	T/C	cg10773587	chr2:69614142	GFPT1	-0.46	-6.7	-0.34	8.78e-11	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg18681998	chr4:17616180	MED28	0.86	16.52	0.67	3.2e-45	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.76	-11.97	-0.55	9.96e-28	Tonsillectomy;
LUSC	cis	rs9837602	1.000	rs17379739	chr3:99724792	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	6.14	0.32	2.35e-9	Breast cancer;
LUSC	cis	rs1395	0.778	rs1439767	chr2:27389634	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.49	7.2	0.37	4.12e-12	Blood metabolite levels;
LUSC	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg09788416	chr12:39539408	NA	0.37	5.7	0.3	2.6e-8	Morning vs. evening chronotype;
LUSC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg00750074	chr16:89608354	SPG7	-0.45	-6.7	-0.34	9.08e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs7808935	0.914	rs757136	chr7:27988939	C/T	cg22168087	chr7:27702803	HIBADH	-0.61	-7.36	-0.37	1.43e-12	Prostate cancer;
LUSC	cis	rs71403859	0.730	rs12447672	chr16:71715131	G/A	cg08717414	chr16:71523259	ZNF19	-0.67	-7.44	-0.38	8.49e-13	Post bronchodilator FEV1;
LUSC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	6.26	0.32	1.19e-9	Tonsillectomy;
LUSC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	5.99	0.31	5.53e-9	Breast cancer;
LUSC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg06197492	chr11:2016605	H19	0.42	6.94	0.35	2.08e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg18002602	chr11:66138449	SLC29A2	-0.48	-8.56	-0.42	4.11e-16	Educational attainment (years of education);
LUSC	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg09876464	chr15:85330779	ZNF592	0.37	6.86	0.35	3.41e-11	P wave terminal force;
LUSC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	13.13	0.58	4.71e-32	Hip circumference adjusted for BMI;
LUSC	trans	rs12310956	0.510	rs10772109	chr12:33839548	A/C	cg13010199	chr12:38710504	ALG10B	-0.47	-7.23	-0.37	3.38e-12	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg13010199	chr12:38710504	ALG10B	-0.39	-6.02	-0.31	4.61e-9	Morning vs. evening chronotype;
LUSC	cis	rs4654899	0.897	rs611658	chr1:21089133	T/G	cg01072550	chr1:21505969	NA	-0.45	-6.7	-0.34	9.04e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.89	0.51	7.95e-24	Ileal carcinoids;
LUSC	trans	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.47	-0.38	7e-13	Menarche (age at onset);
LUSC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg14895029	chr7:2775587	GNA12	-0.38	-6.08	-0.32	3.31e-9	Height;
LUSC	cis	rs10072221	0.836	rs7706926	chr5:75707153	C/G	cg03132911	chr5:75698732	IQGAP2	-0.34	-5.68	-0.3	2.86e-8	Mean platelet volume;
LUSC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg14092988	chr3:52407081	DNAH1	0.33	6.41	0.33	4.93e-10	Bipolar disorder;
LUSC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg21775007	chr8:11205619	TDH	-0.5	-7.01	-0.36	1.3e-11	Triglycerides;
LUSC	cis	rs9473147	1.000	rs9473147	chr6:47609592	A/G	cg12968598	chr6:47444699	CD2AP	0.4	5.87	0.31	1.05e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6424115	0.594	rs10799802	chr1:24009544	C/T	cg10978503	chr1:24200527	CNR2	0.31	6.45	0.33	4.03e-10	Immature fraction of reticulocytes;
LUSC	cis	rs3820068	0.705	rs2042369	chr1:15843244	A/G	cg17385448	chr1:15911702	AGMAT	-0.37	-5.88	-0.31	9.92e-9	Systolic blood pressure;
LUSC	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.86	16.21	0.66	5.07e-44	Body mass index (adult);
LUSC	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg24634471	chr8:143751801	JRK	-0.56	-8.75	-0.43	1.04e-16	Schizophrenia;
LUSC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.03	-0.31	4.28e-9	Platelet count;
LUSC	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg26898376	chr11:64110657	CCDC88B	0.33	6.17	0.32	1.92e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18876405	chr7:65276391	NA	0.56	8.82	0.43	6.35e-17	Aortic root size;
LUSC	cis	rs4919087	0.810	rs10736115	chr10:99031685	A/G	cg25902810	chr10:99078978	FRAT1	0.47	6.85	0.35	3.66e-11	Monocyte count;
LUSC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17467752	chr17:38218738	THRA	-0.51	-7.2	-0.37	4.05e-12	White blood cell count;
LUSC	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg10978503	chr1:24200527	CNR2	0.45	10.08	0.48	4.74e-21	Immature fraction of reticulocytes;
LUSC	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg03806693	chr22:41940476	POLR3H	0.84	12.05	0.55	5.34e-28	Vitiligo;
LUSC	cis	rs7523050	0.908	rs17621621	chr1:109398917	G/T	cg08274380	chr1:109419600	GPSM2	0.92	9.73	0.47	7.24e-20	Fat distribution (HIV);
LUSC	cis	rs2625529	0.586	rs59975112	chr15:72423710	G/T	cg16672083	chr15:72433130	SENP8	0.49	8.16	0.41	6.81e-15	Red blood cell count;
LUSC	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.46	7.77	0.39	9.66e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.7	9.79	0.47	4.77e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.52	-7.1	-0.36	7.64e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg20368463	chr18:77673604	PQLC1	-0.62	-6.77	-0.35	5.69e-11	Opioid sensitivity;
LUSC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs10266483	0.739	rs2692104	chr7:63760955	G/C	cg24201672	chr7:64023550	ZNF680	-0.5	-6.6	-0.34	1.61e-10	Response to statin therapy;
LUSC	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg18099408	chr3:52552593	STAB1	0.35	5.71	0.3	2.46e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25809561	chr17:30822961	MYO1D	0.51	9.19	0.45	4.45e-18	Schizophrenia;
LUSC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg20887711	chr4:1340912	KIAA1530	0.45	7.09	0.36	8.08e-12	Obesity-related traits;
LUSC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg05872129	chr22:39784769	NA	-0.58	-10.59	-0.5	8.65e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs3740540	0.507	rs897293	chr10:126290050	T/G	cg04949429	chr10:126290192	LHPP	0.36	7.71	0.39	1.44e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9807841	0.670	rs2010492	chr19:10803395	A/G	cg09936142	chr19:10668400	KRI1	-0.42	-6.6	-0.34	1.62e-10	Inflammatory skin disease;
LUSC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.99	0.55	8.58e-28	Chronic sinus infection;
LUSC	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg24558204	chr6:135376177	HBS1L	0.59	9.07	0.44	1.01e-17	Red blood cell count;
LUSC	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg23093090	chr10:104574429	C10orf26	-0.37	-6.94	-0.35	2.06e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg01256987	chr12:42539512	GXYLT1	-0.4	-7.3	-0.37	2.05e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6785206	0.614	rs2712430	chr3:128337438	A/C	cg16766828	chr3:128327626	NA	-0.7	-7.66	-0.39	2.01e-13	Lymphocyte percentage of white cells;
LUSC	cis	rs2580764	0.540	rs2920893	chr2:55270629	C/T	cg20993754	chr2:55226987	RTN4	-0.36	-5.97	-0.31	5.96e-9	Mean platelet volume;
LUSC	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg17652424	chr22:38574118	PLA2G6	-0.3	-6.63	-0.34	1.39e-10	Cutaneous nevi;
LUSC	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-8.21	-0.41	4.93e-15	Schizophrenia;
LUSC	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.53	7.51	0.38	5.29e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg07393940	chr7:158741817	NA	-0.54	-8.66	-0.43	2.04e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg05347473	chr6:146136440	FBXO30	0.45	7.84	0.39	6.31e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg13319975	chr6:146136371	FBXO30	0.48	7.21	0.37	3.75e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	0.65	13.74	0.6	2.37e-34	Prudent dietary pattern;
LUSC	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg27532560	chr4:187881888	NA	-0.37	-5.85	-0.31	1.15e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.9	12.96	0.58	2.23e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg01620082	chr3:125678407	NA	-0.82	-7.32	-0.37	1.84e-12	Depression;
LUSC	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	7.35	0.37	1.51e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg22834771	chr12:69754056	YEATS4	0.43	6.12	0.32	2.56e-9	Blood protein levels;
LUSC	cis	rs10189230	0.967	rs12479119	chr2:222354213	C/T	cg14652038	chr2:222343519	EPHA4	0.32	5.72	0.3	2.35e-8	Urate levels in lean individuals;
LUSC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.48	0.38	6.8e-13	Electroencephalogram traits;
LUSC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg20203395	chr5:56204925	C5orf35	0.75	10.35	0.49	6.01e-22	Initial pursuit acceleration;
LUSC	cis	rs17030434	0.953	rs11099906	chr4:154691690	A/T	cg14289246	chr4:154710475	SFRP2	-0.49	-6.53	-0.34	2.46e-10	Electrocardiographic conduction measures;
LUSC	cis	rs1451375	0.652	rs7803440	chr7:50625632	C/T	cg18232548	chr7:50535776	DDC	0.48	6.53	0.34	2.49e-10	Malaria;
LUSC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.78	0.35	5.46e-11	Tonsillectomy;
LUSC	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg04851639	chr8:1020857	NA	-0.4	-8.28	-0.41	3.09e-15	Schizophrenia;
LUSC	cis	rs400736	0.860	rs2294890	chr1:8086527	T/G	cg25007680	chr1:8021821	PARK7	0.55	8.43	0.42	1.06e-15	Response to antidepressants and depression;
LUSC	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg24881330	chr22:46731750	TRMU	0.83	7.24	0.37	3.03e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.62	-9.76	-0.47	5.96e-20	Schizophrenia;
LUSC	trans	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.99	-0.31	5.47e-9	Dementia with Lewy bodies;
LUSC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg13319975	chr6:146136371	FBXO30	0.49	7.42	0.38	9.79e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg00495681	chr13:53174319	NA	-0.4	-5.87	-0.31	1.03e-8	Lewy body disease;
LUSC	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg03340356	chr1:67600835	NA	-0.41	-6.59	-0.34	1.69e-10	Psoriasis;
LUSC	trans	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg25214090	chr10:38739885	LOC399744	0.43	6.56	0.34	2.08e-10	Corneal astigmatism;
LUSC	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.46	0.46	5.81e-19	Blood protein levels;
LUSC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg19318889	chr4:1322082	MAEA	-0.71	-12.13	-0.55	2.74e-28	Obesity-related traits;
LUSC	cis	rs2769264	0.546	rs12071705	chr1:151430504	G/C	cg18801370	chr1:151430492	POGZ	0.86	9.48	0.46	5.02e-19	Blood trace element (Cu levels);
LUSC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.08e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg12751644	chr20:60527061	NA	-0.33	-5.89	-0.31	9.2e-9	Body mass index;
LUSC	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg20503657	chr10:835505	NA	0.87	11.62	0.54	1.95e-26	Eosinophil percentage of granulocytes;
LUSC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg09877947	chr5:131593287	PDLIM4	-0.42	-6.43	-0.33	4.5e-10	Breast cancer;
LUSC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08219700	chr8:58056026	NA	0.69	7.93	0.4	3.34e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg11752832	chr7:134001865	SLC35B4	0.56	8.61	0.43	2.92e-16	Mean platelet volume;
LUSC	trans	rs73019876	0.869	rs2158107	chr19:22151345	T/G	cg16204205	chr18:19753432	GATA6	0.32	6.04	0.31	4.16e-9	Testicular germ cell tumor;
LUSC	cis	rs6681460	0.866	rs1856318	chr1:67024215	T/C	cg02459107	chr1:67143332	SGIP1	0.48	8.65	0.43	2.19e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg18002602	chr11:66138449	SLC29A2	0.45	8.12	0.41	8.95e-15	Educational attainment (years of education);
LUSC	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07080220	chr10:102295463	HIF1AN	0.65	8.4	0.42	1.29e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.03e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg12463550	chr7:65579703	CRCP	0.55	8.17	0.41	6.35e-15	Aortic root size;
LUSC	cis	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs41563	0.607	rs6955349	chr7:104601236	G/A	cg00790307	chr17:17684042	SMCR5;RAI1	-0.29	-5.98	-0.31	5.71e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg25482853	chr8:67687455	SGK3	0.98	14.62	0.62	9.44e-38	Obesity-related traits;
LUSC	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	0.56	8.51	0.42	5.83e-16	Breast cancer;
LUSC	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg01620082	chr3:125678407	NA	-0.74	-7.22	-0.37	3.52e-12	Depression;
LUSC	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg00857998	chr1:205179979	DSTYK	0.66	10.44	0.5	2.8e-22	Red blood cell count;
LUSC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg12560992	chr17:57184187	TRIM37	0.83	15.25	0.64	3.29e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-1.24	-13.96	-0.61	3.38e-35	Diabetic kidney disease;
LUSC	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg19336497	chr11:14380999	RRAS2	-0.5	-9.65	-0.47	1.31e-19	Sense of smell;
LUSC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	12.04	0.55	5.73e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg23625390	chr15:77176239	SCAPER	-0.66	-10.05	-0.48	6.35e-21	Blood metabolite levels;
LUSC	cis	rs2346177	0.781	rs1447563	chr2:46637364	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-7.86	-0.39	5.47e-14	HDL cholesterol;
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg09033563	chr22:24373618	LOC391322	-0.49	-6.82	-0.35	4.29e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7246967	0.673	rs73022763	chr19:22894216	C/T	cg23217946	chr19:22817039	ZNF492	0.41	5.7	0.3	2.67e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs2806561	0.780	rs6650086	chr1:23338384	T/C	cg19743168	chr1:23544995	NA	-0.38	-7.94	-0.4	3.14e-14	Height;
LUSC	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.12	0.32	2.62e-9	Rheumatoid arthritis;
LUSC	cis	rs7833986	0.534	rs2667972	chr8:56906661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	10.98	0.51	3.87e-24	Height;
LUSC	cis	rs2629540	0.889	rs7090422	chr10:126439361	T/A	cg08799069	chr10:126477246	METTL10	-0.7	-10.47	-0.5	2.27e-22	Cocaine dependence;
LUSC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg27284194	chr4:1044797	NA	-0.37	-6.34	-0.33	7.36e-10	Obesity-related traits;
LUSC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg23711669	chr6:146136114	FBXO30	0.86	15.51	0.65	2.94e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.52	-9.96	-0.48	1.29e-20	Prostate cancer;
LUSC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	1.11	16.27	0.66	3.07e-44	Breast cancer;
LUSC	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-7.76	-0.39	1.05e-13	Monocyte percentage of white cells;
LUSC	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg11247378	chr22:39784982	NA	-0.6	-10.6	-0.5	7.82e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-10.18	-0.49	2.2e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.42	6.58	0.34	1.85e-10	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs7903847	0.620	rs2297988	chr10:99118382	A/G	cg20016023	chr10:99160130	RRP12	-0.33	-7.87	-0.4	5.03e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg18306943	chr3:40428807	ENTPD3	-0.38	-6.05	-0.31	3.97e-9	Renal cell carcinoma;
LUSC	cis	rs11997175	0.558	rs9792124	chr8:33797689	A/C	ch.8.33884649F	chr8:33765107	NA	0.42	6.16	0.32	2.07e-9	Body mass index;
LUSC	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.78	-0.39	9.37e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.79	14.96	0.63	4.4e-39	Dental caries;
LUSC	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg05283184	chr6:79620031	NA	-0.46	-8.45	-0.42	9.37e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	1.09	18.29	0.71	2.82e-52	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.88	-0.31	9.99e-9	Resting heart rate;
LUSC	trans	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs9311676	0.656	rs62258120	chr3:58391128	G/A	cg26110898	chr3:58419937	PDHB	0.4	6.46	0.33	3.74e-10	Systemic lupus erythematosus;
LUSC	cis	rs3015497	0.624	rs3015488	chr14:51135309	A/G	cg26011998	chr14:51135199	SAV1	-0.46	-5.76	-0.3	1.9e-8	Mean platelet volume;
LUSC	trans	rs2229238	0.911	rs10047079	chr1:154468135	T/C	cg25273160	chr11:56955011	LRRC55	0.31	6.05	0.31	3.81e-9	Coronary heart disease;
LUSC	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.24	0.37	3.07e-12	Morning vs. evening chronotype;
LUSC	trans	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.59	-0.34	1.72e-10	Life satisfaction;
LUSC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg15790184	chr11:494944	RNH1	0.58	6.26	0.32	1.18e-9	Body mass index;
LUSC	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg08601574	chr20:25228251	PYGB	0.49	8.0	0.4	2.08e-14	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg23711669	chr6:146136114	FBXO30	0.72	12.65	0.57	3.14e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg17469321	chr7:55412551	NA	0.66	10.47	0.5	2.18e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13926468	chr13:115080241	ZNF828	0.45	6.3	0.33	9.33e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg18132916	chr6:79620363	NA	-0.37	-5.74	-0.3	2.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.71	-0.34	8.1e-11	Lung cancer;
LUSC	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02176678	chr2:219576539	TTLL4	-0.6	-10.77	-0.51	2.07e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg27087555	chr16:88793112	FAM38A	0.83	6.84	0.35	3.85e-11	Plateletcrit;
LUSC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.06	16.32	0.67	1.88e-44	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs71403859	0.730	rs12927768	chr16:71645263	G/A	cg08717414	chr16:71523259	ZNF19	-0.69	-7.72	-0.39	1.4e-13	Post bronchodilator FEV1;
LUSC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.22	-14.04	-0.61	1.61e-35	Diabetic kidney disease;
LUSC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg24562669	chr7:97807699	LMTK2	0.35	6.22	0.32	1.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg04586622	chr2:25135609	ADCY3	0.34	7.03	0.36	1.15e-11	Body mass index in non-asthmatics;
LUSC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg13535736	chr9:111863775	C9orf5	-0.41	-6.56	-0.34	2.03e-10	Menarche (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21407906	chr20:61427925	C20orf20	-0.45	-6.09	-0.32	3.12e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs432925	0.600	rs214247	chr16:349221	A/G	cg08823186	chr16:347294	AXIN1	0.35	6.15	0.32	2.19e-9	Morning vs. evening chronotype;
LUSC	cis	rs9549260	0.712	rs1334241	chr13:41223110	C/T	cg21288729	chr13:41239152	FOXO1	0.58	6.41	0.33	5.02e-10	Red blood cell count;
LUSC	cis	rs6714710	0.603	rs11692010	chr2:98397301	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	8.41	0.42	1.17e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg21775007	chr8:11205619	TDH	0.45	6.28	0.32	1.08e-9	Neuroticism;
LUSC	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg10596483	chr8:143751796	JRK	0.53	7.54	0.38	4.49e-13	Schizophrenia;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg07553338	chr16:71598813	NA	0.43	6.52	0.34	2.52e-10	Schizophrenia;
LUSC	cis	rs6088813	1.000	rs1540927	chr20:33931344	A/G	cg14752227	chr20:34000481	UQCC	-0.36	-5.65	-0.3	3.4e-8	Height;
LUSC	cis	rs2040771	0.804	rs7286849	chr22:19223579	C/A	cg02655711	chr22:19163373	SLC25A1	0.47	8.42	0.42	1.13e-15	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26314531	chr2:26401878	FAM59B	-0.7	-9.6	-0.46	2.02e-19	Gut microbiome composition (summer);
LUSC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06850241	chr22:41845214	NA	0.31	5.72	0.3	2.39e-8	Vitiligo;
LUSC	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-11.92	-0.55	1.52e-27	Coronary artery disease;
LUSC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg02773041	chr1:40204384	PPIE	0.5	7.36	0.37	1.4e-12	Blood protein levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08949621	chr15:42265044	EHD4	0.4	6.03	0.31	4.31e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-1.13	-18.17	-0.71	8.74e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg22875332	chr1:76189707	ACADM	0.77	10.28	0.49	9.81e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs6600671	0.934	rs67718113	chr1:121238910	C/T	cg00646200	chr1:148855367	NA	-0.5	-7.87	-0.4	4.94e-14	Hip geometry;
LUSC	cis	rs1784581	0.894	rs1784594	chr6:162382734	A/G	cg17173639	chr6:162384350	PARK2	-0.8	-15.14	-0.64	8.97e-40	Itch intensity from mosquito bite;
LUSC	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg04374321	chr14:90722782	PSMC1	0.71	11.26	0.52	3.66e-25	Mortality in heart failure;
LUSC	cis	rs1113500	0.933	rs11185250	chr1:108616417	A/G	cg06207961	chr1:108661230	NA	0.42	7.8	0.39	8.21e-14	Growth-regulated protein alpha levels;
LUSC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-6.0	-0.31	5.24e-9	Huntington's disease progression;
LUSC	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.78	13.75	0.6	2.07e-34	Prostate cancer;
LUSC	trans	rs629535	0.773	rs72654090	chr8:70118666	G/A	cg21567404	chr3:27674614	NA	-0.97	-15.8	-0.65	2.14e-42	Dupuytren's disease;
LUSC	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg06671706	chr8:8559999	CLDN23	0.48	6.44	0.33	4.23e-10	Obesity-related traits;
LUSC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg03806693	chr22:41940476	POLR3H	-0.96	-13.04	-0.58	1.08e-31	Vitiligo;
LUSC	cis	rs12594515	1.000	rs12592190	chr15:45994028	G/A	cg19682013	chr15:45996608	NA	0.38	5.68	0.3	2.87e-8	Waist circumference;Weight;
LUSC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg06363034	chr20:62225388	GMEB2	-0.46	-7.7	-0.39	1.53e-13	Glioblastoma;
LUSC	cis	rs73200209	0.744	rs7974638	chr12:116462700	C/G	cg01776926	chr12:116560359	MED13L	-0.48	-5.87	-0.31	1.03e-8	Total body bone mineral density;
LUSC	cis	rs8038465	1.000	rs67257650	chr15:73979507	C/T	cg15420318	chr15:73925796	NPTN	0.4	6.26	0.32	1.21e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg15448220	chr1:150897856	SETDB1	0.43	6.3	0.33	9.35e-10	Melanoma;
LUSC	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.07	0.48	5.08e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9677476	0.909	rs10181602	chr2:232121642	G/C	cg07929768	chr2:232055508	NA	0.33	6.1	0.32	2.92e-9	Food antigen IgG levels;
LUSC	cis	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.8	-0.35	4.96e-11	Morning vs. evening chronotype;
LUSC	cis	rs3820068	0.705	rs72645808	chr1:15870118	G/C	cg17385448	chr1:15911702	AGMAT	0.4	5.87	0.31	1.04e-8	Systolic blood pressure;
LUSC	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	8.93	0.44	2.95e-17	Coffee consumption (cups per day);
LUSC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.19	-0.8	2.06e-75	Height;
LUSC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.68	-0.3	2.9e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9311676	0.632	rs34086582	chr3:58419944	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.4	0.33	5.22e-10	Systemic lupus erythematosus;
LUSC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	13.72	0.6	2.65e-34	Platelet count;
LUSC	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg05868516	chr6:26286170	HIST1H4H	0.37	6.05	0.31	3.99e-9	Educational attainment;
LUSC	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	7.12	0.36	6.53e-12	Colorectal cancer;
LUSC	cis	rs9658691	0.607	rs9658757	chr10:90769455	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-6.15	-0.32	2.27e-9	Mosquito bite size;
LUSC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg00310523	chr12:86230176	RASSF9	0.46	8.48	0.42	7.57e-16	Major depressive disorder;
LUSC	cis	rs10887741	0.690	rs4934357	chr10:89439533	G/A	cg24243914	chr10:89418206	PAPSS2	0.31	6.25	0.32	1.25e-9	Exercise (leisure time);
LUSC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06544989	chr22:39130855	UNC84B	-0.33	-5.74	-0.3	2.15e-8	Menopause (age at onset);
LUSC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg10377582	chr12:51612794	POU6F1	-0.37	-5.93	-0.31	7.68e-9	Cisplatin-induced ototoxicity;
LUSC	cis	rs4974559	0.594	rs11946384	chr4:1313566	T/C	cg02980000	chr4:1222292	CTBP1	0.84	9.36	0.46	1.18e-18	Systolic blood pressure;
LUSC	cis	rs10986311	0.832	rs748661	chr9:127095574	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.36	5.74	0.3	2.13e-8	Vitiligo;
LUSC	cis	rs9815354	0.812	rs56290987	chr3:42004882	T/C	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.21e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg12165864	chr7:66369176	NA	-0.52	-6.93	-0.35	2.19e-11	Corneal structure;
LUSC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.22	-13.8	-0.6	1.31e-34	Diabetic kidney disease;
LUSC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	6.83	0.35	3.99e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs6750047	0.771	rs2855658	chr2:38296890	T/C	cg07380506	chr2:38303506	CYP1B1	0.44	6.04	0.31	4.13e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg10978503	chr1:24200527	CNR2	-0.44	-9.16	-0.45	5.42e-18	Immature fraction of reticulocytes;
LUSC	cis	rs1983891	1.000	rs9381082	chr6:41542214	T/C	cg20194872	chr6:41519635	FOXP4	0.37	6.49	0.33	3.11e-10	Prostate cancer;
LUSC	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg22800045	chr5:56110881	MAP3K1	0.43	6.07	0.32	3.52e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs4285028	0.851	rs1986368	chr3:121710969	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-9.01	-0.44	1.58e-17	Multiple sclerosis;
LUSC	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg20243544	chr17:37824526	PNMT	0.5	7.08	0.36	8.32e-12	Asthma;
LUSC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg04800585	chr6:26043546	HIST1H2BB	-0.41	-5.98	-0.31	5.79e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.73	-0.35	7.36e-11	Total body bone mineral density;
LUSC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg17366294	chr4:99064904	C4orf37	0.59	10.54	0.5	1.24e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg03909863	chr11:638404	DRD4	-0.39	-5.74	-0.3	2.17e-8	Systemic lupus erythematosus;
LUSC	trans	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg17675199	chr6:35436792	RPL10A	-0.42	-6.16	-0.32	2.14e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg20887711	chr4:1340912	KIAA1530	0.39	5.82	0.3	1.36e-8	Obesity-related traits;
LUSC	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.9	-0.4	4.02e-14	Glomerular filtration rate;
LUSC	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg14092571	chr14:90743983	NA	-0.36	-5.82	-0.3	1.35e-8	Mortality in heart failure;
LUSC	cis	rs12210905	0.688	rs9393814	chr6:27372978	C/T	cg08851530	chr6:28072375	NA	0.97	6.41	0.33	4.91e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.55	-8.94	-0.44	2.72e-17	Longevity;Endometriosis;
LUSC	cis	rs6546550	0.901	rs3771531	chr2:70164034	T/C	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.49	-0.38	6.3e-13	Prevalent atrial fibrillation;
LUSC	cis	rs7615316	1.000	rs1916639	chr3:142346764	T/C	cg16271453	chr3:142027066	XRN1	-0.34	-5.82	-0.3	1.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg02016764	chr4:38805732	TLR1	-0.54	-5.74	-0.3	2.17e-8	Breast cancer;
LUSC	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	9.95	0.48	1.36e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.76	11.5	0.53	5.11e-26	Itch intensity from mosquito bite;
LUSC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg06713675	chr4:122721982	EXOSC9	-0.46	-8.07	-0.4	1.27e-14	Type 2 diabetes;
LUSC	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg26195577	chr20:24973756	C20orf3	1.12	18.25	0.71	4.21e-52	Blood protein levels;
LUSC	cis	rs113835537	0.935	rs79496339	chr11:66467769	T/A	cg24851651	chr11:66362959	CCS	0.52	6.19	0.32	1.78e-9	Airway imaging phenotypes;
LUSC	cis	rs9928842	0.882	rs1107593	chr16:75261329	G/C	cg09066997	chr16:75300724	BCAR1	0.52	6.39	0.33	5.5e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.31	-0.33	8.87e-10	Lung cancer;
LUSC	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg07930552	chr6:133119739	C6orf192	0.79	10.32	0.49	7.22e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg06096015	chr1:231504339	EGLN1	0.56	9.82	0.47	3.68e-20	Hemoglobin concentration;
LUSC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.67	-8.7	-0.43	1.55e-16	Huntington's disease progression;
LUSC	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg21775007	chr8:11205619	TDH	0.44	6.32	0.33	8.51e-10	Mood instability;
LUSC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg22535103	chr8:58192502	C8orf71	-0.72	-7.78	-0.39	9.08e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2019216	0.500	rs1877497	chr17:21940171	C/T	cg22648282	chr17:21454238	C17orf51	-0.49	-6.88	-0.35	2.93e-11	Pelvic organ prolapse;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14705778	chr4:174254825	HMGB2	0.47	6.18	0.32	1.91e-9	Neuroticism;
LUSC	trans	rs445114	0.527	rs606677	chr8:128334485	T/C	cg10195415	chr17:73887371	TRIM65	0.41	6.57	0.34	1.93e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg13010199	chr12:38710504	ALG10B	0.52	7.91	0.4	3.8e-14	Morning vs. evening chronotype;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03362053	chr11:74699895	NEU3	-0.48	-6.41	-0.33	4.97e-10	Hepatitis;
LUSC	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg05855489	chr10:104503620	C10orf26	0.47	6.24	0.32	1.31e-9	Arsenic metabolism;
LUSC	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg10523679	chr1:76189770	ACADM	-0.53	-7.87	-0.4	5.03e-14	Daytime sleep phenotypes;
LUSC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg03188948	chr7:1209495	NA	0.66	6.96	0.36	1.81e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg10792982	chr14:105748885	BRF1	0.52	9.22	0.45	3.53e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2637266	1.000	rs10824429	chr10:78346196	G/T	cg18941641	chr10:78392320	NA	0.39	7.22	0.37	3.54e-12	Pulmonary function;
LUSC	trans	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg06636001	chr8:8085503	FLJ10661	0.43	6.45	0.33	3.91e-10	Retinal vascular caliber;
LUSC	cis	rs2282802	0.635	rs397463	chr5:139584275	C/G	cg26211634	chr5:139558579	C5orf32	-0.42	-7.87	-0.4	5.06e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg15103426	chr22:29168792	CCDC117	0.59	8.3	0.41	2.69e-15	Lymphocyte counts;
LUSC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	9.47	0.46	5.31e-19	Mean platelet volume;
LUSC	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg04691961	chr3:161091175	C3orf57	-0.36	-6.12	-0.32	2.6e-9	Morning vs. evening chronotype;
LUSC	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg17986701	chr20:44574422	PCIF1	0.38	6.7	0.34	8.99e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs952623	0.622	rs12667652	chr7:39074572	C/G	cg15212455	chr7:39170539	POU6F2	0.36	5.96	0.31	6.42e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-10.0	-0.48	9.04e-21	Migraine;Coronary artery disease;
LUSC	cis	rs9581857	0.547	rs76971629	chr13:28051031	C/T	cg22138327	chr13:27999177	GTF3A	0.77	8.18	0.41	5.82e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.5	0.53	5.33e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg05347473	chr6:146136440	FBXO30	0.38	6.48	0.33	3.36e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7582720	1.000	rs72934740	chr2:203741362	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.54	0.42	4.75e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg03563238	chr19:33554763	RHPN2	-0.37	-6.29	-0.33	1.01e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg11645453	chr3:52864694	ITIH4	0.36	8.4	0.42	1.31e-15	Bipolar disorder;
LUSC	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg18811423	chr2:55921094	PNPT1	0.81	13.7	0.6	3.41e-34	Metabolic syndrome;
LUSC	cis	rs9888739	1.000	rs9938063	chr16:31302938	C/T	cg15817542	chr16:31343056	ITGAM	0.48	5.89	0.31	9.47e-9	Systemic lupus erythematosus;
LUSC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.73	-14.1	-0.61	9.54e-36	Type 2 diabetes;
LUSC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg13319975	chr6:146136371	FBXO30	0.49	7.28	0.37	2.34e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg09323728	chr8:95962352	TP53INP1	-0.37	-7.6	-0.38	3.05e-13	Type 2 diabetes;
LUSC	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.37	-0.91	1.58e-130	Myeloid white cell count;
LUSC	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05901451	chr6:126070800	HEY2	-0.95	-18.74	-0.72	4.51e-54	Brugada syndrome;
LUSC	cis	rs2073300	1.000	rs6137977	chr20:23464191	G/T	cg09953122	chr20:23471693	CST8	-0.88	-7.54	-0.38	4.52e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.33	7.66	0.39	2.05e-13	Coronary artery disease;
LUSC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06221963	chr1:154839813	KCNN3	-0.6	-13.38	-0.59	5.65e-33	Prostate cancer;
LUSC	cis	rs2455601	1.000	rs12418190	chr11:8899818	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-7.54	-0.38	4.43e-13	Schizophrenia;
LUSC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-1.05	-14.81	-0.63	1.65e-38	Vitiligo;
LUSC	trans	rs11088226	0.581	rs7282335	chr21:33905919	A/G	cg09050820	chr6:167586206	TCP10L2	0.54	8.09	0.4	1.14e-14	Gastritis;
LUSC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg02423579	chr7:2872169	GNA12	-0.39	-5.75	-0.3	1.98e-8	Height;
LUSC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-16.93	-0.68	7.7e-47	Gut microbiome composition (summer);
LUSC	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg27471124	chr11:109292789	C11orf87	0.43	7.64	0.39	2.36e-13	Schizophrenia;
LUSC	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs4499344	0.730	rs406470	chr19:33104472	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	12.77	0.57	1.14e-30	Mean platelet volume;
LUSC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg03785755	chr6:26196794	NA	0.53	5.67	0.3	3.12e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg19266014	chr7:2183958	MAD1L1	-0.35	-5.76	-0.3	1.88e-8	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg13206674	chr6:150067644	NUP43	0.59	9.36	0.46	1.17e-18	Lung cancer;
LUSC	cis	rs16917546	1.000	rs7090073	chr10:64423505	G/T	cg03961010	chr10:64397487	ZNF365	-0.41	-6.4	-0.33	5.32e-10	Basal cell carcinoma;
LUSC	cis	rs12541635	0.966	rs62525734	chr8:106984056	T/C	cg10147462	chr8:107024639	NA	0.55	9.54	0.46	3.03e-19	Age of smoking initiation;
LUSC	trans	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-6.05	-0.31	3.93e-9	Mood instability;
LUSC	cis	rs3136441	1.000	rs2306033	chr11:46897446	G/A	cg01183595	chr11:46746236	F2	0.39	5.91	0.31	8.67e-9	HDL cholesterol;
LUSC	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg04310649	chr10:35416472	CREM	-0.42	-6.39	-0.33	5.6e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-6.53	-0.34	2.49e-10	Monocyte percentage of white cells;
LUSC	cis	rs4561483	0.832	rs171656	chr16:11953167	C/T	cg08843971	chr16:11963173	GSPT1	-0.48	-7.19	-0.37	4.34e-12	Testicular germ cell tumor;
LUSC	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.51	-5.79	-0.3	1.58e-8	Red blood cell traits;
LUSC	cis	rs2109514	1.000	rs7795510	chr7:116156961	T/C	cg12739419	chr7:116140593	CAV2	-0.28	-6.24	-0.32	1.32e-9	Prevalent atrial fibrillation;
LUSC	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg19812747	chr11:111475976	SIK2	-0.48	-6.84	-0.35	3.87e-11	Primary sclerosing cholangitis;
LUSC	cis	rs360798	0.532	rs11125942	chr2:62966758	T/C	cg17519650	chr2:63277830	OTX1	-0.47	-6.58	-0.34	1.78e-10	Coronary artery disease;
LUSC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg00074818	chr8:8560427	CLDN23	0.57	9.67	0.47	1.14e-19	Obesity-related traits;
LUSC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg09509183	chr1:209979624	IRF6	0.5	5.9	0.31	8.79e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg23750338	chr8:142222470	SLC45A4	0.58	11.26	0.52	3.68e-25	Immature fraction of reticulocytes;
LUSC	cis	rs1595825	0.891	rs6733834	chr2:198518709	C/G	cg00982548	chr2:198649783	BOLL	0.51	6.45	0.33	3.95e-10	Ulcerative colitis;
LUSC	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg07169764	chr2:136633963	MCM6	0.68	9.86	0.47	2.7e-20	Mosquito bite size;
LUSC	cis	rs8114671	0.647	rs1124511	chr20:33736697	A/C	cg24642439	chr20:33292090	TP53INP2	0.4	5.75	0.3	2.02e-8	Height;
LUSC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-0.82	-15.3	-0.64	1.96e-40	Height;
LUSC	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	6.4	0.33	5.29e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05025164	chr4:1340916	KIAA1530	0.54	8.42	0.42	1.1e-15	Obesity-related traits;
LUSC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.9	0.35	2.55e-11	Tonsillectomy;
LUSC	cis	rs9517320	1.000	rs912337	chr13:99141272	A/G	cg20487152	chr13:99095054	FARP1	-0.38	-7.1	-0.36	7.47e-12	Longevity;
LUSC	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg03342759	chr3:160939853	NMD3	-0.43	-7.08	-0.36	8.65e-12	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg04369109	chr6:150039330	LATS1	-0.53	-7.51	-0.38	5.43e-13	Lung cancer;
LUSC	cis	rs2835872	0.863	rs857979	chr21:38998093	A/G	cg20424643	chr21:39039972	KCNJ6	-0.38	-5.89	-0.31	9.27e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs55675132	0.667	rs1539571	chr1:115634729	C/T	cg01522456	chr1:115632236	TSPAN2	0.47	6.52	0.34	2.53e-10	Schizophrenia;
LUSC	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	7.17	0.37	4.91e-12	Ovarian reserve;
LUSC	cis	rs4774899	0.837	rs11852340	chr15:57402690	C/T	cg21617494	chr15:57618479	NA	-0.33	-5.68	-0.3	2.94e-8	Urinary tract infection frequency;
LUSC	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.58	0.34	1.87e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs778371	0.723	rs13001052	chr2:233683984	C/T	cg08000102	chr2:233561755	GIGYF2	-0.78	-12.25	-0.56	9.29e-29	Schizophrenia;
LUSC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	0.92	13.89	0.61	6.05e-35	Breast cancer;
LUSC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg09365446	chr1:150670422	GOLPH3L	0.55	8.44	0.42	9.59e-16	Urate levels;
LUSC	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.58	-0.46	2.35e-19	Coronary artery disease;
LUSC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.69	0.39	1.71e-13	Electroencephalogram traits;
LUSC	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg02569458	chr12:86230093	RASSF9	0.42	6.85	0.35	3.49e-11	Major depressive disorder;
LUSC	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg11413152	chr1:44687590	ERI3	-0.36	-6.21	-0.32	1.58e-9	Vertical cup-disc ratio;
LUSC	cis	rs2445762	0.659	rs12443032	chr15:51670305	T/C	cg07517944	chr15:51633816	GLDN	0.39	6.6	0.34	1.57e-10	Hormone measurements;
LUSC	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg09184832	chr6:79620586	NA	-0.44	-7.23	-0.37	3.26e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.16	-0.49	2.52e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs2011503	0.509	rs73006705	chr19:19781917	A/G	cg11584989	chr19:19387371	SF4	0.51	5.82	0.3	1.41e-8	Bipolar disorder;
LUSC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg22800045	chr5:56110881	MAP3K1	0.47	6.19	0.32	1.78e-9	Coronary artery disease;
LUSC	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg25344623	chr2:136566232	LCT	0.4	5.99	0.31	5.57e-9	Mosquito bite size;
LUSC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg09365446	chr1:150670422	GOLPH3L	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	cis	rs9420	0.922	rs35808061	chr11:57547000	T/C	cg23127183	chr11:57508653	C11orf31	-0.57	-8.81	-0.43	6.86e-17	Schizophrenia;
LUSC	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg17385448	chr1:15911702	AGMAT	-0.34	-5.74	-0.3	2.09e-8	Systolic blood pressure;
LUSC	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg19052272	chr2:3704530	ALLC	-0.33	-6.33	-0.33	7.72e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg09835421	chr16:68378352	PRMT7	-0.8	-8.49	-0.42	6.81e-16	Schizophrenia;
LUSC	cis	rs8044868	0.586	rs10852511	chr16:72183959	G/A	cg16579770	chr16:72058938	DHODH	0.36	5.83	0.3	1.28e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg10356904	chr22:49881777	NA	-0.31	-6.98	-0.36	1.58e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg08916839	chr5:415575	AHRR	0.75	7.09	0.36	7.88e-12	Fat distribution (HIV);
LUSC	cis	rs3820928	0.967	rs4675118	chr2:227773157	C/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.8	-0.39	8.04e-14	Pulmonary function;
LUSC	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.82e-13	Type 2 diabetes;
LUSC	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg07167872	chr1:205819463	PM20D1	-0.44	-5.94	-0.31	7.24e-9	Menarche (age at onset);
LUSC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg26338869	chr17:61819248	STRADA	0.41	5.95	0.31	6.61e-9	Prudent dietary pattern;
LUSC	cis	rs4588572	0.643	rs10043115	chr5:77692019	T/C	cg11547950	chr5:77652471	NA	0.51	7.55	0.38	4.17e-13	Triglycerides;
LUSC	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.52	-0.5	1.49e-22	Eye color traits;
LUSC	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg06484146	chr7:12443880	VWDE	-0.68	-7.08	-0.36	8.67e-12	Coronary artery disease;
LUSC	cis	rs11030122	0.702	rs10835311	chr11:3949027	G/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.82	-0.3	1.37e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7851660	0.654	rs2120264	chr9:100645728	A/G	cg13688889	chr9:100608707	NA	-0.56	-8.56	-0.42	4.06e-16	Strep throat;
LUSC	cis	rs9326248	0.861	rs4938353	chr11:117046197	G/A	cg26566898	chr11:117069891	TAGLN	0.38	6.21	0.32	1.62e-9	Blood protein levels;
LUSC	cis	rs78366141	0.649	rs7666372	chr4:89687531	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.88	7.46	0.38	7.32e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.17	-0.32	1.98e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02475777	chr4:1388615	CRIPAK	-0.57	-8.7	-0.43	1.49e-16	Obesity-related traits;
LUSC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	6.38	0.33	5.95e-10	Bipolar disorder;
LUSC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.98	0.4	2.33e-14	Prudent dietary pattern;
LUSC	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg00376283	chr12:123451042	ABCB9	0.66	7.62	0.38	2.6e-13	Neutrophil percentage of white cells;
LUSC	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.56	8.61	0.43	3e-16	Blood protein levels;
LUSC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs17767294	1.000	rs17767294	chr6:28054198	A/G	cg08851530	chr6:28072375	NA	0.9	5.83	0.3	1.34e-8	Parkinson's disease;
LUSC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg13206674	chr6:150067644	NUP43	0.59	9.28	0.45	2.26e-18	Lung cancer;
LUSC	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	7.25	0.37	2.95e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg19875535	chr5:140030758	IK	0.51	8.37	0.42	1.55e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs62400317	0.859	rs12211519	chr6:45160530	C/A	cg20913747	chr6:44695427	NA	-0.48	-7.7	-0.39	1.56e-13	Total body bone mineral density;
LUSC	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg06627628	chr2:24431161	ITSN2	-0.58	-7.15	-0.36	5.66e-12	Lymphocyte counts;
LUSC	cis	rs62400317	0.859	rs12191262	chr6:45227016	G/A	cg20913747	chr6:44695427	NA	-0.49	-7.92	-0.4	3.53e-14	Total body bone mineral density;
LUSC	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.41	6.31	0.33	8.89e-10	Height;
LUSC	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg24675056	chr1:15929824	NA	0.48	8.33	0.41	2.17e-15	Systolic blood pressure;
LUSC	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg16950941	chr11:66035639	RAB1B	0.5	7.27	0.37	2.57e-12	Gout;
LUSC	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.17	-0.32	1.98e-9	Resting heart rate;
LUSC	cis	rs611744	0.624	rs2514844	chr8:109064809	A/G	cg18478394	chr8:109455254	TTC35	0.41	6.01	0.31	4.98e-9	Dupuytren's disease;
LUSC	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.52	10.42	0.5	3.46e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg04218760	chr10:45406644	TMEM72	-0.29	-7.05	-0.36	1.06e-11	Mean corpuscular volume;
LUSC	cis	rs240764	0.782	rs395521	chr6:101054999	C/T	cg09795085	chr6:101329169	ASCC3	0.41	6.01	0.31	4.84e-9	Neuroticism;
LUSC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg03808351	chr9:123631620	PHF19	-0.42	-6.68	-0.34	1e-10	Birth weight;
LUSC	cis	rs6500395	1.000	rs1872655	chr16:48670883	A/C	cg04672837	chr16:48644449	N4BP1	0.46	6.91	0.35	2.41e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg00857998	chr1:205179979	DSTYK	0.61	9.85	0.47	2.83e-20	Red blood cell count;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg25348504	chr12:111180878	PPP1CC	0.49	6.31	0.33	9.05e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg04450456	chr4:17643702	FAM184B	0.41	6.89	0.35	2.83e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7715806	0.500	rs72633986	chr5:75006449	T/A	cg19683494	chr5:74908142	NA	0.57	7.68	0.39	1.83e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9902453	0.967	rs34323226	chr17:28517454	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.84	0.44	5.69e-17	Coffee consumption (cups per day);
LUSC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-13.93	-0.61	4.43e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg19592336	chr6:28129416	ZNF389	0.48	6.27	0.32	1.11e-9	Depression;
LUSC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06634786	chr22:41940651	POLR3H	0.53	6.19	0.32	1.79e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg15468180	chr1:107600409	PRMT6	-0.38	-6.1	-0.32	3.01e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg27411982	chr8:10470053	RP1L1	0.4	6.1	0.32	3e-9	Retinal vascular caliber;
LUSC	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.89	-0.31	9.55e-9	Platelet count;
LUSC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg13206674	chr6:150067644	NUP43	0.55	8.68	0.43	1.72e-16	Lung cancer;
LUSC	trans	rs12429206	0.520	rs1870839	chr13:51473868	A/G	cg00778807	chr1:43524347	NA	-0.35	-5.98	-0.31	5.77e-9	Prostate-specific antigen levels (conditioned on lead SNPs);
LUSC	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg21045802	chr8:109455806	TTC35	0.44	6.89	0.35	2.71e-11	Dupuytren's disease;
LUSC	cis	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs500891	0.645	rs1170502	chr6:83991972	A/T	cg08257003	chr6:84140564	ME1	0.33	7.15	0.36	5.67e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs6516091	0.778	rs62199231	chr20:6050133	C/T	cg25325723	chr20:6104886	FERMT1	-0.65	-7.0	-0.36	1.39e-11	Abdominal aortic aneurysm;
LUSC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg22823121	chr1:150693482	HORMAD1	0.46	6.6	0.34	1.57e-10	Melanoma;
LUSC	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg23283495	chr1:209979779	IRF6	0.46	7.41	0.38	1.02e-12	Monobrow;
LUSC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg06145435	chr7:1022769	CYP2W1	0.27	5.84	0.3	1.25e-8	Longevity;Endometriosis;
LUSC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg06740227	chr12:86229804	RASSF9	0.45	7.16	0.36	5.25e-12	Major depressive disorder;
LUSC	cis	rs4629710	0.592	rs11759926	chr6:131571269	G/T	cg12700074	chr6:131571435	AKAP7	-0.36	-5.94	-0.31	7.17e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg27284194	chr4:1044797	NA	0.57	8.29	0.41	2.83e-15	Recombination rate (females);
LUSC	cis	rs11997175	1.000	rs7464996	chr8:33770925	G/T	ch.8.33884649F	chr8:33765107	NA	0.53	8.5	0.42	6.26e-16	Body mass index;
LUSC	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg19743168	chr1:23544995	NA	0.46	9.11	0.45	8.03e-18	Height;
LUSC	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.41	-0.33	5.05e-10	Bipolar disorder;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg22524267	chr4:4543474	STX18	0.41	6.34	0.33	7.47e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs6601327	0.575	rs7001832	chr8:9607235	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.95	-0.36	1.88e-11	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg08079166	chr15:68083412	MAP2K5	0.41	7.27	0.37	2.57e-12	Restless legs syndrome;
LUSC	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-20.56	-0.75	2.74e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-9.36	-0.46	1.23e-18	Eye color traits;
LUSC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08859206	chr1:53392774	SCP2	-0.56	-9.64	-0.47	1.48e-19	Monocyte count;
LUSC	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.5e-8	Breast cancer;
LUSC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06634786	chr22:41940651	POLR3H	0.48	5.65	0.3	3.35e-8	Vitiligo;
LUSC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg05025164	chr4:1340916	KIAA1530	0.39	6.05	0.31	3.95e-9	Obesity-related traits;
LUSC	cis	rs2637266	1.000	rs1907317	chr10:78337849	C/A	cg18941641	chr10:78392320	NA	0.36	6.52	0.34	2.65e-10	Pulmonary function;
LUSC	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg00520135	chr15:63333846	TPM1	0.33	6.75	0.35	6.7e-11	Platelet count;
LUSC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg19046167	chr17:80928561	B3GNTL1	0.4	6.46	0.33	3.81e-10	Breast cancer;
LUSC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg22508957	chr16:3507546	NAT15	-0.92	-10.6	-0.5	7.89e-23	Tuberculosis;
LUSC	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg26893861	chr17:41843967	DUSP3	0.96	14.6	0.62	1.15e-37	Triglycerides;
LUSC	cis	rs6740322	0.748	rs6755601	chr2:43483044	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-7.05	-0.36	1.01e-11	Coronary artery disease;
LUSC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg14552801	chr7:65878734	NA	0.46	6.44	0.33	4.06e-10	Aortic root size;
LUSC	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg24558204	chr6:135376177	HBS1L	0.68	10.65	0.5	5.53e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg15934090	chr1:100435551	SLC35A3	0.48	8.3	0.41	2.53e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4594175	0.926	rs11157803	chr14:51627700	C/T	cg23942311	chr14:51606299	NA	0.31	5.88	0.31	9.94e-9	Cancer;
LUSC	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.6	-8.18	-0.41	5.97e-15	Body mass index (adult);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26880762	chr12:123943063	SNRNP35	0.44	6.56	0.34	2.05e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg10596483	chr8:143751796	JRK	0.52	7.57	0.38	3.79e-13	Schizophrenia;
LUSC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg03806693	chr22:41940476	POLR3H	0.99	13.81	0.6	1.28e-34	Vitiligo;
LUSC	trans	rs6480314	0.542	rs61854824	chr10:70030195	C/T	cg04882175	chr6:131122610	NA	-0.54	-6.15	-0.32	2.17e-9	Optic nerve measurement (disc area);
LUSC	cis	rs4664308	1.000	rs1511218	chr2:160906390	T/C	cg03641300	chr2:160917029	PLA2R1	-0.66	-11.21	-0.52	5.69e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs3750965	0.920	rs10896421	chr11:68863048	T/C	cg06818126	chr11:68850279	TPCN2	-0.43	-6.37	-0.33	6.24e-10	Hair color;
LUSC	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg16447950	chr5:562315	NA	-0.47	-6.36	-0.33	6.51e-10	Obesity-related traits;
LUSC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg09034736	chr1:150693464	HORMAD1	0.46	6.62	0.34	1.45e-10	Melanoma;
LUSC	cis	rs4706831	0.647	rs627240	chr6:80985885	C/A	cg08355045	chr6:80787529	NA	-0.41	-7.07	-0.36	9.25e-12	Joint mobility (Beighton score);
LUSC	cis	rs6500395	0.802	rs13330784	chr16:48661530	A/C	cg04672837	chr16:48644449	N4BP1	0.46	6.97	0.36	1.7e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-11.19	-0.52	6.51e-25	Schizophrenia;
LUSC	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg04374321	chr14:90722782	PSMC1	-0.65	-9.58	-0.46	2.35e-19	Mortality in heart failure;
LUSC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01171360	chr6:293285	DUSP22	-0.53	-8.05	-0.4	1.43e-14	Menopause (age at onset);
LUSC	trans	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-6.81	-0.35	4.63e-11	Monocyte count;
LUSC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg14664628	chr15:75095509	CSK	-0.54	-7.97	-0.4	2.61e-14	Breast cancer;
LUSC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.85	0.47	2.98e-20	Bipolar disorder;
LUSC	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.83	-0.7	1.98e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg05025164	chr4:1340916	KIAA1530	0.53	8.44	0.42	9.73e-16	Longevity;
LUSC	cis	rs77140172	0.677	rs28435799	chr4:89617931	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.0	7.23	0.37	3.23e-12	Post bronchodilator FEV1;
LUSC	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg20503657	chr10:835505	NA	-0.77	-9.59	-0.46	2.07e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs7577696	0.924	rs7561519	chr2:32312700	T/C	cg02381751	chr2:32503542	YIPF4	-0.4	-5.76	-0.3	1.92e-8	Inflammatory biomarkers;
LUSC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18301423	chr5:131593218	PDLIM4	-0.49	-7.58	-0.38	3.52e-13	Acylcarnitine levels;
LUSC	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg06060754	chr5:176797920	RGS14	-0.55	-8.05	-0.4	1.5e-14	Urate levels in lean individuals;
LUSC	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg01884057	chr2:25150051	NA	-0.38	-8.58	-0.42	3.67e-16	Body mass index in non-asthmatics;
LUSC	cis	rs7119	0.717	rs12901100	chr15:77815558	T/A	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.21	-0.49	1.83e-21	Eye color traits;
LUSC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg26566898	chr11:117069891	TAGLN	0.47	8.15	0.41	7.46e-15	Blood protein levels;
LUSC	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.9	-0.31	8.7e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11031096	0.711	rs1348309	chr11:4202000	A/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.8	-0.3	1.51e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg09365446	chr1:150670422	GOLPH3L	0.45	6.54	0.34	2.25e-10	Melanoma;
LUSC	cis	rs6500395	0.962	rs7199625	chr16:48650217	G/C	cg04672837	chr16:48644449	N4BP1	0.47	6.73	0.35	7.28e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9807989	0.839	rs1420099	chr2:102980543	C/G	cg03938978	chr2:103052716	IL18RAP	0.31	5.74	0.3	2.08e-8	Asthma;
LUSC	cis	rs727505	0.866	rs66852389	chr7:124724348	T/A	cg23710748	chr7:124431027	NA	-0.4	-6.96	-0.36	1.79e-11	Lewy body disease;
LUSC	cis	rs57244997	0.860	rs9458425	chr6:162376946	C/T	cg17173639	chr6:162384350	PARK2	-0.59	-6.3	-0.33	9.55e-10	Mosquito bite size;
LUSC	cis	rs6967385	0.560	rs2192833	chr7:12355303	A/T	cg06484146	chr7:12443880	VWDE	0.47	7.11	0.36	7.24e-12	Response to taxane treatment (placlitaxel);
LUSC	cis	rs6546550	0.901	rs6546558	chr2:70145717	C/T	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.18e-12	Prevalent atrial fibrillation;
LUSC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg12560992	chr17:57184187	TRIM37	-0.85	-15.42	-0.64	6.9e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs3931020	0.657	rs10890142	chr1:75179129	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.63	8.37	0.42	1.62e-15	Resistin levels;
LUSC	cis	rs9436747	0.680	rs1171268	chr1:65996166	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.43	-5.83	-0.3	1.29e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg00432049	chr6:150390894	ULBP3	-0.27	-5.76	-0.3	1.93e-8	Alopecia areata;
LUSC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13012494	chr21:47604986	C21orf56	0.4	5.93	0.31	7.68e-9	Testicular germ cell tumor;
LUSC	cis	rs2219968	1.000	rs4333586	chr8:78971965	C/T	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4132509	1.000	rs2290754	chr1:243806268	A/C	cg21452805	chr1:244014465	NA	0.49	5.86	0.31	1.11e-8	RR interval (heart rate);
LUSC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06112835	chr11:68658793	MRPL21	0.52	8.19	0.41	5.43e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1784581	0.802	rs7768986	chr6:162427890	G/C	cg17173639	chr6:162384350	PARK2	0.66	11.67	0.54	1.27e-26	Itch intensity from mosquito bite;
LUSC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg20203395	chr5:56204925	C5orf35	-0.73	-9.82	-0.47	3.59e-20	Initial pursuit acceleration;
LUSC	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.6	-0.43	3.22e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg14500267	chr11:67383377	NA	0.45	8.91	0.44	3.43e-17	Mean corpuscular volume;
LUSC	trans	rs867371	0.722	rs8033050	chr15:82561989	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.48	-7.16	-0.36	5.28e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs7577696	0.597	rs375050	chr2:32413765	C/T	cg02381751	chr2:32503542	YIPF4	0.53	7.13	0.36	6.44e-12	Inflammatory biomarkers;
LUSC	cis	rs2274273	0.870	rs11625001	chr14:55758160	T/C	cg04306507	chr14:55594613	LGALS3	0.54	12.05	0.55	5.23e-28	Protein biomarker;
LUSC	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg07169764	chr2:136633963	MCM6	1.04	13.97	0.61	3.08e-35	Corneal structure;
LUSC	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg06363034	chr20:62225388	GMEB2	-0.46	-7.67	-0.39	1.92e-13	Glioblastoma;
LUSC	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.71	0.43	1.47e-16	Lung cancer in ever smokers;
LUSC	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg21466736	chr12:48725269	NA	-0.32	-6.0	-0.31	5.12e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs72781680	0.821	rs72796369	chr2:24162663	G/T	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg22800045	chr5:56110881	MAP3K1	-0.6	-8.43	-0.42	1.06e-15	Initial pursuit acceleration;
LUSC	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg26876637	chr1:152193138	HRNR	-0.41	-5.73	-0.3	2.23e-8	Atopic dermatitis;
LUSC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19346786	chr7:2764209	NA	-0.47	-7.74	-0.39	1.22e-13	Height;
LUSC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg04414720	chr1:150670196	GOLPH3L	0.58	9.26	0.45	2.51e-18	Tonsillectomy;
LUSC	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg08514558	chr10:81106712	PPIF	0.27	5.87	0.31	1.03e-8	Height;
LUSC	cis	rs3772130	0.923	rs3805127	chr3:121556751	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.67	9.66	0.47	1.25e-19	Cognitive performance;
LUSC	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg10518572	chr11:65560635	OVOL1	-0.27	-6.2	-0.32	1.71e-9	Acne (severe);
LUSC	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg05805236	chr11:65401703	PCNXL3	-0.56	-8.82	-0.43	6.65e-17	Acne (severe);
LUSC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11645453	chr3:52864694	ITIH4	0.38	8.65	0.43	2.25e-16	Bipolar disorder;
LUSC	cis	rs7202877	0.706	rs4888375	chr16:75322356	T/C	cg03315344	chr16:75512273	CHST6	0.42	6.19	0.32	1.72e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg22862634	chr11:62369728	EML3;MTA2	-0.49	-8.02	-0.4	1.82e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	7.94	0.4	3.18e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs965469	1.000	rs2236122	chr20:3305240	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-5.69	-0.3	2.84e-8	IFN-related cytopenia;
LUSC	cis	rs9462027	0.628	rs2814945	chr6:34647978	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.21	-0.32	1.53e-9	Systemic lupus erythematosus;
LUSC	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06636551	chr8:101224915	SPAG1	-0.44	-8.03	-0.4	1.63e-14	Atrioventricular conduction;
LUSC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg16423285	chr20:60520624	NA	-0.63	-8.09	-0.4	1.11e-14	Body mass index;
LUSC	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.89	-0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	8.07	0.4	1.29e-14	Blood metabolite levels;
LUSC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.48	-7.11	-0.36	7.23e-12	Melanoma;
LUSC	trans	rs1941687	0.702	rs4392137	chr18:31316708	T/C	cg27147174	chr7:100797783	AP1S1	-0.46	-6.61	-0.34	1.56e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs2573652	1.000	rs1469829	chr15:100517332	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.46	-8.82	-0.43	6.47e-17	Height;
LUSC	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg02466173	chr16:30829666	NA	-0.52	-10.2	-0.49	1.98e-21	Dementia with Lewy bodies;
LUSC	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	0.97	16.58	0.67	1.87e-45	Gout;Urate levels;Serum uric acid levels;
LUSC	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg11693508	chr17:37793320	STARD3	0.6	7.06	0.36	9.73e-12	Bipolar disorder;
LUSC	cis	rs7582720	1.000	rs72934513	chr2:203927587	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.65	0.43	2.2e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg19418458	chr7:158789849	NA	-0.53	-7.99	-0.4	2.2e-14	Facial morphology (factor 20);
LUSC	cis	rs1413885	0.549	rs7545720	chr1:65856443	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	6.89	0.35	2.73e-11	Anticoagulant levels;
LUSC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg18681998	chr4:17616180	MED28	0.84	14.39	0.62	7.19e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg16524733	chr11:117070046	TAGLN	0.43	7.28	0.37	2.49e-12	Blood protein levels;
LUSC	trans	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg25214090	chr10:38739885	LOC399744	0.43	6.53	0.34	2.51e-10	Corneal astigmatism;
LUSC	cis	rs11229555	0.609	rs12273517	chr11:58201094	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2067615	0.524	rs1922436	chr12:107065258	A/G	cg15890332	chr12:107067104	RFX4	0.33	5.9	0.31	8.75e-9	Heart rate;
LUSC	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg15654264	chr1:150340011	RPRD2	0.61	10.15	0.49	2.84e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg18230493	chr5:56204884	C5orf35	-0.81	-9.42	-0.46	7.53e-19	Type 2 diabetes;
LUSC	cis	rs2137920	0.945	rs1877805	chr10:50234345	A/G	cg27141751	chr10:50231850	C10orf72	-0.37	-5.86	-0.31	1.09e-8	Migraine with aura;
LUSC	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg00310523	chr12:86230176	RASSF9	0.44	7.75	0.39	1.12e-13	Major depressive disorder;
LUSC	trans	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg20587970	chr11:113659929	NA	0.77	9.81	0.47	3.96e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs7605827	0.704	rs62120513	chr2:15537727	T/A	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg00277334	chr10:82204260	NA	-0.54	-7.29	-0.37	2.28e-12	Post bronchodilator FEV1;
LUSC	cis	rs73198271	0.515	rs75660006	chr8:8619594	C/T	cg01851573	chr8:8652454	MFHAS1	0.63	7.22	0.37	3.47e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.34	-0.42	1.96e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03352830	chr11:487213	PTDSS2	0.68	8.61	0.43	2.91e-16	Body mass index;
LUSC	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg11498726	chr8:26250323	BNIP3L	-0.43	-6.24	-0.32	1.3e-9	Red cell distribution width;
LUSC	trans	rs2262909	0.849	rs10420483	chr19:22190378	A/G	cg05197062	chr11:11642011	GALNTL4	-0.52	-7.15	-0.36	5.63e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg25258033	chr6:167368657	RNASET2	0.36	5.66	0.3	3.2e-8	Primary biliary cholangitis;
LUSC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	0.93	16.12	0.66	1.16e-43	Menopause (age at onset);
LUSC	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg23752985	chr2:85803571	VAMP8	0.35	7.72	0.39	1.33e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg05043794	chr9:111880884	C9orf5	-0.35	-7.46	-0.38	7.48e-13	Menarche (age at onset);
LUSC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-1.0	-18.17	-0.71	8.92e-52	Height;
LUSC	cis	rs12956009	0.583	rs9653018	chr18:44895853	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.44	0.33	4.13e-10	Educational attainment (years of education);
LUSC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.82	0.68	1.93e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10979	0.597	rs9399449	chr6:143908376	C/T	cg25407410	chr6:143891975	LOC285740	-0.65	-8.19	-0.41	5.6e-15	Hypospadias;
LUSC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg03929089	chr4:120376271	NA	-0.94	-16.13	-0.66	1.07e-43	Height;
LUSC	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	12.31	0.56	5.94e-29	Blood protein levels;
LUSC	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg27068330	chr11:65405492	SIPA1	-0.74	-10.29	-0.49	9.68e-22	Acne (severe);
LUSC	trans	rs61931739	0.620	rs61927757	chr12:33710109	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-6.12	-0.32	2.68e-9	Morning vs. evening chronotype;
LUSC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg14019146	chr3:50243930	SLC38A3	0.36	8.26	0.41	3.53e-15	Body mass index;
LUSC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-9.92	-0.48	1.68e-20	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17095355	0.818	rs11194981	chr10:111861054	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.51	-6.56	-0.34	2.1e-10	Biliary atresia;
LUSC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg23791538	chr6:167370224	RNASET2	-0.37	-5.69	-0.3	2.82e-8	Crohn's disease;
LUSC	cis	rs7903847	0.642	rs11189206	chr10:99167802	T/C	cg08345082	chr10:99160200	RRP12	-0.35	-7.27	-0.37	2.51e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg09904177	chr6:26538194	HMGN4	-0.71	-6.58	-0.34	1.79e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4285028	0.948	rs12493952	chr3:121708497	C/T	cg11130432	chr3:121712080	ILDR1	-0.65	-10.09	-0.48	4.39e-21	Multiple sclerosis;
LUSC	cis	rs7677751	0.806	rs7698425	chr4:55090656	C/T	cg17187183	chr4:55093834	PDGFRA	0.38	5.83	0.3	1.3e-8	Corneal astigmatism;
LUSC	cis	rs7605827	0.930	rs13398393	chr2:15602804	T/G	cg19274914	chr2:15703543	NA	0.46	9.04	0.44	1.27e-17	Educational attainment (years of education);
LUSC	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.31	-6.54	-0.34	2.35e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.45	-6.97	-0.36	1.75e-11	Tonsillectomy;
LUSC	cis	rs9311676	0.632	rs62259780	chr3:58428078	T/G	cg26110898	chr3:58419937	PDHB	0.4	6.53	0.34	2.51e-10	Systemic lupus erythematosus;
LUSC	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.32	0.45	1.64e-18	Lung cancer in ever smokers;
LUSC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.45	0.33	3.91e-10	Personality dimensions;
LUSC	cis	rs79911532	0.515	rs114616297	chr7:75719576	T/G	cg03592824	chr7:75666768	STYXL1	0.67	6.41	0.33	4.98e-10	Mononucleosis;
LUSC	cis	rs9517320	1.000	rs12864890	chr13:99126457	T/C	cg20487152	chr13:99095054	FARP1	0.36	6.71	0.34	8.35e-11	Longevity;
LUSC	trans	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg06606381	chr12:133084897	FBRSL1	0.52	6.31	0.33	8.98e-10	Depression;
LUSC	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg14196790	chr5:131705035	SLC22A5	0.52	8.9	0.44	3.57e-17	Blood metabolite levels;
LUSC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08048268	chr3:133502702	NA	-0.46	-8.84	-0.44	5.49e-17	Iron status biomarkers;
LUSC	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg02380750	chr20:61661411	NA	0.35	5.94	0.31	7e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4363385	0.747	rs4478766	chr1:152984906	G/A	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.84	-0.39	6.12e-14	Inflammatory skin disease;
LUSC	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg04362960	chr10:104952993	NT5C2	0.57	8.98	0.44	2.02e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg08773314	chr2:239334832	ASB1	0.41	8.83	0.44	5.99e-17	Multiple system atrophy;
LUSC	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg05887092	chr17:76393375	PGS1	0.54	9.77	0.47	5.57e-20	HDL cholesterol levels;
LUSC	cis	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg21775007	chr8:11205619	TDH	-0.57	-8.39	-0.42	1.4e-15	Neuroticism;
LUSC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg24399712	chr22:39784796	NA	-0.65	-12.03	-0.55	6.31e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	6.74	0.35	7.17e-11	Lung cancer in ever smokers;
LUSC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg01448562	chr3:133502909	NA	-0.66	-10.75	-0.51	2.4e-23	Iron status biomarkers;
LUSC	trans	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg18187862	chr3:45730750	SACM1L	0.56	7.06	0.36	9.52e-12	Primary sclerosing cholangitis;
LUSC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg06637938	chr14:75390232	RPS6KL1	0.53	8.42	0.42	1.13e-15	Height;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10735116	chr1:147400532	GPR89B	0.47	6.41	0.33	5.1e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg18758796	chr5:131593413	PDLIM4	0.43	7.26	0.37	2.68e-12	Breast cancer;
LUSC	cis	rs11971779	0.715	rs10265	chr7:139026152	T/G	cg07862535	chr7:139043722	LUC7L2	0.53	6.61	0.34	1.54e-10	Diisocyanate-induced asthma;
LUSC	cis	rs4363385	0.510	rs6664380	chr1:153030365	G/T	cg25856811	chr1:152973957	SPRR3	-0.39	-6.35	-0.33	6.83e-10	Inflammatory skin disease;
LUSC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg26338869	chr17:61819248	STRADA	0.4	5.77	0.3	1.81e-8	Prudent dietary pattern;
LUSC	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg20607287	chr7:12443886	VWDE	-0.59	-6.2	-0.32	1.71e-9	Coronary artery disease;
LUSC	cis	rs1018836	0.608	rs6992512	chr8:91477936	C/A	cg16814680	chr8:91681699	NA	-0.56	-8.3	-0.41	2.68e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17828380	0.920	rs71394506	chr15:63601026	A/T	cg05507819	chr15:63340323	TPM1	-0.75	-6.13	-0.32	2.5e-9	Social communication problems;
LUSC	cis	rs9549260	0.640	rs4943796	chr13:41196016	C/T	cg21288729	chr13:41239152	FOXO1	0.6	9.19	0.45	4.44e-18	Red blood cell count;
LUSC	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg13813247	chr22:41461852	NA	-0.37	-6.76	-0.35	6.12e-11	Neuroticism;
LUSC	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg02574844	chr11:5959923	NA	-0.44	-6.31	-0.33	8.96e-10	DNA methylation (variation);
LUSC	cis	rs2219968	0.923	rs7822053	chr8:78979111	A/G	cg00738934	chr8:78996279	NA	0.38	6.91	0.35	2.52e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.47	-7.4	-0.38	1.08e-12	Height;
LUSC	cis	rs2798269	0.604	rs6490662	chr13:22153280	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.48	-7.69	-0.39	1.63e-13	PR segment;
LUSC	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg20302342	chr1:156215951	PAQR6	0.31	5.99	0.31	5.41e-9	Tonsillectomy;
LUSC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg09796270	chr17:17721594	SREBF1	0.42	7.49	0.38	6.2e-13	Total body bone mineral density;
LUSC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg19622623	chr12:86230825	RASSF9	-0.43	-6.11	-0.32	2.77e-9	Major depressive disorder;
LUSC	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.77	-13.56	-0.6	1.11e-33	Heart rate;
LUSC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.09	0.48	4.54e-21	Electroencephalogram traits;
LUSC	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg05729581	chr11:3078854	CARS	-0.5	-7.25	-0.37	2.98e-12	Longevity;
LUSC	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg26395211	chr5:140044315	WDR55	0.45	6.99	0.36	1.5e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg03146154	chr1:46216737	IPP	0.55	8.21	0.41	5.01e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg03315344	chr16:75512273	CHST6	0.48	9.03	0.44	1.41e-17	Dupuytren's disease;
LUSC	cis	rs17155006	0.664	rs411396	chr7:107744759	A/G	cg05962710	chr7:107745446	LAMB4	-0.34	-6.16	-0.32	2.08e-9	Pneumococcal bacteremia;
LUSC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	trans	rs2562456	0.833	rs2928211	chr19:21541297	A/G	cg00806126	chr19:22604979	ZNF98	0.39	5.98	0.31	5.68e-9	Pain;
LUSC	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.16e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.48	-5.9	-0.31	8.94e-9	Iron status biomarkers;
LUSC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg06238570	chr21:40685208	BRWD1	0.47	7.25	0.37	2.84e-12	Cognitive function;
LUSC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg08859206	chr1:53392774	SCP2	0.52	8.93	0.44	2.96e-17	Monocyte count;
LUSC	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.48	-7.07	-0.36	9.08e-12	Menarche (age at onset);
LUSC	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.73	12.24	0.56	1.02e-28	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21659725	chr3:3221576	CRBN	0.52	8.01	0.4	1.88e-14	Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14787155	chr3:108308533	DZIP3;KIAA1524	0.4	6.57	0.34	1.93e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.31	0.37	1.99e-12	Motion sickness;
LUSC	cis	rs7605827	0.930	rs4668903	chr2:15530051	C/G	cg19274914	chr2:15703543	NA	0.47	9.08	0.44	1e-17	Educational attainment (years of education);
LUSC	cis	rs4253772	0.872	rs14843	chr22:46639462	A/T	cg09491104	chr22:46646882	C22orf40	-0.63	-6.52	-0.34	2.57e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg17385448	chr1:15911702	AGMAT	0.36	6.2	0.32	1.69e-9	Systolic blood pressure;
LUSC	trans	rs637571	0.565	rs570387	chr11:65637076	T/C	cg17712092	chr4:129076599	LARP1B	-0.83	-12.42	-0.56	2.18e-29	Eosinophil percentage of white cells;
LUSC	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.52	10.44	0.5	2.89e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12103840	chr6:108582260	SNX3	-0.42	-6.22	-0.32	1.52e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.43	-6.22	-0.32	1.47e-9	Platelet distribution width;
LUSC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg11406453	chr1:101602562	NA	-0.33	-5.68	-0.3	2.9e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg13114125	chr14:105738426	BRF1	-0.92	-16.03	-0.66	2.78e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg23649088	chr2:200775458	C2orf69	0.54	7.25	0.37	2.86e-12	Schizophrenia;
LUSC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg03929089	chr4:120376271	NA	-1.02	-19.53	-0.73	3.23e-57	Height;
LUSC	cis	rs6484504	0.532	rs1475558	chr11:31263428	A/G	cg26647111	chr11:31128758	NA	-0.41	-5.9	-0.31	9e-9	Red blood cell count;
LUSC	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg22980127	chr19:33182716	NUDT19	0.94	12.81	0.57	7.79e-31	Red blood cell traits;
LUSC	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.49	0.42	7.11e-16	Menarche (age at onset);
LUSC	cis	rs10489525	0.599	rs11102879	chr1:115603504	C/T	cg17147537	chr1:115611705	TSPAN2	0.3	6.04	0.31	4.11e-9	Autism;
LUSC	cis	rs2617583	0.904	rs2937639	chr5:1443728	A/G	cg07148919	chr5:1466943	LPCAT1	0.44	6.8	0.35	4.81e-11	Breast cancer;
LUSC	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg05754148	chr16:3507555	NAT15	0.8	9.5	0.46	4.08e-19	Tuberculosis;
LUSC	cis	rs77633900	0.772	rs2469224	chr15:76651327	T/G	cg21673338	chr15:77095150	SCAPER	-0.72	-6.26	-0.32	1.21e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg02023728	chr11:77925099	USP35	0.51	7.18	0.37	4.62e-12	Testicular germ cell tumor;
LUSC	cis	rs2996428	0.667	rs2368534	chr1:3740640	C/T	cg23277830	chr1:3704460	LRRC47	0.36	6.7	0.34	8.7e-11	Red cell distribution width;
LUSC	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.44	-0.33	4.07e-10	Triglycerides;
LUSC	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg02487331	chr1:146550467	NA	0.44	7.5	0.38	5.75e-13	HIV-1 control;
LUSC	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg14186256	chr22:23484241	RTDR1	0.96	17.8	0.7	2.65e-50	Bone mineral density;
LUSC	cis	rs9311676	0.632	rs6777066	chr3:58361603	T/C	cg13750441	chr3:58318267	PXK	0.34	6.66	0.34	1.1e-10	Systemic lupus erythematosus;
LUSC	cis	rs34638657	0.827	rs11641736	chr16:82206279	G/A	cg09439754	chr16:82129088	HSD17B2	-0.38	-5.83	-0.3	1.34e-8	Lung adenocarcinoma;
LUSC	cis	rs7192380	1.000	rs11647110	chr16:69589363	G/A	cg26679644	chr16:69762563	NA	0.32	5.71	0.3	2.46e-8	Sjögren's syndrome;
LUSC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.72	-0.39	1.35e-13	Lymphocyte counts;
LUSC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg13126279	chr21:47581558	C21orf56	0.41	5.8	0.3	1.57e-8	Testicular germ cell tumor;
LUSC	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.71	8.87	0.44	4.61e-17	Type 2 diabetes;
LUSC	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-1.05	-14.12	-0.61	7.94e-36	Exhaled nitric oxide levels;
LUSC	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg17411546	chr10:75410026	SYNPO2L	-0.53	-7.83	-0.39	6.71e-14	Inflammatory bowel disease;
LUSC	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg24060327	chr5:131705240	SLC22A5	0.48	8.18	0.41	5.94e-15	Blood metabolite levels;
LUSC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10802521	chr3:52805072	NEK4	0.54	8.38	0.42	1.45e-15	Bipolar disorder;
LUSC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.85	-15.04	-0.64	2.21e-39	Cognitive function;
LUSC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg20406979	chr6:167373233	NA	0.26	6.0	0.31	5.2e-9	Crohn's disease;
LUSC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg03146154	chr1:46216737	IPP	0.52	7.57	0.38	3.58e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.06e-9	Testicular germ cell tumor;
LUSC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	0.92	15.42	0.64	7.18e-41	Breast cancer;
LUSC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.42	0.64	7.15e-41	Bladder cancer;
LUSC	trans	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-12.33	-0.56	4.85e-29	Colorectal cancer;
LUSC	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg06552810	chr11:31128660	NA	-0.4	-7.08	-0.36	8.78e-12	Red blood cell count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26080111	chr7:559651	PDGFA	0.51	6.95	0.36	1.98e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.03	0.44	1.37e-17	Lung cancer in ever smokers;
LUSC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg05347473	chr6:146136440	FBXO30	0.49	8.22	0.41	4.64e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2658782	0.507	rs4457713	chr11:93037430	C/T	cg15737290	chr11:93063684	CCDC67	0.9	13.88	0.6	6.67e-35	Pulmonary function decline;
LUSC	cis	rs2298450	0.555	rs2845756	chr21:37611892	A/G	cg02919814	chr21:37666008	DOPEY2	-0.42	-6.26	-0.32	1.15e-9	Schizophrenia;
LUSC	trans	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.54	7.08	0.36	8.34e-12	Ulcerative colitis;
LUSC	cis	rs73198271	0.603	rs571130	chr8:8593691	A/G	cg01851573	chr8:8652454	MFHAS1	0.4	6.22	0.32	1.52e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06028605	chr16:24865363	SLC5A11	0.66	9.6	0.46	2.02e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs71403859	0.502	rs34015581	chr16:71508229	T/A	cg08717414	chr16:71523259	ZNF19	-0.64	-7.54	-0.38	4.54e-13	Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10100465	0.961	rs1813506	chr8:118648439	A/G	cg09430518	chr8:118662568	NA	-0.29	-5.66	-0.3	3.31e-8	Leprosy;
LUSC	trans	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg21659725	chr3:3221576	CRBN	0.67	8.07	0.4	1.29e-14	Menarche (age at onset);
LUSC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg14004847	chr7:1930337	MAD1L1	-0.59	-8.99	-0.44	1.83e-17	Schizophrenia;
LUSC	trans	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg13565492	chr6:43139072	SRF	-0.73	-10.88	-0.51	8.22e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg04362960	chr10:104952993	NT5C2	0.6	9.54	0.46	3.1400000000000002e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg05347473	chr6:146136440	FBXO30	0.58	10.1	0.48	4.28e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg04374321	chr14:90722782	PSMC1	-0.44	-6.63	-0.34	1.34e-10	Mortality in heart failure;
LUSC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg06618935	chr21:46677482	NA	-0.42	-8.56	-0.42	4.14e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs554111	0.656	rs10799680	chr1:21361181	C/T	cg01072550	chr1:21505969	NA	0.4	6.08	0.32	3.33e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg16230307	chr14:35515116	FAM177A1	0.78	10.01	0.48	8.33e-21	Psoriasis;
LUSC	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg01420254	chr6:26195488	NA	0.71	7.44	0.38	8.44e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Smoking initiation;
LUSC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.35	0.33	7.1e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg25208724	chr1:156163844	SLC25A44	1.08	22.65	0.78	1.77e-69	Testicular germ cell tumor;
LUSC	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.43	6.57	0.34	1.92e-10	Dupuytren's disease;
LUSC	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.53	-7.83	-0.39	6.36e-14	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6469656	0.730	rs1317271	chr8:117682668	T/A	cg24004040	chr8:117650383	NA	-0.43	-6.31	-0.33	9.04e-10	Colorectal cancer;
LUSC	cis	rs55665837	1.000	rs12288873	chr11:14450465	C/T	cg05501817	chr11:14380813	RRAS2	-0.41	-6.61	-0.34	1.51e-10	Vitamin D levels;
LUSC	cis	rs6967385	0.902	rs10282726	chr7:12372911	A/C	cg06484146	chr7:12443880	VWDE	0.39	5.8	0.3	1.51e-8	Response to taxane treatment (placlitaxel);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg14515252	chr20:5093771	C20orf30	0.7	6.1	0.32	2.9e-9	Cognitive performance;
LUSC	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.79	-0.6	1.45e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg05527609	chr1:210001259	C1orf107	0.66	9.4	0.46	9.25e-19	Orofacial clefts;
LUSC	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg23625390	chr15:77176239	SCAPER	0.47	7.23	0.37	3.23e-12	Blood metabolite levels;
LUSC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg12935359	chr14:103987150	CKB	-0.52	-7.94	-0.4	3.04e-14	Body mass index;
LUSC	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg04362960	chr10:104952993	NT5C2	0.69	9.95	0.48	1.29e-20	Arsenic metabolism;
LUSC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg02951883	chr7:2050386	MAD1L1	-0.56	-10.39	-0.49	4.28e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs477692	1.000	rs7475154	chr10:131440584	C/T	cg26102564	chr10:131424627	MGMT	-0.39	-6.07	-0.31	3.57e-9	Response to temozolomide;
LUSC	trans	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	5.95	0.31	6.6e-9	Cystic fibrosis severity;
LUSC	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg24562669	chr7:97807699	LMTK2	0.42	7.16	0.36	5.09e-12	Breast cancer;
LUSC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.44	0.53	8.75e-26	Prudent dietary pattern;
LUSC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg12560992	chr17:57184187	TRIM37	-0.89	-17.41	-0.69	8.89e-49	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.66	0.57	2.79e-30	Prudent dietary pattern;
LUSC	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg01966878	chr4:90757139	SNCA	-0.41	-5.82	-0.3	1.38e-8	Neuroticism;
LUSC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	0.95	16.43	0.67	7.01e-45	Menopause (age at onset);
LUSC	cis	rs4523957	0.928	rs11657644	chr17:2175210	C/G	cg16513277	chr17:2031491	SMG6	-0.57	-9.57	-0.46	2.56e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg13012494	chr21:47604986	C21orf56	0.42	5.78	0.3	1.73e-8	Testicular germ cell tumor;
LUSC	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.74	-11.9	-0.55	1.85e-27	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.38	6.48	0.33	3.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg08859206	chr1:53392774	SCP2	-0.42	-6.86	-0.35	3.42e-11	Monocyte count;
LUSC	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-1.1	-17.51	-0.69	3.81e-49	Exhaled nitric oxide output;
LUSC	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.87	15.08	0.64	1.52e-39	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg03806693	chr22:41940476	POLR3H	-0.91	-12.72	-0.57	1.7e-30	Vitiligo;
LUSC	trans	rs2262909	0.962	rs12610034	chr19:22314528	G/A	cg17074339	chr11:11642133	GALNTL4	0.43	6.51	0.34	2.69e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7523050	0.730	rs72984612	chr1:109434826	T/C	cg08274380	chr1:109419600	GPSM2	1.13	11.51	0.53	4.76e-26	Fat distribution (HIV);
LUSC	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg27539214	chr16:67997921	SLC12A4	-0.51	-7.6	-0.38	3.02e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.08	-0.4	1.22e-14	Axial length;
LUSC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg00033643	chr7:134001901	SLC35B4	0.45	7.05	0.36	1.02e-11	Mean platelet volume;
LUSC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg03188948	chr7:1209495	NA	0.66	7.09	0.36	8.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg20243544	chr17:37824526	PNMT	0.39	5.96	0.31	6.31e-9	Self-reported allergy;
LUSC	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg25575065	chr22:51066394	ARSA	-0.43	-6.03	-0.31	4.33e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	21.67	0.76	1.2e-65	Height;
LUSC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	0.65	13.71	0.6	2.93e-34	Prudent dietary pattern;
LUSC	cis	rs28595532	0.557	rs12498329	chr4:119311524	C/T	cg21605333	chr4:119757512	SEC24D	0.55	6.31	0.33	8.75e-10	Cannabis dependence symptom count;
LUSC	cis	rs2414856	0.510	rs72758931	chr15:64661224	T/C	cg08069370	chr15:64387884	SNX1	-0.78	-6.58	-0.34	1.84e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.86	-0.31	1.13e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7119	0.717	rs12911963	chr15:77807175	G/C	cg27398640	chr15:77910606	LINGO1	-0.29	-6.1	-0.32	2.93e-9	Type 2 diabetes;
LUSC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.88	-18.04	-0.7	2.88e-51	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.64	10.63	0.5	6.24e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs7584330	0.554	rs75918156	chr2:238426287	G/A	cg16989719	chr2:238392110	NA	-0.44	-6.3	-0.33	9.5e-10	Prostate cancer;
LUSC	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	16.59	0.67	1.66e-45	Exhaled nitric oxide output;
LUSC	cis	rs977987	0.902	rs34539062	chr16:75493279	C/A	cg03315344	chr16:75512273	CHST6	0.53	9.97	0.48	1.13e-20	Dupuytren's disease;
LUSC	cis	rs920590	0.573	rs6986456	chr8:19680562	A/G	cg03894339	chr8:19674705	INTS10	0.44	6.14	0.32	2.37e-9	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg18187862	chr3:45730750	SACM1L	0.53	6.78	0.35	5.31e-11	Primary sclerosing cholangitis;
LUSC	cis	rs10489525	0.599	rs7516121	chr1:115604317	A/G	cg17147537	chr1:115611705	TSPAN2	0.3	6.04	0.31	4.11e-9	Autism;
LUSC	cis	rs9796	0.870	rs28581803	chr15:41326513	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.41	-7.08	-0.36	8.46e-12	Menopause (age at onset);
LUSC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	16.82	0.68	2.06e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2286885	1.000	rs2277159	chr9:129243383	C/T	cg15282417	chr9:129245246	FAM125B	0.36	6.0	0.31	5.25e-9	Intraocular pressure;
LUSC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11644478	chr21:40555479	PSMG1	-0.6	-9.28	-0.45	2.25e-18	Menarche (age at onset);
LUSC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg06784218	chr1:46089804	CCDC17	0.55	11.22	0.52	5.24e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2274273	0.805	rs7159808	chr14:55624327	G/T	cg04306507	chr14:55594613	LGALS3	0.58	13.67	0.6	4.23e-34	Protein biomarker;
LUSC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs865483	0.895	rs72828253	chr17:35783416	A/G	cg06716730	chr17:35851459	DUSP14	-0.26	-5.73	-0.3	2.2e-8	Monocyte count;
LUSC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.24e-19	Prudent dietary pattern;
LUSC	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg15556689	chr8:8085844	FLJ10661	0.56	8.47	0.42	7.64e-16	Neuroticism;
LUSC	cis	rs7945718	0.935	rs4757059	chr11:12812356	G/A	cg25843174	chr11:12811716	TEAD1	-0.33	-7.45	-0.38	7.84e-13	Educational attainment (years of education);
LUSC	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg09904177	chr6:26538194	HMGN4	0.65	11.7	0.54	9.83e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs10221833	0.602	rs355879	chr2:165633427	T/C	cg26993132	chr16:89239499	CDH15	0.31	5.97	0.31	6.09e-9	Response to statin therapy;
LUSC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.23e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.56	0.38	3.9e-13	Iron status biomarkers;
LUSC	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg02569458	chr12:86230093	RASSF9	0.48	7.64	0.39	2.37e-13	Major depressive disorder;
LUSC	cis	rs34375054	0.525	rs12316499	chr12:125593318	G/A	cg00522288	chr12:125625016	AACS	-0.32	-6.12	-0.32	2.67e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg24648061	chr7:107114615	COG5;GPR22	-0.37	-6.0	-0.31	5.05e-9	Calcium levels;
LUSC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg16049864	chr8:95962084	TP53INP1	-0.68	-13.32	-0.59	9.66e-33	Type 2 diabetes;
LUSC	cis	rs6977660	1.000	rs10275322	chr7:19821220	C/T	cg05791153	chr7:19748676	TWISTNB	0.53	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LUSC	cis	rs10875746	0.951	rs2286021	chr12:48528220	C/T	cg13454099	chr12:49076203	C12orf41	-0.52	-6.15	-0.32	2.27e-9	Longevity (90 years and older);
LUSC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.82	-0.35	4.26e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.82	0.3	1.34e-8	Rheumatoid arthritis;
LUSC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg21782813	chr7:2030301	MAD1L1	0.35	5.8	0.3	1.56e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg17294928	chr15:75287854	SCAMP5	-0.71	-6.4	-0.33	5.27e-10	Lung cancer;
LUSC	cis	rs6545883	0.929	rs2463100	chr2:61659199	C/G	cg15711740	chr2:61764176	XPO1	-0.46	-7.02	-0.36	1.27e-11	Tuberculosis;
LUSC	cis	rs2377585	0.653	rs10505735	chr12:8841741	A/G	cg03761649	chr12:8850719	RIMKLB	0.45	5.68	0.3	2.89e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg06808227	chr14:105710500	BRF1	0.66	10.41	0.5	3.54e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg07148914	chr20:33460835	GGT7	0.47	6.95	0.36	1.92e-11	Height;
LUSC	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg17366294	chr4:99064904	C4orf37	0.6	10.58	0.5	9.38e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg25019033	chr10:957182	NA	-0.5	-6.2	-0.32	1.69e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs10979	0.597	rs9321927	chr6:143913295	A/G	cg25407410	chr6:143891975	LOC285740	0.57	7.4	0.38	1.1e-12	Hypospadias;
LUSC	trans	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg18187862	chr3:45730750	SACM1L	0.54	6.78	0.35	5.48e-11	Primary sclerosing cholangitis;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27555525	chr19:5237619	PTPRS	-0.39	-6.34	-0.33	7.24e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg01629716	chr15:45996671	NA	0.4	5.95	0.31	6.66e-9	Waist circumference;Weight;
LUSC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg01448562	chr3:133502909	NA	-0.61	-9.8	-0.47	4.38e-20	Iron status biomarkers;
LUSC	cis	rs4478858	0.735	rs10914360	chr1:31817476	G/A	cg00250761	chr1:31883323	NA	-0.37	-9.16	-0.45	5.22e-18	Alcohol dependence;
LUSC	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg02018176	chr4:1364513	KIAA1530	0.43	6.12	0.32	2.58e-9	Recombination rate (females);
LUSC	cis	rs8099014	1.000	rs2002088	chr18:56132725	G/A	cg12907477	chr18:56117327	MIR122	0.44	6.84	0.35	3.77e-11	Platelet count;
LUSC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg07507251	chr3:52567010	NT5DC2	0.29	5.68	0.3	2.96e-8	Bipolar disorder;
LUSC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	6.46	0.33	3.77e-10	Electroencephalogram traits;
LUSC	trans	rs629535	0.767	rs72654073	chr8:70081231	G/A	cg21567404	chr3:27674614	NA	-0.98	-15.73	-0.65	4.01e-42	Dupuytren's disease;
LUSC	trans	rs11088226	0.681	rs2833891	chr21:33928821	A/G	cg09050820	chr6:167586206	TCP10L2	0.73	10.12	0.48	3.48e-21	Gastritis;
LUSC	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg05966235	chr16:28915196	ATP2A1	0.34	6.23	0.32	1.43e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg26043149	chr18:55253948	FECH	-0.46	-7.11	-0.36	7.02e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg05283184	chr6:79620031	NA	-0.58	-11.98	-0.55	9.08e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg10755058	chr3:40428713	ENTPD3	0.34	5.86	0.31	1.12e-8	Renal cell carcinoma;
LUSC	cis	rs921665	0.831	rs4497900	chr2:3190754	A/G	cg16434511	chr2:3151078	NA	-0.63	-6.82	-0.35	4.22e-11	World class endurance athleticism;
LUSC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg26677194	chr12:130822605	PIWIL1	0.6	8.97	0.44	2.17e-17	Menopause (age at onset);
LUSC	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg02176678	chr2:219576539	TTLL4	-0.71	-11.63	-0.54	1.7e-26	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	6.18	0.32	1.82e-9	Height;
LUSC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg14668632	chr7:2872130	GNA12	-0.43	-6.5	-0.34	2.85e-10	Height;
LUSC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08736216	chr1:53307985	ZYG11A	0.3	6.19	0.32	1.73e-9	Monocyte count;
LUSC	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg13160058	chr8:26243215	BNIP3L	0.38	6.83	0.35	3.93e-11	Red cell distribution width;
LUSC	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg08601574	chr20:25228251	PYGB	0.42	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.64	-0.34	1.26e-10	Response to antipsychotic treatment;
LUSC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.64	-8.66	-0.43	1.99e-16	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-6.42	-0.33	4.8e-10	Triglycerides;
LUSC	trans	rs4729127	1.000	rs4729125	chr7:93997093	C/G	cg20086523	chr13:52378287	DHRS12	0.59	6.48	0.33	3.37e-10	Intelligence;
LUSC	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg19743168	chr1:23544995	NA	0.43	8.19	0.41	5.49e-15	Height;
LUSC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	0.93	17.54	0.69	2.66e-49	Heart rate;
LUSC	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-7.92	-0.4	3.45e-14	Bone mineral density (spine);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04357272	chr7:102312308	POLR2J2	-0.46	-6.55	-0.34	2.23e-10	Electrocardiographic conduction measures;
LUSC	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg17052675	chr2:3827356	NA	-0.56	-10.88	-0.51	8.15e-24	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg00042356	chr1:8021962	PARK7	0.84	10.02	0.48	8.04e-21	Inflammatory bowel disease;
LUSC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg22906224	chr7:99728672	NA	0.53	7.77	0.39	1e-13	Coronary artery disease;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg12484037	chr17:68165632	KCNJ2	0.4	5.99	0.31	5.49e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg06145435	chr7:1022769	CYP2W1	0.31	6.67	0.34	1.09e-10	Longevity;Endometriosis;
LUSC	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.22	-15.44	-0.65	5.73e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg22166914	chr1:53195759	ZYG11B	0.6	10.15	0.49	2.86e-21	Monocyte count;
LUSC	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.55	-10.61	-0.5	7.6e-23	Educational attainment;
LUSC	cis	rs4363385	0.510	rs6664380	chr1:153030365	G/T	cg00922841	chr1:152955080	SPRR1A	-0.37	-6.15	-0.32	2.26e-9	Inflammatory skin disease;
LUSC	cis	rs1957429	0.901	rs6573583	chr14:65351211	G/T	cg23373153	chr14:65346875	NA	1.07	12.89	0.58	3.85e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs11217036	1	rs11217036	chr11:118675772	C/T	cg19308663	chr11:118741387	NA	0.36	6.47	0.33	3.49e-10	Allergy;
LUSC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.72	-6.72	-0.35	7.85e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs3820928	0.874	rs4234066	chr2:227882180	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.8	-0.39	7.97e-14	Pulmonary function;
LUSC	cis	rs4919694	1.000	rs74749600	chr10:104732996	T/C	cg05855489	chr10:104503620	C10orf26	0.57	5.64	0.3	3.57e-8	Arsenic metabolism;
LUSC	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg00982548	chr2:198649783	BOLL	-0.56	-7.0	-0.36	1.41e-11	Ulcerative colitis;
LUSC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg09365446	chr1:150670422	GOLPH3L	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.42	6.2	0.32	1.71e-9	Systemic lupus erythematosus;
LUSC	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg06917634	chr15:78832804	PSMA4	0.51	6.49	0.33	3.03e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg26528668	chr16:1614120	IFT140	0.44	7.19	0.37	4.24e-12	Coronary artery disease;
LUSC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.78	-9.45	-0.46	6.16e-19	Mean platelet volume;
LUSC	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21659725	chr3:3221576	CRBN	0.6	8.77	0.43	9.54e-17	Resting heart rate;
LUSC	cis	rs3771570	0.901	rs35496488	chr2:242434316	G/A	cg21155796	chr2:242212141	HDLBP	0.62	6.84	0.35	3.68e-11	Prostate cancer;
LUSC	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg09835421	chr16:68378352	PRMT7	-0.78	-8.02	-0.4	1.79e-14	Magnesium levels;
LUSC	cis	rs4343996	0.967	rs4588749	chr7:3363992	A/G	cg21248987	chr7:3385318	SDK1	-0.39	-6.54	-0.34	2.3e-10	Motion sickness;
LUSC	cis	rs6580649	0.941	rs7971668	chr12:48469696	T/C	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	cis	rs7582720	0.945	rs2351524	chr2:203880992	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.76	-8.34	-0.42	1.98e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg13010199	chr12:38710504	ALG10B	0.59	8.84	0.44	5.46e-17	Heart rate;
LUSC	cis	rs6987853	0.901	rs2923429	chr8:42389743	A/G	cg09913449	chr8:42400586	C8orf40	0.5	8.32	0.41	2.25e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg21951975	chr1:209979733	IRF6	0.62	8.06	0.4	1.4e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	0.99	13.83	0.6	1.05e-34	Eosinophil percentage of granulocytes;
LUSC	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg04865166	chr7:105162814	PUS7	0.52	5.92	0.31	7.79e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-9.09	-0.45	8.85e-18	Morning vs. evening chronotype;
LUSC	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg26536354	chr8:144654954	C8orf73	0.67	7.31	0.37	2.05e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs7804356	1.000	rs3934268	chr7:26890572	G/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg04518342	chr5:131593106	PDLIM4	0.36	6.72	0.35	7.84e-11	Blood metabolite levels;
LUSC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.86	0.31	1.13e-8	Menopause (age at onset);
LUSC	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg12002119	chr2:101014098	CHST10	0.35	5.85	0.3	1.19e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00166722	chr3:10149974	C3orf24	0.63	8.61	0.43	2.85e-16	Alzheimer's disease;
LUSC	cis	rs13082711	0.911	rs13078798	chr3:27445971	A/G	cg02860705	chr3:27208620	NA	-0.5	-8.65	-0.43	2.21e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.78	-0.65	2.66e-42	Height;
LUSC	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21028142	chr17:79581711	NPLOC4	0.32	7.6	0.38	2.93e-13	Eye color traits;
LUSC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg24812749	chr6:127587940	RNF146	0.65	9.75	0.47	6.4e-20	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08375754	chr19:40724375	TTC9B	0.41	6.46	0.33	3.7e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg27205649	chr11:78285834	NARS2	-0.5	-5.65	-0.3	3.35e-8	Testicular germ cell tumor;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13401987	chr15:63569418	APH1B	0.46	6.27	0.32	1.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg06060754	chr5:176797920	RGS14	0.6	9.61	0.47	1.78e-19	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.84	-0.3	1.23e-8	Depression;
LUSC	cis	rs713477	0.654	rs7143800	chr14:55917734	A/G	cg13175173	chr14:55914753	NA	-0.29	-6.03	-0.31	4.36e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.71	-12.38	-0.56	3.1e-29	White blood cell count (basophil);
LUSC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24531977	chr5:56204891	C5orf35	-1.09	-15.89	-0.66	9.37e-43	Initial pursuit acceleration;
LUSC	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg25809561	chr17:30822961	MYO1D	0.56	9.78	0.47	4.89e-20	Schizophrenia;
LUSC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg02269571	chr22:50332266	NA	-0.54	-8.08	-0.4	1.24e-14	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg13206674	chr6:150067644	NUP43	0.62	10.17	0.49	2.43e-21	Lung cancer;
LUSC	cis	rs7940866	0.738	rs10894308	chr11:130891895	G/A	cg12179176	chr11:130786555	SNX19	0.65	10.02	0.48	7.91e-21	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg00945038	chr17:61921165	SMARCD2	0.54	9.35	0.46	1.35e-18	Prudent dietary pattern;
LUSC	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg00982548	chr2:198649783	BOLL	-0.57	-7.0	-0.36	1.44e-11	Ulcerative colitis;
LUSC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.84	15.34	0.64	1.44e-40	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7122539	0.646	rs543191	chr11:66583779	T/G	cg24851651	chr11:66362959	CCS	0.56	10.01	0.48	8.26e-21	HIV-1 susceptibility;
LUSC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.65	-10.38	-0.49	4.61e-22	Systemic lupus erythematosus;
LUSC	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.72e-18	Monocyte percentage of white cells;
LUSC	cis	rs16854884	0.657	rs7642774	chr3:143723272	T/A	cg06585982	chr3:143692056	C3orf58	0.5	7.88	0.4	4.76e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg00579200	chr11:133705235	NA	-0.4	-5.88	-0.31	9.73e-9	Childhood ear infection;
LUSC	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg27068330	chr11:65405492	SIPA1	0.72	10.42	0.5	3.36e-22	Systemic lupus erythematosus;
LUSC	cis	rs7590368	0.683	rs56121730	chr2:10960866	C/T	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg22834771	chr12:69754056	YEATS4	-0.42	-6.03	-0.31	4.36e-9	Blood protein levels;
LUSC	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg18302933	chr2:88491318	NA	-0.35	-6.73	-0.35	7.41e-11	Response to metformin (IC50);
LUSC	cis	rs7582720	0.945	rs72936860	chr2:203783484	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg05872129	chr22:39784769	NA	-0.53	-8.69	-0.43	1.66e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg01884057	chr2:25150051	NA	0.4	9.32	0.45	1.59e-18	Breast cancer;
LUSC	cis	rs939658	0.967	rs7172074	chr15:79452726	T/C	cg17916960	chr15:79447300	NA	0.47	9.33	0.45	1.54e-18	Refractive error;
LUSC	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg02023728	chr11:77925099	USP35	0.46	6.7	0.34	8.82e-11	Testicular germ cell tumor;
LUSC	cis	rs5758659	0.633	rs762995	chr22:42672124	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.3	-6.27	-0.32	1.13e-9	Cognitive function;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13787029	chr2:42721631	KCNG3	0.44	6.26	0.32	1.17e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg09479241	chr17:27052676	TLCD1	0.43	5.96	0.31	6.29e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg09165964	chr15:75287851	SCAMP5	-0.97	-8.23	-0.41	4.39e-15	Lung cancer;
LUSC	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg21573476	chr21:45109991	RRP1B	-0.36	-5.76	-0.3	1.87e-8	Mean corpuscular volume;
LUSC	trans	rs4650994	0.544	rs2476560	chr1:178594919	A/G	cg05059571	chr16:84539110	KIAA1609	0.46	8.7	0.43	1.54e-16	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs2282032	0.527	rs57011283	chr14:90767165	G/T	cg14092571	chr14:90743983	NA	0.47	7.95	0.4	2.88e-14	Longevity;
LUSC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs116988415	0.584	rs17180497	chr14:65269707	A/C	cg00114569	chr14:65239327	SPTB	-0.68	-7.57	-0.38	3.63e-13	Daytime sleep phenotypes;
LUSC	cis	rs7605827	0.930	rs6737962	chr2:15526998	T/G	cg19274914	chr2:15703543	NA	0.47	9.24	0.45	2.95e-18	Educational attainment (years of education);
LUSC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.89	0.31	9.39e-9	Rheumatoid arthritis;
LUSC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg16325326	chr1:53192061	ZYG11B	0.69	11.17	0.52	7.98e-25	Monocyte count;
LUSC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.41	-0.38	1.03e-12	Aortic root size;
LUSC	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.92	0.58	3e-31	Bipolar disorder;
LUSC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.13	17.23	0.69	4.9e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26314531	chr2:26401878	FAM59B	0.75	10.1	0.48	4.27e-21	Gut microbiome composition (summer);
LUSC	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg05768032	chr16:30646687	NA	0.4	5.96	0.31	6.32e-9	Multiple myeloma;
LUSC	trans	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.65	-0.43	2.16e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-10.33	-0.49	6.84e-22	Monocyte count;
LUSC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.78	13.94	0.61	4.08e-35	Dental caries;
LUSC	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg26924012	chr15:45694286	SPATA5L1	1.13	20.38	0.74	1.46e-60	Homoarginine levels;
LUSC	cis	rs7106204	0.514	rs2068454	chr11:24256166	C/G	ch.11.24196551F	chr11:24239977	NA	-0.88	-10.0	-0.48	9.35e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs7939886	0.841	rs79254833	chr11:55986896	T/C	cg03929089	chr4:120376271	NA	0.82	6.13	0.32	2.55e-9	Myopia (pathological);
LUSC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg11965913	chr1:205819406	PM20D1	-0.54	-8.83	-0.44	5.98e-17	Menarche (age at onset);
LUSC	trans	rs877282	0.898	rs10904546	chr10:757222	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.51	-0.34	2.71e-10	Uric acid levels;
LUSC	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg13256891	chr4:100009986	ADH5	-0.43	-6.0	-0.31	5.06e-9	Alcohol dependence;
LUSC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg15790184	chr11:494944	RNH1	0.54	5.94	0.31	7.19e-9	Body mass index;
LUSC	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg05043794	chr9:111880884	C9orf5	-0.34	-7.41	-0.38	1.03e-12	Menarche (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27014927	chr22:45403808	PHF21B	-0.4	-6.19	-0.32	1.81e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4654899	1.000	rs4654896	chr1:21356930	T/C	cg01072550	chr1:21505969	NA	-0.56	-8.52	-0.42	5.53e-16	Superior frontal gyrus grey matter volume;
LUSC	trans	rs330071	0.549	rs11785593	chr8:9256324	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	6.28	0.32	1.04e-9	Acne (severe);
LUSC	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.71	-0.39	1.42e-13	Neuroticism;
LUSC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00149659	chr3:10157352	C3orf10	0.91	12.63	0.57	3.62e-30	Alzheimer's disease;
LUSC	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg18721089	chr20:30220636	NA	-0.37	-6.54	-0.34	2.35e-10	Mean corpuscular volume;
LUSC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.15	-14.14	-0.61	6.97e-36	Breast cancer;
LUSC	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg09835421	chr16:68378352	PRMT7	-0.45	-5.69	-0.3	2.78e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7481584	0.926	rs12806061	chr11:3008404	G/A	cg08508325	chr11:3079039	CARS	0.31	5.96	0.31	6.46e-9	Calcium levels;
LUSC	cis	rs3770081	1.000	rs2241435	chr2:86360916	C/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.1	-7.59	-0.38	3.17e-13	Facial emotion recognition (sad faces);
LUSC	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-0.9	-15.71	-0.65	4.81e-42	Height;
LUSC	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.7	-10.8	-0.51	1.57e-23	Alcohol dependence;
LUSC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg26116260	chr4:7069785	GRPEL1	1.04	15.18	0.64	6.1e-40	Monocyte percentage of white cells;
LUSC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg18512352	chr11:47633146	NA	-0.47	-9.55	-0.46	2.96e-19	Subjective well-being;
LUSC	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.5	-0.38	5.85e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	6.03	0.31	4.29e-9	Breast cancer;
LUSC	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg17507749	chr15:85114479	UBE2QP1	0.68	8.74	0.43	1.18e-16	Schizophrenia;
LUSC	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg27246729	chr12:121163418	ACADS	0.47	7.51	0.38	5.56e-13	Mean corpuscular volume;
LUSC	cis	rs4654899	1.000	rs6702110	chr1:21515906	A/G	cg01072550	chr1:21505969	NA	-0.53	-8.08	-0.4	1.23e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg05347473	chr6:146136440	FBXO30	0.5	8.36	0.42	1.66e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg25703541	chr22:24373054	LOC391322	-0.88	-14.47	-0.62	3.69e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg15485101	chr11:133734466	NA	0.4	7.3	0.37	2.14e-12	Childhood ear infection;
LUSC	cis	rs12980942	1.000	rs6957	chr19:41830606	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.15	0.32	2.16e-9	Coronary artery disease;
LUSC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.08	0.32	3.32e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19741500	chr1:27930843	AHDC1	-0.45	-6.8	-0.35	4.74e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg13010199	chr12:38710504	ALG10B	-0.52	-7.91	-0.4	3.89e-14	Bladder cancer;
LUSC	cis	rs2286503	0.650	rs1990279	chr7:22890742	A/G	cg04907244	chr7:22894795	SNORD93	-0.37	-6.25	-0.32	1.28e-9	Fibrinogen;
LUSC	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.7	10.45	0.5	2.72e-22	Corneal astigmatism;
LUSC	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs67539049	1.000	rs67909842	chr8:11293429	A/G	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.4	-6.12	-0.32	2.68e-9	Itch intensity from mosquito bite;
LUSC	cis	rs9815354	0.953	rs1716694	chr3:41986399	G/T	cg03022575	chr3:42003672	ULK4	-0.52	-5.85	-0.3	1.19e-8	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-11.76	-0.54	5.97e-27	Gut microbiome composition (summer);
LUSC	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg05283184	chr6:79620031	NA	-0.47	-8.97	-0.44	2.13e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03576123	chr11:487126	PTDSS2	-1.05	-11.18	-0.52	7.13e-25	Body mass index;
LUSC	cis	rs9648716	0.515	rs38734	chr7:140706708	A/T	cg23214464	chr7:140373596	ADCK2	0.7	6.46	0.33	3.68e-10	Type 2 diabetes;
LUSC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg10356904	chr22:49881777	NA	-0.31	-6.99	-0.36	1.49e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.69	11.25	0.52	4.11e-25	Longevity;
LUSC	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg25566285	chr7:158114605	PTPRN2	0.35	6.53	0.34	2.52e-10	Calcium levels;
LUSC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.69	-0.34	9.34e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9815354	0.812	rs73073364	chr3:41843058	T/C	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	trans	rs2201841	0.501	rs114407826	chr1:67742235	G/A	cg16262963	chr14:104851903	NA	-0.23	-6.03	-0.31	4.45e-9	Ulcerative colitis;Psoriasis;Crohn's disease;
LUSC	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg01657329	chr11:68192670	LRP5	-0.49	-7.67	-0.39	1.84e-13	Total body bone mineral density;
LUSC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.79	-0.3	1.64e-8	Breast cancer;
LUSC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg05084668	chr3:125655381	ALG1L	-0.52	-8.02	-0.4	1.86e-14	Blood pressure (smoking interaction);
LUSC	cis	rs9658691	0.607	rs9658750	chr10:90766596	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-6.14	-0.32	2.35e-9	Mosquito bite size;
LUSC	trans	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17712092	chr4:129076599	LARP1B	0.81	12.03	0.55	6.03e-28	Eosinophil percentage of white cells;
LUSC	cis	rs2346177	0.875	rs4413204	chr2:46647092	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-8.57	-0.42	4.02e-16	HDL cholesterol;
LUSC	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-9.57	-0.46	2.51e-19	Coffee consumption (cups per day);
LUSC	cis	rs6933660	0.610	rs71549125	chr6:151770796	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	6.38	0.33	6.05e-10	Menarche (age at onset);
LUSC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.44	-0.33	4.23e-10	Menopause (age at onset);
LUSC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg21724239	chr8:58056113	NA	0.57	6.62	0.34	1.4e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	0.9	13.19	0.59	3e-32	Breast cancer;
LUSC	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg13852791	chr20:30311386	BCL2L1	0.92	13.96	0.61	3.38e-35	Mean corpuscular hemoglobin;
LUSC	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.54	9.43	0.46	6.95e-19	Weight;
LUSC	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.69	8.65	0.43	2.17e-16	Type 2 diabetes;
LUSC	cis	rs9581857	0.615	rs9581849	chr13:28005782	G/T	cg22138327	chr13:27999177	GTF3A	0.89	9.45	0.46	6.21e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-7.46	-0.38	7.61e-13	Lymphocyte counts;
LUSC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg18402987	chr7:1209562	NA	0.71	7.85	0.39	5.89e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg09092052	chr15:45571596	NA	0.46	6.36	0.33	6.52e-10	Glomerular filtration rate;
LUSC	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg26513180	chr16:89883248	FANCA	0.62	9.92	0.48	1.72e-20	Vitiligo;
LUSC	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	trans	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg13565492	chr6:43139072	SRF	-0.61	-6.97	-0.36	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12493885	0.585	rs61790900	chr3:153642726	A/G	cg17054900	chr3:154042577	DHX36	-0.56	-5.94	-0.31	7.13e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg24006582	chr15:45444508	DUOX1	0.66	9.34	0.46	1.39e-18	Uric acid levels;
LUSC	cis	rs2299587	0.560	rs3913556	chr8:17781401	A/G	cg01800426	chr8:17659068	MTUS1	-0.49	-6.55	-0.34	2.21e-10	Economic and political preferences;
LUSC	cis	rs672059	1.000	rs522372	chr1:183157449	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.55	-8.02	-0.4	1.75e-14	Hypertriglyceridemia;
LUSC	cis	rs9311676	0.656	rs34579268	chr3:58410554	C/T	cg13750441	chr3:58318267	PXK	0.35	6.95	0.36	1.95e-11	Systemic lupus erythematosus;
LUSC	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg09754948	chr16:28834200	ATXN2L	0.44	6.47	0.33	3.56e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg25036284	chr2:26402008	FAM59B	-0.69	-9.95	-0.48	1.35e-20	Gut microbiome composition (summer);
LUSC	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg26061582	chr7:22766209	IL6	0.48	6.97	0.36	1.75e-11	Lung cancer;
LUSC	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg10061532	chr1:201886748	LMOD1	-0.23	-5.66	-0.3	3.22e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.16	0.32	2.11e-9	Mean platelet volume;
LUSC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg11965913	chr1:205819406	PM20D1	-0.78	-16.17	-0.66	7.43e-44	Monocyte percentage of white cells;
LUSC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.66	-0.34	1.11e-10	Lung cancer;
LUSC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.58	-0.38	3.54e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg10523679	chr1:76189770	ACADM	-0.44	-6.26	-0.32	1.16e-9	Daytime sleep phenotypes;
LUSC	cis	rs10779751	0.770	rs2486922	chr1:11124885	T/C	cg04508216	chr1:11107452	MASP2	0.33	5.87	0.31	1.03e-8	Body mass index;
LUSC	trans	rs9929218	0.953	rs9939049	chr16:68812301	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.5	-0.53	5.27e-26	Colorectal cancer;
LUSC	cis	rs1941023	0.503	rs2233238	chr11:60145441	G/C	cg08716584	chr11:60157161	MS4A7	-0.65	-12.39	-0.56	2.92e-29	Congenital heart disease (maternal effect);
LUSC	cis	rs12618769	1.000	rs72825725	chr2:99251259	C/A	cg10123293	chr2:99228465	UNC50	0.43	5.96	0.31	6.29e-9	Bipolar disorder;
LUSC	cis	rs500891	0.533	rs1342827	chr6:84161824	T/C	cg08257003	chr6:84140564	ME1	0.36	8.79	0.43	7.77e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.73	0.35	7.58e-11	Tonsillectomy;
LUSC	cis	rs7267979	0.586	rs6050439	chr20:25192331	T/C	cg08601574	chr20:25228251	PYGB	0.44	6.76	0.35	6.03e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg02972257	chr16:68554789	NA	0.42	5.77	0.3	1.86e-8	Colorectal cancer;
LUSC	cis	rs2898681	0.581	rs11938140	chr4:53678057	T/A	cg00338735	chr4:53728038	RASL11B	0.43	5.83	0.3	1.31e-8	Optic nerve measurement (cup area);
LUSC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.95	-0.31	6.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg17264618	chr3:40429014	ENTPD3	-0.32	-6.88	-0.35	3.02e-11	Renal cell carcinoma;
LUSC	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg03929089	chr4:120376271	NA	-0.58	-6.16	-0.32	2.05e-9	Axial length;
LUSC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg12560992	chr17:57184187	TRIM37	0.85	15.35	0.64	1.26e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg17173187	chr15:85201210	NMB	0.36	6.33	0.33	8.09e-10	Schizophrenia;
LUSC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg13628971	chr7:2884303	GNA12	0.53	7.2	0.37	3.9e-12	Height;
LUSC	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg15934090	chr1:100435551	SLC35A3	0.47	8.09	0.4	1.1e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg04871131	chr7:94954202	PON1	-0.38	-5.95	-0.31	6.61e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg05738196	chr6:26577821	NA	0.82	15.84	0.66	1.48e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.89	16.67	0.67	7.9e-46	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15214567	chr21:44527826	U2AF1	-0.43	-6.47	-0.33	3.39e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.45	5.83	0.3	1.33e-8	Renal function-related traits (BUN);
LUSC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg04315214	chr1:2043799	PRKCZ	-0.4	-8.14	-0.41	8.18e-15	Height;
LUSC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-0.84	-10.03	-0.48	7.15e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg11861562	chr11:117069780	TAGLN	0.34	6.65	0.34	1.16e-10	Blood protein levels;
LUSC	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg23711669	chr6:146136114	FBXO30	0.83	15.19	0.64	5.29e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4959270	1.000	rs4959270	chr6:457748	A/C	cg09757644	chr6:447497	NA	-0.3	-6.21	-0.32	1.59e-9	Limited cutaneous systemic scleroderma;
LUSC	cis	rs13720	0.722	rs163791	chr20:57576174	G/A	cg23907860	chr20:57583709	CTSZ	-0.45	-5.97	-0.31	6e-9	Platelet distribution width;
LUSC	cis	rs12472274	1.000	rs12472274	chr2:239095422	G/A	cg17459225	chr2:239074497	NA	0.63	10.01	0.48	8.55e-21	Phospholipid levels (plasma);
LUSC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-13.76	-0.6	1.97e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs2692947	0.795	rs2252697	chr2:96778190	G/C	cg22654517	chr2:96458247	NA	-0.36	-7.2	-0.37	4.06e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.5	7.67	0.39	1.85e-13	Eosinophil percentage of white cells;
LUSC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.82	-0.3	1.4e-8	Platelet count;
LUSC	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg01028140	chr2:1542097	TPO	-0.44	-6.92	-0.35	2.39e-11	IgG glycosylation;
LUSC	cis	rs1712517	0.873	rs1163083	chr10:105038455	T/A	cg05636881	chr10:105038444	INA	0.4	6.85	0.35	3.63e-11	Migraine;
LUSC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-11.85	-0.54	2.83e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	7.04	0.36	1.12e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg23029597	chr12:123009494	RSRC2	-0.74	-9.97	-0.48	1.17e-20	Body mass index;
LUSC	cis	rs17621444	0.522	rs1889439	chr10:121810861	G/T	cg02041677	chr10:121771263	NA	-0.34	-6.54	-0.34	2.26e-10	IgG glycosylation;
LUSC	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22455342	chr2:225449267	CUL3	0.46	6.16	0.32	2.14e-9	IgE levels in asthmatics (D.p. specific);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg15886017	chr9:96278586	FAM120A	0.4	6.1	0.32	2.92e-9	Cognitive function;Information processing speed;
LUSC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.35	6.32	0.33	8.43e-10	Obesity-related traits;
LUSC	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg18827107	chr12:86230957	RASSF9	0.47	7.02	0.36	1.23e-11	Major depressive disorder;
LUSC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.66	-8.44	-0.42	1e-15	Diastolic blood pressure;
LUSC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg26677194	chr12:130822605	PIWIL1	0.57	8.36	0.42	1.78e-15	Menopause (age at onset);
LUSC	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg27411982	chr8:10470053	RP1L1	-0.46	-7.09	-0.36	7.8e-12	Neuroticism;
LUSC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.26	0.32	1.19e-9	Mean platelet volume;
LUSC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.33	-0.37	1.74e-12	Aortic root size;
LUSC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg24296786	chr1:45957014	TESK2	0.53	8.13	0.41	8.55e-15	High light scatter reticulocyte count;
LUSC	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.12	-0.45	6.98e-18	Monocyte percentage of white cells;
LUSC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg13683864	chr3:40499215	RPL14	-1.06	-18.53	-0.71	3.26e-53	Renal cell carcinoma;
LUSC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg24920358	chr1:40204285	PPIE	0.6	10.8	0.51	1.64e-23	Blood protein levels;
LUSC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg11871910	chr12:69753446	YEATS4	0.93	17.13	0.68	1.14e-47	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7719624	1.000	rs7719624	chr5:135377566	A/G	cg12897067	chr5:135418308	NA	-0.39	-5.73	-0.3	2.22e-8	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs601339	0.938	rs1696344	chr12:123183059	C/T	cg11919336	chr12:123188078	GPR109A	0.44	6.58	0.34	1.87e-10	Adiponectin levels;
LUSC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg02038168	chr22:39784481	NA	0.49	7.97	0.4	2.59e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs3947	0.738	rs1293328	chr8:11695060	C/T	cg00262122	chr8:11665843	FDFT1	-0.47	-6.1	-0.32	2.86e-9	Blood protein levels;
LUSC	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg13010199	chr12:38710504	ALG10B	0.47	7.27	0.37	2.56e-12	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg13206674	chr6:150067644	NUP43	0.45	6.76	0.35	6.32e-11	Lung cancer;
LUSC	trans	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg18876405	chr7:65276391	NA	-0.49	-6.67	-0.34	1.04e-10	Corneal structure;
LUSC	cis	rs4730250	0.707	rs257375	chr7:106799043	A/G	cg02696742	chr7:106810147	HBP1	-0.58	-7.85	-0.39	5.56e-14	Osteoarthritis;
LUSC	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.27	-0.41	3.15e-15	Mean platelet volume;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00411741	chr19:18208476	MAST3	0.7	6.03	0.31	4.35e-9	Cognitive performance;
LUSC	cis	rs6714710	0.603	rs6746768	chr2:98466647	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	8.56	0.42	4.18e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg25838465	chr1:92012736	NA	-0.74	-15.08	-0.64	1.55e-39	Breast cancer;
LUSC	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg17764715	chr19:33622953	WDR88	0.6	8.29	0.41	2.72e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9943753	0.525	rs7952909	chr12:109808573	A/T	cg19025524	chr12:109796872	NA	0.38	7.02	0.36	1.23e-11	HDL cholesterol;
LUSC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.76	-11.85	-0.54	2.74e-27	Tonsillectomy;
LUSC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.77	-0.68	3.24e-46	Primary sclerosing cholangitis;
LUSC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg08798685	chr6:27730294	NA	-0.59	-5.94	-0.31	7.19e-9	Depression;
LUSC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg06640241	chr16:89574553	SPG7	0.88	15.95	0.66	5.51e-43	Multiple myeloma (IgH translocation);
LUSC	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg17691542	chr6:26056736	HIST1H1C	0.49	6.74	0.35	6.78e-11	Iron status biomarkers;
LUSC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg14004847	chr7:1930337	MAD1L1	-0.53	-7.83	-0.39	6.68e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	10.1	0.48	4.26e-21	Hip circumference adjusted for BMI;
LUSC	cis	rs2274273	0.967	rs8013027	chr14:55610940	C/G	cg04306507	chr14:55594613	LGALS3	0.54	12.09	0.55	3.67e-28	Protein biomarker;
LUSC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.35	-0.53	1.73e-25	Mean corpuscular volume;
LUSC	cis	rs5753037	0.838	rs131293	chr22:30171031	T/G	cg11564601	chr22:30592435	NA	0.33	5.8	0.3	1.5e-8	Type 1 diabetes;
LUSC	cis	rs7589342	0.929	rs6725519	chr2:106445209	A/G	cg14210321	chr2:106509881	NCK2	0.54	8.3	0.41	2.54e-15	Addiction;
LUSC	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg10560079	chr2:191398806	TMEM194B	0.67	8.06	0.4	1.41e-14	Diastolic blood pressure;
LUSC	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	1.06	15.22	0.64	4.19e-40	Uric acid levels;
LUSC	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg18099408	chr3:52552593	STAB1	0.36	6.11	0.32	2.72e-9	Electroencephalogram traits;
LUSC	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg04511125	chr2:88470314	THNSL2	0.71	6.64	0.34	1.25e-10	Plasma clusterin levels;
LUSC	cis	rs10208940	0.920	rs7580719	chr2:68833572	A/G	cg12452813	chr2:68675892	NA	-0.56	-6.06	-0.31	3.76e-9	Urate levels in lean individuals;
LUSC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg21361702	chr7:150065534	REPIN1	0.48	6.22	0.32	1.49e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg11473876	chr11:109292803	C11orf87	0.4	6.5	0.34	2.92e-10	Schizophrenia;
LUSC	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg15744005	chr10:104629667	AS3MT	-0.27	-5.71	-0.3	2.44e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs17255340	0.539	rs1144188	chr6:83984097	A/G	cg08257003	chr6:84140564	ME1	0.31	7.54	0.38	4.52e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23583168	chr7:148888333	NA	-0.8	-11.99	-0.55	8.43e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg23505145	chr19:12996616	KLF1	0.64	10.7	0.51	3.62e-23	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10802521	chr3:52805072	NEK4	-0.47	-6.84	-0.35	3.7e-11	Bipolar disorder;
LUSC	cis	rs2078087	0.522	rs594488	chr1:183241262	G/A	cg13843938	chr1:183241246	NMNAT2	-0.42	-6.82	-0.35	4.2e-11	Obesity-related traits;
LUSC	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg02023728	chr11:77925099	USP35	0.47	7.08	0.36	8.67e-12	Testicular germ cell tumor;
LUSC	cis	rs4776059	0.798	rs2414160	chr15:52872530	G/C	cg25063058	chr15:52860530	ARPP19	-0.46	-5.69	-0.3	2.73e-8	Schizophrenia;
LUSC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.95	-0.31	6.87e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22455342	chr2:225449267	CUL3	0.44	6.19	0.32	1.73e-9	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.94	0.55	1.27e-27	Personality dimensions;
LUSC	cis	rs2481665	0.617	rs12732781	chr1:62518459	T/C	cg18591186	chr1:62594603	INADL	-0.39	-6.2	-0.32	1.65e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1775715	0.737	rs1541260	chr10:32105570	C/T	cg18675610	chr10:32216311	ARHGAP12	0.29	6.34	0.33	7.56e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg19592336	chr6:28129416	ZNF389	0.54	7.05	0.36	1.02e-11	Parkinson's disease;
LUSC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08219700	chr8:58056026	NA	0.72	8.29	0.41	2.9e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg08847533	chr14:75593920	NEK9	0.85	14.98	0.63	3.67e-39	Height;
LUSC	cis	rs2004776	0.656	rs4847008	chr1:230865226	G/T	cg07502417	chr1:230849801	AGT	0.25	5.88	0.31	1.01e-8	Diastolic blood pressure;
LUSC	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg14500267	chr11:67383377	NA	0.33	6.18	0.32	1.85e-9	Mean corpuscular volume;
LUSC	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	9.76	0.47	5.78e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3106136	0.546	rs7685121	chr4:95175682	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.52	-0.42	5.42e-16	Capecitabine sensitivity;
LUSC	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg01884057	chr2:25150051	NA	-0.47	-11.27	-0.52	3.54e-25	Body mass index;
LUSC	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg22875332	chr1:76189707	ACADM	-0.4	-6.07	-0.32	3.53e-9	Daytime sleep phenotypes;
LUSC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-1.18	-13.38	-0.59	5.56e-33	Diabetic kidney disease;
LUSC	cis	rs17253792	0.822	rs17253744	chr14:56161950	C/G	cg01858014	chr14:56050164	KTN1	-0.8	-6.05	-0.31	3.82e-9	Putamen volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21012866	chr6:10747898	TMEM14B	-0.43	-6.3	-0.33	9.3e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.46	6.43	0.33	4.34e-10	Alzheimer's disease (late onset);
LUSC	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg23649088	chr2:200775458	C2orf69	0.52	7.36	0.37	1.43e-12	Schizophrenia;
LUSC	cis	rs4713675	0.565	rs9394161	chr6:33669793	G/C	cg14003231	chr6:33640908	ITPR3	0.31	5.96	0.31	6.53e-9	Plateletcrit;
LUSC	cis	rs963731	0.579	rs4643520	chr2:39229464	T/C	cg04010122	chr2:39346883	SOS1	-0.79	-5.73	-0.3	2.2e-8	Corticobasal degeneration;
LUSC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.3	-0.45	1.91e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg11502198	chr6:26597334	ABT1	0.55	8.2	0.41	5.23e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-8.54	-0.42	4.65e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	12.34	0.56	4.46e-29	Colorectal cancer;
LUSC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06481639	chr22:41940642	POLR3H	-0.51	-5.76	-0.3	1.86e-8	Vitiligo;
LUSC	cis	rs61931739	0.591	rs10743834	chr12:33916129	A/C	cg06521331	chr12:34319734	NA	-0.41	-6.68	-0.34	9.72e-11	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg17439093	chr7:107302364	SLC26A4;LOC286002	0.74	6.46	0.33	3.75e-10	Cognitive performance;
LUSC	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.01	-0.36	1.34e-11	Mood instability;
LUSC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg20821713	chr7:1055600	C7orf50	-0.47	-7.7	-0.39	1.58e-13	Longevity;Endometriosis;
LUSC	cis	rs6692729	0.933	rs1295640	chr1:227070378	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.51	-7.32	-0.37	1.91e-12	Electrodermal activity;
LUSC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	0.96	12.87	0.58	4.67e-31	Eosinophil percentage of granulocytes;
LUSC	cis	rs2573652	0.928	rs2581348	chr15:100514063	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.41	-7.54	-0.38	4.45e-13	Height;
LUSC	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg13072238	chr3:49761600	GMPPB	0.65	8.33	0.41	2.14e-15	Menarche (age at onset);
LUSC	cis	rs1322512	0.917	rs2011836	chr6:152954725	A/G	cg27316956	chr6:152958899	SYNE1	-0.36	-6.04	-0.31	4.06e-9	Tonometry;
LUSC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15541040	chr2:3486749	NA	-0.58	-9.1	-0.45	8.15e-18	Neurofibrillary tangles;
LUSC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg23262073	chr20:60523788	NA	-0.42	-5.95	-0.31	6.71e-9	Body mass index;
LUSC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg16584290	chr5:462447	EXOC3	-0.37	-6.43	-0.33	4.39e-10	Cystic fibrosis severity;
LUSC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.61	0.47	1.89e-19	Mean platelet volume;
LUSC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-1.08	-16.08	-0.66	1.79e-43	Initial pursuit acceleration;
LUSC	trans	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg04995722	chr7:26192034	NFE2L3	0.38	6.13	0.32	2.43e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-8.16	-0.41	6.99e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	10.64	0.5	5.82e-23	Bone mineral density;
LUSC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg17971929	chr21:40555470	PSMG1	-0.6	-9.71	-0.47	8.38e-20	Cognitive function;
LUSC	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-6.55	-0.34	2.14e-10	Monocyte percentage of white cells;
LUSC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg27535305	chr1:53392650	SCP2	-0.49	-9.71	-0.47	8.84e-20	Monocyte count;
LUSC	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg07817648	chr10:79422355	NA	-0.57	-7.33	-0.37	1.73e-12	Bone mineral density;
LUSC	cis	rs7851660	0.839	rs7027221	chr9:100662379	T/C	cg13688889	chr9:100608707	NA	-0.54	-8.44	-0.42	9.53e-16	Strep throat;
LUSC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-11.8	-0.54	4.25e-27	Chronic sinus infection;
LUSC	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.74	0.51	2.52e-23	Morning vs. evening chronotype;
LUSC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg26513180	chr16:89883248	FANCA	0.79	6.38	0.33	5.97e-10	Skin colour saturation;
LUSC	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.54	-10.73	-0.51	2.88e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg00105475	chr2:10696890	NA	0.38	6.35	0.33	6.94e-10	Prostate cancer;
LUSC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg20607798	chr8:58055168	NA	0.52	5.66	0.3	3.29e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs2018683	0.768	rs10282015	chr7:29022138	G/A	cg19402173	chr7:128379420	CALU	-0.58	-9.44	-0.46	6.62e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.64	8.49	0.42	6.72e-16	High light scatter reticulocyte count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17498662	chr6:41754992	PRICKLE4;TOMM6	-0.43	-6.36	-0.33	6.72e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg04362960	chr10:104952993	NT5C2	-0.52	-6.55	-0.34	2.15e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.72	-0.39	1.35e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4237845	0.680	rs10877033	chr12:58283731	T/C	cg00677455	chr12:58241039	CTDSP2	0.49	7.29	0.37	2.2e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-7.02	-0.36	1.25e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg21770322	chr7:97807741	LMTK2	0.41	7.25	0.37	2.99e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9463078	0.764	rs9369516	chr6:44833598	C/T	cg25276700	chr6:44698697	NA	-0.29	-5.72	-0.3	2.36e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg02018176	chr4:1364513	KIAA1530	0.51	8.83	0.43	6.12e-17	Obesity-related traits;
LUSC	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg00898013	chr13:113819073	PROZ	-0.59	-8.52	-0.42	5.74e-16	Platelet distribution width;
LUSC	cis	rs12989701	0.877	rs36085158	chr2:127869982	C/T	cg08168897	chr2:127865431	BIN1	0.71	9.36	0.46	1.2e-18	Alzheimer's disease (late onset);
LUSC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg13535736	chr9:111863775	C9orf5	-0.37	-6.12	-0.32	2.68e-9	Menarche (age at onset);
LUSC	cis	rs11030122	0.702	rs10835402	chr11:3990914	T/C	cg18678763	chr11:4115507	RRM1	-0.45	-5.75	-0.3	2.04e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2219968	0.962	rs6995342	chr8:78951749	A/T	cg00738934	chr8:78996279	NA	0.37	6.65	0.34	1.21e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	8.84	0.44	5.69e-17	Menarche (age at onset);
LUSC	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.02e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg00982548	chr2:198649783	BOLL	-0.57	-7.21	-0.37	3.73e-12	Ulcerative colitis;
LUSC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08704250	chr15:31115839	NA	-0.47	-7.11	-0.36	7.03e-12	Huntington's disease progression;
LUSC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.69	-0.34	9.64e-11	Electroencephalogram traits;
LUSC	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.72	0.35	8.08e-11	Corneal astigmatism;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21172538	chr5:68513532	MRPS36	0.74	6.08	0.32	3.23e-9	Cognitive performance;
LUSC	cis	rs10992471	0.528	rs10820975	chr9:95211922	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.27	-0.32	1.14e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg22117172	chr7:91764530	CYP51A1	-0.33	-5.88	-0.31	9.88e-9	Breast cancer;
LUSC	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg04827223	chr11:72435913	ARAP1	-0.71	-8.99	-0.44	1.9e-17	Type 2 diabetes;
LUSC	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.77	-12.99	-0.58	1.66e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2835872	0.965	rs2835850	chr21:39012977	A/G	cg20424643	chr21:39039972	KCNJ6	0.39	5.81	0.3	1.44e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs4363385	0.510	rs6686526	chr1:153044996	T/C	cg25856811	chr1:152973957	SPRR3	-0.37	-6.11	-0.32	2.78e-9	Inflammatory skin disease;
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.64	10.23	0.49	1.5e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.39	-0.49	4.38e-22	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18582848	chr10:72142533	LRRC20	-0.43	-6.17	-0.32	2.01e-9	Electrocardiographic conduction measures;
LUSC	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg07167872	chr1:205819463	PM20D1	-0.44	-6.77	-0.35	5.93e-11	Menarche (age at onset);
LUSC	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18932078	chr1:2524107	MMEL1	0.32	7.04	0.36	1.13e-11	Ulcerative colitis;
LUSC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg18876405	chr7:65276391	NA	-0.53	-8.58	-0.43	3.52e-16	Calcium levels;
LUSC	cis	rs9796	0.870	rs11854472	chr15:41357687	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.98	-0.36	1.55e-11	Menopause (age at onset);
LUSC	cis	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg07460842	chr6:66804631	NA	0.47	5.8	0.3	1.53e-8	Metabolite levels;
LUSC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11764359	chr7:65958608	NA	-0.69	-10.98	-0.51	3.75e-24	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05421946	chr3:58223373	ABHD6	-0.42	-6.22	-0.32	1.45e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	1.1	18.01	0.7	3.59e-51	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.63	11.14	0.52	9.97e-25	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.14	-0.41	8.12e-15	Coronary artery disease;
LUSC	cis	rs968451	0.789	rs1003644	chr22:39676744	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	9.38	0.46	1.03e-18	Primary biliary cholangitis;
LUSC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-8.37	-0.42	1.64e-15	Personality dimensions;
LUSC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-1.06	-15.34	-0.64	1.37e-40	Vitiligo;
LUSC	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.54	-0.38	4.56e-13	Blood metabolite levels;
LUSC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.87	0.4	4.97e-14	Prudent dietary pattern;
LUSC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg06784218	chr1:46089804	CCDC17	-0.5	-9.59	-0.46	2.17e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9309473	0.607	rs7586361	chr2:73601606	G/A	cg20560298	chr2:73613845	ALMS1	-0.56	-8.39	-0.42	1.39e-15	Metabolite levels;
LUSC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	0.93	15.04	0.64	2.15e-39	Parkinson's disease;
LUSC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg25036284	chr2:26402008	FAM59B	-0.74	-10.97	-0.51	3.97e-24	Gut microbiome composition (summer);
LUSC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-6.93	-0.35	2.14e-11	HDL cholesterol;
LUSC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.63	-0.43	2.57e-16	Bipolar disorder and schizophrenia;
LUSC	trans	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-8.69	-0.43	1.65e-16	Obesity-related traits;
LUSC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-7.55	-0.38	4.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.72	10.01	0.48	8.24e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg27494647	chr7:150038898	RARRES2	0.42	6.27	0.32	1.13e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg12754571	chr1:247694271	LOC148824;OR2C3	0.37	5.65	0.3	3.45e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg05340658	chr4:99064831	C4orf37	-0.41	-6.45	-0.33	4.01e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.91	0.35	2.51e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs823156	1.000	rs823156	chr1:205764640	G/A	cg07157834	chr1:205819609	PM20D1	0.48	5.66	0.3	3.21e-8	Parkinson's disease;
LUSC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs4629710	0.592	rs4310080	chr6:131538377	T/G	cg12606694	chr6:131520996	AKAP7	0.61	9.29	0.45	2.09e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	0.9	12.63	0.57	3.59e-30	Vitiligo;
LUSC	cis	rs12318506	0.826	rs11180438	chr12:75668035	T/G	cg04728562	chr12:75699417	CAPS2	-0.76	-5.97	-0.31	6.19e-9	Coronary artery calcification;
LUSC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg19046167	chr17:80928561	B3GNTL1	0.4	6.46	0.33	3.81e-10	Breast cancer;
LUSC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg14416269	chr4:6271139	WFS1	0.54	11.38	0.53	1.35e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg00966380	chr12:47633443	NA	0.53	7.03	0.36	1.18e-11	Cognitive function;Information processing speed;
LUSC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg01620082	chr3:125678407	NA	-0.79	-7.53	-0.38	4.89e-13	Depression;
LUSC	cis	rs8049040	0.609	rs16972805	chr16:71478249	A/G	cg08717414	chr16:71523259	ZNF19	0.4	5.74	0.3	2.07e-8	Blood protein levels;
LUSC	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg21045802	chr8:109455806	TTC35	0.47	7.28	0.37	2.42e-12	Dupuytren's disease;
LUSC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.06	-0.36	9.67e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-8.45	-0.42	9.17e-16	Coffee consumption (cups per day);
LUSC	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.96	-0.44	2.41e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg17554472	chr22:41940697	POLR3H	0.48	5.91	0.31	8.32e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.06	0.36	9.5e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	0.93	17.97	0.7	5.5e-51	Menarche (age at onset);
LUSC	cis	rs2625529	0.529	rs1552133	chr15:72232897	T/A	cg16672083	chr15:72433130	SENP8	0.49	8.08	0.4	1.21e-14	Red blood cell count;
LUSC	cis	rs3736594	0.513	rs62131882	chr2:27765480	T/C	cg27432699	chr2:27873401	GPN1	0.67	8.86	0.44	4.69e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.39	6.26	0.32	1.22e-9	Menopause (age at onset);
LUSC	trans	rs2736345	0.516	rs7844858	chr8:11392659	T/A	cg15556689	chr8:8085844	FLJ10661	0.46	6.49	0.33	3.02e-10	Sjögren's syndrome;Systemic lupus erythematosus;
LUSC	cis	rs7173743	1.000	rs4438276	chr15:79138565	A/G	cg00540400	chr15:79124168	NA	-0.33	-5.69	-0.3	2.85e-8	Coronary artery disease;
LUSC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	trans	rs55944332	0.738	rs3901734	chr2:145769102	T/C	cg12396057	chr1:167508884	NA	0.33	5.98	0.31	5.88e-9	Diastolic blood pressure;
LUSC	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-5.97	-0.31	6.1e-9	IgG glycosylation;
LUSC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.6	8.54	0.42	4.89e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.97	0.4	2.51e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg24375607	chr4:120327624	NA	0.67	10.54	0.5	1.33e-22	Corneal astigmatism;
LUSC	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.95	0.44	2.6e-17	Breast cancer;
LUSC	cis	rs9309473	0.950	rs10169213	chr2:73787234	G/C	cg20560298	chr2:73613845	ALMS1	-0.45	-6.52	-0.34	2.66e-10	Metabolite levels;
LUSC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg16339924	chr4:17578868	LAP3	0.59	9.2	0.45	3.85e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.3	-0.33	9.31e-10	Daytime sleep phenotypes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03115649	chr1:179851535	TOR1AIP1	-0.57	-6.56	-0.34	2.02e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.32	-0.41	2.2e-15	Lung cancer;
LUSC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg21132104	chr15:45694354	SPATA5L1	0.57	8.0	0.4	2.1e-14	Homoarginine levels;
LUSC	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-6.28	-0.33	1.04e-9	Multiple sclerosis;
LUSC	cis	rs3741151	0.773	rs73544720	chr11:73173496	A/G	cg17517138	chr11:73019481	ARHGEF17	0.96	8.16	0.41	6.73e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg22681709	chr2:178499509	PDE11A	0.52	8.28	0.41	3.03e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	0.92	17.52	0.69	3.3e-49	Cognitive function;
LUSC	trans	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.64	0.5	5.68e-23	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.58	9.4	0.46	8.87e-19	Aortic root size;
LUSC	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.92	-0.44	3.02e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs4443100	0.917	rs5996460	chr22:23393090	G/A	cg21100191	chr22:23484243	RTDR1	0.53	6.47	0.33	3.58e-10	Serum parathyroid hormone levels;
LUSC	cis	rs9341808	0.935	rs4706113	chr6:80839315	C/T	cg08355045	chr6:80787529	NA	0.52	9.19	0.45	4.37e-18	Sitting height ratio;
LUSC	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg26384229	chr12:38710491	ALG10B	0.72	11.36	0.53	1.66e-25	Morning vs. evening chronotype;
LUSC	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-9.28	-0.45	2.23e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs7939886	0.920	rs79521305	chr11:55811332	G/A	cg03929089	chr4:120376271	NA	0.77	6.33	0.33	8e-10	Myopia (pathological);
LUSC	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.6	-0.38	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4363385	0.818	rs11205176	chr1:153002481	A/G	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.9	-0.4	4e-14	Inflammatory skin disease;
LUSC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg25039879	chr17:56429692	SUPT4H1	0.49	6.93	0.35	2.24e-11	Cognitive test performance;
LUSC	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg00857998	chr1:205179979	DSTYK	0.6	8.85	0.44	5.12e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg05043794	chr9:111880884	C9orf5	-0.33	-7.14	-0.36	5.75e-12	Menarche (age at onset);
LUSC	cis	rs2387326	0.717	rs10829341	chr10:129944226	G/A	cg16087940	chr10:129947807	NA	-0.39	-6.0	-0.31	5.27e-9	Select biomarker traits;
LUSC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.2	0.32	1.71e-9	Schizophrenia;
LUSC	cis	rs2073300	1.000	rs6137971	chr20:23456429	G/T	cg12062639	chr20:23401060	NAPB	0.76	5.9	0.31	8.97e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg03806693	chr22:41940476	POLR3H	0.6	9.09	0.45	9.19e-18	Alzheimer's disease biomarkers;
LUSC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg21862992	chr11:68658383	NA	0.51	8.13	0.41	8.56e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg13010199	chr12:38710504	ALG10B	0.49	7.48	0.38	6.8e-13	Morning vs. evening chronotype;
LUSC	trans	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-13.93	-0.61	4.45e-35	Colorectal cancer;
LUSC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg24829409	chr8:58192753	C8orf71	-0.47	-5.71	-0.3	2.49e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.8	-13.13	-0.58	4.83e-32	Aortic root size;
LUSC	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg17420585	chr12:42539391	GXYLT1	-0.33	-6.16	-0.32	2.08e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs12410462	0.581	rs73102371	chr1:227554880	G/A	cg04117972	chr1:227635322	NA	0.57	6.36	0.33	6.74e-10	Major depressive disorder;
LUSC	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg16989719	chr2:238392110	NA	-0.48	-6.22	-0.32	1.45e-9	Prostate cancer;
LUSC	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg05373962	chr22:49881684	NA	-0.41	-8.43	-0.42	1.05e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs800082	1.000	rs800082	chr3:144340205	A/G	cg24215973	chr2:240111563	HDAC4	0.42	6.38	0.33	6.07e-10	Smoking behavior;
LUSC	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg01528321	chr10:82214614	TSPAN14	0.93	14.19	0.61	4.26e-36	Post bronchodilator FEV1;
LUSC	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg17810781	chr1:201082982	CACNA1S	0.35	6.45	0.33	3.94e-10	Permanent tooth development;
LUSC	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg17845761	chr1:175162550	KIAA0040	-0.29	-5.7	-0.3	2.66e-8	Alcohol dependence;
LUSC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.27	0.37	2.54e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.19	0.37	4.36e-12	Cognitive ability;
LUSC	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg06784218	chr1:46089804	CCDC17	0.36	6.12	0.32	2.67e-9	Platelet count;
LUSC	cis	rs9811920	0.965	rs9837131	chr3:99854514	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	5.75	0.3	2.02e-8	Axial length;
LUSC	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg13256891	chr4:100009986	ADH5	0.45	6.24	0.32	1.3e-9	Alcohol dependence;
LUSC	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.54	-0.34	2.32e-10	Response to antipsychotic treatment;
LUSC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg16545954	chr1:2118288	C1orf86	0.35	6.72	0.34	8.08e-11	Height;
LUSC	cis	rs6456156	0.774	rs9347175	chr6:167527644	A/T	cg07741184	chr6:167504864	NA	-0.37	-6.51	-0.34	2.78e-10	Primary biliary cholangitis;
LUSC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.76	10.88	0.51	8.71e-24	Corneal astigmatism;
LUSC	cis	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg05299278	chr17:33885742	SLFN14	0.29	6.44	0.33	4.09e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.92	0.51	6.12e-24	Hypertriglyceridemia;
LUSC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.37	-0.49	5.15e-22	Chronic sinus infection;
LUSC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7202877	0.561	rs8050662	chr16:75360734	A/G	cg04384234	chr16:75411784	CFDP1	0.64	9.32	0.45	1.57e-18	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg03188948	chr7:1209495	NA	0.67	7.1	0.36	7.77e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg16586182	chr3:47516702	SCAP	-0.51	-8.03	-0.4	1.73e-14	Colorectal cancer;
LUSC	trans	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg26043149	chr18:55253948	FECH	-0.46	-7.04	-0.36	1.09e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg03929089	chr4:120376271	NA	-0.48	-6.55	-0.34	2.22e-10	Coronary artery disease;
LUSC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13012494	chr21:47604986	C21orf56	-0.44	-6.59	-0.34	1.7e-10	Testicular germ cell tumor;
LUSC	cis	rs1014246	0.807	rs12784789	chr10:118473593	A/T	cg14919929	chr10:118506882	NA	0.4	6.03	0.31	4.27e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg21782813	chr7:2030301	MAD1L1	0.37	6.03	0.31	4.46e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	0.82	12.44	0.56	1.96e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.72e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg02450064	chr17:40260053	DHX58	0.44	6.25	0.32	1.29e-9	Fibrinogen levels;
LUSC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.16	-0.32	2.09e-9	Neuroticism;
LUSC	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.47	0.5	2.18e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg03146154	chr1:46216737	IPP	0.56	8.35	0.42	1.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg02018176	chr4:1364513	KIAA1530	0.56	9.69	0.47	1.03e-19	Obesity-related traits;
LUSC	cis	rs6733011	0.500	rs10182043	chr2:99417433	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-6.25	-0.32	1.29e-9	Bipolar disorder;
LUSC	cis	rs1003719	0.667	rs73201942	chr21:38475164	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.6	9.24	0.45	2.96e-18	Eye color traits;
LUSC	cis	rs4722404	0.592	rs7791687	chr7:3119643	G/A	cg19214707	chr7:3157722	NA	-0.4	-6.66	-0.34	1.14e-10	Atopic dermatitis;
LUSC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.06	16.04	0.66	2.45e-43	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4343996	0.902	rs4722710	chr7:3388254	C/A	cg21248987	chr7:3385318	SDK1	-0.42	-7.27	-0.37	2.57e-12	Motion sickness;
LUSC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg11812906	chr14:75593930	NEK9	-0.67	-11.46	-0.53	7.07e-26	Height;
LUSC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg24060327	chr5:131705240	SLC22A5	0.39	6.51	0.34	2.72e-10	Blood metabolite levels;
LUSC	cis	rs1395	0.922	rs13404327	chr2:27519153	G/T	cg23587288	chr2:27483067	SLC30A3	-0.3	-5.81	-0.3	1.49e-8	Blood metabolite levels;
LUSC	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg16070123	chr10:51489643	NA	0.55	9.1	0.45	8.17e-18	Prostate-specific antigen levels;
LUSC	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.61	-0.34	1.53e-10	Recombination measurement;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12974756	chr20:55043516	C20orf43	0.73	6.0	0.31	5.09e-9	Cognitive performance;
LUSC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg03188948	chr7:1209495	NA	0.66	7.09	0.36	8.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10489202	0.909	rs61809580	chr1:168091602	A/C	cg24449463	chr1:168025552	DCAF6	-0.57	-6.9	-0.35	2.66e-11	Schizophrenia;
LUSC	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-8.3	-0.41	2.64e-15	Schizophrenia;
LUSC	cis	rs6733011	0.538	rs7565614	chr2:99464834	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.92	-0.31	8.04e-9	Bipolar disorder;
LUSC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16414030	chr3:133502952	NA	-0.4	-6.05	-0.31	3.89e-9	Iron status biomarkers;
LUSC	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg01528321	chr10:82214614	TSPAN14	0.61	9.07	0.44	1.06e-17	Post bronchodilator FEV1;
LUSC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg09699651	chr6:150184138	LRP11	0.38	5.75	0.3	2.07e-8	Lung cancer;
LUSC	cis	rs1160297	0.609	rs4525730	chr2:53097497	C/T	cg07782112	chr2:53107842	NA	0.43	6.96	0.36	1.83e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg13010199	chr12:38710504	ALG10B	-0.58	-9.15	-0.45	5.64e-18	Bladder cancer;
LUSC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg13047869	chr3:10149882	C3orf24	0.65	9.34	0.46	1.36e-18	Alzheimer's disease;
LUSC	cis	rs6681460	1.000	rs1325263	chr1:67129791	C/A	cg02459107	chr1:67143332	SGIP1	0.48	9.01	0.44	1.56e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg23173402	chr1:227635558	NA	-0.46	-5.73	-0.3	2.2e-8	Major depressive disorder;
LUSC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.74	-8.97	-0.44	2.22e-17	Refractive error;
LUSC	cis	rs8062405	1.000	rs8061590	chr16:28895130	A/G	cg09754948	chr16:28834200	ATXN2L	0.42	6.02	0.31	4.72e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.76	9.67	0.47	1.14e-19	Migraine;Coronary artery disease;
LUSC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg24296786	chr1:45957014	TESK2	0.53	8.22	0.41	4.65e-15	High light scatter reticulocyte count;
LUSC	cis	rs9399135	0.773	rs1331308	chr6:135405122	G/T	cg24558204	chr6:135376177	HBS1L	-0.47	-6.99	-0.36	1.48e-11	Red blood cell count;
LUSC	cis	rs7615316	0.779	rs7652687	chr3:142123276	G/A	cg16271453	chr3:142027066	XRN1	-0.41	-7.23	-0.37	3.29e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.54	-0.62	1.88e-37	Schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00873521	chr9:95056130	IARS;SNORA84	0.41	6.02	0.31	4.6e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7180079	0.620	rs11635211	chr15:65016298	A/C	cg08069370	chr15:64387884	SNX1	0.53	5.94	0.31	7.07e-9	Monocyte count;
LUSC	cis	rs17095355	0.818	rs12573187	chr10:111856077	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.51	-0.34	2.76e-10	Biliary atresia;
LUSC	cis	rs6121246	0.542	rs76513665	chr20:30450232	T/C	cg13852791	chr20:30311386	BCL2L1	0.68	6.51	0.34	2.79e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg22963979	chr7:1858916	MAD1L1	-0.7	-11.51	-0.53	4.69e-26	Bipolar disorder and schizophrenia;
LUSC	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-9.02	-0.44	1.49e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg00343986	chr7:65444356	GUSB	-0.44	-6.79	-0.35	5.23e-11	Aortic root size;
LUSC	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg26384229	chr12:38710491	ALG10B	0.79	13.58	0.6	9.87e-34	Morning vs. evening chronotype;
LUSC	cis	rs2346177	0.875	rs2346178	chr2:46647061	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-8.77	-0.43	9.35e-17	HDL cholesterol;
LUSC	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	6.7	0.34	8.74e-11	Schizophrenia;
LUSC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.9	16.2	0.66	5.81e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg25258033	chr6:167368657	RNASET2	-0.36	-5.77	-0.3	1.8e-8	Graves' disease;
LUSC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg11247378	chr22:39784982	NA	0.64	13.12	0.58	5.46e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg07701084	chr6:150067640	NUP43	0.47	7.01	0.36	1.32e-11	Testicular germ cell tumor;
LUSC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20135002	chr11:47629003	NA	-0.5	-7.76	-0.39	1.05e-13	Subjective well-being;
LUSC	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.01	0.36	1.33e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.66	-10.34	-0.49	6.42e-22	Menarche (age at onset);
LUSC	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg11946769	chr3:48343235	NME6	-0.71	-11.13	-0.52	1.07e-24	Coronary artery disease;
LUSC	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.96	0.31	6.58e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06112835	chr11:68658793	MRPL21	0.49	7.66	0.39	2.1e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04004882	chr2:215674386	BARD1	0.49	6.44	0.33	4.06e-10	Neuroblastoma;
LUSC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.44	-7.19	-0.37	4.24e-12	IgG glycosylation;
LUSC	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg23649088	chr2:200775458	C2orf69	-0.54	-6.53	-0.34	2.39e-10	Schizophrenia;
LUSC	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg01503450	chr10:980765	NA	-0.4	-5.87	-0.31	1.04e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14169450	chr9:139327907	INPP5E	0.46	8.22	0.41	4.61e-15	Monocyte percentage of white cells;
LUSC	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg13010199	chr12:38710504	ALG10B	-0.64	-10.94	-0.51	5.0600000000000004e-24	Heart rate;
LUSC	cis	rs12618769	0.597	rs4851133	chr2:99050519	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.64	0.39	2.31e-13	Bipolar disorder;
LUSC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06505273	chr16:24850292	NA	0.41	5.81	0.3	1.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg21775007	chr8:11205619	TDH	-0.56	-8.05	-0.4	1.49e-14	Triglycerides;
LUSC	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-8.15	-0.41	7.26e-15	Morning vs. evening chronotype;
LUSC	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg26566898	chr11:117069891	TAGLN	0.38	7.18	0.37	4.57e-12	Blood protein levels;
LUSC	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.52	0.65	2.9e-41	Morning vs. evening chronotype;
LUSC	cis	rs9788721	0.967	rs2036527	chr15:78851615	G/A	cg06917634	chr15:78832804	PSMA4	-0.45	-6.06	-0.31	3.77e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg16031515	chr1:205743344	RAB7L1	-0.28	-6.11	-0.32	2.73e-9	Menarche (age at onset);
LUSC	trans	rs17767294	0.708	rs72848755	chr6:27878553	T/C	cg19566879	chr6:16334128	ATXN1	0.66	5.98	0.31	5.71e-9	Parkinson's disease;
LUSC	cis	rs2692947	0.644	rs1168975	chr2:96814075	G/A	cg22654517	chr2:96458247	NA	0.32	5.88	0.31	9.97e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs11039100	1.000	rs12361754	chr11:5828027	T/C	cg13902645	chr11:5959945	NA	-0.52	-5.84	-0.3	1.25e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg04117972	chr1:227635322	NA	0.61	6.88	0.35	2.9e-11	Major depressive disorder;
LUSC	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg18721089	chr20:30220636	NA	-0.42	-6.94	-0.35	2.05e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.87	0.4	4.86e-14	Coffee consumption (cups per day);
LUSC	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg15997130	chr1:24165203	NA	-0.56	-9.07	-0.44	1.06e-17	Immature fraction of reticulocytes;
LUSC	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg05043794	chr9:111880884	C9orf5	-0.36	-7.76	-0.39	1.06e-13	Menarche (age at onset);
LUSC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg14092988	chr3:52407081	DNAH1	0.33	6.42	0.33	4.7e-10	Bipolar disorder;
LUSC	cis	rs2835872	0.727	rs2835894	chr21:39066042	A/G	cg20424643	chr21:39039972	KCNJ6	0.42	6.55	0.34	2.18e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.8	-13.05	-0.58	1.01e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.7	9.64	0.47	1.44e-19	Chronic sinus infection;
LUSC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg16325326	chr1:53192061	ZYG11B	0.81	14.3	0.62	1.63e-36	Monocyte count;
LUSC	cis	rs2835872	0.726	rs1515056	chr21:39082585	C/G	cg20424643	chr21:39039972	KCNJ6	0.45	6.74	0.35	7.03e-11	Electroencephalographic traits in alcoholism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18156033	chr2:158485580	ACVR1C	0.46	6.3	0.33	9.35e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6494488	0.500	rs72742997	chr15:65009527	G/A	cg08069370	chr15:64387884	SNX1	-0.66	-5.77	-0.3	1.76e-8	Coronary artery disease;
LUSC	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg09307838	chr4:120376055	NA	0.73	10.28	0.49	9.89e-22	Corneal astigmatism;
LUSC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.76	0.39	1.05e-13	Prudent dietary pattern;
LUSC	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg10645314	chr2:3704589	ALLC	0.49	7.85	0.39	5.9e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.18	-0.72	8.14e-56	Height;
LUSC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.75	-0.3	1.98e-8	Personality dimensions;
LUSC	cis	rs4704187	0.687	rs11950665	chr5:74423339	A/G	cg03227963	chr5:74354835	NA	0.31	6.62	0.34	1.45e-10	Response to amphetamines;
LUSC	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg27411982	chr8:10470053	RP1L1	0.49	7.64	0.39	2.24e-13	Monocyte count;
LUSC	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.76	-0.8	1.38e-77	Height;
LUSC	cis	rs2637266	0.783	rs2583070	chr10:78518555	C/T	cg18941641	chr10:78392320	NA	0.4	7.23	0.37	3.31e-12	Pulmonary function;
LUSC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg27284194	chr4:1044797	NA	-0.36	-5.83	-0.3	1.29e-8	Obesity-related traits;
LUSC	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg05791153	chr7:19748676	TWISTNB	-0.76	-8.45	-0.42	8.93e-16	Thyroid stimulating hormone;
LUSC	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg17633681	chr16:88106987	BANP	0.5	9.26	0.45	2.51e-18	Menopause (age at onset);
LUSC	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.74	-0.43	1.15e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg05340658	chr4:99064831	C4orf37	0.62	9.79	0.47	4.44e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg08971769	chr10:75258327	USP54	-0.39	-6.17	-0.32	1.97e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg23422044	chr7:1970798	MAD1L1	-0.65	-7.32	-0.37	1.84e-12	Bipolar disorder;
LUSC	trans	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg25482853	chr8:67687455	SGK3	1.04	15.54	0.65	2.23e-41	Obesity-related traits;
LUSC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.81	-14.26	-0.62	2.34e-36	Sudden cardiac arrest;
LUSC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.53	-0.42	5.09e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00166722	chr3:10149974	C3orf24	0.55	7.51	0.38	5.38e-13	Alzheimer's disease;
LUSC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24110177	chr3:50126178	RBM5	-0.61	-10.5	-0.5	1.74e-22	Body mass index;
LUSC	cis	rs1113500	0.862	rs2336128	chr1:108640739	G/T	cg06207961	chr1:108661230	NA	0.41	7.56	0.38	3.86e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs7336332	0.598	rs75439483	chr13:28010512	A/G	cg22138327	chr13:27999177	GTF3A	0.8	10.02	0.48	7.6e-21	Weight;
LUSC	trans	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.52	8.06	0.4	1.36e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.41	-0.33	4.96e-10	Blood trace element (Cu levels);
LUSC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg11645453	chr3:52864694	ITIH4	0.34	7.77	0.39	9.56e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-5.7	-0.3	2.67e-8	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.35	6.15	0.32	2.23e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg09085632	chr11:111637200	PPP2R1B	0.94	12.79	0.57	9.52e-31	Primary sclerosing cholangitis;
LUSC	cis	rs4363385	1.000	rs310124	chr1:153020275	C/T	cg00922841	chr1:152955080	SPRR1A	-0.48	-8.11	-0.41	9.75e-15	Inflammatory skin disease;
LUSC	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-14.49	-0.62	2.99e-37	Headache;
LUSC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg16362232	chr11:430036	ANO9	0.6	7.87	0.4	4.86e-14	Body mass index;
LUSC	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.9	-0.4	4.05e-14	Blood metabolite levels;
LUSC	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.14	0.41	8.16e-15	Axial length;
LUSC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg16414030	chr3:133502952	NA	0.38	6.19	0.32	1.8e-9	Iron status biomarkers;
LUSC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24110177	chr3:50126178	RBM5	0.58	9.56	0.46	2.63e-19	Intelligence (multi-trait analysis);
LUSC	trans	rs34984545	1.000	rs10032067	chr4:145978910	G/T	cg27525185	chr19:36869526	NA	-0.67	-6.04	-0.31	4.08e-9	Angiotensin-converting enzyme inhibitor intolerance;
LUSC	cis	rs340630	0.967	rs13126334	chr4:87909890	A/G	cg10685359	chr4:87814065	C4orf36	0.33	5.81	0.3	1.49e-8	Systemic lupus erythematosus;
LUSC	cis	rs472402	0.623	rs7727273	chr5:6635933	A/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.48	-7.17	-0.37	4.75e-12	Response to amphetamines;
LUSC	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg15704280	chr7:45808275	SEPT13	0.72	6.82	0.35	4.21e-11	Axial length;
LUSC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.87	14.11	0.61	8.39e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9323205	0.911	rs12587611	chr14:51641399	C/T	cg23942311	chr14:51606299	NA	-0.42	-8.91	-0.44	3.42e-17	Cancer;
LUSC	cis	rs7264396	0.573	rs58355182	chr20:34075687	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.32	-0.33	8.54e-10	Total cholesterol levels;
LUSC	cis	rs62400317	0.859	rs62436778	chr6:45120666	A/G	cg20913747	chr6:44695427	NA	-0.46	-7.49	-0.38	6.35e-13	Total body bone mineral density;
LUSC	trans	rs17112190	1.000	rs17112175	chr10:98616993	G/T	cg25121125	chr3:64674314	ADAMTS9	0.68	5.96	0.31	6.57e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg02493740	chr2:85810744	VAMP5	-0.34	-6.06	-0.31	3.71e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs3772130	0.583	rs12695415	chr3:121398853	C/T	cg20356878	chr3:121714668	ILDR1	0.55	8.91	0.44	3.42e-17	Cognitive performance;
LUSC	trans	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07923666	chr12:49932857	KCNH3	-0.52	-6.75	-0.35	6.56e-11	Resting heart rate;
LUSC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	1.05	17.93	0.7	8.17e-51	Testicular germ cell tumor;
LUSC	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg20019720	chr6:154832845	CNKSR3	0.58	8.55	0.42	4.39e-16	Lipoprotein (a) levels;
LUSC	cis	rs7584330	0.554	rs79020383	chr2:238425834	G/A	cg16989719	chr2:238392110	NA	-0.45	-6.48	-0.33	3.28e-10	Prostate cancer;
LUSC	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg01028140	chr2:1542097	TPO	-0.61	-8.28	-0.41	2.9e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	trans	rs6924906	0.655	rs77382925	chr6:82237514	A/G	cg15052890	chr17:4636830	MED11;CXCL16	-0.58	-6.12	-0.32	2.57e-9	Blood pressure;
LUSC	trans	rs747782	0.536	rs10838873	chr11:48337765	T/C	cg15704280	chr7:45808275	SEPT13	0.61	5.97	0.31	5.98e-9	Intraocular pressure;
LUSC	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.53	-7.74	-0.39	1.23e-13	Reticulocyte count;
LUSC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg08470875	chr2:26401718	FAM59B	-0.68	-9.08	-0.45	9.51e-18	Gut microbiome composition (summer);
LUSC	cis	rs1507153	0.775	rs7763429	chr6:79350769	G/A	cg05283184	chr6:79620031	NA	-0.42	-7.33	-0.37	1.76e-12	Sjögren's syndrome;
LUSC	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	13.27	0.59	1.42e-32	Blood protein levels;
LUSC	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg03522245	chr20:25566470	NINL	0.36	5.89	0.31	9.52e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-6.01	-0.31	4.94e-9	Fear of minor pain;
LUSC	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg26384229	chr12:38710491	ALG10B	0.71	10.03	0.48	7.38e-21	Resting heart rate;
LUSC	cis	rs7923609	1.000	rs4310508	chr10:65138573	A/G	cg01631684	chr10:65280961	REEP3	-0.38	-5.89	-0.31	9.62e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.78	0.3	1.74e-8	Menopause (age at onset);
LUSC	trans	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.4	-0.38	1.1e-12	Breast cancer;
LUSC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	9.91e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.08	0.55	3.89e-28	Menopause (age at onset);
LUSC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg00310523	chr12:86230176	RASSF9	0.47	8.69	0.43	1.7e-16	Major depressive disorder;
LUSC	cis	rs7586879	0.828	rs10195271	chr2:25108650	A/C	cg01884057	chr2:25150051	NA	-0.41	-8.6	-0.43	3.06e-16	Body mass index;
LUSC	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg05855489	chr10:104503620	C10orf26	-0.49	-7.42	-0.38	9.5e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg21856205	chr7:94953877	PON1	0.36	5.84	0.3	1.23e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg00815214	chr21:47717953	NA	0.36	5.83	0.3	1.33e-8	Testicular germ cell tumor;
LUSC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.2	-0.32	1.68e-9	Total body bone mineral density;
LUSC	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.26e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25106220	chr2:113522384	CKAP2L	0.45	6.05	0.31	3.99e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg06637938	chr14:75390232	RPS6KL1	0.53	8.64	0.43	2.32e-16	Height;
LUSC	cis	rs1957429	0.808	rs4902327	chr14:65344803	C/T	cg23373153	chr14:65346875	NA	0.92	10.13	0.48	3.23e-21	Pediatric areal bone mineral density (radius);
LUSC	cis	rs12190007	0.508	rs6605537	chr6:169730781	G/A	cg16388071	chr6:169726476	NA	0.39	6.34	0.33	7.31e-10	Obesity-related traits;
LUSC	cis	rs7432375	0.610	rs4420814	chr3:136513282	T/C	cg15507776	chr3:136538369	TMEM22	0.44	7.37	0.37	1.37e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.7	-10.32	-0.49	7.64e-22	Vitiligo;
LUSC	cis	rs6977660	0.714	rs1468287	chr7:19784210	T/A	cg07541023	chr7:19748670	TWISTNB	0.68	6.79	0.35	5.25e-11	Thyroid stimulating hormone;
LUSC	cis	rs963731	0.649	rs2168044	chr2:39206386	G/A	cg04010122	chr2:39346883	SOS1	-0.78	-5.7	-0.3	2.71e-8	Corticobasal degeneration;
LUSC	cis	rs6546886	0.912	rs10164943	chr2:74306056	C/T	cg14702570	chr2:74259524	NA	-0.3	-5.65	-0.3	3.5e-8	Dialysis-related mortality;
LUSC	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	13.82	0.6	1.12e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg06223162	chr1:101003688	GPR88	0.48	8.92	0.44	3.02e-17	Monocyte count;
LUSC	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.9	12.1	0.55	3.45e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg12940439	chr1:67600707	NA	-0.36	-5.98	-0.31	5.7e-9	Psoriasis;
LUSC	cis	rs7674212	0.570	rs6810571	chr4:104086787	G/T	cg16532752	chr4:104119610	CENPE	-0.49	-7.25	-0.37	2.92e-12	Type 2 diabetes;
LUSC	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg13010199	chr12:38710504	ALG10B	0.62	9.08	0.44	9.91e-18	Bladder cancer;
LUSC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.12	0.58	5.22e-32	Cognitive test performance;
LUSC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	1.08	21.02	0.75	4.3e-63	Cognitive ability;
LUSC	cis	rs79387448	0.745	rs57942521	chr2:103139849	A/G	cg09003973	chr2:102972529	NA	0.89	8.69	0.43	1.62e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9517320	1.000	rs9645890	chr13:99126637	C/T	cg07423050	chr13:99094983	FARP1	0.33	6.32	0.33	8.28e-10	Longevity;
LUSC	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.43	6.63	0.34	1.38e-10	Dupuytren's disease;
LUSC	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21775007	chr8:11205619	TDH	0.79	13.15	0.58	4.25e-32	Retinal vascular caliber;
LUSC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg06238570	chr21:40685208	BRWD1	-0.63	-10.46	-0.5	2.5e-22	Cognitive function;
LUSC	cis	rs977987	0.585	rs62059845	chr16:75430713	A/G	cg03315344	chr16:75512273	CHST6	0.48	9.12	0.45	6.97e-18	Dupuytren's disease;
LUSC	cis	rs1178127	0.580	rs1178177	chr7:18799553	C/T	cg02370815	chr7:18831390	HDAC9	-0.39	-5.86	-0.31	1.13e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
LUSC	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg25301532	chr20:43378953	KCNK15	0.35	6.35	0.33	7.23e-10	Obesity-related traits;
LUSC	cis	rs80130819	0.591	rs10875783	chr12:48649736	G/A	cg24011408	chr12:48396354	COL2A1	0.46	5.84	0.3	1.22e-8	Prostate cancer;
LUSC	cis	rs7640424	1.000	rs7640424	chr3:107820063	C/T	cg09227934	chr3:107805635	CD47	-0.5	-7.65	-0.39	2.18e-13	Body mass index;
LUSC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg07700843	chr1:2391317	NA	-0.43	-7.85	-0.39	5.55e-14	Schizophrenia;
LUSC	trans	rs10432489	0.708	rs10189224	chr2:181764318	A/C	cg25678491	chr13:101327172	TMTC4	-0.82	-6.39	-0.33	5.65e-10	QT interval;
LUSC	cis	rs897984	0.520	rs4889622	chr16:30870957	A/G	cg02466173	chr16:30829666	NA	0.55	9.24	0.45	3.06e-18	Dementia with Lewy bodies;
LUSC	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	8.65	0.43	2.23e-16	Bipolar disorder;
LUSC	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg13010199	chr12:38710504	ALG10B	-0.42	-6.3	-0.33	9.6e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs13253111	1.000	rs62500888	chr8:28061823	A/G	cg26534493	chr8:28060551	NA	0.46	8.81	0.43	7.08e-17	Childhood body mass index;
LUSC	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.42	-7.39	-0.37	1.17e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	7.21	0.37	3.81e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs12618769	0.597	rs17505088	chr2:99149473	C/T	cg10123293	chr2:99228465	UNC50	0.46	7.68	0.39	1.77e-13	Bipolar disorder;
LUSC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.75	-13.21	-0.59	2.51e-32	Personality dimensions;
LUSC	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.35	-0.46	1.34e-18	Joint mobility (Beighton score);
LUSC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg06028605	chr16:24865363	SLC5A11	0.51	9.13	0.45	6.92e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2798269	0.867	rs60181111	chr13:22097453	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.38	-5.77	-0.3	1.86e-8	PR segment;
LUSC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg15790184	chr11:494944	RNH1	0.52	5.98	0.31	5.62e-9	Body mass index;
LUSC	cis	rs1975974	0.872	rs17052352	chr17:21721972	A/G	cg18423549	chr17:21743878	NA	-0.52	-8.21	-0.41	5.05e-15	Psoriasis;
LUSC	trans	rs1325195	0.920	rs2816214	chr1:179181546	T/C	cg11624085	chr17:8464688	MYH10	0.41	6.62	0.34	1.41e-10	IgE grass sensitization;
LUSC	cis	rs7084921	0.547	rs12780035	chr10:101874844	C/T	cg02250046	chr10:101825185	CPN1	-0.35	-6.24	-0.32	1.35e-9	Bone mineral density;
LUSC	cis	rs13006833	0.739	rs291430	chr2:191198727	A/C	cg21644426	chr2:191273491	MFSD6	0.42	6.02	0.31	4.52e-9	Urinary metabolites;
LUSC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	8.81	0.43	6.76e-17	Multiple sclerosis;
LUSC	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg10167378	chr1:228756711	NA	0.76	9.78	0.47	5.16e-20	Chronic lymphocytic leukemia;
LUSC	cis	rs4629710	0.592	rs11758994	chr6:131582022	A/C	cg12606694	chr6:131520996	AKAP7	0.64	9.77	0.47	5.44e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-8.19	-0.41	5.61e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.3	-0.41	2.65e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg20503657	chr10:835505	NA	0.78	9.74	0.47	6.96e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg08132940	chr7:1081526	C7orf50	-0.52	-6.22	-0.32	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg25660036	chr4:7070649	GRPEL1	-0.38	-5.69	-0.3	2.75e-8	Monocyte percentage of white cells;
LUSC	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	ch.11.42038R	chr11:967971	AP2A2	0.53	7.76	0.39	1.05e-13	Alzheimer's disease (late onset);
LUSC	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg21573476	chr21:45109991	RRP1B	-0.36	-5.79	-0.3	1.6e-8	Mean corpuscular volume;
LUSC	cis	rs1775715	0.707	rs2808094	chr10:32133756	T/C	cg26784012	chr10:32216390	ARHGAP12	0.47	7.91	0.4	3.89e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg21782813	chr7:2030301	MAD1L1	0.59	10.47	0.5	2.32e-22	Bipolar disorder and schizophrenia;
LUSC	trans	rs800082	0.507	rs2717379	chr3:144256805	G/A	cg24215973	chr2:240111563	HDAC4	0.48	7.39	0.37	1.17e-12	Smoking behavior;
LUSC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.69	-0.39	1.7e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg17376030	chr22:41985996	PMM1	0.41	5.67	0.3	3.06e-8	Vitiligo;
LUSC	cis	rs4664308	1.000	rs62175515	chr2:160909524	A/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-11.33	-0.53	2.16e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.87	0.35	3.12e-11	Height;
LUSC	cis	rs9837602	0.938	rs17393059	chr3:99761908	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.13	-0.32	2.52e-9	Breast cancer;
LUSC	cis	rs6681460	1.000	rs1445575	chr1:67052164	C/T	cg02459107	chr1:67143332	SGIP1	0.46	8.51	0.42	5.83e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg14664628	chr15:75095509	CSK	-0.74	-11.95	-0.55	1.17e-27	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.69	-0.34	9.39e-11	Tonsillectomy;
LUSC	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg05425664	chr17:57184151	TRIM37	0.48	7.22	0.37	3.63e-12	Testicular germ cell tumor;
LUSC	cis	rs1775715	0.707	rs1541261	chr10:32179523	G/A	cg04359828	chr10:32216031	ARHGAP12	0.41	7.03	0.36	1.2e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.33	-6.92	-0.35	2.33e-11	Longevity;Endometriosis;
LUSC	cis	rs4561483	0.582	rs3850997	chr16:12043512	G/T	cg08843971	chr16:11963173	GSPT1	-0.42	-5.98	-0.31	5.85e-9	Testicular germ cell tumor;
LUSC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.76	13.57	0.6	1.04e-33	Calcium levels;
LUSC	cis	rs7072216	0.763	rs10883090	chr10:100167236	G/C	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	29.2	0.85	5.99e-94	Chronic sinus infection;
LUSC	cis	rs7804356	0.906	rs3801830	chr7:26854870	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg13390004	chr1:15929781	NA	0.4	6.62	0.34	1.44e-10	Systolic blood pressure;
LUSC	trans	rs782590	1.000	rs782590	chr2:55843413	C/T	cg22328901	chr2:86333256	PTCD3;POLR1A	0.41	5.95	0.31	6.82e-9	Metabolic syndrome;
LUSC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg10556349	chr10:835070	NA	0.55	6.21	0.32	1.53e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.79	0.43	8.13e-17	Prudent dietary pattern;
LUSC	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	5.95	0.31	6.92e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs193541	0.632	rs34714850	chr5:122332695	A/G	cg19077854	chr5:122220652	SNX24	-0.39	-8.07	-0.4	1.3e-14	Glucose homeostasis traits;
LUSC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.85	0.3	1.2e-8	Tonsillectomy;
LUSC	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg26384229	chr12:38710491	ALG10B	0.79	13.58	0.6	9.51e-34	Morning vs. evening chronotype;
LUSC	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Alcohol dependence;
LUSC	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg13319975	chr6:146136371	FBXO30	-0.47	-7.1	-0.36	7.7e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.79	11.59	0.54	2.43e-26	Corneal astigmatism;
LUSC	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg00864171	chr11:67383662	NA	0.35	6.22	0.32	1.5e-9	Mean corpuscular volume;
LUSC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07256732	chr16:621771	PIGQ	-0.36	-6.43	-0.33	4.34e-10	Height;
LUSC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg18827107	chr12:86230957	RASSF9	-0.44	-6.58	-0.34	1.78e-10	Major depressive disorder;
LUSC	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.76	0.51	2.2e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs7744392	0.546	rs16872293	chr6:35117996	C/G	cg06087101	chr6:35551932	FKBP5	0.57	5.87	0.31	1.03e-8	Cataracts in type 2 diabetes;
LUSC	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg12863693	chr15:85201151	NMB	0.4	8.02	0.4	1.79e-14	Schizophrenia;
LUSC	cis	rs877282	0.898	rs11253339	chr10:759640	C/T	cg17470449	chr10:769945	NA	0.52	7.39	0.38	1.15e-12	Uric acid levels;
LUSC	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg05163923	chr11:71159392	DHCR7	0.74	10.94	0.51	5.36e-24	Vitamin D levels;
LUSC	cis	rs2857891	0.817	rs2857885	chr11:6967187	G/A	cg14883916	chr11:6947541	ZNF215	0.45	6.03	0.31	4.39e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05472934	chr7:22766657	IL6	0.46	7.35	0.37	1.51e-12	Lung cancer;
LUSC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg15534755	chr11:117069859	TAGLN	0.35	6.15	0.32	2.25e-9	Blood protein levels;
LUSC	cis	rs4499344	0.556	rs259225	chr19:33135458	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.97	14.47	0.62	3.57e-37	Mean platelet volume;
LUSC	cis	rs4363385	0.755	rs1933382	chr1:153003295	G/T	cg00922841	chr1:152955080	SPRR1A	0.42	7.27	0.37	2.52e-12	Inflammatory skin disease;
LUSC	trans	rs9944715	0.954	rs12607898	chr18:43802778	A/G	cg01718231	chr17:29326311	RNF135	-0.49	-6.75	-0.35	6.63e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs7215564	0.908	rs34547024	chr17:78661373	C/G	cg23238734	chr17:78661607	RPTOR	0.46	5.93	0.31	7.67e-9	Myopia (pathological);
LUSC	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg06885757	chr1:42089581	HIVEP3	0.49	10.43	0.5	3.07e-22	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg04111992	chr7:158790115	NA	-0.37	-5.84	-0.3	1.21e-8	Facial morphology (factor 20);
LUSC	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg21211680	chr2:198530	NA	0.66	7.8	0.39	8e-14	Blood protein levels;
LUSC	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg20608306	chr11:116969690	SIK3	0.34	6.33	0.33	7.77e-10	Blood protein levels;
LUSC	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg10840412	chr1:235813424	GNG4	0.67	8.38	0.42	1.48e-15	Bipolar disorder;
LUSC	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.74	0.35	7.17e-11	Corneal astigmatism;
LUSC	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9532580	0.778	rs61963319	chr13:41244220	A/T	cg21288729	chr13:41239152	FOXO1	0.62	9.52	0.46	3.52e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.48	-6.45	-0.33	3.88e-10	Tonsillectomy;
LUSC	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg04362960	chr10:104952993	NT5C2	0.61	9.81	0.47	3.95e-20	Arsenic metabolism;
LUSC	cis	rs2200578	0.732	rs56271621	chr2:99658200	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.64	7.39	0.38	1.15e-12	IgG glycosylation;
LUSC	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.75	-0.35	6.39e-11	Response to antipsychotic treatment;
LUSC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.48	-7.56	-0.38	3.9e-13	Vitiligo;
LUSC	cis	rs3803170	0.513	rs7302763	chr12:111827569	C/T	cg10833066	chr12:111807467	FAM109A	0.38	6.97	0.36	1.68e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg23625390	chr15:77176239	SCAPER	0.46	6.88	0.35	2.96e-11	Blood metabolite levels;
LUSC	cis	rs6967385	0.580	rs3902479	chr7:12329328	T/C	cg06484146	chr7:12443880	VWDE	0.41	6.48	0.33	3.24e-10	Response to taxane treatment (placlitaxel);
LUSC	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg27661571	chr11:113659931	NA	-0.69	-7.81	-0.39	7.56e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-0.82	-13.22	-0.59	2.14e-32	Tonsillectomy;
LUSC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.15	0.58	4.1e-32	Chronic sinus infection;
LUSC	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.68	8.53	0.42	5.16e-16	Type 2 diabetes;
LUSC	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg10978503	chr1:24200527	CNR2	0.54	13.3	0.59	1.11e-32	Immature fraction of reticulocytes;
LUSC	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.66	10.4	0.49	3.9e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4499344	0.622	rs2903752	chr19:33049943	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	9.78	0.47	4.83e-20	Mean platelet volume;
LUSC	cis	rs7633770	0.786	rs4234464	chr3:46679675	C/T	cg11219411	chr3:46661640	NA	-0.36	-7.61	-0.38	2.91e-13	Coronary artery disease;
LUSC	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg13010199	chr12:38710504	ALG10B	0.66	10.16	0.49	2.52e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg12463550	chr7:65579703	CRCP	0.51	7.43	0.38	9.07e-13	Aortic root size;
LUSC	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-1.01	-14.4	-0.62	6.88e-37	Exhaled nitric oxide output;
LUSC	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg01420254	chr6:26195488	NA	0.65	6.99	0.36	1.54e-11	Gout;Renal underexcretion gout;
LUSC	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.41	6.82	0.35	4.21e-11	Alcohol dependence;
LUSC	cis	rs11195062	0.805	rs10884942	chr10:112016926	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.92	-0.31	8e-9	Multiple myeloma;
LUSC	cis	rs2898681	0.618	rs7677726	chr4:53739262	A/G	cg00791764	chr4:53727839	RASL11B	-0.46	-6.06	-0.31	3.67e-9	Optic nerve measurement (cup area);
LUSC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21518248	chr2:162101506	NA	0.45	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs16854884	0.586	rs13081286	chr3:143723757	A/T	cg06585982	chr3:143692056	C3orf58	0.51	8.14	0.41	7.78e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.98	-0.31	5.72e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05969021	chr1:23886005	ID3	0.7	6.26	0.32	1.21e-9	Cognitive performance;
LUSC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg00033643	chr7:134001901	SLC35B4	0.46	7.28	0.37	2.45e-12	Mean platelet volume;
LUSC	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg15704280	chr7:45808275	SEPT13	-0.72	-6.85	-0.35	3.66e-11	Intraocular pressure;
LUSC	cis	rs6982240	0.514	rs72681579	chr8:142263074	G/A	cg00131261	chr8:142287264	NA	-0.36	-6.07	-0.32	3.53e-9	Tonsillectomy;
LUSC	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.88	-0.68	1.16e-46	Primary sclerosing cholangitis;
LUSC	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg11473876	chr11:109292803	C11orf87	0.41	6.58	0.34	1.79e-10	Schizophrenia;
LUSC	trans	rs8022206	0.659	rs72725119	chr14:68329020	G/A	cg15809352	chr2:121748218	GLI2	0.45	6.58	0.34	1.8e-10	Platelet count;Mean platelet volume;
LUSC	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg18806716	chr10:30721971	MAP3K8	-0.6	-9.43	-0.46	7.21e-19	Inflammatory bowel disease;
LUSC	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg01256987	chr12:42539512	GXYLT1	-0.37	-6.71	-0.34	8.58e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.37e-9	Ulcerative colitis;
LUSC	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg22077389	chr15:40226273	EIF2AK4	0.52	6.3	0.33	9.41e-10	Response to haloperidol in psychosis;
LUSC	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg02696742	chr7:106810147	HBP1	0.62	9.3	0.45	1.94e-18	Coronary artery disease;
LUSC	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg13647721	chr17:30228624	UTP6	0.61	6.0	0.31	5.23e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs11711311	0.869	rs12493635	chr3:113373019	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.92	-0.31	7.85e-9	IgG glycosylation;
LUSC	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg06484146	chr7:12443880	VWDE	-0.74	-7.61	-0.38	2.77e-13	Coronary artery disease;
LUSC	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg23093090	chr10:104574429	C10orf26	-0.43	-7.66	-0.39	2.09e-13	Arsenic metabolism;
LUSC	cis	rs1662342	1.000	rs1662345	chr18:3251743	A/G	cg00760847	chr18:3262519	MYL12B	-0.58	-5.68	-0.3	2.97e-8	QRS duration;
LUSC	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg27411982	chr8:10470053	RP1L1	0.39	6.02	0.31	4.61e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg21770322	chr7:97807741	LMTK2	0.45	7.59	0.38	3.1400000000000003e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.52	7.34	0.37	1.65e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4363385	0.654	rs1129654	chr1:152958238	A/G	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.78	-0.39	9.11e-14	Inflammatory skin disease;
LUSC	cis	rs10871290	0.881	rs3863439	chr16:74470644	T/C	cg01733217	chr16:74700730	RFWD3	-0.6	-8.61	-0.43	2.89e-16	Breast cancer;
LUSC	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg05234568	chr11:5960015	NA	-0.64	-9.08	-0.44	1e-17	DNA methylation (variation);
LUSC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06634786	chr22:41940651	POLR3H	0.5	6.04	0.31	4.07e-9	Vitiligo;
LUSC	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg24375607	chr4:120327624	NA	0.76	12.2	0.56	1.5e-28	Corneal astigmatism;
LUSC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg00074818	chr8:8560427	CLDN23	0.58	9.9	0.48	2.04e-20	Obesity-related traits;
LUSC	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg25457927	chr22:38595422	NA	-0.42	-8.92	-0.44	3.05e-17	Cutaneous nevi;
LUSC	trans	rs9393777	0.720	rs56401801	chr6:27301512	T/A	cg06606381	chr12:133084897	FBRSL1	-0.97	-8.61	-0.43	2.92e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg13615516	chr5:77269221	NA	0.39	6.62	0.34	1.39e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg17757837	chr7:157058334	UBE3C	0.82	13.21	0.59	2.34e-32	Body mass index;
LUSC	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg10596483	chr8:143751796	JRK	0.52	7.41	0.38	1.04e-12	Schizophrenia;
LUSC	cis	rs240764	0.658	rs4840148	chr6:101182500	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-6.32	-0.33	8.54e-10	Neuroticism;
LUSC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg16325326	chr1:53192061	ZYG11B	0.92	17.22	0.69	5.28e-48	Monocyte count;
LUSC	cis	rs73206853	0.841	rs4131851	chr12:110812345	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09270044	chr1:186344798	TPR;C1orf27;MIR548F1	-0.41	-6.29	-0.33	1.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg27147174	chr7:100797783	AP1S1	-0.64	-10.25	-0.49	1.33e-21	Life satisfaction;
LUSC	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg08601574	chr20:25228251	PYGB	-0.4	-6.26	-0.32	1.17e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg25237894	chr2:233734115	C2orf82	-0.36	-6.56	-0.34	2.06e-10	Coronary artery disease;
LUSC	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg07828340	chr4:882639	GAK	1.08	11.67	0.54	1.28e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg18795169	chr1:18902165	NA	-1.01	-24.4	-0.8	3.36e-76	Urate levels in lean individuals;
LUSC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.7	0.3	2.6e-8	Self-reported allergy;
LUSC	trans	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg13902645	chr11:5959945	NA	-0.6	-8.36	-0.42	1.71e-15	DNA methylation (variation);
LUSC	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg23933602	chr10:16859644	RSU1	0.54	6.24	0.32	1.29e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg05868516	chr6:26286170	HIST1H4H	0.36	5.99	0.31	5.38e-9	Educational attainment;
LUSC	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg02886208	chr11:14281011	SPON1	-0.33	-5.7	-0.3	2.58e-8	Mitochondrial DNA levels;
LUSC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg07414643	chr4:187882934	NA	0.54	9.87	0.48	2.56e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs36093844	0.800	rs17817326	chr11:85595213	C/T	cg25872744	chr11:85566296	CCDC83	-0.46	-6.04	-0.31	4.16e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs7598759	0.588	rs6737291	chr2:232329559	T/C	cg19187155	chr2:232395269	NMUR1	0.49	7.2	0.37	3.96e-12	Noise-induced hearing loss;
LUSC	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	6.93	0.35	2.21e-11	Mood instability;
LUSC	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-10.0	-0.48	9.34e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.76	-13.42	-0.59	3.9e-33	Dental caries;
LUSC	trans	rs10851478	0.872	rs8032688	chr15:49929664	A/G	cg23074453	chr15:44487924	FRMD5	-0.33	-6.08	-0.32	3.26e-9	Oral cavity cancer;
LUSC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.56	0.6	1.12e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg22166914	chr1:53195759	ZYG11B	0.57	9.29	0.45	2.08e-18	Monocyte count;
LUSC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg14541582	chr5:601475	NA	-0.38	-5.93	-0.31	7.36e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg06784218	chr1:46089804	CCDC17	-0.35	-7.14	-0.36	6e-12	Red blood cell count;Reticulocyte count;
LUSC	trans	rs4650994	0.525	rs4650991	chr1:178511165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.47	-8.94	-0.44	2.8e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg05043794	chr9:111880884	C9orf5	0.3	6.67	0.34	1.04e-10	Menarche (age at onset);
LUSC	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg08462924	chr1:41848221	NA	0.43	7.35	0.37	1.55e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	0.91	12.24	0.56	1.04e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg09307838	chr4:120376055	NA	0.53	8.17	0.41	6.55e-15	Diastolic blood pressure;
LUSC	cis	rs1595825	0.786	rs116046984	chr2:198884413	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-6.25	-0.32	1.26e-9	Ulcerative colitis;
LUSC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.25	0.59	1.67e-32	Chronic sinus infection;
LUSC	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg00083206	chr6:110721305	DDO	-0.43	-7.6	-0.38	2.97e-13	Platelet distribution width;
LUSC	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-13.45	-0.59	2.91e-33	Brugada syndrome;
LUSC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg14664628	chr15:75095509	CSK	-0.58	-8.99	-0.44	1.91e-17	Breast cancer;
LUSC	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23544223	chr18:12777786	NA	0.59	6.27	0.32	1.15e-9	Inflammatory skin disease;
LUSC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.75e-14	Melanoma;
LUSC	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.0	-0.31	5.25e-9	Morning vs. evening chronotype;
LUSC	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg00074818	chr8:8560427	CLDN23	0.48	7.84	0.39	6.16e-14	Obesity-related traits;
LUSC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.26	0.37	2.81e-12	Major depressive disorder;
LUSC	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg18683606	chr7:100471612	SRRT	0.47	6.16	0.32	2.13e-9	Resting heart rate;
LUSC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg17691542	chr6:26056736	HIST1H1C	0.48	7.16	0.36	5.08e-12	Height;
LUSC	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg03161606	chr19:29218774	NA	0.52	6.11	0.32	2.73e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	trans	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.25	-0.37	2.89e-12	Menarche (age at onset);
LUSC	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg24848339	chr3:12840334	CAND2	-0.38	-8.11	-0.41	9.87e-15	QRS complex (12-leadsum);
LUSC	cis	rs432925	0.600	rs214247	chr16:349221	A/G	cg06233593	chr16:337645	AXIN1	0.44	8.41	0.42	1.18e-15	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg23711669	chr6:146136114	FBXO30	-0.92	-17.8	-0.7	2.46e-50	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16341495	chr8:142228727	SLC45A4	-0.41	-6.97	-0.36	1.72e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7615316	0.934	rs13067795	chr3:142263858	G/T	cg16271453	chr3:142027066	XRN1	-0.35	-6.09	-0.32	3.18e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-1.11	-24.54	-0.8	9.94e-77	Triglycerides;
LUSC	trans	rs2055729	0.614	rs17150693	chr8:9741652	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.34	0.33	7.45e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9341808	0.558	rs3805911	chr6:80933996	A/C	cg08355045	chr6:80787529	NA	0.46	7.82	0.39	6.97e-14	Sitting height ratio;
LUSC	cis	rs2718058	0.692	rs2718041	chr7:37783944	A/G	cg15028436	chr7:37888078	TXNDC3	0.34	5.75	0.3	2.02e-8	Alzheimer's disease (late onset);
LUSC	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	7.53	0.38	4.66e-13	Iron status biomarkers;
LUSC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs4285028	0.747	rs3732407	chr3:121416623	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.89	-12.06	-0.55	4.85e-28	Multiple sclerosis;
LUSC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	0.92	15.42	0.64	7.18e-41	Breast cancer;
LUSC	cis	rs7246967	0.673	rs57027767	chr19:22876535	A/G	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs13385	0.769	rs7704262	chr5:139611043	T/A	cg26211634	chr5:139558579	C5orf32	0.45	6.99	0.36	1.47e-11	Atrial fibrillation;
LUSC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg17264618	chr3:40429014	ENTPD3	0.36	7.38	0.37	1.28e-12	Renal cell carcinoma;
LUSC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.75	10.92	0.51	6.17e-24	Chronic sinus infection;
LUSC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	trans	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg21659725	chr3:3221576	CRBN	-0.65	-7.77	-0.39	9.77e-14	Menarche (age at onset);
LUSC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg10729496	chr3:10149963	C3orf24	0.58	7.91	0.4	3.82e-14	Alzheimer's disease;
LUSC	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg24690094	chr11:67383802	NA	0.44	8.5	0.42	6.36e-16	Mean corpuscular volume;
LUSC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg07424592	chr7:64974309	NA	-0.64	-5.72	-0.3	2.33e-8	Diabetic kidney disease;
LUSC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg08219700	chr8:58056026	NA	0.45	6.04	0.31	4.21e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-0.92	-17.33	-0.69	1.88e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg11235426	chr6:292522	DUSP22	-0.65	-10.65	-0.5	5.53e-23	Menopause (age at onset);
LUSC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	1.02	17.47	0.69	5.12e-49	Parkinson's disease;
LUSC	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg05347473	chr6:146136440	FBXO30	0.52	8.94	0.44	2.63e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg02951883	chr7:2050386	MAD1L1	0.51	9.04	0.44	1.26e-17	Schizophrenia;
LUSC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg11812906	chr14:75593930	NEK9	-0.62	-10.08	-0.48	5.03e-21	Height;
LUSC	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg20129853	chr10:51489980	NA	-0.34	-6.93	-0.35	2.19e-11	Prostate-specific antigen levels;
LUSC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg06238570	chr21:40685208	BRWD1	0.46	7.19	0.37	4.25e-12	Cognitive function;
LUSC	cis	rs7572644	0.766	rs4578808	chr2:28081630	G/T	cg27432699	chr2:27873401	GPN1	0.51	6.47	0.33	3.46e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.46	0.5	2.37e-22	Schizophrenia;
LUSC	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg26384229	chr12:38710491	ALG10B	0.6	9.27	0.45	2.36e-18	Morning vs. evening chronotype;
LUSC	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg16230307	chr14:35515116	FAM177A1	0.79	10.05	0.48	6.13e-21	Psoriasis;
LUSC	cis	rs7804356	1.000	rs28550029	chr7:26872581	C/T	cg03456212	chr7:26904342	SKAP2	-0.55	-6.37	-0.33	6.29e-10	Type 1 diabetes;
LUSC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg23933602	chr10:16859644	RSU1	0.55	6.41	0.33	4.99e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg01652190	chr22:50026171	C22orf34	-0.31	-6.37	-0.33	6.44e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg21782813	chr7:2030301	MAD1L1	0.58	10.31	0.49	8.12e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg20243544	chr17:37824526	PNMT	-0.44	-5.66	-0.3	3.24e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg09021430	chr5:549028	NA	-0.55	-7.25	-0.37	2.95e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.81	-0.3	1.49e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg15848620	chr12:58087721	OS9	-0.52	-7.49	-0.38	6.36e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg16606324	chr3:10149918	C3orf24	0.65	9.41	0.46	8.08e-19	Alzheimer's disease;
LUSC	cis	rs6087990	0.748	rs4911255	chr20:31357580	A/T	cg13636640	chr20:31349939	DNMT3B	1.01	23.33	0.79	4.32e-72	Ulcerative colitis;
LUSC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs5770917	1.000	rs2269384	chr22:51011115	C/T	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.62	-5.73	-0.3	2.26e-8	Narcolepsy;
LUSC	cis	rs1775715	0.737	rs2799031	chr10:32173168	C/T	cg03015672	chr10:32216066	ARHGAP12	0.34	6.09	0.32	3.14e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12292205	chr6:26970375	C6orf41	0.56	7.43	0.38	9.01e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2481665	0.739	rs6674622	chr1:62534938	A/G	cg18591186	chr1:62594603	INADL	-0.44	-6.96	-0.36	1.86e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg01620082	chr3:125678407	NA	-0.72	-6.85	-0.35	3.64e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26260540	chr19:589513	HCN2	0.68	6.31	0.33	8.82e-10	Cognitive performance;
LUSC	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	7.16	0.36	5.24e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg06917634	chr15:78832804	PSMA4	-0.48	-5.87	-0.31	1.05e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.53	0.38	4.76e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	0.6	9.65	0.47	1.34e-19	Breast cancer;
LUSC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.54	0.42	4.96e-16	Motion sickness;
LUSC	trans	rs236907	0.859	rs2232824	chr1:171761458	T/C	cg13482142	chr2:234261155	NA	0.48	6.05	0.31	3.8e-9	Mean platelet volume;
LUSC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg27266027	chr21:40555129	PSMG1	-0.4	-5.84	-0.3	1.24e-8	Cognitive function;
LUSC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.1	0.45	8.41e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg17366294	chr4:99064904	C4orf37	0.6	10.68	0.5	4.39e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg04691961	chr3:161091175	C3orf57	-0.35	-6.07	-0.32	3.43e-9	Morning vs. evening chronotype;
LUSC	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg17691542	chr6:26056736	HIST1H1C	0.58	8.11	0.41	9.78e-15	Iron status biomarkers;
LUSC	trans	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg24644049	chr4:85504048	CDS1	0.88	7.56	0.38	3.94e-13	Skin colour saturation;
LUSC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-11.84	-0.54	3.05e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.74	-7.64	-0.39	2.25e-13	Lung cancer in ever smokers;
LUSC	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg05234568	chr11:5960015	NA	-0.6	-8.69	-0.43	1.61e-16	DNA methylation (variation);
LUSC	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg18904891	chr8:8559673	CLDN23	0.6	8.08	0.4	1.2e-14	Obesity-related traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01883208	chr1:233316809	PCNXL2	0.35	6.08	0.32	3.2e-9	Electrocardiographic conduction measures;
LUSC	cis	rs708547	0.957	rs781667	chr4:57798469	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	7.07	0.36	9.29e-12	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7605827	0.930	rs10179765	chr2:15541249	C/T	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.29	-0.37	2.29e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg24250549	chr1:154909240	PMVK	0.65	10.87	0.51	9.05e-24	Prostate cancer;
LUSC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg00149659	chr3:10157352	C3orf10	-0.63	-9.23	-0.45	3.26e-18	Alzheimer's disease;
LUSC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.78	-0.54	4.87e-27	Chronic sinus infection;
LUSC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg08470875	chr2:26401718	FAM59B	-0.65	-8.87	-0.44	4.58e-17	Gut microbiome composition (summer);
LUSC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg15534755	chr11:117069859	TAGLN	0.33	5.66	0.3	3.21e-8	Blood protein levels;
LUSC	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.7	10.49	0.5	1.92e-22	Smoking initiation;
LUSC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg01657329	chr11:68192670	LRP5	-0.45	-7.2	-0.37	4e-12	Total body bone mineral density;
LUSC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	0.92	15.38	0.64	1.02e-40	Breast cancer;
LUSC	trans	rs62238980	0.614	rs77661466	chr22:32520016	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.52	-5.98	-0.31	5.76e-9	Childhood ear infection;
LUSC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.9	-14.05	-0.61	1.47e-35	Systemic lupus erythematosus;
LUSC	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg12179176	chr11:130786555	SNX19	0.57	8.76	0.43	1.01e-16	Schizophrenia;
LUSC	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg21521518	chr4:53727714	RASL11B	0.44	5.78	0.3	1.73e-8	Optic nerve measurement (cup area);
LUSC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	0.93	8.06	0.4	1.33e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.21	-0.32	1.59e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.95	-0.31	6.88e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg23711669	chr6:146136114	FBXO30	0.71	11.83	0.54	3.28e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg09904177	chr6:26538194	HMGN4	-0.76	-6.23	-0.32	1.43e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-0.88	-18.29	-0.71	2.99e-52	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.43	5.83	0.3	1.3e-8	IgG glycosylation;
LUSC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10802521	chr3:52805072	NEK4	-0.52	-8.46	-0.42	8.21e-16	Bipolar disorder;
LUSC	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg03233332	chr7:66118400	NA	-0.43	-6.16	-0.32	2.14e-9	Aortic root size;
LUSC	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.25	-0.41	3.6e-15	Response to antipsychotic treatment;
LUSC	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg23625390	chr15:77176239	SCAPER	0.46	7.13	0.36	6.32e-12	Blood metabolite levels;
LUSC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg18196295	chr10:418757	DIP2C	0.51	8.41	0.42	1.17e-15	Psychosis in Alzheimer's disease;
LUSC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.28	0.56	7.31e-29	Prudent dietary pattern;
LUSC	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	9.44	0.46	6.38e-19	Body mass index;
LUSC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07167872	chr1:205819463	PM20D1	0.84	15.36	0.64	1.16e-40	Menarche (age at onset);
LUSC	cis	rs4478137	0.899	rs10857354	chr4:164239841	A/G	cg06758707	chr4:164254230	NPY1R	0.63	9.88	0.48	2.26e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02176678	chr2:219576539	TTLL4	-0.73	-13.88	-0.6	6.54e-35	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs7103411	0.592	rs11030087	chr11:27646246	T/C	cg15471856	chr13:19448839	NA	-0.44	-6.15	-0.32	2.26e-9	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.46	0.75	6.72e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs17828380	1.000	rs17829047	chr15:63525952	A/C	cg05507819	chr15:63340323	TPM1	-0.7	-5.93	-0.31	7.6e-9	Social communication problems;
LUSC	cis	rs17401966	0.838	rs55676616	chr1:10290126	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-8.53	-0.42	5.04e-16	Hepatocellular carcinoma;
LUSC	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg23985595	chr17:80112537	CCDC57	-0.31	-6.13	-0.32	2.41e-9	Life satisfaction;
LUSC	cis	rs13082711	0.911	rs2370995	chr3:27428216	C/T	cg02860705	chr3:27208620	NA	0.49	8.38	0.42	1.53e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs6723226	0.766	rs455737	chr2:32528234	A/G	cg02381751	chr2:32503542	YIPF4	0.62	9.32	0.45	1.61e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg02023728	chr11:77925099	USP35	0.45	6.79	0.35	5.09e-11	Testicular germ cell tumor;
LUSC	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.46	6.73	0.35	7.43e-11	Schizophrenia;
LUSC	cis	rs886126	0.684	rs10083213	chr12:111654363	A/G	cg10833066	chr12:111807467	FAM109A	-0.41	-6.47	-0.33	3.49e-10	Coronary heart disease;
LUSC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.68	-0.3	2.93e-8	Tonsillectomy;
LUSC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg00509249	chr6:109615579	CCDC162	-0.33	-5.9	-0.31	9.06e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg25237894	chr2:233734115	C2orf82	0.35	6.51	0.34	2.83e-10	Coronary artery disease;
LUSC	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-8.18	-0.41	6.14e-15	Breast cancer;
LUSC	cis	rs4690686	0.500	rs2168032	chr4:177272957	A/G	cg17059388	chr4:177262070	NA	0.45	8.5	0.42	6.35e-16	Essential tremor;
LUSC	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08704250	chr15:31115839	NA	-0.58	-8.86	-0.44	4.74e-17	Huntington's disease progression;
LUSC	trans	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg24192581	chr19:40562106	ZNF780B	0.43	5.99	0.31	5.51e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.92	0.35	2.27e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg18681998	chr4:17616180	MED28	0.88	15.96	0.66	5.35e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg16339924	chr4:17578868	LAP3	0.54	7.95	0.4	3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg21951975	chr1:209979733	IRF6	-0.5	-8.33	-0.41	2.15e-15	Monobrow;
LUSC	cis	rs9462027	0.628	rs9469914	chr6:34827693	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.73	-0.3	2.29e-8	Systemic lupus erythematosus;
LUSC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.13	-0.32	2.47e-9	Bipolar disorder;
LUSC	cis	rs977987	0.806	rs4888388	chr16:75394148	G/A	cg04384234	chr16:75411784	CFDP1	-0.42	-6.95	-0.36	1.94e-11	Dupuytren's disease;
LUSC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg00024416	chr22:24240387	NA	0.47	7.03	0.36	1.19e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	trans	rs12200782	1.000	rs12213722	chr6:26473083	A/G	cg11837749	chr1:55047332	ACOT11	0.59	6.42	0.33	4.55e-10	Small cell lung carcinoma;
LUSC	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg13319975	chr6:146136371	FBXO30	0.49	7.36	0.37	1.42e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg20821713	chr7:1055600	C7orf50	-0.57	-7.58	-0.38	3.37e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06850241	chr22:41845214	NA	0.34	6.15	0.32	2.25e-9	Vitiligo;
LUSC	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg09184832	chr6:79620586	NA	-0.43	-7.02	-0.36	1.27e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-9.62	-0.47	1.64e-19	Bone mineral density;
LUSC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg23791538	chr6:167370224	RNASET2	0.41	6.54	0.34	2.25e-10	Crohn's disease;
LUSC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg07777115	chr5:623756	CEP72	-0.45	-5.7	-0.3	2.62e-8	Obesity-related traits;
LUSC	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg24375607	chr4:120327624	NA	0.7	10.62	0.5	6.76e-23	Corneal astigmatism;
LUSC	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg17385448	chr1:15911702	AGMAT	0.37	5.8	0.3	1.5e-8	Systolic blood pressure;
LUSC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg20203395	chr5:56204925	C5orf35	-0.78	-10.62	-0.5	6.82e-23	Initial pursuit acceleration;
LUSC	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg06271696	chr7:157225062	NA	0.4	7.71	0.39	1.45e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs1865721	1.000	rs62089503	chr18:73177766	C/T	cg26385618	chr18:73139727	C18orf62	-0.48	-8.19	-0.41	5.65e-15	Intelligence;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03637614	chr7:129691233	ZC3HC1	0.45	6.11	0.32	2.74e-9	Neuroticism;
LUSC	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg24642439	chr20:33292090	TP53INP2	0.41	5.97	0.31	6.22e-9	Height;
LUSC	cis	rs6782228	0.606	rs2712419	chr3:128340896	T/C	cg16766828	chr3:128327626	NA	-0.31	-5.66	-0.3	3.3e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg13010199	chr12:38710504	ALG10B	0.68	10.59	0.5	8.44e-23	Bladder cancer;
LUSC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg25214090	chr10:38739885	LOC399744	0.5	7.32	0.37	1.88e-12	Corneal astigmatism;
LUSC	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg18105134	chr13:113819100	PROZ	-0.67	-9.55	-0.46	2.88e-19	Platelet distribution width;
LUSC	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg12219531	chr12:120966889	COQ5	0.59	7.71	0.39	1.41e-13	High light scatter reticulocyte count;
LUSC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg07701084	chr6:150067640	NUP43	0.57	8.78	0.43	8.5e-17	Lung cancer;
LUSC	cis	rs10144321	0.810	rs11624049	chr14:100852820	A/G	cg14882082	chr14:100845427	WDR25	-0.38	-7.13	-0.36	6.34e-12	Menarche (age at onset);
LUSC	cis	rs1775715	0.870	rs7095322	chr10:32248491	C/T	cg26784012	chr10:32216390	ARHGAP12	-0.36	-5.67	-0.3	3.07e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Parkinson's disease;
LUSC	cis	rs6500395	1.000	rs1558817	chr16:48730722	G/A	cg04672837	chr16:48644449	N4BP1	0.46	6.67	0.34	1.06e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg11901034	chr3:128598214	ACAD9	-0.4	-6.09	-0.32	3.11e-9	IgG glycosylation;
LUSC	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg18721089	chr20:30220636	NA	-0.41	-6.57	-0.34	1.93e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs12458462	0.812	rs36073957	chr18:77488441	C/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-6.36	-0.33	6.7e-10	Monocyte count;
LUSC	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.72	-0.43	1.33e-16	Total cholesterol levels;
LUSC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg06784218	chr1:46089804	CCDC17	0.48	9.38	0.46	1.04e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9473147	0.516	rs9349416	chr6:47551938	G/A	cg02130027	chr6:47444894	CD2AP	0.35	5.7	0.3	2.68e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.41	5.68	0.3	2.94e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs367615	0.506	rs246102	chr5:108699695	C/G	cg17395555	chr5:108820864	NA	-0.5	-8.83	-0.44	5.9e-17	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	10.66	0.5	5e-23	Bipolar disorder;
LUSC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	14.02	0.61	1.94e-35	Alzheimer's disease;
LUSC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg17507749	chr15:85114479	UBE2QP1	0.69	8.67	0.43	1.92e-16	Schizophrenia;
LUSC	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg03929089	chr4:120376271	NA	0.65	6.08	0.32	3.36e-9	Intraocular pressure;
LUSC	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12292205	chr6:26970375	C6orf41	-0.62	-9.16	-0.45	5.54e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.6	0.5	8.12e-23	Bone mineral density;
LUSC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg07701084	chr6:150067640	NUP43	0.57	8.88	0.44	4.29e-17	Lung cancer;
LUSC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg22535103	chr8:58192502	C8orf71	-0.79	-8.22	-0.41	4.44e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg21053147	chr12:120880522	NA	0.52	6.45	0.33	3.99e-10	Type 1 diabetes nephropathy;
LUSC	cis	rs72960926	0.744	rs6933439	chr6:75006170	T/C	cg03266952	chr6:74778945	NA	-0.63	-6.02	-0.31	4.7e-9	Metabolite levels (MHPG);
LUSC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	0.6	9.37	0.46	1.14e-18	Breast cancer;
LUSC	cis	rs9581857	0.615	rs9581848	chr13:28003997	C/T	cg22138327	chr13:27999177	GTF3A	0.89	9.45	0.46	6.21e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.05	0.52	2.14e-24	Hypertriglyceridemia;
LUSC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	8.45	0.42	9.26e-16	Obesity-related traits;
LUSC	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.34	-0.46	1.37e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.44	-6.53	-0.34	2.5e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg14895029	chr7:2775587	GNA12	-0.41	-6.35	-0.33	6.89e-10	Height;
LUSC	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg14830002	chr1:247616686	OR2B11	0.49	7.01	0.36	1.33e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.68	14.17	0.61	4.91e-36	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg05340658	chr4:99064831	C4orf37	0.62	9.11	0.45	7.88e-18	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg25482853	chr8:67687455	SGK3	1.12	16.14	0.66	1.01e-43	Obesity-related traits;
LUSC	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg03641300	chr2:160917029	PLA2R1	-0.4	-6.58	-0.34	1.77e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.29	0.37	2.2e-12	Motion sickness;
LUSC	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.33	5.97	0.31	6.08e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-5.92	-0.31	8.21e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1943345	0.686	rs10898088	chr11:82874970	G/A	cg07047830	chr11:82868014	PCF11	0.65	9.63	0.47	1.61e-19	Obesity-related traits;
LUSC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg16329197	chr12:53359506	NA	-0.66	-9.43	-0.46	7.38e-19	Cancer (pleiotropy);
LUSC	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg14835575	chr10:16859367	RSU1	0.76	9.49	0.46	4.65e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg20307385	chr11:47447363	PSMC3	0.55	6.42	0.33	4.77e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg13047869	chr3:10149882	C3orf24	0.64	9.15	0.45	5.9e-18	Alzheimer's disease;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg07332563	chr6:291687	DUSP22	-0.71	-11.95	-0.55	1.26e-27	Menopause (age at onset);
LUSC	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg25801113	chr15:45476975	SHF	0.34	6.97	0.36	1.74e-11	Uric acid levels;
LUSC	cis	rs7739264	0.602	rs6925511	chr6:19773553	C/T	cg02404759	chr6:19790362	NA	0.43	6.76	0.35	6.11e-11	Endometriosis;
LUSC	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg21479132	chr6:26055353	NA	0.6	5.67	0.3	3.1e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg08085267	chr17:45401833	C17orf57	-0.6	-10.0	-0.48	8.85e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg02569458	chr12:86230093	RASSF9	0.53	8.56	0.42	4.18e-16	Major depressive disorder;
LUSC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	8.09e-13	Motion sickness;
LUSC	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.86	-0.39	5.44e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg25428297	chr7:1022841	CYP2W1	0.29	6.13	0.32	2.5e-9	Longevity;Endometriosis;
LUSC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.17	-0.52	7.89e-25	Mean corpuscular volume;
LUSC	cis	rs72960926	0.590	rs56343698	chr6:74749564	C/T	cg03266952	chr6:74778945	NA	-0.82	-6.15	-0.32	2.24e-9	Metabolite levels (MHPG);
LUSC	cis	rs983392	0.679	rs600064	chr11:60013451	A/G	cg20284999	chr11:59952153	MS4A6A	0.38	6.33	0.33	7.75e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9303401	0.555	rs8071831	chr17:57292950	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	6.47	0.33	3.49e-10	Cognitive test performance;
LUSC	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.86	-14.52	-0.62	2.16e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.43	-6.6	-0.34	1.64e-10	Colorectal cancer;
LUSC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	10.77	0.51	1.97e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg09034736	chr1:150693464	HORMAD1	0.51	7.51	0.38	5.57e-13	Tonsillectomy;
LUSC	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg24881330	chr22:46731750	TRMU	0.85	7.28	0.37	2.36e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg04989706	chr14:50066350	PPIL5	-0.46	-5.88	-0.31	9.79e-9	Carotid intima media thickness;
LUSC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.89e-12	Blood metabolite levels;
LUSC	trans	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.39	0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs7712401	0.755	rs3756362	chr5:122108890	C/G	cg19077854	chr5:122220652	SNX24	0.32	7.08	0.36	8.4e-12	Mean platelet volume;
LUSC	cis	rs6504340	0.739	rs1123630	chr17:46671816	C/T	cg09704116	chr17:46666958	LOC404266	-0.39	-6.39	-0.33	5.53e-10	Primary tooth development (number of teeth);
LUSC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg25456477	chr12:86230367	RASSF9	0.35	6.16	0.32	2.14e-9	Major depressive disorder;
LUSC	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.82	-10.48	-0.5	2.13e-22	Exhaled nitric oxide output;
LUSC	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-10.97	-0.51	4.1e-24	Mean corpuscular volume;
LUSC	trans	rs1376359	0.537	rs510385	chr1:103281607	C/T	cg17154563	chr19:40477487	PSMC4	0.48	5.95	0.31	6.87e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4704187	0.687	rs7709707	chr5:74363575	T/G	cg03227963	chr5:74354835	NA	0.33	7.02	0.36	1.28e-11	Response to amphetamines;
LUSC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg08027265	chr7:2291960	NA	-0.37	-5.94	-0.31	7.24e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg11764359	chr7:65958608	NA	0.7	10.31	0.49	7.92e-22	Aortic root size;
LUSC	trans	rs72674100	1.000	rs3960895	chr4:97963659	A/C	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg26752003	chr8:145688521	CYHR1	0.61	10.24	0.49	1.39e-21	Age at first birth;
LUSC	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-5.89	-0.31	9.23e-9	Retinal vascular caliber;
LUSC	trans	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg03785828	chr5:81573306	RPS23	-0.37	-6.02	-0.31	4.65e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17976635	chr11:69490191	ORAOV1	-0.46	-7.04	-0.36	1.1e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.45	0.5	2.68e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg09491104	chr22:46646882	C22orf40	-0.71	-7.48	-0.38	6.49e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-0.91	-19.02	-0.72	3.46e-55	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg05340658	chr4:99064831	C4orf37	-0.46	-7.26	-0.37	2.68e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg27494647	chr7:150038898	RARRES2	0.36	5.75	0.3	2.06e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg10253484	chr15:75165896	SCAMP2	-0.51	-6.71	-0.34	8.44e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg06008330	chr7:65541103	ASL	0.39	6.09	0.32	3.19e-9	Aortic root size;
LUSC	cis	rs859767	0.501	rs11898465	chr2:135431449	G/T	cg12500956	chr2:135428796	TMEM163	-0.29	-6.98	-0.36	1.63e-11	Neuroticism;
LUSC	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg13010199	chr12:38710504	ALG10B	0.56	8.45	0.42	9.2e-16	Morning vs. evening chronotype;
LUSC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.51	-0.34	2.75e-10	Neutrophil percentage of white cells;
LUSC	cis	rs4664308	0.840	rs17218566	chr2:161054748	C/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-10.74	-0.51	2.51e-23	Idiopathic membranous nephropathy;
LUSC	trans	rs62238980	0.614	rs117534689	chr22:32392350	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg06028605	chr16:24865363	SLC5A11	0.44	7.97	0.4	2.6e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg21770322	chr7:97807741	LMTK2	-0.49	-7.98	-0.4	2.31e-14	Breast cancer;
LUSC	cis	rs6500395	0.775	rs1968903	chr16:48664014	C/T	cg04672837	chr16:48644449	N4BP1	0.47	6.96	0.36	1.79e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg23172400	chr8:95962367	TP53INP1	-0.41	-8.19	-0.41	5.46e-15	Type 2 diabetes;
LUSC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.82	-0.57	7.44e-31	Platelet count;
LUSC	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg23192644	chr19:1315876	NA	0.37	5.96	0.31	6.5e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg23625390	chr15:77176239	SCAPER	-0.67	-10.37	-0.49	4.84e-22	Blood metabolite levels;
LUSC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg13395646	chr4:1353034	KIAA1530	0.65	10.98	0.51	3.89e-24	Obesity-related traits;
LUSC	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg19812747	chr11:111475976	SIK2	-0.49	-6.99	-0.36	1.52e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-6.7	-0.34	8.94e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg05714579	chr10:131428358	MGMT	0.45	6.42	0.33	4.8e-10	Response to temozolomide;
LUSC	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg15848620	chr12:58087721	OS9	-0.45	-6.75	-0.35	6.66e-11	Multiple sclerosis;
LUSC	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-8.8	-0.43	7.7e-17	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg18352616	chr4:3374830	RGS12	0.34	6.82	0.35	4.35e-11	Serum sulfate level;
LUSC	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.77	-0.39	1e-13	Systolic blood pressure;
LUSC	cis	rs2835872	0.758	rs1787398	chr21:39037504	A/C	cg20424643	chr21:39039972	KCNJ6	-0.44	-7.43	-0.38	8.98e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs68170813	0.559	rs78553765	chr7:106930787	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.8	-0.47	4.33e-20	Coronary artery disease;
LUSC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg03609598	chr5:56110824	MAP3K1	-0.44	-6.21	-0.32	1.55e-9	Initial pursuit acceleration;
LUSC	cis	rs4474465	0.920	rs12271198	chr11:78158943	G/A	cg27205649	chr11:78285834	NARS2	-0.49	-5.85	-0.3	1.18e-8	Alzheimer's disease (survival time);
LUSC	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg26384229	chr12:38710491	ALG10B	0.69	11.03	0.52	2.52e-24	Morning vs. evening chronotype;
LUSC	trans	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg01584401	chr7:99063876	ATP5J2	-0.4	-6.01	-0.31	4.78e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs10511400	0.541	rs6438564	chr3:119870476	A/T	cg02809009	chr19:50354510	PTOV1	-0.68	-6.19	-0.32	1.81e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg14983838	chr19:29218262	NA	0.45	5.7	0.3	2.59e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg23950597	chr19:37808831	NA	-0.6	-7.22	-0.37	3.49e-12	Coronary artery calcification;
LUSC	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg21951975	chr1:209979733	IRF6	0.41	6.8	0.35	4.89e-11	Monobrow;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18635645	chr1:85667791	SYDE2	0.4	6.1	0.32	2.91e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs354225	0.584	rs10206143	chr2:54817453	A/T	cg01766943	chr2:54829624	SPTBN1	0.51	8.2	0.41	5.15e-15	Schizophrenia;
LUSC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg02569458	chr12:86230093	RASSF9	0.59	10.06	0.48	5.54e-21	Major depressive disorder;
LUSC	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.71	0.47	8.25e-20	Coffee consumption (cups per day);
LUSC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg17719053	chr1:75198211	TYW3;CRYZ	0.38	6.21	0.32	1.6e-9	Resistin levels;
LUSC	cis	rs1044826	0.642	rs407958	chr3:139213632	T/C	cg00490450	chr3:139108681	COPB2	0.46	7.03	0.36	1.19e-11	Obesity-related traits;
LUSC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg20701182	chr2:24300061	SF3B14	0.87	11.27	0.52	3.42e-25	Lymphocyte counts;
LUSC	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg26441486	chr22:50317300	CRELD2	0.46	6.96	0.36	1.82e-11	Schizophrenia;
LUSC	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg09184832	chr6:79620586	NA	-0.44	-7.18	-0.37	4.46e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6977660	0.652	rs10249291	chr7:19844448	C/G	cg07541023	chr7:19748670	TWISTNB	0.7	6.52	0.34	2.55e-10	Thyroid stimulating hormone;
LUSC	trans	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg14227996	chr4:17616232	MED28	-0.54	-6.01	-0.31	4.92e-9	Opioid sensitivity;
LUSC	cis	rs7927771	0.524	rs7933896	chr11:47882782	C/T	cg20307385	chr11:47447363	PSMC3	0.47	6.86	0.35	3.42e-11	Subjective well-being;
LUSC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.58	-8.31	-0.41	2.38e-15	Diastolic blood pressure;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03634592	chr7:43946398	URGCP	-0.53	-6.66	-0.34	1.14e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs6982636	0.967	rs2954027	chr8:126485294	T/A	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.32	-6.2	-0.32	1.65e-9	Lipid metabolism phenotypes;
LUSC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06112835	chr11:68658793	MRPL21	-0.5	-7.76	-0.39	1.04e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.34	0.37	1.62e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21643547	chr1:205240462	TMCC2	-0.49	-9.17	-0.45	4.83e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg19318889	chr4:1322082	MAEA	0.51	8.77	0.43	9.29e-17	Obesity-related traits;
LUSC	cis	rs17824933	0.887	rs12790976	chr11:60767420	T/G	cg16817237	chr11:60793675	NA	0.4	6.37	0.33	6.35e-10	Multiple sclerosis;
LUSC	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.57	9.0	0.44	1.7e-17	Menopause (age at onset);
LUSC	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg12863693	chr15:85201151	NMB	0.37	6.88	0.35	2.97e-11	Schizophrenia;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg07332563	chr6:291687	DUSP22	-0.72	-11.97	-0.55	1.01e-27	Menopause (age at onset);
LUSC	cis	rs12681287	0.547	rs13267858	chr8:87510871	G/A	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07916070	chr3:122283003	PARP9;DTX3L	-0.47	-6.39	-0.33	5.44e-10	Hepatitis;
LUSC	cis	rs4588572	0.688	rs11743511	chr5:77692819	C/T	cg11547950	chr5:77652471	NA	-0.42	-6.53	-0.34	2.44e-10	Triglycerides;
LUSC	trans	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg19862616	chr7:65841803	NCRNA00174	0.9	10.13	0.48	3.31e-21	Eotaxin levels;
LUSC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.76	-0.35	6.2e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.77	-0.51	2.03e-23	Chronic sinus infection;
LUSC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg14809332	chr8:144654887	C8orf73	-0.37	-5.71	-0.3	2.49e-8	Attention deficit hyperactivity disorder;
LUSC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg06064525	chr11:970664	AP2A2	-0.34	-6.76	-0.35	6.06e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg09033563	chr22:24373618	LOC391322	-0.47	-6.62	-0.34	1.43e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg04414720	chr1:150670196	GOLPH3L	0.5	7.76	0.39	1.07e-13	Melanoma;
LUSC	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg05368731	chr17:41323189	NBR1	0.9	12.66	0.57	2.86e-30	Menopause (age at onset);
LUSC	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	7.8	0.39	8.14e-14	Lung cancer;
LUSC	cis	rs6740322	0.895	rs13384080	chr2:43557363	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-7.53	-0.38	4.87e-13	Coronary artery disease;
LUSC	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.76	0.7	3.77e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg08313168	chr12:7315531	NA	0.47	6.05	0.31	3.9e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4654899	0.865	rs12410467	chr1:21356055	G/A	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.39	-0.33	5.7e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9807841	0.592	rs2742313	chr19:10799750	T/C	cg17710535	chr19:10819994	QTRT1	0.42	7.0	0.36	1.38e-11	Inflammatory skin disease;
LUSC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg11752832	chr7:134001865	SLC35B4	0.54	8.13	0.41	8.64e-15	Mean platelet volume;
LUSC	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg16342193	chr10:102329863	NA	-0.34	-6.18	-0.32	1.82e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6906287	0.647	rs4946350	chr6:118945433	A/C	cg21191810	chr6:118973309	C6orf204	0.32	5.9	0.31	9.06e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	5.74	0.3	2.08e-8	Breast cancer;
LUSC	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.87	14.76	0.63	2.57e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg00105475	chr2:10696890	NA	0.38	6.21	0.32	1.54e-9	Prostate cancer;
LUSC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.96	0.7	5.97e-51	Chronic sinus infection;
LUSC	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg19875535	chr5:140030758	IK	0.46	7.38	0.37	1.31e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4363385	0.510	rs6677674	chr1:153037601	A/G	cg25856811	chr1:152973957	SPRR3	-0.36	-5.97	-0.31	6.05e-9	Inflammatory skin disease;
LUSC	trans	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg13565492	chr6:43139072	SRF	-0.42	-6.14	-0.32	2.37e-9	Longevity;Endometriosis;
LUSC	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03352830	chr11:487213	PTDSS2	0.65	8.22	0.41	4.7e-15	Body mass index;
LUSC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.2	-0.32	1.62e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs377070	0.816	rs309416	chr4:123621916	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.41	6.1	0.32	2.87e-9	Mosquito bite size;
LUSC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.65	-11.68	-0.54	1.15e-26	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg14558114	chr2:88469736	THNSL2	0.77	6.96	0.36	1.78e-11	Plasma clusterin levels;
LUSC	cis	rs603446	0.840	rs180329	chr11:116622958	G/A	cg08985259	chr11:116699649	APOC3	-0.25	-5.65	-0.3	3.39e-8	Triglycerides;
LUSC	cis	rs10754283	1.000	rs10754283	chr1:90112431	G/T	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg16558253	chr16:72132732	DHX38	-0.37	-5.77	-0.3	1.85e-8	Fibrinogen levels;
LUSC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg09455208	chr3:40491958	NA	0.53	9.83	0.47	3.34e-20	Renal cell carcinoma;
LUSC	cis	rs974417	0.530	rs11751305	chr6:97296833	G/A	cg10979063	chr6:97285822	GPR63	0.44	7.22	0.37	3.55e-12	Body mass index;
LUSC	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.43	5.96	0.31	6.38e-9	Lung cancer;
LUSC	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg16339924	chr4:17578868	LAP3	0.51	7.58	0.38	3.42e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg26597838	chr10:835615	NA	0.79	9.73	0.47	7.58e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs7539542	0.556	rs10753925	chr1:202854488	C/T	cg19681188	chr1:202830198	LOC148709	0.41	6.03	0.31	4.45e-9	Mean platelet volume;
LUSC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.34	-6.11	-0.32	2.82e-9	Total body bone mineral density;
LUSC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg11344533	chr11:111475393	SIK2	-0.48	-6.78	-0.35	5.35e-11	Primary sclerosing cholangitis;
LUSC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg17366294	chr4:99064904	C4orf37	0.6	10.65	0.5	5.59e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg05579598	chr16:88989069	CBFA2T3	-0.27	-5.95	-0.31	6.75e-9	Social autistic-like traits;
LUSC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.74	-14.06	-0.61	1.38e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.75	-0.63	2.9e-38	Schizophrenia;
LUSC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg16797656	chr11:68205561	LRP5	0.37	6.15	0.32	2.23e-9	Total body bone mineral density;
LUSC	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg04539111	chr16:67997858	SLC12A4	-0.44	-6.08	-0.32	3.27e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg09655341	chr17:79618100	PDE6G	-0.27	-6.12	-0.32	2.58e-9	Eye color traits;
LUSC	cis	rs8044995	0.563	rs55968019	chr16:68398111	G/A	cg05110241	chr16:68378359	PRMT7	-0.78	-8.91	-0.44	3.36e-17	Schizophrenia;
LUSC	cis	rs12472274	0.646	rs11677736	chr2:239087198	A/T	cg17459225	chr2:239074497	NA	0.57	7.94	0.4	3.19e-14	Phospholipid levels (plasma);
LUSC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg06637938	chr14:75390232	RPS6KL1	0.53	8.45	0.42	9.22e-16	Height;
LUSC	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg03522245	chr20:25566470	NINL	-0.35	-5.71	-0.3	2.45e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.38	-0.37	1.27e-12	Bipolar disorder;
LUSC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.89	-0.4	4.41e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs2354432	0.546	rs7539416	chr1:146881586	C/T	cg25205988	chr1:146714368	CHD1L	0.99	9.79	0.47	4.62e-20	Mitochondrial DNA levels;
LUSC	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg06627628	chr2:24431161	ITSN2	-0.78	-11.24	-0.52	4.46e-25	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs4356932	1.000	rs4359936	chr4:76971976	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.85	0.3	1.16e-8	Blood protein levels;
LUSC	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg26061582	chr7:22766209	IL6	0.5	7.56	0.38	3.9e-13	Lung cancer;
LUSC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08677398	chr8:58056175	NA	0.52	6.87	0.35	3.18e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.63	10.68	0.5	4.18e-23	Blood metabolite levels;
LUSC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg03233332	chr7:66118400	NA	-0.43	-6.21	-0.32	1.6e-9	Aortic root size;
LUSC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg25456477	chr12:86230367	RASSF9	-0.32	-5.69	-0.3	2.83e-8	Major depressive disorder;
LUSC	trans	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg25214090	chr10:38739885	LOC399744	-0.46	-7.28	-0.37	2.43e-12	Corneal astigmatism;
LUSC	cis	rs11756438	0.572	rs1771755	chr6:119018877	A/T	cg21191810	chr6:118973309	C6orf204	-0.34	-5.73	-0.3	2.22e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg12257692	chr3:49977190	RBM6	0.24	6.61	0.34	1.49e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.93	-0.44	2.91e-17	Axial length;
LUSC	cis	rs6693567	0.565	rs834235	chr1:150362154	C/T	cg15654264	chr1:150340011	RPRD2	0.45	7.18	0.37	4.62e-12	Migraine;
LUSC	cis	rs926938	0.520	rs969273	chr1:115256669	G/A	cg12756093	chr1:115239321	AMPD1	-0.56	-8.04	-0.4	1.57e-14	Autism;
LUSC	cis	rs2797685	1.000	rs697691	chr1:7885354	A/G	cg04725166	chr1:7887271	PER3	-0.47	-6.42	-0.33	4.55e-10	Crohn's disease;
LUSC	cis	rs2882667	0.690	rs825672	chr5:138095643	A/G	cg04439458	chr5:138467593	SIL1	0.38	7.11	0.36	6.87e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.11	16.34	0.67	1.63e-44	Mean corpuscular hemoglobin;
LUSC	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18854424	chr1:2615690	NA	0.52	10.81	0.51	1.52e-23	Ulcerative colitis;
LUSC	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg08000102	chr2:233561755	GIGYF2	-0.67	-10.98	-0.51	3.84e-24	Coronary artery disease;
LUSC	cis	rs9473147	0.516	rs6903331	chr6:47562915	A/G	cg12968598	chr6:47444699	CD2AP	0.52	8.04	0.4	1.6e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs2688608	0.839	rs2675662	chr10:75599127	A/G	cg17411546	chr10:75410026	SYNPO2L	0.43	6.14	0.32	2.32e-9	Inflammatory bowel disease;
LUSC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg00343986	chr7:65444356	GUSB	-0.48	-7.28	-0.37	2.47e-12	Aortic root size;
LUSC	cis	rs17227506	0.679	rs67768235	chr8:13443286	T/C	cg03566418	chr8:13424080	C8orf48	0.42	6.38	0.33	5.99e-10	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg04871131	chr7:94954202	PON1	-0.36	-5.79	-0.3	1.64e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg03340356	chr1:67600835	NA	0.43	6.67	0.34	1.08e-10	Psoriasis;
LUSC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2073300	1.000	rs6132629	chr20:23451251	G/A	cg09953122	chr20:23471693	CST8	-0.72	-6.61	-0.34	1.54e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg17492904	chr2:223725746	ACSL3	0.77	6.0	0.31	5.16e-9	Cognitive performance;
LUSC	cis	rs2580764	0.566	rs2920900	chr2:55280083	T/C	cg09592903	chr2:55203963	RTN4	0.47	9.33	0.45	1.56e-18	Mean platelet volume;
LUSC	cis	rs2303282	0.682	rs2920706	chr16:56458487	C/T	cg00500540	chr16:56394104	NA	-0.43	-7.35	-0.37	1.52e-12	Breast cancer;
LUSC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-11.82	-0.54	3.67e-27	Mean corpuscular volume;
LUSC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg01206211	chr2:36825736	FEZ2	-0.49	-10.55	-0.5	1.18e-22	Height;
LUSC	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg11019008	chr10:131425282	MGMT	0.41	6.28	0.32	1.08e-9	Response to temozolomide;
LUSC	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg13010199	chr12:38710504	ALG10B	0.48	7.27	0.37	2.56e-12	Morning vs. evening chronotype;
LUSC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg18350739	chr11:68623251	NA	-0.36	-6.4	-0.33	5.23e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg03474202	chr17:45855739	NA	0.29	6.78	0.35	5.55e-11	IgG glycosylation;
LUSC	cis	rs7215564	1.000	rs7215564	chr17:78737287	A/G	cg09596252	chr17:78655493	RPTOR	0.53	5.85	0.31	1.15e-8	Myopia (pathological);
LUSC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.43	6.32	0.33	8.21e-10	Systemic lupus erythematosus;
LUSC	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg04374321	chr14:90722782	PSMC1	0.75	12.09	0.55	3.85e-28	Mortality in heart failure;
LUSC	cis	rs1790761	0.803	rs2302264	chr11:67207426	G/A	cg24690094	chr11:67383802	NA	-0.31	-5.67	-0.3	3.13e-8	Mean corpuscular volume;
LUSC	cis	rs2898681	0.581	rs28618986	chr4:53677902	G/C	cg00338735	chr4:53728038	RASL11B	0.42	5.75	0.3	2.01e-8	Optic nerve measurement (cup area);
LUSC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg19747945	chr6:42946146	PEX6	-0.34	-5.67	-0.3	3.11e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg06521331	chr12:34319734	NA	-0.39	-6.0	-0.31	5.25e-9	Bladder cancer;
LUSC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19717773	chr7:2847554	GNA12	-0.42	-6.69	-0.34	9.16e-11	Height;
LUSC	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg24558204	chr6:135376177	HBS1L	-0.59	-8.72	-0.43	1.37e-16	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	13.51	0.59	1.69e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs16854884	0.586	rs7611326	chr3:143736374	C/T	cg06585982	chr3:143692056	C3orf58	0.52	8.26	0.41	3.46e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs12286929	0.839	rs12421648	chr11:115013447	G/A	cg04055981	chr11:115044050	NA	0.35	6.09	0.32	3.18e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.48	-0.38	6.84e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.53	0.38	4.66e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6845621	0.727	rs1377147	chr4:18917424	T/G	cg12196642	chr4:18937545	NA	-0.34	-6.34	-0.33	7.56e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.39e-8	Aortic root size;
LUSC	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2172802	0.629	rs62304005	chr4:62494219	C/T	cg04118610	chr4:62707027	LPHN3	0.45	6.03	0.31	4.3e-9	Partial epilepsies;
LUSC	cis	rs59698941	0.943	rs66746130	chr5:132245615	A/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg15557168	chr22:42548783	NA	-0.44	-6.68	-0.34	1.01e-10	Schizophrenia;
LUSC	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.56	-9.13	-0.45	6.91e-18	Schizophrenia;
LUSC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg18230493	chr5:56204884	C5orf35	-0.87	-12.94	-0.58	2.55e-31	Initial pursuit acceleration;
LUSC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg21951975	chr1:209979733	IRF6	0.4	6.67	0.34	1.08e-10	Monobrow;
LUSC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.51	6.65	0.34	1.17e-10	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	0.99	13.98	0.61	2.67e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26314531	chr2:26401878	FAM59B	-0.7	-9.8	-0.47	4.11e-20	Gut microbiome composition (summer);
LUSC	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-5.85	-0.3	1.16e-8	Cutaneous nevi;
LUSC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.78	-0.35	5.37e-11	Alzheimer's disease (late onset);
LUSC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg00990874	chr7:1149470	C7orf50	0.51	6.32	0.33	8.3e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs4845459	0.933	rs6662654	chr1:152593081	G/T	cg08895932	chr1:152778580	LCE1C	-0.38	-6.53	-0.34	2.46e-10	Psoriasis;
LUSC	cis	rs1009647	1.000	rs35502084	chr14:55876263	C/T	cg04306507	chr14:55594613	LGALS3	0.45	7.41	0.38	1.02e-12	Testicular germ cell tumor;
LUSC	cis	rs4363385	0.747	rs2075739	chr1:152975495	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.76	-0.39	1.05e-13	Inflammatory skin disease;
LUSC	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-15.15	-0.64	7.76e-40	Exhaled nitric oxide output;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13819586	chr14:24685205	MDP1	0.46	7.13	0.36	6.36e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg04414720	chr1:150670196	GOLPH3L	0.51	7.92	0.4	3.58e-14	Melanoma;
LUSC	cis	rs6700896	0.500	rs4655575	chr1:66135668	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	5.8	0.3	1.51e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7481584	0.926	rs10833024	chr11:3010390	C/T	cg08508325	chr11:3079039	CARS	0.32	6.09	0.32	3.02e-9	Calcium levels;
LUSC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.06e-12	Motion sickness;
LUSC	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg03585969	chr10:35415529	CREM	0.63	9.28	0.45	2.21e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg20406979	chr6:167373233	NA	-0.26	-6.16	-0.32	2.1e-9	Crohn's disease;
LUSC	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg04586622	chr2:25135609	ADCY3	-0.4	-8.51	-0.42	5.85e-16	Body mass index;
LUSC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg22823121	chr1:150693482	HORMAD1	0.59	9.09	0.45	8.83e-18	Tonsillectomy;
LUSC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03576123	chr11:487126	PTDSS2	-1.01	-10.64	-0.5	5.93e-23	Body mass index;
LUSC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg18681998	chr4:17616180	MED28	0.81	14.71	0.63	4.13e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.13	0.36	6.16e-12	IgG glycosylation;
LUSC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg27165867	chr14:105738592	BRF1	-0.52	-7.74	-0.39	1.16e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg15448220	chr1:150897856	SETDB1	0.42	6.14	0.32	2.29e-9	Melanoma;
LUSC	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg00898013	chr13:113819073	PROZ	-0.57	-8.64	-0.43	2.44e-16	Platelet distribution width;
LUSC	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg16342193	chr10:102329863	NA	-0.35	-5.87	-0.31	1.04e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs13418410	0.715	rs10198451	chr2:33801017	G/A	cg04131969	chr2:33951647	MYADML	-0.46	-6.08	-0.32	3.21e-9	Non-response to antidepressants and depression;
LUSC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16680214	chr1:154839983	KCNN3	-0.51	-9.31	-0.45	1.79e-18	Prostate cancer;
LUSC	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg08499158	chr17:42289980	UBTF	0.5	8.58	0.43	3.5e-16	Total body bone mineral density;
LUSC	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg04990556	chr1:26633338	UBXN11	-0.45	-5.9	-0.31	9.17e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg04871131	chr7:94954202	PON1	-0.39	-6.13	-0.32	2.41e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.48	7.11	0.36	6.89e-12	Neuroticism;
LUSC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg12365402	chr11:9010492	NRIP3	0.43	8.03	0.4	1.73e-14	Hemoglobin concentration;
LUSC	cis	rs859767	0.704	rs6750788	chr2:135362981	A/G	cg12500956	chr2:135428796	TMEM163	-0.28	-6.24	-0.32	1.33e-9	Neuroticism;
LUSC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg19230755	chr7:65878503	NA	-0.42	-6.0	-0.31	5.22e-9	Aortic root size;
LUSC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg21361702	chr7:150065534	REPIN1	0.57	9.02	0.44	1.48e-17	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg16423285	chr20:60520624	NA	-0.9	-12.28	-0.56	7.08e-29	Obesity-related traits;
LUSC	cis	rs6554196	0.508	rs6554199	chr4:55522488	G/T	cg18836493	chr4:55524333	KIT	-0.42	-7.23	-0.37	3.41e-12	Monocyte count;
LUSC	cis	rs12493885	0.818	rs61791545	chr3:153768888	G/A	cg17054900	chr3:154042577	DHX36	-0.75	-7.66	-0.39	2.06e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg02023728	chr11:77925099	USP35	0.47	6.77	0.35	5.87e-11	Testicular germ cell tumor;
LUSC	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg17120908	chr11:65337727	SSSCA1	-0.53	-9.23	-0.45	3.22e-18	Bone mineral density;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24409649	chr12:31479318	FAM60A	0.48	6.38	0.33	5.88e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg05347473	chr6:146136440	FBXO30	0.38	6.33	0.33	8.08e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg19812747	chr11:111475976	SIK2	0.54	7.74	0.39	1.16e-13	Primary sclerosing cholangitis;
LUSC	cis	rs737008	0.922	rs1559394	chr16:11369205	A/G	cg00044050	chr16:11439710	C16orf75	-0.55	-8.62	-0.43	2.65e-16	Obesity-related traits;
LUSC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.23	0.32	1.43e-9	Menarche (age at onset);
LUSC	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg12002119	chr2:101014098	CHST10	0.35	5.67	0.3	3.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg21963583	chr11:68658836	MRPL21	0.56	8.37	0.42	1.58e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg16989719	chr2:238392110	NA	-0.49	-6.22	-0.32	1.53e-9	Prostate cancer;
LUSC	cis	rs4851254	0.660	rs1821830	chr2:100680279	C/T	cg22139774	chr2:100720529	AFF3	-0.44	-5.82	-0.3	1.37e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10193935	0.901	rs2118889	chr2:42451683	G/T	cg27598129	chr2:42591480	NA	-0.63	-8.51	-0.42	5.94e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg27535305	chr1:53392650	SCP2	0.36	6.71	0.34	8.29e-11	Monocyte count;
LUSC	cis	rs1160297	0.576	rs67939368	chr2:53093152	G/C	cg07782112	chr2:53107842	NA	0.44	7.18	0.37	4.58e-12	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs4792901	0.802	rs9898286	chr17:41562542	T/G	cg22562494	chr17:41607896	ETV4	-0.33	-6.19	-0.32	1.8e-9	Dupuytren's disease;
LUSC	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg22532475	chr10:104410764	TRIM8	0.24	5.76	0.3	1.93e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg06197492	chr11:2016605	H19	0.37	6.04	0.31	4.22e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg10596483	chr8:143751796	JRK	0.61	9.39	0.46	9.97e-19	Schizophrenia;
LUSC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg20476274	chr7:133979776	SLC35B4	-0.76	-13.6	-0.6	7.86e-34	Mean platelet volume;
LUSC	cis	rs4499344	0.730	rs259285	chr19:33164697	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	11.73	0.54	7.5e-27	Mean platelet volume;
LUSC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	0.95	18.98	0.72	5.3e-55	Cognitive function;
LUSC	cis	rs847577	0.572	rs847573	chr7:97681761	C/T	cg21770322	chr7:97807741	LMTK2	-0.41	-6.33	-0.33	8.11e-10	Breast cancer;
LUSC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.69	-10.54	-0.5	1.28e-22	Aortic root size;
LUSC	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg02023728	chr11:77925099	USP35	0.45	6.62	0.34	1.42e-10	Testicular germ cell tumor;
LUSC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg22532475	chr10:104410764	TRIM8	0.3	5.97	0.31	6.17e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg14541582	chr5:601475	NA	-0.38	-5.93	-0.31	7.36e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg21775007	chr8:11205619	TDH	-0.52	-7.38	-0.37	1.26e-12	Triglycerides;
LUSC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.56	0.65	1.98e-41	Platelet count;
LUSC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18404041	chr3:52824283	ITIH1	-0.56	-10.64	-0.5	5.73e-23	Bipolar disorder;
LUSC	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg04218760	chr10:45406644	TMEM72	-0.3	-7.45	-0.38	8.22e-13	Mean corpuscular volume;
LUSC	cis	rs17014483	0.749	rs2924350	chr4:89626391	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.71	6.47	0.33	3.5e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.86	-0.44	4.97e-17	Response to antipsychotic treatment;
LUSC	cis	rs534126	1.000	rs557797	chr7:142921509	T/C	cg04039957	chr7:143013207	CLCN1	0.3	5.82	0.3	1.39e-8	Cancer;
LUSC	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	1.09	16.98	0.68	4.51e-47	Exhaled nitric oxide output;
LUSC	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg18827107	chr12:86230957	RASSF9	-0.4	-5.99	-0.31	5.49e-9	Major depressive disorder;
LUSC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg10664184	chr19:17420304	DDA1	0.47	6.13	0.32	2.46e-9	Systemic lupus erythematosus;
LUSC	cis	rs193541	0.621	rs898391	chr5:122082166	T/C	cg19077854	chr5:122220652	SNX24	0.36	7.17	0.37	4.75e-12	Glucose homeostasis traits;
LUSC	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-7.38	-0.37	1.28e-12	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08280861	chr8:58055591	NA	0.53	6.41	0.33	5.04e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6445797	0.662	rs1491166	chr3:56570097	A/G	cg13792233	chr3:56591045	CCDC66	-0.41	-5.81	-0.3	1.44e-8	Gastritis;
LUSC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg10360139	chr7:1886902	MAD1L1	-0.39	-5.81	-0.3	1.44e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03517284	chr6:25882590	NA	0.65	11.31	0.53	2.54e-25	Blood metabolite levels;
LUSC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg25036284	chr2:26402008	FAM59B	0.66	8.51	0.42	5.91e-16	Gut microbiome composition (summer);
LUSC	cis	rs7264396	0.832	rs224349	chr20:34045392	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.72	-0.35	7.88e-11	Total cholesterol levels;
LUSC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.21	-13.88	-0.6	6.79e-35	Diabetic kidney disease;
LUSC	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg16850897	chr7:100343110	ZAN	-0.61	-8.5	-0.42	6.61e-16	Other erythrocyte phenotypes;
LUSC	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg22283653	chr8:49824208	NA	0.34	6.78	0.35	5.43e-11	Sudden cardiac arrest;
LUSC	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	7.13	0.36	6.3e-12	IgG glycosylation;
LUSC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.18	0.41	5.91e-15	Height;
LUSC	cis	rs4141404	0.818	rs5997897	chr22:31570436	G/A	cg22777020	chr22:31556080	RNF185	-0.48	-6.91	-0.35	2.51e-11	Paclitaxel-induced neuropathy;
LUSC	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg27284194	chr4:1044797	NA	0.51	8.48	0.42	7.14e-16	Recombination rate (males);
LUSC	cis	rs7523050	0.643	rs35050241	chr1:109404876	T/C	cg08274380	chr1:109419600	GPSM2	1.07	10.65	0.5	5.34e-23	Fat distribution (HIV);
LUSC	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg15485101	chr11:133734466	NA	0.4	7.2	0.37	4.13e-12	Childhood ear infection;
LUSC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg02153584	chr22:29168773	CCDC117	0.6	8.4	0.42	1.32e-15	Lymphocyte counts;
LUSC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg19592336	chr6:28129416	ZNF389	0.46	5.93	0.31	7.48e-9	Depression;
LUSC	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	8.84	0.44	5.79e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg03354898	chr7:1950403	MAD1L1	-0.37	-7.14	-0.36	5.91e-12	Schizophrenia;
LUSC	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg11984989	chr7:158649758	WDR60	-1.0	-17.47	-0.69	5.16e-49	Height;
LUSC	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg25930673	chr12:123319894	HIP1R	-0.72	-7.12	-0.36	6.69e-12	Schizophrenia;
LUSC	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.73	0.39	1.28e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs72781680	0.678	rs56145919	chr2:24088489	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	6.81	0.35	4.57e-11	Lymphocyte counts;
LUSC	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.65	-11.02	-0.52	2.68e-24	Diastolic blood pressure;
LUSC	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg09092052	chr15:45571596	NA	0.46	6.41	0.33	5.09e-10	Glomerular filtration rate;
LUSC	trans	rs1864729	0.688	rs2567768	chr8:98303151	G/A	cg08679828	chr8:102218111	ZNF706	-0.73	-6.43	-0.33	4.38e-10	Estradiol plasma levels (breast cancer);
LUSC	trans	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg19694781	chr19:47549865	TMEM160	0.7	10.77	0.51	2.0500000000000001e-23	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg23625390	chr15:77176239	SCAPER	0.47	7.09	0.36	8.13e-12	Blood metabolite levels;
LUSC	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg21770322	chr7:97807741	LMTK2	0.5	8.48	0.42	7.3e-16	Breast cancer;
LUSC	cis	rs2637266	0.756	rs2583063	chr10:78558048	T/C	cg18941641	chr10:78392320	NA	0.37	6.7	0.34	8.79e-11	Pulmonary function;
LUSC	cis	rs9322817	0.691	rs4142531	chr6:105324811	G/A	cg02098413	chr6:105308735	HACE1	0.27	5.8	0.3	1.52e-8	Thyroid stimulating hormone;
LUSC	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg24006582	chr15:45444508	DUOX1	-0.6	-8.72	-0.43	1.29e-16	Uric acid levels;
LUSC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg06046430	chr4:77819534	ANKRD56	0.5	7.3	0.37	2.1e-12	Emphysema distribution in smoking;
LUSC	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.84	12.52	0.57	9.44e-30	Cognitive ability;
LUSC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-10.01	-0.48	8.56e-21	Personality dimensions;
LUSC	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg22529645	chr1:3704559	LRRC47	0.35	6.12	0.32	2.56e-9	Red cell distribution width;
LUSC	cis	rs524023	0.957	rs561193	chr11:64353029	A/G	cg07220939	chr11:64358617	SLC22A12	0.22	5.81	0.3	1.45e-8	Urate levels in obese individuals;
LUSC	cis	rs1577917	0.570	rs114854865	chr6:86554236	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	trans	rs208520	0.609	rs208436	chr6:66897470	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.81	-11.69	-0.54	1.06e-26	Exhaled nitric oxide output;
LUSC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.33	0.45	1.52e-18	Prudent dietary pattern;
LUSC	cis	rs3784262	0.900	rs12911071	chr15:58314848	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.67	-0.3	3.02e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg08742575	chr21:47604166	C21orf56	0.46	7.04	0.36	1.1e-11	Testicular germ cell tumor;
LUSC	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg15147215	chr3:52552868	STAB1	-0.31	-6.11	-0.32	2.79e-9	Bipolar disorder;
LUSC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg11663144	chr21:46675770	NA	-0.39	-6.68	-0.34	1e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg06618935	chr21:46677482	NA	-0.4	-8.06	-0.4	1.41e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs965513	1.000	rs7864322	chr9:100548934	C/T	cg13688889	chr9:100608707	NA	-0.55	-8.17	-0.41	6.32e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg18678763	chr11:4115507	RRM1	-0.46	-6.02	-0.31	4.53e-9	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.61	-0.38	2.74e-13	Retinal vascular caliber;
LUSC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18932078	chr1:2524107	MMEL1	-0.33	-7.21	-0.37	3.83e-12	Ulcerative colitis;
LUSC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg03146154	chr1:46216737	IPP	0.55	8.21	0.41	5.01e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg22800045	chr5:56110881	MAP3K1	0.78	9.7	0.47	9.52e-20	Initial pursuit acceleration;
LUSC	cis	rs3849570	0.643	rs1969433	chr3:81968869	T/C	cg07356753	chr3:81810745	GBE1	-0.48	-7.13	-0.36	6.17e-12	Waist circumference;Body mass index;
LUSC	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg02176678	chr2:219576539	TTLL4	-0.66	-12.62	-0.57	4.06e-30	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg05585544	chr11:47624801	NA	-0.42	-7.24	-0.37	3.06e-12	Subjective well-being;
LUSC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-6.74	-0.35	6.97e-11	Tonsillectomy;
LUSC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg19052272	chr2:3704530	ALLC	-0.45	-8.3	-0.41	2.54e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs3740713	1.000	rs73440636	chr11:18473556	C/T	cg23797887	chr11:18477753	LDHAL6A	-0.54	-6.53	-0.34	2.45e-10	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-8.09	-0.4	1.13e-14	Type 2 diabetes;
LUSC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg00750074	chr16:89608354	SPG7	-0.47	-8.2	-0.41	5.19e-15	Multiple myeloma (IgH translocation);
LUSC	cis	rs1609391	0.543	rs7651085	chr3:136625339	C/G	cg15507776	chr3:136538369	TMEM22	0.5	8.25	0.41	3.79e-15	Neuroticism;
LUSC	cis	rs10463316	0.817	rs10476770	chr5:150777720	G/C	cg03212797	chr5:150827313	SLC36A1	-0.47	-7.2	-0.37	3.95e-12	Metabolite levels (Pyroglutamine);
LUSC	cis	rs11645898	0.748	rs11647889	chr16:72052034	C/G	cg14768367	chr16:72042858	DHODH	-0.77	-8.3	-0.41	2.53e-15	Blood protein levels;
LUSC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07256732	chr16:621771	PIGQ	-0.35	-6.4	-0.33	5.41e-10	Height;
LUSC	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg06484146	chr7:12443880	VWDE	-0.68	-7.08	-0.36	8.67e-12	Coronary artery disease;
LUSC	trans	rs1927790	0.727	rs1925122	chr13:96938173	T/C	cg03198741	chr6:1003969	LOC285768	-0.39	-5.98	-0.31	5.82e-9	Body mass index;
LUSC	cis	rs7523050	0.908	rs67425757	chr1:109398656	T/G	cg08274380	chr1:109419600	GPSM2	0.92	9.73	0.47	7.24e-20	Fat distribution (HIV);
LUSC	cis	rs6967385	0.560	rs10279958	chr7:12350593	T/C	cg20607287	chr7:12443886	VWDE	0.4	6.03	0.31	4.25e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg04850211	chr1:228464232	OBSCN	0.32	5.75	0.3	1.97e-8	Diastolic blood pressure;
LUSC	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg02569458	chr12:86230093	RASSF9	-0.36	-5.72	-0.3	2.4e-8	Major depressive disorder;
LUSC	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-8.14	-0.41	7.78e-15	Axial length;
LUSC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19717773	chr7:2847554	GNA12	-0.36	-6.28	-0.32	1.07e-9	Height;
LUSC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-7.75	-0.39	1.15e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs9871760	1.000	rs9860652	chr3:126996775	C/T	cg17872838	chr13:52607339	UTP14C	0.35	6.23	0.32	1.44e-9	Whole-brain volume;
LUSC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg25039879	chr17:56429692	SUPT4H1	0.7	9.44	0.46	6.73e-19	Cognitive test performance;
LUSC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg11494091	chr17:61959527	GH2	-0.71	-15.45	-0.65	5.07e-41	Prudent dietary pattern;
LUSC	cis	rs67366981	0.925	rs56245630	chr14:77714185	T/C	cg22824376	chr14:77648248	TMEM63C	0.58	5.67	0.3	3.05e-8	Obsessive-compulsive symptoms;
LUSC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg21770322	chr7:97807741	LMTK2	0.42	7.23	0.37	3.26e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg26513180	chr16:89883248	FANCA	0.61	5.84	0.3	1.22e-8	Skin colour saturation;
LUSC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg09359103	chr1:154839909	KCNN3	-0.69	-16.09	-0.66	1.6e-43	Prostate cancer;
LUSC	cis	rs877282	1.000	rs11253366	chr10:773386	C/T	cg17470449	chr10:769945	NA	0.5	7.0	0.36	1.41e-11	Uric acid levels;
LUSC	cis	rs6692729	0.814	rs2246221	chr1:227075402	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.51	-7.38	-0.37	1.23e-12	Electrodermal activity;
LUSC	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg24375607	chr4:120327624	NA	0.76	12.17	0.55	1.85e-28	Corneal astigmatism;
LUSC	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.01	-0.31	4.97e-9	Retinal vascular caliber;
LUSC	cis	rs11696845	0.761	rs11698203	chr20:43357899	C/T	cg25301532	chr20:43378953	KCNK15	-0.35	-6.27	-0.32	1.1e-9	Obesity-related traits;
LUSC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-8.96	-0.44	2.28e-17	Monocyte percentage of white cells;
LUSC	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.36	-0.56	3.72e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6980507	0.524	rs62510967	chr8:42441374	C/G	cg09913449	chr8:42400586	C8orf40	0.44	7.26	0.37	2.76e-12	Glycated hemoglobin levels;
LUSC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg18196295	chr10:418757	DIP2C	0.45	7.41	0.38	1.05e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg06784218	chr1:46089804	CCDC17	0.29	5.83	0.3	1.31e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg23422044	chr7:1970798	MAD1L1	-0.55	-5.7	-0.3	2.68e-8	Neuroticism;
LUSC	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg09904177	chr6:26538194	HMGN4	0.73	13.28	0.59	1.37e-32	Intelligence (multi-trait analysis);
LUSC	trans	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	6.07	0.32	3.43e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg19622623	chr12:86230825	RASSF9	-0.41	-5.71	-0.3	2.44e-8	Major depressive disorder;
LUSC	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs4964805	1.000	rs73192053	chr12:104190855	A/G	cg02344784	chr12:104178138	NT5DC3	0.45	7.15	0.36	5.34e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg05341575	chr12:125625032	AACS	-0.37	-5.96	-0.31	6.33e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7215564	0.818	rs4075782	chr17:78556325	A/G	cg23238734	chr17:78661607	RPTOR	-0.54	-7.08	-0.36	8.36e-12	Myopia (pathological);
LUSC	cis	rs72781680	0.699	rs72794291	chr2:23897935	C/T	cg08917208	chr2:24149416	ATAD2B	0.97	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	trans	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.54	-0.53	3.86e-26	Colorectal cancer;
LUSC	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg04511125	chr2:88470314	THNSL2	0.6	6.25	0.32	1.25e-9	Plasma clusterin levels;
LUSC	cis	rs4654899	1.000	rs6663452	chr1:21423154	T/C	cg01072550	chr1:21505969	NA	-0.53	-8.09	-0.4	1.15e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6464929	1.000	rs6464929	chr7:148717467	G/A	cg23583168	chr7:148888333	NA	0.48	6.15	0.32	2.2e-9	Pediatric bone mineral content (hip);
LUSC	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.81	-0.6	1.26e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.75	0.3	2.02e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg16325326	chr1:53192061	ZYG11B	0.82	14.59	0.62	1.21e-37	Monocyte count;
LUSC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.4	-6.53	-0.34	2.41e-10	Prudent dietary pattern;
LUSC	cis	rs4343996	0.967	rs10276933	chr7:3349262	C/A	cg21248987	chr7:3385318	SDK1	0.39	6.63	0.34	1.37e-10	Motion sickness;
LUSC	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg14458575	chr2:238380390	NA	0.86	15.27	0.64	2.68e-40	Prostate cancer;
LUSC	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg14664628	chr15:75095509	CSK	-0.99	-16.36	-0.67	1.35e-44	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs2137920	0.945	rs2254409	chr10:50238453	A/G	cg27141751	chr10:50231850	C10orf72	0.39	5.86	0.31	1.14e-8	Migraine with aura;
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18337363	chr3:52569053	NT5DC2	0.24	5.74	0.3	2.16e-8	Electroencephalogram traits;
LUSC	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg23887609	chr12:130822674	PIWIL1	0.47	7.1	0.36	7.61e-12	Menopause (age at onset);
LUSC	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg23283495	chr1:209979779	IRF6	0.63	7.87	0.4	4.97e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg26061582	chr7:22766209	IL6	0.46	6.9	0.35	2.57e-11	Lung cancer;
LUSC	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg24675056	chr1:15929824	NA	0.43	7.46	0.38	7.66e-13	Systolic blood pressure;
LUSC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg26659404	chr1:25747437	RHCE	-0.28	-5.73	-0.3	2.25e-8	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.95	0.36	1.97e-11	Cystic fibrosis severity;
LUSC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg00701064	chr4:6280414	WFS1	0.59	14.34	0.62	1.17e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg17747265	chr1:1875780	NA	-0.75	-17.66	-0.69	9.63e-50	Body mass index;
LUSC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15320075	chr8:145703422	NA	-0.65	-10.62	-0.5	7.07e-23	Age at first birth;
LUSC	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-5.78	-0.3	1.67e-8	Testicular germ cell tumor;
LUSC	cis	rs6722750	0.870	rs35899183	chr2:64408776	C/G	cg22352474	chr2:64371530	PELI1	0.52	7.76	0.39	1.07e-13	Neuroticism;
LUSC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg07414643	chr4:187882934	NA	0.54	9.99	0.48	9.75e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	7.37	0.37	1.36e-12	Height;
LUSC	cis	rs10979	0.965	rs9376759	chr6:143886959	G/A	cg25407410	chr6:143891975	LOC285740	-0.7	-10.98	-0.52	3.66e-24	Hypospadias;
LUSC	cis	rs1215050	0.744	rs966380	chr4:98435389	C/T	cg05340658	chr4:99064831	C4orf37	0.42	6.6	0.34	1.62e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg22961513	chr11:14280813	SPON1	0.34	5.7	0.3	2.65e-8	Mitochondrial DNA levels;
LUSC	cis	rs12760731	0.720	rs1397185	chr1:178381698	G/A	cg00404053	chr1:178313656	RASAL2	0.6	6.25	0.32	1.26e-9	Obesity-related traits;
LUSC	cis	rs9840812	0.683	rs8045	chr3:136055459	T/C	cg15507776	chr3:136538369	TMEM22	-0.48	-6.18	-0.32	1.89e-9	Fibrinogen levels;
LUSC	cis	rs7582720	1.000	rs114520702	chr2:203697092	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.73	0.43	1.22e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg15848620	chr12:58087721	OS9	-0.57	-8.04	-0.4	1.56e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	0.65	13.58	0.6	9.43e-34	Prudent dietary pattern;
LUSC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.79	-0.39	8.44e-14	Type 2 diabetes;
LUSC	cis	rs1712517	0.740	rs4293062	chr10:105052624	G/A	cg05636881	chr10:105038444	INA	0.39	6.32	0.33	8.31e-10	Migraine;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg20683799	chr1:63989117	ITGB3BP;EFCAB7	0.53	6.49	0.33	3.08e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs68170813	0.559	rs6946036	chr7:106853659	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.89	-0.48	2.21e-20	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg00933542	chr6:150070202	PCMT1	0.32	6.68	0.34	1.01e-10	Lung cancer;
LUSC	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg24642439	chr20:33292090	TP53INP2	-0.56	-8.52	-0.42	5.67e-16	Height;
LUSC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg21724239	chr8:58056113	NA	0.83	9.79	0.47	4.72e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs860295	0.812	rs7556519	chr1:155827546	T/C	cg08949192	chr1:155289623	RUSC1;FDPS	-0.34	-5.65	-0.3	3.52e-8	Body mass index;
LUSC	cis	rs4642101	0.534	rs13316229	chr3:12807371	C/T	cg05775895	chr3:12838266	CAND2	0.48	7.41	0.38	1.04e-12	QRS complex (12-leadsum);
LUSC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-5.85	-0.3	1.2e-8	Personality dimensions;
LUSC	cis	rs8099014	0.954	rs9961522	chr18:56107279	T/C	cg12907477	chr18:56117327	MIR122	0.41	6.56	0.34	2.05e-10	Platelet count;
LUSC	cis	rs3849570	1.000	rs3849570	chr3:81792112	C/A	cg07356753	chr3:81810745	GBE1	-0.69	-11.18	-0.52	7.16e-25	Waist circumference;Body mass index;
LUSC	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.59e-25	Corneal astigmatism;
LUSC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg00579200	chr11:133705235	NA	0.41	6.01	0.31	4.82e-9	Childhood ear infection;
LUSC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg04511125	chr2:88470314	THNSL2	0.71	6.64	0.34	1.25e-10	Plasma clusterin levels;
LUSC	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg11965913	chr1:205819406	PM20D1	0.42	6.13	0.32	2.54e-9	Parkinson's disease;
LUSC	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg13010344	chr12:123464640	ARL6IP4	-0.47	-5.78	-0.3	1.76e-8	Neutrophil percentage of white cells;
LUSC	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg17127132	chr2:85788382	GGCX	0.46	7.18	0.37	4.44e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg16850897	chr7:100343110	ZAN	-0.52	-7.15	-0.36	5.63e-12	Other erythrocyte phenotypes;
LUSC	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.34	-0.42	2.03e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg10556349	chr10:835070	NA	0.56	6.34	0.33	7.39e-10	Eosinophil percentage of granulocytes;
LUSC	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.36	-5.85	-0.3	1.2e-8	Longevity;Endometriosis;
LUSC	cis	rs909341	0.868	rs2738758	chr20:62349625	C/G	cg09650180	chr20:62225654	GMEB2	0.46	6.15	0.32	2.26e-9	Atopic dermatitis;
LUSC	cis	rs10875746	0.903	rs3782911	chr12:48483492	T/G	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	1.97e-8	Longevity (90 years and older);
LUSC	cis	rs12286929	0.606	rs11823428	chr11:115071222	C/A	cg04055981	chr11:115044050	NA	0.44	7.83	0.39	6.42e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.9	12.12	0.55	2.84e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs61332075	0.501	rs55706928	chr2:239445806	T/C	cg18131467	chr2:239335373	ASB1	-0.66	-6.18	-0.32	1.82e-9	Lung function (FEV1/FVC);
LUSC	cis	rs2274273	0.840	rs11547116	chr14:55738165	T/C	cg04306507	chr14:55594613	LGALS3	0.56	13.13	0.58	4.79e-32	Protein biomarker;
LUSC	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	8.34	0.42	2.01e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-17.41	-0.69	9.34e-49	Body mass index;
LUSC	cis	rs12155623	0.668	rs6472114	chr8:49789561	T/C	cg22283653	chr8:49824208	NA	-0.49	-10.91	-0.51	6.59e-24	Sudden cardiac arrest;
LUSC	cis	rs4499344	0.633	rs166310	chr19:33155187	G/A	cg22980127	chr19:33182716	NUDT19	-0.44	-6.45	-0.33	3.88e-10	Mean platelet volume;
LUSC	cis	rs791888	0.760	rs10788561	chr10:89423245	A/G	cg13926569	chr10:89418898	PAPSS2	0.33	6.54	0.34	2.3e-10	Magnesium levels;
LUSC	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg21573476	chr21:45109991	RRP1B	-0.39	-6.38	-0.33	5.94e-10	Mean corpuscular volume;
LUSC	cis	rs11630290	0.806	rs11631544	chr15:64098557	A/G	cg12036633	chr15:63758958	NA	-0.59	-7.03	-0.36	1.2e-11	Iris characteristics;
LUSC	cis	rs9653442	0.510	rs12712068	chr2:100764439	A/G	cg22139774	chr2:100720529	AFF3	-0.42	-7.3	-0.37	2.16e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg03929089	chr4:120376271	NA	-0.57	-7.05	-0.36	1.04e-11	Intraocular pressure;
LUSC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg06494592	chr3:125709126	NA	-0.51	-6.25	-0.32	1.23e-9	Blood pressure (smoking interaction);
LUSC	cis	rs500891	0.953	rs580595	chr6:84195751	A/G	cg08257003	chr6:84140564	ME1	-0.33	-6.85	-0.35	3.47e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	12.04	0.55	5.77e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg13647721	chr17:30228624	UTP6	0.59	5.78	0.3	1.76e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg22437258	chr11:111473054	SIK2	0.5	6.89	0.35	2.78e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6500395	1.000	rs11649236	chr16:48632478	C/T	cg04672837	chr16:48644449	N4BP1	0.49	7.34	0.37	1.65e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg13385521	chr17:29058706	SUZ12P	0.56	6.1	0.32	2.9e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs72848980	0.512	rs56033495	chr10:105383611	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.39	5.7	0.3	2.63e-8	White matter hyperintensity burden;
LUSC	cis	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.37e-9	Ulcerative colitis;
LUSC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg22105103	chr4:187893119	NA	0.71	13.88	0.6	6.72e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17021463	0.902	rs10516950	chr4:95254730	C/T	cg11021082	chr4:95130006	SMARCAD1	0.39	7.22	0.37	3.62e-12	Testicular germ cell tumor;
LUSC	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-10.76	-0.51	2.19e-23	Monocyte percentage of white cells;
LUSC	cis	rs4776059	0.798	rs28368342	chr15:52921573	A/G	cg22715398	chr15:52968154	KIAA1370	0.57	7.39	0.37	1.19e-12	Schizophrenia;
LUSC	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg25930673	chr12:123319894	HIP1R	-0.67	-6.83	-0.35	4.15e-11	Schizophrenia;
LUSC	cis	rs143111788	1	rs143111788	chr6:41919175	CCAGCTACT/C	cg17623882	chr6:41773611	USP49	-0.58	-9.45	-0.46	5.97e-19	Red cell distribution width;
LUSC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg27165867	chr14:105738592	BRF1	-0.54	-7.62	-0.39	2.57e-13	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	12.16	0.55	2e-28	Exhaled nitric oxide output;
LUSC	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg08085267	chr17:45401833	C17orf57	-0.51	-7.3	-0.37	2.07e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	1.0	16.07	0.66	1.81e-43	Parkinson's disease;
LUSC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07362569	chr17:61921086	SMARCD2	0.39	7.95	0.4	2.85e-14	Prudent dietary pattern;
LUSC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg04455712	chr21:45112962	RRP1B	0.45	8.64	0.43	2.4e-16	Mean corpuscular volume;
LUSC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07362569	chr17:61921086	SMARCD2	0.35	7.24	0.37	3.11e-12	Prudent dietary pattern;
LUSC	cis	rs11124063	1	rs11124063	chr2:106458806	T/C	cg14210321	chr2:106509881	NCK2	-0.39	-5.71	-0.3	2.43e-8	Platelet distribution width;
LUSC	cis	rs7241530	0.610	rs12455089	chr18:75899708	T/G	cg14642773	chr18:75888474	NA	0.38	5.69	0.3	2.75e-8	Educational attainment (years of education);
LUSC	cis	rs2692947	0.770	rs72492163	chr2:96417816	G/A	cg22654517	chr2:96458247	NA	0.35	6.65	0.34	1.21e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg18850127	chr7:39170497	POU6F2	0.6	9.4	0.46	8.61e-19	IgG glycosylation;
LUSC	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg04450456	chr4:17643702	FAM184B	0.39	6.55	0.34	2.22e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	0.95	8.5	0.42	6.49e-16	Mitochondrial DNA levels;
LUSC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.39	-0.49	4.39e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1461503	0.966	rs11218910	chr11:122842861	G/A	cg27398637	chr11:122830231	C11orf63	-0.41	-6.54	-0.34	2.29e-10	Menarche (age at onset);
LUSC	cis	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg06521331	chr12:34319734	NA	0.41	6.75	0.35	6.66e-11	Morning vs. evening chronotype;
LUSC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg08888203	chr3:10149979	C3orf24	0.63	9.09	0.45	8.92e-18	Alzheimer's disease;
LUSC	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.7	0.75	7.91e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg22546130	chr22:19950026	COMT	0.39	8.68	0.43	1.81e-16	Blood metabolite levels;
LUSC	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.51	-0.42	6.11e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6714710	0.603	rs2044458	chr2:98377512	A/T	cg26665480	chr2:98280029	ACTR1B	0.58	8.37	0.42	1.65e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs6977660	0.619	rs2158379	chr7:19783977	A/G	cg07541023	chr7:19748670	TWISTNB	0.61	6.46	0.33	3.63e-10	Thyroid stimulating hormone;
LUSC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07677032	chr17:61819896	STRADA	0.54	8.94	0.44	2.69e-17	Prudent dietary pattern;
LUSC	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06002616	chr8:101225028	SPAG1	0.42	7.05	0.36	1e-11	Atrioventricular conduction;
LUSC	cis	rs6901250	0.807	rs339303	chr6:117176691	C/T	cg12892004	chr6:117198278	RFX6	-0.45	-8.59	-0.43	3.3e-16	C-reactive protein levels;
LUSC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg11766577	chr21:47581405	C21orf56	0.47	7.09	0.36	8.02e-12	Testicular germ cell tumor;
LUSC	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.36	0.37	1.47e-12	Blood metabolite levels;
LUSC	trans	rs4596713	0.508	rs13289984	chr9:71775047	A/C	cg25283916	chr1:242222868	NA	-0.29	-6.0	-0.31	5.05e-9	Headache;
LUSC	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg08779649	chr13:50194554	NA	0.4	6.92	0.35	2.36e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.91	-0.44	3.33e-17	Response to antipsychotic treatment;
LUSC	cis	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg21775007	chr8:11205619	TDH	-0.47	-6.96	-0.36	1.81e-11	Systolic blood pressure;
LUSC	trans	rs6445525	1.000	rs4417899	chr3:65996110	T/C	cg12639933	chr12:57626296	SHMT2	0.34	6.24	0.32	1.3e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-8.17	-0.41	6.45e-15	Menarche (age at onset);
LUSC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg12463550	chr7:65579703	CRCP	-0.57	-8.62	-0.43	2.65e-16	Aortic root size;
LUSC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg02569458	chr12:86230093	RASSF9	0.57	9.62	0.47	1.64e-19	Major depressive disorder;
LUSC	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg20701182	chr2:24300061	SF3B14	0.88	11.42	0.53	1.05e-25	Lymphocyte counts;
LUSC	cis	rs240764	0.531	rs1070990	chr6:101264412	T/A	cg09795085	chr6:101329169	ASCC3	0.45	6.58	0.34	1.87e-10	Neuroticism;
LUSC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg27631724	chr1:11040367	C1orf127	0.55	9.55	0.46	2.88e-19	Ewing sarcoma;
LUSC	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg10596483	chr8:143751796	JRK	0.52	7.62	0.38	2.67e-13	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16007711	chr8:22857750	RHOBTB2	0.51	7.78	0.39	9.39e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg16339924	chr4:17578868	LAP3	-0.69	-10.91	-0.51	6.43e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg27087555	chr16:88793112	FAM38A	-0.88	-6.56	-0.34	2.03e-10	Hair color;
LUSC	cis	rs1882538	0.512	rs13241734	chr7:133122742	C/G	cg10665199	chr7:133106180	EXOC4	0.56	7.61	0.38	2.76e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg01657329	chr11:68192670	LRP5	-0.39	-5.67	-0.3	3.17e-8	Total body bone mineral density;
LUSC	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-6.86	-0.35	3.41e-11	Menopause (age at onset);
LUSC	cis	rs11051970	0.918	rs7309115	chr12:32541241	A/G	cg24626660	chr12:32551988	NA	0.38	6.07	0.32	3.43e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg25237894	chr2:233734115	C2orf82	-0.35	-6.63	-0.34	1.38e-10	Coronary artery disease;
LUSC	cis	rs72781680	0.716	rs6718631	chr2:24036086	A/G	cg08917208	chr2:24149416	ATAD2B	-0.6	-6.89	-0.35	2.84e-11	Lymphocyte counts;
LUSC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg05043794	chr9:111880884	C9orf5	-0.39	-8.23	-0.41	4.14e-15	Menarche (age at onset);
LUSC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08045932	chr20:61659980	NA	0.59	10.47	0.5	2.2e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4911253	0.527	rs853859	chr20:31402269	A/G	cg13636640	chr20:31349939	DNMT3B	0.82	15.01	0.63	2.89e-39	Lymphocyte counts;
LUSC	cis	rs72634258	0.945	rs34466510	chr1:8147412	T/C	cg00042356	chr1:8021962	PARK7	0.79	9.53	0.46	3.29e-19	Inflammatory bowel disease;
LUSC	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.66	11.42	0.53	9.71e-26	Myeloid white cell count;
LUSC	cis	rs870825	0.616	rs28673855	chr4:185627416	T/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.77e-32	Blood protein levels;
LUSC	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs41271473	1.000	rs4391638	chr1:228878481	A/C	cg16512390	chr1:228756714	NA	0.5	6.04	0.31	4.05e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20887711	chr4:1340912	KIAA1530	-0.7	-11.0	-0.52	3.11e-24	Longevity;
LUSC	cis	rs7560272	0.723	rs4346412	chr2:73843571	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-7.44	-0.38	8.53e-13	Schizophrenia;
LUSC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.78	12.61	0.57	4.21e-30	Cognitive function;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02392688	chr17:27916351	GIT1	-0.4	-6.07	-0.32	3.43e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg19676328	chr12:49525230	TUBA1B	-0.51	-8.01	-0.4	1.97e-14	Total cholesterol levels;
LUSC	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg11244672	chr19:19639970	YJEFN3	-0.6	-7.18	-0.37	4.52e-12	Bipolar disorder;
LUSC	cis	rs16867321	0.694	rs11889207	chr2:181424527	A/C	cg23363182	chr2:181467187	NA	-0.54	-8.46	-0.42	8.35e-16	Obesity;
LUSC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg15691649	chr6:25882328	NA	0.51	7.58	0.38	3.4e-13	Blood metabolite levels;
LUSC	cis	rs7524258	0.868	rs7544314	chr1:7266744	G/C	cg07173049	chr1:7289937	CAMTA1	0.35	7.16	0.36	5.11e-12	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg02023728	chr11:77925099	USP35	0.45	6.68	0.34	9.87e-11	Testicular germ cell tumor;
LUSC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.69	0.3	2.8e-8	Crohn's disease;
LUSC	cis	rs2414856	0.510	rs72758930	chr15:64660853	G/A	cg08069370	chr15:64387884	SNX1	-0.78	-6.58	-0.34	1.84e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg06191203	chr2:152266755	RIF1	-0.55	-7.27	-0.37	2.51e-12	Lung cancer;
LUSC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg22029157	chr1:209979665	IRF6	0.72	8.77	0.43	9.3e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg07978099	chr16:83986941	OSGIN1	-0.55	-7.51	-0.38	5.58e-13	Pursuit maintenance gain;
LUSC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg16606324	chr3:10149918	C3orf24	0.6	8.69	0.43	1.63e-16	Alzheimer's disease;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg01370129	chr11:61735138	FTH1	0.43	6.6	0.34	1.66e-10	Asthma;
LUSC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.42	6.45	0.33	3.98e-10	Height;
LUSC	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg24006582	chr15:45444508	DUOX1	0.65	9.45	0.46	6.25e-19	Uric acid levels;
LUSC	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg25251562	chr2:3704773	ALLC	-0.38	-6.92	-0.35	2.34e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs8141797	0.818	rs762271	chr22:24448082	T/C	cg00411358	chr22:24577142	SUSD2	0.62	6.08	0.32	3.31e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg02569458	chr12:86230093	RASSF9	0.58	9.82	0.47	3.59e-20	Major depressive disorder;
LUSC	cis	rs10489202	0.686	rs6427113	chr1:167845787	C/T	cg24449463	chr1:168025552	DCAF6	0.49	5.78	0.3	1.7e-8	Schizophrenia;
LUSC	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg05163923	chr11:71159392	DHCR7	-0.76	-9.95	-0.48	1.32e-20	Vitamin D levels;
LUSC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg17971929	chr21:40555470	PSMG1	0.78	13.72	0.6	2.7e-34	Cognitive function;
LUSC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg26335602	chr6:28129616	ZNF389	-0.4	-5.79	-0.3	1.66e-8	Depression;
LUSC	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg11189052	chr15:85197271	WDR73	0.49	5.92	0.31	7.95e-9	Schizophrenia;
LUSC	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg20135002	chr11:47629003	NA	-0.45	-7.08	-0.36	8.3e-12	Subjective well-being;
LUSC	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.9	0.35	2.63e-11	Resting heart rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02149880	chr2:216878419	MREG	0.44	7.07	0.36	9.06e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.57	0.5	9.83e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs877282	0.583	rs11595057	chr10:819203	A/C	cg13042288	chr15:90349979	ANPEP	-0.43	-6.86	-0.35	3.27e-11	Uric acid levels;
LUSC	cis	rs17407555	0.606	rs59871456	chr4:10014441	G/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-6.15	-0.32	2.2e-9	Schizophrenia (age at onset);
LUSC	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg21211680	chr2:198530	NA	-0.54	-6.68	-0.34	9.72e-11	Blood protein levels;
LUSC	cis	rs6500395	1.000	rs11076573	chr16:48632758	A/G	cg04672837	chr16:48644449	N4BP1	0.49	7.28	0.37	2.36e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9905704	0.846	rs28363318	chr17:56798207	T/C	cg12560992	chr17:57184187	TRIM37	0.58	8.4	0.42	1.34e-15	Testicular germ cell tumor;
LUSC	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg12884169	chr21:40033163	ERG	0.61	12.34	0.56	4.41e-29	Coronary artery disease;
LUSC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg27129171	chr3:47204927	SETD2	-0.58	-8.55	-0.42	4.42e-16	Birth weight;
LUSC	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg19336497	chr11:14380999	RRAS2	-0.35	-7.1	-0.36	7.52e-12	Vitamin D levels;
LUSC	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.17	0.45	4.85e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg05110241	chr16:68378359	PRMT7	-0.74	-7.94	-0.4	3.13e-14	Magnesium levels;
LUSC	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.48	-10.24	-0.49	1.42e-21	Coronary artery disease;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg17541715	chr7:1216824	NA	-0.4	-6.3	-0.33	9.63e-10	Longevity;Endometriosis;
LUSC	trans	rs11088226	0.846	rs2154500	chr21:33926391	T/C	cg09050820	chr6:167586206	TCP10L2	0.67	10.13	0.48	3.3e-21	Gastritis;
LUSC	cis	rs12620999	0.887	rs10929214	chr2:238037436	C/G	cg23555395	chr2:238036564	NA	-0.52	-8.79	-0.43	8.3e-17	Systemic lupus erythematosus;
LUSC	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.84	0.3	1.25e-8	Breast cancer;
LUSC	cis	rs4494114	1.000	rs9438984	chr1:39361615	G/A	cg25970120	chr1:39325951	RRAGC	-0.4	-6.23	-0.32	1.4e-9	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15556085	chr6:118972834	C6orf204	-0.4	-6.12	-0.32	2.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg01765077	chr12:122356316	WDR66	-0.44	-6.2	-0.32	1.66e-9	Mean corpuscular volume;
LUSC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.9	0.4	4.01e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.62	-0.34	1.42e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9788721	0.836	rs55983731	chr15:78735269	C/T	cg18825076	chr15:78729989	IREB2	-0.59	-9.76	-0.47	5.72e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs3862435	0.572	rs2601164	chr15:90908402	A/G	cg22089800	chr15:90895588	ZNF774	-0.56	-6.01	-0.31	4.85e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs9283706	0.641	rs6414805	chr5:66322600	T/C	cg11590213	chr5:66331682	MAST4	0.46	6.66	0.34	1.13e-10	Coronary artery disease;
LUSC	trans	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.37	-0.33	6.25e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	0.96	10.41	0.49	3.72e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg00310523	chr12:86230176	RASSF9	0.4	7.31	0.37	1.94e-12	Major depressive disorder;
LUSC	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg08916839	chr5:415575	AHRR	0.75	7.09	0.36	7.88e-12	Fat distribution (HIV);
LUSC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08859206	chr1:53392774	SCP2	-0.68	-13.04	-0.58	1.06e-31	Monocyte count;
LUSC	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.89	-0.4	4.34e-14	Glomerular filtration rate;
LUSC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	9.72	0.47	8.11e-20	Personality dimensions;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg16203607	chr17:62500946	DDX5	0.32	6.33	0.33	8.07e-10	Tuberculosis;
LUSC	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg05985134	chr18:33552581	C18orf21	0.51	7.1	0.36	7.51e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7172677	0.732	rs55922358	chr15:75313967	G/C	cg14664628	chr15:75095509	CSK	0.6	7.85	0.39	5.88e-14	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg09184832	chr6:79620586	NA	-0.44	-7.18	-0.37	4.63e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg26811252	chr16:29126840	RRN3P2	0.56	8.92	0.44	3.14e-17	Menopause (age at onset);
LUSC	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg13390004	chr1:15929781	NA	-0.42	-7.1	-0.36	7.39e-12	Systolic blood pressure;
LUSC	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg08085267	chr17:45401833	C17orf57	-0.46	-6.71	-0.34	8.46e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg05340658	chr4:99064831	C4orf37	0.41	6.3	0.33	9.42e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg19700328	chr14:106028568	NA	-0.41	-6.88	-0.35	2.95e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.37	6.52	0.34	2.67e-10	Depressive symptoms;
LUSC	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg20991723	chr1:152506922	NA	0.52	9.83	0.47	3.41e-20	Hair morphology;
LUSC	cis	rs7809950	0.822	rs2712228	chr7:107300340	A/C	cg23024343	chr7:107201750	COG5	0.47	7.13	0.36	6.23e-12	Coronary artery disease;
LUSC	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg00757033	chr12:89920650	WDR51B	-0.56	-10.09	-0.48	4.67e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg11812906	chr14:75593930	NEK9	0.67	11.56	0.53	3.23e-26	Height;
LUSC	cis	rs34638657	0.732	rs2967359	chr16:82202968	G/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.53	-0.34	2.4e-10	Lung adenocarcinoma;
LUSC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg06914050	chr7:56119237	PSPH;CCT6A	0.72	6.44	0.33	4.18e-10	Myocardial infarction;
LUSC	cis	rs7246967	0.551	rs34897132	chr19:22826891	G/A	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg12560992	chr17:57184187	TRIM37	0.83	15.09	0.64	1.4e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00339695	chr16:24857497	SLC5A11	0.58	8.84	0.44	5.78e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	trans	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18876405	chr7:65276391	NA	0.49	6.71	0.34	8.46e-11	Corneal structure;
LUSC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24110177	chr3:50126178	RBM5	-0.54	-9.1	-0.45	8.58e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-14.76	-0.63	2.55e-38	Vitiligo;
LUSC	trans	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.21	-0.37	3.68e-12	Monocyte count;
LUSC	cis	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg06521331	chr12:34319734	NA	-0.44	-7.18	-0.37	4.6e-12	Morning vs. evening chronotype;
LUSC	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg21138405	chr5:131827807	IRF1	-0.34	-5.94	-0.31	7e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs4975709	0.798	rs4975757	chr5:1882579	G/A	cg15595755	chr5:1867978	NA	0.4	6.32	0.33	8.59e-10	Cardiovascular disease risk factors;
LUSC	cis	rs10504073	0.669	rs341801	chr8:50037784	A/G	cg00325661	chr8:49890786	NA	0.59	9.72	0.47	7.68e-20	Blood metabolite ratios;
LUSC	cis	rs6977660	0.660	rs7357202	chr7:19817911	T/A	cg05791153	chr7:19748676	TWISTNB	0.66	7.0	0.36	1.38e-11	Thyroid stimulating hormone;
LUSC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.65	10.61	0.5	7.18e-23	Longevity;
LUSC	cis	rs1451375	1.000	rs1966839	chr7:50627101	T/C	cg18232548	chr7:50535776	DDC	0.52	7.91	0.4	3.76e-14	Malaria;
LUSC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg26695010	chr11:65641043	EFEMP2	-0.47	-7.2	-0.37	3.89e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.01e-30	Aortic root size;
LUSC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg25036284	chr2:26402008	FAM59B	-0.74	-10.81	-0.51	1.52e-23	Gut microbiome composition (summer);
LUSC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06634786	chr22:41940651	POLR3H	-0.53	-6.05	-0.31	3.88e-9	Vitiligo;
LUSC	trans	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg00427296	chr17:8534932	MYH10	-0.55	-5.98	-0.31	5.59e-9	Blood protein levels;
LUSC	cis	rs2692947	0.800	rs61409777	chr2:96581373	C/A	cg22654517	chr2:96458247	NA	0.38	7.62	0.38	2.6e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs6076960	0.652	rs3843045	chr20:6264593	C/T	cg17788362	chr6:86352627	SYNCRIP	-0.47	-7.24	-0.37	3.19e-12	Smooth-surface caries;
LUSC	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg03934865	chr2:198174659	NA	-0.34	-5.7	-0.3	2.7e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg09365446	chr1:150670422	GOLPH3L	0.48	7.12	0.36	6.85e-12	Melanoma;
LUSC	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg13057898	chr1:3703894	LRRC47	0.49	8.63	0.43	2.55e-16	Red cell distribution width;
LUSC	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.75	11.66	0.54	1.35e-26	Blood pressure (smoking interaction);
LUSC	trans	rs1325195	0.537	rs3818433	chr1:179079190	C/T	cg11624085	chr17:8464688	MYH10	0.46	6.93	0.35	2.17e-11	IgE grass sensitization;
LUSC	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-5.7	-0.3	2.66e-8	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	ch.11.42038R	chr11:967971	AP2A2	0.44	6.6	0.34	1.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.74	-0.35	6.91e-11	Neuroticism;
LUSC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.72	-0.3	2.39e-8	Monocyte count;
LUSC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.44	0.53	8.23e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg17031739	chr1:67600172	NA	0.36	5.68	0.3	2.9e-8	Psoriasis;
LUSC	trans	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.31	-0.33	8.95e-10	Bipolar disorder;
LUSC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg05585544	chr11:47624801	NA	0.4	7.01	0.36	1.33e-11	Subjective well-being;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20659025	chr11:126173961	DCPS	-0.51	-6.08	-0.32	3.35e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9309711	0.922	rs13399524	chr2:3480206	C/G	cg10845886	chr2:3471009	TTC15	-0.59	-7.67	-0.39	1.91e-13	Neurofibrillary tangles;
LUSC	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg04374321	chr14:90722782	PSMC1	-0.41	-6.05	-0.31	3.79e-9	Mortality in heart failure;
LUSC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.7	-11.84	-0.54	3.13e-27	Longevity;
LUSC	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg04733989	chr22:42467013	NAGA	0.63	9.9	0.48	1.95e-20	Schizophrenia;
LUSC	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	trans	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	10.7	0.51	3.6e-23	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg07810366	chr2:100720526	AFF3	-0.42	-6.95	-0.36	1.89e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs62400317	0.859	rs4443508	chr6:45235952	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.65	-0.39	2.2e-13	Total body bone mineral density;
LUSC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg11645453	chr3:52864694	ITIH4	0.3	6.87	0.35	3.17e-11	Electroencephalogram traits;
LUSC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.94	13.32	0.59	9.25e-33	Menarche (age at onset);
LUSC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.77	13.94	0.61	3.86e-35	Osteoporosis;
LUSC	cis	rs2742417	0.603	rs2742455	chr3:45767116	A/G	cg04837898	chr3:45731254	SACM1L	-0.45	-7.26	-0.37	2.66e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.21	-0.49	1.8e-21	Hemoglobin concentration;
LUSC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25072359	chr17:41440525	NA	0.66	9.5	0.46	4.09e-19	Menopause (age at onset);
LUSC	trans	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg18187862	chr3:45730750	SACM1L	-0.53	-6.45	-0.33	3.92e-10	Primary sclerosing cholangitis;
LUSC	cis	rs9311676	0.632	rs62258126	chr3:58396114	T/C	cg13750441	chr3:58318267	PXK	0.35	6.76	0.35	6.01e-11	Systemic lupus erythematosus;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07817097	chr1:179851575	TOR1AIP1	-0.52	-6.7	-0.34	9.14e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg06484146	chr7:12443880	VWDE	-0.7	-7.51	-0.38	5.55e-13	Coronary artery disease;
LUSC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.54	-8.49	-0.42	7.06e-16	Personality dimensions;
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.42	-0.42	1.13e-15	Lymphocyte counts;
LUSC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg08213375	chr14:104286397	PPP1R13B	0.44	7.68	0.39	1.78e-13	Reticulocyte count;
LUSC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg12257692	chr3:49977190	RBM6	0.24	6.74	0.35	6.99e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg20607798	chr8:58055168	NA	0.52	5.66	0.3	3.33e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg02569458	chr12:86230093	RASSF9	0.48	7.62	0.38	2.63e-13	Major depressive disorder;
LUSC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg15605315	chr1:45957053	TESK2	0.46	7.19	0.37	4.38e-12	High light scatter reticulocyte count;
LUSC	cis	rs1322512	1.000	rs1727054	chr6:152947742	A/G	cg27316956	chr6:152958899	SYNE1	-0.33	-5.65	-0.3	3.45e-8	Tonometry;
LUSC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.49	8.06	0.4	1.33e-14	Lymphocyte counts;
LUSC	cis	rs11209002	0.738	rs1321154	chr1:67570703	T/C	cg02640540	chr1:67518911	SLC35D1	0.67	6.68	0.34	9.71e-11	Crohn's disease;
LUSC	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg12292205	chr6:26970375	C6orf41	-0.59	-7.2	-0.37	4.06e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg21573476	chr21:45109991	RRP1B	-0.37	-6.0	-0.31	5.14e-9	Mean corpuscular volume;
LUSC	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg17168535	chr8:21777572	XPO7	0.65	9.71	0.47	8.7e-20	Mean corpuscular volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18013306	chr15:68521911	CLN6	0.44	6.08	0.32	3.24e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg07424592	chr7:64974309	NA	0.7	6.04	0.31	4.12e-9	Diabetic kidney disease;
LUSC	cis	rs7945718	0.875	rs7924501	chr11:12813870	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.63	0.39	2.48e-13	Educational attainment (years of education);
LUSC	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg22732515	chr19:44031385	ETHE1	0.66	10.61	0.5	7.2e-23	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg11247378	chr22:39784982	NA	-0.62	-11.12	-0.52	1.17e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	11.31	0.53	2.58e-25	Chronic sinus infection;
LUSC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.59	9.61	0.47	1.82e-19	Aortic root size;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg10482924	chr11:62539163	TAF6L	0.41	6.02	0.31	4.63e-9	Calcium levels;
LUSC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg22601191	chr20:60968625	CABLES2	-0.39	-6.33	-0.33	8.08e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs4285028	0.747	rs7610298	chr3:121419100	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-12.97	-0.58	1.9e-31	Multiple sclerosis;
LUSC	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg24011408	chr12:48396354	COL2A1	0.47	6.86	0.35	3.39e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4722585	0.533	rs6964215	chr7:26196819	G/A	cg07876897	chr7:26191696	NFE2L3	0.46	6.91	0.35	2.49e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUSC	cis	rs4663866	1.000	rs13033501	chr2:239181860	G/A	cg16914508	chr2:239161102	PER2	0.69	7.41	0.38	1.06e-12	Irritable bowel syndrome;
LUSC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg14552801	chr7:65878734	NA	0.45	6.53	0.34	2.38e-10	Aortic root size;
LUSC	cis	rs3736594	0.722	rs12993377	chr2:27952767	G/C	cg27432699	chr2:27873401	GPN1	-0.63	-8.92	-0.44	3.06e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg14696996	chr19:15285081	NOTCH3	0.96	8.62	0.43	2.65e-16	Pulse pressure;
LUSC	cis	rs1957429	0.572	rs3813421	chr14:65347239	G/A	cg23373153	chr14:65346875	NA	1.08	12.76	0.57	1.22e-30	Pediatric areal bone mineral density (radius);
LUSC	cis	rs12410462	0.681	rs113984727	chr1:227553917	C/A	cg23173402	chr1:227635558	NA	0.54	6.27	0.32	1.11e-9	Major depressive disorder;
LUSC	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.54	-0.34	2.35e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg00792783	chr2:198669748	PLCL1	0.43	5.86	0.31	1.12e-8	Dermatomyositis;
LUSC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	9.26	0.45	2.64e-18	Motion sickness;
LUSC	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg20487152	chr13:99095054	FARP1	-0.42	-7.08	-0.36	8.66e-12	Longevity;
LUSC	cis	rs10761482	0.861	rs4948406	chr10:62110146	G/T	cg18175470	chr10:62150864	ANK3	-0.5	-7.04	-0.36	1.13e-11	Schizophrenia;
LUSC	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg24558204	chr6:135376177	HBS1L	0.68	10.82	0.51	1.32e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg21053147	chr12:120880522	NA	-0.49	-5.99	-0.31	5.35e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg05966235	chr16:28915196	ATP2A1	0.34	5.96	0.31	6.43e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs55665837	1.000	rs12287715	chr11:14444575	G/A	cg19336497	chr11:14380999	RRAS2	-0.37	-7.53	-0.38	4.9e-13	Vitamin D levels;
LUSC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg13047869	chr3:10149882	C3orf24	0.55	7.84	0.39	6.12e-14	Alzheimer's disease;
LUSC	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg22532475	chr10:104410764	TRIM8	-0.26	-6.07	-0.32	3.42e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.59	-9.49	-0.46	4.49e-19	Body mass index;
LUSC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg18681998	chr4:17616180	MED28	0.84	15.29	0.64	2.24e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg00012203	chr2:219082015	ARPC2	0.87	16.55	0.67	2.36e-45	Colorectal cancer;
LUSC	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.31e-11	Response to antipsychotic treatment;
LUSC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.67	0.39	1.94e-13	Prudent dietary pattern;
LUSC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg12963246	chr6:28129442	ZNF389	0.51	7.06	0.36	9.81e-12	Depression;
LUSC	cis	rs11971779	0.590	rs6467839	chr7:139062790	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.0	0.36	1.38e-11	Diisocyanate-induced asthma;
LUSC	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg26384229	chr12:38710491	ALG10B	0.53	7.53	0.38	4.83e-13	Morning vs. evening chronotype;
LUSC	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg01620082	chr3:125678407	NA	-0.78	-7.6	-0.38	3.04e-13	Depression;
LUSC	cis	rs8016982	0.531	rs2241622	chr14:81737290	A/G	cg01989461	chr14:81687754	GTF2A1	0.51	6.24	0.32	1.33e-9	Schizophrenia;
LUSC	cis	rs7091068	0.567	rs1572773	chr10:95432968	T/C	cg20715218	chr10:95462985	C10orf4	0.46	5.83	0.3	1.32e-8	Urinary tract infection frequency;
LUSC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg03676636	chr4:99064102	C4orf37	-0.34	-7.49	-0.38	6.14e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg07621104	chr11:117668040	DSCAML1	0.46	6.09	0.32	3.09e-9	Myopia;
LUSC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.58	10.74	0.51	2.64e-23	Homoarginine levels;
LUSC	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg06917634	chr15:78832804	PSMA4	-0.59	-7.31	-0.37	1.97e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg00158530	chr16:69966973	MIR140;WWP2	-0.44	-7.0	-0.36	1.4e-11	Menarche (age at onset);
LUSC	cis	rs708547	0.647	rs1403233	chr4:57885053	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-7.19	-0.37	4.18e-12	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg20203395	chr5:56204925	C5orf35	-0.72	-9.9	-0.48	1.96e-20	Initial pursuit acceleration;
LUSC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.37	0.37	1.32e-12	Bipolar disorder;
LUSC	cis	rs506338	0.517	rs17146216	chr11:64451281	C/G	cg19131476	chr11:64387923	NRXN2	0.38	8.22	0.41	4.43e-15	Body mass index;Urate levels;
LUSC	cis	rs9788721	0.775	rs8040868	chr15:78911181	C/T	cg18825076	chr15:78729989	IREB2	0.52	8.81	0.43	6.82e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs17255340	0.577	rs6937273	chr6:84095513	A/G	cg08257003	chr6:84140564	ME1	0.34	8.31	0.41	2.41e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.85	15.63	0.65	1.01e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.8	0.57	8.38e-31	Prudent dietary pattern;
LUSC	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.49	16.86	0.68	1.38e-46	Opioid sensitivity;
LUSC	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg23711669	chr6:146136114	FBXO30	0.87	15.55	0.65	2.07e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg22508957	chr16:3507546	NAT15	-0.41	-5.84	-0.3	1.25e-8	Body mass index (adult);
LUSC	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg05527609	chr1:210001259	C1orf107	0.7	10.07	0.48	5.22e-21	Orofacial clefts;
LUSC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg06008330	chr7:65541103	ASL	0.4	6.17	0.32	1.96e-9	Aortic root size;
LUSC	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.47	-0.38	7.12e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7589342	0.929	rs13024715	chr2:106433950	A/G	cg14210321	chr2:106509881	NCK2	-0.54	-8.12	-0.41	9.28e-15	Addiction;
LUSC	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg23752985	chr2:85803571	VAMP8	0.34	7.3	0.37	2.16e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.84	-0.44	5.68e-17	Monocyte count;
LUSC	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.53	8.62	0.43	2.76e-16	Breast cancer;
LUSC	cis	rs644148	0.836	rs2571112	chr19:45000319	T/A	cg15540054	chr19:45004280	ZNF180	-0.63	-9.35	-0.46	1.3e-18	Personality dimensions;
LUSC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-0.79	-15.28	-0.64	2.53e-40	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04565464	chr8:145669602	NFKBIL2	0.39	6.43	0.33	4.53e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg26695010	chr11:65641043	EFEMP2	0.4	5.65	0.3	3.53e-8	Breast cancer;
LUSC	cis	rs2361710	0.611	rs3816257	chr17:78074446	G/T	cg09238746	chr17:78121135	EIF4A3	0.42	5.92	0.31	7.84e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06636551	chr8:101224915	SPAG1	-0.45	-8.22	-0.41	4.52e-15	Atrioventricular conduction;
LUSC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.92	-13.28	-0.59	1.3e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1957429	0.614	rs73279812	chr14:65348012	G/A	cg23373153	chr14:65346875	NA	-1.03	-9.4	-0.46	8.72e-19	Pediatric areal bone mineral density (radius);
LUSC	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg22508957	chr16:3507546	NAT15	-0.39	-6.12	-0.32	2.68e-9	Body mass index (adult);
LUSC	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg06212747	chr3:49208901	KLHDC8B	0.53	7.29	0.37	2.22e-12	Parkinson's disease;
LUSC	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4595586	0.679	rs5017082	chr12:39314564	A/C	cg26384229	chr12:38710491	ALG10B	-0.43	-5.88	-0.31	9.69e-9	Morning vs. evening chronotype;
LUSC	cis	rs7818382	1.000	rs7818382	chr8:96054000	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.54	-0.34	2.25e-10	Alzheimer's disease (late onset);
LUSC	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.85	-0.47	2.82e-20	Joint mobility (Beighton score);
LUSC	cis	rs2742417	0.603	rs2742455	chr3:45767116	A/G	cg10512202	chr3:45649293	LIMD1	0.36	5.93	0.31	7.48e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6736093	0.966	rs11683694	chr2:112702647	C/T	cg12686935	chr2:112915763	FBLN7	-0.36	-5.84	-0.3	1.25e-8	Coronary artery disease;
LUSC	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg12935359	chr14:103987150	CKB	0.66	10.81	0.51	1.43e-23	Intelligence (multi-trait analysis);
LUSC	trans	rs11246602	1	rs11246602	chr11:51512090	T/C	cg15704280	chr7:45808275	SEPT13	0.89	7.74	0.39	1.21e-13	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06558623	chr16:89946397	TCF25	0.95	10.21	0.49	1.82e-21	Skin colour saturation;
LUSC	cis	rs10875746	0.951	rs4760689	chr12:48563644	G/A	cg13454099	chr12:49076203	C12orf41	-0.51	-5.95	-0.31	6.91e-9	Longevity (90 years and older);
LUSC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg12310025	chr6:25882481	NA	-0.46	-8.01	-0.4	1.91e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs727505	0.583	rs17147421	chr7:124383948	C/T	cg23710748	chr7:124431027	NA	-0.33	-5.82	-0.3	1.39e-8	Lewy body disease;
LUSC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.65	-0.39	2.19e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg22482690	chr17:47019901	SNF8	0.4	7.47	0.38	7e-13	Type 2 diabetes;
LUSC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg04398451	chr17:18023971	MYO15A	0.57	9.44	0.46	6.61e-19	Total body bone mineral density;
LUSC	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg21772509	chr8:41503840	NKX6-3	0.66	10.91	0.51	6.84e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.34	6.34	0.33	7.52e-10	Platelet count;
LUSC	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg21643547	chr1:205240462	TMCC2	0.42	7.66	0.39	2e-13	Red blood cell count;
LUSC	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.2	0.59	2.54e-32	Blood protein levels;
LUSC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg21770322	chr7:97807741	LMTK2	0.41	7.25	0.37	2.92e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6987853	0.966	rs2974338	chr8:42391945	A/G	cg09913449	chr8:42400586	C8orf40	0.49	8.3	0.41	2.56e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2857891	0.697	rs4757980	chr11:6921840	G/T	cg04053776	chr11:6947353	ZNF215	0.56	7.94	0.4	3.02e-14	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg16680214	chr1:154839983	KCNN3	-0.52	-9.76	-0.47	5.77e-20	Prostate cancer;
LUSC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21545522	chr1:205238299	TMCC2	0.49	9.16	0.45	5.45e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs4594175	0.926	rs7493621	chr14:51623665	C/T	cg23942311	chr14:51606299	NA	0.32	6.03	0.31	4.28e-9	Cancer;
LUSC	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg05738196	chr6:26577821	NA	0.79	15.24	0.64	3.59e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.4	-6.41	-0.33	4.92e-10	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg22834771	chr12:69754056	YEATS4	-0.44	-6.63	-0.34	1.39e-10	Blood protein levels;
LUSC	cis	rs2011503	0.509	rs11668721	chr19:19760916	G/A	cg11584989	chr19:19387371	SF4	0.51	5.74	0.3	2.14e-8	Bipolar disorder;
LUSC	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg13010344	chr12:123464640	ARL6IP4	0.51	6.5	0.33	2.97e-10	Neutrophil percentage of white cells;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg15462925	chr8:12613305	LONRF1	0.37	6.1	0.32	2.94e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	10.16	0.49	2.55e-21	Lymphocyte counts;
LUSC	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg00383909	chr3:49044727	WDR6	1.14	10.58	0.5	9.36e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4629710	0.592	rs749375	chr6:131553692	C/G	cg12606694	chr6:131520996	AKAP7	0.63	9.57	0.46	2.46e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg27266027	chr21:40555129	PSMG1	0.4	5.91	0.31	8.64e-9	Cognitive function;
LUSC	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.69	0.34	9.42e-11	Corneal astigmatism;
LUSC	cis	rs35995292	0.534	rs2008199	chr7:38939678	T/C	cg19327137	chr7:38886074	VPS41	0.54	10.18	0.49	2.18e-21	Subjective well-being (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	9.44	0.46	6.68e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg15445000	chr17:37608096	MED1	-0.38	-6.61	-0.34	1.53e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg17143192	chr8:8559678	CLDN23	0.65	9.49	0.46	4.57e-19	Obesity-related traits;
LUSC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg00431813	chr7:1051703	C7orf50	-0.43	-7.32	-0.37	1.9e-12	Longevity;Endometriosis;
LUSC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	8.09e-13	Motion sickness;
LUSC	trans	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.56	9.02	0.44	1.53e-17	Brugada syndrome;
LUSC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	12.42	0.56	2.15e-29	Menopause (age at onset);
LUSC	trans	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg09781936	chr22:19749961	TBX1	-0.33	-5.95	-0.31	6.84e-9	Inflammatory bowel disease;
LUSC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.78	0.39	9.24e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.31	6.46	0.33	3.64e-10	Hemoglobin concentration;
LUSC	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.98	-0.4	2.38e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.36	0.59	6.42e-33	Cognitive test performance;
LUSC	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg12002119	chr2:101014098	CHST10	0.36	6.06	0.31	3.77e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs17433780	0.964	rs10493821	chr1:89475135	C/T	cg09516651	chr1:89888402	LOC400759	0.52	8.62	0.43	2.81e-16	Carotid intima media thickness;
LUSC	trans	rs11088226	0.581	rs2833860	chr21:33882309	G/A	cg09050820	chr6:167586206	TCP10L2	0.47	7.1	0.36	7.49e-12	Gastritis;
LUSC	cis	rs10743315	0.557	rs74974316	chr12:19344688	A/G	cg02471346	chr12:19282374	PLEKHA5	0.69	5.74	0.3	2.09e-8	Gut microbiota (bacterial taxa);
LUSC	trans	rs230489	0.668	rs13129951	chr4:103374760	G/A	cg20368818	chr11:33800056	NA	-0.46	-5.99	-0.31	5.42e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.81	13.55	0.6	1.19e-33	Aortic root size;
LUSC	cis	rs34526934	0.608	rs72927183	chr2:177033779	C/T	cg26754761	chr2:177040938	NA	-0.39	-7.55	-0.38	4.22e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg23356831	chr14:105996513	TMEM121	-0.3	-5.73	-0.3	2.29e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs4253772	0.872	rs79700435	chr22:46638211	G/A	cg24881330	chr22:46731750	TRMU	0.63	5.79	0.3	1.61e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg15649852	chr7:65879115	NA	0.41	5.79	0.3	1.64e-8	Aortic root size;
LUSC	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	0.89	16.94	0.68	7.06e-47	Heart rate;
LUSC	cis	rs6546550	0.901	rs6741449	chr2:70156589	A/G	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.22e-12	Prevalent atrial fibrillation;
LUSC	cis	rs7575217	0.921	rs2871393	chr2:101770430	C/G	cg23907051	chr2:101730305	TBC1D8	-0.29	-7.51	-0.38	5.34e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	trans	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.47	6.98	0.36	1.61e-11	Endometrial cancer;
LUSC	cis	rs2953174	0.720	rs2975794	chr2:241515813	C/T	cg07929629	chr2:241523174	NA	0.51	7.84	0.39	5.94e-14	Bipolar disorder;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg12646754	chr1:2574751	NA	0.37	6.07	0.32	3.57e-9	Triglycerides;
LUSC	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg18681998	chr4:17616180	MED28	0.77	13.66	0.6	4.65e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.6	9.48	0.46	4.8e-19	Morning vs. evening chronotype;
LUSC	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg11608241	chr8:8085544	FLJ10661	0.41	5.7	0.3	2.59e-8	Mean corpuscular volume;
LUSC	trans	rs17507216	1.000	rs17507216	chr15:83226925	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.44	6.1	0.32	2.91e-9	Excessive daytime sleepiness;
LUSC	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg08601574	chr20:25228251	PYGB	-0.43	-6.62	-0.34	1.47e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2078087	0.522	rs7525417	chr1:183211052	G/A	cg13843938	chr1:183241246	NMNAT2	0.46	6.67	0.34	1.03e-10	Obesity-related traits;
LUSC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg11843238	chr5:131593191	PDLIM4	0.5	8.66	0.43	2.06e-16	Acylcarnitine levels;
LUSC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.7	0.34	8.97e-11	Tonsillectomy;
LUSC	trans	rs17301259	0.662	rs2718304	chr7:88391758	T/C	cg21771463	chr3:44626400	ZNF660	-0.38	-6.16	-0.32	2.13e-9	Heschl's gyrus morphology;
LUSC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg07741184	chr6:167504864	NA	0.39	6.88	0.35	2.9e-11	Primary biliary cholangitis;
LUSC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg16447950	chr5:562315	NA	-0.54	-6.59	-0.34	1.76e-10	Obesity-related traits;
LUSC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg00677455	chr12:58241039	CTDSP2	0.61	8.47	0.42	7.68e-16	Multiple sclerosis;
LUSC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.59	-0.38	3.21e-13	Personality dimensions;
LUSC	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg11887960	chr12:57824829	NA	0.55	7.21	0.37	3.7e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg04362960	chr10:104952993	NT5C2	0.59	9.39	0.46	1e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg08470875	chr2:26401718	FAM59B	-0.69	-9.49	-0.46	4.53e-19	Gut microbiome composition (summer);
LUSC	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.94	0.36	2.01e-11	Retinal vascular caliber;
LUSC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	0.99	13.75	0.6	2.12e-34	Eosinophil percentage of granulocytes;
LUSC	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6062509	0.839	rs6062298	chr20:62301970	G/A	cg27236539	chr20:62289627	RTEL1	0.49	6.62	0.34	1.43e-10	Prostate cancer;
LUSC	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg09184832	chr6:79620586	NA	-0.44	-7.07	-0.36	8.88e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg06784218	chr1:46089804	CCDC17	0.54	10.91	0.51	6.6e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.53	-0.38	4.89e-13	Aortic root size;
LUSC	cis	rs7428496	0.528	rs13068397	chr3:142294425	A/C	cg16271453	chr3:142027066	XRN1	-0.49	-8.44	-0.42	9.81e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs10779751	1.000	rs11121710	chr1:11313244	T/C	cg08854313	chr1:11322531	MTOR	0.87	14.89	0.63	7.85e-39	Body mass index;
LUSC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.77	0.35	5.68e-11	Tonsillectomy;
LUSC	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg18681998	chr4:17616180	MED28	-0.82	-13.88	-0.6	6.84e-35	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1113500	0.933	rs11185261	chr1:108638703	G/A	cg06207961	chr1:108661230	NA	0.41	7.64	0.39	2.29e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg02176678	chr2:219576539	TTLL4	-0.56	-9.63	-0.47	1.53e-19	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	trans	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg21775007	chr8:11205619	TDH	0.42	6.14	0.32	2.39e-9	Neuroticism;
LUSC	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg27411982	chr8:10470053	RP1L1	0.38	5.9	0.31	8.94e-9	Retinal vascular caliber;
LUSC	cis	rs6977660	0.653	rs28537170	chr7:19814239	T/G	cg07541023	chr7:19748670	TWISTNB	0.75	7.66	0.39	1.96e-13	Thyroid stimulating hormone;
LUSC	cis	rs6084875	0.840	rs2422942	chr20:4726116	A/G	cg07258627	chr20:4721683	PRNT	-0.34	-6.16	-0.32	2.05e-9	Systemic lupus erythematosus;
LUSC	cis	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg11146114	chr12:4671731	NA	-0.58	-6.21	-0.32	1.61e-9	Phosphorus levels;
LUSC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg18681998	chr4:17616180	MED28	0.84	15.63	0.65	1.03e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3770081	1.000	rs2118521	chr2:86204379	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.99	-6.65	-0.34	1.2e-10	Facial emotion recognition (sad faces);
LUSC	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg13798780	chr7:105162888	PUS7	0.54	6.06	0.31	3.67e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	0.66	13.94	0.61	3.9e-35	Prudent dietary pattern;
LUSC	cis	rs500891	0.525	rs7768456	chr6:84054779	C/T	cg08257003	chr6:84140564	ME1	0.32	7.08	0.36	8.45e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg27124370	chr19:33622961	WDR88	0.56	7.89	0.4	4.25e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.62	0.43	2.69e-16	Prudent dietary pattern;
LUSC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg00945038	chr17:61921165	SMARCD2	0.52	8.8	0.43	7.26e-17	Prudent dietary pattern;
LUSC	cis	rs5753618	0.583	rs5753632	chr22:31863097	C/T	cg02404636	chr22:31891804	SFI1	0.45	6.62	0.34	1.43e-10	Colorectal cancer;
LUSC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg15445000	chr17:37608096	MED1	0.38	6.53	0.34	2.52e-10	Glomerular filtration rate (creatinine);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26907351	chr6:2765585	WRNIP1	-0.42	-5.98	-0.31	5.74e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg03465714	chr1:152285911	FLG	-0.41	-5.78	-0.3	1.71e-8	Atopic dermatitis;
LUSC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.39	-0.42	1.35e-15	Lung cancer;
LUSC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.03	0.77	4.68e-67	Prudent dietary pattern;
LUSC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.09e-30	Aortic root size;
LUSC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg13334819	chr7:99746414	C7orf59	-0.51	-6.9	-0.35	2.61e-11	Coronary artery disease;
LUSC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg09365446	chr1:150670422	GOLPH3L	0.48	6.93	0.35	2.18e-11	Melanoma;
LUSC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg27284194	chr4:1044797	NA	0.35	5.85	0.31	1.15e-8	Obesity-related traits;
LUSC	cis	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg06521331	chr12:34319734	NA	0.38	6.26	0.32	1.17e-9	Morning vs. evening chronotype;
LUSC	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-7.94	-0.4	3.03e-14	Morning vs. evening chronotype;
LUSC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg03146154	chr1:46216737	IPP	0.57	8.55	0.42	4.4e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3771570	1.000	rs59536819	chr2:242272388	A/G	cg21155796	chr2:242212141	HDLBP	0.63	6.86	0.35	3.32e-11	Prostate cancer;
LUSC	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.18	-0.45	4.78e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.9	-20.73	-0.75	5.85e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg10596483	chr8:143751796	JRK	0.61	9.37	0.46	1.1e-18	Schizophrenia;
LUSC	cis	rs7804356	1.000	rs10486478	chr7:26819465	C/T	cg03456212	chr7:26904342	SKAP2	-0.55	-6.49	-0.33	3.03e-10	Type 1 diabetes;
LUSC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.45	0.33	3.89e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18099408	chr3:52552593	STAB1	-0.41	-6.95	-0.36	1.97e-11	Bipolar disorder;
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.88	17.15	0.68	1.03e-47	Menarche (age at onset);
LUSC	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.52	-0.38	4.99e-13	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.09	16.92	0.68	7.95e-47	Gut microbiome composition (summer);
LUSC	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.52	-7.17	-0.37	4.83e-12	Primary sclerosing cholangitis;
LUSC	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg05294307	chr14:35346193	BAZ1A	-0.58	-6.65	-0.34	1.23e-10	Psoriasis;
LUSC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg13047869	chr3:10149882	C3orf24	0.62	8.87	0.44	4.43e-17	Alzheimer's disease;
LUSC	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.51	-0.34	2.83e-10	Triglycerides;
LUSC	cis	rs1044826	0.642	rs295479	chr3:139223865	C/T	cg00490450	chr3:139108681	COPB2	0.46	7.02	0.36	1.27e-11	Obesity-related traits;
LUSC	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg20243544	chr17:37824526	PNMT	0.43	6.54	0.34	2.28e-10	Self-reported allergy;
LUSC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg00750074	chr16:89608354	SPG7	-0.57	-10.39	-0.49	4.33e-22	Multiple myeloma (IgH translocation);
LUSC	cis	rs921665	0.831	rs3887811	chr2:3182777	A/G	cg02624386	chr2:3182749	NA	0.57	6.31	0.33	8.85e-10	World class endurance athleticism;
LUSC	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg08601574	chr20:25228251	PYGB	0.38	5.66	0.3	3.26e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7760535	1.000	rs7760535	chr6:111747083	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.35	6.44	0.33	4.22e-10	Metabolic traits;
LUSC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg06784218	chr1:46089804	CCDC17	0.48	9.43	0.46	7e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.77	-13.25	-0.59	1.69e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs61931739	0.649	rs12424046	chr12:33714374	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-6.17	-0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg26536354	chr8:144654954	C8orf73	0.64	7.31	0.37	2e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs7212590	0.748	rs7223057	chr17:57936438	G/C	cg10252138	chr17:58120427	NA	-0.73	-7.06	-0.36	9.79e-12	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg15412446	chr2:106886593	NA	-0.51	-6.32	-0.33	8.2e-10	Facial morphology (factor 23);
LUSC	cis	rs7091068	0.754	rs1326224	chr10:95459267	C/T	cg20715218	chr10:95462985	C10orf4	0.62	7.25	0.37	2.98e-12	Urinary tract infection frequency;
LUSC	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	13.58	0.6	9.66e-34	Primary sclerosing cholangitis;
LUSC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg16606324	chr3:10149918	C3orf24	0.6	8.0	0.4	2.03e-14	Alzheimer's disease;
LUSC	cis	rs4566357	0.615	rs10190621	chr2:227914484	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-8.06	-0.4	1.35e-14	Coronary artery disease;
LUSC	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg06207120	chr15:45996521	NA	0.4	6.07	0.32	3.54e-9	Waist circumference;Weight;
LUSC	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg01528321	chr10:82214614	TSPAN14	-0.9	-13.51	-0.59	1.77e-33	Post bronchodilator FEV1;
LUSC	trans	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg06521331	chr12:34319734	NA	-0.4	-6.16	-0.32	2.09e-9	Bladder cancer;
LUSC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.15	-0.32	2.16e-9	Total body bone mineral density;
LUSC	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg12483005	chr1:23474871	LUZP1	-0.47	-7.44	-0.38	8.82e-13	Height;
LUSC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	8.21	0.41	4.78e-15	Iron status biomarkers;
LUSC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg00343986	chr7:65444356	GUSB	0.46	6.79	0.35	5.07e-11	Aortic root size;
LUSC	cis	rs7586879	0.609	rs7608976	chr2:25075281	G/A	cg15423357	chr2:25149977	NA	0.33	6.42	0.33	4.57e-10	Body mass index;
LUSC	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.38	0.53	1.44e-25	Coffee consumption (cups per day);
LUSC	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-10.87	-0.51	9.13e-24	Heart rate;
LUSC	cis	rs7605827	0.897	rs11885852	chr2:15515371	A/C	cg19274914	chr2:15703543	NA	0.47	9.05	0.44	1.19e-17	Educational attainment (years of education);
LUSC	cis	rs600626	0.636	rs11236516	chr11:75451668	C/T	cg24262691	chr11:75473276	NA	-0.54	-6.9	-0.35	2.63e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs1941023	0.584	rs2014121	chr11:60156297	T/C	cg08716584	chr11:60157161	MS4A7	-0.65	-12.38	-0.56	3.12e-29	Congenital heart disease (maternal effect);
LUSC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-7.95	-0.4	2.87e-14	Major depressive disorder;
LUSC	cis	rs7809950	1.000	rs7786801	chr7:107085889	C/T	cg23024343	chr7:107201750	COG5	-0.56	-8.86	-0.44	4.92e-17	Coronary artery disease;
LUSC	cis	rs7193541	0.965	rs7184423	chr16:74709737	C/A	cg01733217	chr16:74700730	RFWD3	0.87	14.86	0.63	1.09e-38	Multiple myeloma;
LUSC	cis	rs17621444	0.522	rs4288683	chr10:121814553	C/T	cg02041677	chr10:121771263	NA	-0.33	-6.31	-0.33	8.94e-10	IgG glycosylation;
LUSC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg15557168	chr22:42548783	NA	-0.42	-6.26	-0.32	1.17e-9	Schizophrenia;
LUSC	cis	rs926938	0.527	rs360667	chr1:115481451	C/G	cg12756093	chr1:115239321	AMPD1	-0.45	-6.84	-0.35	3.89e-11	Autism;
LUSC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14829155	chr15:31115871	NA	0.71	10.81	0.51	1.49e-23	Huntington's disease progression;
LUSC	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-14.09	-0.61	1.04e-35	Exhaled nitric oxide output;
LUSC	cis	rs9653442	0.564	rs10175599	chr2:100787635	C/T	cg07810366	chr2:100720526	AFF3	-0.43	-7.28	-0.37	2.43e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6424115	0.708	rs34570472	chr1:24191720	A/G	cg15997130	chr1:24165203	NA	-0.48	-7.17	-0.37	4.82e-12	Immature fraction of reticulocytes;
LUSC	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg03929089	chr4:120376271	NA	-0.55	-6.81	-0.35	4.54e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07677032	chr17:61819896	STRADA	0.54	8.95	0.44	2.46e-17	Prudent dietary pattern;
LUSC	trans	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg26043149	chr18:55253948	FECH	-0.45	-7.02	-0.36	1.23e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs16949788	1.000	rs74521803	chr15:66832261	T/G	cg08120210	chr15:66682733	MAP2K1	-0.61	-6.28	-0.33	1.04e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.28	-0.59	1.35e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg21361702	chr7:150065534	REPIN1	0.48	6.24	0.32	1.35e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg20920097	chr3:127057149	NA	-0.45	-6.4	-0.33	5.4e-10	Interleukin-10 levels;Interleukin-13 levels;
LUSC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg16339924	chr4:17578868	LAP3	0.57	8.63	0.43	2.51e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg16362232	chr11:430036	ANO9	0.73	9.04	0.44	1.27e-17	Body mass index;
LUSC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.82	0.6	1.14e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs9886428	1.000	rs2059671	chr8:14116229	C/G	cg11959399	chr20:741723	C20orf54	-0.4	-6.45	-0.33	3.98e-10	IgG glycosylation;
LUSC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg21951975	chr1:209979733	IRF6	0.59	7.89	0.4	4.46e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs78707713	0.560	rs61848398	chr10:71226103	G/A	cg14388049	chr10:71211838	TSPAN15	-0.32	-5.82	-0.3	1.35e-8	Venous thromboembolism;
LUSC	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg14581129	chr12:53358946	NA	-0.34	-5.64	-0.3	3.56e-8	Cancer (pleiotropy);
LUSC	cis	rs859767	0.519	rs6707326	chr2:135357705	G/A	cg12500956	chr2:135428796	TMEM163	-0.26	-6.13	-0.32	2.54e-9	Neuroticism;
LUSC	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-7.09	-0.36	8.29e-12	Homocysteine levels;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg16688031	chr5:139091012	NA	0.37	6.16	0.32	2.04e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg03146154	chr1:46216737	IPP	-0.5	-7.15	-0.36	5.41e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.06	16.59	0.67	1.7e-45	Exhaled nitric oxide output;
LUSC	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg12863693	chr15:85201151	NMB	-0.36	-7.4	-0.38	1.11e-12	Schizophrenia;
LUSC	cis	rs3764021	0.870	rs11052710	chr12:9876350	C/T	cg20894963	chr12:9885564	CLECL1	0.34	7.06	0.36	9.92e-12	Type 1 diabetes;
LUSC	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg16262614	chr3:133464971	TF	0.42	7.19	0.37	4.31e-12	Iron status biomarkers (transferrin levels);
LUSC	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.74	-11.82	-0.54	3.48e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs11039798	0.841	rs7294179	chr11:48765408	G/A	cg15704280	chr7:45808275	SEPT13	0.85	7.23	0.37	3.39e-12	Axial length;
LUSC	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26384229	chr12:38710491	ALG10B	0.9	15.57	0.65	1.71e-41	Morning vs. evening chronotype;
LUSC	cis	rs17490626	0.568	rs2033371	chr10:71212310	G/A	cg14388049	chr10:71211838	TSPAN15	-0.33	-6.07	-0.32	3.56e-9	Thrombosis;
LUSC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg13939156	chr17:80058883	NA	-0.34	-6.68	-0.34	9.9e-11	Life satisfaction;
LUSC	trans	rs72674100	1.000	rs7689769	chr4:97968142	G/A	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.57	-8.59	-0.43	3.4e-16	Obesity-related traits;
LUSC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	0.83	13.62	0.6	6.85e-34	Menopause (age at onset);
LUSC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg15605315	chr1:45957053	TESK2	0.46	7.54	0.38	4.53e-13	High light scatter reticulocyte count;
LUSC	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.2	-0.32	1.65e-9	Sudden cardiac arrest;
LUSC	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg00277334	chr10:82204260	NA	0.45	6.55	0.34	2.16e-10	Post bronchodilator FEV1;
LUSC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg12927641	chr6:109611667	NA	-0.43	-7.49	-0.38	6.13e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.96	0.55	1.14e-27	Personality dimensions;
LUSC	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-8.04	-0.4	1.62e-14	Morning vs. evening chronotype;
LUSC	cis	rs2285947	1.000	rs2285949	chr7:21584243	G/A	cg04471919	chr7:21584483	DNAH11	0.34	7.73	0.39	1.29e-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	trans	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.41	-0.33	5.05e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs11018904	0.906	rs35129016	chr11:89948689	T/C	cg26138821	chr11:89956704	CHORDC1	-0.59	-6.82	-0.35	4.4e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg13397359	chr6:42928475	GNMT	0.65	11.11	0.52	1.29e-24	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg03036452	chr22:46663545	TTC38	0.53	5.78	0.3	1.72e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg13385521	chr17:29058706	SUZ12P	0.65	6.26	0.32	1.18e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7424096	0.613	rs72873859	chr2:37246738	T/G	cg14987922	chr2:37194071	STRN	0.63	8.51	0.42	6.03e-16	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs911119	0.955	rs6048952	chr20:23607257	A/G	cg16589663	chr20:23618590	CST3	0.57	6.86	0.35	3.3e-11	Chronic kidney disease;
LUSC	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.97	22.28	0.77	5.14e-68	Longevity;
LUSC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	8.88	0.44	4.25e-17	Prudent dietary pattern;
LUSC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.6	0.47	1.97e-19	Bipolar disorder;
LUSC	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg04310649	chr10:35416472	CREM	0.37	5.73	0.3	2.22e-8	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.64	10.93	0.51	5.65e-24	Bone mineral density;
LUSC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg11752832	chr7:134001865	SLC35B4	0.53	8.17	0.41	6.6e-15	Mean platelet volume;
LUSC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.59	9.13	0.45	6.81e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.46	6.6	0.34	1.63e-10	Systemic lupus erythematosus;
LUSC	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.42	6.46	0.33	3.68e-10	Dupuytren's disease;
LUSC	cis	rs1160297	0.609	rs10167421	chr2:53096163	G/C	cg07782112	chr2:53107842	NA	0.43	6.99	0.36	1.51e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.63	-8.53	-0.42	5.08e-16	Body mass index;
LUSC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg21573476	chr21:45109991	RRP1B	-0.41	-6.66	-0.34	1.11e-10	Mean corpuscular volume;
LUSC	cis	rs7193541	0.965	rs28616016	chr16:74676964	T/C	cg01733217	chr16:74700730	RFWD3	0.87	15.57	0.65	1.79e-41	Multiple myeloma;
LUSC	cis	rs701145	0.537	rs1713815	chr3:153872445	T/C	cg17054900	chr3:154042577	DHX36	0.56	5.7	0.3	2.6e-8	Coronary artery disease;
LUSC	cis	rs9948	0.655	rs2280356	chr2:97366324	C/T	cg01990225	chr2:97406019	LMAN2L	1.03	7.95	0.4	2.9e-14	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs701145	0.556	rs355758	chr3:154007682	C/G	cg10247383	chr3:153839028	SGEF	0.51	6.39	0.33	5.62e-10	Coronary artery disease;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	1.02	24.54	0.8	9.61e-77	Menarche (age at onset);
LUSC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg10547527	chr2:198650123	BOLL	-0.49	-5.79	-0.3	1.65e-8	Ulcerative colitis;
LUSC	cis	rs10875746	0.951	rs10875756	chr12:48562304	C/T	cg13454099	chr12:49076203	C12orf41	-0.5	-5.92	-0.31	8.18e-9	Longevity (90 years and older);
LUSC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg15147215	chr3:52552868	STAB1	-0.33	-6.45	-0.33	3.88e-10	Electroencephalogram traits;
LUSC	cis	rs2769264	1.000	rs6684085	chr1:151357333	C/T	cg18801370	chr1:151430492	POGZ	-0.59	-7.63	-0.39	2.56e-13	Blood trace element (Cu levels);
LUSC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg13699009	chr12:122356056	WDR66	-0.47	-7.4	-0.38	1.08e-12	Mean corpuscular volume;
LUSC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08677398	chr8:58056175	NA	0.45	6.41	0.33	5.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.4	-5.98	-0.31	5.86e-9	Platelet count;
LUSC	trans	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg10756647	chr7:56101905	PSPH	0.86	8.39	0.42	1.36e-15	Diabetic kidney disease;
LUSC	trans	rs1486139	0.935	rs9639951	chr7:46282898	T/C	cg17534202	chr9:96721102	NA	-0.37	-6.56	-0.34	2e-10	Select biomarker traits;
LUSC	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.91	17.8	0.7	2.62e-50	Body mass index (adult);
LUSC	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.74	-0.39	1.21e-13	Retinal vascular caliber;
LUSC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg02380750	chr20:61661411	NA	0.33	5.73	0.3	2.23e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	0.93	16.11	0.66	1.32e-43	Menopause (age at onset);
LUSC	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg18064842	chr5:14874549	NA	0.36	5.78	0.3	1.75e-8	Blood metabolite levels;
LUSC	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.82	0.51	1.39e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg17143192	chr8:8559678	CLDN23	0.6	8.25	0.41	3.65e-15	Obesity-related traits;
LUSC	cis	rs77633900	0.614	rs2439992	chr15:76863023	T/G	cg21673338	chr15:77095150	SCAPER	-0.73	-7.47	-0.38	6.86e-13	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs12210905	1.000	rs7756481	chr6:27115069	G/C	cg11502198	chr6:26597334	ABT1	-0.78	-5.65	-0.3	3.46e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg11843238	chr5:131593191	PDLIM4	0.38	7.0	0.36	1.45e-11	Blood metabolite levels;
LUSC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.89	13.88	0.6	6.48e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.6	0.38	3.1e-13	Iron status biomarkers;
LUSC	cis	rs55728055	0.661	rs62237775	chr22:31965401	A/G	cg01338084	chr22:32026380	PISD	0.93	6.77	0.35	5.67e-11	Age-related hearing impairment;
LUSC	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.26	-0.37	2.65e-12	Bipolar disorder;
LUSC	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg15798862	chr7:76129360	DTX2	-0.51	-8.54	-0.42	4.77e-16	Multiple sclerosis;
LUSC	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg24296786	chr1:45957014	TESK2	-0.52	-8.1	-0.41	1.06e-14	High light scatter reticulocyte count;
LUSC	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21659725	chr3:3221576	CRBN	-0.62	-10.33	-0.49	7e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg04058563	chr4:185651563	MLF1IP	-0.79	-11.92	-0.55	1.5e-27	Blood protein levels;
LUSC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg23788917	chr6:8435910	SLC35B3	-0.52	-7.67	-0.39	1.94e-13	Motion sickness;
LUSC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-6.75	-0.35	6.49e-11	Platelet count;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg25703541	chr22:24373054	LOC391322	-0.89	-14.74	-0.63	3.15e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.12	0.58	5.41e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	14.38	0.62	7.96e-37	Gut microbiome composition (summer);
LUSC	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.84	-0.51	1.2e-23	Glomerular filtration rate;
LUSC	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg08847533	chr14:75593920	NEK9	0.81	14.66	0.63	6.35e-38	Height;
LUSC	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg18721089	chr20:30220636	NA	-0.44	-7.03	-0.36	1.15e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs1178968	0.901	rs9784947	chr7:72748888	C/G	cg25889504	chr7:72793014	NA	0.58	7.53	0.38	4.84e-13	Triglyceride levels;
LUSC	cis	rs13082711	0.595	rs1445114	chr3:27345489	C/A	cg02860705	chr3:27208620	NA	0.73	11.6	0.54	2.24e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg22823121	chr1:150693482	HORMAD1	0.51	7.47	0.38	7.01e-13	Melanoma;
LUSC	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg00191853	chr8:101177733	SPAG1	-0.39	-6.49	-0.33	3.19e-10	Atrioventricular conduction;
LUSC	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg27489772	chr12:121021490	NA	0.56	7.5	0.38	5.82e-13	Type 1 diabetes nephropathy;
LUSC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03517284	chr6:25882590	NA	0.39	6.63	0.34	1.37e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg04576048	chr1:205797593	PM20D1	0.35	6.14	0.32	2.31e-9	Menarche (age at onset);
LUSC	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg27094323	chr7:1216898	NA	-0.49	-8.23	-0.41	4.36e-15	Longevity;Endometriosis;
LUSC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.78	0.3	1.71e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2153535	0.869	rs11962457	chr6:8375855	A/T	cg21535247	chr6:8435926	SLC35B3	-0.45	-6.48	-0.33	3.28e-10	Motion sickness;
LUSC	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg22782873	chr19:19639568	YJEFN3	-0.48	-5.93	-0.31	7.37e-9	Bipolar disorder;
LUSC	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg23992470	chr4:843637	GAK	0.6	6.43	0.33	4.53e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg21775007	chr8:11205619	TDH	0.41	5.74	0.3	2.08e-8	Systolic blood pressure;
LUSC	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg13010199	chr12:38710504	ALG10B	0.65	10.13	0.48	3.32e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg16482183	chr6:26056742	HIST1H1C	0.58	8.02	0.4	1.86e-14	Iron status biomarkers;
LUSC	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg22709100	chr7:91322751	NA	-0.4	-5.92	-0.31	7.94e-9	Breast cancer;
LUSC	cis	rs2625529	0.526	rs16956623	chr15:72536695	T/C	cg16672083	chr15:72433130	SENP8	0.47	7.84	0.39	5.96e-14	Red blood cell count;
LUSC	trans	rs2736337	0.532	rs6998387	chr8:11293458	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	6.24	0.32	1.33e-9	Rheumatoid arthritis;
LUSC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.52	0.57	9.28e-30	Motion sickness;
LUSC	cis	rs10887741	0.646	rs11202502	chr10:89437933	C/T	cg13926569	chr10:89418898	PAPSS2	0.28	6.03	0.31	4.44e-9	Exercise (leisure time);
LUSC	cis	rs6942756	0.806	rs2566877	chr7:128897317	G/A	cg02491457	chr7:128862824	NA	0.51	7.59	0.38	3.18e-13	White matter hyperintensity burden;
LUSC	cis	rs5770917	1.000	rs12627787	chr22:51012381	C/T	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.59	-5.69	-0.3	2.84e-8	Narcolepsy;
LUSC	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg21775007	chr8:11205619	TDH	-0.65	-10.26	-0.49	1.22e-21	Retinal vascular caliber;
LUSC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg15448220	chr1:150897856	SETDB1	0.38	5.69	0.3	2.84e-8	Tonsillectomy;
LUSC	cis	rs2078087	0.522	rs3768593	chr1:183212548	G/T	cg13843938	chr1:183241246	NMNAT2	-0.4	-6.35	-0.33	6.91e-10	Obesity-related traits;
LUSC	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg26816564	chr1:7831052	VAMP3	0.71	9.66	0.47	1.23e-19	Inflammatory bowel disease;
LUSC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.61	-10.47	-0.5	2.29e-22	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs72772090	0.634	rs72773906	chr5:96092274	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.74	-8.36	-0.42	1.74e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg01620082	chr3:125678407	NA	-0.76	-6.58	-0.34	1.86e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	10.3	0.49	8.73e-22	Eye color traits;
LUSC	trans	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	9.93	0.48	1.61e-20	Mean corpuscular volume;
LUSC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg06740227	chr12:86229804	RASSF9	0.43	6.61	0.34	1.48e-10	Major depressive disorder;
LUSC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg18477163	chr1:228402036	OBSCN	0.63	12.33	0.56	4.77e-29	Diastolic blood pressure;
LUSC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg23719950	chr11:63933701	MACROD1	-0.39	-6.12	-0.32	2.58e-9	Platelet count;
LUSC	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg03929089	chr4:120376271	NA	0.51	6.17	0.32	1.98e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs731174	0.797	rs510208	chr1:38147166	A/G	cg14170840	chr1:38155120	C1orf109	-0.38	-6.12	-0.32	2.64e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.78	-0.51	1.91e-23	Glomerular filtration rate;
LUSC	cis	rs9463078	0.764	rs10948194	chr6:44951990	A/C	cg25276700	chr6:44698697	NA	-0.29	-5.85	-0.3	1.16e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-6.89	-0.35	2.72e-11	Neuroticism;
LUSC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.69	11.46	0.53	7.01e-26	Heart rate;
LUSC	cis	rs5758511	0.573	rs2267439	chr22:42237769	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-7.53	-0.38	4.88e-13	Birth weight;
LUSC	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-9.84	-0.47	3.09e-20	Schizophrenia;
LUSC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg14552801	chr7:65878734	NA	-0.43	-6.19	-0.32	1.73e-9	Aortic root size;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17738503	chr17:49244158	NME2;NME1-NME2	-0.51	-6.64	-0.34	1.29e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.12	-0.45	7.26e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg24130564	chr14:104152367	KLC1	-0.45	-6.29	-0.33	9.95e-10	Body mass index;
LUSC	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.26	-0.37	2.78e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10740039	0.810	rs10821800	chr10:62367570	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.87	-0.35	3.12e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg27661571	chr11:113659931	NA	-0.67	-7.72	-0.39	1.4e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.73	-0.35	7.4e-11	Lung cancer;
LUSC	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs13082711	0.911	rs13082777	chr3:27421942	A/G	cg02860705	chr3:27208620	NA	0.49	8.36	0.42	1.76e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg27170947	chr2:26402098	FAM59B	0.72	10.79	0.51	1.8e-23	Gut microbiome composition (summer);
LUSC	cis	rs3737883	1.000	rs2275354	chr1:203036757	T/C	cg00805880	chr1:203045044	PPFIA4	-0.28	-5.7	-0.3	2.7e-8	Early onset atrial fibrillation;
LUSC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg04546413	chr19:29218101	NA	0.56	7.75	0.39	1.08e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg05941027	chr17:61774174	LIMD2	0.23	6.13	0.32	2.52e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg21724239	chr8:58056113	NA	0.56	6.9	0.35	2.7e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg20129853	chr10:51489980	NA	-0.32	-6.4	-0.33	5.23e-10	Prostate-specific antigen levels;
LUSC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg20744362	chr22:50050164	C22orf34	0.4	8.23	0.41	4.3e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.77	-13.54	-0.6	1.3e-33	Cognitive function;
LUSC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06634786	chr22:41940651	POLR3H	0.51	5.87	0.31	1.04e-8	Vitiligo;
LUSC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08677398	chr8:58056175	NA	-0.5	-6.24	-0.32	1.33e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg19875535	chr5:140030758	IK	-0.55	-9.1	-0.45	8.22e-18	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg18904891	chr8:8559673	CLDN23	-0.61	-8.65	-0.43	2.23e-16	Obesity-related traits;
LUSC	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.83	-0.35	3.92e-11	Triglycerides;
LUSC	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.69	-0.34	9.66e-11	Neuroticism;
LUSC	cis	rs10740039	0.846	rs2165690	chr10:62399367	T/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg24562669	chr7:97807699	LMTK2	-0.39	-6.32	-0.33	8.25e-10	Breast cancer;
LUSC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24110177	chr3:50126178	RBM5	-0.57	-9.59	-0.46	2.2e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs7193541	1.000	rs7193541	chr16:74664743	C/T	cg01733217	chr16:74700730	RFWD3	-0.83	-14.89	-0.63	8.15e-39	Multiple myeloma;
LUSC	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg24375607	chr4:120327624	NA	0.66	10.52	0.5	1.48e-22	Corneal astigmatism;
LUSC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg21475434	chr5:93447410	FAM172A	0.62	8.54	0.42	4.8e-16	Diabetic retinopathy;
LUSC	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg26977086	chr12:132329805	MMP17	-0.27	-6.13	-0.32	2.45e-9	Migraine;
LUSC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.87	-14.47	-0.62	3.38e-37	Menarche (age at onset);
LUSC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg00049323	chr5:472564	LOC25845	-0.44	-6.86	-0.35	3.27e-11	Cystic fibrosis severity;
LUSC	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg04310649	chr10:35416472	CREM	-0.43	-6.64	-0.34	1.29e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4974559	0.739	rs1250121	chr4:1263521	A/G	cg02980000	chr4:1222292	CTBP1	-0.99	-9.46	-0.46	5.57e-19	Systolic blood pressure;
LUSC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	trans	rs13011075	0.919	rs2241946	chr2:68615654	T/C	cg14221825	chr19:46271408	SIX5	0.44	6.32	0.33	8.52e-10	Mean corpuscular volume;
LUSC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg02269571	chr22:50332266	NA	-0.55	-8.2	-0.41	5.16e-15	Schizophrenia;
LUSC	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg11584989	chr19:19387371	SF4	0.52	6.29	0.33	9.89e-10	Bipolar disorder;
LUSC	cis	rs62400317	0.731	rs12214435	chr6:44906717	G/A	cg20913747	chr6:44695427	NA	-0.48	-7.4	-0.38	1.08e-12	Total body bone mineral density;
LUSC	cis	rs62400317	0.859	rs12193720	chr6:45103362	A/G	cg18551225	chr6:44695536	NA	-0.42	-6.95	-0.36	1.93e-11	Total body bone mineral density;
LUSC	cis	rs6087990	0.806	rs4911254	chr20:31357579	C/A	cg13636640	chr20:31349939	DNMT3B	1.01	23.33	0.79	4.32e-72	Ulcerative colitis;
LUSC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-0.82	-11.55	-0.53	3.56e-26	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg23229984	chr5:148520753	ABLIM3	0.4	6.41	0.33	4.85e-10	Breast cancer;
LUSC	cis	rs7212590	0.655	rs8070039	chr17:57973585	G/C	cg10252138	chr17:58120427	NA	-0.78	-7.19	-0.37	4.2e-12	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg11861562	chr11:117069780	TAGLN	0.34	6.59	0.34	1.75e-10	Blood protein levels;
LUSC	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg00277334	chr10:82204260	NA	-0.52	-7.08	-0.36	8.7e-12	Post bronchodilator FEV1;
LUSC	cis	rs4073416	0.518	rs7157109	chr14:65900433	C/G	cg03016385	chr14:66212404	NA	-0.39	-5.85	-0.3	1.19e-8	N-glycan levels;
LUSC	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg25208724	chr1:156163844	SLC25A44	0.82	6.53	0.34	2.48e-10	Paclitaxel disposition in epithelial ovarian cancer;
LUSC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.73	-0.3	2.25e-8	Depression;
LUSC	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg12002119	chr2:101014098	CHST10	0.34	5.7	0.3	2.62e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.73	10.34	0.49	6.35e-22	Migraine;Coronary artery disease;
LUSC	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg05110241	chr16:68378359	PRMT7	-0.64	-6.99	-0.36	1.46e-11	Schizophrenia;
LUSC	trans	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04565464	chr8:145669602	NFKBIL2	0.37	5.99	0.31	5.49e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs28595532	0.702	rs72670238	chr4:119322751	C/T	cg21605333	chr4:119757512	SEC24D	1.03	8.59	0.43	3.38e-16	Cannabis dependence symptom count;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10896623	chr1:19923370	C1orf151	0.46	6.08	0.32	3.28e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2637266	0.783	rs58247832	chr10:78471383	C/A	cg18941641	chr10:78392320	NA	0.35	6.25	0.32	1.25e-9	Pulmonary function;
LUSC	cis	rs921665	0.831	rs11688404	chr2:3188755	C/T	cg16434511	chr2:3151078	NA	-0.6	-6.8	-0.35	4.76e-11	World class endurance athleticism;
LUSC	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	1.1	15.67	0.65	7.18e-42	Uric acid levels;
LUSC	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg00579200	chr11:133705235	NA	-0.38	-5.93	-0.31	7.58e-9	Childhood ear infection;
LUSC	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg25922239	chr6:33757077	LEMD2	0.55	8.27	0.41	3.25e-15	Crohn's disease;
LUSC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg15468180	chr1:107600409	PRMT6	-0.39	-6.14	-0.32	2.37e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg04362960	chr10:104952993	NT5C2	0.59	9.35	0.46	1.34e-18	Arsenic metabolism;
LUSC	cis	rs1953600	0.540	rs2784773	chr10:81919800	A/G	cg00277334	chr10:82204260	NA	-0.47	-6.95	-0.36	1.98e-11	Sarcoidosis;
LUSC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg24675658	chr1:53192096	ZYG11B	0.59	9.22	0.45	3.51e-18	Monocyte count;
LUSC	trans	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg02030672	chr11:45687055	CHST1	-0.44	-6.75	-0.35	6.38e-11	Obesity-related traits;
LUSC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.5	6.84	0.35	3.84e-11	Cognitive ability;
LUSC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg04414720	chr1:150670196	GOLPH3L	0.53	8.47	0.42	7.75e-16	Tonsillectomy;
LUSC	cis	rs11630290	0.589	rs1396710	chr15:64168461	C/G	cg12036633	chr15:63758958	NA	0.48	5.98	0.31	5.6e-9	Iris characteristics;
LUSC	cis	rs11997175	0.646	rs55898196	chr8:33765862	A/G	ch.8.33884649F	chr8:33765107	NA	0.53	8.29	0.41	2.89e-15	Body mass index;
LUSC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg26335602	chr6:28129616	ZNF389	0.43	5.74	0.3	2.17e-8	Depression;
LUSC	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.21	-0.37	3.87e-12	Bipolar disorder;
LUSC	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.93	0.35	2.12e-11	Height;
LUSC	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.69	-8.83	-0.43	6.15e-17	Multiple sclerosis;
LUSC	trans	rs2055729	0.645	rs12056944	chr8:9742525	C/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.07	0.32	3.42e-9	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs7178375	1.000	rs7178533	chr15:31215976	C/G	cg04373760	chr16:53404718	NA	0.65	8.9	0.44	3.67e-17	Hypertriglyceridemia;
LUSC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg22532475	chr10:104410764	TRIM8	0.3	5.97	0.31	6.17e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.3	-0.37	2.1e-12	Bipolar disorder;
LUSC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.89	0.31	9.6e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg17366294	chr4:99064904	C4orf37	0.57	10.12	0.48	3.52e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9868809	0.881	rs13324142	chr3:48669447	C/T	cg00383909	chr3:49044727	WDR6	1.01	9.87	0.48	2.43e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25852545	chr3:113775465	KIAA1407;QTRTD1	-0.43	-6.59	-0.34	1.68e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	1.04	18.79	0.72	2.9e-54	Parkinson's disease;
LUSC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-6.16	-0.32	2.06e-9	Total body bone mineral density;
LUSC	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.56	0.46	2.6e-19	Lung cancer in ever smokers;
LUSC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg12163867	chr12:51592794	POU6F1	-0.61	-10.84	-0.51	1.17e-23	Cisplatin-induced ototoxicity;
LUSC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg18190219	chr22:46762943	CELSR1	-0.48	-6.0	-0.31	5.03e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg18721089	chr20:30220636	NA	-0.41	-6.57	-0.34	1.93e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs59698941	0.943	rs66732439	chr5:132234702	A/G	cg02081065	chr5:132209139	LEAP2	-0.65	-6.85	-0.35	3.55e-11	Apolipoprotein A-IV levels;
LUSC	trans	rs4714291	0.802	rs3008833	chr6:39986303	G/A	cg02267698	chr19:7991119	CTXN1	-0.53	-7.85	-0.39	5.68e-14	Strep throat;
LUSC	cis	rs1595825	0.891	rs114426561	chr2:198698891	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-5.94	-0.31	7.2e-9	Ulcerative colitis;
LUSC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg11189052	chr15:85197271	WDR73	-0.66	-10.13	-0.48	3.38e-21	P wave terminal force;
LUSC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg20573242	chr4:122745356	CCNA2	0.43	6.5	0.33	3e-10	Type 2 diabetes;
LUSC	cis	rs113835537	0.529	rs11227510	chr11:66281220	T/C	cg24851651	chr11:66362959	CCS	0.53	7.93	0.4	3.42e-14	Airway imaging phenotypes;
LUSC	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-6.39	-0.33	5.69e-10	Neutrophil percentage of white cells;
LUSC	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.44	-0.46	6.86e-19	Intelligence (multi-trait analysis);
LUSC	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.82	0.68	2.11e-46	Exhaled nitric oxide output;
LUSC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg14092988	chr3:52407081	DNAH1	0.32	6.01	0.31	4.95e-9	Bipolar disorder;
LUSC	cis	rs6087990	0.899	rs1883729	chr20:31363193	G/A	cg13636640	chr20:31349939	DNMT3B	1.0	22.63	0.78	2.14e-69	Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.83	12.08	0.55	3.96e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07677032	chr17:61819896	STRADA	0.52	8.61	0.43	2.91e-16	Prudent dietary pattern;
LUSC	trans	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg10840412	chr1:235813424	GNG4	0.53	6.26	0.32	1.15e-9	Neuroticism;
LUSC	cis	rs7605827	0.930	rs2010881	chr2:15624646	T/A	cg19274914	chr2:15703543	NA	0.46	8.82	0.43	6.51e-17	Educational attainment (years of education);
LUSC	cis	rs7589342	0.801	rs2889605	chr2:106525073	T/C	cg16077055	chr2:106428750	NCK2	0.35	6.53	0.34	2.48e-10	Addiction;
LUSC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.75	-0.35	6.69e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.58	-0.42	3.69e-16	Rheumatoid arthritis;
LUSC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.76	-11.86	-0.54	2.68e-27	Tonsillectomy;
LUSC	cis	rs2882667	0.898	rs4380651	chr5:138391072	A/G	cg04439458	chr5:138467593	SIL1	-0.41	-8.25	-0.41	3.8e-15	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs17655565	0.533	rs12301094	chr12:52707610	A/G	cg08257133	chr12:52711352	KRT83	0.42	9.06	0.44	1.09e-17	Plasma amyloid beta peptide concentrations (ABx-42);
LUSC	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.3	-5.78	-0.3	1.75e-8	Schizophrenia;
LUSC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg12963246	chr6:28129442	ZNF389	0.56	7.89	0.4	4.28e-14	Parkinson's disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06258179	chr7:92463261	CDK6	-0.42	-6.58	-0.34	1.79e-10	Electrocardiographic conduction measures;
LUSC	trans	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg19249749	chr1:223853145	CAPN8	-0.47	-5.95	-0.31	6.59e-9	Gut microbiome composition (summer);
LUSC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg17554472	chr22:41940697	POLR3H	-0.48	-5.77	-0.3	1.83e-8	Vitiligo;
LUSC	cis	rs9976767	0.608	rs9784208	chr21:43824986	A/G	cg20516845	chr21:43823604	UBASH3A	-0.25	-5.86	-0.31	1.08e-8	Type 1 diabetes;
LUSC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg02951883	chr7:2050386	MAD1L1	-0.47	-8.11	-0.41	9.71e-15	Schizophrenia;
LUSC	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21659725	chr3:3221576	CRBN	0.64	9.19	0.45	4.33e-18	Resting heart rate;
LUSC	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg09760422	chr2:128146352	NA	0.32	6.8	0.35	4.87e-11	Self-rated health;
LUSC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.05	0.4	1.43e-14	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg08999081	chr20:33150536	PIGU	-0.42	-7.69	-0.39	1.66e-13	Coronary artery disease;
LUSC	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	0.94	20.49	0.75	5.54e-61	Ulcerative colitis;
LUSC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg18904891	chr8:8559673	CLDN23	0.58	8.07	0.4	1.25e-14	Obesity-related traits;
LUSC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg07395648	chr5:131743802	NA	-0.42	-6.64	-0.34	1.28e-10	Breast cancer;Mosquito bite size;
LUSC	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	12.47	0.56	1.46e-29	Primary sclerosing cholangitis;
LUSC	cis	rs77741769	0.571	rs3883901	chr12:121256520	A/G	cg02419362	chr12:121203948	SPPL3	0.45	8.48	0.42	7.61e-16	Mean corpuscular volume;
LUSC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg02980000	chr4:1222292	CTBP1	-0.4	-5.93	-0.31	7.67e-9	Obesity-related traits;
LUSC	cis	rs7584330	0.554	rs74001384	chr2:238424530	T/C	cg16989719	chr2:238392110	NA	-0.4	-5.84	-0.3	1.27e-8	Prostate cancer;
LUSC	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.6	-0.34	1.66e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08677398	chr8:58056175	NA	0.52	6.01	0.31	4.78e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6554196	0.525	rs12499367	chr4:55505911	C/T	cg18836493	chr4:55524333	KIT	-0.43	-7.38	-0.37	1.29e-12	Monocyte count;
LUSC	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg18964960	chr10:1102726	WDR37	-0.51	-7.67	-0.39	1.93e-13	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg20891283	chr12:69753455	YEATS4	0.62	9.59	0.46	2.18e-19	Response to diuretic therapy;
LUSC	cis	rs7553864	0.614	rs1886634	chr1:87614821	C/T	cg17420885	chr1:87600446	LOC339524	0.49	6.79	0.35	4.99e-11	Smoking behavior;
LUSC	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.51	7.33	0.37	1.78e-12	Coronary heart disease;
LUSC	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg00321850	chr1:175162397	KIAA0040	-0.45	-7.79	-0.39	8.64e-14	Alcohol dependence;
LUSC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg07061783	chr6:25882402	NA	0.43	6.07	0.32	3.5e-9	Blood metabolite levels;
LUSC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21016266	chr12:122356598	WDR66	0.62	9.1	0.45	8.44e-18	Mean corpuscular volume;
LUSC	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg02466173	chr16:30829666	NA	-0.59	-10.83	-0.51	1.28e-23	Multiple myeloma;
LUSC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.32	0.56	5.27e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7180079	1.000	rs12903745	chr15:64632840	G/A	cg08069370	chr15:64387884	SNX1	0.55	5.99	0.31	5.37e-9	Monocyte count;
LUSC	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg05110241	chr16:68378359	PRMT7	-0.51	-6.15	-0.32	2.25e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg27094323	chr7:1216898	NA	-0.46	-8.14	-0.41	8.08e-15	Longevity;Endometriosis;
LUSC	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg11244672	chr19:19639970	YJEFN3	0.6	7.33	0.37	1.72e-12	Bipolar disorder;
LUSC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg02782426	chr3:40428986	ENTPD3	0.41	7.61	0.38	2.87e-13	Renal cell carcinoma;
LUSC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg01448562	chr3:133502909	NA	-0.66	-10.75	-0.51	2.4e-23	Iron status biomarkers;
LUSC	cis	rs55665837	1.000	rs11023214	chr11:14436259	G/C	cg05501817	chr11:14380813	RRAS2	-0.41	-6.73	-0.35	7.47e-11	Vitamin D levels;
LUSC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.21	-0.37	3.87e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg18200150	chr17:30822561	MYO1D	0.51	10.29	0.49	9.48e-22	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-10.34	-0.49	6.17e-22	Gut microbiome composition (summer);
LUSC	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.73	9.11	0.45	7.89e-18	Type 2 diabetes;
LUSC	cis	rs7903847	0.642	rs61863816	chr10:99128503	G/A	cg20016023	chr10:99160130	RRP12	-0.31	-6.49	-0.33	3.05e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg21775007	chr8:11205619	TDH	0.54	7.91	0.4	3.77e-14	Triglycerides;
LUSC	trans	rs587847	0.507	rs1379349	chr15:37809122	T/C	cg18296784	chr11:116147929	NA	-0.35	-6.31	-0.33	9.08e-10	Intraocular pressure;
LUSC	cis	rs6906287	0.537	rs13192336	chr6:118875162	A/T	cg21191810	chr6:118973309	C6orf204	0.33	6.04	0.31	4.16e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg04450456	chr4:17643702	FAM184B	0.37	6.28	0.33	1.03e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg13852791	chr20:30311386	BCL2L1	0.72	8.29	0.41	2.73e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg21918786	chr6:109611834	NA	-0.36	-6.06	-0.31	3.76e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg22815214	chr1:201083145	CACNA1S	-0.47	-6.68	-0.34	9.74e-11	Permanent tooth development;
LUSC	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg09904177	chr6:26538194	HMGN4	0.65	11.7	0.54	9.83e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs427941	0.609	rs4729776	chr7:101830064	A/G	cg06246474	chr7:101738831	CUX1	0.35	5.74	0.3	2.18e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05962382	chr2:130345044	NA	-0.35	-6.14	-0.32	2.28e-9	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg09555818	chr19:45449301	APOC2	0.44	8.18	0.41	5.99e-15	Blood protein levels;
LUSC	cis	rs9398803	0.865	rs9372840	chr6:126822635	A/C	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	2.02e-9	Male-pattern baldness;
LUSC	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg12311346	chr5:56204834	C5orf35	-0.64	-9.41	-0.46	8.57e-19	Coronary artery disease;
LUSC	cis	rs7168353	0.519	rs725458	chr15:93634933	A/G	cg02918577	chr15:93633145	RGMA	-0.32	-5.98	-0.31	5.89e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs1044826	0.642	rs2118981	chr3:139178853	A/G	cg15131784	chr3:139108705	COPB2	0.41	6.71	0.34	8.17e-11	Obesity-related traits;
LUSC	cis	rs12760731	0.565	rs12406779	chr1:178088936	C/G	cg00404053	chr1:178313656	RASAL2	0.67	6.7	0.34	8.81e-11	Obesity-related traits;
LUSC	cis	rs9487051	0.768	rs458740	chr6:109525527	C/T	cg00509249	chr6:109615579	CCDC162	-0.33	-5.73	-0.3	2.23e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs2625529	0.668	rs8192431	chr15:72492352	G/A	cg16672083	chr15:72433130	SENP8	-0.5	-7.36	-0.37	1.48e-12	Red blood cell count;
LUSC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.68	-11.14	-0.52	1.03e-24	Cognitive function;
LUSC	cis	rs4702	0.611	rs1894401	chr15:91429042	C/T	cg05469396	chr15:91419421	FURIN	0.46	8.21	0.41	4.95e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.01	-15.59	-0.65	1.42e-41	Primary sclerosing cholangitis;
LUSC	trans	rs17685	0.849	rs3815455	chr7:75611756	C/T	cg19862616	chr7:65841803	NCRNA00174	0.81	11.8	0.54	4.16e-27	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06544989	chr22:39130855	UNC84B	0.34	5.8	0.3	1.53e-8	Menopause (age at onset);
LUSC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg26338869	chr17:61819248	STRADA	0.41	5.9	0.31	8.95e-9	Prudent dietary pattern;
LUSC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	6.0	0.31	5.01e-9	Renal function-related traits (BUN);
LUSC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.71	10.7	0.51	3.64e-23	Aortic root size;
LUSC	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg19997662	chr15:101784653	CHSY1	-0.44	-6.4	-0.33	5.18e-10	Corneal structure;
LUSC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg09323728	chr8:95962352	TP53INP1	-0.38	-7.61	-0.38	2.79e-13	Type 2 diabetes;
LUSC	cis	rs11676348	0.808	rs4674261	chr2:219005009	G/C	cg00012203	chr2:219082015	ARPC2	-0.54	-8.23	-0.41	4.33e-15	Ulcerative colitis;
LUSC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.46	-6.07	-0.32	3.46e-9	Homoarginine levels;
LUSC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08045932	chr20:61659980	NA	0.59	10.36	0.49	5.39e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.45	0.56	1.78e-29	Prudent dietary pattern;
LUSC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.7	0.34	9.07e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	6.79	0.35	5.03e-11	Lung cancer;
LUSC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16680214	chr1:154839983	KCNN3	-0.51	-9.22	-0.45	3.54e-18	Prostate cancer;
LUSC	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg22089800	chr15:90895588	ZNF774	0.66	10.8	0.51	1.59e-23	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg18350739	chr11:68623251	NA	-0.37	-6.39	-0.33	5.69e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6142102	0.961	rs2300204	chr20:32588773	G/A	cg08999081	chr20:33150536	PIGU	0.35	5.92	0.31	8.15e-9	Skin pigmentation;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg15088822	chr5:140998632	DIAPH1	0.4	6.26	0.32	1.2e-9	Mosquito bite size;
LUSC	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg24375607	chr4:120327624	NA	0.77	12.56	0.57	6.5e-30	Corneal astigmatism;
LUSC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg13206674	chr6:150067644	NUP43	0.6	9.26	0.45	2.6e-18	Lung cancer;
LUSC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.65	0.76	1.42e-65	Prudent dietary pattern;
LUSC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.45	-0.33	3.89e-10	Blood metabolite levels;
LUSC	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs977987	0.843	rs60730309	chr16:75431769	C/G	cg03315344	chr16:75512273	CHST6	0.54	10.38	0.49	4.69e-22	Dupuytren's disease;
LUSC	cis	rs4629180	1.000	rs6744495	chr2:102099956	T/C	cg04415270	chr2:102091202	RFX8	-0.55	-8.67	-0.43	1.84e-16	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg09359103	chr1:154839909	KCNN3	0.55	10.83	0.51	1.28e-23	Prostate cancer;
LUSC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg20476274	chr7:133979776	SLC35B4	0.87	16.95	0.68	5.94e-47	Mean platelet volume;
LUSC	cis	rs72960926	0.744	rs6941436	chr6:74937191	C/T	cg03266952	chr6:74778945	NA	0.76	6.31	0.33	8.87e-10	Metabolite levels (MHPG);
LUSC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13770153	chr20:60521292	NA	-0.64	-8.62	-0.43	2.74e-16	Body mass index;
LUSC	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg06636001	chr8:8085503	FLJ10661	0.55	8.04	0.4	1.6e-14	Neuroticism;
LUSC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.01	-0.55	7.15e-28	Type 2 diabetes;
LUSC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg06028605	chr16:24865363	SLC5A11	0.49	8.49	0.42	6.67e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.45	-0.5	2.56e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17219203	chr10:38645113	HSD17B7P2	0.41	5.86	0.31	1.12e-8	Extrinsic epigenetic age acceleration;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg07638904	chr22:19166425	SLC25A1	0.42	6.16	0.32	2.07e-9	Mosquito bite size;
LUSC	trans	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04565464	chr8:145669602	NFKBIL2	0.38	6.08	0.32	3.2e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	0.41	6.69	0.34	9.52e-11	Resistin levels;
LUSC	cis	rs1577917	0.681	rs4348284	chr6:86350394	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.38	-5.99	-0.31	5.42e-9	Response to antipsychotic treatment;
LUSC	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg06207120	chr15:45996521	NA	0.39	6.04	0.31	4.12e-9	Waist circumference;Weight;
LUSC	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.03	-0.44	1.41e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg02466173	chr16:30829666	NA	0.56	11.25	0.52	4.18e-25	Dementia with Lewy bodies;
LUSC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.18	-0.32	1.86e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.71	12.54	0.57	8.17e-30	Prudent dietary pattern;
LUSC	cis	rs11153306	0.677	rs10872070	chr6:111921804	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.31	-5.88	-0.31	1.02e-8	Tonsillectomy;
LUSC	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg00898013	chr13:113819073	PROZ	-0.55	-7.85	-0.39	5.88e-14	Platelet distribution width;
LUSC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg18402987	chr7:1209562	NA	0.68	7.29	0.37	2.28e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11229555	0.645	rs10896785	chr11:58233395	G/A	cg15696309	chr11:58395628	NA	-0.71	-8.6	-0.43	3.11e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg22437258	chr11:111473054	SIK2	-0.48	-6.62	-0.34	1.44e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg00376283	chr12:123451042	ABCB9	0.8	12.14	0.55	2.4e-28	Platelet count;
LUSC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-0.58	-9.25	-0.45	2.84e-18	Breast cancer;
LUSC	cis	rs240768	1.000	rs3213542	chr6:100966006	C/T	cg12253828	chr6:101329408	ASCC3	0.78	5.69	0.3	2.72e-8	Economic and political preferences (immigration/crime);
LUSC	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg15556689	chr8:8085844	FLJ10661	0.44	5.65	0.3	3.37e-8	Obesity-related traits;
LUSC	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg22705602	chr4:152727874	NA	-0.27	-5.7	-0.3	2.68e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.93	-0.35	2.24e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	16.09	0.66	1.53e-43	Platelet count;
LUSC	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg16339924	chr4:17578868	LAP3	0.61	9.2	0.45	4.05e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg19257562	chr1:2043853	PRKCZ	0.32	6.28	0.32	1.07e-9	Height;
LUSC	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg17173187	chr15:85201210	NMB	0.48	8.78	0.43	8.71e-17	Schizophrenia;
LUSC	cis	rs1891275	0.508	rs2096079	chr10:93496667	C/G	cg07889827	chr10:93443413	NA	-0.41	-9.26	-0.45	2.58e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.14	-0.32	2.3e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2279817	0.863	rs1416854	chr1:18024675	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.47	6.47	0.33	3.5e-10	Neuroticism;
LUSC	cis	rs10203711	0.600	rs1810138	chr2:239561888	T/C	cg14580085	chr2:239553406	NA	0.41	6.96	0.36	1.79e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6977660	1.000	rs714238	chr7:19803925	C/T	cg05791153	chr7:19748676	TWISTNB	0.56	6.24	0.32	1.32e-9	Thyroid stimulating hormone;
LUSC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg13628971	chr7:2884303	GNA12	0.47	6.85	0.35	3.67e-11	Height;
LUSC	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg06609049	chr19:2785107	THOP1	1.15	22.29	0.77	4.43e-68	Total cholesterol levels;
LUSC	cis	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg21775007	chr8:11205619	TDH	-0.55	-7.2	-0.37	4.02e-12	Triglycerides;
LUSC	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg13010199	chr12:38710504	ALG10B	0.46	7.16	0.36	5.33e-12	Morning vs. evening chronotype;
LUSC	trans	rs11264799	0.765	rs6427389	chr1:157632011	C/A	cg25498969	chr3:136062740	STAG1	-0.24	-6.22	-0.32	1.47e-9	IgA nephropathy;
LUSC	cis	rs440932	1.000	rs378974	chr8:9026639	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	6.01	0.31	4.76e-9	High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg18187862	chr3:45730750	SACM1L	-0.53	-6.45	-0.33	3.92e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg17366294	chr4:99064904	C4orf37	0.55	9.77	0.47	5.18e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg17264618	chr3:40429014	ENTPD3	0.34	7.2	0.37	4.12e-12	Renal cell carcinoma;
LUSC	cis	rs713477	0.967	rs4901565	chr14:55912508	T/G	cg13175173	chr14:55914753	NA	-0.32	-6.78	-0.35	5.42e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs67539049	1.000	rs3021517	chr8:11295925	T/C	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.38	-5.77	-0.3	1.77e-8	Itch intensity from mosquito bite;
LUSC	cis	rs9503598	0.636	rs7745968	chr6:3467745	G/T	cg00476032	chr6:3446245	SLC22A23	0.31	6.03	0.31	4.28e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg06877462	chr1:205807181	PM20D1	0.5	9.04	0.44	1.26e-17	Menarche (age at onset);
LUSC	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.62	14.25	0.61	2.57e-36	Sense of smell;
LUSC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg13010199	chr12:38710504	ALG10B	0.7	10.74	0.51	2.65e-23	Bladder cancer;
LUSC	cis	rs722599	0.628	rs12896360	chr14:75278181	A/C	cg08847533	chr14:75593920	NEK9	0.44	6.23	0.32	1.41e-9	IgG glycosylation;
LUSC	cis	rs295140	0.605	rs3739119	chr2:201194279	C/A	cg23649088	chr2:200775458	C2orf69	-0.37	-5.67	-0.3	3.15e-8	QT interval;
LUSC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.01	-0.31	4.78e-9	Initial pursuit acceleration;
LUSC	trans	rs34546498	1	rs34546498	chr6:26961280	C/T	cg01620082	chr3:125678407	NA	-0.78	-6.6	-0.34	1.59e-10	Breast cancer;
LUSC	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg02931644	chr1:25747376	RHCE	0.34	6.19	0.32	1.81e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg02807482	chr3:125708958	NA	-0.5	-6.28	-0.32	1.07e-9	Blood pressure (smoking interaction);
LUSC	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg25237894	chr2:233734115	C2orf82	-0.33	-6.1	-0.32	2.94e-9	Coronary artery disease;
LUSC	trans	rs453301	0.653	rs7853	chr8:8890814	A/G	cg21775007	chr8:11205619	TDH	0.44	6.17	0.32	2.02e-9	Joint mobility (Beighton score);
LUSC	cis	rs3820928	0.845	rs1917126	chr2:227840923	G/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.41	-0.38	1.02e-12	Pulmonary function;
LUSC	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.3	0.45	1.88e-18	Blood protein levels;
LUSC	cis	rs11756438	0.572	rs2638544	chr6:119001978	G/A	cg18833306	chr6:118973337	C6orf204	0.36	5.75	0.3	2.04e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.64	-0.34	1.27e-10	Lung cancer;
LUSC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.29	0.37	2.24e-12	Motion sickness;
LUSC	cis	rs17433780	0.612	rs7911	chr1:89518120	A/G	cg09516651	chr1:89888402	LOC400759	0.59	11.68	0.54	1.16e-26	Carotid intima media thickness;
LUSC	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21659725	chr3:3221576	CRBN	0.61	9.99	0.48	9.76e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs12210905	0.688	rs72843151	chr6:27359268	A/C	cg08851530	chr6:28072375	NA	0.94	6.3	0.33	9.63e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg02549819	chr16:58548995	SETD6	0.96	9.01	0.44	1.62e-17	Schizophrenia;
LUSC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg05347473	chr6:146136440	FBXO30	0.58	10.13	0.48	3.28e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg13206674	chr6:150067644	NUP43	0.61	9.71	0.47	8.23e-20	Lung cancer;
LUSC	trans	rs2018683	0.691	rs4722881	chr7:29001560	A/G	cg19402173	chr7:128379420	CALU	0.52	8.21	0.41	4.97e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.27	0.45	2.37e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21862992	chr11:68658383	NA	0.5	7.95	0.4	2.85e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg16362232	chr11:430036	ANO9	0.6	7.9	0.4	3.97e-14	Body mass index;
LUSC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00149659	chr3:10157352	C3orf10	0.97	13.92	0.61	4.88e-35	Alzheimer's disease;
LUSC	trans	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg26043149	chr18:55253948	FECH	-0.45	-6.89	-0.35	2.86e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24833071	chr7:75115655	POM121C	-0.54	-7.06	-0.36	9.6e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs679087	1.000	rs436124	chr12:29916839	C/T	cg14258853	chr12:29935411	TMTC1	0.96	16.76	0.68	3.62e-46	Schizophrenia;
LUSC	cis	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg06521331	chr12:34319734	NA	-0.47	-7.63	-0.39	2.42e-13	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg23711669	chr6:146136114	FBXO30	-0.89	-16.93	-0.68	7.73e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg16482183	chr6:26056742	HIST1H1C	0.56	7.95	0.4	2.91e-14	Iron status biomarkers;
LUSC	trans	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.86	0.44	4.97e-17	Motion sickness;
LUSC	cis	rs11676855	0.927	rs4663180	chr2:235921195	A/G	cg14917874	chr2:235941519	SH3BP4	0.46	7.48	0.38	6.53e-13	Dialysis-related mortality;
LUSC	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg12927641	chr6:109611667	NA	-0.34	-5.77	-0.3	1.81e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs9547692	0.938	rs7333607	chr13:37462010	A/G	cg01034396	chr13:37494802	SMAD9	0.31	5.69	0.3	2.72e-8	Coronary artery disease;
LUSC	cis	rs4948102	0.595	rs7793921	chr7:56120881	G/A	cg17215666	chr7:56131930	SUMF2	0.44	5.96	0.31	6.26e-9	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.28	0.49	9.78e-22	Lung cancer in ever smokers;
LUSC	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	5.69	0.3	2.8e-8	Rheumatoid arthritis;
LUSC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg14092988	chr3:52407081	DNAH1	0.31	6.18	0.32	1.84e-9	Bipolar disorder;
LUSC	cis	rs1775715	0.870	rs1775735	chr10:32255846	A/G	cg26784012	chr10:32216390	ARHGAP12	0.4	6.45	0.33	3.85e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7315438	0.557	rs11067596	chr12:115873887	C/T	cg24172291	chr12:115889509	NA	-0.35	-5.93	-0.31	7.54e-9	Colorectal cancer;
LUSC	cis	rs62458065	0.513	rs10268803	chr7:32547835	A/G	cg20159608	chr7:32802032	NA	-0.7	-8.96	-0.44	2.41e-17	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg18402987	chr7:1209562	NA	0.74	7.93	0.4	3.36e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg13206674	chr6:150067644	NUP43	0.59	9.15	0.45	5.59e-18	Lung cancer;
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07157834	chr1:205819609	PM20D1	0.86	15.54	0.65	2.33e-41	Menarche (age at onset);
LUSC	cis	rs4654899	0.680	rs6692553	chr1:21221497	C/T	cg01072550	chr1:21505969	NA	0.5	7.56	0.38	3.95e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.52	10.44	0.5	2.89e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg18196295	chr10:418757	DIP2C	-0.41	-6.18	-0.32	1.88e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg17173187	chr15:85201210	NMB	0.36	5.88	0.31	9.91e-9	Schizophrenia;
LUSC	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg04362960	chr10:104952993	NT5C2	0.58	8.7	0.43	1.52e-16	Arsenic metabolism;
LUSC	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg12002119	chr2:101014098	CHST10	0.34	5.65	0.3	3.52e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg00376283	chr12:123451042	ABCB9	-0.66	-7.62	-0.39	2.56e-13	Neutrophil percentage of white cells;
LUSC	cis	rs12618769	0.597	rs55978998	chr2:99049014	A/G	cg10123293	chr2:99228465	UNC50	0.47	7.88	0.4	4.82e-14	Bipolar disorder;
LUSC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.19	-0.49	2.13e-21	Platelet count;
LUSC	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.43	5.68	0.3	2.88e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.65	-0.34	1.23e-10	Schizophrenia;
LUSC	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg08270630	chr22:50330655	NA	-0.44	-6.62	-0.34	1.43e-10	Schizophrenia;
LUSC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg27266027	chr21:40555129	PSMG1	-0.49	-7.35	-0.37	1.54e-12	Cognitive function;
LUSC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	0.91	18.48	0.71	5.16e-53	Dental caries;
LUSC	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-7.56	-0.38	3.93e-13	Atrioventricular conduction;
LUSC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg10167378	chr1:228756711	NA	0.76	9.72	0.47	8.12e-20	Chronic lymphocytic leukemia;
LUSC	cis	rs2425143	1.000	rs6060588	chr20:34337480	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.32	-0.33	8.4e-10	Blood protein levels;
LUSC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg09699651	chr6:150184138	LRP11	0.37	5.76	0.3	1.9e-8	Lung cancer;
LUSC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.94	0.36	2.05e-11	Cystic fibrosis severity;
LUSC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.73	-13.96	-0.61	3.32e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg18765753	chr7:1198926	ZFAND2A	0.35	6.15	0.32	2.22e-9	Longevity;Endometriosis;
LUSC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23221052	chr5:179740743	GFPT2	-0.56	-8.8	-0.43	7.69e-17	Height;
LUSC	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.2	0.52	6.39e-25	Eye color traits;
LUSC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg26924012	chr15:45694286	SPATA5L1	1.12	20.31	0.74	2.75e-60	Homoarginine levels;
LUSC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.25	-0.32	1.24e-9	Personality dimensions;
LUSC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-7.24	-0.37	3.19e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg10857441	chr5:6722123	POLS	-0.47	-9.23	-0.45	3.28e-18	Menopause (age at onset);
LUSC	cis	rs4363385	0.553	rs28924721	chr1:152974254	C/T	cg25856811	chr1:152973957	SPRR3	-0.36	-6.04	-0.31	4.02e-9	Inflammatory skin disease;
LUSC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg14552801	chr7:65878734	NA	-0.39	-6.05	-0.31	3.97e-9	Aortic root size;
LUSC	trans	rs17607347	0.542	rs12325151	chr16:72544825	C/T	cg12945194	chr11:64703312	GPHA2	0.37	6.14	0.32	2.36e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	11.97	0.55	1.05e-27	Nonalcoholic fatty liver disease;
LUSC	cis	rs7560272	0.695	rs10190002	chr2:73794054	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.11	-0.36	7.06e-12	Schizophrenia;
LUSC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg13939156	chr17:80058883	NA	0.34	6.53	0.34	2.42e-10	Life satisfaction;
LUSC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12825880	chr11:69455671	CCND1	0.44	6.11	0.32	2.85e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13972460	chr20:1165703	C20orf46	-0.44	-6.41	-0.33	4.98e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg18753928	chr3:113234510	CCDC52	-0.52	-8.01	-0.4	1.97e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	13.27	0.59	1.46e-32	Electrocardiographic conduction measures;
LUSC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	10.84	0.51	1.18e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2279817	0.780	rs11585339	chr1:18000120	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.77	-0.35	5.9e-11	Neuroticism;
LUSC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg22535103	chr8:58192502	C8orf71	-0.69	-7.61	-0.38	2.77e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12220238	1.000	rs2395077	chr10:75932001	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.88	0.35	2.97e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg14548925	chr7:105516956	ATXN7L1	0.43	5.98	0.31	5.69e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs2652822	0.615	rs7174466	chr15:63425019	A/C	cg05507819	chr15:63340323	TPM1	0.47	6.03	0.31	4.35e-9	Metabolic traits;
LUSC	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg14505434	chr11:89522851	NA	0.39	6.11	0.32	2.83e-9	White blood cell types;
LUSC	cis	rs701145	0.585	rs896013	chr3:153863873	A/G	cg17054900	chr3:154042577	DHX36	0.63	6.18	0.32	1.9e-9	Coronary artery disease;
LUSC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg24675658	chr1:53192096	ZYG11B	-0.55	-8.83	-0.44	5.91e-17	Monocyte count;
LUSC	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg00857998	chr1:205179979	DSTYK	0.61	9.25	0.45	2.78e-18	Red blood cell count;
LUSC	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg03929089	chr4:120376271	NA	-0.58	-7.49	-0.38	6.14e-13	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg26384229	chr12:38710491	ALG10B	0.71	11.27	0.52	3.42e-25	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.35	-0.46	1.31e-18	Chronic sinus infection;
LUSC	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg22601191	chr20:60968625	CABLES2	-0.37	-6.03	-0.31	4.33e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg26384229	chr12:38710491	ALG10B	0.58	8.76	0.43	1.03e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg12863693	chr15:85201151	NMB	0.39	8.05	0.4	1.49e-14	Schizophrenia;
LUSC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24110177	chr3:50126178	RBM5	0.64	10.89	0.51	7.98e-24	Body mass index;
LUSC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.63	-9.64	-0.47	1.46e-19	Menarche (age at onset);
LUSC	trans	rs717267	0.901	rs7026798	chr9:16427378	A/G	cg24331049	chr13:111365604	ING1	-0.39	-6.08	-0.32	3.25e-9	Gestational age at birth (maternal effect);
LUSC	trans	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg10840412	chr1:235813424	GNG4	-0.54	-7.54	-0.38	4.54e-13	Bipolar disorder;
LUSC	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg21153622	chr11:89784906	NA	-0.39	-6.0	-0.31	5.21e-9	HDL cholesterol;
LUSC	cis	rs72829446	0.530	rs4796420	chr17:7379617	A/T	cg02795151	chr17:7402630	POLR2A	0.53	6.45	0.33	4.01e-10	Androgen levels;
LUSC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.17	-0.32	1.95e-9	Total body bone mineral density;
LUSC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg11062466	chr8:58055876	NA	0.5	6.81	0.35	4.69e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.78	0.51	1.94e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21643547	chr1:205240462	TMCC2	-0.51	-9.46	-0.46	5.85e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.39	0.49	4.18e-22	Mean corpuscular volume;
LUSC	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg05182265	chr7:156933206	UBE3C	0.53	7.58	0.38	3.47e-13	Body mass index;
LUSC	cis	rs2835872	0.932	rs73222345	chr21:39036569	G/A	cg20424643	chr21:39039972	KCNJ6	0.5	7.55	0.38	4.17e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10862848	chr6:42927986	GNMT	-0.26	-6.37	-0.33	6.25e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7827545	1.000	rs62523736	chr8:135560916	A/T	cg17885191	chr8:135476712	NA	0.57	8.37	0.42	1.6e-15	Hypertension (SNP x SNP interaction);
LUSC	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg13010199	chr12:38710504	ALG10B	0.55	8.38	0.42	1.44e-15	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg22535103	chr8:58192502	C8orf71	-0.79	-8.22	-0.41	4.44e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.657	rs6107073	chr20:25716363	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.75	14.4	0.62	6.8e-37	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13089785	0.725	rs2222822	chr3:123604788	T/A	cg02012769	chr3:123398346	MYLK	0.36	6.4	0.33	5.33e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9653442	0.900	rs4851269	chr2:100830348	C/T	cg07810366	chr2:100720526	AFF3	0.45	7.95	0.4	2.86e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7705502	1.000	rs113932433	chr5:173357206	G/A	cg18693985	chr5:173351052	CPEB4	-0.37	-5.82	-0.3	1.35e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs7833986	0.534	rs72653924	chr8:56906088	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	10.98	0.51	3.87e-24	Height;
LUSC	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg12927641	chr6:109611667	NA	-0.35	-5.87	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs4722404	0.835	rs28458463	chr7:3139506	G/A	cg19214707	chr7:3157722	NA	0.33	6.11	0.32	2.83e-9	Atopic dermatitis;
LUSC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18404041	chr3:52824283	ITIH1	-0.6	-11.54	-0.53	3.65e-26	Bipolar disorder;
LUSC	cis	rs6076065	0.723	rs2424554	chr20:23415867	T/C	cg11657817	chr20:23433608	CST11	0.4	7.14	0.36	5.68e-12	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs7939886	0.920	rs12223248	chr11:55887633	A/C	cg15704280	chr7:45808275	SEPT13	0.83	6.94	0.36	2e-11	Myopia (pathological);
LUSC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	0.93	16.12	0.66	1.16e-43	Menopause (age at onset);
LUSC	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg13010344	chr12:123464640	ARL6IP4	-0.49	-7.96	-0.4	2.68e-14	Platelet count;
LUSC	trans	rs9380880	0.826	rs12198307	chr6:39550197	C/T	cg19893670	chr10:60097505	UBE2D1	0.65	5.96	0.31	6.24e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg23791538	chr6:167370224	RNASET2	0.41	6.7	0.34	8.84e-11	Crohn's disease;
LUSC	cis	rs877282	0.583	rs112372193	chr10:826602	A/G	cg13775593	chr10:823151	NA	0.31	6.26	0.32	1.18e-9	Uric acid levels;
LUSC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg05844789	chr1:228464394	OBSCN	-0.3	-5.76	-0.3	1.88e-8	Diastolic blood pressure;
LUSC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg07701084	chr6:150067640	NUP43	0.55	8.53	0.42	5.01e-16	Lung cancer;
LUSC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg05855489	chr10:104503620	C10orf26	-0.65	-9.94	-0.48	1.43e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs34734847	1.000	rs55730005	chr12:121157536	C/A	cg27246729	chr12:121163418	ACADS	0.47	7.51	0.38	5.56e-13	Mean corpuscular volume;
LUSC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg20283391	chr11:68216788	NA	-0.54	-8.03	-0.4	1.69e-14	Total body bone mineral density;
LUSC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	11.22	0.52	5.31e-25	Alzheimer's disease;
LUSC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg17376030	chr22:41985996	PMM1	-0.47	-5.84	-0.3	1.25e-8	Vitiligo;
LUSC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg15790184	chr11:494944	RNH1	0.54	6.17	0.32	2e-9	Body mass index;
LUSC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg15212455	chr7:39170539	POU6F2	0.65	11.25	0.52	3.95e-25	IgG glycosylation;
LUSC	cis	rs10489525	0.599	rs910622	chr1:115600424	A/G	cg01522456	chr1:115632236	TSPAN2	-0.5	-7.23	-0.37	3.26e-12	Autism;
LUSC	cis	rs6599077	1.000	rs9822454	chr3:40095771	C/G	cg13683864	chr3:40499215	RPL14	-0.62	-7.86	-0.39	5.47e-14	Sleep-related phenotypes;
LUSC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.41	0.42	1.2e-15	Prudent dietary pattern;
LUSC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.97	-0.4	2.49e-14	Chronic sinus infection;
LUSC	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg14346243	chr4:90757452	SNCA	-0.43	-6.21	-0.32	1.61e-9	Neuroticism;
LUSC	cis	rs28830936	1.000	rs4924575	chr15:42096926	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.69	-0.3	2.81e-8	Diastolic blood pressure;
LUSC	cis	rs9886651	0.935	rs4427135	chr8:128802021	A/C	cg07795030	chr8:128802207	NA	-0.34	-6.33	-0.33	8e-10	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LUSC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg08847533	chr14:75593920	NEK9	-0.8	-13.67	-0.6	4.26e-34	Height;
LUSC	cis	rs4363385	0.626	rs10888531	chr1:153063406	T/C	cg07796016	chr1:152779584	LCE1C	-0.39	-5.87	-0.31	1.08e-8	Inflammatory skin disease;
LUSC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg05425664	chr17:57184151	TRIM37	0.52	7.61	0.38	2.8e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1775715	0.769	rs2808102	chr10:32117749	A/T	cg26784012	chr10:32216390	ARHGAP12	0.46	7.67	0.39	1.89e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg07362569	chr17:61921086	SMARCD2	0.37	7.35	0.37	1.52e-12	Prudent dietary pattern;
LUSC	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg17252645	chr8:143867129	LY6D	-0.55	-10.55	-0.5	1.22e-22	Urinary tract infection frequency;
LUSC	cis	rs977987	0.742	rs34624768	chr16:75331572	G/A	cg04384234	chr16:75411784	CFDP1	-0.37	-5.94	-0.31	7.31e-9	Dupuytren's disease;
LUSC	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.66	-9.69	-0.47	1.02e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19346786	chr7:2764209	NA	-0.38	-6.74	-0.35	6.86e-11	Height;
LUSC	cis	rs751728	0.664	rs2296744	chr6:33740382	G/A	cg25922239	chr6:33757077	LEMD2	0.42	6.22	0.32	1.46e-9	Crohn's disease;
LUSC	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg19812747	chr11:111475976	SIK2	0.55	7.68	0.39	1.72e-13	Primary sclerosing cholangitis;
LUSC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.43	-0.33	4.34e-10	Life satisfaction;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg16157530	chr2:105654526	MRPS9	0.51	6.46	0.33	3.71e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2625529	0.824	rs4776581	chr15:72207071	G/A	cg16672083	chr15:72433130	SENP8	-0.5	-7.35	-0.37	1.56e-12	Red blood cell count;
LUSC	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.6	-9.66	-0.47	1.28e-19	Prudent dietary pattern;
LUSC	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg03690763	chr11:133734501	NA	-0.34	-5.9	-0.31	9.11e-9	Childhood ear infection;
LUSC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg09367891	chr1:107599246	PRMT6	-0.55	-8.71	-0.43	1.38e-16	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-6.23	-0.32	1.37e-9	Lung cancer;
LUSC	trans	rs225245	0.782	rs225272	chr17:33969911	T/C	cg19694781	chr19:47549865	TMEM160	-0.41	-6.54	-0.34	2.35e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg00852041	chr4:2420697	ZFYVE28	0.46	5.96	0.31	6.24e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg20026190	chr17:76395443	PGS1	0.45	8.06	0.4	1.4e-14	HDL cholesterol levels;
LUSC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06850241	chr22:41845214	NA	0.3	5.7	0.3	2.7e-8	Cannabis dependence symptom count;
LUSC	cis	rs1113500	0.805	rs11185244	chr1:108601147	C/T	cg06207961	chr1:108661230	NA	0.3	5.65	0.3	3.53e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs662064	0.852	rs2483677	chr1:10580891	C/T	cg20482658	chr1:10539492	PEX14	0.33	6.61	0.34	1.54e-10	Asthma;
LUSC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00149659	chr3:10157352	C3orf10	0.92	12.28	0.56	7.56e-29	Alzheimer's disease;
LUSC	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg02569458	chr12:86230093	RASSF9	0.4	6.53	0.34	2.48e-10	Major depressive disorder;
LUSC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg00268967	chr12:58002603	GEFT;DTX3	-0.37	-5.82	-0.3	1.4e-8	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg05347473	chr6:146136440	FBXO30	0.53	9.28	0.45	2.26e-18	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg26043149	chr18:55253948	FECH	0.46	7.07	0.36	9.25e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.04	0.36	1.11e-11	Tonsillectomy;
LUSC	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg03676636	chr4:99064102	C4orf37	0.32	6.2	0.32	1.67e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg15133208	chr4:90757351	SNCA	-0.53	-7.61	-0.38	2.88e-13	Neuroticism;
LUSC	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg13010199	chr12:38710504	ALG10B	0.66	10.16	0.49	2.52e-21	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs2665103	0.589	rs2134046	chr15:82524544	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.09	-0.32	3.19e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg17173187	chr15:85201210	NMB	0.38	6.61	0.34	1.52e-10	Schizophrenia;
LUSC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01516881	chr6:292596	DUSP22	-0.52	-7.44	-0.38	8.45e-13	Menopause (age at onset);
LUSC	cis	rs7705502	0.641	rs7731717	chr5:173281685	T/C	cg18693985	chr5:173351052	CPEB4	-0.4	-6.35	-0.33	6.86e-10	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.6	7.99	0.4	2.16e-14	Response to diuretic therapy;
LUSC	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg22431228	chr1:16359049	CLCNKA	0.42	8.44	0.42	9.8e-16	Systolic blood pressure;
LUSC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.97	-0.44	2.18e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	trans	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg18187862	chr3:45730750	SACM1L	-0.53	-6.65	-0.34	1.18e-10	Primary sclerosing cholangitis;
LUSC	cis	rs9341808	0.628	rs1892475	chr6:80862213	T/C	cg08355045	chr6:80787529	NA	0.47	8.11	0.41	9.93e-15	Sitting height ratio;
LUSC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg17507749	chr15:85114479	UBE2QP1	0.69	8.81	0.43	6.98e-17	Schizophrenia;
LUSC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg26513180	chr16:89883248	FANCA	0.61	5.84	0.3	1.22e-8	Skin colour saturation;
LUSC	cis	rs965469	0.947	rs965470	chr20:3381588	C/G	cg25506879	chr20:3388711	C20orf194	-0.53	-5.74	-0.3	2.11e-8	IFN-related cytopenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02470565	chr22:29702866	GAS2L1	-0.46	-6.47	-0.33	3.45e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs227833	0.739	rs663933	chr6:44660748	A/G	cg20913747	chr6:44695427	NA	0.37	5.88	0.31	9.93e-9	Monobrow;
LUSC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	20.89	0.75	1.43e-62	Prudent dietary pattern;
LUSC	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg10326726	chr10:51549505	MSMB	0.35	6.13	0.32	2.45e-9	Prostate-specific antigen levels;
LUSC	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg16576597	chr16:28551801	NUPR1	0.34	6.77	0.35	5.67e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-7.97	-0.4	2.52e-14	Bone mineral density;
LUSC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.52e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12464559	0.649	rs10754989	chr2:152642235	T/C	cg01189475	chr2:152685088	ARL5A	0.65	5.95	0.31	6.78e-9	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs10911363	0.509	rs10911339	chr1:183442097	C/T	cg09173681	chr1:183549694	NCF2	0.63	11.22	0.52	5.46e-25	Systemic lupus erythematosus;
LUSC	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg10326726	chr10:51549505	MSMB	0.35	6.09	0.32	3.14e-9	Prostate-specific antigen levels;
LUSC	cis	rs710216	0.797	rs841855	chr1:43400176	G/A	cg22176566	chr1:43424700	SLC2A1	0.49	6.02	0.31	4.67e-9	Red cell distribution width;
LUSC	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg05340658	chr4:99064831	C4orf37	-0.47	-7.44	-0.38	8.74e-13	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg12927641	chr6:109611667	NA	-0.43	-7.47	-0.38	7.04e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg00033643	chr7:134001901	SLC35B4	0.45	6.91	0.35	2.52e-11	Mean platelet volume;
LUSC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg25039879	chr17:56429692	SUPT4H1	0.68	9.11	0.45	7.7e-18	Cognitive test performance;
LUSC	cis	rs10979	1.000	rs9285500	chr6:143897614	G/C	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg15704280	chr7:45808275	SEPT13	-0.61	-7.53	-0.38	4.82e-13	Intraocular pressure;
LUSC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg15103426	chr22:29168792	CCDC117	0.52	6.45	0.33	3.99e-10	Lymphocyte counts;
LUSC	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg08017756	chr2:100939284	LONRF2	-0.44	-8.24	-0.41	3.91e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4851254	0.584	rs35774174	chr2:100655130	T/A	cg07810366	chr2:100720526	AFF3	-0.46	-5.98	-0.31	5.87e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs10072221	0.805	rs11744637	chr5:75705895	C/T	cg03132911	chr5:75698732	IQGAP2	0.37	6.24	0.32	1.3e-9	Mean platelet volume;
LUSC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.64	-0.34	1.25e-10	Obesity-related traits;
LUSC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	15.29	0.64	2.21e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs7939886	0.920	rs59300271	chr11:55961792	G/A	cg03929089	chr4:120376271	NA	0.81	6.11	0.32	2.73e-9	Myopia (pathological);
LUSC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg14092988	chr3:52407081	DNAH1	0.32	5.89	0.31	9.55e-9	Bipolar disorder;
LUSC	cis	rs600231	0.542	rs11227199	chr11:65238121	G/A	cg17120908	chr11:65337727	SSSCA1	-0.62	-8.95	-0.44	2.47e-17	Bone mineral density;
LUSC	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg18352616	chr4:3374830	RGS12	0.32	6.31	0.33	9.03e-10	Serum sulfate level;
LUSC	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg03788504	chr6:150331562	NA	-0.26	-5.84	-0.3	1.22e-8	Alopecia areata;
LUSC	cis	rs2731664	0.792	rs466256	chr5:176875956	C/A	cg23176889	chr5:176863531	GRK6	-0.66	-13.4	-0.59	4.44e-33	Intelligence (multi-trait analysis);
LUSC	trans	rs12310956	0.510	rs10743832	chr12:33884146	A/C	cg13010199	chr12:38710504	ALG10B	0.44	6.71	0.34	8.41e-11	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06452451	chr5:74062824	NSA2;GFM2	-0.42	-6.29	-0.33	9.92e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg02023728	chr11:77925099	USP35	0.45	6.68	0.34	9.85e-11	Testicular germ cell tumor;
LUSC	cis	rs2200578	1.000	rs62153845	chr2:99887162	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.53	6.19	0.32	1.72e-9	IgG glycosylation;
LUSC	cis	rs7089973	0.549	rs7094440	chr10:116745408	T/C	cg23260525	chr10:116636907	FAM160B1	0.3	5.79	0.3	1.61e-8	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.06	16.59	0.67	1.7e-45	Exhaled nitric oxide output;
LUSC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg16325326	chr1:53192061	ZYG11B	-0.86	-15.96	-0.66	5.09e-43	Monocyte count;
LUSC	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.52	0.5	1.5e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs62400317	0.826	rs62400330	chr6:45321455	G/A	cg20913747	chr6:44695427	NA	-0.47	-7.73	-0.39	1.24e-13	Total body bone mineral density;
LUSC	cis	rs672059	1.000	rs566625	chr1:183161441	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	8.52	0.42	5.4e-16	Hypertriglyceridemia;
LUSC	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg19682013	chr15:45996608	NA	0.39	5.84	0.3	1.24e-8	Waist circumference;Weight;
LUSC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg18758796	chr5:131593413	PDLIM4	0.41	6.69	0.34	9.39e-11	Breast cancer;
LUSC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.84	0.44	5.47e-17	Prudent dietary pattern;
LUSC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.62	-0.47	1.73e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg09165964	chr15:75287851	SCAMP5	0.86	10.23	0.49	1.5e-21	Blood trace element (Zn levels);
LUSC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg27494647	chr7:150038898	RARRES2	0.6	8.82	0.43	6.47e-17	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.63	0.5	6.52e-23	Monocyte percentage of white cells;
LUSC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-1.16	-8.5	-0.42	6.44e-16	Diabetic kidney disease;
LUSC	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs662064	0.748	rs2506892	chr1:10598216	G/A	cg20482658	chr1:10539492	PEX14	0.33	6.6	0.34	1.66e-10	Asthma;
LUSC	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.75	14.47	0.62	3.51e-37	Blood protein levels;
LUSC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg19318889	chr4:1322082	MAEA	0.43	6.99	0.36	1.46e-11	Obesity-related traits;
LUSC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg04287289	chr16:89883240	FANCA	0.78	13.43	0.59	3.64e-33	Vitiligo;
LUSC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg13560548	chr3:10150139	C3orf24	0.55	7.27	0.37	2.55e-12	Alzheimer's disease;
LUSC	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.52	8.0	0.4	2.06e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg14507445	chr22:49886340	NA	-0.29	-5.72	-0.3	2.37e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.76	16.7	0.67	6.16e-46	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4780355	0.877	rs243317	chr16:11357331	G/T	cg00044050	chr16:11439710	C16orf75	-0.55	-8.13	-0.41	8.34e-15	Crohn's disease and psoriasis;
LUSC	cis	rs3857536	0.719	rs9363555	chr6:66930332	T/C	cg07460842	chr6:66804631	NA	-0.47	-6.49	-0.33	3.18e-10	Blood trace element (Cu levels);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20242210	chr6:122931702	PKIB	-0.51	-6.4	-0.33	5.15e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19717773	chr7:2847554	GNA12	-0.39	-6.12	-0.32	2.61e-9	Height;
LUSC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg13010199	chr12:38710504	ALG10B	0.61	9.52	0.46	3.64e-19	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg16230307	chr14:35515116	FAM177A1	0.51	6.39	0.33	5.69e-10	Psoriasis;
LUSC	cis	rs738321	0.671	rs3761446	chr22:38595483	G/A	cg25457927	chr22:38595422	NA	-0.46	-8.94	-0.44	2.7e-17	Breast cancer;
LUSC	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.59	6.44	0.33	4.08e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9359856	0.564	rs72913976	chr6:90390233	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.89	-0.44	3.8e-17	Bipolar disorder;
LUSC	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00321850	chr1:175162397	KIAA0040	-0.45	-7.72	-0.39	1.39e-13	Alcohol dependence;
LUSC	cis	rs911119	0.955	rs55897275	chr20:23595953	A/T	cg16589663	chr20:23618590	CST3	0.57	6.82	0.35	4.18e-11	Chronic kidney disease;
LUSC	cis	rs9888739	0.800	rs7193268	chr16:31340997	A/G	cg15817542	chr16:31343056	ITGAM	0.44	6.04	0.31	4.02e-9	Systemic lupus erythematosus;
LUSC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-12.57	-0.57	6.41e-30	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg22029157	chr1:209979665	IRF6	0.51	8.12	0.41	9e-15	Monobrow;
LUSC	cis	rs2219968	1.000	rs1073445	chr8:78959745	T/C	cg00738934	chr8:78996279	NA	0.35	6.21	0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg17470449	chr10:769945	NA	0.48	6.79	0.35	5.12e-11	Uric acid levels;
LUSC	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg08085267	chr17:45401833	C17orf57	-0.56	-8.48	-0.42	7.23e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg17764715	chr19:33622953	WDR88	0.62	8.47	0.42	8.16e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.72	7.59	0.38	3.32e-13	Initial pursuit acceleration;
LUSC	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	0.58	9.28	0.45	2.15e-18	Breast cancer;
LUSC	cis	rs3849570	0.961	rs3849571	chr3:81777716	A/C	cg07356753	chr3:81810745	GBE1	-0.7	-11.34	-0.53	1.98e-25	Waist circumference;Body mass index;
LUSC	cis	rs1014246	0.813	rs11197797	chr10:118454499	C/T	cg14919929	chr10:118506882	NA	0.47	7.29	0.37	2.27e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs868036	1.000	rs4776376	chr15:68093435	G/A	cg08079166	chr15:68083412	MAP2K5	0.41	8.49	0.42	6.72e-16	Restless legs syndrome;
LUSC	cis	rs4474465	0.688	rs7945812	chr11:78280509	T/C	cg27205649	chr11:78285834	NARS2	0.59	7.39	0.37	1.23e-12	Alzheimer's disease (survival time);
LUSC	trans	rs8073060	1.000	rs8073060	chr17:33875262	T/A	cg19694781	chr19:47549865	TMEM160	0.67	10.13	0.48	3.24e-21	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg16103275	chr6:290800	DUSP22	0.41	7.01	0.36	1.34e-11	Menopause (age at onset);
LUSC	cis	rs9815354	0.812	rs59146151	chr3:41949301	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.49	0.42	6.81e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg23711669	chr6:146136114	FBXO30	0.83	15.28	0.64	2.41e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg00255919	chr5:131827918	IRF1	0.43	8.28	0.41	3.11e-15	Asthma (sex interaction);
LUSC	trans	rs9929218	0.954	rs9928796	chr16:68820718	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-11.06	-0.52	1.97e-24	Colorectal cancer;
LUSC	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg15839431	chr19:19639596	YJEFN3	-0.68	-7.44	-0.38	8.49e-13	Bipolar disorder;
LUSC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg09035930	chr12:129282057	SLC15A4	0.74	16.34	0.67	1.65e-44	Systemic lupus erythematosus;
LUSC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	1.04	20.73	0.75	5.84e-62	Cognitive function;
LUSC	cis	rs11997175	0.655	rs4380889	chr8:33663381	C/T	ch.8.33884649F	chr8:33765107	NA	0.37	5.65	0.3	3.37e-8	Body mass index;
LUSC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.35	6.36	0.33	6.77e-10	Obesity-related traits;
LUSC	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg13755796	chr4:20253514	NA	-0.43	-6.6	-0.34	1.59e-10	Life satisfaction;
LUSC	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg13010199	chr12:38710504	ALG10B	-0.47	-7.24	-0.37	3.1e-12	Morning vs. evening chronotype;
LUSC	cis	rs13082711	0.596	rs683503	chr3:27348094	C/T	cg02860705	chr3:27208620	NA	0.51	9.16	0.45	5.29e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg02951883	chr7:2050386	MAD1L1	-0.6	-10.97	-0.51	4.02e-24	Bipolar disorder and schizophrenia;
LUSC	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-7.46	-0.38	7.48e-13	Neuroticism;
LUSC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06481639	chr22:41940642	POLR3H	0.5	5.77	0.3	1.81e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.58e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg01879757	chr17:41196368	BRCA1	-0.45	-6.85	-0.35	3.63e-11	Menopause (age at onset);
LUSC	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg15704280	chr7:45808275	SEPT13	0.82	7.82	0.39	6.96e-14	Axial length;
LUSC	cis	rs8179	0.648	rs42036	chr7:92241451	C/G	cg15732164	chr7:92237376	CDK6	-0.47	-6.53	-0.34	2.42e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	6.07	0.32	3.55e-9	Lung cancer;
LUSC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs2625529	0.689	rs12161990	chr15:72202440	T/C	cg16672083	chr15:72433130	SENP8	0.49	7.86	0.4	5.21e-14	Red blood cell count;
LUSC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg24154853	chr7:158122151	PTPRN2	0.45	8.87	0.44	4.48e-17	Calcium levels;
LUSC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6845621	0.727	rs11944667	chr4:18911211	A/T	cg12196642	chr4:18937545	NA	-0.34	-6.34	-0.33	7.28e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg16339924	chr4:17578868	LAP3	-0.5	-7.69	-0.39	1.72e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-15.37	-0.64	1.06e-40	Exhaled nitric oxide output;
LUSC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	7.79	0.39	8.71e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs9549260	0.755	rs2721045	chr13:41162632	T/A	cg21288729	chr13:41239152	FOXO1	0.6	9.22	0.45	3.31e-18	Red blood cell count;
LUSC	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg04455712	chr21:45112962	RRP1B	0.46	8.84	0.44	5.73e-17	Mean corpuscular volume;
LUSC	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg22732515	chr19:44031385	ETHE1	0.64	10.53	0.5	1.38e-22	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs367615	0.506	rs2914680	chr5:108787146	A/G	cg17395555	chr5:108820864	NA	-0.52	-9.75	-0.47	6.33e-20	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	13.27	0.59	1.42e-32	Blood protein levels;
LUSC	cis	rs34638657	0.702	rs11866709	chr16:82201017	A/G	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.33	-0.33	7.89e-10	Lung adenocarcinoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22854549	chr19:5904785	VMAC;NDUFA11	0.42	6.59	0.34	1.74e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.09	-0.4	1.12e-14	Type 2 diabetes;
LUSC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.41	-6.17	-0.32	2.02e-9	Platelet count;
LUSC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.07	0.32	3.55e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg10253484	chr15:75165896	SCAMP2	0.52	7.2	0.37	4.09e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs73001065	0.892	rs58542926	chr19:19379549	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	6.41	0.33	4.95e-10	LDL cholesterol;
LUSC	cis	rs4629180	1.000	rs6744495	chr2:102099956	T/C	cg01388757	chr2:102091195	RFX8	-0.45	-7.06	-0.36	9.48e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs9549260	0.755	rs17061450	chr13:41183716	G/A	cg21288729	chr13:41239152	FOXO1	0.59	8.95	0.44	2.45e-17	Red blood cell count;
LUSC	cis	rs9420	0.961	rs71484468	chr11:57632799	G/C	cg02958346	chr11:57425731	CLP1	-0.44	-6.28	-0.33	1.04e-9	Schizophrenia;
LUSC	trans	rs7690543	0.681	rs6552075	chr4:68008700	A/C	cg06097370	chr10:21604082	NA	-0.68	-6.02	-0.31	4.62e-9	Glucose homeostasis traits;
LUSC	trans	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.56	8.61	0.43	3.02e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg04586622	chr2:25135609	ADCY3	0.37	7.73	0.39	1.25e-13	Body mass index in non-asthmatics;
LUSC	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.33	-7.24	-0.37	3.16e-12	Dupuytren's disease;
LUSC	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	10.7	0.51	3.61e-23	Coronary artery disease;
LUSC	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg24558204	chr6:135376177	HBS1L	0.59	9.09	0.45	9.11e-18	Red blood cell count;
LUSC	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.7	-10.2	-0.49	1.88e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs710216	0.763	rs9438964	chr1:43443742	C/T	cg22176566	chr1:43424700	SLC2A1	0.46	5.86	0.31	1.08e-8	Red cell distribution width;
LUSC	trans	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg11645453	chr3:52864694	ITIH4	0.3	6.9	0.35	2.7e-11	Electroencephalogram traits;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.32	-5.69	-0.3	2.81e-8	Lymphocyte counts;
LUSC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.22	0.32	1.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg11062466	chr8:58055876	NA	0.51	6.54	0.34	2.27e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg20283391	chr11:68216788	NA	-0.59	-8.26	-0.41	3.43e-15	Total body bone mineral density;
LUSC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg11941060	chr3:133502564	NA	-0.52	-8.04	-0.4	1.53e-14	Iron status biomarkers;
LUSC	cis	rs983392	0.709	rs1349667	chr11:59993346	T/A	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.11	-0.32	2.79e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3750082	0.582	rs3750079	chr7:32969419	G/A	cg08946731	chr7:32981826	RP9P	0.41	6.58	0.34	1.77e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg08027265	chr7:2291960	NA	-0.64	-11.86	-0.54	2.55e-27	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg22437258	chr11:111473054	SIK2	0.44	5.67	0.3	3.11e-8	Primary sclerosing cholangitis;
LUSC	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-13.89	-0.61	5.93e-35	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	7.25	0.37	3e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.83	8.51	0.42	6.06e-16	Initial pursuit acceleration;
LUSC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-11.87	-0.54	2.4e-27	Prudent dietary pattern;
LUSC	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg03929089	chr4:120376271	NA	-0.87	-11.94	-0.55	1.34e-27	Height;
LUSC	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg09904177	chr6:26538194	HMGN4	-0.8	-6.37	-0.33	6.31e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg10172584	chr19:19639581	YJEFN3	-0.46	-5.65	-0.3	3.42e-8	Bipolar disorder;
LUSC	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.79	11.38	0.53	1.46e-25	Corneal astigmatism;
LUSC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08280861	chr8:58055591	NA	0.58	6.38	0.33	6.01e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06850241	chr22:41845214	NA	-0.31	-5.92	-0.31	7.92e-9	Vitiligo;
LUSC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg17541715	chr7:1216824	NA	-0.37	-5.69	-0.3	2.72e-8	Longevity;Endometriosis;
LUSC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs7084402	1.000	rs12250013	chr10:60265957	C/A	cg07615347	chr10:60278583	BICC1	-0.34	-5.64	-0.3	3.54e-8	Refractive error;
LUSC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06544989	chr22:39130855	UNC84B	0.32	5.68	0.3	2.92e-8	Menopause (age at onset);
LUSC	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg00083206	chr6:110721305	DDO	-0.43	-7.69	-0.39	1.66e-13	Platelet distribution width;
LUSC	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg04455712	chr21:45112962	RRP1B	-0.4	-7.67	-0.39	1.85e-13	Mean corpuscular volume;
LUSC	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg19920283	chr7:105172520	RINT1	0.61	6.67	0.34	1.07e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg02476566	chr12:106696527	TCP11L2	-0.49	-6.15	-0.32	2.21e-9	Tourette syndrome;
LUSC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg23630131	chr7:65973040	NA	0.21	5.83	0.3	1.33e-8	Aortic root size;
LUSC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00149659	chr3:10157352	C3orf10	0.89	12.11	0.55	3.04e-28	Alzheimer's disease;
LUSC	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg17470449	chr10:769945	NA	0.47	6.68	0.34	1.01e-10	Uric acid levels;
LUSC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg18681998	chr4:17616180	MED28	0.84	15.62	0.65	1.13e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg09307838	chr4:120376055	NA	0.68	9.78	0.47	4.89e-20	Corneal astigmatism;
LUSC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	10.84	0.51	1.14e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg26647111	chr11:31128758	NA	0.41	6.11	0.32	2.71e-9	Red blood cell count;
LUSC	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.25	0.37	2.93e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg04691961	chr3:161091175	C3orf57	-0.34	-5.81	-0.3	1.49e-8	Morning vs. evening chronotype;
LUSC	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	12.32	0.56	5.37e-29	Height;
LUSC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg11062466	chr8:58055876	NA	0.65	8.33	0.41	2.12e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2637266	0.756	rs846607	chr10:78561254	A/T	cg18941641	chr10:78392320	NA	0.38	6.91	0.35	2.41e-11	Pulmonary function;
LUSC	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg04218760	chr10:45406644	TMEM72	-0.32	-7.77	-0.39	9.91e-14	Mean corpuscular volume;
LUSC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg09034736	chr1:150693464	HORMAD1	0.42	5.79	0.3	1.63e-8	Melanoma;
LUSC	cis	rs2835872	0.832	rs857978	chr21:38998126	A/G	cg20424643	chr21:39039972	KCNJ6	-0.37	-5.83	-0.3	1.28e-8	Electroencephalographic traits in alcoholism;
LUSC	trans	rs2392780	0.514	rs653605	chr8:128338847	G/T	cg10897648	chr18:56338258	MALT1	-0.42	-6.35	-0.33	6.95e-10	Breast cancer (early onset);
LUSC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg05623727	chr3:50126028	RBM5	-0.33	-6.14	-0.32	2.32e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg16342193	chr10:102329863	NA	-0.34	-5.94	-0.31	7.31e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	7.12	0.36	6.6e-12	Platelet count;
LUSC	cis	rs68170813	0.559	rs9641378	chr7:106868003	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.63	-0.47	1.62e-19	Coronary artery disease;
LUSC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.4	0.56	2.56e-29	Prudent dietary pattern;
LUSC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg24642844	chr7:1081250	C7orf50	-0.46	-7.42	-0.38	9.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.67	11.01	0.52	2.81e-24	Schizophrenia;
LUSC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.85	-11.4	-0.53	1.18e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg01858014	chr14:56050164	KTN1	-0.89	-7.32	-0.37	1.9e-12	Putamen volume;
LUSC	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	5.83	0.3	1.3e-8	Breast cancer;
LUSC	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.38e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	8.15	0.41	7.34e-15	Axial length;
LUSC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.45	-0.38	7.92e-13	Aortic root size;
LUSC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	11.12	0.52	1.17e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	8.84	0.44	5.7e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12545109	0.800	rs1440763	chr8:57410481	C/A	cg09654669	chr8:57350985	NA	-0.52	-6.66	-0.34	1.1e-10	Obesity-related traits;
LUSC	trans	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg12856521	chr11:46389249	DGKZ	0.4	6.27	0.32	1.09e-9	Leprosy;
LUSC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg13939156	chr17:80058883	NA	0.34	6.69	0.34	9.61e-11	Life satisfaction;
LUSC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg13395646	chr4:1353034	KIAA1530	-0.59	-8.45	-0.42	9.09e-16	Longevity;
LUSC	cis	rs7904985	1.000	rs11201991	chr10:88117122	T/C	cg07322936	chr10:88137208	NA	-0.57	-7.23	-0.37	3.37e-12	Barrett's esophagus;
LUSC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-10.52	-0.5	1.48e-22	Body mass index;
LUSC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg09365446	chr1:150670422	GOLPH3L	-0.41	-5.94	-0.31	7.13e-9	Tonsillectomy;
LUSC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	1.05	19.12	0.72	1.42e-55	Menopause (age at onset);
LUSC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg20295408	chr7:1910781	MAD1L1	0.42	5.97	0.31	6.14e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12493885	0.818	rs60023390	chr3:153771056	C/T	cg17054900	chr3:154042577	DHX36	-0.53	-5.71	-0.3	2.51e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.65	-10.29	-0.49	9.74e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs3931020	0.688	rs277396	chr1:75213648	A/C	cg21535942	chr1:75199100	CRYZ;TYW3	-0.48	-6.03	-0.31	4.37e-9	Resistin levels;
LUSC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg21770322	chr7:97807741	LMTK2	0.41	7.25	0.37	2.92e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.56	0.34	2.07e-10	Corneal astigmatism;
LUSC	cis	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg02356786	chr1:243265016	LOC731275	-0.7	-6.94	-0.35	2.08e-11	Obesity (early onset extreme);
LUSC	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.6	9.49	0.46	4.46e-19	Morning vs. evening chronotype;
LUSC	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.9	0.61	5.49e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg26380479	chr7:97908229	NA	-0.27	-6.03	-0.31	4.29e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3847687	1.000	rs3847687	chr12:131525053	C/T	cg25772418	chr12:131519998	GPR133	-0.27	-5.97	-0.31	5.93e-9	Longevity;
LUSC	cis	rs9807989	0.524	rs2110662	chr2:103020139	A/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.72e-12	Asthma;
LUSC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg00945038	chr17:61921165	SMARCD2	0.54	9.64	0.47	1.4e-19	Prudent dietary pattern;
LUSC	cis	rs7804356	1.000	rs73065504	chr7:26825984	A/G	cg03456212	chr7:26904342	SKAP2	-0.55	-6.53	-0.34	2.41e-10	Type 1 diabetes;
LUSC	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg00495681	chr13:53174319	NA	0.75	14.27	0.62	2.09e-36	Lewy body disease;
LUSC	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg23711669	chr6:146136114	FBXO30	0.87	16.13	0.66	1.09e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-1.04	-15.55	-0.65	2.19e-41	Initial pursuit acceleration;
LUSC	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.76	-0.3	1.94e-8	Resting heart rate;
LUSC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.42	0.5	3.24e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg15704280	chr7:45808275	SEPT13	0.73	6.92	0.35	2.32e-11	Axial length;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg05617413	chr12:133065912	FBRSL1	0.33	5.96	0.31	6.53e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	8.09e-13	Motion sickness;
LUSC	cis	rs75804782	0.521	rs56227677	chr2:239449867	C/T	cg18131467	chr2:239335373	ASB1	-0.64	-5.95	-0.31	6.69e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.23	0.32	1.39e-9	Systolic blood pressure;
LUSC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg07741184	chr6:167504864	NA	0.35	6.22	0.32	1.5e-9	Crohn's disease;
LUSC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-11.88	-0.54	2.19e-27	Body mass index;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg12419862	chr22:24373484	LOC391322	-0.94	-17.89	-0.7	1.14e-50	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg27170947	chr2:26402098	FAM59B	0.64	8.96	0.44	2.35e-17	Gut microbiome composition (summer);
LUSC	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg24579218	chr15:68104479	NA	-0.34	-5.74	-0.3	2.18e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg13902645	chr11:5959945	NA	-0.55	-8.63	-0.43	2.55e-16	DNA methylation (variation);
LUSC	cis	rs75920871	0.588	rs3181	chr11:116907043	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.5	-0.33	2.99e-10	Subjective well-being;
LUSC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.69	-11.75	-0.54	6.3100000000000004e-27	Resting heart rate;
LUSC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1568889	1.000	rs9783375	chr11:28033667	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	8.7	0.43	1.52e-16	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24702147	chr12:7071814	MIR141;MIR200C	0.27	6.46	0.33	3.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7939886	0.920	rs11227598	chr11:56000451	G/A	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs10743315	0.599	rs11044451	chr12:19365798	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.62	-7.38	-0.37	1.27e-12	Gut microbiota (bacterial taxa);
LUSC	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg06636001	chr8:8085503	FLJ10661	0.47	6.96	0.36	1.84e-11	Neuroticism;
LUSC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-8.91	-0.44	3.25e-17	Schizophrenia;
LUSC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.9	-0.44	3.51e-17	Electroencephalogram traits;
LUSC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	13.5	0.59	1.85e-33	Total body bone mineral density;
LUSC	trans	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.6	0.34	1.63e-10	Corneal astigmatism;
LUSC	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg13010199	chr12:38710504	ALG10B	0.65	10.25	0.49	1.32e-21	Bladder cancer;
LUSC	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg15432903	chr11:17409602	KCNJ11	0.6	10.66	0.5	4.88e-23	Type 2 diabetes;
LUSC	cis	rs2540226	0.844	rs4670959	chr2:39993167	T/C	cg23576258	chr2:39999331	THUMPD2	0.35	5.85	0.3	1.18e-8	Personality dimensions;
LUSC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg05738196	chr6:26577821	NA	-0.81	-15.03	-0.64	2.27e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg18681998	chr4:17616180	MED28	-0.81	-14.86	-0.63	1.08e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs600231	0.508	rs11227202	chr11:65242717	G/A	cg17120908	chr11:65337727	SSSCA1	-0.62	-8.95	-0.44	2.47e-17	Bone mineral density;
LUSC	trans	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg25214090	chr10:38739885	LOC399744	0.58	8.51	0.42	6.08e-16	Corneal astigmatism;
LUSC	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg03929089	chr4:120376271	NA	0.66	6.25	0.32	1.23e-9	Axial length;
LUSC	cis	rs4737010	0.570	rs7823138	chr8:41644861	C/T	cg17182837	chr8:41585554	ANK1	0.33	6.31	0.33	9.07e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-7.87	-0.4	5.03e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs12541635	0.966	rs2345070	chr8:107072027	A/G	cg10147462	chr8:107024639	NA	-0.53	-9.38	-0.46	1.05e-18	Age of smoking initiation;
LUSC	cis	rs7872515	1.000	rs7872515	chr9:94822540	A/G	cg01248375	chr9:94877805	SPTLC1	-0.54	-5.68	-0.3	3e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs73198271	0.603	rs557892	chr8:8596048	A/C	cg01851573	chr8:8652454	MFHAS1	0.42	6.26	0.32	1.2e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10843647	1.000	rs6487884	chr12:30324920	G/T	cg12718339	chr12:29936407	TMTC1	-0.36	-5.91	-0.31	8.65e-9	Glucose homeostasis traits;
LUSC	cis	rs7202877	0.706	rs37605	chr16:75506572	G/C	cg03315344	chr16:75512273	CHST6	-0.43	-6.23	-0.32	1.38e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	trans	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg18187862	chr3:45730750	SACM1L	-0.53	-6.45	-0.33	3.92e-10	Primary sclerosing cholangitis;
LUSC	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg21775007	chr8:11205619	TDH	-0.44	-6.19	-0.32	1.76e-9	Neuroticism;
LUSC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.45	6.05	0.31	3.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg11693508	chr17:37793320	STARD3	0.5	6.96	0.36	1.86e-11	Bipolar disorder;
LUSC	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg00504896	chr12:9437009	LOC642846	-0.39	-5.8	-0.3	1.58e-8	Breast size;
LUSC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	13.09	0.58	6.77e-32	Platelet count;
LUSC	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg17366294	chr4:99064904	C4orf37	0.5	8.7	0.43	1.54e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg17294928	chr15:75287854	SCAMP5	0.41	5.88	0.31	1e-8	Breast cancer;
LUSC	trans	rs679582	1.000	rs632057	chr6:139834012	G/T	cg15811753	chr2:65454775	ACTR2	-0.35	-6.02	-0.31	4.64e-9	Blood trace element (Se levels);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04713951	chr22:38966166	DMC1	-0.42	-6.36	-0.33	6.69e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10489525	0.599	rs17033129	chr1:115611539	C/T	cg17147537	chr1:115611705	TSPAN2	0.3	5.81	0.3	1.42e-8	Autism;
LUSC	trans	rs11723530	0.513	rs6816345	chr4:170813779	T/C	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.28	-0.32	1.03e-9	Myopia (pathological);
LUSC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg13319975	chr6:146136371	FBXO30	0.45	7.0	0.36	1.39e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg17420585	chr12:42539391	GXYLT1	-0.36	-7.04	-0.36	1.11e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs13315871	1.000	rs28489489	chr3:58443755	C/A	cg12435725	chr3:58293450	RPP14	-0.7	-6.93	-0.35	2.21e-11	Cholesterol, total;
LUSC	trans	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg00953403	chr17:74099816	EXOC7	0.42	6.23	0.32	1.39e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.93	-0.44	2.87e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10193935	1.000	rs10190326	chr2:42388262	A/C	cg27598129	chr2:42591480	NA	0.57	7.97	0.4	2.56e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg09365446	chr1:150670422	GOLPH3L	0.47	6.88	0.35	3.03e-11	Melanoma;
LUSC	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	11.78	0.54	5.18e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7923609	0.756	rs12768534	chr10:65340897	A/G	cg01631684	chr10:65280961	REEP3	-0.39	-5.88	-0.31	9.87e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs113835537	0.597	rs4576	chr11:66331000	A/G	cg24851651	chr11:66362959	CCS	0.56	8.62	0.43	2.68e-16	Airway imaging phenotypes;
LUSC	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg05973401	chr12:123451056	ABCB9	0.54	6.64	0.34	1.24e-10	Neutrophil percentage of white cells;
LUSC	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg04586622	chr2:25135609	ADCY3	0.4	8.17	0.41	6.64e-15	Body mass index in non-asthmatics;
LUSC	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg17517138	chr11:73019481	ARHGEF17	1.09	9.0	0.44	1.69e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg18105134	chr13:113819100	PROZ	-0.67	-9.41	-0.46	8.43e-19	Platelet distribution width;
LUSC	cis	rs7119038	0.731	rs10892283	chr11:118636980	A/G	cg19308663	chr11:118741387	NA	0.36	6.17	0.32	1.96e-9	Sjögren's syndrome;
LUSC	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg06917634	chr15:78832804	PSMA4	-0.44	-5.91	-0.31	8.24e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	trans	rs72674100	1.000	rs2865759	chr4:97992416	C/T	cg16405019	chr1:18959625	PAX7	-0.62	-6.98	-0.36	1.56e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.65	-0.43	2.19e-16	Total cholesterol levels;
LUSC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.69	0.5	3.96e-23	Schizophrenia;
LUSC	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-7.68	-0.39	1.78e-13	Bladder cancer;
LUSC	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	1.08	17.05	0.68	2.37e-47	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg04733989	chr22:42467013	NAGA	-0.62	-9.75	-0.47	6.31e-20	Schizophrenia;
LUSC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg03929089	chr4:120376271	NA	-0.94	-16.11	-0.66	1.31e-43	Height;
LUSC	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03713592	chr11:72463424	ARAP1	0.77	9.1	0.45	8.64e-18	Type 2 diabetes;
LUSC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg04352962	chr1:209979756	IRF6	0.49	6.54	0.34	2.31e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg23752985	chr2:85803571	VAMP8	0.36	8.03	0.4	1.67e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg05347473	chr6:146136440	FBXO30	0.56	9.67	0.47	1.14e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-7.42	-0.38	9.95e-13	Electroencephalogram traits;
LUSC	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-9.55	-0.46	2.82e-19	Response to antipsychotic treatment;
LUSC	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg02974968	chr1:160236444	NA	-0.44	-7.9	-0.4	4.14e-14	Breast size;
LUSC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg20135002	chr11:47629003	NA	-0.51	-7.98	-0.4	2.41e-14	Subjective well-being;
LUSC	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg25251562	chr2:3704773	ALLC	-0.48	-7.39	-0.38	1.15e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg19318889	chr4:1322082	MAEA	0.45	7.5	0.38	5.79e-13	Obesity-related traits;
LUSC	cis	rs3849570	0.961	rs7620240	chr3:81762787	G/T	cg07356753	chr3:81810745	GBE1	-0.7	-11.21	-0.52	5.48e-25	Waist circumference;Body mass index;
LUSC	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.96	-12.45	-0.56	1.77e-29	Exhaled nitric oxide output;
LUSC	trans	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg10756647	chr7:56101905	PSPH	0.87	8.46	0.42	8.32e-16	Diabetic kidney disease;
LUSC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg22484793	chr3:52261325	TLR9	-0.28	-6.17	-0.32	2.03e-9	Bipolar disorder;
LUSC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg12463550	chr7:65579703	CRCP	0.45	6.76	0.35	6.2e-11	Aortic root size;
LUSC	cis	rs250677	0.522	rs6580589	chr5:148360335	C/G	cg18129178	chr5:148520854	ABLIM3	0.52	7.36	0.37	1.41e-12	Breast cancer;
LUSC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08645402	chr16:4508243	NA	0.47	7.2	0.37	4.02e-12	Schizophrenia;
LUSC	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg09165964	chr15:75287851	SCAMP5	-0.96	-11.67	-0.54	1.21e-26	Blood trace element (Zn levels);
LUSC	cis	rs10992471	0.528	rs1924244	chr9:95224952	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.25	-0.32	1.28e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.27	0.52	3.49e-25	Menopause (age at onset);
LUSC	cis	rs61869271	0.871	rs6585309	chr10:116730337	A/G	cg23260525	chr10:116636907	FAM160B1	-0.31	-6.02	-0.31	4.55e-9	Tonsillectomy;
LUSC	cis	rs17824933	0.943	rs11230566	chr11:60780007	G/A	cg16817237	chr11:60793675	NA	0.41	6.46	0.33	3.75e-10	Multiple sclerosis;
LUSC	trans	rs75804782	0.641	rs72987321	chr2:239352765	T/G	cg01134436	chr17:81009848	B3GNTL1	0.66	6.4	0.33	5.11e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg18512352	chr11:47633146	NA	-0.46	-9.17	-0.45	4.87e-18	Neuroticism;
LUSC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg13319975	chr6:146136371	FBXO30	0.49	7.43	0.38	9.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	10.53	0.5	1.44e-22	Homoarginine levels;
LUSC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg16240275	chr20:61666158	NCRNA00029	0.42	9.24	0.45	2.9e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8032315	0.965	rs7497304	chr15:91429176	G/T	cg06330618	chr15:91428456	FES	0.29	5.92	0.31	8.18e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.2	0.49	1.93e-21	Bladder cancer;
LUSC	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg27284194	chr4:1044797	NA	0.6	8.85	0.44	5.26e-17	Recombination rate (females);
LUSC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08859206	chr1:53392774	SCP2	-0.68	-13.18	-0.59	3.02e-32	Monocyte count;
LUSC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11764359	chr7:65958608	NA	0.68	10.96	0.51	4.39e-24	Aortic root size;
LUSC	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-9.6	-0.47	1.9e-19	Platelet distribution width;
LUSC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.57	-8.56	-0.42	4.21e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.59	-9.41	-0.46	8.55e-19	Longevity;Endometriosis;
LUSC	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg13010344	chr12:123464640	ARL6IP4	0.5	6.37	0.33	6.4e-10	Neutrophil percentage of white cells;
LUSC	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	1.11	18.84	0.72	1.94e-54	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03226245	chr19:36486125	SDHAF1	0.48	6.56	0.34	2.04e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg15556689	chr8:8085844	FLJ10661	0.59	8.75	0.43	1.09e-16	Systemic lupus erythematosus;
LUSC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-6.06	-0.31	3.77e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg25214090	chr10:38739885	LOC399744	0.57	8.26	0.41	3.44e-15	Corneal astigmatism;
LUSC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	0.92	12.11	0.55	3.07e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.73	-0.3	2.24e-8	Total body bone mineral density;
LUSC	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.53	-7.03	-0.36	1.15e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.84e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg00677455	chr12:58241039	CTDSP2	0.71	11.0	0.52	3.13e-24	Multiple sclerosis;
LUSC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.09	-0.4	1.14e-14	Lung cancer;
LUSC	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.8	-0.73	2.79e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.83	-19.73	-0.73	5.32e-58	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-7.08	-0.36	8.51e-12	Bipolar disorder;
LUSC	cis	rs7084921	0.608	rs2862948	chr10:101864173	A/G	cg02250046	chr10:101825185	CPN1	-0.33	-6.11	-0.32	2.82e-9	Bone mineral density;
LUSC	cis	rs9283706	0.594	rs1428405	chr5:66327193	A/T	cg11590213	chr5:66331682	MAST4	0.44	6.62	0.34	1.42e-10	Coronary artery disease;
LUSC	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	8.03	0.4	1.68e-14	Iron status biomarkers;
LUSC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.86	11.65	0.54	1.54e-26	Chronic sinus infection;
LUSC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	0.95	18.06	0.7	2.27e-51	Bone mineral density;
LUSC	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg02493740	chr2:85810744	VAMP5	-0.37	-6.5	-0.34	2.89e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs75804782	0.641	rs56396448	chr2:239335234	C/T	cg01134436	chr17:81009848	B3GNTL1	0.65	6.24	0.32	1.3e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs28655083	0.956	rs1485792	chr16:77100439	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.46	-7.04	-0.36	1.12e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg25482853	chr8:67687455	SGK3	1.19	19.12	0.72	1.43e-55	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg13072238	chr3:49761600	GMPPB	-0.4	-6.49	-0.33	3.1e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg06096015	chr1:231504339	EGLN1	0.56	9.88	0.48	2.26e-20	Hemoglobin concentration;
LUSC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05165339	chr4:1420672	NA	0.29	6.97	0.36	1.69e-11	Longevity;
LUSC	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.65	-0.47	1.37e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg22166914	chr1:53195759	ZYG11B	0.67	11.31	0.53	2.54e-25	Monocyte count;
LUSC	cis	rs2074585	0.560	rs1973537	chr15:91062901	T/C	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.75	-0.35	6.69e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs2274459	0.749	rs12190155	chr6:33663241	G/A	cg06253072	chr6:33679850	C6orf125	0.48	5.76	0.3	1.94e-8	Obesity (extreme);
LUSC	cis	rs62400317	0.762	rs12202704	chr6:44819614	G/T	cg20913747	chr6:44695427	NA	-0.49	-7.63	-0.39	2.54e-13	Total body bone mineral density;
LUSC	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg26566898	chr11:117069891	TAGLN	0.37	7.18	0.37	4.46e-12	Blood protein levels;
LUSC	trans	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg13010199	chr12:38710504	ALG10B	0.46	7.02	0.36	1.28e-11	Morning vs. evening chronotype;
LUSC	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.09e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1385374	0.502	rs923077	chr12:129276708	C/A	cg09035930	chr12:129282057	SLC15A4	0.65	6.81	0.35	4.67e-11	Systemic lupus erythematosus;
LUSC	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg18200150	chr17:30822561	MYO1D	0.45	8.87	0.44	4.43e-17	Schizophrenia;
LUSC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.05	-0.4	1.5e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg00990874	chr7:1149470	C7orf50	-0.58	-7.6	-0.38	3.12e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg09626299	chr10:82213104	TSPAN14	-0.19	-5.73	-0.3	2.24e-8	Post bronchodilator FEV1;
LUSC	cis	rs9296092	0.517	rs7743178	chr6:33470462	G/A	cg13560919	chr6:33536144	NA	-0.78	-13.33	-0.59	8.65e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.64	9.32	0.45	1.59e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs2227564	0.794	rs2688607	chr10:75663736	C/T	cg23231163	chr10:75533350	FUT11	0.44	6.25	0.32	1.26e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg22709100	chr7:91322751	NA	-0.41	-6.01	-0.31	4.95e-9	Breast cancer;
LUSC	trans	rs1256061	0.874	rs7156924	chr14:64724834	G/T	cg07874507	chr10:24503148	KIAA1217	0.34	5.97	0.31	6.07e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.9	0.48	2e-20	Migraine;Coronary artery disease;
LUSC	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg06951627	chr6:26196580	NA	0.53	5.72	0.3	2.39e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs1832871	0.672	rs62437399	chr6:158784251	C/A	cg07165851	chr6:158734300	TULP4	0.46	6.7	0.34	8.67e-11	Height;
LUSC	cis	rs727505	1.000	rs7801661	chr7:124483222	C/T	cg23710748	chr7:124431027	NA	0.42	7.7	0.39	1.51e-13	Lewy body disease;
LUSC	cis	rs1832871	0.711	rs12525147	chr6:158683509	A/G	cg07165851	chr6:158734300	TULP4	0.52	7.79	0.39	8.49e-14	Height;
LUSC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg06454157	chr6:167490870	NA	-0.26	-6.13	-0.32	2.42e-9	Crohn's disease;
LUSC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg25039879	chr17:56429692	SUPT4H1	0.67	8.95	0.44	2.48e-17	Cognitive test performance;
LUSC	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-8.06	-0.4	1.39e-14	Retinal vascular caliber;
LUSC	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg25427524	chr10:38739819	LOC399744	0.45	5.95	0.31	6.76e-9	Obesity (extreme);
LUSC	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg04117972	chr1:227635322	NA	-0.69	-7.74	-0.39	1.22e-13	Major depressive disorder;
LUSC	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17467752	chr17:38218738	THRA	-0.51	-7.14	-0.36	5.74e-12	White blood cell count (basophil);White blood cell count;
LUSC	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg16482183	chr6:26056742	HIST1H1C	0.65	9.14	0.45	6.04e-18	Iron status biomarkers;
LUSC	cis	rs9815354	0.857	rs73830583	chr3:41996948	C/T	cg03022575	chr3:42003672	ULK4	0.85	8.86	0.44	4.72e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs28655083	0.509	rs664408	chr16:77104820	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	7.11	0.36	7.24e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9944715	1.000	rs9963843	chr18:43842618	C/A	cg01718231	chr17:29326311	RNF135	-0.5	-6.95	-0.36	1.97e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg18806716	chr10:30721971	MAP3K8	0.44	7.23	0.37	3.3e-12	Inflammatory bowel disease;
LUSC	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	0.89	14.61	0.62	1.04e-37	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg13736514	chr6:26305472	NA	0.44	8.14	0.41	7.95e-15	Mosquito bite size;
LUSC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	9.02	0.44	1.5e-17	Motion sickness;
LUSC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.73	-12.67	-0.57	2.51e-30	Prudent dietary pattern;
LUSC	trans	rs10421385	1.000	rs10421385	chr19:51701891	A/G	cg07580831	chr2:79385573	REG3A	0.3	6.07	0.32	3.41e-9	Blood protein levels;
LUSC	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	10.4	0.49	4.09e-22	Coffee consumption (cups per day);
LUSC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg02018176	chr4:1364513	KIAA1530	0.55	9.67	0.47	1.13e-19	Longevity;
LUSC	cis	rs4285028	0.696	rs3915060	chr3:121712980	C/T	cg20356878	chr3:121714668	ILDR1	0.5	6.87	0.35	3.06e-11	Multiple sclerosis;
LUSC	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg10911889	chr6:126070802	HEY2	0.42	6.39	0.33	5.41e-10	Brugada syndrome;
LUSC	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg22705602	chr4:152727874	NA	-0.33	-6.64	-0.34	1.25e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg18230493	chr5:56204884	C5orf35	-0.79	-12.52	-0.57	9.14e-30	Initial pursuit acceleration;
LUSC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	trans	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-5.97	-0.31	6.17e-9	Myopia (pathological);
LUSC	cis	rs7640424	0.784	rs68044584	chr3:107845395	A/G	cg09227934	chr3:107805635	CD47	-0.43	-6.61	-0.34	1.57e-10	Body mass index;
LUSC	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg12826209	chr6:26865740	GUSBL1	0.51	7.36	0.37	1.43e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg09491104	chr22:46646882	C22orf40	-0.63	-7.19	-0.37	4.35e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg04450456	chr4:17643702	FAM184B	0.39	6.64	0.34	1.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg24562669	chr7:97807699	LMTK2	0.34	6.02	0.31	4.69e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg21827317	chr3:136751795	NA	0.4	7.21	0.37	3.8e-12	Neuroticism;
LUSC	cis	rs7799006	1.000	rs7810970	chr7:2276385	A/G	cg12823233	chr7:2316876	SNX8	-0.33	-5.76	-0.3	1.92e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg21427119	chr20:30132790	HM13	-0.37	-5.69	-0.3	2.8e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg02527881	chr3:46936655	PTH1R	-0.42	-7.57	-0.38	3.75e-13	Colorectal cancer;
LUSC	trans	rs6076960	0.629	rs6054031	chr20:6233657	C/G	cg17788362	chr6:86352627	SYNCRIP	0.42	6.14	0.32	2.34e-9	Smooth-surface caries;
LUSC	cis	rs427941	0.632	rs201493	chr7:101754865	T/C	cg06246474	chr7:101738831	CUX1	0.4	6.51	0.34	2.83e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs9653442	0.511	rs6739695	chr2:100859622	A/G	cg22139774	chr2:100720529	AFF3	-0.38	-6.24	-0.32	1.31e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg13647721	chr17:30228624	UTP6	-0.62	-5.89	-0.31	9.27e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg03676636	chr4:99064102	C4orf37	0.36	8.08	0.4	1.16e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg24558204	chr6:135376177	HBS1L	0.59	9.08	0.44	9.59e-18	Red blood cell count;
LUSC	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg13010199	chr12:38710504	ALG10B	0.49	7.53	0.38	4.89e-13	Morning vs. evening chronotype;
LUSC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg01448562	chr3:133502909	NA	-0.36	-5.77	-0.3	1.76e-8	Iron status biomarkers (transferrin levels);
LUSC	cis	rs3772130	0.962	rs7629369	chr3:121566282	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	9.98	0.48	1.09e-20	Cognitive performance;
LUSC	trans	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs6545883	0.929	rs1209434	chr2:61672958	G/A	cg15711740	chr2:61764176	XPO1	-0.44	-6.73	-0.35	7.36e-11	Tuberculosis;
LUSC	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.89	15.26	0.64	2.9e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.57	-0.38	3.74e-13	Tonsillectomy;
LUSC	cis	rs2224391	0.534	rs2773308	chr6:5246833	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-6.87	-0.35	3.16e-11	Height;
LUSC	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg27129171	chr3:47204927	SETD2	-0.68	-10.37	-0.49	5.08e-22	Colorectal cancer;
LUSC	cis	rs12210905	1.000	rs7759955	chr6:26709424	G/A	cg11502198	chr6:26597334	ABT1	-0.74	-5.81	-0.3	1.5e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.76	-0.39	1.04e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg12564285	chr5:131593104	PDLIM4	0.46	8.12	0.41	8.78e-15	Breast cancer;
LUSC	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg02569458	chr12:86230093	RASSF9	0.48	7.65	0.39	2.21e-13	Major depressive disorder;
LUSC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.77	-13.67	-0.6	4.35e-34	Cognitive function;
LUSC	cis	rs9815354	1.000	rs9856633	chr3:42013850	C/T	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.31	5.91e-9	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg02117656	chr17:79614917	TSPAN10	-0.31	-5.69	-0.3	2.71e-8	Eye color traits;
LUSC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25072359	chr17:41440525	NA	-0.63	-8.87	-0.44	4.51e-17	Menopause (age at onset);
LUSC	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg17145862	chr1:211918768	LPGAT1	0.23	6.01	0.31	4.76e-9	Leprosy;
LUSC	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.92	0.51	6.12e-24	Hypertriglyceridemia;
LUSC	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00631329	chr6:26305371	NA	-0.45	-8.86	-0.44	4.68e-17	Educational attainment;
LUSC	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.82	-0.3	1.41e-8	Bipolar disorder;
LUSC	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg22907277	chr7:1156413	C7orf50	0.53	6.71	0.34	8.32e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	1.02	18.58	0.71	1.93e-53	Parkinson's disease;
LUSC	cis	rs9616064	0.886	rs11703960	chr22:46986423	A/T	cg25730555	chr22:47059586	GRAMD4	0.45	6.51	0.34	2.7e-10	Urate levels in obese individuals;
LUSC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg12463550	chr7:65579703	CRCP	0.52	7.46	0.38	7.59e-13	Aortic root size;
LUSC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	7.27	0.37	2.63e-12	Renal cell carcinoma;
LUSC	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg25237894	chr2:233734115	C2orf82	0.36	6.69	0.34	9.35e-11	Coronary artery disease;
LUSC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg03354898	chr7:1950403	MAD1L1	-0.42	-8.54	-0.42	4.86e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs35883536	0.626	rs7536054	chr1:101047849	A/G	cg06223162	chr1:101003688	GPR88	-0.47	-8.81	-0.43	6.81e-17	Monocyte count;
LUSC	trans	rs2262909	0.962	rs422344	chr19:22230956	C/G	cg05197062	chr11:11642011	GALNTL4	0.54	7.64	0.39	2.3e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06634786	chr22:41940651	POLR3H	-0.6	-6.77	-0.35	5.66e-11	Vitiligo;
LUSC	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.83	13.32	0.59	9.24e-33	Lymphocyte percentage of white cells;
LUSC	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg01884057	chr2:25150051	NA	0.49	11.61	0.54	2.1e-26	Body mass index in non-asthmatics;
LUSC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.62	-10.51	-0.5	1.6400000000000001e-22	Blood metabolite levels;
LUSC	cis	rs11597390	0.867	rs11596837	chr10:101850079	C/A	cg11888571	chr10:102027403	CWF19L1	-0.43	-5.97	-0.31	6.17e-9	Liver enzyme levels;
LUSC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.1	0.32	2.88e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.69	11.46	0.53	7.01e-26	Heart rate;
LUSC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg02428538	chr16:24856791	SLC5A11	-0.52	-5.92	-0.31	8.01e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg17366294	chr4:99064904	C4orf37	0.53	9.15	0.45	5.71e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg05855489	chr10:104503620	C10orf26	0.53	7.96	0.4	2.77e-14	Arsenic metabolism;
LUSC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg18904891	chr8:8559673	CLDN23	0.4	5.93	0.31	7.46e-9	Mood instability;
LUSC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-0.88	-18.62	-0.71	1.43e-53	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7640424	0.819	rs179046	chr3:107840773	A/C	cg09227934	chr3:107805635	CD47	-0.39	-6.15	-0.32	2.16e-9	Body mass index;
LUSC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg09021430	chr5:549028	NA	-0.54	-7.07	-0.36	8.97e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7524258	0.868	rs916393	chr1:7272250	T/C	cg07173049	chr1:7289937	CAMTA1	0.33	6.82	0.35	4.29e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg20404643	chr11:1492543	HCCA2	0.46	6.0	0.31	5.05e-9	Neuroticism;
LUSC	cis	rs7119	0.651	rs12917431	chr15:77850184	C/G	cg27398640	chr15:77910606	LINGO1	-0.34	-7.0	-0.36	1.37e-11	Type 2 diabetes;
LUSC	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.67	-5.89	-0.31	9.54e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.63	-5.9	-0.31	8.74e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1507153	0.775	rs12194701	chr6:79372837	G/A	cg05283184	chr6:79620031	NA	-0.42	-7.21	-0.37	3.75e-12	Sjögren's syndrome;
LUSC	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg18681998	chr4:17616180	MED28	0.77	13.73	0.6	2.53e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs868036	1.000	rs4776975	chr15:68102220	G/C	cg08079166	chr15:68083412	MAP2K5	0.4	8.28	0.41	3.04e-15	Restless legs syndrome;
LUSC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg13319975	chr6:146136371	FBXO30	0.5	7.6	0.38	2.95e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.77	-0.43	9.09e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg08601574	chr20:25228251	PYGB	-0.39	-5.75	-0.3	2.03e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg07701084	chr6:150067640	NUP43	0.52	7.78	0.39	8.84e-14	Lung cancer;
LUSC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-5.82	-0.3	1.35e-8	Vitiligo;
LUSC	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	10.25	0.49	1.31e-21	Mean corpuscular hemoglobin;
LUSC	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg19812747	chr11:111475976	SIK2	-0.53	-7.7	-0.39	1.59e-13	Primary sclerosing cholangitis;
LUSC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-0.88	-13.36	-0.59	6.63e-33	Vitiligo;
LUSC	cis	rs2303282	0.716	rs8056687	chr16:56468561	C/T	cg00500540	chr16:56394104	NA	-0.43	-7.35	-0.37	1.52e-12	Breast cancer;
LUSC	cis	rs11018904	0.861	rs12787117	chr11:89943681	A/G	cg26138821	chr11:89956704	CHORDC1	-0.58	-6.64	-0.34	1.3100000000000001e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.46	-0.33	3.74e-10	Life satisfaction;
LUSC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg15556689	chr8:8085844	FLJ10661	0.66	10.81	0.51	1.49e-23	Mood instability;
LUSC	cis	rs1507153	0.549	rs236862	chr6:79334972	T/C	cg05283184	chr6:79620031	NA	0.38	7.1	0.36	7.78e-12	Sjögren's syndrome;
LUSC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.83	-0.51	1.24e-23	Alzheimer's disease (late onset);
LUSC	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.36	-6.92	-0.35	2.31e-11	Caffeine consumption;
LUSC	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg22705602	chr4:152727874	NA	-0.29	-5.77	-0.3	1.83e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg14583973	chr4:3374767	RGS12	0.36	7.94	0.4	3.14e-14	Serum sulfate level;
LUSC	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18854424	chr1:2615690	NA	0.5	9.97	0.48	1.12e-20	Ulcerative colitis;
LUSC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.63	0.85	1.69e-95	Chronic sinus infection;
LUSC	cis	rs73206853	0.925	rs12297709	chr12:110901758	A/G	cg12870014	chr12:110450643	ANKRD13A	0.5	5.9	0.31	9.03e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.2	0.32	1.62e-9	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19869610	chr19:45996498	RTN2	0.41	6.21	0.32	1.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-8.18	-0.41	6.14e-15	Axial length;
LUSC	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg21775007	chr8:11205619	TDH	0.44	6.26	0.32	1.17e-9	Neuroticism;
LUSC	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg26876637	chr1:152193138	HRNR	0.43	6.24	0.32	1.34e-9	Atopic dermatitis;
LUSC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12136530	0.774	rs10158117	chr1:19766747	G/C	cg01832549	chr1:19774989	CAPZB	-0.31	-5.73	-0.3	2.28e-8	Lead levels in blood;
LUSC	cis	rs806215	0.756	rs806221	chr7:127243426	G/A	cg25922125	chr7:127225783	GCC1	0.52	6.69	0.34	9.51e-11	Type 2 diabetes;
LUSC	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.69	10.59	0.5	8.81e-23	Breast cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg27193377	chr16:75498489	TMEM170A	0.69	5.96	0.31	6.57e-9	Cognitive performance;
LUSC	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg23942311	chr14:51606299	NA	0.47	10.61	0.5	7.21e-23	Cancer;
LUSC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg18404041	chr3:52824283	ITIH1	-0.34	-6.16	-0.32	2.1e-9	Electroencephalogram traits;
LUSC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-15.16	-0.64	7.12e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg09826364	chr7:158789723	NA	-0.37	-5.72	-0.3	2.4e-8	Facial morphology (factor 20);
LUSC	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg12573674	chr2:1569213	NA	-0.55	-6.08	-0.32	3.38e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	8.33	0.41	2.16e-15	Total body bone mineral density;
LUSC	cis	rs926392	0.572	rs6129158	chr20:37673967	A/G	cg16355469	chr20:37678765	NA	0.54	7.42	0.38	9.52e-13	Dialysis-related mortality;
LUSC	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg21535247	chr6:8435926	SLC35B3	-0.58	-8.64	-0.43	2.31e-16	Motion sickness;
LUSC	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.99	-20.52	-0.75	3.99e-61	Ulcerative colitis;
LUSC	cis	rs79387448	0.745	rs74560841	chr2:103149210	G/A	cg09003973	chr2:102972529	NA	0.98	9.33	0.45	1.54e-18	Gut microbiota (bacterial taxa);
LUSC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21659725	chr3:3221576	CRBN	-0.52	-8.33	-0.41	2.05e-15	Body mass index;
LUSC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg00945038	chr17:61921165	SMARCD2	-0.42	-7.18	-0.37	4.59e-12	Prudent dietary pattern;
LUSC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg22166914	chr1:53195759	ZYG11B	-0.55	-8.77	-0.43	9.2e-17	Monocyte count;
LUSC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg00825309	chr19:58991885	ZNF446	-0.5	-7.13	-0.36	6.4e-12	Uric acid clearance;
LUSC	cis	rs1784581	0.588	rs10945792	chr6:162423484	C/T	cg17173639	chr6:162384350	PARK2	0.57	9.98	0.48	1.05e-20	Itch intensity from mosquito bite;
LUSC	trans	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg01620082	chr3:125678407	NA	-0.73	-6.26	-0.32	1.18e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg23241863	chr10:102295624	HIF1AN	0.5	5.98	0.31	5.63e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg14552801	chr7:65878734	NA	0.37	5.68	0.3	2.98e-8	Aortic root size;
LUSC	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.95	12.82	0.57	6.98e-31	Smoking behavior;
LUSC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	0.92	17.57	0.69	2.14e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg22906224	chr7:99728672	NA	0.47	6.51	0.34	2.82e-10	Coronary artery disease;
LUSC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg11812906	chr14:75593930	NEK9	0.67	11.71	0.54	8.78e-27	Height;
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.85	15.31	0.64	1.86e-40	Menarche (age at onset);
LUSC	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg21775007	chr8:11205619	TDH	0.42	6.13	0.32	2.41e-9	Mood instability;
LUSC	cis	rs6545883	0.868	rs2518932	chr2:61801277	T/A	cg15711740	chr2:61764176	XPO1	-0.46	-7.28	-0.37	2.35e-12	Tuberculosis;
LUSC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg16606324	chr3:10149918	C3orf24	0.55	7.4	0.38	1.11e-12	Alzheimer's disease;
LUSC	cis	rs847577	0.569	rs12674083	chr7:97696334	C/T	cg24562669	chr7:97807699	LMTK2	0.47	8.38	0.42	1.52e-15	Breast cancer;
LUSC	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg17168535	chr8:21777572	XPO7	0.66	10.09	0.48	4.62e-21	Mean corpuscular volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22718729	chr4:41216034	APBB2	-0.39	-5.98	-0.31	5.85e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg00933542	chr6:150070202	PCMT1	0.33	6.7	0.34	8.84e-11	Lung cancer;
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.51	-7.79	-0.39	8.61e-14	Lymphocyte counts;
LUSC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg07741184	chr6:167504864	NA	0.49	8.48	0.42	7.31e-16	Crohn's disease;
LUSC	cis	rs10740039	0.768	rs920646	chr10:62463525	C/T	cg18175470	chr10:62150864	ANK3	-0.44	-6.62	-0.34	1.44e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.5	-8.11	-0.41	9.76e-15	Platelet count;
LUSC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-10.93	-0.51	5.49e-24	Menarche (age at onset);
LUSC	trans	rs1508086	0.935	rs4737447	chr8:57812235	A/G	cg01310875	chr8:27938995	C8orf80	0.28	5.95	0.31	6.71e-9	Hand grip strength;
LUSC	cis	rs55910451	0.520	rs11596435	chr10:5841222	C/T	cg11519256	chr10:5708881	ASB13	-0.48	-6.18	-0.32	1.85e-9	Breast cancer;
LUSC	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg04362960	chr10:104952993	NT5C2	0.56	7.98	0.4	2.35e-14	Arsenic metabolism;
LUSC	cis	rs3740713	0.669	rs34740438	chr11:18415330	C/A	cg07915343	chr11:18477680	LDHAL6A	-0.46	-5.78	-0.3	1.68e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2479724	0.846	rs1536702	chr6:41869950	T/A	cg17623882	chr6:41773611	USP49	-0.59	-10.11	-0.48	3.94e-21	Menarche (age at onset);
LUSC	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg01884057	chr2:25150051	NA	0.48	11.45	0.53	8.06e-26	Body mass index;
LUSC	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg21427119	chr20:30132790	HM13	-0.35	-5.73	-0.3	2.24e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg04310649	chr10:35416472	CREM	-0.42	-6.59	-0.34	1.74e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs611744	0.573	rs1457210	chr8:109261562	A/G	cg21045802	chr8:109455806	TTC35	-0.4	-6.34	-0.33	7.59e-10	Dupuytren's disease;
LUSC	cis	rs9811920	0.666	rs793456	chr3:99525631	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-7.33	-0.37	1.8e-12	Axial length;
LUSC	cis	rs4698790	1.000	rs4698790	chr4:110727560	A/C	cg07850274	chr4:110748770	RRH	0.39	6.18	0.32	1.92e-9	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUSC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg11859384	chr17:80120422	CCDC57	0.36	5.65	0.3	3.49e-8	Life satisfaction;
LUSC	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	0.78	10.05	0.48	6.16e-21	Coronary artery disease;
LUSC	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg22852734	chr6:133119734	C6orf192	1.14	13.45	0.59	2.94e-33	Type 2 diabetes nephropathy;
LUSC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	5.98	0.31	5.79e-9	Parkinson's disease;
LUSC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg23711669	chr6:146136114	FBXO30	0.7	10.69	0.5	3.89e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg10253484	chr15:75165896	SCAMP2	-0.46	-6.64	-0.34	1.24e-10	Breast cancer;
LUSC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg00701064	chr4:6280414	WFS1	0.59	14.6	0.62	1.11e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs4792901	0.765	rs2127224	chr17:41569025	C/T	cg22562494	chr17:41607896	ETV4	-0.35	-6.56	-0.34	2.11e-10	Dupuytren's disease;
LUSC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg24531977	chr5:56204891	C5orf35	-0.72	-10.23	-0.49	1.55e-21	Coronary artery disease;
LUSC	cis	rs59104589	0.617	rs61615527	chr2:242342768	T/A	cg14842376	chr2:242211374	HDLBP	0.54	6.33	0.33	7.68e-10	Fibrinogen levels;
LUSC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.87	-0.31	1.07e-8	Tonsillectomy;
LUSC	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg02660097	chr11:68866761	NA	0.43	6.07	0.32	3.44e-9	Blond vs. brown hair color;
LUSC	cis	rs981844	0.754	rs897608	chr4:154754960	C/T	cg14289246	chr4:154710475	SFRP2	0.45	5.94	0.31	7.22e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg04362960	chr10:104952993	NT5C2	0.62	9.83	0.47	3.35e-20	Arsenic metabolism;
LUSC	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.75	-0.73	4.73e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.97	0.36	1.71e-11	Lung cancer in ever smokers;
LUSC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg17366294	chr4:99064904	C4orf37	0.55	9.66	0.47	1.25e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg05855489	chr10:104503620	C10orf26	-0.48	-7.41	-0.38	1.04e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg24675056	chr1:15929824	NA	0.49	8.45	0.42	8.94e-16	Systolic blood pressure;
LUSC	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.61	-9.96	-0.48	1.23e-20	Schizophrenia;
LUSC	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg15506890	chr2:3487001	NA	-0.53	-8.21	-0.41	4.93e-15	Neurofibrillary tangles;
LUSC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg00450029	chr8:599525	NA	0.56	5.73	0.3	2.26e-8	IgG glycosylation;
LUSC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg07212818	chr11:638076	DRD4	-0.38	-6.51	-0.34	2.79e-10	Systemic lupus erythematosus;
LUSC	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg20026190	chr17:76395443	PGS1	-0.4	-7.1	-0.36	7.74e-12	HDL cholesterol levels;
LUSC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg04455712	chr21:45112962	RRP1B	0.43	8.18	0.41	5.82e-15	Mean corpuscular volume;
LUSC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg12863693	chr15:85201151	NMB	0.34	6.78	0.35	5.49e-11	Schizophrenia;
LUSC	cis	rs4654899	0.897	rs7515308	chr1:21085653	G/C	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.36	9.91e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-7.54	-0.38	4.52e-13	Aortic root size;
LUSC	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg22532475	chr10:104410764	TRIM8	0.26	6.14	0.32	2.37e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2227564	0.729	rs2688611	chr10:75653372	G/T	cg23231163	chr10:75533350	FUT11	-0.45	-6.29	-0.33	9.68e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs17092148	1.000	rs6058112	chr20:33322006	G/C	cg16810054	chr20:33298113	TP53INP2	-0.41	-6.24	-0.32	1.36e-9	Neuroticism;
LUSC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg14552801	chr7:65878734	NA	-0.46	-6.61	-0.34	1.5e-10	Aortic root size;
LUSC	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg15704280	chr7:45808275	SEPT13	-0.92	-14.23	-0.61	3.04e-36	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07165811	chr19:3360732	NFIC	0.39	5.99	0.31	5.45e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11645898	0.935	rs72787091	chr16:72190184	C/T	cg14768367	chr16:72042858	DHODH	-0.67	-7.32	-0.37	1.82e-12	Blood protein levels;
LUSC	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg10356904	chr22:49881777	NA	-0.3	-5.94	-0.31	7.14e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.52	10.24	0.49	1.38e-21	Schizophrenia;
LUSC	trans	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.75e-10	Corneal astigmatism;
LUSC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.49	-0.73	4.84e-57	Height;
LUSC	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg21095983	chr6:86352623	SYNCRIP	0.51	8.07	0.4	1.31e-14	Smooth-surface caries;
LUSC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg01283332	chr5:1856932	NA	-0.34	-6.38	-0.33	6.02e-10	Cardiovascular disease risk factors;
LUSC	cis	rs6740322	0.895	rs6711966	chr2:43561989	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.43	-5.93	-0.31	7.56e-9	Coronary artery disease;
LUSC	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg06060754	chr5:176797920	RGS14	-0.62	-8.75	-0.43	1.09e-16	Urate levels in lean individuals;
LUSC	cis	rs10392	0.543	rs748063	chr20:37548730	A/G	cg27552599	chr20:37590471	DHX35	0.45	7.25	0.37	2.95e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg00898013	chr13:113819073	PROZ	-0.56	-8.06	-0.4	1.36e-14	Platelet distribution width;
LUSC	cis	rs73198271	0.740	rs10103163	chr8:8650675	T/C	cg01851573	chr8:8652454	MFHAS1	0.52	8.44	0.42	9.81e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs11018904	0.906	rs36177012	chr11:89933319	T/C	cg26834418	chr11:89957033	CHORDC1	-0.51	-6.13	-0.32	2.53e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg14582100	chr15:45693742	SPATA5L1	0.45	8.4	0.42	1.29e-15	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs6600671	1.000	rs10794671	chr1:121168242	A/C	cg00646200	chr1:148855367	NA	0.43	6.7	0.34	8.89e-11	Hip geometry;
LUSC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.94	-17.99	-0.7	4.38e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg15448220	chr1:150897856	SETDB1	0.41	6.18	0.32	1.84e-9	Melanoma;
LUSC	cis	rs17094222	0.504	rs12267029	chr10:102458677	C/A	cg04918978	chr10:102441148	NA	-0.39	-5.65	-0.3	3.51e-8	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg10978503	chr1:24200527	CNR2	0.52	13.01	0.58	1.41e-31	Immature fraction of reticulocytes;
LUSC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg23791538	chr6:167370224	RNASET2	-0.41	-6.54	-0.34	2.25e-10	Crohn's disease;
LUSC	trans	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg10756647	chr7:56101905	PSPH	0.87	8.43	0.42	1.06e-15	Diabetic kidney disease;
LUSC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.49	0.33	3.07e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7614311	0.636	rs73117047	chr3:63910779	G/A	cg22134162	chr3:63841271	THOC7	-0.49	-6.1	-0.32	3.02e-9	Lung function (FVC);Lung function (FEV1);
LUSC	trans	rs80093141	0.575	rs4899111	chr14:39356991	G/A	cg08262584	chr8:54154426	OPRK1	0.43	5.99	0.31	5.42e-9	Common carotid intima-media thickness in HIV infection;
LUSC	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.87	-0.31	1.05e-8	Testicular germ cell tumor;
LUSC	cis	rs151349	1.000	rs108727	chr20:57584890	C/T	cg23907860	chr20:57583709	CTSZ	0.48	8.01	0.4	1.92e-14	Platelet distribution width;
LUSC	cis	rs2979489	0.841	rs2015311	chr8:30306989	A/G	cg26383811	chr8:30366931	RBPMS	0.48	7.6	0.38	3.05e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg13010199	chr12:38710504	ALG10B	0.58	9.23	0.45	3.24e-18	Morning vs. evening chronotype;
LUSC	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.52	10.42	0.5	3.46e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg18904891	chr8:8559673	CLDN23	0.55	7.53	0.38	4.84e-13	Obesity-related traits;
LUSC	trans	rs3857536	0.813	rs62415859	chr6:66934278	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	trans	rs9341835	0.518	rs6924479	chr6:64173940	A/G	cg19533977	chr17:57719682	CLTC	-0.32	-5.95	-0.31	6.82e-9	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.74	-12.13	-0.55	2.53e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg06618935	chr21:46677482	NA	-0.38	-7.57	-0.38	3.79e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2224391	1.000	rs13191012	chr6:5261292	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.47	-6.74	-0.35	7.14e-11	Height;
LUSC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	13.31	0.59	9.7e-33	Cognitive test performance;
LUSC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.2	0.41	5.41e-15	Electroencephalogram traits;
LUSC	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg02886208	chr11:14281011	SPON1	0.32	5.84	0.3	1.26e-8	Mitochondrial DNA levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19877921	chr17:61904685	PSMC5;FTSJ3	-0.51	-6.47	-0.33	3.44e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.28	5.66	0.3	3.33e-8	Cognitive function;
LUSC	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg05425664	chr17:57184151	TRIM37	0.55	8.49	0.42	7.03e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-1.0	-19.2	-0.72	7.08e-56	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13006833	0.739	rs291472	chr2:191190605	A/G	cg21644426	chr2:191273491	MFSD6	0.44	6.28	0.32	1.05e-9	Urinary metabolites;
LUSC	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-6.77	-0.35	5.7e-11	Major depressive disorder;
LUSC	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg13072238	chr3:49761600	GMPPB	-0.69	-9.06	-0.44	1.08e-17	Menarche (age at onset);
LUSC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg15790184	chr11:494944	RNH1	0.52	6.09	0.32	3.1e-9	Body mass index;
LUSC	trans	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.79	-0.43	8.32e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2078087	0.831	rs12404011	chr1:183247022	G/C	cg13843938	chr1:183241246	NMNAT2	0.47	6.14	0.32	2.4e-9	Obesity-related traits;
LUSC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg22532475	chr10:104410764	TRIM8	-0.39	-8.37	-0.42	1.65e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25072359	chr17:41440525	NA	0.68	9.5	0.46	4.34e-19	Menopause (age at onset);
LUSC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg10523679	chr1:76189770	ACADM	0.85	11.26	0.52	3.77e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-10.39	-0.49	4.23e-22	Bipolar disorder;
LUSC	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg10326726	chr10:51549505	MSMB	0.35	6.09	0.32	3.14e-9	Prostate-specific antigen levels;
LUSC	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg17173187	chr15:85201210	NMB	-0.31	-6.33	-0.33	8.05e-10	P wave terminal force;
LUSC	cis	rs2147959	1.000	rs2147959	chr1:228644232	A/T	cg18477163	chr1:228402036	OBSCN	-0.44	-6.0	-0.31	5.14e-9	Adult asthma;
LUSC	cis	rs868036	0.958	rs3784709	chr15:68072275	C/T	cg08079166	chr15:68083412	MAP2K5	0.38	7.92	0.4	3.48e-14	Restless legs syndrome;
LUSC	cis	rs9811920	0.603	rs2638948	chr3:99501539	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-7.36	-0.37	1.43e-12	Axial length;
LUSC	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.69	11.89	0.55	2e-27	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.4	-0.33	5.3e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg04998671	chr14:104000505	TRMT61A	-0.46	-6.65	-0.34	1.16e-10	Reticulocyte count;
LUSC	cis	rs9309473	1.000	rs10187192	chr2:73713500	T/C	cg20560298	chr2:73613845	ALMS1	-0.49	-7.1	-0.36	7.47e-12	Metabolite levels;
LUSC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg11062466	chr8:58055876	NA	0.51	7.05	0.36	1.06e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg22705602	chr4:152727874	NA	-0.34	-6.84	-0.35	3.79e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg12667521	chr19:29218732	NA	0.51	5.96	0.31	6.4e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06850241	chr22:41845214	NA	0.29	5.71	0.3	2.5e-8	Vitiligo;
LUSC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg27170947	chr2:26402098	FAM59B	0.71	10.74	0.51	2.59e-23	Gut microbiome composition (summer);
LUSC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg09796270	chr17:17721594	SREBF1	-0.43	-7.55	-0.38	4.32e-13	Total body bone mineral density;
LUSC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22496380	chr5:211416	CCDC127	-0.74	-8.61	-0.43	2.96e-16	Breast cancer;
LUSC	cis	rs12575480	0.637	rs7482782	chr11:2097954	C/T	cg15541987	chr11:2077307	NA	-0.43	-6.42	-0.33	4.59e-10	Pursuit maintenance gain;
LUSC	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg00021532	chr16:4324280	TFAP4	0.79	14.34	0.62	1.08e-36	Prostate-specific antigen levels;
LUSC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.72	-16.65	-0.67	9.3e-46	Prostate cancer;
LUSC	trans	rs34421088	0.532	rs1545073	chr8:11167700	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	6.01	0.31	4.74e-9	Neuroticism;
LUSC	cis	rs13082711	0.522	rs640065	chr3:27363937	A/T	cg02860705	chr3:27208620	NA	0.43	7.94	0.4	3.11e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7527798	0.592	rs11118337	chr1:207852693	G/C	cg09232269	chr1:207846808	CR1L	-0.29	-6.26	-0.32	1.21e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs11997175	1.000	rs6468200	chr8:33745191	A/T	ch.8.33884649F	chr8:33765107	NA	0.51	8.05	0.4	1.42e-14	Body mass index;
LUSC	cis	rs6977660	0.607	rs7357321	chr7:19817636	C/T	cg07541023	chr7:19748670	TWISTNB	0.58	6.3	0.33	9.55e-10	Thyroid stimulating hormone;
LUSC	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.97	-0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg00033643	chr7:134001901	SLC35B4	0.44	6.82	0.35	4.34e-11	Mean platelet volume;
LUSC	cis	rs2692947	0.599	rs7561198	chr2:96774981	C/G	cg22654517	chr2:96458247	NA	-0.32	-5.9	-0.31	9.11e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08642237	chr15:45694386	SPATA5L1	0.43	6.2	0.32	1.68e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs59104589	0.617	rs59487360	chr2:242270433	A/G	cg14842376	chr2:242211374	HDLBP	0.58	6.52	0.34	2.54e-10	Fibrinogen levels;
LUSC	cis	rs4654899	1.000	rs6697555	chr1:21287938	C/T	cg01072550	chr1:21505969	NA	-0.53	-8.16	-0.41	6.68e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.79	11.11	0.52	1.32e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg10818794	chr15:86012489	AKAP13	0.42	6.49	0.33	3.03e-10	Coronary artery disease;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg15242686	chr22:24348715	GSTTP1	0.39	5.87	0.31	1.03e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7923609	0.967	rs7912893	chr10:65162000	T/A	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	3.84e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.62	-0.5	6.98e-23	Obesity-related traits;
LUSC	cis	rs3931020	0.688	rs277396	chr1:75213648	A/C	cg10128416	chr1:75198403	TYW3;CRYZ	-0.64	-8.55	-0.42	4.38e-16	Resistin levels;
LUSC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg20573242	chr4:122745356	CCNA2	0.42	6.4	0.33	5.22e-10	Type 2 diabetes;
LUSC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.33	-0.33	7.85e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.58	0.38	3.51e-13	Prudent dietary pattern;
LUSC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.57	-10.59	-0.5	8.49e-23	Homoarginine levels;
LUSC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg23283495	chr1:209979779	IRF6	0.62	9.07	0.44	1.05e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs6905628	1	rs6905628	chr6:90344869	C/G	cg23505970	chr6:90529759	MDN1	0.53	7.65	0.39	2.1e-13	Coronary artery disease;
LUSC	cis	rs6460942	0.591	rs62448728	chr7:12332915	A/T	cg06484146	chr7:12443880	VWDE	-0.56	-5.89	-0.31	9.39e-9	Coronary artery disease;
LUSC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg26818010	chr10:134567672	INPP5A	-0.45	-6.82	-0.35	4.25e-11	Migraine;
LUSC	trans	rs975730	0.801	rs6998301	chr8:129435018	A/G	cg12887701	chr11:96123196	JRKL;CCDC82	0.37	6.06	0.31	3.64e-9	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	0.96	17.69	0.7	7.15e-50	Heart rate;
LUSC	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg23625390	chr15:77176239	SCAPER	0.51	8.01	0.4	1.91e-14	Blood metabolite levels;
LUSC	cis	rs9976767	0.637	rs2156309	chr21:43824529	G/A	cg20516845	chr21:43823604	UBASH3A	-0.25	-5.86	-0.31	1.12e-8	Type 1 diabetes;
LUSC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg25036284	chr2:26402008	FAM59B	-0.73	-10.66	-0.5	4.85e-23	Gut microbiome composition (summer);
LUSC	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg17252645	chr8:143867129	LY6D	0.37	6.56	0.34	2.08e-10	Urinary tract infection frequency;
LUSC	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14159747	chr11:113255604	NA	0.31	8.0	0.4	2.04e-14	Neuroticism;
LUSC	cis	rs1045714	0.895	rs61729413	chr7:2646796	G/A	cg24848437	chr7:2645542	IQCE	0.6	6.92	0.35	2.29e-11	Urate levels in lean individuals;
LUSC	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.12	-0.45	7.32e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.42	0.5	3.24e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg17469321	chr7:55412551	NA	0.65	10.58	0.5	9.11e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs724744	0.772	rs1737232	chr6:22351919	A/G	cg13807341	chr11:118445984	ARCN1	-0.36	-6.16	-0.32	2.06e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg13722127	chr7:150037890	RARRES2	0.38	5.7	0.3	2.63e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg25110126	chr1:46999211	NA	0.73	10.68	0.5	4.35e-23	Monobrow;
LUSC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	6.01	0.31	4.88e-9	Breast cancer;
LUSC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs548181	0.609	rs511822	chr11:125534115	C/T	cg03464685	chr11:125439445	EI24	1.22	14.61	0.62	9.8e-38	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	8.03	0.4	1.68e-14	Iron status biomarkers;
LUSC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg23205692	chr1:25664452	TMEM50A	0.44	6.66	0.34	1.14e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg05163923	chr11:71159392	DHCR7	0.65	8.21	0.41	4.97e-15	Vitamin D levels;
LUSC	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg19743168	chr1:23544995	NA	-0.45	-8.99	-0.44	1.86e-17	Height;
LUSC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg27284194	chr4:1044797	NA	0.36	5.65	0.3	3.46e-8	Longevity;
LUSC	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg02175503	chr12:58329896	NA	0.46	6.8	0.35	4.91e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg21053147	chr12:120880522	NA	0.49	6.08	0.32	3.34e-9	Type 1 diabetes nephropathy;
LUSC	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg10840412	chr1:235813424	GNG4	0.57	7.12	0.36	6.73e-12	Bipolar disorder;
LUSC	cis	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg06521331	chr12:34319734	NA	-0.45	-7.38	-0.37	1.29e-12	Morning vs. evening chronotype;
LUSC	cis	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg06521331	chr12:34319734	NA	0.38	6.34	0.33	7.51e-10	Morning vs. evening chronotype;
LUSC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.8	0.3	1.5e-8	Menopause (age at onset);
LUSC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.72	-12.81	-0.57	7.8e-31	Dental caries;
LUSC	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg05768032	chr16:30646687	NA	0.4	5.94	0.31	7.12e-9	Multiple myeloma;
LUSC	cis	rs8170	0.603	rs11086068	chr19:17420165	T/C	cg04749549	chr19:17459798	NA	-0.31	-5.76	-0.3	1.94e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUSC	cis	rs68170813	0.559	rs7809508	chr7:107004119	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.71	-0.47	8.68e-20	Coronary artery disease;
LUSC	cis	rs12367572	0.930	rs11615964	chr12:45261564	C/T	cg04608330	chr12:45269318	NELL2	-0.56	-8.8	-0.43	7.39e-17	Gut microbiome composition (summer);
LUSC	cis	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.22	-0.32	1.51e-9	Myopia (pathological);
LUSC	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg02023728	chr11:77925099	USP35	0.43	6.58	0.34	1.77e-10	Testicular germ cell tumor;
LUSC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg24503407	chr1:205819492	PM20D1	0.77	13.1	0.58	6.19e-32	Menarche (age at onset);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15826130	chr11:67159072	LOC100130987;RAD9A	-0.47	-6.36	-0.33	6.5e-10	Hepatitis;
LUSC	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	0.6	9.65	0.47	1.34e-19	Breast cancer;
LUSC	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg00982548	chr2:198649783	BOLL	-0.58	-7.29	-0.37	2.32e-12	Ulcerative colitis;
LUSC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg04775059	chr7:64541387	NA	0.49	7.15	0.36	5.64e-12	Calcium levels;
LUSC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	trans	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg13010199	chr12:38710504	ALG10B	0.45	7.04	0.36	1.13e-11	Morning vs. evening chronotype;
LUSC	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-7.39	-0.37	1.21e-12	Axial length;
LUSC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg20811857	chr17:78079795	GAA	-0.32	-5.9	-0.31	8.87e-9	Yeast infection;
LUSC	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg03676636	chr4:99064102	C4orf37	0.3	5.88	0.31	1e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg07080220	chr10:102295463	HIF1AN	0.62	7.49	0.38	6.32e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg06917634	chr15:78832804	PSMA4	-0.46	-6.32	-0.33	8.28e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16249355	chr17:76310516	NA	-0.49	-6.59	-0.34	1.67e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs4363385	0.510	rs7543689	chr1:153046803	A/T	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.39	-0.33	5.43e-10	Inflammatory skin disease;
LUSC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg09165964	chr15:75287851	SCAMP5	-1.02	-15.28	-0.64	2.35e-40	Blood trace element (Zn levels);
LUSC	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg13256891	chr4:100009986	ADH5	-0.44	-6.04	-0.31	4.16e-9	Alcohol dependence;
LUSC	cis	rs12519773	1.000	rs995620	chr5:92452676	A/C	cg18783429	chr5:92414398	NA	0.29	6.38	0.33	6.07e-10	Migraine;
LUSC	cis	rs9398803	0.931	rs1361262	chr6:126701967	T/C	cg19875578	chr6:126661172	C6orf173	0.41	6.1	0.32	2.95e-9	Male-pattern baldness;
LUSC	cis	rs965469	1.000	rs2281503	chr20:3263636	G/A	cg25506879	chr20:3388711	C20orf194	-0.53	-5.93	-0.31	7.54e-9	IFN-related cytopenia;
LUSC	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg08213375	chr14:104286397	PPP1R13B	0.38	6.22	0.32	1.48e-9	Reticulocyte count;
LUSC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg07424592	chr7:64974309	NA	-0.65	-5.75	-0.3	1.99e-8	Diabetic kidney disease;
LUSC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg18240062	chr17:79603768	NPLOC4	0.69	12.86	0.58	4.98e-31	Eye color traits;
LUSC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs752010	0.574	rs12130138	chr1:42117792	A/C	cg06885757	chr1:42089581	HIVEP3	0.44	9.19	0.45	4.4e-18	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.98	19.75	0.73	4.65e-58	Subjective well-being;
LUSC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.8	-15.16	-0.64	7.29e-40	Age at first birth;
LUSC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg02503808	chr4:7069936	GRPEL1	1.05	14.94	0.63	5.16e-39	Monocyte percentage of white cells;
LUSC	trans	rs72674100	1.000	rs77619190	chr4:97991906	C/A	cg16405019	chr1:18959625	PAX7	-0.61	-6.0	-0.31	5.27e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.63	-0.34	1.32e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4499344	0.730	rs7247597	chr19:33102257	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg19875535	chr5:140030758	IK	-0.53	-8.55	-0.42	4.42e-16	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.5e-8	Breast cancer;
LUSC	cis	rs7771547	0.642	rs595954	chr6:36464834	C/G	cg07856975	chr6:36356162	ETV7	0.35	6.2	0.32	1.69e-9	Platelet distribution width;
LUSC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg20821713	chr7:1055600	C7orf50	-0.54	-7.1	-0.36	7.69e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-8.11	-0.41	9.71e-15	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg07211511	chr3:129823064	LOC729375	-0.75	-9.68	-0.47	1.1e-19	Blood pressure (smoking interaction);
LUSC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.79	-0.39	8.44e-14	Type 2 diabetes;
LUSC	cis	rs11997175	0.583	rs7829680	chr8:33794207	C/T	ch.8.33884649F	chr8:33765107	NA	-0.46	-6.77	-0.35	5.71e-11	Body mass index;
LUSC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg11965913	chr1:205819406	PM20D1	-0.47	-7.17	-0.37	4.82e-12	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg13256891	chr4:100009986	ADH5	0.48	7.11	0.36	7.05e-12	Alcohol dependence;
LUSC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.2	-0.32	1.62e-9	Life satisfaction;
LUSC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg01657329	chr11:68192670	LRP5	0.45	7.24	0.37	3.04e-12	Total body bone mineral density;
LUSC	cis	rs13089785	0.791	rs16834826	chr3:123584488	C/T	cg02558132	chr3:123411198	MYLK	-0.36	-6.3	-0.33	9.25e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg21132104	chr15:45694354	SPATA5L1	0.56	7.75	0.39	1.08e-13	Homoarginine levels;
LUSC	cis	rs11645898	0.935	rs4788605	chr16:72154682	G/T	cg14768367	chr16:72042858	DHODH	-0.64	-7.35	-0.37	1.52e-12	Blood protein levels;
LUSC	cis	rs1712517	0.566	rs7076274	chr10:105046007	G/A	cg04362960	chr10:104952993	NT5C2	-0.49	-6.66	-0.34	1.1e-10	Migraine;
LUSC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.36	6.59	0.34	1.75e-10	Neutrophil percentage of white cells;
LUSC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs6460942	0.591	rs4721082	chr7:12341804	A/G	cg06484146	chr7:12443880	VWDE	-0.59	-6.24	-0.32	1.36e-9	Coronary artery disease;
LUSC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg05347473	chr6:146136440	FBXO30	0.58	10.07	0.48	5.23e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12618769	0.652	rs11537554	chr2:99216531	A/G	cg10123293	chr2:99228465	UNC50	0.47	7.7	0.39	1.59e-13	Bipolar disorder;
LUSC	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg17507749	chr15:85114479	UBE2QP1	0.67	8.72	0.43	1.32e-16	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7113850	0.541	rs61875405	chr11:24376359	G/A	ch.11.24196551F	chr11:24239977	NA	0.65	5.73	0.3	2.18e-8	Bone fracture in osteoporosis;
LUSC	cis	rs7833986	1.000	rs34516759	chr8:57097138	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	9.2	0.45	3.84e-18	Height;
LUSC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12826209	chr6:26865740	GUSBL1	-0.76	-9.94	-0.48	1.48e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03576123	chr11:487126	PTDSS2	-0.97	-10.78	-0.51	1.95e-23	Body mass index;
LUSC	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.14	-20.35	-0.74	1.94e-60	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21659725	chr3:3221576	CRBN	0.6	8.72	0.43	1.32e-16	Resting heart rate;
LUSC	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.48	-9.04	-0.44	1.27e-17	Axial length;
LUSC	cis	rs12541635	0.677	rs2029880	chr8:107024649	T/C	cg10147462	chr8:107024639	NA	0.68	14.15	0.61	5.93e-36	Age of smoking initiation;
LUSC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg00376283	chr12:123451042	ABCB9	0.65	8.33	0.41	2.18e-15	Neutrophil percentage of white cells;
LUSC	cis	rs3755132	0.852	rs2302937	chr2:15770061	G/A	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.92	0.31	7.94e-9	Lung cancer;
LUSC	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06636551	chr8:101224915	SPAG1	0.38	7.08	0.36	8.4e-12	Atrioventricular conduction;
LUSC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06022373	chr22:39101656	GTPBP1	0.84	14.01	0.61	2.07e-35	Menopause (age at onset);
LUSC	cis	rs4478858	0.684	rs4949373	chr1:31741577	G/A	cg00250761	chr1:31883323	NA	-0.33	-7.95	-0.4	2.9e-14	Alcohol dependence;
LUSC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg24675658	chr1:53192096	ZYG11B	0.6	9.33	0.45	1.51e-18	Monocyte count;
LUSC	cis	rs3849570	1.000	rs11711331	chr3:81819040	A/G	cg07356753	chr3:81810745	GBE1	0.68	10.96	0.51	4.39e-24	Waist circumference;Body mass index;
LUSC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg08508325	chr11:3079039	CARS	0.46	10.84	0.51	1.2e-23	Longevity;
LUSC	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg06552810	chr11:31128660	NA	-0.4	-7.17	-0.37	4.73e-12	Red blood cell count;
LUSC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg02757194	chr11:44748427	NA	0.66	6.29	0.33	1.01e-9	Myocardial infarction;
LUSC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg16006841	chr5:176797999	RGS14	0.65	10.5	0.5	1.79e-22	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg19592336	chr6:28129416	ZNF389	0.48	5.92	0.31	7.9e-9	Parkinson's disease;
LUSC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21028142	chr17:79581711	NPLOC4	0.32	7.79	0.39	8.41e-14	Eye color traits;
LUSC	cis	rs10992471	0.603	rs755209	chr9:95489671	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-5.64	-0.3	3.58e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.49	-9.43	-0.46	7.05e-19	Axial length;
LUSC	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg05347473	chr6:146136440	FBXO30	-0.41	-6.91	-0.35	2.48e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg24675056	chr1:15929824	NA	0.44	7.57	0.38	3.66e-13	Systolic blood pressure;
LUSC	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg24449463	chr1:168025552	DCAF6	-0.63	-9.47	-0.46	5.4e-19	Schizophrenia;
LUSC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23158103	chr7:148848205	ZNF398	-0.45	-7.5	-0.38	5.76e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs113084984	0.816	rs4669749	chr2:11692664	A/C	cg07314298	chr2:11723111	GREB1	-0.4	-5.96	-0.31	6.26e-9	Breast cancer;
LUSC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg27494647	chr7:150038898	RARRES2	0.51	7.86	0.4	5.3e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7818345	0.904	rs6997164	chr8:19287856	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.64	0.34	1.28e-10	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg23985595	chr17:80112537	CCDC57	0.31	5.94	0.31	7.01e-9	Life satisfaction;
LUSC	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg20991723	chr1:152506922	NA	0.49	9.23	0.45	3.09e-18	Hair morphology;
LUSC	cis	rs7727544	0.582	rs3792894	chr5:131547271	C/T	cg24060327	chr5:131705240	SLC22A5	-0.34	-5.67	-0.3	3.12e-8	Blood metabolite levels;
LUSC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg12963246	chr6:28129442	ZNF389	0.55	7.63	0.39	2.55e-13	Depression;
LUSC	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg00376283	chr12:123451042	ABCB9	-0.72	-10.97	-0.51	4.12e-24	Platelet count;
LUSC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg18230493	chr5:56204884	C5orf35	-0.95	-14.26	-0.62	2.34e-36	Initial pursuit acceleration;
LUSC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg09359103	chr1:154839909	KCNN3	-0.72	-17.47	-0.69	5.45e-49	Prostate cancer;
LUSC	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg14092571	chr14:90743983	NA	-0.36	-5.8	-0.3	1.55e-8	Mortality in heart failure;
LUSC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	7.49	0.38	6.25e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.49	-0.33	3.05e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs72634258	0.945	rs12727642	chr1:8046672	C/A	cg00042356	chr1:8021962	PARK7	0.77	9.78	0.47	5.03e-20	Inflammatory bowel disease;
LUSC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg13397359	chr6:42928475	GNMT	0.63	10.5	0.5	1.78e-22	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.03	0.31	4.23e-9	Recombination rate (females);
LUSC	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg03732007	chr1:2071316	PRKCZ	0.46	7.45	0.38	7.84e-13	Height;
LUSC	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.44	-6.43	-0.33	4.51e-10	Eosinophil percentage of white cells;
LUSC	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg12927641	chr6:109611667	NA	-0.36	-6.12	-0.32	2.57e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs1325195	0.920	rs2793812	chr1:179159399	C/A	cg11624085	chr17:8464688	MYH10	0.41	6.64	0.34	1.29e-10	IgE grass sensitization;
LUSC	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg20628663	chr10:43360327	NA	0.76	10.64	0.5	6.04e-23	Blood protein levels;
LUSC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg04756594	chr16:24857601	SLC5A11	0.46	6.45	0.33	4.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2742234	0.955	rs2075913	chr10:43622368	T/A	cg02780029	chr10:43622663	RET	-0.36	-6.89	-0.35	2.74e-11	Hirschsprung disease;
LUSC	cis	rs6681460	0.549	rs1373909	chr1:67040875	A/G	cg02459107	chr1:67143332	SGIP1	0.32	5.78	0.3	1.75e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.5	0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg20243544	chr17:37824526	PNMT	0.5	7.06	0.36	9.93e-12	Asthma;
LUSC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	8.72	0.43	1.28e-16	Alzheimer's disease;
LUSC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg12560992	chr17:57184187	TRIM37	-0.84	-15.34	-0.64	1.48e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg09184832	chr6:79620586	NA	-0.42	-6.79	-0.35	5.28e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7833986	1.000	rs13281873	chr8:57101799	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	8.74	0.43	1.18e-16	Height;
LUSC	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg14500267	chr11:67383377	NA	0.34	6.43	0.33	4.37e-10	Mean corpuscular volume;
LUSC	trans	rs11123259	0.761	rs34232809	chr2:115711243	C/A	cg00844339	chr9:138873417	NA	0.29	5.99	0.31	5.29e-9	Gut microbiome composition (winter);
LUSC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	6.31	0.33	8.66e-10	Parkinson's disease;
LUSC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg00074818	chr8:8560427	CLDN23	0.57	9.69	0.47	1.01e-19	Obesity-related traits;
LUSC	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.1e-40	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg10756647	chr7:56101905	PSPH	-0.87	-8.66	-0.43	2.02e-16	Diabetic kidney disease;
LUSC	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.47	7.91	0.4	3.88e-14	Alcohol dependence;
LUSC	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	7.02	0.36	1.28e-11	Resting heart rate;
LUSC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21963583	chr11:68658836	MRPL21	-0.5	-7.47	-0.38	6.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg24644049	chr4:85504048	CDS1	0.86	7.56	0.38	3.83e-13	Skin colour saturation;
LUSC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-11.67	-0.54	1.29e-26	Bipolar disorder and schizophrenia;
LUSC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg06784218	chr1:46089804	CCDC17	0.47	9.26	0.45	2.6e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	0.65	9.14	0.45	6.14e-18	Methadone dose in opioid dependence;
LUSC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.42	-5.73	-0.3	2.28e-8	Reticulocyte count;
LUSC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.81	0.35	4.59e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg22508957	chr16:3507546	NAT15	0.66	11.04	0.52	2.2e-24	Tuberculosis;
LUSC	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-7.28	-0.37	2.42e-12	Fear of minor pain;
LUSC	cis	rs77633900	0.614	rs280001	chr15:77003566	C/A	cg21673338	chr15:77095150	SCAPER	-0.78	-7.97	-0.4	2.54e-14	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-7.04	-0.36	1.12e-11	Homocysteine levels;
LUSC	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg05283184	chr6:79620031	NA	-0.46	-8.68	-0.43	1.78e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg05283184	chr6:79620031	NA	-0.45	-8.54	-0.42	4.85e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg06223162	chr1:101003688	GPR88	-0.54	-9.93	-0.48	1.58e-20	Breast cancer;
LUSC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.89	-0.35	2.7e-11	Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22109331	chr1:212003961	LPGAT1	0.39	5.96	0.31	6.42e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg04850211	chr1:228464232	OBSCN	-0.32	-5.75	-0.3	1.98e-8	Diastolic blood pressure;
LUSC	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg05527609	chr1:210001259	C1orf107	1.03	14.69	0.63	5.02e-38	Orofacial clefts;
LUSC	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg22705602	chr4:152727874	NA	0.33	6.61	0.34	1.55e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7246967	0.673	rs7250620	chr19:22853126	A/T	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg12927641	chr6:109611667	NA	-0.43	-7.47	-0.38	7.04e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg27165867	chr14:105738592	BRF1	-0.5	-7.08	-0.36	8.81e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg22437258	chr11:111473054	SIK2	0.52	7.01	0.36	1.29e-11	Primary sclerosing cholangitis;
LUSC	cis	rs983392	0.709	rs11230194	chr11:59980315	C/G	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.09	-0.32	3.18e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs3820928	0.810	rs10175929	chr2:227858609	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.3	-0.37	2.17e-12	Pulmonary function;
LUSC	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg19773385	chr1:10388646	KIF1B	-0.55	-8.69	-0.43	1.6e-16	Hepatocellular carcinoma;
LUSC	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg09594475	chr20:60884601	LAMA5	0.37	5.87	0.31	1.06e-8	Pelvic organ prolapse;
LUSC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.61	-0.43	2.98e-16	Lung cancer;
LUSC	cis	rs7789940	0.904	rs56919252	chr7:75937520	T/C	cg10167463	chr7:75959203	YWHAG	-0.6	-8.74	-0.43	1.13e-16	Multiple sclerosis;
LUSC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-0.92	-17.41	-0.69	9.48e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-1.11	-16.92	-0.68	7.88e-47	Exhaled nitric oxide output;
LUSC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.76	-13.61	-0.6	7.47e-34	Dental caries;
LUSC	cis	rs4494114	0.967	rs9438986	chr1:39369652	T/G	cg25970120	chr1:39325951	RRAGC	-0.41	-6.33	-0.33	7.9e-10	Blood protein levels;
LUSC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg11218175	chr11:495084	RNH1	0.53	5.71	0.3	2.51e-8	Body mass index;
LUSC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg16228356	chr17:43848958	NA	-0.26	-5.98	-0.31	5.81e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg04362960	chr10:104952993	NT5C2	0.64	9.89	0.48	2.21e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11997175	0.603	rs7462153	chr8:33814607	C/T	ch.8.33884649F	chr8:33765107	NA	0.41	6.2	0.32	1.65e-9	Body mass index;
LUSC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg26335602	chr6:28129616	ZNF389	0.42	5.7	0.3	2.63e-8	Depression;
LUSC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-0.92	-16.47	-0.67	4.8e-45	Cognitive function;
LUSC	cis	rs7707921	1.000	rs1543911	chr5:81504841	C/T	cg15871215	chr5:81402204	ATG10	0.45	6.61	0.34	1.53e-10	Breast cancer;
LUSC	cis	rs9311676	0.656	rs7620012	chr3:58373716	G/A	cg26110898	chr3:58419937	PDHB	0.42	6.75	0.35	6.62e-11	Systemic lupus erythematosus;
LUSC	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-6.33	-0.33	7.85e-10	IgG glycosylation;
LUSC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.79	-13.29	-0.59	1.17e-32	Aortic root size;
LUSC	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.26	-0.41	3.4e-15	Response to antipsychotic treatment;
LUSC	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg12935359	chr14:103987150	CKB	-0.56	-8.6	-0.43	3.12e-16	Body mass index;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg01238044	chr22:24384105	GSTT1	-0.57	-8.43	-0.42	1.06e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19717773	chr7:2847554	GNA12	-0.34	-5.65	-0.3	3.48e-8	Height;
LUSC	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg04586622	chr2:25135609	ADCY3	0.42	8.87	0.44	4.58e-17	Body mass index;
LUSC	trans	rs7939886	0.920	rs12224086	chr11:55798259	G/T	cg03929089	chr4:120376271	NA	0.74	6.25	0.32	1.29e-9	Myopia (pathological);
LUSC	trans	rs9929218	1.000	rs12446407	chr16:68804068	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.6	-0.54	2.29e-26	Colorectal cancer;
LUSC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg03146154	chr1:46216737	IPP	0.54	8.11	0.41	9.83e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11676348	0.774	rs13397673	chr2:219047782	A/G	cg00012203	chr2:219082015	ARPC2	-0.58	-9.47	-0.46	5.16e-19	Ulcerative colitis;
LUSC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg20818283	chr2:191399100	TMEM194B	-0.42	-6.47	-0.33	3.45e-10	Pulse pressure;
LUSC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	trans	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg26384229	chr12:38710491	ALG10B	0.65	10.29	0.49	9.41e-22	Morning vs. evening chronotype;
LUSC	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg09915433	chr19:53449742	NA	-0.6	-9.55	-0.46	2.98e-19	Psoriasis;
LUSC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg17366294	chr4:99064904	C4orf37	-0.59	-10.53	-0.5	1.38e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10097731	0.901	rs10464892	chr8:82042991	A/G	cg25230327	chr8:82042993	NA	0.42	6.21	0.32	1.6e-9	Serum total protein level;
LUSC	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg00745463	chr17:30367425	LRRC37B	0.63	7.58	0.38	3.37e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg10207240	chr12:122356781	WDR66	0.48	6.81	0.35	4.6e-11	Mean corpuscular volume;
LUSC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg10057126	chr4:77819792	ANKRD56	0.54	7.97	0.4	2.5e-14	Emphysema distribution in smoking;
LUSC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9399135	0.773	rs949895	chr6:135405359	C/T	cg24558204	chr6:135376177	HBS1L	0.44	6.28	0.32	1.08e-9	Red blood cell count;
LUSC	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg22437258	chr11:111473054	SIK2	0.52	7.05	0.36	1.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg24011408	chr12:48396354	COL2A1	0.53	7.31	0.37	2e-12	Lung cancer;
LUSC	cis	rs2274273	0.805	rs60972460	chr14:55571773	A/T	cg04306507	chr14:55594613	LGALS3	0.54	12.18	0.55	1.78e-28	Protein biomarker;
LUSC	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.77	-0.35	5.85e-11	Retinal vascular caliber;
LUSC	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.32	-0.41	2.25e-15	Response to antipsychotic treatment;
LUSC	cis	rs889512	0.642	rs28595463	chr16:75281235	C/T	cg04987608	chr16:75300043	BCAR1	-0.5	-5.74	-0.3	2.07e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg17848003	chr1:3704513	LRRC47	0.32	5.82	0.3	1.35e-8	Red cell distribution width;
LUSC	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.69	10.46	0.5	2.53e-22	Corneal astigmatism;
LUSC	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	0.97	18.3	0.71	2.62e-52	Bone mineral density;
LUSC	cis	rs3213961	0.554	rs8256	chr2:33789068	C/G	cg04131969	chr2:33951647	MYADML	0.49	5.92	0.31	7.81e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg22676075	chr6:135203613	NA	0.47	7.39	0.37	1.2e-12	Red blood cell count;
LUSC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg20399509	chr21:47717575	C21orf57	0.43	6.34	0.33	7.67e-10	Testicular germ cell tumor;
LUSC	trans	rs3857536	0.813	rs2040591	chr6:66945915	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.3	0.37	2.12e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2041895	0.509	rs1035236	chr12:107310797	C/T	cg13944111	chr12:107296891	NA	0.38	6.7	0.34	8.87e-11	Glaucoma (low intraocular pressure);
LUSC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-8.04	-0.4	1.6e-14	Cystic fibrosis severity;
LUSC	cis	rs7605827	0.930	rs879972	chr2:15703031	G/C	cg19274914	chr2:15703543	NA	0.46	8.64	0.43	2.43e-16	Educational attainment (years of education);
LUSC	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg17385448	chr1:15911702	AGMAT	0.36	6.2	0.32	1.67e-9	Systolic blood pressure;
LUSC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg22823121	chr1:150693482	HORMAD1	0.49	7.2	0.37	4.13e-12	Melanoma;
LUSC	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg27284194	chr4:1044797	NA	0.6	8.76	0.43	9.9900000000000006e-17	Recombination rate (females);
LUSC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg27094323	chr7:1216898	NA	-0.47	-8.4	-0.42	1.32e-15	Longevity;Endometriosis;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg11574612	chr6:46620502	CYP39A1;SLC25A27	0.49	6.09	0.32	3.04e-9	Cognitive function;Information processing speed;
LUSC	cis	rs2857891	0.695	rs2857887	chr11:6984001	A/G	cg04053776	chr11:6947353	ZNF215	0.41	6.0	0.31	5.23e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg02569458	chr12:86230093	RASSF9	0.54	8.82	0.43	6.7e-17	Major depressive disorder;
LUSC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg13395646	chr4:1353034	KIAA1530	0.59	9.04	0.44	1.33e-17	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg21724239	chr8:58056113	NA	0.78	9.32	0.45	1.58e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-6.9	-0.35	2.59e-11	Alzheimer's disease (late onset);
LUSC	cis	rs6693567	0.545	rs1313568	chr1:150344180	C/G	cg15654264	chr1:150340011	RPRD2	0.46	7.35	0.37	1.5e-12	Migraine;
LUSC	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg01884057	chr2:25150051	NA	0.42	9.13	0.45	6.57e-18	Body mass index;
LUSC	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg23649088	chr2:200775458	C2orf69	-0.57	-7.78	-0.39	8.85e-14	Schizophrenia;
LUSC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.59	-9.41	-0.46	8.53e-19	Pulse pressure;
LUSC	cis	rs228769	0.635	rs228754	chr17:42116056	C/A	cg19774624	chr17:42201019	HDAC5	0.59	7.24	0.37	3.09e-12	Bone mineral density (hip);Bone mineral density (spine);
LUSC	cis	rs28830936	1.000	rs11629485	chr15:41904569	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.24	-0.32	1.31e-9	Diastolic blood pressure;
LUSC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg03351412	chr1:154909251	PMVK	0.52	8.08	0.4	1.18e-14	Prostate cancer;
LUSC	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg08000102	chr2:233561755	GIGYF2	0.69	11.4	0.53	1.22e-25	Coronary artery disease;
LUSC	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.75	14.66	0.63	6.23e-38	Metabolite levels;
LUSC	trans	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg12856521	chr11:46389249	DGKZ	0.4	6.37	0.33	6.37e-10	Leprosy;
LUSC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.78	-0.3	1.71e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4285028	0.747	rs12496318	chr3:121561500	A/C	cg11130432	chr3:121712080	ILDR1	0.58	7.51	0.38	5.46e-13	Multiple sclerosis;
LUSC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg27535305	chr1:53392650	SCP2	-0.4	-7.47	-0.38	6.86e-13	Monocyte count;
LUSC	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg01733217	chr16:74700730	RFWD3	0.75	12.2	0.56	1.51e-28	Testicular germ cell tumor;
LUSC	cis	rs9660992	0.967	rs1172135	chr1:205247160	G/C	cg21643547	chr1:205240462	TMCC2	-0.48	-9.06	-0.44	1.1e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10010376	chr1:144932311	PDE4DIP	-0.4	-5.96	-0.31	6.48e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg06453172	chr10:134556979	INPP5A	-0.5	-6.35	-0.33	6.9e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg09034736	chr1:150693464	HORMAD1	0.44	6.02	0.31	4.65e-9	Melanoma;
LUSC	cis	rs4417855	0.665	rs6444247	chr3:187413221	G/A	cg19198148	chr3:187451818	BCL6	0.56	9.81	0.47	4.1e-20	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg22681709	chr2:178499509	PDE11A	0.42	5.83	0.3	1.31e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7572733	0.576	rs1865586	chr2:198758868	C/T	cg00792783	chr2:198669748	PLCL1	-0.45	-6.2	-0.32	1.68e-9	Dermatomyositis;
LUSC	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg06207120	chr15:45996521	NA	0.4	6.22	0.32	1.48e-9	Waist circumference;Weight;
LUSC	cis	rs7923609	0.871	rs2393984	chr10:65314971	A/G	cg01631684	chr10:65280961	REEP3	0.41	6.05	0.31	3.84e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg13073564	chr4:8508604	NA	-0.45	-8.87	-0.44	4.37e-17	Response to antineoplastic agents;
LUSC	cis	rs6987853	0.787	rs2923413	chr8:42455308	A/G	cg09913449	chr8:42400586	C8orf40	0.44	7.42	0.38	9.89e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs116988415	0.584	rs4902311	chr14:65241933	G/A	cg25083366	chr14:65239357	SPTB	0.66	6.37	0.33	6.41e-10	Daytime sleep phenotypes;
LUSC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08439880	chr3:133502540	NA	-0.34	-6.08	-0.32	3.32e-9	Iron status biomarkers;
LUSC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.45e-9	Menopause (age at onset);
LUSC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.05	12.84	0.57	6.06e-31	Sexual dysfunction (female);
LUSC	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.74	14.55	0.62	1.7e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9403521	1.000	rs9390126	chr6:143980432	A/G	cg18240653	chr6:144019428	PHACTR2	-0.51	-6.16	-0.32	2.11e-9	Obesity-related traits;
LUSC	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	cis	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg06521331	chr12:34319734	NA	-0.37	-6.31	-0.33	8.7e-10	Morning vs. evening chronotype;
LUSC	cis	rs372883	0.901	rs13048365	chr21:30740394	T/C	cg24692254	chr21:30365293	RNF160	0.41	5.85	0.3	1.2e-8	Pancreatic cancer;
LUSC	cis	rs136211	0.619	rs9607337	chr22:36758849	A/T	cg16924664	chr22:36878180	TXN2	0.38	5.79	0.3	1.58e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	13.58	0.6	9.53e-34	Platelet count;
LUSC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.7	11.58	0.54	2.64e-26	Heart rate;
LUSC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg18827107	chr12:86230957	RASSF9	0.46	6.92	0.35	2.36e-11	Major depressive disorder;
LUSC	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs243505	0.894	rs243504	chr7:148435393	A/G	cg09806900	chr7:148480153	CUL1	-0.48	-6.92	-0.35	2.35e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.46	-6.71	-0.34	8.37e-11	Gut microbiome composition (summer);
LUSC	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg11342453	chr6:26196699	NA	0.55	5.78	0.3	1.7e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05535760	chr7:792225	HEATR2	0.91	9.57	0.46	2.42e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg17279839	chr7:150038598	RARRES2	0.34	5.65	0.3	3.43e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.67e-24	Hypertriglyceridemia;
LUSC	cis	rs9649465	0.561	rs609953	chr7:123422444	T/A	cg03229431	chr7:123269106	ASB15	0.48	7.82	0.39	7.21e-14	Migraine;
LUSC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg15921436	chr17:44337874	NA	0.75	11.33	0.53	2.08e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg23260525	chr10:116636907	FAM160B1	0.4	8.1	0.41	1.02e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg22532475	chr10:104410764	TRIM8	-0.25	-5.99	-0.31	5.4e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10170310	1.000	rs10803568	chr2:139290914	T/C	cg10095539	chr2:139258744	SPOPL	0.32	5.76	0.3	1.89e-8	Response to antipsychotic treatment;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18344452	chr15:55790608	DYX1C1	0.52	7.54	0.38	4.62e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs41271473	1.000	rs6701241	chr1:228868477	C/G	cg16512390	chr1:228756714	NA	0.48	5.79	0.3	1.59e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs1950626	0.623	rs66722144	chr14:101457434	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.4	7.48	0.38	6.57e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	7.83	0.39	6.69e-14	Menarche (age at onset);
LUSC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.44	-6.35	-0.33	7.05e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-1.17	-16.85	-0.68	1.53e-46	Breast cancer;
LUSC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg25767906	chr1:53392781	SCP2	-0.48	-7.92	-0.4	3.52e-14	Monocyte count;
LUSC	cis	rs3781663	0.581	rs10793018	chr11:70004396	G/A	cg24276624	chr11:69982941	ANO1	-0.44	-6.77	-0.35	5.87e-11	Survival in rectal cancer;
LUSC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.41	6.24	0.32	1.34e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg10978503	chr1:24200527	CNR2	-0.51	-12.44	-0.56	1.95e-29	Immature fraction of reticulocytes;
LUSC	cis	rs2067615	0.579	rs4964492	chr12:107222774	C/T	cg19260189	chr12:106995001	RFX4	0.24	5.96	0.31	6.47e-9	Heart rate;
LUSC	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.45	0.5	2.62e-22	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg05926928	chr17:57297772	GDPD1	0.6	9.4	0.46	8.88e-19	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUSC	cis	rs12476592	0.602	rs2604613	chr2:63832776	G/A	cg10828910	chr2:63850056	LOC388955	0.5	5.81	0.3	1.49e-8	Childhood ear infection;
LUSC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.68	11.62	0.54	1.93e-26	Menarche (age at onset);
LUSC	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg16249355	chr17:76310516	NA	0.38	6.09	0.32	3.1e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg22467129	chr15:76604101	ETFA	0.42	6.65	0.34	1.19e-10	Blood metabolite levels;
LUSC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-7.09	-0.36	8.04e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7178572	0.633	rs11854328	chr15:77840129	A/G	cg22256960	chr15:77711686	NA	-0.48	-7.04	-0.36	1.07e-11	Type 2 diabetes;
LUSC	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	5.8	0.3	1.58e-8	Axial length;
LUSC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.56	-5.79	-0.3	1.66e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg12437481	chr16:420112	MRPL28	-0.38	-6.2	-0.32	1.68e-9	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs9467160	0.871	rs7762593	chr6:24449417	G/A	cg20631270	chr6:24437470	GPLD1	0.44	5.65	0.3	3.37e-8	Liver enzyme levels;
LUSC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg09034736	chr1:150693464	HORMAD1	-0.45	-6.42	-0.33	4.63e-10	Melanoma;
LUSC	cis	rs1322512	0.959	rs2623954	chr6:152966001	G/A	cg03415253	chr6:152958462	SYNE1	-0.38	-5.68	-0.3	2.95e-8	Tonometry;
LUSC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg17264618	chr3:40429014	ENTPD3	0.34	7.24	0.37	3.18e-12	Renal cell carcinoma;
LUSC	cis	rs2901656	0.677	rs2269615	chr1:172415451	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.36	7.41	0.38	1.02e-12	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs3764021	0.870	rs2401394	chr12:9879426	G/A	cg20894963	chr12:9885564	CLECL1	0.34	6.83	0.35	4.12e-11	Type 1 diabetes;
LUSC	cis	rs9359856	0.564	rs72915946	chr6:90447924	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.43	-0.42	1.02e-15	Bipolar disorder;
LUSC	cis	rs9311676	0.656	rs11130636	chr3:58380098	C/A	cg26110898	chr3:58419937	PDHB	0.42	6.83	0.35	4.07e-11	Systemic lupus erythematosus;
LUSC	cis	rs11603020	0.904	rs4926	chr11:57381989	G/A	cg23127183	chr11:57508653	C11orf31	-0.47	-6.57	-0.34	1.95e-10	Blood protein levels;
LUSC	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg03733263	chr8:22462867	KIAA1967	0.85	14.49	0.62	2.9e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.56	-7.16	-0.36	5.02e-12	Schizophrenia;
LUSC	cis	rs611744	0.781	rs656406	chr8:109173843	G/A	cg18478394	chr8:109455254	TTC35	0.43	6.5	0.33	2.98e-10	Dupuytren's disease;
LUSC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02018176	chr4:1364513	KIAA1530	-0.72	-12.94	-0.58	2.63e-31	Longevity;
LUSC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.31	21.44	0.76	9.26e-65	Type 1 diabetes nephropathy;
LUSC	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.21	-0.45	3.59e-18	Schizophrenia;
LUSC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.18	-0.32	1.87e-9	Electroencephalogram traits;
LUSC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-1.1	-22.17	-0.77	1.3e-67	Coronary artery disease;
LUSC	trans	rs61931739	0.635	rs1486883	chr12:33908740	C/T	cg13010199	chr12:38710504	ALG10B	0.4	6.07	0.32	3.52e-9	Morning vs. evening chronotype;
LUSC	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.72	-0.39	1.32e-13	Pulmonary function;
LUSC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-0.98	-14.24	-0.61	2.81e-36	Initial pursuit acceleration;
LUSC	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.32	-0.45	1.69e-18	Morning vs. evening chronotype;
LUSC	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg11189052	chr15:85197271	WDR73	-0.64	-9.86	-0.47	2.7e-20	P wave terminal force;
LUSC	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg11993925	chr19:44307056	LYPD5	0.35	7.67	0.39	1.9e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg04374321	chr14:90722782	PSMC1	0.76	12.13	0.55	2.61e-28	Mortality in heart failure;
LUSC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.8	0.35	4.95e-11	Aortic root size;
LUSC	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.33e-21	Lymphocyte counts;
LUSC	cis	rs2108225	0.872	rs2051955	chr7:107441154	C/T	cg18560240	chr7:107437656	SLC26A3	-0.44	-6.65	-0.34	1.2e-10	Ulcerative colitis;
LUSC	cis	rs1044826	0.642	rs186103	chr3:139211942	C/A	cg15131784	chr3:139108705	COPB2	0.4	6.38	0.33	6.03e-10	Obesity-related traits;
LUSC	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg04545296	chr12:48745243	ZNF641	-0.36	-6.68	-0.34	9.99e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg02580895	chr19:2754563	NA	-0.45	-6.8	-0.35	4.82e-11	Total cholesterol levels;
LUSC	cis	rs9359856	0.517	rs17506515	chr6:90507332	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.84	-8.33	-0.41	2.13e-15	Bipolar disorder;
LUSC	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	5.93	0.31	7.75e-9	Rheumatoid arthritis;
LUSC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21963583	chr11:68658836	MRPL21	0.54	8.13	0.41	8.42e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.07	-0.4	1.31e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs977987	1.000	rs62060550	chr16:75502252	C/T	cg03315344	chr16:75512273	CHST6	0.55	10.7	0.51	3.58e-23	Dupuytren's disease;
LUSC	cis	rs17092148	1.000	rs6060040	chr20:33359054	G/C	cg16810054	chr20:33298113	TP53INP2	-0.45	-6.77	-0.35	5.85e-11	Neuroticism;
LUSC	cis	rs4660306	0.614	rs11211116	chr1:45930038	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.42	5.74	0.3	2.16e-8	Homocysteine levels;
LUSC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg01616529	chr11:638424	DRD4	-0.35	-5.87	-0.31	1.07e-8	Systemic lupus erythematosus;
LUSC	cis	rs9398803	0.965	rs4895807	chr6:126686513	C/G	cg19875578	chr6:126661172	C6orf173	0.41	6.12	0.32	2.65e-9	Male-pattern baldness;
LUSC	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	11.96	0.55	1.09e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs57920188	0.584	rs12080562	chr1:4089697	C/A	cg20703997	chr1:4087676	NA	0.53	7.79	0.39	8.57e-14	Interleukin-17 levels;
LUSC	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg21775007	chr8:11205619	TDH	-0.42	-5.99	-0.31	5.31e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs228769	0.653	rs2523162	chr17:42179281	A/G	cg19774624	chr17:42201019	HDAC5	0.71	8.84	0.44	5.59e-17	Bone mineral density (hip);Bone mineral density (spine);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11327054	chr11:6502632	FXC1;ARFIP2	0.77	6.07	0.32	3.52e-9	Cognitive performance;
LUSC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00149659	chr3:10157352	C3orf10	0.91	12.66	0.57	2.94e-30	Alzheimer's disease;
LUSC	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg23625390	chr15:77176239	SCAPER	0.66	10.37	0.49	5.17e-22	Blood metabolite levels;
LUSC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg07061783	chr6:25882402	NA	-0.38	-5.85	-0.3	1.19e-8	Blood metabolite levels;
LUSC	cis	rs3812762	0.879	rs3844099	chr11:8808252	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.39	6.86	0.35	3.32e-11	Hypospadias;
LUSC	trans	rs9886428	1.000	rs11203588	chr8:14116631	T/A	cg19037007	chr20:741798	C20orf54	-0.39	-6.04	-0.31	4.02e-9	IgG glycosylation;
LUSC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.98	0.31	5.84e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg22089800	chr15:90895588	ZNF774	-0.6	-8.55	-0.42	4.4e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg22709100	chr7:91322751	NA	0.38	5.68	0.3	2.99e-8	Breast cancer;
LUSC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg22029157	chr1:209979665	IRF6	0.8	10.25	0.49	1.27e-21	Cleft lip with or without cleft palate;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	0.94	18.7	0.72	6.71e-54	Menarche (age at onset);
LUSC	cis	rs11630290	0.566	rs4777395	chr15:64161693	T/G	cg12036633	chr15:63758958	NA	0.54	6.92	0.35	2.3e-11	Iris characteristics;
LUSC	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg14196790	chr5:131705035	SLC22A5	0.49	8.47	0.42	7.66e-16	Blood metabolite levels;
LUSC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg03579872	chr1:53393473	SCP2	-0.39	-5.77	-0.3	1.86e-8	Monocyte count;
LUSC	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg06484146	chr7:12443880	VWDE	-0.67	-7.01	-0.36	1.36e-11	Coronary artery disease;
LUSC	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	1.0	18.56	0.71	2.51e-53	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	trans	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg06521331	chr12:34319734	NA	-0.39	-5.96	-0.31	6.28e-9	Bladder cancer;
LUSC	cis	rs12474201	0.928	rs13025984	chr2:46938789	T/C	cg06386533	chr2:46925753	SOCS5	0.78	11.76	0.54	6.04e-27	Height;
LUSC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg15445000	chr17:37608096	MED1	-0.39	-6.63	-0.34	1.35e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.71e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg11645453	chr3:52864694	ITIH4	0.52	11.2	0.52	6.19e-25	Schizophrenia;
LUSC	cis	rs6546886	0.913	rs12713805	chr2:74243380	C/T	cg14702570	chr2:74259524	NA	-0.3	-5.65	-0.3	3.36e-8	Dialysis-related mortality;
LUSC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.96	0.7	5.97e-51	Chronic sinus infection;
LUSC	cis	rs9487051	0.768	rs458740	chr6:109525527	C/T	cg01475377	chr6:109611718	NA	-0.35	-5.89	-0.31	9.21e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-9.47	-0.46	5.3e-19	Response to antipsychotic treatment;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26151740	chr19:54641525	CNOT3	0.62	6.13	0.32	2.48e-9	Cognitive performance;
LUSC	cis	rs1395	1.000	rs1395	chr2:27424636	G/A	cg23587288	chr2:27483067	SLC30A3	0.28	5.7	0.3	2.63e-8	Blood metabolite levels;
LUSC	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-6.61	-0.34	1.53e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	14.43	0.62	5.05e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg06521331	chr12:34319734	NA	0.4	6.61	0.34	1.48e-10	Morning vs. evening chronotype;
LUSC	cis	rs66716358	0.744	rs11037943	chr11:44317445	A/G	cg16977035	chr11:44330474	ALX4	0.36	6.02	0.31	4.69e-9	Monobrow;
LUSC	cis	rs360798	0.532	rs12713468	chr2:62983213	G/A	cg17519650	chr2:63277830	OTX1	-0.52	-7.22	-0.37	3.63e-12	Coronary artery disease;
LUSC	cis	rs7577696	0.785	rs3769602	chr2:32381829	G/A	cg02381751	chr2:32503542	YIPF4	-0.44	-6.27	-0.32	1.09e-9	Inflammatory biomarkers;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.67	-11.16	-0.52	8.75e-25	Longevity;Endometriosis;
LUSC	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg18232548	chr7:50535776	DDC	0.56	7.79	0.39	8.27e-14	Malaria;
LUSC	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	12.79	0.57	9.09e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7759001	0.857	rs766092	chr6:27368031	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.69	0.3	2.84e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs870825	0.616	rs7700216	chr4:185648510	G/T	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs7681440	0.626	rs6812593	chr4:90817991	C/T	cg20003494	chr4:90757398	SNCA	-0.36	-5.87	-0.31	1.06e-8	Dementia with Lewy bodies;
LUSC	cis	rs1113500	0.933	rs10785833	chr1:108639082	A/G	cg11967332	chr1:108735228	SLC25A24	0.39	5.94	0.31	7.31e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg02423579	chr7:2872169	GNA12	-0.47	-6.76	-0.35	6.16e-11	Height;
LUSC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg05872129	chr22:39784769	NA	-0.62	-11.68	-0.54	1.17e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.65	13.96	0.61	3.42e-35	Monocyte percentage of white cells;
LUSC	cis	rs1788820	0.917	rs1652349	chr18:21142734	A/T	cg14672496	chr18:21087552	C18orf8	0.42	6.79	0.35	5.02e-11	Body mass index;
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.76	17.31	0.69	2.35e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg03929089	chr4:120376271	NA	-0.95	-16.34	-0.67	1.59e-44	Height;
LUSC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg02228675	chr17:40259724	DHX58	0.46	6.54	0.34	2.32e-10	Fibrinogen levels;
LUSC	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg16482183	chr6:26056742	HIST1H1C	1.06	13.62	0.6	6.47e-34	Iron status biomarkers;
LUSC	cis	rs9815354	0.761	rs73079307	chr3:41862273	A/C	cg03022575	chr3:42003672	ULK4	0.84	8.78	0.43	8.69e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.76	-0.3	1.92e-8	Height;
LUSC	cis	rs16866061	0.888	rs6748341	chr2:225377574	C/G	cg12698349	chr2:225449008	CUL3	0.85	13.37	0.59	5.85e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06634786	chr22:41940651	POLR3H	-0.55	-6.39	-0.33	5.42e-10	Vitiligo;
LUSC	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg12927641	chr6:109611667	NA	0.35	5.74	0.3	2.09e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg13607699	chr17:42295918	UBTF	-0.69	-11.27	-0.52	3.61e-25	Total body bone mineral density;
LUSC	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg24631222	chr15:78858424	CHRNA5	0.64	8.51	0.42	5.9e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg15649852	chr7:65879115	NA	0.39	5.72	0.3	2.41e-8	Aortic root size;
LUSC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg14582100	chr15:45693742	SPATA5L1	0.59	10.83	0.51	1.25e-23	Homoarginine levels;
LUSC	cis	rs10754283	0.967	rs10801760	chr1:90113824	G/A	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs41308713	0.786	rs8116471	chr20:37034694	A/C	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.0	6.87	0.35	3.1e-11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	trans	rs1493916	0.748	rs1389535	chr18:31310416	A/G	cg27147174	chr7:100797783	AP1S1	0.58	9.15	0.45	5.86e-18	Life satisfaction;
LUSC	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg10426581	chr7:100472382	SRRT	0.86	12.48	0.56	1.36e-29	Resting heart rate;
LUSC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg20849893	chr7:64541193	NA	0.45	6.45	0.33	4.01e-10	Calcium levels;
LUSC	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.71	10.75	0.51	2.33e-23	Alcohol dependence;
LUSC	cis	rs7106204	0.534	rs74650605	chr11:24253414	T/C	ch.11.24196551F	chr11:24239977	NA	0.72	6.09	0.32	3.05e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs12637928	0.560	rs11715486	chr3:110209208	G/T	cg17371621	chr15:61264283	RORA	0.36	5.96	0.31	6.29e-9	Neuroticism;
LUSC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	11.03	0.52	2.5e-24	Hemoglobin concentration;
LUSC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06112835	chr11:68658793	MRPL21	0.49	7.44	0.38	8.85e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg13010199	chr12:38710504	ALG10B	0.66	9.98	0.48	1.04e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg16230307	chr14:35515116	FAM177A1	0.78	10.0	0.48	8.96e-21	Psoriasis;
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18538332	chr22:24372958	LOC391322	0.37	6.66	0.34	1.13e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.48	-0.33	3.3e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21016266	chr12:122356598	WDR66	0.56	8.3	0.41	2.61e-15	Mean corpuscular volume;
LUSC	trans	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	7.1	0.36	7.44e-12	Menarche (age at onset);
LUSC	cis	rs858239	0.601	rs764533	chr7:23153875	C/T	cg23682824	chr7:23144976	KLHL7	0.4	5.78	0.3	1.74e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg05084668	chr3:125655381	ALG1L	-0.47	-6.62	-0.34	1.45e-10	Blood pressure (smoking interaction);
LUSC	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg02574844	chr11:5959923	NA	-0.42	-5.92	-0.31	7.96e-9	DNA methylation (variation);
LUSC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12667521	chr19:29218732	NA	-0.56	-6.86	-0.35	3.3e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg06238570	chr21:40685208	BRWD1	-0.63	-10.39	-0.49	4.34e-22	Cognitive function;
LUSC	cis	rs2637266	0.783	rs2395434	chr10:78476161	T/C	cg18941641	chr10:78392320	NA	0.34	6.22	0.32	1.52e-9	Pulmonary function;
LUSC	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.76e-12	Type 2 diabetes;
LUSC	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg24631222	chr15:78858424	CHRNA5	-0.67	-8.86	-0.44	4.69e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.06	-20.44	-0.75	8.12e-61	Cognitive ability;
LUSC	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg25664220	chr3:72788482	NA	-0.66	-10.66	-0.5	5.14e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg19592336	chr6:28129416	ZNF389	0.5	6.57	0.34	1.94e-10	Parkinson's disease;
LUSC	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.79	12.05	0.55	5.1e-28	Lymphocyte counts;
LUSC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.58	7.77	0.39	9.64e-14	Lung function (FEV1/FVC);
LUSC	cis	rs11958404	0.932	rs72816571	chr5:157429759	C/T	cg05962755	chr5:157440814	NA	0.54	6.34	0.33	7.29e-10	IgG glycosylation;
LUSC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00166722	chr3:10149974	C3orf24	0.61	8.47	0.42	7.9e-16	Alzheimer's disease;
LUSC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	0.99	14.17	0.61	5.16e-36	Vitiligo;
LUSC	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21775007	chr8:11205619	TDH	0.74	12.45	0.56	1.8e-29	Retinal vascular caliber;
LUSC	trans	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg25214090	chr10:38739885	LOC399744	0.44	6.74	0.35	7.16e-11	Corneal astigmatism;
LUSC	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	9.85	0.47	3.02e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs886126	0.950	rs6490025	chr12:111691081	T/C	cg10833066	chr12:111807467	FAM109A	0.4	6.09	0.32	3.06e-9	Coronary heart disease;
LUSC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.53	10.2	0.49	1.84e-21	Monocyte count;
LUSC	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg08917208	chr2:24149416	ATAD2B	0.53	5.97	0.31	6e-9	Lymphocyte counts;
LUSC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18595196	chr3:52726726	GNL3;SNORD69	-0.29	-5.65	-0.3	3.46e-8	Bipolar disorder;
LUSC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg06028605	chr16:24865363	SLC5A11	-0.47	-8.49	-0.42	6.75e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.26	0.56	8.64e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.54	0.5	1.29e-22	Lung cancer in ever smokers;
LUSC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.69	10.55	0.5	1.22e-22	Type 2 diabetes;
LUSC	cis	rs7683537	0.554	rs55830081	chr4:185666477	A/C	cg04058563	chr4:185651563	MLF1IP	0.77	11.02	0.52	2.69e-24	Systemic lupus erythematosus;
LUSC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg13395646	chr4:1353034	KIAA1530	-0.66	-11.08	-0.52	1.67e-24	Longevity;
LUSC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg24250549	chr1:154909240	PMVK	0.65	10.56	0.5	1.15e-22	Prostate cancer;
LUSC	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.98	-0.44	2.06e-17	Triglycerides;
LUSC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.08	-0.4	1.19e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg08085267	chr17:45401833	C17orf57	0.44	6.68	0.34	1.01e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.54	0.46	3.12e-19	Mean corpuscular volume;
LUSC	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg19336497	chr11:14380999	RRAS2	0.45	8.13	0.41	8.49e-15	Mitochondrial DNA levels;
LUSC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg11843238	chr5:131593191	PDLIM4	-0.49	-8.29	-0.41	2.85e-15	Acylcarnitine levels;
LUSC	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg04369109	chr6:150039330	LATS1	-0.58	-8.31	-0.41	2.44e-15	Lung cancer;
LUSC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg04398451	chr17:18023971	MYO15A	0.45	7.03	0.36	1.16e-11	Total body bone mineral density;
LUSC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg14440974	chr22:39074834	NA	-0.37	-6.22	-0.32	1.48e-9	Menopause (age at onset);
LUSC	cis	rs7178572	0.568	rs11632941	chr15:77533888	A/G	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg06092702	chr1:163392909	NA	-0.46	-7.56	-0.38	3.91e-13	Motion sickness;
LUSC	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	1.1	14.56	0.62	1.57e-37	Nonalcoholic fatty liver disease;
LUSC	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg19468946	chr17:37922297	IKZF3	-0.39	-6.15	-0.32	2.18e-9	Self-reported allergy;
LUSC	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg05347473	chr6:146136440	FBXO30	0.41	6.89	0.35	2.73e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4478858	0.746	rs6703593	chr1:31689284	A/C	cg00250761	chr1:31883323	NA	0.36	9.36	0.46	1.18e-18	Alcohol dependence;
LUSC	cis	rs7572644	0.782	rs1870325	chr2:28144067	G/A	cg27432699	chr2:27873401	GPN1	-0.53	-6.91	-0.35	2.45e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg01657329	chr11:68192670	LRP5	-0.5	-7.85	-0.39	5.64e-14	Total body bone mineral density;
LUSC	cis	rs2230307	0.505	rs571579	chr1:100617372	G/A	cg24955406	chr1:100503596	HIAT1	-0.64	-6.95	-0.36	1.88e-11	Carotid intima media thickness;
LUSC	cis	rs9905704	0.801	rs302847	chr17:56687481	C/T	cg12560992	chr17:57184187	TRIM37	0.61	8.78	0.43	8.42e-17	Testicular germ cell tumor;
LUSC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg23711669	chr6:146136114	FBXO30	0.86	16.1	0.66	1.47e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.59	8.62	0.43	2.78e-16	Total cholesterol levels;
LUSC	cis	rs713587	0.935	rs4430895	chr2:25161386	C/T	cg01884057	chr2:25150051	NA	0.44	10.01	0.48	8.36e-21	Body mass index in non-asthmatics;
LUSC	cis	rs4720118	0.875	rs3884597	chr7:33385262	G/T	cg22798885	chr7:33102694	NT5C3	0.44	6.06	0.31	3.71e-9	Leprosy;
LUSC	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	8.89	0.44	3.87e-17	Lung cancer in ever smokers;
LUSC	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg05714579	chr10:131428358	MGMT	-0.5	-7.65	-0.39	2.22e-13	Response to temozolomide;
LUSC	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg01966878	chr4:90757139	SNCA	-0.42	-5.86	-0.31	1.12e-8	Neuroticism;
LUSC	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg09365446	chr1:150670422	GOLPH3L	0.47	6.78	0.35	5.31e-11	Melanoma;
LUSC	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg21466736	chr12:48725269	NA	0.3	5.74	0.3	2.14e-8	Glycated hemoglobin levels;
LUSC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	0.92	19.02	0.72	3.51e-55	Dental caries;
LUSC	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg00757033	chr12:89920650	WDR51B	0.58	9.42	0.46	7.55e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.2e-40	Bladder cancer;
LUSC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.06e-17	Prudent dietary pattern;
LUSC	trans	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.85	-0.35	3.59e-11	Mood instability;
LUSC	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg02640540	chr1:67518911	SLC35D1	0.55	7.83	0.39	6.41e-14	Lymphocyte percentage of white cells;
LUSC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-14.85	-0.63	1.22e-38	Total body bone mineral density;
LUSC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.07	-0.36	8.88e-12	Alzheimer's disease (late onset);
LUSC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11645453	chr3:52864694	ITIH4	0.35	8.22	0.41	4.41e-15	Electroencephalogram traits;
LUSC	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg24642439	chr20:33292090	TP53INP2	0.5	7.43	0.38	8.94e-13	Height;
LUSC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg23625390	chr15:77176239	SCAPER	-0.66	-9.91	-0.48	1.87e-20	Blood metabolite levels;
LUSC	cis	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.51	-6.84	-0.35	3.68e-11	Tonsillectomy;
LUSC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.01	-0.36	1.36e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg19812747	chr11:111475976	SIK2	-0.48	-6.83	-0.35	3.94e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06850241	chr22:41845214	NA	0.31	5.8	0.3	1.56e-8	Vitiligo;
LUSC	trans	rs4596713	0.538	rs7048095	chr9:71745663	G/A	cg25283916	chr1:242222868	NA	-0.29	-6.04	-0.31	4.19e-9	Headache;
LUSC	cis	rs7818345	1.000	rs7833166	chr8:19294634	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.19	0.37	4.24e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs189798	0.738	rs330908	chr8:8995166	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.43	0.33	4.39e-10	Myopia (pathological);
LUSC	trans	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg06521331	chr12:34319734	NA	0.39	6.18	0.32	1.82e-9	Bladder cancer;
LUSC	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-6.53	-0.34	2.52e-10	Colorectal cancer;
LUSC	cis	rs7582720	1.000	rs72926786	chr2:203816494	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg25110126	chr1:46999211	NA	0.72	10.39	0.49	4.37e-22	Monobrow;
LUSC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.37	-0.37	1.38e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7804356	0.906	rs12532796	chr7:26854828	A/G	cg03456212	chr7:26904342	SKAP2	-0.54	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	trans	rs6555855	0.909	rs6896194	chr5:168721048	A/C	cg19626044	chr1:243138527	NA	-0.5	-6.05	-0.31	3.96e-9	Menarche (age at onset);
LUSC	cis	rs9462027	0.606	rs2814979	chr6:34578425	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.01	-0.31	4.88e-9	Systemic lupus erythematosus;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg17747171	chr20:2633605	NOP56;SNORD110	0.43	6.02	0.31	4.47e-9	Mosquito bite size;
LUSC	cis	rs7582720	1.000	rs72934505	chr2:203916487	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.65	0.43	2.2e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2073300	1.000	rs6137976	chr20:23463241	C/T	cg09953122	chr20:23471693	CST8	-0.88	-7.54	-0.38	4.52e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg25214090	chr10:38739885	LOC399744	0.53	7.72	0.39	1.33e-13	Corneal astigmatism;
LUSC	cis	rs2377585	0.653	rs7976729	chr12:8848685	A/G	cg03761649	chr12:8850719	RIMKLB	0.47	6.31	0.33	9.04e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs3760982	1.000	rs3760982	chr19:44286513	A/G	cg11993925	chr19:44307056	LYPD5	0.29	6.32	0.33	8.28e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg13010199	chr12:38710504	ALG10B	0.58	9.26	0.45	2.59e-18	Morning vs. evening chronotype;
LUSC	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	0.56	8.97	0.44	2.11e-17	Breast cancer;
LUSC	cis	rs6545883	0.929	rs3821222	chr2:61713526	C/G	cg15711740	chr2:61764176	XPO1	-0.44	-6.84	-0.35	3.72e-11	Tuberculosis;
LUSC	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.46	-5.77	-0.3	1.8e-8	Schizophrenia;
LUSC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg17143192	chr8:8559678	CLDN23	0.63	9.13	0.45	6.91e-18	Obesity-related traits;
LUSC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg21573476	chr21:45109991	RRP1B	-0.43	-7.14	-0.36	5.96e-12	Mean corpuscular volume;
LUSC	cis	rs12542260	0.871	rs4128469	chr8:125479475	C/T	cg27038428	chr8:125485867	RNF139	0.33	6.56	0.34	2.11e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg23093090	chr10:104574429	C10orf26	-0.37	-7.07	-0.36	9.07e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12529083	chr12:13197360	KIAA1467	-0.43	-6.41	-0.33	4.88e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg00277334	chr10:82204260	NA	-0.49	-6.68	-0.34	9.81e-11	Post bronchodilator FEV1;
LUSC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg22907277	chr7:1156413	C7orf50	0.68	7.31	0.37	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7903847	0.619	rs76094900	chr10:99158164	G/A	cg20016023	chr10:99160130	RRP12	-0.33	-8.1	-0.41	1.01e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-7.91	-0.4	3.79e-14	Chronic sinus infection;
LUSC	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-5.96	-0.31	6.43e-9	Neuroticism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26486377	chr16:2318312	RNPS1	-0.47	-6.0	-0.31	5.28e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg25456477	chr12:86230367	RASSF9	0.41	7.31	0.37	2.04e-12	Major depressive disorder;
LUSC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.59e-9	Menopause (age at onset);
LUSC	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg20503657	chr10:835505	NA	0.78	9.25	0.45	2.78e-18	Eosinophil percentage of granulocytes;
LUSC	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg06640241	chr16:89574553	SPG7	0.68	9.27	0.45	2.35e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.51	0.34	2.69e-10	Menopause (age at onset);
LUSC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg27532560	chr4:187881888	NA	-0.39	-6.41	-0.33	5.1e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg26893861	chr17:41843967	DUSP3	1.0	15.11	0.64	1.15e-39	Triglycerides;
LUSC	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg06026331	chr20:60912101	LAMA5	-0.59	-7.02	-0.36	1.26e-11	Colorectal cancer;
LUSC	cis	rs977987	0.778	rs4888400	chr16:75425596	G/C	cg03315344	chr16:75512273	CHST6	0.48	9.06	0.44	1.1e-17	Dupuytren's disease;
LUSC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25072359	chr17:41440525	NA	0.66	9.42	0.46	7.64e-19	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.61e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs867529	0.620	rs335121	chr2:89084327	G/C	cg26627705	chr2:89060884	NA	0.42	5.81	0.3	1.47e-8	Height;
LUSC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg26380479	chr7:97908229	NA	-0.27	-6.06	-0.31	3.64e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.57	0.34	1.94e-10	Menopause (age at onset);
LUSC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg24130564	chr14:104152367	KLC1	-0.39	-5.64	-0.3	3.54e-8	Body mass index;
LUSC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg18477163	chr1:228402036	OBSCN	-0.58	-10.84	-0.51	1.18e-23	Diastolic blood pressure;
LUSC	cis	rs57590327	0.503	rs13066091	chr3:81589912	T/C	cg07356753	chr3:81810745	GBE1	-0.5	-6.7	-0.34	9.07e-11	Extraversion;
LUSC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11764359	chr7:65958608	NA	0.68	10.96	0.51	4.39e-24	Aortic root size;
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg09033563	chr22:24373618	LOC391322	-0.6	-9.32	-0.45	1.67e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg18350739	chr11:68623251	NA	-0.36	-6.23	-0.32	1.42e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	0.94	17.84	0.7	1.77e-50	Heart rate;
LUSC	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg24562669	chr7:97807699	LMTK2	-0.39	-6.39	-0.33	5.62e-10	Breast cancer;
LUSC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.58	0.34	1.84e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2637266	0.597	rs846615	chr10:78548489	A/G	cg18941641	chr10:78392320	NA	-0.4	-7.29	-0.37	2.25e-12	Pulmonary function;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg13871565	chr1:244973565	NA	-0.34	-6.36	-0.33	6.71e-10	N-glycan levels;
LUSC	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg05340658	chr4:99064831	C4orf37	0.44	7.0	0.36	1.41e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg10609677	chr17:41278573	BRCA1;NBR2	0.35	5.71	0.3	2.54e-8	Menopause (age at onset);
LUSC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.86	0.35	3.39e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg07414643	chr4:187882934	NA	0.55	10.53	0.5	1.41e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11264799	0.539	rs2779160	chr1:157550950	C/T	cg18268488	chr1:157545234	FCRL4	0.38	7.45	0.38	7.86e-13	IgA nephropathy;
LUSC	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg22875332	chr1:76189707	ACADM	-0.68	-9.42	-0.46	7.91e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg17469321	chr7:55412551	NA	0.57	9.53	0.46	3.32e-19	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.39e-22	Alzheimer's disease (late onset);
LUSC	cis	rs4664308	1.000	rs17831191	chr2:160911332	T/C	cg03641300	chr2:160917029	PLA2R1	-0.67	-11.33	-0.53	2.16e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg02176678	chr2:219576539	TTLL4	-0.72	-12.14	-0.55	2.44e-28	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg22709100	chr7:91322751	NA	0.4	5.81	0.3	1.48e-8	Breast cancer;
LUSC	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg17628894	chr11:804452	LRDD	0.42	9.46	0.46	5.61e-19	Breast cancer;
LUSC	trans	rs1949829	0.826	rs6592924	chr7:51535246	C/G	cg20941110	chr15:83953819	BNC1	0.55	6.01	0.31	4.98e-9	Wegener's granulomatosis;
LUSC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-0.99	-17.56	-0.69	2.27e-49	Height;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00787537	chr1:211307839	KCNH1	-0.42	-6.12	-0.32	2.65e-9	Hepatitis;
LUSC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-7.96	-0.4	2.67e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg06238570	chr21:40685208	BRWD1	-0.49	-7.61	-0.38	2.77e-13	Cognitive function;
LUSC	trans	rs2370759	0.945	rs3740237	chr10:32557592	G/C	cg07829597	chr10:77161705	C10orf41;ZNF503	0.64	5.98	0.31	5.62e-9	Sexual dysfunction (female);
LUSC	trans	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg25214090	chr10:38739885	LOC399744	0.4	6.14	0.32	2.39e-9	Corneal astigmatism;
LUSC	cis	rs6733011	0.628	rs6542838	chr2:99452458	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-5.84	-0.3	1.25e-8	Bipolar disorder;
LUSC	cis	rs7572733	0.534	rs1401091	chr2:198790423	T/G	cg00792783	chr2:198669748	PLCL1	-0.44	-5.86	-0.31	1.13e-8	Dermatomyositis;
LUSC	cis	rs760794	0.533	rs2206034	chr6:19796863	C/T	cg02404759	chr6:19790362	NA	-0.38	-5.97	-0.31	6.12e-9	Endometriosis;
LUSC	cis	rs6690583	0.562	rs6665436	chr1:85532894	T/C	cg11262906	chr1:85462892	MCOLN2	0.72	6.32	0.33	8.57e-10	Serum sulfate level;
LUSC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.37	5.65	0.3	3.35e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg23544223	chr18:12777786	NA	-0.54	-5.65	-0.3	3.47e-8	Inflammatory skin disease;
LUSC	cis	rs72772090	0.539	rs72773942	chr5:96123366	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-6.96	-0.36	1.82e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10465746	0.935	rs11163878	chr1:84442654	G/A	cg10977910	chr1:84465055	TTLL7	0.42	6.23	0.32	1.42e-9	Obesity-related traits;
LUSC	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg12559939	chr2:27858050	GPN1	0.41	6.48	0.33	3.28e-10	Oral cavity cancer;
LUSC	cis	rs1018697	1.000	rs7092346	chr10:104559764	A/G	cg04362960	chr10:104952993	NT5C2	0.47	6.51	0.34	2.82e-10	Colorectal adenoma (advanced);
LUSC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-1.16	-16.29	-0.67	2.65e-44	Breast cancer;
LUSC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg02772935	chr3:125709198	NA	-0.48	-5.78	-0.3	1.7e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.82	13.97	0.61	2.99e-35	Blood protein levels;
LUSC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg24060327	chr5:131705240	SLC22A5	-0.52	-8.71	-0.43	1.45e-16	Breast cancer;
LUSC	cis	rs7539409	0.915	rs4001467	chr1:84275858	A/T	cg10977910	chr1:84465055	TTLL7	-0.62	-6.24	-0.32	1.32e-9	Alzheimer's disease;
LUSC	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg12483005	chr1:23474871	LUZP1	0.41	6.5	0.34	2.89e-10	Height;
LUSC	cis	rs7113850	0.541	rs77054343	chr11:24215636	A/G	ch.11.24196551F	chr11:24239977	NA	0.95	7.17	0.37	4.71e-12	Bone fracture in osteoporosis;
LUSC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg13736514	chr6:26305472	NA	-0.48	-9.52	-0.46	3.66e-19	Educational attainment;
LUSC	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg02569458	chr12:86230093	RASSF9	-0.36	-5.68	-0.3	2.93e-8	Major depressive disorder;
LUSC	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-6.55	-0.34	2.14e-10	Monocyte percentage of white cells;
LUSC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.52	-10.48	-0.5	2.04e-22	Iron status biomarkers;
LUSC	cis	rs2282802	0.635	rs199152	chr5:139539235	C/T	cg26211634	chr5:139558579	C5orf32	-0.39	-7.44	-0.38	8.33e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg20243544	chr17:37824526	PNMT	0.49	6.88	0.35	2.98e-11	Asthma;
LUSC	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.94	-0.4	3.06e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg00579200	chr11:133705235	NA	-0.39	-5.67	-0.3	3.03e-8	Childhood ear infection;
LUSC	cis	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg17187183	chr4:55093834	PDGFRA	0.39	5.89	0.31	9.61e-9	Corneal astigmatism;
LUSC	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg05110241	chr16:68378359	PRMT7	-0.52	-6.12	-0.32	2.57e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg09503522	chr19:53445286	ZNF321	0.37	5.87	0.31	1.07e-8	Psoriasis;
LUSC	trans	rs3960554	0.800	rs80002395	chr7:75814902	C/T	cg19862616	chr7:65841803	NCRNA00174	0.88	9.96	0.48	1.28e-20	Eotaxin levels;
LUSC	cis	rs6546886	0.957	rs4364046	chr2:74256305	A/G	cg14702570	chr2:74259524	NA	0.32	6.15	0.32	2.15e-9	Dialysis-related mortality;
LUSC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg08847533	chr14:75593920	NEK9	-0.84	-15.37	-0.64	1.13e-40	Height;
LUSC	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg12257692	chr3:49977190	RBM6	-0.21	-5.68	-0.3	2.9e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg13535736	chr9:111863775	C9orf5	-0.33	-5.74	-0.3	2.11e-8	Menarche (age at onset);
LUSC	cis	rs11051970	0.636	rs1128591	chr12:32569351	T/C	cg02745156	chr12:32552066	NA	0.39	7.09	0.36	8.27e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3733631	1.000	rs3775971	chr4:104641920	C/T	cg24090629	chr4:104641072	TACR3	0.48	6.08	0.32	3.37e-9	Menarche (age at onset);
LUSC	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-14.23	-0.61	3.04e-36	Coronary artery disease;
LUSC	cis	rs7929679	0.551	rs11032849	chr11:34785740	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.9	0.31	8.92e-9	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	cis	rs11642862	1.000	rs75231191	chr16:30788601	C/T	cg02466173	chr16:30829666	NA	-0.66	-7.08	-0.36	8.57e-12	Tonsillectomy;
LUSC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	8.12	0.41	9.21e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21171335	chr12:122356390	WDR66	0.56	8.32	0.41	2.22e-15	Mean corpuscular volume;
LUSC	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg16070123	chr10:51489643	NA	0.57	9.35	0.46	1.29e-18	Prostate-specific antigen levels;
LUSC	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg08017756	chr2:100939284	LONRF2	-0.44	-8.24	-0.41	3.89e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4343996	0.967	rs10268249	chr7:3347074	C/T	cg21248987	chr7:3385318	SDK1	0.4	6.75	0.35	6.45e-11	Motion sickness;
LUSC	cis	rs11648785	0.747	rs3743826	chr16:90094214	C/T	cg16611967	chr16:90144006	NA	0.44	5.86	0.31	1.11e-8	Tanning;
LUSC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg22166914	chr1:53195759	ZYG11B	0.71	12.06	0.55	4.79e-28	Monocyte count;
LUSC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg03929089	chr4:120376271	NA	-0.5	-7.08	-0.36	8.68e-12	Coronary artery disease;
LUSC	cis	rs7210086	0.808	rs4331375	chr17:70640082	A/G	cg04206342	chr17:70636940	NA	-0.4	-6.67	-0.34	1.09e-10	Ulcerative colitis;
LUSC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg12432903	chr7:1882776	MAD1L1	-0.38	-5.95	-0.31	6.69e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2324229	0.927	rs1180196	chr6:83960006	A/G	cg08257003	chr6:84140564	ME1	0.3	7.06	0.36	9.86e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg24375607	chr4:120327624	NA	0.76	12.23	0.56	1.14e-28	Corneal astigmatism;
LUSC	cis	rs9837602	0.938	rs28503408	chr3:99794842	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.06	-0.31	3.72e-9	Breast cancer;
LUSC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg01657329	chr11:68192670	LRP5	-0.44	-6.54	-0.34	2.35e-10	Total body bone mineral density;
LUSC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg24296786	chr1:45957014	TESK2	0.52	8.02	0.4	1.83e-14	High light scatter reticulocyte count;
LUSC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg23590916	chr17:43697445	MGC57346	0.49	6.63	0.34	1.38e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.01	-0.31	4.85e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.01	-0.4	1.87e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg14690467	chr7:148917905	ZNF282	-0.26	-5.69	-0.3	2.71e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg00049323	chr5:472564	LOC25845	-0.44	-6.8	-0.35	4.79e-11	Cystic fibrosis severity;
LUSC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg03289416	chr15:75166202	SCAMP2	-0.47	-7.41	-0.38	1.05e-12	Breast cancer;
LUSC	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg00074818	chr8:8560427	CLDN23	0.59	9.95	0.48	1.32e-20	Obesity-related traits;
LUSC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.22	-0.37	3.59e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.48	-7.21	-0.37	3.74e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-0.96	-13.11	-0.58	5.93e-32	Vitiligo;
LUSC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.37	0.53	1.49e-25	Prudent dietary pattern;
LUSC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg17330251	chr7:94953956	PON1	-0.38	-5.94	-0.31	7.31e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg17168535	chr8:21777572	XPO7	0.83	15.3	0.64	2.11e-40	Mean corpuscular volume;
LUSC	trans	rs12570744	0.745	rs12764177	chr10:6792567	A/C	cg11642127	chr8:142593671	NA	0.3	6.08	0.32	3.2e-9	Response to anti-TNF therapy in rheumatoid arthritis;
LUSC	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg05340658	chr4:99064831	C4orf37	-0.44	-6.95	-0.36	1.94e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg27572855	chr1:25598939	RHD	0.46	8.15	0.41	7.53e-15	Erythrocyte sedimentation rate;
LUSC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg18350739	chr11:68623251	NA	-0.37	-6.61	-0.34	1.48e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs6499188	0.522	rs8046299	chr16:68672346	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.6	7.99	0.4	2.2e-14	Ulcerative colitis;
LUSC	cis	rs2346177	0.874	rs11125075	chr2:46656344	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-7.3	-0.37	2.18e-12	HDL cholesterol;
LUSC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg12463550	chr7:65579703	CRCP	0.52	7.46	0.38	7.59e-13	Aortic root size;
LUSC	trans	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg25214090	chr10:38739885	LOC399744	0.43	6.53	0.34	2.51e-10	Corneal astigmatism;
LUSC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	7.54	0.38	4.55e-13	Schizophrenia;
LUSC	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg17366294	chr4:99064904	C4orf37	0.55	8.77	0.43	9.47e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg26408565	chr15:76604113	ETFA	-0.51	-8.31	-0.41	2.46e-15	Blood metabolite levels;
LUSC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg23985595	chr17:80112537	CCDC57	-0.3	-5.75	-0.3	2.05e-8	Life satisfaction;
LUSC	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.41	-0.33	4.85e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.6	7.68	0.39	1.78e-13	Schizophrenia;
LUSC	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg01733217	chr16:74700730	RFWD3	1.0	22.64	0.78	2.04e-69	Multiple myeloma;
LUSC	trans	rs72674100	1.000	rs28539607	chr4:97977256	T/G	cg16405019	chr1:18959625	PAX7	-0.59	-6.39	-0.33	5.5e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg21880101	chr17:80066754	CCDC57	-0.31	-5.8	-0.3	1.54e-8	Life satisfaction;
LUSC	cis	rs300703	0.678	rs423643	chr2:199648	A/C	cg21211680	chr2:198530	NA	0.69	7.79	0.39	8.61e-14	Blood protein levels;
LUSC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg22732515	chr19:44031385	ETHE1	0.63	10.52	0.5	1.55e-22	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg02493740	chr2:85810744	VAMP5	-0.35	-6.07	-0.32	3.49e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7851660	0.805	rs4255258	chr9:100647545	A/G	cg13688889	chr9:100608707	NA	-0.56	-8.49	-0.42	6.93e-16	Strep throat;
LUSC	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg21775007	chr8:11205619	TDH	0.57	8.26	0.41	3.4e-15	Triglycerides;
LUSC	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg01966878	chr4:90757139	SNCA	-0.34	-5.85	-0.31	1.15e-8	Dementia with Lewy bodies;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg11235426	chr6:292522	DUSP22	0.68	11.09	0.52	1.46e-24	Menopause (age at onset);
LUSC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.65	0.43	2.28e-16	Lung cancer;
LUSC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg11494091	chr17:61959527	GH2	0.4	6.91	0.35	2.47e-11	Height;
LUSC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.52	6.82	0.35	4.31e-11	Blood protein levels;
LUSC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13732083	chr21:47605072	C21orf56	-0.39	-5.84	-0.3	1.25e-8	Testicular germ cell tumor;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07725970	chr12:27091851	FGFR1OP2;C12orf11	0.38	6.0	0.31	5.19e-9	Triglycerides;
LUSC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03934478	chr11:495069	RNH1	0.85	10.05	0.48	6.2e-21	Body mass index;
LUSC	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg18825076	chr15:78729989	IREB2	-0.47	-6.45	-0.33	3.93e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg11916186	chr1:36689760	THRAP3	0.45	6.26	0.32	1.17e-9	Mosquito bite size;
LUSC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.86	0.35	3.42e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg25258033	chr6:167368657	RNASET2	0.47	7.91	0.4	3.91e-14	Crohn's disease;
LUSC	cis	rs1982963	0.585	rs77091361	chr14:52486961	C/T	cg10843707	chr14:52510701	NID2	0.45	6.2	0.32	1.67e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.41	-0.38	1.04e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.64	6.3	0.33	9.42e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.2	-0.37	4.1e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg17178900	chr1:205818956	PM20D1	0.79	13.57	0.6	1.08e-33	Menarche (age at onset);
LUSC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg04733989	chr22:42467013	NAGA	-0.62	-9.72	-0.47	7.81e-20	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs77741769	0.529	rs3901854	chr12:121225526	C/T	cg02419362	chr12:121203948	SPPL3	0.46	8.43	0.42	1.03e-15	Mean corpuscular volume;
LUSC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg00684032	chr4:1343700	KIAA1530	0.33	6.02	0.31	4.69e-9	Longevity;
LUSC	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg15711740	chr2:61764176	XPO1	-0.46	-6.91	-0.35	2.39e-11	Tuberculosis;
LUSC	cis	rs72781680	0.665	rs72788298	chr2:24104293	T/C	cg08917208	chr2:24149416	ATAD2B	0.61	7.08	0.36	8.37e-12	Lymphocyte counts;
LUSC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.47	0.33	3.55e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg24375607	chr4:120327624	NA	0.79	11.23	0.52	4.98e-25	Corneal astigmatism;
LUSC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.84	15.03	0.64	2.3e-39	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg14154082	chr13:112174009	NA	0.37	7.7	0.39	1.54e-13	Menarche (age at onset);
LUSC	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.41	0.46	8.52e-19	Blood protein levels;
LUSC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg14696996	chr19:15285081	NOTCH3	0.96	9.25	0.45	2.69e-18	Pulse pressure;
LUSC	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg25019033	chr10:957182	NA	-0.53	-6.06	-0.31	3.74e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs7075426	0.669	rs3758520	chr10:88233628	C/G	cg07322936	chr10:88137208	NA	0.46	6.57	0.34	1.9e-10	Migraine without aura;
LUSC	cis	rs62400317	0.826	rs11968637	chr6:45348633	G/A	cg18551225	chr6:44695536	NA	-0.44	-7.3	-0.37	2.09e-12	Total body bone mineral density;
LUSC	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	13.82	0.6	1.13e-34	Lymphocyte percentage of white cells;
LUSC	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg11608241	chr8:8085544	FLJ10661	-0.36	-5.67	-0.3	3.08e-8	Mood instability;
LUSC	cis	rs12541635	0.677	rs1429681	chr8:107048808	A/C	cg10147462	chr8:107024639	NA	0.66	13.82	0.6	1.17e-34	Age of smoking initiation;
LUSC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	12.03	0.55	6.07e-28	Chronic sinus infection;
LUSC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg20406979	chr6:167373233	NA	-0.26	-6.16	-0.32	2.1e-9	Crohn's disease;
LUSC	cis	rs3741151	0.773	rs17244602	chr11:73219907	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.71	-6.37	-0.33	6.41e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg02772935	chr3:125709198	NA	-0.48	-6.18	-0.32	1.89e-9	Blood pressure (smoking interaction);
LUSC	trans	rs11699445	0.863	rs6135517	chr20:15770383	A/G	cg07106432	chr2:27593462	SNX17;EIF2B4	-0.38	-6.29	-0.33	9.96e-10	TRAIL levels;
LUSC	trans	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg06636001	chr8:8085503	FLJ10661	0.45	6.56	0.34	2.01e-10	Retinal vascular caliber;
LUSC	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.04	15.68	0.65	6.49e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.22	0.32	1.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg22907277	chr7:1156413	C7orf50	0.55	8.1	0.41	1.02e-14	Longevity;Endometriosis;
LUSC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg02807482	chr3:125708958	NA	-0.51	-6.36	-0.33	6.82e-10	Blood pressure (smoking interaction);
LUSC	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg21100191	chr22:23484243	RTDR1	0.82	13.97	0.61	3.08e-35	Bone mineral density;
LUSC	cis	rs7215564	0.818	rs35638109	chr17:78657367	C/T	cg09596252	chr17:78655493	RPTOR	0.55	6.04	0.31	4.18e-9	Myopia (pathological);
LUSC	cis	rs500891	0.525	rs1144181	chr6:84023171	G/A	cg08257003	chr6:84140564	ME1	0.33	7.85	0.39	5.81e-14	Platelet-derived growth factor BB levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19400780	chr1:10490496	APITD1	-0.45	-6.8	-0.35	4.86e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-8.96	-0.44	2.38e-17	Hemoglobin concentration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01169772	chr5:41904236	C5orf51	0.47	6.46	0.33	3.73e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg03453431	chr7:157225567	NA	-0.59	-10.72	-0.51	3.12e-23	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs360798	0.512	rs34104251	chr2:62995183	A/G	cg17519650	chr2:63277830	OTX1	-0.46	-6.36	-0.33	6.62e-10	Coronary artery disease;
LUSC	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg07212818	chr11:638076	DRD4	-0.38	-6.49	-0.33	3.07e-10	Systemic lupus erythematosus;
LUSC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.4	0.33	5.36e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4363385	0.574	rs6683514	chr1:152984397	A/G	cg00922841	chr1:152955080	SPRR1A	-0.39	-6.55	-0.34	2.18e-10	Inflammatory skin disease;
LUSC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.8	0.47	4.42e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg22029157	chr1:209979665	IRF6	0.8	10.25	0.49	1.27e-21	Cleft lip with or without cleft palate;
LUSC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.66	-11.45	-0.53	7.96e-26	Diastolic blood pressure;
LUSC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.56	8.67	0.43	1.91e-16	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20069020	chr7:108166782	PNPLA8	0.43	6.03	0.31	4.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg16482183	chr6:26056742	HIST1H1C	1.07	14.99	0.63	3.33e-39	Iron status biomarkers;
LUSC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg19680485	chr15:31195859	MTMR15	0.45	6.01	0.31	4.76e-9	Huntington's disease progression;
LUSC	cis	rs55665837	1.000	rs12792120	chr11:14469443	G/T	cg19336497	chr11:14380999	RRAS2	-0.37	-7.49	-0.38	6.29e-13	Vitamin D levels;
LUSC	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg05707623	chr12:122985044	ZCCHC8	0.66	8.11	0.41	9.63e-15	Body mass index;
LUSC	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.51	-6.03	-0.31	4.3e-9	Body mass index;
LUSC	cis	rs500891	0.730	rs1145917	chr6:83988861	T/C	cg08257003	chr6:84140564	ME1	0.33	7.15	0.36	5.67e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg03676636	chr4:99064102	C4orf37	0.27	5.84	0.3	1.26e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.65	-9.02	-0.44	1.55e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.6	9.52	0.46	3.63e-19	Morning vs. evening chronotype;
LUSC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg18827107	chr12:86230957	RASSF9	-0.46	-6.97	-0.36	1.74e-11	Major depressive disorder;
LUSC	trans	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg09781936	chr22:19749961	TBX1	-0.34	-6.02	-0.31	4.72e-9	Inflammatory bowel disease;
LUSC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-6.82	-0.35	4.17e-11	Tonsillectomy;
LUSC	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	7.15	0.36	5.35e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs7084921	0.578	rs12783521	chr10:101871748	C/A	cg11888571	chr10:102027403	CWF19L1	-0.45	-6.07	-0.32	3.44e-9	Bone mineral density;
LUSC	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg04310649	chr10:35416472	CREM	-0.39	-6.05	-0.31	3.92e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7605378	1.000	rs797163	chr2:200696387	G/A	cg23649088	chr2:200775458	C2orf69	0.53	8.21	0.41	4.91e-15	Osteoporosis;
LUSC	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.2e-28	Corneal astigmatism;
LUSC	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06022373	chr22:39101656	GTPBP1	0.74	12.04	0.55	5.83e-28	Menopause (age at onset);
LUSC	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg25664220	chr3:72788482	NA	-0.71	-11.93	-0.55	1.48e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg04362960	chr10:104952993	NT5C2	0.56	8.07	0.4	1.31e-14	Arsenic metabolism;
LUSC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg17554472	chr22:41940697	POLR3H	-0.48	-6.03	-0.31	4.42e-9	Vitiligo;
LUSC	cis	rs4953404	0.613	rs10180473	chr2:46904168	A/G	cg09399716	chr2:46890238	NA	-0.29	-6.5	-0.34	2.86e-10	Pulse pressure (alcohol consumption interaction);
LUSC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.53	0.38	4.69e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.37	0.56	3.34e-29	Prudent dietary pattern;
LUSC	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg24642439	chr20:33292090	TP53INP2	0.47	7.17	0.37	4.81e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg08859206	chr1:53392774	SCP2	-0.42	-6.72	-0.35	7.68e-11	Monocyte count;
LUSC	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.57	10.0	0.48	8.88e-21	Birth weight;
LUSC	cis	rs34891900	0.507	rs2008085	chr22:18204316	T/G	cg08824373	chr22:18117835	NA	-0.41	-6.2	-0.32	1.66e-9	Sum neutrophil eosinophil counts;
LUSC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg26335602	chr6:28129616	ZNF389	0.46	6.29	0.33	9.88e-10	Depression;
LUSC	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg00982548	chr2:198649783	BOLL	-0.57	-7.13	-0.36	6.43e-12	Ulcerative colitis;
LUSC	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	13.34	0.59	8.01e-33	Primary sclerosing cholangitis;
LUSC	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.82	-0.3	1.41e-8	IgG glycosylation;
LUSC	cis	rs1044826	0.692	rs295484	chr3:139231782	A/G	cg15131784	chr3:139108705	COPB2	-0.39	-6.35	-0.33	6.9e-10	Obesity-related traits;
LUSC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06028605	chr16:24865363	SLC5A11	-0.68	-10.39	-0.49	4.11e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs9296092	0.517	rs7743064	chr6:33470529	C/T	cg13560919	chr6:33536144	NA	-0.78	-13.33	-0.59	8.65e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg18681998	chr4:17616180	MED28	-0.84	-15.46	-0.65	4.84e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg02389323	chr16:88786976	FAM38A	-1.03	-10.98	-0.51	3.77e-24	Plateletcrit;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10840526	chr7:100813242	NA	0.41	6.11	0.32	2.77e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.56	-0.42	4.24e-16	Total cholesterol levels;
LUSC	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg26061582	chr7:22766209	IL6	0.49	7.02	0.36	1.25e-11	Lung cancer;
LUSC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg07741184	chr6:167504864	NA	0.36	6.52	0.34	2.55e-10	Crohn's disease;
LUSC	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg15556689	chr8:8085844	FLJ10661	0.59	8.85	0.44	5.14e-17	Systolic blood pressure;
LUSC	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg06612196	chr6:6737390	NA	0.57	11.14	0.52	1.05e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	0.82	11.44	0.53	8.71e-26	Coronary artery disease;
LUSC	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg23752985	chr2:85803571	VAMP8	0.31	6.06	0.31	3.7e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7599312	0.532	rs16848751	chr2:213389346	A/G	cg16329650	chr2:213403929	ERBB4	0.48	7.14	0.36	5.95e-12	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg14582100	chr15:45693742	SPATA5L1	0.45	8.54	0.42	4.94e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs11168618	0.715	rs35367885	chr12:48919660	G/A	cg24011408	chr12:48396354	COL2A1	0.4	6.39	0.33	5.6e-10	Adiponectin levels;
LUSC	cis	rs6060717	0.536	rs6060676	chr20:34498551	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.66	-0.3	3.32e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg10792982	chr14:105748885	BRF1	0.48	8.6	0.43	3.2e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg00343986	chr7:65444356	GUSB	-0.43	-6.45	-0.33	3.86e-10	Aortic root size;
LUSC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	6.29	0.33	9.74e-10	Mean platelet volume;
LUSC	cis	rs13315871	0.929	rs1554124	chr3:58268968	C/G	cg20936604	chr3:58311152	NA	-0.74	-7.39	-0.37	1.19e-12	Cholesterol, total;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg01334818	chr3:38496325	LOC100128640;ACVR2B	0.48	6.08	0.32	3.36e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg06784218	chr1:46089804	CCDC17	-0.47	-9.06	-0.44	1.09e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg26043149	chr18:55253948	FECH	-0.45	-6.99	-0.36	1.5e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg07677032	chr17:61819896	STRADA	-0.49	-8.23	-0.41	4.39e-15	Prudent dietary pattern;
LUSC	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs59698941	0.882	rs68171951	chr5:132290711	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	6.4	0.33	5.21e-10	Total body bone mineral density;
LUSC	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg17366294	chr4:99064904	C4orf37	0.54	9.22	0.45	3.48e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg16342193	chr10:102329863	NA	-0.39	-6.76	-0.35	6.11e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.72	10.31	0.49	8.05e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg03060546	chr3:49711283	APEH	0.7	11.63	0.54	1.78e-26	Resting heart rate;
LUSC	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg25124228	chr12:125621409	AACS	0.41	6.03	0.31	4.25e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg27284194	chr4:1044797	NA	-0.57	-8.37	-0.42	1.56e-15	Recombination rate (females);
LUSC	trans	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	8.94	0.44	2.64e-17	Mean corpuscular volume;
LUSC	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg17517138	chr11:73019481	ARHGEF17	1.04	8.68	0.43	1.78e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg11845111	chr2:191398756	TMEM194B	-0.86	-11.4	-0.53	1.21e-25	Diastolic blood pressure;
LUSC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg20135002	chr11:47629003	NA	-0.51	-7.88	-0.4	4.72e-14	Subjective well-being;
LUSC	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg27411982	chr8:10470053	RP1L1	-0.5	-7.95	-0.4	2.91e-14	Neuroticism;
LUSC	cis	rs6906287	0.669	rs12208253	chr6:118925097	G/C	cg21191810	chr6:118973309	C6orf204	0.31	5.77	0.3	1.83e-8	Electrocardiographic conduction measures;
LUSC	cis	rs11971779	0.680	rs6963867	chr7:139059964	T/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07080220	chr10:102295463	HIF1AN	0.68	9.2	0.45	3.94e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.05	-0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs11677416	1.000	rs11677416	chr2:113529240	A/G	cg27083787	chr2:113543245	IL1A	0.48	7.58	0.38	3.49e-13	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	trans	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-8.89	-0.44	3.79e-17	Depression;
LUSC	trans	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg19862616	chr7:65841803	NCRNA00174	0.9	10.63	0.5	6.43e-23	Eotaxin levels;
LUSC	cis	rs4363385	0.818	rs4845514	chr1:153000820	T/C	cg25856811	chr1:152973957	SPRR3	-0.36	-6.0	-0.31	5.07e-9	Inflammatory skin disease;
LUSC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.52	0.76	4.62e-65	Prudent dietary pattern;
LUSC	cis	rs2798269	0.510	rs7985023	chr13:22123600	A/G	cg18095732	chr13:22033692	ZDHHC20	0.4	6.23	0.32	1.39e-9	PR segment;
LUSC	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg24812749	chr6:127587940	RNF146	0.71	10.21	0.49	1.78e-21	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21218899	chr19:46010592	VASP	-0.42	-6.22	-0.32	1.5e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6500395	1.000	rs2111243	chr16:48724897	C/T	cg04672837	chr16:48644449	N4BP1	-0.48	-7.11	-0.36	7.05e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18876405	chr7:65276391	NA	0.49	6.65	0.34	1.22e-10	Corneal structure;
LUSC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg24531977	chr5:56204891	C5orf35	-0.73	-10.51	-0.5	1.58e-22	Coronary artery disease;
LUSC	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.13	-0.36	6.38e-12	Type 2 diabetes;
LUSC	cis	rs7674212	1.000	rs7691873	chr4:103987899	C/T	cg16532752	chr4:104119610	CENPE	0.41	6.21	0.32	1.53e-9	Type 2 diabetes;
LUSC	cis	rs62408225	1.000	rs55771973	chr6:90981319	T/G	cg06866423	chr6:90926672	BACH2	0.42	5.96	0.31	6.26e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7520050	1.000	rs12143096	chr1:46469763	G/A	cg06784218	chr1:46089804	CCDC17	-0.29	-5.69	-0.3	2.78e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs714027	0.605	rs193476	chr22:30450521	G/A	cg11564601	chr22:30592435	NA	-0.32	-5.65	-0.3	3.52e-8	Lymphocyte counts;
LUSC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg25258033	chr6:167368657	RNASET2	0.47	7.84	0.39	6.15e-14	Crohn's disease;
LUSC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18876405	chr7:65276391	NA	-0.55	-8.77	-0.43	9.25e-17	Aortic root size;
LUSC	cis	rs4363385	0.510	rs12083211	chr1:153032131	A/T	cg25856811	chr1:152973957	SPRR3	0.37	6.13	0.32	2.46e-9	Inflammatory skin disease;
LUSC	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg13010199	chr12:38710504	ALG10B	-0.56	-8.82	-0.43	6.69e-17	Morning vs. evening chronotype;
LUSC	cis	rs8141797	0.901	rs8140812	chr22:24553535	C/T	cg00411358	chr22:24577142	SUSD2	-0.51	-5.82	-0.3	1.37e-8	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs7923609	0.967	rs7896783	chr10:65162153	G/A	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	3.84e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg25214090	chr10:38739885	LOC399744	0.54	7.91	0.4	3.89e-14	Corneal astigmatism;
LUSC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22442454	chr1:209979470	IRF6	0.43	5.88	0.31	9.86e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs3772130	1.000	rs3772128	chr3:121345094	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	9.49	0.46	4.61e-19	Cognitive performance;
LUSC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg22834771	chr12:69754056	YEATS4	-0.52	-7.86	-0.4	5.24e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07677032	chr17:61819896	STRADA	0.53	8.77	0.43	9.58e-17	Prudent dietary pattern;
LUSC	cis	rs9369695	0.883	rs9381581	chr6:47580695	G/A	cg20196966	chr6:47445060	CD2AP	0.43	6.08	0.32	3.24e-9	Reticulocyte count;
LUSC	cis	rs9311676	0.632	rs56033718	chr3:58446398	A/G	cg13750441	chr3:58318267	PXK	0.35	6.83	0.35	4.08e-11	Systemic lupus erythematosus;
LUSC	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg25664220	chr3:72788482	NA	-0.58	-10.82	-0.51	1.34e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg06212747	chr3:49208901	KLHDC8B	0.46	6.37	0.33	6.36e-10	Parkinson's disease;
LUSC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs16912285	0.688	rs7929701	chr11:24357964	A/C	ch.11.24196551F	chr11:24239977	NA	0.85	8.17	0.41	6.47e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.67	-12.11	-0.55	3.2e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.88	17.16	0.68	9.06e-48	Menarche (age at onset);
LUSC	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg03465714	chr1:152285911	FLG	-0.4	-5.75	-0.3	2.05e-8	Atopic dermatitis;
LUSC	cis	rs7202877	0.706	rs247450	chr16:75490017	C/A	cg03315344	chr16:75512273	CHST6	-0.47	-6.39	-0.33	5.59e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg22906224	chr7:99728672	NA	0.52	7.57	0.38	3.59e-13	Coronary artery disease;
LUSC	trans	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg20587970	chr11:113659929	NA	1.04	11.06	0.52	1.91e-24	Hip circumference adjusted for BMI;
LUSC	cis	rs3820928	0.904	rs2195487	chr2:227759720	G/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.73	-0.39	1.3e-13	Pulmonary function;
LUSC	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17467752	chr17:38218738	THRA	0.77	12.45	0.56	1.7e-29	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg12573674	chr2:1569213	NA	-0.55	-6.14	-0.32	2.36e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs727505	1.000	rs56313563	chr7:124507003	G/A	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.29	6.23	0.32	1.38e-9	Electroencephalogram traits;
LUSC	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg08508325	chr11:3079039	CARS	0.38	8.45	0.42	9.13e-16	Calcium levels;
LUSC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.27	0.49	1.13e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg13010199	chr12:38710504	ALG10B	0.47	7.14	0.36	6e-12	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1784581	0.674	rs1789996	chr6:162391895	T/C	cg17173639	chr6:162384350	PARK2	-0.68	-12.21	-0.56	1.3e-28	Itch intensity from mosquito bite;
LUSC	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg00277334	chr10:82204260	NA	0.67	7.98	0.4	2.42e-14	Post bronchodilator FEV1;
LUSC	cis	rs7945718	0.870	rs10831903	chr11:12758660	C/T	cg25843174	chr11:12811716	TEAD1	0.32	6.96	0.36	1.78e-11	Educational attainment (years of education);
LUSC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18404041	chr3:52824283	ITIH1	-0.59	-11.4	-0.53	1.17e-25	Bipolar disorder;
LUSC	trans	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg07393940	chr7:158741817	NA	0.36	6.46	0.33	3.77e-10	Life satisfaction;
LUSC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg07703079	chr11:430292	ANO9	0.61	6.35	0.33	7.1e-10	Body mass index;
LUSC	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg05234568	chr11:5960015	NA	-0.63	-8.89	-0.44	3.96e-17	DNA methylation (variation);
LUSC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.24	0.37	3.09e-12	Mean platelet volume;
LUSC	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg23387468	chr7:139079360	LUC7L2	-0.41	-6.3	-0.33	9.29e-10	Diisocyanate-induced asthma;
LUSC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.7	10.95	0.51	4.71e-24	Aortic root size;
LUSC	cis	rs4499344	0.693	rs8106502	chr19:33097796	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	12.66	0.57	2.92e-30	Mean platelet volume;
LUSC	cis	rs2242663	0.798	rs1945302	chr11:66337498	C/T	cg18002602	chr11:66138449	SLC29A2	-0.35	-6.21	-0.32	1.56e-9	Bipolar disorder;
LUSC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.48	10.29	0.49	9.32e-22	Airflow obstruction;
LUSC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg17376030	chr22:41985996	PMM1	-0.47	-5.84	-0.3	1.25e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg13939156	chr17:80058883	NA	0.34	6.56	0.34	2.06e-10	Life satisfaction;
LUSC	cis	rs9831754	0.906	rs1588650	chr3:78410750	T/G	cg06138941	chr3:78371609	NA	-0.65	-9.37	-0.46	1.09e-18	Calcium levels;
LUSC	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg03342759	chr3:160939853	NMD3	-0.49	-8.17	-0.41	6.3e-15	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg25767906	chr1:53392781	SCP2	-0.41	-7.03	-0.36	1.21e-11	Monocyte count;
LUSC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg10909506	chr17:38081995	ORMDL3	0.34	6.14	0.32	2.39e-9	Self-reported allergy;
LUSC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08736216	chr1:53307985	ZYG11A	0.3	6.06	0.31	3.77e-9	Monocyte count;
LUSC	cis	rs10761482	0.601	rs1954117	chr10:62210588	A/C	cg18175470	chr10:62150864	ANK3	-0.53	-7.37	-0.37	1.32e-12	Schizophrenia;
LUSC	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg18105134	chr13:113819100	PROZ	-0.76	-10.53	-0.5	1.4e-22	Platelet distribution width;
LUSC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.64	0.57	3.36e-30	Motion sickness;
LUSC	cis	rs9650657	0.615	rs1549796	chr8:10692359	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-6.01	-0.31	4.74e-9	Neuroticism;
LUSC	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg22681709	chr2:178499509	PDE11A	-0.4	-5.7	-0.3	2.57e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg11062466	chr8:58055876	NA	0.66	9.08	0.44	9.89e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs9341808	0.667	rs2476826	chr6:80876064	C/T	cg08355045	chr6:80787529	NA	0.48	8.21	0.41	4.82e-15	Sitting height ratio;
LUSC	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg25457927	chr22:38595422	NA	-0.51	-11.35	-0.53	1.74e-25	Cutaneous nevi;
LUSC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg23711669	chr6:146136114	FBXO30	0.76	13.58	0.6	9.4e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg07716408	chr11:68623521	NA	-0.3	-5.77	-0.3	1.8e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg05585544	chr11:47624801	NA	0.41	7.24	0.37	3.2e-12	Subjective well-being;
LUSC	cis	rs6484504	0.532	rs10835756	chr11:31267622	C/T	cg26647111	chr11:31128758	NA	-0.43	-6.14	-0.32	2.36e-9	Red blood cell count;
LUSC	cis	rs7246967	0.604	rs12975793	chr19:22862844	A/C	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs12618769	0.652	rs3820941	chr2:99233781	C/T	cg10123293	chr2:99228465	UNC50	0.46	7.56	0.38	3.95e-13	Bipolar disorder;
LUSC	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg05347473	chr6:146136440	FBXO30	0.42	6.99	0.36	1.52e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.25	0.52	4.16e-25	Fuchs's corneal dystrophy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15941164	chr5:77072171	TBCA	0.43	6.19	0.32	1.78e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.4	-0.38	1.15e-12	Psoriasis;
LUSC	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.45	-7.13	-0.36	6.15e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	12.61	0.57	4.28e-30	Menopause (age at onset);
LUSC	cis	rs2742417	0.603	rs1019129	chr3:45780780	T/C	cg04837898	chr3:45731254	SACM1L	-0.45	-7.45	-0.38	8.27e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg23262073	chr20:60523788	NA	-0.4	-5.67	-0.3	3.15e-8	Body mass index;
LUSC	trans	rs10982256	0.870	rs998547	chr9:117275012	G/A	cg03506640	chr14:85997753	FLRT2	-0.35	-5.95	-0.31	6.65e-9	Bipolar disorder;
LUSC	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.34	-0.49	6.24e-22	Eye color traits;
LUSC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.37	-0.42	1.6e-15	Height;
LUSC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg14092988	chr3:52407081	DNAH1	0.33	6.32	0.33	8.52e-10	Bipolar disorder;
LUSC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg04944784	chr2:26401820	FAM59B	-0.75	-11.0	-0.52	3.24e-24	Gut microbiome composition (summer);
LUSC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg03806693	chr22:41940476	POLR3H	-0.97	-13.87	-0.6	7.3e-35	Vitiligo;
LUSC	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.51	0.46	3.95e-19	Bipolar disorder;
LUSC	trans	rs747782	0.527	rs2279822	chr11:48146114	C/T	cg03929089	chr4:120376271	NA	0.71	6.42	0.33	4.63e-10	Intraocular pressure;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02700454	chr8:126441997	TRIB1	-0.45	-6.55	-0.34	2.16e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7605827	0.897	rs2241238	chr2:15656560	T/C	cg19274914	chr2:15703543	NA	0.46	8.83	0.43	6.22e-17	Educational attainment (years of education);
LUSC	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg02176678	chr2:219576539	TTLL4	-0.57	-10.15	-0.49	2.88e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg25258033	chr6:167368657	RNASET2	-0.47	-7.98	-0.4	2.35e-14	Crohn's disease;
LUSC	trans	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg26043149	chr18:55253948	FECH	-0.45	-6.89	-0.35	2.86e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-7.75	-0.39	1.12e-13	Prudent dietary pattern;
LUSC	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg22508957	chr16:3507546	NAT15	0.84	10.81	0.51	1.45e-23	Tuberculosis;
LUSC	trans	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.68	-0.34	9.77e-11	Depression;
LUSC	cis	rs2354432	0.607	rs11239980	chr1:146782698	G/A	cg25205988	chr1:146714368	CHD1L	-1.02	-9.56	-0.46	2.63e-19	Mitochondrial DNA levels;
LUSC	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.55	-0.42	4.5e-16	Total cholesterol levels;
LUSC	cis	rs1113500	0.933	rs3909076	chr1:108631760	T/C	cg11967332	chr1:108735228	SLC25A24	0.38	5.76	0.3	1.92e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs2540226	0.967	rs12470473	chr2:40005290	A/G	cg23576258	chr2:39999331	THUMPD2	-0.34	-5.94	-0.31	7.32e-9	Personality dimensions;
LUSC	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg13073564	chr4:8508604	NA	0.34	6.44	0.33	4.28e-10	Response to antineoplastic agents;
LUSC	cis	rs4930561	0.765	rs10896304	chr11:67981714	T/G	cg16338278	chr11:67432957	ALDH3B2	0.39	6.47	0.33	3.49e-10	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs1981331	1.000	rs77587985	chr21:47993897	A/G	cg23283320	chr21:48055893	PRMT2	1.12	8.14	0.41	7.72e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	cis	rs4253772	0.872	rs45576734	chr22:46638365	A/G	cg09491104	chr22:46646882	C22orf40	-0.59	-6.48	-0.33	3.23e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs12973672	0.812	rs12984022	chr19:35754011	A/C	cg12095397	chr19:35769544	USF2	0.43	6.56	0.34	2.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg09307838	chr4:120376055	NA	0.74	10.88	0.51	8.49e-24	Corneal astigmatism;
LUSC	cis	rs4704187	0.687	rs2059159	chr5:74451178	G/C	cg03227963	chr5:74354835	NA	0.32	6.91	0.35	2.44e-11	Response to amphetamines;
LUSC	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg11645453	chr3:52864694	ITIH4	-0.47	-10.96	-0.51	4.26e-24	Schizophrenia;
LUSC	cis	rs1014246	1.000	rs1014246	chr10:118466042	C/T	cg14919929	chr10:118506882	NA	0.38	5.88	0.31	9.98e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7727544	0.506	rs10040809	chr5:131343017	A/C	cg14196790	chr5:131705035	SLC22A5	0.41	6.73	0.35	7.33e-11	Blood metabolite levels;
LUSC	cis	rs2067615	0.560	rs10861671	chr12:107220927	T/C	cg15890332	chr12:107067104	RFX4	0.33	5.95	0.31	6.68e-9	Heart rate;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg18538332	chr22:24372958	LOC391322	-0.48	-8.55	-0.42	4.33e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06112835	chr11:68658793	MRPL21	0.51	7.54	0.38	4.53e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg25214090	chr10:38739885	LOC399744	0.52	7.48	0.38	6.57e-13	Corneal astigmatism;
LUSC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg16680214	chr1:154839983	KCNN3	-0.52	-9.74	-0.47	6.53e-20	Prostate cancer;
LUSC	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg00857998	chr1:205179979	DSTYK	0.62	9.52	0.46	3.48e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg09165964	chr15:75287851	SCAMP5	-1.16	-19.52	-0.73	3.81e-57	Blood trace element (Zn levels);
LUSC	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.2	-0.45	3.96e-18	Extrinsic epigenetic age acceleration;
LUSC	trans	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Parkinson's disease;
LUSC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg06219351	chr7:158114137	PTPRN2	-0.52	-9.48	-0.46	4.82e-19	Calcium levels;
LUSC	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg27165867	chr14:105738592	BRF1	-0.57	-8.59	-0.43	3.4e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.75	13.57	0.6	1.02e-33	Aortic root size;
LUSC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg21535247	chr6:8435926	SLC35B3	-0.61	-9.43	-0.46	6.87e-19	Motion sickness;
LUSC	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.28	-0.45	2.17e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg14791747	chr16:20752902	THUMPD1	-0.75	-10.82	-0.51	1.35e-23	Cognitive test performance;
LUSC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.63	0.57	3.75e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg23275502	chr19:41860019	TGFB1	0.44	6.71	0.34	8.32e-11	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs1506636	0.646	rs805789	chr7:123221920	G/T	cg03229431	chr7:123269106	ASB15	-0.61	-9.3	-0.45	1.88e-18	Plateletcrit;Platelet count;
LUSC	cis	rs834603	0.575	rs834595	chr7:47472276	C/T	cg09696706	chr7:47479511	TNS3	0.33	6.0	0.31	5.04e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg16584290	chr5:462447	EXOC3	-0.34	-5.81	-0.3	1.46e-8	Cystic fibrosis severity;
LUSC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg18402987	chr7:1209562	NA	0.73	7.92	0.4	3.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7833986	1.000	rs35883156	chr8:57078933	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	8.85	0.44	5.28e-17	Height;
LUSC	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg00857998	chr1:205179979	DSTYK	0.6	9.01	0.44	1.66e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg21681030	chr2:46777652	RHOQ	0.5	7.66	0.39	2.09e-13	Height;
LUSC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg00750074	chr16:89608354	SPG7	-0.57	-10.17	-0.49	2.36e-21	Multiple myeloma (IgH translocation);
LUSC	trans	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg20935933	chr6:143382018	AIG1	0.5	7.18	0.37	4.55e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg01528321	chr10:82214614	TSPAN14	0.82	12.43	0.56	1.97e-29	Post bronchodilator FEV1;
LUSC	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg24503407	chr1:205819492	PM20D1	-0.47	-6.32	-0.33	8.61e-10	Menarche (age at onset);
LUSC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs16912285	0.584	rs7131124	chr11:24249455	A/G	ch.11.24196551F	chr11:24239977	NA	0.98	11.41	0.53	1.13e-25	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4474465	0.850	rs6592789	chr11:78246767	G/C	cg27205649	chr11:78285834	NARS2	0.49	5.87	0.31	1.05e-8	Alzheimer's disease (survival time);
LUSC	cis	rs8114671	0.967	rs6142323	chr20:33788983	A/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.92	-0.31	7.81e-9	Height;
LUSC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg06287003	chr12:125626642	AACS	-0.38	-6.72	-0.34	8.02e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4363385	0.714	rs4845329	chr1:152974454	G/C	cg25856811	chr1:152973957	SPRR3	-0.34	-5.65	-0.3	3.43e-8	Inflammatory skin disease;
LUSC	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.55	-0.46	2.81e-19	Osteoarthritis;
LUSC	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg10911889	chr6:126070802	HEY2	-0.43	-6.72	-0.35	7.75e-11	Brugada syndrome;
LUSC	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg15839431	chr19:19639596	YJEFN3	-0.61	-6.99	-0.36	1.54e-11	Bipolar disorder;
LUSC	cis	rs57590327	0.508	rs10511101	chr3:81950302	A/C	cg07356753	chr3:81810745	GBE1	-0.59	-8.68	-0.43	1.79e-16	Extraversion;
LUSC	trans	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg07393940	chr7:158741817	NA	-0.37	-6.64	-0.34	1.27e-10	Life satisfaction;
LUSC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg15468180	chr1:107600409	PRMT6	0.38	6.02	0.31	4.53e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs735539	0.914	rs7997065	chr13:21273796	A/G	cg04906043	chr13:21280425	IL17D	0.46	8.89	0.44	3.81e-17	Dental caries;
LUSC	cis	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg05084668	chr3:125655381	ALG1L	0.6	8.73	0.43	1.25e-16	Blood pressure (smoking interaction);
LUSC	trans	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg18634211	chr1:26737262	LIN28	0.54	7.05	0.36	1.02e-11	Atrial fibrillation;
LUSC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-1.15	-16.9	-0.68	9.53e-47	Breast cancer;
LUSC	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg04586622	chr2:25135609	ADCY3	0.34	6.87	0.35	3.25e-11	Body mass index in non-asthmatics;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02884346	chr4:6271501	WFS1	-0.47	-6.27	-0.32	1.15e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg13607699	chr17:42295918	UBTF	0.69	10.86	0.51	9.88e-24	Total body bone mineral density;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg23200371	chr12:56367680	RAB5B	0.68	6.14	0.32	2.38e-9	Cognitive performance;
LUSC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg20936695	chr7:66093774	KCTD7	-0.63	-5.77	-0.3	1.81e-8	Diabetic kidney disease;
LUSC	cis	rs16854884	0.789	rs34096668	chr3:143794483	C/T	cg06585982	chr3:143692056	C3orf58	0.46	6.82	0.35	4.34e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg17366294	chr4:99064904	C4orf37	0.58	10.3	0.49	8.8e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg04036182	chr15:45458818	NA	0.35	5.83	0.3	1.32e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg17652424	chr22:38574118	PLA2G6	-0.3	-6.58	-0.34	1.84e-10	Cutaneous nevi;
LUSC	trans	rs2665103	0.632	rs3902959	chr15:82544927	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.37	-0.33	6.16e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs975210	0.652	rs4777230	chr15:70365762	A/G	cg12349571	chr15:70364359	TLE3	-0.59	-6.8	-0.35	4.93e-11	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LUSC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-0.85	-14.76	-0.63	2.71e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg08085267	chr17:45401833	C17orf57	0.59	9.79	0.47	4.46e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	1e-64	Prudent dietary pattern;
LUSC	cis	rs16976116	0.901	rs28449712	chr15:55500681	A/C	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg06008330	chr7:65541103	ASL	0.4	6.19	0.32	1.77e-9	Aortic root size;
LUSC	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.75	-0.39	1.08e-13	Schizophrenia;
LUSC	cis	rs2227930	0.528	rs7643377	chr3:142114694	C/T	cg16271453	chr3:142027066	XRN1	-0.53	-9.46	-0.46	5.84e-19	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg24154853	chr7:158122151	PTPRN2	-0.41	-7.76	-0.39	1.03e-13	Calcium levels;
LUSC	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.72	10.78	0.51	1.86e-23	Smoking initiation;
LUSC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg23711669	chr6:146136114	FBXO30	0.91	17.52	0.69	3.48e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	8.96	0.44	2.26e-17	Prudent dietary pattern;
LUSC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg03732007	chr1:2071316	PRKCZ	-0.59	-10.95	-0.51	4.62e-24	Height;
LUSC	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg17366294	chr4:99064904	C4orf37	0.6	10.76	0.51	2.22e-23	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7739264	1.000	rs9358270	chr6:19780584	C/G	cg13431028	chr2:169073609	STK39	0.35	6.02	0.31	4.61e-9	Endometriosis;
LUSC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.54	6.69	0.34	9.67e-11	Renal function-related traits (BUN);
LUSC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05535760	chr7:792225	HEATR2	-0.74	-7.46	-0.38	7.6e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg13206674	chr6:150067644	NUP43	0.6	9.48	0.46	4.74e-19	Lung cancer;
LUSC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.93	-0.51	5.8e-24	Alzheimer's disease (late onset);
LUSC	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.07	-0.44	1.06e-17	Monocyte percentage of white cells;
LUSC	cis	rs6845621	0.901	rs7684524	chr4:18920402	C/A	cg12196642	chr4:18937545	NA	-0.36	-6.75	-0.35	6.71e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg12940439	chr1:67600707	NA	0.37	6.03	0.31	4.38e-9	Psoriasis;
LUSC	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	6.57	0.34	1.94e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg09835421	chr16:68378352	PRMT7	-0.73	-7.42	-0.38	9.62e-13	Schizophrenia;
LUSC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg27572855	chr1:25598939	RHD	0.46	8.37	0.42	1.57e-15	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs231513	0.911	rs231517	chr17:41961789	C/T	cg26893861	chr17:41843967	DUSP3	-0.52	-6.28	-0.33	1.03e-9	Cognitive function;
LUSC	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg13393036	chr8:95962371	TP53INP1	-0.42	-8.88	-0.44	4.32e-17	Type 2 diabetes;
LUSC	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg11941060	chr3:133502564	NA	-0.47	-7.42	-0.38	9.53e-13	Iron status biomarkers;
LUSC	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg10518572	chr11:65560635	OVOL1	-0.27	-5.9	-0.31	9.14e-9	Acne (severe);
LUSC	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg03647239	chr10:116582469	FAM160B1	0.45	7.27	0.37	2.55e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.59	-8.76	-0.43	9.75e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs77633900	0.772	rs157769	chr15:76834397	G/A	cg21673338	chr15:77095150	SCAPER	-0.68	-5.76	-0.3	1.93e-8	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs12530845	1.000	rs78186690	chr7:135334991	G/C	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	trans	rs72674100	1.000	rs2865754	chr4:97992711	T/C	cg16405019	chr1:18959625	PAX7	-0.61	-6.43	-0.33	4.48e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.48	-8.96	-0.44	2.27e-17	Metabolite levels;
LUSC	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-15.19	-0.64	5.5e-40	Exhaled nitric oxide output;
LUSC	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-7.4	-0.38	1.1e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	8.98	0.44	2.01e-17	Mean corpuscular volume;
LUSC	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.78	0.35	5.34e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg12564285	chr5:131593104	PDLIM4	0.4	7.18	0.37	4.47e-12	Breast cancer;
LUSC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg22681709	chr2:178499509	PDE11A	-0.59	-11.89	-0.55	1.93e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg00857998	chr1:205179979	DSTYK	0.59	8.8	0.43	7.22e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg19090637	chr4:111119052	ELOVL6	0.5	6.2	0.32	1.64e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs908922	0.743	rs10888499	chr1:152532742	C/A	cg20991723	chr1:152506922	NA	0.5	8.4	0.42	1.28e-15	Hair morphology;
LUSC	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg02018176	chr4:1364513	KIAA1530	0.44	6.11	0.32	2.78e-9	Recombination rate (females);
LUSC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg26587870	chr6:27730563	NA	-0.66	-5.94	-0.31	7.24e-9	Depression;
LUSC	cis	rs11039100	1.000	rs12798823	chr11:5826716	T/G	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.54	-0.38	4.34e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg06623918	chr6:96969491	KIAA0776	-0.87	-14.2	-0.61	3.78e-36	Headache;
LUSC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07157834	chr1:205819609	PM20D1	0.43	5.98	0.31	5.73e-9	Parkinson's disease;
LUSC	cis	rs7945718	0.805	rs6486059	chr11:12824581	A/G	cg25843174	chr11:12811716	TEAD1	-0.31	-6.98	-0.36	1.57e-11	Educational attainment (years of education);
LUSC	cis	rs7843479	0.931	rs1031883	chr8:21788936	G/A	cg17168535	chr8:21777572	XPO7	0.67	10.25	0.49	1.33e-21	Mean corpuscular volume;
LUSC	cis	rs354225	0.544	rs10193692	chr2:54808340	A/T	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg21724239	chr8:58056113	NA	0.58	6.96	0.36	1.85e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs897984	0.806	rs9319588	chr16:30930983	C/T	cg02466173	chr16:30829666	NA	0.56	11.19	0.52	6.77e-25	Dementia with Lewy bodies;
LUSC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.82	12.97	0.58	1.9e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.73	-13.36	-0.59	6.47e-33	Ulcerative colitis;
LUSC	cis	rs9840812	0.769	rs3755636	chr3:135968828	G/C	cg15507776	chr3:136538369	TMEM22	0.45	6.21	0.32	1.54e-9	Fibrinogen levels;
LUSC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg05472934	chr7:22766657	IL6	0.5	7.76	0.39	1.03e-13	Lung cancer;
LUSC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg17173187	chr15:85201210	NMB	0.37	6.56	0.34	2.08e-10	Schizophrenia;
LUSC	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg11984989	chr7:158649758	WDR60	1.06	20.43	0.75	9.16e-61	Height;
LUSC	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg13010199	chr12:38710504	ALG10B	0.51	7.63	0.39	2.46e-13	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs977987	0.931	rs1834013	chr16:75496163	G/T	cg04384234	chr16:75411784	CFDP1	-0.48	-7.96	-0.4	2.62e-14	Dupuytren's disease;
LUSC	cis	rs27434	0.583	rs40091	chr5:96154919	A/G	cg16492584	chr5:96139282	ERAP1	-0.58	-7.91	-0.4	3.9e-14	Ankylosing spondylitis;
LUSC	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.57	0.34	1.9e-10	Corneal astigmatism;
LUSC	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.56	-0.42	4.09e-16	Response to antipsychotic treatment;
LUSC	trans	rs11700980	0.551	rs2832016	chr21:30111397	A/G	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.31e-9	QRS complex (12-leadsum);
LUSC	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg22782873	chr19:19639568	YJEFN3	-0.49	-6.12	-0.32	2.56e-9	Bipolar disorder;
LUSC	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg18132916	chr6:79620363	NA	-0.41	-6.2	-0.32	1.63e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.58	-0.42	3.69e-16	Response to antipsychotic treatment;
LUSC	cis	rs1178127	0.580	rs17139840	chr7:18800603	T/C	cg02370815	chr7:18831390	HDAC9	-0.4	-6.12	-0.32	2.59e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
LUSC	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg01557791	chr16:72042693	DHODH	-0.48	-7.05	-0.36	1.02e-11	Fibrinogen levels;
LUSC	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg12639453	chr1:2035780	PRKCZ	-0.35	-7.5	-0.38	5.99e-13	Height;
LUSC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg09365446	chr1:150670422	GOLPH3L	0.46	7.02	0.36	1.24e-11	Melanoma;
LUSC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.84	-0.51	1.15e-23	Alzheimer's disease (late onset);
LUSC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06656553	chr16:89960601	TCF25	-0.65	-5.7	-0.3	2.65e-8	Skin colour saturation;
LUSC	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.83	-20.25	-0.74	4.69e-60	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs11583043	0.708	rs6577227	chr1:101562132	A/G	cg11406453	chr1:101602562	NA	-0.4	-6.72	-0.35	7.74e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-0.81	-11.79	-0.54	4.7e-27	Vitiligo;
LUSC	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg12473912	chr3:136751656	NA	0.4	7.12	0.36	6.46e-12	Neuroticism;
LUSC	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg26195577	chr20:24973756	C20orf3	-1.09	-17.67	-0.7	8.42e-50	Blood protein levels;
LUSC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg16339924	chr4:17578868	LAP3	0.57	8.63	0.43	2.51e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg22782873	chr19:19639568	YJEFN3	-0.49	-6.12	-0.32	2.56e-9	Bipolar disorder;
LUSC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg12463550	chr7:65579703	CRCP	0.57	8.46	0.42	8.25e-16	Aortic root size;
LUSC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg05564831	chr3:52568323	NT5DC2	-0.3	-5.65	-0.3	3.41e-8	Electroencephalogram traits;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg00770008	chr3:20081585	KAT2B	0.63	6.1	0.32	2.9e-9	Body mass index;
LUSC	cis	rs7572644	0.640	rs11891769	chr2:28025580	G/C	cg27432699	chr2:27873401	GPN1	0.56	7.32	0.37	1.84e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg04508216	chr1:11107452	MASP2	0.31	5.67	0.3	3.17e-8	Body mass index;
LUSC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg27411982	chr8:10470053	RP1L1	-0.45	-6.63	-0.34	1.33e-10	Triglycerides;
LUSC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg05132306	chr1:1846340	CALML6	-0.34	-8.51	-0.42	6.05e-16	Body mass index;
LUSC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg14440974	chr22:39074834	NA	0.4	6.72	0.35	7.88e-11	Menopause (age at onset);
LUSC	cis	rs77633900	0.772	rs79181196	chr15:76656281	G/T	cg21673338	chr15:77095150	SCAPER	-0.72	-6.18	-0.32	1.91e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs3857536	0.813	rs4710580	chr6:66935200	C/T	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs11893307	0.507	rs1465303	chr2:191585440	A/C	cg11845111	chr2:191398756	TMEM194B	-0.42	-5.7	-0.3	2.6e-8	Mean platelet volume;
LUSC	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg25019033	chr10:957182	NA	-0.48	-6.06	-0.31	3.73e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg15556689	chr8:8085844	FLJ10661	0.67	11.06	0.52	1.91e-24	Neuroticism;
LUSC	cis	rs1185460	0.967	rs3825061	chr11:118944675	C/T	cg23280166	chr11:118938394	VPS11	0.46	6.88	0.35	2.97e-11	Coronary artery disease;
LUSC	trans	rs1347297	0.590	rs9288019	chr2:179276894	C/A	cg14011486	chr1:26737247	LIN28	0.47	7.25	0.37	3.01e-12	Alzheimer disease and age of onset;
LUSC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg27411982	chr8:10470053	RP1L1	-0.48	-7.76	-0.39	1.07e-13	Neuroticism;
LUSC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.56	8.64	0.43	2.38e-16	Menopause (age at onset);
LUSC	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg21890820	chr11:65308645	LTBP3	-0.6	-8.6	-0.43	3.05e-16	Bone mineral density;
LUSC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg26043149	chr18:55253948	FECH	-0.45	-6.92	-0.35	2.38e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9653442	0.545	rs4850921	chr2:100762699	G/T	cg22139774	chr2:100720529	AFF3	-0.41	-7.06	-0.36	1e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.818	rs1415965	chr1:153002750	G/A	cg25856811	chr1:152973957	SPRR3	-0.36	-5.94	-0.31	6.97e-9	Inflammatory skin disease;
LUSC	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	12.0	0.55	8.1e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7000551	0.725	rs2249098	chr8:22400098	T/C	cg12081754	chr8:22256438	SLC39A14	0.44	6.42	0.33	4.71e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.43e-14	Retinal vascular caliber;
LUSC	cis	rs4478858	0.662	rs6425735	chr1:31783945	T/C	cg00250761	chr1:31883323	NA	-0.36	-8.69	-0.43	1.61e-16	Alcohol dependence;
LUSC	cis	rs9311676	0.656	rs68021431	chr3:58403136	A/G	cg26110898	chr3:58419937	PDHB	0.39	6.34	0.33	7.61e-10	Systemic lupus erythematosus;
LUSC	cis	rs2346177	0.844	rs13010062	chr2:46644137	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.36	6.23	0.32	1.38e-9	HDL cholesterol;
LUSC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.15	0.41	7.24e-15	Bipolar disorder;
LUSC	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg26384229	chr12:38710491	ALG10B	0.7	11.03	0.52	2.5e-24	Morning vs. evening chronotype;
LUSC	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.61	-10.38	-0.49	4.57e-22	Schizophrenia;
LUSC	cis	rs6681460	0.932	rs618093	chr1:67178428	T/G	cg02459107	chr1:67143332	SGIP1	0.47	8.82	0.43	6.64e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs877282	0.755	rs11253399	chr10:790030	T/A	cg17470449	chr10:769945	NA	0.42	6.32	0.33	8.54e-10	Uric acid levels;
LUSC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.55	-0.42	4.48e-16	Personality dimensions;
LUSC	cis	rs34526934	0.565	rs34729309	chr2:177034121	G/T	cg26754761	chr2:177040938	NA	-0.4	-7.72	-0.39	1.39e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs12681287	0.640	rs4587306	chr8:87385511	T/C	cg27223183	chr8:87520930	FAM82B	0.55	7.36	0.37	1.43e-12	Caudate activity during reward;
LUSC	trans	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg25214090	chr10:38739885	LOC399744	0.42	6.4	0.33	5.2e-10	Corneal astigmatism;
LUSC	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.68	-9.93	-0.48	1.59e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.63	10.52	0.5	1.55e-22	Bone mineral density;
LUSC	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg23985595	chr17:80112537	CCDC57	-0.31	-6.13	-0.32	2.41e-9	Life satisfaction;
LUSC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08219700	chr8:58056026	NA	0.69	8.2	0.41	5.2e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg17507749	chr15:85114479	UBE2QP1	0.65	8.15	0.41	7.64e-15	Schizophrenia;
LUSC	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg17757837	chr7:157058334	UBE3C	0.82	13.01	0.58	1.35e-31	Body mass index;
LUSC	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg12560992	chr17:57184187	TRIM37	-0.78	-12.49	-0.56	1.2e-29	Intelligence (multi-trait analysis);
LUSC	trans	rs11700980	0.551	rs2409326	chr21:30109102	A/G	cg14791747	chr16:20752902	THUMPD1	0.56	6.1	0.32	2.88e-9	QRS complex (12-leadsum);
LUSC	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.99	0.36	1.48e-11	Rheumatoid arthritis;
LUSC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg22437258	chr11:111473054	SIK2	0.53	7.49	0.38	6.36e-13	Primary sclerosing cholangitis;
LUSC	cis	rs8030485	0.728	rs4778886	chr15:79389019	T/C	cg17916960	chr15:79447300	NA	0.33	5.78	0.3	1.69e-8	Left ventricle wall thickness;
LUSC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg16325326	chr1:53192061	ZYG11B	-0.88	-16.25	-0.66	3.69e-44	Monocyte count;
LUSC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	0.92	15.4	0.64	8.61e-41	Menopause (age at onset);
LUSC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg21951975	chr1:209979733	IRF6	-0.54	-8.17	-0.41	6.53e-15	Cleft lip with or without cleft palate;
LUSC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg11764359	chr7:65958608	NA	0.49	6.34	0.33	7.3e-10	Aortic root size;
LUSC	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	trans	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg04995722	chr7:26192034	NFE2L3	-0.36	-5.94	-0.31	7.01e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg18806716	chr10:30721971	MAP3K8	-0.6	-9.06	-0.44	1.09e-17	Inflammatory bowel disease;
LUSC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg10360139	chr7:1886902	MAD1L1	0.38	5.68	0.3	2.88e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg14092571	chr14:90743983	NA	-0.35	-5.71	-0.3	2.45e-8	Mortality in heart failure;
LUSC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.93	15.89	0.66	9.63e-43	Bladder cancer;
LUSC	cis	rs728616	0.558	rs2343302	chr10:82163186	A/G	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.8	-0.3	1.57e-8	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg06238570	chr21:40685208	BRWD1	-0.62	-10.32	-0.49	7.31e-22	Cognitive function;
LUSC	cis	rs500891	0.525	rs9766300	chr6:84083733	T/A	cg08257003	chr6:84140564	ME1	0.35	8.5	0.42	6.18e-16	Platelet-derived growth factor BB levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07590839	chr2:233415449	TIGD1;EIF4E2	0.71	6.01	0.31	4.94e-9	Cognitive performance;
LUSC	cis	rs2742417	0.904	rs2373047	chr3:45747497	C/A	cg09608765	chr3:45636137	LIMD1	-0.38	-7.51	-0.38	5.48e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs394563	0.601	rs376269	chr6:149795154	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.34	-6.93	-0.35	2.23e-11	Dupuytren's disease;
LUSC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg13397359	chr6:42928475	GNMT	0.57	9.41	0.46	8.34e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs75920871	0.528	rs7128772	chr11:116889411	T/A	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.42	-0.33	4.57e-10	Subjective well-being;
LUSC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg04287289	chr16:89883240	FANCA	-0.56	-8.68	-0.43	1.83e-16	Vitiligo;
LUSC	cis	rs67072384	1.000	rs67072384	chr11:72450724	C/T	cg04827223	chr11:72435913	ARAP1	-0.78	-6.71	-0.34	8.4e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg03676636	chr4:99064102	C4orf37	0.36	7.71	0.39	1.45e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08645402	chr16:4508243	NA	0.52	8.77	0.43	9.43e-17	Schizophrenia;
LUSC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg01579765	chr21:45077557	HSF2BP	0.51	10.88	0.51	8.5e-24	Mean corpuscular volume;
LUSC	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg23093090	chr10:104574429	C10orf26	-0.46	-5.74	-0.3	2.12e-8	Arsenic metabolism;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24815885	chr19:36486437	SDHAF1	-0.42	-6.05	-0.31	3.94e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg11062466	chr8:58055876	NA	0.49	6.4	0.33	5.2e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.58	0.34	1.77e-10	Corneal astigmatism;
LUSC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08677398	chr8:58056175	NA	0.52	6.62	0.34	1.46e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6599077	0.951	rs9860463	chr3:40094062	A/C	cg13683864	chr3:40499215	RPL14	-0.55	-6.8	-0.35	4.77e-11	Sleep-related phenotypes;
LUSC	trans	rs10097669	0.704	rs2725072	chr8:4439760	A/G	cg16451306	chr5:71475356	MAP1B	0.29	6.03	0.31	4.43e-9	Trans fatty acid levels;
LUSC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.42	0.33	4.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs757278	0.552	rs1594189	chr7:117311713	T/G	cg10524701	chr7:117356490	CTTNBP2	0.4	5.75	0.3	1.99e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	trans	rs12210905	0.843	rs12208039	chr6:26984004	C/A	cg11837749	chr1:55047332	ACOT11	0.57	6.09	0.32	3.07e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.51	1.26e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg02951883	chr7:2050386	MAD1L1	-0.45	-8.04	-0.4	1.6e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg26441486	chr22:50317300	CRELD2	0.52	7.98	0.4	2.42e-14	Schizophrenia;
LUSC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg10117171	chr1:25599238	RHD	-0.38	-5.86	-0.31	1.12e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs6939532	0.522	rs9358933	chr6:26363688	C/T	cg09904177	chr6:26538194	HMGN4	-0.46	-6.68	-0.34	9.75e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.77	12.05	0.55	5.23e-28	Dilated cardiomyopathy;
LUSC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.46	0.38	7.64e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg11693508	chr17:37793320	STARD3	-0.61	-7.55	-0.38	4.15e-13	Bipolar disorder;
LUSC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.64	0.6	5.79e-34	Cognitive test performance;
LUSC	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg12863693	chr15:85201151	NMB	0.41	8.48	0.42	7.34e-16	Schizophrenia;
LUSC	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg18478394	chr8:109455254	TTC35	0.42	6.57	0.34	1.93e-10	Dupuytren's disease;
LUSC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	0.86	14.57	0.62	1.42e-37	Tonsillectomy;
LUSC	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg23625390	chr15:77176239	SCAPER	-0.66	-10.02	-0.48	7.85e-21	Blood metabolite levels;
LUSC	cis	rs17021463	0.966	rs1565062	chr4:95183000	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.4	-0.42	1.3e-15	Testicular germ cell tumor;
LUSC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.79	-0.43	8.19e-17	Bipolar disorder;
LUSC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg16606324	chr3:10149918	C3orf24	0.44	6.78	0.35	5.34e-11	Alzheimer's disease;
LUSC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.63	0.39	2.5e-13	Bipolar disorder;
LUSC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg23711669	chr6:146136114	FBXO30	-0.91	-17.02	-0.68	3.26e-47	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18655958	chr19:48867355	TMEM143;SYNGR4	-0.44	-6.31	-0.33	8.63e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg07856975	chr6:36356162	ETV7	0.33	5.92	0.31	8e-9	Platelet distribution width;
LUSC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12311346	chr5:56204834	C5orf35	-0.67	-9.93	-0.48	1.59e-20	Coronary artery disease;
LUSC	cis	rs847577	0.508	rs12538837	chr7:97684468	C/T	cg21770322	chr7:97807741	LMTK2	0.39	5.88	0.31	9.94e-9	Breast cancer;
LUSC	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.47	-6.68	-0.34	9.95e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24793903	chr17:45918221	SCRN2	-0.45	-6.12	-0.32	2.65e-9	Hepatitis;
LUSC	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg16386425	chr10:429943	DIP2C	-0.39	-5.72	-0.3	2.31e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs1375194	0.558	rs13418410	chr2:33800899	C/A	cg04131969	chr2:33951647	MYADML	-0.62	-8.67	-0.43	1.92e-16	Response to antidepressants in depression;
LUSC	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-6.32	-0.33	8.47e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs17533156	0.525	rs77932036	chr17:75207586	T/G	cg11416367	chr17:75137675	SEC14L1	0.55	6.66	0.34	1.1e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.22	0.37	3.54e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg05855489	chr10:104503620	C10orf26	-0.68	-9.98	-0.48	1.09e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg11843238	chr5:131593191	PDLIM4	0.39	6.5	0.34	2.91e-10	Breast cancer;
LUSC	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-6.02	-0.31	4.69e-9	Retinal vascular caliber;
LUSC	trans	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.51	-0.34	2.81e-10	Life satisfaction;
LUSC	cis	rs11677416	1.000	rs1516789	chr2:113531024	C/T	cg27083787	chr2:113543245	IL1A	0.48	7.54	0.38	4.51e-13	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg16362232	chr11:430036	ANO9	0.55	7.31	0.37	1.95e-12	Body mass index;
LUSC	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg23093090	chr10:104574429	C10orf26	-0.46	-8.36	-0.42	1.67e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg06600287	chr1:53387719	ECHDC2	-0.3	-6.12	-0.32	2.64e-9	Monocyte count;
LUSC	trans	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg13010199	chr12:38710504	ALG10B	0.51	7.14	0.36	5.95e-12	Resting heart rate;
LUSC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00339695	chr16:24857497	SLC5A11	0.41	7.08	0.36	8.58e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg07636037	chr3:49044803	WDR6	-0.48	-6.39	-0.33	5.58e-10	Prion diseases;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06000050	chr6:119256092	MCM9	-0.49	-6.2	-0.32	1.65e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16780939	chr12:56753945	STAT2	0.4	6.09	0.32	3.12e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg12310025	chr6:25882481	NA	-0.35	-5.79	-0.3	1.63e-8	Height;
LUSC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11644478	chr21:40555479	PSMG1	0.75	9.33	0.45	1.57e-18	Cognitive function;
LUSC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-5.88	-0.31	9.98e-9	Blood pressure (smoking interaction);
LUSC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg12963246	chr6:28129442	ZNF389	0.58	8.07	0.4	1.24e-14	Parkinson's disease;
LUSC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg02807482	chr3:125708958	NA	-0.52	-6.55	-0.34	2.23e-10	Blood pressure (smoking interaction);
LUSC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.58	-7.41	-0.38	1.07e-12	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg22709100	chr7:91322751	NA	-0.39	-5.66	-0.3	3.24e-8	Breast cancer;
LUSC	cis	rs6539267	0.923	rs4964175	chr12:106753984	A/G	cg00173435	chr12:106696525	TCP11L2	-0.44	-6.21	-0.32	1.56e-9	Tourette syndrome;
LUSC	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg09650180	chr20:62225654	GMEB2	-0.66	-9.52	-0.46	3.73e-19	Glioblastoma;
LUSC	cis	rs1018836	0.527	rs13268721	chr8:91481549	G/A	cg16814680	chr8:91681699	NA	-0.68	-10.33	-0.49	6.66e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs11696501	0.688	rs6065859	chr20:44302697	C/T	cg03272292	chr12:48577362	C12orf68	0.5	6.1	0.32	2.93e-9	Brain structure;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02894226	chr20:3190561	ITPA	0.46	6.8	0.35	4.82e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg27539214	chr16:67997921	SLC12A4	-0.46	-5.95	-0.31	6.69e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg11812906	chr14:75593930	NEK9	0.64	10.58	0.5	9.58e-23	Height;
LUSC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg07703079	chr11:430292	ANO9	-0.64	-7.0	-0.36	1.42e-11	Body mass index;
LUSC	cis	rs9311676	0.656	rs11714807	chr3:58405431	A/G	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.3e-10	Systemic lupus erythematosus;
LUSC	cis	rs10740039	0.883	rs10443929	chr10:62405610	C/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.86	-0.35	3.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg16606324	chr3:10149918	C3orf24	0.59	8.55	0.42	4.49e-16	Alzheimer's disease;
LUSC	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.92	-0.35	2.32e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	1.21	16.6	0.67	1.46e-45	Eosinophil percentage of granulocytes;
LUSC	trans	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.34e-10	Corneal astigmatism;
LUSC	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg20129853	chr10:51489980	NA	0.35	7.27	0.37	2.63e-12	Prostate-specific antigen levels;
LUSC	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg06636001	chr8:8085503	FLJ10661	0.4	5.77	0.3	1.85e-8	Platelet distribution width;
LUSC	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg25237894	chr2:233734115	C2orf82	-0.36	-6.63	-0.34	1.38e-10	Coronary artery disease;
LUSC	cis	rs12900413	0.673	rs35308090	chr15:90308026	G/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.92	-0.31	7.96e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs3087591	0.708	rs10438801	chr17:29693785	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.0	0.36	1.43e-11	Hip circumference;
LUSC	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg01579765	chr21:45077557	HSF2BP	-0.57	-12.34	-0.56	4.57e-29	Mean corpuscular volume;
LUSC	cis	rs7246967	0.673	rs34003335	chr19:22925602	T/C	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.04e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-6.58	-0.34	1.79e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs16937	0.711	rs10900465	chr1:205158183	C/T	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.36e-10	Schizophrenia;
LUSC	cis	rs9815354	0.812	rs766286	chr3:41838329	G/A	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1395	1.000	rs1275538	chr2:27441397	C/T	cg23587288	chr2:27483067	SLC30A3	-0.27	-5.75	-0.3	2.06e-8	Blood metabolite levels;
LUSC	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.43	0.59	3.62e-33	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs5758511	0.817	rs133291	chr22:42269628	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.47	8.17	0.41	6.51e-15	Birth weight;
LUSC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg03146154	chr1:46216737	IPP	0.5	7.51	0.38	5.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg17173187	chr15:85201210	NMB	0.36	5.96	0.31	6.46e-9	Schizophrenia;
LUSC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg24060327	chr5:131705240	SLC22A5	-0.67	-11.41	-0.53	1.13e-25	Breast cancer;
LUSC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg03474202	chr17:45855739	NA	-0.29	-6.62	-0.34	1.44e-10	IgG glycosylation;
LUSC	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg05868516	chr6:26286170	HIST1H4H	0.36	5.76	0.3	1.89e-8	Educational attainment;
LUSC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03517284	chr6:25882590	NA	0.39	6.63	0.34	1.37e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg27170947	chr2:26402098	FAM59B	-0.64	-9.35	-0.46	1.31e-18	Gut microbiome composition (summer);
LUSC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg16393715	chr7:1948819	MAD1L1	0.4	6.94	0.36	2.04e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg13683864	chr3:40499215	RPL14	-0.95	-16.55	-0.67	2.31e-45	Renal cell carcinoma;
LUSC	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg08213375	chr14:104286397	PPP1R13B	0.45	8.18	0.41	6.17e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg15704280	chr7:45808275	SEPT13	0.94	13.51	0.59	1.74e-33	Coronary artery disease;
LUSC	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg12850546	chr22:42539477	CYP2D7P1	-0.47	-5.83	-0.3	1.31e-8	Birth weight;
LUSC	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.72	-0.43	1.36e-16	Response to antipsychotic treatment;
LUSC	cis	rs240764	0.658	rs12664626	chr6:101195720	A/G	cg09795085	chr6:101329169	ASCC3	-0.43	-6.27	-0.32	1.11e-9	Neuroticism;
LUSC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.8	0.39	8.08e-14	Major depressive disorder;
LUSC	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.09	15.55	0.65	2.2e-41	Uric acid levels;
LUSC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg12560992	chr17:57184187	TRIM37	-0.69	-12.34	-0.56	4.35e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs12220238	0.915	rs1908334	chr10:75991721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.07	0.36	9.33e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg03146154	chr1:46216737	IPP	0.51	7.68	0.39	1.8e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg05110241	chr16:68378359	PRMT7	-0.56	-6.58	-0.34	1.84e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14607904	chr6:170862125	PSMB1;TBP	0.5	7.61	0.38	2.89e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.64	-0.43	2.38e-16	Total cholesterol levels;
LUSC	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg14500267	chr11:67383377	NA	0.33	6.33	0.33	7.89e-10	Mean corpuscular volume;
LUSC	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.71	10.38	0.49	4.61e-22	Blood protein levels;
LUSC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg17279839	chr7:150038598	RARRES2	0.54	8.09	0.4	1.08e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2455601	0.529	rs2653569	chr11:8986978	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-7.16	-0.36	5.29e-12	Schizophrenia;
LUSC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00152838	chr16:24741724	TNRC6A	-0.48	-5.97	-0.31	6.05e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs9653442	0.900	rs1160544	chr2:100832218	A/C	cg07810366	chr2:100720526	AFF3	-0.48	-8.19	-0.41	5.68e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6906287	0.647	rs13192574	chr6:118875258	C/T	cg21191810	chr6:118973309	C6orf204	0.33	6.04	0.31	4.16e-9	Electrocardiographic conduction measures;
LUSC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg09835421	chr16:68378352	PRMT7	-0.5	-5.72	-0.3	2.39e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs62432291	0.681	rs378339	chr6:159658852	C/T	cg14500486	chr6:159655392	FNDC1	-0.54	-6.06	-0.31	3.76e-9	Joint mobility (Beighton score);
LUSC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.47	6.82	0.35	4.18e-11	Schizophrenia;
LUSC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.83	0.39	6.38e-14	Parkinson's disease;
LUSC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg08859206	chr1:53392774	SCP2	0.37	6.15	0.32	2.2e-9	Monocyte count;
LUSC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg25767906	chr1:53392781	SCP2	-0.47	-8.01	-0.4	1.94e-14	Monocyte count;
LUSC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.2	0.41	5.24e-15	Homoarginine levels;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.62	10.27	0.49	1.07e-21	Lymphocyte counts;
LUSC	cis	rs1595825	0.891	rs7573687	chr2:198893376	A/G	cg00982548	chr2:198649783	BOLL	-0.54	-6.93	-0.35	2.2e-11	Ulcerative colitis;
LUSC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.16	0.36	5.2e-12	Mean platelet volume;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg16357287	chr18:12947517	SEH1L	0.39	6.04	0.31	4.09e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs1790761	0.967	rs7479801	chr11:67213748	G/T	cg24690094	chr11:67383802	NA	-0.33	-6.05	-0.31	3.86e-9	Mean corpuscular volume;
LUSC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg11608241	chr8:8085544	FLJ10661	0.53	7.79	0.39	8.29e-14	Neuroticism;
LUSC	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.61	13.83	0.6	1.01e-34	Height;
LUSC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.49	-0.53	5.85e-26	Schizophrenia;
LUSC	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg21775007	chr8:11205619	TDH	0.43	6.04	0.31	4.1e-9	Neuroticism;
LUSC	cis	rs9517320	0.935	rs9645891	chr13:99126800	A/G	cg20487152	chr13:99095054	FARP1	0.35	6.45	0.33	3.86e-10	Longevity;
LUSC	cis	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg17187183	chr4:55093834	PDGFRA	0.39	5.78	0.3	1.72e-8	Corneal astigmatism;
LUSC	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg23260525	chr10:116636907	FAM160B1	0.42	8.54	0.42	4.79e-16	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4919087	0.810	rs1572437	chr10:99029278	A/G	cg25902810	chr10:99078978	FRAT1	0.5	7.01	0.36	1.32e-11	Monocyte count;
LUSC	trans	rs10851478	0.872	rs925104	chr15:49916655	T/G	cg23074453	chr15:44487924	FRMD5	-0.33	-6.08	-0.32	3.26e-9	Oral cavity cancer;
LUSC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.19	0.52	6.87e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg01802117	chr1:53393560	SCP2	0.36	5.95	0.31	6.65e-9	Monocyte count;
LUSC	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.44	6.55	0.34	2.14e-10	Schizophrenia;
LUSC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg18681998	chr4:17616180	MED28	0.9	17.84	0.7	1.85e-50	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg04369109	chr6:150039330	LATS1	-0.58	-8.5	-0.42	6.24e-16	Lung cancer;
LUSC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.08e-17	Prudent dietary pattern;
LUSC	cis	rs10761482	0.861	rs10821730	chr10:62099271	A/T	cg18175470	chr10:62150864	ANK3	0.47	6.76	0.35	6.34e-11	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.47	-7.23	-0.37	3.34e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.38	-0.37	1.28e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg24733560	chr20:60626293	TAF4	0.39	6.42	0.33	4.73e-10	Body mass index;
LUSC	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg21775007	chr8:11205619	TDH	-0.57	-9.0	-0.44	1.69e-17	Retinal vascular caliber;
LUSC	cis	rs1712517	0.873	rs7894240	chr10:105000369	T/C	cg05636881	chr10:105038444	INA	-0.37	-6.17	-0.32	2.01e-9	Migraine;
LUSC	cis	rs2798269	1.000	rs7990030	chr13:22123819	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.1	-0.32	2.93e-9	PR segment;
LUSC	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	8.65	0.43	2.19e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg25214090	chr10:38739885	LOC399744	0.53	7.69	0.39	1.71e-13	Corneal astigmatism;
LUSC	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg06532163	chr17:45867833	NA	0.34	6.22	0.32	1.5e-9	IgG glycosylation;
LUSC	cis	rs7524258	0.900	rs6689574	chr1:7288534	C/G	cg07173049	chr1:7289937	CAMTA1	0.36	7.34	0.37	1.67e-12	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs10875746	0.807	rs12297004	chr12:48453820	A/G	cg13454099	chr12:49076203	C12orf41	-0.5	-5.69	-0.3	2.77e-8	Longevity (90 years and older);
LUSC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18876405	chr7:65276391	NA	0.55	8.81	0.43	6.74e-17	Aortic root size;
LUSC	cis	rs56161922	1.000	rs41274776	chr1:207812791	A/G	cg11752769	chr1:207818423	CR1L	-0.69	-5.72	-0.3	2.31e-8	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs2522056	1.000	rs886286	chr5:131795597	A/G	cg24060327	chr5:131705240	SLC22A5	0.45	5.96	0.31	6.39e-9	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg12257692	chr3:49977190	RBM6	-0.25	-7.08	-0.36	8.82e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7719624	0.869	rs6893691	chr5:135395433	A/G	cg12897067	chr5:135418308	NA	0.42	6.05	0.31	3.91e-9	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.07	16.07	0.66	1.81e-43	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.16	0.64	7.32e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs7804356	1.000	rs73067475	chr7:26857120	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-6.14	-0.32	2.4e-9	Type 1 diabetes;
LUSC	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.61	0.38	2.9e-13	Iron status biomarkers;
LUSC	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg13010199	chr12:38710504	ALG10B	0.48	7.24	0.37	3.1e-12	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9905704	0.918	rs304272	chr17:56803028	C/A	cg12560992	chr17:57184187	TRIM37	0.56	8.01	0.4	1.92e-14	Testicular germ cell tumor;
LUSC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg08200582	chr11:442649	ANO9	-0.52	-6.1	-0.32	3.02e-9	Body mass index;
LUSC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	10.09	0.48	4.6e-21	Bipolar disorder;
LUSC	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	0.59	10.09	0.48	4.65e-21	Gut microbiome composition (winter);
LUSC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg25204440	chr1:209979598	IRF6	0.49	6.51	0.34	2.81e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg25258033	chr6:167368657	RNASET2	0.38	5.82	0.3	1.38e-8	Primary biliary cholangitis;
LUSC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg23262073	chr20:60523788	NA	-0.63	-9.15	-0.45	5.81e-18	Obesity-related traits;
LUSC	cis	rs713477	0.654	rs6573030	chr14:55913720	T/G	cg13175173	chr14:55914753	NA	-0.29	-5.98	-0.31	5.71e-9	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs17076896	0.881	rs36213078	chr13:19757540	G/C	cg01891818	chr17:73008509	ICT1	0.5	6.17	0.32	1.97e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs8032315	0.965	rs4932373	chr15:91429287	A/C	cg06330618	chr15:91428456	FES	0.28	5.73	0.3	2.25e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg00745463	chr17:30367425	LRRC37B	-0.79	-7.7	-0.39	1.54e-13	Height;
LUSC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	7.55	0.38	4.18e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09665592	chr9:130699885	DPM2	-0.47	-6.14	-0.32	2.36e-9	Hepatitis;
LUSC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg02423579	chr7:2872169	GNA12	-0.49	-6.97	-0.36	1.72e-11	Height;
LUSC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18404041	chr3:52824283	ITIH1	-0.48	-9.13	-0.45	6.49e-18	Electroencephalogram traits;
LUSC	cis	rs6546550	0.935	rs2168115	chr2:70034793	A/G	cg02498382	chr2:70120550	SNRNP27	-0.28	-6.76	-0.35	6.09e-11	Prevalent atrial fibrillation;
LUSC	cis	rs11971779	0.680	rs6954531	chr7:139054706	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg21643547	chr1:205240462	TMCC2	-0.42	-7.65	-0.39	2.15e-13	Red blood cell count;
LUSC	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg04851639	chr8:1020857	NA	-0.39	-8.21	-0.41	4.82e-15	Schizophrenia;
LUSC	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.74	-0.47	6.99e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.3	-0.37	2.19e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg03146154	chr1:46216737	IPP	-0.53	-7.86	-0.39	5.5e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg01097406	chr16:89675127	NA	0.33	6.36	0.33	6.79e-10	Vitiligo;
LUSC	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg13206674	chr6:150067644	NUP43	0.46	6.84	0.35	3.73e-11	Testicular germ cell tumor;
LUSC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg26380479	chr7:97908229	NA	-0.27	-6.14	-0.32	2.37e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.63	10.07	0.48	5.38e-21	Morning vs. evening chronotype;
LUSC	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg06026331	chr20:60912101	LAMA5	-0.52	-6.24	-0.32	1.29e-9	Colorectal cancer;
LUSC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.75	-10.68	-0.5	4.33e-23	Gut microbiome composition (summer);
LUSC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.71	-10.56	-0.5	1.12e-22	Glomerular filtration rate;
LUSC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.97	-13.89	-0.61	5.98e-35	Primary sclerosing cholangitis;
LUSC	trans	rs11700980	0.551	rs2832015	chr21:30111192	G/T	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.31e-9	QRS complex (12-leadsum);
LUSC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg07716408	chr11:68623521	NA	-0.31	-5.94	-0.31	7.27e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.34	6.16	0.32	2.13e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1003719	0.715	rs2835675	chr21:38582815	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-9.98	-0.48	1.08e-20	Eye color traits;
LUSC	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.92	15.65	0.65	8.39e-42	Bladder cancer;
LUSC	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs10465746	0.725	rs10127737	chr1:84368642	G/A	cg10977910	chr1:84465055	TTLL7	0.51	7.34	0.37	1.69e-12	Obesity-related traits;
LUSC	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg14458575	chr2:238380390	NA	0.68	11.58	0.54	2.63e-26	Prostate cancer;
LUSC	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.84	-15.73	-0.65	4.2e-42	Heart rate;
LUSC	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg15556689	chr8:8085844	FLJ10661	0.58	8.71	0.43	1.44e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.81	13.62	0.6	6.38e-34	Aortic root size;
LUSC	trans	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg01620082	chr3:125678407	NA	-0.57	-6.28	-0.32	1.05e-9	Depression;
LUSC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.62	8.37	0.42	1.6e-15	High light scatter reticulocyte count;
LUSC	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg02750262	chr18:72916776	ZADH2	0.64	7.46	0.38	7.33e-13	Vascular endothelial growth factor levels;
LUSC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08280861	chr8:58055591	NA	0.56	6.05	0.31	3.96e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg14440974	chr22:39074834	NA	-0.4	-6.56	-0.34	2.09e-10	Menopause (age at onset);
LUSC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg00031303	chr3:195681400	NA	-0.45	-7.04	-0.36	1.13e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg06454157	chr6:167490870	NA	-0.27	-6.64	-0.34	1.28e-10	Crohn's disease;
LUSC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg24829409	chr8:58192753	C8orf71	-0.55	-6.21	-0.32	1.55e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-5.97	-0.31	5.95e-9	Morning vs. evening chronotype;
LUSC	cis	rs1577917	0.958	rs7382798	chr6:86559834	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg20203395	chr5:56204925	C5orf35	-0.87	-11.74	-0.54	7.07e-27	Initial pursuit acceleration;
LUSC	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.81	0.51	1.45e-23	Fuchs's corneal dystrophy;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg07797438	chr19:37019581	ZNF260	0.43	6.49	0.33	3.04e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs80130819	0.688	rs2732476	chr12:48700691	T/C	cg24011408	chr12:48396354	COL2A1	0.46	6.11	0.32	2.72e-9	Prostate cancer;
LUSC	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg18721089	chr20:30220636	NA	-0.35	-5.98	-0.31	5.83e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg13685833	chr1:53393034	SCP2	0.41	6.33	0.33	7.98e-10	Monocyte count;
LUSC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg23161317	chr6:28129485	ZNF389	0.44	5.67	0.3	3.05e-8	Parkinson's disease;
LUSC	cis	rs3741151	0.892	rs2027761	chr11:73036179	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	8.9	0.44	3.51e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg17168535	chr8:21777572	XPO7	-0.82	-15.98	-0.66	4.34e-43	Mean corpuscular volume;
LUSC	cis	rs2230307	0.536	rs11166385	chr1:100443462	A/G	cg24955406	chr1:100503596	HIAT1	0.56	6.04	0.31	4.01e-9	Carotid intima media thickness;
LUSC	cis	rs6076065	0.723	rs6132607	chr20:23390373	C/G	cg11657817	chr20:23433608	CST11	-0.42	-7.76	-0.39	1.04e-13	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.45e-10	Ulcerative colitis;
LUSC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08704250	chr15:31115839	NA	-0.57	-8.75	-0.43	1.08e-16	Huntington's disease progression;
LUSC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	15.66	0.65	8.05e-42	Platelet count;
LUSC	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg01849466	chr14:104193079	ZFYVE21	0.56	8.47	0.42	7.82e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg09796270	chr17:17721594	SREBF1	0.39	7.06	0.36	9.9e-12	Total body bone mineral density;
LUSC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-1.05	-15.1	-0.64	1.27e-39	Initial pursuit acceleration;
LUSC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-7.29	-0.37	2.19e-12	Aortic root size;
LUSC	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg12559939	chr2:27858050	GPN1	-0.4	-6.18	-0.32	1.82e-9	Oral cavity cancer;
LUSC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg14552801	chr7:65878734	NA	0.38	5.8	0.3	1.51e-8	Aortic root size;
LUSC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.83	-0.39	6.56e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.37	-6.23	-0.32	1.37e-9	Breast cancer;
LUSC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg04414720	chr1:150670196	GOLPH3L	0.57	9.22	0.45	3.31e-18	Tonsillectomy;
LUSC	trans	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg13565492	chr6:43139072	SRF	-0.61	-6.48	-0.33	3.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10992471	0.580	rs10992304	chr9:95085365	G/A	cg14631576	chr9:95140430	CENPP	-0.38	-6.44	-0.33	4.19e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg18110333	chr6:292329	DUSP22	-0.53	-8.02	-0.4	1.83e-14	Menopause (age at onset);
LUSC	trans	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg26384229	chr12:38710491	ALG10B	-0.58	-8.7	-0.43	1.5e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg04166393	chr7:2884313	GNA12	0.46	6.11	0.32	2.74e-9	Height;
LUSC	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07636037	chr3:49044803	WDR6	-0.69	-9.2	-0.45	4.05e-18	Menarche (age at onset);
LUSC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.63	8.35	0.42	1.8e-15	High light scatter reticulocyte count;
LUSC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.3	-0.45	1.91e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs55910451	0.779	rs72774077	chr10:5768089	G/A	cg11519256	chr10:5708881	ASB13	-0.47	-5.7	-0.3	2.61e-8	Breast cancer;
LUSC	trans	rs1027479	0.813	rs3019344	chr8:109723707	T/C	cg14904725	chr13:113777045	F10	-0.26	-6.18	-0.32	1.84e-9	Facial morphology (factor 6, height of vermillion lower lip);
LUSC	cis	rs6469656	0.803	rs10112279	chr8:117716963	T/C	cg24004040	chr8:117650383	NA	-0.44	-6.3	-0.33	9.5e-10	Colorectal cancer;
LUSC	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg13010199	chr12:38710504	ALG10B	0.69	10.77	0.51	2.01e-23	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11264213	0.686	rs645383	chr1:36373823	C/G	cg27506609	chr1:36549197	TEKT2	-0.58	-8.32	-0.41	2.33e-15	Schizophrenia;
LUSC	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg05855489	chr10:104503620	C10orf26	0.56	8.52	0.42	5.53e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	cis	rs10504229	0.516	rs1866994	chr8:57990092	A/C	cg22535103	chr8:58192502	C8orf71	-0.48	-6.41	-0.33	4.99e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs16976116	0.901	rs8028525	chr15:55492317	T/C	cg11288833	chr15:55489084	RSL24D1	0.5	5.88	0.31	1.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4280164	0.551	rs12436194	chr14:24804859	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.61	-7.51	-0.38	5.37e-13	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06022373	chr22:39101656	GTPBP1	0.64	10.11	0.48	3.84e-21	Menopause (age at onset);
LUSC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.8	8.21	0.41	5.03e-15	Initial pursuit acceleration;
LUSC	cis	rs9815354	0.812	rs56183581	chr3:41848492	C/T	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs752010	0.543	rs1570355	chr1:42042317	C/T	cg06885757	chr1:42089581	HIVEP3	0.34	6.87	0.35	3.1e-11	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.58	-0.43	3.5e-16	Total cholesterol levels;
LUSC	trans	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg02800362	chr5:177631904	HNRNPAB	0.88	13.11	0.58	5.56e-32	Obesity-related traits;
LUSC	cis	rs501916	0.634	rs1561482	chr15:48069663	G/A	cg16110827	chr15:48056943	SEMA6D	-0.38	-6.01	-0.31	4.9e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg24558204	chr6:135376177	HBS1L	0.59	9.13	0.45	6.87e-18	Red blood cell count;
LUSC	cis	rs4903214	0.895	rs10130040	chr14:74713682	A/C	cg08255017	chr14:74727001	VSX2	-0.52	-7.3	-0.37	2.17e-12	Inflammatory bowel disease;
LUSC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	19.44	0.73	7.71e-57	Body mass index (adult);
LUSC	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg20243544	chr17:37824526	PNMT	-0.4	-6.07	-0.32	3.43e-9	Self-reported allergy;
LUSC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18876405	chr7:65276391	NA	-0.55	-8.58	-0.43	3.53e-16	Aortic root size;
LUSC	cis	rs73416724	0.920	rs76088627	chr6:43311851	G/A	cg26312998	chr6:43337775	ZNF318	0.57	6.69	0.34	9.53e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg04398451	chr17:18023971	MYO15A	-0.5	-8.0	-0.4	2.12e-14	Total body bone mineral density;
LUSC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.39	-0.42	1.38e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.66	-11.9	-0.55	1.77e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs501916	0.761	rs589889	chr15:48019016	C/G	cg16110827	chr15:48056943	SEMA6D	-0.41	-6.51	-0.34	2.69e-10	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs10144321	0.729	rs2273802	chr14:100842899	G/A	cg14882082	chr14:100845427	WDR25	-0.4	-7.5	-0.38	5.97e-13	Menarche (age at onset);
LUSC	cis	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg06521331	chr12:34319734	NA	-0.41	-6.73	-0.35	7.4e-11	Morning vs. evening chronotype;
LUSC	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg25173405	chr17:45401733	C17orf57	0.39	6.18	0.32	1.86e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.16	-0.45	5.53e-18	Schizophrenia;
LUSC	cis	rs9309473	0.687	rs10165862	chr2:73610743	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-7.95	-0.4	2.85e-14	Metabolite levels;
LUSC	cis	rs11997175	0.766	rs4442096	chr8:33691039	T/C	ch.8.33884649F	chr8:33765107	NA	0.4	6.15	0.32	2.22e-9	Body mass index;
LUSC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg16339924	chr4:17578868	LAP3	-0.54	-8.25	-0.41	3.78e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg03342759	chr3:160939853	NMD3	-0.5	-8.44	-0.42	9.97e-16	Morning vs. evening chronotype;
LUSC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg26566898	chr11:117069891	TAGLN	0.48	8.57	0.42	3.81e-16	Blood protein levels;
LUSC	cis	rs6722750	0.783	rs11125991	chr2:64387765	A/G	cg22352474	chr2:64371530	PELI1	0.63	9.98	0.48	1.07e-20	Neuroticism;
LUSC	cis	rs9462027	0.630	rs2744943	chr6:34643179	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.21	-0.32	1.53e-9	Systemic lupus erythematosus;
LUSC	cis	rs2303282	0.664	rs4924	chr16:56396486	C/T	cg00500540	chr16:56394104	NA	-0.39	-6.73	-0.35	7.2e-11	Breast cancer;
LUSC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg13206674	chr6:150067644	NUP43	0.59	9.22	0.45	3.31e-18	Lung cancer;
LUSC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg05347473	chr6:146136440	FBXO30	0.56	9.77	0.47	5.24e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg27572855	chr1:25598939	RHD	0.46	8.36	0.42	1.69e-15	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs55665837	1.000	rs10047457	chr11:14439459	T/A	cg05501817	chr11:14380813	RRAS2	-0.41	-6.61	-0.34	1.51e-10	Vitamin D levels;
LUSC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg08847533	chr14:75593920	NEK9	-0.79	-13.49	-0.59	2.12e-33	Height;
LUSC	cis	rs17401966	0.964	rs6674843	chr1:10458378	A/T	cg19773385	chr1:10388646	KIF1B	-0.51	-7.42	-0.38	9.95e-13	Hepatocellular carcinoma;
LUSC	cis	rs2235649	0.833	rs9929264	chr16:1851934	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.42	-6.02	-0.31	4.48e-9	Blood metabolite levels;
LUSC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg26876637	chr1:152193138	HRNR	0.43	6.11	0.32	2.84e-9	Atopic dermatitis;
LUSC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg11843238	chr5:131593191	PDLIM4	-0.39	-6.46	-0.33	3.8e-10	Breast cancer;
LUSC	trans	rs7294372	1.000	rs11834213	chr12:114591550	C/T	cg21542643	chr7:99425614	CYP3A43	-0.54	-6.11	-0.32	2.85e-9	Visceral fat;
LUSC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg08888203	chr3:10149979	C3orf24	0.63	8.32	0.41	2.32e-15	Alzheimer's disease;
LUSC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.79	-0.3	1.67e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.25	-0.41	3.75e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg26408565	chr15:76604113	ETFA	-0.38	-5.89	-0.31	9.21e-9	Blood metabolite levels;
LUSC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg17168535	chr8:21777572	XPO7	0.66	9.73	0.47	7.39e-20	Mean corpuscular volume;
LUSC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.66	11.13	0.52	1.11e-24	Bone mineral density;
LUSC	cis	rs1506636	0.962	rs10273985	chr7:123309538	A/T	cg03229431	chr7:123269106	ASB15	-0.65	-10.68	-0.5	4.12e-23	Plateletcrit;Platelet count;
LUSC	cis	rs12776158	0.792	rs12413268	chr10:71205504	G/A	cg12610070	chr10:71211762	TSPAN15	-0.46	-6.7	-0.34	9.11e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07080220	chr10:102295463	HIF1AN	0.68	9.42	0.46	7.59e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1178968	0.901	rs2353066	chr7:72755791	T/G	cg25889504	chr7:72793014	NA	0.59	7.96	0.4	2.69e-14	Triglyceride levels;
LUSC	cis	rs2282802	0.685	rs10051345	chr5:139670932	C/G	cg26211634	chr5:139558579	C5orf32	-0.39	-7.61	-0.38	2.86e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg12658694	chr1:38397304	INPP5B	-0.42	-5.81	-0.3	1.48e-8	Coronary artery disease;
LUSC	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.61e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg11789530	chr4:8429930	ACOX3	-0.41	-6.01	-0.31	4.89e-9	Response to antineoplastic agents;
LUSC	cis	rs9361491	0.508	rs9343786	chr6:79414728	A/C	cg05283184	chr6:79620031	NA	0.38	6.77	0.35	5.78e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg25801113	chr15:45476975	SHF	0.33	6.83	0.35	4.06e-11	Uric acid levels;
LUSC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.7	12.45	0.56	1.71e-29	Diastolic blood pressure;
LUSC	trans	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg14011486	chr1:26737247	LIN28	-0.84	-11.8	-0.54	4.43e-27	Atrial fibrillation;
LUSC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs7084921	0.552	rs11598495	chr10:101889417	T/C	cg02250046	chr10:101825185	CPN1	-0.33	-6.06	-0.31	3.58e-9	Bone mineral density;
LUSC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg00944433	chr1:107599041	PRMT6	-0.38	-7.22	-0.37	3.51e-12	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	0.93	17.85	0.7	1.62e-50	Cognitive function;
LUSC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg06238570	chr21:40685208	BRWD1	-0.52	-8.02	-0.4	1.82e-14	Cognitive function;
LUSC	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg20744362	chr22:50050164	C22orf34	0.39	7.42	0.38	9.81e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs75804782	0.521	rs72994973	chr2:239428315	C/T	cg18131467	chr2:239335373	ASB1	-0.67	-6.01	-0.31	4.73e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg15445000	chr17:37608096	MED1	-0.4	-6.79	-0.35	5.25e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03264133	chr6:25882463	NA	-0.44	-7.74	-0.39	1.16e-13	Blood metabolite levels;
LUSC	cis	rs11676348	0.904	rs10804264	chr2:218955809	T/C	cg00012203	chr2:219082015	ARPC2	-0.54	-8.33	-0.41	2.15e-15	Ulcerative colitis;
LUSC	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg15704280	chr7:45808275	SEPT13	0.73	8.39	0.42	1.38e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg13685833	chr1:53393034	SCP2	-0.39	-5.86	-0.31	1.11e-8	Monocyte count;
LUSC	cis	rs6693567	0.545	rs7553647	chr1:150472666	C/T	cg15654264	chr1:150340011	RPRD2	0.45	7.21	0.37	3.83e-12	Migraine;
LUSC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg12863693	chr15:85201151	NMB	0.37	7.44	0.38	8.69e-13	Schizophrenia;
LUSC	cis	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg07460842	chr6:66804631	NA	-0.46	-6.47	-0.33	3.5e-10	Blood trace element (Cu levels);
LUSC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg09455208	chr3:40491958	NA	0.57	9.87	0.48	2.42e-20	Renal cell carcinoma;
LUSC	cis	rs10740039	0.883	rs1442545	chr10:62410026	T/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.85	-0.35	3.61e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.88	14.29	0.62	1.69e-36	Coronary artery disease;
LUSC	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg14343924	chr8:8086146	FLJ10661	0.44	6.22	0.32	1.48e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs12995849	0.905	rs6712210	chr2:106449251	G/A	cg14210321	chr2:106509881	NCK2	-0.4	-5.96	-0.31	6.39e-9	Addiction;
LUSC	cis	rs478222	0.866	rs11684464	chr2:25340610	A/G	cg01884057	chr2:25150051	NA	-0.26	-5.73	-0.3	2.29e-8	Type 1 diabetes;
LUSC	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg01966878	chr4:90757139	SNCA	-0.43	-6.16	-0.32	2.05e-9	Neuroticism;
LUSC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg06453172	chr10:134556979	INPP5A	-0.47	-5.84	-0.3	1.26e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.91	15.42	0.64	7e-41	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	10.8	0.51	1.6e-23	Mean corpuscular volume;
LUSC	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.57	11.68	0.54	1.17e-26	Sense of smell;
LUSC	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg23231163	chr10:75533350	FUT11	-0.38	-6.29	-0.33	9.72e-10	Inflammatory bowel disease;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06875318	chr12:122064821	ORAI1	-0.45	-5.96	-0.31	6.35e-9	Hepatitis;
LUSC	cis	rs1256061	0.603	rs10148269	chr14:64736924	A/G	cg23250157	chr14:64679961	SYNE2	0.32	5.71	0.3	2.56e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs2219968	0.962	rs4380933	chr8:78944192	A/G	cg00738934	chr8:78996279	NA	0.38	6.81	0.35	4.41e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.01	0.52	2.98e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg22834771	chr12:69754056	YEATS4	-0.48	-7.33	-0.37	1.7e-12	Blood protein levels;
LUSC	cis	rs652260	0.967	rs667295	chr19:7901634	G/A	cg26014689	chr19:7917955	EVI5L	-0.48	-8.35	-0.42	1.83e-15	Menarche (age at onset);
LUSC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg25358565	chr5:93447407	FAM172A	-0.54	-7.78	-0.39	9.36e-14	Diabetic retinopathy;
LUSC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-0.85	-16.73	-0.68	4.42e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg07148914	chr20:33460835	GGT7	-0.46	-6.74	-0.35	7.17e-11	Height;
LUSC	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg00064840	chr7:4784485	FOXK1	0.3	5.72	0.3	2.38e-8	Mosquito bite size;
LUSC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg22800045	chr5:56110881	MAP3K1	0.78	9.7	0.47	9.52e-20	Initial pursuit acceleration;
LUSC	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.55	-7.17	-0.37	4.75e-12	Multiple sclerosis;
LUSC	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg23711669	chr6:146136114	FBXO30	0.8	13.96	0.61	3.3e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg09835421	chr16:68378352	PRMT7	-0.57	-6.19	-0.32	1.77e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7712401	0.580	rs439739	chr5:122318421	G/C	cg19077854	chr5:122220652	SNX24	-0.43	-9.53	-0.46	3.35e-19	Mean platelet volume;
LUSC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20135002	chr11:47629003	NA	-0.48	-7.64	-0.39	2.34e-13	Subjective well-being;
LUSC	trans	rs1015291	0.708	rs941232	chr12:19993733	G/C	cg01501474	chr7:55323552	NA	0.46	6.03	0.31	4.36e-9	Diastolic blood pressure;
LUSC	trans	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-8.03	-0.4	1.66e-14	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.56e-10	Menopause (age at onset);
LUSC	cis	rs10911363	0.570	rs2702204	chr1:183457396	A/G	cg09173681	chr1:183549694	NCF2	0.64	11.43	0.53	9.04e-26	Systemic lupus erythematosus;
LUSC	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg20283391	chr11:68216788	NA	-0.62	-8.62	-0.43	2.7e-16	Total body bone mineral density;
LUSC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-8.57	-0.42	3.93e-16	Bipolar disorder;
LUSC	cis	rs56161922	0.908	rs55689175	chr1:207859699	G/C	cg11752769	chr1:207818423	CR1L	-0.7	-5.91	-0.31	8.43e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs740160	0.558	rs73395508	chr7:98901894	A/C	cg24650262	chr7:98904301	NA	0.61	6.3	0.33	9.42e-10	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs9398803	0.687	rs4629706	chr6:126888331	A/T	cg19875578	chr6:126661172	C6orf173	0.39	5.72	0.3	2.36e-8	Male-pattern baldness;
LUSC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg10596483	chr8:143751796	JRK	0.6	9.21	0.45	3.65e-18	Schizophrenia;
LUSC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.36	-0.37	1.48e-12	Bipolar disorder;
LUSC	cis	rs9788721	0.836	rs7181486	chr15:78741618	C/T	cg18825076	chr15:78729989	IREB2	0.6	9.91	0.48	1.8e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg06238570	chr21:40685208	BRWD1	-0.53	-8.21	-0.41	4.79e-15	Menarche (age at onset);
LUSC	cis	rs259282	0.538	rs62124303	chr19:33113042	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.68	10.07	0.48	5.3e-21	Schizophrenia;
LUSC	trans	rs10090774	0.664	rs28605671	chr8:141655112	T/G	cg02991888	chr19:54260014	MIR1283-2;MIR516A1	0.29	5.95	0.31	6.77e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs11229555	0.645	rs11229462	chr11:58209931	A/T	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs2386661	0.547	rs72781996	chr10:5646485	C/G	cg11398623	chr21:37499189	NA	0.28	6.27	0.32	1.15e-9	Breast cancer;
LUSC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg04871131	chr7:94954202	PON1	-0.39	-6.11	-0.32	2.7e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg07395648	chr5:131743802	NA	0.4	5.83	0.3	1.32e-8	Breast cancer;
LUSC	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg05187965	chr10:45406764	TMEM72	-0.36	-8.47	-0.42	7.95e-16	Mean corpuscular volume;
LUSC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.54	-0.34	2.29e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.73	-11.4	-0.53	1.2e-25	Metabolic syndrome;
LUSC	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15369054	chr17:80825471	TBCD	-0.4	-6.52	-0.34	2.53e-10	Breast cancer;
LUSC	cis	rs62400317	0.826	rs12203466	chr6:45330263	T/A	cg18551225	chr6:44695536	NA	-0.44	-7.32	-0.37	1.92e-12	Total body bone mineral density;
LUSC	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg01475377	chr6:109611718	NA	-0.41	-7.36	-0.37	1.47e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	17.65	0.69	1e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1832871	0.672	rs11751553	chr6:158774750	C/T	cg07165851	chr6:158734300	TULP4	-0.48	-7.38	-0.37	1.31e-12	Height;
LUSC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg16405210	chr4:1374714	KIAA1530	0.55	8.28	0.41	2.95e-15	Obesity-related traits;
LUSC	cis	rs2063714	0.967	rs1012534	chr6:157209663	A/G	cg23222435	chr6:157204239	ARID1B	-0.56	-9.3	-0.45	1.87e-18	Sitting height ratio;
LUSC	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.8	-0.43	7.6e-17	Depression;
LUSC	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.85	-0.3	1.18e-8	Testicular germ cell tumor;
LUSC	cis	rs1614887	1	rs1614887	chr6:26393021	A/G	cg05738196	chr6:26577821	NA	0.54	7.95	0.4	2.87e-14	Intelligence (multi-trait analysis);Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg03465714	chr1:152285911	FLG	-0.4	-5.71	-0.3	2.53e-8	Atopic dermatitis;
LUSC	cis	rs7561273	0.586	rs11892283	chr2:24317850	T/C	cg06627628	chr2:24431161	ITSN2	-0.52	-6.84	-0.35	3.89e-11	Quantitative traits;
LUSC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg07507251	chr3:52567010	NT5DC2	0.32	6.25	0.32	1.28e-9	Bipolar disorder;
LUSC	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg06627628	chr2:24431161	ITSN2	0.53	7.41	0.38	1.07e-12	Asthma;
LUSC	trans	rs9944715	1.000	rs9952654	chr18:43849568	T/G	cg01718231	chr17:29326311	RNF135	-0.51	-7.16	-0.36	5.04e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-8.27	-0.41	3.23e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg07382826	chr16:28625726	SULT1A1	0.28	5.97	0.31	6.13e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs10791323	0.521	rs10894756	chr11:133745852	G/A	cg15485101	chr11:133734466	NA	0.35	6.3	0.33	9.3e-10	Childhood ear infection;
LUSC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg13385521	chr17:29058706	SUZ12P	-0.64	-6.49	-0.33	3.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26543917	chr17:1420092	INPP5K;LOC100306951	-0.41	-6.07	-0.32	3.51e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	0.98	18.87	0.72	1.43e-54	Bone mineral density;
LUSC	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.72e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2230307	0.536	rs7530361	chr1:100462860	T/C	cg24955406	chr1:100503596	HIAT1	0.56	6.08	0.32	3.31e-9	Carotid intima media thickness;
LUSC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14298792	chr15:30685198	CHRFAM7A	0.48	6.06	0.31	3.65e-9	Huntington's disease progression;
LUSC	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg01657329	chr11:68192670	LRP5	-0.39	-5.67	-0.3	3.17e-8	Total body bone mineral density;
LUSC	cis	rs4631830	0.828	rs10763567	chr10:51538169	C/A	cg10326726	chr10:51549505	MSMB	0.34	5.65	0.3	3.42e-8	Prostate-specific antigen levels;
LUSC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg12963246	chr6:28129442	ZNF389	0.55	7.63	0.39	2.55e-13	Depression;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18217145	chr1:40254695	BMP8B	0.74	5.98	0.31	5.84e-9	Cognitive performance;
LUSC	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg13852791	chr20:30311386	BCL2L1	0.94	14.61	0.62	1.01e-37	Mean corpuscular hemoglobin;
LUSC	trans	rs2587949	0.615	rs2629242	chr3:4225060	T/C	cg15139668	chr4:4577005	NA	-0.41	-6.07	-0.32	3.51e-9	Periodontitis (DPAL);
LUSC	trans	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg18187862	chr3:45730750	SACM1L	0.52	6.83	0.35	4e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg14835575	chr10:16859367	RSU1	0.65	9.16	0.45	5.54e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	trans	rs10432489	0.708	rs4436925	chr2:181755933	T/C	cg09897338	chr1:211849090	NEK2	-0.82	-6.07	-0.32	3.4e-9	QT interval;
LUSC	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg03676636	chr4:99064102	C4orf37	0.3	6.1	0.32	2.99e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9650315	0.866	rs13270548	chr8:57196239	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.56	-7.18	-0.37	4.46e-12	Height;
LUSC	cis	rs9905704	0.918	rs390524	chr17:56674173	A/G	cg12560992	chr17:57184187	TRIM37	0.55	7.7	0.39	1.56e-13	Testicular germ cell tumor;
LUSC	cis	rs9831754	0.704	rs7647185	chr3:78468807	T/C	cg06138941	chr3:78371609	NA	-0.52	-6.93	-0.35	2.21e-11	Calcium levels;
LUSC	cis	rs13089785	1.000	rs2271969	chr3:123650432	A/G	cg02012769	chr3:123398346	MYLK	0.34	6.25	0.32	1.26e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg19894588	chr14:64061835	NA	0.49	7.04	0.36	1.1e-11	Glioblastoma;Glioma;
LUSC	trans	rs17597773	0.638	rs12139139	chr1:221000626	G/A	cg25786136	chr2:222575520	NA	0.39	5.94	0.31	6.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs472402	0.560	rs2303705	chr5:6622017	A/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.43	-6.42	-0.33	4.79e-10	Response to amphetamines;
LUSC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg02569458	chr12:86230093	RASSF9	-0.48	-7.95	-0.4	2.87e-14	Major depressive disorder;
LUSC	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg25208724	chr1:156163844	SLC25A44	0.79	6.57	0.34	1.94e-10	Paclitaxel disposition in epithelial ovarian cancer;
LUSC	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg05985134	chr18:33552581	C18orf21	0.52	7.12	0.36	6.56e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg13256891	chr4:100009986	ADH5	-0.45	-6.18	-0.32	1.85e-9	Alcohol dependence;
LUSC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	10.66	0.5	4.78e-23	Homoarginine levels;
LUSC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg05872129	chr22:39784769	NA	-0.61	-11.68	-0.54	1.19e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs1982963	0.901	rs1566131	chr14:52514684	G/A	cg10843707	chr14:52510701	NID2	-0.39	-6.7	-0.34	8.81e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.56	8.42	0.42	1.1e-15	Total body bone mineral density;
LUSC	cis	rs9303542	0.625	rs7207109	chr17:46607817	C/T	cg09704116	chr17:46666958	LOC404266	-0.37	-6.79	-0.35	5.27e-11	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6484504	0.625	rs1535741	chr11:31375072	T/C	cg06552810	chr11:31128660	NA	0.39	6.78	0.35	5.49e-11	Red blood cell count;
LUSC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg00825309	chr19:58991885	ZNF446	-0.49	-7.03	-0.36	1.18e-11	Uric acid clearance;
LUSC	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg27411982	chr8:10470053	RP1L1	0.4	6.18	0.32	1.91e-9	Neuroticism;
LUSC	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08704250	chr15:31115839	NA	0.44	5.8	0.3	1.55e-8	Huntington's disease progression;
LUSC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-6.15	-0.32	2.19e-9	Obesity-related traits;
LUSC	cis	rs4132509	0.793	rs34477525	chr1:243966454	T/A	cg21452805	chr1:244014465	NA	0.49	5.7	0.3	2.58e-8	RR interval (heart rate);
LUSC	cis	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg02972257	chr16:68554789	NA	-0.52	-6.48	-0.33	3.26e-10	Ulcerative colitis;
LUSC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.92	-17.61	-0.69	1.45e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg05855489	chr10:104503620	C10orf26	0.54	7.91	0.4	3.91e-14	Arsenic metabolism;
LUSC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg02782426	chr3:40428986	ENTPD3	0.3	5.76	0.3	1.93e-8	Renal cell carcinoma;
LUSC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.33	0.53	2.21e-25	Menopause (age at onset);
LUSC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg11062466	chr8:58055876	NA	0.74	7.13	0.36	6.08e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg17173187	chr15:85201210	NMB	-0.37	-6.7	-0.34	8.96e-11	Schizophrenia;
LUSC	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg22508957	chr16:3507546	NAT15	0.42	6.08	0.32	3.36e-9	Body mass index (adult);
LUSC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg04450456	chr4:17643702	FAM184B	0.4	6.79	0.35	5.18e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.72	-12.57	-0.57	5.92e-30	White blood cell count (basophil);
LUSC	cis	rs9796	0.866	rs544744	chr15:41366290	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.45	-7.83	-0.39	6.67e-14	Menopause (age at onset);
LUSC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg05855489	chr10:104503620	C10orf26	-0.64	-8.61	-0.43	2.84e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.38	7.93	0.4	3.25e-14	Hemoglobin concentration;
LUSC	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg22674798	chr1:3096360	PRDM16	0.33	7.72	0.39	1.36e-13	Migraine;
LUSC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.61	-0.34	1.55e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9616064	0.886	rs11703960	chr22:46986423	A/T	cg05621596	chr22:47072043	GRAMD4	-0.44	-6.26	-0.32	1.18e-9	Urate levels in obese individuals;
LUSC	trans	rs11165623	0.765	rs12749081	chr1:96970371	A/C	cg10631902	chr5:14652156	NA	-0.44	-6.77	-0.35	5.69e-11	Hip circumference;Waist circumference;
LUSC	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.54	-14.75	-0.63	2.97e-38	Urate levels in overweight individuals;
LUSC	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg04025307	chr7:1156635	C7orf50	0.54	8.46	0.42	8.32e-16	Longevity;Endometriosis;
LUSC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.72	-12.75	-0.57	1.27e-30	Dental caries;
LUSC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.34	0.59	8.12e-33	Cognitive test performance;
LUSC	cis	rs4478858	0.602	rs6425723	chr1:31715204	T/C	cg00250761	chr1:31883323	NA	-0.34	-8.35	-0.42	1.86e-15	Alcohol dependence;
LUSC	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg10434728	chr15:90938212	IQGAP1	-0.44	-8.94	-0.44	2.8e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15369054	chr17:80825471	TBCD	0.49	7.98	0.4	2.44e-14	Breast cancer;
LUSC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg21770322	chr7:97807741	LMTK2	0.4	6.99	0.36	1.47e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1256061	0.603	rs1256036	chr14:64743332	C/T	cg23250157	chr14:64679961	SYNE2	0.32	5.71	0.3	2.56e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg17815252	chr3:142838682	CHST2	0.47	6.02	0.31	4.54e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg04398451	chr17:18023971	MYO15A	-0.5	-7.98	-0.4	2.39e-14	Total body bone mineral density;
LUSC	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg12615879	chr12:58013172	SLC26A10	-0.31	-6.45	-0.33	3.99e-10	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg01879757	chr17:41196368	BRCA1	-0.48	-7.77	-0.39	1.01e-13	Menopause (age at onset);
LUSC	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	6.76	0.35	6.05e-11	Height;
LUSC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg03790207	chr6:42947109	PEX6	-0.45	-6.9	-0.35	2.55e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	8.24	0.41	4.06e-15	Alzheimer's disease;
LUSC	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg09092052	chr15:45571596	NA	0.45	6.26	0.32	1.18e-9	Glomerular filtration rate;
LUSC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21963583	chr11:68658836	MRPL21	0.56	8.56	0.42	4.26e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg16339924	chr4:17578868	LAP3	0.55	8.51	0.42	5.79e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs459482	1.000	rs459498	chr21:42795027	G/A	cg21549285	chr21:42799141	MX1	0.38	5.87	0.31	1.08e-8	IgG glycosylation;
LUSC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	9.86	0.47	2.73e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg03146154	chr1:46216737	IPP	0.56	8.39	0.42	1.39e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	7.63	0.39	2.46e-13	Retinal vascular caliber;
LUSC	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-7.67	-0.39	1.9e-13	Schizophrenia;
LUSC	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs12310956	0.510	rs4931759	chr12:33871969	T/C	cg26384229	chr12:38710491	ALG10B	0.54	8.4	0.42	1.3e-15	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg21724239	chr8:58056113	NA	0.67	7.46	0.38	7.68e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg05738196	chr6:26577821	NA	0.82	15.84	0.66	1.47e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	10.06	0.48	5.59e-21	Bipolar disorder;
LUSC	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg27284194	chr4:1044797	NA	0.58	8.9	0.44	3.65e-17	Recombination rate (females);
LUSC	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-7.01	-0.36	1.31e-11	Monocyte percentage of white cells;
LUSC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00166722	chr3:10149974	C3orf24	0.54	7.42	0.38	9.76e-13	Alzheimer's disease;
LUSC	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.57	-9.56	-0.46	2.63e-19	Breast cancer;
LUSC	trans	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-9.28	-0.45	2.25e-18	Morning vs. evening chronotype;
LUSC	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg13010199	chr12:38710504	ALG10B	0.58	8.88	0.44	4.16e-17	Morning vs. evening chronotype;
LUSC	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg01966878	chr4:90757139	SNCA	-0.35	-6.12	-0.32	2.56e-9	Dementia with Lewy bodies;
LUSC	trans	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg10756647	chr7:56101905	PSPH	-0.87	-8.68	-0.43	1.74e-16	Diabetic kidney disease;
LUSC	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.05	13.89	0.61	5.97e-35	Uric acid levels;
LUSC	cis	rs73206853	0.688	rs55805203	chr12:110819142	G/T	cg12870014	chr12:110450643	ANKRD13A	0.67	6.31	0.33	8.63e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	0.64	13.37	0.59	5.97e-33	Prudent dietary pattern;
LUSC	cis	rs3125734	0.633	rs4979773	chr10:63967731	G/C	cg09941381	chr10:64027924	RTKN2	-0.39	-7.41	-0.38	1.06e-12	Rheumatoid arthritis;
LUSC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.78	0.47	5.05e-20	Bipolar disorder;
LUSC	trans	rs12210905	1.000	rs72838266	chr6:27015052	T/C	cg11837749	chr1:55047332	ACOT11	0.58	6.07	0.32	3.47e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7923452	1.000	rs7923452	chr10:30751171	T/C	cg18806716	chr10:30721971	MAP3K8	0.61	7.4	0.38	1.1e-12	Itch intensity from mosquito bite;
LUSC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg08088566	chr11:430123	ANO9	0.64	7.14	0.36	5.91e-12	Body mass index;
LUSC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg05973401	chr12:123451056	ABCB9	0.51	7.06	0.36	9.93e-12	Neutrophil percentage of white cells;
LUSC	cis	rs748404	0.723	rs512431	chr15:43541939	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.41	-5.94	-0.31	7.03e-9	Lung cancer;
LUSC	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.22	-0.32	1.51e-9	Type 2 diabetes;
LUSC	trans	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg17675199	chr6:35436792	RPL10A	-0.43	-6.31	-0.33	8.84e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg04546413	chr19:29218101	NA	0.71	11.0	0.52	3.19e-24	Methadone dose in opioid dependence;
LUSC	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg15704280	chr7:45808275	SEPT13	0.73	8.22	0.41	4.64e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7712401	0.791	rs6887101	chr5:122109207	C/T	cg19077854	chr5:122220652	SNX24	-0.35	-7.83	-0.39	6.52e-14	Mean platelet volume;
LUSC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-6.56	-0.34	2.03e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11924390	0.789	rs822366	chr3:186452490	A/G	cg12454167	chr3:186435060	KNG1	0.29	7.49	0.38	6.34e-13	Adiponectin levels;
LUSC	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg05855489	chr10:104503620	C10orf26	0.58	9.25	0.45	2.69e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg03929089	chr4:120376271	NA	-0.97	-16.51	-0.67	3.48e-45	Coronary artery disease;
LUSC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg22563815	chr15:78856949	CHRNA5	-0.25	-6.2	-0.32	1.65e-9	Sudden cardiac arrest;
LUSC	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.66	0.43	2.01e-16	Body mass index;
LUSC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.85	-0.35	3.58e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.7	-10.63	-0.5	6.55e-23	Aortic root size;
LUSC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg23985595	chr17:80112537	CCDC57	0.31	5.95	0.31	6.67e-9	Life satisfaction;
LUSC	cis	rs701145	0.556	rs355751	chr3:153971602	T/C	cg17054900	chr3:154042577	DHX36	0.44	5.77	0.3	1.77e-8	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.29	0.33	9.99e-10	Menopause (age at onset);
LUSC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg02475777	chr4:1388615	CRIPAK	0.41	6.13	0.32	2.46e-9	Obesity-related traits;
LUSC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg23711669	chr6:146136114	FBXO30	0.75	13.26	0.59	1.61e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Body mass index;
LUSC	cis	rs4474465	0.915	rs10128737	chr11:78186687	G/A	cg27205649	chr11:78285834	NARS2	-0.48	-5.67	-0.3	3.03e-8	Alzheimer's disease (survival time);
LUSC	cis	rs113835537	0.935	rs117480267	chr11:66398596	C/T	cg24851651	chr11:66362959	CCS	0.55	6.81	0.35	4.42e-11	Airway imaging phenotypes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21395152	chr1:212780243	ATF3	-0.44	-6.69	-0.34	9.65e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg05340658	chr4:99064831	C4orf37	-0.44	-6.96	-0.36	1.85e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.81	-13.1	-0.58	6.17e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21016266	chr12:122356598	WDR66	0.62	9.05	0.44	1.22e-17	Mean corpuscular volume;
LUSC	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg02696742	chr7:106810147	HBP1	-0.63	-9.54	-0.46	3.16e-19	Coronary artery disease;
LUSC	cis	rs6066835	1.000	rs6095270	chr20:47356062	T/C	cg18078177	chr20:47281410	PREX1	0.75	6.44	0.33	4.08e-10	Multiple myeloma;
LUSC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18876405	chr7:65276391	NA	-0.54	-8.52	-0.42	5.73e-16	Aortic root size;
LUSC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg15790184	chr11:494944	RNH1	0.52	5.98	0.31	5.62e-9	Body mass index;
LUSC	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.56	-8.68	-0.43	1.75e-16	Obesity-related traits;
LUSC	cis	rs500891	0.553	rs13215909	chr6:84130396	C/G	cg08257003	chr6:84140564	ME1	0.37	9.11	0.45	7.86e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	6.82	0.35	4.34e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs2637266	0.846	rs2583045	chr10:78412385	C/G	cg18941641	chr10:78392320	NA	-0.37	-6.68	-0.34	9.86e-11	Pulmonary function;
LUSC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg14416269	chr4:6271139	WFS1	0.54	11.41	0.53	1.08e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7589342	0.929	rs12053259	chr2:106428720	G/A	cg16077055	chr2:106428750	NCK2	0.38	7.29	0.37	2.22e-12	Addiction;
LUSC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820928	1.000	rs6723774	chr2:227770592	C/T	cg11843606	chr2:227700838	RHBDD1	0.52	7.68	0.39	1.78e-13	Pulmonary function;
LUSC	cis	rs4293296	0.525	rs28619304	chr14:54823270	A/G	cg02257953	chr14:54816093	NA	-0.44	-6.19	-0.32	1.78e-9	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs12681287	0.547	rs13249177	chr8:87513034	A/G	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	0.92	15.3	0.64	2.12e-40	Breast cancer;
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23978390	chr7:1156363	C7orf50	0.52	7.4	0.38	1.09e-12	Longevity;Endometriosis;
LUSC	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg17252645	chr8:143867129	LY6D	-0.36	-6.31	-0.33	9.04e-10	Urinary tract infection frequency;
LUSC	cis	rs10979	0.669	rs9484764	chr6:143867336	G/T	cg25407410	chr6:143891975	LOC285740	-0.54	-7.34	-0.37	1.63e-12	Hypospadias;
LUSC	cis	rs713477	0.678	rs4901566	chr14:55912663	C/A	cg13175173	chr14:55914753	NA	-0.3	-6.24	-0.32	1.34e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	11.86	0.54	2.65e-27	Menopause (age at onset);
LUSC	cis	rs4845459	0.967	rs75567512	chr1:152587933	C/A	cg08895932	chr1:152778580	LCE1C	-0.36	-6.31	-0.33	9.09e-10	Psoriasis;
LUSC	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21643547	chr1:205240462	TMCC2	0.48	9.28	0.45	2.26e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.6	-13.72	-0.6	2.77e-34	Height;
LUSC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.76	0.39	1.01e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg13010199	chr12:38710504	ALG10B	0.56	8.62	0.43	2.75e-16	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg08219700	chr8:58056026	NA	0.49	6.1	0.32	3.01e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg20090143	chr19:45452003	APOC2	0.47	9.14	0.45	6.27e-18	Blood protein levels;
LUSC	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg19920283	chr7:105172520	RINT1	0.58	6.22	0.32	1.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs3820068	0.608	rs9660255	chr1:16031891	T/G	cg24675056	chr1:15929824	NA	0.4	6.58	0.34	1.87e-10	Systolic blood pressure;
LUSC	cis	rs9341808	0.718	rs9352806	chr6:80980057	G/T	cg08355045	chr6:80787529	NA	0.55	9.71	0.47	8.33e-20	Sitting height ratio;
LUSC	cis	rs6840360	1.000	rs4696283	chr4:152580516	A/G	cg22705602	chr4:152727874	NA	-0.28	-5.84	-0.3	1.26e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11730100	chr11:61560294	FEN1;C11orf10;MIR611	-0.48	-6.44	-0.33	4.09e-10	Hepatitis;
LUSC	cis	rs9359856	0.636	rs4706345	chr6:90301565	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.73	-7.87	-0.4	5.13e-14	Bipolar disorder;
LUSC	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg00083206	chr6:110721305	DDO	-0.45	-8.28	-0.41	2.95e-15	Platelet distribution width;
LUSC	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg06484146	chr7:12443880	VWDE	-0.74	-7.61	-0.38	2.77e-13	Coronary artery disease;
LUSC	cis	rs868036	0.561	rs28376697	chr15:68140315	A/G	cg08079166	chr15:68083412	MAP2K5	0.43	6.66	0.34	1.14e-10	Restless legs syndrome;
LUSC	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg06740227	chr12:86229804	RASSF9	0.36	5.75	0.3	2.04e-8	Major depressive disorder;
LUSC	trans	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Bladder cancer;
LUSC	cis	rs11971779	0.616	rs2883772	chr7:139072756	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1775715	0.870	rs1615256	chr10:32254101	T/C	cg03015672	chr10:32216066	ARHGAP12	0.33	5.69	0.3	2.85e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1035144	0.505	rs10145099	chr14:81456694	C/T	cg06600135	chr14:81408086	NA	-0.59	-8.51	-0.42	5.84e-16	Male sexual orientation;
LUSC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg24154853	chr7:158122151	PTPRN2	0.41	8.16	0.41	7.08e-15	Calcium levels;
LUSC	cis	rs7712401	0.525	rs246312	chr5:122269455	G/A	cg19077854	chr5:122220652	SNX24	0.41	8.94	0.44	2.64e-17	Mean platelet volume;
LUSC	cis	rs7178572	0.598	rs907373	chr15:77844554	T/C	cg22256960	chr15:77711686	NA	-0.41	-6.62	-0.34	1.46e-10	Type 2 diabetes;
LUSC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg00343986	chr7:65444356	GUSB	0.45	6.92	0.35	2.33e-11	Aortic root size;
LUSC	cis	rs9653442	0.545	rs13032454	chr2:100756009	T/C	cg07810366	chr2:100720526	AFF3	-0.45	-7.63	-0.39	2.54e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7760535	0.811	rs7764591	chr6:111783414	G/C	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.46	-0.33	3.79e-10	Metabolic traits;
LUSC	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg19628046	chr18:33552617	C18orf21	0.49	5.87	0.31	1.05e-8	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg05187965	chr10:45406764	TMEM72	-0.38	-8.87	-0.44	4.6e-17	Mean corpuscular volume;
LUSC	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg20607287	chr7:12443886	VWDE	-0.65	-6.59	-0.34	1.74e-10	Coronary artery disease;
LUSC	cis	rs9948	0.786	rs62156226	chr2:97417108	G/A	cg01990225	chr2:97406019	LMAN2L	-0.78	-5.86	-0.31	1.1e-8	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg18850127	chr7:39170497	POU6F2	0.65	10.57	0.5	9.82e-23	IgG glycosylation;
LUSC	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg19683494	chr5:74908142	NA	-0.59	-7.29	-0.37	2.24e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9581857	0.585	rs9581875	chr13:28099678	A/G	cg22138327	chr13:27999177	GTF3A	0.69	6.98	0.36	1.6e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg24375607	chr4:120327624	NA	0.77	11.22	0.52	5.04e-25	Corneal astigmatism;
LUSC	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg00071950	chr4:10020882	SLC2A9	0.53	9.12	0.45	7.46e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.2	-0.41	5.15e-15	Systolic blood pressure;
LUSC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg24562669	chr7:97807699	LMTK2	0.35	6.17	0.32	1.98e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3733606	0.503	rs11734132	chr4:6891519	C/G	cg05012661	chr4:6891264	NA	-0.53	-7.82	-0.39	7.16e-14	Platelet count;
LUSC	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg14092988	chr3:52407081	DNAH1	0.32	6.34	0.33	7.42e-10	Bipolar disorder;
LUSC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg13918804	chr1:2043761	PRKCZ	0.28	6.01	0.31	4.82e-9	Height;
LUSC	cis	rs12530845	1.000	rs6979391	chr7:135328873	C/T	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg01420254	chr6:26195488	NA	0.72	7.48	0.38	6.52e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs9612	0.950	rs11351	chr19:44271066	A/C	cg08581076	chr19:44259116	C19orf61	0.46	5.66	0.3	3.3e-8	Exhaled nitric oxide output;
LUSC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.75	-13.39	-0.59	5.02e-33	Aortic root size;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02084811	chr12:49524778	TUBA1B	-0.52	-6.32	-0.33	8.16e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg10356904	chr22:49881777	NA	-0.29	-6.14	-0.32	2.41e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs12711979	0.904	rs12329356	chr2:3868533	G/C	cg17052675	chr2:3827356	NA	-0.44	-7.9	-0.4	4.04e-14	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs12519773	0.526	rs4869191	chr5:92525434	A/T	cg18783429	chr5:92414398	NA	-0.36	-7.38	-0.37	1.24e-12	Migraine;
LUSC	cis	rs9517320	1.000	rs9584856	chr13:99126551	G/T	cg07423050	chr13:99094983	FARP1	0.35	6.69	0.34	9.29e-11	Longevity;
LUSC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.14	16.33	0.67	1.78e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg03168614	chr20:34253242	RBM12;CPNE1	-0.31	-5.68	-0.3	2.9e-8	Total cholesterol levels;
LUSC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.23	-0.41	4.21e-15	Blood protein levels;
LUSC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	6.33	0.33	7.97e-10	Electroencephalogram traits;
LUSC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg17264618	chr3:40429014	ENTPD3	0.34	7.26	0.37	2.82e-12	Renal cell carcinoma;
LUSC	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg03585969	chr10:35415529	CREM	0.62	9.1	0.45	8.18e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.02	-0.36	1.27e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg04036182	chr15:45458818	NA	0.35	5.75	0.3	2.01e-8	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs2262909	0.962	rs73019844	chr19:22249925	T/C	cg17074339	chr11:11642133	GALNTL4	0.47	7.17	0.37	4.94e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg15704280	chr7:45808275	SEPT13	0.58	7.26	0.37	2.69e-12	Intraocular pressure;
LUSC	trans	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg10756647	chr7:56101905	PSPH	0.87	8.52	0.42	5.71e-16	Diabetic kidney disease;
LUSC	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg01448562	chr3:133502909	NA	-0.52	-7.47	-0.38	6.95e-13	Iron status biomarkers;
LUSC	cis	rs10992471	0.603	rs4743873	chr9:95270781	C/T	cg14631576	chr9:95140430	CENPP	0.33	6.15	0.32	2.17e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs240764	0.604	rs705586	chr6:101268046	C/G	cg09795085	chr6:101329169	ASCC3	0.44	6.21	0.32	1.58e-9	Neuroticism;
LUSC	trans	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	9.75	0.47	6.12e-20	Eotaxin levels;
LUSC	cis	rs4253772	0.872	rs11704508	chr22:46638540	A/G	cg09491104	chr22:46646882	C22orf40	-0.63	-6.52	-0.34	2.57e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg01528321	chr10:82214614	TSPAN14	1.08	11.99	0.55	8.7e-28	Post bronchodilator FEV1;
LUSC	cis	rs3738772	1.000	rs3738773	chr1:110048527	C/T	cg08367326	chr1:110052010	AMIGO1	-0.41	-5.7	-0.3	2.59e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg19468946	chr17:37922297	IKZF3	0.39	6.21	0.32	1.6e-9	Self-reported allergy;
LUSC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg13256891	chr4:100009986	ADH5	0.49	6.85	0.35	3.56e-11	Smoking initiation;
LUSC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-1.13	-24.37	-0.8	4.1e-76	Height;
LUSC	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg07169764	chr2:136633963	MCM6	-1.12	-16.2	-0.66	5.82e-44	Corneal structure;
LUSC	cis	rs13202913	0.837	rs6906667	chr6:151772569	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	5.67	0.3	3.12e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	trans	rs1429264	0.791	rs7188531	chr16:84619996	C/T	cg24066931	chr19:1568534	MEX3D	-0.43	-5.97	-0.31	5.94e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
LUSC	cis	rs10761482	0.775	rs1459725	chr10:62138608	C/T	cg18175470	chr10:62150864	ANK3	-0.56	-8.44	-0.42	9.57e-16	Schizophrenia;
LUSC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg22920501	chr2:26401640	FAM59B	-0.82	-12.2	-0.56	1.41e-28	Gut microbiome composition (summer);
LUSC	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.57	10.64	0.5	5.82e-23	Bone mineral density;
LUSC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	trans	rs9860340	0.690	rs2048292	chr3:87634271	A/G	cg03644585	chr7:884825	UNC84A	0.42	6.09	0.32	3.17e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs9398803	0.897	rs9398804	chr6:126703390	T/A	cg19875578	chr6:126661172	C6orf173	0.39	5.68	0.3	2.96e-8	Male-pattern baldness;
LUSC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg16339924	chr4:17578868	LAP3	0.63	9.98	0.48	1.06e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg23791538	chr6:167370224	RNASET2	-0.36	-5.67	-0.3	3.05e-8	Crohn's disease;
LUSC	cis	rs2357013	0.699	rs1510107	chr2:53160137	C/G	cg07782112	chr2:53107842	NA	-0.37	-5.98	-0.31	5.76e-9	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg03806693	chr22:41940476	POLR3H	1.0	14.25	0.62	2.41e-36	Vitiligo;
LUSC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00684032	chr4:1343700	KIAA1530	-0.33	-5.72	-0.3	2.38e-8	Obesity-related traits;
LUSC	cis	rs2073300	0.826	rs6083136	chr20:23454188	A/G	cg09953122	chr20:23471693	CST8	-0.61	-5.92	-0.31	7.97e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg07148914	chr20:33460835	GGT7	-0.55	-8.49	-0.42	6.66e-16	Height;
LUSC	cis	rs4776059	0.798	rs11855616	chr15:52874833	C/T	cg22715398	chr15:52968154	KIAA1370	0.64	7.97	0.4	2.62e-14	Schizophrenia;
LUSC	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	12.06	0.55	4.66e-28	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg01475377	chr6:109611718	NA	0.37	6.34	0.33	7.25e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg19156104	chr2:198669113	PLCL1	-0.48	-5.77	-0.3	1.82e-8	Ulcerative colitis;
LUSC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.6	8.91	0.44	3.44e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18099408	chr3:52552593	STAB1	0.42	7.16	0.36	5.2e-12	Bipolar disorder;
LUSC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg11645453	chr3:52864694	ITIH4	0.37	8.31	0.41	2.44e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.58	9.57	0.46	2.55e-19	Aortic root size;
LUSC	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.74	-10.78	-0.51	1.93e-23	Glomerular filtration rate;
LUSC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg03395511	chr6:291903	DUSP22	-0.46	-6.74	-0.35	6.91e-11	Menopause (age at onset);
LUSC	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	8.04	0.4	1.62e-14	Colorectal cancer;
LUSC	trans	rs7581030	0.517	rs7605066	chr2:71529331	C/T	cg06465196	chr4:154387603	KIAA0922	0.42	6.04	0.31	4.18e-9	Testicular germ cell tumor;
LUSC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg09021430	chr5:549028	NA	-0.57	-7.7	-0.39	1.61e-13	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6076065	0.541	rs8118688	chr20:23320850	G/A	cg11657817	chr20:23433608	CST11	0.4	7.4	0.38	1.13e-12	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.38	-0.49	4.64e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg23795048	chr12:9217529	LOC144571	0.33	5.76	0.3	1.94e-8	Sjögren's syndrome;
LUSC	cis	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg05084668	chr3:125655381	ALG1L	-0.59	-8.29	-0.41	2.76e-15	Blood pressure (smoking interaction);
LUSC	cis	rs7246657	0.551	rs10419174	chr19:37605341	A/G	cg23950597	chr19:37808831	NA	-0.55	-6.01	-0.31	4.87e-9	Coronary artery calcification;
LUSC	cis	rs79149102	0.850	rs78646589	chr15:75170580	C/T	cg09165964	chr15:75287851	SCAMP5	-0.89	-6.39	-0.33	5.55e-10	Lung cancer;
LUSC	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg06191203	chr2:152266755	RIF1	-0.52	-7.08	-0.36	8.51e-12	Lung cancer;
LUSC	cis	rs9658691	0.646	rs2862834	chr10:90741374	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.69	6.5	0.34	2.85e-10	Mosquito bite size;
LUSC	cis	rs4380275	1.000	rs7562792	chr2:774469	T/C	cg21665850	chr2:731073	NA	0.42	6.75	0.35	6.65e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg11584989	chr19:19387371	SF4	-0.6	-7.08	-0.36	8.81e-12	Bipolar disorder;
LUSC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg17724175	chr1:150552817	MCL1	0.37	6.65	0.34	1.23e-10	Melanoma;
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.37	5.68	0.3	2.91e-8	Longevity;Endometriosis;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22828804	chr20:3140466	UBOX5;FASTKD5	-0.38	-6.51	-0.34	2.82e-10	Electrocardiographic conduction measures;
LUSC	cis	rs11971779	0.680	rs1133067	chr7:139053069	G/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.28	0.37	2.44e-12	Diisocyanate-induced asthma;
LUSC	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg02753203	chr1:228287806	NA	-0.65	-10.72	-0.51	3.15e-23	Diastolic blood pressure;
LUSC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg02951883	chr7:2050386	MAD1L1	-0.51	-9.01	-0.44	1.6e-17	Bipolar disorder and schizophrenia;
LUSC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-1.04	-20.22	-0.74	5.96e-60	Height;
LUSC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg10351095	chr21:47802916	PCNT	0.5	7.07	0.36	9.34e-12	Testicular germ cell tumor;
LUSC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.38	-0.42	1.51e-15	Obesity-related traits;
LUSC	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.24	-0.37	3.11e-12	Mood instability;
LUSC	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.7	10.54	0.5	1.25e-22	Corneal astigmatism;
LUSC	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-20.57	-0.75	2.54e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.03e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9487051	0.768	rs458185	chr6:109524074	A/G	cg00509249	chr6:109615579	CCDC162	-0.33	-5.81	-0.3	1.49e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7178572	0.568	rs1823100	chr15:77402744	C/T	cg22256960	chr15:77711686	NA	-0.51	-8.02	-0.4	1.74e-14	Type 2 diabetes;
LUSC	cis	rs10193935	0.901	rs62142561	chr2:42477808	G/C	cg27598129	chr2:42591480	NA	-0.59	-8.12	-0.41	9.26e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg20908204	chr19:46285434	DMPK	0.41	8.15	0.41	7.21e-15	Coronary artery disease;
LUSC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg04352962	chr1:209979756	IRF6	0.5	6.74	0.35	7.02e-11	Cleft lip with or without cleft palate;
LUSC	trans	rs11700980	1.000	rs58491443	chr21:30056039	G/A	cg05609335	chr17:75789393	NA	0.41	6.02	0.31	4.71e-9	QRS complex (12-leadsum);
LUSC	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg13010199	chr12:38710504	ALG10B	0.56	8.59	0.43	3.38e-16	Morning vs. evening chronotype;
LUSC	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg25801113	chr15:45476975	SHF	0.34	7.04	0.36	1.13e-11	Uric acid levels;
LUSC	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg22117172	chr7:91764530	CYP51A1	0.32	5.74	0.3	2.17e-8	Breast cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00608362	chr4:128802003	PLK4	-0.46	-6.99	-0.36	1.53e-11	Electrocardiographic conduction measures;
LUSC	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg13010199	chr12:38710504	ALG10B	0.46	7.15	0.36	5.43e-12	Heart rate;
LUSC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.61	0.43	2.95e-16	Menarche (age at onset);
LUSC	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg15704280	chr7:45808275	SEPT13	0.7	6.69	0.34	9.51e-11	Axial length;
LUSC	cis	rs7605827	0.866	rs13016989	chr2:15514338	T/A	cg19274914	chr2:15703543	NA	0.46	8.81	0.43	6.94e-17	Educational attainment (years of education);
LUSC	cis	rs9646944	0.501	rs2110736	chr2:103050855	T/C	cg20060108	chr2:102954350	IL1RL1	0.48	6.59	0.34	1.67e-10	Blood protein levels;
LUSC	trans	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.32	-0.33	8.19e-10	Bladder cancer;
LUSC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06634786	chr22:41940651	POLR3H	-0.57	-6.44	-0.33	4.11e-10	Vitiligo;
LUSC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg03929089	chr4:120376271	NA	-0.95	-16.65	-0.67	9.25e-46	Height;
LUSC	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-1.27	-21.47	-0.76	7.64e-65	Blood pressure (smoking interaction);
LUSC	cis	rs62400317	0.859	rs11966878	chr6:45328265	C/T	cg18551225	chr6:44695536	NA	0.43	6.97	0.36	1.72e-11	Total body bone mineral density;
LUSC	cis	rs2970818	0.831	rs1029769	chr12:4645448	T/C	cg11146114	chr12:4671731	NA	-0.56	-5.95	-0.31	6.96e-9	Phosphorus levels;
LUSC	cis	rs2742417	1.000	rs2742452	chr3:45765708	C/T	cg09608765	chr3:45636137	LIMD1	-0.38	-7.49	-0.38	6.08e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg03036452	chr22:46663545	TTC38	0.54	5.89	0.31	9.38e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	7.88	0.4	4.66e-14	Total body bone mineral density;
LUSC	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.54	9.65	0.47	1.39e-19	Birth weight;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10524888	chr4:39529563	UGDH	-0.46	-6.05	-0.31	3.94e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg17173187	chr15:85201210	NMB	0.35	6.29	0.33	9.81e-10	Schizophrenia;
LUSC	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg26195577	chr20:24973756	C20orf3	1.11	18.48	0.71	5e-53	Blood protein levels;
LUSC	cis	rs11642862	1.000	rs11642603	chr16:30886221	C/G	cg02466173	chr16:30829666	NA	-0.69	-6.93	-0.35	2.24e-11	Tonsillectomy;
LUSC	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg23029597	chr12:123009494	RSRC2	-0.73	-9.72	-0.47	7.96e-20	Body mass index;
LUSC	cis	rs9297145	0.761	rs112155177	chr7:98747963	C/T	cg05967295	chr7:98741636	SMURF1	0.93	13.68	0.6	4.08e-34	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg18225595	chr11:63971243	STIP1	0.56	7.54	0.38	4.57e-13	Mean platelet volume;
LUSC	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg26898376	chr11:64110657	CCDC88B	0.33	6.16	0.32	2.06e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg03929089	chr4:120376271	NA	-0.94	-16.25	-0.66	3.8e-44	Height;
LUSC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.53	-7.75	-0.39	1.13e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg01620082	chr3:125678407	NA	-0.78	-7.18	-0.37	4.56e-12	Depression;
LUSC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.84	-0.3	1.24e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	7.46	0.38	7.44e-13	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	0.7	11.09	0.52	1.54e-24	Blood metabolite ratios;
LUSC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg17376030	chr22:41985996	PMM1	0.51	6.31	0.33	8.73e-10	Vitiligo;
LUSC	cis	rs4474465	0.688	rs4457782	chr11:78284733	A/G	cg27205649	chr11:78285834	NARS2	0.55	6.69	0.34	9.59e-11	Alzheimer's disease (survival time);
LUSC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-9.52	-0.46	3.75e-19	Gut microbiome composition (summer);
LUSC	cis	rs73200209	0.744	rs11615877	chr12:116709800	C/T	cg01776926	chr12:116560359	MED13L	-0.49	-5.83	-0.3	1.29e-8	Total body bone mineral density;
LUSC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg22535103	chr8:58192502	C8orf71	-0.75	-9.42	-0.46	7.89e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.24	-14.24	-0.61	2.72e-36	Diabetic kidney disease;
LUSC	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg03585969	chr10:35415529	CREM	0.65	9.46	0.46	5.6e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.39	-0.33	5.71e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13732083	chr21:47605072	C21orf56	0.42	6.21	0.32	1.55e-9	Testicular germ cell tumor;
LUSC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11645453	chr3:52864694	ITIH4	0.34	7.77	0.39	9.51e-14	Bipolar disorder;
LUSC	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg24579218	chr15:68104479	NA	-0.41	-6.56	-0.34	2.05e-10	Restless legs syndrome;
LUSC	cis	rs10754283	0.557	rs1215508	chr1:90088697	C/T	cg21401794	chr1:90099060	LRRC8C	0.54	7.67	0.39	1.86e-13	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2667011	0.756	rs2667023	chr2:160835399	C/T	cg06573604	chr2:160760825	LY75	-0.48	-6.16	-0.32	2.09e-9	Bilirubin levels;
LUSC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg07217954	chr7:1067459	C7orf50	0.52	5.67	0.3	3.02e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.23	-0.69	4.77e-48	Exhaled nitric oxide output;
LUSC	cis	rs7809950	0.678	rs2237659	chr7:106847492	G/T	cg23024343	chr7:107201750	COG5	0.62	8.55	0.42	4.45e-16	Coronary artery disease;
LUSC	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.7	-13.49	-0.59	2.01e-33	Ulcerative colitis;
LUSC	cis	rs56399783	0.901	rs6967664	chr7:2816384	A/G	cg19731401	chr7:2775893	GNA12	0.64	8.52	0.42	5.68e-16	Childhood ear infection;
LUSC	cis	rs1443512	0.773	rs2366146	chr12:54331002	G/A	cg17410650	chr12:54324560	NA	-0.58	-10.51	-0.5	1.61e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs1775715	0.707	rs2778669	chr10:32161541	C/T	cg18675610	chr10:32216311	ARHGAP12	0.3	6.59	0.34	1.68e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6061231	0.505	rs62199217	chr20:60929539	G/A	cg22601191	chr20:60968625	CABLES2	0.46	6.55	0.34	2.19e-10	Colorectal cancer;
LUSC	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.62	0.47	1.72e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg13206674	chr6:150067644	NUP43	0.63	10.48	0.5	2.12e-22	Lung cancer;
LUSC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg10169327	chr19:45448959	APOC2	0.31	6.66	0.34	1.15e-10	Blood protein levels;
LUSC	cis	rs240764	0.658	rs6925823	chr6:101179273	C/A	cg09795085	chr6:101329169	ASCC3	-0.44	-6.42	-0.33	4.68e-10	Neuroticism;
LUSC	cis	rs7216064	1.000	rs9913471	chr17:65874495	C/T	cg12091567	chr17:66097778	LOC651250	-0.73	-9.37	-0.46	1.13e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs656319	0.605	rs60278284	chr8:10003210	G/C	cg27411982	chr8:10470053	RP1L1	-0.4	-5.99	-0.31	5.48e-9	Myopia (pathological);
LUSC	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-6.2	-0.32	1.7e-9	Resting heart rate;
LUSC	cis	rs4474465	0.833	rs6592792	chr11:78271614	A/C	cg27205649	chr11:78285834	NARS2	0.54	6.1	0.32	2.93e-9	Alzheimer's disease (survival time);
LUSC	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg05343316	chr1:45956843	TESK2	-0.41	-5.89	-0.31	9.59e-9	Platelet count;
LUSC	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg17848003	chr1:3704513	LRRC47	0.32	5.81	0.3	1.46e-8	Red cell distribution width;
LUSC	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg22189786	chr22:42395067	WBP2NL	0.43	5.75	0.3	2.05e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.51	8.49	0.42	6.93e-16	Prudent dietary pattern;
LUSC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg27411982	chr8:10470053	RP1L1	0.4	6.17	0.32	1.98e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs10484885	0.887	rs114928443	chr6:90602455	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.79	-8.48	-0.42	7.58e-16	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg12935359	chr14:103987150	CKB	0.66	10.79	0.51	1.81e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg18225595	chr11:63971243	STIP1	0.5	6.17	0.32	2e-9	Mean platelet volume;
LUSC	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg15448220	chr1:150897856	SETDB1	0.42	6.1	0.32	2.93e-9	Melanoma;
LUSC	cis	rs1322512	1.000	rs2250632	chr6:153011126	C/A	cg27316956	chr6:152958899	SYNE1	0.35	6.07	0.32	3.47e-9	Tonometry;
LUSC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg08219700	chr8:58056026	NA	0.45	6.14	0.32	2.28e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.09	-0.32	3.07e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs981844	1.000	rs2606332	chr4:154655372	G/A	cg14289246	chr4:154710475	SFRP2	0.5	6.25	0.32	1.28e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg08079166	chr15:68083412	MAP2K5	0.49	8.17	0.41	6.23e-15	Restless legs syndrome;
LUSC	cis	rs6669072	0.647	rs814544	chr1:91241693	G/A	cg08895590	chr1:91227319	NA	-0.38	-8.64	-0.43	2.43e-16	Cognitive function;
LUSC	cis	rs7659604	0.540	rs4833769	chr4:122672970	A/C	cg19748678	chr4:122722346	EXOSC9	0.4	5.93	0.31	7.37e-9	Type 2 diabetes;
LUSC	trans	rs17685	0.740	rs4732514	chr7:75613998	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.94	-15.13	-0.64	9.37e-40	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.72	-10.99	-0.52	3.57e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs981844	0.666	rs7691303	chr4:154684198	T/C	cg14289246	chr4:154710475	SFRP2	-0.52	-7.43	-0.38	9.38e-13	Response to statins (LDL cholesterol change);
LUSC	cis	rs9309473	1.000	rs1403284	chr2:73726662	A/G	cg20560298	chr2:73613845	ALMS1	0.52	7.62	0.38	2.63e-13	Metabolite levels;
LUSC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg17168535	chr8:21777572	XPO7	0.78	13.9	0.61	5.57e-35	Mean corpuscular volume;
LUSC	cis	rs11641365	0.517	rs73262667	chr16:88779753	C/T	cg06304787	chr16:88772962	CTU2;RNF166	0.63	6.66	0.34	1.13e-10	Autism spectrum disorder-related traits;
LUSC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg17554472	chr22:41940697	POLR3H	-0.48	-5.76	-0.3	1.89e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs34734847	0.787	rs695949	chr12:121149736	A/G	cg27246729	chr12:121163418	ACADS	0.42	6.59	0.34	1.7e-10	Mean corpuscular volume;
LUSC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21963583	chr11:68658836	MRPL21	0.55	8.43	0.42	1.07e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg14558114	chr2:88469736	THNSL2	0.79	7.08	0.36	8.4e-12	Plasma clusterin levels;
LUSC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg10018233	chr7:150070692	REPIN1	0.4	6.65	0.34	1.23e-10	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs3942852	0.910	rs11603850	chr11:48140900	G/A	cg03929089	chr4:120376271	NA	-0.57	-6.44	-0.33	4.12e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs1178968	1.000	rs4717751	chr7:72750627	G/A	cg25889504	chr7:72793014	NA	0.58	7.53	0.38	4.84e-13	Triglyceride levels;
LUSC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg26587870	chr6:27730563	NA	-0.63	-5.96	-0.31	6.45e-9	Depression;
LUSC	cis	rs12618769	1.000	rs3769693	chr2:99259346	T/G	cg10123293	chr2:99228465	UNC50	0.43	5.96	0.31	6.29e-9	Bipolar disorder;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23864632	chr19:47220401	PRKD2	-0.41	-5.97	-0.31	5.93e-9	Electrocardiographic conduction measures;
LUSC	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg13755796	chr4:20253514	NA	-0.43	-6.8	-0.35	4.98e-11	Life satisfaction;
LUSC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-1.04	-20.42	-0.75	1.02e-60	Height;
LUSC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	0.94	16.0	0.66	3.44e-43	Menopause (age at onset);
LUSC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg15839431	chr19:19639596	YJEFN3	-0.44	-6.11	-0.32	2.7e-9	Tonsillectomy;
LUSC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.81e-10	Bipolar disorder;
LUSC	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg05340658	chr4:99064831	C4orf37	-0.41	-6.45	-0.33	4.01e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs701145	0.537	rs357479	chr3:153891489	A/G	cg10247383	chr3:153839028	SGEF	-0.61	-5.74	-0.3	2.09e-8	Coronary artery disease;
LUSC	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg07828340	chr4:882639	GAK	1.1	11.46	0.53	7.38e-26	Intelligence (multi-trait analysis);
LUSC	trans	rs12692738	0.526	rs355862	chr2:165630100	A/G	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.06e-12	Motion sickness;
LUSC	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg22676075	chr6:135203613	NA	0.48	7.48	0.38	6.5e-13	Red blood cell count;
LUSC	trans	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg10756647	chr7:56101905	PSPH	-0.82	-8.16	-0.41	6.72e-15	Diabetic kidney disease;
LUSC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.86	0.4	5.33e-14	Parkinson's disease;
LUSC	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.39	-7.71	-0.39	1.44e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	trans	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg25214090	chr10:38739885	LOC399744	0.45	6.49	0.33	3.17e-10	Corneal astigmatism;
LUSC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg15790184	chr11:494944	RNH1	0.52	5.98	0.31	5.62e-9	Body mass index;
LUSC	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.66e-9	Response to antipsychotic treatment;
LUSC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg00310523	chr12:86230176	RASSF9	0.51	9.73	0.47	7.48e-20	Major depressive disorder;
LUSC	cis	rs600626	0.588	rs10793124	chr11:75452267	C/G	cg24262691	chr11:75473276	NA	0.5	6.19	0.32	1.74e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs1953600	0.870	rs2788295	chr10:81941007	C/G	cg00277334	chr10:82204260	NA	0.45	7.08	0.36	8.35e-12	Sarcoidosis;
LUSC	cis	rs9303280	0.870	rs6503524	chr17:38069809	C/T	cg19468946	chr17:37922297	IKZF3	0.39	6.24	0.32	1.3e-9	Self-reported allergy;
LUSC	trans	rs12692738	0.526	rs650330	chr2:165624861	G/A	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg11502198	chr6:26597334	ABT1	-0.47	-6.68	-0.34	9.78e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7799006	0.862	rs3757439	chr7:2272122	C/T	cg12823233	chr7:2316876	SNX8	-0.35	-6.12	-0.32	2.67e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg00376283	chr12:123451042	ABCB9	-0.66	-9.37	-0.46	1.1e-18	Neutrophil percentage of white cells;
LUSC	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-0.59	-12.15	-0.55	2.3e-28	Obesity-related traits;
LUSC	cis	rs757278	0.526	rs1366912	chr7:117316601	A/G	cg10524701	chr7:117356490	CTTNBP2	0.4	5.7	0.3	2.7e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs7246967	0.673	rs56663398	chr19:22820200	C/T	cg23217946	chr19:22817039	ZNF492	0.43	6.0	0.31	5.14e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg23649088	chr2:200775458	C2orf69	0.54	7.35	0.37	1.58e-12	Schizophrenia;
LUSC	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.69	0.34	9.44e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9361491	0.657	rs1180824	chr6:79433523	G/A	cg05283184	chr6:79620031	NA	-0.33	-5.87	-0.31	1.07e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs13082711	0.519	rs13091109	chr3:27229125	G/A	cg02860705	chr3:27208620	NA	0.61	10.37	0.49	5.19e-22	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-11.66	-0.54	1.38e-26	Chronic sinus infection;
LUSC	cis	rs11971779	0.553	rs36002669	chr7:139113161	T/A	cg23387468	chr7:139079360	LUC7L2	0.42	6.29	0.33	1e-9	Diisocyanate-induced asthma;
LUSC	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.52	-7.04	-0.36	1.13e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg18225595	chr11:63971243	STIP1	0.5	6.19	0.32	1.8e-9	Mean platelet volume;
LUSC	cis	rs6429082	0.521	rs704711	chr1:235629802	G/A	cg26050004	chr1:235667680	B3GALNT2	0.8	14.05	0.61	1.44e-35	Adiposity;
LUSC	trans	rs6600671	0.967	rs11249347	chr1:121188347	G/T	cg00646200	chr1:148855367	NA	0.46	7.33	0.37	1.77e-12	Hip geometry;
LUSC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.52	0.53	4.39e-26	Prudent dietary pattern;
LUSC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg19773385	chr1:10388646	KIF1B	-0.57	-9.73	-0.47	7.08e-20	Hepatocellular carcinoma;
LUSC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	9.91e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg24399712	chr22:39784796	NA	0.6	9.86	0.47	2.67e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg05025164	chr4:1340916	KIAA1530	0.46	7.06	0.36	9.77e-12	Obesity-related traits;
LUSC	cis	rs4308124	0.679	rs7600458	chr2:111963590	G/C	cg04571233	chr2:111982156	NA	-0.5	-6.55	-0.34	2.11e-10	Vitiligo;
LUSC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08048268	chr3:133502702	NA	-0.46	-8.9	-0.44	3.54e-17	Iron status biomarkers;
LUSC	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg08807101	chr21:30365312	RNF160	0.64	9.91	0.48	1.79e-20	Pancreatic cancer;
LUSC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg05084668	chr3:125655381	ALG1L	-0.51	-7.12	-0.36	6.65e-12	Blood pressure (smoking interaction);
LUSC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg24562669	chr7:97807699	LMTK2	-0.35	-6.21	-0.32	1.6e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	0.68	6.84	0.35	3.85e-11	Prostate cancer;
LUSC	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg05283184	chr6:79620031	NA	-0.56	-11.49	-0.53	5.69e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs16976116	0.901	rs2899581	chr15:55491643	T/C	cg11288833	chr15:55489084	RSL24D1	0.49	5.9	0.31	9.16e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.51e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.14	0.32	2.31e-9	Corneal astigmatism;
LUSC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9633740	1.000	rs10749609	chr10:82249752	G/A	cg01528321	chr10:82214614	TSPAN14	1.03	11.38	0.53	1.44e-25	Post bronchodilator FEV1;
LUSC	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg06454157	chr6:167490870	NA	-0.25	-5.71	-0.3	2.52e-8	Crohn's disease;
LUSC	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.44	0.42	9.9e-16	Lung cancer;
LUSC	cis	rs4629710	0.592	rs66533103	chr6:131531016	C/T	cg12606694	chr6:131520996	AKAP7	0.62	9.17	0.45	4.95e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-17.0	-0.68	3.84e-47	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	9.03	0.44	1.38e-17	Prudent dietary pattern;
LUSC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg21770322	chr7:97807741	LMTK2	0.41	7.16	0.36	5.12e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg01420254	chr6:26195488	NA	0.66	7.31	0.37	2.05e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg12560992	chr17:57184187	TRIM37	0.85	15.3	0.64	2e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	0.64	13.62	0.6	6.4e-34	Prudent dietary pattern;
LUSC	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.74	-14.14	-0.61	6.46e-36	Ulcerative colitis;
LUSC	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.73	14.75	0.63	2.86e-38	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04824913	chr4:887549	GAK	0.73	9.91	0.48	1.82e-20	Systemic sclerosis;
LUSC	cis	rs9715521	0.775	rs11723682	chr4:59851969	C/T	cg11281224	chr4:60001000	NA	-0.47	-6.46	-0.33	3.59e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13732083	chr21:47605072	C21orf56	0.4	5.76	0.3	1.93e-8	Testicular germ cell tumor;
LUSC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg00784671	chr22:46762841	CELSR1	-0.46	-5.75	-0.3	1.97e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-9.25	-0.45	2.71e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.64	0.6	5.79e-34	Cognitive test performance;
LUSC	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg03465714	chr1:152285911	FLG	0.42	5.79	0.3	1.65e-8	Atopic dermatitis;
LUSC	cis	rs4974559	0.740	rs11933854	chr4:1315172	G/A	cg02980000	chr4:1222292	CTBP1	0.84	9.43	0.46	7.14e-19	Systolic blood pressure;
LUSC	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.28	0.37	2.47e-12	Menarche (age at onset);
LUSC	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.08	15.19	0.64	5.27e-40	Lung cancer in ever smokers;
LUSC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg06618935	chr21:46677482	NA	-0.38	-7.57	-0.38	3.79e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	1.93e-9	Life satisfaction;
LUSC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.51	0.62	2.44e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs73206853	0.764	rs970228	chr12:111070169	G/C	cg12870014	chr12:110450643	ANKRD13A	0.69	7.58	0.38	3.37e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	6.53	0.34	2.46e-10	Recombination rate (females);
LUSC	cis	rs7216064	1.000	rs6504555	chr17:65940727	A/G	cg12091567	chr17:66097778	LOC651250	0.71	9.52	0.46	3.53e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg17178900	chr1:205818956	PM20D1	0.79	13.18	0.58	3.12e-32	Menarche (age at onset);
LUSC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.97	0.36	1.73e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9341808	0.754	rs1324121	chr6:80946077	A/G	cg08355045	chr6:80787529	NA	0.56	9.66	0.47	1.22e-19	Sitting height ratio;
LUSC	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg04310649	chr10:35416472	CREM	-0.43	-6.54	-0.34	2.35e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg12615879	chr12:58013172	SLC26A10	-0.29	-5.97	-0.31	5.93e-9	Multiple sclerosis;
LUSC	cis	rs61990749	0.544	rs1477259	chr14:78256138	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	6.45	0.33	3.84e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg06238570	chr21:40685208	BRWD1	-0.63	-10.65	-0.5	5.32e-23	Cognitive function;
LUSC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg27121462	chr16:89883253	FANCA	0.54	8.65	0.43	2.27e-16	Vitiligo;
LUSC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg12311346	chr5:56204834	C5orf35	-0.68	-9.71	-0.47	8.36e-20	Type 2 diabetes;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07727872	chr19:33463030	C19orf40;CCDC123	0.42	6.33	0.33	8.11e-10	Triglycerides;
LUSC	cis	rs10905065	0.833	rs6602259	chr10:5844628	C/T	cg11519256	chr10:5708881	ASB13	0.38	5.77	0.3	1.82e-8	Menopause (age at onset);
LUSC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-5.96	-0.31	6.37e-9	Personality dimensions;
LUSC	cis	rs2348418	0.647	rs10843210	chr12:28728733	T/C	cg13890972	chr12:28721907	NA	-0.39	-6.71	-0.34	8.21e-11	Lung function (FVC);Lung function (FEV1);
LUSC	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg21643547	chr1:205240462	TMCC2	-0.39	-6.88	-0.35	3.02e-11	Red blood cell count;
LUSC	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.44e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs983392	0.803	rs56189574	chr11:59933492	A/G	cg00673646	chr11:59950525	MS4A6A	-0.36	-5.79	-0.3	1.65e-8	Alzheimer's disease (late onset);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg08749455	chr11:72492538	STARD10	-0.54	-6.77	-0.35	5.68e-11	Cognitive function;Information processing speed;
LUSC	cis	rs6695223	0.571	rs4907133	chr1:85538947	A/G	cg11262906	chr1:85462892	MCOLN2	-0.57	-6.31	-0.33	8.97e-10	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg23887609	chr12:130822674	PIWIL1	0.49	7.27	0.37	2.65e-12	Menopause (age at onset);
LUSC	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg02753203	chr1:228287806	NA	1.0	19.71	0.73	6.59e-58	Diastolic blood pressure;
LUSC	cis	rs921665	0.831	rs11682390	chr2:3187698	G/A	cg02624386	chr2:3182749	NA	0.61	6.78	0.35	5.34e-11	World class endurance athleticism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16293131	chr17:79885702	LOC92659;MAFG	-0.4	-6.0	-0.31	5.21e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-8.49	-0.42	6.77e-16	Total body bone mineral density;
LUSC	cis	rs911119	1.000	rs1010117	chr20:23608421	G/C	cg16589663	chr20:23618590	CST3	0.59	6.96	0.36	1.8e-11	Chronic kidney disease;
LUSC	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg04374321	chr14:90722782	PSMC1	0.73	11.65	0.54	1.49e-26	Mortality in heart failure;
LUSC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs3740713	0.669	rs2896526	chr11:18419806	A/G	cg23797887	chr11:18477753	LDHAL6A	-0.49	-5.95	-0.31	6.69e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg03060546	chr3:49711283	APEH	0.65	7.62	0.38	2.68e-13	Menarche (age at onset);
LUSC	cis	rs9359856	0.956	rs6933010	chr6:90299879	G/C	cg13799429	chr6:90582589	CASP8AP2	0.56	6.44	0.33	4.08e-10	Bipolar disorder;
LUSC	cis	rs4776059	1.000	rs35372377	chr15:52882281	G/A	cg22715398	chr15:52968154	KIAA1370	-0.7	-10.02	-0.48	8.05e-21	Schizophrenia;
LUSC	cis	rs2041895	0.509	rs7970139	chr12:107312430	T/C	cg13944111	chr12:107296891	NA	0.38	6.63	0.34	1.32e-10	Glaucoma (low intraocular pressure);
LUSC	cis	rs9462027	0.651	rs1543559	chr6:34784104	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.74	-0.3	2.13e-8	Systemic lupus erythematosus;
LUSC	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.01	0.31	4.75e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs1858037	0.867	rs57913336	chr2:65587619	G/A	cg08085232	chr2:65598271	SPRED2	-0.4	-5.95	-0.31	6.88e-9	Rheumatoid arthritis;
LUSC	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg24881330	chr22:46731750	TRMU	0.86	7.79	0.39	8.78e-14	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg15147215	chr3:52552868	STAB1	-0.3	-5.84	-0.3	1.22e-8	Electroencephalogram traits;
LUSC	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.05	-0.91	1.39e-129	Myeloid white cell count;
LUSC	cis	rs12145833	0.596	rs12123491	chr1:243297924	C/G	cg02356786	chr1:243265016	LOC731275	0.71	6.64	0.34	1.29e-10	Obesity (early onset extreme);
LUSC	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg14582100	chr15:45693742	SPATA5L1	0.56	10.09	0.48	4.35e-21	Homoarginine levels;
LUSC	cis	rs8016982	0.633	rs72695758	chr14:81720146	T/C	cg01989461	chr14:81687754	GTF2A1	0.71	12.67	0.57	2.56e-30	Schizophrenia;
LUSC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg23711669	chr6:146136114	FBXO30	0.82	14.76	0.63	2.62e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg17340268	chr14:105411764	AHNAK2	-0.41	-6.63	-0.34	1.34e-10	Rheumatoid arthritis;
LUSC	cis	rs6967385	0.604	rs10258470	chr7:12331516	A/G	cg06484146	chr7:12443880	VWDE	0.41	6.54	0.34	2.26e-10	Response to taxane treatment (placlitaxel);
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg16649755	chr6:88412160	NCRNA00120;AKIRIN2	0.37	7.13	0.36	6.14e-12	Tuberculosis;
LUSC	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg05110241	chr16:68378359	PRMT7	-0.58	-6.72	-0.35	7.89e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg12560992	chr17:57184187	TRIM37	0.9	17.71	0.7	6.08e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs2303282	0.716	rs2587866	chr16:56403899	C/T	cg00500540	chr16:56394104	NA	-0.44	-7.55	-0.38	4.1e-13	Breast cancer;
LUSC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.14	0.36	5.71e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg15704280	chr7:45808275	SEPT13	-0.85	-14.29	-0.62	1.69e-36	Height;
LUSC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg11764359	chr7:65958608	NA	0.48	6.03	0.31	4.34e-9	Aortic root size;
LUSC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.07	0.48	5.27e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg14895029	chr7:2775587	GNA12	-0.36	-5.87	-0.31	1.08e-8	Height;
LUSC	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg12560992	chr17:57184187	TRIM37	0.58	9.31	0.45	1.76e-18	Testicular germ cell tumor;
LUSC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.8	0.3	1.5e-8	Menopause (age at onset);
LUSC	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg13010199	chr12:38710504	ALG10B	0.64	9.77	0.47	5.43e-20	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14454942	chr6:8064764	MUTED	-0.49	-6.37	-0.33	6.37e-10	Hepatitis;
LUSC	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg20891283	chr12:69753455	YEATS4	0.44	5.84	0.3	1.24e-8	Response to diuretic therapy;
LUSC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-6.91	-0.35	2.51e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.516	rs1866994	chr8:57990092	A/C	cg11062466	chr8:58055876	NA	0.39	5.82	0.3	1.37e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.04	-0.36	1.09e-11	Response to antipsychotic treatment;
LUSC	cis	rs13082711	0.911	rs73046191	chr3:27454398	T/A	cg02860705	chr3:27208620	NA	0.5	8.51	0.42	6.09e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg15485101	chr11:133734466	NA	0.41	7.37	0.37	1.31e-12	Childhood ear infection;
LUSC	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg04539111	chr16:67997858	SLC12A4	-0.38	-5.74	-0.3	2.17e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9650657	0.740	rs2277130	chr8:10677601	G/C	cg27411982	chr8:10470053	RP1L1	-0.4	-6.43	-0.33	4.33e-10	Neuroticism;
LUSC	cis	rs4654899	0.643	rs2053981	chr1:21227083	G/A	cg01072550	chr1:21505969	NA	-0.55	-8.28	-0.41	2.93e-15	Superior frontal gyrus grey matter volume;
LUSC	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg06671706	chr8:8559999	CLDN23	0.5	6.46	0.33	3.62e-10	Obesity-related traits;
LUSC	cis	rs2637266	0.626	rs2588329	chr10:78552782	C/T	cg18941641	chr10:78392320	NA	0.37	6.9	0.35	2.59e-11	Pulmonary function;
LUSC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.66	0.57	2.9e-30	Motion sickness;
LUSC	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.61	8.35	0.42	1.8e-15	Body mass index (adult);
LUSC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18404041	chr3:52824283	ITIH1	-0.52	-9.93	-0.48	1.52e-20	Bipolar disorder;
LUSC	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg13263323	chr15:86062960	AKAP13	-0.35	-5.72	-0.3	2.38e-8	Coronary artery disease;
LUSC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg06287003	chr12:125626642	AACS	-0.39	-6.39	-0.33	5.71e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2625529	0.668	rs72733369	chr15:72567260	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-7.11	-0.36	6.98e-12	Red blood cell count;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.68	10.47	0.5	2.3e-22	Lymphocyte counts;
LUSC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-1.01	-22.15	-0.77	1.61e-67	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg00343986	chr7:65444356	GUSB	-0.42	-6.44	-0.33	4.08e-10	Aortic root size;
LUSC	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.98	-13.86	-0.6	7.72e-35	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-7.08	-0.36	8.32e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9807841	0.670	rs2738042	chr19:10790143	C/G	cg09936142	chr19:10668400	KRI1	-0.42	-6.59	-0.34	1.69e-10	Inflammatory skin disease;
LUSC	cis	rs10045504	0.502	rs17352751	chr5:38737836	G/A	cg15396434	chr5:38725168	NA	-0.51	-5.65	-0.3	3.39e-8	Night sleep phenotypes;
LUSC	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg14458575	chr2:238380390	NA	0.66	11.7	0.54	1.01e-26	Prostate cancer;
LUSC	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	11.72	0.54	8.09e-27	Coronary artery disease;
LUSC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-6.55	-0.34	2.23e-10	Daytime sleep phenotypes;
LUSC	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg17173187	chr15:85201210	NMB	0.37	6.43	0.33	4.54e-10	Schizophrenia;
LUSC	cis	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg09307838	chr4:120376055	NA	0.49	7.57	0.38	3.72e-13	Diastolic blood pressure;
LUSC	cis	rs8051149	0.793	rs12445334	chr16:87871213	G/A	cg01412419	chr16:87856264	NA	0.46	6.67	0.34	1.04e-10	Blood metabolite levels;
LUSC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	8.86	0.44	4.9e-17	Alzheimer's disease;
LUSC	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg26897989	chr16:1907736	C16orf73	-0.43	-6.74	-0.35	6.99e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01494614	chr11:10562837	RNF141	-0.5	-5.98	-0.31	5.58e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg11812906	chr14:75593930	NEK9	-0.64	-10.92	-0.51	6.02e-24	Height;
LUSC	cis	rs17253792	0.822	rs78922774	chr14:56115302	T/A	cg01858014	chr14:56050164	KTN1	-0.8	-6.58	-0.34	1.79e-10	Putamen volume;
LUSC	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg14893161	chr1:205819251	PM20D1	-0.4	-5.84	-0.3	1.27e-8	Prostate-specific antigen levels;
LUSC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg07424592	chr7:64974309	NA	0.7	6.17	0.32	2e-9	Diabetic kidney disease;
LUSC	trans	rs11039798	1.000	rs7942042	chr11:48520270	A/G	cg15704280	chr7:45808275	SEPT13	0.71	6.65	0.34	1.21e-10	Axial length;
LUSC	cis	rs2667011	0.512	rs12373732	chr2:160814453	A/C	cg06573604	chr2:160760825	LY75	-0.46	-6.36	-0.33	6.68e-10	Bilirubin levels;
LUSC	cis	rs7680126	0.500	rs4640669	chr4:10145733	A/G	cg11266682	chr4:10021025	SLC2A9	0.42	5.66	0.3	3.28e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUSC	cis	rs16867335	1.000	rs35579320	chr2:181463612	T/C	cg23363182	chr2:181467187	NA	-0.46	-5.87	-0.31	1.05e-8	Survival in rectal cancer;
LUSC	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg12064134	chr16:90016061	DEF8	0.37	5.81	0.3	1.48e-8	Squamous cell carcinoma;
LUSC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.13	-0.41	8.55e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs9831754	0.865	rs9842838	chr3:78387904	A/C	cg06138941	chr3:78371609	NA	-0.66	-8.99	-0.44	1.89e-17	Calcium levels;
LUSC	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.71	-12.99	-0.58	1.63e-31	Ulcerative colitis;
LUSC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg18681998	chr4:17616180	MED28	0.83	14.9	0.63	7.49e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10021803	chr11:74660260	XRRA1;SPCS2	0.44	6.13	0.32	2.46e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.8	0.3	1.51e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs12439619	0.883	rs62012045	chr15:82521707	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.55	-8.31	-0.41	2.5e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1044826	0.642	rs6784684	chr3:139177634	T/C	cg15131784	chr3:139108705	COPB2	0.4	6.48	0.33	3.24e-10	Obesity-related traits;
LUSC	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg00852783	chr1:26633632	UBXN11	0.6	9.59	0.46	2.2e-19	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg23422044	chr7:1970798	MAD1L1	-0.66	-7.49	-0.38	6.29e-13	Bipolar disorder;
LUSC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.08	15.72	0.65	4.61e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1506636	1.000	rs2215553	chr7:123318478	G/T	cg03229431	chr7:123269106	ASB15	-0.64	-10.57	-0.5	1.05e-22	Plateletcrit;Platelet count;
LUSC	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg11993925	chr19:44307056	LYPD5	0.36	7.86	0.4	5.35e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs9473147	0.516	rs9381575	chr6:47528764	C/G	cg02130027	chr6:47444894	CD2AP	0.36	5.71	0.3	2.52e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-7.16	-0.36	5.27e-12	Mood instability;
LUSC	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg17031739	chr1:67600172	NA	0.44	6.87	0.35	3.22e-11	Psoriasis;
LUSC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.81	14.52	0.62	2.21e-37	Mean platelet volume;
LUSC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.51	0.53	4.61e-26	Prudent dietary pattern;
LUSC	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg06092702	chr1:163392909	NA	-0.46	-7.78	-0.39	9.17e-14	Motion sickness;
LUSC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg09238746	chr17:78121135	EIF4A3	-0.59	-8.77	-0.43	9.25e-17	Yeast infection;
LUSC	cis	rs2652822	0.935	rs12594313	chr15:63436662	A/G	cg02713581	chr15:63449717	RPS27L	0.42	6.53	0.34	2.39e-10	Metabolic traits;
LUSC	cis	rs17407555	0.520	rs4292327	chr4:9943700	G/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.66	-0.34	1.11e-10	Schizophrenia (age at onset);
LUSC	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg26647111	chr11:31128758	NA	0.43	6.11	0.32	2.77e-9	Bone mineral density (spine);
LUSC	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-14.0	-0.61	2.26e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg06002616	chr8:101225028	SPAG1	-0.44	-7.33	-0.37	1.73e-12	Atrioventricular conduction;
LUSC	cis	rs11610422	0.953	rs12824490	chr12:31414490	C/T	cg14306366	chr12:31406441	NA	-0.55	-6.6	-0.34	1.58e-10	Coronary artery disease;
LUSC	trans	rs62238980	0.522	rs117307005	chr22:32367511	C/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.03	-0.31	4.42e-9	Childhood ear infection;
LUSC	cis	rs9420	0.961	rs7116341	chr11:57481155	G/A	cg02958346	chr11:57425731	CLP1	-0.43	-6.28	-0.32	1.06e-9	Schizophrenia;
LUSC	cis	rs9403521	1.000	rs116980222	chr6:143998987	C/T	cg18240653	chr6:144019428	PHACTR2	-0.51	-6.16	-0.32	2.13e-9	Obesity-related traits;
LUSC	cis	rs2742234	0.794	rs17153156	chr10:43704637	C/G	cg15436174	chr10:43711423	RASGEF1A	0.34	6.23	0.32	1.41e-9	Hirschsprung disease;
LUSC	cis	rs28647808	0.881	rs7852803	chr9:136245903	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.91	0.35	2.42e-11	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg03676636	chr4:99064102	C4orf37	0.35	7.55	0.38	4.2e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs73198271	1.000	rs73198279	chr8:8608504	A/G	cg01851573	chr8:8652454	MFHAS1	0.58	8.0	0.4	2.04e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.75	-10.93	-0.51	5.59e-24	Body mass index;
LUSC	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg00376283	chr12:123451042	ABCB9	0.71	9.03	0.44	1.4e-17	Neutrophil percentage of white cells;
LUSC	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg22709100	chr7:91322751	NA	-0.4	-5.82	-0.3	1.37e-8	Breast cancer;
LUSC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg00310523	chr12:86230176	RASSF9	0.47	8.69	0.43	1.7e-16	Major depressive disorder;
LUSC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	8.96	0.44	2.3e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.36	6.0	0.31	5.26e-9	Neutrophil percentage of white cells;
LUSC	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg03909863	chr11:638404	DRD4	-0.41	-6.19	-0.32	1.81e-9	Systemic lupus erythematosus;
LUSC	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg13010199	chr12:38710504	ALG10B	0.67	10.23	0.49	1.56e-21	Bladder cancer;
LUSC	cis	rs4786125	0.920	rs6500852	chr16:6896649	A/G	cg03623568	chr16:6915990	A2BP1	-0.42	-6.99	-0.36	1.46e-11	Heart rate variability traits (SDNN);
LUSC	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.55	-5.67	-0.3	3.13e-8	Schizophrenia;
LUSC	cis	rs12618769	0.543	rs72819971	chr2:99034846	T/G	cg10123293	chr2:99228465	UNC50	0.48	8.07	0.4	1.28e-14	Bipolar disorder;
LUSC	trans	rs116175374	0.793	rs6727667	chr2:31431253	T/C	cg15543616	chr12:5019024	KCNA1	-0.77	-6.01	-0.31	4.9e-9	Endometriosis;
LUSC	cis	rs7569084	1.000	rs13385171	chr2:65661843	T/C	cg08085232	chr2:65598271	SPRED2	0.39	6.02	0.31	4.47e-9	Sum eosinophil basophil counts;
LUSC	cis	rs2901656	0.640	rs4916258	chr1:172413526	T/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.39	8.03	0.4	1.7e-14	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs9921338	0.961	rs11545336	chr16:11439496	G/A	cg00044050	chr16:11439710	C16orf75	-0.5	-6.62	-0.34	1.45e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg11062466	chr8:58055876	NA	0.7	8.6	0.43	3.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg03342759	chr3:160939853	NMD3	-0.45	-6.18	-0.32	1.87e-9	Parkinson's disease;
LUSC	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08645402	chr16:4508243	NA	-0.51	-8.68	-0.43	1.73e-16	Schizophrenia;
LUSC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	14.21	0.61	3.55e-36	Platelet count;
LUSC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	0.96	17.69	0.7	7.15e-50	Heart rate;
LUSC	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg25801113	chr15:45476975	SHF	0.34	7.0	0.36	1.37e-11	Uric acid levels;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09763514	chr7:2298050	SNX8	0.38	6.27	0.32	1.11e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs7013285	0.514	rs7833269	chr8:107390396	C/T	cg09394681	chr6:4482990	NA	0.41	5.96	0.31	6.5e-9	Paclitaxel disposition in epithelial ovarian cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01374398	chr3:47516975	SCAP	0.47	7.26	0.37	2.79e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg26924012	chr15:45694286	SPATA5L1	1.08	17.48	0.69	4.71e-49	Homoarginine levels;
LUSC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	16.82	0.68	1.96e-46	Platelet count;
LUSC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17712092	chr4:129076599	LARP1B	0.69	10.36	0.49	5.21e-22	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs9815354	0.812	rs4434125	chr3:42004681	A/G	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.21e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.53	-0.38	4.64e-13	Bipolar disorder and schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24305835	chr1:17380585	SDHB	0.44	6.02	0.31	4.49e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs611744	0.647	rs2298603	chr8:109271426	C/T	cg21045802	chr8:109455806	TTC35	0.41	6.53	0.34	2.4e-10	Dupuytren's disease;
LUSC	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg14227996	chr4:17616232	MED28	0.79	8.14	0.41	7.78e-15	Opioid sensitivity;
LUSC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.96	0.51	4.51e-24	Menopause (age at onset);
LUSC	cis	rs7512552	0.839	rs6703652	chr1:150465953	T/G	cg15654264	chr1:150340011	RPRD2	0.63	10.31	0.49	8.08e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7113850	0.541	rs7948382	chr11:24246608	T/C	ch.11.24196551F	chr11:24239977	NA	1.0	9.14	0.45	6.23e-18	Bone fracture in osteoporosis;
LUSC	cis	rs4851254	0.660	rs77023845	chr2:100712346	G/A	cg07810366	chr2:100720526	AFF3	-0.45	-5.92	-0.31	7.9e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.01	0.36	1.32e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.58	-0.42	3.75e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05170515	chr14:24899109	CBLN3;KHNYN	0.47	7.53	0.38	4.71e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs77972916	0.505	rs11899984	chr2:43578246	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-6.85	-0.35	3.6e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg08088566	chr11:430123	ANO9	0.67	7.35	0.37	1.56e-12	Body mass index;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19116747	chr5:149380656	HMGXB3;TIGD6	-0.52	-6.13	-0.32	2.43e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.93	-0.55	1.44e-27	Mean corpuscular volume;
LUSC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-5.65	-0.3	3.53e-8	Calcium levels;
LUSC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.8	12.59	0.57	5.15e-30	Menopause (age at onset);
LUSC	cis	rs11809207	1.000	rs55695238	chr1:26521931	C/G	cg00147160	chr1:26503991	CNKSR1	0.42	6.96	0.36	1.8e-11	Height;
LUSC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.72	-10.7	-0.51	3.58e-23	Menarche (age at onset);
LUSC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.84	0.39	6.15e-14	Prudent dietary pattern;
LUSC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.83	0.3	1.33e-8	Rheumatoid arthritis;
LUSC	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg15744005	chr10:104629667	AS3MT	-0.27	-5.71	-0.3	2.44e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9400467	0.528	rs456865	chr6:111632928	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.33	-6.14	-0.32	2.3e-9	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg12751644	chr20:60527061	NA	-0.33	-6.04	-0.31	4.14e-9	Body mass index;
LUSC	cis	rs240764	0.583	rs6905113	chr6:101209368	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.24	-0.32	1.32e-9	Neuroticism;
LUSC	cis	rs10276303	0.519	rs11768463	chr7:3396160	A/G	cg21248987	chr7:3385318	SDK1	-0.39	-6.63	-0.34	1.33e-10	Dupuytren's disease;
LUSC	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg08807101	chr21:30365312	RNF160	-0.52	-7.99	-0.4	2.28e-14	Dental caries;
LUSC	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg01629716	chr15:45996671	NA	0.4	6.06	0.31	3.68e-9	Waist circumference;Weight;
LUSC	cis	rs823156	1.000	rs823156	chr1:205764640	G/A	cg11965913	chr1:205819406	PM20D1	0.48	5.93	0.31	7.47e-9	Parkinson's disease;
LUSC	cis	rs9682041	0.627	rs3772172	chr3:170077713	C/T	cg11886554	chr3:170076028	SKIL	-0.68	-9.26	-0.45	2.64e-18	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LUSC	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg11584989	chr19:19387371	SF4	0.6	6.88	0.35	2.9100000000000002e-11	Bipolar disorder;
LUSC	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg15654264	chr1:150340011	RPRD2	0.61	10.04	0.48	6.57e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1018836	0.851	rs2023624	chr8:91618874	T/C	cg16814680	chr8:91681699	NA	-0.79	-13.33	-0.59	8.69e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05301818	chr8:125385252	TMEM65	0.49	7.66	0.39	2.08e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg14092571	chr14:90743983	NA	-0.36	-5.86	-0.31	1.11e-8	Mortality in heart failure;
LUSC	cis	rs11166629	0.606	rs7006582	chr8:135595463	C/T	cg27224718	chr8:135614730	ZFAT	0.54	7.72	0.39	1.37e-13	Smoking quantity;
LUSC	cis	rs4363385	0.531	rs11205188	chr1:153053645	A/T	cg25856811	chr1:152973957	SPRR3	-0.38	-6.21	-0.32	1.61e-9	Inflammatory skin disease;
LUSC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.59	0.34	1.76e-10	Menopause (age at onset);
LUSC	cis	rs11039100	0.573	rs11038960	chr11:5780740	T/C	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.97	0.31	6.23e-9	Schizophrenia;
LUSC	cis	rs2249625	0.545	rs2496495	chr6:72882414	G/A	cg18830697	chr6:72922368	RIMS1	-0.37	-7.38	-0.37	1.25e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg20628663	chr10:43360327	NA	-0.76	-11.02	-0.52	2.71e-24	Blood protein levels;
LUSC	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg13319975	chr6:146136371	FBXO30	-0.47	-7.1	-0.36	7.7e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72949976	0.646	rs1441170	chr2:214033563	A/G	cg08319019	chr2:214017104	IKZF2	-0.66	-10.59	-0.5	8.62e-23	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg10729496	chr3:10149963	C3orf24	0.55	7.23	0.37	3.39e-12	Alzheimer's disease;
LUSC	trans	rs1325195	0.920	rs451088	chr1:179222840	A/C	cg11624085	chr17:8464688	MYH10	-0.39	-6.43	-0.33	4.35e-10	IgE grass sensitization;
LUSC	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg08000102	chr2:233561755	GIGYF2	0.8	13.83	0.6	1.06e-34	Schizophrenia;
LUSC	cis	rs4766566	0.568	rs11065857	chr12:111739500	A/G	cg10833066	chr12:111807467	FAM109A	0.55	10.12	0.48	3.64e-21	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUSC	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg27661571	chr11:113659931	NA	-0.62	-7.4	-0.38	1.08e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.69	-0.3	2.73e-8	Bipolar disorder;
LUSC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	0.99	13.97	0.61	3.1e-35	Vitiligo;
LUSC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg22166914	chr1:53195759	ZYG11B	0.57	9.46	0.46	5.83e-19	Monocyte count;
LUSC	cis	rs6906287	0.647	rs7766375	chr6:118918269	G/A	cg21191810	chr6:118973309	C6orf204	0.33	6.01	0.31	4.83e-9	Electrocardiographic conduction measures;
LUSC	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg05754148	chr16:3507555	NAT15	0.79	9.61	0.47	1.9e-19	Tuberculosis;
LUSC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg03146154	chr1:46216737	IPP	0.56	8.35	0.42	1.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg05714579	chr10:131428358	MGMT	0.44	6.27	0.32	1.12e-9	Response to temozolomide;
LUSC	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg14843632	chr5:14870594	ANKH	-0.36	-6.88	-0.35	2.99e-11	Blood metabolite levels;
LUSC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.27e-9	Life satisfaction;
LUSC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg20203395	chr5:56204925	C5orf35	-0.78	-10.16	-0.49	2.61e-21	Type 2 diabetes;
LUSC	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg22782873	chr19:19639568	YJEFN3	0.52	6.59	0.34	1.76e-10	Bipolar disorder;
LUSC	cis	rs7666738	0.539	rs13150465	chr4:99094892	C/T	cg05340658	chr4:99064831	C4orf37	-0.52	-5.96	-0.31	6.33e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.76	-0.35	6.03e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs708547	0.533	rs3806746	chr4:57773330	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.47	-6.78	-0.35	5.54e-11	Response to bleomycin (chromatid breaks);
LUSC	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.71	-0.39	1.42e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg24375607	chr4:120327624	NA	0.76	11.09	0.52	1.51e-24	Corneal astigmatism;
LUSC	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg27535305	chr1:53392650	SCP2	-0.4	-7.57	-0.38	3.56e-13	Monocyte count;
LUSC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg11645453	chr3:52864694	ITIH4	0.36	8.35	0.42	1.84e-15	Bipolar disorder;
LUSC	cis	rs7572644	0.766	rs10180107	chr2:28240525	C/T	cg27432699	chr2:27873401	GPN1	0.53	6.72	0.35	7.63e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs3755132	0.929	rs4668951	chr2:15781195	A/G	cg12888861	chr2:15731646	DDX1	0.52	7.31	0.37	1.95e-12	Wilms tumor;
LUSC	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	6.73	0.35	7.57e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg21285383	chr16:89894308	SPIRE2	0.31	6.64	0.34	1.24e-10	Vitiligo;
LUSC	cis	rs244293	0.672	rs9901526	chr17:53012379	G/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-6.22	-0.32	1.51e-9	Menarche (age at onset);
LUSC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg06212747	chr3:49208901	KLHDC8B	0.43	5.83	0.3	1.33e-8	Parkinson's disease;
LUSC	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg16576597	chr16:28551801	NUPR1	0.34	6.87	0.35	3.15e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19717773	chr7:2847554	GNA12	-0.36	-6.15	-0.32	2.18e-9	Height;
LUSC	cis	rs4604732	0.631	rs4411161	chr1:247632374	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.77	0.35	5.85e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.29	6.33	0.33	7.88e-10	Coronary artery disease;
LUSC	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg09021430	chr5:549028	NA	-0.57	-7.3	-0.37	2.07e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9815354	0.597	rs60690674	chr3:41997811	G/C	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.42	5.02e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg20356878	chr3:121714668	ILDR1	0.47	6.57	0.34	1.95e-10	Multiple sclerosis;
LUSC	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg04310649	chr10:35416472	CREM	-0.42	-6.56	-0.34	2.01e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs4714291	0.832	rs2984431	chr6:39980900	T/A	cg02267698	chr19:7991119	CTXN1	-0.53	-7.8	-0.39	7.87e-14	Strep throat;
LUSC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg04450456	chr4:17643702	FAM184B	-0.37	-6.3	-0.33	9.46e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08219700	chr8:58056026	NA	0.56	7.73	0.39	1.27e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs2188420	0.688	rs1724278	chr7:106589230	T/C	cg04262465	chr14:101405693	SNORD113-6	-0.4	-6.11	-0.32	2.75e-9	Interferon gamma levels;
LUSC	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg06640241	chr16:89574553	SPG7	0.72	11.72	0.54	8.06e-27	Multiple myeloma (IgH translocation);
LUSC	cis	rs13114435	0.606	rs17272827	chr4:183825774	C/G	cg00486011	chr4:183851557	NA	-0.3	-5.93	-0.31	7.57e-9	Obesity-related traits;
LUSC	trans	rs477692	0.569	rs10764886	chr10:131310680	C/T	cg25636556	chr4:3505128	NA	0.3	5.95	0.31	6.61e-9	Response to temozolomide;
LUSC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs701145	0.617	rs9820619	chr3:154028294	G/T	cg17054900	chr3:154042577	DHX36	0.48	6.37	0.33	6.34e-10	Coronary artery disease;
LUSC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.19	-0.41	5.45e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6543140	0.929	rs11465700	chr2:103057668	G/A	cg09003973	chr2:102972529	NA	0.53	6.91	0.35	2.45e-11	Blood protein levels;
LUSC	cis	rs1044826	0.642	rs295481	chr3:139228811	C/T	cg00490450	chr3:139108681	COPB2	0.46	7.02	0.36	1.27e-11	Obesity-related traits;
LUSC	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg18854424	chr1:2615690	NA	0.51	10.34	0.49	6.36e-22	Ulcerative colitis;
LUSC	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-6.36	-0.33	6.77e-10	Response to antipsychotic treatment;
LUSC	trans	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.46	-0.38	7.39e-13	Myopia (pathological);
LUSC	cis	rs7572644	0.640	rs11127126	chr2:28023284	C/T	cg27432699	chr2:27873401	GPN1	0.57	7.4	0.38	1.15e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg13114125	chr14:105738426	BRF1	-0.94	-15.3	-0.64	2.1e-40	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	7.08	0.36	8.37e-12	Response to antipsychotic treatment;
LUSC	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg12317470	chr15:67143691	NA	0.65	9.12	0.45	6.97e-18	Lung cancer (smoking interaction);
LUSC	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg07169764	chr2:136633963	MCM6	1.06	15.67	0.65	7.43e-42	Corneal structure;
LUSC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg23601095	chr6:26197514	HIST1H3D	0.72	7.7	0.39	1.51e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs11608355	0.515	rs4766609	chr12:109973297	A/G	cg05360138	chr12:110035743	NA	0.93	12.3	0.56	5.99e-29	Neuroticism;
LUSC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.23	-0.32	1.42e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg11062466	chr8:58055876	NA	0.49	6.3	0.33	9.37e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg17178900	chr1:205818956	PM20D1	-0.44	-5.95	-0.31	6.81e-9	Parkinson's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19056515	chr10:105361785	SH3PXD2A	0.49	6.41	0.33	4.83e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg22467129	chr15:76604101	ETFA	-0.42	-6.67	-0.34	1.04e-10	Blood metabolite levels;
LUSC	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	ch.11.42038R	chr11:967971	AP2A2	0.54	7.96	0.4	2.73e-14	Alzheimer's disease (late onset);
LUSC	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg14458575	chr2:238380390	NA	0.58	6.82	0.35	4.36e-11	Prostate cancer;
LUSC	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	0.86	13.53	0.59	1.51e-33	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg16423285	chr20:60520624	NA	-0.47	-5.83	-0.3	1.3e-8	Body mass index;
LUSC	cis	rs9788682	0.655	rs578776	chr15:78888400	G/A	cg24631222	chr15:78858424	CHRNA5	0.61	9.17	0.45	5.03e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1050846	0.564	rs1050863	chr16:87440895	C/T	cg27585878	chr16:87386489	FBXO31	-0.41	-6.81	-0.35	4.42e-11	Neuroticism;
LUSC	cis	rs2286503	0.839	rs2270108	chr7:22862131	A/C	cg11367502	chr7:22862612	TOMM7	0.46	6.22	0.32	1.51e-9	Fibrinogen;
LUSC	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg00105475	chr2:10696890	NA	0.37	6.09	0.32	3.03e-9	Prostate cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21657490	chr7:150815391	AGAP3	0.49	6.13	0.32	2.5e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg03522245	chr20:25566470	NINL	-0.35	-5.78	-0.3	1.68e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg20283391	chr11:68216788	NA	0.51	7.38	0.37	1.3e-12	Total body bone mineral density;
LUSC	cis	rs113835537	0.529	rs11227525	chr11:66308065	T/G	cg24851651	chr11:66362959	CCS	0.53	7.77	0.39	1e-13	Airway imaging phenotypes;
LUSC	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg25019033	chr10:957182	NA	-0.51	-6.35	-0.33	7.22e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs4363385	0.719	rs6664411	chr1:152932857	T/C	cg00922841	chr1:152955080	SPRR1A	-0.41	-6.72	-0.34	8.01e-11	Inflammatory skin disease;
LUSC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.35	-5.71	-0.3	2.45e-8	Total body bone mineral density;
LUSC	trans	rs2262909	0.962	rs73019889	chr19:22277826	C/G	cg17074339	chr11:11642133	GALNTL4	0.44	6.76	0.35	6.13e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg06002616	chr8:101225028	SPAG1	-0.41	-6.9	-0.35	2.62e-11	Atrioventricular conduction;
LUSC	cis	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.43	-0.42	1.05e-15	Morning vs. evening chronotype;
LUSC	cis	rs2463822	0.669	rs72919484	chr11:62043430	T/C	cg06239285	chr11:62104954	ASRGL1	-0.75	-7.26	-0.37	2.74e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	12.84	0.57	6.13e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg21132104	chr15:45694354	SPATA5L1	0.4	5.8	0.3	1.54e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg03676636	chr4:99064102	C4orf37	0.29	6.11	0.32	2.76e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08704250	chr15:31115839	NA	-0.41	-6.3	-0.33	9.64e-10	Huntington's disease progression;
LUSC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	0.91	13.7	0.6	3.3e-34	Breast cancer;
LUSC	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg09491104	chr22:46646882	C22orf40	-0.56	-7.72	-0.39	1.33e-13	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg19676328	chr12:49525230	TUBA1B	-0.52	-7.48	-0.38	6.71e-13	Total cholesterol levels;
LUSC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-5.98	-0.31	5.87e-9	Personality dimensions;
LUSC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg17143192	chr8:8559678	CLDN23	-0.59	-8.79	-0.43	7.83e-17	Obesity-related traits;
LUSC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg26380479	chr7:97908229	NA	-0.26	-5.77	-0.3	1.78e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg09092052	chr15:45571596	NA	0.47	6.53	0.34	2.42e-10	Glomerular filtration rate;
LUSC	cis	rs1375194	0.606	rs935625	chr2:33811516	C/G	cg04131969	chr2:33951647	MYADML	-0.62	-8.67	-0.43	1.93e-16	Response to antidepressants in depression;
LUSC	trans	rs6076960	0.629	rs6054031	chr20:6233657	C/G	cg21095983	chr6:86352623	SYNCRIP	0.5	7.75	0.39	1.08e-13	Smooth-surface caries;
LUSC	cis	rs6087990	0.899	rs4911262	chr20:31393352	G/A	cg13636640	chr20:31349939	DNMT3B	0.97	21.38	0.76	1.61e-64	Ulcerative colitis;
LUSC	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.62	-0.34	1.44e-10	Monocyte percentage of white cells;
LUSC	cis	rs11229555	0.645	rs11229460	chr11:58208343	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg24642439	chr20:33292090	TP53INP2	0.45	6.45	0.33	4.04e-10	Height;
LUSC	trans	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg05926928	chr17:57297772	GDPD1	-0.91	-10.29	-0.49	9.37e-22	Opioid sensitivity;
LUSC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18404041	chr3:52824283	ITIH1	0.63	12.69	0.57	2.26e-30	Bipolar disorder;
LUSC	cis	rs727505	0.954	rs2170352	chr7:124605584	G/A	cg23710748	chr7:124431027	NA	-0.37	-6.57	-0.34	1.9e-10	Lewy body disease;
LUSC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	-0.45	-6.66	-0.34	1.12e-10	Systemic lupus erythematosus;
LUSC	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.73	-12.85	-0.58	5.45e-31	White blood cell count (basophil);
LUSC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg03146154	chr1:46216737	IPP	-0.51	-7.22	-0.37	3.47e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.1	0.36	7.61e-12	Cognitive ability;
LUSC	cis	rs62027291	0.846	rs56307118	chr15:77284742	G/C	cg26408565	chr15:76604113	ETFA	0.49	6.22	0.32	1.5e-9	Plateletcrit;
LUSC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg08270630	chr22:50330655	NA	0.37	5.66	0.3	3.2e-8	Schizophrenia;
LUSC	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg06623918	chr6:96969491	KIAA0776	-0.92	-17.08	-0.68	1.83e-47	Headache;
LUSC	trans	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg19862616	chr7:65841803	NCRNA00174	0.8	9.01	0.44	1.59e-17	Eotaxin levels;
LUSC	trans	rs62238980	0.614	rs74450300	chr22:32403780	C/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg16339924	chr4:17578868	LAP3	0.51	7.78	0.39	9.33e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2580764	0.515	rs7570629	chr2:55255935	A/T	cg09592903	chr2:55203963	RTN4	-0.5	-10.27	-0.49	1.14e-21	Mean platelet volume;
LUSC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg09796270	chr17:17721594	SREBF1	0.42	7.47	0.38	7.26e-13	Total body bone mineral density;
LUSC	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg19824325	chr16:58548873	SETD6	0.93	9.11	0.45	7.52e-18	Schizophrenia;
LUSC	trans	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg27275811	chr11:74457193	NA	-0.64	-6.16	-0.32	2.07e-9	Type 2 diabetes nephropathy;
LUSC	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.18	-0.32	1.81e-9	Alcohol dependence;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg12204362	chr12:98910117	TMPO;LOC100128191	0.48	6.62	0.34	1.43e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg13057898	chr1:3703894	LRRC47	0.48	8.74	0.43	1.17e-16	Red cell distribution width;
LUSC	cis	rs9653442	0.593	rs6737502	chr2:100862903	C/T	cg22139774	chr2:100720529	AFF3	-0.39	-6.45	-0.33	3.95e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs926938	0.505	rs360629	chr1:115414733	A/G	cg12756093	chr1:115239321	AMPD1	0.45	6.53	0.34	2.45e-10	Autism;
LUSC	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg01579765	chr21:45077557	HSF2BP	0.53	10.88	0.51	8.64e-24	Mean corpuscular volume;
LUSC	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-7.04	-0.36	1.11e-11	Mood instability;
LUSC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	7.55	0.38	4.28e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg21782813	chr7:2030301	MAD1L1	0.37	6.1	0.32	3e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6426558	0.502	rs2813970	chr1:227410637	C/T	cg10327440	chr1:227177885	CDC42BPA	0.55	7.35	0.37	1.54e-12	Neutrophil percentage of white cells;
LUSC	cis	rs71636778	0.543	rs34409791	chr1:27245363	A/G	cg12203394	chr1:27248618	NUDC	0.53	5.65	0.3	3.47e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	9.16	0.45	5.28e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg24585782	chr17:78113791	EIF4A3	-0.53	-7.88	-0.4	4.79e-14	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3772130	0.603	rs10470410	chr3:121434977	G/T	cg20356878	chr3:121714668	ILDR1	0.51	8.14	0.41	7.72e-15	Cognitive performance;
LUSC	cis	rs2067615	0.524	rs1882543	chr12:107067160	A/G	cg19260189	chr12:106995001	RFX4	-0.24	-6.11	-0.32	2.7e-9	Heart rate;
LUSC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg22868518	chr11:507468	RNH1	0.59	5.81	0.3	1.44e-8	Body mass index;
LUSC	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg09699651	chr6:150184138	LRP11	0.44	7.06	0.36	9.92e-12	Lung cancer;
LUSC	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.22	-0.41	4.42e-15	Morning vs. evening chronotype;
LUSC	cis	rs16910800	1.000	rs2468649	chr11:23200963	T/C	cg20040320	chr11:23191996	NA	0.44	6.47	0.33	3.59e-10	Cancer;
LUSC	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.43	6.67	0.34	1.06e-10	Dupuytren's disease;
LUSC	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg05368731	chr17:41323189	NBR1	0.92	13.01	0.58	1.44e-31	Menopause (age at onset);
LUSC	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg13010199	chr12:38710504	ALG10B	0.65	9.76	0.47	5.95e-20	Bladder cancer;
LUSC	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg12935359	chr14:103987150	CKB	0.51	8.08	0.4	1.17e-14	Body mass index;
LUSC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg09365446	chr1:150670422	GOLPH3L	-0.43	-6.42	-0.33	4.69e-10	Tonsillectomy;
LUSC	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg26395211	chr5:140044315	WDR55	0.45	6.98	0.36	1.6e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg00857998	chr1:205179979	DSTYK	0.61	9.17	0.45	4.95e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7215564	0.643	rs59992540	chr17:78658265	G/A	cg23238734	chr17:78661607	RPTOR	0.48	6.16	0.32	2.07e-9	Myopia (pathological);
LUSC	cis	rs7712401	0.601	rs371604	chr5:122318432	C/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.53	-0.46	3.35e-19	Mean platelet volume;
LUSC	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg12698349	chr2:225449008	CUL3	0.84	13.4	0.59	4.48e-33	Schizophrenia;
LUSC	cis	rs17401966	0.540	rs6541094	chr1:10467074	G/A	cg19773385	chr1:10388646	KIF1B	-0.42	-7.3	-0.37	2.11e-12	Hepatocellular carcinoma;
LUSC	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	9.74	0.47	6.87e-20	Mood instability;
LUSC	trans	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg26043149	chr18:55253948	FECH	0.49	7.22	0.37	3.43e-12	Bone mineral density;
LUSC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg00431813	chr7:1051703	C7orf50	0.38	6.08	0.32	3.33e-9	Longevity;Endometriosis;
LUSC	cis	rs7605827	0.930	rs3732004	chr2:15713783	C/T	cg19274914	chr2:15703543	NA	0.46	8.9	0.44	3.68e-17	Educational attainment (years of education);
LUSC	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.13	-0.32	2.47e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg00149659	chr3:10157352	C3orf10	-0.64	-9.53	-0.46	3.24e-19	Alzheimer's disease;
LUSC	trans	rs12439619	0.693	rs17269819	chr15:82467001	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.44	-6.22	-0.32	1.46e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg27266027	chr21:40555129	PSMG1	0.43	6.19	0.32	1.76e-9	Cognitive function;
LUSC	cis	rs4851254	0.517	rs13020141	chr2:100653842	G/A	cg22139774	chr2:100720529	AFF3	-0.45	-5.91	-0.31	8.36e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06656553	chr16:89960601	TCF25	-0.64	-5.66	-0.3	3.2e-8	Skin colour saturation;
LUSC	cis	rs7561273	0.722	rs12713161	chr2:24280682	T/C	cg06627628	chr2:24431161	ITSN2	-0.4	-5.72	-0.3	2.4e-8	Quantitative traits;
LUSC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs11677370	0.603	rs10171309	chr2:3851690	C/T	cg17052675	chr2:3827356	NA	-0.62	-10.02	-0.48	7.61e-21	Type 2 diabetes;
LUSC	cis	rs7432375	0.610	rs28458819	chr3:136522314	A/G	cg21827317	chr3:136751795	NA	0.32	5.67	0.3	3.03e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12530845	0.945	rs76298187	chr7:135334534	A/G	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg26513180	chr16:89883248	FANCA	-0.9	-17.47	-0.69	5.26e-49	Vitiligo;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25347033	chr10:105881828	C10orf78	-0.44	-6.44	-0.33	4.2e-10	Electrocardiographic conduction measures;
LUSC	trans	rs17076896	0.881	rs36213076	chr13:19757647	C/T	cg01891818	chr17:73008509	ICT1	0.5	6.17	0.32	1.97e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	trans	rs979233	0.502	rs276272	chr5:42075482	C/G	cg07010552	chr17:7358735	CHRNB1	-0.41	-6.09	-0.32	3.15e-9	Systemic lupus erythematosus;
LUSC	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg24006582	chr15:45444508	DUOX1	-0.62	-9.1	-0.45	8.07e-18	Uric acid levels;
LUSC	cis	rs11648785	0.661	rs870856	chr16:90089463	C/G	cg05270750	chr16:90143788	PRDM7	0.44	5.97	0.31	5.96e-9	Tanning;
LUSC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg15790184	chr11:494944	RNH1	0.58	6.16	0.32	2.09e-9	Body mass index;
LUSC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06022373	chr22:39101656	GTPBP1	0.84	14.01	0.61	2.07e-35	Menopause (age at onset);
LUSC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg10560079	chr2:191398806	TMEM194B	0.51	8.31	0.41	2.48e-15	Pulse pressure;
LUSC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.11	16.38	0.67	1.12e-44	Gut microbiome composition (summer);
LUSC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.07	0.48	5.28e-21	Electroencephalogram traits;
LUSC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg26597838	chr10:835615	NA	-0.48	-6.42	-0.33	4.73e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg00255919	chr5:131827918	IRF1	0.43	8.24	0.41	3.88e-15	Asthma (sex interaction);
LUSC	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg00310523	chr12:86230176	RASSF9	0.35	6.28	0.33	1.03e-9	Major depressive disorder;
LUSC	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg23950597	chr19:37808831	NA	-0.65	-7.91	-0.4	3.76e-14	Coronary artery calcification;
LUSC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-1.07	-24.21	-0.8	1.77e-75	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg10792982	chr14:105748885	BRF1	0.46	8.21	0.41	4.9e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.66	-12.3	-0.56	6.3e-29	Type 2 diabetes;
LUSC	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg11861562	chr11:117069780	TAGLN	0.32	6.22	0.32	1.45e-9	Blood protein levels;
LUSC	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.48	-0.42	7.6e-16	Systolic blood pressure;
LUSC	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.71	11.43	0.53	9.06e-26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUSC	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg12473912	chr3:136751656	NA	0.39	6.82	0.35	4.16e-11	Neuroticism;
LUSC	cis	rs11867934	0.773	rs2090018	chr17:17020967	A/G	cg26176665	chr17:16994978	MPRIP	-0.4	-5.68	-0.3	2.9e-8	Diabetic retinopathy;
LUSC	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg17507749	chr15:85114479	UBE2QP1	0.65	8.1	0.41	1.05e-14	Schizophrenia;
LUSC	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.05	-0.44	1.22e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg04287289	chr16:89883240	FANCA	-0.44	-6.33	-0.33	7.69e-10	Vitiligo;
LUSC	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg18753928	chr3:113234510	CCDC52	-0.5	-7.53	-0.38	4.89e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.6	8.0	0.4	2.09e-14	High light scatter reticulocyte count;
LUSC	trans	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg10756647	chr7:56101905	PSPH	0.89	8.89	0.44	3.83e-17	Diabetic kidney disease;
LUSC	trans	rs72674100	1.000	rs28804793	chr4:97962269	T/C	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	1.0	15.73	0.65	4.13e-42	Menopause (age at onset);
LUSC	cis	rs2742417	0.609	rs2673066	chr3:45771200	C/T	cg04837898	chr3:45731254	SACM1L	-0.44	-7.06	-0.36	9.42e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2067615	0.579	rs6539283	chr12:107222989	C/T	cg15890332	chr12:107067104	RFX4	0.35	6.21	0.32	1.55e-9	Heart rate;
LUSC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg08847533	chr14:75593920	NEK9	-0.8	-13.76	-0.6	1.92e-34	Height;
LUSC	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.3	-0.37	2.1e-12	Bipolar disorder;
LUSC	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg13256891	chr4:100009986	ADH5	-0.45	-6.23	-0.32	1.43e-9	Alcohol dependence;
LUSC	trans	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.47	-0.38	6.98e-13	Menarche (age at onset);
LUSC	cis	rs6690583	0.623	rs12047435	chr1:85452927	T/G	cg11262906	chr1:85462892	MCOLN2	0.68	6.58	0.34	1.82e-10	Serum sulfate level;
LUSC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.27	0.52	3.49e-25	Menopause (age at onset);
LUSC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.78	14.72	0.63	3.88e-38	Longevity;
LUSC	cis	rs4478858	0.684	rs11579845	chr1:31736248	A/G	cg00250761	chr1:31883323	NA	-0.32	-7.77	-0.39	9.54e-14	Alcohol dependence;
LUSC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg02018176	chr4:1364513	KIAA1530	0.51	8.65	0.43	2.19e-16	Obesity-related traits;
LUSC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.44	-7.61	-0.38	2.87e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.65	0.3	3.4e-8	Breast cancer;
LUSC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.5	6.07	0.32	3.48e-9	Renal function-related traits (BUN);
LUSC	cis	rs2354432	0.556	rs2353977	chr1:146839637	G/T	cg25205988	chr1:146714368	CHD1L	0.85	7.61	0.38	2.86e-13	Mitochondrial DNA levels;
LUSC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg26338869	chr17:61819248	STRADA	0.4	5.75	0.3	1.99e-8	Prudent dietary pattern;
LUSC	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg23093090	chr10:104574429	C10orf26	-0.43	-7.67	-0.39	1.86e-13	Arsenic metabolism;
LUSC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg08888203	chr3:10149979	C3orf24	0.59	8.1	0.41	1.08e-14	Alzheimer's disease;
LUSC	cis	rs1461503	0.900	rs7110039	chr11:122834001	C/T	cg27398637	chr11:122830231	C11orf63	0.44	6.97	0.36	1.66e-11	Menarche (age at onset);
LUSC	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.53	-0.34	2.39e-10	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11564042	chr3:150479915	SIAH2	0.44	6.71	0.34	8.47e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6543140	0.964	rs6543143	chr2:103085420	A/C	cg09003973	chr2:102972529	NA	0.53	6.75	0.35	6.5500000000000006e-11	Blood protein levels;
LUSC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.07	-0.48	5.45e-21	Hemoglobin concentration;
LUSC	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg24503407	chr1:205819492	PM20D1	0.42	5.73	0.3	2.23e-8	Parkinson's disease;
LUSC	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.55	-0.34	2.15e-10	Electroencephalogram traits;
LUSC	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg11693508	chr17:37793320	STARD3	0.53	6.48	0.33	3.31e-10	Bipolar disorder;
LUSC	cis	rs7804356	0.861	rs10262414	chr7:26854266	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.26	0.37	2.74e-12	Blood metabolite levels;
LUSC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.4	-0.38	1.09e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4713118	0.824	rs2092075	chr6:27749330	G/C	cg20933634	chr6:27740509	NA	0.42	5.89	0.31	9.49e-9	Parkinson's disease;
LUSC	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg15704280	chr7:45808275	SEPT13	0.63	7.17	0.37	5e-12	Axial length;
LUSC	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.36	-0.33	6.82e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs617219	0.853	rs7448481	chr5:78507410	C/T	cg24856658	chr5:78533917	JMY	-0.3	-5.86	-0.31	1.13e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg15691649	chr6:25882328	NA	-0.39	-6.37	-0.33	6.13e-10	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.58	0.38	3.45e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-9.54	-0.46	3.03e-19	Brugada syndrome;
LUSC	cis	rs9341808	0.519	rs3805872	chr6:81035102	G/A	cg08355045	chr6:80787529	NA	-0.44	-7.51	-0.38	5.61e-13	Sitting height ratio;
LUSC	cis	rs240764	0.817	rs239249	chr6:101087081	G/A	cg09795085	chr6:101329169	ASCC3	0.41	5.94	0.31	7.1e-9	Neuroticism;
LUSC	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg06223162	chr1:101003688	GPR88	-0.48	-9.03	-0.44	1.4e-17	Monocyte count;
LUSC	cis	rs4363385	0.740	rs1697428	chr1:153015761	C/A	cg24667326	chr1:152973720	SPRR3	-0.35	-5.8	-0.3	1.54e-8	Inflammatory skin disease;
LUSC	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg09654669	chr8:57350985	NA	0.57	7.64	0.39	2.39e-13	Obesity-related traits;
LUSC	cis	rs1395	1.000	rs6717980	chr2:27452784	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.38	6.34	0.33	7.53e-10	Blood metabolite levels;
LUSC	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.54	-8.1	-0.41	1.01e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.84	-0.44	5.51e-17	Bipolar disorder;
LUSC	cis	rs9341808	0.718	rs35447745	chr6:80816748	T/C	cg08355045	chr6:80787529	NA	0.56	9.6	0.46	2.04e-19	Sitting height ratio;
LUSC	cis	rs7246967	0.611	rs4933019	chr19:22831986	A/G	cg23217946	chr19:22817039	ZNF492	0.45	6.04	0.31	4.09e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	7.93	0.4	3.22e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs897080	0.515	rs786401	chr2:44712069	G/A	cg00619915	chr2:44497795	NA	-0.44	-6.35	-0.33	7.09e-10	Height;
LUSC	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg01420254	chr6:26195488	NA	0.71	7.5	0.38	5.86e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-5.94	-0.31	7.26e-9	Resting heart rate;
LUSC	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.38	5.89	0.31	9.33e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.97	-0.36	1.73e-11	Lung cancer;
LUSC	cis	rs9653442	0.545	rs1821827	chr2:100764717	T/C	cg07810366	chr2:100720526	AFF3	-0.45	-7.68	-0.39	1.83e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs909002	0.849	rs6663012	chr1:32091779	T/G	cg01639898	chr1:32083012	HCRTR1	0.28	6.61	0.34	1.48e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16386425	chr10:429943	DIP2C	-0.46	-7.36	-0.37	1.42e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs9392556	0.829	rs612022	chr6:4126916	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-6.43	-0.33	4.52e-10	Blood metabolite levels;
LUSC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	0.94	12.48	0.56	1.37e-29	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.13	0.55	2.54e-28	Cognitive test performance;
LUSC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.73	-11.01	-0.52	2.85e-24	Menarche (age at onset);
LUSC	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.6	9.18	0.45	4.46e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg24977338	chr2:113188963	RGPD8;RGPD5	0.5	5.76	0.3	1.86e-8	Yeast infection;
LUSC	cis	rs7216064	0.953	rs4791046	chr17:65851973	G/A	cg12091567	chr17:66097778	LOC651250	-0.7	-8.99	-0.44	1.81e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.23e-28	Corneal astigmatism;
LUSC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-0.93	-18.94	-0.72	7.35e-55	Dental caries;
LUSC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg03146154	chr1:46216737	IPP	0.51	7.41	0.38	1.03e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18641478	chr19:17970431	RPL18AP3;RPL18A	-0.4	-6.03	-0.31	4.45e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	9.63	0.47	1.56e-19	Mean platelet volume;
LUSC	trans	rs2700987	0.692	rs1882079	chr7:37391266	C/T	cg26076750	chr5:98105150	RGMB	-0.36	-6.61	-0.34	1.5e-10	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg15649852	chr7:65879115	NA	-0.42	-5.83	-0.3	1.3e-8	Aortic root size;
LUSC	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg02023728	chr11:77925099	USP35	0.46	7.01	0.36	1.29e-11	Testicular germ cell tumor;
LUSC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg16339924	chr4:17578868	LAP3	0.54	8.27	0.41	3.22e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19096424	chr1:120255104	PHGDH	0.44	6.03	0.31	4.29e-9	Blood metabolite levels;
LUSC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg05347473	chr6:146136440	FBXO30	0.54	9.33	0.45	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs10743315	0.643	rs17505214	chr12:19307139	A/G	cg02471346	chr12:19282374	PLEKHA5	0.79	6.52	0.34	2.53e-10	Gut microbiota (bacterial taxa);
LUSC	cis	rs12681287	0.640	rs13256765	chr8:87457833	C/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.2	0.49	1.94e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg05347473	chr6:146136440	FBXO30	0.57	9.88	0.48	2.24e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.24	0.45	3.04e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4072705	0.967	rs4076333	chr9:127385609	A/G	cg13476313	chr9:127244764	NR5A1	0.3	5.84	0.3	1.21e-8	Menarche (age at onset);
LUSC	cis	rs17102423	0.623	rs2093989	chr14:65553939	C/T	cg11161011	chr14:65562177	MAX	-0.74	-11.07	-0.52	1.79e-24	Obesity-related traits;
LUSC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg24920358	chr1:40204285	PPIE	0.59	10.15	0.49	2.79e-21	Blood protein levels;
LUSC	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg22674798	chr1:3096360	PRDM16	0.31	7.07	0.36	8.95e-12	Migraine;
LUSC	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg25214090	chr10:38739885	LOC399744	0.52	7.54	0.38	4.52e-13	Corneal astigmatism;
LUSC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.99	0.4	2.18e-14	Prudent dietary pattern;
LUSC	cis	rs12545109	0.800	rs2118261	chr8:57393286	A/G	cg09654669	chr8:57350985	NA	0.51	6.78	0.35	5.58e-11	Obesity-related traits;
LUSC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg15534755	chr11:117069859	TAGLN	-0.35	-6.13	-0.32	2.46e-9	Blood protein levels;
LUSC	cis	rs6495367	1.000	rs1007366	chr15:79379541	G/A	cg17916960	chr15:79447300	NA	0.36	6.64	0.34	1.27e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg02569458	chr12:86230093	RASSF9	0.52	8.61	0.43	2.94e-16	Major depressive disorder;
LUSC	cis	rs5758511	0.573	rs5996074	chr22:42236337	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-7.42	-0.38	9.64e-13	Birth weight;
LUSC	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	13.29	0.59	1.19e-32	Blood protein levels;
LUSC	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg24579218	chr15:68104479	NA	-0.36	-6.21	-0.32	1.55e-9	Restless legs syndrome;
LUSC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	0.93	16.81	0.68	2.16e-46	Cognitive function;
LUSC	cis	rs17540621	1.000	rs71423932	chr2:47202613	G/C	cg23978866	chr2:47230407	TTC7A	-0.71	-5.7	-0.3	2.7e-8	Response to statin therapy;
LUSC	cis	rs6961069	0.621	rs34801616	chr7:80240512	T/C	cg04458919	chr7:80252533	CD36	-0.42	-7.29	-0.37	2.23e-12	Platelet count;
LUSC	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg20701182	chr2:24300061	SF3B14	0.56	6.05	0.31	3.84e-9	Lymphocyte counts;
LUSC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.53	-9.27	-0.45	2.33e-18	Bipolar disorder;
LUSC	cis	rs6669072	0.565	rs992544	chr1:91278411	A/T	cg08895590	chr1:91227319	NA	-0.26	-5.67	-0.3	3.03e-8	Cognitive function;
LUSC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg08132940	chr7:1081526	C7orf50	-0.49	-6.17	-0.32	2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg10523860	chr14:103875565	MARK3	-0.36	-5.8	-0.3	1.54e-8	Body mass index;
LUSC	cis	rs10904908	0.931	rs7903137	chr10:17259567	C/T	cg01003015	chr10:17271136	VIM	-0.43	-6.2	-0.32	1.66e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.11	-0.36	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg02503808	chr4:7069936	GRPEL1	1.04	14.7	0.63	4.56e-38	Monocyte percentage of white cells;
LUSC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs11625487	0.609	rs74063206	chr14:77981045	C/T	cg16049707	chr14:77965284	ISM2	-0.59	-6.19	-0.32	1.81e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg02951883	chr7:2050386	MAD1L1	-0.59	-11.17	-0.52	8.06e-25	Bipolar disorder and schizophrenia;
LUSC	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg24375607	chr4:120327624	NA	0.69	10.92	0.51	6.06e-24	Educational attainment;
LUSC	cis	rs7712401	0.546	rs10044921	chr5:122179357	C/G	cg19077854	chr5:122220652	SNX24	0.4	8.86	0.44	4.98e-17	Mean platelet volume;
LUSC	trans	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg26811252	chr16:29126840	RRN3P2	0.57	9.15	0.45	5.58e-18	Menopause (age at onset);
LUSC	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg23093090	chr10:104574429	C10orf26	-0.39	-7.26	-0.37	2.75e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	0.96	16.31	0.67	2.17e-44	Menopause (age at onset);
LUSC	cis	rs2594989	0.779	rs2596815	chr3:11594930	A/G	cg00170343	chr3:11313890	ATG7	-0.49	-6.17	-0.32	1.94e-9	Circulating chemerin levels;
LUSC	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.88	-0.31	9.79e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.61e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg18135555	chr8:22132992	PIWIL2	0.38	7.59	0.38	3.33e-13	Hypertriglyceridemia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14138432	chr3:196295511	WDR53;FBXO45	-0.4	-5.95	-0.31	6.76e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6601327	0.586	rs6601340	chr8:9461315	A/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.41	-0.33	5.04e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg03676636	chr4:99064102	C4orf37	-0.31	-6.57	-0.34	1.92e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg02569458	chr12:86230093	RASSF9	0.48	7.64	0.39	2.37e-13	Major depressive disorder;
LUSC	cis	rs7605827	0.930	rs765432	chr2:15561440	C/T	cg19274914	chr2:15703543	NA	-0.48	-9.32	-0.45	1.6e-18	Educational attainment (years of education);
LUSC	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg04586622	chr2:25135609	ADCY3	0.42	8.87	0.44	4.48e-17	Body mass index;
LUSC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg03289416	chr15:75166202	SCAMP2	0.45	6.87	0.35	3.13e-11	Breast cancer;
LUSC	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg00277334	chr10:82204260	NA	-0.59	-9.81	-0.47	4.05e-20	Post bronchodilator FEV1;
LUSC	cis	rs617219	0.819	rs6889383	chr5:78597058	T/C	cg24856658	chr5:78533917	JMY	0.3	5.93	0.31	7.68e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00166722	chr3:10149974	C3orf24	0.56	7.54	0.38	4.61e-13	Alzheimer's disease;
LUSC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg20821713	chr7:1055600	C7orf50	-0.48	-6.23	-0.32	1.37e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs9653442	0.564	rs10197987	chr2:100790783	A/T	cg07810366	chr2:100720526	AFF3	-0.42	-7.1	-0.36	7.37e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg12564285	chr5:131593104	PDLIM4	0.44	8.13	0.41	8.6e-15	Breast cancer;
LUSC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.29	-0.41	2.74e-15	Cystic fibrosis severity;
LUSC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.62	-10.52	-0.5	1.51e-22	IgG glycosylation;
LUSC	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg24562669	chr7:97807699	LMTK2	-0.48	-8.44	-0.42	1.01e-15	Breast cancer;
LUSC	trans	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg04995722	chr7:26192034	NFE2L3	0.39	6.24	0.32	1.33e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs597583	0.789	rs3741280	chr11:117403235	G/T	cg00716016	chr9:3180374	NA	-0.39	-6.1	-0.32	2.92e-9	Putamen volume;
LUSC	trans	rs6601327	0.585	rs11249934	chr8:9510830	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.45	0.33	3.85e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs2692947	0.673	rs4907279	chr2:96399968	G/C	cg22654517	chr2:96458247	NA	0.35	6.51	0.34	2.71e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg25456477	chr12:86230367	RASSF9	0.44	7.8	0.39	8.08e-14	Major depressive disorder;
LUSC	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg22709100	chr7:91322751	NA	0.39	5.8	0.3	1.56e-8	Breast cancer;
LUSC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.16	0.36	5.3e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg16482183	chr6:26056742	HIST1H1C	0.78	9.86	0.47	2.69e-20	Iron status biomarkers;
LUSC	cis	rs11229555	0.645	rs4347409	chr11:58176252	C/T	cg15696309	chr11:58395628	NA	0.62	7.86	0.4	5.41e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6987853	0.933	rs2974355	chr8:42414117	C/T	cg09913449	chr8:42400586	C8orf40	0.49	8.2	0.41	5.31e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg04155289	chr7:94953770	PON1	-0.36	-6.12	-0.32	2.56e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.71	-12.51	-0.56	1.04e-29	White blood cell count (basophil);
LUSC	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg02023728	chr11:77925099	USP35	-0.45	-6.96	-0.36	1.76e-11	Testicular germ cell tumor;
LUSC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.14	-0.8	3.2e-75	Height;
LUSC	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg20744362	chr22:50050164	C22orf34	0.38	7.24	0.37	3.08e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	1.05	18.78	0.72	3.21e-54	Parkinson's disease;
LUSC	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs73001065	0.636	rs56241616	chr19:19506092	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	8.75	0.43	1.11e-16	LDL cholesterol;
LUSC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg20283391	chr11:68216788	NA	0.57	8.04	0.4	1.55e-14	Total body bone mineral density;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23797073	chr6:15663448	DTNBP1	0.43	7.04	0.36	1.13e-11	Triglycerides;
LUSC	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg20713898	chr8:124780851	FAM91A1	-0.55	-7.51	-0.38	5.55e-13	Pancreatic cancer;
LUSC	cis	rs977987	0.806	rs8050769	chr16:75388434	C/T	cg03315344	chr16:75512273	CHST6	0.51	9.67	0.47	1.19e-19	Dupuytren's disease;
LUSC	cis	rs7246967	0.673	rs67631531	chr19:22830466	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg16512390	chr1:228756714	NA	0.63	8.02	0.4	1.8e-14	Chronic lymphocytic leukemia;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18110333	chr6:292329	DUSP22	0.74	12.28	0.56	7.11e-29	Menopause (age at onset);
LUSC	cis	rs9583531	0.843	rs7999702	chr13:111382264	A/C	cg24331049	chr13:111365604	ING1	-0.64	-7.53	-0.38	4.93e-13	Coronary artery disease;
LUSC	cis	rs9951602	0.850	rs56367211	chr18:76677563	G/T	cg00806245	chr18:76673096	NA	0.43	6.0	0.31	5.08e-9	Obesity-related traits;
LUSC	cis	rs7712401	0.715	rs424262	chr5:122348012	G/A	cg19077854	chr5:122220652	SNX24	-0.41	-8.85	-0.44	5.29e-17	Mean platelet volume;
LUSC	cis	rs7178572	1.000	rs952472	chr15:77776562	A/C	cg22256960	chr15:77711686	NA	-0.55	-9.2	-0.45	4.07e-18	Type 2 diabetes;
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.92	18.09	0.7	1.88e-51	Menarche (age at onset);
LUSC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16680214	chr1:154839983	KCNN3	-0.54	-10.34	-0.49	6.5e-22	Prostate cancer;
LUSC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg06008330	chr7:65541103	ASL	0.4	6.19	0.32	1.77e-9	Aortic root size;
LUSC	cis	rs1904096	0.506	rs13434570	chr4:95168019	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.34	-0.41	2.03e-15	Type 2 diabetes;
LUSC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg11608241	chr8:8085544	FLJ10661	0.44	6.2	0.32	1.63e-9	Neuroticism;
LUSC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg11632617	chr15:75315747	PPCDC	-0.52	-6.73	-0.35	7.58e-11	Blood trace element (Zn levels);
LUSC	cis	rs9462027	0.628	rs9462026	chr6:34797033	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.76	-0.3	1.86e-8	Systemic lupus erythematosus;
LUSC	cis	rs10740039	0.671	rs7919726	chr10:62449506	T/C	cg18175470	chr10:62150864	ANK3	-0.44	-6.67	-0.34	1.08e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.74	-14.3	-0.62	1.59e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs11677416	1.000	rs59674541	chr2:113553824	A/T	cg27083787	chr2:113543245	IL1A	0.46	7.18	0.37	4.69e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.19	0.45	4.24e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2835872	0.828	rs2835838	chr21:38990994	A/G	cg20424643	chr21:39039972	KCNJ6	0.37	5.83	0.3	1.28e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.6	-0.38	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-1.13	-17.99	-0.7	4.71e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01325958	chr17:37793326	STARD3	-0.51	-6.27	-0.32	1.12e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6977660	0.943	rs10270447	chr7:19849823	C/G	cg05791153	chr7:19748676	TWISTNB	-0.51	-5.75	-0.3	1.99e-8	Thyroid stimulating hormone;
LUSC	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	7.32	0.37	1.85e-12	Schizophrenia;
LUSC	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg04310649	chr10:35416472	CREM	-0.4	-6.25	-0.32	1.26e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.71	8.87	0.44	4.36e-17	Type 2 diabetes;
LUSC	cis	rs6500395	1.000	rs3826174	chr16:48591012	T/C	cg04672837	chr16:48644449	N4BP1	0.43	6.47	0.33	3.44e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg07817883	chr1:32538562	TMEM39B	0.6	6.08	0.32	3.29e-9	Monocyte percentage of white cells;
LUSC	cis	rs2806561	0.729	rs35919647	chr1:23326072	C/T	cg19743168	chr1:23544995	NA	-0.42	-8.7	-0.43	1.54e-16	Height;
LUSC	cis	rs7903847	0.620	rs10882907	chr10:99125788	C/G	cg08345082	chr10:99160200	RRP12	0.31	6.29	0.33	9.86e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.73	12.6	0.57	4.74e-30	Colorectal cancer;
LUSC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18099408	chr3:52552593	STAB1	-0.43	-6.98	-0.36	1.58e-11	Bipolar disorder;
LUSC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00475322	chr7:917719	C7orf20	-0.44	-6.54	-0.34	2.34e-10	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	0.97	18.83	0.72	2.07e-54	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg26441486	chr22:50317300	CRELD2	0.52	7.95	0.4	2.85e-14	Schizophrenia;
LUSC	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg11494091	chr17:61959527	GH2	0.37	6.1	0.32	2.94e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg02782426	chr3:40428986	ENTPD3	0.33	6.26	0.32	1.16e-9	Renal cell carcinoma;
LUSC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg05585544	chr11:47624801	NA	-0.41	-7.1	-0.36	7.39e-12	Neuroticism;
LUSC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg17376030	chr22:41985996	PMM1	-0.46	-5.81	-0.3	1.47e-8	Vitiligo;
LUSC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08109568	chr15:31115862	NA	-0.59	-8.22	-0.41	4.66e-15	Huntington's disease progression;
LUSC	cis	rs8133932	0.654	rs413517	chr21:47347545	C/G	cg14185626	chr21:47401492	COL6A1	-0.44	-5.65	-0.3	3.37e-8	Schizophrenia;
LUSC	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg25482853	chr8:67687455	SGK3	1.18	16.74	0.68	4.07e-46	Lung disease severity in cystic fibrosis;
LUSC	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg10857441	chr5:6722123	POLS	-0.44	-8.56	-0.42	4.23e-16	Menopause (age at onset);
LUSC	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg20744362	chr22:50050164	C22orf34	0.35	6.29	0.33	9.69e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs955333	1.000	rs56306994	chr6:154946059	T/C	cg20019720	chr6:154832845	CNKSR3	0.42	5.86	0.31	1.12e-8	Diabetic kidney disease;
LUSC	cis	rs4654899	0.833	rs10916858	chr1:21086602	C/G	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.36	9.91e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg04025307	chr7:1156635	C7orf50	0.45	7.03	0.36	1.14e-11	Longevity;Endometriosis;
LUSC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.82	-0.3	1.37e-8	Tonsillectomy;
LUSC	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg13010199	chr12:38710504	ALG10B	-0.51	-7.71	-0.39	1.41e-13	Morning vs. evening chronotype;
LUSC	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	8.44	0.42	9.68e-16	Neuroticism;
LUSC	trans	rs6767049	0.510	rs4380427	chr3:20310729	G/C	cg15029475	chr5:3028202	NA	0.28	6.07	0.32	3.57e-9	Temperament (bipolar disorder);
LUSC	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg20701182	chr2:24300061	SF3B14	0.55	5.83	0.3	1.32e-8	Lymphocyte counts;
LUSC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	trans	rs8026898	1.000	rs8026898	chr15:69991417	G/A	cg27385734	chr18:15003734	NA	0.3	5.98	0.31	5.64e-9	Rheumatoid arthritis;
LUSC	cis	rs2976388	1.000	rs2717562	chr8:143776668	T/C	cg17252645	chr8:143867129	LY6D	-0.38	-6.5	-0.34	2.85e-10	Urinary tract infection frequency;
LUSC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg18402987	chr7:1209562	NA	0.72	7.69	0.39	1.67e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4363385	0.642	rs58124215	chr1:152916375	C/T	cg07796016	chr1:152779584	LCE1C	-0.5	-7.49	-0.38	6.21e-13	Inflammatory skin disease;
LUSC	cis	rs17767294	0.708	rs72848753	chr6:27878269	C/G	cg08851530	chr6:28072375	NA	1.31	8.29	0.41	2.8e-15	Parkinson's disease;
LUSC	cis	rs7903847	0.596	rs10882934	chr10:99170995	T/G	cg20016023	chr10:99160130	RRP12	-0.33	-7.95	-0.4	2.9e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg00255919	chr5:131827918	IRF1	0.43	8.28	0.41	3.11e-15	Asthma (sex interaction);
LUSC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg06618935	chr21:46677482	NA	-0.4	-8.06	-0.4	1.37e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg05347473	chr6:146136440	FBXO30	0.37	6.27	0.32	1.11e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg13072238	chr3:49761600	GMPPB	0.36	5.84	0.3	1.22e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg04155289	chr7:94953770	PON1	-0.34	-5.76	-0.3	1.9e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg25214090	chr10:38739885	LOC399744	0.55	8.01	0.4	1.89e-14	Corneal astigmatism;
LUSC	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-8.94	-0.44	2.67e-17	Monocyte percentage of white cells;
LUSC	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg18002602	chr11:66138449	SLC29A2	0.45	8.08	0.4	1.17e-14	Educational attainment (years of education);
LUSC	cis	rs28655083	0.956	rs7184167	chr16:77069451	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-6.33	-0.33	7.82e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg23029597	chr12:123009494	RSRC2	-0.66	-9.02	-0.44	1.51e-17	Body mass index;
LUSC	cis	rs9283706	0.548	rs10052424	chr5:66356632	G/T	cg11590213	chr5:66331682	MAST4	0.45	6.72	0.34	8.05e-11	Coronary artery disease;
LUSC	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg19610905	chr11:61596333	FADS2	-0.55	-8.27	-0.41	3.13e-15	Trans fatty acid levels;
LUSC	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg17252645	chr8:143867129	LY6D	0.38	6.68	0.34	1.01e-10	Urinary tract infection frequency;
LUSC	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.38e-20	Coronary artery disease;
LUSC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg17724175	chr1:150552817	MCL1	0.38	6.79	0.35	5.04e-11	Tonsillectomy;
LUSC	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	9.17	0.45	4.82e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg08313168	chr12:7315531	NA	0.47	5.96	0.31	6.34e-9	Obesity-related traits;
LUSC	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg08975724	chr8:8085496	FLJ10661	0.43	6.59	0.34	1.75e-10	Retinal vascular caliber;
LUSC	trans	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg07393940	chr7:158741817	NA	-0.38	-6.87	-0.35	3.1e-11	Life satisfaction;
LUSC	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.56	8.33	0.41	2.12e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs12637928	0.580	rs4682590	chr3:110212334	T/C	cg17371621	chr15:61264283	RORA	0.36	6.03	0.31	4.4e-9	Neuroticism;
LUSC	trans	rs72674100	1.000	rs77493600	chr4:97980332	A/G	cg09670535	chr1:18959427	PAX7	-0.63	-6.47	-0.33	3.55e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.65	0.57	3e-30	Motion sickness;
LUSC	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg24578937	chr1:2090814	PRKCZ	0.46	10.28	0.49	9.95e-22	Height;
LUSC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.1	14.12	0.61	7.99e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg18758796	chr5:131593413	PDLIM4	0.43	7.1	0.36	7.57e-12	Breast cancer;
LUSC	cis	rs2820315	1.000	rs2678204	chr1:201800511	T/G	cg10061532	chr1:201886748	LMOD1	0.25	5.7	0.3	2.68e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs1506636	0.924	rs2402668	chr7:123296605	T/A	cg03229431	chr7:123269106	ASB15	-0.65	-10.62	-0.5	6.66e-23	Plateletcrit;Platelet count;
LUSC	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg21427119	chr20:30132790	HM13	-0.38	-6.01	-0.31	4.83e-9	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg16989086	chr20:62203971	PRIC285	0.46	6.41	0.33	5.09e-10	Glioblastoma;
LUSC	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg10978503	chr1:24200527	CNR2	0.54	13.3	0.59	1.11e-32	Immature fraction of reticulocytes;
LUSC	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg03585969	chr10:35415529	CREM	0.59	8.83	0.44	6.06e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg14582100	chr15:45693742	SPATA5L1	0.46	8.62	0.43	2.7e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg27094323	chr7:1216898	NA	-0.42	-6.99	-0.36	1.54e-11	Longevity;Endometriosis;
LUSC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.74	-0.39	1.17e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg15790184	chr11:494944	RNH1	0.49	6.91	0.35	2.5e-11	Systemic lupus erythematosus;
LUSC	cis	rs259282	0.646	rs34182086	chr19:33125823	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.69	10.51	0.5	1.59e-22	Schizophrenia;
LUSC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.72	-12.6	-0.57	4.65e-30	Aortic root size;
LUSC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.5	-8.41	-0.42	1.17e-15	Prudent dietary pattern;
LUSC	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg19773385	chr1:10388646	KIF1B	-0.52	-8.98	-0.44	1.98e-17	Hepatocellular carcinoma;
LUSC	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg05973401	chr12:123451056	ABCB9	0.52	6.43	0.33	4.29e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg06740227	chr12:86229804	RASSF9	0.39	6.33	0.33	7.71e-10	Major depressive disorder;
LUSC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg17173187	chr15:85201210	NMB	0.38	6.66	0.34	1.16e-10	Schizophrenia;
LUSC	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg18129178	chr5:148520854	ABLIM3	-0.67	-9.95	-0.48	1.3e-20	Breast cancer;
LUSC	cis	rs17685	0.890	rs76021834	chr7:75607155	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.38	-5.65	-0.3	3.43e-8	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs8056893	0.523	rs11647636	chr16:68369740	C/T	cg02226672	chr16:68398533	SMPD3	0.31	5.65	0.3	3.48e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.76	0.84	8.98e-89	Chronic sinus infection;
LUSC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg03526776	chr6:41159608	TREML2	0.33	6.26	0.32	1.2e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg27432699	chr2:27873401	GPN1	-0.9	-17.9	-0.7	1.03e-50	Oral cavity cancer;
LUSC	cis	rs3790645	1.000	rs897641	chr1:26881806	C/A	cg17456097	chr1:26900765	RPS6KA1	0.42	6.08	0.32	3.36e-9	Glucose homeostasis traits;
LUSC	cis	rs7191700	0.601	rs243329	chr16:11352313	A/T	cg00044050	chr16:11439710	C16orf75	0.67	11.92	0.55	1.51e-27	Multiple sclerosis;
LUSC	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg16230307	chr14:35515116	FAM177A1	0.79	10.05	0.48	6.13e-21	Psoriasis;
LUSC	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg09904177	chr6:26538194	HMGN4	0.62	5.97	0.31	5.99e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00608362	chr4:128802003	PLK4	0.46	6.52	0.34	2.6e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.09	0.61	1.02e-35	Platelet count;
LUSC	cis	rs28647808	0.881	rs28602295	chr9:136267471	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.88	-18.04	-0.7	2.96e-51	Intelligence (multi-trait analysis);
LUSC	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	9.71	0.47	8.24e-20	Lymphocyte percentage of white cells;
LUSC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11764359	chr7:65958608	NA	0.61	9.33	0.45	1.55e-18	Aortic root size;
LUSC	cis	rs7267979	0.789	rs4815429	chr20:25521611	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.8	-16.58	-0.67	1.83e-45	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg00677455	chr12:58241039	CTDSP2	0.65	9.14	0.45	6.01e-18	Multiple sclerosis;
LUSC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg18240062	chr17:79603768	NPLOC4	-0.57	-9.84	-0.47	3.25e-20	Eye color traits;
LUSC	cis	rs12900413	0.687	rs12908343	chr15:90319095	C/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.85	-0.31	1.15e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg06562570	chr14:97263560	VRK1	-0.46	-6.27	-0.32	1.12e-9	Hepatitis;
LUSC	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03713592	chr11:72463424	ARAP1	0.76	8.96	0.44	2.38e-17	Type 2 diabetes;
LUSC	cis	rs909674	0.734	rs1005522	chr22:39845898	C/A	cg02038168	chr22:39784481	NA	-0.42	-5.99	-0.31	5.34e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg04166393	chr7:2884313	GNA12	0.45	6.11	0.32	2.72e-9	Height;
LUSC	cis	rs6028335	0.502	rs6028235	chr20:37608550	A/G	cg27552599	chr20:37590471	DHX35	0.45	7.52	0.38	4.97e-13	Alcohol and nicotine co-dependence;
LUSC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08859206	chr1:53392774	SCP2	-0.59	-11.0	-0.52	3.08e-24	Monocyte count;
LUSC	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.53	-8.66	-0.43	1.98e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg12483005	chr1:23474871	LUZP1	0.43	6.69	0.34	9.54e-11	Height;
LUSC	cis	rs11958404	0.932	rs72816541	chr5:157414686	G/A	cg05962755	chr5:157440814	NA	0.49	6.08	0.32	3.24e-9	IgG glycosylation;
LUSC	cis	rs9361491	0.657	rs7382016	chr6:79455781	A/T	cg05283184	chr6:79620031	NA	0.33	5.95	0.31	6.76e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg11502198	chr6:26597334	ABT1	0.6	9.37	0.46	1.11e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg25205988	chr1:146714368	CHD1L	1.05	8.62	0.43	2.81e-16	Mitochondrial DNA levels;
LUSC	cis	rs9462027	0.651	rs4259246	chr6:34803947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.8	-0.3	1.56e-8	Systemic lupus erythematosus;
LUSC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg10018233	chr7:150070692	REPIN1	0.38	6.61	0.34	1.48e-10	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.89	0.35	2.82e-11	Endometrial cancer;
LUSC	cis	rs11158026	0.574	rs58055971	chr14:55436324	C/T	cg04306507	chr14:55594613	LGALS3	0.4	7.23	0.37	3.26e-12	Parkinson's disease;
LUSC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg09904177	chr6:26538194	HMGN4	0.47	7.48	0.38	6.8e-13	Schizophrenia;
LUSC	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg24562669	chr7:97807699	LMTK2	0.43	7.32	0.37	1.86e-12	Breast cancer;
LUSC	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg25237894	chr2:233734115	C2orf82	0.36	6.7	0.34	8.86e-11	Coronary artery disease;
LUSC	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg04539111	chr16:67997858	SLC12A4	-0.43	-5.71	-0.3	2.51e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9309473	0.950	rs7596773	chr2:73846000	C/T	cg20560298	chr2:73613845	ALMS1	-0.43	-6.11	-0.32	2.79e-9	Metabolite levels;
LUSC	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.67	0.6	4.14e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.73	0.39	1.29e-13	Iron status biomarkers;
LUSC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	ch.11.42038R	chr11:967971	AP2A2	0.41	6.08	0.32	3.21e-9	Alzheimer's disease (late onset);
LUSC	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg04851639	chr8:1020857	NA	-0.36	-7.63	-0.39	2.45e-13	Schizophrenia;
LUSC	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg01616529	chr11:638424	DRD4	-0.35	-6.02	-0.31	4.64e-9	Systemic lupus erythematosus;
LUSC	cis	rs2742234	0.541	rs1254958	chr10:43702143	C/T	cg15436174	chr10:43711423	RASGEF1A	0.43	6.99	0.36	1.53e-11	Hirschsprung disease;
LUSC	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.93	-18.02	-0.7	3.37e-51	Brugada syndrome;
LUSC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.88	-0.51	8.54e-24	Chronic sinus infection;
LUSC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.08	15.68	0.65	6.54e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6733011	0.559	rs6711022	chr2:99449536	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-7.07	-0.36	8.96e-12	Bipolar disorder;
LUSC	trans	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg18187862	chr3:45730750	SACM1L	-0.55	-6.98	-0.36	1.6e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9311676	0.632	rs11130646	chr3:58447013	C/G	cg13750441	chr3:58318267	PXK	0.35	6.81	0.35	4.58e-11	Systemic lupus erythematosus;
LUSC	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg03060546	chr3:49711283	APEH	0.57	7.91	0.4	3.89e-14	Resting heart rate;
LUSC	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg00522288	chr12:125625016	AACS	-0.32	-6.14	-0.32	2.28e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7246967	0.673	rs73028776	chr19:22813740	A/C	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.14e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg24642439	chr20:33292090	TP53INP2	-0.44	-6.49	-0.33	3.17e-10	Height;
LUSC	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg24851651	chr11:66362959	CCS	-0.36	-5.68	-0.3	2.92e-8	Educational attainment (years of education);
LUSC	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg13206674	chr6:150067644	NUP43	0.4	5.69	0.3	2.85e-8	Testicular germ cell tumor;
LUSC	cis	rs9921338	0.961	rs8048768	chr16:11396840	T/C	cg00044050	chr16:11439710	C16orf75	-0.48	-6.51	-0.34	2.73e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.91	0.31	8.31e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg18402987	chr7:1209562	NA	0.71	7.63	0.39	2.45e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg06600287	chr1:53387719	ECHDC2	0.3	6.16	0.32	2.1e-9	Monocyte count;
LUSC	trans	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg26043149	chr18:55253948	FECH	-0.55	-8.51	-0.42	5.94e-16	Bone mineral density;
LUSC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg21285383	chr16:89894308	SPIRE2	-0.33	-6.97	-0.36	1.68e-11	Vitiligo;
LUSC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.48	-0.33	3.21e-10	Lung cancer;
LUSC	trans	rs2055729	0.710	rs114038384	chr8:9737519	T/A	cg06636001	chr8:8085503	FLJ10661	0.49	6.17	0.32	2.01e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg19046167	chr17:80928561	B3GNTL1	0.49	7.05	0.36	1.01e-11	Glycated hemoglobin levels;
LUSC	cis	rs877282	0.735	rs111609055	chr10:826539	A/G	cg13775593	chr10:823151	NA	0.31	6.22	0.32	1.48e-9	Uric acid levels;
LUSC	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	12.82	0.57	6.93e-31	Bipolar disorder;
LUSC	cis	rs4629710	0.592	rs13200165	chr6:131549167	G/C	cg12606694	chr6:131520996	AKAP7	0.61	9.3	0.45	1.83e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.08	-0.32	3.33e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	6.67	0.34	1.09e-10	Lung cancer;
LUSC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg23758822	chr17:41437982	NA	0.98	18.21	0.71	6.17e-52	Menopause (age at onset);
LUSC	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg18477163	chr1:228402036	OBSCN	0.53	9.23	0.45	3.15e-18	Diastolic blood pressure;
LUSC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg12963246	chr6:28129442	ZNF389	0.37	5.71	0.3	2.51e-8	Parkinson's disease;
LUSC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg06212747	chr3:49208901	KLHDC8B	0.47	6.15	0.32	2.23e-9	Parkinson's disease;
LUSC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg00166722	chr3:10149974	C3orf24	0.39	5.81	0.3	1.43e-8	Alzheimer's disease;
LUSC	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.18	29.43	0.85	8.55e-95	Testicular germ cell tumor;
LUSC	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg12863693	chr15:85201151	NMB	-0.34	-6.42	-0.33	4.79e-10	Schizophrenia;
LUSC	cis	rs2227930	0.506	rs10935460	chr3:142047041	G/A	cg16271453	chr3:142027066	XRN1	-0.55	-9.95	-0.48	1.35e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.36	-0.33	6.79e-10	Response to antipsychotic treatment;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23193613	chr8:144267725	NA	-0.24	-6.12	-0.32	2.56e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2294693	0.945	rs9462668	chr6:41004194	T/C	cg14769373	chr6:40998127	UNC5CL	-0.51	-7.07	-0.36	9.23e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs2282802	0.685	rs4913079	chr5:139683029	A/G	cg26211634	chr5:139558579	C5orf32	0.39	7.33	0.37	1.75e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg22878388	chr2:105853796	NA	-0.34	-6.22	-0.32	1.5e-9	Type 2 diabetes;
LUSC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg09165964	chr15:75287851	SCAMP5	0.56	8.46	0.42	8.72e-16	Breast cancer;
LUSC	cis	rs2224391	0.628	rs2753236	chr6:5252214	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.48	-6.73	-0.35	7.62e-11	Height;
LUSC	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.72	-0.35	7.82e-11	Triglycerides;
LUSC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg06640241	chr16:89574553	SPG7	-0.68	-9.3	-0.45	1.89e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.33	0.33	7.85e-10	Lung cancer;
LUSC	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg11632617	chr15:75315747	PPCDC	-0.5	-6.45	-0.33	4.03e-10	Blood trace element (Zn levels);
LUSC	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.79	-0.3	1.59e-8	Bipolar disorder;
LUSC	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg21665744	chr7:39171113	POU6F2	0.41	6.61	0.34	1.5e-10	IgG glycosylation;
LUSC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.81	-0.51	1.5e-23	Alzheimer's disease (late onset);
LUSC	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg03929089	chr4:120376271	NA	0.74	6.95	0.36	1.87e-11	Axial length;
LUSC	trans	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg04995722	chr7:26192034	NFE2L3	-0.39	-6.33	-0.33	7.84e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs13385	0.769	rs7705999	chr5:139576049	T/A	cg26211634	chr5:139558579	C5orf32	0.44	6.59	0.34	1.76e-10	Atrial fibrillation;
LUSC	cis	rs9308433	0.529	rs3767842	chr1:214498306	C/T	cg06198575	chr1:214491504	SMYD2	0.45	7.06	0.36	9.75e-12	IgG glycosylation;
LUSC	trans	rs12145833	0.596	rs12123491	chr1:243297924	C/G	cg25284624	chr1:224180302	NA	0.67	6.49	0.33	3.18e-10	Obesity (early onset extreme);
LUSC	cis	rs3093024	0.967	rs1571878	chr6:167540842	C/T	cg07741184	chr6:167504864	NA	-0.48	-8.42	-0.42	1.1e-15	Rheumatoid arthritis;
LUSC	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.43	6.63	0.34	1.38e-10	Dupuytren's disease;
LUSC	cis	rs6942756	0.806	rs7788327	chr7:128986519	C/T	cg02491457	chr7:128862824	NA	-0.46	-7.03	-0.36	1.14e-11	White matter hyperintensity burden;
LUSC	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg07080220	chr10:102295463	HIF1AN	0.59	7.89	0.4	4.34e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs965604	1.000	rs4362358	chr15:78796104	C/T	cg18825076	chr15:78729989	IREB2	-0.43	-6.82	-0.35	4.31e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg13010199	chr12:38710504	ALG10B	-0.46	-6.89	-0.35	2.76e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs73198271	0.740	rs10105690	chr8:8649232	G/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.99	-0.31	5.51e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16414030	chr3:133502952	NA	-0.4	-6.02	-0.31	4.5e-9	Iron status biomarkers;
LUSC	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg16989719	chr2:238392110	NA	-0.42	-7.34	-0.37	1.68e-12	Prostate cancer;
LUSC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg27535305	chr1:53392650	SCP2	-0.49	-9.55	-0.46	2.99e-19	Monocyte count;
LUSC	cis	rs1983891	0.955	rs6917029	chr6:41548540	C/G	cg15051332	chr6:41514432	FOXP4	0.39	5.74	0.3	2.12e-8	Prostate cancer;
LUSC	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg00686598	chr14:53173677	PSMC6	1.12	10.51	0.5	1.65e-22	Alzheimer's disease (late onset);
LUSC	cis	rs9653442	0.564	rs7565895	chr2:100774773	G/A	cg07810366	chr2:100720526	AFF3	-0.45	-7.65	-0.39	2.21e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2235649	0.746	rs113666107	chr16:1848642	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.11	-0.32	2.74e-9	Blood metabolite levels;
LUSC	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg04851639	chr8:1020857	NA	-0.38	-8.01	-0.4	1.92e-14	Schizophrenia;
LUSC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.45	7.45	0.38	8.21e-13	Pulse pressure;
LUSC	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	12.87	0.58	4.57e-31	Platelet count;
LUSC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.82	15.09	0.64	1.34e-39	Blood protein levels;
LUSC	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg21211680	chr2:198530	NA	-0.78	-8.35	-0.42	1.84e-15	Blood protein levels;
LUSC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg23982607	chr1:1823379	GNB1	-0.73	-14.94	-0.63	5.09e-39	Body mass index;
LUSC	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg05295671	chr13:79234353	RNF219	0.46	6.01	0.31	4.86e-9	Large artery stroke;
LUSC	cis	rs497273	0.511	rs1151862	chr12:121331285	G/A	cg02419362	chr12:121203948	SPPL3	-0.43	-7.97	-0.4	2.49e-14	Systemic lupus erythematosus;
LUSC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg06640241	chr16:89574553	SPG7	0.66	9.79	0.47	4.5e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg00933542	chr6:150070202	PCMT1	0.29	5.87	0.31	1.05e-8	Lung cancer;
LUSC	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	1.05	14.32	0.62	1.33e-36	Exhaled nitric oxide levels;
LUSC	cis	rs2455601	1.000	rs12223690	chr11:8901824	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.5	-7.66	-0.39	2e-13	Schizophrenia;
LUSC	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-7.24	-0.37	3.02e-12	Total cholesterol levels;
LUSC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.48	-0.42	7.39e-16	Obesity-related traits;
LUSC	cis	rs62432291	0.681	rs418859	chr6:159649695	A/T	cg14500486	chr6:159655392	FNDC1	0.52	5.84	0.3	1.22e-8	Joint mobility (Beighton score);
LUSC	trans	rs564343	0.563	rs1642958	chr11:65821973	G/C	cg26701943	chr11:108369231	KDELC2	-0.45	-6.1	-0.32	2.93e-9	Obesity (early onset extreme);
LUSC	cis	rs897080	0.552	rs698799	chr2:44690618	C/T	cg00619915	chr2:44497795	NA	-0.45	-6.4	-0.33	5.15e-10	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04599533	chr3:197687209	LMLN;IQCG	-0.41	-6.15	-0.32	2.28e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6964587	0.758	rs7798233	chr7:91500083	G/A	cg17063962	chr7:91808500	NA	-0.53	-7.01	-0.36	1.37e-11	Breast cancer;
LUSC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.72	-9.92	-0.48	1.7e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg25258033	chr6:167368657	RNASET2	0.45	6.53	0.34	2.44e-10	Crohn's disease;
LUSC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.72	-0.35	7.84e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06481639	chr22:41940642	POLR3H	0.47	5.77	0.3	1.79e-8	Cannabis dependence symptom count;
LUSC	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-0.58	-9.19	-0.45	4.34e-18	Breast cancer;
LUSC	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg08807101	chr21:30365312	RNF160	0.68	11.03	0.52	2.44e-24	Pancreatic cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08862778	chr1:11322643	MTOR	0.44	6.57	0.34	1.92e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg16447950	chr5:562315	NA	-0.54	-6.69	-0.34	9.26e-11	Obesity-related traits;
LUSC	cis	rs6580649	0.883	rs4760621	chr12:48561262	A/G	cg24011408	chr12:48396354	COL2A1	0.48	6.52	0.34	2.64e-10	Lung cancer;
LUSC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.91	14.45	0.62	4.09e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08470875	chr2:26401718	FAM59B	0.71	9.86	0.47	2.71e-20	Gut microbiome composition (summer);
LUSC	cis	rs859767	0.501	rs10171371	chr2:135372159	C/T	cg12500956	chr2:135428796	TMEM163	-0.27	-6.47	-0.33	3.56e-10	Neuroticism;
LUSC	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg09021430	chr5:549028	NA	-0.55	-7.25	-0.37	2.95e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.86	-0.31	1.11e-8	Recombination rate (females);
LUSC	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg16359550	chr11:109292809	C11orf87	0.35	6.05	0.31	3.96e-9	Schizophrenia;
LUSC	cis	rs16958440	0.708	rs62096465	chr18:44629624	C/T	cg17192377	chr18:44677553	HDHD2	0.43	5.67	0.3	3.02e-8	Sitting height ratio;
LUSC	cis	rs721399	0.539	rs7460653	chr8:18266983	G/C	cg18736775	chr8:18248649	NAT2	-0.6	-7.09	-0.36	7.9e-12	Blood metabolite levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22468868	chr17:58042029	RNFT1	-0.43	-6.18	-0.32	1.88e-9	Electrocardiographic conduction measures;
LUSC	cis	rs12049351	0.774	rs12125978	chr1:229627722	T/C	cg11742688	chr1:229674241	ABCB10	-0.4	-5.68	-0.3	2.96e-8	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.79	11.43	0.53	9.64e-26	Migraine;Coronary artery disease;
LUSC	cis	rs62400317	0.893	rs62436782	chr6:45143118	T/A	cg20913747	chr6:44695427	NA	-0.46	-7.43	-0.38	8.91e-13	Total body bone mineral density;
LUSC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.91	0.35	2.53e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.77	-13.83	-0.6	1.09e-34	Age at first birth;
LUSC	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg08847533	chr14:75593920	NEK9	-0.66	-10.75	-0.51	2.37e-23	Coronary artery disease;
LUSC	cis	rs4766646	0.524	rs6606743	chr12:110279179	A/G	cg10794374	chr12:110278745	NA	0.31	7.0	0.36	1.44e-11	Metabolite levels (MHPG);
LUSC	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-0.85	-13.98	-0.61	2.67e-35	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-5.96	-0.31	6.29e-9	Neuroticism;
LUSC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg00484396	chr16:3507460	NAT15	-0.71	-9.25	-0.45	2.72e-18	Tuberculosis;
LUSC	cis	rs6977660	1.000	rs7779902	chr7:19803491	G/A	cg07541023	chr7:19748670	TWISTNB	0.53	6.14	0.32	2.4e-9	Thyroid stimulating hormone;
LUSC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg10664184	chr19:17420304	DDA1	0.5	6.4	0.33	5.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg00086871	chr4:6988644	TBC1D14	1.05	8.99	0.44	1.84e-17	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs72781680	0.716	rs2712065	chr2:23973603	C/T	cg08917208	chr2:24149416	ATAD2B	-0.52	-6.01	-0.31	4.74e-9	Lymphocyte counts;
LUSC	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.5	-7.41	-0.38	1.04e-12	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.76	11.48	0.53	6.24e-26	Itch intensity from mosquito bite;
LUSC	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg11693508	chr17:37793320	STARD3	0.59	7.08	0.36	8.53e-12	Bipolar disorder;
LUSC	cis	rs4631830	0.900	rs10763576	chr10:51538813	A/T	cg20129853	chr10:51489980	NA	-0.33	-6.61	-0.34	1.55e-10	Prostate-specific antigen levels;
LUSC	cis	rs672059	1.000	rs547905	chr1:183157924	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.83	0.39	6.6e-14	Hypertriglyceridemia;
LUSC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg06618935	chr21:46677482	NA	-0.41	-8.11	-0.41	9.97e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg22349387	chr12:9600060	DDX12	-0.42	-7.0	-0.36	1.45e-11	Breast size;
LUSC	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23544223	chr18:12777786	NA	0.59	6.25	0.32	1.26e-9	Inflammatory skin disease;
LUSC	cis	rs6665290	0.558	rs1319103	chr1:227219314	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.85	-14.26	-0.62	2.35e-36	Myeloid white cell count;
LUSC	cis	rs4474465	0.736	rs10899550	chr11:78256078	G/A	cg27205649	chr11:78285834	NARS2	0.52	6.2	0.32	1.7e-9	Alzheimer's disease (survival time);
LUSC	cis	rs10761482	0.861	rs4520549	chr10:62104516	C/T	cg18175470	chr10:62150864	ANK3	-0.48	-6.91	-0.35	2.51e-11	Schizophrenia;
LUSC	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg02176678	chr2:219576539	TTLL4	-0.71	-13.63	-0.6	6.11e-34	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1568889	0.838	rs3812738	chr11:28129982	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.71	0.57	1.93e-30	Bipolar disorder;
LUSC	cis	rs10100465	0.961	rs10093382	chr8:118640159	C/T	cg09430518	chr8:118662568	NA	0.32	6.09	0.32	3.15e-9	Leprosy;
LUSC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg27432699	chr2:27873401	GPN1	-0.56	-8.4	-0.42	1.34e-15	Total body bone mineral density;
LUSC	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	8.93	0.44	2.89e-17	Lung cancer;
LUSC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg06640241	chr16:89574553	SPG7	-0.62	-9.32	-0.45	1.69e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs977987	0.806	rs7202596	chr16:75491072	G/T	cg03315344	chr16:75512273	CHST6	0.49	9.39	0.46	9.82e-19	Dupuytren's disease;
LUSC	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	6.51	0.34	2.76e-10	Blood metabolite levels;
LUSC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	cis	rs2282032	0.527	rs41309248	chr14:90767386	C/T	cg14092571	chr14:90743983	NA	0.48	8.01	0.4	1.95e-14	Longevity;
LUSC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.58	-9.51	-0.46	4.03e-19	Aortic root size;
LUSC	cis	rs11264213	0.901	rs72661640	chr1:36447232	T/G	cg27506609	chr1:36549197	TEKT2	0.7	7.98	0.4	2.33e-14	Schizophrenia;
LUSC	cis	rs6546537	0.550	rs4241252	chr2:69777065	C/A	cg10773587	chr2:69614142	GFPT1	-0.42	-6.54	-0.34	2.27e-10	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.6	0.54	2.33e-26	Prudent dietary pattern;
LUSC	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg20283391	chr11:68216788	NA	-0.5	-7.03	-0.36	1.18e-11	Total body bone mineral density;
LUSC	cis	rs7089973	0.836	rs12765350	chr10:116635305	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	7.99	0.4	2.19e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.81	-0.3	1.44e-8	Alzheimer's disease (late onset);
LUSC	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15557168	chr22:42548783	NA	-0.43	-7.23	-0.37	3.41e-12	Cognitive function;
LUSC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg22834771	chr12:69754056	YEATS4	-0.42	-6.03	-0.31	4.36e-9	Blood protein levels;
LUSC	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg24692254	chr21:30365293	RNF160	-0.53	-7.13	-0.36	6.2e-12	Cognitive test performance;
LUSC	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.86e-20	Coronary artery disease;
LUSC	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.67	0.3	3.06e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg26061582	chr7:22766209	IL6	0.48	7.22	0.37	3.56e-12	Lung cancer;
LUSC	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg22437258	chr11:111473054	SIK2	0.54	7.3	0.37	2.1e-12	Primary sclerosing cholangitis;
LUSC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.75	0.35	6.47e-11	Tonsillectomy;
LUSC	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	16.66	0.67	8.82e-46	Exhaled nitric oxide output;
LUSC	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-0.97	-22.69	-0.78	1.31e-69	Urate levels in lean individuals;
LUSC	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg17764715	chr19:33622953	WDR88	0.58	7.82	0.39	6.92e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7215564	0.822	rs2340769	chr17:78755271	C/T	cg06153925	chr17:78755379	RPTOR	-0.38	-5.75	-0.3	2e-8	Myopia (pathological);
LUSC	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	0.93	17.56	0.69	2.32e-49	Headache;
LUSC	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg10518572	chr11:65560635	OVOL1	0.25	5.92	0.31	8.17e-9	Acne (severe);
LUSC	cis	rs4499344	0.556	rs259236	chr19:33116122	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	1.0	14.2	0.61	3.87e-36	Mean platelet volume;
LUSC	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.65	-9.14	-0.45	6.15e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg15335139	chr3:50242325	SLC38A3	-0.27	-5.86	-0.31	1.11e-8	Body mass index;
LUSC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg10609677	chr17:41278573	BRCA1;NBR2	0.35	5.71	0.3	2.54e-8	Menopause (age at onset);
LUSC	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg13535736	chr9:111863775	C9orf5	-0.43	-6.89	-0.35	2.82e-11	Menarche (age at onset);
LUSC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg03289416	chr15:75166202	SCAMP2	-0.45	-7.11	-0.36	7.22e-12	Breast cancer;
LUSC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg04369109	chr6:150039330	LATS1	-0.51	-7.66	-0.39	1.97e-13	Lung cancer;
LUSC	cis	rs11168618	1.000	rs3961921	chr12:48943499	G/A	cg24011408	chr12:48396354	COL2A1	0.41	6.53	0.34	2.51e-10	Adiponectin levels;
LUSC	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg10547527	chr2:198650123	BOLL	0.49	5.82	0.3	1.35e-8	Ulcerative colitis;
LUSC	cis	rs2836633	0.895	rs991816	chr21:40042150	C/A	cg05519781	chr21:40033154	ERG	0.77	13.04	0.58	1.09e-31	Coronary artery disease;
LUSC	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg11887960	chr12:57824829	NA	0.58	7.13	0.36	6.16e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg26958806	chr6:27640298	NA	0.76	6.21	0.32	1.54e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg09877947	chr5:131593287	PDLIM4	0.49	8.01	0.4	1.92e-14	Breast cancer;
LUSC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.7	10.91	0.51	6.34e-24	Breast cancer;
LUSC	trans	rs8002861	0.641	rs2325085	chr13:44410060	G/A	cg12856521	chr11:46389249	DGKZ	0.44	6.43	0.33	4.53e-10	Leprosy;
LUSC	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg13010199	chr12:38710504	ALG10B	-0.48	-7.84	-0.39	6.24e-14	Morning vs. evening chronotype;
LUSC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg14668632	chr7:2872130	GNA12	-0.45	-6.81	-0.35	4.45e-11	Height;
LUSC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg23161317	chr6:28129485	ZNF389	0.44	5.67	0.3	3.05e-8	Parkinson's disease;
LUSC	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg02269571	chr22:50332266	NA	-0.59	-8.38	-0.42	1.47e-15	Schizophrenia;
LUSC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg15556689	chr8:8085844	FLJ10661	0.63	9.62	0.47	1.7e-19	Mood instability;
LUSC	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg04362960	chr10:104952993	NT5C2	0.61	9.55	0.46	2.83e-19	Arsenic metabolism;
LUSC	cis	rs35771425	0.600	rs1020336	chr1:211661016	C/T	cg10512769	chr1:211675356	NA	-0.28	-6.51	-0.34	2.74e-10	Educational attainment (years of education);
LUSC	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg13010344	chr12:123464640	ARL6IP4	-0.46	-6.36	-0.33	6.57e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg12856521	chr11:46389249	DGKZ	0.39	6.13	0.32	2.44e-9	Leprosy;
LUSC	cis	rs977987	0.843	rs12443834	chr16:75438469	C/T	cg04384234	chr16:75411784	CFDP1	-0.41	-6.58	-0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs7186831	1	rs7186831	chr16:75473155	G/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.11	-0.36	6.95e-12	Chronic obstructive pulmonary disease;
LUSC	cis	rs713477	0.967	rs12431542	chr14:55913078	T/C	cg13175173	chr14:55914753	NA	-0.31	-6.5	-0.34	2.9e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg20991723	chr1:152506922	NA	0.51	9.74	0.47	6.76e-20	Hair morphology;
LUSC	cis	rs897984	0.683	rs729482	chr16:31016970	T/C	cg02466173	chr16:30829666	NA	-0.53	-9.78	-0.47	5.15e-20	Dementia with Lewy bodies;
LUSC	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg05283184	chr6:79620031	NA	0.55	11.78	0.54	4.89e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs58785573	0.504	rs62294474	chr4:38628725	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.53	7.79	0.39	8.62e-14	Lymphocyte percentage of white cells;
LUSC	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg27471124	chr11:109292789	C11orf87	-0.37	-6.55	-0.34	2.11e-10	Schizophrenia;
LUSC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg19774624	chr17:42201019	HDAC5	0.82	14.3	0.62	1.55e-36	Total body bone mineral density;
LUSC	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg04362960	chr10:104952993	NT5C2	0.58	9.13	0.45	6.77e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg14416269	chr4:6271139	WFS1	0.54	11.38	0.53	1.35e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg25258033	chr6:167368657	RNASET2	0.39	6.37	0.33	6.11e-10	Crohn's disease;
LUSC	trans	rs72674100	0.881	rs10016957	chr4:97989074	T/C	cg09670535	chr1:18959427	PAX7	-0.62	-6.34	-0.33	7.58e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg00074818	chr8:8560427	CLDN23	0.57	9.76	0.47	5.63e-20	Obesity-related traits;
LUSC	cis	rs2247341	1.000	rs3958122	chr4:1693931	C/T	cg07465881	chr4:1713556	SLBP	-0.39	-5.92	-0.31	8.21e-9	Hip circumference adjusted for BMI;Height;
LUSC	trans	rs6601855	1.000	rs6601855	chr10:4725340	C/T	cg04072323	chr2:229046325	SPHKAP	-0.37	-6.31	-0.33	9.04e-10	Major depressive disorder;
LUSC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg12386194	chr3:101231763	SENP7	0.53	7.46	0.38	7.33e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg00310523	chr12:86230176	RASSF9	0.45	8.31	0.41	2.43e-15	Major depressive disorder;
LUSC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18404041	chr3:52824283	ITIH1	-0.52	-9.84	-0.47	3.16e-20	Bipolar disorder;
LUSC	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17916960	chr15:79447300	NA	-0.52	-10.41	-0.49	3.78e-22	Refractive error;
LUSC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg26408565	chr15:76604113	ETFA	-0.5	-8.03	-0.4	1.68e-14	Blood metabolite levels;
LUSC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06850241	chr22:41845214	NA	0.33	6.19	0.32	1.79e-9	Vitiligo;
LUSC	cis	rs2970818	0.831	rs11063188	chr12:4588230	A/G	cg11146114	chr12:4671731	NA	-0.6	-5.69	-0.3	2.83e-8	Phosphorus levels;
LUSC	cis	rs9324022	0.929	rs59488041	chr14:101180041	T/A	cg18089426	chr14:101175970	NA	0.46	5.78	0.3	1.73e-8	Plateletcrit;
LUSC	trans	rs7043095	1.000	rs7043095	chr9:91604005	A/G	cg07663813	chr8:81785835	ZNF704	0.41	5.97	0.31	5.91e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.18	0.32	1.88e-9	Corneal astigmatism;
LUSC	cis	rs372883	0.935	rs10460703	chr21:30623109	C/T	cg08807101	chr21:30365312	RNF160	-0.4	-5.68	-0.3	2.9e-8	Pancreatic cancer;
LUSC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg11062466	chr8:58055876	NA	0.51	6.51	0.34	2.84e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg16325326	chr1:53192061	ZYG11B	0.83	14.74	0.63	3.23e-38	Monocyte count;
LUSC	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg25809561	chr17:30822961	MYO1D	-0.35	-5.79	-0.3	1.62e-8	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	9.43	0.46	7.11e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg20608306	chr11:116969690	SIK3	0.41	6.8	0.35	4.85e-11	Blood protein levels;
LUSC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	12.77	0.57	1.11e-30	Chronic sinus infection;
LUSC	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.68	-10.79	-0.51	1.78e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11971779	0.680	rs11772026	chr7:139052589	T/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.56	0.38	4e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs975739	0.868	rs5351	chr13:78475313	C/T	cg14966220	chr13:46626929	ZC3H13	-0.38	-6.35	-0.33	7.11e-10	Hair color;
LUSC	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.54	-10.51	-0.5	1.6e-22	Educational attainment;
LUSC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg04455712	chr21:45112962	RRP1B	0.46	8.71	0.43	1.39e-16	Mean corpuscular volume;
LUSC	cis	rs7605827	0.930	rs11675805	chr2:15578274	C/T	cg19274914	chr2:15703543	NA	0.47	8.88	0.44	4.19e-17	Educational attainment (years of education);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18815006	chr10:71906516	TYSND1	-0.46	-6.16	-0.32	2.11e-9	Hepatitis;
LUSC	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg18795169	chr1:18902165	NA	-1.01	-24.29	-0.8	8.47e-76	Urate levels in lean individuals;
LUSC	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg12559939	chr2:27858050	GPN1	-0.39	-6.07	-0.31	3.56e-9	Oral cavity cancer;
LUSC	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg27494647	chr7:150038898	RARRES2	0.46	6.91	0.35	2.52e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg09835421	chr16:68378352	PRMT7	-0.61	-6.38	-0.33	5.77e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	0.95	18.29	0.71	2.94e-52	Heart rate;
LUSC	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.71	9.16	0.45	5.29e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.61	0.5	7.28e-23	Colorectal cancer;
LUSC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.71	-0.47	8.31e-20	Gut microbiome composition (summer);
LUSC	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg24110177	chr3:50126178	RBM5	0.43	6.83	0.35	4.05e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.82	0.6	1.14e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg00024416	chr22:24240387	NA	-0.33	-5.69	-0.3	2.81e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-1.1	-19.28	-0.73	3.33e-56	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs977987	0.966	rs8055490	chr16:75497135	C/T	cg03315344	chr16:75512273	CHST6	0.54	10.49	0.5	1.91e-22	Dupuytren's disease;
LUSC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg13683864	chr3:40499215	RPL14	-1.11	-21.91	-0.77	1.37e-66	Renal cell carcinoma;
LUSC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.27	0.52	3.49e-25	Menopause (age at onset);
LUSC	cis	rs4629180	1.000	rs59246268	chr2:102089021	G/A	cg04415270	chr2:102091202	RFX8	-0.54	-8.66	-0.43	2e-16	Chronic rhinosinusitis with nasal polyps;
LUSC	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	1.11	19.03	0.72	3.14e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1775715	0.674	rs2778670	chr10:32161676	G/A	cg18675610	chr10:32216311	ARHGAP12	0.3	6.59	0.34	1.68e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs12137294	0.829	rs1172154	chr1:205220639	T/G	cg21643547	chr1:205240462	TMCC2	-0.35	-6.4	-0.33	5.2e-10	Red cell distribution width;
LUSC	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg08085267	chr17:45401833	C17orf57	0.61	10.24	0.49	1.44e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg17623882	chr6:41773611	USP49	-0.61	-10.35	-0.49	5.92e-22	Menarche (age at onset);
LUSC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2932538	0.885	rs7516421	chr1:113089696	T/C	cg22162597	chr1:113214053	CAPZA1	0.54	7.8	0.39	7.9e-14	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	trans	rs1864729	1.000	rs2451113	chr8:98273448	G/A	cg08679828	chr8:102218111	ZNF706	-0.79	-7.19	-0.37	4.25e-12	Estradiol plasma levels (breast cancer);
LUSC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.28	0.59	1.28e-32	Cognitive test performance;
LUSC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg16606324	chr3:10149918	C3orf24	0.62	8.87	0.44	4.41e-17	Alzheimer's disease;
LUSC	cis	rs939658	0.683	rs8038464	chr15:79463036	A/T	cg17916960	chr15:79447300	NA	-0.43	-7.79	-0.39	8.72e-14	Refractive error;
LUSC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11764359	chr7:65958608	NA	-0.63	-9.62	-0.47	1.67e-19	Aortic root size;
LUSC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg18681998	chr4:17616180	MED28	0.78	13.66	0.6	4.67e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg27411982	chr8:10470053	RP1L1	0.38	6.01	0.31	4.91e-9	Mood instability;
LUSC	cis	rs7903847	0.620	rs61863813	chr10:99112786	T/C	cg20016023	chr10:99160130	RRP12	-0.34	-8.06	-0.4	1.35e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11785693	0.862	rs62491200	chr8:4998001	A/C	cg26367366	chr8:4980734	NA	0.77	9.01	0.44	1.58e-17	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg15896084	chr13:114927664	NA	0.41	7.22	0.37	3.5e-12	Schizophrenia;
LUSC	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.92	0.51	6.29e-24	Bladder cancer;
LUSC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03264133	chr6:25882463	NA	0.37	6.11	0.32	2.84e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg24829409	chr8:58192753	C8orf71	-0.53	-6.21	-0.32	1.55e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg00033643	chr7:134001901	SLC35B4	0.42	6.61	0.34	1.48e-10	Mean platelet volume;
LUSC	cis	rs12410462	0.579	rs77529417	chr1:227547895	T/C	cg23173402	chr1:227635558	NA	0.56	6.34	0.33	7.53e-10	Major depressive disorder;
LUSC	cis	rs2274273	0.615	rs17672058	chr14:55673394	C/T	cg04306507	chr14:55594613	LGALS3	0.47	9.24	0.45	3.04e-18	Protein biomarker;
LUSC	cis	rs9815354	0.680	rs114478966	chr3:42007050	T/C	cg03022575	chr3:42003672	ULK4	0.79	8.31	0.41	2.48e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.64	-0.39	2.31e-13	Bladder cancer;
LUSC	cis	rs4290604	0.748	rs6431514	chr2:238051064	T/C	cg23555395	chr2:238036564	NA	-0.52	-6.94	-0.35	2.07e-11	Asthma;
LUSC	cis	rs2236918	0.901	rs1635502	chr1:242039382	A/G	cg17736920	chr1:242011382	EXO1	0.41	6.33	0.33	8.08e-10	Menopause (age at onset);
LUSC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg23625390	chr15:77176239	SCAPER	0.6	9.34	0.45	1.45e-18	Blood metabolite levels;
LUSC	cis	rs4280164	0.887	rs11158634	chr14:24776457	C/G	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.6	-7.11	-0.36	7.21e-12	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.84	-0.35	3.9e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.57	0.46	2.51e-19	Bipolar disorder;
LUSC	cis	rs6714710	0.603	rs717417	chr2:98416850	T/G	cg26665480	chr2:98280029	ACTR1B	0.64	9.26	0.45	2.47e-18	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19777998	chr3:11762192	VGLL4	0.46	6.21	0.32	1.61e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-7.67	-0.39	1.93e-13	Personality dimensions;
LUSC	trans	rs2018683	0.834	rs2012754	chr7:29026257	G/A	cg19402173	chr7:128379420	CALU	-0.57	-9.27	-0.45	2.39e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg26897989	chr16:1907736	C16orf73	-0.44	-6.86	-0.35	3.32e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.63	0.5	6.32e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	8.03	0.4	1.68e-14	Iron status biomarkers;
LUSC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg03188948	chr7:1209495	NA	0.66	7.06	0.36	9.67e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg10756647	chr7:56101905	PSPH	0.86	8.74	0.43	1.18e-16	Diabetic kidney disease;
LUSC	cis	rs2742417	0.603	rs6807438	chr3:45778623	G/A	cg10512202	chr3:45649293	LIMD1	0.36	6.02	0.31	4.48e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg06627628	chr2:24431161	ITSN2	-0.68	-9.47	-0.46	5.18e-19	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg02023728	chr11:77925099	USP35	0.46	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg03859395	chr2:55845619	SMEK2	0.81	14.18	0.61	4.69e-36	Metabolic syndrome;
LUSC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg03233332	chr7:66118400	NA	-0.4	-5.98	-0.31	5.74e-9	Aortic root size;
LUSC	cis	rs3820928	0.874	rs59630650	chr2:227786514	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.82	-0.39	7.1e-14	Pulmonary function;
LUSC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.76	0.35	6.02e-11	Lung cancer;
LUSC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.82	14.29	0.62	1.77e-36	Blood protein levels;
LUSC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-1.25	-13.99	-0.61	2.56e-35	Diabetic kidney disease;
LUSC	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg18002602	chr11:66138449	SLC29A2	0.45	8.1	0.41	1.06e-14	Educational attainment (years of education);
LUSC	cis	rs1044826	0.642	rs295482	chr3:139229264	A/T	cg15131784	chr3:139108705	COPB2	-0.4	-6.42	-0.33	4.62e-10	Obesity-related traits;
LUSC	cis	rs4843185	0.576	rs381624	chr16:85728679	G/A	cg00168118	chr16:85669675	KIAA0182	0.39	6.07	0.32	3.47e-9	Platelet distribution width;
LUSC	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg04607235	chr12:12878440	APOLD1	-0.55	-6.43	-0.33	4.42e-10	Systemic lupus erythematosus;
LUSC	cis	rs68170813	0.652	rs17404067	chr7:107168119	G/T	cg02696742	chr7:106810147	HBP1	-0.64	-8.52	-0.42	5.51e-16	Coronary artery disease;
LUSC	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.49	7.06	0.36	9.43e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2857891	0.695	rs1907609	chr11:6991389	G/A	cg04053776	chr11:6947353	ZNF215	0.42	6.15	0.32	2.21e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	0.9	16.3	0.67	2.39e-44	Cognitive function;
LUSC	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg18827107	chr12:86230957	RASSF9	-0.4	-5.99	-0.31	5.31e-9	Major depressive disorder;
LUSC	cis	rs7605827	0.930	rs1997304	chr2:15512073	G/T	cg19274914	chr2:15703543	NA	0.46	8.94	0.44	2.66e-17	Educational attainment (years of education);
LUSC	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.74	-0.3	2.08e-8	Bipolar disorder;
LUSC	cis	rs7188861	0.681	rs34294744	chr16:11407623	C/G	cg00044050	chr16:11439710	C16orf75	0.58	5.94	0.31	7.03e-9	HDL cholesterol;
LUSC	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	1.27	11.7	0.54	9.84e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-7.64	-0.39	2.37e-13	Aortic root size;
LUSC	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.14	0.32	2.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg24675658	chr1:53192096	ZYG11B	-0.63	-9.86	-0.47	2.69e-20	Monocyte count;
LUSC	cis	rs926938	0.584	rs360607	chr1:115392401	C/A	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.53	-0.34	2.51e-10	Autism;
LUSC	cis	rs11229555	0.645	rs12805062	chr11:58214584	A/G	cg15696309	chr11:58395628	NA	-0.64	-7.83	-0.39	6.55e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10489525	0.530	rs11102884	chr1:115612947	A/G	cg01522456	chr1:115632236	TSPAN2	-0.4	-5.82	-0.3	1.41e-8	Autism;
LUSC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg02038168	chr22:39784481	NA	-0.49	-7.96	-0.4	2.72e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg09307838	chr4:120376055	NA	0.69	10.25	0.49	1.3e-21	Corneal astigmatism;
LUSC	trans	rs931812	1.000	rs931812	chr8:101919321	A/G	cg20993868	chr7:22813445	NA	-0.57	-10.47	-0.5	2.19e-22	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs2464469	0.631	rs2704218	chr15:58345001	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.9	-0.31	8.9e-9	Barrett's esophagus  or Esophageal adenocarcinoma;
LUSC	cis	rs11168618	0.967	rs10875831	chr12:48938380	G/A	cg24011408	chr12:48396354	COL2A1	0.39	6.32	0.33	8.21e-10	Adiponectin levels;
LUSC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg03146154	chr1:46216737	IPP	0.56	8.34	0.42	2e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg27471124	chr11:109292789	C11orf87	0.37	6.74	0.35	6.83e-11	Schizophrenia;
LUSC	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.55	7.65	0.39	2.23e-13	Tuberculosis;
LUSC	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.98	-0.36	1.57e-11	Lung cancer;
LUSC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs68092024	0.704	rs792832	chr3:99474862	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.37	-7.27	-0.37	2.59e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.08	0.48	4.91e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9329289	0.510	rs2029604	chr10:2554700	T/C	cg15501526	chr10:2543763	NA	0.53	9.3	0.45	1.89e-18	Age-related hearing impairment;
LUSC	cis	rs977987	0.835	rs3851733	chr16:75370263	G/C	cg03315344	chr16:75512273	CHST6	0.53	10.15	0.49	2.93e-21	Dupuytren's disease;
LUSC	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-7.88	-0.4	4.53e-14	Reticulocyte count;
LUSC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg01097406	chr16:89675127	NA	0.46	9.54	0.46	3.02e-19	Vitiligo;
LUSC	trans	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg13565492	chr6:43139072	SRF	-0.7	-10.42	-0.5	3.44e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2303282	0.716	rs2440466	chr16:56411165	A/G	cg00500540	chr16:56394104	NA	-0.44	-7.58	-0.38	3.53e-13	Breast cancer;
LUSC	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg24450063	chr1:156163899	SLC25A44	1.1	22.68	0.78	1.37e-69	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg21724239	chr8:58056113	NA	0.56	6.92	0.35	2.35e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06634786	chr22:41940651	POLR3H	-0.57	-6.59	-0.34	1.71e-10	Vitiligo;
LUSC	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.45	-6.7	-0.34	8.97e-11	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg26338869	chr17:61819248	STRADA	0.42	6.17	0.32	1.92e-9	Prudent dietary pattern;
LUSC	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg04384234	chr16:75411784	CFDP1	-0.45	-7.1	-0.36	7.75e-12	Dupuytren's disease;
LUSC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg07701084	chr6:150067640	NUP43	0.54	8.08	0.4	1.21e-14	Lung cancer;
LUSC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.67	0.43	1.92e-16	Cognitive test performance;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07627390	chr16:23652638	PALB2;DCTN5	-0.42	-6.99	-0.36	1.49e-11	Electrocardiographic conduction measures;
LUSC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg25039879	chr17:56429692	SUPT4H1	0.69	9.06	0.44	1.12e-17	Cognitive test performance;
LUSC	cis	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg17469321	chr7:55412551	NA	0.64	10.19	0.49	2.02e-21	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg20993868	chr7:22813445	NA	0.61	10.89	0.51	7.97e-24	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs2124969	0.548	rs72982036	chr2:161031590	G/A	cg03641300	chr2:160917029	PLA2R1	-0.46	-5.69	-0.3	2.84e-8	Waist circumference adjusted for body mass index;
LUSC	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg26769984	chr7:1090371	C7orf50	0.69	9.94	0.48	1.43e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.83	-10.57	-0.5	1.04e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs554111	0.613	rs3816455	chr1:21191430	A/G	cg01072550	chr1:21505969	NA	0.41	6.29	0.33	1.01e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	trans	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.34e-10	Life satisfaction;
LUSC	cis	rs2147959	0.941	rs1007686	chr1:228651457	A/G	cg18477163	chr1:228402036	OBSCN	-0.43	-5.97	-0.31	6.22e-9	Adult asthma;
LUSC	cis	rs710216	0.763	rs841857	chr1:43400016	C/T	cg22176566	chr1:43424700	SLC2A1	0.49	6.02	0.31	4.67e-9	Red cell distribution width;
LUSC	cis	rs1572438	1.000	rs9379167	chr6:866372	C/T	cg13447295	chr6:887704	NA	-0.38	-5.65	-0.3	3.43e-8	Aging;
LUSC	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg22508957	chr16:3507546	NAT15	0.41	6.58	0.34	1.8e-10	Body mass index (adult);
LUSC	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg12081754	chr8:22256438	SLC39A14	0.76	11.87	0.54	2.28e-27	Verbal declarative memory;
LUSC	cis	rs10761482	0.768	rs3919830	chr10:62108205	T/C	cg18175470	chr10:62150864	ANK3	-0.51	-7.31	-0.37	2e-12	Schizophrenia;
LUSC	cis	rs11608355	0.521	rs4766469	chr12:109836890	C/G	cg19025524	chr12:109796872	NA	0.4	7.4	0.38	1.11e-12	Neuroticism;
LUSC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	1.01	19.97	0.74	5.81e-59	Menopause (age at onset);
LUSC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg23262073	chr20:60523788	NA	-0.36	-5.74	-0.3	2.18e-8	Body mass index;
LUSC	cis	rs10865541	0.934	rs4627605	chr2:3411923	G/A	cg15807143	chr2:3452624	TTC15	0.34	5.91	0.31	8.31e-9	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-17.03	-0.68	2.87e-47	Coronary artery disease;
LUSC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs8064299	0.655	rs895691	chr17:72766300	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.56	9.41	0.46	8.55e-19	Monocyte count;
LUSC	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg22681709	chr2:178499509	PDE11A	-0.49	-9.08	-0.45	9.43e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.62	10.04	0.48	6.47e-21	Blood metabolite ratios;
LUSC	cis	rs2274273	0.840	rs10150760	chr14:55821548	C/T	cg04306507	chr14:55594613	LGALS3	-0.53	-11.65	-0.54	1.47e-26	Protein biomarker;
LUSC	cis	rs7789940	0.951	rs7787526	chr7:75947553	C/T	cg15798862	chr7:76129360	DTX2	-0.47	-7.68	-0.39	1.77e-13	Multiple sclerosis;
LUSC	cis	rs2742234	0.541	rs12220534	chr10:43734306	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.38	-6.65	-0.34	1.18e-10	Hirschsprung disease;
LUSC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	8.65	0.43	2.23e-16	Height;
LUSC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23158103	chr7:148848205	ZNF398	-0.5	-8.06	-0.4	1.38e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs629535	0.859	rs55803226	chr8:70108965	T/C	cg21567404	chr3:27674614	NA	-0.96	-15.51	-0.65	2.94e-41	Dupuytren's disease;
LUSC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26314531	chr2:26401878	FAM59B	0.74	10.06	0.48	5.92e-21	Gut microbiome composition (summer);
LUSC	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	0.75	9.62	0.47	1.64e-19	Menopause (age at onset);
LUSC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.22e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.57	-0.46	2.49e-19	Mood instability;
LUSC	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.01	-0.31	4.82e-9	Resting heart rate;
LUSC	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg04920474	chr2:44395004	PPM1B	0.65	8.35	0.42	1.9e-15	Height;
LUSC	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg03522245	chr20:25566470	NINL	0.36	5.89	0.31	9.51e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs16854884	0.837	rs6804060	chr3:143804040	C/T	cg06585982	chr3:143692056	C3orf58	0.43	6.17	0.32	2.01e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg01802117	chr1:53393560	SCP2	0.39	6.46	0.33	3.72e-10	Monocyte count;
LUSC	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.24	-0.37	3.08e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs422249	0.634	rs174609	chr11:61627811	T/C	cg06860612	chr11:61641270	FADS3	0.28	5.84	0.3	1.22e-8	Trans fatty acid levels;
LUSC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg13010199	chr12:38710504	ALG10B	0.66	10.03	0.48	7.06e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9811920	0.715	rs6776886	chr3:99906270	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.32	6.11	0.32	2.72e-9	Axial length;
LUSC	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.74	-0.43	1.17e-16	Monocyte percentage of white cells;
LUSC	cis	rs76419734	0.510	rs2553463	chr4:106730663	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.52	-5.84	-0.3	1.27e-8	Post bronchodilator FEV1;
LUSC	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.21	-0.37	3.87e-12	Bipolar disorder;
LUSC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg06618935	chr21:46677482	NA	-0.39	-8.02	-0.4	1.84e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20482337	chr12:104324290	LOC253724;HSP90B1	0.4	5.94	0.31	7.06e-9	Triglycerides;
LUSC	cis	rs7512552	0.839	rs11587575	chr1:150451863	T/C	cg15654264	chr1:150340011	RPRD2	0.62	10.31	0.49	8.23e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1784581	0.532	rs7767219	chr6:162423088	T/C	cg17173639	chr6:162384350	PARK2	0.57	9.98	0.48	1.05e-20	Itch intensity from mosquito bite;
LUSC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg06454157	chr6:167490870	NA	-0.28	-6.67	-0.34	1.08e-10	Primary biliary cholangitis;
LUSC	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.61e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs3087591	0.920	rs4795592	chr17:29612620	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.56	-8.13	-0.41	8.66e-15	Hip circumference;
LUSC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg24209194	chr3:40518798	ZNF619	0.45	6.0	0.31	5.1e-9	Renal cell carcinoma;
LUSC	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg08975724	chr8:8085496	FLJ10661	0.48	6.91	0.35	2.49e-11	Neuroticism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26251429	chr2:28113398	BRE;RBKS;LOC100302650	-0.48	-6.46	-0.33	3.78e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10189230	0.868	rs1367242	chr2:222353441	A/G	cg14652038	chr2:222343519	EPHA4	0.32	5.73	0.3	2.29e-8	Urate levels in lean individuals;
LUSC	cis	rs2361718	0.590	rs4527052	chr17:78140910	A/G	cg21238619	chr17:78079768	GAA	-0.35	-6.65	-0.34	1.23e-10	Yeast infection;
LUSC	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.44	5.91	0.31	8.4e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg06008330	chr7:65541103	ASL	0.4	6.17	0.32	1.96e-9	Aortic root size;
LUSC	cis	rs6942756	1.000	rs6467233	chr7:128868656	C/T	cg02491457	chr7:128862824	NA	-0.56	-8.05	-0.4	1.42e-14	White matter hyperintensity burden;
LUSC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.74	9.13	0.45	6.84e-18	Gut microbiome composition (summer);
LUSC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.89	15.49	0.65	3.73e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs617219	0.819	rs72766705	chr5:78562000	C/T	cg24856658	chr5:78533917	JMY	-0.32	-6.13	-0.32	2.49e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.86	14.17	0.61	4.94e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg04871131	chr7:94954202	PON1	-0.39	-6.08	-0.32	3.27e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1044826	1.000	rs4683818	chr3:139229619	G/T	cg00490450	chr3:139108681	COPB2	0.53	6.91	0.35	2.51e-11	Obesity-related traits;
LUSC	cis	rs11785693	0.862	rs13281354	chr8:4987756	G/T	cg26367366	chr8:4980734	NA	0.8	9.5	0.46	4.24e-19	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg22676075	chr6:135203613	NA	0.57	8.91	0.44	3.35e-17	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg06484146	chr7:12443880	VWDE	-0.62	-6.24	-0.32	1.36e-9	Coronary artery disease;
LUSC	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.55	-0.46	2.81e-19	Coronary artery disease;
LUSC	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg00898013	chr13:113819073	PROZ	-0.62	-8.75	-0.43	1.05e-16	Platelet distribution width;
LUSC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg15445000	chr17:37608096	MED1	0.4	6.7	0.34	9.08e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs3931020	0.745	rs1969111	chr1:75263485	A/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.4	-5.78	-0.3	1.68e-8	Resistin levels;
LUSC	cis	rs9650315	0.852	rs34985835	chr8:57166158	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.07	0.36	9.07e-12	Height;
LUSC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg12963246	chr6:28129442	ZNF389	0.56	7.69	0.39	1.71e-13	Depression;
LUSC	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg22676075	chr6:135203613	NA	0.47	7.18	0.37	4.47e-12	Red blood cell count;
LUSC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg14440974	chr22:39074834	NA	-0.4	-6.54	-0.34	2.25e-10	Menopause (age at onset);
LUSC	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.2e-13	Corneal astigmatism;
LUSC	cis	rs4474465	0.850	rs7936232	chr11:78266602	A/G	cg27205649	chr11:78285834	NARS2	0.52	6.12	0.32	2.64e-9	Alzheimer's disease (survival time);
LUSC	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-7.89	-0.4	4.24e-14	Body mass index;
LUSC	cis	rs1178968	1.000	rs2237285	chr7:72760213	C/T	cg25889504	chr7:72793014	NA	0.58	7.53	0.38	4.72e-13	Triglyceride levels;
LUSC	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.57	-9.45	-0.46	6.08e-19	Breast cancer;
LUSC	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg18200150	chr17:30822561	MYO1D	0.53	10.62	0.5	6.6e-23	Schizophrenia;
LUSC	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08564027	chr20:61660810	NA	0.93	17.11	0.68	1.47e-47	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6693567	0.565	rs4926395	chr1:150405298	T/C	cg15654264	chr1:150340011	RPRD2	0.43	6.79	0.35	5.16e-11	Migraine;
LUSC	cis	rs7572733	0.534	rs4850813	chr2:198775982	C/T	cg00792783	chr2:198669748	PLCL1	-0.45	-6.03	-0.31	4.26e-9	Dermatomyositis;
LUSC	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg22437258	chr11:111473054	SIK2	0.51	6.93	0.35	2.15e-11	Primary sclerosing cholangitis;
LUSC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	21.58	0.76	2.78e-65	Height;
LUSC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06481639	chr22:41940642	POLR3H	0.5	5.77	0.3	1.81e-8	Vitiligo;
LUSC	cis	rs7615316	0.779	rs9289648	chr3:142036520	A/G	cg16271453	chr3:142027066	XRN1	-0.4	-7.03	-0.36	1.21e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1018836	0.700	rs10504894	chr8:91516436	G/A	cg16814680	chr8:91681699	NA	-0.71	-11.06	-0.52	1.98e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.93	15.97	0.66	4.9e-43	Morning vs. evening chronotype;
LUSC	cis	rs59698941	0.550	rs60042615	chr5:132193220	A/G	cg14825688	chr5:132208181	LEAP2	-0.39	-5.91	-0.31	8.65e-9	Apolipoprotein A-IV levels;
LUSC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-10.41	-0.49	3.61e-22	Schizophrenia;
LUSC	cis	rs9549260	0.534	rs4943810	chr13:41297405	C/A	cg21288729	chr13:41239152	FOXO1	0.58	6.65	0.34	1.18e-10	Red blood cell count;
LUSC	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.7	-0.39	1.51e-13	Joint mobility (Beighton score);
LUSC	cis	rs10754283	0.967	rs6657988	chr1:90106745	G/C	cg21401794	chr1:90099060	LRRC8C	0.65	9.74	0.47	6.91e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs72634258	0.786	rs7539807	chr1:8183789	C/T	cg00042356	chr1:8021962	PARK7	0.61	7.34	0.37	1.63e-12	Inflammatory bowel disease;
LUSC	cis	rs2708977	0.730	rs674920	chr2:97070156	C/G	cg01950434	chr2:97203154	ARID5A	-0.48	-6.65	-0.34	1.17e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06022373	chr22:39101656	GTPBP1	0.83	13.64	0.6	5.66e-34	Menopause (age at onset);
LUSC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.48	5.82	0.3	1.4e-8	Renal function-related traits (BUN);
LUSC	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg06627628	chr2:24431161	ITSN2	-0.78	-11.39	-0.53	1.28e-25	Venous thromboembolism (SNP x SNP interaction);
LUSC	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.27	-17.54	-0.69	2.75e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg04775059	chr7:64541387	NA	-0.49	-7.34	-0.37	1.65e-12	Calcium levels;
LUSC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg01516881	chr6:292596	DUSP22	-0.53	-7.9	-0.4	4.11e-14	Menopause (age at onset);
LUSC	cis	rs6920965	0.602	rs10872302	chr6:126180631	G/T	cg05901451	chr6:126070800	HEY2	-0.49	-7.3	-0.37	2.17e-12	High light scatter reticulocyte count;
LUSC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.3	0.33	9.48e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7084921	0.548	rs12776483	chr10:101828600	C/A	cg11888571	chr10:102027403	CWF19L1	-0.41	-5.68	-0.3	2.95e-8	Bone mineral density;
LUSC	cis	rs2979489	0.786	rs2915595	chr8:30402817	A/G	cg26383811	chr8:30366931	RBPMS	0.46	7.24	0.37	3.15e-12	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs3925075	1.000	rs12923297	chr16:31360944	T/C	cg02846316	chr16:31340340	ITGAM	0.36	6.73	0.35	7.2e-11	IgA nephropathy;
LUSC	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07080220	chr10:102295463	HIF1AN	0.68	9.17	0.45	4.81e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs4729127	1.000	rs75903658	chr7:94006668	A/C	cg20086523	chr13:52378287	DHRS12	0.62	6.76	0.35	6.13e-11	Intelligence;
LUSC	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg22437258	chr11:111473054	SIK2	0.51	6.91	0.35	2.42e-11	Primary sclerosing cholangitis;
LUSC	trans	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.71e-10	Life satisfaction;
LUSC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.41	-0.38	1.03e-12	Blood metabolite levels;
LUSC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg24399712	chr22:39784796	NA	0.61	11.22	0.52	5.17e-25	Intelligence (multi-trait analysis);
LUSC	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-7.18	-0.37	4.51e-12	HDL cholesterol;
LUSC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.32	-6.26	-0.32	1.16e-9	Total body bone mineral density;
LUSC	cis	rs367943	0.712	rs1366393	chr5:112729472	A/G	cg12552261	chr5:112820674	MCC	0.37	6.23	0.32	1.42e-9	Type 2 diabetes;
LUSC	cis	rs17125944	0.615	rs7150808	chr14:53304871	C/T	cg00686598	chr14:53173677	PSMC6	-0.69	-6.02	-0.31	4.49e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7605827	0.780	rs2287279	chr2:15667778	G/A	cg19274914	chr2:15703543	NA	0.46	8.9	0.44	3.59e-17	Educational attainment (years of education);
LUSC	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg04539111	chr16:67997858	SLC12A4	-0.47	-6.42	-0.33	4.7e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg16339924	chr4:17578868	LAP3	0.51	7.79	0.39	8.8e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.3	-0.33	9.41e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg10857441	chr5:6722123	POLS	-0.42	-7.73	-0.39	1.25e-13	Menopause (age at onset);
LUSC	cis	rs4588572	0.644	rs7714871	chr5:77754268	G/T	cg11547950	chr5:77652471	NA	-0.48	-7.05	-0.36	1.01e-11	Triglycerides;
LUSC	trans	rs9860340	0.730	rs1509779	chr3:87642462	A/G	cg03644585	chr7:884825	UNC84A	0.42	6.04	0.31	4.05e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg10130564	chr11:117069849	TAGLN	0.37	6.37	0.33	6.42e-10	Blood protein levels;
LUSC	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg13010199	chr12:38710504	ALG10B	0.44	6.34	0.33	7.38e-10	Morning vs. evening chronotype;
LUSC	cis	rs4843185	0.516	rs374029	chr16:85725953	G/A	cg05245094	chr16:85669572	KIAA0182	0.42	6.33	0.33	7.73e-10	Platelet distribution width;
LUSC	cis	rs3755132	0.929	rs6431716	chr2:15734621	G/A	cg12888861	chr2:15731646	DDX1	0.5	7.34	0.37	1.68e-12	Wilms tumor;
LUSC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg20243544	chr17:37824526	PNMT	0.47	5.8	0.3	1.53e-8	Urinary metabolites;
LUSC	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg11645453	chr3:52864694	ITIH4	-0.4	-9.26	-0.45	2.57e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs11681884	0.786	rs11887249	chr2:113809266	C/T	cg19632953	chr13:113635898	MCF2L	0.69	6.03	0.31	4.45e-9	Stroke;
LUSC	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg15556689	chr8:8085844	FLJ10661	0.57	8.6	0.43	3.2e-16	Myopia (pathological);
LUSC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	8.98	0.44	2.09e-17	Post bronchodilator FEV1;
LUSC	cis	rs1419980	0.673	rs10772553	chr12:7768089	G/A	cg25828445	chr12:7781288	NA	-0.6	-6.32	-0.33	8.31e-10	HDL cholesterol levels;
LUSC	cis	rs7590368	1.000	rs7590368	chr2:10961474	T/C	cg15705551	chr2:10952987	PDIA6	0.58	8.0	0.4	2.11e-14	Educational attainment (years of education);
LUSC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05535760	chr7:792225	HEATR2	0.79	9.46	0.46	5.56e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs35079168	0.961	rs66475113	chr9:137284381	C/T	cg13941235	chr9:137270186	RXRA	-0.34	-6.08	-0.32	3.29e-9	Intelligence;
LUSC	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.49	0.33	3.11e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg09904177	chr6:26538194	HMGN4	-0.8	-5.92	-0.31	7.81e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg12963246	chr6:28129442	ZNF389	0.56	7.85	0.39	5.89e-14	Parkinson's disease;
LUSC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	10.94	0.51	5.07e-24	Platelet count;
LUSC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg16928487	chr17:17741425	SREBF1	0.47	9.32	0.45	1.68e-18	Total body bone mineral density;
LUSC	cis	rs7712401	0.601	rs246315	chr5:122266438	C/T	cg19077854	chr5:122220652	SNX24	0.42	9.36	0.46	1.18e-18	Mean platelet volume;
LUSC	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg16586182	chr3:47516702	SCAP	-0.52	-7.99	-0.4	2.25e-14	Colorectal cancer;
LUSC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.73	-11.06	-0.52	2e-24	Menarche (age at onset);
LUSC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.72	0.47	8.01e-20	Bipolar disorder;
LUSC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg23711669	chr6:146136114	FBXO30	-0.93	-17.79	-0.7	2.94e-50	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg27661571	chr11:113659931	NA	-0.58	-6.45	-0.33	3.9e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-0.81	-14.07	-0.61	1.26e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-7.78	-0.39	8.95e-14	Morning vs. evening chronotype;
LUSC	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg09754948	chr16:28834200	ATXN2L	0.44	6.48	0.33	3.35e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7759001	0.817	rs2393928	chr6:27351827	C/T	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	2.04e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs1784581	0.569	rs9365357	chr6:162414913	A/G	cg17173639	chr6:162384350	PARK2	0.57	9.95	0.48	1.32e-20	Itch intensity from mosquito bite;
LUSC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	0.68	12.04	0.55	5.63e-28	Gestational age at birth (maternal effect);
LUSC	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg15819921	chr19:927150	ARID3A	-0.43	-6.35	-0.33	7.14e-10	Life satisfaction;
LUSC	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg15737290	chr11:93063684	CCDC67	0.65	8.08	0.4	1.19e-14	Pulmonary function decline;
LUSC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg17173187	chr15:85201210	NMB	0.38	6.57	0.34	1.98e-10	Schizophrenia;
LUSC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg01879757	chr17:41196368	BRCA1	-0.49	-7.84	-0.39	6.18e-14	Menopause (age at onset);
LUSC	cis	rs4776059	0.959	rs12898644	chr15:52905233	A/G	cg22715398	chr15:52968154	KIAA1370	-0.68	-9.99	-0.48	1.01e-20	Schizophrenia;
LUSC	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg13010199	chr12:38710504	ALG10B	-0.62	-10.23	-0.49	1.55e-21	Heart rate;
LUSC	cis	rs7560272	0.502	rs4513320	chr2:73920741	T/C	cg20560298	chr2:73613845	ALMS1	0.39	6.01	0.31	4.73e-9	Schizophrenia;
LUSC	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg01475377	chr6:109611718	NA	0.4	7.15	0.36	5.47e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg05347473	chr6:146136440	FBXO30	-0.56	-9.76	-0.47	5.69e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs55665837	0.961	rs12795972	chr11:14443775	C/T	cg05501817	chr11:14380813	RRAS2	-0.41	-6.61	-0.34	1.51e-10	Vitamin D levels;
LUSC	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg06002616	chr8:101225028	SPAG1	-0.41	-6.92	-0.35	2.32e-11	Atrioventricular conduction;
LUSC	cis	rs243505	0.732	rs3800949	chr7:148479648	A/T	cg09806900	chr7:148480153	CUL1	-0.52	-7.8	-0.39	8.1e-14	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.03	0.58	1.14e-31	Prudent dietary pattern;
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.37	5.75	0.3	2.07e-8	Lymphocyte counts;
LUSC	trans	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg26043149	chr18:55253948	FECH	0.46	7.16	0.36	5.18e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-7.49	-0.38	6.18e-13	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.85	0.31	1.15e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs62400317	0.859	rs62438877	chr6:45089064	A/G	cg18551225	chr6:44695536	NA	-0.42	-6.87	-0.35	3.22e-11	Total body bone mineral density;
LUSC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.5	0.53	5.42e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.82	-0.35	4.26e-11	Total body bone mineral density;
LUSC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg07395648	chr5:131743802	NA	0.39	5.71	0.3	2.55e-8	Breast cancer;
LUSC	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg15704280	chr7:45808275	SEPT13	-0.71	-10.66	-0.5	4.81e-23	Coronary artery disease;
LUSC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg13628971	chr7:2884303	GNA12	0.5	7.14	0.36	5.82e-12	Height;
LUSC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05165339	chr4:1420672	NA	-0.3	-6.9	-0.35	2.67e-11	Longevity;
LUSC	cis	rs3931020	0.688	rs525487	chr1:75217420	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	-0.45	-5.66	-0.3	3.32e-8	Resistin levels;
LUSC	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-7.63	-0.39	2.54e-13	Schizophrenia;
LUSC	cis	rs6723226	0.806	rs2249109	chr2:32750879	G/A	cg02381751	chr2:32503542	YIPF4	0.61	9.39	0.46	9.38e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg25233709	chr10:116636983	FAM160B1	0.44	7.92	0.4	3.62e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2692947	0.644	rs3821051	chr2:96912787	A/G	cg22654517	chr2:96458247	NA	-0.29	-5.67	-0.3	3.11e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-11.11	-0.52	1.25e-24	Chronic sinus infection;
LUSC	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg23093090	chr10:104574429	C10orf26	-0.41	-6.9	-0.35	2.69e-11	Arsenic metabolism;
LUSC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg00409905	chr10:38381863	ZNF37A	-0.39	-6.61	-0.34	1.52e-10	Extrinsic epigenetic age acceleration;
LUSC	trans	rs34421088	0.506	rs7813424	chr8:11144517	G/A	cg06636001	chr8:8085503	FLJ10661	0.5	7.21	0.37	3.68e-12	Neuroticism;
LUSC	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg00530320	chr1:46809349	NSUN4	0.56	8.67	0.43	1.91e-16	Menopause (age at onset);
LUSC	trans	rs12165098	0.543	rs56190458	chr18:36748753	A/C	cg23858286	chr9:138135095	NA	-0.42	-6.18	-0.32	1.84e-9	Sleep duration;
LUSC	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg26384229	chr12:38710491	ALG10B	-0.55	-8.19	-0.41	5.43e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg17633681	chr16:88106987	BANP	0.5	9.44	0.46	6.8e-19	Menopause (age at onset);
LUSC	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.12	-0.45	7.26e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.08	0.4	1.17e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs78663649	0.614	rs76626935	chr19:16581375	T/C	cg05286348	chr19:16641544	CHERP	-1.36	-10.11	-0.48	3.96e-21	White blood cell count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03195230	chr11:64073135	ESRRA	-0.39	-6.01	-0.31	4.91e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs698813	0.604	rs2340813	chr2:44487398	T/C	cg00619915	chr2:44497795	NA	-0.53	-7.55	-0.38	4.09e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg19773385	chr1:10388646	KIF1B	-0.5	-8.71	-0.43	1.4e-16	Hepatocellular carcinoma;
LUSC	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg22117172	chr7:91764530	CYP51A1	-0.32	-5.82	-0.3	1.41e-8	Breast cancer;
LUSC	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.63	-0.34	1.37e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg02175503	chr12:58329896	NA	0.47	6.8	0.35	4.77e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1943345	0.519	rs11233504	chr11:82886525	A/G	cg07047830	chr11:82868014	PCF11	0.64	9.89	0.48	2.09e-20	Obesity-related traits;
LUSC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.59	9.68	0.47	1.05e-19	Total body bone mineral density;
LUSC	cis	rs4654899	0.931	rs4654726	chr1:21203898	A/C	cg01072550	chr1:21505969	NA	0.5	7.55	0.38	4.25e-13	Superior frontal gyrus grey matter volume;
LUSC	trans	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg15704280	chr7:45808275	SEPT13	-0.55	-6.36	-0.33	6.83e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7582720	1.000	rs72936846	chr2:203774734	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.38	0.42	1.49e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs4622329	0.553	rs12305145	chr12:102312526	A/G	cg23541617	chr12:102225335	GNPTAB	0.27	5.9	0.31	8.95e-9	Systemic lupus erythematosus;
LUSC	cis	rs3770081	1.000	rs6724025	chr2:86200835	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.82	-6.24	-0.32	1.33e-9	Facial emotion recognition (sad faces);
LUSC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.7	-10.7	-0.51	3.47e-23	Aortic root size;
LUSC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg05717871	chr11:638507	DRD4	-0.36	-6.09	-0.32	3.18e-9	Systemic lupus erythematosus;
LUSC	cis	rs2236918	0.622	rs1776177	chr1:242012149	C/T	cg17736920	chr1:242011382	EXO1	0.42	6.62	0.34	1.4e-10	Menopause (age at onset);
LUSC	cis	rs9359856	0.564	rs11962292	chr6:90476788	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.51	-0.42	5.78e-16	Bipolar disorder;
LUSC	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg06002616	chr8:101225028	SPAG1	-0.41	-6.95	-0.36	1.89e-11	Atrioventricular conduction;
LUSC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg25036284	chr2:26402008	FAM59B	-0.7	-9.85	-0.47	3.01e-20	Gut microbiome composition (summer);
LUSC	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.59	-7.65	-0.39	2.24e-13	Schizophrenia;
LUSC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.52	0.34	2.6e-10	Menarche (age at onset);
LUSC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	0.89	16.87	0.68	1.27e-46	Gestational age at birth (maternal effect);
LUSC	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg24375607	chr4:120327624	NA	0.75	11.14	0.52	1.04e-24	Corneal astigmatism;
LUSC	cis	rs1950626	0.750	rs34061904	chr14:101435974	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.77	0.39	9.83e-14	Pelvic organ prolapse (moderate/severe);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg09432166	chr1:109633189	TMEM167B	0.37	6.12	0.32	2.58e-9	Triglycerides;
LUSC	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg02269571	chr22:50332266	NA	-0.61	-9.0	-0.44	1.71e-17	Schizophrenia;
LUSC	cis	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.66	0.43	2.04e-16	Endometrial cancer;
LUSC	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs72960926	0.744	rs6926572	chr6:75044118	A/G	cg03266952	chr6:74778945	NA	-0.66	-6.11	-0.32	2.73e-9	Metabolite levels (MHPG);
LUSC	cis	rs4474465	1.000	rs7102316	chr11:78149365	C/T	cg27205649	chr11:78285834	NARS2	-0.53	-6.2	-0.32	1.69e-9	Alzheimer's disease (survival time);
LUSC	trans	rs72674100	1.000	rs61291954	chr4:97971955	C/T	cg16405019	chr1:18959625	PAX7	-0.58	-6.3	-0.33	9.4e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14442939	chr10:27389572	ANKRD26	0.78	8.57	0.42	3.88e-16	Breast cancer;
LUSC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06634786	chr22:41940651	POLR3H	0.54	6.27	0.32	1.12e-9	Vitiligo;
LUSC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg17264618	chr3:40429014	ENTPD3	0.36	7.51	0.38	5.36e-13	Renal cell carcinoma;
LUSC	cis	rs2637266	1.000	rs7475638	chr10:78358586	G/T	cg18941641	chr10:78392320	NA	-0.39	-7.31	-0.37	1.93e-12	Pulmonary function;
LUSC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.71	12.05	0.55	5.21e-28	Heart rate;
LUSC	cis	rs28830936	1.000	rs12440747	chr15:42036690	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.03	-0.31	4.33e-9	Diastolic blood pressure;
LUSC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg13683864	chr3:40499215	RPL14	-1.13	-20.07	-0.74	2.37e-59	Renal cell carcinoma;
LUSC	cis	rs1507153	0.604	rs236855	chr6:79341891	C/T	cg05283184	chr6:79620031	NA	0.4	7.42	0.38	9.68e-13	Sjögren's syndrome;
LUSC	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg05855489	chr10:104503620	C10orf26	-0.5	-7.57	-0.38	3.65e-13	Arsenic metabolism;
LUSC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg14895029	chr7:2775587	GNA12	-0.41	-6.28	-0.33	1.03e-9	Height;
LUSC	cis	rs730566	0.640	rs6442112	chr3:48316034	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	6.24	0.32	1.35e-9	Prion diseases;
LUSC	cis	rs10193935	1.000	rs13419669	chr2:42387254	T/C	cg27598129	chr2:42591480	NA	-0.59	-8.1	-0.41	1.01e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12476592	0.571	rs196125	chr2:63859268	C/T	cg10828910	chr2:63850056	LOC388955	0.48	5.7	0.3	2.69e-8	Childhood ear infection;
LUSC	cis	rs478607	0.834	rs2666560	chr11:64480308	C/T	cg19131476	chr11:64387923	NRXN2	-0.31	-5.68	-0.3	2.9e-8	Urate levels;
LUSC	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.57	10.0	0.48	8.88e-21	Birth weight;
LUSC	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg23029597	chr12:123009494	RSRC2	-0.71	-9.35	-0.46	1.27e-18	Body mass index;
LUSC	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg02353165	chr6:42928485	GNMT	0.48	6.58	0.34	1.83e-10	Blood protein levels;
LUSC	trans	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg05839875	chr5:39203190	FYB	-0.32	-6.14	-0.32	2.35e-9	Prostate cancer;
LUSC	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.7	-0.43	1.5e-16	Uric acid levels;
LUSC	cis	rs2242663	0.798	rs1945302	chr11:66337498	C/T	cg24851651	chr11:66362959	CCS	0.37	5.9	0.31	8.71e-9	Bipolar disorder;
LUSC	trans	rs9944275	0.860	rs34753049	chr15:97192214	T/C	cg18834029	chr10:103349097	POLL;RP11-529I10.4	-0.6	-5.97	-0.31	6.23e-9	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LUSC	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.92	15.67	0.65	7.3e-42	Bladder cancer;
LUSC	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg24375607	chr4:120327624	NA	0.77	11.56	0.53	3.04e-26	Corneal astigmatism;
LUSC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg21433313	chr16:3507492	NAT15	0.82	8.86	0.44	4.9e-17	Tuberculosis;
LUSC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08280861	chr8:58055591	NA	0.53	5.81	0.3	1.5e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4293296	0.525	rs761509	chr14:54820582	G/T	cg02257953	chr14:54816093	NA	0.43	6.0	0.31	5.23e-9	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg11502198	chr6:26597334	ABT1	0.64	10.06	0.48	5.52e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.79	0.43	8.13e-17	Prudent dietary pattern;
LUSC	cis	rs9815354	0.627	rs73073268	chr3:42021403	C/A	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg23791538	chr6:167370224	RNASET2	-0.43	-6.95	-0.36	1.93e-11	Crohn's disease;
LUSC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.46	-8.14	-0.41	8.08e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18402987	chr7:1209562	NA	0.43	5.78	0.3	1.76e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg13072238	chr3:49761600	GMPPB	-0.36	-5.66	-0.3	3.24e-8	Body mass index;
LUSC	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg24130564	chr14:104152367	KLC1	0.46	6.42	0.33	4.7e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10887741	0.690	rs4934358	chr10:89439744	C/A	cg13926569	chr10:89418898	PAPSS2	0.35	7.69	0.39	1.69e-13	Exercise (leisure time);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17097992	chr2:10443818	HPCAL1	0.44	5.97	0.31	6e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg12257692	chr3:49977190	RBM6	0.26	7.16	0.36	5.28e-12	Body mass index;
LUSC	cis	rs7584330	0.518	rs113812061	chr2:238447934	T/C	cg14458575	chr2:238380390	NA	0.55	6.54	0.34	2.33e-10	Prostate cancer;
LUSC	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg22800045	chr5:56110881	MAP3K1	0.43	5.94	0.31	7.13e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-1.07	-10.45	-0.5	2.57e-22	Alzheimer's disease (late onset);
LUSC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg09904177	chr6:26538194	HMGN4	0.76	14.14	0.61	6.79e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs56804039	1.000	rs11780966	chr8:8383396	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.7	-0.34	8.97e-11	Cervical cancer;
LUSC	cis	rs17789174	0.855	rs57997696	chr16:85082468	C/G	cg01715842	chr16:85045600	ZDHHC7	-0.42	-5.95	-0.31	6.93e-9	Dysphagia;
LUSC	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	7.02	0.36	1.25e-11	IgG glycosylation;
LUSC	trans	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	13.77	0.6	1.75e-34	Exhaled nitric oxide levels;
LUSC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15664640	chr17:80829946	TBCD	0.69	12.05	0.55	5.11e-28	Breast cancer;
LUSC	cis	rs9303542	0.559	rs8079617	chr17:46610028	T/G	cg09704116	chr17:46666958	LOC404266	-0.37	-6.52	-0.34	2.56e-10	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg20573242	chr4:122745356	CCNA2	0.64	9.22	0.45	3.55e-18	Type 2 diabetes;
LUSC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg04450456	chr4:17643702	FAM184B	0.4	6.85	0.35	3.67e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2481665	0.772	rs6661862	chr1:62534854	A/C	cg18591186	chr1:62594603	INADL	0.45	7.07	0.36	9.21e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg27432699	chr2:27873401	GPN1	-0.8	-14.43	-0.62	5.28e-37	Oral cavity cancer;
LUSC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg13393036	chr8:95962371	TP53INP1	-0.46	-10.16	-0.49	2.68e-21	Type 2 diabetes;
LUSC	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.43	-6.7	-0.34	9.04e-11	Systemic lupus erythematosus;
LUSC	cis	rs11229555	0.874	rs11605297	chr11:58296806	G/A	cg15696309	chr11:58395628	NA	-0.69	-8.8	-0.43	7.59e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2580764	0.565	rs6545466	chr2:55228392	C/T	cg09592903	chr2:55203963	RTN4	-0.48	-9.98	-0.48	1.04e-20	Mean platelet volume;
LUSC	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg10596483	chr8:143751796	JRK	0.55	7.85	0.39	5.61e-14	Schizophrenia;
LUSC	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg04998671	chr14:104000505	TRMT61A	-0.44	-6.77	-0.35	5.87e-11	Coronary artery disease;
LUSC	trans	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg25214090	chr10:38739885	LOC399744	0.5	7.28	0.37	2.36e-12	Corneal astigmatism;
LUSC	cis	rs1018836	0.570	rs6471084	chr8:91463666	T/C	cg16814680	chr8:91681699	NA	-0.52	-7.5	-0.38	5.73e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.72	-9.91	-0.48	1.9e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg26408565	chr15:76604113	ETFA	-0.43	-6.72	-0.34	8.07e-11	Blood metabolite levels;
LUSC	cis	rs2124969	0.527	rs72982044	chr2:161049395	G/A	cg03641300	chr2:160917029	PLA2R1	-0.46	-5.69	-0.3	2.72e-8	Waist circumference adjusted for body mass index;
LUSC	cis	rs1476679	1.000	rs34919929	chr7:100012334	G/A	cg19116668	chr7:99932089	PMS2L1	0.42	7.48	0.38	6.71e-13	Alzheimer's disease (late onset);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03923274	chr14:23388278	RBM23	-0.45	-5.95	-0.31	6.69e-9	Hepatitis;
LUSC	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg06623918	chr6:96969491	KIAA0776	0.74	8.79	0.43	8.3e-17	Migraine;Coronary artery disease;
LUSC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg22920501	chr2:26401640	FAM59B	-0.8	-11.89	-0.55	1.96e-27	Gut microbiome composition (summer);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14764512	chr3:49058575	MIR191;DALRD3;NDUFAF3;MIR425	0.38	6.15	0.32	2.21e-9	Asthma;
LUSC	cis	rs1018697	0.966	rs1475643	chr10:104546467	C/T	cg04362960	chr10:104952993	NT5C2	0.46	6.29	0.33	9.99e-10	Colorectal adenoma (advanced);
LUSC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.1	0.48	4.18e-21	Bipolar disorder;
LUSC	trans	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.18	-0.32	1.84e-9	Neuroticism;
LUSC	cis	rs3755132	0.929	rs57349592	chr2:15738959	C/T	cg12888861	chr2:15731646	DDX1	0.5	7.34	0.37	1.68e-12	Wilms tumor;
LUSC	cis	rs926938	0.563	rs360630	chr1:115415132	C/T	cg12756093	chr1:115239321	AMPD1	0.45	6.53	0.34	2.45e-10	Autism;
LUSC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg23711669	chr6:146136114	FBXO30	0.78	12.94	0.58	2.45e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg03254818	chr6:169586852	NA	-0.45	-6.31	-0.33	8.81e-10	Pulse pressure;
LUSC	trans	rs72674100	1.000	rs72882343	chr4:97993924	G/A	cg16405019	chr1:18959625	PAX7	-0.61	-6.41	-0.33	5.09e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs72792276	1.000	rs3805608	chr5:127480998	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	8.07	0.4	1.25e-14	Red cell distribution width;
LUSC	cis	rs1595825	0.786	rs16826740	chr2:198893927	A/G	cg00982548	chr2:198649783	BOLL	-0.54	-6.89	-0.35	2.72e-11	Ulcerative colitis;
LUSC	cis	rs10911363	0.549	rs2794619	chr1:183459670	G/A	cg09173681	chr1:183549694	NCF2	0.64	11.43	0.53	9.04e-26	Systemic lupus erythematosus;
LUSC	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg04352962	chr1:209979756	IRF6	0.52	5.79	0.3	1.65e-8	Cleft lip with or without cleft palate;
LUSC	trans	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	2.03e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6542838	0.641	rs6542841	chr2:99489039	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.65	-0.3	3.4e-8	Fear of minor pain;
LUSC	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	2e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.13	0.32	2.44e-9	Bipolar disorder;
LUSC	cis	rs7267979	0.565	rs4815437	chr20:25584788	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.7	-12.37	-0.56	3.44e-29	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs7568069	0.741	rs6726122	chr2:71583924	A/T	cg06465196	chr4:154387603	KIAA0922	0.43	6.12	0.32	2.67e-9	Height;
LUSC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg21033440	chr11:65409861	SIPA1	-0.54	-7.59	-0.38	3.22e-13	Blood pressure (age interaction);
LUSC	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.78	-0.35	5.37e-11	Neutrophil percentage of white cells;
LUSC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg06784218	chr1:46089804	CCDC17	0.48	9.55	0.46	2.81e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.9	0.35	2.64e-11	Tonsillectomy;
LUSC	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg23093090	chr10:104574429	C10orf26	-0.45	-5.69	-0.3	2.79e-8	Arsenic metabolism;
LUSC	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg04851639	chr8:1020857	NA	-0.34	-6.96	-0.36	1.86e-11	Schizophrenia;
LUSC	trans	rs11700980	1.000	rs16983164	chr21:30121450	C/A	cg05609335	chr17:75789393	NA	0.41	6.32	0.33	8.58e-10	QRS complex (12-leadsum);
LUSC	cis	rs4908769	0.627	rs2252865	chr1:8422676	T/C	cg00546117	chr1:8445545	RERE	0.29	5.68	0.3	2.89e-8	Allergy;
LUSC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.37	-6.48	-0.33	3.32e-10	High light scatter reticulocyte count;
LUSC	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.36	0.53	1.6e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7707921	1.000	rs6884232	chr5:81550043	G/A	cg15871215	chr5:81402204	ATG10	0.44	6.46	0.33	3.68e-10	Breast cancer;
LUSC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.85	17.82	0.7	2.17e-50	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08736216	chr1:53307985	ZYG11A	0.29	6.03	0.31	4.36e-9	Monocyte count;
LUSC	cis	rs1355223	0.573	rs2084970	chr11:34723729	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.13	-0.32	2.44e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00149659	chr3:10157352	C3orf10	0.88	12.24	0.56	9.98e-29	Alzheimer's disease;
LUSC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg25036284	chr2:26402008	FAM59B	0.77	10.94	0.51	5.08e-24	Gut microbiome composition (summer);
LUSC	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.82	-13.55	-0.6	1.28e-33	Morning vs. evening chronotype;
LUSC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg21361702	chr7:150065534	REPIN1	0.54	6.95	0.36	1.89e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.81	14.63	0.62	8.81e-38	Cognitive function;
LUSC	cis	rs12493885	0.585	rs61790899	chr3:153642124	C/T	cg17054900	chr3:154042577	DHX36	-0.59	-6.14	-0.32	2.34e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs367615	0.552	rs2963023	chr5:108730070	C/T	cg17395555	chr5:108820864	NA	-0.46	-7.99	-0.4	2.2e-14	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.9	0.31	9.03e-9	Menopause (age at onset);
LUSC	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg15711740	chr2:61764176	XPO1	-0.46	-6.91	-0.35	2.39e-11	Tuberculosis;
LUSC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18099408	chr3:52552593	STAB1	-0.43	-7.59	-0.38	3.17e-13	Bipolar disorder;
LUSC	cis	rs2274273	0.870	rs6573009	chr14:55682324	A/C	cg04306507	chr14:55594613	LGALS3	0.58	13.84	0.6	9.53e-35	Protein biomarker;
LUSC	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	10.44	0.5	2.85e-22	Electrocardiographic conduction measures;
LUSC	cis	rs2303282	0.716	rs6499837	chr16:56453981	C/T	cg00500540	chr16:56394104	NA	0.43	7.36	0.37	1.49e-12	Breast cancer;
LUSC	cis	rs11679564	0.714	rs4670638	chr2:37164911	C/G	cg14987922	chr2:37194071	STRN	0.63	9.64	0.47	1.43e-19	Immature fraction of reticulocytes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06090383	chr4:174292579	SAP30	0.49	6.8	0.35	4.77e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg02800362	chr5:177631904	HNRNPAB	0.87	12.96	0.58	2.18e-31	Obesity-related traits;
LUSC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg19812747	chr11:111475976	SIK2	0.5	7.32	0.37	1.89e-12	Primary sclerosing cholangitis;
LUSC	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg00745463	chr17:30367425	LRRC37B	-0.81	-9.48	-0.46	4.82e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs2067615	0.507	rs10746063	chr12:107086240	G/T	cg15890332	chr12:107067104	RFX4	0.35	6.13	0.32	2.51e-9	Heart rate;
LUSC	cis	rs2273669	0.588	rs111353760	chr6:109306493	T/G	cg05315195	chr6:109294784	ARMC2	-0.55	-6.21	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg26395211	chr5:140044315	WDR55	-0.38	-5.77	-0.3	1.85e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg25319279	chr11:5960081	NA	-0.39	-6.25	-0.32	1.22e-9	DNA methylation (variation);
LUSC	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg01528321	chr10:82214614	TSPAN14	0.95	14.47	0.62	3.61e-37	Post bronchodilator FEV1;
LUSC	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.5	10.05	0.48	6.07e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg15212455	chr7:39170539	POU6F2	0.51	7.86	0.4	5.17e-14	IgG glycosylation;
LUSC	cis	rs2270431	1	rs2270431	chr14:75270635	T/C	cg08847533	chr14:75593920	NEK9	0.45	6.26	0.32	1.16e-9	Neuroticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24928681	chr11:74700231	NEU3	0.48	7.26	0.37	2.74e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06544989	chr22:39130855	UNC84B	0.33	5.76	0.3	1.86e-8	Menopause (age at onset);
LUSC	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg16060761	chr17:80687452	NA	0.4	6.17	0.32	2.03e-9	Breast cancer;
LUSC	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-6.88	-0.35	3.01e-11	Fear of minor pain;
LUSC	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg26102564	chr10:131424627	MGMT	-0.39	-6.2	-0.32	1.69e-9	Response to temozolomide;
LUSC	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg13256891	chr4:100009986	ADH5	0.48	7.11	0.36	7.05e-12	Alcohol dependence;
LUSC	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg00531865	chr16:30841666	NA	-0.33	-5.92	-0.31	7.93e-9	Dementia with Lewy bodies;
LUSC	cis	rs72960926	0.744	rs11755740	chr6:74934131	C/T	cg03266952	chr6:74778945	NA	-0.84	-7.01	-0.36	1.33e-11	Metabolite levels (MHPG);
LUSC	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12826209	chr6:26865740	GUSBL1	-0.72	-8.99	-0.44	1.84e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-20.57	-0.75	2.54e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg27432699	chr2:27873401	GPN1	0.8	14.99	0.63	3.32e-39	Oral cavity cancer;
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23978390	chr7:1156363	C7orf50	0.48	6.83	0.35	3.98e-11	Longevity;Endometriosis;
LUSC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.75	0.39	1.1e-13	Electroencephalogram traits;
LUSC	cis	rs9796	0.621	rs1659227	chr15:41472398	G/A	cg18705301	chr15:41695430	NDUFAF1	0.49	8.54	0.42	4.68e-16	Menopause (age at onset);
LUSC	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.91	-15.2	-0.64	5.23e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs500891	0.525	rs7774996	chr6:84073387	A/G	cg08257003	chr6:84140564	ME1	0.35	8.49	0.42	6.69e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs1775715	0.707	rs2808081	chr10:32162342	C/T	cg26784012	chr10:32216390	ARHGAP12	-0.42	-7.11	-0.36	7.31e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg06263672	chr7:65235340	NA	0.44	6.26	0.32	1.16e-9	Calcium levels;
LUSC	cis	rs2078087	0.831	rs10494561	chr1:183247090	C/T	cg13843938	chr1:183241246	NMNAT2	0.46	6.08	0.32	3.3e-9	Obesity-related traits;
LUSC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-7.99	-0.4	2.28e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg00101154	chr16:420108	MRPL28	-0.43	-6.45	-0.33	3.84e-10	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs34526934	0.566	rs62624470	chr2:177040907	C/T	cg26754761	chr2:177040938	NA	-0.4	-7.82	-0.39	7.19e-14	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg18177682	chr1:160175593	PEA15	0.4	6.1	0.32	3.01e-9	Schizophrenia;
LUSC	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg25554036	chr4:6271136	WFS1	0.62	13.02	0.58	1.27e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg09307838	chr4:120376055	NA	0.68	9.61	0.47	1.77e-19	Corneal astigmatism;
LUSC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.2	0.49	1.94e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21877580	chr6:97731105	MIR548H3;C6orf167	-0.46	-6.88	-0.35	2.88e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26272105	chr1:47644977	NA	-0.46	-7.14	-0.36	5.77e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02809263	chr1:70671218	LRRC40;SFRS11	0.42	6.23	0.32	1.39e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1864400	0.690	rs7098237	chr10:43740513	T/A	cg07801480	chr10:43725741	RASGEF1A	-0.39	-5.88	-0.31	1.01e-8	Hirschsprung disease;
LUSC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7903847	0.642	rs9888117	chr10:99159963	C/G	cg08345082	chr10:99160200	RRP12	-0.33	-6.87	-0.35	3.15e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg04398451	chr17:18023971	MYO15A	-0.46	-7.38	-0.37	1.31e-12	Total body bone mineral density;
LUSC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg06074448	chr4:187884817	NA	-0.41	-6.89	-0.35	2.85e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.74	15.5	0.65	3.38e-41	Systemic lupus erythematosus;
LUSC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11645453	chr3:52864694	ITIH4	0.34	8.09	0.4	1.13e-14	Bipolar disorder;
LUSC	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg22709100	chr7:91322751	NA	0.39	5.79	0.3	1.67e-8	Breast cancer;
LUSC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00684032	chr4:1343700	KIAA1530	0.35	6.22	0.32	1.52e-9	Obesity-related traits;
LUSC	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	10.02	0.48	7.83e-21	Lymphocyte counts;
LUSC	trans	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Bladder cancer;
LUSC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg10729496	chr3:10149963	C3orf24	0.55	7.48	0.38	6.76e-13	Alzheimer's disease;
LUSC	cis	rs433852	0.898	rs376524	chr19:49116438	A/G	cg06530960	chr19:49140787	SEC1;DBP	-0.72	-9.26	-0.45	2.53e-18	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg14829155	chr15:31115871	NA	0.45	6.27	0.32	1.09e-9	Huntington's disease progression;
LUSC	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg22496339	chr2:162101262	NA	0.52	7.64	0.39	2.35e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg00990874	chr7:1149470	C7orf50	-0.55	-7.17	-0.37	4.94e-12	Bronchopulmonary dysplasia;
LUSC	trans	rs57046232	0.552	rs6085497	chr20:6315937	A/G	cg17788362	chr6:86352627	SYNCRIP	0.46	6.42	0.33	4.68e-10	Colorectal cancer;
LUSC	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	0.98	15.7	0.65	5.44e-42	Dupuytren's disease;
LUSC	cis	rs10193935	0.892	rs12612372	chr2:42414035	A/G	cg27598129	chr2:42591480	NA	-0.61	-8.05	-0.4	1.48e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg09035930	chr12:129282057	SLC15A4	0.73	16.0	0.66	3.52e-43	Systemic lupus erythematosus;
LUSC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	14.7	0.63	4.49e-38	Platelet count;
LUSC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08859206	chr1:53392774	SCP2	-0.54	-9.57	-0.46	2.45e-19	Monocyte count;
LUSC	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg15448220	chr1:150897856	SETDB1	0.39	5.66	0.3	3.19e-8	Melanoma;
LUSC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-7.92	-0.4	3.65e-14	Chronic sinus infection;
LUSC	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg24296786	chr1:45957014	TESK2	-0.51	-7.54	-0.38	4.33e-13	High light scatter reticulocyte count;
LUSC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg07424592	chr7:64974309	NA	0.69	6.19	0.32	1.81e-9	Diabetic kidney disease;
LUSC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg09165964	chr15:75287851	SCAMP5	0.55	7.98	0.4	2.42e-14	Breast cancer;
LUSC	trans	rs12692738	0.526	rs355846	chr2:165624586	C/T	cg26993132	chr16:89239499	CDH15	-0.3	-5.99	-0.31	5.43e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	20.01	0.74	4.1e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.46	8.38	0.42	1.46e-15	Eosinophil percentage of white cells;
LUSC	cis	rs7119	0.623	rs12905318	chr15:77845873	T/C	cg27398640	chr15:77910606	LINGO1	-0.32	-6.92	-0.35	2.32e-11	Type 2 diabetes;
LUSC	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg03585969	chr10:35415529	CREM	0.62	9.22	0.45	3.45e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9807989	0.801	rs6752482	chr2:102967858	T/C	cg09003973	chr2:102972529	NA	0.44	6.05	0.31	3.93e-9	Asthma;
LUSC	cis	rs12541635	0.966	rs6987512	chr8:106998770	C/T	cg10147462	chr8:107024639	NA	0.55	9.93	0.48	1.52e-20	Age of smoking initiation;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23647884	chr3:120315025	NDUFB4	-0.42	-6.24	-0.32	1.33e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs8060598	0.866	rs3135499	chr16:50766127	G/T	ch.13.865492R	chr13:60543691	DIAPH3	-0.45	-6.96	-0.36	1.82e-11	Leprosy;
LUSC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	0.99	14.03	0.61	1.78e-35	Vitiligo;
LUSC	cis	rs1451375	0.698	rs11489736	chr7:50645372	G/A	cg18232548	chr7:50535776	DDC	0.5	7.58	0.38	3.49e-13	Malaria;
LUSC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg10792982	chr14:105748885	BRF1	0.45	7.94	0.4	3.01e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg01483505	chr11:975446	AP2A2	0.43	6.04	0.31	4.05e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4919087	1.000	rs10786327	chr10:99071408	C/T	cg25902810	chr10:99078978	FRAT1	0.49	7.22	0.37	3.48e-12	Monocyte count;
LUSC	trans	rs12210905	0.688	rs10456051	chr6:27463436	T/C	cg14616345	chr9:133901267	LAMC3	-0.7	-5.99	-0.31	5.54e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-7.31	-0.37	2e-12	Coronary artery disease;
LUSC	cis	rs60695258	0.550	rs4693798	chr4:87914288	G/C	cg10685359	chr4:87814065	C4orf36	0.33	5.91	0.31	8.26e-9	Hematocrit;
LUSC	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg10018233	chr7:150070692	REPIN1	0.34	5.7	0.3	2.6e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg09044154	chr16:88155775	NA	-0.56	-7.62	-0.38	2.6e-13	Menopause (age at onset);
LUSC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg18512352	chr11:47633146	NA	-0.46	-9.22	-0.45	3.43e-18	Subjective well-being;
LUSC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.61	0.34	1.5e-10	Menopause (age at onset);
LUSC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.85	0.66	1.36e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.83	0.3	1.29e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs72720396	0.694	rs6689362	chr1:91203251	T/A	cg13456504	chr1:91191583	NA	-0.39	-5.74	-0.3	2.09e-8	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.41	6.54	0.34	2.3e-10	Schizophrenia;
LUSC	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg13010199	chr12:38710504	ALG10B	0.41	6.02	0.31	4.6e-9	Morning vs. evening chronotype;
LUSC	cis	rs2692947	0.727	rs749457	chr2:96795944	A/G	cg22654517	chr2:96458247	NA	0.37	7.36	0.37	1.44e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg03627880	chr6:151815985	C6orf97	-0.56	-5.9	-0.31	8.82e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg11764359	chr7:65958608	NA	0.51	6.67	0.34	1.09e-10	Aortic root size;
LUSC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg06238570	chr21:40685208	BRWD1	-0.57	-9.0	-0.44	1.78e-17	Menarche (age at onset);
LUSC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.7e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg19592336	chr6:28129416	ZNF389	0.49	6.5	0.34	2.96e-10	Depression;
LUSC	trans	rs9650657	0.740	rs34653170	chr8:10676542	G/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.01	-0.31	4.95e-9	Neuroticism;
LUSC	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg03340356	chr1:67600835	NA	0.43	6.93	0.35	2.22e-11	Psoriasis;
LUSC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	0.92	13.89	0.6	6.41e-35	Breast cancer;
LUSC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg17366294	chr4:99064904	C4orf37	0.52	8.46	0.42	8.33e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg25457927	chr22:38595422	NA	-0.41	-8.74	-0.43	1.14e-16	Cutaneous nevi;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10572969	chr11:13690188	FAR1	-0.5	-6.12	-0.32	2.65e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.26	0.37	2.75e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg24578937	chr1:2090814	PRKCZ	0.38	7.83	0.39	6.45e-14	Coronary artery disease;
LUSC	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg17507749	chr15:85114479	UBE2QP1	0.65	8.15	0.41	7.52e-15	Schizophrenia;
LUSC	cis	rs73198271	0.740	rs10100066	chr8:8650393	T/G	cg01851573	chr8:8652454	MFHAS1	0.52	8.36	0.42	1.69e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.86	-0.44	4.94e-17	Metabolite levels;
LUSC	cis	rs3768617	0.811	rs12120747	chr1:183042531	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.64	0.43	2.29e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs9296092	0.517	rs9461876	chr6:33516657	C/T	cg13560919	chr6:33536144	NA	-0.82	-15.45	-0.65	5.48e-41	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg07395648	chr5:131743802	NA	0.39	6.12	0.32	2.55e-9	Asthma (sex interaction);
LUSC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.59	0.38	3.26e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg08847533	chr14:75593920	NEK9	0.84	15.62	0.65	1.14e-41	Height;
LUSC	cis	rs239198	0.602	rs9377236	chr6:101289960	A/G	cg09795085	chr6:101329169	ASCC3	0.45	6.35	0.33	7.02e-10	Menarche (age at onset);
LUSC	cis	rs72772090	0.634	rs10515246	chr5:96099265	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.73	-8.27	-0.41	3.12e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg07677032	chr17:61819896	STRADA	0.44	7.33	0.37	1.78e-12	Prudent dietary pattern;
LUSC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	1.02	17.45	0.69	6.44e-49	Coronary artery disease;
LUSC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg17143192	chr8:8559678	CLDN23	0.39	5.93	0.31	7.36e-9	Mood instability;
LUSC	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg21427119	chr20:30132790	HM13	-0.36	-5.67	-0.3	3.14e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg09365446	chr1:150670422	GOLPH3L	0.5	7.43	0.38	9.44e-13	Melanoma;
LUSC	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg05090351	chr10:126851162	NA	-0.42	-6.78	-0.35	5.5e-11	Menarche (age at onset);
LUSC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.3	0.37	2.16e-12	Motion sickness;
LUSC	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-1.04	-12.47	-0.56	1.5e-29	Schizophrenia;
LUSC	cis	rs9646944	0.501	rs9807934	chr2:103040182	T/G	cg20060108	chr2:102954350	IL1RL1	0.48	6.56	0.34	2.1e-10	Blood protein levels;
LUSC	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg05855489	chr10:104503620	C10orf26	0.53	7.99	0.4	2.26e-14	Arsenic metabolism;
LUSC	cis	rs79387448	0.745	rs17027442	chr2:103164948	A/G	cg09003973	chr2:102972529	NA	-0.87	-8.41	-0.42	1.17e-15	Gut microbiota (bacterial taxa);
LUSC	cis	rs3862435	0.518	rs2589960	chr15:90916387	A/G	cg22089800	chr15:90895588	ZNF774	0.58	6.2	0.32	1.62e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-0.65	-9.59	-0.46	2.1e-19	Platelet distribution width;
LUSC	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg18721089	chr20:30220636	NA	-0.4	-6.72	-0.35	7.91e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg15445000	chr17:37608096	MED1	-0.39	-6.73	-0.35	7.47e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs8002861	0.664	rs4942246	chr13:44404853	A/G	cg12856521	chr11:46389249	DGKZ	0.43	6.33	0.33	7.82e-10	Leprosy;
LUSC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.49	0.53	5.79e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg23102388	chr7:1867652	MAD1L1	-0.32	-6.03	-0.31	4.29e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs67981189	0.572	rs7156009	chr14:71515431	G/A	cg15816911	chr14:71606274	NA	0.33	5.92	0.31	8e-9	Schizophrenia;
LUSC	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg17749961	chr2:30669863	LCLAT1	-0.63	-8.0	-0.4	2.1e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-13.69	-0.6	3.6e-34	Hemoglobin concentration;
LUSC	cis	rs56283067	0.887	rs9463043	chr6:44771114	T/C	cg20913747	chr6:44695427	NA	-0.47	-7.22	-0.37	3.63e-12	Total body bone mineral density;
LUSC	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.56	10.33	0.49	6.79e-22	Bone mineral density;
LUSC	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg19052272	chr2:3704530	ALLC	0.35	6.68	0.34	9.83e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs73206853	0.764	rs7980838	chr12:110672978	T/A	cg12870014	chr12:110450643	ANKRD13A	0.69	7.99	0.4	2.25e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	0.92	17.33	0.69	1.91e-48	Heart rate;
LUSC	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg09904177	chr6:26538194	HMGN4	-0.43	-6.21	-0.32	1.54e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs6076960	0.846	rs6053962	chr20:6176915	A/G	cg17788362	chr6:86352627	SYNCRIP	0.4	6.06	0.31	3.59e-9	Smooth-surface caries;
LUSC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg17330251	chr7:94953956	PON1	-0.38	-5.97	-0.31	6.02e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg04545296	chr12:48745243	ZNF641	0.34	6.26	0.32	1.2e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.59	9.69	0.47	1.01e-19	Aortic root size;
LUSC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	6.3	0.33	9.14e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs897080	0.515	rs1067398	chr2:44678882	A/G	cg00619915	chr2:44497795	NA	-0.45	-6.45	-0.33	3.83e-10	Height;
LUSC	cis	rs2742417	1.000	rs1969624	chr3:45734818	C/T	cg04837898	chr3:45731254	SACM1L	0.36	5.86	0.31	1.13e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	8.93	0.44	2.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg03733263	chr8:22462867	KIAA1967	0.99	17.76	0.7	3.67e-50	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs2742417	1.000	rs2742373	chr3:45784046	C/G	cg18779283	chr3:45636154	LIMD1	-0.33	-5.65	-0.3	3.49e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg03929089	chr4:120376271	NA	0.69	7.63	0.39	2.4e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg27170947	chr2:26402098	FAM59B	0.72	10.94	0.51	5.29e-24	Gut microbiome composition (summer);
LUSC	cis	rs4561483	0.801	rs33640	chr16:11986874	C/T	cg08843971	chr16:11963173	GSPT1	-0.46	-6.95	-0.36	1.95e-11	Testicular germ cell tumor;
LUSC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	7.08	0.36	8.46e-12	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg20503657	chr10:835505	NA	0.79	9.87	0.48	2.49e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	5.89	0.31	9.39e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs72960926	0.744	rs9359077	chr6:74982166	T/C	cg03266952	chr6:74778945	NA	-0.56	-5.72	-0.3	2.37e-8	Metabolite levels (MHPG);
LUSC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg15691649	chr6:25882328	NA	-0.41	-6.0	-0.31	5.04e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg11502198	chr6:26597334	ABT1	0.73	12.25	0.56	9.63e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.51	-0.34	2.79e-10	Bipolar disorder;
LUSC	trans	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg13010199	chr12:38710504	ALG10B	0.52	7.91	0.4	3.72e-14	Morning vs. evening chronotype;
LUSC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg15145296	chr3:125709740	NA	-0.57	-6.36	-0.33	6.67e-10	Blood pressure (smoking interaction);
LUSC	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg22089800	chr15:90895588	ZNF774	-0.62	-9.4	-0.46	9.14e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.53	-7.42	-0.38	9.86e-13	Mean platelet volume;
LUSC	trans	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	6.04	0.31	4.19e-9	Cystic fibrosis severity;
LUSC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.33	0.59	8.6e-33	Cognitive test performance;
LUSC	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.69	-11.65	-0.54	1.44e-26	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6456156	0.875	rs55802221	chr6:167517320	G/A	cg07741184	chr6:167504864	NA	-0.36	-6.4	-0.33	5.39e-10	Primary biliary cholangitis;
LUSC	cis	rs17540621	1.000	rs10196993	chr2:47240485	G/C	cg23978866	chr2:47230407	TTC7A	-0.75	-5.86	-0.31	1.14e-8	Response to statin therapy;
LUSC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.86	0.6	8.34e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg19628046	chr18:33552617	C18orf21	0.52	6.34	0.33	7.31e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg05283184	chr6:79620031	NA	-0.46	-8.63	-0.43	2.52e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26897989	chr16:1907736	C16orf73	-0.47	-7.11	-0.36	7.19e-12	Ankle injury;
LUSC	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.6	-0.38	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg25039879	chr17:56429692	SUPT4H1	0.67	9.01	0.44	1.65e-17	Cognitive test performance;
LUSC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg23711669	chr6:146136114	FBXO30	0.7	10.7	0.51	3.56e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1322512	1.000	rs2800632	chr6:153008632	C/A	cg27316956	chr6:152958899	SYNE1	0.35	6.17	0.32	1.97e-9	Tonometry;
LUSC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.56	7.29	0.37	2.28e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg18132916	chr6:79620363	NA	-0.38	-5.75	-0.3	2.03e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg08975724	chr8:8085496	FLJ10661	0.45	6.47	0.33	3.44e-10	Neuroticism;
LUSC	trans	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg14791747	chr16:20752902	THUMPD1	-0.4	-6.2	-0.32	1.62e-9	Dental caries;
LUSC	cis	rs963731	0.579	rs7594644	chr2:39206456	A/C	cg04010122	chr2:39346883	SOS1	-0.78	-5.7	-0.3	2.71e-8	Corticobasal degeneration;
LUSC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg20476274	chr7:133979776	SLC35B4	0.88	16.77	0.68	3.06e-46	Mean platelet volume;
LUSC	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	17.95	0.7	6.66e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs3862435	0.764	rs16974212	chr15:91015901	C/T	cg22089800	chr15:90895588	ZNF774	0.54	5.79	0.3	1.64e-8	Response to exercise (triglyceride level interaction);
LUSC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.37	5.65	0.3	3.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg05625103	chr10:2543513	NA	-0.43	-6.09	-0.32	3.13e-9	Age-related hearing impairment;
LUSC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	9.76	0.47	5.9e-20	Cognitive test performance;
LUSC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg03351412	chr1:154909251	PMVK	0.42	6.42	0.33	4.69e-10	Prostate cancer;
LUSC	trans	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg07817883	chr1:32538562	TMEM39B	-0.61	-7.45	-0.38	7.97e-13	Monocyte percentage of white cells;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16575025	chr1:112281790	C1orf183	-0.52	-6.2	-0.32	1.71e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.1	0.58	6.42e-32	Prudent dietary pattern;
LUSC	cis	rs231513	0.911	rs124719	chr17:41960343	T/C	cg26893861	chr17:41843967	DUSP3	-0.49	-5.85	-0.3	1.17e-8	Cognitive function;
LUSC	cis	rs6840360	1.000	rs28637056	chr4:152652501	A/G	cg22705602	chr4:152727874	NA	-0.28	-6.06	-0.31	3.76e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg20135002	chr11:47629003	NA	-0.52	-7.99	-0.4	2.2e-14	Subjective well-being;
LUSC	cis	rs9399401	0.925	rs1360194	chr6:142752595	A/G	cg03128060	chr6:142623767	GPR126	-0.31	-5.86	-0.31	1.12e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs941764	0.965	rs941765	chr14:91841358	G/C	cg10511902	chr14:91842949	CCDC88C	0.43	7.27	0.37	2.62e-12	Breast cancer;
LUSC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.94	-0.36	2.04e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs78572108	0.858	rs4468862	chr2:42265846	C/T	cg00607755	chr2:42274082	PKDCC	0.36	6.47	0.33	3.56e-10	Total body bone mineral density;
LUSC	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.7	-5.98	-0.31	5.61e-9	Major depressive disorder;
LUSC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	0.92	15.32	0.64	1.7e-40	Breast cancer;
LUSC	cis	rs35771425	0.619	rs6689078	chr1:211476423	C/G	cg25617285	chr1:211431773	RCOR3	-0.38	-5.74	-0.3	2.15e-8	Educational attainment (years of education);
LUSC	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.71	-12.65	-0.57	3.03e-30	White blood cell count (basophil);
LUSC	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg23544223	chr18:12777786	NA	0.59	6.27	0.32	1.15e-9	Inflammatory skin disease;
LUSC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg11812906	chr14:75593930	NEK9	0.55	8.61	0.43	2.96e-16	Height;
LUSC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12826209	chr6:26865740	GUSBL1	0.73	8.92	0.44	3.1e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-0.83	-13.84	-0.6	9.33e-35	Tonsillectomy;
LUSC	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg15123519	chr2:136567270	LCT	0.39	5.99	0.31	5.49e-9	Mosquito bite size;
LUSC	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg15309053	chr8:964076	NA	0.36	7.1	0.36	7.6e-12	Schizophrenia;
LUSC	cis	rs6500395	1.000	rs904818	chr16:48622582	T/C	cg04672837	chr16:48644449	N4BP1	0.5	7.42	0.38	9.53e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg23752985	chr2:85803571	VAMP8	0.3	6.39	0.33	5.45e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg19875535	chr5:140030758	IK	-0.53	-8.78	-0.43	8.59e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg27494647	chr7:150038898	RARRES2	0.44	6.84	0.35	3.85e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs548181	0.545	rs76179820	chr11:125616379	A/G	cg03464685	chr11:125439445	EI24	-0.92	-10.98	-0.51	3.76e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9888739	1.000	rs11865746	chr16:31326587	T/G	cg15817542	chr16:31343056	ITGAM	-0.51	-6.12	-0.32	2.58e-9	Systemic lupus erythematosus;
LUSC	cis	rs12760731	0.720	rs7524556	chr1:178446659	C/T	cg00404053	chr1:178313656	RASAL2	0.56	6.17	0.32	1.99e-9	Obesity-related traits;
LUSC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg22532475	chr10:104410764	TRIM8	-0.39	-8.14	-0.41	8.16e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg16339924	chr4:17578868	LAP3	0.55	8.48	0.42	7.61e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2302729	1.000	rs2302729	chr12:2783972	T/C	cg19945202	chr12:2788847	CACNA1C	-0.4	-5.71	-0.3	2.54e-8	Sleep quality;
LUSC	cis	rs259282	0.562	rs2021772	chr19:33107651	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	9.64	0.47	1.49e-19	Schizophrenia;
LUSC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg01652190	chr22:50026171	C22orf34	-0.32	-6.68	-0.34	1.02e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	0.9	14.73	0.63	3.34e-38	Breast cancer;
LUSC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg25767906	chr1:53392781	SCP2	0.47	8.41	0.42	1.22e-15	Monocyte count;
LUSC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	20.33	0.74	2.23e-60	Cognitive ability;
LUSC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg10523860	chr14:103875565	MARK3	-0.36	-5.8	-0.3	1.54e-8	Body mass index;
LUSC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13126279	chr21:47581558	C21orf56	-0.46	-6.82	-0.35	4.36e-11	Testicular germ cell tumor;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07761912	chr1:179846929	TOR1AIP2	0.44	7.35	0.37	1.52e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7178572	0.789	rs4886869	chr15:77799657	A/G	cg22256960	chr15:77711686	NA	-0.4	-6.44	-0.33	4.25e-10	Type 2 diabetes;
LUSC	cis	rs6076065	0.723	rs6083119	chr20:23390923	T/G	cg11657817	chr20:23433608	CST11	0.43	8.09	0.4	1.1e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg22782873	chr19:19639568	YJEFN3	-0.49	-6.12	-0.32	2.56e-9	Bipolar disorder;
LUSC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21545522	chr1:205238299	TMCC2	0.5	9.35	0.46	1.32e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	10.57	0.5	9.82e-23	Response to antipsychotic treatment;
LUSC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg04450456	chr4:17643702	FAM184B	0.37	6.08	0.32	3.3e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.19	-0.52	6.71e-25	Mean corpuscular volume;
LUSC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg14440974	chr22:39074834	NA	-0.36	-5.83	-0.3	1.31e-8	Menopause (age at onset);
LUSC	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg14809332	chr8:144654887	C8orf73	0.54	6.53	0.34	2.41e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.7	-10.11	-0.48	3.89e-21	Glomerular filtration rate;
LUSC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.57	-10.04	-0.48	6.85e-21	Extrinsic epigenetic age acceleration;
LUSC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11645453	chr3:52864694	ITIH4	0.4	8.73	0.43	1.26e-16	Bipolar disorder;
LUSC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.71	-0.34	8.54e-11	Lung cancer;
LUSC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg01802117	chr1:53393560	SCP2	0.38	6.25	0.32	1.22e-9	Monocyte count;
LUSC	cis	rs6977660	0.660	rs12531278	chr7:19816439	A/T	cg05791153	chr7:19748676	TWISTNB	0.68	7.22	0.37	3.49e-12	Thyroid stimulating hormone;
LUSC	trans	rs10090774	0.965	rs10111363	chr8:141928350	A/C	cg16477744	chr7:157367142	PTPRN2;MIR153-2	0.29	6.13	0.32	2.51e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg24154853	chr7:158122151	PTPRN2	0.44	8.65	0.43	2.2e-16	Calcium levels;
LUSC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg10057126	chr4:77819792	ANKRD56	0.54	8.04	0.4	1.56e-14	Emphysema distribution in smoking;
LUSC	trans	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.35	0.49	5.71e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7523273	0.606	rs2488253	chr1:207938709	C/A	cg22525895	chr1:207977042	MIR29B2	0.41	6.69	0.34	9.54e-11	Schizophrenia;
LUSC	cis	rs6693567	0.565	rs12093148	chr1:150265173	G/A	cg15654264	chr1:150340011	RPRD2	-0.45	-7.03	-0.36	1.14e-11	Migraine;
LUSC	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg13042288	chr15:90349979	ANPEP	-0.43	-6.23	-0.32	1.42e-9	Uric acid levels;
LUSC	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg00509249	chr6:109615579	CCDC162	-0.34	-6.04	-0.31	4.02e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.71	0.51	3.24e-23	Menopause (age at onset);
LUSC	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-5.77	-0.3	1.8e-8	Retinal vascular caliber;
LUSC	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg21433313	chr16:3507492	NAT15	-0.66	-10.82	-0.51	1.4e-23	Tuberculosis;
LUSC	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg02023728	chr11:77925099	USP35	0.51	7.49	0.38	6.27e-13	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.88e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.02	-0.36	1.27e-11	Alzheimer's disease (late onset);
LUSC	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg17173187	chr15:85201210	NMB	-0.37	-6.7	-0.34	8.96e-11	Schizophrenia;
LUSC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg06238570	chr21:40685208	BRWD1	0.45	6.94	0.36	2.04e-11	Cognitive function;
LUSC	trans	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs483180	0.512	rs598685	chr1:120215269	G/A	cg19096424	chr1:120255104	PHGDH	0.48	6.53	0.34	2.4e-10	Macular telangiectasia type 2;
LUSC	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg22089800	chr15:90895588	ZNF774	-0.63	-9.39	-0.46	9.86e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6704644	0.651	rs3820744	chr2:234361548	T/C	cg05711037	chr2:234359783	DGKD	0.63	6.71	0.34	8.33e-11	Bilirubin levels;
LUSC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg12310025	chr6:25882481	NA	0.44	7.46	0.38	7.36e-13	Blood metabolite levels;
LUSC	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg22244940	chr12:132335942	MMP17	0.41	5.96	0.31	6.36e-9	Migraine;
LUSC	cis	rs1866706	1.000	rs11022517	chr11:12884855	G/A	cg25843174	chr11:12811716	TEAD1	0.29	5.65	0.3	3.36e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg22563815	chr15:78856949	CHRNA5	0.26	6.33	0.33	8.12e-10	Sudden cardiac arrest;
LUSC	cis	rs6445797	0.692	rs28407059	chr3:56566036	C/T	cg13792233	chr3:56591045	CCDC66	0.42	5.65	0.3	3.38e-8	Gastritis;
LUSC	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg20607287	chr7:12443886	VWDE	-0.65	-6.42	-0.33	4.74e-10	Coronary artery disease;
LUSC	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.53	-0.42	5.25e-16	Total cholesterol levels;
LUSC	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg04725166	chr1:7887271	PER3	-0.45	-6.34	-0.33	7.27e-10	Crohn's disease;
LUSC	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg05738196	chr6:26577821	NA	-0.53	-8.37	-0.42	1.57e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg04450456	chr4:17643702	FAM184B	0.37	6.3	0.33	9.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.62	0.34	1.42e-10	Schizophrenia;
LUSC	cis	rs10450586	0.897	rs28416407	chr11:27308244	G/T	cg08958251	chr11:27270390	NA	0.36	5.93	0.31	7.37e-9	Total body bone mineral density;
LUSC	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg21775007	chr8:11205619	TDH	-0.68	-10.68	-0.5	4.35e-23	Retinal vascular caliber;
LUSC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg23985595	chr17:80112537	CCDC57	-0.31	-5.88	-0.31	9.76e-9	Life satisfaction;
LUSC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg22105103	chr4:187893119	NA	0.71	13.88	0.6	6.72e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.78	0.35	5.32e-11	Tonsillectomy;
LUSC	trans	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.46	-8.63	-0.43	2.48e-16	HDL cholesterol levels;HDL cholesterol;
LUSC	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg13010199	chr12:38710504	ALG10B	-0.57	-8.91	-0.44	3.41e-17	Morning vs. evening chronotype;
LUSC	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg02415014	chr8:143852576	LYNX1	0.34	7.9	0.4	4.05e-14	Urinary tract infection frequency;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22162225	chr2:62932835	EHBP1	-0.5	-6.07	-0.32	3.5e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg07936489	chr17:37558343	FBXL20	-0.63	-7.52	-0.38	5.16e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg12311346	chr5:56204834	C5orf35	-0.57	-8.69	-0.43	1.62e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	12.01	0.55	7.13e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg04025307	chr7:1156635	C7orf50	0.45	6.98	0.36	1.6e-11	Longevity;Endometriosis;
LUSC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg19592336	chr6:28129416	ZNF389	0.47	6.48	0.33	3.39e-10	Parkinson's disease;
LUSC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg25036284	chr2:26402008	FAM59B	-0.67	-9.23	-0.45	3.29e-18	Gut microbiome composition (summer);
LUSC	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-8.17	-0.41	6.3e-15	Morning vs. evening chronotype;
LUSC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg23283495	chr1:209979779	IRF6	0.45	7.19	0.37	4.37e-12	Monobrow;
LUSC	cis	rs6977660	0.660	rs10224938	chr7:19816227	A/G	cg05791153	chr7:19748676	TWISTNB	0.69	7.25	0.37	2.85e-12	Thyroid stimulating hormone;
LUSC	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	0.7	11.14	0.52	1.04e-24	Blood metabolite ratios;
LUSC	cis	rs877282	1.000	rs11253362	chr10:770979	G/T	cg17470449	chr10:769945	NA	0.55	7.85	0.39	5.77e-14	Uric acid levels;
LUSC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg16434002	chr17:42200994	HDAC5	0.44	5.86	0.31	1.1e-8	Total body bone mineral density;
LUSC	cis	rs2540226	0.569	rs6717356	chr2:40051216	C/T	cg23576258	chr2:39999331	THUMPD2	-0.34	-5.68	-0.3	2.93e-8	Personality dimensions;
LUSC	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg22563815	chr15:78856949	CHRNA5	-0.25	-5.96	-0.31	6.58e-9	Sudden cardiac arrest;
LUSC	trans	rs9380880	0.826	rs2273062	chr6:39550935	C/A	cg12580580	chr10:74544059	CCDC109A	0.59	6.68	0.34	9.96e-11	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg06096015	chr1:231504339	EGLN1	0.58	10.45	0.5	2.68e-22	Hemoglobin concentration;
LUSC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg01879757	chr17:41196368	BRCA1	-0.46	-6.94	-0.35	2.08e-11	Menopause (age at onset);
LUSC	cis	rs11587400	0.634	rs4839385	chr1:115121461	A/G	cg12756093	chr1:115239321	AMPD1	0.42	6.32	0.33	8.35e-10	Autism;
LUSC	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg12940439	chr1:67600707	NA	0.36	6.04	0.31	4.17e-9	Psoriasis;
LUSC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	9.27	0.45	2.38e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.44	-6.5	-0.34	2.96e-10	Schizophrenia;
LUSC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg00343986	chr7:65444356	GUSB	0.44	6.8	0.35	4.95e-11	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04824553	chr4:103748367	UBE2D3	-0.42	-6.28	-0.32	1.08e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg21095983	chr6:86352623	SYNCRIP	0.53	8.35	0.42	1.85e-15	Smooth-surface caries;
LUSC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-1.04	-15.25	-0.64	3.19e-40	Initial pursuit acceleration;
LUSC	cis	rs7178572	0.889	rs11857450	chr15:77802791	C/G	cg22256960	chr15:77711686	NA	0.5	8.32	0.41	2.3e-15	Type 2 diabetes;
LUSC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00149659	chr3:10157352	C3orf10	1.0	14.38	0.62	7.83e-37	Alzheimer's disease;
LUSC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg26513180	chr16:89883248	FANCA	0.91	17.71	0.7	5.61e-50	Vitiligo;
LUSC	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg24011408	chr12:48396354	COL2A1	-0.51	-8.37	-0.42	1.6e-15	Plateletcrit;
LUSC	cis	rs2282300	0.739	rs10742237	chr11:30310659	C/T	cg25418670	chr11:30344373	C11orf46	0.64	9.15	0.45	5.83e-18	Morning vs. evening chronotype;
LUSC	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg09491104	chr22:46646882	C22orf40	-0.66	-6.9	-0.35	2.55e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg13798912	chr7:905769	UNC84A	-0.56	-5.89	-0.31	9.24e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs3772130	1.000	rs7427165	chr3:121364624	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	9.37	0.46	1.1e-18	Cognitive performance;
LUSC	cis	rs6728642	0.572	rs13403225	chr2:97600827	A/G	cg26665480	chr2:98280029	ACTR1B	-0.71	-7.4	-0.38	1.14e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00890378	chr1:33816159	PHC2	0.7	6.01	0.31	4.82e-9	Cognitive performance;
LUSC	cis	rs2637266	0.745	rs2583039	chr10:78440187	A/G	cg18941641	chr10:78392320	NA	0.35	6.34	0.33	7.66e-10	Pulmonary function;
LUSC	cis	rs10760158	0.865	rs10739594	chr9:124035380	A/G	cg14417974	chr9:124058376	GSN	-0.32	-5.79	-0.3	1.63e-8	Pulse pressure;
LUSC	cis	rs12541635	0.737	rs736627	chr8:107100285	C/T	cg10147462	chr8:107024639	NA	-0.41	-7.34	-0.37	1.65e-12	Age of smoking initiation;
LUSC	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg04850211	chr1:228464232	OBSCN	-0.36	-6.12	-0.32	2.56e-9	Diastolic blood pressure;
LUSC	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg07828340	chr4:882639	GAK	1.1	11.94	0.55	1.33e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg04369109	chr6:150039330	LATS1	-0.57	-8.38	-0.42	1.51e-15	Lung cancer;
LUSC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg22963979	chr7:1858916	MAD1L1	-0.6	-9.44	-0.46	6.63e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	1.1	27.11	0.83	2.32e-86	Testicular germ cell tumor;
LUSC	cis	rs939658	0.728	rs12904789	chr15:79412589	G/A	cg17916960	chr15:79447300	NA	-0.48	-9.02	-0.44	1.45e-17	Refractive error;
LUSC	trans	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg05926928	chr17:57297772	GDPD1	-0.48	-6.71	-0.34	8.57e-11	Schizophrenia;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg07602492	chr1:72750241	NA	0.41	6.38	0.33	5.81e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg07741184	chr6:167504864	NA	0.39	6.95	0.36	1.96e-11	Primary biliary cholangitis;
LUSC	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.48	-7.21	-0.37	3.73e-12	Height;
LUSC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg06494592	chr3:125709126	NA	-0.5	-5.7	-0.3	2.61e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.64	-0.34	1.24e-10	Response to antipsychotic treatment;
LUSC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg10729496	chr3:10149963	C3orf24	0.57	7.42	0.38	9.8e-13	Alzheimer's disease;
LUSC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg02475777	chr4:1388615	CRIPAK	0.38	5.77	0.3	1.82e-8	Obesity-related traits;
LUSC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06634786	chr22:41940651	POLR3H	0.52	6.04	0.31	4.17e-9	Vitiligo;
LUSC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6480314	0.542	rs4403687	chr10:70028052	A/G	cg04882175	chr6:131122610	NA	-0.52	-6.2	-0.32	1.67e-9	Optic nerve measurement (disc area);
LUSC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg14668632	chr7:2872130	GNA12	-0.44	-6.37	-0.33	6.4e-10	Height;
LUSC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg02527881	chr3:46936655	PTH1R	-0.38	-6.74	-0.35	7.06e-11	Colorectal cancer;
LUSC	cis	rs7113850	0.541	rs7928230	chr11:24220604	A/G	ch.11.24196551F	chr11:24239977	NA	0.99	8.89	0.44	3.77e-17	Bone fracture in osteoporosis;
LUSC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg09359103	chr1:154839909	KCNN3	-0.69	-15.84	-0.65	1.53e-42	Prostate cancer;
LUSC	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22496380	chr5:211416	CCDC127	-0.79	-9.25	-0.45	2.68e-18	Breast cancer;
LUSC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.84	0.63	1.31e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.09	0.32	3.15e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.98	-13.61	-0.6	7.15e-34	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9311676	0.632	rs56026131	chr3:58422483	C/G	cg26110898	chr3:58419937	PDHB	0.4	6.39	0.33	5.46e-10	Systemic lupus erythematosus;
LUSC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg25036284	chr2:26402008	FAM59B	0.65	8.63	0.43	2.5e-16	Gut microbiome composition (summer);
LUSC	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	8.46	0.42	8.63e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg19539972	chr4:7069911	GRPEL1	0.7	9.04	0.44	1.28e-17	Monocyte percentage of white cells;
LUSC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg08999081	chr20:33150536	PIGU	0.48	9.39	0.46	9.68e-19	Coronary artery disease;
LUSC	cis	rs3862435	0.706	rs10520686	chr15:90997429	C/G	cg22089800	chr15:90895588	ZNF774	0.56	5.95	0.31	6.67e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg03733263	chr8:22462867	KIAA1967	0.78	12.37	0.56	3.4e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs3755132	0.929	rs16862838	chr2:15788191	A/G	cg12888861	chr2:15731646	DDX1	-0.49	-7.26	-0.37	2.65e-12	Wilms tumor;
LUSC	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.33e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg13010199	chr12:38710504	ALG10B	0.69	10.76	0.51	2.14e-23	Morning vs. evening chronotype;
LUSC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.6	-10.43	-0.5	3.19e-22	Lung cancer;
LUSC	cis	rs7598759	0.712	rs6727372	chr2:232331906	T/G	cg19187155	chr2:232395269	NMUR1	0.49	7.2	0.37	3.99e-12	Noise-induced hearing loss;
LUSC	cis	rs3750965	0.734	rs11604251	chr11:68820429	A/G	cg06818126	chr11:68850279	TPCN2	0.43	6.19	0.32	1.81e-9	Hair color;
LUSC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg19717773	chr7:2847554	GNA12	-0.34	-5.73	-0.3	2.22e-8	Height;
LUSC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg11861562	chr11:117069780	TAGLN	0.45	8.25	0.41	3.7e-15	Blood protein levels;
LUSC	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.06	-14.62	-0.62	8.84e-38	Lung cancer in ever smokers;
LUSC	cis	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05901451	chr6:126070800	HEY2	-0.58	-8.7	-0.43	1.5e-16	Endometrial cancer;
LUSC	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg17376030	chr22:41985996	PMM1	0.43	5.9	0.31	9.1e-9	Vitiligo;
LUSC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	12.4	0.56	2.59e-29	Multiple sclerosis;
LUSC	cis	rs2348418	0.864	rs7136843	chr12:28717808	C/G	cg13890972	chr12:28721907	NA	-0.34	-5.93	-0.31	7.72e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs17685	0.884	rs8565	chr7:75630274	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.45	6.65	0.34	1.16e-10	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs17102423	0.826	rs17825846	chr14:65598752	C/G	cg11161011	chr14:65562177	MAX	-0.67	-10.4	-0.49	4.08e-22	Obesity-related traits;
LUSC	cis	rs2267681	0.603	rs2267679	chr7:139539218	C/T	cg14116596	chr7:139528673	TBXAS1	0.38	6.57	0.34	1.88e-10	Cervical cancer;
LUSC	cis	rs17095355	1.000	rs17095350	chr10:111701708	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.67	-0.39	1.93e-13	Biliary atresia;
LUSC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.79	-0.35	5.24e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg10756647	chr7:56101905	PSPH	0.81	8.47	0.42	7.95e-16	Diabetic kidney disease;
LUSC	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg18512352	chr11:47633146	NA	0.28	5.79	0.3	1.62e-8	Subjective well-being;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00986184	chr20:62151995	PPDPF	0.72	6.29	0.33	1.01e-9	Cognitive performance;
LUSC	cis	rs2835872	0.861	rs67739865	chr21:39049101	G/A	cg20424643	chr21:39039972	KCNJ6	0.42	6.22	0.32	1.51e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11141652	chr22:24348549	GSTTP1	-0.42	-6.54	-0.34	2.26e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs67072384	0.818	rs12284245	chr11:72477668	C/T	cg04827223	chr11:72435913	ARAP1	-0.9	-6.37	-0.33	6.4e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg20821713	chr7:1055600	C7orf50	-0.56	-7.53	-0.38	4.86e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.68	-0.34	9.86e-11	Response to antipsychotic treatment;
LUSC	cis	rs72781680	0.715	rs72796332	chr2:24142060	G/A	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.57	10.82	0.51	1.36e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs977987	0.806	rs34021527	chr16:75474090	A/G	cg04384234	chr16:75411784	CFDP1	-0.43	-7.11	-0.36	6.95e-12	Dupuytren's disease;
LUSC	cis	rs7851660	0.809	rs7032114	chr9:100656459	T/G	cg13688889	chr9:100608707	NA	-0.54	-8.42	-0.42	1.12e-15	Strep throat;
LUSC	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.47	-5.69	-0.3	2.83e-8	Schizophrenia;
LUSC	trans	rs445114	0.509	rs432523	chr8:128337927	A/T	cg10897648	chr18:56338258	MALT1	-0.42	-6.33	-0.33	8.12e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2200578	0.836	rs72957179	chr2:99693578	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.64	7.59	0.38	3.21e-13	IgG glycosylation;
LUSC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.94	-0.44	2.67e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08677398	chr8:58056175	NA	0.57	6.89	0.35	2.79e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11645453	chr3:52864694	ITIH4	0.33	7.6	0.38	3.08e-13	Bipolar disorder;
LUSC	cis	rs7089973	0.872	rs7072356	chr10:116634651	T/C	cg23260525	chr10:116636907	FAM160B1	0.39	7.99	0.4	2.19e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9300255	0.722	rs1060105	chr12:123806219	C/T	cg13010344	chr12:123464640	ARL6IP4	0.5	6.21	0.32	1.58e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg14092988	chr3:52407081	DNAH1	0.31	6.09	0.32	3.04e-9	Bipolar disorder;
LUSC	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg24468199	chr11:65410028	SIPA1	-0.53	-6.95	-0.36	1.93e-11	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg25019033	chr10:957182	NA	-0.52	-7.05	-0.36	1.02e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs240764	0.658	rs846803	chr6:101272801	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-6.65	-0.34	1.19e-10	Neuroticism;
LUSC	cis	rs4737010	0.959	rs4737009	chr8:41630405	A/G	cg17182837	chr8:41585554	ANK1	-0.36	-6.53	-0.34	2.5e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05732436	chr2:68290174	C1D	-0.39	-6.07	-0.32	3.49e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.16	14.74	0.63	3.26e-38	Lung cancer in ever smokers;
LUSC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg13397359	chr6:42928475	GNMT	0.64	10.66	0.5	5.13e-23	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.39	-0.42	1.35e-15	Coffee consumption (cups per day);
LUSC	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg01028140	chr2:1542097	TPO	-0.52	-8.45	-0.42	9.07e-16	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11645453	chr3:52864694	ITIH4	0.34	8.08	0.4	1.21e-14	Electroencephalogram traits;
LUSC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.11	-0.32	2.76e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg03146154	chr1:46216737	IPP	-0.52	-7.39	-0.37	1.21e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.59	-10.49	-0.5	1.97e-22	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.85	0.47	3e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg04036182	chr15:45458818	NA	-0.36	-5.73	-0.3	2.22e-8	Glomerular filtration rate;
LUSC	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg09307838	chr4:120376055	NA	0.73	10.21	0.49	1.75e-21	Corneal astigmatism;
LUSC	cis	rs300890	0.513	rs4277733	chr4:144048046	A/G	cg19326217	chr4:144171750	NA	0.39	5.94	0.31	7.33e-9	Nasopharyngeal carcinoma;
LUSC	cis	rs6961069	0.573	rs10268765	chr7:80240073	C/G	cg04458919	chr7:80252533	CD36	-0.4	-7.28	-0.37	2.39e-12	Platelet count;
LUSC	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.16	-23.13	-0.78	2.51e-71	Exhaled nitric oxide output;
LUSC	trans	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg06606381	chr12:133084897	FBRSL1	-0.45	-5.95	-0.31	6.74e-9	Depression;
LUSC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08219700	chr8:58056026	NA	0.69	8.07	0.4	1.27e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2219968	0.962	rs13266874	chr8:78946400	T/C	cg00738934	chr8:78996279	NA	0.37	6.63	0.34	1.3100000000000001e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7264396	0.887	rs224392	chr20:34107956	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.22	-0.32	1.48e-9	Total cholesterol levels;
LUSC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg22166914	chr1:53195759	ZYG11B	0.56	9.12	0.45	6.96e-18	Monocyte count;
LUSC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12677618	1.000	rs10092931	chr8:142307201	A/G	cg27411547	chr8:142287226	NA	-0.4	-6.69	-0.34	9.66e-11	Plateletcrit;
LUSC	cis	rs60695258	0.550	rs340641	chr4:87951393	C/T	cg10685359	chr4:87814065	C4orf36	0.34	5.99	0.31	5.47e-9	Hematocrit;
LUSC	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg21798802	chr22:38057573	PDXP	0.48	10.51	0.5	1.6400000000000001e-22	Fat distribution (HIV);
LUSC	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg13628971	chr7:2884303	GNA12	0.4	6.0	0.31	5.19e-9	Height;
LUSC	cis	rs113835537	0.529	rs4930379	chr11:66255674	G/A	cg24851651	chr11:66362959	CCS	0.54	8.02	0.4	1.77e-14	Airway imaging phenotypes;
LUSC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg05729581	chr11:3078854	CARS	-0.56	-8.42	-0.42	1.1e-15	Longevity;
LUSC	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg17691542	chr6:26056736	HIST1H1C	0.66	9.56	0.46	2.75e-19	Height;
LUSC	cis	rs4654899	0.865	rs6691824	chr1:21417577	T/G	cg01072550	chr1:21505969	NA	-0.48	-7.1	-0.36	7.67e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs1403694	0.695	rs10937266	chr3:186433075	G/A	cg12454167	chr3:186435060	KNG1	0.34	8.42	0.42	1.1e-15	Blood protein levels;
LUSC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	12.49	0.56	1.27e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg03342759	chr3:160939853	NMD3	0.48	6.68	0.34	9.74e-11	Parkinson's disease;
LUSC	trans	rs16848425	1.000	rs16848442	chr4:73526180	T/C	cg15289899	chr11:2397255	CD81	0.67	5.95	0.31	6.78e-9	Height;
LUSC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	0.93	12.7	0.57	1.98e-30	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs13385	0.769	rs4912707	chr5:139624461	A/G	cg26211634	chr5:139558579	C5orf32	0.47	7.18	0.37	4.7e-12	Atrial fibrillation;
LUSC	cis	rs12594515	1.000	rs8043291	chr15:45996247	T/A	cg06207120	chr15:45996521	NA	0.39	5.86	0.31	1.11e-8	Waist circumference;Weight;
LUSC	cis	rs12200782	0.932	rs12212145	chr6:26646418	T/A	cg11502198	chr6:26597334	ABT1	-0.74	-5.77	-0.3	1.8e-8	Small cell lung carcinoma;
LUSC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg25258033	chr6:167368657	RNASET2	0.38	5.82	0.3	1.38e-8	Primary biliary cholangitis;
LUSC	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg07828024	chr6:149772892	ZC3H12D	0.3	6.56	0.34	2.1e-10	Dupuytren's disease;
LUSC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg00310523	chr12:86230176	RASSF9	-0.46	-8.8	-0.43	7.25e-17	Major depressive disorder;
LUSC	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	7.99	0.4	2.29e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg03522245	chr20:25566470	NINL	0.35	5.74	0.3	2.15e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	0.92	15.4	0.64	8.61e-41	Menopause (age at onset);
LUSC	cis	rs7089973	0.872	rs11818115	chr10:116634891	G/A	cg23260525	chr10:116636907	FAM160B1	0.39	7.99	0.4	2.19e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9398803	0.830	rs1415671	chr6:126759587	T/G	cg19875578	chr6:126661172	C6orf173	0.42	6.14	0.32	2.33e-9	Male-pattern baldness;
LUSC	cis	rs193541	0.632	rs10037044	chr5:122123299	A/G	cg19077854	chr5:122220652	SNX24	-0.39	-8.12	-0.41	8.99e-15	Glucose homeostasis traits;
LUSC	cis	rs2835872	0.758	rs1709832	chr21:39038167	A/C	cg20424643	chr21:39039972	KCNJ6	-0.44	-6.87	-0.35	3.18e-11	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-12.69	-0.57	2.27e-30	Hemoglobin concentration;
LUSC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	0.66	9.24	0.45	3.02e-18	Methadone dose in opioid dependence;
LUSC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg03060546	chr3:49711283	APEH	0.71	11.84	0.54	3.09e-27	Resting heart rate;
LUSC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg20302533	chr7:39170763	POU6F2	0.52	8.63	0.43	2.51e-16	IgG glycosylation;
LUSC	cis	rs4664304	0.772	rs12692572	chr2:160743793	G/A	cg23995753	chr2:160760732	LY75	0.32	6.07	0.32	3.41e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg25482853	chr8:67687455	SGK3	1.12	15.31	0.64	1.89e-40	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.33	0.45	1.52e-18	Prudent dietary pattern;
LUSC	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg05985134	chr18:33552581	C18orf21	0.51	6.97	0.36	1.73e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg14664628	chr15:75095509	CSK	-0.51	-7.27	-0.37	2.49e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.45	-0.5	2.59e-22	Eye color traits;
LUSC	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg24375607	chr4:120327624	NA	0.76	10.98	0.52	3.7e-24	Corneal astigmatism;
LUSC	trans	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg13565492	chr6:43139072	SRF	-0.62	-6.47	-0.33	3.57e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2235642	0.671	rs2235641	chr16:1608177	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.38	-5.71	-0.3	2.52e-8	Coronary artery disease;
LUSC	cis	rs2124969	0.506	rs10497210	chr2:160985549	G/A	cg03641300	chr2:160917029	PLA2R1	-0.47	-5.66	-0.3	3.21e-8	Waist circumference adjusted for body mass index;
LUSC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg00825309	chr19:58991885	ZNF446	-0.84	-13.27	-0.59	1.45e-32	Mean platelet volume;
LUSC	cis	rs10779751	0.770	rs11585553	chr1:11233814	G/A	cg08854313	chr1:11322531	MTOR	-0.83	-12.18	-0.55	1.74e-28	Body mass index;
LUSC	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.68	-11.99	-0.55	8.92e-28	White blood cell count (basophil);
LUSC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg13319975	chr6:146136371	FBXO30	0.48	7.19	0.37	4.4e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg24642844	chr7:1081250	C7orf50	-0.46	-7.32	-0.37	1.92e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg03538708	chr1:25844672	NA	-0.39	-6.35	-0.33	6.94e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	1.23	16.83	0.68	1.93e-46	Eosinophil percentage of granulocytes;
LUSC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg07936489	chr17:37558343	FBXL20	-0.7	-9.7	-0.47	9.12e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.01	-0.52	2.85e-24	Bipolar disorder;
LUSC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.24	-0.49	1.4e-21	Hemoglobin concentration;
LUSC	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.76	12.34	0.56	4.43e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg18402987	chr7:1209562	NA	0.73	7.84	0.39	5.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg04369109	chr6:150039330	LATS1	-0.53	-7.6	-0.38	3.01e-13	Lung cancer;
LUSC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21984481	chr17:79567631	NPLOC4	-0.57	-10.9	-0.51	7.43e-24	Eye color traits;
LUSC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg23262073	chr20:60523788	NA	-0.42	-6.04	-0.31	4.06e-9	Body mass index;
LUSC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg17366294	chr4:99064904	C4orf37	-0.56	-10.17	-0.49	2.4e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-0.89	-16.01	-0.66	3.4e-43	Height;
LUSC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg20887711	chr4:1340912	KIAA1530	0.58	9.09	0.45	9.12e-18	Longevity;
LUSC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg11344533	chr11:111475393	SIK2	-0.49	-6.87	-0.35	3.18e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.4	0.33	5.29e-10	Height;
LUSC	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg17366294	chr4:99064904	C4orf37	0.57	10.08	0.48	4.8e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13315871	1.000	rs35621601	chr3:58323174	A/G	cg20936604	chr3:58311152	NA	-0.77	-7.27	-0.37	2.56e-12	Cholesterol, total;
LUSC	cis	rs7605827	0.930	rs12991640	chr2:15505789	T/C	cg19274914	chr2:15703543	NA	0.45	8.51	0.42	6.15e-16	Educational attainment (years of education);
LUSC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	0.86	11.25	0.52	4.21e-25	Coronary artery disease;
LUSC	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.25	0.45	2.77e-18	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20679082	chr17:1090548	ABR	0.41	6.25	0.32	1.25e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg17211192	chr8:82754475	SNX16	0.79	10.72	0.51	3.12e-23	Diastolic blood pressure;
LUSC	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg06636001	chr8:8085503	FLJ10661	0.62	9.63	0.47	1.61e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.54	8.87	0.44	4.42e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4629710	0.568	rs67021539	chr6:131552900	A/G	cg12606694	chr6:131520996	AKAP7	0.62	9.4	0.46	9.28e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-8.48	-0.42	7.51e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.3e-21	Hemoglobin concentration;
LUSC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg06238570	chr21:40685208	BRWD1	-0.62	-10.47	-0.5	2.18e-22	Cognitive function;
LUSC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11764359	chr7:65958608	NA	0.67	10.71	0.51	3.39e-23	Aortic root size;
LUSC	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg14416269	chr4:6271139	WFS1	0.55	12.22	0.56	1.22e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg23587288	chr2:27483067	SLC30A3	-0.29	-5.75	-0.3	1.99e-8	Blood metabolite levels;
LUSC	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.35	-0.42	1.85e-15	Body mass index;
LUSC	cis	rs977987	0.771	rs12929673	chr16:75470295	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.66	0.47	1.22e-19	Dupuytren's disease;
LUSC	cis	rs713477	0.935	rs10144034	chr14:55914273	C/A	cg13175173	chr14:55914753	NA	-0.31	-6.49	-0.33	3.05e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg13010199	chr12:38710504	ALG10B	-0.51	-7.62	-0.38	2.69e-13	Bladder cancer;
LUSC	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg26102564	chr10:131424627	MGMT	0.45	6.98	0.36	1.58e-11	Response to temozolomide;
LUSC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg10556349	chr10:835070	NA	0.55	6.21	0.32	1.53e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.3	5.94	0.31	7.34e-9	Lymphocyte counts;
LUSC	cis	rs113835537	0.529	rs2298806	chr11:66282095	G/A	cg24851651	chr11:66362959	CCS	0.53	7.93	0.4	3.42e-14	Airway imaging phenotypes;
LUSC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.46	-8.33	-0.41	2.18e-15	Longevity;Endometriosis;
LUSC	cis	rs727505	1.000	rs77718560	chr7:124514544	T/A	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg27426351	chr10:43362370	NA	-0.43	-6.0	-0.31	5.26e-9	Blood protein levels;
LUSC	cis	rs9311676	0.632	rs1126735	chr3:58413408	A/G	cg26110898	chr3:58419937	PDHB	0.41	6.52	0.34	2.6e-10	Systemic lupus erythematosus;
LUSC	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg11245181	chr6:149772854	ZC3H12D	0.3	6.4	0.33	5.29e-10	Dupuytren's disease;
LUSC	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg16624210	chr5:671434	TPPP	0.49	6.13	0.32	2.47e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21963583	chr11:68658836	MRPL21	0.56	8.31	0.41	2.49e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12016809	chr21:47604291	C21orf56	0.45	6.76	0.35	6.01e-11	Testicular germ cell tumor;
LUSC	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21659725	chr3:3221576	CRBN	-0.52	-8.33	-0.41	2.17e-15	Body mass index;
LUSC	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg03676636	chr4:99064102	C4orf37	0.36	7.85	0.39	5.64e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg10547527	chr2:198650123	BOLL	-0.5	-5.91	-0.31	8.37e-9	Ulcerative colitis;
LUSC	trans	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg14011486	chr1:26737247	LIN28	0.85	11.74	0.54	6.95e-27	Atrial fibrillation;
LUSC	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg19875535	chr5:140030758	IK	0.46	7.35	0.37	1.58e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg07828340	chr4:882639	GAK	0.96	10.27	0.49	1.12e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg07716408	chr11:68623521	NA	-0.31	-5.96	-0.31	6.4e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	7.96	0.4	2.74e-14	Neuroticism;
LUSC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08736216	chr1:53307985	ZYG11A	0.3	6.31	0.33	8.63e-10	Monocyte count;
LUSC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	6.2	0.32	1.66e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg02269571	chr22:50332266	NA	-0.57	-8.58	-0.42	3.69e-16	Schizophrenia;
LUSC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.96	-15.5	-0.65	3.22e-41	Coronary artery disease;
LUSC	cis	rs11051970	0.838	rs2651369	chr12:32552769	C/G	cg24626660	chr12:32551988	NA	0.33	5.74	0.3	2.08e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg13852791	chr20:30311386	BCL2L1	0.95	14.9	0.63	7.51e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9807989	0.839	rs9308857	chr2:102979624	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.74	0.3	2.08e-8	Asthma;
LUSC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg19622623	chr12:86230825	RASSF9	0.4	5.75	0.3	2.02e-8	Major depressive disorder;
LUSC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg07741184	chr6:167504864	NA	0.37	6.72	0.35	7.82e-11	Crohn's disease;
LUSC	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg00310523	chr12:86230176	RASSF9	0.41	7.4	0.38	1.12e-12	Major depressive disorder;
LUSC	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg13609457	chr4:120235615	NA	0.39	6.05	0.31	3.88e-9	Diastolic blood pressure;
LUSC	cis	rs72772090	0.539	rs116360011	chr5:96117797	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.57	-0.34	1.92e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg19767477	chr5:127420684	SLC12A2	-0.43	-5.87	-0.31	1.06e-8	Ileal carcinoids;
LUSC	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg26876637	chr1:152193138	HRNR	0.42	5.89	0.31	9.39e-9	Atopic dermatitis;
LUSC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-10.21	-0.49	1.83e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg13042288	chr15:90349979	ANPEP	-0.49	-6.82	-0.35	4.39e-11	Uric acid levels;
LUSC	cis	rs883565	0.528	rs11716902	chr3:38958010	G/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.4	-5.81	-0.3	1.5e-8	Handedness;
LUSC	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg03599575	chr15:90893182	GABARAPL3	0.33	5.68	0.3	2.91e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.51	0.34	2.73e-10	Menopause (age at onset);
LUSC	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg12863693	chr15:85201151	NMB	0.39	8.05	0.4	1.49e-14	Schizophrenia;
LUSC	cis	rs1891275	0.550	rs4933694	chr10:93499213	C/T	cg07889827	chr10:93443413	NA	-0.4	-9.15	-0.45	5.91e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg08270630	chr22:50330655	NA	-0.45	-6.88	-0.35	2.97e-11	Schizophrenia;
LUSC	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg00745463	chr17:30367425	LRRC37B	-0.69	-8.16	-0.41	6.74e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg03146154	chr1:46216737	IPP	0.51	7.66	0.39	2.08e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.81	0.51	1.51e-23	Colorectal cancer;
LUSC	cis	rs1800562	1	rs1800562	chr6:26093141	C/T	cg16482183	chr6:26056742	HIST1H1C	0.89	5.94	0.31	7.01e-9	Hematocrit;Iron status biomarkers (transferrin levels);Diastolic blood pressure;Hemoglobin;Red blood cell count;Cholesterol, total;Hematology traits;Alcohol consumption (transferrin glycosylation);Iron status biomarkers (ferritin levels);LDL cholesterol;Iron status biomarkers;Mean corpuscular hemoglobin;Iron status biomarkers (transferrin saturation);Mean corpuscular volume;Iron status biomarkers (iron levels);Red blood cell traits;Iron status biomarkers (total iron binding capacity);Glycated hemoglobin levels;Hematological parameters;Hepcidin levels;Cardiovascular disease risk factors;
LUSC	cis	rs7528684	0.565	rs10908587	chr1:157643579	G/A	cg18268488	chr1:157545234	FCRL4	0.3	5.69	0.3	2.84e-8	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
LUSC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg16325326	chr1:53192061	ZYG11B	0.94	17.61	0.69	1.53e-49	Monocyte count;
LUSC	cis	rs10979	1.000	rs9390113	chr6:143896205	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.7	10.56	0.5	1.15e-22	Aortic root size;
LUSC	cis	rs2806561	0.769	rs2235547	chr1:23406485	C/G	cg19743168	chr1:23544995	NA	-0.42	-8.65	-0.43	2.24e-16	Height;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13440781	chr1:168148262	TIPRL	0.68	6.11	0.32	2.84e-9	Cognitive performance;
LUSC	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.45	-0.33	3.95e-10	Uric acid levels;
LUSC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg01879757	chr17:41196368	BRCA1	-0.5	-8.04	-0.4	1.53e-14	Menopause (age at onset);
LUSC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg16405210	chr4:1374714	KIAA1530	-0.62	-9.52	-0.46	3.61e-19	Obesity-related traits;
LUSC	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg24596788	chr1:163392923	NA	-0.44	-7.28	-0.37	2.36e-12	Motion sickness;
LUSC	cis	rs17155006	0.530	rs408867	chr7:107743244	C/T	cg05962710	chr7:107745446	LAMB4	-0.33	-5.92	-0.31	8.19e-9	Pneumococcal bacteremia;
LUSC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	12.16	0.55	2.1e-28	Menopause (age at onset);
LUSC	cis	rs9653442	1.000	rs7580200	chr2:100811903	G/T	cg22139774	chr2:100720529	AFF3	0.46	8.3	0.41	2.57e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.510	rs12083211	chr1:153032131	A/T	cg00922841	chr1:152955080	SPRR1A	0.36	6.08	0.32	3.26e-9	Inflammatory skin disease;
LUSC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg16624210	chr5:671434	TPPP	0.47	5.97	0.31	6.06e-9	Obesity-related traits;
LUSC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg27535305	chr1:53392650	SCP2	-0.49	-9.7	-0.47	9.36e-20	Monocyte count;
LUSC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.57	-0.46	2.49e-19	Type 2 diabetes;
LUSC	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg09163369	chr1:210001066	C1orf107	0.48	6.01	0.31	4.86e-9	Orofacial clefts;
LUSC	cis	rs10886558	0.619	rs4752365	chr10:121761989	C/G	cg02041677	chr10:121771263	NA	-0.34	-5.72	-0.3	2.31e-8	Shingles;
LUSC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg20307385	chr11:47447363	PSMC3	0.44	5.72	0.3	2.43e-8	Subjective well-being;
LUSC	cis	rs7589342	0.839	rs11895235	chr2:106432355	C/G	cg16077055	chr2:106428750	NCK2	0.38	7.2	0.37	4.02e-12	Addiction;
LUSC	cis	rs8077577	0.895	rs11655797	chr17:18107850	C/T	cg16794390	chr17:18148240	FLII	0.41	5.71	0.3	2.52e-8	Obesity-related traits;
LUSC	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg25809561	chr17:30822961	MYO1D	0.56	10.14	0.48	3.17e-21	Schizophrenia;
LUSC	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg00277334	chr10:82204260	NA	-0.53	-7.76	-0.39	1.01e-13	Post bronchodilator FEV1;
LUSC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg19266014	chr7:2183958	MAD1L1	-0.36	-6.14	-0.32	2.32e-9	Schizophrenia;
LUSC	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg16579770	chr16:72058938	DHODH	0.34	5.75	0.3	2.04e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg08313168	chr12:7315531	NA	0.46	5.98	0.31	5.65e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7177699	0.557	rs12898452	chr15:79112628	C/A	cg00540400	chr15:79124168	NA	0.46	7.98	0.4	2.33e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.41	6.27	0.32	1.09e-9	Platelet count;
LUSC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.72	13.43	0.59	3.41e-33	Height;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04210991	chr1:226374609	ACBD3	-0.47	-6.08	-0.32	3.29e-9	Hepatitis;
LUSC	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg12924262	chr12:102091054	CHPT1	0.43	6.07	0.32	3.47e-9	Blood protein levels;
LUSC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	1.05	19.12	0.72	1.42e-55	Menopause (age at onset);
LUSC	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.4	0.38	1.13e-12	Neuroticism;
LUSC	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-7.94	-0.4	3.11e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs243505	0.965	rs243501	chr7:148438145	C/G	cg09806900	chr7:148480153	CUL1	-0.51	-7.28	-0.37	2.39e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17954165	chr10:124913710	BUB3	-0.4	-6.01	-0.31	4.75e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg13560548	chr3:10150139	C3orf24	0.5	7.22	0.37	3.44e-12	Alzheimer's disease;
LUSC	cis	rs9309473	0.904	rs79145598	chr2:73821382	T/A	cg20560298	chr2:73613845	ALMS1	-0.44	-6.33	-0.33	7.94e-10	Metabolite levels;
LUSC	cis	rs7119167	0.901	rs7937066	chr11:73124928	C/T	cg17517138	chr11:73019481	ARHGEF17	0.54	6.07	0.32	3.45e-9	Blood protein levels;
LUSC	trans	rs6600671	0.967	rs4844613	chr1:121173773	T/C	cg00646200	chr1:148855367	NA	0.44	6.89	0.35	2.71e-11	Hip geometry;
LUSC	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg13010199	chr12:38710504	ALG10B	-0.65	-11.19	-0.52	6.63e-25	Heart rate;
LUSC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg01802117	chr1:53393560	SCP2	-0.37	-6.32	-0.33	8.28e-10	Monocyte count;
LUSC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.75	0.43	1.09e-16	Menarche (age at onset);
LUSC	cis	rs1572438	0.929	rs9378520	chr6:861685	C/T	cg13447295	chr6:887704	NA	-0.41	-5.86	-0.31	1.08e-8	Aging;
LUSC	cis	rs17828380	0.920	rs71394509	chr15:63605923	G/A	cg05507819	chr15:63340323	TPM1	-0.75	-6.07	-0.32	3.49e-9	Social communication problems;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20860086	chr6:13814875	CCDC90A	0.37	6.0	0.31	5.19e-9	Asthma;
LUSC	cis	rs8099014	0.725	rs12373325	chr18:56087648	C/T	cg12907477	chr18:56117327	MIR122	-0.4	-5.87	-0.31	1.03e-8	Platelet count;
LUSC	trans	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.01	-0.36	1.34e-11	Triglycerides;
LUSC	cis	rs1044826	0.642	rs295470	chr3:139213903	A/G	cg00490450	chr3:139108681	COPB2	0.46	7.06	0.36	9.57e-12	Obesity-related traits;
LUSC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg02569458	chr12:86230093	RASSF9	0.55	9.43	0.46	7.16e-19	Major depressive disorder;
LUSC	cis	rs4474465	1.000	rs12277701	chr11:78140726	A/T	cg27205649	chr11:78285834	NARS2	-0.53	-6.18	-0.32	1.85e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.68	0.34	9.73e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6736093	0.897	rs4848874	chr2:112681500	A/G	cg12686935	chr2:112915763	FBLN7	-0.36	-5.84	-0.3	1.25e-8	Coronary artery disease;
LUSC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.65	-10.18	-0.49	2.18e-21	Menarche (age at onset);
LUSC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-7.38	-0.37	1.25e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9905704	0.874	rs2643126	chr17:56737765	A/G	cg12560992	chr17:57184187	TRIM37	0.55	7.78	0.39	9.24e-14	Testicular germ cell tumor;
LUSC	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.45	-0.33	3.9e-10	Breast cancer;
LUSC	cis	rs5017598	1.000	rs5017598	chr6:169211494	A/G	cg05672967	chr6:169256475	NA	0.42	6.21	0.32	1.6e-9	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
LUSC	trans	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg10756647	chr7:56101905	PSPH	0.85	8.34	0.42	1.93e-15	Diabetic kidney disease;
LUSC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.47	0.38	6.98e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.67	0.43	1.91e-16	Prudent dietary pattern;
LUSC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.73	-0.39	1.29e-13	Type 2 diabetes;
LUSC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-11.72	-0.54	8.37e-27	Systemic lupus erythematosus;
LUSC	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	0.99	19.37	0.73	1.45e-56	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg03342759	chr3:160939853	NMD3	-0.44	-6.79	-0.35	5.01e-11	Morning vs. evening chronotype;
LUSC	cis	rs1322512	0.713	rs1727042	chr6:152939017	A/G	cg27316956	chr6:152958899	SYNE1	0.34	5.71	0.3	2.48e-8	Tonometry;
LUSC	cis	rs80282103	0.764	rs12247779	chr10:1107957	T/G	cg08668510	chr10:1095578	IDI1	0.73	6.58	0.34	1.8e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.06	12.81	0.57	8.04e-31	Sexual dysfunction (female);
LUSC	cis	rs12760731	0.641	rs12727289	chr1:178327027	T/C	cg00404053	chr1:178313656	RASAL2	0.54	6.19	0.32	1.73e-9	Obesity-related traits;
LUSC	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.46	0.65	4.65e-41	Lymphocyte percentage of white cells;
LUSC	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-13.7	-0.6	3.35e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg22907277	chr7:1156413	C7orf50	0.72	7.68	0.39	1.75e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.36e-13	Type 2 diabetes;
LUSC	cis	rs10843647	1.000	rs4931282	chr12:30329500	A/G	cg12718339	chr12:29936407	TMTC1	-0.34	-5.77	-0.3	1.77e-8	Glucose homeostasis traits;
LUSC	cis	rs10740039	0.810	rs10159646	chr10:62380124	A/G	cg18175470	chr10:62150864	ANK3	-0.48	-7.25	-0.37	2.88e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg17252645	chr8:143867129	LY6D	0.38	6.68	0.34	1.02e-10	Urinary tract infection frequency;
LUSC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg11663144	chr21:46675770	NA	-0.43	-7.61	-0.38	2.83e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg24375607	chr4:120327624	NA	0.67	10.54	0.5	1.33e-22	Corneal astigmatism;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg12592908	chr6:36954170	MTCH1	0.38	5.99	0.31	5.53e-9	Schizophrenia (age at onset);
LUSC	cis	rs7119	0.717	rs12910975	chr15:77817487	C/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg18225595	chr11:63971243	STIP1	-0.47	-7.63	-0.39	2.4e-13	Platelet count;
LUSC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02353165	chr6:42928485	GNMT	0.67	11.39	0.53	1.3e-25	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg05347473	chr6:146136440	FBXO30	0.51	8.55	0.42	4.64e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7264396	0.887	rs750487	chr20:34066645	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.42	-0.33	4.74e-10	Total cholesterol levels;
LUSC	cis	rs6084875	0.840	rs2422934	chr20:4720146	G/A	cg07258627	chr20:4721683	PRNT	-0.34	-6.2	-0.32	1.69e-9	Systemic lupus erythematosus;
LUSC	trans	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.44	-0.33	4.28e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs564343	0.583	rs2430978	chr11:65816656	G/C	cg26701943	chr11:108369231	KDELC2	-0.44	-6.0	-0.31	5.28e-9	Obesity (early onset extreme);
LUSC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.27	-0.37	2.57e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg21033440	chr11:65409861	SIPA1	-0.58	-7.63	-0.39	2.42e-13	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg02972257	chr16:68554789	NA	-0.52	-6.39	-0.33	5.65e-10	Ulcerative colitis;
LUSC	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-9.55	-0.46	2.82e-19	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.71	0.34	8.26e-11	Lung cancer;
LUSC	trans	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.15	-0.32	2.16e-9	Depression;
LUSC	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg08847533	chr14:75593920	NEK9	-0.39	-5.67	-0.3	3.06e-8	Caffeine consumption;
LUSC	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg10253484	chr15:75165896	SCAMP2	-0.43	-6.01	-0.31	4.93e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg24375607	chr4:120327624	NA	0.73	10.8	0.51	1.58e-23	Corneal astigmatism;
LUSC	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg03599575	chr15:90893182	GABARAPL3	0.33	5.87	0.31	1.03e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.29e-12	Tonsillectomy;
LUSC	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.3	-0.45	1.85e-18	Schizophrenia;
LUSC	cis	rs965469	1.000	rs6051753	chr20:3315513	G/A	cg25506879	chr20:3388711	C20orf194	-0.52	-5.7	-0.3	2.68e-8	IFN-related cytopenia;
LUSC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg19920283	chr7:105172520	RINT1	0.61	6.62	0.34	1.42e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6845621	0.727	rs4464564	chr4:18907036	A/G	cg12196642	chr4:18937545	NA	-0.33	-6.27	-0.32	1.1e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.25	-0.37	2.87e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg23992470	chr4:843637	GAK	0.56	6.15	0.32	2.18e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs116139393	0.536	rs13247186	chr7:6769155	A/G	cg09896999	chr7:6746977	ZNF12	-0.57	-8.5	-0.42	6.54e-16	Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.97	-0.4	2.62e-14	Lymphocyte counts;
LUSC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg27170947	chr2:26402098	FAM59B	-0.63	-9.22	-0.45	3.41e-18	Gut microbiome composition (summer);
LUSC	cis	rs10865397	0.506	rs6546807	chr2:73386212	C/T	cg24220031	chr2:73402428	NA	-0.26	-6.06	-0.31	3.61e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg17443473	chr1:3703550	LRRC47	0.34	5.89	0.31	9.5e-9	Red cell distribution width;
LUSC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg13319975	chr6:146136371	FBXO30	0.51	7.76	0.39	1.06e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg19468946	chr17:37922297	IKZF3	-0.46	-7.32	-0.37	1.88e-12	Self-reported allergy;
LUSC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.49	7.16	0.36	5.31e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6500395	0.775	rs8050844	chr16:48665696	A/G	cg04672837	chr16:48644449	N4BP1	0.47	7.02	0.36	1.22e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg27471124	chr11:109292789	C11orf87	0.41	7.09	0.36	8.05e-12	Schizophrenia;
LUSC	cis	rs9925964	0.933	rs8050894	chr16:31104509	C/G	cg02466173	chr16:30829666	NA	0.34	6.04	0.31	4.15e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	6.92	0.35	2.31e-11	Mood instability;
LUSC	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-14.0	-0.61	2.26e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.91	15.79	0.65	2.43e-42	Morning vs. evening chronotype;
LUSC	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs2294693	0.891	rs4714421	chr6:40992837	C/T	cg14769373	chr6:40998127	UNC5CL	-0.48	-7.0	-0.36	1.45e-11	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06634786	chr22:41940651	POLR3H	0.49	6.12	0.32	2.56e-9	Vitiligo;
LUSC	cis	rs6066835	1.000	rs4431002	chr20:47316585	C/T	cg18078177	chr20:47281410	PREX1	0.72	6.13	0.32	2.51e-9	Multiple myeloma;
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg02796970	chr10:39023768	NA	-0.49	-7.9	-0.4	4.17e-14	Menopause (age at onset);
LUSC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg21211680	chr2:198530	NA	-0.6	-7.34	-0.37	1.68e-12	Blood protein levels;
LUSC	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg26384229	chr12:38710491	ALG10B	0.7	10.74	0.51	2.52e-23	Morning vs. evening chronotype;
LUSC	trans	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg07923666	chr12:49932857	KCNH3	-0.48	-6.02	-0.31	4.48e-9	Resting heart rate;
LUSC	cis	rs1595825	0.891	rs78198610	chr2:198522769	T/C	cg19156104	chr2:198669113	PLCL1	-0.45	-5.69	-0.3	2.74e-8	Ulcerative colitis;
LUSC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05025164	chr4:1340916	KIAA1530	0.53	8.17	0.41	6.63e-15	Obesity-related traits;
LUSC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg05457628	chr5:178986728	RUFY1	-0.64	-11.8	-0.54	4.18e-27	Lung cancer;
LUSC	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg04362960	chr10:104952993	NT5C2	0.6	9.38	0.46	1.05e-18	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg03676636	chr4:99064102	C4orf37	0.36	7.89	0.4	4.25e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg01448562	chr3:133502909	NA	-0.36	-5.67	-0.3	3.04e-8	Iron status biomarkers (transferrin levels);
LUSC	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg26384229	chr12:38710491	ALG10B	0.74	11.5	0.53	5.04e-26	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	0.99	14.14	0.61	6.88e-36	Vitiligo;
LUSC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.63	0.85	1.69e-95	Chronic sinus infection;
LUSC	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg26384229	chr12:38710491	ALG10B	0.71	11.61	0.54	2.13e-26	Morning vs. evening chronotype;
LUSC	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.38	-0.33	5.88e-10	Breast cancer;
LUSC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg05861140	chr6:150128134	PCMT1	-0.39	-5.83	-0.3	1.3e-8	Lung cancer;
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.45	7.59	0.38	3.2e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26818010	chr10:134567672	INPP5A	-0.87	-11.48	-0.53	6.2e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg15133208	chr4:90757351	SNCA	-0.53	-8.1	-0.41	1.04e-14	Neuroticism;
LUSC	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg21775007	chr8:11205619	TDH	0.57	8.39	0.42	1.43e-15	Retinal vascular caliber;
LUSC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg11752832	chr7:134001865	SLC35B4	0.55	8.66	0.43	2.09e-16	Mean platelet volume;
LUSC	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg13535736	chr9:111863775	C9orf5	-0.39	-6.14	-0.32	2.3e-9	Menarche (age at onset);
LUSC	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg00343986	chr7:65444356	GUSB	-0.41	-6.1	-0.32	3.01e-9	Aortic root size;
LUSC	cis	rs13315871	1.000	rs13060489	chr3:58339287	G/A	cg20936604	chr3:58311152	NA	-0.71	-6.95	-0.36	1.96e-11	Cholesterol, total;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg15785704	chr17:30669010	C17orf75	0.49	6.58	0.34	1.78e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg27144592	chr16:783916	NARFL	-0.63	-9.77	-0.47	5.55e-20	Height;
LUSC	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg24154853	chr7:158122151	PTPRN2	0.35	5.77	0.3	1.82e-8	Response to amphetamines;
LUSC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg04944784	chr2:26401820	FAM59B	0.71	10.03	0.48	7.07e-21	Gut microbiome composition (summer);
LUSC	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg06532163	chr17:45867833	NA	-0.33	-6.21	-0.32	1.6e-9	IgG glycosylation;
LUSC	cis	rs877282	0.797	rs11253329	chr10:753200	A/T	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs72634258	0.945	rs161800	chr1:8042402	A/T	cg00042356	chr1:8021962	PARK7	0.64	8.37	0.42	1.55e-15	Inflammatory bowel disease;
LUSC	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7503807	1.000	rs12939613	chr17:78588202	A/G	cg09596252	chr17:78655493	RPTOR	0.41	7.09	0.36	8.26e-12	Obesity;
LUSC	cis	rs977987	0.806	rs7185640	chr16:75394399	A/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.85	-0.35	3.47e-11	Dupuytren's disease;
LUSC	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg02403541	chr12:121454288	C12orf43	0.59	8.45	0.42	8.98e-16	N-glycan levels;
LUSC	cis	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.23	-0.41	4.35e-15	Coronary artery disease;
LUSC	trans	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg01620082	chr3:125678407	NA	-0.78	-7.29	-0.37	2.28e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg13685833	chr1:53393034	SCP2	-0.38	-5.8	-0.3	1.55e-8	Monocyte count;
LUSC	cis	rs698813	0.674	rs11680456	chr2:44497544	C/G	cg00619915	chr2:44497795	NA	-0.51	-7.03	-0.36	1.14e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg00191853	chr8:101177733	SPAG1	0.5	8.64	0.43	2.3e-16	Atrioventricular conduction;
LUSC	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.59	8.14	0.41	7.69e-15	Total cholesterol levels;
LUSC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.82	0.47	3.65e-20	Bipolar disorder;
LUSC	cis	rs617219	0.853	rs3733892	chr5:78532088	A/C	cg24856658	chr5:78533917	JMY	-0.3	-5.83	-0.3	1.3e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs920590	0.643	rs7012694	chr8:19662732	C/T	cg03894339	chr8:19674705	INTS10	0.41	5.87	0.31	1.05e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg06532163	chr17:45867833	NA	0.35	6.53	0.34	2.48e-10	IgG glycosylation;
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.86	-14.05	-0.61	1.5e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg03929089	chr4:120376271	NA	0.59	6.44	0.33	4.04e-10	Axial length;
LUSC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.72	-0.57	1.7e-30	Bipolar disorder and schizophrenia;
LUSC	cis	rs4964805	1.000	rs4964805	chr12:104192824	C/G	cg02344784	chr12:104178138	NT5DC3	0.45	7.21	0.37	3.74e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs6845621	0.727	rs13129810	chr4:18914830	T/G	cg12196642	chr4:18937545	NA	-0.34	-6.29	-0.33	9.99e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg06808227	chr14:105710500	BRF1	-0.6	-8.39	-0.42	1.37e-15	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs1325195	0.920	rs1078872	chr1:179223726	C/T	cg11624085	chr17:8464688	MYH10	-0.39	-6.34	-0.33	7.46e-10	IgE grass sensitization;
LUSC	cis	rs2652834	1.000	rs2134265	chr15:63398196	G/A	cg05507819	chr15:63340323	TPM1	0.69	8.32	0.41	2.22e-15	HDL cholesterol;
LUSC	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.97	-20.99	-0.75	5.64e-63	Longevity;
LUSC	cis	rs117352156	0.943	rs4367855	chr10:29223312	C/T	cg06394621	chr10:29236369	NA	-0.42	-5.69	-0.3	2.85e-8	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.03	21.06	0.76	2.9e-63	Cognitive function;
LUSC	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg13010199	chr12:38710504	ALG10B	-0.5	-7.52	-0.38	5.12e-13	Morning vs. evening chronotype;
LUSC	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg08807101	chr21:30365312	RNF160	0.63	10.11	0.48	3.91e-21	Pancreatic cancer;
LUSC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	15.17	0.64	6.55e-40	Platelet count;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg10488141	chr10:104264014	SUFU	0.38	5.97	0.31	6.22e-9	Asthma;
LUSC	cis	rs9473147	0.516	rs7767350	chr6:47485126	C/T	cg20196966	chr6:47445060	CD2AP	0.41	5.79	0.3	1.66e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg00750074	chr16:89608354	SPG7	-0.53	-9.55	-0.46	2.96e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg05855489	chr10:104503620	C10orf26	0.54	6.39	0.33	5.67e-10	Arsenic metabolism;
LUSC	cis	rs4144743	0.941	rs7222617	chr17:45324080	G/T	cg18085866	chr17:45331354	ITGB3	-0.7	-7.62	-0.38	2.61e-13	Body mass index;
LUSC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg08088566	chr11:430123	ANO9	0.71	7.64	0.39	2.25e-13	Body mass index;
LUSC	cis	rs1712517	0.771	rs11191676	chr10:105155066	C/A	cg05636881	chr10:105038444	INA	0.42	7.01	0.36	1.28e-11	Migraine;
LUSC	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg08917208	chr2:24149416	ATAD2B	1.0	10.49	0.5	1.94e-22	Lymphocyte counts;
LUSC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg21361702	chr7:150065534	REPIN1	0.49	6.53	0.34	2.42e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg27165867	chr14:105738592	BRF1	-0.52	-7.66	-0.39	2.01e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs965469	1.000	rs2236118	chr20:3302058	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-5.79	-0.3	1.65e-8	IFN-related cytopenia;
LUSC	cis	rs7539542	0.556	rs1539357	chr1:202878454	T/A	cg19681188	chr1:202830198	LOC148709	0.39	5.8	0.3	1.54e-8	Mean platelet volume;
LUSC	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.45	-6.59	-0.34	1.76e-10	Coffee consumption (cups per day);
LUSC	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07080220	chr10:102295463	HIF1AN	0.68	9.2	0.45	3.94e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg19743168	chr1:23544995	NA	0.4	7.96	0.4	2.78e-14	Height;
LUSC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.08	21.02	0.75	4.3e-63	Cognitive ability;
LUSC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg22834771	chr12:69754056	YEATS4	-0.45	-6.5	-0.33	3.01e-10	Blood protein levels;
LUSC	cis	rs7633770	0.786	rs1520488	chr3:46677459	C/T	cg11219411	chr3:46661640	NA	0.36	7.56	0.38	3.82e-13	Coronary artery disease;
LUSC	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg27411982	chr8:10470053	RP1L1	0.43	6.83	0.35	3.99e-11	Mood instability;
LUSC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25072359	chr17:41440525	NA	0.66	9.45	0.46	6.13e-19	Menopause (age at onset);
LUSC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-1.04	-20.09	-0.74	2.02e-59	Height;
LUSC	trans	rs9409565	0.793	rs2486632	chr9:97196979	A/G	cg05679027	chr9:99775184	HIATL2	-0.49	-7.02	-0.36	1.21e-11	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg03060546	chr3:49711283	APEH	0.71	11.95	0.55	1.23e-27	Resting heart rate;
LUSC	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	11.03	0.52	2.56e-24	Hypertriglyceridemia;
LUSC	cis	rs12618769	0.597	rs17032120	chr2:99082938	A/G	cg10123293	chr2:99228465	UNC50	-0.42	-7.17	-0.37	4.76e-12	Bipolar disorder;
LUSC	cis	rs9807989	0.773	rs5010059	chr2:102968826	C/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.88	0.31	9.76e-9	Asthma;
LUSC	cis	rs6681460	0.674	rs4134135	chr1:67012728	A/G	cg02459107	chr1:67143332	SGIP1	0.38	6.11	0.32	2.81e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-1.22	-13.44	-0.59	3.3e-33	Diabetic kidney disease;
LUSC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg17143192	chr8:8559678	CLDN23	0.59	8.58	0.43	3.58e-16	Obesity-related traits;
LUSC	cis	rs2677744	0.626	rs867468	chr15:91498127	G/A	cg23684204	chr15:91497937	RCCD1	0.57	7.92	0.4	3.57e-14	Attention deficit hyperactivity disorder;
LUSC	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg19729930	chr2:74357872	NA	0.85	14.66	0.63	6.27e-38	Gestational age at birth (maternal effect);
LUSC	cis	rs6489882	0.703	rs6489865	chr12:113360302	A/G	cg20102336	chr12:113376681	OAS3	-0.41	-5.75	-0.3	2.02e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.5	-6.8	-0.35	4.96e-11	Renal function-related traits (BUN);
LUSC	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.67	-0.34	1.04e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.57	9.54	0.46	3.09e-19	Breast cancer;
LUSC	trans	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg07424592	chr7:64974309	NA	0.91	6.01	0.31	4.97e-9	Diabetic kidney disease;
LUSC	cis	rs9921338	0.961	rs6498185	chr16:11444726	C/T	cg00044050	chr16:11439710	C16orf75	-0.5	-6.66	-0.34	1.11e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	6.31	0.33	8.94e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9314323	0.692	rs6557914	chr8:26208744	G/C	cg11498726	chr8:26250323	BNIP3L	-0.43	-6.12	-0.32	2.63e-9	Red cell distribution width;
LUSC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-0.55	-9.03	-0.44	1.4e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg24060327	chr5:131705240	SLC22A5	-0.36	-5.69	-0.3	2.85e-8	Breast cancer;Mosquito bite size;
LUSC	trans	rs72674100	1.000	rs7673826	chr4:97978191	A/G	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg00484396	chr16:3507460	NAT15	0.45	7.38	0.37	1.29e-12	Body mass index (adult);
LUSC	cis	rs34638657	0.673	rs62045961	chr16:82199723	A/G	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.47	-0.33	3.55e-10	Lung adenocarcinoma;
LUSC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.61	9.73	0.47	7.24e-20	Pulse pressure;
LUSC	cis	rs483180	0.511	rs496195	chr1:120207182	A/G	cg19096424	chr1:120255104	PHGDH	-0.48	-6.68	-0.34	1.02e-10	Macular telangiectasia type 2;
LUSC	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.11	-0.64	1.09e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs2299587	0.585	rs2073569	chr8:17782158	T/G	cg01800426	chr8:17659068	MTUS1	-0.49	-6.53	-0.34	2.51e-10	Economic and political preferences;
LUSC	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg07157834	chr1:205819609	PM20D1	0.44	5.77	0.3	1.85e-8	Parkinson's disease;
LUSC	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg07169764	chr2:136633963	MCM6	1.17	17.34	0.69	1.75e-48	Corneal structure;
LUSC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg27121462	chr16:89883253	FANCA	0.44	6.23	0.32	1.44e-9	Vitiligo;
LUSC	cis	rs4629180	0.586	rs10172555	chr2:102126837	C/T	cg01388757	chr2:102091195	RFX8	-0.36	-6.38	-0.33	5.88e-10	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7202877	0.610	rs8053632	chr16:75364940	C/T	cg03315344	chr16:75512273	CHST6	0.42	6.21	0.32	1.57e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg14552801	chr7:65878734	NA	0.36	5.69	0.3	2.71e-8	Aortic root size;
LUSC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.9	13.87	0.6	7.3e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.12	-0.32	2.63e-9	Neutrophil percentage of white cells;
LUSC	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg08807101	chr21:30365312	RNF160	0.68	11.0	0.52	3.22e-24	Pancreatic cancer;
LUSC	cis	rs9462027	0.540	rs9469867	chr6:34742449	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.75	-0.3	1.97e-8	Systemic lupus erythematosus;
LUSC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg04414720	chr1:150670196	GOLPH3L	0.53	8.11	0.41	9.43e-15	Melanoma;
LUSC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg03929089	chr4:120376271	NA	-0.94	-16.46	-0.67	5.66e-45	Height;
LUSC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.61	12.55	0.57	7.31e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.31	-0.56	5.64e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4629710	0.592	rs3777476	chr6:131533821	A/C	cg12700074	chr6:131571435	AKAP7	-0.37	-6.25	-0.32	1.25e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs3771570	1.000	rs16843590	chr2:242298228	G/A	cg21155796	chr2:242212141	HDLBP	0.63	6.76	0.35	6.25e-11	Prostate cancer;
LUSC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg25838465	chr1:92012736	NA	-0.74	-15.16	-0.64	7.08e-40	Breast cancer;
LUSC	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.02	0.63	2.62e-39	Lymphocyte percentage of white cells;
LUSC	trans	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg26384229	chr12:38710491	ALG10B	0.53	8.42	0.42	1.11e-15	Morning vs. evening chronotype;
LUSC	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.31	0.64	1.87e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	0.96	12.93	0.58	2.65e-31	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	9.26	0.45	2.51e-18	Bipolar disorder;
LUSC	cis	rs354225	0.584	rs6706263	chr2:54815240	C/T	cg26097391	chr2:54893211	SPTBN1	0.43	6.46	0.33	3.68e-10	Schizophrenia;
LUSC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05665937	chr4:1216051	CTBP1	-0.37	-5.89	-0.31	9.44e-9	Obesity-related traits;
LUSC	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-11.4	-0.53	1.23e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.11	-20.0	-0.74	4.73e-59	Homoarginine levels;
LUSC	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg09904177	chr6:26538194	HMGN4	-0.72	-6.82	-0.35	4.39e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg22823121	chr1:150693482	HORMAD1	-0.44	-6.61	-0.34	1.48e-10	Melanoma;
LUSC	cis	rs3857536	0.707	rs9345793	chr6:66929807	G/C	cg07460842	chr6:66804631	NA	-0.47	-6.42	-0.33	4.68e-10	Blood trace element (Cu levels);
LUSC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06112835	chr11:68658793	MRPL21	0.51	7.81	0.39	7.24e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg08847533	chr14:75593920	NEK9	-0.79	-13.38	-0.59	5.24e-33	Height;
LUSC	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.7	10.65	0.5	5.42e-23	Corneal astigmatism;
LUSC	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg13010199	chr12:38710504	ALG10B	0.52	7.72	0.39	1.34e-13	Morning vs. evening chronotype;
LUSC	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-5.8	-0.3	1.51e-8	Breast cancer;
LUSC	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg05738196	chr6:26577821	NA	0.79	14.86	0.63	1.05e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs11935103	0.569	rs6816112	chr4:187285215	G/A	cg24610901	chr4:187293114	NA	-0.42	-5.72	-0.3	2.38e-8	Response to citalopram treatment;
LUSC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg14552801	chr7:65878734	NA	0.39	6.08	0.32	3.34e-9	Aortic root size;
LUSC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg05347473	chr6:146136440	FBXO30	0.47	8.13	0.41	8.37e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg22676075	chr6:135203613	NA	0.46	7.13	0.36	6.1e-12	Red blood cell count;
LUSC	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.84	-0.39	5.94e-14	Retinal vascular caliber;
LUSC	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg05234568	chr11:5960015	NA	-0.62	-8.77	-0.43	9.03e-17	DNA methylation (variation);
LUSC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg03806693	chr22:41940476	POLR3H	-1.02	-13.69	-0.6	3.75e-34	Vitiligo;
LUSC	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg19875535	chr5:140030758	IK	0.51	8.37	0.42	1.55e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2625529	0.824	rs4445848	chr15:72354598	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.52	-0.38	5.01e-13	Red blood cell count;
LUSC	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-7.97	-0.4	2.56e-14	Schizophrenia;
LUSC	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg23601095	chr6:26197514	HIST1H3D	0.74	7.53	0.38	4.91e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs807669	0.525	rs2282684	chr22:19184244	C/T	cg02655711	chr22:19163373	SLC25A1	0.5	9.04	0.44	1.32e-17	Metabolite levels;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24542126	chr1:27022232	ARID1A	0.37	6.03	0.31	4.46e-9	Asthma;
LUSC	trans	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg17567195	chr5:167378696	ODZ2	-0.4	-6.2	-0.32	1.68e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg09307838	chr4:120376055	NA	0.71	10.24	0.49	1.41e-21	Corneal astigmatism;
LUSC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg19592336	chr6:28129416	ZNF389	0.48	6.47	0.33	3.51e-10	Parkinson's disease;
LUSC	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-8.1	-0.41	1.03e-14	Morning vs. evening chronotype;
LUSC	cis	rs9549260	0.753	rs9549254	chr13:41234763	G/A	cg21288729	chr13:41239152	FOXO1	0.56	6.29	0.33	9.83e-10	Red blood cell count;
LUSC	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg03627880	chr6:151815985	C6orf97	-0.57	-6.18	-0.32	1.91e-9	Menarche (age at onset);
LUSC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-7.41	-0.38	1.03e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg12564285	chr5:131593104	PDLIM4	0.34	6.17	0.32	1.95e-9	Blood metabolite levels;
LUSC	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.55	10.12	0.48	3.47e-21	Bone mineral density;
LUSC	trans	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg27446573	chr6:127587934	RNF146	0.61	9.81	0.47	3.91e-20	Breast cancer;
LUSC	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-7.26	-0.37	2.71e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	1.05	19.08	0.72	1.98e-55	Parkinson's disease;
LUSC	cis	rs7463659	1.000	rs7463659	chr8:135432140	T/C	cg17885191	chr8:135476712	NA	-0.41	-5.83	-0.3	1.32e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11645453	chr3:52864694	ITIH4	-0.34	-7.62	-0.38	2.65e-13	Bipolar disorder;
LUSC	trans	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg26811252	chr16:29126840	RRN3P2	0.61	9.74	0.47	6.53e-20	Menopause (age at onset);
LUSC	cis	rs73198271	0.960	rs12155530	chr8:8610964	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-5.76	-0.3	1.92e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-6.52	-0.34	2.54e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1790761	0.505	rs2370141	chr11:67348529	A/G	cg24690094	chr11:67383802	NA	-0.3	-5.75	-0.3	1.98e-8	Mean corpuscular volume;
LUSC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.92	0.44	3.11e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs6062509	0.630	rs6011058	chr20:62356627	C/T	cg21849932	chr20:62369462	LIME1	-0.4	-5.82	-0.3	1.41e-8	Prostate cancer;
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-8.02	-0.4	1.83e-14	Lymphocyte counts;
LUSC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.47	6.85	0.35	3.62e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.58	9.58	0.46	2.33e-19	Bone mineral density;
LUSC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06634786	chr22:41940651	POLR3H	-0.54	-6.33	-0.33	7.84e-10	Vitiligo;
LUSC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.3	-0.41	2.6e-15	Gut microbiome composition (summer);
LUSC	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06108461	chr20:60628389	TAF4	-0.93	-15.51	-0.65	3.03e-41	Body mass index;
LUSC	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.26e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.9	12.21	0.56	1.35e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg01097406	chr16:89675127	NA	-0.37	-7.61	-0.38	2.9e-13	Vitiligo;
LUSC	cis	rs9888739	1.000	rs13338069	chr16:31299474	A/G	cg15817542	chr16:31343056	ITGAM	-0.51	-6.02	-0.31	4.61e-9	Systemic lupus erythematosus;
LUSC	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg27411982	chr8:10470053	RP1L1	-0.45	-6.95	-0.36	1.93e-11	Neuroticism;
LUSC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg17077180	chr1:38461687	NA	-0.45	-6.11	-0.32	2.8e-9	Coronary artery disease;
LUSC	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-1.06	-12.75	-0.57	1.28e-30	Schizophrenia;
LUSC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg02569458	chr12:86230093	RASSF9	0.6	9.9	0.48	1.94e-20	Major depressive disorder;
LUSC	cis	rs71403859	0.667	rs35538253	chr16:71677975	C/T	cg08717414	chr16:71523259	ZNF19	-0.67	-7.56	-0.38	4.01e-13	Post bronchodilator FEV1;
LUSC	cis	rs1873147	0.861	rs2899687	chr15:63325548	C/T	cg12160578	chr15:63334699	TPM1	-0.46	-6.37	-0.33	6.28e-10	Orofacial clefts;
LUSC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.66	-0.34	1.1e-10	Lymphocyte counts;
LUSC	cis	rs2063714	0.967	rs913971	chr6:157197802	C/T	cg23222435	chr6:157204239	ARID1B	-0.54	-8.86	-0.44	4.99e-17	Sitting height ratio;
LUSC	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg18132916	chr6:79620363	NA	-0.38	-5.77	-0.3	1.83e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7572644	0.713	rs7560060	chr2:28057524	T/C	cg27432699	chr2:27873401	GPN1	0.52	6.62	0.34	1.45e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg22681709	chr2:178499509	PDE11A	-0.47	-6.88	-0.35	2.89e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.67	-0.34	1.08e-10	Response to antipsychotic treatment;
LUSC	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.04	-0.4	1.62e-14	Retinal vascular caliber;
LUSC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	0.92	15.21	0.64	4.64e-40	Breast cancer;
LUSC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.63	-0.43	2.63e-16	Lung cancer;
LUSC	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg05043794	chr9:111880884	C9orf5	-0.37	-7.81	-0.39	7.29e-14	Menarche (age at onset);
LUSC	cis	rs7945705	0.846	rs905290	chr11:8753729	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.33	6.25	0.32	1.25e-9	Hemoglobin concentration;
LUSC	cis	rs72781680	0.566	rs72796106	chr2:23901362	A/C	cg08917208	chr2:24149416	ATAD2B	0.81	8.73	0.43	1.28e-16	Lymphocyte counts;
LUSC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg15147215	chr3:52552868	STAB1	-0.32	-6.35	-0.33	7.09e-10	Electroencephalogram traits;
LUSC	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg23649088	chr2:200775458	C2orf69	0.54	7.37	0.37	1.38e-12	Schizophrenia;
LUSC	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg23649088	chr2:200775458	C2orf69	-0.53	-6.82	-0.35	4.37e-11	Schizophrenia;
LUSC	cis	rs10986311	0.802	rs6478659	chr9:127128274	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.43	-6.85	-0.35	3.65e-11	Vitiligo;
LUSC	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg09165964	chr15:75287851	SCAMP5	-1.15	-18.88	-0.72	1.33e-54	Blood trace element (Zn levels);
LUSC	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg24578937	chr1:2090814	PRKCZ	-0.45	-9.83	-0.47	3.43e-20	Height;
LUSC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-5.68	-0.3	2.86e-8	Major depressive disorder;
LUSC	trans	rs2262909	0.962	rs11667209	chr19:22259467	A/G	cg17074339	chr11:11642133	GALNTL4	0.47	7.17	0.37	4.94e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.35	-0.37	1.52e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19901994	chr8:27288146	PTK2B	0.46	6.77	0.35	5.64e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11039100	0.850	rs12363855	chr11:5830186	G/C	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6580649	0.941	rs72644845	chr12:48503881	G/A	cg24011408	chr12:48396354	COL2A1	-0.45	-6.1	-0.32	2.9e-9	Lung cancer;
LUSC	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg21045802	chr8:109455806	TTC35	0.44	6.89	0.35	2.85e-11	Dupuytren's disease;
LUSC	cis	rs75920871	0.588	rs10892055	chr11:116868371	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-6.76	-0.35	6.07e-11	Subjective well-being;
LUSC	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg02466173	chr16:30829666	NA	-0.6	-11.14	-0.52	1.05e-24	Multiple myeloma;
LUSC	cis	rs2279817	0.735	rs71644064	chr1:18000044	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.2	-0.32	1.71e-9	Neuroticism;
LUSC	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.63	0.39	2.47e-13	Schizophrenia;
LUSC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	13.81	0.6	1.2e-34	Platelet count;
LUSC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2652834	0.851	rs2652792	chr15:63411492	G/C	cg05507819	chr15:63340323	TPM1	0.46	5.94	0.31	7.3e-9	HDL cholesterol;
LUSC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.51	-0.91	6.17e-131	Myeloid white cell count;
LUSC	cis	rs9815354	0.556	rs60966614	chr3:42005166	A/G	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.21e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-6.9	-0.35	2.61e-11	Homocysteine levels;
LUSC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg02487422	chr3:49467188	NICN1	0.43	6.86	0.35	3.36e-11	Parkinson's disease;
LUSC	cis	rs931127	0.692	rs7934517	chr11:65445673	C/T	cg05805236	chr11:65401703	PCNXL3	-0.42	-7.34	-0.37	1.62e-12	Systemic lupus erythematosus;
LUSC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg12823233	chr7:2316876	SNX8	-0.36	-6.02	-0.31	4.7e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.6	0.65	1.31e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg26597838	chr10:835615	NA	-0.44	-6.24	-0.32	1.3e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.07	23.37	0.79	3e-72	Schizophrenia;
LUSC	cis	rs7605827	0.930	rs11900088	chr2:15613994	T/C	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg03146154	chr1:46216737	IPP	0.55	8.25	0.41	3.82e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg00359181	chr2:38893519	GALM	-0.49	-5.79	-0.3	1.63e-8	5-HTT brain serotonin transporter levels;
LUSC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg12564285	chr5:131593104	PDLIM4	0.43	8.42	0.42	1.09e-15	Blood metabolite levels;
LUSC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg21285383	chr16:89894308	SPIRE2	0.31	6.62	0.34	1.42e-10	Vitiligo;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03905905	chr2:63277850	OTX1	-0.4	-6.01	-0.31	4.94e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg15147215	chr3:52552868	STAB1	-0.31	-6.09	-0.32	3.09e-9	Bipolar disorder;
LUSC	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg15557168	chr22:42548783	NA	0.35	5.86	0.31	1.11e-8	Cognitive function;
LUSC	cis	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg21775007	chr8:11205619	TDH	-0.47	-6.67	-0.34	1.06e-10	Neuroticism;
LUSC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg13770153	chr20:60521292	NA	-0.47	-6.85	-0.35	3.55e-11	Body mass index;
LUSC	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg07167872	chr1:205819463	PM20D1	-0.43	-5.89	-0.31	9.36e-9	Menarche (age at onset);
LUSC	cis	rs2797160	1.000	rs78602343	chr6:126019768	T/C	cg05901451	chr6:126070800	HEY2	0.57	8.51	0.42	5.79e-16	Endometrial cancer;
LUSC	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.76	-12.05	-0.55	5.09e-28	Schizophrenia;
LUSC	cis	rs3771570	1.000	rs3771564	chr2:242355701	G/A	cg21155796	chr2:242212141	HDLBP	0.59	6.36	0.33	6.69e-10	Prostate cancer;
LUSC	cis	rs7582720	0.511	rs116219813	chr2:204081675	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.29	0.41	2.71e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg14552801	chr7:65878734	NA	-0.37	-5.64	-0.3	3.53e-8	Aortic root size;
LUSC	cis	rs10779751	0.960	rs2076657	chr1:11318763	C/G	cg08854313	chr1:11322531	MTOR	0.92	16.17	0.66	7.91e-44	Body mass index;
LUSC	cis	rs427941	0.632	rs201503	chr7:101759595	C/G	cg06246474	chr7:101738831	CUX1	0.4	6.65	0.34	1.18e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.39	-0.37	1.19e-12	Triglycerides;
LUSC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg14552801	chr7:65878734	NA	-0.38	-5.96	-0.31	6.31e-9	Aortic root size;
LUSC	cis	rs1595825	0.891	rs6733834	chr2:198518709	C/G	cg19156104	chr2:198669113	PLCL1	0.46	5.69	0.3	2.73e-8	Ulcerative colitis;
LUSC	cis	rs12458462	0.665	rs2035085	chr18:77485280	C/T	cg11879182	chr18:77439856	CTDP1	0.69	10.41	0.49	3.74e-22	Monocyte count;
LUSC	cis	rs7119167	0.673	rs61131329	chr11:73029269	C/G	cg17517138	chr11:73019481	ARHGEF17	0.49	5.72	0.3	2.33e-8	Blood protein levels;
LUSC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg19748678	chr4:122722346	EXOSC9	0.49	7.57	0.38	3.59e-13	Type 2 diabetes;
LUSC	cis	rs977987	0.806	rs7199132	chr16:75450039	C/T	cg04384234	chr16:75411784	CFDP1	-0.41	-6.66	-0.34	1.15e-10	Dupuytren's disease;
LUSC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16680214	chr1:154839983	KCNN3	-0.52	-9.48	-0.46	4.88e-19	Prostate cancer;
LUSC	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.86	12.37	0.56	3.55e-29	Body mass index;
LUSC	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.34	-6.6	-0.34	1.66e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg14019146	chr3:50243930	SLC38A3	0.31	6.91	0.35	2.48e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4730250	0.707	rs257382	chr7:106804249	A/G	cg02696742	chr7:106810147	HBP1	-0.63	-8.79	-0.43	7.83e-17	Osteoarthritis;
LUSC	cis	rs7937682	0.681	rs2156580	chr11:111394328	C/G	cg09085632	chr11:111637200	PPP2R1B	0.52	6.86	0.35	3.28e-11	Primary sclerosing cholangitis;
LUSC	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg25214090	chr10:38739885	LOC399744	0.54	8.06	0.4	1.37e-14	Corneal astigmatism;
LUSC	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg22491629	chr6:157744540	C6orf35	-0.9	-10.83	-0.51	1.29e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.81	14.65	0.63	7.13e-38	Blood protein levels;
LUSC	cis	rs1018836	0.651	rs2339175	chr8:91565805	A/T	cg16814680	chr8:91681699	NA	-0.76	-12.7	-0.57	2.07e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.5	6.03	0.31	4.42e-9	Crohn's disease;
LUSC	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg05084668	chr3:125655381	ALG1L	-0.81	-12.37	-0.56	3.54e-29	Blood pressure (smoking interaction);
LUSC	cis	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.22	-0.37	3.45e-12	Bladder cancer;
LUSC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg04450456	chr4:17643702	FAM184B	0.42	7.16	0.36	5.27e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9976767	0.637	rs2277799	chr21:43824123	G/C	cg20516845	chr21:43823604	UBASH3A	-0.25	-5.76	-0.3	1.9e-8	Type 1 diabetes;
LUSC	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg04662567	chr6:169592167	NA	0.4	5.93	0.31	7.54e-9	Pulse pressure;
LUSC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg12751644	chr20:60527061	NA	-0.34	-6.06	-0.31	3.59e-9	Body mass index;
LUSC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06112835	chr11:68658793	MRPL21	0.52	8.08	0.4	1.21e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg03465714	chr1:152285911	FLG	-0.36	-6.42	-0.33	4.65e-10	Inflammatory skin disease;
LUSC	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg19196401	chr6:110721138	DDO	-0.41	-7.67	-0.39	1.88e-13	Platelet distribution width;
LUSC	cis	rs6596100	0.500	rs67685368	chr5:132292946	T/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Breast cancer;
LUSC	cis	rs6545883	0.894	rs6545845	chr2:61437044	G/C	cg15711740	chr2:61764176	XPO1	0.44	6.7	0.34	8.96e-11	Tuberculosis;
LUSC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg08888203	chr3:10149979	C3orf24	0.64	8.95	0.44	2.55e-17	Alzheimer's disease;
LUSC	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg24375607	chr4:120327624	NA	0.81	12.0	0.55	8.02e-28	Corneal astigmatism;
LUSC	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-1.12	-17.44	-0.69	7.25e-49	Exhaled nitric oxide output;
LUSC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18099408	chr3:52552593	STAB1	-0.41	-6.96	-0.36	1.84e-11	Bipolar disorder;
LUSC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg07424592	chr7:64974309	NA	0.64	5.74	0.3	2.1e-8	Diabetic kidney disease;
LUSC	trans	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg07393940	chr7:158741817	NA	0.36	6.57	0.34	1.98e-10	Life satisfaction;
LUSC	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg07936489	chr17:37558343	FBXL20	0.7	9.64	0.47	1.44e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.86	15.44	0.65	5.83e-41	Menarche (age at onset);
LUSC	cis	rs6840360	0.934	rs6817058	chr4:152603865	T/C	cg22705602	chr4:152727874	NA	-0.27	-5.67	-0.3	3.02e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg07148914	chr20:33460835	GGT7	-0.45	-6.63	-0.34	1.32e-10	Height;
LUSC	cis	rs4073416	0.568	rs1999725	chr14:65904237	C/T	cg03016385	chr14:66212404	NA	-0.4	-6.5	-0.34	2.95e-10	N-glycan levels;
LUSC	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.85	-0.44	5.09e-17	Response to antipsychotic treatment;
LUSC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.42	-0.33	4.68e-10	Life satisfaction;
LUSC	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg04906043	chr13:21280425	IL17D	0.45	8.62	0.43	2.75e-16	Dental caries;
LUSC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	9.63	0.47	1.53e-19	Eosinophil percentage of white cells;
LUSC	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21659725	chr3:3221576	CRBN	0.51	7.93	0.4	3.41e-14	Body mass index;
LUSC	cis	rs400736	0.729	rs9434949	chr1:8006083	C/G	cg25007680	chr1:8021821	PARK7	-0.5	-7.33	-0.37	1.8e-12	Response to antidepressants and depression;
LUSC	cis	rs9309473	0.607	rs2421488	chr2:73590625	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-8.24	-0.41	3.84e-15	Metabolite levels;
LUSC	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg05347473	chr6:146136440	FBXO30	0.41	6.97	0.36	1.67e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9309473	1.000	rs60844734	chr2:73623205	T/A	cg20560298	chr2:73613845	ALMS1	-0.49	-6.83	-0.35	3.95e-11	Metabolite levels;
LUSC	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.4	7.94	0.4	3.05e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg03676636	chr4:99064102	C4orf37	0.36	7.85	0.39	5.64e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg17366294	chr4:99064904	C4orf37	0.55	8.67	0.43	1.95e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.69	9.19	0.45	4.44e-18	Height;
LUSC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg23711669	chr6:146136114	FBXO30	-0.83	-14.97	-0.63	3.94e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg06521331	chr12:34319734	NA	-0.48	-8.04	-0.4	1.53e-14	Morning vs. evening chronotype;
LUSC	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.36	6.18	0.32	1.87e-9	Depressive symptoms;
LUSC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg08859206	chr1:53392774	SCP2	0.52	9.14	0.45	6.18e-18	Monocyte count;
LUSC	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg03465714	chr1:152285911	FLG	-0.41	-5.76	-0.3	1.96e-8	Atopic dermatitis;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04141948	chr7:1023156	CYP2W1	0.3	6.31	0.33	8.81e-10	Longevity;Endometriosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24222746	chr2:148779348	ORC4L	0.4	6.25	0.32	1.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.36	6.49	0.33	3.05e-10	Depressive symptoms;
LUSC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08736216	chr1:53307985	ZYG11A	0.3	6.28	0.33	1.04e-9	Monocyte count;
LUSC	cis	rs2200578	1.000	rs7566277	chr2:99916242	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.56	6.37	0.33	6.27e-10	IgG glycosylation;
LUSC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	cis	rs4363385	0.818	rs61811862	chr1:152995668	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.11	-0.36	7.08e-12	Inflammatory skin disease;
LUSC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.7	-12.5	-0.56	1.1e-29	Aortic root size;
LUSC	cis	rs9296095	0.796	rs3846855	chr6:33555877	G/A	cg14003231	chr6:33640908	ITPR3	0.53	8.06	0.4	1.35e-14	Platelet count;
LUSC	cis	rs1461503	0.966	rs11218905	chr11:122840303	A/G	cg27398637	chr11:122830231	C11orf63	0.4	6.39	0.33	5.44e-10	Menarche (age at onset);
LUSC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-7.73	-0.39	1.25e-13	Mood instability;
LUSC	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg04359828	chr10:32216031	ARHGAP12	0.38	6.52	0.34	2.59e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9815354	0.812	rs73071242	chr3:41993011	T/C	cg03022575	chr3:42003672	ULK4	0.85	8.86	0.44	4.72e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1568889	1.000	rs12797689	chr11:28076042	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	8.94	0.44	2.63e-17	Bipolar disorder;
LUSC	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.64	0.34	1.28e-10	Educational attainment;
LUSC	cis	rs2267681	0.583	rs764746	chr7:139530089	G/A	cg14116596	chr7:139528673	TBXAS1	0.36	6.23	0.32	1.42e-9	Cervical cancer;
LUSC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.28	-0.41	2.93e-15	Obesity-related traits;
LUSC	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg22709100	chr7:91322751	NA	0.4	5.9	0.31	8.7e-9	Breast cancer;
LUSC	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.38	-6.01	-0.31	4.73e-9	Longevity;Endometriosis;
LUSC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg14895029	chr7:2775587	GNA12	-0.36	-5.82	-0.3	1.35e-8	Height;
LUSC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08280861	chr8:58055591	NA	0.54	6.39	0.33	5.52e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg06808227	chr14:105710500	BRF1	-0.61	-8.92	-0.44	3.08e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg26395211	chr5:140044315	WDR55	-0.37	-5.72	-0.3	2.43e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg18002602	chr11:66138449	SLC29A2	0.47	8.52	0.42	5.65e-16	Educational attainment (years of education);
LUSC	cis	rs9462027	0.628	rs7739771	chr6:34779801	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.75	-0.3	2.03e-8	Systemic lupus erythematosus;
LUSC	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg23625390	chr15:77176239	SCAPER	0.51	7.91	0.4	3.79e-14	Blood metabolite levels;
LUSC	trans	rs2825388	0.965	rs9975959	chr21:20549004	A/G	cg18565711	chr19:55870393	FAM71E2	0.26	6.04	0.31	4.05e-9	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);
LUSC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	0.91	14.78	0.63	2.13e-38	IgG glycosylation;
LUSC	cis	rs9487051	0.735	rs352837	chr6:109521806	C/T	cg01475377	chr6:109611718	NA	0.35	6.06	0.31	3.67e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg04315214	chr1:2043799	PRKCZ	-0.4	-8.13	-0.41	8.65e-15	Height;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26316697	chr12:56727976	PAN2	-0.44	-6.03	-0.31	4.36e-9	Hepatitis;
LUSC	cis	rs2580764	0.566	rs2968793	chr2:55285024	C/T	cg09592903	chr2:55203963	RTN4	0.47	9.49	0.46	4.65e-19	Mean platelet volume;
LUSC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg27535305	chr1:53392650	SCP2	0.36	6.66	0.34	1.13e-10	Monocyte count;
LUSC	cis	rs977987	0.843	rs59465235	chr16:75483810	C/G	cg03315344	chr16:75512273	CHST6	0.54	10.42	0.5	3.45e-22	Dupuytren's disease;
LUSC	trans	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.19	0.32	1.8e-9	Corneal astigmatism;
LUSC	cis	rs668210	0.793	rs1192184	chr11:65773382	A/G	cg04700828	chr11:65773979	NA	0.4	5.72	0.3	2.35e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg10911889	chr6:126070802	HEY2	0.42	6.43	0.33	4.48e-10	Brugada syndrome;
LUSC	cis	rs3857536	0.813	rs9294688	chr6:66945904	C/T	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs2281558	0.833	rs12480853	chr20:25522959	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.62	9.33	0.45	1.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.86	-0.31	1.12e-8	Personality dimensions;
LUSC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg07701084	chr6:150067640	NUP43	0.53	7.75	0.39	1.14e-13	Lung cancer;
LUSC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg23887609	chr12:130822674	PIWIL1	-0.48	-7.08	-0.36	8.43e-12	Menopause (age at onset);
LUSC	cis	rs911119	0.913	rs6106685	chr20:23581612	A/C	cg16589663	chr20:23618590	CST3	0.62	7.41	0.38	1.04e-12	Chronic kidney disease;
LUSC	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg04518342	chr5:131593106	PDLIM4	-0.31	-5.65	-0.3	3.48e-8	Blood metabolite levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01304814	chr3:48885189	PRKAR2A	0.46	6.4	0.33	5.31e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4629710	0.592	rs66533103	chr6:131531016	C/T	cg12700074	chr6:131571435	AKAP7	-0.37	-6.01	-0.31	4.9e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs9868809	0.881	rs34368826	chr3:48670827	G/T	cg00383909	chr3:49044727	WDR6	1.07	9.61	0.47	1.86e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6840360	1.000	rs2278304	chr4:152593409	C/T	cg22705602	chr4:152727874	NA	0.27	5.77	0.3	1.85e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs11782517	0.924	rs35474349	chr8:10109654	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.02	0.31	4.5e-9	Nose size;
LUSC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	13.38	0.59	5.27e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.62	10.55	0.5	1.22e-22	Lung cancer;
LUSC	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg08601574	chr20:25228251	PYGB	0.43	6.54	0.34	2.25e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6977660	0.619	rs12534026	chr7:19788687	T/C	cg05791153	chr7:19748676	TWISTNB	0.64	7.2	0.37	4.03e-12	Thyroid stimulating hormone;
LUSC	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg22508957	chr16:3507546	NAT15	0.47	6.51	0.34	2.82e-10	Body mass index (adult);
LUSC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	15.78	0.65	2.56e-42	Platelet count;
LUSC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	14.27	0.62	2.15e-36	Platelet count;
LUSC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	0.97	9.55	0.46	2.87e-19	Plasma clusterin levels;
LUSC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.46e-12	Motion sickness;
LUSC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg04518342	chr5:131593106	PDLIM4	0.5	8.88	0.44	4.09e-17	Acylcarnitine levels;
LUSC	trans	rs13011075	0.919	rs10496165	chr2:68620089	C/T	cg14221825	chr19:46271408	SIX5	0.42	6.08	0.32	3.38e-9	Mean corpuscular volume;
LUSC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg04455712	chr21:45112962	RRP1B	-0.45	-8.42	-0.42	1.09e-15	Mean corpuscular volume;
LUSC	cis	rs2273669	0.667	rs6918331	chr6:109317394	C/G	cg05315195	chr6:109294784	ARMC2	-0.53	-5.94	-0.31	7.15e-9	Prostate cancer;
LUSC	cis	rs7843479	0.932	rs68023663	chr8:21794379	T/C	cg17168535	chr8:21777572	XPO7	0.7	11.12	0.52	1.21e-24	Mean corpuscular volume;
LUSC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.18	-0.32	1.92e-9	Total body bone mineral density;
LUSC	trans	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg01620082	chr3:125678407	NA	-0.66	-7.02	-0.36	1.28e-11	Breast cancer;
LUSC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg04871131	chr7:94954202	PON1	-0.38	-6.1	-0.32	2.98e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs56804039	1.000	rs67611618	chr8:8380939	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.27	-0.32	1.12e-9	Cervical cancer;
LUSC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg21017887	chr14:105400489	NA	0.69	12.97	0.58	1.93e-31	Rheumatoid arthritis;
LUSC	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-7.47	-0.38	7.24e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.58	10.76	0.51	2.21e-23	Bone mineral density;
LUSC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg00255919	chr5:131827918	IRF1	-0.44	-8.38	-0.42	1.53e-15	Asthma (sex interaction);
LUSC	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg06223162	chr1:101003688	GPR88	-0.48	-9.03	-0.44	1.4e-17	Monocyte count;
LUSC	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg22681709	chr2:178499509	PDE11A	-0.34	-6.19	-0.32	1.72e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs4363385	0.740	rs1697428	chr1:153015761	C/A	cg00922841	chr1:152955080	SPRR1A	-0.46	-8.11	-0.41	9.53e-15	Inflammatory skin disease;
LUSC	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg12564285	chr5:131593104	PDLIM4	-0.38	-7.02	-0.36	1.27e-11	Blood metabolite levels;
LUSC	cis	rs17102423	0.755	rs4902358	chr14:65542477	A/G	cg11161011	chr14:65562177	MAX	-0.79	-11.83	-0.54	3.32e-27	Obesity-related traits;
LUSC	cis	rs977987	0.836	rs7198873	chr16:75474754	G/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.21	-0.37	3.89e-12	Dupuytren's disease;
LUSC	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.08	-17.04	-0.68	2.7e-47	Primary sclerosing cholangitis;
LUSC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	11.95	0.55	1.2e-27	Prudent dietary pattern;
LUSC	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.77	-12.99	-0.58	1.66e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg01657329	chr11:68192670	LRP5	-0.44	-6.65	-0.34	1.21e-10	Total body bone mineral density;
LUSC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg14196790	chr5:131705035	SLC22A5	0.48	8.08	0.4	1.24e-14	Blood metabolite levels;
LUSC	cis	rs1461503	0.511	rs4129007	chr11:122811812	T/C	cg27398637	chr11:122830231	C11orf63	-0.39	-6.47	-0.33	3.55e-10	Menarche (age at onset);
LUSC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg17376030	chr22:41985996	PMM1	-0.46	-5.72	-0.3	2.42e-8	Vitiligo;
LUSC	cis	rs6700896	0.500	rs12024269	chr1:66103674	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	6.29	0.33	9.97e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs17001868	0.568	rs55769635	chr22:40790101	G/A	cg07138101	chr22:40742427	ADSL	0.61	7.5	0.38	5.72e-13	Mammographic density (dense area);
LUSC	cis	rs2354432	0.556	rs2353984	chr1:146813358	C/T	cg25205988	chr1:146714368	CHD1L	0.89	8.69	0.43	1.64e-16	Mitochondrial DNA levels;
LUSC	cis	rs6987853	0.787	rs2923405	chr8:42448126	T/G	cg09913449	chr8:42400586	C8orf40	0.5	8.7	0.43	1.52e-16	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.59	0.46	2.1e-19	Breast cancer;
LUSC	cis	rs2692947	0.673	rs2917662	chr2:96794957	G/A	cg23100626	chr2:96804247	ASTL	0.3	7.17	0.37	4.93e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9462027	0.583	rs9469902	chr6:34793768	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.76	-0.3	1.86e-8	Systemic lupus erythematosus;
LUSC	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.35	-0.42	1.88e-15	Coronary artery disease;
LUSC	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	10.4	0.49	3.88e-22	Response to antipsychotic treatment;
LUSC	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg04691961	chr3:161091175	C3orf57	-0.35	-5.99	-0.31	5.34e-9	Morning vs. evening chronotype;
LUSC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg00750074	chr16:89608354	SPG7	0.49	8.81	0.43	6.94e-17	Multiple myeloma (IgH translocation);
LUSC	cis	rs2073300	1.000	rs6106655	chr20:23441982	C/G	cg09953122	chr20:23471693	CST8	-0.77	-6.62	-0.34	1.46e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs28647808	0.881	rs4549850	chr9:136265239	T/C	cg12569217	chr2:109379859	RANBP2	0.6	5.95	0.31	6.83e-9	Blood protein levels;
LUSC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03517284	chr6:25882590	NA	-0.52	-9.67	-0.47	1.16e-19	Blood metabolite levels;
LUSC	cis	rs2857891	0.817	rs1907611	chr11:6968302	A/G	cg14883916	chr11:6947541	ZNF215	0.44	6.0	0.31	5.28e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19346786	chr7:2764209	NA	-0.48	-8.11	-0.41	1e-14	Height;
LUSC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.67	-11.52	-0.53	4.27e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6542838	0.698	rs7565736	chr2:99464952	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.17	-0.32	2.01e-9	Fear of minor pain;
LUSC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.67	11.51	0.53	4.8e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1941023	0.503	rs4528348	chr11:60129505	C/G	cg08716584	chr11:60157161	MS4A7	-0.61	-11.47	-0.53	6.92e-26	Congenital heart disease (maternal effect);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27523423	chr15:75744089	SIN3A	0.39	5.99	0.31	5.48e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs10098647	0.547	rs10086417	chr8:61111078	C/T	cg09970348	chr3:183978600	ECE2;CAMK2N2	0.46	6.15	0.32	2.26e-9	Obesity-related traits;
LUSC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	14.09	0.61	1.07e-35	Monocyte count;
LUSC	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg17385448	chr1:15911702	AGMAT	0.37	6.32	0.33	8.16e-10	Systolic blood pressure;
LUSC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.07	-0.36	9.06e-12	Bipolar disorder;
LUSC	cis	rs28655083	1.000	rs1843456	chr16:77072393	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.38	-5.66	-0.3	3.32e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg04374321	chr14:90722782	PSMC1	0.75	12.0	0.55	8.19e-28	Mortality in heart failure;
LUSC	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg10621924	chr7:39171070	POU6F2	0.44	6.84	0.35	3.75e-11	IgG glycosylation;
LUSC	cis	rs1775715	0.737	rs2799031	chr10:32173168	C/T	cg04359828	chr10:32216031	ARHGAP12	0.4	6.9	0.35	2.69e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9584850	0.834	rs7334078	chr13:99120484	C/T	cg20487152	chr13:99095054	FARP1	-0.34	-5.64	-0.3	3.57e-8	Neuroticism;
LUSC	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg07274523	chr3:49395745	GPX1	0.62	9.41	0.46	8.46e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg05707623	chr12:122985044	ZCCHC8	0.54	7.5	0.38	5.63e-13	Body mass index;
LUSC	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg03676636	chr4:99064102	C4orf37	0.36	7.89	0.4	4.25e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs35000415	0.745	rs117473643	chr7:128698186	G/C	cg19972273	chr7:128594194	NA	0.63	5.72	0.3	2.34e-8	Systemic lupus erythematosus;
LUSC	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg15557168	chr22:42548783	NA	-0.37	-6.27	-0.32	1.11e-9	Cognitive function;
LUSC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg07936489	chr17:37558343	FBXL20	0.73	10.0	0.48	9.44e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs17095355	1.000	rs12570230	chr10:111691614	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.56	-6.81	-0.35	4.65e-11	Biliary atresia;
LUSC	trans	rs9929218	0.954	rs4552018	chr16:68822854	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.09	-0.52	1.52e-24	Colorectal cancer;
LUSC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.7	0.3	2.59e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12476592	0.543	rs262470	chr2:63830559	C/T	cg10828910	chr2:63850056	LOC388955	0.5	5.81	0.3	1.49e-8	Childhood ear infection;
LUSC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	7.34	0.37	1.64e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06634786	chr22:41940651	POLR3H	0.5	6.04	0.31	4.05e-9	Vitiligo;
LUSC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg21854759	chr1:92012499	NA	-0.44	-7.01	-0.36	1.29e-11	Breast cancer;
LUSC	cis	rs3737883	1.000	rs11579055	chr1:203031315	G/T	cg00805880	chr1:203045044	PPFIA4	-0.29	-5.84	-0.3	1.27e-8	Early onset atrial fibrillation;
LUSC	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg23029597	chr12:123009494	RSRC2	-0.68	-8.8	-0.43	7.39e-17	Body mass index;
LUSC	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	0.99	19.66	0.73	1.06e-57	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4692589	0.581	rs6821641	chr4:170960193	C/T	cg19918862	chr4:170955249	NA	0.36	6.64	0.34	1.26e-10	Anxiety disorder;
LUSC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg03146154	chr1:46216737	IPP	0.5	7.49	0.38	6.06e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7712401	0.601	rs4555798	chr5:122332114	C/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.2	-0.45	4.07e-18	Mean platelet volume;
LUSC	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg13256891	chr4:100009986	ADH5	0.43	6.21	0.32	1.57e-9	Alcohol dependence;
LUSC	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	13.38	0.59	5.28e-33	Blood protein levels;
LUSC	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.74	-0.39	1.19e-13	Chronic sinus infection;
LUSC	cis	rs12042938	0.507	rs1765777	chr1:231731742	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-11.61	-0.54	2.08e-26	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg01657329	chr11:68192670	LRP5	-0.45	-6.76	-0.35	6.32e-11	Total body bone mineral density;
LUSC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.44	-5.88	-0.31	1.01e-8	Coronary artery disease;
LUSC	cis	rs4812048	0.649	rs6070706	chr20:57628239	C/T	cg14073986	chr20:57617431	SLMO2	0.91	9.55	0.46	2.78e-19	Mean platelet volume;
LUSC	cis	rs12618769	0.652	rs3754875	chr2:99202747	C/G	cg10123293	chr2:99228465	UNC50	0.46	7.34	0.37	1.63e-12	Bipolar disorder;
LUSC	trans	rs6445967	0.689	rs11714574	chr3:58380465	A/T	cg14253670	chr8:24802149	NA	0.27	6.16	0.32	2.12e-9	Platelet count;
LUSC	cis	rs733592	0.504	rs2261608	chr12:48721634	A/T	cg24011408	chr12:48396354	COL2A1	0.46	7.66	0.39	1.97e-13	Plateletcrit;
LUSC	cis	rs13401104	0.796	rs11680754	chr2:237112384	T/C	cg19324714	chr2:237145437	ASB18	0.43	5.71	0.3	2.46e-8	Educational attainment;
LUSC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg01802117	chr1:53393560	SCP2	0.39	6.36	0.33	6.52e-10	Monocyte count;
LUSC	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	6.95	0.36	1.88e-11	Lung cancer in ever smokers;
LUSC	cis	rs6076065	0.723	rs6137909	chr20:23344728	A/G	cg11657817	chr20:23433608	CST11	0.44	8.18	0.41	6.2e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.13	-0.45	6.87e-18	Gut microbiome composition (summer);
LUSC	cis	rs72777070	0.652	rs10185981	chr2:9795382	C/T	cg14973360	chr2:9800511	NA	-0.39	-5.77	-0.3	1.84e-8	Platelet-derived growth factor BB levels;
LUSC	trans	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg25214090	chr10:38739885	LOC399744	0.41	6.57	0.34	1.89e-10	Diastolic blood pressure;
LUSC	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg00339695	chr16:24857497	SLC5A11	0.37	6.59	0.34	1.72e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg05347473	chr6:146136440	FBXO30	0.45	7.69	0.39	1.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9650315	0.866	rs67752445	chr8:57182034	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.8	0.35	4.85e-11	Height;
LUSC	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg08779649	chr13:50194554	NA	0.4	6.83	0.35	3.95e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08219700	chr8:58056026	NA	-0.68	-7.84	-0.39	6.16e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs1493916	0.837	rs9949631	chr18:31410567	G/A	cg27147174	chr7:100797783	AP1S1	-0.55	-8.73	-0.43	1.21e-16	Life satisfaction;
LUSC	cis	rs11822910	0.737	rs2581924	chr11:57208468	C/T	cg00522883	chr11:57194120	SLC43A3	0.41	6.74	0.35	7.09e-11	Platelet distribution width;
LUSC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	9.63	0.47	1.54e-19	Joint mobility (Beighton score);
LUSC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	1.16	16.26	0.66	3.45e-44	Breast cancer;
LUSC	cis	rs68170813	0.559	rs6964966	chr7:106933099	C/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.82	-0.47	3.55e-20	Coronary artery disease;
LUSC	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg14458575	chr2:238380390	NA	0.66	11.37	0.53	1.48e-25	Prostate cancer;
LUSC	cis	rs6599077	0.901	rs9854779	chr3:40092874	T/C	cg13683864	chr3:40499215	RPL14	-0.6	-7.47	-0.38	7.09e-13	Sleep-related phenotypes;
LUSC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg03146154	chr1:46216737	IPP	0.52	7.75	0.39	1.14e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4462272	0.503	rs34236122	chr10:101845547	C/T	cg02250046	chr10:101825185	CPN1	-0.31	-5.69	-0.3	2.8e-8	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.35	-0.37	1.55e-12	Subjective well-being;
LUSC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg00316803	chr15:76480434	C15orf27	-0.41	-6.97	-0.36	1.7e-11	Blood metabolite levels;
LUSC	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg05714579	chr10:131428358	MGMT	0.52	7.9	0.4	4e-14	Response to temozolomide;
LUSC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6772849	0.930	rs4857912	chr3:128329224	G/A	cg16766828	chr3:128327626	NA	-0.3	-5.65	-0.3	3.47e-8	Monocyte percentage of white cells;Monocyte count;
LUSC	cis	rs7582720	1.000	rs75869289	chr2:203806724	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04565464	chr8:145669602	NFKBIL2	-0.39	-6.61	-0.34	1.51e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.59	0.6	8.31e-34	Platelet count;
LUSC	cis	rs1775715	0.966	rs1251386	chr10:32319114	C/T	cg18675610	chr10:32216311	ARHGAP12	-0.27	-5.71	-0.3	2.52e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6546537	0.869	rs35024605	chr2:69820332	A/G	cg10773587	chr2:69614142	GFPT1	-0.54	-8.29	-0.41	2.87e-15	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg19875535	chr5:140030758	IK	0.54	8.85	0.44	5.37e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.82	-0.3	1.41e-8	Bipolar disorder;
LUSC	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg02466173	chr16:30829666	NA	-0.53	-8.61	-0.43	2.84e-16	Dementia with Lewy bodies;
LUSC	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg25801113	chr15:45476975	SHF	0.35	7.3	0.37	2.15e-12	Uric acid levels;
LUSC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg23172400	chr8:95962367	TP53INP1	-0.39	-8.0	-0.4	2.02e-14	Type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.75	12.64	0.57	3.35e-30	Prudent dietary pattern;
LUSC	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	6.68	0.34	1.02e-10	Lung cancer in ever smokers;
LUSC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-9.84	-0.47	3.04e-20	Alzheimer's disease;
LUSC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg02951883	chr7:2050386	MAD1L1	-0.47	-8.21	-0.41	5.03e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg04455712	chr21:45112962	RRP1B	0.46	8.75	0.43	1.04e-16	Mean corpuscular volume;
LUSC	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg20587970	chr11:113659929	NA	0.8	9.31	0.45	1.72e-18	Hip circumference adjusted for BMI;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg19019321	chr2:159826400	TANC1	0.38	6.06	0.31	3.67e-9	Triglycerides;
LUSC	cis	rs12286929	0.637	rs7125361	chr11:115080042	C/G	cg04055981	chr11:115044050	NA	0.42	7.6	0.38	2.98e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg27489772	chr12:121021490	NA	0.6	7.88	0.4	4.76e-14	Type 1 diabetes nephropathy;
LUSC	cis	rs3018712	0.532	rs948861	chr11:68420622	C/T	cg22747802	chr11:68417633	NA	-0.43	-5.94	-0.31	7.02e-9	Total body bone mineral density;
LUSC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg25019033	chr10:957182	NA	-0.53	-6.66	-0.34	1.13e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg27284194	chr4:1044797	NA	0.59	8.66	0.43	2.08e-16	Recombination rate (females);
LUSC	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg16342193	chr10:102329863	NA	-0.33	-6.21	-0.32	1.56e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.74	-14.27	-0.62	2.05e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg07741184	chr6:167504864	NA	0.35	6.23	0.32	1.41e-9	Crohn's disease;
LUSC	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg07936489	chr17:37558343	FBXL20	-0.81	-10.53	-0.5	1.36e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7123876	0.546	rs11604837	chr11:72360007	G/A	cg04827223	chr11:72435913	ARAP1	-0.61	-6.78	-0.35	5.31e-11	Body mass index;
LUSC	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg08975724	chr8:8085496	FLJ10661	0.47	6.7	0.34	8.8e-11	Neuroticism;
LUSC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.79	0.3	1.59e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.41	5.86	0.31	1.12e-8	Schizophrenia;
LUSC	cis	rs17490626	0.533	rs5030925	chr10:71211150	A/C	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.46	-0.46	5.56e-19	Thrombosis;
LUSC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.82	-0.3	1.42e-8	Depression;
LUSC	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg06627628	chr2:24431161	ITSN2	-0.61	-7.4	-0.38	1.09e-12	Lymphocyte counts;
LUSC	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg22676075	chr6:135203613	NA	0.57	9.13	0.45	6.87e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	14.99	0.63	3.26e-39	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs12600053	0.687	rs11149686	chr16:84847247	A/G	cg09249803	chr16:84846936	NA	0.29	5.97	0.31	6.13e-9	Asthma (childhood onset);
LUSC	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg04850211	chr1:228464232	OBSCN	-0.36	-6.22	-0.32	1.51e-9	Diastolic blood pressure;
LUSC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.77	-0.39	1e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs3764021	0.870	rs10844617	chr12:9879368	G/A	cg20894963	chr12:9885564	CLECL1	0.34	6.85	0.35	3.58e-11	Type 1 diabetes;
LUSC	trans	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	22.63	0.78	2.07e-69	Colorectal cancer;
LUSC	trans	rs979233	0.502	rs276265	chr5:42067881	A/T	cg07010552	chr17:7358735	CHRNB1	0.41	6.03	0.31	4.33e-9	Systemic lupus erythematosus;
LUSC	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg18850127	chr7:39170497	POU6F2	0.41	6.12	0.32	2.57e-9	IgG glycosylation;
LUSC	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg23625390	chr15:77176239	SCAPER	0.6	9.45	0.46	6.27e-19	Blood metabolite levels;
LUSC	trans	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg02030672	chr11:45687055	CHST1	0.52	8.2	0.41	5.28e-15	Obesity-related traits;
LUSC	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.75	14.72	0.63	3.78e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2348418	0.864	rs6487688	chr12:28711211	A/T	cg13890972	chr12:28721907	NA	0.36	6.2	0.32	1.69e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.74	-0.47	6.73e-20	Gut microbiome composition (summer);
LUSC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg25036284	chr2:26402008	FAM59B	-0.73	-10.51	-0.5	1.67e-22	Gut microbiome composition (summer);
LUSC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg26373071	chr5:1325741	CLPTM1L	0.43	8.19	0.41	5.64e-15	Lung cancer;
LUSC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.91	-0.31	8.51e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7189233	0.513	rs10748	chr16:53504721	T/C	cg09728985	chr16:53543985	NA	-0.33	-6.18	-0.32	1.91e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg26304593	chr6:42947056	PEX6	-0.53	-8.23	-0.41	4.2e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4363385	0.818	rs2070963	chr1:153004004	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.23	-0.37	3.4e-12	Inflammatory skin disease;
LUSC	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg02466173	chr16:30829666	NA	-0.5	-9.55	-0.46	2.91e-19	Dementia with Lewy bodies;
LUSC	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.55	0.5	1.18e-22	Lung cancer in ever smokers;
LUSC	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.06	14.16	0.61	5.36e-36	Uric acid levels;
LUSC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg05347473	chr6:146136440	FBXO30	-0.52	-9.04	-0.44	1.28e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg17340268	chr14:105411764	AHNAK2	-0.38	-6.11	-0.32	2.83e-9	Rheumatoid arthritis;
LUSC	cis	rs8008758	0.500	rs1763212	chr14:101693911	G/A	cg26224664	chr14:101693935	NA	-0.37	-9.48	-0.46	4.98e-19	Body mass index (alcohol intake interaction);
LUSC	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg04833646	chr19:10679720	CDKN2D	1.19	17.23	0.69	4.93e-48	Red cell distribution width;
LUSC	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.44	-0.46	6.62e-19	Body mass index;
LUSC	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg19812747	chr11:111475976	SIK2	-0.5	-7.03	-0.36	1.15e-11	Primary sclerosing cholangitis;
LUSC	cis	rs155346	1.000	rs2560711	chr5:139394941	T/C	cg01090482	chr5:139365336	NRG2	-0.4	-6.56	-0.34	2.02e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	trans	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.6	9.61	0.47	1.9e-19	Brugada syndrome;
LUSC	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.84	-0.3	1.23e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	0.64	13.66	0.6	4.76e-34	Prudent dietary pattern;
LUSC	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg05738196	chr6:26577821	NA	-0.49	-7.05	-0.36	1.05e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18854424	chr1:2615690	NA	-0.52	-10.62	-0.5	6.92e-23	Ulcerative colitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10198271	chr20:55966838	RBM38	0.41	7.04	0.36	1.12e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg18099408	chr3:52552593	STAB1	0.36	6.17	0.32	1.97e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg08949735	chr16:89699720	DPEP1	-0.24	-5.89	-0.31	9.33e-9	Vitiligo;
LUSC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.19	0.32	1.81e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs68170813	0.652	rs4730250	chr7:107207695	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-8.53	-0.42	5.3e-16	Coronary artery disease;
LUSC	cis	rs2798269	1.000	rs12877509	chr13:22124028	G/C	cg18095732	chr13:22033692	ZDHHC20	-0.41	-6.4	-0.33	5.32e-10	PR segment;
LUSC	cis	rs6500395	1.000	rs9928051	chr16:48557316	T/A	cg04672837	chr16:48644449	N4BP1	0.45	6.66	0.34	1.15e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	12.25	0.56	9.47e-29	Monocyte percentage of white cells;
LUSC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg09491104	chr22:46646882	C22orf40	-0.63	-7.26	-0.37	2.76e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4363385	0.818	rs2070963	chr1:153004004	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.45e-8	Inflammatory skin disease;
LUSC	cis	rs7589342	0.517	rs6736701	chr2:106390440	G/T	cg09152813	chr2:106391379	NCK2	-0.37	-5.91	-0.31	8.36e-9	Addiction;
LUSC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg17173187	chr15:85201210	NMB	0.37	6.51	0.34	2.83e-10	Schizophrenia;
LUSC	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.2	-0.41	5.27e-15	Neuroticism;
LUSC	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg00495681	chr13:53174319	NA	-0.52	-8.02	-0.4	1.84e-14	Lewy body disease;
LUSC	cis	rs3770081	1.000	rs56326127	chr2:86212201	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.03	-6.61	-0.34	1.53e-10	Facial emotion recognition (sad faces);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg12359592	chr3:138048777	TXNDC6	0.48	7.01	0.36	1.34e-11	Triglycerides;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg10684905	chr12:2999782	TULP3	-0.45	-6.48	-0.33	3.37e-10	Cognitive function;Information processing speed;
LUSC	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg05163923	chr11:71159392	DHCR7	-0.76	-9.95	-0.48	1.32e-20	Vitamin D levels;
LUSC	cis	rs9309473	0.950	rs1052162	chr2:73829372	A/G	cg20560298	chr2:73613845	ALMS1	0.47	6.67	0.34	1.09e-10	Metabolite levels;
LUSC	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	0.58	9.29	0.45	2.01e-18	Breast cancer;
LUSC	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg02176678	chr2:219576539	TTLL4	0.45	7.96	0.4	2.65e-14	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.92	0.31	7.86e-9	Menopause (age at onset);
LUSC	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.93	-0.44	2.92e-17	Coffee consumption (cups per day);
LUSC	cis	rs7580658	0.929	rs4150477	chr2:128032546	A/G	cg09760422	chr2:128146352	NA	0.3	6.56	0.34	2.05e-10	Protein C levels;
LUSC	trans	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg03886242	chr7:26192032	NFE2L3	0.38	6.36	0.33	6.45e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7512552	0.839	rs17597088	chr1:150475772	A/G	cg15654264	chr1:150340011	RPRD2	0.64	10.58	0.5	9.39e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg06064525	chr11:970664	AP2A2	-0.29	-5.68	-0.3	2.94e-8	Alzheimer's disease (late onset);
LUSC	cis	rs11958404	0.932	rs6859826	chr5:157429710	T/C	cg05962755	chr5:157440814	NA	0.54	6.34	0.33	7.29e-10	IgG glycosylation;
LUSC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	9.11	0.45	7.8e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg18132916	chr6:79620363	NA	-0.38	-5.69	-0.3	2.83e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg19622623	chr12:86230825	RASSF9	-0.41	-5.71	-0.3	2.44e-8	Major depressive disorder;
LUSC	cis	rs3849570	0.643	rs10779987	chr3:81970856	C/T	cg07356753	chr3:81810745	GBE1	-0.49	-7.22	-0.37	3.44e-12	Waist circumference;Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15583014	chr1:65468659	NA	-0.4	-6.12	-0.32	2.57e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg17948913	chr5:572064	NA	0.4	5.92	0.31	7.86e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg13334819	chr7:99746414	C7orf59	-0.45	-6.13	-0.32	2.52e-9	Coronary artery disease;
LUSC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg12403142	chr1:92012408	NA	-0.38	-6.15	-0.32	2.25e-9	Breast cancer;
LUSC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg15557168	chr22:42548783	NA	0.42	6.33	0.33	8.02e-10	Schizophrenia;
LUSC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.69	-11.55	-0.53	3.53e-26	Systemic lupus erythematosus;
LUSC	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1320333	0.772	rs2867136	chr2:701455	T/C	cg27237671	chr2:676223	TMEM18	0.5	5.83	0.3	1.31e-8	Obesity-related traits;
LUSC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg02018176	chr4:1364513	KIAA1530	0.49	8.21	0.41	4.86e-15	Obesity-related traits;
LUSC	cis	rs716595	0.867	rs12414179	chr10:111981935	C/A	cg13996003	chr10:112034540	MXI1	-0.7	-5.81	-0.3	1.42e-8	Normalized brain volume;
LUSC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg07741184	chr6:167504864	NA	0.39	6.88	0.35	2.9e-11	Primary biliary cholangitis;
LUSC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg22834771	chr12:69754056	YEATS4	-0.43	-6.03	-0.31	4.37e-9	Blood protein levels;
LUSC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg03929089	chr4:120376271	NA	-0.77	-12.23	-0.56	1.16e-28	Height;
LUSC	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg05340658	chr4:99064831	C4orf37	0.43	6.75	0.35	6.4e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg06740227	chr12:86229804	RASSF9	-0.38	-6.11	-0.32	2.79e-9	Major depressive disorder;
LUSC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.41	0.42	1.19e-15	Prudent dietary pattern;
LUSC	cis	rs1784581	0.855	rs1790002	chr6:162384397	G/T	cg17173639	chr6:162384350	PARK2	-0.84	-15.86	-0.66	1.31e-42	Itch intensity from mosquito bite;
LUSC	cis	rs7584330	0.554	rs74449293	chr2:238426458	G/A	cg16989719	chr2:238392110	NA	-0.43	-6.2	-0.32	1.65e-9	Prostate cancer;
LUSC	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.52	-0.46	3.68e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg24313572	chr1:56050060	NA	-0.3	-6.26	-0.32	1.21e-9	Morning vs. evening chronotype;
LUSC	cis	rs2996428	0.667	rs17412654	chr1:3758493	T/C	cg22529645	chr1:3704559	LRRC47	0.37	6.22	0.32	1.46e-9	Red cell distribution width;
LUSC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06558623	chr16:89946397	TCF25	1.08	9.74	0.47	6.73e-20	Skin colour saturation;
LUSC	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.32e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg05368731	chr17:41323189	NBR1	0.78	12.93	0.58	2.86e-31	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	0.63	13.54	0.6	1.31e-33	Prudent dietary pattern;
LUSC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg20607798	chr8:58055168	NA	0.52	5.66	0.3	3.29e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	12.22	0.56	1.23e-28	Personality dimensions;
LUSC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.18	-0.45	4.76e-18	Type 2 diabetes;
LUSC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg14829155	chr15:31115871	NA	-0.48	-6.86	-0.35	3.34e-11	Huntington's disease progression;
LUSC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-5.99	-0.31	5.34e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg18209359	chr17:80159595	CCDC57	-0.37	-6.33	-0.33	7.82e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg08975724	chr8:8085496	FLJ10661	0.61	9.17	0.45	4.84e-18	Neuroticism;
LUSC	cis	rs34779708	0.966	rs1148245	chr10:35511894	C/T	cg03585969	chr10:35415529	CREM	0.61	9.07	0.44	1.04e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	0.94	18.71	0.72	5.98e-54	Cognitive function;
LUSC	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-5.66	-0.3	3.28e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03113475	chr19:12833063	TNPO2	0.47	7.53	0.38	4.75e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.48	7.24	0.37	3.04e-12	Testicular germ cell tumor;
LUSC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg05738196	chr6:26577821	NA	0.76	13.81	0.6	1.24e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg15790184	chr11:494944	RNH1	0.54	5.93	0.31	7.69e-9	Body mass index;
LUSC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg16362232	chr11:430036	ANO9	0.66	8.17	0.41	6.24e-15	Body mass index;
LUSC	cis	rs12900413	0.562	rs12898229	chr15:90295960	C/T	cg24249390	chr15:90295951	MESP1	-0.39	-6.25	-0.32	1.24e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.43	0.33	4.51e-10	Obesity-related traits;
LUSC	cis	rs7224314	1.000	rs7221926	chr17:65352181	A/T	cg01507342	chr17:65387096	PITPNC1	-0.39	-6.88	-0.35	2.89e-11	Diisocyanate-induced asthma;
LUSC	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.82	0.43	6.31e-17	Menopause (age at onset);
LUSC	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg05110241	chr16:68378359	PRMT7	-0.69	-7.27	-0.37	2.54e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg01657329	chr11:68192670	LRP5	-0.46	-6.88	-0.35	2.94e-11	Total body bone mineral density;
LUSC	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-7.9	-0.4	4.04e-14	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11764359	chr7:65958608	NA	0.63	9.44	0.46	6.65e-19	Aortic root size;
LUSC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg23262073	chr20:60523788	NA	-0.43	-6.2	-0.32	1.69e-9	Body mass index;
LUSC	cis	rs3755132	0.929	rs3755133	chr2:15731583	C/T	cg12888861	chr2:15731646	DDX1	0.5	7.15	0.36	5.48e-12	Wilms tumor;
LUSC	cis	rs6429082	0.702	rs2131922	chr1:235705001	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.46	-6.44	-0.33	4.23e-10	Adiposity;
LUSC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06481639	chr22:41940642	POLR3H	0.49	5.69	0.3	2.85e-8	Vitiligo;
LUSC	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg22089800	chr15:90895588	ZNF774	0.53	7.63	0.39	2.43e-13	Rheumatoid arthritis;
LUSC	trans	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg02113368	chr10:135107346	TUBGCP2	-0.34	-6.01	-0.31	4.73e-9	Dementia with Lewy bodies;
LUSC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg22638593	chr5:131593259	PDLIM4	-0.39	-5.8	-0.3	1.56e-8	Breast cancer;
LUSC	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg05347473	chr6:146136440	FBXO30	0.49	8.06	0.4	1.38e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg25309564	chr22:51001381	C22orf41	0.44	6.23	0.32	1.38e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.69	-10.67	-0.5	4.69e-23	Aortic root size;
LUSC	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg08807101	chr21:30365312	RNF160	0.7	11.26	0.52	3.76e-25	Pancreatic cancer;
LUSC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg11645453	chr3:52864694	ITIH4	0.31	6.86	0.35	3.32e-11	Electroencephalogram traits;
LUSC	cis	rs2637266	1.000	rs10219023	chr10:78364537	G/A	cg18941641	chr10:78392320	NA	0.39	7.11	0.36	7.28e-12	Pulmonary function;
LUSC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.97	-0.31	6.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.57	-0.42	3.93e-16	Mood instability;
LUSC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.74	0.3	2.15e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.68	-9.21	-0.45	3.81e-18	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg15704280	chr7:45808275	SEPT13	0.66	7.22	0.37	3.45e-12	Axial length;
LUSC	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg23283495	chr1:209979779	IRF6	0.66	7.9	0.4	4.2e-14	Coronary artery disease;
LUSC	trans	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg15704280	chr7:45808275	SEPT13	-0.53	-6.12	-0.32	2.64e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg05887092	chr17:76393375	PGS1	0.53	9.35	0.46	1.28e-18	HDL cholesterol levels;
LUSC	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg04310649	chr10:35416472	CREM	-0.42	-6.59	-0.34	1.71e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg17294928	chr15:75287854	SCAMP5	-0.76	-10.12	-0.48	3.67e-21	Blood trace element (Zn levels);
LUSC	cis	rs12530845	0.767	rs7784162	chr7:135305886	G/T	cg23117316	chr7:135346802	PL-5283	-0.49	-8.65	-0.43	2.15e-16	Red blood cell traits;
LUSC	cis	rs9420	0.961	rs7938083	chr11:57493622	C/A	cg02958346	chr11:57425731	CLP1	-0.41	-5.75	-0.3	2.02e-8	Schizophrenia;
LUSC	cis	rs2625529	0.730	rs1481861	chr15:72240129	A/G	cg16672083	chr15:72433130	SENP8	0.5	7.99	0.4	2.24e-14	Red blood cell count;
LUSC	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	1.13	19.75	0.73	4.68e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg05925327	chr15:68127851	NA	-0.46	-6.89	-0.35	2.81e-11	Restless legs syndrome;
LUSC	cis	rs6722750	0.933	rs4671554	chr2:64411122	T/A	cg22352474	chr2:64371530	PELI1	-0.52	-7.76	-0.39	1.06e-13	Neuroticism;
LUSC	cis	rs6687430	0.526	rs12120962	chr1:10609505	G/A	cg17425144	chr1:10567563	PEX14	0.63	12.44	0.56	1.95e-29	Hand grip strength;
LUSC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg20295408	chr7:1910781	MAD1L1	0.52	7.56	0.38	3.91e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg05855489	chr10:104503620	C10orf26	0.52	7.85	0.39	5.83e-14	Arsenic metabolism;
LUSC	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs2235649	0.746	rs35104579	chr16:1848657	A/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.11	-0.32	2.74e-9	Blood metabolite levels;
LUSC	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg03433033	chr1:76189801	ACADM	-0.39	-5.85	-0.3	1.19e-8	Daytime sleep phenotypes;
LUSC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg15147215	chr3:52552868	STAB1	-0.32	-6.27	-0.32	1.14e-9	Bipolar disorder;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04562739	chr20:5107446	CDS2;PCNA	-0.45	-6.64	-0.34	1.29e-10	Electrocardiographic conduction measures;
LUSC	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg04310649	chr10:35416472	CREM	-0.43	-6.56	-0.34	2.05e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg00982548	chr2:198649783	BOLL	-0.56	-7.04	-0.36	1.12e-11	Ulcerative colitis;
LUSC	trans	rs953492	0.672	rs10926964	chr1:243359347	G/A	cg01826367	chr1:224180288	NA	-0.44	-6.46	-0.33	3.73e-10	Diastolic blood pressure;
LUSC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19717773	chr7:2847554	GNA12	-0.38	-6.1	-0.32	2.93e-9	Height;
LUSC	cis	rs77633900	0.614	rs280029	chr15:77031235	A/G	cg21673338	chr15:77095150	SCAPER	-0.79	-7.72	-0.39	1.39e-13	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg03676636	chr4:99064102	C4orf37	0.36	7.85	0.39	5.64e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.62	0.38	2.6e-13	Bipolar disorder;
LUSC	cis	rs977987	0.931	rs1424013	chr16:75495986	T/C	cg03315344	chr16:75512273	CHST6	0.52	9.8	0.47	4.44e-20	Dupuytren's disease;
LUSC	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg03676636	chr4:99064102	C4orf37	0.37	7.65	0.39	2.14e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6984449	0.508	rs62496184	chr8:19319423	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.32	5.85	0.31	1.14e-8	Educational attainment;
LUSC	cis	rs68170813	0.641	rs77397573	chr7:107006892	G/A	cg02696742	chr7:106810147	HBP1	-0.63	-9.36	-0.46	1.24e-18	Coronary artery disease;
LUSC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.51	-11.97	-0.55	1.02e-27	Longevity;
LUSC	cis	rs9473147	0.516	rs9381575	chr6:47528764	C/G	cg12968598	chr6:47444699	CD2AP	0.52	7.97	0.4	2.54e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg11344533	chr11:111475393	SIK2	0.45	5.89	0.31	9.38e-9	Primary sclerosing cholangitis;
LUSC	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg06287003	chr12:125626642	AACS	-0.37	-6.48	-0.33	3.31e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg22549504	chr19:17448937	GTPBP3	0.53	6.68	0.34	1.01e-10	Systemic lupus erythematosus;
LUSC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg22834771	chr12:69754056	YEATS4	-0.45	-6.49	-0.33	3.14e-10	Blood protein levels;
LUSC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	0.99	13.75	0.6	2.05e-34	Eosinophil percentage of granulocytes;
LUSC	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.18	-0.45	4.78e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg16325326	chr1:53192061	ZYG11B	0.71	11.65	0.54	1.54e-26	Monocyte count;
LUSC	trans	rs230489	0.668	rs1585606	chr4:103376409	G/A	cg20368818	chr11:33800056	NA	-0.44	-6.03	-0.31	4.25e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs56283067	0.547	rs12192267	chr6:45393787	C/T	cg18551225	chr6:44695536	NA	-0.4	-5.82	-0.3	1.41e-8	Total body bone mineral density;
LUSC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.48	-8.93	-0.44	2.94e-17	Urinary metabolites;
LUSC	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	1.15	18.46	0.71	6.19e-53	Corneal structure;
LUSC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg15556689	chr8:8085844	FLJ10661	0.72	10.04	0.48	6.81e-21	Red cell distribution width;
LUSC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg00933542	chr6:150070202	PCMT1	0.31	6.52	0.34	2.57e-10	Lung cancer;
LUSC	cis	rs17407555	0.518	rs16891234	chr4:9946163	A/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.11	-0.32	2.75e-9	Schizophrenia (age at onset);
LUSC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.77	0.35	5.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21659725	chr3:3221576	CRBN	0.63	8.96	0.44	2.42e-17	Resting heart rate;
LUSC	cis	rs3087591	0.919	rs2952983	chr17:29470288	G/C	cg24425628	chr17:29625626	OMG;NF1	0.57	8.1	0.41	1.04e-14	Hip circumference;
LUSC	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.31	-0.33	8.95e-10	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18676123	chr18:32870181	ZNF271;ZNF397OS	-0.47	-6.82	-0.35	4.17e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg16482183	chr6:26056742	HIST1H1C	0.56	7.99	0.4	2.27e-14	Iron status biomarkers;
LUSC	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg17845761	chr1:175162550	KIAA0040	-0.31	-5.91	-0.31	8.38e-9	Alcohol dependence;
LUSC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg02475777	chr4:1388615	CRIPAK	0.42	6.22	0.32	1.49e-9	Obesity-related traits;
LUSC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.7	10.59	0.5	8.51e-23	Aortic root size;
LUSC	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg17366294	chr4:99064904	C4orf37	0.55	9.01	0.44	1.63e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12476592	0.602	rs964880	chr2:63826932	C/A	cg10828910	chr2:63850056	LOC388955	0.5	5.81	0.3	1.49e-8	Childhood ear infection;
LUSC	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.46	0.46	5.81e-19	Blood protein levels;
LUSC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.78	-0.47	5.11e-20	Multiple sclerosis;
LUSC	cis	rs713477	0.967	rs6573031	chr14:55913763	C/G	cg13175173	chr14:55914753	NA	-0.31	-6.49	-0.33	3.05e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.31	-0.37	2.01e-12	Bipolar disorder;
LUSC	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-1.12	-15.55	-0.65	2.16e-41	Hip circumference adjusted for BMI;
LUSC	cis	rs7246967	0.551	rs3925175	chr19:22880958	G/A	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg01475377	chr6:109611718	NA	-0.43	-7.78	-0.39	8.93e-14	Reticulocyte fraction of red cells;
LUSC	trans	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg07393940	chr7:158741817	NA	-0.37	-6.61	-0.34	1.52e-10	Life satisfaction;
LUSC	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg08079166	chr15:68083412	MAP2K5	0.41	7.23	0.37	3.29e-12	Restless legs syndrome;
LUSC	cis	rs1160297	0.643	rs6737483	chr2:53041627	G/A	cg07782112	chr2:53107842	NA	0.39	6.13	0.32	2.47e-9	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg09835421	chr16:68378352	PRMT7	-0.48	-5.92	-0.31	7.94e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-10.4	-0.49	3.84e-22	Body mass index;
LUSC	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg08601574	chr20:25228251	PYGB	0.42	6.35	0.33	7.01e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8133932	0.654	rs371587	chr21:47348512	G/A	cg14185626	chr21:47401492	COL6A1	-0.45	-5.8	-0.3	1.54e-8	Schizophrenia;
LUSC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg10018233	chr7:150070692	REPIN1	0.4	6.66	0.34	1.16e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg21724239	chr8:58056113	NA	0.56	6.92	0.35	2.35e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.79	0.57	9.37e-31	Prudent dietary pattern;
LUSC	cis	rs2019216	0.500	rs2880292	chr17:21869537	A/G	cg22648282	chr17:21454238	C17orf51	-0.54	-7.82	-0.39	6.97e-14	Pelvic organ prolapse;
LUSC	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.56	0.38	3.98e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2692947	0.526	rs58719199	chr2:96578247	G/A	cg23100626	chr2:96804247	ASTL	0.3	7.07	0.36	9.39e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs78579285	0.584	rs9922996	chr16:88800670	G/C	cg01900006	chr16:88814613	FAM38A	0.61	6.83	0.35	4.14e-11	Joint mobility (Beighton score);
LUSC	trans	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg07393940	chr7:158741817	NA	0.37	6.7	0.34	8.73e-11	Life satisfaction;
LUSC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.77	-0.39	9.83e-14	Blood metabolite levels;
LUSC	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg24596788	chr1:163392923	NA	-0.35	-6.06	-0.31	3.58e-9	Motion sickness;
LUSC	cis	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg21972741	chr5:435613	AHRR	-0.31	-5.81	-0.3	1.43e-8	Cystic fibrosis severity;
LUSC	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg23950597	chr19:37808831	NA	-0.6	-7.28	-0.37	2.42e-12	Coronary artery calcification;
LUSC	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg08277548	chr1:17600880	PADI3	-0.65	-6.71	-0.34	8.54e-11	Hair shape;
LUSC	cis	rs1775715	0.737	rs2778650	chr10:32106851	A/G	cg26784012	chr10:32216390	ARHGAP12	0.44	7.39	0.37	1.21e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg08219700	chr8:58056026	NA	0.51	6.5	0.34	2.93e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg25024717	chr12:54324583	NA	-0.39	-6.71	-0.34	8.6e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.46	0.46	5.81e-19	Blood protein levels;
LUSC	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.16	0.36	5.04e-12	Educational attainment;
LUSC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.12	-0.36	6.61e-12	Bipolar disorder;
LUSC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.39	6.03	0.31	4.32e-9	Multiple sclerosis;
LUSC	cis	rs9879311	0.966	rs4684685	chr3:10411553	C/T	cg08489410	chr3:10329245	GHRL;GHRLOS	0.43	6.99	0.36	1.5e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg25036284	chr2:26402008	FAM59B	-0.73	-10.66	-0.5	4.85e-23	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.06e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg13565492	chr6:43139072	SRF	-0.57	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg11247378	chr22:39784982	NA	-0.66	-13.01	-0.58	1.35e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.55	-0.38	4.15e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg00343986	chr7:65444356	GUSB	0.39	5.89	0.31	9.38e-9	Aortic root size;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg18718234	chr5:175874660	FAF2	0.54	6.79	0.35	5.2e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs3916	0.955	rs34030695	chr12:121156496	G/A	cg27246729	chr12:121163418	ACADS	0.49	7.15	0.36	5.49e-12	Urinary metabolites (H-NMR features);
LUSC	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg09835421	chr16:68378352	PRMT7	-0.56	-6.31	-0.33	8.67e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4356932	1.000	rs6825045	chr4:76957558	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg02415014	chr8:143852576	LYNX1	0.34	7.85	0.39	5.53e-14	Urinary tract infection frequency;
LUSC	cis	rs7215564	0.908	rs34932625	chr17:78653155	A/G	cg23238734	chr17:78661607	RPTOR	0.49	6.28	0.32	1.08e-9	Myopia (pathological);
LUSC	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg21709803	chr11:61594965	FADS2	0.38	5.92	0.31	8.13e-9	Neutrophil count;Sum basophil neutrophil counts;
LUSC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg08888203	chr3:10149979	C3orf24	0.64	9.15	0.45	5.82e-18	Alzheimer's disease;
LUSC	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg01065977	chr19:18549689	ISYNA1	-0.23	-6.06	-0.31	3.73e-9	Breast cancer;
LUSC	cis	rs1403694	0.695	rs11919484	chr3:186432839	G/T	cg12454167	chr3:186435060	KNG1	0.34	8.4	0.42	1.26e-15	Blood protein levels;
LUSC	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19748678	chr4:122722346	EXOSC9	-0.48	-6.95	-0.36	1.9e-11	Type 2 diabetes;
LUSC	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg16230307	chr14:35515116	FAM177A1	0.78	10.01	0.48	8.72e-21	Psoriasis;
LUSC	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg14582100	chr15:45693742	SPATA5L1	0.46	8.75	0.43	1.1e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-8.76	-0.43	1.01e-16	Bone mineral density;
LUSC	cis	rs3126085	0.935	rs7534716	chr1:152198654	A/G	cg26876637	chr1:152193138	HRNR	0.45	6.22	0.32	1.47e-9	Atopic dermatitis;
LUSC	trans	rs2229238	0.911	rs58348886	chr1:154446198	T/C	cg25273160	chr11:56955011	LRRC55	0.32	6.13	0.32	2.5e-9	Coronary heart disease;
LUSC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg04398451	chr17:18023971	MYO15A	-0.48	-7.72	-0.39	1.34e-13	Total body bone mineral density;
LUSC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.08	-0.32	3.34e-9	Initial pursuit acceleration;
LUSC	trans	rs11723530	0.538	rs4692760	chr4:170813973	C/T	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.35	-0.33	7.2e-10	Myopia (pathological);
LUSC	trans	rs4800353	0.929	rs4389219	chr18:19608334	A/G	cg01841828	chr16:69166849	CHTF8;CIRH1A	-0.58	-6.05	-0.31	3.85e-9	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.56	8.71	0.43	1.42e-16	Menopause (age at onset);
LUSC	cis	rs9494145	0.680	rs9376092	chr6:135427144	A/C	cg22676075	chr6:135203613	NA	-0.6	-8.54	-0.42	4.69e-16	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	0.81	14.23	0.61	3.06e-36	Cognitive function;
LUSC	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg01528321	chr10:82214614	TSPAN14	0.61	8.9	0.44	3.61e-17	Post bronchodilator FEV1;
LUSC	cis	rs11690935	0.838	rs10432423	chr2:172753295	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.81	-12.88	-0.58	4.33e-31	Schizophrenia;
LUSC	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg19773385	chr1:10388646	KIF1B	-0.54	-8.29	-0.41	2.84e-15	Hepatocellular carcinoma;
LUSC	cis	rs2274273	1.000	rs7140872	chr14:55612744	C/T	cg04306507	chr14:55594613	LGALS3	0.54	11.95	0.55	1.23e-27	Protein biomarker;
LUSC	trans	rs6475216	0.900	rs1281350	chr9:18473576	C/G	cg17555624	chr10:134053894	STK32C	-0.31	-5.99	-0.31	5.32e-9	Obesity-related traits;
LUSC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	8.25	0.41	3.68e-15	Personality dimensions;
LUSC	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg24692254	chr21:30365293	RNF160	0.87	16.99	0.68	4.23e-47	Dental caries;
LUSC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg05373962	chr22:49881684	NA	-0.44	-10.5	-0.5	1.77e-22	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg08859206	chr1:53392774	SCP2	-0.49	-7.77	-0.39	9.48e-14	Monocyte count;
LUSC	cis	rs6546537	0.503	rs6718872	chr2:69909977	A/C	cg10773587	chr2:69614142	GFPT1	-0.42	-6.26	-0.32	1.16e-9	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	6.97	0.36	1.66e-11	Mean platelet volume;
LUSC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg19257562	chr1:2043853	PRKCZ	0.32	6.27	0.32	1.13e-9	Height;
LUSC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	7.1	0.36	7.63e-12	Platelet count;
LUSC	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg22852734	chr6:133119734	C6orf192	1.17	14.03	0.61	1.8e-35	Type 2 diabetes nephropathy;
LUSC	cis	rs9398803	0.865	rs4895808	chr6:126781434	C/T	cg19875578	chr6:126661172	C6orf173	0.42	6.18	0.32	1.9e-9	Male-pattern baldness;
LUSC	cis	rs11051970	0.879	rs2467065	chr12:32586065	A/G	cg02745156	chr12:32552066	NA	0.43	7.3	0.37	2.16e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.48	-0.33	3.27e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	0.57	9.05	0.44	1.24e-17	Breast cancer;
LUSC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg16414030	chr3:133502952	NA	-0.42	-6.47	-0.33	3.55e-10	Iron status biomarkers;
LUSC	cis	rs2573652	0.722	rs8034841	chr15:100541593	G/T	cg00587665	chr15:100533223	ADAMTS17	-0.39	-6.92	-0.35	2.36e-11	Height;
LUSC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg11247378	chr22:39784982	NA	-0.64	-12.57	-0.57	6.06e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-7.5	-0.38	5.7e-13	Alzheimer's disease (late onset);
LUSC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.94	-0.31	7.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg01503450	chr10:980765	NA	-0.39	-5.68	-0.3	2.88e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg02696742	chr7:106810147	HBP1	-0.63	-9.54	-0.46	3.16e-19	Coronary artery disease;
LUSC	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.95	0.31	6.74e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg06740227	chr12:86229804	RASSF9	-0.46	-7.41	-0.38	1.02e-12	Major depressive disorder;
LUSC	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.84	14.46	0.62	3.94e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1034435	0.755	rs5767171	chr22:48891881	A/G	cg05992904	chr22:48892994	FAM19A5	-0.41	-7.99	-0.4	2.22e-14	Late-onset Alzheimer's disease;
LUSC	cis	rs6500395	0.926	rs11643272	chr16:48639723	T/C	cg04672837	chr16:48644449	N4BP1	0.48	7.14	0.36	5.91e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2164273	0.565	rs2736387	chr8:11157371	A/C	cg21775007	chr8:11205619	TDH	0.49	7.33	0.37	1.75e-12	Extraversion;
LUSC	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.41	-5.96	-0.31	6.29e-9	Platelet distribution width;
LUSC	cis	rs56283067	0.847	rs12208621	chr6:44752003	G/C	cg18551225	chr6:44695536	NA	-0.49	-8.4	-0.42	1.32e-15	Total body bone mineral density;
LUSC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg00857998	chr1:205179979	DSTYK	0.64	9.83	0.47	3.41e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg15556689	chr8:8085844	FLJ10661	0.54	8.71	0.43	1.42e-16	Retinal vascular caliber;
LUSC	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg00864171	chr11:67383662	NA	0.35	6.14	0.32	2.31e-9	Mean corpuscular volume;
LUSC	trans	rs28647808	0.881	rs7852803	chr9:136245903	A/G	cg12569217	chr2:109379859	RANBP2	0.61	5.98	0.31	5.69e-9	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.52	0.5	1.5e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	1.13	18.42	0.71	8.76e-53	Corneal structure;
LUSC	cis	rs1971762	0.583	rs11170648	chr12:54089660	C/T	cg23533419	chr12:54090519	NA	-0.38	-6.23	-0.32	1.41e-9	Height;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09192942	chr16:75682004	KARS;TERF2IP	-0.47	-6.39	-0.33	5.55e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2273669	0.667	rs2273668	chr6:109323519	G/T	cg05315195	chr6:109294784	ARMC2	-0.56	-6.21	-0.32	1.54e-9	Prostate cancer;
LUSC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg04450456	chr4:17643702	FAM184B	-0.36	-5.86	-0.31	1.11e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2637266	1.000	rs7080883	chr10:78361200	A/G	cg18941641	chr10:78392320	NA	0.4	7.45	0.38	7.84e-13	Pulmonary function;
LUSC	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg18721089	chr20:30220636	NA	-0.35	-5.65	-0.3	3.36e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg08676812	chr11:65308423	LTBP3	1.08	6.91	0.35	2.5e-11	Height;
LUSC	cis	rs977987	0.736	rs4888392	chr16:75412262	T/C	cg04384234	chr16:75411784	CFDP1	-0.44	-7.28	-0.37	2.4e-12	Dupuytren's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21306218	chr16:89787478	ZNF276;C16orf7	-0.56	-6.71	-0.34	8.11e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7560272	0.512	rs4530394	chr2:73929650	T/C	cg20560298	chr2:73613845	ALMS1	0.39	5.9	0.31	8.71e-9	Schizophrenia;
LUSC	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg18683606	chr7:100471612	SRRT	0.46	6.56	0.34	2.04e-10	Resting heart rate;
LUSC	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg22709100	chr7:91322751	NA	-0.4	-5.84	-0.3	1.21e-8	Breast cancer;
LUSC	cis	rs922692	0.744	rs12899147	chr15:79079512	A/G	cg00540400	chr15:79124168	NA	-0.4	-7.02	-0.36	1.22e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg24069376	chr3:38537580	EXOG	0.41	7.95	0.4	2.89e-14	Electrocardiographic conduction measures;
LUSC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg17724175	chr1:150552817	MCL1	0.36	6.5	0.34	2.95e-10	Tonsillectomy;
LUSC	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.35	-0.42	1.82e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs4650994	0.525	rs10913574	chr1:178536482	G/C	cg05059571	chr16:84539110	KIAA1609	-0.47	-9.08	-0.44	9.83e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.35	-0.42	1.81e-15	Response to antipsychotic treatment;
LUSC	cis	rs8179	0.645	rs42046	chr7:92252203	C/G	cg15732164	chr7:92237376	CDK6	-0.43	-6.03	-0.31	4.45e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	trans	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07923666	chr12:49932857	KCNH3	-0.52	-6.48	-0.33	3.31e-10	Resting heart rate;
LUSC	cis	rs6088813	1.000	rs2248393	chr20:33926103	C/G	cg14752227	chr20:34000481	UQCC	0.38	5.94	0.31	7.21e-9	Height;
LUSC	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg18190219	chr22:46762943	CELSR1	-0.49	-6.16	-0.32	2.04e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1521470	1.000	rs1521470	chr7:45646852	A/G	cg26437564	chr7:45808727	SEPT13	-0.53	-5.92	-0.31	8.13e-9	Schizophrenia;Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg13010199	chr12:38710504	ALG10B	0.68	10.45	0.5	2.57e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg20701182	chr2:24300061	SF3B14	0.77	7.83	0.39	6.56e-14	Lymphocyte counts;
LUSC	cis	rs9815354	0.812	rs17215498	chr3:41829679	G/C	cg03022575	chr3:42003672	ULK4	0.85	8.62	0.43	2.78e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	6.21	0.32	1.54e-9	Calcium levels;
LUSC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.53	-7.07	-0.36	9.06e-12	Renal function-related traits (BUN);
LUSC	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg25251562	chr2:3704773	ALLC	-0.49	-7.44	-0.38	8.43e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg26338869	chr17:61819248	STRADA	0.41	5.9	0.31	8.95e-9	Prudent dietary pattern;
LUSC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg18240062	chr17:79603768	NPLOC4	0.58	10.08	0.48	4.8e-21	Eye color traits;
LUSC	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.47	6.97	0.36	1.75e-11	Height;
LUSC	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.48	0.42	7.52e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg24531977	chr5:56204891	C5orf35	0.58	8.54	0.42	4.65e-16	Coronary artery disease;
LUSC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg00933542	chr6:150070202	PCMT1	0.3	6.07	0.32	3.4e-9	Lung cancer;
LUSC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg15839431	chr19:19639596	YJEFN3	-0.44	-6.19	-0.32	1.78e-9	Tonsillectomy;
LUSC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.5	9.41	0.46	8.46e-19	Urinary metabolites;
LUSC	cis	rs2681472	0.524	rs7314459	chr12:89956341	T/A	cg00757033	chr12:89920650	WDR51B	0.5	6.75	0.35	6.46e-11	Diastolic blood pressure;Coronary artery disease;Systolic blood pressure;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Hypertension;
LUSC	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg01973587	chr1:228161476	NA	-0.41	-7.23	-0.37	3.38e-12	Diastolic blood pressure;
LUSC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.16	-0.32	2.06e-9	Total body bone mineral density;
LUSC	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg19743168	chr1:23544995	NA	-0.46	-10.06	-0.48	5.5e-21	Height;
LUSC	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg13615516	chr5:77269221	NA	0.41	6.9	0.35	2.64e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-8.27	-0.41	3.14e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2348418	0.864	rs7312339	chr12:28711684	T/C	cg13890972	chr12:28721907	NA	-0.34	-5.92	-0.31	8.04e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-7.03	-0.36	1.19e-11	Electroencephalogram traits;
LUSC	cis	rs2806561	0.715	rs10753550	chr1:23322471	C/G	cg19743168	chr1:23544995	NA	-0.38	-7.94	-0.4	3.11e-14	Height;
LUSC	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.36	-5.8	-0.3	1.57e-8	Rheumatoid arthritis;
LUSC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg22823121	chr1:150693482	HORMAD1	0.53	7.95	0.4	2.9e-14	Melanoma;
LUSC	cis	rs73206853	0.841	rs6606683	chr12:110712212	T/G	cg12870014	chr12:110450643	ANKRD13A	0.68	6.45	0.33	3.98e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7945718	0.967	rs10765990	chr11:12769444	G/A	cg25843174	chr11:12811716	TEAD1	0.31	7.03	0.36	1.14e-11	Educational attainment (years of education);
LUSC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg25344623	chr2:136566232	LCT	0.38	5.76	0.3	1.92e-8	Mosquito bite size;
LUSC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs2668423	0.922	rs3826942	chr19:1360575	A/G	cg02639931	chr19:1387894	NDUFS7	0.5	8.49	0.42	6.69e-16	Nonalcoholic fatty liver disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07274506	chr1:6614341	TAS1R1;NOL9	-0.52	-6.15	-0.32	2.19e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg05855489	chr10:104503620	C10orf26	-0.59	-8.13	-0.41	8.58e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg24011408	chr12:48396354	COL2A1	-0.54	-8.92	-0.44	3.13e-17	Plateletcrit;
LUSC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.38	-5.83	-0.3	1.32e-8	IgG glycosylation;
LUSC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.92	12.05	0.55	5.3e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs8114671	0.967	rs2093058	chr20:33791281	C/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.18	-0.32	1.84e-9	Height;
LUSC	trans	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg17712092	chr4:129076599	LARP1B	-0.69	-9.7	-0.47	8.89e-20	Breast cancer;
LUSC	trans	rs7939886	0.920	rs17150102	chr11:55904382	A/C	cg15704280	chr7:45808275	SEPT13	0.83	6.64	0.34	1.27e-10	Myopia (pathological);
LUSC	trans	rs2018683	0.624	rs6462119	chr7:29003725	G/C	cg19402173	chr7:128379420	CALU	-0.48	-7.29	-0.37	2.21e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg14458575	chr2:238380390	NA	0.69	8.22	0.41	4.71e-15	Prostate cancer;
LUSC	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	6.75	0.35	6.54e-11	Cognitive test performance;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13938963	chr4:68411314	CENPC1	0.4	6.03	0.31	4.35e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg18402987	chr7:1209562	NA	0.73	7.92	0.4	3.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs62408225	1.000	rs62408236	chr6:90980148	C/T	cg06866423	chr6:90926672	BACH2	0.41	5.92	0.31	7.99e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10121816	chr1:161123804	UFC1	-0.42	-6.16	-0.32	2.13e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg22676075	chr6:135203613	NA	0.47	7.64	0.39	2.28e-13	Red blood cell count;
LUSC	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg07150166	chr2:30669952	LCLAT1	0.56	6.55	0.34	2.23e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23452443	chr1:65210737	RAVER2	-0.5	-6.2	-0.32	1.65e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.59	-8.57	-0.42	3.79e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg07936489	chr17:37558343	FBXL20	-0.63	-7.52	-0.38	5.16e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs2230307	0.536	rs684519	chr1:100604715	T/G	cg24955406	chr1:100503596	HIAT1	-0.64	-6.87	-0.35	3.07e-11	Carotid intima media thickness;
LUSC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs73206853	0.841	rs73191819	chr12:110920182	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg14820908	chr5:178986412	RUFY1	-0.63	-11.08	-0.52	1.7e-24	Lung cancer;
LUSC	trans	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg21775007	chr8:11205619	TDH	-0.41	-6.15	-0.32	2.16e-9	Mood instability;
LUSC	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg13813247	chr22:41461852	NA	-0.37	-6.75	-0.35	6.38e-11	Neuroticism;
LUSC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg26373071	chr5:1325741	CLPTM1L	0.44	8.18	0.41	5.88e-15	Lung cancer;
LUSC	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg26162295	chr17:38119207	GSDMA	-0.26	-6.07	-0.32	3.55e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.3	0.41	2.67e-15	Prudent dietary pattern;
LUSC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg11663144	chr21:46675770	NA	-0.42	-7.34	-0.37	1.66e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg15043801	chr19:10305911	DNMT1	0.4	6.09	0.32	3.11e-9	Triglycerides;
LUSC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18005807	chr22:18506799	MICAL3	0.45	6.53	0.34	2.5e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg02176678	chr2:219576539	TTLL4	0.6	10.75	0.51	2.5e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	14.48	0.62	3.25e-37	Platelet count;
LUSC	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg20307385	chr11:47447363	PSMC3	0.45	6.5	0.34	2.87e-10	Subjective well-being;
LUSC	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg17420585	chr12:42539391	GXYLT1	-0.4	-8.07	-0.4	1.33e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg03146154	chr1:46216737	IPP	0.5	7.41	0.38	1.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg09365446	chr1:150670422	GOLPH3L	0.54	8.33	0.41	2.13e-15	Tonsillectomy;
LUSC	trans	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	8.49	0.42	7.01e-16	Type 2 diabetes;
LUSC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg03676636	chr4:99064102	C4orf37	0.33	6.97	0.36	1.68e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg00684032	chr4:1343700	KIAA1530	0.34	5.95	0.31	6.62e-9	Obesity-related traits;
LUSC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg24399712	chr22:39784796	NA	-0.62	-11.14	-0.52	1e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg14582100	chr15:45693742	SPATA5L1	0.6	10.95	0.51	4.7e-24	Homoarginine levels;
LUSC	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg20587970	chr11:113659929	NA	-1.16	-15.57	-0.65	1.7e-41	Hip circumference adjusted for BMI;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg17468553	chr17:18086889	ALKBH5	0.76	6.15	0.32	2.25e-9	Cognitive performance;
LUSC	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg05347473	chr6:146136440	FBXO30	0.5	8.29	0.41	2.83e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.43	-0.42	1.01e-15	Total cholesterol levels;
LUSC	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg16342193	chr10:102329863	NA	-0.32	-5.71	-0.3	2.49e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1957429	0.614	rs117316280	chr14:65388641	T/C	cg23373153	chr14:65346875	NA	-0.98	-7.73	-0.39	1.3e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00149659	chr3:10157352	C3orf10	0.89	12.11	0.55	3.04e-28	Alzheimer's disease;
LUSC	cis	rs2324229	0.828	rs1180239	chr6:83942604	G/A	cg08257003	chr6:84140564	ME1	0.28	6.38	0.33	5.81e-10	Platelet-derived growth factor BB levels;
LUSC	cis	rs6977660	0.660	rs28663574	chr7:19816905	G/A	cg07541023	chr7:19748670	TWISTNB	0.63	6.84	0.35	3.87e-11	Thyroid stimulating hormone;
LUSC	cis	rs1395	0.778	rs1439768	chr2:27389660	C/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.49	7.2	0.37	4.12e-12	Blood metabolite levels;
LUSC	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg14664628	chr15:75095509	CSK	0.52	6.82	0.35	4.35e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg10621924	chr7:39171070	POU6F2	0.43	6.41	0.33	5.06e-10	IgG glycosylation;
LUSC	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg24642439	chr20:33292090	TP53INP2	0.47	7.2	0.37	3.89e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg20701182	chr2:24300061	SF3B14	0.9	11.62	0.54	1.84e-26	Lymphocyte counts;
LUSC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.24	0.41	3.84e-15	Hemoglobin concentration;
LUSC	cis	rs7428496	0.528	rs11708470	chr3:142240824	A/G	cg16271453	chr3:142027066	XRN1	-0.51	-8.91	-0.44	3.32e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs10743315	0.557	rs74669613	chr12:19313696	T/C	cg02471346	chr12:19282374	PLEKHA5	0.75	6.24	0.32	1.35e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs6066835	0.718	rs60028924	chr20:47359415	A/G	cg18078177	chr20:47281410	PREX1	0.65	5.78	0.3	1.71e-8	Multiple myeloma;
LUSC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.34	6.13	0.32	2.5e-9	Obesity-related traits;
LUSC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg06742321	chr12:123595122	PITPNM2	0.38	5.65	0.3	3.43e-8	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg26618903	chr10:100175079	PYROXD2	0.44	8.34	0.41	2.03e-15	Metabolite levels;
LUSC	cis	rs7106204	0.534	rs78539127	chr11:24256698	T/A	ch.11.24196551F	chr11:24239977	NA	0.75	6.39	0.33	5.58e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.81	-13.47	-0.59	2.57e-33	Morning vs. evening chronotype;
LUSC	trans	rs724744	0.772	rs1772075	chr6:22351325	G/T	cg13807341	chr11:118445984	ARCN1	0.36	6.2	0.32	1.64e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg26816564	chr1:7831052	VAMP3	0.5	5.97	0.31	6.12e-9	Inflammatory bowel disease;
LUSC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2281558	0.876	rs2281562	chr20:25273362	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.63	9.57	0.46	2.5e-19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	trans	rs1864729	1.000	rs2635161	chr8:98282907	A/C	cg08679828	chr8:102218111	ZNF706	0.84	7.78	0.39	9.33e-14	Estradiol plasma levels (breast cancer);
LUSC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.22	-0.32	1.49e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg00383909	chr3:49044727	WDR6	1.14	10.59	0.5	8.4e-23	Cognitive function;
LUSC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg09021430	chr5:549028	NA	0.54	7.49	0.38	6.4e-13	Obesity-related traits;
LUSC	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg22681709	chr2:178499509	PDE11A	-0.45	-6.57	-0.34	1.91e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg13010199	chr12:38710504	ALG10B	0.66	10.21	0.49	1.83e-21	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.7	-12.7	-0.57	2.01e-30	Superior crus of antihelix expression;
LUSC	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg18825076	chr15:78729989	IREB2	-0.5	-7.66	-0.39	2.01e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg26258631	chr2:190648605	PMS1;ORMDL1	0.44	6.17	0.32	1.97e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg05872129	chr22:39784769	NA	-0.59	-10.78	-0.51	1.82e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg18681998	chr4:17616180	MED28	0.86	15.92	0.66	7.62e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg20637307	chr2:213403960	ERBB4	0.44	7.51	0.38	5.38e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg22681709	chr2:178499509	PDE11A	-0.5	-9.31	-0.45	1.72e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.12	-0.32	2.63e-9	Neutrophil percentage of white cells;
LUSC	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg08000102	chr2:233561755	GIGYF2	0.72	9.49	0.46	4.62e-19	Schizophrenia;
LUSC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg02772935	chr3:125709198	NA	-0.48	-6.15	-0.32	2.17e-9	Blood pressure (smoking interaction);
LUSC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg06636001	chr8:8085503	FLJ10661	0.65	10.75	0.51	2.35e-23	Mood instability;
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg11965913	chr1:205819406	PM20D1	0.89	18.27	0.71	3.38e-52	Menarche (age at onset);
LUSC	cis	rs4499344	0.524	rs259242	chr19:33144248	A/C	cg22980127	chr19:33182716	NUDT19	-0.42	-5.69	-0.3	2.77e-8	Mean platelet volume;
LUSC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs9399401	0.710	rs10484733	chr6:142710988	C/G	cg03128060	chr6:142623767	GPR126	0.61	9.98	0.48	1.1e-20	Chronic obstructive pulmonary disease;
LUSC	cis	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg02972257	chr16:68554789	NA	0.44	5.76	0.3	1.93e-8	Colorectal cancer;
LUSC	cis	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg06521331	chr12:34319734	NA	-0.46	-7.55	-0.38	4.16e-13	Morning vs. evening chronotype;
LUSC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.29	-0.37	2.21e-12	Blood metabolite levels;
LUSC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg25174290	chr11:3078921	CARS	0.62	9.88	0.48	2.32e-20	Longevity;
LUSC	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.32	-6.34	-0.33	7.67e-10	Total body bone mineral density;
LUSC	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg16070123	chr10:51489643	NA	0.55	9.19	0.45	4.36e-18	Prostate-specific antigen levels;
LUSC	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg23649088	chr2:200775458	C2orf69	-0.47	-6.31	-0.33	8.98e-10	Schizophrenia;
LUSC	cis	rs9653442	0.564	rs56054309	chr2:100794940	T/C	cg22139774	chr2:100720529	AFF3	-0.4	-6.95	-0.36	1.96e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	trans	rs1493916	0.837	rs1027332	chr18:31410097	A/C	cg27147174	chr7:100797783	AP1S1	-0.55	-8.73	-0.43	1.21e-16	Life satisfaction;
LUSC	cis	rs6693567	0.545	rs6664703	chr1:150459087	G/C	cg15654264	chr1:150340011	RPRD2	0.45	7.24	0.37	3.13e-12	Migraine;
LUSC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06634786	chr22:41940651	POLR3H	-0.55	-6.39	-0.33	5.48e-10	Vitiligo;
LUSC	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg12639453	chr1:2035780	PRKCZ	0.3	6.31	0.33	9.02e-10	Height;
LUSC	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg26898376	chr11:64110657	CCDC88B	0.32	5.93	0.31	7.66e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg13072238	chr3:49761600	GMPPB	-0.67	-8.1	-0.41	1.01e-14	Menarche (age at onset);
LUSC	cis	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.5	-0.34	2.96e-10	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	0.9	12.43	0.56	2.06e-29	Vitiligo;
LUSC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg24829409	chr8:58192753	C8orf71	-0.57	-6.04	-0.31	4.17e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1595825	0.891	rs16826895	chr2:198901642	A/G	cg00982548	chr2:198649783	BOLL	-0.57	-7.09	-0.36	8.04e-12	Ulcerative colitis;
LUSC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08859206	chr1:53392774	SCP2	0.5	8.51	0.42	6.03e-16	Monocyte count;
LUSC	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.47	8.3	0.41	2.68e-15	HDL cholesterol;
LUSC	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg24531977	chr5:56204891	C5orf35	0.45	6.7	0.34	9.09e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg05340658	chr4:99064831	C4orf37	-0.44	-6.94	-0.36	2.02e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4363385	0.647	rs1995308	chr1:153014082	A/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-6.75	-0.35	6.37e-11	Inflammatory skin disease;
LUSC	cis	rs1950626	0.751	rs12883799	chr14:101396850	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.32	0.37	1.82e-12	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	13.38	0.59	5.28e-33	Blood protein levels;
LUSC	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	6.79	0.35	5.13e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.66	-0.65	7.53e-42	Height;
LUSC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg08200582	chr11:442649	ANO9	-0.55	-5.86	-0.31	1.13e-8	Body mass index;
LUSC	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg08000102	chr2:233561755	GIGYF2	0.7	11.54	0.53	3.86e-26	Coronary artery disease;
LUSC	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.78	0.51	1.95e-23	Hypertriglyceridemia;
LUSC	cis	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg24375607	chr4:120327624	NA	0.47	7.27	0.37	2.5e-12	Diastolic blood pressure;
LUSC	cis	rs2463822	0.592	rs72919486	chr11:62043501	G/C	cg06239285	chr11:62104954	ASRGL1	-0.75	-7.26	-0.37	2.74e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.84	-15.09	-0.64	1.33e-39	Age at first birth;
LUSC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg24399712	chr22:39784796	NA	-0.65	-11.99	-0.55	8.41e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg08601574	chr20:25228251	PYGB	0.43	6.5	0.33	2.96e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg18681998	chr4:17616180	MED28	0.91	17.61	0.69	1.5e-49	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.09	-0.32	3.1e-9	Resting heart rate;
LUSC	trans	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.53	-7.76	-0.39	1.05e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.61	7.9	0.4	4.15e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs17253792	0.642	rs10483648	chr14:56104278	T/C	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.28e-10	Putamen volume;
LUSC	cis	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.37	-0.37	1.39e-12	Cervical cancer;
LUSC	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-6.89	-0.35	2.85e-11	Blood metabolite levels;
LUSC	cis	rs4388249	0.687	rs2301002	chr5:109101831	C/T	cg17395555	chr5:108820864	NA	0.35	5.8	0.3	1.55e-8	Schizophrenia;
LUSC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg24324837	chr19:49891574	CCDC155	0.5	6.28	0.33	1.04e-9	Multiple sclerosis;
LUSC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg03351412	chr1:154909251	PMVK	-0.49	-7.48	-0.38	6.62e-13	Prostate cancer;
LUSC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg16414030	chr3:133502952	NA	-0.42	-6.52	-0.34	2.66e-10	Iron status biomarkers;
LUSC	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg05110241	chr16:68378359	PRMT7	-0.72	-8.1	-0.41	1.06e-14	Magnesium levels;
LUSC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg24375607	chr4:120327624	NA	0.79	11.79	0.54	4.81e-27	Corneal astigmatism;
LUSC	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg22437258	chr11:111473054	SIK2	0.51	6.91	0.35	2.42e-11	Primary sclerosing cholangitis;
LUSC	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg01652190	chr22:50026171	C22orf34	-0.29	-5.96	-0.31	6.24e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg15704280	chr7:45808275	SEPT13	-1.09	-22.35	-0.77	2.54e-68	Height;
LUSC	cis	rs4285028	0.747	rs77570895	chr3:121384565	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.89	-11.96	-0.55	1.1e-27	Multiple sclerosis;
LUSC	trans	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	6.33	0.33	7.77e-10	Monocyte count;
LUSC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.96	-0.44	2.32e-17	Gut microbiome composition (summer);
LUSC	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg06207120	chr15:45996521	NA	0.39	6.05	0.31	3.79e-9	Waist circumference;Weight;
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg09509183	chr1:209979624	IRF6	0.63	11.03	0.52	2.51e-24	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg24060327	chr5:131705240	SLC22A5	0.66	10.19	0.49	2.09e-21	Breast cancer;
LUSC	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.23e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg06671706	chr8:8559999	CLDN23	0.48	6.41	0.33	5.01e-10	Obesity-related traits;
LUSC	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg26893861	chr17:41843967	DUSP3	0.96	14.8	0.63	1.86e-38	Triglycerides;
LUSC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.88	-0.51	8.12e-24	Schizophrenia;
LUSC	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.0	-0.44	1.71e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg11843238	chr5:131593191	PDLIM4	0.48	8.48	0.42	7.28e-16	Acylcarnitine levels;
LUSC	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg09904177	chr6:26538194	HMGN4	0.75	14.27	0.62	2.07e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg12463550	chr7:65579703	CRCP	0.55	8.2	0.41	5.07e-15	Aortic root size;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02099313	chr1:231114956	TTC13;ARV1	0.41	6.07	0.32	3.51e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06481639	chr22:41940642	POLR3H	-0.5	-6.09	-0.32	3.05e-9	Vitiligo;
LUSC	cis	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.53	-8.08	-0.4	1.21e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg18232548	chr7:50535776	DDC	0.54	7.58	0.38	3.41e-13	Malaria;
LUSC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg09365446	chr1:150670422	GOLPH3L	0.5	7.27	0.37	2.54e-12	Melanoma;
LUSC	cis	rs1045714	0.895	rs1107690	chr7:2640595	G/T	cg24848437	chr7:2645542	IQCE	0.63	6.91	0.35	2.49e-11	Urate levels in lean individuals;
LUSC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg12615879	chr12:58013172	SLC26A10	0.26	5.65	0.3	3.37e-8	Multiple sclerosis;
LUSC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg22166914	chr1:53195759	ZYG11B	0.64	11.08	0.52	1.66e-24	Monocyte count;
LUSC	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg13010199	chr12:38710504	ALG10B	0.52	7.67	0.39	1.96e-13	Morning vs. evening chronotype;
LUSC	cis	rs4631830	0.812	rs11593361	chr10:51539156	A/G	cg20129853	chr10:51489980	NA	-0.33	-6.72	-0.35	7.85e-11	Prostate-specific antigen levels;
LUSC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg03929089	chr4:120376271	NA	0.68	7.63	0.39	2.56e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12016809	chr21:47604291	C21orf56	0.46	7.0	0.36	1.38e-11	Testicular germ cell tumor;
LUSC	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg19997662	chr15:101784653	CHSY1	-0.37	-5.73	-0.3	2.2e-8	Corneal structure;
LUSC	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg02018176	chr4:1364513	KIAA1530	0.48	6.15	0.32	2.16e-9	Recombination rate (females);
LUSC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.26	0.59	1.63e-32	Cognitive test performance;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg26774385	chr6:35354049	PPARD	-0.34	-5.99	-0.31	5.3300000000000004e-09	Mosquito bite size;
LUSC	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.27	0.52	3.4e-25	Lung cancer in ever smokers;
LUSC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg04414720	chr1:150670196	GOLPH3L	0.51	8.09	0.4	1.11e-14	Melanoma;
LUSC	cis	rs16854884	0.837	rs4380409	chr3:143800896	A/G	cg06585982	chr3:143692056	C3orf58	0.44	6.51	0.34	2.69e-10	Economic and political preferences (feminism/equality);
LUSC	trans	rs2736340	0.539	rs11250138	chr8:11323312	C/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.71	-0.34	8.4e-11	Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;Systemic lupus erythematosus;Kawasaki disease;Systemic lupus erythematosus or rheumatoid arthritis;
LUSC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg16262614	chr3:133464971	TF	0.43	7.48	0.38	6.56e-13	Iron status biomarkers (transferrin levels);
LUSC	trans	rs9860340	0.730	rs57541218	chr3:87643230	T/G	cg03644585	chr7:884825	UNC84A	0.42	6.05	0.31	3.9e-9	Electroencephalographic traits in alcoholism;
LUSC	trans	rs236907	0.859	rs56377810	chr1:171757657	A/C	cg13482142	chr2:234261155	NA	0.5	6.03	0.31	4.37e-9	Mean platelet volume;
LUSC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg05738196	chr6:26577821	NA	0.53	8.33	0.41	2.14e-15	Schizophrenia;
LUSC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg22963979	chr7:1858916	MAD1L1	-0.63	-10.07	-0.48	5.35e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs59918340	0.936	rs6982449	chr8:142234642	T/C	cg23750338	chr8:142222470	SLC45A4	-0.44	-8.01	-0.4	1.97e-14	Immature fraction of reticulocytes;
LUSC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10802521	chr3:52805072	NEK4	0.47	7.77	0.39	9.61e-14	Electroencephalogram traits;
LUSC	cis	rs16854884	0.558	rs6768153	chr3:143667429	C/A	cg06585982	chr3:143692056	C3orf58	0.51	7.97	0.4	2.56e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs4363385	0.818	rs946096	chr1:153006529	T/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.45e-8	Inflammatory skin disease;
LUSC	cis	rs17824933	1.000	rs12791045	chr11:60767964	C/T	cg16817237	chr11:60793675	NA	0.41	6.58	0.34	1.79e-10	Multiple sclerosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08151832	chr16:66835414	CCDC79	0.48	6.06	0.31	3.62e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg25036284	chr2:26402008	FAM59B	-0.73	-10.67	-0.5	4.57e-23	Gut microbiome composition (summer);
LUSC	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg19717773	chr7:2847554	GNA12	0.32	5.91	0.31	8.54e-9	Plateletcrit;
LUSC	cis	rs6681460	0.966	rs4655650	chr1:67142286	A/G	cg02459107	chr1:67143332	SGIP1	0.48	9.19	0.45	4.14e-18	Presence of antiphospholipid antibodies;
LUSC	cis	rs6063312	0.935	rs6095256	chr20:47340806	C/T	cg18078177	chr20:47281410	PREX1	0.62	7.3	0.37	2.09e-12	Tonometry;
LUSC	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg12379764	chr21:47803548	PCNT	-0.73	-9.64	-0.47	1.43e-19	Lymphocyte counts;
LUSC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	0.89	12.29	0.56	6.63e-29	Vitiligo;
LUSC	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.46	-5.69	-0.3	2.75e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.32	0.49	7.54e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.49	-7.02	-0.36	1.26e-11	Mean platelet volume;
LUSC	cis	rs2230307	0.656	rs644835	chr1:100543962	A/G	cg24955406	chr1:100503596	HIAT1	0.66	6.33	0.33	8.05e-10	Carotid intima media thickness;
LUSC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	1.04	18.13	0.7	1.3e-51	Testicular germ cell tumor;
LUSC	cis	rs9322817	0.691	rs6929352	chr6:105204621	T/C	cg02098413	chr6:105308735	HACE1	-0.28	-5.81	-0.3	1.48e-8	Thyroid stimulating hormone;
LUSC	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.31e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs55665837	1.000	rs10832257	chr11:14443316	A/G	cg19336497	chr11:14380999	RRAS2	-0.37	-7.53	-0.38	4.9e-13	Vitamin D levels;
LUSC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg10207240	chr12:122356781	WDR66	0.46	6.41	0.33	4.92e-10	Mean corpuscular volume;
LUSC	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.14	-0.41	7.96e-15	Triglycerides;
LUSC	cis	rs9905704	0.645	rs831952	chr17:56669583	T/C	cg12560992	chr17:57184187	TRIM37	0.51	5.96	0.31	6.45e-9	Testicular germ cell tumor;
LUSC	cis	rs11168618	0.810	rs11168595	chr12:48868211	C/T	cg24011408	chr12:48396354	COL2A1	0.38	6.06	0.31	3.62e-9	Adiponectin levels;
LUSC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.92e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7605827	0.930	rs2277915	chr2:15493881	A/G	cg19274914	chr2:15703543	NA	0.44	8.18	0.41	5.97e-15	Educational attainment (years of education);
LUSC	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.57	10.11	0.48	3.77e-21	Birth weight;
LUSC	cis	rs7605827	0.897	rs12692274	chr2:15707711	A/G	cg19274914	chr2:15703543	NA	0.46	8.84	0.44	5.64e-17	Educational attainment (years of education);
LUSC	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg22244940	chr12:132335942	MMP17	0.54	8.11	0.41	1e-14	Migraine;
LUSC	cis	rs11229555	0.645	rs72917641	chr11:58227320	A/C	cg15696309	chr11:58395628	NA	-0.68	-8.26	-0.41	3.34e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.71	9.96	0.48	1.21e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-10.13	-0.48	3.29e-21	Schizophrenia;
LUSC	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.61	10.7	0.51	3.55e-23	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg11366901	chr6:160182831	ACAT2	0.81	11.23	0.52	4.73e-25	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24549020	chr5:56110836	MAP3K1	-0.44	-5.8	-0.3	1.57e-8	Initial pursuit acceleration;
LUSC	cis	rs7923609	0.902	rs10822182	chr10:65325478	G/A	cg01631684	chr10:65280961	REEP3	-0.42	-6.59	-0.34	1.76e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg04058563	chr4:185651563	MLF1IP	0.46	7.51	0.38	5.55e-13	Kawasaki disease;
LUSC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg16606324	chr3:10149918	C3orf24	0.63	8.77	0.43	8.98e-17	Alzheimer's disease;
LUSC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg15921436	chr17:44337874	NA	0.72	10.94	0.51	5.21e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg18196295	chr10:418757	DIP2C	-0.51	-8.28	-0.41	3.05e-15	Psychosis in Alzheimer's disease;
LUSC	cis	rs9815354	0.680	rs73073250	chr3:42016559	G/T	cg03022575	chr3:42003672	ULK4	0.76	7.6	0.38	3e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25072359	chr17:41440525	NA	-0.58	-8.34	-0.41	2.03e-15	Menopause (age at onset);
LUSC	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg06636001	chr8:8085503	FLJ10661	0.53	8.58	0.42	3.64e-16	Mood instability;
LUSC	trans	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04565464	chr8:145669602	NFKBIL2	0.37	5.98	0.31	5.67e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06866400	chr6:143771904	ADAT2;PEX3	-0.5	-6.62	-0.34	1.4e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg11266682	chr4:10021025	SLC2A9	0.49	9.11	0.45	8.01e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg01097406	chr16:89675127	NA	-0.39	-7.85	-0.39	5.86e-14	Vitiligo;
LUSC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15320075	chr8:145703422	NA	-0.51	-8.55	-0.42	4.64e-16	Age at first birth;
LUSC	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg08000102	chr2:233561755	GIGYF2	0.82	14.01	0.61	2.03e-35	Schizophrenia;
LUSC	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.92	0.35	2.34e-11	IgG glycosylation;
LUSC	cis	rs11166629	1.000	rs1545240	chr8:135642632	A/C	cg27224718	chr8:135614730	ZFAT	0.65	10.82	0.51	1.35e-23	Smoking quantity;
LUSC	cis	rs113835537	0.935	rs117131621	chr11:66422334	C/T	cg24851651	chr11:66362959	CCS	0.53	6.54	0.34	2.38e-10	Airway imaging phenotypes;
LUSC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	0.93	12.87	0.58	4.58e-31	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-0.89	-13.02	-0.58	1.3e-31	Triglycerides;
LUSC	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg13319975	chr6:146136371	FBXO30	0.49	7.4	0.38	1.08e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.56	0.42	4.17e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg16325326	chr1:53192061	ZYG11B	0.97	18.7	0.72	6.96e-54	Monocyte count;
LUSC	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-0.53	-8.1	-0.41	1.01e-14	Breast cancer;
LUSC	trans	rs7939886	0.841	rs79254833	chr11:55986896	T/C	cg15704280	chr7:45808275	SEPT13	0.9	6.77	0.35	5.92e-11	Myopia (pathological);
LUSC	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg05925327	chr15:68127851	NA	-0.39	-6.1	-0.32	2.89e-9	Obesity;
LUSC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg26695010	chr11:65641043	EFEMP2	-0.46	-7.05	-0.36	1.01e-11	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg03233332	chr7:66118400	NA	-0.4	-5.94	-0.31	7.06e-9	Aortic root size;
LUSC	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg13073564	chr4:8508604	NA	0.37	6.89	0.35	2.77e-11	Response to antineoplastic agents;
LUSC	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.81	-13.37	-0.59	6.09e-33	Bladder cancer;
LUSC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg06060754	chr5:176797920	RGS14	0.57	8.97	0.44	2.24e-17	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg16479474	chr6:28041457	NA	0.32	5.72	0.3	2.31e-8	Parkinson's disease;
LUSC	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.69	-13.09	-0.58	6.88e-32	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1973993	0.967	rs10875017	chr1:96949526	C/T	cg10631902	chr5:14652156	NA	0.53	8.97	0.44	2.13e-17	Weight;
LUSC	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg18230493	chr5:56204884	C5orf35	-0.57	-9.01	-0.44	1.62e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg13560548	chr3:10150139	C3orf24	0.49	6.59	0.34	1.76e-10	Alzheimer's disease;
LUSC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.78	-0.3	1.68e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.13	-0.32	2.43e-9	IgG glycosylation;
LUSC	cis	rs34638657	0.702	rs12599988	chr16:82200063	T/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.47	-0.33	3.55e-10	Lung adenocarcinoma;
LUSC	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-10.95	-0.51	4.72e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7560272	0.695	rs13022149	chr2:73641515	T/A	cg20560298	chr2:73613845	ALMS1	0.48	7.48	0.38	6.66e-13	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg11062466	chr8:58055876	NA	0.5	6.32	0.33	8.39e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6500395	0.926	rs2883643	chr16:48693018	C/G	cg04672837	chr16:48644449	N4BP1	0.44	6.43	0.33	4.38e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg27471124	chr11:109292789	C11orf87	0.4	7.01	0.36	1.36e-11	Schizophrenia;
LUSC	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.93	0.35	2.2e-11	Height;
LUSC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.13	15.2	0.64	5.07e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2414856	0.510	rs72758911	chr15:64641404	A/C	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	11.73	0.54	7.46e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1891275	0.515	rs1986941	chr10:93444343	C/T	cg07889827	chr10:93443413	NA	-0.38	-8.55	-0.42	4.34e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs78366141	0.536	rs76432068	chr4:89624219	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.97	7.26	0.37	2.73e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg24397884	chr7:158709396	WDR60	0.6	9.23	0.45	3.26e-18	Height;
LUSC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg00933542	chr6:150070202	PCMT1	-0.31	-6.3	-0.33	9.53e-10	Lung cancer;
LUSC	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg18681998	chr4:17616180	MED28	0.89	15.6	0.65	1.34e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg01879757	chr17:41196368	BRCA1	0.48	7.84	0.39	6.27e-14	Menopause (age at onset);
LUSC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.18	0.45	4.56e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.92	-18.15	-0.7	1.08e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	0.65	13.87	0.6	7.1e-35	Prudent dietary pattern;
LUSC	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg20307385	chr11:47447363	PSMC3	0.45	6.51	0.34	2.74e-10	Subjective well-being;
LUSC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg20302533	chr7:39170763	POU6F2	0.55	9.09	0.45	8.94e-18	IgG glycosylation;
LUSC	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg12615879	chr12:58013172	SLC26A10	-0.27	-5.71	-0.3	2.48e-8	Multiple sclerosis;
LUSC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.65	9.87	0.48	2.53e-20	Height;
LUSC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	13.18	0.58	3.09e-32	Monocyte percentage of white cells;
LUSC	cis	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg24375607	chr4:120327624	NA	0.51	7.93	0.4	3.28e-14	Diastolic blood pressure;
LUSC	cis	rs12928939	0.815	rs12446005	chr16:71655035	G/A	cg03805757	chr16:71968109	PKD1L3	-0.42	-6.0	-0.31	5.05e-9	Post bronchodilator FEV1;
LUSC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg12564285	chr5:131593104	PDLIM4	0.44	7.82	0.39	7.21e-14	Breast cancer;
LUSC	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg05340658	chr4:99064831	C4orf37	0.63	9.93	0.48	1.53e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.71	-11.03	-0.52	2.54e-24	Aortic root size;
LUSC	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg21770322	chr7:97807741	LMTK2	0.5	8.59	0.43	3.5e-16	Breast cancer;
LUSC	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	6.0	0.31	5.19e-9	IgG glycosylation;
LUSC	cis	rs12210905	0.925	rs72838258	chr6:27007681	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-5.68	-0.3	2.93e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs6500395	1.000	rs4785536	chr16:48712980	C/T	cg04672837	chr16:48644449	N4BP1	-0.47	-7.06	-0.36	9.68e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9888739	1.000	rs73534420	chr16:31311374	G/T	cg15817542	chr16:31343056	ITGAM	-0.5	-6.1	-0.32	2.98e-9	Systemic lupus erythematosus;
LUSC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	0.98	14.31	0.62	1.46e-36	Vitiligo;
LUSC	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg02196730	chr15:80188777	MTHFS	0.39	5.82	0.3	1.38e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9653442	0.564	rs2309756	chr2:100780269	G/C	cg07810366	chr2:100720526	AFF3	-0.44	-7.49	-0.38	6.12e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	1.1	25.3	0.81	1.31e-79	Schizophrenia;
LUSC	cis	rs77633900	0.614	rs280005	chr15:77009185	G/C	cg21673338	chr15:77095150	SCAPER	-0.81	-8.34	-0.42	2e-15	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.75	-0.39	1.11e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12190007	0.547	rs3006217	chr6:169862878	A/G	cg15038512	chr6:170123185	PHF10	-0.4	-6.55	-0.34	2.15e-10	Obesity-related traits;
LUSC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.61	8.09	0.4	1.1e-14	High light scatter reticulocyte count;
LUSC	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.96	-0.48	1.26e-20	Mood instability;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19451435	chr6:158402916	SYNJ2	-0.48	-5.96	-0.31	6.25e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg11584989	chr19:19387371	SF4	0.61	7.27	0.37	2.54e-12	Bipolar disorder;
LUSC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg05347473	chr6:146136440	FBXO30	0.53	9.11	0.45	7.97e-18	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg25482853	chr8:67687455	SGK3	1.09	15.45	0.65	5.28e-41	Obesity-related traits;
LUSC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.52	-6.95	-0.36	1.89e-11	Eosinophil percentage of white cells;
LUSC	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.74	14.55	0.62	1.7e-37	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg25173405	chr17:45401733	C17orf57	-0.37	-5.97	-0.31	6.19e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2607426	1.000	rs2607425	chr19:41274885	C/G	cg05508168	chr19:41255947	C19orf54;SNRPA	-0.65	-6.14	-0.32	2.34e-9	Blood protein levels;
LUSC	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg02023728	chr11:77925099	USP35	0.45	6.83	0.35	3.93e-11	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	1.9e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg06565620	chr18:47792949	CCDC11	0.53	5.97	0.31	6.1e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.41	-0.33	4.94e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.53	-0.69	3.06e-49	Exhaled nitric oxide output;
LUSC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.52	7.28	0.37	2.4e-12	Cognitive ability;
LUSC	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg07148914	chr20:33460835	GGT7	-0.47	-6.95	-0.36	1.94e-11	Height;
LUSC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.78	-0.47	4.83e-20	Hemoglobin concentration;
LUSC	trans	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg25214090	chr10:38739885	LOC399744	0.47	7.55	0.38	4.07e-13	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg13010199	chr12:38710504	ALG10B	0.65	9.81	0.47	3.95e-20	Bladder cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12465643	chr17:71640353	SDK2	0.44	6.23	0.32	1.42e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6960043	0.905	rs10264723	chr7:15054370	T/C	cg19272540	chr7:15055459	NA	0.35	8.9	0.44	3.51e-17	Type 2 diabetes;
LUSC	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	0.5	5.74	0.3	2.15e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.75	-0.73	4.73e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2522056	0.932	rs2522064	chr5:131806488	G/A	cg24060327	chr5:131705240	SLC22A5	0.42	5.85	0.3	1.2e-8	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg01849466	chr14:104193079	ZFYVE21	0.58	9.04	0.44	1.29e-17	Schizophrenia;
LUSC	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	11.29	0.53	2.97e-25	Coronary artery disease;
LUSC	cis	rs10740039	0.516	rs1009410	chr10:62354797	T/G	cg18175470	chr10:62150864	ANK3	-0.47	-7.01	-0.36	1.33e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg13263323	chr15:86062960	AKAP13	-0.36	-5.88	-0.31	9.92e-9	Coronary artery disease;
LUSC	cis	rs925255	0.810	rs7574996	chr2:28643523	G/C	cg01273330	chr2:28605224	NA	-0.41	-6.64	-0.34	1.29e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg00049323	chr5:472564	LOC25845	-0.4	-5.98	-0.31	5.77e-9	Cystic fibrosis severity;
LUSC	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg10840412	chr1:235813424	GNG4	-0.69	-9.3	-0.45	1.86e-18	Bipolar disorder;
LUSC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21963583	chr11:68658836	MRPL21	0.55	8.28	0.41	3.08e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg18806716	chr10:30721971	MAP3K8	-0.45	-7.49	-0.38	6.05e-13	Inflammatory bowel disease;
LUSC	cis	rs4692589	0.606	rs34752946	chr4:170951738	G/T	cg19918862	chr4:170955249	NA	0.36	6.07	0.32	3.52e-9	Anxiety disorder;
LUSC	cis	rs9399401	0.961	rs1342060	chr6:142663177	T/C	cg03128060	chr6:142623767	GPR126	0.31	5.65	0.3	3.37e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg19230755	chr7:65878503	NA	0.41	5.75	0.3	2.01e-8	Aortic root size;
LUSC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17739794	0.517	rs35856917	chr8:774395	C/G	cg01971667	chr8:817044	NA	-0.4	-6.31	-0.33	8.78e-10	Clozapine-induced cytotoxicity;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg18147569	chr3:113871615	DRD3	0.4	6.09	0.32	3.06e-9	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01745629	chr6:83775548	UBE2CBP	0.76	6.04	0.31	4.17e-9	Cognitive performance;
LUSC	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg00898013	chr13:113819073	PROZ	-0.63	-8.86	-0.44	4.89e-17	Platelet distribution width;
LUSC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg15534755	chr11:117069859	TAGLN	-0.36	-6.16	-0.32	2.04e-9	Blood protein levels;
LUSC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg06494592	chr3:125709126	NA	-0.5	-5.7	-0.3	2.59e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7607369	0.536	rs12694443	chr2:219664977	G/T	cg02176678	chr2:219576539	TTLL4	-0.51	-8.94	-0.44	2.63e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs7903847	0.642	rs7084654	chr10:99135262	G/A	cg06359132	chr10:99160096	RRP12	-0.24	-5.65	-0.3	3.39e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg18681998	chr4:17616180	MED28	0.84	15.29	0.64	2.27e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg10326726	chr10:51549505	MSMB	-0.36	-6.16	-0.32	2.08e-9	Prostate-specific antigen levels;
LUSC	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg00599273	chr12:58146742	CDK4	0.31	5.81	0.3	1.48e-8	Multiple sclerosis;
LUSC	cis	rs587080	0.559	rs12364730	chr11:65228278	C/T	cg17120908	chr11:65337727	SSSCA1	-0.65	-9.5	-0.46	4.3e-19	Plateletcrit;
LUSC	cis	rs1018836	0.599	rs9643295	chr8:91492283	T/G	cg16814680	chr8:91681699	NA	-0.62	-9.2	-0.45	4.07e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4792901	0.802	rs9908559	chr17:41603161	T/C	cg22562494	chr17:41607896	ETV4	-0.33	-6.07	-0.32	3.49e-9	Dupuytren's disease;
LUSC	cis	rs7106204	0.514	rs12282611	chr11:24271352	A/C	ch.11.24196551F	chr11:24239977	NA	0.84	8.15	0.41	7.36e-15	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.59	-0.34	1.73e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg06238570	chr21:40685208	BRWD1	0.58	9.1	0.45	8.66e-18	Menarche (age at onset);
LUSC	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.35	-6.09	-0.32	3.14e-9	Primary biliary cholangitis;
LUSC	cis	rs5753037	0.803	rs131263	chr22:30133045	C/T	cg11564601	chr22:30592435	NA	0.34	6.05	0.31	3.86e-9	Type 1 diabetes;
LUSC	trans	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	7.37	0.37	1.36e-12	Neuroticism;
LUSC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg20283391	chr11:68216788	NA	0.53	8.02	0.4	1.77e-14	Total body bone mineral density;
LUSC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	12.21	0.56	1.32e-28	Colorectal cancer;
LUSC	cis	rs62400317	0.762	rs12193264	chr6:44930793	T/C	cg20913747	chr6:44695427	NA	-0.46	-7.27	-0.37	2.59e-12	Total body bone mineral density;
LUSC	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-7.15	-0.36	5.48e-12	Homocysteine levels;
LUSC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg20706599	chr15:90777202	CIB1;C15orf58	0.67	6.02	0.31	4.63e-9	Body mass index;
LUSC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.61	12.6	0.57	4.94e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg01528321	chr10:82214614	TSPAN14	0.83	12.43	0.56	2.11e-29	Post bronchodilator FEV1;
LUSC	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg19875535	chr5:140030758	IK	0.4	6.1	0.32	2.93e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.33	0.59	8.18e-33	Blood protein levels;
LUSC	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	6.29	0.33	9.76e-10	Retinal vascular caliber;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05463257	chr3:182782445	MCCC1	0.46	6.04	0.31	4.12e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg03709012	chr19:19516395	GATAD2A	0.88	8.38	0.42	1.46e-15	LDL cholesterol;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10014674	chr1:33430585	RNF19B	0.42	6.3	0.33	9.32e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg05246507	chr14:21493295	NDRG2	0.44	6.37	0.33	6.27e-10	Mosquito bite size;
LUSC	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg07195577	chr17:27052828	TLCD1	0.44	5.71	0.3	2.54e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg27539214	chr16:67997921	SLC12A4	-0.6	-7.17	-0.37	4.72e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-1.03	-16.87	-0.68	1.27e-46	Systemic lupus erythematosus;
LUSC	cis	rs6494488	0.500	rs72742982	chr15:64977055	C/T	cg08069370	chr15:64387884	SNX1	-0.68	-5.9	-0.31	8.97e-9	Coronary artery disease;
LUSC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18404041	chr3:52824283	ITIH1	0.55	11.01	0.52	3.03e-24	Bipolar disorder;
LUSC	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.79	-0.43	8.13e-17	Coffee consumption (cups per day);
LUSC	trans	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg18876405	chr7:65276391	NA	0.49	6.52	0.34	2.54e-10	Corneal structure;
LUSC	cis	rs2290159	0.752	rs3773349	chr3:12649732	T/C	cg23032965	chr3:12705835	RAF1	0.74	8.96	0.44	2.42e-17	Cholesterol, total;
LUSC	cis	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.5	-5.87	-0.31	1.06e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9462027	0.651	rs2395599	chr6:34641415	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.16	-0.32	2.13e-9	Systemic lupus erythematosus;
LUSC	cis	rs7615316	0.751	rs2862745	chr3:142071932	A/G	cg16271453	chr3:142027066	XRN1	-0.41	-7.1	-0.36	7.66e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs73206853	0.841	rs4131850	chr12:110812553	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg06521331	chr12:34319734	NA	-0.37	-6.38	-0.33	5.81e-10	Morning vs. evening chronotype;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg15543754	chr2:54950739	EML6	0.42	6.38	0.33	5.8e-10	Triglycerides;
LUSC	cis	rs4253772	0.872	rs14843	chr22:46639462	A/T	cg18190219	chr22:46762943	CELSR1	-0.52	-6.02	-0.31	4.71e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg02018176	chr4:1364513	KIAA1530	0.49	7.71	0.39	1.42e-13	Obesity-related traits;
LUSC	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg18357645	chr12:58087776	OS9	0.39	5.85	0.3	1.16e-8	Multiple sclerosis;
LUSC	cis	rs936229	0.768	rs12442901	chr15:75083912	A/G	cg10253484	chr15:75165896	SCAMP2	-0.52	-6.79	-0.35	5.27e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg19862616	chr7:65841803	NCRNA00174	0.87	10.06	0.48	5.91e-21	Eotaxin levels;
LUSC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg16060761	chr17:80687452	NA	0.42	6.44	0.33	4.23e-10	Breast cancer;
LUSC	cis	rs6494488	0.500	rs78659827	chr15:64721927	G/T	cg08069370	chr15:64387884	SNX1	-0.64	-5.67	-0.3	3.05e-8	Coronary artery disease;
LUSC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.86	-15.4	-0.64	8.61e-41	Cognitive function;
LUSC	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14169450	chr9:139327907	INPP5E	0.43	7.43	0.38	9.25e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg08470875	chr2:26401718	FAM59B	-0.68	-9.2	-0.45	4.11e-18	Gut microbiome composition (summer);
LUSC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21862992	chr11:68658383	NA	0.51	7.93	0.4	3.29e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7607369	0.719	rs690882	chr2:219640620	T/C	cg02176678	chr2:219576539	TTLL4	-0.54	-9.53	-0.46	3.28e-19	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs12776158	0.901	rs59262400	chr10:71216310	G/A	cg12610070	chr10:71211762	TSPAN15	-0.46	-6.05	-0.31	3.9e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg01420254	chr6:26195488	NA	0.71	7.5	0.38	5.86e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg00033643	chr7:134001901	SLC35B4	0.46	7.24	0.37	3.09e-12	Mean platelet volume;
LUSC	cis	rs2274273	0.870	rs7153612	chr14:55788762	T/C	cg04306507	chr14:55594613	LGALS3	0.54	11.81	0.54	3.97e-27	Protein biomarker;
LUSC	trans	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.35	-0.33	7.23e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg05110241	chr16:68378359	PRMT7	-0.53	-6.53	-0.34	2.4e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg17420585	chr12:42539391	GXYLT1	-0.36	-7.14	-0.36	5.99e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg02466173	chr16:30829666	NA	-0.68	-15.99	-0.66	3.82e-43	Dementia with Lewy bodies;
LUSC	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg09876464	chr15:85330779	ZNF592	0.37	6.93	0.35	2.11e-11	P wave terminal force;
LUSC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg05313129	chr8:58192883	C8orf71	-0.5	-5.79	-0.3	1.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4285028	0.699	rs73855465	chr3:121574219	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.79	-10.65	-0.5	5.28e-23	Multiple sclerosis;
LUSC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	12.23	0.56	1.09e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9309473	0.950	rs10198549	chr2:73794404	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.48	-0.33	3.37e-10	Metabolite levels;
LUSC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	13.27	0.59	1.5e-32	Alzheimer's disease;
LUSC	cis	rs7131987	0.650	rs11050188	chr12:29473108	A/C	cg09582351	chr12:29534625	ERGIC2	-0.34	-6.81	-0.35	4.53e-11	QT interval;
LUSC	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg01420254	chr6:26195488	NA	0.65	7.24	0.37	3.03e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg18196295	chr10:418757	DIP2C	-0.41	-6.16	-0.32	2.06e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg11244672	chr19:19639970	YJEFN3	-0.61	-7.57	-0.38	3.66e-13	Bipolar disorder;
LUSC	cis	rs698813	0.703	rs2053457	chr2:44572164	C/T	cg00619915	chr2:44497795	NA	-0.39	-5.72	-0.3	2.4e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	trans	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg19676328	chr12:49525230	TUBA1B	-0.51	-7.38	-0.37	1.27e-12	Total cholesterol levels;
LUSC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg16339924	chr4:17578868	LAP3	-0.54	-8.22	-0.41	4.53e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg04317338	chr11:64019027	PLCB3	0.67	7.69	0.39	1.71e-13	Mean platelet volume;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.54	-10.0	-0.48	8.76e-21	Longevity;Endometriosis;
LUSC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg02018176	chr4:1364513	KIAA1530	-0.56	-9.75	-0.47	6.08e-20	Obesity-related traits;
LUSC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.49	7.03	0.36	1.2e-11	Renal function-related traits (BUN);
LUSC	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg17385448	chr1:15911702	AGMAT	0.36	6.17	0.32	1.97e-9	Systolic blood pressure;
LUSC	trans	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.4	0.42	1.29e-15	Ulcerative colitis;
LUSC	cis	rs2898681	0.561	rs6855240	chr4:53740787	G/A	cg00791764	chr4:53727839	RASL11B	0.48	6.39	0.33	5.59e-10	Optic nerve measurement (cup area);
LUSC	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.77	-13.25	-0.59	1.69e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.47	0.33	3.52e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg06271696	chr7:157225062	NA	-0.48	-9.91	-0.48	1.9e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg00898013	chr13:113819073	PROZ	-0.65	-8.98	-0.44	2e-17	Platelet distribution width;
LUSC	cis	rs12519773	0.550	rs4242242	chr5:92519387	G/A	cg18783429	chr5:92414398	NA	0.32	6.8	0.35	4.87e-11	Migraine;
LUSC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg13047869	chr3:10149882	C3orf24	0.64	9.04	0.44	1.29e-17	Alzheimer's disease;
LUSC	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg02023728	chr11:77925099	USP35	0.49	7.06	0.36	9.61e-12	Testicular germ cell tumor;
LUSC	cis	rs4343996	0.603	rs4722722	chr7:3398176	T/A	cg21248987	chr7:3385318	SDK1	-0.35	-5.85	-0.3	1.17e-8	Motion sickness;
LUSC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg05552183	chr6:42928497	GNMT	0.49	8.17	0.41	6.42e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.7	-0.34	8.78e-11	Total body bone mineral density;
LUSC	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.96	13.78	0.6	1.66e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7264396	0.887	rs224354	chr20:34054609	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.66	-0.34	1.1e-10	Total cholesterol levels;
LUSC	cis	rs72960926	0.744	rs72964259	chr6:74882885	A/T	cg03266952	chr6:74778945	NA	-0.8	-6.35	-0.33	7.23e-10	Metabolite levels (MHPG);
LUSC	cis	rs977987	0.806	rs12449170	chr16:75463012	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.56	0.46	2.75e-19	Dupuytren's disease;
LUSC	cis	rs6690583	0.623	rs1371140	chr1:85455362	A/C	cg22153463	chr1:85462885	MCOLN2	0.61	5.91	0.31	8.56e-9	Serum sulfate level;
LUSC	cis	rs2692947	0.644	rs1724125	chr2:96831355	G/A	cg23100626	chr2:96804247	ASTL	0.3	6.99	0.36	1.5e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.75	11.85	0.54	2.82e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.07	-17.76	-0.7	3.74e-50	Primary sclerosing cholangitis;
LUSC	cis	rs11123610	0.679	rs34705357	chr2:3716032	C/T	cg10645314	chr2:3704589	ALLC	-0.44	-7.14	-0.36	5.82e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg06521852	chr22:38141419	TRIOBP	-0.35	-5.74	-0.3	2.1e-8	Glioblastoma;Glioma;
LUSC	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg13010199	chr12:38710504	ALG10B	-0.62	-9.56	-0.46	2.65e-19	Bladder cancer;
LUSC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg12292205	chr6:26970375	C6orf41	-0.7	-12.21	-0.56	1.3e-28	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg08000102	chr2:233561755	GIGYF2	-0.74	-10.35	-0.49	6.08e-22	Schizophrenia;
LUSC	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg21970626	chr13:21893289	NA	-0.51	-9.73	-0.47	7.04e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg07636037	chr3:49044803	WDR6	0.9	11.71	0.54	9.27e-27	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08672557	chr10:22292767	DNAJC1	0.5	6.96	0.36	1.85e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg08847533	chr14:75593920	NEK9	-0.41	-6.07	-0.32	3.52e-9	IgG glycosylation;
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg22907277	chr7:1156413	C7orf50	0.6	9.33	0.45	1.56e-18	Longevity;Endometriosis;
LUSC	cis	rs62400317	0.859	rs6919998	chr6:45159289	C/T	cg20913747	chr6:44695427	NA	-0.48	-7.67	-0.39	1.91e-13	Total body bone mineral density;
LUSC	cis	rs1434579	0.526	rs204547	chr19:44947184	T/C	cg15540054	chr19:45004280	ZNF180	-0.46	-6.55	-0.34	2.15e-10	Tuberculosis;
LUSC	cis	rs11608355	0.515	rs7976796	chr12:109928013	C/T	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs4285028	0.699	rs2689285	chr3:121586486	G/A	cg11130432	chr3:121712080	ILDR1	0.6	9.25	0.45	2.71e-18	Multiple sclerosis;
LUSC	cis	rs12493885	0.769	rs61791509	chr3:153753178	T/C	cg17054900	chr3:154042577	DHX36	-0.67	-7.06	-0.36	9.76e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.31	-5.75	-0.3	2.07e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg03477792	chr4:77819574	ANKRD56	0.61	8.59	0.43	3.44e-16	Emphysema distribution in smoking;
LUSC	trans	rs12310956	0.510	rs11052882	chr12:33890017	T/C	cg26384229	chr12:38710491	ALG10B	0.55	8.59	0.43	3.34e-16	Morning vs. evening chronotype;
LUSC	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg18753928	chr3:113234510	CCDC52	-0.53	-8.13	-0.41	8.46e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	trans	rs1874124	0.577	rs2807880	chr1:221043003	A/G	cg00338749	chr11:1036677	MUC6	-0.39	-6.09	-0.32	3.16e-9	Cholesterol, total;
LUSC	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg19610905	chr11:61596333	FADS2	0.53	8.11	0.41	9.83e-15	Trans fatty acid levels;
LUSC	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg18827107	chr12:86230957	RASSF9	-0.39	-5.81	-0.3	1.45e-8	Major depressive disorder;
LUSC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg06784218	chr1:46089804	CCDC17	0.49	9.61	0.47	1.83e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4356932	0.691	rs9995007	chr4:76897791	T/A	cg00809888	chr4:76862425	NAAA	0.37	5.91	0.31	8.4e-9	Blood protein levels;
LUSC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg14552801	chr7:65878734	NA	-0.46	-6.54	-0.34	2.37e-10	Aortic root size;
LUSC	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg14019695	chr9:139328340	INPP5E	0.43	7.92	0.4	3.67e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2274273	0.588	rs9323285	chr14:55863829	A/C	cg04306507	chr14:55594613	LGALS3	-0.47	-9.19	-0.45	4.3e-18	Protein biomarker;
LUSC	trans	rs2262909	0.925	rs404822	chr19:22215967	A/C	cg05197062	chr11:11642011	GALNTL4	-0.52	-7.13	-0.36	6.21e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs713477	0.618	rs6573033	chr14:55919060	C/G	cg13175173	chr14:55914753	NA	-0.3	-6.27	-0.32	1.14e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg02153584	chr22:29168773	CCDC117	0.56	8.51	0.42	5.78e-16	Lymphocyte counts;
LUSC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg12257692	chr3:49977190	RBM6	0.24	6.57	0.34	1.89e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs829883	0.659	rs4762495	chr12:98934105	C/T	cg25150519	chr12:98850993	NA	-0.63	-8.71	-0.43	1.47e-16	Colorectal adenoma (advanced);
LUSC	cis	rs41271473	1.000	rs55956922	chr1:228872549	T/A	cg16512390	chr1:228756714	NA	0.5	6.01	0.31	4.98e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs12681287	0.547	rs13267858	chr8:87510871	G/A	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	cis	rs7577696	0.524	rs12991444	chr2:32265125	G/T	cg02381751	chr2:32503542	YIPF4	-0.45	-5.99	-0.31	5.32e-9	Inflammatory biomarkers;
LUSC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.55	-7.93	-0.4	3.41e-14	Tuberculosis;
LUSC	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg15309053	chr8:964076	NA	0.4	7.97	0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs2481665	0.510	rs2481676	chr1:62627675	C/T	cg18591186	chr1:62594603	INADL	-0.45	-7.61	-0.38	2.86e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg18477163	chr1:228402036	OBSCN	-0.56	-10.37	-0.49	5.11e-22	Diastolic blood pressure;
LUSC	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg24342717	chr2:85555507	TGOLN2	-0.74	-11.95	-0.55	1.24e-27	Ear protrusion;
LUSC	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.89	0.35	2.87e-11	IgG glycosylation;
LUSC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg04944784	chr2:26401820	FAM59B	-0.75	-10.76	-0.51	2.13e-23	Gut microbiome composition (summer);
LUSC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.69e-9	Aortic root size;
LUSC	cis	rs6494488	0.500	rs72742989	chr15:64994464	A/G	cg08069370	chr15:64387884	SNX1	-0.68	-5.9	-0.31	8.97e-9	Coronary artery disease;
LUSC	cis	rs887829	0.570	rs10175809	chr2:234596865	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.28	-0.33	1.04e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs1044573	0.514	rs2268879	chr20:25177805	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.46	-7.87	-0.4	5.04e-14	Allergic rhinitis;
LUSC	cis	rs62400317	0.859	rs12212745	chr6:45166258	C/T	cg18551225	chr6:44695536	NA	-0.43	-6.97	-0.36	1.73e-11	Total body bone mineral density;
LUSC	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg17366294	chr4:99064904	C4orf37	0.56	7.82	0.39	6.99e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6599077	1.000	rs9853406	chr3:40097964	T/C	cg13683864	chr3:40499215	RPL14	-0.61	-7.25	-0.37	2.94e-12	Sleep-related phenotypes;
LUSC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	-0.38	-5.73	-0.3	2.28e-8	Menopause (age at onset);
LUSC	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg23241863	chr10:102295624	HIF1AN	0.48	5.74	0.3	2.18e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg17623882	chr6:41773611	USP49	0.61	10.11	0.48	3.72e-21	Menarche (age at onset);
LUSC	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg22532475	chr10:104410764	TRIM8	0.25	6.13	0.32	2.46e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg26043149	chr18:55253948	FECH	-0.45	-6.9	-0.35	2.65e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12541635	0.739	rs1896915	chr8:107083520	G/T	cg10147462	chr8:107024639	NA	0.59	12.13	0.55	2.6e-28	Age of smoking initiation;
LUSC	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg11693508	chr17:37793320	STARD3	0.56	6.59	0.34	1.67e-10	Bipolar disorder;
LUSC	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	1.11	27.31	0.83	4.24e-87	Testicular germ cell tumor;
LUSC	cis	rs500891	0.645	rs12190945	chr6:84162042	C/T	cg08257003	chr6:84140564	ME1	-0.37	-8.84	-0.44	5.57e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.9	12.12	0.55	2.84e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs12760731	0.565	rs12403070	chr1:178094429	A/G	cg00404053	chr1:178313656	RASAL2	0.68	6.84	0.35	3.79e-11	Obesity-related traits;
LUSC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.9	16.2	0.66	5.81e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg03213289	chr20:61660250	NA	0.65	13.15	0.58	4.23e-32	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.21	-0.32	1.57e-9	Dupuytren's disease;
LUSC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg20283391	chr11:68216788	NA	-0.57	-8.14	-0.41	8.02e-15	Total body bone mineral density;
LUSC	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg01256987	chr12:42539512	GXYLT1	-0.37	-6.86	-0.35	3.28e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg21880101	chr17:80066754	CCDC57	-0.31	-5.78	-0.3	1.76e-8	Life satisfaction;
LUSC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg16558253	chr16:72132732	DHX38	-0.42	-6.45	-0.33	4.03e-10	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LUSC	cis	rs12220238	1.000	rs12355771	chr10:75894404	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	7.24	0.37	3.17e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg14634687	chr17:47094252	IGF2BP1	0.31	6.54	0.34	2.26e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg08132940	chr7:1081526	C7orf50	-0.52	-6.22	-0.32	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7589342	0.801	rs2889605	chr2:106525073	T/C	cg14210321	chr2:106509881	NCK2	-0.61	-9.53	-0.46	3.4e-19	Addiction;
LUSC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg12751644	chr20:60527061	NA	-0.35	-6.22	-0.32	1.52e-9	Body mass index;
LUSC	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg10857441	chr5:6722123	POLS	-0.47	-9.21	-0.45	3.6e-18	Menopause (age at onset);
LUSC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.37	6.49	0.33	3.18e-10	Obesity-related traits;
LUSC	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg10840412	chr1:235813424	GNG4	0.57	7.36	0.37	1.4e-12	Neuroticism;
LUSC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg19812747	chr11:111475976	SIK2	-0.52	-7.34	-0.37	1.67e-12	Primary sclerosing cholangitis;
LUSC	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg00376283	chr12:123451042	ABCB9	0.66	8.34	0.42	1.94e-15	Neutrophil percentage of white cells;
LUSC	cis	rs17102423	0.788	rs35176994	chr14:65596004	T/C	cg11161011	chr14:65562177	MAX	-0.73	-10.99	-0.52	3.55e-24	Obesity-related traits;
LUSC	cis	rs9788721	0.836	rs72738736	chr15:78765122	G/T	cg18825076	chr15:78729989	IREB2	-0.61	-9.95	-0.48	1.31e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs2658782	0.756	rs3019222	chr11:93079718	C/T	cg15737290	chr11:93063684	CCDC67	0.71	8.86	0.44	4.99e-17	Pulmonary function decline;
LUSC	cis	rs427941	0.703	rs201442	chr7:101737627	C/T	cg06246474	chr7:101738831	CUX1	-0.42	-6.92	-0.35	2.32e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23896578	chr20:8000418	TMX4	-0.4	-5.98	-0.31	5.66e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9486719	1.000	rs11153070	chr6:97039720	C/G	cg06623918	chr6:96969491	KIAA0776	-0.83	-9.36	-0.46	1.17e-18	Migraine;Coronary artery disease;
LUSC	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg06096015	chr1:231504339	EGLN1	0.57	10.33	0.49	6.72e-22	Hemoglobin concentration;
LUSC	cis	rs7605827	0.930	rs11684395	chr2:15530870	A/G	cg19274914	chr2:15703543	NA	0.48	9.34	0.46	1.39e-18	Educational attainment (years of education);
LUSC	cis	rs9648716	0.515	rs38715	chr7:140691563	T/C	cg23214464	chr7:140373596	ADCK2	0.74	6.33	0.33	8.04e-10	Type 2 diabetes;
LUSC	cis	rs238295	0.631	rs6038205	chr20:5549073	T/A	cg15842884	chr20:5591925	RP5-1022P6.2	-0.43	-5.87	-0.31	1.07e-8	Occipital cortical area (total cortical area interaction);
LUSC	trans	rs11039798	0.698	rs78553793	chr11:48947336	C/A	cg15704280	chr7:45808275	SEPT13	0.8	6.99	0.36	1.48e-11	Axial length;
LUSC	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg02275930	chr1:2372054	NA	-0.55	-7.75	-0.39	1.08e-13	Non-obstructive azoospermia;
LUSC	cis	rs72772090	0.539	rs111886458	chr5:96125047	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-6.96	-0.36	1.82e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.17	0.61	5.27e-36	Exhaled nitric oxide levels;
LUSC	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.69	-0.34	9.45e-11	Breast cancer;
LUSC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg03146154	chr1:46216737	IPP	-0.51	-7.35	-0.37	1.54e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg14552801	chr7:65878734	NA	0.43	5.89	0.31	9.18e-9	Aortic root size;
LUSC	cis	rs2637266	0.967	rs6480826	chr10:78356154	A/G	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	12.91	0.58	3.43e-31	Lung cancer in ever smokers;
LUSC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg20811857	chr17:78079795	GAA	-0.37	-6.63	-0.34	1.32e-10	Yeast infection;
LUSC	cis	rs2658782	0.593	rs2243410	chr11:93255519	T/G	cg15737290	chr11:93063684	CCDC67	0.59	7.39	0.37	1.2e-12	Pulmonary function decline;
LUSC	trans	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.99e-9	Bladder cancer;
LUSC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg14789911	chr21:47582049	C21orf56	-0.41	-6.46	-0.33	3.66e-10	Testicular germ cell tumor;
LUSC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-8.37	-0.42	1.62e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs3820928	0.874	rs4675130	chr2:227827740	G/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.3	-0.37	2.1e-12	Pulmonary function;
LUSC	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg12386194	chr3:101231763	SENP7	0.65	9.03	0.44	1.4e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg09455208	chr3:40491958	NA	0.56	10.15	0.49	2.77e-21	Renal cell carcinoma;
LUSC	cis	rs6977660	1.000	rs5017191	chr7:19820158	C/A	cg07541023	chr7:19748670	TWISTNB	0.51	5.73	0.3	2.3e-8	Thyroid stimulating hormone;
LUSC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg03929089	chr4:120376271	NA	-0.83	-11.36	-0.53	1.64e-25	Coronary artery disease;
LUSC	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-20.58	-0.75	2.39e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4654899	0.965	rs17418249	chr1:21390582	C/T	cg01072550	chr1:21505969	NA	-0.54	-8.28	-0.41	3.02e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg17158414	chr2:27665306	KRTCAP3	0.32	6.29	0.33	9.71e-10	Total body bone mineral density;
LUSC	cis	rs1832871	0.672	rs9456286	chr6:158734315	A/G	cg07165851	chr6:158734300	TULP4	0.46	6.89	0.35	2.81e-11	Height;
LUSC	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	1.04	14.11	0.61	9.12e-36	Exhaled nitric oxide levels;
LUSC	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg14500267	chr11:67383377	NA	0.34	6.51	0.34	2.75e-10	Mean corpuscular volume;
LUSC	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg17507749	chr15:85114479	UBE2QP1	0.65	8.15	0.41	7.64e-15	Schizophrenia;
LUSC	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.23	-0.32	1.41e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg14092571	chr14:90743983	NA	0.36	5.82	0.3	1.39e-8	Mortality in heart failure;
LUSC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.54	-10.66	-0.5	4.97e-23	Educational attainment;
LUSC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg11812906	chr14:75593930	NEK9	-0.58	-9.76	-0.47	5.61e-20	Height;
LUSC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg18479299	chr3:125709523	NA	-0.51	-5.85	-0.31	1.14e-8	Blood pressure (smoking interaction);
LUSC	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg11502198	chr6:26597334	ABT1	0.59	9.24	0.45	2.88e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.49	-0.46	4.58e-19	Type 2 diabetes;
LUSC	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg03972071	chr18:72917163	ZADH2	0.47	5.74	0.3	2.09e-8	Vascular endothelial growth factor levels;
LUSC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg27170947	chr2:26402098	FAM59B	-0.7	-10.37	-0.49	4.89e-22	Gut microbiome composition (summer);
LUSC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg13560548	chr3:10150139	C3orf24	0.54	7.74	0.39	1.17e-13	Alzheimer's disease;
LUSC	cis	rs6998277	0.830	rs6468838	chr8:103609336	T/C	cg10187029	chr8:103597600	NA	0.78	11.95	0.55	1.18e-27	Migraine;
LUSC	cis	rs6062509	0.839	rs3859579	chr20:62301795	A/G	cg16989086	chr20:62203971	PRIC285	-0.41	-5.84	-0.3	1.24e-8	Prostate cancer;
LUSC	cis	rs8133932	0.654	rs425232	chr21:47346525	G/T	cg14185626	chr21:47401492	COL6A1	-0.44	-5.65	-0.3	3.37e-8	Schizophrenia;
LUSC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.67	-0.39	1.95e-13	Bipolar disorder;
LUSC	cis	rs9473147	0.516	rs9349413	chr6:47511491	A/G	cg12968598	chr6:47444699	CD2AP	0.51	7.32	0.37	1.92e-12	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17449403	chr12:48357323	TMEM106C	-0.52	-6.54	-0.34	2.33e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6977940	0.822	rs6978804	chr7:2902698	T/C	cg19731401	chr7:2775893	GNA12	0.66	8.07	0.4	1.31e-14	White matter integrity;
LUSC	cis	rs36715	1.000	rs36705	chr5:127554486	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	7.37	0.37	1.32e-12	Breast cancer;
LUSC	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg24692254	chr21:30365293	RNF160	-0.54	-8.01	-0.4	1.87e-14	Dental caries;
LUSC	cis	rs672059	1.000	rs549844	chr1:183158143	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.55	-8.14	-0.41	7.71e-15	Hypertriglyceridemia;
LUSC	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg08975724	chr8:8085496	FLJ10661	0.46	6.65	0.34	1.23e-10	Neuroticism;
LUSC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.57	-8.96	-0.44	2.32e-17	Total body bone mineral density;
LUSC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg19901468	chr14:105411992	AHNAK2	-0.67	-11.95	-0.55	1.23e-27	Rheumatoid arthritis;
LUSC	cis	rs593982	0.920	rs76925283	chr11:65548108	C/T	cg08755490	chr11:65554678	OVOL1	-1.5	-15.04	-0.64	2.04e-39	Atopic dermatitis;
LUSC	cis	rs56159542	1	rs56159542	chr19:19682971	T/C	cg11244672	chr19:19639970	YJEFN3	0.47	6.2	0.32	1.69e-9	Attention deficit hyperactivity disorder symptom score;
LUSC	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg10792982	chr14:105748885	BRF1	0.49	8.52	0.42	5.44e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22496380	chr5:211416	CCDC127	-0.85	-8.68	-0.43	1.72e-16	Breast cancer;
LUSC	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.24	0.45	3.04e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs12618769	0.597	rs3769740	chr2:99069208	A/G	cg10123293	chr2:99228465	UNC50	-0.41	-7.03	-0.36	1.16e-11	Bipolar disorder;
LUSC	cis	rs12980942	0.748	rs67511749	chr19:41825158	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.08	0.32	3.22e-9	Coronary artery disease;
LUSC	cis	rs7712401	0.791	rs4836244	chr5:122116232	A/G	cg19077854	chr5:122220652	SNX24	0.33	7.29	0.37	2.33e-12	Mean platelet volume;
LUSC	trans	rs2055729	0.710	rs13257396	chr8:9736383	A/C	cg06636001	chr8:8085503	FLJ10661	0.49	6.22	0.32	1.49e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg02117656	chr17:79614917	TSPAN10	0.31	5.69	0.3	2.75e-8	Eye color traits;
LUSC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs4729127	1.000	rs73426361	chr7:94012656	G/T	cg14660007	chr13:78271894	SLAIN1	0.5	6.44	0.33	4.28e-10	Intelligence;
LUSC	cis	rs35123781	1.000	rs600848	chr5:139057270	T/C	cg10513866	chr5:139070639	NA	0.46	8.9	0.44	3.62e-17	Schizophrenia;
LUSC	trans	rs11165623	0.585	rs6698447	chr1:96999473	C/T	cg10631902	chr5:14652156	NA	-0.41	-6.06	-0.31	3.69e-9	Hip circumference;Waist circumference;
LUSC	cis	rs68170813	0.559	rs12537011	chr7:107027833	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.34	-0.45	1.45e-18	Coronary artery disease;
LUSC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg08798685	chr6:27730294	NA	-0.63	-5.94	-0.31	7.03e-9	Depression;
LUSC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-11.76	-0.54	5.97e-27	Gut microbiome composition (summer);
LUSC	cis	rs4356932	1.000	rs6532158	chr4:76977964	A/G	cg00809888	chr4:76862425	NAAA	0.34	5.69	0.3	2.75e-8	Blood protein levels;
LUSC	cis	rs1030268	0.667	rs12707111	chr7:133330144	C/T	cg10665199	chr7:133106180	EXOC4	0.63	7.39	0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg05738196	chr6:26577821	NA	-0.59	-6.93	-0.35	2.12e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	7.52	0.38	5.23e-13	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05063087	chr10:102133314	C10orf75	0.4	6.0	0.31	5.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.0	0.58	1.44e-31	Cognitive test performance;
LUSC	cis	rs7119	0.651	rs34607443	chr15:77847892	C/T	cg27398640	chr15:77910606	LINGO1	-0.33	-7.04	-0.36	1.12e-11	Type 2 diabetes;
LUSC	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg05738196	chr6:26577821	NA	0.5	5.69	0.3	2.72e-8	Small cell lung carcinoma;
LUSC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.92	-18.2	-0.71	6.3e-52	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg09092052	chr15:45571596	NA	-0.43	-6.07	-0.32	3.38e-9	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg25482853	chr8:67687455	SGK3	1.2	17.05	0.68	2.38e-47	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg27102117	chr16:15229624	NA	-0.4	-6.91	-0.35	2.54e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05535760	chr7:792225	HEATR2	0.79	9.23	0.45	3.21e-18	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	6.87	0.35	3.21e-11	Ovarian reserve;
LUSC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg18230493	chr5:56204884	C5orf35	0.77	12.72	0.57	1.65e-30	Initial pursuit acceleration;
LUSC	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg16482183	chr6:26056742	HIST1H1C	0.86	11.64	0.54	1.65e-26	Iron status biomarkers;
LUSC	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-0.9	-15.26	-0.64	3.01e-40	Height;
LUSC	cis	rs977987	0.866	rs12932606	chr16:75493944	C/T	cg04384234	chr16:75411784	CFDP1	-0.48	-7.89	-0.4	4.26e-14	Dupuytren's disease;
LUSC	cis	rs11608355	0.545	rs2302705	chr12:109898716	C/T	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg05347473	chr6:146136440	FBXO30	-0.59	-10.32	-0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.7	-11.4	-0.53	1.22e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.82	12.65	0.57	3.01e-30	IgG glycosylation;
LUSC	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-1.21	-13.51	-0.59	1.77e-33	Diabetic kidney disease;
LUSC	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg22431228	chr1:16359049	CLCNKA	0.34	6.39	0.33	5.62e-10	Dilated cardiomyopathy;
LUSC	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg18758796	chr5:131593413	PDLIM4	0.34	5.92	0.31	8.06e-9	Blood metabolite levels;
LUSC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.59	0.6	8.31e-34	Platelet count;
LUSC	trans	rs2864527	0.522	rs72939227	chr18:9249117	G/A	cg19809734	chr13:112772980	NA	-0.58	-5.99	-0.31	5.39e-9	Dental caries;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19078334	chr9:113019254	TXN	0.48	6.87	0.35	3.14e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs73129298	0.551	rs6020177	chr20:48603324	C/T	cg25655593	chr20:48599521	SNAI1	0.56	5.94	0.31	7.12e-9	Inflammatory skin disease;
LUSC	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.69	11.82	0.54	3.47e-27	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg20701182	chr2:24300061	SF3B14	0.74	7.28	0.37	2.4e-12	Lymphocyte counts;
LUSC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.63	13.47	0.59	2.44e-33	Monocyte percentage of white cells;
LUSC	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.33e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1385374	0.858	rs959989	chr12:129292708	A/T	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.8	-0.35	4.96e-11	Systemic lupus erythematosus;
LUSC	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg15445000	chr17:37608096	MED1	0.38	6.48	0.33	3.24e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08045932	chr20:61659980	NA	0.58	10.07	0.48	5.3e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg27284194	chr4:1044797	NA	0.38	6.51	0.34	2.73e-10	Obesity-related traits;
LUSC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg00933542	chr6:150070202	PCMT1	0.35	7.05	0.36	1.03e-11	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06474323	chr17:38257020	NR1D1	-0.44	-6.64	-0.34	1.27e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg23283495	chr1:209979779	IRF6	0.65	7.77	0.39	9.56e-14	Coronary artery disease;
LUSC	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg24375607	chr4:120327624	NA	0.76	11.3	0.53	2.66e-25	Corneal astigmatism;
LUSC	cis	rs981844	0.857	rs62325141	chr4:154716407	A/G	cg14289246	chr4:154710475	SFRP2	0.48	6.13	0.32	2.54e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07677032	chr17:61819896	STRADA	0.53	8.91	0.44	3.42e-17	Prudent dietary pattern;
LUSC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg23649088	chr2:200775458	C2orf69	0.54	7.25	0.37	2.86e-12	Schizophrenia;
LUSC	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg11189052	chr15:85197271	WDR73	-0.44	-6.51	-0.34	2.78e-10	P wave terminal force;
LUSC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.01	-0.4	1.87e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23158103	chr7:148848205	ZNF398	-0.48	-7.82	-0.39	6.83e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg06636001	chr8:8085503	FLJ10661	0.45	6.14	0.32	2.31e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs5009270	0.512	rs1024410	chr7:112247542	A/T	cg27282281	chr7:112262583	NA	0.44	5.96	0.31	6.49e-9	Osteoarthritis (hip);
LUSC	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg27087555	chr16:88793112	FAM38A	-1.41	-13.58	-0.6	9.7e-34	Plateletcrit;
LUSC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07256732	chr16:621771	PIGQ	-0.36	-6.54	-0.34	2.33e-10	Height;
LUSC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg25428297	chr7:1022841	CYP2W1	-0.29	-6.29	-0.33	9.88e-10	Longevity;Endometriosis;
LUSC	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.53	0.34	2.41e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg21280719	chr6:42927975	GNMT	-0.31	-7.76	-0.39	1.02e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg13390004	chr1:15929781	NA	0.42	6.95	0.36	1.92e-11	Systolic blood pressure;
LUSC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.45	9.0	0.44	1.75e-17	Obesity-related traits;
LUSC	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.63	-0.43	2.52e-16	Rheumatoid arthritis;
LUSC	cis	rs3820928	1.000	rs11692572	chr2:227774503	C/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.12	-0.41	9.3e-15	Pulmonary function;
LUSC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg05802129	chr4:122689817	NA	-0.34	-5.98	-0.31	5.69e-9	Type 2 diabetes;
LUSC	cis	rs911119	0.913	rs6048923	chr20:23578206	C/T	cg16589663	chr20:23618590	CST3	0.63	7.32	0.37	1.85e-12	Chronic kidney disease;
LUSC	cis	rs76419734	0.510	rs2553456	chr4:106751028	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.51	-5.75	-0.3	1.98e-8	Post bronchodilator FEV1;
LUSC	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.09	-0.32	3.11e-9	Neuroticism;
LUSC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.75	0.3	1.98e-8	Life satisfaction;
LUSC	cis	rs668210	0.793	rs502363	chr11:65775592	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.57	7.6	0.38	3e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg15691649	chr6:25882328	NA	-0.38	-6.28	-0.33	1.04e-9	Blood metabolite levels;
LUSC	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg11062466	chr8:58055876	NA	0.71	8.6	0.43	3.25e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.51	0.56	1e-29	Motion sickness;
LUSC	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg20734569	chr3:48348370	SPINK8	-0.48	-8.29	-0.41	2.74e-15	Coronary artery disease;
LUSC	cis	rs360798	0.512	rs2215870	chr2:63132342	C/G	cg17519650	chr2:63277830	OTX1	0.5	7.03	0.36	1.17e-11	Coronary artery disease;
LUSC	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	9.72	0.47	7.93e-20	Joint mobility (Beighton score);
LUSC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.45	6.21	0.32	1.58e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg00857998	chr1:205179979	DSTYK	0.62	9.52	0.46	3.48e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	0.92	15.58	0.65	1.65e-41	Menopause (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13435101	chr6:74171350	MTO1	-0.5	-6.84	-0.35	3.87e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7084921	0.579	rs2862951	chr10:101844948	A/C	cg02250046	chr10:101825185	CPN1	-0.33	-5.93	-0.31	7.42e-9	Bone mineral density;
LUSC	cis	rs6700559	0.740	rs4072551	chr1:200649121	A/G	cg07804481	chr1:200639085	DDX59	0.41	5.77	0.3	1.85e-8	Coronary artery disease;
LUSC	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.14	0.58	4.36e-32	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	7.16	0.36	5.12e-12	Ovarian reserve;
LUSC	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7267979	0.586	rs1473695	chr20:25186965	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	12.63	0.57	3.69e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6977660	0.891	rs10226962	chr7:19819464	T/C	cg07541023	chr7:19748670	TWISTNB	0.52	5.84	0.3	1.26e-8	Thyroid stimulating hormone;
LUSC	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg00677455	chr12:58241039	CTDSP2	0.62	8.75	0.43	1.09e-16	Multiple sclerosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02484111	chr11:130318594	ADAMTS15	-0.47	-6.25	-0.32	1.25e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.75	13.5	0.59	1.95e-33	Calcium levels;
LUSC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.82	0.39	7.1e-14	Electroencephalogram traits;
LUSC	trans	rs4948088	0.744	rs2189822	chr7:51017361	A/G	cg26816907	chr1:197890812	LHX9	0.56	6.21	0.32	1.62e-9	Type 1 diabetes;
LUSC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.95	0.31	6.59e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg19678392	chr7:94953810	PON1	-0.36	-5.67	-0.3	3.12e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	0.93	17.4	0.69	1.02e-48	Heart rate;
LUSC	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg24459738	chr19:57751996	ZNF805	-0.5	-7.24	-0.37	3.05e-12	Hyperactive-impulsive symptoms;
LUSC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	8.84	0.44	5.57e-17	Motion sickness;
LUSC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg06108461	chr20:60628389	TAF4	0.67	8.89	0.44	4.01e-17	Obesity-related traits;
LUSC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19346786	chr7:2764209	NA	-0.36	-6.2	-0.32	1.62e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg02150526	chr17:38136938	PSMD3	0.41	6.2	0.32	1.62e-9	Schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	ch.1.159013533R	chr1:160746909	NA	0.42	6.49	0.33	3.05e-10	Triglycerides;
LUSC	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	1.06	16.43	0.67	7.12e-45	Exhaled nitric oxide output;
LUSC	cis	rs273573	1.000	rs273605	chr11:30965855	A/T	cg14844989	chr11:31128820	NA	0.36	5.82	0.3	1.38e-8	Total body bone mineral density;
LUSC	trans	rs10096351	0.550	rs78015822	chr8:128336740	A/G	cg10195415	chr17:73887371	TRIM65	0.4	6.37	0.33	6.34e-10	Breast cancer;
LUSC	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg10523679	chr1:76189770	ACADM	-0.46	-6.67	-0.34	1.09e-10	Daytime sleep phenotypes;
LUSC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.74	0.77	6.18e-66	Prudent dietary pattern;
LUSC	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg02018176	chr4:1364513	KIAA1530	0.45	6.42	0.33	4.68e-10	Recombination rate (females);
LUSC	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg11245233	chr1:76251899	SNORD45C;RABGGTB	0.42	6.02	0.31	4.5e-9	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LUSC	cis	rs3857536	0.813	rs7770349	chr6:66946659	G/T	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg09307838	chr4:120376055	NA	0.64	9.64	0.47	1.4e-19	Corneal astigmatism;
LUSC	trans	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg01689657	chr7:91764605	CYP51A1	0.31	5.66	0.3	3.2e-8	Breast cancer;
LUSC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg04287289	chr16:89883240	FANCA	0.79	13.95	0.61	3.5e-35	Vitiligo;
LUSC	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg10657630	chr21:48055338	PRMT2	0.4	6.12	0.32	2.63e-9	Testicular germ cell tumor;
LUSC	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg11752832	chr7:134001865	SLC35B4	0.49	7.13	0.36	6.29e-12	Mean platelet volume;
LUSC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg26408565	chr15:76604113	ETFA	-0.5	-8.11	-0.41	1.01e-14	Blood metabolite levels;
LUSC	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg16070123	chr10:51489643	NA	0.56	9.22	0.45	3.44e-18	Prostate-specific antigen levels;
LUSC	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg11502198	chr6:26597334	ABT1	0.73	12.25	0.56	9.63e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-0.82	-16.44	-0.67	6.37e-45	Gut microbiome composition (winter);
LUSC	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg06484146	chr7:12443880	VWDE	0.55	5.76	0.3	1.92e-8	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03559815	chr11:117199307	CEP164	-0.43	-6.47	-0.33	3.46e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg24130564	chr14:104152367	KLC1	-0.44	-6.47	-0.33	3.43e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.96	-0.31	6.47e-9	Alzheimer's disease (late onset);
LUSC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg08859206	chr1:53392774	SCP2	0.5	8.42	0.42	1.11e-15	Monocyte count;
LUSC	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-12.42	-0.56	2.27e-29	Electrocardiographic conduction measures;
LUSC	cis	rs11630290	0.592	rs1912048	chr15:64155974	G/A	cg12036633	chr15:63758958	NA	0.52	6.64	0.34	1.26e-10	Iris characteristics;
LUSC	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg02023728	chr11:77925099	USP35	0.47	6.74	0.35	6.97e-11	Testicular germ cell tumor;
LUSC	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.22	-0.41	4.54e-15	Response to antipsychotic treatment;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.93	-19.12	-0.72	1.49e-55	Menarche (age at onset);
LUSC	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg13010199	chr12:38710504	ALG10B	0.49	7.5	0.38	6e-13	Morning vs. evening chronotype;
LUSC	cis	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg21775007	chr8:11205619	TDH	-0.52	-7.03	-0.36	1.16e-11	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LUSC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg27529037	chr20:44575021	PCIF1	0.4	7.06	0.36	9.42e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg26384229	chr12:38710491	ALG10B	0.72	11.36	0.53	1.66e-25	Morning vs. evening chronotype;
LUSC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.75	0.43	1.09e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg18187862	chr3:45730750	SACM1L	-0.49	-6.09	-0.32	3.14e-9	Primary sclerosing cholangitis;
LUSC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04644883	chr4:141071988	MAML3	-0.45	-6.0	-0.31	5.13e-9	Hepatitis;
LUSC	cis	rs9513627	0.588	rs9585073	chr13:100128516	A/G	cg25919922	chr13:100150906	NA	-0.75	-6.44	-0.33	4.11e-10	Obesity-related traits;
LUSC	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg09789173	chr7:4769017	FOXK1	0.63	11.51	0.53	4.86e-26	Mosquito bite size;
LUSC	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg22823121	chr1:150693482	HORMAD1	0.46	6.6	0.34	1.64e-10	Melanoma;
LUSC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.72	9.96	0.48	1.28e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg15534755	chr11:117069859	TAGLN	-0.33	-5.82	-0.3	1.39e-8	Blood protein levels;
LUSC	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg04352962	chr1:209979756	IRF6	0.53	7.07	0.36	9.27e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg14703610	chr5:56206110	C5orf35	0.41	5.87	0.31	1.04e-8	Coronary artery disease;
LUSC	cis	rs834811	0.829	rs6980107	chr7:135900757	C/T	cg01726295	chr7:135938950	NA	-0.4	-7.13	-0.36	6.36e-12	Post-traumatic stress disorder;
LUSC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg24675658	chr1:53192096	ZYG11B	0.73	12.29	0.56	6.6e-29	Monocyte count;
LUSC	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg08601574	chr20:25228251	PYGB	0.43	6.5	0.34	2.92e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1472147	0.955	rs3736611	chr7:128509243	C/G	cg00260937	chr7:128520193	KCP	0.44	5.88	0.31	9.92e-9	Calcium levels;
LUSC	cis	rs6714710	0.603	rs895438	chr2:98382886	G/A	cg26665480	chr2:98280029	ACTR1B	0.64	9.18	0.45	4.7e-18	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs17828380	1.000	rs71393141	chr15:63534181	T/C	cg05507819	chr15:63340323	TPM1	-0.7	-5.93	-0.31	7.7e-9	Social communication problems;
LUSC	cis	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg06521331	chr12:34319734	NA	-0.48	-7.77	-0.39	9.54e-14	Morning vs. evening chronotype;
LUSC	cis	rs12760731	0.565	rs12027723	chr1:178090271	A/T	cg00404053	chr1:178313656	RASAL2	0.69	6.75	0.35	6.64e-11	Obesity-related traits;
LUSC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.38	0.37	1.26e-12	Bipolar disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04393675	chr16:28986095	SPNS1	-0.52	-6.39	-0.33	5.54e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13401104	0.796	rs72620808	chr2:237114372	G/A	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.35e-8	Educational attainment;
LUSC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12826209	chr6:26865740	GUSBL1	0.73	8.92	0.44	3.1e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17965230	chr6:106534206	PRDM1	-0.5	-6.49	-0.33	3.19e-10	Hepatitis;
LUSC	cis	rs9314323	0.964	rs3808576	chr8:26266834	G/A	cg11498726	chr8:26250323	BNIP3L	-0.41	-6.0	-0.31	5.03e-9	Red cell distribution width;
LUSC	trans	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg06606381	chr12:133084897	FBRSL1	-1.06	-9.14	-0.45	6.21e-18	Depression;
LUSC	cis	rs601339	1.000	rs635400	chr12:123171089	A/G	cg11919336	chr12:123188078	GPR109A	0.4	5.98	0.31	5.86e-9	Adiponectin levels;
LUSC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg25072359	chr17:41440525	NA	0.63	9.17	0.45	4.92e-18	Menopause (age at onset);
LUSC	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.39	-0.37	1.17e-12	Morning vs. evening chronotype;
LUSC	cis	rs1256061	0.646	rs1256056	chr14:64712626	A/G	cg21174375	chr14:64681225	SYNE2	0.34	6.15	0.32	2.22e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg26958806	chr6:27640298	NA	0.75	6.01	0.31	4.76e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.83	14.14	0.61	6.9e-36	Body mass index (adult);
LUSC	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg09998033	chr7:158218633	PTPRN2	-0.6	-9.57	-0.46	2.48e-19	Obesity-related traits;
LUSC	cis	rs12681287	0.640	rs7460650	chr8:87474085	A/G	cg00550725	chr8:87521180	FAM82B	0.42	5.7	0.3	2.65e-8	Caudate activity during reward;
LUSC	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg26195577	chr20:24973756	C20orf3	-1.12	-18.25	-0.71	4.21e-52	Blood protein levels;
LUSC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	1.0	14.04	0.61	1.6e-35	Eosinophil percentage of granulocytes;
LUSC	trans	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg07393940	chr7:158741817	NA	0.36	6.53	0.34	2.49e-10	Life satisfaction;
LUSC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.36	-6.2	-0.32	1.62e-9	IgG glycosylation;
LUSC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7973719	0.899	rs12424618	chr12:7344802	A/G	cg07052231	chr12:7363540	PEX5	0.53	9.17	0.45	5.13e-18	IgG glycosylation;
LUSC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.58	-9.51	-0.46	4.03e-19	Aortic root size;
LUSC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg00484396	chr16:3507460	NAT15	-0.71	-11.48	-0.53	6.12e-26	Tuberculosis;
LUSC	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.56e-22	Hypertriglyceridemia;
LUSC	cis	rs1728785	0.681	rs4783647	chr16:68558048	G/A	cg02508848	chr16:68573721	ZFP90	0.46	5.88	0.31	9.69e-9	Ulcerative colitis;
LUSC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg13047869	chr3:10149882	C3orf24	0.56	7.73	0.39	1.24e-13	Alzheimer's disease;
LUSC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.04	0.52	2.25e-24	Menopause (age at onset);
LUSC	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg08807101	chr21:30365312	RNF160	-0.49	-7.13	-0.36	6.23e-12	Pancreatic cancer;
LUSC	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg25214090	chr10:38739885	LOC399744	0.54	8.05	0.4	1.44e-14	Corneal astigmatism;
LUSC	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg18404041	chr3:52824283	ITIH1	-0.49	-7.87	-0.4	5.07e-14	Schizophrenia;
LUSC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.58	-0.42	3.67e-16	Obesity-related traits;
LUSC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg26695010	chr11:65641043	EFEMP2	0.42	6.05	0.31	3.93e-9	Breast cancer;
LUSC	cis	rs6700896	0.897	rs2375805	chr1:66156567	C/T	cg04111102	chr1:66153794	NA	0.34	7.45	0.38	8.23e-13	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.8	-12.51	-0.56	1.02e-29	Pancreatic cancer;
LUSC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.88	-0.51	8.54e-24	Chronic sinus infection;
LUSC	cis	rs12760731	0.565	rs12037925	chr1:178160268	C/T	cg00404053	chr1:178313656	RASAL2	0.68	7.0	0.36	1.42e-11	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03168293	chr4:141348581	CLGN	0.45	6.13	0.32	2.53e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg08873628	chr1:175162347	KIAA0040	0.39	5.68	0.3	2.99e-8	Alcohol dependence;
LUSC	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg06096015	chr1:231504339	EGLN1	0.53	9.02	0.44	1.53e-17	Hemoglobin concentration;
LUSC	cis	rs4494114	1.000	rs7547273	chr1:39372590	G/A	cg25970120	chr1:39325951	RRAGC	-0.4	-6.22	-0.32	1.47e-9	Blood protein levels;
LUSC	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg27411982	chr8:10470053	RP1L1	0.39	6.0	0.31	5.02e-9	Neuroticism;
LUSC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg03146154	chr1:46216737	IPP	-0.5	-7.24	-0.37	3.08e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg24631222	chr15:78858424	CHRNA5	-0.41	-5.67	-0.3	3.01e-8	Coronary artery disease or large artery stroke;
LUSC	cis	rs6060717	0.536	rs11699899	chr20:34525646	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-5.8	-0.3	1.53e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg25208724	chr1:156163844	SLC25A44	1.04	21.6	0.76	2.26e-65	Testicular germ cell tumor;
LUSC	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg03806693	chr22:41940476	POLR3H	-0.5	-6.88	-0.35	2.97e-11	Neuroticism;
LUSC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg04369109	chr6:150039330	LATS1	-0.56	-8.22	-0.41	4.65e-15	Lung cancer;
LUSC	trans	rs2285002	0.745	rs229674	chr14:65281472	G/C	cg17546478	chr3:184322189	NA	-0.29	-5.99	-0.31	5.47e-9	Red cell distribution width;
LUSC	cis	rs2219968	0.923	rs35392911	chr8:78976979	C/A	cg00738934	chr8:78996279	NA	0.35	6.33	0.33	7.89e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11764359	chr7:65958608	NA	0.69	11.09	0.52	1.48e-24	Aortic root size;
LUSC	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21798802	chr22:38057573	PDXP	0.48	10.36	0.49	5.35e-22	Fat distribution (HIV);
LUSC	cis	rs10493773	0.577	rs17398175	chr1:86074710	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.39	-7.6	-0.38	2.99e-13	Urate levels in overweight individuals;
LUSC	cis	rs7189233	0.955	rs72801821	chr16:53479652	G/A	cg04059762	chr16:53544020	NA	-0.31	-5.67	-0.3	3.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3931020	0.688	rs968358	chr1:75193989	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.63	8.37	0.42	1.57e-15	Resistin levels;
LUSC	cis	rs155346	1.000	rs645850	chr5:139393417	T/C	cg01090482	chr5:139365336	NRG2	-0.38	-6.56	-0.34	2.1e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg24642439	chr20:33292090	TP53INP2	-0.52	-8.05	-0.4	1.45e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.81	-0.3	1.44e-8	Alzheimer's disease (late onset);
LUSC	cis	rs4629180	1.000	rs13031791	chr2:102108790	T/C	cg04415270	chr2:102091202	RFX8	0.57	9.26	0.45	2.61e-18	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-11.92	-0.55	1.53e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg04756594	chr16:24857601	SLC5A11	0.47	7.02	0.36	1.21e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg02269571	chr22:50332266	NA	0.57	8.58	0.43	3.6e-16	Schizophrenia;
LUSC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.47	7.23	0.37	3.25e-12	Colorectal cancer;
LUSC	cis	rs4285028	0.580	rs12496036	chr3:121640362	G/A	cg20356878	chr3:121714668	ILDR1	-0.45	-6.81	-0.35	4.63e-11	Multiple sclerosis;
LUSC	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.52	7.14	0.36	5.85e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg12560992	chr17:57184187	TRIM37	0.58	9.32	0.45	1.65e-18	Testicular germ cell tumor;
LUSC	cis	rs988712	0.705	rs4923463	chr11:27672500	A/G	cg10635145	chr11:27742435	BDNF	-0.46	-6.06	-0.31	3.76e-9	Obesity;
LUSC	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg13010199	chr12:38710504	ALG10B	0.47	7.3	0.37	2.09e-12	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg23788917	chr6:8435910	SLC35B3	-0.5	-7.18	-0.37	4.56e-12	Motion sickness;
LUSC	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17467752	chr17:38218738	THRA	-0.51	-7.2	-0.37	4.05e-12	White blood cell count;
LUSC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg25258033	chr6:167368657	RNASET2	0.36	5.66	0.3	3.18e-8	Primary biliary cholangitis;
LUSC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg04017836	chr7:65315216	NA	-0.37	-5.95	-0.31	6.75e-9	Height;
LUSC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11644478	chr21:40555479	PSMG1	-0.62	-9.68	-0.47	1.04e-19	Menarche (age at onset);
LUSC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg27284194	chr4:1044797	NA	0.35	5.85	0.31	1.15e-8	Obesity-related traits;
LUSC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg03526776	chr6:41159608	TREML2	0.32	6.12	0.32	2.68e-9	Alzheimer's disease (late onset);
LUSC	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg16482183	chr6:26056742	HIST1H1C	1.01	12.91	0.58	3.43e-31	Iron status biomarkers;
LUSC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-1.09	-22.07	-0.77	3.31e-67	Height;
LUSC	cis	rs6977660	0.562	rs12112698	chr7:19781431	A/G	cg05791153	chr7:19748676	TWISTNB	0.67	7.0	0.36	1.43e-11	Thyroid stimulating hormone;
LUSC	cis	rs977987	0.815	rs11861810	chr16:75461829	A/G	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.39e-11	Dupuytren's disease;
LUSC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.39	6.72	0.35	7.89e-11	High light scatter reticulocyte count;
LUSC	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.75	0.43	1.1e-16	Axial length;
LUSC	trans	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg07393940	chr7:158741817	NA	0.37	6.64	0.34	1.25e-10	Life satisfaction;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26443443	chr7:22396974	RAPGEF5	0.44	6.45	0.33	3.95e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg25206134	chr2:45395956	NA	0.62	7.22	0.37	3.54e-12	Bipolar disorder;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11060661	chr22:24314208	DDT;DDTL	0.45	7.74	0.39	1.17e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs73198271	0.960	rs73198288	chr8:8613940	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-5.95	-0.31	6.85e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.7	12.64	0.57	3.53e-30	Prudent dietary pattern;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	1.05	27.5	0.83	7.93e-88	Menarche (age at onset);
LUSC	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.24	-0.32	1.3e-9	Bipolar disorder;
LUSC	cis	rs4722166	0.704	rs4321884	chr7:22741459	A/T	cg26061582	chr7:22766209	IL6	0.39	5.87	0.31	1.02e-8	Lung cancer;
LUSC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg25036284	chr2:26402008	FAM59B	-0.59	-8.1	-0.41	1.07e-14	Gut microbiome composition (summer);
LUSC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.91	14.17	0.61	5.03e-36	Coronary artery disease;
LUSC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg20821713	chr7:1055600	C7orf50	-0.57	-7.34	-0.37	1.68e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs77633900	0.772	rs157760	chr15:76800260	A/G	cg21673338	chr15:77095150	SCAPER	-0.71	-6.07	-0.32	3.44e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg15839431	chr19:19639596	YJEFN3	-0.56	-6.96	-0.36	1.85e-11	Bipolar disorder;
LUSC	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg22875332	chr1:76189707	ACADM	-0.42	-6.2	-0.32	1.64e-9	Daytime sleep phenotypes;
LUSC	cis	rs6961069	0.777	rs1761667	chr7:80244939	G/A	cg04458919	chr7:80252533	CD36	0.37	6.63	0.34	1.3100000000000001e-10	Platelet count;
LUSC	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.34	0.56	4.24e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.63	-8.94	-0.44	2.75e-17	Obesity-related traits;
LUSC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg17971929	chr21:40555470	PSMG1	0.73	11.94	0.55	1.28e-27	Cognitive function;
LUSC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg11366901	chr6:160182831	ACAT2	0.92	12.0	0.55	8.07e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	0.87	14.79	0.63	1.95e-38	Tonsillectomy;
LUSC	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6700559	0.740	rs4387211	chr1:200645938	A/T	cg07804481	chr1:200639085	DDX59	-0.41	-5.8	-0.3	1.58e-8	Coronary artery disease;
LUSC	trans	rs2275731	0.723	rs10904757	chr10:16548382	A/G	cg00196167	chr7:139026058	C7orf55	-0.4	-6.06	-0.31	3.71e-9	Bone fracture in osteoporosis;
LUSC	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.19	-0.45	4.31e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg08313168	chr12:7315531	NA	0.46	5.98	0.31	5.65e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.7	8.63	0.43	2.62e-16	Type 2 diabetes;
LUSC	cis	rs1712517	0.787	rs1163089	chr10:105043964	G/A	cg05636881	chr10:105038444	INA	0.38	6.28	0.32	1.06e-9	Migraine;
LUSC	cis	rs2282300	0.637	rs10742240	chr11:30429438	A/G	cg25418670	chr11:30344373	C11orf46	-0.41	-6.44	-0.33	4.08e-10	Morning vs. evening chronotype;
LUSC	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg01448562	chr3:133502909	NA	-0.52	-7.56	-0.38	3.94e-13	Iron status biomarkers;
LUSC	cis	rs13315871	0.929	rs79813245	chr3:58318475	G/A	cg12435725	chr3:58293450	RPP14	-0.75	-7.18	-0.37	4.6e-12	Cholesterol, total;
LUSC	trans	rs7939886	0.920	rs7115395	chr11:55877116	G/A	cg15704280	chr7:45808275	SEPT13	0.82	6.75	0.35	6.43e-11	Myopia (pathological);
LUSC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	9.19	0.45	4.16e-18	Height;
LUSC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg04287289	chr16:89883240	FANCA	-0.42	-6.11	-0.32	2.74e-9	Vitiligo;
LUSC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.27	-0.62	2.03e-36	Eye color traits;
LUSC	cis	rs55665837	1.000	rs11023223	chr11:14457112	A/G	cg05501817	chr11:14380813	RRAS2	-0.41	-6.53	-0.34	2.5e-10	Vitamin D levels;
LUSC	cis	rs36093844	0.752	rs113529766	chr11:85583401	G/A	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg18149561	chr19:13905866	ZSWIM4	0.38	6.21	0.32	1.6e-9	Asthma;
LUSC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.69	-0.5	3.93e-23	Alzheimer's disease;
LUSC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg10523860	chr14:103875565	MARK3	-0.39	-6.19	-0.32	1.77e-9	Body mass index;
LUSC	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.46	-0.5	2.51e-22	Eye color traits;
LUSC	cis	rs1577917	0.839	rs6454504	chr6:86580330	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.69e-9	Response to antipsychotic treatment;
LUSC	cis	rs3771570	0.901	rs62190415	chr2:242426692	A/G	cg21155796	chr2:242212141	HDLBP	0.53	6.01	0.31	4.88e-9	Prostate cancer;
LUSC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.38	-0.33	6.05e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.45	-0.38	8.06e-13	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4443100	0.832	rs4434089	chr22:23383863	A/G	cg21100191	chr22:23484243	RTDR1	-0.47	-5.87	-0.31	1.04e-8	Serum parathyroid hormone levels;
LUSC	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.7	-11.21	-0.52	5.93e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg24130564	chr14:104152367	KLC1	-0.45	-6.22	-0.32	1.45e-9	Body mass index;
LUSC	trans	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg26043149	chr18:55253948	FECH	0.51	7.47	0.38	7.04e-13	Bone mineral density;
LUSC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg16339924	chr4:17578868	LAP3	0.62	9.55	0.46	2.92e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg16339924	chr4:17578868	LAP3	0.58	8.68	0.43	1.74e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg21782813	chr7:2030301	MAD1L1	0.59	10.55	0.5	1.22e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs9039	0.959	rs12925781	chr16:9216914	A/G	cg08831531	chr16:9218945	NA	0.68	10.3	0.49	8.49e-22	Menopause (age at onset);
LUSC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.51	-7.37	-0.37	1.32e-12	Mean platelet volume;
LUSC	trans	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.34e-10	Corneal astigmatism;
LUSC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg13683864	chr3:40499215	RPL14	-1.14	-19.9	-0.74	1.12e-58	Renal cell carcinoma;
LUSC	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg20607287	chr7:12443886	VWDE	-0.66	-6.5	-0.33	2.99e-10	Coronary artery disease;
LUSC	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg13010199	chr12:38710504	ALG10B	-0.46	-6.92	-0.35	2.3e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.84	-15.63	-0.65	1.06e-41	Longevity;
LUSC	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg16576597	chr16:28551801	NUPR1	0.29	5.81	0.3	1.44e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs8073060	0.586	rs225294	chr17:33925762	G/A	cg19694781	chr19:47549865	TMEM160	-1.12	-17.91	-0.7	9.17e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg10840412	chr1:235813424	GNG4	0.57	7.51	0.38	5.53e-13	Bipolar disorder;
LUSC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs239198	0.602	rs11758174	chr6:101322595	G/A	cg09795085	chr6:101329169	ASCC3	0.45	6.36	0.33	6.54e-10	Menarche (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06422146	chr16:70488547	FUK	-0.44	-6.69	-0.34	9.59e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs400736	0.671	rs2131630	chr1:7990367	G/A	cg25007680	chr1:8021821	PARK7	-0.47	-6.81	-0.35	4.69e-11	Response to antidepressants and depression;
LUSC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg00343986	chr7:65444356	GUSB	0.47	7.04	0.36	1.08e-11	Calcium levels;
LUSC	trans	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	0.59	9.17	0.45	4.88e-18	Breast cancer;
LUSC	cis	rs259282	0.605	rs8101920	chr19:33109270	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	9.59	0.46	2.07e-19	Schizophrenia;
LUSC	cis	rs2594714	1.000	rs2607276	chr19:13954633	T/G	cg18576835	chr19:13944261	NA	-0.39	-5.67	-0.3	3.11e-8	Breast cancer;
LUSC	cis	rs6674970	1.000	rs61819219	chr1:151084375	C/G	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.45	-6.03	-0.31	4.46e-9	Childhood ear infection;
LUSC	cis	rs6977660	0.714	rs7798760	chr7:19803487	T/C	cg07541023	chr7:19748670	TWISTNB	0.63	6.83	0.35	4.14e-11	Thyroid stimulating hormone;
LUSC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.62	0.43	2.69e-16	Prudent dietary pattern;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23819836	chr6:15663134	DTNBP1	-0.52	-7.14	-0.36	5.84e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.63	8.35	0.42	1.8e-15	High light scatter reticulocyte count;
LUSC	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg25214090	chr10:38739885	LOC399744	0.54	7.82	0.39	6.86e-14	Corneal astigmatism;
LUSC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg24324837	chr19:49891574	CCDC155	0.53	7.39	0.37	1.17e-12	Multiple sclerosis;
LUSC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg19257562	chr1:2043853	PRKCZ	0.33	6.74	0.35	6.97e-11	Height;
LUSC	cis	rs10779751	0.922	rs2295079	chr1:11322565	C/G	cg08854313	chr1:11322531	MTOR	0.91	16.02	0.66	3.05e-43	Body mass index;
LUSC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg26338869	chr17:61819248	STRADA	0.42	5.96	0.31	6.57e-9	Prudent dietary pattern;
LUSC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-7.31	-0.37	2.03e-12	Menopause (age at onset);
LUSC	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.99	0.31	5.41e-9	Morning vs. evening chronotype;
LUSC	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg24634471	chr8:143751801	JRK	0.5	7.01	0.36	1.3e-11	Schizophrenia;
LUSC	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg11812906	chr14:75593930	NEK9	0.66	11.26	0.52	3.83e-25	Height;
LUSC	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17916960	chr15:79447300	NA	-0.53	-10.75	-0.51	2.33e-23	Refractive error;
LUSC	cis	rs10754283	0.905	rs7519969	chr1:90108721	G/C	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-7.6	-0.38	2.98e-13	Chronic sinus infection;
LUSC	cis	rs9653442	0.545	rs4490209	chr2:100766711	C/G	cg22139774	chr2:100720529	AFF3	-0.41	-7.12	-0.36	6.73e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9378688	1.000	rs3823287	chr6:2244721	A/C	cg12303981	chr6:2244766	GMDS	-0.54	-6.99	-0.36	1.49e-11	Caudate nucleus volume;
LUSC	cis	rs7759001	0.857	rs4711148	chr6:27360690	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.69	0.3	2.77e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg07923666	chr12:49932857	KCNH3	-0.5	-6.28	-0.32	1.06e-9	Resting heart rate;
LUSC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.67	0.3	3.05e-8	Breast cancer;
LUSC	cis	rs9443645	0.723	rs9343820	chr6:79480458	T/A	cg05283184	chr6:79620031	NA	-0.53	-10.02	-0.48	7.98e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg02269571	chr22:50332266	NA	0.58	8.61	0.43	2.88e-16	Schizophrenia;
LUSC	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.92	15.65	0.65	8.39e-42	Bladder cancer;
LUSC	cis	rs4654899	0.680	rs4654874	chr1:21156667	C/T	cg01072550	chr1:21505969	NA	-0.47	-6.91	-0.35	2.5e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2235544	0.565	rs72664114	chr1:54471747	C/T	cg25741118	chr1:54482237	LDLRAD1	-0.28	-6.04	-0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg23985595	chr17:80112537	CCDC57	-0.31	-6.13	-0.32	2.41e-9	Life satisfaction;
LUSC	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-0.89	-13.28	-0.59	1.29e-32	Asthma;
LUSC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg08975724	chr8:8085496	FLJ10661	0.54	7.29	0.37	2.28e-12	Red cell distribution width;
LUSC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg06096015	chr1:231504339	EGLN1	0.56	9.73	0.47	7.59e-20	Hemoglobin concentration;
LUSC	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.23	-0.69	4.77e-48	Exhaled nitric oxide output;
LUSC	trans	rs13196614	0.756	rs9485318	chr6:149019833	G/C	cg01343097	chr1:248284971	OR2M1P	0.41	6.04	0.31	4e-9	Migraine;
LUSC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg07701084	chr6:150067640	NUP43	0.57	8.73	0.43	1.28e-16	Lung cancer;
LUSC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.14	-0.49	3.12e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-1.01	-9.21	-0.45	3.57e-18	Mitochondrial DNA levels;
LUSC	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg16989719	chr2:238392110	NA	-0.4	-6.78	-0.35	5.63e-11	Prostate cancer;
LUSC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.58	0.38	3.4e-13	Bipolar disorder;
LUSC	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg05163923	chr11:71159392	DHCR7	0.74	10.94	0.51	5.36e-24	Vitamin D levels;
LUSC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg15448220	chr1:150897856	SETDB1	0.39	5.81	0.3	1.48e-8	Melanoma;
LUSC	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg24579218	chr15:68104479	NA	-0.37	-6.59	-0.34	1.67e-10	Restless legs syndrome;
LUSC	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg00277334	chr10:82204260	NA	-0.51	-7.41	-0.38	1.05e-12	Post bronchodilator FEV1;
LUSC	cis	rs17253792	0.822	rs76472022	chr14:56053660	C/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	8.91e-12	Putamen volume;
LUSC	trans	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-5.97	-0.31	6.07e-9	Depression;
LUSC	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.24	-27.07	-0.83	3.27e-86	Exhaled nitric oxide output;
LUSC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg04398451	chr17:18023971	MYO15A	0.42	6.57	0.34	1.93e-10	Total body bone mineral density;
LUSC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg24675658	chr1:53192096	ZYG11B	0.74	12.74	0.57	1.44e-30	Monocyte count;
LUSC	cis	rs9341808	0.667	rs7746917	chr6:80931503	T/C	cg08355045	chr6:80787529	NA	0.47	7.94	0.4	3.05e-14	Sitting height ratio;
LUSC	cis	rs1614887	1	rs1614887	chr6:26393021	A/G	cg09904177	chr6:26538194	HMGN4	0.51	7.63	0.39	2.43e-13	Intelligence (multi-trait analysis);Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7582720	0.943	rs115130739	chr2:203725677	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	8.17	0.41	6.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg25930673	chr12:123319894	HIP1R	-0.72	-7.24	-0.37	3.14e-12	Schizophrenia;
LUSC	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg24558204	chr6:135376177	HBS1L	-0.57	-8.8	-0.43	7.64e-17	Red blood cell count;
LUSC	cis	rs7561273	0.565	rs6545275	chr2:24331860	A/G	cg06627628	chr2:24431161	ITSN2	-0.52	-6.84	-0.35	3.89e-11	Quantitative traits;
LUSC	cis	rs2354432	0.556	rs2353975	chr1:146837703	C/A	cg25205988	chr1:146714368	CHD1L	0.85	7.57	0.38	3.76e-13	Mitochondrial DNA levels;
LUSC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg25767906	chr1:53392781	SCP2	0.39	6.68	0.34	9.86e-11	Monocyte count;
LUSC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24110177	chr3:50126178	RBM5	0.57	9.61	0.47	1.89e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs12912251	1.000	rs71403553	chr15:38989121	C/A	cg01338139	chr15:38987640	C15orf53	-0.5	-6.83	-0.35	3.95e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs3730682	0.694	rs565903	chr18:51777727	C/T	cg04730925	chr18:51795821	POLI	-0.45	-6.58	-0.34	1.79e-10	Psoriasis;
LUSC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08470875	chr2:26401718	FAM59B	0.74	9.89	0.48	2.15e-20	Gut microbiome composition (summer);
LUSC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.57	7.64	0.39	2.31e-13	Lung function (FEV1/FVC);
LUSC	cis	rs16854884	1.000	rs34730687	chr3:143813193	A/G	cg06585982	chr3:143692056	C3orf58	0.45	6.08	0.32	3.25e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.69	0.5	3.96e-23	Schizophrenia;
LUSC	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	6.87	0.35	3.2e-11	Monocyte percentage of white cells;
LUSC	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18252515	chr7:66147081	NA	-0.58	-7.98	-0.4	2.44e-14	Corneal structure;
LUSC	cis	rs1775715	0.707	rs1541261	chr10:32179523	G/A	cg03015672	chr10:32216066	ARHGAP12	0.34	6.22	0.32	1.49e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg22166914	chr1:53195759	ZYG11B	0.48	7.55	0.38	4.22e-13	Monocyte count;
LUSC	cis	rs73206853	0.764	rs59527539	chr12:110968119	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.51	0.38	5.31e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9837602	0.938	rs9815439	chr3:99785206	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.98	-0.31	5.74e-9	Breast cancer;
LUSC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	9.96	0.48	1.24e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4919687	0.550	rs7904396	chr10:104456838	C/T	cg05855489	chr10:104503620	C10orf26	0.68	10.88	0.51	8.65e-24	Colorectal cancer;
LUSC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	5.81	0.3	1.49e-8	Breast cancer;
LUSC	cis	rs12980942	1.000	rs2241720	chr19:41829309	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.55	5.89	0.31	9.22e-9	Coronary artery disease;
LUSC	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg22532475	chr10:104410764	TRIM8	-0.34	-7.55	-0.38	4.16e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs12043259	0.892	rs35627019	chr1:204793461	T/C	cg05134015	chr14:36973365	SFTA3	-0.5	-6.06	-0.31	3.75e-9	Addiction;
LUSC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.53	-8.99	-0.44	1.93e-17	Multiple sclerosis;
LUSC	cis	rs3741151	0.686	rs12277924	chr11:73219678	T/C	cg17517138	chr11:73019481	ARHGEF17	0.77	7.26	0.37	2.7e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg08213375	chr14:104286397	PPP1R13B	-0.46	-8.49	-0.42	6.86e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	7.93	0.4	3.39e-14	Schizophrenia;
LUSC	cis	rs1712517	0.525	rs2271751	chr10:105175131	A/G	cg04362960	chr10:104952993	NT5C2	-0.49	-6.7	-0.34	8.63e-11	Migraine;
LUSC	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg08601574	chr20:25228251	PYGB	0.47	7.3	0.37	2.12e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3784262	1.000	rs10851631	chr15:58242193	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.04	-0.31	4.06e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11764359	chr7:65958608	NA	0.68	10.89	0.51	7.94e-24	Aortic root size;
LUSC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.55	-0.34	2.2e-10	Longevity;Endometriosis;
LUSC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg18758796	chr5:131593413	PDLIM4	0.51	8.54	0.42	4.99e-16	Acylcarnitine levels;
LUSC	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg23711669	chr6:146136114	FBXO30	0.74	12.45	0.56	1.76e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg17173187	chr15:85201210	NMB	0.47	8.61	0.43	3.02e-16	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.39	6.0	0.31	5.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg24692254	chr21:30365293	RNF160	0.74	11.53	0.53	4.07e-26	Pancreatic cancer;
LUSC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.16	-0.32	2.1e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7814319	0.933	rs13260865	chr8:97238472	A/T	cg20787634	chr8:97240163	UQCRB	-0.35	-6.02	-0.31	4.5e-9	Lung function (FVC);
LUSC	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg10426581	chr7:100472382	SRRT	0.85	12.39	0.56	2.91e-29	Resting heart rate;
LUSC	cis	rs73206853	0.764	rs7312469	chr12:110889072	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg04155289	chr7:94953770	PON1	-0.34	-5.76	-0.3	1.9e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg03983476	chr2:10830698	NOL10	-0.37	-5.66	-0.3	3.31e-8	Prostate cancer;
LUSC	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg03342759	chr3:160939853	NMD3	0.43	6.35	0.33	7.09e-10	Morning vs. evening chronotype;
LUSC	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg18721089	chr20:30220636	NA	-0.37	-6.54	-0.34	2.35e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg26566898	chr11:117069891	TAGLN	0.35	6.69	0.34	9.68e-11	Blood protein levels;
LUSC	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg05738196	chr6:26577821	NA	-0.48	-6.87	-0.35	3.13e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-6.74	-0.35	7.13e-11	Blood metabolite levels;
LUSC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg05425664	chr17:57184151	TRIM37	0.55	8.57	0.42	3.81e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1953600	0.837	rs2573352	chr10:81939813	T/C	cg00277334	chr10:82204260	NA	0.45	7.08	0.36	8.43e-12	Sarcoidosis;
LUSC	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs3007168	0.794	rs7156550	chr14:51620937	T/A	cg23942311	chr14:51606299	NA	-0.35	-6.67	-0.34	1.09e-10	Cancer;
LUSC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg15848620	chr12:58087721	OS9	0.56	8.08	0.4	1.2e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg16989719	chr2:238392110	NA	-0.42	-6.71	-0.34	8.46e-11	Prostate cancer;
LUSC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.96	0.58	2.1e-31	Prudent dietary pattern;
LUSC	cis	rs6700896	0.500	rs10889573	chr1:66129256	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.93	0.31	7.6e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10761482	0.813	rs7100985	chr10:62107166	G/A	cg18175470	chr10:62150864	ANK3	-0.51	-7.24	-0.37	3.06e-12	Schizophrenia;
LUSC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-12.22	-0.56	1.23e-28	Chronic sinus infection;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18954434	chr22:46692881	CN5H6.4;GTSE1	-0.41	-6.15	-0.32	2.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg20302533	chr7:39170763	POU6F2	-0.54	-8.74	-0.43	1.14e-16	IgG glycosylation;
LUSC	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg23649088	chr2:200775458	C2orf69	0.49	7.36	0.37	1.48e-12	Osteoporosis;
LUSC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg04733989	chr22:42467013	NAGA	-0.62	-9.72	-0.47	7.81e-20	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	14.6	0.62	1.14e-37	Total body bone mineral density;
LUSC	cis	rs7615316	0.934	rs7651071	chr3:142243850	T/A	cg16271453	chr3:142027066	XRN1	-0.39	-6.64	-0.34	1.27e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs11696501	0.688	rs6073855	chr20:44309670	C/T	cg03272292	chr12:48577362	C12orf68	0.5	6.03	0.31	4.22e-9	Brain structure;
LUSC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.58	8.88	0.44	4.12e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg17541715	chr7:1216824	NA	-0.37	-5.7	-0.3	2.57e-8	Longevity;Endometriosis;
LUSC	cis	rs1775715	0.737	rs11008695	chr10:32216887	T/G	cg03015672	chr10:32216066	ARHGAP12	0.33	5.94	0.31	7.06e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	8.4	0.42	1.32e-15	Schizophrenia;
LUSC	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg09835421	chr16:68378352	PRMT7	-0.54	-6.08	-0.32	3.32e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs1998174	0.509	rs10798701	chr1:171815431	G/A	cg13482142	chr2:234261155	NA	0.41	6.03	0.31	4.32e-9	Platelet distribution width;
LUSC	cis	rs7605827	0.930	rs1125533	chr2:15617751	C/G	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs4845570	1.000	rs3790514	chr1:151744168	T/C	cg07092448	chr1:151763213	TDRKH	-1.28	-14.57	-0.62	1.44e-37	Coronary artery disease;
LUSC	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg00814883	chr7:100076585	TSC22D4	-0.77	-9.7	-0.47	9.35e-20	Platelet count;
LUSC	cis	rs1044573	0.526	rs6050422	chr20:25177920	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.51	0.34	2.69e-10	Allergic rhinitis;
LUSC	cis	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg06521331	chr12:34319734	NA	-0.47	-7.57	-0.38	3.58e-13	Morning vs. evening chronotype;
LUSC	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	trans	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg18187862	chr3:45730750	SACM1L	0.61	7.48	0.38	6.72e-13	Primary sclerosing cholangitis;
LUSC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg05347473	chr6:146136440	FBXO30	0.51	8.58	0.42	3.66e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg12292205	chr6:26970375	C6orf41	-0.62	-7.36	-0.37	1.41e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs698813	0.642	rs1837702	chr2:44492444	T/A	cg00619915	chr2:44497795	NA	-0.52	-7.14	-0.36	5.75e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs3772130	0.583	rs58088236	chr3:121561765	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.82	13.45	0.59	3.06e-33	Cognitive performance;
LUSC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg25767906	chr1:53392781	SCP2	-0.52	-9.62	-0.47	1.73e-19	Monocyte count;
LUSC	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.29	-0.33	9.96e-10	Neuroticism;
LUSC	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.44	-9.71	-0.47	8.49e-20	Urate levels in overweight individuals;
LUSC	cis	rs35264875	1.000	rs6591370	chr11:68843003	G/A	cg02660097	chr11:68866761	NA	0.43	6.09	0.32	3.16e-9	Blond vs. brown hair color;
LUSC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg11663144	chr21:46675770	NA	-0.41	-7.23	-0.37	3.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs17767294	0.708	rs72847370	chr6:27849424	A/T	cg08851530	chr6:28072375	NA	1.18	7.77	0.39	9.45e-14	Parkinson's disease;
LUSC	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg15704280	chr7:45808275	SEPT13	-0.45	-6.21	-0.32	1.55e-9	Height;
LUSC	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg22709100	chr7:91322751	NA	0.41	6.07	0.32	3.44e-9	Breast cancer;
LUSC	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg12002119	chr2:101014098	CHST10	0.35	5.85	0.31	1.14e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11971779	0.680	rs7788777	chr7:139055193	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg05555928	chr11:63887634	MACROD1	0.32	5.83	0.3	1.31e-8	Platelet count;
LUSC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg11247378	chr22:39784982	NA	-0.59	-11.39	-0.53	1.33e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg05585544	chr11:47624801	NA	-0.4	-7.02	-0.36	1.28e-11	Subjective well-being;
LUSC	trans	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg18876405	chr7:65276391	NA	0.47	7.38	0.37	1.23e-12	Corneal structure;
LUSC	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.33	6.08	0.32	3.23e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs28595532	0.623	rs10016452	chr4:119277490	A/G	cg26518628	chr1:97050305	NA	-0.78	-6.07	-0.32	3.51e-9	Cannabis dependence symptom count;
LUSC	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.71	8.31	0.41	2.39e-15	Type 2 diabetes;
LUSC	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg13072238	chr3:49761600	GMPPB	-0.39	-6.36	-0.33	6.81e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg05343316	chr1:45956843	TESK2	0.65	8.88	0.44	4.17e-17	Platelet count;
LUSC	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg25237894	chr2:233734115	C2orf82	0.34	6.33	0.33	7.67e-10	Coronary artery disease;
LUSC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00166722	chr3:10149974	C3orf24	0.64	9.13	0.45	6.76e-18	Alzheimer's disease;
LUSC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg08017756	chr2:100939284	LONRF2	-0.47	-8.86	-0.44	4.94e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg21775007	chr8:11205619	TDH	-0.68	-10.68	-0.5	4.35e-23	Retinal vascular caliber;
LUSC	cis	rs2067615	0.524	rs10778505	chr12:107143126	G/C	cg15890332	chr12:107067104	RFX4	0.35	6.33	0.33	8.09e-10	Heart rate;
LUSC	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg20283391	chr11:68216788	NA	-0.6	-8.4	-0.42	1.25e-15	Total body bone mineral density;
LUSC	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg21681030	chr2:46777652	RHOQ	0.43	6.03	0.31	4.35e-9	Height;
LUSC	cis	rs714027	0.605	rs4820830	chr22:30531091	C/T	cg11564601	chr22:30592435	NA	-0.33	-5.85	-0.3	1.2e-8	Lymphocyte counts;
LUSC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg11843238	chr5:131593191	PDLIM4	-0.39	-6.37	-0.33	6.18e-10	Breast cancer;
LUSC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs9300255	0.679	rs4759420	chr12:123794871	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-5.77	-0.3	1.85e-8	Neutrophil percentage of white cells;
LUSC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg07741184	chr6:167504864	NA	0.36	6.53	0.34	2.47e-10	Crohn's disease;
LUSC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg14343924	chr8:8086146	FLJ10661	0.43	6.21	0.32	1.61e-9	Mood instability;
LUSC	cis	rs2414856	0.510	rs72756985	chr15:64590694	T/C	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3768617	0.811	rs12144261	chr1:183014148	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.59	0.43	3.46e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.57	10.46	0.5	2.43e-22	Bone mineral density;
LUSC	trans	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.55	-0.34	2.17e-10	Bladder cancer;
LUSC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.61e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg05585544	chr11:47624801	NA	-0.42	-7.31	-0.37	2.04e-12	Subjective well-being;
LUSC	cis	rs3820928	0.934	rs66959645	chr2:227761582	C/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.96	-0.4	2.72e-14	Pulmonary function;
LUSC	cis	rs4786125	0.879	rs11640468	chr16:6895945	C/T	cg03623568	chr16:6915990	A2BP1	-0.4	-6.65	-0.34	1.18e-10	Heart rate variability traits (SDNN);
LUSC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg07701084	chr6:150067640	NUP43	-0.5	-7.52	-0.38	5.2e-13	Lung cancer;
LUSC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg10792982	chr14:105748885	BRF1	0.48	8.93	0.44	2.87e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.63	-5.71	-0.3	2.47e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7011049	1.000	rs11985687	chr8:53832602	G/A	cg26025543	chr8:53854495	NA	0.51	6.25	0.32	1.25e-9	Systolic blood pressure;
LUSC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg09165964	chr15:75287851	SCAMP5	-1.07	-16.47	-0.67	4.95e-45	Blood trace element (Zn levels);
LUSC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg14552801	chr7:65878734	NA	0.45	6.43	0.33	4.5e-10	Aortic root size;
LUSC	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg18721089	chr20:30220636	NA	-0.34	-5.87	-0.31	1.06e-8	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.76	-0.35	5.99e-11	Monocyte percentage of white cells;
LUSC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg00343986	chr7:65444356	GUSB	0.43	6.54	0.34	2.29e-10	Aortic root size;
LUSC	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	8.37	0.42	1.64e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg03859395	chr2:55845619	SMEK2	0.82	14.43	0.62	4.94e-37	Metabolic syndrome;
LUSC	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.93	15.96	0.66	5.05e-43	Bladder cancer;
LUSC	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg25427524	chr10:38739819	LOC399744	0.39	6.42	0.33	4.8e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg05043794	chr9:111880884	C9orf5	-0.37	-7.9	-0.4	4.09e-14	Menarche (age at onset);
LUSC	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg23229984	chr5:148520753	ABLIM3	-0.41	-6.58	-0.34	1.8e-10	Breast cancer;
LUSC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	9.99	0.48	9.46e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg18681998	chr4:17616180	MED28	0.89	17.28	0.69	2.88e-48	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg02466173	chr16:30829666	NA	-0.52	-10.2	-0.49	1.98e-21	Dementia with Lewy bodies;
LUSC	cis	rs2070433	0.749	rs718496	chr21:47904585	A/C	cg12379764	chr21:47803548	PCNT	0.68	9.13	0.45	6.45e-18	Lymphocyte counts;
LUSC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg14895029	chr7:2775587	GNA12	-0.36	-5.71	-0.3	2.56e-8	Height;
LUSC	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg15654264	chr1:150340011	RPRD2	-0.61	-9.89	-0.48	2.11e-20	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.44	-0.33	4.18e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg26513180	chr16:89883248	FANCA	-0.88	-16.9	-0.68	9.89e-47	Vitiligo;
LUSC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg10755058	chr3:40428713	ENTPD3	0.35	5.76	0.3	1.9e-8	Renal cell carcinoma;
LUSC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-1.03	-17.11	-0.68	1.38e-47	Systemic lupus erythematosus;
LUSC	cis	rs4629180	0.917	rs34217240	chr2:102136682	G/A	cg01388757	chr2:102091195	RFX8	0.46	7.23	0.37	3.34e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs2637266	1.000	rs12783273	chr10:78353221	T/C	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg23093090	chr10:104574429	C10orf26	-0.47	-5.76	-0.3	1.93e-8	Arsenic metabolism;
LUSC	cis	rs1160297	0.609	rs1828336	chr2:53096937	G/T	cg07782112	chr2:53107842	NA	0.43	7.0	0.36	1.42e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.69	-6.52	-0.34	2.67e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg12463550	chr7:65579703	CRCP	-0.41	-5.84	-0.3	1.22e-8	Aortic root size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05206910	chr17:80230660	CSNK1D	0.39	6.04	0.31	4e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10779751	0.734	rs2039840	chr1:11125866	G/A	cg08854313	chr1:11322531	MTOR	0.81	12.1	0.55	3.52e-28	Body mass index;
LUSC	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.71	10.85	0.51	1.08e-23	Smoking initiation;
LUSC	cis	rs4654899	0.931	rs4654887	chr1:21234923	A/G	cg01072550	chr1:21505969	NA	0.52	8.06	0.4	1.35e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs12190007	0.547	rs3006217	chr6:169862878	A/G	ch.6.169577133F	chr6:169835210	NA	-0.4	-6.03	-0.31	4.35e-9	Obesity-related traits;
LUSC	cis	rs9837602	1.000	rs6790535	chr3:99807735	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-5.74	-0.3	2.1e-8	Breast cancer;
LUSC	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg03929089	chr4:120376271	NA	0.61	6.55	0.34	2.11e-10	D-dimer levels;
LUSC	cis	rs1953600	0.754	rs2573348	chr10:81925785	C/T	cg00277334	chr10:82204260	NA	-0.44	-6.92	-0.35	2.36e-11	Sarcoidosis;
LUSC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.92	-16.68	-0.67	7.22e-46	Cognitive function;
LUSC	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.59	-9.21	-0.45	3.62e-18	HDL cholesterol;
LUSC	cis	rs1178968	1.000	rs757939	chr7:72778108	T/C	cg25889504	chr7:72793014	NA	0.6	7.77	0.39	9.92e-14	Triglyceride levels;
LUSC	cis	rs9905704	0.918	rs430973	chr17:56709206	T/G	cg05425664	chr17:57184151	TRIM37	-0.42	-5.66	-0.3	3.22e-8	Testicular germ cell tumor;
LUSC	cis	rs2425143	1.000	rs2425078	chr20:34298163	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.6	-0.34	1.6e-10	Blood protein levels;
LUSC	cis	rs9443645	0.723	rs9343820	chr6:79480458	T/A	cg09184832	chr6:79620586	NA	-0.39	-5.89	-0.31	9.51e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.39	-0.56	2.93e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg20821713	chr7:1055600	C7orf50	-0.56	-7.36	-0.37	1.45e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs6723108	0.651	rs6724866	chr2:135407310	C/A	cg12500956	chr2:135428796	TMEM163	-0.27	-6.29	-0.33	9.76e-10	Type 2 diabetes;
LUSC	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg24558204	chr6:135376177	HBS1L	-0.61	-9.29	-0.45	2.02e-18	Red blood cell count;
LUSC	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg02997394	chr19:33096574	ANKRD27	0.83	8.89	0.44	3.93e-17	Eosinophilic esophagitis;
LUSC	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.61	-13.98	-0.61	2.7900000000000003e-35	Sense of smell;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24219704	chr12:107349641	C12orf23	-0.55	-6.36	-0.33	6.62e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg16414030	chr3:133502952	NA	-0.42	-6.55	-0.34	2.2e-10	Iron status biomarkers;
LUSC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	1.0	16.98	0.68	4.6e-47	Coronary artery disease;
LUSC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg18681998	chr4:17616180	MED28	0.84	15.39	0.64	9.38e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg24881330	chr22:46731750	TRMU	0.83	7.49	0.38	6.37e-13	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg17830980	chr10:43048298	ZNF37B	-0.52	-6.1	-0.32	2.96e-9	Obesity (extreme);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11636631	chr22:20428109	NA	-0.46	-6.54	-0.34	2.29e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6464929	0.956	rs28463009	chr7:148708203	G/C	cg23583168	chr7:148888333	NA	0.48	6.02	0.31	4.51e-9	Pediatric bone mineral content (hip);
LUSC	cis	rs7106204	0.702	rs11826172	chr11:24233998	G/A	ch.11.24196551F	chr11:24239977	NA	1.17	14.77	0.63	2.35e-38	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg23791538	chr6:167370224	RNASET2	0.41	6.69	0.34	9.3e-11	Crohn's disease;
LUSC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02187348	chr16:89574699	SPG7	0.59	9.47	0.46	5.16e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.11e-21	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg01620082	chr3:125678407	NA	-0.85	-7.28	-0.37	2.42e-12	Depression;
LUSC	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.52	0.34	2.54e-10	Lung cancer;
LUSC	cis	rs5758511	0.514	rs5758622	chr22:42563933	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.6	10.04	0.48	6.9299999999999992e-21	Birth weight;
LUSC	cis	rs1775715	0.707	rs2808081	chr10:32162342	C/T	cg18675610	chr10:32216311	ARHGAP12	-0.29	-6.32	-0.33	8.29e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.64	-9.82	-0.47	3.57e-20	Menarche (age at onset);
LUSC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.79	0.35	5.25e-11	Tonsillectomy;
LUSC	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg05343316	chr1:45956843	TESK2	0.67	8.96	0.44	2.29e-17	Platelet distribution width;
LUSC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	4.85e-15	Homoarginine levels;
LUSC	cis	rs7927771	0.524	rs10838763	chr11:47794802	C/T	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.18e-10	Subjective well-being;
LUSC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg19748678	chr4:122722346	EXOSC9	0.5	7.57	0.38	3.57e-13	Type 2 diabetes;
LUSC	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.52	7.86	0.4	5.19e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.54	-0.38	4.52e-13	Aortic root size;
LUSC	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg06606381	chr12:133084897	FBRSL1	-0.92	-8.91	-0.44	3.32e-17	Depression;
LUSC	cis	rs7617773	0.963	rs6766754	chr3:48182589	T/C	cg20734569	chr3:48348370	SPINK8	0.45	8.23	0.41	4.14e-15	Coronary artery disease;
LUSC	cis	rs1172822	0.698	rs2384690	chr19:55828794	C/G	cg04391588	chr19:55832610	TMEM150B	0.29	5.72	0.3	2.35e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs4589502	0.841	rs56401320	chr15:67140517	C/G	cg12317470	chr15:67143691	NA	0.66	6.43	0.33	4.51e-10	Lung cancer (smoking interaction);
LUSC	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.63	-0.34	1.3100000000000001e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs5758511	0.573	rs738248	chr22:42196467	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-7.52	-0.38	4.99e-13	Birth weight;
LUSC	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg21775007	chr8:11205619	TDH	-0.45	-6.49	-0.33	3.14e-10	Neuroticism;
LUSC	cis	rs4423214	0.879	rs1792281	chr11:71135496	G/A	cg05163923	chr11:71159392	DHCR7	-0.66	-8.58	-0.42	3.63e-16	Vitamin D levels;
LUSC	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg12292205	chr6:26970375	C6orf41	-0.63	-7.39	-0.37	1.23e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.48	8.02	0.4	1.79e-14	IgG glycosylation;
LUSC	cis	rs6494488	0.500	rs72744719	chr15:65018928	T/C	cg08069370	chr15:64387884	SNX1	-0.66	-5.78	-0.3	1.71e-8	Coronary artery disease;
LUSC	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg13334819	chr7:99746414	C7orf59	0.5	6.76	0.35	6e-11	Coronary artery disease;
LUSC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14893161	chr1:205819251	PM20D1	0.5	7.41	0.38	1.01e-12	Prostate-specific antigen levels;
LUSC	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07080220	chr10:102295463	HIF1AN	0.64	8.53	0.42	5.05e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg06606381	chr12:133084897	FBRSL1	0.58	6.7	0.34	9.02e-11	Depression;
LUSC	trans	rs72674100	1.000	rs1987173	chr4:97973574	G/C	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg08501292	chr6:25962987	TRIM38	0.66	5.92	0.31	7.96e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6460942	0.591	rs62451465	chr7:12364585	A/G	cg06484146	chr7:12443880	VWDE	-0.6	-6.44	-0.33	4.06e-10	Coronary artery disease;
LUSC	cis	rs4474465	1.000	rs10899517	chr11:78180507	A/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.71	-0.3	2.51e-8	Alzheimer's disease (survival time);
LUSC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.56	-0.34	2.01e-10	Electroencephalogram traits;
LUSC	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-6.36	-0.33	6.74e-10	Fear of minor pain;
LUSC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg25456477	chr12:86230367	RASSF9	0.42	7.4	0.38	1.11e-12	Major depressive disorder;
LUSC	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg27284194	chr4:1044797	NA	0.6	8.72	0.43	1.3e-16	Recombination rate (females);
LUSC	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg15605315	chr1:45957053	TESK2	-0.42	-6.88	-0.35	2.96e-11	High light scatter reticulocyte count;
LUSC	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.32	0.45	1.64e-18	Lung cancer in ever smokers;
LUSC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg16680214	chr1:154839983	KCNN3	-0.51	-9.7	-0.47	9.21e-20	Prostate cancer;
LUSC	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg09796270	chr17:17721594	SREBF1	0.43	7.57	0.38	3.78e-13	Total body bone mineral density;
LUSC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg05347473	chr6:146136440	FBXO30	0.55	9.47	0.46	5.36e-19	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.41	-0.33	4.96e-10	Blood trace element (Cu levels);
LUSC	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg11502198	chr6:26597334	ABT1	0.62	9.85	0.47	2.92e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs1018697	1.000	rs10786710	chr10:104548739	C/T	cg04362960	chr10:104952993	NT5C2	0.47	6.47	0.33	3.54e-10	Colorectal adenoma (advanced);
LUSC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg16070123	chr10:51489643	NA	-0.56	-9.4	-0.46	9.02e-19	Prostate-specific antigen levels;
LUSC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg18681998	chr4:17616180	MED28	0.84	15.65	0.65	8.27e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs41271473	1.000	rs6665334	chr1:228868574	A/C	cg16512390	chr1:228756714	NA	0.5	5.98	0.31	5.73e-9	Chronic lymphocytic leukemia;
LUSC	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg13010199	chr12:38710504	ALG10B	0.53	7.92	0.4	3.45e-14	Morning vs. evening chronotype;
LUSC	cis	rs2230307	0.536	rs554742	chr1:100512568	G/A	cg24955406	chr1:100503596	HIAT1	0.57	6.11	0.32	2.73e-9	Carotid intima media thickness;
LUSC	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg16576597	chr16:28551801	NUPR1	0.33	6.7	0.34	8.61e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg15848620	chr12:58087721	OS9	-0.48	-6.54	-0.34	2.26e-10	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg18825076	chr15:78729989	IREB2	-0.5	-7.77	-0.39	9.89e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.86	-12.5	-0.56	1.16e-29	Platelet count;
LUSC	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg23752985	chr2:85803571	VAMP8	0.33	7.06	0.36	9.49e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg06740227	chr12:86229804	RASSF9	-0.37	-5.86	-0.31	1.12e-8	Major depressive disorder;
LUSC	cis	rs73206853	0.764	rs56179460	chr12:111125774	C/G	cg12870014	chr12:110450643	ANKRD13A	0.68	6.52	0.34	2.55e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg17554472	chr22:41940697	POLR3H	0.48	5.95	0.31	6.68e-9	Vitiligo;
LUSC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg22437258	chr11:111473054	SIK2	0.46	6.12	0.32	2.63e-9	Primary sclerosing cholangitis;
LUSC	cis	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.55	-5.98	-0.31	5.87e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9283706	0.608	rs1428407	chr5:66330416	C/T	cg11590213	chr5:66331682	MAST4	0.47	6.85	0.35	3.64e-11	Coronary artery disease;
LUSC	cis	rs67366981	0.800	rs55939042	chr14:77691186	T/A	cg22824376	chr14:77648248	TMEM63C	0.76	7.15	0.36	5.64e-12	Obsessive-compulsive symptoms;
LUSC	cis	rs6901250	0.851	rs168128	chr6:117166865	A/G	cg12892004	chr6:117198278	RFX6	-0.44	-8.44	-0.42	9.93e-16	C-reactive protein levels;
LUSC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07677032	chr17:61819896	STRADA	0.57	9.3	0.45	1.9e-18	Prudent dietary pattern;
LUSC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	9.18	0.45	4.72e-18	Total body bone mineral density;
LUSC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg10018233	chr7:150070692	REPIN1	0.38	6.25	0.32	1.26e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6942756	0.806	rs6467240	chr7:128984018	T/C	cg02491457	chr7:128862824	NA	-0.51	-7.63	-0.39	2.46e-13	White matter hyperintensity burden;
LUSC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.61	-0.43	2.99e-16	Obesity-related traits;
LUSC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg23630131	chr7:65973040	NA	-0.2	-5.68	-0.3	2.97e-8	Aortic root size;
LUSC	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.86	-0.31	1.11e-8	Resting heart rate;
LUSC	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.83	-0.3	1.33e-8	Ileal carcinoids;
LUSC	trans	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg11887960	chr12:57824829	NA	0.54	6.7	0.34	8.71e-11	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg10909506	chr17:38081995	ORMDL3	0.33	5.83	0.3	1.28e-8	Self-reported allergy;
LUSC	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-1.02	-12.7	-0.57	2.08e-30	Blood pressure (smoking interaction);
LUSC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg00033643	chr7:134001901	SLC35B4	0.44	6.83	0.35	4.02e-11	Mean platelet volume;
LUSC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg22963979	chr7:1858916	MAD1L1	-0.54	-8.02	-0.4	1.84e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg22705602	chr4:152727874	NA	-0.39	-8.3	-0.41	2.54e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs708547	0.957	rs781667	chr4:57798469	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.48	-6.0	-0.31	5.25e-9	Response to bleomycin (chromatid breaks);
LUSC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	1.02	17.4	0.69	1e-48	Parkinson's disease;
LUSC	cis	rs12618769	0.625	rs3769736	chr2:99089119	C/T	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg22878388	chr2:105853796	NA	-0.33	-6.37	-0.33	6.25e-10	Type 2 diabetes;
LUSC	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.63	8.97	0.44	2.11e-17	Iron status biomarkers;
LUSC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg02782426	chr3:40428986	ENTPD3	0.32	6.31	0.33	8.92e-10	Renal cell carcinoma;
LUSC	trans	rs9473924	1.000	rs6922746	chr6:50889828	A/T	cg22375689	chr19:34175036	CHST8	0.38	6.15	0.32	2.2e-9	Body mass index;
LUSC	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-9.09	-0.45	9.13e-18	Response to antipsychotic treatment;
LUSC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg18230493	chr5:56204884	C5orf35	-0.64	-10.18	-0.49	2.32e-21	Coronary artery disease;
LUSC	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg10046767	chr12:53297693	KRT8	0.46	6.35	0.33	6.84e-10	Cancer (pleiotropy);
LUSC	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg25174290	chr11:3078921	CARS	-0.4	-5.84	-0.3	1.22e-8	Calcium levels;
LUSC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg24209194	chr3:40518798	ZNF619	-0.42	-5.72	-0.3	2.4e-8	Renal cell carcinoma;
LUSC	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg18827107	chr12:86230957	RASSF9	-0.42	-6.08	-0.32	3.35e-9	Major depressive disorder;
LUSC	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg19743168	chr1:23544995	NA	0.41	7.96	0.4	2.75e-14	Height;
LUSC	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	6.81	0.35	4.47e-11	Blood metabolite levels;
LUSC	trans	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.97	-0.31	6.18e-9	Dementia with Lewy bodies;
LUSC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	6.41	0.33	4.97e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2797685	0.898	rs2071987	chr1:7834026	G/A	cg04725166	chr1:7887271	PER3	-0.49	-6.47	-0.33	3.5e-10	Crohn's disease;
LUSC	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg03676636	chr4:99064102	C4orf37	0.36	7.99	0.4	2.18e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg18135555	chr8:22132992	PIWIL2	0.4	8.09	0.4	1.14e-14	Hypertriglyceridemia;
LUSC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg00857998	chr1:205179979	DSTYK	0.64	9.83	0.47	3.41e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7607369	0.559	rs4674342	chr2:219660064	T/C	cg02176678	chr2:219576539	TTLL4	-0.54	-9.62	-0.47	1.72e-19	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs9473147	0.516	rs1485780	chr6:47556630	A/C	cg02130027	chr6:47444894	CD2AP	0.35	5.7	0.3	2.68e-8	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg16575590	chr16:90015019	DEF8	0.39	6.1	0.32	2.98e-9	Schizophrenia;
LUSC	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-1.06	-12.75	-0.57	1.28e-30	Schizophrenia;
LUSC	cis	rs1395	0.922	rs4665376	chr2:27509032	T/C	cg23587288	chr2:27483067	SLC30A3	-0.3	-5.76	-0.3	1.9e-8	Blood metabolite levels;
LUSC	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-6.33	-0.33	7.7e-10	Menarche (age at onset);
LUSC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg19318889	chr4:1322082	MAEA	0.45	7.28	0.37	2.42e-12	Obesity-related traits;
LUSC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03517284	chr6:25882590	NA	-0.42	-7.13	-0.36	6.32e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6940638	1.000	rs12215773	chr6:27039233	T/C	cg09904177	chr6:26538194	HMGN4	-0.51	-5.91	-0.31	8.36e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg13565492	chr6:43139072	SRF	-0.56	-6.01	-0.31	4.81e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.52	7.37	0.37	1.32e-12	Tonsillectomy;
LUSC	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg13575925	chr12:9217583	LOC144571	0.34	6.42	0.33	4.59e-10	Sjögren's syndrome;
LUSC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.78	11.54	0.53	3.86e-26	Corneal astigmatism;
LUSC	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg20587970	chr11:113659929	NA	-1.27	-17.35	-0.69	1.62e-48	Hip circumference adjusted for BMI;
LUSC	cis	rs2688608	0.933	rs2688614	chr10:75652876	G/A	cg17411546	chr10:75410026	SYNPO2L	-0.47	-6.86	-0.35	3.41e-11	Inflammatory bowel disease;
LUSC	cis	rs16867321	0.853	rs73023563	chr2:181502830	C/T	cg23363182	chr2:181467187	NA	-0.45	-5.92	-0.31	7.98e-9	Obesity;
LUSC	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg16339924	chr4:17578868	LAP3	-0.55	-8.12	-0.41	9.25e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg21951975	chr1:209979733	IRF6	0.57	6.87	0.35	3.14e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg21890820	chr11:65308645	LTBP3	0.49	7.16	0.36	5.14e-12	Bone mineral density;
LUSC	cis	rs9638182	0.636	rs6968170	chr7:73020676	G/A	cg07452164	chr7:72993570	TBL2	0.49	6.91	0.35	2.52e-11	Triglycerides;
LUSC	cis	rs9399401	0.921	rs4637667	chr6:142794021	C/A	cg03128060	chr6:142623767	GPR126	0.33	5.87	0.31	1.03e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	6.87	0.35	3.15e-11	Bipolar disorder;
LUSC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg03060546	chr3:49711283	APEH	-0.7	-11.65	-0.54	1.46e-26	Resting heart rate;
LUSC	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg03585969	chr10:35415529	CREM	0.6	8.8	0.43	7.41e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9677476	0.863	rs4637098	chr2:232075528	C/T	cg07929768	chr2:232055508	NA	0.35	6.78	0.35	5.58e-11	Food antigen IgG levels;
LUSC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg16049864	chr8:95962084	TP53INP1	0.46	7.83	0.39	6.64e-14	Type 2 diabetes;
LUSC	trans	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg10756647	chr7:56101905	PSPH	0.87	8.84	0.44	5.54e-17	Diabetic kidney disease;
LUSC	cis	rs909341	0.710	rs3848669	chr20:62300811	G/T	cg16989086	chr20:62203971	PRIC285	-0.53	-7.34	-0.37	1.62e-12	Atopic dermatitis;
LUSC	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg03806693	chr22:41940476	POLR3H	-0.55	-7.46	-0.38	7.78e-13	Neuroticism;
LUSC	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg01097406	chr16:89675127	NA	0.47	9.61	0.47	1.83e-19	Vitiligo;
LUSC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	6.28	0.33	1.04e-9	Parkinson's disease;
LUSC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-7.87	-0.4	5.01e-14	Major depressive disorder;
LUSC	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg03929089	chr4:120376271	NA	0.7	7.63	0.39	2.43e-13	Axial length;
LUSC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.16	0.45	5.42e-18	Prudent dietary pattern;
LUSC	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg05855489	chr10:104503620	C10orf26	0.53	8.09	0.4	1.1e-14	Arsenic metabolism;
LUSC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg08088566	chr11:430123	ANO9	0.72	7.77	0.39	9.65e-14	Body mass index;
LUSC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	0.92	15.42	0.64	7.18e-41	Breast cancer;
LUSC	cis	rs4853525	0.859	rs11897136	chr2:191711080	C/T	cg11845111	chr2:191398756	TMEM194B	-0.39	-5.87	-0.31	1.07e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06285766	chr7:77167210	PTPN12	-0.42	-6.35	-0.33	7.03e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.92	-9.02	-0.44	1.5e-17	Lung cancer in ever smokers;
LUSC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.65	0.86	4.24e-99	Chronic sinus infection;
LUSC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.31	-0.33	9.03e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg09092052	chr15:45571596	NA	0.46	6.34	0.33	7.51e-10	Glomerular filtration rate;
LUSC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg08470875	chr2:26401718	FAM59B	-0.66	-8.71	-0.43	1.42e-16	Gut microbiome composition (summer);
LUSC	trans	rs72674100	1.000	rs28457587	chr4:97991521	T/C	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg11244672	chr19:19639970	YJEFN3	-0.59	-6.98	-0.36	1.64e-11	Bipolar disorder;
LUSC	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg08501292	chr6:25962987	TRIM38	0.65	5.85	0.31	1.15e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04267008	chr7:1944627	MAD1L1	-0.44	-6.52	-0.34	2.58e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg14791747	chr16:20752902	THUMPD1	0.72	9.58	0.46	2.35e-19	Cognitive test performance;
LUSC	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg24562669	chr7:97807699	LMTK2	0.47	8.39	0.42	1.41e-15	Breast cancer;
LUSC	trans	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg26043149	chr18:55253948	FECH	-0.45	-6.89	-0.35	2.86e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs116988415	0.584	rs4899145	chr14:65241867	G/A	cg25083366	chr14:65239357	SPTB	0.66	6.37	0.33	6.41e-10	Daytime sleep phenotypes;
LUSC	cis	rs686320	1.000	rs1194758	chr11:65238085	A/T	cg21890820	chr11:65308645	LTBP3	-0.74	-7.64	-0.39	2.26e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg25319279	chr11:5960081	NA	-0.45	-6.33	-0.33	7.89e-10	DNA methylation (variation);
LUSC	cis	rs11958404	0.932	rs72816598	chr5:157436017	G/A	cg05962755	chr5:157440814	NA	0.53	6.3	0.33	9.34e-10	IgG glycosylation;
LUSC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg27535305	chr1:53392650	SCP2	-0.39	-7.36	-0.37	1.43e-12	Monocyte count;
LUSC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	0.92	16.06	0.66	2.14e-43	Menopause (age at onset);
LUSC	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg08017756	chr2:100939284	LONRF2	-0.38	-6.58	-0.34	1.8e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.16	-0.32	2.06e-9	Response to antipsychotic treatment;
LUSC	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg00049323	chr5:472564	LOC25845	-0.41	-6.15	-0.32	2.17e-9	Cystic fibrosis severity;
LUSC	cis	rs17253792	0.822	rs10483650	chr14:56145312	A/G	cg01858014	chr14:56050164	KTN1	-0.79	-6.72	-0.35	7.8e-11	Putamen volume;
LUSC	cis	rs7712401	0.562	rs401729	chr5:122264285	G/T	cg19077854	chr5:122220652	SNX24	0.41	8.93	0.44	2.84e-17	Mean platelet volume;
LUSC	cis	rs73206853	0.841	rs73206870	chr12:110819953	T/C	cg12870014	chr12:110450643	ANKRD13A	0.67	6.46	0.33	3.72e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs10754283	0.967	rs7552896	chr1:90103194	A/G	cg21401794	chr1:90099060	LRRC8C	0.65	9.85	0.47	3.02e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg00898013	chr13:113819073	PROZ	-0.59	-8.79	-0.43	8.06e-17	Platelet distribution width;
LUSC	cis	rs10465746	1.000	rs10465746	chr1:84387632	T/G	cg10977910	chr1:84465055	TTLL7	0.43	6.35	0.33	7.05e-10	Obesity-related traits;
LUSC	cis	rs73206853	0.764	rs56273026	chr12:110901691	A/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg17366294	chr4:99064904	C4orf37	-0.56	-10.11	-0.48	3.97e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs16854884	0.657	rs35193361	chr3:143716420	A/G	cg06585982	chr3:143692056	C3orf58	0.45	6.73	0.35	7.59e-11	Economic and political preferences (feminism/equality);
LUSC	trans	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	13.77	0.6	1.75e-34	Exhaled nitric oxide levels;
LUSC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg11812906	chr14:75593930	NEK9	-0.62	-10.45	-0.5	2.6e-22	Height;
LUSC	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	0.96	14.34	0.62	1.14e-36	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg17173187	chr15:85201210	NMB	0.46	8.73	0.43	1.26e-16	Schizophrenia;
LUSC	cis	rs1124376	1.000	rs17006623	chr3:20161043	G/T	cg05072819	chr3:20081367	KAT2B	0.56	6.26	0.32	1.19e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg10756647	chr7:56101905	PSPH	0.86	8.36	0.42	1.7e-15	Diabetic kidney disease;
LUSC	trans	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.0	-0.36	1.39e-11	Subjective well-being;
LUSC	cis	rs12618769	0.652	rs3754878	chr2:99179384	G/A	cg10123293	chr2:99228465	UNC50	0.47	7.44	0.38	8.51e-13	Bipolar disorder;
LUSC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg06212747	chr3:49208901	KLHDC8B	0.43	5.86	0.31	1.1e-8	Parkinson's disease;
LUSC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	0.92	17.99	0.7	4.46e-51	Cognitive function;
LUSC	cis	rs6906287	0.647	rs59671368	chr6:118911430	T/A	cg21191810	chr6:118973309	C6orf204	0.32	5.96	0.31	6.47e-9	Electrocardiographic conduction measures;
LUSC	trans	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg10756647	chr7:56101905	PSPH	0.85	8.47	0.42	7.94e-16	Gout;
LUSC	cis	rs422249	0.547	rs102275	chr11:61557803	T/C	cg19610905	chr11:61596333	FADS2	-0.54	-8.34	-0.42	1.98e-15	Trans fatty acid levels;
LUSC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-7.12	-0.36	6.46e-12	Alzheimer's disease (late onset);
LUSC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg05623727	chr3:50126028	RBM5	-0.31	-5.86	-0.31	1.09e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg24625240	chr11:126081434	RPUSD4;FAM118B	0.5	6.2	0.32	1.7e-9	Cognitive function;Information processing speed;
LUSC	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg24011408	chr12:48396354	COL2A1	-0.4	-5.78	-0.3	1.67e-8	Glycated hemoglobin levels;
LUSC	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg24556660	chr7:106842632	COG5;HBP1	-0.44	-5.68	-0.3	2.95e-8	Coronary artery disease;
LUSC	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.83	-0.43	6.08e-17	Response to antipsychotic treatment;
LUSC	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg19920283	chr7:105172520	RINT1	0.57	6.08	0.32	3.34e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg11812906	chr14:75593930	NEK9	0.66	11.26	0.52	3.87e-25	Height;
LUSC	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg22532475	chr10:104410764	TRIM8	-0.38	-8.19	-0.41	5.55e-15	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg12365402	chr11:9010492	NRIP3	0.44	7.63	0.39	2.51e-13	Hemoglobin concentration;
LUSC	trans	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	7.0	0.36	1.39e-11	Myopia (pathological);
LUSC	cis	rs870825	0.860	rs28799091	chr4:185598594	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	12.67	0.57	2.58e-30	Blood protein levels;
LUSC	cis	rs1143633	0.615	rs11687403	chr2:113643638	G/A	cg06156847	chr2:113672199	IL1F7	0.28	5.83	0.3	1.34e-8	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg13852791	chr20:30311386	BCL2L1	0.95	14.9	0.63	7.51e-39	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs3772130	0.962	rs6789736	chr3:121543084	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.24	0.49	1.44e-21	Cognitive performance;
LUSC	cis	rs6977660	0.714	rs9969381	chr7:19827454	C/T	cg07541023	chr7:19748670	TWISTNB	0.59	6.01	0.31	4.9e-9	Thyroid stimulating hormone;
LUSC	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg05625103	chr10:2543513	NA	0.39	5.65	0.3	3.52e-8	Age-related hearing impairment;
LUSC	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg00376283	chr12:123451042	ABCB9	-0.64	-7.38	-0.37	1.27e-12	Neutrophil percentage of white cells;
LUSC	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg24558204	chr6:135376177	HBS1L	0.57	8.37	0.42	1.63e-15	Red blood cell count;
LUSC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg01802117	chr1:53393560	SCP2	0.39	6.37	0.33	6.36e-10	Monocyte count;
LUSC	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg11812906	chr14:75593930	NEK9	-0.54	-8.74	-0.43	1.16e-16	Coronary artery disease;
LUSC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg06238570	chr21:40685208	BRWD1	0.48	7.49	0.38	6.36e-13	Cognitive function;
LUSC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.06	0.31	3.63e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg16240275	chr20:61666158	NCRNA00029	0.42	9.23	0.45	3.14e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg04352962	chr1:209979756	IRF6	0.56	6.63	0.34	1.35e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-8.52	-0.42	5.59e-16	Personality dimensions;
LUSC	cis	rs7681440	0.647	rs11941682	chr4:90804316	T/G	cg20003494	chr4:90757398	SNCA	-0.36	-5.99	-0.31	5.54e-9	Dementia with Lewy bodies;
LUSC	trans	rs1459104	0.714	rs35789111	chr11:54926634	C/G	cg03929089	chr4:120376271	NA	0.74	6.24	0.32	1.36e-9	Body mass index;
LUSC	cis	rs6469656	1.000	rs6980504	chr8:117680269	T/C	cg24004040	chr8:117650383	NA	-0.45	-6.48	-0.33	3.3e-10	Colorectal cancer;
LUSC	cis	rs7527798	0.592	rs6657161	chr1:207847128	C/T	cg09232269	chr1:207846808	CR1L	-0.29	-6.23	-0.32	1.37e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs3812111	0.510	rs1931892	chr6:116594511	A/C	cg18828861	chr6:116576566	TSPYL4	0.38	6.78	0.35	5.48e-11	Age-related macular degeneration;
LUSC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg19318889	chr4:1322082	MAEA	0.58	10.04	0.48	6.88e-21	Longevity;
LUSC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	7.32	0.37	1.83e-12	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.59	-0.38	3.23e-13	Height;
LUSC	cis	rs9650315	0.929	rs35093016	chr8:57161412	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.07	0.36	9.07e-12	Height;
LUSC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13770153	chr20:60521292	NA	-0.61	-8.19	-0.41	5.59e-15	Body mass index;
LUSC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg14552801	chr7:65878734	NA	0.38	5.9	0.31	8.97e-9	Aortic root size;
LUSC	cis	rs2348418	0.864	rs7968563	chr12:28716777	T/C	cg13890972	chr12:28721907	NA	-0.34	-5.81	-0.3	1.49e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.52	7.71	0.39	1.48e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.6	-9.13	-0.45	6.57e-18	Colorectal cancer;
LUSC	cis	rs4478137	0.931	rs7665672	chr4:164236875	G/A	cg06758707	chr4:164254230	NPY1R	0.63	9.93	0.48	1.52e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs7804356	1.000	rs3801805	chr7:26897640	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.23	-0.32	1.41e-9	Type 1 diabetes;
LUSC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg13397359	chr6:42928475	GNMT	0.58	9.78	0.47	4.8e-20	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs877282	0.898	rs12357995	chr10:765739	T/C	cg17470449	chr10:769945	NA	0.53	7.09	0.36	8.21e-12	Uric acid levels;
LUSC	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.8	-11.57	-0.53	3.01e-26	Exhaled nitric oxide output;
LUSC	cis	rs6942756	0.680	rs691555	chr7:129135770	C/T	cg02491457	chr7:128862824	NA	-0.38	-5.71	-0.3	2.47e-8	White matter hyperintensity burden;
LUSC	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg03806693	chr22:41940476	POLR3H	0.87	12.52	0.57	9.53e-30	Vitiligo;
LUSC	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.68	-10.62	-0.5	6.91e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs16854884	0.657	rs62269895	chr3:143749085	C/G	cg06585982	chr3:143692056	C3orf58	0.5	7.81	0.39	7.3e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg11062466	chr8:58055876	NA	-0.68	-9.08	-0.45	9.4e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.94	0.4	3.02e-14	Parkinson's disease;
LUSC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs735539	0.645	rs7995773	chr13:21251235	T/C	cg04906043	chr13:21280425	IL17D	-0.46	-7.58	-0.38	3.41e-13	Dental caries;
LUSC	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08645402	chr16:4508243	NA	-0.42	-7.06	-0.36	9.91e-12	Schizophrenia;
LUSC	cis	rs3099143	1.000	rs2063542	chr15:77149498	A/G	cg21673338	chr15:77095150	SCAPER	-0.81	-7.57	-0.38	3.61e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg20476274	chr7:133979776	SLC35B4	-0.77	-13.01	-0.58	1.39e-31	Mean platelet volume;
LUSC	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg13010199	chr12:38710504	ALG10B	0.69	10.8	0.51	1.55e-23	Morning vs. evening chronotype;
LUSC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg06145435	chr7:1022769	CYP2W1	0.34	5.71	0.3	2.49e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg27144592	chr16:783916	NARFL	0.36	5.64	0.3	3.54e-8	Height;
LUSC	trans	rs72674100	1.000	rs7689769	chr4:97968142	G/A	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg03859395	chr2:55845619	SMEK2	0.85	15.74	0.65	3.82e-42	Metabolic syndrome;
LUSC	cis	rs7179456	0.544	rs2555357	chr15:59087115	A/G	cg05156742	chr15:59063176	FAM63B	0.56	9.1	0.45	8.59e-18	Asperger disorder;
LUSC	cis	rs79911532	0.515	rs79663210	chr7:75684326	G/A	cg03592824	chr7:75666768	STYXL1	0.69	6.81	0.35	4.46e-11	Mononucleosis;
LUSC	cis	rs16986825	0.664	rs5997409	chr22:29222096	T/C	cg02153584	chr22:29168773	CCDC117	0.52	6.32	0.33	8.43e-10	Pancreatic cancer;
LUSC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	5.8	0.3	1.52e-8	Schizophrenia;
LUSC	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg25456477	chr12:86230367	RASSF9	-0.32	-5.69	-0.3	2.83e-8	Major depressive disorder;
LUSC	cis	rs12824058	0.707	rs2398509	chr12:130816464	T/C	cg23887609	chr12:130822674	PIWIL1	0.45	6.35	0.33	6.92e-10	Menopause (age at onset);
LUSC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19346786	chr7:2764209	NA	-0.42	-7.02	-0.36	1.26e-11	Height;
LUSC	trans	rs1927790	0.643	rs1475296	chr13:97004273	T/C	cg03198741	chr6:1003969	LOC285768	-0.41	-6.22	-0.32	1.5e-9	Body mass index;
LUSC	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.78	-0.3	1.75e-8	IgG glycosylation;
LUSC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg19592336	chr6:28129416	ZNF389	0.46	6.38	0.33	5.9e-10	Parkinson's disease;
LUSC	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg11766577	chr21:47581405	C21orf56	-0.41	-6.12	-0.32	2.67e-9	Testicular germ cell tumor;
LUSC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03264133	chr6:25882463	NA	-0.5	-9.11	-0.45	7.67e-18	Blood metabolite levels;
LUSC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06634786	chr22:41940651	POLR3H	0.49	5.7	0.3	2.6e-8	Vitiligo;
LUSC	cis	rs17095355	0.539	rs3890722	chr10:111925233	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.55	-6.37	-0.33	6.14e-10	Biliary atresia;
LUSC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg13114125	chr14:105738426	BRF1	-0.92	-15.77	-0.65	2.85e-42	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.38	4.39e-13	Morning vs. evening chronotype;
LUSC	trans	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg25214090	chr10:38739885	LOC399744	0.46	6.7	0.34	8.74e-11	Corneal astigmatism;
LUSC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg00334542	chr7:100209784	MOSPD3	-0.48	-5.94	-0.31	7.31e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs34734847	0.703	rs7978125	chr12:121167039	A/G	cg21892295	chr12:121157589	UNC119B	-0.35	-6.08	-0.32	3.37e-9	Mean corpuscular volume;
LUSC	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg09998033	chr7:158218633	PTPRN2	-0.52	-8.34	-0.42	1.98e-15	Obesity-related traits;
LUSC	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg05343316	chr1:45956843	TESK2	0.63	8.52	0.42	5.62e-16	Platelet count;
LUSC	cis	rs73198271	0.603	rs546606	chr8:8595843	A/G	cg01851573	chr8:8652454	MFHAS1	0.41	6.16	0.32	2.12e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.6	-0.43	3.15e-16	Body mass index;
LUSC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.74	11.19	0.52	6.82e-25	Type 2 diabetes;
LUSC	cis	rs17253792	0.822	rs2147114	chr14:56077118	C/T	cg01858014	chr14:56050164	KTN1	-0.86	-6.79	-0.35	5.08e-11	Putamen volume;
LUSC	cis	rs6929568	1.000	rs9406109	chr6:8221425	C/T	cg05398487	chr6:8064678	MUTED	-0.39	-5.82	-0.3	1.35e-8	Coronary artery calcification;
LUSC	cis	rs9837602	0.872	rs1489816	chr3:99769088	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	6.06	0.31	3.73e-9	Breast cancer;
LUSC	cis	rs6596100	0.538	rs67504728	chr5:132194045	G/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.06	-0.31	3.73e-9	Breast cancer;
LUSC	cis	rs870825	0.616	rs6852082	chr4:185645783	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs10489525	0.599	rs17033129	chr1:115611539	C/T	cg01522456	chr1:115632236	TSPAN2	0.49	6.76	0.35	6.21e-11	Autism;
LUSC	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.19	0.59	2.82e-32	Blood protein levels;
LUSC	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-6.75	-0.35	6.71e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs13092825	1.000	rs74803054	chr3:113281370	A/T	cg18753928	chr3:113234510	CCDC52	-0.38	-5.65	-0.3	3.5e-8	Dental caries;
LUSC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-7.66	-0.39	2.01e-13	Alzheimer's disease (late onset);
LUSC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg03948781	chr1:205179583	DSTYK	0.32	6.17	0.32	1.94e-9	Red blood cell count;
LUSC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg04369109	chr6:150039330	LATS1	-0.57	-8.4	-0.42	1.29e-15	Lung cancer;
LUSC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.61	8.09	0.4	1.1e-14	High light scatter reticulocyte count;
LUSC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg08027265	chr7:2291960	NA	-0.38	-6.26	-0.32	1.19e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7799006	0.634	rs34502289	chr7:2311266	G/A	cg12823233	chr7:2316876	SNX8	-0.44	-7.35	-0.37	1.52e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9549260	0.664	rs1360719	chr13:41225874	G/C	cg21288729	chr13:41239152	FOXO1	0.65	10.04	0.48	6.48e-21	Red blood cell count;
LUSC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.69	-10.69	-0.5	3.87e-23	Aortic root size;
LUSC	cis	rs2279817	0.818	rs34036216	chr1:17986046	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.03	-0.31	4.32e-9	Neuroticism;
LUSC	cis	rs6543140	0.964	rs918000	chr2:103067862	C/T	cg09003973	chr2:102972529	NA	0.51	6.61	0.34	1.53e-10	Blood protein levels;
LUSC	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.03	-0.31	4.33e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg09904177	chr6:26538194	HMGN4	0.68	12.21	0.56	1.35e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs72634258	0.554	rs4562654	chr1:7934423	A/T	cg26816564	chr1:7831052	VAMP3	0.72	9.39	0.46	9.85e-19	Inflammatory bowel disease;
LUSC	trans	rs12200782	1.000	rs3800304	chr6:26598798	G/A	cg11837749	chr1:55047332	ACOT11	0.57	6.0	0.31	5.01e-9	Small cell lung carcinoma;
LUSC	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21659725	chr3:3221576	CRBN	-0.64	-10.44	-0.5	2.97e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg12927641	chr6:109611667	NA	-0.35	-5.87	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	trans	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg10756647	chr7:56101905	PSPH	-0.87	-8.68	-0.43	1.74e-16	Diabetic kidney disease;
LUSC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24110177	chr3:50126178	RBM5	0.63	11.06	0.52	1.89e-24	Body mass index;
LUSC	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg18190219	chr22:46762943	CELSR1	-0.57	-6.29	-0.33	9.73e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.71	-11.1	-0.52	1.44e-24	Menarche (age at onset);
LUSC	cis	rs62400317	0.859	rs6919813	chr6:45159177	C/T	cg20913747	chr6:44695427	NA	-0.48	-7.62	-0.38	2.67e-13	Total body bone mineral density;
LUSC	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg07148914	chr20:33460835	GGT7	0.56	8.53	0.42	5.25e-16	Height;
LUSC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-10.46	-0.5	2.44e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg24690094	chr11:67383802	NA	0.41	8.16	0.41	6.97e-15	Mean corpuscular volume;
LUSC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-9.82	-0.47	3.77e-20	Bipolar disorder;
LUSC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.44	-0.5	2.9e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg11279151	chr3:101281821	RG9MTD1	0.39	5.74	0.3	2.13e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10276381	0.786	rs73300665	chr7:28227024	G/A	cg23620719	chr7:28220237	JAZF1	0.64	6.92	0.35	2.34e-11	Crohn's disease;
LUSC	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.58	0.6	9.51e-34	Morning vs. evening chronotype;
LUSC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg16339924	chr4:17578868	LAP3	0.55	8.43	0.42	1.04e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg01802117	chr1:53393560	SCP2	0.38	6.3	0.33	9.42e-10	Monocyte count;
LUSC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg16647868	chr5:131706066	SLC22A5	0.34	5.7	0.3	2.64e-8	Blood metabolite levels;
LUSC	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg02086790	chr16:375327	AXIN1	-0.4	-6.18	-0.32	1.83e-9	Bone mineral density (spine);Bone mineral density;
LUSC	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.83	0.51	1.22e-23	Morning vs. evening chronotype;
LUSC	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg04362960	chr10:104952993	NT5C2	0.59	9.34	0.46	1.42e-18	Arsenic metabolism;
LUSC	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg24375607	chr4:120327624	NA	0.76	11.09	0.52	1.51e-24	Corneal astigmatism;
LUSC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg26441486	chr22:50317300	CRELD2	0.54	8.21	0.41	4.9e-15	Schizophrenia;
LUSC	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg05784532	chr1:230284198	GALNT2	0.5	7.59	0.38	3.26e-13	Coronary artery disease;
LUSC	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg09835421	chr16:68378352	PRMT7	-0.55	-6.17	-0.32	2e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.49	-8.26	-0.41	3.38e-15	Lymphocyte counts;
LUSC	cis	rs9549260	0.753	rs9549238	chr13:41179321	G/A	cg21288729	chr13:41239152	FOXO1	0.53	5.96	0.31	6.31e-9	Red blood cell count;
LUSC	cis	rs9472414	0.510	rs227840	chr6:44686304	C/G	cg20913747	chr6:44695427	NA	-0.4	-5.85	-0.3	1.16e-8	Height;
LUSC	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.21	0.32	1.54e-9	Total body bone mineral density;
LUSC	cis	rs911119	0.955	rs6048945	chr20:23602228	C/T	cg16589663	chr20:23618590	CST3	0.59	7.08	0.36	8.56e-12	Chronic kidney disease;
LUSC	trans	rs2018683	0.584	rs4722880	chr7:28999197	C/T	cg19402173	chr7:128379420	CALU	-0.51	-7.55	-0.38	4.11e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	7.16	0.36	5.05e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs3862435	0.764	rs6496681	chr15:91051011	C/T	cg22089800	chr15:90895588	ZNF774	-0.56	-6.02	-0.31	4.67e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg05347473	chr6:146136440	FBXO30	0.58	10.14	0.49	3.06e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7202877	0.561	rs9933956	chr16:75362813	T/C	cg04384234	chr16:75411784	CFDP1	-0.65	-9.25	-0.45	2.69e-18	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs4718428	1.000	rs4718421	chr7:66350300	C/T	cg18252515	chr7:66147081	NA	-0.39	-5.78	-0.3	1.72e-8	Corneal structure;
LUSC	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.97	-0.61	2.98e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg09307838	chr4:120376055	NA	0.75	10.98	0.51	3.78e-24	Corneal astigmatism;
LUSC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg06027949	chr8:82754900	SNX16	0.43	5.81	0.3	1.43e-8	Diastolic blood pressure;
LUSC	cis	rs4474465	1.000	rs11237499	chr11:78163164	A/T	cg27205649	chr11:78285834	NARS2	-0.51	-5.99	-0.31	5.49e-9	Alzheimer's disease (survival time);
LUSC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-6.44	-0.33	4.08e-10	Aortic root size;
LUSC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg13939156	chr17:80058883	NA	-0.32	-6.36	-0.33	6.6e-10	Life satisfaction;
LUSC	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.72	9.71	0.47	8.5e-20	Response to bleomycin (chromatid breaks);
LUSC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg26752003	chr8:145688521	CYHR1	0.45	7.32	0.37	1.9e-12	Age at first birth;
LUSC	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.78	-12.52	-0.57	9.61e-30	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.67	-11.42	-0.53	1e-25	Dental caries;
LUSC	trans	rs4553720	0.896	rs4383250	chr18:62177797	A/T	cg17502984	chr6:80714315	TTK	0.47	6.37	0.33	6.42e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LUSC	cis	rs17021463	0.902	rs62320439	chr4:95248721	G/C	cg11021082	chr4:95130006	SMARCAD1	0.42	7.6	0.38	3.04e-13	Testicular germ cell tumor;
LUSC	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.32	0.45	1.66e-18	Bipolar disorder;
LUSC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg22907277	chr7:1156413	C7orf50	0.68	7.31	0.37	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05901451	chr6:126070800	HEY2	0.57	8.56	0.42	4.05e-16	Endometrial cancer;
LUSC	trans	rs10016947	0.826	rs7679745	chr4:104266305	C/T	cg02356640	chr11:1501973	HCCA2	0.69	5.98	0.31	5.79e-9	Breast cancer;
LUSC	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg09184832	chr6:79620586	NA	-0.44	-7.2	-0.37	3.94e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg03732007	chr1:2071316	PRKCZ	0.55	9.83	0.47	3.38e-20	Height;
LUSC	cis	rs11585357	0.895	rs34324150	chr1:17632464	C/G	cg08277548	chr1:17600880	PADI3	-0.59	-6.19	-0.32	1.72e-9	Hair shape;
LUSC	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.28	-0.59	1.35e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1712517	0.740	rs11191663	chr10:105118462	C/T	cg05636881	chr10:105038444	INA	0.41	6.75	0.35	6.73e-11	Migraine;
LUSC	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.24	-0.37	3.09e-12	Bipolar disorder;
LUSC	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg17420585	chr12:42539391	GXYLT1	-0.33	-6.39	-0.33	5.65e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7577696	0.785	rs2294179	chr2:32354005	G/A	cg02381751	chr2:32503542	YIPF4	-0.44	-6.22	-0.32	1.46e-9	Inflammatory biomarkers;
LUSC	cis	rs3820928	0.839	rs13398103	chr2:227859693	T/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.52	-0.38	5.01e-13	Pulmonary function;
LUSC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg13683864	chr3:40499215	RPL14	-1.13	-21.68	-0.76	1.11e-65	Renal cell carcinoma;
LUSC	trans	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg25214090	chr10:38739885	LOC399744	0.41	6.34	0.33	7.47e-10	Corneal astigmatism;
LUSC	cis	rs12478296	0.534	rs67092377	chr2:243002171	T/G	cg06360820	chr2:242988706	NA	-0.65	-8.17	-0.41	6.6e-15	Obesity-related traits;
LUSC	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	1.01	15.27	0.64	2.72e-40	Corneal structure;
LUSC	cis	rs6489882	0.867	rs6489869	chr12:113363922	A/C	cg20102336	chr12:113376681	OAS3	-0.41	-5.89	-0.31	9.59e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs2386661	0.547	rs57893347	chr10:5646191	G/A	cg17085576	chr10:5658249	NA	-0.43	-6.42	-0.33	4.72e-10	Breast cancer;
LUSC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg15790184	chr11:494944	RNH1	0.5	5.75	0.3	2.01e-8	Body mass index;
LUSC	cis	rs4785763	0.570	rs4785759	chr16:90050880	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.57	-9.09	-0.45	9.19e-18	Melanoma;
LUSC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg18827107	chr12:86230957	RASSF9	-0.5	-7.41	-0.38	1.05e-12	Major depressive disorder;
LUSC	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg07169764	chr2:136633963	MCM6	-0.6	-7.93	-0.4	3.27e-14	Mosquito bite size;
LUSC	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-7.95	-0.4	2.87e-14	Axial length;
LUSC	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg23093090	chr10:104574429	C10orf26	-0.37	-5.86	-0.31	1.1e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.21	0.37	3.85e-12	Platelet count;
LUSC	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg11846333	chr4:119757529	SEC24D	0.87	6.18	0.32	1.88e-9	Cannabis dependence symptom count;
LUSC	cis	rs7789940	0.809	rs12533836	chr7:75935622	G/T	cg15798862	chr7:76129360	DTX2	-0.49	-7.99	-0.4	2.14e-14	Multiple sclerosis;
LUSC	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg20026190	chr17:76395443	PGS1	0.33	5.79	0.3	1.63e-8	HDL cholesterol levels;
LUSC	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg01420254	chr6:26195488	NA	0.7	7.46	0.38	7.56e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11645453	chr3:52864694	ITIH4	0.33	7.61	0.38	2.76e-13	Bipolar disorder;
LUSC	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg19875535	chr5:140030758	IK	0.47	7.62	0.38	2.66e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg01557791	chr16:72042693	DHODH	-0.6	-9.7	-0.47	9.44e-20	Prostate cancer;
LUSC	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.82	-12.73	-0.57	1.56e-30	Body mass index;
LUSC	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	8.84	0.44	5.69e-17	Lung cancer;
LUSC	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	0.7	11.24	0.52	4.43e-25	Blood metabolite ratios;
LUSC	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg12573674	chr2:1569213	NA	-0.64	-8.84	-0.44	5.53e-17	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs73206853	0.841	rs16940885	chr12:110971666	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.59	-6.38	-0.33	5.85e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-8.96	-0.44	2.37e-17	Metabolite levels;
LUSC	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg26513180	chr16:89883248	FANCA	-0.55	-8.09	-0.4	1.1e-14	Vitiligo;
LUSC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg09877947	chr5:131593287	PDLIM4	-0.58	-9.66	-0.47	1.21e-19	Acylcarnitine levels;
LUSC	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.01	-0.4	1.89e-14	Glomerular filtration rate;
LUSC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	1.01	18.96	0.72	6.39e-55	Cognitive function;
LUSC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg00647820	chr17:40259828	DHX58	0.49	6.74	0.35	7.06e-11	Fibrinogen levels;
LUSC	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg20701182	chr2:24300061	SF3B14	0.57	6.02	0.31	4.55e-9	Lymphocyte counts;
LUSC	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg00484396	chr16:3507460	NAT15	-0.45	-7.51	-0.38	5.39e-13	Body mass index (adult);
LUSC	cis	rs68149176	0.772	rs61527026	chr16:87878783	C/G	cg03553613	chr16:87879502	SLC7A5	-0.45	-5.78	-0.3	1.69e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-0.94	-16.22	-0.66	5.01e-44	Height;
LUSC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	0.92	15.74	0.65	3.76e-42	Menopause (age at onset);
LUSC	cis	rs806215	1.000	rs712700	chr7:127250907	T/C	cg25922125	chr7:127225783	GCC1	0.57	7.17	0.37	4.96e-12	Type 2 diabetes;
LUSC	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg05973401	chr12:123451056	ABCB9	0.55	6.81	0.35	4.68e-11	Neutrophil percentage of white cells;
LUSC	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg12365402	chr11:9010492	NRIP3	-0.42	-7.54	-0.38	4.54e-13	Hemoglobin concentration;
LUSC	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg22532475	chr10:104410764	TRIM8	-0.34	-6.7	-0.34	9.02e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.58	-0.42	3.63e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg03461704	chr1:205818484	PM20D1	0.39	6.69	0.34	9.32e-11	Menarche (age at onset);
LUSC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.44	-6.49	-0.33	3.07e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs977987	0.778	rs12445726	chr16:75465575	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.52	0.46	3.5e-19	Dupuytren's disease;
LUSC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-10.74	-0.51	2.52e-23	Coffee consumption (cups per day);
LUSC	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg15790184	chr11:494944	RNH1	0.42	6.4	0.33	5.37e-10	Systemic lupus erythematosus;
LUSC	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg00071950	chr4:10020882	SLC2A9	0.46	7.63	0.39	2.53e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7681440	0.538	rs2737015	chr4:90745283	T/C	cg06632027	chr4:90757378	SNCA	-0.36	-5.74	-0.3	2.17e-8	Dementia with Lewy bodies;
LUSC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-11.26	-0.52	3.88e-25	Systemic lupus erythematosus;
LUSC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg27535305	chr1:53392650	SCP2	-0.46	-9.07	-0.44	1.05e-17	Monocyte count;
LUSC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4746822	0.954	rs5030938	chr10:70975916	A/G	cg14418922	chr10:70824840	NA	0.38	6.29	0.33	1.02e-9	Glycemic traits (pregnancy);
LUSC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	6.11	0.32	2.7e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg27284194	chr4:1044797	NA	0.6	8.85	0.44	5.26e-17	Recombination rate (females);
LUSC	cis	rs12541635	0.934	rs62527400	chr8:107054229	G/A	cg10147462	chr8:107024639	NA	0.55	9.92	0.48	1.69e-20	Age of smoking initiation;
LUSC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23158103	chr7:148848205	ZNF398	-0.45	-6.87	-0.35	3.25e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg25019033	chr10:957182	NA	0.48	5.89	0.31	9.33e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs7043114	0.563	rs10820988	chr9:95317008	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.35	-6.27	-0.32	1.11e-9	Height;
LUSC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.25	0.52	4.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg00071950	chr4:10020882	SLC2A9	0.53	8.85	0.44	5.07e-17	Bone mineral density;
LUSC	cis	rs7635838	0.654	rs347585	chr3:11286220	C/T	cg00170343	chr3:11313890	ATG7	0.5	7.54	0.38	4.38e-13	HDL cholesterol;
LUSC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.65	13.71	0.6	3.03e-34	Monocyte percentage of white cells;
LUSC	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	0.97	15.48	0.65	3.82e-41	Dupuytren's disease;
LUSC	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg01689657	chr7:91764605	CYP51A1	-0.32	-5.86	-0.31	1.14e-8	Breast cancer;
LUSC	cis	rs10170846	0.789	rs972650	chr2:223520287	C/T	cg25565276	chr2:223520875	FARSB	0.64	9.7	0.47	9.46e-20	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg05585544	chr11:47624801	NA	-0.41	-7.24	-0.37	3.11e-12	Subjective well-being;
LUSC	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.84	-0.39	6.14e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7582720	1.000	rs7560547	chr2:203757916	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23158103	chr7:148848205	ZNF398	-0.45	-7.11	-0.36	7.26e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9612	1.000	rs346523	chr19:44260681	A/C	cg08581076	chr19:44259116	C19orf61	0.53	6.71	0.34	8.22e-11	Exhaled nitric oxide output;
LUSC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg03146154	chr1:46216737	IPP	0.52	7.55	0.38	4.2e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg07460842	chr6:66804631	NA	0.47	5.81	0.3	1.47e-8	Metabolite levels;
LUSC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-8.81	-0.43	7.03e-17	Chronic sinus infection;
LUSC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg26408565	chr15:76604113	ETFA	-0.52	-8.39	-0.42	1.4e-15	Blood metabolite levels;
LUSC	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg11584989	chr19:19387371	SF4	-0.62	-7.26	-0.37	2.72e-12	Bipolar disorder;
LUSC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.38	-0.42	1.45e-15	Obesity-related traits;
LUSC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg04111992	chr7:158790115	NA	-0.44	-7.0	-0.36	1.38e-11	Facial morphology (factor 20);
LUSC	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.02	0.31	4.62e-9	Recombination rate (females);
LUSC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg15448220	chr1:150897856	SETDB1	0.38	5.69	0.3	2.84e-8	Tonsillectomy;
LUSC	cis	rs2625529	0.824	rs12595464	chr15:72294398	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.44	-0.38	8.7e-13	Red blood cell count;
LUSC	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.0	-0.4	2.03e-14	Systolic blood pressure;
LUSC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg12311346	chr5:56204834	C5orf35	-0.61	-9.35	-0.46	1.32e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs2742417	0.935	rs2742393	chr3:45757417	T/A	cg09608765	chr3:45636137	LIMD1	-0.37	-7.42	-0.38	9.87e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg14552801	chr7:65878734	NA	-0.43	-5.97	-0.31	6.01e-9	Aortic root size;
LUSC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.6	0.5	8.15e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6977660	1.000	rs10260360	chr7:19792824	T/C	cg05791153	chr7:19748676	TWISTNB	0.63	7.02	0.36	1.24e-11	Thyroid stimulating hormone;
LUSC	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg00540400	chr15:79124168	NA	0.45	7.83	0.39	6.34e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs6740322	0.748	rs6544636	chr2:43487486	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-6.47	-0.33	3.44e-10	Coronary artery disease;
LUSC	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg03036452	chr22:46663545	TTC38	0.65	5.89	0.31	9.28e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.06e-12	Motion sickness;
LUSC	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg26528668	chr16:1614120	IFT140	0.46	7.64	0.39	2.35e-13	Coronary artery disease;
LUSC	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg13010199	chr12:38710504	ALG10B	0.55	8.27	0.41	3.16e-15	Morning vs. evening chronotype;
LUSC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	0.94	18.8	0.72	2.63e-54	Cognitive function;
LUSC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.74	-0.51	2.52e-23	Alzheimer's disease (late onset);
LUSC	cis	rs6977660	0.660	rs13225400	chr7:19817016	A/G	cg05791153	chr7:19748676	TWISTNB	0.67	7.1	0.36	7.78e-12	Thyroid stimulating hormone;
LUSC	cis	rs1163251	0.623	rs493427	chr1:120207482	A/T	cg19096424	chr1:120255104	PHGDH	-0.43	-6.0	-0.31	5.21e-9	Blood metabolite levels;
LUSC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg06636001	chr8:8085503	FLJ10661	0.67	10.87	0.51	9.25e-24	Neuroticism;
LUSC	cis	rs68170813	0.641	rs79434636	chr7:107105656	A/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.6	-0.46	1.99e-19	Coronary artery disease;
LUSC	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.53	-0.42	5.09e-16	Total cholesterol levels;
LUSC	cis	rs2219968	0.756	rs10283381	chr8:78922806	G/A	cg00738934	chr8:78996279	NA	-0.42	-7.55	-0.38	4.26e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	10.95	0.51	4.92e-24	Lung cancer in ever smokers;
LUSC	cis	rs11039100	0.607	rs11038962	chr11:5781339	C/T	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7584330	0.554	rs10183995	chr2:238433307	G/A	cg16989719	chr2:238392110	NA	-0.39	-5.69	-0.3	2.79e-8	Prostate cancer;
LUSC	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg14196790	chr5:131705035	SLC22A5	0.52	8.63	0.43	2.57e-16	Blood metabolite levels;
LUSC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	8.27	0.41	3.22e-15	Height;
LUSC	cis	rs10979	1.000	rs9386037	chr6:143891950	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-11.93	-0.55	1.41e-27	Hypospadias;
LUSC	cis	rs7575217	0.697	rs796067	chr2:101707009	C/T	cg23907051	chr2:101730305	TBC1D8	-0.29	-7.68	-0.39	1.81e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg09307838	chr4:120376055	NA	0.68	9.61	0.47	1.83e-19	Corneal astigmatism;
LUSC	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg18196295	chr10:418757	DIP2C	-0.47	-7.76	-0.39	1.04e-13	Psychosis in Alzheimer's disease;
LUSC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05535760	chr7:792225	HEATR2	0.79	9.53	0.46	3.23e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs4343996	0.967	rs4722674	chr7:3357188	C/G	cg21248987	chr7:3385318	SDK1	-0.39	-6.58	-0.34	1.83e-10	Motion sickness;
LUSC	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.46	-0.46	5.76e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21643547	chr1:205240462	TMCC2	-0.53	-10.18	-0.49	2.21e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg08270630	chr22:50330655	NA	0.44	6.67	0.34	1.05e-10	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09920549	chr4:2264324	MXD4	-0.4	-6.02	-0.31	4.65e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.63	9.8	0.47	4.22e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.55	-8.73	-0.43	1.28e-16	Personality dimensions;
LUSC	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg25206134	chr2:45395956	NA	0.57	6.52	0.34	2.6200000000000003e-10	Bipolar disorder;
LUSC	cis	rs9420	0.961	rs7949841	chr11:57524700	G/C	cg02958346	chr11:57425731	CLP1	-0.44	-6.44	-0.33	4.22e-10	Schizophrenia;
LUSC	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg18131467	chr2:239335373	ASB1	0.93	17.94	0.7	6.81e-51	Multiple system atrophy;
LUSC	cis	rs2742234	0.590	rs2435338	chr10:43642115	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.36	-0.37	1.49e-12	Hirschsprung disease;
LUSC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4664308	0.905	rs7567781	chr2:160999537	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-11.58	-0.54	2.79e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06634786	chr22:41940651	POLR3H	0.53	6.19	0.32	1.79e-9	Vitiligo;
LUSC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.23	-14.22	-0.61	3.4e-36	Gout;
LUSC	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg12826209	chr6:26865740	GUSBL1	0.76	6.5	0.33	2.98e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.24	-0.41	3.86e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.57	7.72	0.39	1.36e-13	High light scatter reticulocyte count;
LUSC	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg04287289	chr16:89883240	FANCA	-0.39	-6.02	-0.31	4.52e-9	Vitiligo;
LUSC	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg03060546	chr3:49711283	APEH	0.64	6.96	0.36	1.76e-11	Menarche (age at onset);
LUSC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg18479299	chr3:125709523	NA	-0.51	-5.83	-0.3	1.33e-8	Blood pressure (smoking interaction);
LUSC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg10523860	chr14:103875565	MARK3	-0.38	-6.15	-0.32	2.24e-9	Body mass index;
LUSC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	0.88	15.06	0.64	1.84e-39	Tonsillectomy;
LUSC	cis	rs10504229	0.500	rs9772760	chr8:57986999	G/C	cg21724239	chr8:58056113	NA	0.42	5.64	0.3	3.55e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.73	10.36	0.49	5.62e-22	Corneal astigmatism;
LUSC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg23649088	chr2:200775458	C2orf69	0.58	7.15	0.36	5.63e-12	Schizophrenia;
LUSC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg08499158	chr17:42289980	UBTF	0.49	8.36	0.42	1.68e-15	Total body bone mineral density;
LUSC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg23887609	chr12:130822674	PIWIL1	0.48	7.05	0.36	1.04e-11	Menopause (age at onset);
LUSC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg12310025	chr6:25882481	NA	-0.39	-6.35	-0.33	7.08e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg15445000	chr17:37608096	MED1	0.4	6.75	0.35	6.65e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs72781680	0.716	rs2712056	chr2:23959131	C/T	cg08917208	chr2:24149416	ATAD2B	0.61	6.8	0.35	4.74e-11	Lymphocyte counts;
LUSC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2692947	0.800	rs4332959	chr2:96549121	C/T	cg22654517	chr2:96458247	NA	0.37	7.19	0.37	4.37e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg01416388	chr22:39784598	NA	-0.43	-6.66	-0.34	1.12e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs10266483	0.774	rs56055804	chr7:63870801	G/T	cg24201672	chr7:64023550	ZNF680	0.5	6.1	0.32	2.88e-9	Response to statin therapy;
LUSC	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.43	-0.59	3.39e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs12677056	0.739	rs4876463	chr8:113315064	C/A	cg12159992	chr12:102059490	MYBPC1	0.36	6.01	0.31	4.84e-9	Peripheral artery disease;
LUSC	cis	rs6977940	0.598	rs73033411	chr7:2881550	G/C	cg19731401	chr7:2775893	GNA12	0.73	9.53	0.46	3.37e-19	White matter integrity;
LUSC	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.72	-8.39	-0.42	1.36e-15	Refractive error;
LUSC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	0.92	13.16	0.58	3.76e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg08017756	chr2:100939284	LONRF2	-0.45	-8.46	-0.42	8.2e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg17385448	chr1:15911702	AGMAT	0.37	6.23	0.32	1.41e-9	Systolic blood pressure;
LUSC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21545522	chr1:205238299	TMCC2	0.5	9.36	0.46	1.19e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg24060327	chr5:131705240	SLC22A5	0.53	8.78	0.43	8.63e-17	Acylcarnitine levels;
LUSC	cis	rs10875746	0.855	rs12296244	chr12:48441479	C/G	cg13454099	chr12:49076203	C12orf41	-0.5	-5.7	-0.3	2.69e-8	Longevity (90 years and older);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08578305	chr12:25403937	KRAS	-0.4	-6.03	-0.31	4.26e-9	Electrocardiographic conduction measures;
LUSC	cis	rs13082711	0.911	rs77037289	chr3:27512971	C/T	cg02860705	chr3:27208620	NA	0.49	8.2	0.41	5.1e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	10.04	0.48	6.69e-21	Bone mineral density;
LUSC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg09035930	chr12:129282057	SLC15A4	0.65	13.29	0.59	1.2e-32	Systemic lupus erythematosus;
LUSC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	11.1	0.52	1.44e-24	Alzheimer's disease;
LUSC	cis	rs225245	0.782	rs321599	chr17:33905745	C/T	cg05299278	chr17:33885742	SLFN14	0.31	6.9	0.35	2.68e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs4285028	0.699	rs7637495	chr3:121573850	C/T	cg11130432	chr3:121712080	ILDR1	-0.65	-9.83	-0.47	3.45e-20	Multiple sclerosis;
LUSC	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg08355456	chr11:67383691	NA	0.37	6.83	0.35	3.96e-11	Mean corpuscular volume;
LUSC	cis	rs28595532	0.800	rs114321375	chr4:119341663	G/A	cg02775129	chr4:119771670	NA	-0.76	-6.33	-0.33	7.84e-10	Cannabis dependence symptom count;
LUSC	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.62	-5.79	-0.3	1.59e-8	Major depressive disorder;
LUSC	cis	rs4780401	0.632	rs8055462	chr16:11834821	T/C	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.36	-0.42	1.69e-15	Rheumatoid arthritis;
LUSC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.79	12.74	0.57	1.48e-30	Aortic root size;
LUSC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg11608241	chr8:8085544	FLJ10661	0.41	5.75	0.3	2.06e-8	Mood instability;
LUSC	trans	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg21659725	chr3:3221576	CRBN	0.71	8.51	0.42	5.77e-16	Menarche (age at onset);
LUSC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-8.27	-0.41	3.23e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs599083	0.793	rs471966	chr11:68173861	C/T	cg01657329	chr11:68192670	LRP5	0.51	7.71	0.39	1.44e-13	Bone mineral density (spine);
LUSC	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg03713592	chr11:72463424	ARAP1	0.75	8.86	0.44	4.75e-17	Type 2 diabetes;
LUSC	trans	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	8.81	0.43	7.1e-17	Type 2 diabetes;
LUSC	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg23840854	chr1:161414152	NA	-0.92	-11.2	-0.52	6.13e-25	Rheumatoid arthritis;
LUSC	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg21053147	chr12:120880522	NA	-0.48	-5.93	-0.31	7.76e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs9815354	1.000	rs1716661	chr3:41962818	C/T	cg03022575	chr3:42003672	ULK4	-0.51	-5.82	-0.3	1.41e-8	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg17120908	chr11:65337727	SSSCA1	-0.53	-9.36	-0.46	1.21e-18	Bone mineral density;
LUSC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-6.02	-0.31	4.66e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg18247339	chr14:35183597	CFL2	0.48	6.19	0.32	1.72e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs981844	0.725	rs872453	chr4:154727131	T/C	cg14289246	chr4:154710475	SFRP2	0.44	5.82	0.3	1.38e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs9463078	0.547	rs34907292	chr6:44729708	A/G	cg25276700	chr6:44698697	NA	0.3	6.3	0.33	9.28e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-9.3	-0.45	1.95e-18	Morning vs. evening chronotype;
LUSC	cis	rs7106204	0.541	rs75552854	chr11:24231824	G/A	ch.11.24196551F	chr11:24239977	NA	1.0	9.14	0.45	6e-18	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs432925	0.600	rs214249	chr16:348687	T/G	cg08823186	chr16:347294	AXIN1	0.35	6.15	0.32	2.21e-9	Morning vs. evening chronotype;
LUSC	cis	rs11924390	0.749	rs822364	chr3:186452716	A/G	cg12454167	chr3:186435060	KNG1	0.29	7.56	0.38	3.97e-13	Adiponectin levels;
LUSC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg08999081	chr20:33150536	PIGU	0.44	8.14	0.41	7.93e-15	Coronary artery disease;
LUSC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg16325326	chr1:53192061	ZYG11B	-0.91	-16.87	-0.68	1.29e-46	Monocyte count;
LUSC	cis	rs3849570	0.922	rs3772895	chr3:81769493	A/G	cg07356753	chr3:81810745	GBE1	-0.7	-11.43	-0.53	9.49e-26	Waist circumference;Body mass index;
LUSC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	1.04	19.81	0.74	2.6e-58	Menopause (age at onset);
LUSC	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg26924012	chr15:45694286	SPATA5L1	1.1	19.12	0.72	1.38e-55	Homoarginine levels;
LUSC	cis	rs7945718	0.967	rs7930077	chr11:12778769	C/T	cg25843174	chr11:12811716	TEAD1	0.31	6.99	0.36	1.48e-11	Educational attainment (years of education);
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01585723	chr16:33734837	NA	0.46	7.82	0.39	6.81e-14	Menopause (age at onset);
LUSC	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg02997394	chr19:33096574	ANKRD27	0.83	9.61	0.47	1.89e-19	Eosinophilic esophagitis;
LUSC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.94	-19.27	-0.73	3.78e-56	Post bronchodilator FEV1;
LUSC	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	13.14	0.58	4.42e-32	Lymphocyte percentage of white cells;
LUSC	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg04362960	chr10:104952993	NT5C2	0.62	9.62	0.47	1.71e-19	Arsenic metabolism;
LUSC	cis	rs4654899	0.655	rs4654883	chr1:21213708	C/T	cg01072550	chr1:21505969	NA	0.5	7.63	0.39	2.41e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26314531	chr2:26401878	FAM59B	-0.68	-9.19	-0.45	4.28e-18	Gut microbiome composition (summer);
LUSC	trans	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg26043149	chr18:55253948	FECH	0.47	7.16	0.36	5.05e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg00745463	chr17:30367425	LRRC37B	0.78	8.68	0.43	1.8e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs13082711	0.871	rs35572617	chr3:27499247	A/T	cg02860705	chr3:27208620	NA	0.51	8.66	0.43	2.03e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs11166629	1.000	rs6981735	chr8:135635730	T/C	cg21672855	chr8:135614777	ZFAT	0.37	5.93	0.31	7.49e-9	Smoking quantity;
LUSC	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg12564285	chr5:131593104	PDLIM4	-0.38	-6.32	-0.33	8.55e-10	Blood metabolite levels;
LUSC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.35	0.56	4.17e-29	Motion sickness;
LUSC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg20203395	chr5:56204925	C5orf35	-0.7	-9.78	-0.47	4.82e-20	Initial pursuit acceleration;
LUSC	cis	rs6545883	0.811	rs2921718	chr2:61795267	C/A	cg15711740	chr2:61764176	XPO1	-0.47	-7.53	-0.38	4.93e-13	Tuberculosis;
LUSC	cis	rs6815814	0.861	rs28690449	chr4:38789132	C/T	cg06935464	chr4:38784597	TLR10	0.46	5.85	0.3	1.15e-8	Breast cancer;
LUSC	cis	rs4964805	0.865	rs35371470	chr12:104203720	C/G	cg02344784	chr12:104178138	NT5DC3	0.41	6.45	0.33	3.93e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg24829409	chr8:58192753	C8orf71	-0.61	-6.57	-0.34	1.94e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs977987	0.836	rs8055974	chr16:75470986	C/G	cg04384234	chr16:75411784	CFDP1	-0.42	-7.0	-0.36	1.38e-11	Dupuytren's disease;
LUSC	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg02389323	chr16:88786976	FAM38A	0.87	9.42	0.46	7.52e-19	Plateletcrit;
LUSC	cis	rs9463078	0.547	rs764397	chr6:44710771	C/A	cg25276700	chr6:44698697	NA	0.3	6.2	0.32	1.66e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24291776	chr10:1034677	GTPBP4	-0.48	-6.38	-0.33	6.04e-10	Hepatitis;
LUSC	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.27	0.59	1.47e-32	Blood protein levels;
LUSC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.61	0.34	1.55e-10	Lung cancer;
LUSC	cis	rs5753037	0.813	rs9614100	chr22:30288339	A/T	cg11564601	chr22:30592435	NA	0.33	5.84	0.3	1.21e-8	Type 1 diabetes;
LUSC	cis	rs9341835	0.740	rs7763834	chr6:64149357	T/C	cg03326410	chr6:64151739	NA	-0.37	-6.13	-0.32	2.53e-9	Schizophrenia;
LUSC	cis	rs12530845	0.943	rs55889179	chr7:135331631	C/T	cg23117316	chr7:135346802	PL-5283	-0.58	-9.63	-0.47	1.55e-19	Red blood cell traits;
LUSC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02187348	chr16:89574699	SPG7	0.61	9.9	0.48	1.91e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg18230493	chr5:56204884	C5orf35	-0.55	-8.61	-0.43	2.9e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs6723226	0.750	rs10182170	chr2:32704186	G/A	cg02381751	chr2:32503542	YIPF4	0.62	9.45	0.46	5.93e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg00999904	chr2:3704751	ALLC	-0.43	-6.67	-0.34	1.06e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.45	-0.33	3.95e-10	Uric acid levels;
LUSC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.54	-8.46	-0.42	8.5e-16	Personality dimensions;
LUSC	cis	rs2637266	0.507	rs2451911	chr10:78283023	T/C	cg18941641	chr10:78392320	NA	0.31	5.75	0.3	1.97e-8	Pulmonary function;
LUSC	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg19875535	chr5:140030758	IK	0.46	7.32	0.37	1.91e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg05347473	chr6:146136440	FBXO30	0.38	6.1	0.32	2.98e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	13.17	0.58	3.48e-32	Platelet count;
LUSC	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	6.08	0.32	3.28e-9	Neuroticism;
LUSC	cis	rs3744061	0.557	rs9907925	chr17:74646293	G/A	cg27546012	chr17:74684504	MXRA7	-0.37	-6.4	-0.33	5.36e-10	Retinal arteriolar caliber;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg04246999	chr16:71930048	KIAA0174	0.39	6.08	0.32	3.3e-9	N-glycan levels;
LUSC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg25036284	chr2:26402008	FAM59B	-0.68	-9.51	-0.46	3.97e-19	Gut microbiome composition (summer);
LUSC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg03188948	chr7:1209495	NA	0.66	6.93	0.35	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.53	0.34	2.38e-10	Bipolar disorder;
LUSC	cis	rs35000415	0.938	rs12535158	chr7:128625019	C/T	cg19972273	chr7:128594194	NA	0.68	6.9	0.35	2.56e-11	Systemic lupus erythematosus;
LUSC	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.5	0.34	2.86e-10	Schizophrenia;
LUSC	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.86	14.0	0.61	2.4e-35	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg16339924	chr4:17578868	LAP3	0.57	8.63	0.43	2.51e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg13319975	chr6:146136371	FBXO30	0.47	7.23	0.37	3.28e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05901451	chr6:126070800	HEY2	0.57	8.56	0.42	4.23e-16	Endometrial cancer;
LUSC	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg07959070	chr22:50026188	C22orf34	-0.34	-6.98	-0.36	1.59e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg21064579	chr19:49206444	FUT2	0.45	8.61	0.43	2.84e-16	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
LUSC	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-7.04	-0.36	1.1e-11	Response to antipsychotic treatment;
LUSC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg18230493	chr5:56204884	C5orf35	-0.93	-13.72	-0.6	2.66e-34	Initial pursuit acceleration;
LUSC	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.84	-0.35	3.74e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg05347473	chr6:146136440	FBXO30	0.51	8.49	0.42	6.84e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7851660	0.967	rs13288000	chr9:100608980	A/G	cg13688889	chr9:100608707	NA	-0.61	-10.7	-0.51	3.65e-23	Strep throat;
LUSC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	7.03	0.36	1.19e-11	Height;
LUSC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg22907277	chr7:1156413	C7orf50	0.68	7.36	0.37	1.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg05082376	chr22:42548792	NA	0.43	6.59	0.34	1.73e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg00255919	chr5:131827918	IRF1	0.43	8.28	0.41	3.11e-15	Asthma (sex interaction);
LUSC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-1.08	-19.9	-0.74	1.14e-58	Coronary artery disease;
LUSC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg13114125	chr14:105738426	BRF1	-0.91	-15.93	-0.66	7.02e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg05805236	chr11:65401703	PCNXL3	-0.56	-9.1	-0.45	8.47e-18	Acne (severe);
LUSC	cis	rs17407555	0.647	rs55811736	chr4:10014221	G/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-6.15	-0.32	2.2e-9	Schizophrenia (age at onset);
LUSC	cis	rs10100465	0.883	rs10283125	chr8:118644818	A/G	cg09430518	chr8:118662568	NA	-0.3	-5.9	-0.31	8.92e-9	Leprosy;
LUSC	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.61	-0.34	1.53e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.56	0.53	3.14e-26	Menopause (age at onset);
LUSC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg11102782	chr19:18549136	ISYNA1	-0.37	-6.96	-0.36	1.83e-11	Breast cancer;
LUSC	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.57	8.97	0.44	2.12e-17	Schizophrenia;
LUSC	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.36	6.35	0.33	6.91e-10	Depressive symptoms;
LUSC	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.74	-12.74	-0.57	1.45e-30	Bipolar disorder;
LUSC	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg03433033	chr1:76189801	ACADM	-0.43	-6.24	-0.32	1.33e-9	Daytime sleep phenotypes;
LUSC	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.73	14.19	0.61	4.47e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7215564	0.908	rs35128297	chr17:78652909	A/C	cg23238734	chr17:78661607	RPTOR	0.48	6.13	0.32	2.5e-9	Myopia (pathological);
LUSC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg03538708	chr1:25844672	NA	-0.36	-5.97	-0.31	5.96e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg05234568	chr11:5960015	NA	-0.57	-8.29	-0.41	2.82e-15	DNA methylation (variation);
LUSC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg12751644	chr20:60527061	NA	-0.35	-6.07	-0.32	3.43e-9	Body mass index;
LUSC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.59	-9.61	-0.47	1.87e-19	Aortic root size;
LUSC	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg13010199	chr12:38710504	ALG10B	0.7	11.97	0.55	1.04e-27	Heart rate;
LUSC	cis	rs2070997	0.667	rs7869508	chr9:133716802	T/C	cg11464064	chr9:133710261	ABL1	0.48	5.65	0.3	3.47e-8	Response to amphetamines;
LUSC	cis	rs7000551	0.725	rs1075534	chr8:22374074	A/G	cg12081754	chr8:22256438	SLC39A14	0.42	6.42	0.33	4.67e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg23093090	chr10:104574429	C10orf26	-0.43	-7.67	-0.39	1.86e-13	Arsenic metabolism;
LUSC	cis	rs1035144	0.505	rs6574617	chr14:81457615	G/A	cg06600135	chr14:81408086	NA	-0.61	-8.72	-0.43	1.29e-16	Male sexual orientation;
LUSC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.15	0.58	4.24e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg23985595	chr17:80112537	CCDC57	-0.33	-6.5	-0.33	2.99e-10	Life satisfaction;
LUSC	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg23711669	chr6:146136114	FBXO30	0.71	12.38	0.56	3.16e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.73	-12.51	-0.56	1.07e-29	Height;
LUSC	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg15997130	chr1:24165203	NA	-0.37	-5.72	-0.3	2.36e-8	Immature fraction of reticulocytes;
LUSC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs10979	1.000	rs11155300	chr6:143894576	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-12.25	-0.56	9.15e-29	Hypospadias;
LUSC	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg20933634	chr6:27740509	NA	0.4	5.87	0.31	1.06e-8	Parkinson's disease;
LUSC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg15445000	chr17:37608096	MED1	-0.41	-7.02	-0.36	1.21e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs1967309	0.604	rs8061182	chr16:4070333	A/G	cg00061520	chr16:4070371	ADCY9	0.4	8.23	0.41	4.37e-15	Response to Dalcetrapib treatment in acute coronary syndrome;
LUSC	cis	rs2179367	0.600	rs9498354	chr6:149762851	A/G	cg07828024	chr6:149772892	ZC3H12D	0.33	5.72	0.3	2.4e-8	Dupuytren's disease;
LUSC	cis	rs9616064	0.506	rs3747255	chr22:47074281	G/A	cg25730555	chr22:47059586	GRAMD4	0.46	7.0	0.36	1.4e-11	Urate levels in obese individuals;
LUSC	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-7.93	-0.4	3.4e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg12863693	chr15:85201151	NMB	-0.25	-5.74	-0.3	2.12e-8	P wave terminal force;
LUSC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg02951883	chr7:2050386	MAD1L1	0.48	8.65	0.43	2.26e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs859767	0.501	rs6724777	chr2:135407292	C/T	cg12500956	chr2:135428796	TMEM163	-0.27	-6.29	-0.33	9.76e-10	Neuroticism;
LUSC	cis	rs868036	0.958	rs11635424	chr15:68037578	C/T	cg08079166	chr15:68083412	MAP2K5	0.41	8.31	0.41	2.51e-15	Restless legs syndrome;
LUSC	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.7	-12.03	-0.55	6.24e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs354225	0.597	rs10176445	chr2:54845776	G/C	cg01766943	chr2:54829624	SPTBN1	0.48	7.74	0.39	1.19e-13	Schizophrenia;
LUSC	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg24631222	chr15:78858424	CHRNA5	-0.67	-9.05	-0.44	1.25e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17043366	chr19:8578907	ZNF414	-0.43	-6.54	-0.34	2.33e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg20503657	chr10:835505	NA	-0.46	-6.63	-0.34	1.37e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg05805236	chr11:65401703	PCNXL3	-0.38	-5.78	-0.3	1.73e-8	Breast cancer;
LUSC	trans	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg06636001	chr8:8085503	FLJ10661	0.43	6.31	0.33	8.77e-10	Retinal vascular caliber;
LUSC	cis	rs11971779	0.680	rs6965212	chr7:139026465	G/T	cg07862535	chr7:139043722	LUC7L2	0.59	7.35	0.37	1.58e-12	Diisocyanate-induced asthma;
LUSC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg00815214	chr21:47717953	NA	-0.36	-5.95	-0.31	6.76e-9	Testicular germ cell tumor;
LUSC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22496380	chr5:211416	CCDC127	-0.71	-8.12	-0.41	9.34e-15	Breast cancer;
LUSC	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.69e-9	Response to antipsychotic treatment;
LUSC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03576123	chr11:487126	PTDSS2	-0.96	-10.61	-0.5	7.48e-23	Body mass index;
LUSC	trans	rs6480314	0.542	rs61854805	chr10:70015583	A/G	cg04882175	chr6:131122610	NA	-0.55	-6.21	-0.32	1.59e-9	Optic nerve measurement (disc area);
LUSC	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg01256987	chr12:42539512	GXYLT1	0.35	6.4	0.33	5.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg05585544	chr11:47624801	NA	-0.41	-7.12	-0.36	6.69e-12	Subjective well-being;
LUSC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.69	-11.41	-0.53	1.12e-25	Heart rate;
LUSC	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg05973401	chr12:123451056	ABCB9	-0.56	-8.12	-0.41	9.2e-15	Platelet count;
LUSC	cis	rs887829	0.570	rs10203266	chr2:234596368	G/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.22	-0.32	1.47e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg26898376	chr11:64110657	CCDC88B	0.31	5.81	0.3	1.45e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg27432699	chr2:27873401	GPN1	-0.9	-17.64	-0.69	1.13e-49	Oral cavity cancer;
LUSC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg06808227	chr14:105710500	BRF1	-0.71	-11.41	-0.53	1.09e-25	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg11901034	chr3:128598214	ACAD9	-0.4	-6.21	-0.32	1.55e-9	IgG glycosylation;
LUSC	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.03	23.4	0.79	2.27e-72	Ulcerative colitis;
LUSC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg14004847	chr7:1930337	MAD1L1	-0.45	-6.59	-0.34	1.73e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12618769	1.000	rs3769696	chr2:99258927	A/G	cg10123293	chr2:99228465	UNC50	0.43	5.97	0.31	6.09e-9	Bipolar disorder;
LUSC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	0.96	18.51	0.71	3.79e-53	Heart rate;
LUSC	trans	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg03886242	chr7:26192032	NFE2L3	-0.4	-6.48	-0.33	3.34e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg07080220	chr10:102295463	HIF1AN	-0.64	-8.98	-0.44	2.03e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	0.56	8.97	0.44	2.15e-17	Breast cancer;
LUSC	cis	rs12313068	0.656	rs41436646	chr12:110495171	C/G	cg12870014	chr12:110450643	ANKRD13A	0.62	9.13	0.45	6.6e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-6.06	-0.31	3.68e-9	Breast cancer;
LUSC	trans	rs2736337	0.532	rs6998387	chr8:11293458	C/T	cg06636001	chr8:8085503	FLJ10661	0.44	6.02	0.31	4.55e-9	Rheumatoid arthritis;
LUSC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.32	-0.49	7.43e-22	Hemoglobin concentration;
LUSC	cis	rs4280164	0.708	rs78269053	chr14:24794314	A/G	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.59	-7.07	-0.36	9.14e-12	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs981844	1.000	rs2251900	chr4:154654145	C/T	cg14289246	chr4:154710475	SFRP2	0.51	6.1	0.32	2.92e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg22907277	chr7:1156413	C7orf50	0.63	9.5	0.46	4.15e-19	Longevity;Endometriosis;
LUSC	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.93	0.31	7.65e-9	Rheumatoid arthritis;
LUSC	cis	rs394563	0.810	rs480870	chr6:149784818	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.33	-7.06	-0.36	9.69e-12	Dupuytren's disease;
LUSC	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.24	0.49	1.42e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg21252483	chr19:49399788	TULP2	-0.48	-6.77	-0.35	5.81e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs8092503	0.951	rs12457769	chr18:52499801	T/G	cg12377874	chr18:52495404	RAB27B	0.32	5.67	0.3	3.12e-8	Childhood body mass index;
LUSC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.58	0.34	1.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg04362960	chr10:104952993	NT5C2	-0.62	-9.65	-0.47	1.32e-19	Arsenic metabolism;
LUSC	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14240646	chr10:27532245	ACBD5	-0.48	-6.04	-0.31	4.14e-9	Breast cancer;
LUSC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.81	10.78	0.51	1.81e-23	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.19	-13.55	-0.6	1.25e-33	Diabetic kidney disease;
LUSC	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12310025	chr6:25882481	NA	0.49	8.11	0.41	9.49e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.49	-5.99	-0.31	5.48e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21984481	chr17:79567631	NPLOC4	-0.69	-14.08	-0.61	1.09e-35	Eye color traits;
LUSC	cis	rs17641971	0.862	rs341829	chr8:50005758	T/C	cg00325661	chr8:49890786	NA	-0.39	-5.77	-0.3	1.8e-8	Blood metabolite levels;
LUSC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.45	-0.42	9.43e-16	Lung cancer;
LUSC	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg03859395	chr2:55845619	SMEK2	0.86	16.11	0.66	1.33e-43	Metabolic syndrome;
LUSC	cis	rs193541	0.502	rs2061511	chr5:122056727	A/G	cg19077854	chr5:122220652	SNX24	0.33	6.58	0.34	1.77e-10	Glucose homeostasis traits;
LUSC	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg05855489	chr10:104503620	C10orf26	-0.71	-10.46	-0.5	2.47e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg08999081	chr20:33150536	PIGU	0.42	7.79	0.39	8.29e-14	Coronary artery disease;
LUSC	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg01528321	chr10:82214614	TSPAN14	0.89	13.59	0.6	8.81e-34	Post bronchodilator FEV1;
LUSC	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.74	14.55	0.62	1.7e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.79	0.6	1.47e-34	Alzheimer's disease;
LUSC	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg16482183	chr6:26056742	HIST1H1C	-0.42	-6.2	-0.32	1.64e-9	Height;
LUSC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00149659	chr3:10157352	C3orf10	0.98	14.25	0.61	2.48e-36	Alzheimer's disease;
LUSC	cis	rs6681460	0.528	rs10889629	chr1:67032098	T/A	cg02459107	chr1:67143332	SGIP1	0.32	5.68	0.3	2.97e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg21770322	chr7:97807741	LMTK2	0.41	7.21	0.37	3.79e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.43	-0.38	8.93e-13	Height;
LUSC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.82	0.6	1.13e-34	Breast cancer;
LUSC	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg04492858	chr10:133558786	NA	0.38	6.41	0.33	4.92e-10	Survival in rectal cancer;
LUSC	cis	rs2573652	0.722	rs12914180	chr15:100544416	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.3	-5.71	-0.3	2.55e-8	Height;
LUSC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg23985595	chr17:80112537	CCDC57	-0.33	-6.34	-0.33	7.62e-10	Life satisfaction;
LUSC	cis	rs7584330	0.554	rs74832280	chr2:238426625	G/A	cg16989719	chr2:238392110	NA	-0.43	-6.2	-0.32	1.65e-9	Prostate cancer;
LUSC	cis	rs6942756	0.747	rs692697	chr7:129112576	C/T	cg02491457	chr7:128862824	NA	0.39	5.71	0.3	2.45e-8	White matter hyperintensity burden;
LUSC	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg05855489	chr10:104503620	C10orf26	0.53	8.11	0.41	9.87e-15	Arsenic metabolism;
LUSC	cis	rs394563	0.810	rs480870	chr6:149784818	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.36	-7.39	-0.37	1.19e-12	Dupuytren's disease;
LUSC	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg14809332	chr8:144654887	C8orf73	0.52	6.44	0.33	4.15e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg08079166	chr15:68083412	MAP2K5	0.47	8.25	0.41	3.6e-15	Restless legs syndrome;
LUSC	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg11584989	chr19:19387371	SF4	0.58	6.97	0.36	1.74e-11	Bipolar disorder;
LUSC	cis	rs1256061	0.603	rs1256045	chr14:64729760	A/C	cg21174375	chr14:64681225	SYNE2	0.35	6.26	0.32	1.19e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.62	10.46	0.5	2.4e-22	Blood metabolite ratios;
LUSC	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg03806693	chr22:41940476	POLR3H	-0.56	-8.27	-0.41	3.25e-15	Neuroticism;
LUSC	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.87	0.51	9.12e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs714027	0.534	rs140124	chr22:30143693	G/C	cg11564601	chr22:30592435	NA	0.34	6.06	0.31	3.61e-9	Lymphocyte counts;
LUSC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg14196790	chr5:131705035	SLC22A5	0.37	6.32	0.33	8.31e-10	Blood metabolite levels;
LUSC	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg18190219	chr22:46762943	CELSR1	-0.62	-6.21	-0.32	1.62e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg14440974	chr22:39074834	NA	-0.39	-6.44	-0.33	4.23e-10	Menopause (age at onset);
LUSC	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg17173187	chr15:85201210	NMB	0.5	9.38	0.46	1.01e-18	Schizophrenia;
LUSC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg05861140	chr6:150128134	PCMT1	-0.38	-5.91	-0.31	8.58e-9	Lung cancer;
LUSC	trans	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04565464	chr8:145669602	NFKBIL2	0.35	5.95	0.31	6.66e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg13010344	chr12:123464640	ARL6IP4	0.48	5.87	0.31	1.07e-8	Neutrophil percentage of white cells;
LUSC	cis	rs10186029	0.594	rs7594137	chr2:213931662	G/A	cg08319019	chr2:214017104	IKZF2	-0.42	-5.94	-0.31	7.33e-9	Systemic sclerosis;
LUSC	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05901451	chr6:126070800	HEY2	-0.77	-13.31	-0.59	1.02e-32	Brugada syndrome;
LUSC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg14830002	chr1:247616686	OR2B11	0.5	8.01	0.4	1.97e-14	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20516161	chr22:45559322	NUP50	-0.5	-6.57	-0.34	1.93e-10	Hepatitis;
LUSC	cis	rs56399783	0.803	rs17132665	chr7:2802173	T/C	cg19731401	chr7:2775893	GNA12	0.7	9.37	0.46	1.08e-18	Childhood ear infection;
LUSC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs1595825	0.786	rs75619425	chr2:198537281	A/G	cg00982548	chr2:198649783	BOLL	-0.54	-6.77	-0.35	5.79e-11	Ulcerative colitis;
LUSC	cis	rs62408225	0.722	rs766153	chr6:90905047	A/G	cg06866423	chr6:90926672	BACH2	0.41	6.44	0.33	4.09e-10	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg11342453	chr6:26196699	NA	0.54	5.71	0.3	2.52e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg22823121	chr1:150693482	HORMAD1	0.48	6.88	0.35	2.93e-11	Melanoma;
LUSC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.16	-26.53	-0.82	3.11e-84	Chronic sinus infection;
LUSC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.68	0.39	1.75e-13	Vitiligo;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05709362	chr4:113067289	C4orf32	-0.43	-6.39	-0.33	5.63e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7939886	0.920	rs11227434	chr11:55945251	G/T	cg03929089	chr4:120376271	NA	0.79	5.95	0.31	6.68e-9	Myopia (pathological);
LUSC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.35	5.68	0.3	2.99e-8	Systemic lupus erythematosus;
LUSC	cis	rs4730250	0.634	rs257371	chr7:106795043	C/A	cg02696742	chr7:106810147	HBP1	-0.64	-8.94	-0.44	2.79e-17	Osteoarthritis;
LUSC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.19e-10	Alzheimer's disease (late onset);
LUSC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg08798685	chr6:27730294	NA	-0.68	-6.14	-0.32	2.37e-9	Depression;
LUSC	cis	rs7241530	0.662	rs7244362	chr18:75906793	T/C	cg14642773	chr18:75888474	NA	0.39	5.88	0.31	9.8e-9	Educational attainment (years of education);
LUSC	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg05855489	chr10:104503620	C10orf26	-0.67	-9.93	-0.48	1.62e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01339255	chr4:141445245	ELMOD2	-0.51	-6.8	-0.35	4.9e-11	Hepatitis;
LUSC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg23283495	chr1:209979779	IRF6	-0.52	-8.61	-0.43	2.99e-16	Orofacial clefts;
LUSC	cis	rs548181	0.736	rs543389	chr11:125464841	A/G	cg03464685	chr11:125439445	EI24	1.23	14.43	0.62	5.12e-37	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg10518572	chr11:65560635	OVOL1	-0.25	-5.66	-0.3	3.25e-8	Acne (severe);
LUSC	cis	rs12681287	0.640	rs12678720	chr8:87457929	T/G	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs74544699	1.000	rs11574452	chr4:74846661	A/C	cg05509609	chr4:74847829	PF4	-0.79	-6.06	-0.31	3.65e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs62458065	0.713	rs921406	chr7:32486205	G/C	cg20159608	chr7:32802032	NA	-0.73	-9.21	-0.45	3.83e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs13401104	0.796	rs1466205	chr2:237121194	A/G	cg19324714	chr2:237145437	ASB18	0.44	5.66	0.3	3.34e-8	Educational attainment;
LUSC	cis	rs926392	0.932	rs6513588	chr20:37686281	T/C	cg27552599	chr20:37590471	DHX35	0.33	5.77	0.3	1.82e-8	Dialysis-related mortality;
LUSC	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00290607	chr11:67383545	NA	-0.36	-6.43	-0.33	4.3e-10	Mean corpuscular volume;
LUSC	cis	rs7580658	0.857	rs2896980	chr2:128139959	T/C	cg09760422	chr2:128146352	NA	-0.3	-6.36	-0.33	6.57e-10	Protein C levels;
LUSC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07256732	chr16:621771	PIGQ	-0.35	-6.33	-0.33	7.69e-10	Height;
LUSC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06544989	chr22:39130855	UNC84B	0.36	6.42	0.33	4.74e-10	Menopause (age at onset);
LUSC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.48	7.94	0.4	3.17e-14	Pulse pressure;
LUSC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs1775715	0.870	rs10827001	chr10:32229734	C/T	cg03015672	chr10:32216066	ARHGAP12	0.33	5.84	0.3	1.25e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9914988	0.832	rs34901720	chr17:27179518	A/G	cg09479241	chr17:27052676	TLCD1	0.43	6.09	0.32	3.15e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg20203395	chr5:56204925	C5orf35	-0.78	-10.68	-0.5	4.11e-23	Initial pursuit acceleration;
LUSC	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg23795048	chr12:9217529	LOC144571	0.34	5.83	0.3	1.32e-8	Sjögren's syndrome;
LUSC	trans	rs17133449	0.718	rs11252674	chr10:4753422	C/T	cg17844448	chr7:27782764	TAX1BP1	-0.37	-6.08	-0.32	3.3e-9	Major depressive disorder;
LUSC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg10729496	chr3:10149963	C3orf24	0.54	7.17	0.37	4.98e-12	Alzheimer's disease;
LUSC	cis	rs10492096	0.898	rs12426815	chr12:6580314	A/G	cg13857086	chr12:6580257	VAMP1	0.67	7.78	0.39	9.44e-14	Hip geometry;
LUSC	trans	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17712092	chr4:129076599	LARP1B	-0.78	-11.81	-0.54	4.05e-27	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs10911251	0.508	rs2296297	chr1:183105324	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.45	0.5	2.71e-22	Colorectal cancer;
LUSC	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg02475777	chr4:1388615	CRIPAK	0.42	6.52	0.34	2.6e-10	Longevity;
LUSC	cis	rs6496667	0.600	rs28674812	chr15:91077809	G/T	cg03599575	chr15:90893182	GABARAPL3	0.41	5.96	0.31	6.35e-9	Rheumatoid arthritis;
LUSC	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg26408565	chr15:76604113	ETFA	0.48	7.8	0.39	8.05e-14	Blood metabolite levels;
LUSC	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.74	13.22	0.59	2.29e-32	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs9929218	0.817	rs3114405	chr16:68722377	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-13.45	-0.59	2.87e-33	Colorectal cancer;
LUSC	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg19640130	chr10:64028056	RTKN2	-0.4	-7.15	-0.36	5.41e-12	Rheumatoid arthritis;
LUSC	cis	rs12618769	0.652	rs17506535	chr2:99222834	G/C	cg10123293	chr2:99228465	UNC50	0.47	7.7	0.39	1.59e-13	Bipolar disorder;
LUSC	cis	rs4363385	0.667	rs756303	chr1:152908222	C/T	cg07796016	chr1:152779584	LCE1C	-0.44	-6.42	-0.33	4.61e-10	Inflammatory skin disease;
LUSC	cis	rs7793919	0.726	rs4720401	chr7:4780943	G/A	cg09789173	chr7:4769017	FOXK1	0.65	11.93	0.55	1.48e-27	Mosquito bite size;
LUSC	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21775007	chr8:11205619	TDH	0.79	13.15	0.58	4.08e-32	Retinal vascular caliber;
LUSC	cis	rs6977660	0.941	rs10273208	chr7:19816371	T/C	cg05791153	chr7:19748676	TWISTNB	0.57	6.31	0.33	9.06e-10	Thyroid stimulating hormone;
LUSC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg12963246	chr6:28129442	ZNF389	0.4	6.38	0.33	5.91e-10	Parkinson's disease;
LUSC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg05368731	chr17:41323189	NBR1	0.84	13.7	0.6	3.32e-34	Menopause (age at onset);
LUSC	cis	rs116161686	0.500	rs55871867	chr1:210051029	A/G	cg04352962	chr1:209979756	IRF6	0.52	5.78	0.3	1.72e-8	Coronary artery disease;
LUSC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19346786	chr7:2764209	NA	-0.49	-8.08	-0.4	1.21e-14	Height;
LUSC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	0.92	18.7	0.72	6.83e-54	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6840360	0.967	rs10028961	chr4:152668224	A/G	cg22705602	chr4:152727874	NA	-0.27	-5.85	-0.3	1.2e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	7.5	0.38	5.69e-13	Schizophrenia;
LUSC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.78	0.3	1.76e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs225245	0.782	rs321618	chr17:33912404	A/G	cg19694781	chr19:47549865	TMEM160	-0.41	-6.61	-0.34	1.51e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.94	0.31	7.17e-9	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.69	0.54	1.04e-26	Prudent dietary pattern;
LUSC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg17971929	chr21:40555470	PSMG1	-0.51	-7.52	-0.38	5.21e-13	Menarche (age at onset);
LUSC	cis	rs1865721	1.000	rs62089511	chr18:73197629	C/T	cg26385618	chr18:73139727	C18orf62	-0.47	-7.9	-0.4	3.94e-14	Intelligence;
LUSC	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg19622623	chr12:86230825	RASSF9	-0.41	-5.71	-0.3	2.44e-8	Major depressive disorder;
LUSC	cis	rs4780401	0.728	rs7188511	chr16:11773743	G/T	cg01061890	chr16:11836724	TXNDC11	-0.47	-6.83	-0.35	4.02e-11	Rheumatoid arthritis;
LUSC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg22907277	chr7:1156413	C7orf50	0.71	7.44	0.38	8.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02963550	chr12:125256644	NA	0.52	7.28	0.37	2.42e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg02454025	chr1:11042201	C1orf127	1.03	18.59	0.71	1.77e-53	Ewing sarcoma;
LUSC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg06623918	chr6:96969491	KIAA0776	0.8	11.59	0.54	2.38e-26	Migraine;Coronary artery disease;
LUSC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg15448220	chr1:150897856	SETDB1	0.42	6.07	0.32	3.48e-9	Melanoma;
LUSC	cis	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg06521331	chr12:34319734	NA	-0.35	-5.7	-0.3	2.61e-8	Morning vs. evening chronotype;
LUSC	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.62	-11.74	-0.54	6.76e-27	Survival in pancreatic cancer;
LUSC	cis	rs2580764	0.540	rs10210840	chr2:55226009	G/A	cg09592903	chr2:55203963	RTN4	-0.47	-9.59	-0.46	2.12e-19	Mean platelet volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01349858	chr17:75277363	SEPT9	-0.42	-6.34	-0.33	7.25e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.38	0.37	1.24e-12	Bipolar disorder;
LUSC	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg27489772	chr12:121021490	NA	0.6	7.87	0.4	5.06e-14	Type 1 diabetes nephropathy;
LUSC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-8.23	-0.41	4.2e-15	Chronic sinus infection;
LUSC	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg05925327	chr15:68127851	NA	-0.41	-6.6	-0.34	1.6e-10	Restless legs syndrome;
LUSC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg15790184	chr11:494944	RNH1	0.52	5.98	0.31	5.62e-9	Body mass index;
LUSC	trans	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg06636001	chr8:8085503	FLJ10661	0.43	6.27	0.32	1.12e-9	Retinal vascular caliber;
LUSC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	0.97	13.9	0.61	5.68e-35	Vitiligo;
LUSC	cis	rs7923609	0.934	rs10761771	chr10:65230164	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.44	-0.33	4.1e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.45	6.04	0.31	4.01e-9	Renal function-related traits (BUN);
LUSC	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.42	-0.33	4.56e-10	Retinal vascular caliber;
LUSC	cis	rs8049040	0.609	rs11866859	chr16:71478888	G/A	cg08717414	chr16:71523259	ZNF19	-0.39	-5.65	-0.3	3.39e-8	Blood protein levels;
LUSC	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.79	0.3	1.6e-8	Breast cancer;
LUSC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg09626299	chr10:82213104	TSPAN14	-0.2	-5.87	-0.31	1.03e-8	Post bronchodilator FEV1;
LUSC	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg08462924	chr1:41848221	NA	0.5	8.55	0.42	4.49e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg03060546	chr3:49711283	APEH	-0.64	-7.5	-0.38	5.75e-13	Menarche (age at onset);
LUSC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg09455208	chr3:40491958	NA	0.57	10.34	0.49	6.18e-22	Renal cell carcinoma;
LUSC	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.54	-0.34	2.35e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg14395844	chr9:139980277	LOC100289341;MAN1B1	0.45	7.18	0.37	4.65e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.28	0.56	7.31e-29	Prudent dietary pattern;
LUSC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.21	17.25	0.69	3.83e-48	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg11492896	chr2:32581942	BIRC6	0.46	5.97	0.31	6.2e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg17054900	chr3:154042577	DHX36	0.44	5.67	0.3	3.08e-8	Coronary artery disease;
LUSC	cis	rs7582180	0.903	rs7609376	chr2:100905828	A/G	cg08017756	chr2:100939284	LONRF2	-0.37	-6.22	-0.32	1.47e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-8.37	-0.42	1.57e-15	Neuroticism;
LUSC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18404041	chr3:52824283	ITIH1	-0.52	-9.67	-0.47	1.13e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg14675211	chr2:100938903	LONRF2	-0.36	-5.72	-0.3	2.38e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg23711669	chr6:146136114	FBXO30	-0.83	-14.89	-0.63	8.4e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs7707921	0.881	rs73134722	chr5:81326622	G/A	cg15871215	chr5:81402204	ATG10	-0.45	-6.68	-0.34	9.93e-11	Breast cancer;
LUSC	cis	rs11626933	1.000	rs3742669	chr14:90767746	C/A	cg14092571	chr14:90743983	NA	0.84	17.76	0.7	3.87e-50	Gut microbiota (bacterial taxa);
LUSC	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg03676636	chr4:99064102	C4orf37	0.27	5.84	0.3	1.26e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg02176678	chr2:219576539	TTLL4	-0.56	-9.9	-0.48	1.94e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.82	-0.39	7.07e-14	Personality dimensions;
LUSC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg11871910	chr12:69753446	YEATS4	0.84	15.2	0.64	5.09e-40	Blood protein levels;
LUSC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg14092988	chr3:52407081	DNAH1	0.31	6.18	0.32	1.82e-9	Bipolar disorder;
LUSC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg09365446	chr1:150670422	GOLPH3L	0.55	8.3	0.41	2.68e-15	Tonsillectomy;
LUSC	cis	rs12136530	0.714	rs34553579	chr1:19779378	A/C	cg01832549	chr1:19774989	CAPZB	-0.32	-5.92	-0.31	7.97e-9	Lead levels in blood;
LUSC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg01283332	chr5:1856932	NA	-0.33	-6.18	-0.32	1.87e-9	Cardiovascular disease risk factors;
LUSC	cis	rs394563	0.534	rs388335	chr6:149791986	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.46	-8.95	-0.44	2.51e-17	Dupuytren's disease;
LUSC	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg05855489	chr10:104503620	C10orf26	0.52	7.85	0.39	5.83e-14	Arsenic metabolism;
LUSC	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg24375607	chr4:120327624	NA	0.76	11.3	0.53	2.72e-25	Corneal astigmatism;
LUSC	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg17845761	chr1:175162550	KIAA0040	0.31	5.9	0.31	8.94e-9	Alcohol dependence;
LUSC	cis	rs6545883	0.860	rs6749226	chr2:61509783	G/A	cg15711740	chr2:61764176	XPO1	0.44	6.71	0.34	8.14e-11	Tuberculosis;
LUSC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg00129232	chr17:37814104	STARD3	-0.49	-7.28	-0.37	2.35e-12	Asthma;
LUSC	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg12002119	chr2:101014098	CHST10	0.37	6.26	0.32	1.2e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg23173402	chr1:227635558	NA	-0.62	-7.26	-0.37	2.67e-12	Major depressive disorder;
LUSC	cis	rs240764	0.817	rs239230	chr6:101105862	C/A	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.69e-9	Neuroticism;
LUSC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg02782426	chr3:40428986	ENTPD3	0.36	6.8	0.35	4.77e-11	Renal cell carcinoma;
LUSC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg13685833	chr1:53393034	SCP2	0.4	6.0	0.31	5.27e-9	Monocyte count;
LUSC	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02176678	chr2:219576539	TTLL4	0.64	11.82	0.54	3.72e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg19046167	chr17:80928561	B3GNTL1	-0.42	-6.74	-0.35	6.93e-11	Breast cancer;
LUSC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22307029	chr19:49891270	CCDC155	0.61	7.78	0.39	9.21e-14	Multiple sclerosis;
LUSC	cis	rs3741151	0.687	rs7933355	chr11:73236817	G/C	cg17517138	chr11:73019481	ARHGEF17	0.9	7.63	0.39	2.41e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06481639	chr22:41940642	POLR3H	0.5	5.69	0.3	2.8e-8	Vitiligo;
LUSC	cis	rs4680	1.000	rs165722	chr22:19949013	C/T	cg23601416	chr22:19950040	COMT	0.32	6.69	0.34	9.69e-11	Blood metabolite levels;
LUSC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.58	-0.38	3.54e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.68	0.39	1.75e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg00944433	chr1:107599041	PRMT6	-0.36	-6.68	-0.34	1.02e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	trans	rs2262909	0.962	rs11669110	chr19:22296485	A/G	cg17074339	chr11:11642133	GALNTL4	0.43	6.53	0.34	2.45e-10	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6546537	0.824	rs13011186	chr2:69778558	C/T	cg10773587	chr2:69614142	GFPT1	-0.63	-10.28	-0.49	9.87e-22	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg09165964	chr15:75287851	SCAMP5	0.51	7.5	0.38	5.66e-13	Breast cancer;
LUSC	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg22601191	chr20:60968625	CABLES2	-0.4	-5.79	-0.3	1.58e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs981844	0.743	rs17371461	chr4:154759220	C/T	cg14289246	chr4:154710475	SFRP2	0.49	6.62	0.34	1.44e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.65	10.52	0.5	1.48e-22	Eye color traits;
LUSC	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-8.11	-0.41	9.96e-15	Coffee consumption (cups per day);
LUSC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg04369109	chr6:150039330	LATS1	0.62	9.24	0.45	2.95e-18	Lung cancer;
LUSC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg27588902	chr6:42928151	GNMT	-0.3	-6.54	-0.34	2.29e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg07507251	chr3:52567010	NT5DC2	0.33	6.31	0.33	9.09e-10	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg22907277	chr7:1156413	C7orf50	0.68	7.31	0.37	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.57	0.5	9.83e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6700896	0.931	rs12042779	chr1:66133950	T/C	cg04111102	chr1:66153794	NA	0.33	7.23	0.37	3.41e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.48	-0.42	7.27e-16	Height;
LUSC	cis	rs10865541	0.902	rs6739163	chr2:3419011	G/A	cg15807143	chr2:3452624	TTC15	0.32	5.66	0.3	3.3e-8	Obesity-related traits;
LUSC	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg18232548	chr7:50535776	DDC	-0.62	-9.27	-0.45	2.39e-18	Systemic sclerosis;
LUSC	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg10327440	chr1:227177885	CDC42BPA	0.63	5.93	0.31	7.62e-9	Major depressive disorder;
LUSC	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg05714579	chr10:131428358	MGMT	-0.51	-7.62	-0.38	2.7e-13	Response to temozolomide;
LUSC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg10169327	chr19:45448959	APOC2	0.3	6.57	0.34	1.93e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12477438	0.520	rs12467504	chr2:99543208	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-6.57	-0.34	1.89e-10	Chronic sinus infection;
LUSC	cis	rs9324022	0.929	rs72698718	chr14:101178555	G/A	cg18089426	chr14:101175970	NA	0.46	5.65	0.3	3.45e-8	Plateletcrit;
LUSC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.96	-0.36	1.86e-11	Aortic root size;
LUSC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.68	0.54	1.16e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg11244672	chr19:19639970	YJEFN3	-0.57	-7.08	-0.36	8.82e-12	Bipolar disorder;
LUSC	trans	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg12856521	chr11:46389249	DGKZ	0.41	6.31	0.33	9.07e-10	Leprosy;
LUSC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.51	0.59	1.77e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg06207120	chr15:45996521	NA	0.39	6.04	0.31	4.12e-9	Waist circumference;Weight;
LUSC	cis	rs10887741	1.000	rs12761361	chr10:89427203	G/C	cg13926569	chr10:89418898	PAPSS2	0.34	6.84	0.35	3.87e-11	Exercise (leisure time);
LUSC	cis	rs7809950	0.862	rs2299421	chr7:106946195	C/G	cg23024343	chr7:107201750	COG5	-0.5	-7.96	-0.4	2.78e-14	Coronary artery disease;
LUSC	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg04310649	chr10:35416472	CREM	-0.43	-6.48	-0.33	3.21e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	8.13	0.41	8.37e-15	Coronary artery disease;
LUSC	cis	rs1506636	1.000	rs644958	chr7:123400873	C/T	cg03229431	chr7:123269106	ASB15	0.64	10.65	0.5	5.57e-23	Plateletcrit;Platelet count;
LUSC	trans	rs10432489	0.541	rs6724902	chr2:181739323	A/T	cg00055848	chr2:62422984	B3GNT2	-0.88	-6.24	-0.32	1.33e-9	QT interval;
LUSC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.66	-11.36	-0.53	1.65e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.54	-10.72	-0.51	3.14e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.61	0.34	1.5e-10	Menopause (age at onset);
LUSC	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg10426581	chr7:100472382	SRRT	0.86	12.43	0.56	2.07e-29	Resting heart rate;
LUSC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-1.06	-20.24	-0.74	5.01e-60	Coronary artery disease;
LUSC	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg16240275	chr20:61666158	NCRNA00029	0.37	7.0	0.36	1.45e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8017423	0.904	rs2149647	chr14:90769539	C/T	cg04374321	chr14:90722782	PSMC1	-0.67	-10.03	-0.48	7.2e-21	Mortality in heart failure;
LUSC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg07424592	chr7:64974309	NA	-0.64	-5.79	-0.3	1.61e-8	Diabetic kidney disease;
LUSC	cis	rs10186029	0.657	rs11689895	chr2:213938553	G/T	cg08319019	chr2:214017104	IKZF2	0.57	8.25	0.41	3.73e-15	Systemic sclerosis;
LUSC	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg25233709	chr10:116636983	FAM160B1	0.42	7.55	0.38	4.26e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.52	0.53	4.44e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14067052	chr2:73460340	CCT7;C2orf7	-0.41	-6.1	-0.32	2.99e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.66	8.97	0.44	2.22e-17	High light scatter reticulocyte count;
LUSC	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg19610905	chr11:61596333	FADS2	-0.52	-7.66	-0.39	1.98e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.76	-0.3	1.92e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs78579285	0.584	rs35353288	chr16:88800814	G/A	cg01900006	chr16:88814613	FAM38A	0.61	6.83	0.35	4.14e-11	Joint mobility (Beighton score);
LUSC	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.82	-0.47	3.7e-20	Total cholesterol levels;
LUSC	cis	rs11630290	1.000	rs72750990	chr15:64005333	C/T	cg12036633	chr15:63758958	NA	-0.73	-8.15	-0.41	7.26e-15	Iris characteristics;
LUSC	trans	rs17266958	1.000	rs17083746	chr9:83292800	G/C	cg01905489	chr1:26616534	UBXN11	-0.59	-6.46	-0.33	3.65e-10	Preschool internalizing problems;
LUSC	cis	rs2548003	0.518	rs13157411	chr5:28751609	C/T	cg22863700	chr5:28928346	NA	-0.42	-5.74	-0.3	2.08e-8	Hip geometry;
LUSC	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	13.33	0.59	8.18e-33	Blood protein levels;
LUSC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs6479891	0.524	rs10740107	chr10:64944317	T/A	cg10211456	chr7:963471	ADAP1	0.42	6.09	0.32	3.04e-9	Arthritis (juvenile idiopathic);
LUSC	cis	rs56346965	0.506	rs929566	chr2:191521441	C/G	cg11845111	chr2:191398756	TMEM194B	-0.46	-6.22	-0.32	1.51e-9	Bone mineral density (Ward's triangle area);
LUSC	cis	rs7178572	0.524	rs2175941	chr15:77584498	T/C	cg22256960	chr15:77711686	NA	-0.5	-8.02	-0.4	1.83e-14	Type 2 diabetes;
LUSC	cis	rs6669919	0.565	rs10863911	chr1:211686860	C/T	cg10512769	chr1:211675356	NA	-0.24	-5.7	-0.3	2.64e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg17279839	chr7:150038598	RARRES2	0.43	6.58	0.34	1.81e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg13789015	chr9:136890014	NCRNA00094	0.69	12.51	0.56	9.97e-30	Platelet distribution width;
LUSC	cis	rs10392	0.516	rs3752293	chr20:37570725	A/G	cg27552599	chr20:37590471	DHX35	-0.43	-6.94	-0.35	2.05e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg20991723	chr1:152506922	NA	0.53	9.94	0.48	1.42e-20	Hair morphology;
LUSC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg13628971	chr7:2884303	GNA12	0.49	6.82	0.35	4.33e-11	Height;
LUSC	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg13813247	chr22:41461852	NA	-0.32	-5.99	-0.31	5.48e-9	Vitiligo;
LUSC	cis	rs7598759	0.584	rs4973409	chr2:232311871	C/T	cg19187155	chr2:232395269	NMUR1	0.39	5.71	0.3	2.49e-8	Noise-induced hearing loss;
LUSC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg13319975	chr6:146136371	FBXO30	-0.45	-6.71	-0.34	8.53e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9653442	0.593	rs6542920	chr2:100845088	A/G	cg07810366	chr2:100720526	AFF3	-0.37	-6.01	-0.31	4.77e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg14583973	chr4:3374767	RGS12	0.37	7.83	0.39	6.56e-14	Serum sulfate level;
LUSC	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg01420254	chr6:26195488	NA	0.68	7.39	0.37	1.2e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg00495681	chr13:53174319	NA	-0.52	-8.46	-0.42	8.25e-16	Lewy body disease;
LUSC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.25	0.45	2.66e-18	Prudent dietary pattern;
LUSC	cis	rs870825	0.616	rs28490461	chr4:185651638	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	12.42	0.56	2.15e-29	Blood protein levels;
LUSC	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.38	-0.42	1.49e-15	Response to antipsychotic treatment;
LUSC	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg01206211	chr2:36825736	FEZ2	0.51	10.3	0.49	9.01e-22	Height;
LUSC	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg18681998	chr4:17616180	MED28	0.77	13.38	0.59	5.42e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg07414643	chr4:187882934	NA	0.55	10.53	0.5	1.41e-22	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.86	-0.58	5.11e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg20607287	chr7:12443886	VWDE	-0.58	-6.01	-0.31	4.81e-9	Coronary artery disease;
LUSC	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg05768032	chr16:30646687	NA	0.41	5.96	0.31	6.29e-9	Multiple myeloma;
LUSC	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.43	-6.24	-0.32	1.33e-9	Reticulocyte count;
LUSC	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg25801113	chr15:45476975	SHF	-0.34	-6.71	-0.34	8.19e-11	Uric acid levels;
LUSC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.53	10.22	0.49	1.68e-21	Height;
LUSC	cis	rs1983891	1.000	rs6458228	chr6:41543793	C/A	cg20194872	chr6:41519635	FOXP4	0.37	6.49	0.33	3.11e-10	Prostate cancer;
LUSC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg21856205	chr7:94953877	PON1	0.44	8.35	0.42	1.8e-15	Paraoxonase activity;
LUSC	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg25301532	chr20:43378953	KCNK15	-0.35	-6.2	-0.32	1.62e-9	Obesity-related traits;
LUSC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg21782813	chr7:2030301	MAD1L1	0.45	7.39	0.37	1.21e-12	Schizophrenia;
LUSC	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.49	-8.18	-0.41	6.01e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18601261	chr12:27397137	STK38L	0.72	5.96	0.31	6.35e-9	Cognitive performance;
LUSC	cis	rs1790761	0.967	rs12787021	chr11:67204342	A/G	cg24690094	chr11:67383802	NA	-0.32	-5.88	-0.31	9.69e-9	Mean corpuscular volume;
LUSC	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg05044414	chr3:183734942	ABCC5	0.21	7.39	0.38	1.15e-12	Anterior chamber depth;
LUSC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg19592336	chr6:28129416	ZNF389	0.46	6.01	0.31	4.81e-9	Depression;
LUSC	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.49	19.18	0.72	8.55e-56	Opioid sensitivity;
LUSC	cis	rs7254114	0.578	rs7246614	chr19:11310538	C/T	cg02815516	chr19:11306319	KANK2	-0.4	-8.18	-0.41	6.06e-15	Immature fraction of reticulocytes;
LUSC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.3	0.53	2.82e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg05887092	chr17:76393375	PGS1	0.51	9.08	0.44	9.91e-18	HDL cholesterol levels;
LUSC	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs34638657	0.702	rs67612167	chr16:82199598	A/G	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.47	-0.33	3.49e-10	Lung adenocarcinoma;
LUSC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-1.17	-19.78	-0.73	3.41e-58	Blood trace element (Zn levels);
LUSC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.55e-12	Motion sickness;
LUSC	cis	rs1957429	0.614	rs72625640	chr14:65333231	G/A	cg23373153	chr14:65346875	NA	-0.87	-7.57	-0.38	3.78e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	13.63	0.6	6.19e-34	Platelet count;
LUSC	cis	rs9815354	0.812	rs113144620	chr3:42008312	A/G	cg03022575	chr3:42003672	ULK4	0.82	8.57	0.42	3.93e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg09654669	chr8:57350985	NA	-0.55	-7.62	-0.38	2.73e-13	Obesity-related traits;
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-8.12	-0.41	8.96e-15	Lymphocyte counts;
LUSC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21643547	chr1:205240462	TMCC2	-0.5	-9.28	-0.45	2.23e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-10.25	-0.49	1.29e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	7.57	0.38	3.63e-13	Multiple sclerosis;
LUSC	trans	rs71435601	0.628	rs541569	chr2:21398768	G/A	cg20757404	chr19:378427	NA	0.37	6.01	0.31	4.87e-9	Cholesterol, total;
LUSC	cis	rs4356932	0.688	rs59291856	chr4:76970801	T/C	cg00809888	chr4:76862425	NAAA	0.34	5.68	0.3	2.94e-8	Blood protein levels;
LUSC	cis	rs2797160	0.547	rs4144549	chr6:125945251	C/G	cg05901451	chr6:126070800	HEY2	0.41	5.92	0.31	7.85e-9	Endometrial cancer;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg13283942	chr1:153606541	S100A13;C1orf77	0.34	5.99	0.31	5.32e-9	Asthma;
LUSC	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17916960	chr15:79447300	NA	-0.52	-10.24	-0.49	1.39e-21	Refractive error;
LUSC	cis	rs10392	0.543	rs3752292	chr20:37570475	G/A	cg27552599	chr20:37590471	DHX35	0.43	7.1	0.36	7.47e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	trans	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.19	-0.32	1.73e-9	Bladder cancer;
LUSC	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg23422044	chr7:1970798	MAD1L1	-0.66	-7.4	-0.38	1.11e-12	Bipolar disorder;
LUSC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg15448220	chr1:150897856	SETDB1	0.41	6.02	0.31	4.48e-9	Melanoma;
LUSC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg23711669	chr6:146136114	FBXO30	0.86	16.1	0.66	1.47e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2282032	0.527	rs3742666	chr14:90767860	T/C	cg04374321	chr14:90722782	PSMC1	0.44	6.09	0.32	3.08e-9	Longevity;
LUSC	trans	rs3857536	0.785	rs1935895	chr6:66936606	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs2398893	0.960	rs11788176	chr9:96829243	C/T	cg14459158	chr9:96720562	NA	0.33	6.2	0.32	1.68e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.42	-8.82	-0.43	6.26e-17	Hemoglobin concentration;
LUSC	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.52	10.19	0.49	2.04e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs2625529	0.761	rs3743224	chr15:72466799	C/T	cg16672083	chr15:72433130	SENP8	-0.52	-7.49	-0.38	6.36e-13	Red blood cell count;
LUSC	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg18827107	chr12:86230957	RASSF9	-0.4	-5.99	-0.31	5.31e-9	Major depressive disorder;
LUSC	cis	rs60015123	1.000	rs3764031	chr12:7091918	C/T	cg26269324	chr12:6977084	TPI1	0.79	5.73	0.3	2.25e-8	Red cell distribution width;
LUSC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	12.55	0.57	7.18e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4664304	0.966	rs925411	chr2:160745785	G/T	cg23995753	chr2:160760732	LY75	-0.31	-5.77	-0.3	1.84e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9311676	0.656	rs4399910	chr3:58389809	A/G	cg26110898	chr3:58419937	PDHB	0.39	6.38	0.33	6.08e-10	Systemic lupus erythematosus;
LUSC	cis	rs4917833	0.752	rs10883101	chr10:100219916	A/G	cg19043522	chr10:100227446	HPSE2	0.4	5.71	0.3	2.53e-8	Pediatric bone mineral density (femoral neck);
LUSC	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg23241863	chr10:102295624	HIF1AN	0.48	6.01	0.31	4.84e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-6.64	-0.34	1.28e-10	Blood metabolite levels;
LUSC	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-0.79	-11.66	-0.54	1.4e-26	Blood protein levels;
LUSC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs5771069	0.669	rs137879	chr22:50457041	C/T	cg03721641	chr22:50451245	IL17REL	0.29	5.74	0.3	2.18e-8	Ulcerative colitis;
LUSC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg17300311	chr20:3026576	MRPS26	0.47	6.24	0.32	1.33e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs72781680	0.821	rs72796325	chr2:24134537	G/A	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.47	-0.38	7.07e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	14.04	0.61	1.61e-35	Platelet count;
LUSC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg17178900	chr1:205818956	PM20D1	0.74	11.91	0.55	1.62e-27	Menarche (age at onset);
LUSC	cis	rs1904096	0.506	rs11097408	chr4:95165662	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.17	-0.41	6.47e-15	Type 2 diabetes;
LUSC	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg27489772	chr12:121021490	NA	0.52	6.75	0.35	6.37e-11	Type 1 diabetes nephropathy;
LUSC	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.57	-6.64	-0.34	1.27e-10	Iron status biomarkers;
LUSC	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg15704280	chr7:45808275	SEPT13	-0.55	-6.28	-0.32	1.03e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs12681287	0.752	rs12548328	chr8:87311219	G/A	cg27223183	chr8:87520930	FAM82B	-0.47	-5.78	-0.3	1.7e-8	Caudate activity during reward;
LUSC	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg05347473	chr6:146136440	FBXO30	0.53	8.88	0.44	4.06e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-8.01	-0.4	1.92e-14	Colorectal cancer;
LUSC	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	9.4	0.46	8.73e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9560113	1.000	rs9560105	chr13:112175363	A/T	cg14154082	chr13:112174009	NA	-0.41	-8.28	-0.41	2.94e-15	Menarche (age at onset);
LUSC	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.89	-0.35	2.72e-11	Response to antipsychotic treatment;
LUSC	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg02403541	chr12:121454288	C12orf43	0.7	10.19	0.49	2.06e-21	N-glycan levels;
LUSC	cis	rs4363385	0.818	rs2787629	chr1:153011966	A/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02711726	chr17:80685570	FN3KRP	-0.4	-6.09	-0.32	3.17e-9	Glycated hemoglobin levels;
LUSC	cis	rs12200782	0.799	rs72845515	chr6:26646871	A/G	cg11502198	chr6:26597334	ABT1	-0.74	-5.77	-0.3	1.8e-8	Small cell lung carcinoma;
LUSC	cis	rs6489882	0.867	rs4766665	chr12:113363109	T/C	cg20102336	chr12:113376681	OAS3	-0.42	-5.93	-0.31	7.36e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-7.92	-0.4	3.51e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-5.86	-0.31	1.09e-8	Vitiligo;
LUSC	cis	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05901451	chr6:126070800	HEY2	0.52	7.89	0.4	4.42e-14	Endometrial cancer;
LUSC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg23711669	chr6:146136114	FBXO30	0.88	16.1	0.66	1.48e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg24558204	chr6:135376177	HBS1L	0.6	9.13	0.45	6.69e-18	Red blood cell count;
LUSC	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg24397884	chr7:158709396	WDR60	0.8	9.35	0.46	1.28e-18	Height;
LUSC	cis	rs4629710	0.592	rs9492864	chr6:131531306	A/T	cg12700074	chr6:131571435	AKAP7	-0.37	-6.01	-0.31	4.9e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs1322512	0.917	rs2623945	chr6:152961207	A/C	cg27316956	chr6:152958899	SYNE1	0.36	5.84	0.3	1.23e-8	Tonometry;
LUSC	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.65	9.63	0.47	1.61e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg24692254	chr21:30365293	RNF160	-0.7	-10.73	-0.51	2.81e-23	Pancreatic cancer;
LUSC	cis	rs701145	0.556	rs355751	chr3:153971602	T/C	cg10247383	chr3:153839028	SGEF	-0.49	-5.98	-0.31	5.67e-9	Coronary artery disease;
LUSC	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg03647239	chr10:116582469	FAM160B1	0.44	7.06	0.36	9.98e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs10465746	0.780	rs2389648	chr1:84403031	C/T	cg10977910	chr1:84465055	TTLL7	0.43	6.18	0.32	1.88e-9	Obesity-related traits;
LUSC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.2	-0.37	4.03e-12	Bipolar disorder;
LUSC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg11062466	chr8:58055876	NA	-0.49	-6.68	-0.34	1.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg16606324	chr3:10149918	C3orf24	0.65	9.7	0.47	9.37e-20	Alzheimer's disease;
LUSC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg11663144	chr21:46675770	NA	-0.36	-5.98	-0.31	5.68e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg22906224	chr7:99728672	NA	0.55	8.13	0.41	8.36e-15	Coronary artery disease;
LUSC	cis	rs7705502	1.000	rs72812818	chr5:173356752	G/C	cg18693985	chr5:173351052	CPEB4	-0.38	-6.02	-0.31	4.66e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg18854424	chr1:2615690	NA	0.45	9.56	0.46	2.65e-19	Ulcerative colitis;
LUSC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg23711669	chr6:146136114	FBXO30	-0.79	-13.87	-0.6	7.6e-35	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7939886	0.920	rs4489763	chr11:55944474	G/A	cg03929089	chr4:120376271	NA	0.8	6.07	0.32	3.54e-9	Myopia (pathological);
LUSC	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg11861562	chr11:117069780	TAGLN	0.33	6.38	0.33	5.8e-10	Blood protein levels;
LUSC	cis	rs6138458	0.828	rs6132785	chr20:24993414	T/C	cg26195577	chr20:24973756	C20orf3	0.81	12.44	0.56	1.84e-29	Blood protein levels;
LUSC	trans	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	7.1	0.36	7.71e-12	Retinal vascular caliber;
LUSC	cis	rs9341808	0.500	rs2322629	chr6:80811540	C/T	cg08355045	chr6:80787529	NA	0.55	9.9	0.48	2.05e-20	Sitting height ratio;
LUSC	cis	rs9311676	0.618	rs12152337	chr3:58365271	T/C	cg26110898	chr3:58419937	PDHB	0.44	7.22	0.37	3.62e-12	Systemic lupus erythematosus;
LUSC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg00701064	chr4:6280414	WFS1	0.59	14.2	0.61	3.93e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2835872	0.758	rs1709818	chr21:39036211	T/C	cg20424643	chr21:39039972	KCNJ6	-0.44	-7.42	-0.38	9.81e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs4363385	0.818	rs2879487	chr1:152985360	C/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.67	-0.3	3.09e-8	Inflammatory skin disease;
LUSC	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg23711669	chr6:146136114	FBXO30	-0.7	-12.09	-0.55	3.72e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg00540400	chr15:79124168	NA	-0.47	-8.1	-0.41	1.02e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs11039100	0.607	rs1032647	chr11:5781889	A/G	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg26318627	chr11:63887540	MACROD1	0.34	6.49	0.33	3.02e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs9309473	0.514	rs62149659	chr2:73585196	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-5.98	-0.31	5.79e-9	Metabolite levels;
LUSC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19346786	chr7:2764209	NA	-0.51	-8.62	-0.43	2.67e-16	Height;
LUSC	cis	rs17095355	0.786	rs61624875	chr10:111722489	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.44	-0.38	8.8e-13	Biliary atresia;
LUSC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg26335602	chr6:28129616	ZNF389	0.43	5.74	0.3	2.17e-8	Depression;
LUSC	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg21643547	chr1:205240462	TMCC2	-0.41	-7.55	-0.38	4.13e-13	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs4308124	0.708	rs67816163	chr2:111963310	A/G	cg04571233	chr2:111982156	NA	-0.5	-6.55	-0.34	2.11e-10	Vitiligo;
LUSC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.88	-14.18	-0.61	4.78e-36	Cognitive function;
LUSC	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.25	-0.37	2.89e-12	Triglycerides;
LUSC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg05082376	chr22:42548792	NA	-0.4	-5.98	-0.31	5.75e-9	Schizophrenia;
LUSC	trans	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg14061069	chr19:46274453	DMPK	0.68	14.05	0.61	1.51e-35	Coronary artery disease;
LUSC	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-8.45	-0.42	9.27e-16	Prudent dietary pattern;
LUSC	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg19920283	chr7:105172520	RINT1	0.62	6.9	0.35	2.59e-11	Bipolar disorder (body mass index interaction);
LUSC	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg24375607	chr4:120327624	NA	0.79	11.6	0.54	2.32e-26	Corneal astigmatism;
LUSC	cis	rs1775715	0.737	rs2808028	chr10:32101189	G/A	cg26784012	chr10:32216390	ARHGAP12	0.44	7.39	0.37	1.21e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg24375607	chr4:120327624	NA	0.49	7.62	0.38	2.61e-13	Diastolic blood pressure;
LUSC	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg14416269	chr4:6271139	WFS1	0.49	9.78	0.47	4.89e-20	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2979472	0.525	rs62505283	chr8:30459993	C/T	cg26383811	chr8:30366931	RBPMS	-0.42	-6.76	-0.35	6.23e-11	Lymphocyte percentage of white cells;
LUSC	cis	rs2425143	1.000	rs11167275	chr20:34340275	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.29	-0.33	9.76e-10	Blood protein levels;
LUSC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.27	5.75	0.3	2.01e-8	Electroencephalogram traits;
LUSC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg13175981	chr1:150552382	MCL1	0.47	6.7	0.34	8.66e-11	Tonsillectomy;
LUSC	cis	rs10072221	1.000	rs10077372	chr5:75720649	C/T	cg03132911	chr5:75698732	IQGAP2	0.35	5.7	0.3	2.7e-8	Mean platelet volume;
LUSC	cis	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg06521852	chr22:38141419	TRIOBP	0.42	6.29	0.33	9.7e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg19792802	chr11:65647270	CTSW	0.44	6.43	0.33	4.48e-10	Crohn's disease;
LUSC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg07716408	chr11:68623521	NA	-0.3	-5.72	-0.3	2.35e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.75	-10.95	-0.51	4.92e-24	Glomerular filtration rate;
LUSC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg13607699	chr17:42295918	UBTF	0.55	8.64	0.43	2.39e-16	Total body bone mineral density;
LUSC	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg05925327	chr15:68127851	NA	-0.33	-5.86	-0.31	1.13e-8	Restless legs syndrome;
LUSC	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg17509989	chr5:176798049	RGS14	0.64	8.93	0.44	2.9e-17	Urate levels in lean individuals;
LUSC	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg05868516	chr6:26286170	HIST1H4H	0.36	5.77	0.3	1.79e-8	Educational attainment;
LUSC	cis	rs73206853	0.841	rs56122570	chr12:110816291	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg21724239	chr8:58056113	NA	0.78	8.17	0.41	6.56e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg09044154	chr16:88155775	NA	-0.56	-7.55	-0.38	4.16e-13	Menopause (age at onset);
LUSC	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg05855489	chr10:104503620	C10orf26	0.51	7.9	0.4	3.95e-14	Arsenic metabolism;
LUSC	cis	rs9814567	0.727	rs9809344	chr3:134342758	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.86	-0.58	5.11e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00166722	chr3:10149974	C3orf24	0.56	7.84	0.39	5.91e-14	Alzheimer's disease;
LUSC	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg05738196	chr6:26577821	NA	0.78	14.95	0.63	4.82e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26314531	chr2:26401878	FAM59B	-0.69	-9.3	-0.45	1.91e-18	Gut microbiome composition (summer);
LUSC	cis	rs75920871	0.528	rs2513094	chr11:116806412	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-6.11	-0.32	2.75e-9	Subjective well-being;
LUSC	cis	rs96067	0.805	rs1033890	chr1:36608414	C/T	cg24686825	chr1:36642396	MAP7D1	-0.72	-9.68	-0.47	1.11e-19	Corneal structure;
LUSC	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg06937882	chr20:24974362	C20orf3	-0.41	-6.94	-0.36	1.99e-11	Blood protein levels;
LUSC	trans	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg14791747	chr16:20752902	THUMPD1	0.68	9.38	0.46	1.02e-18	Cognitive test performance;
LUSC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg00509249	chr6:109615579	CCDC162	-0.33	-5.9	-0.31	9.06e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg17264618	chr3:40429014	ENTPD3	0.3	6.3	0.33	9.12e-10	Renal cell carcinoma;
LUSC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg09455208	chr3:40491958	NA	0.62	9.43	0.46	7.15e-19	Renal cell carcinoma;
LUSC	cis	rs76878669	0.917	rs10219183	chr11:66090032	A/C	cg18002602	chr11:66138449	SLC29A2	0.39	6.04	0.31	4e-9	Educational attainment (years of education);
LUSC	cis	rs2074585	0.560	rs12903058	chr15:91061121	G/T	cg22089800	chr15:90895588	ZNF774	-0.59	-8.47	-0.42	8.16e-16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	trans	rs6561151	0.645	rs61959960	chr13:44439265	T/G	cg12856521	chr11:46389249	DGKZ	0.79	9.72	0.47	8.13e-20	Crohn's disease;
LUSC	cis	rs831571	0.519	rs13059603	chr3:63827381	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.56	7.39	0.37	1.22e-12	Type 2 diabetes;
LUSC	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.22	-0.37	3.45e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4363385	0.818	rs3820141	chr1:153004778	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.42e-12	Inflammatory skin disease;
LUSC	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07080220	chr10:102295463	HIF1AN	0.66	8.5	0.42	6.62e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg02023728	chr11:77925099	USP35	0.47	6.82	0.35	4.36e-11	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs9359856	0.550	rs1179905	chr6:90322922	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.38	-0.46	1.03e-18	Bipolar disorder;
LUSC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.66	11.36	0.53	1.61e-25	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg13944838	chr5:179740914	GFPT2	-0.59	-9.2	-0.45	4.07e-18	Height;
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg16031515	chr1:205743344	RAB7L1	-0.3	-6.36	-0.33	6.52e-10	Menarche (age at onset);
LUSC	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-16.65	-0.67	9.68e-46	Exhaled nitric oxide output;
LUSC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg03948781	chr1:205179583	DSTYK	0.3	5.65	0.3	3.5e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg20368463	chr18:77673604	PQLC1	-0.63	-6.72	-0.34	8.05e-11	Opioid sensitivity;
LUSC	cis	rs12286929	0.679	rs11606814	chr11:115042513	G/T	cg04055981	chr11:115044050	NA	0.44	7.98	0.4	2.44e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg24796726	chr7:884288	UNC84A	-0.36	-5.77	-0.3	1.79e-8	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg08470875	chr2:26401718	FAM59B	-0.69	-9.37	-0.46	1.16e-18	Gut microbiome composition (summer);
LUSC	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	0.66	9.51	0.46	3.94e-19	Platelet distribution width;
LUSC	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.13	0.45	6.89e-18	Coffee consumption (cups per day);
LUSC	trans	rs7939886	0.920	rs7112815	chr11:55960104	T/C	cg15704280	chr7:45808275	SEPT13	0.89	6.88	0.35	3e-11	Myopia (pathological);
LUSC	cis	rs11031096	0.801	rs1372805	chr11:4085529	A/C	cg18678763	chr11:4115507	RRM1	0.4	5.89	0.31	9.31e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15369054	chr17:80825471	TBCD	0.7	11.66	0.54	1.38e-26	Breast cancer;
LUSC	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg01884057	chr2:25150051	NA	0.48	11.43	0.53	9.6e-26	Body mass index in non-asthmatics;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg14307892	chr10:124767941	IKZF5;ACADSB	0.41	6.24	0.32	1.31e-9	Mosquito bite size;
LUSC	cis	rs3768617	0.811	rs10797828	chr1:183028430	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.78	0.43	8.41e-17	Fuchs's corneal dystrophy;
LUSC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg20406979	chr6:167373233	NA	-0.26	-6.08	-0.32	3.35e-9	Crohn's disease;
LUSC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg21545522	chr1:205238299	TMCC2	0.46	8.71	0.43	1.39e-16	Red blood cell count;
LUSC	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg19052272	chr2:3704530	ALLC	-0.5	-8.38	-0.42	1.48e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.62	-0.38	2.7e-13	Endometrial cancer;
LUSC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.95	0.36	1.97e-11	Cystic fibrosis severity;
LUSC	trans	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg26384229	chr12:38710491	ALG10B	0.53	8.49	0.42	7.1e-16	Morning vs. evening chronotype;
LUSC	cis	rs2463822	0.669	rs72919493	chr11:62049651	C/A	cg06239285	chr11:62104954	ASRGL1	-0.73	-6.88	-0.35	2.9100000000000002e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7084921	0.608	rs12761969	chr10:101832036	G/C	cg11888571	chr10:102027403	CWF19L1	-0.41	-5.68	-0.3	2.95e-8	Bone mineral density;
LUSC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg05623727	chr3:50126028	RBM5	-0.32	-6.09	-0.32	3.11e-9	Body mass index;
LUSC	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.11	-0.41	9.51e-15	Triglycerides;
LUSC	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg00852783	chr1:26633632	UBXN11	0.49	8.61	0.43	2.9e-16	Obesity-related traits;
LUSC	cis	rs6984449	0.508	rs62496184	chr8:19319423	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.5	8.2	0.41	5.3e-15	Educational attainment;
LUSC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-8.37	-0.42	1.59e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs12618769	1.000	rs3769694	chr2:99259239	C/G	cg10123293	chr2:99228465	UNC50	0.43	5.96	0.31	6.29e-9	Bipolar disorder;
LUSC	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg20744362	chr22:50050164	C22orf34	0.35	7.09	0.36	8.17e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.58	-10.26	-0.49	1.17e-21	Extrinsic epigenetic age acceleration;
LUSC	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg26924012	chr15:45694286	SPATA5L1	0.79	12.5	0.56	1.13e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18932078	chr1:2524107	MMEL1	0.33	7.17	0.37	4.87e-12	Ulcerative colitis;
LUSC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg10729496	chr3:10149963	C3orf24	0.52	6.93	0.35	2.21e-11	Alzheimer's disease;
LUSC	cis	rs9534288	0.912	rs2404732	chr13:46618611	C/A	cg15192986	chr13:46630673	CPB2	-0.74	-11.4	-0.53	1.18e-25	Blood protein levels;
LUSC	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg08017756	chr2:100939284	LONRF2	-0.44	-8.15	-0.41	7.43e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs243505	0.964	rs243509	chr7:148433634	G/A	cg09806900	chr7:148480153	CUL1	-0.5	-7.11	-0.36	7.09e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg00376283	chr12:123451042	ABCB9	-0.69	-9.92	-0.48	1.64e-20	Neutrophil percentage of white cells;
LUSC	trans	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17712092	chr4:129076599	LARP1B	0.75	11.4	0.53	1.16e-25	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	0.6	9.65	0.47	1.34e-19	Breast cancer;
LUSC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg04025307	chr7:1156635	C7orf50	0.42	5.89	0.31	9.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg12850546	chr22:42539477	CYP2D7P1	0.51	6.09	0.32	3.05e-9	Birth weight;
LUSC	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.45	-6.75	-0.35	6.62e-11	Height;
LUSC	cis	rs7968679	1	rs7968679	chr12:9313304	A/G	cg20380214	chr12:9217688	LOC144571	-0.41	-7.99	-0.4	2.19e-14	Myopia;
LUSC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg03477792	chr4:77819574	ANKRD56	0.49	6.8	0.35	4.93e-11	Emphysema distribution in smoking;
LUSC	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02176678	chr2:219576539	TTLL4	0.66	13.18	0.59	3.06e-32	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs2625529	0.652	rs2899776	chr15:72268365	A/T	cg16672083	chr15:72433130	SENP8	0.48	7.92	0.4	3.52e-14	Red blood cell count;
LUSC	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.86	-0.44	4.78e-17	Response to antipsychotic treatment;
LUSC	cis	rs2708977	0.637	rs675239	chr2:97076556	A/G	cg01950434	chr2:97203154	ARID5A	-0.44	-6.28	-0.33	1.04e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.47	6.17	0.32	1.95e-9	Tonsillectomy;
LUSC	cis	rs7084921	0.608	rs1853700	chr10:101862694	T/C	cg02250046	chr10:101825185	CPN1	-0.34	-6.19	-0.32	1.75e-9	Bone mineral density;
LUSC	cis	rs727505	1.000	rs10233596	chr7:124556659	A/G	cg23710748	chr7:124431027	NA	-0.41	-7.39	-0.37	1.18e-12	Lewy body disease;
LUSC	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg23093090	chr10:104574429	C10orf26	-0.36	-6.63	-0.34	1.33e-10	Arsenic metabolism;
LUSC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.7	-9.46	-0.46	5.67e-19	Multiple system atrophy;
LUSC	cis	rs9638182	0.582	rs12539351	chr7:72978112	A/G	cg07452164	chr7:72993570	TBL2	0.44	6.3	0.33	9.24e-10	Triglycerides;
LUSC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg03929089	chr4:120376271	NA	-0.95	-16.34	-0.67	1.59e-44	Height;
LUSC	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg08345082	chr10:99160200	RRP12	-0.35	-7.11	-0.36	7.29e-12	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg05062854	chr22:32435553	NA	0.44	6.88	0.35	2.95e-11	Calcium levels;
LUSC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg01065977	chr19:18549689	ISYNA1	-0.23	-5.74	-0.3	2.14e-8	Breast cancer;
LUSC	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	7.77	0.39	9.83e-14	Educational attainment;
LUSC	cis	rs9905704	0.846	rs302863	chr17:56698827	A/G	cg12560992	chr17:57184187	TRIM37	-0.56	-8.02	-0.4	1.79e-14	Testicular germ cell tumor;
LUSC	trans	rs2018683	0.707	rs4722878	chr7:28973031	C/T	cg19402173	chr7:128379420	CALU	-0.47	-7.08	-0.36	8.32e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg15309053	chr8:964076	NA	0.4	7.97	0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs7264396	0.943	rs224421	chr20:34145461	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.81	-0.35	4.57e-11	Total cholesterol levels;
LUSC	cis	rs7582720	1.000	rs79642273	chr2:203830851	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg04865166	chr7:105162814	PUS7	0.52	5.92	0.31	7.79e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg11247378	chr22:39784982	NA	-0.45	-6.97	-0.36	1.72e-11	IgG glycosylation;
LUSC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg11859384	chr17:80120422	CCDC57	-0.36	-5.66	-0.3	3.23e-8	Life satisfaction;
LUSC	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg05925327	chr15:68127851	NA	-0.43	-6.5	-0.34	2.91e-10	Obesity;
LUSC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg16339924	chr4:17578868	LAP3	0.54	8.0	0.4	2.06e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg03146154	chr1:46216737	IPP	-0.5	-7.22	-0.37	3.63e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22633769	chr20:60982531	CABLES2	-0.46	-6.01	-0.31	4.78e-9	Colorectal cancer;
LUSC	cis	rs9581857	0.725	rs1924074	chr13:28015387	C/G	cg22138327	chr13:27999177	GTF3A	-0.87	-9.31	-0.45	1.72e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg01657329	chr11:68192670	LRP5	0.48	6.34	0.33	7.28e-10	Bone mineral density (spine);
LUSC	cis	rs6546550	0.901	rs897120	chr2:70160982	C/T	cg02498382	chr2:70120550	SNRNP27	0.3	7.39	0.37	1.17e-12	Prevalent atrial fibrillation;
LUSC	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg17764715	chr19:33622953	WDR88	0.6	8.29	0.41	2.72e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13849007	chr1:1677539	SLC35E2	-0.43	-6.17	-0.32	2.02e-9	Electrocardiographic conduction measures;
LUSC	cis	rs3857536	0.813	rs6903678	chr6:66931208	C/T	cg07460842	chr6:66804631	NA	0.41	5.88	0.31	9.77e-9	Blood trace element (Cu levels);
LUSC	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg19717773	chr7:2847554	GNA12	-0.4	-7.14	-0.36	5.98e-12	Height;
LUSC	trans	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg26043149	chr18:55253948	FECH	0.49	7.5	0.38	5.95e-13	Bone mineral density;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg23223044	chr19:49990882	RPL13AP5;RPL13A	0.5	5.98	0.31	5.83e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs735539	0.645	rs1329518	chr13:21203611	C/G	cg04906043	chr13:21280425	IL17D	-0.43	-6.71	-0.34	8.15e-11	Dental caries;
LUSC	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02176678	chr2:219576539	TTLL4	0.64	11.63	0.54	1.77e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg24531977	chr5:56204891	C5orf35	-0.71	-10.9	-0.51	7.37e-24	Coronary artery disease;
LUSC	cis	rs858239	0.601	rs6969733	chr7:23168377	T/C	cg23682824	chr7:23144976	KLHL7	0.41	5.86	0.31	1.13e-8	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.31	-0.33	8.93e-10	Monocyte count;
LUSC	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg20701182	chr2:24300061	SF3B14	0.74	7.28	0.37	2.48e-12	Lymphocyte counts;
LUSC	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg26162295	chr17:38119207	GSDMA	-0.29	-6.96	-0.36	1.8e-11	Asthma;
LUSC	trans	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.85	0.35	3.56e-11	Endometrial cancer;
LUSC	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg09904177	chr6:26538194	HMGN4	0.72	13.02	0.58	1.28e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg22834771	chr12:69754056	YEATS4	-0.56	-8.33	-0.41	2.1e-15	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs667920	0.575	rs9861150	chr3:136183320	G/T	cg15507776	chr3:136538369	TMEM22	0.51	6.52	0.34	2.63e-10	Coronary artery disease;
LUSC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.12	15.52	0.65	2.89e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7575217	0.961	rs13397388	chr2:101779648	C/T	cg23907051	chr2:101730305	TBC1D8	-0.26	-6.69	-0.34	9.44e-11	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.29	0.41	2.76e-15	Hemoglobin concentration;
LUSC	cis	rs1358748	0.555	rs2093335	chr1:67537091	C/T	cg02640540	chr1:67518911	SLC35D1	0.62	6.52	0.34	2.6e-10	Tuberculosis;
LUSC	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg21951975	chr1:209979733	IRF6	0.56	7.03	0.36	1.2e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs7827545	1.000	rs6578234	chr8:135566363	A/G	cg17885191	chr8:135476712	NA	0.53	7.76	0.39	1.04e-13	Hypertension (SNP x SNP interaction);
LUSC	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.32	-6.44	-0.33	4.17e-10	Schizophrenia;
LUSC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg24675658	chr1:53192096	ZYG11B	0.62	10.05	0.48	5.99e-21	Monocyte count;
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg00024416	chr22:24240387	NA	0.33	5.86	0.31	1.13e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs72674100	1.000	rs10002900	chr4:97974161	T/A	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.6	0.34	1.66e-10	Lung cancer;
LUSC	cis	rs9341808	0.754	rs9341810	chr6:80974838	G/A	cg08355045	chr6:80787529	NA	0.56	9.76	0.47	5.61e-20	Sitting height ratio;
LUSC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-0.97	-14.11	-0.61	8.63e-36	Vitiligo;
LUSC	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg15556689	chr8:8085844	FLJ10661	0.56	8.58	0.42	3.52e-16	Retinal vascular caliber;
LUSC	cis	rs4343996	0.902	rs4722693	chr7:3374312	C/T	cg21248987	chr7:3385318	SDK1	-0.38	-6.42	-0.33	4.75e-10	Motion sickness;
LUSC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-1.04	-20.46	-0.75	7.01e-61	Height;
LUSC	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg24375607	chr4:120327624	NA	0.75	11.04	0.52	2.38e-24	Corneal astigmatism;
LUSC	cis	rs701145	0.585	rs1632688	chr3:153874139	C/A	cg17054900	chr3:154042577	DHX36	0.69	6.76	0.35	6.15e-11	Coronary artery disease;
LUSC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.59	8.5	0.42	6.33e-16	Obesity-related traits;
LUSC	cis	rs921943	0.957	rs6860801	chr5:78310914	C/G	cg16405876	chr5:78317871	DMGDH	0.28	5.69	0.3	2.84e-8	Blood and toenail selenium levels;Blood trace element (Se levels);
LUSC	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21643547	chr1:205240462	TMCC2	-0.53	-10.19	-0.49	2.1e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg06145435	chr7:1022769	CYP2W1	0.34	5.89	0.31	9.54e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs11650494	0.831	rs11650886	chr17:47449193	G/A	cg08112188	chr17:47440006	ZNF652	1.4	11.55	0.53	3.57e-26	Prostate cancer;
LUSC	cis	rs7614311	0.681	rs73117036	chr3:63892725	G/C	cg22134162	chr3:63841271	THOC7	-0.49	-6.15	-0.32	2.17e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs78366141	0.649	rs77135481	chr4:89689680	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.93	6.8	0.35	4.73e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs72960926	0.744	rs56168817	chr6:75043919	A/G	cg03266952	chr6:74778945	NA	-0.77	-6.63	-0.34	1.34e-10	Metabolite levels (MHPG);
LUSC	cis	rs75229567	0.618	rs1882194	chr12:70215086	C/G	cg10114359	chr12:70132523	RAB3IP	-0.93	-8.92	-0.44	3.24e-17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.54	-11.39	-0.53	1.35e-25	Paraoxonase activity;
LUSC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg23978390	chr7:1156363	C7orf50	0.41	5.98	0.31	5.7e-9	Longevity;Endometriosis;
LUSC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	7.57	0.38	3.58e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg24558204	chr6:135376177	HBS1L	0.61	9.59	0.46	2.15e-19	Red blood cell count;
LUSC	cis	rs9494145	0.531	rs9399136	chr6:135402339	T/C	cg22676075	chr6:135203613	NA	0.67	9.44	0.46	6.57e-19	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg16898833	chr6:26189333	HIST1H4D	0.67	6.51	0.34	2.72e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg04369109	chr6:150039330	LATS1	-0.51	-7.24	-0.37	3.11e-12	Lung cancer;
LUSC	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg15556689	chr8:8085844	FLJ10661	0.64	10.29	0.49	9.4e-22	Joint mobility (Beighton score);
LUSC	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg07741184	chr6:167504864	NA	0.4	6.88	0.35	2.93e-11	Crohn's disease;
LUSC	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg04362960	chr10:104952993	NT5C2	0.9	11.69	0.54	1.06e-26	Arsenic metabolism;
LUSC	trans	rs6561151	0.681	rs2325088	chr13:44424063	T/C	cg12856521	chr11:46389249	DGKZ	0.75	9.56	0.46	2.63e-19	Crohn's disease;
LUSC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.76	12.54	0.57	7.84e-30	Menarche (age at onset);
LUSC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg22496339	chr2:162101262	NA	0.73	11.88	0.54	2.26e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.62	-11.09	-0.52	1.56e-24	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	9.39	0.46	9.86e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg18681998	chr4:17616180	MED28	0.79	13.28	0.59	1.26e-32	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-0.9	-13.07	-0.58	8.49e-32	Initial pursuit acceleration;
LUSC	cis	rs4499344	0.730	rs12460624	chr19:33098042	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	12.64	0.57	3.31e-30	Mean platelet volume;
LUSC	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs977987	0.806	rs2903033	chr16:75389606	T/A	cg03315344	chr16:75512273	CHST6	0.51	9.66	0.47	1.2e-19	Dupuytren's disease;
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.56	8.81	0.43	7.18e-17	Longevity;Endometriosis;
LUSC	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg08755490	chr11:65554678	OVOL1	0.56	7.71	0.39	1.46e-13	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-0.75	-9.1	-0.45	8.37e-18	Refractive error;
LUSC	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.42	-0.33	4.63e-10	Total cholesterol levels;
LUSC	cis	rs1018836	0.637	rs7843684	chr8:91470035	G/C	cg16814680	chr8:91681699	NA	-0.53	-7.75	-0.39	1.13e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg17366294	chr4:99064904	C4orf37	0.54	9.48	0.46	4.75e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg03806693	chr22:41940476	POLR3H	0.95	12.89	0.58	3.76e-31	Vitiligo;
LUSC	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg17330251	chr7:94953956	PON1	-0.37	-5.87	-0.31	1.06e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs11971779	0.680	rs11765421	chr7:139025094	G/A	cg07862535	chr7:139043722	LUC7L2	0.54	6.72	0.35	7.8e-11	Diisocyanate-induced asthma;
LUSC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg11247378	chr22:39784982	NA	-0.65	-11.98	-0.55	9.67e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg16060761	chr17:80687452	NA	0.51	7.99	0.4	2.18e-14	Glycated hemoglobin levels;
LUSC	cis	rs11039100	0.850	rs11039118	chr11:5832601	A/G	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg15147215	chr3:52552868	STAB1	-0.31	-6.34	-0.33	7.65e-10	Bipolar disorder;
LUSC	cis	rs11039100	1.000	rs4319539	chr11:5828846	T/A	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg08888203	chr3:10149979	C3orf24	0.59	8.11	0.41	9.88e-15	Alzheimer's disease;
LUSC	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-28.96	-0.85	4.25e-93	Myeloid white cell count;
LUSC	cis	rs34779708	0.733	rs3853672	chr10:35549606	A/C	cg03585969	chr10:35415529	CREM	0.54	7.41	0.38	1.05e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg26384229	chr12:38710491	ALG10B	0.74	11.5	0.53	5.04e-26	Morning vs. evening chronotype;
LUSC	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg01028140	chr2:1542097	TPO	-0.61	-8.33	-0.41	2.15e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs757081	0.636	rs214934	chr11:17193475	T/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-5.98	-0.31	5.7e-9	Systolic blood pressure;
LUSC	cis	rs4700695	0.719	rs27587	chr5:65444163	C/T	cg21114390	chr5:65439923	SFRS12	-0.62	-8.74	-0.43	1.18e-16	Facial morphology (factor 19);
LUSC	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17916960	chr15:79447300	NA	-0.52	-10.41	-0.49	3.78e-22	Refractive error;
LUSC	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg12002119	chr2:101014098	CHST10	-0.4	-6.76	-0.35	5.98e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg25281562	chr12:121454272	C12orf43	0.42	5.69	0.3	2.76e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg26395211	chr5:140044315	WDR55	-0.4	-5.66	-0.3	3.27e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.94	-19.27	-0.73	3.78e-56	Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg07828024	chr6:149772892	ZC3H12D	0.33	7.21	0.37	3.7e-12	Dupuytren's disease;
LUSC	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg05294307	chr14:35346193	BAZ1A	-0.57	-6.87	-0.35	3.07e-11	Psoriasis;
LUSC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.61	-0.43	2.95e-16	Bipolar disorder and schizophrenia;
LUSC	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.54	0.5	1.25e-22	Morning vs. evening chronotype;
LUSC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg03146154	chr1:46216737	IPP	0.5	7.28	0.37	2.47e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.77	-14.19	-0.61	4.48e-36	Osteoporosis;
LUSC	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg22875332	chr1:76189707	ACADM	-0.42	-6.31	-0.33	8.94e-10	Daytime sleep phenotypes;
LUSC	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg11861562	chr11:117069780	TAGLN	0.33	6.44	0.33	4.22e-10	Blood protein levels;
LUSC	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg13813247	chr22:41461852	NA	-0.36	-6.54	-0.34	2.25e-10	Neuroticism;
LUSC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18099408	chr3:52552593	STAB1	-0.41	-7.21	-0.37	3.83e-12	Electroencephalogram traits;
LUSC	trans	rs399593	0.848	rs449878	chr10:30897264	A/G	cg23813156	chr20:47935243	NA	-0.48	-5.95	-0.31	6.63e-9	Dental caries;
LUSC	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.6	0.5	8.12e-23	Bone mineral density;
LUSC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg11062466	chr8:58055876	NA	0.5	6.57	0.34	1.89e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4285028	0.948	rs34837785	chr3:121657776	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.9	-0.48	1.91e-20	Multiple sclerosis;
LUSC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	1.03	18.02	0.7	3.34e-51	Parkinson's disease;
LUSC	cis	rs7189233	0.955	rs72801821	chr16:53479652	G/A	cg09728985	chr16:53543985	NA	-0.33	-5.87	-0.31	1.08e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19052272	chr2:3704530	ALLC	-0.64	-10.77	-0.51	2.04e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg05347473	chr6:146136440	FBXO30	0.46	7.99	0.4	2.16e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg09307838	chr4:120376055	NA	0.5	7.62	0.38	2.6e-13	Diastolic blood pressure;
LUSC	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.9	-0.4	4.07e-14	Schizophrenia;
LUSC	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg26195577	chr20:24973756	C20orf3	1.1	18.2	0.71	6.62e-52	Blood protein levels;
LUSC	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.8	11.96	0.55	1.07e-27	Diastolic blood pressure;Systolic blood pressure;
LUSC	trans	rs6011368	0.749	rs4809418	chr20:62915231	G/A	cg13869341	chr1:15865	WASH5P	-0.45	-6.97	-0.36	1.74e-11	Clozapine-induced cytotoxicity;
LUSC	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg10434728	chr15:90938212	IQGAP1	0.46	9.16	0.45	5.29e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs921665	0.831	rs7596478	chr2:3176358	A/G	cg16434511	chr2:3151078	NA	-0.61	-6.61	-0.34	1.55e-10	World class endurance athleticism;
LUSC	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.61	9.42	0.46	7.51e-19	Schizophrenia;
LUSC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06873352	chr17:61820015	STRADA	0.56	8.68	0.43	1.83e-16	Height;
LUSC	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-6.36	-0.33	6.47e-10	Reticulocyte count;
LUSC	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg15704280	chr7:45808275	SEPT13	0.67	7.37	0.37	1.35e-12	Axial length;
LUSC	cis	rs16854884	0.657	rs35085196	chr3:143712210	C/T	cg06585982	chr3:143692056	C3orf58	0.48	7.53	0.38	4.94e-13	Economic and political preferences (feminism/equality);
LUSC	cis	rs11958404	0.932	rs72816585	chr5:157433901	A/C	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs62481355	0.963	rs11768389	chr7:127150250	T/C	cg25922125	chr7:127225783	GCC1	-0.43	-5.65	-0.3	3.48e-8	Type 2 diabetes;
LUSC	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg09976142	chr9:130955436	CIZ1	-0.44	-7.4	-0.38	1.14e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg17385448	chr1:15911702	AGMAT	-0.33	-5.69	-0.3	2.75e-8	Systolic blood pressure;
LUSC	trans	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.95	0.36	1.87e-11	Endometrial cancer;
LUSC	cis	rs240764	0.578	rs11155613	chr6:101176642	T/C	cg09795085	chr6:101329169	ASCC3	0.42	6.07	0.32	3.52e-9	Neuroticism;
LUSC	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.41	-0.46	8.46e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12760731	0.720	rs10913535	chr1:178302914	C/A	cg00404053	chr1:178313656	RASAL2	0.56	6.1	0.32	2.98e-9	Obesity-related traits;
LUSC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg17420585	chr12:42539391	GXYLT1	-0.39	-7.67	-0.39	1.93e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.96	-0.31	6.32e-9	Testicular germ cell tumor;
LUSC	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	5.71	0.3	2.56e-8	Schizophrenia;
LUSC	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg16359550	chr11:109292809	C11orf87	0.37	6.33	0.33	7.74e-10	Schizophrenia;
LUSC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg13531842	chr10:38383804	ZNF37A	-0.48	-7.41	-0.38	1.06e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg06740227	chr12:86229804	RASSF9	0.43	6.84	0.35	3.77e-11	Major depressive disorder;
LUSC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.72	-0.39	1.35e-13	Chronic sinus infection;
LUSC	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg25110126	chr1:46999211	NA	0.8	11.1	0.52	1.37e-24	Monobrow;
LUSC	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.43	-6.87	-0.35	3.22e-11	Tonsillectomy;
LUSC	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg06784218	chr1:46089804	CCDC17	-0.31	-6.08	-0.32	3.36e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg05368731	chr17:41323189	NBR1	0.84	14.15	0.61	6.02e-36	Menopause (age at onset);
LUSC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg22166914	chr1:53195759	ZYG11B	0.69	11.68	0.54	1.17e-26	Monocyte count;
LUSC	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg23625390	chr15:77176239	SCAPER	0.46	6.98	0.36	1.61e-11	Blood metabolite levels;
LUSC	cis	rs13223928	0.631	rs12531881	chr7:3156842	C/T	cg19214707	chr7:3157722	NA	-0.57	-11.06	-0.52	2e-24	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-6.75	-0.35	6.63e-11	Parkinson's disease;
LUSC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-10.8	-0.51	1.64e-23	Schizophrenia;
LUSC	cis	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg06521852	chr22:38141419	TRIOBP	0.39	5.88	0.31	1.02e-8	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg26335602	chr6:28129616	ZNF389	0.43	5.77	0.3	1.82e-8	Depression;
LUSC	cis	rs2708377	0.929	rs2597974	chr12:11252845	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg05340658	chr4:99064831	C4orf37	-0.42	-6.7	-0.34	8.99e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg08085267	chr17:45401833	C17orf57	-0.51	-7.18	-0.37	4.58e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs745570	1.000	rs745570	chr17:77781725	A/G	cg04986373	chr17:77768687	CBX8	0.39	7.76	0.39	1.04e-13	Breast cancer;
LUSC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg04287289	chr16:89883240	FANCA	-0.77	-13.22	-0.59	2.26e-32	Vitiligo;
LUSC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg00074818	chr8:8560427	CLDN23	0.58	9.87	0.48	2.46e-20	Obesity-related traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00185336	chr7:73153699	ABHD11	0.45	6.82	0.35	4.31e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg06521331	chr12:34319734	NA	0.47	7.89	0.4	4.41e-14	Morning vs. evening chronotype;
LUSC	cis	rs6977660	0.619	rs71526305	chr7:19785374	G/C	cg05791153	chr7:19748676	TWISTNB	0.67	6.98	0.36	1.63e-11	Thyroid stimulating hormone;
LUSC	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.92	-0.4	3.63e-14	Triglycerides;
LUSC	cis	rs6750047	0.585	rs168054	chr2:38260282	C/G	cg07380506	chr2:38303506	CYP1B1	-0.44	-6.2	-0.32	1.69e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg26897989	chr16:1907736	C16orf73	-0.43	-6.48	-0.33	3.33e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs1044826	0.553	rs295469	chr3:139212900	G/A	cg15131784	chr3:139108705	COPB2	0.43	6.56	0.34	2.04e-10	Obesity-related traits;
LUSC	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg25173405	chr17:45401733	C17orf57	0.37	5.85	0.3	1.19e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12986413	1.000	rs12459350	chr19:2176586	A/G	cg09261902	chr19:2140048	AP3D1	0.32	5.96	0.31	6.42e-9	Height;
LUSC	cis	rs1371867	0.846	rs2083499	chr8:101230534	T/A	cg06002616	chr8:101225028	SPAG1	0.47	7.65	0.39	2.16e-13	Atrioventricular conduction;
LUSC	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg02569458	chr12:86230093	RASSF9	0.53	8.56	0.42	4.18e-16	Major depressive disorder;
LUSC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg20135002	chr11:47629003	NA	-0.51	-8.13	-0.41	8.39e-15	Subjective well-being;
LUSC	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg07148914	chr20:33460835	GGT7	0.58	8.64	0.43	2.3e-16	Height;
LUSC	cis	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg21775007	chr8:11205619	TDH	0.44	5.96	0.31	6.26e-9	Monocyte count;
LUSC	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg14458575	chr2:238380390	NA	0.67	11.51	0.53	4.67e-26	Prostate cancer;
LUSC	cis	rs11166629	0.502	rs2467028	chr8:135663313	A/G	cg27224718	chr8:135614730	ZFAT	-0.48	-7.01	-0.36	1.35e-11	Smoking quantity;
LUSC	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg13010199	chr12:38710504	ALG10B	0.4	5.81	0.3	1.45e-8	Morning vs. evening chronotype;
LUSC	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	6.07	0.32	3.52e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg21856205	chr7:94953877	PON1	-0.37	-5.94	-0.31	7.07e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.62	-8.07	-0.4	1.29e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs4363385	0.818	rs11205175	chr1:153001296	A/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.4	-0.38	1.13e-12	Inflammatory skin disease;
LUSC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg17330251	chr7:94953956	PON1	-0.37	-5.99	-0.31	5.35e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs5758511	0.773	rs1894714	chr22:42349134	T/G	cg12850546	chr22:42539477	CYP2D7P1	0.47	5.82	0.3	1.36e-8	Birth weight;
LUSC	cis	rs3768617	0.811	rs12138049	chr1:182979546	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.42	0.42	1.12e-15	Fuchs's corneal dystrophy;
LUSC	trans	rs7939886	0.920	rs80232778	chr11:55970655	G/A	cg03929089	chr4:120376271	NA	0.82	6.19	0.32	1.79e-9	Myopia (pathological);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19710302	chr4:56915651	NA	0.43	6.22	0.32	1.47e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg22655196	chr4:3374909	RGS12	0.32	6.24	0.32	1.32e-9	Serum sulfate level;
LUSC	trans	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg14791747	chr16:20752902	THUMPD1	0.73	9.55	0.46	2.84e-19	Cognitive test performance;
LUSC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-5.99	-0.31	5.49e-9	Total body bone mineral density;
LUSC	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg23202291	chr11:1979235	NA	0.39	6.1	0.32	2.96e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.34	5.73	0.3	2.19e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3770081	0.793	rs74743393	chr2:86227421	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.09	-6.81	-0.35	4.43e-11	Facial emotion recognition (sad faces);
LUSC	trans	rs1422110	0.718	rs10079231	chr5:85439369	A/G	cg01787110	chr1:109008453	NBPF6	0.56	9.31	0.45	1.7e-18	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg01858014	chr14:56050164	KTN1	-0.88	-7.16	-0.36	5.08e-12	Putamen volume;
LUSC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg20744362	chr22:50050164	C22orf34	0.39	8.01	0.4	1.96e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg22508957	chr16:3507546	NAT15	-0.41	-6.52	-0.34	2.67e-10	Body mass index (adult);
LUSC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-11.1	-0.52	1.41e-24	Mean corpuscular volume;
LUSC	trans	rs7939886	0.920	rs60087290	chr11:55983527	C/G	cg15704280	chr7:45808275	SEPT13	0.9	6.77	0.35	5.92e-11	Myopia (pathological);
LUSC	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg08917208	chr2:24149416	ATAD2B	0.87	9.84	0.47	3.11e-20	Lymphocyte counts;
LUSC	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg19629631	chr7:2060116	MAD1L1	-0.34	-5.79	-0.3	1.62e-8	Neuroticism;
LUSC	cis	rs9309473	0.660	rs62151564	chr2:73615449	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.16	-0.32	2.14e-9	Metabolite levels;
LUSC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.13	-0.32	2.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12195417	0.563	rs496148	chr6:84217801	G/A	cg08257003	chr6:84140564	ME1	-0.28	-6.55	-0.34	2.12e-10	Schizophrenia;
LUSC	cis	rs9462027	0.628	rs2395604	chr6:34787976	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.74	-0.3	2.1e-8	Systemic lupus erythematosus;
LUSC	cis	rs926938	0.527	rs360666	chr1:115481290	C/T	cg12756093	chr1:115239321	AMPD1	0.45	6.86	0.35	3.28e-11	Autism;
LUSC	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg03433033	chr1:76189801	ACADM	-0.48	-7.28	-0.37	2.43e-12	Daytime sleep phenotypes;
LUSC	cis	rs16912285	0.539	rs11027824	chr11:24368141	A/G	ch.11.24196551F	chr11:24239977	NA	0.66	6.07	0.32	3.48e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg05343316	chr1:45956843	TESK2	0.63	9.15	0.45	5.72e-18	Platelet count;
LUSC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg22800045	chr5:56110881	MAP3K1	0.44	6.03	0.31	4.32e-9	Coronary artery disease;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg02796970	chr10:39023768	NA	-0.48	-7.74	-0.39	1.16e-13	Menopause (age at onset);
LUSC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg09491104	chr22:46646882	C22orf40	-0.64	-7.38	-0.37	1.23e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg06671706	chr8:8559999	CLDN23	0.46	6.35	0.33	7.21e-10	Obesity-related traits;
LUSC	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg01629716	chr15:45996671	NA	0.4	5.97	0.31	5.99e-9	Waist circumference;Weight;
LUSC	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg12292205	chr6:26970375	C6orf41	0.38	6.04	0.31	4.1e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	12.59	0.57	5.15e-30	Menopause (age at onset);
LUSC	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.07	0.48	5.33e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2282802	0.660	rs2436390	chr5:139586501	G/A	cg26211634	chr5:139558579	C5orf32	-0.42	-7.95	-0.4	2.96e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg18681998	chr4:17616180	MED28	0.85	15.92	0.66	7.1e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.4	0.33	5.39e-10	Menopause (age at onset);
LUSC	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	19.83	0.74	2.22e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs12902680	0.706	rs12440622	chr15:46525624	C/T	cg04321580	chr8:143696133	ARC	-0.42	-6.0	-0.31	5e-9	Neuroticism;
LUSC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.48	-6.46	-0.33	3.79e-10	Parkinson's disease;
LUSC	cis	rs1577917	0.839	rs1596990	chr6:86550692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.29	-0.33	9.98e-10	Response to antipsychotic treatment;
LUSC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg25039879	chr17:56429692	SUPT4H1	0.68	9.08	0.45	9.54e-18	Cognitive test performance;
LUSC	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg06028605	chr16:24865363	SLC5A11	0.47	8.62	0.43	2.68e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.13	0.32	2.44e-9	Bipolar disorder;
LUSC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg24578937	chr1:2090814	PRKCZ	-0.41	-9.1	-0.45	8.37e-18	Height;
LUSC	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.74	-0.3	2.12e-8	Ileal carcinoids;
LUSC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg26898376	chr11:64110657	CCDC88B	0.36	6.9	0.35	2.6e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg04362960	chr10:104952993	NT5C2	-0.49	-6.49	-0.33	3.15e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9341808	0.667	rs2505944	chr6:80888410	T/C	cg08355045	chr6:80787529	NA	0.47	8.14	0.41	7.73e-15	Sitting height ratio;
LUSC	cis	rs6494488	0.500	rs72742968	chr15:64919920	A/T	cg08069370	chr15:64387884	SNX1	-0.65	-5.78	-0.3	1.75e-8	Coronary artery disease;
LUSC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg01802117	chr1:53393560	SCP2	0.38	6.21	0.32	1.53e-9	Monocyte count;
LUSC	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.96	13.2	0.59	2.67e-32	Cognitive ability;
LUSC	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.77	11.19	0.52	6.74e-25	Blood protein levels;
LUSC	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.56	-9.25	-0.45	2.66e-18	Breast cancer;
LUSC	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.46	-0.46	5.87e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg06028605	chr16:24865363	SLC5A11	0.42	6.76	0.35	6.15e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg20935933	chr6:143382018	AIG1	0.5	7.33	0.37	1.71e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg11062466	chr8:58055876	NA	0.67	8.06	0.4	1.4e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.54	0.57	7.75e-30	Height;
LUSC	cis	rs4285028	0.656	rs2141487	chr3:121482765	A/G	cg11130432	chr3:121712080	ILDR1	0.62	9.17	0.45	5.02e-18	Multiple sclerosis;
LUSC	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg17443473	chr1:3703550	LRRC47	0.32	5.69	0.3	2.78e-8	Red cell distribution width;
LUSC	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg04036182	chr15:45458818	NA	0.35	5.72	0.3	2.33e-8	Glomerular filtration rate;
LUSC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg24675658	chr1:53192096	ZYG11B	-0.64	-10.1	-0.48	4.12e-21	Monocyte count;
LUSC	cis	rs62027291	0.950	rs62027293	chr15:77269918	G/C	cg26408565	chr15:76604113	ETFA	0.48	5.65	0.3	3.43e-8	Plateletcrit;
LUSC	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg13535736	chr9:111863775	C9orf5	-0.43	-6.93	-0.35	2.16e-11	Menarche (age at onset);
LUSC	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.39	6.05	0.31	3.87e-9	Height;
LUSC	cis	rs113835537	0.529	rs11824771	chr11:66262550	T/C	cg24851651	chr11:66362959	CCS	0.55	8.15	0.41	7.63e-15	Airway imaging phenotypes;
LUSC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.52	-0.46	3.65e-19	Chronic sinus infection;
LUSC	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19346786	chr7:2764209	NA	-0.49	-8.52	-0.42	5.47e-16	Height;
LUSC	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg08847533	chr14:75593920	NEK9	-0.79	-13.4	-0.59	4.55e-33	Height;
LUSC	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.02	0.4	1.82e-14	Corneal astigmatism;
LUSC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg24209194	chr3:40518798	ZNF619	0.49	6.42	0.33	4.63e-10	Renal cell carcinoma;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg23397993	chr18:29598919	RNF125	0.72	6.23	0.32	1.39e-9	Cognitive performance;
LUSC	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg11887960	chr12:57824829	NA	0.55	7.21	0.37	3.7e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg25110126	chr1:46999211	NA	-0.56	-7.55	-0.38	4.16e-13	Monobrow;
LUSC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg05347473	chr6:146136440	FBXO30	0.55	9.59	0.46	2.08e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25072359	chr17:41440525	NA	0.65	9.11	0.45	7.81e-18	Menopause (age at onset);
LUSC	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg17127132	chr2:85788382	GGCX	0.47	7.66	0.39	2.03e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.44	6.22	0.32	1.48e-9	Breast cancer;
LUSC	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-7.65	-0.39	2.2e-13	Retinal vascular caliber;
LUSC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg17143192	chr8:8559678	CLDN23	0.59	8.43	0.42	1.07e-15	Obesity-related traits;
LUSC	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg18833306	chr6:118973337	C6orf204	-0.45	-5.78	-0.3	1.67e-8	Diastolic blood pressure;
LUSC	cis	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg21175976	chr8:11421337	BLK	0.38	6.42	0.33	4.66e-10	Systolic blood pressure;
LUSC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.78	-9.22	-0.45	3.45e-18	Mean platelet volume;
LUSC	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg27068330	chr11:65405492	SIPA1	-0.76	-10.92	-0.51	5.9e-24	Acne (severe);
LUSC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg04518342	chr5:131593106	PDLIM4	0.36	6.47	0.33	3.58e-10	Breast cancer;Mosquito bite size;
LUSC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg17330251	chr7:94953956	PON1	-0.36	-5.84	-0.3	1.22e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.39	-0.37	1.16e-12	Morning vs. evening chronotype;
LUSC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg00745463	chr17:30367425	LRRC37B	-0.87	-10.23	-0.49	1.46e-21	Hip circumference adjusted for BMI;
LUSC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg26587870	chr6:27730563	NA	-0.67	-6.01	-0.31	4.99e-9	Depression;
LUSC	trans	rs9929218	0.954	rs12928043	chr16:68828885	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-10.6	-0.5	7.72e-23	Colorectal cancer;
LUSC	trans	rs6557876	1.000	rs1008974	chr8:25904488	G/T	cg20465333	chr22:32061711	NA	0.43	6.15	0.32	2.21e-9	Systolic blood pressure;
LUSC	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	0.69	11.06	0.52	1.87e-24	Blood metabolite ratios;
LUSC	cis	rs9677476	0.863	rs11558174	chr2:232072912	T/C	cg07929768	chr2:232055508	NA	0.37	7.11	0.36	7.2e-12	Food antigen IgG levels;
LUSC	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.69	-0.3	2.8e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg19875535	chr5:140030758	IK	0.47	7.64	0.39	2.37e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18357526	chr6:26021779	HIST1H4A	0.42	6.78	0.35	5.35e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs76248362	0.881	rs7997131	chr13:24438807	A/G	cg26511321	chr7:27196790	HOXA7	0.53	6.18	0.32	1.91e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs748404	0.697	rs554001	chr15:43551919	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.49	0.42	6.83e-16	Lung cancer;
LUSC	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg15083037	chr5:83017644	HAPLN1	-0.6	-7.91	-0.4	3.8e-14	Prostate cancer;
LUSC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08736216	chr1:53307985	ZYG11A	0.3	6.19	0.32	1.81e-9	Monocyte count;
LUSC	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg03676636	chr4:99064102	C4orf37	0.37	8.08	0.4	1.18e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg06145435	chr7:1022769	CYP2W1	0.31	6.54	0.34	2.36e-10	Longevity;Endometriosis;
LUSC	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	7.39	0.37	1.19e-12	Rheumatoid arthritis;
LUSC	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg23950597	chr19:37808831	NA	-0.63	-7.8	-0.39	8.08e-14	Coronary artery calcification;
LUSC	cis	rs6942756	1.000	rs6942756	chr7:128886821	T/G	cg02491457	chr7:128862824	NA	-0.52	-7.42	-0.38	9.94e-13	White matter hyperintensity burden;
LUSC	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg03732007	chr1:2071316	PRKCZ	0.48	7.81	0.39	7.71e-14	Height;
LUSC	cis	rs1018697	0.518	rs284843	chr10:104553566	C/T	cg04362960	chr10:104952993	NT5C2	-0.65	-7.65	-0.39	2.18e-13	Colorectal adenoma (advanced);
LUSC	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg04691961	chr3:161091175	C3orf57	-0.36	-6.09	-0.32	3.16e-9	Morning vs. evening chronotype;
LUSC	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.93	-0.44	2.87e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg16680214	chr1:154839983	KCNN3	-0.51	-9.68	-0.47	1.08e-19	Prostate cancer;
LUSC	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg09184832	chr6:79620586	NA	-0.42	-6.8	-0.35	4.71e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg05425664	chr17:57184151	TRIM37	0.52	7.71	0.39	1.49e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs225245	0.791	rs720774	chr17:34017453	T/G	cg05299278	chr17:33885742	SLFN14	0.29	6.34	0.33	7.44e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg17971929	chr21:40555470	PSMG1	-0.5	-7.35	-0.37	1.5e-12	Menarche (age at onset);
LUSC	cis	rs9283706	0.562	rs10471697	chr5:66328555	A/T	cg11590213	chr5:66331682	MAST4	0.47	7.13	0.36	6.3e-12	Coronary artery disease;
LUSC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-7.87	-0.4	5.01e-14	Hemoglobin concentration;
LUSC	cis	rs7809950	0.723	rs62483634	chr7:106878516	G/A	cg23024343	chr7:107201750	COG5	-0.65	-9.78	-0.47	5.1e-20	Coronary artery disease;
LUSC	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg12140854	chr5:148520817	ABLIM3	-0.36	-5.88	-0.31	9.93e-9	Breast cancer;
LUSC	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg08345082	chr10:99160200	RRP12	-0.35	-7.17	-0.37	4.77e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg26924012	chr15:45694286	SPATA5L1	1.14	20.41	0.75	1.08e-60	Homoarginine levels;
LUSC	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg11189052	chr15:85197271	WDR73	-0.49	-6.2	-0.32	1.65e-9	Schizophrenia;
LUSC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.24	-0.37	3.18e-12	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12234426	chr4:2965388	GRK4;NOP14	-0.46	-7.0	-0.36	1.45e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg14552801	chr7:65878734	NA	-0.44	-6.22	-0.32	1.51e-9	Aortic root size;
LUSC	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg00982548	chr2:198649783	BOLL	-0.56	-7.05	-0.36	1.06e-11	Ulcerative colitis;
LUSC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg07741184	chr6:167504864	NA	0.43	7.59	0.38	3.18e-13	Crohn's disease;
LUSC	cis	rs834603	0.575	rs1620852	chr7:47481786	A/T	cg09696706	chr7:47479511	TNS3	0.35	6.25	0.32	1.24e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	trans	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg10840412	chr1:235813424	GNG4	0.44	6.42	0.33	4.81e-10	Bipolar disorder;
LUSC	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg03806693	chr22:41940476	POLR3H	-0.72	-10.62	-0.5	6.59e-23	Vitiligo;
LUSC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.23	-0.32	1.38e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.7	-11.56	-0.53	3.2e-26	Heart rate;
LUSC	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg08355456	chr11:67383691	NA	-0.38	-6.42	-0.33	4.63e-10	Mean corpuscular volume;
LUSC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg13607699	chr17:42295918	UBTF	0.49	7.62	0.38	2.71e-13	Total body bone mineral density;
LUSC	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.85	-14.33	-0.62	1.22e-36	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg15605315	chr1:45957053	TESK2	0.51	8.59	0.43	3.41e-16	High light scatter reticulocyte count;
LUSC	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.91	-0.31	8.46e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg04362960	chr10:104952993	NT5C2	-0.64	-10.01	-0.48	8.11e-21	Arsenic metabolism;
LUSC	cis	rs10875746	0.807	rs12313300	chr12:48470717	G/A	cg13454099	chr12:49076203	C12orf41	-0.5	-5.71	-0.3	2.47e-8	Longevity (90 years and older);
LUSC	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg14809332	chr8:144654887	C8orf73	0.51	6.43	0.33	4.36e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs4692589	0.606	rs13127322	chr4:170935169	C/T	cg19918862	chr4:170955249	NA	0.4	7.13	0.36	6.11e-12	Anxiety disorder;
LUSC	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg22903471	chr2:27725779	GCKR	-0.41	-6.82	-0.35	4.23e-11	Total body bone mineral density;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	0.95	19.87	0.74	1.49e-58	Menarche (age at onset);
LUSC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg13175981	chr1:150552382	MCL1	0.48	6.81	0.35	4.53e-11	Tonsillectomy;
LUSC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg04450456	chr4:17643702	FAM184B	-0.42	-6.99	-0.36	1.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg26043149	chr18:55253948	FECH	0.47	6.97	0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs965469	0.895	rs6051844	chr20:3402674	G/T	cg25506879	chr20:3388711	C20orf194	0.52	6.3	0.33	9.2e-10	IFN-related cytopenia;
LUSC	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg16724585	chr3:197361211	NA	-0.62	-8.77	-0.43	9.17e-17	Pancreatic cancer;
LUSC	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg17252645	chr8:143867129	LY6D	0.38	6.67	0.34	1.06e-10	Urinary tract infection frequency;
LUSC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg00376283	chr12:123451042	ABCB9	0.7	9.99	0.48	9.55e-21	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg04218760	chr10:45406644	TMEM72	-0.29	-6.99	-0.36	1.53e-11	Mean corpuscular volume;
LUSC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.73	-13.31	-0.59	9.94e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg13607699	chr17:42295918	UBTF	0.55	8.37	0.42	1.62e-15	Total body bone mineral density;
LUSC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg08916839	chr5:415575	AHRR	0.74	7.04	0.36	1.07e-11	Fat distribution (HIV);
LUSC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg11663144	chr21:46675770	NA	-0.43	-7.64	-0.39	2.25e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg27494647	chr7:150038898	RARRES2	0.48	7.2	0.37	4.12e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12618769	0.652	rs6736755	chr2:99204428	A/G	cg10123293	chr2:99228465	UNC50	-0.43	-6.87	-0.35	3.13e-11	Bipolar disorder;
LUSC	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.38	5.89	0.31	9.44e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs72960926	0.590	rs11754945	chr6:74732673	A/C	cg03266952	chr6:74778945	NA	0.76	6.32	0.33	8.5e-10	Metabolite levels (MHPG);
LUSC	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.65	-7.42	-0.38	9.95e-13	Iron status biomarkers;
LUSC	cis	rs1524927	1.000	rs12704872	chr7:96334616	T/C	cg03808172	chr7:96339361	SHFM1	0.43	6.65	0.34	1.21e-10	Total body bone mineral density;
LUSC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-9.02	-0.44	1.52e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg06606381	chr12:133084897	FBRSL1	-0.7	-6.25	-0.32	1.26e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.64	0.39	2.28e-13	Obesity-related traits;
LUSC	cis	rs2742417	1.000	rs2742390	chr3:45756722	A/G	cg09608765	chr3:45636137	LIMD1	0.35	7.06	0.36	9.51e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.8	0.3	1.5e-8	Self-reported allergy;
LUSC	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg00745463	chr17:30367425	LRRC37B	0.89	9.13	0.45	6.79e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs12044355	0.927	rs61835382	chr1:231833225	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.39	5.66	0.3	3.23e-8	Alzheimer's disease;
LUSC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-1.24	-13.61	-0.6	7.37e-34	Diabetic kidney disease;
LUSC	trans	rs4650994	0.544	rs2476561	chr1:178619900	C/T	cg05059571	chr16:84539110	KIAA1609	-0.47	-9.04	-0.44	1.27e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs500891	0.533	rs9968948	chr6:84185074	G/A	cg08257003	chr6:84140564	ME1	0.33	7.97	0.4	2.58e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-1.01	-14.59	-0.62	1.22e-37	Initial pursuit acceleration;
LUSC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg06808227	chr14:105710500	BRF1	-0.67	-10.32	-0.49	7.67e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7084921	0.578	rs12765808	chr10:101872687	A/C	cg11888571	chr10:102027403	CWF19L1	-0.45	-6.07	-0.32	3.44e-9	Bone mineral density;
LUSC	cis	rs2857891	0.773	rs2857900	chr11:6980536	T/C	cg14883916	chr11:6947541	ZNF215	0.44	5.82	0.3	1.37e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg23093090	chr10:104574429	C10orf26	-0.35	-6.33	-0.33	7.69e-10	Arsenic metabolism;
LUSC	cis	rs17102423	0.661	rs4468529	chr14:65611968	C/T	cg11161011	chr14:65562177	MAX	-0.71	-9.62	-0.47	1.75e-19	Obesity-related traits;
LUSC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-1.23	-13.55	-0.6	1.24e-33	Diabetic kidney disease;
LUSC	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg27411982	chr8:10470053	RP1L1	-0.5	-7.96	-0.4	2.66e-14	Neuroticism;
LUSC	cis	rs472402	0.507	rs8192139	chr5:6636973	C/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.48	-7.18	-0.37	4.51e-12	Response to amphetamines;
LUSC	cis	rs3743162	0.553	rs12900463	chr15:85415386	T/C	cg12863693	chr15:85201151	NMB	0.31	5.89	0.31	9.58e-9	Alzheimer's disease (age of onset);
LUSC	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg21918786	chr6:109611834	NA	-0.4	-6.86	-0.35	3.42e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs6931421	1.000	rs6931421	chr6:80880138	A/C	cg08355045	chr6:80787529	NA	0.58	9.24	0.45	2.93e-18	Sitting height ratio;
LUSC	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.86	14.0	0.61	2.4e-35	Bladder cancer;
LUSC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg27121462	chr16:89883253	FANCA	0.56	8.97	0.44	2.23e-17	Vitiligo;
LUSC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg18681998	chr4:17616180	MED28	-0.84	-14.53	-0.62	2.09e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	0.94	18.6	0.71	1.75e-53	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12681287	0.888	rs2976201	chr8:87335937	T/C	cg27223183	chr8:87520930	FAM82B	-0.49	-6.83	-0.35	3.94e-11	Caudate activity during reward;
LUSC	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg15605315	chr1:45957053	TESK2	0.46	7.31	0.37	2.04e-12	High light scatter reticulocyte count;
LUSC	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg24375607	chr4:120327624	NA	-0.63	-10.13	-0.48	3.25e-21	Corneal astigmatism;
LUSC	cis	rs7575217	0.784	rs2241872	chr2:101768774	G/C	cg23907051	chr2:101730305	TBC1D8	-0.3	-7.98	-0.4	2.35e-14	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.78	-12.87	-0.58	4.76e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-8.0	-0.4	2.02e-14	Height;
LUSC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg10053473	chr17:62856997	LRRC37A3	0.64	10.18	0.49	2.22e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs6773957	1.000	rs6773957	chr3:186573705	C/T	cg01963189	chr4:121613795	NA	0.33	6.02	0.31	4.59e-9	Adiponectin levels;
LUSC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg04310649	chr10:35416472	CREM	-0.4	-6.27	-0.32	1.11e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6669919	0.553	rs11587632	chr1:211668437	T/C	cg10512769	chr1:211675356	NA	-0.3	-7.06	-0.36	9.61e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12210905	1.000	rs12192446	chr6:26995638	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-5.94	-0.31	7.29e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg16586182	chr3:47516702	SCAP	-0.51	-8.17	-0.41	6.57e-15	Colorectal cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02050560	chr22:42486888	NDUFA6	-0.49	-6.42	-0.33	4.66e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg12963246	chr6:28129442	ZNF389	0.43	6.53	0.34	2.45e-10	Parkinson's disease;
LUSC	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.99	0.36	1.53e-11	Resting heart rate;
LUSC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.06e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.42	6.53	0.34	2.4e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg24503407	chr1:205819492	PM20D1	-0.43	-6.13	-0.32	2.49e-9	Parkinson's disease;
LUSC	cis	rs12618769	0.597	rs4069739	chr2:99049528	G/C	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.14e-13	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25072359	chr17:41440525	NA	0.65	9.46	0.46	5.86e-19	Menopause (age at onset);
LUSC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	0.96	13.03	0.58	1.21e-31	Eosinophil percentage of granulocytes;
LUSC	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18854424	chr1:2615690	NA	0.52	10.83	0.51	1.22e-23	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.68	10.42	0.5	3.33e-22	Lymphocyte counts;
LUSC	cis	rs7246967	0.551	rs12974117	chr19:22867876	G/A	cg23217946	chr19:22817039	ZNF492	0.45	6.01	0.31	4.91e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg16745616	chr19:8428856	ANGPTL4	-0.4	-6.03	-0.31	4.41e-9	HDL cholesterol;
LUSC	cis	rs9359856	0.957	rs9362666	chr6:90310345	T/C	cg13799429	chr6:90582589	CASP8AP2	0.59	6.92	0.35	2.31e-11	Bipolar disorder;
LUSC	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg03806693	chr22:41940476	POLR3H	-0.85	-11.41	-0.53	1.1e-25	Vitiligo;
LUSC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.93	-0.4	3.36e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.56	-7.5	-0.38	5.77e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.21	0.59	2.34e-32	Total body bone mineral density;
LUSC	cis	rs4713675	0.584	rs942643	chr6:33668370	A/G	cg14003231	chr6:33640908	ITPR3	0.31	5.96	0.31	6.53e-9	Plateletcrit;
LUSC	cis	rs12541635	1.000	rs4734897	chr8:107075518	G/A	cg10147462	chr8:107024639	NA	-0.48	-8.62	-0.43	2.66e-16	Age of smoking initiation;
LUSC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg13042288	chr15:90349979	ANPEP	-0.49	-7.03	-0.36	1.18e-11	Uric acid levels;
LUSC	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg11901034	chr3:128598214	ACAD9	-0.42	-6.61	-0.34	1.5e-10	IgG glycosylation;
LUSC	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg01689657	chr7:91764605	CYP51A1	0.33	5.84	0.3	1.23e-8	Breast cancer;
LUSC	cis	rs13006833	0.668	rs291445	chr2:191176479	G/A	cg21644426	chr2:191273491	MFSD6	0.43	6.14	0.32	2.39e-9	Urinary metabolites;
LUSC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg17376030	chr22:41985996	PMM1	-0.47	-5.81	-0.3	1.49e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg09469691	chr10:81107165	PPIF	0.59	8.9	0.44	3.5e-17	Height;
LUSC	cis	rs6977660	0.607	rs13239423	chr7:19816571	T/C	cg05791153	chr7:19748676	TWISTNB	0.7	7.42	0.38	9.51e-13	Thyroid stimulating hormone;
LUSC	cis	rs9815354	0.812	rs60796012	chr3:41908668	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.67	0.43	1.88e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2108225	0.714	rs10953548	chr7:107436232	G/A	cg18560240	chr7:107437656	SLC26A3	-0.43	-6.55	-0.34	2.14e-10	Ulcerative colitis;
LUSC	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg04920474	chr2:44395004	PPM1B	0.6	7.83	0.39	6.75e-14	Height;
LUSC	cis	rs9472414	0.771	rs720989	chr6:44765535	G/T	cg20913747	chr6:44695427	NA	-0.41	-5.71	-0.3	2.44e-8	Height;
LUSC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg12288994	chr5:1860383	NA	0.29	6.3	0.33	9.33e-10	Cardiovascular disease risk factors;
LUSC	cis	rs727505	0.564	rs4731236	chr7:124827236	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.76	-0.35	6.12e-11	Lewy body disease;
LUSC	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg09462578	chr12:12878428	APOLD1	-0.98	-16.98	-0.68	4.89e-47	Lymphocyte counts;
LUSC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.57	-10.63	-0.5	6.53e-23	Breast cancer;
LUSC	cis	rs2294693	1.000	rs2294693	chr6:41005502	T/C	cg14769373	chr6:40998127	UNC5CL	-0.56	-7.91	-0.4	3.76e-14	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4240897	1.000	rs4240897	chr1:12042755	A/G	cg13216073	chr1:12042593	MFN2	-0.38	-6.5	-0.34	2.88e-10	Tuberculosis;
LUSC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg03804128	chr16:635623	NA	0.31	6.22	0.32	1.51e-9	Height;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg22943607	chr19:4400723	SH3GL1	0.42	6.06	0.31	3.65e-9	Mosquito bite size;
LUSC	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg03342759	chr3:160939853	NMD3	-0.54	-8.01	-0.4	1.88e-14	Parkinson's disease;
LUSC	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.78	-0.3	1.68e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07362569	chr17:61921086	SMARCD2	-0.37	-7.55	-0.38	4.1e-13	Prudent dietary pattern;
LUSC	cis	rs6782228	0.675	rs2253151	chr3:128330137	T/C	cg16766828	chr3:128327626	NA	-0.31	-5.71	-0.3	2.49e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg11366901	chr6:160182831	ACAT2	0.92	12.83	0.57	6.56e-31	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg00031303	chr3:195681400	NA	0.63	9.17	0.45	4.83e-18	Pancreatic cancer;
LUSC	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg13902645	chr11:5959945	NA	-0.57	-8.03	-0.4	1.64e-14	DNA methylation (variation);
LUSC	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.58	-12.02	-0.55	6.94e-28	Sense of smell;
LUSC	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg05925327	chr15:68127851	NA	-0.44	-6.89	-0.35	2.79e-11	Obesity;
LUSC	cis	rs977987	0.806	rs17696696	chr16:75393352	G/T	cg03315344	chr16:75512273	CHST6	-0.48	-9.17	-0.45	4.91e-18	Dupuytren's disease;
LUSC	cis	rs7614311	0.731	rs73117087	chr3:63948696	A/G	cg22134162	chr3:63841271	THOC7	-0.48	-5.92	-0.31	8.11e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.53	-8.97	-0.44	2.12e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-10.02	-0.48	7.88e-21	Migraine;Coronary artery disease;
LUSC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg02073558	chr3:44770973	ZNF501	0.6	9.92	0.48	1.69e-20	Depressive symptoms;
LUSC	trans	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg03886242	chr7:26192032	NFE2L3	0.41	6.49	0.33	3.03e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.72	-0.3	2.36e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.63	8.41	0.42	1.21e-15	High light scatter reticulocyte count;
LUSC	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg23942311	chr14:51606299	NA	-0.55	-12.09	-0.55	3.57e-28	Cancer;
LUSC	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg24450063	chr1:156163899	SLC25A44	1.08	21.15	0.76	1.37e-63	Testicular germ cell tumor;
LUSC	cis	rs2857891	0.773	rs2857897	chr11:6982082	A/C	cg04053776	chr11:6947353	ZNF215	0.42	5.98	0.31	5.62e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	trans	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg09050820	chr6:167586206	TCP10L2	0.73	9.47	0.46	5.31e-19	Gastritis;
LUSC	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg18721089	chr20:30220636	NA	-0.35	-5.94	-0.31	7.09e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19717193	chr7:105162577	PUS7	-0.51	-6.24	-0.32	1.35e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4499344	0.556	rs259228	chr19:33134635	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.95	14.03	0.61	1.78e-35	Mean platelet volume;
LUSC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07167872	chr1:205819463	PM20D1	0.77	14.96	0.63	4.26e-39	Monocyte percentage of white cells;
LUSC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg23630131	chr7:65973040	NA	-0.21	-6.01	-0.31	4.93e-9	Aortic root size;
LUSC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.89	-0.58	3.92e-31	Alzheimer's disease;
LUSC	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg27284194	chr4:1044797	NA	0.6	8.9	0.44	3.71e-17	Recombination rate (females);
LUSC	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg21775007	chr8:11205619	TDH	0.5	7.44	0.38	8.37e-13	Neuroticism;
LUSC	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.82	-0.47	3.7e-20	Total cholesterol levels;
LUSC	cis	rs9309473	0.539	rs6745560	chr2:73827117	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-7.2	-0.37	4.02e-12	Metabolite levels;
LUSC	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg23093090	chr10:104574429	C10orf26	-0.35	-6.61	-0.34	1.53e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg17252645	chr8:143867129	LY6D	-0.36	-6.31	-0.33	9.04e-10	Urinary tract infection frequency;
LUSC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg24550644	chr17:30846204	MYO1D	0.6	10.74	0.51	2.54e-23	Schizophrenia;
LUSC	cis	rs72960926	0.744	rs72957983	chr6:74968228	A/G	cg03266952	chr6:74778945	NA	-0.72	-6.61	-0.34	1.56e-10	Metabolite levels (MHPG);
LUSC	cis	rs11264799	0.603	rs12744410	chr1:157566211	A/G	cg18268488	chr1:157545234	FCRL4	0.33	5.9	0.31	8.76e-9	IgA nephropathy;
LUSC	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg04369109	chr6:150039330	LATS1	0.4	5.81	0.3	1.5e-8	Testicular germ cell tumor;
LUSC	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg17462356	chr17:80056334	FASN	-0.44	-6.08	-0.32	3.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg01283332	chr5:1856932	NA	-0.37	-6.86	-0.35	3.31e-11	Cardiovascular disease risk factors;
LUSC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22590775	chr19:49891494	CCDC155	0.56	7.32	0.37	1.92e-12	Multiple sclerosis;
LUSC	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.92	0.51	6.12e-24	Hypertriglyceridemia;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg11387990	chr12:32260018	BICD1	0.42	6.03	0.31	4.24e-9	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22713941	chr2:105953959	C2orf49	0.48	6.74	0.35	6.86e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg15485101	chr11:133734466	NA	0.4	7.24	0.37	3.03e-12	Childhood ear infection;
LUSC	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.65	10.08	0.48	4.7e-21	Corneal astigmatism;
LUSC	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg13256891	chr4:100009986	ADH5	-0.45	-6.09	-0.32	3.17e-9	Alcohol dependence;
LUSC	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg18105134	chr13:113819100	PROZ	-0.71	-10.09	-0.48	4.47e-21	Platelet distribution width;
LUSC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg22709100	chr7:91322751	NA	0.4	5.81	0.3	1.48e-8	Breast cancer;
LUSC	cis	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg02508848	chr16:68573721	ZFP90	-0.43	-5.82	-0.3	1.42e-8	Ulcerative colitis;
LUSC	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg17595323	chr11:93583763	C11orf90	-0.31	-5.66	-0.3	3.3e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg04733989	chr22:42467013	NAGA	0.4	6.7	0.34	8.67e-11	Cognitive function;
LUSC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.79	-0.39	8.31e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg03036452	chr22:46663545	TTC38	0.58	5.76	0.3	1.88e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.52	8.33	0.41	2.14e-15	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg02423579	chr7:2872169	GNA12	-0.38	-5.91	-0.31	8.38e-9	Height;
LUSC	cis	rs7590368	1.000	rs55968911	chr2:10961840	C/T	cg15705551	chr2:10952987	PDIA6	0.58	8.0	0.4	2.11e-14	Educational attainment (years of education);
LUSC	cis	rs807669	0.525	rs2073740	chr22:19196112	A/C	cg02655711	chr22:19163373	SLC25A1	-0.49	-8.99	-0.44	1.81e-17	Metabolite levels;
LUSC	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg13852791	chr20:30311386	BCL2L1	0.93	14.46	0.62	3.86e-37	Mean corpuscular hemoglobin;
LUSC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.87	-0.31	1.08e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg18240062	chr17:79603768	NPLOC4	-0.79	-15.33	-0.64	1.56e-40	Eye color traits;
LUSC	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg21643547	chr1:205240462	TMCC2	-0.38	-7.02	-0.36	1.23e-11	Red blood cell count;
LUSC	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-7.69	-0.39	1.62e-13	Morning vs. evening chronotype;
LUSC	cis	rs243505	0.898	rs243527	chr7:148416104	G/T	cg09806900	chr7:148480153	CUL1	-0.48	-6.82	-0.35	4.34e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg21724239	chr8:58056113	NA	0.78	9.03	0.44	1.43e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.32	-20.9	-0.75	1.26e-62	Type 1 diabetes nephropathy;
LUSC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.83	-0.57	6.64e-31	Alzheimer's disease;
LUSC	trans	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.71	0.39	1.46e-13	Ulcerative colitis;
LUSC	cis	rs3741151	0.892	rs2027760	chr11:73036481	G/A	cg17517138	chr11:73019481	ARHGEF17	0.97	9.08	0.44	1e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg00343986	chr7:65444356	GUSB	0.48	7.26	0.37	2.76e-12	Calcium levels;
LUSC	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg05283184	chr6:79620031	NA	-0.45	-8.48	-0.42	7.39e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg15073853	chr19:18549131	ISYNA1	-0.31	-5.81	-0.3	1.44e-8	Breast cancer;
LUSC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.78	-0.35	5.48e-11	Neutrophil percentage of white cells;
LUSC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-6.78	-0.35	5.37e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	1.21	16.68	0.67	7.04e-46	Eosinophil percentage of granulocytes;
LUSC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg25258033	chr6:167368657	RNASET2	0.48	7.92	0.4	3.55e-14	Crohn's disease;
LUSC	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.42e-8	Life satisfaction;
LUSC	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.68	9.48	0.46	4.95e-19	Platelet count;
LUSC	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg13852791	chr20:30311386	BCL2L1	0.87	9.76	0.47	5.71e-20	Mean corpuscular hemoglobin;
LUSC	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg02574844	chr11:5959923	NA	-0.42	-5.88	-0.31	1.01e-8	DNA methylation (variation);
LUSC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-10.73	-0.51	2.72e-23	Alzheimer's disease;
LUSC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg02951883	chr7:2050386	MAD1L1	0.51	9.26	0.45	2.48e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs3125734	0.572	rs7896627	chr10:64046354	T/G	cg09941381	chr10:64027924	RTKN2	-0.39	-7.12	-0.36	6.51e-12	Rheumatoid arthritis;
LUSC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg05347473	chr6:146136440	FBXO30	0.57	10.06	0.48	5.7e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8113142	0.614	rs2098038	chr19:29192883	A/T	cg04546413	chr19:29218101	NA	0.44	5.93	0.31	7.76e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	21.34	0.76	2.36e-64	Prudent dietary pattern;
LUSC	cis	rs9925964	1.000	rs9925964	chr16:31129895	A/G	cg02466173	chr16:30829666	NA	0.34	6.16	0.32	2.05e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.72	5.68	0.3	2.95e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs4964805	0.594	rs10861095	chr12:104165387	A/G	cg02344784	chr12:104178138	NT5DC3	0.38	6.05	0.31	3.94e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-11.59	-0.54	2.42e-26	Schizophrenia;
LUSC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg17376030	chr22:41985996	PMM1	-0.47	-5.84	-0.3	1.25e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs10465746	0.725	rs1359331	chr1:84360301	C/A	cg10977910	chr1:84465055	TTLL7	0.52	7.45	0.38	7.96e-13	Obesity-related traits;
LUSC	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.82	10.81	0.51	1.42e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg25801113	chr15:45476975	SHF	0.34	7.17	0.37	4.98e-12	Uric acid levels;
LUSC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.2	0.32	1.71e-9	Schizophrenia;
LUSC	cis	rs4654899	0.897	rs7548649	chr1:21090081	A/G	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.36	9.87e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-6.48	-0.33	3.39e-10	Response to antipsychotic treatment;
LUSC	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.78	-0.43	8.6e-17	Response to antipsychotic treatment;
LUSC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg04944784	chr2:26401820	FAM59B	0.77	11.17	0.52	7.75e-25	Gut microbiome composition (summer);
LUSC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg06600287	chr1:53387719	ECHDC2	0.28	5.68	0.3	3.01e-8	Monocyte count;
LUSC	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg11871910	chr12:69753446	YEATS4	0.45	5.83	0.3	1.3e-8	Response to diuretic therapy;
LUSC	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg04733989	chr22:42467013	NAGA	0.39	6.41	0.33	4.95e-10	Cognitive function;
LUSC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.33	-0.33	7.76e-10	Personality dimensions;
LUSC	cis	rs9837602	1.000	rs793499	chr3:99565576	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-6.06	-0.31	3.76e-9	Breast cancer;
LUSC	trans	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg06521331	chr12:34319734	NA	0.41	6.52	0.34	2.67e-10	Bladder cancer;
LUSC	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg24558204	chr6:135376177	HBS1L	0.68	10.82	0.51	1.32e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg23630131	chr7:65973040	NA	-0.2	-5.66	-0.3	3.22e-8	Aortic root size;
LUSC	cis	rs6537837	0.887	rs1889470	chr1:110141421	A/G	cg05049280	chr1:110155535	GNAT2	0.43	6.61	0.34	1.53e-10	Major depressive disorder;
LUSC	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg00800038	chr16:89945340	TCF25	-0.75	-6.64	-0.34	1.26e-10	Skin colour saturation;
LUSC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg10664184	chr19:17420304	DDA1	0.47	5.81	0.3	1.48e-8	Systemic lupus erythematosus;
LUSC	cis	rs4478858	0.735	rs11576603	chr1:31774031	C/T	cg00250761	chr1:31883323	NA	-0.35	-8.56	-0.42	4.19e-16	Alcohol dependence;
LUSC	trans	rs6600671	1.000	rs6600671	chr1:121200490	T/G	cg00646200	chr1:148855367	NA	-0.49	-7.7	-0.39	1.59e-13	Hip geometry;
LUSC	cis	rs1953600	0.837	rs2819946	chr10:81951635	G/A	cg00277334	chr10:82204260	NA	0.45	7.08	0.36	8.35e-12	Sarcoidosis;
LUSC	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.58	-0.38	3.5e-13	Neuroticism;
LUSC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26314531	chr2:26401878	FAM59B	0.66	8.33	0.41	2.06e-15	Gut microbiome composition (summer);
LUSC	cis	rs2562456	0.833	rs2562487	chr19:21651382	C/T	cg00806126	chr19:22604979	ZNF98	-0.37	-5.78	-0.3	1.73e-8	Pain;
LUSC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.35	-0.8	4.97e-76	Height;
LUSC	cis	rs7799006	0.929	rs6461233	chr7:2261468	G/A	cg12823233	chr7:2316876	SNX8	-0.35	-5.91	-0.31	8.25e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg13647721	chr17:30228624	UTP6	-0.63	-6.11	-0.32	2.85e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs2282300	0.739	rs1222215	chr11:30347596	C/T	cg25418670	chr11:30344373	C11orf46	-0.64	-9.18	-0.45	4.63e-18	Morning vs. evening chronotype;
LUSC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.59	-10.36	-0.49	5.26e-22	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg12564285	chr5:131593104	PDLIM4	-0.44	-7.54	-0.38	4.45e-13	Breast cancer;
LUSC	cis	rs10904908	0.733	rs7080366	chr10:17254832	C/T	cg01003015	chr10:17271136	VIM	-0.38	-5.65	-0.3	3.37e-8	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg03585969	chr10:35415529	CREM	-0.57	-8.4	-0.42	1.27e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.69	-10.09	-0.48	4.37e-21	Systemic lupus erythematosus;
LUSC	cis	rs3087591	0.960	rs10512433	chr17:29600564	T/C	cg24425628	chr17:29625626	OMG;NF1	0.58	8.49	0.42	6.82e-16	Hip circumference;
LUSC	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21640587	chr11:117668038	DSCAML1	0.68	9.85	0.47	2.82e-20	Myopia;
LUSC	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.48	-0.62	3.25e-37	Schizophrenia;
LUSC	cis	rs9549260	0.785	rs2253001	chr13:41145330	A/T	cg21288729	chr13:41239152	FOXO1	0.6	9.24	0.45	2.89e-18	Red blood cell count;
LUSC	cis	rs3931020	0.657	rs277369	chr1:75234661	T/C	cg00121533	chr1:75199117	CRYZ;TYW3	-0.46	-5.87	-0.31	1.06e-8	Resistin levels;
LUSC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg09455208	chr3:40491958	NA	0.59	10.51	0.5	1.59e-22	Renal cell carcinoma;
LUSC	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg13852791	chr20:30311386	BCL2L1	0.95	14.88	0.63	9.12e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	trans	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg25214090	chr10:38739885	LOC399744	-0.4	-6.16	-0.32	2.11e-9	Corneal astigmatism;
LUSC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg06636001	chr8:8085503	FLJ10661	0.57	8.58	0.43	3.5e-16	Mood instability;
LUSC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg18904891	chr8:8559673	CLDN23	-0.41	-6.37	-0.33	6.23e-10	Mood instability;
LUSC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg11632617	chr15:75315747	PPCDC	-0.55	-7.1	-0.36	7.61e-12	Blood trace element (Zn levels);
LUSC	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg18753928	chr3:113234510	CCDC52	-0.52	-7.98	-0.4	2.41e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06544989	chr22:39130855	UNC84B	0.34	6.11	0.32	2.78e-9	Menopause (age at onset);
LUSC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg23630131	chr7:65973040	NA	-0.21	-5.82	-0.3	1.38e-8	Aortic root size;
LUSC	cis	rs76878669	0.917	rs10896110	chr11:66101978	G/A	cg18002602	chr11:66138449	SLC29A2	-0.38	-5.91	-0.31	8.59e-9	Educational attainment (years of education);
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg12419862	chr22:24373484	LOC391322	0.8	12.3	0.56	6.01e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	6.61	0.34	1.54e-10	Rheumatoid arthritis;
LUSC	cis	rs7586879	0.789	rs36029941	chr2:25127801	C/T	cg01884057	chr2:25150051	NA	0.42	8.82	0.43	6.24e-17	Body mass index;
LUSC	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	1.11	13.71	0.6	3.11e-34	Nonalcoholic fatty liver disease;
LUSC	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.2	0.45	3.86e-18	Coffee consumption (cups per day);
LUSC	cis	rs2274273	0.870	rs10134339	chr14:55814380	T/C	cg04306507	chr14:55594613	LGALS3	0.56	12.96	0.58	2.13e-31	Protein biomarker;
LUSC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21963583	chr11:68658836	MRPL21	0.56	8.7	0.43	1.48e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4363385	0.507	rs6587710	chr1:152870716	A/G	cg07796016	chr1:152779584	LCE1C	-0.58	-8.89	-0.44	3.88e-17	Inflammatory skin disease;
LUSC	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	7.55	0.38	4.06e-13	Iron status biomarkers;
LUSC	cis	rs977987	0.843	rs11644741	chr16:75466433	C/A	cg03315344	chr16:75512273	CHST6	0.5	9.52	0.46	3.5e-19	Dupuytren's disease;
LUSC	cis	rs1775715	0.870	rs10827001	chr10:32229734	C/T	cg04359828	chr10:32216031	ARHGAP12	0.38	6.41	0.33	4.83e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg02807482	chr3:125708958	NA	-0.49	-6.1	-0.32	3.01e-9	Blood pressure (smoking interaction);
LUSC	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21545522	chr1:205238299	TMCC2	0.48	9.09	0.45	9.26e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs77633900	0.614	rs2439991	chr15:76877227	A/G	cg21673338	chr15:77095150	SCAPER	-0.69	-6.88	-0.35	2.95e-11	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.17	0.52	7.73e-25	Prudent dietary pattern;
LUSC	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.42	0.64	6.71e-41	Lymphocyte percentage of white cells;
LUSC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg17376030	chr22:41985996	PMM1	-0.48	-6.06	-0.31	3.78e-9	Cannabis dependence symptom count;
LUSC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg02187348	chr16:89574699	SPG7	0.45	7.1	0.36	7.33e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg12560992	chr17:57184187	TRIM37	0.86	15.57	0.65	1.69e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.45	6.23	0.32	1.38e-9	Renal function-related traits (BUN);
LUSC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21984481	chr17:79567631	NPLOC4	-0.73	-15.53	-0.65	2.62e-41	Eye color traits;
LUSC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg19920283	chr7:105172520	RINT1	-0.62	-7.06	-0.36	9.44e-12	Bipolar disorder (body mass index interaction);
LUSC	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg25922239	chr6:33757077	LEMD2	0.44	5.87	0.31	1.07e-8	Crohn's disease;
LUSC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.39e-22	Alzheimer's disease (late onset);
LUSC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.05e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg02527881	chr3:46936655	PTH1R	0.4	6.96	0.36	1.81e-11	Colorectal cancer;
LUSC	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.88	-0.31	1.02e-8	IgG glycosylation;
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23978390	chr7:1156363	C7orf50	0.49	7.09	0.36	8.21e-12	Longevity;Endometriosis;
LUSC	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-7.62	-0.38	2.72e-13	Blood metabolite levels;
LUSC	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg24578937	chr1:2090814	PRKCZ	-0.44	-9.86	-0.47	2.77e-20	Height;
LUSC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.78	-0.57	1.02e-30	Platelet count;
LUSC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg01879757	chr17:41196368	BRCA1	-0.39	-5.96	-0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07636037	chr3:49044803	WDR6	0.7	9.29	0.45	2.11e-18	Menarche (age at onset);
LUSC	cis	rs3741151	1.000	rs79078097	chr11:73049771	G/A	cg17517138	chr11:73019481	ARHGEF17	1.0	8.62	0.43	2.76e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-7.81	-0.39	7.72e-14	Total cholesterol levels;
LUSC	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-1.14	-18.24	-0.71	4.68e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg05519781	chr21:40033154	ERG	0.77	13.3	0.59	1.09e-32	Coronary artery disease;
LUSC	cis	rs981844	0.890	rs55850399	chr4:154684906	C/T	cg14289246	chr4:154710475	SFRP2	0.55	7.04	0.36	1.12e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg19230755	chr7:65878503	NA	-0.44	-6.08	-0.32	3.29e-9	Aortic root size;
LUSC	cis	rs7799006	0.606	rs12669625	chr7:2315950	C/T	cg08027265	chr7:2291960	NA	-0.61	-10.86	-0.51	1e-23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs73198271	0.565	rs575895	chr8:8594247	G/A	cg01851573	chr8:8652454	MFHAS1	0.41	6.28	0.33	1.04e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9811920	0.898	rs7636776	chr3:99840446	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.35	6.63	0.34	1.35e-10	Axial length;
LUSC	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg02493740	chr2:85810744	VAMP5	-0.53	-9.28	-0.45	2.2e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06481639	chr22:41940642	POLR3H	0.48	5.76	0.3	1.93e-8	Vitiligo;
LUSC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg05347473	chr6:146136440	FBXO30	0.5	8.45	0.42	8.8e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg25237894	chr2:233734115	C2orf82	-0.35	-6.55	-0.34	2.15e-10	Coronary artery disease;
LUSC	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	8.46	0.42	8.57e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg06606381	chr12:133084897	FBRSL1	-0.61	-5.95	-0.31	6.75e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.55	-0.34	2.19e-10	Life satisfaction;
LUSC	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg09904177	chr6:26538194	HMGN4	-0.74	-6.12	-0.32	2.61e-9	Depression;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg10835308	chr12:68726120	MDM1	0.69	6.05	0.31	3.94e-9	Cognitive performance;
LUSC	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg02176678	chr2:219576539	TTLL4	0.61	11.03	0.52	2.41e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11997175	0.574	rs4733453	chr8:33650745	A/G	ch.8.33884649F	chr8:33765107	NA	0.51	8.16	0.41	6.83e-15	Body mass index;
LUSC	cis	rs12760731	0.720	rs7537811	chr1:178276421	A/T	cg00404053	chr1:178313656	RASAL2	0.57	6.5	0.33	2.97e-10	Obesity-related traits;
LUSC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.52	-0.34	2.59e-10	Schizophrenia;
LUSC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg06008330	chr7:65541103	ASL	0.4	6.19	0.32	1.77e-9	Aortic root size;
LUSC	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.67	0.39	1.87e-13	Corneal astigmatism;
LUSC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg07741184	chr6:167504864	NA	0.37	6.72	0.35	7.82e-11	Crohn's disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21515243	chr18:21033072	RIOK3	0.44	6.53	0.34	2.51e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03576123	chr11:487126	PTDSS2	-0.93	-10.38	-0.49	4.61e-22	Body mass index;
LUSC	cis	rs17125944	0.656	rs74825460	chr14:53390015	C/T	cg00686598	chr14:53173677	PSMC6	0.87	6.77	0.35	5.66e-11	Alzheimer's disease (late onset);
LUSC	cis	rs6500395	1.000	rs28577888	chr16:48673281	T/G	cg04672837	chr16:48644449	N4BP1	0.45	6.84	0.35	3.75e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.45	0.86	2.28e-98	Chronic sinus infection;
LUSC	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	6.65	0.34	1.17e-10	Lung cancer in ever smokers;
LUSC	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.61	-0.43	2.96e-16	Response to antipsychotic treatment;
LUSC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg06096015	chr1:231504339	EGLN1	0.56	9.88	0.48	2.29e-20	Hemoglobin concentration;
LUSC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	0.91	15.15	0.64	7.89e-40	Breast cancer;
LUSC	cis	rs7945705	0.875	rs11042059	chr11:8795080	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.33	6.55	0.34	2.18e-10	Hemoglobin concentration;
LUSC	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-5.78	-0.3	1.73e-8	IgG glycosylation;
LUSC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08219700	chr8:58056026	NA	0.69	8.2	0.41	5.2e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs72674100	1.000	rs77493600	chr4:97980332	A/G	cg16405019	chr1:18959625	PAX7	-0.63	-6.58	-0.34	1.77e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs701145	0.938	rs355752	chr3:153970796	A/G	cg17054900	chr3:154042577	DHX36	0.85	9.0	0.44	1.75e-17	Coronary artery disease;
LUSC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.9	-0.51	6.9e-24	Aortic root size;
LUSC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg09796270	chr17:17721594	SREBF1	0.36	6.08	0.32	3.26e-9	Total body bone mineral density;
LUSC	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-10.47	-0.5	2.33e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg18225595	chr11:63971243	STIP1	0.43	6.95	0.36	1.98e-11	Platelet count;
LUSC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.36	-0.42	1.66e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9560113	1.000	rs9560109	chr13:112180468	C/T	cg14154082	chr13:112174009	NA	0.37	7.63	0.39	2.5e-13	Menarche (age at onset);
LUSC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg27170947	chr2:26402098	FAM59B	-0.7	-10.61	-0.5	7.11e-23	Gut microbiome composition (summer);
LUSC	cis	rs9646944	0.501	rs7586983	chr2:103028066	C/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.6	0.34	1.65e-10	Blood protein levels;
LUSC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11764359	chr7:65958608	NA	0.68	11.0	0.52	3.08e-24	Aortic root size;
LUSC	cis	rs2455601	0.679	rs2653559	chr11:8900394	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.42	-6.91	-0.35	2.42e-11	Schizophrenia;
LUSC	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg04733989	chr22:42467013	NAGA	0.4	6.44	0.33	4.04e-10	Cognitive function;
LUSC	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	8.86	0.44	4.94e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs13253111	0.624	rs7832318	chr8:28110414	A/G	cg26534493	chr8:28060551	NA	0.38	6.94	0.36	2.03e-11	Childhood body mass index;
LUSC	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg22681709	chr2:178499509	PDE11A	-0.46	-8.38	-0.42	1.5e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-1.01	-14.59	-0.62	1.22e-37	Initial pursuit acceleration;
LUSC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg24578937	chr1:2090814	PRKCZ	-0.45	-10.42	-0.5	3.3e-22	Height;
LUSC	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg13256891	chr4:100009986	ADH5	-0.45	-6.18	-0.32	1.85e-9	Alcohol dependence;
LUSC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	trans	rs7726558	0.642	rs56309111	chr5:118883824	G/A	cg14402224	chr7:50570049	DDC	-0.48	-5.99	-0.31	5.34e-9	QT interval (sulfonylurea treatment interaction);
LUSC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.93	0.44	2.83e-17	Prudent dietary pattern;
LUSC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00149659	chr3:10157352	C3orf10	-0.96	-14.06	-0.61	1.33e-35	Alzheimer's disease;
LUSC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6005807	0.719	rs28818228	chr22:29042025	G/A	cg12565055	chr22:29076175	TTC28	0.54	5.86	0.31	1.12e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg03433033	chr1:76189801	ACADM	-0.43	-6.39	-0.33	5.51e-10	Daytime sleep phenotypes;
LUSC	trans	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg07211511	chr3:129823064	LOC729375	0.76	9.91	0.48	1.78e-20	Blood pressure (smoking interaction);
LUSC	trans	rs979233	0.502	rs276270	chr5:42074932	T/G	cg07010552	chr17:7358735	CHRNB1	-0.42	-6.12	-0.32	2.61e-9	Systemic lupus erythematosus;
LUSC	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg07169764	chr2:136633963	MCM6	-0.6	-8.05	-0.4	1.47e-14	Mosquito bite size;
LUSC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	9.34	0.45	1.45e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg16235748	chr6:149772707	ZC3H12D	0.29	5.83	0.3	1.34e-8	Dupuytren's disease;
LUSC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-7.1	-0.36	7.51e-12	Aortic root size;
LUSC	cis	rs1403694	0.695	rs10439971	chr3:186434188	C/T	cg12454167	chr3:186435060	KNG1	0.34	8.38	0.42	1.49e-15	Blood protein levels;
LUSC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg16434002	chr17:42200994	HDAC5	-0.45	-6.31	-0.33	8.62e-10	Total body bone mineral density;
LUSC	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07080220	chr10:102295463	HIF1AN	0.68	9.04	0.44	1.34e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg17264618	chr3:40429014	ENTPD3	0.27	5.71	0.3	2.49e-8	Renal cell carcinoma;
LUSC	cis	rs12220238	1.000	rs10762582	chr10:75968316	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.25	0.37	2.96e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	0.82	16.35	0.67	1.42e-44	Gut microbiome composition (winter);
LUSC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	cis	rs6542838	0.644	rs7590596	chr2:99467938	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.13	-0.32	2.44e-9	Fear of minor pain;
LUSC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg08219700	chr8:58056026	NA	0.45	5.84	0.3	1.24e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg17366294	chr4:99064904	C4orf37	0.56	8.86	0.44	4.88e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.58	-5.73	-0.3	2.28e-8	Narcolepsy;
LUSC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.34	0.33	7.46e-10	Lung cancer;
LUSC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10892173	0.904	rs10892172	chr11:117672474	C/A	cg21640587	chr11:117668038	DSCAML1	0.4	6.11	0.32	2.76e-9	Myopia;
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.96	-0.4	2.78e-14	Lymphocyte counts;
LUSC	cis	rs506338	0.517	rs530252	chr11:64443465	T/C	cg19131476	chr11:64387923	NRXN2	0.36	7.86	0.4	5.19e-14	Body mass index;Urate levels;
LUSC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.19	-0.41	5.45e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03264133	chr6:25882463	NA	-0.4	-6.92	-0.35	2.28e-11	Height;
LUSC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg05861140	chr6:150128134	PCMT1	-0.39	-6.27	-0.32	1.14e-9	Lung cancer;
LUSC	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg05272587	chr13:111038400	COL4A2	-0.42	-7.09	-0.36	7.83e-12	White matter hyperintensity burden;
LUSC	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05901451	chr6:126070800	HEY2	-0.57	-8.75	-0.43	1.07e-16	Endometrial cancer;
LUSC	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	6.73	0.35	7.22e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg20607798	chr8:58055168	NA	0.57	6.43	0.33	4.5e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg04989706	chr14:50066350	PPIL5	-0.45	-5.89	-0.31	9.5e-9	Carotid intima media thickness;
LUSC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg13902645	chr11:5959945	NA	-0.6	-8.4	-0.42	1.29e-15	DNA methylation (variation);
LUSC	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg22676075	chr6:135203613	NA	0.49	7.56	0.38	3.85e-13	Red blood cell count;
LUSC	cis	rs3825199	0.515	rs2072593	chr12:93970026	T/C	cg18151635	chr12:93972918	NA	-0.62	-8.89	-0.44	3.85e-17	Height;
LUSC	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg06287003	chr12:125626642	AACS	-0.36	-5.7	-0.3	2.6e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg24578937	chr1:2090814	PRKCZ	-0.41	-8.95	-0.44	2.53e-17	Height;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg12335473	chr3:15140786	ZFYVE20	0.46	6.63	0.34	1.38e-10	Mosquito bite size;
LUSC	cis	rs7923452	0.938	rs753173	chr10:30778738	T/C	cg18806716	chr10:30721971	MAP3K8	0.59	6.82	0.35	4.37e-11	Itch intensity from mosquito bite;
LUSC	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg07930552	chr6:133119739	C6orf192	0.79	10.32	0.49	7.22e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-7.12	-0.36	6.84e-12	Blood metabolite levels;
LUSC	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg17691542	chr6:26056736	HIST1H1C	0.58	8.03	0.4	1.68e-14	Iron status biomarkers;
LUSC	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-7.54	-0.38	4.42e-13	Morning vs. evening chronotype;
LUSC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg14337668	chr9:99883682	NA	-0.75	-6.86	-0.35	3.45e-11	Myocardial infarction;
LUSC	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	11.02	0.52	2.78e-24	Hypertriglyceridemia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00590991	chr5:176900010	DBN1	-0.48	-7.41	-0.38	1.04e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.82	-0.43	6.69e-17	Retinal vascular caliber;
LUSC	cis	rs1595825	0.891	rs16826791	chr2:198895133	C/G	cg10547527	chr2:198650123	BOLL	-0.52	-6.25	-0.32	1.23e-9	Ulcerative colitis;
LUSC	cis	rs9925964	0.967	rs749767	chr16:31124407	C/T	cg02466173	chr16:30829666	NA	-0.32	-5.89	-0.31	9.6e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg10857441	chr5:6722123	POLS	-0.45	-8.34	-0.42	1.93e-15	Menopause (age at onset);
LUSC	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-5.94	-0.31	7.24e-9	Fear of minor pain;
LUSC	trans	rs12439619	0.921	rs56042848	chr15:82527585	A/T	cg04831495	chr15:85060580	GOLGA6L5	-0.54	-8.2	-0.41	5.18e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.81	-14.26	-0.62	2.34e-36	Sudden cardiac arrest;
LUSC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.61	0.5	7.35e-23	Monocyte percentage of white cells;
LUSC	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.77	11.37	0.53	1.57e-25	Corneal astigmatism;
LUSC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg23887609	chr12:130822674	PIWIL1	0.49	7.36	0.37	1.48e-12	Menopause (age at onset);
LUSC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg09021430	chr5:549028	NA	-0.55	-7.25	-0.37	2.95e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7074356	0.915	rs1870146	chr10:82210379	A/G	cg00277334	chr10:82204260	NA	-0.65	-6.41	-0.33	5.1e-10	Borderline personality disorder;
LUSC	cis	rs7727544	0.582	rs10478998	chr5:131516531	G/A	cg14196790	chr5:131705035	SLC22A5	0.46	7.7	0.39	1.54e-13	Blood metabolite levels;
LUSC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24110177	chr3:50126178	RBM5	0.55	9.12	0.45	7.29e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	6.24	0.32	1.35e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs977987	0.843	rs62062568	chr16:75445324	T/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.06	-0.36	9.44e-12	Dupuytren's disease;
LUSC	cis	rs2798269	0.902	rs2798280	chr13:22112853	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.41	-6.31	-0.33	8.81e-10	PR segment;
LUSC	cis	rs12137294	0.866	rs1172151	chr1:205221659	A/C	cg21643547	chr1:205240462	TMCC2	-0.33	-5.98	-0.31	5.7e-9	Red cell distribution width;
LUSC	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg23711669	chr6:146136114	FBXO30	0.88	16.26	0.66	3.3e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.48	-0.33	3.34e-10	Lung cancer;
LUSC	trans	rs10486158	0.843	rs1294616	chr7:7391479	A/C	cg01895333	chr3:109035405	DPPA2	-0.38	-6.03	-0.31	4.33e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.86	0.51	9.96e-24	Mean corpuscular volume;
LUSC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg24209194	chr3:40518798	ZNF619	0.42	5.68	0.3	2.95e-8	Renal cell carcinoma;
LUSC	cis	rs2667011	0.653	rs2666998	chr2:160844633	A/T	cg06573604	chr2:160760825	LY75	-0.49	-6.2	-0.32	1.68e-9	Bilirubin levels;
LUSC	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.99	0.31	5.39e-9	Morning vs. evening chronotype;
LUSC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg25039879	chr17:56429692	SUPT4H1	0.68	9.09	0.45	8.81e-18	Cognitive test performance;
LUSC	cis	rs9807989	0.524	rs7594402	chr2:103021267	A/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.72e-12	Asthma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17829816	chr10:102802857	NA	-0.41	-6.08	-0.32	3.23e-9	Electrocardiographic conduction measures;
LUSC	trans	rs6851442	0.614	rs28374811	chr4:109038758	G/A	cg22866579	chr4:146743096	ZNF827	0.65	6.34	0.33	7.61e-10	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-6.71	-0.34	8.22e-11	Alzheimer's disease (late onset);
LUSC	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg06092702	chr1:163392909	NA	-0.42	-7.26	-0.37	2.74e-12	Motion sickness;
LUSC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.61	0.43	3.03e-16	Prudent dietary pattern;
LUSC	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.47	8.78	0.43	8.35e-17	Reticulocyte fraction of red cells;
LUSC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.45	0.65	5.38e-41	Platelet count;
LUSC	trans	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg26043149	chr18:55253948	FECH	-0.46	-6.99	-0.36	1.52e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg16230307	chr14:35515116	FAM177A1	0.77	10.09	0.48	4.44e-21	Psoriasis;
LUSC	cis	rs10465746	0.725	rs6694752	chr1:84389960	C/T	cg10977910	chr1:84465055	TTLL7	0.51	7.3	0.37	2.17e-12	Obesity-related traits;
LUSC	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg08213375	chr14:104286397	PPP1R13B	0.53	10.49	0.5	1.89e-22	Schizophrenia;
LUSC	cis	rs6750795	0.746	rs2916579	chr2:232421159	A/G	cg19187155	chr2:232395269	NMUR1	0.96	19.06	0.72	2.52e-55	Height;
LUSC	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.45	5.65	0.3	3.51e-8	Schizophrenia;
LUSC	trans	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.4	-0.33	5.32e-10	Monocyte count;
LUSC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.83	0.35	3.99e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	9.51	0.46	3.94e-19	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	8.02	0.4	1.76e-14	Schizophrenia;
LUSC	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg03859395	chr2:55845619	SMEK2	0.87	16.12	0.66	1.19e-43	Metabolic syndrome;
LUSC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-0.85	-17.18	-0.69	7.21e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg11062466	chr8:58055876	NA	0.68	7.85	0.39	5.73e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg17127132	chr2:85788382	GGCX	0.43	6.23	0.32	1.39e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.15	10.47	0.5	2.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.47	7.43	0.38	9.07e-13	Blood metabolite levels;
LUSC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg16850897	chr7:100343110	ZAN	-0.6	-8.33	-0.41	2.18e-15	Other erythrocyte phenotypes;
LUSC	cis	rs3820928	0.935	rs113195824	chr2:227769139	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.99	-0.4	2.26e-14	Pulmonary function;
LUSC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg16624210	chr5:671434	TPPP	0.5	6.17	0.32	1.96e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg23649088	chr2:200775458	C2orf69	0.52	7.07	0.36	9.17e-12	Schizophrenia;
LUSC	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg19717773	chr7:2847554	GNA12	-0.34	-5.8	-0.3	1.55e-8	Height;
LUSC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg13699009	chr12:122356056	WDR66	0.48	7.58	0.38	3.54e-13	Mean corpuscular volume;
LUSC	cis	rs7605827	0.930	rs6733519	chr2:15525567	T/C	cg19274914	chr2:15703543	NA	0.47	9.24	0.45	2.95e-18	Educational attainment (years of education);
LUSC	cis	rs2274273	0.516	rs2149482	chr14:55368627	C/T	cg04306507	chr14:55594613	LGALS3	0.31	5.9	0.31	8.84e-9	Protein biomarker;
LUSC	cis	rs2324229	0.797	rs1180236	chr6:83944147	T/G	cg08257003	chr6:84140564	ME1	0.27	6.23	0.32	1.37e-9	Platelet-derived growth factor BB levels;
LUSC	cis	rs11153306	0.677	rs3777921	chr6:111924410	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.31	5.89	0.31	9.19e-9	Tonsillectomy;
LUSC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.81	-0.39	7.54e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.54	0.34	2.33e-10	Menopause (age at onset);
LUSC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-6.54	-0.34	2.35e-10	High light scatter reticulocyte count;
LUSC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg02034447	chr16:89574710	SPG7	-0.39	-5.78	-0.3	1.68e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg00149659	chr3:10157352	C3orf10	0.61	8.75	0.43	1.07e-16	Alzheimer's disease;
LUSC	cis	rs11608355	0.521	rs7976839	chr12:109830534	C/A	cg19025524	chr12:109796872	NA	-0.4	-7.5	-0.38	6e-13	Neuroticism;
LUSC	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg00191853	chr8:101177733	SPAG1	0.36	5.93	0.31	7.61e-9	Atrioventricular conduction;
LUSC	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.54	8.12	0.41	8.79e-15	Response to bleomycin (chromatid breaks);
LUSC	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg23229984	chr5:148520753	ABLIM3	-0.44	-6.35	-0.33	7.11e-10	Breast cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23612142	chr6:158589101	GTF2H5;SERAC1	-0.41	-5.96	-0.31	6.26e-9	Triglycerides;
LUSC	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg14703610	chr5:56206110	C5orf35	0.4	5.74	0.3	2.13e-8	Coronary artery disease;
LUSC	trans	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg20587970	chr11:113659929	NA	0.81	9.8	0.47	4.41e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	22.9	0.78	1.85e-70	Height;
LUSC	cis	rs6692729	0.933	rs1295641	chr1:227070695	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.51	-7.32	-0.37	1.91e-12	Electrodermal activity;
LUSC	cis	rs7246967	0.611	rs66866654	chr19:22813739	A/G	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg25258033	chr6:167368657	RNASET2	0.47	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	cis	rs10203711	1.000	rs907103	chr2:239564541	A/G	cg14580085	chr2:239553406	NA	0.43	7.46	0.38	7.41e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4363385	0.693	rs608509	chr1:153034650	G/C	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.28	-0.37	2.39e-12	Inflammatory skin disease;
LUSC	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg08601574	chr20:25228251	PYGB	0.43	6.6	0.34	1.59e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11785693	0.862	rs17435612	chr8:4987896	C/T	cg26367366	chr8:4980734	NA	-0.73	-8.63	-0.43	2.6e-16	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg05043794	chr9:111880884	C9orf5	-0.33	-7.11	-0.36	7.27e-12	Menarche (age at onset);
LUSC	cis	rs116988415	0.584	rs2269307	chr14:65245007	G/A	cg25083366	chr14:65239357	SPTB	0.6	6.16	0.32	2.11e-9	Daytime sleep phenotypes;
LUSC	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg24060327	chr5:131705240	SLC22A5	0.45	6.75	0.35	6.71e-11	Blood metabolite levels;
LUSC	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg25237894	chr2:233734115	C2orf82	0.35	6.5	0.34	2.87e-10	Coronary artery disease;
LUSC	cis	rs79387448	0.810	rs76229479	chr2:103123912	A/C	cg09003973	chr2:102972529	NA	0.91	8.67	0.43	1.95e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	0.56	8.33	0.41	2.15e-15	Breast cancer;
LUSC	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23598886	chr18:12777645	NA	0.65	6.6	0.34	1.61e-10	Inflammatory skin disease;
LUSC	cis	rs77633900	0.614	rs2439982	chr15:76925071	T/G	cg21673338	chr15:77095150	SCAPER	-0.74	-7.31	-0.37	1.99e-12	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg05585544	chr11:47624801	NA	-0.42	-7.31	-0.37	2.04e-12	Subjective well-being;
LUSC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.71	0.7	5.89e-50	Chronic sinus infection;
LUSC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg05043794	chr9:111880884	C9orf5	-0.37	-7.91	-0.4	3.86e-14	Menarche (age at onset);
LUSC	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	8.1	0.41	1.04e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.86	12.46	0.56	1.57e-29	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg02807482	chr3:125708958	NA	-0.48	-6.07	-0.32	3.42e-9	Blood pressure (smoking interaction);
LUSC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07677032	chr17:61819896	STRADA	0.54	9.06	0.44	1.15e-17	Prudent dietary pattern;
LUSC	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.31	-0.45	1.73e-18	Total cholesterol levels;
LUSC	cis	rs2354432	0.607	rs4314933	chr1:146821386	T/C	cg25205988	chr1:146714368	CHD1L	0.93	8.91	0.44	3.48e-17	Mitochondrial DNA levels;
LUSC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg11843238	chr5:131593191	PDLIM4	0.41	6.92	0.35	2.33e-11	Breast cancer;
LUSC	cis	rs13040088	0.580	rs11905041	chr20:61563408	C/T	cg23096297	chr20:61557774	DIDO1	0.73	10.07	0.48	5.26e-21	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04621676	chr1:9599380	SLC25A33	0.52	8.14	0.41	8.03e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.69	10.39	0.49	4.29e-22	Alcohol dependence;
LUSC	trans	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg07211511	chr3:129823064	LOC729375	-0.8	-10.52	-0.5	1.46e-22	Blood pressure (smoking interaction);
LUSC	cis	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg20368463	chr18:77673604	PQLC1	-0.67	-6.98	-0.36	1.64e-11	Opioid sensitivity;
LUSC	cis	rs2652834	0.696	rs34317102	chr15:63414083	A/C	cg05507819	chr15:63340323	TPM1	0.46	5.93	0.31	7.53e-9	HDL cholesterol;
LUSC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-5.79	-0.3	1.63e-8	Tonsillectomy;
LUSC	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.35	6.14	0.32	2.29e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg23711669	chr6:146136114	FBXO30	0.88	16.22	0.66	4.99e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6083	0.549	rs11858020	chr15:58852422	A/T	cg05156742	chr15:59063176	FAM63B	0.4	6.1	0.32	2.94e-9	Schizophrenia;
LUSC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg01097406	chr16:89675127	NA	0.48	10.13	0.48	3.25e-21	Vitiligo;
LUSC	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg17218026	chr1:154582156	ADAR	0.59	10.55	0.5	1.24e-22	Blood protein levels;
LUSC	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg03676636	chr4:99064102	C4orf37	0.36	7.92	0.4	3.47e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11958404	0.932	rs72816572	chr5:157429818	T/C	cg05962755	chr5:157440814	NA	0.54	6.34	0.33	7.29e-10	IgG glycosylation;
LUSC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.48	-6.25	-0.32	1.29e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.74	-0.39	1.2e-13	Triglycerides;
LUSC	cis	rs500891	0.525	rs1361784	chr6:84090690	A/T	cg08257003	chr6:84140564	ME1	0.35	8.5	0.42	6.18e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.04	15.58	0.65	1.58e-41	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg09835421	chr16:68378352	PRMT7	-0.54	-6.05	-0.31	3.98e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs71403859	0.502	rs12927006	chr16:71549911	A/G	cg08717414	chr16:71523259	ZNF19	-0.72	-8.46	-0.42	8.21e-16	Post bronchodilator FEV1;
LUSC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg15744005	chr10:104629667	AS3MT	-0.29	-6.25	-0.32	1.27e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7264396	0.836	rs6058276	chr20:34187728	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.76	-0.39	1.02e-13	Total cholesterol levels;
LUSC	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg27432699	chr2:27873401	GPN1	0.8	15.01	0.63	2.67e-39	Oral cavity cancer;
LUSC	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.7	-0.51	3.49e-23	Glomerular filtration rate;
LUSC	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg02527881	chr3:46936655	PTH1R	-0.37	-6.59	-0.34	1.67e-10	Colorectal cancer;
LUSC	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg00268967	chr12:58002603	GEFT;DTX3	-0.37	-5.86	-0.31	1.14e-8	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-10.92	-0.51	6.32e-24	Schizophrenia;
LUSC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.84	-14.92	-0.63	6.12e-39	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg10609677	chr17:41278573	BRCA1;NBR2	0.36	5.86	0.31	1.09e-8	Menopause (age at onset);
LUSC	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg24578937	chr1:2090814	PRKCZ	0.46	10.09	0.48	4.45e-21	Height;
LUSC	cis	rs1190596	0.525	rs7152627	chr14:102698399	C/T	cg18135206	chr14:102964638	TECPR2	-0.51	-6.2	-0.32	1.62e-9	Behavioural disinhibition (generation interaction);
LUSC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	1.02	14.32	0.62	1.37e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg24375607	chr4:120327624	NA	0.75	11.3	0.53	2.65e-25	Corneal astigmatism;
LUSC	cis	rs2835872	0.965	rs2835852	chr21:39014128	A/G	cg20424643	chr21:39039972	KCNJ6	-0.42	-6.54	-0.34	2.26e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs3820928	0.874	rs4461255	chr2:227846524	C/T	cg11843606	chr2:227700838	RHBDD1	0.54	7.92	0.4	3.58e-14	Pulmonary function;
LUSC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-0.97	-16.59	-0.67	1.62e-45	Body mass index;
LUSC	cis	rs9467773	0.529	rs7356988	chr6:26396727	G/T	cg05738196	chr6:26577821	NA	-0.46	-6.56	-0.34	2.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg22681709	chr2:178499509	PDE11A	-0.49	-9.09	-0.45	8.97e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06634786	chr22:41940651	POLR3H	-0.6	-6.81	-0.35	4.48e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.81	0.35	4.44e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg16584290	chr5:462447	EXOC3	-0.38	-6.62	-0.34	1.43e-10	Cystic fibrosis severity;
LUSC	cis	rs4704187	0.687	rs1345704	chr5:74489998	G/A	cg03227963	chr5:74354835	NA	0.31	6.72	0.35	7.65e-11	Response to amphetamines;
LUSC	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg02807482	chr3:125708958	NA	-0.54	-6.06	-0.31	3.65e-9	Blood pressure (smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18082322	chr5:148725041	GRPEL2	-0.4	-6.1	-0.32	3e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4646450	0.636	rs6955490	chr7:98974588	C/T	cg24650262	chr7:98904301	NA	0.55	6.25	0.32	1.26e-9	Blood metabolite levels;
LUSC	cis	rs6460942	0.908	rs73677559	chr7:12270819	A/C	cg06484146	chr7:12443880	VWDE	-0.55	-6.02	-0.31	4.54e-9	Coronary artery disease;
LUSC	cis	rs9807841	0.670	rs2569512	chr19:10790162	A/G	cg09936142	chr19:10668400	KRI1	-0.44	-7.02	-0.36	1.22e-11	Inflammatory skin disease;
LUSC	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg11062466	chr8:58055876	NA	0.5	6.57	0.34	1.89e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs8060598	0.866	rs3135499	chr16:50766127	G/T	cg15463457	chr4:90823130	MMRN1	-0.38	-5.98	-0.31	5.88e-9	Leprosy;
LUSC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg16405210	chr4:1374714	KIAA1530	0.53	8.07	0.4	1.32e-14	Obesity-related traits;
LUSC	cis	rs2242663	0.798	rs1791679	chr11:66337874	C/A	cg18002602	chr11:66138449	SLC29A2	-0.35	-6.21	-0.32	1.56e-9	Bipolar disorder;
LUSC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg24977027	chr2:88469347	THNSL2	0.56	5.84	0.3	1.21e-8	Plasma clusterin levels;
LUSC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg27165867	chr14:105738592	BRF1	-0.52	-7.75	-0.39	1.13e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7605827	0.930	rs7605727	chr2:15598693	A/G	cg19274914	chr2:15703543	NA	0.46	8.79	0.43	8.29e-17	Educational attainment (years of education);
LUSC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23158103	chr7:148848205	ZNF398	-0.5	-8.45	-0.42	9.1e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg23630131	chr7:65973040	NA	-0.22	-6.17	-0.32	2e-9	Aortic root size;
LUSC	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg06784218	chr1:46089804	CCDC17	0.36	6.12	0.32	2.67e-9	Platelet count;
LUSC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.4	-6.61	-0.34	1.49e-10	Monocyte percentage of white cells;
LUSC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg22437258	chr11:111473054	SIK2	-0.44	-5.87	-0.31	1.08e-8	Primary sclerosing cholangitis;
LUSC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg03465714	chr1:152285911	FLG	-0.36	-6.43	-0.33	4.48e-10	Inflammatory skin disease;
LUSC	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg16797656	chr11:68205561	LRP5	0.49	8.82	0.43	6.53e-17	Total body bone mineral density;
LUSC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg09365446	chr1:150670422	GOLPH3L	0.54	7.89	0.4	4.22e-14	Melanoma;
LUSC	cis	rs3741151	0.686	rs7114009	chr11:73115314	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.85	-8.15	-0.41	7.26e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1178968	1.000	rs1178968	chr7:72767451	T/C	cg25889504	chr7:72793014	NA	0.6	7.76	0.39	1.02e-13	Triglyceride levels;
LUSC	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.44	-0.46	6.59e-19	Total cholesterol levels;
LUSC	trans	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg27411982	chr8:10470053	RP1L1	0.42	6.33	0.33	7.72e-10	Monocyte count;
LUSC	cis	rs7640424	0.929	rs17828045	chr3:107821546	A/C	cg09227934	chr3:107805635	CD47	-0.45	-7.24	-0.37	3.17e-12	Body mass index;
LUSC	cis	rs9398803	0.865	rs9388495	chr6:126782457	G/A	cg19875578	chr6:126661172	C6orf173	0.41	5.93	0.31	7.72e-9	Male-pattern baldness;
LUSC	trans	rs9467603	0.925	rs28412066	chr6:25775570	T/A	cg06606381	chr12:133084897	FBRSL1	0.59	5.95	0.31	6.9e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.9	17.03	0.68	2.99e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg04450456	chr4:17643702	FAM184B	0.39	6.56	0.34	2.06e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg25930673	chr12:123319894	HIP1R	-0.63	-6.2	-0.32	1.66e-9	Schizophrenia;
LUSC	cis	rs9814567	0.752	rs9846111	chr3:134335034	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.51	-0.56	1.02e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.66	10.14	0.49	3.13e-21	Lymphocyte counts;
LUSC	cis	rs3849570	1.000	rs9817181	chr3:81827765	A/C	cg07356753	chr3:81810745	GBE1	-0.68	-11.09	-0.52	1.46e-24	Waist circumference;Body mass index;
LUSC	trans	rs7939886	0.920	rs7940563	chr11:55875133	C/T	cg15704280	chr7:45808275	SEPT13	0.79	6.65	0.34	1.23e-10	Myopia (pathological);
LUSC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg04369109	chr6:150039330	LATS1	-0.6	-8.85	-0.44	5.18e-17	Lung cancer;
LUSC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.7	10.83	0.51	1.22e-23	Aortic root size;
LUSC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg19077165	chr18:44547161	KATNAL2	-0.41	-5.89	-0.31	9.19e-9	Personality dimensions;
LUSC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-7.86	-0.39	5.42e-14	Obesity-related traits;
LUSC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs354225	0.544	rs10182836	chr2:54808504	T/G	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg25173405	chr17:45401733	C17orf57	0.39	6.34	0.33	7.47e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg16624210	chr5:671434	TPPP	0.5	6.32	0.33	8.21e-10	Obesity-related traits;
LUSC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg23172400	chr8:95962367	TP53INP1	-0.35	-6.72	-0.34	8.05e-11	Type 2 diabetes;
LUSC	cis	rs2970818	0.831	rs11063202	chr12:4593690	A/G	cg11146114	chr12:4671731	NA	-0.59	-5.71	-0.3	2.44e-8	Phosphorus levels;
LUSC	cis	rs12410462	0.681	rs113316536	chr1:227547033	T/G	cg10327440	chr1:227177885	CDC42BPA	-0.66	-6.47	-0.33	3.44e-10	Major depressive disorder;
LUSC	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg00310523	chr12:86230176	RASSF9	0.36	6.49	0.33	3.04e-10	Major depressive disorder;
LUSC	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-8.06	-0.4	1.33e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg26384229	chr12:38710491	ALG10B	0.75	11.76	0.54	5.77e-27	Morning vs. evening chronotype;
LUSC	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.48	-0.42	7.36e-16	Body mass index;
LUSC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	11.71	0.54	9.17e-27	Alzheimer's disease;
LUSC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg12639453	chr1:2035780	PRKCZ	-0.31	-6.54	-0.34	2.26e-10	Height;
LUSC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg26752003	chr8:145688521	CYHR1	0.63	10.1	0.48	4.2e-21	Age at first birth;
LUSC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	1.09	17.2	0.69	6.12e-48	Exhaled nitric oxide output;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03190379	chr12:49690636	PRPH	0.43	6.21	0.32	1.62e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg03315344	chr16:75512273	CHST6	-0.53	-9.41	-0.46	8.15e-19	Dupuytren's disease;
LUSC	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg04586622	chr2:25135609	ADCY3	0.4	8.34	0.42	1.98e-15	Body mass index;
LUSC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.68	0.47	1.09e-19	Bipolar disorder;
LUSC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg05425664	chr17:57184151	TRIM37	0.55	8.04	0.4	1.55e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs377070	0.717	rs6534359	chr4:123596694	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.43	-6.36	-0.33	6.48e-10	Mosquito bite size;
LUSC	cis	rs12701220	0.762	rs7777565	chr7:1003011	C/A	cg26769984	chr7:1090371	C7orf50	0.45	6.39	0.33	5.52e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg01191920	chr7:158217561	PTPRN2	0.46	9.3	0.45	1.84e-18	Obesity-related traits;
LUSC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.93	0.31	7.45e-9	Lung cancer;
LUSC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.26	-0.32	1.2e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21016266	chr12:122356598	WDR66	0.61	9.11	0.45	7.83e-18	Mean corpuscular volume;
LUSC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg10862848	chr6:42927986	GNMT	-0.28	-6.56	-0.34	2.01e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs834811	0.831	rs1097147	chr7:135880446	C/T	cg01726295	chr7:135938950	NA	0.39	6.83	0.35	3.95e-11	Post-traumatic stress disorder;
LUSC	cis	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.3	-0.41	2.67e-15	Coronary artery disease;
LUSC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg21782813	chr7:2030301	MAD1L1	-0.52	-9.11	-0.45	7.87e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.03	0.4	1.64e-14	Homoarginine levels;
LUSC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.3	-0.41	2.63e-15	Obesity-related traits;
LUSC	cis	rs8017423	1.000	rs1959001	chr14:90667739	G/A	cg04374321	chr14:90722782	PSMC1	0.68	10.67	0.5	4.48e-23	Mortality in heart failure;
LUSC	cis	rs11625487	1.000	rs11625487	chr14:77961609	G/C	cg16049707	chr14:77965284	ISM2	0.59	8.26	0.41	3.43e-15	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs2708377	0.860	rs7962445	chr12:11305844	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg00383909	chr3:49044727	WDR6	-0.44	-5.91	-0.31	8.64e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs9814567	0.574	rs7650509	chr3:134170971	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	8.21	0.41	4.9e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg06784218	chr1:46089804	CCDC17	0.55	11.09	0.52	1.49e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.43	-0.38	9.16e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.38	-7.49	-0.38	6.17e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.39	0.56	2.97e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg23241863	chr10:102295624	HIF1AN	0.47	5.94	0.31	7.14e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg13390004	chr1:15929781	NA	-0.39	-6.52	-0.34	2.64e-10	Systolic blood pressure;
LUSC	trans	rs9929218	1.000	rs12930371	chr16:68802936	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	12.11	0.55	3.21e-28	Colorectal cancer;
LUSC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.43	0.38	9.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg24399712	chr22:39784796	NA	-0.61	-10.28	-0.49	9.79e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs193541	0.507	rs9327274	chr5:122076870	A/C	cg19077854	chr5:122220652	SNX24	-0.27	-5.99	-0.31	5.38e-9	Glucose homeostasis traits;
LUSC	cis	rs6977660	0.714	rs10229108	chr7:19824253	G/A	cg07541023	chr7:19748670	TWISTNB	0.6	6.37	0.33	6.35e-10	Thyroid stimulating hormone;
LUSC	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg03676636	chr4:99064102	C4orf37	0.37	8.31	0.41	2.4e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg21433313	chr16:3507492	NAT15	0.41	5.99	0.31	5.54e-9	Body mass index (adult);
LUSC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg22800045	chr5:56110881	MAP3K1	0.68	9.25	0.45	2.66e-18	Initial pursuit acceleration;
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg05420668	chr16:28891176	ATP2A1	0.44	6.59	0.34	1.69e-10	Eotaxin levels;
LUSC	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg19318889	chr4:1322082	MAEA	0.43	5.66	0.3	3.22e-8	Recombination rate (females);
LUSC	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg04310649	chr10:35416472	CREM	-0.43	-6.52	-0.34	2.59e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7923609	0.902	rs10733793	chr10:65323809	T/G	cg01631684	chr10:65280961	REEP3	-0.42	-6.59	-0.34	1.76e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11677370	0.561	rs13003140	chr2:3816759	G/T	cg17052675	chr2:3827356	NA	-0.64	-9.49	-0.46	4.37e-19	Type 2 diabetes;
LUSC	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.56	-9.25	-0.45	2.75e-18	Breast cancer;
LUSC	cis	rs6840360	1.000	rs751012	chr4:152602247	A/C	cg22705602	chr4:152727874	NA	-0.27	-5.71	-0.3	2.48e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg18187862	chr3:45730750	SACM1L	-0.55	-6.65	-0.34	1.16e-10	Primary sclerosing cholangitis;
LUSC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg19318889	chr4:1322082	MAEA	0.44	6.95	0.36	1.95e-11	Obesity-related traits;
LUSC	cis	rs8141797	0.748	rs2051199	chr22:24465845	A/G	cg00411358	chr22:24577142	SUSD2	0.62	6.19	0.32	1.76e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg04827223	chr11:72435913	ARAP1	-0.65	-8.46	-0.42	8.6e-16	Type 2 diabetes;
LUSC	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs56399783	0.614	rs73047368	chr7:2766396	G/T	cg19731401	chr7:2775893	GNA12	0.73	8.79	0.43	8.04e-17	Childhood ear infection;
LUSC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg20887711	chr4:1340912	KIAA1530	0.44	6.81	0.35	4.49e-11	Obesity-related traits;
LUSC	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.29	-0.33	9.76e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs67072384	0.818	rs7926287	chr11:72464525	A/G	cg04827223	chr11:72435913	ARAP1	-0.66	-6.51	-0.34	2.82e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg16414030	chr3:133502952	NA	-0.41	-6.37	-0.33	6.09e-10	Iron status biomarkers;
LUSC	trans	rs1325195	0.881	rs2816202	chr1:179162437	C/T	cg11624085	chr17:8464688	MYH10	0.41	6.64	0.34	1.29e-10	IgE grass sensitization;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25045127	chr20:23402051	NAPB	-0.4	-6.0	-0.31	5.02e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg23791538	chr6:167370224	RNASET2	-0.43	-6.95	-0.36	1.93e-11	Crohn's disease;
LUSC	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg10547527	chr2:198650123	BOLL	-0.49	-5.65	-0.3	3.53e-8	Ulcerative colitis;
LUSC	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.79	0.57	9.36e-31	Bipolar disorder;
LUSC	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg04733989	chr22:42467013	NAGA	0.39	6.62	0.34	1.45e-10	Cognitive function;
LUSC	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg12756686	chr19:29218302	NA	0.56	6.28	0.33	1.03e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs7246657	0.653	rs10414983	chr19:37665732	T/C	cg23950597	chr19:37808831	NA	-0.57	-5.79	-0.3	1.64e-8	Coronary artery calcification;
LUSC	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg13010199	chr12:38710504	ALG10B	0.47	7.28	0.37	2.43e-12	Morning vs. evening chronotype;
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.84	-13.78	-0.6	1.6e-34	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7605827	0.930	rs2111458	chr2:15598039	T/A	cg19274914	chr2:15703543	NA	0.47	9.08	0.45	9.55e-18	Educational attainment (years of education);
LUSC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg11663144	chr21:46675770	NA	-0.38	-6.4	-0.33	5.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01813026	chr11:809279	RPLP2	-0.42	-6.16	-0.32	2.13e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	12.53	0.57	8.69e-30	Platelet count;
LUSC	cis	rs9807841	0.670	rs10405617	chr19:10752968	C/T	cg09936142	chr19:10668400	KRI1	0.42	6.64	0.34	1.27e-10	Inflammatory skin disease;
LUSC	cis	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.56	0.42	4.25e-16	Endometrial cancer;
LUSC	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg08847533	chr14:75593920	NEK9	0.84	15.63	0.65	1.04e-41	Height;
LUSC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.46	-7.2	-0.37	4e-12	Systemic lupus erythematosus;
LUSC	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg21775007	chr8:11205619	TDH	0.46	6.46	0.33	3.81e-10	Neuroticism;
LUSC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.87	10.37	0.49	4.93e-22	Alzheimer's disease;
LUSC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	12.21	0.56	1.32e-28	Colorectal cancer;
LUSC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	0.94	13.65	0.6	5.2e-34	Eosinophil percentage of granulocytes;
LUSC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg12564285	chr5:131593104	PDLIM4	0.47	8.66	0.43	1.98e-16	Blood metabolite levels;
LUSC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.65	-0.3	3.36e-8	Life satisfaction;
LUSC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg26373071	chr5:1325741	CLPTM1L	0.41	7.54	0.38	4.61e-13	Lung cancer;
LUSC	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg22491629	chr6:157744540	C6orf35	-0.89	-10.89	-0.51	7.48e-24	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.72	13.95	0.61	3.66e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.13	-0.45	6.87e-18	Gut microbiome composition (summer);
LUSC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg02807482	chr3:125708958	NA	-0.5	-6.21	-0.32	1.55e-9	Blood pressure (smoking interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05477027	chr19:46295590	DMWD	0.41	6.12	0.32	2.64e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg25344623	chr2:136566232	LCT	0.39	5.85	0.3	1.19e-8	Mosquito bite size;
LUSC	cis	rs9323205	0.677	rs4264315	chr14:51728356	G/A	cg23942311	chr14:51606299	NA	-0.4	-7.37	-0.37	1.31e-12	Cancer;
LUSC	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.84	-0.35	3.86e-11	Daytime sleep phenotypes;
LUSC	cis	rs354225	0.544	rs10184128	chr2:54803816	A/G	cg01766943	chr2:54829624	SPTBN1	0.48	7.69	0.39	1.64e-13	Schizophrenia;
LUSC	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.6	0.65	1.31e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg12292205	chr6:26970375	C6orf41	0.51	8.56	0.42	4.11e-16	Schizophrenia;
LUSC	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg25174290	chr11:3078921	CARS	-0.38	-5.69	-0.3	2.78e-8	Calcium levels;
LUSC	cis	rs679087	1.000	rs679087	chr12:29917265	C/A	cg14258853	chr12:29935411	TMTC1	-0.98	-16.21	-0.66	5.08e-44	Schizophrenia;
LUSC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg18681998	chr4:17616180	MED28	0.84	15.22	0.64	4.34e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4629710	0.545	rs3777477	chr6:131534374	T/C	cg12606694	chr6:131520996	AKAP7	0.55	8.09	0.4	1.09e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs9398803	0.865	rs4565329	chr6:126752798	A/G	cg19875578	chr6:126661172	C6orf173	-0.42	-6.3	-0.33	9.61e-10	Male-pattern baldness;
LUSC	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg01475377	chr6:109611718	NA	-0.43	-7.86	-0.4	5.3e-14	Reticulocyte fraction of red cells;
LUSC	cis	rs965513	0.901	rs7045465	chr9:100534823	A/T	cg13688889	chr9:100608707	NA	-0.42	-6.49	-0.33	3.1e-10	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg06238570	chr21:40685208	BRWD1	-0.63	-10.76	-0.51	2.26e-23	Cognitive function;
LUSC	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg14830002	chr1:247616686	OR2B11	0.49	7.15	0.36	5.55e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg03351412	chr1:154909251	PMVK	0.53	8.06	0.4	1.4e-14	Prostate cancer;
LUSC	cis	rs10740039	0.883	rs1837945	chr10:62393515	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4363385	0.693	rs662506	chr1:153048386	A/C	cg00922841	chr1:152955080	SPRR1A	0.42	7.4	0.38	1.08e-12	Inflammatory skin disease;
LUSC	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg03806693	chr22:41940476	POLR3H	-0.91	-12.72	-0.57	1.7e-30	Vitiligo;
LUSC	cis	rs4664308	0.967	rs34248629	chr2:160902497	C/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-10.81	-0.51	1.5e-23	Idiopathic membranous nephropathy;
LUSC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.69	-0.57	2.24e-30	Platelet count;
LUSC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.72	0.35	7.92e-11	Aortic root size;
LUSC	cis	rs7605827	0.930	rs2052437	chr2:15697819	A/G	cg19274914	chr2:15703543	NA	0.45	8.6	0.43	3.1e-16	Educational attainment (years of education);
LUSC	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-1.06	-15.7	-0.65	5.45e-42	Exhaled nitric oxide output;
LUSC	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg18904891	chr8:8559673	CLDN23	0.59	8.1	0.41	1.03e-14	Obesity-related traits;
LUSC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg02423579	chr7:2872169	GNA12	-0.41	-6.22	-0.32	1.46e-9	Height;
LUSC	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg24558204	chr6:135376177	HBS1L	0.68	10.85	0.51	1.08e-23	High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24877792	chr5:180287685	ZFP62	0.42	6.19	0.32	1.74e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg17633681	chr16:88106987	BANP	0.43	8.62	0.43	2.65e-16	Menopause (age at onset);
LUSC	cis	rs72781680	0.652	rs72794281	chr2:23893265	G/A	cg20701182	chr2:24300061	SF3B14	0.77	7.45	0.38	8.07e-13	Lymphocyte counts;
LUSC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.29	-0.37	2.29e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.36	0.53	1.66e-25	Menopause (age at onset);
LUSC	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.18	-0.45	4.78e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg06636001	chr8:8085503	FLJ10661	0.45	6.84	0.35	3.82e-11	Retinal vascular caliber;
LUSC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg09365446	chr1:150670422	GOLPH3L	0.47	7.05	0.36	1.02e-11	Melanoma;
LUSC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg13319975	chr6:146136371	FBXO30	0.48	7.37	0.37	1.31e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg01765077	chr12:122356316	WDR66	0.52	7.48	0.38	6.84e-13	Mean corpuscular volume;
LUSC	cis	rs9400467	0.528	rs7451051	chr6:111744818	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.38	-7.19	-0.37	4.39e-12	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg09904177	chr6:26538194	HMGN4	0.66	11.74	0.54	7.2e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs11626933	1.000	rs3825661	chr14:90767607	C/T	cg14092571	chr14:90743983	NA	0.84	17.76	0.7	3.62e-50	Gut microbiota (bacterial taxa);
LUSC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg19622623	chr12:86230825	RASSF9	-0.45	-6.22	-0.32	1.53e-9	Major depressive disorder;
LUSC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg15145296	chr3:125709740	NA	-0.56	-6.31	-0.33	9e-10	Blood pressure (smoking interaction);
LUSC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.51	-0.46	4.02e-19	Chronic sinus infection;
LUSC	cis	rs2742417	0.967	rs2742462	chr3:45774696	G/A	cg09608765	chr3:45636137	LIMD1	-0.37	-7.38	-0.37	1.29e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18932078	chr1:2524107	MMEL1	0.32	6.96	0.36	1.77e-11	Ulcerative colitis;
LUSC	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg01765077	chr12:122356316	WDR66	0.47	6.67	0.34	1.05e-10	Mean corpuscular volume;
LUSC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14829155	chr15:31115871	NA	0.72	10.7	0.51	3.74e-23	Huntington's disease progression;
LUSC	trans	rs12210905	0.920	rs72839468	chr6:27301734	A/G	cg11837749	chr1:55047332	ACOT11	0.65	6.05	0.31	3.86e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg06096015	chr1:231504339	EGLN1	0.56	9.92	0.48	1.75e-20	Hemoglobin concentration;
LUSC	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg24069376	chr3:38537580	EXOG	-0.39	-7.56	-0.38	4.02e-13	Electrocardiographic conduction measures;
LUSC	cis	rs6906287	0.647	rs35962656	chr6:118919593	G/T	cg21191810	chr6:118973309	C6orf204	0.32	5.96	0.31	6.53e-9	Electrocardiographic conduction measures;
LUSC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg14552801	chr7:65878734	NA	0.39	6.08	0.32	3.34e-9	Aortic root size;
LUSC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.91	0.31	8.55e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6554196	0.508	rs6554200	chr4:55529409	G/C	cg18836493	chr4:55524333	KIT	-0.46	-7.88	-0.4	4.6e-14	Monocyte count;
LUSC	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.65	-11.12	-0.52	1.23e-24	Diastolic blood pressure;
LUSC	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg13852791	chr20:30311386	BCL2L1	0.9	13.6	0.6	7.89e-34	Mean corpuscular hemoglobin;
LUSC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.19	0.59	2.89e-32	Chronic sinus infection;
LUSC	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg18196295	chr10:418757	DIP2C	-0.47	-7.03	-0.36	1.14e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs11587400	0.574	rs2268696	chr1:115219083	T/A	cg12756093	chr1:115239321	AMPD1	-0.42	-6.26	-0.32	1.16e-9	Autism;
LUSC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.88	0.4	4.57e-14	Parkinson's disease;
LUSC	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.61	-10.29	-0.49	9.65e-22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg02023728	chr11:77925099	USP35	0.46	6.85	0.35	3.58e-11	Testicular germ cell tumor;
LUSC	cis	rs4700695	0.841	rs251614	chr5:65228251	C/G	cg21114390	chr5:65439923	SFRS12	-0.52	-6.17	-0.32	1.95e-9	Facial morphology (factor 19);
LUSC	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-5.69	-0.3	2.78e-8	Arsenic metabolism;
LUSC	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg05707623	chr12:122985044	ZCCHC8	0.65	8.08	0.4	1.23e-14	Body mass index;
LUSC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg18904891	chr8:8559673	CLDN23	0.56	7.84	0.39	6.25e-14	Obesity-related traits;
LUSC	cis	rs2969070	0.867	rs2906166	chr7:2508072	A/G	cg03277898	chr7:2518824	NA	-0.27	-5.81	-0.3	1.49e-8	Diastolic blood pressure;
LUSC	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	7.14	0.36	5.78e-12	Menarche (age at onset);
LUSC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-8.45	-0.42	8.83e-16	Monocyte percentage of white cells;
LUSC	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg17376030	chr22:41985996	PMM1	-0.42	-5.69	-0.3	2.76e-8	Vitiligo;
LUSC	cis	rs9837602	1.000	rs6806178	chr3:99780393	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.15	0.32	2.16e-9	Breast cancer;
LUSC	trans	rs9650657	0.801	rs718741	chr8:10614384	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-5.97	-0.31	6.19e-9	Neuroticism;
LUSC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg07716408	chr11:68623521	NA	-0.29	-5.77	-0.3	1.84e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg10356904	chr22:49881777	NA	-0.33	-7.39	-0.37	1.21e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2637266	1.000	rs11001829	chr10:78343387	A/T	cg18941641	chr10:78392320	NA	0.4	7.41	0.38	1.04e-12	Pulmonary function;
LUSC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg18758796	chr5:131593413	PDLIM4	0.34	5.86	0.31	1.14e-8	Blood metabolite levels;
LUSC	cis	rs8099014	1.000	rs9319930	chr18:56123799	C/T	cg12907477	chr18:56117327	MIR122	0.43	6.81	0.35	4.67e-11	Platelet count;
LUSC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg12935359	chr14:103987150	CKB	-0.51	-7.74	-0.39	1.17e-13	Body mass index;
LUSC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	11.14	0.52	9.84e-25	Prudent dietary pattern;
LUSC	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg14438399	chr17:27053147	TLCD1	0.52	5.75	0.3	2.05e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs55665837	1.000	rs34382046	chr11:14451318	C/T	cg19336497	chr11:14380999	RRAS2	-0.37	-7.47	-0.38	7.25e-13	Vitamin D levels;
LUSC	trans	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.08	-0.32	3.28e-9	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg13010199	chr12:38710504	ALG10B	0.45	6.9	0.35	2.69e-11	Morning vs. evening chronotype;
LUSC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg11965913	chr1:205819406	PM20D1	0.6	10.45	0.5	2.57e-22	Menarche (age at onset);
LUSC	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg13390004	chr1:15929781	NA	-0.39	-6.47	-0.33	3.51e-10	Systolic blood pressure;
LUSC	cis	rs7582720	1.000	rs72926791	chr2:203822891	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg04733989	chr22:42467013	NAGA	0.4	6.49	0.33	3.03e-10	Cognitive function;
LUSC	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg17652424	chr22:38574118	PLA2G6	-0.31	-6.67	-0.34	1.05e-10	Cutaneous nevi;
LUSC	cis	rs6987853	0.933	rs2974340	chr8:42397731	T/C	cg09913449	chr8:42400586	C8orf40	0.49	8.26	0.41	3.35e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04267008	chr7:1944627	MAD1L1	0.64	9.97	0.48	1.12e-20	Bipolar disorder and schizophrenia;
LUSC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-13.0	-0.58	1.54e-31	Platelet count;
LUSC	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg13390004	chr1:15929781	NA	0.41	6.91	0.35	2.44e-11	Systolic blood pressure;
LUSC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.83	-0.3	1.27e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg11584989	chr19:19387371	SF4	0.59	6.99	0.36	1.46e-11	Bipolar disorder;
LUSC	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg13514129	chr1:39547527	MACF1	0.71	11.62	0.54	1.96e-26	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg07741184	chr6:167504864	NA	0.35	6.23	0.32	1.38e-9	Crohn's disease;
LUSC	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg17788362	chr6:86352627	SYNCRIP	0.43	6.48	0.33	3.38e-10	Smooth-surface caries;
LUSC	cis	rs3981351	0.528	rs12768908	chr10:115443894	C/T	cg24846397	chr10:115438155	CASP7	-0.39	-6.59	-0.34	1.76e-10	Obesity-related traits;
LUSC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-7.69	-0.39	1.63e-13	Personality dimensions;
LUSC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13770153	chr20:60521292	NA	-0.72	-9.87	-0.48	2.45e-20	Body mass index;
LUSC	cis	rs3740713	1.000	rs75740864	chr11:18470689	C/G	cg15463284	chr11:18477534	LDHAL6A	-0.5	-5.73	-0.3	2.21e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs68092024	0.731	rs792841	chr3:99471308	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.38	-5.8	-0.3	1.52e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg03342759	chr3:160939853	NMD3	-0.45	-6.01	-0.31	4.9e-9	Parkinson's disease;
LUSC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.81	0.3	1.48e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg23950597	chr19:37808831	NA	0.61	7.52	0.38	4.98e-13	Coronary artery calcification;
LUSC	cis	rs11645898	0.748	rs11641424	chr16:72066879	C/T	cg14768367	chr16:72042858	DHODH	-0.75	-8.07	-0.4	1.32e-14	Blood protein levels;
LUSC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	16.11	0.66	1.32e-43	Platelet count;
LUSC	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg08601574	chr20:25228251	PYGB	0.42	6.4	0.33	5.18e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs174775	0.513	rs2283849	chr22:29743482	T/C	cg07256473	chr22:29710276	RASL10A	-0.44	-8.12	-0.41	8.8e-15	Immature fraction of reticulocytes;
LUSC	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg23241863	chr10:102295624	HIF1AN	0.49	6.17	0.32	1.98e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg02997394	chr19:33096574	ANKRD27	0.82	9.17	0.45	4.89e-18	Eosinophilic esophagitis;
LUSC	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg12311346	chr5:56204834	C5orf35	-0.6	-9.31	-0.45	1.7e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs17286411	0.750	rs4788568	chr16:71913025	C/T	cg03805757	chr16:71968109	PKD1L3	0.42	6.89	0.35	2.77e-11	Blood protein levels;
LUSC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg23887609	chr12:130822674	PIWIL1	-0.43	-6.56	-0.34	2.03e-10	Menopause (age at onset);
LUSC	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg00852783	chr1:26633632	UBXN11	0.48	8.47	0.42	8.07e-16	Obesity-related traits;
LUSC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-0.9	-13.02	-0.58	1.22e-31	Initial pursuit acceleration;
LUSC	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg13939156	chr17:80058883	NA	-0.34	-6.75	-0.35	6.49e-11	Life satisfaction;
LUSC	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg22676075	chr6:135203613	NA	0.48	7.47	0.38	7.29e-13	Red blood cell count;
LUSC	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	9.54	0.46	3.16e-19	Lung cancer in ever smokers;
LUSC	cis	rs9648716	0.515	rs79329624	chr7:140622362	T/C	cg23214464	chr7:140373596	ADCK2	0.73	5.83	0.3	1.31e-8	Type 2 diabetes;
LUSC	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg25427524	chr10:38739819	LOC399744	-0.5	-6.04	-0.31	4.1e-9	Obesity (extreme);
LUSC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg27535305	chr1:53392650	SCP2	-0.48	-9.51	-0.46	3.88e-19	Monocyte count;
LUSC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-10.75	-0.51	2.39e-23	Gut microbiome composition (summer);
LUSC	cis	rs10782582	0.609	rs78556436	chr1:76352875	G/A	cg03433033	chr1:76189801	ACADM	-0.39	-5.65	-0.3	3.42e-8	Daytime sleep phenotypes;
LUSC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11764359	chr7:65958608	NA	-0.66	-10.57	-0.5	1e-22	Aortic root size;
LUSC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-9.15	-0.45	5.98e-18	Gut microbiome composition (summer);
LUSC	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	9.69	0.47	9.79e-20	Lung cancer in ever smokers;
LUSC	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg17366294	chr4:99064904	C4orf37	0.57	10.07	0.48	5.24e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg10911889	chr6:126070802	HEY2	-0.43	-6.6	-0.34	1.63e-10	Brugada syndrome;
LUSC	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg03563238	chr19:33554763	RHPN2	-0.39	-6.14	-0.32	2.36e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.24	0.37	3.08e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	7.36	0.37	1.42e-12	Response to antipsychotic treatment;
LUSC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-7.47	-0.38	7.26e-13	Aortic root size;
LUSC	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	0.84	11.57	0.53	2.85e-26	Menopause (age at onset);
LUSC	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.85	13.39	0.59	5e-33	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs12617721	0.574	rs6542754	chr2:99025400	C/T	cg10123293	chr2:99228465	UNC50	0.46	7.74	0.39	1.2e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.91e-9	Menopause (age at onset);
LUSC	cis	rs7945705	0.846	rs4929912	chr11:8816695	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.33	-6.53	-0.34	2.5e-10	Hemoglobin concentration;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15603734	chr19:2236704	PLEKHJ1;SF3A2	-0.41	-6.09	-0.32	3.07e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg02275930	chr1:2372054	NA	-0.58	-10.0	-0.48	9.34e-21	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg11062466	chr8:58055876	NA	0.66	9.08	0.44	9.89e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg22549504	chr19:17448937	GTPBP3	0.54	6.77	0.35	5.67e-11	Systemic lupus erythematosus;
LUSC	cis	rs6460942	0.630	rs62451487	chr7:12390464	G/A	cg06484146	chr7:12443880	VWDE	-0.57	-5.97	-0.31	6.08e-9	Coronary artery disease;
LUSC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg04455712	chr21:45112962	RRP1B	0.49	9.19	0.45	4.25e-18	Mean corpuscular volume;
LUSC	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.46	6.6	0.34	1.6e-10	Schizophrenia;
LUSC	cis	rs1881797	0.527	rs74227706	chr1:247638315	A/C	cg14830002	chr1:247616686	OR2B11	0.65	7.41	0.38	1.06e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg11608241	chr8:8085544	FLJ10661	0.51	7.46	0.38	7.57e-13	Neuroticism;
LUSC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg05347473	chr6:146136440	FBXO30	0.51	8.58	0.43	3.52e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.8	-12.86	-0.58	5.09e-31	Schizophrenia;
LUSC	cis	rs16912285	0.688	rs10834313	chr11:24348447	G/C	ch.11.24196551F	chr11:24239977	NA	0.83	7.83	0.39	6.33e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs11828289	0.660	rs11027043	chr11:23212893	C/T	cg20040320	chr11:23191996	NA	-0.58	-6.08	-0.32	3.32e-9	Cancer;
LUSC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg21862992	chr11:68658383	NA	0.51	8.01	0.4	1.99e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg20307385	chr11:47447363	PSMC3	0.44	6.48	0.33	3.2e-10	Subjective well-being;
LUSC	cis	rs73200209	0.744	rs56159580	chr12:116420448	T/C	cg01776926	chr12:116560359	MED13L	-0.52	-5.94	-0.31	7.14e-9	Total body bone mineral density;
LUSC	cis	rs6961069	0.806	rs12706912	chr7:80252295	A/C	cg04458919	chr7:80252533	CD36	-0.37	-6.69	-0.34	9.31e-11	Platelet count;
LUSC	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg22676075	chr6:135203613	NA	0.59	9.41	0.46	8.46e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17916960	chr15:79447300	NA	-0.53	-10.55	-0.5	1.24e-22	Refractive error;
LUSC	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.18	-0.32	1.82e-9	Neutrophil percentage of white cells;
LUSC	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg01884057	chr2:25150051	NA	0.41	9.23	0.45	3.08e-18	Body mass index in non-asthmatics;
LUSC	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg05855489	chr10:104503620	C10orf26	0.47	6.48	0.33	3.34e-10	Arsenic metabolism;
LUSC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg00149659	chr3:10157352	C3orf10	0.62	8.72	0.43	1.36e-16	Alzheimer's disease;
LUSC	cis	rs2191566	1.000	rs367499	chr19:44504981	G/A	cg03039196	chr19:44506973	ZNF230	-0.38	-5.9	-0.31	8.99e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg17652424	chr22:38574118	PLA2G6	-0.3	-6.58	-0.34	1.84e-10	Cutaneous nevi;
LUSC	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg03676636	chr4:99064102	C4orf37	0.37	8.16	0.41	7.06e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg27068330	chr11:65405492	SIPA1	-0.44	-5.69	-0.3	2.71e-8	Breast cancer;
LUSC	cis	rs9309473	0.583	rs6705203	chr2:73574600	T/C	cg20560298	chr2:73613845	ALMS1	-0.56	-8.2	-0.41	5.2e-15	Metabolite levels;
LUSC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg13175981	chr1:150552382	MCL1	0.47	6.7	0.34	9.06e-11	Tonsillectomy;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg13685329	chr2:73460476	CCT7;C2orf7	0.42	6.0	0.31	5.22e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs10761482	0.500	rs10821779	chr10:62274525	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.48	-0.33	3.39e-10	Schizophrenia;
LUSC	cis	rs1028488	0.504	rs9460129	chr6:170696222	G/A	cg20370364	chr6:170703943	FAM120B	-0.49	-7.06	-0.36	9.5e-12	Interferon alpha levels in systemic lupus erythematosus;
LUSC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg06637938	chr14:75390232	RPS6KL1	0.5	7.47	0.38	7.21e-13	Height;
LUSC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02711726	chr17:80685570	FN3KRP	-0.4	-6.09	-0.32	3.17e-9	Glycated hemoglobin levels;
LUSC	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.31	0.45	1.77e-18	Blood protein levels;
LUSC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg24060327	chr5:131705240	SLC22A5	-0.43	-7.15	-0.36	5.49e-12	Blood metabolite levels;
LUSC	cis	rs8018967	0.622	rs2041073	chr14:73972535	C/T	cg08936952	chr14:74026160	HEATR4	-0.36	-6.71	-0.34	8.34e-11	Blood metabolite ratios;
LUSC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2067615	0.579	rs12312782	chr12:107135647	G/A	cg15890332	chr12:107067104	RFX4	0.33	6.11	0.32	2.82e-9	Heart rate;
LUSC	cis	rs11640533	1.000	rs11640533	chr16:53412862	A/G	cg09728985	chr16:53543985	NA	0.3	5.82	0.3	1.41e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.53	8.48	0.42	7.42e-16	Facial morphology (factor 20);
LUSC	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg17470449	chr10:769945	NA	0.55	7.78	0.39	9.07e-14	Uric acid levels;
LUSC	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg21231944	chr12:82153410	PPFIA2	0.39	6.03	0.31	4.26e-9	Resting heart rate;
LUSC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg23630131	chr7:65973040	NA	-0.2	-5.64	-0.3	3.55e-8	Aortic root size;
LUSC	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.71	0.43	1.42e-16	Menopause (age at onset);
LUSC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.77	-13.52	-0.59	1.54e-33	Cognitive function;
LUSC	cis	rs8179	0.700	rs42041	chr7:92246744	C/G	cg15732164	chr7:92237376	CDK6	-0.46	-6.44	-0.33	4.1e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg09044154	chr16:88155775	NA	-0.55	-7.36	-0.37	1.48e-12	Menopause (age at onset);
LUSC	cis	rs1865721	0.804	rs7229401	chr18:73148127	T/G	cg26385618	chr18:73139727	C18orf62	-0.52	-9.51	-0.46	3.94e-19	Intelligence;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25632300	chr5:174905618	SFXN1	-0.35	-6.68	-0.34	1.01e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.45	-7.14	-0.36	5.75e-12	Blood metabolite levels;
LUSC	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg01884057	chr2:25150051	NA	0.45	10.42	0.5	3.41e-22	Body mass index in non-asthmatics;
LUSC	cis	rs3849570	0.673	rs13068700	chr3:81975817	G/C	cg07356753	chr3:81810745	GBE1	-0.57	-8.23	-0.41	4.36e-15	Waist circumference;Body mass index;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09755102	chr1:33283495	S100PBP;YARS	0.45	6.95	0.36	1.92e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg06740227	chr12:86229804	RASSF9	0.39	6.33	0.33	7.71e-10	Major depressive disorder;
LUSC	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	1.13	20.03	0.74	3.52e-59	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4423214	0.879	rs1790345	chr11:71145941	G/A	cg05163923	chr11:71159392	DHCR7	-0.69	-9.03	-0.44	1.35e-17	Vitamin D levels;
LUSC	cis	rs394563	0.625	rs384306	chr6:149796140	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.34	-6.96	-0.36	1.76e-11	Dupuytren's disease;
LUSC	trans	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.59	-0.34	1.71e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9583531	0.628	rs9521914	chr13:111382231	C/A	cg24331049	chr13:111365604	ING1	0.55	7.36	0.37	1.48e-12	Coronary artery disease;
LUSC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg27572855	chr1:25598939	RHD	0.47	8.58	0.42	3.74e-16	Erythrocyte sedimentation rate;
LUSC	cis	rs16937	0.711	rs10751430	chr1:205107497	A/G	cg00857998	chr1:205179979	DSTYK	0.47	6.59	0.34	1.71e-10	Schizophrenia;
LUSC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	0.65	9.14	0.45	6.14e-18	Methadone dose in opioid dependence;
LUSC	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg15212455	chr7:39170539	POU6F2	0.61	9.78	0.47	4.97e-20	IgG glycosylation;
LUSC	cis	rs4845459	0.967	rs9633406	chr1:152591446	C/G	cg08895932	chr1:152778580	LCE1C	-0.37	-6.35	-0.33	6.86e-10	Psoriasis;
LUSC	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg05343316	chr1:45956843	TESK2	-0.6	-8.38	-0.42	1.47e-15	Platelet count;
LUSC	trans	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg04995722	chr7:26192034	NFE2L3	-0.37	-6.05	-0.31	3.95e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18163118	chr11:67250585	AIP	-0.48	-6.31	-0.33	8.93e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3741151	0.686	rs11544310	chr11:73107592	A/G	cg17517138	chr11:73019481	ARHGEF17	0.9	8.32	0.41	2.21e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg22777020	chr22:31556080	RNF185	-0.47	-5.94	-0.31	7.04e-9	Colorectal cancer;
LUSC	cis	rs4474465	1.000	rs873311	chr11:78145886	G/C	cg27205649	chr11:78285834	NARS2	-0.53	-6.11	-0.32	2.8e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7089973	0.523	rs7099590	chr10:116749706	G/A	cg23260525	chr10:116636907	FAM160B1	0.29	5.75	0.3	1.97e-8	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	trans	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.88	0.35	3.01e-11	Endometrial cancer;
LUSC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.35	-0.33	6.93e-10	Retinal vascular caliber;
LUSC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg11062466	chr8:58055876	NA	0.66	8.52	0.42	5.47e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1505368	0.817	rs1283310	chr2:213273891	A/G	cg16329650	chr2:213403929	ERBB4	0.52	7.87	0.4	4.93e-14	Symmetrical dimethylarginine levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12940557	chr2:198299971	SF3B1	-0.43	-6.04	-0.31	4.13e-9	Hepatitis;
LUSC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs7598759	0.712	rs12991636	chr2:232333666	T/C	cg19187155	chr2:232395269	NMUR1	0.48	7.03	0.36	1.15e-11	Noise-induced hearing loss;
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.5	7.29	0.37	2.29e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.79	-0.3	1.67e-8	Bipolar disorder;
LUSC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg00857998	chr1:205179979	DSTYK	0.57	8.58	0.43	3.5e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg21545522	chr1:205238299	TMCC2	0.46	8.35	0.42	1.82e-15	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.67	11.93	0.55	1.38e-27	Aortic root size;
LUSC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg08200582	chr11:442649	ANO9	-0.52	-5.96	-0.31	6.31e-9	Body mass index;
LUSC	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-6.15	-0.32	2.19e-9	Fear of minor pain;
LUSC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11764359	chr7:65958608	NA	0.58	8.82	0.43	6.39e-17	Aortic root size;
LUSC	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg14458575	chr2:238380390	NA	0.68	12.06	0.55	4.8e-28	Prostate cancer;
LUSC	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg14061069	chr19:46274453	DMPK	-0.54	-9.24	-0.45	2.85e-18	Coronary artery disease;
LUSC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-6.78	-0.35	5.36e-11	Bipolar disorder;
LUSC	cis	rs7123876	0.587	rs72962169	chr11:72365669	C/T	cg04827223	chr11:72435913	ARAP1	-0.63	-7.42	-0.38	9.67e-13	Body mass index;
LUSC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg17366294	chr4:99064904	C4orf37	0.55	9.59	0.46	2.1e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg04455712	chr21:45112962	RRP1B	0.48	8.88	0.44	4.18e-17	Mean corpuscular volume;
LUSC	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg27284194	chr4:1044797	NA	0.49	7.77	0.39	9.7e-14	Recombination rate (males);
LUSC	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg10909506	chr17:38081995	ORMDL3	0.34	6.08	0.32	3.23e-9	Self-reported allergy;
LUSC	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	7.27	0.37	2.55e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.87	-0.31	1.03e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg23711669	chr6:146136114	FBXO30	0.87	16.1	0.66	1.44e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9309473	0.519	rs35421685	chr2:73910138	T/C	cg20560298	chr2:73613845	ALMS1	0.41	6.25	0.32	1.28e-9	Metabolite levels;
LUSC	cis	rs6005807	0.719	rs9625514	chr22:29022188	T/C	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.23e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7818345	0.967	rs4921638	chr8:19274793	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.92	0.35	2.31e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.8	-0.51	1.62e-23	Glomerular filtration rate;
LUSC	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.23	0.45	3.24e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg17971929	chr21:40555470	PSMG1	-0.5	-7.32	-0.37	1.81e-12	Menarche (age at onset);
LUSC	cis	rs1018836	0.665	rs7000724	chr8:91516335	A/T	cg16814680	chr8:91681699	NA	-0.72	-10.92	-0.51	6.18e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg16434002	chr17:42200994	HDAC5	-0.46	-6.61	-0.34	1.54e-10	Total body bone mineral density;
LUSC	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg16850897	chr7:100343110	ZAN	0.38	6.26	0.32	1.17e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-0.94	-17.96	-0.7	6.19e-51	Cognitive function;
LUSC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.97	-0.68	4.92e-47	Monocyte count;
LUSC	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg04827223	chr11:72435913	ARAP1	-0.72	-12.8	-0.57	8.64e-31	Body mass index;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12935497	chr15:82339233	MEX3B	0.41	6.1	0.32	2.89e-9	Asthma;
LUSC	cis	rs4077468	1.000	rs9662221	chr1:205915745	G/T	cg24503407	chr1:205819492	PM20D1	-0.44	-6.24	-0.32	1.3e-9	Cystic fibrosis-related diabetes;
LUSC	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg21775007	chr8:11205619	TDH	-0.59	-8.52	-0.42	5.4e-16	Neuroticism;
LUSC	cis	rs7202877	0.656	rs9923834	chr16:75507253	T/A	cg03315344	chr16:75512273	CHST6	0.42	6.06	0.31	3.71e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-10.14	-0.49	3.15e-21	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-7.69	-0.39	1.68e-13	Longevity;Endometriosis;
LUSC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.25	-0.49	1.32e-21	Hemoglobin concentration;
LUSC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.64	-7.28	-0.37	2.37e-12	Diabetic retinopathy;
LUSC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.73	-0.3	2.2e-8	Monocyte count;
LUSC	cis	rs73198271	0.595	rs56152067	chr8:8592992	G/A	cg01851573	chr8:8652454	MFHAS1	0.46	5.75	0.3	2.04e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs1113500	0.548	rs7541433	chr1:108645641	G/A	cg06207961	chr1:108661230	NA	0.34	5.68	0.3	2.93e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg20203395	chr5:56204925	C5orf35	0.58	8.55	0.42	4.48e-16	Initial pursuit acceleration;
LUSC	cis	rs73198271	0.531	rs17630714	chr8:8657681	C/T	cg01851573	chr8:8652454	MFHAS1	0.67	8.75	0.43	1.11e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs3755132	1.000	rs60016948	chr2:15728544	G/T	cg12888861	chr2:15731646	DDX1	0.53	7.59	0.38	3.24e-13	Wilms tumor;
LUSC	cis	rs829883	0.966	rs249815	chr12:98893709	A/G	cg25150519	chr12:98850993	NA	0.64	9.72	0.47	7.74e-20	Colorectal adenoma (advanced);
LUSC	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg10523679	chr1:76189770	ACADM	-0.47	-6.7	-0.34	8.69e-11	Daytime sleep phenotypes;
LUSC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-8.16	-0.41	6.99e-15	Hemoglobin concentration;
LUSC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg04871131	chr7:94954202	PON1	-0.39	-6.11	-0.32	2.7e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13126279	chr21:47581558	C21orf56	-0.42	-6.14	-0.32	2.3e-9	Testicular germ cell tumor;
LUSC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.92e-23	Gut microbiome composition (summer);
LUSC	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.55	-7.88	-0.4	4.53e-14	Reticulocyte count;
LUSC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg16325326	chr1:53192061	ZYG11B	0.71	11.61	0.54	2.03e-26	Monocyte count;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg24388789	chr13:24463533	MIPEP;PCOTH	0.46	6.02	0.31	4.55e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6088813	0.961	rs6060371	chr20:33913322	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.09	-0.32	3.08e-9	Height;
LUSC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg25174290	chr11:3078921	CARS	-0.41	-6.03	-0.31	4.44e-9	Calcium levels;
LUSC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.75e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg11608241	chr8:8085544	FLJ10661	0.4	5.8	0.3	1.55e-8	Mood instability;
LUSC	cis	rs4363385	0.747	rs61811427	chr1:152968419	C/T	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.86	-0.39	5.51e-14	Inflammatory skin disease;
LUSC	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg05425664	chr17:57184151	TRIM37	-0.4	-5.92	-0.31	8.06e-9	Cognitive function;
LUSC	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg21960279	chr19:17905606	B3GNT3	0.39	6.07	0.32	3.56e-9	Tumor biomarkers;
LUSC	cis	rs2290159	0.948	rs11711270	chr3:12639596	C/T	cg23032965	chr3:12705835	RAF1	0.54	7.01	0.36	1.32e-11	Cholesterol, total;
LUSC	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg08601574	chr20:25228251	PYGB	0.43	6.6	0.34	1.59e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg03859395	chr2:55845619	SMEK2	0.84	14.79	0.63	2.08e-38	Metabolic syndrome;
LUSC	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.86	-14.52	-0.62	2.16e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.76	10.86	0.51	9.89e-24	Corneal astigmatism;
LUSC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-5.83	-0.3	1.34e-8	Tonsillectomy;
LUSC	cis	rs6690583	0.623	rs893618	chr1:85513770	C/T	cg11262906	chr1:85462892	MCOLN2	0.67	6.12	0.32	2.68e-9	Serum sulfate level;
LUSC	trans	rs953492	0.672	rs1766030	chr1:243314577	C/T	cg25284624	chr1:224180302	NA	-0.5	-7.78	-0.39	9.01e-14	Diastolic blood pressure;
LUSC	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.66	-0.57	2.86e-30	Chronic sinus infection;
LUSC	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg11568697	chr18:72916393	ZADH2	0.56	6.49	0.33	3.16e-10	Vascular endothelial growth factor levels;
LUSC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4144743	1.000	rs4144745	chr17:45323349	T/C	cg18085866	chr17:45331354	ITGB3	-0.7	-7.62	-0.38	2.61e-13	Body mass index;
LUSC	cis	rs6674970	0.748	rs56299877	chr1:151115645	C/T	cg11822372	chr1:151115635	SEMA6C	-0.93	-15.48	-0.65	4.08e-41	Childhood ear infection;
LUSC	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.4	0.38	1.11e-12	Lung cancer in ever smokers;
LUSC	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg25801113	chr15:45476975	SHF	0.33	6.83	0.35	4.06e-11	Uric acid levels;
LUSC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg06618935	chr21:46677482	NA	-0.37	-7.52	-0.38	5.25e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08859206	chr1:53392774	SCP2	-0.53	-9.2	-0.45	3.85e-18	Monocyte count;
LUSC	cis	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg02972257	chr16:68554789	NA	-0.53	-6.6	-0.34	1.64e-10	Ulcerative colitis;
LUSC	cis	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg12800200	chr2:69260302	ANTXR1	0.4	6.2	0.32	1.7e-9	Breast cancer;
LUSC	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg03684893	chr10:554711	DIP2C	-0.37	-6.76	-0.35	6.33e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg01191920	chr7:158217561	PTPRN2	-0.53	-10.89	-0.51	7.94e-24	Obesity-related traits;
LUSC	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.32	-0.41	2.26e-15	Body mass index;
LUSC	cis	rs6722750	0.818	rs12104940	chr2:64385774	A/G	cg22352474	chr2:64371530	PELI1	0.64	10.01	0.48	8.15e-21	Neuroticism;
LUSC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.21	0.59	2.51e-32	Cognitive test performance;
LUSC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg00369194	chr7:157950511	PTPRN2	0.31	6.21	0.32	1.53e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.51	0.34	2.77e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.28	-0.41	3.08e-15	Joint mobility (Beighton score);
LUSC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg09034736	chr1:150693464	HORMAD1	-0.4	-5.72	-0.3	2.41e-8	Lymphocyte counts;
LUSC	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.93	15.97	0.66	4.9e-43	Morning vs. evening chronotype;
LUSC	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg13010199	chr12:38710504	ALG10B	0.71	10.9	0.51	7.24e-24	Bladder cancer;
LUSC	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg02527881	chr3:46936655	PTH1R	0.4	7.09	0.36	7.98e-12	Colorectal cancer;
LUSC	cis	rs6500395	1.000	rs1477134	chr16:48706973	G/A	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg26528668	chr16:1614120	IFT140	0.46	7.71	0.39	1.48e-13	Coronary artery disease;
LUSC	cis	rs9311676	0.632	rs62258075	chr3:58359851	G/A	cg26110898	chr3:58419937	PDHB	0.4	6.53	0.34	2.46e-10	Systemic lupus erythematosus;
LUSC	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg21775007	chr8:11205619	TDH	-0.54	-7.87	-0.4	5.07e-14	Neuroticism;
LUSC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.51	-6.82	-0.35	4.27e-11	Renal function-related traits (BUN);
LUSC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.66	-0.34	1.15e-10	Lung cancer;
LUSC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.08	0.32	3.26e-9	Personality dimensions;
LUSC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.38	0.67	1.08e-44	Platelet count;
LUSC	cis	rs2658782	0.547	rs4753453	chr11:93041174	T/G	cg15737290	chr11:93063684	CCDC67	0.9	13.82	0.6	1.15e-34	Pulmonary function decline;
LUSC	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg16482183	chr6:26056742	HIST1H1C	0.62	8.41	0.42	1.18e-15	Height;
LUSC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19346786	chr7:2764209	NA	-0.4	-6.72	-0.35	7.79e-11	Height;
LUSC	cis	rs9715521	0.677	rs62301200	chr4:59855179	G/A	cg11281224	chr4:60001000	NA	-0.5	-7.03	-0.36	1.18e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7072216	0.770	rs1739	chr10:100176339	A/G	cg26618903	chr10:100175079	PYROXD2	-0.34	-6.47	-0.33	3.58e-10	Metabolite levels;
LUSC	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.56	-11.61	-0.54	2.14e-26	Sense of smell;
LUSC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.97	-0.68	4.92e-47	Monocyte count;
LUSC	trans	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg18187862	chr3:45730750	SACM1L	0.52	6.83	0.35	4e-11	Primary sclerosing cholangitis;
LUSC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg14668632	chr7:2872130	GNA12	-0.42	-6.19	-0.32	1.77e-9	Height;
LUSC	cis	rs6545883	0.894	rs778143	chr2:61581890	A/C	cg15711740	chr2:61764176	XPO1	-0.44	-6.66	-0.34	1.15e-10	Tuberculosis;
LUSC	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg03676636	chr4:99064102	C4orf37	0.28	6.17	0.32	1.98e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.51	-0.42	5.88e-16	Longevity;
LUSC	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg22508957	chr16:3507546	NAT15	-0.41	-5.93	-0.31	7.71e-9	Body mass index (adult);
LUSC	cis	rs2463822	0.513	rs72919445	chr11:62029078	A/C	cg06239285	chr11:62104954	ASRGL1	-0.59	-5.97	-0.31	6.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.08	0.52	1.68e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2562456	0.833	rs62110429	chr19:21613786	C/T	cg00806126	chr19:22604979	ZNF98	-0.4	-5.69	-0.3	2.73e-8	Pain;
LUSC	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.64	-0.43	2.32e-16	Systolic blood pressure;
LUSC	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg02023728	chr11:77925099	USP35	0.46	6.7	0.34	8.82e-11	Testicular germ cell tumor;
LUSC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.87	-0.35	3.19e-11	Menopause (age at onset);
LUSC	cis	rs6469656	1.000	rs1436765	chr8:117652626	A/G	cg24004040	chr8:117650383	NA	-0.45	-6.46	-0.33	3.68e-10	Colorectal cancer;
LUSC	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg08048268	chr3:133502702	NA	0.35	6.39	0.33	5.68e-10	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs4144743	0.759	rs34251886	chr17:45320299	G/T	cg18085866	chr17:45331354	ITGB3	-0.84	-7.94	-0.4	3.02e-14	Body mass index;
LUSC	trans	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg20935933	chr6:143382018	AIG1	0.49	7.08	0.36	8.48e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs28830936	1.000	rs28754734	chr15:42093152	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.77	-0.3	1.78e-8	Diastolic blood pressure;
LUSC	cis	rs2840044	1.000	rs8073935	chr17:33985849	C/T	cg05299278	chr17:33885742	SLFN14	0.28	5.91	0.31	8.23e-9	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg25344623	chr2:136566232	LCT	0.4	5.94	0.31	6.98e-9	Mosquito bite size;
LUSC	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg18827107	chr12:86230957	RASSF9	0.5	7.36	0.37	1.43e-12	Major depressive disorder;
LUSC	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.66	-0.65	7.6e-42	Height;
LUSC	cis	rs4842666	0.915	rs12579302	chr12:90050503	C/T	cg00757033	chr12:89920650	WDR51B	-0.42	-6.06	-0.31	3.59e-9	Blood pressure;
LUSC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.96	-0.31	6.47e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.63	-0.43	2.52e-16	Bipolar disorder and schizophrenia;
LUSC	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.39	-0.37	1.16e-12	Neuroticism;
LUSC	cis	rs7523273	0.606	rs2761433	chr1:207917361	G/A	cg22525895	chr1:207977042	MIR29B2	0.4	6.62	0.34	1.42e-10	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg22709100	chr7:91322751	NA	0.39	5.75	0.3	1.98e-8	Breast cancer;
LUSC	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg10434728	chr15:90938212	IQGAP1	0.45	9.08	0.45	9.44e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg12564285	chr5:131593104	PDLIM4	0.45	7.79	0.39	8.44e-14	Breast cancer;
LUSC	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg15997130	chr1:24165203	NA	0.52	8.54	0.42	4.67e-16	Immature fraction of reticulocytes;
LUSC	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg16342193	chr10:102329863	NA	-0.34	-6.27	-0.32	1.1e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg23601095	chr6:26197514	HIST1H3D	0.75	7.59	0.38	3.21e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs9921338	0.961	rs56010295	chr16:11378907	G/A	cg00044050	chr16:11439710	C16orf75	-0.5	-6.96	-0.36	1.78e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-39.96	-0.91	2.76e-129	Myeloid white cell count;
LUSC	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-15.62	-0.65	1.1e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs113835537	0.597	rs11227527	chr11:66313026	A/G	cg24851651	chr11:66362959	CCS	0.53	7.84	0.39	6.15e-14	Airway imaging phenotypes;
LUSC	trans	rs7893279	0.822	rs6482408	chr10:18715540	A/G	cg01840055	chr3:141338555	NA	0.5	5.99	0.31	5.41e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg04944784	chr2:26401820	FAM59B	-0.75	-10.71	-0.51	3.38e-23	Gut microbiome composition (summer);
LUSC	cis	rs2153535	1.000	rs2153535	chr6:8369679	C/G	cg21535247	chr6:8435926	SLC35B3	-0.45	-6.53	-0.34	2.38e-10	Motion sickness;
LUSC	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg04545296	chr12:48745243	ZNF641	0.37	6.75	0.35	6.61e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.39	-0.49	4.23e-22	Electroencephalogram traits;
LUSC	trans	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg20935933	chr6:143382018	AIG1	0.5	7.2	0.37	3.9e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg17143192	chr8:8559678	CLDN23	0.63	9.03	0.44	1.37e-17	Obesity-related traits;
LUSC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg14993813	chr1:46806288	NSUN4	0.49	6.97	0.36	1.7e-11	Menopause (age at onset);
LUSC	cis	rs983392	0.651	rs718376	chr11:60002935	C/T	cg24026212	chr11:59952134	MS4A6A	-0.34	-5.84	-0.3	1.25e-8	Alzheimer's disease (late onset);
LUSC	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.07	0.48	5.24e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21284376	chr1:72748601	NEGR1	0.38	6.31	0.33	8.81e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01398415	chr1:226309536	NA	0.43	6.47	0.33	3.41e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs3125734	0.633	rs4979772	chr10:63967600	C/T	cg09941381	chr10:64027924	RTKN2	0.4	7.44	0.38	8.63e-13	Rheumatoid arthritis;
LUSC	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg24459738	chr19:57751996	ZNF805	-0.51	-7.53	-0.38	4.91e-13	Hyperactive-impulsive symptoms;
LUSC	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.31	-0.45	1.78e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg00191853	chr8:101177733	SPAG1	-0.38	-6.31	-0.33	8.89e-10	Atrioventricular conduction;
LUSC	cis	rs983392	0.559	rs1426249	chr11:60002261	C/A	cg02771260	chr11:59836817	MS4A3	-0.36	-5.92	-0.31	8.14e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg00277334	chr10:82204260	NA	-0.46	-6.41	-0.33	5.07e-10	Post bronchodilator FEV1;
LUSC	cis	rs10189230	0.967	rs13026378	chr2:222352712	G/A	cg14652038	chr2:222343519	EPHA4	0.32	5.76	0.3	1.91e-8	Urate levels in lean individuals;
LUSC	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg25730555	chr22:47059586	GRAMD4	-0.43	-6.94	-0.36	2e-11	Urate levels in obese individuals;
LUSC	cis	rs259282	0.605	rs3760939	chr19:33106911	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	9.64	0.47	1.49e-19	Schizophrenia;
LUSC	cis	rs4654899	1.000	rs10916938	chr1:21446883	A/G	cg01072550	chr1:21505969	NA	-0.51	-7.86	-0.39	5.44e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs3799379	0.550	rs2072804	chr6:26391190	G/A	cg09904177	chr6:26538194	HMGN4	-0.51	-6.87	-0.35	3.09e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg04362960	chr10:104952993	NT5C2	0.53	8.05	0.4	1.51e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08219700	chr8:58056026	NA	0.59	6.96	0.36	1.8e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg06212747	chr3:49208901	KLHDC8B	0.45	5.7	0.3	2.57e-8	Menarche (age at onset);
LUSC	cis	rs3820928	0.874	rs10194663	chr2:227875369	T/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.75	-0.39	1.09e-13	Pulmonary function;
LUSC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg06462663	chr19:18546047	ISYNA1	0.5	8.52	0.42	5.69e-16	Breast cancer;
LUSC	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg20848291	chr7:100343083	ZAN	-0.61	-8.43	-0.42	1.07e-15	Other erythrocyte phenotypes;
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg09704166	chr2:114031854	PAX8;LOC440839	0.46	7.77	0.39	1e-13	Lymphocyte counts;
LUSC	trans	rs62238980	0.614	rs75348576	chr22:32395467	A/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08439880	chr3:133502540	NA	-0.34	-6.12	-0.32	2.59e-9	Iron status biomarkers;
LUSC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg09365446	chr1:150670422	GOLPH3L	0.54	8.36	0.42	1.77e-15	Tonsillectomy;
LUSC	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg22508957	chr16:3507546	NAT15	0.44	6.18	0.32	1.83e-9	Body mass index (adult);
LUSC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg11752832	chr7:134001865	SLC35B4	0.55	8.4	0.42	1.32e-15	Mean platelet volume;
LUSC	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.43	-0.33	4.34e-10	Dupuytren's disease;
LUSC	cis	rs9467711	0.720	rs3857546	chr6:26157762	C/T	cg16898833	chr6:26189333	HIST1H4D	0.71	6.92	0.35	2.31e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-7.21	-0.37	3.69e-12	Response to antipsychotic treatment;
LUSC	cis	rs2074585	0.517	rs11638010	chr15:91079920	A/G	cg22089800	chr15:90895588	ZNF774	-0.57	-8.08	-0.4	1.17e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs34734847	0.814	rs17847	chr12:121149475	A/G	cg21892295	chr12:121157589	UNC119B	-0.36	-6.3	-0.33	9.46e-10	Mean corpuscular volume;
LUSC	cis	rs7607369	0.559	rs6741592	chr2:219658609	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-9.18	-0.45	4.5e-18	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg12620499	chr2:216877984	MREG	0.93	14.14	0.61	6.66e-36	Alcohol dependence;
LUSC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg06618935	chr21:46677482	NA	-0.39	-7.81	-0.39	7.65e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg05855489	chr10:104503620	C10orf26	0.45	6.91	0.35	2.44e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg04518342	chr5:131593106	PDLIM4	0.44	7.71	0.39	1.47e-13	Acylcarnitine levels;
LUSC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg08132940	chr7:1081526	C7orf50	-0.52	-6.19	-0.32	1.8e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg24687543	chr11:63912206	MACROD1	0.46	5.94	0.31	7.22e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg00800038	chr16:89945340	TCF25	-0.64	-6.63	-0.34	1.37e-10	Skin colour saturation;
LUSC	cis	rs2625529	0.652	rs2929508	chr15:72246964	A/T	cg16672083	chr15:72433130	SENP8	0.5	8.22	0.41	4.49e-15	Red blood cell count;
LUSC	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.43	8.05	0.4	1.51e-14	Monocyte percentage of white cells;
LUSC	cis	rs34779708	0.733	rs7083266	chr10:35541632	C/A	cg03585969	chr10:35415529	CREM	0.55	7.61	0.38	2.86e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg27411982	chr8:10470053	RP1L1	0.48	7.19	0.37	4.19e-12	Monocyte count;
LUSC	trans	rs9784649	1.000	rs9784649	chr5:25011524	G/A	cg08600765	chr20:34638493	LOC647979	-0.53	-6.09	-0.32	3.03e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs35883536	0.647	rs10875315	chr1:101044062	G/A	cg06223162	chr1:101003688	GPR88	-0.49	-9.24	-0.45	2.89e-18	Monocyte count;
LUSC	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.38	9.5	0.46	4.17e-19	Diastolic blood pressure;
LUSC	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg05527609	chr1:210001259	C1orf107	0.67	9.63	0.47	1.5700000000000001e-19	Orofacial clefts;
LUSC	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1953600	0.837	rs2236556	chr10:81932790	T/C	cg04850286	chr10:81895943	PLAC9	0.34	5.98	0.31	5.82e-9	Sarcoidosis;
LUSC	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg16339924	chr4:17578868	LAP3	-0.58	-8.39	-0.42	1.36e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-6.51	-0.34	2.69e-10	High light scatter reticulocyte count;
LUSC	cis	rs2219968	0.828	rs1871788	chr8:78945481	T/C	cg00738934	chr8:78996279	NA	-0.38	-6.9	-0.35	2.59e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.5	-0.42	6.28e-16	Neuroticism;
LUSC	cis	rs7605827	0.836	rs4396684	chr2:15634404	C/T	cg19274914	chr2:15703543	NA	0.45	8.57	0.42	3.81e-16	Educational attainment (years of education);
LUSC	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg04450456	chr4:17643702	FAM184B	0.41	6.98	0.36	1.62e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg21123913	chr4:89513664	HERC3	0.37	6.21	0.32	1.54e-9	Schizophrenia (age at onset);
LUSC	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	10.14	0.49	3.03e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1256061	0.564	rs1256043	chr14:64734282	A/G	cg23250157	chr14:64679961	SYNE2	0.32	5.7	0.3	2.68e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs6845621	0.727	rs10020540	chr4:18908628	T/C	cg12196642	chr4:18937545	NA	-0.33	-6.22	-0.32	1.45e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg15103426	chr22:29168792	CCDC117	0.46	6.02	0.31	4.71e-9	Lymphocyte counts;
LUSC	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-7.59	-0.38	3.32e-13	Morning vs. evening chronotype;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg20749510	chr20:62374070	SLC2A4RG	-0.42	-6.96	-0.36	1.76e-11	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.19	-0.32	1.79e-9	Monocyte count;
LUSC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg23788917	chr6:8435910	SLC35B3	-0.5	-7.42	-0.38	9.83e-13	Motion sickness;
LUSC	cis	rs2652834	0.851	rs4468558	chr15:63346681	T/C	cg05507819	chr15:63340323	TPM1	0.67	8.47	0.42	8.1e-16	HDL cholesterol;
LUSC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg07424592	chr7:64974309	NA	0.63	5.69	0.3	2.81e-8	Diabetic kidney disease;
LUSC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg17971929	chr21:40555470	PSMG1	-0.51	-7.59	-0.38	3.3e-13	Menarche (age at onset);
LUSC	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg27147174	chr7:100797783	AP1S1	-0.64	-10.24	-0.49	1.34e-21	Life satisfaction;
LUSC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg00033643	chr7:134001901	SLC35B4	0.46	7.27	0.37	2.61e-12	Mean platelet volume;
LUSC	trans	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg16724585	chr3:197361211	NA	-0.61	-8.66	-0.43	2e-16	Pancreatic cancer;
LUSC	cis	rs7903847	0.642	rs2275581	chr10:99126249	G/A	cg20016023	chr10:99160130	RRP12	-0.3	-6.35	-0.33	7.17e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7605827	0.897	rs6734288	chr2:15526222	T/G	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg05110241	chr16:68378359	PRMT7	-0.81	-8.41	-0.42	1.25e-15	Magnesium levels;
LUSC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.16	-0.32	2.06e-9	Total body bone mineral density;
LUSC	cis	rs1775715	0.870	rs10827001	chr10:32229734	C/T	cg18675610	chr10:32216311	ARHGAP12	0.29	6.28	0.33	1.04e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg25214090	chr10:38739885	LOC399744	0.6	8.81	0.43	6.84e-17	Corneal astigmatism;
LUSC	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg00254258	chr1:3105189	PRDM16	-0.3	-5.93	-0.31	7.57e-9	Migraine;
LUSC	cis	rs4356932	1.000	rs4257674	chr4:76945685	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg18099408	chr3:52552593	STAB1	-0.35	-6.08	-0.32	3.22e-9	Electroencephalogram traits;
LUSC	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	0.86	13.38	0.59	5.34e-33	Blood protein levels;
LUSC	cis	rs4474465	1.000	rs10899523	chr11:78190808	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-6.1	-0.32	2.95e-9	Alzheimer's disease (survival time);
LUSC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg15557168	chr22:42548783	NA	-0.45	-6.88	-0.35	2.98e-11	Schizophrenia;
LUSC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg16850897	chr7:100343110	ZAN	-0.45	-5.65	-0.3	3.4e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg27572855	chr1:25598939	RHD	-0.41	-7.11	-0.36	7.16e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs12681287	0.752	rs4389908	chr8:87274852	A/G	cg27223183	chr8:87520930	FAM82B	-0.46	-5.92	-0.31	7.82e-9	Caudate activity during reward;
LUSC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.79	0.35	5.13e-11	Tonsillectomy;
LUSC	cis	rs4654899	0.714	rs12133972	chr1:21091338	A/T	cg01072550	chr1:21505969	NA	-0.44	-6.53	-0.34	2.39e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08704250	chr15:31115839	NA	-0.47	-6.97	-0.36	1.71e-11	Huntington's disease progression;
LUSC	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg13010199	chr12:38710504	ALG10B	0.57	8.64	0.43	2.29e-16	Bladder cancer;
LUSC	cis	rs9309473	0.500	rs4852953	chr2:73869908	G/A	cg20560298	chr2:73613845	ALMS1	0.42	6.37	0.33	6.27e-10	Metabolite levels;
LUSC	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.4	6.78	0.35	5.41e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg20295408	chr7:1910781	MAD1L1	-0.47	-6.7	-0.34	8.92e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs2108225	0.837	rs6466186	chr7:107446966	G/C	cg18560240	chr7:107437656	SLC26A3	-0.4	-6.13	-0.32	2.43e-9	Ulcerative colitis;
LUSC	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg23289794	chr7:2394357	EIF3B	-0.7	-9.41	-0.46	8.6e-19	Multiple sclerosis;
LUSC	cis	rs6484504	0.652	rs578666	chr11:31404484	C/T	cg06552810	chr11:31128660	NA	0.37	6.1	0.32	2.99e-9	Red blood cell count;
LUSC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	6.57	0.34	1.92e-10	Multiple sclerosis;
LUSC	trans	rs870142	0.883	rs931998	chr4:4639613	G/A	cg04017672	chr1:182359056	GLUL	0.41	6.04	0.31	4.2e-9	Congenital heart disease;
LUSC	trans	rs34421088	0.506	rs2409755	chr8:11169983	G/A	cg06636001	chr8:8085503	FLJ10661	0.47	6.96	0.36	1.76e-11	Neuroticism;
LUSC	cis	rs909002	1.000	rs1474182	chr1:32136398	C/T	cg13919466	chr1:32135498	COL16A1	-0.32	-6.01	-0.31	4.8e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs250677	0.522	rs891920	chr5:148369418	G/T	cg18129178	chr5:148520854	ABLIM3	-0.5	-7.29	-0.37	2.21e-12	Breast cancer;
LUSC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-8.18	-0.41	6.14e-15	Systemic lupus erythematosus;
LUSC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg01802117	chr1:53393560	SCP2	0.37	6.0	0.31	5.15e-9	Monocyte count;
LUSC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg21361702	chr7:150065534	REPIN1	0.46	6.29	0.33	1.01e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6977660	0.943	rs10263564	chr7:19842898	G/C	cg07541023	chr7:19748670	TWISTNB	0.53	6.06	0.31	3.64e-9	Thyroid stimulating hormone;
LUSC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.36	5.68	0.3	2.87e-8	Vitiligo;
LUSC	cis	rs2274273	1.000	rs11621351	chr14:55616740	C/A	cg04306507	chr14:55594613	LGALS3	0.55	12.08	0.55	3.99e-28	Protein biomarker;
LUSC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg00933542	chr6:150070202	PCMT1	0.29	5.93	0.31	7.45e-9	Lung cancer;
LUSC	cis	rs9952991	0.883	rs11663253	chr18:12789556	A/G	cg23598886	chr18:12777645	NA	-0.58	-5.73	-0.3	2.22e-8	Inflammatory skin disease;
LUSC	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	0.94	17.57	0.69	2.21e-49	Headache;
LUSC	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg26408565	chr15:76604113	ETFA	-0.46	-7.36	-0.37	1.43e-12	Blood metabolite levels;
LUSC	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.64	-0.34	1.24e-10	Response to antipsychotic treatment;
LUSC	cis	rs6942756	1.000	rs66864889	chr7:128952560	G/A	cg02491457	chr7:128862824	NA	-0.48	-6.68	-0.34	9.93e-11	White matter hyperintensity burden;
LUSC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg24631222	chr15:78858424	CHRNA5	0.83	11.48	0.53	5.98e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg05299278	chr17:33885742	SLFN14	0.3	6.62	0.34	1.43e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg02023728	chr11:77925099	USP35	0.48	6.76	0.35	6.33e-11	Testicular germ cell tumor;
LUSC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg25214090	chr10:38739885	LOC399744	0.45	6.6	0.34	1.61e-10	Corneal astigmatism;
LUSC	trans	rs8105895	0.825	rs62112369	chr19:22313901	C/T	cg05197062	chr11:11642011	GALNTL4	-0.48	-5.97	-0.31	6.03e-9	Body mass index (change over time);
LUSC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-21.69	-0.76	1e-65	Height;
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.78	17.87	0.7	1.41e-50	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7215564	0.908	rs4243240	chr17:78660342	T/C	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg17366294	chr4:99064904	C4orf37	0.6	10.73	0.51	2.76e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.63	8.41	0.42	1.21e-15	High light scatter reticulocyte count;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg21652505	chr19:40023540	EID2B	0.41	6.15	0.32	2.25e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6700559	0.740	rs4437908	chr1:200648439	A/G	cg07804481	chr1:200639085	DDX59	0.41	5.77	0.3	1.85e-8	Coronary artery disease;
LUSC	cis	rs79149102	0.737	rs16973172	chr15:75156944	G/A	cg09165964	chr15:75287851	SCAMP5	-0.89	-6.46	-0.33	3.72e-10	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07205460	chr22:24236375	MIF	-0.42	-6.4	-0.33	5.32e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06112835	chr11:68658793	MRPL21	0.48	7.4	0.38	1.09e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg10556349	chr10:835070	NA	0.57	6.38	0.33	5.77e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg03161606	chr19:29218774	NA	0.64	9.82	0.47	3.67e-20	Methadone dose in opioid dependence;
LUSC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.93	0.35	2.12e-11	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg00945038	chr17:61921165	SMARCD2	-0.53	-9.28	-0.45	2.2e-18	Prudent dietary pattern;
LUSC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg11608241	chr8:8085544	FLJ10661	0.42	6.27	0.32	1.14e-9	Neuroticism;
LUSC	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg04374321	chr14:90722782	PSMC1	-0.68	-10.17	-0.49	2.42e-21	Mortality in heart failure;
LUSC	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.66	-0.34	1.1e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3857536	0.776	rs9294687	chr6:66942919	C/T	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.73	0.35	7.27e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6460942	0.908	rs6978877	chr7:12232690	A/G	cg06484146	chr7:12443880	VWDE	-0.56	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg00484396	chr16:3507460	NAT15	0.51	7.09	0.36	7.95e-12	Body mass index (adult);
LUSC	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg02018176	chr4:1364513	KIAA1530	0.45	6.34	0.33	7.29e-10	Recombination rate (females);
LUSC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.89	12.1	0.55	3.42e-28	Smoking behavior;
LUSC	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg05714579	chr10:131428358	MGMT	0.5	7.56	0.38	3.97e-13	Response to temozolomide;
LUSC	cis	rs1028488	0.511	rs7738313	chr6:170704356	C/A	cg20370364	chr6:170703943	FAM120B	-0.49	-7.33	-0.37	1.77e-12	Interferon alpha levels in systemic lupus erythematosus;
LUSC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.36e-10	Menopause (age at onset);
LUSC	cis	rs4363385	0.818	rs423692	chr1:153005681	T/G	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.45e-8	Inflammatory skin disease;
LUSC	cis	rs4478858	0.735	rs2889730	chr1:31827159	C/T	cg00250761	chr1:31883323	NA	-0.36	-8.64	-0.43	2.28e-16	Alcohol dependence;
LUSC	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.99	0.36	1.52e-11	Rheumatoid arthritis;
LUSC	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg12002119	chr2:101014098	CHST10	0.35	5.96	0.31	6.41e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.61	0.38	2.81e-13	Bipolar disorder;
LUSC	trans	rs225245	0.817	rs225297	chr17:33924587	G/A	cg19694781	chr19:47549865	TMEM160	-0.41	-6.61	-0.34	1.51e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg26384229	chr12:38710491	ALG10B	0.5	7.24	0.37	3.07e-12	Morning vs. evening chronotype;
LUSC	cis	rs11640436	0.544	rs12921392	chr16:77320605	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.39	-6.28	-0.33	1.03e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg18357645	chr12:58087776	OS9	0.58	8.67	0.43	1.94e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6700896	0.966	rs7516341	chr1:66088143	T/C	cg04111102	chr1:66153794	NA	0.32	7.03	0.36	1.14e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs3741151	0.572	rs12290623	chr11:73121872	C/G	cg17517138	chr11:73019481	ARHGEF17	0.81	7.45	0.38	8.18e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg00277334	chr10:82204260	NA	-0.58	-8.71	-0.43	1.47e-16	Post bronchodilator FEV1;
LUSC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg06740227	chr12:86229804	RASSF9	0.43	6.76	0.35	6.18e-11	Major depressive disorder;
LUSC	cis	rs72960926	0.744	rs6923498	chr6:74913523	C/T	cg03266952	chr6:74778945	NA	-0.67	-5.92	-0.31	8.1e-9	Metabolite levels (MHPG);
LUSC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg09904177	chr6:26538194	HMGN4	-0.48	-5.94	-0.31	7.23e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6445797	0.632	rs114096928	chr3:56637772	C/T	cg13792233	chr3:56591045	CCDC66	0.4	5.68	0.3	2.98e-8	Gastritis;
LUSC	cis	rs10207060	0.500	rs1316923	chr2:240719792	A/G	cg07506560	chr2:240697449	NA	-0.39	-6.1	-0.32	2.99e-9	Obesity-related traits;
LUSC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.49	0.33	3.13e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg05585544	chr11:47624801	NA	-0.41	-7.22	-0.37	3.44e-12	Subjective well-being;
LUSC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg19774624	chr17:42201019	HDAC5	-0.8	-12.48	-0.56	1.39e-29	Total body bone mineral density;
LUSC	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.86	-0.4	5.4e-14	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs469568	0.901	rs338874	chr5:178668964	G/C	cg08999896	chr5:178685787	ADAMTS2	0.29	6.13	0.32	2.46e-9	Stroke (pediatric);
LUSC	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg15848620	chr12:58087721	OS9	0.56	8.09	0.4	1.14e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs72772090	0.539	rs11743410	chr5:96124453	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-6.96	-0.36	1.82e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs17030434	1.000	rs79094565	chr4:154718997	T/C	cg14289246	chr4:154710475	SFRP2	-0.53	-6.84	-0.35	3.69e-11	Electrocardiographic conduction measures;
LUSC	cis	rs7189233	0.955	rs8054299	chr16:53498655	C/G	cg09728985	chr16:53543985	NA	0.33	5.75	0.3	2.03e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg18449964	chr18:72917101	ZADH2	0.45	5.66	0.3	3.21e-8	Vascular endothelial growth factor levels;
LUSC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg07493874	chr5:1342172	CLPTM1L	0.28	5.91	0.31	8.58e-9	Lung cancer;
LUSC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg12963246	chr6:28129442	ZNF389	0.53	7.43	0.38	9.21e-13	Parkinson's disease;
LUSC	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg22437258	chr11:111473054	SIK2	-0.43	-5.67	-0.3	3.09e-8	Primary sclerosing cholangitis;
LUSC	cis	rs6066835	0.867	rs11698171	chr20:47359645	A/G	cg18078177	chr20:47281410	PREX1	0.65	5.78	0.3	1.71e-8	Multiple myeloma;
LUSC	trans	rs11700980	0.551	rs2832036	chr21:30115170	T/G	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.58	-7.7	-0.39	1.56e-13	Body mass index;
LUSC	cis	rs6681460	1.000	rs4655647	chr1:67106077	C/G	cg02459107	chr1:67143332	SGIP1	0.47	8.68	0.43	1.82e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs9815354	0.812	rs17216919	chr3:41888938	G/C	cg03022575	chr3:42003672	ULK4	0.84	8.74	0.43	1.14e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7104764	0.507	rs6598054	chr11:254010	C/T	cg00562011	chr11:252351	PSMD13	0.49	6.19	0.32	1.8e-9	Menarche (age at onset);
LUSC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21171335	chr12:122356390	WDR66	0.59	9.02	0.44	1.55e-17	Mean corpuscular volume;
LUSC	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg06937882	chr20:24974362	C20orf3	-0.45	-7.86	-0.4	5.32e-14	Blood protein levels;
LUSC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg24130564	chr14:104152367	KLC1	-0.42	-6.05	-0.31	3.79e-9	Body mass index;
LUSC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.19	0.45	4.42e-18	Menarche (age at onset);
LUSC	cis	rs10788264	0.504	rs4751886	chr10:124020396	T/C	cg09507567	chr10:124027408	NA	0.55	9.76	0.47	5.62e-20	Total body bone mineral density;
LUSC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg16524733	chr11:117070046	TAGLN	0.43	7.48	0.38	6.56e-13	Blood protein levels;
LUSC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg06618935	chr21:46677482	NA	-0.39	-7.78	-0.39	9.05e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg14298792	chr15:30685198	CHRFAM7A	0.47	6.08	0.32	3.25e-9	Huntington's disease progression;
LUSC	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg09491104	chr22:46646882	C22orf40	-0.65	-6.9	-0.35	2.55e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.78	0.39	9.25e-14	Colorectal cancer;
LUSC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg10130564	chr11:117069849	TAGLN	0.4	6.99	0.36	1.53e-11	Blood protein levels;
LUSC	cis	rs7615316	0.934	rs7647573	chr3:142251583	C/T	cg16271453	chr3:142027066	XRN1	-0.4	-6.83	-0.35	3.93e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.73	11.12	0.52	1.19e-24	Eosinophil percentage of white cells;
LUSC	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.76	-0.39	1.07e-13	Pulmonary function;
LUSC	cis	rs11229555	1.000	rs11603890	chr11:58402251	T/C	cg15696309	chr11:58395628	NA	-0.7	-9.28	-0.45	2.12e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7771547	0.573	rs619011	chr6:36476592	A/G	cg07856975	chr6:36356162	ETV7	0.37	6.61	0.34	1.49e-10	Platelet distribution width;
LUSC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14159672	chr1:205819179	PM20D1	0.47	6.71	0.34	8.19e-11	Prostate-specific antigen levels;
LUSC	cis	rs12532214	0.690	rs6971710	chr7:3140173	G/A	cg19214707	chr7:3157722	NA	-0.38	-5.84	-0.3	1.24e-8	Itch intensity from mosquito bite;
LUSC	trans	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg21775007	chr8:11205619	TDH	0.42	6.14	0.32	2.32e-9	Mood instability;
LUSC	cis	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs9905704	0.589	rs2632509	chr17:56487887	C/T	cg12560992	chr17:57184187	TRIM37	-0.48	-5.77	-0.3	1.85e-8	Testicular germ cell tumor;
LUSC	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg24130564	chr14:104152367	KLC1	-0.41	-5.86	-0.31	1.12e-8	Body mass index;
LUSC	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg05340658	chr4:99064831	C4orf37	-0.43	-6.82	-0.35	4.3e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	0.95	18.8	0.72	2.6e-54	Cognitive function;
LUSC	trans	rs3857536	0.741	rs9363558	chr6:66937260	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs7106204	0.534	rs16912285	chr11:24252528	A/G	ch.11.24196551F	chr11:24239977	NA	0.72	6.09	0.32	3.05e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg06784218	chr1:46089804	CCDC17	0.48	9.43	0.46	7e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg12863693	chr15:85201151	NMB	0.34	6.24	0.32	1.36e-9	Schizophrenia;
LUSC	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg13010344	chr12:123464640	ARL6IP4	0.51	6.5	0.33	2.97e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7674212	0.531	rs7665026	chr4:103936648	T/C	cg16532752	chr4:104119610	CENPE	-0.42	-5.78	-0.3	1.69e-8	Type 2 diabetes;
LUSC	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.42	0.53	9.82e-26	Eye color traits;
LUSC	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.23e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg02187348	chr16:89574699	SPG7	0.47	7.39	0.37	1.2e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs4845459	0.967	rs4845446	chr1:152590750	C/T	cg08895932	chr1:152778580	LCE1C	0.37	6.44	0.33	4.2e-10	Psoriasis;
LUSC	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	7.07	0.36	9.12e-12	HDL cholesterol;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg09040699	chr11:8009242	EIF3F	0.37	6.17	0.32	2e-9	Tuberculosis;
LUSC	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.87	14.76	0.63	2.57e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12286929	0.577	rs7101437	chr11:115063641	A/G	cg04055981	chr11:115044050	NA	-0.4	-7.22	-0.37	3.53e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.15	-0.32	2.19e-9	Neutrophil percentage of white cells;
LUSC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg22920501	chr2:26401640	FAM59B	-0.8	-12.27	-0.56	8.04e-29	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.59	0.78	3.14e-69	Prudent dietary pattern;
LUSC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.82	0.6	1.14e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg20887711	chr4:1340912	KIAA1530	0.53	8.61	0.43	2.97e-16	Longevity;
LUSC	trans	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg07393940	chr7:158741817	NA	0.51	8.0	0.4	2.07e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg03563238	chr19:33554763	RHPN2	-0.39	-6.16	-0.32	2.14e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs62458065	0.850	rs62458066	chr7:32464484	C/T	cg00845942	chr12:64062724	DPY19L2	-0.54	-6.23	-0.32	1.38e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs3820928	0.874	rs4423583	chr2:227874957	A/G	cg11843606	chr2:227700838	RHBDD1	0.53	7.48	0.38	6.83e-13	Pulmonary function;
LUSC	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg13010344	chr12:123464640	ARL6IP4	-0.49	-6.69	-0.34	9.46e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.56	0.65	1.98e-41	Platelet count;
LUSC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg15704280	chr7:45808275	SEPT13	0.89	12.91	0.58	3.35e-31	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg08132940	chr7:1081526	C7orf50	-0.51	-5.93	-0.31	7.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg18357645	chr12:58087776	OS9	0.53	8.05	0.4	1.47e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.69	-0.3	2.8e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg18477163	chr1:228402036	OBSCN	-0.56	-10.39	-0.49	4.2e-22	Diastolic blood pressure;
LUSC	trans	rs6601327	0.641	rs4840437	chr8:9606264	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.46	-0.33	3.67e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg22800045	chr5:56110881	MAP3K1	-0.61	-8.48	-0.42	7.25e-16	Initial pursuit acceleration;
LUSC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg12564285	chr5:131593104	PDLIM4	0.46	8.86	0.44	4.87e-17	Blood metabolite levels;
LUSC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.11	14.24	0.61	2.64e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg07507251	chr3:52567010	NT5DC2	0.35	6.7	0.34	8.79e-11	Bipolar disorder;
LUSC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21963583	chr11:68658836	MRPL21	0.56	8.54	0.42	4.94e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06911149	chr19:10613456	KEAP1	-0.4	-5.98	-0.31	5.79e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg13825663	chr2:96873994	STARD7	0.38	5.98	0.31	5.75e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg20476274	chr7:133979776	SLC35B4	0.86	15.96	0.66	5.29e-43	Mean platelet volume;
LUSC	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.77	0.51	2.06e-23	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.46	-0.38	7.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg04508216	chr1:11107452	MASP2	0.31	5.67	0.3	3.17e-8	Body mass index;
LUSC	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-13.16	-0.58	3.67e-32	Primary sclerosing cholangitis;
LUSC	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg04455712	chr21:45112962	RRP1B	0.45	8.46	0.42	8.54e-16	Mean corpuscular volume;
LUSC	cis	rs6700896	0.931	rs1938498	chr1:66098653	T/C	cg04111102	chr1:66153794	NA	0.32	7.08	0.36	8.57e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg08875078	chr22:50639485	SELO	0.45	6.18	0.32	1.84e-9	Obesity-related traits;
LUSC	cis	rs2274273	0.712	rs1002054	chr14:55528913	A/C	cg04306507	chr14:55594613	LGALS3	0.49	10.73	0.51	2.75e-23	Protein biomarker;
LUSC	cis	rs9650657	0.707	rs4593498	chr8:10655470	C/G	cg27411982	chr8:10470053	RP1L1	-0.36	-5.88	-0.31	1.01e-8	Neuroticism;
LUSC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg21963583	chr11:68658836	MRPL21	0.56	8.44	0.42	9.71e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	7.34	0.37	1.68e-12	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11971779	0.648	rs6947309	chr7:139035830	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.32	0.33	8.48e-10	Diisocyanate-induced asthma;
LUSC	cis	rs75920871	0.528	rs7930264	chr11:116870766	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.48	-0.33	3.26e-10	Subjective well-being;
LUSC	cis	rs17253792	0.822	rs58569951	chr14:56152245	T/C	cg01858014	chr14:56050164	KTN1	-0.73	-6.4	-0.33	5.12e-10	Putamen volume;
LUSC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg02931644	chr1:25747376	RHCE	0.38	6.87	0.35	3.11e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg03354898	chr7:1950403	MAD1L1	-0.42	-8.51	-0.42	5.81e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg17031739	chr1:67600172	NA	0.45	7.02	0.36	1.27e-11	Psoriasis;
LUSC	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg02176678	chr2:219576539	TTLL4	-0.57	-10.21	-0.49	1.77e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.59	-11.7	-0.54	1e-26	Monocyte percentage of white cells;
LUSC	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs6580649	0.824	rs1635534	chr12:48386553	A/G	cg24011408	chr12:48396354	COL2A1	0.49	6.07	0.32	3.52e-9	Lung cancer;
LUSC	cis	rs243505	0.732	rs10255478	chr7:148501985	C/G	cg09806900	chr7:148480153	CUL1	0.58	8.43	0.42	1.08e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22496380	chr5:211416	CCDC127	-0.7	-7.95	-0.4	2.97e-14	Breast cancer;
LUSC	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg17366294	chr4:99064904	C4orf37	0.53	8.2	0.41	5.33e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24110177	chr3:50126178	RBM5	-0.55	-8.98	-0.44	2e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg24130564	chr14:104152367	KLC1	-0.4	-5.69	-0.3	2.78e-8	Body mass index;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg12461364	chr10:12084985	UPF2	0.36	6.0	0.31	5.06e-9	Mosquito bite size;
LUSC	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg03213289	chr20:61660250	NA	0.66	12.81	0.57	7.61e-31	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25152348	chr22:50946712	NCAPH2;LMF2	-0.36	-6.63	-0.34	1.34e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg10018233	chr7:150070692	REPIN1	0.39	6.35	0.33	7.01e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs713477	0.901	rs7146306	chr14:55905853	C/T	cg13175173	chr14:55914753	NA	-0.32	-6.77	-0.35	5.7e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.7	11.16	0.52	8.54e-25	Coronary artery disease;
LUSC	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg20487152	chr13:99095054	FARP1	-0.42	-7.15	-0.36	5.42e-12	Longevity;
LUSC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg23283495	chr1:209979779	IRF6	0.73	9.34	0.46	1.37e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg11812906	chr14:75593930	NEK9	0.67	11.51	0.53	4.89e-26	Height;
LUSC	trans	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg08017606	chr5:145316274	SH3RF2	-0.58	-6.04	-0.31	4.11e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs1538970	0.962	rs3219463	chr1:45806432	C/T	cg05343316	chr1:45956843	TESK2	0.58	7.77	0.39	1.01e-13	Platelet count;
LUSC	cis	rs394563	0.663	rs415434	chr6:149772645	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.34	-7.16	-0.36	5.08e-12	Dupuytren's disease;
LUSC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.85	0.31	1.15e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-7.22	-0.37	3.57e-12	Height;
LUSC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs1443512	0.812	rs1867299	chr12:54329975	T/C	cg17410650	chr12:54324560	NA	-0.59	-10.58	-0.5	9.56e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg03806693	chr22:41940476	POLR3H	1.0	14.26	0.62	2.35e-36	Vitiligo;
LUSC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg16524733	chr11:117070046	TAGLN	0.44	7.73	0.39	1.29e-13	Blood protein levels;
LUSC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg06238570	chr21:40685208	BRWD1	-0.65	-10.63	-0.5	6.1e-23	Cognitive function;
LUSC	cis	rs7804356	1.000	rs55739485	chr7:26860741	T/C	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.05e-9	Type 1 diabetes;
LUSC	cis	rs2857891	0.817	rs2857901	chr11:6980511	A/G	cg04053776	chr11:6947353	ZNF215	0.41	5.69	0.3	2.73e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-7.93	-0.4	3.36e-14	Depression;
LUSC	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.8	-11.75	-0.54	6.33e-27	Blood pressure (smoking interaction);
LUSC	cis	rs12986413	0.651	rs2238610	chr19:2146852	T/C	cg09261902	chr19:2140048	AP3D1	0.34	6.07	0.32	3.48e-9	Height;
LUSC	cis	rs10484885	0.887	rs17707738	chr6:90602735	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.78	-8.4	-0.42	1.31e-15	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9807989	0.839	rs10182710	chr2:102981306	A/G	cg03938978	chr2:103052716	IL18RAP	0.31	5.74	0.3	2.08e-8	Asthma;
LUSC	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg02023728	chr11:77925099	USP35	0.48	6.71	0.34	8.31e-11	Testicular germ cell tumor;
LUSC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg09034736	chr1:150693464	HORMAD1	0.44	6.02	0.31	4.65e-9	Melanoma;
LUSC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg16339924	chr4:17578868	LAP3	-0.63	-9.72	-0.47	7.72e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.63	-9.64	-0.47	1.4e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg17173187	chr15:85201210	NMB	0.46	8.73	0.43	1.26e-16	Schizophrenia;
LUSC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	6.44	0.33	4.18e-10	Joint mobility (Beighton score);
LUSC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg02569458	chr12:86230093	RASSF9	0.52	8.64	0.43	2.29e-16	Major depressive disorder;
LUSC	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg01689657	chr7:91764605	CYP51A1	-0.32	-5.81	-0.3	1.47e-8	Breast cancer;
LUSC	cis	rs1904096	0.506	rs10034781	chr4:95169682	A/C	cg11021082	chr4:95130006	SMARCAD1	0.42	7.62	0.38	2.64e-13	Type 2 diabetes;
LUSC	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg07701084	chr6:150067640	NUP43	0.53	7.89	0.4	4.29e-14	Lung cancer;
LUSC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.69	12.32	0.56	5.24e-29	Diastolic blood pressure;
LUSC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.45	0.42	9.2e-16	Melanoma;
LUSC	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg21854759	chr1:92012499	NA	0.43	5.66	0.3	3.29e-8	Eosinophil percentage of white cells;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16090273	chr5:149737303	TCOF1	-0.41	-6.01	-0.31	4.95e-9	Electrocardiographic conduction measures;
LUSC	cis	rs877282	0.583	rs10904564	chr10:819459	C/G	cg13775593	chr10:823151	NA	0.29	5.98	0.31	5.67e-9	Uric acid levels;
LUSC	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.84	-0.44	5.48e-17	Response to antipsychotic treatment;
LUSC	cis	rs7923609	0.811	rs4746204	chr10:65328518	C/T	cg01631684	chr10:65280961	REEP3	0.4	5.97	0.31	6.15e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4363385	0.693	rs6668311	chr1:152964586	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.59	-0.38	3.28e-13	Inflammatory skin disease;
LUSC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg00945038	chr17:61921165	SMARCD2	0.54	9.34	0.46	1.38e-18	Prudent dietary pattern;
LUSC	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.82	-14.55	-0.62	1.77e-37	Sudden cardiac arrest;
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24739457	chr1:205821442	NA	0.35	6.07	0.32	3.56e-9	Menarche (age at onset);
LUSC	cis	rs7215564	0.818	rs1032130	chr17:78610636	A/G	cg23238734	chr17:78661607	RPTOR	-0.46	-6.13	-0.32	2.47e-9	Myopia (pathological);
LUSC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-17.48	-0.69	4.68e-49	Height;
LUSC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00339695	chr16:24857497	SLC5A11	-0.39	-6.84	-0.35	3.82e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg01620082	chr3:125678407	NA	-0.69	-6.54	-0.34	2.33e-10	Depression;
LUSC	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg15534755	chr11:117069859	TAGLN	0.36	5.85	0.3	1.17e-8	Blood protein levels;
LUSC	cis	rs4474465	1.000	rs11237508	chr11:78173297	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.71	-0.3	2.51e-8	Alzheimer's disease (survival time);
LUSC	cis	rs2235649	0.746	rs113666107	chr16:1848642	C/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.46	-6.12	-0.32	2.65e-9	Blood metabolite levels;
LUSC	cis	rs6599192	1	rs6599192	chr3:41992408	G/A	cg03022575	chr3:42003672	ULK4	-0.51	-5.79	-0.3	1.64e-8	Multiple myeloma;
LUSC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	9.14	0.45	6.03e-18	Motion sickness;
LUSC	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.44	-9.43	-0.46	7.18e-19	Urate levels in overweight individuals;
LUSC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	22.14	0.77	1.81e-67	Height;
LUSC	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00132208	chr4:10120780	NA	0.36	5.69	0.3	2.82e-8	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.99	-0.36	1.46e-11	Coronary artery disease;
LUSC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg25258033	chr6:167368657	RNASET2	0.47	7.84	0.39	6.02e-14	Crohn's disease;
LUSC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg24060327	chr5:131705240	SLC22A5	-0.51	-8.49	-0.42	6.9e-16	Breast cancer;
LUSC	cis	rs68170813	0.617	rs10464499	chr7:107137571	C/T	cg02696742	chr7:106810147	HBP1	-0.64	-8.62	-0.43	2.66e-16	Coronary artery disease;
LUSC	cis	rs2970818	0.831	rs11063191	chr12:4588579	C/T	cg11146114	chr12:4671731	NA	-0.6	-5.69	-0.3	2.83e-8	Phosphorus levels;
LUSC	cis	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg26958806	chr6:27640298	NA	0.73	6.17	0.32	2.01e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg08680598	chr22:49984980	NA	-0.34	-6.29	-0.33	1e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	7.07	0.36	9.05e-12	Height;
LUSC	cis	rs738321	0.694	rs4821749	chr22:38542074	A/G	cg25457927	chr22:38595422	NA	-0.42	-8.01	-0.4	1.93e-14	Breast cancer;
LUSC	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.03	14.55	0.62	1.74e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg22508957	chr16:3507546	NAT15	0.84	10.69	0.5	3.89e-23	Tuberculosis;
LUSC	cis	rs7674212	0.541	rs17217473	chr4:104114742	A/C	cg16532752	chr4:104119610	CENPE	-0.48	-6.82	-0.35	4.31e-11	Type 2 diabetes;
LUSC	cis	rs4919687	0.550	rs4264100	chr10:104454113	C/G	cg04362960	chr10:104952993	NT5C2	0.47	6.93	0.35	2.15e-11	Colorectal cancer;
LUSC	trans	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg24643429	chr1:3562429	WDR8	0.33	6.05	0.31	3.88e-9	Monocyte count;
LUSC	cis	rs77741769	0.571	rs11065292	chr12:121289155	T/C	cg02419362	chr12:121203948	SPPL3	0.46	8.51	0.42	5.9e-16	Mean corpuscular volume;
LUSC	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg17173187	chr15:85201210	NMB	0.46	8.73	0.43	1.26e-16	Schizophrenia;
LUSC	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg13256891	chr4:100009986	ADH5	0.48	7.11	0.36	7.05e-12	Alcohol dependence;
LUSC	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg17376030	chr22:41985996	PMM1	0.42	5.71	0.3	2.53e-8	Vitiligo;
LUSC	cis	rs714027	0.566	rs1548389	chr22:30573552	T/C	cg11564601	chr22:30592435	NA	0.32	5.67	0.3	3.03e-8	Lymphocyte counts;
LUSC	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg17366294	chr4:99064904	C4orf37	-0.47	-7.64	-0.39	2.33e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7577851	0.716	rs72833929	chr2:69678853	T/C	cg10773587	chr2:69614142	GFPT1	0.55	6.23	0.32	1.44e-9	Parkinson's disease (age of onset);
LUSC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-9.45	-0.46	6.1e-19	Gut microbiome composition (summer);
LUSC	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg06917634	chr15:78832804	PSMA4	-0.48	-6.49	-0.33	3.02e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6690583	0.623	rs11588160	chr1:85444226	T/G	cg11262906	chr1:85462892	MCOLN2	0.69	6.56	0.34	2.1e-10	Serum sulfate level;
LUSC	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.33	-0.56	4.74e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg24558204	chr6:135376177	HBS1L	0.57	8.58	0.43	3.55e-16	Red blood cell count;
LUSC	cis	rs78545713	0.649	rs11753717	chr6:26220202	G/C	cg23601095	chr6:26197514	HIST1H3D	0.66	5.79	0.3	1.64e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg17757837	chr7:157058334	UBE3C	0.83	13.33	0.59	8.46e-33	Body mass index;
LUSC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.98	0.36	1.57e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg08270630	chr22:50330655	NA	0.4	5.93	0.31	7.52e-9	Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25377475	chr1:236030556	LYST	-0.57	-6.73	-0.35	7.29e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg22189786	chr22:42395067	WBP2NL	0.43	5.76	0.3	1.91e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11357813	chr19:52693064	PPP2R1A	-0.43	-6.44	-0.33	4.22e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17227506	0.704	rs66965169	chr8:13454056	C/T	cg03566418	chr8:13424080	C8orf48	0.4	5.98	0.31	5.6e-9	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs427941	0.655	rs2529095	chr7:101749663	C/T	cg06246474	chr7:101738831	CUX1	0.39	6.33	0.33	8.12e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg17127132	chr2:85788382	GGCX	-0.43	-6.73	-0.35	7.59e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg17712092	chr4:129076599	LARP1B	-0.69	-9.72	-0.47	7.89e-20	Breast cancer;
LUSC	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	9.47	0.46	5.4e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs3824867	0.920	rs9734013	chr11:47451517	G/T	cg20307385	chr11:47447363	PSMC3	-0.64	-9.52	-0.46	3.67e-19	Mean corpuscular hemoglobin;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg02037503	chr14:23540729	ACIN1	0.53	6.44	0.33	4.24e-10	Cognitive function;Information processing speed;
LUSC	cis	rs7789940	0.951	rs7787526	chr7:75947553	C/T	cg10167463	chr7:75959203	YWHAG	-0.63	-9.35	-0.46	1.26e-18	Multiple sclerosis;
LUSC	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg12002119	chr2:101014098	CHST10	-0.37	-6.31	-0.33	8.67e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs34638657	0.732	rs62045963	chr16:82200661	A/G	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.31	-0.33	8.83e-10	Lung adenocarcinoma;
LUSC	trans	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.6	8.16	0.41	6.69e-15	Ulcerative colitis;
LUSC	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg01884057	chr2:25150051	NA	0.5	11.78	0.54	4.96e-27	Body mass index in non-asthmatics;
LUSC	trans	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg25214090	chr10:38739885	LOC399744	0.45	6.42	0.33	4.79e-10	Corneal astigmatism;
LUSC	trans	rs702885	0.655	rs702911	chr2:65767902	T/C	cg06379192	chr1:3157287	PRDM16	-0.73	-6.18	-0.32	1.92e-9	Electroencephalogram traits;
LUSC	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.94	0.51	4.97e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg11845111	chr2:191398756	TMEM194B	0.55	9.43	0.46	6.96e-19	Pulse pressure;
LUSC	cis	rs6599077	1.000	rs9832726	chr3:40097576	C/G	cg13683864	chr3:40499215	RPL14	-0.62	-7.54	-0.38	4.57e-13	Sleep-related phenotypes;
LUSC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-0.83	-14.22	-0.61	3.2e-36	Tonsillectomy;
LUSC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg17366294	chr4:99064904	C4orf37	0.55	9.77	0.47	5.18e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9658691	0.607	rs9658766	chr10:90771612	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-6.17	-0.32	1.95e-9	Mosquito bite size;
LUSC	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.94e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg02581963	chr10:102133317	C10orf75	0.38	6.32	0.33	8.54e-10	Calcium levels;
LUSC	cis	rs977987	0.806	rs2285225	chr16:75429252	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.22	0.45	3.5e-18	Dupuytren's disease;
LUSC	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg08000102	chr2:233561755	GIGYF2	-0.69	-11.63	-0.54	1.75e-26	Coronary artery disease;
LUSC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg16405210	chr4:1374714	KIAA1530	-0.53	-8.02	-0.4	1.84e-14	Obesity-related traits;
LUSC	cis	rs7851660	0.967	rs7043885	chr9:100596439	C/T	cg13688889	chr9:100608707	NA	-0.6	-10.04	-0.48	6.78e-21	Strep throat;
LUSC	cis	rs10740039	1.000	rs6479723	chr10:62417885	T/C	cg18175470	chr10:62150864	ANK3	-0.43	-6.79	-0.35	5.23e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg04553112	chr3:125709451	NA	-0.5	-5.68	-0.3	2.9e-8	Blood pressure (smoking interaction);
LUSC	trans	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.71	10.66	0.5	5.06e-23	Aortic root size;
LUSC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg19678392	chr7:94953810	PON1	-0.36	-5.65	-0.3	3.47e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg03585969	chr10:35415529	CREM	0.59	8.58	0.42	3.65e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg05585544	chr11:47624801	NA	0.41	7.12	0.36	6.53e-12	Subjective well-being;
LUSC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.75	-13.33	-0.59	8.42e-33	Dental caries;
LUSC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg08270630	chr22:50330655	NA	0.4	5.93	0.31	7.52e-9	Schizophrenia;
LUSC	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg20307385	chr11:47447363	PSMC3	0.45	6.52	0.34	2.68e-10	Subjective well-being;
LUSC	trans	rs1459104	0.925	rs34666788	chr11:55138501	T/A	cg15704280	chr7:45808275	SEPT13	0.74	6.06	0.31	3.78e-9	Body mass index;
LUSC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25072359	chr17:41440525	NA	0.66	9.54	0.46	3.2e-19	Menopause (age at onset);
LUSC	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg13042288	chr15:90349979	ANPEP	-0.49	-6.92	-0.35	2.31e-11	Uric acid levels;
LUSC	cis	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.79	-0.39	8.8e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg03060546	chr3:49711283	APEH	0.56	8.06	0.4	1.36e-14	Resting heart rate;
LUSC	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg05855489	chr10:104503620	C10orf26	-0.49	-7.47	-0.38	7.25e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg14458575	chr2:238380390	NA	0.68	11.77	0.54	5.35e-27	Prostate cancer;
LUSC	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg22482690	chr17:47019901	SNF8	-0.37	-6.98	-0.36	1.63e-11	Type 2 diabetes;
LUSC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.63	9.72	0.47	7.61e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg20129853	chr10:51489980	NA	-0.33	-6.63	-0.34	1.36e-10	Prostate-specific antigen levels;
LUSC	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg10426581	chr7:100472382	SRRT	0.8	11.26	0.52	3.73e-25	Resting heart rate;
LUSC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.85	0.3	1.2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg22437258	chr11:111473054	SIK2	0.53	7.53	0.38	4.93e-13	Primary sclerosing cholangitis;
LUSC	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg24375607	chr4:120327624	NA	0.49	7.56	0.38	3.9e-13	Diastolic blood pressure;
LUSC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg04317338	chr11:64019027	PLCB3	0.68	7.65	0.39	2.23e-13	Mean platelet volume;
LUSC	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg00750074	chr16:89608354	SPG7	-0.44	-7.46	-0.38	7.64e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs9400467	0.528	rs11153290	chr6:111718132	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.98	-0.36	1.57e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.88	-0.31	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07677032	chr17:61819896	STRADA	0.55	8.97	0.44	2.1e-17	Prudent dietary pattern;
LUSC	cis	rs2046867	0.862	rs6778168	chr3:72840206	T/A	cg25664220	chr3:72788482	NA	-0.67	-11.67	-0.54	1.29e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7043114	0.525	rs4744136	chr9:95275024	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.4	7.09	0.36	8.02e-12	Height;
LUSC	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.67	8.69	0.43	1.71e-16	Schizophrenia;
LUSC	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg11693508	chr17:37793320	STARD3	0.5	6.29	0.33	1e-9	Bipolar disorder;
LUSC	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg11843238	chr5:131593191	PDLIM4	0.37	6.33	0.33	7.93e-10	Breast cancer;
LUSC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg11218175	chr11:495084	RNH1	0.53	5.69	0.3	2.84e-8	Body mass index;
LUSC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.87	0.4	5.04e-14	Prudent dietary pattern;
LUSC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg18538332	chr22:24372958	LOC391322	-0.37	-6.71	-0.34	8.28e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-7.66	-0.39	2.06e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg15704280	chr7:45808275	SEPT13	-0.45	-6.22	-0.32	1.49e-9	HDL cholesterol;
LUSC	cis	rs1595825	0.891	rs2045244	chr2:198506466	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.61	-0.34	1.52e-10	Ulcerative colitis;
LUSC	trans	rs12902680	0.618	rs12439798	chr15:46584787	G/T	cg04321580	chr8:143696133	ARC	-0.41	-6.13	-0.32	2.49e-9	Neuroticism;
LUSC	cis	rs7616215	0.519	rs2133664	chr3:46101774	T/A	cg08033130	chr3:45983597	CXCR6;FYCO1	0.37	6.3	0.33	9.44e-10	Behcet's disease;
LUSC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg01879757	chr17:41196368	BRCA1	-0.46	-6.92	-0.35	2.26e-11	Menopause (age at onset);
LUSC	cis	rs4409675	0.576	rs6700473	chr1:28236682	C/T	cg23691781	chr1:28212827	C1orf38	0.29	6.6	0.34	1.62e-10	Corneal astigmatism;
LUSC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg00149659	chr3:10157352	C3orf10	-0.61	-7.85	-0.39	5.87e-14	Alzheimer's disease;
LUSC	cis	rs6076065	0.748	rs4815198	chr20:23343491	T/C	cg11657817	chr20:23433608	CST11	0.56	11.41	0.53	1.06e-25	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.94	0.48	1.4e-20	Bipolar disorder;
LUSC	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg06627628	chr2:24431161	ITSN2	0.54	7.47	0.38	7.13e-13	Asthma;
LUSC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.46	-6.51	-0.34	2.79e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	trans	rs1325195	0.920	rs9727252	chr1:179089518	C/G	cg11624085	chr17:8464688	MYH10	-0.45	-7.39	-0.37	1.16e-12	IgE grass sensitization;
LUSC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg06808227	chr14:105710500	BRF1	-0.63	-9.63	-0.47	1.54e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10761482	0.500	rs2153525	chr10:62269574	G/T	cg18175470	chr10:62150864	ANK3	0.47	6.66	0.34	1.11e-10	Schizophrenia;
LUSC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.56	-10.56	-0.5	1.07e-22	Multiple system atrophy;
LUSC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg07424592	chr7:64974309	NA	0.7	6.05	0.31	3.99e-9	Diabetic kidney disease;
LUSC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.76	-0.43	9.98e-17	Response to antipsychotic treatment;
LUSC	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.52	-0.46	3.61e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg05890377	chr2:74357713	NA	0.73	13.5	0.59	1.99e-33	Gestational age at birth (maternal effect);
LUSC	cis	rs886126	1.000	rs7973104	chr12:111670774	C/G	cg10833066	chr12:111807467	FAM109A	0.38	6.16	0.32	2.14e-9	Coronary heart disease;
LUSC	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg02655711	chr22:19163373	SLC25A1	0.9	17.05	0.68	2.45e-47	Metabolite levels;
LUSC	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg23625390	chr15:77176239	SCAPER	-0.54	-8.26	-0.41	3.44e-15	Blood metabolite levels;
LUSC	cis	rs4561483	0.801	rs33631	chr16:11995387	G/C	cg08843971	chr16:11963173	GSPT1	-0.45	-6.6	-0.34	1.61e-10	Testicular germ cell tumor;
LUSC	cis	rs2637266	1.000	rs2637268	chr10:78332213	G/T	cg18941641	chr10:78392320	NA	0.37	6.58	0.34	1.84e-10	Pulmonary function;
LUSC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg08859206	chr1:53392774	SCP2	-0.43	-7.04	-0.36	1.09e-11	Monocyte count;
LUSC	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg09033563	chr22:24373618	LOC391322	-0.53	-7.99	-0.4	2.27e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs714027	1.000	rs4823075	chr22:30519152	T/C	cg11564601	chr22:30592435	NA	-0.37	-6.78	-0.35	5.4e-11	Lymphocyte counts;
LUSC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-11.83	-0.54	3.43e-27	Schizophrenia;
LUSC	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	6.2	0.32	1.71e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs12701220	0.596	rs10274383	chr7:1002013	T/C	cg26769984	chr7:1090371	C7orf50	0.44	6.27	0.32	1.13e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.88	-0.31	9.94e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs354225	0.544	rs7599241	chr2:54801856	G/A	cg26097391	chr2:54893211	SPTBN1	0.46	6.92	0.35	2.38e-11	Schizophrenia;
LUSC	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg05294307	chr14:35346193	BAZ1A	-0.6	-7.05	-0.36	1.06e-11	Psoriasis;
LUSC	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg08000102	chr2:233561755	GIGYF2	-0.5	-7.72	-0.39	1.35e-13	Coronary artery disease;
LUSC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg13175981	chr1:150552382	MCL1	0.43	6.06	0.31	3.71e-9	Tonsillectomy;
LUSC	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg09904177	chr6:26538194	HMGN4	-0.7	-6.65	-0.34	1.17e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7937890	0.681	rs4756784	chr11:14270904	G/A	cg05501817	chr11:14380813	RRAS2	0.44	6.21	0.32	1.56e-9	Mitochondrial DNA levels;
LUSC	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg27432699	chr2:27873401	GPN1	-0.57	-8.53	-0.42	5.15e-16	Total body bone mineral density;
LUSC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.83	10.7	0.51	3.71e-23	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14240646	chr10:27532245	ACBD5	0.73	8.72	0.43	1.3e-16	Breast cancer;
LUSC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.98	16.68	0.67	7.26e-46	Systemic lupus erythematosus;
LUSC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg24250549	chr1:154909240	PMVK	0.63	10.2	0.49	1.98e-21	Prostate cancer;
LUSC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg00310523	chr12:86230176	RASSF9	0.49	9.26	0.45	2.64e-18	Major depressive disorder;
LUSC	cis	rs8032315	1.000	rs6227	chr15:91425232	C/T	cg04510874	chr15:91427884	FES	0.3	5.89	0.31	9.17e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9650315	0.789	rs13269647	chr8:57203809	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.33	0.37	1.73e-12	Height;
LUSC	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg03585969	chr10:35415529	CREM	0.64	9.13	0.45	6.65e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg08601574	chr20:25228251	PYGB	0.42	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg09796270	chr17:17721594	SREBF1	0.43	7.63	0.39	2.41e-13	Total body bone mineral density;
LUSC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg06742321	chr12:123595122	PITPNM2	-0.39	-5.72	-0.3	2.36e-8	Neutrophil percentage of white cells;
LUSC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.35	0.56	3.93e-29	Prudent dietary pattern;
LUSC	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg03585969	chr10:35415529	CREM	0.61	8.97	0.44	2.24e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs71636778	0.596	rs2095637	chr1:27232845	A/G	cg12203394	chr1:27248618	NUDC	0.54	5.71	0.3	2.52e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs870825	0.550	rs10000507	chr4:185619281	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	13.39	0.59	5.13e-33	Blood protein levels;
LUSC	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.17	-0.41	6.53e-15	Axial length;
LUSC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg11247378	chr22:39784982	NA	-0.65	-13.31	-0.59	9.7e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg16576597	chr16:28551801	NUPR1	0.34	6.91	0.35	2.5e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg05714579	chr10:131428358	MGMT	0.51	7.68	0.39	1.78e-13	Response to temozolomide;
LUSC	cis	rs3849570	0.615	rs6778265	chr3:81985745	C/T	cg07356753	chr3:81810745	GBE1	0.42	6.15	0.32	2.23e-9	Waist circumference;Body mass index;
LUSC	cis	rs6546550	0.901	rs6736408	chr2:70137774	C/T	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg12962167	chr3:53033115	SFMBT1	-0.58	-5.69	-0.3	2.81e-8	Immune reponse to smallpox (secreted IL-2);
LUSC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-8.04	-0.4	1.6e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03445127	chr3:101232168	SENP7	-0.45	-6.08	-0.32	3.32e-9	Hepatitis;
LUSC	cis	rs977987	0.835	rs4888380	chr16:75347690	T/C	cg04384234	chr16:75411784	CFDP1	-0.41	-6.71	-0.34	8.56e-11	Dupuytren's disease;
LUSC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg23262073	chr20:60523788	NA	-0.42	-6.11	-0.32	2.7e-9	Body mass index;
LUSC	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	1.03	14.32	0.62	1.35e-36	Exhaled nitric oxide levels;
LUSC	cis	rs1044826	0.642	rs295478	chr3:139223135	G/A	cg15131784	chr3:139108705	COPB2	0.39	6.34	0.33	7.33e-10	Obesity-related traits;
LUSC	cis	rs2348418	0.864	rs6487687	chr12:28711163	A/C	cg13890972	chr12:28721907	NA	-0.36	-6.27	-0.32	1.14e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg14584255	chr6:163149320	PACRG;PARK2	-0.38	-7.48	-0.38	6.75e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06505273	chr16:24850292	NA	-0.41	-5.89	-0.31	9.18e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4629180	0.675	rs10183203	chr2:102095080	C/T	cg04415270	chr2:102091202	RFX8	0.45	7.78	0.39	9.3e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg16342193	chr10:102329863	NA	-0.34	-6.29	-0.33	9.9e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs354225	0.544	rs12713269	chr2:54809154	C/G	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs16976116	0.901	rs62020114	chr15:55501116	T/C	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6840360	1.000	rs6823194	chr4:152604543	T/C	cg22705602	chr4:152727874	NA	-0.28	-5.84	-0.3	1.22e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs3942852	0.869	rs4752806	chr11:48118199	G/C	cg03929089	chr4:120376271	NA	-0.54	-6.21	-0.32	1.56e-9	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-0.99	-17.46	-0.69	5.58e-49	Height;
LUSC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg02807482	chr3:125708958	NA	-0.52	-6.49	-0.33	3.08e-10	Blood pressure (smoking interaction);
LUSC	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg12084011	chr7:107220368	BCAP29	0.42	6.7	0.34	9e-11	Bladder cancer;
LUSC	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.72	11.96	0.55	1.11e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.99	-0.36	1.5e-11	Monocyte percentage of white cells;
LUSC	cis	rs28655083	1.000	rs7198870	chr16:77072963	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.38	-5.77	-0.3	1.83e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg10169327	chr19:45448959	APOC2	0.3	6.38	0.33	5.74e-10	Blood protein levels;
LUSC	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.81	-12.04	-0.55	5.6e-28	Cognitive ability;
LUSC	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg03806693	chr22:41940476	POLR3H	0.52	7.27	0.37	2.62e-12	Neuroticism;
LUSC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.45	0.33	3.89e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7804356	1.000	rs17376018	chr7:26889862	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg01028140	chr2:1542097	TPO	-0.6	-7.99	-0.4	2.16e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg10909506	chr17:38081995	ORMDL3	0.32	5.75	0.3	2.06e-8	Self-reported allergy;
LUSC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg23625390	chr15:77176239	SCAPER	0.45	6.87	0.35	3.13e-11	Blood metabolite levels;
LUSC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg07212818	chr11:638076	DRD4	-0.44	-7.5	-0.38	5.65e-13	Systemic lupus erythematosus;
LUSC	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg07701084	chr6:150067640	NUP43	0.53	7.97	0.4	2.51e-14	Lung cancer;
LUSC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg27535305	chr1:53392650	SCP2	0.38	7.08	0.36	8.63e-12	Monocyte count;
LUSC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg04414720	chr1:150670196	GOLPH3L	0.54	8.46	0.42	8.59e-16	Melanoma;
LUSC	trans	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	7.93	0.4	3.24e-14	Retinal vascular caliber;
LUSC	cis	rs9818941	1.000	rs7429574	chr3:157703589	G/A	cg08654915	chr3:157813417	NA	-0.24	-5.79	-0.3	1.59e-8	Height;
LUSC	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg18755752	chr8:142205143	DENND3	-0.51	-6.68	-0.34	1e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs4851254	0.618	rs7596359	chr2:100665274	T/G	cg22139774	chr2:100720529	AFF3	-0.44	-5.81	-0.3	1.43e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg16006841	chr5:176797999	RGS14	0.63	10.03	0.48	6.99e-21	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.87	14.76	0.63	2.57e-38	Bladder cancer;
LUSC	trans	rs62458065	0.640	rs4141788	chr7:32519264	T/C	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.29	-0.33	1.01e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.16	-0.32	2.1e-9	Bipolar disorder;
LUSC	cis	rs62400317	0.859	rs62400293	chr6:45233580	A/T	cg20913747	chr6:44695427	NA	-0.47	-7.65	-0.39	2.2e-13	Total body bone mineral density;
LUSC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg00074818	chr8:8560427	CLDN23	0.6	9.86	0.47	2.72e-20	Obesity-related traits;
LUSC	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.85	0.51	1.05e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg18681998	chr4:17616180	MED28	0.92	18.35	0.71	1.66e-52	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg14440974	chr22:39074834	NA	-0.35	-5.84	-0.3	1.23e-8	Menopause (age at onset);
LUSC	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg23625390	chr15:77176239	SCAPER	0.54	8.48	0.42	7.12e-16	Blood metabolite levels;
LUSC	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg08975724	chr8:8085496	FLJ10661	0.5	7.16	0.36	5.12e-12	Myopia (pathological);
LUSC	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg16989719	chr2:238392110	NA	-0.41	-7.25	-0.37	3e-12	Prostate cancer;
LUSC	cis	rs12122100	0.696	rs12752148	chr1:146557073	T/C	cg03526459	chr1:146549940	NA	-0.41	-6.45	-0.33	3.86e-10	HIV-1 control;
LUSC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-0.89	-18.54	-0.71	2.95e-53	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-1.04	-13.87	-0.6	7.08e-35	Orofacial clefts;
LUSC	cis	rs2200578	0.841	rs116668293	chr2:99596991	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.63	7.53	0.38	4.78e-13	IgG glycosylation;
LUSC	cis	rs2219968	1.000	rs1121552	chr8:78958699	T/G	cg00738934	chr8:78996279	NA	0.34	6.19	0.32	1.81e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg14343924	chr8:8086146	FLJ10661	-0.45	-6.23	-0.32	1.43e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg06462663	chr19:18546047	ISYNA1	0.46	7.91	0.4	3.7e-14	Breast cancer;
LUSC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg03885332	chr11:832357	CD151	-0.35	-5.9	-0.31	8.82e-9	Mean platelet volume;
LUSC	cis	rs35094601	0.731	rs34305589	chr2:139217803	T/C	cg10095539	chr2:139258744	SPOPL	0.25	5.84	0.3	1.21e-8	Schizophrenia;
LUSC	cis	rs4363385	0.818	rs2651413	chr1:153012068	T/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg12615879	chr12:58013172	SLC26A10	-0.29	-6.12	-0.32	2.62e-9	Multiple sclerosis;
LUSC	cis	rs2970818	0.665	rs11063183	chr12:4583182	A/T	cg11146114	chr12:4671731	NA	-0.61	-5.77	-0.3	1.84e-8	Phosphorus levels;
LUSC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.78	0.77	4.41e-66	Prudent dietary pattern;
LUSC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg13628971	chr7:2884303	GNA12	0.39	5.79	0.3	1.64e-8	Height;
LUSC	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg08999081	chr20:33150536	PIGU	0.37	6.74	0.35	6.92e-11	Height;
LUSC	cis	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.79	-0.39	8.61e-14	Morning vs. evening chronotype;
LUSC	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.52	-7.64	-0.39	2.34e-13	Menarche (age at onset);
LUSC	cis	rs1018836	0.575	rs17635255	chr8:91518135	A/T	cg16814680	chr8:91681699	NA	-0.54	-7.1	-0.36	7.39e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-7.29	-0.37	2.2e-12	Neuroticism;
LUSC	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg11342453	chr6:26196699	NA	0.55	5.78	0.3	1.7e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg05425664	chr17:57184151	TRIM37	-0.52	-7.83	-0.39	6.51e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg24581572	chr1:205197876	TMCC2	0.44	6.17	0.32	2.02e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs738322	0.804	rs2076116	chr22:38517405	A/G	cg25457927	chr22:38595422	NA	-0.35	-6.82	-0.35	4.36e-11	Cutaneous nevi;
LUSC	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.77	7.13	0.36	6.43e-12	Yeast infection;
LUSC	cis	rs16854884	0.770	rs7621093	chr3:143814542	C/G	cg06585982	chr3:143692056	C3orf58	0.39	5.9	0.31	8.91e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs9650315	0.866	rs7838504	chr8:57187301	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.88	0.35	3.01e-11	Height;
LUSC	cis	rs9644630	0.841	rs4292704	chr8:19329303	G/C	cg01280390	chr8:19363452	CSGALNACT1	0.36	6.27	0.32	1.11e-9	Oropharynx cancer;
LUSC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg03474202	chr17:45855739	NA	-0.29	-6.7	-0.34	8.99e-11	IgG glycosylation;
LUSC	cis	rs354225	0.626	rs7591204	chr2:54829458	C/G	cg26097391	chr2:54893211	SPTBN1	-0.43	-6.24	-0.32	1.35e-9	Schizophrenia;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg04665974	chr16:30103391	TBX6	0.67	5.94	0.31	7.02e-9	Body mass index;
LUSC	cis	rs7246967	0.611	rs8104052	chr19:22857804	T/C	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg21141812	chr3:48556323	PFKFB4	0.33	5.7	0.3	2.64e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs7945718	0.934	rs4553350	chr11:12759834	A/G	cg25843174	chr11:12811716	TEAD1	-0.32	-7.14	-0.36	5.71e-12	Educational attainment (years of education);
LUSC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	7.82e-13	Motion sickness;
LUSC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	10.51	0.5	1.62e-22	Menarche (age at onset);
LUSC	cis	rs9612	0.948	rs12609056	chr19:44258702	G/T	cg08581076	chr19:44259116	C19orf61	0.53	6.67	0.34	1.05e-10	Exhaled nitric oxide output;
LUSC	cis	rs4499344	0.556	rs259230	chr19:33133865	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.94	13.79	0.6	1.51e-34	Mean platelet volume;
LUSC	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg03929089	chr4:120376271	NA	0.73	6.8	0.35	4.71e-11	Axial length;
LUSC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08859206	chr1:53392774	SCP2	0.56	9.9	0.48	2e-20	Monocyte count;
LUSC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg21171335	chr12:122356390	WDR66	0.62	9.02	0.44	1.51e-17	Mean corpuscular volume;
LUSC	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg20129853	chr10:51489980	NA	0.36	7.5	0.38	5.8e-13	Prostate-specific antigen levels;
LUSC	cis	rs9398803	0.865	rs1120786	chr6:126808637	T/G	cg19875578	chr6:126661172	C6orf173	0.42	6.18	0.32	1.88e-9	Male-pattern baldness;
LUSC	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.25	-0.45	2.82e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9815354	0.597	rs73073281	chr3:42026366	C/T	cg03022575	chr3:42003672	ULK4	0.78	7.76	0.39	1.05e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7246967	0.611	rs73030511	chr19:22826034	T/C	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg26395211	chr5:140044315	WDR55	0.46	7.09	0.36	8.28e-12	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg13010199	chr12:38710504	ALG10B	0.56	8.45	0.42	9.2e-16	Morning vs. evening chronotype;
LUSC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.49	-7.82	-0.39	7.05e-14	Melanoma;
LUSC	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg05347473	chr6:146136440	FBXO30	0.51	8.57	0.42	3.95e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6499755	0.965	rs9889178	chr16:55353110	G/T	cg02859129	chr16:55357253	IRX6	0.35	5.9	0.31	8.94e-9	Hypospadias;
LUSC	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg19678392	chr7:94953810	PON1	-0.35	-5.68	-0.3	2.9e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	7.04	0.36	1.13e-11	Renal cell carcinoma;
LUSC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11764359	chr7:65958608	NA	0.68	10.85	0.51	1.06e-23	Aortic root size;
LUSC	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg15704280	chr7:45808275	SEPT13	0.73	8.21	0.41	4.83e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg09904177	chr6:26538194	HMGN4	0.65	11.67	0.54	1.3e-26	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg13010199	chr12:38710504	ALG10B	0.51	7.65	0.39	2.24e-13	Morning vs. evening chronotype;
LUSC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00149659	chr3:10157352	C3orf10	0.98	14.09	0.61	1.08e-35	Alzheimer's disease;
LUSC	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg11502198	chr6:26597334	ABT1	0.71	12.06	0.55	4.63e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.33	-0.37	1.74e-12	Bipolar disorder and schizophrenia;
LUSC	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-1.13	-17.99	-0.7	4.71e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg21733973	chr7:65235735	NA	-0.45	-6.46	-0.33	3.73e-10	Calcium levels;
LUSC	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg07211511	chr3:129823064	LOC729375	-1.24	-20.32	-0.74	2.39e-60	Blood pressure (smoking interaction);
LUSC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.8	0.63	1.84e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg03806693	chr22:41940476	POLR3H	-1.03	-13.99	-0.61	2.43e-35	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs7178375	1.000	rs7176351	chr15:31208727	G/A	cg04373760	chr16:53404718	NA	0.63	8.53	0.42	5.13e-16	Hypertriglyceridemia;
LUSC	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg05347473	chr6:146136440	FBXO30	0.55	9.58	0.46	2.21e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg22903657	chr4:1355424	KIAA1530	-0.4	-6.85	-0.35	3.51e-11	Longevity;
LUSC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.91	-0.35	2.47e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg17173187	chr15:85201210	NMB	0.36	6.34	0.33	7.63e-10	Schizophrenia;
LUSC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.51	6.68	0.34	9.92e-11	Blood protein levels;
LUSC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	0.92	15.89	0.66	9.31e-43	Heart rate;
LUSC	cis	rs6546537	1.000	rs4852867	chr2:69831449	G/A	cg10773587	chr2:69614142	GFPT1	-0.47	-7.37	-0.37	1.33e-12	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs6977660	0.714	rs6959039	chr7:19818182	T/C	cg07541023	chr7:19748670	TWISTNB	0.6	6.51	0.34	2.7e-10	Thyroid stimulating hormone;
LUSC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.78	0.35	5.42e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg09307838	chr4:120376055	NA	0.64	9.64	0.47	1.4e-19	Corneal astigmatism;
LUSC	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg24631222	chr15:78858424	CHRNA5	-0.66	-8.64	-0.43	2.3e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10779751	0.734	rs12569242	chr1:11127511	A/C	cg08854313	chr1:11322531	MTOR	0.83	12.26	0.56	8.43e-29	Body mass index;
LUSC	cis	rs16976116	0.901	rs8027256	chr15:55492323	C/A	cg11288833	chr15:55489084	RSL24D1	0.5	5.88	0.31	1.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs151349	0.743	rs151353	chr20:57604343	A/C	cg23907860	chr20:57583709	CTSZ	-0.37	-6.04	-0.31	4.02e-9	Platelet distribution width;
LUSC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg14552801	chr7:65878734	NA	-0.45	-6.51	-0.34	2.84e-10	Aortic root size;
LUSC	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.17	-0.41	6.52e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg19302996	chr17:73780495	UNK	-0.5	-7.23	-0.37	3.42e-12	White matter hyperintensity burden;
LUSC	cis	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg06637938	chr14:75390232	RPS6KL1	0.42	6.12	0.32	2.64e-9	IgG glycosylation;
LUSC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.05	-0.36	1.02e-11	Bipolar disorder;
LUSC	cis	rs1832871	0.643	rs9456282	chr6:158724743	A/G	cg07165851	chr6:158734300	TULP4	0.51	7.22	0.37	3.43e-12	Height;
LUSC	cis	rs5758659	0.716	rs86669	chr22:42680800	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.31	-6.46	-0.33	3.77e-10	Cognitive function;
LUSC	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg11244672	chr19:19639970	YJEFN3	-0.56	-7.21	-0.37	3.76e-12	Bipolar disorder;
LUSC	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg12826209	chr6:26865740	GUSBL1	0.64	5.71	0.3	2.51e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs78579285	0.544	rs4782321	chr16:88780175	G/A	cg01900006	chr16:88814613	FAM38A	0.53	5.74	0.3	2.18e-8	Joint mobility (Beighton score);
LUSC	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg22676075	chr6:135203613	NA	0.59	9.41	0.46	8.54e-19	High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs7127129	0.503	rs7105001	chr11:70051949	T/C	cg14529173	chr6:28048874	ZNF165	-0.41	-6.01	-0.31	4.86e-9	Aortic root size;
LUSC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg21433313	chr16:3507492	NAT15	0.79	10.04	0.48	6.81e-21	Tuberculosis;
LUSC	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg17294928	chr15:75287854	SCAMP5	-0.71	-6.51	-0.34	2.68e-10	Lung cancer;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26272237	chr13:111358862	CARS2	-0.41	-6.01	-0.31	4.79e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.94	0.31	7.31e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg02931644	chr1:25747376	RHCE	-0.34	-6.3	-0.33	9.4e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.67	-8.82	-0.43	6.53e-17	Menarche (age at onset);
LUSC	cis	rs1570989	0.543	rs6458035	chr6:12015296	A/G	cg17804551	chr6:12015979	HIVEP1	0.39	6.9	0.35	2.55e-11	Alcohol and nicotine co-dependence;
LUSC	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg14993813	chr1:46806288	NSUN4	-0.5	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs9372498	0.505	rs62422248	chr6:118987610	T/C	cg18833306	chr6:118973337	C6orf204	-0.45	-5.76	-0.3	1.93e-8	Diastolic blood pressure;
LUSC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.85	-0.35	3.62e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg16473166	chr22:50639996	SELO	0.66	9.25	0.45	2.83e-18	Obesity-related traits;
LUSC	cis	rs72634258	0.891	rs404381	chr1:8080745	C/T	cg00042356	chr1:8021962	PARK7	0.65	8.48	0.42	7.38e-16	Inflammatory bowel disease;
LUSC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg06618935	chr21:46677482	NA	-0.39	-7.86	-0.39	5.51e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg05707623	chr12:122985044	ZCCHC8	0.66	8.18	0.41	5.92e-15	Body mass index;
LUSC	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg20848291	chr7:100343083	ZAN	-0.57	-6.93	-0.35	2.14e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg13047869	chr3:10149882	C3orf24	0.59	7.75	0.39	1.13e-13	Alzheimer's disease;
LUSC	trans	rs7726558	0.731	rs80248925	chr5:118865325	C/T	cg14402224	chr7:50570049	DDC	-0.51	-6.52	-0.34	2.6e-10	QT interval (sulfonylurea treatment interaction);
LUSC	cis	rs7432375	0.610	rs28458819	chr3:136522314	A/G	cg12473912	chr3:136751656	NA	0.33	5.83	0.3	1.31e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg23933602	chr10:16859644	RSU1	0.53	6.44	0.33	4.16e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	ch.11.42038R	chr11:967971	AP2A2	-0.43	-6.48	-0.33	3.28e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7605827	0.930	rs4668445	chr2:15515838	C/T	cg19274914	chr2:15703543	NA	0.46	8.8	0.43	7.49e-17	Educational attainment (years of education);
LUSC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg12310025	chr6:25882481	NA	-0.45	-7.82	-0.39	7.19e-14	Blood metabolite levels;
LUSC	trans	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg14791747	chr16:20752902	THUMPD1	0.73	9.55	0.46	2.84e-19	Cognitive test performance;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04350358	chr6:117996341	NUS1	0.44	6.61	0.34	1.52e-10	Triglycerides;
LUSC	cis	rs954108	0.966	rs9508155	chr13:29372016	C/T	cg11788234	chr13:29393811	NA	0.39	6.89	0.35	2.74e-11	Obesity-related traits;
LUSC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg11752832	chr7:134001865	SLC35B4	0.55	8.61	0.43	2.94e-16	Mean platelet volume;
LUSC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg19592336	chr6:28129416	ZNF389	0.53	7.05	0.36	1.02e-11	Parkinson's disease;
LUSC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.63	0.5	6.32e-23	Schizophrenia;
LUSC	cis	rs6496044	0.568	rs12899946	chr15:86066082	C/T	cg13263323	chr15:86062960	AKAP13	-0.38	-6.27	-0.32	1.12e-9	Interstitial lung disease;
LUSC	cis	rs909341	0.678	rs2738778	chr20:62291830	C/T	cg16989086	chr20:62203971	PRIC285	0.5	6.58	0.34	1.77e-10	Atopic dermatitis;
LUSC	cis	rs4776059	0.798	rs2414167	chr15:52907428	A/G	cg22715398	chr15:52968154	KIAA1370	0.59	7.6	0.38	3.07e-13	Schizophrenia;
LUSC	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg03684893	chr10:554711	DIP2C	0.38	6.65	0.34	1.18e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg04733989	chr22:42467013	NAGA	0.39	6.51	0.34	2.77e-10	Cognitive function;
LUSC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-8.22	-0.41	4.49e-15	Blood metabolite levels;
LUSC	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg24375607	chr4:120327624	NA	0.7	10.11	0.48	3.82e-21	Corneal astigmatism;
LUSC	cis	rs12286929	0.609	rs11601751	chr11:115094117	C/T	cg04055981	chr11:115044050	NA	0.37	6.65	0.34	1.19e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg16386425	chr10:429943	DIP2C	-0.44	-7.06	-0.36	9.96e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg04727924	chr7:799746	HEATR2	-0.54	-6.49	-0.33	3.05e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7131987	0.903	rs11050153	chr12:29405148	T/C	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.23	-0.32	1.38e-9	QT interval;
LUSC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-17.0	-0.68	3.84e-47	Gut microbiome composition (summer);
LUSC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23158103	chr7:148848205	ZNF398	-0.45	-7.06	-0.36	9.42e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg22705602	chr4:152727874	NA	-0.39	-8.26	-0.41	3.38e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg03676636	chr4:99064102	C4orf37	0.36	7.72	0.39	1.36e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs460214	0.539	rs55819392	chr21:40038207	G/A	cg21578987	chr21:40029669	ERG	0.42	6.26	0.32	1.16e-9	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.07	15.67	0.65	7.17e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg23649088	chr2:200775458	C2orf69	0.5	6.88	0.35	2.97e-11	Schizophrenia;
LUSC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.27	-0.45	2.32e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg27494647	chr7:150038898	RARRES2	0.48	7.34	0.37	1.64e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12220238	1.000	rs3812638	chr10:75896072	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	6.91	0.35	2.46e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg16576597	chr16:28551801	NUPR1	0.31	6.31	0.33	8.81e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.52	0.5	1.49e-22	Colorectal cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07661818	chr3:190040250	CLDN1	-0.4	-6.6	-0.34	1.61e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00576259	chr1:78225345	USP33	0.47	6.66	0.34	1.11e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg19812747	chr11:111475976	SIK2	0.55	7.77	0.39	1.01e-13	Primary sclerosing cholangitis;
LUSC	cis	rs7833986	0.501	rs2667978	chr8:56897951	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	11.17	0.52	8.23e-25	Height;
LUSC	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg25512537	chr17:76250053	NA	0.48	8.62	0.43	2.76e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.43	6.35	0.33	6.96e-10	Longevity;Endometriosis;
LUSC	cis	rs1506636	1.000	rs676755	chr7:123439082	A/G	cg03229431	chr7:123269106	ASB15	-0.63	-10.24	-0.49	1.43e-21	Plateletcrit;Platelet count;
LUSC	cis	rs3812111	0.510	rs1569825	chr6:116590807	T/G	cg18828861	chr6:116576566	TSPYL4	0.38	6.73	0.35	7.41e-11	Age-related macular degeneration;
LUSC	trans	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.09	-0.36	8.24e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg19592336	chr6:28129416	ZNF389	0.47	6.04	0.31	4.21e-9	Depression;
LUSC	cis	rs2073300	0.826	rs6137968	chr20:23449550	G/A	cg09953122	chr20:23471693	CST8	-0.68	-6.16	-0.32	2.05e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg15790184	chr11:494944	RNH1	-0.51	-5.81	-0.3	1.45e-8	Body mass index;
LUSC	cis	rs1028488	0.511	rs7738104	chr6:170704196	C/G	cg20370364	chr6:170703943	FAM120B	-0.51	-7.69	-0.39	1.66e-13	Interferon alpha levels in systemic lupus erythematosus;
LUSC	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg20703242	chr1:230279135	GALNT2	0.59	8.84	0.44	5.49e-17	Coronary artery disease;
LUSC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	6.88	0.35	2.89e-11	Menarche (age at onset);
LUSC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg21724239	chr8:58056113	NA	0.59	6.75	0.35	6.42e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.72e-10	Bipolar disorder;
LUSC	cis	rs11051970	0.918	rs7309706	chr12:32538208	A/T	cg24626660	chr12:32551988	NA	0.38	6.08	0.32	3.36e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg25817165	chr18:72167213	CNDP2	-0.75	-9.1	-0.45	8.37e-18	Refractive error;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg11235426	chr6:292522	DUSP22	-0.66	-10.76	-0.51	2.13e-23	Menopause (age at onset);
LUSC	cis	rs5753618	0.583	rs738657	chr22:31841749	T/A	cg02404636	chr22:31891804	SFI1	0.38	5.69	0.3	2.77e-8	Colorectal cancer;
LUSC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.66	-0.39	2.04e-13	Lymphocyte counts;
LUSC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg21724239	chr8:58056113	NA	0.78	8.01	0.4	1.92e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg02891314	chr5:179741120	GFPT2	-0.65	-10.62	-0.5	7.07e-23	Height;
LUSC	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2346177	0.844	rs4953371	chr2:46651143	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.72	-0.39	1.4e-13	HDL cholesterol;
LUSC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	0.98	13.92	0.61	4.77e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs8027181	0.797	rs8033580	chr15:72994968	C/A	cg25632853	chr15:73088954	NA	0.32	6.62	0.34	1.47e-10	Triglyceride levels;
LUSC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg16928487	chr17:17741425	SREBF1	-0.43	-8.43	-0.42	1.03e-15	Total body bone mineral density;
LUSC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg13256891	chr4:100009986	ADH5	0.4	5.87	0.31	1.07e-8	Alcohol dependence;
LUSC	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg27129171	chr3:47204927	SETD2	0.55	6.82	0.35	4.28e-11	Birth weight;
LUSC	cis	rs11997175	0.603	rs7001603	chr8:33680978	T/G	ch.8.33884649F	chr8:33765107	NA	0.48	7.11	0.36	6.95e-12	Body mass index;
LUSC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.88e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs936229	0.768	rs12442901	chr15:75083912	A/G	cg14664628	chr15:75095509	CSK	-1.01	-17.21	-0.69	5.52e-48	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.19	-0.32	1.76e-9	Ulcerative colitis;
LUSC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.48	0.53	6.04e-26	Prudent dietary pattern;
LUSC	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.29	-0.33	1.02e-9	Bipolar disorder;
LUSC	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg08017756	chr2:100939284	LONRF2	-0.45	-8.56	-0.42	4.15e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg05861140	chr6:150128134	PCMT1	-0.41	-6.45	-0.33	3.88e-10	Lung cancer;
LUSC	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-36.86	-0.9	9.46e-120	Myeloid white cell count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07344583	chr15:89456631	MFGE8	-0.52	-6.18	-0.32	1.9e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7523273	0.606	rs2488255	chr1:207941741	C/T	cg22525895	chr1:207977042	MIR29B2	0.42	6.77	0.35	5.95e-11	Schizophrenia;
LUSC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19052272	chr2:3704530	ALLC	-0.65	-11.19	-0.52	6.48e-25	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2067615	0.524	rs10861645	chr12:107071130	C/T	cg15890332	chr12:107067104	RFX4	0.36	6.33	0.33	7.72e-10	Heart rate;
LUSC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	0.8	14.01	0.61	2.13e-35	Cognitive function;
LUSC	cis	rs10484885	0.775	rs17584945	chr6:90512776	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.06	-0.4	1.4e-14	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg02023728	chr11:77925099	USP35	0.43	6.53	0.34	2.41e-10	Testicular germ cell tumor;
LUSC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.97	0.58	1.89e-31	Prudent dietary pattern;
LUSC	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-0.91	-17.2	-0.69	6.17e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs3087591	0.708	rs2525574	chr17:29705947	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	7.42	0.38	9.68e-13	Hip circumference;
LUSC	cis	rs12681287	0.517	rs34367154	chr8:87508749	A/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg22963979	chr7:1858916	MAD1L1	-0.56	-8.82	-0.43	6.3e-17	Bipolar disorder and schizophrenia;
LUSC	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-16.56	-0.67	2.13e-45	Exhaled nitric oxide output;
LUSC	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.68	-0.34	1e-10	Arsenic metabolism;
LUSC	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	6.99	0.36	1.47e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg16482183	chr6:26056742	HIST1H1C	0.56	8.34	0.42	2.02e-15	Height;
LUSC	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg26727032	chr16:67993705	SLC12A4	-0.39	-6.01	-0.31	4.8e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg17385448	chr1:15911702	AGMAT	0.37	6.15	0.32	2.24e-9	Systolic blood pressure;
LUSC	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.37	6.81	0.35	4.53e-11	Monocyte percentage of white cells;
LUSC	cis	rs62408225	0.962	rs2325292	chr6:90986749	T/C	cg06866423	chr6:90926672	BACH2	0.42	6.03	0.31	4.37e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg22823121	chr1:150693482	HORMAD1	0.46	6.6	0.34	1.64e-10	Melanoma;
LUSC	cis	rs9796	0.870	rs7169375	chr15:41311046	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.4	-7.02	-0.36	1.24e-11	Menopause (age at onset);
LUSC	cis	rs1385374	0.858	rs11059928	chr12:129296103	A/T	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.8	-0.35	4.96e-11	Systemic lupus erythematosus;
LUSC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg23262073	chr20:60523788	NA	-0.4	-5.71	-0.3	2.5e-8	Body mass index;
LUSC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg04850211	chr1:228464232	OBSCN	0.32	5.91	0.31	8.29e-9	Diastolic blood pressure;
LUSC	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.01	-0.31	4.82e-9	Resting heart rate;
LUSC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18099408	chr3:52552593	STAB1	-0.37	-6.41	-0.33	5.01e-10	Electroencephalogram traits;
LUSC	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.64	0.43	2.3e-16	Lung cancer in ever smokers;
LUSC	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-1.12	-15.43	-0.65	6.09e-41	Hip circumference adjusted for BMI;
LUSC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg04450456	chr4:17643702	FAM184B	0.35	5.86	0.31	1.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3760047	0.668	rs2858922	chr16:207218	G/A	cg08400316	chr16:204221	HBZ	0.56	6.75	0.35	6.54e-11	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg25258033	chr6:167368657	RNASET2	0.44	6.61	0.34	1.53e-10	Crohn's disease;
LUSC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.8	13.45	0.59	3.01e-33	Aortic root size;
LUSC	cis	rs7727544	0.545	rs17674015	chr5:131361778	C/A	cg14196790	chr5:131705035	SLC22A5	0.4	6.34	0.33	7.28e-10	Blood metabolite levels;
LUSC	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	6.63	0.34	1.38e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg20368463	chr18:77673604	PQLC1	-0.51	-6.63	-0.34	1.37e-10	Schizophrenia;
LUSC	cis	rs9635231	1	rs9635231	chr14:55887703	C/T	cg13175173	chr14:55914753	NA	-0.28	-5.85	-0.3	1.18e-8	Pediatric bone mineral density (femoral neck);
LUSC	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.65	10.22	0.49	1.58e-21	Eye color traits;
LUSC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08045932	chr20:61659980	NA	0.58	10.21	0.49	1.78e-21	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-14.63	-0.62	8.2e-38	Coronary artery disease;
LUSC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg02475777	chr4:1388615	CRIPAK	0.44	6.61	0.34	1.56e-10	Obesity-related traits;
LUSC	cis	rs4595586	0.525	rs4511319	chr12:39340457	T/C	cg26384229	chr12:38710491	ALG10B	0.5	7.03	0.36	1.15e-11	Morning vs. evening chronotype;
LUSC	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.59	10.88	0.51	8.19e-24	Bone mineral density;
LUSC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg26769984	chr7:1090371	C7orf50	0.47	6.95	0.36	1.9e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg19743168	chr1:23544995	NA	0.46	9.11	0.45	8.03e-18	Height;
LUSC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.5	-7.04	-0.36	1.1e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg04362960	chr10:104952993	NT5C2	0.56	8.07	0.4	1.31e-14	Arsenic metabolism;
LUSC	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-9.74	-0.47	6.6e-20	Mood instability;
LUSC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg02187348	chr16:89574699	SPG7	0.49	7.72	0.39	1.37e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg12573674	chr2:1569213	NA	-0.55	-6.03	-0.31	4.38e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.44	-0.33	4.21e-10	Resting heart rate;
LUSC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg04398451	chr17:18023971	MYO15A	-0.55	-9.23	-0.45	3.16e-18	Total body bone mineral density;
LUSC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg02569458	chr12:86230093	RASSF9	-0.59	-10.11	-0.48	3.76e-21	Major depressive disorder;
LUSC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.04	20.98	0.75	6.45e-63	Cognitive function;
LUSC	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg13798780	chr7:105162888	PUS7	0.56	6.15	0.32	2.23e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg10840412	chr1:235813424	GNG4	0.45	6.01	0.31	4.74e-9	Bipolar disorder;
LUSC	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg16342193	chr10:102329863	NA	-0.35	-6.14	-0.32	2.39e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg25233709	chr10:116636983	FAM160B1	0.44	7.84	0.39	6.17e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.55	-0.34	2.12e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.6	13.63	0.6	6e-34	Height;
LUSC	trans	rs4650994	0.544	rs4652301	chr1:178499799	T/C	cg05059571	chr16:84539110	KIAA1609	-0.48	-9.16	-0.45	5.48e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg06002616	chr8:101225028	SPAG1	-0.41	-6.82	-0.35	4.37e-11	Atrioventricular conduction;
LUSC	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg14343924	chr8:8086146	FLJ10661	0.45	6.19	0.32	1.77e-9	Neuroticism;
LUSC	cis	rs3760982	1.000	rs10421887	chr19:44294849	C/T	cg11993925	chr19:44307056	LYPD5	-0.27	-5.96	-0.31	6.55e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg15884721	chr4:492965	ZNF721;PIGG	0.47	6.16	0.32	2.07e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1561296	0.552	rs2278515	chr2:201282338	C/T	cg23649088	chr2:200775458	C2orf69	-0.38	-5.74	-0.3	2.11e-8	Schizophrenia;
LUSC	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21659725	chr3:3221576	CRBN	-0.65	-10.65	-0.5	5.55e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs2625529	0.617	rs3784313	chr15:72187519	G/T	cg16672083	chr15:72433130	SENP8	0.47	7.85	0.39	5.71e-14	Red blood cell count;
LUSC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg02018176	chr4:1364513	KIAA1530	0.47	7.81	0.39	7.68e-14	Obesity-related traits;
LUSC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16405210	chr4:1374714	KIAA1530	-0.56	-9.02	-0.44	1.56e-17	Longevity;
LUSC	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.63	-0.43	2.59e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.66	13.9	0.61	5.76e-35	Monocyte percentage of white cells;
LUSC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08470875	chr2:26401718	FAM59B	-0.68	-9.27	-0.45	2.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.8	-13.21	-0.59	2.42e-32	Aortic root size;
LUSC	cis	rs17155006	0.664	rs6974722	chr7:107738836	T/C	cg05962710	chr7:107745446	LAMB4	-0.36	-6.3	-0.33	9.63e-10	Pneumococcal bacteremia;
LUSC	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.94	0.7	7.29e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg18477163	chr1:228402036	OBSCN	0.63	12.24	0.56	1.05e-28	Diastolic blood pressure;
LUSC	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg23093090	chr10:104574429	C10orf26	-0.39	-7.41	-0.38	1.08e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg21724239	chr8:58056113	NA	0.59	6.73	0.35	7.5e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg20744362	chr22:50050164	C22orf34	0.37	6.78	0.35	5.38e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	16.59	0.67	1.6e-45	Platelet count;
LUSC	cis	rs12195417	0.563	rs531081	chr6:84216259	G/A	cg08257003	chr6:84140564	ME1	-0.28	-6.51	-0.34	2.75e-10	Schizophrenia;
LUSC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.51	-7.54	-0.38	4.35e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg13047869	chr3:10149882	C3orf24	0.56	7.88	0.4	4.57e-14	Alzheimer's disease;
LUSC	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg17470723	chr8:74884337	TCEB1	0.51	7.87	0.4	4.83e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-6.79	-0.35	5.03e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9818941	0.826	rs11714264	chr3:157655018	A/G	cg08654915	chr3:157813417	NA	0.29	6.56	0.34	2.08e-10	Height;
LUSC	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg27102117	chr16:15229624	NA	0.42	7.24	0.37	3.04e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.52	6.93	0.35	2.18e-11	Menarche (age at onset);
LUSC	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4409675	0.576	rs1474908	chr1:28213213	C/T	cg23691781	chr1:28212827	C1orf38	-0.25	-5.73	-0.3	2.2e-8	Corneal astigmatism;
LUSC	trans	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.82	-0.35	4.36e-11	Endometrial cancer;
LUSC	cis	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg06521331	chr12:34319734	NA	-0.39	-5.81	-0.3	1.43e-8	Resting heart rate;
LUSC	cis	rs9314323	0.767	rs13271042	chr8:26190212	T/G	cg11498726	chr8:26250323	BNIP3L	-0.41	-5.84	-0.3	1.24e-8	Red cell distribution width;
LUSC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg07424592	chr7:64974309	NA	0.66	5.82	0.3	1.39e-8	Diabetic kidney disease;
LUSC	trans	rs62103177	0.713	rs3744886	chr18:77659561	G/T	cg05926928	chr17:57297772	GDPD1	1.56	16.05	0.66	2.18e-43	Opioid sensitivity;
LUSC	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg26384229	chr12:38710491	ALG10B	0.6	9.56	0.46	2.62e-19	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg22705602	chr4:152727874	NA	0.38	7.92	0.4	3.61e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs8114671	0.967	rs6142322	chr20:33788538	C/A	cg07148914	chr20:33460835	GGT7	-0.43	-6.51	-0.34	2.78e-10	Height;
LUSC	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg10560079	chr2:191398806	TMEM194B	-0.76	-9.35	-0.46	1.35e-18	Diastolic blood pressure;
LUSC	trans	rs1864729	1.000	rs2053481	chr8:98278923	C/T	cg08679828	chr8:102218111	ZNF706	-0.87	-7.9	-0.4	3.95e-14	Estradiol plasma levels (breast cancer);
LUSC	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.5	-5.65	-0.3	3.48e-8	Red blood cell traits;
LUSC	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg03806693	chr22:41940476	POLR3H	0.85	12.41	0.56	2.33e-29	Vitiligo;
LUSC	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg02018176	chr4:1364513	KIAA1530	0.42	5.89	0.31	9.58e-9	Recombination rate (females);
LUSC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg09877947	chr5:131593287	PDLIM4	0.4	6.58	0.34	1.81e-10	Lung function (FEV1/FVC);
LUSC	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg08213375	chr14:104286397	PPP1R13B	0.39	6.33	0.33	7.82e-10	Reticulocyte count;
LUSC	cis	rs2762353	0.526	rs6912391	chr6:25710763	C/G	cg16482183	chr6:26056742	HIST1H1C	-0.41	-5.83	-0.3	1.3e-8	Blood metabolite levels;
LUSC	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg26384229	chr12:38710491	ALG10B	0.74	11.5	0.53	5.04e-26	Morning vs. evening chronotype;
LUSC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg12564285	chr5:131593104	PDLIM4	0.47	8.25	0.41	3.83e-15	Acylcarnitine levels;
LUSC	cis	rs7712401	0.601	rs13185741	chr5:122338010	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.22	-0.45	3.4e-18	Mean platelet volume;
LUSC	trans	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg10756647	chr7:56101905	PSPH	-0.85	-8.45	-0.42	8.99e-16	Gout;
LUSC	cis	rs11031096	0.754	rs10742242	chr11:4156851	T/C	cg18678763	chr11:4115507	RRM1	-0.53	-7.58	-0.38	3.49e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg04450456	chr4:17643702	FAM184B	0.37	6.34	0.33	7.37e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6969780	1.000	rs6948297	chr7:27149404	A/G	cg26364809	chr7:27145159	NA	-0.62	-6.16	-0.32	2.15e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg11859384	chr17:80120422	CCDC57	-0.36	-5.67	-0.3	3.11e-8	Life satisfaction;
LUSC	cis	rs4680	0.712	rs740601	chr22:19950763	T/G	cg06346307	chr22:19949965	COMT	-0.34	-7.03	-0.36	1.18e-11	Blood metabolite levels;
LUSC	cis	rs2932538	0.922	rs17438324	chr1:113100573	C/T	cg22162597	chr1:113214053	CAPZA1	0.69	9.93	0.48	1.6e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg07424592	chr7:64974309	NA	0.69	6.18	0.32	1.88e-9	Diabetic kidney disease;
LUSC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg19729930	chr2:74357872	NA	0.93	17.38	0.69	1.23e-48	Gestational age at birth (maternal effect);
LUSC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.68	-0.43	1.72e-16	Bipolar disorder;
LUSC	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-6.37	-0.33	6.1e-10	Major depressive disorder;
LUSC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg20243544	chr17:37824526	PNMT	0.55	8.06	0.4	1.33e-14	Asthma;
LUSC	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg01206211	chr2:36825736	FEZ2	-0.47	-9.55	-0.46	2.83e-19	Height;
LUSC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.87	13.84	0.6	9.42e-35	Multiple system atrophy;
LUSC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.62	0.43	2.69e-16	Prudent dietary pattern;
LUSC	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg18302933	chr2:88491318	NA	-0.35	-6.73	-0.35	7.35e-11	Response to metformin (IC50);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02693249	chr1:205600567	ELK4	0.39	5.96	0.31	6.44e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.19	-0.32	1.8e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg11608241	chr8:8085544	FLJ10661	0.39	5.74	0.3	2.14e-8	Mood instability;
LUSC	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg26856596	chr11:1961893	NA	0.31	6.19	0.32	1.74e-9	DNA methylation (variation);
LUSC	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg04450456	chr4:17643702	FAM184B	0.4	6.67	0.34	1.09e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23951618	chr1:205782099	SLC41A1	0.44	6.15	0.32	2.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	14.84	0.63	1.25e-38	Platelet count;
LUSC	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-17.41	-0.69	9.13e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg06713675	chr4:122721982	EXOSC9	0.39	6.38	0.33	6.06e-10	Type 2 diabetes;
LUSC	cis	rs12638540	0.543	rs12487678	chr3:32603358	A/C	cg11605617	chr3:32612461	DYNC1LI1	0.85	7.57	0.38	3.77e-13	Mortality in heart failure;
LUSC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg22800045	chr5:56110881	MAP3K1	0.74	9.49	0.46	4.49e-19	Initial pursuit acceleration;
LUSC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg08470875	chr2:26401718	FAM59B	-0.7	-9.38	-0.46	1.07e-18	Gut microbiome composition (summer);
LUSC	cis	rs597583	0.715	rs11216436	chr11:117391374	G/A	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.43	-0.42	1.02e-15	Putamen volume;
LUSC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.88e-8	Tonsillectomy;
LUSC	cis	rs7903847	0.642	rs11817852	chr10:99158426	C/T	cg08345082	chr10:99160200	RRP12	-0.35	-6.99	-0.36	1.53e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7605827	0.893	rs6734024	chr2:15718180	A/G	cg19274914	chr2:15703543	NA	0.46	8.77	0.43	9.43e-17	Educational attainment (years of education);
LUSC	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg05855489	chr10:104503620	C10orf26	-0.49	-7.42	-0.38	9.5e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.86	-0.4	5.4e-14	Retinal vascular caliber;
LUSC	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg06552810	chr11:31128660	NA	0.4	7.04	0.36	1.08e-11	Red blood cell count;
LUSC	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.88e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg20848291	chr7:100343083	ZAN	0.4	5.8	0.3	1.51e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	6.56	0.34	2.07e-10	Height;
LUSC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg06074448	chr4:187884817	NA	-0.41	-6.91	-0.35	2.47e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4588572	0.688	rs2115436	chr5:77692617	A/T	cg11547950	chr5:77652471	NA	-0.39	-5.94	-0.31	6.99e-9	Triglycerides;
LUSC	cis	rs16910800	0.638	rs12273883	chr11:23164569	C/G	cg20040320	chr11:23191996	NA	0.59	7.56	0.38	3.86e-13	Cancer;
LUSC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08677398	chr8:58056175	NA	0.54	7.01	0.36	1.34e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg03146154	chr1:46216737	IPP	0.54	8.25	0.41	3.79e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.79	0.35	5.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.23	0.37	3.23e-12	Blood metabolite levels;
LUSC	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg15490075	chr13:100150979	NA	-0.6	-6.38	-0.33	5.94e-10	Obesity-related traits;
LUSC	cis	rs12989701	0.825	rs873270	chr2:127859418	T/C	cg08168897	chr2:127865431	BIN1	0.68	8.47	0.42	7.99e-16	Alzheimer's disease (late onset);
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg26272228	chr1:95538484	ALG14	0.4	6.08	0.32	3.29e-9	Schizophrenia (age at onset);
LUSC	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.1	27.08	0.83	2.9e-86	Colorectal cancer;
LUSC	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg24375607	chr4:120327624	NA	0.69	10.58	0.5	9.19e-23	Corneal astigmatism;
LUSC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg17143192	chr8:8559678	CLDN23	0.63	8.9	0.44	3.56e-17	Obesity-related traits;
LUSC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg16928487	chr17:17741425	SREBF1	0.46	8.97	0.44	2.17e-17	Total body bone mineral density;
LUSC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg05896524	chr21:47604654	C21orf56	0.43	6.5	0.33	2.98e-10	Testicular germ cell tumor;
LUSC	trans	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.32	0.41	2.28e-15	Resting heart rate;
LUSC	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg05855489	chr10:104503620	C10orf26	0.53	8.09	0.4	1.1e-14	Arsenic metabolism;
LUSC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	ch.11.42038R	chr11:967971	AP2A2	0.54	8.18	0.41	6.06e-15	Alzheimer's disease (late onset);
LUSC	cis	rs10203711	0.866	rs66849943	chr2:239580956	T/C	cg14580085	chr2:239553406	NA	0.41	6.71	0.34	8.12e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg03929089	chr4:120376271	NA	0.72	6.77	0.35	5.71e-11	Axial length;
LUSC	cis	rs6076065	0.723	rs2424534	chr20:23378866	A/G	cg11657817	chr20:23433608	CST11	-0.43	-8.02	-0.4	1.81e-14	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19477600	chr11:124632081	ESAM	-0.4	-5.96	-0.31	6.48e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.08	-0.36	8.81e-12	Response to antipsychotic treatment;
LUSC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.99	-0.36	1.51e-11	Obesity-related traits;
LUSC	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg08601574	chr20:25228251	PYGB	0.44	6.76	0.35	6.11e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.94	-0.31	7.16e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	0.89	16.15	0.66	8.8e-44	Cognitive function;
LUSC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.77	14.82	0.63	1.48e-38	Monocyte count;
LUSC	cis	rs7119	0.651	rs12904533	chr15:77845928	G/A	cg27398640	chr15:77910606	LINGO1	-0.33	-6.98	-0.36	1.58e-11	Type 2 diabetes;
LUSC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg22532475	chr10:104410764	TRIM8	0.3	5.97	0.31	6.17e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.67	9.31	0.45	1.82e-18	Menarche (age at onset);
LUSC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg09034736	chr1:150693464	HORMAD1	0.45	6.43	0.33	4.36e-10	Melanoma;
LUSC	cis	rs3862435	0.610	rs2601204	chr15:90961518	G/A	cg22089800	chr15:90895588	ZNF774	0.58	6.33	0.33	7.74e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg22676075	chr6:135203613	NA	0.48	7.51	0.38	5.6e-13	Red blood cell count;
LUSC	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg21053147	chr12:120880522	NA	-0.49	-6.03	-0.31	4.43e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-10.27	-0.49	1.09e-21	Schizophrenia;
LUSC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg07716408	chr11:68623521	NA	-0.3	-5.67	-0.3	3.18e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2708377	0.929	rs2255418	chr12:11216972	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs8141797	0.901	rs4820581	chr22:24480503	G/A	cg00411358	chr22:24577142	SUSD2	0.61	6.32	0.33	8.56e-10	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.45	-6.2	-0.32	1.66e-9	Platelet count;
LUSC	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg04896959	chr15:78267971	NA	0.51	10.88	0.51	8.18e-24	Coronary artery disease or large artery stroke;
LUSC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg02487422	chr3:49467188	NICN1	0.48	7.63	0.39	2.46e-13	Resting heart rate;
LUSC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.25	0.56	9.27e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg14343924	chr8:8086146	FLJ10661	0.45	6.17	0.32	2e-9	Myopia (pathological);
LUSC	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg00857998	chr1:205179979	DSTYK	0.64	10.09	0.48	4.63e-21	Red blood cell count;
LUSC	cis	rs6733011	0.519	rs6739097	chr2:99458601	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.44	-0.33	4.1e-10	Bipolar disorder;
LUSC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.62	-0.5	6.88e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08645402	chr16:4508243	NA	0.49	8.42	0.42	1.12e-15	Schizophrenia;
LUSC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg05043794	chr9:111880884	C9orf5	-0.34	-7.25	-0.37	3e-12	Menarche (age at onset);
LUSC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.17	-0.41	6.24e-15	Chronic sinus infection;
LUSC	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg03929089	chr4:120376271	NA	0.61	6.6	0.34	1.65e-10	Axial length;
LUSC	cis	rs7818345	0.967	rs4549789	chr8:19284015	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	7.48	0.38	6.81e-13	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17467752	chr17:38218738	THRA	0.77	12.39	0.56	2.84e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	12.32	0.56	5.06e-29	Cognitive test performance;
LUSC	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg03522245	chr20:25566470	NINL	0.36	5.83	0.3	1.29e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08280861	chr8:58055591	NA	0.54	6.25	0.32	1.26e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg19682013	chr15:45996608	NA	0.38	5.88	0.31	1.02e-8	Waist circumference;Weight;
LUSC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg25039879	chr17:56429692	SUPT4H1	0.68	9.08	0.45	9.42e-18	Cognitive test performance;
LUSC	cis	rs136211	0.577	rs9607339	chr22:36768932	G/T	cg10790723	chr22:36903033	FOXRED2	0.42	6.28	0.32	1.07e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs193541	0.632	rs1460040	chr5:122105232	A/G	cg19077854	chr5:122220652	SNX24	0.38	7.9	0.4	4.15e-14	Glucose homeostasis traits;
LUSC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14893161	chr1:205819251	PM20D1	0.43	6.05	0.31	3.86e-9	Parkinson's disease;
LUSC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-1.01	-15.08	-0.64	1.44e-39	Blood trace element (Zn levels);
LUSC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-0.88	-18.58	-0.71	2.09e-53	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11158026	0.603	rs7151670	chr14:55452759	C/G	cg04306507	chr14:55594613	LGALS3	0.4	7.43	0.38	8.92e-13	Parkinson's disease;
LUSC	cis	rs11650494	0.831	rs73324348	chr17:47455752	G/A	cg08112188	chr17:47440006	ZNF652	1.24	10.91	0.51	6.64e-24	Prostate cancer;
LUSC	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg01420254	chr6:26195488	NA	0.71	7.46	0.38	7.79e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs17102423	0.559	rs3783720	chr14:65475411	A/G	cg11161011	chr14:65562177	MAX	-0.72	-9.64	-0.47	1.49e-19	Obesity-related traits;
LUSC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg20295408	chr7:1910781	MAD1L1	-0.49	-6.81	-0.35	4.49e-11	Schizophrenia;
LUSC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16405210	chr4:1374714	KIAA1530	-0.66	-10.81	-0.51	1.45e-23	Longevity;
LUSC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg03161606	chr19:29218774	NA	0.62	9.08	0.44	9.9e-18	Methadone dose in opioid dependence;
LUSC	cis	rs7953249	0.791	rs1920792	chr12:121404584	T/C	cg02403541	chr12:121454288	C12orf43	-0.5	-7.4	-0.38	1.11e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.59	0.43	3.4e-16	Lung cancer;
LUSC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg21280719	chr6:42927975	GNMT	-0.32	-7.96	-0.4	2.77e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg15117754	chr3:10150083	C3orf24	0.44	5.75	0.3	1.97e-8	Alzheimer's disease;
LUSC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg19318889	chr4:1322082	MAEA	0.49	8.44	0.42	9.82e-16	Longevity;
LUSC	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg12884169	chr21:40033163	ERG	0.61	12.33	0.56	4.83e-29	Coronary artery disease;
LUSC	cis	rs7809950	0.862	rs62482502	chr7:106987810	A/C	cg23024343	chr7:107201750	COG5	-0.53	-8.36	-0.42	1.69e-15	Coronary artery disease;
LUSC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg20821713	chr7:1055600	C7orf50	-0.39	-6.14	-0.32	2.29e-9	Longevity;Endometriosis;
LUSC	cis	rs11195062	0.521	rs4918485	chr10:111949323	A/T	cg00817464	chr10:111662876	XPNPEP1	0.46	7.17	0.37	4.72e-12	Multiple myeloma;
LUSC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.62	0.38	2.59e-13	Electroencephalogram traits;
LUSC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg06453172	chr10:134556979	INPP5A	-0.46	-5.78	-0.3	1.69e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg05941027	chr17:61774174	LIMD2	0.21	5.71	0.3	2.44e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs295140	1.000	rs3769476	chr2:201181428	T/C	cg04283868	chr2:201171347	SPATS2L	0.42	6.35	0.33	7.15e-10	QT interval;
LUSC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs2979489	0.945	rs11988541	chr8:30334273	G/A	cg26383811	chr8:30366931	RBPMS	-0.51	-7.93	-0.4	3.24e-14	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg22963979	chr7:1858916	MAD1L1	-0.54	-8.08	-0.4	1.2e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg25767906	chr1:53392781	SCP2	0.51	9.41	0.46	8.33e-19	Monocyte count;
LUSC	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg00990874	chr7:1149470	C7orf50	-0.51	-5.92	-0.31	8.18e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg26384229	chr12:38710491	ALG10B	-0.59	-8.92	-0.44	3.09e-17	Heart rate;
LUSC	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg15557168	chr22:42548783	NA	0.38	6.28	0.32	1.07e-9	Cognitive function;
LUSC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-0.93	-15.71	-0.65	5.06e-42	Menopause (age at onset);
LUSC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs73200209	0.744	rs17498760	chr12:116636803	C/G	cg01776926	chr12:116560359	MED13L	-0.5	-6.07	-0.32	3.4e-9	Total body bone mineral density;
LUSC	cis	rs2286503	0.839	rs10276099	chr7:22862950	G/A	cg11367502	chr7:22862612	TOMM7	0.46	6.22	0.32	1.51e-9	Fibrinogen;
LUSC	cis	rs955333	0.685	rs17539620	chr6:154896235	G/T	cg20019720	chr6:154832845	CNKSR3	0.48	6.23	0.32	1.37e-9	Diabetic kidney disease;
LUSC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg17366294	chr4:99064904	C4orf37	0.57	9.94	0.48	1.46e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs62458065	0.850	rs7785659	chr7:32461015	C/T	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.25	-0.32	1.28e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.05e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg13206674	chr6:150067644	NUP43	0.62	9.88	0.48	2.38e-20	Lung cancer;
LUSC	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg20243544	chr17:37824526	PNMT	0.43	6.54	0.34	2.28e-10	Self-reported allergy;
LUSC	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.59	-0.34	1.73e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-6.09	-0.32	3.18e-9	Bipolar disorder;
LUSC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg04450456	chr4:17643702	FAM184B	0.36	6.15	0.32	2.2e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.9e-20	Migraine;Coronary artery disease;
LUSC	cis	rs137603	0.623	rs137657	chr22:39733242	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.5	-7.91	-0.4	3.7e-14	Primary biliary cholangitis;
LUSC	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	7.67	0.39	1.86e-13	Retinal vascular caliber;
LUSC	cis	rs17539620	0.507	rs6927301	chr6:154872080	G/T	cg20019720	chr6:154832845	CNKSR3	-0.38	-6.41	-0.33	4.86e-10	Lipoprotein (a) levels;
LUSC	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg05738196	chr6:26577821	NA	-0.45	-6.37	-0.33	6.2e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs668210	0.793	rs540584	chr11:65765866	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.58	-7.38	-0.37	1.25e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg21775007	chr8:11205619	TDH	0.77	12.32	0.56	5.47e-29	Retinal vascular caliber;
LUSC	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.79	11.66	0.54	1.39e-26	Corneal astigmatism;
LUSC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.93	-0.48	1.55e-20	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.54	-0.38	4.38e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12474201	1.000	rs12474201	chr2:46921285	C/T	cg06386533	chr2:46925753	SOCS5	0.8	12.83	0.57	6.63e-31	Height;
LUSC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg07716408	chr11:68623521	NA	-0.31	-5.81	-0.3	1.43e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg04851639	chr8:1020857	NA	-0.35	-6.99	-0.36	1.54e-11	Schizophrenia;
LUSC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06634786	chr22:41940651	POLR3H	-0.52	-6.41	-0.33	4.95e-10	Vitiligo;
LUSC	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-6.69	-0.34	9.7e-11	Blood protein levels;
LUSC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.76	-0.35	6.35e-11	Mean corpuscular volume;
LUSC	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg24531977	chr5:56204891	C5orf35	-0.67	-9.93	-0.48	1.59e-20	Coronary artery disease;
LUSC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg15147215	chr3:52552868	STAB1	-0.29	-5.83	-0.3	1.28e-8	Bipolar disorder;
LUSC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	14.66	0.63	6.32e-38	Platelet count;
LUSC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-9.12	-0.45	7.02e-18	Obesity-related traits;
LUSC	cis	rs76878669	0.617	rs10896114	chr11:66143797	A/G	cg18002602	chr11:66138449	SLC29A2	-0.37	-5.8	-0.3	1.57e-8	Educational attainment (years of education);
LUSC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg20821713	chr7:1055600	C7orf50	-0.39	-6.2	-0.32	1.67e-9	Longevity;Endometriosis;
LUSC	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg23260525	chr10:116636907	FAM160B1	0.4	7.99	0.4	2.26e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg27147174	chr7:100797783	AP1S1	0.64	10.25	0.49	1.32e-21	Life satisfaction;
LUSC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg09555818	chr19:45449301	APOC2	0.44	8.18	0.41	5.99e-15	Blood protein levels;
LUSC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg13395646	chr4:1353034	KIAA1530	-0.63	-10.14	-0.49	2.94e-21	Obesity-related traits;
LUSC	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg05855489	chr10:104503620	C10orf26	0.59	9.44	0.46	6.85e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg17410650	chr12:54324560	NA	-0.58	-10.33	-0.49	6.72e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg18129178	chr5:148520854	ABLIM3	-0.65	-10.24	-0.49	1.38e-21	Breast cancer;
LUSC	trans	rs9929218	0.954	rs4420522	chr16:68822971	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.09	-0.52	1.52e-24	Colorectal cancer;
LUSC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg22823121	chr1:150693482	HORMAD1	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	cis	rs7246967	0.541	rs16999009	chr19:22909658	A/G	cg23217946	chr19:22817039	ZNF492	-0.43	-5.79	-0.3	1.61e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.24e-19	Prudent dietary pattern;
LUSC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.95	-0.31	6.83e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg07332563	chr6:291687	DUSP22	0.47	7.28	0.37	2.43e-12	Menopause (age at onset);
LUSC	cis	rs738322	0.577	rs4820320	chr22:38572977	G/A	cg25457927	chr22:38595422	NA	-0.33	-6.28	-0.33	1.04e-9	Cutaneous nevi;
LUSC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07167872	chr1:205819463	PM20D1	-0.52	-8.37	-0.42	1.57e-15	Menarche (age at onset);
LUSC	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.38	-0.37	1.29e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.43	6.85	0.35	3.61e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.72	-0.3	2.4e-8	Allergy;
LUSC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.05	0.31	3.81e-9	Schizophrenia;
LUSC	trans	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg25835954	chr13:50160062	RCBTB1	0.53	7.62	0.38	2.62e-13	Cortisol levels (saliva);
LUSC	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.6	0.34	1.57e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-11.3	-0.53	2.68e-25	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7267979	0.586	rs6050429	chr20:25183058	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	12.49	0.56	1.28e-29	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg03886242	chr7:26192032	NFE2L3	0.37	6.26	0.32	1.16e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg16339924	chr4:17578868	LAP3	0.5	7.55	0.38	4.31e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg17830980	chr10:43048298	ZNF37B	0.46	7.12	0.36	6.73e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg08088566	chr11:430123	ANO9	0.67	7.4	0.38	1.08e-12	Body mass index;
LUSC	trans	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.45	-0.42	9.12e-16	Obesity-related traits;
LUSC	cis	rs8036030	0.691	rs11852760	chr15:74718699	A/G	cg10253484	chr15:75165896	SCAMP2	-0.41	-5.94	-0.31	7e-9	Airflow obstruction;
LUSC	cis	rs240764	0.658	rs12212435	chr6:101196080	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-6.27	-0.32	1.11e-9	Neuroticism;
LUSC	cis	rs2050392	0.965	rs2265368	chr10:30690289	G/C	cg18806716	chr10:30721971	MAP3K8	-0.43	-6.99	-0.36	1.52e-11	Inflammatory bowel disease;
LUSC	trans	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg25214090	chr10:38739885	LOC399744	0.43	6.59	0.34	1.72e-10	Corneal astigmatism;
LUSC	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg06627628	chr2:24431161	ITSN2	-0.63	-9.37	-0.46	1.16e-18	Asthma;
LUSC	cis	rs6840360	0.582	rs6535796	chr4:152304728	G/A	cg20465933	chr4:152376761	FAM160A1	0.32	5.68	0.3	2.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs722599	0.683	rs11848876	chr14:75224626	C/G	cg06637938	chr14:75390232	RPS6KL1	0.41	5.96	0.31	6.34e-9	IgG glycosylation;
LUSC	cis	rs738321	0.725	rs4821747	chr22:38538856	T/C	cg25457927	chr22:38595422	NA	-0.34	-6.37	-0.33	6.24e-10	Breast cancer;
LUSC	cis	rs4363385	0.647	rs4845513	chr1:152998066	T/C	cg25856811	chr1:152973957	SPRR3	-0.41	-6.63	-0.34	1.34e-10	Inflammatory skin disease;
LUSC	cis	rs9359856	0.564	rs7682	chr6:90352862	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.86	-8.64	-0.43	2.39e-16	Bipolar disorder;
LUSC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18854424	chr1:2615690	NA	0.5	10.1	0.48	4.29e-21	Ulcerative colitis;
LUSC	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.24	-0.37	3.14e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.34	-0.46	1.42e-18	Brugada syndrome;
LUSC	cis	rs9815354	0.680	rs57945879	chr3:42038842	C/G	cg03022575	chr3:42003672	ULK4	0.78	7.87	0.4	5.1e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-12.73	-0.57	1.56e-30	Total body bone mineral density;
LUSC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-11.05	-0.52	2.07e-24	Bipolar disorder;
LUSC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg09034736	chr1:150693464	HORMAD1	0.46	6.49	0.33	3.16e-10	Melanoma;
LUSC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.4	5.75	0.3	2e-8	Tonsillectomy;
LUSC	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17467752	chr17:38218738	THRA	-0.71	-11.37	-0.53	1.49e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg18078305	chr2:65215753	SLC1A4	0.4	6.53	0.34	2.44e-10	Triglycerides;
LUSC	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg22029157	chr1:209979665	IRF6	0.47	7.24	0.37	3.02e-12	Monobrow;
LUSC	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg04850211	chr1:228464232	OBSCN	-0.32	-5.82	-0.3	1.42e-8	Diastolic blood pressure;
LUSC	trans	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg03886242	chr7:26192032	NFE2L3	-0.37	-6.06	-0.31	3.65e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg11102782	chr19:18549136	ISYNA1	-0.33	-6.41	-0.33	4.86e-10	Breast cancer;
LUSC	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg22676075	chr6:135203613	NA	0.47	7.37	0.37	1.32e-12	Red blood cell count;
LUSC	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg26597838	chr10:835615	NA	0.53	7.13	0.36	6.44e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg20991723	chr1:152506922	NA	0.5	9.44	0.46	6.51e-19	Hair morphology;
LUSC	cis	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg06521331	chr12:34319734	NA	0.44	7.11	0.36	6.9e-12	Morning vs. evening chronotype;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25228510	chr10:62538235	CDK1;CDC2	-0.58	-6.82	-0.35	4.39e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg07810366	chr2:100720526	AFF3	-0.53	-9.25	-0.45	2.81e-18	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.34	-0.37	1.62e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg16339924	chr4:17578868	LAP3	0.58	9.09	0.45	9.01e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg11812906	chr14:75593930	NEK9	0.65	10.6	0.5	8.14e-23	Height;
LUSC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg07507251	chr3:52567010	NT5DC2	-0.36	-7.03	-0.36	1.15e-11	Bipolar disorder;
LUSC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.59	0.38	3.31e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg08999081	chr20:33150536	PIGU	-0.41	-7.56	-0.38	3.88e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg24209194	chr3:40518798	ZNF619	0.49	6.5	0.34	2.87e-10	Renal cell carcinoma;
LUSC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02788857	chr8:22132959	PIWIL2	0.39	7.5	0.38	6.01e-13	Hypertriglyceridemia;
LUSC	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg16359550	chr11:109292809	C11orf87	0.37	6.37	0.33	6.29e-10	Schizophrenia;
LUSC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06634786	chr22:41940651	POLR3H	-0.54	-6.32	-0.33	8.48e-10	Vitiligo;
LUSC	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-6.89	-0.35	2.73e-11	Arsenic metabolism;
LUSC	trans	rs656319	0.580	rs17690549	chr8:9998538	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.51	-0.38	5.53e-13	Myopia (pathological);
LUSC	cis	rs6987853	0.933	rs6474401	chr8:42367068	T/C	cg09913449	chr8:42400586	C8orf40	-0.48	-7.95	-0.4	2.82e-14	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.61	-0.43	2.88e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg27411982	chr8:10470053	RP1L1	-0.39	-5.93	-0.31	7.4e-9	Myopia (pathological);
LUSC	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg26597838	chr10:835615	NA	0.76	9.03	0.44	1.37e-17	Eosinophil percentage of granulocytes;
LUSC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.45	-6.33	-0.33	8.1e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.69	0.34	9.17e-11	Axial length;
LUSC	cis	rs34891900	0.507	rs12167771	chr22:18124332	G/A	cg08824373	chr22:18117835	NA	-0.44	-6.74	-0.35	7.05e-11	Sum neutrophil eosinophil counts;
LUSC	cis	rs10193935	0.901	rs7570083	chr2:42517859	G/A	cg27598129	chr2:42591480	NA	-0.58	-8.08	-0.4	1.19e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	0.63	13.84	0.6	9.97e-35	Prudent dietary pattern;
LUSC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	13.0	0.58	1.5e-31	Alzheimer's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11948688	chr8:1712330	CLN8	-0.42	-6.57	-0.34	1.91e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs17607347	0.542	rs7199954	chr16:72489414	C/T	cg24341770	chr6:105148882	NA	0.48	5.95	0.31	6.63e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.99	0.4	2.24e-14	Prudent dietary pattern;
LUSC	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.37	0.37	1.39e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg02997394	chr19:33096574	ANKRD27	0.83	9.48	0.46	4.95e-19	Eosinophilic esophagitis;
LUSC	trans	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg19894588	chr14:64061835	NA	-0.51	-6.67	-0.34	1.07e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.09	0.58	7.01e-32	Prudent dietary pattern;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27561072	chr1:19812431	CAPZB	-0.41	-6.07	-0.32	3.41e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg06212747	chr3:49208901	KLHDC8B	0.59	8.24	0.41	3.86e-15	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg03676636	chr4:99064102	C4orf37	0.36	8.04	0.4	1.54e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg00944433	chr1:107599041	PRMT6	0.38	6.96	0.36	1.83e-11	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg09307838	chr4:120376055	NA	0.61	8.84	0.44	5.79e-17	Educational attainment;
LUSC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	20.48	0.75	5.81e-61	Prudent dietary pattern;
LUSC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.2	0.41	5.24e-15	Homoarginine levels;
LUSC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.62	9.9	0.48	1.91e-20	Blood protein levels;
LUSC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-9.02	-0.44	1.56e-17	Personality dimensions;
LUSC	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.02	20.48	0.75	5.84e-61	Cognitive function;
LUSC	cis	rs308403	0.509	rs1849430	chr4:123674701	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.96	16.63	0.67	1.1e-45	Blood protein levels;
LUSC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.81	-0.35	4.64e-11	Alzheimer's disease (late onset);
LUSC	cis	rs897080	0.552	rs1085443	chr2:44635015	A/G	cg00619915	chr2:44497795	NA	-0.41	-5.8	-0.3	1.54e-8	Height;
LUSC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg12963246	chr6:28129442	ZNF389	0.48	6.73	0.35	7.46e-11	Depression;
LUSC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.64	9.95	0.48	1.3e-20	Blood protein levels;
LUSC	cis	rs6882046	0.513	rs625970	chr5:88042296	A/G	cg22951263	chr5:87985283	NA	-0.47	-7.91	-0.4	3.8e-14	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LUSC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg13628971	chr7:2884303	GNA12	0.46	6.58	0.34	1.84e-10	Height;
LUSC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.08e-17	Prudent dietary pattern;
LUSC	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg13390004	chr1:15929781	NA	0.43	7.12	0.36	6.55e-12	Systolic blood pressure;
LUSC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg09877947	chr5:131593287	PDLIM4	-0.38	-6.19	-0.32	1.72e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg03605463	chr16:89740564	NA	0.48	7.11	0.36	7.25e-12	Vitiligo;
LUSC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg20790798	chr5:1857306	NA	-0.5	-8.42	-0.42	1.09e-15	Cardiovascular disease risk factors;
LUSC	cis	rs365132	0.875	rs4490607	chr5:176349386	T/C	cg25401027	chr5:176370377	UIMC1	0.35	5.74	0.3	2.11e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg04362960	chr10:104952993	NT5C2	-0.48	-6.02	-0.31	4.52e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9648716	0.515	rs58901822	chr7:140683175	G/A	cg23214464	chr7:140373596	ADCK2	0.7	5.92	0.31	7.78e-9	Type 2 diabetes;
LUSC	cis	rs59104589	0.583	rs28386824	chr2:242349893	A/G	cg14842376	chr2:242211374	HDLBP	0.53	6.22	0.32	1.53e-9	Fibrinogen levels;
LUSC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.71	10.76	0.51	2.23e-23	Smoking initiation;
LUSC	cis	rs3771570	0.901	rs55811034	chr2:242406245	C/T	cg21155796	chr2:242212141	HDLBP	0.61	6.93	0.35	2.13e-11	Prostate cancer;
LUSC	cis	rs11997175	0.653	rs4268089	chr8:33626532	G/A	ch.8.33884649F	chr8:33765107	NA	0.44	7.13	0.36	6.37e-12	Body mass index;
LUSC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg06212747	chr3:49208901	KLHDC8B	0.43	5.86	0.31	1.1e-8	Parkinson's disease;
LUSC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg17911788	chr17:44343683	NA	-0.31	-5.88	-0.31	1.02e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg21724239	chr8:58056113	NA	0.59	6.76	0.35	6.3e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.47	-0.33	3.58e-10	Monocyte count;
LUSC	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg04155289	chr7:94953770	PON1	-0.34	-5.83	-0.3	1.33e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs3774830	0.714	rs17464616	chr4:5465004	G/A	cg26943120	chr4:5472116	STK32B	0.29	5.77	0.3	1.84e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.37	-6.4	-0.33	5.39e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs34779708	0.931	rs4934704	chr10:35332164	C/T	cg04310649	chr10:35416472	CREM	-0.4	-6.14	-0.32	2.32e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg06096015	chr1:231504339	EGLN1	0.55	9.58	0.46	2.23e-19	Hemoglobin concentration;
LUSC	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14169450	chr9:139327907	INPP5E	-0.41	-7.25	-0.37	2.86e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22713941	chr2:105953959	C2orf49	-0.45	-6.63	-0.34	1.36e-10	Electrocardiographic conduction measures;
LUSC	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg03929089	chr4:120376271	NA	-0.55	-6.74	-0.35	6.84e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.16	-0.49	2.58e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.4	-0.33	5.2400000000000005e-10	Breast cancer;
LUSC	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg06197492	chr11:2016605	H19	0.42	7.36	0.37	1.4e-12	DNA methylation (variation);
LUSC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg15352829	chr14:105391018	PLD4	-0.41	-8.48	-0.42	7.48e-16	Rheumatoid arthritis;
LUSC	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg13798780	chr7:105162888	PUS7	0.6	6.46	0.33	3.61e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6681460	0.898	rs1032635	chr1:67195184	C/G	cg02459107	chr1:67143332	SGIP1	-0.47	-8.74	-0.43	1.14e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg21724239	chr8:58056113	NA	0.54	6.14	0.32	2.28e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.6	9.88	0.48	2.28e-20	Blood metabolite levels;
LUSC	cis	rs73129298	0.551	rs6091078	chr20:48603066	G/A	cg25655593	chr20:48599521	SNAI1	0.58	6.18	0.32	1.88e-9	Inflammatory skin disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10480950	chr6:5067127	NA	0.4	6.15	0.32	2.26e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2446066	0.872	rs2002555	chr12:53817237	A/G	cg20730629	chr12:53886622	MAP3K12	-0.42	-5.69	-0.3	2.71e-8	Red blood cell count;
LUSC	cis	rs8027181	0.839	rs62017600	chr15:73072236	T/A	cg25632853	chr15:73088954	NA	0.33	6.68	0.34	9.78e-11	Triglyceride levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15672331	chr15:85923765	AKAP13	0.47	7.61	0.38	2.81e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg09904177	chr6:26538194	HMGN4	-0.68	-12.02	-0.55	6.8e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg20203395	chr5:56204925	C5orf35	-0.78	-10.48	-0.5	2.01e-22	Initial pursuit acceleration;
LUSC	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg05872129	chr22:39784769	NA	-0.62	-11.7	-0.54	9.59e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs34638657	0.536	rs2967327	chr16:82188657	C/T	cg09439754	chr16:82129088	HSD17B2	-0.33	-5.99	-0.31	5.54e-9	Lung adenocarcinoma;
LUSC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg20821713	chr7:1055600	C7orf50	-0.54	-7.15	-0.36	5.67e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg04310649	chr10:35416472	CREM	-0.38	-6.14	-0.32	2.28e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.73	11.94	0.55	1.37e-27	Coronary artery disease;
LUSC	cis	rs73198271	0.562	rs17631022	chr8:8662197	G/A	cg01851573	chr8:8652454	MFHAS1	0.62	7.89	0.4	4.28e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg01475377	chr6:109611718	NA	-0.41	-7.36	-0.37	1.47e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.02	0.4	1.82e-14	Lung cancer;
LUSC	trans	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg04995722	chr7:26192034	NFE2L3	0.37	6.13	0.32	2.51e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1395	0.922	rs11693052	chr2:27484620	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.39	6.3	0.33	9.31e-10	Blood metabolite levels;
LUSC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg19774624	chr17:42201019	HDAC5	-0.8	-13.41	-0.59	4.28e-33	Total body bone mineral density;
LUSC	trans	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg20935933	chr6:143382018	AIG1	0.5	7.42	0.38	9.57e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.42	6.58	0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg04733989	chr22:42467013	NAGA	0.37	6.13	0.32	2.41e-9	Cognitive function;
LUSC	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-1.13	-18.17	-0.71	8.74e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg07080220	chr10:102295463	HIF1AN	0.65	7.96	0.4	2.68e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.43	-0.62	4.96e-37	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg16342193	chr10:102329863	NA	-0.34	-6.15	-0.32	2.22e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4478037	1.000	rs57477065	chr3:33162532	A/C	cg19404215	chr3:33155277	CRTAP	0.95	9.99	0.48	9.87e-21	Major depressive disorder;
LUSC	cis	rs8133932	0.701	rs2839054	chr21:47328449	A/G	cg14185626	chr21:47401492	COL6A1	0.44	5.68	0.3	2.98e-8	Schizophrenia;
LUSC	cis	rs8062405	0.688	rs3924376	chr16:28925978	T/C	cg05966235	chr16:28915196	ATP2A1	-0.34	-5.74	-0.3	2.16e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg22166914	chr1:53195759	ZYG11B	0.68	11.33	0.53	2.09e-25	Monocyte count;
LUSC	trans	rs1459104	0.714	rs1851614	chr11:54836269	C/T	cg03929089	chr4:120376271	NA	0.75	6.45	0.33	3.92e-10	Body mass index;
LUSC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.18	15.2	0.64	5.15e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs983392	0.667	rs631853	chr11:59944898	T/G	cg20284999	chr11:59952153	MS4A6A	0.36	6.36	0.33	6.5e-10	Alzheimer's disease (late onset);
LUSC	trans	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg25214090	chr10:38739885	LOC399744	0.42	6.45	0.33	4.03e-10	Corneal astigmatism;
LUSC	cis	rs10740039	0.846	rs10761529	chr10:62386810	C/G	cg18175470	chr10:62150864	ANK3	-0.45	-6.89	-0.35	2.8e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.53	-8.87	-0.44	4.4e-17	Blood metabolite levels;
LUSC	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.36	-0.33	6.79e-10	Response to antipsychotic treatment;
LUSC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg00409905	chr10:38381863	ZNF37A	-0.4	-6.79	-0.35	5e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg24675056	chr1:15929824	NA	0.47	8.07	0.4	1.32e-14	Systolic blood pressure;
LUSC	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.36	-0.56	3.88e-29	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.51	8.02	0.4	1.79e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs10186029	0.676	rs4673720	chr2:213941581	G/A	cg08319019	chr2:214017104	IKZF2	0.61	8.95	0.44	2.55e-17	Systemic sclerosis;
LUSC	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.04	-0.36	1.13e-11	Menopause (age at onset);
LUSC	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg24642439	chr20:33292090	TP53INP2	0.47	7.02	0.36	1.23e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg05585544	chr11:47624801	NA	-0.44	-7.65	-0.39	2.15e-13	Subjective well-being;
LUSC	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-8.07	-0.4	1.29e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs55675132	0.833	rs7543383	chr1:115647658	T/A	cg01522456	chr1:115632236	TSPAN2	-0.46	-5.82	-0.3	1.39e-8	Schizophrenia;
LUSC	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg05535760	chr7:792225	HEATR2	0.77	9.06	0.44	1.13e-17	Cerebrospinal P-tau181p levels;
LUSC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.76	-12.12	-0.55	2.8e-28	Height;
LUSC	cis	rs4664308	1.000	rs56297666	chr2:160902023	G/C	cg03641300	chr2:160917029	PLA2R1	-0.65	-10.91	-0.51	6.44e-24	Idiopathic membranous nephropathy;
LUSC	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg24375607	chr4:120327624	NA	0.79	11.7	0.54	1.01e-26	Corneal astigmatism;
LUSC	cis	rs7107174	1.000	rs2512550	chr11:77943848	C/T	cg02023728	chr11:77925099	USP35	0.43	6.28	0.33	1.04e-9	Testicular germ cell tumor;
LUSC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.44	5.78	0.3	1.7e-8	Renal function-related traits (BUN);
LUSC	cis	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08380311	chr19:3435252	NFIC	0.85	15.96	0.66	5.12e-43	Height;
LUSC	cis	rs11039100	0.834	rs11039053	chr11:5812827	T/C	cg05234568	chr11:5960015	NA	-0.51	-5.78	-0.3	1.71e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg13206674	chr6:150067644	NUP43	0.58	9.08	0.45	9.37e-18	Lung cancer;
LUSC	cis	rs6987853	0.966	rs1901282	chr8:42392942	C/G	cg09913449	chr8:42400586	C8orf40	0.49	8.3	0.41	2.56e-15	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs870142	0.922	rs10012393	chr4:4637186	G/A	cg04017672	chr1:182359056	GLUL	0.41	6.12	0.32	2.59e-9	Congenital heart disease;
LUSC	cis	rs4561483	0.799	rs33635	chr16:11991944	C/T	cg08843971	chr16:11963173	GSPT1	-0.44	-6.3	-0.33	9.13e-10	Testicular germ cell tumor;
LUSC	cis	rs6554196	0.508	rs7695300	chr4:55512066	T/C	cg18836493	chr4:55524333	KIT	-0.45	-7.92	-0.4	3.67e-14	Monocyte count;
LUSC	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg26102564	chr10:131424627	MGMT	0.38	5.93	0.31	7.52e-9	Response to temozolomide;
LUSC	cis	rs6546537	0.911	rs4852898	chr2:69872797	C/T	cg10773587	chr2:69614142	GFPT1	-0.53	-7.92	-0.4	3.65e-14	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg05340658	chr4:99064831	C4orf37	-0.47	-7.43	-0.38	8.98e-13	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg01966878	chr4:90757139	SNCA	-0.42	-5.92	-0.31	7.9e-9	Neuroticism;
LUSC	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.91	0.31	8.37e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg04450456	chr4:17643702	FAM184B	0.37	6.33	0.33	7.86e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.26	0.64	2.81e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg15921436	chr17:44337874	NA	-0.7	-10.71	-0.51	3.28e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-6.22	-0.32	1.51e-9	Asthma;
LUSC	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-7.09	-0.36	8.2e-12	Mood instability;
LUSC	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg23711669	chr6:146136114	FBXO30	-0.89	-16.73	-0.68	4.43e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.7	10.83	0.51	1.22e-23	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13980079	chr4:1980637	WHSC1	0.39	5.99	0.31	5.35e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.97	-0.31	6.07e-9	Resting heart rate;
LUSC	cis	rs2742417	1.000	rs2673034	chr3:45755138	A/G	cg09608765	chr3:45636137	LIMD1	-0.39	-7.81	-0.39	7.4e-14	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg06096015	chr1:231504339	EGLN1	0.55	9.59	0.46	2.18e-19	Hemoglobin concentration;
LUSC	cis	rs6445967	0.530	rs12634132	chr3:58409082	A/G	cg13705284	chr3:58523313	ACOX2	-0.27	-5.71	-0.3	2.46e-8	Platelet count;
LUSC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.85	-14.94	-0.63	5.1e-39	Neuroticism;
LUSC	cis	rs2871473	1.000	rs2871473	chr2:103107280	A/C	cg09003973	chr2:102972529	NA	0.64	7.28	0.37	2.36e-12	Blood protein levels;
LUSC	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg18132916	chr6:79620363	NA	-0.38	-5.81	-0.3	1.44e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg20991723	chr1:152506922	NA	0.48	8.82	0.43	6.41e-17	Hair morphology;
LUSC	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.47	-0.42	7.8e-16	Response to antipsychotic treatment;
LUSC	cis	rs7903847	0.642	rs11817852	chr10:99158426	C/T	cg20016023	chr10:99160130	RRP12	-0.33	-8.04	-0.4	1.59e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4654899	0.965	rs61779124	chr1:21513306	C/T	cg01072550	chr1:21505969	NA	-0.55	-8.54	-0.42	4.89e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.79	10.76	0.51	2.27e-23	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg15383120	chr6:291909	DUSP22	-0.44	-6.47	-0.33	3.59e-10	Menopause (age at onset);
LUSC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg20821713	chr7:1055600	C7orf50	-0.46	-7.42	-0.38	9.63e-13	Longevity;Endometriosis;
LUSC	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.18	0.41	6.07e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4478858	0.746	rs12136121	chr1:31689743	G/C	cg00250761	chr1:31883323	NA	0.37	9.4	0.46	8.95e-19	Alcohol dependence;
LUSC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg09877947	chr5:131593287	PDLIM4	0.59	10.02	0.48	7.64e-21	Acylcarnitine levels;
LUSC	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg03563238	chr19:33554763	RHPN2	-0.41	-6.47	-0.33	3.59e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs17401966	0.558	rs6541090	chr1:10402842	A/G	cg17425144	chr1:10567563	PEX14	-0.34	-6.16	-0.32	2.1e-9	Hepatocellular carcinoma;
LUSC	trans	rs8030485	0.571	rs939654	chr15:79415218	G/A	cg16586880	chr8:140854244	TRAPPC9	-0.37	-5.98	-0.31	5.84e-9	Left ventricle wall thickness;
LUSC	cis	rs3808502	0.527	rs2736389	chr8:11161310	C/A	cg27411982	chr8:10470053	RP1L1	0.38	5.73	0.3	2.21e-8	Neuroticism;
LUSC	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg11189052	chr15:85197271	WDR73	0.48	5.93	0.31	7.56e-9	Schizophrenia;
LUSC	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg08645402	chr16:4508243	NA	0.51	8.42	0.42	1.15e-15	Schizophrenia;
LUSC	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.24	-0.32	1.3e-9	Bipolar disorder;
LUSC	trans	rs4714291	0.963	rs1304602	chr6:40013471	T/G	cg02267698	chr19:7991119	CTXN1	0.54	7.47	0.38	7.11e-13	Strep throat;
LUSC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg22105103	chr4:187893119	NA	0.71	13.88	0.6	6.72e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	11.7	0.54	1.01e-26	Colorectal cancer;
LUSC	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg01528321	chr10:82214614	TSPAN14	1.1	12.08	0.55	3.98e-28	Post bronchodilator FEV1;
LUSC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg25258033	chr6:167368657	RNASET2	0.46	6.71	0.34	8.33e-11	Crohn's disease;
LUSC	trans	rs61931739	0.649	rs861526	chr12:33726434	A/G	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs11264213	0.901	rs72661632	chr1:36420715	G/A	cg27506609	chr1:36549197	TEKT2	0.7	7.98	0.4	2.39e-14	Schizophrenia;
LUSC	trans	rs4811340	0.600	rs6068252	chr20:51180373	A/C	cg15736553	chr3:11610338	VGLL4	0.34	6.13	0.32	2.54e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	14.98	0.63	3.56e-39	Platelet count;
LUSC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg03538708	chr1:25844672	NA	-0.35	-5.69	-0.3	2.74e-8	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs67072384	1.000	rs55957377	chr11:72445476	A/G	cg04827223	chr11:72435913	ARAP1	-0.82	-7.76	-0.39	1.04e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg00191853	chr8:101177733	SPAG1	-0.41	-6.56	-0.34	2.08e-10	Atrioventricular conduction;
LUSC	cis	rs4363385	0.510	rs61811886	chr1:153035743	G/A	cg25856811	chr1:152973957	SPRR3	-0.38	-6.2	-0.32	1.63e-9	Inflammatory skin disease;
LUSC	cis	rs10743315	0.778	rs10841184	chr12:19370768	T/G	cg02471346	chr12:19282374	PLEKHA5	-0.53	-6.68	-0.34	1.01e-10	Gut microbiota (bacterial taxa);
LUSC	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg22437258	chr11:111473054	SIK2	0.52	7.03	0.36	1.2e-11	Primary sclerosing cholangitis;
LUSC	cis	rs13223928	0.536	rs12700594	chr7:3156701	G/A	cg19214707	chr7:3157722	NA	0.44	9.04	0.44	1.33e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.29	-5.9	-0.31	8.87e-9	Total body bone mineral density;
LUSC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg13206674	chr6:150067644	NUP43	0.59	9.34	0.46	1.37e-18	Lung cancer;
LUSC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-6.75	-0.35	6.74e-11	Personality dimensions;
LUSC	cis	rs4285028	0.747	rs58367397	chr3:121451700	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-12.86	-0.58	5.27e-31	Multiple sclerosis;
LUSC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg08219700	chr8:58056026	NA	0.5	6.18	0.32	1.84e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs8099014	1.000	rs4384676	chr18:56125973	T/A	cg12907477	chr18:56117327	MIR122	0.43	6.86	0.35	3.44e-11	Platelet count;
LUSC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.17	-0.37	4.88e-12	Alzheimer's disease (late onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00815440	chr19:29704028	UQCRFS1	-0.41	-6.0	-0.31	5.1e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg13149276	chr1:160232740	DCAF8	0.41	6.16	0.32	2.14e-9	Triglycerides;
LUSC	trans	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg06606381	chr12:133084897	FBRSL1	0.45	6.05	0.31	3.89e-9	Depression;
LUSC	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg21880101	chr17:80066754	CCDC57	-0.31	-5.8	-0.3	1.54e-8	Life satisfaction;
LUSC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg13319975	chr6:146136371	FBXO30	-0.53	-7.83	-0.39	6.65e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg10356904	chr22:49881777	NA	-0.33	-7.3	-0.37	2.15e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.37	-0.42	1.6e-15	Systolic blood pressure;
LUSC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.34	0.56	4.44e-29	Prudent dietary pattern;
LUSC	cis	rs6558174	0.965	rs7831119	chr8:22489678	C/T	cg03733263	chr8:22462867	KIAA1967	-0.46	-6.27	-0.32	1.12e-9	Breast cancer;
LUSC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg21782813	chr7:2030301	MAD1L1	0.45	7.41	0.38	1.02e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	9.51	0.46	4.03e-19	Lung cancer in ever smokers;
LUSC	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg03585969	chr10:35415529	CREM	0.6	8.77	0.43	9.27e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs73001065	0.551	rs79954596	chr19:19548643	T/G	cg03709012	chr19:19516395	GATAD2A	0.97	9.4	0.46	8.69e-19	LDL cholesterol;
LUSC	cis	rs80130819	0.515	rs1635536	chr12:48385945	A/G	cg24011408	chr12:48396354	COL2A1	0.54	6.7	0.34	8.61e-11	Prostate cancer;
LUSC	cis	rs7789940	0.904	rs73140040	chr7:75936240	C/T	cg15798862	chr7:76129360	DTX2	-0.47	-7.67	-0.39	1.96e-13	Multiple sclerosis;
LUSC	cis	rs7091068	0.616	rs7093903	chr10:95484010	C/T	cg20715218	chr10:95462985	C10orf4	-0.6	-6.81	-0.35	4.55e-11	Urinary tract infection frequency;
LUSC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg09436375	chr6:42928200	GNMT	-0.29	-6.76	-0.35	6.23e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09974566	chr22:32150118	DEPDC5	0.43	6.12	0.32	2.68e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg16362232	chr11:430036	ANO9	0.7	8.64	0.43	2.3e-16	Body mass index;
LUSC	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	14.08	0.61	1.14e-35	Exhaled nitric oxide levels;
LUSC	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg08313168	chr12:7315531	NA	0.48	6.15	0.32	2.2e-9	Lung disease severity in cystic fibrosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07920855	chr1:185286635	IVNS1ABP	0.37	6.01	0.31	4.9e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg15147215	chr3:52552868	STAB1	-0.3	-5.91	-0.31	8.67e-9	Bipolar disorder;
LUSC	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg18964960	chr10:1102726	WDR37	0.62	6.02	0.31	4.72e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.18	0.37	4.54e-12	Mean platelet volume;
LUSC	cis	rs4919687	0.577	rs12765459	chr10:104465687	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-6.02	-0.31	4.64e-9	Colorectal cancer;
LUSC	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg03732007	chr1:2071316	PRKCZ	0.46	7.48	0.38	6.51e-13	Height;
LUSC	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg24531977	chr5:56204891	C5orf35	-0.58	-8.68	-0.43	1.83e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs9443645	0.507	rs1475046	chr6:79461801	G/A	cg05283184	chr6:79620031	NA	-0.37	-7.01	-0.36	1.36e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6942756	0.774	rs2402944	chr7:128951402	G/T	cg02491457	chr7:128862824	NA	-0.47	-7.18	-0.37	4.5e-12	White matter hyperintensity burden;
LUSC	cis	rs73198271	0.653	rs10087742	chr8:8660474	A/G	cg01851573	chr8:8652454	MFHAS1	0.48	8.18	0.41	6.19e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-10.52	-0.5	1.46e-22	Morning vs. evening chronotype;
LUSC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg09904177	chr6:26538194	HMGN4	0.47	7.47	0.38	7.28e-13	Schizophrenia;
LUSC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg05347473	chr6:146136440	FBXO30	-0.58	-10.06	-0.48	5.68e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg14830002	chr1:247616686	OR2B11	-0.52	-7.95	-0.4	2.99e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9420	0.961	rs7121169	chr11:57452543	G/A	cg02958346	chr11:57425731	CLP1	-0.44	-6.44	-0.33	4.18e-10	Schizophrenia;
LUSC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12756686	chr19:29218302	NA	0.72	10.91	0.51	6.58e-24	Methadone dose in opioid dependence;
LUSC	cis	rs6060717	0.536	rs6058356	chr20:34491530	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.67	-0.3	3.14e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs983392	0.679	rs1530914	chr11:60028940	C/T	cg24026212	chr11:59952134	MS4A6A	0.36	6.23	0.32	1.41e-9	Alzheimer's disease (late onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18187726	chr12:69080414	NUP107	0.43	6.22	0.32	1.47e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg13628971	chr7:2884303	GNA12	0.46	6.91	0.35	2.48e-11	Height;
LUSC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.74	11.4	0.53	1.17e-25	Menopause (age at onset);
LUSC	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg03585969	chr10:35415529	CREM	0.6	8.53	0.42	5.07e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-11.57	-0.53	2.96e-26	Monocyte count;
LUSC	cis	rs11024102	1.000	rs4141194	chr11:17011176	A/C	cg15084286	chr11:17036142	PLEKHA7	-0.43	-5.93	-0.31	7.61e-9	Glaucoma (primary angle closure);
LUSC	cis	rs908922	0.887	rs1538084	chr1:152496012	A/C	cg20991723	chr1:152506922	NA	0.52	8.67	0.43	1.94e-16	Hair morphology;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg14627760	chr17:79860435	NPB	0.39	6.18	0.32	1.86e-9	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.64	-0.47	1.44e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs113835537	0.877	rs77239910	chr11:66329639	G/A	cg24851651	chr11:66362959	CCS	0.5	6.13	0.32	2.41e-9	Airway imaging phenotypes;
LUSC	trans	rs12406019	0.548	rs7524877	chr1:78615645	A/G	cg20826526	chr3:156266748	SSR3	-0.45	-6.74	-0.35	7.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08439880	chr3:133502540	NA	-0.38	-6.83	-0.35	4.06e-11	Iron status biomarkers;
LUSC	cis	rs3862435	0.706	rs2238323	chr15:90986403	G/A	cg22089800	chr15:90895588	ZNF774	0.54	5.7	0.3	2.7e-8	Response to exercise (triglyceride level interaction);
LUSC	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg26384229	chr12:38710491	ALG10B	0.69	10.78	0.51	1.84e-23	Morning vs. evening chronotype;
LUSC	cis	rs7894407	0.760	rs1163072	chr10:105024378	C/T	cg05636881	chr10:105038444	INA	-0.35	-5.72	-0.3	2.38e-8	White matter hyperintensity burden;
LUSC	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg14689365	chr7:158441557	NCAPG2	0.55	8.01	0.4	1.94e-14	Height;
LUSC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.75	-0.3	1.98e-8	Personality dimensions;
LUSC	cis	rs4589502	1.000	rs12440279	chr15:67133339	G/A	cg12317470	chr15:67143691	NA	0.66	6.06	0.31	3.76e-9	Lung cancer (smoking interaction);
LUSC	cis	rs2294693	0.945	rs2073015	chr6:41008747	A/G	cg14769373	chr6:40998127	UNC5CL	-0.54	-7.22	-0.37	3.59e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg09462578	chr12:12878428	APOLD1	-0.68	-7.89	-0.4	4.41e-14	Systemic lupus erythematosus;
LUSC	cis	rs7712401	0.601	rs30067	chr5:122293668	A/T	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs1783925	1.000	rs1615640	chr11:125308076	C/G	cg03464685	chr11:125439445	EI24	0.48	6.56	0.34	2.08e-10	Formal thought disorder in schizophrenia;
LUSC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.88	0.66	1.09e-42	Platelet count;
LUSC	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg06713675	chr4:122721982	EXOSC9	0.37	5.95	0.31	6.9e-9	Type 2 diabetes;
LUSC	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg15556689	chr8:8085844	FLJ10661	0.68	11.37	0.53	1.47e-25	Mood instability;
LUSC	cis	rs679087	1.000	rs302317	chr12:29921443	G/A	cg14258853	chr12:29935411	TMTC1	-1.0	-17.05	-0.68	2.48e-47	Schizophrenia;
LUSC	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.7	10.52	0.5	1.55e-22	Corneal astigmatism;
LUSC	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.65	-7.59	-0.38	3.16e-13	Yeast infection;
LUSC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.8	-0.35	4.73e-11	Lung cancer;
LUSC	cis	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg09044154	chr16:88155775	NA	-0.45	-6.49	-0.33	3.18e-10	Menopause (age at onset);
LUSC	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg09699651	chr6:150184138	LRP11	0.44	6.97	0.36	1.74e-11	Testicular germ cell tumor;
LUSC	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	0.91	15.73	0.65	4.16e-42	Alcohol dependence;
LUSC	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg08755490	chr11:65554678	OVOL1	0.4	5.83	0.3	1.31e-8	Acne (severe);
LUSC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.74	-12.97	-0.58	1.92e-31	Aortic root size;
LUSC	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg24342717	chr2:85555507	TGOLN2	-0.74	-12.3	-0.56	6.28e-29	Ear protrusion;
LUSC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.8	12.74	0.57	1.38e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg05347473	chr6:146136440	FBXO30	0.59	9.69	0.47	9.97e-20	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg05528280	chr10:464225	DIP2C	0.37	5.73	0.3	2.24e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15369054	chr17:80825471	TBCD	-0.58	-9.74	-0.47	6.79e-20	Breast cancer;
LUSC	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg21772509	chr8:41503840	NKX6-3	0.66	11.32	0.53	2.26e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs1595825	0.891	rs16826873	chr2:198898222	A/C	cg00982548	chr2:198649783	BOLL	0.53	6.83	0.35	4.02e-11	Ulcerative colitis;
LUSC	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.69	9.5	0.46	4.35e-19	Platelet count;
LUSC	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg14835575	chr10:16859367	RSU1	0.71	9.05	0.44	1.18e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs4356932	1.000	rs4859595	chr4:76950062	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.74	0.3	2.07e-8	Blood protein levels;
LUSC	cis	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg17469321	chr7:55412551	NA	0.66	10.62	0.5	6.87e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25134081	chr14:64931936	AKAP5	-1.01	-8.5	-0.42	6.57e-16	Cognitive performance;
LUSC	cis	rs9920506	0.536	rs11072768	chr15:78929478	A/C	cg05914723	chr15:78953907	NA	-0.34	-5.69	-0.3	2.8e-8	Post bronchodilator FEV1;
LUSC	trans	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg06636001	chr8:8085503	FLJ10661	0.44	5.95	0.31	6.68e-9	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg11887960	chr12:57824829	NA	0.48	6.47	0.33	3.46e-10	Obesity-related traits;
LUSC	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.81e-20	Migraine;Coronary artery disease;
LUSC	cis	rs2236918	0.710	rs1635510	chr1:242027500	G/T	cg17736920	chr1:242011382	EXO1	0.4	6.37	0.33	6.43e-10	Menopause (age at onset);
LUSC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg09359103	chr1:154839909	KCNN3	-0.73	-17.8	-0.7	2.59e-50	Prostate cancer;
LUSC	cis	rs9902453	0.967	rs4473252	chr17:28454423	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.19	0.41	5.57e-15	Coffee consumption (cups per day);
LUSC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg07424592	chr7:64974309	NA	0.69	6.08	0.32	3.28e-9	Diabetic kidney disease;
LUSC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.51	-0.42	5.93e-16	Chronic sinus infection;
LUSC	cis	rs9296092	0.517	rs62405949	chr6:33522800	G/A	cg13560919	chr6:33536144	NA	-0.82	-15.68	-0.65	6.77e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs6906287	0.647	rs10457338	chr6:118784018	T/C	cg21191810	chr6:118973309	C6orf204	0.33	6.0	0.31	5.17e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg18681998	chr4:17616180	MED28	0.84	15.29	0.64	2.27e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg25566285	chr7:158114605	PTPRN2	0.31	5.74	0.3	2.15e-8	Calcium levels;
LUSC	cis	rs2108225	0.900	rs7805114	chr7:107450033	G/T	cg18560240	chr7:107437656	SLC26A3	0.41	6.31	0.33	8.65e-10	Ulcerative colitis;
LUSC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.91	-0.31	8.53e-9	Tonsillectomy;
LUSC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.81	-0.35	4.6e-11	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	1.95e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12541635	0.677	rs1496180	chr8:106973877	T/G	cg10147462	chr8:107024639	NA	0.64	12.92	0.58	3.03e-31	Age of smoking initiation;
LUSC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.54e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs858239	0.601	rs10263110	chr7:23160551	G/A	cg23682824	chr7:23144976	KLHL7	0.39	5.69	0.3	2.85e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg14458575	chr2:238380390	NA	0.69	8.22	0.41	4.52e-15	Prostate cancer;
LUSC	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.62	0.34	1.4e-10	IgG glycosylation;
LUSC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg06494592	chr3:125709126	NA	-0.52	-5.85	-0.3	1.16e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.7e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg21770322	chr7:97807741	LMTK2	0.39	6.89	0.35	2.72e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9287719	0.649	rs58633964	chr2:10736382	T/G	cg00105475	chr2:10696890	NA	0.39	6.3	0.33	9.37e-10	Prostate cancer;
LUSC	trans	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg06521331	chr12:34319734	NA	0.42	6.67	0.34	1.06e-10	Bladder cancer;
LUSC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08280861	chr8:58055591	NA	-0.57	-6.5	-0.33	2.99e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.21	11.24	0.52	4.31e-25	Alzheimer's disease (late onset);
LUSC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg04414720	chr1:150670196	GOLPH3L	0.54	8.32	0.41	2.29e-15	Melanoma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14065121	chr9:77643271	C9orf41	-0.48	-5.96	-0.31	6.29e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs243505	0.660	rs3779037	chr7:148539323	T/C	cg09806900	chr7:148480153	CUL1	0.49	6.44	0.33	4.23e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg11871910	chr12:69753446	YEATS4	0.68	10.47	0.5	2.28e-22	Blood protein levels;
LUSC	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24531977	chr5:56204891	C5orf35	-0.86	-13.82	-0.6	1.11e-34	Initial pursuit acceleration;
LUSC	cis	rs1808579	0.935	rs2510344	chr18:21113285	C/T	cg14672496	chr18:21087552	C18orf8	-0.33	-5.65	-0.3	3.44e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg24829409	chr8:58192753	C8orf71	-0.59	-6.49	-0.33	3.04e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12190007	0.573	rs3006218	chr6:169868769	G/A	ch.6.169577133F	chr6:169835210	NA	-0.4	-6.03	-0.31	4.38e-9	Obesity-related traits;
LUSC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg25036284	chr2:26402008	FAM59B	-0.68	-9.4	-0.46	9.11e-19	Gut microbiome composition (summer);
LUSC	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg25456477	chr12:86230367	RASSF9	0.4	6.92	0.35	2.34e-11	Major depressive disorder;
LUSC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	5.78	0.3	1.69e-8	Parkinson's disease;
LUSC	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg22508957	chr16:3507546	NAT15	0.36	5.87	0.31	1.03e-8	Body mass index (adult);
LUSC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.52	10.35	0.49	5.86e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg05501817	chr11:14380813	RRAS2	-0.57	-8.9	-0.44	3.72e-17	Sense of smell;
LUSC	trans	rs62238980	0.614	rs4821015	chr22:32402549	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs9815354	0.812	rs73071356	chr3:41829486	C/T	cg03022575	chr3:42003672	ULK4	0.85	8.62	0.43	2.78e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg18230493	chr5:56204884	C5orf35	-0.89	-13.72	-0.6	2.68e-34	Initial pursuit acceleration;
LUSC	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	7.53	0.38	4.66e-13	Iron status biomarkers;
LUSC	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-9.56	-0.46	2.74e-19	Morning vs. evening chronotype;
LUSC	trans	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg13565492	chr6:43139072	SRF	-0.57	-6.68	-0.34	1.03e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-10.07	-0.48	5.45e-21	Gut microbiome composition (summer);
LUSC	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg00321850	chr1:175162397	KIAA0040	-0.44	-7.58	-0.38	3.4e-13	Alcohol dependence;
LUSC	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg03806693	chr22:41940476	POLR3H	-0.54	-7.39	-0.37	1.18e-12	Neuroticism;
LUSC	trans	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.8	12.24	0.56	1.05e-28	Colorectal cancer;
LUSC	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	9.0	0.44	1.76e-17	Retinal vascular caliber;
LUSC	trans	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.43	-6.22	-0.32	1.47e-9	Platelet distribution width;
LUSC	trans	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg09781936	chr22:19749961	TBX1	-0.34	-6.02	-0.31	4.72e-9	Inflammatory bowel disease;
LUSC	cis	rs200367988	1	rs200367988	chr10:122674849	G/A	cg14149699	chr10:122610679	WDR11	-0.46	-7.01	-0.36	1.29e-11	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;
LUSC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg18850929	chr19:1828978	REXO1	-0.42	-6.19	-0.32	1.78e-9	Bipolar disorder;
LUSC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg08270630	chr22:50330655	NA	-0.43	-6.42	-0.33	4.8e-10	Schizophrenia;
LUSC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg03036452	chr22:46663545	TTC38	0.54	5.82	0.3	1.41e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg05926928	chr17:57297772	GDPD1	0.62	8.69	0.43	1.59e-16	Schizophrenia;
LUSC	cis	rs62400317	0.762	rs1329711	chr6:44963401	A/G	cg18551225	chr6:44695536	NA	-0.43	-6.96	-0.36	1.76e-11	Total body bone mineral density;
LUSC	cis	rs4363385	0.510	rs61811886	chr1:153035743	G/A	cg00922841	chr1:152955080	SPRR1A	-0.37	-6.11	-0.32	2.84e-9	Inflammatory skin disease;
LUSC	cis	rs360798	0.532	rs1553832	chr2:63013515	C/G	cg17519650	chr2:63277830	OTX1	-0.52	-7.3	-0.37	2.16e-12	Coronary artery disease;
LUSC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg13939156	chr17:80058883	NA	-0.33	-6.52	-0.34	2.63e-10	Life satisfaction;
LUSC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg23649088	chr2:200775458	C2orf69	0.53	7.25	0.37	2.9e-12	Schizophrenia;
LUSC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.2	16.31	0.67	2.22e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-0.58	-9.19	-0.45	4.34e-18	Breast cancer;
LUSC	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg00982548	chr2:198649783	BOLL	-0.57	-7.13	-0.36	6.43e-12	Ulcerative colitis;
LUSC	cis	rs10743315	0.557	rs74465549	chr12:19344365	A/C	cg02471346	chr12:19282374	PLEKHA5	0.69	5.74	0.3	2.09e-8	Gut microbiota (bacterial taxa);
LUSC	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg03894339	chr8:19674705	INTS10	0.55	7.65	0.39	2.22e-13	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg14343924	chr8:8086146	FLJ10661	0.45	6.31	0.33	9.04e-10	Myopia (pathological);
LUSC	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.38	6.21	0.32	1.6e-9	Response to antipsychotic treatment;
LUSC	trans	rs459571	0.959	rs455381	chr9:136905577	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.76	-12.5	-0.56	1.17e-29	Platelet distribution width;
LUSC	cis	rs11690462	0.817	rs7571948	chr2:26542155	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.48	6.17	0.32	2.03e-9	Coronary artery disease;
LUSC	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.76	0.35	6.23e-11	Educational attainment;
LUSC	cis	rs3744061	0.569	rs2240769	chr17:74718155	C/T	cg27546012	chr17:74684504	MXRA7	-0.46	-7.68	-0.39	1.75e-13	Retinal arteriolar caliber;
LUSC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg21918786	chr6:109611834	NA	-0.42	-7.36	-0.37	1.41e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg22823121	chr1:150693482	HORMAD1	0.59	9.09	0.45	9.12e-18	Tonsillectomy;
LUSC	cis	rs12286929	0.607	rs10891808	chr11:115071301	T/C	cg04055981	chr11:115044050	NA	-0.42	-7.51	-0.38	5.28e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9296095	1.000	rs5745582	chr6:33546498	C/T	cg14003231	chr6:33640908	ITPR3	0.46	7.16	0.36	5.28e-12	Platelet count;
LUSC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg14440974	chr22:39074834	NA	-0.38	-6.37	-0.33	6.2e-10	Menopause (age at onset);
LUSC	cis	rs7215564	0.908	rs2316061	chr17:78663660	A/G	cg09596252	chr17:78655493	RPTOR	0.54	5.87	0.31	1.04e-8	Myopia (pathological);
LUSC	cis	rs983392	0.679	rs600064	chr11:60013451	A/G	cg02771260	chr11:59836817	MS4A3	0.37	6.16	0.32	2.12e-9	Alzheimer's disease (late onset);
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11829371	chr17:981724	ABR	0.45	6.1	0.32	2.95e-9	Neuroticism;
LUSC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg11859384	chr17:80120422	CCDC57	0.36	5.65	0.3	3.4e-8	Life satisfaction;
LUSC	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg27432699	chr2:27873401	GPN1	0.79	14.87	0.63	9.46e-39	Oral cavity cancer;
LUSC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg06238570	chr21:40685208	BRWD1	0.48	7.37	0.37	1.34e-12	Cognitive function;
LUSC	cis	rs9650315	0.586	rs13249464	chr8:57208233	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.8	0.39	7.83e-14	Height;
LUSC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg25019033	chr10:957182	NA	-0.49	-6.3	-0.33	9.18e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg06808227	chr14:105710500	BRF1	-0.67	-10.31	-0.49	8.31e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg23711669	chr6:146136114	FBXO30	0.76	13.72	0.6	2.65e-34	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg03929089	chr4:120376271	NA	-0.83	-12.09	-0.55	3.76e-28	Coronary artery disease;
LUSC	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.38	0.49	4.53e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.45	-8.2	-0.41	5.2e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg26441486	chr22:50317300	CRELD2	-0.54	-8.21	-0.41	4.86e-15	Schizophrenia;
LUSC	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.07	-25.35	-0.81	7.98e-80	Colorectal cancer;
LUSC	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg22532475	chr10:104410764	TRIM8	0.26	6.2	0.32	1.64e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09713877	chr2:85198553	KCMF1	-0.42	-6.38	-0.33	6e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs1147199	0.585	rs2579375	chr9:87261958	T/C	cg18287975	chr5:88178977	MEF2C	0.72	6.13	0.32	2.45e-9	Body mass index;
LUSC	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg13390004	chr1:15929781	NA	0.42	6.98	0.36	1.61e-11	Systolic blood pressure;
LUSC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg14784868	chr12:69753453	YEATS4	-0.44	-5.69	-0.3	2.84e-8	Response to diuretic therapy;
LUSC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg17252645	chr8:143867129	LY6D	-0.54	-10.28	-0.49	1.02e-21	Urinary tract infection frequency;
LUSC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.65	0.47	1.35e-19	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg08477640	chr19:41863820	B9D2	-0.44	-6.72	-0.35	7.69e-11	Migraine;Coronary artery disease;
LUSC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg25838465	chr1:92012736	NA	-0.76	-15.54	-0.65	2.24e-41	Breast cancer;
LUSC	trans	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.94	0.55	1.29e-27	Exhaled nitric oxide output;
LUSC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg13683864	chr3:40499215	RPL14	-1.0	-16.94	-0.68	6.89e-47	Renal cell carcinoma;
LUSC	cis	rs17014483	0.749	rs2860408	chr4:89639032	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.69	6.08	0.32	3.28e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-9.53	-0.46	3.27e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.77	-11.14	-0.52	1.05e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg11984989	chr7:158649758	WDR60	1.06	21.01	0.75	4.78e-63	Height;
LUSC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-15.62	-0.65	1.1e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg16524733	chr11:117070046	TAGLN	0.3	5.73	0.3	2.2e-8	Blood protein levels;
LUSC	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg17691542	chr6:26056736	HIST1H1C	0.52	7.08	0.36	8.65e-12	Iron status biomarkers;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00923919	chr22:26879581	HPS4;SRRD	-0.4	-6.29	-0.33	9.96e-10	Electrocardiographic conduction measures;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg23558158	chr2:220094171	ANKZF1;ATG9A	0.39	6.05	0.31	3.84e-9	Educational attainment (years of education);
LUSC	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg02275930	chr1:2372054	NA	-0.54	-7.85	-0.39	5.56e-14	Non-obstructive azoospermia;
LUSC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.92	0.31	7.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-5.84	-0.3	1.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9905704	0.633	rs2680687	chr17:56491966	T/C	cg19466818	chr17:56409534	MIR142	-0.32	-5.88	-0.31	1e-8	Testicular germ cell tumor;
LUSC	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg02569458	chr12:86230093	RASSF9	0.42	6.68	0.34	9.91e-11	Major depressive disorder;
LUSC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	6.11	0.32	2.7e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg17127132	chr2:85788382	GGCX	0.47	7.6	0.38	3.01e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.48	8.21	0.41	4.74e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg27661571	chr11:113659931	NA	-0.6	-7.26	-0.37	2.74e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs1044826	0.642	rs9826544	chr3:139162831	A/G	cg00490450	chr3:139108681	COPB2	0.49	7.74	0.39	1.18e-13	Obesity-related traits;
LUSC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.7	-9.79	-0.47	4.75e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs6484504	0.600	rs208063	chr11:31159777	C/T	cg26647111	chr11:31128758	NA	-0.41	-6.05	-0.31	3.84e-9	Red blood cell count;
LUSC	trans	rs724744	0.772	rs1772078	chr6:22353844	G/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.19	-0.32	1.77e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01341218	chr17:43662625	NA	0.77	11.18	0.52	7.31e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs4650994	0.525	rs4316329	chr1:178509333	C/T	cg05059571	chr16:84539110	KIAA1609	-0.47	-9.02	-0.44	1.55e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg09877947	chr5:131593287	PDLIM4	-0.37	-6.0	-0.31	5.25e-9	Blood metabolite levels;
LUSC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg09034736	chr1:150693464	HORMAD1	0.49	7.1	0.36	7.45e-12	Tonsillectomy;
LUSC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg15448220	chr1:150897856	SETDB1	0.42	5.95	0.31	6.69e-9	Melanoma;
LUSC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg18404041	chr3:52824283	ITIH1	-0.38	-6.93	-0.35	2.21e-11	Electroencephalogram traits;
LUSC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg25039879	chr17:56429692	SUPT4H1	0.67	8.95	0.44	2.48e-17	Cognitive test performance;
LUSC	cis	rs2637266	1.000	rs7082587	chr10:78386328	C/T	cg18941641	chr10:78392320	NA	0.4	7.33	0.37	1.79e-12	Pulmonary function;
LUSC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg18230493	chr5:56204884	C5orf35	-0.94	-13.79	-0.6	1.43e-34	Initial pursuit acceleration;
LUSC	cis	rs9921338	0.961	rs55707838	chr16:11378075	C/T	cg00044050	chr16:11439710	C16orf75	-0.5	-6.97	-0.36	1.74e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs2692947	0.800	rs4332959	chr2:96549121	C/T	cg23100626	chr2:96804247	ASTL	0.25	5.95	0.31	6.87e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1775715	0.678	rs2778649	chr10:32146803	C/G	cg03015672	chr10:32216066	ARHGAP12	0.36	6.46	0.33	3.77e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg06212747	chr3:49208901	KLHDC8B	0.43	5.83	0.3	1.33e-8	Parkinson's disease;
LUSC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21724239	chr8:58056113	NA	0.85	9.53	0.46	3.26e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg04362960	chr10:104952993	NT5C2	0.59	9.39	0.46	1e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs597583	0.664	rs4938395	chr11:117384673	C/T	cg27161313	chr11:117392002	DSCAML1	0.47	7.78	0.39	9.25e-14	Putamen volume;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13826618	chr2:11828697	NA	-0.41	-6.05	-0.31	3.8e-9	Hepatitis;
LUSC	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.94	16.03	0.66	2.61e-43	Morning vs. evening chronotype;
LUSC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.68	12.13	0.55	2.6e-28	Aortic root size;
LUSC	cis	rs9399401	0.961	rs6570509	chr6:142716286	G/T	cg03128060	chr6:142623767	GPR126	0.33	6.0	0.31	5.15e-9	Chronic obstructive pulmonary disease;
LUSC	trans	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.16	-0.32	2.14e-9	Bladder cancer;
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.49	-8.47	-0.42	8.09e-16	Lymphocyte counts;
LUSC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg25173405	chr17:45401733	C17orf57	0.36	5.72	0.3	2.36e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.47	-0.33	3.44e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1953600	0.870	rs2245168	chr10:81921918	T/C	cg04850286	chr10:81895943	PLAC9	-0.33	-5.72	-0.3	2.32e-8	Sarcoidosis;
LUSC	cis	rs9549260	0.816	rs7328594	chr13:41253764	T/C	cg21288729	chr13:41239152	FOXO1	0.57	8.5	0.42	6.36e-16	Red blood cell count;
LUSC	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-1.26	-20.29	-0.74	3.29e-60	Type 1 diabetes nephropathy;
LUSC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.62	-9.91	-0.48	1.88e-20	Iron status biomarkers;
LUSC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg02018176	chr4:1364513	KIAA1530	0.5	8.93	0.44	2.9e-17	Obesity-related traits;
LUSC	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg05890377	chr2:74357713	NA	0.75	14.26	0.62	2.24e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs4901869	0.966	rs12878614	chr14:59339477	A/C	cg02291164	chr14:59296302	NA	0.58	11.11	0.52	1.31e-24	Panic disorder;
LUSC	cis	rs2271400	0.547	rs167999	chr8:56792685	G/A	cg08894788	chr8:56792171	LYN	-0.43	-5.88	-0.31	1e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
LUSC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18876405	chr7:65276391	NA	0.54	8.62	0.43	2.72e-16	Aortic root size;
LUSC	cis	rs7553864	0.574	rs6576867	chr1:87615796	A/T	cg17420885	chr1:87600446	LOC339524	-0.52	-6.98	-0.36	1.57e-11	Smoking behavior;
LUSC	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg07169764	chr2:136633963	MCM6	-0.85	-11.71	-0.54	8.79e-27	Corneal structure;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27537453	chr16:2732578	KCTD5	0.47	6.65	0.34	1.19e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg22535103	chr8:58192502	C8orf71	-0.57	-6.54	-0.34	2.29e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg02428538	chr16:24856791	SLC5A11	-0.52	-5.8	-0.3	1.51e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg06417522	chr17:66508098	PRKAR1A	0.44	6.13	0.32	2.46e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7192380	0.964	rs6499231	chr16:69588016	A/G	cg26679644	chr16:69762563	NA	0.34	6.07	0.32	3.52e-9	Sjögren's syndrome;
LUSC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.24	0.37	3.13e-12	Mean platelet volume;
LUSC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg25039879	chr17:56429692	SUPT4H1	0.8	10.99	0.52	3.51e-24	Cognitive test performance;
LUSC	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg00857998	chr1:205179979	DSTYK	0.57	8.98	0.44	1.99e-17	Red blood cell count;
LUSC	cis	rs4654899	0.714	rs12401630	chr1:21495049	G/A	cg01072550	chr1:21505969	NA	-0.51	-7.55	-0.38	4.21e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg18827107	chr12:86230957	RASSF9	-0.47	-6.95	-0.36	1.94e-11	Major depressive disorder;
LUSC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	0.92	15.28	0.64	2.43e-40	Breast cancer;
LUSC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	0.93	15.97	0.66	4.83e-43	Menopause (age at onset);
LUSC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg16797656	chr11:68205561	LRP5	0.37	6.11	0.32	2.78e-9	Total body bone mineral density;
LUSC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg24060327	chr5:131705240	SLC22A5	-0.54	-8.94	-0.44	2.71e-17	Acylcarnitine levels;
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg17541715	chr7:1216824	NA	-0.41	-6.36	-0.33	6.59e-10	Longevity;Endometriosis;
LUSC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg07701084	chr6:150067640	NUP43	0.57	8.96	0.44	2.36e-17	Lung cancer;
LUSC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	1.01	13.96	0.61	3.21e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	14.51	0.62	2.45e-37	Platelet count;
LUSC	cis	rs10875595	0.836	rs59933130	chr5:140667303	G/A	cg24830062	chr5:140700576	TAF7	-0.51	-6.25	-0.32	1.23e-9	Pulmonary function decline;
LUSC	cis	rs4654899	1.000	rs4654905	chr1:21509558	A/G	cg01072550	chr1:21505969	NA	-0.55	-8.49	-0.42	7e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg09796270	chr17:17721594	SREBF1	-0.43	-7.44	-0.38	8.5e-13	Total body bone mineral density;
LUSC	cis	rs1030268	0.505	rs80305547	chr7:133259400	A/G	cg10665199	chr7:133106180	EXOC4	0.63	7.12	0.36	6.59e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18876405	chr7:65276391	NA	-0.53	-8.44	-0.42	9.69e-16	Aortic root size;
LUSC	cis	rs225245	0.817	rs225273	chr17:33970935	A/T	cg05299278	chr17:33885742	SLFN14	0.31	6.65	0.34	1.23e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs524023	0.958	rs11231825	chr11:64360274	T/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.33	-0.49	6.6e-22	Urate levels in obese individuals;
LUSC	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.23	-0.41	4.25e-15	Neuroticism;
LUSC	cis	rs2425143	1.000	rs1118233	chr20:34228349	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.54	-0.34	2.27e-10	Blood protein levels;
LUSC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.72	0.43	1.34e-16	Prudent dietary pattern;
LUSC	trans	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg06521331	chr12:34319734	NA	-0.39	-6.0	-0.31	5.25e-9	Bladder cancer;
LUSC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg26659404	chr1:25747437	RHCE	-0.28	-5.88	-0.31	1.01e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg16342193	chr10:102329863	NA	-0.34	-6.21	-0.32	1.57e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg03340356	chr1:67600835	NA	-0.42	-6.71	-0.34	8.21e-11	Psoriasis;
LUSC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08219700	chr8:58056026	NA	0.66	7.9	0.4	3.96e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.48	8.17	0.41	6.27e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg18240062	chr17:79603768	NPLOC4	0.57	9.8	0.47	4.17e-20	Eye color traits;
LUSC	cis	rs34779708	0.931	rs7079205	chr10:35324619	C/T	cg04310649	chr10:35416472	CREM	-0.38	-5.69	-0.3	2.81e-8	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.29	-0.41	2.82e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg04374321	chr14:90722782	PSMC1	0.73	11.56	0.53	3.22e-26	Mortality in heart failure;
LUSC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	0.92	15.3	0.64	2.12e-40	Breast cancer;
LUSC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg12463550	chr7:65579703	CRCP	-0.55	-8.19	-0.41	5.77e-15	Aortic root size;
LUSC	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.64	-0.43	2.3e-16	Response to antipsychotic treatment;
LUSC	cis	rs2012796	1.000	rs10450894	chr14:81825172	T/A	cg02996355	chr14:81879375	NA	0.5	7.25	0.37	2.83e-12	Night sleep phenotypes;
LUSC	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg16006841	chr5:176797999	RGS14	0.63	8.44	0.42	9.53e-16	Urate levels in lean individuals;
LUSC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.81	11.23	0.52	4.73e-25	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs354225	0.544	rs11902987	chr2:54805587	C/T	cg01766943	chr2:54829624	SPTBN1	0.48	7.67	0.39	1.91e-13	Schizophrenia;
LUSC	cis	rs713477	1.000	rs12888234	chr14:55911352	T/A	cg13175173	chr14:55914753	NA	-0.32	-6.74	-0.35	7.01e-11	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs208520	0.837	rs208498	chr6:66931560	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.71	-0.6	2.88e-34	Exhaled nitric oxide output;
LUSC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01788568	chr2:74154043	DGUOK	-0.47	-6.96	-0.36	1.77e-11	Electrocardiographic conduction measures;
LUSC	trans	rs7939886	0.844	rs12421584	chr11:55937410	G/A	cg15704280	chr7:45808275	SEPT13	0.88	6.69	0.34	9.39e-11	Myopia (pathological);
LUSC	trans	rs330048	0.509	rs36111783	chr8:9145588	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	7.12	0.36	6.76e-12	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg03676636	chr4:99064102	C4orf37	0.34	7.45	0.38	8.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2522056	1.000	rs2522056	chr5:131801726	C/T	cg24060327	chr5:131705240	SLC22A5	0.43	5.8	0.3	1.53e-8	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg14664628	chr15:75095509	CSK	0.47	6.53	0.34	2.51e-10	Systemic lupus erythematosus;
LUSC	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg09904177	chr6:26538194	HMGN4	-0.54	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg12292205	chr6:26970375	C6orf41	-0.51	-8.5	-0.42	6.5e-16	Schizophrenia;
LUSC	cis	rs4400599	0.642	rs4072431	chr1:154167116	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.76	-0.3	1.87e-8	Platelet distribution width;
LUSC	cis	rs12995491	0.843	rs1878809	chr2:88518315	C/T	cg18302933	chr2:88491318	NA	-0.32	-6.1	-0.32	2.91e-9	Response to metformin (IC50);
LUSC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg21361702	chr7:150065534	REPIN1	0.46	6.29	0.33	1.01e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs654950	0.934	rs638859	chr1:42001444	A/G	cg06885757	chr1:42089581	HIVEP3	0.41	7.72	0.39	1.41e-13	Airway imaging phenotypes;
LUSC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs16867335	1.000	rs11887445	chr2:181490442	C/T	cg23363182	chr2:181467187	NA	-0.45	-5.91	-0.31	8.35e-9	Survival in rectal cancer;
LUSC	trans	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg18335740	chr13:41363409	SLC25A15	0.78	14.42	0.62	5.56e-37	Lewy body disease;
LUSC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06634786	chr22:41940651	POLR3H	0.51	6.12	0.32	2.59e-9	Vitiligo;
LUSC	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg06627628	chr2:24431161	ITSN2	-0.59	-7.06	-0.36	9.71e-12	Lymphocyte counts;
LUSC	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg05283184	chr6:79620031	NA	-0.57	-11.99	-0.55	8.43e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs354225	0.597	rs4347868	chr2:54830616	G/A	cg26097391	chr2:54893211	SPTBN1	0.42	6.35	0.33	6.91e-10	Schizophrenia;
LUSC	cis	rs7178572	0.568	rs1602925	chr15:77685857	T/C	cg22256960	chr15:77711686	NA	-0.5	-7.92	-0.4	3.57e-14	Type 2 diabetes;
LUSC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg10360139	chr7:1886902	MAD1L1	0.38	5.86	0.31	1.14e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs6084875	0.840	rs1885357	chr20:4727427	G/A	cg07258627	chr20:4721683	PRNT	-0.32	-5.81	-0.3	1.43e-8	Systemic lupus erythematosus;
LUSC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg05738196	chr6:26577821	NA	0.47	6.77	0.35	5.98e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg04369109	chr6:150039330	LATS1	-0.52	-7.5	-0.38	5.95e-13	Lung cancer;
LUSC	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg01884057	chr2:25150051	NA	0.48	11.35	0.53	1.83e-25	Body mass index;
LUSC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	0.99	15.03	0.64	2.29e-39	Obesity-related traits;
LUSC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg09455208	chr3:40491958	NA	-0.54	-9.6	-0.47	1.96e-19	Renal cell carcinoma;
LUSC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08677398	chr8:58056175	NA	0.52	6.08	0.32	3.29e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg20991723	chr1:152506922	NA	0.49	9.22	0.45	3.33e-18	Hair morphology;
LUSC	trans	rs564343	0.563	rs493320	chr11:65832367	C/A	cg26701943	chr11:108369231	KDELC2	-0.46	-6.16	-0.32	2.1e-9	Obesity (early onset extreme);
LUSC	cis	rs4660306	0.677	rs781062	chr1:45932738	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.41	5.66	0.3	3.22e-8	Homocysteine levels;
LUSC	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg07274523	chr3:49395745	GPX1	0.61	9.4	0.46	9.27e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-0.76	-9.13	-0.45	6.5e-18	Refractive error;
LUSC	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg07930552	chr6:133119739	C6orf192	0.59	6.85	0.35	3.5e-11	Type 2 diabetes nephropathy;
LUSC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg24468199	chr11:65410028	SIPA1	-0.54	-7.66	-0.39	2.08e-13	Blood pressure (age interaction);
LUSC	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg02747822	chr19:1826707	REXO1	-0.36	-5.78	-0.3	1.72e-8	Bipolar disorder;
LUSC	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg08085267	chr17:45401833	C17orf57	-0.54	-8.54	-0.42	4.99e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg16434002	chr17:42200994	HDAC5	0.47	6.81	0.35	4.66e-11	Total body bone mineral density;
LUSC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg16535667	chr11:65410126	SIPA1	-0.44	-5.86	-0.31	1.13e-8	Blood pressure (age interaction);
LUSC	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg27631724	chr1:11040367	C1orf127	0.54	9.52	0.46	3.6e-19	Ewing sarcoma;
LUSC	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	0.84	12.06	0.55	4.82e-28	Blood protein levels;
LUSC	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.49	-0.33	3.05e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4917300	0.605	rs4917279	chr8:143095690	C/T	cg25363559	chr8:143086065	NA	-0.32	-7.16	-0.36	5.06e-12	Amyotrophic lateral sclerosis;
LUSC	cis	rs897080	0.515	rs698767	chr2:44576417	A/G	cg00619915	chr2:44497795	NA	-0.39	-5.72	-0.3	2.4e-8	Height;
LUSC	cis	rs6906287	0.647	rs11153763	chr6:118938738	G/A	cg21191810	chr6:118973309	C6orf204	0.32	5.97	0.31	6.09e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.49	-0.33	3.09e-10	Lung cancer;
LUSC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.2	-0.72	6.74e-56	Height;
LUSC	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20135002	chr11:47629003	NA	-0.49	-7.66	-0.39	2.06e-13	Subjective well-being;
LUSC	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg04310649	chr10:35416472	CREM	-0.42	-6.47	-0.33	3.51e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg05283184	chr6:79620031	NA	-0.58	-12.44	-0.56	1.93e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs1728785	0.892	rs9928950	chr16:68557114	G/A	cg02972257	chr16:68554789	NA	0.58	6.9	0.35	2.69e-11	Ulcerative colitis;
LUSC	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	0.88	12.82	0.57	7.43e-31	Coronary artery disease;
LUSC	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	0.65	8.95	0.44	2.6e-17	Platelet distribution width;
LUSC	cis	rs1865721	1.000	rs62089509	chr18:73194519	G/A	cg26385618	chr18:73139727	C18orf62	-0.48	-8.07	-0.4	1.32e-14	Intelligence;
LUSC	cis	rs73195822	0.667	rs55799214	chr12:111229700	G/T	cg12870014	chr12:110450643	ANKRD13A	0.69	6.37	0.33	6.43e-10	Itch intensity from mosquito bite;
LUSC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.67	-10.62	-0.5	6.81e-23	Menarche (age at onset);
LUSC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg13560548	chr3:10150139	C3orf24	0.46	6.26	0.32	1.21e-9	Alzheimer's disease;
LUSC	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg00677455	chr12:58241039	CTDSP2	0.5	7.49	0.38	6.04e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs12692738	0.526	rs355859	chr2:165629520	T/A	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs8077577	0.895	rs13284	chr17:18112130	C/T	cg16794390	chr17:18148240	FLII	0.41	5.75	0.3	2.01e-8	Obesity-related traits;
LUSC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg00343986	chr7:65444356	GUSB	0.44	6.71	0.34	8.31e-11	Aortic root size;
LUSC	cis	rs6577655	0.517	rs6983560	chr8:135584553	C/T	cg17885191	chr8:135476712	NA	-0.56	-7.5	-0.38	5.85e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.72	10.95	0.51	4.7e-24	Type 2 diabetes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21771171	chr6:692465	EXOC2	-0.45	-6.02	-0.31	4.6e-9	Hepatitis;
LUSC	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg25173405	chr17:45401733	C17orf57	-0.37	-5.73	-0.3	2.21e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs16937	0.662	rs10900468	chr1:205163057	A/G	cg00857998	chr1:205179979	DSTYK	0.46	6.45	0.33	4e-10	Schizophrenia;
LUSC	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-7.28	-0.37	2.35e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1045714	0.895	rs4721860	chr7:2639994	C/T	cg24848437	chr7:2645542	IQCE	0.62	6.86	0.35	3.33e-11	Urate levels in lean individuals;
LUSC	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg13010199	chr12:38710504	ALG10B	0.55	8.26	0.41	3.54e-15	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg14552801	chr7:65878734	NA	-0.37	-5.73	-0.3	2.2e-8	Aortic root size;
LUSC	cis	rs72960926	0.744	rs72964209	chr6:74861734	C/T	cg03266952	chr6:74778945	NA	-0.85	-7.25	-0.37	2.94e-12	Metabolite levels (MHPG);
LUSC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.87	-0.31	1.05e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg09034736	chr1:150693464	HORMAD1	0.51	7.51	0.38	5.57e-13	Tonsillectomy;
LUSC	cis	rs41271473	1.000	rs6701241	chr1:228868477	C/G	cg10167378	chr1:228756711	NA	0.53	6.37	0.33	6.16e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg17143192	chr8:8559678	CLDN23	0.61	9.17	0.45	5.05e-18	Obesity-related traits;
LUSC	cis	rs5009270	0.553	rs2188548	chr7:112235267	C/T	cg23628563	chr7:112262597	NA	0.43	5.92	0.31	8.16e-9	Osteoarthritis (hip);
LUSC	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg25457927	chr22:38595422	NA	-0.42	-8.93	-0.44	2.89e-17	Cutaneous nevi;
LUSC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg23719950	chr11:63933701	MACROD1	0.59	7.82	0.39	6.89e-14	Mean platelet volume;
LUSC	cis	rs9807841	0.592	rs7250071	chr19:10765819	A/G	cg09936142	chr19:10668400	KRI1	0.4	6.35	0.33	7.15e-10	Inflammatory skin disease;
LUSC	cis	rs7789940	0.904	rs61294900	chr7:75937212	A/T	cg15798862	chr7:76129360	DTX2	-0.45	-7.15	-0.36	5.43e-12	Multiple sclerosis;
LUSC	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg22139774	chr2:100720529	AFF3	-0.53	-9.53	-0.46	3.37e-19	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg08219700	chr8:58056026	NA	0.45	5.87	0.31	1.07e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2729354	1.000	rs2511983	chr11:57346874	A/G	cg24343310	chr11:57249947	NA	0.35	6.32	0.33	8.15e-10	Blood protein levels;
LUSC	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg04850211	chr1:228464232	OBSCN	-0.35	-5.89	-0.31	9.62e-9	Diastolic blood pressure;
LUSC	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg27373749	chr11:63775612	MACROD1	0.35	6.0	0.31	5.27e-9	Pulse pressure;
LUSC	trans	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg21775007	chr8:11205619	TDH	0.5	6.93	0.35	2.18e-11	Neuroticism;
LUSC	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.24	0.45	3.04e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg13010199	chr12:38710504	ALG10B	-0.6	-9.19	-0.45	4.27e-18	Morning vs. evening chronotype;
LUSC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg26924012	chr15:45694286	SPATA5L1	1.12	20.31	0.74	2.75e-60	Homoarginine levels;
LUSC	trans	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg25214090	chr10:38739885	LOC399744	0.44	6.62	0.34	1.46e-10	Corneal astigmatism;
LUSC	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg23625390	chr15:77176239	SCAPER	-0.61	-9.37	-0.46	1.14e-18	Blood metabolite levels;
LUSC	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg18209359	chr17:80159595	CCDC57	-0.36	-5.82	-0.3	1.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs981844	0.961	rs56148270	chr4:154660874	C/T	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26314531	chr2:26401878	FAM59B	-0.7	-9.6	-0.47	1.92e-19	Gut microbiome composition (summer);
LUSC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg14440974	chr22:39074834	NA	-0.36	-6.03	-0.31	4.42e-9	Menopause (age at onset);
LUSC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.53	-5.75	-0.3	2.05e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9837602	1.000	rs71313585	chr3:99770696	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.92	-0.31	7.91e-9	Breast cancer;
LUSC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg01802117	chr1:53393560	SCP2	0.46	7.51	0.38	5.37e-13	Monocyte count;
LUSC	trans	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg04995722	chr7:26192034	NFE2L3	-0.39	-6.31	-0.33	8.65e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg17971929	chr21:40555470	PSMG1	-0.49	-7.33	-0.37	1.78e-12	Menarche (age at onset);
LUSC	cis	rs2797685	0.898	rs3753503	chr1:7841971	G/A	cg04725166	chr1:7887271	PER3	-0.49	-6.37	-0.33	6.43e-10	Crohn's disease;
LUSC	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg07423050	chr13:99094983	FARP1	-0.53	-9.67	-0.47	1.13e-19	Longevity;
LUSC	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg24812749	chr6:127587940	RNF146	0.73	10.48	0.5	2.02e-22	Breast cancer;
LUSC	cis	rs6961069	0.550	rs62461690	chr7:80245792	C/A	cg04458919	chr7:80252533	CD36	-0.41	-7.04	-0.36	1.09e-11	Platelet count;
LUSC	trans	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.48	0.33	3.25e-10	Corneal astigmatism;
LUSC	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.89	-0.31	9.23e-9	Height;
LUSC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg18477163	chr1:228402036	OBSCN	0.59	10.96	0.51	4.23e-24	Diastolic blood pressure;
LUSC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg10700019	chr8:145984882	NA	0.3	5.67	0.3	3.1e-8	Age at first birth;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg08524221	chr17:74732291	SFRS2;MFSD11	0.4	6.75	0.35	6.66e-11	Triglycerides;
LUSC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg06096015	chr1:231504339	EGLN1	0.56	10.02	0.48	8.05e-21	Hemoglobin concentration;
LUSC	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg08085267	chr17:45401833	C17orf57	-0.43	-6.29	-0.33	9.92e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg26380479	chr7:97908229	NA	0.29	6.53	0.34	2.48e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.48	6.95	0.36	1.88e-11	Schizophrenia;
LUSC	trans	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg25482853	chr8:67687455	SGK3	1.12	15.55	0.65	2.19e-41	Obesity-related traits;
LUSC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg00701064	chr4:6280414	WFS1	0.59	14.09	0.61	1.05e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg17507749	chr15:85114479	UBE2QP1	0.53	6.54	0.34	2.25e-10	Schizophrenia;
LUSC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg05855489	chr10:104503620	C10orf26	0.59	9.49	0.46	4.66e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg06641503	chr3:48959341	ARIH2	-0.39	-5.98	-0.31	5.63e-9	Parkinson's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04125300	chr20:3388262	C20orf194	-0.51	-6.24	-0.32	1.34e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg24642439	chr20:33292090	TP53INP2	0.55	8.19	0.41	5.74e-15	Height;
LUSC	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg22782873	chr19:19639568	YJEFN3	-0.48	-6.11	-0.32	2.7e-9	Bipolar disorder;
LUSC	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.94	-0.36	1.99e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	trans	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg10840412	chr1:235813424	GNG4	0.61	8.54	0.42	4.74e-16	Bipolar disorder;
LUSC	cis	rs9311676	0.656	rs56232415	chr3:58394850	C/T	cg13750441	chr3:58318267	PXK	0.35	6.76	0.35	6.01e-11	Systemic lupus erythematosus;
LUSC	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg11244672	chr19:19639970	YJEFN3	-0.57	-6.94	-0.36	2.02e-11	Bipolar disorder;
LUSC	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg21984481	chr17:79567631	NPLOC4	-0.55	-10.05	-0.48	6.13e-21	Eye color traits;
LUSC	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg07169764	chr2:136633963	MCM6	1.2	18.44	0.71	7.27e-53	Corneal structure;
LUSC	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg17385448	chr1:15911702	AGMAT	0.39	5.93	0.31	7.69e-9	Systolic blood pressure;
LUSC	cis	rs9581857	0.685	rs9319372	chr13:28042796	C/T	cg22138327	chr13:27999177	GTF3A	-0.74	-8.26	-0.41	3.34e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs7903847	0.620	rs7923385	chr10:99117097	T/A	cg08345082	chr10:99160200	RRP12	-0.36	-7.25	-0.37	2.99e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg01733217	chr16:74700730	RFWD3	0.85	15.15	0.64	7.84e-40	Multiple myeloma;
LUSC	cis	rs11195062	0.766	rs1891375	chr10:112001009	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.4	-6.04	-0.31	4.07e-9	Multiple myeloma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05045294	chr13:111214096	RAB20	-0.39	-6.25	-0.32	1.27e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg17173187	chr15:85201210	NMB	0.37	6.51	0.34	2.74e-10	Schizophrenia;
LUSC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg25258033	chr6:167368657	RNASET2	0.36	5.66	0.3	3.2e-8	Primary biliary cholangitis;
LUSC	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	7.42	0.38	9.78e-13	Glomerular filtration rate (creatinine);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13837552	chr12:112819996	NA	-0.49	-6.28	-0.32	1.04e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.46	-6.26	-0.32	1.2e-9	Corneal astigmatism;
LUSC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs997295	0.684	rs4776970	chr15:68080886	A/T	cg08079166	chr15:68083412	MAP2K5	0.32	6.28	0.32	1.08e-9	Motion sickness;
LUSC	cis	rs1832871	0.672	rs7750011	chr6:158746802	A/C	cg07165851	chr6:158734300	TULP4	0.46	6.89	0.35	2.81e-11	Height;
LUSC	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg04362960	chr10:104952993	NT5C2	0.6	9.66	0.47	1.21e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg17507749	chr15:85114479	UBE2QP1	0.53	6.56	0.34	2.09e-10	Schizophrenia;
LUSC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.49	-0.33	3.13e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.8	13.15	0.58	4.19e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg04518342	chr5:131593106	PDLIM4	-0.39	-7.16	-0.36	5.29e-12	Breast cancer;
LUSC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg15103426	chr22:29168792	CCDC117	0.46	6.06	0.31	3.69e-9	Lymphocyte counts;
LUSC	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg06547715	chr2:218990976	CXCR2	0.36	7.3	0.37	2.19e-12	Ulcerative colitis;
LUSC	trans	rs656319	0.513	rs1484641	chr8:9986524	A/C	cg21775007	chr8:11205619	TDH	0.48	6.52	0.34	2.58e-10	Myopia (pathological);
LUSC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.82	0.35	4.36e-11	Platelet count;
LUSC	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.81	-13.82	-0.6	1.12e-34	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.22	0.64	4.2e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg05535760	chr7:792225	HEATR2	0.74	7.33	0.37	1.7e-12	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg17328964	chr8:145687451	CYHR1	0.65	10.75	0.51	2.33e-23	Age at first birth;
LUSC	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.55	-0.42	4.59e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs72949976	0.864	rs62186566	chr2:214024421	G/A	cg08319019	chr2:214017104	IKZF2	-0.65	-10.28	-0.49	1.06e-21	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	0.96	19.94	0.74	7.67e-59	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg26441486	chr22:50317300	CRELD2	0.47	7.14	0.36	5.88e-12	Schizophrenia;
LUSC	trans	rs72674100	1.000	rs17026382	chr4:97995366	A/G	cg09670535	chr1:18959427	PAX7	-0.61	-6.66	-0.34	1.15e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.83	0.3	1.31e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg18306943	chr3:40428807	ENTPD3	0.38	5.86	0.31	1.13e-8	Renal cell carcinoma;
LUSC	trans	rs804280	1.000	rs804281	chr8:11611865	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	9.01	0.44	1.61e-17	Myopia (pathological);
LUSC	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg24011408	chr12:48396354	COL2A1	0.41	6.03	0.31	4.35e-9	Glycated hemoglobin levels;
LUSC	cis	rs9323205	0.634	rs61987266	chr14:51734909	C/T	cg23942311	chr14:51606299	NA	-0.4	-7.55	-0.38	4.22e-13	Cancer;
LUSC	cis	rs240764	0.631	rs6932158	chr6:101246010	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-6.63	-0.34	1.33e-10	Neuroticism;
LUSC	trans	rs7980799	0.935	rs2389194	chr12:33529164	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-6.01	-0.31	4.83e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg22800045	chr5:56110881	MAP3K1	0.77	10.0	0.48	9.42e-21	Initial pursuit acceleration;
LUSC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.88	17.86	0.7	1.47e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs7216064	1.000	rs7223930	chr17:65842186	G/A	cg12091567	chr17:66097778	LOC651250	-0.73	-9.42	-0.46	7.94e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg21643547	chr1:205240462	TMCC2	-0.43	-7.71	-0.39	1.47e-13	Red blood cell count;
LUSC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21984481	chr17:79567631	NPLOC4	-0.59	-11.22	-0.52	5.11e-25	Eye color traits;
LUSC	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg18721089	chr20:30220636	NA	-0.35	-5.97	-0.31	6.21e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-8.66	-0.43	2.05e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg17385448	chr1:15911702	AGMAT	0.37	6.15	0.32	2.19e-9	Systolic blood pressure;
LUSC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg15147215	chr3:52552868	STAB1	-0.29	-5.65	-0.3	3.39e-8	Electroencephalogram traits;
LUSC	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.86	-0.44	4.89e-17	Body mass index;
LUSC	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg16339924	chr4:17578868	LAP3	0.61	9.29	0.45	2.07e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg25206134	chr2:45395956	NA	0.57	6.54	0.34	2.36e-10	Bipolar disorder;
LUSC	trans	rs1864729	1.000	rs2853318	chr8:98283509	A/T	cg08679828	chr8:102218111	ZNF706	-0.85	-7.71	-0.39	1.45e-13	Estradiol plasma levels (breast cancer);
LUSC	trans	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg07211511	chr3:129823064	LOC729375	-0.77	-9.85	-0.47	2.89e-20	Blood pressure (smoking interaction);
LUSC	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg25554036	chr4:6271136	WFS1	0.63	12.98	0.58	1.72e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg16482183	chr6:26056742	HIST1H1C	0.46	6.62	0.34	1.43e-10	Height;
LUSC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-1.14	-16.44	-0.67	6.7e-45	Breast cancer;
LUSC	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.99	-0.36	1.54e-11	Blood metabolite levels;
LUSC	cis	rs926938	0.527	rs360685	chr1:115499795	G/C	cg12756093	chr1:115239321	AMPD1	0.45	6.87	0.35	3.2e-11	Autism;
LUSC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg00933542	chr6:150070202	PCMT1	0.31	6.52	0.34	2.66e-10	Lung cancer;
LUSC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg00166722	chr3:10149974	C3orf24	0.39	5.84	0.3	1.24e-8	Alzheimer's disease;
LUSC	cis	rs7560272	0.538	rs7599453	chr2:73937901	T/G	cg20560298	chr2:73613845	ALMS1	0.41	6.16	0.32	2.14e-9	Schizophrenia;
LUSC	cis	rs9400467	0.528	rs458486	chr6:111696852	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs11051970	0.918	rs73084099	chr12:32539751	C/T	cg02745156	chr12:32552066	NA	0.44	6.92	0.35	2.36e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.31e-15	Tonsillectomy;
LUSC	cis	rs4478858	0.698	rs11802155	chr1:31805012	T/C	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg15848620	chr12:58087721	OS9	-0.56	-7.94	-0.4	3.07e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs506338	0.517	rs1207179	chr11:64450795	C/T	cg19395706	chr11:64412079	NRXN2	0.28	5.75	0.3	1.99e-8	Body mass index;Urate levels;
LUSC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg13397359	chr6:42928475	GNMT	0.58	9.85	0.47	2.9e-20	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg10360139	chr7:1886902	MAD1L1	-0.38	-5.66	-0.3	3.18e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs834811	1.000	rs834811	chr7:135884571	A/G	cg01726295	chr7:135938950	NA	0.37	6.43	0.33	4.38e-10	Post-traumatic stress disorder;
LUSC	cis	rs10992471	0.631	rs2296667	chr9:95274338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.37	-6.48	-0.33	3.27e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12516959	chr21:47718080	NA	0.39	6.39	0.33	5.56e-10	Testicular germ cell tumor;
LUSC	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.53	8.16	0.41	7e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg03599575	chr15:90893182	GABARAPL3	-0.33	-5.66	-0.3	3.3e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg22089800	chr15:90895588	ZNF774	-0.65	-9.76	-0.47	5.71e-20	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.89	-15.03	-0.64	2.32e-39	Schizophrenia;
LUSC	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-1.04	-20.32	-0.74	2.46e-60	Height;
LUSC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg20476274	chr7:133979776	SLC35B4	0.85	16.0	0.66	3.61e-43	Mean platelet volume;
LUSC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg00031303	chr3:195681400	NA	0.68	9.68	0.47	1.11e-19	Pancreatic cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12550816	chr19:47163979	DACT3	-0.45	-5.99	-0.31	5.34e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9513627	1.000	rs3928271	chr13:100186958	G/A	cg25919922	chr13:100150906	NA	0.78	6.56	0.34	2.11e-10	Obesity-related traits;
LUSC	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg13318129	chr22:45737514	FAM118A	0.74	9.07	0.44	1.04e-17	Tonsillectomy;
LUSC	cis	rs79387448	0.638	rs78123896	chr2:103075417	T/C	cg09003973	chr2:102972529	NA	0.97	9.74	0.47	6.57e-20	Gut microbiota (bacterial taxa);
LUSC	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.42	-0.38	1.01e-12	Joint mobility (Beighton score);
LUSC	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs3772130	0.962	rs11719093	chr3:121487686	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.7	10.05	0.48	6.12e-21	Cognitive performance;
LUSC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-0.78	-11.56	-0.53	3.28e-26	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.64	0.54	1.65e-26	Prudent dietary pattern;
LUSC	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg24675056	chr1:15929824	NA	0.46	7.84	0.39	6.02e-14	Systolic blood pressure;
LUSC	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.64	9.79	0.47	4.53e-20	Corneal astigmatism;
LUSC	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg17633681	chr16:88106987	BANP	0.52	9.88	0.48	2.27e-20	Menopause (age at onset);
LUSC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-9.33	-0.45	1.48e-18	Chronic sinus infection;
LUSC	cis	rs7169223	0.653	rs12905740	chr15:79082364	C/T	cg21242079	chr15:79101063	ADAMTS7	-0.42	-6.21	-0.32	1.57e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg26695010	chr11:65641043	EFEMP2	-0.47	-7.1	-0.36	7.54e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg23795048	chr12:9217529	LOC144571	-0.33	-5.82	-0.3	1.4e-8	Sjögren's syndrome;
LUSC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.81	11.59	0.54	2.51e-26	Alzheimer's disease;
LUSC	cis	rs4132509	0.744	rs58594024	chr1:243862702	C/A	cg21452805	chr1:244014465	NA	0.6	6.59	0.34	1.7e-10	RR interval (heart rate);
LUSC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22968622	chr17:43663579	NA	-0.78	-12.12	-0.55	2.81e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs4698048	0.510	rs12509714	chr4:10107091	C/G	cg26043149	chr18:55253948	FECH	0.42	6.68	0.34	9.94e-11	Skin aging (microtopography measurement);
LUSC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21984481	chr17:79567631	NPLOC4	0.73	15.54	0.65	2.39e-41	Eye color traits;
LUSC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	15.14	0.64	8.98e-40	Platelet count;
LUSC	cis	rs6977660	0.660	rs13225400	chr7:19817016	A/G	cg07541023	chr7:19748670	TWISTNB	0.61	6.57	0.34	1.91e-10	Thyroid stimulating hormone;
LUSC	cis	rs977987	0.931	rs8057084	chr16:75492706	G/T	cg03315344	chr16:75512273	CHST6	-0.52	-9.86	-0.47	2.65e-20	Dupuytren's disease;
LUSC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.66	0.63	6.18e-38	Platelet count;
LUSC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg05347473	chr6:146136440	FBXO30	0.56	9.47	0.46	5.19e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg13395646	chr4:1353034	KIAA1530	-0.63	-9.8	-0.47	4.25e-20	Longevity;
LUSC	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg02466173	chr16:30829666	NA	-0.53	-10.24	-0.49	1.36e-21	Dementia with Lewy bodies;
LUSC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-8.27	-0.41	3.29e-15	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.12	-19.94	-0.74	7.72e-59	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.42	-6.2	-0.32	1.68e-9	Schizophrenia;
LUSC	cis	rs926938	0.527	rs360584	chr1:115463181	G/A	cg12756093	chr1:115239321	AMPD1	0.46	7.0	0.36	1.43e-11	Autism;
LUSC	cis	rs8179	0.645	rs10264916	chr7:92286376	A/G	cg15732164	chr7:92237376	CDK6	-0.42	-6.15	-0.32	2.22e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs4629180	0.920	rs4851458	chr2:102108794	T/C	cg04415270	chr2:102091202	RFX8	-0.56	-9.14	-0.45	6.37e-18	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg24562669	chr7:97807699	LMTK2	0.47	8.48	0.42	7.39e-16	Breast cancer;
LUSC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-6.38	-0.33	5.96e-10	High light scatter reticulocyte count;
LUSC	cis	rs4774899	0.872	rs11855648	chr15:57394050	A/G	cg21617494	chr15:57618479	NA	0.37	6.19	0.32	1.77e-9	Urinary tract infection frequency;
LUSC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	0.59	9.38	0.46	1.07e-18	Breast cancer;
LUSC	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-0.84	-13.78	-0.6	1.56e-34	Blood protein levels;
LUSC	cis	rs12900413	0.959	rs28430604	chr15:90313782	C/T	cg24249390	chr15:90295951	MESP1	-0.44	-6.52	-0.34	2.61e-10	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs17401966	0.597	rs2180185	chr1:10246129	C/G	cg19773385	chr1:10388646	KIF1B	-0.4	-7.1	-0.36	7.54e-12	Hepatocellular carcinoma;
LUSC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg00106254	chr7:1943704	MAD1L1	-0.41	-5.97	-0.31	6.05e-9	Schizophrenia;
LUSC	cis	rs738321	0.762	rs4820321	chr22:38579569	T/A	cg25457927	chr22:38595422	NA	-0.42	-8.04	-0.4	1.54e-14	Breast cancer;
LUSC	cis	rs11645898	0.935	rs28419077	chr16:72196776	A/G	cg14768367	chr16:72042858	DHODH	-0.61	-6.74	-0.35	7.01e-11	Blood protein levels;
LUSC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg05347473	chr6:146136440	FBXO30	-0.49	-8.27	-0.41	3.14e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	9.77	0.47	5.27e-20	Eosinophil percentage of white cells;
LUSC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06028605	chr16:24865363	SLC5A11	-0.7	-11.16	-0.52	8.77e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10140922	0.966	rs10132397	chr14:35822447	G/T	cg07166546	chr14:35805898	NA	-0.24	-5.96	-0.31	6.55e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9549260	0.755	rs9532579	chr13:41243458	T/C	cg21288729	chr13:41239152	FOXO1	0.63	9.84	0.47	3.22e-20	Red blood cell count;
LUSC	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg23601095	chr6:26197514	HIST1H3D	-0.68	-6.99	-0.36	1.53e-11	Gout;Renal underexcretion gout;
LUSC	cis	rs6599077	0.951	rs9860449	chr3:40094033	T/A	cg13683864	chr3:40499215	RPL14	-0.57	-7.31	-0.37	2.02e-12	Sleep-related phenotypes;
LUSC	cis	rs10489202	0.632	rs6659713	chr1:168072249	G/T	cg24449463	chr1:168025552	DCAF6	0.62	9.48	0.46	4.92e-19	Schizophrenia;
LUSC	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg24505687	chr6:33548425	BAK1	0.45	6.51	0.34	2.78e-10	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
LUSC	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.66	-8.47	-0.42	7.9e-16	Body mass index;
LUSC	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg21827317	chr3:136751795	NA	0.4	7.21	0.37	3.8e-12	Neuroticism;
LUSC	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg24130564	chr14:104152367	KLC1	0.44	6.42	0.33	4.68e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10465746	0.747	rs1952066	chr1:84436456	T/C	cg10977910	chr1:84465055	TTLL7	0.43	6.29	0.33	1.02e-9	Obesity-related traits;
LUSC	cis	rs134594	1.000	rs20037	chr22:29477841	T/G	cg03665785	chr22:29458676	C22orf31	0.28	5.69	0.3	2.78e-8	Birth weight;
LUSC	cis	rs745570	0.833	rs1696757	chr17:77800743	C/T	cg04986373	chr17:77768687	CBX8	-0.33	-6.49	-0.33	3.17e-10	Breast cancer;
LUSC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg26304593	chr6:42947056	PEX6	-0.52	-8.2	-0.41	5.06e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg15704280	chr7:45808275	SEPT13	0.65	7.19	0.37	4.24e-12	Axial length;
LUSC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg05623727	chr3:50126028	RBM5	0.33	6.11	0.32	2.77e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg06877462	chr1:205807181	PM20D1	0.49	8.82	0.43	6.26e-17	Menarche (age at onset);
LUSC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.69	10.65	0.5	5.38e-23	Aortic root size;
LUSC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.58	0.34	1.86e-10	Lung cancer;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05031797	chr17:60557085	TLK2	-0.47	-6.24	-0.32	1.32e-9	Hepatitis;
LUSC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-7.77	-0.39	9.7e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs73206853	0.841	rs56184938	chr12:110817193	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.07	0.36	9.13e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.14	0.32	2.33e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs806215	1.000	rs712701	chr7:127251188	T/G	cg25922125	chr7:127225783	GCC1	0.58	7.2	0.37	4.04e-12	Type 2 diabetes;
LUSC	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg05855489	chr10:104503620	C10orf26	0.59	9.44	0.46	6.79e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg20887711	chr4:1340912	KIAA1530	0.56	8.64	0.43	2.31e-16	Longevity;
LUSC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19346786	chr7:2764209	NA	-0.44	-6.97	-0.36	1.68e-11	Height;
LUSC	cis	rs3754214	0.823	rs10888579	chr1:150261925	C/T	cg15654264	chr1:150340011	RPRD2	-0.45	-7.29	-0.37	2.25e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6901250	0.610	rs9400964	chr6:117144808	G/T	cg12892004	chr6:117198278	RFX6	0.4	7.68	0.39	1.81e-13	C-reactive protein levels;
LUSC	trans	rs72674100	1.000	rs7672690	chr4:97954777	A/G	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.44e-17	Iron status biomarkers;
LUSC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7180079	1.000	rs7183694	chr15:64538955	G/C	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.82	-0.3	1.38e-8	Monocyte count;
LUSC	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg05941027	chr17:61774174	LIMD2	0.22	5.71	0.3	2.5e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg24644049	chr4:85504048	CDS1	0.88	7.53	0.38	4.81e-13	Skin colour saturation;
LUSC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.84	-0.57	5.88e-31	Platelet count;
LUSC	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg08085267	chr17:45401833	C17orf57	-0.42	-6.25	-0.32	1.25e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg05501817	chr11:14380813	RRAS2	-0.6	-9.17	-0.45	5.03e-18	Sense of smell;
LUSC	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg03733263	chr8:22462867	KIAA1967	0.83	14.01	0.61	2.07e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg22532475	chr10:104410764	TRIM8	-0.25	-6.01	-0.31	4.97e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.95	-0.36	1.97e-11	Neuroticism;
LUSC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06558623	chr16:89946397	TCF25	1.11	9.73	0.47	7.07e-20	Skin colour saturation;
LUSC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg22638593	chr5:131593259	PDLIM4	0.4	6.37	0.33	6.11e-10	Blood metabolite levels;
LUSC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg02187348	chr16:89574699	SPG7	-0.49	-7.68	-0.39	1.77e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18876405	chr7:65276391	NA	0.54	8.35	0.42	1.84e-15	Aortic root size;
LUSC	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg02175503	chr12:58329896	NA	0.61	9.99	0.48	9.8e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs16937	0.662	rs11240376	chr1:205146460	A/G	cg00857998	chr1:205179979	DSTYK	0.46	6.45	0.33	3.99e-10	Schizophrenia;
LUSC	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg13246856	chr1:44399776	ARTN	-0.27	-6.0	-0.31	5.11e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00339695	chr16:24857497	SLC5A11	0.62	9.02	0.44	1.52e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.77	11.37	0.53	1.54e-25	Corneal astigmatism;
LUSC	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg26924012	chr15:45694286	SPATA5L1	0.79	12.5	0.56	1.13e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg26335602	chr6:28129616	ZNF389	-0.42	-5.73	-0.3	2.25e-8	Depression;
LUSC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg06637938	chr14:75390232	RPS6KL1	0.52	8.41	0.42	1.21e-15	Height;
LUSC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03517284	chr6:25882590	NA	0.64	11.21	0.52	5.66e-25	Blood metabolite levels;
LUSC	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg04865166	chr7:105162814	PUS7	0.51	5.67	0.3	3.06e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg12011299	chr4:100065546	ADH4	0.64	10.2	0.49	1.98e-21	Alcohol dependence;
LUSC	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.51	8.04	0.4	1.53e-14	Birth weight;
LUSC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.13	-0.32	2.42e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg22868518	chr11:507468	RNH1	-0.65	-6.12	-0.32	2.61e-9	Body mass index;
LUSC	cis	rs73200209	0.744	rs3741768	chr12:116446445	C/T	cg01776926	chr12:116560359	MED13L	-0.51	-6.0	-0.31	5.27e-9	Total body bone mineral density;
LUSC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg03433033	chr1:76189801	ACADM	0.73	9.54	0.46	3.12e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.17	-0.32	1.94e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3768617	0.811	rs10911232	chr1:183052533	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.64	9.41	0.46	8.24e-19	Fuchs's corneal dystrophy;
LUSC	cis	rs9581857	0.685	rs78595793	chr13:28031881	C/T	cg22138327	chr13:27999177	GTF3A	0.79	8.22	0.41	4.57e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	0.79	13.73	0.6	2.61e-34	Cognitive function;
LUSC	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg04111992	chr7:158790115	NA	-0.37	-5.84	-0.3	1.21e-8	Facial morphology (factor 20);
LUSC	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg26384229	chr12:38710491	ALG10B	0.67	10.54	0.5	1.33e-22	Morning vs. evening chronotype;
LUSC	cis	rs4363385	0.510	rs11588463	chr1:152901984	T/C	cg00922841	chr1:152955080	SPRR1A	-0.39	-6.41	-0.33	4.9e-10	Inflammatory skin disease;
LUSC	cis	rs12575480	0.637	rs6578976	chr11:2095968	T/C	cg15541987	chr11:2077307	NA	-0.41	-6.13	-0.32	2.48e-9	Pursuit maintenance gain;
LUSC	cis	rs2455601	1.000	rs12223690	chr11:8901824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.56	-0.34	2e-10	Schizophrenia;
LUSC	cis	rs225245	0.817	rs225297	chr17:33924587	G/A	cg05299278	chr17:33885742	SLFN14	0.31	6.9	0.35	2.68e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg03264133	chr6:25882463	NA	-0.34	-5.66	-0.3	3.22e-8	Height;
LUSC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	1.36	11.7	0.54	1.01e-26	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs9309473	0.606	rs62149804	chr2:73837006	T/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.34	-0.33	7.34e-10	Metabolite levels;
LUSC	cis	rs9649213	0.519	rs3735258	chr7:97866291	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.69	-9.64	-0.47	1.46e-19	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg06212747	chr3:49208901	KLHDC8B	0.46	5.86	0.31	1.09e-8	Menarche (age at onset);
LUSC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08859206	chr1:53392774	SCP2	-0.55	-9.66	-0.47	1.26e-19	Monocyte count;
LUSC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg06618935	chr21:46677482	NA	-0.37	-7.44	-0.38	8.78e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-8.13	-0.41	8.43e-15	Response to antipsychotic treatment;
LUSC	trans	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-5.95	-0.31	6.74e-9	Depression;
LUSC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg16434002	chr17:42200994	HDAC5	-0.45	-6.19	-0.32	1.75e-9	Total body bone mineral density;
LUSC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg23978390	chr7:1156363	C7orf50	0.52	7.23	0.37	3.36e-12	Longevity;Endometriosis;
LUSC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg27124370	chr19:33622961	WDR88	0.52	6.71	0.34	8.59e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	15.38	0.64	1.02e-40	Platelet count;
LUSC	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg13798780	chr7:105162888	PUS7	0.6	6.46	0.33	3.61e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg19875535	chr5:140030758	IK	0.49	8.09	0.4	1.13e-14	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg21361702	chr7:150065534	REPIN1	0.5	6.51	0.34	2.8e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.6	10.06	0.48	5.68e-21	Lymphocyte counts;
LUSC	cis	rs34421088	0.506	rs4841518	chr8:11145963	G/C	cg21775007	chr8:11205619	TDH	0.49	7.0	0.36	1.43e-11	Neuroticism;
LUSC	cis	rs7940866	0.903	rs1820353	chr11:130870765	A/G	cg12179176	chr11:130786555	SNX19	0.61	9.41	0.46	8.49e-19	Schizophrenia;
LUSC	cis	rs3820068	0.603	rs59475085	chr1:15911131	G/A	cg17385448	chr1:15911702	AGMAT	0.37	5.95	0.31	6.81e-9	Systolic blood pressure;
LUSC	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.4	-6.41	-0.33	4.92e-10	Systemic lupus erythematosus;
LUSC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	0.93	16.11	0.66	1.32e-43	Menopause (age at onset);
LUSC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.36	-7.56	-0.38	3.85e-13	Schizophrenia;
LUSC	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg05802129	chr4:122689817	NA	-0.48	-8.29	-0.41	2.76e-15	Type 2 diabetes;
LUSC	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg00898013	chr13:113819073	PROZ	-0.57	-8.28	-0.41	3.05e-15	Platelet distribution width;
LUSC	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg14458575	chr2:238380390	NA	0.58	7.16	0.36	5.03e-12	Prostate cancer;
LUSC	cis	rs3018712	0.532	rs2513294	chr11:68421194	C/T	cg22747802	chr11:68417633	NA	-0.43	-6.13	-0.32	2.51e-9	Total body bone mineral density;
LUSC	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-5.99	-0.31	5.3e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11072805	1	rs11072805	chr15:79078518	T/C	cg00540400	chr15:79124168	NA	-0.4	-6.99	-0.36	1.46e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	15.83	0.65	1.68e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg19920283	chr7:105172520	RINT1	0.54	5.72	0.3	2.39e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg09436375	chr6:42928200	GNMT	-0.3	-6.88	-0.35	3.04e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08020660	chr16:30076480	ALDOA	-0.4	-6.31	-0.33	9.08e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg19318889	chr4:1322082	MAEA	0.47	7.94	0.4	3.12e-14	Obesity-related traits;
LUSC	cis	rs11630290	0.575	rs7169210	chr15:64165069	T/C	cg12036633	chr15:63758958	NA	0.5	5.91	0.31	8.67e-9	Iris characteristics;
LUSC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.45	-6.79	-0.35	5.08e-11	Breast cancer;
LUSC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg05802129	chr4:122689817	NA	-0.46	-7.79	-0.39	8.59e-14	Type 2 diabetes;
LUSC	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg15848620	chr12:58087721	OS9	-0.41	-5.82	-0.3	1.38e-8	Multiple sclerosis;
LUSC	cis	rs1865721	0.804	rs59187673	chr18:73143964	A/G	cg26385618	chr18:73139727	C18orf62	-0.53	-9.69	-0.47	9.64e-20	Intelligence;
LUSC	cis	rs11997175	0.846	rs6999445	chr8:33732693	G/A	ch.8.33884649F	chr8:33765107	NA	0.56	9.07	0.44	1.01e-17	Body mass index;
LUSC	cis	rs7582720	1.000	rs72928620	chr2:203840973	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.35	0.42	1.88e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs10266483	0.705	rs1111649	chr7:63756813	G/T	cg24201672	chr7:64023550	ZNF680	-0.45	-5.75	-0.3	2.05e-8	Response to statin therapy;
LUSC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15506890	chr2:3487001	NA	-0.58	-9.58	-0.46	2.23e-19	Neurofibrillary tangles;
LUSC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.9	12.53	0.57	8.66e-30	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg00321850	chr1:175162397	KIAA0040	-0.43	-7.3	-0.37	2.06e-12	Alcohol dependence;
LUSC	trans	rs1459104	0.636	rs559362	chr11:55275456	T/G	cg15704280	chr7:45808275	SEPT13	0.62	6.67	0.34	1.09e-10	Body mass index;
LUSC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg03060546	chr3:49711283	APEH	0.71	11.95	0.55	1.23e-27	Resting heart rate;
LUSC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.69	-0.34	9.51e-11	Blood metabolite levels;
LUSC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs11997175	0.510	rs10503953	chr8:33797783	C/T	ch.8.33884649F	chr8:33765107	NA	0.47	6.92	0.35	2.34e-11	Body mass index;
LUSC	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg02696742	chr7:106810147	HBP1	-0.66	-9.26	-0.45	2.62e-18	Osteoarthritis;
LUSC	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg17366294	chr4:99064904	C4orf37	0.59	10.62	0.5	6.67e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg05855489	chr10:104503620	C10orf26	-0.49	-7.47	-0.38	7.25e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg00376283	chr12:123451042	ABCB9	0.66	8.32	0.41	2.27e-15	Neutrophil percentage of white cells;
LUSC	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg06627628	chr2:24431161	ITSN2	-0.62	-9.16	-0.45	5.21e-18	Asthma;
LUSC	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg18681998	chr4:17616180	MED28	0.84	15.64	0.65	9.43e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.15	0.52	9.13e-25	Hypertriglyceridemia;
LUSC	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.71	-0.47	8.47e-20	Joint mobility (Beighton score);
LUSC	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg21132104	chr15:45694354	SPATA5L1	0.4	5.86	0.31	1.1e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.78	-12.27	-0.56	8.07e-29	Pancreatic cancer;
LUSC	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg18721089	chr20:30220636	NA	-0.36	-6.14	-0.32	2.35e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg21545522	chr1:205238299	TMCC2	0.46	8.4	0.42	1.27e-15	Red blood cell count;
LUSC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg12463550	chr7:65579703	CRCP	0.5	7.25	0.37	2.97e-12	Aortic root size;
LUSC	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg18721089	chr20:30220636	NA	-0.35	-6.05	-0.31	3.82e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.74	-0.3	2.12e-8	Ileal carcinoids;
LUSC	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.63	6.79	0.35	5e-11	Schizophrenia;
LUSC	cis	rs7246967	0.611	rs8107724	chr19:22867414	G/A	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs13385	0.769	rs17118785	chr5:139653208	A/G	cg26211634	chr5:139558579	C5orf32	-0.42	-6.06	-0.31	3.76e-9	Atrial fibrillation;
LUSC	cis	rs548181	0.611	rs609200	chr11:125383808	G/A	cg03464685	chr11:125439445	EI24	-1.39	-14.31	-0.62	1.46e-36	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7582720	0.943	rs72936879	chr2:203792628	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg25046584	chr21:32932016	TIAM1	0.5	7.06	0.36	9.52e-12	Cognitive function;Information processing speed;
LUSC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg11663144	chr21:46675770	NA	-0.43	-7.5	-0.38	5.85e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs16910800	0.731	rs55908012	chr11:23191640	G/A	cg20040320	chr11:23191996	NA	-0.59	-7.63	-0.39	2.4e-13	Cancer;
LUSC	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg01733217	chr16:74700730	RFWD3	0.75	12.23	0.56	1.14e-28	Testicular germ cell tumor;
LUSC	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-6.9	-0.35	2.67e-11	Blood metabolite levels;
LUSC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.91	-0.31	8.41e-9	Crohn's disease;
LUSC	cis	rs9473147	0.516	rs7754971	chr6:47590476	C/T	cg02130027	chr6:47444894	CD2AP	0.36	5.76	0.3	1.86e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg04586622	chr2:25135609	ADCY3	0.41	8.63	0.43	2.52e-16	Body mass index;
LUSC	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7605827	0.930	rs1019359	chr2:15524615	T/C	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.51e-22	Colorectal cancer;
LUSC	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg04733989	chr22:42467013	NAGA	-0.41	-6.78	-0.35	5.46e-11	Cognitive function;
LUSC	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg00262122	chr8:11665843	FDFT1	0.4	5.9	0.31	8.84e-9	Neuroticism;
LUSC	trans	rs2262909	0.962	rs73019842	chr19:22249909	T/G	cg05197062	chr11:11642011	GALNTL4	0.56	7.88	0.4	4.75e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6961069	0.708	rs2065668	chr7:80220608	A/G	cg04458919	chr7:80252533	CD36	0.4	7.01	0.36	1.29e-11	Platelet count;
LUSC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-10.38	-0.49	4.55e-22	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-10.39	-0.49	4.15e-22	Alcohol dependence;
LUSC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg20790798	chr5:1857306	NA	-0.5	-8.62	-0.43	2.74e-16	Cardiovascular disease risk factors;
LUSC	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg04398451	chr17:18023971	MYO15A	0.5	8.03	0.4	1.73e-14	Total body bone mineral density;
LUSC	cis	rs35995292	0.534	rs10274968	chr7:38939254	C/T	cg19327137	chr7:38886074	VPS41	0.56	10.52	0.5	1.51e-22	Subjective well-being (multi-trait analysis);
LUSC	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg05865280	chr17:75406074	SEPT9	0.49	10.49	0.5	1.86e-22	Airflow obstruction;
LUSC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19717773	chr7:2847554	GNA12	-0.34	-5.67	-0.3	3.12e-8	Height;
LUSC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg18681998	chr4:17616180	MED28	0.85	15.93	0.66	6.57e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7580658	0.963	rs12622436	chr2:128081682	C/A	cg09760422	chr2:128146352	NA	-0.32	-7.24	-0.37	3.13e-12	Protein C levels;
LUSC	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg24642439	chr20:33292090	TP53INP2	-0.39	-5.74	-0.3	2.07e-8	Height;
LUSC	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	13.16	0.58	3.88e-32	Lung cancer in ever smokers;
LUSC	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.91	0.31	8.5e-9	Rheumatoid arthritis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06547771	chr11:43380393	TTC17	-0.41	-6.14	-0.32	2.34e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1451375	0.712	rs11974297	chr7:50618260	A/G	cg18232548	chr7:50535776	DDC	0.56	8.79	0.43	8.24e-17	Malaria;
LUSC	cis	rs9815354	0.812	rs17283929	chr3:41941898	C/G	cg03022575	chr3:42003672	ULK4	-0.82	-8.99	-0.44	1.94e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.68	12.94	0.58	2.53e-31	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1322512	0.917	rs2475783	chr6:153022912	G/A	cg27316956	chr6:152958899	SYNE1	0.37	6.19	0.32	1.75e-9	Tonometry;
LUSC	cis	rs9296092	0.538	rs75501442	chr6:33519493	A/G	cg13560919	chr6:33536144	NA	-0.82	-15.68	-0.65	6.59e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24669129	chr7:155089712	INSIG1	-0.42	-6.19	-0.32	1.74e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg04352962	chr1:209979756	IRF6	0.55	6.3	0.33	9.18e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg14092571	chr14:90743983	NA	-0.35	-5.81	-0.3	1.47e-8	Mortality in heart failure;
LUSC	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.76	-0.51	2.15e-23	Glomerular filtration rate;
LUSC	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.61	-9.62	-0.47	1.63e-19	Response to antineoplastic agents;
LUSC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg13683864	chr3:40499215	RPL14	-1.05	-18.15	-0.7	1.07e-51	Renal cell carcinoma;
LUSC	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg08807101	chr21:30365312	RNF160	0.63	9.72	0.47	7.67e-20	Pancreatic cancer;
LUSC	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg00982548	chr2:198649783	BOLL	-0.56	-7.05	-0.36	1.03e-11	Ulcerative colitis;
LUSC	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg20891558	chr2:74357851	NA	0.85	15.73	0.65	4.07e-42	Gestational age at birth (maternal effect);
LUSC	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-9.27	-0.45	2.31e-18	Mitochondrial DNA levels;
LUSC	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg26668828	chr6:292823	DUSP22	-0.51	-7.68	-0.39	1.78e-13	Menopause (age at onset);
LUSC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-0.98	-13.99	-0.61	2.6e-35	Vitiligo;
LUSC	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.33	5.98	0.31	5.6e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg26977086	chr12:132329805	MMP17	0.26	5.85	0.3	1.19e-8	Migraine;
LUSC	trans	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg13010199	chr12:38710504	ALG10B	0.48	7.56	0.38	3.82e-13	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.5	0.62	2.75e-37	Platelet count;
LUSC	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg15395560	chr15:45543142	SLC28A2	0.33	5.66	0.3	3.25e-8	Uric acid levels;
LUSC	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-8.25	-0.41	3.65e-15	Retinal vascular caliber;
LUSC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg05738196	chr6:26577821	NA	0.49	7.7	0.39	1.54e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg13852791	chr20:30311386	BCL2L1	0.86	11.5	0.53	5.04e-26	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg19052272	chr2:3704530	ALLC	-0.51	-8.46	-0.42	8.67e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07157834	chr1:205819609	PM20D1	0.81	14.1	0.61	9.44e-36	Menarche (age at onset);
LUSC	trans	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.23	-0.32	1.39e-9	Morning vs. evening chronotype;
LUSC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.51	-0.34	2.75e-10	Neutrophil percentage of white cells;
LUSC	cis	rs4144743	1.000	rs4144744	chr17:45323262	A/G	cg18085866	chr17:45331354	ITGB3	-0.7	-7.62	-0.38	2.61e-13	Body mass index;
LUSC	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg10523679	chr1:76189770	ACADM	-0.45	-6.61	-0.34	1.49e-10	Daytime sleep phenotypes;
LUSC	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6714788	0.523	rs6542905	chr2:100654707	C/G	cg07810366	chr2:100720526	AFF3	-0.39	-6.08	-0.32	3.25e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs62458065	0.513	rs10245103	chr7:32534829	T/G	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.62	-0.34	1.47e-10	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.67	-11.95	-0.55	1.23e-27	Dental caries;
LUSC	cis	rs240764	0.817	rs239245	chr6:101090377	C/A	cg09795085	chr6:101329169	ASCC3	0.42	6.12	0.32	2.68e-9	Neuroticism;
LUSC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg16393715	chr7:1948819	MAD1L1	-0.41	-7.05	-0.36	1.02e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.7e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12422267	0.536	rs61944635	chr12:132575652	C/T	cg26561844	chr12:132562101	EP400	-0.57	-5.66	-0.3	3.3e-8	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg05283184	chr6:79620031	NA	0.54	11.07	0.52	1.75e-24	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22927696	chr12:45269992	NELL2	-0.43	-6.57	-0.34	1.98e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg25233709	chr10:116636983	FAM160B1	0.44	7.89	0.4	4.28e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs27434	0.583	rs149544	chr5:96157854	C/G	cg16492584	chr5:96139282	ERAP1	-0.56	-7.53	-0.38	4.91e-13	Ankylosing spondylitis;
LUSC	cis	rs11024102	1.000	rs11024102	chr11:17008605	T/C	cg15084286	chr11:17036142	PLEKHA7	0.44	5.86	0.31	1.1e-8	Glaucoma (primary angle closure);
LUSC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg07701084	chr6:150067640	NUP43	0.57	8.88	0.44	4.29e-17	Lung cancer;
LUSC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg20135002	chr11:47629003	NA	-0.52	-8.12	-0.41	8.82e-15	Subjective well-being;
LUSC	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg05340658	chr4:99064831	C4orf37	-0.44	-6.93	-0.35	2.18e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2236918	0.710	rs1776138	chr1:242027075	G/A	cg17736920	chr1:242011382	EXO1	0.42	6.76	0.35	5.99e-11	Menopause (age at onset);
LUSC	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg04310649	chr10:35416472	CREM	-0.4	-6.25	-0.32	1.23e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs12439619	0.705	rs17354185	chr15:82426170	C/G	cg04831495	chr15:85060580	GOLGA6L5	0.49	6.35	0.33	7.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2742234	0.541	rs11238490	chr10:43747598	G/A	cg15436174	chr10:43711423	RASGEF1A	0.43	6.83	0.35	4.03e-11	Hirschsprung disease;
LUSC	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg05973401	chr12:123451056	ABCB9	0.55	6.81	0.35	4.68e-11	Neutrophil percentage of white cells;
LUSC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg05738196	chr6:26577821	NA	-0.52	-5.76	-0.3	1.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	9.61	0.47	1.88e-19	Joint mobility (Beighton score);
LUSC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00166722	chr3:10149974	C3orf24	0.56	7.57	0.38	3.75e-13	Alzheimer's disease;
LUSC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg15117754	chr3:10150083	C3orf24	0.43	5.69	0.3	2.82e-8	Alzheimer's disease;
LUSC	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg01620082	chr3:125678407	NA	-0.79	-6.92	-0.35	2.32e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	7.02	0.36	1.25e-11	IgG glycosylation;
LUSC	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg00579484	chr14:23475993	C14orf93	0.4	5.96	0.31	6.38e-9	Cognitive ability (multi-trait analysis);
LUSC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11764359	chr7:65958608	NA	-0.68	-11.05	-0.52	2.2e-24	Aortic root size;
LUSC	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg00129232	chr17:37814104	STARD3	-0.43	-6.35	-0.33	7.24e-10	Asthma;
LUSC	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg11887960	chr12:57824829	NA	-0.52	-6.69	-0.34	9.6e-11	Obesity-related traits;
LUSC	cis	rs59104589	0.617	rs7568	chr2:242291743	A/G	cg14842376	chr2:242211374	HDLBP	0.55	6.24	0.32	1.3e-9	Fibrinogen levels;
LUSC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.7	6.6	0.34	1.61e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.57e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg04756594	chr16:24857601	SLC5A11	0.47	6.94	0.35	2.05e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs877282	0.898	rs34490091	chr10:765800	A/C	cg17470449	chr10:769945	NA	0.53	7.09	0.36	8.21e-12	Uric acid levels;
LUSC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg02772935	chr3:125709198	NA	-0.49	-5.92	-0.31	7.84e-9	Blood pressure (smoking interaction);
LUSC	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.38	-6.43	-0.33	4.51e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1395	0.778	rs2580759	chr2:27432500	G/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.47	-7.28	-0.37	2.44e-12	Blood metabolite levels;
LUSC	cis	rs41271473	0.898	rs3738073	chr1:228871693	C/T	cg10167378	chr1:228756711	NA	0.55	6.58	0.34	1.84e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs9359856	0.636	rs9294440	chr6:90308666	C/G	cg13799429	chr6:90582589	CASP8AP2	0.71	7.6	0.38	3.07e-13	Bipolar disorder;
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.66	10.12	0.48	3.51e-21	Lymphocyte counts;
LUSC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.79	12.7	0.57	1.97e-30	Aortic root size;
LUSC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.12	0.52	1.15e-24	Menopause (age at onset);
LUSC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg00255919	chr5:131827918	IRF1	0.43	8.25	0.41	3.62e-15	Asthma (sex interaction);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12498453	chr20:61557976	DIDO1	0.75	5.97	0.31	6.1e-9	Cognitive performance;
LUSC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02018176	chr4:1364513	KIAA1530	0.58	10.23	0.49	1.46e-21	Longevity;
LUSC	cis	rs17014483	0.749	rs3017905	chr4:89632132	C/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.68	5.97	0.31	5.92e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs80282103	0.764	rs12244052	chr10:1103266	G/A	cg08668510	chr10:1095578	IDI1	0.73	6.4	0.33	5.18e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg12615879	chr12:58013172	SLC26A10	-0.27	-5.7	-0.3	2.66e-8	Multiple sclerosis;
LUSC	cis	rs1729407	0.741	rs1263177	chr11:116690712	C/T	cg08985259	chr11:116699649	APOC3	-0.25	-5.83	-0.3	1.3e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06481639	chr22:41940642	POLR3H	-0.46	-5.68	-0.3	2.97e-8	Vitiligo;
LUSC	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg13660082	chr14:53194042	PSMC6	-0.77	-6.7	-0.34	8.66e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg09998033	chr7:158218633	PTPRN2	0.57	9.11	0.45	7.93e-18	Obesity-related traits;
LUSC	cis	rs926938	0.618	rs3121506	chr1:115363207	T/G	cg12756093	chr1:115239321	AMPD1	0.53	7.92	0.4	3.61e-14	Autism;
LUSC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	12.91	0.58	3.23e-31	Cognitive test performance;
LUSC	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg16447950	chr5:562315	NA	-0.55	-6.63	-0.34	1.38e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg08219700	chr8:58056026	NA	0.5	6.28	0.33	1.03e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2731664	0.792	rs1130857	chr5:176863519	G/C	cg23176889	chr5:176863531	GRK6	-0.7	-14.83	-0.63	1.34e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg04058563	chr4:185651563	MLF1IP	0.42	6.88	0.35	3.01e-11	Kawasaki disease;
LUSC	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs28647808	0.748	rs28721280	chr9:136267318	C/G	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00339695	chr16:24857497	SLC5A11	0.38	6.66	0.34	1.15e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg10578991	chr7:12443926	VWDE	-0.48	-5.85	-0.3	1.2e-8	Coronary artery disease;
LUSC	cis	rs6494488	0.500	rs72744726	chr15:65030995	C/T	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg21733973	chr7:65235735	NA	-0.42	-6.06	-0.31	3.71e-9	Calcium levels;
LUSC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg07507251	chr3:52567010	NT5DC2	0.31	6.12	0.32	2.59e-9	Bipolar disorder;
LUSC	cis	rs6456156	0.742	rs6456157	chr6:167527818	C/A	cg07741184	chr6:167504864	NA	-0.37	-6.51	-0.34	2.78e-10	Primary biliary cholangitis;
LUSC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.67	-0.34	1.04e-10	Total body bone mineral density;
LUSC	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.77	12.98	0.58	1.82e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7759001	0.817	rs6456774	chr6:27344831	C/G	cg18711553	chr6:27366782	ZNF391	0.41	5.95	0.31	6.67e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg02782426	chr3:40428986	ENTPD3	0.43	7.98	0.4	2.44e-14	Renal cell carcinoma;
LUSC	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg23992470	chr4:843637	GAK	0.6	6.42	0.33	4.58e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs892961	1.000	rs1110638	chr17:75400690	T/C	cg05865280	chr17:75406074	SEPT9	0.47	9.61	0.47	1.87e-19	Airflow obstruction;
LUSC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.85	-15.47	-0.65	4.55e-41	Cognitive function;
LUSC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.55	-14.02	-0.61	1.89e-35	Longevity;
LUSC	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg18681998	chr4:17616180	MED28	0.84	15.64	0.65	9.43e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.73	-9.52	-0.46	3.49e-19	Gastritis;
LUSC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg25039879	chr17:56429692	SUPT4H1	0.68	9.09	0.45	8.71e-18	Cognitive test performance;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14507132	chr15:57210852	TCF12;LOC145783	-0.43	-6.22	-0.32	1.46e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.81	-13.12	-0.58	5.39e-32	Bladder cancer;
LUSC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.15	-0.32	2.24e-9	Extrinsic epigenetic age acceleration;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26311208	chr1:59012484	OMA1	-0.57	-7.41	-0.38	1.01e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs16958440	0.581	rs72907280	chr18:44681130	C/T	cg17192377	chr18:44677553	HDHD2	0.52	6.12	0.32	2.6e-9	Sitting height ratio;
LUSC	cis	rs73200209	0.744	rs61939683	chr12:116508474	T/G	cg01776926	chr12:116560359	MED13L	-0.49	-6.03	-0.31	4.4e-9	Total body bone mineral density;
LUSC	cis	rs2235544	0.542	rs679801	chr1:54470757	T/C	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs7119038	0.818	rs17122453	chr11:118683564	G/A	cg19308663	chr11:118741387	NA	0.34	6.09	0.32	3.06e-9	Sjögren's syndrome;
LUSC	cis	rs7241530	0.662	rs8096274	chr18:75909734	T/C	cg14642773	chr18:75888474	NA	0.39	5.74	0.3	2.17e-8	Educational attainment (years of education);
LUSC	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg27124370	chr19:33622961	WDR88	0.53	6.81	0.35	4.56e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg26395211	chr5:140044315	WDR55	0.38	5.78	0.3	1.76e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs3770081	1.000	rs3770066	chr2:86392350	A/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.94	-6.75	-0.35	6.59e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg00784671	chr22:46762841	CELSR1	-0.62	-6.93	-0.35	2.23e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14159672	chr1:205819179	PM20D1	0.43	5.97	0.31	5.99e-9	Menarche (age at onset);
LUSC	cis	rs60154123	0.614	rs11119456	chr1:210458323	C/A	cg22029157	chr1:209979665	IRF6	0.52	6.08	0.32	3.32e-9	Coronary artery disease;
LUSC	cis	rs4654899	0.802	rs10737452	chr1:21199764	C/T	cg01072550	chr1:21505969	NA	0.44	6.61	0.34	1.52e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.3	-6.02	-0.31	4.61e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04511125	chr2:88470314	THNSL2	-0.64	-9.2	-0.45	3.86e-18	Response to metformin (IC50);
LUSC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg01097406	chr16:89675127	NA	0.33	6.28	0.33	1.04e-9	Vitiligo;
LUSC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg09509183	chr1:209979624	IRF6	0.44	5.94	0.31	7.29e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs4654899	0.865	rs9426730	chr1:21452255	A/T	cg02927042	chr1:21476669	EIF4G3	-0.35	-5.66	-0.3	3.27e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2137920	0.945	rs2254412	chr10:50238272	C/T	cg27141751	chr10:50231850	C10orf72	0.38	5.73	0.3	2.28e-8	Migraine with aura;
LUSC	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.22	-0.45	3.54e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg17279839	chr7:150038598	RARRES2	0.49	7.44	0.38	8.59e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.93	-18.89	-0.72	1.19e-54	Post bronchodilator FEV1;
LUSC	cis	rs10207628	0.653	rs7601287	chr2:127881243	G/A	cg06223080	chr2:127868745	NA	0.38	6.58	0.34	1.79e-10	Psychosis and Alzheimer's disease;
LUSC	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.71	-0.3	2.56e-8	Resting heart rate;
LUSC	cis	rs12472274	0.941	rs6748440	chr2:239100375	C/T	cg17459225	chr2:239074497	NA	0.62	10.03	0.48	7.36e-21	Phospholipid levels (plasma);
LUSC	cis	rs10208940	0.920	rs35118992	chr2:68699460	G/A	cg12452813	chr2:68675892	NA	0.56	5.88	0.31	1.01e-8	Urate levels in lean individuals;
LUSC	trans	rs17086172	0.841	rs76610733	chr18:70268315	C/G	cg00123055	chr8:55370951	SOX17	-0.68	-6.08	-0.32	3.31e-9	Airflow obstruction;
LUSC	trans	rs931812	0.825	rs34153562	chr8:101893441	T/C	cg20993868	chr7:22813445	NA	0.59	10.4	0.49	4.05e-22	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs72792276	1.000	rs17164395	chr5:127395526	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.9	7.72	0.39	1.36e-13	Red cell distribution width;
LUSC	cis	rs2835872	0.758	rs1787399	chr21:39037883	A/G	cg20424643	chr21:39039972	KCNJ6	-0.45	-7.47	-0.38	7.24e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg12863693	chr15:85201151	NMB	0.37	7.29	0.37	2.24e-12	Schizophrenia;
LUSC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.75	13.57	0.6	1.01e-33	Calcium levels;
LUSC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.54	-8.5	-0.42	6.35e-16	Menopause (age at onset);
LUSC	cis	rs6500395	0.963	rs2883642	chr16:48685146	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.84	-0.35	3.77e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs17401966	0.597	rs6667639	chr1:10246471	C/A	cg19773385	chr1:10388646	KIF1B	-0.42	-7.36	-0.37	1.48e-12	Hepatocellular carcinoma;
LUSC	trans	rs12509991	0.741	rs17010688	chr4:127024000	A/T	cg17848407	chr5:126408806	FLJ44606	0.46	5.97	0.31	6.02e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	0.92	15.33	0.64	1.58e-40	Breast cancer;
LUSC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7903847	0.620	rs10882903	chr10:99115584	A/T	cg08345082	chr10:99160200	RRP12	-0.36	-7.28	-0.37	2.43e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-1.24	-13.61	-0.6	7.37e-34	Diabetic kidney disease;
LUSC	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg12639453	chr1:2035780	PRKCZ	-0.34	-7.29	-0.37	2.23e-12	Height;
LUSC	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg25817165	chr18:72167213	CNDP2	-0.72	-8.06	-0.4	1.34e-14	Refractive error;
LUSC	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.81	0.35	4.44e-11	Rheumatoid arthritis;
LUSC	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-0.7	-8.96	-0.44	2.4e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg05738196	chr6:26577821	NA	-0.6	-7.21	-0.37	3.78e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10465746	0.780	rs1570691	chr1:84370393	A/C	cg10977910	chr1:84465055	TTLL7	0.44	6.23	0.32	1.42e-9	Obesity-related traits;
LUSC	cis	rs6076065	0.802	rs2424527	chr20:23357329	A/C	cg11657817	chr20:23433608	CST11	0.55	11.39	0.53	1.33e-25	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2235649	0.798	rs78540053	chr16:1853275	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-5.82	-0.3	1.41e-8	Blood metabolite levels;
LUSC	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg15848620	chr12:58087721	OS9	-0.53	-7.64	-0.39	2.36e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg00990874	chr7:1149470	C7orf50	-0.51	-6.36	-0.33	6.76e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.72	-10.81	-0.51	1.47e-23	Menarche (age at onset);
LUSC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg05623727	chr3:50126028	RBM5	-0.33	-6.21	-0.32	1.54e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-0.92	-13.2	-0.59	2.68e-32	Vitiligo;
LUSC	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-1.0	-14.14	-0.61	6.61e-36	Exhaled nitric oxide output;
LUSC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg05084668	chr3:125655381	ALG1L	-0.51	-7.15	-0.36	5.46e-12	Blood pressure (smoking interaction);
LUSC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg08859206	chr1:53392774	SCP2	0.52	9.03	0.44	1.39e-17	Monocyte count;
LUSC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg21361702	chr7:150065534	REPIN1	0.5	6.79	0.35	5.18e-11	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg13010199	chr12:38710504	ALG10B	-0.46	-7.25	-0.37	2.83e-12	Morning vs. evening chronotype;
LUSC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.75	0.65	3.43e-42	Platelet count;
LUSC	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-9.84	-0.47	3.04e-20	Alzheimer's disease;
LUSC	cis	rs250677	0.522	rs4705301	chr5:148354902	C/G	cg18129178	chr5:148520854	ABLIM3	-0.52	-7.38	-0.37	1.23e-12	Breast cancer;
LUSC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg04450456	chr4:17643702	FAM184B	0.43	7.21	0.37	3.8e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2262909	0.719	rs12461632	chr19:22245089	G/A	cg11619707	chr19:22235551	ZNF257	0.4	6.0	0.31	5e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25789201	chr7:72395803	POM121	0.43	6.26	0.32	1.16e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	9.1	0.45	8.61e-18	Mood instability;
LUSC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.27	0.37	2.58e-12	Bipolar disorder;
LUSC	cis	rs2273669	0.667	rs12206423	chr6:109353216	C/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg22431228	chr1:16359049	CLCNKA	0.45	8.79	0.43	8.09e-17	Dilated cardiomyopathy;
LUSC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg20933634	chr6:27740509	NA	0.43	5.65	0.3	3.37e-8	Parkinson's disease;
LUSC	cis	rs4423214	0.592	rs11234027	chr11:71234107	G/A	cg05163923	chr11:71159392	DHCR7	-0.69	-7.12	-0.36	6.62e-12	Vitamin D levels;
LUSC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg02569458	chr12:86230093	RASSF9	0.54	9.21	0.45	3.78e-18	Major depressive disorder;
LUSC	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg25173405	chr17:45401733	C17orf57	0.36	5.71	0.3	2.56e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg06096015	chr1:231504339	EGLN1	0.58	10.37	0.49	5e-22	Hemoglobin concentration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02529627	chr17:1618713	C17orf91;WDR81;MIR22	0.43	6.12	0.32	2.69e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg06521331	chr12:34319734	NA	-0.4	-6.26	-0.32	1.2e-9	Morning vs. evening chronotype;
LUSC	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-9.81	-0.47	4.11e-20	Morning vs. evening chronotype;
LUSC	cis	rs950893	0.597	rs2942219	chr8:23439308	A/G	cg08026493	chr8:23430824	NA	0.35	5.68	0.3	2.91e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.93	-0.44	2.88e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg19920283	chr7:105172520	RINT1	0.57	6.09	0.32	3.12e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg16524733	chr11:117070046	TAGLN	0.42	7.33	0.37	1.74e-12	Blood protein levels;
LUSC	cis	rs6076065	0.676	rs6076057	chr20:23335982	G/T	cg11657817	chr20:23433608	CST11	-0.44	-8.05	-0.4	1.49e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg15110403	chr19:17392923	ANKLE1	-0.59	-8.02	-0.4	1.85e-14	Systemic lupus erythematosus;
LUSC	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg25214090	chr10:38739885	LOC399744	0.54	8.02	0.4	1.78e-14	Corneal astigmatism;
LUSC	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg03342759	chr3:160939853	NMD3	-0.45	-6.33	-0.33	7.76e-10	Parkinson's disease;
LUSC	cis	rs13089785	1.000	rs13092912	chr3:123604942	C/T	cg19611163	chr3:123411211	MYLK	0.35	5.9	0.31	8.73e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs877282	0.945	rs12767287	chr10:787310	A/G	cg17470449	chr10:769945	NA	0.49	6.71	0.34	8.1e-11	Uric acid levels;
LUSC	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg23691090	chr22:46449981	C22orf26;LOC150381	0.47	7.74	0.39	1.17e-13	Dupuytren's disease;Subjective well-being;
LUSC	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.85	0.39	5.64e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-1.17	-16.86	-0.68	1.46e-46	Breast cancer;
LUSC	cis	rs13315871	0.929	rs71311853	chr3:58319152	C/T	cg12435725	chr3:58293450	RPP14	-0.72	-7.21	-0.37	3.87e-12	Cholesterol, total;
LUSC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg26513180	chr16:89883248	FANCA	0.79	6.37	0.33	6.26e-10	Skin colour saturation;
LUSC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-1.01	-19.18	-0.72	8.42e-56	Height;
LUSC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg23188684	chr11:67383651	NA	-0.37	-6.58	-0.34	1.81e-10	Mean corpuscular volume;
LUSC	cis	rs10779751	0.960	rs1883964	chr1:11294942	T/A	cg08854313	chr1:11322531	MTOR	0.87	15.21	0.64	4.52e-40	Body mass index;
LUSC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	8.55	0.42	4.56e-16	Motion sickness;
LUSC	trans	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg21775007	chr8:11205619	TDH	0.42	5.99	0.31	5.34e-9	Mood instability;
LUSC	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg23176889	chr5:176863531	GRK6	-0.66	-13.54	-0.6	1.32e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs877282	0.853	rs11595510	chr10:756757	C/G	cg17470449	chr10:769945	NA	0.51	7.04	0.36	1.1e-11	Uric acid levels;
LUSC	cis	rs6429082	0.818	rs704722	chr1:235669988	G/A	cg26050004	chr1:235667680	B3GALNT2	0.62	8.38	0.42	1.51e-15	Adiposity;
LUSC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg11812906	chr14:75593930	NEK9	-0.63	-10.93	-0.51	5.52e-24	Height;
LUSC	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg14675211	chr2:100938903	LONRF2	0.37	5.73	0.3	2.29e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs28647808	0.881	rs7042326	chr9:136266636	T/C	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg10621924	chr7:39171070	POU6F2	0.49	7.73	0.39	1.32e-13	IgG glycosylation;
LUSC	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg02073558	chr3:44770973	ZNF501	0.58	9.73	0.47	7.34e-20	Depressive symptoms;
LUSC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.49	-0.59	2.14e-33	Alzheimer's disease;
LUSC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg26769984	chr7:1090371	C7orf50	0.58	7.81	0.39	7.67e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg17330251	chr7:94953956	PON1	-0.37	-5.97	-0.31	6.03e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	1.11	14.26	0.62	2.29e-36	Nonalcoholic fatty liver disease;
LUSC	cis	rs113835537	0.877	rs2275998	chr11:66326581	T/C	cg24851651	chr11:66362959	CCS	0.47	6.08	0.32	3.29e-9	Airway imaging phenotypes;
LUSC	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg13010199	chr12:38710504	ALG10B	0.67	10.35	0.49	5.86e-22	Morning vs. evening chronotype;
LUSC	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.62	-13.46	-0.59	2.73e-33	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg06627628	chr2:24431161	ITSN2	-0.74	-10.26	-0.49	1.16e-21	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs6546537	1.000	rs6546537	chr2:69839633	T/C	cg10773587	chr2:69614142	GFPT1	-0.49	-7.5	-0.38	5.78e-13	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.67	-9.05	-0.44	1.22e-17	Cognitive test performance;
LUSC	cis	rs2708977	0.692	rs17685766	chr2:97319534	G/C	cg01950434	chr2:97203154	ARID5A	0.53	7.69	0.39	1.65e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg14196790	chr5:131705035	SLC22A5	0.41	6.66	0.34	1.13e-10	Breast cancer;Mosquito bite size;
LUSC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg04267008	chr7:1944627	MAD1L1	-0.51	-7.35	-0.37	1.52e-12	Schizophrenia;
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg25703541	chr22:24373054	LOC391322	-0.89	-15.65	-0.65	8.55e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg06618935	chr21:46677482	NA	-0.4	-8.06	-0.4	1.37e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg13010199	chr12:38710504	ALG10B	0.42	6.03	0.31	4.27e-9	Morning vs. evening chronotype;
LUSC	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-1.14	-15.67	-0.65	7.35e-42	Hip circumference adjusted for BMI;
LUSC	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg09307838	chr4:120376055	NA	0.75	10.98	0.51	3.78e-24	Corneal astigmatism;
LUSC	cis	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg06521852	chr22:38141419	TRIOBP	0.4	5.93	0.31	7.63e-9	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs16937	0.662	rs11588199	chr1:205164580	C/T	cg00857998	chr1:205179979	DSTYK	0.46	6.45	0.33	4e-10	Schizophrenia;
LUSC	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg06937882	chr20:24974362	C20orf3	-0.44	-7.67	-0.39	1.89e-13	Blood protein levels;
LUSC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg00800038	chr16:89945340	TCF25	-0.75	-6.56	-0.34	2.08e-10	Skin colour saturation;
LUSC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	1.2	13.15	0.58	4.19e-32	Diabetic kidney disease;
LUSC	trans	rs17645023	1.000	rs17645023	chr17:64917033	A/T	cg22953960	chr10:22766081	NA	-0.3	-6.14	-0.32	2.28e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7106204	0.686	rs12803558	chr11:24288205	C/A	ch.11.24196551F	chr11:24239977	NA	0.73	5.89	0.31	9.68e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg03563238	chr19:33554763	RHPN2	-0.4	-6.39	-0.33	5.41e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10072221	1.000	rs10044370	chr5:75719788	A/G	cg03132911	chr5:75698732	IQGAP2	-0.35	-5.86	-0.31	1.1e-8	Mean platelet volume;
LUSC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg12705353	chr12:122356852	WDR66	-0.38	-5.65	-0.3	3.38e-8	Mean corpuscular volume;
LUSC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.4	5.82	0.3	1.37e-8	Tonsillectomy;
LUSC	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg02466173	chr16:30829666	NA	-0.53	-10.43	-0.5	3.1e-22	Dementia with Lewy bodies;
LUSC	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.75	-0.35	6.64e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.71e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg09835421	chr16:68378352	PRMT7	-0.48	-5.86	-0.31	1.09e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs603424	0.597	rs574122	chr10:102089174	C/A	cg10365880	chr10:102089681	PKD2L1	0.6	6.95	0.36	1.91e-11	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
LUSC	cis	rs6500395	1.000	rs3848322	chr16:48620964	C/A	cg04672837	chr16:48644449	N4BP1	0.5	7.54	0.38	4.58e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14893161	chr1:205819251	PM20D1	0.59	10.14	0.49	3.12e-21	Menarche (age at onset);
LUSC	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg11019008	chr10:131425282	MGMT	0.44	6.7	0.34	8.65e-11	Response to temozolomide;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13479780	chr6:41909532	CCND3	-0.4	-5.95	-0.31	6.89e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6469656	0.892	rs10085939	chr8:117684153	C/T	cg24004040	chr8:117650383	NA	-0.43	-6.31	-0.33	9.04e-10	Colorectal cancer;
LUSC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg15123519	chr2:136567270	LCT	0.37	5.73	0.3	2.25e-8	Mosquito bite size;
LUSC	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-0.75	-11.42	-0.53	1.01e-25	Refractive error;
LUSC	cis	rs9308433	0.529	rs6660335	chr1:214501855	C/T	cg06198575	chr1:214491504	SMYD2	0.45	7.02	0.36	1.24e-11	IgG glycosylation;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06874399	chr5:79704109	ZFYVE16	0.4	6.05	0.31	3.94e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg16083849	chr15:59063210	FAM63B	0.58	7.0	0.36	1.38e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg16482183	chr6:26056742	HIST1H1C	0.46	6.83	0.35	4.07e-11	Height;
LUSC	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg27426351	chr10:43362370	NA	-0.42	-5.73	-0.3	2.26e-8	Blood protein levels;
LUSC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg17052675	chr2:3827356	NA	-0.64	-10.2	-0.49	1.87e-21	Type 2 diabetes;
LUSC	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.72	13.13	0.58	4.83e-32	Pulse pressure;
LUSC	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg00857998	chr1:205179979	DSTYK	0.63	9.68	0.47	1.11e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg09796270	chr17:17721594	SREBF1	0.43	7.5	0.38	5.86e-13	Total body bone mineral density;
LUSC	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg22029157	chr1:209979665	IRF6	0.71	8.39	0.42	1.39e-15	Coronary artery disease;
LUSC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18876405	chr7:65276391	NA	-0.55	-8.77	-0.43	9.25e-17	Aortic root size;
LUSC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg21435336	chr19:17392852	ANKLE1	-0.47	-6.33	-0.33	7.95e-10	Systemic lupus erythematosus;
LUSC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg00277334	chr10:82204260	NA	-0.53	-7.33	-0.37	1.73e-12	Post bronchodilator FEV1;
LUSC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	22.14	0.77	1.81e-67	Height;
LUSC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg17294928	chr15:75287854	SCAMP5	0.41	5.88	0.31	1e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg03806693	chr22:41940476	POLR3H	1.01	13.96	0.61	3.31e-35	Vitiligo;
LUSC	cis	rs2236918	1.000	rs2236918	chr1:242017826	C/G	cg17736920	chr1:242011382	EXO1	-0.44	-6.92	-0.35	2.29e-11	Menopause (age at onset);
LUSC	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg27284194	chr4:1044797	NA	0.55	7.97	0.4	2.57e-14	Recombination rate (females);
LUSC	cis	rs6681460	0.966	rs10749765	chr1:67150280	C/T	cg02459107	chr1:67143332	SGIP1	0.48	8.87	0.44	4.51e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg21782813	chr7:2030301	MAD1L1	0.35	5.85	0.3	1.19e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs10193935	0.901	rs997288	chr2:42525582	C/G	cg27598129	chr2:42591480	NA	-0.58	-7.9	-0.4	3.95e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09234622	chr22:39240094	NPTXR	-0.42	-6.31	-0.33	8.96e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4343996	0.837	rs10228151	chr7:3472757	G/T	cg21248987	chr7:3385318	SDK1	-0.39	-6.5	-0.33	3.01e-10	Motion sickness;
LUSC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg21141812	chr3:48556323	PFKFB4	0.36	6.07	0.32	3.42e-9	Menarche (age at onset);
LUSC	cis	rs6940638	0.956	rs10946899	chr6:27023694	T/A	cg05738196	chr6:26577821	NA	-0.47	-5.77	-0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.12	-0.32	2.63e-9	Neutrophil percentage of white cells;
LUSC	cis	rs472402	0.560	rs10065299	chr5:6654489	T/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.54	-7.77	-0.39	1.01e-13	Response to amphetamines;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17960051	chr7:87257673	ABCB1;RUNDC3B	0.47	6.86	0.35	3.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg13047869	chr3:10149882	C3orf24	0.63	9.07	0.44	1.02e-17	Alzheimer's disease;
LUSC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.3	6.71	0.34	8.24e-11	Coronary artery disease;
LUSC	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.48	-9.07	-0.44	1.08e-17	Axial length;
LUSC	cis	rs79387448	0.745	rs78136548	chr2:103103740	T/G	cg09003973	chr2:102972529	NA	1.0	9.33	0.45	1.52e-18	Gut microbiota (bacterial taxa);
LUSC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.56	-8.66	-0.43	2.03e-16	Height;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14283194	chr7:91763737	CYP51A1	0.36	6.34	0.33	7.38e-10	Triglycerides;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.66	10.12	0.48	3.51e-21	Lymphocyte counts;
LUSC	cis	rs9487051	0.768	rs371960	chr6:109525082	A/G	cg00509249	chr6:109615579	CCDC162	-0.33	-5.7	-0.3	2.69e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg09877947	chr5:131593287	PDLIM4	0.49	8.01	0.4	1.9e-14	Breast cancer;
LUSC	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg23649088	chr2:200775458	C2orf69	-0.53	-6.31	-0.33	8.85e-10	Schizophrenia;
LUSC	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg24006582	chr15:45444508	DUOX1	-0.6	-8.62	-0.43	2.8e-16	Uric acid levels;
LUSC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg02782426	chr3:40428986	ENTPD3	0.39	7.45	0.38	8.01e-13	Renal cell carcinoma;
LUSC	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.4	-6.11	-0.32	2.76e-9	Ulcerative colitis;
LUSC	cis	rs9308433	0.529	rs10465697	chr1:214499948	T/C	cg06198575	chr1:214491504	SMYD2	0.45	6.99	0.36	1.46e-11	IgG glycosylation;
LUSC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-9.03	-0.44	1.35e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg21361702	chr7:150065534	REPIN1	0.47	5.92	0.31	7.88e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg20135002	chr11:47629003	NA	-0.51	-7.98	-0.4	2.36e-14	Subjective well-being;
LUSC	trans	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg04995722	chr7:26192034	NFE2L3	-0.37	-6.16	-0.32	2.08e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.6	14.15	0.61	6.34e-36	Height;
LUSC	cis	rs7119	0.604	rs2667781	chr15:77858619	A/C	cg27398640	chr15:77910606	LINGO1	0.37	7.87	0.4	4.99e-14	Type 2 diabetes;
LUSC	cis	rs983392	0.667	rs634475	chr11:59942081	G/A	cg24026212	chr11:59952134	MS4A6A	0.34	6.03	0.31	4.27e-9	Alzheimer's disease (late onset);
LUSC	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.6	0.34	1.6e-10	IgG glycosylation;
LUSC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg16339924	chr4:17578868	LAP3	0.54	8.12	0.41	9.26e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg06521331	chr12:34319734	NA	-0.4	-6.91	-0.35	2.47e-11	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.25	-0.49	1.27e-21	Platelet count;
LUSC	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg05901451	chr6:126070800	HEY2	-0.51	-7.46	-0.38	7.44e-13	High light scatter reticulocyte count;
LUSC	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.93	0.31	7.55e-9	Rheumatoid arthritis;
LUSC	cis	rs500891	0.525	rs12524968	chr6:84076466	C/G	cg08257003	chr6:84140564	ME1	0.35	8.63	0.43	2.58e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg11130432	chr3:121712080	ILDR1	-0.63	-9.59	-0.46	2.19e-19	Multiple sclerosis;
LUSC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.08	-0.32	3.25e-9	Alzheimer's disease (late onset);
LUSC	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	1.14	19.67	0.73	9.55e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg01557791	chr16:72042693	DHODH	-0.52	-7.54	-0.38	4.42e-13	Fibrinogen levels;
LUSC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg09455208	chr3:40491958	NA	0.57	10.01	0.48	8.12e-21	Renal cell carcinoma;
LUSC	cis	rs72627509	0.857	rs55762216	chr4:57765731	G/C	cg26694713	chr4:57773883	REST	0.53	6.31	0.33	9.03e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs73198271	0.562	rs35432123	chr8:8671018	G/T	cg01851573	chr8:8652454	MFHAS1	0.65	8.41	0.42	1.23e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.61	-9.37	-0.46	1.1e-18	Personality dimensions;
LUSC	cis	rs6537837	1.000	rs6537837	chr1:110119732	C/T	cg05049280	chr1:110155535	GNAT2	0.5	6.73	0.35	7.44e-11	Major depressive disorder;
LUSC	cis	rs8112211	0.954	rs7252835	chr19:38832946	G/A	cg14299480	chr19:38876666	GGN	-0.35	-6.02	-0.31	4.63e-9	Blood protein levels;
LUSC	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.62	-0.57	4.01e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.48	0.53	6.39e-26	Mean corpuscular volume;
LUSC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg14004847	chr7:1930337	MAD1L1	-0.58	-9.11	-0.45	7.67e-18	Schizophrenia;
LUSC	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg13010199	chr12:38710504	ALG10B	0.43	6.33	0.33	7.88e-10	Morning vs. evening chronotype;
LUSC	cis	rs3741151	0.686	rs17851510	chr11:73106294	A/C	cg17517138	chr11:73019481	ARHGEF17	0.88	8.15	0.41	7.15e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg08470875	chr2:26401718	FAM59B	-0.68	-9.16	-0.45	5.18e-18	Gut microbiome composition (summer);
LUSC	cis	rs6494488	0.500	rs72744713	chr15:65015534	G/T	cg08069370	chr15:64387884	SNX1	-0.66	-6.09	-0.32	3.06e-9	Coronary artery disease;
LUSC	trans	rs853679	0.599	rs149990	chr6:27998258	G/A	cg01620082	chr3:125678407	NA	-0.62	-6.95	-0.36	1.94e-11	Depression;
LUSC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg21724239	chr8:58056113	NA	0.77	9.21	0.45	3.76e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg02423579	chr7:2872169	GNA12	-0.44	-6.24	-0.32	1.32e-9	Height;
LUSC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg26380479	chr7:97908229	NA	-0.26	-5.77	-0.3	1.78e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-7.77	-0.39	9.89e-14	Eosinophil percentage of white cells;
LUSC	cis	rs11587682	0.714	rs41264139	chr1:150460850	C/T	cg11822372	chr1:151115635	SEMA6C	-0.42	-5.71	-0.3	2.53e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg07541023	chr7:19748670	TWISTNB	-0.93	-9.49	-0.46	4.39e-19	Thyroid stimulating hormone;
LUSC	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg08645402	chr16:4508243	NA	-0.44	-7.33	-0.37	1.79e-12	Schizophrenia;
LUSC	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.58	9.75	0.47	6.46e-20	Breast cancer;
LUSC	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg15934090	chr1:100435551	SLC35A3	0.49	8.35	0.42	1.84e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.93	18.33	0.71	1.99e-52	Brugada syndrome;
LUSC	cis	rs77633900	0.772	rs157768	chr15:76833779	C/T	cg21673338	chr15:77095150	SCAPER	-0.71	-6.21	-0.32	1.58e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs11264213	0.901	rs631202	chr1:36449099	G/C	cg27506609	chr1:36549197	TEKT2	0.62	7.23	0.37	3.37e-12	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07362569	chr17:61921086	SMARCD2	0.36	7.58	0.38	3.47e-13	Prudent dietary pattern;
LUSC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg14343924	chr8:8086146	FLJ10661	-0.42	-5.71	-0.3	2.5e-8	Mood instability;
LUSC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg01689657	chr7:91764605	CYP51A1	-0.31	-5.72	-0.3	2.36e-8	Breast cancer;
LUSC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg09021430	chr5:549028	NA	-0.42	-7.49	-0.38	6.29e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg09826364	chr7:158789723	NA	-0.38	-6.08	-0.32	3.3e-9	Facial morphology (factor 20);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27660165	chr1:156784036	SH2D2A	0.42	6.31	0.33	9.01e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.45	-6.4	-0.33	5.2400000000000005e-10	Alzheimer's disease (late onset);
LUSC	cis	rs8099014	1.000	rs4940393	chr18:56109540	C/T	cg12907477	chr18:56117327	MIR122	0.43	6.72	0.35	7.8e-11	Platelet count;
LUSC	trans	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg07393940	chr7:158741817	NA	-0.36	-6.37	-0.33	6.38e-10	Life satisfaction;
LUSC	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg06612196	chr6:6737390	NA	-0.55	-10.68	-0.5	4.13e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs968451	0.619	rs2267407	chr22:39747050	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.56	7.11	0.36	7.24e-12	Primary biliary cholangitis;
LUSC	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.83	0.39	6.66e-14	Colorectal cancer;
LUSC	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg26769984	chr7:1090371	C7orf50	0.67	10.31	0.49	7.92e-22	Bronchopulmonary dysplasia;
LUSC	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg02574844	chr11:5959923	NA	-0.45	-6.26	-0.32	1.17e-9	DNA methylation (variation);
LUSC	cis	rs12220238	1.000	rs12256105	chr10:75909634	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.27	0.37	2.54e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13686143	chr2:201828163	ORC2L	0.45	6.43	0.33	4.38e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg11645453	chr3:52864694	ITIH4	-0.29	-6.28	-0.33	1.03e-9	Bipolar disorder;
LUSC	trans	rs11700980	1.000	rs56103672	chr21:30122076	G/A	cg05609335	chr17:75789393	NA	0.41	6.32	0.33	8.58e-10	QRS complex (12-leadsum);
LUSC	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg26384229	chr12:38710491	ALG10B	0.88	14.87	0.63	9.73e-39	Morning vs. evening chronotype;
LUSC	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg05343316	chr1:45956843	TESK2	0.7	9.29	0.45	2.04e-18	Platelet count;
LUSC	trans	rs57046232	0.508	rs2148814	chr20:6352589	G/A	cg21095983	chr6:86352623	SYNCRIP	0.46	6.97	0.36	1.67e-11	Colorectal cancer;
LUSC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg14433983	chr11:636460	DRD4	-0.35	-5.85	-0.31	1.15e-8	Systemic lupus erythematosus;
LUSC	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg24375607	chr4:120327624	NA	0.75	10.83	0.51	1.25e-23	Corneal astigmatism;
LUSC	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg12935359	chr14:103987150	CKB	0.65	10.44	0.5	2.83e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg16989719	chr2:238392110	NA	-0.38	-6.41	-0.33	4.88e-10	Prostate cancer;
LUSC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.54	0.42	4.97e-16	Homoarginine levels;
LUSC	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg09796270	chr17:17721594	SREBF1	-0.46	-8.31	-0.41	2.42e-15	Total body bone mineral density;
LUSC	cis	rs7944584	0.610	rs2596407	chr11:47361838	A/G	cg20307385	chr11:47447363	PSMC3	-0.71	-10.92	-0.51	6.3e-24	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs11997175	0.574	rs7001404	chr8:33645219	G/A	ch.8.33884649F	chr8:33765107	NA	0.52	8.38	0.42	1.53e-15	Body mass index;
LUSC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg25554036	chr4:6271136	WFS1	0.61	12.18	0.55	1.74e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg03929089	chr4:120376271	NA	-0.59	-6.42	-0.33	4.81e-10	Axial length;
LUSC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg26513180	chr16:89883248	FANCA	0.6	5.72	0.3	2.31e-8	Skin colour saturation;
LUSC	cis	rs4899554	0.509	rs78368951	chr14:75730348	A/G	cg18117039	chr14:75741733	NA	0.53	7.1	0.36	7.78e-12	Inflammatory bowel disease;
LUSC	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg23601416	chr22:19950040	COMT	0.32	6.78	0.35	5.51e-11	Blood metabolite levels;
LUSC	cis	rs3099143	1.000	rs3099134	chr15:77133168	T/G	cg21673338	chr15:77095150	SCAPER	-0.78	-7.26	-0.37	2.77e-12	Recalcitrant atopic dermatitis;
LUSC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24531977	chr5:56204891	C5orf35	-0.93	-10.72	-0.51	3.03e-23	Type 2 diabetes;
LUSC	cis	rs7072216	0.763	rs1061437	chr10:100176154	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-8.52	-0.42	5.48e-16	Metabolite levels;
LUSC	cis	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg20368463	chr18:77673604	PQLC1	0.67	5.85	0.3	1.19e-8	Opioid sensitivity;
LUSC	cis	rs7561273	0.586	rs12477718	chr2:24330539	A/G	cg06627628	chr2:24431161	ITSN2	-0.52	-6.84	-0.35	3.89e-11	Quantitative traits;
LUSC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg27170947	chr2:26402098	FAM59B	-0.63	-9.18	-0.45	4.77e-18	Gut microbiome composition (summer);
LUSC	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg16230307	chr14:35515116	FAM177A1	0.82	10.3	0.49	8.57e-22	Psoriasis;
LUSC	cis	rs3772130	1.000	rs33988592	chr3:121415610	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.64	9.28	0.45	2.14e-18	Cognitive performance;
LUSC	cis	rs1419980	0.643	rs10772588	chr12:7796738	G/A	cg10578777	chr12:7781093	NA	0.61	5.72	0.3	2.34e-8	HDL cholesterol levels;
LUSC	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg03585969	chr10:35415529	CREM	-0.6	-8.81	-0.43	7.02e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg24375607	chr4:120327624	NA	0.79	12.03	0.55	6.08e-28	Corneal astigmatism;
LUSC	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg24375607	chr4:120327624	NA	0.75	11.23	0.52	5.02e-25	Corneal astigmatism;
LUSC	cis	rs11214589	0.905	rs12805699	chr11:113241810	T/A	cg14159747	chr11:113255604	NA	0.29	7.01	0.36	1.33e-11	Neuroticism;
LUSC	trans	rs7618314	0.504	rs2922111	chr3:108533911	A/C	cg05749855	chr16:89472771	ANKRD11	0.56	6.18	0.32	1.85e-9	Airway responsiveness in chronic obstructive pulmonary disease;
LUSC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02475777	chr4:1388615	CRIPAK	0.62	9.24	0.45	2.93e-18	Longevity;
LUSC	cis	rs599083	0.793	rs314750	chr11:68182028	G/A	cg01657329	chr11:68192670	LRP5	0.51	7.5	0.38	5.81e-13	Bone mineral density (spine);
LUSC	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg22508957	chr16:3507546	NAT15	0.49	6.76	0.35	6.33e-11	Body mass index (adult);
LUSC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-6.48	-0.33	3.38e-10	Schizophrenia;
LUSC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg06618935	chr21:46677482	NA	-0.37	-7.33	-0.37	1.75e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs58235267	0.543	rs2539990	chr2:63170185	C/T	cg17519650	chr2:63277830	OTX1	0.66	9.63	0.47	1.62e-19	Prostate-specific antigen levels (conditioned on lead SNPs);
LUSC	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg09911534	chr15:67153556	NA	0.51	6.58	0.34	1.78e-10	Lung cancer (smoking interaction);
LUSC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	15.03	0.64	2.29e-39	Platelet count;
LUSC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg23711669	chr6:146136114	FBXO30	0.74	12.36	0.56	3.86e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg00074818	chr8:8560427	CLDN23	0.58	9.66	0.47	1.23e-19	Obesity-related traits;
LUSC	cis	rs10203711	1.000	rs6716457	chr2:239577621	C/T	cg14580085	chr2:239553406	NA	0.42	7.11	0.36	7.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8032158	0.574	rs56093337	chr15:56133199	A/T	cg05129572	chr15:56138634	NEDD4	-0.4	-5.84	-0.3	1.26e-8	Keloid;
LUSC	cis	rs6987853	0.736	rs6991995	chr8:42436219	A/C	cg09913449	chr8:42400586	C8orf40	0.53	9.23	0.45	3.26e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3741151	0.773	rs73548688	chr11:73279544	C/T	cg17517138	chr11:73019481	ARHGEF17	0.98	8.21	0.41	4.85e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs2562456	0.920	rs2650784	chr19:21666597	T/C	cg00806126	chr19:22604979	ZNF98	0.36	5.81	0.3	1.49e-8	Pain;
LUSC	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	25.83	0.82	1.3e-81	Colorectal cancer;
LUSC	cis	rs11625487	0.609	rs17824567	chr14:77976450	G/T	cg16049707	chr14:77965284	ISM2	0.61	6.74	0.35	6.99e-11	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.18e-10	Subjective well-being;
LUSC	cis	rs34734847	0.842	rs696337	chr12:121159380	T/C	cg21892295	chr12:121157589	UNC119B	-0.36	-6.31	-0.33	9.08e-10	Mean corpuscular volume;
LUSC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg04025307	chr7:1156635	C7orf50	0.43	6.48	0.33	3.33e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg05855489	chr10:104503620	C10orf26	0.53	7.96	0.4	2.73e-14	Arsenic metabolism;
LUSC	cis	rs3755132	0.929	rs976016	chr2:15772865	A/G	cg12888861	chr2:15731646	DDX1	0.5	7.17	0.37	5e-12	Wilms tumor;
LUSC	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg21573476	chr21:45109991	RRP1B	-0.37	-6.01	-0.31	4.75e-9	Mean corpuscular volume;
LUSC	cis	rs9920506	0.518	rs11072774	chr15:78952697	C/T	cg04896959	chr15:78267971	NA	-0.44	-7.47	-0.38	7.24e-13	Post bronchodilator FEV1;
LUSC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs9399401	0.677	rs6925979	chr6:142651052	G/A	cg04461802	chr6:142623433	GPR126	0.47	5.95	0.31	6.76e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.18	0.55	1.76e-28	Motion sickness;
LUSC	cis	rs4786125	0.596	rs12149100	chr16:6922512	T/G	cg03623568	chr16:6915990	A2BP1	-0.5	-8.41	-0.42	1.22e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg12744634	chr1:26560303	CCDC21	0.39	5.84	0.3	1.25e-8	Obesity-related traits;
LUSC	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-8.02	-0.4	1.81e-14	Morning vs. evening chronotype;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01171360	chr6:293285	DUSP22	-0.68	-11.15	-0.52	9.34e-25	Menopause (age at onset);
LUSC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg18404041	chr3:52824283	ITIH1	0.4	7.14	0.36	5.74e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.36	-0.37	1.4e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg23630131	chr7:65973040	NA	0.2	5.72	0.3	2.4e-8	Aortic root size;
LUSC	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	0.89	14.72	0.63	3.87e-38	Schizophrenia;
LUSC	trans	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	8.57	0.42	3.77e-16	Ulcerative colitis;
LUSC	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg05110241	chr16:68378359	PRMT7	-0.61	-6.63	-0.34	1.37e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg25319279	chr11:5960081	NA	-0.45	-6.27	-0.32	1.09e-9	DNA methylation (variation);
LUSC	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg14835575	chr10:16859367	RSU1	0.72	9.08	0.44	9.7e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs1044826	1.000	rs13083195	chr3:139067890	A/G	cg00490450	chr3:139108681	COPB2	0.56	7.41	0.38	1.05e-12	Obesity-related traits;
LUSC	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg18721089	chr20:30220636	NA	-0.34	-5.86	-0.31	1.13e-8	Mean corpuscular hemoglobin;
LUSC	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.1	-0.61	9.35e-36	Exhaled nitric oxide output;
LUSC	trans	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.65	0.39	2.18e-13	Ulcerative colitis;
LUSC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg24399712	chr22:39784796	NA	-0.57	-10.04	-0.48	6.46e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg24375607	chr4:120327624	NA	0.75	12.14	0.55	2.34e-28	Corneal astigmatism;
LUSC	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg08975724	chr8:8085496	FLJ10661	0.53	8.0	0.4	2.02e-14	Neuroticism;
LUSC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg00310523	chr12:86230176	RASSF9	0.52	9.81	0.47	3.97e-20	Major depressive disorder;
LUSC	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08109568	chr15:31115862	NA	0.49	6.91	0.35	2.43e-11	Huntington's disease progression;
LUSC	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg04586622	chr2:25135609	ADCY3	0.43	9.06	0.44	1.16e-17	Body mass index;
LUSC	cis	rs666930	0.519	rs477992	chr1:120257576	A/G	cg19096424	chr1:120255104	PHGDH	0.6	8.81	0.43	6.88e-17	Breast cancer;
LUSC	cis	rs7180079	1.000	rs2062248	chr15:64672319	C/T	cg02848875	chr15:64387786	SNX1	0.44	5.68	0.3	2.88e-8	Monocyte count;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02632015	chr17:19551762	ALDH3A2	0.66	5.95	0.31	6.59e-9	Cognitive performance;
LUSC	cis	rs4499344	0.633	rs411328	chr19:33140178	T/G	cg22980127	chr19:33182716	NUDT19	-0.41	-6.08	-0.32	3.19e-9	Mean platelet volume;
LUSC	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-0.99	-16.84	-0.68	1.61e-46	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	9.75	0.47	6.31e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-1.14	-18.19	-0.71	7.14e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	13.27	0.59	1.39e-32	Post bronchodilator FEV1;
LUSC	cis	rs41271473	1.000	rs72751929	chr1:228884358	A/G	cg10167378	chr1:228756711	NA	0.54	6.54	0.34	2.33e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-1.07	-15.85	-0.66	1.39e-42	Initial pursuit acceleration;
LUSC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg22907277	chr7:1156413	C7orf50	0.66	7.25	0.37	2.83e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.53	0.38	4.76e-13	Colorectal cancer;
LUSC	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg21053147	chr12:120880522	NA	-0.5	-6.22	-0.32	1.45e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs11971779	0.680	rs6949599	chr7:139054188	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg09455208	chr3:40491958	NA	-0.4	-7.41	-0.38	1.06e-12	Renal cell carcinoma;
LUSC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg22166914	chr1:53195759	ZYG11B	-0.69	-12.06	-0.55	4.87e-28	Monocyte count;
LUSC	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg24579218	chr15:68104479	NA	-0.36	-6.27	-0.32	1.13e-9	Obesity;
LUSC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg01097406	chr16:89675127	NA	0.3	5.69	0.3	2.72e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs1595825	0.628	rs6760078	chr2:198563742	A/T	cg00982548	chr2:198649783	BOLL	-0.55	-7.12	-0.36	6.68e-12	Ulcerative colitis;
LUSC	trans	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg26384229	chr12:38710491	ALG10B	0.54	8.35	0.42	1.9e-15	Morning vs. evening chronotype;
LUSC	cis	rs4654899	0.865	rs12123300	chr1:21323568	T/C	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.52	-0.34	2.56e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg10253484	chr15:75165896	SCAMP2	-0.5	-6.55	-0.34	2.17e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg07936489	chr17:37558343	FBXL20	0.61	7.55	0.38	4.13e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg13770153	chr20:60521292	NA	-0.61	-8.34	-0.42	1.99e-15	Body mass index;
LUSC	cis	rs686320	1.000	rs35940245	chr11:65232673	G/A	cg21890820	chr11:65308645	LTBP3	0.8	8.14	0.41	7.68e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg08886695	chr4:3369023	RGS12	-0.34	-5.68	-0.3	2.96e-8	Parental longevity (mother's age at death);
LUSC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10802521	chr3:52805072	NEK4	-0.51	-7.98	-0.4	2.32e-14	Bipolar disorder;
LUSC	cis	rs7011049	1.000	rs72640863	chr8:53841706	A/T	cg26025543	chr8:53854495	NA	0.52	6.3	0.33	9.5e-10	Systolic blood pressure;
LUSC	cis	rs1595825	0.786	rs1902246	chr2:198492827	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.52	-0.34	2.61e-10	Ulcerative colitis;
LUSC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg13047869	chr3:10149882	C3orf24	0.6	8.36	0.42	1.77e-15	Alzheimer's disease;
LUSC	cis	rs7582720	0.945	rs114604411	chr2:203811912	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg06521331	chr12:34319734	NA	-0.4	-6.91	-0.35	2.47e-11	Morning vs. evening chronotype;
LUSC	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg05340658	chr4:99064831	C4orf37	0.43	6.87	0.35	3.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1322512	0.713	rs1405693	chr6:152937189	T/C	cg27316956	chr6:152958899	SYNE1	-0.36	-5.94	-0.31	7.06e-9	Tonometry;
LUSC	cis	rs4776059	0.798	rs2414160	chr15:52872530	G/C	cg22715398	chr15:52968154	KIAA1370	0.63	7.74	0.39	1.18e-13	Schizophrenia;
LUSC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.95	-0.31	6.75e-9	Tonsillectomy;
LUSC	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg22906224	chr7:99728672	NA	0.42	5.68	0.3	2.88e-8	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21183028	chr2:37384229	EIF2AK2	0.5	6.9	0.35	2.63e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.79	0.3	1.59e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg11130432	chr3:121712080	ILDR1	-0.63	-9.59	-0.46	2.19e-19	Multiple sclerosis;
LUSC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.2	-0.37	3.9e-12	Bipolar disorder;
LUSC	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg06484146	chr7:12443880	VWDE	-0.68	-7.08	-0.36	8.65e-12	Coronary artery disease;
LUSC	cis	rs11630290	0.589	rs2414845	chr15:64167954	T/C	cg12036633	chr15:63758958	NA	0.47	5.78	0.3	1.71e-8	Iris characteristics;
LUSC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.17	-0.52	7.89e-25	Mean corpuscular volume;
LUSC	trans	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17712092	chr4:129076599	LARP1B	0.74	11.3	0.53	2.67e-25	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg06784218	chr1:46089804	CCDC17	0.35	5.99	0.31	5.39e-9	Platelet count;
LUSC	cis	rs9473147	0.516	rs6904764	chr6:47503497	A/T	cg20196966	chr6:47445060	CD2AP	0.41	5.64	0.3	3.58e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg05585544	chr11:47624801	NA	-0.42	-7.36	-0.37	1.45e-12	Subjective well-being;
LUSC	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg19676328	chr12:49525230	TUBA1B	-0.51	-8.16	-0.41	6.98e-15	Total cholesterol levels;
LUSC	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg24558204	chr6:135376177	HBS1L	0.58	8.7	0.43	1.51e-16	Red blood cell count;
LUSC	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.12	-0.55	2.86e-28	Mean corpuscular volume;
LUSC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg00343986	chr7:65444356	GUSB	0.44	6.73	0.35	7.5e-11	Aortic root size;
LUSC	trans	rs17039065	1.000	rs11736209	chr4:109394658	A/T	cg07444054	chr2:108107501	NA	0.41	6.11	0.32	2.74e-9	Gut microbiome composition (summer);
LUSC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	0.93	16.07	0.66	1.86e-43	Menopause (age at onset);
LUSC	cis	rs4132509	0.592	rs12076373	chr1:243851947	G/C	cg21452805	chr1:244014465	NA	0.6	6.62	0.34	1.4e-10	RR interval (heart rate);
LUSC	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg22467129	chr15:76604101	ETFA	-0.45	-7.14	-0.36	5.89e-12	Blood metabolite levels;
LUSC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg09359103	chr1:154839909	KCNN3	-0.71	-16.2	-0.66	6.03e-44	Prostate cancer;
LUSC	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg00334542	chr7:100209784	MOSPD3	-0.65	-7.55	-0.38	4.28e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs11229555	0.645	rs10466679	chr11:58188257	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.55	-0.38	4.06e-13	Depression;
LUSC	cis	rs1524927	0.966	rs1524920	chr7:96362894	C/T	cg03808172	chr7:96339361	SHFM1	-0.4	-6.1	-0.32	2.89e-9	Total body bone mineral density;
LUSC	cis	rs3820928	0.874	rs7563644	chr2:227846932	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.6	-0.38	3.07e-13	Pulmonary function;
LUSC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg22907277	chr7:1156413	C7orf50	0.68	7.31	0.37	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg19912559	chr1:40204330	PPIE	0.53	8.18	0.41	6.17e-15	Blood protein levels;
LUSC	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg26876637	chr1:152193138	HRNR	0.47	6.6	0.34	1.66e-10	Atopic dermatitis;
LUSC	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg22491629	chr6:157744540	C6orf35	-0.92	-10.95	-0.51	4.68e-24	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.22	-15.44	-0.65	5.73e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg12483005	chr1:23474871	LUZP1	0.45	6.92	0.35	2.28e-11	Height;
LUSC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.82	-15.1	-0.64	1.19e-39	Dental caries;
LUSC	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg19812747	chr11:111475976	SIK2	-0.5	-7.04	-0.36	1.1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg22823121	chr1:150693482	HORMAD1	0.57	8.85	0.44	5.33e-17	Tonsillectomy;
LUSC	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg13852791	chr20:30311386	BCL2L1	0.93	14.3	0.62	1.67e-36	Mean corpuscular hemoglobin;
LUSC	cis	rs2067615	0.524	rs10778504	chr12:107120424	C/T	cg19260189	chr12:106995001	RFX4	0.23	5.69	0.3	2.85e-8	Heart rate;
LUSC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg12463550	chr7:65579703	CRCP	-0.45	-6.65	-0.34	1.23e-10	Aortic root size;
LUSC	cis	rs7119	0.717	rs12916973	chr15:77808099	C/T	cg27398640	chr15:77910606	LINGO1	0.3	6.5	0.34	2.96e-10	Type 2 diabetes;
LUSC	trans	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg21775007	chr8:11205619	TDH	-0.42	-6.53	-0.34	2.48e-10	Mood instability;
LUSC	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.18	-0.37	4.7e-12	Type 2 diabetes;
LUSC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	16.58	0.67	1.84e-45	Platelet count;
LUSC	trans	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg05926928	chr17:57297772	GDPD1	-0.9	-10.32	-0.49	7.2e-22	Opioid sensitivity;
LUSC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg13319975	chr6:146136371	FBXO30	0.43	6.61	0.34	1.53e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7712401	0.541	rs42537	chr5:122274688	A/G	cg19077854	chr5:122220652	SNX24	0.42	9.32	0.45	1.68e-18	Mean platelet volume;
LUSC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02018176	chr4:1364513	KIAA1530	0.72	13.64	0.6	5.68e-34	Longevity;
LUSC	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg00846580	chr14:60632234	DHRS7	0.63	6.93	0.35	2.15e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.7	-0.39	1.6e-13	Glomerular filtration rate;
LUSC	cis	rs2580764	0.565	rs7562292	chr2:55230219	C/T	cg09592903	chr2:55203963	RTN4	-0.49	-10.1	-0.48	4.03e-21	Mean platelet volume;
LUSC	cis	rs10754283	0.934	rs6661282	chr1:90119992	C/T	cg21401794	chr1:90099060	LRRC8C	0.62	8.82	0.43	6.46e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-1.04	-19.98	-0.74	5.38e-59	Height;
LUSC	cis	rs6546550	0.835	rs3755389	chr2:70119469	T/C	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.17e-12	Prevalent atrial fibrillation;
LUSC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg12560992	chr17:57184187	TRIM37	0.74	12.23	0.56	1.15e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.28	0.53	3.13e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs9811920	0.809	rs902159	chr3:99747445	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.43	6.47	0.33	3.5e-10	Axial length;
LUSC	cis	rs11779988	0.545	rs208762	chr8:17806734	G/A	cg01800426	chr8:17659068	MTUS1	-0.47	-5.91	-0.31	8.27e-9	Breast cancer;
LUSC	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.4	-0.33	5.18e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg05064044	chr6:292385	DUSP22	0.49	7.35	0.37	1.58e-12	Menopause (age at onset);
LUSC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.44	0.33	4.07e-10	Menopause (age at onset);
LUSC	cis	rs7188861	0.603	rs2113260	chr16:11455993	C/T	cg00044050	chr16:11439710	C16orf75	0.59	9.03	0.44	1.41e-17	HDL cholesterol;
LUSC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.75	0.39	1.12e-13	Gut microbiome composition (summer);
LUSC	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg09367891	chr1:107599246	PRMT6	0.47	7.26	0.37	2.75e-12	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.27	-6.04	-0.31	4.18e-9	Renal function-related traits (BUN);
LUSC	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg06637938	chr14:75390232	RPS6KL1	0.5	7.74	0.39	1.21e-13	Caffeine consumption;
LUSC	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22980127	chr19:33182716	NUDT19	0.9	12.96	0.58	2.15e-31	Red blood cell traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12662162	chr6:34664887	C6orf106	0.42	6.11	0.32	2.7e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg10840412	chr1:235813424	GNG4	0.65	8.73	0.43	1.21e-16	Bipolar disorder;
LUSC	cis	rs1783925	1.000	rs1783925	chr11:125304009	C/T	cg03464685	chr11:125439445	EI24	0.45	6.05	0.31	3.95e-9	Formal thought disorder in schizophrenia;
LUSC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg02569458	chr12:86230093	RASSF9	0.61	10.31	0.49	8.24e-22	Major depressive disorder;
LUSC	cis	rs1298062	0.605	rs12327751	chr19:50968890	G/T	cg17071417	chr19:50962282	MYBPC2	0.34	5.7	0.3	2.67e-8	Age of smoking initiation;
LUSC	cis	rs9322817	0.691	rs9391241	chr6:105223663	T/C	cg02098413	chr6:105308735	HACE1	-0.28	-5.71	-0.3	2.51e-8	Thyroid stimulating hormone;
LUSC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg04414720	chr1:150670196	GOLPH3L	0.56	9.1	0.45	8.47e-18	Tonsillectomy;
LUSC	cis	rs16910800	0.953	rs73481416	chr11:23204663	T/A	cg20040320	chr11:23191996	NA	-0.44	-6.46	-0.33	3.8e-10	Cancer;
LUSC	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg27661571	chr11:113659931	NA	-0.55	-6.73	-0.35	7.54e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-0.82	-11.25	-0.52	4.12e-25	Eosinophil percentage of granulocytes;
LUSC	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg03433033	chr1:76189801	ACADM	-0.38	-5.84	-0.3	1.21e-8	Daytime sleep phenotypes;
LUSC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg07701084	chr6:150067640	NUP43	0.58	9.03	0.44	1.36e-17	Lung cancer;
LUSC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	0.89	16.91	0.68	9.05e-47	Gestational age at birth (maternal effect);
LUSC	cis	rs2067615	0.560	rs12298717	chr12:107099883	C/T	cg15890332	chr12:107067104	RFX4	-0.34	-6.16	-0.32	2.15e-9	Heart rate;
LUSC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.62	10.15	0.49	2.76e-21	Prostate cancer;
LUSC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-7.58	-0.38	3.35e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.33	0.37	1.74e-12	Motion sickness;
LUSC	trans	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg26043149	chr18:55253948	FECH	0.51	7.66	0.39	2.01e-13	Bone mineral density;
LUSC	cis	rs16910800	0.954	rs7123141	chr11:23203403	G/A	cg20040320	chr11:23191996	NA	-0.44	-6.46	-0.33	3.8e-10	Cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08018789	chr16:90039187	AFG3L1;CENPBD1	-0.43	-6.34	-0.33	7.35e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.42	-6.47	-0.33	3.59e-10	Platelet count;
LUSC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.4	-0.56	2.6e-29	Type 2 diabetes;
LUSC	cis	rs2249625	0.545	rs9791273	chr6:72891016	G/T	cg18830697	chr6:72922368	RIMS1	0.37	7.38	0.37	1.3e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	trans	rs10946292	0.656	rs6456170	chr6:170439920	G/C	cg17832364	chr10:94847294	NA	0.38	6.28	0.32	1.06e-9	Obesity-related traits;
LUSC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.8	-9.81	-0.47	3.97e-20	Refractive error;
LUSC	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	6.01	0.31	4.78e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg15017067	chr4:17643749	FAM184B	0.34	5.66	0.3	3.25e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-5.85	-0.31	1.15e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7539542	0.556	rs6686801	chr1:202874730	C/T	cg19681188	chr1:202830198	LOC148709	0.39	5.75	0.3	1.99e-8	Mean platelet volume;
LUSC	cis	rs4363385	0.818	rs3181787	chr1:153004809	T/C	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.44e-12	Inflammatory skin disease;
LUSC	cis	rs78579285	0.510	rs78759106	chr16:88788535	T/C	cg01900006	chr16:88814613	FAM38A	0.54	6.13	0.32	2.49e-9	Joint mobility (Beighton score);
LUSC	cis	rs73200209	0.744	rs56350518	chr12:116556775	A/G	cg01776926	chr12:116560359	MED13L	-0.5	-5.99	-0.31	5.44e-9	Total body bone mineral density;
LUSC	cis	rs11166629	1.000	rs2873014	chr8:135645860	C/T	cg21672855	chr8:135614777	ZFAT	-0.36	-5.74	-0.3	2.13e-8	Smoking quantity;
LUSC	cis	rs2290159	0.800	rs5746191	chr3:12658774	G/A	cg23032965	chr3:12705835	RAF1	0.74	8.94	0.44	2.75e-17	Cholesterol, total;
LUSC	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg00540400	chr15:79124168	NA	-0.47	-8.15	-0.41	7.33e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs1459104	0.925	rs35473011	chr11:54881353	G/A	cg15704280	chr7:45808275	SEPT13	0.71	6.34	0.33	7.62e-10	Body mass index;
LUSC	cis	rs72772090	0.634	rs12186366	chr5:96088850	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.74	-8.36	-0.42	1.74e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.41	6.2	0.32	1.63e-9	Colorectal cancer;
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	0.94	18.91	0.72	9.99e-55	Menarche (age at onset);
LUSC	cis	rs7178572	0.633	rs4886875	chr15:77838419	C/T	cg22256960	chr15:77711686	NA	0.47	7.06	0.36	9.54e-12	Type 2 diabetes;
LUSC	cis	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg05299278	chr17:33885742	SLFN14	-0.3	-6.31	-0.33	8.91e-10	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg09455208	chr3:40491958	NA	0.57	9.97	0.48	1.15e-20	Renal cell carcinoma;
LUSC	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg01448562	chr3:133502909	NA	-0.54	-8.06	-0.4	1.34e-14	Iron status biomarkers;
LUSC	cis	rs8092503	1.000	rs3764513	chr18:52495089	A/G	cg12377874	chr18:52495404	RAB27B	0.34	6.01	0.31	4.91e-9	Childhood body mass index;
LUSC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg14993813	chr1:46806288	NSUN4	0.49	6.81	0.35	4.49e-11	Menopause (age at onset);
LUSC	cis	rs2046867	0.661	rs9861834	chr3:72909272	C/T	cg25664220	chr3:72788482	NA	-0.47	-7.75	-0.39	1.08e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12928939	0.815	rs8049163	chr16:71719353	C/T	cg08717414	chr16:71523259	ZNF19	-0.41	-5.76	-0.3	1.96e-8	Post bronchodilator FEV1;
LUSC	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg24848339	chr3:12840334	CAND2	0.35	7.54	0.38	4.52e-13	QRS complex (12-leadsum);
LUSC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg15147215	chr3:52552868	STAB1	-0.32	-6.21	-0.32	1.56e-9	Bipolar disorder;
LUSC	cis	rs7572644	0.713	rs4233718	chr2:28066360	A/G	cg27432699	chr2:27873401	GPN1	0.52	6.62	0.34	1.45e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs113835537	0.559	rs74933537	chr11:66274958	A/C	cg24851651	chr11:66362959	CCS	0.53	7.92	0.4	3.47e-14	Airway imaging phenotypes;
LUSC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08219700	chr8:58056026	NA	0.65	7.22	0.37	3.52e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-16.29	-0.67	2.44e-44	Primary sclerosing cholangitis;
LUSC	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg18825076	chr15:78729989	IREB2	0.46	6.12	0.32	2.65e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg03060546	chr3:49711283	APEH	0.55	6.72	0.35	7.87e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs12594515	0.935	rs8042519	chr15:45996341	G/C	cg01629716	chr15:45996671	NA	0.4	5.93	0.31	7.63e-9	Waist circumference;Weight;
LUSC	cis	rs9687065	1.000	rs6885467	chr5:148379555	C/G	cg23229984	chr5:148520753	ABLIM3	-0.45	-6.91	-0.35	2.42e-11	Diastolic blood pressure;
LUSC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg09034736	chr1:150693464	HORMAD1	-0.44	-6.22	-0.32	1.53e-9	Melanoma;
LUSC	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg21775007	chr8:11205619	TDH	-0.59	-9.28	-0.45	2.18e-18	Retinal vascular caliber;
LUSC	cis	rs10499694	0.868	rs1470749	chr7:50578023	G/T	cg18232548	chr7:50535776	DDC	-0.4	-5.88	-0.31	1.02e-8	Body mass index;
LUSC	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.35	-0.37	1.56e-12	Morning vs. evening chronotype;
LUSC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg14784868	chr12:69753453	YEATS4	0.63	8.92	0.44	3.09e-17	Response to diuretic therapy;
LUSC	cis	rs7173743	0.967	rs28580532	chr15:79134724	C/T	cg00540400	chr15:79124168	NA	-0.33	-5.67	-0.3	3.08e-8	Coronary artery disease;
LUSC	cis	rs10492096	0.945	rs1045546	chr12:6567907	C/T	cg13857086	chr12:6580257	VAMP1	0.82	9.17	0.45	4.96e-18	Hip geometry;
LUSC	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.99	-0.36	1.49e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg25703541	chr22:24373054	LOC391322	-0.87	-14.94	-0.63	5.19e-39	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg23795048	chr12:9217529	LOC144571	0.34	5.88	0.31	1.02e-8	Sjögren's syndrome;
LUSC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg05535760	chr7:792225	HEATR2	0.79	9.26	0.45	2.63e-18	Cerebrospinal P-tau181p levels;
LUSC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg06454157	chr6:167490870	NA	-0.27	-6.64	-0.34	1.28e-10	Primary biliary cholangitis;
LUSC	cis	rs17253792	0.822	rs74940664	chr14:56135065	A/G	cg01858014	chr14:56050164	KTN1	-0.77	-6.57	-0.34	1.95e-10	Putamen volume;
LUSC	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.0	0.4	2.01e-14	Homoarginine levels;
LUSC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg09034736	chr1:150693464	HORMAD1	0.41	5.75	0.3	2.04e-8	Melanoma;
LUSC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.67	-0.5	4.64e-23	Alzheimer's disease (late onset);
LUSC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg02423579	chr7:2872169	GNA12	-0.5	-7.18	-0.37	4.56e-12	Height;
LUSC	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg11584989	chr19:19387371	SF4	0.58	6.97	0.36	1.74e-11	Bipolar disorder;
LUSC	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.2e-15	Neuroticism;
LUSC	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-8.01	-0.4	1.91e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-0.94	-18.88	-0.72	1.24e-54	Cognitive function;
LUSC	trans	rs2268344	0.562	rs909290	chr10:124264032	A/G	cg11199862	chr13:46108984	COG3	-0.67	-5.99	-0.31	5.3300000000000004e-09	Coronary artery disease;
LUSC	cis	rs60695258	0.550	rs6531948	chr4:87972968	T/C	cg10685359	chr4:87814065	C4orf36	-0.35	-6.24	-0.32	1.3e-9	Hematocrit;
LUSC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg18876405	chr7:65276391	NA	-0.52	-8.24	-0.41	3.85e-15	Calcium levels;
LUSC	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg20059928	chr15:40361485	NA	-0.51	-6.05	-0.31	3.94e-9	Corneal curvature;
LUSC	cis	rs17255340	0.539	rs1170342	chr6:84034415	T/G	cg08257003	chr6:84140564	ME1	0.34	8.19	0.41	5.61e-15	Platelet-derived growth factor BB levels;
LUSC	trans	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.85	0.35	3.56e-11	Endometrial cancer;
LUSC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg26695010	chr11:65641043	EFEMP2	-0.47	-6.91	-0.35	2.39e-11	Eosinophil percentage of white cells;
LUSC	cis	rs3741151	0.687	rs56857598	chr11:73234173	G/A	cg17517138	chr11:73019481	ARHGEF17	0.96	8.06	0.4	1.35e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg05926928	chr17:57297772	GDPD1	-0.46	-6.53	-0.34	2.38e-10	Schizophrenia;
LUSC	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg13042288	chr15:90349979	ANPEP	-0.44	-6.41	-0.33	4.87e-10	Uric acid levels;
LUSC	cis	rs4474465	0.646	rs4945301	chr11:78283362	A/G	cg27205649	chr11:78285834	NARS2	0.56	6.83	0.35	4.11e-11	Alzheimer's disease (survival time);
LUSC	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg03585969	chr10:35415529	CREM	0.62	8.97	0.44	2.2e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg18827107	chr12:86230957	RASSF9	-0.38	-5.67	-0.3	3.15e-8	Major depressive disorder;
LUSC	cis	rs7605827	0.930	rs2160691	chr2:15598197	G/A	cg19274914	chr2:15703543	NA	0.46	8.9	0.44	3.54e-17	Educational attainment (years of education);
LUSC	cis	rs1775715	0.707	rs2065443	chr10:32164236	C/G	cg26784012	chr10:32216390	ARHGAP12	0.46	7.84	0.39	6.07e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4356932	0.967	rs28681694	chr4:76972594	A/C	cg00809888	chr4:76862425	NAAA	0.35	5.85	0.3	1.2e-8	Blood protein levels;
LUSC	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg11244672	chr19:19639970	YJEFN3	0.61	7.59	0.38	3.3e-13	Bipolar disorder;
LUSC	trans	rs4588	0.626	rs2091395	chr4:72596468	G/A	cg14203426	chr7:101723947	CUX1	-0.39	-5.95	-0.31	6.84e-9	Vitamin D levels;
LUSC	cis	rs7246967	0.673	rs7253063	chr19:22865897	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs9309473	1.000	rs7607014	chr2:73730174	C/T	cg20560298	chr2:73613845	ALMS1	0.42	6.1	0.32	3e-9	Metabolite levels;
LUSC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	6.79	0.35	5.25e-11	Lung cancer in ever smokers;
LUSC	cis	rs12618769	0.597	rs17031139	chr2:99036530	A/G	cg10123293	chr2:99228465	UNC50	-0.47	-8.01	-0.4	1.93e-14	Bipolar disorder;
LUSC	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.95	12.18	0.55	1.74e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs2734839	0.927	rs2734837	chr11:113286829	C/T	cg14159747	chr11:113255604	NA	0.26	6.56	0.34	2.1e-10	Information processing speed;
LUSC	cis	rs10887741	0.646	rs10218939	chr10:89436853	A/G	cg13926569	chr10:89418898	PAPSS2	0.32	6.92	0.35	2.27e-11	Exercise (leisure time);
LUSC	trans	rs6076960	0.629	rs6054024	chr20:6229282	A/C	cg21095983	chr6:86352623	SYNCRIP	0.5	7.74	0.39	1.19e-13	Smooth-surface caries;
LUSC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs73206853	0.563	rs73194046	chr12:111191665	A/G	cg12870014	chr12:110450643	ANKRD13A	0.66	6.91	0.35	2.49e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg13628971	chr7:2884303	GNA12	0.48	6.69	0.34	9.35e-11	Height;
LUSC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	13.58	0.6	9.2e-34	Chronic sinus infection;
LUSC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs4499344	0.633	rs259258	chr19:33152523	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	11.42	0.53	1.02e-25	Mean platelet volume;
LUSC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.56	8.72	0.43	1.29e-16	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03698702	chr19:36236336	PSENEN;U2AF1L4	0.43	6.55	0.34	2.17e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg24476569	chr13:95954382	ABCC4	-0.5	-7.94	-0.4	3.11e-14	Blood metabolite levels;
LUSC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.94	0.44	2.75e-17	Prudent dietary pattern;
LUSC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.35	-0.37	1.56e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs75920871	0.528	rs11600552	chr11:116900947	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.42	-0.33	4.68e-10	Subjective well-being;
LUSC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg27432699	chr2:27873401	GPN1	-0.56	-8.31	-0.41	2.49e-15	Total body bone mineral density;
LUSC	cis	rs981844	0.826	rs4585278	chr4:154684145	A/G	cg14289246	chr4:154710475	SFRP2	0.5	6.71	0.34	8.26e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs12900413	0.603	rs4448912	chr15:90299690	G/A	cg24249390	chr15:90295951	MESP1	-0.37	-5.91	-0.31	8.58e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs11167764	0.638	rs7729747	chr5:141478055	C/A	cg08523384	chr5:141488047	NDFIP1	-0.51	-6.86	-0.35	3.42e-11	Crohn's disease;
LUSC	trans	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg07817883	chr1:32538562	TMEM39B	-0.61	-7.39	-0.37	1.17e-12	Monocyte percentage of white cells;
LUSC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg13206674	chr6:150067644	NUP43	0.58	9.05	0.44	1.19e-17	Lung cancer;
LUSC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg13736514	chr6:26305472	NA	-0.47	-9.43	-0.46	7.21e-19	Educational attainment;
LUSC	cis	rs4588572	0.644	rs6873144	chr5:77741784	C/T	cg11547950	chr5:77652471	NA	-0.46	-6.74	-0.35	7.08e-11	Triglycerides;
LUSC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg22166914	chr1:53195759	ZYG11B	-0.62	-10.21	-0.49	1.73e-21	Monocyte count;
LUSC	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg21141812	chr3:48556323	PFKFB4	-0.32	-6.48	-0.33	3.25e-10	Prion diseases;
LUSC	cis	rs2637266	1.000	rs6480824	chr10:78355705	G/A	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs9302690	0.557	rs223875	chr16:57506915	C/T	cg16753122	chr16:57506917	DOK4	0.56	6.98	0.36	1.55e-11	Blood protein levels;
LUSC	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg08557956	chr11:4115526	RRM1	-0.45	-5.69	-0.3	2.74e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.58	-0.57	5.63e-30	Alzheimer's disease;
LUSC	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg04155231	chr12:9217510	LOC144571	0.31	5.69	0.3	2.82e-8	Sjögren's syndrome;
LUSC	cis	rs4974559	0.947	rs10000012	chr4:1357325	C/G	cg02980000	chr4:1222292	CTBP1	-0.68	-7.07	-0.36	9.03e-12	Systolic blood pressure;
LUSC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg11845111	chr2:191398756	TMEM194B	0.57	9.65	0.47	1.36e-19	Pulse pressure;
LUSC	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg21545522	chr1:205238299	TMCC2	0.46	8.63	0.43	2.61e-16	Red blood cell count;
LUSC	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg03806693	chr22:41940476	POLR3H	-0.78	-11.17	-0.52	7.84e-25	Vitiligo;
LUSC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.81	-0.35	4.6e-11	Menopause (age at onset);
LUSC	trans	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.5	-7.15	-0.36	5.39e-12	Blood trace element (Cu levels);
LUSC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.56	8.67	0.43	1.9e-16	Longevity;
LUSC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg02423579	chr7:2872169	GNA12	-0.43	-6.1	-0.32	2.95e-9	Height;
LUSC	cis	rs9326248	0.520	rs10892060	chr11:116881662	C/A	cg11861562	chr11:117069780	TAGLN	0.31	6.09	0.32	3.08e-9	Blood protein levels;
LUSC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg07507251	chr3:52567010	NT5DC2	0.32	6.3	0.33	9.19e-10	Bipolar disorder;
LUSC	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg27068330	chr11:65405492	SIPA1	-0.75	-10.45	-0.5	2.65e-22	Acne (severe);
LUSC	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg10523679	chr1:76189770	ACADM	0.48	7.14	0.36	5.75e-12	Daytime sleep phenotypes;
LUSC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg03146154	chr1:46216737	IPP	0.56	8.36	0.42	1.77e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12190007	0.508	rs9406321	chr6:169726841	A/T	cg16388071	chr6:169726476	NA	0.44	6.79	0.35	5.29e-11	Obesity-related traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02836487	chr3:128206457	GATA2	0.41	6.18	0.32	1.82e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.85	13.93	0.61	4.13e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg13072238	chr3:49761600	GMPPB	-0.7	-8.8	-0.43	7.28e-17	Menarche (age at onset);
LUSC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg22800045	chr5:56110881	MAP3K1	0.78	9.7	0.47	9.52e-20	Initial pursuit acceleration;
LUSC	trans	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg25214090	chr10:38739885	LOC399744	-0.49	-7.33	-0.37	1.77e-12	Corneal astigmatism;
LUSC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	0.83	14.06	0.61	1.38e-35	Menopause (age at onset);
LUSC	cis	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg21775007	chr8:11205619	TDH	0.47	6.71	0.34	8.33e-11	Triglycerides;
LUSC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg04455712	chr21:45112962	RRP1B	0.44	8.29	0.41	2.74e-15	Mean corpuscular volume;
LUSC	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg22676075	chr6:135203613	NA	0.49	7.68	0.39	1.72e-13	Red blood cell count;
LUSC	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg25828445	chr12:7781288	NA	-0.76	-7.14	-0.36	5.97e-12	HDL cholesterol levels;
LUSC	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg14227996	chr4:17616232	MED28	0.82	7.87	0.4	4.98e-14	Opioid sensitivity;
LUSC	cis	rs7264396	0.887	rs3818441	chr20:34046501	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.71	-0.34	8.33e-11	Total cholesterol levels;
LUSC	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg06462663	chr19:18546047	ISYNA1	0.49	8.25	0.41	3.75e-15	Breast cancer;
LUSC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08859206	chr1:53392774	SCP2	0.56	9.9	0.48	1.93e-20	Monocyte count;
LUSC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.98	0.58	1.75e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg09796270	chr17:17721594	SREBF1	-0.43	-7.55	-0.38	4.32e-13	Total body bone mineral density;
LUSC	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.84	14.89	0.63	8.18e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg24209194	chr3:40518798	ZNF619	0.47	6.38	0.33	6.01e-10	Renal cell carcinoma;
LUSC	cis	rs11630290	1.000	rs72750981	chr15:63983737	A/T	cg12036633	chr15:63758958	NA	-0.73	-8.15	-0.41	7.63e-15	Iris characteristics;
LUSC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15369054	chr17:80825471	TBCD	0.69	11.31	0.53	2.57e-25	Breast cancer;
LUSC	cis	rs1891275	0.515	rs7098763	chr10:93444827	C/T	cg07889827	chr10:93443413	NA	-0.38	-8.55	-0.42	4.34e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg08270630	chr22:50330655	NA	-0.43	-6.42	-0.33	4.8e-10	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	8.34	0.42	1.94e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs16949788	1.000	rs7183477	chr15:66748212	T/A	cg08120210	chr15:66682733	MAP2K1	-0.62	-6.2	-0.32	1.65e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1172822	0.828	rs11668344	chr19:55833664	A/G	cg04391588	chr19:55832610	TMEM150B	0.31	5.71	0.3	2.53e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg04508216	chr1:11107452	MASP2	-0.34	-6.08	-0.32	3.2e-9	Body mass index;
LUSC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	0.99	13.49	0.59	2.17e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs7072216	0.763	rs7914401	chr10:100163928	A/G	cg26618903	chr10:100175079	PYROXD2	-0.44	-8.53	-0.42	5.25e-16	Metabolite levels;
LUSC	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg17517138	chr11:73019481	ARHGEF17	1.11	9.05	0.44	1.23e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg03678062	chr6:149772716	ZC3H12D	0.33	6.8	0.35	4.78e-11	Dupuytren's disease;
LUSC	cis	rs16895831	0.519	rs12196856	chr6:42554187	T/A	cg10605015	chr6:42532144	UBR2	-0.49	-5.88	-0.31	1.01e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs9467773	0.550	rs4712987	chr6:26399615	A/C	cg09904177	chr6:26538194	HMGN4	-0.55	-8.16	-0.41	6.83e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9309473	0.615	rs62153183	chr2:73763366	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-6.76	-0.35	6.3e-11	Metabolite levels;
LUSC	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs11051970	0.918	rs6488050	chr12:32532499	A/T	cg02745156	chr12:32552066	NA	0.44	6.98	0.36	1.58e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg07936489	chr17:37558343	FBXL20	-0.72	-9.84	-0.47	3.07e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs1355223	0.934	rs5010670	chr11:34766649	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.85	-0.3	1.15e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs7572644	0.679	rs17006365	chr2:28123374	T/G	cg27432699	chr2:27873401	GPN1	-0.52	-6.95	-0.36	1.91e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg07701084	chr6:150067640	NUP43	0.47	6.98	0.36	1.56e-11	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.6	0.57	4.77e-30	Motion sickness;
LUSC	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.68	9.59	0.46	2.11e-19	Methadone dose in opioid dependence;
LUSC	trans	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.64	10.19	0.49	2.01e-21	Endometrial cancer;
LUSC	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg05714579	chr10:131428358	MGMT	0.53	8.08	0.4	1.19e-14	Response to temozolomide;
LUSC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg01065977	chr19:18549689	ISYNA1	-0.22	-5.65	-0.3	3.51e-8	Breast cancer;
LUSC	trans	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03911494	chr16:71660463	MARVELD3	-0.43	-6.61	-0.34	1.51e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg24675658	chr1:53192096	ZYG11B	0.58	9.11	0.45	7.92e-18	Monocyte count;
LUSC	cis	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05901451	chr6:126070800	HEY2	-0.57	-8.56	-0.42	4.29e-16	Endometrial cancer;
LUSC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg08470875	chr2:26401718	FAM59B	-0.7	-9.1	-0.45	8.49e-18	Gut microbiome composition (summer);
LUSC	trans	rs2894969	0.664	rs11252703	chr10:4795125	A/T	cg11399754	chr5:64920452	C5orf44;TRIM23	0.39	6.08	0.32	3.29e-9	Major depressive disorder;
LUSC	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.39	-0.42	1.41e-15	Response to antipsychotic treatment;
LUSC	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg09238746	chr17:78121135	EIF4A3	0.72	10.73	0.51	2.88e-23	Yeast infection;
LUSC	cis	rs4654899	0.743	rs61781069	chr1:21130735	T/C	cg01072550	chr1:21505969	NA	-0.52	-7.6	-0.38	2.97e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg00339695	chr16:24857497	SLC5A11	0.37	6.5	0.34	2.96e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.84	13.65	0.6	4.98e-34	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.52	-6.09	-0.32	3.13e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg08798685	chr6:27730294	NA	-0.48	-5.92	-0.31	7.91e-9	Breast cancer;
LUSC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00149659	chr3:10157352	C3orf10	0.9	11.91	0.55	1.63e-27	Alzheimer's disease;
LUSC	cis	rs1322512	0.876	rs1744372	chr6:152944926	C/G	cg27316956	chr6:152958899	SYNE1	-0.33	-5.66	-0.3	3.25e-8	Tonometry;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11380545	chr4:83351682	ENOPH1;HNRPDL	-0.43	-6.39	-0.33	5.5e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1535500	1.000	rs3734618	chr6:39284184	A/G	cg03252829	chr6:39282164	KCNK17	-0.32	-5.67	-0.3	3.1e-8	Type 2 diabetes;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04031383	chr16:84088007	MBTPS1	-0.73	-6.07	-0.32	3.48e-9	Cognitive performance;
LUSC	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg15571903	chr15:79123663	NA	-0.36	-6.58	-0.34	1.8e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg12935359	chr14:103987150	CKB	-0.54	-9.01	-0.44	1.62e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg06636001	chr8:8085503	FLJ10661	0.56	8.34	0.42	1.98e-15	Retinal vascular caliber;
LUSC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07677032	chr17:61819896	STRADA	0.53	8.93	0.44	2.87e-17	Prudent dietary pattern;
LUSC	cis	rs62458065	0.850	rs62458066	chr7:32464484	C/T	cg20159608	chr7:32802032	NA	-0.69	-8.19	-0.41	5.6e-15	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs10486158	0.689	rs2052137	chr7:7385180	C/T	cg01895333	chr3:109035405	DPPA2	-0.38	-6.02	-0.31	4.65e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.63	-0.43	2.59e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg14631576	chr9:95140430	CENPP	0.33	5.88	0.31	9.97e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.94	12.35	0.56	4.02e-29	Exhaled nitric oxide output;
LUSC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg15017067	chr4:17643749	FAM184B	-0.35	-5.72	-0.3	2.34e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6840360	0.607	rs1561918	chr4:152446832	T/A	cg20465933	chr4:152376761	FAM160A1	0.33	5.97	0.31	6.02e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.89	-0.55	2.03e-27	Type 2 diabetes;
LUSC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.84	0.3	1.22e-8	Menopause (age at onset);
LUSC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.46	-7.64	-0.39	2.34e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.89	0.61	5.9e-35	Platelet count;
LUSC	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg00810483	chr4:3375144	RGS12	0.3	5.66	0.3	3.19e-8	Serum sulfate level;
LUSC	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg18827107	chr12:86230957	RASSF9	-0.41	-5.93	-0.31	7.42e-9	Major depressive disorder;
LUSC	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg22139774	chr2:100720529	AFF3	0.48	8.39	0.42	1.42e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7607369	0.559	rs13027908	chr2:219660374	T/C	cg02176678	chr2:219576539	TTLL4	-0.54	-9.62	-0.47	1.72e-19	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.61	11.01	0.52	2.95e-24	Weight;
LUSC	cis	rs4889855	0.556	rs74003969	chr17:78526212	C/T	cg16591659	chr17:78472290	NA	0.33	5.83	0.3	1.34e-8	Fractional excretion of uric acid;
LUSC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg06618935	chr21:46677482	NA	-0.41	-8.04	-0.4	1.58e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg02269571	chr22:50332266	NA	0.58	7.48	0.38	6.75e-13	Schizophrenia;
LUSC	trans	rs6480314	0.542	rs61854813	chr10:70027221	G/T	cg04882175	chr6:131122610	NA	-0.55	-6.39	-0.33	5.64e-10	Optic nerve measurement (disc area);
LUSC	trans	rs7939886	0.920	rs11227507	chr11:55972274	G/A	cg03929089	chr4:120376271	NA	0.83	6.2	0.32	1.71e-9	Myopia (pathological);
LUSC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg04369109	chr6:150039330	LATS1	-0.58	-8.57	-0.42	4e-16	Lung cancer;
LUSC	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg08085267	chr17:45401833	C17orf57	0.47	6.92	0.35	2.37e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg09594475	chr20:60884601	LAMA5	0.46	6.93	0.35	2.12e-11	Pelvic organ prolapse;
LUSC	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg04310649	chr10:35416472	CREM	-0.41	-6.32	-0.33	8.17e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg17724175	chr1:150552817	MCL1	-0.37	-6.72	-0.35	7.92e-11	Tonsillectomy;
LUSC	cis	rs9359856	0.518	rs10944451	chr6:90262341	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.57	-6.07	-0.32	3.45e-9	Bipolar disorder;
LUSC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs75763843	1.000	rs12456660	chr18:42101049	C/T	cg12620806	chr12:5602045	NTF3	-0.53	-6.01	-0.31	4.8e-9	Mean platelet volume;
LUSC	cis	rs240764	0.658	rs9404053	chr6:101254456	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-6.56	-0.34	2.01e-10	Neuroticism;
LUSC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg07701084	chr6:150067640	NUP43	0.51	7.27	0.37	2.65e-12	Lung cancer;
LUSC	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg04851639	chr8:1020857	NA	-0.38	-7.78	-0.39	9.14e-14	Schizophrenia;
LUSC	cis	rs7584330	0.554	rs76605518	chr2:238425992	G/A	cg16989719	chr2:238392110	NA	-0.43	-6.2	-0.32	1.65e-9	Prostate cancer;
LUSC	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg24675056	chr1:15929824	NA	0.47	8.2	0.41	5.31e-15	Systolic blood pressure;
LUSC	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg04362960	chr10:104952993	NT5C2	-0.61	-9.11	-0.45	7.55e-18	Immature fraction of reticulocytes;Schizophrenia;
LUSC	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.4	-0.42	1.34e-15	Retinal vascular caliber;
LUSC	cis	rs354225	0.544	rs10208225	chr2:54806049	G/A	cg26097391	chr2:54893211	SPTBN1	0.46	6.95	0.36	1.88e-11	Schizophrenia;
LUSC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg25072359	chr17:41440525	NA	0.58	7.51	0.38	5.43e-13	Menopause (age at onset);
LUSC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg25456477	chr12:86230367	RASSF9	-0.32	-5.69	-0.3	2.83e-8	Major depressive disorder;
LUSC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg06618935	chr21:46677482	NA	-0.37	-7.41	-0.38	1.02e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11756438	0.572	rs1857312	chr6:119001526	A/C	cg18833306	chr6:118973337	C6orf204	0.36	5.76	0.3	1.88e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1185460	0.904	rs1003081	chr11:118913993	A/G	cg23280166	chr11:118938394	VPS11	-0.38	-5.66	-0.3	3.23e-8	Coronary artery disease;
LUSC	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg00191853	chr8:101177733	SPAG1	-0.4	-6.39	-0.33	5.48e-10	Atrioventricular conduction;
LUSC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg21535247	chr6:8435926	SLC35B3	0.57	9.02	0.44	1.5e-17	Motion sickness;
LUSC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.31	-0.37	1.94e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.16	0.32	2.05e-9	Corneal astigmatism;
LUSC	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.41	-0.33	4.83e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg13072238	chr3:49761600	GMPPB	-0.63	-8.04	-0.4	1.57e-14	Menarche (age at onset);
LUSC	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg20821713	chr7:1055600	C7orf50	-0.4	-5.66	-0.3	3.2e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs7572644	0.640	rs11901133	chr2:28069713	T/G	cg27432699	chr2:27873401	GPN1	0.51	6.96	0.36	1.78e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg04896959	chr15:78267971	NA	-0.46	-9.11	-0.45	7.57e-18	Coronary artery disease or large artery stroke;
LUSC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg22166914	chr1:53195759	ZYG11B	0.61	10.25	0.49	1.29e-21	Monocyte count;
LUSC	cis	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05901451	chr6:126070800	HEY2	0.57	8.61	0.43	2.85e-16	Endometrial cancer;
LUSC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.31	-0.56	5.76e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg21775007	chr8:11205619	TDH	-0.67	-10.66	-0.5	5.14e-23	Retinal vascular caliber;
LUSC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg06600287	chr1:53387719	ECHDC2	-0.31	-6.42	-0.33	4.8e-10	Monocyte count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19483816	chr5:180670343	GNB2L1;SNORD95;SNORD96A	0.43	6.42	0.33	4.8e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs72949976	0.646	rs1441169	chr2:214033530	A/G	cg08319019	chr2:214017104	IKZF2	0.63	10.34	0.49	6.58e-22	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg08219700	chr8:58056026	NA	0.49	6.11	0.32	2.75e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg08601574	chr20:25228251	PYGB	0.44	6.79	0.35	5.29e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12760731	0.720	rs2862379	chr1:178442906	T/A	cg00404053	chr1:178313656	RASAL2	0.59	6.32	0.33	8.28e-10	Obesity-related traits;
LUSC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg00945038	chr17:61921165	SMARCD2	0.54	9.36	0.46	1.17e-18	Prudent dietary pattern;
LUSC	trans	rs853679	1.000	rs853676	chr6:28299687	C/T	cg01620082	chr3:125678407	NA	-0.59	-6.6	-0.34	1.62e-10	Depression;
LUSC	cis	rs4964805	0.770	rs11111779	chr12:104185496	G/A	cg02344784	chr12:104178138	NT5DC3	0.43	6.97	0.36	1.7e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg00495681	chr13:53174319	NA	0.79	15.33	0.64	1.48e-40	Lewy body disease;
LUSC	cis	rs6977660	0.714	rs10232870	chr7:19818040	A/G	cg05791153	chr7:19748676	TWISTNB	0.66	7.0	0.36	1.38e-11	Thyroid stimulating hormone;
LUSC	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.59	-9.61	-0.47	1.89e-19	Body mass index;
LUSC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.34	0.59	7.79e-33	Cognitive test performance;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21369679	chr16:47007757	DNAJA2	0.47	6.53	0.34	2.39e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.73	14.19	0.61	4.47e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2303282	0.639	rs11644357	chr16:56445252	G/T	cg00500540	chr16:56394104	NA	-0.39	-6.72	-0.34	8.01e-11	Breast cancer;
LUSC	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.14e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg24733560	chr20:60626293	TAF4	0.43	7.82	0.39	6.95e-14	Body mass index;
LUSC	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.8	11.88	0.55	2.12e-27	Lymphocyte counts;
LUSC	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.54	-10.72	-0.51	2.94e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg02972257	chr16:68554789	NA	0.45	5.87	0.31	1.06e-8	Colorectal cancer;
LUSC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.74	0.3	2.14e-8	Menopause (age at onset);
LUSC	cis	rs7246967	0.611	rs2885222	chr19:22839944	T/G	cg23217946	chr19:22817039	ZNF492	0.49	6.87	0.35	3.18e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg05855489	chr10:104503620	C10orf26	0.53	8.07	0.4	1.28e-14	Arsenic metabolism;
LUSC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08736216	chr1:53307985	ZYG11A	0.31	6.27	0.32	1.1e-9	Monocyte count;
LUSC	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.15	-0.45	5.6e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12220238	0.908	rs10824124	chr10:75997360	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.09	0.36	8.18e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs941898	0.957	rs3783337	chr14:100595278	T/A	cg26002632	chr14:100625216	DEGS2	-0.31	-5.66	-0.3	3.22e-8	White matter hyperintensity burden;
LUSC	cis	rs72949976	0.934	rs10197392	chr2:214038178	G/A	cg08319019	chr2:214017104	IKZF2	-0.62	-9.4	-0.46	9.07e-19	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg23711669	chr6:146136114	FBXO30	0.82	14.71	0.63	4.15e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.01	-0.4	1.87e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs2274273	0.840	rs28568813	chr14:55794114	C/G	cg04306507	chr14:55594613	LGALS3	0.56	12.93	0.58	2.87e-31	Protein biomarker;
LUSC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.87	14.2	0.61	3.99e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg25922239	chr6:33757077	LEMD2	0.53	8.0	0.4	2.01e-14	Crohn's disease;
LUSC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.27	-0.32	1.13e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg12292205	chr6:26970375	C6orf41	-0.68	-9.12	-0.45	7.09e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	0.97	10.96	0.51	4.58e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06481639	chr22:41940642	POLR3H	-0.53	-6.11	-0.32	2.81e-9	Vitiligo;
LUSC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg05347473	chr6:146136440	FBXO30	0.57	10.06	0.48	5.62e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.9	-0.4	4.04e-14	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.4e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	ch.11.42038R	chr11:967971	AP2A2	0.47	7.07	0.36	8.92e-12	Alzheimer's disease (late onset);
LUSC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-1.11	-24.45	-0.8	2.07e-76	Height;
LUSC	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg05729581	chr11:3078854	CARS	0.39	5.74	0.3	2.08e-8	Calcium levels;
LUSC	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.56	7.48	0.38	6.69e-13	HIV-1 control;
LUSC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg25319279	chr11:5960081	NA	0.41	6.51	0.34	2.71e-10	DNA methylation (variation);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00556719	chr9:108457484	TMEM38B	0.44	6.36	0.33	6.72e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg14092571	chr14:90743983	NA	0.36	5.8	0.3	1.58e-8	Mortality in heart failure;
LUSC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg18404041	chr3:52824283	ITIH1	0.43	7.63	0.39	2.46e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg05025164	chr4:1340916	KIAA1530	0.4	5.91	0.31	8.66e-9	Obesity-related traits;
LUSC	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg10547527	chr2:198650123	BOLL	-0.52	-6.07	-0.31	3.57e-9	Ulcerative colitis;
LUSC	cis	rs4474465	0.688	rs10751296	chr11:78277277	C/T	cg27205649	chr11:78285834	NARS2	-0.56	-6.87	-0.35	3.11e-11	Alzheimer's disease (survival time);
LUSC	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg26528668	chr16:1614120	IFT140	0.47	7.95	0.4	2.83e-14	Coronary artery disease;
LUSC	cis	rs2357013	0.752	rs55992015	chr2:53170717	C/T	cg07782112	chr2:53107842	NA	-0.39	-6.25	-0.32	1.23e-9	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs3087591	0.922	rs12939969	chr17:29463577	A/G	cg24425628	chr17:29625626	OMG;NF1	0.54	7.89	0.4	4.39e-14	Hip circumference;
LUSC	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-6.63	-0.34	1.32e-10	Morning vs. evening chronotype;
LUSC	cis	rs4974559	0.790	rs7654152	chr4:1325042	G/A	cg02980000	chr4:1222292	CTBP1	0.97	9.05	0.44	1.17e-17	Systolic blood pressure;
LUSC	cis	rs2652834	0.904	rs2937859	chr15:63366282	C/T	cg05507819	chr15:63340323	TPM1	0.71	9.15	0.45	5.9e-18	HDL cholesterol;
LUSC	cis	rs7202877	0.610	rs4888381	chr16:75356847	C/A	cg04384234	chr16:75411784	CFDP1	-0.62	-8.55	-0.42	4.57e-16	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs977987	0.750	rs4888406	chr16:75432334	G/T	cg03315344	chr16:75512273	CHST6	0.54	10.38	0.49	4.79e-22	Dupuytren's disease;
LUSC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-11.96	-0.55	1.08e-27	Personality dimensions;
LUSC	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg05855489	chr10:104503620	C10orf26	-0.67	-9.93	-0.48	1.62e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	0.92	13.86	0.6	7.74e-35	Breast cancer;
LUSC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-10.85	-0.51	1.06e-23	Gut microbiome composition (summer);
LUSC	cis	rs757081	0.667	rs12577525	chr11:17260116	G/A	cg15432903	chr11:17409602	KCNJ11	-0.36	-5.69	-0.3	2.77e-8	Systolic blood pressure;
LUSC	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.33	-0.37	1.75e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.73	-0.57	1.52e-30	Type 2 diabetes;
LUSC	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg00031303	chr3:195681400	NA	0.75	10.94	0.51	5.04e-24	Pancreatic cancer;
LUSC	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-8.21	-0.41	4.93e-15	Schizophrenia;
LUSC	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg27068330	chr11:65405492	SIPA1	-0.74	-10.3	-0.49	8.46e-22	Acne (severe);
LUSC	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg08680598	chr22:49984980	NA	-0.33	-6.13	-0.32	2.53e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25867694	chr22:31503597	SELM	-0.47	-6.0	-0.31	5.08e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9398803	0.965	rs2027299	chr6:126685827	G/C	cg19875578	chr6:126661172	C6orf173	0.39	5.83	0.3	1.31e-8	Male-pattern baldness;
LUSC	cis	rs2346177	0.844	rs13010062	chr2:46644137	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.58	-0.38	3.43e-13	HDL cholesterol;
LUSC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg05472934	chr7:22766657	IL6	0.54	8.46	0.42	8.79e-16	Lung cancer;
LUSC	cis	rs10740039	0.883	rs10761544	chr10:62415405	C/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.92	-0.35	2.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7216064	1.000	rs4791299	chr17:65930937	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-9.56	-0.46	2.67e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg14664628	chr15:75095509	CSK	-0.53	-7.77	-0.39	1e-13	Breast cancer;
LUSC	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.93	0.48	1.57e-20	Migraine;Coronary artery disease;
LUSC	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg17218026	chr1:154582156	ADAR	-0.56	-10.08	-0.48	4.72e-21	Blood protein levels;
LUSC	cis	rs10254118	0.757	rs6467491	chr7:133138761	A/G	cg10665199	chr7:133106180	EXOC4	0.59	8.08	0.4	1.19e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05776053	chr2:74358815	NA	0.46	7.31	0.37	1.94e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs4692589	0.606	rs12645495	chr4:170933909	T/C	cg19918862	chr4:170955249	NA	0.38	7.02	0.36	1.23e-11	Anxiety disorder;
LUSC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg13047869	chr3:10149882	C3orf24	0.57	7.9	0.4	4.11e-14	Alzheimer's disease;
LUSC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg20243544	chr17:37824526	PNMT	0.39	5.76	0.3	1.96e-8	Self-reported allergy;
LUSC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	28.4	0.84	4.39e-91	Chronic sinus infection;
LUSC	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg08854313	chr1:11322531	MTOR	0.8	12.45	0.56	1.77e-29	Body mass index;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg02731540	chr11:31391568	DCDC1;DNAJC24	0.34	6.0	0.31	5.18e-9	Tuberculosis;
LUSC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06850241	chr22:41845214	NA	0.34	6.3	0.33	9.5e-10	Vitiligo;
LUSC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg15556689	chr8:8085844	FLJ10661	0.72	12.16	0.55	2.12e-28	Mood instability;
LUSC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg15605315	chr1:45957053	TESK2	0.46	7.54	0.38	4.34e-13	High light scatter reticulocyte count;
LUSC	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02176678	chr2:219576539	TTLL4	-0.67	-13.27	-0.59	1.38e-32	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs6494488	0.500	rs72744704	chr15:65011507	G/A	cg08069370	chr15:64387884	SNX1	-0.66	-5.78	-0.3	1.71e-8	Coronary artery disease;
LUSC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg09877947	chr5:131593287	PDLIM4	-0.46	-7.06	-0.36	9.84e-12	Blood metabolite levels;
LUSC	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg13010199	chr12:38710504	ALG10B	0.63	9.25	0.45	2.81e-18	Morning vs. evening chronotype;
LUSC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.47	8.7	0.43	1.54e-16	Blood metabolite levels;
LUSC	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	8.46	0.42	8.63e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.69	0.39	1.71e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7106204	0.609	rs12801799	chr11:24300630	A/T	ch.11.24196551F	chr11:24239977	NA	0.71	5.95	0.31	6.89e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg24399712	chr22:39784796	NA	-0.65	-12.13	-0.55	2.73e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs955333	0.925	rs56344141	chr6:154927189	G/T	cg20019720	chr6:154832845	CNKSR3	0.46	5.84	0.3	1.26e-8	Diabetic kidney disease;
LUSC	cis	rs7178572	1.000	rs34591043	chr15:77713586	A/G	cg22256960	chr15:77711686	NA	-0.54	-9.02	-0.44	1.51e-17	Type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.82	0.39	7.02e-14	Prudent dietary pattern;
LUSC	cis	rs72960926	0.744	rs56020332	chr6:75030022	C/G	cg03266952	chr6:74778945	NA	-0.83	-7.03	-0.36	1.14e-11	Metabolite levels (MHPG);
LUSC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg03709012	chr19:19516395	GATAD2A	-0.8	-12.76	-0.57	1.25e-30	Tonsillectomy;
LUSC	cis	rs8099014	0.770	rs1135519	chr18:56117145	C/T	cg12907477	chr18:56117327	MIR122	0.45	7.05	0.36	1.01e-11	Platelet count;
LUSC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02711726	chr17:80685570	FN3KRP	-0.42	-6.48	-0.33	3.22e-10	Glycated hemoglobin levels;
LUSC	cis	rs1775715	0.674	rs2778670	chr10:32161676	G/A	cg26784012	chr10:32216390	ARHGAP12	0.45	7.77	0.39	9.75e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.61	-0.34	1.55e-10	Triglycerides;
LUSC	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg12863693	chr15:85201151	NMB	0.35	7.11	0.36	7.15e-12	Schizophrenia;
LUSC	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg26647111	chr11:31128758	NA	-0.43	-6.13	-0.32	2.47e-9	Red blood cell count;
LUSC	cis	rs2692947	0.727	rs749459	chr2:96795714	G/A	cg22654517	chr2:96458247	NA	0.35	6.78	0.35	5.34e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.24	0.45	2.87e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.12	26.1	0.82	1.27e-82	Schizophrenia;
LUSC	cis	rs7605827	0.930	rs4668898	chr2:15511502	T/C	cg19274914	chr2:15703543	NA	0.46	8.89	0.44	3.98e-17	Educational attainment (years of education);
LUSC	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg25797454	chr6:150327115	RAET1K	0.37	8.57	0.42	3.82e-16	Alopecia areata;
LUSC	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg06454157	chr6:167490870	NA	-0.28	-6.38	-0.33	5.76e-10	Primary biliary cholangitis;
LUSC	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg07636037	chr3:49044803	WDR6	0.77	10.02	0.48	7.64e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs8113142	0.614	rs2108771	chr19:29187422	C/T	cg04546413	chr19:29218101	NA	0.44	5.99	0.31	5.4e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg24503407	chr1:205819492	PM20D1	0.83	14.37	0.62	8.47e-37	Menarche (age at onset);
LUSC	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-6.53	-0.34	2.52e-10	Colorectal cancer;
LUSC	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg27165867	chr14:105738592	BRF1	-0.53	-7.72	-0.39	1.36e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11605924	0.967	rs6485646	chr11:45865764	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.54	-8.12	-0.41	9.37e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg00012203	chr2:219082015	ARPC2	-0.57	-9.07	-0.44	1.08e-17	Ulcerative colitis;
LUSC	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg03188948	chr7:1209495	NA	0.49	6.23	0.32	1.39e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.87	14.22	0.61	3.36e-36	Bladder cancer;
LUSC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg00933542	chr6:150070202	PCMT1	-0.29	-6.03	-0.31	4.42e-9	Lung cancer;
LUSC	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg19784903	chr17:45786737	TBKBP1	-0.4	-6.43	-0.33	4.33e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.44	-0.46	6.52e-19	Joint mobility (Beighton score);
LUSC	cis	rs2835872	0.758	rs1709833	chr21:39037805	C/T	cg20424643	chr21:39039972	KCNJ6	0.44	7.53	0.38	4.67e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs6500395	0.926	rs1039342	chr16:48577498	G/A	cg04672837	chr16:48644449	N4BP1	0.43	6.34	0.33	7.63e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg20701182	chr2:24300061	SF3B14	0.76	7.7	0.39	1.59e-13	Lymphocyte counts;
LUSC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg07741184	chr6:167504864	NA	0.34	6.1	0.32	2.92e-9	Crohn's disease;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg00760200	chr1:115053833	TRIM33	0.4	5.99	0.31	5.42e-9	Mosquito bite size;
LUSC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg18827107	chr12:86230957	RASSF9	-0.47	-7.05	-0.36	1.05e-11	Major depressive disorder;
LUSC	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg00852783	chr1:26633632	UBXN11	-0.5	-5.86	-0.31	1.13e-8	Obesity-related traits;
LUSC	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.45	-0.42	9.36e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs77741769	0.571	rs11065300	chr12:121298512	G/C	cg02419362	chr12:121203948	SPPL3	0.45	8.41	0.42	1.18e-15	Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2274273	0.516	rs3759665	chr14:55371605	C/T	cg04306507	chr14:55594613	LGALS3	0.32	6.0	0.31	5.19e-9	Protein biomarker;
LUSC	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	10.11	0.48	3.82e-21	Lymphocyte counts;
LUSC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg02415014	chr8:143852576	LYNX1	0.34	8.21	0.41	4.99e-15	Urinary tract infection frequency;
LUSC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg23711669	chr6:146136114	FBXO30	0.72	11.07	0.52	1.74e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg03233332	chr7:66118400	NA	-0.41	-6.02	-0.31	4.49e-9	Aortic root size;
LUSC	cis	rs9398803	0.687	rs4549631	chr6:126966308	A/G	cg19875578	chr6:126661172	C6orf173	0.43	6.28	0.32	1.08e-9	Male-pattern baldness;
LUSC	cis	rs1408224	0.626	rs912434	chr13:47189928	G/T	cg19833103	chr13:47126551	LRCH1	-0.39	-5.73	-0.3	2.27e-8	QRS complex (12-leadsum);
LUSC	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	0.7	6.98	0.36	1.63e-11	Prostate cancer;
LUSC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.3e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6062509	1.000	rs6011066	chr20:62364180	G/A	cg01176363	chr20:62369445	LIME1	-0.47	-6.98	-0.36	1.62e-11	Prostate cancer;
LUSC	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg17757837	chr7:157058334	UBE3C	0.81	13.12	0.58	5.09e-32	Body mass index;
LUSC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.09	15.49	0.65	3.62e-41	Gut microbiome composition (summer);
LUSC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.58	7.11	0.36	7.02e-12	Lung function (FEV1/FVC);
LUSC	cis	rs17102423	0.602	rs1007914	chr14:65566261	C/A	cg11161011	chr14:65562177	MAX	-0.77	-11.44	-0.53	8.43e-26	Obesity-related traits;
LUSC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.01	0.4	1.9e-14	Parkinson's disease;
LUSC	cis	rs9837602	1.000	rs9832186	chr3:99728503	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.09	-0.32	3.14e-9	Breast cancer;
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg10150615	chr22:24372951	LOC391322	-0.38	-6.31	-0.33	8.91e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg03732007	chr1:2071316	PRKCZ	-0.53	-9.45	-0.46	6.24e-19	Height;
LUSC	cis	rs4663866	1.000	rs6734408	chr2:239137481	A/C	cg16914508	chr2:239161102	PER2	0.62	6.58	0.34	1.79e-10	Irritable bowel syndrome;
LUSC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs4561483	0.864	rs190461	chr16:12005745	A/G	cg08843971	chr16:11963173	GSPT1	-0.46	-6.72	-0.35	7.8e-11	Testicular germ cell tumor;
LUSC	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	ch.11.42038R	chr11:967971	AP2A2	0.45	6.58	0.34	1.79e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.14	-18.36	-0.71	1.46e-52	Primary sclerosing cholangitis;
LUSC	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg09238746	chr17:78121135	EIF4A3	-0.65	-10.17	-0.49	2.39e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg02403541	chr12:121454288	C12orf43	0.61	9.51	0.46	3.8e-19	Subjective well-being;Cardiovascular disease risk factors;
LUSC	cis	rs6084875	0.812	rs2422938	chr20:4721926	G/C	cg26097573	chr20:4721490	PRNT	-0.31	-5.7	-0.3	2.69e-8	Systemic lupus erythematosus;
LUSC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg15147215	chr3:52552868	STAB1	-0.35	-6.84	-0.35	3.78e-11	Electroencephalogram traits;
LUSC	trans	rs7939886	0.920	rs7946368	chr11:55804219	C/T	cg03929089	chr4:120376271	NA	0.74	6.28	0.32	1.07e-9	Myopia (pathological);
LUSC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs4903604	0.581	rs11159278	chr14:78034001	C/G	cg18872420	chr14:78023429	SPTLC2	0.4	6.06	0.31	3.75e-9	Gut microbiome composition (winter);
LUSC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg04727924	chr7:799746	HEATR2	-0.57	-6.06	-0.31	3.75e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs748404	0.697	rs493444	chr15:43566470	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.44	6.12	0.32	2.57e-9	Lung cancer;
LUSC	cis	rs2652834	1.000	rs7182618	chr15:63398622	T/C	cg05507819	chr15:63340323	TPM1	0.66	7.98	0.4	2.39e-14	HDL cholesterol;
LUSC	trans	rs61931739	0.635	rs10743836	chr12:33961680	C/T	cg13010199	chr12:38710504	ALG10B	0.4	6.03	0.31	4.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.64	11.35	0.53	1.82e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs953492	0.517	rs2247527	chr1:243309983	A/C	cg01826367	chr1:224180288	NA	0.44	6.47	0.33	3.43e-10	Diastolic blood pressure;
LUSC	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg02023728	chr11:77925099	USP35	0.43	6.47	0.33	3.57e-10	Testicular germ cell tumor;
LUSC	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg03433033	chr1:76189801	ACADM	0.46	7.07	0.36	9.21e-12	Daytime sleep phenotypes;
LUSC	cis	rs10489202	0.608	rs3753934	chr1:168074677	C/T	cg24449463	chr1:168025552	DCAF6	-0.64	-9.68	-0.47	1.05e-19	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26481784	chr15:35837840	ATPBD4	0.44	6.01	0.31	4.77e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg04673462	chr1:38461896	NA	-0.5	-7.61	-0.38	2.87e-13	Coronary artery disease;
LUSC	trans	rs12692738	0.526	rs355853	chr2:165627618	T/C	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg18301423	chr5:131593218	PDLIM4	0.41	6.45	0.33	3.93e-10	Blood metabolite levels;
LUSC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.53	0.57	8.85e-30	Motion sickness;
LUSC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.65e-9	Alzheimer's disease (late onset);
LUSC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.8	-0.43	7.35e-17	Obesity-related traits;
LUSC	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg18196295	chr10:418757	DIP2C	0.38	5.9	0.31	8.94e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.95	12.04	0.55	5.59e-28	Exhaled nitric oxide output;
LUSC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.23	-0.32	1.42e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16316507	chr7:144533041	TPK1	0.51	6.96	0.36	1.82e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.95	0.44	2.52e-17	Prudent dietary pattern;
LUSC	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-9.38	-0.46	1.06e-18	Coffee consumption (cups per day);
LUSC	cis	rs7043114	0.507	rs6479420	chr9:95116406	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.6	-0.34	1.6e-10	Height;
LUSC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg15445000	chr17:37608096	MED1	-0.39	-6.8	-0.35	4.94e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg26408565	chr15:76604113	ETFA	0.47	7.68	0.39	1.81e-13	Blood metabolite levels;
LUSC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	6.15	0.32	2.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg15309053	chr8:964076	NA	0.31	6.03	0.31	4.3e-9	Schizophrenia;
LUSC	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg24503407	chr1:205819492	PM20D1	-0.47	-6.28	-0.32	1.06e-9	Menarche (age at onset);
LUSC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7980799	0.565	rs2200159	chr12:33648544	G/C	cg13010199	chr12:38710504	ALG10B	-0.4	-5.95	-0.31	6.71e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg22875332	chr1:76189707	ACADM	0.71	9.82	0.47	3.6e-20	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs1922233	0.943	rs1922235	chr4:92367917	G/A	cg24250684	chr1:219729030	NA	-0.34	-6.08	-0.32	3.19e-9	Gut microbiome composition (summer and winter);
LUSC	cis	rs1190552	0.739	rs1998421	chr14:102979644	C/T	cg18135206	chr14:102964638	TECPR2	0.46	5.76	0.3	1.92e-8	Blood protein levels;
LUSC	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg09904177	chr6:26538194	HMGN4	0.72	13.02	0.58	1.28e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-17.7	-0.7	6.65e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4478858	0.709	rs937786	chr1:31857869	G/A	cg00250761	chr1:31883323	NA	0.33	7.46	0.38	7.59e-13	Alcohol dependence;
LUSC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.67	-10.38	-0.49	4.48e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4842666	0.915	rs2681472	chr12:90008959	A/G	cg00757033	chr12:89920650	WDR51B	0.47	6.31	0.33	8.99e-10	Blood pressure;
LUSC	cis	rs2425143	1.000	rs6058303	chr20:34290281	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.16	-0.32	2.04e-9	Blood protein levels;
LUSC	cis	rs11650494	0.710	rs61427980	chr17:47473580	A/G	cg08112188	chr17:47440006	ZNF652	0.93	7.93	0.4	3.3e-14	Prostate cancer;
LUSC	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08564027	chr20:61660810	NA	0.93	17.11	0.68	1.47e-47	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9807989	0.839	rs10204137	chr2:102968212	A/G	cg09003973	chr2:102972529	NA	0.44	6.01	0.31	4.83e-9	Asthma;
LUSC	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg26384229	chr12:38710491	ALG10B	0.74	11.77	0.54	5.6e-27	Morning vs. evening chronotype;
LUSC	cis	rs3764563	1.000	rs4239612	chr19:15727442	A/G	cg20725493	chr19:15740067	CYP4F8	-0.63	-6.2	-0.32	1.62e-9	Inflammatory biomarkers;
LUSC	cis	rs9653442	0.545	rs4851252	chr2:100757280	C/T	cg22139774	chr2:100720529	AFF3	-0.4	-6.63	-0.34	1.36e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg16342193	chr10:102329863	NA	-0.35	-6.24	-0.32	1.32e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4901869	0.966	rs12148052	chr14:59338970	C/T	cg02291164	chr14:59296302	NA	0.58	11.11	0.52	1.33e-24	Panic disorder;
LUSC	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-7.91	-0.4	3.89e-14	Bladder cancer;
LUSC	cis	rs9807989	0.507	rs2041739	chr2:102994333	A/G	cg03938978	chr2:103052716	IL18RAP	-0.37	-6.98	-0.36	1.61e-11	Asthma;
LUSC	cis	rs6681460	0.899	rs502690	chr1:67182403	A/T	cg02459107	chr1:67143332	SGIP1	0.48	8.92	0.44	3.24e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg21918786	chr6:109611834	NA	-0.4	-6.96	-0.36	1.79e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	12.7	0.57	2.1000000000000002e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.56	-0.34	2.02e-10	Lung cancer;
LUSC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18876405	chr7:65276391	NA	0.55	8.59	0.43	3.48e-16	Aortic root size;
LUSC	cis	rs9487051	0.799	rs351724	chr6:109546577	T/C	cg01475377	chr6:109611718	NA	-0.35	-5.83	-0.3	1.28e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg16624210	chr5:671434	TPPP	0.5	6.2	0.32	1.63e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs2120243	0.572	rs3816528	chr3:157127290	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	-0.36	-5.7	-0.3	2.6e-8	Hepatocellular carcinoma in hepatitis B infection;
LUSC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.73	-12.82	-0.57	7.16e-31	Dental caries;
LUSC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg11766577	chr21:47581405	C21orf56	-0.43	-6.41	-0.33	4.9e-10	Testicular germ cell tumor;
LUSC	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.66	-12.16	-0.55	1.97e-28	Type 2 diabetes;
LUSC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg20476274	chr7:133979776	SLC35B4	0.83	15.25	0.64	3.29e-40	Mean platelet volume;
LUSC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.35	0.56	3.93e-29	Prudent dietary pattern;
LUSC	cis	rs12542260	0.871	rs7836802	chr8:125473730	C/T	cg27038428	chr8:125485867	RNF139	0.33	6.68	0.34	9.77e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg16576597	chr16:28551801	NUPR1	0.34	6.79	0.35	5.07e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-8.64	-0.43	2.3e-16	Alzheimer's disease (late onset);
LUSC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg20573242	chr4:122745356	CCNA2	0.63	9.34	0.46	1.36e-18	Type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26706201	chr11:57103334	SSRP1	0.42	6.41	0.33	5.07e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11471957	1	rs11471957	chr20:57598332	C/CAA	cg14073986	chr20:57617431	SLMO2	0.59	6.58	0.34	1.86e-10	Platelet count;Mean platelet volume;
LUSC	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg24397884	chr7:158709396	WDR60	0.6	9.28	0.45	2.26e-18	Height;
LUSC	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	11.94	0.55	1.27e-27	Height;
LUSC	cis	rs3733418	0.929	rs4691138	chr4:165908641	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-5.92	-0.31	7.89e-9	Obesity-related traits;
LUSC	cis	rs2346177	0.874	rs11125075	chr2:46656344	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.37	6.45	0.33	4.04e-10	HDL cholesterol;
LUSC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.63	0.5	6.47e-23	Menopause (age at onset);
LUSC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs1861353	0.863	rs16952252	chr16:53483980	G/T	cg09728985	chr16:53543985	NA	-0.32	-6.1	-0.32	2.88e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg24130564	chr14:104152367	KLC1	-0.44	-6.13	-0.32	2.53e-9	Body mass index;
LUSC	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg20487152	chr13:99095054	FARP1	-0.45	-7.84	-0.39	5.93e-14	Longevity;
LUSC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03934478	chr11:495069	RNH1	0.91	10.38	0.49	4.61e-22	Body mass index;
LUSC	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg21385522	chr1:16154831	NA	-0.55	-8.29	-0.41	2.72e-15	Systolic blood pressure;
LUSC	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg16576597	chr16:28551801	NUPR1	0.34	6.87	0.35	3.15e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-11.1	-0.52	1.36e-24	Response to antipsychotic treatment;
LUSC	cis	rs859767	0.709	rs1516990	chr2:135369630	C/G	cg12500956	chr2:135428796	TMEM163	-0.28	-6.43	-0.33	4.49e-10	Neuroticism;
LUSC	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg08270630	chr22:50330655	NA	-0.39	-5.93	-0.31	7.36e-9	Schizophrenia;
LUSC	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg10255544	chr17:80519551	FOXK2	0.4	6.57	0.34	1.88e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg02018176	chr4:1364513	KIAA1530	0.52	8.88	0.44	4.11e-17	Obesity-related traits;
LUSC	cis	rs12101261	1.000	rs8003061	chr14:81451956	G/A	cg06600135	chr14:81408086	NA	0.44	6.48	0.33	3.38e-10	Graves' disease;
LUSC	cis	rs1113500	0.614	rs6677839	chr1:108599341	G/T	cg11967332	chr1:108735228	SLC25A24	-0.42	-5.91	-0.31	8.29e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.03	-0.31	4.25e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.92	15.81	0.65	1.92e-42	Bladder cancer;
LUSC	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg26446133	chr18:72167187	CNDP2	-0.85	-13.41	-0.59	4.32e-33	Refractive error;
LUSC	cis	rs9886651	0.776	rs12155669	chr8:128779931	A/G	cg07795030	chr8:128802207	NA	0.36	6.56	0.34	2.01e-10	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LUSC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.72	11.69	0.54	1.07e-26	Coronary artery disease;
LUSC	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg24324837	chr19:49891574	CCDC155	0.45	5.78	0.3	1.74e-8	Multiple sclerosis;
LUSC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg06238570	chr21:40685208	BRWD1	0.48	7.37	0.37	1.34e-12	Cognitive function;
LUSC	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg24375607	chr4:120327624	NA	0.75	11.04	0.52	2.38e-24	Corneal astigmatism;
LUSC	cis	rs71718386	1	rs71718386	chr13:41224287	CTATA/C	cg21288729	chr13:41239152	FOXO1	0.65	10.04	0.48	6.48e-21	Eosinophil counts;
LUSC	cis	rs6700896	0.832	rs11208693	chr1:66108063	C/T	cg04111102	chr1:66153794	NA	0.32	7.1	0.36	7.54e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs600626	0.636	rs11236514	chr11:75451343	A/C	cg24262691	chr11:75473276	NA	-0.45	-5.89	-0.31	9.61e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs6500395	1.000	rs8059819	chr16:48682834	A/G	cg04672837	chr16:48644449	N4BP1	-0.48	-7.31	-0.37	1.94e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg15595755	chr5:1867978	NA	0.46	8.29	0.41	2.73e-15	Cardiovascular disease risk factors;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15730116	chr12:76953768	OSBPL8	-0.47	-6.07	-0.32	3.46e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg06697600	chr4:7070879	GRPEL1	-0.4	-6.61	-0.34	1.49e-10	Monocyte percentage of white cells;
LUSC	cis	rs10193935	1.000	rs12622910	chr2:42398918	C/A	cg27598129	chr2:42591480	NA	-0.6	-8.03	-0.4	1.65e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4845570	0.749	rs11576810	chr1:151712201	C/G	cg07092448	chr1:151763213	TDRKH	-1.05	-10.93	-0.51	5.7e-24	Coronary artery disease;
LUSC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	12.3	0.56	6.15e-29	Colorectal cancer;
LUSC	trans	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg27411982	chr8:10470053	RP1L1	0.45	7.46	0.38	7.56e-13	Mood instability;
LUSC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.46	-0.38	7.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	7.34	0.37	1.64e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg12963246	chr6:28129442	ZNF389	0.45	6.09	0.32	3.16e-9	Parkinson's disease;
LUSC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs11031096	0.502	rs1442726	chr11:4094748	G/C	cg08557956	chr11:4115526	RRM1	-0.46	-5.83	-0.3	1.31e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg01475377	chr6:109611718	NA	-0.46	-8.39	-0.42	1.4e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs9650315	0.850	rs6984782	chr8:57135889	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	-0.54	-7.25	-0.37	2.83e-12	Height;
LUSC	trans	rs2288327	1.000	rs2288327	chr2:179411665	A/G	cg14011486	chr1:26737247	LIN28	0.47	6.06	0.31	3.77e-9	Atrial fibrillation;
LUSC	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg05729581	chr11:3078854	CARS	0.4	6.0	0.31	5.01e-9	Calcium levels;
LUSC	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg21095983	chr6:86352623	SYNCRIP	0.57	8.83	0.44	5.94e-17	Smooth-surface caries;
LUSC	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs870825	0.616	rs10428373	chr4:185639002	A/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.55	0.6	1.23e-33	Blood protein levels;
LUSC	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg12091567	chr17:66097778	LOC651250	-0.71	-9.12	-0.45	7.15e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs80130819	0.688	rs10783232	chr12:48583491	A/G	cg24011408	chr12:48396354	COL2A1	0.45	5.87	0.31	1.05e-8	Prostate cancer;
LUSC	cis	rs7539542	0.556	rs2000331	chr1:202857578	G/T	cg19681188	chr1:202830198	LOC148709	0.41	6.03	0.31	4.23e-9	Mean platelet volume;
LUSC	cis	rs1185460	0.934	rs1006195	chr11:118958869	A/C	cg01677386	chr11:118938358	VPS11	0.44	6.09	0.32	3.14e-9	Coronary artery disease;
LUSC	cis	rs73001065	0.901	rs739846	chr19:19419071	G/A	cg03709012	chr19:19516395	GATAD2A	0.89	6.89	0.35	2.79e-11	LDL cholesterol;
LUSC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg04450456	chr4:17643702	FAM184B	0.33	5.74	0.3	2.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs737008	0.922	rs28567501	chr16:11378928	C/A	cg00044050	chr16:11439710	C16orf75	-0.52	-8.01	-0.4	1.89e-14	Obesity-related traits;
LUSC	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg25344623	chr2:136566232	LCT	0.37	5.68	0.3	2.96e-8	Mosquito bite size;
LUSC	trans	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg13565492	chr6:43139072	SRF	-0.73	-10.83	-0.51	1.25e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg01028140	chr2:1542097	TPO	-0.6	-8.02	-0.4	1.86e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00330279	chr16:87584184	NA	-0.42	-6.05	-0.31	3.97e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg25457927	chr22:38595422	NA	-0.43	-8.09	-0.4	1.15e-14	Breast cancer;
LUSC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11764359	chr7:65958608	NA	0.54	7.11	0.36	7.23e-12	Aortic root size;
LUSC	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.72	-0.47	8.18e-20	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg11584989	chr19:19387371	SF4	0.61	7.38	0.37	1.25e-12	Bipolar disorder;
LUSC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.87	13.84	0.6	9.42e-35	Multiple system atrophy;
LUSC	cis	rs9905704	0.709	rs758378	chr17:56607746	G/C	cg12560992	chr17:57184187	TRIM37	-0.48	-5.85	-0.3	1.19e-8	Testicular germ cell tumor;
LUSC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg21972741	chr5:435613	AHRR	0.36	6.8	0.35	4.8e-11	Cystic fibrosis severity;
LUSC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg15605315	chr1:45957053	TESK2	0.51	8.43	0.42	1.06e-15	High light scatter reticulocyte count;
LUSC	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg02782426	chr3:40428986	ENTPD3	-0.28	-5.74	-0.3	2.16e-8	Renal cell carcinoma;
LUSC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg24060327	chr5:131705240	SLC22A5	-0.67	-11.55	-0.53	3.51e-26	Breast cancer;
LUSC	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg22482690	chr17:47019901	SNF8	0.4	7.59	0.38	3.17e-13	Type 2 diabetes;
LUSC	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg09092052	chr15:45571596	NA	0.46	6.36	0.33	6.52e-10	Glomerular filtration rate;
LUSC	cis	rs7072216	0.881	rs4345897	chr10:100147060	A/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-5.72	-0.3	2.36e-8	Metabolite levels;
LUSC	cis	rs983392	0.805	rs7926354	chr11:59962189	G/A	cg20284999	chr11:59952153	MS4A6A	-0.4	-6.77	-0.35	5.72e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg09655341	chr17:79618100	PDE6G	-0.28	-6.58	-0.34	1.86e-10	Eye color traits;
LUSC	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg12850546	chr22:42539477	CYP2D7P1	-0.56	-6.39	-0.33	5.49e-10	Birth weight;
LUSC	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg08000102	chr2:233561755	GIGYF2	0.71	11.68	0.54	1.19e-26	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg21724239	chr8:58056113	NA	0.79	9.55	0.46	2.99e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs6138458	0.546	rs6050118	chr20:24891895	C/T	cg26195577	chr20:24973756	C20orf3	-0.89	-9.52	-0.46	3.59e-19	Blood protein levels;
LUSC	cis	rs10992471	0.603	rs6479422	chr9:95190694	G/T	cg14631576	chr9:95140430	CENPP	-0.35	-6.31	-0.33	8.94e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg10911889	chr6:126070802	HEY2	-0.39	-5.9	-0.31	8.84e-9	Brugada syndrome;
LUSC	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg03676636	chr4:99064102	C4orf37	0.36	7.86	0.4	5.35e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15369054	chr17:80825471	TBCD	-0.37	-6.08	-0.32	3.24e-9	Breast cancer;
LUSC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg14789911	chr21:47582049	C21orf56	0.4	6.42	0.33	4.79e-10	Testicular germ cell tumor;
LUSC	trans	rs72674100	0.737	rs2865756	chr4:97992626	C/T	cg16405019	chr1:18959625	PAX7	-0.61	-6.41	-0.33	5.09e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg16482183	chr6:26056742	HIST1H1C	0.44	6.52	0.34	2.67e-10	Height;
LUSC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg09640425	chr7:158790006	NA	-0.52	-8.15	-0.41	7.58e-15	Facial morphology (factor 20);
LUSC	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg04176472	chr15:90893244	GABARAPL3	-0.32	-5.71	-0.3	2.52e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg00042356	chr1:8021962	PARK7	-0.57	-6.84	-0.35	3.83e-11	Inflammatory bowel disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24170511	chr14:23341280	LRP10	-0.45	-6.73	-0.35	7.51e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs56399783	0.901	rs757788	chr7:2836433	A/G	cg14895029	chr7:2775587	GNA12	0.49	5.94	0.31	6.96e-9	Childhood ear infection;
LUSC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg12311346	chr5:56204834	C5orf35	0.6	9.06	0.44	1.15e-17	Coronary artery disease;
LUSC	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-8.89	-0.44	3.85e-17	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg06521331	chr12:34319734	NA	0.4	6.24	0.32	1.36e-9	Morning vs. evening chronotype;
LUSC	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07169764	chr2:136633963	MCM6	1.2	18.36	0.71	1.52e-52	Corneal structure;
LUSC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	15.26	0.64	2.89e-40	Platelet count;
LUSC	cis	rs12318506	0.826	rs34128238	chr12:75731819	T/C	cg04728562	chr12:75699417	CAPS2	-0.84	-5.91	-0.31	8.43e-9	Coronary artery calcification;
LUSC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg19773385	chr1:10388646	KIF1B	-0.5	-8.72	-0.43	1.3e-16	Hepatocellular carcinoma;
LUSC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	6.36	0.33	6.53e-10	Mean platelet volume;
LUSC	cis	rs9811920	0.683	rs7650727	chr3:99688976	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.34	-6.46	-0.33	3.75e-10	Axial length;
LUSC	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg05714579	chr10:131428358	MGMT	0.5	7.43	0.38	9.36e-13	Response to temozolomide;
LUSC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg08499158	chr17:42289980	UBTF	-0.49	-8.31	-0.41	2.46e-15	Total body bone mineral density;
LUSC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg20887711	chr4:1340912	KIAA1530	0.44	6.67	0.34	1.09e-10	Obesity-related traits;
LUSC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.55	9.43	0.46	6.92e-19	IgG glycosylation;
LUSC	trans	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg07393940	chr7:158741817	NA	0.38	6.88	0.35	2.92e-11	Life satisfaction;
LUSC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-1.03	-15.74	-0.65	3.72e-42	Initial pursuit acceleration;
LUSC	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg12002119	chr2:101014098	CHST10	0.36	6.02	0.31	4.56e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.71	-0.39	1.44e-13	Blood metabolite levels;
LUSC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg11645453	chr3:52864694	ITIH4	0.37	8.7	0.43	1.56e-16	Bipolar disorder;
LUSC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg08888203	chr3:10149979	C3orf24	-0.61	-8.89	-0.44	3.97e-17	Alzheimer's disease;
LUSC	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg15744005	chr10:104629667	AS3MT	-0.29	-6.34	-0.33	7.55e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg13047869	chr3:10149882	C3orf24	0.42	6.44	0.33	4.21e-10	Alzheimer's disease;
LUSC	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.62	-14.05	-0.61	1.42e-35	Sense of smell;
LUSC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07092213	chr7:1199455	ZFAND2A	0.56	8.84	0.44	5.44e-17	Longevity;Endometriosis;
LUSC	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg00852783	chr1:26633632	UBXN11	-0.5	-5.77	-0.3	1.84e-8	Obesity-related traits;
LUSC	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg13073564	chr4:8508604	NA	-0.44	-8.47	-0.42	8.03e-16	Response to antineoplastic agents;
LUSC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.59	-11.53	-0.53	4.07e-26	Prostate cancer;
LUSC	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.55	0.46	2.95e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.89	14.89	0.63	8.25e-39	Bladder cancer;
LUSC	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg27661571	chr11:113659931	NA	0.62	7.11	0.36	7.18e-12	Hip circumference adjusted for BMI;
LUSC	trans	rs72674100	0.609	rs7677697	chr4:97981842	T/C	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12620999	0.938	rs4575672	chr2:238070572	T/C	cg23555395	chr2:238036564	NA	-0.47	-8.15	-0.41	7.56e-15	Systemic lupus erythematosus;
LUSC	cis	rs6977660	1.000	rs6977660	chr7:19805480	C/T	cg07541023	chr7:19748670	TWISTNB	0.54	6.21	0.32	1.6e-9	Thyroid stimulating hormone;
LUSC	cis	rs9650657	0.741	rs10100333	chr8:10584288	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.32	-0.33	8.17e-10	Neuroticism;
LUSC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg12641515	chr19:46296257	DMWD	0.48	7.19	0.37	4.36e-12	Coronary artery disease;
LUSC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00631329	chr6:26305371	NA	0.46	9.3	0.45	1.93e-18	Educational attainment;
LUSC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg13126279	chr21:47581558	C21orf56	-0.43	-6.37	-0.33	6.09e-10	Testicular germ cell tumor;
LUSC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.09	-0.32	3.17e-9	Schizophrenia;
LUSC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg16339924	chr4:17578868	LAP3	0.6	9.3	0.45	1.94e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9462027	0.606	rs2814987	chr6:34605145	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.76	-0.3	1.95e-8	Systemic lupus erythematosus;
LUSC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg15595755	chr5:1867978	NA	0.45	8.05	0.4	1.42e-14	Cardiovascular disease risk factors;
LUSC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.62	0.43	2.64e-16	Menarche (age at onset);
LUSC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg10356904	chr22:49881777	NA	-0.34	-7.69	-0.39	1.69e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.09	-0.36	8.17e-12	Major depressive disorder;
LUSC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg11062466	chr8:58055876	NA	0.72	8.8	0.43	7.7e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs16854884	0.632	rs4535221	chr3:143658607	A/G	cg06585982	chr3:143692056	C3orf58	0.48	7.39	0.37	1.17e-12	Economic and political preferences (feminism/equality);
LUSC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg15790184	chr11:494944	RNH1	0.61	6.44	0.33	4.27e-10	Body mass index;
LUSC	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.65	8.62	0.43	2.78e-16	Total cholesterol levels;
LUSC	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg17507749	chr15:85114479	UBE2QP1	0.67	8.58	0.43	3.57e-16	Schizophrenia;
LUSC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	13.98	0.61	2.7e-35	Platelet count;
LUSC	trans	rs72674100	1.000	rs2865759	chr4:97992416	C/T	cg09670535	chr1:18959427	PAX7	-0.62	-6.89	-0.35	2.71e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2092850	1	rs2092850	chr6:88100419	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-5.72	-0.3	2.43e-8	Itch intensity from mosquito bite;
LUSC	cis	rs11676348	0.808	rs61700947	chr2:219046171	C/G	cg23569941	chr2:219139048	TMBIM1;PNKD	-0.37	-5.89	-0.31	9.2e-9	Ulcerative colitis;
LUSC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	16.97	0.68	5.24e-47	Gut microbiome composition (summer);
LUSC	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg02038168	chr22:39784481	NA	-0.43	-6.37	-0.33	6.14e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg04287289	chr16:89883240	FANCA	0.8	14.09	0.61	1.04e-35	Vitiligo;
LUSC	cis	rs9447004	0.584	rs7747167	chr6:74430673	T/G	cg03006477	chr6:74432658	CD109	0.27	5.68	0.3	2.85e-8	Blood protein levels;Calcium levels;
LUSC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	7.75	0.39	1.09e-13	Cognitive ability;
LUSC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg22166914	chr1:53195759	ZYG11B	-0.73	-12.91	-0.58	3.18e-31	Monocyte count;
LUSC	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.9	0.35	2.64e-11	Resting heart rate;
LUSC	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg02196655	chr2:10830764	NOL10	0.34	5.79	0.3	1.64e-8	Prostate cancer;
LUSC	cis	rs3820928	0.804	rs4144327	chr2:227790262	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.72	-0.39	1.38e-13	Pulmonary function;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02354839	chr5:72794086	BTF3	-0.41	-6.2	-0.32	1.66e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.55	-8.69	-0.43	1.61e-16	Personality dimensions;
LUSC	trans	rs724744	0.743	rs1205930	chr6:22359007	A/G	cg13807341	chr11:118445984	ARCN1	-0.35	-5.96	-0.31	6.54e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg05347473	chr6:146136440	FBXO30	0.48	7.87	0.4	4.9e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-10.47	-0.5	2.22e-22	Gut microbiome composition (summer);
LUSC	cis	rs2729354	0.729	rs2729353	chr11:57248003	C/T	cg24343310	chr11:57249947	NA	0.46	8.45	0.42	9.18e-16	Blood protein levels;
LUSC	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.61	-0.43	2.96e-16	Response to antipsychotic treatment;
LUSC	cis	rs9976767	0.637	rs9984108	chr21:43825628	T/G	cg20516845	chr21:43823604	UBASH3A	-0.25	-5.77	-0.3	1.78e-8	Type 1 diabetes;
LUSC	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.44	0.5	2.97e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17255340	0.530	rs6923627	chr6:84064858	G/A	cg08257003	chr6:84140564	ME1	0.35	8.58	0.42	3.7e-16	Platelet-derived growth factor BB levels;
LUSC	trans	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg26043149	chr18:55253948	FECH	-0.43	-6.75	-0.35	6.73e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	6.25	0.32	1.27e-9	Mean platelet volume;
LUSC	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg19628046	chr18:33552617	C18orf21	0.52	6.26	0.32	1.15e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg15556689	chr8:8085844	FLJ10661	0.55	7.73	0.39	1.24e-13	Morning vs. evening chronotype;
LUSC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08564027	chr20:61660810	NA	0.91	17.35	0.69	1.58e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504073	0.669	rs818558	chr8:50030855	A/G	cg00325661	chr8:49890786	NA	0.59	9.58	0.46	2.26e-19	Blood metabolite ratios;
LUSC	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.66e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs713477	0.901	rs1572612	chr14:55909939	C/T	cg13175173	chr14:55914753	NA	-0.32	-6.74	-0.35	7.01e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.61	-10.25	-0.49	1.28e-21	Extrinsic epigenetic age acceleration;
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg07157834	chr1:205819609	PM20D1	0.84	15.62	0.65	1.15e-41	Menarche (age at onset);
LUSC	cis	rs4900538	0.927	rs8005804	chr14:102957803	A/G	cg18135206	chr14:102964638	TECPR2	1.05	23.09	0.78	3.61e-71	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06090383	chr4:174292579	SAP30	-0.52	-6.3	-0.33	9.28e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18876405	chr7:65276391	NA	-0.54	-8.61	-0.43	2.89e-16	Aortic root size;
LUSC	cis	rs4970988	0.607	rs7548516	chr1:150980281	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.46	-6.66	-0.34	1.14e-10	Urate levels;
LUSC	trans	rs1133146	1.000	rs1133146	chr19:53666660	A/G	cg20908785	chr14:54863471	CDKN3	-0.37	-5.96	-0.31	6.28e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	1.02	19.7	0.73	7.26e-58	Menopause (age at onset);
LUSC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg11211951	chr8:145729740	GPT	0.59	11.26	0.52	3.89e-25	Age at first birth;
LUSC	cis	rs7799006	0.929	rs71525363	chr7:2268792	G/A	cg02951883	chr7:2050386	MAD1L1	-0.37	-6.18	-0.32	1.87e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.58	-0.42	3.63e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	8.19	0.41	5.57e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.52	-0.34	2.57e-10	Blood metabolite levels;
LUSC	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg04310649	chr10:35416472	CREM	-0.43	-6.65	-0.34	1.23e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3750965	1.000	rs61881024	chr11:68837794	A/G	cg06818126	chr11:68850279	TPCN2	-0.44	-6.31	-0.33	8.83e-10	Hair color;
LUSC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg27129171	chr3:47204927	SETD2	0.57	8.15	0.41	7.2e-15	Birth weight;
LUSC	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg16950941	chr11:66035639	RAB1B	0.49	7.14	0.36	5.82e-12	Gout;
LUSC	cis	rs7809950	0.815	rs62482495	chr7:106965009	A/G	cg23024343	chr7:107201750	COG5	-0.66	-9.86	-0.47	2.6e-20	Coronary artery disease;
LUSC	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg18357645	chr12:58087776	OS9	0.5	7.42	0.38	9.78e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg24829409	chr8:58192753	C8orf71	-0.59	-7.63	-0.39	2.43e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.58	-9.01	-0.44	1.59e-17	Menarche (age at onset);
LUSC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.17	-0.45	4.96e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.68	-10.38	-0.49	4.67e-22	Monocyte percentage of white cells;
LUSC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-12.86	-0.58	5.14e-31	Alzheimer's disease;
LUSC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.92	-0.44	3.1e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg16262614	chr3:133464971	TF	0.41	7.15	0.36	5.56e-12	Iron status biomarkers (transferrin levels);
LUSC	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg20368463	chr18:77673604	PQLC1	-0.59	-9.26	-0.45	2.52e-18	Schizophrenia;
LUSC	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	5.72	0.3	2.36e-8	Response to antipsychotic treatment;
LUSC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-1.04	-20.22	-0.74	5.96e-60	Height;
LUSC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg06238570	chr21:40685208	BRWD1	0.45	6.93	0.35	2.15e-11	Cognitive function;
LUSC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.83	10.74	0.51	2.65e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs11088226	0.645	rs2409457	chr21:33929895	T/C	cg09050820	chr6:167586206	TCP10L2	0.75	9.74	0.47	6.57e-20	Gastritis;
LUSC	cis	rs11583043	0.546	rs35363849	chr1:101591293	A/G	cg11406453	chr1:101602562	NA	-0.41	-6.81	-0.35	4.42e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg17127132	chr2:85788382	GGCX	0.47	7.66	0.39	1.99e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7241530	0.662	rs34015835	chr18:75905509	A/C	cg14642773	chr18:75888474	NA	0.39	5.97	0.31	5.98e-9	Educational attainment (years of education);
LUSC	cis	rs11971779	0.941	rs4732368	chr7:139034207	A/C	cg07862535	chr7:139043722	LUC7L2	0.73	8.2	0.41	5.39e-15	Diisocyanate-induced asthma;
LUSC	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.54	-0.34	2.28e-10	Bladder cancer;
LUSC	cis	rs4776059	1.000	rs3751614	chr15:52901638	T/C	cg22715398	chr15:52968154	KIAA1370	-0.67	-9.97	-0.48	1.18e-20	Schizophrenia;
LUSC	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg18357645	chr12:58087776	OS9	-0.43	-5.9	-0.31	8.78e-9	Multiple sclerosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16080015	chr7:5085479	RBAK	0.52	7.27	0.37	2.53e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg24006582	chr15:45444508	DUOX1	-0.61	-8.95	-0.44	2.44e-17	Uric acid levels;
LUSC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22496380	chr5:211416	CCDC127	-0.72	-8.41	-0.42	1.24e-15	Breast cancer;
LUSC	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.6	8.66	0.43	2.08e-16	Bipolar disorder;
LUSC	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	6.97	0.36	1.71e-11	Multiple sclerosis;
LUSC	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.51	0.53	4.85e-26	Menopause (age at onset);
LUSC	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg14993813	chr1:46806288	NSUN4	-0.52	-7.32	-0.37	1.82e-12	Menopause (age at onset);
LUSC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg07741184	chr6:167504864	NA	0.42	7.56	0.38	3.9e-13	Crohn's disease;
LUSC	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.71	-0.3	2.53e-8	Height;
LUSC	trans	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg07393940	chr7:158741817	NA	0.36	6.55	0.34	2.13e-10	Life satisfaction;
LUSC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	14.09	0.61	1.09e-35	Platelet count;
LUSC	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.67	-0.34	1.07e-10	Response to antipsychotic treatment;
LUSC	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.56	9.5	0.46	4.23e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.57	-8.7	-0.43	1.58e-16	Lymphocyte counts;
LUSC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.51	-7.81	-0.39	7.59e-14	Personality dimensions;
LUSC	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-9.83	-0.47	3.36e-20	Morning vs. evening chronotype;
LUSC	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg21775007	chr8:11205619	TDH	-0.52	-7.48	-0.38	6.58e-13	Triglycerides;
LUSC	cis	rs752010	0.523	rs943376	chr1:42122117	A/G	cg06885757	chr1:42089581	HIVEP3	0.5	10.29	0.49	9.67e-22	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg22467129	chr15:76604101	ETFA	0.44	7.15	0.36	5.51e-12	Blood metabolite levels;
LUSC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	11.69	0.54	1.09e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-10.32	-0.49	7.61e-22	Schizophrenia;
LUSC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg03233332	chr7:66118400	NA	0.42	6.08	0.32	3.22e-9	Aortic root size;
LUSC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg23719950	chr11:63933701	MACROD1	-0.6	-7.9	-0.4	4.11e-14	Mean platelet volume;
LUSC	cis	rs62458065	1.000	rs79538247	chr7:32467792	A/G	cg20159608	chr7:32802032	NA	-0.56	-6.8	-0.35	4.97e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9341808	0.528	rs2322753	chr6:81042865	C/G	cg08355045	chr6:80787529	NA	0.46	8.04	0.4	1.53e-14	Sitting height ratio;
LUSC	cis	rs35079168	0.661	rs3118529	chr9:137304915	C/T	cg24164254	chr9:137329341	RXRA	-0.38	-6.14	-0.32	2.36e-9	Intelligence;
LUSC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19748678	chr4:122722346	EXOSC9	0.62	9.49	0.46	4.65e-19	Type 2 diabetes;
LUSC	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	9.09	0.45	9.27e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg03474202	chr17:45855739	NA	-0.3	-6.95	-0.36	1.91e-11	IgG glycosylation;
LUSC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg07703079	chr11:430292	ANO9	0.6	6.52	0.34	2.66e-10	Body mass index;
LUSC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14829155	chr15:31115871	NA	-0.72	-10.66	-0.5	5.02e-23	Huntington's disease progression;
LUSC	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg25206134	chr2:45395956	NA	0.56	6.45	0.33	3.98e-10	Bipolar disorder;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03300291	chr11:82868085	PCF11	0.37	6.08	0.32	3.36e-9	Asthma;
LUSC	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg06937882	chr20:24974362	C20orf3	-0.43	-7.41	-0.38	1.04e-12	Blood protein levels;
LUSC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08109568	chr15:31115862	NA	-0.61	-9.0	-0.44	1.75e-17	Huntington's disease progression;
LUSC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg06238570	chr21:40685208	BRWD1	-0.56	-8.91	-0.44	3.33e-17	Menarche (age at onset);
LUSC	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg00745463	chr17:30367425	LRRC37B	-0.45	-6.29	-0.33	1.01e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12292205	chr6:26970375	C6orf41	-0.58	-7.39	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.86e-13	Depression;
LUSC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.02	0.4	1.76e-14	Parkinson's disease;
LUSC	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.62	11.08	0.52	1.61e-24	Weight;
LUSC	cis	rs28595532	0.800	rs111626798	chr4:119352517	C/T	cg21605333	chr4:119757512	SEC24D	1.02	8.32	0.41	2.28e-15	Cannabis dependence symptom count;
LUSC	cis	rs1044826	1.000	rs17336869	chr3:139194247	T/C	cg00490450	chr3:139108681	COPB2	0.52	6.78	0.35	5.37e-11	Obesity-related traits;
LUSC	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg06223162	chr1:101003688	GPR88	0.47	9.12	0.45	7.41e-18	Monocyte count;
LUSC	trans	rs800082	0.516	rs12486882	chr3:144228481	A/G	cg24215973	chr2:240111563	HDAC4	0.45	6.85	0.35	3.61e-11	Smoking behavior;
LUSC	cis	rs2970818	0.831	rs10849085	chr12:4644879	C/T	cg11146114	chr12:4671731	NA	-0.59	-5.88	-0.31	1.01e-8	Phosphorus levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12084011	chr7:107220368	BCAP29	0.4	6.09	0.32	3.11e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg24562669	chr7:97807699	LMTK2	0.34	5.91	0.31	8.4e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4478858	0.698	rs10914370	chr1:31854955	T/C	cg00250761	chr1:31883323	NA	-0.36	-8.55	-0.42	4.65e-16	Alcohol dependence;
LUSC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.33	-0.41	2.15e-15	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	9.46	0.46	5.64e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.79	11.24	0.52	4.54e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg25039879	chr17:56429692	SUPT4H1	0.66	8.88	0.44	4.12e-17	Cognitive test performance;
LUSC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg02782426	chr3:40428986	ENTPD3	-0.33	-6.43	-0.33	4.44e-10	Renal cell carcinoma;
LUSC	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg27661571	chr11:113659931	NA	-0.69	-7.91	-0.4	3.77e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs7586879	0.765	rs6545758	chr2:25074874	C/T	cg01884057	chr2:25150051	NA	-0.35	-7.11	-0.36	6.87e-12	Body mass index;
LUSC	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-8.45	-0.42	8.99e-16	Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23328329	chr17:20059227	CYTSB	0.49	6.83	0.35	4.01e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs41271473	0.898	rs17352535	chr1:228822284	C/G	cg16512390	chr1:228756714	NA	0.55	6.53	0.34	2.42e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg00106254	chr7:1943704	MAD1L1	-0.41	-5.89	-0.31	9.36e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg07806771	chr7:64541737	NA	0.42	6.05	0.31	3.89e-9	Calcium levels;
LUSC	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.78	-0.35	5.41e-11	Response to antipsychotic treatment;
LUSC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg02569458	chr12:86230093	RASSF9	0.6	9.85	0.47	2.84e-20	Major depressive disorder;
LUSC	cis	rs870825	0.616	rs28582728	chr4:185646920	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs13385	0.769	rs13359060	chr5:139605202	C/T	cg26211634	chr5:139558579	C5orf32	0.45	6.75	0.35	6.51e-11	Atrial fibrillation;
LUSC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	0.98	14.03	0.61	1.75e-35	Eosinophil percentage of granulocytes;
LUSC	trans	rs7916697	0.626	rs3858145	chr10:70011838	A/G	cg04882175	chr6:131122610	NA	-0.52	-6.88	-0.35	2.96e-11	Optic disc area;
LUSC	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	7.86	0.4	5.29e-14	Menarche (age at onset);
LUSC	cis	rs2274273	0.934	rs10139337	chr14:55742113	C/T	cg04306507	chr14:55594613	LGALS3	0.55	12.14	0.55	2.37e-28	Protein biomarker;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg08206623	chr11:2907334	CDKN1C	0.36	6.27	0.32	1.1e-9	Calcium levels;
LUSC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.77	-12.23	-0.56	1.14e-28	Height;
LUSC	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.4	5.75	0.3	2.04e-8	Lung cancer;
LUSC	trans	rs9929218	1.000	rs8045022	chr16:68807087	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-11.75	-0.54	6.51e-27	Colorectal cancer;
LUSC	trans	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-7.84	-0.39	6.12e-14	Morning vs. evening chronotype;
LUSC	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg24375607	chr4:120327624	NA	0.49	7.53	0.38	4.8e-13	Diastolic blood pressure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05565475	chr9:136223383	SURF2;SURF1	-0.43	-6.65	-0.34	1.22e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg25237894	chr2:233734115	C2orf82	0.35	6.55	0.34	2.22e-10	Coronary artery disease;
LUSC	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.46	7.52	0.38	5.02e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg04944784	chr2:26401820	FAM59B	0.63	8.11	0.41	9.46e-15	Gut microbiome composition (summer);
LUSC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg05347473	chr6:146136440	FBXO30	0.46	7.89	0.4	4.48e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs897080	0.552	rs698793	chr2:44685685	C/T	cg00619915	chr2:44497795	NA	-0.43	-6.16	-0.32	2.08e-9	Height;
LUSC	cis	rs9807989	0.811	rs4485585	chr2:102970759	T/C	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.67e-9	Asthma;
LUSC	cis	rs4888262	0.545	rs7342732	chr16:74698716	A/C	cg01733217	chr16:74700730	RFWD3	0.78	13.23	0.59	2.08e-32	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg05340658	chr4:99064831	C4orf37	0.57	9.54	0.46	3.03e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07167872	chr1:205819463	PM20D1	0.82	14.84	0.63	1.28e-38	Menarche (age at onset);
LUSC	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg24642439	chr20:33292090	TP53INP2	0.44	6.33	0.33	8.09e-10	Height;
LUSC	cis	rs9399401	0.696	rs174441	chr6:142824299	G/A	cg03128060	chr6:142623767	GPR126	0.31	5.7	0.3	2.58e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg11752832	chr7:134001865	SLC35B4	-0.53	-8.14	-0.41	7.84e-15	Mean platelet volume;
LUSC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg23791538	chr6:167370224	RNASET2	0.41	6.7	0.34	8.84e-11	Crohn's disease;
LUSC	cis	rs9325144	0.872	rs11183390	chr12:38729942	G/T	cg26384229	chr12:38710491	ALG10B	-0.48	-7.13	-0.36	6.43e-12	Morning vs. evening chronotype;
LUSC	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg05347473	chr6:146136440	FBXO30	0.55	9.73	0.47	7.59e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg05855489	chr10:104503620	C10orf26	0.54	8.27	0.41	3.14e-15	Arsenic metabolism;
LUSC	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.3	-0.45	1.93e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg18825076	chr15:78729989	IREB2	0.51	8.03	0.4	1.67e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg13073564	chr4:8508604	NA	0.36	6.6	0.34	1.59e-10	Response to antineoplastic agents;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg14668821	chr17:77704760	ENPP7	0.29	6.01	0.31	4.95e-9	Menopause (age at onset);
LUSC	cis	rs11051970	0.918	rs73084101	chr12:32544339	A/C	cg02745156	chr12:32552066	NA	0.43	6.82	0.35	4.29e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg03983476	chr2:10830698	NOL10	-0.38	-5.71	-0.3	2.54e-8	Prostate cancer;
LUSC	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg20744362	chr22:50050164	C22orf34	0.38	7.82	0.39	6.8e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg09904177	chr6:26538194	HMGN4	-0.84	-5.96	-0.31	6.39e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg04166393	chr7:2884313	GNA12	0.44	5.69	0.3	2.76e-8	Height;
LUSC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg00757033	chr12:89920650	WDR51B	0.59	10.19	0.49	2.14e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6693567	0.565	rs6684939	chr1:150440563	G/A	cg15654264	chr1:150340011	RPRD2	-0.46	-7.46	-0.38	7.73e-13	Migraine;
LUSC	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg13073564	chr4:8508604	NA	0.48	8.93	0.44	2.94e-17	Response to antineoplastic agents;
LUSC	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg15017067	chr4:17643749	FAM184B	0.35	5.69	0.3	2.71e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7216064	1.000	rs1976053	chr17:65833002	C/G	cg12091567	chr17:66097778	LOC651250	-0.73	-9.74	-0.47	6.71e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg08975724	chr8:8085496	FLJ10661	0.47	6.99	0.36	1.5e-11	Mood instability;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg25621393	chr5:149737060	TCOF1	0.39	5.95	0.31	6.8e-9	Mosquito bite size;
LUSC	cis	rs3820068	0.577	rs41270271	chr1:15913582	G/C	cg17385448	chr1:15911702	AGMAT	0.37	5.95	0.31	6.81e-9	Systolic blood pressure;
LUSC	cis	rs77505915	0.512	rs12921808	chr16:75383984	T/C	cg07303275	chr16:75499416	TMEM170A	-0.44	-5.77	-0.3	1.82e-8	Migraine;
LUSC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg03676636	chr4:99064102	C4orf37	0.32	6.99	0.36	1.48e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg20849893	chr7:64541193	NA	0.47	6.77	0.35	5.8200000000000003e-11	Calcium levels;
LUSC	trans	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg03886242	chr7:26192032	NFE2L3	0.39	6.55	0.34	2.22e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-0.75	-11.17	-0.52	8.07e-25	Refractive error;
LUSC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg15212455	chr7:39170539	POU6F2	0.68	11.64	0.54	1.63e-26	IgG glycosylation;
LUSC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg16325326	chr1:53192061	ZYG11B	-0.7	-10.88	-0.51	8.17e-24	Monocyte count;
LUSC	cis	rs7523273	0.606	rs2724388	chr1:207933577	T/G	cg22525895	chr1:207977042	MIR29B2	0.41	6.61	0.34	1.48e-10	Schizophrenia;
LUSC	cis	rs9648716	0.515	rs2688430	chr7:140728682	T/C	cg23214464	chr7:140373596	ADCK2	-0.72	-6.24	-0.32	1.34e-9	Type 2 diabetes;
LUSC	cis	rs2108225	0.872	rs7792139	chr7:107445433	G/A	cg18560240	chr7:107437656	SLC26A3	-0.45	-6.71	-0.34	8.26e-11	Ulcerative colitis;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg22907277	chr7:1156413	C7orf50	0.47	7.14	0.36	5.91e-12	Longevity;Endometriosis;
LUSC	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-11.76	-0.54	5.79e-27	Systemic lupus erythematosus;
LUSC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg05738196	chr6:26577821	NA	-0.56	-6.9	-0.35	2.58e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-0.85	-14.73	-0.63	3.44e-38	Prostate cancer;
LUSC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00166722	chr3:10149974	C3orf24	0.54	7.55	0.38	4.16e-13	Alzheimer's disease;
LUSC	cis	rs7712401	0.601	rs30060	chr5:122296700	T/C	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg03894339	chr8:19674705	INTS10	0.53	7.05	0.36	1.04e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg07936489	chr17:37558343	FBXL20	0.72	10.05	0.48	5.95e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.66	10.82	0.51	1.39e-23	Eye color traits;
LUSC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg03233332	chr7:66118400	NA	-0.42	-5.99	-0.31	5.55e-9	Aortic root size;
LUSC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.6	-0.43	3.1e-16	Bladder cancer;
LUSC	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg02896835	chr1:92012615	NA	0.53	9.06	0.44	1.14e-17	Breast cancer;
LUSC	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.86	-12.77	-0.57	1.12e-30	Asthma;
LUSC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00345343	chr16:89422185	ANKRD11	0.45	6.25	0.32	1.22e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2599510	0.703	rs762023	chr2:32713170	G/A	cg02381751	chr2:32503542	YIPF4	0.4	5.95	0.31	6.76e-9	Interleukin-18 levels;
LUSC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg10434728	chr15:90938212	IQGAP1	0.39	7.96	0.4	2.74e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7560272	0.538	rs1806683	chr2:73939812	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-6.83	-0.35	4.15e-11	Schizophrenia;
LUSC	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11645453	chr3:52864694	ITIH4	0.51	11.11	0.52	1.26e-24	Schizophrenia;
LUSC	trans	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg25482853	chr8:67687455	SGK3	1.11	15.36	0.64	1.15e-40	Obesity-related traits;
LUSC	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg23260525	chr10:116636907	FAM160B1	0.49	10.57	0.5	1.05e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg27205649	chr11:78285834	NARS2	-0.54	-6.66	-0.34	1.13e-10	Alzheimer's disease (survival time);
LUSC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-11.15	-0.52	8.96e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs701145	0.878	rs187357	chr3:153958876	C/A	cg17054900	chr3:154042577	DHX36	0.85	9.0	0.44	1.75e-17	Coronary artery disease;
LUSC	cis	rs9549260	0.816	rs7337995	chr13:41249040	A/G	cg21288729	chr13:41239152	FOXO1	0.58	8.69	0.43	1.65e-16	Red blood cell count;
LUSC	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg16359550	chr11:109292809	C11orf87	0.34	5.99	0.31	5.43e-9	Schizophrenia;
LUSC	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg26668828	chr6:292823	DUSP22	0.49	7.48	0.38	6.7e-13	Menopause (age at onset);
LUSC	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg13010199	chr12:38710504	ALG10B	0.68	10.55	0.5	1.16e-22	Morning vs. evening chronotype;
LUSC	trans	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg20935933	chr6:143382018	AIG1	0.5	7.27	0.37	2.61e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg15556689	chr8:8085844	FLJ10661	0.54	7.96	0.4	2.74e-14	Myopia (pathological);
LUSC	trans	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg26043149	chr18:55253948	FECH	-0.45	-6.78	-0.35	5.62e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg22823121	chr1:150693482	HORMAD1	0.59	9.08	0.44	1e-17	Tonsillectomy;
LUSC	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg13736514	chr6:26305472	NA	-0.47	-9.18	-0.45	4.48e-18	Educational attainment;
LUSC	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg18825076	chr15:78729989	IREB2	0.45	6.36	0.33	6.6e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg20744362	chr22:50050164	C22orf34	0.38	7.04	0.36	1.12e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg08747591	chr11:789928	CEND1	0.41	6.94	0.35	2.05e-11	Breast cancer;
LUSC	cis	rs6732160	0.650	rs7560224	chr2:73406182	A/G	cg24220031	chr2:73402428	NA	-0.23	-5.73	-0.3	2.27e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg24642439	chr20:33292090	TP53INP2	0.45	6.36	0.33	6.73e-10	Height;
LUSC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg15352829	chr14:105391018	PLD4	-0.42	-8.89	-0.44	3.84e-17	Rheumatoid arthritis;
LUSC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.28	0.49	9.91e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11586313	0.571	rs11583382	chr1:152874096	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.8	-0.3	1.58e-8	Vitamin D levels;
LUSC	trans	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg25482853	chr8:67687455	SGK3	1.03	15.45	0.65	5.41e-41	Obesity-related traits;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02522757	chr12:48298992	VDR	0.37	6.61	0.34	1.49e-10	Triglycerides;
LUSC	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg23625390	chr15:77176239	SCAPER	0.51	8.01	0.4	1.91e-14	Blood metabolite levels;
LUSC	cis	rs68170813	0.652	rs11532774	chr7:107201579	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.46	-5.72	-0.3	2.4e-8	Coronary artery disease;
LUSC	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-1.13	-17.64	-0.69	1.06e-49	Exhaled nitric oxide output;
LUSC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg20887711	chr4:1340912	KIAA1530	0.53	8.08	0.4	1.19e-14	Obesity-related traits;
LUSC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg24503407	chr1:205819492	PM20D1	0.84	14.77	0.63	2.3e-38	Menarche (age at onset);
LUSC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg04518342	chr5:131593106	PDLIM4	0.5	8.99	0.44	1.83e-17	Acylcarnitine levels;
LUSC	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg23241863	chr10:102295624	HIF1AN	0.5	6.08	0.32	3.24e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs10097731	0.901	rs10464891	chr8:82042900	C/A	cg25230327	chr8:82042993	NA	-0.48	-6.78	-0.35	5.55e-11	Serum total protein level;
LUSC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10802521	chr3:52805072	NEK4	-0.5	-8.15	-0.41	7.33e-15	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg07701084	chr6:150067640	NUP43	0.56	8.74	0.43	1.15e-16	Lung cancer;
LUSC	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg01191920	chr7:158217561	PTPRN2	-0.5	-10.11	-0.48	3.72e-21	Obesity-related traits;
LUSC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.54	-9.03	-0.44	1.42e-17	IgG glycosylation;
LUSC	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.67	-0.5	4.42e-23	Glomerular filtration rate;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05237023	chr16:75182837	ZFP1	-0.46	-6.1	-0.32	2.93e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs16854884	1.000	rs35887108	chr3:143780632	C/T	cg06585982	chr3:143692056	C3orf58	0.46	6.43	0.33	4.42e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs7184046	0.797	rs13737	chr15:75932129	G/T	cg20655648	chr15:75932815	IMP3	0.44	5.87	0.31	1.06e-8	Height;
LUSC	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09307838	chr4:120376055	NA	0.74	10.53	0.5	1.36e-22	Corneal astigmatism;
LUSC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.54	9.0	0.44	1.75e-17	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	1.12	14.37	0.62	8.44e-37	Arsenic metabolism;
LUSC	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg12179176	chr11:130786555	SNX19	0.58	8.67	0.43	1.85e-16	Schizophrenia;
LUSC	cis	rs6426558	0.537	rs648877	chr1:227283614	A/G	cg10327440	chr1:227177885	CDC42BPA	0.54	7.34	0.37	1.62e-12	Neutrophil percentage of white cells;
LUSC	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg11693508	chr17:37793320	STARD3	-0.54	-6.87	-0.35	3.21e-11	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07362569	chr17:61921086	SMARCD2	-0.37	-7.56	-0.38	3.94e-13	Prudent dietary pattern;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05654711	chr1:85930865	DDAH1	0.75	5.99	0.31	5.35e-9	Cognitive performance;
LUSC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg22920501	chr2:26401640	FAM59B	0.77	10.82	0.51	1.34e-23	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.31e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg00815214	chr21:47717953	NA	-0.35	-5.7	-0.3	2.6e-8	Testicular germ cell tumor;
LUSC	cis	rs10761482	1.000	rs1350631	chr10:62082569	T/A	cg18175470	chr10:62150864	ANK3	-0.48	-6.62	-0.34	1.41e-10	Schizophrenia;
LUSC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.72	-10.04	-0.48	6.81e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg15556689	chr8:8085844	FLJ10661	0.69	11.03	0.52	2.52e-24	Joint mobility (Beighton score);
LUSC	trans	rs9393777	0.920	rs35716472	chr6:27406607	C/G	cg01620082	chr3:125678407	NA	-0.7	-6.75	-0.35	6.57e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg01579765	chr21:45077557	HSF2BP	-0.49	-10.24	-0.49	1.36e-21	Mean corpuscular volume;
LUSC	cis	rs2806561	0.780	rs12117752	chr1:23360223	T/C	cg19743168	chr1:23544995	NA	-0.44	-9.02	-0.44	1.5e-17	Height;
LUSC	trans	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg27661571	chr11:113659931	NA	-0.57	-6.48	-0.33	3.25e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs62238980	0.614	rs117721418	chr22:32394519	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.02	-0.31	4.68e-9	Childhood ear infection;
LUSC	cis	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg00806126	chr19:22604979	ZNF98	-0.4	-6.06	-0.31	3.61e-9	Pain;
LUSC	cis	rs6084875	0.840	rs1999664	chr20:4721148	C/T	cg26097573	chr20:4721490	PRNT	-0.31	-5.74	-0.3	2.1e-8	Systemic lupus erythematosus;
LUSC	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg23229984	chr5:148520753	ABLIM3	0.41	6.48	0.33	3.22e-10	Breast cancer;
LUSC	cis	rs394563	0.601	rs367133	chr6:149797720	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.34	-6.95	-0.36	1.91e-11	Dupuytren's disease;
LUSC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg27398817	chr8:82754497	SNX16	0.44	5.95	0.31	6.79e-9	Diastolic blood pressure;
LUSC	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg05110241	chr16:68378359	PRMT7	-0.52	-6.18	-0.32	1.85e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg14440974	chr22:39074834	NA	-0.35	-5.86	-0.31	1.1e-8	Menopause (age at onset);
LUSC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg05855489	chr10:104503620	C10orf26	-0.64	-8.45	-0.42	9.23e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.43	-5.93	-0.31	7.63e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06544989	chr22:39130855	UNC84B	0.34	6.02	0.31	4.58e-9	Menopause (age at onset);
LUSC	cis	rs17540621	1.000	rs10194115	chr2:47240012	G/T	cg23978866	chr2:47230407	TTC7A	-0.76	-6.11	-0.32	2.83e-9	Response to statin therapy;
LUSC	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00631329	chr6:26305371	NA	-0.47	-9.2	-0.45	3.84e-18	Educational attainment;
LUSC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg00634984	chr7:65235879	NA	0.4	5.74	0.3	2.08e-8	Calcium levels;
LUSC	cis	rs9921338	0.961	rs4780358	chr16:11374212	G/T	cg00044050	chr16:11439710	C16orf75	-0.5	-6.93	-0.35	2.21e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.3	-7.72	-0.39	1.41e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg26769984	chr7:1090371	C7orf50	0.48	5.76	0.3	1.86e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg24209194	chr3:40518798	ZNF619	0.47	6.37	0.33	6.32e-10	Renal cell carcinoma;
LUSC	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg10326726	chr10:51549505	MSMB	-0.36	-6.33	-0.33	7.98e-10	Prostate-specific antigen levels;
LUSC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.57	-0.42	3.89e-16	Bipolar disorder;
LUSC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg23173402	chr1:227635558	NA	0.59	7.23	0.37	3.41e-12	Major depressive disorder;
LUSC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	-0.47	-6.76	-0.35	6.27e-11	Resistin levels;
LUSC	cis	rs9400467	0.508	rs11153283	chr6:111597143	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.27	-0.32	1.11e-9	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg14456004	chr13:21872349	NA	0.43	6.02	0.31	4.68e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg26597838	chr10:835615	NA	0.8	9.93	0.48	1.6e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs3126085	0.935	rs10888475	chr1:152226012	C/T	cg03465714	chr1:152285911	FLG	-0.4	-5.73	-0.3	2.25e-8	Atopic dermatitis;
LUSC	cis	rs6599077	1.000	rs9842085	chr3:40095544	T/C	cg13683864	chr3:40499215	RPL14	-0.6	-7.66	-0.39	2.06e-13	Sleep-related phenotypes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11698762	chr2:74648964	WDR54	0.44	6.02	0.31	4.65e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11650494	0.710	rs73987294	chr17:47474730	T/C	cg08112188	chr17:47440006	ZNF652	0.93	7.93	0.4	3.3e-14	Prostate cancer;
LUSC	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg15704280	chr7:45808275	SEPT13	0.75	8.49	0.42	7.09e-16	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg04450456	chr4:17643702	FAM184B	0.39	6.6	0.34	1.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.22	-13.79	-0.6	1.47e-34	Diabetic kidney disease;
LUSC	cis	rs73200209	0.744	rs1865787	chr12:116429689	A/G	cg01776926	chr12:116560359	MED13L	-0.49	-5.84	-0.3	1.26e-8	Total body bone mineral density;
LUSC	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg05163923	chr11:71159392	DHCR7	0.74	10.94	0.51	5.36e-24	Vitamin D levels;
LUSC	cis	rs6942756	0.774	rs2566876	chr7:128890055	A/G	cg02491457	chr7:128862824	NA	0.51	7.65	0.39	2.22e-13	White matter hyperintensity burden;
LUSC	cis	rs4843185	0.669	rs889502	chr16:85716832	A/G	cg26571870	chr16:85723150	GINS2	-0.33	-5.98	-0.31	5.71e-9	Platelet distribution width;
LUSC	trans	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg07211511	chr3:129823064	LOC729375	-0.74	-9.45	-0.46	6.14e-19	Blood pressure (smoking interaction);
LUSC	cis	rs4443100	0.631	rs13054904	chr22:23410918	A/T	cg21100191	chr22:23484243	RTDR1	-0.57	-7.24	-0.37	3.16e-12	Serum parathyroid hormone levels;
LUSC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg26513180	chr16:89883248	FANCA	0.79	6.36	0.33	6.64e-10	Skin colour saturation;
LUSC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12311346	chr5:56204834	C5orf35	-0.83	-13.82	-0.6	1.19e-34	Initial pursuit acceleration;
LUSC	cis	rs11608355	0.521	rs7978210	chr12:109835990	A/G	cg19025524	chr12:109796872	NA	-0.38	-7.14	-0.36	5.97e-12	Neuroticism;
LUSC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg06618935	chr21:46677482	NA	-0.39	-7.84	-0.39	6.1e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg25258033	chr6:167368657	RNASET2	0.39	6.36	0.33	6.72e-10	Crohn's disease;
LUSC	trans	rs3960554	0.569	rs1894761	chr7:75876754	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.6	-7.56	-0.38	3.84e-13	Eotaxin levels;
LUSC	cis	rs72634258	0.786	rs7514098	chr1:8177632	G/A	cg26816564	chr1:7831052	VAMP3	0.43	5.66	0.3	3.24e-8	Inflammatory bowel disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13627451	chr15:52043674	TMOD2;LYSMD2	-0.46	-6.37	-0.33	6.32e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs1325195	0.537	rs2636290	chr1:179096088	A/G	cg11624085	chr17:8464688	MYH10	-0.43	-6.45	-0.33	3.96e-10	IgE grass sensitization;
LUSC	cis	rs11711311	1.000	rs891574	chr3:113537639	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.69	-0.3	2.76e-8	IgG glycosylation;
LUSC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18404041	chr3:52824283	ITIH1	-0.63	-12.28	-0.56	7.14e-29	Bipolar disorder;
LUSC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg09021430	chr5:549028	NA	-0.56	-7.67	-0.39	1.96e-13	Obesity-related traits;
LUSC	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg26384229	chr12:38710491	ALG10B	0.73	11.8	0.54	4.28e-27	Morning vs. evening chronotype;
LUSC	cis	rs1506636	0.962	rs1506640	chr7:123349627	T/G	cg03229431	chr7:123269106	ASB15	-0.64	-10.38	-0.49	4.73e-22	Plateletcrit;Platelet count;
LUSC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19717773	chr7:2847554	GNA12	-0.39	-6.1	-0.32	2.87e-9	Height;
LUSC	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg05855489	chr10:104503620	C10orf26	-0.49	-7.42	-0.38	9.5e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.47	7.9	0.4	4.11e-14	Vitiligo;
LUSC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	1.07	18.33	0.71	1.96e-52	Parkinson's disease;
LUSC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.69	-11.44	-0.53	8.9e-26	Cognitive function;
LUSC	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg15704280	chr7:45808275	SEPT13	0.82	7.82	0.39	6.96e-14	Axial length;
LUSC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg21770322	chr7:97807741	LMTK2	0.41	7.06	0.36	9.44e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00441741	chr2:172290573	DCAF17;METTL8	-0.43	-6.53	-0.34	2.39e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4588572	0.643	rs10474554	chr5:77799158	C/T	cg11547950	chr5:77652471	NA	-0.53	-7.41	-0.38	1.07e-12	Triglycerides;
LUSC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	0.97	13.07	0.58	8.01e-32	Eosinophil percentage of granulocytes;
LUSC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.38	7.41e-13	Bipolar disorder;
LUSC	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg07148914	chr20:33460835	GGT7	-0.53	-8.18	-0.41	5.91e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg06521331	chr12:34319734	NA	-0.47	-7.55	-0.38	4.27e-13	Morning vs. evening chronotype;
LUSC	trans	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	8.76	0.43	9.74e-17	Exhaled nitric oxide output;
LUSC	cis	rs4921915	0.519	rs35583283	chr8:18254509	G/C	cg18736775	chr8:18248649	NAT2	-0.59	-7.09	-0.36	8.13e-12	Iron status biomarkers (transferrin levels);
LUSC	cis	rs55665837	1.000	rs12288873	chr11:14450465	C/T	cg19336497	chr11:14380999	RRAS2	-0.37	-7.53	-0.38	4.9e-13	Vitamin D levels;
LUSC	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.43	-0.46	7.33e-19	Neuroticism;
LUSC	cis	rs6066835	1.000	rs6066830	chr20:47353897	C/T	cg18078177	chr20:47281410	PREX1	0.71	6.21	0.32	1.61e-9	Multiple myeloma;
LUSC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg03433033	chr1:76189801	ACADM	0.72	9.47	0.46	5.43e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs62400317	0.731	rs12214435	chr6:44906717	G/A	cg18551225	chr6:44695536	NA	-0.48	-7.63	-0.39	2.53e-13	Total body bone mineral density;
LUSC	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg20607287	chr7:12443886	VWDE	-0.59	-6.06	-0.31	3.74e-9	Coronary artery disease;
LUSC	cis	rs10789491	1.000	rs2218191	chr1:47130628	C/T	cg15501359	chr1:47185051	KIAA0494	0.65	8.94	0.44	2.63e-17	Response to hepatitis C treatment;
LUSC	cis	rs6960043	0.875	rs2215382	chr7:15055010	C/G	cg19272540	chr7:15055459	NA	0.35	8.89	0.44	3.86e-17	Type 2 diabetes;
LUSC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.65	-10.46	-0.5	2.41e-22	Type 2 diabetes;
LUSC	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg23711669	chr6:146136114	FBXO30	-0.81	-13.84	-0.6	9.75e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg25258033	chr6:167368657	RNASET2	-0.47	-7.83	-0.39	6.38e-14	Crohn's disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg10088075	chr16:30407103	ZNF48	0.77	6.5	0.34	2.9e-10	Cognitive performance;
LUSC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg23982607	chr1:1823379	GNB1	-0.73	-15.0	-0.63	2.94e-39	Body mass index;
LUSC	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg03732007	chr1:2071316	PRKCZ	-0.47	-7.75	-0.39	1.11e-13	Height;
LUSC	trans	rs564343	0.545	rs2241303	chr11:65819661	C/A	cg26701943	chr11:108369231	KDELC2	-0.47	-6.38	-0.33	5.81e-10	Obesity (early onset extreme);
LUSC	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg03342759	chr3:160939853	NMD3	-0.5	-8.27	-0.41	3.24e-15	Morning vs. evening chronotype;
LUSC	trans	rs17266958	1.000	rs62574523	chr9:83284859	C/G	cg01905489	chr1:26616534	UBXN11	-0.52	-5.96	-0.31	6.31e-9	Preschool internalizing problems;
LUSC	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg21361702	chr7:150065534	REPIN1	0.58	8.17	0.41	6.39e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg03859395	chr2:55845619	SMEK2	0.76	13.0	0.58	1.51e-31	Metabolic syndrome;
LUSC	cis	rs4654899	0.865	rs6685831	chr1:21507888	G/A	cg02927042	chr1:21476669	EIF4G3	-0.36	-5.68	-0.3	2.92e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg08499158	chr17:42289980	UBTF	-0.37	-6.0	-0.31	5.1e-9	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820928	0.874	rs116652884	chr2:227902285	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.89	-0.4	4.48e-14	Pulmonary function;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13402217	chr1:151584375	SNX27	-0.37	-6.3	-0.33	9.6e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	0.42	7.02	0.36	1.23e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10100465	0.889	rs7838659	chr8:118684994	C/T	cg09430518	chr8:118662568	NA	-0.32	-5.94	-0.31	7.11e-9	Leprosy;
LUSC	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-6.91	-0.35	2.41e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs472402	0.580	rs7720479	chr5:6640049	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.43	-6.34	-0.33	7.48e-10	Response to amphetamines;
LUSC	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg13010199	chr12:38710504	ALG10B	0.39	6.25	0.32	1.23e-9	Morning vs. evening chronotype;
LUSC	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg19418458	chr7:158789849	NA	0.46	6.33	0.33	7.95e-10	Facial morphology (factor 20);
LUSC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12016809	chr21:47604291	C21orf56	0.39	5.66	0.3	3.33e-8	Testicular germ cell tumor;
LUSC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg11632617	chr15:75315747	PPCDC	-0.54	-6.97	-0.36	1.67e-11	Blood trace element (Zn levels);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20454520	chr14:24584429	DCAF11	-0.5	-6.16	-0.32	2.06e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg21463023	chr3:42623862	SEC22C	0.44	5.99	0.31	5.3300000000000004e-09	Mosquito bite size;
LUSC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg03477792	chr4:77819574	ANKRD56	0.61	8.93	0.44	2.88e-17	Emphysema distribution in smoking;
LUSC	trans	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg10756647	chr7:56101905	PSPH	0.82	8.41	0.42	1.18e-15	Diabetic kidney disease;
LUSC	cis	rs9303280	0.806	rs36095411	chr17:38031865	T/G	cg19468946	chr17:37922297	IKZF3	-0.44	-6.79	-0.35	5.19e-11	Self-reported allergy;
LUSC	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg07080220	chr10:102295463	HIF1AN	0.59	7.64	0.39	2.24e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06544989	chr22:39130855	UNC84B	0.34	6.03	0.31	4.39e-9	Menopause (age at onset);
LUSC	cis	rs9815354	1.000	rs1716987	chr3:41970516	A/G	cg03022575	chr3:42003672	ULK4	-0.59	-6.52	-0.34	2.53e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg06108461	chr20:60628389	TAF4	0.68	8.81	0.43	7.02e-17	Obesity-related traits;
LUSC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg11189052	chr15:85197271	WDR73	0.47	5.78	0.3	1.68e-8	Schizophrenia;
LUSC	cis	rs9309473	0.500	rs4852308	chr2:73834035	T/G	cg20560298	chr2:73613845	ALMS1	0.48	7.38	0.37	1.31e-12	Metabolite levels;
LUSC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg10792982	chr14:105748885	BRF1	0.48	8.31	0.41	2.39e-15	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs2587949	0.593	rs1872415	chr3:4211374	A/G	cg15139668	chr4:4577005	NA	0.41	6.08	0.32	3.23e-9	Periodontitis (DPAL);
LUSC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg12639453	chr1:2035780	PRKCZ	0.33	7.21	0.37	3.74e-12	Height;
LUSC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg12564285	chr5:131593104	PDLIM4	0.39	7.05	0.36	1.01e-11	Breast cancer;
LUSC	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg24579218	chr15:68104479	NA	-0.39	-6.78	-0.35	5.61e-11	Restless legs syndrome;
LUSC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-0.79	-9.6	-0.46	2.04e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg23985595	chr17:80112537	CCDC57	-0.31	-5.94	-0.31	7.27e-9	Life satisfaction;
LUSC	cis	rs7095944	0.584	rs4962692	chr10:126424823	G/A	cg08799069	chr10:126477246	METTL10	-0.4	-6.08	-0.32	3.26e-9	Asthma;
LUSC	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg08999081	chr20:33150536	PIGU	0.37	6.84	0.35	3.71e-11	Height;
LUSC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21963583	chr11:68658836	MRPL21	0.53	8.16	0.41	6.72e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11871801	0.517	rs60929812	chr17:40759448	G/A	cg16308533	chr17:40838983	CNTNAP1	0.39	5.76	0.3	1.89e-8	Crohn's disease;
LUSC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg11062466	chr8:58055876	NA	0.47	6.44	0.33	4.09e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg27572855	chr1:25598939	RHD	-0.4	-7.06	-0.36	9.98e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg11247378	chr22:39784982	NA	-0.59	-10.22	-0.49	1.62e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg02931644	chr1:25747376	RHCE	0.33	5.89	0.31	9.3e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg05973401	chr12:123451056	ABCB9	0.49	5.97	0.31	5.95e-9	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	0.7	11.24	0.52	4.39e-25	Blood metabolite ratios;
LUSC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg09509183	chr1:209979624	IRF6	0.48	5.78	0.3	1.71e-8	Cleft lip with or without cleft palate;
LUSC	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.64	-0.39	2.39e-13	Neuroticism;
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg07167872	chr1:205819463	PM20D1	0.85	16.7	0.67	6.24e-46	Menarche (age at onset);
LUSC	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.69	10.35	0.49	5.71e-22	Corneal astigmatism;
LUSC	cis	rs7131987	0.868	rs737160	chr12:29429012	T/C	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.19	-0.32	1.74e-9	QT interval;
LUSC	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg10840412	chr1:235813424	GNG4	0.45	6.17	0.32	1.96e-9	Bipolar disorder;
LUSC	trans	rs800082	0.734	rs1726536	chr3:144249504	G/T	cg24215973	chr2:240111563	HDAC4	0.41	6.09	0.32	3.07e-9	Smoking behavior;
LUSC	cis	rs17540621	1.000	rs114356926	chr2:47222236	G/T	cg23978866	chr2:47230407	TTC7A	-0.97	-6.65	-0.34	1.21e-10	Response to statin therapy;
LUSC	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg21573476	chr21:45109991	RRP1B	-0.38	-6.02	-0.31	4.48e-9	Mean corpuscular volume;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02668984	chr17:48172022	PDK2	0.43	6.35	0.33	7.22e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07636037	chr3:49044803	WDR6	0.94	13.17	0.58	3.42e-32	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs6960043	1.000	rs6972516	chr7:15051789	G/T	cg19272540	chr7:15055459	NA	-0.29	-6.75	-0.35	6.51e-11	Type 2 diabetes;
LUSC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg22535103	chr8:58192502	C8orf71	-0.85	-8.34	-0.42	1.95e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.14	-0.45	6.37e-18	Monocyte percentage of white cells;
LUSC	trans	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.51	0.38	5.46e-13	Colorectal cancer;
LUSC	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23158103	chr7:148848205	ZNF398	-0.47	-7.88	-0.4	4.73e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg27532560	chr4:187881888	NA	-0.37	-6.08	-0.32	3.33e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg21854759	chr1:92012499	NA	-0.55	-9.23	-0.45	3.13e-18	Breast cancer;
LUSC	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg03264133	chr6:25882463	NA	-0.34	-5.93	-0.31	7.65e-9	Height;
LUSC	cis	rs10754283	0.967	rs7523518	chr1:90110010	G/A	cg21401794	chr1:90099060	LRRC8C	0.64	9.65	0.47	1.33e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.86	14.34	0.62	1.08e-36	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg22029157	chr1:209979665	IRF6	0.74	8.74	0.43	1.14e-16	Coronary artery disease;
LUSC	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg23093090	chr10:104574429	C10orf26	-0.38	-7.08	-0.36	8.32e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7582720	1.000	rs72936881	chr2:203794262	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7709377	0.574	rs13162293	chr5:115507893	A/G	cg23108291	chr5:115420582	COMMD10	0.43	6.13	0.32	2.44e-9	Metabolite levels  (X-11787);
LUSC	cis	rs3741151	0.773	rs57673166	chr11:73232557	T/A	cg17517138	chr11:73019481	ARHGEF17	0.96	8.06	0.4	1.35e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21862992	chr11:68658383	NA	0.49	7.88	0.4	4.55e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.34e-10	Life satisfaction;
LUSC	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg11812906	chr14:75593930	NEK9	-0.4	-5.85	-0.3	1.2e-8	Caffeine consumption;
LUSC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg08219700	chr8:58056026	NA	0.54	6.56	0.34	2.05e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.44	-6.29	-0.33	1.02e-9	Breast cancer;
LUSC	cis	rs4622329	0.615	rs6539019	chr12:102303086	A/G	cg23541617	chr12:102225335	GNPTAB	0.27	6.18	0.32	1.9e-9	Systemic lupus erythematosus;
LUSC	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg13813247	chr22:41461852	NA	-0.37	-6.77	-0.35	5.91e-11	Neuroticism;
LUSC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.14	0.32	2.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg24634471	chr8:143751801	JRK	0.51	7.24	0.37	3.1e-12	Schizophrenia;
LUSC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg02807482	chr3:125708958	NA	-0.51	-6.3	-0.33	9.37e-10	Blood pressure (smoking interaction);
LUSC	trans	rs11700980	0.551	rs2832037	chr21:30115246	A/C	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg14298792	chr15:30685198	CHRFAM7A	0.48	5.99	0.31	5.47e-9	Huntington's disease progression;
LUSC	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg15309053	chr8:964076	NA	0.41	8.04	0.4	1.58e-14	Schizophrenia;
LUSC	cis	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg07460842	chr6:66804631	NA	0.45	5.76	0.3	1.88e-8	Metabolite levels;
LUSC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg07741184	chr6:167504864	NA	0.4	7.09	0.36	8.08e-12	Crohn's disease;
LUSC	cis	rs7705502	1.000	rs1484803	chr5:173349840	A/G	cg18693985	chr5:173351052	CPEB4	-0.38	-6.03	-0.31	4.32e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs1499972	0.941	rs55929115	chr3:117614158	T/A	cg07612923	chr3:117604196	NA	0.6	5.66	0.3	3.29e-8	Schizophrenia;
LUSC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.46	7.29	0.37	2.2e-12	Alzheimer's disease (late onset);
LUSC	cis	rs77633900	0.614	rs280013	chr15:76978139	C/T	cg21673338	chr15:77095150	SCAPER	0.76	7.6	0.38	3.04e-13	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.68	11.6	0.54	2.24e-26	Colorectal cancer;
LUSC	cis	rs17739794	0.517	rs6982473	chr8:773986	G/T	cg01971667	chr8:817044	NA	-0.41	-6.52	-0.34	2.54e-10	Clozapine-induced cytotoxicity;
LUSC	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.59	-0.34	1.73e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg00933542	chr6:150070202	PCMT1	0.3	6.01	0.31	4.73e-9	Lung cancer;
LUSC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.5	-0.38	6e-13	Hemoglobin concentration;
LUSC	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg16624210	chr5:671434	TPPP	0.49	6.05	0.31	3.83e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6977660	0.943	rs10263564	chr7:19842898	G/C	cg05791153	chr7:19748676	TWISTNB	0.57	6.43	0.33	4.54e-10	Thyroid stimulating hormone;
LUSC	cis	rs4629180	0.586	rs1848699	chr2:102137903	C/G	cg04415270	chr2:102091202	RFX8	-0.43	-7.37	-0.37	1.38e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs356992	0.915	rs76674	chr2:60749109	C/T	cg08426369	chr2:60753602	BCL11A	-0.44	-6.2	-0.32	1.69e-9	Educational attainment (years of education);
LUSC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.73	10.83	0.51	1.3e-23	Type 2 diabetes;
LUSC	trans	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.2	-0.37	4.11e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs3772130	0.962	rs13433692	chr3:121484714	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.13	0.48	3.38e-21	Cognitive performance;
LUSC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.59	-8.57	-0.42	3.86e-16	Total body bone mineral density;
LUSC	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	0.57	9.03	0.44	1.42e-17	Breast cancer;
LUSC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg09796270	chr17:17721594	SREBF1	0.41	7.24	0.37	3.06e-12	Total body bone mineral density;
LUSC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-1.11	-24.8	-0.81	9.96e-78	Height;
LUSC	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg04920474	chr2:44395004	PPM1B	0.68	8.74	0.43	1.14e-16	Height;
LUSC	cis	rs17001868	0.568	rs742140	chr22:40781586	G/A	cg07138101	chr22:40742427	ADSL	0.61	7.37	0.37	1.37e-12	Mammographic density (dense area);
LUSC	cis	rs67072384	0.901	rs72964856	chr11:72473299	T/G	cg04827223	chr11:72435913	ARAP1	-0.83	-6.47	-0.33	3.44e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs9391997	0.568	rs7454545	chr6:434348	A/G	cg09757644	chr6:447497	NA	-0.28	-5.77	-0.3	1.85e-8	Chronic lymphocytic leukemia;
LUSC	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.27	-0.32	1.1e-9	Triglycerides;
LUSC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.7	0.6	3.39e-34	Chronic sinus infection;
LUSC	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg08601574	chr20:25228251	PYGB	0.45	6.95	0.36	1.98e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.41	5.99	0.31	5.48e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9921338	1.000	rs9921338	chr16:11416839	T/C	cg00044050	chr16:11439710	C16orf75	0.49	6.53	0.34	2.38e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg23093090	chr10:104574429	C10orf26	-0.38	-7.11	-0.36	7e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9910055	0.550	rs850856	chr17:42157739	C/T	cg16434002	chr17:42200994	HDAC5	0.47	6.09	0.32	3.15e-9	Total body bone mineral density;
LUSC	trans	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	8.12	0.41	9.26e-15	Ulcerative colitis;
LUSC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04565464	chr8:145669602	NFKBIL2	0.38	6.14	0.32	2.33e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs56283067	0.887	rs4644056	chr6:44776136	G/T	cg20913747	chr6:44695427	NA	0.5	7.57	0.38	3.64e-13	Total body bone mineral density;
LUSC	cis	rs12900413	0.687	rs12908489	chr15:90304269	A/G	cg24249390	chr15:90295951	MESP1	-0.37	-5.68	-0.3	2.88e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg13010344	chr12:123464640	ARL6IP4	-0.53	-8.39	-0.42	1.42e-15	Platelet count;
LUSC	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg27219399	chr15:67835830	MAP2K5	-0.31	-5.66	-0.3	3.18e-8	Restless legs syndrome;
LUSC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15664640	chr17:80829946	TBCD	-0.74	-13.29	-0.59	1.2e-32	Breast cancer;
LUSC	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.76	0.43	1e-16	Lung cancer in ever smokers;
LUSC	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-9.71	-0.47	8.8e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs12210905	1.000	rs72843633	chr6:27182949	C/T	cg11837749	chr1:55047332	ACOT11	0.59	6.23	0.32	1.37e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg26384229	chr12:38710491	ALG10B	0.72	11.29	0.53	2.92e-25	Morning vs. evening chronotype;
LUSC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg09849774	chr21:43526787	UMODL1;C21orf128	0.41	6.19	0.32	1.79e-9	IgG glycosylation;
LUSC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.81	0.35	4.6e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-9.45	-0.46	6.01e-19	Platelet count;
LUSC	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg01420254	chr6:26195488	NA	0.65	6.98	0.36	1.63e-11	Gout;Renal underexcretion gout;
LUSC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg23711669	chr6:146136114	FBXO30	0.82	14.9	0.63	7.22e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-6.09	-0.32	3.05e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11608355	1.000	rs10774695	chr12:109868040	G/A	cg19025524	chr12:109796872	NA	-0.37	-5.67	-0.3	3.16e-8	Neuroticism;
LUSC	cis	rs7614311	0.636	rs73117066	chr3:63926236	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-5.84	-0.3	1.25e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.91	-14.45	-0.62	4.21e-37	Prostate cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21497417	chr3:185655402	TRA2B	-0.41	-5.95	-0.31	6.6e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4964805	0.657	rs1866293	chr12:104186655	C/T	cg02344784	chr12:104178138	NT5DC3	0.46	8.86	0.44	4.96e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg15448220	chr1:150897856	SETDB1	0.39	5.77	0.3	1.84e-8	Melanoma;
LUSC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg06263672	chr7:65235340	NA	0.41	6.0	0.31	5.2e-9	Calcium levels;
LUSC	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg24881330	chr22:46731750	TRMU	0.83	7.49	0.38	6.37e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg01017244	chr2:74357527	NA	0.68	13.07	0.58	7.9e-32	Gestational age at birth (maternal effect);
LUSC	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg00579200	chr11:133705235	NA	0.39	5.91	0.31	8.32e-9	Childhood ear infection;
LUSC	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg06937882	chr20:24974362	C20orf3	-0.41	-6.94	-0.36	2.02e-11	Blood protein levels;
LUSC	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	13.5	0.59	1.99e-33	Blood protein levels;
LUSC	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg26876637	chr1:152193138	HRNR	0.45	6.66	0.34	1.16e-10	Atopic dermatitis;
LUSC	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg17173187	chr15:85201210	NMB	0.36	5.8	0.3	1.51e-8	Schizophrenia;
LUSC	cis	rs113835537	0.597	rs11227523	chr11:66305938	C/T	cg24851651	chr11:66362959	CCS	0.53	7.97	0.4	2.52e-14	Airway imaging phenotypes;
LUSC	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg02997394	chr19:33096574	ANKRD27	0.8	9.1	0.45	8.16e-18	Eosinophilic esophagitis;
LUSC	cis	rs7605827	0.930	rs1125534	chr2:15618339	G/A	cg19274914	chr2:15703543	NA	0.46	8.87	0.44	4.51e-17	Educational attainment (years of education);
LUSC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg08888203	chr3:10149979	C3orf24	0.62	8.05	0.4	1.45e-14	Alzheimer's disease;
LUSC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg24920358	chr1:40204285	PPIE	0.61	10.88	0.51	8.73e-24	Blood protein levels;
LUSC	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg00310523	chr12:86230176	RASSF9	0.49	9.42	0.46	7.56e-19	Major depressive disorder;
LUSC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.01	-0.4	1.98e-14	Chronic sinus infection;
LUSC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06634786	chr22:41940651	POLR3H	0.51	6.13	0.32	2.43e-9	Vitiligo;
LUSC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	cis	rs1018697	1.000	rs7092051	chr10:104559477	C/T	cg04362960	chr10:104952993	NT5C2	0.46	6.41	0.33	5.1e-10	Colorectal adenoma (advanced);
LUSC	cis	rs6901250	0.851	rs339361	chr6:117162515	C/T	cg12892004	chr6:117198278	RFX6	0.45	8.63	0.43	2.63e-16	C-reactive protein levels;
LUSC	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	8.55	0.42	4.63e-16	Menarche (age at onset);
LUSC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg07424592	chr7:64974309	NA	0.67	5.88	0.31	9.86e-9	Diabetic kidney disease;
LUSC	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.84	-14.6	-0.62	1.14e-37	Body mass index (adult);
LUSC	cis	rs3741151	0.773	rs17310374	chr11:73274874	T/C	cg17517138	chr11:73019481	ARHGEF17	0.98	8.18	0.41	6.04e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg03929089	chr4:120376271	NA	-0.58	-6.19	-0.32	1.73e-9	Axial length;
LUSC	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg19920283	chr7:105172520	RINT1	0.6	6.38	0.33	5.76e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg06740227	chr12:86229804	RASSF9	0.45	7.16	0.36	5.25e-12	Major depressive disorder;
LUSC	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	6.73	0.35	7.32e-11	Schizophrenia;
LUSC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg07606381	chr6:8435919	SLC35B3	0.72	11.92	0.55	1.52e-27	Motion sickness;
LUSC	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg13334819	chr7:99746414	C7orf59	0.5	6.79	0.35	5.04e-11	Coronary artery disease;
LUSC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Depression;
LUSC	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.91	0.35	2.49e-11	Educational attainment;
LUSC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg02915803	chr1:1606292	LOC728661;CDK11B	0.38	5.89	0.31	9.63e-9	Body mass index;
LUSC	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.9	-0.4	4.09e-14	Glomerular filtration rate;
LUSC	cis	rs2795502	0.564	rs72777192	chr10:43436778	G/A	cg08461752	chr10:43522343	NA	-0.55	-6.45	-0.33	3.85e-10	Blood protein levels;
LUSC	cis	rs427941	0.562	rs6970800	chr7:101780471	T/C	cg06246474	chr7:101738831	CUX1	0.38	6.11	0.32	2.76e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg26536354	chr8:144654954	C8orf73	0.68	7.37	0.37	1.32e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg02023728	chr11:77925099	USP35	0.41	6.26	0.32	1.16e-9	Testicular germ cell tumor;
LUSC	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg10596483	chr8:143751796	JRK	0.61	9.38	0.46	1.02e-18	Schizophrenia;
LUSC	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.19	0.45	4.34e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs68170813	0.652	rs56949084	chr7:107157387	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.45	-5.65	-0.3	3.52e-8	Coronary artery disease;
LUSC	cis	rs76878669	0.754	rs10896113	chr11:66117111	C/T	cg18002602	chr11:66138449	SLC29A2	-0.38	-6.01	-0.31	4.73e-9	Educational attainment (years of education);
LUSC	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg13010199	chr12:38710504	ALG10B	0.67	10.53	0.5	1.43e-22	Morning vs. evening chronotype;
LUSC	trans	rs2587949	0.615	rs2600114	chr3:4225064	G/A	cg15139668	chr4:4577005	NA	-0.41	-6.11	-0.32	2.76e-9	Periodontitis (DPAL);
LUSC	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-7.93	-0.4	3.39e-14	Bladder cancer;
LUSC	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.91	15.81	0.65	2.07e-42	Morning vs. evening chronotype;
LUSC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.89	0.35	2.8e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg03395511	chr6:291903	DUSP22	-0.49	-7.45	-0.38	8.13e-13	Menopause (age at onset);
LUSC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg03806693	chr22:41940476	POLR3H	0.98	13.91	0.61	5.01e-35	Vitiligo;
LUSC	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg04362960	chr10:104952993	NT5C2	-0.61	-9.23	-0.45	3.3e-18	Arsenic metabolism;
LUSC	cis	rs2239815	0.515	rs9625600	chr22:29244395	T/C	cg02153584	chr22:29168773	CCDC117	0.53	6.04	0.31	4.15e-9	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.33	0.53	2.21e-25	Menopause (age at onset);
LUSC	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.96	-12.45	-0.56	1.77e-29	Exhaled nitric oxide output;
LUSC	cis	rs4268898	0.735	rs34125395	chr2:24558242	C/T	cg06627628	chr2:24431161	ITSN2	0.57	8.05	0.4	1.45e-14	Asthma;
LUSC	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg25456477	chr12:86230367	RASSF9	0.39	6.88	0.35	2.96e-11	Major depressive disorder;
LUSC	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	5.93	0.31	7.75e-9	Rheumatoid arthritis;
LUSC	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	1.1	26.44	0.82	6.48e-84	Testicular germ cell tumor;
LUSC	cis	rs68170813	0.559	rs1989814	chr7:107045076	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.28	-0.45	2.28e-18	Coronary artery disease;
LUSC	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	5.84	0.3	1.24e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg00945038	chr17:61921165	SMARCD2	0.54	9.47	0.46	5.4e-19	Prudent dietary pattern;
LUSC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg25319279	chr11:5960081	NA	0.42	6.21	0.32	1.59e-9	DNA methylation (variation);
LUSC	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg03929089	chr4:120376271	NA	0.71	7.27	0.37	2.61e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	6.94	0.36	2.02e-11	Schizophrenia;
LUSC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg11645453	chr3:52864694	ITIH4	0.32	7.62	0.38	2.61e-13	Bipolar disorder;
LUSC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-6.92	-0.35	2.27e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg17623882	chr6:41773611	USP49	-0.57	-9.58	-0.46	2.36e-19	Menarche (age at onset);
LUSC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	11.65	0.54	1.51e-26	Menarche (age at onset);
LUSC	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg04539111	chr16:67997858	SLC12A4	-0.42	-5.86	-0.31	1.12e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs977987	0.872	rs4888422	chr16:75470576	A/G	cg04384234	chr16:75411784	CFDP1	-0.42	-7.12	-0.36	6.5e-12	Dupuytren's disease;
LUSC	cis	rs10186029	0.667	rs6734174	chr2:213981428	A/C	cg08319019	chr2:214017104	IKZF2	-0.54	-7.59	-0.38	3.3e-13	Systemic sclerosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05372549	chr1:11119861	SRM	0.48	6.68	0.34	1e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg18350739	chr11:68623251	NA	-0.38	-6.87	-0.35	3.16e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg09184832	chr6:79620586	NA	0.45	7.15	0.36	5.35e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg01657329	chr11:68192670	LRP5	-0.43	-6.39	-0.33	5.53e-10	Total body bone mineral density;
LUSC	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.54	-0.34	2.32e-10	Response to antipsychotic treatment;
LUSC	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg23422044	chr7:1970798	MAD1L1	-0.55	-5.7	-0.3	2.68e-8	Neuroticism;
LUSC	cis	rs858239	0.539	rs10225608	chr7:23188908	A/G	cg23682824	chr7:23144976	KLHL7	0.4	5.71	0.3	2.52e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.73e-23	Bladder cancer;
LUSC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg09455208	chr3:40491958	NA	0.58	9.77	0.47	5.57e-20	Renal cell carcinoma;
LUSC	cis	rs1572438	0.811	rs9379179	chr6:879853	A/C	cg21062780	chr6:887772	NA	0.35	5.81	0.3	1.43e-8	Aging;
LUSC	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg24130564	chr14:104152367	KLC1	-0.47	-6.82	-0.35	4.31e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	5.85	0.3	1.19e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg03465714	chr1:152285911	FLG	0.41	5.66	0.3	3.22e-8	Atopic dermatitis;
LUSC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg21782813	chr7:2030301	MAD1L1	0.52	9.21	0.45	3.81e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	7.59	0.38	3.23e-13	Mean platelet volume;
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.82	-13.22	-0.59	2.27e-32	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg10326726	chr10:51549505	MSMB	-0.34	-5.87	-0.31	1.06e-8	Prostate-specific antigen levels;
LUSC	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg00509249	chr6:109615579	CCDC162	-0.34	-6.12	-0.32	2.6e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-7.04	-0.36	1.13e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs80346118	0.850	rs17366644	chr20:47466627	A/G	cg16950247	chr11:62911616	SLC22A24	0.48	5.95	0.31	6.79e-9	Diastolic blood pressure;
LUSC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg21856205	chr7:94953877	PON1	-0.36	-5.8	-0.3	1.56e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg09626299	chr10:82213104	TSPAN14	-0.21	-6.29	-0.33	9.7e-10	Post bronchodilator FEV1;
LUSC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-7.04	-0.36	1.08e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7582720	0.945	rs116773016	chr2:203811902	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs12530845	0.673	rs73721607	chr7:135335822	C/T	cg23117316	chr7:135346802	PL-5283	-0.62	-9.56	-0.46	2.64e-19	Red blood cell traits;
LUSC	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg01689657	chr7:91764605	CYP51A1	0.31	5.66	0.3	3.32e-8	Breast cancer;
LUSC	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg06484146	chr7:12443880	VWDE	-0.73	-7.35	-0.37	1.58e-12	Coronary artery disease;
LUSC	trans	rs10511400	0.618	rs6438559	chr3:119867015	A/G	cg02809009	chr19:50354510	PTOV1	-0.67	-6.12	-0.32	2.67e-9	Economic and political preferences (feminism/equality);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16058774	chr6:107349438	C6orf203	-0.41	-6.12	-0.32	2.62e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg15229027	chr14:64805542	ESR2	0.44	6.12	0.32	2.56e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg16797656	chr11:68205561	LRP5	0.36	6.01	0.31	4.74e-9	Total body bone mineral density;
LUSC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg05973401	chr12:123451056	ABCB9	0.52	7.01	0.36	1.32e-11	Neutrophil percentage of white cells;
LUSC	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.48	6.47	0.33	3.59e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.66	14.6	0.62	1.14e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs16910800	0.953	rs73481423	chr11:23205302	T/C	cg20040320	chr11:23191996	NA	-0.44	-6.45	-0.33	3.85e-10	Cancer;
LUSC	trans	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg11887960	chr12:57824829	NA	0.55	6.81	0.35	4.57e-11	Obesity-related traits;
LUSC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18357526	chr6:26021779	HIST1H4A	0.42	6.28	0.32	1.08e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06022373	chr22:39101656	GTPBP1	0.84	13.96	0.61	3.35e-35	Menopause (age at onset);
LUSC	cis	rs36405	0.500	rs4622450	chr14:72355812	T/C	cg23396177	chr14:72358413	NA	-0.38	-7.04	-0.36	1.11e-11	Yang-deficiency constitution;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg11351687	chr6:170863423	PSMB1;TBP	0.53	6.42	0.33	4.64e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs870142	0.883	rs73203669	chr4:4641569	C/G	cg04017672	chr1:182359056	GLUL	0.4	5.99	0.31	5.39e-9	Congenital heart disease;
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.93	-0.4	3.38e-14	Lymphocyte counts;
LUSC	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-16.94	-0.68	6.8e-47	Exhaled nitric oxide output;
LUSC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg19747945	chr6:42946146	PEX6	-0.34	-5.67	-0.3	3.11e-8	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg05896524	chr21:47604654	C21orf56	0.58	8.96	0.44	2.37e-17	Testicular germ cell tumor;
LUSC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg13798780	chr7:105162888	PUS7	0.57	6.06	0.31	3.62e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.74	-14.14	-0.61	6.46e-36	Ulcerative colitis;
LUSC	cis	rs7560272	0.723	rs780395	chr2:73700853	G/A	cg20560298	chr2:73613845	ALMS1	0.46	7.19	0.37	4.24e-12	Schizophrenia;
LUSC	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.38	-6.26	-0.32	1.2e-9	Longevity;Endometriosis;
LUSC	cis	rs1143633	0.530	rs4538207	chr2:113701863	G/T	cg06156847	chr2:113672199	IL1F7	-0.28	-5.83	-0.3	1.32e-8	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9807841	0.568	rs1560708	chr19:10749236	T/C	cg17710535	chr19:10819994	QTRT1	0.4	6.59	0.34	1.69e-10	Inflammatory skin disease;
LUSC	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg05472934	chr7:22766657	IL6	-0.53	-8.1	-0.41	1.04e-14	Lung cancer;
LUSC	cis	rs10484885	0.877	rs17735389	chr6:90323139	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.59	-0.38	3.16e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.31	5.87	0.31	1.06e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.82	0.35	4.17e-11	Platelet count;
LUSC	trans	rs72674100	0.737	rs72874649	chr4:97965312	T/C	cg16405019	chr1:18959625	PAX7	-0.64	-6.78	-0.35	5.33e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg12564285	chr5:131593104	PDLIM4	0.37	6.87	0.35	3.17e-11	Blood metabolite levels;
LUSC	cis	rs12980942	0.515	rs12980839	chr19:41820213	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.45	5.66	0.3	3.23e-8	Coronary artery disease;
LUSC	trans	rs2975734	0.709	rs6988826	chr8:10109625	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.51	-0.34	2.71e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs73195822	0.614	rs17190144	chr12:111214767	A/G	cg12870014	chr12:110450643	ANKRD13A	0.69	7.06	0.36	9.82e-12	Itch intensity from mosquito bite;
LUSC	cis	rs17407555	0.779	rs4459989	chr4:10112602	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-6.01	-0.31	4.94e-9	Schizophrenia (age at onset);
LUSC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.76	0.57	1.24e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02559264	chr11:73490474	NA	0.43	6.47	0.33	3.39e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2274273	0.804	rs28428911	chr14:55843596	G/T	cg04306507	chr14:55594613	LGALS3	0.53	11.62	0.54	1.94e-26	Protein biomarker;
LUSC	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg23887609	chr12:130822674	PIWIL1	0.49	7.27	0.37	2.65e-12	Menopause (age at onset);
LUSC	cis	rs3764021	0.870	rs7976584	chr12:9878655	C/T	cg20894963	chr12:9885564	CLECL1	0.34	6.9	0.35	2.57e-11	Type 1 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18632100	chr19:59028615	ZBTB45	0.49	6.82	0.35	4.27e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg00763151	chr12:98987211	SLC25A3	0.35	6.06	0.31	3.73e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg27284194	chr4:1044797	NA	0.58	8.61	0.43	2.92e-16	Recombination rate (females);
LUSC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg19318889	chr4:1322082	MAEA	-0.78	-13.96	-0.61	3.39e-35	Longevity;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14107975	chr11:96076498	MAML2	-0.5	-6.71	-0.34	8.35e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg10756647	chr7:56101905	PSPH	0.88	8.96	0.44	2.32e-17	Gout;
LUSC	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg15704280	chr7:45808275	SEPT13	-0.6	-7.31	-0.37	1.99e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7715806	0.500	rs17563589	chr5:74980019	A/G	cg19683494	chr5:74908142	NA	0.58	7.92	0.4	3.64e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11166629	1.000	rs1036820	chr8:135646571	C/T	cg27224718	chr8:135614730	ZFAT	-0.62	-10.36	-0.49	5.35e-22	Smoking quantity;
LUSC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	0.87	14.72	0.63	3.76e-38	Tonsillectomy;
LUSC	cis	rs6005807	0.719	rs12169071	chr22:29033210	C/G	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs4474465	0.920	rs908002	chr11:78144753	T/A	cg27205649	chr11:78285834	NARS2	-0.52	-5.96	-0.31	6.28e-9	Alzheimer's disease (survival time);
LUSC	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg03929089	chr4:120376271	NA	0.54	6.65	0.34	1.19e-10	Intraocular pressure;
LUSC	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08645402	chr16:4508243	NA	0.53	9.08	0.45	9.4e-18	Schizophrenia;
LUSC	cis	rs806215	1.000	rs806196	chr7:127248414	A/G	cg25922125	chr7:127225783	GCC1	0.57	7.17	0.37	4.96e-12	Type 2 diabetes;
LUSC	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg01256987	chr12:42539512	GXYLT1	-0.39	-7.15	-0.36	5.43e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23158103	chr7:148848205	ZNF398	-0.48	-7.98	-0.4	2.33e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.96	15.46	0.65	4.83e-41	Lymphocyte percentage of white cells;
LUSC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-8.21	-0.41	4.89e-15	Mood instability;
LUSC	cis	rs7640424	0.754	rs182736	chr3:107838891	C/A	cg09227934	chr3:107805635	CD47	0.43	6.68	0.34	1.01e-10	Body mass index;
LUSC	cis	rs12617721	0.645	rs114544871	chr2:99045485	T/G	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.14e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4356932	0.935	rs7677924	chr4:76977023	C/A	cg00809888	chr4:76862425	NAAA	0.34	5.66	0.3	3.25e-8	Blood protein levels;
LUSC	trans	rs1486139	1.000	rs1903673	chr7:46282628	A/G	cg17534202	chr9:96721102	NA	-0.37	-6.56	-0.34	2.01e-10	Select biomarker traits;
LUSC	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg03433033	chr1:76189801	ACADM	-0.41	-6.13	-0.32	2.47e-9	Daytime sleep phenotypes;
LUSC	cis	rs11748023	0.605	rs152409	chr5:139521808	T/C	cg26211634	chr5:139558579	C5orf32	0.32	5.69	0.3	2.81e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg14582100	chr15:45693742	SPATA5L1	0.57	10.0	0.48	9.11e-21	Homoarginine levels;
LUSC	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg11764359	chr7:65958608	NA	-0.42	-6.01	-0.31	4.94e-9	Calcium levels;
LUSC	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg22431228	chr1:16359049	CLCNKA	-0.42	-8.46	-0.42	8.3e-16	Systolic blood pressure;
LUSC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg24531977	chr5:56204891	C5orf35	-0.71	-10.4	-0.49	3.84e-22	Coronary artery disease;
LUSC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg17948913	chr5:572064	NA	0.33	5.7	0.3	2.63e-8	Ulcerative colitis;
LUSC	cis	rs367943	0.712	rs10035686	chr5:112683357	C/T	cg12552261	chr5:112820674	MCC	0.39	6.37	0.33	6.4e-10	Type 2 diabetes;
LUSC	cis	rs11030122	0.673	rs4910597	chr11:4094923	G/A	cg08557956	chr11:4115526	RRM1	-0.46	-5.83	-0.3	1.31e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs367943	0.712	rs9326886	chr5:112728458	A/C	cg12552261	chr5:112820674	MCC	0.36	5.84	0.3	1.21e-8	Type 2 diabetes;
LUSC	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg25251562	chr2:3704773	ALLC	-0.48	-7.28	-0.37	2.45e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.4	-0.33	5.23e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8018808	0.870	rs11159264	chr14:77937017	T/C	cg20045696	chr14:77926864	AHSA1	0.34	5.74	0.3	2.11e-8	Myeloid white cell count;
LUSC	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.68	-12.4	-0.56	2.55e-29	Platelet distribution width;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22050555	chr5:171615449	STK10	-0.52	-6.63	-0.34	1.33e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12077875	chr20:47835964	DDX27	0.4	6.33	0.33	7.69e-10	Asthma;
LUSC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18854424	chr1:2615690	NA	-0.52	-10.73	-0.51	2.77e-23	Ulcerative colitis;
LUSC	cis	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg21775007	chr8:11205619	TDH	0.44	5.87	0.31	1.05e-8	Neuroticism;
LUSC	cis	rs3126085	0.935	rs10888473	chr1:152220235	G/A	cg26876637	chr1:152193138	HRNR	0.46	6.28	0.32	1.05e-9	Atopic dermatitis;
LUSC	cis	rs68170813	0.559	rs12537733	chr7:106965447	A/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.77	-0.47	5.25e-20	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg02175503	chr12:58329896	NA	0.59	8.91	0.44	3.36e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs11723530	0.538	rs4692763	chr4:170814362	T/G	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.28	-0.32	1.03e-9	Myopia (pathological);
LUSC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.15	-0.36	5.66e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg25174290	chr11:3078921	CARS	0.58	9.15	0.45	5.85e-18	Longevity;
LUSC	cis	rs73206853	0.698	rs73191806	chr12:110899913	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg02569458	chr12:86230093	RASSF9	0.58	9.82	0.47	3.54e-20	Major depressive disorder;
LUSC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg17294928	chr15:75287854	SCAMP5	0.43	6.26	0.32	1.18e-9	Breast cancer;
LUSC	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg05340658	chr4:99064831	C4orf37	0.44	7.0	0.36	1.41e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg19824325	chr16:58548873	SETD6	0.95	9.65	0.47	1.36e-19	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.15	0.32	2.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg08999081	chr20:33150536	PIGU	-0.37	-6.83	-0.35	3.93e-11	Height;
LUSC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg21573476	chr21:45109991	RRP1B	0.37	5.91	0.31	8.65e-9	Mean corpuscular volume;
LUSC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.89	0.48	2.14e-20	Bipolar disorder;
LUSC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21545522	chr1:205238299	TMCC2	0.49	9.19	0.45	4.28e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg03886242	chr7:26192032	NFE2L3	-0.4	-6.47	-0.33	3.54e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11229555	0.609	rs12286421	chr11:58174898	A/G	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.75	-0.3	1.97e-8	IgG glycosylation;
LUSC	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg12863693	chr15:85201151	NMB	0.37	7.69	0.39	1.63e-13	Schizophrenia;
LUSC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg03609598	chr5:56110824	MAP3K1	-0.39	-5.86	-0.31	1.08e-8	Initial pursuit acceleration;
LUSC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg06618935	chr21:46677482	NA	-0.41	-8.22	-0.41	4.49e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.79	11.11	0.52	1.32e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg12940439	chr1:67600707	NA	0.39	6.2	0.32	1.7e-9	Psoriasis;
LUSC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21028142	chr17:79581711	NPLOC4	-0.32	-7.79	-0.39	8.41e-14	Eye color traits;
LUSC	cis	rs7215564	0.822	rs2340771	chr17:78752947	A/C	cg23238734	chr17:78661607	RPTOR	-0.44	-5.65	-0.3	3.4e-8	Myopia (pathological);
LUSC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.76	-0.35	6.3e-11	Total body bone mineral density;
LUSC	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg15485101	chr11:133734466	NA	0.38	7.17	0.37	4.98e-12	Childhood ear infection;
LUSC	trans	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg24644049	chr4:85504048	CDS1	-0.86	-7.74	-0.39	1.22e-13	Skin colour saturation;
LUSC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg00409905	chr10:38381863	ZNF37A	-0.33	-5.75	-0.3	1.99e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg16797656	chr11:68205561	LRP5	0.46	8.29	0.41	2.75e-15	Total body bone mineral density;
LUSC	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-6.76	-0.35	6.22e-11	Colorectal cancer;
LUSC	cis	rs77633900	0.614	rs2439993	chr15:76861532	G/A	cg21673338	chr15:77095150	SCAPER	-0.71	-7.14	-0.36	6.05e-12	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg01299579	chr2:10830716	NOL10	0.36	5.73	0.3	2.21e-8	Prostate cancer;
LUSC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06028605	chr16:24865363	SLC5A11	0.68	10.63	0.5	6.19e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg12365402	chr11:9010492	NRIP3	-0.52	-9.88	-0.48	2.31e-20	Hemoglobin concentration;
LUSC	cis	rs950881	0.601	rs3771164	chr2:102991786	A/T	cg20060108	chr2:102954350	IL1RL1	0.47	6.25	0.32	1.22e-9	Allergy;
LUSC	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg19773385	chr1:10388646	KIF1B	-0.53	-8.3	-0.41	2.57e-15	Hepatocellular carcinoma;
LUSC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.21	-0.32	1.61e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07923666	chr12:49932857	KCNH3	0.48	6.06	0.31	3.64e-9	Resting heart rate;
LUSC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg20203395	chr5:56204925	C5orf35	-0.73	-9.87	-0.48	2.58e-20	Initial pursuit acceleration;
LUSC	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg23649088	chr2:200775458	C2orf69	-0.57	-7.0	-0.36	1.41e-11	Schizophrenia;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.4	6.35	0.33	7.23e-10	Metabolite levels (Pyroglutamine);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg17032565	chr2:110260096	SH3RF3	-0.37	-6.44	-0.33	4.28e-10	Schizophrenia;
LUSC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02463440	chr8:22132932	PIWIL2	-0.43	-7.95	-0.4	2.86e-14	Hypertriglyceridemia;
LUSC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg21782813	chr7:2030301	MAD1L1	-0.47	-8.04	-0.4	1.61e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18854424	chr1:2615690	NA	0.49	9.83	0.47	3.49e-20	Ulcerative colitis;
LUSC	cis	rs6736093	0.966	rs3811633	chr2:112754880	G/A	cg12686935	chr2:112915763	FBLN7	-0.37	-6.06	-0.31	3.65e-9	Coronary artery disease;
LUSC	cis	rs13385	0.769	rs7715649	chr5:139605517	G/A	cg26211634	chr5:139558579	C5orf32	0.45	6.75	0.35	6.51e-11	Atrial fibrillation;
LUSC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg22166914	chr1:53195759	ZYG11B	0.64	10.62	0.5	6.66e-23	Monocyte count;
LUSC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.14	0.32	2.31e-9	Schizophrenia;
LUSC	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg01304814	chr3:48885189	PRKAR2A	0.86	5.83	0.3	1.31e-8	Cognitive function;
LUSC	cis	rs877282	0.898	rs11253338	chr10:759559	C/T	cg17470449	chr10:769945	NA	0.48	6.78	0.35	5.49e-11	Uric acid levels;
LUSC	cis	rs6599077	0.616	rs11716640	chr3:40175332	T/A	cg13683864	chr3:40499215	RPL14	-0.55	-6.9	-0.35	2.55e-11	Sleep-related phenotypes;
LUSC	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg12935359	chr14:103987150	CKB	-0.56	-8.49	-0.42	6.64e-16	Body mass index;
LUSC	cis	rs4722404	0.643	rs4722443	chr7:3156031	T/C	cg19214707	chr7:3157722	NA	0.35	6.47	0.33	3.58e-10	Atopic dermatitis;
LUSC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.05	-0.31	3.93e-9	Platelet count;
LUSC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23158103	chr7:148848205	ZNF398	-0.51	-8.49	-0.42	6.87e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg01528321	chr10:82214614	TSPAN14	0.82	12.33	0.56	4.69e-29	Post bronchodilator FEV1;
LUSC	cis	rs7119	0.604	rs2682927	chr15:77859168	C/T	cg27398640	chr15:77910606	LINGO1	0.36	7.72	0.39	1.35e-13	Type 2 diabetes;
LUSC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg27170947	chr2:26402098	FAM59B	-0.62	-9.21	-0.45	3.74e-18	Gut microbiome composition (summer);
LUSC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg09034736	chr1:150693464	HORMAD1	-0.41	-5.88	-0.31	1.01e-8	Tonsillectomy;
LUSC	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg00277334	chr10:82204260	NA	-0.48	-6.5	-0.34	2.94e-10	Post bronchodilator FEV1;
LUSC	cis	rs13082711	0.911	rs7640929	chr3:27513944	C/A	cg02860705	chr3:27208620	NA	0.48	8.0	0.4	2e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs2011503	0.739	rs8108659	chr19:19680738	T/A	cg11244672	chr19:19639970	YJEFN3	0.46	6.05	0.31	3.94e-9	Bipolar disorder;
LUSC	cis	rs1448094	0.617	rs7297449	chr12:86468442	A/C	cg00310523	chr12:86230176	RASSF9	-0.34	-6.21	-0.32	1.59e-9	Major depressive disorder;
LUSC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.72	-0.3	2.39e-8	Monocyte count;
LUSC	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg17366294	chr4:99064904	C4orf37	0.61	10.78	0.51	1.87e-23	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg12856521	chr11:46389249	DGKZ	0.42	6.67	0.34	1.04e-10	Leprosy;
LUSC	cis	rs4073416	0.542	rs7145500	chr14:65884212	G/A	cg03016385	chr14:66212404	NA	-0.38	-5.83	-0.3	1.29e-8	N-glycan levels;
LUSC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg18876405	chr7:65276391	NA	-0.58	-9.31	-0.45	1.8e-18	Aortic root size;
LUSC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.47	-8.29	-0.41	2.78e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs6546550	0.901	rs6546553	chr2:70111711	C/A	cg02498382	chr2:70120550	SNRNP27	-0.31	-7.49	-0.38	6.21e-13	Prevalent atrial fibrillation;
LUSC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.41	-0.42	1.23e-15	Height;
LUSC	cis	rs11756438	0.572	rs2638529	chr6:119006459	T/C	cg18833306	chr6:118973337	C6orf204	0.37	5.77	0.3	1.8e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	11.6	0.54	2.28e-26	Alzheimer's disease;
LUSC	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.56	-0.38	3.86e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.79	-14.4	-0.62	6.32e-37	Dental caries;
LUSC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.44	0.33	4.12e-10	Menopause (age at onset);
LUSC	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-7.93	-0.4	3.43e-14	Bladder cancer;
LUSC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg04362960	chr10:104952993	NT5C2	0.58	9.38	0.46	1.02e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg00431813	chr7:1051703	C7orf50	-0.39	-6.41	-0.33	4.98e-10	Longevity;Endometriosis;
LUSC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg20135002	chr11:47629003	NA	0.48	7.51	0.38	5.54e-13	Subjective well-being;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27288777	chr17:30264551	SUZ12	-0.41	-5.95	-0.31	6.61e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.83	-0.81	7.74e-78	Height;
LUSC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.42	6.32	0.33	8.21e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01737828	chr15:75230659	COX5A	0.43	5.98	0.31	5.59e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4631830	0.863	rs2843549	chr10:51521247	C/A	cg16070123	chr10:51489643	NA	-0.51	-8.08	-0.4	1.23e-14	Prostate-specific antigen levels;
LUSC	cis	rs983392	0.679	rs10736700	chr11:60031399	T/C	cg24026212	chr11:59952134	MS4A6A	0.36	6.2	0.32	1.71e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3741151	0.773	rs73542979	chr11:73127526	G/C	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs10740039	0.961	rs2083696	chr10:62416188	G/C	cg18175470	chr10:62150864	ANK3	-0.43	-6.8	-0.35	4.8e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12458462	0.851	rs60298379	chr18:77488422	C/T	cg11879182	chr18:77439856	CTDP1	0.7	10.45	0.5	2.56e-22	Monocyte count;
LUSC	cis	rs7250872	0.647	rs12976128	chr19:1817113	A/C	cg18850929	chr19:1828978	REXO1	0.41	5.97	0.31	6.2e-9	Bipolar disorder;
LUSC	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-0.98	-19.19	-0.72	7.44e-56	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7659604	0.540	rs10020581	chr4:122676559	A/C	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.91	-0.31	8.47e-9	Type 2 diabetes;
LUSC	cis	rs3772130	0.545	rs7340674	chr3:121574215	T/C	cg11130432	chr3:121712080	ILDR1	0.36	5.77	0.3	1.84e-8	Cognitive performance;
LUSC	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.66	9.25	0.45	2.67e-18	Response to bleomycin (chromatid breaks);
LUSC	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg04725166	chr1:7887271	PER3	-0.45	-6.19	-0.32	1.75e-9	Crohn's disease;
LUSC	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg22431228	chr1:16359049	CLCNKA	-0.47	-9.1	-0.45	8.22e-18	Dilated cardiomyopathy;
LUSC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg04315214	chr1:2043799	PRKCZ	0.47	9.63	0.47	1.59e-19	Height;
LUSC	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg14458575	chr2:238380390	NA	0.66	11.6	0.54	2.28e-26	Prostate cancer;
LUSC	cis	rs9303542	0.559	rs12951076	chr17:46625109	T/C	cg09704116	chr17:46666958	LOC404266	-0.37	-5.97	-0.31	6.11e-9	Ovarian cancer;Epithelial ovarian cancer;
LUSC	trans	rs3960554	0.932	rs4728614	chr7:75841589	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.85	-9.6	-0.47	2e-19	Eotaxin levels;
LUSC	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg00290607	chr11:67383545	NA	0.35	6.66	0.34	1.14e-10	Mean corpuscular volume;
LUSC	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg14664628	chr15:75095509	CSK	-0.54	-8.05	-0.4	1.42e-14	Breast cancer;
LUSC	cis	rs909341	1.000	rs909341	chr20:62328742	C/T	cg09650180	chr20:62225654	GMEB2	-0.44	-5.78	-0.3	1.73e-8	Atopic dermatitis;
LUSC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-1.11	-24.8	-0.81	9.96e-78	Height;
LUSC	cis	rs4704187	0.663	rs7735057	chr5:74403857	T/A	cg03227963	chr5:74354835	NA	0.33	7.06	0.36	9.4e-12	Response to amphetamines;
LUSC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs244293	0.760	rs1990673	chr17:53050025	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.38	-5.71	-0.3	2.54e-8	Menarche (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13682044	chr17:41623249	ETV4	0.72	6.06	0.31	3.62e-9	Cognitive performance;
LUSC	cis	rs1568889	1.000	rs12802157	chr11:28060285	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.51	0.46	3.95e-19	Bipolar disorder;
LUSC	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.77	-12.95	-0.58	2.23e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg16482183	chr6:26056742	HIST1H1C	0.68	9.3	0.45	1.91e-18	Iron status biomarkers;
LUSC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.36	0.46	1.24e-18	Monocyte percentage of white cells;
LUSC	cis	rs116988415	0.584	rs747858	chr14:65239772	G/A	cg25083366	chr14:65239357	SPTB	0.7	6.65	0.34	1.19e-10	Daytime sleep phenotypes;
LUSC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg12963246	chr6:28129442	ZNF389	0.52	7.17	0.37	4.94e-12	Depression;
LUSC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg14696996	chr19:15285081	NOTCH3	0.84	7.51	0.38	5.49e-13	Pulse pressure;
LUSC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg07169764	chr2:136633963	MCM6	-0.58	-7.55	-0.38	4.09e-13	Mosquito bite size;
LUSC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg07414643	chr4:187882934	NA	0.55	10.53	0.5	1.41e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12824058	0.737	rs2398510	chr12:130816637	G/A	cg23887609	chr12:130822674	PIWIL1	0.44	6.34	0.33	7.46e-10	Menopause (age at onset);
LUSC	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-9.1	-0.45	8.64e-18	Retinal vascular caliber;
LUSC	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg15485101	chr11:133734466	NA	0.38	7.17	0.37	4.98e-12	Childhood ear infection;
LUSC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg27535305	chr1:53392650	SCP2	0.39	7.23	0.37	3.27e-12	Monocyte count;
LUSC	cis	rs12118280	0.531	rs2336019	chr1:108757756	T/C	cg11967332	chr1:108735228	SLC25A24	0.43	6.13	0.32	2.55e-9	Myeloid white cell count;
LUSC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg17541715	chr7:1216824	NA	-0.36	-5.8	-0.3	1.54e-8	Longevity;Endometriosis;
LUSC	cis	rs6722750	0.651	rs2901646	chr2:64414892	A/G	cg22352474	chr2:64371530	PELI1	0.52	7.94	0.4	3.18e-14	Neuroticism;
LUSC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg26597838	chr10:835615	NA	0.85	11.84	0.54	3e-27	Eosinophil percentage of granulocytes;
LUSC	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg20503657	chr10:835505	NA	0.52	7.0	0.36	1.45e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg25457927	chr22:38595422	NA	-0.35	-6.82	-0.35	4.17e-11	Cutaneous nevi;
LUSC	cis	rs1358748	0.522	rs2144656	chr1:67579386	A/G	cg02640540	chr1:67518911	SLC35D1	0.63	6.1	0.32	2.9e-9	Tuberculosis;
LUSC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg03732007	chr1:2071316	PRKCZ	-0.54	-10.0	-0.48	9.19e-21	Height;
LUSC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg27446573	chr6:127587934	RNF146	0.62	9.85	0.47	2.86e-20	Breast cancer;
LUSC	cis	rs62400317	0.826	rs10807321	chr6:45330974	T/C	cg20913747	chr6:44695427	NA	-0.48	-7.8	-0.39	7.82e-14	Total body bone mineral density;
LUSC	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	1.1	17.23	0.69	4.59e-48	Exhaled nitric oxide output;
LUSC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.69	0.39	1.65e-13	Bipolar disorder;
LUSC	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg15839431	chr19:19639596	YJEFN3	0.6	6.63	0.34	1.33e-10	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.65	10.84	0.51	1.15e-23	Prudent dietary pattern;
LUSC	cis	rs6674970	0.966	rs4512652	chr1:151115690	G/C	cg11822372	chr1:151115635	SEMA6C	0.52	8.03	0.4	1.71e-14	Childhood ear infection;
LUSC	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.19	-0.41	5.46e-15	Mood instability;
LUSC	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	7.03	0.36	1.14e-11	Rheumatoid arthritis;
LUSC	cis	rs1866706	0.739	rs7116989	chr11:12856087	G/A	cg25843174	chr11:12811716	TEAD1	-0.28	-5.69	-0.3	2.79e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	0.8	14.05	0.61	1.48e-35	Cognitive function;
LUSC	cis	rs2230307	0.536	rs534252	chr1:100472604	A/G	cg24955406	chr1:100503596	HIAT1	0.56	6.04	0.31	4.01e-9	Carotid intima media thickness;
LUSC	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg00105475	chr2:10696890	NA	0.37	6.17	0.32	1.99e-9	Prostate cancer;
LUSC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg22535103	chr8:58192502	C8orf71	-0.61	-6.94	-0.36	1.99e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs75804782	0.641	rs56134361	chr2:239318905	A/G	cg01134436	chr17:81009848	B3GNTL1	0.64	6.08	0.32	3.37e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg11632617	chr15:75315747	PPCDC	-0.51	-6.62	-0.34	1.46e-10	Blood trace element (Zn levels);
LUSC	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg05187965	chr10:45406764	TMEM72	-0.38	-9.02	-0.44	1.47e-17	Mean corpuscular volume;
LUSC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.81	13.41	0.59	4.23e-33	Aortic root size;
LUSC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg26958806	chr6:27640298	NA	0.68	5.76	0.3	1.93e-8	Depression;
LUSC	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.19	-0.41	5.43e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg07701084	chr6:150067640	NUP43	0.47	7.03	0.36	1.15e-11	Testicular germ cell tumor;
LUSC	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg03929089	chr4:120376271	NA	0.68	6.37	0.33	6.29e-10	Axial length;
LUSC	cis	rs6060717	0.571	rs6060761	chr20:34612487	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.31	-0.33	8.76e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.35	-0.37	1.57e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9888739	0.591	rs4632147	chr16:31363381	C/T	cg15817542	chr16:31343056	ITGAM	-0.53	-7.17	-0.37	4.82e-12	Systemic lupus erythematosus;
LUSC	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	1.12	19.83	0.74	2.22e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.71	-11.04	-0.52	2.31e-24	Aortic root size;
LUSC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs4363385	0.720	rs1415967	chr1:152965585	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.66	-0.39	2.08e-13	Inflammatory skin disease;
LUSC	trans	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg25214090	chr10:38739885	LOC399744	0.45	6.77	0.35	5.65e-11	Corneal astigmatism;
LUSC	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-7.05	-0.36	1.05e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg21775007	chr8:11205619	TDH	-0.53	-6.86	-0.35	3.37e-11	Triglycerides;
LUSC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03576123	chr11:487126	PTDSS2	-1.01	-10.64	-0.5	5.61e-23	Body mass index;
LUSC	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg15133208	chr4:90757351	SNCA	-0.51	-7.61	-0.38	2.85e-13	Neuroticism;
LUSC	cis	rs10761482	0.500	rs2393644	chr10:62311274	T/A	cg18175470	chr10:62150864	ANK3	-0.48	-6.81	-0.35	4.5e-11	Schizophrenia;
LUSC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.1	-0.58	6.18e-32	Platelet count;
LUSC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg13395646	chr4:1353034	KIAA1530	-0.66	-10.36	-0.49	5.61e-22	Obesity-related traits;
LUSC	cis	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg24459738	chr19:57751996	ZNF805	-0.52	-7.69	-0.39	1.66e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg18478394	chr8:109455254	TTC35	0.46	7.13	0.36	6.27e-12	Dupuytren's disease;
LUSC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg06640241	chr16:89574553	SPG7	0.7	11.11	0.52	1.31e-24	Multiple myeloma (IgH translocation);
LUSC	cis	rs6546550	0.933	rs1454498	chr2:70149225	C/A	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.6	13.79	0.6	1.46e-34	Height;
LUSC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg07703079	chr11:430292	ANO9	0.66	6.77	0.35	5.66e-11	Body mass index;
LUSC	cis	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg21775007	chr8:11205619	TDH	0.41	5.74	0.3	2.08e-8	Systolic blood pressure;
LUSC	cis	rs6700896	0.931	rs1938492	chr1:66117829	A/C	cg04111102	chr1:66153794	NA	0.32	7.1	0.36	7.54e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg26380479	chr7:97908229	NA	-0.26	-5.77	-0.3	1.78e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg08736216	chr1:53307985	ZYG11A	0.28	5.74	0.3	2.12e-8	Monocyte count;
LUSC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg21770322	chr7:97807741	LMTK2	0.41	7.06	0.36	9.86e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg03676636	chr4:99064102	C4orf37	-0.26	-5.65	-0.3	3.5e-8	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg17462356	chr17:80056334	FASN	-0.46	-6.21	-0.32	1.53e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.37	0.59	6.16e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9311676	0.632	rs56398717	chr3:58404355	G/A	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg06191203	chr2:152266755	RIF1	-0.54	-7.28	-0.37	2.44e-12	Lung cancer;
LUSC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.49	7.69	0.39	1.71e-13	Colorectal cancer;
LUSC	cis	rs9473147	0.516	rs2171089	chr6:47515811	A/G	cg20196966	chr6:47445060	CD2AP	0.42	5.89	0.31	9.59e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg10609677	chr17:41278573	BRCA1;NBR2	0.36	5.86	0.31	1.09e-8	Menopause (age at onset);
LUSC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg06454157	chr6:167490870	NA	-0.28	-6.58	-0.34	1.78e-10	Primary biliary cholangitis;
LUSC	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.6	9.91	0.48	1.78e-20	Body mass index;
LUSC	cis	rs12541635	0.934	rs11776139	chr8:106983966	A/G	cg10147462	chr8:107024639	NA	0.56	9.7	0.47	9.18e-20	Age of smoking initiation;
LUSC	cis	rs55665837	1.000	rs12295888	chr11:14450531	T/C	cg05501817	chr11:14380813	RRAS2	-0.41	-6.61	-0.34	1.51e-10	Vitamin D levels;
LUSC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg18479299	chr3:125709523	NA	-0.5	-5.7	-0.3	2.65e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg04518342	chr5:131593106	PDLIM4	0.34	6.03	0.31	4.47e-9	Blood metabolite levels;
LUSC	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg25251562	chr2:3704773	ALLC	-0.54	-8.2	-0.41	5.24e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2224391	0.628	rs2773319	chr6:5258941	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.48	6.55	0.34	2.13e-10	Height;
LUSC	cis	rs7580658	0.926	rs79789049	chr2:128145472	G/A	cg09760422	chr2:128146352	NA	-0.33	-7.25	-0.37	2.91e-12	Protein C levels;
LUSC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.73	0.39	1.26e-13	Bipolar disorder;
LUSC	cis	rs7590368	0.561	rs80325720	chr2:10958803	T/C	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg15798862	chr7:76129360	DTX2	-0.51	-8.54	-0.42	4.77e-16	Multiple sclerosis;
LUSC	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06636551	chr8:101224915	SPAG1	-0.43	-7.82	-0.39	6.79e-14	Atrioventricular conduction;
LUSC	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg25457927	chr22:38595422	NA	0.44	8.08	0.4	1.18e-14	Breast cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01586524	chr8:67341819	RRS1	0.46	6.42	0.33	4.58e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs1541010	0.762	rs2015015	chr10:13766692	C/T	cg04685003	chr17:57696515	CLTC	-0.43	-6.26	-0.32	1.15e-9	RR interval (heart rate);
LUSC	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg06096015	chr1:231504339	EGLN1	0.55	9.95	0.48	1.35e-20	Hemoglobin concentration;
LUSC	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg06740227	chr12:86229804	RASSF9	-0.36	-5.81	-0.3	1.43e-8	Major depressive disorder;
LUSC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-6.1	-0.32	2.93e-9	Lung cancer;
LUSC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs7712401	0.601	rs35699701	chr5:122333756	G/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.2	-0.45	4.07e-18	Mean platelet volume;
LUSC	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg14830002	chr1:247616686	OR2B11	0.52	7.47	0.38	7.16e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.3	-0.41	2.63e-15	Obesity-related traits;
LUSC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg05347473	chr6:146136440	FBXO30	0.39	6.49	0.33	3.16e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-12.67	-0.57	2.7e-30	Platelet count;
LUSC	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.84	-15.9	-0.66	8.8e-43	Heart rate;
LUSC	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.9	0.31	8.87e-9	Eosinophil percentage of white cells;
LUSC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg02800362	chr5:177631904	HNRNPAB	0.88	13.12	0.58	5.45e-32	Obesity-related traits;
LUSC	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.74	10.7	0.51	3.6e-23	Corneal astigmatism;
LUSC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg22166914	chr1:53195759	ZYG11B	0.52	8.64	0.43	2.29e-16	Monocyte count;
LUSC	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg03684893	chr10:554711	DIP2C	0.38	7.03	0.36	1.18e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	13.16	0.58	3.88e-32	Lung cancer in ever smokers;
LUSC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg17143192	chr8:8559678	CLDN23	-0.65	-9.56	-0.46	2.6e-19	Obesity-related traits;
LUSC	cis	rs4144743	1.000	rs72823473	chr17:45321775	A/T	cg18085866	chr17:45331354	ITGB3	-0.75	-8.07	-0.4	1.24e-14	Body mass index;
LUSC	cis	rs28647808	0.881	rs4962139	chr9:136267869	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	-0.67	-6.76	-0.35	6.29e-11	Blood protein levels;
LUSC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg00509249	chr6:109615579	CCDC162	-0.34	-6.14	-0.32	2.36e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7709377	0.595	rs149131	chr5:115639459	T/A	cg23108291	chr5:115420582	COMMD10	-0.4	-5.65	-0.3	3.46e-8	Metabolite levels  (X-11787);
LUSC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.32	0.53	2.26e-25	Menopause (age at onset);
LUSC	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg22089800	chr15:90895588	ZNF774	0.52	7.46	0.38	7.52e-13	Rheumatoid arthritis;
LUSC	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg13902645	chr11:5959945	NA	-0.53	-7.87	-0.4	5e-14	DNA methylation (variation);
LUSC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.78	-12.62	-0.57	4.11e-30	Aortic root size;
LUSC	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.44	0.75	8.43e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.52	-0.34	2.56e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg24399712	chr22:39784796	NA	-0.6	-10.85	-0.51	1.06e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs10887741	0.646	rs4934355	chr10:89425411	G/A	cg13926569	chr10:89418898	PAPSS2	0.31	6.6	0.34	1.6e-10	Exercise (leisure time);
LUSC	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg05738196	chr6:26577821	NA	-0.47	-7.28	-0.37	2.42e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	cis	rs2629540	0.889	rs4962696	chr10:126445630	A/G	cg08799069	chr10:126477246	METTL10	-0.7	-10.56	-0.5	1.12e-22	Cocaine dependence;
LUSC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.99	-15.21	-0.64	4.58e-40	Gut microbiome composition (summer);
LUSC	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg20790798	chr5:1857306	NA	-0.4	-6.02	-0.31	4.48e-9	Cardiovascular disease risk factors;
LUSC	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg02018176	chr4:1364513	KIAA1530	-0.47	-6.59	-0.34	1.75e-10	Recombination rate (females);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14902356	chr20:10015648	ANKRD5	-0.41	-6.38	-0.33	5.76e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg27446573	chr6:127587934	RNF146	0.46	7.02	0.36	1.24e-11	Breast cancer;
LUSC	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg06096015	chr1:231504339	EGLN1	0.56	9.93	0.48	1.52e-20	Hemoglobin concentration;
LUSC	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg00129232	chr17:37814104	STARD3	-0.4	-5.83	-0.3	1.27e-8	Asthma;
LUSC	cis	rs62458065	1.000	rs10250808	chr7:32466153	T/C	cg20159608	chr7:32802032	NA	-0.57	-7.01	-0.36	1.34e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06022373	chr22:39101656	GTPBP1	0.74	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25072359	chr17:41440525	NA	0.65	9.38	0.46	1.06e-18	Menopause (age at onset);
LUSC	cis	rs4494114	1.000	rs4494114	chr1:39339682	C/T	cg25970120	chr1:39325951	RRAGC	0.43	6.86	0.35	3.26e-11	Blood protein levels;
LUSC	trans	rs6561151	0.681	rs7989702	chr13:44439150	T/C	cg12856521	chr11:46389249	DGKZ	0.75	9.65	0.47	1.36e-19	Crohn's disease;
LUSC	cis	rs58804349	0.685	rs9422448	chr10:43288816	A/G	cg08461752	chr10:43522343	NA	-0.6	-6.1	-0.32	2.94e-9	Pediatric bone mineral content (radius);
LUSC	cis	rs6543140	0.964	rs13390895	chr2:103075499	G/A	cg09003973	chr2:102972529	NA	0.54	7.02	0.36	1.25e-11	Blood protein levels;
LUSC	cis	rs12220238	1.000	rs10824101	chr10:75947438	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.58	6.69	0.34	9.3e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs62400317	0.859	rs62438863	chr6:45040592	C/T	cg20913747	chr6:44695427	NA	-0.46	-7.29	-0.37	2.3e-12	Total body bone mineral density;
LUSC	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg13256891	chr4:100009986	ADH5	-0.53	-7.05	-0.36	1.01e-11	Smoking initiation;
LUSC	trans	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg19249749	chr1:223853145	CAPN8	-0.49	-5.95	-0.31	6.69e-9	Gut microbiome composition (summer);
LUSC	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.34	0.33	7.48e-10	Corneal astigmatism;
LUSC	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg22467129	chr15:76604101	ETFA	-0.4	-6.42	-0.33	4.79e-10	Blood metabolite levels;
LUSC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18440127	chr12:108155221	PRDM4	0.56	6.4	0.33	5.2e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.06	-0.64	1.78e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs73206853	0.620	rs73194038	chr12:111172339	G/T	cg12870014	chr12:110450643	ANKRD13A	0.69	6.67	0.34	1.08e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.39	0.53	1.32e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.01	0.31	4.73e-9	Menopause (age at onset);
LUSC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-6.93	-0.35	2.2e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg14552801	chr7:65878734	NA	0.39	6.07	0.32	3.46e-9	Aortic root size;
LUSC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg06640241	chr16:89574553	SPG7	0.73	11.96	0.55	1.12e-27	Multiple myeloma (IgH translocation);
LUSC	cis	rs2279817	1.000	rs10788681	chr1:18019524	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.5	7.07	0.36	9.03e-12	Neuroticism;
LUSC	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg23752985	chr2:85803571	VAMP8	0.34	6.55	0.34	2.21e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg18225595	chr11:63971243	STIP1	0.5	6.13	0.32	2.48e-9	Mean platelet volume;
LUSC	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-0.75	-11.17	-0.52	8.07e-25	Refractive error;
LUSC	cis	rs6546550	0.935	rs7563062	chr2:70050725	G/A	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.11	-0.36	7.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs240764	0.604	rs705583	chr6:101261408	C/A	cg09795085	chr6:101329169	ASCC3	0.44	6.54	0.34	2.34e-10	Neuroticism;
LUSC	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg14829155	chr15:31115871	NA	-0.65	-8.78	-0.43	8.92e-17	Huntington's disease progression;
LUSC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg06238570	chr21:40685208	BRWD1	0.59	9.92	0.48	1.75e-20	Cognitive function;
LUSC	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg19554555	chr3:13937349	NA	0.4	6.14	0.32	2.39e-9	Ovarian reserve;
LUSC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg18350739	chr11:68623251	NA	-0.38	-6.87	-0.35	3.16e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs3947	0.906	rs1692821	chr8:11699988	C/T	cg00262122	chr8:11665843	FDFT1	-0.56	-7.5	-0.38	5.87e-13	Blood protein levels;
LUSC	cis	rs6840360	0.642	rs1470280	chr4:152431770	C/T	cg20465933	chr4:152376761	FAM160A1	0.33	5.94	0.31	7.12e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg06092702	chr1:163392909	NA	-0.39	-6.67	-0.34	1.09e-10	Motion sickness;
LUSC	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg16576597	chr16:28551801	NUPR1	0.34	6.73	0.35	7.35e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03517284	chr6:25882590	NA	0.53	10.21	0.49	1.74e-21	Blood metabolite levels;
LUSC	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.58	0.5	9.32e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg20283391	chr11:68216788	NA	-0.5	-7.17	-0.37	4.79e-12	Total body bone mineral density;
LUSC	cis	rs6087990	0.835	rs4911106	chr20:31331330	A/G	cg13636640	chr20:31349939	DNMT3B	0.98	21.42	0.76	1.15e-64	Ulcerative colitis;
LUSC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.02	0.36	1.21e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg01073479	chr16:3509474	NAT15	0.44	5.77	0.3	1.85e-8	Tuberculosis;
LUSC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg24829409	chr8:58192753	C8orf71	-0.5	-6.1	-0.32	2.86e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.81	11.81	0.54	3.95e-27	Breast cancer;
LUSC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg07703079	chr11:430292	ANO9	0.58	6.41	0.33	4.99e-10	Body mass index;
LUSC	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg02175503	chr12:58329896	NA	0.57	8.74	0.43	1.14e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6967385	0.580	rs6962273	chr7:12330166	G/C	cg06484146	chr7:12443880	VWDE	0.41	6.52	0.34	2.56e-10	Response to taxane treatment (placlitaxel);
LUSC	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21659725	chr3:3221576	CRBN	-0.64	-10.61	-0.5	7.4e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg05347473	chr6:146136440	FBXO30	0.48	7.89	0.4	4.3e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg11845111	chr2:191398756	TMEM194B	-0.88	-11.28	-0.53	3.28e-25	Diastolic blood pressure;
LUSC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	14.11	0.61	9.1e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg00431813	chr7:1051703	C7orf50	-0.56	-9.99	-0.48	1.01e-20	Longevity;Endometriosis;
LUSC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.08	-0.36	8.44e-12	Bipolar disorder;
LUSC	cis	rs3736594	0.513	rs56725354	chr2:27824168	G/C	cg27432699	chr2:27873401	GPN1	0.65	8.74	0.43	1.17e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.76	10.36	0.49	5.53e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.82	14.75	0.63	2.93e-38	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.17	0.37	4.83e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg22138327	chr13:27999177	GTF3A	0.83	10.88	0.51	8.38e-24	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.67	0.43	1.91e-16	Prudent dietary pattern;
LUSC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.75	0.77	5.71e-66	Prudent dietary pattern;
LUSC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	1.1	26.31	0.82	2.03e-83	Testicular germ cell tumor;
LUSC	cis	rs9815354	0.812	rs55788971	chr3:41843965	T/A	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg12826209	chr6:26865740	GUSBL1	-0.64	-7.3	-0.37	2.15e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg26043149	chr18:55253948	FECH	-0.45	-6.89	-0.35	2.86e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1419980	0.643	rs10845600	chr12:7796463	C/T	cg10578777	chr12:7781093	NA	-0.62	-5.76	-0.3	1.88e-8	HDL cholesterol levels;
LUSC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg03188948	chr7:1209495	NA	0.66	7.09	0.36	8.04e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10754283	0.967	rs7515375	chr1:90109854	T/C	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.06	16.41	0.67	8.89e-45	Exhaled nitric oxide output;
LUSC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.55	0.46	2.9e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs10098647	0.632	rs28689904	chr8:61111338	T/A	cg09970348	chr3:183978600	ECE2;CAMK2N2	0.46	6.15	0.32	2.26e-9	Obesity-related traits;
LUSC	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg27205649	chr11:78285834	NARS2	0.53	6.45	0.33	4.02e-10	Alzheimer's disease (survival time);
LUSC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg27102117	chr16:15229624	NA	0.53	8.21	0.41	4.81e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg18350739	chr11:68623251	NA	-0.38	-6.77	-0.35	5.88e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg22431228	chr1:16359049	CLCNKA	-0.41	-8.22	-0.41	4.47e-15	Systolic blood pressure;
LUSC	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.83	-15.1	-0.64	1.23e-39	Longevity;
LUSC	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg23262073	chr20:60523788	NA	-0.42	-6.09	-0.32	3.18e-9	Body mass index;
LUSC	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg12826209	chr6:26865740	GUSBL1	-0.46	-6.1	-0.32	2.85e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	11.7	0.54	1e-26	Tonsillectomy;
LUSC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg22800045	chr5:56110881	MAP3K1	0.45	6.03	0.31	4.3e-9	Coronary artery disease;
LUSC	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg13575925	chr12:9217583	LOC144571	-0.33	-6.03	-0.31	4.37e-9	Sjögren's syndrome;
LUSC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	9.51	0.46	3.79e-19	Menarche (age at onset);
LUSC	cis	rs67072384	0.818	rs2291291	chr11:72466897	T/C	cg04827223	chr11:72435913	ARAP1	-0.74	-6.42	-0.33	4.6e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg13607699	chr17:42295918	UBTF	-0.53	-8.18	-0.41	6.11e-15	Total body bone mineral density;
LUSC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg13699009	chr12:122356056	WDR66	0.45	6.79	0.35	5e-11	Mean corpuscular volume;
LUSC	cis	rs11112613	0.609	rs11112636	chr12:106047204	G/A	cg03607813	chr12:105948248	NA	0.62	7.7	0.39	1.51e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg23625390	chr15:77176239	SCAPER	-0.65	-9.66	-0.47	1.26e-19	Blood metabolite levels;
LUSC	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06636551	chr8:101224915	SPAG1	-0.46	-8.33	-0.41	2.19e-15	Atrioventricular conduction;
LUSC	cis	rs2137920	0.891	rs2254754	chr10:50235335	G/A	cg27141751	chr10:50231850	C10orf72	0.38	5.75	0.3	1.98e-8	Migraine with aura;
LUSC	cis	rs80130819	0.748	rs2732446	chr12:48690177	T/C	cg24011408	chr12:48396354	COL2A1	0.46	5.88	0.31	9.77e-9	Prostate cancer;
LUSC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg14552801	chr7:65878734	NA	-0.48	-6.65	-0.34	1.18e-10	Aortic root size;
LUSC	cis	rs11229555	0.645	rs35735990	chr11:58187371	G/A	cg15696309	chr11:58395628	NA	-0.64	-7.78	-0.39	9.19e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg17469321	chr7:55412551	NA	-0.66	-10.8	-0.51	1.6e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg19318889	chr4:1322082	MAEA	0.46	7.37	0.37	1.32e-12	Obesity-related traits;
LUSC	cis	rs701145	0.938	rs701138	chr3:154063609	T/C	cg17054900	chr3:154042577	DHX36	0.79	8.25	0.41	3.74e-15	Coronary artery disease;
LUSC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.02	0.36	1.21e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00152838	chr16:24741724	TNRC6A	-0.48	-6.03	-0.31	4.26e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.17	-0.37	4.8e-12	Platelet count;
LUSC	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg04374321	chr14:90722782	PSMC1	0.73	11.56	0.53	3.22e-26	Mortality in heart failure;
LUSC	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg02153584	chr22:29168773	CCDC117	0.44	6.68	0.34	1.01e-10	Red cell distribution width;
LUSC	cis	rs2742234	0.518	rs2505514	chr10:43633248	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.15	-0.36	5.41e-12	Hirschsprung disease;
LUSC	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg02423579	chr7:2872169	GNA12	-0.43	-6.18	-0.32	1.89e-9	Height;
LUSC	cis	rs7712401	0.791	rs1531340	chr5:122108017	G/A	cg19077854	chr5:122220652	SNX24	0.35	7.73	0.39	1.25e-13	Mean platelet volume;
LUSC	cis	rs7804356	1.000	rs73069510	chr7:26877567	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.12	-0.32	2.58e-9	Type 1 diabetes;
LUSC	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg24375607	chr4:120327624	NA	0.75	11.05	0.52	2.18e-24	Corneal astigmatism;
LUSC	trans	rs724744	0.660	rs1737233	chr6:22351805	T/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.15	-0.32	2.18e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00321850	chr1:175162397	KIAA0040	0.45	7.78	0.39	9.36e-14	Alcohol dependence;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg19983627	chr4:108852959	CYP2U1	-0.53	-7.01	-0.36	1.3e-11	Cognitive function;Information processing speed;
LUSC	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg21775007	chr8:11205619	TDH	0.52	7.09	0.36	8.23e-12	Morning vs. evening chronotype;
LUSC	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg11244672	chr19:19639970	YJEFN3	0.57	7.25	0.37	2.99e-12	Bipolar disorder;
LUSC	cis	rs2625529	0.938	rs2742323	chr15:72116778	A/T	cg16672083	chr15:72433130	SENP8	0.52	7.62	0.38	2.64e-13	Red blood cell count;
LUSC	cis	rs2078087	0.831	rs58734925	chr1:183234177	A/G	cg13843938	chr1:183241246	NMNAT2	0.44	5.89	0.31	9.45e-9	Obesity-related traits;
LUSC	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg05855489	chr10:104503620	C10orf26	0.58	8.73	0.43	1.24e-16	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg05585544	chr11:47624801	NA	-0.41	-7.09	-0.36	7.89e-12	Subjective well-being;
LUSC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.49	-7.1	-0.36	7.33e-12	Coronary heart disease;
LUSC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.66	14.46	0.62	3.92e-37	Bone mineral density;
LUSC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg05313129	chr8:58192883	C8orf71	-0.54	-6.03	-0.31	4.37e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg18721089	chr20:30220636	NA	-0.36	-6.15	-0.32	2.17e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg05585544	chr11:47624801	NA	-0.42	-7.46	-0.38	7.63e-13	Subjective well-being;
LUSC	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg10978503	chr1:24200527	CNR2	-0.49	-11.52	-0.53	4.41e-26	Immature fraction of reticulocytes;
LUSC	cis	rs6961069	0.585	rs2691199	chr7:80239666	T/C	cg04458919	chr7:80252533	CD36	-0.4	-7.32	-0.37	1.91e-12	Platelet count;
LUSC	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg27411982	chr8:10470053	RP1L1	-0.37	-5.75	-0.3	2e-8	Retinal vascular caliber;
LUSC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.79	14.9	0.63	7.27e-39	Dental caries;
LUSC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg23788917	chr6:8435910	SLC35B3	0.51	7.56	0.38	3.85e-13	Motion sickness;
LUSC	cis	rs12541635	0.934	rs60482457	chr8:106970504	A/G	cg10147462	chr8:107024639	NA	0.55	9.79	0.47	4.53e-20	Age of smoking initiation;
LUSC	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg02825527	chr7:2087843	MAD1L1	-0.45	-5.84	-0.3	1.23e-8	Neuroticism;
LUSC	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.31	21.86	0.77	2.15e-66	Type 1 diabetes nephropathy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25116269	chr2:55509523	PRDXDD1P	0.42	6.55	0.34	2.2e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg18402987	chr7:1209562	NA	0.73	7.84	0.39	5.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.03	0.44	1.42e-17	Menarche (age at onset);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03012876	chr2:179315436	PRKRA;MIR548N;DFNB59	-0.41	-6.26	-0.32	1.18e-9	Hepatitis;
LUSC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.95	0.44	2.48e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.67	11.95	0.55	1.2100000000000001e-27	Aortic root size;
LUSC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg23719950	chr11:63933701	MACROD1	-0.6	-7.63	-0.39	2.42e-13	Mean platelet volume;
LUSC	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.8	-0.54	4.25e-27	Mean corpuscular volume;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg06544376	chr20:18548101	LOC388789	0.38	6.36	0.33	6.61e-10	Educational attainment (years of education);
LUSC	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg08645402	chr16:4508243	NA	0.5	8.69	0.43	1.64e-16	Schizophrenia;
LUSC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg18512352	chr11:47633146	NA	-0.48	-9.63	-0.47	1.52e-19	Subjective well-being;
LUSC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16680214	chr1:154839983	KCNN3	-0.54	-10.1	-0.48	4.04e-21	Prostate cancer;
LUSC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07677032	chr17:61819896	STRADA	-0.52	-8.51	-0.42	5.9e-16	Prudent dietary pattern;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg15695626	chr1:44445202	B4GALT2	0.45	5.94	0.31	6.98e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7512552	0.525	rs2298161	chr1:150237624	A/G	cg15654264	chr1:150340011	RPRD2	0.44	7.04	0.36	1.13e-11	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg03734322	chr17:1532856	SLC43A2	0.46	6.09	0.32	3.08e-9	Cognitive function;Information processing speed;
LUSC	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg20933634	chr6:27740509	NA	0.44	6.28	0.33	1.04e-9	Parkinson's disease;
LUSC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg08917208	chr2:24149416	ATAD2B	0.56	6.27	0.32	1.14e-9	Lymphocyte counts;
LUSC	cis	rs6939532	0.522	rs4712981	chr6:26361430	C/T	cg09904177	chr6:26538194	HMGN4	-0.46	-6.68	-0.34	9.75e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1957429	0.808	rs763346	chr14:65330386	A/G	cg23373153	chr14:65346875	NA	-0.95	-10.82	-0.51	1.34e-23	Pediatric areal bone mineral density (radius);
LUSC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-1.13	-24.62	-0.8	4.6e-77	Height;
LUSC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg08798685	chr6:27730294	NA	-0.63	-5.94	-0.31	7.28e-9	Depression;
LUSC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg20734569	chr3:48348370	SPINK8	0.47	8.35	0.42	1.82e-15	Coronary artery disease;
LUSC	cis	rs1018836	0.828	rs7012741	chr8:91536065	A/G	cg16814680	chr8:91681699	NA	-0.68	-10.65	-0.5	5.16e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg06627628	chr2:24431161	ITSN2	0.55	7.94	0.4	3.06e-14	Asthma;
LUSC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg24812749	chr6:127587940	RNF146	0.73	10.48	0.5	2.02e-22	Breast cancer;
LUSC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg12560992	chr17:57184187	TRIM37	-0.76	-12.11	-0.55	3.11e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs73198271	0.640	rs7838012	chr8:8656630	A/G	cg01851573	chr8:8652454	MFHAS1	0.47	7.74	0.39	1.22e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.37	0.56	3.48e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18404041	chr3:52824283	ITIH1	-0.62	-11.92	-0.55	1.52e-27	Bipolar disorder;
LUSC	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.34	5.96	0.31	6.35e-9	Hematocrit;
LUSC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.19	-0.41	5.46e-15	Personality dimensions;
LUSC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg17366294	chr4:99064904	C4orf37	0.55	9.59	0.46	2.07e-19	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.85	16.25	0.66	3.65e-44	Intelligence (multi-trait analysis);
LUSC	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	11.06	0.52	2e-24	Lung cancer in ever smokers;
LUSC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg09165964	chr15:75287851	SCAMP5	0.48	7.13	0.36	6.18e-12	Breast cancer;
LUSC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs3862435	0.518	rs2601169	chr15:90913890	T/C	cg22089800	chr15:90895588	ZNF774	0.57	6.12	0.32	2.56e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs62400317	0.762	rs9367210	chr6:44863395	G/A	cg20913747	chr6:44695427	NA	-0.48	-7.44	-0.38	8.79e-13	Total body bone mineral density;
LUSC	cis	rs12594515	1.000	rs56220882	chr15:45997075	C/G	cg19682013	chr15:45996608	NA	0.38	5.77	0.3	1.8e-8	Waist circumference;Weight;
LUSC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg12560992	chr17:57184187	TRIM37	0.85	15.26	0.64	3e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg05874882	chr4:1763078	NA	0.53	8.36	0.42	1.75e-15	Bladder cancer;Urinary bladder cancer;
LUSC	cis	rs3849570	0.961	rs3821548	chr3:81758728	C/G	cg07356753	chr3:81810745	GBE1	-0.69	-11.08	-0.52	1.72e-24	Waist circumference;Body mass index;
LUSC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	13.5	0.59	1.91e-33	Platelet count;
LUSC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00149659	chr3:10157352	C3orf10	0.9	11.91	0.55	1.63e-27	Alzheimer's disease;
LUSC	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-0.57	-9.57	-0.46	2.45e-19	Breast cancer;
LUSC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.43	6.16	0.32	2.14e-9	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19747852	chr7:23571693	TRA2A	-0.41	-5.97	-0.31	6.15e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg05110241	chr16:68378359	PRMT7	-0.55	-6.36	-0.33	6.78e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg20821713	chr7:1055600	C7orf50	-0.46	-7.58	-0.38	3.44e-13	Longevity;Endometriosis;
LUSC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.69	0.63	5.12e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg17757837	chr7:157058334	UBE3C	0.82	13.42	0.59	3.94e-33	Body mass index;
LUSC	cis	rs7119038	0.818	rs10892289	chr11:118646003	C/T	cg19308663	chr11:118741387	NA	0.37	6.33	0.33	7.82e-10	Sjögren's syndrome;
LUSC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg13114125	chr14:105738426	BRF1	-0.91	-14.92	-0.63	6.02e-39	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1832871	1.000	rs827864	chr6:158711023	A/G	cg07165851	chr6:158734300	TULP4	0.37	6.37	0.33	6.31e-10	Height;
LUSC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg02153584	chr22:29168773	CCDC117	0.66	10.6	0.5	8.09e-23	Lymphocyte counts;
LUSC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg06697600	chr4:7070879	GRPEL1	0.36	5.77	0.3	1.76e-8	Monocyte percentage of white cells;
LUSC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg13685833	chr1:53393034	SCP2	-0.41	-6.32	-0.33	8.23e-10	Monocyte count;
LUSC	cis	rs116988415	0.584	rs4902314	chr14:65254415	T/C	cg25083366	chr14:65239357	SPTB	0.66	6.81	0.35	4.41e-11	Daytime sleep phenotypes;
LUSC	cis	rs394563	0.625	rs384306	chr6:149796140	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.38	-7.89	-0.4	4.39e-14	Dupuytren's disease;
LUSC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg23791538	chr6:167370224	RNASET2	-0.37	-5.72	-0.3	2.38e-8	Crohn's disease;
LUSC	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg24130564	chr14:104152367	KLC1	-0.47	-6.69	-0.34	9.23e-11	Body mass index;
LUSC	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg12257692	chr3:49977190	RBM6	-0.21	-5.68	-0.3	2.9e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg08213375	chr14:104286397	PPP1R13B	0.48	8.55	0.42	4.38e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.91	-0.31	8.57e-9	Resting heart rate;
LUSC	cis	rs3824867	0.920	rs9919526	chr11:47451623	C/T	cg20307385	chr11:47447363	PSMC3	-0.64	-9.52	-0.46	3.67e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	6.06	0.31	3.59e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg25456477	chr12:86230367	RASSF9	0.36	6.42	0.33	4.55e-10	Major depressive disorder;
LUSC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.75	10.76	0.51	2.18e-23	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	9.66	0.47	1.22e-19	Eotaxin levels;
LUSC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg20203395	chr5:56204925	C5orf35	-0.56	-8.0	-0.4	2.07e-14	Coronary artery disease;
LUSC	cis	rs9296092	0.500	rs9469503	chr6:33527234	G/T	cg13560919	chr6:33536144	NA	-0.85	-16.44	-0.67	6.54e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs2425143	0.908	rs75331436	chr20:34391052	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.71	-0.3	2.51e-8	Blood protein levels;
LUSC	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.26e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg16512390	chr1:228756714	NA	0.7	8.89	0.44	4.03e-17	Chronic lymphocytic leukemia;
LUSC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg21782813	chr7:2030301	MAD1L1	0.41	6.79	0.35	5.2e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9807989	0.839	rs10206753	chr2:102968362	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.91	0.31	8.63e-9	Asthma;
LUSC	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg21775007	chr8:11205619	TDH	-0.64	-10.41	-0.49	3.61e-22	Neuroticism;
LUSC	cis	rs757081	0.667	rs3950680	chr11:17138666	G/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-6.1	-0.32	2.97e-9	Systolic blood pressure;
LUSC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.03	-0.44	1.39e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.65	10.78	0.51	1.87e-23	Cognitive function;
LUSC	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.1	-0.36	7.61e-12	Neuroticism;
LUSC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg13114125	chr14:105738426	BRF1	-0.93	-16.05	-0.66	2.2e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs701145	0.585	rs401162	chr3:153905988	T/A	cg17054900	chr3:154042577	DHX36	0.68	6.76	0.35	5.99e-11	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.29	0.33	9.92e-10	Menopause (age at onset);
LUSC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg26304593	chr6:42947056	PEX6	-0.52	-8.28	-0.41	3.03e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg27494647	chr7:150038898	RARRES2	0.44	6.76	0.35	6.18e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs17401966	0.838	rs11579365	chr1:10470846	G/T	cg19773385	chr1:10388646	KIF1B	-0.5	-8.9	-0.44	3.59e-17	Hepatocellular carcinoma;
LUSC	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.26	-0.41	3.56e-15	Neuroticism;
LUSC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.77	14.5	0.62	2.69e-37	Longevity;
LUSC	cis	rs155346	1.000	rs265159	chr5:139390752	A/G	cg01090482	chr5:139365336	NRG2	-0.38	-6.5	-0.34	2.87e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07030052	chr1:162531143	UAP1	-0.34	-5.98	-0.31	5.67e-9	Electrocardiographic conduction measures;
LUSC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.54	0.53	3.87e-26	Prudent dietary pattern;
LUSC	cis	rs11756438	0.547	rs1343287	chr6:119001805	T/C	cg21191810	chr6:118973309	C6orf204	0.34	5.81	0.3	1.46e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg02175503	chr12:58329896	NA	0.58	8.82	0.43	6.64e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs6961069	0.609	rs7789369	chr7:80226147	A/C	cg04458919	chr7:80252533	CD36	-0.4	-7.17	-0.37	4.75e-12	Platelet count;
LUSC	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	0.88	12.81	0.57	7.75e-31	Coronary artery disease;
LUSC	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg26394196	chr10:1453818	ADARB2	-0.39	-6.73	-0.35	7.37e-11	Radiation response;
LUSC	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg15839431	chr19:19639596	YJEFN3	-0.66	-7.28	-0.37	2.39e-12	Bipolar disorder;
LUSC	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.77	12.87	0.58	4.61e-31	Selective IgA deficiency;
LUSC	cis	rs13223928	0.651	rs4722435	chr7:3152962	C/T	cg19214707	chr7:3157722	NA	0.45	9.11	0.45	7.55e-18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs3087591	0.960	rs11080146	chr17:29578724	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.58	-8.48	-0.42	7.37e-16	Hip circumference;
LUSC	cis	rs9517302	0.615	rs7983522	chr13:99098055	C/T	cg22223119	chr13:99095684	FARP1	-0.66	-9.58	-0.46	2.22e-19	Obesity-related traits;
LUSC	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg11502198	chr6:26597334	ABT1	0.59	9.21	0.45	3.63e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	1.03	12.73	0.57	1.59e-30	Sexual dysfunction (female);
LUSC	cis	rs36093844	0.800	rs59179556	chr11:85573897	A/G	cg25872744	chr11:85566296	CCDC83	-0.45	-5.78	-0.3	1.69e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	trans	rs800082	0.671	rs800099	chr3:144398547	A/T	cg24215973	chr2:240111563	HDAC4	-0.71	-10.4	-0.49	3.8e-22	Smoking behavior;
LUSC	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg25214090	chr10:38739885	LOC399744	0.55	8.02	0.4	1.87e-14	Corneal astigmatism;
LUSC	trans	rs72674100	1.000	rs55633486	chr4:97984679	A/G	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg02187348	chr16:89574699	SPG7	-0.39	-5.83	-0.3	1.31e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg24449463	chr1:168025552	DCAF6	-0.65	-9.73	-0.47	7.4e-20	Schizophrenia;
LUSC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.58	-0.67	1.75e-45	Coronary artery disease;
LUSC	trans	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg10756647	chr7:56101905	PSPH	0.85	8.28	0.41	3.01e-15	Diabetic kidney disease;
LUSC	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg21521518	chr4:53727714	RASL11B	0.43	5.77	0.3	1.79e-8	Optic nerve measurement (cup area);
LUSC	cis	rs10740039	0.804	rs10761531	chr10:62397935	G/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg01620082	chr3:125678407	NA	-0.77	-6.9	-0.35	2.57e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6977940	0.818	rs73033460	chr7:2900662	C/T	cg19731401	chr7:2775893	GNA12	0.66	7.79	0.39	8.55e-14	White matter integrity;
LUSC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg06784218	chr1:46089804	CCDC17	0.48	9.39	0.46	1e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg03354898	chr7:1950403	MAD1L1	-0.31	-6.17	-0.32	2e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg23795048	chr12:9217529	LOC144571	-0.33	-6.1	-0.32	2.91e-9	Sjögren's syndrome;
LUSC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg09021430	chr5:549028	NA	-0.53	-7.49	-0.38	6.08e-13	Lung disease severity in cystic fibrosis;
LUSC	cis	rs13315871	0.929	rs13077539	chr3:58267846	T/C	cg12435725	chr3:58293450	RPP14	-0.78	-7.71	-0.39	1.45e-13	Cholesterol, total;
LUSC	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg01475377	chr6:109611718	NA	-0.41	-7.26	-0.37	2.81e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.75	12.38	0.56	3.14e-29	Coronary artery disease;
LUSC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18758796	chr5:131593413	PDLIM4	0.47	7.59	0.38	3.13e-13	Acylcarnitine levels;
LUSC	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg00810483	chr4:3375144	RGS12	0.3	5.7	0.3	2.58e-8	Serum sulfate level;
LUSC	cis	rs2274273	0.905	rs8007620	chr14:55586587	T/C	cg04306507	chr14:55594613	LGALS3	0.51	11.08	0.52	1.65e-24	Protein biomarker;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04868132	chr11:65265060	MALAT1	-0.42	-6.26	-0.32	1.18e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg27398817	chr8:82754497	SNX16	-0.65	-8.09	-0.4	1.09e-14	Diastolic blood pressure;
LUSC	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg20243544	chr17:37824526	PNMT	0.49	6.87	0.35	3.17e-11	Asthma;
LUSC	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.62	6.55	0.34	2.16e-10	Schizophrenia;
LUSC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg01802117	chr1:53393560	SCP2	-0.37	-6.31	-0.33	8.86e-10	Monocyte count;
LUSC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.37	0.33	6.27e-10	Lung cancer;
LUSC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg27432699	chr2:27873401	GPN1	-0.57	-8.49	-0.42	6.77e-16	Total body bone mineral density;
LUSC	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg21770322	chr7:97807741	LMTK2	0.57	10.37	0.49	5.03e-22	Breast cancer;
LUSC	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.5	6.83	0.35	3.91e-11	Corneal astigmatism;
LUSC	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21643547	chr1:205240462	TMCC2	-0.5	-9.46	-0.46	5.68e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg17366294	chr4:99064904	C4orf37	0.54	8.76	0.43	1.01e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg09877947	chr5:131593287	PDLIM4	0.46	7.07	0.36	8.9e-12	Breast cancer;
LUSC	cis	rs12210905	0.925	rs72838245	chr6:26987316	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg00961166	chr12:50236992	BCDIN3D	-0.48	-6.03	-0.31	4.44e-9	Neuroticism;
LUSC	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-0.76	-9.13	-0.45	6.5e-18	Refractive error;
LUSC	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.76	0.39	1.04e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs911119	0.913	rs6036461	chr20:23576754	C/G	cg16589663	chr20:23618590	CST3	0.62	7.44	0.38	8.78e-13	Chronic kidney disease;
LUSC	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	1.03	12.16	0.55	2.04e-28	Schizophrenia;
LUSC	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg12615879	chr12:58013172	SLC26A10	-0.32	-6.59	-0.34	1.67e-10	Multiple sclerosis;
LUSC	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg09323728	chr8:95962352	TP53INP1	-0.29	-5.72	-0.3	2.39e-8	Type 2 diabetes;
LUSC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.72	12.3	0.56	6.11e-29	Motion sickness;
LUSC	cis	rs477692	1.000	rs473073	chr10:131429646	G/T	cg11019008	chr10:131425282	MGMT	0.41	6.02	0.31	4.72e-9	Response to temozolomide;
LUSC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	15.92	0.66	7.26e-43	Platelet count;
LUSC	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg18904891	chr8:8559673	CLDN23	0.59	8.15	0.41	7.49e-15	Obesity-related traits;
LUSC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg18306943	chr3:40428807	ENTPD3	0.39	6.09	0.32	3.09e-9	Renal cell carcinoma;
LUSC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.59	11.7	0.54	9.44e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg19824325	chr16:58548873	SETD6	0.94	9.15	0.45	5.74e-18	Schizophrenia;
LUSC	cis	rs36093844	1.000	rs36093844	chr11:85576127	A/G	cg25872744	chr11:85566296	CCDC83	0.5	7.66	0.39	2.06e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg02018176	chr4:1364513	KIAA1530	0.43	5.76	0.3	1.92e-8	Recombination rate (females);
LUSC	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg13334819	chr7:99746414	C7orf59	0.5	6.73	0.35	7.39e-11	Coronary artery disease;
LUSC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg00343986	chr7:65444356	GUSB	0.44	6.73	0.35	7.5e-11	Aortic root size;
LUSC	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg22709100	chr7:91322751	NA	0.44	6.28	0.32	1.06e-9	Breast cancer;
LUSC	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg12573674	chr2:1569213	NA	-0.52	-5.67	-0.3	3.07e-8	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21171335	chr12:122356390	WDR66	0.64	9.57	0.46	2.4e-19	Mean corpuscular volume;
LUSC	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg13393036	chr8:95962371	TP53INP1	-0.31	-6.1	-0.32	2.92e-9	Type 2 diabetes;
LUSC	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg19418458	chr7:158789849	NA	0.51	6.6	0.34	1.63e-10	Facial morphology (factor 20);
LUSC	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg02018176	chr4:1364513	KIAA1530	0.46	6.42	0.33	4.76e-10	Recombination rate (females);
LUSC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.56	0.78	4.18e-69	Prudent dietary pattern;
LUSC	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.98	0.36	1.55e-11	Rheumatoid arthritis;
LUSC	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg00701064	chr4:6280414	WFS1	0.61	15.07	0.64	1.62e-39	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9650657	0.740	rs10481451	chr8:10649328	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.25	-0.32	1.25e-9	Neuroticism;
LUSC	cis	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg07460842	chr6:66804631	NA	0.47	5.8	0.3	1.53e-8	Metabolite levels;
LUSC	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.74	-14.22	-0.61	3.41e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	6.15	0.32	2.21e-9	Tonsillectomy;
LUSC	cis	rs2625529	0.824	rs12901886	chr15:72408069	G/A	cg16672083	chr15:72433130	SENP8	-0.52	-7.59	-0.38	3.22e-13	Red blood cell count;
LUSC	cis	rs7119038	0.818	rs10892286	chr11:118642085	A/C	cg19308663	chr11:118741387	NA	0.36	6.17	0.32	1.96e-9	Sjögren's syndrome;
LUSC	cis	rs6545883	1.000	rs6742276	chr2:61768745	G/A	cg15711740	chr2:61764176	XPO1	-0.49	-7.84	-0.39	6.3e-14	Tuberculosis;
LUSC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20307385	chr11:47447363	PSMC3	-0.46	-5.96	-0.31	6.46e-9	Subjective well-being;
LUSC	cis	rs713477	1.000	rs12888361	chr14:55906187	A/G	cg04306507	chr14:55594613	LGALS3	-0.29	-5.65	-0.3	3.41e-8	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg10756647	chr7:56101905	PSPH	0.85	8.34	0.42	2.04e-15	Diabetic kidney disease;
LUSC	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg01528321	chr10:82214614	TSPAN14	0.84	12.88	0.58	4.21e-31	Post bronchodilator FEV1;
LUSC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg00409905	chr10:38381863	ZNF37A	-0.34	-6.02	-0.31	4.7e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1507153	0.847	rs9341741	chr6:79426838	G/A	cg05283184	chr6:79620031	NA	-0.42	-7.21	-0.37	3.86e-12	Sjögren's syndrome;
LUSC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	6.6	0.34	1.6e-10	Tonsillectomy;
LUSC	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.51	-8.37	-0.42	1.64e-15	Birth weight;
LUSC	cis	rs2806561	0.808	rs2235546	chr1:23409538	A/G	cg19743168	chr1:23544995	NA	0.44	9.19	0.45	4.39e-18	Height;
LUSC	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.97	0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-7.1	-0.36	7.36e-12	Aortic root size;
LUSC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg06494592	chr3:125709126	NA	-0.52	-5.91	-0.31	8.54e-9	Blood pressure (smoking interaction);
LUSC	cis	rs2224391	0.628	rs11752747	chr6:5272671	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.48	-6.2	-0.32	1.65e-9	Height;
LUSC	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	cis	rs7605827	0.897	rs10929371	chr2:15662299	A/G	cg19274914	chr2:15703543	NA	0.46	8.83	0.43	6.22e-17	Educational attainment (years of education);
LUSC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg08219700	chr8:58056026	NA	0.46	5.98	0.31	5.71e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.13	-0.32	2.47e-9	Triglycerides;
LUSC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2652834	1.000	rs7181141	chr15:63398552	A/G	cg05507819	chr15:63340323	TPM1	0.67	8.15	0.41	7.6e-15	HDL cholesterol;
LUSC	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg17366294	chr4:99064904	C4orf37	0.56	9.85	0.47	2.83e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs34421088	0.506	rs2572426	chr8:11147123	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	6.74	0.35	6.91e-11	Neuroticism;
LUSC	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg07777115	chr5:623756	CEP72	-0.44	-5.83	-0.3	1.3e-8	Obesity-related traits;
LUSC	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.36e-13	Type 2 diabetes;
LUSC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-7.13	-0.36	6.1e-12	Height;
LUSC	cis	rs6138458	0.717	rs2179732	chr20:25000446	A/T	cg26195577	chr20:24973756	C20orf3	0.8	12.45	0.56	1.73e-29	Blood protein levels;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg04630321	chr11:74204613	LIPT2	0.47	6.18	0.32	1.91e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs790123	1.000	rs790116	chr3:122380923	G/C	cg00926285	chr3:122398533	PARP14	-0.38	-5.93	-0.31	7.62e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg17264618	chr3:40429014	ENTPD3	0.31	6.63	0.34	1.37e-10	Renal cell carcinoma;
LUSC	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.23	0.56	1.12e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.38	-6.47	-0.33	3.46e-10	Breast cancer;
LUSC	cis	rs73206853	0.686	rs60439011	chr12:110909179	T/C	cg12870014	chr12:110450643	ANKRD13A	0.69	7.51	0.38	5.56e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg09796270	chr17:17721594	SREBF1	0.42	7.51	0.38	5.43e-13	Total body bone mineral density;
LUSC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg00033643	chr7:134001901	SLC35B4	0.47	7.42	0.38	9.63e-13	Mean platelet volume;
LUSC	cis	rs597583	0.951	rs636530	chr11:117421858	C/T	cg27161313	chr11:117392002	DSCAML1	0.4	7.22	0.37	3.52e-12	Putamen volume;
LUSC	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg12091567	chr17:66097778	LOC651250	-0.68	-8.93	-0.44	2.92e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs28785552	0.554	rs10424921	chr19:53211087	T/C	cg10871876	chr19:53194124	ZNF83	0.38	6.01	0.31	4.97e-9	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs2766692	0.956	rs35696661	chr14:100742355	G/C	cg14866419	chr14:100704911	YY1	0.45	6.07	0.32	3.44e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7215564	0.730	rs34806161	chr17:78573839	T/C	cg23238734	chr17:78661607	RPTOR	0.47	5.69	0.3	2.84e-8	Myopia (pathological);
LUSC	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg09479241	chr17:27052676	TLCD1	-0.44	-6.05	-0.31	3.92e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg23625390	chr15:77176239	SCAPER	0.46	7.04	0.36	1.09e-11	Blood metabolite levels;
LUSC	cis	rs28655083	1.000	rs1843455	chr16:77072343	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.38	-5.69	-0.3	2.72e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg20476274	chr7:133979776	SLC35B4	0.8	13.24	0.59	1.87e-32	Mean platelet volume;
LUSC	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21659725	chr3:3221576	CRBN	-0.56	-8.86	-0.44	5.01e-17	Body mass index;
LUSC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg06238570	chr21:40685208	BRWD1	-0.59	-9.78	-0.47	4.87e-20	Cognitive function;
LUSC	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg17366294	chr4:99064904	C4orf37	0.54	8.83	0.43	6.14e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3093024	0.904	rs3093019	chr6:167539655	C/G	cg07741184	chr6:167504864	NA	-0.41	-7.43	-0.38	9.43e-13	Rheumatoid arthritis;
LUSC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg07148914	chr20:33460835	GGT7	-0.46	-6.74	-0.35	7.17e-11	Height;
LUSC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg06074448	chr4:187884817	NA	-0.41	-6.89	-0.35	2.85e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13082711	0.911	rs13089870	chr3:27447626	C/T	cg02860705	chr3:27208620	NA	0.5	8.36	0.42	1.74e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	trans	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg14791747	chr16:20752902	THUMPD1	0.72	9.86	0.47	2.59e-20	Cognitive test performance;
LUSC	cis	rs911119	0.913	rs3004145	chr20:23582876	C/G	cg16589663	chr20:23618590	CST3	-0.59	-7.36	-0.37	1.4e-12	Chronic kidney disease;
LUSC	cis	rs9815354	0.812	rs73071208	chr3:41978738	A/T	cg03022575	chr3:42003672	ULK4	0.85	8.85	0.44	5.2e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg04310649	chr10:35416472	CREM	-0.41	-6.3	-0.33	9.65e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg22244940	chr12:132335942	MMP17	0.42	6.21	0.32	1.6e-9	Migraine;
LUSC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	8.13	0.41	8.44e-15	Acne (severe);
LUSC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11764359	chr7:65958608	NA	-0.69	-11.1	-0.52	1.42e-24	Aortic root size;
LUSC	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg24375607	chr4:120327624	NA	0.76	11.19	0.52	6.46e-25	Corneal astigmatism;
LUSC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg24060327	chr5:131705240	SLC22A5	0.48	8.03	0.4	1.71e-14	Breast cancer;
LUSC	cis	rs4901869	0.966	rs1820557	chr14:59334863	C/G	cg02291164	chr14:59296302	NA	0.58	11.0	0.52	3.07e-24	Panic disorder;
LUSC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg12963246	chr6:28129442	ZNF389	0.55	7.63	0.39	2.55e-13	Depression;
LUSC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.37e-9	Life satisfaction;
LUSC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	cis	rs1572438	0.811	rs6916731	chr6:880428	G/C	cg13447295	chr6:887704	NA	0.4	6.29	0.33	1.01e-9	Aging;
LUSC	trans	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg13319975	chr6:146136371	FBXO30	0.48	7.25	0.37	3.01e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4964805	0.580	rs1866292	chr12:104174192	C/T	cg02344784	chr12:104178138	NT5DC3	0.43	6.82	0.35	4.37e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs7674212	0.541	rs4699050	chr4:104114297	A/G	cg16532752	chr4:104119610	CENPE	-0.48	-6.82	-0.35	4.31e-11	Type 2 diabetes;
LUSC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.88	0.6	6.61e-35	Cognitive test performance;
LUSC	cis	rs9653442	0.593	rs6542920	chr2:100845088	A/G	cg22139774	chr2:100720529	AFF3	-0.37	-6.05	-0.31	3.87e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg07167872	chr1:205819463	PM20D1	-0.39	-5.71	-0.3	2.55e-8	Parkinson's disease;
LUSC	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-9.17	-0.45	4.98e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg22963979	chr7:1858916	MAD1L1	-0.58	-8.97	-0.44	2.09e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg20203395	chr5:56204925	C5orf35	-0.76	-10.12	-0.48	3.5e-21	Initial pursuit acceleration;
LUSC	cis	rs1021993	0.597	rs10494921	chr1:209513501	A/G	cg24446417	chr1:209558027	NA	-0.35	-5.72	-0.3	2.43e-8	Gut microbiome composition (winter);
LUSC	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg20607287	chr7:12443886	VWDE	-0.65	-6.47	-0.33	3.52e-10	Coronary artery disease;
LUSC	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg01191920	chr7:158217561	PTPRN2	0.42	8.32	0.41	2.23e-15	Obesity-related traits;
LUSC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18876405	chr7:65276391	NA	-0.54	-8.6	-0.43	3.19e-16	Aortic root size;
LUSC	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg08854313	chr1:11322531	MTOR	0.86	14.51	0.62	2.46e-37	Body mass index;
LUSC	cis	rs11039100	0.834	rs11039053	chr11:5812827	T/C	cg13902645	chr11:5959945	NA	-0.54	-5.97	-0.31	6.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg09835421	chr16:68378352	PRMT7	-0.47	-5.78	-0.3	1.69e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg22920501	chr2:26401640	FAM59B	-0.74	-10.78	-0.51	1.84e-23	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07677032	chr17:61819896	STRADA	0.52	8.7	0.43	1.53e-16	Prudent dietary pattern;
LUSC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg26850624	chr5:429559	AHRR	-0.41	-8.0	-0.4	2.1e-14	Cystic fibrosis severity;
LUSC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg12257692	chr3:49977190	RBM6	0.24	6.54	0.34	2.35e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg03806693	chr22:41940476	POLR3H	-0.97	-13.97	-0.61	3.06e-35	Vitiligo;
LUSC	cis	rs1904096	0.506	rs4693381	chr4:95206855	A/T	cg11021082	chr4:95130006	SMARCAD1	0.43	7.99	0.4	2.17e-14	Type 2 diabetes;
LUSC	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.65	-10.77	-0.51	2.03e-23	Caffeine consumption;
LUSC	cis	rs73206853	0.764	rs56123836	chr12:110999032	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	7.54	0.38	4.6e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs2926702	0.810	rs34726915	chr8:71055610	G/T	cg16517358	chr11:46164796	NA	0.39	6.18	0.32	1.9e-9	Non-small cell lung cancer;
LUSC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.57	-8.8	-0.43	7.23e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs12043259	1.000	rs11240299	chr1:204847819	G/A	cg23865240	chr7:27134109	HOXA1	-0.57	-6.01	-0.31	4.86e-9	Addiction;
LUSC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg16606324	chr3:10149918	C3orf24	0.62	9.08	0.44	1e-17	Alzheimer's disease;
LUSC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13732083	chr21:47605072	C21orf56	0.4	5.66	0.3	3.22e-8	Testicular germ cell tumor;
LUSC	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.88	-0.35	2.89e-11	Response to antipsychotic treatment;
LUSC	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.71	8.87	0.44	4.36e-17	Type 2 diabetes;
LUSC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg14582100	chr15:45693742	SPATA5L1	0.58	10.31	0.49	7.78e-22	Homoarginine levels;
LUSC	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg25237894	chr2:233734115	C2orf82	0.36	6.16	0.32	2.14e-9	Coronary artery disease;
LUSC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg23711669	chr6:146136114	FBXO30	0.87	16.12	0.66	1.19e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	15.66	0.65	8.05e-42	Platelet count;
LUSC	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.69	0.3	2.75e-8	Life satisfaction;
LUSC	trans	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg25214090	chr10:38739885	LOC399744	0.42	6.54	0.34	2.26e-10	Corneal astigmatism;
LUSC	cis	rs4285028	0.580	rs2293611	chr3:121643163	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.48	-6.68	-0.34	9.9e-11	Multiple sclerosis;
LUSC	cis	rs4588572	0.643	rs2012562	chr5:77768088	T/A	cg11547950	chr5:77652471	NA	-0.53	-7.61	-0.38	2.89e-13	Triglycerides;
LUSC	trans	rs2262909	1.000	rs2017962	chr19:22208751	T/C	cg05197062	chr11:11642011	GALNTL4	-0.51	-7.08	-0.36	8.34e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.73	-0.47	7.04e-20	Total cholesterol levels;
LUSC	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.59	-0.34	1.7e-10	Daytime sleep phenotypes;
LUSC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg22920501	chr2:26401640	FAM59B	0.83	12.02	0.55	6.49e-28	Gut microbiome composition (summer);
LUSC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg06637938	chr14:75390232	RPS6KL1	0.53	8.64	0.43	2.32e-16	Height;
LUSC	cis	rs6574644	1.000	rs7155930	chr14:81776026	G/C	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg05110241	chr16:68378359	PRMT7	-0.51	-6.12	-0.32	2.69e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08677398	chr8:58056175	NA	0.53	7.06	0.36	9.83e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08677398	chr8:58056175	NA	0.49	6.25	0.32	1.26e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.4	5.78	0.3	1.75e-8	Lung cancer;
LUSC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	9.22	0.45	3.51e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.05	-0.31	3.82e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg10596483	chr8:143751796	JRK	0.61	9.39	0.46	9.97e-19	Schizophrenia;
LUSC	cis	rs2200578	0.841	rs112377545	chr2:99774823	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.51	5.87	0.31	1.03e-8	IgG glycosylation;
LUSC	cis	rs4493873	0.731	rs7846412	chr8:92044528	A/G	cg16814680	chr8:91681699	NA	0.41	5.67	0.3	3.17e-8	Migraine - clinic-based;
LUSC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg08200582	chr11:442649	ANO9	-0.51	-5.8	-0.3	1.51e-8	Body mass index;
LUSC	trans	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.35	-0.33	6.96e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.82	0.51	1.35e-23	Colorectal cancer;
LUSC	cis	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.39	-0.33	5.57e-10	Morning vs. evening chronotype;
LUSC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06112835	chr11:68658793	MRPL21	0.51	7.82	0.39	7.13e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg03433033	chr1:76189801	ACADM	0.61	8.59	0.43	3.38e-16	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.85	12.46	0.56	1.55e-29	Alcohol dependence;
LUSC	cis	rs6546537	1.000	rs4852892	chr2:69866769	T/A	cg10773587	chr2:69614142	GFPT1	-0.53	-7.83	-0.39	6.43e-14	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06636551	chr8:101224915	SPAG1	-0.44	-8.01	-0.4	1.89e-14	Atrioventricular conduction;
LUSC	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17467752	chr17:38218738	THRA	-0.5	-7.12	-0.36	6.64e-12	White blood cell count;
LUSC	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg24851651	chr11:66362959	CCS	-0.36	-5.68	-0.3	2.92e-8	Educational attainment (years of education);
LUSC	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg22437258	chr11:111473054	SIK2	0.5	6.89	0.35	2.78e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg24324837	chr19:49891574	CCDC155	0.52	7.38	0.37	1.31e-12	Multiple sclerosis;
LUSC	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-0.83	-12.1	-0.55	3.35e-28	Migraine;Coronary artery disease;
LUSC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg20398880	chr6:41068722	NFYA;LOC221442	0.45	6.81	0.35	4.51e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.91	0.35	2.42e-11	Height;
LUSC	cis	rs926938	0.563	rs360586	chr1:115467489	A/G	cg01522456	chr1:115632236	TSPAN2	-0.39	-5.81	-0.3	1.46e-8	Autism;
LUSC	cis	rs9815354	0.716	rs73087368	chr3:41930379	A/G	cg03022575	chr3:42003672	ULK4	0.82	8.55	0.42	4.49e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg08132940	chr7:1081526	C7orf50	-0.48	-5.95	-0.31	6.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	11.36	0.53	1.61e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.64	0.57	3.36e-30	Motion sickness;
LUSC	cis	rs2742234	0.955	rs2075910	chr10:43614230	G/A	cg02780029	chr10:43622663	RET	-0.33	-6.12	-0.32	2.61e-9	Hirschsprung disease;
LUSC	cis	rs6554196	0.508	rs3819393	chr4:55526615	C/T	cg18836493	chr4:55524333	KIT	-0.44	-7.51	-0.38	5.51e-13	Monocyte count;
LUSC	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg24562669	chr7:97807699	LMTK2	0.43	7.32	0.37	1.86e-12	Breast cancer;
LUSC	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg16482183	chr6:26056742	HIST1H1C	0.56	8.34	0.42	2.02e-15	Height;
LUSC	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg00310523	chr12:86230176	RASSF9	0.47	8.62	0.43	2.74e-16	Major depressive disorder;
LUSC	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg05340658	chr4:99064831	C4orf37	0.63	9.23	0.45	3.25e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6577655	0.501	rs7004326	chr8:135610915	G/T	cg17885191	chr8:135476712	NA	-0.43	-5.92	-0.31	7.98e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs56146971	0.670	rs12590074	chr14:91867390	T/G	cg10511902	chr14:91842949	CCDC88C	0.44	5.8	0.3	1.54e-8	Alzheimer disease and age of onset;
LUSC	cis	rs3733418	0.929	rs12510464	chr4:165919040	A/G	cg06481168	chr4:165878055	C4orf39;TRIM61	-0.5	-5.69	-0.3	2.79e-8	Obesity-related traits;
LUSC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-6.44	-0.33	4.08e-10	Aortic root size;
LUSC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24110177	chr3:50126178	RBM5	-0.54	-8.79	-0.43	7.87e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs422249	0.615	rs174612	chr11:61628266	C/G	cg06860612	chr11:61641270	FADS3	0.28	5.93	0.31	7.47e-9	Trans fatty acid levels;
LUSC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.62	0.5	6.6e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg11693508	chr17:37793320	STARD3	0.51	6.3	0.33	9.61e-10	Bipolar disorder;
LUSC	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg14675211	chr2:100938903	LONRF2	0.37	5.73	0.3	2.29e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6120849	0.707	rs6120798	chr20:33610822	T/G	cg24642439	chr20:33292090	TP53INP2	0.62	6.89	0.35	2.79e-11	Protein C levels;
LUSC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg11062466	chr8:58055876	NA	0.77	8.62	0.43	2.76e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg16606324	chr3:10149918	C3orf24	0.65	8.98	0.44	1.96e-17	Alzheimer's disease;
LUSC	trans	rs877282	0.583	rs10904562	chr10:819058	T/C	cg22713356	chr15:30763199	NA	0.74	9.48	0.46	4.8e-19	Uric acid levels;
LUSC	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg25237894	chr2:233734115	C2orf82	-0.33	-6.11	-0.32	2.73e-9	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25613101	chr22:38577875	PLA2G6	0.44	6.64	0.34	1.3e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.27	-0.32	1.1e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.11	-0.41	9.58e-15	Chronic sinus infection;
LUSC	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg16145915	chr7:1198662	ZFAND2A	0.45	8.34	0.42	2e-15	Longevity;Endometriosis;
LUSC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg27432699	chr2:27873401	GPN1	0.55	8.3	0.41	2.68e-15	Total body bone mineral density;
LUSC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg08200582	chr11:442649	ANO9	-0.52	-6.1	-0.32	3.02e-9	Body mass index;
LUSC	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg22484793	chr3:52261325	TLR9	0.27	6.06	0.31	3.6e-9	Electroencephalogram traits;
LUSC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08219700	chr8:58056026	NA	0.56	7.68	0.39	1.81e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs617219	0.889	rs1717560	chr5:78438743	A/G	cg24856658	chr5:78533917	JMY	-0.31	-5.79	-0.3	1.62e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg16414030	chr3:133502952	NA	0.44	6.63	0.34	1.32e-10	Iron status biomarkers;
LUSC	cis	rs4974559	0.790	rs6850727	chr4:1323273	G/C	cg02980000	chr4:1222292	CTBP1	0.85	9.71	0.47	8.27e-20	Systolic blood pressure;
LUSC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg05738196	chr6:26577821	NA	-0.55	-6.13	-0.32	2.54e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.46	9.67	0.47	1.13e-19	Airflow obstruction;
LUSC	cis	rs4594175	0.926	rs9323206	chr14:51621800	C/T	cg23942311	chr14:51606299	NA	0.33	6.22	0.32	1.46e-9	Cancer;
LUSC	cis	rs7072216	0.770	rs3830020	chr10:100176615	C/G	cg26618903	chr10:100175079	PYROXD2	0.32	6.28	0.32	1.06e-9	Metabolite levels;
LUSC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg15468180	chr1:107600409	PRMT6	0.4	6.45	0.33	4e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg00745463	chr17:30367425	LRRC37B	-0.68	-8.53	-0.42	5.02e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.49	-8.86	-0.44	4.73e-17	Longevity;Endometriosis;
LUSC	cis	rs17253792	0.822	rs77182097	chr14:56136695	G/A	cg01858014	chr14:56050164	KTN1	-0.77	-6.57	-0.34	1.95e-10	Putamen volume;
LUSC	cis	rs4631830	0.863	rs4486572	chr10:51531805	A/G	cg10326726	chr10:51549505	MSMB	-0.36	-6.03	-0.31	4.23e-9	Prostate-specific antigen levels;
LUSC	trans	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg10756647	chr7:56101905	PSPH	-0.76	-6.95	-0.36	1.87e-11	Diabetic kidney disease;
LUSC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg02269571	chr22:50332266	NA	-0.66	-8.17	-0.41	6.29e-15	Schizophrenia;
LUSC	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-1.22	-16.28	-0.67	2.71e-44	Hip circumference adjusted for BMI;
LUSC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.96	0.36	1.76e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg02389323	chr16:88786976	FAM38A	0.87	9.07	0.44	1.01e-17	Plateletcrit;
LUSC	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg10560079	chr2:191398806	TMEM194B	-0.65	-8.18	-0.41	5.91e-15	Diastolic blood pressure;
LUSC	cis	rs57549656	0.799	rs741105	chr19:2711529	T/C	cg06609049	chr19:2785107	THOP1	0.49	6.43	0.33	4.51e-10	Schizophrenia;
LUSC	cis	rs11112613	0.609	rs7966960	chr12:106032152	G/A	cg03607813	chr12:105948248	NA	0.62	7.85	0.39	5.7e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20891558	chr2:74357851	NA	0.8	14.51	0.62	2.53e-37	Gestational age at birth (maternal effect);
LUSC	cis	rs3087591	0.960	rs8067021	chr17:29555078	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.55	-8.0	-0.4	2.06e-14	Hip circumference;
LUSC	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg13010199	chr12:38710504	ALG10B	0.55	8.37	0.42	1.63e-15	Morning vs. evening chronotype;
LUSC	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg17385448	chr1:15911702	AGMAT	0.38	5.73	0.3	2.22e-8	Systolic blood pressure;
LUSC	cis	rs12530845	1.000	rs12531468	chr7:135336264	T/G	cg23117316	chr7:135346802	PL-5283	-0.55	-9.3	-0.45	1.88e-18	Red blood cell traits;
LUSC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.73	-0.47	7.44e-20	Bipolar disorder;
LUSC	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg11901034	chr3:128598214	ACAD9	-0.4	-6.21	-0.32	1.57e-9	IgG glycosylation;
LUSC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg13010199	chr12:38710504	ALG10B	0.7	10.81	0.51	1.44e-23	Bladder cancer;
LUSC	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg21211680	chr2:198530	NA	-0.67	-7.87	-0.4	4.97e-14	Blood protein levels;
LUSC	cis	rs9427116	0.502	rs9426829	chr1:154592201	T/C	cg17218026	chr1:154582156	ADAR	0.56	10.0	0.48	9.16e-21	Blood protein levels;
LUSC	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	0.58	8.91	0.44	3.39e-17	Breast cancer;
LUSC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.53	-0.34	2.44e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg25281562	chr12:121454272	C12orf43	-0.43	-5.65	-0.3	3.48e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg10645314	chr2:3704589	ALLC	0.52	9.04	0.44	1.31e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg13010344	chr12:123464640	ARL6IP4	-0.47	-6.34	-0.33	7.45e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg05738196	chr6:26577821	NA	-0.82	-15.12	-0.64	1.06e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs4899260	0.779	rs4899261	chr14:69283375	C/T	cg03189333	chr14:69283534	NA	-0.48	-5.99	-0.31	5.58e-9	Celiac disease;
LUSC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7216064	1.000	rs8071463	chr17:65938655	C/T	cg12091567	chr17:66097778	LOC651250	0.74	9.54	0.46	3.19e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7589342	0.894	rs7557976	chr2:106435061	C/A	cg16077055	chr2:106428750	NCK2	0.38	7.26	0.37	2.75e-12	Addiction;
LUSC	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.39	-5.92	-0.31	7.88e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.71e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg21659725	chr3:3221576	CRBN	0.69	8.16	0.41	6.93e-15	Menarche (age at onset);
LUSC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.76	-10.09	-0.48	4.42e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.51	-0.34	2.69e-10	Retinal vascular caliber;
LUSC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.63	9.9	0.48	2e-20	Type 2 diabetes;
LUSC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg25036284	chr2:26402008	FAM59B	0.78	11.06	0.52	1.94e-24	Gut microbiome composition (summer);
LUSC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.7	0.54	1.01e-26	Hip circumference adjusted for BMI;
LUSC	cis	rs10465746	0.967	rs5028806	chr1:84329295	G/A	cg10977910	chr1:84465055	TTLL7	0.44	6.39	0.33	5.72e-10	Obesity-related traits;
LUSC	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg14343924	chr8:8086146	FLJ10661	0.45	6.19	0.32	1.76e-9	Neuroticism;
LUSC	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.7	10.49	0.5	1.92e-22	Smoking initiation;
LUSC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg07703079	chr11:430292	ANO9	0.64	6.48	0.33	3.23e-10	Body mass index;
LUSC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg06238570	chr21:40685208	BRWD1	0.5	7.69	0.39	1.66e-13	Cognitive function;
LUSC	cis	rs17155006	0.691	rs403731	chr7:107744217	C/T	cg05962710	chr7:107745446	LAMB4	0.34	6.15	0.32	2.26e-9	Pneumococcal bacteremia;
LUSC	trans	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg20993868	chr7:22813445	NA	0.59	10.86	0.51	9.58e-24	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs2731664	0.819	rs449351	chr5:176872591	T/C	cg23176889	chr5:176863531	GRK6	-0.69	-14.17	-0.61	5.16e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs7607369	0.559	rs4674340	chr2:219659799	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-9.51	-0.46	4.03e-19	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	trans	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg26043149	chr18:55253948	FECH	-0.51	-7.32	-0.37	1.87e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg07930552	chr6:133119739	C6orf192	0.79	10.32	0.49	7.22e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs679087	0.612	rs7970465	chr12:29905251	C/T	cg14258853	chr12:29935411	TMTC1	-0.99	-14.83	-0.63	1.43e-38	Schizophrenia;
LUSC	cis	rs8056893	0.513	rs3785111	chr16:68309971	A/T	cg02226672	chr16:68398533	SMPD3	0.3	5.83	0.3	1.31e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	trans	rs10090774	0.710	rs13264524	chr8:141654658	A/G	cg02991888	chr19:54260014	MIR1283-2;MIR516A1	0.29	5.96	0.31	6.4e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs10744422	0.800	rs11059724	chr12:123235978	T/G	cg25930673	chr12:123319894	HIP1R	0.58	5.98	0.31	5.68e-9	Schizophrenia;
LUSC	cis	rs2274273	0.713	rs56725788	chr14:55540101	A/G	cg04306507	chr14:55594613	LGALS3	0.5	10.72	0.51	3.17e-23	Protein biomarker;
LUSC	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.12	0.52	1.15e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.69	10.56	0.5	1.14e-22	Aortic root size;
LUSC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.63	-0.34	1.36e-10	Tonsillectomy;
LUSC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg07741184	chr6:167504864	NA	0.43	7.61	0.38	2.8e-13	Primary biliary cholangitis;
LUSC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	9.48	0.46	4.79e-19	Total body bone mineral density;
LUSC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg06671706	chr8:8559999	CLDN23	0.5	6.86	0.35	3.37e-11	Obesity-related traits;
LUSC	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg18132916	chr6:79620363	NA	-0.38	-5.74	-0.3	2.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs877282	0.853	rs11596346	chr10:756673	A/T	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg09479241	chr17:27052676	TLCD1	0.44	6.17	0.32	1.96e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9311676	0.656	rs7642652	chr3:58373667	C/T	cg26110898	chr3:58419937	PDHB	0.42	6.75	0.35	6.62e-11	Systemic lupus erythematosus;
LUSC	cis	rs239198	0.578	rs13193416	chr6:101299602	A/T	cg09795085	chr6:101329169	ASCC3	0.45	6.36	0.33	6.54e-10	Menarche (age at onset);
LUSC	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg07173049	chr1:7289937	CAMTA1	0.34	7.04	0.36	1.07e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs500891	0.645	rs6454330	chr6:84175552	G/T	cg08257003	chr6:84140564	ME1	-0.31	-7.01	-0.36	1.36e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.32	22.06	0.77	3.52e-67	Type 1 diabetes nephropathy;
LUSC	cis	rs4889855	0.578	rs7216808	chr17:78484187	A/G	cg00066239	chr17:78472159	NA	-0.43	-7.23	-0.37	3.4e-12	Fractional excretion of uric acid;
LUSC	cis	rs6464929	1.000	rs1551926	chr7:148719583	C/T	cg23583168	chr7:148888333	NA	0.46	5.99	0.31	5.56e-9	Pediatric bone mineral content (hip);
LUSC	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg25173405	chr17:45401733	C17orf57	-0.37	-5.92	-0.31	8e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg02569458	chr12:86230093	RASSF9	0.53	8.59	0.43	3.31e-16	Major depressive disorder;
LUSC	cis	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg27411982	chr8:10470053	RP1L1	0.41	6.1	0.32	2.91e-9	Neuroticism;
LUSC	trans	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg26384229	chr12:38710491	ALG10B	0.55	8.85	0.44	5.15e-17	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.45	-0.46	6.32e-19	Body mass index;
LUSC	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg01420254	chr6:26195488	NA	0.72	7.48	0.38	6.52e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs17155006	0.664	rs448833	chr7:107739181	A/G	cg05962710	chr7:107745446	LAMB4	-0.36	-6.3	-0.33	9.63e-10	Pneumococcal bacteremia;
LUSC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg05855489	chr10:104503620	C10orf26	-0.69	-9.87	-0.48	2.54e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9888739	1.000	rs7190018	chr16:31301478	G/A	cg15817542	chr16:31343056	ITGAM	-0.5	-6.02	-0.31	4.65e-9	Systemic lupus erythematosus;
LUSC	cis	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg09307838	chr4:120376055	NA	0.48	7.19	0.37	4.23e-12	Diastolic blood pressure;
LUSC	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg06606381	chr12:133084897	FBRSL1	-0.92	-8.75	-0.43	1.06e-16	Depression;
LUSC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg14668632	chr7:2872130	GNA12	-0.48	-7.11	-0.36	7.01e-12	Height;
LUSC	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg26516362	chr5:178986906	RUFY1	0.48	8.27	0.41	3.2e-15	Lung cancer;
LUSC	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg20587970	chr11:113659929	NA	0.78	9.92	0.48	1.72e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg12179176	chr11:130786555	SNX19	0.65	9.91	0.48	1.81e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.02	0.44	1.53e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10886558	0.674	rs883448	chr10:121772123	G/C	cg02041677	chr10:121771263	NA	-0.33	-6.15	-0.32	2.19e-9	Shingles;
LUSC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16346588	chr10:242978	ZMYND11	0.4	5.67	0.3	3.15e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg06008330	chr7:65541103	ASL	0.4	6.17	0.32	1.96e-9	Aortic root size;
LUSC	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg25182066	chr10:30743637	MAP3K8	0.43	6.08	0.32	3.3e-9	Inflammatory bowel disease;
LUSC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg00149659	chr3:10157352	C3orf10	0.62	8.72	0.43	1.36e-16	Alzheimer's disease;
LUSC	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.48	-0.38	6.76e-13	Neuroticism;
LUSC	trans	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.93	-0.4	3.24e-14	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6736093	0.796	rs13024271	chr2:112814326	G/A	cg12686935	chr2:112915763	FBLN7	-0.4	-6.37	-0.33	6.41e-10	Coronary artery disease;
LUSC	trans	rs67133203	0.851	rs12366756	chr12:51403206	A/G	cg17484237	chr5:156536107	HAVCR2	0.44	6.01	0.31	4.95e-9	Urinary tract infection frequency;
LUSC	cis	rs17407555	0.738	rs56402960	chr4:10086473	T/A	cg11266682	chr4:10021025	SLC2A9	-0.45	-5.88	-0.31	1.02e-8	Schizophrenia (age at onset);
LUSC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-9.44	-0.46	6.42e-19	Mood instability;
LUSC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	6.66	0.34	1.16e-10	Height;
LUSC	cis	rs77972916	0.611	rs61552842	chr2:43584036	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.49	-6.21	-0.32	1.61e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.72	9.05	0.44	1.2e-17	Type 2 diabetes;
LUSC	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-15.55	-0.65	2.11e-41	Heart rate;
LUSC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg13072238	chr3:49761600	GMPPB	-0.69	-8.14	-0.41	8.15e-15	Menarche (age at onset);
LUSC	cis	rs13089785	1.000	rs34159794	chr3:123645893	A/G	cg01860459	chr3:123419554	MYLK	0.35	5.85	0.3	1.19e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7523273	0.606	rs2796262	chr1:207915180	G/A	cg22525895	chr1:207977042	MIR29B2	0.4	6.51	0.34	2.76e-10	Schizophrenia;
LUSC	cis	rs10754283	0.901	rs10922683	chr1:90116068	G/A	cg21401794	chr1:90099060	LRRC8C	0.63	9.02	0.44	1.46e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg20643362	chr19:30206369	C19orf12	-0.53	-6.44	-0.33	4.1e-10	Cognitive function;Information processing speed;
LUSC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26314531	chr2:26401878	FAM59B	-0.71	-9.69	-0.47	1.03e-19	Gut microbiome composition (summer);
LUSC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.54	-9.31	-0.45	1.77e-18	Homoarginine levels;
LUSC	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg05966235	chr16:28915196	ATP2A1	0.34	5.96	0.31	6.43e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg18478394	chr8:109455254	TTC35	0.41	6.41	0.33	5.06e-10	Dupuytren's disease;
LUSC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg22508957	chr16:3507546	NAT15	0.67	11.19	0.52	6.72e-25	Tuberculosis;
LUSC	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.57	10.15	0.49	2.81e-21	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs2580764	0.573	rs13387751	chr2:55227375	C/G	cg09592903	chr2:55203963	RTN4	-0.49	-10.11	-0.48	4e-21	Mean platelet volume;
LUSC	cis	rs13385	0.769	rs7703595	chr5:139611190	A/C	cg26211634	chr5:139558579	C5orf32	0.45	7.38	0.37	1.23e-12	Atrial fibrillation;
LUSC	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg08017756	chr2:100939284	LONRF2	-0.43	-8.13	-0.41	8.43e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg22437258	chr11:111473054	SIK2	0.54	7.58	0.38	3.45e-13	Primary sclerosing cholangitis;
LUSC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg06074448	chr4:187884817	NA	-0.4	-6.53	-0.34	2.45e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2580764	0.566	rs2968794	chr2:55290651	C/G	cg20993754	chr2:55226987	RTN4	0.36	6.14	0.32	2.29e-9	Mean platelet volume;
LUSC	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg03465714	chr1:152285911	FLG	0.42	5.82	0.3	1.36e-8	Atopic dermatitis;
LUSC	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	0.53	8.01	0.4	1.91e-14	Breast cancer;
LUSC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg06784218	chr1:46089804	CCDC17	0.46	9.13	0.45	6.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4908769	0.660	rs13596	chr1:8421203	T/C	cg00546117	chr1:8445545	RERE	0.29	5.68	0.3	2.89e-8	Allergy;
LUSC	cis	rs11645898	0.748	rs56387295	chr16:72055336	C/A	cg14768367	chr16:72042858	DHODH	-0.78	-8.38	-0.42	1.54e-15	Blood protein levels;
LUSC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.82	-12.31	-0.56	5.67e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-8.12	-0.41	8.96e-15	Lymphocyte counts;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	0.74	13.36	0.59	6.47e-33	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs3942852	0.955	rs7117386	chr11:48125371	G/A	cg15704280	chr7:45808275	SEPT13	-0.55	-6.36	-0.33	6.83e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.98	0.44	1.97e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg12091567	chr17:66097778	LOC651250	-0.75	-9.35	-0.46	1.27e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2742417	0.609	rs11709306	chr3:45773732	G/A	cg10512202	chr3:45649293	LIMD1	0.36	5.94	0.31	7.3e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg13939156	chr17:80058883	NA	-0.34	-6.68	-0.34	9.94e-11	Life satisfaction;
LUSC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.75	0.3	2.03e-8	Tonsillectomy;
LUSC	cis	rs732765	0.648	rs8019391	chr14:75409682	T/C	cg06637938	chr14:75390232	RPS6KL1	0.55	6.72	0.35	7.72e-11	Non-small cell lung cancer;
LUSC	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-0.49	-7.42	-0.38	9.77e-13	Breast cancer;
LUSC	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.6	10.05	0.48	6.31e-21	Birth weight;
LUSC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.77	-12.96	-0.58	2.08e-31	Iron status biomarkers;
LUSC	cis	rs72772090	0.539	rs55996659	chr5:96114150	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-7.05	-0.36	1.05e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg07217954	chr7:1067459	C7orf50	0.53	5.71	0.3	2.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7524258	0.835	rs7521425	chr1:7306543	C/T	cg07173049	chr1:7289937	CAMTA1	0.32	6.53	0.34	2.38e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7172677	1.000	rs4886659	chr15:75414760	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.76	-0.3	1.9e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.51	7.98	0.4	2.37e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.3	0.49	8.56e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18404041	chr3:52824283	ITIH1	-0.6	-11.64	-0.54	1.58e-26	Bipolar disorder;
LUSC	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg09699651	chr6:150184138	LRP11	0.45	7.17	0.37	4.98e-12	Testicular germ cell tumor;
LUSC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg01802117	chr1:53393560	SCP2	0.39	6.49	0.33	3.15e-10	Monocyte count;
LUSC	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg27471124	chr11:109292789	C11orf87	0.37	6.74	0.35	6.83e-11	Schizophrenia;
LUSC	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg02023728	chr11:77925099	USP35	0.41	5.89	0.31	9.37e-9	Testicular germ cell tumor;
LUSC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07677032	chr17:61819896	STRADA	0.53	8.99	0.44	1.89e-17	Prudent dietary pattern;
LUSC	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.78	11.3	0.53	2.71e-25	Corneal astigmatism;
LUSC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.04	-0.31	4.09e-9	Bipolar disorder;
LUSC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	10.09	0.48	4.6e-21	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg00757033	chr12:89920650	WDR51B	0.58	9.91	0.48	1.8e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7215564	0.908	rs2873060	chr17:78663497	A/C	cg23238734	chr17:78661607	RPTOR	0.47	6.1	0.32	2.98e-9	Myopia (pathological);
LUSC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg12564285	chr5:131593104	PDLIM4	0.56	10.79	0.51	1.81e-23	Acylcarnitine levels;
LUSC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg15790184	chr11:494944	RNH1	0.42	6.42	0.33	4.69e-10	Systemic lupus erythematosus;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02991799	chr19:35168510	ZNF302	-0.41	-5.99	-0.31	5.36e-9	Electrocardiographic conduction measures;
LUSC	trans	rs9929218	0.954	rs17715799	chr16:68830511	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-10.58	-0.5	9.67e-23	Colorectal cancer;
LUSC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg12463550	chr7:65579703	CRCP	-0.51	-7.33	-0.37	1.74e-12	Aortic root size;
LUSC	trans	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg06606381	chr12:133084897	FBRSL1	0.44	5.96	0.31	6.56e-9	Depression;
LUSC	cis	rs2354432	0.607	rs11579626	chr1:146741960	A/C	cg25205988	chr1:146714368	CHD1L	-1.0	-9.35	-0.46	1.26e-18	Mitochondrial DNA levels;
LUSC	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg27147174	chr7:100797783	AP1S1	-0.64	-10.29	-0.49	9.09e-22	Life satisfaction;
LUSC	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg12908607	chr1:44402522	ARTN	-0.45	-7.05	-0.36	1e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03105603	chr7:39772936	LOC349114	-0.49	-5.97	-0.31	5.91e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7588746	0.621	rs4672726	chr2:201149413	C/T	cg23649088	chr2:200775458	C2orf69	-0.41	-5.72	-0.3	2.32e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25356086	chr21:33764900	C21orf119;URB1	0.46	6.46	0.33	3.62e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg20933634	chr6:27740509	NA	0.41	5.72	0.3	2.43e-8	Parkinson's disease;
LUSC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	0.87	14.82	0.63	1.61e-38	Cognitive function;
LUSC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.08	0.32	3.32e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg03146154	chr1:46216737	IPP	0.56	8.34	0.42	1.94e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg15309053	chr8:964076	NA	0.37	7.52	0.38	5.18e-13	Schizophrenia;
LUSC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg23711669	chr6:146136114	FBXO30	0.9	17.22	0.69	5.31e-48	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1706867	0.633	rs823537	chr2:2493938	A/G	cg16599136	chr19:49561594	NA	-0.32	-6.05	-0.31	3.79e-9	Facial morphology (factor 14, intercanthal width);
LUSC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-5.97	-0.31	5.98e-9	Major depressive disorder;
LUSC	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg10911889	chr6:126070802	HEY2	0.43	6.55	0.34	2.11e-10	Brugada syndrome;
LUSC	cis	rs905938	0.559	rs74520550	chr1:155006450	C/A	cg16256492	chr1:154989843	ZBTB7B	0.63	7.23	0.37	3.24e-12	Waist-to-hip ratio adjusted for body mass index;Birth length;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	8.84	0.44	5.41e-17	Lymphocyte counts;Red cell distribution width;
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg06877462	chr1:205807181	PM20D1	0.56	10.34	0.49	6.48e-22	Menarche (age at onset);
LUSC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg05585544	chr11:47624801	NA	0.4	6.98	0.36	1.55e-11	Subjective well-being;
LUSC	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg02176678	chr2:219576539	TTLL4	0.6	10.75	0.51	2.34e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg09654669	chr8:57350985	NA	-0.56	-7.78	-0.39	9.24e-14	Obesity-related traits;
LUSC	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.22	0.52	5.39e-25	Morning vs. evening chronotype;
LUSC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00149659	chr3:10157352	C3orf10	0.89	11.83	0.54	3.19e-27	Alzheimer's disease;
LUSC	cis	rs1957429	0.614	rs62621845	chr14:65403525	T/A	cg23373153	chr14:65346875	NA	-0.98	-7.73	-0.39	1.3e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs16949788	1.000	rs12323975	chr15:66674634	T/C	cg08120210	chr15:66682733	MAP2K1	-0.58	-5.82	-0.3	1.41e-8	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg11843606	chr2:227700838	RHBDD1	0.61	9.66	0.47	1.27e-19	Pulmonary function;
LUSC	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg21770322	chr7:97807741	LMTK2	0.44	7.53	0.38	4.88e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs295140	1.000	rs10931897	chr2:201162520	T/C	cg04283868	chr2:201171347	SPATS2L	0.43	6.57	0.34	1.95e-10	QT interval;
LUSC	trans	rs804280	1.000	rs804281	chr8:11611865	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	8.83	0.44	5.85e-17	Myopia (pathological);
LUSC	cis	rs7091068	0.616	rs4322326	chr10:95483382	A/T	cg20715218	chr10:95462985	C10orf4	0.62	7.06	0.36	9.91e-12	Urinary tract infection frequency;
LUSC	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg04117972	chr1:227635322	NA	0.58	6.73	0.35	7.61e-11	Major depressive disorder;
LUSC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.18	0.55	1.67e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg13319975	chr6:146136371	FBXO30	-0.53	-7.94	-0.4	3.06e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg00579200	chr11:133705235	NA	-0.4	-5.86	-0.31	1.09e-8	Childhood ear infection;
LUSC	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg04362960	chr10:104952993	NT5C2	0.53	7.58	0.38	3.34e-13	Waist circumference;Hip circumference;
LUSC	cis	rs983392	0.679	rs1026253	chr11:60030556	G/A	cg02771260	chr11:59836817	MS4A3	0.37	5.99	0.31	5.34e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1413885	0.549	rs1334877	chr1:65846406	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	6.77	0.35	5.79e-11	Anticoagulant levels;
LUSC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg05785598	chr3:49045655	WDR6	0.33	5.9	0.31	8.92e-9	Parkinson's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01485948	chr17:2296549	MNT	-0.49	-6.25	-0.32	1.25e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg01251360	chr16:68772225	CDH1	-0.26	-6.29	-0.33	1e-9	Colorectal cancer;
LUSC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg04398451	chr17:18023971	MYO15A	-0.48	-7.72	-0.39	1.34e-13	Total body bone mineral density;
LUSC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg21724239	chr8:58056113	NA	0.78	9.03	0.44	1.43e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs2346177	0.816	rs74179078	chr2:46654651	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-9.3	-0.45	1.94e-18	HDL cholesterol;
LUSC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg14552801	chr7:65878734	NA	-0.45	-6.52	-0.34	2.6e-10	Aortic root size;
LUSC	trans	rs979233	0.502	rs905098	chr5:42110159	T/C	cg07010552	chr17:7358735	CHRNB1	-0.41	-6.03	-0.31	4.29e-9	Systemic lupus erythematosus;
LUSC	cis	rs7189233	0.531	rs9941254	chr16:53487218	C/T	cg09728985	chr16:53543985	NA	-0.31	-5.81	-0.3	1.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg01191920	chr7:158217561	PTPRN2	-0.5	-10.31	-0.49	7.8e-22	Obesity-related traits;
LUSC	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg15485101	chr11:133734466	NA	0.43	7.72	0.39	1.4e-13	Childhood ear infection;
LUSC	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg06636001	chr8:8085503	FLJ10661	0.52	7.18	0.37	4.49e-12	Neuroticism;
LUSC	cis	rs11931598	1.000	rs11931598	chr4:7047102	A/G	cg02503808	chr4:7069936	GRPEL1	0.41	5.76	0.3	1.9e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg01966878	chr4:90757139	SNCA	-0.35	-6.12	-0.32	2.56e-9	Dementia with Lewy bodies;
LUSC	cis	rs4654899	0.772	rs12404954	chr1:21074727	A/G	cg01072550	chr1:21505969	NA	-0.43	-6.33	-0.33	7.97e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7615316	0.779	rs10935461	chr3:142079379	A/G	cg16271453	chr3:142027066	XRN1	-0.4	-6.96	-0.36	1.85e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.33e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg17366294	chr4:99064904	C4orf37	0.55	8.84	0.44	5.57e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg24375607	chr4:120327624	NA	0.78	11.63	0.54	1.74e-26	Corneal astigmatism;
LUSC	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.47	8.27	0.41	3.14e-15	HDL cholesterol;
LUSC	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.07	0.36	9.17e-12	Morning vs. evening chronotype;
LUSC	cis	rs12989701	0.935	rs12994284	chr2:127874020	T/C	cg08168897	chr2:127865431	BIN1	0.71	9.36	0.46	1.2e-18	Alzheimer's disease (late onset);
LUSC	cis	rs9902453	0.836	rs62070337	chr17:28466257	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.19	0.41	5.57e-15	Coffee consumption (cups per day);
LUSC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	trans	rs11700980	1.000	rs2832053	chr21:30130977	G/A	cg05609335	chr17:75789393	NA	0.4	6.01	0.31	4.82e-9	QRS complex (12-leadsum);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16202598	chr3:179322434	NDUFB5;MRPL47	-0.42	-6.08	-0.32	3.22e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.72	10.11	0.48	3.92e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg05623727	chr3:50126028	RBM5	0.32	6.04	0.31	4.04e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6424115	1.000	rs7521961	chr1:24157634	C/T	cg10978503	chr1:24200527	CNR2	-0.51	-11.96	-0.55	1.15e-27	Immature fraction of reticulocytes;
LUSC	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg01657329	chr11:68192670	LRP5	-0.4	-5.73	-0.3	2.24e-8	Total body bone mineral density;
LUSC	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg23601095	chr6:26197514	HIST1H3D	0.7	7.47	0.38	7.17e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg21045802	chr8:109455806	TTC35	0.46	7.12	0.36	6.47e-12	Dupuytren's disease;
LUSC	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg04310649	chr10:35416472	CREM	-0.4	-6.22	-0.32	1.52e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg15038512	chr6:170123185	PHF10	0.53	7.5	0.38	5.9e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg24375607	chr4:120327624	NA	0.5	7.45	0.38	8.07e-13	Diastolic blood pressure;
LUSC	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg18352616	chr4:3374830	RGS12	0.32	6.28	0.33	1.03e-9	Serum sulfate level;
LUSC	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg26893861	chr17:41843967	DUSP3	1.01	15.04	0.64	2.13e-39	Triglycerides;
LUSC	cis	rs11650494	0.908	rs117853079	chr17:47421593	G/C	cg08112188	chr17:47440006	ZNF652	1.22	10.05	0.48	6.07e-21	Prostate cancer;
LUSC	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg02389323	chr16:88786976	FAM38A	0.88	9.09	0.45	8.81e-18	Plateletcrit;
LUSC	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg00290607	chr11:67383545	NA	0.31	5.78	0.3	1.74e-8	Mean corpuscular volume;
LUSC	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg11657440	chr19:46296263	DMWD	-0.72	-11.14	-0.52	9.88e-25	Coronary artery disease;
LUSC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.22	-0.32	1.5e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg19920283	chr7:105172520	RINT1	0.6	6.28	0.33	1.04e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs3916	0.955	rs12828810	chr12:121152017	T/G	cg27246729	chr12:121163418	ACADS	0.49	7.13	0.36	6.19e-12	Urinary metabolites (H-NMR features);
LUSC	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.5	-7.51	-0.38	5.61e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.56	9.51	0.46	3.77e-19	Bone mineral density;
LUSC	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg11871910	chr12:69753446	YEATS4	0.48	6.43	0.33	4.48e-10	Response to diuretic therapy;
LUSC	cis	rs10189230	0.967	rs13026380	chr2:222352715	G/A	cg14652038	chr2:222343519	EPHA4	0.32	5.76	0.3	1.91e-8	Urate levels in lean individuals;
LUSC	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.45	9.4	0.46	8.7e-19	Airflow obstruction;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07843583	chr10:135143563	CALY	0.74	6.34	0.33	7.25e-10	Cognitive performance;
LUSC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg16524733	chr11:117070046	TAGLN	0.4	6.84	0.35	3.79e-11	Blood protein levels;
LUSC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg24846343	chr22:24311635	DDTL	-0.58	-9.22	-0.45	3.44e-18	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg18404041	chr3:52824283	ITIH1	0.55	9.18	0.45	4.67e-18	Schizophrenia;
LUSC	cis	rs4629180	0.675	rs4851459	chr2:102109006	T/A	cg04415270	chr2:102091202	RFX8	-0.46	-8.02	-0.4	1.86e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.5	8.02	0.4	1.84e-14	Menarche (age at onset);
LUSC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.11	0.36	7.23e-12	Cognitive ability;
LUSC	cis	rs7091068	0.522	rs10882322	chr10:95483273	C/G	cg20715218	chr10:95462985	C10orf4	0.6	7.32	0.37	1.86e-12	Urinary tract infection frequency;
LUSC	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg06484146	chr7:12443880	VWDE	-0.72	-7.12	-0.36	6.86e-12	Coronary artery disease;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg06877462	chr1:205807181	PM20D1	0.5	9.0	0.44	1.77e-17	Menarche (age at onset);
LUSC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-1.02	-15.49	-0.65	3.7e-41	Initial pursuit acceleration;
LUSC	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg18806716	chr10:30721971	MAP3K8	-0.61	-9.82	-0.47	3.63e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.4	1.9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg23188684	chr11:67383651	NA	0.34	5.96	0.31	6.54e-9	Mean corpuscular volume;
LUSC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06221963	chr1:154839813	KCNN3	-0.61	-14.18	-0.61	4.82e-36	Prostate cancer;
LUSC	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg12856521	chr11:46389249	DGKZ	0.4	6.13	0.32	2.54e-9	Leprosy;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg05397039	chr1:243419179	SDCCAG8;CEP170	0.37	6.06	0.31	3.61e-9	Triglycerides;
LUSC	cis	rs920590	0.643	rs2083640	chr8:19660212	T/C	cg03894339	chr8:19674705	INTS10	0.41	5.85	0.31	1.15e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs258324	0.720	rs154663	chr16:89726035	T/C	cg04287289	chr16:89883240	FANCA	-0.66	-5.85	-0.3	1.19e-8	Height;
LUSC	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg17143192	chr8:8559678	CLDN23	0.58	8.33	0.41	2.07e-15	Obesity-related traits;
LUSC	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg16342193	chr10:102329863	NA	-0.36	-6.27	-0.32	1.12e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg13010199	chr12:38710504	ALG10B	0.7	10.93	0.51	5.81e-24	Bladder cancer;
LUSC	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.56	-8.94	-0.44	2.7e-17	Personality dimensions;
LUSC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	0.65	13.74	0.6	2.37e-34	Prudent dietary pattern;
LUSC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs17401966	1.000	rs11121552	chr1:10435324	C/A	cg19773385	chr1:10388646	KIF1B	-0.55	-8.23	-0.41	4.12e-15	Hepatocellular carcinoma;
LUSC	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs1163251	0.902	rs639216	chr1:120217414	C/T	cg19096424	chr1:120255104	PHGDH	0.48	6.53	0.34	2.39e-10	Blood metabolite levels;
LUSC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg26769984	chr7:1090371	C7orf50	0.56	8.04	0.4	1.57e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg13319975	chr6:146136371	FBXO30	0.49	7.48	0.38	6.82e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs644148	0.836	rs2571110	chr19:45000712	T/C	cg15540054	chr19:45004280	ZNF180	-0.65	-9.69	-0.47	9.94e-20	Personality dimensions;
LUSC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg09699651	chr6:150184138	LRP11	0.37	5.73	0.3	2.22e-8	Lung cancer;
LUSC	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.68	-0.34	1.02e-10	Monocyte percentage of white cells;
LUSC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.14	0.36	5.97e-12	Cognitive ability;
LUSC	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg25801113	chr15:45476975	SHF	0.35	7.18	0.37	4.61e-12	Uric acid levels;
LUSC	trans	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.96	-0.31	6.49e-9	Dementia with Lewy bodies;
LUSC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg18827107	chr12:86230957	RASSF9	-0.47	-7.1	-0.36	7.78e-12	Major depressive disorder;
LUSC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-7.3	-0.37	2.11e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.24	0.37	3.18e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg05855489	chr10:104503620	C10orf26	-0.49	-7.42	-0.38	9.5e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.54	8.83	0.43	6.16e-17	Breast cancer;
LUSC	trans	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.4	-0.33	5.29e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	10.65	0.5	5.26e-23	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg03733263	chr8:22462867	KIAA1967	0.77	12.69	0.57	2.29e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs897080	0.515	rs1067337	chr2:44624859	A/G	cg00619915	chr2:44497795	NA	-0.41	-5.82	-0.3	1.35e-8	Height;
LUSC	cis	rs6430585	0.591	rs724326	chr2:136485971	T/C	cg07169764	chr2:136633963	MCM6	0.83	10.63	0.5	6.49e-23	Corneal structure;
LUSC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-5.85	-0.3	1.16e-8	Calcium levels;
LUSC	cis	rs12940923	0.748	rs56298529	chr17:56363859	T/A	cg19466818	chr17:56409534	MIR142	-0.38	-6.74	-0.35	7.07e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs9644630	0.930	rs6586840	chr8:19365832	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.36	-6.75	-0.35	6.62e-11	Oropharynx cancer;
LUSC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg06917634	chr15:78832804	PSMA4	0.82	14.69	0.63	4.94e-38	Sudden cardiac arrest;
LUSC	cis	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg06521852	chr22:38141419	TRIOBP	-0.34	-5.71	-0.3	2.47e-8	Glioblastoma;Glioma;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-1.03	-22.02	-0.77	5.16e-67	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg15448220	chr1:150897856	SETDB1	0.41	5.88	0.31	9.89e-9	Melanoma;
LUSC	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg02569458	chr12:86230093	RASSF9	0.53	8.56	0.42	4.18e-16	Major depressive disorder;
LUSC	cis	rs9311676	0.632	rs12487420	chr3:58399511	A/G	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	-0.32	-7.52	-0.38	5.12e-13	Coronary artery disease;
LUSC	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg22437258	chr11:111473054	SIK2	0.51	7.05	0.36	1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg22508957	chr16:3507546	NAT15	-0.76	-9.53	-0.46	3.24e-19	Tuberculosis;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg02624855	chr19:41111297	LTBP4	0.4	6.02	0.31	4.58e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg11845111	chr2:191398756	TMEM194B	0.59	9.82	0.47	3.56e-20	Pulse pressure;
LUSC	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.69	-10.72	-0.51	3.17e-23	Alcohol dependence;
LUSC	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.07	-0.72	2.2e-55	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs34638657	0.500	rs7405197	chr16:82169833	C/A	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.84	-0.35	3.73e-11	Lung adenocarcinoma;
LUSC	cis	rs2795502	0.873	rs2795527	chr10:43270240	T/C	cg20628663	chr10:43360327	NA	-0.64	-8.09	-0.4	1.14e-14	Blood protein levels;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg26005766	chr6:125475650	TPD52L1	0.38	6.11	0.32	2.74e-9	Schizophrenia (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg19867517	chr1:224622813	WDR26	0.69	6.26	0.32	1.19e-9	Cognitive performance;
LUSC	cis	rs240764	0.580	rs4839789	chr6:101233235	T/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.46	-0.33	3.75e-10	Neuroticism;
LUSC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg16586182	chr3:47516702	SCAP	-0.51	-8.0	-0.4	2e-14	Colorectal cancer;
LUSC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg18190219	chr22:46762943	CELSR1	0.49	6.67	0.34	1.04e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2076346	0.638	rs571479	chr1:24053465	A/T	cg10978503	chr1:24200527	CNR2	0.3	5.94	0.31	7.06e-9	Inflammatory skin disease;
LUSC	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.24	0.37	3.07e-12	Morning vs. evening chronotype;
LUSC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg21862992	chr11:68658383	NA	0.52	8.03	0.4	1.63e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.28	-0.32	1.07e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg08888203	chr3:10149979	C3orf24	0.59	7.98	0.4	2.29e-14	Alzheimer's disease;
LUSC	cis	rs11603020	0.950	rs3824988	chr11:57377968	C/T	cg23127183	chr11:57508653	C11orf31	0.45	6.24	0.32	1.34e-9	Blood protein levels;
LUSC	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg26102564	chr10:131424627	MGMT	0.38	5.72	0.3	2.36e-8	Response to temozolomide;
LUSC	cis	rs9309473	0.519	rs6730785	chr2:73642403	A/C	cg20560298	chr2:73613845	ALMS1	0.48	7.4	0.38	1.1e-12	Metabolite levels;
LUSC	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg05855489	chr10:104503620	C10orf26	-0.69	-9.87	-0.48	2.54e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.98	16.79	0.68	2.68e-46	Myeloid white cell count;
LUSC	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg24375607	chr4:120327624	NA	0.69	10.58	0.5	9.19e-23	Corneal astigmatism;
LUSC	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg03948781	chr1:205179583	DSTYK	0.33	6.46	0.33	3.63e-10	Red blood cell count;
LUSC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg04369109	chr6:150039330	LATS1	-0.57	-8.49	-0.42	6.66e-16	Lung cancer;
LUSC	cis	rs61542988	0.570	rs10950919	chr7:22833821	A/G	cg11367502	chr7:22862612	TOMM7	0.48	5.84	0.3	1.27e-8	Fibrinogen levels;
LUSC	cis	rs7582720	1.000	rs75141346	chr2:203685119	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.97	0.4	2.46e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg10247383	chr3:153839028	SGEF	-0.47	-5.79	-0.3	1.61e-8	Coronary artery disease;
LUSC	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg02569458	chr12:86230093	RASSF9	0.48	7.64	0.39	2.37e-13	Major depressive disorder;
LUSC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg22800045	chr5:56110881	MAP3K1	0.77	9.63	0.47	1.5700000000000001e-19	Initial pursuit acceleration;
LUSC	cis	rs72634258	0.945	rs7522911	chr1:8097145	C/T	cg26816564	chr1:7831052	VAMP3	0.49	5.93	0.31	7.64e-9	Inflammatory bowel disease;
LUSC	cis	rs7131987	0.621	rs6487805	chr12:29457550	A/T	cg09582351	chr12:29534625	ERGIC2	0.33	6.63	0.34	1.34e-10	QT interval;
LUSC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg24829409	chr8:58192753	C8orf71	-0.47	-5.71	-0.3	2.49e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg14169450	chr9:139327907	INPP5E	-0.41	-7.35	-0.37	1.54e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs80130819	0.688	rs4760692	chr12:48587549	T/C	cg24011408	chr12:48396354	COL2A1	0.45	5.89	0.31	9.18e-9	Prostate cancer;
LUSC	cis	rs727505	1.000	rs10264060	chr7:124486413	C/A	cg23710748	chr7:124431027	NA	-0.41	-7.46	-0.38	7.78e-13	Lewy body disease;
LUSC	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg10578777	chr12:7781093	NA	0.54	5.96	0.31	6.58e-9	HDL cholesterol levels;
LUSC	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg02018176	chr4:1364513	KIAA1530	0.44	6.02	0.31	4.62e-9	Recombination rate (females);
LUSC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.18	0.58	3.19e-32	Cognitive test performance;
LUSC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg07148914	chr20:33460835	GGT7	0.54	8.25	0.41	3.73e-15	Height;
LUSC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg07473001	chr8:73920952	TERF1	0.5	6.21	0.32	1.56e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg17691542	chr6:26056736	HIST1H1C	0.41	6.05	0.31	3.81e-9	Schizophrenia;
LUSC	cis	rs7106204	0.609	rs12791360	chr11:24286239	T/G	ch.11.24196551F	chr11:24239977	NA	0.69	5.98	0.31	5.82e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg02023728	chr11:77925099	USP35	0.49	6.87	0.35	3.11e-11	Testicular germ cell tumor;
LUSC	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.38	-0.42	1.49e-15	Response to antipsychotic treatment;
LUSC	cis	rs7759001	0.857	rs6903254	chr6:27362359	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg05855489	chr10:104503620	C10orf26	0.53	7.8	0.39	7.97e-14	Arsenic metabolism;
LUSC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.38	-0.42	1.51e-15	Bipolar disorder;
LUSC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.83	10.78	0.51	1.82e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4588572	0.643	rs1019803	chr5:77739154	A/G	cg11547950	chr5:77652471	NA	-0.55	-7.61	-0.38	2.81e-13	Triglycerides;
LUSC	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.71	-0.3	2.47e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs11603020	0.851	rs10896631	chr11:57381263	T/C	cg23127183	chr11:57508653	C11orf31	-0.47	-6.57	-0.34	1.95e-10	Blood protein levels;
LUSC	trans	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg13010199	chr12:38710504	ALG10B	0.46	6.46	0.33	3.7e-10	Resting heart rate;
LUSC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.49	-5.67	-0.3	3.13e-8	Schizophrenia;
LUSC	trans	rs10511400	0.618	rs6438562	chr3:119870132	C/T	cg02809009	chr19:50354510	PTOV1	-0.67	-6.16	-0.32	2.06e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs1775715	0.737	rs2808072	chr10:32205504	A/T	cg18675610	chr10:32216311	ARHGAP12	0.3	6.45	0.33	3.88e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg24060327	chr5:131705240	SLC22A5	0.48	6.72	0.34	8.09e-11	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg26924012	chr15:45694286	SPATA5L1	1.13	20.81	0.75	2.85e-62	Homoarginine levels;
LUSC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg08219700	chr8:58056026	NA	0.47	5.94	0.31	7.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg13560548	chr3:10150139	C3orf24	0.53	7.43	0.38	9.1e-13	Alzheimer's disease;
LUSC	cis	rs4629180	0.675	rs10195061	chr2:102093974	T/G	cg04415270	chr2:102091202	RFX8	-0.46	-7.91	-0.4	3.88e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs4766566	0.609	rs1344438	chr12:111735954	C/G	cg10833066	chr12:111807467	FAM109A	0.55	10.24	0.49	1.39e-21	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUSC	trans	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-6.62	-0.34	1.46e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7131987	0.903	rs7308125	chr12:29425211	T/C	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.63	-0.34	1.34e-10	QT interval;
LUSC	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg24375607	chr4:120327624	NA	0.77	11.4	0.53	1.16e-25	Corneal astigmatism;
LUSC	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg27446573	chr6:127587934	RNF146	0.64	10.41	0.5	3.59e-22	Breast cancer;
LUSC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06873352	chr17:61820015	STRADA	0.56	8.69	0.43	1.7e-16	Height;
LUSC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.72	12.98	0.58	1.83e-31	Prudent dietary pattern;
LUSC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg00815214	chr21:47717953	NA	-0.42	-6.29	-0.33	9.95e-10	Testicular germ cell tumor;
LUSC	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	13.28	0.59	1.28e-32	Total body bone mineral density;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25833238	chr6:153304325	FBXO5	-0.48	-6.72	-0.35	8.08e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18854424	chr1:2615690	NA	0.48	9.39	0.46	9.32e-19	Ulcerative colitis;
LUSC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.44	9.05	0.44	1.2e-17	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs3858145	0.588	rs55888445	chr10:70036456	C/T	cg04882175	chr6:131122610	NA	-0.65	-8.71	-0.43	1.4e-16	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUSC	cis	rs6596100	0.538	rs17594964	chr5:132188712	A/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.02	-0.31	4.6e-9	Breast cancer;
LUSC	cis	rs9400467	0.508	rs11756643	chr6:111726146	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.89	-0.35	2.72e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs11756438	0.572	rs2638552	chr6:118999412	C/T	cg18833306	chr6:118973337	C6orf204	0.36	5.73	0.3	2.2e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7584330	0.554	rs10173100	chr2:238433040	A/G	cg16989719	chr2:238392110	NA	-0.39	-5.69	-0.3	2.79e-8	Prostate cancer;
LUSC	cis	rs2046867	0.818	rs62249879	chr3:72917171	A/G	cg25664220	chr3:72788482	NA	-0.63	-10.42	-0.5	3.27e-22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7084921	0.552	rs2862991	chr10:101876736	C/G	cg02250046	chr10:101825185	CPN1	-0.3	-5.66	-0.3	3.32e-8	Bone mineral density;
LUSC	cis	rs9807841	0.568	rs1560707	chr19:10750738	A/C	cg17710535	chr19:10819994	QTRT1	0.41	6.82	0.35	4.38e-11	Inflammatory skin disease;
LUSC	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg05925327	chr15:68127851	NA	-0.47	-7.35	-0.37	1.54e-12	Restless legs syndrome;
LUSC	cis	rs4629710	0.592	rs13200165	chr6:131549167	G/C	cg12700074	chr6:131571435	AKAP7	-0.36	-6.02	-0.31	4.65e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg27535305	chr1:53392650	SCP2	-0.41	-7.61	-0.38	2.8e-13	Monocyte count;
LUSC	cis	rs11997175	0.546	rs4733448	chr8:33628575	G/A	ch.8.33884649F	chr8:33765107	NA	0.51	8.17	0.41	6.62e-15	Body mass index;
LUSC	cis	rs6815814	0.808	rs11721824	chr4:38767749	G/A	cg02016764	chr4:38805732	TLR1	-0.53	-5.79	-0.3	1.65e-8	Breast cancer;
LUSC	cis	rs886126	0.901	rs4766557	chr12:111664044	G/C	cg10833066	chr12:111807467	FAM109A	0.4	6.36	0.33	6.74e-10	Coronary heart disease;
LUSC	cis	rs7577696	0.626	rs212754	chr2:32421628	A/G	cg02381751	chr2:32503542	YIPF4	0.53	7.1	0.36	7.62e-12	Inflammatory biomarkers;
LUSC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg24060327	chr5:131705240	SLC22A5	0.65	11.23	0.52	4.87e-25	Breast cancer;
LUSC	cis	rs7804356	1.000	rs12536560	chr7:26822876	G/C	cg03456212	chr7:26904342	SKAP2	-0.56	-6.63	-0.34	1.36e-10	Type 1 diabetes;
LUSC	cis	rs4964805	0.802	rs934847	chr12:104185693	C/T	cg02344784	chr12:104178138	NT5DC3	0.44	7.1	0.36	7.43e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg02153584	chr22:29168773	CCDC117	0.66	10.6	0.5	8e-23	Lymphocyte counts;
LUSC	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.47	-6.49	-0.33	3.08e-10	Reticulocyte count;
LUSC	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg04287289	chr16:89883240	FANCA	0.5	7.26	0.37	2.81e-12	Vitiligo;
LUSC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.05	-0.31	3.94e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg12257692	chr3:49977190	RBM6	-0.26	-7.22	-0.37	3.46e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg00945038	chr17:61921165	SMARCD2	0.4	6.02	0.31	4.51e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg18402987	chr7:1209562	NA	0.71	7.53	0.38	4.64e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7605827	0.930	rs3954894	chr2:15517656	T/C	cg19274914	chr2:15703543	NA	0.47	9.2	0.45	4.07e-18	Educational attainment (years of education);
LUSC	cis	rs500891	0.830	rs28360575	chr6:84138270	G/A	cg08257003	chr6:84140564	ME1	0.35	7.27	0.37	2.56e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07157834	chr1:205819609	PM20D1	0.81	13.95	0.61	3.6e-35	Menarche (age at onset);
LUSC	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg05340658	chr4:99064831	C4orf37	0.44	6.88	0.35	3.05e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg21548813	chr6:291882	DUSP22	-0.71	-11.59	-0.54	2.56e-26	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16636153	chr7:5553333	FBXL18	-0.41	-6.28	-0.32	1.04e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg27535305	chr1:53392650	SCP2	-0.36	-6.7	-0.34	8.74e-11	Monocyte count;
LUSC	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg17127132	chr2:85788382	GGCX	0.48	7.67	0.39	1.91e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs3820928	0.839	rs35068645	chr2:227844265	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.4	-0.38	1.13e-12	Pulmonary function;
LUSC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg27170947	chr2:26402098	FAM59B	-0.7	-10.76	-0.51	2.29e-23	Gut microbiome composition (summer);
LUSC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17890828	chr19:36103534	HAUS5	-0.56	-7.02	-0.36	1.23e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg18240062	chr17:79603768	NPLOC4	0.79	15.25	0.64	3.23e-40	Eye color traits;
LUSC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg23283495	chr1:209979779	IRF6	0.73	9.34	0.46	1.37e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg25344623	chr2:136566232	LCT	0.38	5.71	0.3	2.55e-8	Mosquito bite size;
LUSC	cis	rs13242816	1.000	rs34325296	chr7:116122409	C/T	cg16553024	chr7:116138462	CAV2	-0.52	-5.68	-0.3	2.89e-8	P wave duration;
LUSC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg06494592	chr3:125709126	NA	-0.5	-5.77	-0.3	1.86e-8	Blood pressure (smoking interaction);
LUSC	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg02466173	chr16:30829666	NA	-0.53	-10.36	-0.49	5.4e-22	Dementia with Lewy bodies;
LUSC	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg16989719	chr2:238392110	NA	-0.41	-5.75	-0.3	2.01e-8	Prostate cancer;
LUSC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg24733560	chr20:60626293	TAF4	0.43	6.92	0.35	2.25e-11	Body mass index;
LUSC	cis	rs2274273	0.868	rs1572611	chr14:55833874	T/A	cg04306507	chr14:55594613	LGALS3	0.54	11.9	0.55	1.87e-27	Protein biomarker;
LUSC	cis	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg06521331	chr12:34319734	NA	-0.46	-7.53	-0.38	4.69e-13	Morning vs. evening chronotype;
LUSC	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg09184832	chr6:79620586	NA	-0.44	-7.06	-0.36	9.88e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2414856	0.510	rs72758914	chr15:64643203	C/T	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs5769707	0.681	rs739240	chr22:50052607	C/A	cg05373962	chr22:49881684	NA	-0.4	-8.44	-0.42	9.44e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg04455712	chr21:45112962	RRP1B	0.45	8.46	0.42	8.61e-16	Mean corpuscular volume;
LUSC	cis	rs9309473	0.898	rs10197755	chr2:73797623	T/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.53	-0.34	2.47e-10	Metabolite levels;
LUSC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.94	0.4	3.18e-14	Bipolar disorder;
LUSC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	1.05	19.21	0.72	6.06e-56	Parkinson's disease;
LUSC	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg05182265	chr7:156933206	UBE3C	0.48	7.37	0.37	1.33e-12	Body mass index;
LUSC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	1.21	13.5	0.59	1.92e-33	Diabetic kidney disease;
LUSC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg05896524	chr21:47604654	C21orf56	0.4	5.84	0.3	1.24e-8	Testicular germ cell tumor;
LUSC	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg24955955	chr5:415729	AHRR	0.62	5.7	0.3	2.6e-8	Fat distribution (HIV);
LUSC	cis	rs909341	0.810	rs2427529	chr20:62359564	T/A	cg09650180	chr20:62225654	GMEB2	-0.47	-6.11	-0.32	2.75e-9	Atopic dermatitis;
LUSC	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.83	-0.43	6.07e-17	Response to antipsychotic treatment;
LUSC	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg18827107	chr12:86230957	RASSF9	0.45	6.91	0.35	2.45e-11	Major depressive disorder;
LUSC	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.68	-0.47	1.07e-19	Multiple sclerosis;
LUSC	cis	rs9311676	0.632	rs62259779	chr3:58425692	C/G	cg26110898	chr3:58419937	PDHB	0.39	6.33	0.33	7.88e-10	Systemic lupus erythematosus;
LUSC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg15649852	chr7:65879115	NA	-0.41	-5.64	-0.3	3.53e-8	Aortic root size;
LUSC	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg09184832	chr6:79620586	NA	-0.43	-6.96	-0.36	1.83e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.49	-0.33	3.13e-10	Lung cancer;
LUSC	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg07777224	chr19:58919807	ZNF584	-0.43	-5.83	-0.3	1.3e-8	Uric acid clearance;
LUSC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-10.12	-0.48	3.7e-21	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.7	-10.64	-0.5	5.91e-23	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg20135002	chr11:47629003	NA	-0.47	-7.44	-0.38	8.7e-13	Subjective well-being;
LUSC	cis	rs3733631	1.000	rs3796951	chr4:104628158	A/T	cg24090629	chr4:104641072	TACR3	0.45	5.83	0.3	1.29e-8	Menarche (age at onset);
LUSC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg22800045	chr5:56110881	MAP3K1	0.78	9.56	0.46	2.6e-19	Initial pursuit acceleration;
LUSC	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-1.13	-17.73	-0.7	5.05e-50	Exhaled nitric oxide output;
LUSC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg20203395	chr5:56204925	C5orf35	-0.78	-10.4	-0.49	4.07e-22	Initial pursuit acceleration;
LUSC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.71	-12.5	-0.56	1.12e-29	Colorectal cancer;
LUSC	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-6.48	-0.33	3.39e-10	Response to antipsychotic treatment;
LUSC	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg13010199	chr12:38710504	ALG10B	0.42	6.66	0.34	1.13e-10	Morning vs. evening chronotype;
LUSC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg12560992	chr17:57184187	TRIM37	0.84	15.05	0.64	1.94e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs2108225	0.837	rs6959729	chr7:107446180	A/C	cg18560240	chr7:107437656	SLC26A3	-0.47	-7.25	-0.37	2.9e-12	Ulcerative colitis;
LUSC	cis	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg06521331	chr12:34319734	NA	0.4	6.21	0.32	1.62e-9	Morning vs. evening chronotype;
LUSC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	10.66	0.5	4.78e-23	Homoarginine levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20284025	chr1:119683198	WARS2	-0.47	-7.09	-0.36	8.17e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg11245181	chr6:149772854	ZC3H12D	-0.3	-6.62	-0.34	1.46e-10	Dupuytren's disease;
LUSC	cis	rs11997175	0.522	rs10954930	chr8:33588352	C/T	ch.8.33884649F	chr8:33765107	NA	0.49	7.72	0.39	1.33e-13	Body mass index;
LUSC	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.59	0.38	3.3e-13	Corneal astigmatism;
LUSC	cis	rs7247513	0.964	rs12104149	chr19:12721088	A/G	cg01871581	chr19:12707946	ZNF490	-0.61	-9.89	-0.48	2.12e-20	Bipolar disorder;
LUSC	cis	rs7119	0.717	rs12910594	chr15:77817103	G/A	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.47	6.84	0.35	3.69e-11	Schizophrenia;
LUSC	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg20908204	chr19:46285434	DMPK	-0.46	-8.71	-0.43	1.42e-16	Coronary artery disease;
LUSC	cis	rs2692947	0.696	rs1724121	chr2:96808549	T/C	cg22654517	chr2:96458247	NA	0.37	7.39	0.38	1.16e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg19622623	chr12:86230825	RASSF9	0.4	5.72	0.3	2.33e-8	Major depressive disorder;
LUSC	cis	rs4566357	0.595	rs10206912	chr2:227921095	A/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-7.45	-0.38	7.94e-13	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg18402987	chr7:1209562	NA	0.7	7.64	0.39	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg16362232	chr11:430036	ANO9	0.66	8.14	0.41	7.66e-15	Body mass index;
LUSC	cis	rs9308433	0.529	rs4655336	chr1:214499667	A/C	cg06198575	chr1:214491504	SMYD2	0.45	7.06	0.36	9.75e-12	IgG glycosylation;
LUSC	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg05234568	chr11:5960015	NA	-0.6	-8.7	-0.43	1.55e-16	DNA methylation (variation);
LUSC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg17507749	chr15:85114479	UBE2QP1	0.56	6.76	0.35	6.35e-11	Schizophrenia;
LUSC	cis	rs9948	0.786	rs62156227	chr2:97417942	C/A	cg01990225	chr2:97406019	LMAN2L	-0.78	-5.86	-0.31	1.1e-8	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.65	-0.63	6.79e-38	Schizophrenia;
LUSC	cis	rs7940866	0.838	rs1118137	chr11:130890970	G/A	cg12179176	chr11:130786555	SNX19	0.63	9.86	0.47	2.62e-20	Schizophrenia;
LUSC	cis	rs10740039	1.000	rs10821818	chr10:62416936	C/T	cg18175470	chr10:62150864	ANK3	-0.43	-6.8	-0.35	4.8e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3820928	0.874	rs10210963	chr2:227821845	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.67	-0.39	1.95e-13	Pulmonary function;
LUSC	cis	rs1044826	0.597	rs6772199	chr3:139178133	C/T	cg00490450	chr3:139108681	COPB2	0.45	7.05	0.36	1.05e-11	Obesity-related traits;
LUSC	cis	rs56399783	0.901	rs55767077	chr7:2774608	C/T	cg19731401	chr7:2775893	GNA12	0.74	8.92	0.44	3.18e-17	Childhood ear infection;
LUSC	cis	rs11997175	0.574	rs58858314	chr8:33658221	T/C	ch.8.33884649F	chr8:33765107	NA	0.51	8.36	0.42	1.69e-15	Body mass index;
LUSC	trans	rs724744	0.742	rs1205937	chr6:22357993	A/C	cg13807341	chr11:118445984	ARCN1	-0.35	-5.96	-0.31	6.54e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	trans	rs3784262	0.528	rs1994926	chr15:58334587	C/T	cg04124740	chr17:64400691	PRKCA	0.31	5.95	0.31	6.73e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs2224391	0.628	rs2773310	chr6:5250828	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.48	-6.59	-0.34	1.75e-10	Height;
LUSC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg03146154	chr1:46216737	IPP	0.56	8.37	0.42	1.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg19622623	chr12:86230825	RASSF9	-0.44	-6.27	-0.32	1.11e-9	Major depressive disorder;
LUSC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg07703079	chr11:430292	ANO9	0.61	6.64	0.34	1.26e-10	Body mass index;
LUSC	cis	rs10193935	1.000	rs72796507	chr2:42409840	A/G	cg27598129	chr2:42591480	NA	-0.58	-7.8	-0.39	7.83e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg27661571	chr11:113659931	NA	-0.71	-7.94	-0.4	3.05e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg02493740	chr2:85810744	VAMP5	-0.5	-8.67	-0.43	1.92e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6076065	0.723	rs2424552	chr20:23402833	G/A	cg11657817	chr20:23433608	CST11	0.42	7.44	0.38	8.44e-13	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs4629710	0.592	rs11759793	chr6:131546384	G/A	cg12606694	chr6:131520996	AKAP7	0.62	9.44	0.46	6.45e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-17.02	-0.68	3.39e-47	Primary sclerosing cholangitis;
LUSC	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg00745463	chr17:30367425	LRRC37B	0.57	7.2	0.37	4.07e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg14552801	chr7:65878734	NA	-0.37	-5.73	-0.3	2.19e-8	Aortic root size;
LUSC	cis	rs6005807	0.588	rs6519751	chr22:28845498	G/T	cg12565055	chr22:29076175	TTC28	0.48	5.7	0.3	2.65e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs7904985	1.000	rs10887586	chr10:88113521	G/A	cg07322936	chr10:88137208	NA	-0.56	-7.05	-0.36	1.05e-11	Barrett's esophagus;
LUSC	cis	rs6722750	0.782	rs7608530	chr2:64412043	T/A	cg22352474	chr2:64371530	PELI1	-0.5	-7.24	-0.37	3.19e-12	Neuroticism;
LUSC	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg22437258	chr11:111473054	SIK2	0.51	6.91	0.35	2.42e-11	Primary sclerosing cholangitis;
LUSC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19346786	chr7:2764209	NA	-0.49	-8.35	-0.42	1.9e-15	Height;
LUSC	cis	rs9463078	0.526	rs1159131	chr6:44972209	T/C	cg25276700	chr6:44698697	NA	0.29	6.1	0.32	3e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7727544	0.582	rs6896703	chr5:131521295	C/G	cg14196790	chr5:131705035	SLC22A5	-0.48	-7.71	-0.39	1.42e-13	Blood metabolite levels;
LUSC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.98	-0.52	3.66e-24	Alzheimer's disease;
LUSC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg19318889	chr4:1322082	MAEA	-0.48	-7.76	-0.39	1.02e-13	Obesity-related traits;
LUSC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg05623727	chr3:50126028	RBM5	-0.34	-6.24	-0.32	1.34e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg00129232	chr17:37814104	STARD3	-0.5	-7.48	-0.38	6.46e-13	Asthma;
LUSC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.6	-0.43	3.08e-16	Personality dimensions;
LUSC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg13047869	chr3:10149882	C3orf24	0.42	6.44	0.33	4.21e-10	Alzheimer's disease;
LUSC	trans	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.61	-0.43	2.87e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs929596	0.785	rs17862875	chr2:234649302	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.71	-12.11	-0.55	3.22e-28	Total bilirubin levels in HIV-1 infection;
LUSC	trans	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg18187862	chr3:45730750	SACM1L	-0.6	-7.48	-0.38	6.71e-13	Primary sclerosing cholangitis;
LUSC	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg26597838	chr10:835615	NA	0.64	8.05	0.4	1.46e-14	Eosinophil percentage of granulocytes;
LUSC	cis	rs12286929	0.802	rs12787954	chr11:115020328	T/C	cg04055981	chr11:115044050	NA	0.34	5.76	0.3	1.95e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1595825	0.891	rs16866980	chr2:198513009	A/C	cg19156104	chr2:198669113	PLCL1	-0.46	-5.78	-0.3	1.69e-8	Ulcerative colitis;
LUSC	cis	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg02018176	chr4:1364513	KIAA1530	0.43	5.9	0.31	8.71e-9	Recombination rate (females);
LUSC	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg05855489	chr10:104503620	C10orf26	-0.49	-7.47	-0.38	7.25e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1595825	0.679	rs3792157	chr2:198416859	G/A	cg00982548	chr2:198649783	BOLL	-0.52	-5.99	-0.31	5.3e-9	Ulcerative colitis;
LUSC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg22800045	chr5:56110881	MAP3K1	0.61	8.71	0.43	1.45e-16	Initial pursuit acceleration;
LUSC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg00677455	chr12:58241039	CTDSP2	0.59	8.48	0.42	7.35e-16	Multiple sclerosis;
LUSC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg06145435	chr7:1022769	CYP2W1	0.27	5.83	0.3	1.33e-8	Longevity;Endometriosis;
LUSC	trans	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg13010199	chr12:38710504	ALG10B	0.48	7.33	0.37	1.73e-12	Morning vs. evening chronotype;
LUSC	cis	rs244293	0.730	rs9898020	chr17:53057715	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.38	-5.71	-0.3	2.54e-8	Menarche (age at onset);
LUSC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg16506815	chr2:162101123	NA	0.42	6.28	0.32	1.06e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs72634258	0.503	rs697675	chr1:7838113	A/C	cg26816564	chr1:7831052	VAMP3	0.94	13.56	0.6	1.14e-33	Inflammatory bowel disease;
LUSC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg13206674	chr6:150067644	NUP43	0.64	10.44	0.5	2.78e-22	Lung cancer;
LUSC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg06238570	chr21:40685208	BRWD1	-0.58	-9.02	-0.44	1.51e-17	Menarche (age at onset);
LUSC	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg03859395	chr2:55845619	SMEK2	0.88	16.46	0.67	5.44e-45	Metabolic syndrome;
LUSC	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-9.19	-0.45	4.28e-18	Neuroticism;
LUSC	cis	rs77741769	0.549	rs57697145	chr12:121333552	T/G	cg02419362	chr12:121203948	SPPL3	0.46	8.71	0.43	1.42e-16	Mean corpuscular volume;
LUSC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg02475777	chr4:1388615	CRIPAK	0.46	6.77	0.35	5.88e-11	Obesity-related traits;
LUSC	trans	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg18187862	chr3:45730750	SACM1L	-0.61	-7.52	-0.38	5.26e-13	Primary sclerosing cholangitis;
LUSC	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.48	7.92	0.4	3.63e-14	Alcohol dependence;
LUSC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.65	0.39	2.21e-13	Prudent dietary pattern;
LUSC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.29	0.45	2.02e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg07507251	chr3:52567010	NT5DC2	0.43	9.04	0.44	1.26e-17	Electroencephalogram traits;
LUSC	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg05805236	chr11:65401703	PCNXL3	0.39	6.63	0.34	1.33e-10	Acne (severe);
LUSC	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.76	-0.43	9.88e-17	Response to antipsychotic treatment;
LUSC	cis	rs727505	1.000	rs7791430	chr7:124429953	G/T	cg23710748	chr7:124431027	NA	-0.43	-7.72	-0.39	1.33e-13	Lewy body disease;
LUSC	cis	rs4290604	0.748	rs4663241	chr2:238085960	T/C	cg23555395	chr2:238036564	NA	-0.46	-6.23	-0.32	1.4e-9	Asthma;
LUSC	cis	rs2953174	0.744	rs2975748	chr2:241518989	A/G	cg07929629	chr2:241523174	NA	0.54	8.11	0.41	1e-14	Bipolar disorder;
LUSC	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg26195577	chr20:24973756	C20orf3	1.11	18.17	0.71	8.49e-52	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11653406	chr1:40367713	MYCL1	-0.48	-7.1	-0.36	7.7e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.8	-0.39	7.87e-14	Blood metabolite levels;
LUSC	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg05585544	chr11:47624801	NA	-0.35	-6.32	-0.33	8.52e-10	Subjective well-being;
LUSC	cis	rs193541	0.626	rs4343835	chr5:122088731	C/T	cg19077854	chr5:122220652	SNX24	-0.27	-6.14	-0.32	2.31e-9	Glucose homeostasis traits;
LUSC	cis	rs17401966	1.000	rs35766535	chr1:10284659	T/C	cg19773385	chr1:10388646	KIF1B	-0.54	-8.31	-0.41	2.52e-15	Hepatocellular carcinoma;
LUSC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.71	0.51	3.24e-23	Menopause (age at onset);
LUSC	cis	rs559928	1.000	rs72924202	chr11:64133228	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	7.27	0.37	2.53e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4664304	0.772	rs17830558	chr2:160878364	A/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.32	-0.33	8.23e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg12935359	chr14:103987150	CKB	0.65	10.62	0.5	6.78e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg02951883	chr7:2050386	MAD1L1	0.58	10.55	0.5	1.24e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg05855489	chr10:104503620	C10orf26	-0.68	-10.08	-0.48	4.71e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs2514895	0.660	rs56160070	chr11:127112022	C/G	cg22738642	chr12:43137977	NA	0.5	6.26	0.32	1.17e-9	IgG glycosylation;
LUSC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.44	-0.42	9.51e-16	Cystic fibrosis severity;
LUSC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	10.5	0.5	1.8e-22	Bone mineral density;
LUSC	trans	rs890100	0.673	rs10170366	chr2:56662366	A/G	cg01657744	chr10:88471748	LDB3	0.43	5.95	0.31	6.75e-9	Gut microbiome composition (summer);
LUSC	trans	rs61931739	0.513	rs10844698	chr12:33890158	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.8	0.35	4.74e-11	Morning vs. evening chronotype;
LUSC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.49	8.03	0.4	1.74e-14	IgG glycosylation;
LUSC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08439880	chr3:133502540	NA	-0.33	-6.02	-0.31	4.66e-9	Iron status biomarkers;
LUSC	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg27124370	chr19:33622961	WDR88	0.55	7.86	0.39	5.46e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg12386194	chr3:101231763	SENP7	0.53	7.36	0.37	1.45e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg18681998	chr4:17616180	MED28	0.83	14.53	0.62	2.08e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg23283495	chr1:209979779	IRF6	-0.61	-9.05	-0.44	1.17e-17	Cleft lip with or without cleft palate;
LUSC	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg03929089	chr4:120376271	NA	0.74	6.95	0.36	1.87e-11	Axial length;
LUSC	trans	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg26811252	chr16:29126840	RRN3P2	0.59	9.32	0.45	1.63e-18	Menopause (age at onset);
LUSC	cis	rs9311676	0.632	rs1126722	chr3:58413518	T/G	cg26110898	chr3:58419937	PDHB	0.4	6.48	0.33	3.3e-10	Systemic lupus erythematosus;
LUSC	cis	rs4474465	0.850	rs4245460	chr11:78258147	G/C	cg27205649	chr11:78285834	NARS2	0.54	6.32	0.33	8.2e-10	Alzheimer's disease (survival time);
LUSC	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg05855489	chr10:104503620	C10orf26	-0.48	-7.41	-0.38	1.04e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg22823121	chr1:150693482	HORMAD1	0.47	6.66	0.34	1.13e-10	Melanoma;
LUSC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18404041	chr3:52824283	ITIH1	-0.63	-12.4	-0.56	2.57e-29	Bipolar disorder;
LUSC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07157834	chr1:205819609	PM20D1	-0.43	-5.92	-0.31	7.8e-9	Parkinson's disease;
LUSC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.96	0.77	8.44e-67	Prudent dietary pattern;
LUSC	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.68	10.78	0.51	1.93e-23	Total cholesterol levels;
LUSC	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-8.2	-0.41	5.16e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.5	0.59	1.89e-33	Cognitive test performance;
LUSC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.55	-8.13	-0.41	8.73e-15	Platelet count;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11905131	chr22:24372483	LOC391322	-0.61	-10.45	-0.5	2.74e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg13722127	chr7:150037890	RARRES2	0.38	5.8	0.3	1.52e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	5.88	0.31	1.02e-8	Personality dimensions;
LUSC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.82	-13.07	-0.58	8.52e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg11645453	chr3:52864694	ITIH4	0.35	8.08	0.4	1.16e-14	Bipolar disorder;
LUSC	cis	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg21775007	chr8:11205619	TDH	0.44	5.78	0.3	1.7e-8	Neuroticism;
LUSC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg11766577	chr21:47581405	C21orf56	0.47	7.09	0.36	8.02e-12	Testicular germ cell tumor;
LUSC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg02782426	chr3:40428986	ENTPD3	0.39	7.46	0.38	7.62e-13	Renal cell carcinoma;
LUSC	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-0.84	-13.96	-0.61	3.19e-35	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.21	0.59	2.34e-32	Total body bone mineral density;
LUSC	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg03433033	chr1:76189801	ACADM	-0.44	-6.47	-0.33	3.5e-10	Daytime sleep phenotypes;
LUSC	cis	rs2279817	0.955	rs2270977	chr1:18023509	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.46	6.43	0.33	4.39e-10	Neuroticism;
LUSC	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	0.99	19.5	0.73	4.42e-57	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg05868516	chr6:26286170	HIST1H4H	0.35	5.69	0.3	2.8e-8	Educational attainment;
LUSC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg18825076	chr15:78729989	IREB2	0.47	6.4	0.33	5.32e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg17366294	chr4:99064904	C4orf37	0.55	9.59	0.46	2.1e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	0.58	9.34	0.46	1.35e-18	Breast cancer;
LUSC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg14019146	chr3:50243930	SLC38A3	0.31	6.78	0.35	5.6e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs870825	0.929	rs55635512	chr4:185589982	G/T	cg04058563	chr4:185651563	MLF1IP	0.81	10.77	0.51	2e-23	Blood protein levels;
LUSC	cis	rs790123	1.000	rs2650950	chr3:122382048	C/T	cg00926285	chr3:122398533	PARP14	-0.38	-5.87	-0.31	1.06e-8	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.84	15.34	0.64	1.48e-40	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.01	-0.36	1.3e-11	Triglycerides;
LUSC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg10664184	chr19:17420304	DDA1	0.46	5.7	0.3	2.6e-8	Systemic lupus erythematosus;
LUSC	trans	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.09	0.32	3.14e-9	Corneal astigmatism;
LUSC	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg26850624	chr5:429559	AHRR	-0.39	-7.72	-0.39	1.4e-13	Cystic fibrosis severity;
LUSC	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg01620082	chr3:125678407	NA	-0.8	-7.24	-0.37	3.11e-12	Depression;
LUSC	cis	rs35883536	0.609	rs1577513	chr1:101044402	C/A	cg06223162	chr1:101003688	GPR88	0.5	9.38	0.46	1.03e-18	Monocyte count;
LUSC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg08847533	chr14:75593920	NEK9	0.64	10.55	0.5	1.17e-22	Coronary artery disease;
LUSC	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg18002602	chr11:66138449	SLC29A2	0.47	8.52	0.42	5.65e-16	Educational attainment (years of education);
LUSC	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg05555928	chr11:63887634	MACROD1	-0.35	-6.7	-0.34	9.06e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs2587949	0.571	rs2322589	chr3:4229371	G/C	cg15139668	chr4:4577005	NA	-0.42	-6.12	-0.32	2.63e-9	Periodontitis (DPAL);
LUSC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.18	-0.32	1.9e-9	Depression;
LUSC	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg06547715	chr2:218990976	CXCR2	0.33	6.37	0.33	6.09e-10	Ulcerative colitis;
LUSC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg04025307	chr7:1156635	C7orf50	0.42	5.89	0.31	9.54e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-7.93	-0.4	3.42e-14	Morning vs. evening chronotype;
LUSC	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg17507749	chr15:85114479	UBE2QP1	0.65	8.15	0.41	7.64e-15	Schizophrenia;
LUSC	cis	rs4363385	0.510	rs6673356	chr1:153041903	C/T	cg25856811	chr1:152973957	SPRR3	0.36	6.07	0.32	3.56e-9	Inflammatory skin disease;
LUSC	cis	rs56399783	0.901	rs757788	chr7:2836433	A/G	cg19731401	chr7:2775893	GNA12	0.68	9.01	0.44	1.64e-17	Childhood ear infection;
LUSC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg25039879	chr17:56429692	SUPT4H1	0.72	9.25	0.45	2.82e-18	Cognitive test performance;
LUSC	cis	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.8	-0.35	4.96e-11	Morning vs. evening chronotype;
LUSC	cis	rs6977660	1.000	rs7791038	chr7:19798833	G/A	cg07541023	chr7:19748670	TWISTNB	0.58	6.55	0.34	2.16e-10	Thyroid stimulating hormone;
LUSC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg01879757	chr17:41196368	BRCA1	-0.46	-7.13	-0.36	6.39e-12	Menopause (age at onset);
LUSC	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.64	-0.43	2.36e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-5.8	-0.3	1.51e-8	Triglycerides;
LUSC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg00255919	chr5:131827918	IRF1	-0.4	-7.61	-0.38	2.89e-13	Asthma (sex interaction);
LUSC	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg09491104	chr22:46646882	C22orf40	-0.6	-8.59	-0.43	3.3e-16	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6138458	0.717	rs2179732	chr20:25000446	A/T	cg06937882	chr20:24974362	C20orf3	-0.31	-5.66	-0.3	3.2e-8	Blood protein levels;
LUSC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg13319975	chr6:146136371	FBXO30	0.72	11.13	0.52	1.11e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.12	0.32	2.64e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12286929	0.687	rs6589487	chr11:115089927	T/C	cg04055981	chr11:115044050	NA	-0.36	-6.31	-0.33	8.72e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg08508325	chr11:3079039	CARS	-0.51	-12.75	-0.57	1.32e-30	Longevity;
LUSC	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.77	-12.62	-0.57	4.14e-30	Testicular germ cell tumor;
LUSC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg20503657	chr10:835505	NA	0.82	11.71	0.54	8.84e-27	Eosinophil percentage of granulocytes;
LUSC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg25258033	chr6:167368657	RNASET2	0.4	6.02	0.31	4.59e-9	Primary biliary cholangitis;
LUSC	cis	rs290268	0.817	rs291006	chr9:93540244	A/C	cg02608019	chr9:93564028	SYK	0.46	7.36	0.37	1.41e-12	Platelet count;
LUSC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg06742321	chr12:123595122	PITPNM2	0.39	5.74	0.3	2.17e-8	Platelet count;
LUSC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg06238570	chr21:40685208	BRWD1	-0.64	-10.71	-0.51	3.2e-23	Cognitive function;
LUSC	trans	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg18187862	chr3:45730750	SACM1L	-0.55	-6.98	-0.36	1.6e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11608355	0.810	rs12424599	chr12:109866615	A/G	cg05360138	chr12:110035743	NA	0.58	7.44	0.38	8.34e-13	Neuroticism;
LUSC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg00484396	chr16:3507460	NAT15	-0.71	-12.59	-0.57	5.03e-30	Tuberculosis;
LUSC	cis	rs9653442	0.545	rs11681966	chr2:100759457	A/C	cg22139774	chr2:100720529	AFF3	0.41	6.91	0.35	2.51e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9677476	0.779	rs7569597	chr2:232102754	G/A	cg07929768	chr2:232055508	NA	0.36	6.14	0.32	2.28e-9	Food antigen IgG levels;
LUSC	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg23283495	chr1:209979779	IRF6	0.44	7.16	0.36	5.23e-12	Monobrow;
LUSC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg00310523	chr12:86230176	RASSF9	-0.44	-8.28	-0.41	3.05e-15	Major depressive disorder;
LUSC	trans	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg13565492	chr6:43139072	SRF	-0.71	-10.51	-0.5	1.6e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg19622623	chr12:86230825	RASSF9	-0.41	-5.71	-0.3	2.44e-8	Major depressive disorder;
LUSC	cis	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg24375607	chr4:120327624	NA	-0.47	-7.24	-0.37	3.09e-12	Diastolic blood pressure;
LUSC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11764359	chr7:65958608	NA	0.62	9.4	0.46	8.7e-19	Aortic root size;
LUSC	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	6.34	0.33	7.66e-10	Lung cancer in ever smokers;
LUSC	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg05985134	chr18:33552581	C18orf21	0.51	6.9	0.35	2.7e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs11088226	1.000	rs2833888	chr21:33927560	A/G	cg09050820	chr6:167586206	TCP10L2	0.56	7.33	0.37	1.71e-12	Gastritis;
LUSC	trans	rs970548	0.697	rs11239540	chr10:45999209	T/C	cg14222797	chr10:16859974	RSU1	-0.6	-5.96	-0.31	6.36e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg13010199	chr12:38710504	ALG10B	0.54	7.45	0.38	7.8e-13	Resting heart rate;
LUSC	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg02660097	chr11:68866761	NA	0.43	6.07	0.32	3.44e-9	Blond vs. brown hair color;
LUSC	trans	rs4948088	1.000	rs7776597	chr7:51015582	A/G	cg26816907	chr1:197890812	LHX9	0.58	6.46	0.33	3.72e-10	Type 1 diabetes;
LUSC	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg21251018	chr6:28226885	NKAPL	0.34	6.42	0.33	4.73e-10	Pubertal anthropometrics;
LUSC	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.4	-0.38	1.15e-12	Psoriasis;
LUSC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg08798685	chr6:27730294	NA	-0.68	-6.05	-0.31	3.97e-9	Depression;
LUSC	cis	rs829883	0.934	rs249814	chr12:98892964	A/G	cg25150519	chr12:98850993	NA	0.64	9.72	0.47	7.74e-20	Colorectal adenoma (advanced);
LUSC	cis	rs931127	0.547	rs3886859	chr11:65458310	C/T	cg05805236	chr11:65401703	PCNXL3	-0.42	-7.3	-0.37	2.13e-12	Systemic lupus erythematosus;
LUSC	cis	rs2219968	0.923	rs2101106	chr8:78948481	A/C	cg00738934	chr8:78996279	NA	0.37	6.57	0.34	1.93e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs472402	0.623	rs8192130	chr5:6636450	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.53	-7.91	-0.4	3.89e-14	Response to amphetamines;
LUSC	trans	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg26384229	chr12:38710491	ALG10B	0.67	9.4	0.46	8.99e-19	Resting heart rate;
LUSC	cis	rs4664304	0.900	rs3828327	chr2:160742095	G/A	cg23995753	chr2:160760732	LY75	-0.33	-6.06	-0.31	3.61e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	9.57	0.46	2.41e-19	Mood instability;
LUSC	cis	rs2219968	0.961	rs12056471	chr8:78962821	T/C	cg00738934	chr8:78996279	NA	0.34	6.18	0.32	1.89e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7246967	0.673	rs55744741	chr19:22959973	C/T	cg23217946	chr19:22817039	ZNF492	0.43	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg18132916	chr6:79620363	NA	-0.38	-5.74	-0.3	2.18e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	10.55	0.5	1.24e-22	Response to antipsychotic treatment;
LUSC	cis	rs73198271	0.603	rs777705	chr8:8586868	C/T	cg01851573	chr8:8652454	MFHAS1	0.39	6.02	0.31	4.63e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg11812906	chr14:75593930	NEK9	-0.53	-8.56	-0.42	4.33e-16	Coronary artery disease;
LUSC	trans	rs2587949	0.593	rs1872416	chr3:4211269	G/T	cg15139668	chr4:4577005	NA	0.41	6.08	0.32	3.23e-9	Periodontitis (DPAL);
LUSC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg10729496	chr3:10149963	C3orf24	-0.53	-6.63	-0.34	1.36e-10	Alzheimer's disease;
LUSC	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg03929089	chr4:120376271	NA	0.68	7.54	0.38	4.38e-13	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.68	-0.34	1.03e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.65	-0.39	2.21e-13	Longevity;Endometriosis;
LUSC	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7241530	0.610	rs7235552	chr18:75892776	T/G	cg14642773	chr18:75888474	NA	0.37	5.65	0.3	3.53e-8	Educational attainment (years of education);
LUSC	cis	rs757081	0.643	rs665311	chr11:17206740	A/T	cg15432903	chr11:17409602	KCNJ11	-0.38	-5.85	-0.3	1.18e-8	Systolic blood pressure;
LUSC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg14668632	chr7:2872130	GNA12	-0.45	-6.78	-0.35	5.42e-11	Height;
LUSC	trans	rs3857536	0.813	rs2188589	chr6:66939570	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg07395648	chr5:131743802	NA	0.37	5.8	0.3	1.52e-8	Asthma (sex interaction);
LUSC	cis	rs7147624	1.000	rs4902408	chr14:66111901	A/T	cg03016385	chr14:66212404	NA	-0.78	-8.5	-0.42	6.58e-16	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg18721089	chr20:30220636	NA	-0.36	-6.16	-0.32	2.14e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg26513180	chr16:89883248	FANCA	0.61	5.84	0.3	1.22e-8	Skin colour saturation;
LUSC	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.9	-15.29	-0.64	2.14e-40	Schizophrenia;
LUSC	trans	rs2085496	0.764	rs1596751	chr2:193807860	A/G	cg25750719	chr6:26033975	HIST1H2AB	0.37	6.07	0.32	3.52e-9	Neuroticism;
LUSC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg18350739	chr11:68623251	NA	-0.37	-6.69	-0.34	9.24e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs8073060	0.671	rs9894813	chr17:33873848	C/T	cg19694781	chr19:47549865	TMEM160	0.84	12.6	0.57	4.67e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg24562669	chr7:97807699	LMTK2	-0.35	-6.14	-0.32	2.38e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs988712	0.516	rs6484320	chr11:27703188	T/A	cg10635145	chr11:27742435	BDNF	0.46	6.24	0.32	1.36e-9	Obesity;
LUSC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg04850211	chr1:228464232	OBSCN	-0.33	-6.17	-0.32	2.03e-9	Diastolic blood pressure;
LUSC	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg00495681	chr13:53174319	NA	0.55	8.64	0.43	2.39e-16	Lewy body disease;
LUSC	cis	rs11690935	0.550	rs6730085	chr2:172864845	C/A	cg13550731	chr2:172543902	DYNC1I2	0.52	7.81	0.39	7.49e-14	Schizophrenia;
LUSC	cis	rs713477	0.901	rs7146306	chr14:55905853	C/T	cg04306507	chr14:55594613	LGALS3	-0.29	-5.65	-0.3	3.41e-8	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs7188861	0.768	rs181694	chr16:11384829	C/T	cg00044050	chr16:11439710	C16orf75	0.56	6.42	0.33	4.64e-10	HDL cholesterol;
LUSC	cis	rs2219968	0.717	rs4610733	chr8:78914112	T/G	cg00738934	chr8:78996279	NA	-0.4	-7.18	-0.37	4.55e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.03	20.36	0.74	1.73e-60	Cognitive function;
LUSC	trans	rs7939886	0.920	rs17149859	chr11:55795356	G/A	cg15704280	chr7:45808275	SEPT13	0.79	6.74	0.35	7.14e-11	Myopia (pathological);
LUSC	cis	rs1979679	0.608	rs3803087	chr12:28726634	T/C	cg13890972	chr12:28721907	NA	-0.43	-6.24	-0.32	1.31e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg04369109	chr6:150039330	LATS1	-0.58	-8.57	-0.42	4e-16	Lung cancer;
LUSC	cis	rs977987	0.806	rs4888388	chr16:75394148	G/A	cg03315344	chr16:75512273	CHST6	0.48	9.2	0.45	4.05e-18	Dupuytren's disease;
LUSC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	7.16	0.36	5.02e-12	Platelet count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04611479	chr17:41910366	MPP3	-0.41	-6.06	-0.31	3.77e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.73	0.35	7.5e-11	Aortic root size;
LUSC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg06138931	chr13:21896616	NA	0.39	6.62	0.34	1.43e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17509989	chr5:176798049	RGS14	0.68	10.69	0.5	3.87e-23	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7091068	0.518	rs913045	chr10:95431535	C/T	cg20715218	chr10:95462985	C10orf4	0.46	5.88	0.31	1.01e-8	Urinary tract infection frequency;
LUSC	cis	rs9398803	0.865	rs2152876	chr6:126761228	A/G	cg19875578	chr6:126661172	C6orf173	-0.41	-6.09	-0.32	3.17e-9	Male-pattern baldness;
LUSC	trans	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg17294928	chr15:75287854	SCAMP5	0.4	5.65	0.3	3.47e-8	Breast cancer;
LUSC	cis	rs240764	0.817	rs239242	chr6:101092776	C/T	cg09795085	chr6:101329169	ASCC3	0.41	5.99	0.31	5.54e-9	Neuroticism;
LUSC	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg25237894	chr2:233734115	C2orf82	-0.35	-6.58	-0.34	1.84e-10	Coronary artery disease;
LUSC	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.19	-0.32	1.81e-9	Triglycerides;
LUSC	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg15423357	chr2:25149977	NA	0.4	8.02	0.4	1.84e-14	Body mass index;
LUSC	cis	rs7267979	0.789	rs6083810	chr20:25329759	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.77	-15.6	-0.65	1.39e-41	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6076065	1.000	rs2424547	chr20:23392690	A/G	cg11657817	chr20:23433608	CST11	0.44	8.72	0.43	1.34e-16	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg16680214	chr1:154839983	KCNN3	-0.52	-9.74	-0.47	6.53e-20	Prostate cancer;
LUSC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.7	11.44	0.53	8.42e-26	Blood protein levels;
LUSC	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-10.51	-0.5	1.68e-22	Bladder cancer;
LUSC	cis	rs977987	0.815	rs11861810	chr16:75461829	A/G	cg03315344	chr16:75512273	CHST6	0.5	9.56	0.46	2.75e-19	Dupuytren's disease;
LUSC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.44	-6.91	-0.35	2.4e-11	Tonsillectomy;
LUSC	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.83	-0.35	4.11e-11	Monocyte percentage of white cells;
LUSC	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg06191203	chr2:152266755	RIF1	-0.54	-6.92	-0.35	2.26e-11	Lung cancer;
LUSC	cis	rs240764	0.658	rs4839792	chr6:101253788	A/T	cg09795085	chr6:101329169	ASCC3	-0.47	-6.71	-0.34	8.18e-11	Neuroticism;
LUSC	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg08079166	chr15:68083412	MAP2K5	0.41	7.23	0.37	3.29e-12	Restless legs syndrome;
LUSC	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg03684893	chr10:554711	DIP2C	0.4	7.42	0.38	9.74e-13	Psychosis in Alzheimer's disease;
LUSC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg04727924	chr7:799746	HEATR2	-0.51	-6.29	-0.33	9.83e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg04398451	chr17:18023971	MYO15A	0.51	8.17	0.41	6.29e-15	Total body bone mineral density;
LUSC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg24733560	chr20:60626293	TAF4	0.43	7.87	0.4	4.88e-14	Body mass index;
LUSC	trans	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg05839875	chr5:39203190	FYB	-0.31	-5.95	-0.31	6.92e-9	Prostate cancer;
LUSC	cis	rs6906287	0.631	rs9320663	chr6:118986172	A/G	cg21191810	chr6:118973309	C6orf204	0.32	6.05	0.31	3.83e-9	Electrocardiographic conduction measures;
LUSC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg16325326	chr1:53192061	ZYG11B	-0.88	-16.23	-0.66	4.26e-44	Monocyte count;
LUSC	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg23711669	chr6:146136114	FBXO30	-0.81	-14.85	-0.63	1.16e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg15448220	chr1:150897856	SETDB1	0.38	5.69	0.3	2.84e-8	Tonsillectomy;
LUSC	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg16262614	chr3:133464971	TF	0.43	7.51	0.38	5.41e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg15654264	chr1:150340011	RPRD2	0.64	10.58	0.5	9.37e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs73198271	0.515	rs11780216	chr8:8625720	G/T	cg01851573	chr8:8652454	MFHAS1	0.62	7.34	0.37	1.61e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.17	0.45	4.8e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs6565180	0.963	rs4787642	chr16:30359408	T/C	cg17640201	chr16:30407289	ZNF48	-0.85	-14.3	-0.62	1.56e-36	Tonsillectomy;
LUSC	trans	rs11700980	0.551	rs2832028	chr21:30114431	T/C	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.66	8.37	0.42	1.55e-15	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg23625390	chr15:77176239	SCAPER	0.53	8.42	0.42	1.09e-15	Blood metabolite levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22164287	chr1:178995540	FAM20B	-0.41	-6.1	-0.32	2.91e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4474465	1.000	rs1567889	chr11:78147055	A/G	cg27205649	chr11:78285834	NARS2	-0.54	-6.28	-0.32	1.08e-9	Alzheimer's disease (survival time);
LUSC	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg27490568	chr2:178487706	NA	0.38	5.72	0.3	2.39e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg21775007	chr8:11205619	TDH	0.48	6.54	0.34	2.3e-10	Neuroticism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17181325	chr17:1613831	TLCD2	-0.51	-6.76	-0.35	6.09e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-0.98	-18.07	-0.7	2.09e-51	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg15839431	chr19:19639596	YJEFN3	0.66	7.17	0.37	4.73e-12	Bipolar disorder;
LUSC	cis	rs2414856	0.510	rs76861340	chr15:64601854	T/C	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.62	-0.38	2.7e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg00129232	chr17:37814104	STARD3	-0.4	-5.77	-0.3	1.85e-8	Asthma;
LUSC	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg20016023	chr10:99160130	RRP12	-0.33	-8.06	-0.4	1.41e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7914558	0.646	rs7909591	chr10:104659018	G/T	cg05855489	chr10:104503620	C10orf26	0.42	5.76	0.3	1.92e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7192380	0.895	rs2917670	chr16:69758963	T/C	cg26679644	chr16:69762563	NA	-0.34	-5.66	-0.3	3.22e-8	Sjögren's syndrome;
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.67	10.35	0.49	5.63e-22	Lymphocyte counts;
LUSC	trans	rs4729127	1.000	rs17166212	chr7:94008385	A/G	cg20086523	chr13:52378287	DHRS12	0.54	6.31	0.33	9.11e-10	Intelligence;
LUSC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.69	0.34	9.34e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9473147	0.516	rs6931478	chr6:47461913	C/A	cg20196966	chr6:47445060	CD2AP	0.42	5.81	0.3	1.49e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg15687855	chr3:44754131	ZNF502	-0.37	-5.94	-0.31	7.13e-9	Depressive symptoms;
LUSC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.58	-9.25	-0.45	2.82e-18	Prudent dietary pattern;
LUSC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.6e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg21775007	chr8:11205619	TDH	0.43	6.13	0.32	2.46e-9	Mood instability;
LUSC	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg01657329	chr11:68192670	LRP5	0.5	7.5	0.38	5.88e-13	Bone mineral density (spine);
LUSC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg14583973	chr4:3374767	RGS12	0.38	8.2	0.41	5.06e-15	Serum sulfate level;
LUSC	cis	rs56283067	0.578	rs12211510	chr6:45361189	A/G	cg20913747	chr6:44695427	NA	-0.44	-6.42	-0.33	4.68e-10	Total body bone mineral density;
LUSC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg17330251	chr7:94953956	PON1	-0.37	-5.91	-0.31	8.61e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg06238570	chr21:40685208	BRWD1	0.5	7.51	0.38	5.57e-13	Cognitive function;
LUSC	cis	rs9837602	1.000	rs71313585	chr3:99770696	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.26	0.32	1.18e-9	Breast cancer;
LUSC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg23758822	chr17:41437982	NA	1.01	18.64	0.71	1.21e-53	Menopause (age at onset);
LUSC	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg00944433	chr1:107599041	PRMT6	-0.38	-7.07	-0.36	9.07e-12	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg14893161	chr1:205819251	PM20D1	-0.46	-7.02	-0.36	1.28e-11	Menarche (age at onset);
LUSC	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.47	8.3	0.41	2.68e-15	HDL cholesterol;
LUSC	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.65	-7.03	-0.36	1.19e-11	Fibroblast growth factor basic levels;
LUSC	trans	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.98	0.36	1.64e-11	Endometrial cancer;
LUSC	trans	rs72674100	1.000	rs28368345	chr4:97991439	T/C	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg04287289	chr16:89883240	FANCA	0.79	13.83	0.6	1.08e-34	Vitiligo;
LUSC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.2	0.49	1.94e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg04025307	chr7:1156635	C7orf50	0.44	6.87	0.35	3.21e-11	Longevity;Endometriosis;
LUSC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.95	-0.36	1.87e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg06917634	chr15:78832804	PSMA4	0.83	14.99	0.63	3.39e-39	Sudden cardiac arrest;
LUSC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11764359	chr7:65958608	NA	0.63	9.47	0.46	5.1e-19	Aortic root size;
LUSC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.75	-0.8	1.56e-77	Height;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg00024416	chr22:24240387	NA	-0.34	-6.01	-0.31	4.96e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.58	0.46	2.23e-19	Mean corpuscular volume;
LUSC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg09904177	chr6:26538194	HMGN4	0.42	6.16	0.32	2.04e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg26384229	chr12:38710491	ALG10B	0.67	10.54	0.5	1.33e-22	Morning vs. evening chronotype;
LUSC	cis	rs1453414	1	rs1453414	chr11:5829084	G/C	cg05234568	chr11:5960015	NA	-0.52	-5.85	-0.31	1.14e-8	Oral cavity and pharyngeal cancer;Oropharynx cancer;
LUSC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-10.87	-0.51	8.81e-24	Schizophrenia;
LUSC	cis	rs75804782	0.641	rs72987328	chr2:239360097	C/T	cg18131467	chr2:239335373	ASB1	-0.73	-6.63	-0.34	1.36e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs5167	0.777	rs56784978	chr19:45499388	T/C	cg13119609	chr19:45449297	APOC2	0.34	5.83	0.3	1.33e-8	Blood protein levels;
LUSC	trans	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17712092	chr4:129076599	LARP1B	0.71	10.71	0.51	3.3e-23	Eosinophil percentage of white cells;
LUSC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg15445000	chr17:37608096	MED1	0.39	6.7	0.34	9.12e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg17830980	chr10:43048298	ZNF37B	-0.55	-6.39	-0.33	5.49e-10	Obesity (extreme);
LUSC	cis	rs13082711	0.911	rs34098124	chr3:27451242	G/T	cg02860705	chr3:27208620	NA	0.51	8.3	0.41	2.6e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	12.73	0.57	1.55e-30	Personality dimensions;
LUSC	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg08079166	chr15:68083412	MAP2K5	0.4	8.32	0.41	2.28e-15	Restless legs syndrome;
LUSC	cis	rs7113850	0.541	rs7101719	chr11:24234947	T/C	ch.11.24196551F	chr11:24239977	NA	0.97	9.02	0.44	1.53e-17	Bone fracture in osteoporosis;
LUSC	cis	rs2230307	0.536	rs834164	chr1:100603948	A/C	cg24955406	chr1:100503596	HIAT1	-0.59	-6.18	-0.32	1.88e-9	Carotid intima media thickness;
LUSC	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg22431228	chr1:16359049	CLCNKA	0.38	6.9	0.35	2.55e-11	Dilated cardiomyopathy;
LUSC	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02176678	chr2:219576539	TTLL4	0.63	11.63	0.54	1.76e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.76	-0.3	1.9e-8	Monocyte count;
LUSC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg09021430	chr5:549028	NA	-0.54	-7.23	-0.37	3.23e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg11019008	chr10:131425282	MGMT	0.41	5.9	0.31	9.1e-9	Response to temozolomide;
LUSC	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	0.6	9.63	0.47	1.56e-19	Breast cancer;
LUSC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg18758796	chr5:131593413	PDLIM4	0.43	7.43	0.38	9.2e-13	Breast cancer;
LUSC	cis	rs11209002	0.567	rs2755269	chr1:67541065	T/C	cg02640540	chr1:67518911	SLC35D1	0.62	8.53	0.42	5.27e-16	Crohn's disease;
LUSC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg26924012	chr15:45694286	SPATA5L1	1.13	20.23	0.74	5.87e-60	Homoarginine levels;
LUSC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.56	0.46	2.71e-19	Bipolar disorder;
LUSC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg08683831	chr4:1404607	NA	0.36	6.01	0.31	4.87e-9	Obesity-related traits;
LUSC	cis	rs8016982	0.617	rs2241621	chr14:81737076	G/T	cg01989461	chr14:81687754	GTF2A1	-0.63	-10.42	-0.5	3.49e-22	Schizophrenia;
LUSC	cis	rs6733011	0.644	rs6542839	chr2:99464530	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.42	5.79	0.3	1.59e-8	Bipolar disorder;
LUSC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg17150465	chr8:144897558	SCRIB	0.45	6.2	0.32	1.66e-9	Thyroid stimulating hormone;
LUSC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg24060327	chr5:131705240	SLC22A5	0.67	11.07	0.52	1.82e-24	Blood metabolite levels;
LUSC	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg09367891	chr1:107599246	PRMT6	-0.47	-6.9	-0.35	2.64e-11	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg13010199	chr12:38710504	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg12935359	chr14:103987150	CKB	-0.55	-8.44	-0.42	9.86e-16	Body mass index;
LUSC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg13047869	chr3:10149882	C3orf24	-0.6	-8.92	-0.44	3.18e-17	Alzheimer's disease;
LUSC	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg04455712	chr21:45112962	RRP1B	-0.45	-8.16	-0.41	6.89e-15	Mean corpuscular volume;
LUSC	cis	rs865483	0.895	rs2522966	chr17:35816616	A/G	cg06716730	chr17:35851459	DUSP14	-0.27	-6.07	-0.32	3.38e-9	Monocyte count;
LUSC	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg21770322	chr7:97807741	LMTK2	-0.5	-8.23	-0.41	4.36e-15	Breast cancer;
LUSC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.59	9.72	0.47	8.16e-20	Aortic root size;
LUSC	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg05283184	chr6:79620031	NA	-0.58	-11.98	-0.55	9.08e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.72	-12.81	-0.57	7.8e-31	Dental caries;
LUSC	trans	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg06521331	chr12:34319734	NA	-0.39	-6.0	-0.31	5.25e-9	Morning vs. evening chronotype;
LUSC	cis	rs155346	1.000	rs265144	chr5:139397155	A/G	cg01090482	chr5:139365336	NRG2	-0.36	-6.05	-0.31	3.84e-9	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs1322512	0.665	rs2800647	chr6:152931491	C/T	cg27316956	chr6:152958899	SYNE1	-0.35	-5.85	-0.31	1.15e-8	Tonometry;
LUSC	cis	rs1662342	1.000	rs1662342	chr18:3255301	G/A	cg00760847	chr18:3262519	MYL12B	-0.6	-5.82	-0.3	1.39e-8	QRS duration;
LUSC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.7	-10.7	-0.51	3.47e-23	Aortic root size;
LUSC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03352830	chr11:487213	PTDSS2	0.62	7.85	0.39	5.52e-14	Body mass index;
LUSC	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg13072238	chr3:49761600	GMPPB	-0.65	-8.27	-0.41	3.11e-15	Menarche (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03297593	chr15:48470205	MYEF2	0.39	6.06	0.31	3.71e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14442939	chr10:27389572	ANKRD26	0.77	9.47	0.46	5.25e-19	Breast cancer;
LUSC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg12292205	chr6:26970375	C6orf41	0.51	8.57	0.42	3.88e-16	Schizophrenia;
LUSC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg21643547	chr1:205240462	TMCC2	0.42	7.65	0.39	2.23e-13	Red blood cell count;
LUSC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	12.03	0.55	6.02e-28	Monocyte percentage of white cells;
LUSC	cis	rs9905704	0.881	rs302846	chr17:56687536	T/A	cg12560992	chr17:57184187	TRIM37	0.61	8.78	0.43	8.42e-17	Testicular germ cell tumor;
LUSC	trans	rs1015291	0.708	rs1565592	chr12:19997502	T/G	cg01501474	chr7:55323552	NA	-0.45	-5.97	-0.31	6.09e-9	Diastolic blood pressure;
LUSC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg21963583	chr11:68658836	MRPL21	-0.56	-8.74	-0.43	1.16e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7605827	0.866	rs11678132	chr2:15533998	C/T	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-9.58	-0.46	2.35e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.37	-7.91	-0.4	3.84e-14	Dupuytren's disease;
LUSC	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg27411982	chr8:10470053	RP1L1	0.45	7.26	0.37	2.71e-12	Mood instability;
LUSC	cis	rs5756813	0.754	rs4821706	chr22:38154690	A/G	cg06521852	chr22:38141419	TRIOBP	0.44	6.57	0.34	1.92e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs12760731	0.641	rs10494513	chr1:178252377	C/G	cg00404053	chr1:178313656	RASAL2	0.58	6.52	0.34	2.53e-10	Obesity-related traits;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg24491122	chr3:124774370	HEG1	0.4	6.21	0.32	1.55e-9	Schizophrenia;
LUSC	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.7	13.04	0.58	1.07e-31	Platelet distribution width;
LUSC	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg19920283	chr7:105172520	RINT1	0.61	6.43	0.33	4.54e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg02023728	chr11:77925099	USP35	0.44	6.67	0.34	1.03e-10	Testicular germ cell tumor;
LUSC	cis	rs847577	0.569	rs12674083	chr7:97696334	C/T	cg21770322	chr7:97807741	LMTK2	0.53	9.45	0.46	6.18e-19	Breast cancer;
LUSC	cis	rs12295403	0.691	rs12808592	chr11:18677315	G/A	cg09887367	chr11:18690185	NA	-0.34	-6.87	-0.35	3.13e-11	Ovarian reserve;
LUSC	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	7.38	0.37	1.26e-12	Iron status biomarkers;
LUSC	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg24562669	chr7:97807699	LMTK2	0.37	6.41	0.33	4.87e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	7.84	0.39	6.24e-14	Coffee consumption (cups per day);
LUSC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg18402987	chr7:1209562	NA	0.7	7.64	0.39	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs62400317	0.859	rs10948226	chr6:45299174	G/C	cg18551225	chr6:44695536	NA	-0.44	-7.35	-0.37	1.54e-12	Total body bone mineral density;
LUSC	cis	rs7760949	0.963	rs7453814	chr6:13918291	C/G	cg27413430	chr6:13925136	RNF182	0.57	8.56	0.42	4.2e-16	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4499344	0.696	rs2868153	chr19:33099277	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	13.09	0.58	6.76e-32	Mean platelet volume;
LUSC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg20821713	chr7:1055600	C7orf50	-0.49	-5.69	-0.3	2.72e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.87	-0.31	1.07e-8	Platelet count;
LUSC	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg04283868	chr2:201171347	SPATS2L	0.42	6.22	0.32	1.45e-9	QT interval;
LUSC	cis	rs4631830	0.828	rs10763567	chr10:51538169	C/A	cg20129853	chr10:51489980	NA	0.33	6.6	0.34	1.61e-10	Prostate-specific antigen levels;
LUSC	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.1	0.32	2.9e-9	Rheumatoid arthritis;
LUSC	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.51	1.26e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.69	-0.5	3.88e-23	Aortic root size;
LUSC	cis	rs9815354	0.767	rs73079350	chr3:41876310	C/T	cg03022575	chr3:42003672	ULK4	0.85	8.86	0.44	4.85e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg13789015	chr9:136890014	NCRNA00094	0.66	12.25	0.56	9.34e-29	Platelet distribution width;
LUSC	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.08	0.52	1.71e-24	Hypertriglyceridemia;
LUSC	cis	rs11264213	0.901	rs584873	chr1:36431806	C/A	cg27506609	chr1:36549197	TEKT2	0.7	7.98	0.4	2.33e-14	Schizophrenia;
LUSC	cis	rs6967385	0.836	rs62451463	chr7:12359513	T/G	cg06484146	chr7:12443880	VWDE	0.4	5.89	0.31	9.3e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg23950597	chr19:37808831	NA	0.59	6.94	0.35	2.1e-11	Coronary artery calcification;
LUSC	cis	rs7818345	1.000	rs4430112	chr8:19293365	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.37	7.15	0.36	5.62e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs9420	0.961	rs12807250	chr11:57600285	C/T	cg23127183	chr11:57508653	C11orf31	-0.57	-8.77	-0.43	9.53e-17	Schizophrenia;
LUSC	cis	rs7180079	1.000	rs2062249	chr15:64672159	C/A	cg02848875	chr15:64387786	SNX1	0.44	5.68	0.3	2.88e-8	Monocyte count;
LUSC	cis	rs2816316	0.887	rs2760522	chr1:192529414	C/G	cg02586212	chr1:192544902	RGS1	0.31	5.71	0.3	2.56e-8	Celiac disease;
LUSC	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.32	0.45	1.64e-18	Lung cancer in ever smokers;
LUSC	cis	rs3790645	1.000	rs282176	chr1:26898956	T/C	cg17456097	chr1:26900765	RPS6KA1	0.44	6.7	0.34	8.73e-11	Glucose homeostasis traits;
LUSC	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg10560079	chr2:191398806	TMEM194B	-0.51	-6.59	-0.34	1.71e-10	Diastolic blood pressure;
LUSC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg03146154	chr1:46216737	IPP	0.56	8.36	0.42	1.77e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg16049864	chr8:95962084	TP53INP1	0.44	7.47	0.38	7.28e-13	Type 2 diabetes;
LUSC	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg20848291	chr7:100343083	ZAN	0.39	6.14	0.32	2.33e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05776053	chr2:74358815	NA	0.48	7.5	0.38	5.8e-13	Gestational age at birth (maternal effect);
LUSC	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg16584676	chr17:46985605	UBE2Z	0.42	5.81	0.3	1.49e-8	Type 2 diabetes;
LUSC	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21963583	chr11:68658836	MRPL21	0.55	8.57	0.42	3.94e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11997175	0.902	rs7009022	chr8:33700404	A/G	ch.8.33884649F	chr8:33765107	NA	0.42	6.55	0.34	2.2e-10	Body mass index;
LUSC	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg19418458	chr7:158789849	NA	0.48	6.01	0.31	4.75e-9	Facial morphology (factor 20);
LUSC	cis	rs2573652	1.000	rs2727195	chr15:100513117	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.39	-7.17	-0.37	4.87e-12	Height;
LUSC	cis	rs6469656	1.000	rs7843852	chr8:117676506	C/T	cg24004040	chr8:117650383	NA	-0.45	-6.48	-0.33	3.3e-10	Colorectal cancer;
LUSC	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.8	-8.8	-0.43	7.44e-17	Lung cancer in ever smokers;
LUSC	cis	rs72634258	0.945	rs397349	chr1:8074872	A/C	cg26816564	chr1:7831052	VAMP3	0.47	6.52	0.34	2.53e-10	Inflammatory bowel disease;
LUSC	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.21	-0.37	3.66e-12	Type 2 diabetes;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.54	-8.99	-0.44	1.92e-17	Lymphocyte counts;
LUSC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08109568	chr15:31115862	NA	-0.74	-11.09	-0.52	1.47e-24	Huntington's disease progression;
LUSC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2073300	1.000	rs6106656	chr20:23444301	A/G	cg09953122	chr20:23471693	CST8	-0.77	-6.62	-0.34	1.46e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg00343986	chr7:65444356	GUSB	0.47	7.07	0.36	9.11e-12	Aortic root size;
LUSC	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.41	-6.5	-0.33	2.99e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	13.81	0.6	1.2e-34	Platelet count;
LUSC	trans	rs4674124	0.938	rs35956698	chr2:217756348	A/G	cg18563886	chr10:135203102	PAOX	-0.44	-6.07	-0.32	3.56e-9	Breast cancer;
LUSC	cis	rs977987	0.843	rs62062564	chr16:75442622	G/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.04	-0.36	1.09e-11	Dupuytren's disease;
LUSC	cis	rs4786125	0.665	rs7201025	chr16:6920592	C/T	cg03623568	chr16:6915990	A2BP1	-0.5	-8.3	-0.41	2.7e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs2742234	1.000	rs1864395	chr10:43655697	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.37	-6.75	-0.35	6.38e-11	Hirschsprung disease;
LUSC	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg16482183	chr6:26056742	HIST1H1C	0.44	6.59	0.34	1.72e-10	Height;
LUSC	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.26	-0.37	2.65e-12	Bipolar disorder;
LUSC	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg12615879	chr12:58013172	SLC26A10	0.36	8.08	0.4	1.17e-14	Multiple sclerosis;
LUSC	cis	rs950881	0.932	rs72823635	chr2:102931612	T/C	cg20060108	chr2:102954350	IL1RL1	0.48	6.36	0.33	6.7e-10	Allergy;
LUSC	cis	rs2625529	0.730	rs4777485	chr15:72389384	G/C	cg16672083	chr15:72433130	SENP8	-0.51	-8.14	-0.41	8.07e-15	Red blood cell count;
LUSC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.33	-0.33	7.76e-10	Personality dimensions;
LUSC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.41	-6.27	-0.32	1.14e-9	Tonsillectomy;
LUSC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.75	11.95	0.55	1.18e-27	Coronary artery disease;
LUSC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg22907277	chr7:1156413	C7orf50	0.7	10.2	0.49	1.87e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg02018176	chr4:1364513	KIAA1530	0.46	6.45	0.33	3.83e-10	Recombination rate (females);
LUSC	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.57	-0.34	1.92e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7674212	0.539	rs6815783	chr4:104122146	A/C	cg16532752	chr4:104119610	CENPE	-0.47	-6.8	-0.35	4.81e-11	Type 2 diabetes;
LUSC	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17467752	chr17:38218738	THRA	-0.51	-7.11	-0.36	6.9e-12	White blood cell count;
LUSC	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.7	11.72	0.54	8.25e-27	Colorectal cancer;
LUSC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg03146154	chr1:46216737	IPP	0.56	8.34	0.42	2e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg04450456	chr4:17643702	FAM184B	0.39	6.65	0.34	1.21e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg14416269	chr4:6271139	WFS1	0.49	10.35	0.49	5.91e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7945718	0.967	rs1440286	chr11:12809152	G/A	cg25843174	chr11:12811716	TEAD1	0.34	7.59	0.38	3.31e-13	Educational attainment (years of education);
LUSC	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg02175503	chr12:58329896	NA	-0.65	-10.81	-0.51	1.47e-23	Intelligence (multi-trait analysis);
LUSC	trans	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg01596870	chr19:55963115	NA	-0.54	-7.42	-0.38	9.91e-13	Obesity-related traits;
LUSC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg04287289	chr16:89883240	FANCA	0.77	6.23	0.32	1.42e-9	Skin colour saturation;
LUSC	cis	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg07988820	chr12:82153109	PPFIA2	-0.4	-5.76	-0.3	1.96e-8	Resting heart rate;
LUSC	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-7.56	-0.38	3.81e-13	Atrioventricular conduction;
LUSC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21016266	chr12:122356598	WDR66	0.61	9.13	0.45	6.9e-18	Mean corpuscular volume;
LUSC	trans	rs2262909	0.925	rs73019838	chr19:22247732	T/A	cg17074339	chr11:11642133	GALNTL4	0.47	7.17	0.37	4.92e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg21433313	chr16:3507492	NAT15	0.42	5.9	0.31	8.78e-9	Body mass index (adult);
LUSC	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg15017067	chr4:17643749	FAM184B	0.35	5.76	0.3	1.95e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7945705	0.846	rs11042055	chr11:8756856	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.52	9.69	0.47	9.67e-20	Hemoglobin concentration;
LUSC	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg04310649	chr10:35416472	CREM	-0.43	-6.86	-0.35	3.34e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.55	-7.97	-0.4	2.59e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg26120584	chr12:50795366	LARP4	0.35	5.99	0.31	5.55e-9	Triglycerides;
LUSC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-11.29	-0.53	2.99e-25	Chronic sinus infection;
LUSC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg14196790	chr5:131705035	SLC22A5	0.42	7.12	0.36	6.49e-12	Blood metabolite levels;
LUSC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.68	-8.84	-0.44	5.66e-17	Menarche (age at onset);
LUSC	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg08650961	chr10:104748594	CNNM2	0.28	5.93	0.31	7.4e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg04058563	chr4:185651563	MLF1IP	0.9	12.21	0.56	1.33e-28	Blood protein levels;
LUSC	trans	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg06521331	chr12:34319734	NA	-0.39	-5.98	-0.31	5.82e-9	Bladder cancer;
LUSC	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg22029157	chr1:209979665	IRF6	0.79	9.22	0.45	3.43e-18	Cleft lip with or without cleft palate;
LUSC	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-16.13	-0.66	1.07e-43	Exhaled nitric oxide output;
LUSC	cis	rs4077515	0.839	rs10781518	chr9:139300547	C/T	cg14019695	chr9:139328340	INPP5E	-0.42	-7.53	-0.38	4.93e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg05714579	chr10:131428358	MGMT	0.46	6.34	0.33	7.43e-10	Response to temozolomide;
LUSC	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.46	-6.27	-0.32	1.08e-9	Height;
LUSC	trans	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.19	-0.32	1.8e-9	Bladder cancer;
LUSC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg27398817	chr8:82754497	SNX16	0.61	7.65	0.39	2.16e-13	Diastolic blood pressure;
LUSC	cis	rs2573652	1.000	rs2573650	chr15:100514097	A/G	cg09918751	chr15:100517450	ADAMTS17	0.38	6.86	0.35	3.44e-11	Height;
LUSC	cis	rs1144713	0.531	rs1716941	chr12:32255094	A/G	cg01321189	chr12:32259338	BICD1	0.47	6.51	0.34	2.77e-10	Obesity-related traits;
LUSC	cis	rs4474465	0.920	rs7113559	chr11:78205703	T/G	cg27205649	chr11:78285834	NARS2	0.52	6.11	0.32	2.73e-9	Alzheimer's disease (survival time);
LUSC	cis	rs4786125	0.555	rs7196838	chr16:6920457	A/G	cg03623568	chr16:6915990	A2BP1	-0.45	-7.54	-0.38	4.59e-13	Heart rate variability traits (SDNN);
LUSC	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg12935359	chr14:103987150	CKB	0.65	10.5	0.5	1.85e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg04398451	chr17:18023971	MYO15A	0.57	9.53	0.46	3.41e-19	Total body bone mineral density;
LUSC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg03188948	chr7:1209495	NA	0.66	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	8.09	0.4	1.12e-14	Height;
LUSC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg25214090	chr10:38739885	LOC399744	0.54	7.98	0.4	2.39e-14	Corneal astigmatism;
LUSC	cis	rs2290159	0.948	rs5746255	chr3:12624321	A/G	cg23032965	chr3:12705835	RAF1	0.51	6.92	0.35	2.36e-11	Cholesterol, total;
LUSC	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.61	10.58	0.5	9.51e-23	Red cell distribution width;
LUSC	cis	rs67981189	0.613	rs221892	chr14:71611606	C/A	cg15816911	chr14:71606274	NA	-0.35	-6.19	-0.32	1.72e-9	Schizophrenia;
LUSC	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg15309053	chr8:964076	NA	0.33	6.86	0.35	3.33e-11	Schizophrenia;
LUSC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg20887711	chr4:1340912	KIAA1530	0.45	6.68	0.34	9.71e-11	Obesity-related traits;
LUSC	trans	rs7939886	0.920	rs11227212	chr11:55873334	A/G	cg15704280	chr7:45808275	SEPT13	0.79	6.65	0.34	1.23e-10	Myopia (pathological);
LUSC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg25767906	chr1:53392781	SCP2	-0.62	-12.01	-0.55	7.07e-28	Monocyte count;
LUSC	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg17366294	chr4:99064904	C4orf37	0.55	8.62	0.43	2.63e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2835872	0.965	rs1515050	chr21:39003142	T/C	cg20424643	chr21:39039972	KCNJ6	-0.42	-6.36	-0.33	6.7e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05535760	chr7:792225	HEATR2	0.8	9.58	0.46	2.37e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg08975724	chr8:8085496	FLJ10661	0.52	7.7	0.39	1.53e-13	Mood instability;
LUSC	cis	rs9807841	0.538	rs892086	chr19:10837677	C/T	cg17710535	chr19:10819994	QTRT1	0.36	5.85	0.3	1.16e-8	Inflammatory skin disease;
LUSC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg14895029	chr7:2775587	GNA12	-0.42	-6.37	-0.33	6.22e-10	Height;
LUSC	cis	rs10761482	0.500	rs1938524	chr10:62303573	T/A	cg18175470	chr10:62150864	ANK3	-0.47	-6.96	-0.36	1.84e-11	Schizophrenia;
LUSC	cis	rs911119	0.955	rs12625716	chr20:23606845	A/G	cg16589663	chr20:23618590	CST3	-0.61	-7.23	-0.37	3.4e-12	Chronic kidney disease;
LUSC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg25258033	chr6:167368657	RNASET2	0.47	7.99	0.4	2.21e-14	Crohn's disease;
LUSC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-8.59	-0.43	3.46e-16	Schizophrenia;
LUSC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg05084668	chr3:125655381	ALG1L	-0.49	-7.01	-0.36	1.33e-11	Blood pressure (smoking interaction);
LUSC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg18230493	chr5:56204884	C5orf35	-0.78	-12.28	-0.56	7.36e-29	Initial pursuit acceleration;
LUSC	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg21890820	chr11:65308645	LTBP3	0.49	7.16	0.36	5.14e-12	Bone mineral density;
LUSC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg14092988	chr3:52407081	DNAH1	-0.36	-6.94	-0.36	2.02e-11	Bipolar disorder;
LUSC	trans	rs6601327	0.504	rs2048655	chr8:9645562	G/T	cg15556689	chr8:8085844	FLJ10661	0.44	6.03	0.31	4.27e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg09035930	chr12:129282057	SLC15A4	0.74	16.34	0.67	1.65e-44	Systemic lupus erythematosus;
LUSC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-7.77	-0.39	9.74e-14	Longevity;Endometriosis;
LUSC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg26554054	chr8:600488	NA	0.53	5.76	0.3	1.93e-8	IgG glycosylation;
LUSC	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg24634471	chr8:143751801	JRK	0.51	7.21	0.37	3.71e-12	Schizophrenia;
LUSC	cis	rs524023	0.874	rs506338	chr11:64440920	T/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.56	-0.5	1.11e-22	Urate levels in obese individuals;
LUSC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg09359103	chr1:154839909	KCNN3	-0.7	-16.12	-0.66	1.23e-43	Prostate cancer;
LUSC	cis	rs6977660	0.882	rs7781975	chr7:19849629	A/G	cg05791153	chr7:19748676	TWISTNB	0.55	6.21	0.32	1.58e-9	Thyroid stimulating hormone;
LUSC	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.96	-12.45	-0.56	1.77e-29	Exhaled nitric oxide output;
LUSC	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.94	0.35	2.1e-11	Rheumatoid arthritis;
LUSC	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg26384229	chr12:38710491	ALG10B	-0.5	-7.23	-0.37	3.3e-12	Morning vs. evening chronotype;
LUSC	cis	rs751728	0.664	rs747694	chr6:33736490	A/G	cg25922239	chr6:33757077	LEMD2	0.43	6.37	0.33	6.28e-10	Crohn's disease;
LUSC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg24578937	chr1:2090814	PRKCZ	0.46	10.44	0.5	2.8e-22	Height;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg11102611	chr3:182971663	MCF2L2;B3GNT5	0.47	6.33	0.33	7.85e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg23306229	chr2:178417860	TTC30B	0.6	6.97	0.36	1.74e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	1.21	9.66	0.47	1.21e-19	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg09359103	chr1:154839909	KCNN3	-0.69	-15.34	-0.64	1.47e-40	Prostate cancer;
LUSC	cis	rs8092503	1.000	rs35413162	chr18:52498290	C/G	cg12377874	chr18:52495404	RAB27B	0.33	5.71	0.3	2.49e-8	Childhood body mass index;
LUSC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23158103	chr7:148848205	ZNF398	-0.41	-6.56	-0.34	2.09e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10465746	0.967	rs28445286	chr1:84430483	A/G	cg10977910	chr1:84465055	TTLL7	0.43	6.29	0.33	1.01e-9	Obesity-related traits;
LUSC	cis	rs793571	0.590	rs474875	chr15:59086703	A/C	cg05156742	chr15:59063176	FAM63B	0.58	8.84	0.44	5.65e-17	Schizophrenia;
LUSC	cis	rs6840360	0.837	rs4696294	chr4:152713089	C/A	cg22705602	chr4:152727874	NA	0.29	6.28	0.33	1.04e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7113850	0.541	rs7933381	chr11:24237534	T/C	ch.11.24196551F	chr11:24239977	NA	1.0	9.1	0.45	8.45e-18	Bone fracture in osteoporosis;
LUSC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.2	-0.41	5.09e-15	Lung cancer;
LUSC	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg14631576	chr9:95140430	CENPP	-0.34	-6.03	-0.31	4.38e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.71	12.32	0.56	5.43e-29	Mood instability;
LUSC	cis	rs6542838	0.698	rs6732017	chr2:99434381	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-6.74	-0.35	7.13e-11	Fear of minor pain;
LUSC	cis	rs35150201	0.557	rs10258155	chr7:135345319	A/G	cg23117316	chr7:135346802	PL-5283	0.36	7.29	0.37	2.25e-12	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
LUSC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.84	-0.35	3.67e-11	Total body bone mineral density;
LUSC	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg06917634	chr15:78832804	PSMA4	-0.56	-7.11	-0.36	6.93e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.7	-0.39	1.58e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg04450456	chr4:17643702	FAM184B	0.38	6.35	0.33	6.88e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg00033643	chr7:134001901	SLC35B4	0.45	6.82	0.35	4.23e-11	Mean platelet volume;
LUSC	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.31	-5.77	-0.3	1.84e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg18758796	chr5:131593413	PDLIM4	-0.39	-6.18	-0.32	1.89e-9	Breast cancer;
LUSC	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg07549590	chr16:15018862	NA	-0.46	-7.69	-0.39	1.63e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg07080220	chr10:102295463	HIF1AN	0.61	8.15	0.41	7.63e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg03354898	chr7:1950403	MAD1L1	-0.32	-6.3	-0.33	9.32e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg25815440	chr2:42134162	NA	-0.27	-5.95	-0.31	6.65e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08704250	chr15:31115839	NA	-0.59	-9.2	-0.45	3.95e-18	Huntington's disease progression;
LUSC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.01	0.36	1.32e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg17076397	chr5:10353763	MARCH6	0.36	6.44	0.33	4.27e-10	Schizophrenia (age at onset);
LUSC	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg02269571	chr22:50332266	NA	0.37	5.89	0.31	9.28e-9	Schizophrenia;
LUSC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-20.14	-0.74	1.34e-59	Coronary artery disease;
LUSC	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg02660097	chr11:68866761	NA	0.43	6.1	0.32	2.9e-9	Blond vs. brown hair color;
LUSC	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg23625390	chr15:77176239	SCAPER	0.46	7.02	0.36	1.25e-11	Blood metabolite levels;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg27049318	chr5:68514098	MRPS36	0.47	6.65	0.34	1.23e-10	Triglycerides;
LUSC	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg06627628	chr2:24431161	ITSN2	0.51	7.27	0.37	2.53e-12	Asthma;
LUSC	cis	rs3741151	1.000	rs3741149	chr11:73021084	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.9	-8.37	-0.42	1.57e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21842301	chr20:31989203	CDK5RAP1	-0.42	-6.14	-0.32	2.28e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6489882	0.867	rs4766664	chr12:113362997	T/G	cg20102336	chr12:113376681	OAS3	-0.42	-5.93	-0.31	7.58e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg14689365	chr7:158441557	NCAPG2	0.51	7.4	0.38	1.13e-12	Height;
LUSC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06481639	chr22:41940642	POLR3H	-0.54	-6.46	-0.33	3.63e-10	Vitiligo;
LUSC	trans	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg06606381	chr12:133084897	FBRSL1	0.65	7.08	0.36	8.52e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4409675	0.576	rs7536088	chr1:28234325	A/G	cg23691781	chr1:28212827	C1orf38	0.33	7.64	0.39	2.31e-13	Corneal astigmatism;
LUSC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg16586182	chr3:47516702	SCAP	0.5	7.85	0.39	5.59e-14	Colorectal cancer;
LUSC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	0.94	13.9	0.61	5.76e-35	Vitiligo;
LUSC	cis	rs977987	0.778	rs12929908	chr16:75462071	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.39e-11	Dupuytren's disease;
LUSC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.95	15.5	0.65	3.26e-41	Coronary artery disease;
LUSC	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg08645402	chr16:4508243	NA	0.52	8.37	0.42	1.59e-15	Schizophrenia;
LUSC	cis	rs12912251	1.000	rs2172835	chr15:38990171	C/T	cg01338139	chr15:38987640	C15orf53	-0.48	-6.54	-0.34	2.38e-10	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg14983838	chr19:29218262	NA	0.65	8.85	0.44	5.33e-17	Methadone dose in opioid dependence;
LUSC	cis	rs11608355	1.000	rs930356	chr12:109852372	T/C	cg19025524	chr12:109796872	NA	-0.4	-6.35	-0.33	7.14e-10	Neuroticism;
LUSC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg12927641	chr6:109611667	NA	-0.43	-7.5	-0.38	5.64e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg19318889	chr4:1322082	MAEA	0.43	6.91	0.35	2.44e-11	Obesity-related traits;
LUSC	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg15790184	chr11:494944	RNH1	0.5	7.41	0.38	1.03e-12	Systemic lupus erythematosus;
LUSC	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg00898013	chr13:113819073	PROZ	-0.57	-8.06	-0.4	1.38e-14	Platelet distribution width;
LUSC	trans	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.33	0.49	6.61e-22	Mean corpuscular volume;
LUSC	cis	rs1062746	0.528	rs891092	chr16:87338226	G/A	cg02258303	chr16:87377426	FBXO31	-0.56	-9.01	-0.44	1.66e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs793571	0.590	rs442495	chr15:59022615	T/C	cg05156742	chr15:59063176	FAM63B	0.51	7.57	0.38	3.79e-13	Schizophrenia;
LUSC	cis	rs2046867	0.774	rs9820293	chr3:72876237	T/A	cg25664220	chr3:72788482	NA	-0.67	-11.7	-0.54	9.78e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg04586622	chr2:25135609	ADCY3	0.32	6.18	0.32	1.92e-9	Body mass index;
LUSC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg14552801	chr7:65878734	NA	-0.43	-6.13	-0.32	2.45e-9	Aortic root size;
LUSC	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg16579770	chr16:72058938	DHODH	0.34	5.74	0.3	2.11e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg04518342	chr5:131593106	PDLIM4	0.4	7.56	0.38	3.91e-13	Blood metabolite levels;
LUSC	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.69	-0.6	3.63e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2279817	0.775	rs35493100	chr1:17993120	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.49	-6.0	-0.31	5.24e-9	Neuroticism;
LUSC	cis	rs6669072	0.647	rs2954561	chr1:91240853	G/A	cg08895590	chr1:91227319	NA	-0.39	-8.68	-0.43	1.81e-16	Cognitive function;
LUSC	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-0.74	-11.77	-0.54	5.68e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg18187862	chr3:45730750	SACM1L	-0.66	-8.79	-0.43	7.96e-17	Primary sclerosing cholangitis;
LUSC	cis	rs968451	1.000	rs62228376	chr22:39701097	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	9.0	0.44	1.8e-17	Primary biliary cholangitis;
LUSC	trans	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg27121462	chr16:89883253	FANCA	0.53	8.48	0.42	7.58e-16	Vitiligo;
LUSC	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.45	0.75	7.97e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg07777115	chr5:623756	CEP72	-0.46	-5.86	-0.31	1.09e-8	Obesity-related traits;
LUSC	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-16.63	-0.67	1.16e-45	Exhaled nitric oxide output;
LUSC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg21573476	chr21:45109991	RRP1B	-0.38	-6.13	-0.32	2.51e-9	Mean corpuscular volume;
LUSC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.67	11.95	0.55	1.19e-27	Aortic root size;
LUSC	trans	rs7710178	0.617	rs11951246	chr5:155987523	C/T	cg05087909	chr2:9771142	YWHAQ	-0.52	-6.03	-0.31	4.39e-9	Airway responsiveness in chronic obstructive pulmonary disease;
LUSC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg27266027	chr21:40555129	PSMG1	0.4	5.95	0.31	6.66e-9	Cognitive function;
LUSC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02187348	chr16:89574699	SPG7	0.64	10.59	0.5	8.86e-23	Multiple myeloma (IgH translocation);
LUSC	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg08824895	chr13:115047677	UPF3A	0.55	8.42	0.42	1.09e-15	Schizophrenia;
LUSC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.61	7.59	0.38	3.2e-13	Lung function (FEV1/FVC);
LUSC	cis	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg06521331	chr12:34319734	NA	-0.45	-7.38	-0.37	1.29e-12	Morning vs. evening chronotype;
LUSC	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs6901250	0.851	rs339360	chr6:117160872	G/T	cg12892004	chr6:117198278	RFX6	-0.44	-8.24	-0.41	4e-15	C-reactive protein levels;
LUSC	cis	rs4363385	0.818	rs378010	chr1:153007987	A/G	cg25856811	chr1:152973957	SPRR3	-0.35	-5.87	-0.31	1.04e-8	Inflammatory skin disease;
LUSC	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.2e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg20734569	chr3:48348370	SPINK8	-0.47	-8.17	-0.41	6.44e-15	Coronary artery disease;
LUSC	cis	rs11756438	0.547	rs1343287	chr6:119001805	T/C	cg18833306	chr6:118973337	C6orf204	0.36	5.75	0.3	2.04e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg13160058	chr8:26243215	BNIP3L	0.4	7.27	0.37	2.58e-12	Red cell distribution width;
LUSC	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-10.09	-0.48	4.38e-21	Monocyte count;
LUSC	cis	rs10392	0.543	rs4812333	chr20:37536119	T/A	cg27552599	chr20:37590471	DHX35	0.41	6.56	0.34	2.03e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	trans	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6601327	0.670	rs6990418	chr8:9422006	C/G	cg06636001	chr8:8085503	FLJ10661	0.44	6.12	0.32	2.62e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg27398817	chr8:82754497	SNX16	-0.46	-6.17	-0.32	1.96e-9	Diastolic blood pressure;
LUSC	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg08773314	chr2:239334832	ASB1	0.42	9.08	0.45	9.38e-18	Multiple system atrophy;
LUSC	cis	rs1044826	0.642	rs1080371	chr3:139210894	C/T	cg15131784	chr3:139108705	COPB2	0.4	6.38	0.33	6.03e-10	Obesity-related traits;
LUSC	cis	rs16854884	0.657	rs13078840	chr3:143700753	A/G	cg06585982	chr3:143692056	C3orf58	0.45	6.86	0.35	3.29e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs12165098	0.516	rs11082127	chr18:36744599	A/G	cg23858286	chr9:138135095	NA	-0.42	-6.16	-0.32	2.1e-9	Sleep duration;
LUSC	cis	rs9311676	0.656	rs11915480	chr3:58377159	A/G	cg26110898	chr3:58419937	PDHB	0.4	6.65	0.34	1.23e-10	Systemic lupus erythematosus;
LUSC	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg17507749	chr15:85114479	UBE2QP1	0.56	6.96	0.36	1.8e-11	Schizophrenia;
LUSC	cis	rs2625529	0.824	rs2279283	chr15:72243666	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-7.08	-0.36	8.38e-12	Red blood cell count;
LUSC	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.8e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.04	0.36	1.09e-11	Platelet count;
LUSC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg18512352	chr11:47633146	NA	-0.47	-9.6	-0.46	2.03e-19	Subjective well-being;
LUSC	cis	rs7577696	0.962	rs11681731	chr2:32345325	A/T	cg02381751	chr2:32503542	YIPF4	-0.4	-5.66	-0.3	3.23e-8	Inflammatory biomarkers;
LUSC	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.88	-0.31	9.79e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg20129853	chr10:51489980	NA	0.36	7.4	0.38	1.14e-12	Prostate-specific antigen levels;
LUSC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.49	0.46	4.51e-19	Bipolar disorder;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-0.44	-7.36	-0.37	1.43e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9943753	0.508	rs5013021	chr12:109790752	C/A	cg19025524	chr12:109796872	NA	-0.38	-6.89	-0.35	2.82e-11	HDL cholesterol;
LUSC	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	0.88	13.29	0.59	1.19e-32	Blood protein levels;
LUSC	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.53	-0.38	4.91e-13	Retinal vascular caliber;
LUSC	cis	rs7589342	0.628	rs11886675	chr2:106409118	G/T	cg14210321	chr2:106509881	NCK2	-0.46	-5.87	-0.31	1.04e-8	Addiction;
LUSC	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg04352962	chr1:209979756	IRF6	0.52	6.16	0.32	2.13e-9	Cleft lip with or without cleft palate;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11747516	chr1:2518503	C1orf93	-0.4	-6.01	-0.31	4.78e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7523273	0.606	rs2724387	chr1:207932617	T/G	cg22525895	chr1:207977042	MIR29B2	0.41	6.66	0.34	1.14e-10	Schizophrenia;
LUSC	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg24642439	chr20:33292090	TP53INP2	0.5	7.56	0.38	3.81e-13	Height;
LUSC	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.23	-0.49	1.53e-21	Eye color traits;
LUSC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.92	-0.31	8e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.89	-0.31	9.56e-9	Tonsillectomy;
LUSC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg03146154	chr1:46216737	IPP	0.55	8.25	0.41	3.82e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-6.19	-0.32	1.76e-9	Testicular germ cell tumor;
LUSC	cis	rs911119	1.000	rs6048956	chr20:23609301	C/T	cg16589663	chr20:23618590	CST3	0.59	6.96	0.36	1.8e-11	Chronic kidney disease;
LUSC	trans	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg10756647	chr7:56101905	PSPH	-0.87	-8.66	-0.43	2.02e-16	Diabetic kidney disease;
LUSC	cis	rs4792901	0.722	rs12603085	chr17:41545847	G/A	cg22562494	chr17:41607896	ETV4	-0.32	-6.02	-0.31	4.69e-9	Dupuytren's disease;
LUSC	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.61	9.64	0.47	1.49e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9807989	0.811	rs11688573	chr2:102969971	C/A	cg09003973	chr2:102972529	NA	0.44	6.04	0.31	4.15e-9	Asthma;
LUSC	cis	rs2629751	0.512	rs2723845	chr12:104446721	T/C	cg14987745	chr12:104360022	TDG	-0.7	-8.37	-0.42	1.54e-15	Hepatitis C induced liver fibrosis;
LUSC	cis	rs4561483	0.801	rs33620	chr16:12008546	C/G	cg08843971	chr16:11963173	GSPT1	-0.49	-7.46	-0.38	7.71e-13	Testicular germ cell tumor;
LUSC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03352830	chr11:487213	PTDSS2	0.69	8.64	0.43	2.43e-16	Body mass index;
LUSC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg05025164	chr4:1340916	KIAA1530	0.42	6.23	0.32	1.39e-9	Obesity-related traits;
LUSC	cis	rs16854884	0.586	rs6796460	chr3:143756367	G/A	cg06585982	chr3:143692056	C3orf58	0.51	8.26	0.41	3.45e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs754466	1.000	rs2278218	chr10:79680399	G/A	cg17075019	chr10:79541650	NA	-0.64	-8.4	-0.42	1.32e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.46	7.19	0.37	4.18e-12	Response to antipsychotic treatment;
LUSC	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.2	-0.32	1.62e-9	Bipolar disorder;
LUSC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.3	6.69	0.34	9.4e-11	Coronary artery disease;
LUSC	cis	rs4704187	0.687	rs4361493	chr5:74405097	A/G	cg03227963	chr5:74354835	NA	0.33	7.07	0.36	8.83e-12	Response to amphetamines;
LUSC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03576123	chr11:487126	PTDSS2	-1.1	-11.52	-0.53	4.56e-26	Body mass index;
LUSC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg09165964	chr15:75287851	SCAMP5	-0.48	-7.16	-0.36	5.05e-12	Breast cancer;
LUSC	cis	rs2285947	1.000	rs6970985	chr7:21583597	G/T	cg04471919	chr7:21584483	DNAH11	0.34	7.73	0.39	1.29e-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	cis	rs6500395	1.000	rs7195684	chr16:48710750	G/A	cg04672837	chr16:48644449	N4BP1	-0.47	-6.98	-0.36	1.62e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.48	-7.14	-0.36	5.89e-12	Melanoma;
LUSC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg01475377	chr6:109611718	NA	-0.46	-8.44	-0.42	1e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs10426930	0.671	rs57900491	chr19:4995295	A/T	cg25246084	chr19:4971487	KDM4B	-0.34	-6.19	-0.32	1.76e-9	Monocyte percentage of white cells;
LUSC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-7.86	-0.4	5.19e-14	Total body bone mineral density;
LUSC	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.08	13.44	0.59	3.21e-33	Sexual dysfunction (female);
LUSC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg13607699	chr17:42295918	UBTF	0.75	13.68	0.6	3.96e-34	Total body bone mineral density;
LUSC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.56	0.42	4.06e-16	Motion sickness;
LUSC	cis	rs8077889	0.719	rs4793033	chr17:41879627	C/T	cg26893861	chr17:41843967	DUSP3	1.0	18.88	0.72	1.29e-54	Triglycerides;
LUSC	cis	rs921665	0.680	rs4411731	chr2:3189324	C/A	cg16434511	chr2:3151078	NA	-0.63	-6.78	-0.35	5.3e-11	World class endurance athleticism;
LUSC	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-1.01	-14.37	-0.62	8.5e-37	Exhaled nitric oxide output;
LUSC	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg05347473	chr6:146136440	FBXO30	0.52	8.62	0.43	2.82e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg04166393	chr7:2884313	GNA12	0.46	6.03	0.31	4.26e-9	Height;
LUSC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg24675056	chr1:15929824	NA	0.44	7.65	0.39	2.11e-13	Systolic blood pressure;
LUSC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	0.92	16.06	0.66	2.14e-43	Menopause (age at onset);
LUSC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03517284	chr6:25882590	NA	-0.52	-9.67	-0.47	1.16e-19	Blood metabolite levels;
LUSC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	0.94	13.57	0.6	1.01e-33	Vitiligo;
LUSC	trans	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg07461501	chr17:79650226	HGS;ARL16	0.62	8.4	0.42	1.28e-15	Obesity-related traits;
LUSC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg26380479	chr7:97908229	NA	-0.28	-6.27	-0.32	1.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.46e-35	Breast cancer;
LUSC	cis	rs887829	0.570	rs4347832	chr2:234593041	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.38	-6.16	-0.32	2.13e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg11752832	chr7:134001865	SLC35B4	0.55	8.46	0.42	8.45e-16	Mean platelet volume;
LUSC	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.11	-0.64	1.09e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg17633681	chr16:88106987	BANP	0.53	10.16	0.49	2.64e-21	Menopause (age at onset);
LUSC	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg08917208	chr2:24149416	ATAD2B	0.87	9.73	0.47	7.07e-20	Lymphocyte counts;
LUSC	cis	rs7512552	0.803	rs9436127	chr1:150490565	G/A	cg15654264	chr1:150340011	RPRD2	0.6	9.71	0.47	8.82e-20	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.55	8.31	0.41	2.49e-15	Colorectal cancer;
LUSC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg10556349	chr10:835070	NA	0.59	6.55	0.34	2.24e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg18478394	chr8:109455254	TTC35	0.42	6.47	0.33	3.57e-10	Dupuytren's disease;
LUSC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg22963979	chr7:1858916	MAD1L1	-0.65	-10.71	-0.51	3.4e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg11861562	chr11:117069780	TAGLN	0.45	8.16	0.41	6.97e-15	Blood protein levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04346879	chr19:4402785	CHAF1A	-0.5	-6.05	-0.31	3.83e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-6.61	-0.34	1.56e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg16797656	chr11:68205561	LRP5	0.37	6.16	0.32	2.13e-9	Total body bone mineral density;
LUSC	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg16482183	chr6:26056742	HIST1H1C	0.64	9.02	0.44	1.49e-17	Iron status biomarkers;
LUSC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.66	0.6	4.84e-34	Platelet count;
LUSC	trans	rs10517480	0.806	rs9996588	chr4:60764949	G/A	cg15257681	chr4:727544	PCGF3	0.35	5.97	0.31	5.93e-9	Metabolite levels;
LUSC	cis	rs524023	1.000	rs505802	chr11:64357072	T/C	cg19131476	chr11:64387923	NRXN2	0.37	9.91	0.48	1.88e-20	Urate levels in obese individuals;
LUSC	trans	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg17567195	chr5:167378696	ODZ2	-0.39	-6.24	-0.32	1.35e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7202877	0.706	rs11149812	chr16:75323645	T/C	cg03315344	chr16:75512273	CHST6	0.42	6.19	0.32	1.72e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs2692947	0.673	rs2692894	chr2:96784934	T/G	cg22654517	chr2:96458247	NA	-0.31	-5.84	-0.3	1.23e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.89	12.61	0.57	4.5e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg21775007	chr8:11205619	TDH	-0.45	-6.51	-0.34	2.82e-10	Joint mobility (Beighton score);
LUSC	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.38	-0.37	1.27e-12	Bipolar disorder;
LUSC	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg03806693	chr22:41940476	POLR3H	0.86	12.66	0.57	2.85e-30	Vitiligo;
LUSC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg03676636	chr4:99064102	C4orf37	0.35	7.66	0.39	2.01e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg22467129	chr15:76604101	ETFA	-0.45	-7.19	-0.37	4.36e-12	Blood metabolite levels;
LUSC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.71	11.17	0.52	8.16e-25	Methadone dose in opioid dependence;
LUSC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.87	0.31	1.03e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7580658	0.895	rs7589451	chr2:128128775	T/C	cg09760422	chr2:128146352	NA	-0.29	-6.26	-0.32	1.18e-9	Protein C levels;
LUSC	cis	rs2011503	0.509	rs10403579	chr19:19770329	T/C	cg11584989	chr19:19387371	SF4	0.51	5.72	0.3	2.37e-8	Bipolar disorder;
LUSC	cis	rs4478858	0.735	rs7547897	chr1:31797593	G/A	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18876405	chr7:65276391	NA	-0.54	-8.57	-0.42	3.82e-16	Aortic root size;
LUSC	trans	rs9929218	0.911	rs4783686	chr16:68834156	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.21	-0.52	5.78e-25	Colorectal cancer;
LUSC	cis	rs737008	1.000	rs737008	chr16:11374866	G/T	cg00044050	chr16:11439710	C16orf75	-0.52	-7.88	-0.4	4.65e-14	Obesity-related traits;
LUSC	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg18825076	chr15:78729989	IREB2	0.46	6.45	0.33	4.04e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14159672	chr1:205819179	PM20D1	0.53	8.71	0.43	1.39e-16	Menarche (age at onset);
LUSC	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.41	0.53	1.1e-25	Eye color traits;
LUSC	cis	rs10875746	0.551	rs2054903	chr12:48724493	C/T	cg13454099	chr12:49076203	C12orf41	-0.51	-5.65	-0.3	3.52e-8	Longevity (90 years and older);
LUSC	cis	rs10887741	0.690	rs4934357	chr10:89439533	G/A	cg13926569	chr10:89418898	PAPSS2	0.34	7.42	0.38	9.91e-13	Exercise (leisure time);
LUSC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg13206674	chr6:150067644	NUP43	0.56	8.89	0.44	3.91e-17	Lung cancer;
LUSC	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg20016023	chr10:99160130	RRP12	-0.37	-8.72	-0.43	1.36e-16	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs1541010	0.762	rs7912523	chr10:13767732	C/G	cg04685003	chr17:57696515	CLTC	0.43	6.21	0.32	1.59e-9	RR interval (heart rate);
LUSC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg24531977	chr5:56204891	C5orf35	-0.56	-8.52	-0.42	5.75e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.9	-10.62	-0.5	6.81e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs10823500	0.604	rs10762345	chr10:71939374	A/G	cg26699283	chr10:71892715	AIFM2	-0.38	-6.18	-0.32	1.92e-9	Blood protein levels;
LUSC	cis	rs4363385	0.818	rs1750309	chr1:153013630	G/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.71	-0.39	1.41e-13	Inflammatory skin disease;
LUSC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07167872	chr1:205819463	PM20D1	0.53	9.11	0.45	7.48e-18	Menarche (age at onset);
LUSC	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg01579765	chr21:45077557	HSF2BP	-0.48	-9.94	-0.48	1.41e-20	Mean corpuscular volume;
LUSC	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-7.17	-0.37	4.83e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg26597838	chr10:835615	NA	0.84	11.66	0.54	1.33e-26	Eosinophil percentage of granulocytes;
LUSC	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.44	-6.19	-0.32	1.77e-9	Insulin-like growth factors;
LUSC	cis	rs17253792	0.915	rs79100824	chr14:56179606	C/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.86	-0.35	3.35e-11	Putamen volume;
LUSC	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.7	-0.47	8.88e-20	Coronary artery disease;
LUSC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg00431813	chr7:1051703	C7orf50	-0.43	-6.99	-0.36	1.5e-11	Longevity;Endometriosis;
LUSC	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg17691542	chr6:26056736	HIST1H1C	0.54	7.51	0.38	5.48e-13	Iron status biomarkers;
LUSC	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.46	6.36	0.33	6.49e-10	Multiple sclerosis;
LUSC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg16049864	chr8:95962084	TP53INP1	-0.49	-8.77	-0.43	9.11e-17	Type 2 diabetes;
LUSC	cis	rs1595825	0.891	rs4422151	chr2:198544183	A/T	cg00982548	chr2:198649783	BOLL	-0.56	-6.94	-0.35	2.09e-11	Ulcerative colitis;
LUSC	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg21466736	chr12:48725269	NA	-0.32	-5.65	-0.3	3.49e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs56077333	1	rs56077333	chr15:78899003	C/A	cg18825076	chr15:78729989	IREB2	-0.52	-8.05	-0.4	1.45e-14	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1784581	0.722	rs1621456	chr6:162399985	C/T	cg17173639	chr6:162384350	PARK2	-0.66	-11.63	-0.54	1.74e-26	Itch intensity from mosquito bite;
LUSC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.19	0.37	4.33e-12	Motion sickness;
LUSC	cis	rs4654899	0.758	rs9426652	chr1:21458151	G/A	cg01072550	chr1:21505969	NA	-0.53	-7.99	-0.4	2.16e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg00277334	chr10:82204260	NA	-0.5	-7.16	-0.36	5.24e-12	Post bronchodilator FEV1;
LUSC	trans	rs9944715	0.954	rs8094706	chr18:43770146	A/G	cg01718231	chr17:29326311	RNF135	-0.48	-7.15	-0.36	5.52e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg02772935	chr3:125709198	NA	-0.47	-6.04	-0.31	4.14e-9	Blood pressure (smoking interaction);
LUSC	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg05347473	chr6:146136440	FBXO30	0.4	6.78	0.35	5.5e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs909341	0.909	rs2427530	chr20:62361737	G/A	cg09650180	chr20:62225654	GMEB2	-0.47	-6.11	-0.32	2.75e-9	Atopic dermatitis;
LUSC	cis	rs7107174	1.000	rs2510048	chr11:77987464	T/C	cg02023728	chr11:77925099	USP35	0.48	6.82	0.35	4.26e-11	Testicular germ cell tumor;
LUSC	cis	rs68170813	0.559	rs79778437	chr7:107004972	T/A	cg02696742	chr7:106810147	HBP1	-0.61	-9.29	-0.45	2.08e-18	Coronary artery disease;
LUSC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg13319975	chr6:146136371	FBXO30	0.49	7.47	0.38	7.15e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.7	-12.18	-0.55	1.72e-28	White blood cell count (basophil);
LUSC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg05754148	chr16:3507555	NAT15	0.8	9.8	0.47	4.18e-20	Tuberculosis;
LUSC	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-8.0	-0.4	2.05e-14	Lymphocyte counts;
LUSC	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.69	-10.98	-0.52	3.69e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs225245	0.694	rs321616	chr17:33882720	C/T	cg19694781	chr19:47549865	TMEM160	-0.39	-6.36	-0.33	6.65e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg24977027	chr2:88469347	THNSL2	-0.57	-5.83	-0.3	1.3e-8	Plasma clusterin levels;
LUSC	cis	rs6445967	0.722	rs6445961	chr3:58232659	C/T	cg23715586	chr3:58305044	RPP14	0.5	8.71	0.43	1.4e-16	Platelet count;
LUSC	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.74	-14.17	-0.61	4.95e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9341808	0.519	rs676311	chr6:80989750	T/G	cg08355045	chr6:80787529	NA	-0.42	-7.17	-0.37	4.93e-12	Sitting height ratio;
LUSC	cis	rs28829049	0.597	rs12566296	chr1:19498443	A/C	cg13387374	chr1:19411106	UBR4	0.44	6.13	0.32	2.44e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.13	0.45	6.72e-18	Motion sickness;
LUSC	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg24642844	chr7:1081250	C7orf50	-0.76	-6.94	-0.36	2.04e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4356932	0.967	rs28433437	chr4:76972653	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.83	0.3	1.33e-8	Blood protein levels;
LUSC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	7.43	0.38	9.18e-13	Menarche (age at onset);
LUSC	cis	rs17030434	0.953	rs10014299	chr4:154700858	A/G	cg14289246	chr4:154710475	SFRP2	-0.5	-6.56	-0.34	2.08e-10	Electrocardiographic conduction measures;
LUSC	cis	rs1007190	0.881	rs3816275	chr17:42957327	G/A	cg15406952	chr17:42872593	NA	0.55	5.68	0.3	2.97e-8	DNA methylation (variation);
LUSC	cis	rs1595825	0.891	rs1016883	chr2:198881668	A/G	cg10547527	chr2:198650123	BOLL	0.52	6.34	0.33	7.52e-10	Ulcerative colitis;
LUSC	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-7.67	-0.39	1.91e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs7000551	0.556	rs12674913	chr8:22263617	G/C	cg12081754	chr8:22256438	SLC39A14	0.91	13.77	0.6	1.81e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg26893861	chr17:41843967	DUSP3	0.95	14.72	0.63	3.72e-38	Triglycerides;
LUSC	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg11965913	chr1:205819406	PM20D1	0.46	5.92	0.31	8.18e-9	White blood cell types;
LUSC	cis	rs76878669	0.561	rs2236679	chr11:66108894	G/C	cg18002602	chr11:66138449	SLC29A2	-0.49	-8.69	-0.43	1.71e-16	Educational attainment (years of education);
LUSC	cis	rs9811920	0.535	rs704572	chr3:99482314	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.3	-5.79	-0.3	1.61e-8	Axial length;
LUSC	cis	rs9677476	0.818	rs7598728	chr2:232086055	C/T	cg07929768	chr2:232055508	NA	0.36	6.79	0.35	4.99e-11	Food antigen IgG levels;
LUSC	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg05040210	chr1:18807594	KLHDC7A	-0.39	-7.11	-0.36	7.13e-12	Breast cancer;
LUSC	cis	rs273573	0.922	rs927224	chr11:30810665	T/C	cg14844989	chr11:31128820	NA	-0.37	-5.78	-0.3	1.67e-8	Total body bone mineral density;
LUSC	cis	rs4704187	0.687	rs10051422	chr5:74502573	G/A	cg03227963	chr5:74354835	NA	0.3	6.64	0.34	1.24e-10	Response to amphetamines;
LUSC	cis	rs9443645	0.527	rs949846	chr6:79817596	C/T	cg05283184	chr6:79620031	NA	-0.46	-8.7	-0.43	1.58e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9399401	0.601	rs643975	chr6:142844251	C/G	cg03128060	chr6:142623767	GPR126	-0.51	-8.86	-0.44	4.84e-17	Chronic obstructive pulmonary disease;
LUSC	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.51	-0.46	3.89e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg01528321	chr10:82214614	TSPAN14	0.83	12.69	0.57	2.27e-30	Post bronchodilator FEV1;
LUSC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg20991723	chr1:152506922	NA	0.52	9.58	0.46	2.27e-19	Hair morphology;
LUSC	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23158103	chr7:148848205	ZNF398	-0.42	-6.85	-0.35	3.5e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15541040	chr2:3486749	NA	0.56	8.67	0.43	1.92e-16	Neurofibrillary tangles;
LUSC	cis	rs4363385	0.818	rs61811863	chr1:152995721	T/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.92	-0.4	3.57e-14	Inflammatory skin disease;
LUSC	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.13	17.23	0.69	4.9e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12760731	0.720	rs10913542	chr1:178348568	A/G	cg00404053	chr1:178313656	RASAL2	0.48	5.82	0.3	1.38e-8	Obesity-related traits;
LUSC	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg16950941	chr11:66035639	RAB1B	0.5	7.28	0.37	2.34e-12	Gout;
LUSC	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs7605827	0.930	rs11681344	chr2:15711885	C/A	cg19274914	chr2:15703543	NA	0.45	8.44	0.42	9.9e-16	Educational attainment (years of education);
LUSC	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg01770232	chr7:22766155	IL6	0.4	5.73	0.3	2.27e-8	Lung cancer;
LUSC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.9	-0.35	2.64e-11	Monocyte percentage of white cells;
LUSC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	8.02	0.4	1.76e-14	Schizophrenia;
LUSC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	0.77	13.48	0.59	2.3e-33	Cognitive function;
LUSC	cis	rs9818941	0.824	rs1574064	chr3:157801204	C/G	cg08654915	chr3:157813417	NA	-0.32	-7.57	-0.38	3.57e-13	Height;
LUSC	cis	rs911119	1.000	rs3088162	chr20:23607752	C/A	cg16589663	chr20:23618590	CST3	0.61	7.19	0.37	4.24e-12	Chronic kidney disease;
LUSC	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg27205649	chr11:78285834	NARS2	0.53	6.46	0.33	3.72e-10	Alzheimer's disease (survival time);
LUSC	cis	rs963731	0.579	rs4670269	chr2:39198036	C/T	cg04010122	chr2:39346883	SOS1	0.67	5.83	0.3	1.3e-8	Corticobasal degeneration;
LUSC	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg05887092	chr17:76393375	PGS1	0.52	9.5	0.46	4.27e-19	HDL cholesterol levels;
LUSC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg11812906	chr14:75593930	NEK9	0.66	11.33	0.53	2.12e-25	Height;
LUSC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg05025164	chr4:1340916	KIAA1530	0.42	6.7	0.34	8.83e-11	Longevity;
LUSC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18854424	chr1:2615690	NA	-0.49	-9.83	-0.47	3.4e-20	Ulcerative colitis;
LUSC	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.08	-0.44	9.93e-18	Depression;
LUSC	cis	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-8.54	-0.42	4.97e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	0.9	16.15	0.66	9.23e-44	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg12963246	chr6:28129442	ZNF389	0.41	6.44	0.33	4.24e-10	Parkinson's disease;
LUSC	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg26408565	chr15:76604113	ETFA	-0.5	-8.02	-0.4	1.82e-14	Blood metabolite levels;
LUSC	cis	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg07460842	chr6:66804631	NA	-0.46	-6.47	-0.33	3.5e-10	Blood trace element (Cu levels);
LUSC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.52e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05535760	chr7:792225	HEATR2	0.95	10.13	0.48	3.4e-21	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg08807101	chr21:30365312	RNF160	-0.54	-8.2	-0.41	5.09e-15	Dental caries;
LUSC	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg22482690	chr17:47019901	SNF8	-0.38	-7.25	-0.37	2.92e-12	Type 2 diabetes;
LUSC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	13.05	0.58	9.94e-32	Platelet count;
LUSC	cis	rs9309473	0.519	rs2421545	chr2:73639476	T/C	cg20560298	chr2:73613845	ALMS1	0.47	7.4	0.38	1.13e-12	Metabolite levels;
LUSC	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg27102117	chr16:15229624	NA	0.41	7.14	0.36	5.96e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-8.16	-0.41	6.75e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg27205649	chr11:78285834	NARS2	0.53	6.46	0.33	3.72e-10	Alzheimer's disease (survival time);
LUSC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-6.38	-0.33	5.87e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.42e-9	Ulcerative colitis;
LUSC	cis	rs243505	0.733	rs9987055	chr7:148501758	G/A	cg09806900	chr7:148480153	CUL1	0.55	8.09	0.4	1.09e-14	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-6.93	-0.35	2.17e-11	Bipolar disorder;
LUSC	trans	rs2679649	1.000	rs2684268	chr6:122354079	T/C	cg00167820	chr8:131663355	NA	0.54	6.3	0.33	9.21e-10	Subcutaneous adipose tissue;
LUSC	cis	rs9650315	0.733	rs55771752	chr8:57206332	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.33	0.37	1.73e-12	Height;
LUSC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg03605463	chr16:89740564	NA	0.59	9.39	0.46	9.44e-19	Vitiligo;
LUSC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-7.24	-0.37	3.11e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.57	0.78	3.62e-69	Prudent dietary pattern;
LUSC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg23034840	chr1:205782522	SLC41A1	0.51	7.03	0.36	1.18e-11	Menarche (age at onset);
LUSC	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.84	14.47	0.62	3.51e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11645898	0.748	rs72791120	chr16:72224583	G/T	cg14768367	chr16:72042858	DHODH	-0.57	-6.16	-0.32	2.13e-9	Blood protein levels;
LUSC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg15691649	chr6:25882328	NA	-0.4	-5.75	-0.3	1.97e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.05	-0.31	3.93e-9	Platelet count;
LUSC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg11663144	chr21:46675770	NA	-0.41	-6.97	-0.36	1.66e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.25	0.45	2.83e-18	Monocyte percentage of white cells;
LUSC	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg07211511	chr3:129823064	LOC729375	-0.62	-8.21	-0.41	4.72e-15	Blood pressure (smoking interaction);
LUSC	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg22491629	chr6:157744540	C6orf35	-0.91	-10.85	-0.51	1.06e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.58	11.94	0.55	1.29e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6977660	0.619	rs71526305	chr7:19785374	G/C	cg07541023	chr7:19748670	TWISTNB	0.61	6.46	0.33	3.63e-10	Thyroid stimulating hormone;
LUSC	trans	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg24644049	chr4:85504048	CDS1	0.74	7.45	0.38	7.81e-13	Skin colour saturation;
LUSC	cis	rs17533156	0.612	rs12603478	chr17:75128651	A/G	cg11416367	chr17:75137675	SEC14L1	0.5	5.91	0.31	8.41e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4462272	0.554	rs7068215	chr10:101859870	C/T	cg02250046	chr10:101825185	CPN1	0.33	6.0	0.31	5.05e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg05855489	chr10:104503620	C10orf26	0.53	7.87	0.4	4.96e-14	Arsenic metabolism;
LUSC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg22549504	chr19:17448937	GTPBP3	0.55	7.06	0.36	9.83e-12	Systemic lupus erythematosus;
LUSC	cis	rs10740039	0.842	rs10821819	chr10:62418615	G/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.92	-0.35	2.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs548181	0.611	rs562599	chr11:125459951	A/C	cg03464685	chr11:125439445	EI24	1.28	13.82	0.6	1.1e-34	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg25456477	chr12:86230367	RASSF9	0.37	6.43	0.33	4.34e-10	Major depressive disorder;
LUSC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg09877947	chr5:131593287	PDLIM4	0.43	6.81	0.35	4.56e-11	Breast cancer;
LUSC	cis	rs1997103	1.000	rs7779040	chr7:55412947	T/C	cg17469321	chr7:55412551	NA	0.65	10.53	0.5	1.45e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs4363385	0.747	rs9919227	chr1:152970867	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.74	-0.39	1.21e-13	Inflammatory skin disease;
LUSC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.44	-5.95	-0.31	6.63e-9	Neutrophil percentage of white cells;
LUSC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg16362232	chr11:430036	ANO9	0.6	7.87	0.4	4.86e-14	Body mass index;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25569575	chr11:67007811	KDM2A	0.36	5.99	0.31	5.42e-9	Schizophrenia;
LUSC	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.5	-6.42	-0.33	4.76e-10	Neutrophil percentage of white cells;
LUSC	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.89	0.51	8.07e-24	Hypertriglyceridemia;
LUSC	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg21545522	chr1:205238299	TMCC2	0.46	8.41	0.42	1.21e-15	Red blood cell count;
LUSC	trans	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.45	6.74	0.35	7.03e-11	Endometrial cancer;
LUSC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg05343316	chr1:45956843	TESK2	0.69	8.97	0.44	2.16e-17	Platelet count;
LUSC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.79	-10.62	-0.5	6.95e-23	Refractive error;
LUSC	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg06636001	chr8:8085503	FLJ10661	0.87	14.66	0.63	6.57e-38	Neuroticism;
LUSC	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg08213375	chr14:104286397	PPP1R13B	0.44	8.5	0.42	6.43e-16	Schizophrenia;
LUSC	cis	rs10979	0.644	rs12527367	chr6:143918718	C/T	cg25407410	chr6:143891975	LOC285740	-0.49	-7.54	-0.38	4.54e-13	Hypospadias;
LUSC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	11.56	0.53	3.05e-26	Hip circumference adjusted for BMI;
LUSC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg06740227	chr12:86229804	RASSF9	0.39	6.25	0.32	1.23e-9	Major depressive disorder;
LUSC	cis	rs926938	0.563	rs360661	chr1:115455280	G/A	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.28	-0.32	1.05e-9	Autism;
LUSC	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg05347473	chr6:146136440	FBXO30	0.53	8.88	0.44	4.06e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1595825	0.891	rs76637837	chr2:198529496	G/A	cg00982548	chr2:198649783	BOLL	-0.52	-6.63	-0.34	1.34e-10	Ulcerative colitis;
LUSC	cis	rs4499344	0.633	rs259229	chr19:33134425	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.73	-10.84	-0.51	1.13e-23	Mean platelet volume;
LUSC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg18876405	chr7:65276391	NA	0.53	8.61	0.43	2.86e-16	Calcium levels;
LUSC	cis	rs7577696	0.962	rs4952248	chr2:32343669	G/A	cg02381751	chr2:32503542	YIPF4	-0.4	-5.71	-0.3	2.47e-8	Inflammatory biomarkers;
LUSC	cis	rs698833	0.506	rs713448	chr2:44504877	T/C	cg00619915	chr2:44497795	NA	-0.5	-6.92	-0.35	2.33e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	cis	rs1891275	0.515	rs1361552	chr10:93534624	T/C	cg07889827	chr10:93443413	NA	-0.4	-9.07	-0.44	1.04e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg26513180	chr16:89883248	FANCA	0.53	7.93	0.4	3.4e-14	Vitiligo;
LUSC	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.53	0.62	2.03e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg08742575	chr21:47604166	C21orf56	0.45	6.74	0.35	7e-11	Testicular germ cell tumor;
LUSC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg27532560	chr4:187881888	NA	-0.39	-6.41	-0.33	5.1e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7582720	1.000	rs35212307	chr2:203765756	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.66	0.43	2.06e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1124376	0.505	rs9854447	chr3:20305234	A/G	cg05072819	chr3:20081367	KAT2B	0.58	5.76	0.3	1.96e-8	Bipolar disorder and schizophrenia;
LUSC	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs12995491	0.933	rs7590305	chr2:88513131	C/T	cg18302933	chr2:88491318	NA	-0.35	-6.8	-0.35	4.82e-11	Response to metformin (IC50);
LUSC	cis	rs79387448	0.745	rs7587856	chr2:103144305	C/A	cg09003973	chr2:102972529	NA	0.88	8.67	0.43	1.93e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs6700896	0.966	rs12067936	chr1:66088701	C/A	cg04111102	chr1:66153794	NA	0.32	7.04	0.36	1.11e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg05368731	chr17:41323189	NBR1	0.82	13.47	0.59	2.59e-33	Menopause (age at onset);
LUSC	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-1.14	-18.03	-0.7	3.05e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.64	-11.92	-0.55	1.55e-27	Platelet distribution width;
LUSC	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg16482183	chr6:26056742	HIST1H1C	0.49	7.38	0.37	1.3e-12	Height;
LUSC	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.52	-7.25	-0.37	2.87e-12	IgG glycosylation;
LUSC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08645402	chr16:4508243	NA	0.48	7.45	0.38	8.16e-13	Schizophrenia;
LUSC	cis	rs356992	0.915	rs76673	chr2:60749078	G/T	cg08426369	chr2:60753602	BCL11A	-0.44	-6.14	-0.32	2.38e-9	Educational attainment (years of education);
LUSC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.08	0.32	3.24e-9	Menarche (age at onset);
LUSC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg16606324	chr3:10149918	C3orf24	0.64	9.26	0.45	2.48e-18	Alzheimer's disease;
LUSC	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg07423050	chr13:99094983	FARP1	-0.52	-9.33	-0.45	1.54e-18	Longevity;
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg13453750	chr1:205783389	SLC41A1	-0.33	-6.51	-0.34	2.82e-10	Menarche (age at onset);
LUSC	cis	rs4285028	0.948	rs7640872	chr3:121697168	C/A	cg11130432	chr3:121712080	ILDR1	-0.64	-9.79	-0.47	4.65e-20	Multiple sclerosis;
LUSC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg13699009	chr12:122356056	WDR66	0.47	7.26	0.37	2.71e-12	Mean corpuscular volume;
LUSC	cis	rs6845621	0.901	rs9991568	chr4:18922645	A/G	cg12196642	chr4:18937545	NA	0.34	6.35	0.33	6.9e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01570182	chr17:44337453	NA	-0.66	-9.86	-0.47	2.66e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs259282	0.538	rs6510273	chr19:33117884	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.68	10.09	0.48	4.65e-21	Schizophrenia;
LUSC	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg05973401	chr12:123451056	ABCB9	0.52	6.49	0.33	3.19e-10	Neutrophil percentage of white cells;
LUSC	cis	rs17433780	0.892	rs72726528	chr1:89455980	C/A	cg09516651	chr1:89888402	LOC400759	0.48	7.91	0.4	3.7e-14	Carotid intima media thickness;
LUSC	cis	rs3824867	0.676	rs7104366	chr11:47462115	G/A	cg20307385	chr11:47447363	PSMC3	0.65	9.68	0.47	1.04e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg21427119	chr20:30132790	HM13	-0.43	-6.15	-0.32	2.26e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg09904177	chr6:26538194	HMGN4	0.75	14.22	0.61	3.18e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs1160297	0.576	rs724860	chr2:53099406	A/G	cg07782112	chr2:53107842	NA	0.43	6.98	0.36	1.59e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg09754948	chr16:28834200	ATXN2L	0.41	5.9	0.31	8.9e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.52	0.34	2.67e-10	Testicular germ cell tumor;
LUSC	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg05973401	chr12:123451056	ABCB9	0.52	6.53	0.34	2.39e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg15147215	chr3:52552868	STAB1	-0.32	-6.33	-0.33	7.76e-10	Electroencephalogram traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg07420484	chr1:210484920	NA	0.47	6.38	0.33	6.02e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7589342	0.745	rs11124066	chr2:106516925	T/A	cg16077055	chr2:106428750	NCK2	0.35	6.64	0.34	1.29e-10	Addiction;
LUSC	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg00191853	chr8:101177733	SPAG1	-0.39	-6.49	-0.33	3.19e-10	Atrioventricular conduction;
LUSC	cis	rs651907	0.640	rs771574	chr3:101620682	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.47	6.15	0.32	2.22e-9	Colorectal cancer;
LUSC	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg00792783	chr2:198669748	PLCL1	0.44	6.02	0.31	4.7e-9	Dermatomyositis;
LUSC	cis	rs11031096	0.503	rs67065286	chr11:4105273	A/C	cg08557956	chr11:4115526	RRM1	-0.47	-6.06	-0.31	3.6e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg03342759	chr3:160939853	NMD3	-0.52	-8.74	-0.43	1.15e-16	Morning vs. evening chronotype;
LUSC	trans	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg13010199	chr12:38710504	ALG10B	0.49	6.8	0.35	4.78e-11	Resting heart rate;
LUSC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg19774624	chr17:42201019	HDAC5	0.79	12.79	0.57	9.43e-31	Total body bone mineral density;
LUSC	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.62	6.55	0.34	2.16e-10	Schizophrenia;
LUSC	cis	rs4499344	0.556	rs259243	chr19:33144726	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	13.68	0.6	4e-34	Mean platelet volume;
LUSC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.94	-19.27	-0.73	3.78e-56	Post bronchodilator FEV1;
LUSC	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.43	-6.96	-0.36	1.86e-11	Tonsillectomy;
LUSC	cis	rs1395	1.000	rs1659695	chr2:27406944	T/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.4	-6.62	-0.34	1.42e-10	Blood metabolite levels;
LUSC	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg03433033	chr1:76189801	ACADM	-0.47	-7.04	-0.36	1.09e-11	Daytime sleep phenotypes;
LUSC	cis	rs1065852	0.906	rs5751230	chr22:42553353	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.58	9.91	0.48	1.77e-20	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg16584290	chr5:462447	EXOC3	-0.37	-6.43	-0.33	4.39e-10	Cystic fibrosis severity;
LUSC	cis	rs9612	0.948	rs189408	chr19:44268006	T/C	cg08581076	chr19:44259116	C19orf61	0.48	5.85	0.3	1.2e-8	Exhaled nitric oxide output;
LUSC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.56	0.46	2.65e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.65	8.66	0.43	2.07e-16	High light scatter reticulocyte count;
LUSC	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg03806693	chr22:41940476	POLR3H	-0.57	-8.48	-0.42	7.63e-16	Vitiligo;
LUSC	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.24	-0.37	3.08e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg05729581	chr11:3078854	CARS	-0.53	-8.17	-0.41	6.57e-15	Longevity;
LUSC	cis	rs1358748	0.522	rs4655676	chr1:67580054	C/T	cg02640540	chr1:67518911	SLC35D1	0.67	6.53	0.34	2.5e-10	Tuberculosis;
LUSC	cis	rs7173743	0.756	rs6495339	chr15:79128272	T/C	cg00540400	chr15:79124168	NA	0.35	5.99	0.31	5.29e-9	Coronary artery disease;
LUSC	cis	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg21775007	chr8:11205619	TDH	0.47	6.67	0.34	1.09e-10	Neuroticism;
LUSC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg05802129	chr4:122689817	NA	-0.49	-8.56	-0.42	4.31e-16	Type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.27e-31	Prudent dietary pattern;
LUSC	cis	rs2051773	0.567	rs7130826	chr11:17037793	T/G	cg15084286	chr11:17036142	PLEKHA7	0.46	5.88	0.31	9.87e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01965872	chr20:33291894	TP53INP2	-0.41	-6.0	-0.31	5.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21810621	chr11:1331345	LOC255512;TOLLIP	-0.47	-6.19	-0.32	1.77e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.77	9.44	0.46	6.53e-19	Gut microbiome composition (summer);
LUSC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg19622623	chr12:86230825	RASSF9	-0.45	-6.4	-0.33	5.37e-10	Major depressive disorder;
LUSC	cis	rs9311676	0.632	rs62258094	chr3:58371770	T/G	cg26110898	chr3:58419937	PDHB	0.41	6.69	0.34	9.67e-11	Systemic lupus erythematosus;
LUSC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg15839431	chr19:19639596	YJEFN3	0.44	6.13	0.32	2.45e-9	Tonsillectomy;
LUSC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg04369109	chr6:150039330	LATS1	-0.58	-8.5	-0.42	6.24e-16	Lung cancer;
LUSC	cis	rs7586879	0.765	rs10171663	chr2:25086431	T/C	cg01884057	chr2:25150051	NA	0.39	8.18	0.41	5.87e-15	Body mass index;
LUSC	cis	rs11676348	0.774	rs13397673	chr2:219047782	A/G	cg23569941	chr2:219139048	TMBIM1;PNKD	0.38	6.26	0.32	1.18e-9	Ulcerative colitis;
LUSC	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg05985134	chr18:33552581	C18orf21	0.5	6.75	0.35	6.38e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs9309473	0.607	rs1403412	chr2:73598092	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-7.84	-0.39	6.02e-14	Metabolite levels;
LUSC	cis	rs2235649	0.833	rs9933168	chr16:1848361	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.46	-6.15	-0.32	2.21e-9	Blood metabolite levels;
LUSC	cis	rs72627509	0.904	rs17081935	chr4:57823476	C/T	cg26694713	chr4:57773883	REST	0.5	5.95	0.31	6.8e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.16	0.32	2.04e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11997175	0.574	rs872489	chr8:33646401	T/C	ch.8.33884649F	chr8:33765107	NA	0.51	8.26	0.41	3.38e-15	Body mass index;
LUSC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg00310523	chr12:86230176	RASSF9	0.46	8.5	0.42	6.35e-16	Major depressive disorder;
LUSC	cis	rs713477	1.000	rs7148481	chr14:55909267	G/A	cg13175173	chr14:55914753	NA	-0.32	-6.63	-0.34	1.35e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs9462027	0.606	rs2744941	chr6:34646917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.21	-0.32	1.53e-9	Systemic lupus erythematosus;
LUSC	cis	rs11958404	0.932	rs72818113	chr5:157439825	G/T	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.83	0.35	3.98e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg06784218	chr1:46089804	CCDC17	0.54	11.03	0.52	2.42e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4132509	1.000	rs4132509	chr1:243943084	A/C	cg21452805	chr1:244014465	NA	-0.49	-5.65	-0.3	3.47e-8	RR interval (heart rate);
LUSC	cis	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg02508848	chr16:68573721	ZFP90	-0.42	-5.75	-0.3	2.07e-8	Ulcerative colitis;
LUSC	cis	rs6537837	0.838	rs71657105	chr1:110114122	G/A	cg05049280	chr1:110155535	GNAT2	0.45	6.03	0.31	4.37e-9	Major depressive disorder;
LUSC	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg19508488	chr2:152266495	RIF1	0.53	7.14	0.36	5.99e-12	Lung cancer;
LUSC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.11	0.32	2.78e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	1.0	20.73	0.75	5.74e-62	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	8.24	0.41	4.06e-15	Axial length;
LUSC	trans	rs1470506	0.507	rs55985303	chr2:77224951	G/A	cg01707656	chr12:12503030	MANSC1	0.45	5.94	0.31	7.05e-9	IgG glycosylation;
LUSC	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.24	-0.37	3.08e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg00631329	chr6:26305371	NA	-0.46	-8.9	-0.44	3.63e-17	Educational attainment;
LUSC	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	0.57	8.81	0.43	7.14e-17	Breast cancer;
LUSC	trans	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg12856521	chr11:46389249	DGKZ	0.41	6.52	0.34	2.54e-10	Leprosy;
LUSC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.15	-0.32	2.24e-9	Total body bone mineral density;
LUSC	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg22467129	chr15:76604101	ETFA	-0.42	-6.64	-0.34	1.28e-10	Blood metabolite levels;
LUSC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.68	-11.4	-0.53	1.18e-25	Monocyte count;
LUSC	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg17127132	chr2:85788382	GGCX	0.43	6.13	0.32	2.42e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg24147428	chr11:65409760	SIPA1	-0.6	-8.08	-0.4	1.18e-14	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-6.44	-0.33	4.18e-10	Aortic root size;
LUSC	cis	rs9309473	1.000	rs7572722	chr2:73724675	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-6.37	-0.33	6.24e-10	Metabolite levels;
LUSC	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg08017756	chr2:100939284	LONRF2	-0.45	-8.61	-0.43	2.9e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg24209194	chr3:40518798	ZNF619	0.44	5.88	0.31	1.02e-8	Renal cell carcinoma;
LUSC	cis	rs701145	0.585	rs17817774	chr3:153779868	A/G	cg17054900	chr3:154042577	DHX36	-0.55	-5.97	-0.31	5.93e-9	Coronary artery disease;
LUSC	cis	rs9399401	0.890	rs7755109	chr6:142750392	C/T	cg03128060	chr6:142623767	GPR126	-0.31	-5.74	-0.3	2.08e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	15.1	0.64	1.27e-39	Platelet count;
LUSC	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg01973587	chr1:228161476	NA	-0.4	-6.98	-0.36	1.64e-11	Diastolic blood pressure;
LUSC	cis	rs4700695	0.719	rs1643415	chr5:65447087	T/C	cg21114390	chr5:65439923	SFRS12	-0.63	-9.15	-0.45	5.7e-18	Facial morphology (factor 19);
LUSC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-1.24	-16.72	-0.68	4.91e-46	Eosinophil percentage of granulocytes;
LUSC	cis	rs56283067	0.847	rs56172130	chr6:44696262	G/A	cg20913747	chr6:44695427	NA	-0.48	-7.82	-0.39	6.86e-14	Total body bone mineral density;
LUSC	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg05738196	chr6:26577821	NA	0.81	15.74	0.65	3.8e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs6442522	1.000	rs6762167	chr3:15445037	A/T	cg16303742	chr3:15540471	COLQ	-0.29	-5.87	-0.31	1.04e-8	Uric acid levels;
LUSC	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg23752985	chr2:85803571	VAMP8	0.34	7.45	0.38	7.85e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg00191853	chr8:101177733	SPAG1	-0.41	-6.53	-0.34	2.46e-10	Atrioventricular conduction;
LUSC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	7.71	0.39	1.45e-13	Obesity-related traits;
LUSC	cis	rs12980942	0.591	rs1946613	chr19:41767785	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.69	7.22	0.37	3.45e-12	Coronary artery disease;
LUSC	cis	rs35123781	1.000	rs601324	chr5:139057179	C/G	cg10513866	chr5:139070639	NA	0.46	8.9	0.44	3.62e-17	Schizophrenia;
LUSC	cis	rs1979679	0.573	rs4931087	chr12:28735091	A/C	cg13890972	chr12:28721907	NA	0.42	5.96	0.31	6.56e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg08470875	chr2:26401718	FAM59B	0.73	9.29	0.45	1.97e-18	Gut microbiome composition (summer);
LUSC	cis	rs4936323	0.504	rs10891812	chr11:115096431	T/C	cg04055981	chr11:115044050	NA	0.4	7.1	0.36	7.38e-12	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs9341808	0.538	rs9443742	chr6:81016929	T/G	cg08355045	chr6:80787529	NA	-0.39	-6.79	-0.35	5.05e-11	Sitting height ratio;
LUSC	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg13256891	chr4:100009986	ADH5	-0.5	-6.47	-0.33	3.53e-10	Alcohol dependence;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01958203	chr7:99098094	ZNF394	0.45	6.73	0.35	7.61e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg05966235	chr16:28915196	ATP2A1	0.33	5.77	0.3	1.79e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.08	-0.48	4.71e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1568889	0.838	rs11030229	chr11:28173634	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	12.46	0.56	1.59e-29	Bipolar disorder;
LUSC	trans	rs4650994	0.525	rs2493864	chr1:178545003	A/C	cg05059571	chr16:84539110	KIAA1609	-0.47	-9.1	-0.45	8.3e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-0.81	-11.07	-0.52	1.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg20821713	chr7:1055600	C7orf50	-0.48	-5.78	-0.3	1.76e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg18105134	chr13:113819100	PROZ	0.62	9.33	0.45	1.55e-18	Platelet distribution width;
LUSC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.59	8.38	0.42	1.54e-15	Large artery stroke;
LUSC	cis	rs62400317	0.762	rs72865923	chr6:44878942	T/G	cg18551225	chr6:44695536	NA	-0.46	-7.44	-0.38	8.7e-13	Total body bone mineral density;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27147807	chr6:122931281	PKIB	0.44	6.19	0.32	1.75e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg05855489	chr10:104503620	C10orf26	0.58	9.25	0.45	2.73e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs17255340	0.520	rs1145912	chr6:83994757	G/C	cg08257003	chr6:84140564	ME1	0.32	7.89	0.4	4.39e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg05623727	chr3:50126028	RBM5	0.32	5.98	0.31	5.71e-9	Body mass index;
LUSC	cis	rs17401966	0.522	rs6541085	chr1:10285709	A/G	cg17425144	chr1:10567563	PEX14	-0.33	-5.81	-0.3	1.43e-8	Hepatocellular carcinoma;
LUSC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg23815491	chr16:72088622	HP	-0.35	-6.02	-0.31	4.58e-9	Fibrinogen levels;
LUSC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.89	12.46	0.56	1.56e-29	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.44	6.1	0.32	2.96e-9	Multiple sclerosis;
LUSC	cis	rs4478858	0.684	rs2050816	chr1:31721708	G/T	cg00250761	chr1:31883323	NA	-0.33	-8.19	-0.41	5.59e-15	Alcohol dependence;
LUSC	trans	rs12692738	0.526	rs355858	chr2:165629457	G/A	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11679564	0.714	rs10490657	chr2:37178255	C/T	cg14987922	chr2:37194071	STRN	0.6	8.84	0.44	5.57e-17	Immature fraction of reticulocytes;
LUSC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg14440974	chr22:39074834	NA	0.38	6.24	0.32	1.32e-9	Menopause (age at onset);
LUSC	cis	rs12801636	0.512	rs11227247	chr11:65422853	A/C	cg26668713	chr11:65405903	SIPA1	0.61	6.13	0.32	2.44e-9	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg26384229	chr12:38710491	ALG10B	-0.63	-9.94	-0.48	1.47e-20	Morning vs. evening chronotype;
LUSC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg17971929	chr21:40555470	PSMG1	-0.64	-10.44	-0.5	2.82e-22	Cognitive function;
LUSC	cis	rs16910800	0.953	rs77585463	chr11:23205379	T/C	cg20040320	chr11:23191996	NA	-0.44	-6.45	-0.33	3.85e-10	Cancer;
LUSC	cis	rs11229555	0.645	rs12797488	chr11:58174653	A/T	cg15696309	chr11:58395628	NA	-0.67	-8.23	-0.41	4.39e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.15	-0.49	2.83e-21	Alzheimer's disease;
LUSC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.39	-0.33	5.5e-10	Blood metabolite levels;
LUSC	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg16586182	chr3:47516702	SCAP	0.5	7.2	0.37	4.01e-12	Colorectal cancer;
LUSC	cis	rs3125734	0.608	rs7094950	chr10:64019744	T/C	cg19640130	chr10:64028056	RTKN2	-0.39	-7.02	-0.36	1.26e-11	Rheumatoid arthritis;
LUSC	cis	rs7809950	0.723	rs62483633	chr7:106876644	T/G	cg23024343	chr7:107201750	COG5	-0.66	-9.9	-0.48	1.98e-20	Coronary artery disease;
LUSC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-15.88	-0.66	1.05e-42	Gut microbiome composition (summer);
LUSC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg11843238	chr5:131593191	PDLIM4	0.41	6.92	0.35	2.35e-11	Breast cancer;
LUSC	trans	rs4714291	0.862	rs2984433	chr6:39973445	T/G	cg02267698	chr19:7991119	CTXN1	-0.51	-7.55	-0.38	4.29e-13	Strep throat;
LUSC	cis	rs354225	0.544	rs7340302	chr2:54803671	A/C	cg26097391	chr2:54893211	SPTBN1	0.43	6.42	0.33	4.68e-10	Schizophrenia;
LUSC	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg24450063	chr1:156163899	SLC25A44	1.1	22.14	0.77	1.73e-67	Testicular germ cell tumor;
LUSC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg02428538	chr16:24856791	SLC5A11	0.54	6.06	0.31	3.7e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs644148	0.770	rs2571113	chr19:44999814	A/G	cg15540054	chr19:45004280	ZNF180	-0.63	-9.36	-0.46	1.18e-18	Personality dimensions;
LUSC	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg03859395	chr2:55845619	SMEK2	0.79	13.91	0.61	5.29e-35	Metabolic syndrome;
LUSC	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.21	-0.45	3.82e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg00677455	chr12:58241039	CTDSP2	-0.4	-5.85	-0.3	1.19e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs847577	0.572	rs847573	chr7:97681761	C/T	cg24562669	chr7:97807699	LMTK2	-0.36	-5.71	-0.3	2.44e-8	Breast cancer;
LUSC	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.43	6.57	0.34	1.92e-10	Dupuytren's disease;
LUSC	trans	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg18187862	chr3:45730750	SACM1L	0.53	7.03	0.36	1.16e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs9811920	0.928	rs2130369	chr3:99873317	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.32	5.94	0.31	7.22e-9	Axial length;
LUSC	trans	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg24247370	chr13:99142703	STK24	-0.35	-6.46	-0.33	3.62e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg02822958	chr2:46747628	ATP6V1E2	-0.46	-8.25	-0.41	3.73e-15	HDL cholesterol;
LUSC	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.77	0.35	5.7e-11	Rheumatoid arthritis;
LUSC	cis	rs113835537	0.597	rs57288351	chr11:66307489	C/T	cg24851651	chr11:66362959	CCS	0.53	7.77	0.39	1e-13	Airway imaging phenotypes;
LUSC	cis	rs9650315	0.929	rs66518479	chr8:57180675	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.8	0.35	4.85e-11	Height;
LUSC	cis	rs7011049	1.000	rs72643574	chr8:53844501	G/C	cg26025543	chr8:53854495	NA	0.53	6.35	0.33	7.13e-10	Systolic blood pressure;
LUSC	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg12940439	chr1:67600707	NA	0.39	6.53	0.34	2.47e-10	Psoriasis;
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg15242686	chr22:24348715	GSTTP1	0.53	8.26	0.41	3.49e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg19774624	chr17:42201019	HDAC5	-0.8	-13.44	-0.59	3.23e-33	Total body bone mineral density;
LUSC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.37	5.85	0.3	1.18e-8	Total body bone mineral density;
LUSC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg20283391	chr11:68216788	NA	-0.61	-8.45	-0.42	8.91e-16	Total body bone mineral density;
LUSC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-5.88	-0.31	9.89e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg25456477	chr12:86230367	RASSF9	0.4	7.2	0.37	4.03e-12	Major depressive disorder;
LUSC	cis	rs2230307	0.572	rs11166408	chr1:100641350	A/T	cg24955406	chr1:100503596	HIAT1	-0.57	-5.88	-0.31	1.01e-8	Carotid intima media thickness;
LUSC	cis	rs11608355	0.515	rs4766605	chr12:109895636	C/A	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.38	-0.33	5.88e-10	Breast cancer;
LUSC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.91	12.02	0.55	6.63e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs17086172	0.841	rs76001318	chr18:70271977	G/A	cg02919422	chr8:55370544	SOX17	-0.74	-6.62	-0.34	1.44e-10	Airflow obstruction;
LUSC	cis	rs554111	0.656	rs10799682	chr1:21424030	G/C	cg01072550	chr1:21505969	NA	0.38	5.82	0.3	1.41e-8	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs10193935	0.901	rs55978605	chr2:42573402	C/A	cg27598129	chr2:42591480	NA	-0.6	-8.24	-0.41	4.04e-15	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9929218	0.906	rs4783571	chr16:68806778	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-11.75	-0.54	6.51e-27	Colorectal cancer;
LUSC	cis	rs760805	1.000	rs7517302	chr1:25254317	C/T	cg22509179	chr1:25234806	RUNX3	-0.6	-10.16	-0.49	2.59e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs13401104	0.796	rs10929167	chr2:237115248	G/A	cg19324714	chr2:237145437	ASB18	0.43	5.88	0.31	9.94e-9	Educational attainment;
LUSC	cis	rs1113500	0.933	rs11185261	chr1:108638703	G/A	cg11967332	chr1:108735228	SLC25A24	0.39	5.92	0.31	7.96e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg00105475	chr2:10696890	NA	0.36	5.94	0.31	7.35e-9	Prostate cancer;
LUSC	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg05340658	chr4:99064831	C4orf37	0.41	6.25	0.32	1.28e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7804356	1.000	rs57135974	chr7:26850699	C/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg18306943	chr3:40428807	ENTPD3	0.4	6.31	0.33	8.75e-10	Renal cell carcinoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13247668	chr7:2272740	MAD1L1	-0.42	-6.25	-0.32	1.27e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13253111	0.624	rs35990565	chr8:28107815	C/T	cg26534493	chr8:28060551	NA	0.37	6.9	0.35	2.56e-11	Childhood body mass index;
LUSC	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.73	14.19	0.61	4.47e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg06221963	chr1:154839813	KCNN3	-0.63	-13.98	-0.61	2.74e-35	Prostate cancer;
LUSC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs10986311	0.706	rs7854989	chr9:127133584	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.44	7.14	0.36	5.99e-12	Vitiligo;
LUSC	cis	rs1172822	0.698	rs10420693	chr19:55830777	G/A	cg04391588	chr19:55832610	TMEM150B	0.3	5.83	0.3	1.29e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-1.22	-13.44	-0.59	3.3e-33	Diabetic kidney disease;
LUSC	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg26384229	chr12:38710491	ALG10B	0.72	11.36	0.53	1.66e-25	Morning vs. evening chronotype;
LUSC	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.86	11.12	0.52	1.14e-24	Exhaled nitric oxide levels;
LUSC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	12.8	0.57	8.5e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7939886	0.920	rs7936219	chr11:55977335	C/T	cg03929089	chr4:120376271	NA	0.83	6.2	0.32	1.71e-9	Myopia (pathological);
LUSC	cis	rs9788682	0.948	rs905739	chr15:78845110	A/G	cg18825076	chr15:78729989	IREB2	0.48	6.49	0.33	3.1e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4947962	0.618	rs73131825	chr7:55098150	G/A	cg23757825	chr7:55092271	EGFR	-0.66	-8.51	-0.42	5.97e-16	Subjective response to lithium treatment;
LUSC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg15649852	chr7:65879115	NA	-0.41	-5.64	-0.3	3.53e-8	Aortic root size;
LUSC	trans	rs7178375	1.000	rs1474382	chr15:31214649	A/G	cg04373760	chr16:53404718	NA	0.65	8.8	0.43	7.59e-17	Hypertriglyceridemia;
LUSC	cis	rs10189230	0.967	rs13012331	chr2:222350600	G/A	cg14652038	chr2:222343519	EPHA4	0.33	5.93	0.31	7.56e-9	Urate levels in lean individuals;
LUSC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg12257692	chr3:49977190	RBM6	-0.25	-7.11	-0.36	6.87e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg22532475	chr10:104410764	TRIM8	-0.32	-7.11	-0.36	6.97e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg16558253	chr16:72132732	DHX38	-0.37	-5.92	-0.31	8.15e-9	Fibrinogen levels;
LUSC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg18681998	chr4:17616180	MED28	0.81	14.81	0.63	1.65e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9311676	0.618	rs12152336	chr3:58365146	T/A	cg26110898	chr3:58419937	PDHB	0.44	7.22	0.37	3.62e-12	Systemic lupus erythematosus;
LUSC	cis	rs231513	1.000	rs231519	chr17:41961051	C/T	cg26893861	chr17:41843967	DUSP3	0.51	5.9	0.31	8.71e-9	Cognitive function;
LUSC	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.64	11.14	0.52	9.8e-25	White blood cell count (basophil);
LUSC	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.66	-0.34	1.13e-10	Reticulocyte count;
LUSC	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg17633681	chr16:88106987	BANP	0.53	10.13	0.48	3.21e-21	Menopause (age at onset);
LUSC	cis	rs7000551	0.663	rs11778844	chr8:22335170	C/T	cg12081754	chr8:22256438	SLC39A14	0.46	6.95	0.36	1.87e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9487051	0.724	rs13200047	chr6:109633244	T/C	cg01475377	chr6:109611718	NA	-0.38	-5.75	-0.3	2.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg04414720	chr1:150670196	GOLPH3L	0.51	7.88	0.4	4.63e-14	Melanoma;
LUSC	cis	rs983392	0.679	rs7930318	chr11:60033371	C/T	cg20284999	chr11:59952153	MS4A6A	0.38	6.38	0.33	5.85e-10	Alzheimer's disease (late onset);
LUSC	cis	rs10203711	1.000	rs7582256	chr2:239587446	C/T	cg14580085	chr2:239553406	NA	0.42	7.02	0.36	1.25e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	11.5	0.53	5.02e-26	Personality dimensions;
LUSC	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg23711669	chr6:146136114	FBXO30	0.88	16.22	0.66	4.78e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs56283067	0.577	rs114009236	chr6:44897517	T/C	cg20913747	chr6:44695427	NA	-0.48	-7.51	-0.38	5.55e-13	Total body bone mineral density;
LUSC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg11062466	chr8:58055876	NA	-0.7	-8.68	-0.43	1.73e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg00701064	chr4:6280414	WFS1	0.59	14.2	0.61	3.93e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg12560992	chr17:57184187	TRIM37	0.5	7.58	0.38	3.48e-13	Cognitive test performance;
LUSC	cis	rs238295	0.843	rs238288	chr20:5591903	T/G	cg15842884	chr20:5591925	RP5-1022P6.2	-0.48	-6.82	-0.35	4.39e-11	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.46	7.96	0.4	2.72e-14	Blood metabolite levels;
LUSC	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.34	-0.42	1.98e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9341835	0.772	rs9294202	chr6:64138954	A/G	cg03326410	chr6:64151739	NA	-0.37	-6.16	-0.32	2.11e-9	Schizophrenia;
LUSC	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg14530993	chr4:882597	GAK	0.73	7.54	0.38	4.37e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg16724585	chr3:197361211	NA	-0.62	-8.77	-0.43	9.17e-17	Pancreatic cancer;
LUSC	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.38	-0.33	6.04e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1113500	0.933	rs61797344	chr1:108622580	C/T	cg06207961	chr1:108661230	NA	0.42	7.72	0.39	1.37e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg07541023	chr7:19748670	TWISTNB	0.67	7.16	0.36	5.25e-12	Thyroid stimulating hormone;
LUSC	cis	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg10665199	chr7:133106180	EXOC4	0.55	7.78	0.39	9.12e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.22	0.88	3.18e-111	Chronic sinus infection;
LUSC	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.23e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg18230493	chr5:56204884	C5orf35	-0.59	-9.29	-0.45	2.07e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs9677476	0.863	rs10187005	chr2:232077948	C/T	cg07929768	chr2:232055508	NA	0.36	6.9	0.35	2.68e-11	Food antigen IgG levels;
LUSC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.69	-0.34	9.34e-11	Lung cancer;
LUSC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg07777115	chr5:623756	CEP72	-0.47	-5.97	-0.31	5.94e-9	Obesity-related traits;
LUSC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg09877947	chr5:131593287	PDLIM4	0.43	7.24	0.37	3.2e-12	Blood metabolite levels;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg19857457	chr18:47018947	RPL17;SNORD58A;SNORD58B	0.33	6.39	0.33	5.7e-10	Tuberculosis;
LUSC	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-6.67	-0.34	1.05e-10	Monocyte percentage of white cells;
LUSC	cis	rs10097731	0.901	rs28505206	chr8:82044410	A/G	cg25230327	chr8:82042993	NA	-0.48	-6.96	-0.36	1.77e-11	Serum total protein level;
LUSC	cis	rs524023	0.756	rs576076	chr11:64360623	G/A	cg19131476	chr11:64387923	NRXN2	0.35	8.12	0.41	9.04e-15	Urate levels in obese individuals;
LUSC	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-1.14	-17.9	-0.7	1.07e-50	Exhaled nitric oxide output;
LUSC	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg25173405	chr17:45401733	C17orf57	-0.36	-5.69	-0.3	2.85e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2742417	1.000	rs2742418	chr3:45731920	C/T	cg09608765	chr3:45636137	LIMD1	-0.37	-7.21	-0.37	3.68e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.91	-0.55	1.73e-27	Mean corpuscular volume;
LUSC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg26513180	chr16:89883248	FANCA	0.9	17.67	0.7	8.3e-50	Vitiligo;
LUSC	cis	rs10743315	0.643	rs7962924	chr12:19341989	G/A	cg02471346	chr12:19282374	PLEKHA5	0.63	6.02	0.31	4.59e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg19318889	chr4:1322082	MAEA	0.47	7.67	0.39	1.93e-13	Obesity-related traits;
LUSC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg11871910	chr12:69753446	YEATS4	0.95	17.8	0.7	2.59e-50	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs17253792	0.915	rs74580958	chr14:56181511	G/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.87	-0.35	3.09e-11	Putamen volume;
LUSC	cis	rs73193808	0.639	rs2832241	chr21:30552036	A/G	cg03476357	chr21:30257390	N6AMT1	0.44	5.9	0.31	8.88e-9	Coronary artery disease;
LUSC	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21659725	chr3:3221576	CRBN	0.63	10.24	0.49	1.43e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs9807989	0.801	rs6734742	chr2:102967857	C/T	cg03938978	chr2:103052716	IL18RAP	0.32	5.9	0.31	9.04e-9	Asthma;
LUSC	cis	rs524023	0.874	rs518053	chr11:64456099	C/T	cg19131476	chr11:64387923	NRXN2	-0.38	-10.5	-0.5	1.75e-22	Urate levels in obese individuals;
LUSC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg16006841	chr5:176797999	RGS14	-0.62	-9.98	-0.48	1.09e-20	Hemoglobin concentration;Hematocrit;
LUSC	trans	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05039488	chr6:79577232	IRAK1BP1	-0.71	-11.84	-0.54	3.15e-27	Brugada syndrome;
LUSC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg18402987	chr7:1209562	NA	0.7	7.64	0.39	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9341808	0.538	rs9343980	chr6:81023432	A/G	cg08355045	chr6:80787529	NA	-0.4	-6.92	-0.35	2.38e-11	Sitting height ratio;
LUSC	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg00033643	chr7:134001901	SLC35B4	0.46	7.09	0.36	7.83e-12	Mean platelet volume;
LUSC	cis	rs4629710	0.592	rs35017713	chr6:131581212	G/A	cg12606694	chr6:131520996	AKAP7	0.63	9.56	0.46	2.57e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg07169764	chr2:136633963	MCM6	0.52	7.2	0.37	4.1e-12	Mosquito bite size;
LUSC	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.45	-0.42	9.36e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg26441486	chr22:50317300	CRELD2	0.48	7.15	0.36	5.35e-12	Schizophrenia;
LUSC	cis	rs4478858	0.684	rs7519766	chr1:31735512	C/A	cg00250761	chr1:31883323	NA	-0.33	-7.91	-0.4	3.81e-14	Alcohol dependence;
LUSC	cis	rs34421088	0.506	rs2409755	chr8:11169983	G/A	cg27411982	chr8:10470053	RP1L1	0.36	5.67	0.3	3.15e-8	Neuroticism;
LUSC	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg10172584	chr19:19639581	YJEFN3	-0.49	-5.78	-0.3	1.75e-8	Bipolar disorder;
LUSC	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg25801113	chr15:45476975	SHF	0.35	7.17	0.37	4.84e-12	Uric acid levels;
LUSC	cis	rs7091068	0.671	rs591392	chr10:95406081	G/A	cg20715218	chr10:95462985	C10orf4	-0.61	-7.16	-0.36	5.29e-12	Urinary tract infection frequency;
LUSC	cis	rs77633900	0.772	rs2957613	chr15:76700589	C/T	cg21673338	chr15:77095150	SCAPER	-0.7	-5.97	-0.31	6.14e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs7586879	0.828	rs1077641	chr2:25123665	G/A	cg01884057	chr2:25150051	NA	0.42	8.8	0.43	7.49e-17	Body mass index;
LUSC	cis	rs73198271	1.000	rs11775821	chr8:8609153	A/G	cg01851573	chr8:8652454	MFHAS1	0.58	8.01	0.4	1.9e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg08773314	chr2:239334832	ASB1	0.42	8.99	0.44	1.93e-17	Multiple system atrophy;
LUSC	cis	rs2273669	0.667	rs76747161	chr6:109305456	G/A	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg05585544	chr11:47624801	NA	-0.37	-6.47	-0.33	3.53e-10	Neuroticism;
LUSC	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-20.09	-0.74	2.1e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg13206674	chr6:150067644	NUP43	0.51	7.76	0.39	1.08e-13	Lung cancer;
LUSC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg21724239	chr8:58056113	NA	0.55	6.25	0.32	1.24e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.76	-0.43	1.02e-16	Gut microbiome composition (summer);
LUSC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21963583	chr11:68658836	MRPL21	0.59	8.76	0.43	9.71e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7614311	0.681	rs6809100	chr3:63901180	A/G	cg22134162	chr3:63841271	THOC7	-0.47	-5.93	-0.31	7.72e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg01884057	chr2:25150051	NA	0.44	10.42	0.5	3.42e-22	Body mass index in non-asthmatics;
LUSC	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg22782873	chr19:19639568	YJEFN3	-0.53	-6.5	-0.34	2.92e-10	Bipolar disorder;
LUSC	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg10911889	chr6:126070802	HEY2	0.42	6.39	0.33	5.41e-10	Brugada syndrome;
LUSC	cis	rs73198271	1.000	rs11776513	chr8:8609057	T/C	cg01851573	chr8:8652454	MFHAS1	0.58	8.01	0.4	1.9e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg17757837	chr7:157058334	UBE3C	0.82	13.21	0.59	2.34e-32	Body mass index;
LUSC	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.7	10.65	0.5	5.42e-23	Corneal astigmatism;
LUSC	cis	rs2562152	0.613	rs216599	chr16:109671	A/G	cg02949481	chr16:131562	MPG	0.48	5.76	0.3	1.89e-8	Glioblastoma;
LUSC	cis	rs7575217	0.740	rs12468712	chr2:101746066	A/T	cg23907051	chr2:101730305	TBC1D8	-0.28	-7.39	-0.37	1.17e-12	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg23029597	chr12:123009494	RSRC2	-0.73	-9.33	-0.45	1.47e-18	Body mass index;
LUSC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.2	22.43	0.78	1.32e-68	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12476592	0.571	rs166384	chr2:63863630	G/T	cg10828910	chr2:63850056	LOC388955	0.49	5.78	0.3	1.71e-8	Childhood ear infection;
LUSC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.03	0.44	1.43e-17	Motion sickness;
LUSC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-14.23	-0.61	2.9e-36	Total body bone mineral density;
LUSC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	15.17	0.64	6.84e-40	Total body bone mineral density;
LUSC	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg23587288	chr2:27483067	SLC30A3	-0.29	-5.74	-0.3	2.17e-8	Blood metabolite levels;
LUSC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.86	-11.92	-0.55	1.56e-27	Platelet count;
LUSC	cis	rs1775715	0.737	rs2799018	chr10:32202069	C/T	cg26784012	chr10:32216390	ARHGAP12	0.47	7.94	0.4	3.05e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02176678	chr2:219576539	TTLL4	-0.71	-13.33	-0.59	8.65e-33	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg11344533	chr11:111475393	SIK2	0.47	6.28	0.33	1.03e-9	Primary sclerosing cholangitis;
LUSC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.84	0.6	9.65e-35	Cognitive test performance;
LUSC	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg17366294	chr4:99064904	C4orf37	0.54	8.93	0.44	2.96e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.09	-0.4	1.11e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg19812747	chr11:111475976	SIK2	0.41	5.66	0.3	3.23e-8	Primary sclerosing cholangitis;
LUSC	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg02389323	chr16:88786976	FAM38A	1.28	11.61	0.54	2.03e-26	Plateletcrit;
LUSC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.44	7.74	0.39	1.17e-13	Obesity-related traits;
LUSC	cis	rs9391997	0.567	rs4256472	chr6:434915	A/G	cg09757644	chr6:447497	NA	-0.27	-5.72	-0.3	2.33e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19346786	chr7:2764209	NA	-0.46	-7.93	-0.4	3.32e-14	Height;
LUSC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	11.38	0.53	1.36e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	0.97	13.35	0.59	7.23e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs28647808	0.881	rs4962047	chr9:136262916	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg15704280	chr7:45808275	SEPT13	-0.45	-6.23	-0.32	1.38e-9	HDL cholesterol;
LUSC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg07777115	chr5:623756	CEP72	-0.47	-5.77	-0.3	1.78e-8	Lung disease severity in cystic fibrosis;
LUSC	trans	rs12677056	0.651	rs62514387	chr8:113283969	C/T	cg12159992	chr12:102059490	MYBPC1	0.37	6.19	0.32	1.72e-9	Peripheral artery disease;
LUSC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg25258033	chr6:167368657	RNASET2	0.44	6.61	0.34	1.53e-10	Crohn's disease;
LUSC	trans	rs9380880	0.826	rs12175102	chr6:39554898	C/T	cg14673904	chr12:46609063	SLC38A1	-0.52	-5.98	-0.31	5.58e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs513349	1.000	rs210145	chr6:33547440	G/C	cg24505687	chr6:33548425	BAK1	0.37	6.18	0.32	1.88e-9	Platelet count;
LUSC	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg25801113	chr15:45476975	SHF	-0.34	-6.71	-0.34	8.19e-11	Uric acid levels;
LUSC	cis	rs3820068	0.608	rs12091326	chr1:16048005	A/G	cg13390004	chr1:15929781	NA	0.4	6.48	0.33	3.3e-10	Systolic blood pressure;
LUSC	cis	rs3755132	0.929	rs61446904	chr2:15748873	A/C	cg12888861	chr2:15731646	DDX1	0.5	7.3	0.37	2.16e-12	Wilms tumor;
LUSC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg20887711	chr4:1340912	KIAA1530	0.44	6.61	0.34	1.48e-10	Obesity-related traits;
LUSC	cis	rs10761482	0.500	rs1890926	chr10:62290105	T/C	cg18175470	chr10:62150864	ANK3	-0.48	-7.22	-0.37	3.47e-12	Schizophrenia;
LUSC	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg19683494	chr5:74908142	NA	0.56	7.63	0.39	2.54e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg16362232	chr11:430036	ANO9	0.7	8.64	0.43	2.3e-16	Body mass index;
LUSC	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg26597838	chr10:835615	NA	0.74	9.26	0.45	2.62e-18	Eosinophil percentage of granulocytes;
LUSC	cis	rs7017697	1.000	rs6980875	chr8:19685948	C/T	cg03894339	chr8:19674705	INTS10	-0.47	-6.83	-0.35	4.14e-11	Breast cancer;
LUSC	trans	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.46	0.42	8.24e-16	Resting heart rate;
LUSC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	0.74	11.27	0.52	3.4e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs394563	0.901	rs448874	chr6:149796967	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.32	-7.04	-0.36	1.1e-11	Dupuytren's disease;
LUSC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-6.97	-0.36	1.67e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs4729127	1.000	rs4729122	chr7:93988850	T/C	cg20086523	chr13:52378287	DHRS12	0.57	6.12	0.32	2.64e-9	Intelligence;
LUSC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg25019033	chr10:957182	NA	-0.51	-6.49	-0.33	3.03e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg02800362	chr5:177631904	HNRNPAB	0.85	12.77	0.57	1.09e-30	Obesity-related traits;
LUSC	cis	rs7147624	1.000	rs1009465	chr14:65970370	G/C	cg03016385	chr14:66212404	NA	-0.81	-9.47	-0.46	5.1e-19	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg18240062	chr17:79603768	NPLOC4	0.64	11.34	0.53	1.91e-25	Eye color traits;
LUSC	cis	rs295140	0.632	rs4673905	chr2:201163783	A/G	cg04283868	chr2:201171347	SPATS2L	0.4	5.78	0.3	1.75e-8	QT interval;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03791497	chr17:21118194	TMEM11	-0.47	-6.42	-0.33	4.77e-10	Hepatitis;
LUSC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg08859206	chr1:53392774	SCP2	-0.41	-6.72	-0.35	7.81e-11	Monocyte count;
LUSC	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg25922239	chr6:33757077	LEMD2	0.45	6.69	0.34	9.64e-11	Crohn's disease;
LUSC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg22437258	chr11:111473054	SIK2	0.52	7.44	0.38	8.76e-13	Primary sclerosing cholangitis;
LUSC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.9	-15.7	-0.65	5.27e-42	Chronic sinus infection;
LUSC	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.32	0.45	1.64e-18	Lung cancer in ever smokers;
LUSC	cis	rs12541491	0.506	rs11250007	chr8:10285086	C/G	cg12940923	chr8:10282607	MSRA	-0.47	-8.11	-0.41	9.76e-15	Schizophrenia;
LUSC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg04317338	chr11:64019027	PLCB3	0.68	7.75	0.39	1.12e-13	Mean platelet volume;
LUSC	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg06207120	chr15:45996521	NA	0.39	6.09	0.32	3.08e-9	Waist circumference;Weight;
LUSC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.84	13.87	0.6	7.24e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6987853	0.814	rs2923447	chr8:42439848	G/T	cg09913449	chr8:42400586	C8orf40	0.5	8.67	0.43	1.87e-16	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg22437258	chr11:111473054	SIK2	-0.48	-6.24	-0.32	1.33e-9	Primary sclerosing cholangitis;
LUSC	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg15704280	chr7:45808275	SEPT13	-0.44	-6.1	-0.32	3e-9	HDL cholesterol;
LUSC	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.81	0.35	4.63e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.89	16.47	0.67	5.01e-45	Menarche (age at onset);
LUSC	cis	rs9359856	0.564	rs72913954	chr6:90361589	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.76	-0.43	1e-16	Bipolar disorder;
LUSC	cis	rs4664308	0.935	rs6739867	chr2:160942818	G/A	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.62	-0.54	1.97e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs727505	0.954	rs7789055	chr7:124677543	G/T	cg23710748	chr7:124431027	NA	-0.38	-6.79	-0.35	5.21e-11	Lewy body disease;
LUSC	cis	rs11997175	0.624	rs67643247	chr8:33700790	G/A	ch.8.33884649F	chr8:33765107	NA	0.44	6.19	0.32	1.72e-9	Body mass index;
LUSC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.49	-11.87	-0.54	2.37e-27	Longevity;
LUSC	cis	rs6961069	0.722	rs4626520	chr7:80260023	G/A	cg04458919	chr7:80252533	CD36	0.38	6.7	0.34	8.83e-11	Platelet count;
LUSC	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg22482690	chr17:47019901	SNF8	0.4	7.47	0.38	7e-13	Type 2 diabetes;
LUSC	cis	rs6977660	0.714	rs6943204	chr7:19818671	A/G	cg05791153	chr7:19748676	TWISTNB	0.65	7.0	0.36	1.44e-11	Thyroid stimulating hormone;
LUSC	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	1.11	19.05	0.72	2.85e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1524927	1.000	rs7805658	chr7:96328466	G/A	cg03808172	chr7:96339361	SHFM1	0.43	6.54	0.34	2.32e-10	Total body bone mineral density;
LUSC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.62	8.23	0.41	4.34e-15	High light scatter reticulocyte count;
LUSC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.53	0.57	8.73e-30	Motion sickness;
LUSC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.84	0.51	1.21e-23	Heart rate;
LUSC	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg09835421	chr16:68378352	PRMT7	-0.59	-6.34	-0.33	7.28e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs17092148	1.000	rs6060047	chr20:33367400	G/T	cg16810054	chr20:33298113	TP53INP2	0.42	6.13	0.32	2.45e-9	Neuroticism;
LUSC	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg15212455	chr7:39170539	POU6F2	0.6	9.6	0.46	2.02e-19	IgG glycosylation;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07211384	chr2:86668246	KDM3A	0.5	7.61	0.38	2.86e-13	Calcium levels;
LUSC	cis	rs500891	0.574	rs3798889	chr6:84121512	G/T	cg08257003	chr6:84140564	ME1	0.36	8.73	0.43	1.23e-16	Platelet-derived growth factor BB levels;
LUSC	trans	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg18187862	chr3:45730750	SACM1L	-0.59	-7.2	-0.37	4.1e-12	Primary sclerosing cholangitis;
LUSC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01570182	chr17:44337453	NA	-0.66	-9.9	-0.48	1.94e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg17385448	chr1:15911702	AGMAT	0.37	6.17	0.32	2.03e-9	Systolic blood pressure;
LUSC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg18240062	chr17:79603768	NPLOC4	0.79	15.37	0.64	1.1e-40	Eye color traits;
LUSC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-11.31	-0.53	2.47e-25	Monocyte count;
LUSC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.58	-9.96	-0.48	1.21e-20	Blood metabolite levels;
LUSC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.75	12.78	0.57	1.01e-30	Motion sickness;
LUSC	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg13010199	chr12:38710504	ALG10B	0.58	9.16	0.45	5.51e-18	Morning vs. evening chronotype;
LUSC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.58	-10.55	-0.5	1.19e-22	Homoarginine levels;
LUSC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg13206674	chr6:150067644	NUP43	0.59	9.19	0.45	4.18e-18	Lung cancer;
LUSC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg02380750	chr20:61661411	NA	0.33	5.73	0.3	2.23e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11608355	1.000	rs10850135	chr12:109866528	C/A	cg05360138	chr12:110035743	NA	0.46	6.28	0.32	1.07e-9	Neuroticism;
LUSC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	trans	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg07211511	chr3:129823064	LOC729375	-1.09	-12.34	-0.56	4.43e-29	Blood pressure (smoking interaction);
LUSC	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg25214090	chr10:38739885	LOC399744	0.52	7.7	0.39	1.61e-13	Corneal astigmatism;
LUSC	cis	rs244293	0.965	rs244290	chr17:53231231	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.4	-5.71	-0.3	2.52e-8	Menarche (age at onset);
LUSC	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg17168535	chr8:21777572	XPO7	0.69	11.81	0.54	3.76e-27	Mean corpuscular volume;
LUSC	cis	rs73206853	0.841	rs56017468	chr12:110653857	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	6.45	0.33	3.99e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg27572855	chr1:25598939	RHD	0.46	8.29	0.41	2.81e-15	Erythrocyte sedimentation rate;
LUSC	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-1.0	-14.14	-0.61	6.61e-36	Exhaled nitric oxide output;
LUSC	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.49	16.86	0.68	1.38e-46	Opioid sensitivity;
LUSC	cis	rs7215564	0.908	rs57778244	chr17:78653798	T/G	cg09596252	chr17:78655493	RPTOR	0.56	6.05	0.31	3.85e-9	Myopia (pathological);
LUSC	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-0.89	-17.36	-0.69	1.5e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	8.98	0.44	1.99e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.51	0.38	5.48e-13	Iron status biomarkers;
LUSC	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-8.27	-0.41	3.27e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg11845111	chr2:191398756	TMEM194B	-0.91	-10.73	-0.51	2.84e-23	Diastolic blood pressure;
LUSC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.39	-0.42	1.41e-15	Schizophrenia;
LUSC	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.79	13.23	0.59	2.03e-32	Testicular germ cell tumor;
LUSC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg22868518	chr11:507468	RNH1	-0.59	-5.8	-0.3	1.56e-8	Body mass index;
LUSC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.41	-0.33	4.83e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs7712401	0.623	rs26372	chr5:122206447	C/T	cg19077854	chr5:122220652	SNX24	-0.4	-8.57	-0.42	3.89e-16	Mean platelet volume;
LUSC	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg08824895	chr13:115047677	UPF3A	0.56	8.63	0.43	2.48e-16	Schizophrenia;
LUSC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg09165964	chr15:75287851	SCAMP5	0.51	7.54	0.38	4.35e-13	Breast cancer;
LUSC	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg24130564	chr14:104152367	KLC1	-0.52	-7.72	-0.39	1.35e-13	Body mass index;
LUSC	trans	rs877282	0.838	rs11253374	chr10:774961	C/T	cg22713356	chr15:30763199	NA	1.07	14.98	0.63	3.58e-39	Uric acid levels;
LUSC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.79	0.35	5.02e-11	Urate levels;
LUSC	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg19920283	chr7:105172520	RINT1	0.6	6.35	0.33	7.01e-10	Bipolar disorder (body mass index interaction);
LUSC	trans	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg14227996	chr4:17616232	MED28	-0.6	-6.42	-0.33	4.59e-10	Opioid sensitivity;
LUSC	trans	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.82	-0.43	6.37e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg16342193	chr10:102329863	NA	-0.35	-6.39	-0.33	5.63e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9296092	0.538	rs34222093	chr6:33519584	G/C	cg13560919	chr6:33536144	NA	-0.82	-15.74	-0.65	3.89e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.83	0.3	1.3e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg17971929	chr21:40555470	PSMG1	-0.53	-7.77	-0.39	9.69e-14	Menarche (age at onset);
LUSC	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg11843606	chr2:227700838	RHBDD1	-0.64	-10.05	-0.48	6.33e-21	Pulmonary function;
LUSC	cis	rs7586879	0.828	rs10184813	chr2:25090236	T/C	cg01884057	chr2:25150051	NA	0.4	8.18	0.41	5.86e-15	Body mass index;
LUSC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg11608241	chr8:8085544	FLJ10661	0.43	6.07	0.32	3.43e-9	Neuroticism;
LUSC	cis	rs17094222	0.504	rs12267029	chr10:102458677	C/A	cg26540559	chr10:102447443	NA	0.53	9.17	0.45	4.98e-18	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21016266	chr12:122356598	WDR66	0.57	8.64	0.43	2.41e-16	Mean corpuscular volume;
LUSC	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg17691542	chr6:26056736	HIST1H1C	-0.46	-6.56	-0.34	2.02e-10	Iron status biomarkers;
LUSC	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg20744362	chr22:50050164	C22orf34	0.41	8.39	0.42	1.4e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg12064134	chr16:90016061	DEF8	0.36	5.7	0.3	2.69e-8	Squamous cell carcinoma;
LUSC	cis	rs295140	0.605	rs3769471	chr2:201195403	G/A	cg23649088	chr2:200775458	C2orf69	-0.37	-5.67	-0.3	3.15e-8	QT interval;
LUSC	trans	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg21775007	chr8:11205619	TDH	0.41	6.0	0.31	5.1e-9	Systolic blood pressure;
LUSC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg14895029	chr7:2775587	GNA12	-0.41	-6.07	-0.32	3.41e-9	Height;
LUSC	cis	rs7146395	1	rs7146395	chr14:75228647	A/C	cg08847533	chr14:75593920	NEK9	0.42	5.88	0.31	9.78e-9	Platelet count;
LUSC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg23711669	chr6:146136114	FBXO30	0.88	16.1	0.66	1.48e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4363385	0.720	rs6672735	chr1:152981086	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.82	-0.39	6.89e-14	Inflammatory skin disease;
LUSC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.77	-0.43	9.05e-17	Bipolar disorder;
LUSC	cis	rs6084875	0.785	rs2050370	chr20:4719781	G/T	cg26097573	chr20:4721490	PRNT	-0.31	-5.67	-0.3	3.11e-8	Systemic lupus erythematosus;
LUSC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	0.89	17.19	0.69	6.71e-48	Cognitive function;
LUSC	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.49	-0.38	6.11e-13	Retinal vascular caliber;
LUSC	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.5	-0.34	2.9e-10	Retinal vascular caliber;
LUSC	trans	rs7618314	0.504	rs2715694	chr3:108541143	C/T	cg12062537	chr1:1496856	SSU72	-0.57	-6.03	-0.31	4.35e-9	Airway responsiveness in chronic obstructive pulmonary disease;
LUSC	cis	rs59104589	0.583	rs3771573	chr2:242387346	G/A	cg14842376	chr2:242211374	HDLBP	0.53	6.15	0.32	2.2e-9	Fibrinogen levels;
LUSC	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg06937882	chr20:24974362	C20orf3	-0.43	-7.36	-0.37	1.42e-12	Blood protein levels;
LUSC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg03146154	chr1:46216737	IPP	-0.5	-7.23	-0.37	3.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg08017634	chr8:144659831	NAPRT1	-0.78	-9.21	-0.45	3.72e-18	Attention deficit hyperactivity disorder;
LUSC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.16	0.32	2.14e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6681460	0.966	rs6588215	chr1:67141949	A/G	cg02459107	chr1:67143332	SGIP1	0.48	8.87	0.44	4.54e-17	Presence of antiphospholipid antibodies;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg17440077	chr20:18122816	PET117;CSRP2BP	-0.73	-6.04	-0.31	4.09e-9	Cognitive performance;
LUSC	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.38	-0.42	1.49e-15	Total cholesterol levels;
LUSC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.72	-9.92	-0.48	1.7e-20	Urinary metabolites;
LUSC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.12	-0.36	6.49e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	7.49	0.38	6.34e-13	Body mass index;
LUSC	cis	rs909341	0.716	rs71325464	chr20:62363453	A/G	cg09650180	chr20:62225654	GMEB2	-0.47	-6.11	-0.32	2.75e-9	Atopic dermatitis;
LUSC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg08088566	chr11:430123	ANO9	0.6	7.04	0.36	1.09e-11	Body mass index;
LUSC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	0.97	13.15	0.58	3.92e-32	Eosinophil percentage of granulocytes;
LUSC	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg05340658	chr4:99064831	C4orf37	0.43	6.83	0.35	4.08e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg09904177	chr6:26538194	HMGN4	-0.71	-6.8	-0.35	4.92e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs6545883	0.895	rs6545871	chr2:61692203	G/T	cg15711740	chr2:61764176	XPO1	-0.45	-6.91	-0.35	2.46e-11	Tuberculosis;
LUSC	cis	rs4561483	0.549	rs154149	chr16:11956118	T/A	cg08843971	chr16:11963173	GSPT1	-0.43	-6.6	-0.34	1.64e-10	Testicular germ cell tumor;
LUSC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-1.03	-20.05	-0.74	3.02e-59	Height;
LUSC	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg13798780	chr7:105162888	PUS7	0.56	6.07	0.32	3.43e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg20887711	chr4:1340912	KIAA1530	0.46	7.19	0.37	4.23e-12	Longevity;
LUSC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg23630131	chr7:65973040	NA	0.22	5.99	0.31	5.5e-9	Aortic root size;
LUSC	trans	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg26811252	chr16:29126840	RRN3P2	0.59	9.83	0.47	3.47e-20	Menopause (age at onset);
LUSC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06850241	chr22:41845214	NA	0.34	6.22	0.32	1.46e-9	Vitiligo;
LUSC	cis	rs7113850	0.541	rs11820983	chr11:24211705	T/C	ch.11.24196551F	chr11:24239977	NA	0.93	7.86	0.39	5.41e-14	Bone fracture in osteoporosis;
LUSC	cis	rs12368653	0.651	rs2307097	chr12:58195801	T/C	cg12615879	chr12:58013172	SLC26A10	0.37	8.37	0.42	1.64e-15	Multiple sclerosis;
LUSC	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg16482183	chr6:26056742	HIST1H1C	0.61	8.7	0.43	1.57e-16	Iron status biomarkers;
LUSC	cis	rs3931020	0.688	rs277375	chr1:75204143	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.44	5.73	0.3	2.3e-8	Resistin levels;
LUSC	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg03859395	chr2:55845619	SMEK2	0.86	15.72	0.65	4.52e-42	Metabolic syndrome;
LUSC	cis	rs11785693	0.862	rs11782556	chr8:5002389	C/G	cg26367366	chr8:4980734	NA	0.73	8.36	0.42	1.71e-15	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg00310523	chr12:86230176	RASSF9	0.51	9.68	0.47	1.07e-19	Major depressive disorder;
LUSC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	cis	rs790123	0.565	rs17269087	chr3:122379262	A/C	cg00926285	chr3:122398533	PARP14	-0.48	-6.16	-0.32	2.1e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg13256891	chr4:100009986	ADH5	0.44	6.62	0.34	1.43e-10	Alcohol dependence;
LUSC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.33	5.97	0.31	6.08e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1535500	0.905	rs2146262	chr6:39283793	C/T	cg06347083	chr6:39282316	KCNK17	-0.27	-6.11	-0.32	2.76e-9	Type 2 diabetes;
LUSC	cis	rs9341808	0.556	rs1474791	chr6:81033097	A/G	cg08355045	chr6:80787529	NA	0.51	8.87	0.44	4.41e-17	Sitting height ratio;
LUSC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	1.04	19.77	0.73	3.88e-58	Menopause (age at onset);
LUSC	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg05295671	chr13:79234353	RNF219	0.46	6.01	0.31	4.86e-9	Large artery stroke;
LUSC	cis	rs7808935	0.768	rs739704	chr7:27989768	G/A	cg22168087	chr7:27702803	HIBADH	0.53	6.4	0.33	5.39e-10	Prostate cancer;
LUSC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg13206674	chr6:150067644	NUP43	0.55	8.59	0.43	3.41e-16	Lung cancer;
LUSC	cis	rs12208915	0.848	rs9343834	chr6:79517671	G/A	cg05283184	chr6:79620031	NA	0.42	5.68	0.3	2.92e-8	Left atrial antero-posterior diameter;
LUSC	cis	rs4654899	1.000	rs10916921	chr1:21334542	C/T	cg01072550	chr1:21505969	NA	-0.55	-8.41	-0.42	1.23e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg01770232	chr7:22766155	IL6	0.39	5.66	0.3	3.29e-8	Lung cancer;
LUSC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-17.83	-0.7	2.02e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg07169764	chr2:136633963	MCM6	-0.63	-8.27	-0.41	3.24e-15	Mosquito bite size;
LUSC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg03146154	chr1:46216737	IPP	0.56	8.5	0.42	6.44e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg11845111	chr2:191398756	TMEM194B	0.54	9.31	0.45	1.71e-18	Pulse pressure;
LUSC	cis	rs11676348	0.772	rs12694427	chr2:218945045	C/T	cg18102446	chr2:218934044	RUFY4	0.37	5.94	0.31	7.21e-9	Ulcerative colitis;
LUSC	cis	rs7202877	0.610	rs4888381	chr16:75356847	C/A	cg03315344	chr16:75512273	CHST6	0.43	6.22	0.32	1.51e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg13798780	chr7:105162888	PUS7	0.56	6.15	0.32	2.23e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg06951627	chr6:26196580	NA	0.53	5.79	0.3	1.59e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.47	-7.29	-0.37	2.29e-12	Height;
LUSC	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.18	-0.32	1.82e-9	Neutrophil percentage of white cells;
LUSC	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg04851639	chr8:1020857	NA	-0.39	-8.07	-0.4	1.24e-14	Schizophrenia;
LUSC	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.69	-11.22	-0.52	5.09e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg20283391	chr11:68216788	NA	-0.54	-7.97	-0.4	2.57e-14	Total body bone mineral density;
LUSC	cis	rs9815354	0.812	rs73073233	chr3:42010550	A/G	cg03022575	chr3:42003672	ULK4	0.82	8.57	0.42	3.93e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.17	0.58	3.43e-32	Chronic sinus infection;
LUSC	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg04691961	chr3:161091175	C3orf57	-0.35	-5.9	-0.31	8.87e-9	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	8.7	0.43	1.53e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-6.0	-0.31	5.25e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2274273	0.905	rs28429419	chr14:55574793	T/C	cg04306507	chr14:55594613	LGALS3	0.55	12.54	0.57	7.81e-30	Protein biomarker;
LUSC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg10909506	chr17:38081995	ORMDL3	0.33	5.95	0.31	6.59e-9	Self-reported allergy;
LUSC	cis	rs4629180	0.586	rs1848699	chr2:102137903	C/G	cg01388757	chr2:102091195	RFX8	-0.36	-6.27	-0.32	1.12e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	trans	rs61931739	0.613	rs6488174	chr12:33756569	T/C	cg26384229	chr12:38710491	ALG10B	0.43	6.24	0.32	1.31e-9	Morning vs. evening chronotype;
LUSC	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.71	13.07	0.58	7.86e-32	Platelet distribution width;
LUSC	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-0.81	-10.89	-0.51	7.72e-24	Eosinophil percentage of granulocytes;
LUSC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg05717871	chr11:638507	DRD4	-0.36	-6.05	-0.31	3.95e-9	Systemic lupus erythematosus;
LUSC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs829883	0.659	rs12366275	chr12:98920276	G/C	cg25150519	chr12:98850993	NA	-0.64	-8.7	-0.43	1.53e-16	Colorectal adenoma (advanced);
LUSC	cis	rs7216064	1.000	rs12600941	chr17:65918807	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-9.19	-0.45	4.35e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg05340658	chr4:99064831	C4orf37	0.63	9.97	0.48	1.17e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg21775007	chr8:11205619	TDH	-0.52	-7.74	-0.39	1.16e-13	Systolic blood pressure;
LUSC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg03395651	chr16:88107091	BANP	0.37	5.65	0.3	3.49e-8	Menopause (age at onset);
LUSC	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg12940439	chr1:67600707	NA	0.36	6.12	0.32	2.63e-9	Psoriasis;
LUSC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg11764359	chr7:65958608	NA	-0.41	-5.87	-0.31	1.04e-8	Calcium levels;
LUSC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg18306943	chr3:40428807	ENTPD3	0.41	6.15	0.32	2.21e-9	Renal cell carcinoma;
LUSC	cis	rs17255340	0.520	rs6935935	chr6:84130734	C/G	cg08257003	chr6:84140564	ME1	0.37	9.11	0.45	7.7e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs73206853	0.841	rs73191828	chr12:110946121	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	7.83e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg21724239	chr8:58056113	NA	0.57	6.58	0.34	1.84e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11690935	0.632	rs35854151	chr2:172657439	G/A	cg13550731	chr2:172543902	DYNC1I2	0.57	8.75	0.43	1.04e-16	Schizophrenia;
LUSC	cis	rs72772090	0.539	rs11748519	chr5:96119328	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.58	-0.34	1.83e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.8	0.3	1.56e-8	Lymphocyte counts;
LUSC	trans	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg01620082	chr3:125678407	NA	-0.78	-7.29	-0.37	2.28e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs12406019	0.510	rs12126464	chr1:78608215	T/C	cg20826526	chr3:156266748	SSR3	-0.5	-7.58	-0.38	3.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.56	-0.34	2.03e-10	Lung cancer;
LUSC	cis	rs3847687	1.000	rs3847688	chr12:131525310	C/T	cg13586425	chr12:131519906	GPR133	-0.26	-5.87	-0.31	1.02e-8	Longevity;
LUSC	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-1.06	-12.49	-0.56	1.19e-29	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.05	-0.4	1.45e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg02196655	chr2:10830764	NOL10	0.34	5.79	0.3	1.64e-8	Prostate cancer;
LUSC	cis	rs4792901	0.759	rs34409913	chr17:41564293	T/G	cg22562494	chr17:41607896	ETV4	-0.32	-6.18	-0.32	1.85e-9	Dupuytren's disease;
LUSC	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	1.01	13.91	0.61	4.95e-35	Exhaled nitric oxide levels;
LUSC	trans	rs9755467	0.665	rs57706556	chr3:127181579	T/A	cg12446303	chr6:168709593	DACT2	0.38	5.95	0.31	6.88e-9	Educational attainment (years of education);
LUSC	cis	rs73198271	0.515	rs75990942	chr8:8639761	C/T	cg01851573	chr8:8652454	MFHAS1	0.56	6.24	0.32	1.32e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16249894	chr13:21141322	IFT88	0.42	7.12	0.36	6.86e-12	Asthma;
LUSC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg06784218	chr1:46089804	CCDC17	-0.48	-9.34	-0.46	1.41e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs308403	0.600	rs309366	chr4:123661408	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	11.36	0.53	1.72e-25	Blood protein levels;
LUSC	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04850017	chr11:63683019	RCOR2	0.3	5.82	0.3	1.4e-8	Pulse pressure;
LUSC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.29	0.37	2.24e-12	Platelet count;
LUSC	cis	rs501916	0.634	rs8037600	chr15:48060331	A/G	cg16110827	chr15:48056943	SEMA6D	-0.4	-6.26	-0.32	1.16e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	trans	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-8.79	-0.43	8.05e-17	Morning vs. evening chronotype;
LUSC	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg16989719	chr2:238392110	NA	-0.42	-7.16	-0.36	5.07e-12	Prostate cancer;
LUSC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg16647868	chr5:131706066	SLC22A5	0.4	6.18	0.32	1.86e-9	Breast cancer;
LUSC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.47	7.77	0.39	9.47e-14	Pulse pressure;
LUSC	cis	rs10504229	0.516	rs4060631	chr8:57990757	G/A	cg11062466	chr8:58055876	NA	0.39	5.79	0.3	1.58e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs722599	0.683	rs10144860	chr14:75286426	T/C	cg08847533	chr14:75593920	NEK9	0.45	6.36	0.33	6.47e-10	IgG glycosylation;
LUSC	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.64	-9.55	-0.46	2.97e-19	LDL cholesterol to HDL cholesterol ratio;
LUSC	cis	rs6558174	0.965	rs1564595	chr8:22488939	A/G	cg03733263	chr8:22462867	KIAA1967	0.48	6.46	0.33	3.61e-10	Breast cancer;
LUSC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-13.0	-0.58	1.54e-31	Platelet count;
LUSC	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg09307838	chr4:120376055	NA	0.75	10.89	0.51	7.5e-24	Corneal astigmatism;
LUSC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	7.25	0.37	2.87e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6546537	0.824	rs3771543	chr2:69784255	C/T	cg10773587	chr2:69614142	GFPT1	-0.59	-9.35	-0.46	1.35e-18	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.72	0.43	1.34e-16	Prudent dietary pattern;
LUSC	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.54	-0.34	2.36e-10	QT interval;
LUSC	cis	rs7605827	0.930	rs6718736	chr2:15525875	C/T	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.53	7.31	0.37	1.99e-12	IgG glycosylation;
LUSC	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg09754948	chr16:28834200	ATXN2L	-0.41	-5.84	-0.3	1.25e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.7	8.92	0.44	3.06e-17	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg18230493	chr5:56204884	C5orf35	-0.78	-11.07	-0.52	1.73e-24	Initial pursuit acceleration;
LUSC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg22166914	chr1:53195759	ZYG11B	-0.73	-12.91	-0.58	3.18e-31	Monocyte count;
LUSC	cis	rs68170813	0.523	rs12535093	chr7:107020182	C/T	cg02696742	chr7:106810147	HBP1	-0.61	-9.06	-0.44	1.16e-17	Coronary artery disease;
LUSC	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.52	9.58	0.46	2.31e-19	Bone mineral density;
LUSC	cis	rs28655083	1.000	rs8059347	chr16:77068259	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.41	-6.05	-0.31	3.88e-9	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg26043149	chr18:55253948	FECH	-0.44	-6.81	-0.35	4.65e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg24733560	chr20:60626293	TAF4	0.41	6.7	0.34	8.69e-11	Body mass index;
LUSC	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg21211680	chr2:198530	NA	-0.57	-6.91	-0.35	2.54e-11	Blood protein levels;
LUSC	trans	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg02673351	chr19:3532544	FZR1	-0.41	-5.96	-0.31	6.28e-9	Longevity;Endometriosis;
LUSC	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg00078996	chr12:132293329	NA	-0.36	-5.65	-0.3	3.48e-8	Migraine;
LUSC	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg13206674	chr6:150067644	NUP43	0.56	8.77	0.43	9.31e-17	Lung cancer;
LUSC	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.42	-0.62	5.29e-37	Schizophrenia;
LUSC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.11e-11	Crohn's disease;
LUSC	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg24675056	chr1:15929824	NA	0.43	7.11	0.36	7.09e-12	Systolic blood pressure;
LUSC	cis	rs1957429	0.614	rs17767870	chr14:65321737	G/A	cg23373153	chr14:65346875	NA	-0.84	-7.35	-0.37	1.55e-12	Pediatric areal bone mineral density (radius);
LUSC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.91	-0.4	3.78e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	0.95	18.03	0.7	3.12e-51	Heart rate;
LUSC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.41	6.76	0.35	6.23e-11	Cystic fibrosis severity;
LUSC	cis	rs228769	0.673	rs228787	chr17:42099488	C/T	cg19774624	chr17:42201019	HDAC5	0.63	8.28	0.41	2.98e-15	Bone mineral density (hip);Bone mineral density (spine);
LUSC	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.42	6.56	0.34	2.04e-10	Dupuytren's disease;
LUSC	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg09876464	chr15:85330779	ZNF592	0.36	6.72	0.35	7.65e-11	P wave terminal force;
LUSC	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg08999081	chr20:33150536	PIGU	0.37	6.84	0.35	3.89e-11	Height;
LUSC	cis	rs12210905	0.688	rs72843177	chr6:27367414	A/G	cg08851530	chr6:28072375	NA	0.97	6.41	0.33	4.91e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg01475377	chr6:109611718	NA	-0.43	-7.79	-0.39	8.73e-14	Reticulocyte fraction of red cells;
LUSC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg15147215	chr3:52552868	STAB1	-0.32	-6.33	-0.33	7.76e-10	Electroencephalogram traits;
LUSC	trans	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs57244997	0.872	rs11759694	chr6:162405705	C/G	cg17173639	chr6:162384350	PARK2	0.61	6.01	0.31	4.98e-9	Mosquito bite size;
LUSC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg06096015	chr1:231504339	EGLN1	0.56	9.8	0.47	4.44e-20	Hemoglobin concentration;
LUSC	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-6.38	-0.33	6.06e-10	Fibrinogen levels;
LUSC	cis	rs78572108	0.858	rs10173801	chr2:42262132	C/T	cg00607755	chr2:42274082	PKDCC	0.35	6.24	0.32	1.34e-9	Total body bone mineral density;
LUSC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg23283495	chr1:209979779	IRF6	0.66	8.49	0.42	6.64e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg22875332	chr1:76189707	ACADM	0.75	10.04	0.48	6.69e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg12463550	chr7:65579703	CRCP	-0.43	-6.31	-0.33	8.67e-10	Aortic root size;
LUSC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.41	0.42	1.2e-15	Prudent dietary pattern;
LUSC	cis	rs17001868	0.568	rs9607701	chr22:40739116	A/G	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	cis	rs7712401	0.525	rs2910150	chr5:122296745	G/T	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	trans	rs9944715	0.954	rs6507691	chr18:43808648	T/C	cg01718231	chr17:29326311	RNF135	-0.53	-7.36	-0.37	1.42e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg15839431	chr19:19639596	YJEFN3	-0.58	-6.27	-0.32	1.12e-9	Bipolar disorder;
LUSC	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg23176889	chr5:176863531	GRK6	-0.67	-12.7	-0.57	2.05e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg20573242	chr4:122745356	CCNA2	0.64	9.03	0.44	1.36e-17	Type 2 diabetes;
LUSC	cis	rs7241530	0.662	rs12966267	chr18:75900507	T/C	cg14642773	chr18:75888474	NA	0.37	5.74	0.3	2.08e-8	Educational attainment (years of education);
LUSC	trans	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-21.15	-0.76	1.34e-63	Prudent dietary pattern;
LUSC	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg25801113	chr15:45476975	SHF	0.35	7.35	0.37	1.58e-12	Uric acid levels;
LUSC	cis	rs3916	1.000	rs2014355	chr12:121175524	A/G	cg27246729	chr12:121163418	ACADS	0.44	6.53	0.34	2.49e-10	Urinary metabolites (H-NMR features);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21037378	chr4:142142045	ZNF330	-0.41	-6.06	-0.31	3.75e-9	Electrocardiographic conduction measures;
LUSC	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg05294307	chr14:35346193	BAZ1A	-0.56	-6.3	-0.33	9.49e-10	Psoriasis;
LUSC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg08270630	chr22:50330655	NA	0.4	5.93	0.31	7.51e-9	Schizophrenia;
LUSC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-10.57	-0.5	1.02e-22	Mood instability;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23418208	chr14:104182045	ZFYVE21;XRCC3	0.44	6.13	0.32	2.42e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7605827	0.930	rs10929374	chr2:15676884	T/A	cg19274914	chr2:15703543	NA	0.44	8.34	0.41	2.04e-15	Educational attainment (years of education);
LUSC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-14.4	-0.62	6.79e-37	Monocyte count;
LUSC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs17030434	0.954	rs17030570	chr4:154755186	A/G	cg14289246	chr4:154710475	SFRP2	0.52	6.4	0.33	5.29e-10	Electrocardiographic conduction measures;
LUSC	cis	rs12704876	0.530	rs2177675	chr7:96342253	A/T	cg03808172	chr7:96339361	SHFM1	0.54	8.17	0.41	6.37e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.41	-0.42	1.24e-15	Joint mobility (Beighton score);
LUSC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg14552801	chr7:65878734	NA	0.46	6.58	0.34	1.79e-10	Aortic root size;
LUSC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	0.91	13.51	0.59	1.7e-33	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08131848	chr9:88420837	LOC389765	-0.41	-5.98	-0.31	5.58e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg21699342	chr2:239360505	ASB1	0.54	10.38	0.49	4.51e-22	Multiple system atrophy;
LUSC	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg15744005	chr10:104629667	AS3MT	-0.29	-6.28	-0.32	1.05e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.73	-0.47	7.36e-20	Hemoglobin concentration;
LUSC	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg06627628	chr2:24431161	ITSN2	-0.6	-7.32	-0.37	1.86e-12	Lymphocyte counts;
LUSC	trans	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg19694781	chr19:47549865	TMEM160	-0.59	-9.41	-0.46	8.5e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	trans	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.26e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg07701084	chr6:150067640	NUP43	0.47	7.01	0.36	1.35e-11	Lung cancer;
LUSC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg08481491	chr3:125900108	ALDH1L1	-0.31	-6.44	-0.33	4.27e-10	Metabolite levels;
LUSC	cis	rs4356932	1.000	rs6826163	chr4:76973445	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.83	0.3	1.33e-8	Blood protein levels;
LUSC	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.67	-0.54	1.26e-26	Coffee consumption (cups per day);
LUSC	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	0.96	13.28	0.59	1.29e-32	Primary sclerosing cholangitis;
LUSC	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg05855489	chr10:104503620	C10orf26	0.59	9.35	0.46	1.29e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs853679	1.000	rs853685	chr6:28288785	C/T	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.29	-0.33	9.79e-10	Depression;
LUSC	cis	rs35000415	0.873	rs13246321	chr7:128701331	T/C	cg19972273	chr7:128594194	NA	0.63	5.72	0.3	2.34e-8	Systemic lupus erythematosus;
LUSC	cis	rs73001065	0.901	rs73004951	chr19:19695228	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	7.18	0.37	4.52e-12	LDL cholesterol;
LUSC	cis	rs67366981	1.000	rs8006117	chr14:77713279	G/A	cg22824376	chr14:77648248	TMEM63C	0.65	6.19	0.32	1.75e-9	Obsessive-compulsive symptoms;
LUSC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg00564555	chr16:1970112	NA	-0.35	-5.87	-0.31	1.02e-8	Insulin-like growth factors;
LUSC	cis	rs12681287	0.517	rs34596274	chr8:87517679	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.28	-0.37	2.44e-12	Caudate activity during reward;
LUSC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg19318889	chr4:1322082	MAEA	-0.78	-13.96	-0.61	3.39e-35	Longevity;
LUSC	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg16579770	chr16:72058938	DHODH	0.34	5.78	0.3	1.73e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg16060761	chr17:80687452	NA	0.41	6.32	0.33	8.3e-10	Breast cancer;
LUSC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg05347473	chr6:146136440	FBXO30	0.37	5.99	0.31	5.53e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.68	0.63	5.62e-38	Platelet count;
LUSC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg16624210	chr5:671434	TPPP	0.48	6.04	0.31	4.04e-9	Obesity-related traits;
LUSC	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg09021430	chr5:549028	NA	-0.6	-9.39	-0.46	9.53e-19	Obesity-related traits;
LUSC	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg00757033	chr12:89920650	WDR51B	0.58	9.71	0.47	8.6e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg03146154	chr1:46216737	IPP	0.56	8.37	0.42	1.57e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-9.8	-0.47	4.44e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.59	0.5	8.45e-23	Bone mineral density;
LUSC	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg26395211	chr5:140044315	WDR55	0.41	6.4	0.33	5.34e-10	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03934478	chr11:495069	RNH1	0.84	9.68	0.47	1.11e-19	Body mass index;
LUSC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.51	0.65	3.1e-41	Platelet count;
LUSC	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg05340658	chr4:99064831	C4orf37	0.44	7.19	0.37	4.24e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4343996	0.558	rs10281401	chr7:3416173	T/C	cg21248987	chr7:3385318	SDK1	0.36	6.14	0.32	2.28e-9	Motion sickness;
LUSC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg12560992	chr17:57184187	TRIM37	0.83	15.3	0.64	2e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg06521331	chr12:34319734	NA	-0.35	-5.7	-0.3	2.61e-8	Morning vs. evening chronotype;
LUSC	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg04117972	chr1:227635322	NA	0.61	7.06	0.36	9.55e-12	Major depressive disorder;
LUSC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	0.89	16.19	0.66	6.46e-44	Height;
LUSC	cis	rs7191700	0.511	rs12923756	chr16:11359675	C/T	cg00044050	chr16:11439710	C16orf75	-0.7	-12.27	-0.56	7.97e-29	Multiple sclerosis;
LUSC	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.44	6.89	0.35	2.85e-11	Dupuytren's disease;
LUSC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-1.06	-20.17	-0.74	9.4e-60	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	0.93	16.17	0.66	7.55e-44	Menopause (age at onset);
LUSC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg21132104	chr15:45694354	SPATA5L1	0.45	5.98	0.31	5.68e-9	Homoarginine levels;
LUSC	cis	rs7119	0.689	rs12901765	chr15:77819103	C/A	cg27398640	chr15:77910606	LINGO1	-0.31	-6.63	-0.34	1.34e-10	Type 2 diabetes;
LUSC	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.82	0.35	4.29e-11	Height;
LUSC	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg07169764	chr2:136633963	MCM6	0.68	9.43	0.46	7.28e-19	Mosquito bite size;
LUSC	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg00334542	chr7:100209784	MOSPD3	-0.48	-5.68	-0.3	2.87e-8	Other erythrocyte phenotypes;
LUSC	trans	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.52	-0.34	2.55e-10	Life satisfaction;
LUSC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07677032	chr17:61819896	STRADA	0.53	8.77	0.43	9.43e-17	Prudent dietary pattern;
LUSC	cis	rs6578985	1.000	rs6578986	chr11:2138152	A/G	cg25742037	chr11:2171694	INS-IGF2;IGF2	0.33	6.18	0.32	1.89e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10553204	chr2:20871195	GDF7	-0.34	-5.95	-0.31	6.86e-9	Abdominal aortic aneurysm;
LUSC	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.53	10.54	0.5	1.31e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg12560992	chr17:57184187	TRIM37	0.84	15.48	0.65	3.82e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg14036092	chr11:66035641	RAB1B	0.44	6.34	0.33	7.65e-10	Gout;
LUSC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg22907277	chr7:1156413	C7orf50	0.62	7.4	0.38	1.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg03886242	chr7:26192032	NFE2L3	0.36	6.03	0.31	4.39e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg23711669	chr6:146136114	FBXO30	0.88	16.26	0.66	3.3e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg07701084	chr6:150067640	NUP43	-0.56	-7.99	-0.4	2.24e-14	Lung cancer;
LUSC	cis	rs2267681	0.603	rs194152	chr7:139539936	C/G	cg14116596	chr7:139528673	TBXAS1	-0.37	-6.45	-0.33	3.96e-10	Cervical cancer;
LUSC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg18351406	chr4:77819688	ANKRD56	-0.55	-8.18	-0.41	5.87e-15	Emphysema distribution in smoking;
LUSC	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg00750074	chr16:89608354	SPG7	-0.46	-6.92	-0.35	2.35e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg02423579	chr7:2872169	GNA12	-0.41	-6.52	-0.34	2.66e-10	Height;
LUSC	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.78	11.46	0.53	7.35e-26	Corneal astigmatism;
LUSC	cis	rs10992471	0.603	rs11792019	chr9:95195229	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-7.95	-0.4	2.84e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05347473	chr6:146136440	FBXO30	-0.55	-9.55	-0.46	2.84e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg08999081	chr20:33150536	PIGU	0.32	5.65	0.3	3.51e-8	Height;
LUSC	cis	rs9653442	0.932	rs893245	chr2:100814893	C/T	cg22139774	chr2:100720529	AFF3	-0.45	-7.73	-0.39	1.24e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2688608	0.905	rs2633300	chr10:75656647	A/C	cg23231163	chr10:75533350	FUT11	-0.38	-6.23	-0.32	1.39e-9	Inflammatory bowel disease;
LUSC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg13319975	chr6:146136371	FBXO30	-0.67	-10.06	-0.48	5.76e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg27471124	chr11:109292789	C11orf87	0.38	6.94	0.35	2.08e-11	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg16339924	chr4:17578868	LAP3	0.55	8.37	0.42	1.62e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg16070123	chr10:51489643	NA	-0.51	-8.04	-0.4	1.59e-14	Prostate-specific antigen levels;
LUSC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.77	10.43	0.5	3.11e-22	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs9403521	1.000	rs6901659	chr6:143985106	T/C	cg18240653	chr6:144019428	PHACTR2	-0.51	-6.21	-0.32	1.56e-9	Obesity-related traits;
LUSC	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg00383909	chr3:49044727	WDR6	1.14	10.58	0.5	9.36e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2729354	0.768	rs2729384	chr11:57258617	T/C	cg24343310	chr11:57249947	NA	0.46	8.65	0.43	2.19e-16	Blood protein levels;
LUSC	cis	rs367943	0.712	rs1120091	chr5:112684229	C/A	cg12552261	chr5:112820674	MCC	0.39	6.37	0.33	6.4e-10	Type 2 diabetes;
LUSC	cis	rs13082711	0.863	rs13062327	chr3:27495573	G/A	cg02860705	chr3:27208620	NA	0.47	7.8	0.39	8.1e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg09877947	chr5:131593287	PDLIM4	0.41	6.83	0.35	4.02e-11	Blood metabolite levels;
LUSC	cis	rs4642101	0.534	rs13316229	chr3:12807371	C/T	cg24848339	chr3:12840334	CAND2	0.33	6.44	0.33	4.24e-10	QRS complex (12-leadsum);
LUSC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs870825	0.929	rs871253	chr4:185589234	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	10.8	0.51	1.6e-23	Blood protein levels;
LUSC	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg08999081	chr20:33150536	PIGU	0.38	6.8	0.35	4.87e-11	Height;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18909525	chr9:132403873	ASB6	0.42	6.03	0.31	4.34e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6960043	0.738	rs10950549	chr7:15057829	G/A	cg19272540	chr7:15055459	NA	0.34	8.21	0.41	4.77e-15	Type 2 diabetes;
LUSC	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg20821713	chr7:1055600	C7orf50	-0.55	-7.24	-0.37	3.2e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs10489202	1.000	rs12408205	chr1:167982332	A/G	cg24449463	chr1:168025552	DCAF6	-0.59	-7.39	-0.37	1.21e-12	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg18402987	chr7:1209562	NA	0.72	7.69	0.39	1.67e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04565464	chr8:145669602	NFKBIL2	0.38	6.05	0.31	3.89e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7189233	0.531	rs7204758	chr16:53482365	G/A	cg09728985	chr16:53543985	NA	-0.3	-5.78	-0.3	1.73e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg11062466	chr8:58055876	NA	0.51	6.7	0.34	8.73e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg09835421	chr16:68378352	PRMT7	-0.8	-8.45	-0.42	9.21e-16	Magnesium levels;
LUSC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18099408	chr3:52552593	STAB1	-0.46	-8.2	-0.41	5.26e-15	Bipolar disorder;
LUSC	cis	rs4588572	0.643	rs11744479	chr5:77729220	T/G	cg11547950	chr5:77652471	NA	-0.55	-7.98	-0.4	2.43e-14	Triglycerides;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	ch.3.343413R	chr3:15058168	NR2C2	0.37	6.02	0.31	4.55e-9	Schizophrenia;
LUSC	cis	rs921665	0.831	rs3792156	chr2:3196859	C/T	cg02624386	chr2:3182749	NA	-0.63	-6.19	-0.32	1.8e-9	World class endurance athleticism;
LUSC	cis	rs9297145	0.916	rs6969140	chr7:98753900	G/A	cg05967295	chr7:98741636	SMURF1	-0.96	-16.39	-0.67	1.01e-44	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03934478	chr11:495069	RNH1	0.84	9.73	0.47	7.23e-20	Body mass index;
LUSC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.71	13.9	0.61	5.76e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11645898	0.745	rs55824906	chr16:72064905	A/G	cg14768367	chr16:72042858	DHODH	-0.73	-7.83	-0.39	6.44e-14	Blood protein levels;
LUSC	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg18825076	chr15:78729989	IREB2	0.47	6.31	0.33	9.03e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7903847	0.701	rs11189173	chr10:99138792	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-6.49	-0.33	3.06e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg20628663	chr10:43360327	NA	-0.76	-11.4	-0.53	1.23e-25	Blood protein levels;
LUSC	cis	rs12760731	0.720	rs35905053	chr1:178441618	A/T	cg00404053	chr1:178313656	RASAL2	0.59	6.32	0.33	8.28e-10	Obesity-related traits;
LUSC	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.53	-0.38	4.87e-13	Body mass index;
LUSC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg02782426	chr3:40428986	ENTPD3	0.42	7.79	0.39	8.29e-14	Renal cell carcinoma;
LUSC	cis	rs500891	1.000	rs34681854	chr6:84162641	C/T	cg08257003	chr6:84140564	ME1	0.35	7.14	0.36	5.99e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg24910161	chr17:38119198	GSDMA	-0.28	-5.95	-0.31	6.67e-9	Asthma;
LUSC	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-15.9	-0.66	8.8e-43	Heart rate;
LUSC	cis	rs897984	0.609	rs1108431	chr16:31054607	C/T	cg02466173	chr16:30829666	NA	-0.54	-10.37	-0.49	5.05e-22	Dementia with Lewy bodies;
LUSC	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	6.0	0.31	5.2e-9	IgG glycosylation;
LUSC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.7	0.6	3.15e-34	Cognitive test performance;
LUSC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg14019146	chr3:50243930	SLC38A3	0.32	7.1	0.36	7.5e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.61	0.38	2.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg16405210	chr4:1374714	KIAA1530	-0.52	-8.17	-0.41	6.39e-15	Obesity-related traits;
LUSC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg00310523	chr12:86230176	RASSF9	0.54	10.05	0.48	5.93e-21	Major depressive disorder;
LUSC	trans	rs72674100	1.000	rs2865757	chr4:97992597	C/T	cg09670535	chr1:18959427	PAX7	-0.61	-6.23	-0.32	1.41e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01035528	chr12:123460159	OGFOD2;ABCB9	-0.47	-6.32	-0.33	8.53e-10	Hepatitis;
LUSC	cis	rs981844	1.000	rs2251994	chr4:154654097	C/T	cg14289246	chr4:154710475	SFRP2	0.51	6.5	0.34	2.93e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs6009527	0.752	rs7288176	chr22:49568462	A/G	cg12746016	chr22:49560550	NA	-0.48	-9.03	-0.44	1.38e-17	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.33	0.56	4.72e-29	Lymphocyte percentage of white cells;
LUSC	trans	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg24644049	chr4:85504048	CDS1	0.69	7.03	0.36	1.15e-11	Skin colour saturation;
LUSC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4680	1.000	rs165656	chr22:19948863	C/G	cg23601416	chr22:19950040	COMT	-0.3	-6.23	-0.32	1.43e-9	Blood metabolite levels;
LUSC	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg22875332	chr1:76189707	ACADM	-0.41	-6.04	-0.31	4.06e-9	Daytime sleep phenotypes;
LUSC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg26587870	chr6:27730563	NA	-0.66	-5.94	-0.31	7.24e-9	Depression;
LUSC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg04450456	chr4:17643702	FAM184B	0.4	6.67	0.34	1.09e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg04727924	chr7:799746	HEATR2	-0.54	-6.77	-0.35	5.72e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2652834	0.851	rs1126312	chr15:63427638	C/T	cg05507819	chr15:63340323	TPM1	-0.45	-5.84	-0.3	1.23e-8	HDL cholesterol;
LUSC	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.56	-0.34	2.09e-10	Breast cancer;
LUSC	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg04362960	chr10:104952993	NT5C2	1.1	12.9	0.58	3.57e-31	Arsenic metabolism;
LUSC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.54	0.34	2.24e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-7.36	-0.37	1.4e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg04414720	chr1:150670196	GOLPH3L	0.56	9.1	0.45	8.47e-18	Tonsillectomy;
LUSC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.87	0.31	1.07e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18876405	chr7:65276391	NA	-0.53	-8.4	-0.42	1.28e-15	Aortic root size;
LUSC	cis	rs11997175	0.520	rs6994803	chr8:33817796	A/G	ch.8.33884649F	chr8:33765107	NA	0.43	6.64	0.34	1.3e-10	Body mass index;
LUSC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	0.91	13.39	0.59	5.07e-33	Breast cancer;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	0.98	21.23	0.76	6.43e-64	Menarche (age at onset);
LUSC	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg12744634	chr1:26560303	CCDC21	0.39	5.84	0.3	1.25e-8	Obesity-related traits;
LUSC	cis	rs1044826	0.692	rs295484	chr3:139231782	A/G	cg00490450	chr3:139108681	COPB2	-0.45	-7.01	-0.36	1.3e-11	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02796621	chr17:19248565	MIR1180;B9D1	-0.37	-6.28	-0.32	1.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg03859395	chr2:55845619	SMEK2	0.86	16.21	0.66	5.09e-44	Metabolic syndrome;
LUSC	cis	rs710216	0.797	rs841856	chr1:43400113	G/T	cg22176566	chr1:43424700	SLC2A1	0.49	6.02	0.31	4.67e-9	Red cell distribution width;
LUSC	cis	rs2219968	1.000	rs4541901	chr8:78971715	G/A	cg00738934	chr8:78996279	NA	0.37	6.78	0.35	5.62e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg23752985	chr2:85803571	VAMP8	0.34	7.13	0.36	6.21e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2179367	0.600	rs9498355	chr6:149763410	C/T	cg07828024	chr6:149772892	ZC3H12D	0.36	6.25	0.32	1.28e-9	Dupuytren's disease;
LUSC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg18350739	chr11:68623251	NA	-0.36	-6.2	-0.32	1.67e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24110177	chr3:50126178	RBM5	-0.55	-8.97	-0.44	2.12e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21659725	chr3:3221576	CRBN	0.63	10.53	0.5	1.38e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.68	10.72	0.51	3.03e-23	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg18402987	chr7:1209562	NA	0.72	7.69	0.39	1.67e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg25174290	chr11:3078921	CARS	-0.42	-6.16	-0.32	2.11e-9	Calcium levels;
LUSC	cis	rs7605827	0.866	rs4668901	chr2:15521677	A/G	cg19274914	chr2:15703543	NA	0.45	8.78	0.43	8.82e-17	Educational attainment (years of education);
LUSC	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg01884057	chr2:25150051	NA	0.47	11.03	0.52	2.54e-24	Body mass index;
LUSC	cis	rs4654899	0.895	rs7515590	chr1:21216664	T/C	cg01072550	chr1:21505969	NA	0.52	7.72	0.39	1.32e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4843185	0.769	rs12149168	chr16:85705611	A/C	cg05245094	chr16:85669572	KIAA0182	-0.43	-6.19	-0.32	1.76e-9	Platelet distribution width;
LUSC	trans	rs1422110	0.519	rs12055343	chr5:85437684	T/C	cg01787110	chr1:109008453	NBPF6	0.57	9.46	0.46	5.68e-19	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.62	9.91	0.48	1.8899999999999998e-20	Blood metabolite ratios;
LUSC	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg02017074	chr12:117425053	FBXW8	0.63	7.41	0.38	1.06e-12	Subcortical brain region volumes;Hippocampal volume;
LUSC	cis	rs4363385	0.510	rs11577384	chr1:152899728	C/T	cg25856811	chr1:152973957	SPRR3	-0.38	-6.16	-0.32	2.04e-9	Inflammatory skin disease;
LUSC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	0.64	13.79	0.6	1.46e-34	Prudent dietary pattern;
LUSC	cis	rs11718455	0.585	rs17076170	chr3:43917946	C/T	cg08738300	chr3:44038990	NA	0.51	6.98	0.36	1.57e-11	Coronary artery disease;
LUSC	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg15556689	chr8:8085844	FLJ10661	0.58	8.82	0.43	6.58e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg16339924	chr4:17578868	LAP3	0.64	10.13	0.48	3.35e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg07424592	chr7:64974309	NA	0.67	5.89	0.31	9.46e-9	Diabetic kidney disease;
LUSC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg21854759	chr1:92012499	NA	0.52	8.61	0.43	2.92e-16	Breast cancer;
LUSC	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.56	8.04	0.4	1.55e-14	Response to antipsychotic treatment;
LUSC	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg12826209	chr6:26865740	GUSBL1	0.76	6.5	0.33	2.98e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg16482183	chr6:26056742	HIST1H1C	0.66	9.22	0.45	3.37e-18	Iron status biomarkers;
LUSC	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg23241863	chr10:102295624	HIF1AN	0.47	5.65	0.3	3.41e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9309473	0.898	rs28879089	chr2:73812886	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.56	-0.34	2.1e-10	Metabolite levels;
LUSC	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg03929089	chr4:120376271	NA	-0.56	-6.1	-0.32	2.87e-9	Axial length;
LUSC	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg00757033	chr12:89920650	WDR51B	0.58	10.23	0.49	1.51e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25450837	chr19:49631297	PPFIA3	-0.45	-6.67	-0.34	1.05e-10	Electrocardiographic conduction measures;
LUSC	cis	rs17767294	0.572	rs11965137	chr6:27624749	G/A	cg08851530	chr6:28072375	NA	0.78	5.75	0.3	2.04e-8	Parkinson's disease;
LUSC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs12760731	0.565	rs10913520	chr1:178200760	A/T	cg00404053	chr1:178313656	RASAL2	0.66	6.86	0.35	3.32e-11	Obesity-related traits;
LUSC	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg02153584	chr22:29168773	CCDC117	0.51	6.82	0.35	4.23e-11	Lymphocyte counts;
LUSC	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.51	7.91	0.4	3.93e-14	Depressive symptoms;
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg06145435	chr7:1022769	CYP2W1	0.28	5.67	0.3	3.17e-8	Longevity;Endometriosis;
LUSC	cis	rs12210905	0.688	rs12205044	chr6:27478990	A/G	cg08851530	chr6:28072375	NA	0.93	5.93	0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21963583	chr11:68658836	MRPL21	-0.56	-8.53	-0.42	5.15e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2652822	0.967	rs1472631	chr15:63423739	A/G	cg02713581	chr15:63449717	RPS27L	0.42	6.62	0.34	1.4e-10	Metabolic traits;
LUSC	cis	rs7589342	0.894	rs6736932	chr2:106444854	A/G	cg14210321	chr2:106509881	NCK2	-0.55	-8.36	-0.42	1.66e-15	Addiction;
LUSC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg27165867	chr14:105738592	BRF1	-0.54	-7.42	-0.38	9.61e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg18753928	chr3:113234510	CCDC52	-0.53	-8.05	-0.4	1.51e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg23029597	chr12:123009494	RSRC2	0.69	9.61	0.47	1.85e-19	Body mass index;
LUSC	cis	rs6740322	0.895	rs10172375	chr2:43572047	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-6.82	-0.35	4.4e-11	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.09	-0.32	3.05e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7106204	0.609	rs72874176	chr11:24330205	C/T	ch.11.24196551F	chr11:24239977	NA	0.69	5.71	0.3	2.48e-8	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg00522288	chr12:125625016	AACS	-0.31	-5.95	-0.31	6.86e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg26102564	chr10:131424627	MGMT	0.4	6.18	0.32	1.89e-9	Response to temozolomide;
LUSC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg24596788	chr1:163392923	NA	-0.38	-6.54	-0.34	2.3e-10	Motion sickness;
LUSC	cis	rs4308124	0.708	rs6749633	chr2:111988016	A/G	cg04571233	chr2:111982156	NA	0.51	6.71	0.34	8.39e-11	Vitiligo;
LUSC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg05347473	chr6:146136440	FBXO30	0.48	7.9	0.4	4.04e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs977987	0.843	rs4888415	chr16:75448921	C/T	cg03315344	chr16:75512273	CHST6	0.52	9.95	0.48	1.32e-20	Dupuytren's disease;
LUSC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg13607699	chr17:42295918	UBTF	-0.76	-14.48	-0.62	3.3e-37	Total body bone mineral density;
LUSC	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg15848620	chr12:58087721	OS9	-0.53	-7.55	-0.38	4.25e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.41	5.99	0.31	5.3e-9	Lung cancer;
LUSC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.45	-0.33	4.04e-10	Vitiligo;
LUSC	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.94	-0.36	1.99e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-21.89	-0.77	1.67e-66	Height;
LUSC	cis	rs6906287	0.625	rs11968351	chr6:118901509	G/A	cg21191810	chr6:118973309	C6orf204	0.33	6.11	0.32	2.77e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.75e-9	Morning vs. evening chronotype;
LUSC	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.48	-6.57	-0.34	1.95e-10	Neutrophil percentage of white cells;
LUSC	cis	rs17030434	1.000	rs78249279	chr4:154718783	C/T	cg14289246	chr4:154710475	SFRP2	-0.52	-6.7	-0.34	8.97e-11	Electrocardiographic conduction measures;
LUSC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17216600	chr6:52442344	TRAM2	-0.51	-6.27	-0.32	1.12e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg00845942	chr12:64062724	DPY19L2	-0.62	-7.87	-0.4	5.15e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.38	7.74	0.39	1.22e-13	Hemoglobin concentration;
LUSC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg06784218	chr1:46089804	CCDC17	-0.58	-11.51	-0.53	4.82e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg17143192	chr8:8559678	CLDN23	0.64	8.81	0.43	6.71e-17	Obesity-related traits;
LUSC	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg02079420	chr8:82753780	SNX16	0.4	5.99	0.31	5.57e-9	Diastolic blood pressure;
LUSC	trans	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	7.25	0.37	2.87e-12	Retinal vascular caliber;
LUSC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg19592336	chr6:28129416	ZNF389	0.45	5.85	0.3	1.16e-8	Depression;
LUSC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.65	-0.47	1.38e-19	Subjective well-being;
LUSC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.72	0.35	7.92e-11	Aortic root size;
LUSC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs77741769	0.700	rs7980311	chr12:121355860	C/T	cg02403541	chr12:121454288	C12orf43	0.48	7.24	0.37	3.15e-12	Mean corpuscular volume;
LUSC	cis	rs7605827	0.930	rs1473178	chr2:15576750	T/C	cg19274914	chr2:15703543	NA	0.47	8.88	0.44	4.19e-17	Educational attainment (years of education);
LUSC	cis	rs732765	0.602	rs2359192	chr14:75410523	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.51	-6.31	-0.33	9.11e-10	Non-small cell lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03698729	chr19:2328812	SPPL2B;LSM7	-0.38	-6.08	-0.32	3.27e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg17127132	chr2:85788382	GGCX	0.46	7.55	0.38	4.3e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg06640241	chr16:89574553	SPG7	0.69	11.04	0.52	2.35e-24	Multiple myeloma (IgH translocation);
LUSC	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg19774624	chr17:42201019	HDAC5	-0.79	-12.73	-0.57	1.57e-30	Total body bone mineral density;
LUSC	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg11861562	chr11:117069780	TAGLN	0.33	6.36	0.33	6.48e-10	Blood protein levels;
LUSC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs6066835	1.000	rs6066820	chr20:47318444	T/C	cg18078177	chr20:47281410	PREX1	0.72	6.13	0.32	2.51e-9	Multiple myeloma;
LUSC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.73	12.16	0.55	1.97e-28	Developmental language disorder (linguistic errors);
LUSC	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	7.02	0.36	1.22e-11	Rheumatoid arthritis;
LUSC	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg24375607	chr4:120327624	NA	-0.75	-10.82	-0.51	1.32e-23	Corneal astigmatism;
LUSC	cis	rs4566357	0.615	rs1800517	chr2:227915832	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.11	-0.41	9.41e-15	Coronary artery disease;
LUSC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg20821713	chr7:1055600	C7orf50	-0.47	-6.38	-0.33	5.81e-10	Bronchopulmonary dysplasia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	ch.7.118285014F	chr7:118497780	NA	-0.54	-7.16	-0.36	5.01e-12	Hepatitis;
LUSC	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg23649088	chr2:200775458	C2orf69	-0.43	-6.47	-0.33	3.41e-10	QT interval;
LUSC	trans	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg07663200	chr17:42030104	NA	-0.38	-6.04	-0.31	4.14e-9	Post bronchodilator FEV1;
LUSC	cis	rs7940866	0.838	rs7949071	chr11:130877478	T/C	cg12179176	chr11:130786555	SNX19	0.59	9.25	0.45	2.78e-18	Schizophrenia;
LUSC	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	16.51	0.67	3.54e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg19622623	chr12:86230825	RASSF9	-0.41	-5.66	-0.3	3.31e-8	Major depressive disorder;
LUSC	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg07211511	chr3:129823064	LOC729375	-0.62	-8.21	-0.41	4.72e-15	Blood pressure (smoking interaction);
LUSC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.58	10.66	0.5	5.01e-23	Bone mineral density;
LUSC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg22166914	chr1:53195759	ZYG11B	-0.63	-10.77	-0.51	1.99e-23	Monocyte count;
LUSC	trans	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg18187862	chr3:45730750	SACM1L	-0.54	-6.6	-0.34	1.62e-10	Primary sclerosing cholangitis;
LUSC	cis	rs926938	0.563	rs360576	chr1:115459174	A/C	cg12756093	chr1:115239321	AMPD1	-0.43	-5.92	-0.31	7.78e-9	Autism;
LUSC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14159672	chr1:205819179	PM20D1	0.45	6.11	0.32	2.7e-9	Parkinson's disease;
LUSC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	trans	rs1493916	0.837	rs11876492	chr18:31413804	T/C	cg13755796	chr4:20253514	NA	-0.39	-6.08	-0.32	3.21e-9	Life satisfaction;
LUSC	cis	rs859767	0.741	rs1467194	chr2:135430621	A/G	cg12500956	chr2:135428796	TMEM163	-0.27	-6.27	-0.32	1.09e-9	Neuroticism;
LUSC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg01765077	chr12:122356316	WDR66	0.56	7.88	0.4	4.67e-14	Mean corpuscular volume;
LUSC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg20283391	chr11:68216788	NA	0.55	8.43	0.42	1.03e-15	Total body bone mineral density;
LUSC	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg10547527	chr2:198650123	BOLL	-0.49	-5.79	-0.3	1.65e-8	Ulcerative colitis;
LUSC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg26513180	chr16:89883248	FANCA	0.9	17.69	0.7	6.93e-50	Vitiligo;
LUSC	cis	rs7809950	1.000	rs17154077	chr7:107077941	C/T	cg23024343	chr7:107201750	COG5	0.55	8.78	0.43	8.71e-17	Coronary artery disease;
LUSC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	9.79	0.47	4.77e-20	Cognitive test performance;
LUSC	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.38	-0.42	1.49e-15	Response to antipsychotic treatment;
LUSC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg13395646	chr4:1353034	KIAA1530	0.61	9.62	0.47	1.7e-19	Obesity-related traits;
LUSC	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg00191853	chr8:101177733	SPAG1	0.41	6.64	0.34	1.3100000000000001e-10	Atrioventricular conduction;
LUSC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.81	-13.99	-0.61	2.55e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs73129298	0.551	rs60541386	chr20:48602508	T/C	cg25655593	chr20:48599521	SNAI1	0.58	6.28	0.33	1.03e-9	Inflammatory skin disease;
LUSC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg23283495	chr1:209979779	IRF6	0.73	9.47	0.46	5.2e-19	Cleft lip with or without cleft palate;
LUSC	cis	rs9925964	0.900	rs56813533	chr16:31070481	A/T	cg02466173	chr16:30829666	NA	0.36	6.59	0.34	1.7e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg08824895	chr13:115047677	UPF3A	0.54	8.25	0.41	3.6e-15	Schizophrenia;
LUSC	cis	rs7107174	0.892	rs2512534	chr11:77970039	T/A	cg02023728	chr11:77925099	USP35	0.52	7.2	0.37	4.11e-12	Testicular germ cell tumor;
LUSC	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg05527609	chr1:210001259	C1orf107	0.68	9.79	0.47	4.7e-20	Orofacial clefts;
LUSC	cis	rs2172802	0.693	rs7660566	chr4:62481231	G/T	cg04118610	chr4:62707027	LPHN3	0.46	6.31	0.33	8.99e-10	Partial epilepsies;
LUSC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg06636001	chr8:8085503	FLJ10661	0.85	14.7	0.63	4.66e-38	Neuroticism;
LUSC	cis	rs524023	1.000	rs10792441	chr11:64360629	C/T	cg19131476	chr11:64387923	NRXN2	-0.38	-10.33	-0.49	6.6e-22	Urate levels in obese individuals;
LUSC	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg19875535	chr5:140030758	IK	0.47	7.57	0.38	3.58e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs12101261	0.580	rs3783949	chr14:81448382	A/C	cg06600135	chr14:81408086	NA	0.44	6.84	0.35	3.82e-11	Graves' disease;
LUSC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg06675483	chr6:26987649	LOC100270746;C6orf41	0.31	6.36	0.33	6.53e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7715806	0.500	rs17563974	chr5:75004175	G/A	cg19683494	chr5:74908142	NA	0.57	7.68	0.39	1.83e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg20553930	chr7:120590671	ING3	0.4	6.2	0.32	1.71e-9	Asthma;
LUSC	cis	rs7241530	0.610	rs7226819	chr18:75892508	C/T	cg14642773	chr18:75888474	NA	0.39	5.9	0.31	8.96e-9	Educational attainment (years of education);
LUSC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg09359103	chr1:154839909	KCNN3	-0.71	-16.53	-0.67	2.9e-45	Prostate cancer;
LUSC	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.1e-40	Bladder cancer;
LUSC	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg03806693	chr22:41940476	POLR3H	-0.51	-6.98	-0.36	1.55e-11	Neuroticism;
LUSC	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg21427119	chr20:30132790	HM13	-0.42	-6.12	-0.32	2.63e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.13	0.45	6.89e-18	Coffee consumption (cups per day);
LUSC	cis	rs977987	0.527	rs62059844	chr16:75429737	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.22	0.45	3.5e-18	Dupuytren's disease;
LUSC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg26695010	chr11:65641043	EFEMP2	0.41	5.74	0.3	2.13e-8	Breast cancer;
LUSC	cis	rs2019216	0.542	rs7217513	chr17:21933536	C/A	cg22648282	chr17:21454238	C17orf51	-0.53	-7.9	-0.4	4.08e-14	Pelvic organ prolapse;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03208850	chr16:3333472	ZNF263	0.72	6.11	0.32	2.73e-9	Cognitive performance;
LUSC	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.98	-0.4	2.38e-14	Glomerular filtration rate;
LUSC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.47	-0.33	3.41e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26615712	chr19:34856250	GPI	-0.45	-6.7	-0.34	8.98e-11	Electrocardiographic conduction measures;
LUSC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg22143856	chr6:28129313	ZNF389	0.41	5.68	0.3	2.98e-8	Parkinson's disease;
LUSC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg06096015	chr1:231504339	EGLN1	0.58	10.45	0.5	2.68e-22	Hemoglobin concentration;
LUSC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg11502198	chr6:26597334	ABT1	0.64	10.07	0.48	5.3e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07677032	chr17:61819896	STRADA	0.55	9.1	0.45	8.12e-18	Prudent dietary pattern;
LUSC	trans	rs208520	0.874	rs208514	chr6:66945520	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-13.76	-0.6	1.92e-34	Exhaled nitric oxide output;
LUSC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg05043794	chr9:111880884	C9orf5	-0.34	-7.3	-0.37	2.15e-12	Menarche (age at onset);
LUSC	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg17031739	chr1:67600172	NA	-0.43	-6.8	-0.35	4.96e-11	Psoriasis;
LUSC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg18225595	chr11:63971243	STIP1	0.5	6.13	0.32	2.48e-9	Mean platelet volume;
LUSC	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg04362960	chr10:104952993	NT5C2	0.6	9.38	0.46	1.07e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs10193935	0.901	rs59984817	chr2:42566909	C/G	cg27598129	chr2:42591480	NA	-0.61	-8.26	-0.41	3.47e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.66	-0.39	2.08e-13	Bone mineral density;
LUSC	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.09	24.26	0.8	1.12e-75	Schizophrenia;
LUSC	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg25801113	chr15:45476975	SHF	0.36	7.35	0.37	1.52e-12	Uric acid levels;
LUSC	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg24851651	chr11:66362959	CCS	-0.36	-5.73	-0.3	2.25e-8	Educational attainment (years of education);
LUSC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg02951883	chr7:2050386	MAD1L1	-0.53	-9.4	-0.46	8.68e-19	Schizophrenia;
LUSC	cis	rs7818345	0.967	rs12679712	chr8:19271032	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.84	0.35	3.82e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs7804356	1.000	rs3801826	chr7:26856720	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-6.14	-0.32	2.4e-9	Type 1 diabetes;
LUSC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	0.92	18.96	0.72	6.03e-55	Dental caries;
LUSC	cis	rs1568889	1.000	rs7102106	chr11:28343953	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	8.77	0.43	9.11e-17	Bipolar disorder;
LUSC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.02	0.36	1.22e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2625529	0.526	rs11634622	chr15:72562327	G/A	cg16672083	chr15:72433130	SENP8	0.47	7.8	0.39	7.96e-14	Red blood cell count;
LUSC	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.65	0.3	3.35e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00929050	chr14:50359216	ARF6	-0.44	-6.73	-0.35	7.45e-11	Electrocardiographic conduction measures;
LUSC	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg21427119	chr20:30132790	HM13	-0.43	-6.15	-0.32	2.26e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg18187862	chr3:45730750	SACM1L	0.56	7.06	0.36	9.52e-12	Primary sclerosing cholangitis;
LUSC	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.26	-0.49	1.18e-21	Platelet count;
LUSC	cis	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg21775007	chr8:11205619	TDH	0.47	6.67	0.34	1.09e-10	Neuroticism;
LUSC	cis	rs6469656	0.881	rs10505287	chr8:117727850	C/T	cg24004040	chr8:117650383	NA	-0.45	-6.48	-0.33	3.3e-10	Colorectal cancer;
LUSC	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-5.71	-0.3	2.54e-8	Type 2 diabetes;
LUSC	cis	rs3764563	1.000	rs8107240	chr19:15737392	A/G	cg20725493	chr19:15740067	CYP4F8	-0.64	-6.62	-0.34	1.44e-10	Inflammatory biomarkers;
LUSC	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg04850211	chr1:228464232	OBSCN	0.32	5.76	0.3	1.89e-8	Diastolic blood pressure;
LUSC	cis	rs66679842	1	rs66679842	chr6:88171407	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.4	-6.24	-0.32	1.34e-9	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.24	14.21	0.61	3.56e-36	Diabetic kidney disease;
LUSC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg18681998	chr4:17616180	MED28	0.88	17.22	0.69	5.12e-48	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg03585969	chr10:35415529	CREM	-0.57	-8.36	-0.42	1.73e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg14500267	chr11:67383377	NA	-0.35	-6.13	-0.32	2.41e-9	Mean corpuscular volume;
LUSC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg02951883	chr7:2050386	MAD1L1	-0.4	-7.01	-0.36	1.31e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg24675056	chr1:15929824	NA	0.45	7.77	0.39	1.01e-13	Systolic blood pressure;
LUSC	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	8.33	0.41	2.17e-15	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.56	-0.46	2.76e-19	Joint mobility (Beighton score);
LUSC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg21854759	chr1:92012499	NA	-0.53	-8.95	-0.44	2.58e-17	Breast cancer;
LUSC	cis	rs2835872	0.758	rs8134288	chr21:39036989	T/C	cg20424643	chr21:39039972	KCNJ6	-0.44	-7.43	-0.38	8.98e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg09165964	chr15:75287851	SCAMP5	-1.01	-15.29	-0.64	2.16e-40	Blood trace element (Zn levels);
LUSC	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.1	27.1	0.83	2.38e-86	Colorectal cancer;
LUSC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.43e-14	Prudent dietary pattern;
LUSC	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg04155231	chr12:9217510	LOC144571	0.3	5.66	0.3	3.26e-8	Sjögren's syndrome;
LUSC	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.07	0.4	1.27e-14	Axial length;
LUSC	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg06207120	chr15:45996521	NA	0.39	5.99	0.31	5.51e-9	Waist circumference;Weight;
LUSC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg22166914	chr1:53195759	ZYG11B	0.56	9.26	0.45	2.64e-18	Monocyte count;
LUSC	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg01448562	chr3:133502909	NA	0.59	9.3	0.45	1.82e-18	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs11997175	0.598	rs4599769	chr8:33601425	T/C	ch.8.33884649F	chr8:33765107	NA	0.42	6.63	0.34	1.38e-10	Body mass index;
LUSC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg06740227	chr12:86229804	RASSF9	-0.36	-5.7	-0.3	2.61e-8	Major depressive disorder;
LUSC	cis	rs1957429	0.808	rs9783609	chr14:65352282	A/G	cg23373153	chr14:65346875	NA	1.06	12.75	0.57	1.36e-30	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7197653	0.748	rs2279538	chr16:68397106	C/G	cg09835421	chr16:68378352	PRMT7	-0.77	-8.61	-0.43	3.01e-16	Magnesium levels;
LUSC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07677032	chr17:61819896	STRADA	0.52	8.85	0.44	5.18e-17	Prudent dietary pattern;
LUSC	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg01256987	chr12:42539512	GXYLT1	0.41	7.26	0.37	2.74e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg24642439	chr20:33292090	TP53INP2	0.62	7.08	0.36	8.72e-12	Protein C levels;
LUSC	cis	rs1595825	0.891	rs75163179	chr2:198895402	G/A	cg00982548	chr2:198649783	BOLL	-0.54	-6.84	-0.35	3.78e-11	Ulcerative colitis;
LUSC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10862848	chr6:42927986	GNMT	0.27	6.53	0.34	2.45e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11764359	chr7:65958608	NA	0.55	7.32	0.37	1.86e-12	Aortic root size;
LUSC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg21285383	chr16:89894308	SPIRE2	0.33	6.98	0.36	1.63e-11	Vitiligo;
LUSC	cis	rs62408225	1.000	rs62408237	chr6:90980345	C/G	cg06866423	chr6:90926672	BACH2	0.41	5.92	0.31	7.99e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg22903657	chr4:1355424	KIAA1530	-0.35	-5.68	-0.3	2.93e-8	Obesity-related traits;
LUSC	cis	rs4654899	0.802	rs57351360	chr1:21229538	T/A	cg01072550	chr1:21505969	NA	-0.48	-7.01	-0.36	1.33e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg08470875	chr2:26401718	FAM59B	0.65	8.3	0.41	2.67e-15	Gut microbiome composition (summer);
LUSC	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg06917634	chr15:78832804	PSMA4	0.5	7.04	0.36	1.09e-11	Sudden cardiac arrest;
LUSC	cis	rs62400317	0.826	rs12194682	chr6:45320520	T/A	cg18551225	chr6:44695536	NA	-0.44	-7.28	-0.37	2.35e-12	Total body bone mineral density;
LUSC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg13770153	chr20:60521292	NA	0.45	6.44	0.33	4.19e-10	Body mass index;
LUSC	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-1.14	-18.17	-0.71	8.4e-52	Exhaled nitric oxide output;
LUSC	cis	rs3924048	0.574	rs3923904	chr1:12616535	T/C	cg00291366	chr1:12616550	NA	0.39	10.01	0.48	8.2e-21	Optic cup area;
LUSC	cis	rs4964805	0.913	rs12229276	chr12:104204771	G/T	cg02344784	chr12:104178138	NT5DC3	-0.45	-7.34	-0.37	1.63e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg01236616	chr12:121019343	POP5	1.31	21.22	0.76	7.27e-64	Type 1 diabetes nephropathy;
LUSC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00166722	chr3:10149974	C3orf24	0.54	7.43	0.38	8.88e-13	Alzheimer's disease;
LUSC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.43	7.28	0.37	2.47e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg04998671	chr14:104000505	TRMT61A	-0.57	-7.81	-0.39	7.67e-14	Coronary artery disease;
LUSC	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs4664308	0.935	rs58354887	chr2:160927112	C/T	cg03641300	chr2:160917029	PLA2R1	-0.69	-11.62	-0.54	1.97e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg17554472	chr22:41940697	POLR3H	-0.48	-5.76	-0.3	1.89e-8	Vitiligo;
LUSC	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg18753928	chr3:113234510	CCDC52	-0.51	-7.93	-0.4	3.26e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.42	0.33	4.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	5.86	0.31	1.11e-8	Schizophrenia;
LUSC	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg19875535	chr5:140030758	IK	0.47	7.56	0.38	4.05e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs12677618	0.623	rs28506950	chr8:142261967	C/T	cg27411547	chr8:142287226	NA	-0.47	-7.98	-0.4	2.4e-14	Plateletcrit;
LUSC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg24399712	chr22:39784796	NA	-0.6	-10.94	-0.51	5.23e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs912057	0.671	rs1294417	chr6:6741932	T/C	cg06612196	chr6:6737390	NA	0.58	11.4	0.53	1.23e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg19468946	chr17:37922297	IKZF3	-0.43	-6.89	-0.35	2.82e-11	Self-reported allergy;
LUSC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06544989	chr22:39130855	UNC84B	-0.34	-5.87	-0.31	1.05e-8	Menopause (age at onset);
LUSC	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg22709100	chr7:91322751	NA	-0.39	-5.8	-0.3	1.56e-8	Breast cancer;
LUSC	cis	rs968451	0.685	rs61616683	chr22:39755773	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.55	6.88	0.35	2.96e-11	Primary biliary cholangitis;
LUSC	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02176678	chr2:219576539	TTLL4	-0.64	-11.5	-0.53	5.36e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg18512352	chr11:47633146	NA	-0.46	-9.19	-0.45	4.42e-18	Subjective well-being;
LUSC	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg05026186	chr5:148520876	ABLIM3	-0.38	-6.07	-0.32	3.55e-9	Breast cancer;
LUSC	cis	rs907683	0.546	rs1058261	chr2:220285309	C/T	cg15015639	chr2:220282977	DES	-0.31	-7.23	-0.37	3.27e-12	Resting heart rate;
LUSC	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg08807101	chr21:30365312	RNF160	0.63	10.11	0.48	3.91e-21	Selective IgA deficiency;
LUSC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg24829409	chr8:58192753	C8orf71	-0.5	-6.1	-0.32	2.86e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs17253792	0.822	rs79538158	chr14:56051365	G/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	8.91e-12	Putamen volume;
LUSC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.81	0.3	1.45e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11822739	chr20:57251485	STX16	-0.7	-5.97	-0.31	6.01e-9	Cognitive performance;
LUSC	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg22705602	chr4:152727874	NA	-0.32	-6.49	-0.33	3.05e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg16031515	chr1:205743344	RAB7L1	-0.3	-6.34	-0.33	7.5e-10	Menarche (age at onset);
LUSC	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg12473912	chr3:136751656	NA	-0.38	-6.68	-0.34	1.03e-10	Neuroticism;
LUSC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.78	0.35	5.42e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.83	11.4	0.53	1.22e-25	Schizophrenia;
LUSC	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg09184832	chr6:79620586	NA	-0.45	-7.31	-0.37	1.96e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg15309053	chr8:964076	NA	0.33	6.79	0.35	5.27e-11	Schizophrenia;
LUSC	cis	rs7172677	0.737	rs4886669	chr15:75448181	C/T	cg14664628	chr15:75095509	CSK	-0.42	-5.8	-0.3	1.5e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.65	8.36	0.42	1.67e-15	Chronic sinus infection;
LUSC	cis	rs9583531	0.509	rs12184676	chr13:111396484	A/G	cg24331049	chr13:111365604	ING1	-0.57	-6.22	-0.32	1.48e-9	Coronary artery disease;
LUSC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03934478	chr11:495069	RNH1	0.85	9.9	0.48	2e-20	Body mass index;
LUSC	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.98	-0.48	1.1e-20	Migraine;Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg07701084	chr6:150067640	NUP43	0.58	8.9	0.44	3.58e-17	Lung cancer;
LUSC	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg18252515	chr7:66147081	NA	-1.25	-8.41	-0.42	1.19e-15	Diabetic kidney disease;
LUSC	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg12560992	chr17:57184187	TRIM37	0.58	9.29	0.45	1.99e-18	Testicular germ cell tumor;
LUSC	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg01851573	chr8:8652454	MFHAS1	-0.53	-8.79	-0.43	8.03e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22968622	chr17:43663579	NA	-0.77	-11.68	-0.54	1.21e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg01528321	chr10:82214614	TSPAN14	1.03	15.99	0.66	3.98e-43	Post bronchodilator FEV1;
LUSC	trans	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg15704280	chr7:45808275	SEPT13	-0.51	-5.98	-0.31	5.88e-9	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	8.49	0.42	7.08e-16	Ulcerative colitis;
LUSC	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg23422044	chr7:1970798	MAD1L1	-0.59	-6.66	-0.34	1.11e-10	Bipolar disorder;
LUSC	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg15557168	chr22:42548783	NA	-0.43	-7.21	-0.37	3.71e-12	Cognitive function;
LUSC	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg07041428	chr4:1763019	NA	0.36	5.75	0.3	2.06e-8	Bladder cancer;Urinary bladder cancer;
LUSC	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-8.21	-0.41	4.93e-15	Schizophrenia;
LUSC	cis	rs7633770	0.805	rs11710264	chr3:46661579	T/C	cg11219411	chr3:46661640	NA	0.49	10.34	0.49	6.45e-22	Coronary artery disease;
LUSC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg08470875	chr2:26401718	FAM59B	-0.65	-8.72	-0.43	1.32e-16	Gut microbiome composition (summer);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15988734	chr14:103411822	CDC42BPB	-0.7	-6.04	-0.31	4.03e-9	Cognitive performance;
LUSC	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.76	-0.51	2.15e-23	Glomerular filtration rate;
LUSC	cis	rs2078087	0.522	rs539443	chr1:183215457	T/C	cg13843938	chr1:183241246	NMNAT2	0.41	6.77	0.35	5.85e-11	Obesity-related traits;
LUSC	trans	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg15556689	chr8:8085844	FLJ10661	0.65	9.33	0.45	1.56e-18	Neuroticism;
LUSC	trans	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg19894588	chr14:64061835	NA	-0.56	-7.51	-0.38	5.41e-13	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg21521518	chr4:53727714	RASL11B	0.51	6.24	0.32	1.36e-9	Optic nerve measurement (cup area);
LUSC	cis	rs2692947	0.696	rs2969490	chr2:96803904	A/G	cg22654517	chr2:96458247	NA	0.37	7.48	0.38	6.82e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24110177	chr3:50126178	RBM5	0.65	10.99	0.52	3.41e-24	Body mass index;
LUSC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg23172400	chr8:95962367	TP53INP1	-0.45	-9.4	-0.46	8.89e-19	Type 2 diabetes;
LUSC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg16339924	chr4:17578868	LAP3	0.59	9.2	0.45	3.85e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.85	0.66	1.36e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07677032	chr17:61819896	STRADA	0.54	9.09	0.45	9.32e-18	Prudent dietary pattern;
LUSC	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg14500267	chr11:67383377	NA	0.34	6.43	0.33	4.37e-10	Mean corpuscular volume;
LUSC	cis	rs9811920	0.838	rs12488245	chr3:99835254	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.37	6.86	0.35	3.44e-11	Axial length;
LUSC	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg08807101	chr21:30365312	RNF160	0.62	9.93	0.48	1.59e-20	Pancreatic cancer;
LUSC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg03676636	chr4:99064102	C4orf37	0.34	7.31	0.37	1.98e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.98	-0.31	5.89e-9	Type 2 diabetes;
LUSC	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg21064579	chr19:49206444	FUT2	0.44	8.35	0.42	1.87e-15	Dietary macronutrient intake;
LUSC	cis	rs1595825	0.838	rs7603283	chr2:198517592	A/G	cg00982548	chr2:198649783	BOLL	-0.52	-6.63	-0.34	1.32e-10	Ulcerative colitis;
LUSC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg05084668	chr3:125655381	ALG1L	-0.48	-6.79	-0.35	5.17e-11	Blood pressure (smoking interaction);
LUSC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.62	-7.96	-0.4	2.76e-14	Systemic lupus erythematosus;
LUSC	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg17252645	chr8:143867129	LY6D	0.38	6.7	0.34	8.75e-11	Urinary tract infection frequency;
LUSC	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg05084668	chr3:125655381	ALG1L	-0.63	-9.99	-0.48	1e-20	Blood pressure (smoking interaction);
LUSC	cis	rs11650494	0.908	rs73340399	chr17:47372743	G/C	cg08112188	chr17:47440006	ZNF652	1.18	10.16	0.49	2.53e-21	Prostate cancer;
LUSC	cis	rs11645898	0.622	rs4788463	chr16:72223716	G/T	cg14768367	chr16:72042858	DHODH	-0.57	-6.16	-0.32	2.13e-9	Blood protein levels;
LUSC	cis	rs3790645	0.874	rs9438508	chr1:26893069	T/C	cg17456097	chr1:26900765	RPS6KA1	0.42	6.08	0.32	3.36e-9	Glucose homeostasis traits;
LUSC	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	8.45	0.42	9.29e-16	Neuroticism;
LUSC	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg18209359	chr17:80159595	CCDC57	0.4	6.61	0.34	1.52e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg25237894	chr2:233734115	C2orf82	-0.3	-5.69	-0.3	2.71e-8	Coronary artery disease;
LUSC	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg01503450	chr10:980765	NA	-0.4	-5.81	-0.3	1.45e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs10761482	0.861	rs2061486	chr10:62105916	A/G	cg18175470	chr10:62150864	ANK3	-0.49	-7.11	-0.36	7.29e-12	Schizophrenia;
LUSC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18876405	chr7:65276391	NA	-0.54	-8.6	-0.43	3.17e-16	Aortic root size;
LUSC	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.4	-0.33	5.4e-10	Arsenic metabolism;
LUSC	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.67	-0.47	1.2e-19	Coronary artery disease;
LUSC	cis	rs11123610	0.679	rs34705357	chr2:3716032	C/T	cg00999904	chr2:3704751	ALLC	-0.38	-6.35	-0.33	7.21e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg24579218	chr15:68104479	NA	0.35	6.24	0.32	1.32e-9	Restless legs syndrome;
LUSC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.24	0.37	3.13e-12	Mean platelet volume;
LUSC	cis	rs11971779	0.616	rs1133068	chr7:139053143	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg21775007	chr8:11205619	TDH	0.44	5.79	0.3	1.63e-8	Neuroticism;
LUSC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg02487422	chr3:49467188	NICN1	0.48	7.63	0.39	2.46e-13	Resting heart rate;
LUSC	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg10326726	chr10:51549505	MSMB	-0.35	-5.9	-0.31	8.86e-9	Prostate-specific antigen levels;
LUSC	cis	rs4478858	0.647	rs6425720	chr1:31709555	A/G	cg00250761	chr1:31883323	NA	-0.34	-8.26	-0.41	3.37e-15	Alcohol dependence;
LUSC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg13531842	chr10:38383804	ZNF37A	-0.43	-6.71	-0.34	8.54e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg18681998	chr4:17616180	MED28	0.83	15.19	0.64	5.34e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23249336	chr13:47127304	LRCH1	0.45	6.04	0.31	4.21e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg11663144	chr21:46675770	NA	-0.35	-5.75	-0.3	2.05e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs17815608	1.000	rs17759214	chr12:77399915	T/C	cg18631743	chr22:20104954	RANBP1;TRMT2A	0.56	6.46	0.33	3.68e-10	Type 2 diabetes;
LUSC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	7.01	0.36	1.36e-11	Bipolar disorder;
LUSC	cis	rs1163251	0.902	rs640195	chr1:120217650	T/A	cg19096424	chr1:120255104	PHGDH	0.48	6.53	0.34	2.39e-10	Blood metabolite levels;
LUSC	cis	rs4722404	0.592	rs6461820	chr7:3118246	T/C	cg19214707	chr7:3157722	NA	-0.36	-6.0	-0.31	5.13e-9	Atopic dermatitis;
LUSC	trans	rs62055045	0.528	rs62056195	chr16:71549485	A/G	cg15281710	chr15:96890452	NA	-0.5	-7.1	-0.36	7.77e-12	Schizophrenia;
LUSC	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.69	-11.31	-0.53	2.57e-25	Sudden cardiac arrest;
LUSC	trans	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg26043149	chr18:55253948	FECH	0.48	7.16	0.36	5.16e-12	Bone mineral density;
LUSC	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg02896835	chr1:92012615	NA	-0.46	-6.48	-0.33	3.31e-10	Eosinophil percentage of white cells;
LUSC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-11.64	-0.54	1.6e-26	Systemic lupus erythematosus;
LUSC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs2078087	0.568	rs779153	chr1:183233018	A/G	cg13843938	chr1:183241246	NMNAT2	-0.43	-7.01	-0.36	1.36e-11	Obesity-related traits;
LUSC	cis	rs9660992	1.000	rs3851296	chr1:205253839	A/C	cg00857998	chr1:205179979	DSTYK	0.46	6.88	0.35	3e-11	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	0.97	14.27	0.62	2.18e-36	Primary sclerosing cholangitis;
LUSC	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg08601574	chr20:25228251	PYGB	0.45	6.81	0.35	4.56e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.4	6.3	0.33	9.5e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg19539972	chr4:7069911	GRPEL1	0.69	8.38	0.42	1.45e-15	Monocyte percentage of white cells;
LUSC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg14829360	chr17:73884958	NA	0.35	5.88	0.31	9.75e-9	White matter hyperintensity burden;
LUSC	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23598886	chr18:12777645	NA	0.65	6.58	0.34	1.83e-10	Inflammatory skin disease;
LUSC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08280861	chr8:58055591	NA	0.52	5.7	0.3	2.58e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7512552	0.803	rs59898460	chr1:150493004	T/C	cg15654264	chr1:150340011	RPRD2	0.6	9.71	0.47	8.82e-20	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	1.06	17.08	0.68	1.85e-47	Testicular germ cell tumor;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17010941	chr8:102218219	ZNF706	-0.43	-6.61	-0.34	1.48e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs16910800	1.000	rs11027021	chr11:23183529	C/T	cg20040320	chr11:23191996	NA	0.46	6.74	0.35	7.06e-11	Cancer;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20342374	chr4:140005160	ELF2	-0.46	-5.98	-0.31	5.83e-9	Hepatitis;
LUSC	cis	rs6445967	0.530	rs12634132	chr3:58409082	A/G	cg23715586	chr3:58305044	RPP14	0.42	7.14	0.36	5.81e-12	Platelet count;
LUSC	trans	rs1486139	1.000	rs10258322	chr7:46261337	T/C	cg17534202	chr9:96721102	NA	-0.35	-6.15	-0.32	2.26e-9	Select biomarker traits;
LUSC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	cis	rs2294015	1.000	rs2294015	chr8:124696867	C/T	cg07200421	chr8:124693396	ANXA13	0.29	5.9	0.31	8.71e-9	Event-related brain oscillations;
LUSC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07636037	chr3:49044803	WDR6	-0.66	-8.47	-0.42	7.89e-16	Menarche (age at onset);
LUSC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg09703963	chr11:616879	IRF7;MUPCDH	-0.45	-7.33	-0.37	1.76e-12	Systemic lupus erythematosus;
LUSC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg02896835	chr1:92012615	NA	-0.67	-12.54	-0.57	8e-30	Breast cancer;
LUSC	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg17425144	chr1:10567563	PEX14	0.62	12.49	0.56	1.18e-29	Prostate cancer;
LUSC	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.41	8.37	0.42	1.61e-15	Airflow obstruction;
LUSC	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg04539111	chr16:67997858	SLC12A4	-0.41	-5.83	-0.3	1.31e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs977987	0.933	rs1834014	chr16:75501274	G/A	cg03315344	chr16:75512273	CHST6	0.57	10.83	0.51	1.26e-23	Dupuytren's disease;
LUSC	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg21466736	chr12:48725269	NA	-0.33	-5.76	-0.3	1.92e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.29	-0.41	2.74e-15	Cystic fibrosis severity;
LUSC	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.49	-8.45	-0.42	9.1e-16	Rheumatoid arthritis;
LUSC	cis	rs1775715	0.707	rs1541262	chr10:32179771	A/G	cg18675610	chr10:32216311	ARHGAP12	0.3	6.65	0.34	1.22e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg16447950	chr5:562315	NA	-0.53	-6.95	-0.36	1.87e-11	Obesity-related traits;
LUSC	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.02	-0.31	4.67e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs34779708	0.702	rs4007272	chr10:35546859	T/G	cg03585969	chr10:35415529	CREM	0.53	7.38	0.37	1.3e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg00990874	chr7:1149470	C7orf50	-0.49	-6.07	-0.32	3.38e-9	Bronchopulmonary dysplasia;
LUSC	trans	rs3857536	0.813	rs7757647	chr6:66947207	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.55	-7.86	-0.39	5.47e-14	Tuberculosis;
LUSC	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg05234568	chr11:5960015	NA	0.55	7.54	0.38	4.35e-13	DNA methylation (variation);
LUSC	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg21972741	chr5:435613	AHRR	0.32	5.76	0.3	1.92e-8	Cystic fibrosis severity;
LUSC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	14.11	0.61	8.82e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg01881094	chr2:180872142	CWC22	0.8	10.31	0.49	8.34e-22	Schizophrenia;
LUSC	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-10.8	-0.51	1.64e-23	Schizophrenia;
LUSC	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13596040	chr4:37828581	PGM2	0.69	6.15	0.32	2.17e-9	Cognitive performance;
LUSC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg22903471	chr2:27725779	GCKR	0.43	7.42	0.38	1.01e-12	Total body bone mineral density;
LUSC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-1.17	-19.23	-0.72	5.36e-56	Initial pursuit acceleration;
LUSC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00149659	chr3:10157352	C3orf10	0.99	14.08	0.61	1.17e-35	Alzheimer's disease;
LUSC	cis	rs10208940	0.920	rs6751531	chr2:68794528	G/T	cg12452813	chr2:68675892	NA	0.57	5.92	0.31	7.99e-9	Urate levels in lean individuals;
LUSC	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg03342759	chr3:160939853	NMD3	0.4	5.76	0.3	1.89e-8	Parkinson's disease;
LUSC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.27	0.37	2.52e-12	Bipolar disorder;
LUSC	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22857025	chr5:266934	NA	-1.19	-13.86	-0.6	7.97e-35	Breast cancer;
LUSC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg02175503	chr12:58329896	NA	0.59	9.04	0.44	1.31e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg15654264	chr1:150340011	RPRD2	0.62	10.17	0.49	2.32e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6456156	0.774	rs1556413	chr6:167524743	G/A	cg07741184	chr6:167504864	NA	-0.34	-5.99	-0.31	5.54e-9	Primary biliary cholangitis;
LUSC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg18681998	chr4:17616180	MED28	0.84	15.62	0.65	1.13e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg21535247	chr6:8435926	SLC35B3	0.57	9.02	0.44	1.5e-17	Motion sickness;
LUSC	cis	rs7572644	0.656	rs10196483	chr2:28221182	A/T	cg27432699	chr2:27873401	GPN1	-0.49	-6.14	-0.32	2.39e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs11640436	0.565	rs2162957	chr16:77297193	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.37	5.8	0.3	1.52e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg18352616	chr4:3374830	RGS12	0.34	6.76	0.35	6.06e-11	Serum sulfate level;
LUSC	cis	rs1545257	0.537	rs11125583	chr2:24646278	C/A	cg06627628	chr2:24431161	ITSN2	-0.4	-5.66	-0.3	3.27e-8	Sjögren's syndrome;
LUSC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21862992	chr11:68658383	NA	0.51	7.94	0.4	3.05e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs877282	0.700	rs816311	chr10:796490	C/A	cg17470449	chr10:769945	NA	0.4	6.05	0.31	3.84e-9	Uric acid levels;
LUSC	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg00310523	chr12:86230176	RASSF9	0.43	7.72	0.39	1.38e-13	Major depressive disorder;
LUSC	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.9	15.66	0.65	7.82e-42	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.4	0.38	1.15e-12	Schizophrenia;
LUSC	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg10434728	chr15:90938212	IQGAP1	-0.46	-9.47	-0.46	5.36e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7180079	1.000	rs1533378	chr15:64646777	A/G	cg08069370	chr15:64387884	SNX1	-0.53	-5.85	-0.3	1.19e-8	Monocyte count;
LUSC	cis	rs1322512	0.917	rs2623948	chr6:152963087	C/T	cg27316956	chr6:152958899	SYNE1	-0.37	-6.32	-0.33	8.6e-10	Tonometry;
LUSC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg07936489	chr17:37558343	FBXL20	-0.71	-10.08	-0.48	4.97e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg00864171	chr11:67383662	NA	0.35	6.19	0.32	1.81e-9	Mean corpuscular volume;
LUSC	cis	rs9473147	0.516	rs6903331	chr6:47562915	A/G	cg02130027	chr6:47444894	CD2AP	0.35	5.76	0.3	1.92e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs78572108	0.858	rs4952582	chr2:42268672	C/T	cg00607755	chr2:42274082	PKDCC	0.35	5.98	0.31	5.72e-9	Total body bone mineral density;
LUSC	cis	rs73416724	1.000	rs74690967	chr6:43370915	C/T	cg26312998	chr6:43337775	ZNF318	0.53	6.2	0.32	1.68e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12210905	0.688	rs75968505	chr6:27476996	T/C	cg08851530	chr6:28072375	NA	0.95	6.15	0.32	2.21e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	6.29	0.33	1.01e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9399401	0.732	rs9389996	chr6:142826771	G/A	cg03128060	chr6:142623767	GPR126	0.31	5.7	0.3	2.58e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17467752	chr17:38218738	THRA	-0.71	-11.37	-0.53	1.55e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg12927641	chr6:109611667	NA	-0.36	-6.09	-0.32	3.05e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.04	0.4	1.62e-14	Parkinson's disease;
LUSC	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-8.66	-0.43	2.09e-16	Mood instability;
LUSC	cis	rs2219968	0.828	rs1486923	chr8:78883445	T/C	cg00738934	chr8:78996279	NA	-0.39	-6.93	-0.35	2.16e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.93	0.31	7.75e-9	Menopause (age at onset);
LUSC	trans	rs800082	0.690	rs2575191	chr3:144279228	G/A	cg24215973	chr2:240111563	HDAC4	0.61	9.63	0.47	1.54e-19	Smoking behavior;
LUSC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg20406979	chr6:167373233	NA	0.25	5.99	0.31	5.28e-9	Crohn's disease;
LUSC	cis	rs983392	0.679	rs1019671	chr11:60008151	T/C	cg24026212	chr11:59952134	MS4A6A	-0.34	-5.7	-0.3	2.63e-8	Alzheimer's disease (late onset);
LUSC	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg09201001	chr11:18656081	SPTY2D1	0.92	15.18	0.64	6.23e-40	Breast cancer;
LUSC	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg07701084	chr6:150067640	NUP43	0.53	8.14	0.41	7.72e-15	Lung cancer;
LUSC	cis	rs259282	0.584	rs10416758	chr19:33107716	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	9.53	0.46	3.47e-19	Schizophrenia;
LUSC	cis	rs662064	0.852	rs1411402	chr1:10579545	G/T	cg20482658	chr1:10539492	PEX14	0.32	6.28	0.33	1.04e-9	Asthma;
LUSC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.76	12.86	0.58	5.07e-31	Brugada syndrome;
LUSC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg09165964	chr15:75287851	SCAMP5	0.94	8.95	0.44	2.44e-17	Lung cancer;
LUSC	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.36	7.14	0.36	5.74e-12	Hemoglobin concentration;
LUSC	cis	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg09904177	chr6:26538194	HMGN4	0.76	6.04	0.31	4.16e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2688608	0.967	rs2633299	chr10:75656754	T/G	cg23231163	chr10:75533350	FUT11	-0.38	-6.23	-0.32	1.39e-9	Inflammatory bowel disease;
LUSC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg19748678	chr4:122722346	EXOSC9	0.49	7.54	0.38	4.44e-13	Type 2 diabetes;
LUSC	cis	rs4073416	0.518	rs10150412	chr14:65916791	C/T	cg03016385	chr14:66212404	NA	-0.41	-6.23	-0.32	1.39e-9	N-glycan levels;
LUSC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg22903471	chr2:27725779	GCKR	-0.41	-6.94	-0.35	2.1e-11	Total body bone mineral density;
LUSC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg13395646	chr4:1353034	KIAA1530	-0.65	-10.2	-0.49	1.85e-21	Obesity-related traits;
LUSC	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	8.77	0.43	9.44e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.72	0.35	8.08e-11	Corneal astigmatism;
LUSC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.63	8.41	0.42	1.21e-15	High light scatter reticulocyte count;
LUSC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg08847533	chr14:75593920	NEK9	-0.84	-15.12	-0.64	9.89e-40	Height;
LUSC	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg21385522	chr1:16154831	NA	0.52	7.82	0.39	7.04e-14	Systolic blood pressure;
LUSC	cis	rs7107174	1.000	rs1385601	chr11:77936064	A/C	cg02023728	chr11:77925099	USP35	0.49	7.2	0.37	4.01e-12	Testicular germ cell tumor;
LUSC	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-7.12	-0.36	6.83e-12	Total body bone mineral density;
LUSC	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.55	-8.87	-0.44	4.46e-17	Breast cancer;
LUSC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-0.84	-14.37	-0.62	8.92e-37	Menopause (age at onset);
LUSC	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg22356347	chr1:167427500	CD247	-0.35	-8.38	-0.42	1.49e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08280861	chr8:58055591	NA	0.54	5.89	0.31	9.6e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	7.81	0.39	7.32e-14	Height;
LUSC	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg06740227	chr12:86229804	RASSF9	0.36	5.75	0.3	2.04e-8	Major depressive disorder;
LUSC	cis	rs11264799	0.603	rs11799853	chr1:157557957	T/C	cg18268488	chr1:157545234	FCRL4	0.33	5.86	0.31	1.11e-8	IgA nephropathy;
LUSC	cis	rs7512552	0.803	rs7513205	chr1:150472781	A/G	cg15654264	chr1:150340011	RPRD2	0.64	10.58	0.5	9.39e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.54	7.66	0.39	2.04e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22618164	chr12:122356400	WDR66	0.64	9.47	0.46	5.45e-19	Mean corpuscular volume;
LUSC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg27398817	chr8:82754497	SNX16	-0.46	-6.12	-0.32	2.56e-9	Diastolic blood pressure;
LUSC	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.64	-0.43	2.4e-16	Retinal vascular caliber;
LUSC	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg05472934	chr7:22766657	IL6	-0.57	-8.02	-0.4	1.75e-14	Lung cancer;
LUSC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.82	14.56	0.62	1.52e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.76	13.55	0.6	1.28e-33	Colorectal cancer;
LUSC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-9.17	-0.45	5.12e-18	Gut microbiome composition (summer);
LUSC	cis	rs6700559	0.740	rs6663322	chr1:200649869	G/A	cg07804481	chr1:200639085	DDX59	0.4	5.76	0.3	1.94e-8	Coronary artery disease;
LUSC	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg08000102	chr2:233561755	GIGYF2	-0.67	-11.26	-0.52	3.67e-25	Coronary artery disease;
LUSC	trans	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg10756647	chr7:56101905	PSPH	0.88	8.45	0.42	8.8e-16	Diabetic kidney disease;
LUSC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06505273	chr16:24850292	NA	0.41	5.67	0.3	3.16e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2274273	0.773	rs8012380	chr14:55735010	T/G	cg04306507	chr14:55594613	LGALS3	0.57	13.56	0.6	1.14e-33	Protein biomarker;
LUSC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg18477163	chr1:228402036	OBSCN	-0.57	-10.55	-0.5	1.18e-22	Diastolic blood pressure;
LUSC	cis	rs2559856	1.000	rs2695291	chr12:102087543	G/A	cg12924262	chr12:102091054	CHPT1	0.43	6.05	0.31	3.96e-9	Blood protein levels;
LUSC	trans	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.44	6.59	0.34	1.7e-10	Endometrial cancer;
LUSC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9815354	0.812	rs78342280	chr3:41948810	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.49	0.42	6.81e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.03	0.48	7.2e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00152838	chr16:24741724	TNRC6A	-0.46	-5.68	-0.3	2.92e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs11949289	0.967	rs4339359	chr5:28334807	A/T	cg18220921	chr1:242687527	PLD5	0.35	6.05	0.31	3.9e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg10596483	chr8:143751796	JRK	-0.53	-7.9	-0.4	4.07e-14	Schizophrenia;
LUSC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg27121462	chr16:89883253	FANCA	0.55	8.95	0.44	2.54e-17	Vitiligo;
LUSC	cis	rs7180079	0.620	rs11632113	chr15:65040445	T/G	cg08069370	chr15:64387884	SNX1	0.52	5.72	0.3	2.32e-8	Monocyte count;
LUSC	cis	rs96067	0.652	rs7553155	chr1:36568236	A/T	cg27506609	chr1:36549197	TEKT2	0.63	8.75	0.43	1.05e-16	Corneal structure;
LUSC	cis	rs6840360	1.000	rs6845944	chr4:152604520	C/T	cg22705602	chr4:152727874	NA	-0.28	-5.84	-0.3	1.22e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19021960	chr1:228291175	C1orf35	-0.43	-6.26	-0.32	1.16e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12681287	0.752	rs13277670	chr8:87259920	T/G	cg27223183	chr8:87520930	FAM82B	-0.47	-5.94	-0.31	7.1e-9	Caudate activity during reward;
LUSC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg17330251	chr7:94953956	PON1	-0.36	-5.88	-0.31	9.79e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg18404041	chr3:52824283	ITIH1	0.6	10.32	0.49	7.46e-22	Schizophrenia;
LUSC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.71	10.7	0.51	3.64e-23	Aortic root size;
LUSC	cis	rs6901250	1.000	rs6901250	chr6:117114025	A/G	cg12892004	chr6:117198278	RFX6	-0.42	-7.86	-0.39	5.5e-14	C-reactive protein levels;
LUSC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg24634471	chr8:143751801	JRK	0.59	9.01	0.44	1.66e-17	Schizophrenia;
LUSC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg13114125	chr14:105738426	BRF1	-0.95	-15.9	-0.66	9.24e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6977660	0.652	rs4721826	chr7:19823804	T/C	cg07541023	chr7:19748670	TWISTNB	0.6	6.37	0.33	6.35e-10	Thyroid stimulating hormone;
LUSC	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21545522	chr1:205238299	TMCC2	0.51	9.69	0.47	9.59e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-6.22	-0.32	1.5e-9	Vitiligo;
LUSC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg16325326	chr1:53192061	ZYG11B	0.78	14.03	0.61	1.72e-35	Monocyte count;
LUSC	cis	rs2387326	0.717	rs10829337	chr10:129943548	T/C	cg16087940	chr10:129947807	NA	-0.39	-5.81	-0.3	1.48e-8	Select biomarker traits;
LUSC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18758796	chr5:131593413	PDLIM4	0.47	7.68	0.39	1.79e-13	Acylcarnitine levels;
LUSC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg03732007	chr1:2071316	PRKCZ	-0.6	-10.57	-0.5	1.03e-22	Height;
LUSC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg12560992	chr17:57184187	TRIM37	-0.82	-14.87	-0.63	9.48e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg04545296	chr12:48745243	ZNF641	0.34	6.27	0.32	1.14e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.33	-0.33	8.04e-10	Morning vs. evening chronotype;
LUSC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg11247378	chr22:39784982	NA	-0.66	-13.31	-0.59	1.03e-32	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg13852791	chr20:30311386	BCL2L1	0.84	10.19	0.49	2.01e-21	Mean corpuscular hemoglobin;
LUSC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-8.17	-0.41	6.41e-15	Cystic fibrosis severity;
LUSC	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.62	12.64	0.57	3.5e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.89	-0.44	3.98e-17	Neuroticism;
LUSC	trans	rs7980799	0.933	rs11052705	chr12:33588388	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-6.53	-0.34	2.39e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.69	10.47	0.5	2.2e-22	Corneal astigmatism;
LUSC	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg00277334	chr10:82204260	NA	-0.47	-6.61	-0.34	1.51e-10	Post bronchodilator FEV1;
LUSC	cis	rs6012953	0.654	rs2206656	chr20:49130119	C/G	cg13958625	chr20:49123093	NA	0.28	5.83	0.3	1.29e-8	Vitiligo;
LUSC	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.25	-0.41	3.62e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6542838	0.641	rs4553869	chr2:99505940	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.67	-0.3	3.08e-8	Fear of minor pain;
LUSC	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.72	-0.35	7.65e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg12016809	chr21:47604291	C21orf56	0.4	6.02	0.31	4.57e-9	Testicular germ cell tumor;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.69	10.48	0.5	2.02e-22	Lymphocyte counts;
LUSC	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg05501817	chr11:14380813	RRAS2	-0.57	-8.9	-0.44	3.5e-17	Sense of smell;
LUSC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg03806693	chr22:41940476	POLR3H	-0.89	-12.63	-0.57	3.75e-30	Vitiligo;
LUSC	cis	rs7809950	1.000	rs2250414	chr7:107140987	T/G	cg23024343	chr7:107201750	COG5	-0.55	-8.75	-0.43	1.07e-16	Coronary artery disease;
LUSC	trans	rs11723530	0.538	rs4692761	chr4:170814074	T/C	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.28	-0.32	1.03e-9	Myopia (pathological);
LUSC	trans	rs6852435	1.000	rs34421418	chr4:175306470	G/A	cg23753247	chr11:8615842	STK33	-0.53	-5.97	-0.31	5.91e-9	Response to acetaminophen (hepatotoxicity);
LUSC	cis	rs7202877	0.706	rs42472	chr16:75473320	T/A	cg03315344	chr16:75512273	CHST6	-0.45	-6.46	-0.33	3.64e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs4851254	0.961	rs11680485	chr2:100749744	A/G	cg07810366	chr2:100720526	AFF3	-0.37	-5.74	-0.3	2.08e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg09998033	chr7:158218633	PTPRN2	-0.4	-6.35	-0.33	7.18e-10	Obesity-related traits;
LUSC	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg17077180	chr1:38461687	NA	0.45	7.0	0.36	1.43e-11	Coronary artery disease;
LUSC	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs8038465	0.662	rs7497012	chr15:73968719	G/A	cg15420318	chr15:73925796	NPTN	0.56	9.23	0.45	3.29e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg08501292	chr6:25962987	TRIM38	0.64	5.84	0.3	1.24e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg12560992	chr17:57184187	TRIM37	0.84	15.44	0.65	5.6e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg17376030	chr22:41985996	PMM1	-0.47	-5.9	-0.31	8.94e-9	Vitiligo;
LUSC	cis	rs9399401	0.626	rs7756434	chr6:142775295	A/G	cg03128060	chr6:142623767	GPR126	0.53	9.12	0.45	6.95e-18	Chronic obstructive pulmonary disease;
LUSC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg13683864	chr3:40499215	RPL14	-1.14	-20.56	-0.75	2.88e-61	Renal cell carcinoma;
LUSC	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg00750074	chr16:89608354	SPG7	-0.45	-7.76	-0.39	1.01e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg14154082	chr13:112174009	NA	0.37	7.7	0.39	1.54e-13	Menarche (age at onset);
LUSC	cis	rs1832871	0.521	rs62437410	chr6:158822888	G/C	cg07165851	chr6:158734300	TULP4	0.38	6.1	0.32	2.9e-9	Height;
LUSC	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg17173187	chr15:85201210	NMB	0.37	6.68	0.34	1.03e-10	Schizophrenia;
LUSC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.52	-7.85	-0.39	5.77e-14	Systemic lupus erythematosus;
LUSC	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	0.57	9.15	0.45	5.75e-18	Breast cancer;
LUSC	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg13010199	chr12:38710504	ALG10B	0.5	7.81	0.39	7.51e-14	Morning vs. evening chronotype;
LUSC	cis	rs7605827	0.930	rs11688071	chr2:15612626	T/G	cg19274914	chr2:15703543	NA	0.45	8.55	0.42	4.36e-16	Educational attainment (years of education);
LUSC	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg23791538	chr6:167370224	RNASET2	0.54	9.07	0.44	1.01e-17	Graves' disease;
LUSC	cis	rs7172677	1.000	rs4243032	chr15:75426884	C/G	cg14664628	chr15:75095509	CSK	-0.44	-5.81	-0.3	1.43e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs308447	0.516	rs13127908	chr4:123720933	G/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.83	11.33	0.53	2.2e-25	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-0.98	-14.68	-0.63	5.64e-38	Initial pursuit acceleration;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21815536	chr7:35840623	SEPT7	-0.48	-6.14	-0.32	2.35e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.19	-0.32	1.74e-9	Bladder cancer;
LUSC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.4	0.56	2.7e-29	Prudent dietary pattern;
LUSC	cis	rs113835537	0.735	rs519380	chr11:66409409	G/A	cg24851651	chr11:66362959	CCS	0.56	8.42	0.42	1.11e-15	Airway imaging phenotypes;
LUSC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.79	-0.39	8.83e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.93	-20.2	-0.74	7.22e-60	Longevity;
LUSC	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.03	-0.31	4.24e-9	Resting heart rate;
LUSC	cis	rs9395066	0.545	rs6925467	chr6:44998038	T/A	cg25276700	chr6:44698697	NA	0.28	5.72	0.3	2.39e-8	Height;
LUSC	cis	rs1009647	0.633	rs11626485	chr14:55826764	A/G	cg04306507	chr14:55594613	LGALS3	0.44	6.1	0.32	2.89e-9	Testicular germ cell tumor;
LUSC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg09877947	chr5:131593287	PDLIM4	0.59	10.05	0.48	6.22e-21	Acylcarnitine levels;
LUSC	cis	rs11585357	0.947	rs2977304	chr1:17611615	T/C	cg08277548	chr1:17600880	PADI3	0.63	6.78	0.35	5.57e-11	Hair shape;
LUSC	cis	rs240764	0.578	rs62422070	chr6:101260827	T/G	cg09795085	chr6:101329169	ASCC3	0.44	6.23	0.32	1.4e-9	Neuroticism;
LUSC	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.85	-0.3	1.18e-8	Testicular germ cell tumor;
LUSC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.92	-14.71	-0.63	4.14e-38	Coronary artery disease;
LUSC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	15.13	0.64	9.03e-40	Platelet count;
LUSC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg00933542	chr6:150070202	PCMT1	0.31	6.62	0.34	1.47e-10	Lung cancer;
LUSC	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22496380	chr5:211416	CCDC127	-0.8	-8.86	-0.44	4.83e-17	Breast cancer;
LUSC	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.7	-0.54	9.69e-27	Type 2 diabetes;
LUSC	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg00191853	chr8:101177733	SPAG1	-0.39	-6.49	-0.33	3.19e-10	Atrioventricular conduction;
LUSC	trans	rs6725041	0.805	rs6745249	chr2:213130571	A/G	cg13882712	chr2:27603741	ZNF513	-0.4	-6.1	-0.32	2.87e-9	QT interval (ambient particulate matter interaction);
LUSC	cis	rs727505	1.000	rs17246404	chr7:124462661	C/T	cg23710748	chr7:124431027	NA	-0.42	-7.46	-0.38	7.37e-13	Lewy body disease;
LUSC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.77	0.3	1.77e-8	Menopause (age at onset);
LUSC	cis	rs7759001	0.857	rs2393927	chr6:27348095	G/C	cg18711553	chr6:27366782	ZNF391	0.4	5.81	0.3	1.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg03676636	chr4:99064102	C4orf37	-0.27	-5.77	-0.3	1.84e-8	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg04362960	chr10:104952993	NT5C2	0.46	6.86	0.35	3.38e-11	Waist circumference;Hip circumference;
LUSC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	1.0	17.59	0.69	1.69e-49	Cognitive function;
LUSC	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg03585969	chr10:35415529	CREM	0.62	8.93	0.44	2.97e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg12667521	chr19:29218732	NA	0.52	6.07	0.32	3.41e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg22834771	chr12:69754056	YEATS4	-0.5	-7.4	-0.38	1.15e-12	Blood protein levels;
LUSC	cis	rs7241530	0.662	rs55694606	chr18:75902149	A/G	cg14642773	chr18:75888474	NA	0.41	6.27	0.32	1.14e-9	Educational attainment (years of education);
LUSC	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18854424	chr1:2615690	NA	0.5	10.16	0.49	2.69e-21	Ulcerative colitis;
LUSC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.59	0.34	1.68e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2742417	0.967	rs1883096	chr3:45750015	C/T	cg09608765	chr3:45636137	LIMD1	-0.38	-7.51	-0.38	5.47e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs60787346	0.883	rs3788070	chr21:45068077	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.42	6.24	0.32	1.29e-9	Coronary artery disease;
LUSC	cis	rs9311676	0.632	rs11923181	chr3:58380569	A/C	cg26110898	chr3:58419937	PDHB	0.41	6.72	0.35	7.94e-11	Systemic lupus erythematosus;
LUSC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg20818283	chr2:191399100	TMEM194B	0.45	6.9	0.35	2.54e-11	Pulse pressure;
LUSC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-0.68	-9.68	-0.47	1.05e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg17340268	chr14:105411764	AHNAK2	-0.4	-6.42	-0.33	4.76e-10	Rheumatoid arthritis;
LUSC	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg21775007	chr8:11205619	TDH	-0.54	-7.58	-0.38	3.55e-13	Neuroticism;
LUSC	cis	rs559555	0.597	rs502139	chr2:31811268	T/C	cg02381751	chr2:32503542	YIPF4	0.4	5.71	0.3	2.55e-8	Blood metabolite ratios;Blood metabolite levels;
LUSC	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06022373	chr22:39101656	GTPBP1	0.45	6.33	0.33	7.87e-10	Menopause (age at onset);
LUSC	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg22681709	chr2:178499509	PDE11A	-0.51	-9.34	-0.46	1.4e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg13699009	chr12:122356056	WDR66	0.48	7.36	0.37	1.47e-12	Mean corpuscular volume;
LUSC	cis	rs6087990	0.899	rs1003521	chr20:31366598	T/C	cg13636640	chr20:31349939	DNMT3B	1.0	22.4	0.77	1.62e-68	Ulcerative colitis;
LUSC	cis	rs17125944	0.556	rs7152229	chr14:53313405	T/C	cg00686598	chr14:53173677	PSMC6	-0.61	-5.64	-0.3	3.54e-8	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.75	13.67	0.6	4.47e-34	Aortic root size;
LUSC	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg16989719	chr2:238392110	NA	-0.45	-7.25	-0.37	2.85e-12	Prostate cancer;
LUSC	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg27124370	chr19:33622961	WDR88	-0.57	-7.67	-0.39	1.89e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7674212	0.570	rs6813563	chr4:104099110	G/A	cg16532752	chr4:104119610	CENPE	-0.48	-6.91	-0.35	2.4e-11	Type 2 diabetes;
LUSC	cis	rs921665	0.831	rs12476669	chr2:3195428	A/T	cg02624386	chr2:3182749	NA	0.56	5.74	0.3	2.12e-8	World class endurance athleticism;
LUSC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg07741184	chr6:167504864	NA	-0.4	-7.13	-0.36	6.36e-12	Crohn's disease;
LUSC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.54	0.38	4.59e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7703051	0.901	rs5744680	chr5:74879890	C/T	cg06933384	chr5:74808293	COL4A3BP;POLK	0.37	5.96	0.31	6.45e-9	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08971981	chr7:44163271	POLD2	-0.56	-6.59	-0.34	1.75e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9535307	0.929	rs7984061	chr13:50337340	G/A	cg04663916	chr13:50265991	EBPL	0.52	5.7	0.3	2.64e-8	Obesity-related traits;
LUSC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg25039879	chr17:56429692	SUPT4H1	0.66	8.83	0.44	6e-17	Cognitive test performance;
LUSC	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg11342453	chr6:26196699	NA	0.55	5.78	0.3	1.7e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg25019033	chr10:957182	NA	-0.54	-6.88	-0.35	3.03e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg26566898	chr11:117069891	TAGLN	-0.34	-6.46	-0.33	3.78e-10	Blood protein levels;
LUSC	cis	rs7712401	0.560	rs13168225	chr5:122347264	C/T	cg19077854	chr5:122220652	SNX24	-0.38	-7.89	-0.4	4.33e-14	Mean platelet volume;
LUSC	cis	rs6577655	0.517	rs9693237	chr8:135578218	G/A	cg17885191	chr8:135476712	NA	0.58	7.49	0.38	6.04e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.67	-8.67	-0.43	1.96e-16	Schizophrenia;
LUSC	trans	rs6011368	0.585	rs13043326	chr20:62914092	C/A	cg13869341	chr1:15865	WASH5P	0.4	6.13	0.32	2.52e-9	Clozapine-induced cytotoxicity;
LUSC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.7	10.97	0.51	4.14e-24	Obesity-related traits;
LUSC	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg00944433	chr1:107599041	PRMT6	0.38	6.88	0.35	2.97e-11	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.59	0.38	3.26e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg07061783	chr6:25882402	NA	-0.36	-5.64	-0.3	3.55e-8	Blood metabolite levels;
LUSC	cis	rs4776059	1.000	rs4776059	chr15:52886962	C/T	cg22715398	chr15:52968154	KIAA1370	-0.71	-10.09	-0.48	4.56e-21	Schizophrenia;
LUSC	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-9.29	-0.45	2.02e-18	Mosquito bite size;
LUSC	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg01733217	chr16:74700730	RFWD3	0.79	13.33	0.59	8.25e-33	Testicular germ cell tumor;
LUSC	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg16482183	chr6:26056742	HIST1H1C	0.58	8.02	0.4	1.86e-14	Iron status biomarkers;
LUSC	cis	rs2274273	0.773	rs10147765	chr14:55827826	G/A	cg04306507	chr14:55594613	LGALS3	0.54	12.0	0.55	8.2e-28	Protein biomarker;
LUSC	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg24634471	chr8:143751801	JRK	0.51	7.34	0.37	1.59e-12	Schizophrenia;
LUSC	cis	rs4423214	0.610	rs3763856	chr11:71125345	G/A	cg05163923	chr11:71159392	DHCR7	0.54	8.02	0.4	1.76e-14	Vitamin D levels;
LUSC	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg18755752	chr8:142205143	DENND3	-0.74	-13.12	-0.58	5.17e-32	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg23887609	chr12:130822674	PIWIL1	0.47	7.14	0.36	5.81e-12	Menopause (age at onset);
LUSC	trans	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg12856521	chr11:46389249	DGKZ	0.4	6.29	0.33	9.82e-10	Leprosy;
LUSC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg06784218	chr1:46089804	CCDC17	0.47	9.26	0.45	2.6e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.82	14.07	0.61	1.28e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg11663144	chr21:46675770	NA	-0.42	-7.25	-0.37	3.01e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.53	-0.38	4.89e-13	Bipolar disorder and schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17397028	chr4:91048584	FAM190A	-0.43	-6.02	-0.31	4.68e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.81	0.3	1.49e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg13010199	chr12:38710504	ALG10B	0.53	8.06	0.4	1.39e-14	Morning vs. evening chronotype;
LUSC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	6.25	0.32	1.23e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.46	-8.34	-0.42	2e-15	Crohn's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16101572	chr14:21566698	ZNF219;C14orf176	0.45	6.63	0.34	1.37e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg03538708	chr1:25844672	NA	-0.36	-5.89	-0.31	9.44e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg22676075	chr6:135203613	NA	0.6	9.57	0.46	2.49e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg12179176	chr11:130786555	SNX19	0.76	12.67	0.57	2.65e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg16031515	chr1:205743344	RAB7L1	-0.27	-5.65	-0.3	3.42e-8	Menarche (age at onset);
LUSC	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-1.13	-17.91	-0.7	9.52e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs6714710	0.535	rs13033383	chr2:98339513	C/T	cg26665480	chr2:98280029	ACTR1B	0.62	8.55	0.42	4.34e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg06238570	chr21:40685208	BRWD1	-0.56	-9.03	-0.44	1.37e-17	Menarche (age at onset);
LUSC	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-0.57	-8.75	-0.43	1.07e-16	Breast cancer;
LUSC	cis	rs6736093	0.965	rs4264571	chr2:112674149	T/C	cg12686935	chr2:112915763	FBLN7	-0.37	-5.83	-0.3	1.29e-8	Coronary artery disease;
LUSC	cis	rs10207060	0.500	rs4380264	chr2:240699378	G/T	cg20333904	chr2:240724165	NA	-0.38	-6.33	-0.33	7.69e-10	Obesity-related traits;
LUSC	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg21573476	chr21:45109991	RRP1B	-0.39	-6.25	-0.32	1.29e-9	Mean corpuscular volume;
LUSC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.57	-8.43	-0.42	1.06e-15	Alzheimer's disease;
LUSC	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg03929089	chr4:120376271	NA	-0.83	-12.09	-0.55	3.76e-28	Coronary artery disease;
LUSC	cis	rs7192380	0.639	rs12448486	chr16:69802878	G/A	cg00738113	chr16:70207722	CLEC18C	0.33	6.71	0.34	8.21e-11	Sjögren's syndrome;
LUSC	cis	rs3106136	0.527	rs2664894	chr4:95153831	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.41	-0.42	1.2e-15	Capecitabine sensitivity;
LUSC	cis	rs67696533	0.600	rs4911238	chr20:31122639	C/T	cg13636640	chr20:31349939	DNMT3B	0.46	6.04	0.31	4.18e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg13628971	chr7:2884303	GNA12	0.49	6.76	0.35	6.35e-11	Height;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg22048132	chr17:60005312	INTS2	0.48	7.1	0.36	7.43e-12	Triglycerides;
LUSC	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg03929089	chr4:120376271	NA	-0.58	-7.46	-0.38	7.43e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4423214	0.879	rs1792284	chr11:71134966	A/G	cg05163923	chr11:71159392	DHCR7	0.68	8.61	0.43	2.94e-16	Vitamin D levels;
LUSC	cis	rs2274273	0.870	rs13379169	chr14:55741287	C/T	cg04306507	chr14:55594613	LGALS3	0.57	13.25	0.59	1.67e-32	Protein biomarker;
LUSC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.32	-0.33	8.26e-10	Total body bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03001986	chr5:176433640	UIMC1	-0.42	-6.26	-0.32	1.18e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg20933634	chr6:27740509	NA	0.4	5.87	0.31	1.06e-8	Parkinson's disease;
LUSC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg05717871	chr11:638507	DRD4	-0.39	-6.36	-0.33	6.61e-10	Systemic lupus erythematosus;
LUSC	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg25801113	chr15:45476975	SHF	0.34	7.0	0.36	1.37e-11	Uric acid levels;
LUSC	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg05373962	chr22:49881684	NA	-0.39	-8.64	-0.43	2.4e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg17252645	chr8:143867129	LY6D	0.38	6.58	0.34	1.8e-10	Urinary tract infection frequency;
LUSC	cis	rs472402	0.507	rs8192139	chr5:6636973	C/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.39	-5.88	-0.31	9.78e-9	Response to amphetamines;
LUSC	trans	rs6920965	0.583	rs9388456	chr6:126147197	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-7.25	-0.37	2.98e-12	High light scatter reticulocyte count;
LUSC	cis	rs11039100	0.599	rs34123108	chr11:5834724	A/G	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.3	0.49	9.03e-22	Heart rate;
LUSC	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08704250	chr15:31115839	NA	-0.47	-6.88	-0.35	3.01e-11	Huntington's disease progression;
LUSC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg08219700	chr8:58056026	NA	0.46	6.08	0.32	3.28e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.13	-0.36	6.31e-12	Neuroticism;
LUSC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg16339924	chr4:17578868	LAP3	0.57	8.83	0.44	5.87e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.9	-0.31	8.93e-9	Total body bone mineral density;
LUSC	cis	rs9435732	1.000	rs9435732	chr1:17308158	C/T	cg14981532	chr1:17215477	NA	-0.38	-5.85	-0.3	1.16e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg09655341	chr17:79618100	PDE6G	-0.28	-6.58	-0.34	1.81e-10	Eye color traits;
LUSC	cis	rs10754283	0.967	rs10737706	chr1:90112579	G/T	cg21401794	chr1:90099060	LRRC8C	0.64	9.54	0.46	3.04e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg20503657	chr10:835505	NA	0.86	12.06	0.55	4.85e-28	Eosinophil percentage of granulocytes;
LUSC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg16393715	chr7:1948819	MAD1L1	0.39	6.82	0.35	4.18e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg14154082	chr13:112174009	NA	0.38	7.88	0.4	4.53e-14	Menarche (age at onset);
LUSC	trans	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg25482853	chr8:67687455	SGK3	1.09	15.45	0.65	5.28e-41	Obesity-related traits;
LUSC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	6.15	0.32	2.2e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg06521331	chr12:34319734	NA	-0.49	-8.19	-0.41	5.73e-15	Morning vs. evening chronotype;
LUSC	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg03859395	chr2:55845619	SMEK2	-0.68	-10.08	-0.48	4.75e-21	Metabolic syndrome;
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.3	6.07	0.32	3.56e-9	Lymphocyte counts;
LUSC	cis	rs4704187	0.687	rs4621540	chr5:74371203	T/G	cg03227963	chr5:74354835	NA	0.33	7.22	0.37	3.47e-12	Response to amphetamines;
LUSC	cis	rs7247513	1.000	rs2042947	chr19:12693103	A/G	cg01871581	chr19:12707946	ZNF490	-0.58	-9.08	-0.44	9.86e-18	Bipolar disorder;
LUSC	cis	rs7106204	0.748	rs2403888	chr11:24208071	C/G	ch.11.24196551F	chr11:24239977	NA	-1.12	-13.34	-0.59	8.11e-33	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs72634258	0.842	rs4908727	chr1:8163122	C/T	cg26816564	chr1:7831052	VAMP3	0.42	5.77	0.3	1.78e-8	Inflammatory bowel disease;
LUSC	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg05272587	chr13:111038400	COL4A2	0.4	6.8	0.35	4.93e-11	White matter hyperintensity burden;
LUSC	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg01475377	chr6:109611718	NA	-0.38	-6.7	-0.34	9.02e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs16910800	0.689	rs7101737	chr11:23165031	C/T	cg20040320	chr11:23191996	NA	-0.59	-7.4	-0.38	1.1e-12	Cancer;
LUSC	trans	rs10221833	0.602	rs429376	chr2:165634361	A/G	cg26993132	chr16:89239499	CDH15	0.31	5.99	0.31	5.47e-9	Response to statin therapy;
LUSC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg04398451	chr17:18023971	MYO15A	0.55	9.28	0.45	2.23e-18	Total body bone mineral density;
LUSC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg04518342	chr5:131593106	PDLIM4	0.33	5.97	0.31	6.02e-9	Blood metabolite levels;
LUSC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.58	-9.41	-0.46	8.44e-19	Aortic root size;
LUSC	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg00579200	chr11:133705235	NA	-0.39	-5.97	-0.31	6.21e-9	Childhood ear infection;
LUSC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg13628971	chr7:2884303	GNA12	0.45	6.29	0.33	9.81e-10	Height;
LUSC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.18	0.52	7.37e-25	Menopause (age at onset);
LUSC	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.51	-0.38	5.47e-13	Monocyte count;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06463759	chr7:128502823	ATP6V1F	-0.37	-6.15	-0.32	2.25e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg22676075	chr6:135203613	NA	0.47	7.37	0.37	1.32e-12	Reticulocyte count;High light scatter reticulocyte count;
LUSC	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-7.36	-0.37	1.47e-12	Schizophrenia;
LUSC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.63	6.1	0.32	2.87e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg16359550	chr11:109292809	C11orf87	0.37	6.33	0.33	7.74e-10	Schizophrenia;
LUSC	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg13010199	chr12:38710504	ALG10B	0.56	8.62	0.43	2.75e-16	Morning vs. evening chronotype;
LUSC	cis	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg12223502	chr10:5658492	NA	-0.37	-5.77	-0.3	1.81e-8	Breast cancer;
LUSC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.95	0.31	6.69e-9	Lung cancer;
LUSC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02475777	chr4:1388615	CRIPAK	-0.58	-8.59	-0.43	3.33e-16	Obesity-related traits;
LUSC	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	8.07	0.4	1.32e-14	Axial length;
LUSC	trans	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg03886242	chr7:26192032	NFE2L3	-0.42	-6.67	-0.34	1.05e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg05043794	chr9:111880884	C9orf5	-0.36	-7.78	-0.39	9.33e-14	Menarche (age at onset);
LUSC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg13206674	chr6:150067644	NUP43	0.55	8.56	0.42	4.22e-16	Lung cancer;
LUSC	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg01851573	chr8:8652454	MFHAS1	0.53	8.45	0.42	8.97e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs35883536	0.588	rs10465764	chr1:101105030	A/G	cg06223162	chr1:101003688	GPR88	0.35	6.3	0.33	9.4e-10	Monocyte count;
LUSC	cis	rs13385	0.769	rs7722986	chr5:139617386	G/A	cg26211634	chr5:139558579	C5orf32	0.44	6.86	0.35	3.4e-11	Atrial fibrillation;
LUSC	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg02269571	chr22:50332266	NA	-0.59	-9.03	-0.44	1.36e-17	Schizophrenia;
LUSC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg02527881	chr3:46936655	PTH1R	0.4	7.0	0.36	1.41e-11	Colorectal cancer;
LUSC	cis	rs62400317	0.762	rs72865924	chr6:44878943	G/A	cg20913747	chr6:44695427	NA	-0.48	-7.44	-0.38	8.79e-13	Total body bone mineral density;
LUSC	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg13010199	chr12:38710504	ALG10B	0.65	10.06	0.48	5.87e-21	Bladder cancer;
LUSC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg22618164	chr12:122356400	WDR66	0.55	7.77	0.39	9.9e-14	Mean corpuscular volume;
LUSC	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg15744005	chr10:104629667	AS3MT	0.3	6.13	0.32	2.48e-9	Waist circumference;Hip circumference;
LUSC	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg03929089	chr4:120376271	NA	-0.55	-6.77	-0.35	5.8e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.27	-0.45	2.31e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg13010199	chr12:38710504	ALG10B	0.38	6.09	0.32	3.17e-9	Morning vs. evening chronotype;
LUSC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg21251018	chr6:28226885	NKAPL	0.31	5.99	0.31	5.55e-9	Cardiac Troponin-T levels;
LUSC	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg21827317	chr3:136751795	NA	0.39	6.96	0.36	1.84e-11	Neuroticism;
LUSC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.43	6.87	0.35	3.19e-11	Menopause (age at onset);
LUSC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs16937	0.711	rs10751431	chr1:205128059	C/T	cg00857998	chr1:205179979	DSTYK	0.47	6.7	0.34	8.64e-11	Schizophrenia;
LUSC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.66	-0.3	3.2e-8	Life satisfaction;
LUSC	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-1.07	-17.03	-0.68	2.93e-47	Exhaled nitric oxide output;
LUSC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg07701084	chr6:150067640	NUP43	0.57	8.66	0.43	1.98e-16	Lung cancer;
LUSC	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg17509989	chr5:176798049	RGS14	-0.61	-8.79	-0.43	8e-17	Urate levels in lean individuals;
LUSC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18099408	chr3:52552593	STAB1	-0.41	-7.14	-0.36	5.86e-12	Bipolar disorder;
LUSC	cis	rs7523273	0.606	rs2796266	chr1:207922945	C/T	cg22525895	chr1:207977042	MIR29B2	-0.41	-6.71	-0.34	8.38e-11	Schizophrenia;
LUSC	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg17691542	chr6:26056736	HIST1H1C	0.53	7.38	0.37	1.26e-12	Iron status biomarkers;
LUSC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.51	-0.42	6.1e-16	Obesity-related traits;
LUSC	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg12311346	chr5:56204834	C5orf35	0.61	9.37	0.46	1.09e-18	Coronary artery disease;
LUSC	cis	rs7945718	0.811	rs7104832	chr11:12786489	A/G	cg25843174	chr11:12811716	TEAD1	0.33	7.34	0.37	1.64e-12	Educational attainment (years of education);
LUSC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07677032	chr17:61819896	STRADA	0.52	8.7	0.43	1.55e-16	Prudent dietary pattern;
LUSC	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg01973587	chr1:228161476	NA	0.47	8.35	0.42	1.89e-15	Diastolic blood pressure;
LUSC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg27124370	chr19:33622961	WDR88	0.56	7.74	0.39	1.17e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.51	-8.39	-0.42	1.41e-15	Lymphocyte counts;
LUSC	cis	rs7916697	0.578	rs1900002	chr10:70004552	G/C	cg06988349	chr10:69991859	ATOH7	0.33	5.8	0.3	1.56e-8	Optic disc area;
LUSC	cis	rs10761482	0.859	rs1599166	chr10:62163729	G/A	cg18175470	chr10:62150864	ANK3	-0.58	-8.72	-0.43	1.34e-16	Schizophrenia;
LUSC	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg09877947	chr5:131593287	PDLIM4	-0.37	-5.87	-0.31	1.03e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs10465746	0.780	rs11163867	chr1:84384847	C/T	cg10977910	chr1:84465055	TTLL7	0.42	6.1	0.32	3.01e-9	Obesity-related traits;
LUSC	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg15704280	chr7:45808275	SEPT13	0.75	7.06	0.36	9.46e-12	Axial length;
LUSC	cis	rs2179367	0.600	rs1001305	chr6:149757944	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.35	-5.86	-0.31	1.12e-8	Dupuytren's disease;
LUSC	cis	rs6545883	0.894	rs778144	chr2:61583128	A/C	cg15711740	chr2:61764176	XPO1	0.42	6.59	0.34	1.69e-10	Tuberculosis;
LUSC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.03	-0.4	1.71e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7173743	0.756	rs8032842	chr15:79125849	G/A	cg00540400	chr15:79124168	NA	0.37	6.44	0.33	4.18e-10	Coronary artery disease;
LUSC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg13114125	chr14:105738426	BRF1	-0.96	-15.52	-0.65	2.85e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg17507749	chr15:85114479	UBE2QP1	0.5	5.88	0.31	9.94e-9	Schizophrenia;
LUSC	cis	rs1775715	0.737	rs2799000	chr10:32124894	C/T	cg26784012	chr10:32216390	ARHGAP12	0.44	7.39	0.37	1.21e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg05623727	chr3:50126028	RBM5	0.32	5.96	0.31	6.24e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs41271473	0.898	rs12028277	chr1:228829657	A/G	cg10167378	chr1:228756711	NA	0.64	8.08	0.4	1.22e-14	Chronic lymphocytic leukemia;
LUSC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-0.83	-13.78	-0.6	1.6e-34	Tonsillectomy;
LUSC	trans	rs3960554	0.867	rs76408713	chr7:75829540	G/A	cg19862616	chr7:65841803	NCRNA00174	0.89	9.7	0.47	8.88e-20	Eotaxin levels;
LUSC	trans	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg26043149	chr18:55253948	FECH	0.49	7.47	0.38	7.27e-13	Bone mineral density;
LUSC	cis	rs2235649	0.592	rs8051883	chr16:1958978	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-6.16	-0.32	2.09e-9	Blood metabolite levels;
LUSC	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg11941060	chr3:133502564	NA	-0.46	-6.78	-0.35	5.4e-11	Iron status biomarkers;
LUSC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18932078	chr1:2524107	MMEL1	0.3	6.61	0.34	1.55e-10	Ulcerative colitis;
LUSC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg09796270	chr17:17721594	SREBF1	0.39	6.85	0.35	3.47e-11	Total body bone mineral density;
LUSC	cis	rs9039	1.000	rs67302637	chr16:9221100	C/T	cg08831531	chr16:9218945	NA	-0.65	-9.82	-0.47	3.59e-20	Menopause (age at onset);
LUSC	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg21775007	chr8:11205619	TDH	0.48	7.08	0.36	8.29e-12	Mood instability;
LUSC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg02269571	chr22:50332266	NA	-0.51	-7.53	-0.38	4.88e-13	Schizophrenia;
LUSC	trans	rs28647808	0.786	rs4962137	chr9:136256826	G/T	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs79390637	1	rs79390637	chr11:47456867	C/A	cg20307385	chr11:47447363	PSMC3	0.66	9.74	0.47	6.62e-20	Intraocular pressure;
LUSC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg17971929	chr21:40555470	PSMG1	-0.52	-7.67	-0.39	1.85e-13	Menarche (age at onset);
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	0.98	20.81	0.75	2.81e-62	Menarche (age at onset);
LUSC	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg10518543	chr12:38710700	ALG10B	0.41	5.76	0.3	1.86e-8	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.97	-0.68	4.92e-47	Monocyte count;
LUSC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg03609598	chr5:56110824	MAP3K1	-0.39	-5.77	-0.3	1.81e-8	Initial pursuit acceleration;
LUSC	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg11693508	chr17:37793320	STARD3	0.65	7.95	0.4	2.93e-14	Bipolar disorder;
LUSC	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg01677386	chr11:118938358	VPS11	-0.48	-6.86	-0.35	3.37e-11	Coronary artery disease;
LUSC	cis	rs977987	0.835	rs4888379	chr16:75340231	A/T	cg04384234	chr16:75411784	CFDP1	-0.39	-6.4	-0.33	5.36e-10	Dupuytren's disease;
LUSC	cis	rs10788264	0.716	rs7091348	chr10:124016160	C/T	cg09507567	chr10:124027408	NA	0.51	8.49	0.42	6.65e-16	Total body bone mineral density;
LUSC	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	8.6	0.43	3.12e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Depression;
LUSC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11644478	chr21:40555479	PSMG1	0.93	17.29	0.69	2.65e-48	Cognitive function;
LUSC	cis	rs10779751	0.922	rs2295080	chr1:11322628	G/T	cg08854313	chr1:11322531	MTOR	0.89	15.39	0.64	9.02e-41	Body mass index;
LUSC	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg05707623	chr12:122985044	ZCCHC8	0.7	8.42	0.42	1.14e-15	Body mass index;
LUSC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg02475777	chr4:1388615	CRIPAK	0.44	6.56	0.34	2.1e-10	Obesity-related traits;
LUSC	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	0.51	7.81	0.39	7.3e-14	Breast cancer;
LUSC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.86e-14	Melanoma;
LUSC	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg19773385	chr1:10388646	KIF1B	0.57	10.09	0.48	4.41e-21	Hepatocellular carcinoma;
LUSC	cis	rs3849570	0.925	rs6799080	chr3:81905591	G/A	cg07356753	chr3:81810745	GBE1	-0.68	-11.34	-0.53	2.02e-25	Waist circumference;Body mass index;
LUSC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21782813	chr7:2030301	MAD1L1	-0.46	-7.95	-0.4	2.9e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.56	8.46	0.42	8.5e-16	Blood protein levels;
LUSC	cis	rs679087	1.000	rs439639	chr12:29917641	A/C	cg14258853	chr12:29935411	TMTC1	-0.98	-16.17	-0.66	7.67e-44	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg12310025	chr6:25882481	NA	-0.53	-9.71	-0.47	8.83e-20	Blood metabolite levels;
LUSC	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg03342759	chr3:160939853	NMD3	-0.57	-9.81	-0.47	4.11e-20	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-6.26	-0.32	1.17e-9	Monocyte count;
LUSC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.42	-7.8	-0.39	8.05e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg01858014	chr14:56050164	KTN1	0.89	7.26	0.37	2.75e-12	Putamen volume;
LUSC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg23711669	chr6:146136114	FBXO30	0.72	12.88	0.58	4.13e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg01802117	chr1:53393560	SCP2	0.38	6.2	0.32	1.63e-9	Monocyte count;
LUSC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	0.64	13.65	0.6	5.1e-34	Prudent dietary pattern;
LUSC	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.89	0.35	2.84e-11	Rheumatoid arthritis;
LUSC	cis	rs7000551	0.715	rs1879793	chr8:22313986	G/A	cg12081754	chr8:22256438	SLC39A14	0.48	7.33	0.37	1.72e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs668210	0.793	rs622779	chr11:65744247	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.56	-7.17	-0.37	4.83e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg07895657	chr22:50616420	PANX2	-0.37	-6.34	-0.33	7.63e-10	Obesity-related traits;
LUSC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg19318889	chr4:1322082	MAEA	0.52	8.86	0.44	5.02e-17	Longevity;
LUSC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg00745463	chr17:30367425	LRRC37B	-0.87	-10.22	-0.49	1.66e-21	Hip circumference adjusted for BMI;
LUSC	cis	rs3736594	0.959	rs6547796	chr2:27975394	T/C	cg27432699	chr2:27873401	GPN1	-0.64	-9.13	-0.45	6.53e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs2463822	0.583	rs72919462	chr11:62035663	G/A	cg06239285	chr11:62104954	ASRGL1	-0.59	-5.99	-0.31	5.44e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs701145	0.585	rs1527800	chr3:153875075	A/G	cg17054900	chr3:154042577	DHX36	0.71	6.94	0.36	1.98e-11	Coronary artery disease;
LUSC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.54	-10.26	-0.49	1.2e-21	Prostate cancer;
LUSC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	12.0	0.55	7.98e-28	Prudent dietary pattern;
LUSC	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.15	-0.32	2.25e-9	Morning vs. evening chronotype;
LUSC	trans	rs9831754	1.000	rs9855903	chr3:78347988	C/A	cg06695833	chr19:18220682	MAST3	0.48	6.03	0.31	4.23e-9	Calcium levels;
LUSC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg12463550	chr7:65579703	CRCP	-0.51	-7.45	-0.38	8.18e-13	Aortic root size;
LUSC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg12826209	chr6:26865740	GUSBL1	0.68	7.82	0.39	7.17e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6542838	0.641	rs4499468	chr2:99475204	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.14	-0.32	2.38e-9	Fear of minor pain;
LUSC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.86e-14	Melanoma;
LUSC	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.81	-13.67	-0.6	4.37e-34	Body mass index (adult);
LUSC	cis	rs12928939	1.000	rs12928939	chr16:71800045	G/A	cg03805757	chr16:71968109	PKD1L3	-0.43	-6.15	-0.32	2.16e-9	Post bronchodilator FEV1;
LUSC	trans	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.41	-0.33	5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-5.9	-0.31	8.72e-9	Retinal vascular caliber;
LUSC	cis	rs9420	0.961	rs7949841	chr11:57524700	G/C	cg23127183	chr11:57508653	C11orf31	-0.57	-8.81	-0.43	6.86e-17	Schizophrenia;
LUSC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13012494	chr21:47604986	C21orf56	0.46	6.81	0.35	4.68e-11	Testicular germ cell tumor;
LUSC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg10596483	chr8:143751796	JRK	0.61	9.39	0.46	9.87e-19	Schizophrenia;
LUSC	cis	rs10761482	0.954	rs12261675	chr10:62065257	C/A	cg18175470	chr10:62150864	ANK3	-0.45	-6.26	-0.32	1.2e-9	Schizophrenia;
LUSC	cis	rs2235649	0.624	rs2076427	chr16:1817754	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.49	6.26	0.32	1.18e-9	Blood metabolite levels;
LUSC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg21782813	chr7:2030301	MAD1L1	0.37	6.03	0.31	4.46e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg26924012	chr15:45694286	SPATA5L1	1.14	20.94	0.75	9e-63	Homoarginine levels;
LUSC	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.93	-0.44	2.88e-17	Response to antipsychotic treatment;
LUSC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg07959070	chr22:50026188	C22orf34	-0.34	-6.88	-0.35	3.05e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	trans	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg10167378	chr1:228756711	NA	0.75	9.63	0.47	1.54e-19	Chronic lymphocytic leukemia;
LUSC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.99	0.44	1.9e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6469656	1.000	rs6988841	chr8:117730893	A/G	cg24004040	chr8:117650383	NA	-0.42	-6.22	-0.32	1.48e-9	Colorectal cancer;
LUSC	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.54	-0.34	2.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.95	-20.11	-0.74	1.7e-59	Post bronchodilator FEV1;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02723399	chr22:19420170	HIRA;MRPL40	0.45	6.19	0.32	1.73e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.47	6.9	0.35	2.62e-11	Height;
LUSC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg21724239	chr8:58056113	NA	0.8	8.59	0.43	3.29e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs806215	1.000	rs327511	chr7:127257261	G/T	cg25922125	chr7:127225783	GCC1	0.49	6.33	0.33	7.92e-10	Type 2 diabetes;
LUSC	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg13647721	chr17:30228624	UTP6	0.66	7.73	0.39	1.26e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg21659725	chr3:3221576	CRBN	-0.71	-7.82	-0.39	7.08e-14	Menarche (age at onset);
LUSC	trans	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg25214090	chr10:38739885	LOC399744	0.39	6.04	0.31	4.14e-9	Diastolic blood pressure;
LUSC	cis	rs9807841	0.592	rs6511707	chr19:10767790	C/T	cg17710535	chr19:10819994	QTRT1	0.41	6.85	0.35	3.48e-11	Inflammatory skin disease;
LUSC	cis	rs11958404	0.932	rs72816543	chr5:157416464	A/G	cg05962755	chr5:157440814	NA	0.54	6.49	0.33	3.12e-10	IgG glycosylation;
LUSC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.61	-0.43	2.97e-16	Aortic root size;
LUSC	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.84	0.35	3.88e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg02030672	chr11:45687055	CHST1	0.55	8.95	0.44	2.6e-17	Obesity-related traits;
LUSC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg06145435	chr7:1022769	CYP2W1	0.3	5.98	0.31	5.83e-9	Longevity;Endometriosis;
LUSC	cis	rs2742234	0.910	rs2505505	chr10:43648221	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.37	-6.8	-0.35	4.71e-11	Hirschsprung disease;
LUSC	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg13010199	chr12:38710504	ALG10B	-0.41	-6.07	-0.32	3.49e-9	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs4148689	0.951	rs1820871	chr7:117189272	G/A	cg10450175	chr16:88689712	ZC3H18	0.46	5.99	0.31	5.37e-9	Gout;
LUSC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg00933542	chr6:150070202	PCMT1	0.29	6.0	0.31	5.2e-9	Lung cancer;
LUSC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.52e-24	Aortic root size;
LUSC	cis	rs1021993	0.597	rs79455200	chr1:209507767	G/A	cg24446417	chr1:209558027	NA	-0.35	-5.73	-0.3	2.25e-8	Gut microbiome composition (winter);
LUSC	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21028142	chr17:79581711	NPLOC4	0.35	8.23	0.41	4.36e-15	Eye color traits;
LUSC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg02807482	chr3:125708958	NA	-0.48	-6.01	-0.31	4.79e-9	Blood pressure (smoking interaction);
LUSC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg22166914	chr1:53195759	ZYG11B	-0.7	-12.07	-0.55	4.3e-28	Monocyte count;
LUSC	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg25930673	chr12:123319894	HIP1R	-0.6	-5.93	-0.31	7.41e-9	Schizophrenia;
LUSC	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg20628663	chr10:43360327	NA	-0.76	-11.4	-0.53	1.23e-25	Blood protein levels;
LUSC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.87	16.74	0.68	4.24e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg15556689	chr8:8085844	FLJ10661	0.56	8.67	0.43	1.89e-16	Retinal vascular caliber;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12433217	chr1:25758112	TMEM57	-0.44	-6.89	-0.35	2.82e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4417855	0.665	rs6806459	chr3:187406785	C/T	cg19198148	chr3:187451818	BCL6	0.55	9.95	0.48	1.39e-20	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.66	-11.29	-0.53	3.03e-25	Diastolic blood pressure;
LUSC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg25456477	chr12:86230367	RASSF9	0.43	7.73	0.39	1.24e-13	Major depressive disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18470852	chr19:18682598	UBA52	0.8	6.29	0.33	9.99e-10	Cognitive performance;
LUSC	cis	rs6499755	0.897	rs8046197	chr16:55346012	A/C	cg02859129	chr16:55357253	IRX6	0.36	6.12	0.32	2.69e-9	Hypospadias;
LUSC	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.32	0.56	5.19e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02788857	chr8:22132959	PIWIL2	0.4	7.77	0.39	9.75e-14	Hypertriglyceridemia;
LUSC	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg03213289	chr20:61660250	NA	0.67	13.29	0.59	1.21e-32	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs76248362	1.000	rs9510910	chr13:24437265	C/G	cg00599770	chr7:27196825	HOXA7	0.48	5.99	0.31	5.56e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs151234	0.676	rs231970	chr16:28567004	A/G	cg01378222	chr16:28622494	SULT1A1	-0.62	-8.36	-0.42	1.69e-15	Platelet distribution width;
LUSC	cis	rs6580649	0.941	rs11609399	chr12:48501161	A/T	cg24011408	chr12:48396354	COL2A1	-0.45	-6.1	-0.32	2.9e-9	Lung cancer;
LUSC	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.71	-12.37	-0.56	3.57e-29	White blood cell count (basophil);
LUSC	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg23711669	chr6:146136114	FBXO30	0.9	16.87	0.68	1.33e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.94	0.55	1.29e-27	Personality dimensions;
LUSC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg06008330	chr7:65541103	ASL	0.42	6.55	0.34	2.19e-10	Aortic root size;
LUSC	trans	rs724744	0.742	rs1205938	chr6:22357296	A/G	cg13807341	chr11:118445984	ARCN1	-0.36	-6.06	-0.31	3.61e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg03929089	chr4:120376271	NA	0.74	6.95	0.36	1.87e-11	Axial length;
LUSC	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg13072238	chr3:49761600	GMPPB	-0.39	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4664304	0.714	rs66496937	chr2:160738509	A/G	cg03641300	chr2:160917029	PLA2R1	-0.36	-5.76	-0.3	1.87e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg00129232	chr17:37814104	STARD3	-0.45	-6.49	-0.33	3.15e-10	Asthma;
LUSC	cis	rs11229555	0.645	rs7931394	chr11:58212617	T/A	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9300255	0.679	rs10846507	chr12:123786492	G/T	cg00376283	chr12:123451042	ABCB9	0.68	8.06	0.4	1.35e-14	Neutrophil percentage of white cells;
LUSC	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg09201001	chr11:18656081	SPTY2D1	0.92	15.18	0.64	6.23e-40	Breast cancer;
LUSC	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg13010199	chr12:38710504	ALG10B	0.58	9.23	0.45	3.14e-18	Morning vs. evening chronotype;
LUSC	cis	rs6076065	0.723	rs7988	chr20:23352685	C/A	cg11657817	chr20:23433608	CST11	0.42	7.87	0.4	4.89e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs295140	0.565	rs295139	chr2:201159988	T/A	cg23649088	chr2:200775458	C2orf69	0.38	5.75	0.3	1.98e-8	QT interval;
LUSC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	31.21	0.86	5.03e-101	Chronic sinus infection;
LUSC	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg06818126	chr11:68850279	TPCN2	0.45	6.68	0.34	9.75e-11	Hair color;
LUSC	cis	rs11645898	0.810	rs72787046	chr16:72079342	A/G	cg14768367	chr16:72042858	DHODH	-0.71	-7.76	-0.39	1.02e-13	Blood protein levels;
LUSC	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02187348	chr16:89574699	SPG7	0.61	10.08	0.48	4.71e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg16006841	chr5:176797999	RGS14	-0.66	-9.69	-0.47	9.83e-20	Urate levels in lean individuals;
LUSC	cis	rs117352156	0.943	rs7899136	chr10:29211322	A/T	cg06394621	chr10:29236369	NA	-0.48	-6.53	-0.34	2.47e-10	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.25	-0.45	2.79e-18	Acne (severe);
LUSC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.09	0.48	4.54e-21	Bipolar disorder;
LUSC	trans	rs2587949	0.550	rs80182329	chr3:4226282	A/T	cg15139668	chr4:4577005	NA	-0.43	-6.32	-0.33	8.57e-10	Periodontitis (DPAL);
LUSC	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg00132208	chr4:10120780	NA	0.36	5.72	0.3	2.36e-8	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg24812749	chr6:127587940	RNF146	0.63	9.34	0.46	1.37e-18	Breast cancer;
LUSC	cis	rs10465746	0.967	rs12140068	chr1:84394286	A/C	cg10977910	chr1:84465055	TTLL7	0.44	6.35	0.33	7e-10	Obesity-related traits;
LUSC	trans	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg26043149	chr18:55253948	FECH	-0.54	-7.74	-0.39	1.19e-13	Bone mineral density;
LUSC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg04310649	chr10:35416472	CREM	-0.43	-6.65	-0.34	1.23e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22029157	chr1:209979665	IRF6	0.68	9.35	0.46	1.3e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs7107174	1.000	rs4128206	chr11:78015952	A/C	cg02023728	chr11:77925099	USP35	0.44	6.73	0.35	7.44e-11	Testicular germ cell tumor;
LUSC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.14e-35	Breast cancer;
LUSC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg23630131	chr7:65973040	NA	0.2	5.72	0.3	2.4e-8	Aortic root size;
LUSC	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-1.01	-20.19	-0.74	7.86e-60	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg03188948	chr7:1209495	NA	0.66	6.93	0.35	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.89	0.6	6.41e-35	Breast cancer;
LUSC	cis	rs926938	0.527	rs11084	chr1:115537933	A/G	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.36	-0.33	6.75e-10	Autism;
LUSC	trans	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg16011800	chr17:1958478	HIC1	0.45	6.14	0.32	2.37e-9	Lymphocyte counts;Red cell distribution width;
LUSC	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg00530320	chr1:46809349	NSUN4	0.55	8.47	0.42	7.65e-16	Menopause (age at onset);
LUSC	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg17366294	chr4:99064904	C4orf37	0.5	8.81	0.43	6.78e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg03146154	chr1:46216737	IPP	0.52	7.77	0.39	9.58e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-8.64	-0.43	2.43e-16	Schizophrenia;
LUSC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.58	10.45	0.5	2.55e-22	Bone mineral density;
LUSC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.31	0.53	2.59e-25	Prudent dietary pattern;
LUSC	trans	rs1927790	0.759	rs7982697	chr13:96988839	A/G	cg03198741	chr6:1003969	LOC285768	-0.4	-5.99	-0.31	5.55e-9	Body mass index;
LUSC	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg25922239	chr6:33757077	LEMD2	0.55	8.38	0.42	1.53e-15	Crohn's disease;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg25390199	chr17:18761479	PRPSAP2	0.39	6.12	0.32	2.58e-9	Mosquito bite size;
LUSC	cis	rs9420	0.807	rs12807357	chr11:57656902	C/T	cg02958346	chr11:57425731	CLP1	-0.44	-6.08	-0.32	3.28e-9	Schizophrenia;
LUSC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg11168104	chr5:1857477	NA	-0.32	-5.65	-0.3	3.35e-8	Cardiovascular disease risk factors;
LUSC	trans	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg07211511	chr3:129823064	LOC729375	-0.75	-9.67	-0.47	1.2e-19	Blood pressure (smoking interaction);
LUSC	cis	rs7582720	1.000	rs72932561	chr2:203848402	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.35	0.42	1.88e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-1.04	-12.47	-0.56	1.5e-29	Schizophrenia;
LUSC	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg25512537	chr17:76250053	NA	-0.48	-8.57	-0.42	4.02e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.22	0.32	1.53e-9	Systolic blood pressure;
LUSC	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg11130432	chr3:121712080	ILDR1	-0.63	-9.59	-0.46	2.19e-19	Multiple sclerosis;
LUSC	cis	rs9937943	0.615	rs35495670	chr16:74610422	T/C	cg01733217	chr16:74700730	RFWD3	0.61	6.49	0.33	3.02e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg24060327	chr5:131705240	SLC22A5	-0.38	-6.25	-0.32	1.27e-9	Blood metabolite levels;
LUSC	cis	rs2294693	0.891	rs9381024	chr6:40984262	A/C	cg14769373	chr6:40998127	UNC5CL	0.52	5.9	0.31	8.88e-9	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg24558204	chr6:135376177	HBS1L	-0.58	-8.93	-0.44	2.96e-17	Red blood cell count;
LUSC	cis	rs78366141	0.649	rs10428273	chr4:89672738	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.96	7.68	0.39	1.82e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs12765878	1.000	rs3814220	chr10:105647300	A/G	cg11005552	chr10:105648138	OBFC1	0.36	5.68	0.3	2.86e-8	Coronary artery disease;
LUSC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.82	0.39	6.91e-14	Electroencephalogram traits;
LUSC	trans	rs724744	0.742	rs1205932	chr6:22358391	T/G	cg13807341	chr11:118445984	ARCN1	-0.36	-6.07	-0.32	3.43e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg00999904	chr2:3704751	ALLC	-0.46	-7.12	-0.36	6.61e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs273573	0.816	rs604672	chr11:30853226	C/G	cg14844989	chr11:31128820	NA	0.36	5.74	0.3	2.18e-8	Total body bone mineral density;
LUSC	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg08330031	chr10:104623503	C10orf32	0.31	5.64	0.3	3.54e-8	Arsenic metabolism;
LUSC	cis	rs17001868	0.527	rs73167009	chr22:40734249	T/C	cg07138101	chr22:40742427	ADSL	0.64	7.62	0.38	2.72e-13	Mammographic density (dense area);
LUSC	trans	rs1941687	0.831	rs12958029	chr18:31388680	A/G	cg27147174	chr7:100797783	AP1S1	-0.45	-6.56	-0.34	2.05e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs9473147	0.516	rs2171089	chr6:47515811	A/G	cg02130027	chr6:47444894	CD2AP	0.36	5.74	0.3	2.07e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg05855489	chr10:104503620	C10orf26	0.63	8.77	0.43	9.4e-17	Arsenic metabolism;
LUSC	cis	rs12776158	0.901	rs79980322	chr10:71201715	C/T	cg12610070	chr10:71211762	TSPAN15	-0.46	-6.68	-0.34	9.75e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	6.01	0.31	4.85e-9	Tonsillectomy;
LUSC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg18827107	chr12:86230957	RASSF9	-0.5	-7.29	-0.37	2.3e-12	Major depressive disorder;
LUSC	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg25456477	chr12:86230367	RASSF9	0.33	5.82	0.3	1.39e-8	Major depressive disorder;
LUSC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg18964960	chr10:1102726	WDR37	-0.46	-6.22	-0.32	1.5e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg02487422	chr3:49467188	NICN1	0.45	7.08	0.36	8.74e-12	Resting heart rate;
LUSC	cis	rs1127311	0.875	rs9427102	chr1:154586957	A/G	cg17218026	chr1:154582156	ADAR	0.55	9.75	0.47	6.48e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2658782	0.654	rs2605620	chr11:93247646	C/T	cg15737290	chr11:93063684	CCDC67	0.62	8.03	0.4	1.64e-14	Pulmonary function decline;
LUSC	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg26816564	chr1:7831052	VAMP3	1.04	14.2	0.61	4.06e-36	Inflammatory bowel disease;
LUSC	cis	rs3770081	1.000	rs2164879	chr2:86261579	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.8	-5.68	-0.3	2.96e-8	Facial emotion recognition (sad faces);
LUSC	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg05472934	chr7:22766657	IL6	0.5	7.76	0.39	1.03e-13	Lung cancer;
LUSC	trans	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg13565492	chr6:43139072	SRF	-0.63	-6.57	-0.34	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg26373071	chr5:1325741	CLPTM1L	0.43	8.11	0.41	9.51e-15	Lung cancer;
LUSC	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg05340658	chr4:99064831	C4orf37	0.43	6.74	0.35	7.11e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9287719	0.601	rs12996735	chr2:10716716	C/A	cg00105475	chr2:10696890	NA	0.35	5.92	0.31	8.12e-9	Prostate cancer;
LUSC	cis	rs4964805	1.000	rs12228207	chr12:104196734	T/C	cg02344784	chr12:104178138	NT5DC3	0.43	6.71	0.34	8.11e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg22532475	chr10:104410764	TRIM8	-0.28	-5.85	-0.31	1.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9796	0.621	rs12324159	chr15:41462468	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.51	-8.81	-0.43	6.79e-17	Menopause (age at onset);
LUSC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	12.88	0.58	4.13e-31	Platelet count;
LUSC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg06454157	chr6:167490870	NA	-0.24	-6.04	-0.31	4.19e-9	Crohn's disease;
LUSC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.77	-0.35	5.93e-11	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg17366294	chr4:99064904	C4orf37	0.6	10.77	0.51	2.0500000000000001e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28655083	0.529	rs285026	chr16:77100089	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.37	5.87	0.31	1.06e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg10130564	chr11:117069849	TAGLN	0.32	6.19	0.32	1.78e-9	Blood protein levels;
LUSC	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.88	-0.31	9.74e-9	Birth weight;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03112782	chr1:37979729	MEAF6	0.43	6.45	0.33	3.83e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs35000415	0.938	rs71581958	chr7:128665542	C/T	cg19972273	chr7:128594194	NA	0.68	6.9	0.35	2.56e-11	Systemic lupus erythematosus;
LUSC	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.71	-12.52	-0.57	9.7e-30	White blood cell count (basophil);
LUSC	trans	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg21775007	chr8:11205619	TDH	0.45	6.63	0.34	1.34e-10	Mood instability;
LUSC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg09359103	chr1:154839909	KCNN3	-0.7	-16.12	-0.66	1.23e-43	Prostate cancer;
LUSC	cis	rs9815354	1.000	rs17063584	chr3:41861463	A/G	cg03022575	chr3:42003672	ULK4	0.59	6.55	0.34	2.18e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs3820928	0.904	rs4129884	chr2:227820943	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.66	-0.39	2e-13	Pulmonary function;
LUSC	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg16586182	chr3:47516702	SCAP	-0.52	-7.99	-0.4	2.18e-14	Colorectal cancer;
LUSC	cis	rs887829	0.570	rs6724485	chr2:234592816	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.38	-6.16	-0.32	2.13e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg14343924	chr8:8086146	FLJ10661	0.45	6.23	0.32	1.39e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17691542	chr6:26056736	HIST1H1C	1.01	13.97	0.61	3.15e-35	Iron status biomarkers;
LUSC	cis	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg06521331	chr12:34319734	NA	0.37	6.2	0.32	1.7e-9	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg05347473	chr6:146136440	FBXO30	0.56	9.49	0.46	4.63e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg04155289	chr7:94953770	PON1	-0.34	-5.76	-0.3	1.9e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg10130564	chr11:117069849	TAGLN	0.36	6.24	0.32	1.35e-9	Blood protein levels;
LUSC	cis	rs8092503	1.000	rs3764516	chr18:52494374	A/C	cg12377874	chr18:52495404	RAB27B	-0.34	-6.18	-0.32	1.9e-9	Childhood body mass index;
LUSC	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg09165964	chr15:75287851	SCAMP5	0.51	7.42	0.38	9.85e-13	Breast cancer;
LUSC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg02807482	chr3:125708958	NA	-0.53	-7.08	-0.36	8.57e-12	Blood pressure (smoking interaction);
LUSC	cis	rs6460942	0.908	rs3887296	chr7:12257966	A/G	cg06484146	chr7:12443880	VWDE	-0.59	-6.05	-0.31	3.93e-9	Coronary artery disease;
LUSC	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg25930673	chr12:123319894	HIP1R	-0.72	-7.12	-0.36	6.69e-12	Schizophrenia;
LUSC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg00316803	chr15:76480434	C15orf27	-0.4	-6.77	-0.35	5.8e-11	Blood metabolite levels;
LUSC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.61	-0.6	7.34e-34	Chronic sinus infection;
LUSC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06850241	chr22:41845214	NA	0.34	6.22	0.32	1.46e-9	Vitiligo;
LUSC	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.94	-0.35	2.1e-11	Bipolar disorder;
LUSC	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg15704280	chr7:45808275	SEPT13	0.74	8.4	0.42	1.26e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21659725	chr3:3221576	CRBN	-0.53	-8.46	-0.42	8.33e-16	Body mass index;
LUSC	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.56	-0.38	3.86e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg27471124	chr11:109292789	C11orf87	0.41	7.22	0.37	3.52e-12	Schizophrenia;
LUSC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg19592336	chr6:28129416	ZNF389	0.48	6.29	0.33	9.69e-10	Depression;
LUSC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.64	0.6	5.58e-34	Cognitive test performance;
LUSC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.84	-15.3	-0.64	2.06e-40	Cognitive function;
LUSC	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg23750338	chr8:142222470	SLC45A4	0.58	11.27	0.52	3.44e-25	Immature fraction of reticulocytes;
LUSC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.51	8.22	0.41	4.69e-15	Schizophrenia;
LUSC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08564027	chr20:61660810	NA	0.91	17.38	0.69	1.19e-48	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs10511400	0.541	rs2131174	chr3:119921317	C/T	cg02809009	chr19:50354510	PTOV1	-0.73	-6.52	-0.34	2.64e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg25427524	chr10:38739819	LOC399744	0.43	5.66	0.3	3.19e-8	Obesity (extreme);
LUSC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs9807989	0.507	rs4851572	chr2:103019031	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.17e-12	Asthma;
LUSC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg08470875	chr2:26401718	FAM59B	-0.66	-8.86	-0.44	4.75e-17	Gut microbiome composition (summer);
LUSC	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.91	0.58	3.18e-31	Bipolar disorder;
LUSC	cis	rs858239	0.600	rs13438179	chr7:23143851	T/C	cg23682824	chr7:23144976	KLHL7	0.38	5.66	0.3	3.28e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7681440	0.583	rs2736988	chr4:90776345	C/T	cg06632027	chr4:90757378	SNCA	-0.36	-5.76	-0.3	1.93e-8	Dementia with Lewy bodies;
LUSC	trans	rs34421088	0.506	rs2409755	chr8:11169983	G/A	cg08975724	chr8:8085496	FLJ10661	0.43	6.29	0.33	9.99e-10	Neuroticism;
LUSC	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg03433033	chr1:76189801	ACADM	-0.4	-5.86	-0.31	1.08e-8	Daytime sleep phenotypes;
LUSC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg15704280	chr7:45808275	SEPT13	-0.82	-10.34	-0.49	6.21e-22	Coronary artery disease;
LUSC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.48	-8.54	-0.42	4.81e-16	Total body bone mineral density;
LUSC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	-0.36	-5.91	-0.31	8.47e-9	Menopause (age at onset);
LUSC	cis	rs2835872	0.965	rs2835848	chr21:39011073	C/T	cg20424643	chr21:39039972	KCNJ6	0.39	6.05	0.31	3.87e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-0.82	-13.53	-0.59	1.5e-33	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg17366294	chr4:99064904	C4orf37	0.55	8.67	0.43	1.95e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12044355	0.827	rs16854783	chr1:231827371	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.39	-5.75	-0.3	1.99e-8	Alzheimer's disease;
LUSC	cis	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg12850546	chr22:42539477	CYP2D7P1	-0.5	-6.14	-0.32	2.4e-9	Birth weight;
LUSC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.45	-9.13	-0.45	6.92e-18	Type 2 diabetes;
LUSC	trans	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	2.01e-12	Bone mineral density;
LUSC	cis	rs6500395	0.963	rs12919278	chr16:48692537	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg05283184	chr6:79620031	NA	-0.57	-11.99	-0.55	8.45e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs2354432	0.607	rs58941651	chr1:146784919	T/C	cg25205988	chr1:146714368	CHD1L	-1.02	-9.56	-0.46	2.63e-19	Mitochondrial DNA levels;
LUSC	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-1.05	-15.96	-0.66	5.02e-43	Exhaled nitric oxide output;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04226365	chr6:44355287	CDC5L	0.77	6.24	0.32	1.3e-9	Cognitive performance;
LUSC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24110177	chr3:50126178	RBM5	-0.61	-10.26	-0.49	1.15e-21	Body mass index;
LUSC	trans	rs890100	0.612	rs62161882	chr2:56660263	T/A	cg01657744	chr10:88471748	LDB3	0.43	5.95	0.31	6.76e-9	Gut microbiome composition (summer);
LUSC	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg00898013	chr13:113819073	PROZ	-0.65	-9.04	-0.44	1.28e-17	Platelet distribution width;
LUSC	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg06346307	chr22:19949965	COMT	0.35	7.32	0.37	1.88e-12	Blood metabolite levels;
LUSC	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg14092571	chr14:90743983	NA	0.36	5.92	0.31	8.11e-9	Mortality in heart failure;
LUSC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg00316803	chr15:76480434	C15orf27	-0.38	-6.58	-0.34	1.78e-10	Blood metabolite levels;
LUSC	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg26384229	chr12:38710491	ALG10B	0.55	8.13	0.41	8.25e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12928939	0.815	rs61753635	chr16:71660404	G/A	cg08717414	chr16:71523259	ZNF19	-0.42	-5.9	-0.31	8.85e-9	Post bronchodilator FEV1;
LUSC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.73	-11.23	-0.52	4.71e-25	Menarche (age at onset);
LUSC	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg20713898	chr8:124780851	FAM91A1	-0.53	-7.09	-0.36	7.83e-12	Pancreatic cancer;
LUSC	cis	rs7973719	0.868	rs12825629	chr12:7355583	T/C	cg07052231	chr12:7363540	PEX5	0.54	9.42	0.46	7.85e-19	IgG glycosylation;
LUSC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.67	11.37	0.53	1.49e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15320075	chr8:145703422	NA	0.63	10.98	0.51	3.83e-24	Age at first birth;
LUSC	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg08017756	chr2:100939284	LONRF2	-0.43	-7.99	-0.4	2.18e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg24503407	chr1:205819492	PM20D1	0.44	5.89	0.31	9.62e-9	Parkinson's disease;
LUSC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg05855489	chr10:104503620	C10orf26	-0.61	-8.36	-0.42	1.76e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg03060546	chr3:49711283	APEH	0.52	7.28	0.37	2.48e-12	Resting heart rate;
LUSC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	cis	rs17818399	0.633	rs2242033	chr2:46842410	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.36	6.13	0.32	2.42e-9	Height;
LUSC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	1.03	18.84	0.72	1.82e-54	Menopause (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	0.47	6.55	0.34	2.11e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg05182265	chr7:156933206	UBE3C	0.59	9.67	0.47	1.14e-19	Body mass index;
LUSC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg25036284	chr2:26402008	FAM59B	0.77	10.94	0.51	5.08e-24	Gut microbiome composition (summer);
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.42	8.49e-16	Lymphocyte counts;
LUSC	cis	rs4700695	0.511	rs29443	chr5:65504927	G/A	cg21114390	chr5:65439923	SFRS12	-0.51	-7.46	-0.38	7.57e-13	Facial morphology (factor 19);
LUSC	cis	rs62400317	0.859	rs10948226	chr6:45299174	G/C	cg20913747	chr6:44695427	NA	-0.48	-7.77	-0.39	9.74e-14	Total body bone mineral density;
LUSC	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.57e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-7.14	-0.36	5.73e-12	Mood instability;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10019429	chr19:32836659	ZNF507	-0.42	-6.35	-0.33	7.19e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-7.32	-0.37	1.85e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.85	-0.44	5.17e-17	Total cholesterol levels;
LUSC	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg16482183	chr6:26056742	HIST1H1C	0.63	8.97	0.44	2.11e-17	Iron status biomarkers;
LUSC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg16850897	chr7:100343110	ZAN	-0.52	-7.15	-0.36	5.63e-12	Other erythrocyte phenotypes;
LUSC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg18351406	chr4:77819688	ANKRD56	0.59	8.57	0.42	3.94e-16	Emphysema distribution in smoking;
LUSC	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.58	7.95	0.4	2.81e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7939886	0.920	rs11534518	chr11:55808146	C/T	cg03929089	chr4:120376271	NA	0.74	6.28	0.32	1.07e-9	Myopia (pathological);
LUSC	cis	rs2562152	0.786	rs216594	chr16:103009	A/T	cg02949481	chr16:131562	MPG	0.51	6.2	0.32	1.66e-9	Glioblastoma;
LUSC	cis	rs62400317	0.762	rs857601	chr6:44805214	G/T	cg18551225	chr6:44695536	NA	0.43	7.0	0.36	1.44e-11	Total body bone mineral density;
LUSC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-6.63	-0.34	1.39e-10	Type 2 diabetes;
LUSC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg22834771	chr12:69754056	YEATS4	-0.44	-6.24	-0.32	1.33e-9	Blood protein levels;
LUSC	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg11843606	chr2:227700838	RHBDD1	-0.66	-10.66	-0.5	4.85e-23	Pulmonary function;
LUSC	cis	rs1979679	0.541	rs4931085	chr12:28727510	C/T	cg13890972	chr12:28721907	NA	-0.41	-6.0	-0.31	5.13e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg22709100	chr7:91322751	NA	0.4	5.9	0.31	8.7e-9	Breast cancer;
LUSC	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg09323728	chr8:95962352	TP53INP1	-0.3	-5.67	-0.3	3.1e-8	Type 2 diabetes;
LUSC	cis	rs36093844	0.898	rs11234462	chr11:85596924	C/T	cg16165120	chr11:85566439	CCDC83	-0.35	-5.72	-0.3	2.33e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.64	7.21	0.37	3.77e-12	Schizophrenia;
LUSC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg10207240	chr12:122356781	WDR66	0.45	6.63	0.34	1.32e-10	Mean corpuscular volume;
LUSC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg07701084	chr6:150067640	NUP43	0.53	7.78	0.39	8.86e-14	Lung cancer;
LUSC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03934478	chr11:495069	RNH1	0.88	9.99	0.48	9.94e-21	Body mass index;
LUSC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg07701084	chr6:150067640	NUP43	0.5	7.44	0.38	8.36e-13	Lung cancer;
LUSC	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg23933602	chr10:16859644	RSU1	0.62	7.71	0.39	1.49e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg18132916	chr6:79620363	NA	-0.38	-5.81	-0.3	1.44e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	6.69	0.34	9.37e-11	Schizophrenia;
LUSC	trans	rs7849782	0.870	rs10819966	chr9:104418731	C/T	cg22914338	chr19:14376960	NA	0.26	6.36	0.33	6.45e-10	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg09503522	chr19:53445286	ZNF321	-0.36	-5.68	-0.3	2.89e-8	Psoriasis;
LUSC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg16624210	chr5:671434	TPPP	0.5	6.34	0.33	7.37e-10	Obesity-related traits;
LUSC	trans	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.87	0.4	4.83e-14	Systemic lupus erythematosus;
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	10.17	0.49	2.43e-21	Lymphocyte counts;
LUSC	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg16512390	chr1:228756714	NA	0.7	8.79	0.43	8.07e-17	Chronic lymphocytic leukemia;
LUSC	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.33	-0.33	8.06e-10	Response to antipsychotic treatment;
LUSC	cis	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg06521852	chr22:38141419	TRIOBP	-0.39	-6.04	-0.31	4.16e-9	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	9.33	0.45	1.54e-18	Menarche (age at onset);
LUSC	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg24634471	chr8:143751801	JRK	0.51	7.18	0.37	4.68e-12	Schizophrenia;
LUSC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg05785598	chr3:49045655	WDR6	0.32	5.73	0.3	2.21e-8	Parkinson's disease;
LUSC	cis	rs367943	0.634	rs6594701	chr5:112685743	C/T	cg12552261	chr5:112820674	MCC	0.39	6.41	0.33	4.93e-10	Type 2 diabetes;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg11564042	chr3:150479915	SIAH2	0.45	6.07	0.32	3.55e-9	Neuroticism;
LUSC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-1.23	-13.78	-0.6	1.62e-34	Diabetic kidney disease;
LUSC	trans	rs72674100	1.000	rs17026330	chr4:97969873	G/A	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-6.4	-0.33	5.41e-10	Red blood cell count;Reticulocyte count;
LUSC	trans	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg07393940	chr7:158741817	NA	-0.51	-8.15	-0.41	7.32e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg19773385	chr1:10388646	KIF1B	-0.58	-9.67	-0.47	1.13e-19	Hepatocellular carcinoma;
LUSC	cis	rs2738048	0.545	rs2978950	chr8:6825284	C/G	cg24860332	chr8:6827800	DEFA10P	-0.4	-6.42	-0.33	4.67e-10	IgA nephropathy;
LUSC	cis	rs611744	0.839	rs672552	chr8:109164223	A/G	cg18478394	chr8:109455254	TTC35	0.42	6.32	0.33	8.15e-10	Dupuytren's disease;
LUSC	cis	rs886126	0.684	rs10744769	chr12:111650780	G/T	cg10833066	chr12:111807467	FAM109A	0.42	6.5	0.34	2.9e-10	Coronary heart disease;
LUSC	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg14458575	chr2:238380390	NA	0.64	11.23	0.52	4.87e-25	Prostate cancer;
LUSC	trans	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.22	0.41	4.57e-15	Ulcerative colitis;
LUSC	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-9.39	-0.46	9.4e-19	Chronic sinus infection;
LUSC	cis	rs7215564	0.818	rs1872431	chr17:78635200	T/C	cg23238734	chr17:78661607	RPTOR	0.49	6.2	0.32	1.66e-9	Myopia (pathological);
LUSC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg10360139	chr7:1886902	MAD1L1	-0.44	-6.9	-0.35	2.61e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.71e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.76	-0.39	1.07e-13	Blood metabolite levels;
LUSC	cis	rs4343996	0.701	rs4255031	chr7:3378350	G/T	cg21248987	chr7:3385318	SDK1	-0.37	-6.18	-0.32	1.88e-9	Motion sickness;
LUSC	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06544989	chr22:39130855	UNC84B	0.33	5.74	0.3	2.18e-8	Menopause (age at onset);
LUSC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg12963246	chr6:28129442	ZNF389	0.53	7.52	0.38	5.24e-13	Depression;
LUSC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.68	9.99	0.48	9.49e-21	Methadone dose in opioid dependence;
LUSC	cis	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg26958806	chr6:27640298	NA	0.81	6.24	0.32	1.35e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg09479241	chr17:27052676	TLCD1	-0.42	-5.76	-0.3	1.91e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg22535103	chr8:58192502	C8orf71	-0.8	-8.61	-0.43	2.94e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg11901034	chr3:128598214	ACAD9	-0.41	-6.5	-0.34	2.89e-10	IgG glycosylation;
LUSC	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	8.94	0.44	2.66e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg04166393	chr7:2884313	GNA12	0.43	5.89	0.31	9.37e-9	Height;
LUSC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	8.55	0.42	4.4e-16	Schizophrenia;
LUSC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	0.98	15.22	0.64	4.11e-40	Parkinson's disease;
LUSC	cis	rs727505	0.520	rs1454125	chr7:124862733	C/T	cg23710748	chr7:124431027	NA	-0.4	-6.87	-0.35	3.21e-11	Lewy body disease;
LUSC	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg02493740	chr2:85810744	VAMP5	-0.5	-8.64	-0.43	2.37e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg24768116	chr2:27665128	KRTCAP3	0.3	5.82	0.3	1.36e-8	Total body bone mineral density;
LUSC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg21862992	chr11:68658383	NA	0.51	8.18	0.41	6.18e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.41	0.42	1.24e-15	Lung cancer;
LUSC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.48	-7.33	-0.37	1.8e-12	Systemic lupus erythematosus;
LUSC	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.97	-0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	trans	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.4	-0.33	5.18e-10	Endometrial cancer;
LUSC	cis	rs2108225	0.967	rs7785790	chr7:107449896	C/T	cg18560240	chr7:107437656	SLC26A3	0.39	6.0	0.31	5.05e-9	Ulcerative colitis;
LUSC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg04998671	chr14:104000505	TRMT61A	-0.4	-5.8	-0.3	1.51e-8	Reticulocyte count;
LUSC	cis	rs12618769	0.597	rs72821908	chr2:99085359	A/G	cg10123293	chr2:99228465	UNC50	0.45	7.58	0.38	3.5e-13	Bipolar disorder;
LUSC	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg23093090	chr10:104574429	C10orf26	-0.38	-7.05	-0.36	1.05e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg12927641	chr6:109611667	NA	-0.36	-6.12	-0.32	2.69e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs11158026	0.603	rs17832269	chr14:55432091	C/T	cg04306507	chr14:55594613	LGALS3	0.35	6.19	0.32	1.76e-9	Parkinson's disease;
LUSC	trans	rs750134	0.901	rs77866012	chr12:109115755	G/A	cg23338993	chr2:234600423	UGT1A10;UGT1A6;UGT1A9;UGT1A7;UGT1A8	0.48	6.05	0.31	3.96e-9	Low high density lipoprotein cholesterol levels;
LUSC	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg04117972	chr1:227635322	NA	0.58	6.73	0.35	7.61e-11	Major depressive disorder;
LUSC	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.83	0.35	4e-11	IgG glycosylation;
LUSC	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg12863693	chr15:85201151	NMB	0.42	8.65	0.43	2.14e-16	Schizophrenia;
LUSC	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.55	-8.02	-0.4	1.77e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10761482	0.861	rs7084499	chr10:62106882	A/G	cg18175470	chr10:62150864	ANK3	-0.49	-6.95	-0.36	1.87e-11	Schizophrenia;
LUSC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg00990874	chr7:1149470	C7orf50	-0.5	-6.33	-0.33	7.99e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.58	-0.42	3.61e-16	Bipolar disorder;
LUSC	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.57e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08280861	chr8:58055591	NA	0.55	6.51	0.34	2.73e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.07	-0.31	3.56e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg00982548	chr2:198649783	BOLL	-0.6	-7.29	-0.37	2.2e-12	Ulcerative colitis;
LUSC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg13395646	chr4:1353034	KIAA1530	0.58	8.88	0.44	4.26e-17	Obesity-related traits;
LUSC	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.72	-0.35	7.84e-11	Response to antipsychotic treatment;
LUSC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.58	11.76	0.54	5.83e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs62400317	0.518	rs1321080	chr6:45358323	G/T	cg20913747	chr6:44695427	NA	-0.43	-6.33	-0.33	7.72e-10	Total body bone mineral density;
LUSC	cis	rs1775715	0.870	rs11008696	chr10:32218614	G/A	cg18675610	chr10:32216311	ARHGAP12	0.28	6.13	0.32	2.53e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.26	-0.41	3.4e-15	Response to antipsychotic treatment;
LUSC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg05861140	chr6:150128134	PCMT1	-0.4	-6.3	-0.33	9.14e-10	Lung cancer;
LUSC	trans	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	9.99	0.48	1.01e-20	Mean corpuscular volume;
LUSC	trans	rs2834506	0.521	rs2300385	chr21:35900932	G/C	cg00397714	chr2:192815005	TMEFF2	-0.33	-6.01	-0.31	4.9e-9	Cancer;
LUSC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg15468180	chr1:107600409	PRMT6	0.4	6.31	0.33	8.99e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	trans	rs12986445	0.625	rs3856394	chr2:26110143	A/G	cg18530251	chr8:22409574	SORBS3	-0.42	-5.99	-0.31	5.38e-9	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
LUSC	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg01475377	chr6:109611718	NA	0.45	8.04	0.4	1.53e-14	Reticulocyte fraction of red cells;
LUSC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg09034736	chr1:150693464	HORMAD1	-0.42	-5.66	-0.3	3.2e-8	Blood protein levels;
LUSC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg08132940	chr7:1081526	C7orf50	-0.5	-5.9	-0.31	8.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg00129232	chr17:37814104	STARD3	-0.5	-7.49	-0.38	6.21e-13	Asthma;
LUSC	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.68	-13.02	-0.58	1.21e-31	Monocyte count;
LUSC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg16743903	chr16:89593216	SPG7	-0.42	-6.32	-0.33	8.53e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs9581857	0.547	rs9579086	chr13:28058537	T/A	cg22138327	chr13:27999177	GTF3A	0.81	8.41	0.42	1.24e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs73206853	0.841	rs55972509	chr12:110992755	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.13	0.36	6.24e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.43	-0.33	4.53e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	11.42	0.53	1.05e-25	Lung cancer in ever smokers;
LUSC	cis	rs7084921	0.578	rs12765808	chr10:101872687	A/C	cg02250046	chr10:101825185	CPN1	-0.35	-6.24	-0.32	1.34e-9	Bone mineral density;
LUSC	trans	rs7939886	0.920	rs11231885	chr11:55804022	T/A	cg03929089	chr4:120376271	NA	0.74	6.28	0.32	1.07e-9	Myopia (pathological);
LUSC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg05347473	chr6:146136440	FBXO30	-0.53	-9.14	-0.45	6.36e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00290607	chr11:67383545	NA	0.34	6.4	0.33	5.14e-10	Mean corpuscular volume;
LUSC	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.19	-0.32	1.76e-9	Retinal vascular caliber;
LUSC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.4	-0.38	1.12e-12	Bipolar disorder and schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg21144673	chr22:42017783	PPPDE2;XRCC6	0.4	7.16	0.36	5.09e-12	Triglycerides;
LUSC	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg22782873	chr19:19639568	YJEFN3	0.5	6.11	0.32	2.84e-9	Bipolar disorder;
LUSC	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	11.3	0.53	2.64e-25	Lung cancer in ever smokers;
LUSC	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg08975724	chr8:8085496	FLJ10661	0.48	6.33	0.33	7.74e-10	Neuroticism;
LUSC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg22963979	chr7:1858916	MAD1L1	-0.53	-8.04	-0.4	1.6e-14	Schizophrenia;
LUSC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19346786	chr7:2764209	NA	-0.45	-7.69	-0.39	1.63e-13	Height;
LUSC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg08999081	chr20:33150536	PIGU	0.44	8.04	0.4	1.57e-14	Coronary artery disease;
LUSC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg12564285	chr5:131593104	PDLIM4	0.35	6.33	0.33	7.98e-10	Blood metabolite levels;
LUSC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.46	-0.33	3.63e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.25	-0.49	1.28e-21	Eye color traits;
LUSC	cis	rs12291225	0.883	rs1864658	chr11:14256444	C/T	cg05501817	chr11:14380813	RRAS2	0.44	6.39	0.33	5.63e-10	Sense of smell;
LUSC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg23719950	chr11:63933701	MACROD1	-0.61	-7.83	-0.39	6.47e-14	Mean platelet volume;
LUSC	cis	rs9581857	0.725	rs117947621	chr13:28022267	T/C	cg22138327	chr13:27999177	GTF3A	0.81	9.21	0.45	3.79e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs4974559	0.739	rs10029534	chr4:1322908	C/A	cg02980000	chr4:1222292	CTBP1	1.04	9.6	0.46	2e-19	Systolic blood pressure;
LUSC	trans	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg10573190	chr2:85843190	USP39	-0.42	-6.05	-0.31	3.78e-9	Mean corpuscular volume;
LUSC	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg20991723	chr1:152506922	NA	0.5	9.16	0.45	5.28e-18	Hair morphology;
LUSC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06481639	chr22:41940642	POLR3H	-0.48	-5.84	-0.3	1.26e-8	Vitiligo;
LUSC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg06238570	chr21:40685208	BRWD1	0.6	9.9	0.48	1.99e-20	Cognitive function;
LUSC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg00166722	chr3:10149974	C3orf24	0.41	6.03	0.31	4.33e-9	Alzheimer's disease;
LUSC	cis	rs4792901	0.918	rs12603189	chr17:41618677	C/G	cg22562494	chr17:41607896	ETV4	0.28	5.72	0.3	2.37e-8	Dupuytren's disease;
LUSC	cis	rs6733011	0.628	rs4850888	chr2:99456946	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-5.75	-0.3	1.98e-8	Bipolar disorder;
LUSC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg04287289	chr16:89883240	FANCA	0.78	13.7	0.6	3.2e-34	Vitiligo;
LUSC	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg24375607	chr4:120327624	NA	0.75	11.24	0.52	4.44e-25	Corneal astigmatism;
LUSC	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg09307838	chr4:120376055	NA	0.71	9.77	0.47	5.19e-20	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg04756594	chr16:24857601	SLC5A11	0.36	6.33	0.33	7.97e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg04369109	chr6:150039330	LATS1	-0.57	-8.39	-0.42	1.35e-15	Lung cancer;
LUSC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13126279	chr21:47581558	C21orf56	0.56	8.61	0.43	2.92e-16	Testicular germ cell tumor;
LUSC	cis	rs55675132	1.000	rs55675132	chr1:115619634	C/T	cg01522456	chr1:115632236	TSPAN2	-0.46	-5.66	-0.3	3.18e-8	Schizophrenia;
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg23131131	chr22:24373011	LOC391322	-0.49	-6.72	-0.35	7.89e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg06363034	chr20:62225388	GMEB2	-0.46	-7.64	-0.39	2.3e-13	Glioblastoma;
LUSC	cis	rs2835872	0.733	rs1709822	chr21:39035485	A/G	cg20424643	chr21:39039972	KCNJ6	-0.44	-7.46	-0.38	7.63e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs2235649	0.833	rs7190337	chr16:1850469	A/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.44	-5.93	-0.31	7.67e-9	Blood metabolite levels;
LUSC	cis	rs1982963	0.627	rs17124901	chr14:52488009	C/T	cg10843707	chr14:52510701	NID2	0.46	6.51	0.34	2.73e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg20283391	chr11:68216788	NA	-0.58	-8.13	-0.41	8.67e-15	Total body bone mineral density;
LUSC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg02551604	chr5:131831745	NA	-0.43	-6.93	-0.35	2.15e-11	Asthma (sex interaction);
LUSC	trans	rs4714291	0.925	rs847755	chr6:40030378	T/C	cg02267698	chr19:7991119	CTXN1	0.53	7.35	0.37	1.53e-12	Strep throat;
LUSC	cis	rs10203711	1.000	rs2334022	chr2:239565612	T/C	cg14580085	chr2:239553406	NA	0.4	6.9	0.35	2.57e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.3	-0.37	2.18e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.89	0.51	7.63e-24	Hypertriglyceridemia;
LUSC	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	7.31	0.37	1.94e-12	Monocyte percentage of white cells;
LUSC	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg07817648	chr10:79422355	NA	-0.54	-7.49	-0.38	6.11e-13	Bone mineral density;
LUSC	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg04310649	chr10:35416472	CREM	-0.42	-6.25	-0.32	1.27e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg20476274	chr7:133979776	SLC35B4	0.8	13.9	0.61	5.79e-35	Mean platelet volume;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg24498587	chr11:123596947	ZNF202	-0.46	-6.1	-0.32	2.99e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg22903471	chr2:27725779	GCKR	-0.41	-7.05	-0.36	1.05e-11	Total body bone mineral density;
LUSC	cis	rs67072384	0.892	rs11235578	chr11:72452970	G/T	cg04827223	chr11:72435913	ARAP1	-0.78	-6.8	-0.35	4.98e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs9463078	0.616	rs2211393	chr6:44716366	A/C	cg25276700	chr6:44698697	NA	0.31	6.45	0.33	3.88e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg12473912	chr3:136751656	NA	0.4	7.12	0.36	6.46e-12	Neuroticism;
LUSC	cis	rs12200560	0.505	rs1334321	chr6:97079571	C/T	cg06623918	chr6:96969491	KIAA0776	-0.48	-6.94	-0.36	2.02e-11	Coronary heart disease;
LUSC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg09034736	chr1:150693464	HORMAD1	0.46	6.29	0.33	9.77e-10	Melanoma;
LUSC	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21640587	chr11:117668038	DSCAML1	0.64	9.27	0.45	2.29e-18	Myopia;
LUSC	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg15448220	chr1:150897856	SETDB1	0.43	6.22	0.32	1.45e-9	Melanoma;
LUSC	cis	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15369054	chr17:80825471	TBCD	-0.65	-11.08	-0.52	1.59e-24	Breast cancer;
LUSC	cis	rs8040855	0.579	rs28521166	chr15:85728032	C/T	cg04831495	chr15:85060580	GOLGA6L5	0.4	6.69	0.34	9.4e-11	Bulimia nervosa;
LUSC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg11861562	chr11:117069780	TAGLN	0.45	8.1	0.41	1.02e-14	Blood protein levels;
LUSC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg12432903	chr7:1882776	MAD1L1	-0.49	-8.13	-0.41	8.74e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22307029	chr19:49891270	CCDC155	0.59	8.4	0.42	1.26e-15	Multiple sclerosis;
LUSC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.43e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg25703541	chr22:24373054	LOC391322	0.9	14.74	0.63	3.01e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg17764715	chr19:33622953	WDR88	0.6	8.25	0.41	3.8e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg05973401	chr12:123451056	ABCB9	0.52	7.13	0.36	6.38e-12	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs4400599	0.618	rs1194602	chr1:154231943	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.77	-0.3	1.81e-8	Platelet distribution width;
LUSC	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg25173405	chr17:45401733	C17orf57	-0.37	-5.73	-0.3	2.19e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs897984	0.542	rs35713203	chr16:31090407	G/C	cg02466173	chr16:30829666	NA	-0.48	-8.9	-0.44	3.6e-17	Dementia with Lewy bodies;
LUSC	cis	rs3741151	1.000	rs60924672	chr11:73098724	A/C	cg17517138	chr11:73019481	ARHGEF17	1.0	8.32	0.41	2.26e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg11764359	chr7:65958608	NA	0.52	6.85	0.35	3.5e-11	Aortic root size;
LUSC	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs71403859	0.504	rs12926413	chr16:71972325	T/C	cg03805757	chr16:71968109	PKD1L3	-0.59	-6.35	-0.33	7.15e-10	Post bronchodilator FEV1;
LUSC	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg21951975	chr1:209979733	IRF6	0.4	6.67	0.34	1.08e-10	Monobrow;
LUSC	cis	rs9473147	0.571	rs9463335	chr6:47479136	G/A	cg12968598	chr6:47444699	CD2AP	0.53	8.05	0.4	1.43e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs73198271	0.628	rs11777742	chr8:8589858	C/T	cg01851573	chr8:8652454	MFHAS1	0.46	5.77	0.3	1.83e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	7.96e-13	Motion sickness;
LUSC	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.85	10.91	0.51	6.79e-24	Monocyte count;
LUSC	cis	rs7705502	1.000	rs59755656	chr5:173378180	A/G	cg18693985	chr5:173351052	CPEB4	-0.4	-6.22	-0.32	1.5e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg04691961	chr3:161091175	C3orf57	0.35	6.04	0.31	4.03e-9	Morning vs. evening chronotype;
LUSC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg07741184	chr6:167504864	NA	0.44	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg09835421	chr16:68378352	PRMT7	-0.84	-8.39	-0.42	1.38e-15	Schizophrenia;
LUSC	cis	rs780094	0.500	rs12473139	chr2:27765587	T/C	cg27432699	chr2:27873401	GPN1	0.41	5.7	0.3	2.69e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg10523679	chr1:76189770	ACADM	-0.45	-6.52	-0.34	2.53e-10	Daytime sleep phenotypes;
LUSC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg11062466	chr8:58055876	NA	0.67	8.14	0.41	7.83e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	9.5	0.46	4.12e-19	Eotaxin levels;
LUSC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-7.85	-0.39	5.57e-14	Reticulocyte count;
LUSC	cis	rs9653442	0.545	rs4850921	chr2:100762699	G/T	cg07810366	chr2:100720526	AFF3	-0.44	-7.55	-0.38	4.3e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg13319975	chr6:146136371	FBXO30	0.49	7.34	0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-10.85	-0.51	1.09e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs713477	1.000	rs12886860	chr14:55911150	G/C	cg13175173	chr14:55914753	NA	-0.32	-6.74	-0.35	7.01e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs897984	0.542	rs59061704	chr16:31062704	G/C	cg02466173	chr16:30829666	NA	-0.52	-9.94	-0.48	1.42e-20	Dementia with Lewy bodies;
LUSC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.05	21.7	0.76	9.2e-66	Cognitive function;
LUSC	trans	rs6600671	0.934	rs7528274	chr1:121286901	A/T	cg08727972	chr1:148025634	NBPF14	0.44	6.03	0.31	4.46e-9	Hip geometry;
LUSC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg06713675	chr4:122721982	EXOSC9	-0.47	-8.23	-0.41	4.19e-15	Type 2 diabetes;
LUSC	cis	rs654950	0.776	rs2759254	chr1:42035683	G/C	cg06885757	chr1:42089581	HIVEP3	-0.43	-8.49	-0.42	7.03e-16	Airway imaging phenotypes;
LUSC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21293242	chr8:11204541	TDH	0.34	6.18	0.32	1.81e-9	Retinal vascular caliber;
LUSC	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg04310649	chr10:35416472	CREM	-0.44	-6.56	-0.34	2.03e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.64	-0.39	2.32e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs394563	0.517	rs385303	chr6:149779064	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.45	-9.17	-0.45	5.11e-18	Dupuytren's disease;
LUSC	cis	rs12900413	0.687	rs13343254	chr15:90311283	G/A	cg24249390	chr15:90295951	MESP1	-0.37	-5.91	-0.31	8.6e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg12856521	chr11:46389249	DGKZ	0.43	6.44	0.33	4.28e-10	Leprosy;
LUSC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-5.84	-0.3	1.26e-8	Vitiligo;
LUSC	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg05340658	chr4:99064831	C4orf37	0.57	9.54	0.46	3.04e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06634786	chr22:41940651	POLR3H	-0.55	-6.46	-0.33	3.75e-10	Vitiligo;
LUSC	cis	rs6433857	0.536	rs12464424	chr2:181349137	A/G	cg23363182	chr2:181467187	NA	-0.43	-6.89	-0.35	2.73e-11	Body mass index;
LUSC	cis	rs62458065	0.568	rs62466415	chr7:32518254	C/T	cg20159608	chr7:32802032	NA	-0.71	-8.62	-0.43	2.77e-16	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9359856	0.623	rs1179906	chr6:90323624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.82	-10.23	-0.49	1.51e-21	Bipolar disorder;
LUSC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.44	0.53	8.79e-26	Prudent dietary pattern;
LUSC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg04455712	chr21:45112962	RRP1B	0.49	9.19	0.45	4.28e-18	Mean corpuscular volume;
LUSC	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg26688816	chr2:46740690	ATP6V1E2	0.48	7.08	0.36	8.81e-12	Height;
LUSC	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg06640241	chr16:89574553	SPG7	0.73	10.3	0.49	8.45e-22	Multiple myeloma (IgH translocation);
LUSC	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg12483005	chr1:23474871	LUZP1	0.41	6.5	0.34	2.89e-10	Height;
LUSC	trans	rs7556950	0.572	rs61552231	chr2:41931799	T/C	cg13792581	chr20:43590115	TOMM34	0.77	6.26	0.32	1.17e-9	Major depression and alcohol dependence;
LUSC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg11062466	chr8:58055876	NA	0.7	8.92	0.44	3.22e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs983392	0.617	rs617135	chr11:59936757	A/G	cg20284999	chr11:59952153	MS4A6A	-0.32	-5.72	-0.3	2.33e-8	Alzheimer's disease (late onset);
LUSC	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg13010199	chr12:38710504	ALG10B	0.7	11.94	0.55	1.35e-27	Heart rate;
LUSC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg27494647	chr7:150038898	RARRES2	0.57	8.55	0.42	4.64e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.58	-8.69	-0.43	1.64e-16	Response to antineoplastic agents;
LUSC	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg24812749	chr6:127587940	RNF146	0.6	8.9	0.44	3.54e-17	Breast cancer;
LUSC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg21017887	chr14:105400489	NA	0.7	13.2	0.59	2.69e-32	Rheumatoid arthritis;
LUSC	cis	rs2346177	0.844	rs34712412	chr2:46652428	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.36	6.19	0.32	1.75e-9	HDL cholesterol;
LUSC	cis	rs929596	0.563	rs1105880	chr2:234601965	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-6.82	-0.35	4.19e-11	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	11.0	0.52	3.16e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10979	0.965	rs7754452	chr6:143889028	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	1.02	19.7	0.73	7.26e-58	Menopause (age at onset);
LUSC	cis	rs7202877	0.706	rs247423	chr16:75456631	C/A	cg04384234	chr16:75411784	CFDP1	0.69	9.64	0.47	1.43e-19	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.42e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7572644	0.662	rs9309658	chr2:28256831	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-7.07	-0.36	9.22e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg07148914	chr20:33460835	GGT7	-0.53	-8.1	-0.41	1.05e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs62400317	0.859	rs1324536	chr6:45116261	C/T	cg18551225	chr6:44695536	NA	0.35	5.68	0.3	2.86e-8	Total body bone mineral density;
LUSC	cis	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg02972257	chr16:68554789	NA	0.42	5.68	0.3	3.01e-8	Colorectal cancer;
LUSC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg00684032	chr4:1343700	KIAA1530	0.35	6.23	0.32	1.37e-9	Longevity;
LUSC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg18230493	chr5:56204884	C5orf35	-0.61	-9.72	-0.47	7.75e-20	Coronary artery disease;
LUSC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg18825076	chr15:78729989	IREB2	-0.6	-9.84	-0.47	3.17e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9309473	0.519	rs2421670	chr2:73886661	T/G	cg20560298	chr2:73613845	ALMS1	0.48	7.31	0.37	1.97e-12	Metabolite levels;
LUSC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg10578777	chr12:7781093	NA	0.57	6.31	0.33	8.68e-10	HDL cholesterol levels;
LUSC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.8	0.63	1.84e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg20243544	chr17:37824526	PNMT	-0.46	-5.67	-0.3	3.1e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.49	7.34	0.37	1.67e-12	Renal function-related traits (BUN);
LUSC	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg07148914	chr20:33460835	GGT7	-0.44	-6.54	-0.34	2.25e-10	Height;
LUSC	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg03060546	chr3:49711283	APEH	0.65	6.77	0.35	5.86e-11	Menarche (age at onset);
LUSC	cis	rs1712517	1.000	rs1163084	chr10:105039048	T/C	cg05636881	chr10:105038444	INA	0.39	6.63	0.34	1.32e-10	Migraine;
LUSC	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg26384229	chr12:38710491	ALG10B	0.54	8.67	0.43	1.9e-16	Morning vs. evening chronotype;
LUSC	cis	rs8014204	0.566	rs7145575	chr14:75145528	T/A	cg06637938	chr14:75390232	RPS6KL1	0.52	8.01	0.4	1.88e-14	Caffeine consumption;
LUSC	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.2	-0.32	1.63e-9	Dupuytren's disease;
LUSC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg19077165	chr18:44547161	KATNAL2	0.39	5.88	0.31	9.96e-9	Personality dimensions;
LUSC	cis	rs7674212	0.541	rs2720464	chr4:104073201	G/A	cg16532752	chr4:104119610	CENPE	-0.46	-6.45	-0.33	4.02e-10	Type 2 diabetes;
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg10150615	chr22:24372951	LOC391322	-0.42	-6.91	-0.35	2.51e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs11958404	0.932	rs112683473	chr5:157437819	T/C	cg05962755	chr5:157440814	NA	0.53	6.3	0.33	9.34e-10	IgG glycosylation;
LUSC	cis	rs59698941	0.765	rs67045943	chr5:132219956	C/T	cg02081065	chr5:132209139	LEAP2	-0.65	-6.75	-0.35	6.45e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg02079420	chr8:82753780	SNX16	0.41	7.1	0.36	7.48e-12	Diastolic blood pressure;
LUSC	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg19812747	chr11:111475976	SIK2	-0.49	-7.0	-0.36	1.4e-11	Primary sclerosing cholangitis;
LUSC	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg22906224	chr7:99728672	NA	-0.48	-6.68	-0.34	9.94e-11	Coronary artery disease;
LUSC	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg26566898	chr11:117069891	TAGLN	0.37	7.06	0.36	9.8e-12	Blood protein levels;
LUSC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg04455712	chr21:45112962	RRP1B	0.47	8.64	0.43	2.38e-16	Mean corpuscular volume;
LUSC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg13683864	chr3:40499215	RPL14	-1.14	-21.28	-0.76	3.98e-64	Renal cell carcinoma;
LUSC	cis	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.74	-0.35	6.92e-11	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.18	0.45	4.55e-18	Prudent dietary pattern;
LUSC	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg18825076	chr15:78729989	IREB2	0.46	6.16	0.32	2.07e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs422249	0.727	rs174606	chr11:61626973	G/T	cg06860612	chr11:61641270	FADS3	0.28	5.74	0.3	2.15e-8	Trans fatty acid levels;
LUSC	cis	rs1178968	0.901	rs7783232	chr7:72765171	C/G	cg25889504	chr7:72793014	NA	0.6	7.82	0.39	6.99e-14	Triglyceride levels;
LUSC	trans	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg04995722	chr7:26192034	NFE2L3	-0.42	-6.3	-0.33	9.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg12292205	chr6:26970375	C6orf41	0.51	8.57	0.42	3.88e-16	Schizophrenia;
LUSC	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg10840412	chr1:235813424	GNG4	-0.45	-6.33	-0.33	7.83e-10	Bipolar disorder;
LUSC	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	7.05	0.36	1.06e-11	Joint mobility (Beighton score);
LUSC	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg23711669	chr6:146136114	FBXO30	0.86	15.13	0.64	9.49e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg22563815	chr15:78856949	CHRNA5	-0.25	-6.13	-0.32	2.44e-9	Sudden cardiac arrest;
LUSC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg09955084	chr16:413813	NA	0.29	6.21	0.32	1.59e-9	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.51	1.26e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg22482690	chr17:47019901	SNF8	0.39	7.43	0.38	9.3e-13	Type 2 diabetes;
LUSC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	6.03	0.31	4.41e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1775715	0.677	rs2799034	chr10:32175896	A/G	cg26784012	chr10:32216390	ARHGAP12	0.46	7.84	0.39	6.07e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.09	-0.32	3.07e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg04518342	chr5:131593106	PDLIM4	0.47	8.53	0.42	5.3e-16	Blood metabolite levels;
LUSC	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg27411982	chr8:10470053	RP1L1	-0.46	-6.83	-0.35	4.03e-11	Morning vs. evening chronotype;
LUSC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03352830	chr11:487213	PTDSS2	0.69	8.38	0.42	1.45e-15	Body mass index;
LUSC	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-7.93	-0.4	3.37e-14	Parkinson's disease;
LUSC	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg09307838	chr4:120376055	NA	-0.73	-10.72	-0.51	3.18e-23	Corneal astigmatism;
LUSC	cis	rs965469	0.947	rs4611719	chr20:3228423	G/A	cg25506879	chr20:3388711	C20orf194	-0.55	-6.02	-0.31	4.62e-9	IFN-related cytopenia;
LUSC	cis	rs6840360	1.000	rs6535814	chr4:152609694	A/G	cg22705602	chr4:152727874	NA	-0.31	-6.6	-0.34	1.58e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.66	0.5	4.89e-23	Mean corpuscular volume;
LUSC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg01181863	chr3:195395398	SDHAP2	-0.61	-8.32	-0.41	2.21e-15	Pancreatic cancer;
LUSC	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg17252645	chr8:143867129	LY6D	-0.33	-6.16	-0.32	2.09e-9	Urinary tract infection frequency;
LUSC	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg18904891	chr8:8559673	CLDN23	-0.39	-5.75	-0.3	2e-8	Mood instability;
LUSC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.19	-0.41	5.78e-15	Lung cancer;
LUSC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.76e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10492096	0.947	rs10849482	chr12:6635274	G/A	cg13857086	chr12:6580257	VAMP1	0.64	7.69	0.39	1.64e-13	Hip geometry;
LUSC	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg24829409	chr8:58192753	C8orf71	-0.46	-5.72	-0.3	2.39e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg21573476	chr21:45109991	RRP1B	-0.4	-6.26	-0.32	1.19e-9	Mean corpuscular volume;
LUSC	trans	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg07393940	chr7:158741817	NA	0.34	5.98	0.31	5.7e-9	Life satisfaction;
LUSC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg24250549	chr1:154909240	PMVK	0.66	10.99	0.52	3.44e-24	Prostate cancer;
LUSC	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg20243544	chr17:37824526	PNMT	0.59	8.49	0.42	6.77e-16	Asthma;
LUSC	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg23202291	chr11:1979235	NA	0.54	8.89	0.44	3.99e-17	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.71	-12.36	-0.56	3.73e-29	Obesity-related traits;
LUSC	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg05340658	chr4:99064831	C4orf37	0.57	9.54	0.46	3.03e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg24011408	chr12:48396354	COL2A1	0.53	8.76	0.43	9.88e-17	Plateletcrit;
LUSC	cis	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg21775007	chr8:11205619	TDH	-0.7	-10.87	-0.51	9.1e-24	Retinal vascular caliber;
LUSC	cis	rs13223928	0.516	rs1872880	chr7:3148389	G/C	cg19214707	chr7:3157722	NA	-0.46	-8.54	-0.42	4.65e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg15896084	chr13:114927664	NA	-0.38	-6.9	-0.35	2.62e-11	Schizophrenia;
LUSC	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg09092052	chr15:45571596	NA	0.47	6.53	0.34	2.4e-10	Glomerular filtration rate;
LUSC	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg13010199	chr12:38710504	ALG10B	-0.6	-9.33	-0.45	1.56e-18	Morning vs. evening chronotype;
LUSC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg03395511	chr6:291903	DUSP22	-0.46	-6.72	-0.35	7.64e-11	Menopause (age at onset);
LUSC	cis	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01585723	chr16:33734837	NA	0.36	5.85	0.3	1.16e-8	Menopause (age at onset);
LUSC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-6.75	-0.35	6.51e-11	Crohn's disease;
LUSC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg03161606	chr19:29218774	NA	-0.52	-6.44	-0.33	4.06e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg03733263	chr8:22462867	KIAA1967	1.02	18.64	0.71	1.13e-53	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg06092702	chr1:163392909	NA	0.43	7.3	0.37	2.06e-12	Motion sickness;
LUSC	cis	rs1190552	0.846	rs11623570	chr14:102959277	G/T	cg18135206	chr14:102964638	TECPR2	0.46	5.81	0.3	1.49e-8	Blood protein levels;
LUSC	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg20608306	chr11:116969690	SIK3	0.37	6.94	0.35	2.1e-11	Blood protein levels;
LUSC	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg06784218	chr1:46089804	CCDC17	0.52	7.7	0.39	1.53e-13	Platelet count;
LUSC	cis	rs17095355	1.000	rs11194933	chr10:111725862	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.44	-0.38	8.8e-13	Biliary atresia;
LUSC	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-10.14	-0.48	3.18e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.82	-0.35	4.27e-11	Inflammatory bowel disease;
LUSC	cis	rs4665630	0.764	rs2098769	chr2:23891540	C/T	cg08063864	chr2:24346004	PFN4;LOC375190	-0.55	-5.65	-0.3	3.46e-8	Hypertension;
LUSC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-8.73	-0.43	1.21e-16	Monocyte count;
LUSC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg13206674	chr6:150067644	NUP43	0.62	10.08	0.48	4.87e-21	Lung cancer;
LUSC	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.82	11.3	0.53	2.78e-25	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg19610905	chr11:61596333	FADS2	-0.43	-5.88	-0.31	9.75e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg03354898	chr7:1950403	MAD1L1	-0.3	-5.92	-0.31	8.1e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs2285002	0.745	rs229674	chr14:65281472	G/C	cg27302963	chr3:184322008	NA	-0.29	-5.97	-0.31	6.09e-9	Red cell distribution width;
LUSC	cis	rs2652834	0.750	rs11637947	chr15:63397538	C/T	cg05507819	chr15:63340323	TPM1	0.55	7.07	0.36	8.99e-12	HDL cholesterol;
LUSC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg12143784	chr7:64541923	NA	0.44	6.81	0.35	4.49e-11	Calcium levels;
LUSC	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg24375607	chr4:120327624	NA	0.71	10.36	0.49	5.29e-22	Corneal astigmatism;
LUSC	cis	rs36093844	0.752	rs75639684	chr11:85571576	A/G	cg25872744	chr11:85566296	CCDC83	-0.45	-5.78	-0.3	1.69e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg04384234	chr16:75411784	CFDP1	0.46	7.11	0.36	7.18e-12	Dupuytren's disease;
LUSC	cis	rs11608355	1.000	rs7970482	chr12:109862335	G/A	cg19025524	chr12:109796872	NA	-0.38	-5.94	-0.31	7.28e-9	Neuroticism;
LUSC	cis	rs6977660	0.714	rs10257947	chr7:19824099	A/C	cg07541023	chr7:19748670	TWISTNB	0.61	6.4	0.33	5.2400000000000005e-10	Thyroid stimulating hormone;
LUSC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg12564285	chr5:131593104	PDLIM4	0.46	8.86	0.44	4.99e-17	Blood metabolite levels;
LUSC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-1.25	-13.96	-0.61	3.34e-35	Diabetic kidney disease;
LUSC	cis	rs4343996	0.870	rs6974257	chr7:3392195	A/G	cg21248987	chr7:3385318	SDK1	-0.4	-6.77	-0.35	5.71e-11	Motion sickness;
LUSC	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg08917208	chr2:24149416	ATAD2B	0.62	6.81	0.35	4.62e-11	Lymphocyte counts;
LUSC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg17971929	chr21:40555470	PSMG1	-0.49	-7.39	-0.37	1.21e-12	Menarche (age at onset);
LUSC	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg24642439	chr20:33292090	TP53INP2	-0.39	-5.79	-0.3	1.65e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs1922233	0.943	rs1922216	chr4:92366263	A/G	cg24250684	chr1:219729030	NA	-0.32	-6.0	-0.31	5.17e-9	Gut microbiome composition (summer and winter);
LUSC	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.86	-9.31	-0.45	1.81e-18	Lung cancer in ever smokers;
LUSC	cis	rs11018904	0.906	rs61903722	chr11:89967042	C/T	cg26834418	chr11:89957033	CHORDC1	-0.5	-6.35	-0.33	7.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.11e-21	Bladder cancer;
LUSC	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg11584989	chr19:19387371	SF4	-0.59	-6.68	-0.34	1e-10	Bipolar disorder;
LUSC	trans	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.35	-0.33	7.23e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg12963246	chr6:28129442	ZNF389	0.52	7.18	0.37	4.53e-12	Depression;
LUSC	cis	rs524023	1.000	rs10897518	chr11:64360705	A/G	cg19131476	chr11:64387923	NRXN2	0.38	10.31	0.49	8.05e-22	Urate levels in obese individuals;
LUSC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg23324259	chr8:82754387	SNX16	-0.43	-5.65	-0.3	3.48e-8	Diastolic blood pressure;
LUSC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg04267008	chr7:1944627	MAD1L1	-0.51	-7.68	-0.39	1.8e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs12532214	0.617	rs76620680	chr7:3160046	C/A	cg19214707	chr7:3157722	NA	-0.47	-7.46	-0.38	7.75e-13	Itch intensity from mosquito bite;
LUSC	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg23625390	chr15:77176239	SCAPER	-0.6	-9.58	-0.46	2.37e-19	Blood metabolite levels;
LUSC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.63	8.41	0.42	1.21e-15	High light scatter reticulocyte count;
LUSC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.19	0.49	2.13e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg10523860	chr14:103875565	MARK3	-0.37	-5.92	-0.31	8.18e-9	Body mass index;
LUSC	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg20713898	chr8:124780851	FAM91A1	-0.54	-7.52	-0.38	5.18e-13	Pancreatic cancer;
LUSC	trans	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.45	-6.17	-0.32	2.01e-9	Corneal astigmatism;
LUSC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg18230493	chr5:56204884	C5orf35	-0.58	-9.34	-0.46	1.36e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg24562669	chr7:97807699	LMTK2	0.48	8.76	0.43	1.01e-16	Breast cancer;
LUSC	cis	rs4843185	0.669	rs889502	chr16:85716832	A/G	cg00168118	chr16:85669675	KIAA0182	0.38	5.86	0.31	1.14e-8	Platelet distribution width;
LUSC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3087591	0.919	rs2072131	chr17:29559588	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.56	-8.15	-0.41	7.32e-15	Hip circumference;
LUSC	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg16006841	chr5:176797999	RGS14	0.66	10.6	0.5	7.88e-23	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg16928487	chr17:17741425	SREBF1	-0.42	-8.21	-0.41	4.86e-15	Total body bone mineral density;
LUSC	cis	rs7580658	0.864	rs34832797	chr2:128119441	T/C	cg09760422	chr2:128146352	NA	-0.3	-6.36	-0.33	6.57e-10	Protein C levels;
LUSC	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg10792982	chr14:105748885	BRF1	0.46	8.16	0.41	6.69e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg05110241	chr16:68378359	PRMT7	-0.69	-7.31	-0.37	2.01e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18932078	chr1:2524107	MMEL1	0.29	6.24	0.32	1.33e-9	Ulcerative colitis;
LUSC	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg08601574	chr20:25228251	PYGB	0.44	6.78	0.35	5.3e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg03806693	chr22:41940476	POLR3H	-0.87	-12.23	-0.56	1.1e-28	Vitiligo;
LUSC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.7	-0.34	8.88e-11	Tonsillectomy;
LUSC	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg05340658	chr4:99064831	C4orf37	0.59	9.58	0.46	2.28e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg20307385	chr11:47447363	PSMC3	-0.44	-6.61	-0.34	1.51e-10	Subjective well-being;
LUSC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg06008330	chr7:65541103	ASL	0.4	6.17	0.32	1.96e-9	Aortic root size;
LUSC	trans	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg09050820	chr6:167586206	TCP10L2	0.73	9.47	0.46	5.31e-19	Gastritis;
LUSC	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg13531842	chr10:38383804	ZNF37A	0.45	6.95	0.36	1.96e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21171335	chr12:122356390	WDR66	0.65	9.63	0.47	1.52e-19	Mean corpuscular volume;
LUSC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-9.61	-0.47	1.89e-19	Mood instability;
LUSC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg15445000	chr17:37608096	MED1	-0.39	-6.67	-0.34	1.05e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg26924012	chr15:45694286	SPATA5L1	1.14	20.79	0.75	3.36e-62	Homoarginine levels;
LUSC	cis	rs9463078	0.817	rs3799967	chr6:44798701	A/G	cg25276700	chr6:44698697	NA	-0.29	-5.84	-0.3	1.26e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg01448562	chr3:133502909	NA	-0.46	-7.31	-0.37	2.01e-12	Iron status biomarkers;
LUSC	cis	rs7605827	0.754	rs13017772	chr2:15699660	A/T	cg19274914	chr2:15703543	NA	0.47	9.07	0.44	1.04e-17	Educational attainment (years of education);
LUSC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg26850624	chr5:429559	AHRR	-0.42	-8.21	-0.41	4.79e-15	Cystic fibrosis severity;
LUSC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg03538708	chr1:25844672	NA	0.37	6.22	0.32	1.51e-9	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	1.03	18.01	0.7	3.7700000000000003e-51	Parkinson's disease;
LUSC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg03609598	chr5:56110824	MAP3K1	-0.44	-6.44	-0.33	4.27e-10	Initial pursuit acceleration;
LUSC	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg13798780	chr7:105162888	PUS7	0.56	6.09	0.32	3.05e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	8.74	0.43	1.18e-16	Mood instability;
LUSC	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg09165964	chr15:75287851	SCAMP5	0.47	6.88	0.35	2.89e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-0.87	-12.57	-0.57	6.19e-30	Dilated cardiomyopathy;
LUSC	cis	rs17433780	0.928	rs12127787	chr1:89458761	T/C	cg09516651	chr1:89888402	LOC400759	0.49	8.13	0.41	8.65e-15	Carotid intima media thickness;
LUSC	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	1.13	15.07	0.64	1.58e-39	Nonalcoholic fatty liver disease;
LUSC	cis	rs9341808	0.644	rs76102095	chr6:80942026	G/C	cg08355045	chr6:80787529	NA	-0.42	-7.13	-0.36	6.17e-12	Sitting height ratio;
LUSC	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08109568	chr15:31115862	NA	-0.59	-8.28	-0.41	2.99e-15	Huntington's disease progression;
LUSC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg02807482	chr3:125708958	NA	-0.53	-7.03	-0.36	1.18e-11	Blood pressure (smoking interaction);
LUSC	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg18404041	chr3:52824283	ITIH1	0.55	9.1	0.45	8.6e-18	Schizophrenia;
LUSC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg09455208	chr3:40491958	NA	0.5	9.37	0.46	1.16e-18	Renal cell carcinoma;
LUSC	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg23950597	chr19:37808831	NA	-0.63	-7.68	-0.39	1.82e-13	Coronary artery calcification;
LUSC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23158103	chr7:148848205	ZNF398	-0.45	-7.14	-0.36	5.77e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg09876464	chr15:85330779	ZNF592	0.36	6.66	0.34	1.14e-10	P wave terminal force;
LUSC	cis	rs7267979	0.565	rs6076364	chr20:25556801	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.7	-12.69	-0.57	2.26e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg03585969	chr10:35415529	CREM	0.62	9.07	0.44	1.01e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1018836	0.770	rs4324886	chr8:91651943	A/G	cg16814680	chr8:91681699	NA	-0.88	-15.75	-0.65	3.53e-42	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2708377	0.858	rs4763632	chr12:11307278	A/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.56	-0.38	3.9e-13	Bipolar disorder;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12977448	chr10:14920832	SUV39H2	-0.44	-6.22	-0.32	1.47e-9	Hepatitis;
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11905131	chr22:24372483	LOC391322	0.51	8.2	0.41	5.32e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg11062466	chr8:58055876	NA	0.76	9.09	0.45	9.22e-18	Developmental language disorder (linguistic errors);
LUSC	trans	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg04995722	chr7:26192034	NFE2L3	-0.37	-6.06	-0.31	3.67e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg04036182	chr15:45458818	NA	-0.35	-5.98	-0.31	5.6e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg06627628	chr2:24431161	ITSN2	0.54	7.47	0.38	7.13e-13	Asthma;
LUSC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg04414720	chr1:150670196	GOLPH3L	0.56	9.12	0.45	6.99e-18	Tonsillectomy;
LUSC	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.81	-15.16	-0.64	6.89e-40	Endometriosis;
LUSC	cis	rs7180079	0.620	rs4777571	chr15:65055182	C/G	cg08069370	chr15:64387884	SNX1	0.49	5.71	0.3	2.54e-8	Monocyte count;
LUSC	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs559928	1.000	rs7105178	chr11:64145109	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.6	-6.46	-0.33	3.77e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg20203395	chr5:56204925	C5orf35	-0.72	-9.78	-0.47	5.14e-20	Initial pursuit acceleration;
LUSC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-1.03	-20.21	-0.74	7.12e-60	Height;
LUSC	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	0.57	8.74	0.43	1.15e-16	Breast cancer;
LUSC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06634786	chr22:41940651	POLR3H	-0.55	-6.39	-0.33	5.42e-10	Vitiligo;
LUSC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg23283495	chr1:209979779	IRF6	0.64	9.35	0.46	1.26e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg19773385	chr1:10388646	KIF1B	-0.51	-8.88	-0.44	4.33e-17	Hepatocellular carcinoma;
LUSC	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg13175981	chr1:150552382	MCL1	0.43	6.15	0.32	2.26e-9	Tonsillectomy;
LUSC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs9341835	0.740	rs9294198	chr6:64136993	T/C	cg03326410	chr6:64151739	NA	-0.37	-6.16	-0.32	2.09e-9	Schizophrenia;
LUSC	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg22676075	chr6:135203613	NA	0.48	7.48	0.38	6.5e-13	Red blood cell count;
LUSC	cis	rs7605827	0.930	rs4668450	chr2:15675011	C/T	cg19274914	chr2:15703543	NA	0.45	8.7	0.43	1.49e-16	Educational attainment (years of education);
LUSC	cis	rs4423214	0.592	rs10898186	chr11:71188800	G/A	cg05163923	chr11:71159392	DHCR7	-0.7	-7.29	-0.37	2.32e-12	Vitamin D levels;
LUSC	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg12395012	chr8:11607386	GATA4	-0.31	-6.04	-0.31	4.1e-9	Myopia (pathological);
LUSC	trans	rs11782517	0.883	rs12544801	chr8:10107382	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.89	0.35	2.73e-11	Nose size;
LUSC	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg27432699	chr2:27873401	GPN1	-0.58	-8.67	-0.43	1.92e-16	Total body bone mineral density;
LUSC	cis	rs28647808	0.881	rs4549850	chr9:136265239	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.89	0.35	2.73e-11	Blood protein levels;
LUSC	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	6.85	0.35	3.54e-11	Neuroticism;
LUSC	cis	rs3744061	0.557	rs2098093	chr17:74646469	G/C	cg27546012	chr17:74684504	MXRA7	-0.36	-6.23	-0.32	1.43e-9	Retinal arteriolar caliber;
LUSC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-1.14	-15.68	-0.65	6.61e-42	Breast cancer;
LUSC	cis	rs4499344	0.730	rs405858	chr19:33106621	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.77	-12.3	-0.56	6.48e-29	Mean platelet volume;
LUSC	cis	rs11958404	0.615	rs7704746	chr5:157450601	C/G	cg05962755	chr5:157440814	NA	0.39	5.71	0.3	2.53e-8	IgG glycosylation;
LUSC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg02187348	chr16:89574699	SPG7	0.5	7.92	0.4	3.62e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg10434728	chr15:90938212	IQGAP1	0.33	6.45	0.33	3.81e-10	Rheumatoid arthritis;
LUSC	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg18478394	chr8:109455254	TTC35	0.42	6.51	0.34	2.79e-10	Dupuytren's disease;
LUSC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg14440974	chr22:39074834	NA	-0.35	-5.86	-0.31	1.11e-8	Menopause (age at onset);
LUSC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.65	-9.02	-0.44	1.53e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg10253484	chr15:75165896	SCAMP2	-0.49	-7.29	-0.37	2.33e-12	Breast cancer;
LUSC	cis	rs7577696	0.785	rs11694630	chr2:32376201	G/A	cg02381751	chr2:32503542	YIPF4	-0.43	-6.07	-0.32	3.43e-9	Inflammatory biomarkers;
LUSC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.29	-5.86	-0.31	1.1e-8	Cognitive function;
LUSC	cis	rs829880	0.558	rs249817	chr12:98896910	T/A	cg25150519	chr12:98850993	NA	0.44	5.65	0.3	3.52e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg07936489	chr17:37558343	FBXL20	0.71	9.88	0.48	2.23e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs1982963	0.901	rs2516589	chr14:52512610	A/G	cg10843707	chr14:52510701	NID2	-0.38	-6.68	-0.34	1.02e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6120849	0.754	rs6120797	chr20:33606002	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	6.82	0.35	4.29e-11	Protein C levels;
LUSC	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg10523679	chr1:76189770	ACADM	-0.49	-7.26	-0.37	2.66e-12	Daytime sleep phenotypes;
LUSC	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg18129178	chr5:148520854	ABLIM3	0.7	9.73	0.47	7.29e-20	Breast cancer;
LUSC	cis	rs41271473	1.000	rs41270189	chr1:228878888	C/T	cg16512390	chr1:228756714	NA	0.5	6.04	0.31	4.05e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg00071950	chr4:10020882	SLC2A9	0.61	10.31	0.49	8.33e-22	Bone mineral density;
LUSC	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg08601574	chr20:25228251	PYGB	0.44	6.76	0.35	6.18e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23158103	chr7:148848205	ZNF398	0.48	8.11	0.41	9.72e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08859206	chr1:53392774	SCP2	0.51	8.88	0.44	4.07e-17	Monocyte count;
LUSC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	0.93	17.78	0.7	2.99e-50	Heart rate;
LUSC	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.89	-0.35	2.71e-11	Monocyte percentage of white cells;
LUSC	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg05347473	chr6:146136440	FBXO30	0.39	6.15	0.32	2.21e-9	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	16.92	0.68	7.94e-47	Exhaled nitric oxide output;
LUSC	cis	rs2692947	0.726	rs13019188	chr2:96774199	A/G	cg22654517	chr2:96458247	NA	-0.36	-7.19	-0.37	4.28e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.79	0.35	5.19e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.85	-0.35	3.55e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-1.07	-15.83	-0.65	1.64e-42	Initial pursuit acceleration;
LUSC	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg24375607	chr4:120327624	NA	0.79	11.77	0.54	5.27e-27	Corneal astigmatism;
LUSC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg11062466	chr8:58055876	NA	0.5	6.43	0.33	4.37e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00684032	chr4:1343700	KIAA1530	0.38	6.6	0.34	1.63e-10	Obesity-related traits;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg05064044	chr6:292385	DUSP22	-0.72	-11.78	-0.54	4.92e-27	Menopause (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07973470	chr16:47178359	NETO2	0.78	6.39	0.33	5.43e-10	Cognitive performance;
LUSC	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg25930673	chr12:123319894	HIP1R	-0.72	-7.24	-0.37	3.14e-12	Schizophrenia;
LUSC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg24250549	chr1:154909240	PMVK	0.59	9.45	0.46	6.2800000000000005e-19	Prostate cancer;
LUSC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.57	-9.24	-0.45	2.86e-18	Height;
LUSC	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	0.95	18.06	0.7	2.38e-51	Bone mineral density;
LUSC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg19592336	chr6:28129416	ZNF389	-0.47	-6.32	-0.33	8.48e-10	Depression;
LUSC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg23791538	chr6:167370224	RNASET2	-0.37	-5.75	-0.3	2.03e-8	Crohn's disease;
LUSC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg16325326	chr1:53192061	ZYG11B	0.96	18.47	0.71	5.49e-53	Monocyte count;
LUSC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg11871910	chr12:69753446	YEATS4	0.46	6.12	0.32	2.6e-9	Response to diuretic therapy;
LUSC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg01416388	chr22:39784598	NA	0.45	7.62	0.38	2.66e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6942756	1.000	rs56026912	chr7:128913937	A/G	cg02491457	chr7:128862824	NA	-0.5	-7.1	-0.36	7.68e-12	White matter hyperintensity burden;
LUSC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg20476274	chr7:133979776	SLC35B4	0.88	16.9	0.68	1.01e-46	Mean platelet volume;
LUSC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.19	16.05	0.66	2.2e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg21132104	chr15:45694354	SPATA5L1	0.58	8.12	0.41	9.01e-15	Homoarginine levels;
LUSC	trans	rs225245	0.817	rs225290	chr17:33927904	C/G	cg19694781	chr19:47549865	TMEM160	-0.41	-6.53	-0.34	2.46e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg06784218	chr1:46089804	CCDC17	0.54	10.91	0.51	6.6e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3770081	1.000	rs2278086	chr2:86281905	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.94	-6.99	-0.36	1.51e-11	Facial emotion recognition (sad faces);
LUSC	trans	rs62238980	0.614	rs74534759	chr22:32383419	T/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs2692947	0.683	rs62153700	chr2:96581338	C/T	cg22654517	chr2:96458247	NA	0.36	6.43	0.33	4.29e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg06697600	chr4:7070879	GRPEL1	-0.38	-5.8	-0.3	1.52e-8	Monocyte percentage of white cells;
LUSC	cis	rs2692947	0.655	rs2315668	chr2:96429562	T/C	cg22654517	chr2:96458247	NA	0.37	6.89	0.35	2.85e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-20.34	-0.74	2.17e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.3	0.33	9.18e-10	Corneal astigmatism;
LUSC	cis	rs2324229	0.828	rs1180200	chr6:83958340	A/C	cg08257003	chr6:84140564	ME1	0.29	6.84	0.35	3.69e-11	Platelet-derived growth factor BB levels;
LUSC	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg26384229	chr12:38710491	ALG10B	0.7	10.84	0.51	1.21e-23	Morning vs. evening chronotype;
LUSC	cis	rs7091068	0.671	rs604489	chr10:95405408	T/C	cg20715218	chr10:95462985	C10orf4	-0.61	-7.16	-0.36	5.32e-12	Urinary tract infection frequency;
LUSC	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg22482690	chr17:47019901	SNF8	-0.34	-6.12	-0.32	2.56e-9	Type 2 diabetes;
LUSC	cis	rs9925964	0.933	rs56314408	chr16:31117389	T/C	cg03418659	chr16:31128414	MYST1	-0.39	-6.14	-0.32	2.3e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12208915	0.848	rs12203336	chr6:79518315	G/T	cg05283184	chr6:79620031	NA	0.42	5.68	0.3	2.92e-8	Left atrial antero-posterior diameter;
LUSC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg10518543	chr12:38710700	ALG10B	-0.41	-5.65	-0.3	3.36e-8	Morning vs. evening chronotype;
LUSC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg14541582	chr5:601475	NA	-0.38	-6.0	-0.31	5.23e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6977660	0.660	rs7357202	chr7:19817911	T/A	cg07541023	chr7:19748670	TWISTNB	0.6	6.51	0.34	2.7e-10	Thyroid stimulating hormone;
LUSC	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg24558204	chr6:135376177	HBS1L	-0.66	-10.35	-0.49	6.06e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg04287289	chr16:89883240	FANCA	0.6	8.66	0.43	1.98e-16	Vitiligo;
LUSC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.4	-5.71	-0.3	2.53e-8	Platelet count;
LUSC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg05802129	chr4:122689817	NA	-0.46	-7.7	-0.39	1.53e-13	Type 2 diabetes;
LUSC	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg08270630	chr22:50330655	NA	-0.38	-5.74	-0.3	2.09e-8	Schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16123774	chr13:52733565	NEK3	-0.41	-6.01	-0.31	4.86e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18099408	chr3:52552593	STAB1	0.37	6.57	0.34	1.91e-10	Bipolar disorder;
LUSC	trans	rs4596713	0.568	rs6560585	chr9:71747395	A/G	cg25283916	chr1:242222868	NA	-0.31	-6.48	-0.33	3.23e-10	Headache;
LUSC	cis	rs6460942	0.591	rs7804805	chr7:12332066	C/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.98	-0.31	5.79e-9	Coronary artery disease;
LUSC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg16060761	chr17:80687452	NA	0.57	10.88	0.51	8.58e-24	Glycated hemoglobin levels;
LUSC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg08470875	chr2:26401718	FAM59B	-0.69	-9.06	-0.44	1.1e-17	Gut microbiome composition (summer);
LUSC	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	6.48	0.33	3.38e-10	Height;
LUSC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg00310523	chr12:86230176	RASSF9	0.51	9.68	0.47	1.07e-19	Major depressive disorder;
LUSC	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	13.27	0.59	1.39e-32	Post bronchodilator FEV1;
LUSC	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg26528668	chr16:1614120	IFT140	0.45	7.5	0.38	5.74e-13	Coronary artery disease;
LUSC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg04455712	chr21:45112962	RRP1B	0.48	9.18	0.45	4.58e-18	Mean corpuscular volume;
LUSC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.45	-5.75	-0.3	1.99e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.9	15.19	0.64	5.67e-40	Bladder cancer;
LUSC	cis	rs7607369	0.536	rs6436090	chr2:219669002	A/G	cg02176678	chr2:219576539	TTLL4	-0.51	-8.94	-0.44	2.63e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg21775007	chr8:11205619	TDH	0.79	13.48	0.59	2.26e-33	Retinal vascular caliber;
LUSC	cis	rs11229555	0.598	rs11229426	chr11:58180063	T/C	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10203711	0.789	rs6431616	chr2:239540279	A/G	cg14580085	chr2:239553406	NA	0.35	5.78	0.3	1.69e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.41	6.08	0.32	3.29e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg27057602	chr19:49403306	TULP2;NUCB1	0.38	6.04	0.31	4.19e-9	Schizophrenia;
LUSC	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-8.03	-0.4	1.65e-14	Axial length;
LUSC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg18252515	chr7:66147081	NA	-1.24	-8.45	-0.42	9.39e-16	Diabetic kidney disease;
LUSC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	13.71	0.6	2.89e-34	Cognitive test performance;
LUSC	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	9.13	0.45	6.54e-18	Lymphocyte counts;Red cell distribution width;
LUSC	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg14433983	chr11:636460	DRD4	-0.37	-6.01	-0.31	4.77e-9	Systemic lupus erythematosus;
LUSC	trans	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg04995722	chr7:26192034	NFE2L3	-0.41	-6.4	-0.33	5.19e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	11.79	0.54	4.59e-27	Ileal carcinoids;
LUSC	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg27572855	chr1:25598939	RHD	0.41	7.15	0.36	5.55e-12	Erythrocyte sedimentation rate;
LUSC	trans	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.39	-0.33	5.5e-10	Endometrial cancer;
LUSC	trans	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg18187862	chr3:45730750	SACM1L	-0.55	-6.78	-0.35	5.52e-11	Primary sclerosing cholangitis;
LUSC	cis	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.69	-0.34	9.21e-11	Morning vs. evening chronotype;
LUSC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg06636001	chr8:8085503	FLJ10661	0.47	6.87	0.35	3.08e-11	Neuroticism;
LUSC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg23711669	chr6:146136114	FBXO30	0.83	15.42	0.64	6.99e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg13685833	chr1:53393034	SCP2	-0.4	-5.98	-0.31	5.82e-9	Monocyte count;
LUSC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg11645453	chr3:52864694	ITIH4	0.36	8.3	0.41	2.64e-15	Bipolar disorder;
LUSC	cis	rs422421	0.729	rs387598	chr5:176517170	C/T	cg00618323	chr5:176515533	FGFR4	0.32	5.65	0.3	3.44e-8	Height;
LUSC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg10729496	chr3:10149963	C3orf24	0.56	7.62	0.38	2.62e-13	Alzheimer's disease;
LUSC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg18402987	chr7:1209562	NA	0.63	7.58	0.38	3.48e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.53	0.34	2.52e-10	Neuroticism;
LUSC	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	1.19	39.53	0.91	5.26e-128	Myeloid white cell count;
LUSC	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg03948781	chr1:205179583	DSTYK	0.31	5.86	0.31	1.08e-8	Red blood cell count;
LUSC	cis	rs6484504	0.576	rs208103	chr11:31167400	A/G	cg26647111	chr11:31128758	NA	-0.41	-6.01	-0.31	4.93e-9	Red blood cell count;
LUSC	cis	rs2479106	0.553	rs3739827	chr9:126690157	A/G	cg16191174	chr9:126692580	DENND1A	-0.49	-6.17	-0.32	1.93e-9	Polycystic ovary syndrome;
LUSC	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.39	-0.42	1.35e-15	Coffee consumption (cups per day);
LUSC	cis	rs757278	0.591	rs34331324	chr7:117300188	A/C	cg10524701	chr7:117356490	CTTNBP2	0.4	5.74	0.3	2.08e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07677032	chr17:61819896	STRADA	0.55	9.09	0.45	9.21e-18	Prudent dietary pattern;
LUSC	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg25214090	chr10:38739885	LOC399744	0.58	8.45	0.42	9.1e-16	Corneal astigmatism;
LUSC	cis	rs6543140	0.964	rs2310301	chr2:103072935	C/T	cg09003973	chr2:102972529	NA	0.54	7.02	0.36	1.25e-11	Blood protein levels;
LUSC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg01416388	chr22:39784598	NA	-0.41	-6.76	-0.35	6.18e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7804356	1.000	rs10267950	chr7:26826757	T/A	cg03456212	chr7:26904342	SKAP2	-0.56	-6.63	-0.34	1.36e-10	Type 1 diabetes;
LUSC	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.02	0.31	4.62e-9	Recombination rate (females);
LUSC	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg11266682	chr4:10021025	SLC2A9	0.49	9.05	0.44	1.17e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.64	-0.34	1.29e-10	Obesity-related traits;
LUSC	trans	rs656319	0.669	rs56279061	chr8:9873980	T/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.93	-0.35	2.22e-11	Myopia (pathological);
LUSC	cis	rs981844	0.775	rs17299211	chr4:154738284	G/A	cg14289246	chr4:154710475	SFRP2	0.46	6.22	0.32	1.5e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.4	5.86	0.31	1.13e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.73	10.36	0.49	5.62e-22	Corneal astigmatism;
LUSC	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg23260525	chr10:116636907	FAM160B1	0.47	10.26	0.49	1.19e-21	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-6.01	-0.31	4.99e-9	Morning vs. evening chronotype;
LUSC	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.63	-10.19	-0.49	2.12e-21	Height;
LUSC	trans	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg26043149	chr18:55253948	FECH	-0.45	-7.02	-0.36	1.27e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.57	9.17	0.45	4.99e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg03585969	chr10:35415529	CREM	0.58	8.43	0.42	1.02e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06544989	chr22:39130855	UNC84B	0.33	5.67	0.3	3.02e-8	Menopause (age at onset);
LUSC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg17178900	chr1:205818956	PM20D1	0.51	8.07	0.4	1.29e-14	Menarche (age at onset);
LUSC	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.39	-0.42	1.41e-15	Schizophrenia;
LUSC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg00290607	chr11:67383545	NA	0.36	6.71	0.34	8.33e-11	Mean corpuscular volume;
LUSC	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg01657329	chr11:68192670	LRP5	0.48	6.32	0.33	8.42e-10	Bone mineral density (spine);
LUSC	cis	rs12541635	0.833	rs4099936	chr8:107099297	G/A	cg10147462	chr8:107024639	NA	-0.45	-7.78	-0.39	8.87e-14	Age of smoking initiation;
LUSC	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg04398451	chr17:18023971	MYO15A	0.43	6.72	0.35	7.88e-11	Total body bone mineral density;
LUSC	cis	rs2677744	1.000	rs1266483	chr15:91462406	A/G	cg00526711	chr15:91477898	UNC45A	0.3	6.1	0.32	2.95e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg11812906	chr14:75593930	NEK9	0.67	11.71	0.54	8.78e-27	Height;
LUSC	cis	rs2354432	0.556	rs885305	chr1:146786080	G/A	cg25205988	chr1:146714368	CHD1L	-1.02	-9.56	-0.46	2.63e-19	Mitochondrial DNA levels;
LUSC	cis	rs9398803	0.865	rs9372839	chr6:126809870	G/A	cg19875578	chr6:126661172	C6orf173	0.42	6.18	0.32	1.88e-9	Male-pattern baldness;
LUSC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg17097710	chr5:1061055	SLC12A7	-0.4	-6.2	-0.32	1.65e-9	QT interval;
LUSC	cis	rs16917546	1.000	rs12768538	chr10:64406358	C/G	cg03961010	chr10:64397487	ZNF365	0.41	6.53	0.34	2.44e-10	Basal cell carcinoma;
LUSC	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg22782873	chr19:19639568	YJEFN3	0.46	5.65	0.3	3.45e-8	Bipolar disorder;
LUSC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	12.03	0.55	6.09e-28	Personality dimensions;
LUSC	trans	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg18187862	chr3:45730750	SACM1L	0.52	6.84	0.35	3.74e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg09033563	chr22:24373618	LOC391322	-0.49	-6.81	-0.35	4.54e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg17764715	chr19:33622953	WDR88	0.58	7.86	0.4	5.25e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.74	-0.3	2.15e-8	Tonsillectomy;
LUSC	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg01884057	chr2:25150051	NA	0.48	11.43	0.53	9.67e-26	Body mass index;
LUSC	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg03732007	chr1:2071316	PRKCZ	-0.5	-8.73	-0.43	1.23e-16	Height;
LUSC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	0.93	16.17	0.66	7.55e-44	Menopause (age at onset);
LUSC	cis	rs4664308	0.618	rs17830755	chr2:160888835	T/C	cg03641300	chr2:160917029	PLA2R1	-0.49	-7.97	-0.4	2.59e-14	Idiopathic membranous nephropathy;
LUSC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg22823121	chr1:150693482	HORMAD1	0.59	9.05	0.44	1.17e-17	Tonsillectomy;
LUSC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-0.79	-9.6	-0.46	2.04e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-12.46	-0.56	1.52e-29	Colorectal cancer;
LUSC	cis	rs10465746	0.725	rs2024591	chr1:84329235	C/T	cg10977910	chr1:84465055	TTLL7	0.52	7.26	0.37	2.77e-12	Obesity-related traits;
LUSC	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg18721089	chr20:30220636	NA	-0.41	-6.57	-0.34	1.93e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs713477	1.000	rs10134905	chr14:55911792	G/A	cg13175173	chr14:55914753	NA	-0.32	-6.68	-0.34	9.96e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg16339924	chr4:17578868	LAP3	0.6	9.22	0.45	3.39e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6942756	1.000	rs73472312	chr7:128925217	T/C	cg02491457	chr7:128862824	NA	-0.5	-6.91	-0.35	2.52e-11	White matter hyperintensity burden;
LUSC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg12560992	chr17:57184187	TRIM37	-0.85	-15.51	-0.65	2.95e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg21724239	chr8:58056113	NA	0.53	6.49	0.33	3.17e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg10792982	chr14:105748885	BRF1	0.5	8.85	0.44	5.37e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11229555	0.574	rs66573492	chr11:58183797	G/A	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg00540400	chr15:79124168	NA	0.46	8.1	0.41	1.06e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg12432903	chr7:1882776	MAD1L1	-0.49	-5.97	-0.31	5.98e-9	Bipolar disorder;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24771266	chr19:44576270	ZNF284	-0.4	-5.95	-0.31	6.73e-9	Electrocardiographic conduction measures;
LUSC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.05	0.31	3.81e-9	Schizophrenia;
LUSC	trans	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg19894588	chr14:64061835	NA	0.44	6.45	0.33	3.95e-10	Glioblastoma;Glioma;
LUSC	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg05425664	chr17:57184151	TRIM37	0.39	5.82	0.3	1.4e-8	Primary tooth development (time to first tooth eruption);
LUSC	trans	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-8.94	-0.44	2.71e-17	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs13287066	0.651	rs10992716	chr9:96134897	C/T	cg13717394	chr9:96054313	WNK2	-0.39	-6.68	-0.34	1.03e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7119038	0.818	rs11217042	chr11:118682528	G/A	cg19308663	chr11:118741387	NA	0.34	6.06	0.31	3.73e-9	Sjögren's syndrome;
LUSC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg15556689	chr8:8085844	FLJ10661	0.68	10.87	0.51	9.21e-24	Mood instability;
LUSC	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg13010199	chr12:38710504	ALG10B	0.46	7.15	0.36	5.45e-12	Morning vs. evening chronotype;
LUSC	cis	rs73206853	0.841	rs17625767	chr12:111102627	A/C	cg12870014	chr12:110450643	ANKRD13A	0.7	6.48	0.33	3.23e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg26924012	chr15:45694286	SPATA5L1	-1.11	-18.27	-0.71	3.32e-52	Homoarginine levels;
LUSC	cis	rs2235649	0.833	rs4335769	chr16:1849376	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.02	-0.31	4.6e-9	Blood metabolite levels;
LUSC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.34	-6.53	-0.34	2.45e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg25214090	chr10:38739885	LOC399744	0.54	8.02	0.4	1.78e-14	Corneal astigmatism;
LUSC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.91	0.51	6.82e-24	Hip circumference adjusted for BMI;
LUSC	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg21427119	chr20:30132790	HM13	-0.44	-6.32	-0.33	8.34e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs4899554	0.640	rs72719935	chr14:75724345	C/T	cg18117039	chr14:75741733	NA	0.55	7.29	0.37	2.32e-12	Inflammatory bowel disease;
LUSC	cis	rs2279817	0.863	rs11203441	chr1:18026725	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.47	6.79	0.35	5.08e-11	Neuroticism;
LUSC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg27121462	chr16:89883253	FANCA	0.54	8.45	0.42	9e-16	Vitiligo;
LUSC	cis	rs6901250	0.587	rs339357	chr6:117198291	G/C	cg12892004	chr6:117198278	RFX6	-0.44	-8.12	-0.41	9e-15	C-reactive protein levels;
LUSC	cis	rs13242816	1.000	rs6979182	chr7:116119345	T/G	cg16553024	chr7:116138462	CAV2	-0.52	-5.68	-0.3	2.89e-8	P wave duration;
LUSC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.53	-0.38	4.67e-13	Aortic root size;
LUSC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg04727924	chr7:799746	HEATR2	-0.56	-6.65	-0.34	1.2e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg24531977	chr5:56204891	C5orf35	-0.59	-8.69	-0.43	1.59e-16	Coronary artery disease;
LUSC	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21643547	chr1:205240462	TMCC2	-0.53	-10.11	-0.48	3.82e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs3931020	0.720	rs927904	chr1:75260328	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.46	5.7	0.3	2.58e-8	Resistin levels;
LUSC	cis	rs7582720	1.000	rs72926793	chr2:203826396	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg02772935	chr3:125709198	NA	-0.48	-5.82	-0.3	1.36e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg06784218	chr1:46089804	CCDC17	0.53	11.03	0.52	2.54e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2857891	0.650	rs2857928	chr11:6989721	C/G	cg04053776	chr11:6947353	ZNF215	-0.42	-6.14	-0.32	2.39e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg22676075	chr6:135203613	NA	0.58	9.1	0.45	8.57e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.21	-0.45	3.6e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.72	-0.3	2.39e-8	Huntington's disease progression;
LUSC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	6.43	0.33	4.39e-10	Obesity-related traits;
LUSC	cis	rs6594499	0.872	rs10038177	chr5:110436450	C/T	cg04022379	chr5:110408740	TSLP	0.45	6.82	0.35	4.3e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11785693	0.862	rs6990234	chr8:4996812	A/G	cg26367366	chr8:4980734	NA	0.71	8.4	0.42	1.33e-15	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs76793172	1.000	rs56006974	chr19:46330636	C/A	cg27118825	chr19:46318748	RSPH6A;SYMPK	0.46	5.69	0.3	2.75e-8	Eosinophil counts;
LUSC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg16928487	chr17:17741425	SREBF1	0.47	9.28	0.45	2.25e-18	Total body bone mineral density;
LUSC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg24154853	chr7:158122151	PTPRN2	0.45	8.74	0.43	1.19e-16	Calcium levels;
LUSC	cis	rs72781680	0.821	rs72790329	chr2:24129277	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	6.79	0.35	5.04e-11	Lymphocyte counts;
LUSC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg24829409	chr8:58192753	C8orf71	-0.57	-6.06	-0.31	3.7e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7712401	0.720	rs10075963	chr5:122185421	T/A	cg19077854	chr5:122220652	SNX24	0.32	7.29	0.37	2.32e-12	Mean platelet volume;
LUSC	cis	rs9420	0.528	rs7102271	chr11:57396825	G/T	cg23127183	chr11:57508653	C11orf31	-0.45	-6.32	-0.33	8.19e-10	Schizophrenia;
LUSC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg05585544	chr11:47624801	NA	-0.42	-7.34	-0.37	1.62e-12	Subjective well-being;
LUSC	cis	rs793571	0.536	rs7183336	chr15:58966236	C/T	cg05156742	chr15:59063176	FAM63B	0.56	7.62	0.38	2.62e-13	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg06618935	chr21:46677482	NA	-0.42	-8.59	-0.43	3.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7289126	1.000	rs8142686	chr22:38634266	C/T	cg25457927	chr22:38595422	NA	-0.31	-6.05	-0.31	3.95e-9	Mammographic density (dense area);Percent mammographic density;
LUSC	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg20607287	chr7:12443886	VWDE	-0.61	-6.34	-0.33	7.27e-10	Coronary artery disease;
LUSC	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.64	-0.34	1.24e-10	Response to antipsychotic treatment;
LUSC	cis	rs1775715	0.811	rs1775741	chr10:32267284	C/T	cg03015672	chr10:32216066	ARHGAP12	-0.33	-5.81	-0.3	1.44e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg15352829	chr14:105391018	PLD4	-0.39	-8.1	-0.41	1.03e-14	Rheumatoid arthritis;
LUSC	cis	rs4319547	0.955	rs6489159	chr12:123112806	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.37	-0.42	1.64e-15	Body mass index;
LUSC	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg04362960	chr10:104952993	NT5C2	0.54	8.07	0.4	1.26e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9462027	0.628	rs9296131	chr6:34776361	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.68	-0.3	3e-8	Systemic lupus erythematosus;
LUSC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.06	0.36	9.75e-12	Bipolar disorder;
LUSC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-14.06	-0.61	1.38e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9837602	1.000	rs9864437	chr3:99764754	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.18	0.32	1.82e-9	Breast cancer;
LUSC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-6.83	-0.35	4.1e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg17376030	chr22:41985996	PMM1	-0.47	-5.84	-0.3	1.25e-8	Vitiligo;
LUSC	trans	rs890100	0.902	rs13421558	chr2:56736073	A/T	cg08299783	chr2:48920986	GTF2A1L;LHCGR	-0.31	-5.99	-0.31	5.5e-9	Gut microbiome composition (summer);
LUSC	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg14458575	chr2:238380390	NA	0.64	11.2	0.52	6.32e-25	Prostate cancer;
LUSC	cis	rs6500395	0.928	rs7199206	chr16:48702538	A/G	cg04672837	chr16:48644449	N4BP1	-0.48	-7.15	-0.36	5.48e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg16342193	chr10:102329863	NA	-0.33	-5.97	-0.31	6.01e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-10.01	-0.48	8.2e-21	Gut microbiome composition (summer);
LUSC	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-5.85	-0.3	1.2e-8	Recombination rate (females);
LUSC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg19622623	chr12:86230825	RASSF9	-0.44	-6.28	-0.32	1.08e-9	Major depressive disorder;
LUSC	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.28	0.59	1.28e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg13319975	chr6:146136371	FBXO30	-0.51	-7.69	-0.39	1.66e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg18129178	chr5:148520854	ABLIM3	-0.68	-10.92	-0.51	6.2e-24	Breast cancer;
LUSC	cis	rs9487051	0.704	rs1741930	chr6:109519797	T/A	cg01475377	chr6:109611718	NA	-0.36	-6.11	-0.32	2.7e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg23711669	chr6:146136114	FBXO30	-0.91	-17.88	-0.7	1.27e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg01528321	chr10:82214614	TSPAN14	0.85	12.99	0.58	1.65e-31	Post bronchodilator FEV1;
LUSC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg23711669	chr6:146136114	FBXO30	0.88	16.19	0.66	6.45e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg20135002	chr11:47629003	NA	0.42	5.95	0.31	6.7e-9	Subjective well-being;
LUSC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	9.97	0.48	1.11e-20	Coronary artery disease;
LUSC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg18876405	chr7:65276391	NA	0.46	7.15	0.36	5.67e-12	Aortic root size;
LUSC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-11.61	-0.54	2.12e-26	Extrinsic epigenetic age acceleration;
LUSC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg04455712	chr21:45112962	RRP1B	0.46	8.84	0.44	5.51e-17	Mean corpuscular volume;
LUSC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg06784218	chr1:46089804	CCDC17	0.48	9.63	0.47	1.62e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3784262	0.528	rs4553566	chr15:58336319	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.31	-5.65	-0.3	3.44e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs7851660	0.874	rs7860144	chr9:100626884	A/G	cg13688889	chr9:100608707	NA	-0.57	-8.98	-0.44	1.98e-17	Strep throat;
LUSC	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.46	-0.33	3.69e-10	Arsenic metabolism;
LUSC	cis	rs62400317	0.701	rs12194924	chr6:44961513	T/C	cg20913747	chr6:44695427	NA	-0.45	-7.06	-0.36	9.49e-12	Total body bone mineral density;
LUSC	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.87	0.51	9.05e-24	Morning vs. evening chronotype;
LUSC	cis	rs73200209	0.744	rs17498893	chr12:116674831	G/C	cg01776926	chr12:116560359	MED13L	-0.49	-5.98	-0.31	5.8e-9	Total body bone mineral density;
LUSC	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg13390004	chr1:15929781	NA	-0.38	-6.34	-0.33	7.51e-10	Systolic blood pressure;
LUSC	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg22431228	chr1:16359049	CLCNKA	0.43	8.47	0.42	8.12e-16	Systolic blood pressure;
LUSC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg21724239	chr8:58056113	NA	0.6	7.07	0.36	9.38e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs12310956	0.510	rs10743832	chr12:33884146	A/C	cg06521331	chr12:34319734	NA	-0.36	-5.86	-0.31	1.14e-8	Morning vs. evening chronotype;
LUSC	cis	rs7945705	0.875	rs11042059	chr11:8795080	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.54	10.48	0.5	2.11e-22	Hemoglobin concentration;
LUSC	trans	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg26384229	chr12:38710491	ALG10B	0.54	8.63	0.43	2.46e-16	Morning vs. evening chronotype;
LUSC	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg13010199	chr12:38710504	ALG10B	-0.69	-10.65	-0.5	5.57e-23	Bladder cancer;
LUSC	trans	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg24313572	chr1:56050060	NA	-0.31	-6.43	-0.33	4.53e-10	Morning vs. evening chronotype;
LUSC	cis	rs6500395	1.000	rs55671623	chr16:48631154	A/G	cg04672837	chr16:48644449	N4BP1	0.5	7.48	0.38	6.47e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1322512	1.000	rs1631457	chr6:152946514	C/T	cg27316956	chr6:152958899	SYNE1	-0.33	-5.65	-0.3	3.45e-8	Tonometry;
LUSC	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg11584989	chr19:19387371	SF4	0.57	6.78	0.35	5.44e-11	Bipolar disorder;
LUSC	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg26384229	chr12:38710491	ALG10B	0.49	6.99	0.36	1.51e-11	Morning vs. evening chronotype;
LUSC	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg20628663	chr10:43360327	NA	0.64	9.49	0.46	4.44e-19	Blood protein levels;
LUSC	cis	rs73416724	1.000	rs41281798	chr6:43325787	C/A	cg26312998	chr6:43337775	ZNF318	0.57	6.66	0.34	1.16e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6580649	0.941	rs72644847	chr12:48516093	C/A	cg24011408	chr12:48396354	COL2A1	-0.54	-7.01	-0.36	1.36e-11	Lung cancer;
LUSC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.86	16.22	0.66	4.67e-44	Mean platelet volume;
LUSC	cis	rs11997175	0.646	rs12678266	chr8:33689254	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	7.11	0.36	7.29e-12	Body mass index;
LUSC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg22920501	chr2:26401640	FAM59B	0.82	11.99	0.55	8.49e-28	Gut microbiome composition (summer);
LUSC	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg18681998	chr4:17616180	MED28	0.77	13.73	0.6	2.54e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg10665199	chr7:133106180	EXOC4	0.58	8.16	0.41	6.67e-15	Intelligence;Intelligence (multi-trait analysis);
LUSC	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-9.13	-0.45	6.48e-18	Neuroticism;
LUSC	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.65	-10.42	-0.5	3.44e-22	Pulmonary function;
LUSC	cis	rs3018712	0.532	rs2510399	chr11:68421458	A/G	cg22747802	chr11:68417633	NA	-0.45	-6.18	-0.32	1.91e-9	Total body bone mineral density;
LUSC	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg24375607	chr4:120327624	NA	0.71	11.34	0.53	1.94e-25	Educational attainment;
LUSC	cis	rs7705502	1.000	rs10516107	chr5:173348156	G/A	cg18693985	chr5:173351052	CPEB4	-0.36	-5.72	-0.3	2.39e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs78707713	0.560	rs61848398	chr10:71226103	G/A	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.28	-0.45	2.13e-18	Venous thromboembolism;
LUSC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg06784218	chr1:46089804	CCDC17	-0.46	-8.86	-0.44	4.7e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.01	0.44	1.59e-17	Motion sickness;
LUSC	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg17691542	chr6:26056736	HIST1H1C	0.76	9.72	0.47	8.07e-20	Iron status biomarkers;
LUSC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.87	-0.81	5.11e-78	Height;
LUSC	trans	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg26043149	chr18:55253948	FECH	0.49	7.14	0.36	5.76e-12	Bone mineral density;
LUSC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg24397884	chr7:158709396	WDR60	0.62	9.58	0.46	2.38e-19	Height;
LUSC	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.46	-0.5	2.51e-22	Eye color traits;
LUSC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg11344533	chr11:111475393	SIK2	0.48	6.34	0.33	7.31e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7336332	0.662	rs9581862	chr13:28039993	T/G	cg22138327	chr13:27999177	GTF3A	0.7	9.5	0.46	4.1e-19	Weight;
LUSC	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg16342193	chr10:102329863	NA	-0.4	-6.51	-0.34	2.75e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg01745370	chr2:109065127	GCC2	0.52	9.17	0.45	4.98e-18	Mean platelet volume;
LUSC	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg17757837	chr7:157058334	UBE3C	-0.92	-15.44	-0.65	5.63e-41	Body mass index;
LUSC	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-8.88	-0.44	4.14e-17	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs859767	0.501	rs71348712	chr2:135391590	T/A	cg12500956	chr2:135428796	TMEM163	-0.28	-6.61	-0.34	1.55e-10	Neuroticism;
LUSC	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	7.89	0.4	4.26e-14	Breast cancer;
LUSC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7827545	1.000	rs7463007	chr8:135567143	C/T	cg17885191	chr8:135476712	NA	0.57	8.58	0.43	3.61e-16	Hypertension (SNP x SNP interaction);
LUSC	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.03	0.36	1.19e-11	Schizophrenia;
LUSC	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg24631222	chr15:78858424	CHRNA5	-0.66	-8.68	-0.43	1.79e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs12317459	0.591	rs10778913	chr12:83202336	C/G	cg10237817	chr1:154519846	TDRD10	0.31	6.23	0.32	1.43e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.03	-0.36	1.17e-11	Colorectal cancer;
LUSC	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg17168535	chr8:21777572	XPO7	-0.8	-14.19	-0.61	4.19e-36	Mean corpuscular volume;
LUSC	cis	rs2540226	0.844	rs1035138	chr2:39999341	G/A	cg23576258	chr2:39999331	THUMPD2	0.34	5.73	0.3	2.24e-8	Personality dimensions;
LUSC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg05347473	chr6:146136440	FBXO30	0.59	10.32	0.49	7.64e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg13531842	chr10:38383804	ZNF37A	-0.48	-7.42	-0.38	9.51e-13	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.75	12.42	0.56	2.24e-29	Body mass index;
LUSC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.98	15.5	0.65	3.28e-41	Platelet count;
LUSC	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg12863693	chr15:85201151	NMB	0.35	7.14	0.36	6e-12	Schizophrenia;
LUSC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-6.03	-0.31	4.27e-9	Total body bone mineral density;
LUSC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg13206674	chr6:150067644	NUP43	0.6	9.53	0.46	3.38e-19	Lung cancer;
LUSC	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg23093090	chr10:104574429	C10orf26	-0.34	-6.26	-0.32	1.21e-9	Arsenic metabolism;
LUSC	cis	rs6445797	0.632	rs11921326	chr3:56664322	C/A	cg13792233	chr3:56591045	CCDC66	0.41	5.72	0.3	2.33e-8	Gastritis;
LUSC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg00431813	chr7:1051703	C7orf50	-0.38	-5.86	-0.31	1.13e-8	Longevity;Endometriosis;
LUSC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	9.29	0.45	2.08e-18	Mean platelet volume;
LUSC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg14154082	chr13:112174009	NA	0.38	7.95	0.4	2.97e-14	Menarche (age at onset);
LUSC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg05347473	chr6:146136440	FBXO30	0.65	11.4	0.53	1.16e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs244293	1.000	rs2628314	chr17:53235182	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-5.84	-0.3	1.23e-8	Menarche (age at onset);
LUSC	cis	rs6733011	0.500	rs7560696	chr2:99405800	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.44	-0.33	4.23e-10	Bipolar disorder;
LUSC	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.77	11.38	0.53	1.43e-25	Corneal astigmatism;
LUSC	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.65	-0.34	1.21e-10	Response to antipsychotic treatment;
LUSC	cis	rs6062509	0.929	rs55791529	chr20:62363858	C/T	cg21849932	chr20:62369462	LIME1	-0.4	-5.91	-0.31	8.37e-9	Prostate cancer;
LUSC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg02772935	chr3:125709198	NA	-0.49	-5.89	-0.31	9.62e-9	Blood pressure (smoking interaction);
LUSC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg13647721	chr17:30228624	UTP6	0.61	6.44	0.33	4.27e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs6901250	1.000	rs6924002	chr6:117114223	A/T	cg12892004	chr6:117198278	RFX6	0.4	7.22	0.37	3.53e-12	C-reactive protein levels;
LUSC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg23711669	chr6:146136114	FBXO30	-0.83	-14.97	-0.63	3.94e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg04315214	chr1:2043799	PRKCZ	0.38	7.83	0.39	6.42e-14	Height;
LUSC	cis	rs7215564	0.818	rs1531946	chr17:78630807	G/A	cg23238734	chr17:78661607	RPTOR	0.48	5.89	0.31	9.26e-9	Myopia (pathological);
LUSC	cis	rs11603020	1.000	rs11603020	chr11:57374332	C/T	cg23127183	chr11:57508653	C11orf31	0.44	6.05	0.31	3.99e-9	Blood protein levels;
LUSC	cis	rs1044826	0.913	rs9831108	chr3:139098357	A/C	cg00490450	chr3:139108681	COPB2	0.55	7.39	0.37	1.18e-12	Obesity-related traits;
LUSC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg18240062	chr17:79603768	NPLOC4	0.69	12.86	0.58	4.98e-31	Eye color traits;
LUSC	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	6.62	0.34	1.46e-10	Schizophrenia;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg27497049	chr8:94712646	FAM92A1	0.44	5.96	0.31	6.35e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	9.31	0.45	1.75e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.69	12.39	0.56	2.96e-29	Longevity;
LUSC	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg11887960	chr12:57824829	NA	0.52	6.6	0.34	1.59e-10	Obesity-related traits;
LUSC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.62	10.16	0.49	2.7e-21	Iron status biomarkers;
LUSC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.66	-0.39	2.07e-13	Bipolar disorder;
LUSC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg27121462	chr16:89883253	FANCA	0.54	8.65	0.43	2.21e-16	Vitiligo;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg27523951	chr13:46038867	COG3	0.38	6.21	0.32	1.57e-9	Triglycerides;
LUSC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg09877947	chr5:131593287	PDLIM4	0.4	6.39	0.33	5.42e-10	Breast cancer;Mosquito bite size;
LUSC	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg05872129	chr22:39784769	NA	-0.53	-8.79	-0.43	7.83e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg23082867	chr19:19030255	DDX49;COPE	0.37	6.25	0.32	1.26e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.49	0.33	3.19e-10	Platelet count;
LUSC	cis	rs1044826	0.642	rs9833307	chr3:139181370	G/A	cg15131784	chr3:139108705	COPB2	0.4	6.48	0.33	3.22e-10	Obesity-related traits;
LUSC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg22709100	chr7:91322751	NA	-0.4	-5.82	-0.3	1.38e-8	Breast cancer;
LUSC	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg15556689	chr8:8085844	FLJ10661	0.55	8.1	0.41	1.07e-14	Retinal vascular caliber;
LUSC	cis	rs9399401	0.845	rs263185	chr6:142861729	G/A	cg03128060	chr6:142623767	GPR126	0.32	5.95	0.31	6.72e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs3007168	1.000	rs2999365	chr14:51600192	A/G	cg23942311	chr14:51606299	NA	0.35	5.7	0.3	2.61e-8	Cancer;
LUSC	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg14092571	chr14:90743983	NA	-0.36	-5.87	-0.31	1.04e-8	Mortality in heart failure;
LUSC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg03188948	chr7:1209495	NA	0.7	8.02	0.4	1.85e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg17279839	chr7:150038598	RARRES2	0.51	7.38	0.37	1.29e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg08798685	chr6:27730294	NA	-0.7	-6.08	-0.32	3.22e-9	Depression;
LUSC	cis	rs7503807	1.000	rs8079537	chr17:78600818	A/G	cg09596252	chr17:78655493	RPTOR	0.45	7.57	0.38	3.67e-13	Obesity;
LUSC	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg02086790	chr16:375327	AXIN1	-0.39	-6.03	-0.31	4.36e-9	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg09904177	chr6:26538194	HMGN4	-0.8	-6.37	-0.33	6.31e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.39	-0.33	5.44e-10	Bladder cancer;
LUSC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg12403142	chr1:92012408	NA	-0.37	-6.09	-0.32	3.16e-9	Breast cancer;
LUSC	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg27284194	chr4:1044797	NA	0.6	8.85	0.44	5.26e-17	Recombination rate (females);
LUSC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.92	15.67	0.65	7.13e-42	Heart rate;
LUSC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.65	7.95	0.4	2.89e-14	Lung function (FEV1/FVC);
LUSC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00166722	chr3:10149974	C3orf24	0.62	8.7	0.43	1.55e-16	Alzheimer's disease;
LUSC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg02951883	chr7:2050386	MAD1L1	-0.64	-12.37	-0.56	3.35e-29	Bipolar disorder and schizophrenia;
LUSC	cis	rs4845459	0.967	rs6677595	chr1:152590187	C/T	cg08895932	chr1:152778580	LCE1C	-0.36	-6.26	-0.32	1.17e-9	Psoriasis;
LUSC	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg07828340	chr4:882639	GAK	1.12	10.96	0.51	4.38e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs4077468	1.000	rs9662221	chr1:205915745	G/T	cg07157834	chr1:205819609	PM20D1	-0.42	-5.92	-0.31	8.05e-9	Cystic fibrosis-related diabetes;
LUSC	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg21238619	chr17:78079768	GAA	-0.3	-5.75	-0.3	2.05e-8	Yeast infection;
LUSC	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg25457927	chr22:38595422	NA	-0.37	-7.62	-0.39	2.57e-13	Cutaneous nevi;
LUSC	trans	rs672889	0.520	rs312953	chr2:21339932	G/A	cg20757404	chr19:378427	NA	0.37	6.02	0.31	4.62e-9	Cholesterol, total;
LUSC	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg26876637	chr1:152193138	HRNR	0.42	5.89	0.31	9.39e-9	Atopic dermatitis;
LUSC	cis	rs11637445	0.589	rs7497457	chr15:68132723	C/A	cg08079166	chr15:68083412	MAP2K5	0.35	7.1	0.36	7.57e-12	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.65	-0.47	1.37e-19	Total cholesterol levels;
LUSC	trans	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg11019008	chr10:131425282	MGMT	-0.42	-6.43	-0.33	4.29e-10	Response to temozolomide;
LUSC	trans	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg13010199	chr12:38710504	ALG10B	0.5	7.54	0.38	4.5e-13	Morning vs. evening chronotype;
LUSC	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	6.59	0.34	1.69e-10	Systemic lupus erythematosus;
LUSC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18301423	chr5:131593218	PDLIM4	0.47	7.42	0.38	9.66e-13	Acylcarnitine levels;
LUSC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08677398	chr8:58056175	NA	0.54	6.99	0.36	1.48e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.83	-0.35	4.14e-11	Response to antipsychotic treatment;
LUSC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg09035930	chr12:129282057	SLC15A4	-0.66	-13.32	-0.59	8.98e-33	Systemic lupus erythematosus;
LUSC	cis	rs2908197	0.762	rs2908192	chr7:75949617	C/T	cg10167463	chr7:75959203	YWHAG	-0.38	-5.75	-0.3	2e-8	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg22532475	chr10:104410764	TRIM8	-0.41	-8.5	-0.42	6.24e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.9	17.05	0.68	2.53e-47	Menarche (age at onset);
LUSC	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg19773385	chr1:10388646	KIF1B	-0.5	-8.74	-0.43	1.19e-16	Hepatocellular carcinoma;
LUSC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.65e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.64	10.93	0.51	5.73e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11141652	chr22:24348549	GSTTP1	-0.38	-5.7	-0.3	2.61e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.67	11.85	0.54	2.92e-27	Aortic root size;
LUSC	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg06937882	chr20:24974362	C20orf3	-0.44	-7.65	-0.39	2.15e-13	Blood protein levels;
LUSC	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.55	-0.6	1.2e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	1.14	15.73	0.65	3.98e-42	Uric acid levels;
LUSC	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg05973401	chr12:123451056	ABCB9	0.54	7.34	0.37	1.63e-12	Neutrophil percentage of white cells;
LUSC	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg09184832	chr6:79620586	NA	-0.44	-7.01	-0.36	1.33e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs911119	0.955	rs7265178	chr20:23603382	C/G	cg16589663	chr20:23618590	CST3	0.57	6.82	0.35	4.18e-11	Chronic kidney disease;
LUSC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-7.52	-0.38	5.25e-13	Personality dimensions;
LUSC	cis	rs4974559	0.947	rs12639938	chr4:1343135	G/C	cg02980000	chr4:1222292	CTBP1	0.73	7.25	0.37	2.9e-12	Systolic blood pressure;
LUSC	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg04998671	chr14:104000505	TRMT61A	-0.46	-7.22	-0.37	3.44e-12	Coronary artery disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06367659	chr22:50919817	ADM2	0.68	6.06	0.31	3.77e-9	Cognitive performance;
LUSC	cis	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.37e-9	Ulcerative colitis;
LUSC	cis	rs7712401	0.601	rs30048	chr5:122270393	A/G	cg19077854	chr5:122220652	SNX24	0.4	8.59	0.43	3.34e-16	Mean platelet volume;
LUSC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg05802129	chr4:122689817	NA	-0.5	-8.12	-0.41	9.17e-15	Type 2 diabetes;
LUSC	cis	rs2731664	0.792	rs2630767	chr5:176870700	T/C	cg23176889	chr5:176863531	GRK6	-0.66	-13.22	-0.59	2.23e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	0.89	12.29	0.56	6.97e-29	Glomerular filtration rate (creatinine);
LUSC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg24631222	chr15:78858424	CHRNA5	0.64	8.5	0.42	6.2e-16	Post bronchodilator FEV1;
LUSC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg11752832	chr7:134001865	SLC35B4	0.5	7.59	0.38	3.15e-13	Mean platelet volume;
LUSC	cis	rs7000551	0.689	rs6984908	chr8:22316901	A/G	cg12081754	chr8:22256438	SLC39A14	-0.45	-6.95	-0.36	1.89e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.31	-0.33	8.95e-10	Bipolar disorder;
LUSC	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	6.85	0.35	3.49e-11	Height;
LUSC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.71	0.3	2.55e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg00376283	chr12:123451042	ABCB9	0.71	10.94	0.51	5.25e-24	Platelet count;
LUSC	cis	rs7561273	0.609	rs6720226	chr2:24295853	A/G	cg20701182	chr2:24300061	SF3B14	0.45	5.77	0.3	1.78e-8	Quantitative traits;
LUSC	cis	rs870825	0.929	rs1405939	chr4:185591444	C/T	cg04058563	chr4:185651563	MLF1IP	0.76	9.24	0.45	2.93e-18	Blood protein levels;
LUSC	cis	rs17286411	0.814	rs12708918	chr16:71984941	C/G	cg03805757	chr16:71968109	PKD1L3	0.4	6.51	0.34	2.73e-10	Blood protein levels;
LUSC	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg06627628	chr2:24431161	ITSN2	-0.61	-7.4	-0.38	1.09e-12	Lymphocyte counts;
LUSC	cis	rs12946454	0.696	rs4792819	chr17:43247957	A/C	cg10701640	chr17:43249399	NA	0.5	12.06	0.55	4.93e-28	Systolic blood pressure;
LUSC	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.99	-13.64	-0.6	5.62e-34	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg08975724	chr8:8085496	FLJ10661	0.42	5.94	0.31	7.16e-9	Neuroticism;
LUSC	trans	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg25214090	chr10:38739885	LOC399744	0.53	7.61	0.38	2.81e-13	Corneal astigmatism;
LUSC	cis	rs73200209	0.744	rs61939693	chr12:116540478	G/A	cg01776926	chr12:116560359	MED13L	-0.49	-6.03	-0.31	4.36e-9	Total body bone mineral density;
LUSC	cis	rs3824867	0.920	rs7111873	chr11:47469439	A/G	cg20307385	chr11:47447363	PSMC3	0.64	9.48	0.46	4.83e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-0.98	-19.45	-0.73	7.03e-57	Menopause (age at onset);
LUSC	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg00898013	chr13:113819073	PROZ	-0.53	-7.85	-0.39	5.78e-14	Platelet distribution width;
LUSC	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg12292205	chr6:26970375	C6orf41	-0.49	-8.07	-0.4	1.31e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs3772130	1.000	rs11714406	chr3:121372513	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	9.98	0.48	1.07e-20	Cognitive performance;
LUSC	trans	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg13010199	chr12:38710504	ALG10B	0.47	7.6	0.38	3.03e-13	Morning vs. evening chronotype;
LUSC	cis	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg01251360	chr16:68772225	CDH1	-0.26	-6.1	-0.32	2.96e-9	Colorectal cancer;
LUSC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg24250549	chr1:154909240	PMVK	0.58	9.36	0.46	1.23e-18	Prostate cancer;
LUSC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	6.89	0.35	2.82e-11	Mean platelet volume;
LUSC	cis	rs62400317	0.859	rs62400293	chr6:45233580	A/T	cg18551225	chr6:44695536	NA	-0.44	-7.28	-0.37	2.46e-12	Total body bone mineral density;
LUSC	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg18753928	chr3:113234510	CCDC52	-0.52	-8.01	-0.4	1.99e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg14154082	chr13:112174009	NA	0.38	7.76	0.39	1.03e-13	Menarche (age at onset);
LUSC	cis	rs2019216	0.502	rs1842113	chr17:21872137	G/A	cg22648282	chr17:21454238	C17orf51	-0.5	-7.26	-0.37	2.8e-12	Pelvic organ prolapse;
LUSC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg04450456	chr4:17643702	FAM184B	0.36	5.9	0.31	8.88e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg16240275	chr20:61666158	NCRNA00029	0.42	9.36	0.46	1.17e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg00033643	chr7:134001901	SLC35B4	-0.42	-6.35	-0.33	6.94e-10	Mean platelet volume;
LUSC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	1.04	19.84	0.74	1.98e-58	Menopause (age at onset);
LUSC	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg15556689	chr8:8085844	FLJ10661	0.58	8.8	0.43	7.22e-17	Myopia (pathological);
LUSC	cis	rs61931739	0.635	rs1405024	chr12:33937939	A/T	cg06521331	chr12:34319734	NA	0.41	6.73	0.35	7.5e-11	Morning vs. evening chronotype;
LUSC	cis	rs1568889	0.838	rs10835273	chr11:28156598	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.66	0.57	2.85e-30	Bipolar disorder;
LUSC	cis	rs6693567	0.545	rs35705743	chr1:150451832	G/A	cg15654264	chr1:150340011	RPRD2	0.43	6.81	0.35	4.66e-11	Migraine;
LUSC	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.61	-0.43	2.88e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4595586	0.679	rs7955725	chr12:39322903	C/T	cg26384229	chr12:38710491	ALG10B	0.47	6.48	0.33	3.33e-10	Morning vs. evening chronotype;
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg25703541	chr22:24373054	LOC391322	-0.9	-14.58	-0.62	1.38e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7000551	0.700	rs2461491	chr8:22361252	C/T	cg12081754	chr8:22256438	SLC39A14	-0.41	-6.21	-0.32	1.59e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs17401966	0.838	rs11121551	chr1:10435170	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-8.88	-0.44	4.31e-17	Hepatocellular carcinoma;
LUSC	cis	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.84	-0.35	3.88e-11	Morning vs. evening chronotype;
LUSC	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg21775007	chr8:11205619	TDH	0.44	6.26	0.32	1.2e-9	Neuroticism;
LUSC	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg26384229	chr12:38710491	ALG10B	0.72	11.29	0.53	3.03e-25	Morning vs. evening chronotype;
LUSC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg22823121	chr1:150693482	HORMAD1	0.5	7.32	0.37	1.86e-12	Melanoma;
LUSC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg24562669	chr7:97807699	LMTK2	0.34	5.95	0.31	6.83e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg00191853	chr8:101177733	SPAG1	-0.41	-6.49	-0.33	3.05e-10	Atrioventricular conduction;
LUSC	cis	rs10484885	0.818	rs117562849	chr6:90249804	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.19	-0.37	4.18e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg22681709	chr2:178499509	PDE11A	-0.57	-10.75	-0.51	2.45e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.59	-0.34	1.72e-10	Myopia (pathological);
LUSC	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg11984989	chr7:158649758	WDR60	1.14	13.85	0.6	8.5e-35	Height;
LUSC	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg04369109	chr6:150039330	LATS1	-0.56	-8.22	-0.41	4.62e-15	Lung cancer;
LUSC	cis	rs73198271	0.855	rs57301822	chr8:8608642	C/T	cg01851573	chr8:8652454	MFHAS1	0.53	7.94	0.4	3.02e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg19774624	chr17:42201019	HDAC5	0.71	10.39	0.49	4.28e-22	Total body bone mineral density;
LUSC	cis	rs4363385	0.818	rs378010	chr1:153007987	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.91	-0.4	3.76e-14	Inflammatory skin disease;
LUSC	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg15468180	chr1:107600409	PRMT6	-0.39	-6.25	-0.32	1.24e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13012494	chr21:47604986	C21orf56	0.45	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.77	10.41	0.49	3.77e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs68170813	0.559	rs2107318	chr7:106845969	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.82	-0.47	3.71e-20	Coronary artery disease;
LUSC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-6.95	-0.36	1.88e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2742234	0.915	rs2742233	chr10:43610558	C/T	cg02780029	chr10:43622663	RET	-0.34	-6.22	-0.32	1.44e-9	Hirschsprung disease;
LUSC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg07701084	chr6:150067640	NUP43	0.57	8.9	0.44	3.64e-17	Lung cancer;
LUSC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.76	9.6	0.47	1.92e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg03585969	chr10:35415529	CREM	0.59	8.81	0.43	7.15e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.34	-0.37	1.64e-12	Morning vs. evening chronotype;
LUSC	cis	rs12760731	0.720	rs12035174	chr1:178314311	A/T	cg00404053	chr1:178313656	RASAL2	0.57	6.06	0.31	3.65e-9	Obesity-related traits;
LUSC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.4	-0.33	5.38e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.72	-13.32	-0.59	9.19e-33	Ulcerative colitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07627390	chr16:23652638	PALB2;DCTN5	0.43	6.69	0.34	9.35e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs829880	0.570	rs4488248	chr12:98853688	G/C	cg25150519	chr12:98850993	NA	0.75	11.92	0.55	1.6e-27	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1595825	0.627	rs77353793	chr2:198470546	C/T	cg00982548	chr2:198649783	BOLL	-0.53	-6.22	-0.32	1.46e-9	Ulcerative colitis;
LUSC	cis	rs4561483	0.798	rs33629	chr16:11997490	G/A	cg08843971	chr16:11963173	GSPT1	-0.42	-6.02	-0.31	4.59e-9	Testicular germ cell tumor;
LUSC	trans	rs10098647	0.632	rs74459651	chr8:61111651	T/C	cg09970348	chr3:183978600	ECE2;CAMK2N2	0.46	6.15	0.32	2.26e-9	Obesity-related traits;
LUSC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17509989	chr5:176798049	RGS14	0.66	10.5	0.5	1.81e-22	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg15468180	chr1:107600409	PRMT6	0.41	6.13	0.32	2.54e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs865483	0.895	rs2107105	chr17:35835080	C/T	cg06716730	chr17:35851459	DUSP14	0.27	5.97	0.31	6.23e-9	Monocyte count;
LUSC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-1.03	-20.48	-0.75	5.94e-61	Height;
LUSC	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-7.17	-0.37	4.99e-12	Morning vs. evening chronotype;
LUSC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg25456477	chr12:86230367	RASSF9	0.35	6.18	0.32	1.84e-9	Major depressive disorder;
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.39	-6.48	-0.33	3.3e-10	Longevity;Endometriosis;
LUSC	cis	rs7246967	0.673	rs12979848	chr19:22820798	G/A	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-8.74	-0.43	1.16e-16	Morning vs. evening chronotype;
LUSC	cis	rs1005224	0.963	rs11623813	chr14:76138194	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.66	-8.97	-0.44	2.15e-17	Large artery stroke;
LUSC	cis	rs4737010	0.536	rs6474365	chr8:41662940	G/T	cg17182837	chr8:41585554	ANK1	-0.36	-6.52	-0.34	2.59e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg13708869	chr17:38444121	CDC6	0.39	6.06	0.31	3.62e-9	N-glycan levels;
LUSC	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg18904891	chr8:8559673	CLDN23	0.6	8.08	0.4	1.2e-14	Obesity-related traits;
LUSC	cis	rs12137294	0.866	rs1077883	chr1:205210415	G/T	cg21643547	chr1:205240462	TMCC2	-0.35	-6.43	-0.33	4.48e-10	Red cell distribution width;
LUSC	cis	rs6714710	0.603	rs4311104	chr2:98424802	A/G	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs62400317	0.762	rs12198308	chr6:44911886	C/T	cg18551225	chr6:44695536	NA	-0.48	-7.69	-0.39	1.65e-13	Total body bone mineral density;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg13453750	chr1:205783389	SLC41A1	0.32	6.38	0.33	5.76e-10	Menarche (age at onset);
LUSC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.66	-0.43	2.01e-16	Bipolar disorder;
LUSC	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.56	-8.86	-0.44	4.75e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.8	-0.35	4.79e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4356932	1.000	rs10017431	chr4:76955406	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.59	0.38	3.18e-13	Vitiligo;
LUSC	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.69	0.54	1.11e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg25214090	chr10:38739885	LOC399744	0.43	6.48	0.33	3.35e-10	Corneal astigmatism;
LUSC	cis	rs1044826	1.000	rs10935323	chr3:139110135	T/G	cg00490450	chr3:139108681	COPB2	0.56	7.38	0.37	1.29e-12	Obesity-related traits;
LUSC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg09034736	chr1:150693464	HORMAD1	0.42	5.85	0.3	1.16e-8	Melanoma;
LUSC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.8	0.47	4.42e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg14210321	chr2:106509881	NCK2	-0.56	-8.43	-0.42	1.02e-15	Addiction;
LUSC	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg22117172	chr7:91764530	CYP51A1	0.32	5.65	0.3	3.43e-8	Breast cancer;
LUSC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg13206674	chr6:150067644	NUP43	0.62	9.9	0.48	2e-20	Lung cancer;
LUSC	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-7.99	-0.4	2.21e-14	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg14092988	chr3:52407081	DNAH1	0.31	6.18	0.32	1.82e-9	Bipolar disorder;
LUSC	cis	rs72781680	1.000	rs72781663	chr2:24221694	C/G	cg08917208	chr2:24149416	ATAD2B	0.89	9.99	0.48	9.47e-21	Lymphocyte counts;
LUSC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg06618935	chr21:46677482	NA	-0.4	-7.99	-0.4	2.2e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg11062466	chr8:58055876	NA	0.49	6.52	0.34	2.59e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg17385448	chr1:15911702	AGMAT	0.38	5.79	0.3	1.61e-8	Systolic blood pressure;
LUSC	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg12379764	chr21:47803548	PCNT	0.75	9.31	0.45	1.8e-18	Lymphocyte counts;
LUSC	cis	rs11214589	0.651	rs11214596	chr11:113264511	C/G	cg14159747	chr11:113255604	NA	0.3	7.8	0.39	8.03e-14	Neuroticism;
LUSC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.96	-16.24	-0.66	4.12e-44	Coronary artery disease;
LUSC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg14664628	chr15:75095509	CSK	-0.58	-8.79	-0.43	7.96e-17	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02351056	chr10:126480372	METTL10	0.49	6.94	0.36	2.1e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.2	-0.41	5.16e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs7582180	0.903	rs13032368	chr2:100896112	C/T	cg08017756	chr2:100939284	LONRF2	-0.36	-6.01	-0.31	4.77e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs3106136	0.967	rs3113862	chr4:95143122	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.1	-0.32	2.86e-9	Capecitabine sensitivity;
LUSC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg02167203	chr6:41068553	NFYA;LOC221442	-0.43	-6.07	-0.32	3.48e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21293242	chr8:11204541	TDH	0.32	5.91	0.31	8.66e-9	Retinal vascular caliber;
LUSC	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.67	-10.33	-0.49	6.6e-22	Brugada syndrome;
LUSC	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg26566898	chr11:117069891	TAGLN	0.34	6.46	0.33	3.77e-10	Blood protein levels;
LUSC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.92	-0.35	2.35e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg09654669	chr8:57350985	NA	-0.6	-8.05	-0.4	1.43e-14	Obesity-related traits;
LUSC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg06808227	chr14:105710500	BRF1	-0.65	-9.66	-0.47	1.29e-19	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg06606381	chr12:133084897	FBRSL1	-1.03	-9.51	-0.46	3.88e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg12639453	chr1:2035780	PRKCZ	-0.34	-7.29	-0.37	2.32e-12	Height;
LUSC	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg05283184	chr6:79620031	NA	-0.57	-11.99	-0.55	8.45e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg09455208	chr3:40491958	NA	-0.62	-11.01	-0.52	3.04e-24	Renal cell carcinoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10935138	chr17:73851978	WBP2	0.48	6.4	0.33	5.2400000000000005e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07067085	chr12:120638762	RPLP0	-0.48	-7.13	-0.36	6.38e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg06454157	chr6:167490870	NA	-0.27	-6.5	-0.34	2.93e-10	Primary biliary cholangitis;
LUSC	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg09835421	chr16:68378352	PRMT7	-0.8	-8.49	-0.42	6.81e-16	Magnesium levels;
LUSC	cis	rs11676348	0.774	rs57545959	chr2:219047718	A/G	cg23569941	chr2:219139048	TMBIM1;PNKD	-0.39	-6.43	-0.33	4.31e-10	Ulcerative colitis;
LUSC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-7.12	-0.36	6.51e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	8.2	0.41	5.13e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.71	-12.37	-0.56	3.47e-29	White blood cell count (basophil);
LUSC	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22455342	chr2:225449267	CUL3	0.47	6.62	0.34	1.45e-10	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs2274273	0.840	rs6573013	chr14:55735873	A/C	cg04306507	chr14:55594613	LGALS3	0.56	12.96	0.58	2.05e-31	Protein biomarker;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09693464	chr7:41744949	LOC285954	-0.47	-7.26	-0.37	2.69e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg08917208	chr2:24149416	ATAD2B	0.88	9.72	0.47	7.6e-20	Lymphocyte counts;
LUSC	cis	rs1124376	0.832	rs6793985	chr3:20136485	T/C	cg05072819	chr3:20081367	KAT2B	0.67	8.19	0.41	5.56e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.17	0.32	1.95e-9	Corneal astigmatism;
LUSC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.02	0.58	1.28e-31	Chronic sinus infection;
LUSC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg27535305	chr1:53392650	SCP2	0.32	5.82	0.3	1.37e-8	Monocyte count;
LUSC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	6.53	0.34	2.49e-10	Bipolar disorder;
LUSC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg06618935	chr21:46677482	NA	-0.39	-7.7	-0.39	1.5700000000000001e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.01	-0.36	1.29e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7903847	0.527	rs11189221	chr10:99198217	C/T	cg20016023	chr10:99160130	RRP12	-0.26	-5.65	-0.3	3.47e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs8056893	0.714	rs6499173	chr16:68388115	G/A	cg02226672	chr16:68398533	SMPD3	0.32	5.77	0.3	1.83e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.3	0.49	8.52e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4474465	1.000	rs4474465	chr11:78204380	C/T	cg27205649	chr11:78285834	NARS2	0.51	5.91	0.31	8.55e-9	Alzheimer's disease (survival time);
LUSC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg00631329	chr6:26305371	NA	0.34	5.92	0.31	7.93e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4737010	0.501	rs2111805	chr8:41643457	G/C	cg17182837	chr8:41585554	ANK1	-0.38	-6.81	-0.35	4.63e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	13.86	0.6	7.9e-35	Platelet count;
LUSC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg18512352	chr11:47633146	NA	-0.46	-9.22	-0.45	3.55e-18	Subjective well-being;
LUSC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg13010199	chr12:38710504	ALG10B	0.41	5.94	0.31	7.08e-9	Morning vs. evening chronotype;
LUSC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.89	0.31	9.63e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg24851651	chr11:66362959	CCS	-0.36	-5.76	-0.3	1.93e-8	Educational attainment (years of education);
LUSC	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.37	3.79e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.44	-0.38	8.32e-13	Schizophrenia;
LUSC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.58	-10.98	-0.51	3.77e-24	Longevity;Endometriosis;
LUSC	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg17075019	chr10:79541650	NA	-0.69	-10.39	-0.49	4.34e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03264133	chr6:25882463	NA	-0.43	-7.36	-0.37	1.42e-12	Height;
LUSC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	0.94	18.23	0.71	5.01e-52	Cognitive function;
LUSC	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg10845886	chr2:3471009	TTC15	-0.6	-7.79	-0.39	8.4e-14	Neurofibrillary tangles;
LUSC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg02782426	chr3:40428986	ENTPD3	0.43	8.1	0.41	1.03e-14	Renal cell carcinoma;
LUSC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg21963583	chr11:68658836	MRPL21	0.59	8.7	0.43	1.59e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1775715	0.811	rs1775741	chr10:32267284	C/T	cg18675610	chr10:32216311	ARHGAP12	-0.29	-6.06	-0.31	3.64e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg05855489	chr10:104503620	C10orf26	-0.49	-7.45	-0.38	7.83e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.89	-0.31	9.23e-9	Height;
LUSC	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.7	12.22	0.56	1.2e-28	White blood cell count (neutrophil);
LUSC	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg24803719	chr17:45855879	NA	-0.29	-5.79	-0.3	1.64e-8	IgG glycosylation;
LUSC	cis	rs4664308	0.935	rs4292050	chr2:160940899	G/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.62	-0.54	1.97e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg05855489	chr10:104503620	C10orf26	-0.61	-7.89	-0.4	4.24e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.88	0.48	2.31e-20	Mean corpuscular volume;
LUSC	trans	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg21775007	chr8:11205619	TDH	0.45	6.66	0.34	1.14e-10	Mood instability;
LUSC	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg12615879	chr12:58013172	SLC26A10	0.39	9.11	0.45	7.9e-18	Multiple sclerosis;
LUSC	cis	rs9650657	0.812	rs6993841	chr8:10632684	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-6.59	-0.34	1.75e-10	Neuroticism;
LUSC	cis	rs12618769	0.597	rs3769712	chr2:99153443	A/T	cg10123293	chr2:99228465	UNC50	0.5	8.12	0.41	9.4e-15	Bipolar disorder;
LUSC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	6.31	0.33	8.74e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg06808227	chr14:105710500	BRF1	-0.63	-9.13	-0.45	6.81e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1113500	0.933	rs10785834	chr1:108639101	A/C	cg11967332	chr1:108735228	SLC25A24	0.39	5.84	0.3	1.24e-8	Growth-regulated protein alpha levels;
LUSC	trans	rs67539049	1.000	rs68063127	chr8:11303726	G/C	cg26241650	chr22:40417538	FAM83F	0.45	6.08	0.32	3.31e-9	Itch intensity from mosquito bite;
LUSC	cis	rs926938	0.527	rs360594	chr1:115472401	G/A	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.43	-0.33	4.47e-10	Autism;
LUSC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg22800045	chr5:56110881	MAP3K1	0.44	6.22	0.32	1.49e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg05805236	chr11:65401703	PCNXL3	0.4	6.84	0.35	3.82e-11	Acne (severe);
LUSC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.46	-0.33	3.73e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg26566898	chr11:117069891	TAGLN	0.32	5.99	0.31	5.46e-9	Blood protein levels;
LUSC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg19318889	chr4:1322082	MAEA	-0.71	-12.13	-0.55	2.74e-28	Obesity-related traits;
LUSC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20307385	chr11:47447363	PSMC3	0.45	5.86	0.31	1.09e-8	Subjective well-being;
LUSC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg12560992	chr17:57184187	TRIM37	0.8	14.17	0.61	5.27e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	5.68	0.3	2.86e-8	Response to antipsychotic treatment;
LUSC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg02269571	chr22:50332266	NA	-0.75	-9.41	-0.46	8.48e-19	Schizophrenia;
LUSC	cis	rs10193935	0.892	rs13413028	chr2:42394865	C/G	cg27598129	chr2:42591480	NA	-0.59	-7.96	-0.4	2.75e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs16937	0.521	rs78176224	chr1:205178609	G/A	cg21643547	chr1:205240462	TMCC2	-0.33	-5.71	-0.3	2.52e-8	Schizophrenia;
LUSC	cis	rs9399401	0.961	rs6937121	chr6:142707133	G/T	cg03128060	chr6:142623767	GPR126	-0.34	-6.19	-0.32	1.8e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	9.66	0.47	1.3e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs6600671	0.967	rs11249349	chr1:121179169	G/C	cg08727972	chr1:148025634	NBPF14	0.46	6.3	0.33	9.5e-10	Hip geometry;
LUSC	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg24375607	chr4:120327624	NA	0.69	10.92	0.51	6.06e-24	Corneal astigmatism;
LUSC	cis	rs12042107	0.818	rs12568187	chr1:91193691	T/C	cg13456504	chr1:91191583	NA	0.41	6.79	0.35	5.29e-11	Educational attainment;
LUSC	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg23283495	chr1:209979779	IRF6	-0.63	-7.97	-0.4	2.47e-14	Cleft lip with or without cleft palate;
LUSC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-1.04	-19.98	-0.74	5.38e-59	Height;
LUSC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.58	-7.69	-0.39	1.63e-13	Response to diuretic therapy;
LUSC	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.56	9.75	0.47	6.24e-20	Birth weight;
LUSC	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg16586182	chr3:47516702	SCAP	-0.5	-6.16	-0.32	2.11e-9	Birth weight;
LUSC	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.81	-0.65	2.07e-42	Height;
LUSC	cis	rs6690583	0.623	rs74689037	chr1:85439268	C/T	cg22153463	chr1:85462885	MCOLN2	0.63	6.02	0.31	4.6e-9	Serum sulfate level;
LUSC	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg17848003	chr1:3704513	LRRC47	-0.32	-6.1	-0.32	2.89e-9	Red cell distribution width;
LUSC	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg23505145	chr19:12996616	KLF1	0.64	10.74	0.51	2.69e-23	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg03804128	chr16:635623	NA	0.33	6.65	0.34	1.23e-10	Height;
LUSC	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg22356347	chr1:167427500	CD247	-0.35	-8.26	-0.41	3.52e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg06917634	chr15:78832804	PSMA4	-0.49	-6.5	-0.34	2.91e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg08859206	chr1:53392774	SCP2	-0.55	-9.29	-0.45	2.06e-18	Monocyte count;
LUSC	cis	rs6754311	0.593	rs7608045	chr2:136413359	T/C	cg07169764	chr2:136633963	MCM6	0.55	7.25	0.37	2.94e-12	Mosquito bite size;
LUSC	trans	rs11165623	0.792	rs1931180	chr1:96914049	C/T	cg10631902	chr5:14652156	NA	-0.53	-8.75	-0.43	1.1e-16	Hip circumference;Waist circumference;
LUSC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-7.24	-0.37	3.19e-12	Chronic sinus infection;
LUSC	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg03877680	chr5:178157825	ZNF354A	0.61	8.03	0.4	1.68e-14	Neutrophil percentage of white cells;
LUSC	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07080220	chr10:102295463	HIF1AN	0.64	8.56	0.42	4.06e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.51	7.8	0.39	8.2e-14	Axial length;
LUSC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.11	-0.48	3.72e-21	Monocyte count;
LUSC	cis	rs4363385	0.747	rs7529110	chr1:152966247	A/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.66	-0.39	2.03e-13	Inflammatory skin disease;
LUSC	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg09904177	chr6:26538194	HMGN4	-0.79	-5.88	-0.31	1e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs7202877	0.611	rs4888395	chr16:75413715	T/G	cg03315344	chr16:75512273	CHST6	0.43	6.42	0.33	4.69e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg13683864	chr3:40499215	RPL14	-1.15	-21.24	-0.76	5.91e-64	Renal cell carcinoma;
LUSC	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg07148914	chr20:33460835	GGT7	0.52	7.8	0.39	8.1e-14	Height;
LUSC	cis	rs6464929	0.955	rs6952916	chr7:148724945	T/C	cg23583168	chr7:148888333	NA	0.46	5.71	0.3	2.46e-8	Pediatric bone mineral content (hip);
LUSC	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.99	0.31	5.5e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	0.81	13.88	0.6	6.48e-35	Menopause (age at onset);
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg01238044	chr22:24384105	GSTT1	-0.73	-12.34	-0.56	4.3e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9463078	0.605	rs17422760	chr6:44885288	C/T	cg25276700	chr6:44698697	NA	0.29	6.16	0.32	2.06e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07677032	chr17:61819896	STRADA	0.53	8.61	0.43	2.94e-16	Prudent dietary pattern;
LUSC	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.76	15.2	0.64	5.15e-40	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.06	-0.36	9.78e-12	Coronary artery disease;
LUSC	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg26395211	chr5:140044315	WDR55	-0.37	-5.77	-0.3	1.78e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg14403583	chr14:105418241	AHNAK2	-0.58	-9.66	-0.47	1.28e-19	Rheumatoid arthritis;
LUSC	cis	rs2742417	0.603	rs2742371	chr3:45782763	G/A	cg10512202	chr3:45649293	LIMD1	0.36	6.11	0.32	2.71e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg00677455	chr12:58241039	CTDSP2	0.5	7.6	0.38	3.04e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4589502	0.841	rs55855162	chr15:67140523	C/A	cg12317470	chr15:67143691	NA	0.66	6.43	0.33	4.51e-10	Lung cancer (smoking interaction);
LUSC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.5	7.76	0.39	1.03e-13	Colorectal cancer;
LUSC	cis	rs41271473	0.948	rs72750016	chr1:228816786	G/C	cg10167378	chr1:228756711	NA	0.59	7.18	0.37	4.58e-12	Chronic lymphocytic leukemia;
LUSC	cis	rs13114435	0.510	rs6823077	chr4:183833942	A/C	cg00486011	chr4:183851557	NA	0.27	5.77	0.3	1.81e-8	Obesity-related traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00558053	chr19:1905303	ADAT3;SCAMP4	-0.43	-6.36	-0.33	6.46e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7833787	1.000	rs12546946	chr8:18703078	C/G	cg17701159	chr8:18705777	PSD3	-0.38	-6.21	-0.32	1.55e-9	Obesity-related traits;
LUSC	trans	rs10880689	1	rs10880689	chr12:37930102	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.48	-0.33	3.26e-10	Resting heart rate;
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.64	-12.38	-0.56	3.08e-29	Longevity;Endometriosis;
LUSC	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg15212455	chr7:39170539	POU6F2	0.6	9.6	0.46	2.02e-19	IgG glycosylation;
LUSC	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.72	12.74	0.57	1.47e-30	Colorectal cancer;
LUSC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	1.21	16.6	0.67	1.46e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg03146154	chr1:46216737	IPP	0.51	7.66	0.39	2.08e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg05863683	chr7:1912471	MAD1L1	0.3	5.87	0.31	1.08e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg22906224	chr7:99728672	NA	0.46	6.5	0.34	2.94e-10	Coronary artery disease;
LUSC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.76	14.68	0.63	5.27e-38	Monocyte count;
LUSC	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg14227996	chr4:17616232	MED28	0.82	7.87	0.4	4.98e-14	Opioid sensitivity;
LUSC	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.85	0.47	2.83e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.04	-0.31	4.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg25258033	chr6:167368657	RNASET2	0.37	5.83	0.3	1.28e-8	Primary biliary cholangitis;
LUSC	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg20607287	chr7:12443886	VWDE	-0.61	-6.34	-0.33	7.27e-10	Coronary artery disease;
LUSC	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg12756686	chr19:29218302	NA	0.56	6.32	0.33	8.42e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs17641971	0.645	rs10504073	chr8:50024944	C/T	cg00325661	chr8:49890786	NA	0.36	5.77	0.3	1.82e-8	Blood metabolite levels;
LUSC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg11645453	chr3:52864694	ITIH4	0.34	7.95	0.4	2.95e-14	Bipolar disorder;
LUSC	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.76	-12.82	-0.57	6.94e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg02153584	chr22:29168773	CCDC117	0.59	8.89	0.44	3.81e-17	Lymphocyte counts;
LUSC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22509189	chr2:225307070	NA	-0.47	-6.13	-0.32	2.41e-9	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg23172400	chr8:95962367	TP53INP1	0.34	6.63	0.34	1.33e-10	Type 2 diabetes;
LUSC	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg09003973	chr2:102972529	NA	1.21	12.78	0.57	9.76e-31	Gut microbiota (bacterial taxa);
LUSC	cis	rs9807841	0.545	rs4804514	chr19:10764203	G/T	cg09936142	chr19:10668400	KRI1	-0.41	-6.68	-0.34	9.95e-11	Inflammatory skin disease;
LUSC	cis	rs6500395	1.000	rs9931123	chr16:48614293	G/T	cg04672837	chr16:48644449	N4BP1	0.49	7.46	0.38	7.78e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-1.19	-12.84	-0.57	5.85e-31	Diabetic kidney disease;
LUSC	trans	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.29	0.33	1.01e-9	Corneal astigmatism;
LUSC	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.53	-7.78	-0.39	9.23e-14	Reticulocyte count;
LUSC	cis	rs9646944	0.501	rs34946515	chr2:103043320	C/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.55	0.34	2.23e-10	Blood protein levels;
LUSC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg09839279	chr12:125627357	AACS	-0.34	-6.48	-0.33	3.32e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7683537	0.692	rs12509936	chr4:185662203	G/A	cg07424746	chr4:185654737	MLF1IP	-0.52	-5.79	-0.3	1.62e-8	Systemic lupus erythematosus;
LUSC	cis	rs9300255	0.722	rs67624109	chr12:123824635	C/T	cg13010344	chr12:123464640	ARL6IP4	0.5	6.28	0.33	1.03e-9	Neutrophil percentage of white cells;
LUSC	cis	rs4072705	0.615	rs6478666	chr9:127249343	C/G	cg13476313	chr9:127244764	NR5A1	-0.33	-6.38	-0.33	5.98e-10	Menarche (age at onset);
LUSC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.51	-8.0	-0.4	2.05e-14	Height;
LUSC	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg21643547	chr1:205240462	TMCC2	-0.4	-7.13	-0.36	6.24e-12	Red blood cell count;
LUSC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.62	-12.62	-0.57	3.87e-30	Longevity;Endometriosis;
LUSC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-5.77	-0.3	1.79e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.56	0.42	4.25e-16	Endometrial cancer;
LUSC	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg09491104	chr22:46646882	C22orf40	-0.72	-6.21	-0.32	1.57e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1997103	0.863	rs6956287	chr7:55415107	T/C	cg17469321	chr7:55412551	NA	0.68	10.43	0.5	3.23e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs806215	0.950	rs2073561	chr7:127227769	G/C	cg25922125	chr7:127225783	GCC1	-0.6	-7.34	-0.37	1.6e-12	Type 2 diabetes;
LUSC	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg12179176	chr11:130786555	SNX19	0.8	13.67	0.6	4.36e-34	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.6	-0.38	3.06e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.35	0.37	1.5e-12	Motion sickness;
LUSC	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg23711669	chr6:146136114	FBXO30	0.88	16.24	0.66	4.15e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7605827	0.930	rs12692275	chr2:15716781	C/T	cg19274914	chr2:15703543	NA	0.47	9.09	0.45	9.3e-18	Educational attainment (years of education);
LUSC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg25019033	chr10:957182	NA	-0.51	-6.42	-0.33	4.67e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.6	-0.38	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-7.0	-0.36	1.4e-11	Axial length;
LUSC	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg23241863	chr10:102295624	HIF1AN	0.48	5.85	0.3	1.16e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2908197	0.806	rs12534035	chr7:75980946	G/C	cg10167463	chr7:75959203	YWHAG	-0.43	-6.41	-0.33	4.87e-10	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs10465746	0.905	rs12127266	chr1:84360767	T/G	cg10977910	chr1:84465055	TTLL7	0.43	6.18	0.32	1.92e-9	Obesity-related traits;
LUSC	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-9.46	-0.46	5.63e-19	Morning vs. evening chronotype;
LUSC	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.41	-6.01	-0.31	4.93e-9	IgG glycosylation;
LUSC	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg01475377	chr6:109611718	NA	-0.38	-6.69	-0.34	9.16e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.6	-0.38	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg25036284	chr2:26402008	FAM59B	0.71	9.71	0.47	8.82e-20	Gut microbiome composition (summer);
LUSC	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.47	0.42	8.02e-16	Response to antipsychotic treatment;
LUSC	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg21951975	chr1:209979733	IRF6	0.57	6.87	0.35	3.14e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg05861140	chr6:150128134	PCMT1	-0.37	-5.89	-0.31	9.44e-9	Lung cancer;
LUSC	trans	rs10411161	0.702	rs8113768	chr19:52383938	C/T	cg22319618	chr22:45562946	NUP50	-0.49	-5.94	-0.31	6.97e-9	Breast cancer;
LUSC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg25258033	chr6:167368657	RNASET2	0.47	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	cis	rs4478858	0.746	rs10798832	chr1:31688630	C/G	cg00250761	chr1:31883323	NA	0.36	9.37	0.46	1.1e-18	Alcohol dependence;
LUSC	trans	rs8073060	0.963	rs11080353	chr17:33871281	C/T	cg19694781	chr19:47549865	TMEM160	0.73	11.26	0.52	3.7e-25	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19346786	chr7:2764209	NA	-0.5	-8.36	-0.42	1.76e-15	Height;
LUSC	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.21	-14.28	-0.62	1.93e-36	Diabetic kidney disease;
LUSC	cis	rs3930017	1.000	rs3930017	chr7:76720582	A/G	cg15770687	chr7:76625569	PMS2L11	0.41	5.88	0.31	9.84e-9	Body mass index;
LUSC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.67	0.43	1.91e-16	Menopause (age at onset);
LUSC	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg15485101	chr11:133734466	NA	0.43	7.69	0.39	1.63e-13	Childhood ear infection;
LUSC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg25319279	chr11:5960081	NA	-0.39	-6.15	-0.32	2.17e-9	DNA methylation (variation);
LUSC	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg01256987	chr12:42539512	GXYLT1	0.34	6.35	0.33	7.16e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs1864585	0.520	rs78050613	chr8:10657451	G/A	cg26278703	chr11:58910052	FAM111A	0.53	6.0	0.31	5.2e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUSC	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg06609049	chr19:2785107	THOP1	1.12	21.61	0.76	2.01e-65	Total cholesterol levels;
LUSC	cis	rs67072384	1.000	rs7120700	chr11:72444676	A/G	cg04827223	chr11:72435913	ARAP1	-0.75	-6.98	-0.36	1.58e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11327383	chr6:34216670	C6orf1	0.47	6.33	0.33	7.67e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.4	0.42	1.29e-15	Ulcerative colitis;
LUSC	cis	rs10788264	0.569	rs7089468	chr10:124019052	T/C	cg09507567	chr10:124027408	NA	0.56	9.87	0.48	2.46e-20	Total body bone mineral density;
LUSC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	9.51	0.46	4.05e-19	Multiple sclerosis;
LUSC	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg09165964	chr15:75287851	SCAMP5	-0.97	-11.87	-0.54	2.38e-27	Blood trace element (Zn levels);
LUSC	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg03975922	chr5:140080575	ZMAT2	0.31	5.7	0.3	2.69e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-7.19	-0.37	4.23e-12	Aortic root size;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg01238044	chr22:24384105	GSTT1	-0.67	-10.7	-0.51	3.59e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs911119	0.913	rs67483168	chr20:23581312	T/C	cg16589663	chr20:23618590	CST3	0.66	7.76	0.39	1.06e-13	Chronic kidney disease;
LUSC	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.66	-0.39	2e-13	Type 2 diabetes;
LUSC	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.74	-0.39	1.17e-13	Neuroticism;
LUSC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg09796270	chr17:17721594	SREBF1	-0.45	-7.94	-0.4	3.14e-14	Total body bone mineral density;
LUSC	cis	rs677665	0.722	rs10746487	chr1:9338689	T/C	cg25755851	chr1:9335794	NA	-0.61	-9.51	-0.46	3.81e-19	Eosinophil percentage of white cells;
LUSC	cis	rs909341	0.537	rs13041528	chr20:62385446	C/G	cg14758556	chr20:62440591	NA	-0.43	-5.71	-0.3	2.44e-8	Atopic dermatitis;
LUSC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg17971929	chr21:40555470	PSMG1	0.78	13.13	0.58	5.05e-32	Cognitive function;
LUSC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.5	0.42	6.55e-16	Prudent dietary pattern;
LUSC	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg10547527	chr2:198650123	BOLL	-0.49	-5.69	-0.3	2.76e-8	Ulcerative colitis;
LUSC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg19622623	chr12:86230825	RASSF9	-0.45	-6.5	-0.34	2.91e-10	Major depressive disorder;
LUSC	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06022373	chr22:39101656	GTPBP1	-0.75	-12.13	-0.55	2.74e-28	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23125898	chr21:42539633	BACE2	0.4	5.99	0.31	5.49e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8048589	0.559	rs35542345	chr16:12210618	T/C	cg02910054	chr16:12241554	SNX29	0.47	6.03	0.31	4.33e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg00579200	chr11:133705235	NA	-0.39	-5.97	-0.31	6.21e-9	Childhood ear infection;
LUSC	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs16854884	0.632	rs35629416	chr3:143748424	C/T	cg06585982	chr3:143692056	C3orf58	0.46	7.01	0.36	1.33e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.9	-0.31	9.11e-9	Platelet count;
LUSC	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg22467129	chr15:76604101	ETFA	-0.43	-6.84	-0.35	3.67e-11	Blood metabolite levels;
LUSC	cis	rs13315871	1.000	rs74834816	chr3:58321828	G/A	cg12435725	chr3:58293450	RPP14	-0.72	-7.21	-0.37	3.87e-12	Cholesterol, total;
LUSC	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg24692254	chr21:30365293	RNF160	0.71	11.0	0.52	3.08e-24	Pancreatic cancer;
LUSC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.84	0.39	6.3e-14	Prudent dietary pattern;
LUSC	cis	rs6906287	0.647	rs6936178	chr6:118718242	C/T	cg21191810	chr6:118973309	C6orf204	0.34	6.12	0.32	2.64e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.66	-10.07	-0.48	5.11e-21	Platelet distribution width;
LUSC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.04	0.31	4.11e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4285028	0.747	rs11916169	chr3:121403211	A/G	cg11130432	chr3:121712080	ILDR1	-0.54	-7.83	-0.39	6.54e-14	Multiple sclerosis;
LUSC	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg16482183	chr6:26056742	HIST1H1C	0.65	9.05	0.44	1.21e-17	Iron status biomarkers;
LUSC	cis	rs9309473	0.583	rs35885918	chr2:73612234	T/C	cg20560298	chr2:73613845	ALMS1	-0.59	-8.68	-0.43	1.78e-16	Metabolite levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10836402	chr12:31226622	DDX11	0.42	6.11	0.32	2.73e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.44	5.93	0.31	7.41e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-6.93	-0.35	2.23e-11	Blood metabolite levels;
LUSC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.39	0.49	4.32e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg08917208	chr2:24149416	ATAD2B	0.53	5.97	0.31	6e-9	Lymphocyte counts;
LUSC	cis	rs714027	0.526	rs73164755	chr22:30590015	A/G	cg11564601	chr22:30592435	NA	0.33	5.78	0.3	1.67e-8	Lymphocyte counts;
LUSC	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg23711669	chr6:146136114	FBXO30	0.86	15.52	0.65	2.69e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.78	-0.43	8.75e-17	Coffee consumption (cups per day);
LUSC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg14895029	chr7:2775587	GNA12	0.4	5.92	0.31	7.92e-9	Height;
LUSC	trans	rs2562456	0.752	rs7258562	chr19:21514564	C/T	cg00806126	chr19:22604979	ZNF98	-0.43	-6.16	-0.32	2.07e-9	Pain;
LUSC	trans	rs7680591	1.000	rs1458046	chr4:81199966	C/T	cg14075934	chr2:200137014	SATB2	0.35	6.06	0.31	3.61e-9	Male-pattern baldness;
LUSC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg02153584	chr22:29168773	CCDC117	-0.55	-8.3	-0.41	2.62e-15	Lymphocyte counts;
LUSC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10802521	chr3:52805072	NEK4	0.59	9.9	0.48	1.95e-20	Electroencephalogram traits;
LUSC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg18758796	chr5:131593413	PDLIM4	-0.43	-6.88	-0.35	2.93e-11	Breast cancer;
LUSC	cis	rs9329289	0.510	rs1155447	chr10:2553240	C/T	cg15501526	chr10:2543763	NA	0.53	9.47	0.46	5.12e-19	Age-related hearing impairment;
LUSC	trans	rs73019876	0.869	rs1859093	chr19:22143339	T/G	cg16204205	chr18:19753432	GATA6	0.31	5.94	0.31	7.01e-9	Testicular germ cell tumor;
LUSC	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg15790184	chr11:494944	RNH1	0.42	6.4	0.33	5.37e-10	Systemic lupus erythematosus;
LUSC	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.5	-8.78	-0.43	8.74e-17	Menopause (age at onset);
LUSC	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.28	0.37	2.47e-12	Menarche (age at onset);
LUSC	cis	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg02574844	chr11:5959923	NA	-0.45	-6.36	-0.33	6.66e-10	DNA methylation (variation);
LUSC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg15017067	chr4:17643749	FAM184B	0.35	5.72	0.3	2.41e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg22089800	chr15:90895588	ZNF774	0.64	9.56	0.46	2.68e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg15704280	chr7:45808275	SEPT13	-0.55	-6.31	-0.33	8.92e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-1.11	-16.94	-0.68	6.59e-47	Exhaled nitric oxide output;
LUSC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.67	-0.3	3.04e-8	Life satisfaction;
LUSC	cis	rs11023332	0.617	rs1879888	chr11:14679247	A/G	cg05501817	chr11:14380813	RRAS2	-0.39	-5.92	-0.31	7.96e-9	Adiponectin levels;Vitamin D levels;
LUSC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg26898376	chr11:64110657	CCDC88B	0.35	6.75	0.35	6.45e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg00071950	chr4:10020882	SLC2A9	0.49	8.26	0.41	3.51e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2282032	0.527	rs2282033	chr14:90769635	G/T	cg04374321	chr14:90722782	PSMC1	-0.41	-5.8	-0.3	1.56e-8	Longevity;
LUSC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg06271696	chr7:157225062	NA	-0.43	-8.47	-0.42	8.09e-16	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg18225595	chr11:63971243	STIP1	0.5	6.19	0.32	1.73e-9	Mean platelet volume;
LUSC	cis	rs2286885	1.000	rs10733677	chr9:129242209	A/G	cg15282417	chr9:129245246	FAM125B	0.34	5.79	0.3	1.65e-8	Intraocular pressure;
LUSC	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	0.71	15.48	0.65	4.01e-41	Prudent dietary pattern;
LUSC	cis	rs72772090	0.539	rs55773007	chr5:96124918	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-6.96	-0.36	1.82e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg12863693	chr15:85201151	NMB	0.36	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	trans	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg25482853	chr8:67687455	SGK3	1.11	15.6	0.65	1.35e-41	Obesity-related traits;
LUSC	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg02023728	chr11:77925099	USP35	0.52	7.2	0.37	4.11e-12	Testicular germ cell tumor;
LUSC	cis	rs9322817	0.691	rs2499666	chr6:105318576	A/G	cg02098413	chr6:105308735	HACE1	0.27	5.8	0.3	1.52e-8	Thyroid stimulating hormone;
LUSC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg05425664	chr17:57184151	TRIM37	0.54	8.01	0.4	1.99e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg10360139	chr7:1886902	MAD1L1	-0.45	-6.96	-0.36	1.83e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18876405	chr7:65276391	NA	-0.55	-8.75	-0.43	1.09e-16	Aortic root size;
LUSC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg23985595	chr17:80112537	CCDC57	0.3	5.82	0.3	1.41e-8	Life satisfaction;
LUSC	cis	rs2710642	0.927	rs6705798	chr2:63259881	C/T	cg17519650	chr2:63277830	OTX1	0.49	6.73	0.35	7.25e-11	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg24296786	chr1:45957014	TESK2	-0.49	-7.22	-0.37	3.62e-12	Red blood cell count;Reticulocyte count;
LUSC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg24675658	chr1:53192096	ZYG11B	-0.55	-8.68	-0.43	1.83e-16	Monocyte count;
LUSC	cis	rs6840360	1.000	rs6846114	chr4:152604558	A/G	cg22705602	chr4:152727874	NA	0.32	6.58	0.34	1.85e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Bladder cancer;
LUSC	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg17366294	chr4:99064904	C4orf37	0.6	10.35	0.49	5.73e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.62	0.34	1.41e-10	Menopause (age at onset);
LUSC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg18850127	chr7:39170497	POU6F2	0.59	9.68	0.47	1.07e-19	IgG glycosylation;
LUSC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg25039879	chr17:56429692	SUPT4H1	0.81	11.08	0.52	1.59e-24	Cognitive test performance;
LUSC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg13047869	chr3:10149882	C3orf24	0.65	9.3	0.45	1.96e-18	Alzheimer's disease;
LUSC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.81	13.74	0.6	2.28e-34	Monocyte count;
LUSC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg03790207	chr6:42947109	PEX6	-0.4	-5.93	-0.31	7.39e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.11	-0.36	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11779988	0.545	rs422746	chr8:17784486	C/A	cg01800426	chr8:17659068	MTUS1	-0.5	-6.17	-0.32	1.97e-9	Breast cancer;
LUSC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg18681998	chr4:17616180	MED28	0.92	18.35	0.71	1.66e-52	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9341835	0.772	rs4710254	chr6:64137609	C/T	cg00787780	chr6:64151745	NA	-0.34	-5.78	-0.3	1.72e-8	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg22907277	chr7:1156413	C7orf50	0.66	7.17	0.37	4.73e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs62400317	0.859	rs56337964	chr6:45039786	G/A	cg18551225	chr6:44695536	NA	-0.42	-6.84	-0.35	3.83e-11	Total body bone mineral density;
LUSC	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg00857998	chr1:205179979	DSTYK	0.65	10.19	0.49	2.14e-21	Red blood cell count;
LUSC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs8092503	1.000	rs7243785	chr18:52475162	C/T	cg12377874	chr18:52495404	RAB27B	-0.32	-5.84	-0.3	1.26e-8	Childhood body mass index;
LUSC	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg18833306	chr6:118973337	C6orf204	-0.45	-5.73	-0.3	2.28e-8	Diastolic blood pressure;
LUSC	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg01448562	chr3:133502909	NA	0.47	7.8	0.39	8.01e-14	Iron status biomarkers;
LUSC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg16339924	chr4:17578868	LAP3	0.5	7.52	0.38	5.22e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6722750	0.933	rs1370390	chr2:64410193	G/T	cg22352474	chr2:64371530	PELI1	0.52	7.76	0.39	1.07e-13	Neuroticism;
LUSC	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg13010199	chr12:38710504	ALG10B	0.69	10.56	0.5	1.13e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7241530	0.662	rs12970916	chr18:75901198	A/T	cg14642773	chr18:75888474	NA	-0.4	-6.06	-0.31	3.72e-9	Educational attainment (years of education);
LUSC	cis	rs7084921	0.608	rs12775433	chr10:101834092	C/T	cg02250046	chr10:101825185	CPN1	-0.33	-6.02	-0.31	4.59e-9	Bone mineral density;
LUSC	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg12935359	chr14:103987150	CKB	-0.55	-8.44	-0.42	9.86e-16	Body mass index;
LUSC	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14769373	chr6:40998127	UNC5CL	-0.55	-7.89	-0.4	4.23e-14	Gastric cancer;Non-cardia gastric cancer;
LUSC	trans	rs73019876	0.869	rs7247121	chr19:22161490	T/C	cg16204205	chr18:19753432	GATA6	0.31	5.96	0.31	6.42e-9	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg05340658	chr4:99064831	C4orf37	0.59	8.86	0.44	4.91e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs981844	0.848	rs72731652	chr4:154641123	A/T	cg14289246	chr4:154710475	SFRP2	0.46	5.88	0.31	9.88e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs6120849	0.754	rs7268266	chr20:33581889	T/C	cg24642439	chr20:33292090	TP53INP2	0.62	6.78	0.35	5.58e-11	Protein C levels;
LUSC	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-1.13	-17.69	-0.7	6.9e-50	Exhaled nitric oxide output;
LUSC	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg20203395	chr5:56204925	C5orf35	-0.45	-6.5	-0.34	2.95e-10	Coronary artery disease;
LUSC	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg01557791	chr16:72042693	DHODH	-0.43	-6.53	-0.34	2.42e-10	Fibrinogen levels;
LUSC	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg04362960	chr10:104952993	NT5C2	0.63	9.69	0.47	1.01e-19	Arsenic metabolism;
LUSC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.57	-0.5	1.04e-22	Alzheimer's disease;
LUSC	cis	rs3741151	0.686	rs1002127	chr11:73103835	G/C	cg17517138	chr11:73019481	ARHGEF17	0.9	8.31	0.41	2.42e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs724744	0.742	rs1205935	chr6:22358129	A/G	cg13807341	chr11:118445984	ARCN1	-0.36	-6.07	-0.32	3.43e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs10857712	0.950	rs11101744	chr10:135226041	G/C	cg01444801	chr10:135216882	MTG1	-0.5	-6.54	-0.34	2.27e-10	Systemic lupus erythematosus;
LUSC	cis	rs6754311	0.593	rs2034276	chr2:136422171	A/T	cg07169764	chr2:136633963	MCM6	0.55	7.3	0.37	2.16e-12	Mosquito bite size;
LUSC	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.51	10.18	0.49	2.2e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	1.04	19.54	0.73	3.11e-57	Menopause (age at onset);
LUSC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg18402987	chr7:1209562	NA	0.67	7.08	0.36	8.56e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11165623	0.792	rs6701031	chr1:96975515	C/T	cg10631902	chr5:14652156	NA	-0.43	-6.67	-0.34	1.09e-10	Hip circumference;Waist circumference;
LUSC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12195417	0.758	rs4706996	chr6:84135539	C/T	cg08257003	chr6:84140564	ME1	0.37	9.11	0.45	7.7e-18	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.69	-12.42	-0.56	2.3e-29	Prudent dietary pattern;
LUSC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.6	-5.66	-0.3	3.24e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg17252645	chr8:143867129	LY6D	-0.37	-6.47	-0.33	3.45e-10	Urinary tract infection frequency;
LUSC	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg00677455	chr12:58241039	CTDSP2	0.39	5.88	0.31	9.81e-9	Multiple sclerosis;
LUSC	cis	rs4589502	0.841	rs75991095	chr15:67123224	C/G	cg09911534	chr15:67153556	NA	-0.69	-6.82	-0.35	4.27e-11	Lung cancer (smoking interaction);
LUSC	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg21918786	chr6:109611834	NA	-0.37	-6.24	-0.32	1.32e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-8.01	-0.4	1.87e-14	Dental caries;
LUSC	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.75	10.73	0.51	2.87e-23	Corneal astigmatism;
LUSC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg22166914	chr1:53195759	ZYG11B	-0.67	-11.6	-0.54	2.25e-26	Monocyte count;
LUSC	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg14343924	chr8:8086146	FLJ10661	0.44	6.11	0.32	2.74e-9	Myopia (pathological);
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg00431813	chr7:1051703	C7orf50	-0.37	-5.69	-0.3	2.77e-8	Longevity;Endometriosis;
LUSC	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg11663144	chr21:46675770	NA	-0.34	-6.03	-0.31	4.33e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12891047	0.804	rs17783094	chr14:68282920	G/A	cg20999565	chr14:68265668	ZFYVE26	0.38	5.79	0.3	1.58e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg12615879	chr12:58013172	SLC26A10	-0.29	-5.94	-0.31	7.18e-9	Multiple sclerosis;
LUSC	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-1.12	-19.31	-0.73	2.52e-56	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg27411982	chr8:10470053	RP1L1	0.36	5.82	0.3	1.39e-8	Retinal vascular caliber;
LUSC	cis	rs10276381	0.786	rs740261	chr7:28241276	A/G	cg23620719	chr7:28220237	JAZF1	0.67	6.85	0.35	3.65e-11	Crohn's disease;
LUSC	cis	rs11997175	0.656	rs2350007	chr8:33585353	C/G	ch.8.33884649F	chr8:33765107	NA	0.38	6.01	0.31	4.96e-9	Body mass index;
LUSC	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03281426	chr2:240109471	HDAC4	0.62	11.41	0.53	1.11e-25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg02176678	chr2:219576539	TTLL4	-0.56	-9.81	-0.47	4.09e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs977987	0.806	rs35263058	chr16:75391937	T/C	cg04384234	chr16:75411784	CFDP1	-0.41	-6.63	-0.34	1.36e-10	Dupuytren's disease;
LUSC	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.75	-12.17	-0.55	1.86e-28	Lymphocyte percentage of white cells;
LUSC	cis	rs17095355	1.000	rs17126877	chr10:111672786	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.64	-7.47	-0.38	6.94e-13	Biliary atresia;
LUSC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg04850211	chr1:228464232	OBSCN	-0.33	-6.15	-0.32	2.27e-9	Diastolic blood pressure;
LUSC	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg13609457	chr4:120235615	NA	0.39	5.93	0.31	7.36e-9	Diastolic blood pressure;
LUSC	cis	rs12220238	1.000	rs11000931	chr10:75984800	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.67	-7.61	-0.38	2.81e-13	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg22437258	chr11:111473054	SIK2	0.52	7.05	0.36	1.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs4285028	0.747	rs9824235	chr3:121432177	G/T	cg11130432	chr3:121712080	ILDR1	-0.53	-7.79	-0.39	8.68e-14	Multiple sclerosis;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg15073462	chr3:172469117	NA	0.45	6.13	0.32	2.5e-9	Neuroticism;
LUSC	cis	rs1775715	0.737	rs2778672	chr10:32122419	T/C	cg04359828	chr10:32216031	ARHGAP12	0.4	6.75	0.35	6.56e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6076065	0.630	rs2424559	chr20:23430519	A/G	cg11657817	chr20:23433608	CST11	0.51	10.71	0.51	3.39e-23	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-1.08	-25.56	-0.81	1.33e-80	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg11766577	chr21:47581405	C21orf56	-0.57	-8.71	-0.43	1.48e-16	Testicular germ cell tumor;
LUSC	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg04554929	chr8:105342491	NA	-0.38	-6.72	-0.35	7.73e-11	Paget's disease;
LUSC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19346786	chr7:2764209	NA	-0.4	-6.74	-0.35	6.88e-11	Height;
LUSC	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-7.07	-0.36	9.06e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs2677744	0.626	rs12905855	chr15:91498429	G/C	cg23684204	chr15:91497937	RCCD1	0.56	7.68	0.39	1.8e-13	Attention deficit hyperactivity disorder;
LUSC	cis	rs513349	0.964	rs210141	chr6:33546825	T/C	cg24505687	chr6:33548425	BAK1	0.36	6.04	0.31	4.04e-9	Platelet count;
LUSC	cis	rs870825	0.746	rs1107908	chr4:185620113	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg23625390	chr15:77176239	SCAPER	-0.67	-10.04	-0.48	6.78e-21	Blood metabolite levels;
LUSC	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.59	-0.34	1.67e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.79	11.36	0.53	1.63e-25	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12528394	chr19:59056208	TRIM28	-0.41	-6.25	-0.32	1.27e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.94	-0.68	7.04e-47	Exhaled nitric oxide output;
LUSC	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	8.92	0.44	3.05e-17	Monocyte percentage of white cells;
LUSC	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg15103426	chr22:29168792	CCDC117	0.58	7.86	0.4	5.24e-14	Lymphocyte counts;
LUSC	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg18758796	chr5:131593413	PDLIM4	0.37	6.17	0.32	2.02e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs1609391	0.543	rs6761993	chr3:136625902	C/T	cg15507776	chr3:136538369	TMEM22	0.5	8.25	0.41	3.79e-15	Neuroticism;
LUSC	trans	rs976337	0.872	rs4753661	chr11:95000894	A/G	cg04211581	chr6:152011656	ESR1	0.33	6.16	0.32	2.04e-9	Positive affect;
LUSC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.95	0.55	1.17e-27	Prudent dietary pattern;
LUSC	trans	rs6725041	0.805	rs6745249	chr2:213130571	A/G	cg14884256	chr3:50374861	RASSF1	-0.39	-5.99	-0.31	5.44e-9	QT interval (ambient particulate matter interaction);
LUSC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg02475777	chr4:1388615	CRIPAK	0.45	6.69	0.34	9.62e-11	Obesity-related traits;
LUSC	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	1.04	14.11	0.61	9.12e-36	Exhaled nitric oxide levels;
LUSC	cis	rs62400317	0.731	rs72867436	chr6:44975488	T/G	cg20913747	chr6:44695427	NA	-0.46	-7.23	-0.37	3.41e-12	Total body bone mineral density;
LUSC	cis	rs1322512	0.874	rs2758804	chr6:152956289	T/A	cg27316956	chr6:152958899	SYNE1	-0.37	-6.22	-0.32	1.49e-9	Tonometry;
LUSC	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.83	-0.39	6.5e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10802521	chr3:52805072	NEK4	-0.57	-9.3	-0.45	1.87e-18	Electroencephalogram traits;
LUSC	cis	rs6489882	0.867	rs2384073	chr12:113367595	A/G	cg20102336	chr12:113376681	OAS3	-0.4	-5.74	-0.3	2.17e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	0.95	17.72	0.7	5.52e-50	Heart rate;
LUSC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg27170947	chr2:26402098	FAM59B	-0.64	-9.5	-0.46	4.26e-19	Gut microbiome composition (summer);
LUSC	cis	rs16976116	0.951	rs8043029	chr15:55486011	C/G	cg11288833	chr15:55489084	RSL24D1	0.54	6.55	0.34	2.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2742417	1.000	rs2673025	chr3:45760483	A/G	cg18779283	chr3:45636154	LIMD1	-0.33	-5.76	-0.3	1.91e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg24692254	chr21:30365293	RNF160	0.73	11.33	0.53	2.05e-25	Pancreatic cancer;
LUSC	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg07148914	chr20:33460835	GGT7	0.55	8.35	0.42	1.79e-15	Height;
LUSC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg20684491	chr1:25596433	NA	0.4	6.28	0.32	1.07e-9	Plateletcrit;Mean corpuscular volume;
LUSC	trans	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg18187862	chr3:45730750	SACM1L	0.52	6.82	0.35	4.21e-11	Primary sclerosing cholangitis;
LUSC	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg04036182	chr15:45458818	NA	0.35	5.79	0.3	1.63e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg05025164	chr4:1340916	KIAA1530	0.41	6.19	0.32	1.71e-9	Obesity-related traits;
LUSC	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-1.01	-14.4	-0.62	6.44e-37	Exhaled nitric oxide output;
LUSC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg03354898	chr7:1950403	MAD1L1	-0.3	-5.68	-0.3	2.97e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.43	-6.42	-0.33	4.6e-10	Tonsillectomy;
LUSC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg06618935	chr21:46677482	NA	0.35	6.97	0.36	1.69e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	1.13	19.75	0.73	4.68e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg26384229	chr12:38710491	ALG10B	0.67	10.61	0.5	7.65e-23	Morning vs. evening chronotype;
LUSC	cis	rs4713675	0.584	rs749847	chr6:33665001	G/C	cg14003231	chr6:33640908	ITPR3	0.31	6.03	0.31	4.31e-9	Plateletcrit;
LUSC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24110177	chr3:50126178	RBM5	0.56	9.25	0.45	2.66e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-17.8	-0.7	2.49e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4073416	0.542	rs2898814	chr14:66023961	T/C	cg03016385	chr14:66212404	NA	-0.38	-5.7	-0.3	2.59e-8	N-glycan levels;
LUSC	cis	rs1775715	0.835	rs11008701	chr10:32241096	A/G	cg04359828	chr10:32216031	ARHGAP12	0.38	6.4	0.33	5.38e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1979679	0.573	rs7315906	chr12:28728545	A/C	cg13890972	chr12:28721907	NA	-0.4	-5.85	-0.3	1.16e-8	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs4474465	0.646	rs7936011	chr11:78275931	G/T	cg27205649	chr11:78285834	NARS2	0.55	6.78	0.35	5.41e-11	Alzheimer's disease (survival time);
LUSC	cis	rs4862307	0.688	rs6552743	chr4:184990516	C/G	cg06737308	chr4:185021514	ENPP6	0.43	6.46	0.33	3.66e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUSC	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg14530993	chr4:882597	GAK	0.73	7.42	0.38	9.98e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg08680598	chr22:49984980	NA	-0.34	-6.36	-0.33	6.69e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg01557791	chr16:72042693	DHODH	0.62	9.77	0.47	5.35e-20	Prostate cancer;
LUSC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg08888203	chr3:10149979	C3orf24	0.67	9.61	0.47	1.8e-19	Alzheimer's disease;
LUSC	cis	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg21775007	chr8:11205619	TDH	0.44	5.79	0.3	1.62e-8	Neuroticism;
LUSC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.57	-9.32	-0.45	1.58e-18	IgG glycosylation;
LUSC	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg04455712	chr21:45112962	RRP1B	-0.41	-7.19	-0.37	4.2e-12	Mean corpuscular volume;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14331148	chr19:47551893	TMEM160	-0.42	-7.14	-0.36	5.78e-12	Electrocardiographic conduction measures;
LUSC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg06917634	chr15:78832804	PSMA4	-0.49	-6.51	-0.34	2.74e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2298450	0.717	rs2835328	chr21:37622915	A/C	cg02919814	chr21:37666008	DOPEY2	-0.48	-6.63	-0.34	1.32e-10	Schizophrenia;
LUSC	cis	rs9311676	0.656	rs11712213	chr3:58384995	G/A	cg26110898	chr3:58419937	PDHB	0.4	6.49	0.33	3.05e-10	Systemic lupus erythematosus;
LUSC	cis	rs3781663	0.553	rs875108	chr11:70004695	G/A	cg06393558	chr11:69982916	ANO1	-0.41	-6.1	-0.32	2.9e-9	Survival in rectal cancer;
LUSC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.58	-10.46	-0.5	2.46e-22	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg13010199	chr12:38710504	ALG10B	0.66	10.18	0.49	2.16e-21	Bladder cancer;
LUSC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg09509183	chr1:209979624	IRF6	0.52	6.21	0.32	1.61e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg01657329	chr11:68192670	LRP5	0.5	7.5	0.38	5.88e-13	Bone mineral density (spine);
LUSC	trans	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-6.8	-0.35	4.8e-11	Monocyte count;
LUSC	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg06917634	chr15:78832804	PSMA4	0.51	6.49	0.33	3.03e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.69	8.93	0.44	2.94e-17	Huntington's disease progression;
LUSC	cis	rs2677744	0.626	rs12915155	chr15:91490894	G/T	cg23684204	chr15:91497937	RCCD1	0.53	7.37	0.37	1.32e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg21770322	chr7:97807741	LMTK2	0.4	7.03	0.36	1.14e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07741184	chr6:167504864	NA	0.39	6.9	0.35	2.56e-11	Crohn's disease;
LUSC	cis	rs4478858	0.684	rs7549245	chr1:31752187	A/G	cg00250761	chr1:31883323	NA	-0.33	-7.95	-0.4	2.9e-14	Alcohol dependence;
LUSC	cis	rs9653442	0.527	rs11123812	chr2:100761548	T/C	cg07810366	chr2:100720526	AFF3	-0.45	-7.75	-0.39	1.13e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg08017756	chr2:100939284	LONRF2	-0.41	-7.56	-0.38	3.89e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg07741184	chr6:167504864	NA	0.43	7.69	0.39	1.68e-13	Crohn's disease;
LUSC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.23	14.12	0.61	8.1e-36	Diabetic kidney disease;
LUSC	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	0.85	13.38	0.59	5.28e-33	Blood protein levels;
LUSC	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg13010199	chr12:38710504	ALG10B	-0.6	-9.33	-0.45	1.56e-18	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.46	-6.64	-0.34	1.27e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7107174	0.901	rs10899500	chr11:78125246	A/G	cg02023728	chr11:77925099	USP35	0.48	6.76	0.35	6.29e-11	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg04369109	chr6:150039330	LATS1	-0.57	-8.49	-0.42	6.66e-16	Lung cancer;
LUSC	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg12667521	chr19:29218732	NA	-0.56	-6.86	-0.35	3.39e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-7.27	-0.37	2.64e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12016809	chr21:47604291	C21orf56	0.43	6.45	0.33	4.02e-10	Testicular germ cell tumor;
LUSC	cis	rs981844	0.712	rs4525952	chr4:154746606	G/T	cg14289246	chr4:154710475	SFRP2	0.47	6.02	0.31	4.58e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg14036092	chr11:66035641	RAB1B	0.44	6.34	0.33	7.65e-10	Gout;
LUSC	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg13334819	chr7:99746414	C7orf59	0.52	6.96	0.36	1.76e-11	Coronary artery disease;
LUSC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg16362232	chr11:430036	ANO9	-0.61	-8.0	-0.4	2.02e-14	Body mass index;
LUSC	trans	rs1256061	0.874	rs7146434	chr14:64726503	A/G	cg07874507	chr10:24503148	KIAA1217	0.36	6.21	0.32	1.59e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg03929089	chr4:120376271	NA	-0.55	-6.64	-0.34	1.28e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg12863693	chr15:85201151	NMB	0.39	8.05	0.4	1.49e-14	Schizophrenia;
LUSC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	8.61	0.43	2.91e-16	Height;
LUSC	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg08079166	chr15:68083412	MAP2K5	0.36	6.2	0.32	1.7e-9	Obesity;
LUSC	cis	rs11587400	0.572	rs2268697	chr1:115227493	A/G	cg12756093	chr1:115239321	AMPD1	0.46	7.1	0.36	7.33e-12	Autism;
LUSC	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg00792783	chr2:198669748	PLCL1	0.41	5.68	0.3	2.89e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	0.99	21.45	0.76	9e-65	Migraine;
LUSC	cis	rs7804356	0.954	rs10225924	chr7:26839954	C/T	cg03456212	chr7:26904342	SKAP2	-0.55	-6.47	-0.33	3.54e-10	Type 1 diabetes;
LUSC	cis	rs2629540	0.765	rs7097254	chr10:126512248	A/C	cg08799069	chr10:126477246	METTL10	-0.56	-8.73	-0.43	1.23e-16	Cocaine dependence;
LUSC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg07701084	chr6:150067640	NUP43	0.52	7.42	0.38	9.6e-13	Lung cancer;
LUSC	cis	rs4493873	0.731	rs34213675	chr8:92043378	C/T	cg16814680	chr8:91681699	NA	0.42	5.79	0.3	1.58e-8	Migraine - clinic-based;
LUSC	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg00495681	chr13:53174319	NA	-0.5	-7.74	-0.39	1.2e-13	Lewy body disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19617932	chr12:1703704	FBXL14	-0.45	-6.78	-0.35	5.46e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs34638657	0.529	rs2059276	chr16:82223123	A/T	cg09439754	chr16:82129088	HSD17B2	-0.33	-5.95	-0.31	6.96e-9	Lung adenocarcinoma;
LUSC	cis	rs12474201	0.925	rs17822294	chr2:46960004	G/A	cg06386533	chr2:46925753	SOCS5	0.73	10.89	0.51	8e-24	Height;
LUSC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.18	0.88	4.53e-111	Chronic sinus infection;
LUSC	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg01733217	chr16:74700730	RFWD3	1.0	22.88	0.78	2.26e-70	Multiple myeloma;
LUSC	cis	rs96067	0.772	rs6664471	chr1:36606757	A/G	cg24686825	chr1:36642396	MAP7D1	-0.49	-6.63	-0.34	1.35e-10	Corneal structure;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.66	10.84	0.51	1.19e-23	Lymphocyte counts;
LUSC	trans	rs7939886	0.844	rs17150088	chr11:55894862	T/G	cg03929089	chr4:120376271	NA	0.74	6.11	0.32	2.7e-9	Myopia (pathological);
LUSC	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg00898013	chr13:113819073	PROZ	-0.59	-8.47	-0.42	7.84e-16	Platelet distribution width;
LUSC	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	10.78	0.51	1.92e-23	Response to antipsychotic treatment;
LUSC	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg06223162	chr1:101003688	GPR88	-0.48	-9.03	-0.44	1.4e-17	Monocyte count;
LUSC	trans	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.98	-0.36	1.63e-11	Subjective well-being;
LUSC	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg05714579	chr10:131428358	MGMT	0.53	7.87	0.4	5.09e-14	Response to temozolomide;
LUSC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.83	11.19	0.52	6.51e-25	Schizophrenia;
LUSC	cis	rs9815354	0.723	rs77572508	chr3:41938044	C/A	cg03022575	chr3:42003672	ULK4	0.83	8.64	0.43	2.32e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg13660082	chr14:53194042	PSMC6	-0.76	-6.76	-0.35	6.03e-11	Alzheimer's disease (late onset);
LUSC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg11663144	chr21:46675770	NA	-0.41	-7.08	-0.36	8.51e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg15704280	chr7:45808275	SEPT13	-0.46	-6.37	-0.33	6.38e-10	Height;
LUSC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg06637938	chr14:75390232	RPS6KL1	0.53	8.42	0.42	1.11e-15	Height;
LUSC	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05731713	chr7:157510257	PTPRN2	0.46	8.99	0.44	1.81e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs12410462	0.581	rs12402691	chr1:227543693	G/A	cg23173402	chr1:227635558	NA	0.56	6.4	0.33	5.15e-10	Major depressive disorder;
LUSC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg13114125	chr14:105738426	BRF1	-0.93	-16.39	-0.67	1.07e-44	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg04374321	chr14:90722782	PSMC1	-0.42	-6.39	-0.33	5.65e-10	Mortality in heart failure;
LUSC	cis	rs13089785	1.000	rs13081955	chr3:123600144	A/G	cg19611163	chr3:123411211	MYLK	0.35	5.86	0.31	1.11e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg17385448	chr1:15911702	AGMAT	0.37	5.81	0.3	1.45e-8	Systolic blood pressure;
LUSC	cis	rs4499344	0.526	rs8111902	chr19:33032243	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.8	-10.68	-0.5	4.31e-23	Mean platelet volume;
LUSC	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg09835421	chr16:68378352	PRMT7	-0.82	-8.7	-0.43	1.52e-16	Schizophrenia;
LUSC	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.71	6.86	0.35	3.34e-11	Initial pursuit acceleration;
LUSC	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg06092702	chr1:163392909	NA	-0.42	-7.16	-0.36	5.1e-12	Motion sickness;
LUSC	trans	rs11165623	0.564	rs6593611	chr1:97001996	T/C	cg10631902	chr5:14652156	NA	-0.42	-6.22	-0.32	1.52e-9	Hip circumference;Waist circumference;
LUSC	cis	rs360798	0.532	rs7573756	chr2:62990637	G/A	cg17519650	chr2:63277830	OTX1	-0.52	-7.22	-0.37	3.63e-12	Coronary artery disease;
LUSC	cis	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.55	-0.38	4.09e-13	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.16	-0.41	7e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg16850897	chr7:100343110	ZAN	-0.56	-7.93	-0.4	3.36e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06544989	chr22:39130855	UNC84B	0.33	5.87	0.31	1.06e-8	Menopause (age at onset);
LUSC	cis	rs9399401	0.710	rs12190271	chr6:142681409	A/G	cg04461802	chr6:142623433	GPR126	-0.44	-5.74	-0.3	2.15e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs5770917	1.000	rs2073604	chr22:51008925	G/A	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.62	-5.74	-0.3	2.15e-8	Narcolepsy;
LUSC	cis	rs9534288	0.830	rs1409435	chr13:46631660	G/A	cg15192986	chr13:46630673	CPB2	-0.8	-12.69	-0.57	2.14e-30	Blood protein levels;
LUSC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg12463550	chr7:65579703	CRCP	0.43	6.22	0.32	1.51e-9	Aortic root size;
LUSC	cis	rs1595825	0.735	rs2228135	chr2:198950029	A/G	cg00982548	chr2:198649783	BOLL	-0.54	-6.58	-0.34	1.86e-10	Ulcerative colitis;
LUSC	cis	rs6066835	0.850	rs3827042	chr20:47319307	G/A	cg18078177	chr20:47281410	PREX1	0.71	5.96	0.31	6.29e-9	Multiple myeloma;
LUSC	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-8.96	-0.44	2.27e-17	Retinal vascular caliber;
LUSC	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg26566898	chr11:117069891	TAGLN	0.33	6.39	0.33	5.73e-10	Blood protein levels;
LUSC	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg03465714	chr1:152285911	FLG	0.42	5.72	0.3	2.42e-8	Atopic dermatitis;
LUSC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	16.38	0.67	1.1e-44	Platelet count;
LUSC	cis	rs4926611	0.729	rs17382457	chr1:54071428	A/G	cg08927728	chr1:54059983	GLIS1	-0.27	-5.75	-0.3	1.98e-8	Hand grip strength;
LUSC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.96	-20.98	-0.75	5.98e-63	Prudent dietary pattern;
LUSC	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-7.97	-0.4	2.48e-14	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06481639	chr22:41940642	POLR3H	0.49	5.81	0.3	1.48e-8	Vitiligo;
LUSC	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg20503657	chr10:835505	NA	0.85	12.05	0.55	5.19e-28	Eosinophil percentage of granulocytes;
LUSC	trans	rs6725041	0.805	rs6745249	chr2:213130571	A/G	cg14015726	chr22:40807049	MKL1	0.38	6.09	0.32	3.1e-9	QT interval (ambient particulate matter interaction);
LUSC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-19.9	-0.74	1.14e-58	Coronary artery disease;
LUSC	cis	rs262150	0.625	rs55882200	chr7:158769280	G/C	cg19418458	chr7:158789849	NA	0.57	7.01	0.36	1.32e-11	Facial morphology (factor 20);
LUSC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg16647868	chr5:131706066	SLC22A5	-0.38	-5.7	-0.3	2.64e-8	Breast cancer;
LUSC	cis	rs983392	0.679	rs6591559	chr11:60025565	C/T	cg24026212	chr11:59952134	MS4A6A	-0.37	-6.37	-0.33	6.38e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg18681998	chr4:17616180	MED28	0.84	14.53	0.62	2.14e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg26769984	chr7:1090371	C7orf50	0.56	7.34	0.37	1.67e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg17340268	chr14:105411764	AHNAK2	-0.39	-6.3	-0.33	9.59e-10	Rheumatoid arthritis;
LUSC	cis	rs2692947	0.644	rs1168970	chr2:96816606	C/T	cg22654517	chr2:96458247	NA	0.32	5.82	0.3	1.4e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg06454157	chr6:167490870	NA	-0.28	-6.37	-0.33	6.26e-10	Primary biliary cholangitis;
LUSC	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg03522245	chr20:25566470	NINL	0.35	5.66	0.3	3.26e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg06618935	chr21:46677482	NA	-0.39	-7.99	-0.4	2.22e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10761482	0.668	rs1002710	chr10:62122120	C/T	cg18175470	chr10:62150864	ANK3	-0.41	-6.19	-0.32	1.75e-9	Schizophrenia;
LUSC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs983392	0.679	rs1026254	chr11:60030457	A/G	cg02771260	chr11:59836817	MS4A3	0.38	6.24	0.32	1.3e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7107174	1.000	rs4492844	chr11:78026516	A/G	cg02023728	chr11:77925099	USP35	0.47	6.73	0.35	7.32e-11	Testicular germ cell tumor;
LUSC	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg15839431	chr19:19639596	YJEFN3	-0.6	-6.9	-0.35	2.58e-11	Bipolar disorder;
LUSC	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg05457628	chr5:178986728	RUFY1	0.57	9.77	0.47	5.57e-20	Lung cancer;
LUSC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.26	-0.41	3.56e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg17264618	chr3:40429014	ENTPD3	0.29	6.07	0.32	3.46e-9	Renal cell carcinoma;
LUSC	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg00334542	chr7:100209784	MOSPD3	-0.48	-5.75	-0.3	2.05e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19717773	chr7:2847554	GNA12	-0.4	-6.39	-0.33	5.47e-10	Height;
LUSC	cis	rs68170813	0.559	rs114221457	chr7:107019913	C/G	cg02696742	chr7:106810147	HBP1	-0.64	-9.4	-0.46	8.95e-19	Coronary artery disease;
LUSC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.49	-8.92	-0.44	3.11e-17	Urinary metabolites;
LUSC	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg27432699	chr2:27873401	GPN1	-0.83	-15.97	-0.66	4.84e-43	Oral cavity cancer;
LUSC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg05347473	chr6:146136440	FBXO30	0.57	9.79	0.47	4.77e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs193541	0.642	rs42538	chr5:122292352	A/T	cg19077854	chr5:122220652	SNX24	0.39	8.38	0.42	1.48e-15	Glucose homeostasis traits;
LUSC	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.74	11.25	0.52	4.02e-25	Eosinophil percentage of white cells;
LUSC	cis	rs36093844	0.800	rs78356210	chr11:85581267	G/A	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs4499344	0.730	rs614361	chr19:33106387	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	12.93	0.58	2.86e-31	Mean platelet volume;
LUSC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-8.86	-0.44	4.84e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg05234568	chr11:5960015	NA	0.6	9.77	0.47	5.44e-20	DNA methylation (variation);
LUSC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg21724239	chr8:58056113	NA	0.55	6.55	0.34	2.17e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.55	9.02	0.44	1.54e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg22777020	chr22:31556080	RNF185	-0.44	-5.66	-0.3	3.24e-8	Colorectal cancer;
LUSC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg14004847	chr7:1930337	MAD1L1	0.54	8.02	0.4	1.75e-14	Bipolar disorder and schizophrenia;
LUSC	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg22491629	chr6:157744540	C6orf35	-0.9	-10.83	-0.51	1.29e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.63	-0.39	2.42e-13	Type 2 diabetes;
LUSC	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg17385448	chr1:15911702	AGMAT	0.37	6.32	0.33	8.16e-10	Systolic blood pressure;
LUSC	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg04317338	chr11:64019027	PLCB3	0.57	5.81	0.3	1.48e-8	Mean platelet volume;
LUSC	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14019695	chr9:139328340	INPP5E	0.5	9.54	0.46	3.01e-19	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg01097406	chr16:89675127	NA	0.34	6.75	0.35	6.49e-11	Vitiligo;
LUSC	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg24296786	chr1:45957014	TESK2	-0.47	-6.76	-0.35	6.33e-11	High light scatter reticulocyte count;
LUSC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg18512352	chr11:47633146	NA	-0.48	-9.69	-0.47	9.85e-20	Subjective well-being;
LUSC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg27535305	chr1:53392650	SCP2	0.37	6.78	0.35	5.46e-11	Monocyte count;
LUSC	cis	rs714027	0.605	rs2412976	chr22:30567907	C/G	cg11564601	chr22:30592435	NA	0.32	5.68	0.3	2.99e-8	Lymphocyte counts;
LUSC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.23	0.45	3.24e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1405069	0.809	rs1046279	chr6:36932571	C/T	cg26433444	chr6:36932349	PI16	-0.3	-7.3	-0.37	2.09e-12	Chemerin levels;
LUSC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg16393715	chr7:1948819	MAD1L1	0.34	5.88	0.31	9.8e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.54	6.82	0.35	4.22e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-6.17	-0.32	2.01e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg21643547	chr1:205240462	TMCC2	-0.41	-7.6	-0.38	2.93e-13	Red blood cell count;
LUSC	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.55	-15.01	-0.63	2.84e-39	Urate levels in overweight individuals;
LUSC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg00684032	chr4:1343700	KIAA1530	-0.36	-6.21	-0.32	1.56e-9	Obesity-related traits;
LUSC	cis	rs11779988	0.545	rs404186	chr8:17795496	A/G	cg01800426	chr8:17659068	MTUS1	-0.49	-5.92	-0.31	7.82e-9	Breast cancer;
LUSC	cis	rs2806561	0.754	rs10917344	chr1:23342193	C/G	cg19743168	chr1:23544995	NA	-0.4	-8.26	-0.41	3.43e-15	Height;
LUSC	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg02073558	chr3:44770973	ZNF501	0.6	9.94	0.48	1.48e-20	Depressive symptoms;
LUSC	cis	rs6728642	0.572	rs7574488	chr2:97599618	T/C	cg26665480	chr2:98280029	ACTR1B	-0.75	-7.48	-0.38	6.53e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs2764208	0.599	rs9368828	chr6:34661449	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.35	6.28	0.32	1.05e-9	Systemic lupus erythematosus;
LUSC	trans	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg09060275	chr22:27053596	MIAT	-0.4	-6.03	-0.31	4.45e-9	Height;
LUSC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg05234568	chr11:5960015	NA	-0.54	-8.24	-0.41	4.05e-15	DNA methylation (variation);
LUSC	cis	rs7927771	0.524	rs7101597	chr11:47797917	A/T	cg20307385	chr11:47447363	PSMC3	0.44	6.47	0.33	3.54e-10	Subjective well-being;
LUSC	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.56	7.61	0.38	2.74e-13	Response to antipsychotic treatment;
LUSC	cis	rs6961069	0.585	rs6972923	chr7:80239318	G/C	cg04458919	chr7:80252533	CD36	-0.4	-7.32	-0.37	1.91e-12	Platelet count;
LUSC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.61	-8.04	-0.4	1.57e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.53	-7.09	-0.36	8.11e-12	Neutrophil percentage of white cells;
LUSC	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg21951975	chr1:209979733	IRF6	0.58	7.59	0.38	3.32e-13	Cleft lip with or without cleft palate;
LUSC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg12403142	chr1:92012408	NA	-0.42	-6.94	-0.35	2.05e-11	Breast cancer;
LUSC	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg24006582	chr15:45444508	DUOX1	-0.6	-8.7	-0.43	1.5e-16	Uric acid levels;
LUSC	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg09835421	chr16:68378352	PRMT7	-0.49	-6.02	-0.31	4.49e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4409675	0.527	rs1884469	chr1:28239434	G/A	cg23691781	chr1:28212827	C1orf38	0.33	8.01	0.4	1.99e-14	Corneal astigmatism;
LUSC	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg17075019	chr10:79541650	NA	-0.76	-12.19	-0.55	1.55e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7712401	0.623	rs426877	chr5:122314635	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.57	-0.46	2.46e-19	Mean platelet volume;
LUSC	cis	rs2479724	0.598	rs4415146	chr6:41941980	G/T	cg17623882	chr6:41773611	USP49	0.46	7.56	0.38	3.97e-13	Menarche (age at onset);
LUSC	trans	rs2715157	1.000	rs2715148	chr7:82450035	A/C	cg09060496	chr12:54674110	HNRNPA1;HNRPA1L-2;CBX5	0.37	6.0	0.31	5.12e-9	Major depressive disorder;
LUSC	cis	rs11690935	0.632	rs9789538	chr2:172618474	G/C	cg13550731	chr2:172543902	DYNC1I2	0.58	8.95	0.44	2.5e-17	Schizophrenia;
LUSC	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.35e-33	Morning vs. evening chronotype;
LUSC	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.49	-0.33	3.16e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26314531	chr2:26401878	FAM59B	0.71	8.93	0.44	2.92e-17	Gut microbiome composition (summer);
LUSC	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-9.4	-0.46	8.9e-19	Chronic sinus infection;
LUSC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg06238570	chr21:40685208	BRWD1	-0.63	-10.77	-0.51	2.09e-23	Cognitive function;
LUSC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.19	21.84	0.77	2.62e-66	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.69	-0.3	2.74e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	6.91	0.35	2.39e-11	Bipolar disorder;
LUSC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.92	-0.31	7.84e-9	Platelet count;
LUSC	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-7.33	-0.37	1.75e-12	Testicular germ cell tumor;
LUSC	cis	rs1983170	0.808	rs12080863	chr1:92018721	T/C	cg25838465	chr1:92012736	NA	0.42	5.86	0.31	1.09e-8	Eosinophil percentage of white cells;
LUSC	cis	rs2963155	0.590	rs258757	chr5:142620736	A/G	cg17617527	chr5:142782415	NR3C1	-0.59	-6.75	-0.35	6.47e-11	Breast cancer;
LUSC	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg03733263	chr8:22462867	KIAA1967	0.84	14.44	0.62	4.79e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-6.51	-0.34	2.82e-10	Colorectal cancer;
LUSC	cis	rs6700896	0.931	rs2154382	chr1:66131681	C/T	cg04111102	chr1:66153794	NA	0.33	7.26	0.37	2.81e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg13010199	chr12:38710504	ALG10B	0.54	7.46	0.38	7.77e-13	Resting heart rate;
LUSC	cis	rs7577696	0.785	rs6723154	chr2:32365161	C/T	cg02381751	chr2:32503542	YIPF4	-0.42	-6.04	-0.31	4.1e-9	Inflammatory biomarkers;
LUSC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-6.32	-0.33	8.33e-10	Tonsillectomy;
LUSC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.78	0.35	5.6e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg10792982	chr14:105748885	BRF1	0.49	8.81	0.43	6.97e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg14829360	chr17:73884958	NA	-0.35	-5.78	-0.3	1.73e-8	White matter hyperintensity burden;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03341697	chr11:94277138	FUT4	0.42	6.06	0.31	3.72e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.75	13.73	0.6	2.5e-34	Calcium levels;
LUSC	cis	rs71636778	0.543	rs75305560	chr1:27242521	T/G	cg12203394	chr1:27248618	NUDC	0.53	5.65	0.3	3.47e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg23985595	chr17:80112537	CCDC57	0.34	6.44	0.33	4.21e-10	Life satisfaction;
LUSC	cis	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg26958806	chr6:27640298	NA	0.83	6.57	0.34	1.94e-10	Depression;
LUSC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg12016809	chr21:47604291	C21orf56	0.46	7.08	0.36	8.7e-12	Testicular germ cell tumor;
LUSC	cis	rs10979	0.597	rs9496687	chr6:143908815	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-7.38	-0.37	1.23e-12	Hypospadias;
LUSC	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg09915433	chr19:53449742	NA	-0.57	-9.22	-0.45	3.49e-18	Psoriasis;
LUSC	cis	rs2073300	1.000	rs6114141	chr20:23460620	T/G	cg09953122	chr20:23471693	CST8	-0.76	-7.5	-0.38	5.87e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg00484396	chr16:3507460	NAT15	0.86	11.33	0.53	2.21e-25	Tuberculosis;
LUSC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.69	0.47	9.83e-20	Bipolar disorder;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg17091998	chr17:7531155	SHBG;SAT2	0.47	5.95	0.31	6.91e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg05163923	chr11:71159392	DHCR7	-0.76	-9.87	-0.48	2.56e-20	Vitamin D levels;
LUSC	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg15556689	chr8:8085844	FLJ10661	0.56	8.91	0.44	3.28e-17	Joint mobility (Beighton score);
LUSC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	10.0	0.48	8.76e-21	Coronary artery disease;
LUSC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg21361702	chr7:150065534	REPIN1	-0.5	-6.43	-0.33	4.41e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg04844267	chr4:1394941	NA	0.32	6.4	0.33	5.29e-10	Obesity-related traits;
LUSC	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	6.52	0.34	2.67e-10	Height;
LUSC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.52	0.57	9.28e-30	Motion sickness;
LUSC	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.93	15.74	0.65	3.8e-42	Bladder cancer;
LUSC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg12935359	chr14:103987150	CKB	-0.53	-8.29	-0.41	2.76e-15	Body mass index;
LUSC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg18240062	chr17:79603768	NPLOC4	0.7	13.06	0.58	8.67e-32	Eye color traits;
LUSC	cis	rs897984	0.520	rs4889536	chr16:30871755	G/T	cg02466173	chr16:30829666	NA	0.55	9.23	0.45	3.17e-18	Dementia with Lewy bodies;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26090534	chr13:111314603	CARS2	-0.79	-6.19	-0.32	1.75e-9	Cognitive performance;
LUSC	cis	rs1775715	0.870	rs7912121	chr10:32228995	T/G	cg03015672	chr10:32216066	ARHGAP12	0.32	5.81	0.3	1.43e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg08308459	chr2:38893161	GALM	-0.57	-5.66	-0.3	3.25e-8	5-HTT brain serotonin transporter levels;
LUSC	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg12927641	chr6:109611667	NA	-0.36	-6.27	-0.32	1.09e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg21972741	chr5:435613	AHRR	0.36	6.8	0.35	4.8e-11	Cystic fibrosis severity;
LUSC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg21724239	chr8:58056113	NA	0.66	7.4	0.38	1.14e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1904096	0.506	rs10024642	chr4:95179295	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.19	-0.41	5.43e-15	Type 2 diabetes;
LUSC	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.78	-12.71	-0.57	1.84e-30	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1961456	0.542	rs10095159	chr8:18244684	G/A	cg18736775	chr8:18248649	NAT2	-0.55	-6.57	-0.34	1.88e-10	Total cholesterol levels;
LUSC	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg03806693	chr22:41940476	POLR3H	-0.55	-7.51	-0.38	5.5e-13	Neuroticism;
LUSC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.48e-28	Motion sickness;
LUSC	cis	rs4704187	0.687	rs10051040	chr5:74501976	G/C	cg03227963	chr5:74354835	NA	0.31	6.76	0.35	6.31e-11	Response to amphetamines;
LUSC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg07936489	chr17:37558343	FBXL20	-0.71	-9.8	-0.47	4.38e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg27535305	chr1:53392650	SCP2	-0.5	-9.81	-0.47	4.08e-20	Monocyte count;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg15242686	chr22:24348715	GSTTP1	0.43	6.39	0.33	5.53e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg02807482	chr3:125708958	NA	-0.52	-6.91	-0.35	2.4e-11	Blood pressure (smoking interaction);
LUSC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11645453	chr3:52864694	ITIH4	-0.34	-7.96	-0.4	2.64e-14	Bipolar disorder;
LUSC	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-7.36	-0.37	1.4e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg06454157	chr6:167490870	NA	-0.26	-6.19	-0.32	1.75e-9	Crohn's disease;
LUSC	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.89	9.8	0.47	4.13e-20	Body mass index;
LUSC	cis	rs1784581	0.851	rs1784591	chr6:162388893	C/G	cg17173639	chr6:162384350	PARK2	-0.84	-16.11	-0.66	1.27e-43	Itch intensity from mosquito bite;
LUSC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	0.92	15.94	0.66	5.93e-43	Menopause (age at onset);
LUSC	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg25019033	chr10:957182	NA	-0.48	-5.92	-0.31	7.79e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg01017244	chr2:74357527	NA	0.56	8.91	0.44	3.25e-17	Gestational age at birth (maternal effect);
LUSC	cis	rs400736	0.602	rs4601608	chr1:8168808	A/G	cg25007680	chr1:8021821	PARK7	-0.44	-6.57	-0.34	1.96e-10	Response to antidepressants and depression;
LUSC	trans	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg26043149	chr18:55253948	FECH	0.52	7.74	0.39	1.16e-13	Bone mineral density;
LUSC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.08	-0.36	8.62e-12	Blood metabolite levels;
LUSC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.7	-0.3	2.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg12667521	chr19:29218732	NA	0.51	5.91	0.31	8.28e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.46	-0.33	3.77e-10	Daytime sleep phenotypes;
LUSC	cis	rs6580649	0.941	rs60681522	chr12:48464195	T/C	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg10792982	chr14:105748885	BRF1	0.5	9.08	0.45	9.35e-18	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs11229555	0.645	rs61905183	chr11:58228463	T/A	cg15696309	chr11:58395628	NA	-0.68	-8.26	-0.41	3.34e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.28	-20.57	-0.75	2.54e-61	Type 1 diabetes nephropathy;
LUSC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg27124370	chr19:33622961	WDR88	0.56	7.83	0.39	6.54e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg04310649	chr10:35416472	CREM	-0.41	-6.48	-0.33	3.22e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg11406453	chr1:101602562	NA	0.41	7.06	0.36	9.53e-12	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs4971059	0.507	rs11264321	chr1:155085898	C/A	cg23973274	chr1:155060172	NA	-0.29	-5.72	-0.3	2.38e-8	Breast cancer;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	1.01	22.85	0.78	3.1e-70	Menarche (age at onset);
LUSC	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-0.93	-17.6	-0.69	1.57e-49	Headache;
LUSC	cis	rs6920965	0.527	rs7763515	chr6:126174714	C/G	cg05901451	chr6:126070800	HEY2	-0.39	-5.65	-0.3	3.48e-8	High light scatter reticulocyte count;
LUSC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg16339924	chr4:17578868	LAP3	0.56	8.67	0.43	1.94e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs62458065	0.640	rs10271491	chr7:32530665	C/A	cg20159608	chr7:32802032	NA	-0.76	-9.58	-0.46	2.32e-19	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg24632597	chr12:121648093	P2RX4	0.39	6.12	0.32	2.6e-9	Educational attainment (years of education);
LUSC	trans	rs17807624	0.780	rs11250152	chr8:11454200	A/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.69	-0.34	9.46e-11	Systemic lupus erythematosus;
LUSC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.58	-0.34	1.77e-10	Longevity;Endometriosis;
LUSC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	13.74	0.6	2.27e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg16405210	chr4:1374714	KIAA1530	-0.59	-9.04	-0.44	1.26e-17	Obesity-related traits;
LUSC	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg14582100	chr15:45693742	SPATA5L1	0.45	8.57	0.42	3.77e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08704250	chr15:31115839	NA	-0.48	-6.76	-0.35	6.35e-11	Huntington's disease progression;
LUSC	trans	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.87	0.35	3.16e-11	Endometrial cancer;
LUSC	cis	rs7605827	0.897	rs6431697	chr2:15540034	G/C	cg19274914	chr2:15703543	NA	0.47	9.24	0.45	3.06e-18	Educational attainment (years of education);
LUSC	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg20243544	chr17:37824526	PNMT	0.48	6.75	0.35	6.7e-11	Asthma;
LUSC	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg03929089	chr4:120376271	NA	0.71	7.71	0.39	1.5e-13	Axial length;
LUSC	cis	rs988712	0.672	rs36029218	chr11:27648371	A/T	cg10635145	chr11:27742435	BDNF	-0.46	-5.97	-0.31	6.2e-9	Obesity;
LUSC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg12564285	chr5:131593104	PDLIM4	-0.44	-7.85	-0.39	5.52e-14	Breast cancer;
LUSC	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg01509843	chr8:143695822	ARC	0.39	5.91	0.31	8.25e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.54	8.36	0.42	1.71e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-12.05	-0.55	5.39e-28	Systemic lupus erythematosus;
LUSC	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg17075019	chr10:79541650	NA	-0.76	-11.98	-0.55	9.44e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg18131467	chr2:239335373	ASB1	0.87	13.86	0.6	8.26e-35	Multiple system atrophy;
LUSC	cis	rs6574644	0.920	rs1957542	chr14:81777303	G/C	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg16479474	chr6:28041457	NA	0.34	5.89	0.31	9.45e-9	Parkinson's disease;
LUSC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	0.91	16.19	0.66	6.39e-44	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg21545522	chr1:205238299	TMCC2	-0.4	-7.63	-0.39	2.4e-13	Red blood cell count;
LUSC	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg00129232	chr17:37814104	STARD3	-0.43	-6.25	-0.32	1.26e-9	Asthma;
LUSC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg01802117	chr1:53393560	SCP2	0.38	6.14	0.32	2.4e-9	Monocyte count;
LUSC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.81	-0.43	6.75e-17	Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23779087	chr6:151711584	ZBTB2	0.46	6.52	0.34	2.61e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.24	-11.41	-0.53	1.14e-25	Reticulocyte fraction of red cells;Reticulocyte count;
LUSC	cis	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg01585723	chr16:33734837	NA	0.37	5.88	0.31	1.01e-8	Menopause (age at onset);
LUSC	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg20811857	chr17:78079795	GAA	-0.32	-6.04	-0.31	4.06e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07080220	chr10:102295463	HIF1AN	0.68	8.76	0.43	9.71e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.7	10.74	0.51	2.56e-23	Aortic root size;
LUSC	cis	rs6736093	0.863	rs35757708	chr2:112769902	T/C	cg12686935	chr2:112915763	FBLN7	-0.37	-6.03	-0.31	4.43e-9	Coronary artery disease;
LUSC	cis	rs16854884	0.657	rs35877644	chr3:143701755	A/G	cg06585982	chr3:143692056	C3orf58	0.49	7.47	0.38	7.17e-13	Economic and political preferences (feminism/equality);
LUSC	cis	rs3847687	0.901	rs12370258	chr12:131527301	G/T	cg13586425	chr12:131519906	GPR133	-0.26	-5.96	-0.31	6.27e-9	Longevity;
LUSC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	0.92	15.38	0.64	1.02e-40	Breast cancer;
LUSC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.43	-6.29	-0.33	9.99e-10	Bronchopulmonary dysplasia;
LUSC	trans	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg02800362	chr5:177631904	HNRNPAB	0.88	13.11	0.58	5.56e-32	Obesity-related traits;
LUSC	cis	rs2652834	0.950	rs4774474	chr15:63405580	C/G	cg05507819	chr15:63340323	TPM1	0.56	6.98	0.36	1.57e-11	HDL cholesterol;
LUSC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.58	-0.38	3.35e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.81	14.5	0.62	2.68e-37	Mean platelet volume;
LUSC	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg01579765	chr21:45077557	HSF2BP	0.45	8.36	0.42	1.73e-15	Mean corpuscular volume;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12637942	chr11:65190225	NEAT1	0.47	6.24	0.32	1.33e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg01579765	chr21:45077557	HSF2BP	-0.5	-10.36	-0.49	5.28e-22	Mean corpuscular volume;
LUSC	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.61	-7.92	-0.4	3.5e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg08859206	chr1:53392774	SCP2	-0.4	-6.57	-0.34	1.94e-10	Monocyte count;
LUSC	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg12744634	chr1:26560303	CCDC21	0.4	5.92	0.31	8.03e-9	Obesity-related traits;
LUSC	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.88	-0.31	1e-8	Schizophrenia;
LUSC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.48	6.24	0.32	1.34e-9	Blood protein levels;
LUSC	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg26513180	chr16:89883248	FANCA	0.66	10.66	0.5	4.79e-23	Vitiligo;
LUSC	cis	rs13089785	0.965	rs62263719	chr3:123672787	T/C	cg02558132	chr3:123411198	MYLK	0.35	5.87	0.31	1.05e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg27266027	chr21:40555129	PSMG1	-0.4	-5.84	-0.3	1.24e-8	Cognitive function;
LUSC	cis	rs10254118	0.757	rs13241123	chr7:133135507	A/T	cg10665199	chr7:133106180	EXOC4	0.61	8.18	0.41	5.83e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg01097406	chr16:89675127	NA	-0.36	-7.17	-0.37	4.72e-12	Vitiligo;
LUSC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.28	-0.37	2.39e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg00031303	chr3:195681400	NA	0.67	9.55	0.46	2.79e-19	Pancreatic cancer;
LUSC	trans	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg25206134	chr2:45395956	NA	0.56	6.14	0.32	2.38e-9	Neuroticism;
LUSC	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg02569458	chr12:86230093	RASSF9	-0.37	-5.93	-0.31	7.51e-9	Major depressive disorder;
LUSC	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg11984989	chr7:158649758	WDR60	1.12	13.46	0.59	2.68e-33	Height;
LUSC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg11062466	chr8:58055876	NA	0.51	6.53	0.34	2.49e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg22907277	chr7:1156413	C7orf50	0.47	7.61	0.38	2.88e-13	Longevity;Endometriosis;
LUSC	cis	rs6469656	0.892	rs7836549	chr8:117697574	G/C	cg24004040	chr8:117650383	NA	-0.43	-6.31	-0.33	9.04e-10	Colorectal cancer;
LUSC	cis	rs4363385	0.782	rs2152993	chr1:152991695	C/A	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.45	-0.38	8.32e-13	Inflammatory skin disease;
LUSC	trans	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17712092	chr4:129076599	LARP1B	-0.86	-12.99	-0.58	1.64e-31	Eosinophil percentage of white cells;
LUSC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	7.39	0.37	1.17e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4819143	0.517	rs451920	chr21:47374699	A/C	cg14185626	chr21:47401492	COL6A1	-0.46	-5.68	-0.3	2.89e-8	Insulin resistance/response;
LUSC	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg05283184	chr6:79620031	NA	-0.57	-12.2	-0.56	1.41e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs2625529	0.775	rs4777477	chr15:72269612	G/A	cg16672083	chr15:72433130	SENP8	-0.51	-7.41	-0.38	1.02e-12	Red blood cell count;
LUSC	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg00852783	chr1:26633632	UBXN11	-0.5	-5.86	-0.31	1.13e-8	Obesity-related traits;
LUSC	cis	rs240764	0.697	rs846799	chr6:101270345	A/G	cg09795085	chr6:101329169	ASCC3	0.46	6.57	0.34	1.91e-10	Neuroticism;
LUSC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg18230493	chr5:56204884	C5orf35	-0.65	-9.8	-0.47	4.27e-20	Coronary artery disease;
LUSC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg01973587	chr1:228161476	NA	0.46	8.28	0.41	2.98e-15	Diastolic blood pressure;
LUSC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.47	7.81	0.39	7.67e-14	Lymphocyte counts;
LUSC	cis	rs668210	0.793	rs645571	chr11:65752852	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.59	-7.48	-0.38	6.61e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs3936840	0.514	rs8007356	chr14:102975266	G/A	cg18135206	chr14:102964638	TECPR2	0.52	6.89	0.35	2.75e-11	Plateletcrit;
LUSC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-11.84	-0.54	3.05e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg11344533	chr11:111475393	SIK2	0.47	6.15	0.32	2.21e-9	Primary sclerosing cholangitis;
LUSC	cis	rs11630290	0.589	rs12324851	chr15:64163495	G/A	cg12036633	chr15:63758958	NA	0.49	6.23	0.32	1.37e-9	Iris characteristics;
LUSC	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg09365446	chr1:150670422	GOLPH3L	-0.44	-6.37	-0.33	6.29e-10	Tonsillectomy;
LUSC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg21775007	chr8:11205619	TDH	0.46	6.05	0.31	3.92e-9	Neuroticism;
LUSC	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.85	-0.39	5.63e-14	Neuroticism;
LUSC	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg12379764	chr21:47803548	PCNT	0.77	10.1	0.48	4.32e-21	Lymphocyte counts;
LUSC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg12564285	chr5:131593104	PDLIM4	0.32	5.87	0.31	1.04e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg11301795	chr4:187892539	NA	0.46	6.78	0.35	5.63e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8113142	0.651	rs4309511	chr19:29094875	G/A	cg04546413	chr19:29218101	NA	0.43	5.9	0.31	8.86e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg24579218	chr15:68104479	NA	-0.39	-6.81	-0.35	4.68e-11	Restless legs syndrome;
LUSC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg26597838	chr10:835615	NA	1.07	13.74	0.6	2.38e-34	Eosinophil percentage of granulocytes;
LUSC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.15	0.49	2.78e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs885518	0.636	rs10811612	chr9:21774167	C/G	cg03374820	chr3:103513634	NA	-0.62	-6.0	-0.31	5.27e-9	Lung adenocarcinoma;
LUSC	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg00105475	chr2:10696890	NA	0.38	6.29	0.33	1e-9	Prostate cancer;
LUSC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg16393715	chr7:1948819	MAD1L1	0.37	6.53	0.34	2.43e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	11.92	0.55	1.59e-27	Exhaled nitric oxide output;
LUSC	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg02466173	chr16:30829666	NA	-0.6	-11.22	-0.52	5.43e-25	Multiple myeloma;
LUSC	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17467752	chr17:38218738	THRA	-0.48	-6.68	-0.34	9.96e-11	Myeloid white cell count;
LUSC	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg04998671	chr14:104000505	TRMT61A	-0.41	-5.92	-0.31	7.94e-9	Reticulocyte count;
LUSC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg09365446	chr1:150670422	GOLPH3L	0.54	8.28	0.41	2.91e-15	Tonsillectomy;
LUSC	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg04155231	chr12:9217510	LOC144571	0.3	5.69	0.3	2.75e-8	Sjögren's syndrome;
LUSC	cis	rs9549260	0.755	rs1413482	chr13:41218451	C/T	cg21288729	chr13:41239152	FOXO1	0.64	10.0	0.48	9.34e-21	Red blood cell count;
LUSC	cis	rs3768617	0.782	rs10752893	chr1:183046261	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.64	0.43	2.29e-16	Fuchs's corneal dystrophy;
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg11172286	chr11:47600544	KBTBD4;NDUFS3	0.39	5.98	0.31	5.81e-9	Eotaxin levels;
LUSC	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg23093090	chr10:104574429	C10orf26	-0.35	-6.35	-0.33	6.93e-10	Arsenic metabolism;
LUSC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg10729496	chr3:10149963	C3orf24	0.57	7.42	0.38	9.8e-13	Alzheimer's disease;
LUSC	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg11693508	chr17:37793320	STARD3	0.52	6.2	0.32	1.63e-9	Bipolar disorder;
LUSC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.59	0.5	8.51e-23	Schizophrenia;
LUSC	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg05768032	chr16:30646687	NA	0.38	5.68	0.3	2.96e-8	Multiple myeloma;
LUSC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.68	11.05	0.52	2.08e-24	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg06627628	chr2:24431161	ITSN2	-0.61	-7.4	-0.38	1.09e-12	Lymphocyte counts;
LUSC	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.39e-12	Asthma (childhood onset);
LUSC	cis	rs13401104	0.796	rs72620805	chr2:237113711	G/C	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.35e-8	Educational attainment;
LUSC	cis	rs6977660	0.943	rs6959678	chr7:19821759	C/A	cg07541023	chr7:19748670	TWISTNB	0.51	5.73	0.3	2.3e-8	Thyroid stimulating hormone;
LUSC	cis	rs7605827	0.866	rs7598936	chr2:15597289	A/G	cg19274914	chr2:15703543	NA	0.46	8.8	0.43	7.47e-17	Educational attainment (years of education);
LUSC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg25456477	chr12:86230367	RASSF9	0.43	7.69	0.39	1.69e-13	Major depressive disorder;
LUSC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg23978390	chr7:1156363	C7orf50	0.48	5.98	0.31	5.68e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs847577	1.000	rs847577	chr7:97694858	T/A	cg24562669	chr7:97807699	LMTK2	-0.44	-7.96	-0.4	2.65e-14	Breast cancer;
LUSC	cis	rs9457247	0.668	rs2236313	chr6:167360389	C/T	cg07741184	chr6:167504864	NA	0.36	6.52	0.34	2.53e-10	Crohn's disease;
LUSC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.49	-0.46	4.67e-19	Platelet count;
LUSC	cis	rs34779708	0.931	rs12268745	chr10:35305989	C/G	cg03585969	chr10:35415529	CREM	0.61	8.81	0.43	7.16e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7589342	0.745	rs11124066	chr2:106516925	T/A	cg14210321	chr2:106509881	NCK2	-0.62	-9.47	-0.46	5.26e-19	Addiction;
LUSC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.26	-0.32	1.2e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg24399712	chr22:39784796	NA	-0.64	-12.0	-0.55	8.04e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	8.04	0.4	1.61e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.39	0.42	1.41e-15	Menarche (age at onset);
LUSC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.78	0.39	8.84e-14	Prudent dietary pattern;
LUSC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00290607	chr11:67383545	NA	0.36	6.33	0.33	8e-10	Mean corpuscular volume;
LUSC	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.2	0.49	1.97e-21	Birth weight;
LUSC	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg26688816	chr2:46740690	ATP6V1E2	0.56	8.86	0.44	4.85e-17	HDL cholesterol;
LUSC	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg11062466	chr8:58055876	NA	0.51	6.46	0.33	3.65e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08564027	chr20:61660810	NA	0.9	16.84	0.68	1.64e-46	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg23188684	chr11:67383651	NA	0.35	6.19	0.32	1.76e-9	Mean corpuscular volume;
LUSC	cis	rs4494114	1.000	rs6675245	chr1:39356820	T/A	cg25970120	chr1:39325951	RRAGC	-0.4	-6.22	-0.32	1.46e-9	Blood protein levels;
LUSC	cis	rs2274273	0.868	rs6573007	chr14:55625938	T/G	cg04306507	chr14:55594613	LGALS3	0.59	13.65	0.6	5.06e-34	Protein biomarker;
LUSC	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg24642439	chr20:33292090	TP53INP2	0.42	6.02	0.31	4.72e-9	Height;
LUSC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg15445000	chr17:37608096	MED1	0.4	6.83	0.35	4.04e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs10392	0.571	rs4812335	chr20:37537612	C/T	cg27552599	chr20:37590471	DHX35	0.41	6.44	0.33	4.08e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	-0.46	-7.51	-0.38	5.41e-13	Menarche (age at onset);
LUSC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg25456477	chr12:86230367	RASSF9	0.44	7.83	0.39	6.31e-14	Major depressive disorder;
LUSC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg25456477	chr12:86230367	RASSF9	0.43	7.75	0.39	1.15e-13	Major depressive disorder;
LUSC	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg06740227	chr12:86229804	RASSF9	0.39	6.25	0.32	1.23e-9	Major depressive disorder;
LUSC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg09877947	chr5:131593287	PDLIM4	0.48	8.24	0.41	4.1e-15	Blood metabolite levels;
LUSC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	1.02	20.24	0.74	5.16e-60	Menopause (age at onset);
LUSC	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	0.59	9.25	0.45	2.65e-18	Breast cancer;
LUSC	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg21665744	chr7:39171113	POU6F2	0.44	6.69	0.34	9.23e-11	IgG glycosylation;
LUSC	cis	rs858239	0.570	rs10242166	chr7:23162799	A/G	cg23682824	chr7:23144976	KLHL7	0.38	5.67	0.3	3.1e-8	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs8016982	0.662	rs9806020	chr14:81668555	A/C	cg01989461	chr14:81687754	GTF2A1	0.49	6.72	0.35	7.73e-11	Schizophrenia;
LUSC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg13770153	chr20:60521292	NA	-0.44	-6.11	-0.32	2.83e-9	Body mass index;
LUSC	cis	rs3106136	0.967	rs66581998	chr4:95196901	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.36	-6.4	-0.33	5.19e-10	Capecitabine sensitivity;
LUSC	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14442939	chr10:27389572	ANKRD26	0.84	9.84	0.47	3.2e-20	Breast cancer;
LUSC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg13395646	chr4:1353034	KIAA1530	-0.61	-9.9	-0.48	2.03e-20	Obesity-related traits;
LUSC	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg23277830	chr1:3704460	LRRC47	0.36	6.84	0.35	3.9e-11	Red cell distribution width;
LUSC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg05896524	chr21:47604654	C21orf56	-0.53	-8.12	-0.41	8.81e-15	Testicular germ cell tumor;
LUSC	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg24812749	chr6:127587940	RNF146	0.64	9.56	0.46	2.76e-19	Breast cancer;
LUSC	cis	rs7107174	0.892	rs2512540	chr11:77979299	A/G	cg02023728	chr11:77925099	USP35	0.48	6.82	0.35	4.26e-11	Testicular germ cell tumor;
LUSC	cis	rs16976116	0.901	rs28714578	chr15:55491121	G/A	cg11288833	chr15:55489084	RSL24D1	0.49	5.84	0.3	1.24e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18854424	chr1:2615690	NA	0.51	10.31	0.49	7.93e-22	Ulcerative colitis;
LUSC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg18681998	chr4:17616180	MED28	0.92	18.35	0.71	1.66e-52	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg01765077	chr12:122356316	WDR66	-0.44	-6.2	-0.32	1.68e-9	Mean corpuscular volume;
LUSC	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg23093090	chr10:104574429	C10orf26	-0.36	-6.54	-0.34	2.28e-10	Arsenic metabolism;
LUSC	cis	rs72781680	0.821	rs113014365	chr2:24159903	C/T	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.51	-0.38	5.53e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.62	-8.34	-0.42	1.95e-15	Body mass index;
LUSC	trans	rs2926702	0.810	rs2979638	chr8:71067368	G/A	cg16517358	chr11:46164796	NA	-0.37	-5.98	-0.31	5.84e-9	Non-small cell lung cancer;
LUSC	cis	rs1832871	0.965	rs705953	chr6:158775332	A/G	cg07165851	chr6:158734300	TULP4	-0.34	-5.87	-0.31	1.07e-8	Height;
LUSC	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg19784903	chr17:45786737	TBKBP1	-0.42	-6.11	-0.32	2.76e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg11812906	chr14:75593930	NEK9	0.66	11.33	0.53	2.14e-25	Height;
LUSC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.47	8.68	0.43	1.77e-16	Blood metabolite levels;
LUSC	trans	rs6480314	0.542	rs12570281	chr10:70026994	T/G	cg04882175	chr6:131122610	NA	-0.55	-6.39	-0.33	5.64e-10	Optic nerve measurement (disc area);
LUSC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.72	-13.51	-0.59	1.8e-33	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.38e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10875746	0.855	rs12310999	chr12:48447658	A/G	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	trans	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg10756647	chr7:56101905	PSPH	-0.84	-8.39	-0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg22532475	chr10:104410764	TRIM8	0.3	6.16	0.32	2.03e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg06454157	chr6:167490870	NA	-0.25	-5.99	-0.31	5.58e-9	Crohn's disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25728723	chr11:3818859	PGAP2;NUP98	0.77	6.62	0.34	1.44e-10	Cognitive performance;
LUSC	trans	rs272594	1.000	rs272594	chr8:81470120	A/C	cg01004056	chr1:230560318	NA	-0.43	-5.97	-0.31	6.16e-9	Neutrophil count;
LUSC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg26116260	chr4:7069785	GRPEL1	-1.08	-12.72	-0.57	1.75e-30	Monocyte percentage of white cells;
LUSC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.78	-0.51	1.85e-23	Glomerular filtration rate;
LUSC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.7	12.71	0.57	1.91e-30	Prudent dietary pattern;
LUSC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg06784218	chr1:46089804	CCDC17	-0.6	-11.93	-0.55	1.37e-27	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg24675658	chr1:53192096	ZYG11B	-0.64	-10.09	-0.48	4.52e-21	Monocyte count;
LUSC	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-13.85	-0.6	9.01e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg16423285	chr20:60520624	NA	-0.92	-12.73	-0.57	1.5e-30	Obesity-related traits;
LUSC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg18681998	chr4:17616180	MED28	0.81	13.89	0.61	5.89e-35	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg12559939	chr2:27858050	GPN1	-0.4	-6.25	-0.32	1.23e-9	Oral cavity cancer;
LUSC	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.38	0.33	5.74e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg16230307	chr14:35515116	FAM177A1	0.77	10.07	0.48	5.28e-21	Psoriasis;
LUSC	cis	rs35000415	0.872	rs2070197	chr7:128589000	T/C	cg19972273	chr7:128594194	NA	0.67	6.79	0.35	5.17e-11	Systemic lupus erythematosus;
LUSC	cis	rs6484504	0.576	rs2616792	chr11:31324298	T/G	cg26647111	chr11:31128758	NA	0.4	5.67	0.3	3.02e-8	Red blood cell count;
LUSC	cis	rs2658782	0.654	rs2248524	chr11:93255715	G/A	cg15737290	chr11:93063684	CCDC67	0.57	7.4	0.38	1.14e-12	Pulmonary function decline;
LUSC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg17764715	chr19:33622953	WDR88	0.57	8.35	0.42	1.84e-15	Bone properties (heel);
LUSC	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg03585969	chr10:35415529	CREM	0.58	8.68	0.43	1.82e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6982240	0.514	rs72681579	chr8:142263074	G/A	cg27411547	chr8:142287226	NA	-0.47	-7.95	-0.4	2.98e-14	Tonsillectomy;
LUSC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.59	11.91	0.55	1.73e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs3741151	0.773	rs73542967	chr11:73123512	C/T	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.7	9.81	0.47	4.06e-20	Multiple sclerosis;
LUSC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.66	-11.27	-0.52	3.4e-25	Lung cancer;
LUSC	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg09184832	chr6:79620586	NA	-0.44	-7.09	-0.36	7.85e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs11039100	0.920	rs11039075	chr11:5820917	C/A	cg13902645	chr11:5959945	NA	-0.53	-5.94	-0.31	7.09e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7572644	0.766	rs13399709	chr2:28167450	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-6.49	-0.33	3.1e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg05973401	chr12:123451056	ABCB9	0.52	6.56	0.34	2e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.5	-0.42	6.5e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg26384229	chr12:38710491	ALG10B	0.88	15.13	0.64	9.83e-40	Bladder cancer;
LUSC	cis	rs1322512	0.837	rs2800627	chr6:153006507	C/A	cg03415253	chr6:152958462	SYNE1	0.38	5.65	0.3	3.38e-8	Tonometry;
LUSC	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg24596788	chr1:163392923	NA	-0.44	-7.27	-0.37	2.55e-12	Motion sickness;
LUSC	trans	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg26043149	chr18:55253948	FECH	0.47	7.16	0.36	5.05e-12	Bone mineral density;
LUSC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg04362960	chr10:104952993	NT5C2	0.52	6.54	0.34	2.35e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6484504	0.576	rs158136	chr11:31220712	C/T	cg26647111	chr11:31128758	NA	-0.42	-6.03	-0.31	4.44e-9	Red blood cell count;
LUSC	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg00376283	chr12:123451042	ABCB9	0.67	8.36	0.42	1.68e-15	Neutrophil percentage of white cells;
LUSC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg03146154	chr1:46216737	IPP	-0.5	-7.23	-0.37	3.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg09307838	chr4:120376055	NA	-0.59	-8.99	-0.44	1.88e-17	Corneal astigmatism;
LUSC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.39	0.53	1.32e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg08888203	chr3:10149979	C3orf24	0.45	6.79	0.35	5.25e-11	Alzheimer's disease;
LUSC	cis	rs7560272	0.564	rs4852939	chr2:73856769	C/G	cg20560298	chr2:73613845	ALMS1	-0.46	-6.99	-0.36	1.5e-11	Schizophrenia;
LUSC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg10057126	chr4:77819792	ANKRD56	0.54	7.89	0.4	4.25e-14	Emphysema distribution in smoking;
LUSC	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03713592	chr11:72463424	ARAP1	0.84	9.78	0.47	4.81e-20	Type 2 diabetes;
LUSC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg16520312	chr17:43971471	MAPT;LOC100128977	0.38	6.51	0.34	2.78e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7799006	0.757	rs2398668	chr7:2298227	A/G	cg08027265	chr7:2291960	NA	0.6	11.31	0.53	2.45e-25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2952156	1.000	rs4252627	chr17:37868715	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-7.06	-0.36	9.53e-12	Asthma;
LUSC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg08888203	chr3:10149979	C3orf24	0.46	6.72	0.35	7.83e-11	Alzheimer's disease;
LUSC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.47	0.42	7.7e-16	Hemoglobin concentration;
LUSC	cis	rs2273669	0.667	rs2356575	chr6:109367255	T/C	cg05315195	chr6:109294784	ARMC2	-0.52	-5.72	-0.3	2.42e-8	Prostate cancer;
LUSC	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg12826209	chr6:26865740	GUSBL1	0.68	7.85	0.39	5.75e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.71	-0.43	1.46e-16	Mood instability;
LUSC	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg05347473	chr6:146136440	FBXO30	0.53	8.96	0.44	2.33e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg00750074	chr16:89608354	SPG7	-0.57	-10.24	-0.49	1.4e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs72781680	0.559	rs72796103	chr2:23900382	G/A	cg20701182	chr2:24300061	SF3B14	0.75	7.32	0.37	1.87e-12	Lymphocyte counts;
LUSC	cis	rs73198271	0.562	rs17698256	chr8:8659613	C/T	cg01851573	chr8:8652454	MFHAS1	0.65	9.19	0.45	4.29e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg21772509	chr8:41503840	NKX6-3	0.69	11.53	0.53	4.11e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-1.07	-26.09	-0.82	1.35e-82	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg25214090	chr10:38739885	LOC399744	-0.41	-6.26	-0.32	1.2e-9	Corneal astigmatism;
LUSC	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg14019695	chr9:139328340	INPP5E	-0.39	-7.36	-0.37	1.49e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg21827317	chr3:136751795	NA	0.39	6.96	0.36	1.84e-11	Neuroticism;
LUSC	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg26587870	chr6:27730563	NA	-0.61	-5.79	-0.3	1.62e-8	Breast cancer;
LUSC	cis	rs2200578	0.626	rs72959128	chr2:99769602	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.62	7.31	0.37	2.01e-12	IgG glycosylation;
LUSC	trans	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg07211511	chr3:129823064	LOC729375	-1.23	-21.07	-0.76	2.67e-63	Blood pressure (smoking interaction);
LUSC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg15445000	chr17:37608096	MED1	0.39	6.63	0.34	1.38e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg18876405	chr7:65276391	NA	-0.53	-8.67	-0.43	1.86e-16	Calcium levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05871997	chr6:56819623	BEND6;DST	0.69	6.26	0.32	1.19e-9	Cognitive performance;
LUSC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.24	-0.32	1.32e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg16586182	chr3:47516702	SCAP	0.57	8.92	0.44	3.05e-17	Colorectal cancer;
LUSC	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg16482183	chr6:26056742	HIST1H1C	0.63	8.86	0.44	4.85e-17	Iron status biomarkers;
LUSC	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg02038168	chr22:39784481	NA	-0.49	-8.04	-0.4	1.55e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs62400317	0.859	rs10948213	chr6:45158515	T/C	cg20913747	chr6:44695427	NA	-0.48	-7.7	-0.39	1.56e-13	Total body bone mineral density;
LUSC	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	7.8	0.39	7.8e-14	Neuroticism;
LUSC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg12559939	chr2:27858050	GPN1	0.41	6.45	0.33	3.94e-10	Oral cavity cancer;
LUSC	cis	rs1113500	0.548	rs11185269	chr1:108647636	T/C	cg11967332	chr1:108735228	SLC25A24	0.43	5.88	0.31	1.02e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.3	7.66	0.39	2.04e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg13332499	chr17:408570	NA	-0.37	-6.44	-0.33	4.08e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2580764	0.566	rs2968795	chr2:55287989	G/A	cg20993754	chr2:55226987	RTN4	-0.36	-5.92	-0.31	8.2e-9	Mean platelet volume;
LUSC	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-0.73	-12.57	-0.57	6.2e-30	Gut microbiome composition (winter);
LUSC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	1.14	16.81	0.68	2.21e-46	Monocyte percentage of white cells;
LUSC	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg12573674	chr2:1569213	NA	-0.55	-6.13	-0.32	2.44e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-6.23	-0.32	1.38e-9	Neuroticism;
LUSC	cis	rs71403859	0.502	rs35394108	chr16:71540639	T/C	cg08717414	chr16:71523259	ZNF19	-0.72	-8.57	-0.42	3.89e-16	Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6012953	0.874	rs1885176	chr20:49175289	C/T	cg13958625	chr20:49123093	NA	-0.26	-5.76	-0.3	1.91e-8	Vitiligo;
LUSC	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	17.57	0.69	2.21e-49	Headache;
LUSC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.81	-0.43	6.75e-17	Platelet count;
LUSC	trans	rs9944715	1.000	rs4890634	chr18:43854259	C/T	cg01718231	chr17:29326311	RNF135	-0.53	-7.4	-0.38	1.11e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.14	-0.49	3.1e-21	Obesity-related traits;
LUSC	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.44	-0.56	1.94e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	0.97	21.55	0.76	3.54e-65	Longevity;
LUSC	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg12850546	chr22:42539477	CYP2D7P1	-0.46	-5.66	-0.3	3.18e-8	Birth weight;
LUSC	cis	rs6942756	0.758	rs13226649	chr7:128977598	C/T	cg02491457	chr7:128862824	NA	-0.48	-7.17	-0.37	4.71e-12	White matter hyperintensity burden;
LUSC	cis	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg03859395	chr2:55845619	SMEK2	0.81	14.18	0.61	4.69e-36	Metabolic syndrome;
LUSC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg18190219	chr22:46762943	CELSR1	-0.48	-6.02	-0.31	4.53e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.66	10.29	0.49	9.3e-22	Colorectal cancer;
LUSC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.96	-0.36	1.83e-11	Total body bone mineral density;
LUSC	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-18.45	-0.71	6.86e-53	Primary sclerosing cholangitis;
LUSC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.79	12.63	0.57	3.84e-30	Chronic sinus infection;
LUSC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-0.54	-10.76	-0.51	2.29e-23	Obesity-related traits;
LUSC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg26850624	chr5:429559	AHRR	-0.43	-8.43	-0.42	1.08e-15	Cystic fibrosis severity;
LUSC	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg06627628	chr2:24431161	ITSN2	0.5	7.0	0.36	1.39e-11	Asthma;
LUSC	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.18	-0.45	4.78e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg08470875	chr2:26401718	FAM59B	-0.72	-9.37	-0.46	1.1e-18	Gut microbiome composition (summer);
LUSC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg15704280	chr7:45808275	SEPT13	-1.1	-21.26	-0.76	4.93e-64	Coronary artery disease;
LUSC	cis	rs9420	0.528	rs11229080	chr11:57399511	T/C	cg23127183	chr11:57508653	C11orf31	-0.46	-6.46	-0.33	3.73e-10	Schizophrenia;
LUSC	cis	rs6484504	0.532	rs1929019	chr11:31267030	C/T	cg26647111	chr11:31128758	NA	-0.43	-6.12	-0.32	2.58e-9	Red blood cell count;
LUSC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-0.81	-15.84	-0.66	1.49e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05901451	chr6:126070800	HEY2	-0.58	-8.78	-0.43	8.6e-17	Endometrial cancer;
LUSC	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg14582100	chr15:45693742	SPATA5L1	0.46	8.62	0.43	2.7e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg14440974	chr22:39074834	NA	-0.35	-5.89	-0.31	9.41e-9	Menopause (age at onset);
LUSC	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.15	-0.49	2.8e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs886126	1.000	rs10082818	chr12:111663177	C/G	cg10833066	chr12:111807467	FAM109A	0.4	6.28	0.33	1.03e-9	Coronary heart disease;
LUSC	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg00530320	chr1:46809349	NSUN4	0.56	8.28	0.41	3.01e-15	Menopause (age at onset);
LUSC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg02153584	chr22:29168773	CCDC117	0.66	10.61	0.5	7.45e-23	Lymphocyte counts;
LUSC	cis	rs17095355	1.000	rs56273398	chr10:111708183	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.67	-8.11	-0.41	9.41e-15	Biliary atresia;
LUSC	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg20701182	chr2:24300061	SF3B14	0.77	7.73	0.39	1.25e-13	Lymphocyte counts;
LUSC	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg11244672	chr19:19639970	YJEFN3	-0.52	-6.49	-0.33	3.05e-10	Bipolar disorder;
LUSC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg25258033	chr6:167368657	RNASET2	0.46	7.56	0.38	3.94e-13	Crohn's disease;
LUSC	cis	rs7106204	0.609	rs34102968	chr11:24304149	C/T	ch.11.24196551F	chr11:24239977	NA	0.69	5.68	0.3	2.86e-8	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs3770081	0.590	rs34522092	chr2:86208305	G/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.03	-6.6	-0.34	1.57e-10	Facial emotion recognition (sad faces);
LUSC	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg23649088	chr2:200775458	C2orf69	-0.56	-6.69	-0.34	9.64e-11	Schizophrenia;
LUSC	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	19.83	0.74	2.22e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.06	0.48	5.86e-21	Electroencephalogram traits;
LUSC	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg21100191	chr22:23484243	RTDR1	0.67	8.73	0.43	1.22e-16	Serum parathyroid hormone levels;
LUSC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06481639	chr22:41940642	POLR3H	0.51	5.93	0.31	7.37e-9	Vitiligo;
LUSC	cis	rs9487051	0.735	rs1260594	chr6:109519891	A/C	cg01475377	chr6:109611718	NA	-0.36	-6.18	-0.32	1.9e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7428496	0.510	rs13072355	chr3:142300006	G/A	cg16271453	chr3:142027066	XRN1	-0.48	-8.13	-0.41	8.33e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-1.07	-15.83	-0.65	1.64e-42	Initial pursuit acceleration;
LUSC	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.62	9.47	0.46	5.25e-19	Corneal astigmatism;
LUSC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg19318889	chr4:1322082	MAEA	0.47	7.87	0.4	5.07e-14	Longevity;
LUSC	cis	rs12760731	0.720	rs10913553	chr1:178423062	G/C	cg00404053	chr1:178313656	RASAL2	0.59	6.28	0.33	1.02e-9	Obesity-related traits;
LUSC	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.69	0.5	3.9e-23	Schizophrenia;
LUSC	trans	rs7944735	0.767	rs1017875	chr11:47999218	C/T	cg03929089	chr4:120376271	NA	0.59	6.25	0.32	1.26e-9	Intraocular pressure;
LUSC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.16	0.32	2.11e-9	Menopause (age at onset);
LUSC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06873352	chr17:61820015	STRADA	0.56	8.68	0.43	1.83e-16	Height;
LUSC	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.73	14.21	0.61	3.48e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.86	-0.35	3.34e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg14154082	chr13:112174009	NA	0.38	7.88	0.4	4.53e-14	Menarche (age at onset);
LUSC	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.09	-0.4	1.1e-14	Axial length;
LUSC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg05313129	chr8:58192883	C8orf71	-0.5	-6.86	-0.35	3.28e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg18825076	chr15:78729989	IREB2	-0.49	-7.85	-0.39	5.87e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.59	9.27	0.45	2.44e-18	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.31	-0.41	2.42e-15	Gut microbiome composition (summer);
LUSC	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	9.41	0.46	8.51e-19	Nonalcoholic fatty liver disease;
LUSC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg20243544	chr17:37824526	PNMT	0.5	7.2	0.37	4.09e-12	Asthma;
LUSC	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg19920283	chr7:105172520	RINT1	0.59	6.08	0.32	3.38e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	6.83	0.35	3.92e-11	Eosinophil percentage of white cells;
LUSC	cis	rs11039100	0.527	rs968991	chr11:5783816	G/A	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.72	0.3	2.39e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4903604	0.505	rs11623595	chr14:78037547	A/G	cg18872420	chr14:78023429	SPTLC2	0.38	5.81	0.3	1.47e-8	Gut microbiome composition (winter);
LUSC	cis	rs1322512	0.917	rs2623946	chr6:152962073	C/G	cg27316956	chr6:152958899	SYNE1	-0.36	-6.22	-0.32	1.51e-9	Tonometry;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03486307	chr16:86597223	NA	-0.45	-6.27	-0.32	1.14e-9	Hepatitis;
LUSC	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-9.54	-0.46	3.22e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg10729496	chr3:10149963	C3orf24	0.55	7.21	0.37	3.79e-12	Alzheimer's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11282556	chr22:28314999	PITPNB;LOC284900	-0.44	-6.57	-0.34	1.91e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6815814	0.861	rs12233670	chr4:38787216	C/T	cg06935464	chr4:38784597	TLR10	0.45	5.98	0.31	5.86e-9	Breast cancer;
LUSC	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg09307838	chr4:120376055	NA	-0.75	-11.04	-0.52	2.34e-24	Corneal astigmatism;
LUSC	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg18478394	chr8:109455254	TTC35	0.41	6.29	0.33	9.7e-10	Dupuytren's disease;
LUSC	cis	rs9314323	0.862	rs7813520	chr8:26263260	C/T	cg11498726	chr8:26250323	BNIP3L	-0.44	-6.43	-0.33	4.45e-10	Red cell distribution width;
LUSC	cis	rs500891	0.553	rs7745251	chr6:84171756	G/T	cg08257003	chr6:84140564	ME1	-0.27	-6.27	-0.32	1.09e-9	Platelet-derived growth factor BB levels;
LUSC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.91	-18.94	-0.72	7.49e-55	Birth weight;
LUSC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.47	7.29	0.37	2.24e-12	Colorectal cancer;
LUSC	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg23241863	chr10:102295624	HIF1AN	0.5	6.15	0.32	2.17e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7674212	0.507	rs223471	chr4:103698786	G/C	cg16532752	chr4:104119610	CENPE	-0.41	-5.76	-0.3	1.86e-8	Type 2 diabetes;
LUSC	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.66	0.34	1.15e-10	Lung cancer;
LUSC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg15145296	chr3:125709740	NA	-0.56	-6.32	-0.33	8.59e-10	Blood pressure (smoking interaction);
LUSC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.63	8.35	0.42	1.8e-15	High light scatter reticulocyte count;
LUSC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06022373	chr22:39101656	GTPBP1	0.7	10.84	0.51	1.14e-23	Menopause (age at onset);
LUSC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.56	0.38	3.9e-13	Colorectal cancer;
LUSC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg23093090	chr10:104574429	C10orf26	-0.4	-7.3	-0.37	2.18e-12	Arsenic metabolism;
LUSC	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg06636001	chr8:8085503	FLJ10661	0.42	6.21	0.32	1.57e-9	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs909002	0.720	rs4949459	chr1:32142354	G/T	cg01639898	chr1:32083012	HCRTR1	0.26	6.07	0.32	3.5e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg07424592	chr7:64974309	NA	0.65	5.83	0.3	1.32e-8	Diabetic kidney disease;
LUSC	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg01475377	chr6:109611718	NA	-0.42	-7.39	-0.37	1.17e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg11657440	chr19:46296263	DMWD	0.87	16.5	0.67	3.87e-45	Coronary artery disease;
LUSC	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg03474202	chr17:45855739	NA	-0.3	-6.69	-0.34	9.5e-11	IgG glycosylation;
LUSC	cis	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs4474465	0.920	rs10899529	chr11:78207848	T/C	cg27205649	chr11:78285834	NARS2	0.51	5.91	0.31	8.55e-9	Alzheimer's disease (survival time);
LUSC	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg06454157	chr6:167490870	NA	-0.24	-5.68	-0.3	2.89e-8	Crohn's disease;
LUSC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg10792982	chr14:105748885	BRF1	0.5	9.28	0.45	2.2e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg17366294	chr4:99064904	C4orf37	0.61	10.9	0.51	7.28e-24	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg05926928	chr17:57297772	GDPD1	0.6	9.55	0.46	2.93e-19	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUSC	cis	rs3820928	0.874	rs13413235	chr2:227893863	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.57	-0.38	3.59e-13	Pulmonary function;
LUSC	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.84	-0.44	5.62e-17	Metabolite levels;
LUSC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	12.6	0.57	4.58e-30	Cognitive test performance;
LUSC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg11843238	chr5:131593191	PDLIM4	0.46	7.74	0.39	1.19e-13	Acylcarnitine levels;
LUSC	cis	rs9653442	1.000	rs11676922	chr2:100806940	T/A	cg07810366	chr2:100720526	AFF3	-0.45	-7.91	-0.4	3.9e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-8.1	-0.41	1.03e-14	Morning vs. evening chronotype;
LUSC	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg21775007	chr8:11205619	TDH	-0.5	-7.54	-0.38	4.57e-13	Neuroticism;
LUSC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.86	14.12	0.61	7.7e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.56	0.38	3.85e-13	Prudent dietary pattern;
LUSC	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg20503657	chr10:835505	NA	0.86	12.15	0.55	2.24e-28	Eosinophil percentage of granulocytes;
LUSC	cis	rs977987	0.843	rs11860231	chr16:75385159	A/G	cg03315344	chr16:75512273	CHST6	0.51	9.61	0.47	1.88e-19	Dupuytren's disease;
LUSC	cis	rs13315871	1.000	rs13066269	chr3:58449244	T/C	cg20936604	chr3:58311152	NA	-0.72	-6.77	-0.35	5.83e-11	Cholesterol, total;
LUSC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg11764359	chr7:65958608	NA	0.51	6.35	0.33	7.11e-10	Aortic root size;
LUSC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg13319975	chr6:146136371	FBXO30	0.48	7.19	0.37	4.4e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26314531	chr2:26401878	FAM59B	0.69	8.92	0.44	3.21e-17	Gut microbiome composition (summer);
LUSC	cis	rs400736	0.602	rs7553544	chr1:8165719	C/T	cg25007680	chr1:8021821	PARK7	-0.48	-6.69	-0.34	9.47e-11	Response to antidepressants and depression;
LUSC	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.14	-20.32	-0.74	2.42e-60	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg22601191	chr20:60968625	CABLES2	-0.39	-6.33	-0.33	8.08e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg07061783	chr6:25882402	NA	0.43	6.07	0.32	3.51e-9	Blood metabolite levels;
LUSC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.91	0.4	3.86e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.85	-14.14	-0.61	6.94e-36	Schizophrenia;
LUSC	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.58	0.34	1.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg11802864	chr11:65308245	LTBP3	0.79	6.03	0.31	4.25e-9	Height;
LUSC	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg25801113	chr15:45476975	SHF	0.33	6.9	0.35	2.62e-11	Uric acid levels;
LUSC	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg24397884	chr7:158709396	WDR60	0.55	6.23	0.32	1.44e-9	Height;
LUSC	trans	rs6600671	1.000	rs2319969	chr1:121207335	A/G	cg00646200	chr1:148855367	NA	0.47	7.5	0.38	5.94e-13	Hip geometry;
LUSC	cis	rs9287719	0.615	rs12613769	chr2:10742290	C/T	cg00105475	chr2:10696890	NA	0.34	5.75	0.3	2.03e-8	Prostate cancer;
LUSC	cis	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05901451	chr6:126070800	HEY2	0.57	8.57	0.42	3.96e-16	Endometrial cancer;
LUSC	cis	rs56399783	0.901	rs73033403	chr7:2877941	G/A	cg19731401	chr7:2775893	GNA12	0.7	9.38	0.46	1.03e-18	Childhood ear infection;
LUSC	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.83	-0.3	1.32e-8	Coronary artery disease;
LUSC	cis	rs10761482	0.859	rs2219533	chr10:62094914	G/C	cg18175470	chr10:62150864	ANK3	-0.45	-6.71	-0.34	8.5e-11	Schizophrenia;
LUSC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg02772935	chr3:125709198	NA	-0.47	-5.67	-0.3	3.15e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	0.96	10.41	0.49	3.72e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-16.59	-0.67	1.66e-45	Gut microbiome composition (summer);
LUSC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.24	-0.37	3.09e-12	Alzheimer's disease (late onset);
LUSC	cis	rs17539620	0.628	rs62432729	chr6:154830044	T/C	cg20019720	chr6:154832845	CNKSR3	0.63	8.58	0.43	3.6e-16	Lipoprotein (a) levels;
LUSC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg21643547	chr1:205240462	TMCC2	-0.41	-7.63	-0.39	2.49e-13	Red blood cell count;
LUSC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg18876405	chr7:65276391	NA	0.55	8.99	0.44	1.88e-17	Calcium levels;
LUSC	cis	rs11648785	0.747	rs12920767	chr16:90094570	A/G	cg16611967	chr16:90144006	NA	0.42	5.64	0.3	3.56e-8	Tanning;
LUSC	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg16049864	chr8:95962084	TP53INP1	0.41	7.01	0.36	1.3e-11	Type 2 diabetes;
LUSC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg05585544	chr11:47624801	NA	-0.42	-7.36	-0.37	1.45e-12	Subjective well-being;
LUSC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg10523860	chr14:103875565	MARK3	-0.36	-5.78	-0.3	1.72e-8	Body mass index;
LUSC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg02187348	chr16:89574699	SPG7	0.51	7.59	0.38	3.2e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	0.6	9.45	0.46	5.98e-19	Breast cancer;
LUSC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	5.67	0.3	3.05e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg15848620	chr12:58087721	OS9	-0.56	-8.04	-0.4	1.62e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg22676075	chr6:135203613	NA	0.46	7.13	0.36	6.1e-12	Red blood cell count;
LUSC	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg13010199	chr12:38710504	ALG10B	0.7	10.59	0.5	8.81e-23	Bladder cancer;
LUSC	trans	rs311904	0.793	rs4776427	chr15:69337180	A/C	cg07092097	chr10:88720025	SNCG	-0.64	-6.15	-0.32	2.2e-9	Obesity-related traits;
LUSC	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg19682013	chr15:45996608	NA	0.38	5.88	0.31	1.02e-8	Waist circumference;Weight;
LUSC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.29e-31	Prudent dietary pattern;
LUSC	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg00898013	chr13:113819073	PROZ	-0.56	-8.48	-0.42	7.28e-16	Platelet distribution width;
LUSC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.36	-0.37	1.42e-12	Reticulocyte count;
LUSC	trans	rs6600671	1.000	rs4844616	chr1:121171208	A/G	cg00646200	chr1:148855367	NA	0.43	6.77	0.35	5.68e-11	Hip geometry;
LUSC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-5.94	-0.31	7.22e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg00933542	chr6:150070202	PCMT1	-0.31	-6.57	-0.34	1.89e-10	Lung cancer;
LUSC	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg19743168	chr1:23544995	NA	0.4	7.89	0.4	4.45e-14	Height;
LUSC	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg05973401	chr12:123451056	ABCB9	0.55	8.05	0.4	1.5e-14	Neutrophil percentage of white cells;
LUSC	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg22676075	chr6:135203613	NA	-0.5	-7.88	-0.4	4.81e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg11871910	chr12:69753446	YEATS4	0.94	17.4	0.69	1.05e-48	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg17143192	chr8:8559678	CLDN23	0.63	9.03	0.44	1.37e-17	Obesity-related traits;
LUSC	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	0.59	9.49	0.46	4.59e-19	Breast cancer;
LUSC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg07701084	chr6:150067640	NUP43	0.57	8.66	0.43	1.98e-16	Lung cancer;
LUSC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.94	-15.05	-0.64	2.01e-39	Coronary artery disease;
LUSC	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg23262073	chr20:60523788	NA	-0.4	-5.93	-0.31	7.46e-9	Body mass index;
LUSC	cis	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg27411982	chr8:10470053	RP1L1	0.44	6.81	0.35	4.56e-11	Neuroticism;
LUSC	trans	rs10432489	0.708	rs12328545	chr2:181771545	T/A	cg16818443	chr4:2965195	GRK4;NOP14	0.82	6.01	0.31	4.74e-9	QT interval;
LUSC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg14664628	chr15:75095509	CSK	-0.55	-8.01	-0.4	1.97e-14	Breast cancer;
LUSC	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.44	-8.22	-0.41	4.65e-15	Monocyte percentage of white cells;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26868354	chr6:35699952	LOC285847	-0.39	-6.09	-0.32	3.18e-9	Electrocardiographic conduction measures;
LUSC	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg13010199	chr12:38710504	ALG10B	0.55	8.49	0.42	6.68e-16	Morning vs. evening chronotype;
LUSC	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.81e-20	Migraine;Coronary artery disease;
LUSC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg21280719	chr6:42927975	GNMT	-0.31	-7.84	-0.39	6.14e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.64	-10.0	-0.48	8.98e-21	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg18825076	chr15:78729989	IREB2	0.47	6.37	0.33	6.15e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg08345082	chr10:99160200	RRP12	-0.35	-7.04	-0.36	1.12e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.72	9.96	0.48	1.28e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg03806693	chr22:41940476	POLR3H	-1.02	-13.77	-0.6	1.74e-34	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs11785693	0.866	rs11782170	chr8:4976942	A/G	cg26367366	chr8:4980734	NA	-0.67	-7.55	-0.38	4.18e-13	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg02534363	chr3:47050950	NBEAL2	0.36	5.77	0.3	1.84e-8	Colorectal cancer;
LUSC	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.53	-8.92	-0.44	3.14e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs2274273	0.624	rs7147247	chr14:55777713	A/T	cg04306507	chr14:55594613	LGALS3	0.47	9.5	0.46	4.28e-19	Protein biomarker;
LUSC	cis	rs16867321	1.000	rs16867330	chr2:181446202	T/G	cg23363182	chr2:181467187	NA	-0.43	-5.91	-0.31	8.31e-9	Obesity;
LUSC	cis	rs7739264	0.564	rs2223361	chr6:19790809	C/T	cg02404759	chr6:19790362	NA	-0.44	-6.93	-0.35	2.2e-11	Endometriosis;
LUSC	cis	rs7923609	0.902	rs10822158	chr10:65094383	A/G	cg01631684	chr10:65280961	REEP3	-0.41	-6.43	-0.33	4.53e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	9.5	0.46	4.21e-19	Lung cancer in ever smokers;
LUSC	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg06640241	chr16:89574553	SPG7	0.73	10.13	0.48	3.42e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg08999081	chr20:33150536	PIGU	0.33	5.77	0.3	1.8e-8	Height;
LUSC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.52	-0.34	2.67e-10	Breast cancer;
LUSC	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.79	-0.43	8.32e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg18357645	chr12:58087776	OS9	0.52	7.86	0.4	5.41e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6681460	0.671	rs628655	chr1:67213573	T/G	cg02459107	chr1:67143332	SGIP1	-0.48	-8.53	-0.42	5.3e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs61863818	0.842	rs11189214	chr10:99181008	A/G	cg20016023	chr10:99160130	RRP12	0.29	6.38	0.33	6e-10	Monocyte percentage of white cells;
LUSC	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.7	-0.39	1.5700000000000001e-13	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs983392	0.591	rs3132886	chr11:60016387	T/A	cg24026212	chr11:59952134	MS4A6A	0.37	6.32	0.33	8.18e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1376303	0.558	rs12533180	chr7:32944132	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.68	5.94	0.31	7.35e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	0.93	12.78	0.57	9.74e-31	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg13042288	chr15:90349979	ANPEP	-0.47	-6.41	-0.33	4.97e-10	Uric acid levels;
LUSC	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.06	-0.48	5.7e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg23711669	chr6:146136114	FBXO30	-0.74	-13.4	-0.59	4.57e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.59	-9.63	-0.47	1.6e-19	Schizophrenia;
LUSC	cis	rs7804356	1.000	rs73067472	chr7:26855959	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.14	-0.32	2.4e-9	Type 1 diabetes;
LUSC	cis	rs16867335	0.625	rs7573877	chr2:181478111	A/G	cg23363182	chr2:181467187	NA	-0.62	-9.58	-0.46	2.34e-19	Survival in rectal cancer;
LUSC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.24	0.41	3.98e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg17764715	chr19:33622953	WDR88	0.59	8.81	0.43	6.71e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg22875332	chr1:76189707	ACADM	-0.4	-5.97	-0.31	5.93e-9	Daytime sleep phenotypes;
LUSC	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg22709100	chr7:91322751	NA	0.48	6.98	0.36	1.59e-11	Breast cancer;
LUSC	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.39	-7.16	-0.36	5.02e-12	Axial length;
LUSC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg09904177	chr6:26538194	HMGN4	0.47	7.47	0.38	7.28e-13	Schizophrenia;
LUSC	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.65	-0.63	6.79e-38	Schizophrenia;
LUSC	cis	rs10992471	0.528	rs1924243	chr9:95224847	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.22	-0.32	1.49e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg23289794	chr7:2394357	EIF3B	-0.73	-9.74	-0.47	6.8e-20	Multiple sclerosis;
LUSC	trans	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg25482853	chr8:67687455	SGK3	1.04	15.58	0.65	1.6e-41	Obesity-related traits;
LUSC	cis	rs12286929	0.556	rs11605461	chr11:115053011	C/T	cg04055981	chr11:115044050	NA	-0.43	-7.75	-0.39	1.12e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg02820040	chr2:241836501	C2orf54	0.27	5.7	0.3	2.62e-8	Urinary metabolites;
LUSC	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg02023728	chr11:77925099	USP35	0.43	6.53	0.34	2.41e-10	Testicular germ cell tumor;
LUSC	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	7.08	0.36	8.57e-12	Schizophrenia;
LUSC	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg23029597	chr12:123009494	RSRC2	-0.67	-8.74	-0.43	1.14e-16	Body mass index;
LUSC	cis	rs9296092	0.560	rs3846854	chr6:33528466	T/C	cg13560919	chr6:33536144	NA	-0.85	-16.44	-0.67	6.54e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs8073060	0.963	rs35614987	chr17:33869466	A/C	cg19694781	chr19:47549865	TMEM160	0.7	10.43	0.5	3.08e-22	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs9308433	0.529	rs1391553	chr1:214474119	T/C	cg06198575	chr1:214491504	SMYD2	0.46	7.14	0.36	5.95e-12	IgG glycosylation;
LUSC	cis	rs6500395	1.000	rs1106386	chr16:48593065	C/A	cg04672837	chr16:48644449	N4BP1	0.43	6.47	0.33	3.44e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9341808	0.538	rs613588	chr6:80978928	A/C	cg08355045	chr6:80787529	NA	-0.41	-7.01	-0.36	1.31e-11	Sitting height ratio;
LUSC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg05425664	chr17:57184151	TRIM37	0.53	7.79	0.39	8.64e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs113835537	0.866	rs59566349	chr11:66365994	A/T	cg24851651	chr11:66362959	CCS	0.52	6.41	0.33	5.01e-10	Airway imaging phenotypes;
LUSC	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.61	-9.47	-0.46	5.23e-19	Response to antineoplastic agents;
LUSC	cis	rs7119038	0.774	rs11217038	chr11:118677355	G/A	cg19308663	chr11:118741387	NA	0.36	6.47	0.33	3.49e-10	Sjögren's syndrome;
LUSC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg18306943	chr3:40428807	ENTPD3	0.4	6.18	0.32	1.87e-9	Renal cell carcinoma;
LUSC	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-11.39	-0.53	1.28e-25	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs4474465	1.000	rs7925034	chr11:78193242	A/G	cg27205649	chr11:78285834	NARS2	-0.5	-5.88	-0.31	1.01e-8	Alzheimer's disease (survival time);
LUSC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg22437258	chr11:111473054	SIK2	0.52	7.44	0.38	8.76e-13	Primary sclerosing cholangitis;
LUSC	cis	rs977987	0.898	rs12918797	chr16:75493810	T/C	cg03315344	chr16:75512273	CHST6	0.53	9.97	0.48	1.13e-20	Dupuytren's disease;
LUSC	cis	rs75804782	0.641	rs72987321	chr2:239352765	T/G	cg18131467	chr2:239335373	ASB1	-0.73	-6.63	-0.34	1.37e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg06096015	chr1:231504339	EGLN1	0.58	10.39	0.49	4.18e-22	Hemoglobin concentration;
LUSC	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg14582100	chr15:45693742	SPATA5L1	0.45	8.54	0.42	4.94e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg08680598	chr22:49984980	NA	-0.34	-6.36	-0.33	6.69e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	6.03	0.31	4.35e-9	Rheumatoid arthritis;
LUSC	cis	rs9309473	0.519	rs12991161	chr2:73871371	G/A	cg20560298	chr2:73613845	ALMS1	0.46	6.93	0.35	2.16e-11	Metabolite levels;
LUSC	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg23422044	chr7:1970798	MAD1L1	0.59	6.7	0.34	9.02e-11	Bipolar disorder;
LUSC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.73	-0.3	2.24e-8	Total body bone mineral density;
LUSC	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.79	-0.3	1.62e-8	Triglycerides;
LUSC	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg15644404	chr18:77186268	NFATC1	-0.68	-7.62	-0.38	2.63e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg05776053	chr2:74358815	NA	0.47	7.39	0.37	1.17e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs7759001	0.817	rs1534936	chr6:27354195	C/T	cg18711553	chr6:27366782	ZNF391	0.39	5.78	0.3	1.73e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg14844989	chr11:31128820	NA	-0.39	-6.02	-0.31	4.6e-9	Red blood cell count;
LUSC	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.57	10.83	0.51	1.21e-23	Hemoglobin concentration;
LUSC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg23978390	chr7:1156363	C7orf50	-0.45	-6.46	-0.33	3.68e-10	Longevity;Endometriosis;
LUSC	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg00277334	chr10:82204260	NA	-0.57	-8.67	-0.43	1.9e-16	Post bronchodilator FEV1;
LUSC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg19629631	chr7:2060116	MAD1L1	-0.34	-5.68	-0.3	2.89e-8	Neuroticism;
LUSC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg03161606	chr19:29218774	NA	0.61	9.29	0.45	2.07e-18	Methadone dose in opioid dependence;
LUSC	cis	rs59698941	0.882	rs67414627	chr5:132258165	A/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg03806693	chr22:41940476	POLR3H	-0.63	-9.21	-0.45	3.59e-18	Neuroticism;
LUSC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg12463550	chr7:65579703	CRCP	-0.42	-5.98	-0.31	5.67e-9	Aortic root size;
LUSC	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg11861562	chr11:117069780	TAGLN	0.32	6.2	0.32	1.64e-9	Blood protein levels;
LUSC	cis	rs11168618	0.904	rs7136845	chr12:48907029	C/T	cg24011408	chr12:48396354	COL2A1	0.4	6.31	0.33	8.92e-10	Adiponectin levels;
LUSC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.78	0.43	8.88e-17	Motion sickness;
LUSC	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg20701182	chr2:24300061	SF3B14	0.87	11.34	0.53	1.97e-25	Lymphocyte counts;
LUSC	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7615952	0.546	rs2979307	chr3:125309574	C/T	cg07211511	chr3:129823064	LOC729375	0.52	6.04	0.31	4.11e-9	Blood pressure (smoking interaction);
LUSC	cis	rs6500395	1.000	rs2080508	chr16:48690665	G/C	cg04672837	chr16:48644449	N4BP1	-0.46	-6.87	-0.35	3.2e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg09640425	chr7:158790006	NA	-0.55	-8.41	-0.42	1.18e-15	Facial morphology (factor 20);
LUSC	cis	rs600231	0.542	rs10896010	chr11:65246220	C/A	cg17120908	chr11:65337727	SSSCA1	-0.61	-8.89	-0.44	3.89e-17	Bone mineral density;
LUSC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12311346	chr5:56204834	C5orf35	-0.84	-12.95	-0.58	2.23e-31	Initial pursuit acceleration;
LUSC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	6.29	0.33	1.01e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9925964	0.935	rs4527034	chr16:31131614	A/G	cg02466173	chr16:30829666	NA	-0.32	-5.96	-0.31	6.46e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg10792982	chr14:105748885	BRF1	0.49	8.47	0.42	7.68e-16	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02980416	chr19:40502895	ZNF546	-0.43	-6.42	-0.33	4.64e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4423214	0.559	rs7949129	chr11:71193135	G/C	cg05163923	chr11:71159392	DHCR7	-0.67	-7.06	-0.36	9.6e-12	Vitamin D levels;
LUSC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg12963246	chr6:28129442	ZNF389	0.41	6.48	0.33	3.33e-10	Parkinson's disease;
LUSC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	15.63	0.65	9.98e-42	Platelet count;
LUSC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	0.97	13.35	0.59	7.23e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg00599273	chr12:58146742	CDK4	0.31	5.8	0.3	1.51e-8	Multiple sclerosis;
LUSC	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg26384229	chr12:38710491	ALG10B	0.53	7.42	0.38	9.66e-13	Morning vs. evening chronotype;
LUSC	cis	rs713477	1.000	rs8014526	chr14:55885054	C/G	cg04306507	chr14:55594613	LGALS3	-0.32	-6.47	-0.33	3.43e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs7178572	0.568	rs4886856	chr15:77510585	A/G	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	cis	rs28647808	0.748	rs114667516	chr9:136258537	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.2	-0.37	3.99e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	0.6	9.36	0.46	1.17e-18	Breast cancer;
LUSC	cis	rs3741151	0.686	rs7129990	chr11:73124441	A/G	cg17517138	chr11:73019481	ARHGEF17	0.61	5.94	0.31	7.29e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27114094	chr18:3262035	MYL12B	-0.41	-6.15	-0.32	2.19e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs3857536	0.813	rs6455083	chr6:66935406	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	trans	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs34638657	0.732	rs2911425	chr16:82203026	T/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.53	-0.34	2.4e-10	Lung adenocarcinoma;
LUSC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06634786	chr22:41940651	POLR3H	-0.53	-6.44	-0.33	4.05e-10	Vitiligo;
LUSC	cis	rs62458065	0.713	rs62463967	chr7:32498329	G/A	cg20159608	chr7:32802032	NA	-0.73	-9.16	-0.45	5.35e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg12863693	chr15:85201151	NMB	0.37	7.52	0.38	4.96e-13	Schizophrenia;
LUSC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg04518342	chr5:131593106	PDLIM4	0.54	10.21	0.49	1.82e-21	Acylcarnitine levels;
LUSC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg13206674	chr6:150067644	NUP43	0.62	10.12	0.48	3.66e-21	Lung cancer;
LUSC	cis	rs7605827	0.930	rs13006997	chr2:15700872	T/C	cg19274914	chr2:15703543	NA	0.46	8.64	0.43	2.43e-16	Educational attainment (years of education);
LUSC	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg14458575	chr2:238380390	NA	0.73	12.14	0.55	2.51e-28	Prostate cancer;
LUSC	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg13010199	chr12:38710504	ALG10B	0.57	9.09	0.45	9.21e-18	Morning vs. evening chronotype;
LUSC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg03146154	chr1:46216737	IPP	0.56	8.37	0.42	1.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg26752003	chr8:145688521	CYHR1	0.45	7.26	0.37	2.8e-12	Age at first birth;
LUSC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.17	-0.32	2e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg05340658	chr4:99064831	C4orf37	0.58	8.47	0.42	7.94e-16	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.69	0.39	1.62e-13	Corneal astigmatism;
LUSC	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg03522245	chr20:25566470	NINL	-0.36	-5.83	-0.3	1.33e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.02	0.31	4.49e-9	Menopause (age at onset);
LUSC	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg27124370	chr19:33622961	WDR88	0.59	7.69	0.39	1.64e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg08481491	chr3:125900108	ALDH1L1	-0.34	-6.79	-0.35	5.09e-11	Metabolite levels;
LUSC	cis	rs367943	0.712	rs26966	chr5:112740434	T/C	cg12552261	chr5:112820674	MCC	0.34	5.65	0.3	3.42e-8	Type 2 diabetes;
LUSC	trans	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.77	-0.35	5.94e-11	Brugada syndrome;
LUSC	cis	rs6088813	1.000	rs1570004	chr20:33958253	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.36	5.93	0.31	7.4e-9	Height;
LUSC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg13628971	chr7:2884303	GNA12	0.45	6.72	0.35	7.91e-11	Height;
LUSC	cis	rs981844	1.000	rs72731669	chr4:154662464	G/A	cg14289246	chr4:154710475	SFRP2	0.5	6.44	0.33	4.05e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs3784262	1.000	rs3784262	chr15:58253106	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.77	-0.3	1.78e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg15423357	chr2:25149977	NA	-0.37	-7.29	-0.37	2.3e-12	Body mass index in non-asthmatics;
LUSC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs36051895	0.623	rs10118434	chr9:5238460	A/G	cg02405213	chr9:5042618	JAK2	-0.56	-8.44	-0.42	9.86e-16	Pediatric autoimmune diseases;
LUSC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-6.3	-0.33	9.36e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs7818345	0.613	rs13261732	chr8:19330215	T/C	cg07611933	chr16:2773245	NA	-0.23	-6.08	-0.32	3.21e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg09796270	chr17:17721594	SREBF1	-0.45	-7.94	-0.4	3.09e-14	Total body bone mineral density;
LUSC	cis	rs1385374	1.000	rs12311303	chr12:129301592	C/T	cg09035930	chr12:129282057	SLC15A4	-0.63	-7.0	-0.36	1.45e-11	Systemic lupus erythematosus;
LUSC	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg06808227	chr14:105710500	BRF1	-0.65	-9.89	-0.48	2.06e-20	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs11935423	0.825	rs28789770	chr4:100489821	C/G	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.07	-0.32	3.51e-9	Gut microbiome composition (summer);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24859484	chr2:174830050	SP3	-0.4	-6.29	-0.33	9.67e-10	Triglycerides;
LUSC	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg27432699	chr2:27873401	GPN1	0.8	14.94	0.63	5.09e-39	Oral cavity cancer;
LUSC	cis	rs9796	0.558	rs7166205	chr15:41514733	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.5	-8.88	-0.44	4.17e-17	Menopause (age at onset);
LUSC	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.74	0.65	3.85e-42	Morning vs. evening chronotype;
LUSC	cis	rs67981189	0.593	rs221924	chr14:71580778	G/A	cg15816911	chr14:71606274	NA	-0.33	-5.76	-0.3	1.93e-8	Schizophrenia;
LUSC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg06641503	chr3:48959341	ARIH2	-0.38	-5.77	-0.3	1.86e-8	Parkinson's disease;
LUSC	cis	rs6961069	0.935	rs819437	chr7:80223996	C/T	cg04458919	chr7:80252533	CD36	-0.35	-6.53	-0.34	2.44e-10	Platelet count;
LUSC	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.83	14.38	0.62	7.71e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06634786	chr22:41940651	POLR3H	0.51	6.11	0.32	2.82e-9	Vitiligo;
LUSC	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg26769984	chr7:1090371	C7orf50	0.71	10.06	0.48	5.5e-21	Bronchopulmonary dysplasia;
LUSC	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg11965913	chr1:205819406	PM20D1	0.45	6.28	0.33	1.03e-9	Parkinson's disease;
LUSC	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg24503407	chr1:205819492	PM20D1	-0.48	-6.36	-0.33	6.68e-10	Menarche (age at onset);
LUSC	cis	rs2742417	0.609	rs11709306	chr3:45773732	G/A	cg04837898	chr3:45731254	SACM1L	-0.45	-7.25	-0.37	2.97e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.53	-8.11	-0.41	9.51e-15	Lymphocyte counts;
LUSC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08219700	chr8:58056026	NA	0.66	8.37	0.42	1.55e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs259282	0.605	rs66489063	chr19:33108959	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.66	9.84	0.47	3.07e-20	Schizophrenia;
LUSC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24531977	chr5:56204891	C5orf35	-0.91	-12.62	-0.57	4.11e-30	Initial pursuit acceleration;
LUSC	cis	rs10887741	0.646	rs1358865	chr10:89432645	C/A	cg13926569	chr10:89418898	PAPSS2	0.33	7.23	0.37	3.21e-12	Exercise (leisure time);
LUSC	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg19920283	chr7:105172520	RINT1	0.6	6.35	0.33	7.01e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs8016982	0.855	rs10149681	chr14:81686319	G/A	cg01989461	chr14:81687754	GTF2A1	0.55	8.29	0.41	2.75e-15	Schizophrenia;
LUSC	cis	rs6722750	0.716	rs2037862	chr2:64416533	C/T	cg22352474	chr2:64371530	PELI1	-0.53	-7.96	-0.4	2.76e-14	Neuroticism;
LUSC	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05962382	chr2:130345044	NA	-0.36	-6.31	-0.33	9.06e-10	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg01528321	chr10:82214614	TSPAN14	-0.81	-11.96	-0.55	1.14e-27	Post bronchodilator FEV1;
LUSC	cis	rs12760731	0.641	rs12691479	chr1:178328754	G/A	cg00404053	chr1:178313656	RASAL2	0.57	6.07	0.32	3.44e-9	Obesity-related traits;
LUSC	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-7.06	-0.36	9.55e-12	Lung cancer;
LUSC	cis	rs2692947	0.666	rs7566050	chr2:96626030	T/C	cg22654517	chr2:96458247	NA	0.32	6.22	0.32	1.52e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4499344	0.556	rs259217	chr19:33138368	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	13.73	0.6	2.52e-34	Mean platelet volume;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27492928	chr17:11993871	MAP2K4	-0.38	-6.22	-0.32	1.46e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs686320	1.000	rs686320	chr11:65244538	G/C	cg21890820	chr11:65308645	LTBP3	0.75	7.48	0.38	6.58e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg18850127	chr7:39170497	POU6F2	0.66	10.7	0.51	3.71e-23	IgG glycosylation;
LUSC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg15335139	chr3:50242325	SLC38A3	-0.25	-5.64	-0.3	3.57e-8	Body mass index;
LUSC	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg17764715	chr19:33622953	WDR88	0.57	7.59	0.38	3.29e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg21918786	chr6:109611834	NA	0.41	7.1	0.36	7.41e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs4654899	0.680	rs10916900	chr1:21239059	C/G	cg01072550	chr1:21505969	NA	-0.52	-7.65	-0.39	2.24e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg17845761	chr1:175162550	KIAA0040	-0.31	-6.0	-0.31	5.07e-9	Alcohol dependence;
LUSC	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.92	-0.44	3.08e-17	Bone mineral density;
LUSC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.55	8.71	0.43	1.38e-16	Aortic root size;
LUSC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg24562669	chr7:97807699	LMTK2	0.35	6.12	0.32	2.64e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10276381	1.000	rs10281214	chr7:28185544	G/C	cg23620719	chr7:28220237	JAZF1	0.59	6.55	0.34	2.15e-10	Crohn's disease;
LUSC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg26335602	chr6:28129616	ZNF389	0.43	5.75	0.3	1.98e-8	Depression;
LUSC	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg07828340	chr4:882639	GAK	1.03	10.42	0.5	3.42e-22	Intelligence (multi-trait analysis);
LUSC	trans	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg11887960	chr12:57824829	NA	0.54	6.74	0.35	7.11e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs8170	0.603	rs3810204	chr19:17448660	T/C	cg04749549	chr19:17459798	NA	-0.34	-6.09	-0.32	3.11e-9	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUSC	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg27411982	chr8:10470053	RP1L1	0.41	6.4	0.33	5.23e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.59	-0.34	1.73e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg19767477	chr5:127420684	SLC12A2	-0.43	-5.87	-0.31	1.06e-8	Ileal carcinoids;
LUSC	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg11887960	chr12:57824829	NA	0.58	7.13	0.36	6.16e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg10150615	chr22:24372951	LOC391322	-0.42	-6.86	-0.35	3.4e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	0.91	16.06	0.66	2.01e-43	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.78	9.42	0.46	7.77e-19	Body mass index;
LUSC	cis	rs10489202	1.000	rs7538251	chr1:168001752	C/G	cg24449463	chr1:168025552	DCAF6	-0.62	-7.91	-0.4	3.71e-14	Schizophrenia;
LUSC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07256732	chr16:621771	PIGQ	-0.35	-6.41	-0.33	4.98e-10	Height;
LUSC	trans	rs9409565	0.787	rs11789704	chr9:97233408	C/T	cg05679027	chr9:99775184	HIATL2	-0.47	-6.59	-0.34	1.73e-10	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs10489202	1.000	rs7523437	chr1:168029365	A/G	cg24449463	chr1:168025552	DCAF6	-0.58	-7.26	-0.37	2.71e-12	Schizophrenia;
LUSC	cis	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs9392556	0.829	rs659025	chr6:4119051	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.35	-6.0	-0.31	5.14e-9	Blood metabolite levels;
LUSC	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg19812747	chr11:111475976	SIK2	0.5	6.7	0.34	8.87e-11	Primary sclerosing cholangitis;
LUSC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg00990874	chr7:1149470	C7orf50	-0.5	-6.33	-0.33	7.99e-10	Bronchopulmonary dysplasia;
LUSC	trans	rs953492	0.517	rs2247527	chr1:243309983	A/C	cg25284624	chr1:224180302	NA	0.48	7.44	0.38	8.53e-13	Diastolic blood pressure;
LUSC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg13175981	chr1:150552382	MCL1	0.43	6.09	0.32	3.19e-9	Tonsillectomy;
LUSC	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg25173405	chr17:45401733	C17orf57	0.37	5.9	0.31	8.79e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.59	9.61	0.47	1.82e-19	Aortic root size;
LUSC	cis	rs1018836	0.828	rs7008172	chr8:91551613	C/T	cg16814680	chr8:91681699	NA	-0.69	-11.05	-0.52	2.13e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg21775007	chr8:11205619	TDH	0.52	7.86	0.4	5.17e-14	Retinal vascular caliber;
LUSC	cis	rs10911363	0.659	rs6669960	chr1:183436577	C/G	cg09173681	chr1:183549694	NCF2	-0.62	-11.1	-0.52	1.43e-24	Systemic lupus erythematosus;
LUSC	cis	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg02972257	chr16:68554789	NA	-0.54	-6.74	-0.35	7.02e-11	Ulcerative colitis;
LUSC	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.48	-5.9	-0.31	8.74e-9	Neutrophil percentage of white cells;
LUSC	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.72	-11.66	-0.54	1.33e-26	Schizophrenia;
LUSC	cis	rs6967385	0.560	rs7790370	chr7:12353523	G/C	cg06484146	chr7:12443880	VWDE	0.5	7.42	0.38	1.01e-12	Response to taxane treatment (placlitaxel);
LUSC	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.26	-0.37	2.7e-12	Monocyte count;
LUSC	cis	rs710865	1.000	rs710865	chr1:19568972	A/G	cg13387374	chr1:19411106	UBR4	0.44	6.42	0.33	4.62e-10	Brain structure;
LUSC	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg09491104	chr22:46646882	C22orf40	-0.7	-7.1	-0.36	7.44e-12	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs7493138	0.967	rs1951257	chr14:29008123	A/G	cg10573181	chr4:170533618	NEK1	0.41	6.09	0.32	3.14e-9	Longevity;
LUSC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg08219700	chr8:58056026	NA	0.47	6.24	0.32	1.29e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-7.42	-0.38	9.98e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg07424592	chr7:64974309	NA	0.67	5.88	0.31	9.86e-9	Diabetic kidney disease;
LUSC	cis	rs4819052	0.635	rs2838808	chr21:46621106	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.46	6.62	0.34	1.41e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21724239	chr8:58056113	NA	0.85	9.05	0.44	1.18e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg24596788	chr1:163392923	NA	-0.42	-7.17	-0.37	4.99e-12	Motion sickness;
LUSC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg25019033	chr10:957182	NA	-0.5	-6.41	-0.33	4.95e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg00857998	chr1:205179979	DSTYK	0.64	9.73	0.47	7.18e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg09904177	chr6:26538194	HMGN4	0.75	14.04	0.61	1.66e-35	Intelligence (multi-trait analysis);
LUSC	trans	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-8.86	-0.44	4.74e-17	Obesity-related traits;
LUSC	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg16989719	chr2:238392110	NA	-0.43	-7.34	-0.37	1.61e-12	Prostate cancer;
LUSC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08109568	chr15:31115862	NA	0.74	11.21	0.52	5.84e-25	Huntington's disease progression;
LUSC	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.7	0.34	8.95e-11	Corneal astigmatism;
LUSC	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg20991723	chr1:152506922	NA	0.53	9.93	0.48	1.56e-20	Hair morphology;
LUSC	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	0.53	7.63	0.39	2.54e-13	Breast cancer;
LUSC	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg24375607	chr4:120327624	NA	0.49	7.36	0.37	1.42e-12	Diastolic blood pressure;
LUSC	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg01884057	chr2:25150051	NA	-0.38	-8.46	-0.42	8.22e-16	Body mass index in non-asthmatics;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11123972	chr11:68228042	SAPS3	-0.4	-6.06	-0.31	3.75e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs61931739	0.591	rs10743834	chr12:33916129	A/C	cg13010199	chr12:38710504	ALG10B	0.41	6.11	0.32	2.76e-9	Morning vs. evening chronotype;
LUSC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg12927641	chr6:109611667	NA	-0.41	-7.04	-0.36	1.08e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	cis	rs1256061	0.603	rs1256041	chr14:64738029	A/G	cg21174375	chr14:64681225	SYNE2	0.35	6.26	0.32	1.19e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs6076065	0.723	rs6083110	chr20:23373674	C/T	cg11657817	chr20:23433608	CST11	0.43	8.07	0.4	1.25e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg16989719	chr2:238392110	NA	-0.48	-7.68	-0.39	1.77e-13	Prostate cancer;
LUSC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg25206134	chr2:45395956	NA	0.62	7.23	0.37	3.24e-12	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg08219700	chr8:58056026	NA	0.49	6.06	0.31	3.73e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg03929089	chr4:120376271	NA	0.61	6.5	0.34	2.97e-10	Axial length;
LUSC	cis	rs3862435	0.764	rs2601200	chr15:90955177	C/T	cg22089800	chr15:90895588	ZNF774	0.58	6.32	0.33	8.53e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.41	-6.24	-0.32	1.33e-9	Breast cancer;
LUSC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.85	15.67	0.65	6.91e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg19729930	chr2:74357872	NA	0.88	16.81	0.68	2.13e-46	Gestational age at birth (maternal effect);
LUSC	cis	rs13082711	0.595	rs4973762	chr3:27364789	A/T	cg02860705	chr3:27208620	NA	0.73	12.1	0.55	3.33e-28	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	0.92	15.86	0.66	1.26e-42	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.71	13.3	0.59	1.12e-32	Height;
LUSC	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.0	0.52	3.23e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg08847533	chr14:75593920	NEK9	0.84	15.41	0.64	7.39e-41	Height;
LUSC	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg05925327	chr15:68127851	NA	-0.39	-6.1	-0.32	2.89e-9	Obesity;
LUSC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.27	0.52	3.49e-25	Menopause (age at onset);
LUSC	cis	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05901451	chr6:126070800	HEY2	-0.57	-8.56	-0.42	4.29e-16	Endometrial cancer;
LUSC	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg00898013	chr13:113819073	PROZ	-0.6	-8.82	-0.43	6.27e-17	Platelet distribution width;
LUSC	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.75	-0.3	1.99e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.34	-0.42	1.97e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.08	-0.32	3.26e-9	Neutrophil percentage of white cells;
LUSC	trans	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg06521331	chr12:34319734	NA	-0.4	-6.27	-0.32	1.15e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg14196790	chr5:131705035	SLC22A5	-0.43	-6.99	-0.36	1.53e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.81	-14.43	-0.62	4.97e-37	Sudden cardiac arrest;
LUSC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-9.0	-0.44	1.72e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.58	-0.6	9.2e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg21775007	chr8:11205619	TDH	-0.41	-6.22	-0.32	1.49e-9	Mood instability;
LUSC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg04455712	chr21:45112962	RRP1B	-0.44	-8.13	-0.41	8.72e-15	Mean corpuscular volume;
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.62	10.14	0.49	3.07e-21	Lymphocyte counts;
LUSC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.62	12.64	0.57	3.5e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1957429	0.901	rs1957435	chr14:65349697	G/A	cg23373153	chr14:65346875	NA	1.07	12.89	0.58	3.85e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.77	-0.6	1.81e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.88	14.18	0.61	4.69e-36	Coronary artery disease;
LUSC	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs977987	0.843	rs12149063	chr16:75451758	G/A	cg03315344	chr16:75512273	CHST6	0.48	8.93	0.44	3.01e-17	Dupuytren's disease;
LUSC	cis	rs10266483	0.739	rs12671185	chr7:63793707	G/A	cg24201672	chr7:64023550	ZNF680	0.44	5.8	0.3	1.5e-8	Response to statin therapy;
LUSC	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg13852791	chr20:30311386	BCL2L1	0.93	14.46	0.62	3.86e-37	Mean corpuscular hemoglobin;
LUSC	trans	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg09781936	chr22:19749961	TBX1	-0.33	-5.95	-0.31	6.84e-9	Inflammatory bowel disease;
LUSC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.05	-0.4	1.45e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs554111	0.634	rs12026318	chr1:21316623	T/C	cg01072550	chr1:21505969	NA	0.41	6.28	0.32	1.05e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-5.95	-0.31	6.8e-9	Vitiligo;
LUSC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-5.99	-0.31	5.34e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1403694	0.515	rs1622922	chr3:186449884	C/T	cg12454167	chr3:186435060	KNG1	0.28	7.63	0.39	2.46e-13	Blood protein levels;
LUSC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	0.94	13.74	0.6	2.27e-34	Vitiligo;
LUSC	cis	rs11690935	0.550	rs6718013	chr2:172869185	A/G	cg13550731	chr2:172543902	DYNC1I2	0.53	7.96	0.4	2.7e-14	Schizophrenia;
LUSC	cis	rs981844	0.683	rs1037653	chr4:154749992	A/T	cg14289246	chr4:154710475	SFRP2	-0.46	-6.32	-0.33	8.22e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs2562456	0.793	rs2562474	chr19:21646282	A/C	cg00806126	chr19:22604979	ZNF98	0.39	6.01	0.31	4.87e-9	Pain;
LUSC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg14558114	chr2:88469736	THNSL2	-0.76	-6.66	-0.34	1.15e-10	Plasma clusterin levels;
LUSC	trans	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.08	-0.32	3.3e-9	Depression;
LUSC	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg05283184	chr6:79620031	NA	-0.46	-8.72	-0.43	1.36e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	12.03	0.55	6.38e-28	Exhaled nitric oxide output;
LUSC	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg25251562	chr2:3704773	ALLC	-0.37	-6.56	-0.34	2.02e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs34734847	0.787	rs695948	chr12:121149596	A/G	cg21892295	chr12:121157589	UNC119B	-0.49	-8.96	-0.44	2.27e-17	Mean corpuscular volume;
LUSC	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg04362960	chr10:104952993	NT5C2	0.51	7.17	0.37	4.77e-12	Waist circumference;Hip circumference;
LUSC	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg13010199	chr12:38710504	ALG10B	-0.67	-10.83	-0.51	1.27e-23	Heart rate;
LUSC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg04287289	chr16:89883240	FANCA	0.78	6.24	0.32	1.29e-9	Skin colour saturation;
LUSC	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg11845111	chr2:191398756	TMEM194B	-0.68	-9.15	-0.45	5.95e-18	Diastolic blood pressure;
LUSC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11645453	chr3:52864694	ITIH4	0.34	7.87	0.4	5.04e-14	Electroencephalogram traits;
LUSC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg05896524	chr21:47604654	C21orf56	0.4	5.91	0.31	8.52e-9	Testicular germ cell tumor;
LUSC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.67	-12.11	-0.55	3.17e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg19508488	chr2:152266495	RIF1	0.4	5.8	0.3	1.58e-8	Lung cancer;
LUSC	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg06637938	chr14:75390232	RPS6KL1	0.49	7.57	0.38	3.61e-13	Height;
LUSC	cis	rs3730682	0.694	rs648383	chr18:51778993	G/C	cg04730925	chr18:51795821	POLI	0.4	6.14	0.32	2.39e-9	Psoriasis;
LUSC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg15649852	chr7:65879115	NA	-0.41	-5.75	-0.3	2.05e-8	Aortic root size;
LUSC	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg00129232	chr17:37814104	STARD3	-0.43	-6.25	-0.32	1.28e-9	Asthma;
LUSC	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg02423579	chr7:2872169	GNA12	-0.4	-6.34	-0.33	7.58e-10	Height;
LUSC	cis	rs7818345	0.935	rs6990217	chr8:19276661	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.37	7.12	0.36	6.47e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.87	14.22	0.61	3.36e-36	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg09491104	chr22:46646882	C22orf40	-0.64	-7.22	-0.37	3.64e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08280861	chr8:58055591	NA	-0.56	-6.2	-0.32	1.62e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.82	-0.3	1.41e-8	Bipolar disorder;
LUSC	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg00677455	chr12:58241039	CTDSP2	0.5	7.6	0.38	3.06e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9322817	0.691	rs2486143	chr6:105308593	A/G	cg02098413	chr6:105308735	HACE1	0.27	5.76	0.3	1.92e-8	Thyroid stimulating hormone;
LUSC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg01416388	chr22:39784598	NA	-0.43	-7.21	-0.37	3.82e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21908287	chr1:155225385	FAM189B	0.69	6.04	0.31	4.02e-9	Cognitive performance;
LUSC	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	1.24	19.67	0.73	9.29e-58	Corneal structure;
LUSC	trans	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg13565492	chr6:43139072	SRF	-0.61	-6.4	-0.33	5.21e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7939886	0.688	rs11227290	chr11:55896577	A/G	cg03929089	chr4:120376271	NA	0.74	6.19	0.32	1.74e-9	Myopia (pathological);
LUSC	trans	rs7849782	0.967	rs10760799	chr9:104414056	G/T	cg22914338	chr19:14376960	NA	0.25	6.13	0.32	2.48e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	trans	rs12902680	0.706	rs12439680	chr15:46528391	A/C	cg04321580	chr8:143696133	ARC	-0.42	-6.18	-0.32	1.83e-9	Neuroticism;
LUSC	cis	rs10214930	0.560	rs42088	chr7:27701861	C/T	cg22168087	chr7:27702803	HIBADH	-0.46	-6.2	-0.32	1.63e-9	Hypospadias;
LUSC	cis	rs1594829	0.500	rs4871973	chr8:26199883	A/G	cg13160058	chr8:26243215	BNIP3L	-0.33	-6.0	-0.31	5.09e-9	Height;
LUSC	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.84	-0.3	1.23e-8	Type 2 diabetes;
LUSC	cis	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-6.75	-0.35	6.45e-11	Total cholesterol levels;
LUSC	cis	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg06521331	chr12:34319734	NA	-0.51	-8.93	-0.44	2.96e-17	Morning vs. evening chronotype;
LUSC	trans	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	2.03e-12	Bone mineral density;
LUSC	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg23176889	chr5:176863531	GRK6	-0.66	-13.67	-0.6	4.36e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.77e-22	Eye color traits;
LUSC	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.95	17.97	0.7	5.24e-51	Bone mineral density;
LUSC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg18230493	chr5:56204884	C5orf35	-0.87	-13.11	-0.58	5.69e-32	Initial pursuit acceleration;
LUSC	cis	rs2806561	0.729	rs649664	chr1:23324263	C/T	cg19743168	chr1:23544995	NA	-0.38	-7.94	-0.4	3.02e-14	Height;
LUSC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg11843238	chr5:131593191	PDLIM4	-0.49	-8.75	-0.43	1.09e-16	Acylcarnitine levels;
LUSC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg19318889	chr4:1322082	MAEA	0.55	9.14	0.45	6.3e-18	Obesity-related traits;
LUSC	cis	rs1775715	0.870	rs10827001	chr10:32229734	C/T	cg26784012	chr10:32216390	ARHGAP12	0.41	6.81	0.35	4.63e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg06740227	chr12:86229804	RASSF9	0.37	5.84	0.3	1.27e-8	Major depressive disorder;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24503407	chr1:205819492	PM20D1	-0.85	-15.77	-0.65	2.77e-42	Menarche (age at onset);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg08215925	chr3:71633214	FOXP1	0.43	6.68	0.34	1.01e-10	Triglycerides;
LUSC	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-0.84	-13.58	-0.6	9.18e-34	Refractive error;
LUSC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg04287289	chr16:89883240	FANCA	-0.43	-6.14	-0.32	2.3e-9	Vitiligo;
LUSC	cis	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg21775007	chr8:11205619	TDH	-0.5	-7.54	-0.38	4.51e-13	Systolic blood pressure;
LUSC	trans	rs7939886	0.920	rs11227372	chr11:55919682	C/A	cg03929089	chr4:120376271	NA	0.77	6.12	0.32	2.62e-9	Myopia (pathological);
LUSC	cis	rs11997175	0.574	rs4538830	chr8:33653741	C/G	ch.8.33884649F	chr8:33765107	NA	0.52	8.45	0.42	8.95e-16	Body mass index;
LUSC	cis	rs243505	0.964	rs243517	chr7:148425915	T/A	cg09806900	chr7:148480153	CUL1	-0.48	-6.94	-0.35	2.08e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9653442	0.527	rs4850923	chr2:100782256	A/C	cg22139774	chr2:100720529	AFF3	-0.42	-7.27	-0.37	2.55e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06634786	chr22:41940651	POLR3H	0.5	6.01	0.31	4.81e-9	Vitiligo;
LUSC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg22800045	chr5:56110881	MAP3K1	0.77	9.5	0.46	4.11e-19	Initial pursuit acceleration;
LUSC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg27432699	chr2:27873401	GPN1	-0.56	-8.36	-0.42	1.67e-15	Total body bone mineral density;
LUSC	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg21775007	chr8:11205619	TDH	0.42	5.99	0.31	5.42e-9	Neuroticism;
LUSC	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.73	-0.47	7.04e-20	Total cholesterol levels;
LUSC	cis	rs11608355	0.515	rs3742018	chr12:109949134	C/T	cg05360138	chr12:110035743	NA	0.92	12.22	0.56	1.23e-28	Neuroticism;
LUSC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg17385448	chr1:15911702	AGMAT	0.38	6.42	0.33	4.64e-10	Systolic blood pressure;
LUSC	cis	rs12195417	0.563	rs607259	chr6:84217876	G/A	cg08257003	chr6:84140564	ME1	-0.28	-6.55	-0.34	2.12e-10	Schizophrenia;
LUSC	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg00191853	chr8:101177733	SPAG1	-0.41	-6.56	-0.34	2.08e-10	Atrioventricular conduction;
LUSC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg02079420	chr8:82753780	SNX16	-0.41	-7.03	-0.36	1.13e-11	Diastolic blood pressure;
LUSC	cis	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg07988820	chr12:82153109	PPFIA2	-0.42	-6.04	-0.31	4.05e-9	Resting heart rate;
LUSC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg04691961	chr3:161091175	C3orf57	-0.35	-5.92	-0.31	7.79e-9	Morning vs. evening chronotype;
LUSC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06656553	chr16:89960601	TCF25	-0.55	-5.66	-0.3	3.24e-8	Skin colour saturation;
LUSC	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg00504896	chr12:9437009	LOC642846	-0.48	-7.63	-0.39	2.41e-13	Breast size;
LUSC	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	8.86	0.44	4.85e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2637266	0.935	rs7477361	chr10:78393586	G/A	cg18941641	chr10:78392320	NA	0.41	7.45	0.38	8.16e-13	Pulmonary function;
LUSC	cis	rs7180079	1.000	rs12148898	chr15:64643691	T/C	cg02848875	chr15:64387786	SNX1	0.4	5.64	0.3	3.54e-8	Monocyte count;
LUSC	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.65	-0.43	2.13e-16	Systolic blood pressure;
LUSC	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg19682013	chr15:45996608	NA	0.38	5.75	0.3	2.03e-8	Waist circumference;Weight;
LUSC	cis	rs921665	0.680	rs76494865	chr2:3191204	G/A	cg16434511	chr2:3151078	NA	-0.63	-6.83	-0.35	3.92e-11	World class endurance athleticism;
LUSC	cis	rs2625529	0.824	rs12592044	chr15:72419115	A/G	cg16672083	chr15:72433130	SENP8	-0.51	-7.52	-0.38	5.23e-13	Red blood cell count;
LUSC	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.71	-9.72	-0.47	7.63e-20	Coronary artery disease;
LUSC	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg03929089	chr4:120376271	NA	0.71	7.93	0.4	3.34e-14	Axial length;
LUSC	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.15	-0.36	5.34e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg00080972	chr5:178986291	RUFY1	-0.61	-10.85	-0.51	1.05e-23	Lung cancer;
LUSC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg17691542	chr6:26056736	HIST1H1C	0.47	7.03	0.36	1.19e-11	Height;
LUSC	cis	rs8018808	0.935	rs7146595	chr14:77932017	A/C	cg20045696	chr14:77926864	AHSA1	0.34	5.76	0.3	1.95e-8	Myeloid white cell count;
LUSC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg00129232	chr17:37814104	STARD3	0.49	7.46	0.38	7.64e-13	Asthma;
LUSC	cis	rs2041895	0.509	rs10861676	chr12:107311235	G/A	cg13944111	chr12:107296891	NA	0.38	6.7	0.34	8.87e-11	Glaucoma (low intraocular pressure);
LUSC	cis	rs965513	1.000	rs7027030	chr9:100550455	A/C	cg13688889	chr9:100608707	NA	-0.54	-8.05	-0.4	1.51e-14	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg02153584	chr22:29168773	CCDC117	0.58	8.65	0.43	2.26e-16	Lymphocyte counts;
LUSC	cis	rs6834538	0.597	rs1486865	chr4:113465651	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.36	5.82	0.3	1.37e-8	Free thyroxine concentration;
LUSC	cis	rs977987	0.806	rs11149833	chr16:75464002	G/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.42e-11	Dupuytren's disease;
LUSC	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg01689657	chr7:91764605	CYP51A1	0.32	5.68	0.3	2.88e-8	Breast cancer;
LUSC	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg13010199	chr12:38710504	ALG10B	0.48	7.28	0.37	2.47e-12	Heart rate;
LUSC	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.51	-9.0	-0.44	1.78e-17	Menopause (age at onset);
LUSC	cis	rs7927592	0.789	rs2291467	chr11:68216756	C/T	cg20283391	chr11:68216788	NA	-0.65	-8.75	-0.43	1.04e-16	Total body bone mineral density;
LUSC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg20135002	chr11:47629003	NA	-0.51	-8.11	-0.41	9.83e-15	Subjective well-being;
LUSC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg20476274	chr7:133979776	SLC35B4	0.88	16.76	0.68	3.47e-46	Mean platelet volume;
LUSC	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg02527881	chr3:46936655	PTH1R	0.39	6.87	0.35	3.23e-11	Colorectal cancer;
LUSC	cis	rs6722750	0.933	rs4671553	chr2:64408476	A/T	cg22352474	chr2:64371530	PELI1	-0.53	-7.8	-0.39	7.95e-14	Neuroticism;
LUSC	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg23711669	chr6:146136114	FBXO30	-0.83	-14.85	-0.63	1.13e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg02428538	chr16:24856791	SLC5A11	-0.5	-5.79	-0.3	1.64e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg27588902	chr6:42928151	GNMT	-0.3	-6.67	-0.34	1.05e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg18132916	chr6:79620363	NA	-0.38	-5.76	-0.3	1.9e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12210905	0.688	rs12202956	chr6:27356476	T/C	cg08851530	chr6:28072375	NA	0.93	6.11	0.32	2.71e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.63	9.9	0.48	2.05e-20	Morning vs. evening chronotype;
LUSC	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg02569458	chr12:86230093	RASSF9	0.58	9.93	0.48	1.6e-20	Major depressive disorder;
LUSC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.03	-0.44	1.43e-17	Bipolar disorder and schizophrenia;
LUSC	trans	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg09060275	chr22:27053596	MIAT	-0.4	-5.99	-0.31	5.46e-9	Height;
LUSC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.19	-0.49	2.13e-21	Hemoglobin concentration;
LUSC	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg19640130	chr10:64028056	RTKN2	-0.41	-7.4	-0.38	1.08e-12	Rheumatoid arthritis;
LUSC	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.96	0.48	1.29e-20	Lung cancer in ever smokers;
LUSC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg13683864	chr3:40499215	RPL14	-0.93	-15.98	-0.66	4.34e-43	Renal cell carcinoma;
LUSC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg03146154	chr1:46216737	IPP	0.54	7.93	0.4	3.32e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.43e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg00806126	chr19:22604979	ZNF98	0.37	5.71	0.3	2.43e-8	Pain;
LUSC	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg07150166	chr2:30669952	LCLAT1	0.65	7.03	0.36	1.17e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg24642844	chr7:1081250	C7orf50	-0.8	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.24	-0.37	3.09e-12	Alzheimer's disease (late onset);
LUSC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg13683864	chr3:40499215	RPL14	-0.92	-15.88	-0.66	1.03e-42	Renal cell carcinoma;
LUSC	cis	rs17102423	0.623	rs12100752	chr14:65611546	G/C	cg11161011	chr14:65562177	MAX	-0.63	-8.8	-0.43	7.71e-17	Obesity-related traits;
LUSC	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg17757837	chr7:157058334	UBE3C	0.83	13.32	0.59	9.37e-33	Body mass index;
LUSC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.55	8.01	0.4	1.92e-14	Alzheimer's disease (late onset);
LUSC	cis	rs9378688	1.000	rs9392374	chr6:2223002	T/G	cg12303981	chr6:2244766	GMDS	-0.48	-5.68	-0.3	2.96e-8	Caudate nucleus volume;
LUSC	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.54	-8.81	-0.43	6.73e-17	Breast cancer;
LUSC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24838063	chr12:130822603	PIWIL1	0.69	10.79	0.51	1.69e-23	Menopause (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00029397	chr12:57940957	DCTN2	0.42	6.01	0.31	4.79e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs668210	0.643	rs549334	chr11:65774659	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.59	7.87	0.4	4.86e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	0.8	11.33	0.53	2.2e-25	Platelet distribution width;
LUSC	trans	rs12210905	0.925	rs72838243	chr6:26984198	A/T	cg11837749	chr1:55047332	ACOT11	0.57	6.09	0.32	3.07e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1044573	0.514	rs2268879	chr20:25177805	C/T	cg13962466	chr20:25176127	ENTPD6	-0.38	-6.18	-0.32	1.9e-9	Allergic rhinitis;
LUSC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10484885	0.878	rs72921955	chr6:90588789	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.35	-0.42	1.88e-15	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.26	-27.65	-0.83	2.31e-88	Exhaled nitric oxide output;
LUSC	cis	rs67981189	0.593	rs8006046	chr14:71498991	A/G	cg15816911	chr14:71606274	NA	0.33	5.86	0.31	1.12e-8	Schizophrenia;
LUSC	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.94	0.36	2.04e-11	IgG glycosylation;
LUSC	trans	rs17266958	1.000	rs62577010	chr9:83304978	T/G	cg01905489	chr1:26616534	UBXN11	-0.58	-6.38	-0.33	6.04e-10	Preschool internalizing problems;
LUSC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.82	0.3	1.41e-8	Lung cancer;
LUSC	cis	rs6674970	1.000	rs61819219	chr1:151084375	C/G	cg03258749	chr1:151040405	MLLT11	-0.43	-6.59	-0.34	1.76e-10	Childhood ear infection;
LUSC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16405210	chr4:1374714	KIAA1530	-0.85	-13.93	-0.61	4.38e-35	Longevity;
LUSC	cis	rs6908843	0.582	rs60948137	chr6:166666777	G/A	cg06878426	chr6:166666287	NA	0.46	6.69	0.34	9.57e-11	Macrophage inflammatory protein 1b levels;
LUSC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	0.84	14.44	0.62	4.48e-37	Tonsillectomy;
LUSC	trans	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg04995722	chr7:26192034	NFE2L3	0.36	6.01	0.31	4.92e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg26769984	chr7:1090371	C7orf50	0.53	7.19	0.37	4.26e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs1355223	0.525	rs7129533	chr11:34872292	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.74	-0.35	7e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6469656	0.892	rs6469657	chr8:117668389	G/A	cg24004040	chr8:117650383	NA	-0.42	-6.26	-0.32	1.16e-9	Colorectal cancer;
LUSC	cis	rs10203711	1.000	rs907113	chr2:239567724	T/C	cg14580085	chr2:239553406	NA	0.42	7.1	0.36	7.48e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg22963979	chr7:1858916	MAD1L1	-0.64	-10.45	-0.5	2.56e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg03859395	chr2:55845619	SMEK2	-0.68	-10.4	-0.49	3.9e-22	Metabolic syndrome;
LUSC	cis	rs4363385	0.818	rs10788856	chr1:153011517	G/C	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs7809950	0.817	rs2701679	chr7:107283908	A/G	cg23024343	chr7:107201750	COG5	0.55	8.2	0.41	5.4e-15	Coronary artery disease;
LUSC	cis	rs68170813	0.652	rs77056542	chr7:107089751	G/C	cg02696742	chr7:106810147	HBP1	-0.66	-8.43	-0.42	1.06e-15	Coronary artery disease;
LUSC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.74	0.3	2.14e-8	Menopause (age at onset);
LUSC	cis	rs3750082	0.754	rs35110377	chr7:32971770	C/G	cg08946731	chr7:32981826	RP9P	-0.36	-5.73	-0.3	2.29e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg00277334	chr10:82204260	NA	-0.51	-7.41	-0.38	1.05e-12	Post bronchodilator FEV1;
LUSC	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg12062639	chr20:23401060	NAPB	0.97	8.33	0.41	2.08e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs954108	0.809	rs715705	chr13:29369467	T/C	cg11788234	chr13:29393811	NA	-0.39	-6.7	-0.34	8.88e-11	Obesity-related traits;
LUSC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06873352	chr17:61820015	STRADA	0.7	12.6	0.57	4.58e-30	Prudent dietary pattern;
LUSC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg00784671	chr22:46762841	CELSR1	-0.49	-6.06	-0.31	3.75e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg16031515	chr1:205743344	RAB7L1	-0.28	-6.11	-0.32	2.81e-9	Menarche (age at onset);
LUSC	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs500891	0.525	rs1145899	chr6:84039558	G/C	cg08257003	chr6:84140564	ME1	0.32	7.12	0.36	6.58e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs6681460	0.933	rs7554101	chr1:67156472	A/G	cg02459107	chr1:67143332	SGIP1	-0.45	-8.36	-0.42	1.76e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg09904177	chr6:26538194	HMGN4	-0.66	-11.71	-0.54	8.71e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	0.68	6.8	0.35	4.89e-11	Prostate cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04523929	chr3:10168401	C3orf10	-0.41	-6.61	-0.34	1.54e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.71	-8.69	-0.43	1.71e-16	Lung function (FEV1/FVC);
LUSC	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg13395646	chr4:1353034	KIAA1530	-0.6	-9.39	-0.46	9.79e-19	Longevity;
LUSC	cis	rs7674212	0.531	rs4698876	chr4:103933567	T/G	cg16532752	chr4:104119610	CENPE	-0.42	-5.78	-0.3	1.69e-8	Type 2 diabetes;
LUSC	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg21045802	chr8:109455806	TTC35	0.42	6.65	0.34	1.17e-10	Dupuytren's disease;
LUSC	cis	rs7809950	0.678	rs982447	chr7:106973534	T/C	cg23024343	chr7:107201750	COG5	-0.66	-9.86	-0.47	2.6e-20	Coronary artery disease;
LUSC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.76	-0.68	3.56e-46	Monocyte count;
LUSC	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.11	0.41	9.42e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2637266	1.000	rs12251568	chr10:78345667	C/T	cg18941641	chr10:78392320	NA	0.37	6.92	0.35	2.34e-11	Pulmonary function;
LUSC	cis	rs9905704	0.681	rs8081247	chr17:56557837	G/A	cg12560992	chr17:57184187	TRIM37	-0.51	-5.8	-0.3	1.57e-8	Testicular germ cell tumor;
LUSC	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg08807101	chr21:30365312	RNF160	-0.52	-6.44	-0.33	4.06e-10	Cognitive test performance;
LUSC	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg08601574	chr20:25228251	PYGB	0.46	7.03	0.36	1.2e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs12210905	0.925	rs72838245	chr6:26987316	A/C	cg11837749	chr1:55047332	ACOT11	0.57	6.09	0.32	3.07e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg02951883	chr7:2050386	MAD1L1	0.55	10.14	0.49	3.12e-21	Bipolar disorder and schizophrenia;
LUSC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.92	-0.81	3.6e-78	Height;
LUSC	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.52	-10.48	-0.5	2.13e-22	Schizophrenia;
LUSC	cis	rs3862260	1.000	rs3862260	chr1:120160789	G/A	cg11530693	chr1:120165357	ZNF697	0.51	7.92	0.4	3.49e-14	Systemic lupus erythematosus;
LUSC	cis	rs9473147	0.503	rs2171086	chr6:47590104	C/T	cg12968598	chr6:47444699	CD2AP	0.53	8.12	0.41	9.35e-15	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg13010344	chr12:123464640	ARL6IP4	-0.48	-6.51	-0.34	2.81e-10	Neutrophil percentage of white cells;
LUSC	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg06627628	chr2:24431161	ITSN2	0.51	7.26	0.37	2.7e-12	Asthma;
LUSC	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg10130564	chr11:117069849	TAGLN	0.3	5.65	0.3	3.37e-8	Blood protein levels;
LUSC	cis	rs3771570	1.000	rs62193207	chr2:242318501	G/C	cg21155796	chr2:242212141	HDLBP	0.62	6.67	0.34	1.07e-10	Prostate cancer;
LUSC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.23	0.52	4.67e-25	Prudent dietary pattern;
LUSC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.14	0.36	5.93e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg10911889	chr6:126070802	HEY2	0.38	5.77	0.3	1.81e-8	Brugada syndrome;
LUSC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg06640241	chr16:89574553	SPG7	0.86	16.11	0.66	1.33e-43	Multiple myeloma (IgH translocation);
LUSC	cis	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.24	-0.41	3.97e-15	Morning vs. evening chronotype;
LUSC	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg07988820	chr12:82153109	PPFIA2	-0.42	-5.78	-0.3	1.69e-8	Resting heart rate;
LUSC	cis	rs1472147	0.955	rs3736614	chr7:128509048	T/G	cg00260937	chr7:128520193	KCP	0.43	5.8	0.3	1.55e-8	Calcium levels;
LUSC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg08219700	chr8:58056026	NA	0.5	6.57	0.34	1.98e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	29.22	0.85	5e-94	Chronic sinus infection;
LUSC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.43	-0.59	3.51e-33	Chronic sinus infection;
LUSC	cis	rs7937682	0.564	rs1944114	chr11:111366460	T/C	cg09085632	chr11:111637200	PPP2R1B	0.44	5.84	0.3	1.24e-8	Primary sclerosing cholangitis;
LUSC	cis	rs10779751	0.734	rs2791653	chr1:11129848	A/G	cg08854313	chr1:11322531	MTOR	0.84	12.9	0.58	3.7e-31	Body mass index;
LUSC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08677398	chr8:58056175	NA	0.51	6.53	0.34	2.38e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs997295	0.675	rs17242605	chr15:67963436	A/G	cg08079166	chr15:68083412	MAP2K5	-0.33	-6.56	-0.34	2.11e-10	Motion sickness;
LUSC	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.41	-0.38	1.01e-12	Neuroticism;
LUSC	trans	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg10756647	chr7:56101905	PSPH	0.85	8.22	0.41	4.44e-15	Diabetic kidney disease;
LUSC	cis	rs11997175	0.509	rs67427312	chr8:33674377	A/G	ch.8.33884649F	chr8:33765107	NA	0.44	6.31	0.33	8.73e-10	Body mass index;
LUSC	cis	rs1044826	0.642	rs9859864	chr3:139091219	G/T	cg15131784	chr3:139108705	COPB2	-0.42	-6.97	-0.36	1.74e-11	Obesity-related traits;
LUSC	cis	rs231513	0.813	rs231495	chr17:41976748	G/C	cg26893861	chr17:41843967	DUSP3	-0.51	-6.06	-0.31	3.74e-9	Cognitive function;
LUSC	cis	rs17286411	0.814	rs12708919	chr16:71986995	A/G	cg03805757	chr16:71968109	PKD1L3	-0.4	-6.75	-0.35	6.62e-11	Blood protein levels;
LUSC	cis	rs56399783	0.901	rs11971014	chr7:2778444	C/T	cg19731401	chr7:2775893	GNA12	0.67	8.33	0.41	2.07e-15	Childhood ear infection;
LUSC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	11.77	0.54	5.6e-27	Menopause (age at onset);
LUSC	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg12454169	chr2:30669597	LCLAT1	0.7	8.71	0.43	1.43e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg27494647	chr7:150038898	RARRES2	0.46	6.98	0.36	1.61e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg06623918	chr6:96969491	KIAA0776	0.77	9.7	0.47	9.04e-20	Migraine;Coronary artery disease;
LUSC	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg17757837	chr7:157058334	UBE3C	-0.82	-13.32	-0.59	9.02e-33	Body mass index;
LUSC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.99	0.36	1.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg06238570	chr21:40685208	BRWD1	0.49	7.5	0.38	5.77e-13	Cognitive function;
LUSC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.37	0.46	1.14e-18	Bipolar disorder;
LUSC	trans	rs16944687	0.536	rs4843349	chr16:86131064	A/G	cg17191256	chr10:131665419	EBF3	-0.53	-6.02	-0.31	4.54e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg26897989	chr16:1907736	C16orf73	-0.42	-6.63	-0.34	1.37e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.61	10.85	0.51	1.06e-23	Type 2 diabetes;
LUSC	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg08684580	chr7:98029266	BAIAP2L1	0.39	5.88	0.31	9.82e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6906287	0.647	rs13220480	chr6:118916627	G/A	cg21191810	chr6:118973309	C6orf204	0.32	5.92	0.31	7.82e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg22764044	chr5:178986830	RUFY1	0.53	8.99	0.44	1.81e-17	Lung cancer;
LUSC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg07701084	chr6:150067640	NUP43	0.57	8.95	0.44	2.49e-17	Lung cancer;
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.33	-0.41	2.09e-15	Lymphocyte counts;
LUSC	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg07828024	chr6:149772892	ZC3H12D	-0.32	-6.92	-0.35	2.3e-11	Dupuytren's disease;
LUSC	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg24060327	chr5:131705240	SLC22A5	0.49	6.82	0.35	4.19e-11	Lymphocyte counts;Fibrinogen;
LUSC	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg13010199	chr12:38710504	ALG10B	0.52	7.72	0.39	1.34e-13	Morning vs. evening chronotype;
LUSC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.7	13.46	0.59	2.74e-33	Gestational age at birth (maternal effect);
LUSC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	12.01	0.55	7.58e-28	Personality dimensions;
LUSC	cis	rs7561273	0.609	rs10200844	chr2:24293363	A/C	cg20701182	chr2:24300061	SF3B14	0.45	5.77	0.3	1.76e-8	Quantitative traits;
LUSC	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg01733217	chr16:74700730	RFWD3	1.0	22.46	0.78	1.02e-68	Multiple myeloma;
LUSC	cis	rs59104589	0.617	rs57696929	chr2:242380382	T/C	cg14842376	chr2:242211374	HDLBP	0.5	5.78	0.3	1.73e-8	Fibrinogen levels;
LUSC	cis	rs886126	1.000	rs3809286	chr12:111664404	C/T	cg10833066	chr12:111807467	FAM109A	0.42	6.6	0.34	1.59e-10	Coronary heart disease;
LUSC	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.65	-11.12	-0.52	1.19e-24	Schizophrenia;
LUSC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	0.93	12.7	0.57	2.1000000000000002e-30	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.31	-0.33	8.87e-10	Personality dimensions;
LUSC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg16434002	chr17:42200994	HDAC5	-0.44	-6.3	-0.33	9.53e-10	Total body bone mineral density;
LUSC	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.46	-0.42	8.72e-16	Response to antipsychotic treatment;
LUSC	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg13072238	chr3:49761600	GMPPB	0.4	6.6	0.34	1.62e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4629180	0.586	rs290773	chr2:102125930	G/A	cg04415270	chr2:102091202	RFX8	0.46	8.03	0.4	1.71e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-10.36	-0.49	5.62e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg15242686	chr22:24348715	GSTTP1	-0.39	-6.38	-0.33	5.91e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs259282	0.707	rs1103851	chr19:33146414	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.82	12.23	0.56	1.09e-28	Schizophrenia;
LUSC	cis	rs524023	0.915	rs531763	chr11:64352063	A/G	cg19131476	chr11:64387923	NRXN2	0.37	9.89	0.48	2.14e-20	Urate levels in obese individuals;
LUSC	cis	rs4268898	0.760	rs11125535	chr2:24528114	T/C	cg06627628	chr2:24431161	ITSN2	0.58	8.23	0.41	4.39e-15	Asthma;
LUSC	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg05784532	chr1:230284198	GALNT2	0.65	9.02	0.44	1.45e-17	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg06092702	chr1:163392909	NA	0.35	6.18	0.32	1.9e-9	Motion sickness;
LUSC	cis	rs4589502	0.920	rs77518050	chr15:67138089	T/C	cg12317470	chr15:67143691	NA	0.7	6.02	0.31	4.7e-9	Lung cancer (smoking interaction);
LUSC	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg18753928	chr3:113234510	CCDC52	-0.5	-7.69	-0.39	1.66e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	8.6	0.43	3.15e-16	Diabetic retinopathy;
LUSC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg04398451	chr17:18023971	MYO15A	-0.56	-9.15	-0.45	5.87e-18	Total body bone mineral density;
LUSC	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg02389323	chr16:88786976	FAM38A	1.22	10.31	0.49	8.08e-22	Plateletcrit;
LUSC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg24250549	chr1:154909240	PMVK	0.62	10.16	0.49	2.61e-21	Prostate cancer;
LUSC	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg27661571	chr11:113659931	NA	-0.64	-7.52	-0.38	5e-13	Hip circumference adjusted for BMI;
LUSC	trans	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	9.98	0.48	1.04e-20	Mean corpuscular volume;
LUSC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg06108461	chr20:60628389	TAF4	-0.65	-8.47	-0.42	8.04e-16	Obesity-related traits;
LUSC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg26380479	chr7:97908229	NA	-0.26	-5.87	-0.31	1.06e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg02772935	chr3:125709198	NA	-0.48	-5.82	-0.3	1.36e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1595825	1.000	rs7579905	chr2:198868109	T/A	cg00982548	chr2:198649783	BOLL	-0.5	-6.26	-0.32	1.21e-9	Ulcerative colitis;
LUSC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-8.1	-0.41	1.06e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.52	0.57	9.53e-30	Motion sickness;
LUSC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21862992	chr11:68658383	NA	0.51	8.4	0.42	1.32e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg21231944	chr12:82153410	PPFIA2	-0.39	-6.0	-0.31	5.16e-9	Resting heart rate;
LUSC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9644630	0.932	rs4922048	chr8:19360814	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.35	6.7	0.34	8.83e-11	Oropharynx cancer;
LUSC	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg00383909	chr3:49044727	WDR6	0.81	7.55	0.38	4.26e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg05347473	chr6:146136440	FBXO30	-0.57	-9.79	-0.47	4.48e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg03585969	chr10:35415529	CREM	0.62	9.23	0.45	3.2e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.05e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg16359550	chr11:109292809	C11orf87	-0.38	-6.59	-0.34	1.76e-10	Schizophrenia;
LUSC	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.47	6.6	0.34	1.58e-10	Bipolar disorder;
LUSC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.71	10.14	0.49	3.03e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10779751	1.000	rs718206	chr1:11294474	T/A	cg08854313	chr1:11322531	MTOR	0.87	15.04	0.64	2.13e-39	Body mass index;
LUSC	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.07e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	14.57	0.62	1.47e-37	Platelet count;
LUSC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21963583	chr11:68658836	MRPL21	0.55	8.17	0.41	6.57e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	7.23	0.37	3.36e-12	Resting heart rate;
LUSC	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-7.59	-0.38	3.32e-13	Morning vs. evening chronotype;
LUSC	trans	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg06606381	chr12:133084897	FBRSL1	-0.9	-7.7	-0.39	1.51e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg11871910	chr12:69753446	YEATS4	0.46	6.14	0.32	2.3e-9	Response to diuretic therapy;
LUSC	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg22532475	chr10:104410764	TRIM8	0.32	7.23	0.37	3.33e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.48	-0.42	7.3e-16	Obesity-related traits;
LUSC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg02018176	chr4:1364513	KIAA1530	0.52	8.86	0.44	5e-17	Obesity-related traits;
LUSC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg12751644	chr20:60527061	NA	-0.35	-6.43	-0.33	4.43e-10	Body mass index;
LUSC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg03146154	chr1:46216737	IPP	0.49	7.35	0.37	1.49e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg09904177	chr6:26538194	HMGN4	-0.51	-8.08	-0.4	1.17e-14	Schizophrenia;
LUSC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07677032	chr17:61819896	STRADA	0.52	8.7	0.43	1.53e-16	Prudent dietary pattern;
LUSC	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.88	-12.24	-0.56	1.05e-28	Ileal carcinoids;
LUSC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.62	8.23	0.41	4.34e-15	High light scatter reticulocyte count;
LUSC	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg03859395	chr2:55845619	SMEK2	0.87	16.39	0.67	1.02e-44	Metabolic syndrome;
LUSC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg06784218	chr1:46089804	CCDC17	0.45	8.37	0.42	1.62e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg16339924	chr4:17578868	LAP3	0.59	9.18	0.45	4.48e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg08847533	chr14:75593920	NEK9	0.85	15.93	0.66	6.91e-43	Height;
LUSC	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg10840412	chr1:235813424	GNG4	0.66	8.83	0.44	6.18e-17	Bipolar disorder;
LUSC	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg13852791	chr20:30311386	BCL2L1	0.95	14.8	0.63	1.85e-38	Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg05519781	chr21:40033154	ERG	0.77	13.34	0.59	7.52e-33	Coronary artery disease;
LUSC	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg16989719	chr2:238392110	NA	-0.46	-7.39	-0.37	1.21e-12	Prostate cancer;
LUSC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-1.14	-18.11	-0.7	1.5e-51	Exhaled nitric oxide output;
LUSC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg01802117	chr1:53393560	SCP2	-0.38	-6.41	-0.33	5.02e-10	Monocyte count;
LUSC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.96	0.77	8.49e-67	Prudent dietary pattern;
LUSC	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.97	-0.31	6.04e-9	Neuroticism;
LUSC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg14004847	chr7:1930337	MAD1L1	0.55	8.52	0.42	5.39e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg05043794	chr9:111880884	C9orf5	-0.34	-7.15	-0.36	5.56e-12	Menarche (age at onset);
LUSC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg23172400	chr8:95962367	TP53INP1	0.36	6.67	0.34	1.03e-10	Type 2 diabetes;
LUSC	trans	rs72674100	1.000	rs7672661	chr4:97954691	C/A	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9341808	0.527	rs7453746	chr6:80810013	T/G	cg08355045	chr6:80787529	NA	0.62	11.55	0.53	3.41e-26	Sitting height ratio;
LUSC	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01256987	chr12:42539512	GXYLT1	-0.61	-13.42	-0.59	3.98e-33	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.87	16.61	0.67	1.39e-45	Mean platelet volume;
LUSC	cis	rs9394152	0.845	rs9366823	chr6:33471059	C/T	cg13560919	chr6:33536144	NA	0.6	10.63	0.5	6.18e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs10392	0.543	rs1733	chr20:37581506	G/A	cg27552599	chr20:37590471	DHX35	0.43	7.03	0.36	1.19e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs72634258	0.945	rs225131	chr1:8095486	T/C	cg26816564	chr1:7831052	VAMP3	0.47	6.18	0.32	1.89e-9	Inflammatory bowel disease;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg02599293	chr5:137090023	HNRNPA0	0.38	6.45	0.33	3.91e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.87	14.22	0.61	3.36e-36	Bladder cancer;
LUSC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg22823121	chr1:150693482	HORMAD1	0.52	7.84	0.39	6.31e-14	Melanoma;
LUSC	cis	rs909341	0.909	rs67616625	chr20:62363487	A/G	cg09650180	chr20:62225654	GMEB2	-0.47	-6.11	-0.32	2.75e-9	Atopic dermatitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21144462	chr17:42082647	PYY;NAGS	0.38	5.99	0.31	5.54e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg03585969	chr10:35415529	CREM	0.6	8.8	0.43	7.41e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-6.8	-0.35	4.71e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.55	6.04	0.31	4.07e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs2587949	0.615	rs1485248	chr3:4238123	G/A	cg15139668	chr4:4577005	NA	-0.4	-5.98	-0.31	5.86e-9	Periodontitis (DPAL);
LUSC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07677032	chr17:61819896	STRADA	0.52	8.61	0.43	2.91e-16	Prudent dietary pattern;
LUSC	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-7.74	-0.39	1.22e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg27411982	chr8:10470053	RP1L1	-0.48	-7.21	-0.37	3.65e-12	Neuroticism;
LUSC	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.46	-0.5	2.51e-22	Eye color traits;
LUSC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg07741184	chr6:167504864	NA	-0.35	-6.39	-0.33	5.46e-10	Crohn's disease;
LUSC	cis	rs3741151	0.773	rs7951072	chr11:73221721	G/A	cg17517138	chr11:73019481	ARHGEF17	0.96	8.13	0.41	8.27e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs629535	0.814	rs55873935	chr8:70081646	G/A	cg21567404	chr3:27674614	NA	-0.97	-15.65	-0.65	8.2e-42	Dupuytren's disease;
LUSC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg11812906	chr14:75593930	NEK9	-0.65	-11.23	-0.52	4.73e-25	Height;
LUSC	cis	rs11608355	0.515	rs4766476	chr12:109934700	A/G	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs9807841	0.568	rs1560708	chr19:10749236	T/C	cg09936142	chr19:10668400	KRI1	-0.4	-6.34	-0.33	7.33e-10	Inflammatory skin disease;
LUSC	cis	rs9463078	0.625	rs12190136	chr6:44767072	A/G	cg25276700	chr6:44698697	NA	-0.28	-5.7	-0.3	2.64e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg20849893	chr7:64541193	NA	-0.65	-5.68	-0.3	2.99e-8	Diabetic kidney disease;
LUSC	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg23093090	chr10:104574429	C10orf26	0.35	6.45	0.33	3.91e-10	Arsenic metabolism;
LUSC	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg05555928	chr11:63887634	MACROD1	-0.52	-6.35	-0.33	7.06e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs394563	0.625	rs394526	chr6:149796975	T/G	cg11245181	chr6:149772854	ZC3H12D	-0.3	-5.98	-0.31	5.73e-9	Dupuytren's disease;
LUSC	cis	rs3936840	0.686	rs2896439	chr14:102806291	A/G	cg18135206	chr14:102964638	TECPR2	0.49	7.28	0.37	2.44e-12	Plateletcrit;
LUSC	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.52	-10.34	-0.49	6.18e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-5.98	-0.31	5.62e-9	Retinal vascular caliber;
LUSC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.19e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.81	-0.35	4.59e-11	Lung cancer;
LUSC	cis	rs12997796	0.556	rs35594332	chr2:86982651	G/A	cg25203885	chr2:87302643	LOC285074	-0.86	-8.64	-0.43	2.35e-16	Schizophrenia;
LUSC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg00343986	chr7:65444356	GUSB	0.44	6.79	0.35	5.23e-11	Aortic root size;
LUSC	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-0.96	-10.27	-0.49	1.13e-21	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg12002119	chr2:101014098	CHST10	0.34	5.7	0.3	2.62e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs377070	0.934	rs309414	chr4:123620912	A/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.46	6.73	0.35	7.46e-11	Mosquito bite size;
LUSC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg05861140	chr6:150128134	PCMT1	-0.39	-6.23	-0.32	1.37e-9	Lung cancer;
LUSC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg01528321	chr10:82214614	TSPAN14	0.63	9.08	0.44	9.59e-18	Post bronchodilator FEV1;
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-8.35	-0.42	1.9e-15	Longevity;Endometriosis;
LUSC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.75	0.43	1.05e-16	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg10845886	chr2:3471009	TTC15	0.52	6.65	0.34	1.21e-10	Neurofibrillary tangles;
LUSC	cis	rs62458065	0.850	rs10239812	chr7:32460348	A/G	cg20159608	chr7:32802032	NA	-0.68	-7.86	-0.4	5.33e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg08854313	chr1:11322531	MTOR	0.8	12.45	0.56	1.6800000000000001e-29	Body mass index;
LUSC	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.25	-0.45	2.79e-18	Acne (severe);
LUSC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	8.5	0.42	6.57e-16	Colorectal cancer;
LUSC	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-7.02	-0.36	1.27e-11	Triglycerides;
LUSC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.39	5.75	0.3	2.01e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10983056	chr13:113344077	ATP11A	-0.41	-6.04	-0.31	4.08e-9	Hepatitis;
LUSC	cis	rs7215564	0.908	rs34914062	chr17:78655909	C/T	cg23238734	chr17:78661607	RPTOR	0.5	6.1	0.32	2.95e-9	Myopia (pathological);
LUSC	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg20991723	chr1:152506922	NA	-0.5	-9.39	-0.46	9.93e-19	Hair morphology;
LUSC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg23815491	chr16:72088622	HP	0.34	6.01	0.31	4.87e-9	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LUSC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg04673462	chr1:38461896	NA	-0.55	-10.16	-0.49	2.61e-21	Coronary artery disease;
LUSC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg00409905	chr10:38381863	ZNF37A	0.37	6.32	0.33	8.19e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg04374321	chr14:90722782	PSMC1	0.71	11.29	0.53	2.87e-25	Mortality in heart failure;
LUSC	cis	rs6542838	0.644	rs7590596	chr2:99467938	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.6	-0.34	1.64e-10	Fear of minor pain;
LUSC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg05347473	chr6:146136440	FBXO30	0.44	7.45	0.38	8.04e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg27432699	chr2:27873401	GPN1	0.78	14.13	0.61	7.32e-36	Oral cavity cancer;
LUSC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.71	-0.34	8.3e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg09998033	chr7:158218633	PTPRN2	-0.5	-7.99	-0.4	2.24e-14	Obesity-related traits;
LUSC	cis	rs7804356	1.000	rs3801827	chr7:26856626	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-6.14	-0.32	2.4e-9	Type 1 diabetes;
LUSC	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg22431228	chr1:16359049	CLCNKA	0.34	6.41	0.33	5.1e-10	Dilated cardiomyopathy;
LUSC	cis	rs10465746	0.747	rs10493741	chr1:84388118	G/C	cg10977910	chr1:84465055	TTLL7	0.46	6.61	0.34	1.53e-10	Obesity-related traits;
LUSC	cis	rs3106136	0.967	rs282449	chr4:95141228	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.12	-0.32	2.68e-9	Capecitabine sensitivity;
LUSC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg05347473	chr6:146136440	FBXO30	-0.6	-10.43	-0.5	3.17e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg16434002	chr17:42200994	HDAC5	-0.47	-6.9	-0.35	2.68e-11	Total body bone mineral density;
LUSC	cis	rs17533156	0.954	rs73376341	chr17:75116150	C/T	cg11416367	chr17:75137675	SEC14L1	0.49	5.84	0.3	1.21e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.3	0.33	9.41e-10	Lung cancer;
LUSC	cis	rs2637266	0.756	rs846621	chr10:78545171	G/T	cg18941641	chr10:78392320	NA	0.38	6.8	0.35	4.76e-11	Pulmonary function;
LUSC	trans	rs853679	0.546	rs200949	chr6:27835435	A/G	cg06606381	chr12:133084897	FBRSL1	-0.67	-6.85	-0.35	3.65e-11	Depression;
LUSC	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25427524	chr10:38739819	LOC399744	0.45	7.41	0.38	1.08e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1211375	0.628	rs3859141	chr16:245079	T/C	cg00126636	chr16:237282	NA	-0.38	-5.82	-0.3	1.35e-8	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs55882075	0.634	rs12518476	chr5:179110850	A/G	cg14593053	chr5:179126677	CANX	0.38	5.98	0.31	5.63e-9	Monocyte percentage of white cells;
LUSC	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg18305652	chr10:134549665	INPP5A	0.46	6.99	0.36	1.49e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-7.66	-0.39	2.1e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg10573190	chr2:85843190	USP39	-0.43	-6.08	-0.32	3.3e-9	Mean corpuscular volume;
LUSC	cis	rs501916	0.714	rs11854427	chr15:48047421	G/A	cg16110827	chr15:48056943	SEMA6D	-0.45	-6.24	-0.32	1.3e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	7.0	0.36	1.38e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg03732007	chr1:2071316	PRKCZ	0.48	7.72	0.39	1.34e-13	Height;
LUSC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.05	0.55	5e-28	Prudent dietary pattern;
LUSC	cis	rs4285028	0.747	rs9850439	chr3:121393075	T/C	cg11130432	chr3:121712080	ILDR1	-0.56	-8.13	-0.41	8.7e-15	Multiple sclerosis;
LUSC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg04450456	chr4:17643702	FAM184B	0.4	6.77	0.35	5.72e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg25204440	chr1:209979598	IRF6	0.53	6.98	0.36	1.63e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs1322512	0.917	rs1407485	chr6:152963665	G/A	cg27316956	chr6:152958899	SYNE1	-0.37	-6.32	-0.33	8.6e-10	Tonometry;
LUSC	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg05738196	chr6:26577821	NA	0.83	16.17	0.66	7.5e-44	Intelligence (multi-trait analysis);
LUSC	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	11.98	0.55	9.1e-28	Ileal carcinoids;
LUSC	cis	rs2046867	0.628	rs1393584	chr3:72917193	G/T	cg25664220	chr3:72788482	NA	-0.56	-9.93	-0.48	1.53e-20	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7091068	0.522	rs11187621	chr10:95483074	T/C	cg20715218	chr10:95462985	C10orf4	0.6	7.38	0.37	1.3e-12	Urinary tract infection frequency;
LUSC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	9.97	0.48	1.17e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg20487152	chr13:99095054	FARP1	-0.41	-7.05	-0.36	1.01e-11	Longevity;
LUSC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19717773	chr7:2847554	GNA12	-0.35	-5.78	-0.3	1.7e-8	Height;
LUSC	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg26727032	chr16:67993705	SLC12A4	-0.46	-6.27	-0.32	1.11e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg05585544	chr11:47624801	NA	0.4	7.03	0.36	1.16e-11	Subjective well-being;
LUSC	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg17178900	chr1:205818956	PM20D1	-0.4	-5.68	-0.3	2.96e-8	Prostate-specific antigen levels;
LUSC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg05347473	chr6:146136440	FBXO30	-0.6	-10.6	-0.5	7.93e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg21770322	chr7:97807741	LMTK2	0.41	7.06	0.36	9.5e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg24596788	chr1:163392923	NA	0.37	6.37	0.33	6.21e-10	Motion sickness;
LUSC	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02176678	chr2:219576539	TTLL4	0.6	11.12	0.52	1.23e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2292864	0.764	rs3892085	chr17:45340480	A/G	cg18085866	chr17:45331354	ITGB3	-0.71	-6.06	-0.31	3.65e-9	Left atrial antero-posterior diameter;
LUSC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.2	-0.52	5.98e-25	Bipolar disorder;
LUSC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.46	-0.38	7.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg09904177	chr6:26538194	HMGN4	-0.79	-5.78	-0.3	1.73e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.29	-0.41	2.74e-15	Cystic fibrosis severity;
LUSC	cis	rs7608623	0.804	rs3795938	chr2:23912712	C/T	cg08917208	chr2:24149416	ATAD2B	-0.42	-5.73	-0.3	2.19e-8	Obesity-related traits;
LUSC	cis	rs8092503	0.904	rs12606230	chr18:52492252	T/C	cg12377874	chr18:52495404	RAB27B	0.33	6.05	0.31	3.85e-9	Childhood body mass index;
LUSC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-9.57	-0.46	2.52e-19	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.76	-0.3	1.91e-8	Menopause (age at onset);
LUSC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg02423579	chr7:2872169	GNA12	-0.4	-6.35	-0.33	7.18e-10	Height;
LUSC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg19318889	chr4:1322082	MAEA	0.48	7.88	0.4	4.54e-14	Obesity-related traits;
LUSC	trans	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.42	0.53	9.87e-26	Mean corpuscular volume;
LUSC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.37	-0.33	6.25e-10	Lung cancer;
LUSC	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg25730555	chr22:47059586	GRAMD4	0.45	7.07	0.36	9.04e-12	Urate levels in obese individuals;
LUSC	cis	rs10189230	0.868	rs5002064	chr2:222353508	G/A	cg14652038	chr2:222343519	EPHA4	0.32	5.73	0.3	2.29e-8	Urate levels in lean individuals;
LUSC	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg07936489	chr17:37558343	FBXL20	-0.71	-9.83	-0.47	3.52e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg13939156	chr17:80058883	NA	0.37	7.46	0.38	7.64e-13	Life satisfaction;
LUSC	cis	rs11051970	0.679	rs2931554	chr12:32556162	G/A	cg02745156	chr12:32552066	NA	0.37	6.81	0.35	4.42e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg00310523	chr12:86230176	RASSF9	0.44	7.92	0.4	3.51e-14	Major depressive disorder;
LUSC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg15448220	chr1:150897856	SETDB1	0.42	6.07	0.32	3.43e-9	Melanoma;
LUSC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg12379764	chr21:47803548	PCNT	-0.41	-5.65	-0.3	3.42e-8	Testicular germ cell tumor;
LUSC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1178968	0.901	rs799306	chr7:72801939	C/T	cg25889504	chr7:72793014	NA	0.66	8.29	0.41	2.73e-15	Triglyceride levels;
LUSC	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg07959070	chr22:50026188	C22orf34	-0.33	-6.32	-0.33	8.55e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg06637938	chr14:75390232	RPS6KL1	0.52	8.21	0.41	4.86e-15	Height;
LUSC	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg24375607	chr4:120327624	NA	0.75	11.83	0.54	3.24e-27	Corneal astigmatism;
LUSC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg09517075	chr8:22133004	PIWIL2	-0.41	-8.45	-0.42	9e-16	Hypertriglyceridemia;
LUSC	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.61	-5.68	-0.3	2.92e-8	Narcolepsy;
LUSC	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	9.56	0.46	2.66e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.61	-0.43	3e-16	Neuroticism;
LUSC	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs2281558	0.833	rs6115202	chr20:25497538	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.62	-9.36	-0.46	1.17e-18	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs16976116	0.901	rs28589609	chr15:55503630	C/T	cg11288833	chr15:55489084	RSL24D1	0.5	5.93	0.31	7.52e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg13565492	chr6:43139072	SRF	-0.74	-10.74	-0.51	2.65e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23978390	chr7:1156363	C7orf50	0.43	5.93	0.31	7.56e-9	Longevity;Endometriosis;
LUSC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg17294928	chr15:75287854	SCAMP5	0.48	7.16	0.36	5.3e-12	Breast cancer;
LUSC	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.19e-33	Morning vs. evening chronotype;
LUSC	cis	rs877282	0.898	rs11253348	chr10:765852	C/T	cg17470449	chr10:769945	NA	0.53	7.08	0.36	8.43e-12	Uric acid levels;
LUSC	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg06627628	chr2:24431161	ITSN2	-0.6	-7.35	-0.37	1.56e-12	Lymphocyte counts;
LUSC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg20203395	chr5:56204925	C5orf35	0.56	8.05	0.4	1.43e-14	Initial pursuit acceleration;
LUSC	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg16898833	chr6:26189333	HIST1H4D	0.79	6.09	0.32	3.19e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LUSC	trans	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.55e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg22834771	chr12:69754056	YEATS4	-0.54	-8.08	-0.4	1.23e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg00509249	chr6:109615579	CCDC162	-0.33	-5.99	-0.31	5.31e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs4144743	0.759	rs16969966	chr17:45318452	G/T	cg18085866	chr17:45331354	ITGB3	-0.66	-6.56	-0.34	2.02e-10	Body mass index;
LUSC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.23e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg06718696	chr17:78121285	EIF4A3	-0.5	-7.72	-0.39	1.41e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg15848620	chr12:58087721	OS9	-0.53	-7.75	-0.39	1.13e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg00677455	chr12:58241039	CTDSP2	0.7	10.51	0.5	1.69e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07080220	chr10:102295463	HIF1AN	0.69	9.38	0.46	1.06e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg15133208	chr4:90757351	SNCA	-0.54	-8.18	-0.41	6.05e-15	Neuroticism;
LUSC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg20608306	chr11:116969690	SIK3	0.41	6.75	0.35	6.72e-11	Blood protein levels;
LUSC	cis	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg02508848	chr16:68573721	ZFP90	-0.43	-5.82	-0.3	1.42e-8	Ulcerative colitis;
LUSC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.54	-0.42	4.65e-16	Personality dimensions;
LUSC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs4499344	0.920	rs752719	chr19:33086091	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.6	-7.86	-0.4	5.19e-14	Mean platelet volume;
LUSC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg22535103	chr8:58192502	C8orf71	-0.66	-7.41	-0.38	1.02e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.88	0.35	2.9e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.3	0.56	6.22e-29	Motion sickness;
LUSC	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg13010199	chr12:38710504	ALG10B	0.65	10.01	0.48	8.37e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	10.64	0.5	5.72e-23	Homoarginine levels;
LUSC	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg20503657	chr10:835505	NA	-0.51	-6.97	-0.36	1.73e-11	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg18721089	chr20:30220636	NA	-0.38	-6.22	-0.32	1.49e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs75804782	0.641	rs11902599	chr2:239348400	C/T	cg18131467	chr2:239335373	ASB1	-0.73	-6.63	-0.34	1.33e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs67072384	1.000	rs7128364	chr11:72451941	A/C	cg04827223	chr11:72435913	ARAP1	-0.82	-7.39	-0.37	1.22e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg24459738	chr19:57751996	ZNF805	-0.54	-8.1	-0.41	1.06e-14	Hyperactive-impulsive symptoms;
LUSC	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.16	-0.45	5.39e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7809615	0.551	rs952319	chr7:99171449	C/T	cg24650262	chr7:98904301	NA	0.5	6.27	0.32	1.09e-9	Blood metabolite ratios;
LUSC	cis	rs7084402	1.000	rs7084402	chr10:60265404	C/T	cg07615347	chr10:60278583	BICC1	0.36	5.76	0.3	1.93e-8	Refractive error;
LUSC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-0.82	-14.69	-0.63	5.05e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08280861	chr8:58055591	NA	0.54	5.8	0.3	1.52e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs72674100	1.000	rs77619190	chr4:97991906	C/A	cg09670535	chr1:18959427	PAX7	-0.64	-6.12	-0.32	2.68e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.64	-13.35	-0.59	6.98e-33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2898681	0.561	rs7699960	chr4:53735661	C/A	cg00791764	chr4:53727839	RASL11B	0.57	7.88	0.4	4.76e-14	Optic nerve measurement (cup area);
LUSC	cis	rs6686643	1.000	rs957644	chr1:165616157	C/T	cg16553119	chr1:165599451	MGST3	-0.46	-6.79	-0.35	5.1e-11	Total ventricular volume;
LUSC	cis	rs2742234	0.541	rs11238479	chr10:43717423	C/T	cg02780029	chr10:43622663	RET	0.34	5.67	0.3	3.03e-8	Hirschsprung disease;
LUSC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg06074448	chr4:187884817	NA	0.39	6.49	0.33	3.04e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00290607	chr11:67383545	NA	-0.36	-6.39	-0.33	5.41e-10	Mean corpuscular volume;
LUSC	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-15.07	-0.64	1.64e-39	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs11018904	0.906	rs35129016	chr11:89948689	T/C	cg26028595	chr11:89956573	CHORDC1	-0.52	-5.88	-0.31	9.96e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26509722	chr12:6833059	COPS7A	0.45	6.11	0.32	2.8e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg04944784	chr2:26401820	FAM59B	0.67	8.82	0.43	6.53e-17	Gut microbiome composition (summer);
LUSC	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg25801113	chr15:45476975	SHF	0.35	7.3	0.37	2.15e-12	Uric acid levels;
LUSC	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg23711669	chr6:146136114	FBXO30	0.87	16.13	0.66	1.08e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg19774624	chr17:42201019	HDAC5	-0.79	-12.74	-0.57	1.48e-30	Total body bone mineral density;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05654483	chr10:122610929	WDR11	-0.47	-6.31	-0.33	8.82e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24836204	chr8:144450966	RHPN1;C8orf51	-0.46	-7.16	-0.36	5.17e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02176678	chr2:219576539	TTLL4	-0.75	-14.09	-0.61	1.01e-35	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg24642439	chr20:33292090	TP53INP2	0.63	9.83	0.47	3.51e-20	Coronary artery disease;
LUSC	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg06714761	chr1:201096289	NA	-0.43	-7.99	-0.4	2.21e-14	Permanent tooth development;
LUSC	cis	rs400736	0.655	rs11121086	chr1:8151224	C/T	cg25007680	chr1:8021821	PARK7	-0.45	-6.8	-0.35	4.94e-11	Response to antidepressants and depression;
LUSC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg08975724	chr8:8085496	FLJ10661	0.51	7.94	0.4	3.05e-14	Mood instability;
LUSC	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.5	8.43	0.42	1.07e-15	Axial length;
LUSC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	11.17	0.52	7.62e-25	Platelet count;
LUSC	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg17425144	chr1:10567563	PEX14	0.64	13.33	0.59	8.73e-33	Breast size;
LUSC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	16.09	0.66	1.53e-43	Platelet count;
LUSC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.03	0.4	1.66e-14	Prudent dietary pattern;
LUSC	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.32	0.45	1.64e-18	Lung cancer in ever smokers;
LUSC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-7.17	-0.37	4.8e-12	Platelet count;
LUSC	cis	rs7615316	0.934	rs4273389	chr3:142213930	A/G	cg16271453	chr3:142027066	XRN1	-0.4	-6.87	-0.35	3.22e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23158103	chr7:148848205	ZNF398	-0.49	-8.32	-0.41	2.32e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg18904891	chr8:8559673	CLDN23	0.38	5.91	0.31	8.65e-9	Mood instability;
LUSC	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg24154853	chr7:158122151	PTPRN2	0.45	8.8	0.43	7.55e-17	Calcium levels;
LUSC	cis	rs68170813	0.652	rs7807154	chr7:107161391	T/G	cg02696742	chr7:106810147	HBP1	-0.64	-8.63	-0.43	2.46e-16	Coronary artery disease;
LUSC	cis	rs2901656	0.701	rs4916266	chr1:172450795	G/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.3	5.85	0.3	1.18e-8	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21775007	chr8:11205619	TDH	0.71	11.49	0.53	5.55e-26	Retinal vascular caliber;
LUSC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg26566898	chr11:117069891	TAGLN	0.45	7.86	0.39	5.45e-14	Blood protein levels;
LUSC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg25039879	chr17:56429692	SUPT4H1	0.73	10.46	0.5	2.52e-22	Cognitive test performance;
LUSC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.59	0.5	8.66e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg08501292	chr6:25962987	TRIM38	0.66	5.92	0.31	7.96e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.49	-8.92	-0.44	3.11e-17	Urinary metabolites;
LUSC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	0.92	17.62	0.69	1.4e-49	Heart rate;
LUSC	cis	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg06521331	chr12:34319734	NA	-0.38	-5.66	-0.3	3.3e-8	Resting heart rate;
LUSC	cis	rs1775715	0.737	rs2799012	chr10:32103077	C/T	cg03015672	chr10:32216066	ARHGAP12	0.33	5.84	0.3	1.22e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6688613	0.685	rs6427047	chr1:166914258	A/G	cg07049167	chr1:166818506	POGK	0.46	6.79	0.35	5.2e-11	Refractive astigmatism;
LUSC	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-1.01	-14.32	-0.62	1.29e-36	Exhaled nitric oxide output;
LUSC	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.6	8.62	0.43	2.71e-16	Bipolar disorder;
LUSC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.91	-16.14	-0.66	9.77e-44	Cognitive function;
LUSC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	19.1	0.72	1.79e-55	Chronic sinus infection;
LUSC	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.23	0.45	3.24e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg10053473	chr17:62856997	LRRC37A3	0.65	10.22	0.49	1.69e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs193541	0.632	rs2407402	chr5:122107105	G/C	cg19077854	chr5:122220652	SNX24	0.38	7.9	0.4	4.04e-14	Glucose homeostasis traits;
LUSC	cis	rs599083	0.590	rs10791984	chr11:68407835	T/G	cg01657329	chr11:68192670	LRP5	0.38	5.78	0.3	1.75e-8	Bone mineral density (spine);
LUSC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg08470875	chr2:26401718	FAM59B	-0.65	-8.87	-0.44	4.58e-17	Gut microbiome composition (summer);
LUSC	trans	rs12210905	0.688	rs12205044	chr6:27478990	A/G	cg11837749	chr1:55047332	ACOT11	0.7	6.03	0.31	4.34e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-7.22	-0.37	3.59e-12	Lung cancer;
LUSC	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg20701182	chr2:24300061	SF3B14	0.75	7.67	0.39	1.89e-13	Lymphocyte counts;
LUSC	cis	rs78572108	0.777	rs72613888	chr2:42267941	C/T	cg00607755	chr2:42274082	PKDCC	0.34	5.83	0.3	1.28e-8	Total body bone mineral density;
LUSC	trans	rs2562456	0.520	rs660063	chr19:21453905	T/G	cg00806126	chr19:22604979	ZNF98	0.43	6.14	0.32	2.37e-9	Pain;
LUSC	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg17366294	chr4:99064904	C4orf37	0.53	8.57	0.42	3.77e-16	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs3960554	0.800	rs112463197	chr7:75622912	C/T	cg19862616	chr7:65841803	NCRNA00174	0.88	9.85	0.47	2.92e-20	Eotaxin levels;
LUSC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs9311676	0.656	rs7647078	chr3:58369912	C/T	cg26110898	chr3:58419937	PDHB	0.42	6.72	0.35	7.93e-11	Systemic lupus erythematosus;
LUSC	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg02466173	chr16:30829666	NA	-0.48	-9.19	-0.45	4.22e-18	Dementia with Lewy bodies;
LUSC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.77	9.4	0.46	9.26e-19	Gut microbiome composition (summer);
LUSC	cis	rs9494145	0.680	rs35959442	chr6:135424179	C/G	cg22676075	chr6:135203613	NA	0.6	8.76	0.43	9.63e-17	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs6484504	0.576	rs158144	chr11:31211795	A/C	cg26647111	chr11:31128758	NA	-0.41	-5.94	-0.31	7.27e-9	Red blood cell count;
LUSC	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	11.38	0.53	1.44e-25	Coffee consumption (cups per day);
LUSC	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	cis	rs12541635	0.677	rs7846149	chr8:107053417	T/C	cg10147462	chr8:107024639	NA	0.66	13.82	0.6	1.17e-34	Age of smoking initiation;
LUSC	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg12552261	chr5:112820674	MCC	-0.44	-7.02	-0.36	1.25e-11	Type 2 diabetes;
LUSC	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg25233709	chr10:116636983	FAM160B1	0.37	6.59	0.34	1.69e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg16339924	chr4:17578868	LAP3	0.66	10.14	0.48	3.16e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	8.03	0.4	1.68e-14	Iron status biomarkers;
LUSC	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.21	0.45	3.72e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg25039879	chr17:56429692	SUPT4H1	0.66	8.81	0.43	6.99e-17	Cognitive test performance;
LUSC	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg17168535	chr8:21777572	XPO7	0.64	9.82	0.47	3.68e-20	Mean corpuscular volume;
LUSC	trans	rs12439619	0.846	rs62013464	chr15:82580591	A/C	cg04831495	chr15:85060580	GOLGA6L5	-0.48	-6.55	-0.34	2.15e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05367846	chr22:18507520	MICAL3	0.44	7.14	0.36	5.79e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs897984	0.806	rs4889571	chr16:30949047	A/G	cg02466173	chr16:30829666	NA	0.57	11.43	0.53	9.44e-26	Dementia with Lewy bodies;
LUSC	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg02466173	chr16:30829666	NA	-0.56	-10.49	-0.5	1.97e-22	Multiple myeloma;
LUSC	cis	rs72634258	0.786	rs6577468	chr1:8183921	T/C	cg26816564	chr1:7831052	VAMP3	0.45	5.75	0.3	1.98e-8	Inflammatory bowel disease;
LUSC	trans	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg24247370	chr13:99142703	STK24	-0.34	-6.17	-0.32	1.96e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg20587970	chr11:113659929	NA	-1.3	-16.21	-0.66	5.22e-44	Hip circumference adjusted for BMI;
LUSC	cis	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg26958806	chr6:27640298	NA	0.74	6.04	0.31	4.02e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24110177	chr3:50126178	RBM5	-0.55	-8.99	-0.44	1.87e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg23029597	chr12:123009494	RSRC2	-0.76	-10.16	-0.49	2.57e-21	Body mass index;
LUSC	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	8.73	0.43	1.26e-16	Lung cancer in ever smokers;
LUSC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.2	0.37	3.91e-12	Platelet count;
LUSC	cis	rs4629710	0.545	rs11154621	chr6:131547341	A/G	cg12700074	chr6:131571435	AKAP7	-0.33	-5.65	-0.3	3.4e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08859206	chr1:53392774	SCP2	0.5	8.6	0.43	3.21e-16	Monocyte count;
LUSC	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg03929089	chr4:120376271	NA	0.7	7.85	0.39	5.6e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg20684491	chr1:25596433	NA	-0.37	-5.77	-0.3	1.84e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.57	-0.5	1.04e-22	Alzheimer's disease;
LUSC	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg27129171	chr3:47204927	SETD2	-0.68	-11.39	-0.53	1.3e-25	Colorectal cancer;
LUSC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.55	-0.34	2.2e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg17747265	chr1:1875780	NA	-0.73	-16.86	-0.68	1.44e-46	Body mass index;
LUSC	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.11e-21	Bladder cancer;
LUSC	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.44	-0.33	4.15e-10	Arsenic metabolism;
LUSC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.67	10.2	0.49	1.95e-21	P wave terminal force;
LUSC	cis	rs988712	0.587	rs117567901	chr11:27706040	T/C	cg10635145	chr11:27742435	BDNF	-0.46	-6.24	-0.32	1.36e-9	Obesity;
LUSC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.59	-9.77	-0.47	5.45e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg26441486	chr22:50317300	CRELD2	-0.54	-8.25	-0.41	3.75e-15	Schizophrenia;
LUSC	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.64	11.37	0.53	1.52e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs10779751	0.922	rs11121708	chr1:11307253	G/C	cg08854313	chr1:11322531	MTOR	0.87	14.95	0.63	4.62e-39	Body mass index;
LUSC	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.7	-0.39	1.52e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg13047869	chr3:10149882	C3orf24	0.64	8.79	0.43	8.31e-17	Alzheimer's disease;
LUSC	cis	rs12368653	0.651	rs2307097	chr12:58195801	T/C	cg00677455	chr12:58241039	CTDSP2	-0.42	-5.78	-0.3	1.73e-8	Multiple sclerosis;
LUSC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.23	-0.37	3.33e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7254114	0.578	rs6511727	chr19:11315817	G/T	cg02815516	chr19:11306319	KANK2	-0.39	-7.92	-0.4	3.44e-14	Immature fraction of reticulocytes;
LUSC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg09455208	chr3:40491958	NA	0.53	9.39	0.46	9.5e-19	Renal cell carcinoma;
LUSC	cis	rs3740713	0.748	rs35292478	chr11:18429991	A/C	cg23797887	chr11:18477753	LDHAL6A	-0.54	-6.62	-0.34	1.44e-10	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg03351412	chr1:154909251	PMVK	-0.55	-8.69	-0.43	1.62e-16	Prostate cancer;
LUSC	trans	rs613391	0.736	rs3012992	chr9:22647014	C/T	cg05038977	chr17:7476167	EIF4A1	0.4	6.11	0.32	2.81e-9	Quantitative traits;
LUSC	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg01629716	chr15:45996671	NA	0.39	5.96	0.31	6.31e-9	Waist circumference;Weight;
LUSC	trans	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg07701084	chr6:150067640	NUP43	0.57	8.71	0.43	1.47e-16	Lung cancer;
LUSC	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.67	0.65	7.43e-42	Bladder cancer;
LUSC	cis	rs6545883	0.894	rs6760075	chr2:61612881	C/A	cg15711740	chr2:61764176	XPO1	0.43	6.7	0.34	8.66e-11	Tuberculosis;
LUSC	trans	rs2587949	0.571	rs2600136	chr3:4208947	T/C	cg15139668	chr4:4577005	NA	-0.41	-6.03	-0.31	4.44e-9	Periodontitis (DPAL);
LUSC	cis	rs4948102	0.642	rs6593297	chr7:56122058	A/T	cg17215666	chr7:56131930	SUMF2	-0.43	-5.86	-0.31	1.11e-8	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs7215564	0.908	rs80183474	chr17:78655070	T/A	cg09596252	chr17:78655493	RPTOR	0.55	5.92	0.31	7.92e-9	Myopia (pathological);
LUSC	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg20090690	chr10:134436459	INPP5A	0.48	5.91	0.31	8.35e-9	Primary sclerosing cholangitis;
LUSC	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg22676075	chr6:135203613	NA	0.48	7.51	0.38	5.47e-13	Red blood cell count;
LUSC	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.43	6.8	0.35	4.78e-11	Platelet count;
LUSC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg03146154	chr1:46216737	IPP	0.51	7.63	0.39	2.44e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3126085	0.935	rs11204952	chr1:152227321	G/A	cg26876637	chr1:152193138	HRNR	0.43	6.11	0.32	2.71e-9	Atopic dermatitis;
LUSC	cis	rs7000551	0.779	rs2443507	chr8:22373231	G/A	cg12081754	chr8:22256438	SLC39A14	0.42	6.24	0.32	1.3e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-5.84	-0.3	1.22e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	6.41	0.33	4.84e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02176678	chr2:219576539	TTLL4	0.64	11.55	0.53	3.54e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2637266	0.756	rs7079818	chr10:78469935	T/A	cg18941641	chr10:78392320	NA	0.35	6.25	0.32	1.26e-9	Pulmonary function;
LUSC	cis	rs262150	0.625	rs55974535	chr7:158769145	C/G	cg19418458	chr7:158789849	NA	0.58	7.18	0.37	4.59e-12	Facial morphology (factor 20);
LUSC	trans	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg02800362	chr5:177631904	HNRNPAB	0.88	13.05	0.58	9.85e-32	Obesity-related traits;
LUSC	cis	rs28785552	1.000	rs28785552	chr19:53234161	G/A	cg10871876	chr19:53194124	ZNF83	0.55	8.35	0.42	1.91e-15	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg16339924	chr4:17578868	LAP3	0.63	9.88	0.48	2.3e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.46	-0.42	8.72e-16	Response to antipsychotic treatment;
LUSC	cis	rs4664308	0.740	rs877635	chr2:160902847	A/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.0	-0.31	5.24e-9	Idiopathic membranous nephropathy;
LUSC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-15.85	-0.66	1.37e-42	Gut microbiome composition (summer);
LUSC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08439880	chr3:133502540	NA	-0.33	-5.94	-0.31	7.34e-9	Iron status biomarkers;
LUSC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.49e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg06521331	chr12:34319734	NA	-0.38	-5.66	-0.3	3.31e-8	Resting heart rate;
LUSC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg08859206	chr1:53392774	SCP2	0.52	9.03	0.44	1.35e-17	Monocyte count;
LUSC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.31	-0.37	2.02e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg20302533	chr7:39170763	POU6F2	0.55	9.13	0.45	6.58e-18	IgG glycosylation;
LUSC	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg05855489	chr10:104503620	C10orf26	0.53	8.1	0.41	1.05e-14	Arsenic metabolism;
LUSC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg23172400	chr8:95962367	TP53INP1	-0.41	-8.5	-0.42	6.24e-16	Type 2 diabetes;
LUSC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg15445000	chr17:37608096	MED1	-0.39	-6.73	-0.35	7.47e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg06637938	chr14:75390232	RPS6KL1	0.52	8.33	0.41	2.12e-15	Height;
LUSC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22509189	chr2:225307070	NA	0.44	5.77	0.3	1.81e-8	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs78545713	0.649	rs79662647	chr6:26217845	G/A	cg23601095	chr6:26197514	HIST1H3D	0.69	5.72	0.3	2.34e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg02782426	chr3:40428986	ENTPD3	0.41	7.76	0.39	1.02e-13	Renal cell carcinoma;
LUSC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg26924012	chr15:45694286	SPATA5L1	1.13	20.69	0.75	8.44e-62	Homoarginine levels;
LUSC	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg04865166	chr7:105162814	PUS7	0.52	5.69	0.3	2.74e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.6	8.37	0.42	1.62e-15	Body mass index (adult);
LUSC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.47	-9.16	-0.45	5.39e-18	Monocyte percentage of white cells;
LUSC	trans	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg13565492	chr6:43139072	SRF	-0.72	-10.91	-0.51	6.55e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11608355	0.515	rs12579916	chr12:109924528	T/G	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.92	-0.35	2.28e-11	Menopause (age at onset);
LUSC	cis	rs968451	0.813	rs5757619	chr22:39724558	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	8.7	0.43	1.5e-16	Primary biliary cholangitis;
LUSC	cis	rs6460942	0.591	rs62448729	chr7:12333720	G/C	cg06484146	chr7:12443880	VWDE	-0.56	-5.89	-0.31	9.39e-9	Coronary artery disease;
LUSC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.83	-0.51	1.23e-23	Alzheimer's disease (late onset);
LUSC	cis	rs7147624	1.000	rs7160390	chr14:66052460	G/A	cg03016385	chr14:66212404	NA	-0.84	-9.37	-0.46	1.12e-18	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg23711669	chr6:146136114	FBXO30	0.78	12.85	0.58	5.36e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg03859395	chr2:55845619	SMEK2	0.67	10.82	0.51	1.32e-23	Metabolic syndrome;
LUSC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg00933542	chr6:150070202	PCMT1	0.32	6.79	0.35	5.14e-11	Lung cancer;
LUSC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg00031303	chr3:195681400	NA	0.67	9.55	0.46	2.79e-19	Pancreatic cancer;
LUSC	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg17120908	chr11:65337727	SSSCA1	-0.53	-9.23	-0.45	3.09e-18	Bone mineral density;
LUSC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg04844267	chr4:1394941	NA	0.29	5.69	0.3	2.84e-8	Obesity-related traits;
LUSC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg24977027	chr2:88469347	THNSL2	0.56	5.93	0.31	7.76e-9	Plasma clusterin levels;
LUSC	trans	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg07393940	chr7:158741817	NA	0.37	6.75	0.35	6.53e-11	Life satisfaction;
LUSC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08439880	chr3:133502540	NA	-0.34	-6.07	-0.32	3.55e-9	Iron status biomarkers;
LUSC	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg23625390	chr15:77176239	SCAPER	-0.6	-9.24	-0.45	2.9e-18	Blood metabolite levels;
LUSC	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.16	0.45	5.47e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg19773385	chr1:10388646	KIF1B	-0.54	-8.39	-0.42	1.42e-15	Hepatocellular carcinoma;
LUSC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg11060661	chr22:24314208	DDT;DDTL	-0.46	-6.29	-0.33	9.84e-10	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	1.01	14.49	0.62	2.93e-37	Vitiligo;
LUSC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.8	-0.47	4.39e-20	Platelet count;
LUSC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10193935	0.582	rs13394853	chr2:42630900	T/C	cg27598129	chr2:42591480	NA	-0.61	-8.29	-0.41	2.79e-15	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs961253	0.501	rs6054145	chr20:6335730	T/C	cg21095983	chr6:86352623	SYNCRIP	0.49	7.22	0.37	3.64e-12	Colorectal cancer;
LUSC	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg22800045	chr5:56110881	MAP3K1	0.43	6.02	0.31	4.49e-9	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.73	0.35	7.58e-11	Lung cancer;
LUSC	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg05110241	chr16:68378359	PRMT7	-0.55	-6.32	-0.33	8.3e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg25456477	chr12:86230367	RASSF9	0.39	6.88	0.35	2.96e-11	Major depressive disorder;
LUSC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg10057126	chr4:77819792	ANKRD56	-0.52	-7.88	-0.4	4.68e-14	Emphysema distribution in smoking;
LUSC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg16558253	chr16:72132732	DHX38	-0.44	-6.56	-0.34	2.07e-10	Fibrinogen levels;
LUSC	cis	rs4588572	0.644	rs10061149	chr5:77744201	G/A	cg11547950	chr5:77652471	NA	-0.46	-6.87	-0.35	3.19e-11	Triglycerides;
LUSC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	6.52	0.34	2.61e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg22681709	chr2:178499509	PDE11A	-0.48	-8.23	-0.41	4.23e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg17971929	chr21:40555470	PSMG1	-0.51	-7.49	-0.38	6.3e-13	Menarche (age at onset);
LUSC	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg18232548	chr7:50535776	DDC	-0.6	-9.34	-0.46	1.39e-18	Malaria;
LUSC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.35	0.56	3.93e-29	Prudent dietary pattern;
LUSC	cis	rs2742234	0.910	rs2505513	chr10:43633537	C/G	cg15436174	chr10:43711423	RASGEF1A	-0.37	-6.66	-0.34	1.16e-10	Hirschsprung disease;
LUSC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.83	15.11	0.64	1.11e-39	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg06145435	chr7:1022769	CYP2W1	0.33	7.15	0.36	5.36e-12	Longevity;Endometriosis;
LUSC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.87	-0.35	3.2e-11	Lung cancer;
LUSC	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg19773385	chr1:10388646	KIF1B	-0.5	-8.74	-0.43	1.18e-16	Hepatocellular carcinoma;
LUSC	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg23791538	chr6:167370224	RNASET2	-0.43	-6.95	-0.36	1.93e-11	Crohn's disease;
LUSC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg06637938	chr14:75390232	RPS6KL1	0.53	8.52	0.42	5.74e-16	Height;
LUSC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-6.47	-0.33	3.44e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00149659	chr3:10157352	C3orf10	0.97	14.18	0.61	4.85e-36	Alzheimer's disease;
LUSC	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs59698941	0.709	rs12163973	chr5:132226664	G/A	cg02081065	chr5:132209139	LEAP2	-0.65	-6.75	-0.35	6.45e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg12463550	chr7:65579703	CRCP	0.64	5.83	0.3	1.3e-8	Diabetic kidney disease;
LUSC	cis	rs73200209	0.744	rs11615595	chr12:116470876	T/C	cg01776926	chr12:116560359	MED13L	-0.5	-6.0	-0.31	5.21e-9	Total body bone mineral density;
LUSC	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg20573242	chr4:122745356	CCNA2	-0.46	-6.86	-0.35	3.36e-11	Type 2 diabetes;
LUSC	cis	rs34734847	1.000	rs10431385	chr12:121128882	T/C	cg21892295	chr12:121157589	UNC119B	-0.45	-8.02	-0.4	1.78e-14	Mean corpuscular volume;
LUSC	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.73	-0.39	1.26e-13	Morning vs. evening chronotype;
LUSC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg16423285	chr20:60520624	NA	-0.47	-5.75	-0.3	2.06e-8	Body mass index;
LUSC	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-7.89	-0.4	4.32e-14	Total body bone mineral density;
LUSC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg17507749	chr15:85114479	UBE2QP1	0.67	8.49	0.42	6.75e-16	Schizophrenia;
LUSC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg04553112	chr3:125709451	NA	-0.49	-5.86	-0.31	1.11e-8	Blood pressure (smoking interaction);
LUSC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg15445000	chr17:37608096	MED1	0.4	6.86	0.35	3.35e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg02751453	chr18:77725136	HSBP1L1	0.43	5.93	0.31	7.5e-9	Opioid sensitivity;
LUSC	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg25930673	chr12:123319894	HIP1R	0.68	6.87	0.35	3.06e-11	Schizophrenia;
LUSC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg06008330	chr7:65541103	ASL	-0.4	-6.2	-0.32	1.66e-9	Aortic root size;
LUSC	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg17294928	chr15:75287854	SCAMP5	-0.76	-8.8	-0.43	7.3e-17	Blood trace element (Zn levels);
LUSC	cis	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.37e-9	Ulcerative colitis;
LUSC	cis	rs599083	0.744	rs603129	chr11:68186669	A/T	cg16797656	chr11:68205561	LRP5	-0.36	-5.81	-0.3	1.46e-8	Bone mineral density (spine);
LUSC	cis	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg17469321	chr7:55412551	NA	0.65	10.54	0.5	1.31e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg21775007	chr8:11205619	TDH	0.43	6.2	0.32	1.68e-9	Neuroticism;
LUSC	cis	rs7582720	1.000	rs72934714	chr2:203711581	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	8.17	0.41	6.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs928736	0.557	rs2834083	chr21:34436973	A/G	cg00274965	chr21:34405681	NA	0.29	5.66	0.3	3.24e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs12973672	0.812	rs12979058	chr19:35750684	G/A	cg12095397	chr19:35769544	USF2	0.43	6.55	0.34	2.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-0.85	-13.48	-0.59	2.36e-33	Refractive error;
LUSC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.53	-0.5	1.4e-22	Electroencephalogram traits;
LUSC	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.14	0.36	5.87e-12	IgG glycosylation;
LUSC	cis	rs9796	0.621	rs2578655	chr15:41462809	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-8.94	-0.44	2.78e-17	Menopause (age at onset);
LUSC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.64	10.33	0.49	7e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07923666	chr12:49932857	KCNH3	-0.51	-6.26	-0.32	1.15e-9	Resting heart rate;
LUSC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.29	6.39	0.33	5.54e-10	Electroencephalogram traits;
LUSC	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg12002119	chr2:101014098	CHST10	0.36	5.99	0.31	5.44e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.93	0.35	2.21e-11	Iron status biomarkers;
LUSC	cis	rs2742417	1.000	rs2673038	chr3:45748632	A/G	cg09608765	chr3:45636137	LIMD1	-0.38	-7.51	-0.38	5.48e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg00677455	chr12:58241039	CTDSP2	0.59	8.65	0.43	2.25e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg24375607	chr4:120327624	NA	0.75	10.61	0.5	7.54e-23	Corneal astigmatism;
LUSC	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg26924012	chr15:45694286	SPATA5L1	0.78	12.42	0.56	2.27e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs7712401	0.601	rs35339188	chr5:122317685	A/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.53	-0.46	3.35e-19	Mean platelet volume;
LUSC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.67	11.46	0.53	7.03e-26	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg01134436	chr17:81009848	B3GNTL1	0.65	6.24	0.32	1.3e-9	Chronotype;
LUSC	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg11584989	chr19:19387371	SF4	0.58	6.97	0.36	1.74e-11	Bipolar disorder;
LUSC	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.67e-24	Hypertriglyceridemia;
LUSC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.49	-0.53	5.57e-26	Type 2 diabetes;
LUSC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg05623727	chr3:50126028	RBM5	0.31	5.82	0.3	1.37e-8	Body mass index;
LUSC	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg13010199	chr12:38710504	ALG10B	0.56	8.52	0.42	5.71e-16	Morning vs. evening chronotype;
LUSC	cis	rs7582720	1.000	rs72934573	chr2:204005072	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.83	8.78	0.43	8.34e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs738322	0.555	rs6001027	chr22:38545619	A/G	cg25457927	chr22:38595422	NA	-0.42	-8.38	-0.42	1.53e-15	Cutaneous nevi;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15680975	chr20:3870297	PANK2	-0.41	-6.21	-0.32	1.57e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg22029157	chr1:209979665	IRF6	0.6	9.87	0.48	2.53e-20	Monobrow;
LUSC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.76	0.84	8.98e-89	Chronic sinus infection;
LUSC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg13939156	chr17:80058883	NA	0.34	6.54	0.34	2.35e-10	Life satisfaction;
LUSC	trans	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.34	-0.46	1.38e-18	Brugada syndrome;
LUSC	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg04511125	chr2:88470314	THNSL2	0.65	6.17	0.32	1.98e-9	Plasma clusterin levels;
LUSC	cis	rs6429082	0.608	rs4659838	chr1:235565315	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.51	-6.96	-0.36	1.77e-11	Adiposity;
LUSC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg13319975	chr6:146136371	FBXO30	0.7	11.14	0.52	9.86e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.46	-7.1	-0.36	7.58e-12	Menarche (age at onset);
LUSC	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.22	-25.51	-0.81	1.96e-80	Exhaled nitric oxide levels;
LUSC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg17173187	chr15:85201210	NMB	0.37	6.56	0.34	2.08e-10	Schizophrenia;
LUSC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.26	0.41	3.35e-15	Hemoglobin concentration;
LUSC	cis	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg07862535	chr7:139043722	LUC7L2	-0.55	-6.92	-0.35	2.32e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2227930	0.506	rs13067197	chr3:142033531	G/A	cg16271453	chr3:142027066	XRN1	-0.55	-9.86	-0.47	2.71e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg09455208	chr3:40491958	NA	0.59	10.51	0.5	1.59e-22	Renal cell carcinoma;
LUSC	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg21427119	chr20:30132790	HM13	-0.44	-6.3	-0.33	9.21e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg05855489	chr10:104503620	C10orf26	0.6	9.5	0.46	4.33e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg06740227	chr12:86229804	RASSF9	0.36	5.75	0.3	2.04e-8	Major depressive disorder;
LUSC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg05564831	chr3:52568323	NT5DC2	-0.31	-5.86	-0.31	1.13e-8	Electroencephalogram traits;
LUSC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg19230755	chr7:65878503	NA	-0.41	-5.75	-0.3	2e-8	Aortic root size;
LUSC	cis	rs10875746	1.000	rs10875746	chr12:48518264	A/C	cg13454099	chr12:49076203	C12orf41	-0.49	-6.15	-0.32	2.26e-9	Longevity (90 years and older);
LUSC	cis	rs752010	0.630	rs11210507	chr1:42105488	T/C	cg06885757	chr1:42089581	HIVEP3	0.44	8.68	0.43	1.78e-16	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7605827	0.897	rs9973344	chr2:15632583	G/T	cg19274914	chr2:15703543	NA	0.46	8.86	0.44	4.79e-17	Educational attainment (years of education);
LUSC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg24642844	chr7:1081250	C7orf50	-0.79	-10.59	-0.5	8.72e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	8.94	0.44	2.66e-17	Lung cancer in ever smokers;
LUSC	cis	rs7903847	0.642	rs11189174	chr10:99139600	C/G	cg08345082	chr10:99160200	RRP12	-0.37	-7.46	-0.38	7.51e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs34779708	0.801	rs12098720	chr10:35538683	G/A	cg03585969	chr10:35415529	CREM	0.55	7.67	0.39	1.92e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.42	-6.09	-0.32	3.15e-9	IgG glycosylation;
LUSC	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg02018176	chr4:1364513	KIAA1530	0.46	6.33	0.33	7.73e-10	Recombination rate (females);
LUSC	cis	rs73206853	0.841	rs3893403	chr12:111083980	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	6.66	0.34	1.12e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	8.88	0.44	4.25e-17	Prudent dietary pattern;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.66	14.66	0.63	6.47e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.61	0.5	7.44e-23	Mean corpuscular volume;
LUSC	cis	rs6704644	0.656	rs11681704	chr2:234338402	G/A	cg05711037	chr2:234359783	DGKD	0.58	6.14	0.32	2.36e-9	Bilirubin levels;
LUSC	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg12432903	chr7:1882776	MAD1L1	-0.53	-6.61	-0.34	1.55e-10	Bipolar disorder;
LUSC	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg06917634	chr15:78832804	PSMA4	0.82	14.7	0.63	4.46e-38	Sudden cardiac arrest;
LUSC	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg13609457	chr4:120235615	NA	0.38	5.76	0.3	1.87e-8	Diastolic blood pressure;
LUSC	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.56	0.46	2.6e-19	Lung cancer in ever smokers;
LUSC	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg27471124	chr11:109292789	C11orf87	0.41	7.15	0.36	5.5e-12	Schizophrenia;
LUSC	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg26876637	chr1:152193138	HRNR	0.46	6.57	0.34	1.89e-10	Atopic dermatitis;
LUSC	cis	rs4948102	0.924	rs13241866	chr7:56090878	C/G	cg17215666	chr7:56131930	SUMF2	0.5	6.84	0.35	3.7e-11	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg09835421	chr16:68378352	PRMT7	-0.44	-5.78	-0.3	1.69e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg05182265	chr7:156933206	UBE3C	0.44	6.88	0.35	2.95e-11	Body mass index;
LUSC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-5.94	-0.31	7.16e-9	Vitiligo;
LUSC	cis	rs7246657	0.722	rs958305	chr19:38189440	A/G	cg23950597	chr19:37808831	NA	0.5	5.64	0.3	3.55e-8	Coronary artery calcification;
LUSC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-10.61	-0.5	7.14e-23	Gut microbiome composition (summer);
LUSC	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.13	0.41	8.28e-15	Corneal astigmatism;
LUSC	trans	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg03785828	chr5:81573306	RPS23	-0.37	-5.99	-0.31	5.58e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-6.76	-0.35	6.1e-11	Type 2 diabetes;
LUSC	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg08917208	chr2:24149416	ATAD2B	1.01	10.6	0.5	7.75e-23	Lymphocyte counts;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20024953	chr12:57584802	LRP1	-0.7	-6.27	-0.32	1.14e-9	Cognitive performance;
LUSC	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg26784012	chr10:32216390	ARHGAP12	0.46	7.71	0.39	1.47e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-0.87	-15.8	-0.65	2.3e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	6.02	0.31	4.51e-9	Axial length;
LUSC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.01	0.77	5.62e-67	Prudent dietary pattern;
LUSC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg24733560	chr20:60626293	TAF4	0.41	6.7	0.34	8.69e-11	Body mass index;
LUSC	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.09	0.45	9.18e-18	Menarche (age at onset);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07017284	chr1:173684020	KLHL20	0.34	6.0	0.31	5.13e-9	Triglycerides;
LUSC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.49	-0.33	3.04e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg05896524	chr21:47604654	C21orf56	0.45	6.78	0.35	5.51e-11	Testicular germ cell tumor;
LUSC	trans	rs7833787	0.725	rs12544660	chr8:18678404	C/T	cg25885280	chr11:70760166	SHANK2	-0.25	-6.18	-0.32	1.9e-9	Obesity-related traits;
LUSC	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg14458575	chr2:238380390	NA	0.65	11.29	0.53	2.88e-25	Prostate cancer;
LUSC	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg08270630	chr22:50330655	NA	-0.4	-6.07	-0.32	3.4e-9	Schizophrenia;
LUSC	cis	rs925550	0.800	rs6837455	chr4:123588942	G/C	cg10495464	chr4:123653540	BBS12;LOC729338	-0.6	-5.77	-0.3	1.85e-8	Primary biliary cholangitis;
LUSC	cis	rs80130819	0.688	rs11168455	chr12:48592792	G/A	cg24011408	chr12:48396354	COL2A1	0.45	5.82	0.3	1.39e-8	Prostate cancer;
LUSC	cis	rs2857891	0.817	rs2239730	chr11:6977175	G/C	cg14883916	chr11:6947541	ZNF215	0.44	5.83	0.3	1.29e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg11439826	chr17:76250004	NA	0.38	5.73	0.3	2.29e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.6	8.66	0.43	2e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg03015672	chr10:32216066	ARHGAP12	0.32	5.67	0.3	3.16e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10743315	0.557	rs77299796	chr12:19365100	T/C	cg02471346	chr12:19282374	PLEKHA5	0.78	6.28	0.33	1.03e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg06784218	chr1:46089804	CCDC17	-0.52	-9.87	-0.48	2.51e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2806561	0.780	rs12409321	chr1:23398065	C/T	cg19743168	chr1:23544995	NA	-0.44	-9.14	-0.45	6.38e-18	Height;
LUSC	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg26924012	chr15:45694286	SPATA5L1	0.79	12.51	0.56	1.02e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg06641503	chr3:48959341	ARIH2	-0.38	-5.83	-0.3	1.3e-8	Parkinson's disease;
LUSC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15506890	chr2:3487001	NA	-0.57	-9.38	-0.46	1.06e-18	Neurofibrillary tangles;
LUSC	cis	rs59698941	0.943	rs12517073	chr5:132240151	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.31	-0.33	8.76e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs73195822	0.667	rs2339634	chr12:111231277	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	6.37	0.33	6.43e-10	Itch intensity from mosquito bite;
LUSC	cis	rs9646944	0.501	rs741284	chr2:103083324	G/C	cg20060108	chr2:102954350	IL1RL1	0.44	5.87	0.31	1.07e-8	Blood protein levels;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14791831	chr16:28565295	CCDC101	0.44	6.76	0.35	6.29e-11	Asthma;
LUSC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7000551	0.689	rs6996872	chr8:22316753	T/C	cg12081754	chr8:22256438	SLC39A14	0.45	6.84	0.35	3.9e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.5	7.2	0.37	4.01e-12	Renal function-related traits (BUN);
LUSC	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	9.18	0.45	4.75e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02176678	chr2:219576539	TTLL4	0.64	11.7	0.54	9.61e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg00343986	chr7:65444356	GUSB	0.47	7.03	0.36	1.14e-11	Aortic root size;
LUSC	trans	rs3857536	0.741	rs4710582	chr6:66939984	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	trans	rs9944715	0.859	rs7236687	chr18:43736484	C/G	cg01718231	chr17:29326311	RNF135	0.45	6.12	0.32	2.63e-9	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs9987353	0.830	rs7010108	chr8:9130674	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.07	-0.32	3.42e-9	Recombination measurement;
LUSC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	8.52	0.42	5.41e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg06606381	chr12:133084897	FBRSL1	-0.66	-6.55	-0.34	2.11e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00631329	chr6:26305371	NA	-0.47	-9.41	-0.46	8.03e-19	Educational attainment;
LUSC	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg20307385	chr11:47447363	PSMC3	0.45	6.58	0.34	1.82e-10	Subjective well-being;
LUSC	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg20503657	chr10:835505	NA	0.5	5.81	0.3	1.42e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg25767906	chr1:53392781	SCP2	0.61	11.83	0.54	3.29e-27	Monocyte count;
LUSC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.03	0.31	4.3e-9	Schizophrenia;
LUSC	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs6546537	1.000	rs12478540	chr2:69844524	C/T	cg10773587	chr2:69614142	GFPT1	-0.49	-7.46	-0.38	7.61e-13	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs3736594	0.559	rs1919129	chr2:27818721	C/G	cg27432699	chr2:27873401	GPN1	0.63	8.61	0.43	2.91e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-17.57	-0.69	2.11e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6700896	1.000	rs6700896	chr1:66089782	C/T	cg04111102	chr1:66153794	NA	0.32	6.96	0.36	1.84e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9815354	0.812	rs61661916	chr3:41921915	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.57	0.42	3.85e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.69	-0.34	9.35e-11	Morning vs. evening chronotype;
LUSC	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg21775007	chr8:11205619	TDH	-0.52	-7.47	-0.38	7.16e-13	Triglycerides;
LUSC	trans	rs3857536	0.813	rs1891600	chr6:66941645	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg21724239	chr8:58056113	NA	0.78	9.79	0.47	4.58e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06873352	chr17:61820015	STRADA	0.54	8.22	0.41	4.53e-15	Height;
LUSC	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg26373071	chr5:1325741	CLPTM1L	0.42	7.78	0.39	9.38e-14	Lung cancer;
LUSC	cis	rs9815354	0.812	rs4577439	chr3:41952540	T/A	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.55e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	9.0	0.44	1.77e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7949030	1.000	rs3018561	chr11:62392229	C/A	cg22862634	chr11:62369728	EML3;MTA2	-0.49	-7.94	-0.4	3.2e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.66	-9.24	-0.45	3.03e-18	Multiple sclerosis;
LUSC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg03579872	chr1:53393473	SCP2	-0.39	-5.85	-0.3	1.17e-8	Monocyte count;
LUSC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg12463550	chr7:65579703	CRCP	-0.47	-6.96	-0.36	1.86e-11	Aortic root size;
LUSC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21984481	chr17:79567631	NPLOC4	-0.54	-10.05	-0.48	5.99e-21	Eye color traits;
LUSC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg08736216	chr1:53307985	ZYG11A	-0.29	-5.83	-0.3	1.33e-8	Monocyte count;
LUSC	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg13798780	chr7:105162888	PUS7	0.56	6.07	0.32	3.43e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.78	0.51	1.83e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg04450456	chr4:17643702	FAM184B	0.37	6.09	0.32	3.05e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg21573476	chr21:45109991	RRP1B	-0.37	-5.96	-0.31	6.34e-9	Mean corpuscular volume;
LUSC	cis	rs9462027	0.606	rs2814981	chr6:34581055	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.09	-0.32	3.17e-9	Systemic lupus erythematosus;
LUSC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	8.83	0.43	6.1e-17	Mean platelet volume;
LUSC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06634786	chr22:41940651	POLR3H	0.5	6.02	0.31	4.64e-9	Vitiligo;
LUSC	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg23601095	chr6:26197514	HIST1H3D	-0.67	-7.25	-0.37	2.94e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg24846343	chr22:24311635	DDTL	0.73	14.86	0.63	1.1e-38	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08392591	chr16:89556376	ANKRD11	0.52	8.08	0.4	1.22e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs9517320	0.934	rs9517319	chr13:99125956	T/G	cg20487152	chr13:99095054	FARP1	0.34	6.37	0.33	6.33e-10	Longevity;
LUSC	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg13575925	chr12:9217583	LOC144571	0.34	6.35	0.33	7e-10	Sjögren's syndrome;
LUSC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg11244672	chr19:19639970	YJEFN3	-0.47	-6.45	-0.33	3.9e-10	Bipolar disorder;
LUSC	cis	rs2908197	0.806	rs2961047	chr7:75935056	A/G	cg10167463	chr7:75959203	YWHAG	-0.38	-5.8	-0.3	1.5e-8	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	0.92	19.47	0.73	5.73e-57	Ulcerative colitis;
LUSC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.62	-8.05	-0.4	1.49e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg03233332	chr7:66118400	NA	-0.43	-6.15	-0.32	2.22e-9	Aortic root size;
LUSC	cis	rs2439831	1.000	rs2467426	chr15:43989518	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	9.0	0.44	1.79e-17	Lung cancer in ever smokers;
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg13453750	chr1:205783389	SLC41A1	-0.33	-6.51	-0.34	2.83e-10	Menarche (age at onset);
LUSC	cis	rs6681460	0.898	rs536527	chr1:67193793	A/C	cg02459107	chr1:67143332	SGIP1	0.47	8.86	0.44	4.67e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs240764	0.817	rs151573	chr6:101086333	T/C	cg09795085	chr6:101329169	ASCC3	0.41	5.99	0.31	5.5e-9	Neuroticism;
LUSC	cis	rs2742417	1.000	rs1969626	chr3:45746836	A/G	cg09608765	chr3:45636137	LIMD1	-0.38	-7.51	-0.38	5.48e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-11.32	-0.53	2.22e-25	Coffee consumption (cups per day);
LUSC	cis	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.48	-6.67	-0.34	1.04e-10	Primary sclerosing cholangitis;
LUSC	trans	rs1941687	0.509	rs7238029	chr18:31317755	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-8.23	-0.41	4.24e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg24112000	chr20:60950667	NA	0.36	6.8	0.35	4.72e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs2625529	0.824	rs2415130	chr15:72242554	G/A	cg16672083	chr15:72433130	SENP8	-0.5	-7.47	-0.38	7.18e-13	Red blood cell count;
LUSC	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg26395211	chr5:140044315	WDR55	-0.38	-5.84	-0.3	1.25e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	6.01	0.31	4.91e-9	Rheumatoid arthritis;
LUSC	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg08558340	chr7:100472263	SRRT	0.51	6.27	0.32	1.11e-9	Resting heart rate;
LUSC	cis	rs4144743	0.759	rs1009312	chr17:45332140	G/A	cg18085866	chr17:45331354	ITGB3	-0.75	-7.81	-0.39	7.38e-14	Body mass index;
LUSC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.56e-10	Menopause (age at onset);
LUSC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg05872129	chr22:39784769	NA	0.62	11.7	0.54	1.01e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	0.94	18.56	0.71	2.36e-53	Cognitive function;
LUSC	cis	rs9399401	0.845	rs263183	chr6:142862181	C/T	cg03128060	chr6:142623767	GPR126	0.33	6.16	0.32	2.14e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg12963246	chr6:28129442	ZNF389	-0.52	-7.43	-0.38	9.41e-13	Depression;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg19853413	chr5:135468610	SMAD5;SMAD5OS	0.43	6.18	0.32	1.88e-9	Mosquito bite size;
LUSC	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg26384229	chr12:38710491	ALG10B	0.74	12.08	0.55	4.07e-28	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg23711669	chr6:146136114	FBXO30	0.82	14.57	0.62	1.5e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-1.17	-16.86	-0.68	1.46e-46	Breast cancer;
LUSC	cis	rs3925075	0.934	rs9673522	chr16:31347648	T/C	cg02846316	chr16:31340340	ITGAM	0.36	6.66	0.34	1.11e-10	IgA nephropathy;
LUSC	cis	rs7552167	1.000	rs59960858	chr1:24519437	C/A	cg01960748	chr1:24522592	NA	0.63	8.92	0.44	3.07e-17	Psoriasis vulgaris;
LUSC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00166722	chr3:10149974	C3orf24	0.61	7.9	0.4	3.96e-14	Alzheimer's disease;
LUSC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	0.91	18.54	0.71	2.79e-53	Dental caries;
LUSC	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8044868	0.586	rs7199261	chr16:72082788	A/G	cg16579770	chr16:72058938	DHODH	0.34	5.77	0.3	1.86e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00166722	chr3:10149974	C3orf24	0.56	7.54	0.38	4.61e-13	Alzheimer's disease;
LUSC	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg00750074	chr16:89608354	SPG7	-0.48	-8.12	-0.41	9.4e-15	Multiple myeloma (IgH translocation);
LUSC	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg12927641	chr6:109611667	NA	-0.36	-6.12	-0.32	2.69e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.7	10.74	0.51	2.63e-23	Aortic root size;
LUSC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg03146154	chr1:46216737	IPP	-0.48	-7.13	-0.36	6.25e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg15556689	chr8:8085844	FLJ10661	0.69	11.73	0.54	7.82e-27	Mood instability;
LUSC	cis	rs4144743	0.759	rs4289057	chr17:45321030	G/A	cg18085866	chr17:45331354	ITGB3	-0.83	-8.12	-0.41	9.07e-15	Body mass index;
LUSC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-7.14	-0.36	5.87e-12	Lung cancer;
LUSC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg03354898	chr7:1950403	MAD1L1	-0.37	-7.09	-0.36	8.22e-12	Schizophrenia;
LUSC	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg08017756	chr2:100939284	LONRF2	-0.45	-8.46	-0.42	8.2e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	1.0	17.44	0.69	7.17e-49	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs12439619	0.508	rs17354842	chr15:82469600	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.44	6.83	0.35	4.02e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00767644	chr1:174968745	CACYBP	0.4	6.11	0.32	2.73e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	12.18	0.55	1.74e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2516839	0.652	rs2774276	chr1:161011716	G/C	cg11578532	chr1:161008127	TSTD1	0.35	7.29	0.37	2.28e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs877282	0.583	rs7072970	chr10:822757	G/A	cg13775593	chr10:823151	NA	0.31	6.1	0.32	2.96e-9	Uric acid levels;
LUSC	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg09796270	chr17:17721594	SREBF1	-0.46	-8.29	-0.41	2.85e-15	Total body bone mineral density;
LUSC	cis	rs3125734	0.633	rs4979754	chr10:64048959	G/A	cg09941381	chr10:64027924	RTKN2	-0.4	-7.19	-0.37	4.18e-12	Rheumatoid arthritis;
LUSC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.6	0.34	1.59e-10	Menopause (age at onset);
LUSC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.25	-0.32	1.22e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2652834	1.000	rs2729780	chr15:63404639	C/G	cg05507819	chr15:63340323	TPM1	0.67	8.16	0.41	7.01e-15	HDL cholesterol;
LUSC	trans	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg06606381	chr12:133084897	FBRSL1	-1.08	-9.49	-0.46	4.57e-19	Depression;
LUSC	cis	rs2029213	0.523	rs3773739	chr3:53268429	A/G	cg16894138	chr3:53270350	TKT	-0.33	-7.0	-0.36	1.4e-11	Heart rate;
LUSC	cis	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.82	-0.3	1.35e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg07395648	chr5:131743802	NA	-0.44	-7.04	-0.36	1.07e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs870825	0.929	rs72689261	chr4:185590897	C/A	cg04058563	chr4:185651563	MLF1IP	0.83	11.29	0.53	2.87e-25	Blood protein levels;
LUSC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg26380479	chr7:97908229	NA	0.26	5.77	0.3	1.78e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg20744362	chr22:50050164	C22orf34	0.39	7.19	0.37	4.38e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.74	0.35	6.95e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.69	0.5	4.02e-23	Morning vs. evening chronotype;
LUSC	cis	rs11779988	0.545	rs397096	chr8:17798848	C/G	cg01800426	chr8:17659068	MTUS1	0.52	6.31	0.33	8.63e-10	Breast cancer;
LUSC	cis	rs6845621	0.901	rs2159971	chr4:18917125	A/T	cg12196642	chr4:18937545	NA	-0.34	-6.44	-0.33	4.14e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg03060546	chr3:49711283	APEH	0.66	7.33	0.37	1.74e-12	Menarche (age at onset);
LUSC	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg15133208	chr4:90757351	SNCA	-0.53	-8.22	-0.41	4.69e-15	Neuroticism;
LUSC	cis	rs10089	0.953	rs2190797	chr5:127352875	C/A	cg19767477	chr5:127420684	SLC12A2	-0.41	-5.83	-0.3	1.28e-8	Ileal carcinoids;
LUSC	cis	rs11785693	0.862	rs11774842	chr8:4979769	A/C	cg26367366	chr8:4980734	NA	0.78	9.28	0.45	2.24e-18	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg16325326	chr1:53192061	ZYG11B	0.81	12.61	0.57	4.39e-30	Monocyte count;
LUSC	cis	rs1595825	0.891	rs59617443	chr2:198653204	C/A	cg10547527	chr2:198650123	BOLL	-0.51	-5.97	-0.31	5.92e-9	Ulcerative colitis;
LUSC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg17366294	chr4:99064904	C4orf37	0.52	9.54	0.46	3.05e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg20476274	chr7:133979776	SLC35B4	0.78	13.04	0.58	1.1e-31	Mean platelet volume;
LUSC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg00033643	chr7:134001901	SLC35B4	0.47	7.33	0.37	1.7e-12	Mean platelet volume;
LUSC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-7.39	-0.38	1.16e-12	Aortic root size;
LUSC	cis	rs11997175	0.766	rs56803376	chr8:33687676	T/C	ch.8.33884649F	chr8:33765107	NA	0.39	6.1	0.32	3e-9	Body mass index;
LUSC	cis	rs56399783	0.901	rs79932907	chr7:2827901	C/G	cg14895029	chr7:2775587	GNA12	0.5	6.14	0.32	2.4e-9	Childhood ear infection;
LUSC	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg06096015	chr1:231504339	EGLN1	0.55	9.62	0.47	1.75e-19	Hemoglobin concentration;
LUSC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg06671660	chr6:41068741	NFYA;LOC221442	-0.39	-5.67	-0.3	3.08e-8	Alzheimer's disease (late onset);
LUSC	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg13852791	chr20:30311386	BCL2L1	-0.71	-8.03	-0.4	1.73e-14	Mean corpuscular hemoglobin;
LUSC	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg03585969	chr10:35415529	CREM	0.58	8.43	0.42	1.02e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg11766577	chr21:47581405	C21orf56	0.56	8.77	0.43	9.59e-17	Testicular germ cell tumor;
LUSC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg21132104	chr15:45694354	SPATA5L1	0.54	7.3	0.37	2.09e-12	Homoarginine levels;
LUSC	trans	rs1171606	0.731	rs1171650	chr10:61450153	C/T	cg14119616	chr11:17099403	RPS13	-0.41	-6.16	-0.32	2.1e-9	Acylcarnitine levels;
LUSC	cis	rs6733011	0.581	rs4851162	chr2:99466659	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.71	-0.34	8.42e-11	Bipolar disorder;
LUSC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg07507251	chr3:52567010	NT5DC2	0.31	6.25	0.32	1.26e-9	Bipolar disorder;
LUSC	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-39.76	-0.91	1.1e-128	Myeloid white cell count;
LUSC	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg13385521	chr17:29058706	SUZ12P	-0.68	-6.94	-0.36	1.99e-11	Body mass index;
LUSC	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.45	6.95	0.36	1.92e-11	Systolic blood pressure;
LUSC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06634786	chr22:41940651	POLR3H	-0.54	-6.33	-0.33	7.84e-10	Vitiligo;
LUSC	cis	rs1953600	0.645	rs2819950	chr10:81935279	G/A	cg00277334	chr10:82204260	NA	0.5	7.98	0.4	2.36e-14	Sarcoidosis;
LUSC	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg12002119	chr2:101014098	CHST10	0.37	6.19	0.32	1.72e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7043114	0.507	rs10820971	chr9:95161740	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.63	-0.34	1.36e-10	Height;
LUSC	cis	rs2540226	0.550	rs2160198	chr2:39930224	A/G	cg23576258	chr2:39999331	THUMPD2	0.37	6.3	0.33	9.56e-10	Personality dimensions;
LUSC	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	7.43	0.38	9.21e-13	Response to antipsychotic treatment;
LUSC	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg01973587	chr1:228161476	NA	0.47	8.54	0.42	4.76e-16	Diastolic blood pressure;
LUSC	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg08085267	chr17:45401833	C17orf57	-0.46	-6.71	-0.34	8.46e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg04691961	chr3:161091175	C3orf57	-0.34	-5.78	-0.3	1.73e-8	Morning vs. evening chronotype;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.76	16.98	0.68	4.84e-47	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7129220	0.858	rs2957657	chr11:10287810	A/G	cg06252276	chr11:34852392	NA	-0.53	-6.07	-0.32	3.53e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg15103426	chr22:29168792	CCDC117	-0.44	-5.76	-0.3	1.96e-8	Lymphocyte counts;
LUSC	cis	rs977987	0.806	rs1030262	chr16:75491327	C/A	cg03315344	chr16:75512273	CHST6	0.49	9.36	0.46	1.19e-18	Dupuytren's disease;
LUSC	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-6.85	-0.35	3.46e-11	Blood metabolite levels;
LUSC	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-7.23	-0.37	3.3e-12	Response to antipsychotic treatment;
LUSC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg17264618	chr3:40429014	ENTPD3	-0.33	-7.25	-0.37	2.9e-12	Renal cell carcinoma;
LUSC	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	10.13	0.48	3.23e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	6.71	0.34	8.14e-11	Lung cancer in ever smokers;
LUSC	cis	rs983392	0.805	rs1834550	chr11:59959843	T/C	cg02771260	chr11:59836817	MS4A3	-0.36	-5.77	-0.3	1.82e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg23172400	chr8:95962367	TP53INP1	-0.31	-5.88	-0.31	9.97e-9	Type 2 diabetes;
LUSC	cis	rs62400317	0.859	rs6920046	chr6:45159431	A/C	cg18551225	chr6:44695536	NA	-0.45	-7.22	-0.37	3.47e-12	Total body bone mineral density;
LUSC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs4631830	0.863	rs7081532	chr10:51526093	A/G	cg16070123	chr10:51489643	NA	-0.5	-8.06	-0.4	1.4e-14	Prostate-specific antigen levels;
LUSC	trans	rs1486139	0.967	rs2010427	chr7:46283836	A/G	cg17534202	chr9:96721102	NA	-0.37	-6.56	-0.34	2.01e-10	Select biomarker traits;
LUSC	cis	rs7043114	0.563	rs10820990	chr9:95323297	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.35	6.41	0.33	4.99e-10	Height;
LUSC	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg18827107	chr12:86230957	RASSF9	-0.39	-5.69	-0.3	2.76e-8	Major depressive disorder;
LUSC	cis	rs9646944	0.501	rs1403552	chr2:103088777	C/T	cg20060108	chr2:102954350	IL1RL1	0.45	5.97	0.31	6.13e-9	Blood protein levels;
LUSC	cis	rs1754541	0.517	rs514793	chr1:101604554	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.56	-5.89	-0.31	9.46e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
LUSC	cis	rs6845621	0.835	rs11728202	chr4:18937351	G/T	cg12196642	chr4:18937545	NA	-0.36	-6.76	-0.35	6.33e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.15	-0.45	5.94e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg22166914	chr1:53195759	ZYG11B	0.57	9.28	0.45	2.22e-18	Monocyte count;
LUSC	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg05805236	chr11:65401703	PCNXL3	0.4	6.82	0.35	4.28e-11	Acne (severe);
LUSC	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.51	0.5	1.61e-22	Coffee consumption (cups per day);
LUSC	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg16070123	chr10:51489643	NA	0.57	9.36	0.46	1.24e-18	Prostate-specific antigen levels;
LUSC	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg18099408	chr3:52552593	STAB1	0.35	5.71	0.3	2.46e-8	Body mass index;
LUSC	cis	rs2395909	1	rs2395909	chr7:107292663	G/A	cg23024343	chr7:107201750	COG5	0.4	6.08	0.32	3.36e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg26335602	chr6:28129616	ZNF389	0.42	5.7	0.3	2.63e-8	Depression;
LUSC	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg12179176	chr11:130786555	SNX19	0.65	9.69	0.47	9.71e-20	Schizophrenia;
LUSC	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2820315	0.867	rs2820318	chr1:201878620	T/C	cg10061532	chr1:201886748	LMOD1	0.28	6.45	0.33	3.87e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.74	7.65	0.39	2.11e-13	Yeast infection;
LUSC	cis	rs1507153	0.549	rs699183	chr6:79336011	A/G	cg05283184	chr6:79620031	NA	-0.39	-7.15	-0.36	5.61e-12	Sjögren's syndrome;
LUSC	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg23750338	chr8:142222470	SLC45A4	0.58	11.04	0.52	2.3e-24	Immature fraction of reticulocytes;
LUSC	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg12935359	chr14:103987150	CKB	0.66	10.71	0.51	3.27e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.44	-0.38	8.8e-13	Height;
LUSC	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.6	9.49	0.46	4.46e-19	Morning vs. evening chronotype;
LUSC	cis	rs11209002	0.567	rs2815385	chr1:67542083	A/G	cg02640540	chr1:67518911	SLC35D1	0.6	8.15	0.41	7.39e-15	Crohn's disease;
LUSC	cis	rs7179456	0.547	rs653765	chr15:59042012	T/C	cg05156742	chr15:59063176	FAM63B	0.52	7.73	0.39	1.31e-13	Asperger disorder;
LUSC	cis	rs4363385	0.934	rs1415964	chr1:152955085	T/C	cg00922841	chr1:152955080	SPRR1A	-0.49	-8.26	-0.41	3.39e-15	Inflammatory skin disease;
LUSC	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.84	15.37	0.64	1.07e-40	Colorectal cancer;
LUSC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-7.88	-0.4	4.51e-14	Chronic sinus infection;
LUSC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg07701084	chr6:150067640	NUP43	0.53	7.99	0.4	2.25e-14	Lung cancer;
LUSC	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-0.9	-15.71	-0.65	4.81e-42	Height;
LUSC	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21545522	chr1:205238299	TMCC2	0.5	9.45	0.46	5.97e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg08213375	chr14:104286397	PPP1R13B	0.35	5.78	0.3	1.74e-8	Reticulocyte count;
LUSC	cis	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg20368463	chr18:77673604	PQLC1	-0.68	-10.48	-0.5	2.03e-22	Schizophrenia;
LUSC	cis	rs6693567	0.545	rs1260391	chr1:150373077	T/C	cg15654264	chr1:150340011	RPRD2	0.44	7.16	0.36	5.09e-12	Migraine;
LUSC	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg04374321	chr14:90722782	PSMC1	0.72	11.41	0.53	1.14e-25	Mortality in heart failure;
LUSC	cis	rs12530845	0.832	rs56306315	chr7:135329107	C/T	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg12559939	chr2:27858050	GPN1	0.41	6.33	0.33	8.01e-10	Oral cavity cancer;
LUSC	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.24	-0.41	4.09e-15	Neuroticism;
LUSC	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg15309053	chr8:964076	NA	0.42	8.73	0.43	1.22e-16	Schizophrenia;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg00024416	chr22:24240387	NA	-0.35	-6.08	-0.32	3.23e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg04369109	chr6:150039330	LATS1	-0.4	-5.78	-0.3	1.67e-8	Testicular germ cell tumor;
LUSC	cis	rs7267979	0.546	rs8115804	chr20:25438783	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.74	-13.06	-0.58	9.11e-32	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.58	0.34	1.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.09	-0.32	3.11e-9	Neuroticism;
LUSC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg08493051	chr2:3487164	NA	-0.55	-8.5	-0.42	6.19e-16	Neurofibrillary tangles;
LUSC	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg08213375	chr14:104286397	PPP1R13B	0.54	10.89	0.51	7.59e-24	Schizophrenia;
LUSC	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg04362960	chr10:104952993	NT5C2	0.57	8.99	0.44	1.92e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27051171	chr2:7005923	CMPK2	-0.46	-5.96	-0.31	6.39e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs867371	0.519	rs1566560	chr15:82524457	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.38	-6.33	-0.33	7.96e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs72960926	0.590	rs117275111	chr6:74750921	G/A	cg03266952	chr6:74778945	NA	-0.82	-6.15	-0.32	2.24e-9	Metabolite levels (MHPG);
LUSC	cis	rs9921338	0.961	rs66555362	chr16:11388833	G/T	cg00044050	chr16:11439710	C16orf75	-0.5	-6.99	-0.36	1.52e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg03599575	chr15:90893182	GABARAPL3	-0.34	-5.84	-0.3	1.22e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg05022225	chr19:49866942	DKKL1;TEAD2	-0.51	-6.27	-0.32	1.09e-9	Multiple sclerosis;
LUSC	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg05283184	chr6:79620031	NA	-0.46	-8.84	-0.44	5.56e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg01879757	chr17:41196368	BRCA1	-0.4	-6.01	-0.31	4.86e-9	Menopause (age at onset);
LUSC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.1	16.51	0.67	3.47e-45	Gut microbiome composition (summer);
LUSC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg19266014	chr7:2183958	MAD1L1	-0.34	-5.78	-0.3	1.75e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.8	12.79	0.57	9.44e-31	Platelet count;
LUSC	trans	rs17607347	0.542	rs62052911	chr16:72567301	G/T	cg12945194	chr11:64703312	GPHA2	0.38	6.06	0.31	3.74e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg05925327	chr15:68127851	NA	0.33	5.86	0.31	1.12e-8	Restless legs syndrome;
LUSC	trans	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-9.67	-0.47	1.2e-19	Blood pressure (smoking interaction);
LUSC	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	6.07	0.32	3.38e-9	Blood metabolite levels;
LUSC	cis	rs34779708	0.966	rs1148245	chr10:35511894	C/T	cg04310649	chr10:35416472	CREM	-0.37	-5.68	-0.3	2.96e-8	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg23590916	chr17:43697445	MGC57346	0.49	6.63	0.34	1.38e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg04450456	chr4:17643702	FAM184B	0.38	6.28	0.33	1.03e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.83	-0.35	4.12e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg02016764	chr4:38805732	TLR1	-0.54	-5.75	-0.3	2.06e-8	Breast cancer;
LUSC	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg13385521	chr17:29058706	SUZ12P	0.59	5.81	0.3	1.49e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.42e-19	Prudent dietary pattern;
LUSC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-1.12	-16.47	-0.67	5.1e-45	Monocyte percentage of white cells;
LUSC	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg12940439	chr1:67600707	NA	0.35	5.86	0.31	1.12e-8	Psoriasis;
LUSC	trans	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg05887092	chr17:76393375	PGS1	0.65	12.68	0.57	2.45e-30	HDL cholesterol levels;
LUSC	trans	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg26043149	chr18:55253948	FECH	-0.45	-7.03	-0.36	1.18e-11	Bone mineral density;
LUSC	cis	rs6500395	0.962	rs9936883	chr16:48676443	G/A	cg04672837	chr16:48644449	N4BP1	0.45	6.8	0.35	4.86e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs8133932	0.608	rs413246	chr21:47346066	G/A	cg14185626	chr21:47401492	COL6A1	-0.45	-5.8	-0.3	1.54e-8	Schizophrenia;
LUSC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.03	0.31	4.3e-9	Schizophrenia;
LUSC	cis	rs6087990	1.000	rs1007124	chr20:31345752	G/C	cg13636640	chr20:31349939	DNMT3B	1.03	23.38	0.79	2.6e-72	Ulcerative colitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22996605	chr6:43138883	SRF	0.44	6.4	0.33	5.16e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs5771069	0.931	rs137864	chr22:50446988	C/T	cg27068297	chr22:50451975	IL17REL	0.29	5.97	0.31	5.98e-9	Ulcerative colitis;
LUSC	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg21361702	chr7:150065534	REPIN1	0.58	8.25	0.41	3.58e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-1.13	-17.98	-0.7	4.92e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs62400317	0.821	rs12206568	chr6:45152747	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.49	-0.38	6.14e-13	Total body bone mineral density;
LUSC	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg10909506	chr17:38081995	ORMDL3	0.34	6.01	0.31	4.74e-9	Self-reported allergy;
LUSC	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg11812906	chr14:75593930	NEK9	-0.64	-10.99	-0.52	3.49e-24	Height;
LUSC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg24399712	chr22:39784796	NA	-0.62	-11.12	-0.52	1.19e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg02574844	chr11:5959923	NA	-0.41	-6.39	-0.33	5.65e-10	DNA methylation (variation);
LUSC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg02221750	chr19:17393354	ANKLE1	-0.9	-14.05	-0.61	1.47e-35	Systemic lupus erythematosus;
LUSC	cis	rs4363385	0.693	rs10788849	chr1:152902240	C/A	cg00922841	chr1:152955080	SPRR1A	-0.4	-6.55	-0.34	2.16e-10	Inflammatory skin disease;
LUSC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg24562669	chr7:97807699	LMTK2	0.35	6.16	0.32	2.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4792901	0.802	rs9894910	chr17:41574306	T/A	cg22562494	chr17:41607896	ETV4	-0.33	-6.18	-0.32	1.9e-9	Dupuytren's disease;
LUSC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	12.66	0.57	2.81e-30	Cognitive test performance;
LUSC	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg03585969	chr10:35415529	CREM	0.6	8.66	0.43	2.08e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.5	0.56	1.14e-29	Motion sickness;
LUSC	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg02403541	chr12:121454288	C12orf43	0.6	8.66	0.43	2.08e-16	N-glycan levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02013961	chr6:142468197	VTA1	-0.41	-6.09	-0.32	3.19e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg08999081	chr20:33150536	PIGU	0.32	5.66	0.3	3.32e-8	Height;
LUSC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	1.05	20.45	0.75	7.54e-61	Menopause (age at onset);
LUSC	cis	rs79911532	0.515	rs10245109	chr7:75846115	G/T	cg03592824	chr7:75666768	STYXL1	0.59	6.02	0.31	4.62e-9	Mononucleosis;
LUSC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg03790207	chr6:42947109	PEX6	-0.45	-6.76	-0.35	6.08e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg00701064	chr4:6280414	WFS1	0.59	14.24	0.61	2.82e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg10909506	chr17:38081995	ORMDL3	0.35	6.22	0.32	1.45e-9	Self-reported allergy;
LUSC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg03233332	chr7:66118400	NA	-0.41	-6.07	-0.32	3.5e-9	Aortic root size;
LUSC	cis	rs17373728	0.585	rs1912709	chr8:76178563	C/T	cg07016329	chr8:76221503	NA	0.48	6.43	0.33	4.45e-10	Diabetic kidney disease;
LUSC	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg25482853	chr8:67687455	SGK3	1.15	16.65	0.67	9.36e-46	Lung disease severity in cystic fibrosis;
LUSC	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	12.78	0.57	1.04e-30	Platelet count;
LUSC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-8.31	-0.41	2.44e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg02972257	chr16:68554789	NA	-0.53	-6.52	-0.34	2.6200000000000003e-10	Ulcerative colitis;
LUSC	cis	rs1950626	0.833	rs2400963	chr14:101395706	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.33	0.37	1.78e-12	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.77	-10.81	-0.51	1.51e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg17143192	chr8:8559678	CLDN23	0.64	9.14	0.45	6.38e-18	Obesity-related traits;
LUSC	cis	rs6543140	0.964	rs6543142	chr2:103082006	T/C	cg09003973	chr2:102972529	NA	0.54	6.84	0.35	3.74e-11	Blood protein levels;
LUSC	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg08645402	chr16:4508243	NA	0.54	8.91	0.44	3.31e-17	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.78	0.3	1.72e-8	Menopause (age at onset);
LUSC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg09699651	chr6:150184138	LRP11	0.38	5.86	0.31	1.13e-8	Lung cancer;
LUSC	cis	rs12999616	0.857	rs34459720	chr2:98325447	T/C	cg26665480	chr2:98280029	ACTR1B	0.51	5.88	0.31	9.81e-9	Colorectal cancer;
LUSC	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg02158880	chr13:53174818	NA	0.58	9.85	0.47	2.84e-20	Lewy body disease;
LUSC	cis	rs6687430	0.526	rs7555790	chr1:10613167	A/G	cg17425144	chr1:10567563	PEX14	-0.62	-12.05	-0.55	5.4e-28	Hand grip strength;
LUSC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg15557168	chr22:42548783	NA	-0.45	-6.88	-0.35	2.98e-11	Schizophrenia;
LUSC	cis	rs11250464	0.794	rs11250487	chr10:1434168	C/A	cg08668359	chr10:1443807	ADARB2	0.42	6.32	0.33	8.16e-10	Radiation response;
LUSC	cis	rs7945705	0.846	rs905290	chr11:8753729	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.53	9.98	0.48	1.04e-20	Hemoglobin concentration;
LUSC	cis	rs6546537	0.868	rs62133967	chr2:69891708	G/C	cg10773587	chr2:69614142	GFPT1	-0.53	-8.12	-0.41	9.2e-15	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs76662990	0.764	rs77704408	chr5:73884165	G/A	cg01264639	chr5:73839484	NA	0.55	5.77	0.3	1.78e-8	Residual cognition;
LUSC	cis	rs7523050	0.643	rs34801874	chr1:109404382	C/T	cg08274380	chr1:109419600	GPSM2	1.07	10.65	0.5	5.34e-23	Fat distribution (HIV);
LUSC	cis	rs17095355	0.892	rs7085888	chr10:111713930	A/G	cg00817464	chr10:111662876	XPNPEP1	0.52	6.55	0.34	2.16e-10	Biliary atresia;
LUSC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.82	14.21	0.61	3.48e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg01475377	chr6:109611718	NA	-0.45	-8.21	-0.41	4.87e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.19	-0.37	4.36e-12	Type 2 diabetes;
LUSC	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg02023728	chr11:77925099	USP35	0.49	6.88	0.35	3.02e-11	Testicular germ cell tumor;
LUSC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg21782813	chr7:2030301	MAD1L1	-0.56	-9.78	-0.47	5.07e-20	Bipolar disorder and schizophrenia;
LUSC	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.41	-0.33	5.07e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14074924	chr1:1167315	SDF4;B3GALT6	0.46	6.53	0.34	2.5e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg11645453	chr3:52864694	ITIH4	0.59	14.12	0.61	8.31e-36	Schizophrenia;
LUSC	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.21	-0.37	3.87e-12	Bipolar disorder;
LUSC	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.93	15.97	0.66	4.9e-43	Morning vs. evening chronotype;
LUSC	cis	rs9462027	0.628	rs2814971	chr6:34714209	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.34	5.87	0.31	1.07e-8	Systemic lupus erythematosus;
LUSC	cis	rs1832871	0.965	rs1832872	chr6:158721813	G/A	cg07165851	chr6:158734300	TULP4	-0.37	-6.57	-0.34	1.93e-10	Height;
LUSC	cis	rs4499344	0.589	rs259233	chr19:33127000	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.98	14.42	0.62	5.52e-37	Mean platelet volume;
LUSC	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg12002119	chr2:101014098	CHST10	0.37	6.27	0.32	1.12e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg09365446	chr1:150670422	GOLPH3L	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg17507749	chr15:85114479	UBE2QP1	0.69	8.87	0.44	4.5e-17	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3126085	0.935	rs4845431	chr1:152227977	A/G	cg26876637	chr1:152193138	HRNR	0.44	6.42	0.33	4.8e-10	Atopic dermatitis;
LUSC	cis	rs10193935	0.901	rs9309082	chr2:42581412	A/G	cg27598129	chr2:42591480	NA	-0.64	-8.42	-0.42	1.15e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.89	0.48	2.11e-20	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	0.63	13.47	0.59	2.57e-33	Prudent dietary pattern;
LUSC	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg08179530	chr6:36648295	CDKN1A	-0.47	-6.7	-0.34	8.94e-11	QRS duration;
LUSC	cis	rs4499344	0.556	rs259231	chr19:33129067	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.97	14.29	0.62	1.76e-36	Mean platelet volume;
LUSC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-5.76	-0.3	1.87e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	8.18	0.41	5.91e-15	Height;
LUSC	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.69	0.3	2.81e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9469578	0.579	rs7744811	chr6:33692368	T/C	cg18708504	chr6:33715942	IP6K3	0.67	6.69	0.34	9.52e-11	Phosphorus levels;
LUSC	cis	rs7561273	0.586	rs11902756	chr2:24300932	A/G	cg20701182	chr2:24300061	SF3B14	0.51	6.57	0.34	1.98e-10	Quantitative traits;
LUSC	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg00262122	chr8:11665843	FDFT1	0.39	5.82	0.3	1.37e-8	Neuroticism;
LUSC	cis	rs7804356	1.000	rs28733208	chr7:26830825	G/A	cg03456212	chr7:26904342	SKAP2	-0.56	-6.62	-0.34	1.47e-10	Type 1 diabetes;
LUSC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.6	0.38	3.08e-13	Bipolar disorder;
LUSC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg25258033	chr6:167368657	RNASET2	0.36	5.68	0.3	2.88e-8	Primary biliary cholangitis;
LUSC	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.43	-6.37	-0.33	6.19e-10	Schizophrenia;
LUSC	cis	rs4363385	0.818	rs3795381	chr1:153004848	T/C	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.46e-8	Inflammatory skin disease;
LUSC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.47	-6.39	-0.33	5.54e-10	Renal function-related traits (BUN);
LUSC	cis	rs4901869	0.902	rs10149194	chr14:59308198	A/G	cg02291164	chr14:59296302	NA	-0.59	-11.64	-0.54	1.6e-26	Panic disorder;
LUSC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10492096	0.853	rs7300092	chr12:6607364	T/C	cg13857086	chr12:6580257	VAMP1	0.59	6.98	0.36	1.57e-11	Hip geometry;
LUSC	cis	rs10871290	0.650	rs2288054	chr16:74491733	A/G	cg01733217	chr16:74700730	RFWD3	0.71	10.46	0.5	2.54e-22	Breast cancer;
LUSC	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg17757837	chr7:157058334	UBE3C	0.82	13.01	0.58	1.35e-31	Body mass index;
LUSC	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg04450456	chr4:17643702	FAM184B	0.34	5.64	0.3	3.58e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg08601574	chr20:25228251	PYGB	0.46	7.02	0.36	1.27e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9513627	1.000	rs73556170	chr13:100121612	T/A	cg25919922	chr13:100150906	NA	-0.8	-6.96	-0.36	1.83e-11	Obesity-related traits;
LUSC	cis	rs6494488	0.500	rs72744714	chr15:65016050	G/A	cg08069370	chr15:64387884	SNX1	-0.66	-5.78	-0.3	1.71e-8	Coronary artery disease;
LUSC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg06627628	chr2:24431161	ITSN2	-0.6	-7.21	-0.37	3.78e-12	Lymphocyte counts;
LUSC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.86	14.2	0.61	4.1e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2286503	0.780	rs1304431	chr7:22865412	T/C	cg11367502	chr7:22862612	TOMM7	0.45	5.9	0.31	8.89e-9	Fibrinogen;
LUSC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg12560992	chr17:57184187	TRIM37	0.85	15.35	0.64	1.26e-40	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.682	rs2265092	chr10:780293	C/T	cg22713356	chr15:30763199	NA	-0.74	-10.75	-0.51	2.36e-23	Uric acid levels;
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18110333	chr6:292329	DUSP22	-0.72	-11.92	-0.55	1.57e-27	Menopause (age at onset);
LUSC	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg15934090	chr1:100435551	SLC35A3	0.48	8.26	0.41	3.47e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg17691542	chr6:26056736	HIST1H1C	0.52	7.9	0.4	4.01e-14	Height;
LUSC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg04455712	chr21:45112962	RRP1B	0.48	9.0	0.44	1.68e-17	Mean corpuscular volume;
LUSC	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.73	0.35	7.39e-11	Corneal astigmatism;
LUSC	cis	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg21775007	chr8:11205619	TDH	-0.48	-6.47	-0.33	3.55e-10	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.81	0.39	7.58e-14	Prudent dietary pattern;
LUSC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.53	-8.21	-0.41	4.98e-15	Melanoma;
LUSC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg22823121	chr1:150693482	HORMAD1	0.44	6.18	0.32	1.85e-9	Melanoma;
LUSC	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.75	-12.74	-0.57	1.46e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	4.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03264133	chr6:25882463	NA	-0.5	-9.11	-0.45	7.57e-18	Blood metabolite levels;
LUSC	cis	rs11025559	0.631	rs11025571	chr11:20482801	C/G	cg19653624	chr11:20408972	PRMT3	0.7	8.27	0.41	3.32e-15	Pursuit maintenance gain;
LUSC	cis	rs2625529	0.590	rs2607090	chr15:72496011	C/A	cg16672083	chr15:72433130	SENP8	-0.49	-7.27	-0.37	2.59e-12	Red blood cell count;
LUSC	cis	rs68170813	0.652	rs17482494	chr7:107168487	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-8.63	-0.43	2.46e-16	Coronary artery disease;
LUSC	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.87	12.57	0.57	6.3e-30	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs6120849	0.707	rs752075	chr20:33591591	C/A	cg24642439	chr20:33292090	TP53INP2	0.62	6.85	0.35	3.66e-11	Protein C levels;
LUSC	trans	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	10.34	0.49	6.44e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs3771570	1.000	rs62193210	chr2:242323616	G/A	cg21155796	chr2:242212141	HDLBP	0.63	6.92	0.35	2.29e-11	Prostate cancer;
LUSC	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg21238619	chr17:78079768	GAA	0.28	5.69	0.3	2.78e-8	Yeast infection;
LUSC	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg26924012	chr15:45694286	SPATA5L1	1.14	19.87	0.74	1.48e-58	Homoarginine levels;
LUSC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	trans	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg20587970	chr11:113659929	NA	0.81	9.8	0.47	4.41e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-1.02	-15.49	-0.65	3.7e-41	Initial pursuit acceleration;
LUSC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.41	-0.42	1.24e-15	Longevity;
LUSC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.71	0.54	9.03e-27	Prudent dietary pattern;
LUSC	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg06937882	chr20:24974362	C20orf3	0.42	7.0	0.36	1.43e-11	Blood protein levels;
LUSC	trans	rs7737355	1.000	rs6596010	chr5:130625411	G/A	cg07715041	chr7:99302981	CYP3A7	-0.39	-6.26	-0.32	1.2e-9	Life satisfaction;
LUSC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg22535103	chr8:58192502	C8orf71	-0.6	-6.96	-0.36	1.76e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg05855489	chr10:104503620	C10orf26	-0.53	-8.18	-0.41	6.11e-15	Arsenic metabolism;
LUSC	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg01579765	chr21:45077557	HSF2BP	0.55	11.45	0.53	8.04e-26	Mean corpuscular volume;
LUSC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg12564285	chr5:131593104	PDLIM4	0.56	10.76	0.51	2.22e-23	Acylcarnitine levels;
LUSC	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg05519781	chr21:40033154	ERG	0.77	13.35	0.59	7.23e-33	Coronary artery disease;
LUSC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg07061783	chr6:25882402	NA	-0.38	-5.94	-0.31	7.17e-9	Blood metabolite levels;
LUSC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg04166393	chr7:2884313	GNA12	-0.41	-5.74	-0.3	2.12e-8	Height;
LUSC	cis	rs3849570	0.925	rs7641973	chr3:81910489	G/A	cg07356753	chr3:81810745	GBE1	-0.68	-11.26	-0.52	3.89e-25	Waist circumference;Body mass index;
LUSC	cis	rs977987	0.843	rs7499872	chr16:75426529	G/A	cg03315344	chr16:75512273	CHST6	0.53	10.31	0.49	8.06e-22	Dupuytren's disease;
LUSC	trans	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.47	6.98	0.36	1.61e-11	Endometrial cancer;
LUSC	trans	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.08	-0.32	3.31e-9	Depression;
LUSC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	0.88	15.91	0.66	8.4e-43	Cognitive function;
LUSC	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg00857998	chr1:205179979	DSTYK	0.64	10.11	0.48	3.78e-21	Red blood cell count;
LUSC	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg20703242	chr1:230279135	GALNT2	0.57	8.95	0.44	2.56e-17	Coronary artery disease;
LUSC	trans	rs7538876	0.903	rs7528427	chr1:17746273	C/T	cg13009662	chr5:127419527	SLC12A2;FLJ33630	0.42	6.16	0.32	2.07e-9	Basal cell carcinoma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25867650	chr15:75743273	SIN3A	-0.47	-6.32	-0.33	8.29e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg25258033	chr6:167368657	RNASET2	0.4	6.02	0.31	4.59e-9	Primary biliary cholangitis;
LUSC	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg06640241	chr16:89574553	SPG7	-0.51	-7.86	-0.4	5.21e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg06640241	chr16:89574553	SPG7	0.91	16.62	0.67	1.26e-45	Multiple myeloma (IgH translocation);
LUSC	cis	rs742132	0.527	rs17252870	chr6:25494666	A/C	cg12310025	chr6:25882481	NA	-0.44	-5.99	-0.31	5.55e-9	Uric acid levels;
LUSC	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg02176678	chr2:219576539	TTLL4	0.59	10.02	0.48	7.78e-21	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg23788917	chr6:8435910	SLC35B3	0.51	7.62	0.38	2.58e-13	Motion sickness;
LUSC	cis	rs11030122	0.632	rs11030599	chr11:4031677	A/G	cg18678763	chr11:4115507	RRM1	-0.47	-6.14	-0.32	2.36e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.21	-13.88	-0.6	6.79e-35	Diabetic kidney disease;
LUSC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.54e-29	Motion sickness;
LUSC	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.03	0.52	2.5300000000000002e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4285028	0.747	rs7153	chr3:121383297	G/A	cg11130432	chr3:121712080	ILDR1	-0.57	-8.29	-0.41	2.88e-15	Multiple sclerosis;
LUSC	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.69	10.52	0.5	1.51e-22	Educational attainment;
LUSC	cis	rs11608355	0.960	rs10774691	chr12:109859830	C/T	cg19025524	chr12:109796872	NA	-0.38	-5.96	-0.31	6.58e-9	Neuroticism;
LUSC	cis	rs4499344	0.633	rs166310	chr19:33155187	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	11.42	0.53	1.02e-25	Mean platelet volume;
LUSC	cis	rs1322512	1.000	rs2250006	chr6:153006401	T/A	cg27316956	chr6:152958899	SYNE1	0.34	5.98	0.31	5.72e-9	Tonometry;
LUSC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg17330251	chr7:94953956	PON1	0.36	5.89	0.31	9.64e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	9.37	0.46	1.13e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs11264213	0.901	rs72661641	chr1:36448130	A/G	cg27506609	chr1:36549197	TEKT2	0.7	7.98	0.4	2.33e-14	Schizophrenia;
LUSC	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg08079166	chr15:68083412	MAP2K5	0.4	7.31	0.37	1.98e-12	Restless legs syndrome;
LUSC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg13206674	chr6:150067644	NUP43	0.59	9.24	0.45	2.87e-18	Lung cancer;
LUSC	cis	rs7799006	0.527	rs6967286	chr7:2212758	C/A	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.65	-0.34	1.23e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg00376283	chr12:123451042	ABCB9	0.65	8.24	0.41	3.99e-15	Neutrophil percentage of white cells;
LUSC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	15.66	0.65	7.59e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9549260	0.592	rs9532588	chr13:41302913	G/A	cg21288729	chr13:41239152	FOXO1	0.54	7.91	0.4	3.9e-14	Red blood cell count;
LUSC	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4629180	0.959	rs11896771	chr2:102098328	T/C	cg04415270	chr2:102091202	RFX8	-0.54	-8.56	-0.42	4.3e-16	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg07677032	chr17:61819896	STRADA	-0.5	-8.38	-0.42	1.46e-15	Prudent dietary pattern;
LUSC	cis	rs6545883	0.826	rs777591	chr2:61417617	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.77	-0.35	5.76e-11	Tuberculosis;
LUSC	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg21827317	chr3:136751795	NA	-0.38	-6.78	-0.35	5.43e-11	Neuroticism;
LUSC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Parkinson's disease;
LUSC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg14664628	chr15:75095509	CSK	-0.59	-9.1	-0.45	8.28e-18	Breast cancer;
LUSC	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.39	6.27	0.32	1.09e-9	Response to antipsychotic treatment;
LUSC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.82	-0.43	6.62e-17	Lung cancer;
LUSC	cis	rs4478858	0.684	rs3737755	chr1:31744168	G/A	cg00250761	chr1:31883323	NA	-0.35	-8.37	-0.42	1.61e-15	Alcohol dependence;
LUSC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg13939156	chr17:80058883	NA	0.33	6.42	0.33	4.73e-10	Life satisfaction;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg14159367	chr14:82000258	SEL1L	0.44	6.25	0.32	1.27e-9	Mosquito bite size;
LUSC	cis	rs4692589	0.581	rs34149802	chr4:170960284	A/G	cg19918862	chr4:170955249	NA	0.36	6.68	0.34	9.71e-11	Anxiety disorder;
LUSC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.05	-0.31	3.82e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2742417	1.000	rs1534876	chr3:45741257	G/T	cg09608765	chr3:45636137	LIMD1	-0.39	-7.72	-0.39	1.37e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-6.53	-0.34	2.52e-10	Colorectal cancer;
LUSC	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg16482183	chr6:26056742	HIST1H1C	0.46	6.72	0.35	7.77e-11	Height;
LUSC	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08645402	chr16:4508243	NA	0.53	9.08	0.45	9.43e-18	Schizophrenia;
LUSC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg05872129	chr22:39784769	NA	-0.6	-10.9	-0.51	7.18e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.74	-0.39	1.2e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg16586182	chr3:47516702	SCAP	0.52	7.46	0.38	7.78e-13	Birth weight;
LUSC	cis	rs6556937	0.627	rs4590196	chr5:95997285	G/T	cg07690455	chr5:95997198	CAST	0.49	6.73	0.35	7.37e-11	Blood protein levels;
LUSC	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg24558204	chr6:135376177	HBS1L	0.58	8.54	0.42	4.94e-16	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg07080220	chr10:102295463	HIF1AN	0.59	7.86	0.4	5.23e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg03146154	chr1:46216737	IPP	-0.58	-8.42	-0.42	1.11e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg24846343	chr22:24311635	DDTL	0.77	17.35	0.69	1.61e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs73200209	0.744	rs74349961	chr12:116467560	T/C	cg01776926	chr12:116560359	MED13L	-0.51	-6.1	-0.32	2.88e-9	Total body bone mineral density;
LUSC	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg18806716	chr10:30721971	MAP3K8	-0.59	-9.72	-0.47	7.71e-20	Inflammatory bowel disease;
LUSC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg11766577	chr21:47581405	C21orf56	0.52	8.03	0.4	1.67e-14	Testicular germ cell tumor;
LUSC	cis	rs12220238	1.000	rs73284257	chr10:76000710	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	6.8	0.35	4.87e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs1044826	0.692	rs169824	chr3:139235006	G/C	cg00490450	chr3:139108681	COPB2	-0.45	-6.95	-0.36	1.95e-11	Obesity-related traits;
LUSC	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.03	0.52	2.51e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg18357645	chr12:58087776	OS9	0.54	8.19	0.41	5.5e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg03146154	chr1:46216737	IPP	0.5	7.51	0.38	5.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.54	11.01	0.52	2.88e-24	Coronary artery disease;
LUSC	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg04539111	chr16:67997858	SLC12A4	-0.43	-5.96	-0.31	6.31e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs59104589	0.617	rs56663202	chr2:242262311	A/G	cg14842376	chr2:242211374	HDLBP	0.53	5.99	0.31	5.31e-9	Fibrinogen levels;
LUSC	cis	rs4629710	0.562	rs3798252	chr6:131583758	A/T	cg12606694	chr6:131520996	AKAP7	0.62	9.34	0.45	1.43e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg02018176	chr4:1364513	KIAA1530	0.43	6.09	0.32	3.17e-9	Recombination rate (females);
LUSC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg16928487	chr17:17741425	SREBF1	-0.36	-6.72	-0.35	7.67e-11	Total body bone mineral density;
LUSC	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg20026190	chr17:76395443	PGS1	0.33	5.71	0.3	2.47e-8	HDL cholesterol levels;
LUSC	cis	rs2354432	0.556	rs34602039	chr1:146850972	G/A	cg25205988	chr1:146714368	CHD1L	-0.89	-7.6	-0.38	3.04e-13	Mitochondrial DNA levels;
LUSC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21643547	chr1:205240462	TMCC2	-0.52	-10.14	-0.49	3.04e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.33	0.33	7.8e-10	Renal cell carcinoma;
LUSC	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.52	11.15	0.52	9.69e-25	Vitamin D levels;
LUSC	cis	rs7580658	0.895	rs9636237	chr2:128076022	T/C	cg09760422	chr2:128146352	NA	-0.29	-6.15	-0.32	2.2e-9	Protein C levels;
LUSC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.67	6.42	0.33	4.63e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg17420585	chr12:42539391	GXYLT1	-0.55	-12.26	-0.56	8.8e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg23625390	chr15:77176239	SCAPER	0.51	7.83	0.39	6.52e-14	Blood metabolite levels;
LUSC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg15557168	chr22:42548783	NA	-0.44	-6.8	-0.35	4.69e-11	Schizophrenia;
LUSC	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg18230493	chr5:56204884	C5orf35	-0.57	-9.05	-0.44	1.17e-17	Coronary artery disease;
LUSC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg14092988	chr3:52407081	DNAH1	0.33	6.32	0.33	8.52e-10	Bipolar disorder;
LUSC	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg13042288	chr15:90349979	ANPEP	-0.48	-6.93	-0.35	2.24e-11	Uric acid levels;
LUSC	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg13010199	chr12:38710504	ALG10B	0.65	10.25	0.49	1.26e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg05340658	chr4:99064831	C4orf37	0.65	11.05	0.52	2.15e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.78	-0.3	1.67e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg17366294	chr4:99064904	C4orf37	0.57	9.91	0.48	1.76e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	ch.11.42038R	chr11:967971	AP2A2	0.41	6.08	0.32	3.21e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4561483	0.801	rs33623	chr16:12007435	A/G	cg08843971	chr16:11963173	GSPT1	0.52	8.01	0.4	1.87e-14	Testicular germ cell tumor;
LUSC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08859206	chr1:53392774	SCP2	0.56	9.89	0.48	2.05e-20	Monocyte count;
LUSC	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs1459104	0.704	rs12806568	chr11:54892378	G/A	cg15704280	chr7:45808275	SEPT13	0.76	6.64	0.34	1.24e-10	Body mass index;
LUSC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08219700	chr8:58056026	NA	0.72	7.76	0.39	1.05e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg22676075	chr6:135203613	NA	-0.65	-10.25	-0.49	1.27e-21	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg26876637	chr1:152193138	HRNR	0.45	6.66	0.34	1.16e-10	Atopic dermatitis;
LUSC	cis	rs4889855	0.556	rs4890039	chr17:78517883	C/T	cg16591659	chr17:78472290	NA	0.32	5.68	0.3	2.99e-8	Fractional excretion of uric acid;
LUSC	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg15848620	chr12:58087721	OS9	-0.39	-5.65	-0.3	3.4e-8	Multiple sclerosis;
LUSC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg09359103	chr1:154839909	KCNN3	-0.69	-15.34	-0.64	1.36e-40	Prostate cancer;
LUSC	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg04871131	chr7:94954202	PON1	-0.39	-6.18	-0.32	1.85e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg24851651	chr11:66362959	CCS	-0.38	-6.05	-0.31	3.84e-9	Educational attainment (years of education);
LUSC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg07636037	chr3:49044803	WDR6	0.44	6.51	0.34	2.69e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg15448220	chr1:150897856	SETDB1	0.41	6.02	0.31	4.61e-9	Melanoma;
LUSC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-6.41	-0.33	4.87e-10	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-7.86	-0.4	5.3e-14	Reticulocyte count;
LUSC	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg02574844	chr11:5959923	NA	-0.42	-6.09	-0.32	3.08e-9	DNA methylation (variation);
LUSC	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg18105134	chr13:113819100	PROZ	-0.75	-10.61	-0.5	7.22e-23	Platelet distribution width;
LUSC	cis	rs10754283	0.934	rs7529653	chr1:90111851	G/A	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs922692	1.000	rs4887077	chr15:78978364	A/G	cg00540400	chr15:79124168	NA	0.34	5.75	0.3	2.02e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs78707713	0.512	rs35793747	chr10:71182165	A/G	cg14388049	chr10:71211838	TSPAN15	-0.31	-5.71	-0.3	2.44e-8	Venous thromboembolism;
LUSC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	1e-64	Prudent dietary pattern;
LUSC	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg03433033	chr1:76189801	ACADM	-0.42	-6.05	-0.31	3.96e-9	Daytime sleep phenotypes;
LUSC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	0.91	15.67	0.65	7.28e-42	Parkinson's disease;
LUSC	cis	rs1044826	0.642	rs9826544	chr3:139162831	A/G	cg15131784	chr3:139108705	COPB2	0.42	6.85	0.35	3.55e-11	Obesity-related traits;
LUSC	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.45	-0.5	2.55e-22	Eye color traits;
LUSC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	29.0	0.85	2.96e-93	Chronic sinus infection;
LUSC	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg04121214	chr22:50244548	NA	-0.32	-5.97	-0.31	5.93e-9	Schizophrenia;
LUSC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.09	0.55	3.63e-28	Cognitive test performance;
LUSC	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg08873628	chr1:175162347	KIAA0040	0.39	5.72	0.3	2.39e-8	Alcohol dependence;
LUSC	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.34	-0.42	1.91e-15	Glomerular filtration rate (creatinine);
LUSC	trans	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.01	20.98	0.75	6.06e-63	Colorectal cancer;
LUSC	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg08017634	chr8:144659831	NAPRT1	0.7	6.06	0.31	3.64e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg18209359	chr17:80159595	CCDC57	0.39	6.44	0.33	4.06e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6570726	0.526	rs4896805	chr6:145735429	C/A	cg23711669	chr6:146136114	FBXO30	-0.52	-7.96	-0.4	2.73e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2625529	0.652	rs11072350	chr15:72464609	T/G	cg16672083	chr15:72433130	SENP8	0.48	7.98	0.4	2.35e-14	Red blood cell count;
LUSC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg11766577	chr21:47581405	C21orf56	-0.54	-8.17	-0.41	6.53e-15	Testicular germ cell tumor;
LUSC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg13047869	chr3:10149882	C3orf24	0.6	8.27	0.41	3.15e-15	Alzheimer's disease;
LUSC	cis	rs2708377	0.929	rs73066828	chr12:11270654	A/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.81	7.88	0.4	4.71e-14	Bitter taste perception;
LUSC	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg02018176	chr4:1364513	KIAA1530	0.43	5.98	0.31	5.7e-9	Recombination rate (females);
LUSC	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.56	0.34	2.07e-10	Corneal astigmatism;
LUSC	cis	rs73206853	0.841	rs55885183	chr12:110877682	A/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2348418	0.681	rs10771435	chr12:28735702	C/T	cg13890972	chr12:28721907	NA	-0.37	-6.35	-0.33	7.09e-10	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg07148914	chr20:33460835	GGT7	0.47	6.93	0.35	2.24e-11	Height;
LUSC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg02972257	chr16:68554789	NA	-0.5	-6.23	-0.32	1.4e-9	Ulcerative colitis;
LUSC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.71	12.45	0.56	1.7e-29	Heart rate;
LUSC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg14440974	chr22:39074834	NA	-0.36	-5.92	-0.31	7.79e-9	Menopause (age at onset);
LUSC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg18230493	chr5:56204884	C5orf35	-0.54	-8.35	-0.42	1.85e-15	Coronary artery disease;
LUSC	cis	rs981844	0.712	rs6855093	chr4:154754050	A/G	cg14289246	chr4:154710475	SFRP2	-0.46	-6.26	-0.32	1.16e-9	Response to statins (LDL cholesterol change);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07032473	chr8:95274411	GEM	0.42	6.45	0.33	3.86e-10	Triglycerides;
LUSC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg06697600	chr4:7070879	GRPEL1	-0.4	-6.66	-0.34	1.16e-10	Monocyte percentage of white cells;
LUSC	trans	rs12543645	0.609	rs35112858	chr8:10277269	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	6.14	0.32	2.32e-9	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24464101	chr4:38690487	KLF3	0.41	6.29	0.33	1.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs524023	0.958	rs2021860	chr11:64361384	G/T	cg19131476	chr11:64387923	NRXN2	-0.38	-10.39	-0.49	4.39e-22	Urate levels in obese individuals;
LUSC	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg25233709	chr10:116636983	FAM160B1	0.38	6.63	0.34	1.36e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2273669	0.667	rs117412830	chr6:109336617	A/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.91	-0.31	8.57e-9	Prostate cancer;
LUSC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs9359856	0.673	rs1179897	chr6:90318624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-8.05	-0.4	1.45e-14	Bipolar disorder;
LUSC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00149659	chr3:10157352	C3orf10	0.89	11.92	0.55	1.53e-27	Alzheimer's disease;
LUSC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.39	6.02	0.31	4.63e-9	Multiple sclerosis;
LUSC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06022373	chr22:39101656	GTPBP1	0.78	11.75	0.54	6.69e-27	Menopause (age at onset);
LUSC	cis	rs858239	0.600	rs7776649	chr7:23119317	C/T	cg23682824	chr7:23144976	KLHL7	0.41	5.88	0.31	1.01e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	8.95	0.44	2.51e-17	Lung cancer in ever smokers;
LUSC	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.77	-10.74	-0.51	2.53e-23	HIV-1 control;
LUSC	cis	rs9309473	1.000	rs7594511	chr2:73681639	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-6.35	-0.33	6.9e-10	Metabolite levels;
LUSC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg11062466	chr8:58055876	NA	0.65	8.59	0.43	3.4e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs240764	0.658	rs60658003	chr6:101201191	C/A	cg09795085	chr6:101329169	ASCC3	-0.43	-6.27	-0.32	1.11e-9	Neuroticism;
LUSC	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg18099408	chr3:52552593	STAB1	-0.35	-6.03	-0.31	4.35e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.63	0.34	1.34e-10	Lung cancer;
LUSC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg02551604	chr5:131831745	NA	-0.42	-6.62	-0.34	1.39e-10	Asthma (sex interaction);
LUSC	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg23283495	chr1:209979779	IRF6	0.64	7.9	0.4	4.2e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs155346	1.000	rs265143	chr5:139397066	A/C	cg01090482	chr5:139365336	NRG2	-0.37	-6.18	-0.32	1.87e-9	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg18225595	chr11:63971243	STIP1	0.49	6.1	0.32	2.88e-9	Mean platelet volume;
LUSC	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg13042288	chr15:90349979	ANPEP	-0.48	-6.91	-0.35	2.46e-11	Uric acid levels;
LUSC	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.86	0.44	4.97e-17	Axial length;
LUSC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg06740227	chr12:86229804	RASSF9	0.43	6.76	0.35	6.18e-11	Major depressive disorder;
LUSC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-5.73	-0.3	2.23e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg18678763	chr11:4115507	RRM1	-0.53	-7.61	-0.38	2.73e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg24459738	chr19:57751996	ZNF805	-0.52	-7.69	-0.39	1.67e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg04369109	chr6:150039330	LATS1	-0.57	-8.54	-0.42	4.92e-16	Lung cancer;
LUSC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	0.93	15.69	0.65	5.75e-42	Menopause (age at onset);
LUSC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.49	-0.42	6.81e-16	Platelet count;
LUSC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg16393715	chr7:1948819	MAD1L1	0.34	5.82	0.3	1.35e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00149659	chr3:10157352	C3orf10	1.0	14.66	0.63	6.41e-38	Alzheimer's disease;
LUSC	cis	rs12681287	0.647	rs2953510	chr8:87341914	T/C	cg27223183	chr8:87520930	FAM82B	-0.54	-7.1	-0.36	7.54e-12	Caudate activity during reward;
LUSC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg20891283	chr12:69753455	YEATS4	0.67	10.51	0.5	1.69e-22	Blood protein levels;
LUSC	trans	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg09781936	chr22:19749961	TBX1	-0.34	-6.01	-0.31	4.74e-9	Inflammatory bowel disease;
LUSC	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg24596788	chr1:163392923	NA	-0.43	-7.19	-0.37	4.22e-12	Motion sickness;
LUSC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.5	-0.34	2.94e-10	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9837602	0.872	rs35154249	chr3:99738230	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	5.74	0.3	2.12e-8	Breast cancer;
LUSC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg11871910	chr12:69753446	YEATS4	0.6	7.95	0.4	2.88e-14	Response to diuretic therapy;
LUSC	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg05855489	chr10:104503620	C10orf26	0.49	7.55	0.38	4.25e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg22709100	chr7:91322751	NA	0.4	5.81	0.3	1.48e-8	Breast cancer;
LUSC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg05025164	chr4:1340916	KIAA1530	0.39	5.83	0.3	1.34e-8	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07677032	chr17:61819896	STRADA	0.54	9.03	0.44	1.36e-17	Prudent dietary pattern;
LUSC	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.73	12.11	0.55	3.07e-28	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs859767	0.741	rs10803548	chr2:135396738	C/A	cg12500956	chr2:135428796	TMEM163	-0.27	-6.28	-0.32	1.07e-9	Neuroticism;
LUSC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	13.28	0.59	1.28e-32	Total body bone mineral density;
LUSC	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.61	8.37	0.42	1.62e-15	Adiposity;
LUSC	cis	rs8049040	0.609	rs9940485	chr16:71486105	C/T	cg08717414	chr16:71523259	ZNF19	-0.42	-5.95	-0.31	6.65e-9	Blood protein levels;
LUSC	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg08085267	chr17:45401833	C17orf57	0.54	8.83	0.44	6.02e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg09184832	chr6:79620586	NA	-0.45	-7.35	-0.37	1.58e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10193935	0.901	rs6544536	chr2:42522042	G/A	cg27598129	chr2:42591480	NA	-0.59	-8.4	-0.42	1.31e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.92	-0.4	3.5e-14	Schizophrenia;
LUSC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.73	0.35	7.31e-11	Aortic root size;
LUSC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg11965913	chr1:205819406	PM20D1	0.47	6.67	0.34	1.06e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	9.0	0.44	1.76e-17	Motion sickness;
LUSC	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg08501292	chr6:25962987	TRIM38	-0.65	-6.0	-0.31	5.17e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9625935	0.748	rs2412974	chr22:30539821	C/T	cg11564601	chr22:30592435	NA	-0.33	-5.73	-0.3	2.2e-8	Tonsillectomy;
LUSC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg17173187	chr15:85201210	NMB	0.37	6.56	0.34	2.08e-10	Schizophrenia;
LUSC	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg00579200	chr11:133705235	NA	-0.4	-5.98	-0.31	5.83e-9	Childhood ear infection;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg15357518	chr19:36120356	RBM42	0.46	6.81	0.35	4.48e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg00857998	chr1:205179979	DSTYK	0.57	8.6	0.43	3.18e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.02	0.58	1.28e-31	Chronic sinus infection;
LUSC	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.83	-0.39	6.41e-14	Retinal vascular caliber;
LUSC	cis	rs56283067	0.578	rs12203052	chr6:45398958	C/G	cg18551225	chr6:44695536	NA	-0.39	-5.83	-0.3	1.34e-8	Total body bone mineral density;
LUSC	trans	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	10.47	0.5	2.28e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg24069376	chr3:38537580	EXOG	0.35	6.29	0.33	9.81e-10	Electrocardiographic conduction measures;
LUSC	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.82	-0.35	4.24e-11	Total body bone mineral density;
LUSC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.79	-12.47	-0.56	1.5e-29	Pancreatic cancer;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg24827620	chr21:34961125	DONSON	0.49	6.36	0.33	6.52e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs890100	0.673	rs13420553	chr2:56660502	T/C	cg01657744	chr10:88471748	LDB3	0.43	5.95	0.31	6.75e-9	Gut microbiome composition (summer);
LUSC	cis	rs9311676	0.656	rs11712139	chr3:58384775	C/T	cg26110898	chr3:58419937	PDHB	0.44	7.1	0.36	7.5e-12	Systemic lupus erythematosus;
LUSC	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg25801113	chr15:45476975	SHF	-0.33	-6.58	-0.34	1.86e-10	Uric acid levels;
LUSC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-11.91	-0.55	1.71e-27	Platelet count;
LUSC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	1.11	9.74	0.47	6.79e-20	Skin colour saturation;
LUSC	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.52	0.34	2.54e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6570726	0.526	rs4895674	chr6:145735860	T/G	cg23711669	chr6:146136114	FBXO30	-0.52	-7.9	-0.4	4.19e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg21782813	chr7:2030301	MAD1L1	0.59	10.2	0.49	1.85e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg02380750	chr20:61661411	NA	0.35	6.16	0.32	2.04e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7241530	0.717	rs9949518	chr18:75889092	C/A	cg14642773	chr18:75888474	NA	0.36	6.01	0.31	4.91e-9	Educational attainment (years of education);
LUSC	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-7.1	-0.36	7.74e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs11828289	0.660	rs79043125	chr11:23203646	T/A	cg20040320	chr11:23191996	NA	-0.58	-6.07	-0.31	3.57e-9	Cancer;
LUSC	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg02466173	chr16:30829666	NA	-0.5	-9.54	-0.46	3.13e-19	Dementia with Lewy bodies;
LUSC	cis	rs2806561	0.808	rs12128178	chr1:23354814	C/T	cg19743168	chr1:23544995	NA	-0.44	-9.11	-0.45	7.89e-18	Height;
LUSC	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg08975724	chr8:8085496	FLJ10661	0.49	7.26	0.37	2.7e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg05025164	chr4:1340916	KIAA1530	0.42	6.34	0.33	7.29e-10	Obesity-related traits;
LUSC	cis	rs58785573	0.504	rs12646137	chr4:38609650	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.48	6.35	0.33	7.02e-10	Lymphocyte percentage of white cells;
LUSC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.3	-0.37	2.18e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs2274273	0.905	rs8007614	chr14:55586575	A/G	cg04306507	chr14:55594613	LGALS3	0.52	11.6	0.54	2.29e-26	Protein biomarker;
LUSC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg13047869	chr3:10149882	C3orf24	0.57	7.97	0.4	2.55e-14	Alzheimer's disease;
LUSC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.64	10.88	0.51	8.36e-24	Aortic root size;
LUSC	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg04374321	chr14:90722782	PSMC1	-0.69	-10.43	-0.5	3.22e-22	Mortality in heart failure;
LUSC	cis	rs1044826	0.642	rs6787649	chr3:139193321	C/T	cg15131784	chr3:139108705	COPB2	0.39	6.29	0.33	9.81e-10	Obesity-related traits;
LUSC	cis	rs4780401	0.546	rs3743588	chr16:11836508	G/A	cg01061890	chr16:11836724	TXNDC11	0.64	8.33	0.41	2.13e-15	Rheumatoid arthritis;
LUSC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.58	8.66	0.43	2.09e-16	Eosinophil percentage of white cells;
LUSC	cis	rs8040855	0.621	rs6496796	chr15:85726848	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.4	6.48	0.33	3.23e-10	Bulimia nervosa;
LUSC	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.88	0.48	2.24e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12620999	0.555	rs4073396	chr2:238111471	A/C	cg23555395	chr2:238036564	NA	0.33	6.46	0.33	3.79e-10	Systemic lupus erythematosus;
LUSC	cis	rs7605827	0.930	rs7577436	chr2:15528281	C/T	cg19274914	chr2:15703543	NA	0.45	8.62	0.43	2.64e-16	Educational attainment (years of education);
LUSC	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg06636001	chr8:8085503	FLJ10661	0.66	10.5	0.5	1.84e-22	Mood instability;
LUSC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.1	-0.45	8.15e-18	Bipolar disorder;
LUSC	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg08085267	chr17:45401833	C17orf57	0.5	6.75	0.35	6.59e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg05802129	chr4:122689817	NA	-0.37	-6.69	-0.34	9.46e-11	Type 2 diabetes;
LUSC	cis	rs2019216	0.500	rs2169916	chr17:21884670	G/C	cg22648282	chr17:21454238	C17orf51	-0.54	-7.76	-0.39	1.06e-13	Pelvic organ prolapse;
LUSC	cis	rs9534288	0.699	rs9534320	chr13:46665572	A/G	cg15192986	chr13:46630673	CPB2	-0.69	-10.15	-0.49	2.77e-21	Blood protein levels;
LUSC	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg22508957	chr16:3507546	NAT15	0.85	11.0	0.52	3.09e-24	Tuberculosis;
LUSC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg20203395	chr5:56204925	C5orf35	-0.6	-9.13	-0.45	6.88e-18	Coronary artery disease;
LUSC	cis	rs4722404	0.620	rs6978200	chr7:3118835	A/G	cg19214707	chr7:3157722	NA	-0.35	-5.83	-0.3	1.31e-8	Atopic dermatitis;
LUSC	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg01528321	chr10:82214614	TSPAN14	0.89	13.66	0.6	4.65e-34	Post bronchodilator FEV1;
LUSC	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg00757033	chr12:89920650	WDR51B	0.6	10.4	0.49	4.04e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7107174	0.786	rs2450134	chr11:77925778	A/G	cg02023728	chr11:77925099	USP35	0.54	7.64	0.39	2.3e-13	Testicular germ cell tumor;
LUSC	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg03877680	chr5:178157825	ZNF354A	0.69	10.1	0.48	4.28e-21	Neutrophil percentage of white cells;
LUSC	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg00191853	chr8:101177733	SPAG1	-0.39	-6.5	-0.33	2.97e-10	Atrioventricular conduction;
LUSC	cis	rs7597155	0.875	rs6752048	chr2:69986136	C/T	cg02498382	chr2:70120550	SNRNP27	-0.24	-5.73	-0.3	2.23e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11642862	1.000	rs11642466	chr16:30781942	A/G	cg02466173	chr16:30829666	NA	-0.67	-7.21	-0.37	3.66e-12	Tonsillectomy;
LUSC	cis	rs34734847	0.814	rs17847	chr12:121149475	A/G	cg27246729	chr12:121163418	ACADS	0.41	6.5	0.34	2.86e-10	Mean corpuscular volume;
LUSC	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.95	0.31	6.63e-9	Lung cancer;
LUSC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg17366294	chr4:99064904	C4orf37	0.55	9.66	0.47	1.25e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3820068	0.608	rs58140482	chr1:16043979	A/G	cg13390004	chr1:15929781	NA	0.42	6.82	0.35	4.38e-11	Systolic blood pressure;
LUSC	cis	rs73195822	0.667	rs59789826	chr12:111235110	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	6.72	0.34	8.08e-11	Itch intensity from mosquito bite;
LUSC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26314531	chr2:26401878	FAM59B	-0.68	-9.19	-0.45	4.28e-18	Gut microbiome composition (summer);
LUSC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg26850624	chr5:429559	AHRR	-0.43	-8.39	-0.42	1.35e-15	Cystic fibrosis severity;
LUSC	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	0.94	14.08	0.61	1.14e-35	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg06145435	chr7:1022769	CYP2W1	0.32	6.99	0.36	1.54e-11	Longevity;Endometriosis;
LUSC	cis	rs440932	1.000	rs440932	chr8:9026929	T/C	cg15556689	chr8:8085844	FLJ10661	0.43	6.08	0.32	3.31e-9	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg02079420	chr8:82753780	SNX16	0.4	6.82	0.35	4.3e-11	Diastolic blood pressure;
LUSC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg14668632	chr7:2872130	GNA12	-0.45	-6.78	-0.35	5.42e-11	Height;
LUSC	cis	rs4664304	0.772	rs17830558	chr2:160878364	A/C	cg23995753	chr2:160760732	LY75	-0.34	-6.33	-0.33	7.96e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2387326	0.717	rs10829335	chr10:129943515	A/G	cg16087940	chr10:129947807	NA	-0.39	-5.81	-0.3	1.48e-8	Select biomarker traits;
LUSC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.9e-23	Bladder cancer;
LUSC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.01	0.4	1.9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg13175981	chr1:150552382	MCL1	0.45	6.23	0.32	1.4e-9	Tonsillectomy;
LUSC	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	1.07	17.23	0.69	4.64e-48	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.05	-0.36	1.02e-11	Lung cancer;
LUSC	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg25828445	chr12:7781288	NA	-0.65	-6.78	-0.35	5.52e-11	HDL cholesterol levels;
LUSC	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg16230307	chr14:35515116	FAM177A1	0.79	10.05	0.48	6.13e-21	Psoriasis;
LUSC	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg23029597	chr12:123009494	RSRC2	-0.74	-9.13	-0.45	6.67e-18	Body mass index;
LUSC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg04398451	chr17:18023971	MYO15A	-0.46	-7.38	-0.37	1.31e-12	Total body bone mineral density;
LUSC	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg11861562	chr11:117069780	TAGLN	0.32	6.28	0.32	1.05e-9	Blood protein levels;
LUSC	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg26816564	chr1:7831052	VAMP3	0.49	5.86	0.31	1.1e-8	Inflammatory bowel disease;
LUSC	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg22618164	chr12:122356400	WDR66	0.41	5.75	0.3	2.05e-8	Mean corpuscular volume;
LUSC	cis	rs1957429	0.614	rs79411360	chr14:65378856	T/C	cg23373153	chr14:65346875	NA	-0.98	-7.72	-0.39	1.39e-13	Pediatric areal bone mineral density (radius);
LUSC	trans	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg07148914	chr20:33460835	GGT7	0.54	8.32	0.41	2.3e-15	Height;
LUSC	cis	rs10740039	0.883	rs1561850	chr10:62391341	T/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.86	-0.35	3.42e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7424096	0.651	rs58370258	chr2:37167191	T/C	cg14987922	chr2:37194071	STRN	0.47	6.25	0.32	1.24e-9	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs17604090	0.816	rs10248839	chr7:29697253	T/C	cg19413766	chr7:29689036	LOC646762	-0.64	-7.64	-0.39	2.34e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs9473147	0.516	rs6904764	chr6:47503497	A/T	cg12968598	chr6:47444699	CD2AP	0.53	8.07	0.4	1.3e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.21	0.32	1.62e-9	Schizophrenia;
LUSC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg09877947	chr5:131593287	PDLIM4	-0.46	-7.03	-0.36	1.19e-11	Breast cancer;
LUSC	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg17507749	chr15:85114479	UBE2QP1	0.54	6.49	0.33	3.11e-10	Schizophrenia;
LUSC	cis	rs2688608	1.000	rs2675680	chr10:75658864	T/C	cg23231163	chr10:75533350	FUT11	-0.37	-6.05	-0.31	3.89e-9	Inflammatory bowel disease;
LUSC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg08219700	chr8:58056026	NA	0.45	5.83	0.3	1.28e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2637266	0.777	rs1907302	chr10:78310828	T/C	cg18941641	chr10:78392320	NA	0.35	6.19	0.32	1.75e-9	Pulmonary function;
LUSC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.46	-6.96	-0.36	1.8e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9309473	1.000	rs13432605	chr2:73810981	C/G	cg20560298	chr2:73613845	ALMS1	-0.46	-6.6	-0.34	1.59e-10	Metabolite levels;
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24739457	chr1:205821442	NA	0.35	6.02	0.31	4.66e-9	Menarche (age at onset);
LUSC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg13047869	chr3:10149882	C3orf24	0.6	8.36	0.42	1.74e-15	Alzheimer's disease;
LUSC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.84	-15.34	-0.64	1.37e-40	Dental caries;
LUSC	cis	rs7953249	0.807	rs2393775	chr12:121424574	G/A	cg02403541	chr12:121454288	C12orf43	-0.62	-9.08	-0.44	9.97e-18	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	trans	rs57046232	0.552	rs932828	chr20:6340080	G/A	cg21095983	chr6:86352623	SYNCRIP	0.46	7.01	0.36	1.32e-11	Colorectal cancer;
LUSC	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg13010199	chr12:38710504	ALG10B	-0.5	-7.61	-0.38	2.86e-13	Morning vs. evening chronotype;
LUSC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.85	-15.03	-0.64	2.4e-39	Cognitive function;
LUSC	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg17810781	chr1:201082982	CACNA1S	-0.35	-6.69	-0.34	9.47e-11	Permanent tooth development;
LUSC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.55	0.46	2.98e-19	Eosinophil percentage of white cells;
LUSC	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg12062639	chr20:23401060	NAPB	0.97	7.94	0.4	3.07e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg13010199	chr12:38710504	ALG10B	0.41	6.0	0.31	5.07e-9	Morning vs. evening chronotype;
LUSC	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg13660082	chr14:53194042	PSMC6	-0.78	-6.81	-0.35	4.55e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.55	10.26	0.49	1.23e-21	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.41	-0.46	8.25e-19	Chronic sinus infection;
LUSC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.24	14.21	0.61	3.56e-36	Diabetic kidney disease;
LUSC	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg15848620	chr12:58087721	OS9	-0.52	-7.56	-0.38	3.89e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg12963246	chr6:28129442	ZNF389	0.49	6.74	0.35	6.8e-11	Depression;
LUSC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg02487422	chr3:49467188	NICN1	0.45	7.08	0.36	8.74e-12	Resting heart rate;
LUSC	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-0.95	-18.89	-0.72	1.23e-54	Cognitive function;
LUSC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.85	15.67	0.65	6.91e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.45	0.33	3.98e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.87	-0.48	2.56e-20	Hemoglobin concentration;
LUSC	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07080220	chr10:102295463	HIF1AN	0.65	8.72	0.43	1.34e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg16049864	chr8:95962084	TP53INP1	-0.62	-11.6	-0.54	2.27e-26	Type 2 diabetes;
LUSC	cis	rs6977660	0.714	rs34451907	chr7:19824538	A/G	cg07541023	chr7:19748670	TWISTNB	0.6	6.3	0.33	9.49e-10	Thyroid stimulating hormone;
LUSC	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-10.94	-0.51	5.23e-24	Response to antipsychotic treatment;
LUSC	cis	rs4474465	0.833	rs10793320	chr11:78217460	G/A	cg27205649	chr11:78285834	NARS2	0.5	5.86	0.31	1.09e-8	Alzheimer's disease (survival time);
LUSC	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	0.7	11.14	0.52	1.01e-24	Blood metabolite ratios;
LUSC	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg06495924	chr8:145149574	CYC1	-0.65	-5.86	-0.31	1.12e-8	Blood metabolite levels;
LUSC	cis	rs668210	0.793	rs1192184	chr11:65773382	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.59	-7.62	-0.38	2.73e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg13560548	chr3:10150139	C3orf24	0.54	7.37	0.37	1.33e-12	Alzheimer's disease;
LUSC	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg17127132	chr2:85788382	GGCX	0.47	7.51	0.38	5.54e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg14830002	chr1:247616686	OR2B11	0.51	7.05	0.36	1.05e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2348418	0.864	rs2175464	chr12:28717111	A/C	cg13890972	chr12:28721907	NA	0.35	6.01	0.31	4.85e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg01097406	chr16:89675127	NA	-0.34	-6.82	-0.35	4.39e-11	Vitiligo;
LUSC	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg04851639	chr8:1020857	NA	-0.4	-8.05	-0.4	1.43e-14	Schizophrenia;
LUSC	cis	rs11608355	1.000	rs7969719	chr12:109883577	C/T	cg05360138	chr12:110035743	NA	0.45	6.31	0.33	8.73e-10	Neuroticism;
LUSC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	0.93	15.91	0.66	8.22e-43	Menopause (age at onset);
LUSC	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18876405	chr7:65276391	NA	0.55	8.81	0.43	7.07e-17	Aortic root size;
LUSC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	0.93	17.84	0.7	1.8e-50	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg06636001	chr8:8085503	FLJ10661	0.66	10.88	0.51	8.63e-24	Systolic blood pressure;
LUSC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg04450456	chr4:17643702	FAM184B	0.35	5.81	0.3	1.47e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg22166914	chr1:53195759	ZYG11B	0.47	7.4	0.38	1.14e-12	Monocyte count;
LUSC	cis	rs11229555	0.874	rs11229505	chr11:58274155	T/C	cg15696309	chr11:58395628	NA	-0.71	-8.98	-0.44	2.06e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg01620082	chr3:125678407	NA	-0.82	-7.24	-0.37	3.06e-12	Lung cancer in ever smokers;
LUSC	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg17764715	chr19:33622953	WDR88	0.59	8.16	0.41	6.86e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg04450456	chr4:17643702	FAM184B	0.38	6.38	0.33	6e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg00484396	chr16:3507460	NAT15	0.5	8.17	0.41	6.47e-15	Body mass index (adult);
LUSC	cis	rs4947962	0.585	rs17172435	chr7:55146471	C/T	cg23757825	chr7:55092271	EGFR	-0.46	-5.83	-0.3	1.34e-8	Subjective response to lithium treatment;
LUSC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg12403142	chr1:92012408	NA	-0.38	-6.17	-0.32	1.95e-9	Breast cancer;
LUSC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg08132940	chr7:1081526	C7orf50	-0.51	-6.08	-0.32	3.35e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04730029	chr22:42915845	RRP7A	0.39	5.99	0.31	5.48e-9	Triglycerides;
LUSC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg09034736	chr1:150693464	HORMAD1	0.42	5.85	0.3	1.17e-8	Melanoma;
LUSC	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg26384229	chr12:38710491	ALG10B	0.49	6.96	0.36	1.76e-11	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24398956	chr15:40331323	SRP14	-0.39	-5.99	-0.31	5.54e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11018904	0.906	rs17227345	chr11:89954685	A/T	cg26028595	chr11:89956573	CHORDC1	0.5	5.81	0.3	1.42e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.45	5.79	0.3	1.67e-8	Renal function-related traits (BUN);
LUSC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg14019146	chr3:50243930	SLC38A3	0.39	8.57	0.42	3.81e-16	Menarche (age at onset);
LUSC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg24977027	chr2:88469347	THNSL2	-0.42	-6.56	-0.34	2.08e-10	Response to metformin (IC50);
LUSC	cis	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg05084668	chr3:125655381	ALG1L	-0.79	-11.85	-0.54	2.72e-27	Blood pressure (smoking interaction);
LUSC	cis	rs2236918	0.901	rs1776132	chr1:242024473	C/G	cg17736920	chr1:242011382	EXO1	0.44	7.02	0.36	1.22e-11	Menopause (age at onset);
LUSC	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.42	5.81	0.3	1.44e-8	Lung cancer;
LUSC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.75	0.39	1.08e-13	Bipolar disorder;
LUSC	trans	rs9372498	0.764	rs9489369	chr6:118720704	A/C	cg07666134	chr16:1331609	NA	-0.44	-6.13	-0.32	2.52e-9	Diastolic blood pressure;
LUSC	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.63	10.13	0.48	3.24e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg04362960	chr10:104952993	NT5C2	0.57	8.99	0.44	1.92e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg26384229	chr12:38710491	ALG10B	0.79	13.44	0.59	3.1e-33	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg06484146	chr7:12443880	VWDE	-0.73	-7.29	-0.37	2.26e-12	Coronary artery disease;
LUSC	cis	rs4964805	0.913	rs11111795	chr12:104204830	C/A	cg02344784	chr12:104178138	NT5DC3	0.45	7.39	0.37	1.18e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg02493740	chr2:85810744	VAMP5	-0.53	-9.28	-0.45	2.2e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg25182066	chr10:30743637	MAP3K8	-0.47	-6.7	-0.34	8.99e-11	Inflammatory bowel disease;
LUSC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg05084668	chr3:125655381	ALG1L	-0.51	-7.16	-0.36	5.26e-12	Blood pressure (smoking interaction);
LUSC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.35	-0.37	1.52e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	14.09	0.61	1.09e-35	Platelet count;
LUSC	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.18	-0.41	6.2e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05808815	chr1:54666250	CYB5RL;MRPL37	-0.48	-6.13	-0.32	2.43e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs116988415	0.584	rs2269305	chr14:65245650	C/G	cg25083366	chr14:65239357	SPTB	0.58	6.12	0.32	2.67e-9	Daytime sleep phenotypes;
LUSC	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-14.04	-0.61	1.56e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.76	7.33	0.37	1.77e-12	Cerebrospinal P-tau181p levels;
LUSC	cis	rs62400317	0.859	rs12205860	chr6:45157323	G/A	cg18551225	chr6:44695536	NA	-0.44	-7.2	-0.37	4.1e-12	Total body bone mineral density;
LUSC	cis	rs9462027	0.561	rs2814972	chr6:34566975	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.17	-0.32	1.94e-9	Systemic lupus erythematosus;
LUSC	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg24375607	chr4:120327624	NA	0.76	11.36	0.53	1.73e-25	Corneal astigmatism;
LUSC	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg27539214	chr16:67997921	SLC12A4	0.61	7.4	0.38	1.09e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg07169764	chr2:136633963	MCM6	-0.63	-8.46	-0.42	8.42e-16	Mosquito bite size;
LUSC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg13531842	chr10:38383804	ZNF37A	0.43	6.68	0.34	9.87e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg22980127	chr19:33182716	NUDT19	0.87	11.26	0.52	3.63e-25	Red blood cell traits;
LUSC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	0.88	17.68	0.7	7.91e-50	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs62238980	0.614	rs116941748	chr22:32404361	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.59	-0.43	3.48e-16	Response to antipsychotic treatment;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14598950	chr3:37035355	MLH1;EPM2AIP1	0.4	6.53	0.34	2.39e-10	Triglycerides;
LUSC	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-7.03	-0.36	1.2e-11	Monocyte percentage of white cells;
LUSC	cis	rs921665	0.915	rs11127382	chr2:3185675	A/T	cg16434511	chr2:3151078	NA	-0.53	-6.35	-0.33	7.11e-10	World class endurance athleticism;
LUSC	cis	rs9314614	0.933	rs2741098	chr8:6690276	C/T	cg27319216	chr8:6693540	XKR5	0.31	5.77	0.3	1.85e-8	IgA nephropathy;White blood cell count (basophil);
LUSC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11645453	chr3:52864694	ITIH4	-0.32	-7.43	-0.38	9.38e-13	Bipolar disorder;
LUSC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg06618935	chr21:46677482	NA	-0.4	-8.07	-0.4	1.32e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.06	-0.36	9.46e-12	Coronary artery disease;
LUSC	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg12002119	chr2:101014098	CHST10	0.34	5.65	0.3	3.48e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24061580	chr7:151573966	PRKAG2	0.46	6.6	0.34	1.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9905704	0.918	rs34430710	chr17:56876627	A/T	cg12560992	chr17:57184187	TRIM37	0.57	7.9	0.4	4.02e-14	Testicular germ cell tumor;
LUSC	cis	rs4964805	1.000	rs4964794	chr12:104194418	T/C	cg02344784	chr12:104178138	NT5DC3	0.45	7.15	0.36	5.34e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs10740039	0.883	rs7097818	chr10:62394864	G/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg00012203	chr2:219082015	ARPC2	0.7	11.63	0.54	1.73e-26	Colorectal cancer;
LUSC	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg06627628	chr2:24431161	ITSN2	0.62	9.14	0.45	6.05e-18	Asthma;
LUSC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg15147215	chr3:52552868	STAB1	-0.31	-6.2	-0.32	1.65e-9	Bipolar disorder;
LUSC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-0.62	-13.07	-0.58	8.41e-32	Prudent dietary pattern;
LUSC	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg21775007	chr8:11205619	TDH	-0.65	-10.26	-0.49	1.22e-21	Retinal vascular caliber;
LUSC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg11764359	chr7:65958608	NA	-0.51	-6.23	-0.32	1.44e-9	Aortic root size;
LUSC	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17830980	chr10:43048298	ZNF37B	0.59	9.52	0.46	3.53e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg24110177	chr3:50126178	RBM5	0.43	6.78	0.35	5.49e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs727505	0.721	rs11536526	chr7:124749441	G/A	cg23710748	chr7:124431027	NA	-0.4	-7.08	-0.36	8.69e-12	Lewy body disease;
LUSC	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg25024717	chr12:54324583	NA	-0.39	-6.84	-0.35	3.88e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	cis	rs34734847	1.000	rs35360964	chr12:121156290	T/C	cg21892295	chr12:121157589	UNC119B	-0.52	-9.54	-0.46	3.07e-19	Mean corpuscular volume;
LUSC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.49	-0.38	6.15e-13	Aortic root size;
LUSC	trans	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg07393940	chr7:158741817	NA	-0.56	-8.53	-0.42	5.23e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg16606324	chr3:10149918	C3orf24	0.64	9.39	0.46	9.87e-19	Alzheimer's disease;
LUSC	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg04362960	chr10:104952993	NT5C2	0.62	9.62	0.47	1.71e-19	Arsenic metabolism;
LUSC	cis	rs7172677	0.768	rs72730586	chr15:75354165	G/A	cg14664628	chr15:75095509	CSK	0.47	6.13	0.32	2.5e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs12190007	0.547	rs2981944	chr6:169801753	T/G	cg15038512	chr6:170123185	PHF10	-0.38	-6.14	-0.32	2.34e-9	Obesity-related traits;
LUSC	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg22823121	chr1:150693482	HORMAD1	0.47	6.47	0.33	3.59e-10	Melanoma;
LUSC	cis	rs11039100	0.850	rs11039116	chr11:5831551	T/A	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg03929089	chr4:120376271	NA	-0.85	-11.65	-0.54	1.45e-26	Coronary artery disease;
LUSC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg12935359	chr14:103987150	CKB	-0.52	-7.95	-0.4	2.93e-14	Bone mineral density;
LUSC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	14.23	0.61	3.08e-36	Platelet count;
LUSC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.87	0.31	1.03e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs4729127	1.000	rs8180725	chr7:94010953	G/C	cg14660007	chr13:78271894	SLAIN1	0.49	6.23	0.32	1.39e-9	Intelligence;
LUSC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	13.49	0.59	2.06e-33	Menarche (age at onset);
LUSC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg16647868	chr5:131706066	SLC22A5	0.39	6.04	0.31	4.05e-9	Blood metabolite levels;
LUSC	cis	rs10746514	0.786	rs9308486	chr1:232246418	A/G	cg09506761	chr1:232265262	NA	0.51	8.24	0.41	3.92e-15	Response to statin therapy;
LUSC	cis	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.81	-0.39	7.42e-14	Morning vs. evening chronotype;
LUSC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg10792982	chr14:105748885	BRF1	0.48	8.81	0.43	7.05e-17	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.9	15.7	0.65	5.49e-42	Morning vs. evening chronotype;
LUSC	cis	rs7493	0.901	rs17882539	chr7:95026408	G/A	cg17330251	chr7:94953956	PON1	-0.35	-5.74	-0.3	2.08e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg26752657	chr1:75199075	CRYZ;TYW3	0.4	6.05	0.31	3.79e-9	Resistin levels;
LUSC	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg05283184	chr6:79620031	NA	-0.45	-8.44	-0.42	9.95e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg09904177	chr6:26538194	HMGN4	0.42	6.14	0.32	2.41e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.67	11.74	0.54	7.23e-27	Aortic root size;
LUSC	cis	rs7267979	0.789	rs62213729	chr20:25363426	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.76	-15.39	-0.64	9.26e-41	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg05373962	chr22:49881684	NA	-0.44	-10.74	-0.51	2.5e-23	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	1.03	19.75	0.73	4.62e-58	Menopause (age at onset);
LUSC	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg09307838	chr4:120376055	NA	0.63	9.31	0.45	1.77e-18	Corneal astigmatism;
LUSC	cis	rs1953600	0.837	rs2236556	chr10:81932790	T/C	cg00277334	chr10:82204260	NA	0.45	7.0	0.36	1.37e-11	Sarcoidosis;
LUSC	cis	rs7507204	0.767	rs12982509	chr19:3412057	C/T	cg08380311	chr19:3435252	NFIC	-0.69	-9.71	-0.47	8.67e-20	Height;
LUSC	trans	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg25214090	chr10:38739885	LOC399744	0.45	6.6	0.34	1.61e-10	Corneal astigmatism;
LUSC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.44	-8.02	-0.4	1.75e-14	Monocyte percentage of white cells;
LUSC	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg04827223	chr11:72435913	ARAP1	-0.86	-14.52	-0.62	2.24e-37	Type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.67	-11.13	-0.52	1.07e-24	Prudent dietary pattern;
LUSC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.43	-0.46	6.97e-19	Chronic sinus infection;
LUSC	cis	rs12681287	0.640	rs13253296	chr8:87448245	C/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg15445000	chr17:37608096	MED1	0.38	6.4	0.33	5.21e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg24733560	chr20:60626293	TAF4	0.39	6.4	0.33	5.13e-10	Body mass index;
LUSC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4363385	0.510	rs6587724	chr1:153034501	T/A	cg00922841	chr1:152955080	SPRR1A	-0.37	-6.16	-0.32	2.05e-9	Inflammatory skin disease;
LUSC	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	0.48	7.48	0.38	6.8e-13	Uric acid clearance;
LUSC	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg12826209	chr6:26865740	GUSBL1	0.65	7.55	0.38	4.31e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg04100463	chr1:3540901	TPRG1L	0.41	6.03	0.31	4.31e-9	Mosquito bite size;
LUSC	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg18683606	chr7:100471612	SRRT	0.44	5.86	0.31	1.13e-8	Resting heart rate;
LUSC	trans	rs4596713	0.538	rs11145460	chr9:71766091	T/G	cg25283916	chr1:242222868	NA	-0.31	-6.44	-0.33	4.09e-10	Headache;
LUSC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg21856205	chr7:94953877	PON1	-0.36	-5.73	-0.3	2.29e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs17039065	1.000	rs76088375	chr4:109393181	C/T	cg07444054	chr2:108107501	NA	0.44	6.43	0.33	4.35e-10	Gut microbiome composition (summer);
LUSC	cis	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg05528280	chr10:464225	DIP2C	-0.41	-6.17	-0.32	1.99e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.49	-0.42	6.7e-16	Response to antipsychotic treatment;
LUSC	trans	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg01620082	chr3:125678407	NA	-0.83	-7.18	-0.37	4.64e-12	Depression;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04567173	chr4:25379221	ANAPC4	-0.49	-6.5	-0.34	2.85e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs7178375	1.000	rs9806159	chr15:31209654	G/T	cg04373760	chr16:53404718	NA	0.61	8.66	0.43	2e-16	Hypertriglyceridemia;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg01266880	chr12:56552110	MYL6	0.42	5.97	0.31	6.1e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg23950597	chr19:37808831	NA	-0.63	-7.63	-0.39	2.43e-13	Coronary artery calcification;
LUSC	trans	rs11264213	0.901	rs72661616	chr1:36370512	G/A	cg05872835	chr6:75796125	COL12A1	0.51	5.97	0.31	5.97e-9	Schizophrenia;
LUSC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg19912559	chr1:40204330	PPIE	0.52	8.08	0.4	1.18e-14	Blood protein levels;
LUSC	cis	rs6496667	0.683	rs1869180	chr15:90895467	T/C	cg22089800	chr15:90895588	ZNF774	0.6	8.58	0.43	3.6e-16	Rheumatoid arthritis;
LUSC	cis	rs7851660	0.844	rs993501	chr9:100623377	A/G	cg13688889	chr9:100608707	NA	0.54	8.32	0.41	2.3e-15	Strep throat;
LUSC	cis	rs10843647	1.000	rs4931279	chr12:30327704	C/A	cg12718339	chr12:29936407	TMTC1	-0.35	-5.82	-0.3	1.41e-8	Glucose homeostasis traits;
LUSC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg22437258	chr11:111473054	SIK2	-0.45	-6.03	-0.31	4.26e-9	Primary sclerosing cholangitis;
LUSC	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg22709100	chr7:91322751	NA	-0.4	-5.89	-0.31	9.18e-9	Breast cancer;
LUSC	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg21775007	chr8:11205619	TDH	-0.44	-6.75	-0.35	6.57e-11	Neuroticism;
LUSC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.44	-6.71	-0.34	8.59e-11	Mean platelet volume;
LUSC	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.97	0.4	2.55e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg24675658	chr1:53192096	ZYG11B	-0.65	-10.16	-0.49	2.65e-21	Monocyte count;
LUSC	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.12	0.32	2.66e-9	Myopia (pathological);
LUSC	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg14092571	chr14:90743983	NA	-0.35	-5.83	-0.3	1.29e-8	Mortality in heart failure;
LUSC	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	8.88	0.44	4.19e-17	Schizophrenia;
LUSC	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.86	14.04	0.61	1.65e-35	Coronary artery disease;
LUSC	cis	rs11828289	0.660	rs17306433	chr11:23223034	C/G	cg20040320	chr11:23191996	NA	-0.61	-6.3	-0.33	9.26e-10	Cancer;
LUSC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg09455208	chr3:40491958	NA	-0.54	-10.02	-0.48	7.77e-21	Renal cell carcinoma;
LUSC	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg09835421	chr16:68378352	PRMT7	-0.51	-6.28	-0.32	1.06e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12760731	0.720	rs10798606	chr1:178372965	G/A	cg00404053	chr1:178313656	RASAL2	0.56	6.24	0.32	1.31e-9	Obesity-related traits;
LUSC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg12292205	chr6:26970375	C6orf41	0.51	8.56	0.42	4.13e-16	Schizophrenia;
LUSC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg13699009	chr12:122356056	WDR66	-0.43	-6.6	-0.34	1.66e-10	Mean corpuscular volume;
LUSC	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.11	-28.89	-0.85	7.41e-93	Myeloid white cell count;
LUSC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg18681998	chr4:17616180	MED28	0.84	15.56	0.65	1.9e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17401966	0.540	rs58014725	chr1:10474457	T/A	cg17425144	chr1:10567563	PEX14	-0.33	-5.75	-0.3	2.06e-8	Hepatocellular carcinoma;
LUSC	cis	rs926392	0.965	rs6129168	chr20:37689360	T/C	cg27552599	chr20:37590471	DHX35	0.34	5.95	0.31	6.89e-9	Dialysis-related mortality;
LUSC	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-7.32	-0.37	1.9e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4665630	0.522	rs1862902	chr2:23886622	A/C	cg08063864	chr2:24346004	PFN4;LOC375190	-0.72	-6.38	-0.33	5.98e-10	Hypertension;
LUSC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg15921436	chr17:44337874	NA	-0.7	-10.7	-0.51	3.72e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs727505	0.954	rs59379598	chr7:124596903	C/G	cg23710748	chr7:124431027	NA	-0.38	-6.63	-0.34	1.32e-10	Lewy body disease;
LUSC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg07424592	chr7:64974309	NA	0.7	6.05	0.31	3.99e-9	Diabetic kidney disease;
LUSC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19346786	chr7:2764209	NA	0.49	8.21	0.41	4.8e-15	Height;
LUSC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg13813247	chr22:41461852	NA	-0.37	-6.73	-0.35	7.49e-11	Neuroticism;
LUSC	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg11584989	chr19:19387371	SF4	0.61	7.35	0.37	1.54e-12	Bipolar disorder;
LUSC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg08470875	chr2:26401718	FAM59B	-0.65	-8.57	-0.42	3.91e-16	Gut microbiome composition (summer);
LUSC	cis	rs3768617	0.740	rs28533496	chr1:183019885	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.5	0.42	6.29e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg13319975	chr6:146136371	FBXO30	-0.7	-10.88	-0.51	8.17e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs965469	1.000	rs2236108	chr20:3286331	A/C	cg25506879	chr20:3388711	C20orf194	-0.52	-5.67	-0.3	3.07e-8	IFN-related cytopenia;
LUSC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.86	-0.48	2.59e-20	Hemoglobin concentration;
LUSC	cis	rs134594	1.000	rs134603	chr22:29473896	T/A	cg03665785	chr22:29458676	C22orf31	0.28	5.75	0.3	2.04e-8	Birth weight;
LUSC	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.58	-0.42	3.56e-16	Systolic blood pressure;
LUSC	cis	rs4588572	0.688	rs1594055	chr5:77695088	G/A	cg11547950	chr5:77652471	NA	-0.42	-6.56	-0.34	2.03e-10	Triglycerides;
LUSC	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg06742321	chr12:123595122	PITPNM2	0.39	5.67	0.3	3.17e-8	Neutrophil percentage of white cells;
LUSC	cis	rs7804356	1.000	rs3801807	chr7:26897439	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.23	-0.32	1.41e-9	Type 1 diabetes;
LUSC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.02	-0.36	1.22e-11	Blood metabolite levels;
LUSC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg05564831	chr3:52568323	NT5DC2	0.32	5.69	0.3	2.8e-8	Electroencephalogram traits;
LUSC	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.61	-0.43	2.97e-16	Total cholesterol levels;
LUSC	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.36	5.96	0.31	6.55e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg06521331	chr12:34319734	NA	-0.39	-5.98	-0.31	5.82e-9	Bladder cancer;
LUSC	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg05347473	chr6:146136440	FBXO30	0.51	8.55	0.42	4.64e-16	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg13010199	chr12:38710504	ALG10B	0.55	8.37	0.42	1.63e-15	Morning vs. evening chronotype;
LUSC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg18230493	chr5:56204884	C5orf35	-0.57	-9.02	-0.44	1.51e-17	Coronary artery disease;
LUSC	cis	rs11677416	1.000	rs6542094	chr2:113528625	A/G	cg27083787	chr2:113543245	IL1A	0.44	6.97	0.36	1.65e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs9473147	0.543	rs1004173	chr6:47445017	C/T	cg20196966	chr6:47445060	CD2AP	0.41	5.75	0.3	2.02e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg13939156	chr17:80058883	NA	0.33	6.5	0.34	2.87e-10	Life satisfaction;
LUSC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg07817648	chr10:79422355	NA	-0.54	-7.35	-0.37	1.53e-12	Bone mineral density;
LUSC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg06238570	chr21:40685208	BRWD1	0.47	7.29	0.37	2.25e-12	Cognitive function;
LUSC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg24631222	chr15:78858424	CHRNA5	-0.66	-8.92	-0.44	3.17e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.87	-17.82	-0.7	2.21e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.83	-0.54	3.32e-27	Chronic sinus infection;
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg03395511	chr6:291903	DUSP22	-0.7	-11.51	-0.53	4.95e-26	Menopause (age at onset);
LUSC	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg15133208	chr4:90757351	SNCA	-0.53	-8.27	-0.41	3.2e-15	Neuroticism;
LUSC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18876405	chr7:65276391	NA	-0.57	-9.18	-0.45	4.69e-18	Aortic root size;
LUSC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-5.89	-0.31	9.29e-9	Major depressive disorder;
LUSC	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg01884057	chr2:25150051	NA	0.47	10.88	0.51	8.51e-24	Body mass index;
LUSC	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-11.13	-0.52	1.13e-24	Mean corpuscular volume;
LUSC	trans	rs28647808	0.881	rs28625799	chr9:136264557	C/T	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg03909863	chr11:638404	DRD4	-0.41	-6.18	-0.32	1.84e-9	Systemic lupus erythematosus;
LUSC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.72	11.88	0.55	2.09e-27	Motion sickness;
LUSC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg16928487	chr17:17741425	SREBF1	0.37	7.11	0.36	7.27e-12	Total body bone mineral density;
LUSC	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg08975724	chr8:8085496	FLJ10661	0.47	6.78	0.35	5.43e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg11214544	chr1:2391121	NA	-0.61	-9.63	-0.47	1.54e-19	Non-obstructive azoospermia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22334543	chr19:3506226	FZR1	0.55	8.3	0.41	2.59e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.64	8.08	0.4	1.23e-14	Schizophrenia;
LUSC	cis	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg27102117	chr16:15229624	NA	0.35	6.04	0.31	4.17e-9	Triglycerides;
LUSC	cis	rs9837602	1.000	rs34626154	chr3:99756312	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.43	-5.95	-0.31	6.87e-9	Breast cancer;
LUSC	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.53	-7.76	-0.39	1.01e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs9807841	0.592	rs10419865	chr19:10772685	C/G	cg09936142	chr19:10668400	KRI1	-0.4	-6.55	-0.34	2.15e-10	Inflammatory skin disease;
LUSC	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.6	0.65	1.31e-41	Bladder cancer;
LUSC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.63	-8.62	-0.43	2.78e-16	Multiple sclerosis;
LUSC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-10.2	-0.49	1.97e-21	Electroencephalogram traits;
LUSC	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg05283184	chr6:79620031	NA	-0.57	-11.96	-0.55	1.1e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-7.0	-0.36	1.42e-11	Retinal vascular caliber;
LUSC	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.2	0.41	5.14e-15	Lung cancer;
LUSC	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.04	-0.36	1.11e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg25214090	chr10:38739885	LOC399744	0.43	6.53	0.34	2.51e-10	Corneal astigmatism;
LUSC	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg12002119	chr2:101014098	CHST10	0.36	5.96	0.31	6.51e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg11871910	chr12:69753446	YEATS4	-0.61	-8.03	-0.4	1.73e-14	Response to diuretic therapy;
LUSC	cis	rs72634258	0.842	rs4908727	chr1:8163122	C/T	cg00042356	chr1:8021962	PARK7	0.61	7.92	0.4	3.47e-14	Inflammatory bowel disease;
LUSC	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg05110241	chr16:68378359	PRMT7	-0.53	-6.16	-0.32	2.11e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg05182265	chr7:156933206	UBE3C	0.48	7.32	0.37	1.91e-12	Body mass index;
LUSC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg00750074	chr16:89608354	SPG7	-0.45	-7.69	-0.39	1.66e-13	Multiple myeloma (IgH translocation);
LUSC	trans	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg09268963	chr14:64692302	SYNE2	0.45	6.17	0.32	1.92e-9	Menarche (age at onset);
LUSC	trans	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg06521331	chr12:34319734	NA	-0.39	-6.12	-0.32	2.68e-9	Bladder cancer;
LUSC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	0.94	18.81	0.72	2.4e-54	Cognitive function;
LUSC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.45e-9	Menopause (age at onset);
LUSC	cis	rs4144743	0.938	rs35069360	chr17:45321270	C/T	cg18085866	chr17:45331354	ITGB3	-0.79	-8.33	-0.41	2.06e-15	Body mass index;
LUSC	cis	rs10992471	0.603	rs12336884	chr9:95234183	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.68	-0.39	1.78e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs568617	0.626	rs78028320	chr11:65582015	G/A	cg19792802	chr11:65647270	CTSW	0.44	6.21	0.32	1.56e-9	Crohn's disease;
LUSC	cis	rs7113850	0.541	rs77699762	chr11:24236448	C/T	ch.11.24196551F	chr11:24239977	NA	1.0	9.04	0.44	1.31e-17	Bone fracture in osteoporosis;
LUSC	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.29	-0.37	2.33e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg25456477	chr12:86230367	RASSF9	0.34	5.96	0.31	6.44e-9	Major depressive disorder;
LUSC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.06	-0.31	3.72e-9	Total body bone mineral density;
LUSC	cis	rs73206853	0.764	rs76142162	chr12:110884307	C/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg12935359	chr14:103987150	CKB	-0.4	-5.72	-0.3	2.38e-8	Body mass index;
LUSC	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg13072238	chr3:49761600	GMPPB	0.65	8.33	0.41	2.14e-15	Menarche (age at onset);
LUSC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.93	15.89	0.66	9.63e-43	Bladder cancer;
LUSC	cis	rs9653442	0.593	rs10865036	chr2:100860595	A/G	cg22139774	chr2:100720529	AFF3	-0.39	-6.41	-0.33	4.94e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-6.93	-0.35	2.12e-11	Bipolar disorder;
LUSC	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg18904891	chr8:8559673	CLDN23	0.6	8.23	0.41	4.27e-15	Obesity-related traits;
LUSC	cis	rs909341	0.629	rs3761124	chr20:62288752	T/C	cg09650180	chr20:62225654	GMEB2	0.44	5.73	0.3	2.19e-8	Atopic dermatitis;
LUSC	cis	rs2303282	0.717	rs11640819	chr16:56486248	A/G	cg00500540	chr16:56394104	NA	-0.43	-7.31	-0.37	1.93e-12	Breast cancer;
LUSC	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg14696996	chr19:15285081	NOTCH3	1.02	9.37	0.46	1.15e-18	Pulse pressure;
LUSC	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.04	-0.4	1.57e-14	Neuroticism;
LUSC	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.77e-9	Morning vs. evening chronotype;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23100370	chr2:109336342	RANBP2	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs79387448	0.745	rs7575867	chr2:103120179	C/T	cg09003973	chr2:102972529	NA	0.83	8.42	0.42	1.16e-15	Gut microbiota (bacterial taxa);
LUSC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg14092988	chr3:52407081	DNAH1	0.33	6.36	0.33	6.54e-10	Bipolar disorder;
LUSC	cis	rs7833986	1.000	rs34952804	chr8:57097399	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	9.2	0.45	3.84e-18	Height;
LUSC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg12365402	chr11:9010492	NRIP3	0.47	8.78	0.43	8.61e-17	Hemoglobin concentration;
LUSC	cis	rs9341808	0.667	rs2490251	chr6:80895164	A/G	cg08355045	chr6:80787529	NA	0.47	7.97	0.4	2.48e-14	Sitting height ratio;
LUSC	cis	rs354225	0.584	rs6749802	chr2:54824146	A/G	cg26097391	chr2:54893211	SPTBN1	0.44	6.62	0.34	1.41e-10	Schizophrenia;
LUSC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg23625390	chr15:77176239	SCAPER	0.5	7.8	0.39	7.99e-14	Blood metabolite levels;
LUSC	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg23283495	chr1:209979779	IRF6	0.63	7.76	0.39	1.04e-13	Cleft lip with or without cleft palate;
LUSC	cis	rs3741151	0.773	rs74881062	chr11:73245769	G/A	cg17517138	chr11:73019481	ARHGEF17	0.97	8.13	0.41	8.58e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.47	6.68	0.34	9.73e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.74	15.5	0.65	3.38e-41	Systemic lupus erythematosus;
LUSC	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22307029	chr19:49891270	CCDC155	-0.53	-7.18	-0.37	4.41e-12	Multiple sclerosis;
LUSC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08439880	chr3:133502540	NA	-0.35	-6.36	-0.33	6.8e-10	Iron status biomarkers;
LUSC	cis	rs4561483	0.624	rs2215928	chr16:11927918	A/T	cg08843971	chr16:11963173	GSPT1	-0.39	-5.79	-0.3	1.65e-8	Testicular germ cell tumor;
LUSC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg03929089	chr4:120376271	NA	-0.94	-16.31	-0.67	2.11e-44	Height;
LUSC	trans	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-8.86	-0.44	4.86e-17	Obesity-related traits;
LUSC	cis	rs7267979	0.738	rs2892409	chr20:25638138	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	15.3	0.64	1.98e-40	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs961253	0.501	rs6054183	chr20:6354161	T/C	cg21095983	chr6:86352623	SYNCRIP	0.49	7.37	0.37	1.37e-12	Colorectal cancer;
LUSC	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg07701084	chr6:150067640	NUP43	0.46	6.93	0.35	2.23e-11	Testicular germ cell tumor;
LUSC	cis	rs73198271	0.586	rs3789850	chr8:8686845	G/T	cg01851573	chr8:8652454	MFHAS1	0.4	5.97	0.31	5.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18876405	chr7:65276391	NA	0.54	8.27	0.41	3.22e-15	Aortic root size;
LUSC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	13.53	0.59	1.52e-33	Total body bone mineral density;
LUSC	cis	rs7605827	0.893	rs6733695	chr2:15525714	T/C	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06634786	chr22:41940651	POLR3H	-0.53	-6.47	-0.33	3.57e-10	Vitiligo;
LUSC	cis	rs12618769	0.597	rs11884553	chr2:99131206	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	cis	rs11997175	0.766	rs6983113	chr8:33699513	G/A	ch.8.33884649F	chr8:33765107	NA	0.37	5.82	0.3	1.36e-8	Body mass index;
LUSC	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg01528321	chr10:82214614	TSPAN14	1.06	12.04	0.55	5.81e-28	Post bronchodilator FEV1;
LUSC	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg12473912	chr3:136751656	NA	0.39	6.82	0.35	4.16e-11	Neuroticism;
LUSC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg26441486	chr22:50317300	CRELD2	-0.54	-8.25	-0.41	3.81e-15	Schizophrenia;
LUSC	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg03340356	chr1:67600835	NA	0.42	6.6	0.34	1.57e-10	Psoriasis;
LUSC	cis	rs60154123	0.730	rs10489391	chr1:210458861	C/T	cg22029157	chr1:209979665	IRF6	-0.49	-5.72	-0.3	2.31e-8	Coronary artery disease;
LUSC	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.5	0.46	4.34e-19	Bipolar disorder;
LUSC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8014204	0.762	rs8016389	chr14:75287554	T/C	cg06637938	chr14:75390232	RPS6KL1	0.53	8.32	0.41	2.34e-15	Caffeine consumption;
LUSC	cis	rs7193541	0.695	rs7199490	chr16:74716026	G/A	cg01733217	chr16:74700730	RFWD3	0.81	12.41	0.56	2.46e-29	Multiple myeloma;
LUSC	cis	rs7408868	0.764	rs12610803	chr19:15260682	A/C	cg14696996	chr19:15285081	NOTCH3	0.97	8.71	0.43	1.48e-16	Pulse pressure;
LUSC	cis	rs11031096	0.621	rs12282967	chr11:4191477	A/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.76	-0.3	1.96e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg13010199	chr12:38710504	ALG10B	0.56	8.54	0.42	4.86e-16	Morning vs. evening chronotype;
LUSC	cis	rs668210	0.793	rs590531	chr11:65773939	C/A	cg04700828	chr11:65773979	NA	0.4	5.72	0.3	2.35e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6961069	0.868	rs1194177	chr7:80235095	A/G	cg04458919	chr7:80252533	CD36	-0.36	-6.59	-0.34	1.75e-10	Platelet count;
LUSC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.77	-0.43	9.4e-17	Bipolar disorder;
LUSC	cis	rs30380	0.586	rs28119	chr5:96131733	G/A	cg16492584	chr5:96139282	ERAP1	-0.56	-7.56	-0.38	3.94e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.92	-16.68	-0.67	7.22e-46	Cognitive function;
LUSC	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.89	15.25	0.64	3.11e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2275620	1.000	rs1891071	chr10:96805371	C/T	cg09036531	chr10:96991505	NA	-0.39	-5.68	-0.3	2.95e-8	Gout;
LUSC	trans	rs2487048	0.725	rs2422493	chr9:107690995	G/A	cg17444859	chr7:41543664	NA	0.27	6.3	0.33	9.61e-10	Intraocular pressure;
LUSC	cis	rs3750965	0.959	rs3168115	chr11:68858090	A/T	cg06818126	chr11:68850279	TPCN2	0.42	6.22	0.32	1.49e-9	Hair color;
LUSC	cis	rs6599077	1.000	rs7637811	chr3:40096412	C/G	cg13683864	chr3:40499215	RPL14	-0.6	-7.66	-0.39	2.06e-13	Sleep-related phenotypes;
LUSC	cis	rs78545713	0.649	rs79759076	chr6:26223694	C/G	cg23601095	chr6:26197514	HIST1H3D	0.64	5.76	0.3	1.87e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg20573242	chr4:122745356	CCNA2	0.64	9.03	0.44	1.36e-17	Type 2 diabetes;
LUSC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12826209	chr6:26865740	GUSBL1	0.76	9.18	0.45	4.6e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.3e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg25258033	chr6:167368657	RNASET2	0.39	6.3	0.33	9.49e-10	Crohn's disease;
LUSC	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg15744005	chr10:104629667	AS3MT	-0.29	-6.33	-0.33	7.86e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-6.11	-0.32	2.71e-9	Menarche (age at onset);
LUSC	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg19875535	chr5:140030758	IK	-0.53	-8.69	-0.43	1.67e-16	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.5	-8.12	-0.41	9.24e-15	Platelet count;
LUSC	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg01990225	chr2:97406019	LMAN2L	-1.06	-7.21	-0.37	3.87e-12	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg14552801	chr7:65878734	NA	-0.38	-5.96	-0.31	6.31e-9	Aortic root size;
LUSC	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg04218760	chr10:45406644	TMEM72	-0.28	-6.85	-0.35	3.52e-11	Mean corpuscular volume;
LUSC	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg09201001	chr11:18656081	SPTY2D1	0.94	15.29	0.64	2.25e-40	Breast cancer;
LUSC	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg07169764	chr2:136633963	MCM6	1.16	17.45	0.69	6.42e-49	Corneal structure;
LUSC	cis	rs3101457	0.530	rs9782996	chr1:244528127	C/T	cg09033006	chr1:244517177	C1orf100	0.39	5.72	0.3	2.38e-8	Smoking behavior;
LUSC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	5.89	0.31	9.6e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs983392	0.679	rs655231	chr11:60013857	A/G	cg02771260	chr11:59836817	MS4A3	-0.37	-6.11	-0.32	2.79e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg05738196	chr6:26577821	NA	0.78	14.76	0.63	2.72e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs2235649	0.828	rs9936486	chr16:1849888	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-6.11	-0.32	2.71e-9	Blood metabolite levels;
LUSC	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg18681998	chr4:17616180	MED28	-0.74	-12.53	-0.57	8.96e-30	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg00310523	chr12:86230176	RASSF9	0.36	6.56	0.34	2.08e-10	Major depressive disorder;
LUSC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.24	-0.32	1.33e-9	Initial pursuit acceleration;
LUSC	cis	rs9905704	0.918	rs2611779	chr17:56791832	A/G	cg12560992	chr17:57184187	TRIM37	0.54	7.75	0.39	1.15e-13	Testicular germ cell tumor;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23041332	chr4:185395887	IRF2	-0.44	-6.61	-0.34	1.54e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11585357	0.895	rs72633814	chr1:17626456	T/C	cg08277548	chr1:17600880	PADI3	-0.58	-5.9	-0.31	8.89e-9	Hair shape;
LUSC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg12963246	chr6:28129442	ZNF389	0.49	7.19	0.37	4.21e-12	Parkinson's disease;
LUSC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg17143192	chr8:8559678	CLDN23	0.59	8.48	0.42	7.54e-16	Obesity-related traits;
LUSC	cis	rs2124969	0.548	rs62175388	chr2:161019664	G/A	cg03641300	chr2:160917029	PLA2R1	-0.47	-5.7	-0.3	2.7e-8	Waist circumference adjusted for body mass index;
LUSC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.77	0.51	2e-23	Alzheimer's disease;
LUSC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg03351412	chr1:154909251	PMVK	0.55	8.85	0.44	5.3e-17	Prostate cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04860157	chr6:36842651	PPIL1	0.42	5.98	0.31	5.77e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg25930673	chr12:123319894	HIP1R	-0.72	-7.24	-0.37	3.08e-12	Schizophrenia;
LUSC	cis	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg13550731	chr2:172543902	DYNC1I2	0.53	7.98	0.4	2.31e-14	Schizophrenia;
LUSC	cis	rs7809950	0.817	rs2222845	chr7:107281829	C/T	cg23024343	chr7:107201750	COG5	0.64	9.36	0.46	1.23e-18	Coronary artery disease;
LUSC	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg04365224	chr3:72788183	NA	-0.46	-5.72	-0.3	2.41e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg00339695	chr16:24857497	SLC5A11	0.37	6.56	0.34	1.99e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg17340268	chr14:105411764	AHNAK2	-0.38	-6.02	-0.31	4.47e-9	Rheumatoid arthritis;
LUSC	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs5771225	0.544	rs1555048	chr22:50688348	A/G	cg16473166	chr22:50639996	SELO	0.59	7.76	0.39	1.03e-13	Late-onset Alzheimer's disease;
LUSC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg14789911	chr21:47582049	C21orf56	-0.36	-5.69	-0.3	2.76e-8	Testicular germ cell tumor;
LUSC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.7	10.61	0.5	7.26e-23	Type 2 diabetes;
LUSC	cis	rs28655083	0.913	rs7190129	chr16:77071456	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.38	-5.68	-0.3	2.9e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4400599	0.618	rs1194603	chr1:154228287	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.34	5.66	0.3	3.22e-8	Platelet distribution width;
LUSC	cis	rs7539409	0.604	rs910183	chr1:84297285	A/G	cg10977910	chr1:84465055	TTLL7	0.67	7.1	0.36	7.44e-12	Alzheimer's disease;
LUSC	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.57	0.57	6.34e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2637266	0.626	rs846617	chr10:78546881	A/G	cg18941641	chr10:78392320	NA	0.4	7.25	0.37	2.87e-12	Pulmonary function;
LUSC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20887711	chr4:1340912	KIAA1530	-0.65	-9.97	-0.48	1.12e-20	Obesity-related traits;
LUSC	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg27284194	chr4:1044797	NA	0.6	8.84	0.44	5.8e-17	Recombination rate (females);
LUSC	cis	rs55665837	0.539	rs10766196	chr11:14913131	A/G	cg19336497	chr11:14380999	RRAS2	-0.33	-5.92	-0.31	7.78e-9	Vitamin D levels;
LUSC	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg05347473	chr6:146136440	FBXO30	0.51	8.55	0.42	4.64e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg00012203	chr2:219082015	ARPC2	-0.58	-9.23	-0.45	3.29e-18	Ulcerative colitis;
LUSC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.5	7.79	0.39	8.68e-14	Testicular germ cell tumor;
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.53	-8.13	-0.41	8.36e-15	Lymphocyte counts;
LUSC	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg15848620	chr12:58087721	OS9	0.46	6.4	0.33	5.36e-10	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.13	0.41	8.34e-15	Axial length;
LUSC	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.51	-0.42	5.99e-16	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg10339542	chr17:10600919	C17orf48;SCO1	0.36	6.36	0.33	6.61e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs4363385	0.747	rs11205151	chr1:152961496	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.64	-0.39	2.3e-13	Inflammatory skin disease;
LUSC	cis	rs6120849	0.754	rs3746446	chr20:33574765	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	6.68	0.34	1.01e-10	Protein C levels;
LUSC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg13319975	chr6:146136371	FBXO30	0.7	11.08	0.52	1.65e-24	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11668770	chr19:56125740	NA	0.45	6.0	0.31	5.18e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.47	-0.46	5.29e-19	Platelet count;
LUSC	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.63	0.65	9.84e-42	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg09517075	chr8:22133004	PIWIL2	0.43	8.54	0.42	4.89e-16	Hypertriglyceridemia;
LUSC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-12.64	-0.57	3.31e-30	Platelet count;
LUSC	cis	rs7224314	1.000	rs8070689	chr17:65387405	G/T	cg01507342	chr17:65387096	PITPNC1	-0.44	-7.79	-0.39	8.5e-14	Diisocyanate-induced asthma;
LUSC	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg03676636	chr4:99064102	C4orf37	0.31	6.13	0.32	2.47e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg00024416	chr22:24240387	NA	-0.37	-6.45	-0.33	4.03e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg21681030	chr2:46777652	RHOQ	0.44	6.3	0.33	9.63e-10	Height;
LUSC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg26338869	chr17:61819248	STRADA	0.42	5.96	0.31	6.57e-9	Prudent dietary pattern;
LUSC	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg02825527	chr7:2087843	MAD1L1	-0.5	-5.73	-0.3	2.29e-8	Bipolar disorder;
LUSC	cis	rs12493885	0.585	rs787812	chr3:153622217	A/G	cg17054900	chr3:154042577	DHX36	0.59	6.17	0.32	2e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg26043149	chr18:55253948	FECH	-0.45	-6.94	-0.36	2.01e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.6	-0.34	1.63e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg24733560	chr20:60626293	TAF4	0.45	8.31	0.41	2.47e-15	Body mass index;
LUSC	trans	rs11088226	0.581	rs2236430	chr21:33973408	A/G	cg09050820	chr6:167586206	TCP10L2	-0.54	-8.66	-0.43	2.05e-16	Gastritis;
LUSC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg20821713	chr7:1055600	C7orf50	-0.56	-7.36	-0.37	1.42e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg03585969	chr10:35415529	CREM	0.62	9.05	0.44	1.23e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg25214090	chr10:38739885	LOC399744	0.51	7.79	0.39	8.53e-14	Corneal astigmatism;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg21403912	chr1:155239301	CLK2	-0.41	-6.66	-0.34	1.13e-10	Educational attainment (years of education);
LUSC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg12560992	chr17:57184187	TRIM37	0.84	15.11	0.64	1.16e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs10875595	0.836	rs1363450	chr5:140658363	A/T	cg24830062	chr5:140700576	TAF7	0.48	6.09	0.32	3.18e-9	Pulmonary function decline;
LUSC	cis	rs7674212	1.000	rs7674212	chr4:103988899	G/T	cg16532752	chr4:104119610	CENPE	-0.43	-6.34	-0.33	7.51e-10	Type 2 diabetes;
LUSC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-0.86	-16.16	-0.66	8.43e-44	Height;
LUSC	trans	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg03973167	chr4:185394988	IRF2	0.43	6.07	0.32	3.49e-9	Schizophrenia;
LUSC	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg05738196	chr6:26577821	NA	0.8	15.3	0.64	2.07e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg08975724	chr8:8085496	FLJ10661	0.51	7.98	0.4	2.29e-14	Mood instability;
LUSC	trans	rs703108	0.869	rs12767559	chr10:22469145	A/G	cg15415259	chr6:134158982	MGC34034	0.4	5.97	0.31	5.91e-9	Monocyte percentage of white cells;
LUSC	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.86	-0.63	1.03e-38	Schizophrenia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24808674	chr1:51702659	RNF11	-0.46	-6.2	-0.32	1.7e-9	Hepatitis;
LUSC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.51e-14	Prudent dietary pattern;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06666157	chr19:4791552	FEM1A	0.42	6.13	0.32	2.49e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg08999081	chr20:33150536	PIGU	-0.39	-7.12	-0.36	6.76e-12	Height;
LUSC	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-5.86	-0.31	1.09e-8	Immature fraction of reticulocytes;Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23359048	chr12:2921757	ITFG2	0.43	6.35	0.33	6.88e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg03733263	chr8:22462867	KIAA1967	0.89	15.58	0.65	1.59e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06634786	chr22:41940651	POLR3H	0.51	6.1	0.32	2.91e-9	Vitiligo;
LUSC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg05863683	chr7:1912471	MAD1L1	0.3	5.87	0.31	1.07e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg21211680	chr2:198530	NA	0.66	7.45	0.38	7.91e-13	Blood protein levels;
LUSC	cis	rs10450586	0.932	rs10082611	chr11:27320108	C/G	cg08958251	chr11:27270390	NA	0.33	5.65	0.3	3.47e-8	Total body bone mineral density;
LUSC	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg04398451	chr17:18023971	MYO15A	-0.46	-7.3	-0.37	2.13e-12	Total body bone mineral density;
LUSC	trans	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg25214090	chr10:38739885	LOC399744	0.44	6.57	0.34	1.9e-10	Corneal astigmatism;
LUSC	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg06606381	chr12:133084897	FBRSL1	-0.98	-8.54	-0.42	4.67e-16	Lung cancer in ever smokers;
LUSC	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg15485101	chr11:133734466	NA	0.4	7.23	0.37	3.23e-12	Childhood ear infection;
LUSC	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg04545296	chr12:48745243	ZNF641	0.33	6.04	0.31	4.14e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs4889855	0.545	rs61171555	chr17:78465975	T/G	cg00066239	chr17:78472159	NA	-0.42	-7.28	-0.37	2.46e-12	Fractional excretion of uric acid;
LUSC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12379764	chr21:47803548	PCNT	0.49	7.0	0.36	1.4e-11	Testicular germ cell tumor;
LUSC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.72	-0.57	1.7e-30	Bipolar disorder and schizophrenia;
LUSC	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg15848620	chr12:58087721	OS9	-0.57	-8.14	-0.41	8.09e-15	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs7916697	0.520	rs12265247	chr10:70038398	A/G	cg04882175	chr6:131122610	NA	-0.56	-7.63	-0.39	2.49e-13	Optic disc area;
LUSC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-7.02	-0.36	1.27e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7804356	1.000	rs73067435	chr7:26850195	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs926938	0.527	rs6680112	chr1:115548915	G/C	cg12756093	chr1:115239321	AMPD1	0.47	6.93	0.35	2.15e-11	Autism;
LUSC	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg11266682	chr4:10021025	SLC2A9	0.45	8.29	0.41	2.86e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs13067593	1.000	rs73199038	chr3:188581584	G/A	cg17809494	chr3:188572244	LPP	0.45	6.25	0.32	1.25e-9	Immune reponse to smallpox (secreted IFN-alpha);
LUSC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23158103	chr7:148848205	ZNF398	-0.48	-7.84	-0.39	6.12e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg11752832	chr7:134001865	SLC35B4	0.59	9.3	0.45	1.94e-18	Mean platelet volume;
LUSC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg22535103	chr8:58192502	C8orf71	0.7	7.63	0.39	2.51e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs57590327	0.503	rs1464790	chr3:81852923	A/T	cg07356753	chr3:81810745	GBE1	0.63	10.09	0.48	4.41e-21	Extraversion;
LUSC	trans	rs8060598	0.866	rs3135499	chr16:50766127	G/T	cg19083779	chr1:57110724	PRKAA2	-0.37	-6.09	-0.32	3.11e-9	Leprosy;
LUSC	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.21	-0.49	1.82e-21	Hemoglobin concentration;
LUSC	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg05163923	chr11:71159392	DHCR7	0.74	11.07	0.52	1.79e-24	Vitamin D levels;
LUSC	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06022373	chr22:39101656	GTPBP1	0.78	12.2	0.56	1.47e-28	Menopause (age at onset);
LUSC	cis	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-8.13	-0.41	8.48e-15	Coronary artery disease;
LUSC	trans	rs61931739	0.635	rs1852224	chr12:33963080	A/C	cg26384229	chr12:38710491	ALG10B	0.51	7.63	0.39	2.54e-13	Morning vs. evening chronotype;
LUSC	cis	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg06521331	chr12:34319734	NA	0.35	5.81	0.3	1.42e-8	Morning vs. evening chronotype;
LUSC	cis	rs4629710	0.592	rs13206776	chr6:131576679	T/G	cg12700074	chr6:131571435	AKAP7	-0.36	-5.92	-0.31	8.04e-9	Multiple myeloma (IgH translocation);
LUSC	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.57	0.65	1.71e-41	Morning vs. evening chronotype;
LUSC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg23791538	chr6:167370224	RNASET2	-0.41	-5.85	-0.3	1.19e-8	Crohn's disease;
LUSC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.94	0.48	1.45e-20	Personality dimensions;
LUSC	cis	rs2573652	0.722	rs11630930	chr15:100544145	G/T	cg00587665	chr15:100533223	ADAMTS17	-0.38	-6.91	-0.35	2.44e-11	Height;
LUSC	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.54	-10.68	-0.5	4.35e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg15691649	chr6:25882328	NA	0.5	7.41	0.38	1.03e-12	Blood metabolite levels;
LUSC	cis	rs59698941	0.943	rs57880964	chr5:132210674	G/C	cg02081065	chr5:132209139	LEAP2	-0.66	-6.89	-0.35	2.8e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs57908212	1	rs57908212	chr19:2161321	T/C	cg09261902	chr19:2140048	AP3D1	0.33	6.12	0.32	2.62e-9	Red blood cell count;Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg00277334	chr10:82204260	NA	-0.59	-9.0	-0.44	1.78e-17	Post bronchodilator FEV1;
LUSC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg10792982	chr14:105748885	BRF1	-0.52	-9.53	-0.46	3.28e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg11502198	chr6:26597334	ABT1	0.69	11.45	0.53	7.68e-26	Intelligence (multi-trait analysis);
LUSC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	0.88	13.23	0.59	1.98e-32	IgG glycosylation;
LUSC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg17366294	chr4:99064904	C4orf37	0.57	9.73	0.47	7.43e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg00945038	chr17:61921165	SMARCD2	0.54	9.72	0.47	8.06e-20	Prudent dietary pattern;
LUSC	cis	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg09904177	chr6:26538194	HMGN4	-0.76	-6.23	-0.32	1.43e-9	Urinary tract infection frequency;
LUSC	cis	rs2625529	0.652	rs2957736	chr15:72265344	A/G	cg16672083	chr15:72433130	SENP8	0.48	7.95	0.4	2.86e-14	Red blood cell count;
LUSC	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.69	9.72	0.47	8.13e-20	HIV-1 control;
LUSC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.78	-11.0	-0.52	3.18e-24	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.78	0.3	1.72e-8	Menopause (age at onset);
LUSC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg17971929	chr21:40555470	PSMG1	-0.49	-7.22	-0.37	3.59e-12	Menarche (age at onset);
LUSC	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.6	9.08	0.44	9.79e-18	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg02569458	chr12:86230093	RASSF9	-0.48	-7.95	-0.4	2.87e-14	Major depressive disorder;
LUSC	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.54	10.96	0.51	4.23e-24	Coronary artery disease;
LUSC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.89	0.44	3.86e-17	Schizophrenia;
LUSC	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg07061783	chr6:25882402	NA	-0.38	-5.86	-0.31	1.08e-8	Blood metabolite levels;
LUSC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg10621924	chr7:39171070	POU6F2	0.48	7.58	0.38	3.36e-13	IgG glycosylation;
LUSC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg08847533	chr14:75593920	NEK9	-0.81	-14.02	-0.61	2.01e-35	Height;
LUSC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg21782813	chr7:2030301	MAD1L1	0.49	8.22	0.41	4.52e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs240768	0.826	rs75352517	chr6:101085728	G/A	cg12253828	chr6:101329408	ASCC3	0.87	5.95	0.31	6.66e-9	Economic and political preferences (immigration/crime);
LUSC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg15691649	chr6:25882328	NA	-0.38	-6.22	-0.32	1.49e-9	Blood metabolite levels;
LUSC	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg18825076	chr15:78729989	IREB2	0.47	6.28	0.32	1.07e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.74	12.95	0.58	2.37e-31	Colorectal cancer;
LUSC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	0.92	15.32	0.64	1.7e-40	Breast cancer;
LUSC	cis	rs534126	1.000	rs534126	chr7:142921234	C/T	cg04039957	chr7:143013207	CLCN1	0.31	5.94	0.31	7.14e-9	Cancer;
LUSC	cis	rs6977660	0.619	rs10263780	chr7:19778086	A/G	cg05791153	chr7:19748676	TWISTNB	-0.72	-7.82	-0.39	7.14e-14	Thyroid stimulating hormone;
LUSC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg12463550	chr7:65579703	CRCP	0.41	5.66	0.3	3.21e-8	Calcium levels;
LUSC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg12002119	chr2:101014098	CHST10	0.36	6.11	0.32	2.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7172677	0.960	rs1602360	chr15:75420761	G/A	cg14664628	chr15:75095509	CSK	-0.43	-5.72	-0.3	2.41e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	9.05	0.44	1.2e-17	Menarche (age at onset);
LUSC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg23649088	chr2:200775458	C2orf69	0.55	7.39	0.38	1.15e-12	Schizophrenia;
LUSC	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-10.55	-0.5	1.2e-22	Morning vs. evening chronotype;
LUSC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg09034736	chr1:150693464	HORMAD1	0.41	5.85	0.3	1.19e-8	Melanoma;
LUSC	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.65	13.97	0.61	3.15e-35	Hemoglobin concentration;
LUSC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg13647721	chr17:30228624	UTP6	0.63	6.83	0.35	3.96e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg11130432	chr3:121712080	ILDR1	-0.63	-9.57	-0.46	2.41e-19	Multiple sclerosis;
LUSC	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.96	0.4	2.77e-14	Systolic blood pressure;
LUSC	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg25922239	chr6:33757077	LEMD2	0.55	8.26	0.41	3.56e-15	Crohn's disease;
LUSC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-0.84	-14.78	-0.63	2.16e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.3	-6.03	-0.31	4.44e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg03388025	chr16:89894329	SPIRE2	0.33	6.93	0.35	2.24e-11	Vitiligo;
LUSC	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg02176678	chr2:219576539	TTLL4	-0.57	-10.1	-0.48	4.29e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.34	-0.33	7.59e-10	Response to antipsychotic treatment;
LUSC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg07636037	chr3:49044803	WDR6	0.59	6.25	0.32	1.28e-9	Menarche (age at onset);
LUSC	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.14	-0.32	2.39e-9	Retinal vascular caliber;
LUSC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg08999081	chr20:33150536	PIGU	0.44	8.12	0.41	8.93e-15	Coronary artery disease;
LUSC	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg17691542	chr6:26056736	HIST1H1C	0.53	7.36	0.37	1.4e-12	Iron status biomarkers;
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	1.03	21.96	0.77	8.84e-67	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11711311	1.000	rs891574	chr3:113537639	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.43	0.33	4.3e-10	IgG glycosylation;
LUSC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg15704280	chr7:45808275	SEPT13	-0.55	-7.83	-0.39	6.43e-14	Coronary artery disease;
LUSC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg23711669	chr6:146136114	FBXO30	0.72	12.82	0.57	7.47e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg13114125	chr14:105738426	BRF1	-0.88	-14.64	-0.63	7.72e-38	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9928842	0.882	rs9319481	chr16:75259478	T/C	cg09066997	chr16:75300724	BCAR1	0.52	6.46	0.33	3.75e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs1950626	0.623	rs34603287	chr14:101433831	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.4	7.47	0.38	7.07e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg11189052	chr15:85197271	WDR73	0.54	6.13	0.32	2.42e-9	Schizophrenia;
LUSC	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.47	8.73	0.43	1.26e-16	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.59	0.5	8.44e-23	Bladder cancer;
LUSC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.84	-0.39	6.14e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs394563	0.602	rs409111	chr6:149766860	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.33	-7.37	-0.37	1.34e-12	Dupuytren's disease;
LUSC	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.67	-0.34	1.03e-10	Bladder cancer;
LUSC	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg24692254	chr21:30365293	RNF160	-0.75	-11.68	-0.54	1.18e-26	Pancreatic cancer;
LUSC	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg03676636	chr4:99064102	C4orf37	0.37	7.68	0.39	1.8e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21862992	chr11:68658383	NA	0.51	7.94	0.4	3.03e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11229555	1.000	rs2298608	chr11:58404467	A/G	cg15696309	chr11:58395628	NA	0.7	9.25	0.45	2.82e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg08684580	chr7:98029266	BAIAP2L1	0.37	5.64	0.3	3.56e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-10.81	-0.51	1.47e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9420	0.961	rs7121169	chr11:57452543	G/A	cg23127183	chr11:57508653	C11orf31	-0.58	-8.99	-0.44	1.86e-17	Schizophrenia;
LUSC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg14668632	chr7:2872130	GNA12	-0.42	-6.38	-0.33	5.87e-10	Height;
LUSC	cis	rs9359856	0.636	rs9344946	chr6:90298371	T/G	cg13799429	chr6:90582589	CASP8AP2	0.71	7.5	0.38	5.9e-13	Bipolar disorder;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg20821713	chr7:1055600	C7orf50	-0.39	-6.1	-0.32	3.01e-9	Longevity;Endometriosis;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg17073432	chr10:104221224	TMEM180	0.37	6.0	0.31	5.06e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg04362960	chr10:104952993	NT5C2	0.61	9.9	0.48	1.98e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6893807	1.000	rs16903275	chr5:87950543	A/C	cg09002922	chr5:87956389	LOC645323	0.43	5.67	0.3	3.03e-8	Body mass index;
LUSC	trans	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg15556689	chr8:8085844	FLJ10661	0.48	7.21	0.37	3.87e-12	Retinal vascular caliber;
LUSC	cis	rs56161922	1.000	rs56235509	chr1:207839769	C/G	cg11752769	chr1:207818423	CR1L	-0.67	-5.78	-0.3	1.73e-8	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg26304593	chr6:42947056	PEX6	-0.53	-8.4	-0.42	1.3e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06873352	chr17:61820015	STRADA	0.56	8.57	0.42	3.99e-16	Height;
LUSC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-12.17	-0.55	1.89e-28	Platelet count;
LUSC	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4654899	0.571	rs6692677	chr1:21251717	C/T	cg01072550	chr1:21505969	NA	-0.51	-7.74	-0.39	1.22e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg16743903	chr16:89593216	SPG7	-0.43	-6.44	-0.33	4.05e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg01251360	chr16:68772225	CDH1	-0.27	-6.53	-0.34	2.43e-10	Colorectal cancer;
LUSC	cis	rs13401104	0.796	rs11894118	chr2:237119192	C/A	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.27	0.52	3.49e-25	Menopause (age at onset);
LUSC	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08704250	chr15:31115839	NA	-0.47	-7.06	-0.36	9.84e-12	Huntington's disease progression;
LUSC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	8.4	0.42	1.34e-15	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7589342	0.929	rs1465640	chr2:106439103	C/T	cg16077055	chr2:106428750	NCK2	0.37	7.1	0.36	7.78e-12	Addiction;
LUSC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg14440974	chr22:39074834	NA	-0.38	-6.37	-0.33	6.21e-10	Menopause (age at onset);
LUSC	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg11887960	chr12:57824829	NA	0.58	7.11	0.36	7.27e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg09092052	chr15:45571596	NA	0.45	6.26	0.32	1.18e-9	Glomerular filtration rate;
LUSC	cis	rs1832871	0.683	rs62437360	chr6:158720162	G/A	cg07165851	chr6:158734300	TULP4	0.5	7.66	0.39	2.05e-13	Height;
LUSC	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg19336497	chr11:14380999	RRAS2	-0.43	-7.77	-0.39	9.84e-14	Mitochondrial DNA levels;
LUSC	trans	rs75804782	0.641	rs41264155	chr2:239342096	G/A	cg01134436	chr17:81009848	B3GNTL1	0.66	6.08	0.32	3.31e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg11584989	chr19:19387371	SF4	0.67	7.76	0.39	1.05e-13	Bipolar disorder;
LUSC	cis	rs3099143	0.901	rs1813479	chr15:77168646	T/C	cg21673338	chr15:77095150	SCAPER	0.82	7.79	0.39	8.72e-14	Recalcitrant atopic dermatitis;
LUSC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.63	10.55	0.5	1.17e-22	Blood metabolite levels;
LUSC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.71	12.23	0.56	1.13e-28	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.81	10.73	0.51	2.77e-23	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg12384639	chr17:618140	VPS53	0.33	5.7	0.3	2.61e-8	Prostate cancer;
LUSC	cis	rs73198271	0.562	rs17631052	chr8:8663787	G/A	cg01851573	chr8:8652454	MFHAS1	0.63	8.04	0.4	1.53e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	1.1	17.23	0.69	4.59e-48	Exhaled nitric oxide output;
LUSC	cis	rs4363385	0.818	rs2711	chr1:153005156	C/T	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.45e-8	Inflammatory skin disease;
LUSC	cis	rs9287719	0.649	rs11684537	chr2:10734832	C/T	cg00105475	chr2:10696890	NA	0.35	5.85	0.3	1.18e-8	Prostate cancer;
LUSC	trans	rs1864729	0.748	rs2583509	chr8:98294151	G/A	cg08679828	chr8:102218111	ZNF706	-0.69	-6.06	-0.31	3.77e-9	Estradiol plasma levels (breast cancer);
LUSC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18854424	chr1:2615690	NA	-0.49	-9.76	-0.47	5.92e-20	Ulcerative colitis;
LUSC	cis	rs2625529	0.618	rs6494992	chr15:72420750	G/C	cg16672083	chr15:72433130	SENP8	0.49	8.11	0.41	9.85e-15	Red blood cell count;
LUSC	trans	rs7849782	0.967	rs4743480	chr9:104421888	G/T	cg22914338	chr19:14376960	NA	0.26	6.36	0.33	6.77e-10	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg22467129	chr15:76604101	ETFA	-0.49	-8.0	-0.4	2.04e-14	Blood metabolite levels;
LUSC	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.58	5.67	0.3	3.09e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6939532	0.648	rs9379862	chr6:26370707	T/C	cg09904177	chr6:26538194	HMGN4	-0.48	-6.69	-0.34	9.2e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	13.12	0.58	5.24e-32	Platelet count;
LUSC	cis	rs11969893	0.850	rs9498414	chr6:101322976	C/T	cg12253828	chr6:101329408	ASCC3	1.09	9.89	0.48	2.2e-20	Economic and political preferences (immigration/crime);
LUSC	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg18190219	chr22:46762943	CELSR1	-0.52	-6.0	-0.31	5.08e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-6.85	-0.35	3.62e-11	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.28	0.45	2.15e-18	Prudent dietary pattern;
LUSC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.72	-9.65	-0.47	1.32e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13126279	chr21:47581558	C21orf56	-0.42	-6.14	-0.32	2.3e-9	Testicular germ cell tumor;
LUSC	cis	rs11603020	0.950	rs78364821	chr11:57370742	C/T	cg23127183	chr11:57508653	C11orf31	-0.46	-6.4	-0.33	5.22e-10	Blood protein levels;
LUSC	cis	rs10865541	0.902	rs7593978	chr2:3415544	C/T	cg15807143	chr2:3452624	TTC15	0.33	5.75	0.3	2.02e-8	Obesity-related traits;
LUSC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.11	-0.32	2.85e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.7	0.3	2.64e-8	Menopause (age at onset);
LUSC	cis	rs2324229	0.828	rs1180231	chr6:83948817	G/A	cg08257003	chr6:84140564	ME1	0.28	6.78	0.35	5.51e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7804356	0.953	rs73069539	chr7:26903661	C/T	cg03456212	chr7:26904342	SKAP2	-0.55	-6.27	-0.32	1.14e-9	Type 1 diabetes;
LUSC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-1.07	-19.03	-0.72	3.19e-55	Parkinson's disease;
LUSC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	6.0	0.31	5.19e-9	Personality dimensions;
LUSC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg11843238	chr5:131593191	PDLIM4	0.38	7.0	0.36	1.45e-11	Blood metabolite levels;
LUSC	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg06640241	chr16:89574553	SPG7	0.39	5.77	0.3	1.81e-8	Hemoglobin concentration;
LUSC	trans	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg19676328	chr12:49525230	TUBA1B	-0.52	-7.37	-0.37	1.37e-12	Total cholesterol levels;
LUSC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.59	9.1	0.45	8.43e-18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs2840044	0.534	rs2124246	chr17:33885431	G/A	cg19694781	chr19:47549865	TMEM160	-0.42	-6.73	-0.35	7.62e-11	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg08975724	chr8:8085496	FLJ10661	0.5	7.38	0.37	1.3e-12	Joint mobility (Beighton score);
LUSC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.64	-0.5	5.9e-23	Aortic root size;
LUSC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.98	0.77	7.28e-67	Prudent dietary pattern;
LUSC	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg08601574	chr20:25228251	PYGB	0.39	5.9	0.31	9.14e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg17294928	chr15:75287854	SCAMP5	-0.76	-10.13	-0.48	3.23e-21	Blood trace element (Zn levels);
LUSC	trans	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.6	-10.36	-0.49	5.53e-22	Mean corpuscular volume;
LUSC	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg24692254	chr21:30365293	RNF160	-0.69	-10.64	-0.5	5.98e-23	Pancreatic cancer;
LUSC	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg15501526	chr10:2543763	NA	0.57	10.12	0.48	3.63e-21	Age-related hearing impairment;
LUSC	trans	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg21659725	chr3:3221576	CRBN	0.51	7.9	0.4	4.12e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg07211511	chr3:129823064	LOC729375	-0.59	-8.01	-0.4	1.94e-14	Blood pressure (smoking interaction);
LUSC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.87	0.31	1.07e-8	Menopause (age at onset);
LUSC	cis	rs7589342	0.929	rs1465640	chr2:106439103	C/T	cg14210321	chr2:106509881	NCK2	-0.54	-8.15	-0.41	7.26e-15	Addiction;
LUSC	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.59	-0.46	2.1e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9902453	0.704	rs1972305	chr17:28533880	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	7.22	0.37	3.56e-12	Coffee consumption (cups per day);
LUSC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.72	-0.39	1.4e-13	Aortic root size;
LUSC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.47	-7.77	-0.39	9.61e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.71	0.51	3.24e-23	Menopause (age at onset);
LUSC	trans	rs4942242	0.659	rs1105586	chr13:44232633	C/T	cg19169023	chr15:41853346	TYRO3	0.63	10.45	0.5	2.59e-22	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	6.28	0.32	1.08e-9	Tonsillectomy;
LUSC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.56	11.17	0.52	7.79e-25	Asthma (sex interaction);
LUSC	trans	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg25214090	chr10:38739885	LOC399744	0.5	7.47	0.38	6.93e-13	Corneal astigmatism;
LUSC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg09655341	chr17:79618100	PDE6G	-0.28	-6.53	-0.34	2.47e-10	Eye color traits;
LUSC	cis	rs950881	0.932	rs13408661	chr2:102955082	G/A	cg20060108	chr2:102954350	IL1RL1	0.45	5.9	0.31	8.86e-9	Allergy;
LUSC	cis	rs231513	0.954	rs231497	chr17:41975947	A/G	cg26893861	chr17:41843967	DUSP3	-0.51	-6.1	-0.32	2.93e-9	Cognitive function;
LUSC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21963583	chr11:68658836	MRPL21	0.56	8.35	0.42	1.89e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-8.44	-0.42	9.58e-16	Lymphocyte counts;
LUSC	cis	rs9902453	0.967	rs55744550	chr17:28475729	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	7.95	0.4	2.9e-14	Coffee consumption (cups per day);
LUSC	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg18964960	chr10:1102726	WDR37	-0.67	-6.1	-0.32	2.97e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	13.86	0.6	7.72e-35	Blood protein levels;
LUSC	cis	rs617219	0.889	rs10942887	chr5:78464012	G/T	cg24856658	chr5:78533917	JMY	-0.29	-5.67	-0.3	3.1e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg17264618	chr3:40429014	ENTPD3	0.32	6.81	0.35	4.57e-11	Renal cell carcinoma;
LUSC	cis	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg07460842	chr6:66804631	NA	-0.48	-6.72	-0.35	7.74e-11	Blood trace element (Cu levels);
LUSC	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg12615879	chr12:58013172	SLC26A10	0.28	6.62	0.34	1.4e-10	Multiple sclerosis;
LUSC	cis	rs4665630	0.522	rs114880940	chr2:23930352	G/A	cg08063864	chr2:24346004	PFN4;LOC375190	0.96	8.2	0.41	5.06e-15	Hypertension;
LUSC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg02423579	chr7:2872169	GNA12	-0.44	-6.09	-0.32	3.19e-9	Height;
LUSC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19717773	chr7:2847554	GNA12	-0.38	-5.88	-0.31	1.01e-8	Height;
LUSC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg10729496	chr3:10149963	C3orf24	0.52	6.88	0.35	2.9100000000000002e-11	Alzheimer's disease;
LUSC	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg10523860	chr14:103875565	MARK3	0.38	6.02	0.31	4.67e-9	Body mass index;
LUSC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg15556689	chr8:8085844	FLJ10661	0.69	11.15	0.52	9.5e-25	Joint mobility (Beighton score);
LUSC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.27	-0.62	2.03e-36	Eye color traits;
LUSC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11764359	chr7:65958608	NA	-0.68	-10.89	-0.51	7.48e-24	Aortic root size;
LUSC	cis	rs4622329	0.615	rs7975321	chr12:102288613	C/T	cg23541617	chr12:102225335	GNPTAB	0.26	6.07	0.32	3.51e-9	Systemic lupus erythematosus;
LUSC	cis	rs73129298	0.551	rs6012789	chr20:48601519	T/C	cg25655593	chr20:48599521	SNAI1	0.59	6.36	0.33	6.69e-10	Inflammatory skin disease;
LUSC	cis	rs7809950	1.000	rs2712191	chr7:107182724	C/G	cg23024343	chr7:107201750	COG5	-0.56	-8.82	-0.43	6.64e-17	Coronary artery disease;
LUSC	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg11395062	chr17:14139857	CDRT15	-0.51	-7.9	-0.4	4.15e-14	Temperament;
LUSC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.08	-0.4	1.19e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg05110241	chr16:68378359	PRMT7	-0.85	-9.05	-0.44	1.19e-17	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg06784218	chr1:46089804	CCDC17	-0.45	-8.95	-0.44	2.57e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8179	0.700	rs42039	chr7:92244422	A/G	cg15732164	chr7:92237376	CDK6	0.49	6.79	0.35	5.18e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs9311676	0.632	rs56026131	chr3:58422483	C/G	cg13750441	chr3:58318267	PXK	0.35	6.82	0.35	4.28e-11	Systemic lupus erythematosus;
LUSC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs793571	0.523	rs12439457	chr15:58982390	T/C	cg05156742	chr15:59063176	FAM63B	0.52	7.74	0.39	1.17e-13	Schizophrenia;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg16821394	chr5:141488611	NDFIP1	0.48	6.22	0.32	1.48e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7605827	0.930	rs10201564	chr2:15623608	C/G	cg19274914	chr2:15703543	NA	0.46	8.87	0.44	4.51e-17	Educational attainment (years of education);
LUSC	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg24642439	chr20:33292090	TP53INP2	0.46	6.4	0.33	5.17e-10	Height;
LUSC	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg09835421	chr16:68378352	PRMT7	-0.82	-8.62	-0.43	2.76e-16	Schizophrenia;
LUSC	cis	rs244293	0.965	rs244300	chr17:53239240	T/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.4	-5.79	-0.3	1.65e-8	Menarche (age at onset);
LUSC	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg14092571	chr14:90743983	NA	0.36	5.76	0.3	1.91e-8	Mortality in heart failure;
LUSC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.5	-10.46	-0.5	2.45e-22	Type 2 diabetes;
LUSC	cis	rs7075426	0.669	rs4934211	chr10:88203735	C/T	cg07322936	chr10:88137208	NA	0.46	6.57	0.34	1.88e-10	Migraine without aura;
LUSC	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.88	14.99	0.63	3.21e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg08742575	chr21:47604166	C21orf56	-0.48	-7.36	-0.37	1.42e-12	Testicular germ cell tumor;
LUSC	cis	rs4474465	0.920	rs10793321	chr11:78237566	A/G	cg27205649	chr11:78285834	NARS2	0.52	5.87	0.31	1.05e-8	Alzheimer's disease (survival time);
LUSC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg27494647	chr7:150038898	RARRES2	0.58	8.54	0.42	4.69e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg25566285	chr7:158114605	PTPRN2	-0.39	-7.37	-0.37	1.35e-12	Calcium levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04605084	chr1:91487590	ZNF644	-0.41	-6.21	-0.32	1.53e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2092850	1	rs2092850	chr6:88100419	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-5.9	-0.31	9.15e-9	Itch intensity from mosquito bite;
LUSC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.4	-0.33	5.23e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg25237894	chr2:233734115	C2orf82	-0.35	-6.64	-0.34	1.29e-10	Coronary artery disease;
LUSC	cis	rs7180079	1.000	rs6494477	chr15:64667334	T/C	cg02848875	chr15:64387786	SNX1	0.42	5.84	0.3	1.25e-8	Monocyte count;
LUSC	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.89	15.83	0.65	1.63e-42	Metabolic syndrome;
LUSC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.85	-0.39	5.73e-14	Chronic sinus infection;
LUSC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.49	-0.38	6.04e-13	Schizophrenia;
LUSC	cis	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg05901451	chr6:126070800	HEY2	0.57	8.58	0.43	3.59e-16	Endometrial cancer;
LUSC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.84	-0.44	5.51e-17	Bipolar disorder;
LUSC	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.43	6.41	0.33	4.93e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs834603	0.575	rs940861	chr7:47469429	A/T	cg09696706	chr7:47479511	TNS3	0.32	5.75	0.3	2.01e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs10789491	1.000	rs1545206	chr1:47185082	C/G	cg15501359	chr1:47185051	KIAA0494	0.82	11.28	0.53	3.23e-25	Response to hepatitis C treatment;
LUSC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg07507251	chr3:52567010	NT5DC2	-0.35	-6.86	-0.35	3.27e-11	Bipolar disorder;
LUSC	cis	rs6693567	0.565	rs698921	chr1:150379517	G/A	cg15654264	chr1:150340011	RPRD2	0.44	7.16	0.36	5.07e-12	Migraine;
LUSC	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg21672276	chr3:44754072	ZNF502	-0.36	-5.71	-0.3	2.45e-8	Depressive symptoms;
LUSC	cis	rs4388249	0.651	rs31608	chr5:108999512	A/G	cg17395555	chr5:108820864	NA	0.43	5.74	0.3	2.12e-8	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.32	0.56	5.14e-29	Prudent dietary pattern;
LUSC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg05347473	chr6:146136440	FBXO30	0.59	9.64	0.47	1.41e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs483180	0.512	rs606312	chr1:120222582	G/A	cg19096424	chr1:120255104	PHGDH	0.48	6.46	0.33	3.61e-10	Macular telangiectasia type 2;
LUSC	cis	rs9650315	0.929	rs36076243	chr8:57180599	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.8	0.35	4.85e-11	Height;
LUSC	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg09044154	chr16:88155775	NA	-0.61	-8.03	-0.4	1.69e-14	Menopause (age at onset);
LUSC	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg02023728	chr11:77925099	USP35	0.52	7.27	0.37	2.56e-12	Testicular germ cell tumor;
LUSC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.09	-0.48	4.5e-21	Hemoglobin concentration;
LUSC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06481639	chr22:41940642	POLR3H	-0.47	-5.82	-0.3	1.41e-8	Vitiligo;
LUSC	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.82	-0.39	6.78e-14	Glomerular filtration rate;
LUSC	cis	rs4478137	1.000	rs4478137	chr4:164238385	G/A	cg06758707	chr4:164254230	NPY1R	0.65	10.03	0.48	7.17e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.63	10.18	0.49	2.21e-21	Longevity;
LUSC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg11764359	chr7:65958608	NA	-0.68	-10.32	-0.49	7.66e-22	Aortic root size;
LUSC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.54	0.6	1.33e-33	Cognitive test performance;
LUSC	cis	rs9905704	0.846	rs302878	chr17:56762964	G/A	cg12560992	chr17:57184187	TRIM37	0.58	8.42	0.42	1.15e-15	Testicular germ cell tumor;
LUSC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg19592336	chr6:28129416	ZNF389	0.47	6.38	0.33	5.77e-10	Parkinson's disease;
LUSC	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.7	10.12	0.48	3.71e-21	Corneal astigmatism;
LUSC	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg15556689	chr8:8085844	FLJ10661	0.46	6.53	0.34	2.42e-10	Myopia (pathological);
LUSC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	0.92	15.23	0.64	3.94e-40	Breast cancer;
LUSC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg13319975	chr6:146136371	FBXO30	0.5	7.51	0.38	5.52e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg01881094	chr2:180872142	CWC22	-0.81	-10.49	-0.5	1.85e-22	Schizophrenia;
LUSC	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg25214090	chr10:38739885	LOC399744	0.52	7.78	0.39	8.9e-14	Corneal astigmatism;
LUSC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	8.83	0.43	6.15e-17	Height;
LUSC	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg03929089	chr4:120376271	NA	-1.03	-19.41	-0.73	1.04e-56	Height;
LUSC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg03806693	chr22:41940476	POLR3H	1.0	14.33	0.62	1.24e-36	Vitiligo;
LUSC	cis	rs7177699	0.526	rs7166764	chr15:79123509	T/G	cg00540400	chr15:79124168	NA	0.43	7.51	0.38	5.6e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs68170813	0.652	rs7784906	chr7:107148386	C/T	cg02696742	chr7:106810147	HBP1	-0.64	-8.62	-0.43	2.79e-16	Coronary artery disease;
LUSC	cis	rs7582720	1.000	rs72936872	chr2:203790889	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2625529	0.617	rs8557	chr15:72115733	T/C	cg16672083	chr15:72433130	SENP8	-0.47	-7.62	-0.38	2.7e-13	Red blood cell count;
LUSC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-0.84	-12.06	-0.55	4.68e-28	Breast cancer;
LUSC	cis	rs644148	0.730	rs2686766	chr19:44991595	T/G	cg15540054	chr19:45004280	ZNF180	-0.52	-7.19	-0.37	4.4e-12	Personality dimensions;
LUSC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06544989	chr22:39130855	UNC84B	0.33	5.65	0.3	3.51e-8	Menopause (age at onset);
LUSC	cis	rs35995292	0.926	rs10259755	chr7:38897012	A/C	cg19327137	chr7:38886074	VPS41	0.34	5.67	0.3	3.17e-8	Subjective well-being (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg18681998	chr4:17616180	MED28	0.88	16.94	0.68	7.03e-47	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2230307	0.536	rs2784173	chr1:100639752	A/G	cg24955406	chr1:100503596	HIAT1	-0.58	-6.37	-0.33	6.09e-10	Carotid intima media thickness;
LUSC	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg13390004	chr1:15929781	NA	0.41	6.9	0.35	2.66e-11	Systolic blood pressure;
LUSC	trans	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.48	-0.33	3.26e-10	Morning vs. evening chronotype;
LUSC	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg15704280	chr7:45808275	SEPT13	0.71	6.75	0.35	6.59e-11	Intraocular pressure;
LUSC	cis	rs9303401	0.555	rs8071831	chr17:57292950	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	7.14	0.36	5.99e-12	Cognitive test performance;
LUSC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.73	-0.35	7.19e-11	Alzheimer's disease (late onset);
LUSC	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07080220	chr10:102295463	HIF1AN	-0.58	-7.95	-0.4	2.99e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg22907277	chr7:1156413	C7orf50	0.68	7.26	0.37	2.68e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs909002	0.811	rs11575883	chr1:32085485	G/A	cg01639898	chr1:32083012	HCRTR1	0.27	6.35	0.33	7.1e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	0.95	10.39	0.49	4.15e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg02782426	chr3:40428986	ENTPD3	0.39	7.31	0.37	2.04e-12	Renal cell carcinoma;
LUSC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg03609598	chr5:56110824	MAP3K1	-0.4	-5.68	-0.3	2.94e-8	Initial pursuit acceleration;
LUSC	cis	rs6977660	0.714	rs10950753	chr7:19817302	G/A	cg05791153	chr7:19748676	TWISTNB	0.67	7.1	0.36	7.78e-12	Thyroid stimulating hormone;
LUSC	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg27284194	chr4:1044797	NA	-0.51	-8.12	-0.41	9.27e-15	Recombination rate (males);
LUSC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.65	8.72	0.43	1.35e-16	Reticulocyte fraction of red cells;
LUSC	trans	rs17815608	1.000	rs17815608	chr12:77398721	A/T	cg18631743	chr22:20104954	RANBP1;TRMT2A	-0.6	-7.29	-0.37	2.23e-12	Type 2 diabetes;
LUSC	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg21770322	chr7:97807741	LMTK2	0.47	8.0	0.4	2.04e-14	Breast cancer;
LUSC	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg15704280	chr7:45808275	SEPT13	-0.73	-10.72	-0.51	3.02e-23	Height;
LUSC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg09555818	chr19:45449301	APOC2	0.47	8.56	0.42	4.22e-16	Blood protein levels;
LUSC	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg25024717	chr12:54324583	NA	-0.38	-6.39	-0.33	5.68e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg08017756	chr2:100939284	LONRF2	-0.43	-8.0	-0.4	2.04e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.32	0.37	1.83e-12	Motion sickness;
LUSC	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg17376030	chr22:41985996	PMM1	-0.47	-5.76	-0.3	1.89e-8	Vitiligo;
LUSC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06481639	chr22:41940642	POLR3H	-0.54	-6.26	-0.32	1.17e-9	Vitiligo;
LUSC	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.14	-0.36	5.81e-12	Blood metabolite levels;
LUSC	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg24634471	chr8:143751801	JRK	0.51	7.16	0.36	5.14e-12	Schizophrenia;
LUSC	cis	rs11608355	0.810	rs2217971	chr12:109857666	G/C	cg19025524	chr12:109796872	NA	-0.38	-5.7	-0.3	2.6e-8	Neuroticism;
LUSC	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19748678	chr4:122722346	EXOSC9	-0.48	-6.92	-0.35	2.26e-11	Type 2 diabetes;
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-8.44	-0.42	9.58e-16	Lymphocyte counts;
LUSC	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg14689365	chr7:158441557	NCAPG2	0.47	6.55	0.34	2.12e-10	Height;
LUSC	cis	rs7095944	0.614	rs3824765	chr10:126433570	C/G	cg08799069	chr10:126477246	METTL10	-0.41	-6.35	-0.33	6.97e-10	Asthma;
LUSC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg06454157	chr6:167490870	NA	-0.3	-6.88	-0.35	3e-11	Crohn's disease;
LUSC	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg06627628	chr2:24431161	ITSN2	0.54	7.47	0.38	7.13e-13	Asthma;
LUSC	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.18	-0.41	5.94e-15	Axial length;
LUSC	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.81	0.3	1.49e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg06784218	chr1:46089804	CCDC17	0.55	11.08	0.52	1.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg08975724	chr8:8085496	FLJ10661	0.47	6.73	0.35	7.34e-11	Neuroticism;
LUSC	cis	rs7267979	0.586	rs6050429	chr20:25183058	G/A	cg08601574	chr20:25228251	PYGB	0.44	6.68	0.34	9.8e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg12002119	chr2:101014098	CHST10	0.34	5.71	0.3	2.48e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg00376283	chr12:123451042	ABCB9	0.67	8.52	0.42	5.51e-16	Neutrophil percentage of white cells;
LUSC	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.51	8.6	0.43	3.08e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.81	14.37	0.62	8.78e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs752010	0.838	rs11210505	chr1:42104731	G/C	cg06885757	chr1:42089581	HIVEP3	0.41	8.01	0.4	1.87e-14	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.79	-0.43	8.22e-17	Mood instability;
LUSC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg13206674	chr6:150067644	NUP43	0.54	8.42	0.42	1.15e-15	Lung cancer;
LUSC	cis	rs6977660	0.714	rs2390156	chr7:19786138	A/T	cg07541023	chr7:19748670	TWISTNB	0.67	6.71	0.34	8.19e-11	Thyroid stimulating hormone;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07589166	chr19:12902806	JUNB	-0.45	-6.1	-0.32	2.98e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-5.98	-0.31	5.75e-9	Personality dimensions;
LUSC	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.37	0.49	4.91e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg12419862	chr22:24373484	LOC391322	0.88	14.47	0.62	3.55e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg23630131	chr7:65973040	NA	0.2	5.72	0.3	2.4e-8	Aortic root size;
LUSC	cis	rs7927771	0.800	rs11039200	chr11:47379646	A/C	cg18512352	chr11:47633146	NA	-0.45	-8.59	-0.43	3.47e-16	Subjective well-being;
LUSC	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg24375607	chr4:120327624	NA	0.76	11.48	0.53	6.02e-26	Corneal astigmatism;
LUSC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg00810483	chr4:3375144	RGS12	0.34	6.67	0.34	1.07e-10	Serum sulfate level;
LUSC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg18225595	chr11:63971243	STIP1	0.49	6.1	0.32	2.88e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs7084402	1.000	rs1427204	chr10:60267640	A/C	cg07615347	chr10:60278583	BICC1	-0.36	-5.85	-0.3	1.18e-8	Refractive error;
LUSC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg23262073	chr20:60523788	NA	-0.42	-6.07	-0.32	3.45e-9	Body mass index;
LUSC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.14e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	1.02	17.78	0.7	3.23e-50	Parkinson's disease;
LUSC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.51	7.23	0.37	3.38e-12	Gut microbiome composition (summer);
LUSC	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg14458575	chr2:238380390	NA	0.71	12.11	0.55	3.02e-28	Prostate cancer;
LUSC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23158103	chr7:148848205	ZNF398	-0.49	-8.0	-0.4	2.01e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg13939156	chr17:80058883	NA	-0.34	-6.82	-0.35	4.37e-11	Life satisfaction;
LUSC	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg04362960	chr10:104952993	NT5C2	0.61	9.55	0.46	2.79e-19	Arsenic metabolism;
LUSC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18099408	chr3:52552593	STAB1	-0.41	-6.96	-0.36	1.84e-11	Bipolar disorder;
LUSC	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg26195577	chr20:24973756	C20orf3	1.11	18.48	0.71	5e-53	Blood protein levels;
LUSC	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg22089800	chr15:90895588	ZNF774	0.59	9.22	0.45	3.56e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.3	-0.37	2.1e-12	Bipolar disorder;
LUSC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg20821713	chr7:1055600	C7orf50	-0.5	-6.62	-0.34	1.46e-10	Bronchopulmonary dysplasia;
LUSC	trans	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg19694781	chr19:47549865	TMEM160	0.59	9.55	0.46	2.96e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	11.48	0.53	5.92e-26	Coronary artery disease;
LUSC	trans	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg25214090	chr10:38739885	LOC399744	0.46	6.95	0.36	1.94e-11	Corneal astigmatism;
LUSC	cis	rs4380275	0.965	rs4375894	chr2:772567	G/C	cg21665850	chr2:731073	NA	0.42	6.84	0.35	3.75e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	cis	rs672059	1.000	rs672059	chr1:183162539	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.1	0.41	1.02e-14	Hypertriglyceridemia;
LUSC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg13072238	chr3:49761600	GMPPB	-0.36	-5.81	-0.3	1.43e-8	Body mass index;
LUSC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.6	-5.66	-0.3	3.24e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.73	14.19	0.61	4.47e-36	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	10.28	0.49	1.01e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg02493740	chr2:85810744	VAMP5	0.35	6.4	0.33	5.41e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg23034840	chr1:205782522	SLC41A1	0.61	8.53	0.42	5e-16	Menarche (age at onset);
LUSC	cis	rs7527798	1.000	rs12738067	chr1:207858527	G/C	cg09232269	chr1:207846808	CR1L	-0.32	-5.66	-0.3	3.33e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg07636037	chr3:49044803	WDR6	0.57	6.12	0.32	2.62e-9	Menarche (age at onset);
LUSC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.15	-0.32	2.18e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs72960926	0.744	rs72967299	chr6:75034041	C/T	cg03266952	chr6:74778945	NA	-0.83	-7.04	-0.36	1.12e-11	Metabolite levels (MHPG);
LUSC	cis	rs472402	0.560	rs10037161	chr5:6624294	C/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.41	-6.1	-0.32	2.9e-9	Response to amphetamines;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22448930	chr20:62205785	PRIC285	-0.45	-6.58	-0.34	1.84e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg05738196	chr6:26577821	NA	0.79	14.91	0.63	6.82e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs4908769	0.624	rs2708633	chr1:8439625	C/A	cg00546117	chr1:8445545	RERE	0.29	5.7	0.3	2.65e-8	Allergy;
LUSC	cis	rs6700896	0.500	rs4655555	chr1:66080269	T/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.35	0.33	7.09e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg02475777	chr4:1388615	CRIPAK	0.4	5.99	0.31	5.49e-9	Obesity-related traits;
LUSC	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg04450456	chr4:17643702	FAM184B	0.38	6.41	0.33	5.02e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.68	10.6	0.5	8.17e-23	Lymphocyte counts;
LUSC	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg11502198	chr6:26597334	ABT1	-0.48	-6.72	-0.35	7.63e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg01579765	chr21:45077557	HSF2BP	-0.51	-10.96	-0.51	4.46e-24	Mean corpuscular volume;
LUSC	cis	rs10203711	0.933	rs11693286	chr2:239585278	A/T	cg14580085	chr2:239553406	NA	0.39	6.47	0.33	3.56e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg19266014	chr7:2183958	MAD1L1	-0.35	-5.84	-0.3	1.23e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.11	-0.32	2.7e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9942416	0.559	rs7734618	chr5:75033762	A/T	cg19683494	chr5:74908142	NA	-0.43	-5.85	-0.31	1.15e-8	Age-related disease endophenotypes;
LUSC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg13395646	chr4:1353034	KIAA1530	-0.78	-13.22	-0.59	2.24e-32	Obesity-related traits;
LUSC	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-8.8	-0.43	7.7e-17	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs1858037	0.867	rs2118305	chr2:65605220	A/C	cg08085232	chr2:65598271	SPRED2	-0.42	-6.21	-0.32	1.57e-9	Rheumatoid arthritis;
LUSC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg12463550	chr7:65579703	CRCP	-0.56	-8.33	-0.41	2.14e-15	Aortic root size;
LUSC	trans	rs1478897	0.898	rs2248696	chr8:11393803	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-6.26	-0.32	1.19e-9	Systemic lupus erythematosus;
LUSC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs17824933	0.778	rs17752099	chr11:60760794	G/C	cg16817237	chr11:60793675	NA	0.41	6.42	0.33	4.78e-10	Multiple sclerosis;
LUSC	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg08999081	chr20:33150536	PIGU	-0.37	-6.77	-0.35	5.86e-11	Height;
LUSC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.25	-5.65	-0.3	3.39e-8	Electroencephalogram traits;
LUSC	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg11645453	chr3:52864694	ITIH4	0.59	14.12	0.61	8.31e-36	Schizophrenia;
LUSC	cis	rs12220238	1.000	rs10824128	chr10:76007903	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.3	0.37	2.18e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs1784581	1.000	rs1618170	chr6:162400337	C/T	cg17173639	chr6:162384350	PARK2	-0.81	-14.8	-0.63	1.77e-38	Itch intensity from mosquito bite;
LUSC	cis	rs4478858	0.698	rs7543348	chr1:31804805	A/C	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	trans	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg25214090	chr10:38739885	LOC399744	0.43	6.17	0.32	1.94e-9	Corneal astigmatism;
LUSC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg26061582	chr7:22766209	IL6	0.51	7.42	0.38	9.69e-13	Lung cancer;
LUSC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.77	7.4	0.38	1.13e-12	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21984481	chr17:79567631	NPLOC4	0.68	14.27	0.62	2.03e-36	Eye color traits;
LUSC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg15242686	chr22:24348715	GSTTP1	0.39	5.83	0.3	1.33e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg12091567	chr17:66097778	LOC651250	-0.76	-9.59	-0.46	2.18e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg00376283	chr12:123451042	ABCB9	0.65	7.51	0.38	5.51e-13	Neutrophil percentage of white cells;
LUSC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg11812906	chr14:75593930	NEK9	0.68	11.93	0.55	1.47e-27	Height;
LUSC	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg23093090	chr10:104574429	C10orf26	-0.35	-6.51	-0.34	2.77e-10	Arsenic metabolism;
LUSC	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg09835421	chr16:68378352	PRMT7	-0.52	-5.77	-0.3	1.8e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg02551604	chr5:131831745	NA	-0.4	-6.25	-0.32	1.26e-9	Asthma (sex interaction);
LUSC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.88	-0.81	4.68e-78	Height;
LUSC	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg22800045	chr5:56110881	MAP3K1	0.44	6.04	0.31	4.08e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg09904177	chr6:26538194	HMGN4	-0.76	-6.23	-0.32	1.43e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg14664628	chr15:75095509	CSK	-1.0	-16.98	-0.68	4.82e-47	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs9398803	0.865	rs4418209	chr6:126819699	T/G	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	1.97e-9	Male-pattern baldness;
LUSC	cis	rs28830936	0.966	rs2303518	chr15:42109975	T/G	cg17847044	chr15:42102381	MAPKBP1	-0.27	-6.0	-0.31	5.05e-9	Diastolic blood pressure;
LUSC	cis	rs80130819	0.515	rs1793912	chr12:48387052	A/C	cg05342945	chr12:48394962	COL2A1	-0.44	-5.71	-0.3	2.54e-8	Prostate cancer;
LUSC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.19e-30	Aortic root size;
LUSC	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg04545296	chr12:48745243	ZNF641	-0.33	-6.23	-0.32	1.44e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg26061582	chr7:22766209	IL6	0.48	6.91	0.35	2.51e-11	Lung cancer;
LUSC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.59	-8.54	-0.42	4.69e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs965604	1.000	rs11637656	chr15:78751961	C/T	cg18825076	chr15:78729989	IREB2	-0.43	-6.9	-0.35	2.64e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.45	-0.38	8e-13	Retinal vascular caliber;
LUSC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg03806693	chr22:41940476	POLR3H	0.99	13.85	0.6	9.09e-35	Vitiligo;
LUSC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg05872129	chr22:39784769	NA	-0.6	-11.15	-0.52	9.57e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.69	-12.08	-0.55	3.97e-28	Dental caries;
LUSC	cis	rs10170310	1.000	rs12691947	chr2:139264471	A/G	cg03782584	chr2:139258740	SPOPL	0.33	5.86	0.31	1.12e-8	Response to antipsychotic treatment;
LUSC	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg00376283	chr12:123451042	ABCB9	0.65	7.59	0.38	3.19e-13	Neutrophil percentage of white cells;
LUSC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg07741184	chr6:167504864	NA	0.4	7.2	0.37	3.96e-12	Crohn's disease;
LUSC	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg14634687	chr17:47094252	IGF2BP1	0.31	6.63	0.34	1.36e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs10979	0.928	rs9496676	chr6:143895610	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-12.0	-0.55	7.59e-28	Hypospadias;
LUSC	trans	rs57046232	0.552	rs6139968	chr20:6319606	A/C	cg21095983	chr6:86352623	SYNCRIP	0.5	7.35	0.37	1.49e-12	Colorectal cancer;
LUSC	cis	rs9318086	0.712	rs9318100	chr13:24442482	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.4	-6.05	-0.31	3.84e-9	Myopia (pathological);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11078358	chr6:71377548	SMAP1	0.69	5.96	0.31	6.29e-9	Cognitive performance;
LUSC	cis	rs2279817	0.780	rs71644065	chr1:18001669	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.49	-5.99	-0.31	5.49e-9	Neuroticism;
LUSC	cis	rs9309473	1.000	rs62151652	chr2:73700131	A/C	cg20560298	chr2:73613845	ALMS1	-0.44	-6.35	-0.33	6.9e-10	Metabolite levels;
LUSC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.74	-11.15	-0.52	9.24e-25	Menarche (age at onset);
LUSC	cis	rs909341	0.909	rs914559	chr20:62369300	C/G	cg09650180	chr20:62225654	GMEB2	0.46	5.85	0.3	1.18e-8	Atopic dermatitis;
LUSC	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.96	-0.4	2.72e-14	Glomerular filtration rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02243437	chr10:61469599	SLC16A9	0.4	5.97	0.31	6.06e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28647808	0.881	rs71483208	chr9:136258824	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	trans	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.11	-0.32	2.77e-9	Depression;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.76	17.33	0.69	1.95e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg16989086	chr20:62203971	PRIC285	0.47	6.64	0.34	1.28e-10	Glioblastoma;
LUSC	cis	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg06521331	chr12:34319734	NA	-0.41	-6.33	-0.33	8.04e-10	Morning vs. evening chronotype;
LUSC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.96	12.68	0.57	2.39e-30	Menarche (age at onset);
LUSC	cis	rs733592	0.560	rs61918773	chr12:48421774	G/A	cg24011408	chr12:48396354	COL2A1	-0.5	-8.01	-0.4	1.91e-14	Plateletcrit;
LUSC	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg24631222	chr15:78858424	CHRNA5	-0.67	-8.94	-0.44	2.76e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs1864729	1.000	rs2635162	chr8:98283629	C/T	cg08679828	chr8:102218111	ZNF706	-0.85	-8.0	-0.4	2.04e-14	Estradiol plasma levels (breast cancer);
LUSC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06634786	chr22:41940651	POLR3H	0.52	6.18	0.32	1.91e-9	Vitiligo;
LUSC	cis	rs11642862	1.000	rs113454775	chr16:30809534	A/G	cg02466173	chr16:30829666	NA	-0.69	-7.33	-0.37	1.8e-12	Tonsillectomy;
LUSC	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg16070123	chr10:51489643	NA	-0.51	-8.16	-0.41	6.7e-15	Prostate-specific antigen levels;
LUSC	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg13813247	chr22:41461852	NA	-0.36	-6.52	-0.34	2.53e-10	Neuroticism;
LUSC	cis	rs1028488	0.508	rs6456197	chr6:170620089	G/A	cg20370364	chr6:170703943	FAM120B	-0.51	-7.8	-0.39	7.94e-14	Interferon alpha levels in systemic lupus erythematosus;
LUSC	cis	rs6460942	0.643	rs7780093	chr7:12233661	C/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.09	-0.32	3.08e-9	Coronary artery disease;
LUSC	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg14631576	chr9:95140430	CENPP	-0.33	-5.93	-0.31	7.77e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg13685833	chr1:53393034	SCP2	0.4	6.1	0.32	2.93e-9	Monocyte count;
LUSC	cis	rs9303542	0.694	rs9906950	chr17:46577167	A/G	cg09704116	chr17:46666958	LOC404266	0.31	5.95	0.31	6.69e-9	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg18758796	chr5:131593413	PDLIM4	0.39	6.6	0.34	1.57e-10	Breast cancer;
LUSC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.91	0.4	3.87e-14	Bipolar disorder;
LUSC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	0.84	11.37	0.53	1.59e-25	Corneal structure;
LUSC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg13531842	chr10:38383804	ZNF37A	-0.42	-6.49	-0.33	3.19e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg23791538	chr6:167370224	RNASET2	0.4	6.4	0.33	5.15e-10	Crohn's disease;
LUSC	cis	rs295140	1.000	rs12614621	chr2:201171207	G/C	cg04283868	chr2:201171347	SPATS2L	0.44	6.63	0.34	1.36e-10	QT interval;
LUSC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg21782813	chr7:2030301	MAD1L1	0.34	5.69	0.3	2.85e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9815354	0.951	rs17063653	chr3:41863817	A/G	cg03022575	chr3:42003672	ULK4	0.58	6.52	0.34	2.6e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg06640241	chr16:89574553	SPG7	0.9	15.94	0.66	5.93e-43	Multiple myeloma (IgH translocation);
LUSC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg20607287	chr7:12443886	VWDE	0.58	7.01	0.36	1.32e-11	Coronary artery disease;
LUSC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg10729496	chr3:10149963	C3orf24	0.54	7.21	0.37	3.76e-12	Alzheimer's disease;
LUSC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-6.77	-0.35	5.81e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	5.84	0.3	1.23e-8	Breast cancer;
LUSC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg14440974	chr22:39074834	NA	-0.38	-6.28	-0.33	1.04e-9	Menopause (age at onset);
LUSC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg00555438	chr3:195578280	NA	-0.35	-5.86	-0.31	1.14e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg00784671	chr22:46762841	CELSR1	-0.45	-6.18	-0.32	1.89e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-9.53	-0.46	3.37e-19	Monocyte count;
LUSC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.39	0.56	3.01e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	9.16	0.45	5.27e-18	Bipolar disorder;
LUSC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg07507251	chr3:52567010	NT5DC2	0.34	6.54	0.34	2.35e-10	Bipolar disorder;
LUSC	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg26384229	chr12:38710491	ALG10B	0.5	7.23	0.37	3.24e-12	Morning vs. evening chronotype;
LUSC	cis	rs7674212	0.581	rs10516496	chr4:103942165	C/T	cg16532752	chr4:104119610	CENPE	-0.43	-5.83	-0.3	1.33e-8	Type 2 diabetes;
LUSC	cis	rs9341808	0.558	rs2490234	chr6:80816966	G/C	cg08355045	chr6:80787529	NA	0.48	8.21	0.41	5.05e-15	Sitting height ratio;
LUSC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg05872129	chr22:39784769	NA	-0.6	-11.15	-0.52	9.57e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg05025164	chr4:1340916	KIAA1530	0.42	6.38	0.33	6.07e-10	Obesity-related traits;
LUSC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg21724239	chr8:58056113	NA	0.59	7.11	0.36	6.93e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2303282	0.716	rs8059717	chr16:56465425	C/T	cg00500540	chr16:56394104	NA	-0.43	-7.35	-0.37	1.52e-12	Breast cancer;
LUSC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.82e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.7	-0.3	2.59e-8	Bipolar disorder;
LUSC	cis	rs6692729	0.901	rs1295643	chr1:227071364	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.51	-7.32	-0.37	1.91e-12	Electrodermal activity;
LUSC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg23791538	chr6:167370224	RNASET2	-0.41	-6.47	-0.33	3.42e-10	Crohn's disease;
LUSC	trans	rs12406019	0.548	rs11162415	chr1:78612934	G/A	cg20826526	chr3:156266748	SSR3	-0.45	-6.77	-0.35	5.96e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg21709803	chr11:61594965	FADS2	-0.4	-5.8	-0.3	1.57e-8	Neutrophil count;Sum basophil neutrophil counts;
LUSC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg01017244	chr2:74357527	NA	-0.65	-12.09	-0.55	3.56e-28	Gestational age at birth (maternal effect);
LUSC	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.75	-0.39	1.13e-13	Neuroticism;
LUSC	cis	rs10792830	1.000	rs7114331	chr11:85839719	G/A	cg07180834	chr11:85838833	NA	-0.3	-5.69	-0.3	2.82e-8	Psychosis and Alzheimer's disease;
LUSC	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg22674798	chr1:3096360	PRDM16	0.31	7.15	0.36	5.64e-12	Migraine;
LUSC	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg17366294	chr4:99064904	C4orf37	0.57	10.08	0.48	5.06e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.01	22.39	0.77	1.93e-68	Colorectal cancer;
LUSC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.62	-9.92	-0.48	1.72e-20	Longevity;Endometriosis;
LUSC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21963583	chr11:68658836	MRPL21	0.55	8.28	0.41	2.98e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12940923	1.000	rs34861306	chr17:56377187	G/A	cg19466818	chr17:56409534	MIR142	-0.38	-6.51	-0.34	2.71e-10	Circulating myeloperoxidase levels (plasma);
LUSC	trans	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	2.03e-12	Bone mineral density;
LUSC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00149659	chr3:10157352	C3orf10	-1.06	-14.92	-0.63	6.03e-39	Alzheimer's disease;
LUSC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg00945038	chr17:61921165	SMARCD2	-0.46	-8.15	-0.41	7.59e-15	Prudent dietary pattern;
LUSC	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg23241863	chr10:102295624	HIF1AN	0.48	5.74	0.3	2.18e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg03647239	chr10:116582469	FAM160B1	0.44	7.15	0.36	5.58e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg03465714	chr1:152285911	FLG	-0.42	-5.85	-0.3	1.19e-8	Atopic dermatitis;
LUSC	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg17764715	chr19:33622953	WDR88	0.59	8.88	0.44	4.04e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.8	-0.81	9.79e-78	Height;
LUSC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	6.42	0.33	4.61e-10	Tonsillectomy;
LUSC	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg18755752	chr8:142205143	DENND3	0.53	7.31	0.37	2.05e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg00339695	chr16:24857497	SLC5A11	-0.41	-7.17	-0.37	4.76e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.46	7.41	0.38	1.07e-12	Uric acid clearance;
LUSC	cis	rs12997796	0.556	rs13004867	chr2:86982504	C/G	cg25203885	chr2:87302643	LOC285074	-0.84	-8.58	-0.42	3.67e-16	Schizophrenia;
LUSC	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.45	-7.17	-0.37	4.89e-12	IgG glycosylation;
LUSC	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg09975044	chr14:104007538	NA	0.36	5.67	0.3	3.06e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg04827223	chr11:72435913	ARAP1	-0.7	-8.78	-0.43	8.88e-17	Type 2 diabetes;
LUSC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg05368731	chr17:41323189	NBR1	0.86	14.33	0.62	1.21e-36	Menopause (age at onset);
LUSC	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.92	-0.44	3.04e-17	Axial length;
LUSC	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.2e-13	Corneal astigmatism;
LUSC	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg23840854	chr1:161414152	NA	-0.9	-11.13	-0.52	1.11e-24	Rheumatoid arthritis;
LUSC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg04518342	chr5:131593106	PDLIM4	0.46	8.41	0.42	1.19e-15	Breast cancer;
LUSC	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg21385522	chr1:16154831	NA	-0.98	-18.46	-0.71	6.21e-53	Dilated cardiomyopathy;
LUSC	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.64	-0.47	1.44e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg01475377	chr6:109611718	NA	-0.43	-7.85	-0.39	5.56e-14	Reticulocyte fraction of red cells;
LUSC	trans	rs7939886	0.920	rs61742348	chr11:55905078	C/T	cg15704280	chr7:45808275	SEPT13	0.83	6.64	0.34	1.27e-10	Myopia (pathological);
LUSC	cis	rs231513	0.906	rs11657681	chr17:42005363	G/A	cg26893861	chr17:41843967	DUSP3	0.56	5.76	0.3	1.91e-8	Cognitive function;
LUSC	cis	rs2067615	0.579	rs4964489	chr12:107171808	A/G	cg15890332	chr12:107067104	RFX4	0.34	6.2	0.32	1.66e-9	Heart rate;
LUSC	cis	rs1358748	0.522	rs11208997	chr1:67560956	C/T	cg02640540	chr1:67518911	SLC35D1	0.66	6.61	0.34	1.5e-10	Tuberculosis;
LUSC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08219700	chr8:58056026	NA	0.68	7.92	0.4	3.63e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg25173405	chr17:45401733	C17orf57	0.39	6.19	0.32	1.74e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg03351412	chr1:154909251	PMVK	0.5	7.65	0.39	2.2e-13	Prostate cancer;
LUSC	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.32	-0.41	2.26e-15	Body mass index;
LUSC	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-1.14	-18.19	-0.71	7.14e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09409496	chr21:38738374	DYRK1A	-0.55	-7.16	-0.36	5.21e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg20203395	chr5:56204925	C5orf35	-0.72	-9.9	-0.48	1.96e-20	Initial pursuit acceleration;
LUSC	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg09764611	chr12:132620959	NA	-0.57	-8.28	-0.41	2.97e-15	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs500891	0.693	rs1170497	chr6:83987234	C/T	cg08257003	chr6:84140564	ME1	0.33	7.29	0.37	2.25e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs77741769	0.571	rs35905305	chr12:121328082	T/G	cg02419362	chr12:121203948	SPPL3	0.46	8.57	0.42	4.01e-16	Mean corpuscular volume;
LUSC	cis	rs7215564	0.818	rs901063	chr17:78595696	A/T	cg23238734	chr17:78661607	RPTOR	-0.47	-6.02	-0.31	4.69e-9	Myopia (pathological);
LUSC	cis	rs4704187	0.595	rs6859176	chr5:74379425	T/C	cg03227963	chr5:74354835	NA	0.31	6.73	0.35	7.4e-11	Response to amphetamines;
LUSC	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg07395648	chr5:131743802	NA	0.43	6.84	0.35	3.84e-11	Breast cancer;Mosquito bite size;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg14071762	chr20:61904060	ARFGAP1	0.68	5.94	0.31	7.03e-9	Cognitive performance;
LUSC	cis	rs1080500	1.000	rs1080500	chr3:53175017	C/T	cg14092988	chr3:52407081	DNAH1	0.32	5.91	0.31	8.26e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.48	-6.36	-0.33	6.48e-10	Schizophrenia;
LUSC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg03886242	chr7:26192032	NFE2L3	-0.42	-6.66	-0.34	1.1e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg14416269	chr4:6271139	WFS1	0.54	11.38	0.53	1.35e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7178572	0.568	rs12909924	chr15:77551445	T/G	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	trans	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg07393940	chr7:158741817	NA	0.35	6.36	0.33	6.65e-10	Life satisfaction;
LUSC	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg02423579	chr7:2872169	GNA12	-0.37	-5.73	-0.3	2.21e-8	Height;
LUSC	cis	rs4853525	0.923	rs7578618	chr2:191733357	A/T	cg11845111	chr2:191398756	TMEM194B	-0.41	-6.05	-0.31	3.93e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg21231944	chr12:82153410	PPFIA2	-0.39	-6.2	-0.32	1.7e-9	Resting heart rate;
LUSC	cis	rs4561483	0.583	rs33636	chr16:11990323	C/G	cg08843971	chr16:11963173	GSPT1	-0.41	-6.27	-0.32	1.12e-9	Testicular germ cell tumor;
LUSC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	0.94	13.56	0.6	1.12e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg23711669	chr6:146136114	FBXO30	0.82	14.11	0.61	9.06e-36	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6076065	0.676	rs6083085	chr20:23336119	C/T	cg11657817	chr20:23433608	CST11	-0.43	-8.11	-0.41	1e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs10992471	0.603	rs11794346	chr9:95247288	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.72	-0.39	1.36e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.14	-0.45	6.37e-18	Monocyte percentage of white cells;
LUSC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.13	15.93	0.66	6.52e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg08949621	chr15:42265044	EHD4	0.51	6.36	0.33	6.8e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-6.04	-0.31	4.14e-9	Obesity-related traits;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.4	6.11	0.32	2.83e-9	Longevity;Endometriosis;
LUSC	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg17127132	chr2:85788382	GGCX	0.43	6.13	0.32	2.42e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7264396	0.887	rs10359	chr20:34099789	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.54	-0.34	2.28e-10	Total cholesterol levels;
LUSC	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg22117172	chr7:91764530	CYP51A1	0.31	5.7	0.3	2.7e-8	Breast cancer;
LUSC	cis	rs11608355	0.545	rs11615336	chr12:109914802	C/A	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs7681440	0.630	rs356195	chr4:90683168	T/C	cg06632027	chr4:90757378	SNCA	0.38	5.69	0.3	2.71e-8	Dementia with Lewy bodies;
LUSC	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg15133208	chr4:90757351	SNCA	-0.54	-8.4	-0.42	1.27e-15	Neuroticism;
LUSC	cis	rs17001868	0.568	rs909669	chr22:40742417	C/T	cg07138101	chr22:40742427	ADSL	0.61	7.31	0.37	2.03e-12	Mammographic density (dense area);
LUSC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg01973587	chr1:228161476	NA	0.46	8.19	0.41	5.58e-15	Diastolic blood pressure;
LUSC	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.02	-21.31	-0.76	3.14e-64	Ulcerative colitis;
LUSC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg15352829	chr14:105391018	PLD4	-0.42	-8.9	-0.44	3.73e-17	Rheumatoid arthritis;
LUSC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-0.84	-10.26	-0.49	1.19e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg18681998	chr4:17616180	MED28	-0.85	-14.96	-0.63	4.39e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.55	9.59	0.46	2.09e-19	Osteoporosis;
LUSC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg03526776	chr6:41159608	TREML2	0.33	6.12	0.32	2.67e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-11.77	-0.54	5.29e-27	Systemic lupus erythematosus;
LUSC	cis	rs12760731	0.565	rs12028024	chr1:178087423	G/T	cg00404053	chr1:178313656	RASAL2	0.69	6.75	0.35	6.64e-11	Obesity-related traits;
LUSC	cis	rs859767	0.679	rs1104801	chr2:135436601	G/A	cg12500956	chr2:135428796	TMEM163	-0.28	-6.45	-0.33	3.96e-10	Neuroticism;
LUSC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	0.78	13.38	0.59	5.42e-33	Cognitive function;
LUSC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg05340658	chr4:99064831	C4orf37	0.63	9.98	0.48	1.09e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.45	0.33	3.89e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11166629	1.000	rs6981735	chr8:135635730	T/C	cg27224718	chr8:135614730	ZFAT	0.67	11.32	0.53	2.38e-25	Smoking quantity;
LUSC	cis	rs2742417	1.000	rs1969624	chr3:45734818	C/T	cg09608765	chr3:45636137	LIMD1	0.34	6.68	0.34	9.78e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg05110241	chr16:68378359	PRMT7	-0.64	-6.94	-0.36	1.99e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	0.8	14.27	0.62	2.18e-36	Cognitive function;
LUSC	cis	rs9513627	0.833	rs73556129	chr13:100113167	C/T	cg25919922	chr13:100150906	NA	-0.77	-6.69	-0.34	9.2e-11	Obesity-related traits;
LUSC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg14092988	chr3:52407081	DNAH1	0.31	6.17	0.32	2e-9	Bipolar disorder;
LUSC	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg23422044	chr7:1970798	MAD1L1	-0.65	-7.31	-0.37	2.04e-12	Bipolar disorder;
LUSC	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg11693508	chr17:37793320	STARD3	0.65	7.91	0.4	3.9e-14	Bipolar disorder;
LUSC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-9.83	-0.47	3.34e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.67	-12.09	-0.55	3.73e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg03233332	chr7:66118400	NA	0.45	6.39	0.33	5.58e-10	Aortic root size;
LUSC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.96	0.36	1.86e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs11785693	0.862	rs11774126	chr8:4979583	A/C	cg26367366	chr8:4980734	NA	0.79	9.47	0.46	5.27e-19	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs7572644	0.766	rs1911127	chr2:28279693	G/A	cg27432699	chr2:27873401	GPN1	-0.54	-6.86	-0.35	3.44e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-10.4	-0.49	3.84e-22	Body mass index;
LUSC	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.54	-9.01	-0.44	1.68e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.68	-0.34	1.01e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12620999	0.941	rs62183343	chr2:237979163	T/C	cg23555395	chr2:238036564	NA	0.45	7.87	0.4	5.05e-14	Systemic lupus erythematosus;
LUSC	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.76e-12	Type 2 diabetes;
LUSC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.43	-0.67	7.04e-45	Monocyte count;
LUSC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.44e-12	Motion sickness;
LUSC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	10.05	0.48	6.3e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-8.59	-0.43	3.46e-16	Morning vs. evening chronotype;
LUSC	trans	rs72674100	1.000	rs72882343	chr4:97993924	G/A	cg09670535	chr1:18959427	PAX7	-0.61	-6.23	-0.32	1.41e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9341835	0.593	rs9449297	chr6:64164249	T/C	cg03326410	chr6:64151739	NA	-0.36	-5.8	-0.3	1.53e-8	Schizophrenia;
LUSC	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg16850897	chr7:100343110	ZAN	-0.47	-5.77	-0.3	1.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19717773	chr7:2847554	GNA12	0.37	5.91	0.31	8.47e-9	Height;
LUSC	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	0.81	9.89	0.48	2.19e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs3824867	0.920	rs4752836	chr11:47465095	T/C	cg20307385	chr11:47447363	PSMC3	0.64	9.48	0.46	4.83e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.67	-0.47	1.19e-19	Multiple sclerosis;
LUSC	cis	rs7712401	0.601	rs30072	chr5:122292220	C/A	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg09796270	chr17:17721594	SREBF1	0.33	5.66	0.3	3.25e-8	Total body bone mineral density;
LUSC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg27494647	chr7:150038898	RARRES2	0.59	8.75	0.43	1.03e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.72	9.15	0.45	5.67e-18	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg18681998	chr4:17616180	MED28	0.85	15.84	0.65	1.54e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg03676636	chr4:99064102	C4orf37	0.36	7.99	0.4	2.15e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.62	8.19	0.41	5.57e-15	Gut microbiome composition (summer);
LUSC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.73	-0.3	2.2e-8	Breast cancer;
LUSC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-6.28	-0.33	1.03e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3755132	0.866	rs6755261	chr2:15761783	T/G	cg12888861	chr2:15731646	DDX1	0.51	7.15	0.36	5.42e-12	Wilms tumor;
LUSC	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-7.05	-0.36	1.04e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	1.0	20.94	0.75	8.61e-63	Menarche (age at onset);
LUSC	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg26195577	chr20:24973756	C20orf3	1.14	18.86	0.72	1.6e-54	Blood protein levels;
LUSC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-0.84	-16.67	-0.67	7.72e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg13770153	chr20:60521292	NA	-1.03	-15.91	-0.66	7.98e-43	Obesity-related traits;
LUSC	cis	rs138341189	1	rs138341189	chr11:68224411	GATTGTGCCAAT/G	cg20283391	chr11:68216788	NA	-0.62	-5.9	-0.31	8.9e-9	Monobrow;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23563507	chr2:44001149	DYNC2LI1	-0.43	-6.57	-0.34	1.92e-10	Electrocardiographic conduction measures;
LUSC	cis	rs16910800	1.000	rs2449439	chr11:23200798	C/T	cg20040320	chr11:23191996	NA	0.44	6.52	0.34	2.58e-10	Cancer;
LUSC	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg11901034	chr3:128598214	ACAD9	0.43	6.83	0.35	3.97e-11	IgG glycosylation;
LUSC	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.51	-0.38	5.52e-13	Retinal vascular caliber;
LUSC	cis	rs9888739	1.000	rs36001237	chr16:31318257	A/T	cg15817542	chr16:31343056	ITGAM	-0.51	-6.13	-0.32	2.49e-9	Systemic lupus erythematosus;
LUSC	cis	rs4704187	0.687	rs10050948	chr5:74484275	C/T	cg03227963	chr5:74354835	NA	0.31	6.65	0.34	1.2e-10	Response to amphetamines;
LUSC	cis	rs11997175	0.624	rs10435522	chr8:33698608	G/A	ch.8.33884649F	chr8:33765107	NA	0.42	5.91	0.31	8.61e-9	Body mass index;
LUSC	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg12863693	chr15:85201151	NMB	0.41	8.58	0.42	3.65e-16	Schizophrenia;
LUSC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg08499158	chr17:42289980	UBTF	-0.5	-8.46	-0.42	8.61e-16	Total body bone mineral density;
LUSC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg15147215	chr3:52552868	STAB1	-0.31	-6.13	-0.32	2.47e-9	Bipolar disorder;
LUSC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.69	0.34	9.58e-11	Lung cancer;
LUSC	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg14809332	chr8:144654887	C8orf73	0.54	6.51	0.34	2.83e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs10992471	0.603	rs10992342	chr9:95212068	C/T	cg14631576	chr9:95140430	CENPP	-0.33	-6.0	-0.31	5.14e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs3087591	0.959	rs9893872	chr17:29571195	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.57	-8.26	-0.41	3.47e-15	Hip circumference;
LUSC	cis	rs909685	0.590	rs3747177	chr22:39746168	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.55	6.97	0.36	1.74e-11	Rheumatoid arthritis;
LUSC	cis	rs61935443	0.832	rs11107773	chr12:95282000	C/T	cg21533806	chr12:95267307	NA	0.52	6.5	0.34	2.95e-10	Schizophrenia;
LUSC	cis	rs6961069	0.671	rs28369066	chr7:80223327	A/G	cg04458919	chr7:80252533	CD36	-0.41	-7.26	-0.37	2.77e-12	Platelet count;
LUSC	cis	rs3744061	0.530	rs12450896	chr17:74629867	C/T	cg27546012	chr17:74684504	MXRA7	0.35	5.79	0.3	1.58e-8	Retinal arteriolar caliber;
LUSC	cis	rs12618769	0.597	rs17502889	chr2:99031745	A/G	cg10123293	chr2:99228465	UNC50	0.47	7.9	0.4	3.99e-14	Bipolar disorder;
LUSC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg22532475	chr10:104410764	TRIM8	-0.32	-7.08	-0.36	8.35e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18099408	chr3:52552593	STAB1	-0.4	-6.92	-0.35	2.26e-11	Bipolar disorder;
LUSC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg09365446	chr1:150670422	GOLPH3L	0.53	8.02	0.4	1.75e-14	Tonsillectomy;
LUSC	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg14458575	chr2:238380390	NA	0.68	12.14	0.55	2.41e-28	Prostate cancer;
LUSC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg07701084	chr6:150067640	NUP43	0.54	8.15	0.41	7.58e-15	Lung cancer;
LUSC	cis	rs61935443	0.720	rs11107776	chr12:95294283	T/G	cg21533806	chr12:95267307	NA	0.5	6.16	0.32	2.06e-9	Schizophrenia;
LUSC	cis	rs12530845	0.943	rs11984203	chr7:135325947	C/T	cg23117316	chr7:135346802	PL-5283	0.56	9.47	0.46	5.18e-19	Red blood cell traits;
LUSC	trans	rs72674100	1.000	rs13353562	chr4:97977235	T/C	cg16405019	chr1:18959625	PAX7	-0.59	-6.39	-0.33	5.5e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg20607798	chr8:58055168	NA	0.53	5.99	0.31	5.44e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9311676	0.618	rs62258135	chr3:58403330	C/T	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs28493229	0.881	rs59459325	chr19:41175390	C/T	cg21869046	chr19:41225005	ITPKC	0.54	7.0	0.36	1.45e-11	Kawasaki disease;
LUSC	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg09184832	chr6:79620586	NA	-0.44	-7.01	-0.36	1.33e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg08132940	chr7:1081526	C7orf50	-0.52	-6.22	-0.32	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg15083037	chr5:83017644	HAPLN1	-0.52	-6.79	-0.35	5.27e-11	Prostate cancer;
LUSC	cis	rs240764	0.717	rs239236	chr6:101099217	A/G	cg09795085	chr6:101329169	ASCC3	0.41	5.92	0.31	7.91e-9	Neuroticism;
LUSC	cis	rs2882667	0.858	rs10900856	chr5:138417746	C/T	cg04439458	chr5:138467593	SIL1	0.47	9.2	0.45	3.88e-18	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg00409905	chr10:38381863	ZNF37A	0.39	6.7	0.34	8.99e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.63	-10.12	-0.48	3.46e-21	Longevity;Endometriosis;
LUSC	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg07169764	chr2:136633963	MCM6	0.78	10.81	0.51	1.44e-23	Mosquito bite size;
LUSC	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg13798780	chr7:105162888	PUS7	0.58	6.1	0.32	2.86e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg26384229	chr12:38710491	ALG10B	0.68	10.68	0.5	4.36e-23	Morning vs. evening chronotype;
LUSC	cis	rs7523273	0.606	rs2488254	chr1:207941539	A/G	cg22525895	chr1:207977042	MIR29B2	0.41	6.67	0.34	1.07e-10	Schizophrenia;
LUSC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.54	8.34	0.42	1.98e-15	Colorectal cancer;
LUSC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.23e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg11244672	chr19:19639970	YJEFN3	-0.62	-7.63	-0.39	2.47e-13	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.86	0.4	5.31e-14	Prudent dietary pattern;
LUSC	trans	rs11039798	0.925	rs7482967	chr11:48613527	T/A	cg15704280	chr7:45808275	SEPT13	0.68	6.41	0.33	4.99e-10	Axial length;
LUSC	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg22467129	chr15:76604101	ETFA	-0.42	-6.74	-0.35	7.16e-11	Blood metabolite levels;
LUSC	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg15423357	chr2:25149977	NA	0.37	7.32	0.37	1.84e-12	Body mass index in non-asthmatics;
LUSC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg25258033	chr6:167368657	RNASET2	0.37	5.83	0.3	1.28e-8	Primary biliary cholangitis;
LUSC	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg00757033	chr12:89920650	WDR51B	0.6	10.53	0.5	1.42e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs36093844	0.800	rs2044390	chr11:85569834	C/T	cg25872744	chr11:85566296	CCDC83	-0.45	-5.85	-0.3	1.19e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-6.54	-0.34	2.29e-10	Blood metabolite levels;
LUSC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.07	0.32	3.49e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1595825	0.891	rs7592344	chr2:198572461	C/T	cg00982548	chr2:198649783	BOLL	-0.53	-6.77	-0.35	5.8200000000000003e-11	Ulcerative colitis;
LUSC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00166722	chr3:10149974	C3orf24	-0.58	-8.16	-0.41	6.77e-15	Alzheimer's disease;
LUSC	cis	rs7113850	0.541	rs78048500	chr11:24217764	T/G	ch.11.24196551F	chr11:24239977	NA	1.0	8.78	0.43	8.73e-17	Bone fracture in osteoporosis;
LUSC	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	8.19	0.41	5.7e-15	Lung cancer in ever smokers;
LUSC	trans	rs17607347	0.542	rs62052909	chr16:72564986	G/A	cg12945194	chr11:64703312	GPHA2	0.38	6.06	0.31	3.74e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs593982	0.777	rs72941015	chr11:65457514	A/C	cg08755490	chr11:65554678	OVOL1	-1.59	-12.17	-0.55	1.8e-28	Atopic dermatitis;
LUSC	cis	rs10792830	0.640	rs572979	chr11:85803276	C/T	cg07180834	chr11:85838833	NA	-0.3	-5.95	-0.31	6.62e-9	Psychosis and Alzheimer's disease;
LUSC	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg08847533	chr14:75593920	NEK9	0.68	11.2	0.52	6.27e-25	Coronary artery disease;
LUSC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.69	-0.47	1e-19	Bipolar disorder;
LUSC	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg06714761	chr1:201096289	NA	0.43	7.73	0.39	1.25e-13	Permanent tooth development;
LUSC	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg00376283	chr12:123451042	ABCB9	0.71	10.02	0.48	7.85e-21	Neutrophil percentage of white cells;
LUSC	cis	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.1	-0.32	2.89e-9	Resting heart rate;
LUSC	cis	rs2625529	0.730	rs12908882	chr15:72437572	G/A	cg16672083	chr15:72433130	SENP8	-0.51	-7.53	-0.38	4.86e-13	Red blood cell count;
LUSC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg13560548	chr3:10150139	C3orf24	0.51	6.98	0.36	1.56e-11	Alzheimer's disease;
LUSC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg05043794	chr9:111880884	C9orf5	-0.35	-7.62	-0.38	2.65e-13	Menarche (age at onset);
LUSC	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg02187348	chr16:89574699	SPG7	0.47	7.36	0.37	1.43e-12	Multiple myeloma (IgH translocation);
LUSC	trans	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg04995722	chr7:26192034	NFE2L3	-0.39	-6.31	-0.33	8.65e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs977987	0.806	rs11862095	chr16:75385418	T/A	cg04384234	chr16:75411784	CFDP1	-0.4	-6.44	-0.33	4.23e-10	Dupuytren's disease;
LUSC	cis	rs886126	0.761	rs4766556	chr12:111659074	A/G	cg10833066	chr12:111807467	FAM109A	0.43	6.74	0.35	6.95e-11	Coronary heart disease;
LUSC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg04553112	chr3:125709451	NA	-0.5	-5.7	-0.3	2.7e-8	Blood pressure (smoking interaction);
LUSC	cis	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.37	0.37	1.4e-12	Birth weight;
LUSC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg16584290	chr5:462447	EXOC3	-0.34	-5.81	-0.3	1.46e-8	Cystic fibrosis severity;
LUSC	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg06951627	chr6:26196580	NA	0.53	5.72	0.3	2.39e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs6076065	0.775	rs761723	chr20:23330720	A/G	cg11657817	chr20:23433608	CST11	0.54	10.85	0.51	1.06e-23	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7923609	1.000	rs10761723	chr10:64955581	C/T	cg01631684	chr10:65280961	REEP3	-0.41	-6.46	-0.33	3.62e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg24596788	chr1:163392923	NA	0.41	6.89	0.35	2.75e-11	Motion sickness;
LUSC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg17143192	chr8:8559678	CLDN23	0.4	6.24	0.32	1.34e-9	Mood instability;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14029663	chr14:50582909	C14orf138	-0.42	-6.1	-0.32	3e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06022373	chr22:39101656	GTPBP1	0.8	12.42	0.56	2.15e-29	Menopause (age at onset);
LUSC	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.68	-0.43	1.8e-16	Response to antipsychotic treatment;
LUSC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.57	-0.42	3.98e-16	Lung cancer;
LUSC	cis	rs4343996	0.727	rs4506106	chr7:3370201	C/T	cg21248987	chr7:3385318	SDK1	-0.36	-6.28	-0.32	1.07e-9	Motion sickness;
LUSC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg27398817	chr8:82754497	SNX16	-0.46	-6.12	-0.32	2.56e-9	Diastolic blood pressure;
LUSC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-6.11	-0.32	2.81e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2439831	0.717	rs10518820	chr15:43888976	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	6.37	0.33	6.12e-10	Lung cancer in ever smokers;
LUSC	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg17385448	chr1:15911702	AGMAT	0.37	6.29	0.33	1e-9	Systolic blood pressure;
LUSC	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.33	-0.41	2.18e-15	Schizophrenia;
LUSC	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg17143192	chr8:8559678	CLDN23	0.57	8.34	0.42	2.01e-15	Obesity-related traits;
LUSC	cis	rs2859741	0.528	rs59729868	chr1:37493710	G/A	cg09363841	chr1:37513479	NA	-0.39	-7.3	-0.37	2.15e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg11887960	chr12:57824829	NA	0.52	6.49	0.33	3.12e-10	Obesity-related traits;
LUSC	trans	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg18187862	chr3:45730750	SACM1L	0.55	7.15	0.36	5.64e-12	Primary sclerosing cholangitis;
LUSC	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg27631724	chr1:11040367	C1orf127	0.52	9.04	0.44	1.31e-17	Ewing sarcoma;
LUSC	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg03859395	chr2:55845619	SMEK2	0.81	14.43	0.62	5.07e-37	Metabolic syndrome;
LUSC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.48	-0.38	6.64e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9650315	0.733	rs11991218	chr8:57206016	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.33	0.37	1.73e-12	Height;
LUSC	cis	rs7216064	1.000	rs6504542	chr17:65836642	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-9.44	-0.46	6.6e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs1007190	0.570	rs8064954	chr17:42867443	A/C	cg15406952	chr17:42872593	NA	-0.53	-5.65	-0.3	3.46e-8	DNA methylation (variation);
LUSC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06634786	chr22:41940651	POLR3H	0.51	5.65	0.3	3.44e-8	Vitiligo;
LUSC	cis	rs28655083	0.529	rs589002	chr16:77104044	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	7.04	0.36	1.12e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9807989	0.507	rs4851004	chr2:103009537	A/G	cg03938978	chr2:103052716	IL18RAP	-0.37	-7.06	-0.36	9.66e-12	Asthma;
LUSC	cis	rs3768617	0.727	rs12066735	chr1:183101451	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.79	0.43	8.22e-17	Fuchs's corneal dystrophy;
LUSC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14240646	chr10:27532245	ACBD5	0.71	8.19	0.41	5.42e-15	Breast cancer;
LUSC	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21659725	chr3:3221576	CRBN	0.63	10.36	0.49	5.25e-22	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21949518	chr2:264910	ACP1;SH3YL1	-0.45	-6.46	-0.33	3.7e-10	Electrocardiographic conduction measures;
LUSC	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg16342193	chr10:102329863	NA	-0.34	-5.99	-0.31	5.39e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg18512352	chr11:47633146	NA	-0.46	-8.99	-0.44	1.87e-17	Subjective well-being;
LUSC	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.65	-0.3	3.37e-8	Ileal carcinoids;
LUSC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg08270630	chr22:50330655	NA	0.4	5.93	0.31	7.52e-9	Schizophrenia;
LUSC	cis	rs60154123	0.505	rs76426571	chr1:210041634	C/T	cg21951975	chr1:209979733	IRF6	0.56	6.86	0.35	3.26e-11	Coronary artery disease;
LUSC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg06454157	chr6:167490870	NA	-0.3	-6.93	-0.35	2.21e-11	Crohn's disease;
LUSC	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg08847533	chr14:75593920	NEK9	0.86	16.04	0.66	2.53e-43	Height;
LUSC	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg26752888	chr8:11627280	NEIL2	-0.46	-6.79	-0.35	5.14e-11	Myopia (pathological);
LUSC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg06387496	chr7:2775674	GNA12	0.38	6.04	0.31	4.02e-9	Height;
LUSC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg04944784	chr2:26401820	FAM59B	-0.74	-10.91	-0.51	6.48e-24	Gut microbiome composition (summer);
LUSC	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-14.94	-0.63	5.4300000000000003e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg02423579	chr7:2872169	GNA12	-0.4	-6.19	-0.32	1.72e-9	Height;
LUSC	cis	rs7131987	0.650	rs3782509	chr12:29453778	G/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.58	-0.34	1.84e-10	QT interval;
LUSC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg10792982	chr14:105748885	BRF1	0.52	9.44	0.46	6.49e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg24425727	chr6:36645648	CDKN1A	0.29	6.19	0.32	1.8e-9	QRS duration;
LUSC	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.33	7.73	0.39	1.29e-13	Coronary artery disease;
LUSC	cis	rs6967385	0.900	rs10155958	chr7:12367943	T/G	cg06484146	chr7:12443880	VWDE	0.4	5.84	0.3	1.21e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs73206853	0.841	rs73194013	chr12:111100677	T/C	cg12870014	chr12:110450643	ANKRD13A	0.71	7.16	0.36	5.01e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2652834	0.851	rs2729815	chr15:63412843	A/G	cg05507819	chr15:63340323	TPM1	0.46	5.97	0.31	6.09e-9	HDL cholesterol;
LUSC	cis	rs7538876	0.787	rs57142672	chr1:17744536	A/G	cg07965774	chr1:17746286	RCC2	0.32	5.98	0.31	5.88e-9	Basal cell carcinoma;
LUSC	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.17	15.85	0.66	1.35e-42	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.52	5.95	0.31	6.75e-9	Schizophrenia;
LUSC	cis	rs10761482	0.861	rs7909961	chr10:62165578	T/C	cg18175470	chr10:62150864	ANK3	-0.58	-8.72	-0.43	1.34e-16	Schizophrenia;
LUSC	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.37	0.37	1.39e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg08213375	chr14:104286397	PPP1R13B	0.43	8.32	0.41	2.31e-15	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg22117172	chr7:91764530	CYP51A1	0.31	5.69	0.3	2.76e-8	Breast cancer;
LUSC	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg14696996	chr19:15285081	NOTCH3	1.02	9.38	0.46	1.03e-18	Pulse pressure;
LUSC	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.64	-0.39	2.3e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.82	10.51	0.5	1.63e-22	Body mass index;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22987389	chr8:22428557	SORBS3	-0.44	-6.61	-0.34	1.55e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg20368463	chr18:77673604	PQLC1	-0.71	-10.96	-0.51	4.56e-24	Schizophrenia;
LUSC	cis	rs11997175	0.646	rs4463379	chr8:33692719	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	6.71	0.34	8.6e-11	Body mass index;
LUSC	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.62	-0.38	2.63e-13	Depression;
LUSC	cis	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg06521331	chr12:34319734	NA	-0.4	-6.19	-0.32	1.75e-9	Morning vs. evening chronotype;
LUSC	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg17757837	chr7:157058334	UBE3C	0.84	13.51	0.59	1.71e-33	Body mass index;
LUSC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.58	9.4	0.46	9.19e-19	Aortic root size;
LUSC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.74	0.43	1.12e-16	Prudent dietary pattern;
LUSC	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg01528321	chr10:82214614	TSPAN14	0.82	12.33	0.56	4.69e-29	Post bronchodilator FEV1;
LUSC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg00376283	chr12:123451042	ABCB9	0.67	8.42	0.42	1.1e-15	Neutrophil percentage of white cells;
LUSC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06022373	chr22:39101656	GTPBP1	0.76	11.75	0.54	6.21e-27	Menopause (age at onset);
LUSC	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg02175503	chr12:58329896	NA	0.57	8.64	0.43	2.43e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs11258747	0.865	rs7910023	chr10:6468630	C/T	cg04902529	chr1:4193806	NA	0.36	5.98	0.31	5.75e-9	Type 1 diabetes;
LUSC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg10729496	chr3:10149963	C3orf24	0.52	6.88	0.35	2.9100000000000002e-11	Alzheimer's disease;
LUSC	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg08668359	chr10:1443807	ADARB2	0.4	6.09	0.32	3.19e-9	Radiation response;
LUSC	cis	rs983392	0.679	rs1026254	chr11:60030457	A/G	cg20284999	chr11:59952153	MS4A6A	0.36	6.02	0.31	4.68e-9	Alzheimer's disease (late onset);
LUSC	trans	rs2392780	0.536	rs34628978	chr8:128336744	G/A	cg10195415	chr17:73887371	TRIM65	0.4	6.37	0.33	6.34e-10	Breast cancer (early onset);
LUSC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.27	-0.32	1.11e-9	Menopause (age at onset);
LUSC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg21435336	chr19:17392852	ANKLE1	0.43	6.09	0.32	3.08e-9	Systemic lupus erythematosus;
LUSC	trans	rs3857536	0.813	rs1029399	chr6:66952476	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-5.99	-0.31	5.34e-9	Blood trace element (Cu levels);
LUSC	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg08975724	chr8:8085496	FLJ10661	0.48	7.0	0.36	1.44e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.08	15.38	0.64	9.93e-41	Uric acid levels;
LUSC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.35	-0.8	4.97e-76	Height;
LUSC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg11812906	chr14:75593930	NEK9	-0.67	-11.65	-0.54	1.43e-26	Height;
LUSC	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.19e-14	Retinal vascular caliber;
LUSC	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg17294928	chr15:75287854	SCAMP5	-0.75	-8.75	-0.43	1.07e-16	Blood trace element (Zn levels);
LUSC	cis	rs7000551	0.659	rs2280521	chr8:22271995	G/T	cg12081754	chr8:22256438	SLC39A14	-0.53	-6.87	-0.35	3.07e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg01475377	chr6:109611718	NA	-0.43	-7.83	-0.39	6.39e-14	Reticulocyte fraction of red cells;
LUSC	trans	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.28	-0.37	2.41e-12	Triglycerides;
LUSC	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg23093090	chr10:104574429	C10orf26	-0.4	-7.38	-0.37	1.24e-12	Arsenic metabolism;
LUSC	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg24375607	chr4:120327624	NA	0.73	11.45	0.53	7.91e-26	Corneal astigmatism;
LUSC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg00343986	chr7:65444356	GUSB	0.48	7.14	0.36	5.8e-12	Aortic root size;
LUSC	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg18132916	chr6:79620363	NA	-0.38	-5.74	-0.3	2.18e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg05025164	chr4:1340916	KIAA1530	0.38	5.72	0.3	2.33e-8	Obesity-related traits;
LUSC	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.68	-0.34	9.94e-11	Resting heart rate;
LUSC	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg13010199	chr12:38710504	ALG10B	0.45	6.35	0.33	6.97e-10	Morning vs. evening chronotype;
LUSC	cis	rs6908843	0.532	rs9459624	chr6:166671008	T/C	cg06878426	chr6:166666287	NA	0.42	6.15	0.32	2.25e-9	Macrophage inflammatory protein 1b levels;
LUSC	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg02023728	chr11:77925099	USP35	0.42	6.24	0.32	1.35e-9	Testicular germ cell tumor;
LUSC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.7e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs68170813	0.599	rs12532514	chr7:107000952	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.65	-0.47	1.34e-19	Coronary artery disease;
LUSC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg05347473	chr6:146136440	FBXO30	0.52	8.84	0.44	5.74e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17604090	0.938	rs850027	chr7:29675792	G/T	cg19413766	chr7:29689036	LOC646762	-0.58	-6.89	-0.35	2.76e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs4654899	0.802	rs935918	chr1:21145660	C/T	cg01072550	chr1:21505969	NA	-0.46	-6.84	-0.35	3.81e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg16031515	chr1:205743344	RAB7L1	0.29	6.37	0.33	6.15e-10	Menarche (age at onset);
LUSC	cis	rs8017423	0.967	rs2151748	chr14:90694897	G/C	cg04374321	chr14:90722782	PSMC1	0.71	11.22	0.52	5.33e-25	Mortality in heart failure;
LUSC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.88	14.1	0.61	9.28e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10489202	0.657	rs3767478	chr1:168069626	G/A	cg24449463	chr1:168025552	DCAF6	-0.68	-10.19	-0.49	2.04e-21	Schizophrenia;
LUSC	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg18827107	chr12:86230957	RASSF9	-0.41	-5.99	-0.31	5.43e-9	Major depressive disorder;
LUSC	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg26395211	chr5:140044315	WDR55	-0.38	-5.83	-0.3	1.28e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg15557168	chr22:42548783	NA	0.45	6.85	0.35	3.47e-11	Schizophrenia;
LUSC	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg14438399	chr17:27053147	TLCD1	0.54	5.91	0.31	8.3e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9287719	0.649	rs12473957	chr2:10717714	C/G	cg00105475	chr2:10696890	NA	-0.36	-6.08	-0.32	3.35e-9	Prostate cancer;
LUSC	cis	rs1267303	0.562	rs2476162	chr1:47007324	G/A	cg25110126	chr1:46999211	NA	0.71	10.13	0.48	3.36e-21	Monobrow;
LUSC	cis	rs28374715	0.733	rs7167706	chr15:41569644	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.99	-19.05	-0.72	2.83e-55	Ulcerative colitis;
LUSC	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.39	-0.42	1.35e-15	Response to antipsychotic treatment;
LUSC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.84	-0.35	3.9e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.13	0.45	6.72e-18	Motion sickness;
LUSC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.03	-0.31	4.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11958404	0.932	rs6870420	chr5:157437166	T/C	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-10.95	-0.51	4.72e-24	Coffee consumption (cups per day);
LUSC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.7	10.57	0.5	1.02e-22	Aortic root size;
LUSC	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.4	-6.31	-0.33	8.95e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07677032	chr17:61819896	STRADA	0.54	9.07	0.44	1.05e-17	Prudent dietary pattern;
LUSC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg20203395	chr5:56204925	C5orf35	-0.78	-10.4	-0.49	4.07e-22	Initial pursuit acceleration;
LUSC	trans	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs9547692	1.000	rs9547692	chr13:37473243	A/C	cg01493522	chr13:37497338	NA	-0.44	-6.3	-0.33	9.24e-10	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22801127	chr1:93544761	MTF2	-0.47	-7.13	-0.36	6.25e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3771570	1.000	rs55634485	chr2:242268994	T/C	cg21155796	chr2:242212141	HDLBP	0.63	6.86	0.35	3.32e-11	Prostate cancer;
LUSC	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	0.93	16.11	0.66	1.32e-43	Menopause (age at onset);
LUSC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg11766577	chr21:47581405	C21orf56	0.57	8.92	0.44	3.18e-17	Testicular germ cell tumor;
LUSC	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg24375607	chr4:120327624	NA	0.77	11.58	0.54	2.78e-26	Corneal astigmatism;
LUSC	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	13.48	0.59	2.2e-33	Total body bone mineral density;
LUSC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.27	5.96	0.31	6.29e-9	Electroencephalogram traits;
LUSC	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.84	-0.51	1.2e-23	Glomerular filtration rate;
LUSC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs6977940	0.558	rs117222922	chr7:2891608	G/A	cg19346786	chr7:2764209	NA	0.53	5.76	0.3	1.93e-8	White matter integrity;
LUSC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg17279839	chr7:150038598	RARRES2	0.49	7.44	0.38	8.59e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg19812747	chr11:111475976	SIK2	-0.57	-8.47	-0.42	7.76e-16	Primary sclerosing cholangitis;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg03395511	chr6:291903	DUSP22	-0.7	-11.69	-0.54	1.03e-26	Menopause (age at onset);
LUSC	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg23029597	chr12:123009494	RSRC2	-0.69	-8.97	-0.44	2.24e-17	Body mass index;
LUSC	cis	rs7043114	0.525	rs10820969	chr9:95106678	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.72	-0.35	7.86e-11	Height;
LUSC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	0.63	13.42	0.59	3.77e-33	Prudent dietary pattern;
LUSC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg08859206	chr1:53392774	SCP2	-0.43	-7.3	-0.37	2.09e-12	Monocyte count;
LUSC	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-8.97	-0.44	2.22e-17	Blood protein levels;
LUSC	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg08999081	chr20:33150536	PIGU	0.37	6.82	0.35	4.16e-11	Height;
LUSC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg20203395	chr5:56204925	C5orf35	-0.78	-10.32	-0.49	7.47e-22	Initial pursuit acceleration;
LUSC	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg19920283	chr7:105172520	RINT1	0.58	6.11	0.32	2.71e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1832871	0.683	rs9457224	chr6:158666139	C/T	cg07165851	chr6:158734300	TULP4	0.5	7.61	0.38	2.81e-13	Height;
LUSC	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-1.02	-20.61	-0.75	1.73e-61	Dilated cardiomyopathy;
LUSC	cis	rs12760731	0.623	rs10798604	chr1:178254568	A/G	cg00404053	chr1:178313656	RASAL2	-0.45	-5.9	-0.31	8.86e-9	Obesity-related traits;
LUSC	cis	rs6987853	0.933	rs2923424	chr8:42382222	A/G	cg09913449	chr8:42400586	C8orf40	-0.49	-8.1	-0.41	1.07e-14	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12295403	0.691	rs12808591	chr11:18677311	G/A	cg09887367	chr11:18690185	NA	-0.34	-6.87	-0.35	3.13e-11	Ovarian reserve;
LUSC	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg24692254	chr21:30365293	RNF160	-0.51	-7.42	-0.38	9.63e-13	Dental caries;
LUSC	cis	rs1403694	0.669	rs10440056	chr3:186433822	C/T	cg12454167	chr3:186435060	KNG1	0.34	8.38	0.42	1.49e-15	Blood protein levels;
LUSC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg19622623	chr12:86230825	RASSF9	-0.42	-6.01	-0.31	4.85e-9	Major depressive disorder;
LUSC	cis	rs3106136	0.527	rs2883	chr4:95158610	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.36	-0.42	1.67e-15	Capecitabine sensitivity;
LUSC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg07424592	chr7:64974309	NA	-0.63	-5.65	-0.3	3.53e-8	Diabetic kidney disease;
LUSC	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	10.82	0.51	1.33e-23	Response to antipsychotic treatment;
LUSC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.21	-0.32	1.57e-9	Initial pursuit acceleration;
LUSC	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.7	-0.3	2.59e-8	Bipolar disorder;
LUSC	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	1.24	19.91	0.74	1.02e-58	Corneal structure;
LUSC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-1.19	-12.75	-0.57	1.35e-30	Diabetic kidney disease;
LUSC	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.9	15.7	0.65	5.49e-42	Morning vs. evening chronotype;
LUSC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg25039879	chr17:56429692	SUPT4H1	0.66	8.82	0.43	6.62e-17	Cognitive test performance;
LUSC	cis	rs12286929	1.000	rs12286929	chr11:115022404	A/G	cg04055981	chr11:115044050	NA	0.36	6.28	0.33	1.02e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg13560548	chr3:10150139	C3orf24	0.47	6.6	0.34	1.58e-10	Alzheimer's disease;
LUSC	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg05973401	chr12:123451056	ABCB9	-0.51	-5.69	-0.3	2.8e-8	Neutrophil percentage of white cells;
LUSC	trans	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg19894588	chr14:64061835	NA	-0.53	-7.5	-0.38	5.74e-13	Glioblastoma;Glioma;
LUSC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs11229555	1.000	rs7102510	chr11:58371283	T/G	cg15696309	chr11:58395628	NA	-0.69	-9.27	-0.45	2.43e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg05729581	chr11:3078854	CARS	-0.51	-7.32	-0.37	1.91e-12	Longevity;
LUSC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg04727924	chr7:799746	HEATR2	-0.55	-6.75	-0.35	6.66e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	9.04	0.44	1.26e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-9.36	-0.46	1.17e-18	Morning vs. evening chronotype;
LUSC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg13560548	chr3:10150139	C3orf24	0.49	6.89	0.35	2.82e-11	Alzheimer's disease;
LUSC	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg27471124	chr11:109292789	C11orf87	-0.55	-10.09	-0.48	4.63e-21	Schizophrenia;
LUSC	cis	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg17411546	chr10:75410026	SYNPO2L	0.43	6.15	0.32	2.24e-9	Inflammatory bowel disease;
LUSC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.08	20.95	0.75	7.86e-63	Cognitive ability;
LUSC	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg04310649	chr10:35416472	CREM	-0.42	-6.39	-0.33	5.5e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Depression;
LUSC	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg25554036	chr4:6271136	WFS1	0.59	12.15	0.55	2.29e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs4729127	0.708	rs17166230	chr7:94017794	G/C	cg19058453	chr19:9879420	ZNF846	0.62	6.17	0.32	1.99e-9	Intelligence;
LUSC	cis	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs3849570	0.695	rs6804587	chr3:81873423	T/C	cg07356753	chr3:81810745	GBE1	-0.59	-8.78	-0.43	8.46e-17	Waist circumference;Body mass index;
LUSC	cis	rs12220238	0.818	rs16931294	chr10:75999169	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.78	0.39	8.92e-14	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs10843647	1.000	rs973484	chr12:30326090	A/G	cg12718339	chr12:29936407	TMTC1	-0.35	-5.84	-0.3	1.27e-8	Glucose homeostasis traits;
LUSC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg00033643	chr7:134001901	SLC35B4	0.43	6.67	0.34	1.04e-10	Mean platelet volume;
LUSC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg14703610	chr5:56206110	C5orf35	0.41	6.02	0.31	4.48e-9	Coronary artery disease;
LUSC	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.73	9.92	0.48	1.64e-20	Platelet count;
LUSC	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg16482183	chr6:26056742	HIST1H1C	0.45	6.46	0.33	3.67e-10	Height;
LUSC	trans	rs2786098	0.656	rs12747786	chr1:197565832	T/C	cg16005942	chr6:160526640	IGF2R	0.5	6.02	0.31	4.61e-9	Asthma;
LUSC	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg03433033	chr1:76189801	ACADM	-0.39	-5.77	-0.3	1.85e-8	Daytime sleep phenotypes;
LUSC	cis	rs12145833	0.596	rs12043646	chr1:243281992	G/A	cg02356786	chr1:243265016	LOC731275	0.69	6.48	0.33	3.38e-10	Obesity (early onset extreme);
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg15242686	chr22:24348715	GSTTP1	-0.53	-8.4	-0.42	1.3e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-7.65	-0.39	2.16e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg08601574	chr20:25228251	PYGB	0.57	9.13	0.45	6.57e-18	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs231513	0.954	rs231510	chr17:41966470	T/C	cg26893861	chr17:41843967	DUSP3	-0.51	-6.13	-0.32	2.44e-9	Cognitive function;
LUSC	cis	rs977987	0.778	rs2113232	chr16:75391185	T/C	cg04384234	chr16:75411784	CFDP1	-0.4	-6.6	-0.34	1.64e-10	Dupuytren's disease;
LUSC	cis	rs11971779	0.648	rs9656512	chr7:139054046	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg23289794	chr7:2394357	EIF3B	-0.76	-9.99	-0.48	9.5e-21	Multiple sclerosis;
LUSC	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg05082376	chr22:42548792	NA	-0.44	-6.82	-0.35	4.16e-11	Schizophrenia;
LUSC	cis	rs9517320	0.935	rs9645891	chr13:99126800	A/G	cg07423050	chr13:99094983	FARP1	0.34	6.46	0.33	3.69e-10	Longevity;
LUSC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg05347473	chr6:146136440	FBXO30	0.46	7.66	0.39	1.98e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.66	11.31	0.53	2.51e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg07169764	chr2:136633963	MCM6	1.21	18.28	0.71	3.2e-52	Corneal structure;
LUSC	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg08601574	chr20:25228251	PYGB	-0.43	-6.67	-0.34	1.04e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.51	-8.12	-0.41	8.81e-15	Platelet count;
LUSC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg00933542	chr6:150070202	PCMT1	0.33	6.79	0.35	5.03e-11	Lung cancer;
LUSC	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23158103	chr7:148848205	ZNF398	-0.49	-8.32	-0.41	2.29e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg10018233	chr7:150070692	REPIN1	0.34	6.01	0.31	4.96e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06634786	chr22:41940651	POLR3H	0.53	5.72	0.3	2.31e-8	Vitiligo;
LUSC	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg14696996	chr19:15285081	NOTCH3	1.02	9.37	0.46	1.1e-18	Pulse pressure;
LUSC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg04414720	chr1:150670196	GOLPH3L	-0.49	-7.75	-0.39	1.1e-13	Tonsillectomy;
LUSC	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg07332563	chr6:291687	DUSP22	-0.49	-7.41	-0.38	1.03e-12	Menopause (age at onset);
LUSC	cis	rs9427116	0.502	rs9426827	chr1:154589965	T/C	cg17218026	chr1:154582156	ADAR	0.56	10.01	0.48	8.47e-21	Blood protein levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02473084	chr2:37551451	NA	-0.53	-6.39	-0.33	5.54e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg16342193	chr10:102329863	NA	-0.38	-6.44	-0.33	4.28e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg18806716	chr10:30721971	MAP3K8	-0.49	-7.77	-0.39	9.54e-14	Inflammatory bowel disease;
LUSC	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-7.07	-0.36	9.32e-12	Fear of minor pain;
LUSC	trans	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg00579200	chr11:133705235	NA	-0.41	-5.9	-0.31	8.94e-9	Childhood ear infection;
LUSC	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg08847533	chr14:75593920	NEK9	-0.83	-15.25	-0.64	3.16e-40	Height;
LUSC	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	7.16	0.36	5.24e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.44	7.46	0.38	7.39e-13	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	ch.11.42038R	chr11:967971	AP2A2	0.53	7.88	0.4	4.59e-14	Alzheimer's disease (late onset);
LUSC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg05585544	chr11:47624801	NA	-0.42	-7.32	-0.37	1.85e-12	Subjective well-being;
LUSC	cis	rs6543140	0.964	rs6543136	chr2:103065547	G/A	cg09003973	chr2:102972529	NA	0.55	7.1	0.36	7.72e-12	Blood protein levels;
LUSC	cis	rs9479482	0.648	rs912557	chr6:150385977	C/T	cg25797454	chr6:150327115	RAET1K	0.29	6.49	0.33	3.08e-10	Alopecia areata;
LUSC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.2	22.43	0.78	1.32e-68	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg26395211	chr5:140044315	WDR55	0.45	7.0	0.36	1.39e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg21211680	chr2:198530	NA	0.68	7.31	0.37	2e-12	Blood protein levels;
LUSC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.65	-10.0	-0.48	8.86e-21	Menarche (age at onset);
LUSC	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg21100191	chr22:23484243	RTDR1	0.91	15.59	0.65	1.42e-41	Bone mineral density;
LUSC	cis	rs4795519	0.557	rs12451105	chr17:22179841	T/A	cg22648282	chr17:21454238	C17orf51	-0.42	-5.7	-0.3	2.69e-8	Chronic myeloid leukemia;
LUSC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	4.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg07395648	chr5:131743802	NA	-0.38	-5.67	-0.3	3.14e-8	Blood metabolite levels;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg07177001	chr8:22926478	TNFRSF10B	0.69	6.18	0.32	1.91e-9	Body mass index;
LUSC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06481639	chr22:41940642	POLR3H	0.49	5.85	0.3	1.19e-8	Vitiligo;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18484294	chr2:202645530	ALS2	0.45	6.13	0.32	2.52e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg20628663	chr10:43360327	NA	-0.76	-11.4	-0.53	1.23e-25	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg12473912	chr3:136751656	NA	0.37	6.44	0.33	4.2e-10	Neuroticism;
LUSC	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg13042288	chr15:90349979	ANPEP	-0.49	-7.25	-0.37	2.9e-12	Uric acid levels;
LUSC	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg10645314	chr2:3704589	ALLC	-0.37	-6.49	-0.33	3.16e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.4	6.18	0.32	1.89e-9	Menopause (age at onset);
LUSC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg11645453	chr3:52864694	ITIH4	0.35	7.93	0.4	3.28e-14	Bipolar disorder;
LUSC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg05754148	chr16:3507555	NAT15	-0.8	-9.27	-0.45	2.45e-18	Tuberculosis;
LUSC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.13	-0.32	2.47e-9	Bipolar disorder;
LUSC	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg19875535	chr5:140030758	IK	-0.54	-8.91	-0.44	3.48e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg10596483	chr8:143751796	JRK	0.53	7.58	0.38	3.35e-13	Schizophrenia;
LUSC	cis	rs977987	0.806	rs2865531	chr16:75390316	T/A	cg03315344	chr16:75512273	CHST6	0.5	9.62	0.47	1.68e-19	Dupuytren's disease;
LUSC	cis	rs6546886	0.912	rs10168410	chr2:74294110	A/T	cg14702570	chr2:74259524	NA	-0.31	-5.83	-0.3	1.32e-8	Dialysis-related mortality;
LUSC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.45	-7.14	-0.36	6.03e-12	Menarche (age at onset);
LUSC	cis	rs10419226	0.555	rs876982	chr19:18782377	C/T	cg22001208	chr19:18782374	NA	0.37	6.36	0.33	6.75e-10	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03720838	chr6:90529562	MDN1	-0.41	-5.97	-0.31	6.07e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4664308	0.935	rs4520994	chr2:160937750	G/A	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.62	-0.54	1.97e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg11752832	chr7:134001865	SLC35B4	0.53	8.04	0.4	1.59e-14	Mean platelet volume;
LUSC	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg04310649	chr10:35416472	CREM	-0.4	-6.05	-0.31	3.86e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.83	-0.3	1.3e-8	Mood instability;
LUSC	cis	rs10986311	1.000	rs748741	chr9:127089775	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.37	5.9	0.31	9.14e-9	Vitiligo;
LUSC	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg18225595	chr11:63971243	STIP1	0.5	6.11	0.32	2.79e-9	Mean platelet volume;
LUSC	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg12935359	chr14:103987150	CKB	-0.49	-7.4	-0.38	1.14e-12	Body mass index;
LUSC	cis	rs240764	0.658	rs2050549	chr6:101216645	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.26	-0.32	1.21e-9	Neuroticism;
LUSC	cis	rs2637266	0.597	rs846622	chr10:78543005	G/A	cg18941641	chr10:78392320	NA	0.39	7.15	0.36	5.46e-12	Pulmonary function;
LUSC	cis	rs2286885	1.000	rs2286885	chr9:129246487	A/C	cg15282417	chr9:129245246	FAM125B	0.38	6.34	0.33	7.26e-10	Intraocular pressure;
LUSC	cis	rs3771570	0.786	rs62186378	chr2:242211554	G/A	cg21155796	chr2:242212141	HDLBP	0.69	7.65	0.39	2.1e-13	Prostate cancer;
LUSC	cis	rs524023	0.957	rs538737	chr11:64355772	C/G	cg07220939	chr11:64358617	SLC22A12	0.23	5.88	0.31	9.83e-9	Urate levels in obese individuals;
LUSC	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-8.29	-0.41	2.71e-15	Lung cancer;
LUSC	trans	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg09060275	chr22:27053596	MIAT	-0.4	-6.16	-0.32	2.14e-9	Height;
LUSC	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg06287003	chr12:125626642	AACS	-0.39	-6.75	-0.35	6.73e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg21775007	chr8:11205619	TDH	-0.64	-10.41	-0.49	3.61e-22	Retinal vascular caliber;
LUSC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg16479474	chr6:28041457	NA	0.32	5.72	0.3	2.31e-8	Parkinson's disease;
LUSC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg22823121	chr1:150693482	HORMAD1	0.51	7.19	0.37	4.16e-12	Tonsillectomy;
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-8.75	-0.43	1.1e-16	Lymphocyte counts;
LUSC	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.27	-0.32	1.1e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.7	10.91	0.51	6.78e-24	Obesity-related traits;
LUSC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	1.01	17.3	0.69	2.6e-48	Testicular germ cell tumor;
LUSC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13126279	chr21:47581558	C21orf56	-0.48	-7.33	-0.37	1.75e-12	Testicular germ cell tumor;
LUSC	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	0.78	11.93	0.55	1.39e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg10356904	chr22:49881777	NA	-0.32	-7.08	-0.36	8.51e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg05163923	chr11:71159392	DHCR7	0.76	11.28	0.53	3.28e-25	Vitamin D levels;
LUSC	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg11752832	chr7:134001865	SLC35B4	-0.5	-7.34	-0.37	1.66e-12	Mean platelet volume;
LUSC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19346786	chr7:2764209	NA	-0.45	-7.5	-0.38	6e-13	Height;
LUSC	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	0.88	15.45	0.65	5.08e-41	Prostate cancer;
LUSC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	0.98	15.22	0.64	4.11e-40	Parkinson's disease;
LUSC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg19318889	chr4:1322082	MAEA	0.42	6.94	0.36	2.02e-11	Obesity-related traits;
LUSC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg23625390	chr15:77176239	SCAPER	-0.48	-7.28	-0.37	2.43e-12	Blood metabolite levels;
LUSC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-12.3	-0.56	5.96e-29	Hemoglobin concentration;
LUSC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-1.04	-20.22	-0.74	5.96e-60	Height;
LUSC	cis	rs2235544	0.565	rs634532	chr1:54468947	G/C	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.91	0.31	8.4e-9	Lung cancer;
LUSC	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg07148914	chr20:33460835	GGT7	0.47	6.93	0.35	2.22e-11	Height;
LUSC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.01	0.52	2.98e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs3857536	0.706	rs2157963	chr6:66945449	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs9905704	0.918	rs654743	chr17:56736490	T/C	cg12560992	chr17:57184187	TRIM37	0.55	7.85	0.39	5.74e-14	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg14552801	chr7:65878734	NA	0.38	5.81	0.3	1.42e-8	Aortic root size;
LUSC	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.14	0.41	8.16e-15	Axial length;
LUSC	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg09796270	chr17:17721594	SREBF1	0.42	7.51	0.38	5.43e-13	Total body bone mineral density;
LUSC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.75	0.43	1.1e-16	Prudent dietary pattern;
LUSC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-10.9	-0.51	7.31e-24	Bipolar disorder;
LUSC	cis	rs4363385	0.574	rs61813182	chr1:152943868	T/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.76	-0.3	1.87e-8	Inflammatory skin disease;
LUSC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	0.99	13.86	0.6	8.34e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs2147959	0.883	rs7529055	chr1:228636824	T/G	cg18477163	chr1:228402036	OBSCN	-0.43	-5.96	-0.31	6.29e-9	Adult asthma;
LUSC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.7	10.95	0.51	4.71e-24	Aortic root size;
LUSC	cis	rs36093844	0.752	rs17817308	chr11:85593529	G/A	cg16165120	chr11:85566439	CCDC83	-0.39	-5.65	-0.3	3.42e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.64	8.18	0.41	6e-15	Schizophrenia;
LUSC	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.45	0.33	4.01e-10	Corneal astigmatism;
LUSC	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg20243544	chr17:37824526	PNMT	0.53	7.55	0.38	4.15e-13	Asthma;
LUSC	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	8.9	0.44	3.51e-17	Lung cancer;
LUSC	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.65	10.26	0.49	1.22e-21	Body mass index (adult);
LUSC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.29	-5.81	-0.3	1.43e-8	Total body bone mineral density;
LUSC	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg20476274	chr7:133979776	SLC35B4	0.69	11.67	0.54	1.29e-26	Mean platelet volume;
LUSC	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg12292205	chr6:26970375	C6orf41	0.5	8.5	0.42	6.55e-16	Schizophrenia;
LUSC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg23985595	chr17:80112537	CCDC57	-0.3	-5.75	-0.3	2.05e-8	Blood metabolite levels;
LUSC	cis	rs13242816	1.000	rs67652573	chr7:116109958	T/C	cg16553024	chr7:116138462	CAV2	-0.54	-5.92	-0.31	7.84e-9	P wave duration;
LUSC	cis	rs12145833	0.596	rs1060643	chr1:243429976	G/C	cg02356786	chr1:243265016	LOC731275	0.69	6.27	0.32	1.14e-9	Obesity (early onset extreme);
LUSC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	4.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg01973587	chr1:228161476	NA	-0.41	-7.26	-0.37	2.71e-12	Diastolic blood pressure;
LUSC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07167872	chr1:205819463	PM20D1	0.5	8.35	0.42	1.88e-15	Menarche (age at onset);
LUSC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg22823121	chr1:150693482	HORMAD1	0.62	9.51	0.46	3.97e-19	Tonsillectomy;
LUSC	cis	rs10740039	0.516	rs2393645	chr10:62315027	C/T	cg18175470	chr10:62150864	ANK3	-0.45	-6.78	-0.35	5.44e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10162002	0.935	rs9578603	chr13:24040733	C/G	cg00158254	chr13:24040743	NA	0.52	5.8	0.3	1.55e-8	Hypothyroidism;
LUSC	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.37	0.49	5.04e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg03474202	chr17:45855739	NA	-0.28	-6.32	-0.33	8.45e-10	IgG glycosylation;
LUSC	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg12292205	chr6:26970375	C6orf41	-0.38	-5.65	-0.3	3.37e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg22823121	chr1:150693482	HORMAD1	0.58	8.83	0.44	5.82e-17	Tonsillectomy;
LUSC	trans	rs61931739	0.620	rs708143	chr12:33719962	A/C	cg26384229	chr12:38710491	ALG10B	0.49	7.61	0.38	2.74e-13	Morning vs. evening chronotype;
LUSC	cis	rs8027181	1.000	rs4776613	chr15:73080731	C/T	cg25632853	chr15:73088954	NA	0.34	6.62	0.34	1.42e-10	Triglyceride levels;
LUSC	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	11.63	0.54	1.73e-26	Mean corpuscular hemoglobin;
LUSC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg07424592	chr7:64974309	NA	0.64	5.72	0.3	2.34e-8	Diabetic kidney disease;
LUSC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.59	0.43	3.49e-16	Lung cancer;
LUSC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg22431228	chr1:16359049	CLCNKA	-0.33	-6.12	-0.32	2.57e-9	Dilated cardiomyopathy;
LUSC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg01475377	chr6:109611718	NA	-0.46	-8.37	-0.42	1.59e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg12667521	chr19:29218732	NA	0.51	5.96	0.31	6.4e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.69	-0.3	2.82e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg06618935	chr21:46677482	NA	-0.39	-7.93	-0.4	3.34e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.13	-0.41	8.27e-15	Retinal vascular caliber;
LUSC	cis	rs1953600	0.645	rs2819945	chr10:81952956	G/A	cg00277334	chr10:82204260	NA	0.5	7.95	0.4	2.97e-14	Sarcoidosis;
LUSC	cis	rs7833787	1.000	rs34270955	chr8:18705250	G/C	cg17701159	chr8:18705777	PSD3	-0.39	-6.43	-0.33	4.52e-10	Obesity-related traits;
LUSC	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-1.11	-17.3	-0.69	2.55e-48	Exhaled nitric oxide output;
LUSC	cis	rs2224391	0.628	rs2773317	chr6:5254509	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.51	-6.92	-0.35	2.37e-11	Height;
LUSC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11645453	chr3:52864694	ITIH4	0.35	8.1	0.41	1.04e-14	Bipolar disorder;
LUSC	cis	rs4776059	1.000	rs17614559	chr15:52878719	G/A	cg25063058	chr15:52860530	ARPP19	0.44	6.15	0.32	2.23e-9	Schizophrenia;
LUSC	cis	rs2019216	0.564	rs907707	chr17:21910083	G/C	cg22648282	chr17:21454238	C17orf51	-0.49	-7.36	-0.37	1.45e-12	Pelvic organ prolapse;
LUSC	cis	rs4494114	1.000	rs6674910	chr1:39357157	C/T	cg25970120	chr1:39325951	RRAGC	0.39	6.27	0.32	1.09e-9	Blood protein levels;
LUSC	cis	rs7119167	0.686	rs7342249	chr11:73046299	T/C	cg17517138	chr11:73019481	ARHGEF17	0.48	5.69	0.3	2.77e-8	Blood protein levels;
LUSC	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg13902645	chr11:5959945	NA	-0.64	-9.17	-0.45	5.06e-18	DNA methylation (variation);
LUSC	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg13010199	chr12:38710504	ALG10B	0.55	8.34	0.42	1.98e-15	Morning vs. evening chronotype;
LUSC	trans	rs2386661	0.547	rs11259540	chr10:5646706	A/T	cg11398623	chr21:37499189	NA	0.27	6.17	0.32	2.01e-9	Breast cancer;
LUSC	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg16576597	chr16:28551801	NUPR1	0.34	6.91	0.35	2.4e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs7637701	0.713	rs9878566	chr3:156493213	C/T	cg11006288	chr14:69012387	RAD51L1	0.39	6.23	0.32	1.41e-9	Breast cancer;
LUSC	cis	rs7131987	0.650	rs7301188	chr12:29455391	C/T	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.51	-0.34	2.71e-10	QT interval;
LUSC	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.04	0.36	1.12e-11	Asthma (childhood onset);
LUSC	cis	rs1519814	1.000	rs7826920	chr8:121121010	T/C	cg22335954	chr8:121166405	COL14A1	-0.41	-5.65	-0.3	3.44e-8	Breast cancer;
LUSC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.35	0.33	7.13e-10	Aortic root size;
LUSC	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg19774624	chr17:42201019	HDAC5	0.72	10.6	0.5	7.91e-23	Total body bone mineral density;
LUSC	cis	rs6426558	0.572	rs2670471	chr1:227454328	T/C	cg10327440	chr1:227177885	CDC42BPA	0.55	7.45	0.38	8.09e-13	Neutrophil percentage of white cells;
LUSC	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg00074818	chr8:8560427	CLDN23	0.52	9.0	0.44	1.8e-17	Obesity-related traits;
LUSC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.67	-12.11	-0.55	3.2e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg02958346	chr11:57425731	CLP1	0.43	5.99	0.31	5.3e-9	Schizophrenia;
LUSC	cis	rs116988415	0.584	rs4902313	chr14:65242164	T/C	cg25083366	chr14:65239357	SPTB	0.67	6.72	0.35	7.91e-11	Daytime sleep phenotypes;
LUSC	trans	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg26384229	chr12:38710491	ALG10B	0.7	11.02	0.52	2.75e-24	Morning vs. evening chronotype;
LUSC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.9	0.48	2e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg02023728	chr11:77925099	USP35	0.48	6.81	0.35	4.5e-11	Testicular germ cell tumor;
LUSC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg06877462	chr1:205807181	PM20D1	-0.47	-8.43	-0.42	1.07e-15	Menarche (age at onset);
LUSC	trans	rs7939886	0.920	rs12223067	chr11:55915420	C/A	cg03929089	chr4:120376271	NA	0.77	6.09	0.32	3.03e-9	Myopia (pathological);
LUSC	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.54	-0.42	4.88e-16	Depression;
LUSC	cis	rs6961069	0.585	rs17263407	chr7:80259908	G/C	cg04458919	chr7:80252533	CD36	-0.41	-7.16	-0.36	5.25e-12	Platelet count;
LUSC	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg09323728	chr8:95962352	TP53INP1	-0.37	-7.57	-0.38	3.65e-13	Hemoglobin concentration;
LUSC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9467603	0.800	rs28360585	chr6:25790356	A/T	cg08501292	chr6:25962987	TRIM38	0.6	6.13	0.32	2.51e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg26664455	chr2:73298989	SFXN5	0.38	6.16	0.32	2.1e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.13	-0.41	8.74e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.49	-6.84	-0.35	3.72e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg02527881	chr3:46936655	PTH1R	-0.36	-6.38	-0.33	5.97e-10	Colorectal cancer;
LUSC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg23758822	chr17:41437982	NA	1.04	20.72	0.75	6.67e-62	Menopause (age at onset);
LUSC	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg08807101	chr21:30365312	RNF160	-0.56	-8.5	-0.42	6.36e-16	Dental caries;
LUSC	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-8.37	-0.42	1.63e-15	Monocyte percentage of white cells;
LUSC	cis	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg06521331	chr12:34319734	NA	-0.36	-6.22	-0.32	1.51e-9	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.55	-0.38	4.21e-13	Aortic root size;
LUSC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.54	0.5	1.33e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg12403142	chr1:92012408	NA	-0.41	-6.66	-0.34	1.13e-10	Breast cancer;
LUSC	cis	rs11997175	0.626	rs12155927	chr8:33789851	A/G	ch.8.33884649F	chr8:33765107	NA	0.42	6.37	0.33	6.35e-10	Body mass index;
LUSC	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg26879891	chr1:152191343	HRNR	-0.37	-6.6	-0.34	1.65e-10	Inflammatory skin disease;
LUSC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.34	-0.37	1.62e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.52	10.04	0.48	6.43e-21	Monocyte count;
LUSC	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg02569458	chr12:86230093	RASSF9	0.43	7.08	0.36	8.62e-12	Major depressive disorder;
LUSC	cis	rs295140	1.000	rs1431766	chr2:201191034	A/G	cg04283868	chr2:201171347	SPATS2L	0.42	6.33	0.33	7.7e-10	QT interval;
LUSC	cis	rs2224391	0.628	rs2753239	chr6:5252826	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.47	-6.37	-0.33	6.4e-10	Height;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg22813821	chr12:72148853	RAB21	0.76	5.99	0.31	5.3e-9	Cognitive performance;
LUSC	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg21211680	chr2:198530	NA	-0.75	-8.08	-0.4	1.18e-14	Blood protein levels;
LUSC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg08219700	chr8:58056026	NA	0.56	6.75	0.35	6.65e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg08888203	chr3:10149979	C3orf24	0.65	9.31	0.45	1.82e-18	Alzheimer's disease;
LUSC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.49	-0.59	2.14e-33	Alzheimer's disease;
LUSC	cis	rs7923609	1.000	rs7923609	chr10:65133822	A/G	cg01631684	chr10:65280961	REEP3	-0.38	-5.89	-0.31	9.58e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.13	0.52	1.08e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs4631830	0.863	rs6481329	chr10:51529746	G/A	cg16070123	chr10:51489643	NA	-0.5	-7.95	-0.4	2.83e-14	Prostate-specific antigen levels;
LUSC	cis	rs6700896	0.931	rs10789192	chr1:66125770	G/A	cg04111102	chr1:66153794	NA	0.33	7.26	0.37	2.81e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg01620082	chr3:125678407	NA	-0.81	-7.0	-0.36	1.37e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2932538	0.583	rs2279500	chr1:113244433	T/C	cg22162597	chr1:113214053	CAPZA1	-0.67	-7.42	-0.38	9.8e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs6012953	1.000	rs6091173	chr20:49134099	C/T	cg13958625	chr20:49123093	NA	0.31	6.75	0.35	6.63e-11	Vitiligo;
LUSC	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg13334819	chr7:99746414	C7orf59	0.5	6.69	0.34	9.48e-11	Coronary artery disease;
LUSC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg03354898	chr7:1950403	MAD1L1	0.34	6.82	0.35	4.19e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6906287	0.647	rs3798420	chr6:118786486	T/C	cg21191810	chr6:118973309	C6orf204	0.33	6.0	0.31	5.17e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg20703242	chr1:230279135	GALNT2	0.61	8.49	0.42	6.72e-16	Coronary artery disease;
LUSC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg11912956	chr7:73588697	EIF4H	0.39	6.62	0.34	1.46e-10	Triglycerides;
LUSC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg26958806	chr6:27640298	NA	0.81	6.28	0.32	1.05e-9	Breast cancer;
LUSC	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.18	0.49	2.23e-21	Bladder cancer;
LUSC	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.94	12.36	0.56	3.8e-29	Menarche (age at onset);
LUSC	cis	rs35995292	1.000	rs35995292	chr7:38913017	T/G	cg19327137	chr7:38886074	VPS41	0.34	5.67	0.3	3.1e-8	Subjective well-being (multi-trait analysis);
LUSC	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg21427119	chr20:30132790	HM13	-0.45	-6.43	-0.33	4.44e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg23985595	chr17:80112537	CCDC57	0.3	5.69	0.3	2.74e-8	Life satisfaction;
LUSC	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.7e-12	Type 2 diabetes;
LUSC	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.09	0.32	3.12e-9	Corneal astigmatism;
LUSC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg24250549	chr1:154909240	PMVK	0.62	10.1	0.48	4.18e-21	Prostate cancer;
LUSC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.27	-0.32	1.1e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg13852791	chr20:30311386	BCL2L1	0.94	14.81	0.63	1.69e-38	Mean corpuscular hemoglobin;
LUSC	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.62	-8.85	-0.44	5.18e-17	Inhibitory control;
LUSC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg15147215	chr3:52552868	STAB1	-0.29	-5.76	-0.3	1.93e-8	Electroencephalogram traits;
LUSC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg11663144	chr21:46675770	NA	-0.42	-7.25	-0.37	2.93e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs3858145	0.588	rs78041174	chr10:70038771	G/A	cg04882175	chr6:131122610	NA	-0.64	-8.62	-0.43	2.79e-16	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUSC	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg06640241	chr16:89574553	SPG7	-0.58	-8.72	-0.43	1.35e-16	Multiple myeloma (IgH translocation);
LUSC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg24675658	chr1:53192096	ZYG11B	-0.69	-11.9	-0.55	1.91e-27	Monocyte count;
LUSC	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg17252645	chr8:143867129	LY6D	0.42	8.07	0.4	1.29e-14	Urinary tract infection frequency;
LUSC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg06784218	chr1:46089804	CCDC17	0.48	9.43	0.46	7e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.93	-0.4	3.28e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs10779751	1.000	rs12120734	chr1:11262020	A/G	cg08854313	chr1:11322531	MTOR	0.91	16.28	0.67	2.74e-44	Body mass index;
LUSC	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg00530320	chr1:46809349	NSUN4	0.56	8.59	0.43	3.45e-16	Menopause (age at onset);
LUSC	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg06454157	chr6:167490870	NA	0.23	5.76	0.3	1.89e-8	Crohn's disease;
LUSC	cis	rs9427116	0.740	rs11264230	chr1:154608418	G/T	cg17218026	chr1:154582156	ADAR	0.56	9.92	0.48	1.69e-20	Blood protein levels;
LUSC	cis	rs7424096	0.560	rs7560263	chr2:37183303	G/T	cg14987922	chr2:37194071	STRN	0.49	6.59	0.34	1.7e-10	High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs9944715	0.954	rs4542747	chr18:43802169	C/T	cg01718231	chr17:29326311	RNF135	-0.5	-6.94	-0.36	2.05e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg15556689	chr8:8085844	FLJ10661	0.63	8.85	0.44	5.09e-17	Neuroticism;
LUSC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	12.54	0.57	8.27e-30	Cognitive test performance;
LUSC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.39	6.59	0.34	1.73e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	14.35	0.62	1e-36	Platelet count;
LUSC	cis	rs10992471	0.603	rs7033979	chr9:95223980	A/G	cg14631576	chr9:95140430	CENPP	-0.33	-6.03	-0.31	4.35e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs12540874	0.500	rs12719030	chr7:50485073	T/C	cg18232548	chr7:50535776	DDC	-0.59	-9.05	-0.44	1.23e-17	Systemic sclerosis;
LUSC	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-5.78	-0.3	1.67e-8	Testicular germ cell tumor;
LUSC	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg15571903	chr15:79123663	NA	0.32	5.9	0.31	9.02e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg15556689	chr8:8085844	FLJ10661	0.8	13.53	0.59	1.52e-33	Mood instability;
LUSC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06481639	chr22:41940642	POLR3H	-0.5	-5.69	-0.3	2.72e-8	Vitiligo;
LUSC	cis	rs72781680	0.821	rs56064672	chr2:24156769	G/T	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg13390004	chr1:15929781	NA	0.41	6.83	0.35	4.13e-11	Systolic blood pressure;
LUSC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08677398	chr8:58056175	NA	0.42	5.86	0.31	1.11e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00908189	chr16:619842	PIGQ	0.66	10.15	0.49	2.75e-21	Height;
LUSC	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg06112835	chr11:68658793	MRPL21	-0.36	-6.06	-0.31	3.76e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg06207120	chr15:45996521	NA	0.39	5.99	0.31	5.51e-9	Waist circumference;Weight;
LUSC	cis	rs1950626	0.532	rs61991120	chr14:101455222	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.4	7.48	0.38	6.57e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.93	15.03	0.64	2.28e-39	Parkinson's disease;
LUSC	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.33	0.59	8.18e-33	Blood protein levels;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg16799998	chr3:48343164	NME6	0.46	6.05	0.31	3.94e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs10170846	0.861	rs6740452	chr2:223518452	C/T	cg25565276	chr2:223520875	FARSB	0.64	9.7	0.47	9.46e-20	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg08824895	chr13:115047677	UPF3A	0.58	8.86	0.44	4.78e-17	Schizophrenia;
LUSC	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	10.16	0.49	2.53e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg05110241	chr16:68378359	PRMT7	-0.58	-6.72	-0.35	7.89e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg03909863	chr11:638404	DRD4	-0.39	-5.74	-0.3	2.17e-8	Systemic lupus erythematosus;
LUSC	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg10518543	chr12:38710700	ALG10B	0.41	5.79	0.3	1.66e-8	Morning vs. evening chronotype;
LUSC	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg24562669	chr7:97807699	LMTK2	-0.36	-6.15	-0.32	2.18e-9	Breast cancer;
LUSC	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg14227996	chr4:17616232	MED28	0.7	7.31	0.37	1.95e-12	Opioid sensitivity;
LUSC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg08888203	chr3:10149979	C3orf24	0.59	8.11	0.41	9.88e-15	Alzheimer's disease;
LUSC	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg14631576	chr9:95140430	CENPP	-0.34	-6.02	-0.31	4.5e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06008401	chr16:75657298	ADAT1	-0.41	-6.06	-0.31	3.72e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17828380	1.000	rs34742909	chr15:63529980	C/T	cg05507819	chr15:63340323	TPM1	-0.72	-6.21	-0.32	1.54e-9	Social communication problems;
LUSC	cis	rs4363385	0.818	rs1415966	chr1:153002864	A/G	cg25856811	chr1:152973957	SPRR3	-0.36	-5.94	-0.31	6.97e-9	Inflammatory skin disease;
LUSC	cis	rs1007190	0.881	rs75199539	chr17:42930246	A/C	cg15406952	chr17:42872593	NA	0.59	5.75	0.3	2.06e-8	DNA methylation (variation);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg14305139	chr8:142180543	DENND3	-0.4	-6.0	-0.31	5.11e-9	Mosquito bite size;
LUSC	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg24375607	chr4:120327624	NA	-0.76	-11.5	-0.53	5e-26	Corneal astigmatism;
LUSC	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9283706	0.623	rs1567316	chr5:66312103	T/G	cg11590213	chr5:66331682	MAST4	0.43	6.46	0.33	3.66e-10	Coronary artery disease;
LUSC	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.67	-0.39	1.9e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.75	-0.54	6.51e-27	Mean corpuscular volume;
LUSC	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18932078	chr1:2524107	MMEL1	0.29	6.26	0.32	1.18e-9	Ulcerative colitis;
LUSC	cis	rs2067615	0.524	rs4246257	chr12:107062329	C/T	cg15890332	chr12:107067104	RFX4	0.34	6.05	0.31	3.79e-9	Heart rate;
LUSC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.48e-28	Motion sickness;
LUSC	cis	rs6599077	1.000	rs6809231	chr3:40097789	A/G	cg13683864	chr3:40499215	RPL14	-0.6	-7.36	-0.37	1.4e-12	Sleep-related phenotypes;
LUSC	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg17385448	chr1:15911702	AGMAT	0.35	5.94	0.31	7.27e-9	Systolic blood pressure;
LUSC	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-17.98	-0.7	4.8e-51	Primary sclerosing cholangitis;
LUSC	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg27068330	chr11:65405492	SIPA1	-0.76	-10.88	-0.51	8.57e-24	Acne (severe);
LUSC	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07080220	chr10:102295463	HIF1AN	0.66	9.42	0.46	7.42e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg17127132	chr2:85788382	GGCX	0.46	7.18	0.37	4.44e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.03	-0.31	4.28e-9	Platelet count;
LUSC	cis	rs72781680	0.665	rs2675356	chr2:24074734	C/T	cg08917208	chr2:24149416	ATAD2B	0.59	6.81	0.35	4.57e-11	Lymphocyte counts;
LUSC	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg19468946	chr17:37922297	IKZF3	-0.44	-7.0	-0.36	1.38e-11	Self-reported allergy;
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg06877462	chr1:205807181	PM20D1	0.49	9.1	0.45	8.47e-18	Menarche (age at onset);
LUSC	trans	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.49	-6.81	-0.35	4.43e-11	Corneal astigmatism;
LUSC	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg05738196	chr6:26577821	NA	0.77	13.99	0.61	2.45e-35	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg25214090	chr10:38739885	LOC399744	0.55	8.01	0.4	2e-14	Corneal astigmatism;
LUSC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg13939156	chr17:80058883	NA	-0.33	-6.43	-0.33	4.45e-10	Life satisfaction;
LUSC	cis	rs4356932	1.000	rs4859584	chr4:76943137	C/G	cg00809888	chr4:76862425	NAAA	0.34	5.67	0.3	3.12e-8	Blood protein levels;
LUSC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.27	-0.32	1.1e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.63	-5.92	-0.31	8.15e-9	Major depressive disorder;
LUSC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.66	10.97	0.51	3.93e-24	Bone mineral density;
LUSC	cis	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.38	-0.37	1.29e-12	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg23711669	chr6:146136114	FBXO30	-0.92	-17.48	-0.69	4.69e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2273669	0.504	rs57212784	chr6:109481678	A/G	cg05315195	chr6:109294784	ARMC2	-0.55	-5.85	-0.3	1.18e-8	Prostate cancer;
LUSC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.43e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg12473912	chr3:136751656	NA	0.39	6.82	0.35	4.27e-11	Neuroticism;
LUSC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.97	-0.31	5.93e-9	Obesity-related traits;
LUSC	cis	rs2446066	0.872	rs11170558	chr12:53835035	G/T	cg20730629	chr12:53886622	MAP3K12	-0.43	-5.81	-0.3	1.43e-8	Red blood cell count;
LUSC	cis	rs9796	0.870	rs3101436	chr15:41287689	A/G	cg18705301	chr15:41695430	NDUFAF1	0.45	7.89	0.4	4.43e-14	Menopause (age at onset);
LUSC	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg05340658	chr4:99064831	C4orf37	0.45	7.1	0.36	7.68e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg01134436	chr17:81009848	B3GNTL1	0.63	6.13	0.32	2.54e-9	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs61931739	0.649	rs708136	chr12:33737411	A/G	cg26384229	chr12:38710491	ALG10B	0.42	6.03	0.31	4.23e-9	Morning vs. evening chronotype;
LUSC	trans	rs800082	0.516	rs9852425	chr3:144215405	A/C	cg24215973	chr2:240111563	HDAC4	0.45	6.93	0.35	2.24e-11	Smoking behavior;
LUSC	trans	rs72674100	1.000	rs28645642	chr4:97971149	C/T	cg09670535	chr1:18959427	PAX7	-0.57	-6.0	-0.31	5.04e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.68	11.53	0.53	3.94e-26	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.5	0.56	1.14e-29	Motion sickness;
LUSC	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.54e-8	Breast cancer;
LUSC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg10645314	chr2:3704589	ALLC	-0.73	-11.69	-0.54	1.05e-26	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	0.93	17.84	0.7	1.8e-50	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs12692738	0.526	rs355875	chr2:165632755	G/A	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg17595323	chr11:93583763	C11orf90	-0.31	-5.67	-0.3	3.09e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg12165864	chr7:66369176	NA	-0.53	-7.07	-0.36	9.3e-12	Corneal structure;
LUSC	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.81	0.65	1.92e-42	Bladder cancer;
LUSC	cis	rs2625529	0.652	rs2957740	chr15:72307691	A/G	cg16672083	chr15:72433130	SENP8	0.49	8.16	0.41	6.87e-15	Red blood cell count;
LUSC	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.47	7.63	0.39	2.4e-13	Sum eosinophil basophil counts;
LUSC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg25036284	chr2:26402008	FAM59B	0.76	11.07	0.52	1.74e-24	Gut microbiome composition (summer);
LUSC	cis	rs6599077	1.000	rs9848462	chr3:40097204	A/T	cg13683864	chr3:40499215	RPL14	0.58	7.57	0.38	3.76e-13	Sleep-related phenotypes;
LUSC	cis	rs11785693	0.862	rs11783719	chr8:4991311	G/T	cg26367366	chr8:4980734	NA	0.8	9.4	0.46	8.78e-19	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07677032	chr17:61819896	STRADA	0.55	8.97	0.44	2.1e-17	Prudent dietary pattern;
LUSC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg07703079	chr11:430292	ANO9	0.63	6.88	0.35	2.92e-11	Body mass index;
LUSC	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg11645453	chr3:52864694	ITIH4	0.59	14.12	0.61	8.31e-36	Schizophrenia;
LUSC	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg13010199	chr12:38710504	ALG10B	0.55	8.38	0.42	1.44e-15	Morning vs. evening chronotype;
LUSC	cis	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg07988820	chr12:82153109	PPFIA2	-0.42	-6.07	-0.32	3.48e-9	Resting heart rate;
LUSC	cis	rs9394438	0.628	rs4714078	chr6:37543852	G/A	cg00985040	chr6:37553208	NA	-0.4	-8.95	-0.44	2.42e-17	IgG glycosylation;
LUSC	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	8.52	0.42	5.36e-16	Lung cancer in ever smokers;
LUSC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg14949292	chr17:78079608	GAA	-0.39	-6.51	-0.34	2.69e-10	Yeast infection;
LUSC	cis	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.21	-0.32	1.56e-9	Resting heart rate;
LUSC	cis	rs9929218	0.954	rs12919719	chr16:68822341	C/G	cg02972257	chr16:68554789	NA	0.4	5.71	0.3	2.46e-8	Colorectal cancer;
LUSC	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.32	-18.53	-0.71	3.15e-53	Hip circumference adjusted for BMI;
LUSC	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg05925327	chr15:68127851	NA	-0.4	-6.13	-0.32	2.41e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.64	0.54	1.68e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg15711740	chr2:61764176	XPO1	-0.47	-7.39	-0.37	1.21e-12	Tuberculosis;
LUSC	trans	rs7939886	0.920	rs59168428	chr11:55956018	G/A	cg15704280	chr7:45808275	SEPT13	0.89	6.88	0.35	3e-11	Myopia (pathological);
LUSC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg05043794	chr9:111880884	C9orf5	-0.3	-6.58	-0.34	1.84e-10	Menarche (age at onset);
LUSC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg26338869	chr17:61819248	STRADA	0.42	6.1	0.32	2.96e-9	Prudent dietary pattern;
LUSC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Depression;
LUSC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.48	-7.99	-0.4	2.21e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg16414030	chr3:133502952	NA	-0.39	-5.85	-0.3	1.17e-8	Iron status biomarkers;
LUSC	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.9	-0.4	4.2e-14	Height;
LUSC	cis	rs727505	0.721	rs55890146	chr7:124755461	A/T	cg23710748	chr7:124431027	NA	-0.4	-7.08	-0.36	8.69e-12	Lewy body disease;
LUSC	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg24631222	chr15:78858424	CHRNA5	0.64	8.51	0.42	5.9e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18876405	chr7:65276391	NA	-0.55	-8.71	-0.43	1.44e-16	Aortic root size;
LUSC	cis	rs807669	0.505	rs28651174	chr22:19236489	C/T	cg02655711	chr22:19163373	SLC25A1	0.47	8.41	0.42	1.23e-15	Metabolite levels;
LUSC	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.57	10.07	0.48	5.38e-21	Birth weight;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11594513	chr5:134734934	H2AFY	0.46	6.44	0.33	4.22e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18000306	chr6:288505	NA	0.33	6.33	0.33	7.8e-10	Menopause (age at onset);
LUSC	cis	rs2637266	1.000	rs7073355	chr10:78354419	G/A	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	1.21	21.86	0.77	2.17e-66	Primary sclerosing cholangitis;
LUSC	cis	rs9309473	0.607	rs11686504	chr2:73579812	T/C	cg20560298	chr2:73613845	ALMS1	-0.55	-8.06	-0.4	1.39e-14	Metabolite levels;
LUSC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20127549	chr11:118868876	CCDC84	-0.4	-5.96	-0.31	6.3e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg07741184	chr6:167504864	NA	0.45	7.6	0.38	2.99e-13	Primary biliary cholangitis;
LUSC	cis	rs2109514	1.000	rs6466579	chr7:116151155	T/C	cg12739419	chr7:116140593	CAV2	-0.29	-6.36	-0.33	6.46e-10	Prevalent atrial fibrillation;
LUSC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.73	-0.39	1.24e-13	Blood metabolite levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26708548	chr2:232791101	NPPC	-0.42	-6.02	-0.31	4.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg22709100	chr7:91322751	NA	0.4	5.86	0.31	1.13e-8	Breast cancer;
LUSC	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg19792802	chr11:65647270	CTSW	-0.41	-6.28	-0.32	1.05e-9	Crohn's disease;
LUSC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.04e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg17366294	chr4:99064904	C4orf37	0.52	8.55	0.42	4.5e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	0.96	12.98	0.58	1.79e-31	Eosinophil percentage of granulocytes;
LUSC	cis	rs8141797	0.901	rs4306797	chr22:24453375	C/T	cg00411358	chr22:24577142	SUSD2	0.58	5.83	0.3	1.32e-8	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.48	-6.71	-0.34	8.55e-11	IgG glycosylation;
LUSC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg06096015	chr1:231504339	EGLN1	0.58	10.39	0.49	4.2e-22	Hemoglobin concentration;
LUSC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08859206	chr1:53392774	SCP2	0.56	9.89	0.48	2.16e-20	Monocyte count;
LUSC	cis	rs10992471	0.603	rs10761160	chr9:95208701	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.77	-0.39	9.49e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.54	-0.38	4.48e-13	Blood metabolite levels;
LUSC	cis	rs1395	0.922	rs11608	chr2:27435374	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.4	-6.57	-0.34	1.99e-10	Blood metabolite levels;
LUSC	trans	rs800082	0.934	rs1007566	chr3:144311752	G/A	cg24215973	chr2:240111563	HDAC4	-0.46	-7.04	-0.36	1.08e-11	Smoking behavior;
LUSC	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.68	-11.83	-0.54	3.3699999999999996e-27	Electrocardiographic conduction measures;
LUSC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg18240062	chr17:79603768	NPLOC4	0.58	10.12	0.48	3.7e-21	Eye color traits;
LUSC	cis	rs965469	1.000	rs77763497	chr20:3250007	A/G	cg25506879	chr20:3388711	C20orf194	-0.55	-6.3	-0.33	9.53e-10	IFN-related cytopenia;
LUSC	cis	rs7084921	0.579	rs11597870	chr10:101847857	T/C	cg11888571	chr10:102027403	CWF19L1	-0.47	-6.36	-0.33	6.53e-10	Bone mineral density;
LUSC	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-7.27	-0.37	2.62e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg00105475	chr2:10696890	NA	0.35	5.92	0.31	7.8e-9	Prostate cancer;
LUSC	trans	rs4650994	0.544	rs2811311	chr1:178617337	A/G	cg05059571	chr16:84539110	KIAA1609	0.47	8.87	0.44	4.44e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg13010199	chr12:38710504	ALG10B	0.65	10.19	0.49	2.11e-21	Bladder cancer;
LUSC	cis	rs1775715	0.737	rs2808078	chr10:32172552	C/T	cg18675610	chr10:32216311	ARHGAP12	0.3	6.56	0.34	2.04e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05165339	chr4:1420672	NA	-0.3	-6.93	-0.35	2.15e-11	Longevity;
LUSC	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.42	-7.56	-0.38	4.01e-13	Glomerular filtration rate;
LUSC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg06713675	chr4:122721982	EXOSC9	-0.56	-9.68	-0.47	1.09e-19	Type 2 diabetes;
LUSC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.46	8.03	0.4	1.72e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2200578	0.841	rs112377545	chr2:99774823	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.6	6.84	0.35	3.84e-11	IgG glycosylation;
LUSC	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg11789530	chr4:8429930	ACOX3	-0.41	-6.04	-0.31	4.01e-9	Response to antineoplastic agents;
LUSC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg06145435	chr7:1022769	CYP2W1	0.34	7.39	0.37	1.18e-12	Longevity;Endometriosis;
LUSC	cis	rs2580764	0.566	rs2920878	chr2:55296415	C/T	cg09592903	chr2:55203963	RTN4	0.47	9.51	0.46	4.04e-19	Mean platelet volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14094333	chr4:38666051	KLF3;FLJ13197	-0.49	-5.96	-0.31	6.36e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	9.75	0.47	6.31e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg16342193	chr10:102329863	NA	-0.34	-6.13	-0.32	2.41e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs75920871	0.557	rs7123336	chr11:116782819	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-6.06	-0.31	3.78e-9	Subjective well-being;
LUSC	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg04733989	chr22:42467013	NAGA	0.4	6.7	0.34	8.93e-11	Cognitive function;
LUSC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.75	0.39	1.11e-13	Bipolar disorder;
LUSC	cis	rs7851660	0.874	rs7847010	chr9:100630439	T/C	cg13688889	chr9:100608707	NA	-0.57	-8.85	-0.44	5.03e-17	Strep throat;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13015042	chr6:170102002	WDR27;C6orf120	-0.44	-6.13	-0.32	2.45e-9	Hepatitis;
LUSC	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg14675211	chr2:100938903	LONRF2	0.37	5.76	0.3	1.94e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg17507749	chr15:85114479	UBE2QP1	0.59	7.46	0.38	7.38e-13	Schizophrenia;
LUSC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg05484376	chr2:27715224	FNDC4	-0.3	-5.65	-0.3	3.46e-8	Total body bone mineral density;
LUSC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05535760	chr7:792225	HEATR2	-0.72	-8.81	-0.43	6.85e-17	Cerebrospinal P-tau181p levels;
LUSC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg01802117	chr1:53393560	SCP2	-0.43	-7.19	-0.37	4.19e-12	Monocyte count;
LUSC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg24675658	chr1:53192096	ZYG11B	-0.58	-9.04	-0.44	1.31e-17	Monocyte count;
LUSC	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg00898013	chr13:113819073	PROZ	0.53	7.96	0.4	2.75e-14	Platelet distribution width;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg12419862	chr22:24373484	LOC391322	-0.88	-14.24	-0.61	2.64e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.8	11.44	0.53	8.58e-26	Corneal astigmatism;
LUSC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.89	0.31	9.52e-9	Menopause (age at onset);
LUSC	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg00277334	chr10:82204260	NA	-0.51	-7.34	-0.37	1.64e-12	Post bronchodilator FEV1;
LUSC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg22875332	chr1:76189707	ACADM	0.72	9.26	0.45	2.47e-18	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs1941687	0.797	rs7228309	chr18:31412519	A/G	cg27147174	chr7:100797783	AP1S1	0.45	6.78	0.35	5.47e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg00339695	chr16:24857497	SLC5A11	0.35	5.67	0.3	3.13e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11630290	0.592	rs12232336	chr15:64153357	T/C	cg12036633	chr15:63758958	NA	0.52	6.67	0.34	1.05e-10	Iris characteristics;
LUSC	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg04362960	chr10:104952993	NT5C2	0.65	9.37	0.46	1.13e-18	Arsenic metabolism;
LUSC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg22166914	chr1:53195759	ZYG11B	0.66	11.28	0.53	3.19e-25	Monocyte count;
LUSC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.85	0.3	1.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg08742575	chr21:47604166	C21orf56	0.46	6.95	0.36	1.88e-11	Testicular germ cell tumor;
LUSC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	13.48	0.59	2.34e-33	Total body bone mineral density;
LUSC	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.59	-0.38	3.28e-13	Retinal vascular caliber;
LUSC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-8.07	-0.4	1.27e-14	Personality dimensions;
LUSC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11166629	0.637	rs6577657	chr8:135594153	G/C	cg27224718	chr8:135614730	ZFAT	0.56	8.08	0.4	1.19e-14	Smoking quantity;
LUSC	cis	rs11674184	0.686	rs2358039	chr2:11729606	A/G	cg07314298	chr2:11723111	GREB1	-0.73	-12.33	-0.56	4.75e-29	Endometriosis;
LUSC	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg13556452	chr1:2391241	NA	-0.34	-6.13	-0.32	2.41e-9	Schizophrenia;
LUSC	trans	rs1997103	0.954	rs7811098	chr7:55413012	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.38	0.37	1.26e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs1459104	0.571	rs10459012	chr11:55091574	C/A	cg03929089	chr4:120376271	NA	0.55	6.15	0.32	2.25e-9	Body mass index;
LUSC	cis	rs2219968	0.828	rs62508223	chr8:78941534	G/C	cg00738934	chr8:78996279	NA	-0.41	-7.25	-0.37	2.94e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs450533	0.826	rs429941	chr4:107836311	C/T	cg19546012	chr19:752860	C19orf21	0.31	6.03	0.31	4.37e-9	Cancer;
LUSC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg04518342	chr5:131593106	PDLIM4	0.42	7.57	0.38	3.6e-13	Breast cancer;
LUSC	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg03929089	chr4:120376271	NA	-0.58	-7.47	-0.38	6.9e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.81	13.15	0.58	4.07e-32	Selective IgA deficiency;
LUSC	cis	rs1983170	0.808	rs10874789	chr1:92017990	T/C	cg25838465	chr1:92012736	NA	0.41	5.8	0.3	1.57e-8	Eosinophil percentage of white cells;
LUSC	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.41	6.6	0.34	1.65e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.05	0.31	3.83e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4499344	0.604	rs259245	chr19:33145106	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.7	10.31	0.49	8.26e-22	Mean platelet volume;
LUSC	cis	rs2932538	0.961	rs6537746	chr1:113163529	C/T	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.73	-0.47	7.19e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg19729930	chr2:74357872	NA	0.87	15.13	0.64	9.49e-40	Gestational age at birth (maternal effect);
LUSC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg03522245	chr20:25566470	NINL	0.35	5.7	0.3	2.58e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1975974	1.000	rs4889703	chr17:21721663	T/C	cg18423549	chr17:21743878	NA	-0.51	-7.73	-0.39	1.29e-13	Psoriasis;
LUSC	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg05507819	chr15:63340323	TPM1	-0.62	-8.73	-0.43	1.26e-16	Platelet count;
LUSC	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg15448220	chr1:150897856	SETDB1	0.43	6.38	0.33	5.75e-10	Melanoma;
LUSC	cis	rs117623576	0.941	rs72778716	chr10:32370541	G/A	cg03047570	chr10:32398778	NA	-0.7	-6.6	-0.34	1.62e-10	Anti-saccade response;
LUSC	cis	rs6500395	0.775	rs4471681	chr16:48665946	C/T	cg04672837	chr16:48644449	N4BP1	0.47	7.02	0.36	1.22e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs10100465	0.961	rs4876727	chr8:118633834	G/A	cg09430518	chr8:118662568	NA	-0.28	-5.66	-0.3	3.28e-8	Leprosy;
LUSC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.93	0.4	3.23e-14	Prudent dietary pattern;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22792432	chr18:18691067	ROCK1	-0.44	-6.42	-0.33	4.64e-10	Electrocardiographic conduction measures;
LUSC	cis	rs981844	0.740	rs12644642	chr4:154686550	G/C	cg14289246	chr4:154710475	SFRP2	-0.53	-7.57	-0.38	3.58e-13	Response to statins (LDL cholesterol change);
LUSC	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.22	0.32	1.5e-9	Schizophrenia;
LUSC	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg04058563	chr4:185651563	MLF1IP	-0.79	-11.9	-0.55	1.77e-27	Blood protein levels;
LUSC	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg04374321	chr14:90722782	PSMC1	-0.44	-6.57	-0.34	1.89e-10	Mortality in heart failure;
LUSC	cis	rs17014483	0.749	rs3017897	chr4:89646706	C/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.62	5.78	0.3	1.68e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18854424	chr1:2615690	NA	0.51	10.18	0.49	2.18e-21	Ulcerative colitis;
LUSC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-12.45	-0.56	1.77e-29	Alzheimer's disease;
LUSC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg04450456	chr4:17643702	FAM184B	-0.39	-6.71	-0.34	8.38e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9341808	0.538	rs12176343	chr6:81027387	G/A	cg08355045	chr6:80787529	NA	-0.42	-7.15	-0.36	5.41e-12	Sitting height ratio;
LUSC	cis	rs7640424	0.929	rs326358	chr3:107822310	C/T	cg09227934	chr3:107805635	CD47	0.46	7.49	0.38	6.14e-13	Body mass index;
LUSC	cis	rs9462027	0.540	rs4282407	chr6:34830162	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.73	-0.3	2.29e-8	Systemic lupus erythematosus;
LUSC	cis	rs7580658	0.963	rs12052483	chr2:128136820	T/G	cg09760422	chr2:128146352	NA	-0.33	-7.25	-0.37	2.91e-12	Protein C levels;
LUSC	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg09092052	chr15:45571596	NA	-0.45	-6.18	-0.32	1.86e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	0.97	22.52	0.78	5.93e-69	Urate levels in lean individuals;
LUSC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs472402	0.540	rs3776431	chr5:6618756	T/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.4	-5.91	-0.31	8.3e-9	Response to amphetamines;
LUSC	cis	rs977987	0.966	rs62060551	chr16:75502312	A/C	cg04384234	chr16:75411784	CFDP1	-0.49	-8.11	-0.41	9.52e-15	Dupuytren's disease;
LUSC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg20203395	chr5:56204925	C5orf35	-0.56	-8.06	-0.4	1.39e-14	Coronary artery disease;
LUSC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg07952391	chr2:88470173	THNSL2	0.76	6.71	0.34	8.5e-11	Plasma clusterin levels;
LUSC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02018176	chr4:1364513	KIAA1530	0.74	13.67	0.6	4.37e-34	Longevity;
LUSC	cis	rs11229555	0.574	rs12292024	chr11:58186716	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.78	-0.39	9.19e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12900413	0.687	rs28650972	chr15:90311941	C/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.82	-0.3	1.37e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg24579218	chr15:68104479	NA	-0.37	-6.46	-0.33	3.68e-10	Obesity;
LUSC	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.4	5.94	0.31	7.05e-9	Lung cancer;
LUSC	cis	rs9462027	0.628	rs9469917	chr6:34831369	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.64	-0.3	3.58e-8	Systemic lupus erythematosus;
LUSC	cis	rs501916	0.833	rs59184310	chr15:48050205	A/T	cg16110827	chr15:48056943	SEMA6D	-0.47	-7.16	-0.36	5.29e-12	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg24011408	chr12:48396354	COL2A1	-0.39	-5.69	-0.3	2.82e-8	Glycated hemoglobin levels;
LUSC	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11952622	chr19:58962976	ZNF324B	0.61	8.91	0.44	3.43e-17	Mean platelet volume;
LUSC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg14092988	chr3:52407081	DNAH1	0.31	5.93	0.31	7.63e-9	Bipolar disorder;
LUSC	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-7.05	-0.36	1.06e-11	Blood metabolite levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25654301	chr17:73511699	TSEN54;CASKIN2	-0.37	-6.55	-0.34	2.11e-10	Electrocardiographic conduction measures;
LUSC	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg27661571	chr11:113659931	NA	-0.56	-6.33	-0.33	8.02e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs2286885	0.896	rs62578061	chr9:129248219	C/T	cg15282417	chr9:129245246	FAM125B	0.38	6.36	0.33	6.52e-10	Intraocular pressure;
LUSC	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg05343316	chr1:45956843	TESK2	0.66	9.01	0.44	1.62e-17	Platelet count;
LUSC	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg22777020	chr22:31556080	RNF185	-0.46	-5.8	-0.3	1.55e-8	Paclitaxel-induced neuropathy;
LUSC	trans	rs7939886	0.920	rs76934983	chr11:55993334	A/C	cg03929089	chr4:120376271	NA	0.82	6.13	0.32	2.55e-9	Myopia (pathological);
LUSC	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg13393036	chr8:95962371	TP53INP1	-0.31	-6.14	-0.32	2.39e-9	Type 2 diabetes;
LUSC	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.18	0.45	4.53e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg01503450	chr10:980765	NA	-0.37	-5.84	-0.3	1.26e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.74	12.0	0.55	7.69e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg05738196	chr6:26577821	NA	-0.48	-7.14	-0.36	5.85e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.74	-11.5	-0.53	5.13e-26	Menarche (age at onset);
LUSC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16680214	chr1:154839983	KCNN3	-0.53	-10.03	-0.48	7.38e-21	Prostate cancer;
LUSC	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg21045802	chr8:109455806	TTC35	0.46	7.15	0.36	5.42e-12	Dupuytren's disease;
LUSC	trans	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-6.32	-0.33	8.54e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs67072384	0.688	rs66948758	chr11:72440074	A/G	cg04827223	chr11:72435913	ARAP1	-0.82	-8.06	-0.4	1.37e-14	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.56	0.34	2.02e-10	Iron status biomarkers;
LUSC	cis	rs4363385	0.747	rs1015995	chr1:152976114	G/C	cg25856811	chr1:152973957	SPRR3	-0.34	-5.65	-0.3	3.43e-8	Inflammatory skin disease;
LUSC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	8.88	0.44	4.31e-17	Alzheimer's disease;
LUSC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08564027	chr20:61660810	NA	-0.93	-17.4	-0.69	1.01e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg07212818	chr11:638076	DRD4	-0.38	-6.49	-0.33	3.07e-10	Systemic lupus erythematosus;
LUSC	cis	rs17401966	0.522	rs4845930	chr1:10319049	G/A	cg17425144	chr1:10567563	PEX14	-0.32	-5.74	-0.3	2.15e-8	Hepatocellular carcinoma;
LUSC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08645402	chr16:4508243	NA	0.47	7.87	0.4	5.11e-14	Schizophrenia;
LUSC	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg23711669	chr6:146136114	FBXO30	0.81	14.02	0.61	1.86e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs58235267	0.591	rs4671457	chr2:63346356	C/T	cg17519650	chr2:63277830	OTX1	0.64	9.52	0.46	3.72e-19	Prostate-specific antigen levels (conditioned on lead SNPs);
LUSC	cis	rs1322639	0.614	rs4708414	chr6:169574144	C/G	cg04662567	chr6:169592167	NA	-0.33	-5.7	-0.3	2.64e-8	Pulse pressure;
LUSC	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-7.52	-0.38	5.11e-13	Height;
LUSC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09844983	chr1:28240714	RPA2	0.45	6.35	0.33	7.13e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.53	-7.19	-0.37	4.21e-12	Renal function-related traits (BUN);
LUSC	cis	rs11577318	0.579	rs35456934	chr1:26686864	G/A	cg00852783	chr1:26633632	UBXN11	-0.54	-7.44	-0.38	8.85e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.47	-7.2	-0.37	3.92e-12	Asthma (bronchodilator response);
LUSC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-0.81	-10.9	-0.51	7.43e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6543140	0.964	rs2080288	chr2:103022166	G/A	cg09003973	chr2:102972529	NA	0.55	7.14	0.36	5.69e-12	Blood protein levels;
LUSC	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg05283184	chr6:79620031	NA	-0.57	-12.05	-0.55	5.09e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg02475777	chr4:1388615	CRIPAK	0.4	6.11	0.32	2.76e-9	Obesity-related traits;
LUSC	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.89	15.26	0.64	2.9e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.61	0.38	2.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs13315871	1.000	rs13078787	chr3:58430487	C/T	cg20936604	chr3:58311152	NA	-0.72	-6.77	-0.35	5.83e-11	Cholesterol, total;
LUSC	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg07701084	chr6:150067640	NUP43	0.46	6.93	0.35	2.23e-11	Testicular germ cell tumor;
LUSC	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.66	-0.34	1.13e-10	Systolic blood pressure;
LUSC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg03929089	chr4:120376271	NA	-0.94	-16.25	-0.66	3.61e-44	Height;
LUSC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.69	6.55	0.34	2.23e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg12091567	chr17:66097778	LOC651250	-0.75	-9.37	-0.46	1.08e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg07148914	chr20:33460835	GGT7	0.57	8.63	0.43	2.56e-16	Height;
LUSC	cis	rs983392	0.836	rs17602572	chr11:59948374	C/G	cg02771260	chr11:59836817	MS4A3	-0.37	-6.09	-0.32	3.02e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.49	-11.92	-0.55	1.51e-27	Urate levels in overweight individuals;
LUSC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg05738196	chr6:26577821	NA	-0.48	-7.12	-0.36	6.61e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg24069376	chr3:38537580	EXOG	-0.39	-7.6	-0.38	3.01e-13	Electrocardiographic conduction measures;
LUSC	cis	rs117352156	0.628	rs7068466	chr10:29215600	C/T	cg06394621	chr10:29236369	NA	-0.39	-5.67	-0.3	3.13e-8	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg08975724	chr8:8085496	FLJ10661	0.44	6.35	0.33	6.86e-10	Neuroticism;
LUSC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.59	-0.5	8.37e-23	Gut microbiome composition (summer);
LUSC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg19622623	chr12:86230825	RASSF9	-0.42	-6.01	-0.31	4.85e-9	Major depressive disorder;
LUSC	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg03522245	chr20:25566470	NINL	0.36	5.89	0.31	9.51e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9341808	0.727	rs9361599	chr6:81025242	C/G	cg08355045	chr6:80787529	NA	0.56	9.99	0.48	9.78e-21	Sitting height ratio;
LUSC	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg00677455	chr12:58241039	CTDSP2	0.66	9.59	0.46	2.09e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg00945038	chr17:61921165	SMARCD2	0.54	9.61	0.47	1.85e-19	Prudent dietary pattern;
LUSC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14298792	chr15:30685198	CHRFAM7A	-0.47	-5.77	-0.3	1.78e-8	Huntington's disease progression;
LUSC	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg19875535	chr5:140030758	IK	0.5	8.28	0.41	3.06e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs57920188	0.584	rs12128330	chr1:4092926	G/A	cg20703997	chr1:4087676	NA	0.56	8.04	0.4	1.57e-14	Interleukin-17 levels;
LUSC	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg15423357	chr2:25149977	NA	0.4	7.86	0.4	5.23e-14	Body mass index;
LUSC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.23	-0.32	1.42e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.12	-19.31	-0.73	2.46e-56	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4953404	0.613	rs2346877	chr2:46892958	C/G	cg09399716	chr2:46890238	NA	-0.31	-7.12	-0.36	6.66e-12	Pulse pressure (alcohol consumption interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17470227	chr3:111579551	PHLDB2	0.43	6.41	0.33	4.9e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg25797454	chr6:150327115	RAET1K	0.34	7.8	0.39	8.18e-14	Alopecia areata;
LUSC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg22920501	chr2:26401640	FAM59B	-0.79	-11.76	-0.54	5.97e-27	Gut microbiome composition (summer);
LUSC	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg09479241	chr17:27052676	TLCD1	0.44	5.85	0.3	1.16e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06850241	chr22:41845214	NA	0.31	5.98	0.31	5.69e-9	Vitiligo;
LUSC	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg26597838	chr10:835615	NA	1.24	17.01	0.68	3.72e-47	Eosinophil percentage of granulocytes;
LUSC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	1.01	13.98	0.61	2.84e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs2625529	0.668	rs34487006	chr15:72462350	G/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.38	-0.37	1.26e-12	Red blood cell count;
LUSC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg12560992	chr17:57184187	TRIM37	-0.78	-13.67	-0.6	4.15e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs1461503	0.966	rs10892939	chr11:122841959	T/C	cg27398637	chr11:122830231	C11orf63	-0.41	-6.54	-0.34	2.29e-10	Menarche (age at onset);
LUSC	trans	rs1927790	0.697	rs7981931	chr13:96934176	C/T	cg03198741	chr6:1003969	LOC285768	-0.4	-6.01	-0.31	4.94e-9	Body mass index;
LUSC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg13047869	chr3:10149882	C3orf24	-0.66	-9.86	-0.47	2.63e-20	Alzheimer's disease;
LUSC	cis	rs11031096	0.678	rs12222136	chr11:4180148	T/C	cg18678763	chr11:4115507	RRM1	-0.4	-5.67	-0.3	3.07e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07080220	chr10:102295463	HIF1AN	0.69	8.87	0.44	4.46e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	0.91	18.43	0.71	7.95e-53	Dental caries;
LUSC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.74	-11.36	-0.53	1.59e-25	Menarche (age at onset);
LUSC	cis	rs12464559	0.522	rs12472627	chr2:152633114	C/T	cg01189475	chr2:152685088	ARL5A	0.62	6.81	0.35	4.62e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg18721089	chr20:30220636	NA	-0.37	-6.54	-0.34	2.35e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg17143192	chr8:8559678	CLDN23	0.66	9.61	0.47	1.84e-19	Obesity-related traits;
LUSC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.03	20.82	0.75	2.6e-62	Cognitive function;
LUSC	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg14346243	chr4:90757452	SNCA	-0.39	-5.65	-0.3	3.46e-8	Neuroticism;
LUSC	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg03563238	chr19:33554763	RHPN2	-0.41	-6.47	-0.33	3.59e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.13e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg01879757	chr17:41196368	BRCA1	-0.54	-8.77	-0.43	9.2e-17	Menopause (age at onset);
LUSC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg23625390	chr15:77176239	SCAPER	0.46	6.96	0.36	1.82e-11	Blood metabolite levels;
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg03461704	chr1:205818484	PM20D1	0.35	5.75	0.3	2.04e-8	Menarche (age at onset);
LUSC	cis	rs6987853	0.933	rs55881007	chr8:42367290	A/G	cg09913449	chr8:42400586	C8orf40	-0.48	-7.95	-0.4	2.82e-14	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg26408565	chr15:76604113	ETFA	-0.49	-7.89	-0.4	4.31e-14	Blood metabolite levels;
LUSC	cis	rs9420	0.961	rs11229148	chr11:57621460	A/T	cg23127183	chr11:57508653	C11orf31	-0.56	-8.52	-0.42	5.43e-16	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25072359	chr17:41440525	NA	0.65	9.38	0.46	1.06e-18	Menopause (age at onset);
LUSC	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg09365446	chr1:150670422	GOLPH3L	0.47	7.01	0.36	1.33e-11	Melanoma;
LUSC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.68	-10.45	-0.5	2.72e-22	Aortic root size;
LUSC	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg21775007	chr8:11205619	TDH	0.8	13.51	0.59	1.82e-33	Retinal vascular caliber;
LUSC	cis	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg06521331	chr12:34319734	NA	0.37	6.2	0.32	1.62e-9	Morning vs. evening chronotype;
LUSC	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-1.0	-9.46	-0.46	5.9e-19	Mitochondrial DNA levels;
LUSC	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg11502198	chr6:26597334	ABT1	0.6	9.37	0.46	1.09e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg17173187	chr15:85201210	NMB	0.5	9.39	0.46	9.83e-19	Schizophrenia;
LUSC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg13560548	chr3:10150139	C3orf24	0.54	7.47	0.38	6.97e-13	Alzheimer's disease;
LUSC	cis	rs7674212	0.570	rs2711898	chr4:104063071	C/T	cg16532752	chr4:104119610	CENPE	-0.43	-5.9	-0.31	9.13e-9	Type 2 diabetes;
LUSC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg01528321	chr10:82214614	TSPAN14	0.61	8.9	0.44	3.62e-17	Post bronchodilator FEV1;
LUSC	trans	rs853679	0.546	rs200996	chr6:27811828	G/A	cg01620082	chr3:125678407	NA	-0.7	-7.27	-0.37	2.53e-12	Depression;
LUSC	cis	rs981844	0.712	rs4302444	chr4:154745663	A/G	cg14289246	chr4:154710475	SFRP2	-0.44	-6.06	-0.31	3.74e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs2282802	0.685	rs35214989	chr5:139636127	T/C	cg26211634	chr5:139558579	C5orf32	0.44	8.2	0.41	5.25e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08028037	chr13:52027479	INTS6	-0.5	-5.94	-0.31	7.01e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06481639	chr22:41940642	POLR3H	-0.49	-6.02	-0.31	4.66e-9	Vitiligo;
LUSC	cis	rs2708377	0.790	rs73051387	chr12:11314463	A/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.84	7.99	0.4	2.15e-14	Bitter taste perception;
LUSC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg16339924	chr4:17578868	LAP3	0.59	9.2	0.45	3.85e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	1.03	17.7	0.7	6.21e-50	Coronary artery disease;
LUSC	cis	rs7428496	0.510	rs13089219	chr3:142305956	C/G	cg16271453	chr3:142027066	XRN1	-0.48	-8.1	-0.41	1.07e-14	Mean corpuscular hemoglobin;
LUSC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6546886	0.912	rs4853009	chr2:74296411	G/A	cg14702570	chr2:74259524	NA	-0.31	-5.81	-0.3	1.45e-8	Dialysis-related mortality;
LUSC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg23029597	chr12:123009494	RSRC2	-0.73	-10.02	-0.48	7.75e-21	Body mass index;
LUSC	cis	rs1018836	0.663	rs56784954	chr8:91505094	C/T	cg16814680	chr8:91681699	NA	-0.71	-10.89	-0.51	7.52e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1662342	1.000	rs56309710	chr18:3252391	C/A	cg00760847	chr18:3262519	MYL12B	-0.59	-5.74	-0.3	2.16e-8	QRS duration;
LUSC	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.83	0.47	3.35e-20	Arsenic metabolism;
LUSC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg16339924	chr4:17578868	LAP3	0.59	9.02	0.44	1.52e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08089702	chr22:21822289	NA	0.46	6.31	0.33	9.04e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg05855489	chr10:104503620	C10orf26	-0.76	-12.89	-0.58	3.89e-31	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg11709110	chr19:1989583	BTBD2	0.33	5.69	0.3	2.78e-8	Coronary artery disease;
LUSC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg16060761	chr17:80687452	NA	-0.53	-8.0	-0.4	2.1e-14	Glycated hemoglobin levels;
LUSC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	10.75	0.51	2.33e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs11700980	0.551	rs56852856	chr21:30114177	G/A	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg00033643	chr7:134001901	SLC35B4	0.45	7.11	0.36	7.11e-12	Mean platelet volume;
LUSC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg04369109	chr6:150039330	LATS1	-0.56	-8.17	-0.41	6.41e-15	Lung cancer;
LUSC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.63	0.65	1.06e-41	Platelet count;
LUSC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.28	0.32	1.08e-9	Lung cancer;
LUSC	cis	rs1865721	0.682	rs1561080	chr18:73145847	A/G	cg26385618	chr18:73139727	C18orf62	-0.49	-9.32	-0.45	1.65e-18	Intelligence;
LUSC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg22437258	chr11:111473054	SIK2	0.53	7.49	0.38	6.36e-13	Primary sclerosing cholangitis;
LUSC	cis	rs2652834	0.851	rs7175185	chr15:63425337	A/G	cg05507819	chr15:63340323	TPM1	0.45	5.82	0.3	1.37e-8	HDL cholesterol;
LUSC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg16325326	chr1:53192061	ZYG11B	0.94	17.8	0.7	2.46e-50	Monocyte count;
LUSC	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg20607287	chr7:12443886	VWDE	-0.62	-7.49	-0.38	6.29e-13	Coronary artery disease;
LUSC	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg16524733	chr11:117070046	TAGLN	0.3	5.73	0.3	2.2e-8	Blood protein levels;
LUSC	cis	rs2267137	0.836	rs2283855	chr22:29796775	T/C	cg07256473	chr22:29710276	RASL10A	0.37	7.07	0.36	9.28e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs12681287	0.547	rs6998303	chr8:87510185	T/C	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg11693508	chr17:37793320	STARD3	0.53	6.43	0.33	4.36e-10	Bipolar disorder;
LUSC	trans	rs2262909	0.962	rs409439	chr19:22227432	C/T	cg17074339	chr11:11642133	GALNTL4	-0.46	-7.07	-0.36	9.1e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	9.1	0.45	8.06e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg21231944	chr12:82153410	PPFIA2	-0.38	-6.09	-0.32	3.07e-9	Resting heart rate;
LUSC	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg11245181	chr6:149772854	ZC3H12D	0.29	6.28	0.33	1.04e-9	Dupuytren's disease;
LUSC	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-6.43	-0.33	4.33e-10	Eosinophil percentage of white cells;
LUSC	cis	rs56399783	0.901	rs73033408	chr7:2879755	C/T	cg14895029	chr7:2775587	GNA12	0.57	6.41	0.33	4.84e-10	Childhood ear infection;
LUSC	cis	rs6599077	1.000	rs6599078	chr3:40096671	T/G	cg13683864	chr3:40499215	RPL14	-0.6	-7.64	-0.39	2.38e-13	Sleep-related phenotypes;
LUSC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.8	-0.43	7.24e-17	Platelet count;
LUSC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	7.5	0.38	5.86e-13	Personality dimensions;
LUSC	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg00310523	chr12:86230176	RASSF9	-0.42	-7.52	-0.38	5.04e-13	Major depressive disorder;
LUSC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg22920501	chr2:26401640	FAM59B	0.75	10.46	0.5	2.42e-22	Gut microbiome composition (summer);
LUSC	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg12935359	chr14:103987150	CKB	-0.63	-10.34	-0.49	6.52e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg17764715	chr19:33622953	WDR88	0.6	8.33	0.41	2.08e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24110177	chr3:50126178	RBM5	-0.55	-9.07	-0.44	1e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-6.95	-0.36	1.93e-11	Blood metabolite levels;
LUSC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg24675658	chr1:53192096	ZYG11B	0.62	9.91	0.48	1.78e-20	Monocyte count;
LUSC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.26	0.49	1.23e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs57024841	0.500	rs6560652	chr9:139830940	C/T	cg00693599	chr9:139836323	FBXW5	-0.48	-8.07	-0.4	1.28e-14	Beta-trace protein levels;
LUSC	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg03894339	chr8:19674705	INTS10	0.8	9.9	0.48	1.92e-20	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	0.88	13.17	0.58	3.34e-32	Menopause (age at onset);
LUSC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.61	0.5	7.35e-23	Monocyte percentage of white cells;
LUSC	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg26727032	chr16:67993705	SLC12A4	-0.41	-6.48	-0.33	3.32e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg06917634	chr15:78832804	PSMA4	0.49	6.05	0.31	3.95e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs2262909	0.924	rs4290587	chr19:22164646	A/G	cg05197062	chr11:11642011	GALNTL4	-0.51	-7.0	-0.36	1.39e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg20887711	chr4:1340912	KIAA1530	0.46	7.09	0.36	8.2e-12	Obesity-related traits;
LUSC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg05025164	chr4:1340916	KIAA1530	0.43	6.43	0.33	4.39e-10	Obesity-related traits;
LUSC	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg05768032	chr16:30646687	NA	0.38	5.65	0.3	3.5e-8	Multiple myeloma;
LUSC	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg18825076	chr15:78729989	IREB2	0.46	6.42	0.33	4.77e-10	Post bronchodilator FEV1;
LUSC	cis	rs2742234	0.666	rs715106	chr10:43616751	C/A	cg02780029	chr10:43622663	RET	-0.35	-5.9	-0.31	8.98e-9	Hirschsprung disease;
LUSC	trans	rs11165623	0.792	rs13375510	chr1:96920723	A/G	cg10631902	chr5:14652156	NA	-0.55	-8.99	-0.44	1.9e-17	Hip circumference;Waist circumference;
LUSC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg07212818	chr11:638076	DRD4	-0.38	-6.49	-0.33	3.07e-10	Systemic lupus erythematosus;
LUSC	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg18105134	chr13:113819100	PROZ	0.66	9.88	0.48	2.32e-20	Platelet distribution width;
LUSC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg13047869	chr3:10149882	C3orf24	0.63	9.09	0.45	9.2e-18	Alzheimer's disease;
LUSC	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.87	14.46	0.62	3.85e-37	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg15556689	chr8:8085844	FLJ10661	0.65	9.15	0.45	5.69e-18	Neuroticism;
LUSC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.69	12.31	0.56	5.48e-29	Diastolic blood pressure;
LUSC	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg25319279	chr11:5960081	NA	-0.43	-6.69	-0.34	9.44e-11	DNA methylation (variation);
LUSC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.38	-0.49	4.71e-22	Gut microbiome composition (summer);
LUSC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.48e-9	Menopause (age at onset);
LUSC	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg16342193	chr10:102329863	NA	-0.35	-6.22	-0.32	1.53e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.95	0.44	2.53e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg05714579	chr10:131428358	MGMT	0.51	7.66	0.39	2e-13	Response to temozolomide;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg16817946	chr17:40950804	CNTD1;CCDC56	0.36	6.26	0.32	1.16e-9	Educational attainment (years of education);
LUSC	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg06623918	chr6:96969491	KIAA0776	0.92	16.46	0.67	5.46e-45	Headache;
LUSC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12379764	chr21:47803548	PCNT	-0.45	-6.17	-0.32	2.01e-9	Testicular germ cell tumor;
LUSC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.92	0.58	2.97e-31	Prudent dietary pattern;
LUSC	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08564027	chr20:61660810	NA	0.91	17.46	0.69	5.62e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	12.25	0.56	9.75e-29	Menarche (age at onset);
LUSC	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg26384229	chr12:38710491	ALG10B	0.93	15.61	0.65	1.21e-41	Bladder cancer;
LUSC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg15110403	chr19:17392923	ANKLE1	-0.59	-7.94	-0.4	3.09e-14	Systemic lupus erythematosus;
LUSC	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg05925327	chr15:68127851	NA	-0.38	-6.04	-0.31	4.22e-9	Restless legs syndrome;
LUSC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg11645453	chr3:52864694	ITIH4	0.32	7.55	0.38	4.18e-13	Bipolar disorder;
LUSC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg26441486	chr22:50317300	CRELD2	-0.54	-8.21	-0.41	4.86e-15	Schizophrenia;
LUSC	cis	rs72781680	0.821	rs1022346	chr2:24127849	T/C	cg08917208	chr2:24149416	ATAD2B	0.59	6.83	0.35	3.96e-11	Lymphocyte counts;
LUSC	cis	rs7089973	0.872	rs11818114	chr10:116634878	G/C	cg23260525	chr10:116636907	FAM160B1	0.39	7.99	0.4	2.19e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs12980942	0.872	rs11879562	chr19:41804976	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.56	6.26	0.32	1.21e-9	Coronary artery disease;
LUSC	cis	rs73200209	0.744	rs11610671	chr12:116411562	C/T	cg01776926	chr12:116560359	MED13L	-0.52	-5.82	-0.3	1.38e-8	Total body bone mineral density;
LUSC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg27535305	chr1:53392650	SCP2	0.39	7.32	0.37	1.91e-12	Monocyte count;
LUSC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07362569	chr17:61921086	SMARCD2	-0.39	-7.82	-0.39	7e-14	Prudent dietary pattern;
LUSC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.77	-0.39	1e-13	Type 2 diabetes;
LUSC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg06454157	chr6:167490870	NA	-0.25	-6.12	-0.32	2.67e-9	Crohn's disease;
LUSC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.39	-5.66	-0.3	3.21e-8	Tonsillectomy;
LUSC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.17	-0.32	1.97e-9	Retinal vascular caliber;
LUSC	cis	rs654950	0.875	rs2810550	chr1:41995339	T/C	cg06885757	chr1:42089581	HIVEP3	-0.34	-6.54	-0.34	2.34e-10	Airway imaging phenotypes;
LUSC	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg15704280	chr7:45808275	SEPT13	0.69	6.48	0.33	3.28e-10	Intraocular pressure;
LUSC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg11766577	chr21:47581405	C21orf56	-0.5	-7.56	-0.38	3.88e-13	Testicular germ cell tumor;
LUSC	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg00677455	chr12:58241039	CTDSP2	0.56	7.95	0.4	2.88e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs17092148	0.943	rs4911160	chr20:33349940	G/A	cg16810054	chr20:33298113	TP53INP2	-0.43	-6.81	-0.35	4.68e-11	Neuroticism;
LUSC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg06627628	chr2:24431161	ITSN2	-0.61	-7.32	-0.37	1.88e-12	Lymphocyte counts;
LUSC	cis	rs4474465	0.850	rs4597089	chr11:78262244	A/G	cg27205649	chr11:78285834	NARS2	0.51	6.14	0.32	2.29e-9	Alzheimer's disease (survival time);
LUSC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-8.4	-0.42	1.3e-15	Menarche (age at onset);
LUSC	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg05110241	chr16:68378359	PRMT7	-0.5	-6.35	-0.33	7.05e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg25801113	chr15:45476975	SHF	0.33	6.72	0.35	7.78e-11	Uric acid levels;
LUSC	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.77	-0.3	1.85e-8	Total body bone mineral density;
LUSC	cis	rs4285028	0.898	rs4305455	chr3:121619774	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.76	-10.29	-0.49	9.28e-22	Multiple sclerosis;
LUSC	cis	rs12618769	0.597	rs72821930	chr2:99127525	C/T	cg10123293	chr2:99228465	UNC50	0.45	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00590991	chr5:176900010	DBN1	0.75	6.08	0.32	3.35e-9	Cognitive performance;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12832228	chr8:28244096	ZNF395	0.4	6.2	0.32	1.69e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg15997130	chr1:24165203	NA	-0.54	-8.72	-0.43	1.3e-16	Immature fraction of reticulocytes;
LUSC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg06784218	chr1:46089804	CCDC17	-0.53	-11.02	-0.52	2.64e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg00431813	chr7:1051703	C7orf50	-0.47	-7.98	-0.4	2.35e-14	Longevity;Endometriosis;
LUSC	cis	rs231513	0.911	rs231511	chr17:41966335	T/C	cg26893861	chr17:41843967	DUSP3	-0.54	-6.02	-0.31	4.52e-9	Cognitive function;
LUSC	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.55	-0.38	4.15e-13	Triglycerides;
LUSC	cis	rs1904096	0.506	rs13435702	chr4:95167751	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.44	-0.42	9.59e-16	Type 2 diabetes;
LUSC	cis	rs2637266	0.934	rs2395408	chr10:78380929	G/A	cg18941641	chr10:78392320	NA	0.38	6.94	0.35	2.08e-11	Pulmonary function;
LUSC	cis	rs75229567	0.618	rs10219700	chr12:70201730	A/G	cg10114359	chr12:70132523	RAB3IP	-0.91	-8.96	-0.44	2.36e-17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg05896524	chr21:47604654	C21orf56	-0.45	-6.51	-0.34	2.77e-10	Testicular germ cell tumor;
LUSC	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg14505434	chr11:89522851	NA	0.39	5.98	0.31	5.77e-9	White blood cell types;
LUSC	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg00376283	chr12:123451042	ABCB9	0.65	7.67	0.39	1.91e-13	Neutrophil percentage of white cells;
LUSC	cis	rs4443100	0.670	rs3788338	chr22:23412058	G/A	cg14186256	chr22:23484241	RTDR1	0.55	7.03	0.36	1.17e-11	Serum parathyroid hormone levels;
LUSC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.57	9.25	0.45	2.85e-18	Aortic root size;
LUSC	cis	rs8092503	1.000	rs1965662	chr18:52486080	C/T	cg12377874	chr18:52495404	RAB27B	0.35	6.25	0.32	1.27e-9	Childhood body mass index;
LUSC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg25767906	chr1:53392781	SCP2	-0.36	-6.1	-0.32	2.89e-9	Monocyte count;
LUSC	cis	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg21775007	chr8:11205619	TDH	-0.53	-7.43	-0.38	9.07e-13	Neuroticism;
LUSC	cis	rs9837602	0.872	rs1489816	chr3:99769088	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-6.19	-0.32	1.79e-9	Breast cancer;
LUSC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg11752832	chr7:134001865	SLC35B4	0.57	8.85	0.44	5.24e-17	Mean platelet volume;
LUSC	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	7.97	0.4	2.45e-14	LDL cholesterol;
LUSC	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	9.7	0.47	9e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg04989706	chr14:50066350	PPIL5	-0.47	-6.39	-0.33	5.61e-10	Carotid intima media thickness;
LUSC	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg23093090	chr10:104574429	C10orf26	-0.45	-8.24	-0.41	3.99e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	8.77	0.43	9.6e-17	Mean platelet volume;
LUSC	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg04733989	chr22:42467013	NAGA	0.63	9.91	0.48	1.8899999999999998e-20	Schizophrenia;
LUSC	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-8.16	-0.41	7.01e-15	Retinal vascular caliber;
LUSC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.59	9.4	0.46	9.08e-19	Pulse pressure;
LUSC	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg03732007	chr1:2071316	PRKCZ	0.47	7.61	0.38	2.91e-13	Height;
LUSC	trans	rs72674100	1.000	rs9993686	chr4:97974447	C/T	cg16405019	chr1:18959625	PAX7	-0.55	-6.47	-0.33	3.4e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs9309473	0.607	rs7560272	chr2:73561485	A/T	cg20560298	chr2:73613845	ALMS1	-0.53	-8.02	-0.4	1.76e-14	Metabolite levels;
LUSC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg04317338	chr11:64019027	PLCB3	0.71	8.07	0.4	1.25e-14	Mean platelet volume;
LUSC	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg13902645	chr11:5959945	NA	-0.56	-7.87	-0.4	5.12e-14	DNA methylation (variation);
LUSC	trans	rs11165623	0.792	rs6593599	chr1:96911468	C/T	cg10631902	chr5:14652156	NA	-0.55	-8.87	-0.44	4.43e-17	Hip circumference;Waist circumference;
LUSC	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg05163923	chr11:71159392	DHCR7	0.76	11.31	0.53	2.55e-25	Vitamin D levels;
LUSC	cis	rs4664308	0.967	rs62175559	chr2:160955833	G/A	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.63	-0.54	1.74e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg23711669	chr6:146136114	FBXO30	0.87	16.45	0.67	5.85e-45	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg01256987	chr12:42539512	GXYLT1	0.36	6.59	0.34	1.71e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6772849	0.930	rs68090762	chr3:128343907	C/T	cg16766828	chr3:128327626	NA	-0.31	-5.68	-0.3	2.93e-8	Monocyte percentage of white cells;Monocyte count;
LUSC	cis	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg17469321	chr7:55412551	NA	0.64	10.19	0.49	2.02e-21	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg00191853	chr8:101177733	SPAG1	-0.41	-6.69	-0.34	9.6e-11	Atrioventricular conduction;
LUSC	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.83	-15.23	-0.64	3.98e-40	Longevity;
LUSC	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg02569458	chr12:86230093	RASSF9	0.42	6.86	0.35	3.31e-11	Major depressive disorder;
LUSC	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg03676636	chr4:99064102	C4orf37	0.32	6.9	0.35	2.61e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg02454025	chr1:11042201	C1orf127	0.91	16.95	0.68	6.13e-47	Ewing sarcoma;
LUSC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.82	12.4	0.56	2.57e-29	Cognitive test performance;
LUSC	cis	rs7572644	0.699	rs10177845	chr2:28124171	G/A	cg27432699	chr2:27873401	GPN1	-0.52	-6.96	-0.36	1.78e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg00933542	chr6:150070202	PCMT1	0.31	6.52	0.34	2.66e-10	Lung cancer;
LUSC	cis	rs8040855	0.599	rs6496800	chr15:85728286	G/C	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.89	0.35	2.73e-11	Bulimia nervosa;
LUSC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.68	-10.54	-0.5	1.28e-22	Aortic root size;
LUSC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg16386425	chr10:429943	DIP2C	-0.45	-7.06	-0.36	9.68e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg06521331	chr12:34319734	NA	-0.46	-7.27	-0.37	2.65e-12	Morning vs. evening chronotype;
LUSC	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg08755490	chr11:65554678	OVOL1	0.42	6.02	0.31	4.69e-9	Acne (severe);
LUSC	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg24631222	chr15:78858424	CHRNA5	0.64	8.51	0.42	5.9e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg24006582	chr15:45444508	DUOX1	-0.62	-9.12	-0.45	7.21e-18	Uric acid levels;
LUSC	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg18196295	chr10:418757	DIP2C	-0.44	-6.73	-0.35	7.54e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19346786	chr7:2764209	NA	-0.42	-7.27	-0.37	2.49e-12	Height;
LUSC	trans	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg25214090	chr10:38739885	LOC399744	0.56	8.2	0.41	5.17e-15	Corneal astigmatism;
LUSC	cis	rs472402	0.580	rs11134173	chr5:6659696	C/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.53	-7.42	-0.38	9.69e-13	Response to amphetamines;
LUSC	cis	rs2857891	0.695	rs2857896	chr11:6982825	A/T	cg04053776	chr11:6947353	ZNF215	0.41	6.05	0.31	3.98e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs7582180	0.677	rs2067783	chr2:100877370	T/C	cg08017756	chr2:100939284	LONRF2	-0.36	-6.21	-0.32	1.53e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg03806693	chr22:41940476	POLR3H	1.0	14.25	0.62	2.41e-36	Vitiligo;
LUSC	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg25214090	chr10:38739885	LOC399744	0.55	7.99	0.4	2.16e-14	Corneal astigmatism;
LUSC	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg04850286	chr10:81895943	PLAC9	-0.33	-5.74	-0.3	2.08e-8	Sarcoidosis;
LUSC	cis	rs17014483	0.749	rs2924934	chr4:89628242	G/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.71	6.47	0.33	3.5e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17156255	chr2:27632527	PPM1G	-0.41	-6.05	-0.31	3.87e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03526776	chr6:41159608	TREML2	0.5	9.76	0.47	5.72e-20	Alzheimer's disease (late onset);
LUSC	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg15704280	chr7:45808275	SEPT13	-0.46	-6.37	-0.33	6.38e-10	Height;
LUSC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg08132940	chr7:1081526	C7orf50	-0.52	-6.16	-0.32	2.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7106204	0.514	rs7935857	chr11:24252420	C/T	ch.11.24196551F	chr11:24239977	NA	0.92	10.2	0.49	1.98e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2303282	0.639	rs4462584	chr16:56443850	T/C	cg00500540	chr16:56394104	NA	-0.43	-7.32	-0.37	1.88e-12	Breast cancer;
LUSC	cis	rs983392	0.709	rs4939320	chr11:59981801	T/C	cg20284999	chr11:59952153	MS4A6A	-0.36	-6.08	-0.32	3.24e-9	Alzheimer's disease (late onset);
LUSC	trans	rs4942242	0.967	rs58325557	chr13:44217771	A/G	cg19169023	chr15:41853346	TYRO3	0.46	7.42	0.38	9.88e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.73	0.65	4.14e-42	Morning vs. evening chronotype;
LUSC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-7.03	-0.36	1.17e-11	Blood metabolite levels;
LUSC	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg03676636	chr4:99064102	C4orf37	0.28	5.91	0.31	8.64e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg10978503	chr1:24200527	CNR2	0.48	11.24	0.52	4.32e-25	Immature fraction of reticulocytes;
LUSC	cis	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg24375607	chr4:120327624	NA	0.49	7.49	0.38	6.14e-13	Diastolic blood pressure;
LUSC	cis	rs7640424	0.589	rs7612356	chr3:107811037	C/G	cg09227934	chr3:107805635	CD47	-0.54	-7.65	-0.39	2.12e-13	Body mass index;
LUSC	cis	rs4132509	0.649	rs12140040	chr1:243871922	G/A	cg21452805	chr1:244014465	NA	0.61	5.95	0.31	6.71e-9	RR interval (heart rate);
LUSC	trans	rs62238980	0.614	rs117586262	chr22:32406424	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs4478858	0.775	rs59865338	chr1:31706643	A/G	cg00250761	chr1:31883323	NA	-0.36	-9.42	-0.46	7.74e-19	Alcohol dependence;
LUSC	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07636037	chr3:49044803	WDR6	0.71	9.64	0.47	1.48e-19	Menarche (age at onset);
LUSC	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg22532475	chr10:104410764	TRIM8	-0.32	-7.11	-0.36	6.97e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg09462578	chr12:12878428	APOLD1	-0.53	-6.61	-0.34	1.5e-10	Systemic lupus erythematosus;
LUSC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg03351412	chr1:154909251	PMVK	0.56	8.9	0.44	3.73e-17	Prostate cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg20645649	chr9:127624485	RPL35	0.45	6.17	0.32	1.95e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg06197492	chr11:2016605	H19	0.42	6.87	0.35	3.23e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs8099014	0.954	rs7230036	chr18:56098397	C/T	cg12907477	chr18:56117327	MIR122	0.43	6.88	0.35	2.98e-11	Platelet count;
LUSC	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg07837209	chr13:79184101	NA	-0.5	-7.1	-0.36	7.7e-12	Large artery stroke;
LUSC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg20135002	chr11:47629003	NA	-0.51	-7.78	-0.39	9.07e-14	Subjective well-being;
LUSC	trans	rs57046232	0.552	rs1305008	chr20:6324198	T/G	cg17788362	chr6:86352627	SYNCRIP	0.44	6.15	0.32	2.15e-9	Colorectal cancer;
LUSC	cis	rs6456156	0.711	rs1855025	chr6:167537594	A/G	cg07741184	chr6:167504864	NA	-0.34	-6.1	-0.32	2.94e-9	Primary biliary cholangitis;
LUSC	cis	rs4343996	0.754	rs1525557	chr7:3351405	A/C	cg21248987	chr7:3385318	SDK1	-0.36	-6.24	-0.32	1.33e-9	Motion sickness;
LUSC	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg20016023	chr10:99160130	RRP12	-0.33	-8.07	-0.4	1.26e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	1.04	15.58	0.65	1.65e-41	Initial pursuit acceleration;
LUSC	cis	rs3772130	0.583	rs6767409	chr3:121564989	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.83	13.54	0.6	1.29e-33	Cognitive performance;
LUSC	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg24130564	chr14:104152367	KLC1	0.46	6.59	0.34	1.7e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg02475777	chr4:1388615	CRIPAK	0.44	6.51	0.34	2.7e-10	Obesity-related traits;
LUSC	cis	rs4494114	1.000	rs9439081	chr1:39343012	A/G	cg25970120	chr1:39325951	RRAGC	-0.41	-6.46	-0.33	3.78e-10	Blood protein levels;
LUSC	cis	rs17154702	0.506	rs2427	chr8:8641125	A/G	cg01851573	chr8:8652454	MFHAS1	-0.6	-7.28	-0.37	2.33e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LUSC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg01171360	chr6:293285	DUSP22	-0.49	-7.05	-0.36	1.02e-11	Menopause (age at onset);
LUSC	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	8.91	0.44	3.37e-17	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs79911532	0.515	rs116006876	chr7:75775918	G/C	cg03592824	chr7:75666768	STYXL1	0.65	6.2	0.32	1.7e-9	Mononucleosis;
LUSC	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	7.35	0.37	1.52e-12	Schizophrenia;
LUSC	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg20243544	chr17:37824526	PNMT	0.45	6.3	0.33	9.6e-10	Asthma;
LUSC	cis	rs6987853	0.787	rs2923441	chr8:42429937	G/T	cg09913449	chr8:42400586	C8orf40	-0.51	-9.04	-0.44	1.28e-17	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.36	-0.33	6.54e-10	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22917801	chr14:24665198	TM9SF1	-0.4	-6.02	-0.31	4.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	7.41	0.38	1.03e-12	Educational attainment;
LUSC	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.97	0.66	4.9e-43	Morning vs. evening chronotype;
LUSC	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg02466173	chr16:30829666	NA	-0.59	-10.72	-0.51	2.97e-23	Multiple myeloma;
LUSC	cis	rs3105593	0.521	rs3098205	chr15:50742977	G/T	cg08437265	chr15:50716283	USP8	0.39	5.74	0.3	2.09e-8	QT interval;
LUSC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg16680214	chr1:154839983	KCNN3	-0.51	-9.67	-0.47	1.18e-19	Prostate cancer;
LUSC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg13397359	chr6:42928475	GNMT	0.57	9.39	0.46	9.63e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs62400317	0.859	rs10948204	chr6:45124300	T/C	cg18551225	chr6:44695536	NA	-0.42	-6.8	-0.35	4.79e-11	Total body bone mineral density;
LUSC	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-8.17	-0.41	6.4e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg22709100	chr7:91322751	NA	0.4	5.86	0.31	1.09e-8	Breast cancer;
LUSC	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg20587970	chr11:113659929	NA	-1.19	-16.23	-0.66	4.39e-44	Hip circumference adjusted for BMI;
LUSC	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	11.03	0.52	2.45e-24	Hypertriglyceridemia;
LUSC	cis	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg05299278	chr17:33885742	SLFN14	0.3	6.28	0.32	1.05e-9	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg07828024	chr6:149772892	ZC3H12D	-0.33	-7.27	-0.37	2.58e-12	Dupuytren's disease;
LUSC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06634786	chr22:41940651	POLR3H	0.53	6.3	0.33	9.15e-10	Vitiligo;
LUSC	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg25457927	chr22:38595422	NA	-0.39	-8.07	-0.4	1.25e-14	Cutaneous nevi;
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg13453750	chr1:205783389	SLC41A1	-0.31	-6.03	-0.31	4.41e-9	Menarche (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03795608	chr3:127872288	EEFSEC	0.81	6.28	0.32	1.07e-9	Cognitive performance;
LUSC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg00784671	chr22:46762841	CELSR1	-0.47	-6.31	-0.33	8.66e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg21827317	chr3:136751795	NA	0.39	6.93	0.35	2.22e-11	Neuroticism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21586955	chr2:220042941	FAM134A;C2orf24	-0.43	-6.19	-0.32	1.76e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg07169764	chr2:136633963	MCM6	1.18	17.58	0.69	2e-49	Corneal structure;
LUSC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.59	0.38	3.32e-13	Bipolar disorder;
LUSC	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg04374321	chr14:90722782	PSMC1	0.76	12.12	0.55	2.88e-28	Mortality in heart failure;
LUSC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg24250549	chr1:154909240	PMVK	-0.62	-9.7	-0.47	9.19e-20	Prostate cancer;
LUSC	cis	rs9463078	0.764	rs494982	chr6:44937255	C/T	cg25276700	chr6:44698697	NA	-0.29	-6.06	-0.31	3.76e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg22705602	chr4:152727874	NA	0.38	7.97	0.4	2.5e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg04450456	chr4:17643702	FAM184B	0.4	6.57	0.34	1.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg09904177	chr6:26538194	HMGN4	0.76	14.14	0.61	6.7e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg20243544	chr17:37824526	PNMT	0.49	6.95	0.36	1.91e-11	Asthma;
LUSC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg09021430	chr5:549028	NA	-0.53	-6.97	-0.36	1.7e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs34779708	0.643	rs4275563	chr10:35545286	G/A	cg03585969	chr10:35415529	CREM	0.54	7.59	0.38	3.28e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg00677455	chr12:58241039	CTDSP2	0.61	8.57	0.42	3.9e-16	Multiple sclerosis;
LUSC	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	0.87	14.27	0.62	2.17e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg18721089	chr20:30220636	NA	-0.37	-6.54	-0.34	2.35e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-19.5	-0.73	4.38e-57	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07167872	chr1:205819463	PM20D1	0.87	16.79	0.68	2.62e-46	Menarche (age at onset);
LUSC	trans	rs1941687	0.735	rs8085989	chr18:31415929	G/A	cg27147174	chr7:100797783	AP1S1	-0.46	-6.88	-0.35	2.97e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00149659	chr3:10157352	C3orf10	0.89	12.11	0.55	3.04e-28	Alzheimer's disease;
LUSC	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg10356904	chr22:49881777	NA	-0.29	-5.78	-0.3	1.7e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2996428	0.561	rs72640913	chr1:3747023	C/G	cg13057898	chr1:3703894	LRRC47	0.48	7.9	0.4	3.95e-14	Red cell distribution width;
LUSC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg11344533	chr11:111475393	SIK2	-0.48	-6.78	-0.35	5.35e-11	Primary sclerosing cholangitis;
LUSC	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg27489772	chr12:121021490	NA	-0.59	-7.63	-0.39	2.45e-13	Type 1 diabetes nephropathy;
LUSC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg07701084	chr6:150067640	NUP43	0.54	8.09	0.4	1.14e-14	Lung cancer;
LUSC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg06784218	chr1:46089804	CCDC17	-0.51	-9.59	-0.46	2.15e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs61990749	0.597	rs8016416	chr14:78213100	T/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	6.59	0.34	1.76e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs6500395	0.735	rs7204345	chr16:48666726	T/C	cg04672837	chr16:48644449	N4BP1	0.46	6.8	0.35	4.8e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs524023	0.874	rs475642	chr11:64424691	C/A	cg19131476	chr11:64387923	NRXN2	-0.38	-10.48	-0.5	2.17e-22	Urate levels in obese individuals;
LUSC	trans	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg26043149	chr18:55253948	FECH	-0.55	-7.16	-0.36	5.11e-12	Bone mineral density;
LUSC	cis	rs6700896	0.898	rs1938495	chr1:66106469	A/G	cg04111102	chr1:66153794	NA	0.32	7.1	0.36	7.36e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7178572	0.568	rs28584877	chr15:77599003	C/A	cg22256960	chr15:77711686	NA	0.49	7.8	0.39	7.96e-14	Type 2 diabetes;
LUSC	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg03453431	chr7:157225567	NA	-0.55	-9.82	-0.47	3.7e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.07	-0.32	3.42e-9	Resting heart rate;
LUSC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg07507251	chr3:52567010	NT5DC2	0.31	6.21	0.32	1.6e-9	Bipolar disorder;
LUSC	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-6.48	-0.33	3.33e-10	Morning vs. evening chronotype;
LUSC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg12564285	chr5:131593104	PDLIM4	0.45	7.95	0.4	2.97e-14	Breast cancer;
LUSC	trans	rs488628	0.798	rs504005	chr3:118138143	A/C	cg06621744	chr14:37052470	NKX2-8	-0.3	-6.72	-0.35	7.68e-11	White matter integrity (bipolar disorder risk interaction);
LUSC	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	0.88	12.53	0.57	8.92e-30	Blood protein levels;
LUSC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-0.82	-13.96	-0.61	3.29e-35	Menopause (age at onset);
LUSC	trans	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg03886242	chr7:26192032	NFE2L3	0.37	6.26	0.32	1.2e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg23649088	chr2:200775458	C2orf69	0.52	6.79	0.35	5.29e-11	Schizophrenia;
LUSC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg15147215	chr3:52552868	STAB1	-0.3	-5.96	-0.31	6.55e-9	Bipolar disorder;
LUSC	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg25214090	chr10:38739885	LOC399744	0.56	8.16	0.41	7.08e-15	Corneal astigmatism;
LUSC	cis	rs9341808	0.718	rs2143887	chr6:80917287	T/C	cg08355045	chr6:80787529	NA	0.58	10.2	0.49	1.97e-21	Sitting height ratio;
LUSC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg01416388	chr22:39784598	NA	-0.45	-7.51	-0.38	5.32e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.04	15.66	0.65	8.17e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg22782873	chr19:19639568	YJEFN3	0.53	6.45	0.33	3.94e-10	Bipolar disorder;
LUSC	cis	rs7246967	0.673	rs2885221	chr19:22839387	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.87	0.35	3.18e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs7561273	0.609	rs10200844	chr2:24293363	A/C	cg06627628	chr2:24431161	ITSN2	-0.51	-6.83	-0.35	3.93e-11	Quantitative traits;
LUSC	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg21153622	chr11:89784906	NA	-0.39	-6.04	-0.31	4.16e-9	HDL cholesterol;
LUSC	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.57	10.06	0.48	5.53e-21	Birth weight;
LUSC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs921665	0.831	rs7566188	chr2:3199057	C/T	cg16434511	chr2:3151078	NA	-0.61	-6.42	-0.33	4.8e-10	World class endurance athleticism;
LUSC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.8	12.65	0.57	3.02e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs500891	0.525	rs1170483	chr6:84038253	G/C	cg08257003	chr6:84140564	ME1	0.34	8.09	0.4	1.15e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg13073564	chr4:8508604	NA	-0.49	-9.14	-0.45	6.1e-18	Response to antineoplastic agents;
LUSC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs16937	0.686	rs3851285	chr1:205155753	C/T	cg00857998	chr1:205179979	DSTYK	0.46	6.52	0.34	2.67e-10	Schizophrenia;
LUSC	trans	rs867371	0.820	rs7164362	chr15:82486742	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.09	-0.32	3.17e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg06008330	chr7:65541103	ASL	-0.4	-6.22	-0.32	1.52e-9	Aortic root size;
LUSC	cis	rs12815613	1.000	rs7961554	chr12:121400244	G/T	cg02403541	chr12:121454288	C12orf43	0.46	5.86	0.31	1.13e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1178968	1.000	rs12534600	chr7:72762721	C/T	cg25889504	chr7:72793014	NA	-0.6	-7.8	-0.39	7.86e-14	Triglyceride levels;
LUSC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg23711669	chr6:146136114	FBXO30	0.75	13.38	0.59	5.42e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg24692254	chr21:30365293	RNF160	0.74	11.82	0.54	3.48e-27	Pancreatic cancer;
LUSC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11645453	chr3:52864694	ITIH4	0.34	8.07	0.4	1.26e-14	Electroencephalogram traits;
LUSC	cis	rs10465746	0.967	rs12748268	chr1:84374438	T/C	cg10977910	chr1:84465055	TTLL7	0.43	6.16	0.32	2.1e-9	Obesity-related traits;
LUSC	cis	rs477692	1.000	rs4750759	chr10:131436603	G/A	cg05714579	chr10:131428358	MGMT	-0.47	-6.9	-0.35	2.62e-11	Response to temozolomide;
LUSC	cis	rs12956009	0.583	rs11082575	chr18:44905068	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-6.39	-0.33	5.51e-10	Educational attainment (years of education);
LUSC	trans	rs34421088	0.506	rs4841518	chr8:11145963	G/C	cg15556689	chr8:8085844	FLJ10661	0.46	6.73	0.35	7.34e-11	Neuroticism;
LUSC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg00310523	chr12:86230176	RASSF9	0.51	9.63	0.47	1.6e-19	Major depressive disorder;
LUSC	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6681460	0.649	rs1947083	chr1:67004801	G/A	cg02459107	chr1:67143332	SGIP1	0.37	6.32	0.33	8.4e-10	Presence of antiphospholipid antibodies;
LUSC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg05347473	chr6:146136440	FBXO30	-0.57	-9.76	-0.47	5.78e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg09034736	chr1:150693464	HORMAD1	0.51	7.42	0.38	9.6e-13	Tonsillectomy;
LUSC	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.4	-6.22	-0.32	1.52e-9	Educational attainment;
LUSC	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg18827107	chr12:86230957	RASSF9	-0.4	-5.99	-0.31	5.31e-9	Major depressive disorder;
LUSC	trans	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.66	-0.34	1.16e-10	Endometrial cancer;
LUSC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17261708	chr5:176794207	RGS14	0.33	5.91	0.31	8.29e-9	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9815354	0.761	rs73083326	chr3:41927150	G/T	cg03022575	chr3:42003672	ULK4	0.82	8.74	0.43	1.14e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg14036092	chr11:66035641	RAB1B	0.41	5.81	0.3	1.49e-8	Gout;
LUSC	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg22532475	chr10:104410764	TRIM8	-0.3	-6.59	-0.34	1.7e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs3741151	0.773	rs73542938	chr11:73103012	G/C	cg17517138	chr11:73019481	ARHGEF17	1.03	8.66	0.43	1.99e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg15212455	chr7:39170539	POU6F2	0.62	10.76	0.51	2.29e-23	IgG glycosylation;
LUSC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs3106136	0.967	rs12646184	chr4:95183216	A/G	cg11021082	chr4:95130006	SMARCAD1	0.35	6.1	0.32	2.96e-9	Capecitabine sensitivity;
LUSC	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg16414030	chr3:133502952	NA	-0.43	-6.72	-0.35	7.96e-11	Iron status biomarkers;
LUSC	cis	rs243505	0.898	rs243544	chr7:148402710	T/A	cg09806900	chr7:148480153	CUL1	-0.49	-6.93	-0.35	2.18e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11264799	0.765	rs67805319	chr1:157622853	G/A	cg18268488	chr1:157545234	FCRL4	0.33	5.74	0.3	2.13e-8	IgA nephropathy;
LUSC	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.82	0.43	6.31e-17	Menopause (age at onset);
LUSC	cis	rs10992471	0.603	rs987553	chr9:95298694	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-6.97	-0.36	1.7e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg08888203	chr3:10149979	C3orf24	0.59	8.21	0.41	4.83e-15	Alzheimer's disease;
LUSC	cis	rs7178572	0.568	rs1389436	chr15:77665848	G/T	cg22256960	chr15:77711686	NA	-0.51	-8.09	-0.4	1.11e-14	Type 2 diabetes;
LUSC	cis	rs61935443	0.666	rs73218073	chr12:95314346	A/G	cg21533806	chr12:95267307	NA	0.49	5.72	0.3	2.38e-8	Schizophrenia;
LUSC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg11645453	chr3:52864694	ITIH4	-0.36	-8.36	-0.42	1.77e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg16482183	chr6:26056742	HIST1H1C	0.57	7.96	0.4	2.78e-14	Height;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07360250	chr5:176830358	F12	-0.4	-7.37	-0.37	1.39e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg09307838	chr4:120376055	NA	0.69	10.01	0.48	8.32e-21	Corneal astigmatism;
LUSC	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg13813247	chr22:41461852	NA	-0.37	-6.59	-0.34	1.67e-10	Neuroticism;
LUSC	cis	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg21175976	chr8:11421337	BLK	0.38	6.42	0.33	4.66e-10	Systolic blood pressure;
LUSC	cis	rs11166629	1.000	rs935119	chr8:135638353	C/T	cg21672855	chr8:135614777	ZFAT	-0.35	-5.73	-0.3	2.3e-8	Smoking quantity;
LUSC	cis	rs9473147	0.571	rs9463335	chr6:47479136	G/A	cg20196966	chr6:47445060	CD2AP	0.43	5.98	0.31	5.68e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-12.43	-0.56	1.99e-29	Body mass index;
LUSC	cis	rs12042938	0.600	rs823165	chr1:231769446	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.46	6.89	0.35	2.73e-11	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs11756438	0.572	rs2638550	chr6:118998481	C/G	cg21191810	chr6:118973309	C6orf204	0.35	5.91	0.31	8.34e-9	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.73	0.3	2.27e-8	Personality dimensions;
LUSC	cis	rs9322817	0.653	rs9486002	chr6:105162823	A/G	cg02098413	chr6:105308735	HACE1	-0.28	-5.79	-0.3	1.59e-8	Thyroid stimulating hormone;
LUSC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg24578937	chr1:2090814	PRKCZ	-0.45	-9.89	-0.48	2.11e-20	Height;
LUSC	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-12.6	-0.57	4.93e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11945232	1.000	rs28609242	chr4:88342497	T/C	cg23841344	chr4:88312519	HSD17B11	-0.64	-9.88	-0.48	2.32e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg00898013	chr13:113819073	PROZ	-0.63	-8.82	-0.43	6.52e-17	Platelet distribution width;
LUSC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg12963246	chr6:28129442	ZNF389	0.52	7.18	0.37	4.53e-12	Depression;
LUSC	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.5	-6.46	-0.33	3.71e-10	Response to bleomycin (chromatid breaks);
LUSC	cis	rs4792901	0.802	rs28532791	chr17:41589479	G/A	cg22562494	chr17:41607896	ETV4	-0.32	-5.9	-0.31	8.99e-9	Dupuytren's disease;
LUSC	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg24642439	chr20:33292090	TP53INP2	0.43	6.13	0.32	2.54e-9	Height;
LUSC	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg08027265	chr7:2291960	NA	-0.45	-7.44	-0.38	8.77e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	7.44	0.38	8.54e-13	Electroencephalogram traits;
LUSC	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg09826364	chr7:158789723	NA	-0.4	-6.12	-0.32	2.57e-9	Facial morphology (factor 20);
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	10.19	0.49	2.03e-21	Lymphocyte counts;
LUSC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg00316803	chr15:76480434	C15orf27	-0.39	-6.67	-0.34	1.09e-10	Blood metabolite levels;
LUSC	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	8.65	0.43	2.23e-16	Height;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg17367996	chr5:130506478	LYRM7	0.39	6.24	0.32	1.32e-9	Schizophrenia;
LUSC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	0.97	13.34	0.59	7.77e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg00277334	chr10:82204260	NA	-0.58	-8.81	-0.43	7.06e-17	Post bronchodilator FEV1;
LUSC	cis	rs10737909	1.000	rs10737909	chr1:15548636	A/C	cg21012057	chr1:15538911	TMEM51	0.33	5.65	0.3	3.35e-8	Migraine;
LUSC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg11494091	chr17:61959527	GH2	0.39	6.67	0.34	1.07e-10	Height;
LUSC	trans	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg25214090	chr10:38739885	LOC399744	0.44	6.28	0.32	1.04e-9	Corneal astigmatism;
LUSC	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg13660082	chr14:53194042	PSMC6	-0.78	-6.81	-0.35	4.55e-11	Alzheimer's disease (late onset);
LUSC	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg00042356	chr1:8021962	PARK7	0.72	9.39	0.46	9.92e-19	Inflammatory bowel disease;
LUSC	cis	rs870825	0.616	rs28649620	chr4:185648997	G/A	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-0.8	-13.93	-0.61	4.36e-35	Sudden cardiac arrest;
LUSC	cis	rs34638657	0.732	rs12595971	chr16:82200309	T/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.44	-0.33	4.11e-10	Lung adenocarcinoma;
LUSC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg00049323	chr5:472564	LOC25845	0.49	7.75	0.39	1.08e-13	Cystic fibrosis severity;
LUSC	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg21466736	chr12:48725269	NA	0.33	5.93	0.31	7.77e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.42	0.69	8.19e-49	Chronic sinus infection;
LUSC	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg18678763	chr11:4115507	RRM1	0.46	5.98	0.31	5.62e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg05855489	chr10:104503620	C10orf26	0.65	9.77	0.47	5.21e-20	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg07169764	chr2:136633963	MCM6	-0.85	-11.91	-0.55	1.72e-27	Corneal structure;
LUSC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	12.96	0.58	2.18e-31	Platelet count;
LUSC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg11247378	chr22:39784982	NA	-0.64	-12.57	-0.57	6.06e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.94	15.01	0.63	2.7e-39	Coronary artery disease;
LUSC	cis	rs185694	1.000	rs846495	chr13:30894250	T/C	cg07600127	chr13:30881527	KATNAL1	-0.54	-5.9	-0.31	8.68e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
LUSC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg08975724	chr8:8085496	FLJ10661	0.55	8.5	0.42	6.3e-16	Mood instability;
LUSC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg16524733	chr11:117070046	TAGLN	0.43	7.52	0.38	5.14e-13	Blood protein levels;
LUSC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg04315214	chr1:2043799	PRKCZ	0.48	10.04	0.48	6.84e-21	Height;
LUSC	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg23173402	chr1:227635558	NA	0.57	7.08	0.36	8.35e-12	Major depressive disorder;
LUSC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.04	-0.4	1.62e-14	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.34	-0.46	1.38e-18	Brugada syndrome;
LUSC	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg23601095	chr6:26197514	HIST1H3D	0.73	7.46	0.38	7.42e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-1.19	-12.84	-0.57	5.85e-31	Diabetic kidney disease;
LUSC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg23887609	chr12:130822674	PIWIL1	0.48	7.1	0.36	7.75e-12	Menopause (age at onset);
LUSC	cis	rs877426	0.515	rs57506460	chr13:114767789	G/A	cg02745494	chr13:114771098	RASA3	0.34	5.7	0.3	2.63e-8	Facial morphology (factor 14, intercanthal width);
LUSC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-9.31	-0.45	1.73e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg06238570	chr21:40685208	BRWD1	0.47	7.25	0.37	2.84e-12	Cognitive function;
LUSC	cis	rs4594175	0.707	rs12432912	chr14:51739395	T/C	cg23942311	chr14:51606299	NA	0.3	6.01	0.31	4.87e-9	Cancer;
LUSC	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-9.96	-0.48	1.27e-20	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg18681998	chr4:17616180	MED28	0.82	14.9	0.63	7.75e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	12.61	0.57	4.32e-30	Exhaled nitric oxide output;
LUSC	cis	rs11631955	1	rs11631955	chr15:79085915	A/G	cg00540400	chr15:79124168	NA	-0.43	-7.56	-0.38	3.82e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.95	-14.23	-0.61	3.05e-36	Platelet count;
LUSC	cis	rs9921338	0.961	rs11074958	chr16:11397079	C/T	cg00044050	chr16:11439710	C16orf75	-0.48	-6.51	-0.34	2.73e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-7.96	-0.4	2.63e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs13401104	0.796	rs12471212	chr2:237112191	G/C	cg19324714	chr2:237145437	ASB18	0.43	5.71	0.3	2.46e-8	Educational attainment;
LUSC	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.14	-0.41	8.1e-15	Triglycerides;
LUSC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	14.96	0.63	4.37e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	9.51	0.46	3.94e-19	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs3737883	1.000	rs4950913	chr1:203032153	A/G	cg00805880	chr1:203045044	PPFIA4	-0.29	-5.81	-0.3	1.43e-8	Early onset atrial fibrillation;
LUSC	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.81	0.51	1.45e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg05714579	chr10:131428358	MGMT	0.44	6.29	0.33	9.88e-10	Response to temozolomide;
LUSC	cis	rs7246967	0.673	rs60675447	chr19:22810892	G/A	cg23217946	chr19:22817039	ZNF492	0.45	6.33	0.33	7.68e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-1.0	-16.97	-0.68	5.14e-47	Systemic lupus erythematosus;
LUSC	cis	rs2067615	0.579	rs12424114	chr12:107144328	A/G	cg15890332	chr12:107067104	RFX4	0.34	6.18	0.32	1.88e-9	Heart rate;
LUSC	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg05926928	chr17:57297772	GDPD1	1.47	18.48	0.71	4.97e-53	Opioid sensitivity;
LUSC	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.51e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs478607	0.831	rs11602411	chr11:64449223	A/G	cg19131476	chr11:64387923	NRXN2	-0.34	-5.91	-0.31	8.35e-9	Urate levels;
LUSC	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.14	0.32	2.28e-9	Corneal astigmatism;
LUSC	cis	rs6977660	0.714	rs12334001	chr7:19814399	T/C	cg07541023	chr7:19748670	TWISTNB	0.66	7.21	0.37	3.71e-12	Thyroid stimulating hormone;
LUSC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg11752832	chr7:134001865	SLC35B4	0.55	8.61	0.43	2.94e-16	Mean platelet volume;
LUSC	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.59	-8.04	-0.4	1.6e-14	Red cell distribution width;
LUSC	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.31e-11	Response to antipsychotic treatment;
LUSC	cis	rs3770081	1.000	rs3770089	chr2:86263815	C/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.95	-6.26	-0.32	1.19e-9	Facial emotion recognition (sad faces);
LUSC	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-1.13	-17.91	-0.7	9.52e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7189233	0.531	rs8045674	chr16:53509936	G/A	cg09728985	chr16:53543985	NA	-0.33	-6.18	-0.32	1.91e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-5.7	-0.3	2.67e-8	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg02158880	chr13:53174818	NA	0.37	6.18	0.32	1.85e-9	Lewy body disease;
LUSC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19717773	chr7:2847554	GNA12	0.36	6.06	0.31	3.6e-9	Height;
LUSC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.38	0.33	5.95e-10	Menopause (age at onset);
LUSC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg08847533	chr14:75593920	NEK9	0.85	15.75	0.65	3.43e-42	Height;
LUSC	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg08085267	chr17:45401833	C17orf57	-0.46	-6.69	-0.34	9.41e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg23630131	chr7:65973040	NA	0.21	5.84	0.3	1.24e-8	Aortic root size;
LUSC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.62	0.38	2.61e-13	Prudent dietary pattern;
LUSC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg08773314	chr2:239334832	ASB1	0.38	6.92	0.35	2.28e-11	Multiple system atrophy;
LUSC	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg17366294	chr4:99064904	C4orf37	0.56	8.94	0.44	2.61e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg22089800	chr15:90895588	ZNF774	-0.65	-10.23	-0.49	1.52e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12291552	chr3:167813648	GOLIM4	0.36	6.15	0.32	2.2e-9	Asthma;
LUSC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.67	0.34	1.05e-10	Lung cancer;
LUSC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08280861	chr8:58055591	NA	0.52	5.73	0.3	2.21e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg08621418	chr6:79944414	HMGN3	0.48	6.11	0.32	2.83e-9	Thyroid stimulating hormone;
LUSC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg17294928	chr15:75287854	SCAMP5	-0.83	-11.25	-0.52	4.02e-25	Blood trace element (Zn levels);
LUSC	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21659725	chr3:3221576	CRBN	0.6	7.73	0.39	1.24e-13	Resting heart rate;
LUSC	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.81	-0.39	7.24e-14	Response to antipsychotic treatment;
LUSC	cis	rs7786877	0.582	rs2075674	chr7:100225031	G/A	cg00334542	chr7:100209784	MOSPD3	-0.67	-7.39	-0.37	1.21e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	12.9	0.58	3.67e-31	Platelet count;
LUSC	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.39	-0.33	5.45e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7119167	0.901	rs11235746	chr11:73127168	T/G	cg17517138	chr11:73019481	ARHGEF17	0.54	6.07	0.32	3.45e-9	Blood protein levels;
LUSC	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.54	10.32	0.49	7.37e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	trans	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg00814883	chr7:100076585	TSC22D4	-0.69	-8.91	-0.44	3.42e-17	Platelet count;
LUSC	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg06636001	chr8:8085503	FLJ10661	0.52	8.3	0.41	2.54e-15	Retinal vascular caliber;
LUSC	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg05340658	chr4:99064831	C4orf37	-0.46	-7.27	-0.37	2.5e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg12564285	chr5:131593104	PDLIM4	0.43	7.86	0.4	5.33e-14	Breast cancer;
LUSC	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.94	-0.44	2.61e-17	Monocyte percentage of white cells;
LUSC	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs13394619	0.605	rs12476319	chr2:11748406	A/G	cg07314298	chr2:11723111	GREB1	0.42	7.22	0.37	3.51e-12	Endometriosis;
LUSC	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg09796270	chr17:17721594	SREBF1	-0.45	-7.95	-0.4	2.89e-14	Total body bone mineral density;
LUSC	cis	rs3126085	0.935	rs10888470	chr1:152200472	T/C	cg26876637	chr1:152193138	HRNR	0.45	6.29	0.33	9.81e-10	Atopic dermatitis;
LUSC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.78	-0.43	8.36e-17	Bipolar disorder;
LUSC	cis	rs6967385	0.867	rs2216046	chr7:12360630	G/A	cg06484146	chr7:12443880	VWDE	0.38	5.7	0.3	2.68e-8	Response to taxane treatment (placlitaxel);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26342398	chr1:85156326	SSX2IP	-0.47	-5.99	-0.31	5.29e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs6076960	0.811	rs6053960	chr20:6176778	T/C	cg21095983	chr6:86352623	SYNCRIP	0.41	6.34	0.33	7.38e-10	Smooth-surface caries;
LUSC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.51	-0.38	5.54e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.84	-7.84	-0.39	6.09e-14	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.86	-0.47	2.63e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg06636001	chr8:8085503	FLJ10661	0.67	11.26	0.52	3.8e-25	Mood instability;
LUSC	cis	rs11971779	0.646	rs58682779	chr7:139084712	C/T	cg07862535	chr7:139043722	LUC7L2	0.74	8.31	0.41	2.47e-15	Diisocyanate-induced asthma;
LUSC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg13798912	chr7:905769	UNC84A	-0.59	-6.06	-0.31	3.58e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.69	-0.39	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg10756647	chr7:56101905	PSPH	0.86	8.62	0.43	2.8e-16	Diabetic kidney disease;
LUSC	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg03647239	chr10:116582469	FAM160B1	0.45	7.27	0.37	2.55e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-6.8	-0.35	4.83e-11	Menarche (age at onset);
LUSC	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-11.67	-0.54	1.29e-26	Coffee consumption (cups per day);
LUSC	trans	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg07393940	chr7:158741817	NA	-0.51	-8.2	-0.41	5.29e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs11723530	0.538	rs6855275	chr4:170809649	C/T	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.2	-0.32	1.62e-9	Myopia (pathological);
LUSC	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg07930552	chr6:133119739	C6orf192	0.94	8.39	0.42	1.41e-15	Type 2 diabetes nephropathy;
LUSC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.66	-10.28	-0.49	1.04e-21	Menarche (age at onset);
LUSC	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg19875535	chr5:140030758	IK	0.48	7.76	0.39	1.01e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg11645453	chr3:52864694	ITIH4	0.35	8.14	0.41	7.76e-15	Bipolar disorder;
LUSC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.73	0.39	1.26e-13	Bipolar disorder;
LUSC	cis	rs17092148	1.000	rs6060025	chr20:33326876	A/G	cg16810054	chr20:33298113	TP53INP2	-0.41	-6.47	-0.33	3.42e-10	Neuroticism;
LUSC	trans	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg16286249	chr1:33625400	TRIM62	0.5	6.06	0.31	3.68e-9	Menarche (age at onset);
LUSC	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg18105134	chr13:113819100	PROZ	0.62	9.07	0.44	1.03e-17	Platelet distribution width;
LUSC	cis	rs2200578	0.841	rs62154623	chr2:99611488	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.55	6.61	0.34	1.49e-10	IgG glycosylation;
LUSC	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg03453431	chr7:157225567	NA	-0.51	-8.47	-0.42	7.93e-16	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs897080	0.515	rs786617	chr2:44593158	G/A	cg00619915	chr2:44497795	NA	-0.41	-5.93	-0.31	7.72e-9	Height;
LUSC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg06784218	chr1:46089804	CCDC17	0.49	9.71	0.47	8.23e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01570182	chr17:44337453	NA	-0.7	-10.56	-0.5	1.09e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg08270630	chr22:50330655	NA	-0.45	-6.67	-0.34	1.07e-10	Schizophrenia;
LUSC	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg12863693	chr15:85201151	NMB	0.4	8.45	0.42	8.81e-16	Schizophrenia;
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg14789911	chr21:47582049	C21orf56	0.4	6.27	0.32	1.14e-9	Testicular germ cell tumor;
LUSC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg12310025	chr6:25882481	NA	-0.5	-9.07	-0.44	1.07e-17	Blood metabolite levels;
LUSC	cis	rs7264396	0.887	rs6060442	chr20:34093757	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.62	-0.34	1.47e-10	Total cholesterol levels;
LUSC	cis	rs9549260	0.785	rs6563842	chr13:41244297	G/T	cg21288729	chr13:41239152	FOXO1	0.63	9.73	0.47	7.31e-20	Red blood cell count;
LUSC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg22834771	chr12:69754056	YEATS4	-0.41	-5.65	-0.3	3.48e-8	Response to diuretic therapy;
LUSC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg12365402	chr11:9010492	NRIP3	0.43	7.9	0.4	4.21e-14	Hemoglobin concentration;
LUSC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg21138405	chr5:131827807	IRF1	-0.33	-5.81	-0.3	1.45e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg26102564	chr10:131424627	MGMT	0.38	6.0	0.31	5.11e-9	Response to temozolomide;
LUSC	cis	rs8040855	0.644	rs4635318	chr15:85726737	C/A	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.54	0.34	2.34e-10	Bulimia nervosa;
LUSC	trans	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.64e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4474465	1.000	rs11237514	chr11:78180179	A/G	cg27205649	chr11:78285834	NARS2	-0.53	-6.13	-0.32	2.49e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.0	0.4	2.11e-14	Melanoma;
LUSC	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg22709100	chr7:91322751	NA	0.39	5.81	0.3	1.48e-8	Breast cancer;
LUSC	cis	rs2274273	1.000	rs67805055	chr14:55587552	C/T	cg04306507	chr14:55594613	LGALS3	0.53	11.43	0.53	9.65e-26	Protein biomarker;
LUSC	cis	rs10193935	0.605	rs10169492	chr2:42401961	G/T	cg27598129	chr2:42591480	NA	-0.62	-8.15	-0.41	7.49e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7809950	1.000	rs2066735	chr7:107188719	G/T	cg23024343	chr7:107201750	COG5	-0.54	-8.65	-0.43	2.14e-16	Coronary artery disease;
LUSC	cis	rs7523273	0.606	rs2796283	chr1:207978732	C/T	cg22525895	chr1:207977042	MIR29B2	-0.4	-6.39	-0.33	5.42e-10	Schizophrenia;
LUSC	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg24375607	chr4:120327624	NA	0.77	12.51	0.56	1.08e-29	Corneal astigmatism;
LUSC	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg01689657	chr7:91764605	CYP51A1	0.32	5.89	0.31	9.34e-9	Breast cancer;
LUSC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.7	-0.43	1.57e-16	Bipolar disorder;
LUSC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs16912285	0.688	rs7126291	chr11:24312936	A/C	ch.11.24196551F	chr11:24239977	NA	0.9	9.61	0.47	1.78e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg05738196	chr6:26577821	NA	0.75	13.11	0.58	5.56e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs2354432	0.556	rs11239965	chr1:146753907	C/A	cg25205988	chr1:146714368	CHD1L	-1.04	-9.38	-0.46	1.05e-18	Mitochondrial DNA levels;
LUSC	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.66	9.44	0.46	6.8e-19	Adiposity;
LUSC	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg14092571	chr14:90743983	NA	-0.35	-5.66	-0.3	3.27e-8	Mortality in heart failure;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11461694	chr4:103266404	SLC39A8	-0.42	-6.23	-0.32	1.43e-9	Hepatitis;
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.51	-7.82	-0.39	6.83e-14	Lymphocyte counts;
LUSC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg24060327	chr5:131705240	SLC22A5	0.68	11.39	0.53	1.26e-25	Breast cancer;
LUSC	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	14.95	0.63	4.68e-39	Lung cancer in ever smokers;
LUSC	cis	rs4722585	0.605	rs3753098	chr7:26198040	C/T	cg07876897	chr7:26191696	NFE2L3	-0.46	-7.06	-0.36	9.95e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUSC	cis	rs600231	0.577	rs35826299	chr11:65240964	T/C	cg17120908	chr11:65337727	SSSCA1	-0.62	-8.95	-0.44	2.47e-17	Bone mineral density;
LUSC	trans	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg07393940	chr7:158741817	NA	0.36	6.4	0.33	5.36e-10	Life satisfaction;
LUSC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg23711669	chr6:146136114	FBXO30	0.72	12.88	0.58	4.13e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs500891	0.553	rs7744602	chr6:84127591	C/T	cg08257003	chr6:84140564	ME1	0.36	8.73	0.43	1.27e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg03188948	chr7:1209495	NA	0.67	7.1	0.36	7.38e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.16	-0.32	2.04e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2952768	0.965	rs2551640	chr2:208407893	G/A	cg22739477	chr2:208394512	CREB1	0.36	5.82	0.3	1.39e-8	Opioid sensitivity;
LUSC	cis	rs7180079	1.000	rs77627789	chr15:64444276	G/C	cg08069370	chr15:64387884	SNX1	-0.71	-6.98	-0.36	1.59e-11	Monocyte count;
LUSC	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.83	0.47	3.35e-20	Arsenic metabolism;
LUSC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg22535103	chr8:58192502	C8orf71	-0.65	-7.33	-0.37	1.7e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg06552810	chr11:31128660	NA	-0.41	-7.33	-0.37	1.76e-12	Red blood cell count;
LUSC	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg05738196	chr6:26577821	NA	0.83	16.17	0.66	7.5e-44	Intelligence (multi-trait analysis);
LUSC	cis	rs9420	0.961	rs7938083	chr11:57493622	C/A	cg23127183	chr11:57508653	C11orf31	-0.63	-9.44	-0.46	6.64e-19	Schizophrenia;
LUSC	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg17845761	chr1:175162550	KIAA0040	-0.31	-6.01	-0.31	4.99e-9	Alcohol dependence;
LUSC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.46	-5.96	-0.31	6.51e-9	Menarche (age at onset);
LUSC	cis	rs11214589	0.747	rs11214577	chr11:113204266	A/G	cg14159747	chr11:113255604	NA	-0.27	-6.76	-0.35	6.11e-11	Neuroticism;
LUSC	cis	rs10489202	1.000	rs12404574	chr1:167961235	C/T	cg24449463	chr1:168025552	DCAF6	0.57	7.52	0.38	5e-13	Schizophrenia;
LUSC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg11764359	chr7:65958608	NA	0.65	6.35	0.33	6.97e-10	Diabetic kidney disease;
LUSC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06544989	chr22:39130855	UNC84B	0.33	5.66	0.3	3.28e-8	Menopause (age at onset);
LUSC	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06636551	chr8:101224915	SPAG1	-0.43	-7.92	-0.4	3.51e-14	Atrioventricular conduction;
LUSC	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.42	6.45	0.33	3.98e-10	Height;
LUSC	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg02423579	chr7:2872169	GNA12	-0.39	-5.81	-0.3	1.49e-8	Height;
LUSC	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg12395012	chr8:11607386	GATA4	-0.35	-5.81	-0.3	1.48e-8	Myopia (pathological);
LUSC	cis	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg06521331	chr12:34319734	NA	-0.39	-5.83	-0.3	1.32e-8	Resting heart rate;
LUSC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.08	-0.32	3.35e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.33	-0.56	4.74e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg15103426	chr22:29168792	CCDC117	0.55	7.52	0.38	5.21e-13	Lymphocyte counts;
LUSC	cis	rs4654899	1.000	rs6426659	chr1:21361302	G/A	cg01072550	chr1:21505969	NA	-0.56	-8.54	-0.42	4.74e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4474465	0.573	rs7101478	chr11:78272517	C/A	cg27205649	chr11:78285834	NARS2	0.58	7.13	0.36	6.24e-12	Alzheimer's disease (survival time);
LUSC	cis	rs67539049	0.891	rs73209223	chr8:11304944	A/G	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.41	-6.41	-0.33	5.04e-10	Itch intensity from mosquito bite;
LUSC	cis	rs77633900	0.772	rs2957612	chr15:76703688	C/T	cg21673338	chr15:77095150	SCAPER	-0.7	-5.99	-0.31	5.4e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg04369109	chr6:150039330	LATS1	-0.54	-7.45	-0.38	8.03e-13	Lung cancer;
LUSC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg23985595	chr17:80112537	CCDC57	-0.31	-6.06	-0.31	3.71e-9	Life satisfaction;
LUSC	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg03806693	chr22:41940476	POLR3H	0.84	12.06	0.55	4.75e-28	Vitiligo;
LUSC	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-15.94	-0.66	6.34e-43	Height;
LUSC	trans	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg25482853	chr8:67687455	SGK3	1.02	15.96	0.66	5.27e-43	Ulcerative colitis;
LUSC	cis	rs7267979	0.586	rs1473695	chr20:25186965	A/G	cg08601574	chr20:25228251	PYGB	0.44	6.71	0.34	8.25e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg13319975	chr6:146136371	FBXO30	0.51	7.68	0.39	1.74e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg09835421	chr16:68378352	PRMT7	-0.51	-6.28	-0.32	1.06e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg00852783	chr1:26633632	UBXN11	-0.49	-5.8	-0.3	1.52e-8	Obesity-related traits;
LUSC	cis	rs34779708	0.736	rs34195979	chr10:35549817	T/C	cg03585969	chr10:35415529	CREM	0.52	7.09	0.36	8.09e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.82	-0.35	4.38e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.06e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.95	0.36	1.89e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg18479299	chr3:125709523	NA	-0.51	-5.8	-0.3	1.55e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08677398	chr8:58056175	NA	0.51	6.15	0.32	2.19e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26930643	chr1:48463304	NA	-0.48	-6.37	-0.33	6.15e-10	Hepatitis;
LUSC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg01879757	chr17:41196368	BRCA1	-0.47	-7.16	-0.36	5.11e-12	Menopause (age at onset);
LUSC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg13939156	chr17:80058883	NA	0.34	6.74	0.35	7.09e-11	Life satisfaction;
LUSC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg04317338	chr11:64019027	PLCB3	0.67	7.64	0.39	2.25e-13	Mean platelet volume;
LUSC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	6.61	0.34	1.55e-10	Renal function-related traits (BUN);
LUSC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg20203395	chr5:56204925	C5orf35	-0.78	-10.4	-0.49	4.07e-22	Initial pursuit acceleration;
LUSC	cis	rs11958404	0.932	rs72816574	chr5:157429882	T/C	cg05962755	chr5:157440814	NA	0.54	6.34	0.33	7.29e-10	IgG glycosylation;
LUSC	cis	rs6942756	0.876	rs1559486	chr7:129015894	C/T	cg02491457	chr7:128862824	NA	-0.41	-5.95	-0.31	6.71e-9	White matter hyperintensity burden;
LUSC	trans	rs7944735	0.817	rs747782	chr11:47940925	A/G	cg15704280	chr7:45808275	SEPT13	0.6	6.49	0.33	3.13e-10	Intraocular pressure;
LUSC	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg10636054	chr15:40330586	SRP14	-0.92	-8.81	-0.43	6.95e-17	Corneal curvature;
LUSC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	0.99	14.06	0.61	1.39e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs2979489	0.891	rs2915594	chr8:30401367	T/C	cg26383811	chr8:30366931	RBPMS	-0.51	-8.13	-0.41	8.49e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs981844	1.000	rs55722886	chr4:154668335	A/G	cg14289246	chr4:154710475	SFRP2	0.48	6.1	0.32	2.87e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-0.74	-12.57	-0.57	6.41e-30	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs35000415	0.873	rs12539741	chr7:128596805	C/T	cg19972273	chr7:128594194	NA	0.67	6.79	0.35	5.17e-11	Systemic lupus erythematosus;
LUSC	cis	rs4654899	0.549	rs4654873	chr1:21152384	G/A	cg01072550	chr1:21505969	NA	-0.46	-6.84	-0.35	3.68e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6960043	0.748	rs10228561	chr7:15063961	C/T	cg19272540	chr7:15055459	NA	-0.32	-7.79	-0.39	8.77e-14	Type 2 diabetes;
LUSC	trans	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg06606381	chr12:133084897	FBRSL1	-1.04	-8.89	-0.44	3.79e-17	Depression;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03258011	chr17:54857409	NA	0.39	5.98	0.31	5.65e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg13736514	chr6:26305472	NA	-0.45	-8.94	-0.44	2.72e-17	Educational attainment;
LUSC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg08200582	chr11:442649	ANO9	-0.52	-6.1	-0.32	3.02e-9	Body mass index;
LUSC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.89	0.35	2.81e-11	Tonsillectomy;
LUSC	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg18721089	chr20:30220636	NA	-0.44	-7.06	-0.36	9.51e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs6736093	0.966	rs11687451	chr2:112682561	G/A	cg12686935	chr2:112915763	FBLN7	-0.36	-5.84	-0.3	1.25e-8	Coronary artery disease;
LUSC	cis	rs56399783	0.901	rs73047387	chr7:2774125	G/A	cg19731401	chr7:2775893	GNA12	0.74	8.97	0.44	2.17e-17	Childhood ear infection;
LUSC	cis	rs2944755	1.000	rs2944755	chr8:141574194	A/G	cg08444833	chr8:141574162	EIF2C2	0.47	6.05	0.31	3.79e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs5758659	0.716	rs2143138	chr22:42618340	T/C	cg00645731	chr22:42541494	CYP2D7P1	-0.31	-6.52	-0.34	2.65e-10	Cognitive function;
LUSC	cis	rs965469	0.947	rs6037529	chr20:3261006	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-5.8	-0.3	1.57e-8	IFN-related cytopenia;
LUSC	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg14092571	chr14:90743983	NA	-0.35	-5.71	-0.3	2.45e-8	Mortality in heart failure;
LUSC	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg14227996	chr4:17616232	MED28	0.83	7.96	0.4	2.69e-14	Opioid sensitivity;
LUSC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.3	0.56	6.13e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg21892295	chr12:121157589	UNC119B	-0.33	-5.79	-0.3	1.65e-8	Mean corpuscular volume;
LUSC	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg21194808	chr1:2205498	SKI	0.37	5.96	0.31	6.49e-9	Coronary artery disease;
LUSC	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-0.86	-16.5	-0.67	3.69e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg17691542	chr6:26056736	HIST1H1C	0.6	8.12	0.41	9.15e-15	Iron status biomarkers;
LUSC	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg05738196	chr6:26577821	NA	0.79	15.22	0.64	4.38e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg21385522	chr1:16154831	NA	-0.53	-8.37	-0.42	1.55e-15	Systolic blood pressure;
LUSC	cis	rs9650315	0.866	rs55752715	chr8:57196353	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	7.48	0.38	6.82e-13	Height;
LUSC	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.16e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4663866	1.000	rs6741269	chr2:239179418	A/G	cg16914508	chr2:239161102	PER2	0.68	7.15	0.36	5.4e-12	Irritable bowel syndrome;
LUSC	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.9	0.4	3.95e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs147120681	1	rs147120681	chr1:101239293	CT/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.39	-5.65	-0.3	3.37e-8	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUSC	cis	rs12980942	1.000	rs2241719	chr19:41829581	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.14	0.32	2.37e-9	Coronary artery disease;
LUSC	cis	rs56283067	0.847	rs12204270	chr6:44697502	A/T	cg20913747	chr6:44695427	NA	-0.48	-7.93	-0.4	3.41e-14	Total body bone mineral density;
LUSC	cis	rs2625529	0.824	rs1074330	chr15:72250741	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.44	-0.38	8.62e-13	Red blood cell count;
LUSC	cis	rs17286411	0.669	rs4788547	chr16:71634544	G/A	cg10085824	chr16:71800315	AP1G1	0.35	5.71	0.3	2.47e-8	Blood protein levels;
LUSC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg22508957	chr16:3507546	NAT15	-0.68	-11.39	-0.53	1.25e-25	Tuberculosis;
LUSC	cis	rs34375054	0.624	rs12832525	chr12:125680366	T/C	cg25124228	chr12:125621409	AACS	-0.4	-5.7	-0.3	2.65e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg17054900	chr3:154042577	DHX36	0.43	5.65	0.3	3.52e-8	Coronary artery disease;
LUSC	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg22467129	chr15:76604101	ETFA	-0.43	-6.96	-0.36	1.84e-11	Blood metabolite levels;
LUSC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	5.76	0.3	1.96e-8	Renal function-related traits (BUN);
LUSC	cis	rs977987	0.872	rs4888422	chr16:75470576	A/G	cg03315344	chr16:75512273	CHST6	0.52	10.35	0.49	5.68e-22	Dupuytren's disease;
LUSC	cis	rs4964805	0.641	rs11111755	chr12:104159667	G/A	cg02344784	chr12:104178138	NT5DC3	0.37	5.96	0.31	6.51e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs7809950	0.954	rs2520241	chr7:107135443	A/G	cg23024343	chr7:107201750	COG5	-0.55	-8.99	-0.44	1.88e-17	Coronary artery disease;
LUSC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg09436375	chr6:42928200	GNMT	0.28	6.69	0.34	9.49e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg10523679	chr1:76189770	ACADM	-0.49	-7.28	-0.37	2.36e-12	Daytime sleep phenotypes;
LUSC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.51	7.32	0.37	1.91e-12	Gut microbiome composition (summer);
LUSC	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg07395648	chr5:131743802	NA	0.43	6.22	0.32	1.45e-9	Blood metabolite levels;
LUSC	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25581826	chr20:2821485	FAM113A;VPS16	0.66	6.14	0.32	2.4e-9	Cognitive performance;
LUSC	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg23096020	chr7:158799433	NA	0.36	6.09	0.32	3.05e-9	Facial morphology (factor 20);
LUSC	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg11812906	chr14:75593930	NEK9	-0.64	-10.55	-0.5	1.16e-22	Height;
LUSC	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg05855489	chr10:104503620	C10orf26	0.5	7.5	0.38	5.98e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.45	-6.6	-0.34	1.66e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	0.64	13.66	0.6	4.76e-34	Prudent dietary pattern;
LUSC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg09436375	chr6:42928200	GNMT	-0.25	-5.73	-0.3	2.25e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg14403583	chr14:105418241	AHNAK2	-0.54	-9.03	-0.44	1.44e-17	Rheumatoid arthritis;
LUSC	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.58	-0.42	3.56e-16	Systolic blood pressure;
LUSC	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg25182066	chr10:30743637	MAP3K8	0.44	6.16	0.32	2.13e-9	Inflammatory bowel disease;
LUSC	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg13319975	chr6:146136371	FBXO30	-0.69	-10.69	-0.5	3.9699999999999997e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.63	9.07	0.44	1.01e-17	Iron status biomarkers;
LUSC	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg12179176	chr11:130786555	SNX19	0.76	11.98	0.55	9.75e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs6987853	0.583	rs2974311	chr8:42455166	G/A	cg09913449	chr8:42400586	C8orf40	0.38	6.05	0.31	3.83e-9	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg00339695	chr16:24857497	SLC5A11	-0.38	-6.71	-0.34	8.22e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15342139	chr6:170124938	PHF10	-0.5	-6.38	-0.33	5.95e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg09034736	chr1:150693464	HORMAD1	0.5	7.3	0.37	2.18e-12	Tonsillectomy;
LUSC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.03	-0.4	1.63e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	7.64	0.39	2.32e-13	Height;
LUSC	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	1.18	13.88	0.6	7.01e-35	Arsenic metabolism;
LUSC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg14092988	chr3:52407081	DNAH1	0.3	5.81	0.3	1.46e-8	Bipolar disorder;
LUSC	cis	rs1009647	0.645	rs68153899	chr14:55702908	C/T	cg04306507	chr14:55594613	LGALS3	0.42	5.64	0.3	3.56e-8	Testicular germ cell tumor;
LUSC	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg24642439	chr20:33292090	TP53INP2	0.41	5.93	0.31	7.42e-9	Height;
LUSC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.08	-0.48	4.83e-21	Obesity-related traits;
LUSC	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg21433313	chr16:3507492	NAT15	-0.7	-8.62	-0.43	2.8e-16	Tuberculosis;
LUSC	cis	rs8062405	0.655	rs7184597	chr16:28921809	T/C	cg05966235	chr16:28915196	ATP2A1	-0.35	-5.89	-0.31	9.2e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg01097406	chr16:89675127	NA	0.36	7.32	0.37	1.84e-12	Vitiligo;
LUSC	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.46	-0.46	5.58e-19	Schizophrenia;
LUSC	cis	rs1864400	0.645	rs2249005	chr10:43627280	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.03	-0.36	1.16e-11	Hirschsprung disease;
LUSC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.23	0.56	1.17e-28	Prudent dietary pattern;
LUSC	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg06002616	chr8:101225028	SPAG1	-0.42	-7.0	-0.36	1.39e-11	Atrioventricular conduction;
LUSC	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.76	-0.35	6.03e-11	Systemic lupus erythematosus;
LUSC	cis	rs7247513	0.964	rs8100964	chr19:12720631	C/T	cg01871581	chr19:12707946	ZNF490	-0.52	-8.01	-0.4	1.91e-14	Bipolar disorder;
LUSC	cis	rs6580649	1.000	rs9805048	chr12:48403692	C/T	cg24011408	chr12:48396354	COL2A1	0.54	7.6	0.38	3.09e-13	Lung cancer;
LUSC	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg11887960	chr12:57824829	NA	0.48	6.47	0.33	3.46e-10	Obesity-related traits;
LUSC	cis	rs73206853	0.688	rs73191809	chr12:110907639	T/A	cg12870014	chr12:110450643	ANKRD13A	0.68	6.44	0.33	4.21e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg17143192	chr8:8559678	CLDN23	0.67	9.7	0.47	9.24e-20	Obesity-related traits;
LUSC	cis	rs55871839	0.708	rs13268621	chr8:59811724	T/G	cg07426533	chr8:59803705	TOX	-0.36	-5.93	-0.31	7.66e-9	Pneumonia;
LUSC	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.14	-0.32	2.29e-9	HDL cholesterol;
LUSC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7131987	0.621	rs3782506	chr12:29445422	A/C	cg09582351	chr12:29534625	ERGIC2	0.34	6.94	0.36	2.03e-11	QT interval;
LUSC	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.69	10.56	0.5	1.09e-22	Breast cancer;
LUSC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-6.92	-0.35	2.26e-11	Bipolar disorder;
LUSC	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg03676636	chr4:99064102	C4orf37	0.33	6.3	0.33	9.43e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs75920871	0.528	rs11216244	chr11:116912730	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.38	-0.33	5.93e-10	Subjective well-being;
LUSC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg10729496	chr3:10149963	C3orf24	-0.54	-7.43	-0.38	9.37e-13	Alzheimer's disease;
LUSC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg21782813	chr7:2030301	MAD1L1	0.57	10.31	0.49	7.81e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg22532475	chr10:104410764	TRIM8	-0.33	-7.53	-0.38	4.69e-13	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs72634258	0.842	rs6668846	chr1:8152102	C/G	cg00042356	chr1:8021962	PARK7	-0.6	-7.62	-0.38	2.69e-13	Inflammatory bowel disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03698729	chr19:2328812	SPPL2B;LSM7	-0.57	-7.47	-0.38	7.16e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg18350739	chr11:68623251	NA	-0.38	-6.76	-0.35	6.02e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13184539	chr1:241683111	FH	0.43	5.98	0.31	5.64e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-1.0	-18.39	-0.71	1.12e-52	Height;
LUSC	cis	rs2197308	0.549	rs10785517	chr12:38577992	G/T	cg13010199	chr12:38710504	ALG10B	0.49	7.23	0.37	3.29e-12	Morning vs. evening chronotype;
LUSC	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg24110177	chr3:50126178	RBM5	0.42	6.7	0.34	8.64e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs4720118	0.967	rs4723288	chr7:33487086	C/T	cg23247845	chr10:3679085	NA	-0.34	-6.04	-0.31	4.21e-9	Leprosy;
LUSC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg13939156	chr17:80058883	NA	0.34	6.59	0.34	1.74e-10	Life satisfaction;
LUSC	cis	rs10887741	0.646	rs11202501	chr10:89437208	C/T	cg13926569	chr10:89418898	PAPSS2	0.32	6.92	0.35	2.27e-11	Exercise (leisure time);
LUSC	cis	rs11676348	0.772	rs12471105	chr2:218950209	G/A	cg18102446	chr2:218934044	RUFY4	0.36	5.75	0.3	2.06e-8	Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08677398	chr8:58056175	NA	0.52	7.2	0.37	4.08e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg07703079	chr11:430292	ANO9	0.69	6.97	0.36	1.72e-11	Body mass index;
LUSC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg08219700	chr8:58056026	NA	0.46	5.98	0.31	5.71e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6546550	0.901	rs34586537	chr2:70163316	G/T	cg02498382	chr2:70120550	SNRNP27	0.28	6.86	0.35	3.4e-11	Prevalent atrial fibrillation;
LUSC	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.54	0.57	8.07e-30	White blood cell count;
LUSC	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.84	-15.53	-0.65	2.43e-41	Longevity;
LUSC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg17279839	chr7:150038598	RARRES2	0.48	7.25	0.37	2.96e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-7.1	-0.36	7.37e-12	Mood instability;
LUSC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg05941027	chr17:61774174	LIMD2	0.22	5.75	0.3	2e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.31	-0.33	8.87e-10	Personality dimensions;
LUSC	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.19	0.37	4.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg08601574	chr20:25228251	PYGB	-0.4	-5.95	-0.31	6.79e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg22875332	chr1:76189707	ACADM	-0.41	-5.97	-0.31	6.2e-9	Daytime sleep phenotypes;
LUSC	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg04218760	chr10:45406644	TMEM72	-0.28	-6.78	-0.35	5.54e-11	Mean corpuscular volume;
LUSC	cis	rs4919687	0.550	rs10748828	chr10:104456794	C/T	cg05855489	chr10:104503620	C10orf26	-0.71	-11.53	-0.53	4.03e-26	Colorectal cancer;
LUSC	trans	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.75	0.51	2.31e-23	Mean corpuscular volume;
LUSC	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	0.78	9.96	0.48	1.27e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-6.51	-0.34	2.78e-10	High light scatter reticulocyte count;
LUSC	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg06462663	chr19:18546047	ISYNA1	0.45	7.42	0.38	9.48e-13	Breast cancer;
LUSC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg14440974	chr22:39074834	NA	0.39	6.42	0.33	4.58e-10	Menopause (age at onset);
LUSC	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg09307838	chr4:120376055	NA	0.7	10.57	0.5	1.04e-22	Corneal astigmatism;
LUSC	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.37	-7.49	-0.38	6.32e-13	Dupuytren's disease;
LUSC	cis	rs4478037	1.000	rs4074417	chr3:33161153	A/C	cg19404215	chr3:33155277	CRTAP	0.96	9.76	0.47	5.72e-20	Major depressive disorder;
LUSC	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs2637266	0.783	rs846634	chr10:78535323	C/A	cg18941641	chr10:78392320	NA	0.4	7.16	0.36	5.14e-12	Pulmonary function;
LUSC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.34e-17	Motion sickness;
LUSC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs7911264	0.739	rs7096101	chr10:94362928	G/A	cg25093409	chr10:94429542	NA	0.36	6.21	0.32	1.59e-9	Inflammatory bowel disease;
LUSC	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg03433033	chr1:76189801	ACADM	-0.42	-6.28	-0.33	1.03e-9	Daytime sleep phenotypes;
LUSC	cis	rs34638657	0.789	rs2303264	chr16:82203711	G/T	cg09439754	chr16:82129088	HSD17B2	-0.4	-6.66	-0.34	1.11e-10	Lung adenocarcinoma;
LUSC	trans	rs7586604	0.748	rs6542892	chr2:100382958	A/C	cg26466323	chr19:19729535	PBX4	-0.83	-6.0	-0.31	5.1e-9	Cannabis dependence symptom count;
LUSC	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg07080220	chr10:102295463	HIF1AN	0.61	8.15	0.41	7.58e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7577696	0.568	rs410469	chr2:32476992	G/T	cg02381751	chr2:32503542	YIPF4	-0.5	-6.67	-0.34	1.06e-10	Inflammatory biomarkers;
LUSC	cis	rs240764	0.604	rs4840153	chr6:101213723	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-6.27	-0.32	1.12e-9	Neuroticism;
LUSC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.69	0.63	4.85e-38	Menopause (age at onset);
LUSC	cis	rs34638657	0.872	rs6420435	chr16:82184201	A/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.03	-0.31	4.38e-9	Lung adenocarcinoma;
LUSC	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg14809332	chr8:144654887	C8orf73	0.54	6.53	0.34	2.41e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg05347473	chr6:146136440	FBXO30	0.66	11.74	0.54	6.84e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.62	0.43	2.69e-16	Prudent dietary pattern;
LUSC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-8.21	-0.41	4.78e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg13531842	chr10:38383804	ZNF37A	-0.45	-6.71	-0.34	8.33e-11	Breast cancer;
LUSC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	0.92	19.45	0.73	6.89e-57	Dental caries;
LUSC	cis	rs17828380	0.920	rs12903186	chr15:63605364	C/T	cg05507819	chr15:63340323	TPM1	-0.75	-6.07	-0.32	3.49e-9	Social communication problems;
LUSC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg01657329	chr11:68192670	LRP5	-0.44	-6.5	-0.34	2.93e-10	Total body bone mineral density;
LUSC	cis	rs6138458	0.743	rs3746330	chr20:24999795	A/G	cg06937882	chr20:24974362	C20orf3	-0.32	-5.87	-0.31	1.06e-8	Blood protein levels;
LUSC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.51	0.59	1.77e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg22676075	chr6:135203613	NA	0.47	7.31	0.37	1.95e-12	Red blood cell count;
LUSC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg00310523	chr12:86230176	RASSF9	0.51	9.56	0.46	2.65e-19	Major depressive disorder;
LUSC	cis	rs921665	0.831	rs921666	chr2:3192141	G/C	cg02624386	chr2:3182749	NA	0.59	6.61	0.34	1.56e-10	World class endurance athleticism;
LUSC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg11843238	chr5:131593191	PDLIM4	-0.39	-6.01	-0.31	4.94e-9	Breast cancer;
LUSC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.08	0.55	4.01e-28	Prudent dietary pattern;
LUSC	cis	rs2282802	0.635	rs270162	chr5:139539090	A/G	cg26211634	chr5:139558579	C5orf32	-0.36	-6.71	-0.34	8.52e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1322512	0.874	rs2623955	chr6:152966375	C/T	cg27316956	chr6:152958899	SYNE1	-0.36	-6.24	-0.32	1.33e-9	Tonometry;
LUSC	trans	rs71435601	0.723	rs17041988	chr2:21420697	A/G	cg20757404	chr19:378427	NA	-0.41	-6.32	-0.33	8.46e-10	Cholesterol, total;
LUSC	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg13902645	chr11:5959945	NA	-0.58	-8.2	-0.41	5.23e-15	DNA methylation (variation);
LUSC	cis	rs28655083	0.529	rs682081	chr16:77103050	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	7.04	0.36	1.12e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs295140	1.000	rs7580924	chr2:201172628	G/C	cg04283868	chr2:201171347	SPATS2L	0.44	6.64	0.34	1.29e-10	QT interval;
LUSC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12379764	chr21:47803548	PCNT	0.49	7.0	0.36	1.4e-11	Testicular germ cell tumor;
LUSC	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg21775007	chr8:11205619	TDH	0.81	13.69	0.6	3.69e-34	Retinal vascular caliber;
LUSC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg04553112	chr3:125709451	NA	-0.49	-5.81	-0.3	1.47e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6445797	0.632	rs4681963	chr3:56687637	C/T	cg13792233	chr3:56591045	CCDC66	0.41	5.72	0.3	2.33e-8	Gastritis;
LUSC	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg17757837	chr7:157058334	UBE3C	-0.82	-13.21	-0.59	2.44e-32	Body mass index;
LUSC	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg24375607	chr4:120327624	NA	0.78	11.55	0.53	3.41e-26	Corneal astigmatism;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg16945982	chr2:25016118	CENPO;C2orf79	-0.49	-6.16	-0.32	2.15e-9	Neuroticism;
LUSC	cis	rs500891	0.574	rs12194258	chr6:84137202	T/C	cg08257003	chr6:84140564	ME1	0.37	9.1	0.45	8.48e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg06207120	chr15:45996521	NA	0.39	6.0	0.31	5.11e-9	Waist circumference;Weight;
LUSC	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	10.21	0.49	1.81e-21	Migraine;Coronary artery disease;
LUSC	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.15	10.48	0.5	2.05e-22	Alzheimer's disease (late onset);
LUSC	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg12935359	chr14:103987150	CKB	-0.54	-8.25	-0.41	3.74e-15	Body mass index;
LUSC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg05802129	chr4:122689817	NA	0.35	6.22	0.32	1.49e-9	Type 2 diabetes;
LUSC	cis	rs7000551	0.715	rs2461477	chr8:22378314	A/G	cg12081754	chr8:22256438	SLC39A14	0.47	7.02	0.36	1.23e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg07332563	chr6:291687	DUSP22	-0.5	-7.65	-0.39	2.18e-13	Menopause (age at onset);
LUSC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg16797656	chr11:68205561	LRP5	0.36	6.06	0.31	3.66e-9	Total body bone mineral density;
LUSC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.86	-0.54	2.57e-27	Chronic sinus infection;
LUSC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06028605	chr16:24865363	SLC5A11	0.67	10.58	0.5	9.21e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg15423357	chr2:25149977	NA	0.45	9.22	0.45	3.51e-18	Body mass index;
LUSC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg00106254	chr7:1943704	MAD1L1	-0.41	-5.94	-0.31	7.06e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.45	-0.33	3.9e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07080220	chr10:102295463	HIF1AN	0.67	9.18	0.45	4.45e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.33	0.74	2.37e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg23205692	chr1:25664452	TMEM50A	-0.43	-6.39	-0.33	5.6e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs11608355	0.545	rs34737994	chr12:109901621	C/T	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs929596	0.556	rs4477910	chr2:234643737	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-9.0	-0.44	1.81e-17	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg12573674	chr2:1569213	NA	-0.57	-8.09	-0.4	1.15e-14	IgG glycosylation;
LUSC	cis	rs7168353	0.948	rs10520720	chr15:93634724	A/G	cg24217984	chr15:93633278	RGMA	-0.38	-6.12	-0.32	2.67e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg25457927	chr22:38595422	NA	-0.42	-8.91	-0.44	3.45e-17	Cutaneous nevi;
LUSC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg23711669	chr6:146136114	FBXO30	0.82	15.02	0.63	2.64e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg04733989	chr22:42467013	NAGA	-0.41	-6.64	-0.34	1.24e-10	Cognitive function;
LUSC	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg05805236	chr11:65401703	PCNXL3	-0.62	-10.15	-0.49	2.79e-21	Acne (severe);
LUSC	cis	rs2742417	0.609	rs2673066	chr3:45771200	C/T	cg10512202	chr3:45649293	LIMD1	0.36	6.01	0.31	4.96e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24158363	chr17:73401717	GRB2	-0.43	-6.05	-0.31	3.97e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg26380479	chr7:97908229	NA	-0.28	-6.2	-0.32	1.67e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	6.56	0.34	2.07e-10	Height;
LUSC	cis	rs9515201	0.859	rs9521735	chr13:111037328	G/C	cg05272587	chr13:111038400	COL4A2	-0.41	-6.92	-0.35	2.27e-11	White matter hyperintensity burden;
LUSC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.52	-0.38	5.19e-13	Electroencephalogram traits;
LUSC	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.62	-0.34	1.4e-10	High light scatter reticulocyte count;
LUSC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg08200582	chr11:442649	ANO9	-0.57	-6.38	-0.33	5.99e-10	Body mass index;
LUSC	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	6.01	0.31	4.83e-9	Rheumatoid arthritis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08943809	chr16:58059531	MMP15	-0.45	-6.02	-0.31	4.48e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs500891	0.525	rs12697921	chr6:84071913	G/C	cg08257003	chr6:84140564	ME1	0.35	8.62	0.43	2.8e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg23625390	chr15:77176239	SCAPER	0.55	8.63	0.43	2.54e-16	Blood metabolite levels;
LUSC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg00262263	chr6:170184901	NA	0.38	5.86	0.31	1.13e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.49	0.42	6.73e-16	Response to antipsychotic treatment;
LUSC	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg13939156	chr17:80058883	NA	-0.34	-6.76	-0.35	6.08e-11	Life satisfaction;
LUSC	cis	rs12760731	0.623	rs10913551	chr1:178410131	T/G	cg00404053	chr1:178313656	RASAL2	0.48	5.76	0.3	1.91e-8	Obesity-related traits;
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.61	-11.76	-0.54	5.96e-27	Longevity;Endometriosis;
LUSC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	cis	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg21775007	chr8:11205619	TDH	-0.49	-6.65	-0.34	1.2e-10	Morning vs. evening chronotype;
LUSC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg13175981	chr1:150552382	MCL1	-0.5	-6.66	-0.34	1.14e-10	Tonsillectomy;
LUSC	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg02176678	chr2:219576539	TTLL4	-0.57	-10.08	-0.48	4.89e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7215564	0.818	rs4889776	chr17:78592385	C/T	cg23238734	chr17:78661607	RPTOR	0.49	6.18	0.32	1.85e-9	Myopia (pathological);
LUSC	cis	rs2710642	0.927	rs1468748	chr2:63204611	C/T	cg17519650	chr2:63277830	OTX1	0.5	6.77	0.35	5.72e-11	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg12311346	chr5:56204834	C5orf35	-0.63	-9.59	-0.46	2.1e-19	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs240764	0.658	rs2132169	chr6:101177663	C/A	cg09795085	chr6:101329169	ASCC3	-0.43	-6.27	-0.32	1.12e-9	Neuroticism;
LUSC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg21573476	chr21:45109991	RRP1B	-0.41	-6.6	-0.34	1.63e-10	Mean corpuscular volume;
LUSC	cis	rs721399	0.539	rs57180587	chr8:18269581	A/T	cg18736775	chr8:18248649	NAT2	-0.57	-6.76	-0.35	6.02e-11	Blood metabolite levels;
LUSC	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg18232548	chr7:50535776	DDC	0.5	7.49	0.38	6.04e-13	Malaria;
LUSC	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg12927641	chr6:109611667	NA	-0.37	-6.27	-0.32	1.14e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs9309473	0.607	rs7604588	chr2:73571417	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-7.24	-0.37	3.14e-12	Metabolite levels;
LUSC	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg27124370	chr19:33622961	WDR88	0.55	7.38	0.37	1.3e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg17507749	chr15:85114479	UBE2QP1	0.71	9.24	0.45	3.02e-18	Schizophrenia;
LUSC	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg13010199	chr12:38710504	ALG10B	0.7	10.93	0.51	5.81e-24	Bladder cancer;
LUSC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg20203395	chr5:56204925	C5orf35	-0.47	-7.03	-0.36	1.16e-11	Breast cancer;Breast cancer (early onset);
LUSC	trans	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs8014204	0.762	rs7144654	chr14:75298637	A/G	cg06637938	chr14:75390232	RPS6KL1	0.51	8.09	0.4	1.15e-14	Caffeine consumption;
LUSC	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.04	0.31	4.1e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6545883	0.868	rs778755	chr2:61781037	A/G	cg15711740	chr2:61764176	XPO1	0.43	6.8	0.35	4.73e-11	Tuberculosis;
LUSC	trans	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg25214090	chr10:38739885	LOC399744	0.46	6.95	0.36	1.94e-11	Corneal astigmatism;
LUSC	cis	rs926938	0.541	rs360623	chr1:115407268	G/C	cg12756093	chr1:115239321	AMPD1	0.44	6.42	0.33	4.63e-10	Autism;
LUSC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.96	-0.31	6.52e-9	Longevity;
LUSC	trans	rs10838798	0.517	rs1967210	chr11:48096692	G/T	cg03929089	chr4:120376271	NA	-0.6	-6.11	-0.32	2.78e-9	Height;
LUSC	trans	rs62238980	0.614	rs75691061	chr22:32381222	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg18225595	chr11:63971243	STIP1	0.5	6.18	0.32	1.9e-9	Mean platelet volume;
LUSC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg24296786	chr1:45957014	TESK2	0.48	7.31	0.37	2.04e-12	High light scatter reticulocyte count;
LUSC	cis	rs2652834	1.000	rs2729785	chr15:63402574	G/A	cg05507819	chr15:63340323	TPM1	0.67	8.16	0.41	7.01e-15	HDL cholesterol;
LUSC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg21724239	chr8:58056113	NA	0.61	7.21	0.37	3.7e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg03146154	chr1:46216737	IPP	0.53	7.89	0.4	4.27e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg17971929	chr21:40555470	PSMG1	-0.51	-7.63	-0.39	2.48e-13	Menarche (age at onset);
LUSC	cis	rs4629710	0.592	rs13195700	chr6:131585299	C/T	cg12606694	chr6:131520996	AKAP7	0.63	9.61	0.47	1.82e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg03611598	chr17:48586076	MYCBPAP	0.51	6.4	0.33	5.36e-10	Visceral fat;
LUSC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg18225595	chr11:63971243	STIP1	0.5	6.17	0.32	2e-9	Mean platelet volume;
LUSC	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg09307838	chr4:120376055	NA	0.73	10.23	0.49	1.47e-21	Corneal astigmatism;
LUSC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg16680214	chr1:154839983	KCNN3	-0.52	-9.8	-0.47	4.2e-20	Prostate cancer;
LUSC	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.76	-0.35	6.11e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7719624	1.000	rs1989972	chr5:135377802	A/C	cg12897067	chr5:135418308	NA	0.41	5.99	0.31	5.35e-9	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03517284	chr6:25882590	NA	0.42	7.42	0.38	9.55e-13	Blood metabolite levels;
LUSC	cis	rs73198271	0.531	rs3827812	chr8:8654898	C/T	cg01851573	chr8:8652454	MFHAS1	0.67	8.56	0.42	4.13e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg10909506	chr17:38081995	ORMDL3	-0.34	-6.24	-0.32	1.33e-9	Self-reported allergy;
LUSC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg08088566	chr11:430123	ANO9	0.68	7.56	0.38	3.85e-13	Body mass index;
LUSC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg02221750	chr19:17393354	ANKLE1	-0.91	-13.6	-0.6	8.08e-34	Systemic lupus erythematosus;
LUSC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg18512352	chr11:47633146	NA	-0.47	-9.79	-0.47	4.46e-20	Subjective well-being;
LUSC	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-7.99	-0.4	2.21e-14	Monocyte percentage of white cells;
LUSC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22968622	chr17:43663579	NA	-0.78	-11.93	-0.55	1.4e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg14552801	chr7:65878734	NA	-0.39	-6.02	-0.31	4.6e-9	Aortic root size;
LUSC	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg05283184	chr6:79620031	NA	-0.45	-8.33	-0.41	2.18e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2742417	0.603	rs2742372	chr3:45783472	T/C	cg04837898	chr3:45731254	SACM1L	-0.46	-7.46	-0.38	7.62e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg23422044	chr7:1970798	MAD1L1	-0.6	-6.32	-0.33	8.52e-10	Bipolar disorder;
LUSC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg07741184	chr6:167504864	NA	0.4	7.13	0.36	6.36e-12	Crohn's disease;
LUSC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-6.38	-0.33	5.92e-10	Reticulocyte count;
LUSC	cis	rs6736093	0.966	rs11682629	chr2:112744299	G/A	cg12686935	chr2:112915763	FBLN7	-0.37	-6.03	-0.31	4.39e-9	Coronary artery disease;
LUSC	cis	rs2200578	0.841	rs111592987	chr2:99601250	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.55	6.66	0.34	1.1e-10	IgG glycosylation;
LUSC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.81	-0.43	6.81e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.73	0.43	1.28e-16	Type 2 diabetes;
LUSC	cis	rs6901004	0.570	rs783084	chr6:111477887	T/C	cg15721981	chr6:111408429	SLC16A10	0.59	7.89	0.4	4.47e-14	Blood metabolite levels;
LUSC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.06	-0.36	9.65e-12	Lung cancer;
LUSC	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-1.06	-23.4	-0.79	2.34e-72	IgG glycosylation;
LUSC	cis	rs7607369	0.536	rs6436092	chr2:219669148	T/A	cg02176678	chr2:219576539	TTLL4	-0.52	-9.15	-0.45	5.72e-18	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.89	-0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs16976116	0.901	rs7172108	chr15:55501551	C/G	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg13010199	chr12:38710504	ALG10B	0.42	6.16	0.32	2.05e-9	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.7	9.18	0.45	4.53e-18	Gut microbiome composition (summer);
LUSC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	8.49	0.42	6.76e-16	Motion sickness;
LUSC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00166722	chr3:10149974	C3orf24	0.56	7.54	0.38	4.61e-13	Alzheimer's disease;
LUSC	cis	rs12681287	0.605	rs2953509	chr8:87343194	C/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.1	-0.36	7.54e-12	Caudate activity during reward;
LUSC	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.79	11.58	0.54	2.77e-26	Corneal astigmatism;
LUSC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.48	7.57	0.38	3.6e-13	Resistin levels;
LUSC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.6	0.47	1.95e-19	Bipolar disorder;
LUSC	cis	rs6542838	0.611	rs1878589	chr2:99517979	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-6.03	-0.31	4.3e-9	Fear of minor pain;
LUSC	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg07169764	chr2:136633963	MCM6	-1.06	-13.41	-0.59	4.34e-33	Corneal structure;
LUSC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1524927	0.966	rs7788744	chr7:96358649	T/A	cg03808172	chr7:96339361	SHFM1	0.43	6.53	0.34	2.45e-10	Total body bone mineral density;
LUSC	cis	rs7122539	0.646	rs682842	chr11:66568943	A/G	cg24851651	chr11:66362959	CCS	-0.54	-9.89	-0.48	2.07e-20	HIV-1 susceptibility;
LUSC	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	9.02	0.44	1.52e-17	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg18230493	chr5:56204884	C5orf35	-0.88	-13.39	-0.59	4.99e-33	Initial pursuit acceleration;
LUSC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg05347473	chr6:146136440	FBXO30	0.59	9.69	0.47	9.97e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg03806693	chr22:41940476	POLR3H	0.99	14.18	0.61	4.51e-36	Cannabis dependence symptom count;
LUSC	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg17757837	chr7:157058334	UBE3C	0.82	12.99	0.58	1.6e-31	Body mass index;
LUSC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-7.94	-0.4	3.14e-14	Total body bone mineral density;
LUSC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg07636037	chr3:49044803	WDR6	1.03	17.66	0.69	9.24e-50	Parkinson's disease;
LUSC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	6.67	0.34	1.05e-10	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg21053147	chr12:120880522	NA	-0.48	-5.81	-0.3	1.46e-8	Type 1 diabetes nephropathy;
LUSC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg16362232	chr11:430036	ANO9	0.62	8.11	0.41	9.85e-15	Body mass index;
LUSC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg04546413	chr19:29218101	NA	0.71	11.0	0.52	3.19e-24	Methadone dose in opioid dependence;
LUSC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.62	0.34	1.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7808935	0.628	rs62451116	chr7:27938980	A/G	cg22168087	chr7:27702803	HIBADH	0.7	8.17	0.41	6.56e-15	Prostate cancer;
LUSC	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg01966878	chr4:90757139	SNCA	-0.42	-5.99	-0.31	5.43e-9	Neuroticism;
LUSC	trans	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg13990129	chr9:108311111	FSD1L	-0.39	-6.59	-0.34	1.67e-10	Vitiligo;
LUSC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg22800045	chr5:56110881	MAP3K1	0.76	9.72	0.47	7.77e-20	Initial pursuit acceleration;
LUSC	cis	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg21775007	chr8:11205619	TDH	-0.52	-7.91	-0.4	3.91e-14	Retinal vascular caliber;
LUSC	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg15445000	chr17:37608096	MED1	0.38	6.49	0.33	3.1e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs939658	1.000	rs12439908	chr15:79456381	T/C	cg17916960	chr15:79447300	NA	0.47	9.51	0.46	3.94e-19	Refractive error;
LUSC	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg14169450	chr9:139327907	INPP5E	0.42	7.56	0.38	3.97e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	cis	rs2413583	0.591	rs17000981	chr22:39708017	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.62	6.31	0.33	8.86e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg27005118	chr17:13972210	COX10	-0.46	-8.68	-0.43	1.72e-16	Temperament;
LUSC	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg04013166	chr16:89971882	TCF25	0.62	7.24	0.37	3.1e-12	Skin colour saturation;
LUSC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.91	0.61	5.12e-35	Cognitive test performance;
LUSC	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg03465714	chr1:152285911	FLG	-0.4	-5.69	-0.3	2.82e-8	Atopic dermatitis;
LUSC	cis	rs9311676	0.656	rs55727087	chr3:58404547	G/A	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs9807841	0.592	rs2742313	chr19:10799750	T/C	cg09936142	chr19:10668400	KRI1	-0.4	-6.4	-0.33	5.32e-10	Inflammatory skin disease;
LUSC	cis	rs2354432	0.607	rs7516430	chr1:146767062	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-10.76	-0.51	2.28e-23	Mitochondrial DNA levels;
LUSC	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17916960	chr15:79447300	NA	-0.53	-10.49	-0.5	1.93e-22	Refractive error;
LUSC	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	8.14	0.41	8.14e-15	Coronary artery disease;
LUSC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08470875	chr2:26401718	FAM59B	0.7	9.09	0.45	8.81e-18	Gut microbiome composition (summer);
LUSC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg24977027	chr2:88469347	THNSL2	0.56	5.84	0.3	1.21e-8	Plasma clusterin levels;
LUSC	cis	rs7586879	0.789	rs17046737	chr2:25127835	C/T	cg01884057	chr2:25150051	NA	0.42	8.82	0.43	6.24e-17	Body mass index;
LUSC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg02423579	chr7:2872169	GNA12	-0.37	-5.73	-0.3	2.24e-8	Height;
LUSC	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg03585969	chr10:35415529	CREM	0.62	9.23	0.45	3.12e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3087591	1.000	rs7220483	chr17:29577248	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.56	-8.15	-0.41	7.29e-15	Hip circumference;
LUSC	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21028142	chr17:79581711	NPLOC4	-0.33	-7.75	-0.39	1.09e-13	Eye color traits;
LUSC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg17264618	chr3:40429014	ENTPD3	0.34	7.25	0.37	2.94e-12	Renal cell carcinoma;
LUSC	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg05855489	chr10:104503620	C10orf26	-0.7	-10.32	-0.49	7.49e-22	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg00106254	chr7:1943704	MAD1L1	-0.39	-5.68	-0.3	2.88e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.48	-6.52	-0.34	2.59e-10	Longevity;Endometriosis;
LUSC	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.74	0.35	6.99e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg14983838	chr19:29218262	NA	0.65	9.18	0.45	4.46e-18	Methadone dose in opioid dependence;
LUSC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg22823121	chr1:150693482	HORMAD1	-0.52	-7.54	-0.38	4.62e-13	Melanoma;
LUSC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg22166914	chr1:53195759	ZYG11B	0.46	7.62	0.38	2.64e-13	Monocyte count;
LUSC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	9.02	0.44	1.56e-17	Total body bone mineral density;
LUSC	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-10.42	-0.5	3.41e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.81	-12.4	-0.56	2.7e-29	Cognitive ability;
LUSC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25072359	chr17:41440525	NA	0.66	9.43	0.46	7.13e-19	Menopause (age at onset);
LUSC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg01256987	chr12:42539512	GXYLT1	-0.47	-8.99	-0.44	1.83e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg09044154	chr16:88155775	NA	-0.56	-7.56	-0.38	3.96e-13	Menopause (age at onset);
LUSC	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.69	-0.54	1.07e-26	Coffee consumption (cups per day);
LUSC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg08132940	chr7:1081526	C7orf50	-0.52	-6.25	-0.32	1.25e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2274273	0.673	rs2209808	chr14:55807695	A/T	cg04306507	chr14:55594613	LGALS3	0.53	11.32	0.53	2.4e-25	Protein biomarker;
LUSC	cis	rs2729354	0.953	rs2649663	chr11:57357305	C/T	cg24343310	chr11:57249947	NA	0.35	6.45	0.33	4e-10	Blood protein levels;
LUSC	cis	rs6546537	1.000	rs4286306	chr2:69885647	G/C	cg10773587	chr2:69614142	GFPT1	-0.47	-7.37	-0.37	1.37e-12	Serum thyroid-stimulating hormone levels;
LUSC	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg26384229	chr12:38710491	ALG10B	0.74	11.96	0.55	1.15e-27	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06481639	chr22:41940642	POLR3H	-0.51	-6.13	-0.32	2.41e-9	Vitiligo;
LUSC	cis	rs3857536	0.776	rs9363560	chr6:66949686	T/G	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg07424592	chr7:64974309	NA	1.07	6.61	0.34	1.53e-10	Diabetic kidney disease;
LUSC	cis	rs72781680	0.821	rs72796401	chr2:24180078	T/A	cg08917208	chr2:24149416	ATAD2B	0.61	6.96	0.36	1.82e-11	Lymphocyte counts;
LUSC	trans	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg02113368	chr10:135107346	TUBGCP2	-0.34	-6.0	-0.31	5.12e-9	Dementia with Lewy bodies;
LUSC	cis	rs62400317	0.859	rs11964690	chr6:45258068	A/G	cg20913747	chr6:44695427	NA	-0.47	-7.6	-0.38	2.96e-13	Total body bone mineral density;
LUSC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg27170947	chr2:26402098	FAM59B	-0.64	-9.37	-0.46	1.1e-18	Gut microbiome composition (summer);
LUSC	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg22437258	chr11:111473054	SIK2	0.48	6.44	0.33	4.18e-10	Primary sclerosing cholangitis;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg01684318	chr3:183415696	YEATS2	0.35	5.96	0.31	6.24e-9	Asthma;
LUSC	trans	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.56	-0.42	4.08e-16	Depression;
LUSC	cis	rs4363385	0.747	rs1055935	chr1:152975941	C/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.71	-0.39	1.44e-13	Inflammatory skin disease;
LUSC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg16482183	chr6:26056742	HIST1H1C	0.47	6.72	0.34	7.98e-11	Height;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.47	0.33	3.41e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.58	12.79	0.57	9.32e-31	Tonsillectomy;
LUSC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	cis	rs11809207	0.953	rs17163666	chr1:26525383	A/G	cg00147160	chr1:26503991	CNKSR1	0.41	6.85	0.35	3.52e-11	Height;
LUSC	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.92	0.51	6.12e-24	Hypertriglyceridemia;
LUSC	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg02153584	chr22:29168773	CCDC117	0.51	6.71	0.34	8.23e-11	Lymphocyte counts;
LUSC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg24634471	chr8:143751801	JRK	0.59	8.97	0.44	2.12e-17	Schizophrenia;
LUSC	trans	rs514406	0.505	rs835609	chr1:53170494	T/C	cg24643429	chr1:3562429	WDR8	0.33	5.94	0.31	7.03e-9	Monocyte count;
LUSC	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg08755490	chr11:65554678	OVOL1	0.41	5.84	0.3	1.21e-8	Acne (severe);
LUSC	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg00049323	chr5:472564	LOC25845	-0.41	-6.05	-0.31	3.87e-9	Cystic fibrosis severity;
LUSC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg06808227	chr14:105710500	BRF1	-0.66	-10.08	-0.48	4.97e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg22823121	chr1:150693482	HORMAD1	0.53	7.91	0.4	3.84e-14	Melanoma;
LUSC	cis	rs3743266	0.613	rs1869485	chr15:60746605	G/A	cg21667061	chr15:60772094	NARG2	-0.38	-6.41	-0.33	4.94e-10	Menarche (age at onset);
LUSC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.09	-0.32	3.02e-9	Initial pursuit acceleration;
LUSC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg18827107	chr12:86230957	RASSF9	-0.45	-6.73	-0.35	7.51e-11	Major depressive disorder;
LUSC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg13206674	chr6:150067644	NUP43	0.59	9.28	0.45	2.26e-18	Lung cancer;
LUSC	trans	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg18876405	chr7:65276391	NA	0.45	7.06	0.36	9.62e-12	Corneal structure;
LUSC	cis	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg17187183	chr4:55093834	PDGFRA	0.39	5.89	0.31	9.61e-9	Corneal astigmatism;
LUSC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	1.05	20.05	0.74	2.97e-59	Menopause (age at onset);
LUSC	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg27286337	chr10:134555280	INPP5A	0.53	5.69	0.3	2.83e-8	Primary sclerosing cholangitis;
LUSC	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg09044154	chr16:88155775	NA	-0.55	-7.32	-0.37	1.88e-12	Menopause (age at onset);
LUSC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-6.7	-0.34	9.03e-11	Mean platelet volume;
LUSC	trans	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.3	-0.41	2.59e-15	Retinal vascular caliber;
LUSC	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.49	-8.17	-0.41	6.23e-15	Asthma and hay fever;
LUSC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.76	-13.97	-0.61	2.97e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs6060717	0.536	rs8125393	chr20:34496162	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.67	-0.3	3.14e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.72	-0.43	1.37e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg00531865	chr16:30841666	NA	-0.34	-6.2	-0.32	1.65e-9	Dementia with Lewy bodies;
LUSC	cis	rs7640424	0.589	rs78673584	chr3:107813133	A/G	cg09227934	chr3:107805635	CD47	-0.55	-7.86	-0.4	5.26e-14	Body mass index;
LUSC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03352830	chr11:487213	PTDSS2	0.77	9.18	0.45	4.71e-18	Body mass index;
LUSC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg16606324	chr3:10149918	C3orf24	0.58	8.18	0.41	5.99e-15	Alzheimer's disease;
LUSC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg08499158	chr17:42289980	UBTF	-0.52	-8.58	-0.42	3.63e-16	Total body bone mineral density;
LUSC	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg00982548	chr2:198649783	BOLL	-0.56	-7.01	-0.36	1.33e-11	Ulcerative colitis;
LUSC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.87	-0.35	3.2e-11	Lung cancer;
LUSC	cis	rs3740540	0.507	rs10794161	chr10:126291327	C/A	cg04949429	chr10:126290192	LHPP	0.36	7.56	0.38	3.95e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs800082	1.000	rs1405599	chr3:144328759	T/C	cg24215973	chr2:240111563	HDAC4	-0.45	-6.91	-0.35	2.49e-11	Smoking behavior;
LUSC	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg26441486	chr22:50317300	CRELD2	-0.45	-7.43	-0.38	9.42e-13	Schizophrenia;
LUSC	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg13175981	chr1:150552382	MCL1	0.43	6.09	0.32	3.16e-9	Tonsillectomy;
LUSC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg22903471	chr2:27725779	GCKR	0.41	6.95	0.36	1.91e-11	Total body bone mineral density;
LUSC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg03909863	chr11:638404	DRD4	-0.39	-5.89	-0.31	9.34e-9	Systemic lupus erythematosus;
LUSC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg26695010	chr11:65641043	EFEMP2	-0.48	-6.96	-0.36	1.85e-11	Eosinophil percentage of white cells;
LUSC	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-0.59	-9.28	-0.45	2.13e-18	Breast cancer;
LUSC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg06505273	chr16:24850292	NA	-0.38	-5.98	-0.31	5.89e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs67072384	1.000	rs12292781	chr11:72448385	A/C	cg04827223	chr11:72435913	ARAP1	-0.82	-7.65	-0.39	2.12e-13	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	trans	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg21775007	chr8:11205619	TDH	0.43	6.05	0.31	3.96e-9	Joint mobility (Beighton score);
LUSC	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.83	-0.35	4.05e-11	Monocyte percentage of white cells;
LUSC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg17507749	chr15:85114479	UBE2QP1	0.69	8.71	0.43	1.38e-16	Schizophrenia;
LUSC	cis	rs1564271	0.961	rs2927921	chr10:27016001	A/C	cg13837822	chr10:26931731	LOC731789	0.44	8.85	0.44	5.32e-17	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUSC	cis	rs7178572	1.000	rs11633054	chr15:77747276	A/G	cg22256960	chr15:77711686	NA	-0.52	-8.74	-0.43	1.12e-16	Type 2 diabetes;
LUSC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.98	0.4	2.35e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7789940	0.810	rs12533978	chr7:75943352	T/C	cg10167463	chr7:75959203	YWHAG	-0.63	-9.32	-0.45	1.61e-18	Multiple sclerosis;
LUSC	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-0.84	-13.7	-0.6	3.2e-34	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.94	-0.36	2.04e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg05347473	chr6:146136440	FBXO30	0.58	10.1	0.48	4.16e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg04727924	chr7:799746	HEATR2	-0.57	-6.06	-0.31	3.75e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg24690094	chr11:67383802	NA	0.42	8.13	0.41	8.26e-15	Mean corpuscular volume;
LUSC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg13683864	chr3:40499215	RPL14	-1.12	-21.22	-0.76	7.32e-64	Renal cell carcinoma;
LUSC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg05872129	chr22:39784769	NA	-0.62	-11.66	-0.54	1.36e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg07169764	chr2:136633963	MCM6	-0.62	-8.24	-0.41	4.08e-15	Mosquito bite size;
LUSC	cis	rs477692	0.604	rs1008982	chr10:131445731	T/C	cg05714579	chr10:131428358	MGMT	-0.7	-10.81	-0.51	1.46e-23	Response to temozolomide;
LUSC	trans	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg08975724	chr8:8085496	FLJ10661	0.43	6.26	0.32	1.22e-9	Retinal vascular caliber;
LUSC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.34	5.81	0.3	1.49e-8	Menopause (age at onset);
LUSC	cis	rs10465746	0.658	rs980418	chr1:84365653	T/G	cg10977910	chr1:84465055	TTLL7	0.51	7.29	0.37	2.21e-12	Obesity-related traits;
LUSC	cis	rs7608623	0.804	rs11675585	chr2:24237180	T/C	cg08917208	chr2:24149416	ATAD2B	-0.44	-5.85	-0.3	1.19e-8	Obesity-related traits;
LUSC	cis	rs9796	0.870	rs8042088	chr15:41337487	C/T	cg18705301	chr15:41695430	NDUFAF1	0.42	7.32	0.37	1.81e-12	Menopause (age at onset);
LUSC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	1.04	16.9	0.68	1.01e-46	Testicular germ cell tumor;
LUSC	cis	rs4654899	1.000	rs6703227	chr1:21374810	A/G	cg01072550	chr1:21505969	NA	-0.56	-8.38	-0.42	1.48e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg05925327	chr15:68127851	NA	-0.4	-6.16	-0.32	2.13e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs3106136	1.000	rs3106136	chr4:95153349	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.92	-0.31	7.99e-9	Capecitabine sensitivity;
LUSC	cis	rs701145	0.824	rs355767	chr3:154045895	G/A	cg17054900	chr3:154042577	DHX36	0.81	8.73	0.43	1.21e-16	Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13582782	chr10:27793181	RAB18	0.43	6.08	0.32	3.21e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	9.74	0.47	6.64e-20	Joint mobility (Beighton score);
LUSC	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg15654264	chr1:150340011	RPRD2	0.62	10.29	0.49	9.57e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.89	0.31	9.57e-9	Menopause (age at onset);
LUSC	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg26597838	chr10:835615	NA	0.74	9.26	0.45	2.62e-18	Eosinophil percentage of granulocytes;
LUSC	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.47	-5.83	-0.3	1.31e-8	Birth weight;
LUSC	cis	rs1904096	0.506	rs6823404	chr4:95197520	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.44	-0.42	9.73e-16	Type 2 diabetes;
LUSC	cis	rs10905065	0.895	rs3736462	chr10:5804455	A/G	cg11519256	chr10:5708881	ASB13	0.4	5.8	0.3	1.51e-8	Menopause (age at onset);
LUSC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs3892630	0.620	rs10413279	chr19:33182746	A/G	cg22980127	chr19:33182716	NUDT19	0.97	15.11	0.64	1.08e-39	Red blood cell traits;
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg17541715	chr7:1216824	NA	-0.39	-6.18	-0.32	1.89e-9	Longevity;Endometriosis;
LUSC	cis	rs7712401	0.601	rs144597	chr5:122223232	A/C	cg19077854	chr5:122220652	SNX24	0.4	8.85	0.44	5.36e-17	Mean platelet volume;
LUSC	trans	rs488628	1.000	rs517313	chr3:118134320	T/C	cg06621744	chr14:37052470	NKX2-8	-0.29	-6.47	-0.33	3.56e-10	White matter integrity (bipolar disorder risk interaction);
LUSC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg24675056	chr1:15929824	NA	0.48	8.17	0.41	6.51e-15	Systolic blood pressure;
LUSC	cis	rs1981331	1.000	rs77587985	chr21:47993897	A/G	cg17243659	chr21:48055224	PRMT2	0.86	6.24	0.32	1.31e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg13560548	chr3:10150139	C3orf24	0.48	6.75	0.35	6.63e-11	Alzheimer's disease;
LUSC	trans	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg25214090	chr10:38739885	LOC399744	0.43	6.46	0.33	3.61e-10	Corneal astigmatism;
LUSC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg20302533	chr7:39170763	POU6F2	0.52	8.18	0.41	6.03e-15	IgG glycosylation;
LUSC	cis	rs6693567	0.545	rs7411534	chr1:150447269	C/T	cg09579323	chr1:150459698	TARS2	0.4	5.7	0.3	2.59e-8	Migraine;
LUSC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg07061783	chr6:25882402	NA	-0.45	-6.43	-0.33	4.45e-10	Blood metabolite levels;
LUSC	trans	rs3010562	1.000	rs3010562	chr6:167765251	A/G	cg13679164	chr6:161258479	NA	-0.44	-6.58	-0.34	1.77e-10	Gut microbiome composition (summer and winter);
LUSC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.24	0.52	4.35e-25	Menopause (age at onset);
LUSC	cis	rs4776059	0.958	rs933860	chr15:52965468	T/C	cg22715398	chr15:52968154	KIAA1370	-0.67	-9.27	-0.45	2.33e-18	Schizophrenia;
LUSC	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg06484146	chr7:12443880	VWDE	-0.68	-7.23	-0.37	3.41e-12	Coronary artery disease;
LUSC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.55	8.46	0.42	8.61e-16	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.69	-12.3	-0.56	6.25e-29	Aortic root size;
LUSC	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg23711669	chr6:146136114	FBXO30	0.88	16.22	0.66	4.99e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	cis	rs12979813	1.000	rs12979813	chr19:11342703	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	-0.39	-5.74	-0.3	2.1e-8	HDL cholesterol;
LUSC	cis	rs3105593	0.575	rs4318151	chr15:50729274	A/G	cg08437265	chr15:50716283	USP8	0.45	6.53	0.34	2.38e-10	QT interval;
LUSC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg07636037	chr3:49044803	WDR6	0.44	6.49	0.33	3.04e-10	Resting heart rate;
LUSC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg19077165	chr18:44547161	KATNAL2	0.43	6.51	0.34	2.72e-10	Personality dimensions;
LUSC	cis	rs6732160	0.691	rs13402225	chr2:73416906	T/G	cg24220031	chr2:73402428	NA	-0.23	-5.81	-0.3	1.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.8	-0.35	4.89e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.37	1.18e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg27165867	chr14:105738592	BRF1	-0.51	-7.5	-0.38	5.75e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg22681709	chr2:178499509	PDE11A	-0.45	-7.47	-0.38	7.03e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6495367	1.000	rs745030	chr15:79381705	G/A	cg17916960	chr15:79447300	NA	0.35	6.6	0.34	1.64e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg24397884	chr7:158709396	WDR60	0.77	8.64	0.43	2.39e-16	Height;
LUSC	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.34	6.91	0.35	2.51e-11	Schizophrenia;
LUSC	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.96	15.44	0.65	6e-41	Lymphocyte percentage of white cells;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11688874	chr10:28822482	WAC	0.46	6.8	0.35	4.79e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04746670	chr2:122288182	CLASP1;RNU4ATAC	-0.4	-6.06	-0.31	3.74e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs977987	0.800	rs3784935	chr16:75336430	T/G	cg03315344	chr16:75512273	CHST6	0.48	8.9	0.44	3.61e-17	Dupuytren's disease;
LUSC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.42	0.53	9.8e-26	Prudent dietary pattern;
LUSC	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg22482690	chr17:47019901	SNF8	0.39	7.38	0.37	1.3e-12	Type 2 diabetes;
LUSC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.74	-0.39	1.23e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg09509183	chr1:209979624	IRF6	0.53	5.71	0.3	2.46e-8	Coronary artery disease;
LUSC	cis	rs240764	0.555	rs11967951	chr6:101231905	G/A	cg09795085	chr6:101329169	ASCC3	0.44	6.25	0.32	1.24e-9	Neuroticism;
LUSC	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg16339924	chr4:17578868	LAP3	0.55	8.21	0.41	4.77e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9359856	0.564	rs61739327	chr6:90340446	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.88	-8.41	-0.42	1.19e-15	Bipolar disorder;
LUSC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00149659	chr3:10157352	C3orf10	-0.87	-11.59	-0.54	2.51e-26	Alzheimer's disease;
LUSC	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg08601574	chr20:25228251	PYGB	0.42	6.56	0.34	2.05e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	10.85	0.51	1.1e-23	Total body bone mineral density;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13731338	chr3:128145454	NA	0.72	6.05	0.31	3.96e-9	Cognitive performance;
LUSC	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg20026190	chr17:76395443	PGS1	0.44	7.72	0.39	1.32e-13	HDL cholesterol levels;
LUSC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg06671706	chr8:8559999	CLDN23	0.43	5.87	0.31	1.07e-8	Obesity-related traits;
LUSC	cis	rs6736093	0.966	rs11686647	chr2:112684397	T/A	cg12686935	chr2:112915763	FBLN7	-0.37	-5.9	-0.31	8.73e-9	Coronary artery disease;
LUSC	trans	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg26043149	chr18:55253948	FECH	0.46	6.59	0.34	1.75e-10	Bone mineral density;
LUSC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg15790184	chr11:494944	RNH1	0.5	5.7	0.3	2.67e-8	Body mass index;
LUSC	cis	rs16917546	1.000	rs7094595	chr10:64415413	T/A	cg03961010	chr10:64397487	ZNF365	-0.41	-6.49	-0.33	3.1e-10	Basal cell carcinoma;
LUSC	trans	rs1147199	0.585	rs7468983	chr9:87247277	C/T	cg18287975	chr5:88178977	MEF2C	-0.7	-6.02	-0.31	4.56e-9	Body mass index;
LUSC	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	6.97	0.36	1.74e-11	Response to antipsychotic treatment;
LUSC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg02551604	chr5:131831745	NA	0.46	7.15	0.36	5.38e-12	Asthma (sex interaction);
LUSC	cis	rs11608355	0.545	rs4766604	chr12:109892179	T/C	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.1e-26	Neuroticism;
LUSC	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13789015	chr9:136890014	NCRNA00094	0.62	11.09	0.52	1.49e-24	Platelet distribution width;
LUSC	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg11189052	chr15:85197271	WDR73	0.49	6.19	0.32	1.79e-9	Schizophrenia;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg26468274	chr6:43544000	XPO5;POLH	0.42	6.09	0.32	3.08e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg21775007	chr8:11205619	TDH	-0.51	-7.55	-0.38	4.24e-13	Triglycerides;
LUSC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.67	0.43	1.96e-16	Motion sickness;
LUSC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.69	0.39	1.65e-13	Bipolar disorder;
LUSC	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg17366294	chr4:99064904	C4orf37	0.52	7.32	0.37	1.92e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg15654264	chr1:150340011	RPRD2	0.66	11.01	0.52	2.84e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	0.92	15.57	0.65	1.75e-41	Menopause (age at onset);
LUSC	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg27284194	chr4:1044797	NA	0.48	7.85	0.39	5.73e-14	Recombination rate (males);
LUSC	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.44	0.46	6.65e-19	Bipolar disorder;
LUSC	cis	rs4919694	1.000	rs111622998	chr10:104953021	C/A	cg04362960	chr10:104952993	NT5C2	1.21	14.43	0.62	4.84e-37	Arsenic metabolism;
LUSC	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg17652424	chr22:38574118	PLA2G6	-0.31	-6.79	-0.35	4.99e-11	Cutaneous nevi;
LUSC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg12292205	chr6:26970375	C6orf41	-0.67	-11.61	-0.54	2e-26	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1568889	0.774	rs11030235	chr11:28212375	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	12.69	0.57	2.12e-30	Bipolar disorder;
LUSC	cis	rs231513	0.911	rs124721	chr17:41959808	T/C	cg26893861	chr17:41843967	DUSP3	-0.53	-5.84	-0.3	1.26e-8	Cognitive function;
LUSC	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.44	5.92	0.31	7.99e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg00784671	chr22:46762841	CELSR1	-0.63	-6.63	-0.34	1.33e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs67079557	1	rs67079557	chr15:75930300	ATAATAAG/A	cg20655648	chr15:75932815	IMP3	0.45	5.94	0.31	7.16e-9	Breast cancer;
LUSC	cis	rs10186029	0.509	rs7566029	chr2:213941189	A/G	cg08319019	chr2:214017104	IKZF2	-0.43	-6.22	-0.32	1.5e-9	Systemic sclerosis;
LUSC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg04414720	chr1:150670196	GOLPH3L	-0.42	-6.4	-0.33	5.4e-10	Tonsillectomy;
LUSC	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.18	0.55	1.7e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs62238980	0.614	rs74928243	chr22:32439681	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs11585357	0.843	rs72646796	chr1:17612503	T/C	cg08277548	chr1:17600880	PADI3	-0.64	-6.62	-0.34	1.42e-10	Hair shape;
LUSC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.11	0.32	2.72e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.86	-0.58	5.11e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs7246967	0.673	rs2361260	chr19:22914144	C/T	cg23217946	chr19:22817039	ZNF492	-0.41	-5.69	-0.3	2.8e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs2279817	1.000	rs4920620	chr1:18023154	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.46	6.34	0.33	7.58e-10	Neuroticism;
LUSC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	0.63	13.49	0.59	2.1e-33	Prudent dietary pattern;
LUSC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.25	0.41	3.79e-15	Melanoma;
LUSC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.63	8.35	0.42	1.8e-15	High light scatter reticulocyte count;
LUSC	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg00310523	chr12:86230176	RASSF9	0.37	6.77	0.35	5.98e-11	Major depressive disorder;
LUSC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg03146154	chr1:46216737	IPP	0.5	7.32	0.37	1.88e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-7.16	-0.36	5.16e-12	Asthma;
LUSC	cis	rs11650494	0.908	rs73324308	chr17:47405338	T/G	cg08112188	chr17:47440006	ZNF652	1.22	10.65	0.5	5.21e-23	Prostate cancer;
LUSC	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.69	10.41	0.49	3.68e-22	Corneal astigmatism;
LUSC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg05347473	chr6:146136440	FBXO30	0.52	8.65	0.43	2.21e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.61	8.11	0.41	9.99e-15	High light scatter reticulocyte count;
LUSC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg07061783	chr6:25882402	NA	-0.42	-6.0	-0.31	5.03e-9	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.11	0.36	6.98e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg18225595	chr11:63971243	STIP1	0.51	6.22	0.32	1.47e-9	Mean platelet volume;
LUSC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.82e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg13319975	chr6:146136371	FBXO30	-0.45	-6.91	-0.35	2.48e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6545883	0.894	rs2694642	chr2:61596180	A/G	cg15711740	chr2:61764176	XPO1	0.44	6.72	0.35	7.83e-11	Tuberculosis;
LUSC	cis	rs6484504	0.600	rs7122895	chr11:31346620	G/C	cg26647111	chr11:31128758	NA	0.4	5.74	0.3	2.17e-8	Red blood cell count;
LUSC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.33	0.45	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2652834	1.000	rs4344684	chr15:63397318	C/T	cg05507819	chr15:63340323	TPM1	0.69	8.35	0.42	1.85e-15	HDL cholesterol;
LUSC	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg00677455	chr12:58241039	CTDSP2	0.61	9.16	0.45	5.27e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs4654899	0.865	rs1472831	chr1:21435940	C/T	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.21	-0.32	1.53e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.19	-0.32	1.76e-9	Resting heart rate;
LUSC	cis	rs1775715	0.737	rs2799018	chr10:32202069	C/T	cg03015672	chr10:32216066	ARHGAP12	0.34	6.23	0.32	1.39e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs12815613	0.539	rs7300883	chr12:121459440	C/G	cg02403541	chr12:121454288	C12orf43	-0.43	-5.96	-0.31	6.45e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4786125	0.920	rs6500851	chr16:6896521	A/G	cg03623568	chr16:6915990	A2BP1	-0.42	-7.04	-0.36	1.1e-11	Heart rate variability traits (SDNN);
LUSC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	6.28	0.32	1.07e-9	Electroencephalogram traits;
LUSC	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg05501817	chr11:14380813	RRAS2	-0.47	-6.84	-0.35	3.81e-11	Sense of smell;
LUSC	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.84	-0.39	6.21e-14	Chronic sinus infection;
LUSC	cis	rs1322512	0.917	rs2250013	chr6:153006539	A/T	cg27316956	chr6:152958899	SYNE1	0.35	6.09	0.32	3.07e-9	Tonometry;
LUSC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg03146154	chr1:46216737	IPP	0.51	7.63	0.39	2.5e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4964805	0.594	rs3751204	chr12:104171455	C/T	cg02344784	chr12:104178138	NT5DC3	0.37	5.97	0.31	6.08e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg15556689	chr8:8085844	FLJ10661	0.73	10.26	0.49	1.17e-21	Red cell distribution width;
LUSC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.63	-9.64	-0.47	1.4e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.56	-0.42	4.1e-16	Systolic blood pressure;
LUSC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-7.22	-0.37	3.55e-12	Alzheimer's disease (late onset);
LUSC	cis	rs6692729	0.933	rs6759	chr1:227069737	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.51	-7.32	-0.37	1.91e-12	Electrodermal activity;
LUSC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9790314	0.631	rs9867582	chr3:160797405	A/G	cg03342759	chr3:160939853	NMD3	-0.42	-6.91	-0.35	2.48e-11	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.11	-0.36	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10802521	chr3:52805072	NEK4	0.5	8.08	0.4	1.19e-14	Bipolar disorder;
LUSC	cis	rs12931792	0.782	rs12927190	chr16:30169393	C/G	cg17640201	chr16:30407289	ZNF48	0.6	9.72	0.47	7.66e-20	Tonsillectomy;
LUSC	cis	rs599083	0.744	rs603129	chr11:68186669	A/T	cg20283391	chr11:68216788	NA	0.5	6.7	0.34	9.02e-11	Bone mineral density (spine);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg06643390	chr1:168106157	GPR161	0.41	6.26	0.32	1.19e-9	N-glycan levels;
LUSC	trans	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg19894588	chr14:64061835	NA	-0.57	-7.49	-0.38	6.32e-13	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs11608355	0.538	rs11611957	chr12:109801803	A/G	cg19025524	chr12:109796872	NA	-0.42	-7.65	-0.39	2.18e-13	Neuroticism;
LUSC	trans	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	6.96	0.36	1.84e-11	Retinal vascular caliber;
LUSC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.6	7.99	0.4	2.16e-14	Response to diuretic therapy;
LUSC	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.37	-0.33	6.31e-10	Retinal vascular caliber;
LUSC	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg13010344	chr12:123464640	ARL6IP4	-0.5	-7.02	-0.36	1.27e-11	Neutrophil percentage of white cells;
LUSC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg18357645	chr12:58087776	OS9	0.42	6.3	0.33	9.19e-10	Multiple sclerosis;
LUSC	trans	rs8073060	0.586	rs72829933	chr17:34056406	C/T	cg19694781	chr19:47549865	TMEM160	1.14	17.37	0.69	1.31e-48	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs11168618	0.626	rs11609074	chr12:48819335	C/A	cg24011408	chr12:48396354	COL2A1	0.41	6.51	0.34	2.7e-10	Adiponectin levels;
LUSC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.58	10.66	0.5	4.78e-23	Homoarginine levels;
LUSC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg27170947	chr2:26402098	FAM59B	0.71	10.77	0.51	2.03e-23	Gut microbiome composition (summer);
LUSC	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	0.95	17.79	0.7	2.76e-50	Bone mineral density;
LUSC	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg19875535	chr5:140030758	IK	0.48	7.79	0.39	8.62e-14	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7617773	0.963	rs9822496	chr3:48181333	T/C	cg11946769	chr3:48343235	NME6	0.62	9.43	0.46	7.23e-19	Coronary artery disease;
LUSC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg25767906	chr1:53392781	SCP2	0.52	9.44	0.46	6.73e-19	Monocyte count;
LUSC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg18827107	chr12:86230957	RASSF9	-0.47	-6.99	-0.36	1.55e-11	Major depressive disorder;
LUSC	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.1	0.32	2.95e-9	Mean platelet volume;
LUSC	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21659725	chr3:3221576	CRBN	0.63	10.41	0.49	3.61e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg04121214	chr22:50244548	NA	-0.34	-5.65	-0.3	3.35e-8	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.85	0.3	1.16e-8	Menopause (age at onset);
LUSC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg14895029	chr7:2775587	GNA12	-0.41	-6.22	-0.32	1.51e-9	Height;
LUSC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	0.9	12.55	0.57	7.32e-30	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9392556	0.829	rs853416	chr6:4113047	A/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.34	-5.84	-0.3	1.22e-8	Blood metabolite levels;
LUSC	cis	rs7582720	1.000	rs1541853	chr2:203835177	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg23262073	chr20:60523788	NA	0.48	6.82	0.35	4.33e-11	Body mass index;
LUSC	cis	rs151349	0.555	rs151343	chr20:57583298	C/G	cg23907860	chr20:57583709	CTSZ	0.56	9.59	0.46	2.14e-19	Platelet distribution width;
LUSC	cis	rs72792276	1.000	rs17839658	chr5:127423013	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	7.8	0.39	8.18e-14	Red cell distribution width;
LUSC	trans	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg13565492	chr6:43139072	SRF	-0.61	-6.37	-0.33	6.1e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg09455208	chr3:40491958	NA	-0.47	-8.23	-0.41	4.23e-15	Renal cell carcinoma;
LUSC	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg01657329	chr11:68192670	LRP5	0.51	6.81	0.35	4.5e-11	Bone mineral density (spine);
LUSC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg04756594	chr16:24857601	SLC5A11	-0.35	-5.83	-0.3	1.3e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg14844989	chr11:31128820	NA	-0.37	-5.77	-0.3	1.83e-8	Red blood cell count;
LUSC	cis	rs7527798	0.592	rs960087	chr1:207826858	C/G	cg09232269	chr1:207846808	CR1L	-0.3	-6.37	-0.33	6.16e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs68170813	0.641	rs75254991	chr7:106938903	C/T	cg02696742	chr7:106810147	HBP1	-0.58	-8.87	-0.44	4.46e-17	Coronary artery disease;
LUSC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg22907277	chr7:1156413	C7orf50	0.68	7.3	0.37	2.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg25258033	chr6:167368657	RNASET2	0.39	6.37	0.33	6.22e-10	Crohn's disease;
LUSC	cis	rs7605827	0.930	rs11902128	chr2:15515269	T/G	cg19274914	chr2:15703543	NA	0.47	9.07	0.44	1.03e-17	Educational attainment (years of education);
LUSC	cis	rs4474465	0.850	rs4387376	chr11:78257662	T/C	cg27205649	chr11:78285834	NARS2	0.52	6.2	0.32	1.7e-9	Alzheimer's disease (survival time);
LUSC	cis	rs2124969	0.548	rs62175384	chr2:161011128	C/T	cg03641300	chr2:160917029	PLA2R1	-0.48	-5.77	-0.3	1.77e-8	Waist circumference adjusted for body mass index;
LUSC	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	6.37	0.33	6.14e-10	Recombination rate (females);
LUSC	cis	rs977987	0.843	rs11649638	chr16:75488285	G/A	cg03315344	chr16:75512273	CHST6	0.55	10.67	0.5	4.65e-23	Dupuytren's disease;
LUSC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg12463550	chr7:65579703	CRCP	0.45	6.73	0.35	7.31e-11	Aortic root size;
LUSC	cis	rs4343996	0.580	rs10262464	chr7:3406961	A/C	cg21248987	chr7:3385318	SDK1	0.36	6.13	0.32	2.49e-9	Motion sickness;
LUSC	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg17623882	chr6:41773611	USP49	0.65	10.65	0.5	5.18e-23	Menarche (age at onset);
LUSC	cis	rs13082711	0.911	rs17019721	chr3:27424799	A/G	cg02860705	chr3:27208620	NA	0.49	8.38	0.42	1.53e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg06484146	chr7:12443880	VWDE	-0.73	-7.29	-0.37	2.26e-12	Coronary artery disease;
LUSC	cis	rs2692947	0.655	rs2315668	chr2:96429562	T/C	cg23100626	chr2:96804247	ASTL	0.27	6.36	0.33	6.54e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg00495681	chr13:53174319	NA	-0.75	-14.47	-0.62	3.39e-37	Lewy body disease;
LUSC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.55	0.34	2.22e-10	Schizophrenia;
LUSC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg27535305	chr1:53392650	SCP2	-0.49	-9.76	-0.47	6e-20	Monocyte count;
LUSC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11645453	chr3:52864694	ITIH4	-0.34	-8.12	-0.41	8.83e-15	Bipolar disorder;
LUSC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg06145435	chr7:1022769	CYP2W1	0.3	6.19	0.32	1.77e-9	Longevity;Endometriosis;
LUSC	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.96	-0.48	1.2e-20	Coronary artery disease;
LUSC	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.08	-0.32	3.2e-9	Resting heart rate;
LUSC	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg08997352	chr12:9597637	DDX12	-0.71	-11.07	-0.52	1.83e-24	Breast size;
LUSC	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg13852791	chr20:30311386	BCL2L1	0.88	13.16	0.58	3.87e-32	Mean corpuscular hemoglobin;
LUSC	cis	rs9287719	0.745	rs4997809	chr2:10755542	G/A	cg00105475	chr2:10696890	NA	0.36	5.81	0.3	1.42e-8	Prostate cancer;
LUSC	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg03859395	chr2:55845619	SMEK2	0.88	16.64	0.67	1.09e-45	Metabolic syndrome;
LUSC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg04850211	chr1:228464232	OBSCN	-0.33	-6.14	-0.32	2.28e-9	Diastolic blood pressure;
LUSC	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-6.07	-0.31	3.56e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs853679	1.000	rs853678	chr6:28297313	T/A	cg01620082	chr3:125678407	NA	-0.57	-6.5	-0.34	2.91e-10	Depression;
LUSC	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg03676636	chr4:99064102	C4orf37	0.27	5.81	0.3	1.46e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg26162295	chr17:38119207	GSDMA	-0.28	-6.33	-0.33	8.07e-10	Myeloid white cell count;
LUSC	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.35e-17	Iron status biomarkers;
LUSC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	1.04	18.83	0.72	2.12e-54	Parkinson's disease;
LUSC	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg01448562	chr3:133502909	NA	-0.52	-7.75	-0.39	1.12e-13	Iron status biomarkers;
LUSC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg08270630	chr22:50330655	NA	-0.42	-6.29	-0.33	1e-9	Schizophrenia;
LUSC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.77	10.46	0.5	2.41e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs12542260	0.871	rs62527884	chr8:125483344	A/G	cg27038428	chr8:125485867	RNF139	0.33	6.71	0.34	8.12e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg10978503	chr1:24200527	CNR2	0.53	13.15	0.58	4.1e-32	Immature fraction of reticulocytes;
LUSC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.81	11.85	0.54	2.82e-27	Breast cancer;
LUSC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-6.11	-0.32	2.81e-9	Body mass index;
LUSC	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg09092052	chr15:45571596	NA	0.48	6.67	0.34	1.04e-10	Glomerular filtration rate;
LUSC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	0.94	18.8	0.72	2.63e-54	Cognitive function;
LUSC	trans	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg07393940	chr7:158741817	NA	-0.55	-8.33	-0.41	2.08e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10911363	0.615	rs12024309	chr1:183419981	A/G	cg09173681	chr1:183549694	NCF2	-0.63	-11.13	-0.52	1.12e-24	Systemic lupus erythematosus;
LUSC	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg24558204	chr6:135376177	HBS1L	0.59	9.12	0.45	7.4e-18	Red blood cell count;
LUSC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	11.54	0.53	3.79e-26	Menarche (age at onset);
LUSC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg07701084	chr6:150067640	NUP43	0.49	7.27	0.37	2.56e-12	Lung cancer;
LUSC	cis	rs5758659	0.679	rs134870	chr22:42652317	T/C	cg00645731	chr22:42541494	CYP2D7P1	-0.29	-6.16	-0.32	2.03e-9	Cognitive function;
LUSC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg17279839	chr7:150038598	RARRES2	0.48	7.55	0.38	4.17e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs727505	0.564	rs67745021	chr7:124868018	T/C	cg23710748	chr7:124431027	NA	-0.39	-6.71	-0.34	8.19e-11	Lewy body disease;
LUSC	cis	rs16910800	1.000	rs73479578	chr11:23197173	C/T	cg20040320	chr11:23191996	NA	-0.45	-6.59	-0.34	1.68e-10	Cancer;
LUSC	cis	rs727505	0.564	rs56068095	chr7:124831906	A/T	cg23710748	chr7:124431027	NA	-0.4	-6.85	-0.35	3.6e-11	Lewy body disease;
LUSC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-0.83	-13.78	-0.6	1.6e-34	Tonsillectomy;
LUSC	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.74	12.09	0.55	3.65e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.67	-0.43	1.97e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg00484396	chr16:3507460	NAT15	-0.91	-10.66	-0.5	4.91e-23	Tuberculosis;
LUSC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg19748678	chr4:122722346	EXOSC9	0.49	7.67	0.39	1.92e-13	Type 2 diabetes;
LUSC	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14240646	chr10:27532245	ACBD5	-0.67	-7.68	-0.39	1.74e-13	Breast cancer;
LUSC	cis	rs6901250	0.851	rs339307	chr6:117177340	A/G	cg12892004	chr6:117198278	RFX6	-0.45	-8.51	-0.42	5.97e-16	C-reactive protein levels;
LUSC	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg05707623	chr12:122985044	ZCCHC8	0.66	8.18	0.41	5.92e-15	Body mass index;
LUSC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.56	10.55	0.5	1.18e-22	Multiple system atrophy;
LUSC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg17470449	chr10:769945	NA	0.5	7.0	0.36	1.41e-11	Uric acid levels;
LUSC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg17948913	chr5:572064	NA	0.33	5.64	0.3	3.56e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	1.05	23.79	0.79	7.14e-74	Platelet distribution width;
LUSC	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	0.9	17.96	0.7	5.85e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	7.27	0.37	2.55e-12	Renal cell carcinoma;
LUSC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.68	-10.94	-0.51	5.01e-24	Cognitive function;
LUSC	trans	rs2894969	0.664	rs11252703	chr10:4795125	A/T	cg11496811	chr1:181058973	IER5	0.37	5.99	0.31	5.5e-9	Major depressive disorder;
LUSC	cis	rs2857891	0.817	rs2239732	chr11:6976689	C/G	cg14883916	chr11:6947541	ZNF215	0.46	5.91	0.31	8.31e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs2637266	0.905	rs34173296	chr10:78343389	C/T	cg18941641	chr10:78392320	NA	0.32	5.76	0.3	1.9e-8	Pulmonary function;
LUSC	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.35	-0.46	1.28e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	1.03	15.05	0.64	1.87e-39	Orofacial clefts;
LUSC	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.84	-0.35	3.74e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg11244672	chr19:19639970	YJEFN3	0.61	7.8	0.39	7.88e-14	Bipolar disorder;
LUSC	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg05855489	chr10:104503620	C10orf26	0.47	6.51	0.34	2.69e-10	Arsenic metabolism;
LUSC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	6.21	0.32	1.61e-9	Menopause (age at onset);
LUSC	trans	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.73	0.43	1.28e-16	Type 2 diabetes;
LUSC	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg10621924	chr7:39171070	POU6F2	0.44	6.4	0.33	5.35e-10	IgG glycosylation;
LUSC	cis	rs1190552	0.595	rs2403039	chr14:102820163	C/A	cg18135206	chr14:102964638	TECPR2	-0.42	-5.82	-0.3	1.35e-8	Blood protein levels;
LUSC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.73	10.59	0.5	8.79e-23	Alzheimer's disease;
LUSC	trans	rs13314892	1.000	rs9817946	chr3:69795157	A/G	cg24703757	chr4:183838736	DCTD	0.47	6.19	0.32	1.79e-9	QRS complex (12-leadsum);
LUSC	cis	rs34734847	0.787	rs658521	chr12:121162414	G/T	cg21892295	chr12:121157589	UNC119B	-0.36	-6.31	-0.33	9.08e-10	Mean corpuscular volume;
LUSC	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg26876637	chr1:152193138	HRNR	0.43	6.24	0.32	1.34e-9	Atopic dermatitis;
LUSC	cis	rs8027181	1.000	rs3850986	chr15:73091283	G/T	cg25632853	chr15:73088954	NA	0.34	6.61	0.34	1.55e-10	Triglyceride levels;
LUSC	cis	rs2074977	0.530	rs10401784	chr19:3445721	A/C	cg08380311	chr19:3435252	NFIC	0.63	10.04	0.48	6.46e-21	Height;
LUSC	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg08017756	chr2:100939284	LONRF2	-0.45	-8.56	-0.42	4.3e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.69	0.39	1.71e-13	Bipolar disorder;
LUSC	trans	rs4942242	0.663	rs9525812	chr13:44200099	T/C	cg19169023	chr15:41853346	TYRO3	-0.61	-9.17	-0.45	4.87e-18	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06544989	chr22:39130855	UNC84B	0.32	5.65	0.3	3.48e-8	Menopause (age at onset);
LUSC	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg19610905	chr11:61596333	FADS2	0.49	7.49	0.38	6.31e-13	Trans fatty acid levels;
LUSC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg07424592	chr7:64974309	NA	0.68	5.96	0.31	6.3e-9	Diabetic kidney disease;
LUSC	cis	rs4474465	0.920	rs7396701	chr11:78202699	A/C	cg27205649	chr11:78285834	NARS2	0.51	6.0	0.31	5.07e-9	Alzheimer's disease (survival time);
LUSC	trans	rs57046232	0.552	rs6038445	chr20:6329093	A/G	cg17788362	chr6:86352627	SYNCRIP	0.45	6.23	0.32	1.38e-9	Colorectal cancer;
LUSC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.44	-7.21	-0.37	3.88e-12	Monocyte percentage of white cells;
LUSC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg13390004	chr1:15929781	NA	0.4	6.6	0.34	1.6e-10	Systolic blood pressure;
LUSC	cis	rs4704187	0.687	rs4703655	chr5:74455063	A/G	cg03227963	chr5:74354835	NA	0.31	6.8	0.35	4.74e-11	Response to amphetamines;
LUSC	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg12935359	chr14:103987150	CKB	-0.56	-8.94	-0.44	2.72e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs243505	0.898	rs243529	chr7:148413801	G/A	cg09806900	chr7:148480153	CUL1	-0.47	-6.64	-0.34	1.3e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg00310523	chr12:86230176	RASSF9	0.44	8.25	0.41	3.7e-15	Major depressive disorder;
LUSC	trans	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg17712092	chr4:129076599	LARP1B	-0.73	-10.26	-0.49	1.19e-21	Breast cancer;
LUSC	cis	rs12681287	0.517	rs34367154	chr8:87508749	A/T	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	cis	rs10761482	0.906	rs2199209	chr10:62094738	A/G	cg18175470	chr10:62150864	ANK3	-0.45	-6.52	-0.34	2.65e-10	Schizophrenia;
LUSC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.25	0.45	2.7e-18	Lung cancer in ever smokers;
LUSC	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg02825527	chr7:2087843	MAD1L1	-0.5	-5.73	-0.3	2.29e-8	Bipolar disorder;
LUSC	trans	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg06521331	chr12:34319734	NA	0.4	6.32	0.33	8.45e-10	Morning vs. evening chronotype;
LUSC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.67	0.39	1.95e-13	Vitiligo;
LUSC	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07080220	chr10:102295463	HIF1AN	0.68	9.51	0.46	3.98e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06481639	chr22:41940642	POLR3H	0.51	5.8	0.3	1.51e-8	Vitiligo;
LUSC	cis	rs56283067	0.578	rs62400353	chr6:45387899	G/A	cg18551225	chr6:44695536	NA	-0.4	-5.82	-0.3	1.41e-8	Total body bone mineral density;
LUSC	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-6.26	-0.32	1.15e-9	Height;
LUSC	trans	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg25214090	chr10:38739885	LOC399744	0.41	6.28	0.32	1.05e-9	Corneal astigmatism;
LUSC	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg20744362	chr22:50050164	C22orf34	0.39	7.07	0.36	9.14e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.4	0.62	6.35e-37	Platelet count;
LUSC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg04155289	chr7:94953770	PON1	-0.34	-5.76	-0.3	1.9e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg09754948	chr16:28834200	ATXN2L	0.43	6.33	0.33	8.06e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04358685	chr3:12598421	MKRN2	0.48	7.87	0.4	5e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.58	-0.46	2.3e-19	Total cholesterol levels;
LUSC	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg19920283	chr7:105172520	RINT1	0.58	6.22	0.32	1.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1775715	0.707	rs2808087	chr10:32146444	C/G	cg18675610	chr10:32216311	ARHGAP12	0.31	6.87	0.35	3.21e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs3126085	0.935	rs11204951	chr1:152224404	A/G	cg26876637	chr1:152193138	HRNR	0.45	6.5	0.34	2.94e-10	Atopic dermatitis;
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg12432903	chr7:1882776	MAD1L1	-0.39	-6.38	-0.33	6.06e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs317689	1.000	rs317689	chr12:69727190	G/A	cg20891283	chr12:69753455	YEATS4	0.54	7.2	0.37	3.95e-12	Response to diuretic therapy;
LUSC	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg18209359	chr17:80159595	CCDC57	0.4	6.76	0.35	6.12e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6076065	0.775	rs6083114	chr20:23379528	G/T	cg11657817	chr20:23433608	CST11	0.53	11.03	0.52	2.42e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7903847	0.620	rs7923385	chr10:99117097	T/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.69	-0.39	1.72e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7809950	0.678	rs62482499	chr7:106975059	C/G	cg23024343	chr7:107201750	COG5	-0.64	-9.62	-0.47	1.75e-19	Coronary artery disease;
LUSC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg15790184	chr11:494944	RNH1	0.52	5.98	0.31	5.62e-9	Body mass index;
LUSC	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.4	-0.42	1.28e-15	Mood instability;
LUSC	trans	rs6852435	1.000	rs35920928	chr4:175315923	G/C	cg23753247	chr11:8615842	STK33	-0.53	-5.97	-0.31	5.91e-9	Response to acetaminophen (hepatotoxicity);
LUSC	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg13390004	chr1:15929781	NA	0.42	7.02	0.36	1.23e-11	Systolic blood pressure;
LUSC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg02018176	chr4:1364513	KIAA1530	0.52	8.93	0.44	2.96e-17	Obesity-related traits;
LUSC	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg05855489	chr10:104503620	C10orf26	0.64	9.26	0.45	2.55e-18	Arsenic metabolism;
LUSC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg06713675	chr4:122721982	EXOSC9	-0.66	-11.42	-0.53	1.02e-25	Type 2 diabetes;
LUSC	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08704250	chr15:31115839	NA	-0.46	-6.84	-0.35	3.88e-11	Huntington's disease progression;
LUSC	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg27266060	chr8:22091797	NA	0.41	7.57	0.38	3.69e-13	Hypertriglyceridemia;
LUSC	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg18825076	chr15:78729989	IREB2	-0.64	-10.33	-0.49	6.71e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg05623727	chr3:50126028	RBM5	0.31	5.81	0.3	1.43e-8	Body mass index;
LUSC	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg10645314	chr2:3704589	ALLC	-0.45	-5.95	-0.31	6.64e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	13.48	0.59	2.34e-33	Platelet count;
LUSC	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg25214090	chr10:38739885	LOC399744	0.54	7.81	0.39	7.48e-14	Corneal astigmatism;
LUSC	cis	rs748404	0.697	rs505249	chr15:43559960	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.41	5.82	0.3	1.35e-8	Lung cancer;
LUSC	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg00509249	chr6:109615579	CCDC162	-0.33	-5.98	-0.31	5.87e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg15691649	chr6:25882328	NA	-0.47	-6.62	-0.34	1.44e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg27170947	chr2:26402098	FAM59B	0.69	8.86	0.44	4.85e-17	Gut microbiome composition (summer);
LUSC	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg06740227	chr12:86229804	RASSF9	0.36	5.75	0.3	2.04e-8	Major depressive disorder;
LUSC	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg16339924	chr4:17578868	LAP3	0.55	8.37	0.42	1.57e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg15790184	chr11:494944	RNH1	0.42	6.4	0.33	5.37e-10	Systemic lupus erythematosus;
LUSC	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	6.38	0.33	5.85e-10	Cognitive test performance;
LUSC	cis	rs6500395	1.000	rs2354579	chr16:48601521	T/C	cg04672837	chr16:48644449	N4BP1	0.43	6.47	0.33	3.44e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-7.43	-0.38	9.29e-13	Morning vs. evening chronotype;
LUSC	cis	rs2387326	0.717	rs77277629	chr10:129944462	C/T	cg16087940	chr10:129947807	NA	-0.38	-5.78	-0.3	1.7e-8	Select biomarker traits;
LUSC	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.33	6.58	0.34	1.85e-10	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg13319975	chr6:146136371	FBXO30	0.52	7.73	0.39	1.29e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.51	-0.38	5.35e-13	Aortic root size;
LUSC	trans	rs4538187	0.951	rs17562177	chr2:64160385	A/G	cg06706163	chr13:25497100	CENPJ	0.54	6.05	0.31	3.95e-9	Systolic blood pressure;
LUSC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg19592336	chr6:28129416	ZNF389	0.48	6.27	0.32	1.11e-9	Depression;
LUSC	cis	rs9653442	0.576	rs6542921	chr2:100864498	C/A	cg22139774	chr2:100720529	AFF3	-0.38	-6.21	-0.32	1.58e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	13.38	0.59	5.72e-33	Menarche (age at onset);
LUSC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.01	0.4	1.9e-14	Parkinson's disease;
LUSC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.58	0.34	1.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg05738196	chr6:26577821	NA	-0.52	-5.76	-0.3	1.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg00152838	chr16:24741724	TNRC6A	-0.43	-5.65	-0.3	3.5e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9837602	1.000	rs1688766	chr3:99647850	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.43	0.33	4.49e-10	Breast cancer;
LUSC	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	0.91	18.15	0.7	9.95e-52	Metabolite levels;
LUSC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg06494592	chr3:125709126	NA	-0.51	-5.81	-0.3	1.47e-8	Blood pressure (smoking interaction);
LUSC	cis	rs394563	0.601	rs432582	chr6:149794143	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.39	-7.94	-0.4	3.11e-14	Dupuytren's disease;
LUSC	cis	rs11428934	1	rs11428934	chr19:49144245	T/TG	cg06530960	chr19:49140787	SEC1;DBP	0.53	7.27	0.37	2.57e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;
LUSC	cis	rs6692729	0.966	rs6426548	chr1:227013878	C/T	cg10327440	chr1:227177885	CDC42BPA	0.48	6.9	0.35	2.63e-11	Electrodermal activity;
LUSC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg13319975	chr6:146136371	FBXO30	0.49	7.47	0.38	7.15e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg10518572	chr11:65560635	OVOL1	-0.27	-6.2	-0.32	1.71e-9	Acne (severe);
LUSC	cis	rs11822910	0.654	rs2439450	chr11:57213061	C/G	cg24343310	chr11:57249947	NA	-0.42	-7.72	-0.39	1.34e-13	Platelet distribution width;
LUSC	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-8.67	-0.43	1.94e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg25482853	chr8:67687455	SGK3	1.21	19.41	0.73	1e-56	Lung disease severity in cystic fibrosis;
LUSC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg19592336	chr6:28129416	ZNF389	0.49	6.36	0.33	6.73e-10	Depression;
LUSC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.59	-11.59	-0.54	2.39e-26	Asthma (sex interaction);
LUSC	cis	rs4629180	0.727	rs10188564	chr2:102101064	C/A	cg01388757	chr2:102091195	RFX8	-0.45	-7.06	-0.36	9.48e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	5.84	0.3	1.23e-8	Educational attainment;
LUSC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.55	0.46	2.84e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10489202	0.608	rs10800334	chr1:168075613	T/C	cg24449463	chr1:168025552	DCAF6	-0.65	-9.67	-0.47	1.13e-19	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4654899	0.865	rs6685831	chr1:21507888	G/A	cg01072550	chr1:21505969	NA	-0.49	-7.34	-0.37	1.63e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.72	12.12	0.55	2.87e-28	Motion sickness;
LUSC	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg13615516	chr5:77269221	NA	0.4	6.76	0.35	6.09e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	10.09	0.48	4.47e-21	Lymphocyte counts;
LUSC	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg13647721	chr17:30228624	UTP6	0.64	6.43	0.33	4.46e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg02503808	chr4:7069936	GRPEL1	0.56	8.75	0.43	1.04e-16	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.66	-11.19	-0.52	6.69e-25	Diastolic blood pressure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23989878	chr6:42018162	TAF8	-0.4	-5.98	-0.31	5.78e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.64	-0.3	3.56e-8	Recombination rate (females);
LUSC	cis	rs9549260	0.755	rs7985364	chr13:41179580	C/G	cg21288729	chr13:41239152	FOXO1	0.59	8.8	0.43	7.54e-17	Red blood cell count;
LUSC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg27432699	chr2:27873401	GPN1	-0.57	-8.49	-0.42	6.77e-16	Total body bone mineral density;
LUSC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg17971929	chr21:40555470	PSMG1	-0.63	-10.25	-0.49	1.31e-21	Cognitive function;
LUSC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	trans	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg07211511	chr3:129823064	LOC729375	-0.5	-5.97	-0.31	5.9e-9	Blood pressure (smoking interaction);
LUSC	cis	rs1950626	0.577	rs61991118	chr14:101441974	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.4	7.47	0.38	6.94e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg09904177	chr6:26538194	HMGN4	0.66	11.81	0.54	3.86e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg03878208	chr11:72483293	STARD10	0.37	5.86	0.31	1.11e-8	Body mass index;
LUSC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg22166914	chr1:53195759	ZYG11B	0.67	11.31	0.53	2.54e-25	Monocyte count;
LUSC	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg20701182	chr2:24300061	SF3B14	0.72	7.07	0.36	8.9e-12	Lymphocyte counts;
LUSC	cis	rs17092148	0.895	rs4417778	chr20:33350987	T/C	cg16810054	chr20:33298113	TP53INP2	-0.43	-6.81	-0.35	4.68e-11	Neuroticism;
LUSC	cis	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.19	-0.32	1.76e-9	Ulcerative colitis;
LUSC	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.67	-0.39	1.9e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.52	-10.55	-0.5	1.24e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07923666	chr12:49932857	KCNH3	-0.54	-6.63	-0.34	1.38e-10	Resting heart rate;
LUSC	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-1.13	-17.99	-0.7	4.71e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.68	-11.29	-0.53	2.85e-25	Systemic lupus erythematosus;
LUSC	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	7.23	0.37	3.4e-12	Iron status biomarkers;
LUSC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.88	0.48	2.35e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg17469321	chr7:55412551	NA	0.66	10.63	0.5	6.09e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg25208724	chr1:156163844	SLC25A44	0.78	6.37	0.33	6.32e-10	Paclitaxel disposition in epithelial ovarian cancer;
LUSC	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.81	-0.39	7.32e-14	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs17278117	0.614	rs73010754	chr4:182595778	G/A	cg11957848	chr6:169575326	NA	0.64	6.08	0.32	3.31e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs400736	0.930	rs225100	chr1:8066914	C/T	cg25007680	chr1:8021821	PARK7	-0.58	-9.09	-0.45	9.16e-18	Response to antidepressants and depression;
LUSC	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-5.99	-0.31	5.34e-9	Retinal vascular caliber;
LUSC	trans	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg26043149	chr18:55253948	FECH	-0.45	-6.93	-0.35	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6489882	0.836	rs10774676	chr12:113362407	C/T	cg20102336	chr12:113376681	OAS3	0.43	6.13	0.32	2.43e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg25019033	chr10:957182	NA	-0.52	-6.57	-0.34	1.95e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg16031515	chr1:205743344	RAB7L1	-0.28	-6.12	-0.32	2.63e-9	Menarche (age at onset);
LUSC	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg14664628	chr15:75095509	CSK	-0.9	-14.12	-0.61	7.87e-36	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.14	-0.32	2.37e-9	Life satisfaction;
LUSC	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg20019720	chr6:154832845	CNKSR3	0.63	8.74	0.43	1.17e-16	Lipoprotein (a) levels;
LUSC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	0.65	13.92	0.61	4.91e-35	Prudent dietary pattern;
LUSC	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg08000102	chr2:233561755	GIGYF2	-0.7	-11.58	-0.54	2.72e-26	Coronary artery disease;
LUSC	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.85	-13.86	-0.6	7.84e-35	Coronary artery disease;
LUSC	trans	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-6.81	-0.35	4.59e-11	Systolic blood pressure;
LUSC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg12639453	chr1:2035780	PRKCZ	-0.3	-6.36	-0.33	6.48e-10	Height;
LUSC	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg12935359	chr14:103987150	CKB	-0.51	-7.87	-0.4	4.9e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs11158026	0.757	rs2183085	chr14:55472391	A/C	cg04306507	chr14:55594613	LGALS3	0.36	7.15	0.36	5.6e-12	Parkinson's disease;
LUSC	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg00484396	chr16:3507460	NAT15	-0.42	-6.75	-0.35	6.69e-11	Body mass index (adult);
LUSC	cis	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg02972257	chr16:68554789	NA	0.42	5.89	0.31	9.48e-9	Colorectal cancer;
LUSC	cis	rs1941023	0.606	rs7926219	chr11:60180335	C/T	cg08716584	chr11:60157161	MS4A7	-0.56	-10.26	-0.49	1.16e-21	Congenital heart disease (maternal effect);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg19777998	chr3:11762192	VGLL4	0.42	6.58	0.34	1.86e-10	Schizophrenia;
LUSC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-0.68	-10.94	-0.51	5.14e-24	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.47	5.88	0.31	9.99e-9	Renal function-related traits (BUN);
LUSC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.66	-0.39	2.07e-13	Bipolar disorder;
LUSC	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg04586622	chr2:25135609	ADCY3	0.43	9.16	0.45	5.26e-18	Body mass index;
LUSC	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.71	-12.56	-0.57	7e-30	White blood cell count (basophil);
LUSC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg05623727	chr3:50126028	RBM5	0.34	6.39	0.33	5.71e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.55	-0.46	2.91e-19	Extrinsic epigenetic age acceleration;
LUSC	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.78	0.68	2.97e-46	Exhaled nitric oxide output;
LUSC	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg01528321	chr10:82214614	TSPAN14	1.15	18.48	0.71	5.09e-53	Post bronchodilator FEV1;
LUSC	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg17691542	chr6:26056736	HIST1H1C	0.47	7.03	0.36	1.17e-11	Height;
LUSC	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg11789530	chr4:8429930	ACOX3	-0.44	-6.52	-0.34	2.56e-10	Response to antineoplastic agents;
LUSC	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.23	0.52	4.92e-25	Coffee consumption (cups per day);
LUSC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06634786	chr22:41940651	POLR3H	0.51	6.11	0.32	2.72e-9	Vitiligo;
LUSC	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg00277334	chr10:82204260	NA	-0.51	-7.41	-0.38	1.05e-12	Post bronchodilator FEV1;
LUSC	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg02023728	chr11:77925099	USP35	0.5	7.24	0.37	3.13e-12	Testicular germ cell tumor;
LUSC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-10.28	-0.49	9.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6480314	0.542	rs17231644	chr10:70030058	C/T	cg04882175	chr6:131122610	NA	0.53	6.03	0.31	4.46e-9	Optic nerve measurement (disc area);
LUSC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	8.78	0.43	8.68e-17	Colorectal cancer;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.54	-9.72	-0.47	8.16e-20	Longevity;Endometriosis;
LUSC	cis	rs3772130	1.000	rs56314138	chr3:121356656	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.67	9.62	0.47	1.71e-19	Cognitive performance;
LUSC	trans	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg05926928	chr17:57297772	GDPD1	0.51	7.33	0.37	1.8e-12	Schizophrenia;
LUSC	cis	rs977987	0.843	rs12927562	chr16:75482860	G/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.04	-0.36	1.07e-11	Dupuytren's disease;
LUSC	cis	rs7527798	0.592	rs10746386	chr1:207855095	C/T	cg09232269	chr1:207846808	CR1L	-0.31	-6.71	-0.34	8.55e-11	Erythrocyte sedimentation rate;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05571413	chr17:47841772	FAM117A	-0.4	-5.95	-0.31	6.83e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg23791538	chr6:167370224	RNASET2	0.41	5.82	0.3	1.4e-8	Graves' disease;
LUSC	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.06	-0.36	9.65e-12	Alzheimer's disease (late onset);
LUSC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg13334819	chr7:99746414	C7orf59	-0.44	-5.8	-0.3	1.51e-8	Coronary artery disease;
LUSC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg00484396	chr16:3507460	NAT15	0.71	12.42	0.56	2.24e-29	Tuberculosis;
LUSC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg04414720	chr1:150670196	GOLPH3L	0.56	8.68	0.43	1.78e-16	Melanoma;
LUSC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg02038168	chr22:39784481	NA	-0.49	-8.22	-0.41	4.44e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-11.45	-0.53	7.86e-26	Bipolar disorder and schizophrenia;
LUSC	trans	rs7980799	0.649	rs12819439	chr12:33684509	A/C	cg26384229	chr12:38710491	ALG10B	0.57	8.16	0.41	6.8e-15	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Smoking initiation;
LUSC	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.74	-14.43	-0.62	5.11e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg09904177	chr6:26538194	HMGN4	-0.47	-6.89	-0.35	2.83e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg15147215	chr3:52552868	STAB1	-0.3	-5.96	-0.31	6.55e-9	Bipolar disorder;
LUSC	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg07930552	chr6:133119739	C6orf192	0.94	8.39	0.42	1.41e-15	Type 2 diabetes nephropathy;
LUSC	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg24449463	chr1:168025552	DCAF6	-0.64	-9.52	-0.46	3.62e-19	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg04450456	chr4:17643702	FAM184B	0.4	6.74	0.35	6.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg06636001	chr8:8085503	FLJ10661	0.54	7.99	0.4	2.18e-14	Retinal vascular caliber;
LUSC	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg03676636	chr4:99064102	C4orf37	0.31	6.13	0.32	2.47e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.43	-7.6	-0.38	2.99e-13	Breast cancer;
LUSC	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg14530993	chr4:882597	GAK	0.63	6.66	0.34	1.15e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26314531	chr2:26401878	FAM59B	0.73	10.21	0.49	1.79e-21	Gut microbiome composition (summer);
LUSC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-6.35	-0.33	7.24e-10	Vitiligo;
LUSC	cis	rs1419980	0.730	rs12321773	chr12:7797967	G/A	cg10578777	chr12:7781093	NA	0.6	5.65	0.3	3.42e-8	HDL cholesterol levels;
LUSC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.51	-0.73	4.02e-57	Height;
LUSC	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg23460707	chr10:133558971	NA	0.33	5.81	0.3	1.48e-8	Survival in rectal cancer;
LUSC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs73195822	0.773	rs10849903	chr12:111112319	T/C	cg12870014	chr12:110450643	ANKRD13A	0.75	9.66	0.47	1.3e-19	Itch intensity from mosquito bite;
LUSC	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.58	-11.35	-0.53	1.78e-25	Educational attainment;
LUSC	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg27446573	chr6:127587934	RNF146	0.64	10.35	0.49	6.01e-22	Breast cancer;
LUSC	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.84	13.8	0.6	1.32e-34	Bladder cancer;
LUSC	cis	rs9462027	0.583	rs2744974	chr6:34579431	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.97	-0.31	5.9e-9	Systemic lupus erythematosus;
LUSC	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg25457927	chr22:38595422	NA	0.44	9.26	0.45	2.64e-18	Cutaneous nevi;
LUSC	cis	rs17092148	1.000	rs1884431	chr20:33338585	G/A	cg16810054	chr20:33298113	TP53INP2	-0.39	-6.26	-0.32	1.18e-9	Neuroticism;
LUSC	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg05855489	chr10:104503620	C10orf26	0.6	9.44	0.46	6.77e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4919087	1.000	rs4919089	chr10:99087905	G/A	cg25902810	chr10:99078978	FRAT1	-0.46	-6.7	-0.34	8.72e-11	Monocyte count;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22728323	chr8:37887713	EIF4EBP1	-0.4	-6.02	-0.31	4.55e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg06238570	chr21:40685208	BRWD1	0.46	7.08	0.36	8.59e-12	Cognitive function;
LUSC	trans	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg10297561	chr8:49231655	NA	0.36	5.97	0.31	5.99e-9	Educational attainment;
LUSC	cis	rs926392	0.896	rs742276	chr20:37679849	C/T	cg27552599	chr20:37590471	DHX35	0.34	5.99	0.31	5.35e-9	Dialysis-related mortality;
LUSC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.49	-5.84	-0.3	1.26e-8	Menarche (age at onset);
LUSC	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg23601095	chr6:26197514	HIST1H3D	0.73	7.46	0.38	7.42e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg20203395	chr5:56204925	C5orf35	-0.56	-7.95	-0.4	2.99e-14	Coronary artery disease;
LUSC	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.79	12.94	0.58	2.49e-31	Bladder cancer;
LUSC	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg08601574	chr20:25228251	PYGB	-0.45	-6.91	-0.35	2.43e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11756438	0.572	rs1844964	chr6:119002528	C/T	cg21191810	chr6:118973309	C6orf204	0.34	5.88	0.31	9.9e-9	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg00310523	chr12:86230176	RASSF9	0.38	6.82	0.35	4.32e-11	Major depressive disorder;
LUSC	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg03732007	chr1:2071316	PRKCZ	-0.5	-8.73	-0.43	1.23e-16	Height;
LUSC	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.75	9.99	0.48	1.02e-20	Gastritis;
LUSC	cis	rs789859	0.965	rs812583	chr3:194406505	C/G	cg02072170	chr3:194406190	FAM43A	0.36	7.65	0.39	2.21e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	0.86	11.69	0.54	1.07e-26	Eosinophil percentage of granulocytes;
LUSC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg17515076	chr17:73810948	UNK	-0.39	-6.64	-0.34	1.27e-10	White matter hyperintensity burden;
LUSC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg09044154	chr16:88155775	NA	-0.55	-7.35	-0.37	1.55e-12	Menopause (age at onset);
LUSC	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg21918786	chr6:109611834	NA	-0.4	-6.9	-0.35	2.59e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs12681287	0.640	rs7017706	chr8:87480890	C/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.36	6.24e-12	Caudate activity during reward;
LUSC	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg05283184	chr6:79620031	NA	0.52	10.52	0.5	1.49e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg14458575	chr2:238380390	NA	0.62	7.16	0.36	5.25e-12	Prostate cancer;
LUSC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg20203395	chr5:56204925	C5orf35	0.68	9.3	0.45	1.89e-18	Initial pursuit acceleration;
LUSC	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg11693508	chr17:37793320	STARD3	0.6	7.16	0.36	5.12e-12	Bipolar disorder;
LUSC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg15534755	chr11:117069859	TAGLN	-0.35	-6.08	-0.32	3.35e-9	Blood protein levels;
LUSC	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg26816564	chr1:7831052	VAMP3	0.98	13.48	0.59	2.29e-33	Inflammatory bowel disease;
LUSC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06873352	chr17:61820015	STRADA	0.56	8.68	0.43	1.83e-16	Height;
LUSC	cis	rs68170813	0.559	rs12538769	chr7:106984288	C/T	cg02696742	chr7:106810147	HBP1	-0.62	-9.31	-0.45	1.75e-18	Coronary artery disease;
LUSC	trans	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.29	0.41	2.71e-15	Ulcerative colitis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18815779	chr20:9819789	PAK7	-0.47	-6.5	-0.34	2.95e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7577851	0.715	rs7602427	chr2:69640145	G/A	cg10773587	chr2:69614142	GFPT1	0.57	7.11	0.36	7.1e-12	Parkinson's disease (age of onset);
LUSC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.46e-35	Breast cancer;
LUSC	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg06026331	chr20:60912101	LAMA5	0.55	6.65	0.34	1.21e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg23950597	chr19:37808831	NA	-0.65	-7.74	-0.39	1.17e-13	Coronary artery calcification;
LUSC	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.73	11.79	0.54	4.55e-27	Inhibitory control;
LUSC	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-7.34	-0.37	1.69e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.44	0.53	8.42e-26	Menopause (age at onset);
LUSC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg23172400	chr8:95962367	TP53INP1	-0.4	-7.92	-0.4	3.54e-14	Type 2 diabetes;
LUSC	cis	rs983392	0.719	rs610932	chr11:59939307	T/G	cg20284999	chr11:59952153	MS4A6A	0.35	6.11	0.32	2.85e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9472414	0.510	rs227857	chr6:44704392	A/T	cg20913747	chr6:44695427	NA	0.39	5.85	0.3	1.18e-8	Height;
LUSC	cis	rs17095355	1.000	rs7921609	chr10:111691599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.3	-0.37	2.16e-12	Biliary atresia;
LUSC	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg08392591	chr16:89556376	ANKRD11	0.39	5.82	0.3	1.38e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs983392	0.679	rs672399	chr11:60020112	T/G	cg24026212	chr11:59952134	MS4A6A	0.37	6.36	0.33	6.64e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg23711669	chr6:146136114	FBXO30	0.87	15.63	0.65	1.03e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg15448220	chr1:150897856	SETDB1	0.44	6.43	0.33	4.41e-10	Melanoma;
LUSC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.54	10.09	0.48	4.63e-21	Asthma (sex interaction);
LUSC	cis	rs9392556	0.829	rs7166	chr6:4116262	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.36	-6.3	-0.33	9.22e-10	Blood metabolite levels;
LUSC	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.19	0.59	2.99e-32	Total body bone mineral density;
LUSC	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-6.5	-0.34	2.95e-10	Fear of minor pain;
LUSC	cis	rs2274273	0.662	rs67092614	chr14:55672055	G/A	cg04306507	chr14:55594613	LGALS3	0.47	9.24	0.45	3.04e-18	Protein biomarker;
LUSC	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg15704280	chr7:45808275	SEPT13	0.54	6.21	0.32	1.6e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7180079	1.000	rs8034610	chr15:64628917	G/A	cg08069370	chr15:64387884	SNX1	0.57	6.28	0.32	1.05e-9	Monocyte count;
LUSC	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.79	11.8	0.54	4.37e-27	Corneal astigmatism;
LUSC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10802521	chr3:52805072	NEK4	-0.57	-8.97	-0.44	2.22e-17	Bipolar disorder;
LUSC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	12.66	0.57	2.81e-30	Cognitive test performance;
LUSC	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg22823121	chr1:150693482	HORMAD1	0.46	6.6	0.34	1.64e-10	Melanoma;
LUSC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.02	0.48	7.73e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9400467	0.528	rs12190634	chr6:111725160	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.98	-0.36	1.56e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg14438399	chr17:27053147	TLCD1	0.53	5.84	0.3	1.22e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.62	-8.87	-0.44	4.52e-17	Inhibitory control;
LUSC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.7	10.66	0.5	5e-23	Aortic root size;
LUSC	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg08079166	chr15:68083412	MAP2K5	0.36	6.22	0.32	1.51e-9	Obesity;
LUSC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg12310025	chr6:25882481	NA	0.61	10.17	0.49	2.33e-21	Blood metabolite levels;
LUSC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg23711669	chr6:146136114	FBXO30	0.82	14.36	0.62	9.24e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.62	10.99	0.52	3.43e-24	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	0.6	9.45	0.46	6.13e-19	Breast cancer;
LUSC	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg27631724	chr1:11040367	C1orf127	0.54	9.4	0.46	8.69e-19	Ewing sarcoma;
LUSC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg13560548	chr3:10150139	C3orf24	0.49	6.8	0.35	4.69e-11	Alzheimer's disease;
LUSC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11645453	chr3:52864694	ITIH4	-0.37	-7.78	-0.39	9.24e-14	Bipolar disorder;
LUSC	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg08601574	chr20:25228251	PYGB	-0.41	-6.3	-0.33	9.64e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg01884057	chr2:25150051	NA	0.43	9.37	0.46	1.1e-18	Body mass index;
LUSC	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg07234876	chr8:600039	NA	-0.68	-5.94	-0.31	7.15e-9	IgG glycosylation;
LUSC	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.56	0.46	2.6e-19	Lung cancer in ever smokers;
LUSC	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg24675056	chr1:15929824	NA	-0.47	-8.14	-0.41	8.1e-15	Systolic blood pressure;
LUSC	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.7	-9.93	-0.48	1.56e-20	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9513627	0.834	rs73556197	chr13:100128479	A/G	cg25919922	chr13:100150906	NA	-0.75	-6.44	-0.33	4.11e-10	Obesity-related traits;
LUSC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg25214090	chr10:38739885	LOC399744	0.57	8.42	0.42	1.14e-15	Corneal astigmatism;
LUSC	cis	rs909341	0.859	rs2258056	chr20:62328453	T/C	cg09650180	chr20:62225654	GMEB2	-0.45	-5.94	-0.31	7.04e-9	Atopic dermatitis;
LUSC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00149659	chr3:10157352	C3orf10	0.94	12.49	0.56	1.18e-29	Alzheimer's disease;
LUSC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.81	-0.35	4.42e-11	Menopause (age at onset);
LUSC	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg05343316	chr1:45956843	TESK2	0.61	8.59	0.43	3.38e-16	Platelet count;
LUSC	cis	rs4629180	0.675	rs4851459	chr2:102109006	T/A	cg01388757	chr2:102091195	RFX8	-0.37	-6.37	-0.33	6.14e-10	Chronic rhinosinusitis with nasal polyps;
LUSC	trans	rs2587949	0.593	rs1843303	chr3:4185124	T/C	cg15139668	chr4:4577005	NA	-0.42	-6.02	-0.31	4.64e-9	Periodontitis (DPAL);
LUSC	cis	rs17095355	0.818	rs56367935	chr10:111783266	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.58	-6.72	-0.34	8.01e-11	Biliary atresia;
LUSC	cis	rs7809950	1.000	rs2520277	chr7:107130234	C/T	cg23024343	chr7:107201750	COG5	-0.55	-8.81	-0.43	7.13e-17	Coronary artery disease;
LUSC	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg09904177	chr6:26538194	HMGN4	0.74	13.91	0.61	5.2e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg24375607	chr4:120327624	NA	0.74	10.89	0.51	7.53e-24	Corneal astigmatism;
LUSC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg19622623	chr12:86230825	RASSF9	-0.45	-6.22	-0.32	1.53e-9	Major depressive disorder;
LUSC	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.93	-17.6	-0.69	1.54e-49	Headache;
LUSC	cis	rs7580658	0.750	rs6731176	chr2:128071003	C/T	cg09760422	chr2:128146352	NA	-0.29	-6.73	-0.35	7.45e-11	Protein C levels;
LUSC	cis	rs11608355	0.597	rs7300290	chr12:109832545	T/G	cg19025524	chr12:109796872	NA	-0.46	-8.8	-0.43	7.27e-17	Neuroticism;
LUSC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg14552801	chr7:65878734	NA	-0.44	-6.38	-0.33	5.99e-10	Aortic root size;
LUSC	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.31	-0.37	2.01e-12	Bipolar disorder;
LUSC	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.75e-14	Melanoma;
LUSC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg14664628	chr15:75095509	CSK	-0.57	-8.47	-0.42	8.13e-16	Breast cancer;
LUSC	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg03733263	chr8:22462867	KIAA1967	0.77	12.42	0.56	2.29e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg21573476	chr21:45109991	RRP1B	-0.38	-6.09	-0.32	3.17e-9	Mean corpuscular volume;
LUSC	cis	rs56283067	0.578	rs62400353	chr6:45387899	G/A	cg20913747	chr6:44695427	NA	-0.42	-6.07	-0.32	3.56e-9	Total body bone mineral density;
LUSC	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg23625390	chr15:77176239	SCAPER	-0.65	-9.98	-0.48	1.09e-20	Blood metabolite levels;
LUSC	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	8.09	0.4	1.1e-14	Response to antipsychotic treatment;
LUSC	cis	rs9513112	0.754	rs9513113	chr13:29007143	A/G	cg22753668	chr13:29013387	FLT1	0.34	6.12	0.32	2.56e-9	Coronary artery disease;
LUSC	cis	rs9951602	0.651	rs2959408	chr18:76681702	T/C	cg00806245	chr18:76673096	NA	0.44	6.22	0.32	1.48e-9	Obesity-related traits;
LUSC	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.85	14.78	0.63	2.22e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs4851254	0.584	rs56935201	chr2:100637788	G/A	cg07810366	chr2:100720526	AFF3	-0.47	-5.98	-0.31	5.65e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	6.88	0.35	2.88e-11	Neuroticism;
LUSC	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-9.57	-0.46	2.46e-19	Platelet distribution width;
LUSC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg03605463	chr16:89740564	NA	-0.38	-5.81	-0.3	1.47e-8	Vitiligo;
LUSC	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg04989706	chr14:50066350	PPIL5	0.44	5.75	0.3	2.04e-8	Carotid intima media thickness;
LUSC	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg23840854	chr1:161414152	NA	-0.92	-11.15	-0.52	9.48e-25	Rheumatoid arthritis;
LUSC	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.52	-6.09	-0.32	3.13e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.36	-5.82	-0.3	1.37e-8	Height;
LUSC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.07	-0.4	1.25e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg07701084	chr6:150067640	NUP43	0.58	8.92	0.44	3.05e-17	Lung cancer;
LUSC	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg24296786	chr1:45957014	TESK2	-0.41	-5.7	-0.3	2.7e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg05340658	chr4:99064831	C4orf37	0.43	6.87	0.35	3.2e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs754466	0.914	rs12218917	chr10:79701479	C/T	cg17075019	chr10:79541650	NA	-0.61	-7.96	-0.4	2.75e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.64	10.05	0.48	5.93e-21	Morning vs. evening chronotype;
LUSC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-0.97	-13.38	-0.59	5.45e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs4478858	0.735	rs6425736	chr1:31784376	T/A	cg00250761	chr1:31883323	NA	-0.34	-8.46	-0.42	8.22e-16	Alcohol dependence;
LUSC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.71	-13.32	-0.59	9.28e-33	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2580764	0.516	rs2860453	chr2:55270485	T/G	cg20993754	chr2:55226987	RTN4	-0.36	-5.97	-0.31	5.96e-9	Mean platelet volume;
LUSC	cis	rs9534288	0.956	rs962694	chr13:46619026	T/C	cg15192986	chr13:46630673	CPB2	-0.74	-11.41	-0.53	1.1e-25	Blood protein levels;
LUSC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg21782813	chr7:2030301	MAD1L1	0.57	10.27	0.49	1.06e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg09754948	chr16:28834200	ATXN2L	0.43	6.3	0.33	9.33e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg05738196	chr6:26577821	NA	-0.6	-7.21	-0.37	3.78e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.510	rs56241316	chr1:152901748	A/G	cg00922841	chr1:152955080	SPRR1A	-0.37	-6.01	-0.31	4.92e-9	Inflammatory skin disease;
LUSC	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg05373962	chr22:49881684	NA	-0.4	-8.73	-0.43	1.24e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs597583	0.951	rs579239	chr11:117425009	T/C	cg27161313	chr11:117392002	DSCAML1	-0.4	-7.05	-0.36	1.02e-11	Putamen volume;
LUSC	cis	rs62400317	0.859	rs11964690	chr6:45258068	A/G	cg18551225	chr6:44695536	NA	-0.39	-6.48	-0.33	3.39e-10	Total body bone mineral density;
LUSC	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03517284	chr6:25882590	NA	0.44	7.78	0.39	9.2e-14	Blood metabolite levels;
LUSC	cis	rs4660306	0.672	rs532639	chr1:46024481	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.03	-0.31	4.3e-9	Homocysteine levels;
LUSC	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg22529645	chr1:3704559	LRRC47	0.34	6.03	0.31	4.27e-9	Red cell distribution width;
LUSC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	0.8	13.95	0.61	3.66e-35	Cognitive function;
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12516959	chr21:47718080	NA	0.36	5.99	0.31	5.43e-9	Testicular germ cell tumor;
LUSC	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-12.08	-0.55	4.14e-28	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs9650315	0.866	rs13260033	chr8:57194966	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	6.62	0.34	1.39e-10	Height;
LUSC	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg12552261	chr5:112820674	MCC	-0.44	-7.02	-0.36	1.25e-11	Type 2 diabetes;
LUSC	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg17385448	chr1:15911702	AGMAT	0.34	5.88	0.31	9.88e-9	Systolic blood pressure;
LUSC	trans	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.45	6.0	0.31	5.14e-9	Renal function-related traits (BUN);
LUSC	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg18827107	chr12:86230957	RASSF9	-0.39	-5.68	-0.3	2.9e-8	Major depressive disorder;
LUSC	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg23241863	chr10:102295624	HIF1AN	0.49	5.94	0.31	7.05e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	11.6	0.54	2.36e-26	Hip circumference adjusted for BMI;
LUSC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00166722	chr3:10149974	C3orf24	0.61	8.66	0.43	2.1e-16	Alzheimer's disease;
LUSC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-8.44	-0.42	9.6e-16	Monocyte count;
LUSC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg11645453	chr3:52864694	ITIH4	0.35	8.15	0.41	7.34e-15	Bipolar disorder;
LUSC	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.22	0.56	1.26e-28	Ileal carcinoids;
LUSC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg25456477	chr12:86230367	RASSF9	-0.42	-7.57	-0.38	3.72e-13	Major depressive disorder;
LUSC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06505273	chr16:24850292	NA	-0.4	-5.76	-0.3	1.91e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.07	0.32	3.44e-9	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg26338869	chr17:61819248	STRADA	-0.43	-6.18	-0.32	1.83e-9	Prudent dietary pattern;
LUSC	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg13010199	chr12:38710504	ALG10B	0.63	9.74	0.47	6.66e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3764021	0.870	rs7970116	chr12:9880114	C/T	cg20894963	chr12:9885564	CLECL1	-0.33	-6.68	-0.34	9.76e-11	Type 1 diabetes;
LUSC	cis	rs4363385	0.693	rs6656812	chr1:152930254	C/T	cg00922841	chr1:152955080	SPRR1A	0.41	6.93	0.35	2.16e-11	Inflammatory skin disease;
LUSC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg24399712	chr22:39784796	NA	-0.61	-10.22	-0.49	1.6e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg04851639	chr8:1020857	NA	-0.37	-7.44	-0.38	8.56e-13	Schizophrenia;
LUSC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-0.93	-17.81	-0.7	2.46e-50	Heart rate;
LUSC	cis	rs12928939	0.911	rs8051878	chr16:71818431	C/G	cg03805757	chr16:71968109	PKD1L3	-0.46	-6.65	-0.34	1.23e-10	Post bronchodilator FEV1;
LUSC	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.95	0.36	1.96e-11	Height;
LUSC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg15110403	chr19:17392923	ANKLE1	-0.59	-8.02	-0.4	1.85e-14	Systemic lupus erythematosus;
LUSC	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.25	0.56	9.52e-29	Height;
LUSC	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21659725	chr3:3221576	CRBN	0.64	9.39	0.46	9.3e-19	Resting heart rate;
LUSC	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg14227996	chr4:17616232	MED28	0.82	7.87	0.4	4.98e-14	Opioid sensitivity;
LUSC	cis	rs7712401	0.755	rs10071705	chr5:122132725	T/C	cg19077854	chr5:122220652	SNX24	0.34	7.71	0.39	1.49e-13	Mean platelet volume;
LUSC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07677032	chr17:61819896	STRADA	0.52	8.79	0.43	7.84e-17	Prudent dietary pattern;
LUSC	cis	rs9303280	0.617	rs6503525	chr17:38095174	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.36	6.05	0.31	3.95e-9	Self-reported allergy;
LUSC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg27535305	chr1:53392650	SCP2	-0.39	-7.48	-0.38	6.64e-13	Monocyte count;
LUSC	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg24006582	chr15:45444508	DUOX1	0.66	9.6	0.47	1.92e-19	Uric acid levels;
LUSC	cis	rs55665837	1.000	rs10832268	chr11:14465068	C/A	cg19336497	chr11:14380999	RRAS2	-0.37	-7.54	-0.38	4.47e-13	Vitamin D levels;
LUSC	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg06781209	chr11:61594997	FADS2	-0.42	-6.95	-0.36	1.88e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-7.84	-0.39	6.21e-14	Personality dimensions;
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg10802521	chr3:52805072	NEK4	-0.41	-6.47	-0.33	3.48e-10	Electroencephalogram traits;
LUSC	cis	rs1030877	0.515	rs2576736	chr2:105890971	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.65	8.65	0.43	2.25e-16	Obesity-related traits;
LUSC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-6.19	-0.32	1.78e-9	Height;
LUSC	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg17252645	chr8:143867129	LY6D	0.38	6.65	0.34	1.21e-10	Urinary tract infection frequency;
LUSC	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg05347473	chr6:146136440	FBXO30	-0.48	-7.98	-0.4	2.41e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-0.89	-9.91	-0.48	1.85e-20	Diabetic kidney disease;
LUSC	cis	rs7177699	0.550	rs7182103	chr15:79123946	G/T	cg15571903	chr15:79123663	NA	0.34	6.32	0.33	8.21e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs10193935	0.901	rs12622153	chr2:42598386	C/A	cg27598129	chr2:42591480	NA	-0.65	-8.73	-0.43	1.21e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg09537434	chr19:41945824	ATP5SL	0.93	15.95	0.66	5.75e-43	Height;
LUSC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg13918804	chr1:2043761	PRKCZ	0.27	5.78	0.3	1.75e-8	Height;
LUSC	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg15557168	chr22:42548783	NA	-0.41	-7.16	-0.36	5.21e-12	Cognitive function;
LUSC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg14440974	chr22:39074834	NA	-0.38	-6.32	-0.33	8.52e-10	Menopause (age at onset);
LUSC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg07507251	chr3:52567010	NT5DC2	0.32	5.91	0.31	8.59e-9	Bipolar disorder;
LUSC	cis	rs3931020	0.657	rs7522428	chr1:75178360	C/T	cg21906852	chr1:75198582	TYW3;CRYZ	0.45	5.87	0.31	1.07e-8	Resistin levels;
LUSC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg22166914	chr1:53195759	ZYG11B	0.61	10.29	0.49	9.15e-22	Monocyte count;
LUSC	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-15.87	-0.66	1.12e-42	Height;
LUSC	cis	rs7267979	0.844	rs6076343	chr20:25376663	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.79	-16.62	-0.67	1.28e-45	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9341808	0.667	rs2490239	chr6:80826289	G/A	cg08355045	chr6:80787529	NA	0.49	8.44	0.42	9.45e-16	Sitting height ratio;
LUSC	cis	rs2580764	0.598	rs7340476	chr2:55227346	G/C	cg20993754	chr2:55226987	RTN4	0.34	5.69	0.3	2.82e-8	Mean platelet volume;
LUSC	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.86	0.4	5.28e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05901451	chr6:126070800	HEY2	-0.59	-8.96	-0.44	2.28e-17	Endometrial cancer;
LUSC	trans	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg10388307	chr1:82828058	NA	0.39	6.13	0.32	2.44e-9	Testicular germ cell tumor;
LUSC	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg09835421	chr16:68378352	PRMT7	-0.54	-5.92	-0.31	7.97e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg19694781	chr19:47549865	TMEM160	-0.38	-6.17	-0.32	1.95e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-7.52	-0.38	4.96e-13	Aortic root size;
LUSC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg16240275	chr20:61666158	NCRNA00029	-0.42	-8.97	-0.44	2.09e-17	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs72772090	0.710	rs17400685	chr5:96066366	A/C	cg17330273	chr5:96107758	CAST;ERAP1	0.59	6.65	0.34	1.2e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	11.15	0.52	9.59e-25	Mean corpuscular hemoglobin;
LUSC	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg18196295	chr10:418757	DIP2C	0.41	6.69	0.34	9.62e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.86	0.63	1.06e-38	Platelet count;
LUSC	trans	rs3942852	1.000	rs3942852	chr11:48115089	C/T	cg15704280	chr7:45808275	SEPT13	-0.54	-6.24	-0.32	1.3e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg03733263	chr8:22462867	KIAA1967	0.77	12.42	0.56	2.29e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg24733560	chr20:60626293	TAF4	0.35	6.04	0.31	4.22e-9	Body mass index;
LUSC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg06951627	chr6:26196580	NA	0.55	5.94	0.31	7.14e-9	Gout;Renal underexcretion gout;
LUSC	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg27411982	chr8:10470053	RP1L1	-0.5	-7.82	-0.39	6.76e-14	Neuroticism;
LUSC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg09165964	chr15:75287851	SCAMP5	-1.01	-15.29	-0.64	2.16e-40	Blood trace element (Zn levels);
LUSC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.88	0.4	4.65e-14	Bipolar disorder;
LUSC	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-6.74	-0.35	6.89e-11	Blood metabolite levels;
LUSC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg02569458	chr12:86230093	RASSF9	0.51	8.53	0.42	5.01e-16	Major depressive disorder;
LUSC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14893161	chr1:205819251	PM20D1	-0.78	-15.71	-0.65	4.85e-42	Monocyte percentage of white cells;
LUSC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg00033643	chr7:134001901	SLC35B4	0.46	7.24	0.37	3.13e-12	Mean platelet volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08548086	chr5:73980929	HEXB	0.45	6.16	0.32	2.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg21665744	chr7:39171113	POU6F2	0.48	7.86	0.4	5.38e-14	IgG glycosylation;
LUSC	trans	rs2055729	0.813	rs55999429	chr8:9741185	G/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.58	-0.34	1.81e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.76	11.15	0.52	8.96e-25	Corneal astigmatism;
LUSC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg26380479	chr7:97908229	NA	0.28	6.3	0.33	9.49e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.72	-14.25	-0.61	2.59e-36	Type 2 diabetes;
LUSC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.63	-0.43	2.53e-16	Type 2 diabetes;
LUSC	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg22431228	chr1:16359049	CLCNKA	-0.4	-8.38	-0.42	1.45e-15	Systolic blood pressure;
LUSC	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg01943577	chr7:158741284	NA	-0.4	-5.79	-0.3	1.62e-8	Height;
LUSC	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg08017756	chr2:100939284	LONRF2	-0.45	-8.44	-0.42	9.64e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg15423357	chr2:25149977	NA	-0.4	-8.05	-0.4	1.5e-14	Body mass index;
LUSC	cis	rs2303282	0.933	rs14306	chr16:56510299	A/C	cg00500540	chr16:56394104	NA	-0.44	-7.04	-0.36	1.09e-11	Breast cancer;
LUSC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg23711669	chr6:146136114	FBXO30	0.88	15.9	0.66	8.82e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	9.07	0.44	1.01e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.47	8.07	0.4	1.26e-14	Lymphocyte counts;
LUSC	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg04362960	chr10:104952993	NT5C2	-0.49	-7.44	-0.38	8.41e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18876405	chr7:65276391	NA	-0.55	-8.76	-0.43	9.78e-17	Aortic root size;
LUSC	cis	rs9837602	0.938	rs9828079	chr3:99806645	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.4	-5.71	-0.3	2.49e-8	Breast cancer;
LUSC	cis	rs13385	0.769	rs2291878	chr5:139539514	A/G	cg26211634	chr5:139558579	C5orf32	0.38	5.75	0.3	1.99e-8	Atrial fibrillation;
LUSC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06505273	chr16:24850292	NA	-0.43	-6.37	-0.33	6.41e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg01657329	chr11:68192670	LRP5	-0.42	-6.3	-0.33	9.42e-10	Total body bone mineral density;
LUSC	trans	rs9650657	0.707	rs10098699	chr8:10676756	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.01	-0.31	4.95e-9	Neuroticism;
LUSC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg04414720	chr1:150670196	GOLPH3L	0.51	8.12	0.41	9.37e-15	Melanoma;
LUSC	cis	rs11158026	0.603	rs4325453	chr14:55439318	G/A	cg04306507	chr14:55594613	LGALS3	0.4	7.44	0.38	8.33e-13	Parkinson's disease;
LUSC	cis	rs9341808	0.667	rs742833	chr6:80921446	C/T	cg08355045	chr6:80787529	NA	0.46	7.77	0.39	9.69e-14	Sitting height ratio;
LUSC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg27094323	chr7:1216898	NA	-0.35	-6.07	-0.32	3.43e-9	Longevity;Endometriosis;
LUSC	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	8.79	0.43	7.85e-17	Bipolar disorder;
LUSC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03934478	chr11:495069	RNH1	0.82	9.84	0.47	3.08e-20	Body mass index;
LUSC	cis	rs1298062	0.605	rs10409679	chr19:50983930	C/T	cg11430371	chr19:50961752	MYBPC2	0.29	5.74	0.3	2.12e-8	Age of smoking initiation;
LUSC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg16482183	chr6:26056742	HIST1H1C	0.44	6.44	0.33	4.13e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10208940	0.764	rs34744266	chr2:68782606	G/A	cg12452813	chr2:68675892	NA	0.56	5.81	0.3	1.45e-8	Urate levels in lean individuals;
LUSC	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs877282	0.583	rs11253428	chr10:823233	C/T	cg13775593	chr10:823151	NA	0.31	6.06	0.31	3.75e-9	Uric acid levels;
LUSC	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg13010199	chr12:38710504	ALG10B	0.42	6.16	0.32	2.05e-9	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg05738196	chr6:26577821	NA	-0.6	-7.21	-0.37	3.78e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	15.56	0.65	1.93e-41	Total body bone mineral density;
LUSC	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.31e-13	Type 2 diabetes;
LUSC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18099408	chr3:52552593	STAB1	-0.39	-6.28	-0.32	1.07e-9	Bipolar disorder;
LUSC	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg03929089	chr4:120376271	NA	0.6	7.35	0.37	1.59e-12	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.98	0.4	2.3e-14	Corneal astigmatism;
LUSC	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg02503808	chr4:7069936	GRPEL1	-0.68	-6.14	-0.32	2.35e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg06454157	chr6:167490870	NA	-0.27	-6.65	-0.34	1.22e-10	Primary biliary cholangitis;
LUSC	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.74	-0.35	7.05e-11	Lung cancer;
LUSC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg11663144	chr21:46675770	NA	-0.37	-6.07	-0.32	3.52e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg09021430	chr5:549028	NA	-0.57	-7.7	-0.39	1.61e-13	Obesity-related traits;
LUSC	cis	rs1461503	0.934	rs7107560	chr11:122845380	T/C	cg27398637	chr11:122830231	C11orf63	-0.41	-6.57	-0.34	1.98e-10	Menarche (age at onset);
LUSC	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.72	-0.39	1.36e-13	Morning vs. evening chronotype;
LUSC	cis	rs4343996	0.902	rs4719894	chr7:3381789	C/T	cg21248987	chr7:3385318	SDK1	-0.41	-7.1	-0.36	7.44e-12	Motion sickness;
LUSC	cis	rs1018836	0.886	rs12545351	chr8:91636668	C/T	cg16814680	chr8:91681699	NA	-0.78	-13.01	-0.58	1.39e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg08847533	chr14:75593920	NEK9	-0.8	-13.65	-0.6	5.02e-34	Height;
LUSC	cis	rs7605827	0.930	rs6431695	chr2:15539816	T/C	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs977987	0.872	rs7206665	chr16:75475287	A/C	cg04384234	chr16:75411784	CFDP1	-0.45	-7.54	-0.38	4.62e-13	Dupuytren's disease;
LUSC	cis	rs6693567	0.565	rs4926422	chr1:150315436	T/C	cg15654264	chr1:150340011	RPRD2	0.44	7.02	0.36	1.22e-11	Migraine;
LUSC	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg23711669	chr6:146136114	FBXO30	0.82	14.47	0.62	3.41e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg10434728	chr15:90938212	IQGAP1	0.44	9.1	0.45	8.45e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg23173402	chr1:227635558	NA	0.77	8.13	0.41	8.58e-15	Major depressive disorder;
LUSC	cis	rs10489202	1.000	rs2420	chr1:167886502	A/T	cg24449463	chr1:168025552	DCAF6	-0.55	-6.67	-0.34	1.04e-10	Schizophrenia;
LUSC	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg24130564	chr14:104152367	KLC1	0.43	6.15	0.32	2.22e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03517284	chr6:25882590	NA	-0.51	-9.58	-0.46	2.35e-19	Blood metabolite levels;
LUSC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	9.79	0.47	4.77e-20	Personality dimensions;
LUSC	cis	rs9322817	0.691	rs9377679	chr6:105345036	C/T	cg02098413	chr6:105308735	HACE1	0.28	5.96	0.31	6.43e-9	Thyroid stimulating hormone;
LUSC	cis	rs7709377	0.595	rs253952	chr5:115633670	A/G	cg23108291	chr5:115420582	COMMD10	-0.41	-5.66	-0.3	3.34e-8	Metabolite levels  (X-11787);
LUSC	cis	rs11608355	0.515	rs12818537	chr12:109902150	C/T	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg12432903	chr7:1882776	MAD1L1	-0.39	-6.28	-0.32	1.07e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg12863693	chr15:85201151	NMB	0.35	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs859767	0.672	rs10203582	chr2:135362839	C/A	cg12500956	chr2:135428796	TMEM163	-0.28	-6.44	-0.33	4.17e-10	Neuroticism;
LUSC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg17554472	chr22:41940697	POLR3H	-0.47	-5.67	-0.3	3.13e-8	Vitiligo;
LUSC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg26395211	chr5:140044315	WDR55	-0.39	-5.99	-0.31	5.32e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.52	-11.05	-0.52	2.05e-24	Type 2 diabetes;
LUSC	cis	rs6700896	0.500	rs4655566	chr1:66088951	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	6.31	0.33	8.83e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg26149032	chr3:158519514	MFSD1	0.51	6.47	0.33	3.54e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg20607287	chr7:12443886	VWDE	-0.57	-6.03	-0.31	4.43e-9	Coronary artery disease;
LUSC	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg00999904	chr2:3704751	ALLC	0.32	5.86	0.31	1.13e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg02175503	chr12:58329896	NA	0.51	7.31	0.37	1.96e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9905704	0.718	rs1271647	chr17:56655872	G/C	cg12560992	chr17:57184187	TRIM37	-0.51	-5.91	-0.31	8.67e-9	Testicular germ cell tumor;
LUSC	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg04362960	chr10:104952993	NT5C2	0.59	8.86	0.44	4.75e-17	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs28374715	0.662	rs1554445	chr15:41503198	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.84	-14.43	-0.62	4.99e-37	Ulcerative colitis;
LUSC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg06784218	chr1:46089804	CCDC17	-0.48	-9.23	-0.45	3.17e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg02640540	chr1:67518911	SLC35D1	0.55	7.83	0.39	6.41e-14	Lymphocyte percentage of white cells;
LUSC	cis	rs2285947	1.000	rs2285947	chr7:21584088	A/G	cg04471919	chr7:21584483	DNAH11	-0.34	-7.86	-0.4	5.28e-14	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	cis	rs12681287	0.640	rs4490816	chr8:87384938	T/C	cg27223183	chr8:87520930	FAM82B	0.55	7.37	0.37	1.37e-12	Caudate activity during reward;
LUSC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg09796270	chr17:17721594	SREBF1	-0.4	-6.98	-0.36	1.56e-11	Total body bone mineral density;
LUSC	trans	rs9650657	0.836	rs1073913	chr8:10611708	A/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-5.99	-0.31	5.31e-9	Neuroticism;
LUSC	cis	rs7572644	0.640	rs4666015	chr2:28019367	G/A	cg27432699	chr2:27873401	GPN1	0.55	7.26	0.37	2.74e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs735860	0.726	rs209490	chr6:53179047	C/T	cg10236188	chr6:53219634	NA	0.37	5.67	0.3	3.15e-8	Glaucoma;
LUSC	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg21775007	chr8:11205619	TDH	-0.58	-8.89	-0.44	3.95e-17	Retinal vascular caliber;
LUSC	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg22676075	chr6:135203613	NA	-0.46	-7.19	-0.37	4.25e-12	Red blood cell count;
LUSC	cis	rs11711311	0.955	rs78029398	chr3:113421321	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.83	0.35	4.12e-11	IgG glycosylation;
LUSC	cis	rs4280164	0.551	rs882726	chr14:24797997	C/A	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.62	-7.65	-0.39	2.15e-13	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs897080	0.552	rs1067378	chr2:44648047	A/G	cg00619915	chr2:44497795	NA	-0.42	-6.03	-0.31	4.26e-9	Height;
LUSC	trans	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg04995722	chr7:26192034	NFE2L3	0.37	6.07	0.32	3.54e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.43	6.63	0.34	1.34e-10	Resistin levels;
LUSC	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-6.15	-0.32	2.15e-9	Crohn's disease;
LUSC	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	8.42	0.42	1.09e-15	Menarche (age at onset);
LUSC	cis	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg24692254	chr21:30365293	RNF160	0.54	6.83	0.35	4.1e-11	Cognitive test performance;
LUSC	cis	rs174479	0.677	rs174456	chr11:61656182	G/T	cg01500311	chr11:61656094	FADS3	0.41	7.32	0.37	1.87e-12	Sphingolipid levels;
LUSC	cis	rs7804356	1.000	rs6461979	chr7:26888918	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.11e-9	Type 1 diabetes;
LUSC	cis	rs16912285	0.685	rs16912402	chr11:24313135	C/G	ch.11.24196551F	chr11:24239977	NA	0.71	5.87	0.31	1.08e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg06521331	chr12:34319734	NA	-0.49	-8.19	-0.41	5.73e-15	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24779145	chr19:40030822	EID2	-0.42	-6.3	-0.33	9.61e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7192380	0.571	rs10852456	chr16:69605613	G/T	cg26679644	chr16:69762563	NA	0.35	6.17	0.32	1.94e-9	Sjögren's syndrome;
LUSC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.07	15.41	0.64	7.55e-41	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9807989	0.811	rs4485584	chr2:102970750	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.88	0.31	9.76e-9	Asthma;
LUSC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg02951883	chr7:2050386	MAD1L1	0.4	6.86	0.35	3.35e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15557168	chr22:42548783	NA	-0.43	-7.15	-0.36	5.57e-12	Cognitive function;
LUSC	trans	rs2392780	0.667	rs432470	chr8:128339044	C/T	cg10897648	chr18:56338258	MALT1	-0.44	-6.6	-0.34	1.59e-10	Breast cancer (early onset);
LUSC	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.74	-13.06	-0.58	9e-32	Dental caries;
LUSC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg23711669	chr6:146136114	FBXO30	0.72	12.46	0.56	1.59e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17828380	0.920	rs8025816	chr15:63448554	C/G	cg05507819	chr15:63340323	TPM1	-0.78	-5.91	-0.31	8.37e-9	Social communication problems;
LUSC	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg04920474	chr2:44395004	PPM1B	0.69	8.86	0.44	4.83e-17	Height;
LUSC	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg09035930	chr12:129282057	SLC15A4	0.75	15.94	0.66	6.21e-43	Systemic lupus erythematosus;
LUSC	cis	rs7605827	0.930	rs1990754	chr2:15615910	A/G	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.5	-7.57	-0.38	3.65e-13	Menarche (age at onset);
LUSC	trans	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg13565492	chr6:43139072	SRF	-0.63	-6.57	-0.34	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg22823121	chr1:150693482	HORMAD1	0.58	8.85	0.44	5.37e-17	Blood protein levels;
LUSC	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg12559939	chr2:27858050	GPN1	0.38	5.95	0.31	6.89e-9	Oral cavity cancer;
LUSC	cis	rs4654899	0.865	rs6664532	chr1:21515800	G/A	cg02927042	chr1:21476669	EIF4G3	-0.39	-6.23	-0.32	1.4e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg18230493	chr5:56204884	C5orf35	-0.8	-12.52	-0.57	9.31e-30	Initial pursuit acceleration;
LUSC	cis	rs4363385	0.747	rs2339490	chr1:152984612	A/G	cg00922841	chr1:152955080	SPRR1A	0.38	6.6	0.34	1.66e-10	Inflammatory skin disease;
LUSC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg06618935	chr21:46677482	NA	-0.38	-7.55	-0.38	4.33e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg21775007	chr8:11205619	TDH	-0.48	-6.76	-0.35	6.19e-11	Neuroticism;
LUSC	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg12647142	chr7:26240901	CBX3;HNRNPA2B1	0.4	6.22	0.32	1.51e-9	Schizophrenia;
LUSC	cis	rs4363385	0.588	rs12082627	chr1:153023650	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.8	-0.3	1.54e-8	Inflammatory skin disease;
LUSC	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg17507749	chr15:85114479	UBE2QP1	0.69	9.15	0.45	5.91e-18	Schizophrenia;
LUSC	cis	rs4601821	0.823	rs4938015	chr11:113264644	C/T	cg14159747	chr11:113255604	NA	-0.25	-6.04	-0.31	4.15e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg19875535	chr5:140030758	IK	0.51	8.25	0.41	3.64e-15	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg20993868	chr7:22813445	NA	0.57	10.46	0.5	2.43e-22	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.98	0.31	5.84e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-8.53	-0.42	5.02e-16	Longevity;
LUSC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg12963246	chr6:28129442	ZNF389	0.55	8.17	0.41	6.55e-15	Parkinson's disease;
LUSC	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	9.51	0.46	4.03e-19	Lung cancer in ever smokers;
LUSC	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg15309053	chr8:964076	NA	0.38	7.72	0.39	1.4e-13	Schizophrenia;
LUSC	trans	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-6.74	-0.35	6.9e-11	Endometrial cancer;
LUSC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg20887711	chr4:1340912	KIAA1530	0.47	7.22	0.37	3.42e-12	Obesity-related traits;
LUSC	trans	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.55	-8.5	-0.42	6.19e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	0.39	6.04	0.31	4.18e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7605827	0.930	rs6759785	chr2:15529269	A/C	cg19274914	chr2:15703543	NA	0.46	8.93	0.44	3.01e-17	Educational attainment (years of education);
LUSC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.27	-0.37	2.64e-12	Subjective well-being;
LUSC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg23985595	chr17:80112537	CCDC57	-0.31	-5.88	-0.31	9.82e-9	Life satisfaction;
LUSC	cis	rs2840044	1.000	rs225295	chr17:33925755	A/G	cg05299278	chr17:33885742	SLFN14	0.3	6.28	0.33	1.05e-9	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs540254	0.578	rs3817407	chr1:160788131	T/C	cg20255094	chr1:160771763	LY9	0.49	6.22	0.32	1.47e-9	Blood protein levels;
LUSC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg12257692	chr3:49977190	RBM6	0.24	6.62	0.34	1.39e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg26384229	chr12:38710491	ALG10B	-0.78	-13.29	-0.59	1.25e-32	Morning vs. evening chronotype;
LUSC	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg19875535	chr5:140030758	IK	-0.48	-7.72	-0.39	1.34e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.64	-0.3	3.56e-8	Life satisfaction;
LUSC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg20849893	chr7:64541193	NA	-0.65	-5.68	-0.3	2.99e-8	Diabetic kidney disease;
LUSC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg09436375	chr6:42928200	GNMT	-0.28	-6.35	-0.33	6.84e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg15704280	chr7:45808275	SEPT13	0.55	6.81	0.35	4.55e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.12	-0.45	7.26e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18404041	chr3:52824283	ITIH1	-0.61	-11.95	-0.55	1.16e-27	Bipolar disorder;
LUSC	trans	rs724744	0.772	rs1772076	chr6:22352957	G/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.2	-0.32	1.71e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg23711669	chr6:146136114	FBXO30	-0.49	-7.37	-0.37	1.38e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7945705	0.791	rs7944560	chr11:8817276	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.41	7.17	0.37	4.88e-12	Hemoglobin concentration;
LUSC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.3	-0.49	8.36e-22	Hemoglobin concentration;
LUSC	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-10.94	-0.51	5.23e-24	Response to antipsychotic treatment;
LUSC	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.77	0.35	5.84e-11	Rheumatoid arthritis;
LUSC	trans	rs12200782	1.000	rs72844496	chr6:26611608	G/A	cg11837749	chr1:55047332	ACOT11	0.57	5.98	0.31	5.64e-9	Small cell lung carcinoma;
LUSC	cis	rs151349	1.000	rs151346	chr20:57587040	C/A	cg23907860	chr20:57583709	CTSZ	-0.47	-7.66	-0.39	2.08e-13	Platelet distribution width;
LUSC	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg08079166	chr15:68083412	MAP2K5	0.39	7.08	0.36	8.32e-12	Restless legs syndrome;
LUSC	cis	rs7608623	0.773	rs7560892	chr2:23928637	A/G	cg08917208	chr2:24149416	ATAD2B	-0.42	-5.71	-0.3	2.48e-8	Obesity-related traits;
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11060661	chr22:24314208	DDT;DDTL	0.48	7.85	0.39	5.73e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-0.88	-12.73	-0.57	1.55e-30	Initial pursuit acceleration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16860267	chr18:11908803	MPPE1	0.47	7.04	0.36	1.08e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7809950	0.953	rs3094383	chr7:107143164	G/A	cg23024343	chr7:107201750	COG5	-0.55	-8.73	-0.43	1.27e-16	Coronary artery disease;
LUSC	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg26876637	chr1:152193138	HRNR	0.44	6.29	0.33	1.01e-9	Atopic dermatitis;
LUSC	cis	rs977987	0.843	rs12443904	chr16:75438770	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.04	-0.36	1.08e-11	Dupuytren's disease;
LUSC	cis	rs3126085	0.935	rs10888467	chr1:152171707	C/T	cg26876637	chr1:152193138	HRNR	0.46	6.45	0.33	3.84e-10	Atopic dermatitis;
LUSC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg27535305	chr1:53392650	SCP2	-0.41	-7.61	-0.38	2.8e-13	Monocyte count;
LUSC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	0.92	15.94	0.66	5.93e-43	Menopause (age at onset);
LUSC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.75	-0.35	6.42e-11	Total body bone mineral density;
LUSC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg01802117	chr1:53393560	SCP2	-0.41	-6.89	-0.35	2.8e-11	Monocyte count;
LUSC	trans	rs11039798	1.000	rs3902928	chr11:48581458	A/T	cg15704280	chr7:45808275	SEPT13	0.69	6.51	0.34	2.81e-10	Axial length;
LUSC	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.69	10.49	0.5	1.94e-22	Corneal astigmatism;
LUSC	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07080220	chr10:102295463	HIF1AN	0.65	8.72	0.43	1.3e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg21775007	chr8:11205619	TDH	0.48	6.82	0.35	4.23e-11	Systolic blood pressure;
LUSC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.27e-31	Prudent dietary pattern;
LUSC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg26924012	chr15:45694286	SPATA5L1	1.13	20.73	0.75	5.96e-62	Homoarginine levels;
LUSC	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	1.01	18.64	0.71	1.2e-53	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg26677194	chr12:130822605	PIWIL1	0.6	8.97	0.44	2.13e-17	Menopause (age at onset);
LUSC	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg25214090	chr10:38739885	LOC399744	0.53	7.72	0.39	1.33e-13	Corneal astigmatism;
LUSC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg15103426	chr22:29168792	CCDC117	0.6	8.34	0.42	1.91e-15	Lymphocyte counts;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04885475	chr3:157827967	RSRC1	-0.4	-6.04	-0.31	4.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14829155	chr15:31115871	NA	0.55	7.8	0.39	8.02e-14	Huntington's disease progression;
LUSC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	0.98	14.09	0.61	1.01e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.01	0.36	1.35e-11	Morning vs. evening chronotype;
LUSC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg16339924	chr4:17578868	LAP3	0.61	9.32	0.45	1.66e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6494488	0.500	rs72744738	chr15:65048334	C/G	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg03909902	chr12:108154529	PRDM4	-0.45	-6.59	-0.34	1.75e-10	Cognitive function;Information processing speed;
LUSC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.68	6.46	0.33	3.8e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg00074818	chr8:8560427	CLDN23	0.53	8.51	0.42	5.86e-16	Obesity-related traits;
LUSC	cis	rs62458065	0.568	rs62463963	chr7:32486691	C/T	cg20159608	chr7:32802032	NA	-0.74	-9.29	-0.45	1.96e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs10805346	0.531	rs12498927	chr4:10115523	C/T	cg26043149	chr18:55253948	FECH	-0.42	-6.56	-0.34	2.09e-10	Urate levels in overweight individuals;Urate levels in obese individuals;
LUSC	trans	rs9329221	0.576	rs1986972	chr8:10268805	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	6.34	0.33	7.59e-10	Neuroticism;
LUSC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.76	-0.47	5.88e-20	Platelet count;
LUSC	cis	rs7705502	0.962	rs72812847	chr5:173377817	G/A	cg18693985	chr5:173351052	CPEB4	-0.37	-5.83	-0.3	1.33e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg00945038	chr17:61921165	SMARCD2	0.54	9.64	0.47	1.4e-19	Prudent dietary pattern;
LUSC	cis	rs4776059	1.000	rs2288271	chr15:52886466	A/G	cg22715398	chr15:52968154	KIAA1370	-0.72	-10.28	-0.49	1.01e-21	Schizophrenia;
LUSC	cis	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.45e-10	Ulcerative colitis;
LUSC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg05347473	chr6:146136440	FBXO30	0.54	9.12	0.45	7.02e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9818941	0.824	rs60410659	chr3:157811198	A/T	cg08654915	chr3:157813417	NA	0.32	7.45	0.38	7.89e-13	Height;
LUSC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.7	-10.78	-0.51	1.87e-23	Platelet count;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg09033563	chr22:24373618	LOC391322	-0.59	-9.09	-0.45	8.91e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg22189786	chr22:42395067	WBP2NL	0.43	5.7	0.3	2.65e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs806215	1.000	rs327512	chr7:127257251	G/A	cg25922125	chr7:127225783	GCC1	0.49	6.33	0.33	7.92e-10	Type 2 diabetes;
LUSC	cis	rs11971779	0.680	rs28579232	chr7:139073116	C/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg06582575	chr6:163149167	PACRG;PARK2	1.13	15.81	0.65	2.04e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9326248	0.520	rs10892060	chr11:116881662	C/A	cg20608306	chr11:116969690	SIK3	0.34	6.37	0.33	6.33e-10	Blood protein levels;
LUSC	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg23029597	chr12:123009494	RSRC2	0.77	9.63	0.47	1.6e-19	Body mass index;
LUSC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.94	0.48	1.49e-20	Bipolar disorder;
LUSC	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg04218760	chr10:45406644	TMEM72	-0.29	-6.96	-0.36	1.8e-11	Mean corpuscular volume;
LUSC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg01181863	chr3:195395398	SDHAP2	-0.6	-8.11	-0.41	9.77e-15	Pancreatic cancer;
LUSC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg16680214	chr1:154839983	KCNN3	-0.35	-6.27	-0.32	1.14e-9	Schizophrenia;
LUSC	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg22906224	chr7:99728672	NA	0.55	8.13	0.41	8.36e-15	Coronary artery disease;
LUSC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.85	16.36	0.67	1.29e-44	Mean platelet volume;
LUSC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg06618935	chr21:46677482	NA	-0.36	-7.12	-0.36	6.71e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-1.14	-18.17	-0.71	8.4e-52	Exhaled nitric oxide output;
LUSC	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg06640241	chr16:89574553	SPG7	0.4	5.85	0.3	1.17e-8	Hemoglobin concentration;
LUSC	cis	rs59698941	0.943	rs10491277	chr5:132236361	G/C	cg02081065	chr5:132209139	LEAP2	-0.65	-6.85	-0.35	3.55e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg20887711	chr4:1340912	KIAA1530	0.44	6.57	0.34	1.97e-10	Obesity-related traits;
LUSC	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.75e-14	Melanoma;
LUSC	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.28	-0.41	3.05e-15	Body mass index;
LUSC	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg01503450	chr10:980765	NA	-0.4	-5.85	-0.3	1.15e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs9398803	0.931	rs2045258	chr6:126674354	A/G	cg19875578	chr6:126661172	C6orf173	0.41	6.1	0.32	2.95e-9	Male-pattern baldness;
LUSC	trans	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.02	-0.31	4.66e-9	Bladder cancer;
LUSC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg06454157	chr6:167490870	NA	-0.26	-6.02	-0.31	4.55e-9	Crohn's disease;
LUSC	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg18190219	chr22:46762943	CELSR1	-0.55	-6.38	-0.33	5.88e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13819250	chr17:41560934	DHX8	0.44	6.24	0.32	1.35e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg14582100	chr15:45693742	SPATA5L1	0.57	10.11	0.48	3.77e-21	Homoarginine levels;
LUSC	cis	rs13401104	0.796	rs11887905	chr2:237114756	C/T	cg19324714	chr2:237145437	ASB18	0.43	5.88	0.31	9.94e-9	Educational attainment;
LUSC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg18240062	chr17:79603768	NPLOC4	-0.79	-15.38	-0.64	9.93e-41	Eye color traits;
LUSC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.93	-18.89	-0.72	1.19e-54	Post bronchodilator FEV1;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.42	0.33	4.64e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg00701064	chr4:6280414	WFS1	0.59	14.24	0.61	2.82e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg10756647	chr7:56101905	PSPH	-0.87	-8.68	-0.43	1.81e-16	Diabetic kidney disease;
LUSC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg11764359	chr7:65958608	NA	0.53	6.88	0.35	2.9e-11	Aortic root size;
LUSC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.83	15.21	0.64	4.51e-40	Mean platelet volume;
LUSC	cis	rs7246967	0.673	rs3844578	chr19:22880610	G/C	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08048268	chr3:133502702	NA	-0.45	-8.75	-0.43	1.09e-16	Iron status biomarkers;
LUSC	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	0.53	8.2	0.41	5.16e-15	Breast cancer;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg19372772	chr2:264904	ACP1;SH3YL1	-0.55	-6.13	-0.32	2.41e-9	Height;
LUSC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.47	0.46	5.12e-19	Bipolar disorder;
LUSC	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	0.96	13.28	0.59	1.29e-32	Primary sclerosing cholangitis;
LUSC	trans	rs459571	0.916	rs467303	chr9:136904835	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.76	-12.43	-0.56	2.09e-29	Platelet distribution width;
LUSC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg21972741	chr5:435613	AHRR	0.34	6.37	0.33	6.38e-10	Cystic fibrosis severity;
LUSC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg21880101	chr17:80066754	CCDC57	-0.31	-5.68	-0.3	3e-8	Life satisfaction;
LUSC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.58	-0.5	9.69e-23	Chronic sinus infection;
LUSC	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg21366198	chr4:185655624	MLF1IP	-0.42	-5.94	-0.31	7.05e-9	Kawasaki disease;
LUSC	trans	rs656319	0.513	rs17746227	chr8:9981654	T/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.74	-0.35	7e-11	Myopia (pathological);
LUSC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg12863693	chr15:85201151	NMB	0.34	6.79	0.35	5.23e-11	Schizophrenia;
LUSC	cis	rs7129727	1	rs7129727	chr11:57484660	G/A	cg02958346	chr11:57425731	CLP1	-0.41	-6.04	-0.31	4.19e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-0.94	-13.39	-0.59	4.94e-33	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs6030	0.869	rs9332599	chr1:169512980	G/A	cg16792071	chr10:134842795	NA	0.3	6.16	0.32	2.05e-9	Uric acid levels;
LUSC	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4664308	0.618	rs3792192	chr2:160886875	G/A	cg03641300	chr2:160917029	PLA2R1	-0.48	-7.96	-0.4	2.79e-14	Idiopathic membranous nephropathy;
LUSC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	trans	rs877282	0.583	rs11253425	chr10:815173	G/A	cg13042288	chr15:90349979	ANPEP	-0.42	-6.26	-0.32	1.21e-9	Uric acid levels;
LUSC	trans	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07923666	chr12:49932857	KCNH3	-0.48	-6.22	-0.32	1.51e-9	Resting heart rate;
LUSC	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg18753928	chr3:113234510	CCDC52	-0.53	-8.27	-0.41	3.16e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs7106204	0.562	rs7109606	chr11:24251314	G/T	ch.11.24196551F	chr11:24239977	NA	0.91	10.09	0.48	4.56e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg16576597	chr16:28551801	NUPR1	0.28	5.71	0.3	2.54e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs6733011	0.582	rs6757099	chr2:99415235	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.78	-0.3	1.73e-8	Bipolar disorder;
LUSC	cis	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg00806126	chr19:22604979	ZNF98	0.36	5.7	0.3	2.67e-8	Pain;
LUSC	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg00310523	chr12:86230176	RASSF9	-0.42	-8.0	-0.4	2e-14	Major depressive disorder;
LUSC	cis	rs67696533	0.600	rs4911097	chr20:31121370	G/A	cg13636640	chr20:31349939	DNMT3B	0.47	6.36	0.33	6.45e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs7712401	0.601	rs34233716	chr5:122316365	C/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.53	-0.46	3.35e-19	Mean platelet volume;
LUSC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg22907277	chr7:1156413	C7orf50	0.7	7.45	0.38	8.01e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.65	11.1	0.52	1.41e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs68170813	0.559	rs79705824	chr7:106848325	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.87e-20	Coronary artery disease;
LUSC	cis	rs1044826	0.642	rs2071388	chr3:139236683	C/T	cg00490450	chr3:139108681	COPB2	-0.47	-7.12	-0.36	6.7e-12	Obesity-related traits;
LUSC	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06636551	chr8:101224915	SPAG1	-0.45	-8.26	-0.41	3.54e-15	Atrioventricular conduction;
LUSC	cis	rs11997175	0.583	rs7460295	chr8:33812288	C/T	ch.8.33884649F	chr8:33765107	NA	0.45	6.49	0.33	3.06e-10	Body mass index;
LUSC	cis	rs9420	0.961	rs17455520	chr11:57540458	C/A	cg02958346	chr11:57425731	CLP1	-0.44	-6.44	-0.33	4.22e-10	Schizophrenia;
LUSC	cis	rs9902453	0.817	rs59420007	chr17:28196114	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.79	0.47	4.72e-20	Coffee consumption (cups per day);
LUSC	cis	rs672059	1.000	rs510642	chr1:183162776	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.1	0.41	1.02e-14	Hypertriglyceridemia;
LUSC	trans	rs17169634	1.000	rs17169634	chr7:34093997	A/G	cg18512313	chr14:70700886	NA	0.61	6.15	0.32	2.25e-9	Alzheimer's disease;
LUSC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-0.98	-16.85	-0.68	1.54e-46	Coronary artery disease;
LUSC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-10.99	-0.52	3.54e-24	Gut microbiome composition (summer);
LUSC	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg10604040	chr11:65559109	OVOL1	0.31	5.78	0.3	1.72e-8	Eosinophil percentage of white cells;
LUSC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg02807482	chr3:125708958	NA	-0.52	-6.49	-0.33	3.08e-10	Blood pressure (smoking interaction);
LUSC	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	9.63	0.47	1.62e-19	Lung cancer in ever smokers;
LUSC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg23172400	chr8:95962367	TP53INP1	-0.43	-8.83	-0.43	6.16e-17	Type 2 diabetes;
LUSC	cis	rs7189233	0.531	rs9921587	chr16:53475650	A/G	cg09728985	chr16:53543985	NA	-0.31	-5.81	-0.3	1.45e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg19402173	chr7:128379420	CALU	-0.46	-6.92	-0.35	2.31e-11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	trans	rs12310956	0.532	rs2171534	chr12:33838998	C/T	cg13010199	chr12:38710504	ALG10B	0.43	6.59	0.34	1.74e-10	Morning vs. evening chronotype;
LUSC	cis	rs231513	0.954	rs231516	chr17:41963205	G/A	cg26893861	chr17:41843967	DUSP3	-0.52	-6.29	-0.33	1e-9	Cognitive function;
LUSC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg10360139	chr7:1886902	MAD1L1	-0.39	-5.96	-0.31	6.39e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg12463550	chr7:65579703	CRCP	0.62	5.67	0.3	3.04e-8	Diabetic kidney disease;
LUSC	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg15432903	chr11:17409602	KCNJ11	0.62	11.29	0.53	2.95e-25	Type 2 diabetes;
LUSC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-0.81	-13.97	-0.61	2.91e-35	Longevity;
LUSC	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg05340658	chr4:99064831	C4orf37	-0.47	-7.4	-0.38	1.14e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2692947	0.770	rs58730124	chr2:96413338	T/C	cg22654517	chr2:96458247	NA	0.35	6.65	0.34	1.21e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	0.91	12.24	0.56	1.04e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.93e-12	Blood metabolite levels;
LUSC	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg02023728	chr11:77925099	USP35	0.46	6.7	0.34	8.82e-11	Testicular germ cell tumor;
LUSC	cis	rs12760731	0.546	rs6699087	chr1:178433200	G/T	cg00404053	chr1:178313656	RASAL2	0.48	5.74	0.3	2.17e-8	Obesity-related traits;
LUSC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.12	-0.48	3.44e-21	Obesity-related traits;
LUSC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg25456477	chr12:86230367	RASSF9	0.42	7.54	0.38	4.42e-13	Major depressive disorder;
LUSC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg03036452	chr22:46663545	TTC38	0.52	5.7	0.3	2.62e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10779751	0.960	rs6661859	chr1:11301063	T/C	cg08854313	chr1:11322531	MTOR	0.88	15.21	0.64	4.59e-40	Body mass index;
LUSC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg06671706	chr8:8559999	CLDN23	0.48	6.48	0.33	3.29e-10	Obesity-related traits;
LUSC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg24250549	chr1:154909240	PMVK	0.66	11.06	0.52	2.01e-24	Prostate cancer;
LUSC	trans	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg03785828	chr5:81573306	RPS23	-0.37	-6.02	-0.31	4.56e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	12.05	0.55	5.02e-28	Nonalcoholic fatty liver disease;
LUSC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg14558114	chr2:88469736	THNSL2	0.76	6.66	0.34	1.15e-10	Plasma clusterin levels;
LUSC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg18876405	chr7:65276391	NA	0.6	9.57	0.46	2.42e-19	Aortic root size;
LUSC	cis	rs8077577	0.895	rs11078412	chr17:18100618	C/T	cg16794390	chr17:18148240	FLII	-0.39	-5.69	-0.3	2.73e-8	Obesity-related traits;
LUSC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.61	0.54	2.13e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg16434002	chr17:42200994	HDAC5	-0.46	-6.24	-0.32	1.31e-9	Total body bone mineral density;
LUSC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg11871910	chr12:69753446	YEATS4	0.67	10.32	0.49	7.44e-22	Blood protein levels;
LUSC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.55	0.57	7.07e-30	Motion sickness;
LUSC	cis	rs7640424	0.750	rs13074183	chr3:107851467	G/A	cg09227934	chr3:107805635	CD47	-0.41	-6.3	-0.33	9.21e-10	Body mass index;
LUSC	cis	rs3857067	0.506	rs282450	chr4:95139598	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.46	-0.42	8.25e-16	QT interval;
LUSC	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg15556689	chr8:8085844	FLJ10661	0.45	6.51	0.34	2.68e-10	Neuroticism;
LUSC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	12.29	0.56	6.52e-29	Personality dimensions;
LUSC	cis	rs7940866	0.803	rs10894307	chr11:130876350	G/A	cg12179176	chr11:130786555	SNX19	0.64	9.79	0.47	4.58e-20	Schizophrenia;
LUSC	cis	rs11051970	0.879	rs2651379	chr12:32581778	A/G	cg02745156	chr12:32552066	NA	0.43	7.32	0.37	1.88e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	8.77	0.43	9.61e-17	Menopause (age at onset);
LUSC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg17279839	chr7:150038598	RARRES2	0.43	6.61	0.34	1.5e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg03585969	chr10:35415529	CREM	0.64	9.52	0.46	3.56e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs911119	0.955	rs4815224	chr20:23594112	C/G	cg16589663	chr20:23618590	CST3	0.64	7.68	0.39	1.82e-13	Chronic kidney disease;
LUSC	cis	rs9595066	1.000	rs9595066	chr13:44706268	C/T	cg04068111	chr13:44716778	NA	-0.56	-7.95	-0.4	2.87e-14	Schizophrenia;
LUSC	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.61	8.23	0.41	4.14e-15	Adiposity;
LUSC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg06001716	chr17:41278141	BRCA1;NBR2	-0.35	-5.75	-0.3	1.99e-8	Menopause (age at onset);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22307414	chr1:205601417	ELK4	-0.47	-6.22	-0.32	1.5e-9	Hepatitis;
LUSC	cis	rs72829446	0.556	rs9907042	chr17:7402985	A/G	cg02795151	chr17:7402630	POLR2A	-0.59	-7.9	-0.4	4.19e-14	Androgen levels;
LUSC	cis	rs7712401	0.601	rs30045	chr5:122271619	C/T	cg19077854	chr5:122220652	SNX24	0.41	8.86	0.44	4.97e-17	Mean platelet volume;
LUSC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg05973401	chr12:123451056	ABCB9	0.51	7.06	0.36	9.93e-12	Neutrophil percentage of white cells;
LUSC	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.5	6.03	0.31	4.42e-9	Crohn's disease;
LUSC	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	1.24	14.17	0.61	5.13e-36	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg03929089	chr4:120376271	NA	-0.59	-7.11	-0.36	7.13e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs12474201	0.630	rs897529	chr2:46948175	T/C	cg06386533	chr2:46925753	SOCS5	0.57	8.5	0.42	6.33e-16	Height;
LUSC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg04155289	chr7:94953770	PON1	-0.34	-5.76	-0.3	1.9e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	9.04	0.44	1.31e-17	Menopause (age at onset);
LUSC	cis	rs8114671	0.935	rs6142313	chr20:33780427	A/G	cg24642439	chr20:33292090	TP53INP2	-0.39	-5.72	-0.3	2.31e-8	Height;
LUSC	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.51	7.15	0.36	5.47e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg23719950	chr11:63933701	MACROD1	-0.6	-7.48	-0.38	6.57e-13	Mean platelet volume;
LUSC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.56	9.99	0.48	9.83e-21	Bone mineral density;
LUSC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	7.42	0.38	9.76e-13	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4776059	0.798	rs58018557	chr15:52901284	T/C	cg25063058	chr15:52860530	ARPP19	-0.48	-6.12	-0.32	2.64e-9	Schizophrenia;
LUSC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg13397359	chr6:42928475	GNMT	0.58	9.83	0.47	3.48e-20	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17916960	chr15:79447300	NA	-0.54	-10.92	-0.51	6.05e-24	Refractive error;
LUSC	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	0.94	17.57	0.69	2.21e-49	Headache;
LUSC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.84	-0.51	1.15e-23	Alzheimer's disease (late onset);
LUSC	cis	rs7712401	0.601	rs154506	chr5:122202781	A/G	cg19077854	chr5:122220652	SNX24	0.41	9.11	0.45	7.65e-18	Mean platelet volume;
LUSC	cis	rs9398803	0.865	rs1572569	chr6:126771687	G/A	cg19875578	chr6:126661172	C6orf173	0.41	5.93	0.31	7.72e-9	Male-pattern baldness;
LUSC	cis	rs4285028	0.948	rs35902163	chr3:121649526	G/A	cg11130432	chr3:121712080	ILDR1	-0.65	-10.0	-0.48	9.21e-21	Multiple sclerosis;
LUSC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg20476274	chr7:133979776	SLC35B4	0.87	17.01	0.68	3.4e-47	Mean platelet volume;
LUSC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg11062466	chr8:58055876	NA	0.71	8.85	0.44	5.13e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-10.14	-0.48	3.18e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg11861562	chr11:117069780	TAGLN	-0.45	-8.14	-0.41	7.83e-15	Blood protein levels;
LUSC	trans	rs7581030	0.958	rs6761251	chr2:71521191	T/G	cg08113661	chr1:39457270	AKIRIN1	0.52	6.13	0.32	2.54e-9	Testicular germ cell tumor;
LUSC	cis	rs3850699	0.666	rs7905481	chr10:104476292	T/C	cg04362960	chr10:104952993	NT5C2	0.46	6.61	0.34	1.55e-10	Prostate cancer;
LUSC	trans	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.33	-0.33	7.81e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	0.88	16.98	0.68	4.65e-47	Menarche (age at onset);
LUSC	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg05714579	chr10:131428358	MGMT	-0.71	-11.46	-0.53	7.06e-26	Response to temozolomide;
LUSC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg23711669	chr6:146136114	FBXO30	0.91	17.06	0.68	2.16e-47	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01498883	chr20:2451474	SNRPB	0.66	6.22	0.32	1.5e-9	Cognitive performance;
LUSC	cis	rs2857891	0.773	rs2857897	chr11:6982082	A/C	cg14883916	chr11:6947541	ZNF215	0.46	6.03	0.31	4.23e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs17604090	0.938	rs115369413	chr7:29685040	T/G	cg19413766	chr7:29689036	LOC646762	-0.57	-6.65	-0.34	1.18e-10	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-8.03	-0.4	1.69e-14	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg13560548	chr3:10150139	C3orf24	0.51	7.22	0.37	3.61e-12	Alzheimer's disease;
LUSC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg13854012	chr2:162103682	NA	-0.45	-8.11	-0.41	9.4e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg24692254	chr21:30365293	RNF160	-0.56	-8.16	-0.41	7.09e-15	Dental caries;
LUSC	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg16476235	chr8:21771668	DOK2	0.24	5.68	0.3	2.92e-8	Mean corpuscular volume;
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.7	-14.49	-0.62	2.97e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg22676075	chr6:135203613	NA	0.59	9.48	0.46	5e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs1983891	1.000	rs1983891	chr6:41536427	A/G	cg20194872	chr6:41519635	FOXP4	-0.36	-6.53	-0.34	2.5e-10	Prostate cancer;
LUSC	cis	rs1322512	0.917	rs1744380	chr6:152942821	A/G	cg27316956	chr6:152958899	SYNE1	0.36	5.99	0.31	5.4e-9	Tonometry;
LUSC	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg00792783	chr2:198669748	PLCL1	0.43	5.68	0.3	3.01e-8	Dermatomyositis;
LUSC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg15790184	chr11:494944	RNH1	0.42	6.42	0.33	4.69e-10	Systemic lupus erythematosus;
LUSC	cis	rs6574644	0.959	rs12146981	chr14:81780858	C/T	cg01989461	chr14:81687754	GTF2A1	0.49	6.0	0.31	5.11e-9	Obesity-related traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03323092	chr20:42219682	IFT52	-0.43	-6.35	-0.33	7.23e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg23711669	chr6:146136114	FBXO30	0.84	14.93	0.63	5.97e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg07395648	chr5:131743802	NA	0.37	5.8	0.3	1.52e-8	Asthma (sex interaction);
LUSC	cis	rs7911264	0.739	rs10882094	chr10:94387676	T/A	cg25093409	chr10:94429542	NA	0.36	6.21	0.32	1.59e-9	Inflammatory bowel disease;
LUSC	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg15083037	chr5:83017644	HAPLN1	-0.61	-7.75	-0.39	1.13e-13	Prostate cancer;
LUSC	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg16386425	chr10:429943	DIP2C	-0.44	-7.06	-0.36	9.96e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg02951883	chr7:2050386	MAD1L1	-0.57	-10.53	-0.5	1.36e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.45	-8.05	-0.4	1.44e-14	Electroencephalogram traits;
LUSC	cis	rs9304742	0.611	rs10415443	chr19:53464864	C/G	cg09503522	chr19:53445286	ZNF321	-0.36	-5.77	-0.3	1.79e-8	Psoriasis;
LUSC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-13.71	-0.6	3.02e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	6.88	0.35	2.98e-11	Eosinophil percentage of white cells;
LUSC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg03605463	chr16:89740564	NA	0.6	9.58	0.46	2.31e-19	Vitiligo;
LUSC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg17971929	chr21:40555470	PSMG1	-0.48	-7.24	-0.37	3.08e-12	Menarche (age at onset);
LUSC	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg27411982	chr8:10470053	RP1L1	0.47	7.28	0.37	2.44e-12	Neuroticism;
LUSC	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.8	-0.39	8.08e-14	Pulmonary function;
LUSC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs28830936	0.966	rs1531140	chr15:42125234	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.72	-0.3	2.37e-8	Diastolic blood pressure;
LUSC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg04450456	chr4:17643702	FAM184B	0.4	6.6	0.34	1.57e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg00757033	chr12:89920650	WDR51B	0.59	10.25	0.49	1.3e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg04166393	chr7:2884313	GNA12	0.42	5.66	0.3	3.24e-8	Height;
LUSC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg15145296	chr3:125709740	NA	-0.53	-6.06	-0.31	3.63e-9	Blood pressure (smoking interaction);
LUSC	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg03474202	chr17:45855739	NA	-0.29	-6.69	-0.34	9.62e-11	IgG glycosylation;
LUSC	cis	rs983392	0.709	rs1349667	chr11:59993346	T/A	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.03	-0.31	4.31e-9	Alzheimer's disease (late onset);
LUSC	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg05110241	chr16:68378359	PRMT7	-0.55	-6.32	-0.33	8.3e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6545883	0.894	rs7602859	chr2:61458206	A/T	cg15711740	chr2:61764176	XPO1	0.43	6.5	0.33	2.96e-10	Tuberculosis;
LUSC	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg17366294	chr4:99064904	C4orf37	-0.51	-8.05	-0.4	1.5e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg21892295	chr12:121157589	UNC119B	-0.52	-9.54	-0.46	3.07e-19	Mean corpuscular volume;
LUSC	cis	rs17604090	0.878	rs4000284	chr7:29726917	G/A	cg19413766	chr7:29689036	LOC646762	-0.68	-8.66	-0.43	2.05e-16	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg12257692	chr3:49977190	RBM6	-0.21	-5.7	-0.3	2.69e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg18904891	chr8:8559673	CLDN23	0.43	6.34	0.33	7.51e-10	Mood instability;
LUSC	trans	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg18187862	chr3:45730750	SACM1L	-0.54	-6.5	-0.34	2.98e-10	Primary sclerosing cholangitis;
LUSC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg06238570	chr21:40685208	BRWD1	-0.53	-8.21	-0.41	4.79e-15	Menarche (age at onset);
LUSC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg25258033	chr6:167368657	RNASET2	0.37	5.76	0.3	1.91e-8	Primary biliary cholangitis;
LUSC	cis	rs10186029	0.676	rs10187830	chr2:213964796	C/G	cg08319019	chr2:214017104	IKZF2	0.6	8.84	0.44	5.61e-17	Systemic sclerosis;
LUSC	cis	rs6066835	1.000	rs6125448	chr20:47353178	G/A	cg18078177	chr20:47281410	PREX1	0.75	6.33	0.33	7.83e-10	Multiple myeloma;
LUSC	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.27	0.37	2.53e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4478858	0.684	rs4949369	chr1:31723845	T/A	cg00250761	chr1:31883323	NA	-0.33	-8.01	-0.4	1.93e-14	Alcohol dependence;
LUSC	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.57	-0.42	3.85e-16	Response to antipsychotic treatment;
LUSC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg18190219	chr22:46762943	CELSR1	-0.48	-6.0	-0.31	5.01e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23248424	chr5:179741104	GFPT2	-0.48	-7.3	-0.37	2.08e-12	Height;
LUSC	cis	rs12101261	1.000	rs12101261	chr14:81451229	C/T	cg06600135	chr14:81408086	NA	0.44	6.44	0.33	4.17e-10	Graves' disease;
LUSC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg05084668	chr3:125655381	ALG1L	-0.48	-6.79	-0.35	5.06e-11	Blood pressure (smoking interaction);
LUSC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg14004847	chr7:1930337	MAD1L1	-0.44	-6.41	-0.33	5.02e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg11764359	chr7:65958608	NA	0.54	6.96	0.36	1.83e-11	Aortic root size;
LUSC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg13395646	chr4:1353034	KIAA1530	-0.78	-13.06	-0.58	8.75e-32	Obesity-related traits;
LUSC	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg07169764	chr2:136633963	MCM6	-0.6	-7.9	-0.4	4.09e-14	Mosquito bite size;
LUSC	cis	rs9341835	0.709	rs4358600	chr6:64153219	G/A	cg00787780	chr6:64151745	NA	-0.33	-5.7	-0.3	2.57e-8	Schizophrenia;
LUSC	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg15557168	chr22:42548783	NA	-0.33	-5.69	-0.3	2.81e-8	Cognitive function;
LUSC	trans	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg25214090	chr10:38739885	LOC399744	0.43	6.68	0.34	1e-10	Corneal astigmatism;
LUSC	cis	rs965469	0.652	rs6051837	chr20:3388994	G/T	cg25506879	chr20:3388711	C20orf194	-0.47	-6.16	-0.32	2.12e-9	IFN-related cytopenia;
LUSC	cis	rs3931020	0.688	rs452242	chr1:75225625	G/T	cg21535942	chr1:75199100	CRYZ;TYW3	-0.46	-5.73	-0.3	2.19e-8	Resistin levels;
LUSC	trans	rs10758161	1.000	rs10758161	chr9:32755028	A/G	cg10613332	chr19:13368845	CACNA1A	0.37	6.1	0.32	2.9e-9	Immune response to anthrax vaccine;
LUSC	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.55e-13	Putamen volume;
LUSC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.76	0.39	1.01e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.88	17.27	0.69	3.45e-48	Menarche (age at onset);
LUSC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg06618935	chr21:46677482	NA	-0.39	-7.95	-0.4	2.83e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg00105475	chr2:10696890	NA	-0.45	-7.69	-0.39	1.67e-13	Prostate cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02513924	chr11:124823857	CCDC15	0.41	6.01	0.31	4.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg22638593	chr5:131593259	PDLIM4	0.41	6.54	0.34	2.35e-10	Blood metabolite levels;
LUSC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-0.91	-16.4	-0.67	9.03e-45	Cognitive function;
LUSC	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg04608330	chr12:45269318	NELL2	0.55	8.98	0.44	1.98e-17	Gut microbiome composition (summer);
LUSC	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg23029597	chr12:123009494	RSRC2	-0.69	-9.39	-0.46	9.83e-19	Body mass index;
LUSC	cis	rs981844	0.775	rs17299561	chr4:154765480	C/T	cg14289246	chr4:154710475	SFRP2	0.51	6.89	0.35	2.87e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-9.82	-0.47	3.69e-20	Schizophrenia;
LUSC	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg18721089	chr20:30220636	NA	-0.35	-6.01	-0.31	4.91e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09368129	chr5:140071347	HARS2;HARS	0.43	6.14	0.32	2.34e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.93	-13.04	-0.58	1.08e-31	Initial pursuit acceleration;
LUSC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.5	0.34	2.87e-10	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg04450456	chr4:17643702	FAM184B	0.41	7.0	0.36	1.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08677398	chr8:58056175	NA	0.52	7.0	0.36	1.41e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.8	13.03	0.58	1.16e-31	Selective IgA deficiency;
LUSC	cis	rs7508	0.511	rs208056	chr8:17822884	C/T	cg01800426	chr8:17659068	MTUS1	-0.49	-6.1	-0.32	2.98e-9	Atrial fibrillation;
LUSC	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg10253484	chr15:75165896	SCAMP2	-0.5	-7.34	-0.37	1.61e-12	Breast cancer;
LUSC	cis	rs4654899	0.758	rs6693055	chr1:21421813	C/T	cg01072550	chr1:21505969	NA	-0.51	-7.78	-0.39	9.1e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg05738196	chr6:26577821	NA	0.81	15.7	0.65	5.64e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs8048589	0.604	rs62038898	chr16:12223637	A/G	cg02910054	chr16:12241554	SNX29	0.47	5.8	0.3	1.56e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg09034736	chr1:150693464	HORMAD1	0.46	6.62	0.34	1.45e-10	Melanoma;
LUSC	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-0.98	-12.25	-0.56	9.56e-29	Blood pressure (smoking interaction);
LUSC	cis	rs11955175	1.000	rs79575541	chr5:40672422	C/G	cg04002187	chr5:40835754	RPL37	0.67	5.87	0.31	1.04e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg08847533	chr14:75593920	NEK9	-0.55	-8.18	-0.41	6.01e-15	Neuroticism;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07421368	chr2:67624930	ETAA1	0.38	6.14	0.32	2.32e-9	Triglycerides;
LUSC	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.86	-0.44	4.82e-17	Breast cancer;
LUSC	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12367572	0.965	rs10785539	chr12:45233023	G/C	cg04608330	chr12:45269318	NELL2	-0.57	-9.26	-0.45	2.6e-18	Gut microbiome composition (summer);
LUSC	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	7.54	0.38	4.47e-13	Educational attainment;
LUSC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg02038168	chr22:39784481	NA	-0.47	-7.53	-0.38	4.64e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg00095276	chr5:1068111	SLC12A7	0.45	6.32	0.33	8.34e-10	Cognitive function;Information processing speed;
LUSC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg14092988	chr3:52407081	DNAH1	0.32	6.27	0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs7575217	0.643	rs2309996	chr2:101735838	T/G	cg23907051	chr2:101730305	TBC1D8	-0.28	-7.59	-0.38	3.24e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs11229555	0.645	rs12273638	chr11:58186335	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.76	-0.39	1.05e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2361710	0.611	rs3816257	chr17:78074446	G/T	cg06718696	chr17:78121285	EIF4A3	-0.59	-8.82	-0.43	6.43e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg08999081	chr20:33150536	PIGU	0.43	7.84	0.39	6.3e-14	Coronary artery disease;
LUSC	cis	rs7804356	1.000	rs17315334	chr7:26852860	G/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg18904891	chr8:8559673	CLDN23	0.55	7.56	0.38	3.95e-13	Obesity-related traits;
LUSC	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	7.99	0.4	2.26e-14	Iron status biomarkers;
LUSC	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg23752985	chr2:85803571	VAMP8	0.29	6.08	0.32	3.25e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg26061582	chr7:22766209	IL6	0.46	6.47	0.33	3.41e-10	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUSC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg15212455	chr7:39170539	POU6F2	-0.64	-10.67	-0.5	4.67e-23	IgG glycosylation;
LUSC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg22823121	chr1:150693482	HORMAD1	0.59	9.05	0.44	1.17e-17	Tonsillectomy;
LUSC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg23791538	chr6:167370224	RNASET2	0.41	6.6	0.34	1.64e-10	Crohn's disease;
LUSC	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg25281562	chr12:121454272	C12orf43	0.43	5.71	0.3	2.5e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	trans	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg11887960	chr12:57824829	NA	0.54	6.73	0.35	7.51e-11	Obesity-related traits;
LUSC	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg18200150	chr17:30822561	MYO1D	0.36	6.85	0.35	3.56e-11	Schizophrenia;
LUSC	cis	rs10905065	0.965	rs10795541	chr10:5811954	A/G	cg11519256	chr10:5708881	ASB13	-0.44	-6.56	-0.34	2.05e-10	Menopause (age at onset);
LUSC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg19539972	chr4:7069911	GRPEL1	0.71	8.92	0.44	3.19e-17	Monocyte percentage of white cells;
LUSC	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.66	0.65	7.82e-42	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	9.71	0.47	8.24e-20	Lymphocyte percentage of white cells;
LUSC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg16545954	chr1:2118288	C1orf86	-0.35	-6.73	-0.35	7.36e-11	Height;
LUSC	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg04607235	chr12:12878440	APOLD1	-0.48	-5.79	-0.3	1.64e-8	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg06937882	chr20:24974362	C20orf3	-0.42	-7.22	-0.37	3.45e-12	Blood protein levels;
LUSC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.67	0.43	1.96e-16	Motion sickness;
LUSC	cis	rs9303280	0.806	rs36095411	chr17:38031865	T/G	cg10909506	chr17:38081995	ORMDL3	0.35	6.05	0.31	3.84e-9	Self-reported allergy;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26044038	chr1:113261488	NA	-0.4	-6.05	-0.31	3.98e-9	Electrocardiographic conduction measures;
LUSC	trans	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg25815440	chr2:42134162	NA	-0.25	-5.96	-0.31	6.49e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.38	-0.37	1.31e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg19266014	chr7:2183958	MAD1L1	-0.35	-5.91	-0.31	8.66e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	trans	rs17007017	1.000	rs11100712	chr4:142160229	C/T	cg23562473	chr19:51334972	KLK15	0.3	6.16	0.32	2.09e-9	Conduct disorder;
LUSC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.46	-6.07	-0.31	3.57e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.52	-0.34	2.56e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg04414720	chr1:150670196	GOLPH3L	0.51	7.81	0.39	7.35e-14	Melanoma;
LUSC	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.73	11.12	0.52	1.21e-24	Alcohol dependence;
LUSC	cis	rs7681440	0.583	rs2737034	chr4:90777464	C/G	cg06632027	chr4:90757378	SNCA	-0.37	-5.75	-0.3	1.99e-8	Dementia with Lewy bodies;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12698343	chr2:158485436	ACVR1C	-0.38	-6.13	-0.32	2.48e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2970818	0.614	rs11063213	chr12:4632967	A/G	cg11146114	chr12:4671731	NA	-0.57	-6.06	-0.31	3.63e-9	Phosphorus levels;
LUSC	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg00321850	chr1:175162397	KIAA0040	-0.43	-7.4	-0.38	1.14e-12	Alcohol dependence;
LUSC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	8.74	0.43	1.13e-16	Exhaled nitric oxide output;
LUSC	cis	rs1858037	0.836	rs1396209	chr2:65601234	A/G	cg08085232	chr2:65598271	SPRED2	-0.42	-6.27	-0.32	1.09e-9	Rheumatoid arthritis;
LUSC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg01503450	chr10:980765	NA	-0.39	-5.72	-0.3	2.34e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs4499344	0.881	rs6510263	chr19:33067367	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.61	-7.73	-0.39	1.29e-13	Mean platelet volume;
LUSC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg08508325	chr11:3079039	CARS	-0.55	-13.66	-0.6	4.51e-34	Longevity;
LUSC	cis	rs9311676	0.632	rs57700771	chr3:58360327	G/A	cg13750441	chr3:58318267	PXK	0.34	6.66	0.34	1.1e-10	Systemic lupus erythematosus;
LUSC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.39e-8	Aortic root size;
LUSC	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg06636001	chr8:8085503	FLJ10661	0.62	9.55	0.46	2.94e-19	Neuroticism;
LUSC	cis	rs10904908	0.763	rs10795469	chr10:17334935	A/G	cg01003015	chr10:17271136	VIM	0.42	5.91	0.31	8.52e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs7264396	0.887	rs6060435	chr20:34069370	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.4	6.21	0.32	1.57e-9	Total cholesterol levels;
LUSC	trans	rs62238980	0.614	rs116982428	chr22:32381272	G/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs12760731	0.565	rs78577576	chr1:178141982	A/G	cg00404053	chr1:178313656	RASAL2	0.66	6.8	0.35	4.85e-11	Obesity-related traits;
LUSC	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg22705602	chr4:152727874	NA	0.36	7.73	0.39	1.31e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg02951883	chr7:2050386	MAD1L1	-0.35	-5.94	-0.31	7.07e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg27487227	chr17:77813221	CBX4	0.38	6.05	0.31	3.85e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9359856	0.518	rs11962279	chr6:90233695	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.58	-6.04	-0.31	4.19e-9	Bipolar disorder;
LUSC	cis	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg02972257	chr16:68554789	NA	-0.51	-6.57	-0.34	1.94e-10	Ulcerative colitis;
LUSC	cis	rs11608355	0.618	rs11066368	chr12:109790342	C/T	cg19025524	chr12:109796872	NA	-0.47	-9.01	-0.44	1.67e-17	Neuroticism;
LUSC	trans	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-6.74	-0.35	6.9e-11	Endometrial cancer;
LUSC	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg26893861	chr17:41843967	DUSP3	0.87	13.46	0.59	2.75e-33	Triglycerides;
LUSC	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg17470449	chr10:769945	NA	0.54	7.31	0.37	1.96e-12	Uric acid levels;
LUSC	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg10518543	chr12:38710700	ALG10B	0.41	5.79	0.3	1.62e-8	Morning vs. evening chronotype;
LUSC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg17971929	chr21:40555470	PSMG1	-0.48	-6.96	-0.36	1.83e-11	Menarche (age at onset);
LUSC	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg24375607	chr4:120327624	NA	0.77	11.23	0.52	4.84e-25	Corneal astigmatism;
LUSC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg15448220	chr1:150897856	SETDB1	0.41	5.88	0.31	9.89e-9	Melanoma;
LUSC	trans	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.48	0.33	3.25e-10	Corneal astigmatism;
LUSC	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.68e-19	Airflow obstruction;
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.51	-7.82	-0.39	6.83e-14	Lymphocyte counts;
LUSC	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg21521518	chr4:53727714	RASL11B	0.44	5.78	0.3	1.73e-8	Optic nerve measurement (cup area);
LUSC	cis	rs9811920	0.965	rs9837131	chr3:99854514	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.35	6.64	0.34	1.26e-10	Axial length;
LUSC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.82	-13.32	-0.59	9.32e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs4148689	0.904	rs10953847	chr7:117191819	T/C	cg10450175	chr16:88689712	ZC3H18	0.47	6.09	0.32	3.08e-9	Gout;
LUSC	cis	rs11971779	0.648	rs10230407	chr7:139103893	A/G	cg23387468	chr7:139079360	LUC7L2	0.42	6.3	0.33	9.36e-10	Diisocyanate-induced asthma;
LUSC	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.9	20.74	0.75	5.32e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg21775007	chr8:11205619	TDH	-0.41	-5.79	-0.3	1.62e-8	Monocyte count;
LUSC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg17366294	chr4:99064904	C4orf37	0.61	10.91	0.51	6.72e-24	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.19	0.32	1.77e-9	Neuroticism;
LUSC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg01765077	chr12:122356316	WDR66	0.5	7.28	0.37	2.47e-12	Mean corpuscular volume;
LUSC	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg22029157	chr1:209979665	IRF6	0.74	8.76	0.43	9.93e-17	Cleft lip with or without cleft palate;
LUSC	trans	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.75	0.47	6.15e-20	Mean corpuscular volume;
LUSC	cis	rs2835872	0.896	rs721014	chr21:39008109	A/G	cg20424643	chr21:39039972	KCNJ6	-0.39	-6.03	-0.31	4.26e-9	Electroencephalographic traits in alcoholism;
LUSC	trans	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-11.02	-0.52	2.75e-24	Colorectal cancer;
LUSC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg04608330	chr12:45269318	NELL2	-0.58	-9.3	-0.45	1.96e-18	Gut microbiome composition (summer);
LUSC	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg09835421	chr16:68378352	PRMT7	0.68	7.2	0.37	3.97e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.45	-8.15	-0.41	7.36e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01570182	chr17:44337453	NA	0.71	10.62	0.5	6.7e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg22903657	chr4:1355424	KIAA1530	-0.47	-7.88	-0.4	4.59e-14	Obesity-related traits;
LUSC	cis	rs4343996	1.000	rs6959702	chr7:3356286	G/C	cg21248987	chr7:3385318	SDK1	-0.38	-6.5	-0.34	2.9e-10	Motion sickness;
LUSC	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg13010199	chr12:38710504	ALG10B	0.43	6.17	0.32	2e-9	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.79	13.07	0.58	8.12e-32	Aortic root size;
LUSC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-9.95	-0.48	1.31e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.27	-0.32	1.1e-9	Total body bone mineral density;
LUSC	trans	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg20587970	chr11:113659929	NA	-0.98	-12.25	-0.56	9.9e-29	Hip circumference adjusted for BMI;
LUSC	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg03522245	chr20:25566470	NINL	-0.35	-5.71	-0.3	2.45e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg18390621	chr1:3553628	WDR8	-0.39	-6.08	-0.32	3.23e-9	N-glycan levels;
LUSC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg12463550	chr7:65579703	CRCP	0.42	6.04	0.31	4.09e-9	Calcium levels;
LUSC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.5	-8.62	-0.43	2.77e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg05901451	chr6:126070800	HEY2	0.57	8.76	0.43	1.03e-16	Endometrial cancer;
LUSC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg09796270	chr17:17721594	SREBF1	-0.45	-7.9	-0.4	4.09e-14	Strep throat;
LUSC	cis	rs17401966	0.540	rs1467653	chr1:10413123	A/G	cg19773385	chr1:10388646	KIF1B	0.37	6.48	0.33	3.33e-10	Hepatocellular carcinoma;
LUSC	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg23752985	chr2:85803571	VAMP8	0.36	7.77	0.39	9.6e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg16325326	chr1:53192061	ZYG11B	-0.88	-16.23	-0.66	4.26e-44	Monocyte count;
LUSC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg11812906	chr14:75593930	NEK9	-0.63	-10.39	-0.49	4.37e-22	Height;
LUSC	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg03522245	chr20:25566470	NINL	-0.35	-5.69	-0.3	2.85e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg14456004	chr13:21872349	NA	0.43	6.01	0.31	4.74e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg23985595	chr17:80112537	CCDC57	0.33	6.29	0.33	1.01e-9	Life satisfaction;
LUSC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.1	-0.32	2.98e-9	Total body bone mineral density;
LUSC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg25072359	chr17:41440525	NA	0.56	8.35	0.42	1.79e-15	Menopause (age at onset);
LUSC	cis	rs7809950	0.817	rs2807	chr7:107260778	G/A	cg23024343	chr7:107201750	COG5	0.66	9.63	0.47	1.5700000000000001e-19	Coronary artery disease;
LUSC	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg25206134	chr2:45395956	NA	0.59	6.91	0.35	2.4e-11	Bipolar disorder;
LUSC	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.14	0.32	2.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs78572108	0.858	rs13409978	chr2:42265702	A/C	cg00607755	chr2:42274082	PKDCC	0.34	6.17	0.32	1.94e-9	Total body bone mineral density;
LUSC	cis	rs55882075	0.537	rs62406698	chr5:179110429	C/T	cg14593053	chr5:179126677	CANX	0.38	5.93	0.31	7.71e-9	Monocyte percentage of white cells;
LUSC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	0.67	12.07	0.55	4.42e-28	Total body bone mineral density;
LUSC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.55	5.77	0.3	1.8e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg13390004	chr1:15929781	NA	0.41	6.87	0.35	3.15e-11	Systolic blood pressure;
LUSC	cis	rs7267979	0.753	rs404148	chr20:25447931	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.77	15.22	0.64	4.14e-40	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg08917208	chr2:24149416	ATAD2B	0.86	9.71	0.47	8.84e-20	Lymphocyte counts;
LUSC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg17173187	chr15:85201210	NMB	0.37	6.4	0.33	5.31e-10	Schizophrenia;
LUSC	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg01884057	chr2:25150051	NA	0.43	10.03	0.48	7.09e-21	Body mass index in non-asthmatics;
LUSC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.74	-0.35	6.77e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	12.79	0.57	9.23e-31	Hip circumference adjusted for BMI;
LUSC	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg17376030	chr22:41985996	PMM1	-0.45	-5.97	-0.31	6.19e-9	Vitiligo;
LUSC	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg01448562	chr3:133502909	NA	-0.52	-7.75	-0.39	1.12e-13	Iron status biomarkers;
LUSC	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	10.48	0.5	2.1e-22	Monocyte percentage of white cells;
LUSC	cis	rs3733418	0.929	rs13120990	chr4:165905118	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-5.93	-0.31	7.64e-9	Obesity-related traits;
LUSC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.28	0.37	2.47e-12	Mean platelet volume;
LUSC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg20821713	chr7:1055600	C7orf50	-0.46	-6.91	-0.35	2.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.06e-12	Motion sickness;
LUSC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.06	-0.55	4.59e-28	Type 2 diabetes;
LUSC	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.73	0.3	2.2e-8	Lymphocyte counts;
LUSC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-1.0	-14.65	-0.63	7.31e-38	Initial pursuit acceleration;
LUSC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.3	0.41	2.67e-15	Prudent dietary pattern;
LUSC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg06618935	chr21:46677482	NA	0.36	7.28	0.37	2.35e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg22532475	chr10:104410764	TRIM8	0.26	6.07	0.32	3.5e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20703375	chr7:98957328	ARPC1A	-0.4	-6.24	-0.32	1.31e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg27170947	chr2:26402098	FAM59B	-0.67	-10.25	-0.49	1.29e-21	Gut microbiome composition (summer);
LUSC	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.5	-6.86	-0.35	3.31e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2267681	0.508	rs4726815	chr7:139514460	C/G	cg14116596	chr7:139528673	TBXAS1	0.36	6.31	0.33	9.11e-10	Cervical cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07077507	chr14:89290791	TTC8	0.33	6.0	0.31	5.15e-9	Triglycerides;
LUSC	cis	rs4474465	0.790	rs4945293	chr11:78254554	T/C	cg27205649	chr11:78285834	NARS2	0.52	6.2	0.32	1.7e-9	Alzheimer's disease (survival time);
LUSC	trans	rs4942242	0.663	rs9590779	chr13:44234886	A/G	cg19169023	chr15:41853346	TYRO3	0.61	9.36	0.46	1.24e-18	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg24399712	chr22:39784796	NA	-0.63	-11.38	-0.53	1.38e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg21724239	chr8:58056113	NA	0.56	6.86	0.35	3.37e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg22153463	chr1:85462885	MCOLN2	-0.66	-8.14	-0.41	7.78e-15	Serum sulfate level;
LUSC	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.68	-0.47	1.04e-19	Coronary artery disease;
LUSC	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg24692254	chr21:30365293	RNF160	0.66	10.22	0.49	1.68e-21	Selective IgA deficiency;
LUSC	cis	rs12760731	0.720	rs35781686	chr1:178261262	G/A	cg00404053	chr1:178313656	RASAL2	0.64	6.76	0.35	6.32e-11	Obesity-related traits;
LUSC	trans	rs76248362	1.000	rs4770507	chr13:24434744	T/G	cg26511321	chr7:27196790	HOXA7	0.54	6.24	0.32	1.35e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	12.66	0.57	2.81e-30	Cognitive test performance;
LUSC	cis	rs6693567	0.565	rs10157197	chr1:150250636	G/A	cg09579323	chr1:150459698	TARS2	-0.43	-6.03	-0.31	4.43e-9	Migraine;
LUSC	cis	rs6591182	0.935	rs11606601	chr11:65354439	C/G	cg27068330	chr11:65405492	SIPA1	-0.47	-6.58	-0.34	1.79e-10	Non-alcoholic fatty liver disease histology (lobular);
LUSC	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg00852783	chr1:26633632	UBXN11	0.49	8.71	0.43	1.45e-16	Obesity-related traits;
LUSC	cis	rs62400317	0.762	rs62436374	chr6:44874785	C/G	cg20913747	chr6:44695427	NA	-0.48	-7.44	-0.38	8.79e-13	Total body bone mineral density;
LUSC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg26850624	chr5:429559	AHRR	-0.43	-8.43	-0.42	1.08e-15	Cystic fibrosis severity;
LUSC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	19.1	0.72	1.79e-55	Chronic sinus infection;
LUSC	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg21775007	chr8:11205619	TDH	0.44	6.27	0.32	1.09e-9	Mood instability;
LUSC	cis	rs13089785	1.000	rs13071800	chr3:123626813	C/A	cg01860459	chr3:123419554	MYLK	0.35	5.95	0.31	6.6e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs11264799	0.765	rs12136747	chr1:157636930	C/G	cg25498969	chr3:136062740	STAG1	0.23	5.99	0.31	5.46e-9	IgA nephropathy;
LUSC	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-6.7	-0.34	8.96e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg15147215	chr3:52552868	STAB1	-0.3	-6.08	-0.32	3.29e-9	Bipolar disorder;
LUSC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	13.35	0.59	7.2e-33	Menarche (age at onset);
LUSC	cis	rs7215564	0.730	rs2316066	chr17:78659785	A/G	cg23238734	chr17:78661607	RPTOR	0.47	6.1	0.32	3e-9	Myopia (pathological);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg19603075	chr15:89010536	MRPS11;MRPL46	0.45	6.26	0.32	1.18e-9	Mosquito bite size;
LUSC	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg12165864	chr7:66369176	NA	-0.54	-7.26	-0.37	2.8e-12	Corneal structure;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg14916315	chr19:4581550	NA	0.73	5.97	0.31	5.93e-9	Cognitive performance;
LUSC	trans	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg05059571	chr16:84539110	KIAA1609	-0.47	-8.95	-0.44	2.49e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-8.27	-0.41	3.23e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.31	-0.33	8.95e-10	Bipolar disorder;
LUSC	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg08601574	chr20:25228251	PYGB	-0.44	-6.79	-0.35	5.03e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7851660	0.874	rs10818175	chr9:100633386	T/C	cg13688889	chr9:100608707	NA	-0.56	-8.91	-0.44	3.48e-17	Strep throat;
LUSC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	0.96	16.31	0.67	2.17e-44	Menopause (age at onset);
LUSC	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7539409	0.651	rs970457	chr1:84296540	C/T	cg10977910	chr1:84465055	TTLL7	0.65	6.8	0.35	4.97e-11	Alzheimer's disease;
LUSC	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg12863693	chr15:85201151	NMB	0.36	6.93	0.35	2.24e-11	Schizophrenia;
LUSC	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	7.02	0.36	1.24e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg07148914	chr20:33460835	GGT7	0.57	8.62	0.43	2.74e-16	Height;
LUSC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17219203	chr10:38645113	HSD17B7P2	0.4	5.81	0.3	1.48e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg24642439	chr20:33292090	TP53INP2	0.47	7.17	0.37	4.84e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs28655083	1.000	rs1875582	chr16:77063147	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	5.95	0.31	6.86e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2835872	1.000	rs2835872	chr21:39027272	G/A	cg20424643	chr21:39039972	KCNJ6	0.48	7.13	0.36	6.13e-12	Electroencephalographic traits in alcoholism;
LUSC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg17294928	chr15:75287854	SCAMP5	-0.9	-12.79	-0.57	8.94e-31	Blood trace element (Zn levels);
LUSC	trans	rs2587949	0.577	rs2166024	chr3:4211758	C/A	cg15139668	chr4:4577005	NA	0.41	6.08	0.32	3.23e-9	Periodontitis (DPAL);
LUSC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	16.76	0.68	3.58e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05181322	chr16:19078982	COQ7	-0.45	-6.13	-0.32	2.47e-9	Hepatitis;
LUSC	cis	rs1322512	1.000	rs1282551	chr6:153009944	C/T	cg27316956	chr6:152958899	SYNE1	0.35	6.06	0.31	3.59e-9	Tonometry;
LUSC	cis	rs1322512	1.000	rs9371626	chr6:153008926	G/A	cg27316956	chr6:152958899	SYNE1	0.35	6.06	0.31	3.59e-9	Tonometry;
LUSC	cis	rs10979	0.679	rs9321918	chr6:143883460	T/C	cg25407410	chr6:143891975	LOC285740	-0.64	-8.67	-0.43	1.86e-16	Hypospadias;
LUSC	cis	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg07460842	chr6:66804631	NA	-0.48	-6.72	-0.35	7.74e-11	Blood trace element (Cu levels);
LUSC	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	6.52	0.34	2.57e-10	Neuroticism;
LUSC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg21770322	chr7:97807741	LMTK2	0.4	7.01	0.36	1.31e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg17462356	chr17:80056334	FASN	-0.44	-6.08	-0.32	3.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	7.62	0.38	2.61e-13	Prudent dietary pattern;
LUSC	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg18825076	chr15:78729989	IREB2	-0.63	-9.96	-0.48	1.23e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.59	-0.38	3.25e-13	Personality dimensions;
LUSC	cis	rs9517320	1.000	rs7994160	chr13:99132749	C/A	cg20487152	chr13:99095054	FARP1	0.34	6.27	0.32	1.09e-9	Longevity;
LUSC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06028605	chr16:24865363	SLC5A11	0.68	10.63	0.5	6.19e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg09184832	chr6:79620586	NA	-0.44	-7.1	-0.36	7.73e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg12863693	chr15:85201151	NMB	0.35	6.89	0.35	2.86e-11	Schizophrenia;
LUSC	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-0.89	-12.9	-0.58	3.52e-31	Blood pressure (smoking interaction);
LUSC	cis	rs3857536	0.813	rs7766786	chr6:66932889	C/A	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.56e-10	Blood trace element (Cu levels);
LUSC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06850241	chr22:41845214	NA	0.32	5.83	0.3	1.28e-8	Vitiligo;
LUSC	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.93	15.94	0.66	5.93e-43	Bladder cancer;
LUSC	cis	rs4917833	0.789	rs1060445	chr10:100218766	C/T	cg19043522	chr10:100227446	HPSE2	0.41	5.87	0.31	1.06e-8	Pediatric bone mineral density (femoral neck);
LUSC	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.2	-0.52	6.27e-25	Mean corpuscular volume;
LUSC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg03609598	chr5:56110824	MAP3K1	-0.41	-5.87	-0.31	1.04e-8	Initial pursuit acceleration;
LUSC	trans	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg06521331	chr12:34319734	NA	-0.4	-6.18	-0.32	1.88e-9	Bladder cancer;
LUSC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg04733989	chr22:42467013	NAGA	0.63	9.69	0.47	1.02e-19	Schizophrenia;
LUSC	cis	rs926938	0.563	rs360630	chr1:115415132	C/T	cg01522456	chr1:115632236	TSPAN2	-0.38	-5.77	-0.3	1.82e-8	Autism;
LUSC	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.24	-0.32	1.3e-9	Bipolar disorder;
LUSC	cis	rs870825	0.655	rs28604350	chr4:185638723	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	13.12	0.58	5.36e-32	Blood protein levels;
LUSC	cis	rs2346177	0.875	rs2346178	chr2:46647061	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.37	6.32	0.33	8.54e-10	HDL cholesterol;
LUSC	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.25	0.32	1.25e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.72	-0.3	2.39e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9630089	0.622	rs7906782	chr10:98961596	C/T	cg07221526	chr10:99185307	PGAM1	0.33	5.65	0.3	3.49e-8	Neutrophil percentage of white cells;
LUSC	cis	rs9815354	0.812	rs73828505	chr3:42042714	C/T	cg03022575	chr3:42003672	ULK4	0.6	6.33	0.33	7.76e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg07460842	chr6:66804631	NA	0.47	5.8	0.3	1.53e-8	Metabolite levels;
LUSC	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-8.67	-0.43	1.93e-16	Response to antipsychotic treatment;
LUSC	cis	rs422249	0.634	rs174614	chr11:61628915	T/C	cg06860612	chr11:61641270	FADS3	0.28	5.86	0.31	1.09e-8	Trans fatty acid levels;
LUSC	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.55	0.38	4.06e-13	Iron status biomarkers;
LUSC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg08859206	chr1:53392774	SCP2	0.49	8.26	0.41	3.56e-15	Monocyte count;
LUSC	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg22029157	chr1:209979665	IRF6	0.52	8.47	0.42	7.93e-16	Monobrow;
LUSC	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg20302533	chr7:39170763	POU6F2	0.51	7.94	0.4	3.05e-14	IgG glycosylation;
LUSC	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg00898013	chr13:113819073	PROZ	-0.56	-8.08	-0.4	1.21e-14	Platelet distribution width;
LUSC	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg26446133	chr18:72167187	CNDP2	-0.79	-9.76	-0.47	5.72e-20	Refractive error;
LUSC	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.57	8.9	0.44	3.72e-17	Menopause (age at onset);
LUSC	cis	rs4631830	0.863	rs10826125	chr10:51530505	G/A	cg10326726	chr10:51549505	MSMB	-0.37	-6.32	-0.33	8.4e-10	Prostate-specific antigen levels;
LUSC	cis	rs9928842	1.000	rs7202566	chr16:75247644	C/A	cg09066997	chr16:75300724	BCAR1	0.53	6.34	0.33	7.41e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.48	7.47	0.38	7.16e-13	Schizophrenia;
LUSC	cis	rs3931020	0.657	rs10890142	chr1:75179129	G/A	cg21535942	chr1:75199100	CRYZ;TYW3	0.46	5.75	0.3	2.06e-8	Resistin levels;
LUSC	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg00310523	chr12:86230176	RASSF9	0.42	7.87	0.4	5.05e-14	Major depressive disorder;
LUSC	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg00806126	chr19:22604979	ZNF98	0.37	5.71	0.3	2.5e-8	Pain;
LUSC	trans	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	10.26	0.49	1.16e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg16850897	chr7:100343110	ZAN	0.37	5.89	0.31	9.47e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26317405	chr11:67188521	ATPGD1	0.44	5.96	0.31	6.36e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1163251	0.902	rs627707	chr1:120217133	C/G	cg19096424	chr1:120255104	PHGDH	0.48	6.53	0.34	2.39e-10	Blood metabolite levels;
LUSC	cis	rs9400467	0.528	rs10872067	chr6:111788391	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.32	-0.33	8.41e-10	Blood metabolite levels;Amino acid levels;
LUSC	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg13010199	chr12:38710504	ALG10B	0.53	8.06	0.4	1.38e-14	Morning vs. evening chronotype;
LUSC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.12e-18	Menopause (age at onset);
LUSC	cis	rs911119	1.000	rs35488434	chr20:23620401	T/C	cg16589663	chr20:23618590	CST3	0.59	6.95	0.36	1.9e-11	Chronic kidney disease;
LUSC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg14703610	chr5:56206110	C5orf35	0.39	5.66	0.3	3.19e-8	Coronary artery disease;
LUSC	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.7	11.72	0.54	8.25e-27	Colorectal cancer;
LUSC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.67	11.29	0.53	2.84e-25	Blood protein levels;
LUSC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10761482	0.813	rs2169081	chr10:62102389	G/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	0.87	12.71	0.57	1.93e-30	Vitiligo;
LUSC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.96	-0.36	1.84e-11	Aortic root size;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg17502267	chr15:59981239	BNIP2	-0.45	-6.02	-0.31	4.48e-9	Cognitive function;Information processing speed;
LUSC	cis	rs6967385	0.560	rs10248602	chr7:12347113	G/C	cg20607287	chr7:12443886	VWDE	0.5	7.51	0.38	5.31e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	1.3	11.92	0.55	1.51e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.49	-6.89	-0.35	2.81e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.36	6.09	0.32	3.1e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg22709100	chr7:91322751	NA	0.39	5.7	0.3	2.58e-8	Breast cancer;
LUSC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg18681998	chr4:17616180	MED28	0.85	15.67	0.65	6.85e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7539409	0.604	rs6689821	chr1:84316605	A/G	cg10977910	chr1:84465055	TTLL7	0.75	7.9	0.4	4.07e-14	Alzheimer's disease;
LUSC	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg26924012	chr15:45694286	SPATA5L1	0.81	12.93	0.58	2.68e-31	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	8.09e-13	Motion sickness;
LUSC	cis	rs7094131	0.523	rs10764342	chr10:22882081	A/G	cg19500236	chr10:22911537	PIP4K2A	0.36	6.31	0.33	8.99e-10	Obesity-related traits;
LUSC	cis	rs12618769	0.625	rs113342082	chr2:99034198	G/A	cg10123293	chr2:99228465	UNC50	0.47	7.9	0.4	3.99e-14	Bipolar disorder;
LUSC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg01657329	chr11:68192670	LRP5	-0.45	-7.24	-0.37	3.17e-12	Total body bone mineral density;
LUSC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.66	0.39	2.07e-13	Prudent dietary pattern;
LUSC	cis	rs12891047	0.804	rs72725114	chr14:68317854	G/A	cg20999565	chr14:68265668	ZFYVE26	0.39	5.86	0.31	1.11e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs983392	0.680	rs11230201	chr11:59996994	C/G	cg02771260	chr11:59836817	MS4A3	-0.36	-5.93	-0.31	7.71e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4664304	0.772	rs12692572	chr2:160743793	G/A	cg03641300	chr2:160917029	PLA2R1	0.35	5.68	0.3	2.91e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg12432903	chr7:1882776	MAD1L1	0.44	6.05	0.31	3.79e-9	Bipolar disorder;
LUSC	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.73	14.19	0.61	4.47e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg11062466	chr8:58055876	NA	0.51	7.05	0.36	1.06e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg17279839	chr7:150038598	RARRES2	0.45	6.93	0.35	2.24e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.35	-0.42	1.87e-15	Total cholesterol levels;
LUSC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-1.01	-17.92	-0.7	8.54e-51	Coronary artery disease;
LUSC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg26924012	chr15:45694286	SPATA5L1	1.14	20.79	0.75	3.36e-62	Homoarginine levels;
LUSC	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.29	0.33	1.02e-9	Rheumatoid arthritis;
LUSC	cis	rs806215	0.950	rs3757793	chr7:127225780	G/A	cg25922125	chr7:127225783	GCC1	-0.61	-7.4	-0.38	1.11e-12	Type 2 diabetes;
LUSC	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg18357645	chr12:58087776	OS9	0.51	7.46	0.38	7.74e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg17366294	chr4:99064904	C4orf37	-0.56	-10.09	-0.48	4.4e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.5	7.05	0.36	1e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg22029157	chr1:209979665	IRF6	0.75	8.41	0.42	1.24e-15	Coronary artery disease;
LUSC	cis	rs7605827	0.930	rs3805105	chr2:15535312	T/A	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg15147215	chr3:52552868	STAB1	-0.32	-6.33	-0.33	7.69e-10	Electroencephalogram traits;
LUSC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.46e-35	Breast cancer;
LUSC	trans	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg02030672	chr11:45687055	CHST1	0.5	8.09	0.4	1.12e-14	Obesity-related traits;
LUSC	cis	rs7927771	0.524	rs6485786	chr11:47837408	G/C	cg20307385	chr11:47447363	PSMC3	0.45	6.5	0.34	2.94e-10	Subjective well-being;
LUSC	cis	rs16854884	0.770	rs920158	chr3:143799289	A/T	cg06585982	chr3:143692056	C3orf58	0.45	6.79	0.35	5.13e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg12365402	chr11:9010492	NRIP3	0.47	8.96	0.44	2.41e-17	Hemoglobin concentration;
LUSC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg00376283	chr12:123451042	ABCB9	0.69	9.81	0.47	3.98e-20	Neutrophil percentage of white cells;
LUSC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.61	-8.14	-0.41	7.98e-15	Systemic lupus erythematosus;
LUSC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg18225595	chr11:63971243	STIP1	0.65	11.24	0.52	4.33e-25	Platelet count;
LUSC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg03354898	chr7:1950403	MAD1L1	-0.42	-8.36	-0.42	1.69e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg03984733	chr9:116139085	HDHD3	0.5	6.38	0.33	5.81e-10	Cognitive function;Information processing speed;
LUSC	cis	rs7851660	0.967	rs4743134	chr9:100598568	C/A	cg13688889	chr9:100608707	NA	-0.6	-10.34	-0.49	6.18e-22	Strep throat;
LUSC	cis	rs7572644	0.766	rs11886375	chr2:28155748	A/C	cg27432699	chr2:27873401	GPN1	0.53	6.54	0.34	2.37e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg17450446	chr1:160002111	PIGM	0.44	6.16	0.32	2.15e-9	Neuroticism;
LUSC	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.69	10.48	0.5	2.02e-22	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01067626	chr5:133512870	SKP1	-0.41	-6.08	-0.32	3.37e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-12.02	-0.55	6.75e-28	Colorectal cancer;
LUSC	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg02574844	chr11:5959923	NA	-0.45	-6.26	-0.32	1.2e-9	DNA methylation (variation);
LUSC	cis	rs2835872	0.965	rs857975	chr21:39001613	T/G	cg20424643	chr21:39039972	KCNJ6	-0.4	-6.09	-0.32	3.09e-9	Electroencephalographic traits in alcoholism;
LUSC	trans	rs12885221	0.542	rs7146994	chr14:33275517	A/T	cg10551270	chr5:892523	TRIP13;BRD9	-0.39	-5.95	-0.31	6.94e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg07741184	chr6:167504864	NA	-0.33	-5.8	-0.3	1.57e-8	Primary biliary cholangitis;
LUSC	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	8.28	0.41	3.07e-15	Axial length;
LUSC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg12963246	chr6:28129442	ZNF389	0.52	7.12	0.36	6.72e-12	Depression;
LUSC	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg01557791	chr16:72042693	DHODH	-0.55	-7.91	-0.4	3.78e-14	Fibrinogen levels;
LUSC	cis	rs6733011	0.628	rs6542838	chr2:99452458	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.68	-0.34	9.98e-11	Bipolar disorder;
LUSC	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg26876637	chr1:152193138	HRNR	0.43	6.24	0.32	1.34e-9	Atopic dermatitis;
LUSC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23158103	chr7:148848205	ZNF398	-0.5	-8.06	-0.4	1.38e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.52	5.95	0.31	6.75e-9	Schizophrenia;
LUSC	cis	rs778371	0.748	rs1878287	chr2:233790649	G/T	cg08000102	chr2:233561755	GIGYF2	-0.6	-8.0	-0.4	2.05e-14	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04987883	chr5:153826560	SAP30L	0.44	6.31	0.33	9.02e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7119038	0.818	rs57494551	chr11:118661398	C/T	cg19308663	chr11:118741387	NA	0.4	6.8	0.35	4.79e-11	Sjögren's syndrome;
LUSC	cis	rs8113142	0.614	rs4804847	chr19:29127396	C/T	cg04546413	chr19:29218101	NA	0.43	5.94	0.31	7.07e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.19	30.59	0.86	6.84e-99	Testicular germ cell tumor;
LUSC	trans	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs12760731	0.565	rs12049568	chr1:178154345	A/G	cg00404053	chr1:178313656	RASAL2	0.66	6.8	0.35	4.85e-11	Obesity-related traits;
LUSC	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.37	0.46	1.16e-18	Lung cancer in ever smokers;
LUSC	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg00495681	chr13:53174319	NA	-0.6	-10.99	-0.52	3.38e-24	Lewy body disease;
LUSC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg03060546	chr3:49711283	APEH	0.7	11.78	0.54	5.06e-27	Resting heart rate;
LUSC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-6.38	-0.33	5.87e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.75	0.3	1.99e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg13010199	chr12:38710504	ALG10B	0.48	6.61	0.34	1.56e-10	Resting heart rate;
LUSC	trans	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-8.71	-0.43	1.42e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg25214090	chr10:38739885	LOC399744	0.56	7.82	0.39	7.03e-14	Corneal astigmatism;
LUSC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.94	0.61	3.82e-35	Platelet count;
LUSC	cis	rs2236918	0.932	rs1776131	chr1:242024245	T/A	cg17736920	chr1:242011382	EXO1	0.46	7.22	0.37	3.6e-12	Menopause (age at onset);
LUSC	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.82	-0.39	7.05e-14	Retinal vascular caliber;
LUSC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg18758796	chr5:131593413	PDLIM4	0.43	7.0	0.36	1.4e-11	Breast cancer;
LUSC	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg10840412	chr1:235813424	GNG4	0.45	6.0	0.31	5.2e-9	Bipolar disorder;
LUSC	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg13010199	chr12:38710504	ALG10B	0.48	7.49	0.38	6.31e-13	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.06	0.36	9.75e-12	Bipolar disorder;
LUSC	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg00173435	chr12:106696525	TCP11L2	0.61	8.82	0.43	6.31e-17	Tourette syndrome;
LUSC	cis	rs7119	0.651	rs8041398	chr15:77839173	A/G	cg27398640	chr15:77910606	LINGO1	-0.31	-6.44	-0.33	4.27e-10	Type 2 diabetes;
LUSC	cis	rs11030122	0.632	rs10835556	chr11:4083013	A/G	cg18678763	chr11:4115507	RRM1	-0.47	-6.29	-0.33	1e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9815354	0.556	rs73073276	chr3:42025354	G/A	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs981844	0.775	rs921884	chr4:154753059	G/A	cg14289246	chr4:154710475	SFRP2	-0.49	-6.73	-0.35	7.37e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg01652190	chr22:50026171	C22orf34	-0.31	-6.35	-0.33	7.04e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11764359	chr7:65958608	NA	0.68	11.03	0.52	2.49e-24	Aortic root size;
LUSC	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg24579218	chr15:68104479	NA	-0.38	-6.24	-0.32	1.36e-9	Restless legs syndrome;
LUSC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg23711669	chr6:146136114	FBXO30	0.9	17.22	0.69	5.31e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6464929	0.956	rs4727006	chr7:148704935	A/G	cg23583168	chr7:148888333	NA	0.46	5.83	0.3	1.31e-8	Pediatric bone mineral content (hip);
LUSC	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg08601574	chr20:25228251	PYGB	0.46	7.18	0.37	4.43e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.75	0.77	5.98e-66	Prudent dietary pattern;
LUSC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.61	8.46	0.42	8.64e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg27411982	chr8:10470053	RP1L1	0.37	5.71	0.3	2.55e-8	Retinal vascular caliber;
LUSC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.52	0.34	2.52e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg23029597	chr12:123009494	RSRC2	-0.74	-9.23	-0.45	3.1e-18	Body mass index;
LUSC	cis	rs34779708	0.931	rs7923172	chr10:35309367	G/A	cg03585969	chr10:35415529	CREM	0.61	8.82	0.43	6.24e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.11	-0.36	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.57	-9.51	-0.46	3.77e-19	Lung cancer;
LUSC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18357526	chr6:26021779	HIST1H4A	0.42	6.8	0.35	4.97e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2354432	0.556	rs4424557	chr1:146871119	A/G	cg25205988	chr1:146714368	CHD1L	0.88	7.86	0.39	5.45e-14	Mitochondrial DNA levels;
LUSC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.31	0.37	1.98e-12	Motion sickness;
LUSC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg05347473	chr6:146136440	FBXO30	0.41	6.91	0.35	2.54e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg17063962	chr7:91808500	NA	-0.56	-8.6	-0.43	3.19e-16	Breast cancer;
LUSC	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg21890820	chr11:65308645	LTBP3	0.51	7.55	0.38	4.3e-13	Bone mineral density;
LUSC	cis	rs11792861	0.566	rs11792635	chr9:111848819	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	7.09	0.36	7.8e-12	Menarche (age at onset);
LUSC	cis	rs1832871	0.683	rs11756200	chr6:158657736	A/G	cg07165851	chr6:158734300	TULP4	0.51	7.63	0.39	2.43e-13	Height;
LUSC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg21856205	chr7:94953877	PON1	-0.36	-5.8	-0.3	1.56e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg12826209	chr6:26865740	GUSBL1	0.66	7.76	0.39	1.04e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg15848620	chr12:58087721	OS9	-0.55	-7.83	-0.39	6.43e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6700896	0.931	rs11208716	chr1:66158825	C/T	cg04111102	chr1:66153794	NA	0.33	7.34	0.37	1.61e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg11766577	chr21:47581405	C21orf56	0.47	7.09	0.36	8.02e-12	Testicular germ cell tumor;
LUSC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg18350739	chr11:68623251	NA	0.38	6.9	0.35	2.55e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg00074818	chr8:8560427	CLDN23	0.55	9.39	0.46	9.44e-19	Obesity-related traits;
LUSC	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg05768032	chr16:30646687	NA	0.4	5.81	0.3	1.47e-8	Multiple myeloma;
LUSC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24549020	chr5:56110836	MAP3K1	0.51	5.82	0.3	1.39e-8	Type 2 diabetes;
LUSC	cis	rs4629180	0.586	rs1509495	chr2:102134834	C/T	cg01388757	chr2:102091195	RFX8	-0.37	-6.43	-0.33	4.49e-10	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs9309473	0.607	rs10196402	chr2:73572081	A/C	cg20560298	chr2:73613845	ALMS1	-0.49	-7.18	-0.37	4.69e-12	Metabolite levels;
LUSC	cis	rs2835872	0.759	rs2835900	chr21:39075749	G/T	cg20424643	chr21:39039972	KCNJ6	0.42	6.39	0.33	5.53e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs77741769	0.571	rs989986	chr12:121274178	A/C	cg02419362	chr12:121203948	SPPL3	0.46	8.57	0.42	3.78e-16	Mean corpuscular volume;
LUSC	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.89	14.84	0.63	1.26e-38	Bladder cancer;
LUSC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06850241	chr22:41845214	NA	-0.3	-5.73	-0.3	2.26e-8	Vitiligo;
LUSC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg25036284	chr2:26402008	FAM59B	-0.68	-9.42	-0.46	7.91e-19	Gut microbiome composition (summer);
LUSC	cis	rs12286929	0.644	rs3793957	chr11:115095654	C/T	cg04055981	chr11:115044050	NA	0.37	6.63	0.34	1.39e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17621444	0.522	rs10788023	chr10:121812114	C/T	cg02041677	chr10:121771263	NA	-0.32	-6.09	-0.32	3.11e-9	IgG glycosylation;
LUSC	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg23093090	chr10:104574429	C10orf26	-0.48	-5.8	-0.3	1.53e-8	Arsenic metabolism;
LUSC	trans	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg11244813	chr1:145039882	PDE4DIP	0.38	6.04	0.31	4.08e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.37	-0.33	6.27e-10	Resting heart rate;
LUSC	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg22906224	chr7:99728672	NA	0.47	6.52	0.34	2.67e-10	Coronary artery disease;
LUSC	cis	rs8017423	0.647	rs4900037	chr14:90821478	A/G	cg04374321	chr14:90722782	PSMC1	0.41	6.2	0.32	1.68e-9	Mortality in heart failure;
LUSC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.48	-6.54	-0.34	2.3e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4654899	0.680	rs10799670	chr1:21179445	T/C	cg01072550	chr1:21505969	NA	0.48	7.2	0.37	3.92e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg18827107	chr12:86230957	RASSF9	0.49	7.34	0.37	1.6e-12	Major depressive disorder;
LUSC	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg09165964	chr15:75287851	SCAMP5	0.52	7.51	0.38	5.61e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg03342759	chr3:160939853	NMD3	-0.55	-8.04	-0.4	1.62e-14	Parkinson's disease;
LUSC	cis	rs6960043	0.818	rs10238625	chr7:15054232	A/G	cg19272540	chr7:15055459	NA	0.36	8.95	0.44	2.48e-17	Type 2 diabetes;
LUSC	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg24450063	chr1:156163899	SLC25A44	1.06	20.26	0.74	4.47e-60	Testicular germ cell tumor;
LUSC	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg23601416	chr22:19950040	COMT	-0.45	-9.27	-0.45	2.39e-18	Blood metabolite levels;
LUSC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.38	7.15	0.36	5.66e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-6.9	-0.35	2.67e-11	Height;
LUSC	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg16006841	chr5:176797999	RGS14	-0.65	-9.36	-0.46	1.19e-18	Urate levels in lean individuals;
LUSC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19346786	chr7:2764209	NA	-0.42	-7.01	-0.36	1.32e-11	Height;
LUSC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	11.16	0.52	8.78e-25	Prudent dietary pattern;
LUSC	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg06287003	chr12:125626642	AACS	-0.41	-7.38	-0.37	1.25e-12	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg04586622	chr2:25135609	ADCY3	0.41	8.88	0.44	4.05e-17	Body mass index;
LUSC	trans	rs1493916	0.748	rs34501189	chr18:31314196	A/G	cg27147174	chr7:100797783	AP1S1	-0.56	-8.85	-0.44	5.33e-17	Life satisfaction;
LUSC	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg05163923	chr11:71159392	DHCR7	0.78	11.49	0.53	5.51e-26	Vitamin D levels;
LUSC	trans	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.9	0.35	2.57e-11	Endometrial cancer;
LUSC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg02772935	chr3:125709198	NA	-0.5	-6.03	-0.31	4.34e-9	Blood pressure (smoking interaction);
LUSC	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	10.04	0.48	6.44e-21	Coffee consumption (cups per day);
LUSC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg01802117	chr1:53393560	SCP2	0.38	6.17	0.32	1.97e-9	Monocyte count;
LUSC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg13939156	chr17:80058883	NA	0.34	6.78	0.35	5.54e-11	Life satisfaction;
LUSC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg22963979	chr7:1858916	MAD1L1	-0.6	-9.44	-0.46	6.45e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	9.51	0.46	3.94e-19	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.74	0.6	2.26e-34	Platelet count;
LUSC	cis	rs6060960	0.537	rs6087787	chr20:30452089	G/A	cg13852791	chr20:30311386	BCL2L1	0.67	6.66	0.34	1.11e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06028605	chr16:24865363	SLC5A11	0.67	10.26	0.49	1.2e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	7.48	0.38	6.79e-13	Coffee consumption (cups per day);
LUSC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg09021430	chr5:549028	NA	-0.53	-7.49	-0.38	6.08e-13	Lung disease severity in cystic fibrosis;
LUSC	cis	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg09307838	chr4:120376055	NA	0.46	6.81	0.35	4.45e-11	Diastolic blood pressure;
LUSC	cis	rs11955175	0.850	rs111959286	chr5:40704141	A/T	cg17351974	chr5:40835760	RPL37	0.67	5.8	0.3	1.54e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.16e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg24692254	chr21:30365293	RNF160	-0.58	-7.22	-0.37	3.57e-12	Cognitive test performance;
LUSC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08677398	chr8:58056175	NA	0.54	7.01	0.36	1.34e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.81	-0.43	6.73e-17	Metabolite levels;
LUSC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg11062466	chr8:58055876	NA	0.5	6.42	0.33	4.75e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs6030	1.000	rs6701330	chr1:169501056	T/C	cg16792071	chr10:134842795	NA	0.29	6.0	0.31	5.07e-9	Uric acid levels;
LUSC	cis	rs1878931	0.559	rs2106863	chr16:3391330	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.63	10.03	0.48	7.36e-21	Body mass index (adult);
LUSC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.16	0.32	2.11e-9	Mean platelet volume;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg16527491	chr14:38065127	FOXA1	-0.39	-5.99	-0.31	5.5e-9	Hepatitis;
LUSC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.46	-0.33	3.62e-10	Life satisfaction;
LUSC	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg01966878	chr4:90757139	SNCA	-0.4	-5.89	-0.31	9.59e-9	Neuroticism;
LUSC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg19622623	chr12:86230825	RASSF9	0.4	5.75	0.3	2.02e-8	Major depressive disorder;
LUSC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg05941027	chr17:61774174	LIMD2	0.22	5.95	0.31	6.89e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg10994292	chr5:110074295	SLC25A46	0.41	6.34	0.33	7.46e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10170846	0.924	rs3768973	chr2:223436402	C/T	cg25565276	chr2:223520875	FARSB	0.68	10.03	0.48	6.98e-21	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.4e-10	Ulcerative colitis;
LUSC	cis	rs666930	1.000	rs666930	chr1:120258970	A/G	cg19096424	chr1:120255104	PHGDH	0.41	6.32	0.33	8.19e-10	Breast cancer;
LUSC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.07	-0.32	3.41e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-11.68	-0.54	1.17e-26	Chronic sinus infection;
LUSC	cis	rs253664	0.948	rs1308362	chr3:138103927	A/T	cg25188949	chr3:137893707	DBR1	-0.48	-5.75	-0.3	2.01e-8	Body mass index;
LUSC	trans	rs3857536	0.813	rs9360189	chr6:66933424	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.44e-9	Blood trace element (Cu levels);
LUSC	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg27471124	chr11:109292789	C11orf87	0.43	7.46	0.38	7.48e-13	Schizophrenia;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17524151	chr16:475494	RAB11FIP3	0.41	6.36	0.33	6.5e-10	Calcium levels;
LUSC	cis	rs10203711	0.966	rs10929288	chr2:239583146	A/G	cg14580085	chr2:239553406	NA	0.42	7.1	0.36	7.48e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg20935933	chr6:143382018	AIG1	0.51	7.43	0.38	8.96e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg05925327	chr15:68127851	NA	-0.38	-6.02	-0.31	4.7e-9	Restless legs syndrome;
LUSC	trans	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg06606381	chr12:133084897	FBRSL1	-0.51	-6.05	-0.31	3.8e-9	Lung cancer in ever smokers;
LUSC	trans	rs7939886	0.920	rs7113835	chr11:55947007	C/T	cg03929089	chr4:120376271	NA	0.82	6.22	0.32	1.53e-9	Myopia (pathological);
LUSC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.36e-8	Lung cancer;
LUSC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg10792982	chr14:105748885	BRF1	0.51	8.74	0.43	1.12e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg23788917	chr6:8435910	SLC35B3	0.51	7.48	0.38	6.55e-13	Motion sickness;
LUSC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.4	0.49	3.98e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.52	10.19	0.49	2e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs2348418	0.966	rs7316351	chr12:28698528	G/A	cg13890972	chr12:28721907	NA	-0.34	-5.75	-0.3	2.06e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs10992471	0.603	rs11792019	chr9:95195229	C/T	cg14631576	chr9:95140430	CENPP	-0.35	-6.48	-0.33	3.26e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs3087591	0.597	rs731759	chr17:29722809	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.4	-5.92	-0.31	8.1e-9	Hip circumference;
LUSC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	7.16	0.36	5.32e-12	Platelet count;
LUSC	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.75	0.6	2.12e-34	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg10792982	chr14:105748885	BRF1	0.51	9.08	0.44	9.87e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg14166395	chr21:42792516	MX1	-0.57	-8.4	-0.42	1.33e-15	IgG glycosylation;
LUSC	trans	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg03886242	chr7:26192032	NFE2L3	-0.41	-6.26	-0.32	1.22e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg10729496	chr3:10149963	C3orf24	0.49	6.28	0.32	1.07e-9	Alzheimer's disease;
LUSC	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	9.86	0.47	2.6e-20	Lymphocyte counts;
LUSC	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg04865166	chr7:105162814	PUS7	0.53	5.65	0.3	3.42e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.83	14.09	0.61	1.05e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.04	-0.31	4.05e-9	Morning vs. evening chronotype;
LUSC	cis	rs12928939	0.859	rs11670	chr16:71679027	G/T	cg08717414	chr16:71523259	ZNF19	-0.41	-5.65	-0.3	3.39e-8	Post bronchodilator FEV1;
LUSC	cis	rs7173743	0.518	rs12899452	chr15:79112550	T/A	cg00540400	chr15:79124168	NA	0.45	8.02	0.4	1.76e-14	Coronary artery disease;
LUSC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg00815214	chr21:47717953	NA	-0.43	-6.66	-0.34	1.14e-10	Testicular germ cell tumor;
LUSC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg20203395	chr5:56204925	C5orf35	-0.4	-5.83	-0.3	1.3e-8	Coronary artery disease;
LUSC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg05623727	chr3:50126028	RBM5	-0.35	-6.5	-0.34	2.92e-10	Body mass index;
LUSC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	10.22	0.49	1.57e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.84	13.58	0.6	9.16e-34	Breast cancer;
LUSC	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg03678062	chr6:149772716	ZC3H12D	0.28	5.82	0.3	1.35e-8	Dupuytren's disease;
LUSC	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.46	-0.46	5.87e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg22143856	chr6:28129313	ZNF389	0.43	5.94	0.31	7.28e-9	Parkinson's disease;
LUSC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18099408	chr3:52552593	STAB1	-0.4	-6.85	-0.35	3.62e-11	Bipolar disorder;
LUSC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg16240275	chr20:61666158	NCRNA00029	0.42	9.17	0.45	5.01e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9311676	0.609	rs62258077	chr3:58363371	T/C	cg26110898	chr3:58419937	PDHB	0.41	6.64	0.34	1.29e-10	Systemic lupus erythematosus;
LUSC	trans	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg25214090	chr10:38739885	LOC399744	-0.41	-6.22	-0.32	1.52e-9	Corneal astigmatism;
LUSC	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg24558204	chr6:135376177	HBS1L	0.57	8.72	0.43	1.3e-16	Red blood cell count;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.56	9.55	0.46	2.89e-19	Lymphocyte counts;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01898370	chr4:1283560	MAEA	-0.42	-6.14	-0.32	2.29e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6693567	0.545	rs1694380	chr1:150292341	A/G	cg15654264	chr1:150340011	RPRD2	0.45	7.27	0.37	2.62e-12	Migraine;
LUSC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg18681998	chr4:17616180	MED28	0.86	16.47	0.67	5.09e-45	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14829155	chr15:31115871	NA	0.71	10.73	0.51	2.8e-23	Huntington's disease progression;
LUSC	cis	rs4363385	0.626	rs1108410	chr1:153005662	T/C	cg00922841	chr1:152955080	SPRR1A	-0.39	-6.46	-0.33	3.67e-10	Inflammatory skin disease;
LUSC	cis	rs34779708	0.931	rs3740083	chr10:35320383	C/T	cg03585969	chr10:35415529	CREM	0.61	8.82	0.43	6.24e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	0.9	17.22	0.69	5.31e-48	Heart rate;
LUSC	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg11757124	chr7:157526947	PTPRN2	-0.42	-6.24	-0.32	1.3e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg00857998	chr1:205179979	DSTYK	0.51	7.84	0.39	6e-14	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.66	8.81	0.43	6.88e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg22705602	chr4:152727874	NA	-0.36	-7.87	-0.4	4.89e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00166722	chr3:10149974	C3orf24	0.59	7.49	0.38	6.02e-13	Alzheimer's disease;
LUSC	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg11584989	chr19:19387371	SF4	0.6	7.08	0.36	8.81e-12	Bipolar disorder;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10516465	chr14:102695515	RAGE	-0.45	-6.98	-0.36	1.57e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg27284194	chr4:1044797	NA	0.6	8.88	0.44	4.09e-17	Recombination rate (females);
LUSC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg27631724	chr1:11040367	C1orf127	0.55	10.95	0.51	4.6e-24	Ewing sarcoma;
LUSC	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg19116668	chr7:99932089	PMS2L1	-0.33	-5.66	-0.3	3.25e-8	Coronary artery disease;
LUSC	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg22961513	chr11:14280813	SPON1	0.34	5.71	0.3	2.53e-8	Mitochondrial DNA levels;
LUSC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg12927641	chr6:109611667	NA	-0.43	-7.46	-0.38	7.43e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg02023728	chr11:77925099	USP35	0.5	7.11	0.36	7.29e-12	Testicular germ cell tumor;
LUSC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.18	29.42	0.85	9.33e-95	Testicular germ cell tumor;
LUSC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg09034736	chr1:150693464	HORMAD1	0.44	6.04	0.31	4.12e-9	Melanoma;
LUSC	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg05110241	chr16:68378359	PRMT7	-0.83	-9.18	-0.45	4.55e-18	Schizophrenia;
LUSC	cis	rs11025559	1.000	rs11025559	chr11:20443875	A/G	cg19653624	chr11:20408972	PRMT3	0.58	6.6	0.34	1.59e-10	Pursuit maintenance gain;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02523415	chr8:82633572	ZFAND1	-0.5	-6.11	-0.32	2.81e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg19717773	chr7:2847554	GNA12	0.41	6.63	0.34	1.33e-10	Loneliness (linear analysis);
LUSC	cis	rs1044826	0.619	rs6439856	chr3:139134868	A/T	cg00490450	chr3:139108681	COPB2	-0.5	-7.87	-0.4	4.85e-14	Obesity-related traits;
LUSC	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg07148914	chr20:33460835	GGT7	0.53	8.27	0.41	3.25e-15	Height;
LUSC	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg13010199	chr12:38710504	ALG10B	0.65	9.82	0.47	3.81e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10871290	0.650	rs28484753	chr16:74489395	G/C	cg01733217	chr16:74700730	RFWD3	0.69	10.4	0.49	3.82e-22	Breast cancer;
LUSC	cis	rs2652834	1.000	rs2729830	chr15:63395812	G/C	cg05507819	chr15:63340323	TPM1	0.67	8.2	0.41	5.33e-15	HDL cholesterol;
LUSC	trans	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg06636001	chr8:8085503	FLJ10661	0.47	7.33	0.37	1.78e-12	Retinal vascular caliber;
LUSC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.81	-0.3	1.48e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.83	14.55	0.62	1.7e-37	Metabolic syndrome;
LUSC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg07741184	chr6:167504864	NA	0.35	6.48	0.33	3.38e-10	Crohn's disease;
LUSC	cis	rs6693567	0.565	rs471657	chr1:150276461	G/A	cg15654264	chr1:150340011	RPRD2	-0.47	-7.69	-0.39	1.67e-13	Migraine;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09080729	chr16:81069740	ATMIN	0.45	6.1	0.32	2.88e-9	Neuroticism;
LUSC	cis	rs1957429	0.808	rs7144718	chr14:65333831	G/A	cg23373153	chr14:65346875	NA	0.97	11.0	0.52	3.19e-24	Pediatric areal bone mineral density (radius);
LUSC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.7	12.15	0.55	2.24e-28	Prudent dietary pattern;
LUSC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg06008330	chr7:65541103	ASL	0.39	6.14	0.32	2.38e-9	Aortic root size;
LUSC	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.57	10.0	0.48	8.88e-21	Birth weight;
LUSC	cis	rs9326248	0.769	rs499910	chr11:116763034	G/A	cg11861562	chr11:117069780	TAGLN	0.37	6.42	0.33	4.7e-10	Blood protein levels;
LUSC	cis	rs4700695	0.719	rs27085	chr5:65435063	C/T	cg21114390	chr5:65439923	SFRS12	0.63	8.71	0.43	1.43e-16	Facial morphology (factor 19);
LUSC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	0.92	15.38	0.64	1.02e-40	Breast cancer;
LUSC	cis	rs34638657	0.752	rs2967374	chr16:82209861	A/G	cg09439754	chr16:82129088	HSD17B2	-0.37	-5.65	-0.3	3.42e-8	Lung adenocarcinoma;
LUSC	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg17366294	chr4:99064904	C4orf37	0.51	8.78	0.43	8.69e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg04240660	chr16:89714849	CHMP1A	-0.43	-6.93	-0.35	2.17e-11	Hemoglobin concentration;
LUSC	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	6.87	0.35	3.21e-11	Ovarian reserve;
LUSC	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.9	-0.31	9.07e-9	IgG glycosylation;
LUSC	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	trans	rs28647808	0.881	rs57394597	chr9:136261030	G/A	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs2637266	0.935	rs6480822	chr10:78354092	A/C	cg18941641	chr10:78392320	NA	0.39	7.26	0.37	2.75e-12	Pulmonary function;
LUSC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg23034840	chr1:205782522	SLC41A1	0.63	9.15	0.45	5.67e-18	Menarche (age at onset);
LUSC	trans	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg01620082	chr3:125678407	NA	-0.57	-6.53	-0.34	2.51e-10	Depression;
LUSC	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg03599575	chr15:90893182	GABARAPL3	0.36	6.55	0.34	2.21e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs12940923	1.000	rs35433894	chr17:56376042	A/G	cg19466818	chr17:56409534	MIR142	-0.38	-6.63	-0.34	1.39e-10	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg10664184	chr19:17420304	DDA1	-0.46	-6.04	-0.31	4.2e-9	Systemic lupus erythematosus;
LUSC	cis	rs72781680	0.756	rs2712059	chr2:24020539	T/C	cg08917208	chr2:24149416	ATAD2B	0.6	6.91	0.35	2.44e-11	Lymphocyte counts;
LUSC	cis	rs9810089	0.814	rs864437	chr3:136119909	C/G	cg12473912	chr3:136751656	NA	0.36	5.91	0.31	8.41e-9	Gestational age at birth (child effect);
LUSC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00166722	chr3:10149974	C3orf24	0.6	8.26	0.41	3.38e-15	Alzheimer's disease;
LUSC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18404041	chr3:52824283	ITIH1	-0.5	-9.53	-0.46	3.33e-19	Bipolar disorder;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26059836	chr10:72575605	SGPL1	-0.42	-6.06	-0.31	3.72e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.33	0.45	1.49e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg26384229	chr12:38710491	ALG10B	0.67	10.53	0.5	1.41e-22	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg01802117	chr1:53393560	SCP2	-0.45	-7.46	-0.38	7.37e-13	Monocyte count;
LUSC	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg26395211	chr5:140044315	WDR55	0.38	5.84	0.3	1.21e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs981844	1.000	rs1371161	chr4:154655171	T/C	cg14289246	chr4:154710475	SFRP2	0.5	6.25	0.32	1.28e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg09654669	chr8:57350985	NA	-0.58	-8.12	-0.41	9.15e-15	Obesity-related traits;
LUSC	cis	rs735539	0.574	rs10870743	chr13:21258756	C/A	cg04906043	chr13:21280425	IL17D	-0.43	-6.72	-0.34	7.99e-11	Dental caries;
LUSC	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg00310523	chr12:86230176	RASSF9	0.37	6.77	0.35	5.98e-11	Major depressive disorder;
LUSC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg07959070	chr22:50026188	C22orf34	-0.37	-7.52	-0.38	5e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08109568	chr15:31115862	NA	-0.58	-8.15	-0.41	7.28e-15	Huntington's disease progression;
LUSC	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg22117172	chr7:91764530	CYP51A1	0.32	5.71	0.3	2.49e-8	Breast cancer;
LUSC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs12681287	0.570	rs10956830	chr8:87430483	T/A	cg27223183	chr8:87520930	FAM82B	0.54	7.45	0.38	7.84e-13	Caudate activity during reward;
LUSC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg20406979	chr6:167373233	NA	-0.26	-6.27	-0.32	1.1e-9	Crohn's disease;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15849282	chr3:38537770	EXOG	-0.42	-6.18	-0.32	1.86e-9	Hepatitis;
LUSC	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.51	1.26e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg12658694	chr1:38397304	INPP5B	0.43	6.48	0.33	3.24e-10	Coronary artery disease;
LUSC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.52	-8.99	-0.44	1.92e-17	Menopause (age at onset);
LUSC	cis	rs1858037	0.867	rs964505	chr2:65623189	G/A	cg08085232	chr2:65598271	SPRED2	-0.42	-6.15	-0.32	2.19e-9	Rheumatoid arthritis;
LUSC	cis	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg08847533	chr14:75593920	NEK9	0.46	6.46	0.33	3.69e-10	IgG glycosylation;
LUSC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00166722	chr3:10149974	C3orf24	0.58	7.42	0.38	9.7e-13	Alzheimer's disease;
LUSC	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg00225070	chr15:80189496	MTHFS	0.63	9.68	0.47	1.05e-19	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg05043794	chr9:111880884	C9orf5	-0.34	-7.09	-0.36	8.09e-12	Menarche (age at onset);
LUSC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.84	0.35	3.76e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs16912285	0.591	rs12796137	chr11:24364459	T/G	ch.11.24196551F	chr11:24239977	NA	0.77	8.35	0.42	1.9e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg19774624	chr17:42201019	HDAC5	0.65	9.37	0.46	1.1e-18	Total body bone mineral density;
LUSC	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	6.74	0.35	7.17e-11	Lung cancer in ever smokers;
LUSC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00166722	chr3:10149974	C3orf24	0.61	8.64	0.43	2.44e-16	Alzheimer's disease;
LUSC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg11812906	chr14:75593930	NEK9	-0.63	-10.29	-0.49	9.29e-22	Height;
LUSC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg04317338	chr11:64019027	PLCB3	0.68	7.75	0.39	1.12e-13	Mean platelet volume;
LUSC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg00339695	chr16:24857497	SLC5A11	0.35	6.24	0.32	1.34e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg10326726	chr10:51549505	MSMB	-0.38	-6.57	-0.34	1.93e-10	Prostate-specific antigen levels;
LUSC	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg13072238	chr3:49761600	GMPPB	0.68	8.73	0.43	1.21e-16	Menarche (age at onset);
LUSC	cis	rs240764	0.687	rs239209	chr6:101140977	T/C	cg09795085	chr6:101329169	ASCC3	0.41	5.93	0.31	7.56e-9	Neuroticism;
LUSC	cis	rs1113500	0.862	rs3853494	chr1:108637334	G/A	cg06207961	chr1:108661230	NA	0.41	7.57	0.38	3.61e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg05025164	chr4:1340916	KIAA1530	0.43	6.43	0.33	4.39e-10	Obesity-related traits;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg22001924	chr5:162887193	HMMR;NUDCD2	0.71	6.73	0.35	7.51e-11	Cognitive performance;
LUSC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.56e-13	Motion sickness;
LUSC	cis	rs56399783	0.901	rs17300022	chr7:2808517	C/T	cg14895029	chr7:2775587	GNA12	-0.52	-6.23	-0.32	1.4e-9	Childhood ear infection;
LUSC	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg06484146	chr7:12443880	VWDE	-0.68	-7.26	-0.37	2.76e-12	Coronary artery disease;
LUSC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-7.97	-0.4	2.45e-14	Monocyte percentage of white cells;
LUSC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg17971929	chr21:40555470	PSMG1	-0.69	-11.27	-0.52	3.43e-25	Cognitive function;
LUSC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	8.66	0.43	2.09e-16	Mood instability;
LUSC	cis	rs3857536	0.813	rs4710581	chr6:66939954	T/C	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg00033643	chr7:134001901	SLC35B4	0.43	6.6	0.34	1.65e-10	Mean platelet volume;
LUSC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.64	0.47	1.43e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg23601095	chr6:26197514	HIST1H3D	0.7	7.47	0.38	7.17e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg12552261	chr5:112820674	MCC	-0.44	-7.02	-0.36	1.25e-11	Type 2 diabetes;
LUSC	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg11584989	chr19:19387371	SF4	0.6	7.33	0.37	1.78e-12	Bipolar disorder;
LUSC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg13206674	chr6:150067644	NUP43	0.62	10.17	0.49	2.43e-21	Lung cancer;
LUSC	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg05729581	chr11:3078854	CARS	0.39	5.68	0.3	2.96e-8	Calcium levels;
LUSC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-0.99	-16.85	-0.68	1.54e-46	Coronary artery disease;
LUSC	cis	rs9677476	0.863	rs13423632	chr2:232079116	T/C	cg07929768	chr2:232055508	NA	0.36	6.83	0.35	4.13e-11	Food antigen IgG levels;
LUSC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg14668632	chr7:2872130	GNA12	-0.46	-6.56	-0.34	2e-10	Height;
LUSC	cis	rs9311676	0.656	rs11708895	chr3:58403042	T/C	cg26110898	chr3:58419937	PDHB	0.39	6.3	0.33	9.58e-10	Systemic lupus erythematosus;
LUSC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg13126279	chr21:47581558	C21orf56	-0.43	-6.3	-0.33	9.53e-10	Testicular germ cell tumor;
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	0.96	20.06	0.74	2.79e-59	Menarche (age at onset);
LUSC	cis	rs2625529	0.586	rs7173626	chr15:72186926	C/A	cg16672083	chr15:72433130	SENP8	0.47	7.67	0.39	1.84e-13	Red blood cell count;
LUSC	cis	rs7527798	0.592	rs6667118	chr1:207822724	G/T	cg09232269	chr1:207846808	CR1L	-0.3	-6.46	-0.33	3.78e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08564027	chr20:61660810	NA	0.8	11.81	0.54	3.8e-27	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg01884057	chr2:25150051	NA	0.4	8.93	0.44	2.93e-17	Body mass index;
LUSC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg14092988	chr3:52407081	DNAH1	0.31	6.08	0.32	3.37e-9	Bipolar disorder;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg04224864	chr1:179851825	TOR1AIP1	0.53	6.17	0.32	2.01e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg12165864	chr7:66369176	NA	0.49	6.57	0.34	1.95e-10	Corneal structure;
LUSC	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg05805236	chr11:65401703	PCNXL3	0.41	6.85	0.35	3.63e-11	Acne (severe);
LUSC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg24399712	chr22:39784796	NA	-0.63	-11.44	-0.53	8.7e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg09323728	chr8:95962352	TP53INP1	0.37	7.22	0.37	3.6e-12	Type 2 diabetes;
LUSC	cis	rs7605827	0.930	rs7571679	chr2:15596603	C/T	cg19274914	chr2:15703543	NA	0.47	8.98	0.44	2.02e-17	Educational attainment (years of education);
LUSC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg01879757	chr17:41196368	BRCA1	-0.46	-6.97	-0.36	1.72e-11	Menopause (age at onset);
LUSC	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg24558204	chr6:135376177	HBS1L	0.65	9.81	0.47	3.81e-20	Red blood cell count;
LUSC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg15557168	chr22:42548783	NA	-0.47	-7.65	-0.39	2.21e-13	Schizophrenia;
LUSC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.61	8.09	0.4	1.1e-14	High light scatter reticulocyte count;
LUSC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg11812906	chr14:75593930	NEK9	-0.65	-10.52	-0.5	1.55e-22	Height;
LUSC	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.97	12.55	0.57	7.08e-30	Mean corpuscular hemoglobin;
LUSC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.55	-7.74	-0.39	1.19e-13	Menarche (age at onset);
LUSC	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg13010199	chr12:38710504	ALG10B	0.69	10.6	0.5	8.32e-23	Bladder cancer;
LUSC	cis	rs7264396	0.561	rs2050930	chr20:34579397	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.6	-0.34	1.57e-10	Total cholesterol levels;
LUSC	cis	rs4631830	0.863	rs4486572	chr10:51531805	A/G	cg16070123	chr10:51489643	NA	-0.52	-8.15	-0.41	7.51e-15	Prostate-specific antigen levels;
LUSC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg13683864	chr3:40499215	RPL14	-1.0	-16.83	-0.68	1.83e-46	Renal cell carcinoma;
LUSC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg01879757	chr17:41196368	BRCA1	-0.45	-6.66	-0.34	1.16e-10	Menopause (age at onset);
LUSC	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21293242	chr8:11204541	TDH	0.32	6.01	0.31	4.95e-9	Retinal vascular caliber;
LUSC	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg05855489	chr10:104503620	C10orf26	0.52	7.77	0.39	9.93e-14	Arsenic metabolism;
LUSC	cis	rs2742234	0.541	rs10899786	chr10:43744583	G/A	cg15436174	chr10:43711423	RASGEF1A	0.42	6.72	0.34	7.99e-11	Hirschsprung disease;
LUSC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-0.92	-13.11	-0.58	5.99e-32	Blood trace element (Zn levels);
LUSC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18404041	chr3:52824283	ITIH1	-0.62	-12.01	-0.55	7.56e-28	Bipolar disorder;
LUSC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg08200582	chr11:442649	ANO9	-0.5	-5.94	-0.31	7.01e-9	Body mass index;
LUSC	cis	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg09307838	chr4:120376055	NA	-0.48	-7.37	-0.37	1.32e-12	Plateletcrit;
LUSC	cis	rs68170813	0.559	rs5002976	chr7:107050620	C/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.36	-0.46	1.25e-18	Coronary artery disease;
LUSC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.85	-0.47	3e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.1	0.32	2.85e-9	Schizophrenia;
LUSC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.92	0.31	7.84e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2154427	1.000	rs2833963	chr21:34175553	C/T	cg21871883	chr21:34145043	C21orf49;C21orf66	0.62	5.96	0.31	6.27e-9	Bilirubin levels;
LUSC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg19622623	chr12:86230825	RASSF9	-0.43	-6.08	-0.32	3.25e-9	Major depressive disorder;
LUSC	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-0.63	-9.36	-0.46	1.2e-18	Platelet distribution width;
LUSC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	6.74	0.35	6.94e-11	Renal function-related traits (BUN);
LUSC	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27286337	chr10:134555280	INPP5A	0.89	11.74	0.54	7.12e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg26043149	chr18:55253948	FECH	0.42	6.34	0.33	7.52e-10	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg04450456	chr4:17643702	FAM184B	0.38	6.21	0.32	1.54e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14829155	chr15:31115871	NA	-0.56	-7.82	-0.39	7.04e-14	Huntington's disease progression;
LUSC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg09323728	chr8:95962352	TP53INP1	-0.33	-6.17	-0.32	1.93e-9	Type 2 diabetes;
LUSC	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg14835575	chr10:16859367	RSU1	0.76	9.5	0.46	4.15e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.7	-9.79	-0.47	4.49e-20	Gut microbiome composition (summer);
LUSC	cis	rs9840812	0.623	rs1145106	chr3:136111917	G/A	cg15507776	chr3:136538369	TMEM22	0.4	5.81	0.3	1.46e-8	Fibrinogen levels;
LUSC	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg13615516	chr5:77269221	NA	0.4	6.69	0.34	9.31e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg18306943	chr3:40428807	ENTPD3	0.4	6.07	0.32	3.44e-9	Renal cell carcinoma;
LUSC	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg14458575	chr2:238380390	NA	0.68	12.06	0.55	4.8e-28	Prostate cancer;
LUSC	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg03563238	chr19:33554763	RHPN2	-0.39	-6.25	-0.32	1.22e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00166722	chr3:10149974	C3orf24	0.56	7.54	0.38	4.61e-13	Alzheimer's disease;
LUSC	cis	rs11018904	0.817	rs11601793	chr11:89946354	T/G	cg26834418	chr11:89957033	CHORDC1	-0.52	-6.24	-0.32	1.32e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg26876637	chr1:152193138	HRNR	0.45	6.39	0.33	5.53e-10	Atopic dermatitis;
LUSC	cis	rs2274273	0.588	rs7158791	chr14:55828607	A/G	cg04306507	chr14:55594613	LGALS3	0.49	9.82	0.47	3.79e-20	Protein biomarker;
LUSC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg11663144	chr21:46675770	NA	-0.41	-7.06	-0.36	9.82e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg25174290	chr11:3078921	CARS	0.6	9.41	0.46	8.29e-19	Longevity;
LUSC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.94	0.36	2.01e-11	Tonsillectomy;
LUSC	cis	rs17255340	0.539	rs1145908	chr6:84014398	C/T	cg08257003	chr6:84140564	ME1	-0.31	-7.59	-0.38	3.3e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg17120908	chr11:65337727	SSSCA1	-0.53	-9.32	-0.45	1.58e-18	Bone mineral density;
LUSC	trans	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	10.49	0.5	1.91e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19545258	chr7:73703601	CLIP2	-0.44	-5.95	-0.31	6.68e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9653442	0.576	rs6542921	chr2:100864498	C/A	cg07810366	chr2:100720526	AFF3	-0.38	-6.23	-0.32	1.42e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg16928487	chr17:17741425	SREBF1	-0.37	-7.05	-0.36	1.06e-11	Total body bone mineral density;
LUSC	trans	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs6126344	0.957	rs6021436	chr20:50405191	G/C	cg03643032	chr16:85954903	IRF8	0.3	6.11	0.32	2.71e-9	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs2742417	0.624	rs2742394	chr3:45757591	C/T	cg10512202	chr3:45649293	LIMD1	0.36	6.14	0.32	2.33e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg18827107	chr12:86230957	RASSF9	0.42	6.36	0.33	6.46e-10	Major depressive disorder;
LUSC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg19318889	chr4:1322082	MAEA	0.57	9.7	0.47	8.91e-20	Longevity;
LUSC	cis	rs870825	0.550	rs59051283	chr4:185646476	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs17102423	0.755	rs884683	chr14:65574482	C/T	cg11161011	chr14:65562177	MAX	-0.81	-12.19	-0.55	1.57e-28	Obesity-related traits;
LUSC	cis	rs2798269	0.966	rs17679490	chr13:22139291	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.11	-0.32	2.82e-9	PR segment;
LUSC	cis	rs642803	0.933	rs644740	chr11:65561468	C/T	cg27068330	chr11:65405492	SIPA1	0.49	6.53	0.34	2.41e-10	Urate levels;
LUSC	cis	rs926392	0.547	rs6129161	chr20:37678327	T/G	cg16355469	chr20:37678765	NA	0.54	7.2	0.37	4.03e-12	Dialysis-related mortality;
LUSC	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg21427119	chr20:30132790	HM13	-0.43	-5.65	-0.3	3.36e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg03676636	chr4:99064102	C4orf37	0.27	5.84	0.3	1.24e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg13206674	chr6:150067644	NUP43	0.43	6.56	0.34	2.01e-10	Testicular germ cell tumor;
LUSC	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-8.11	-0.41	9.55e-15	Morning vs. evening chronotype;
LUSC	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg20908204	chr19:46285434	DMPK	-0.46	-8.8	-0.43	7.37e-17	Coronary artery disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16786661	chr2:234160315	ATG16L1	-0.54	-7.08	-0.36	8.43e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.7	10.65	0.5	5.42e-23	Corneal astigmatism;
LUSC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.3e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4654899	0.861	rs10916876	chr1:21169996	T/C	cg01072550	chr1:21505969	NA	0.48	7.28	0.37	2.44e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg00310523	chr12:86230176	RASSF9	0.45	8.31	0.41	2.43e-15	Major depressive disorder;
LUSC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25072359	chr17:41440525	NA	0.65	9.4	0.46	9.16e-19	Menopause (age at onset);
LUSC	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg07274523	chr3:49395745	GPX1	0.37	6.17	0.32	1.94e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg11965913	chr1:205819406	PM20D1	0.42	5.91	0.31	8.35e-9	Parkinson's disease;
LUSC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-12.85	-0.58	5.64e-31	Platelet count;
LUSC	trans	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg19694781	chr19:47549865	TMEM160	0.56	8.92	0.44	3.09e-17	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22029157	chr1:209979665	IRF6	0.76	11.23	0.52	4.66e-25	Cleft lip with or without cleft palate;
LUSC	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg23711669	chr6:146136114	FBXO30	0.84	15.12	0.64	9.9e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6693567	0.565	rs11205371	chr1:150398510	A/G	cg15654264	chr1:150340011	RPRD2	0.44	7.09	0.36	8.16e-12	Migraine;
LUSC	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg25319279	chr11:5960081	NA	-0.41	-5.82	-0.3	1.35e-8	DNA methylation (variation);
LUSC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg02551604	chr5:131831745	NA	0.45	7.15	0.36	5.61e-12	Asthma (sex interaction);
LUSC	trans	rs12210905	0.925	rs72838258	chr6:27007681	G/A	cg11837749	chr1:55047332	ACOT11	0.55	5.96	0.31	6.51e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.67	0.43	1.91e-16	Prudent dietary pattern;
LUSC	cis	rs72634258	0.945	rs12735338	chr1:8078569	T/C	cg26816564	chr1:7831052	VAMP3	0.48	6.15	0.32	2.2e-9	Inflammatory bowel disease;
LUSC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.6	10.05	0.48	6.13e-21	Blood metabolite levels;
LUSC	trans	rs2018683	0.600	rs717891	chr7:29000374	C/T	cg19402173	chr7:128379420	CALU	-0.49	-6.66	-0.34	1.1e-10	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg25566285	chr7:158114605	PTPRN2	0.34	6.31	0.33	8.85e-10	Calcium levels;
LUSC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-12.34	-0.56	4.47e-29	Hemoglobin concentration;
LUSC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg23283495	chr1:209979779	IRF6	0.44	7.16	0.36	5.23e-12	Monobrow;
LUSC	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg17644776	chr2:200775616	C2orf69	0.36	5.69	0.3	2.78e-8	Osteoporosis;
LUSC	cis	rs9308433	0.529	rs867444	chr1:214502160	T/C	cg06198575	chr1:214491504	SMYD2	0.45	6.95	0.36	1.89e-11	IgG glycosylation;
LUSC	cis	rs593982	0.719	rs11606668	chr11:65472758	A/G	cg08755490	chr11:65554678	OVOL1	-0.85	-8.54	-0.42	4.87e-16	Atopic dermatitis;
LUSC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.42	0.46	7.67e-19	Prudent dietary pattern;
LUSC	cis	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg04384234	chr16:75411784	CFDP1	-0.38	-6.17	-0.32	1.98e-9	Dupuytren's disease;
LUSC	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg13628971	chr7:2884303	GNA12	0.43	6.42	0.33	4.57e-10	Height;
LUSC	cis	rs868036	1.000	rs1026731	chr15:68095018	G/A	cg08079166	chr15:68083412	MAP2K5	0.41	8.49	0.42	6.72e-16	Restless legs syndrome;
LUSC	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg01028140	chr2:1542097	TPO	-0.44	-6.92	-0.35	2.39e-11	IgG glycosylation;
LUSC	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.48	10.2	0.49	1.97e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg04944784	chr2:26401820	FAM59B	0.8	11.35	0.53	1.86e-25	Mean corpuscular hemoglobin;
LUSC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.9	11.66	0.54	1.37e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs243505	0.661	rs887570	chr7:148505255	A/G	cg09806900	chr7:148480153	CUL1	0.57	8.44	0.42	1e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.75	12.36	0.56	3.69e-29	Alcohol dependence;
LUSC	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg15819921	chr19:927150	ARID3A	-0.43	-6.45	-0.33	3.99e-10	Life satisfaction;
LUSC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.67	0.43	1.96e-16	Motion sickness;
LUSC	trans	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.07	24.31	0.8	7.19e-76	Schizophrenia;
LUSC	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-10.87	-0.51	9.13e-24	Heart rate;
LUSC	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-6.09	-0.32	3.18e-9	Bipolar disorder;
LUSC	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17467752	chr17:38218738	THRA	-0.7	-11.27	-0.52	3.54e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg21427119	chr20:30132790	HM13	-0.35	-5.76	-0.3	1.86e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg06532163	chr17:45867833	NA	0.33	6.19	0.32	1.76e-9	IgG glycosylation;
LUSC	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-0.6	-9.36	-0.46	1.24e-18	Breast cancer;
LUSC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	13.39	0.59	4.97e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg05163923	chr11:71159392	DHCR7	0.74	11.0	0.52	3.15e-24	Vitamin D levels;
LUSC	cis	rs360798	0.512	rs6545973	chr2:63089434	C/T	cg17519650	chr2:63277830	OTX1	0.48	6.61	0.34	1.54e-10	Coronary artery disease;
LUSC	trans	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.31	0.33	8.83e-10	Corneal astigmatism;
LUSC	cis	rs965469	0.901	rs7270135	chr20:3247922	T/C	cg25506879	chr20:3388711	C20orf194	-0.54	-6.22	-0.32	1.5e-9	IFN-related cytopenia;
LUSC	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.83	-19.85	-0.74	1.89e-58	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs2274273	0.662	rs4040064	chr14:55678088	G/T	cg04306507	chr14:55594613	LGALS3	0.48	9.52	0.46	3.52e-19	Protein biomarker;
LUSC	cis	rs2658782	0.724	rs1563445	chr11:93246042	A/G	cg15737290	chr11:93063684	CCDC67	0.61	7.52	0.38	5.17e-13	Pulmonary function decline;
LUSC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg05941027	chr17:61774174	LIMD2	0.23	6.4	0.33	5.39e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6977660	0.714	rs13230381	chr7:19833896	T/C	cg05791153	chr7:19748676	TWISTNB	0.65	6.68	0.34	1e-10	Thyroid stimulating hormone;
LUSC	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg20991723	chr1:152506922	NA	0.51	9.6	0.47	1.93e-19	Hair morphology;
LUSC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg26924012	chr15:45694286	SPATA5L1	0.79	12.5	0.56	1.13e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg20203395	chr5:56204925	C5orf35	0.49	7.3	0.37	2.13e-12	Initial pursuit acceleration;
LUSC	cis	rs11971779	0.616	rs1133068	chr7:139053143	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15773482	chr3:101395972	ZBTB11;LOC100009676	0.76	6.05	0.31	3.97e-9	Cognitive performance;
LUSC	cis	rs642803	0.591	rs620088	chr11:65508986	G/A	cg27068330	chr11:65405492	SIPA1	0.55	7.56	0.38	3.84e-13	Urate levels;
LUSC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg22823121	chr1:150693482	HORMAD1	0.59	9.08	0.44	1e-17	Tonsillectomy;
LUSC	cis	rs2346177	0.844	rs4953365	chr2:46644946	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.35	5.96	0.31	6.48e-9	HDL cholesterol;
LUSC	trans	rs7939886	0.920	rs11227180	chr11:55855611	G/C	cg03929089	chr4:120376271	NA	0.73	6.06	0.31	3.74e-9	Myopia (pathological);
LUSC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg24562669	chr7:97807699	LMTK2	0.35	6.25	0.32	1.25e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg11632617	chr15:75315747	PPCDC	-0.57	-7.15	-0.36	5.53e-12	Blood trace element (Zn levels);
LUSC	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.21	0.32	1.54e-9	Total body bone mineral density;
LUSC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg03146154	chr1:46216737	IPP	0.55	8.34	0.42	1.96e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg08000102	chr2:233561755	GIGYF2	0.8	12.63	0.57	3.75e-30	Schizophrenia;
LUSC	cis	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg06521331	chr12:34319734	NA	-0.37	-6.31	-0.33	8.65e-10	Morning vs. evening chronotype;
LUSC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-11.84	-0.54	3.05e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg04756594	chr16:24857601	SLC5A11	0.48	6.78	0.35	5.37e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	0.64	13.49	0.59	2.05e-33	Prudent dietary pattern;
LUSC	cis	rs921665	0.831	rs2167961	chr2:3177617	C/G	cg02624386	chr2:3182749	NA	0.58	6.43	0.33	4.43e-10	World class endurance athleticism;
LUSC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg22823121	chr1:150693482	HORMAD1	0.5	7.32	0.37	1.9e-12	Melanoma;
LUSC	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.74	-0.3	2.1e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22618164	chr12:122356400	WDR66	0.65	9.54	0.46	3.04e-19	Mean corpuscular volume;
LUSC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg04756594	chr16:24857601	SLC5A11	0.48	6.82	0.35	4.32e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs2262909	0.962	rs436662	chr19:22232107	C/T	cg05197062	chr11:11642011	GALNTL4	-0.56	-7.81	-0.39	7.34e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg24634471	chr8:143751801	JRK	0.51	7.25	0.37	2.97e-12	Schizophrenia;
LUSC	cis	rs9378357	0.702	rs4521639	chr6:3280600	C/G	cg08754725	chr6:3293098	SLC22A23	0.52	5.79	0.3	1.66e-8	Obesity-related traits;
LUSC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg05347473	chr6:146136440	FBXO30	0.56	9.66	0.47	1.28e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.79	-12.14	-0.55	2.42e-28	Menarche (age at onset);
LUSC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg08499158	chr17:42289980	UBTF	-0.52	-8.7	-0.43	1.54e-16	Total body bone mineral density;
LUSC	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg03676636	chr4:99064102	C4orf37	0.3	6.6	0.34	1.64e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.7	-11.03	-0.52	2.41e-24	Colorectal cancer;
LUSC	cis	rs2153535	0.869	rs11962457	chr6:8375855	A/T	cg07606381	chr6:8435919	SLC35B3	-0.52	-7.73	-0.39	1.27e-13	Motion sickness;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05409435	chr17:41561730	DHX8	0.44	6.35	0.33	6.83e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	0.36	5.92	0.31	8.04e-9	Metabolite levels;
LUSC	cis	rs2901656	0.934	rs9425311	chr1:172388778	G/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.31	6.3	0.33	9.46e-10	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs2692947	0.832	rs2579550	chr2:96741944	G/A	cg23100626	chr2:96804247	ASTL	0.3	7.09	0.36	7.8e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg23950597	chr19:37808831	NA	0.62	7.42	0.38	9.87e-13	Coronary artery calcification;
LUSC	cis	rs2235544	0.513	rs10158824	chr1:54480398	C/G	cg25741118	chr1:54482237	LDLRAD1	0.34	7.67	0.39	1.93e-13	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg09877947	chr5:131593287	PDLIM4	0.44	7.36	0.37	1.46e-12	Blood metabolite levels;
LUSC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.77	-0.43	8.98e-17	Gut microbiome composition (summer);
LUSC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg08088566	chr11:430123	ANO9	0.61	7.07	0.36	8.89e-12	Body mass index;
LUSC	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	8.73	0.43	1.25e-16	Total body bone mineral density;
LUSC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-1.03	-19.84	-0.74	2.02e-58	Height;
LUSC	cis	rs7177699	0.550	rs7182103	chr15:79123946	G/T	cg00540400	chr15:79124168	NA	0.43	7.5	0.38	5.63e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13770153	chr20:60521292	NA	-0.61	-8.15	-0.41	7.58e-15	Body mass index;
LUSC	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg09092052	chr15:45571596	NA	0.46	6.36	0.33	6.52e-10	Glomerular filtration rate;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08946801	chr12:100594395	ACTR6	0.41	6.33	0.33	7.85e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6500395	1.000	rs8044519	chr16:48669081	G/T	cg04672837	chr16:48644449	N4BP1	0.48	7.11	0.36	7.24e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg17691542	chr6:26056736	HIST1H1C	0.48	7.07	0.36	9.02e-12	Height;
LUSC	cis	rs7923609	0.783	rs4746203	chr10:65323997	G/T	cg01631684	chr10:65280961	REEP3	0.4	5.85	0.3	1.19e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4363385	0.510	rs11803710	chr1:153053096	C/G	cg25856811	chr1:152973957	SPRR3	-0.37	-6.15	-0.32	2.19e-9	Inflammatory skin disease;
LUSC	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	12.58	0.57	5.89e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11645898	0.935	rs11641721	chr16:72155241	G/A	cg14768367	chr16:72042858	DHODH	-0.63	-7.27	-0.37	2.55e-12	Blood protein levels;
LUSC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.59	-0.46	2.18e-19	Chronic sinus infection;
LUSC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-1.0	-18.17	-0.71	8.92e-52	Height;
LUSC	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.09	26.05	0.82	1.98e-82	Schizophrenia;
LUSC	cis	rs7267979	0.565	rs6107059	chr20:25592431	C/A	cg03522245	chr20:25566470	NINL	-0.4	-6.15	-0.32	2.25e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.65	-10.47	-0.5	2.26e-22	Menarche (age at onset);
LUSC	trans	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.38	-0.33	5.79e-10	Monocyte count;
LUSC	cis	rs6142102	0.961	rs6120519	chr20:32688113	A/G	cg08999081	chr20:33150536	PIGU	0.35	5.98	0.31	5.81e-9	Skin pigmentation;
LUSC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.78	11.22	0.52	5.18e-25	Corneal astigmatism;
LUSC	cis	rs2522056	1.000	rs2522054	chr5:131799526	G/T	cg24060327	chr5:131705240	SLC22A5	0.46	6.17	0.32	1.96e-9	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg05373962	chr22:49881684	NA	-0.4	-8.71	-0.43	1.43e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs239198	0.568	rs34555037	chr6:101327153	G/C	cg09795085	chr6:101329169	ASCC3	0.44	6.37	0.33	6.26e-10	Menarche (age at onset);
LUSC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12016809	chr21:47604291	C21orf56	0.42	6.2	0.32	1.66e-9	Testicular germ cell tumor;
LUSC	cis	rs28595532	0.748	rs17594978	chr4:119336398	T/C	cg21605333	chr4:119757512	SEC24D	1.02	8.3	0.41	2.57e-15	Cannabis dependence symptom count;
LUSC	cis	rs7561273	0.545	rs6733127	chr2:24325805	G/A	cg08063864	chr2:24346004	PFN4;LOC375190	-0.44	-6.14	-0.32	2.34e-9	Quantitative traits;
LUSC	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg03433033	chr1:76189801	ACADM	-0.46	-6.98	-0.36	1.64e-11	Daytime sleep phenotypes;
LUSC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg06784218	chr1:46089804	CCDC17	0.58	11.41	0.53	1.09e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg08508325	chr11:3079039	CARS	-0.54	-13.57	-0.6	1.07e-33	Longevity;
LUSC	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg03929089	chr4:120376271	NA	0.59	6.32	0.33	8.17e-10	Axial length;
LUSC	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg18806716	chr10:30721971	MAP3K8	-0.56	-8.95	-0.44	2.52e-17	Inflammatory bowel disease;
LUSC	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.49	-0.5	1.87e-22	Coffee consumption (cups per day);
LUSC	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg24579218	chr15:68104479	NA	-0.38	-6.8	-0.35	4.93e-11	Restless legs syndrome;
LUSC	cis	rs1160297	0.609	rs6545310	chr2:53103542	T/C	cg07782112	chr2:53107842	NA	0.43	7.01	0.36	1.32e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg06454157	chr6:167490870	NA	-0.24	-6.04	-0.31	4.19e-9	Crohn's disease;
LUSC	cis	rs60695258	0.512	rs2053769	chr4:87908007	T/C	cg10685359	chr4:87814065	C4orf36	0.33	5.81	0.3	1.48e-8	Hematocrit;
LUSC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg06494592	chr3:125709126	NA	-0.5	-5.77	-0.3	1.86e-8	Blood pressure (smoking interaction);
LUSC	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg17757837	chr7:157058334	UBE3C	0.82	13.03	0.58	1.18e-31	Body mass index;
LUSC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg13206674	chr6:150067644	NUP43	0.62	9.97	0.48	1.16e-20	Lung cancer;
LUSC	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg20573242	chr4:122745356	CCNA2	-0.42	-6.08	-0.32	3.31e-9	Type 2 diabetes;
LUSC	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg00012203	chr2:219082015	ARPC2	-0.77	-13.8	-0.6	1.38e-34	Colorectal cancer;
LUSC	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-7.87	-0.4	4.85e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg09904177	chr6:26538194	HMGN4	-0.7	-6.46	-0.33	3.79e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg23093090	chr10:104574429	C10orf26	-0.47	-8.34	-0.42	1.96e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg16950941	chr11:66035639	RAB1B	0.49	7.09	0.36	8.16e-12	Gout;
LUSC	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg05729581	chr11:3078854	CARS	0.41	6.05	0.31	3.99e-9	Calcium levels;
LUSC	cis	rs988712	0.622	rs10767664	chr11:27725986	T/A	cg10635145	chr11:27742435	BDNF	0.48	6.46	0.33	3.66e-10	Obesity;
LUSC	trans	rs4596713	0.508	rs7862404	chr9:71779903	G/A	cg25283916	chr1:242222868	NA	-0.29	-6.0	-0.31	5.05e-9	Headache;
LUSC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg19302996	chr17:73780495	UNK	-0.49	-7.18	-0.37	4.51e-12	White matter hyperintensity burden;
LUSC	cis	rs10392	0.543	rs6028208	chr20:37556075	T/A	cg27552599	chr20:37590471	DHX35	0.45	7.37	0.37	1.31e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg08859206	chr1:53392774	SCP2	-0.44	-7.23	-0.37	3.36e-12	Monocyte count;
LUSC	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg05985134	chr18:33552581	C18orf21	0.5	7.14	0.36	5.92e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg13010199	chr12:38710504	ALG10B	-0.56	-8.82	-0.43	6.69e-17	Morning vs. evening chronotype;
LUSC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg13535736	chr9:111863775	C9orf5	-0.41	-6.51	-0.34	2.72e-10	Menarche (age at onset);
LUSC	cis	rs2932538	0.922	rs12402929	chr1:113072293	G/C	cg22162597	chr1:113214053	CAPZA1	0.73	10.05	0.48	6.32e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.48	-6.6	-0.34	1.63e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.55	0.5	1.17e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg07148914	chr20:33460835	GGT7	-0.45	-6.62	-0.34	1.44e-10	Height;
LUSC	cis	rs1953600	0.715	rs1079242	chr10:81917708	C/T	cg00277334	chr10:82204260	NA	0.41	6.35	0.33	7e-10	Sarcoidosis;
LUSC	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg24375607	chr4:120327624	NA	0.69	10.55	0.5	1.22e-22	Corneal astigmatism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20946600	chr2:27294721	LOC100128731	0.44	5.95	0.31	6.61e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg13256891	chr4:100009986	ADH5	0.51	6.97	0.36	1.66e-11	Smoking initiation;
LUSC	cis	rs3916	1.000	rs1799958	chr12:121176083	G/A	cg27246729	chr12:121163418	ACADS	0.46	6.69	0.34	9.59e-11	Urinary metabolites (H-NMR features);
LUSC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg21724239	chr8:58056113	NA	0.78	9.03	0.44	1.43e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg01557791	chr16:72042693	DHODH	-0.46	-6.84	-0.35	3.81e-11	Fibrinogen levels;
LUSC	cis	rs899997	0.906	rs1809415	chr15:79028201	C/T	cg04896959	chr15:78267971	NA	-0.55	-10.62	-0.5	6.79e-23	Coronary artery disease or large artery stroke;
LUSC	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-5.85	-0.31	1.15e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs17102423	0.755	rs35769504	chr14:65576857	G/A	cg11161011	chr14:65562177	MAX	-0.81	-12.26	-0.56	8.99e-29	Obesity-related traits;
LUSC	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg23093090	chr10:104574429	C10orf26	-0.34	-6.25	-0.32	1.25e-9	Arsenic metabolism;
LUSC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg03188948	chr7:1209495	NA	0.45	6.14	0.32	2.35e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17092148	0.945	rs6060042	chr20:33361721	A/G	cg16810054	chr20:33298113	TP53INP2	-0.45	-6.77	-0.35	5.85e-11	Neuroticism;
LUSC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.5	-7.13	-0.36	6.34e-12	Diastolic blood pressure;
LUSC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.53e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg25922239	chr6:33757077	LEMD2	0.54	7.96	0.4	2.75e-14	Crohn's disease;
LUSC	cis	rs80282103	0.764	rs12244052	chr10:1103266	G/A	cg18964960	chr10:1102726	WDR37	0.71	6.42	0.33	4.61e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs9650657	0.615	rs4840519	chr8:10693113	T/C	cg27411982	chr8:10470053	RP1L1	-0.36	-5.82	-0.3	1.38e-8	Neuroticism;
LUSC	cis	rs72634258	0.786	rs7524424	chr1:8173369	A/G	cg00042356	chr1:8021962	PARK7	0.55	6.76	0.35	6.13e-11	Inflammatory bowel disease;
LUSC	cis	rs4253772	0.872	rs41362646	chr22:46633505	G/A	cg09491104	chr22:46646882	C22orf40	-0.63	-6.67	-0.34	1.04e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.74	-12.49	-0.56	1.25e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4851254	0.920	rs11123808	chr2:100750750	A/C	cg07810366	chr2:100720526	AFF3	-0.38	-5.91	-0.31	8.42e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.46	-6.66	-0.34	1.1e-10	Menarche (age at onset);
LUSC	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg23422044	chr7:1970798	MAD1L1	-0.65	-7.32	-0.37	1.84e-12	Bipolar disorder;
LUSC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg27284194	chr4:1044797	NA	0.59	9.04	0.44	1.25e-17	Recombination rate (females);
LUSC	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.61	9.79	0.47	4.52e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs62238980	0.614	rs78017579	chr22:32381234	T/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs6982240	0.514	rs10095322	chr8:142262327	A/G	cg00131261	chr8:142287264	NA	-0.36	-6.03	-0.31	4.38e-9	Tonsillectomy;
LUSC	cis	rs10788264	0.652	rs9633732	chr10:124056473	G/T	cg09507567	chr10:124027408	NA	0.45	7.53	0.38	4.83e-13	Total body bone mineral density;
LUSC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg05294307	chr14:35346193	BAZ1A	-0.5	-6.5	-0.34	2.88e-10	Psoriasis;
LUSC	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg20243544	chr17:37824526	PNMT	0.38	5.84	0.3	1.21e-8	Self-reported allergy;
LUSC	cis	rs6681460	0.546	rs1998716	chr1:67117106	T/A	cg02459107	chr1:67143332	SGIP1	0.45	8.37	0.42	1.56e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs34779708	0.733	rs7087099	chr10:35541982	C/T	cg03585969	chr10:35415529	CREM	0.55	7.61	0.38	2.84e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg00999904	chr2:3704751	ALLC	-0.33	-6.04	-0.31	4.16e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	0.59	9.37	0.46	1.15e-18	Breast cancer;
LUSC	cis	rs2249625	0.564	rs2496489	chr6:72877338	G/A	cg18830697	chr6:72922368	RIMS1	-0.36	-7.26	-0.37	2.7e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg06917634	chr15:78832804	PSMA4	-0.59	-7.17	-0.37	4.85e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg27411982	chr8:10470053	RP1L1	0.48	7.66	0.39	2.05e-13	Neuroticism;
LUSC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-17.06	-0.68	2.25e-47	Gut microbiome composition (summer);
LUSC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.55	10.64	0.5	5.75e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1775715	0.675	rs2808085	chr10:32148599	C/T	cg04359828	chr10:32216031	ARHGAP12	0.41	7.01	0.36	1.31e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs78572108	0.777	rs12475676	chr2:42268975	A/G	cg00607755	chr2:42274082	PKDCC	0.35	5.98	0.31	5.72e-9	Total body bone mineral density;
LUSC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.3	-0.33	9.44e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs394563	0.901	rs448874	chr6:149796967	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.31	-0.33	8.79e-10	Dupuytren's disease;
LUSC	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg06386533	chr2:46925753	SOCS5	0.44	5.77	0.3	1.86e-8	Height;
LUSC	cis	rs28785552	0.966	rs7247272	chr19:53236331	C/T	cg22067481	chr19:53234126	ZNF611	0.47	6.49	0.33	3.13e-10	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg16586182	chr3:47516702	SCAP	-0.5	-7.81	-0.39	7.3e-14	Colorectal cancer;
LUSC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg22920501	chr2:26401640	FAM59B	-0.71	-10.4	-0.49	3.83e-22	Gut microbiome composition (summer);
LUSC	cis	rs4356932	1.000	rs6532156	chr4:76974351	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.83	0.3	1.33e-8	Blood protein levels;
LUSC	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.81	0.3	1.42e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg07930552	chr6:133119739	C6orf192	0.95	8.36	0.42	1.71e-15	Type 2 diabetes nephropathy;
LUSC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg27068330	chr11:65405492	SIPA1	-0.46	-6.04	-0.31	4.12e-9	Breast cancer;
LUSC	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg07856975	chr6:36356162	ETV7	0.34	6.21	0.32	1.61e-9	Platelet distribution width;
LUSC	cis	rs1595825	1.000	rs61605589	chr2:198876532	T/C	cg19156104	chr2:198669113	PLCL1	-0.46	-5.68	-0.3	2.91e-8	Ulcerative colitis;
LUSC	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg04310649	chr10:35416472	CREM	-0.4	-6.22	-0.32	1.45e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	5.96e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.73	-12.82	-0.57	7.16e-31	Dental caries;
LUSC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg14552801	chr7:65878734	NA	-0.45	-6.44	-0.33	4.23e-10	Aortic root size;
LUSC	trans	rs890100	0.900	rs11125633	chr2:56744481	G/A	cg08299783	chr2:48920986	GTF2A1L;LHCGR	-0.31	-6.1	-0.32	2.96e-9	Gut microbiome composition (summer);
LUSC	cis	rs11997175	0.713	rs4733455	chr8:33651290	C/T	ch.8.33884649F	chr8:33765107	NA	-0.48	-7.72	-0.39	1.36e-13	Body mass index;
LUSC	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg21385522	chr1:16154831	NA	0.56	8.49	0.42	6.77e-16	Systolic blood pressure;
LUSC	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg13852791	chr20:30311386	BCL2L1	0.95	14.9	0.63	7.51e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg00745463	chr17:30367425	LRRC37B	0.79	8.83	0.44	5.9e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs829883	1.000	rs2908843	chr12:98889332	C/G	cg25150519	chr12:98850993	NA	-0.64	-9.85	-0.47	2.93e-20	Colorectal adenoma (advanced);
LUSC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18876405	chr7:65276391	NA	0.56	8.89	0.44	3.88e-17	Aortic root size;
LUSC	cis	rs4343996	0.934	rs10261250	chr7:3340187	C/G	cg21248987	chr7:3385318	SDK1	0.39	6.62	0.34	1.41e-10	Motion sickness;
LUSC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	0.99	13.57	0.6	1.01e-33	Eosinophil percentage of granulocytes;
LUSC	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.21	0.41	4.96e-15	Neuroticism;
LUSC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.93	-0.51	5.8e-24	Alzheimer's disease (late onset);
LUSC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg15335139	chr3:50242325	SLC38A3	-0.25	-5.64	-0.3	3.57e-8	Body mass index;
LUSC	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.51	1.26e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	13.19	0.59	2.77e-32	Lung cancer in ever smokers;
LUSC	trans	rs4729127	1.000	rs8180727	chr7:94011085	A/G	cg20086523	chr13:52378287	DHRS12	-0.54	-6.09	-0.32	3.06e-9	Intelligence;
LUSC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg01733217	chr16:74700730	RFWD3	0.78	12.74	0.57	1.44e-30	Testicular germ cell tumor;
LUSC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.64	-0.6	5.38e-34	Chronic sinus infection;
LUSC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.67	0.47	1.16e-19	Coffee consumption (cups per day);
LUSC	cis	rs7674212	0.772	rs13113099	chr4:103974122	A/G	cg16532752	chr4:104119610	CENPE	-0.45	-6.23	-0.32	1.42e-9	Type 2 diabetes;
LUSC	cis	rs11051970	0.879	rs2728682	chr12:32580193	G/A	cg02745156	chr12:32552066	NA	0.43	7.32	0.37	1.88e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11756438	0.572	rs2798326	chr6:119005226	C/T	cg21191810	chr6:118973309	C6orf204	0.33	5.65	0.3	3.45e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.6	0.69	1.6e-49	Chronic sinus infection;
LUSC	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg13175981	chr1:150552382	MCL1	0.45	6.29	0.33	9.75e-10	Tonsillectomy;
LUSC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.53	-9.59	-0.46	2.16e-19	Electroencephalogram traits;
LUSC	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03878208	chr11:72483293	STARD10	0.54	6.9	0.35	2.56e-11	Type 2 diabetes;
LUSC	cis	rs11158026	0.603	rs3783646	chr14:55471887	T/C	cg04306507	chr14:55594613	LGALS3	0.39	7.22	0.37	3.56e-12	Parkinson's disease;
LUSC	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg09835421	chr16:68378352	PRMT7	-0.54	-5.95	-0.31	6.89e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.33	-0.45	1.56e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	6.08	0.32	3.27e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg27147174	chr7:100797783	AP1S1	-0.54	-8.53	-0.42	5.07e-16	Life satisfaction;
LUSC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg06713675	chr4:122721982	EXOSC9	-0.46	-8.17	-0.41	6.44e-15	Type 2 diabetes;
LUSC	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13647721	chr17:30228624	UTP6	0.67	7.94	0.4	3.05e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.62	-0.38	2.62e-13	Bone mineral density;
LUSC	trans	rs4718428	1.000	rs868961	chr7:66437208	G/T	cg18876405	chr7:65276391	NA	0.45	6.9	0.35	2.56e-11	Corneal structure;
LUSC	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg22903471	chr2:27725779	GCKR	-0.4	-6.68	-0.34	9.9e-11	Total body bone mineral density;
LUSC	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg24375607	chr4:120327624	NA	0.79	12.03	0.55	6.08e-28	Corneal astigmatism;
LUSC	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg07661805	chr8:143867942	LY6D	-0.27	-6.23	-0.32	1.41e-9	Urinary tract infection frequency;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06857516	chr19:48205035	GLTSCR1	-0.74	-6.15	-0.32	2.23e-9	Cognitive performance;
LUSC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg03929089	chr4:120376271	NA	0.82	11.07	0.52	1.75e-24	Coronary artery disease;
LUSC	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.89	15.25	0.64	3.33e-40	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs1922233	0.943	rs10009559	chr4:92409889	T/C	cg24250684	chr1:219729030	NA	-0.33	-6.33	-0.33	8.11e-10	Gut microbiome composition (summer and winter);
LUSC	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg04283868	chr2:201171347	SPATS2L	0.41	6.13	0.32	2.48e-9	QT interval;
LUSC	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg21972741	chr5:435613	AHRR	0.33	5.92	0.31	7.94e-9	Cystic fibrosis severity;
LUSC	cis	rs2573652	0.723	rs2573655	chr15:100515709	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.51	-9.58	-0.46	2.32e-19	Height;
LUSC	trans	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg07211511	chr3:129823064	LOC729375	-1.22	-19.03	-0.72	3.23e-55	Blood pressure (smoking interaction);
LUSC	cis	rs11039100	0.765	rs35863959	chr11:5834622	T/A	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg00012203	chr2:219082015	ARPC2	-0.77	-13.72	-0.6	2.88e-34	Colorectal cancer;
LUSC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	6.42	0.33	4.58e-10	Renal function-related traits (BUN);
LUSC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-0.92	-16.7	-0.67	5.83e-46	Cognitive function;
LUSC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg13206674	chr6:150067644	NUP43	0.59	9.05	0.44	1.18e-17	Lung cancer;
LUSC	cis	rs240768	0.655	rs240155	chr6:101063213	C/T	cg12253828	chr6:101329408	ASCC3	0.83	5.73	0.3	2.27e-8	Economic and political preferences (immigration/crime);
LUSC	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg13813247	chr22:41461852	NA	-0.4	-7.14	-0.36	5.69e-12	Neuroticism;
LUSC	cis	rs11608355	0.521	rs6606707	chr12:109830241	T/G	cg19025524	chr12:109796872	NA	-0.4	-7.31	-0.37	1.98e-12	Neuroticism;
LUSC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06873352	chr17:61820015	STRADA	-0.7	-11.94	-0.55	1.36e-27	Prudent dietary pattern;
LUSC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.5	-10.92	-0.51	5.84e-24	Type 2 diabetes;
LUSC	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.68	-0.6	3.86e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg17294928	chr15:75287854	SCAMP5	0.41	5.88	0.31	1e-8	Breast cancer;
LUSC	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg09876464	chr15:85330779	ZNF592	0.38	6.96	0.36	1.81e-11	P wave terminal force;
LUSC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-1.17	-19.43	-0.73	8.65e-57	Blood trace element (Zn levels);
LUSC	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	1.13	17.53	0.69	2.98e-49	Corneal structure;
LUSC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg23262073	chr20:60523788	NA	0.47	6.64	0.34	1.25e-10	Body mass index;
LUSC	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg12826209	chr6:26865740	GUSBL1	0.76	6.5	0.33	2.98e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7833986	1.000	rs56699713	chr8:57096670	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	8.87	0.44	4.64e-17	Height;
LUSC	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg18678763	chr11:4115507	RRM1	-0.53	-7.61	-0.38	2.73e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9888739	0.858	rs60312440	chr16:31340086	C/T	cg15817542	chr16:31343056	ITGAM	-0.52	-7.01	-0.36	1.33e-11	Systemic lupus erythematosus;
LUSC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.84	15.19	0.64	5.34e-40	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7560272	0.538	rs13006448	chr2:73924424	G/T	cg20560298	chr2:73613845	ALMS1	0.39	5.95	0.31	6.69e-9	Schizophrenia;
LUSC	trans	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18876405	chr7:65276391	NA	0.49	6.71	0.34	8.46e-11	Corneal structure;
LUSC	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	1.41	17.72	0.7	5.44e-50	Atopic dermatitis;
LUSC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.92	11.97	0.55	1.05e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg19789473	chr17:27170043	C17orf63	-0.31	-5.78	-0.3	1.73e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg12751644	chr20:60527061	NA	-0.43	-7.41	-0.38	1.07e-12	Obesity-related traits;
LUSC	trans	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs12519773	0.967	rs4242239	chr5:92482226	A/G	cg18783429	chr5:92414398	NA	0.32	6.97	0.36	1.72e-11	Migraine;
LUSC	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg17757837	chr7:157058334	UBE3C	-0.82	-13.33	-0.59	8.54e-33	Body mass index;
LUSC	cis	rs10986311	0.851	rs10818940	chr9:127063459	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.38	5.83	0.3	1.3e-8	Vitiligo;
LUSC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-7.47	-0.38	7.29e-13	Lung function (FEV1/FVC);
LUSC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.89	0.31	9.63e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	5.84	0.3	1.24e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs240764	0.817	rs239237	chr6:101094940	A/G	cg09795085	chr6:101329169	ASCC3	0.42	6.09	0.32	3.09e-9	Neuroticism;
LUSC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-10.01	-0.48	8.12e-21	Electroencephalogram traits;
LUSC	cis	rs3740713	1.000	rs73440634	chr11:18473546	T/A	cg15463284	chr11:18477534	LDHAL6A	-0.5	-5.84	-0.3	1.21e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg25182066	chr10:30743637	MAP3K8	-0.43	-6.29	-0.33	9.9e-10	Inflammatory bowel disease;
LUSC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.25	0.49	1.34e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg05347473	chr6:146136440	FBXO30	0.57	10.06	0.48	5.51e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9346649	0.606	rs6940383	chr6:168491688	G/A	cg02770688	chr6:168491649	NA	0.51	9.72	0.47	7.94e-20	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs6591341	0.515	rs599301	chr11:68189945	G/C	cg20283391	chr11:68216788	NA	-0.51	-7.09	-0.36	7.92e-12	Lean body mass;
LUSC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg01802117	chr1:53393560	SCP2	-0.37	-6.32	-0.33	8.28e-10	Monocyte count;
LUSC	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.22	-0.32	1.48e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2970818	0.831	rs4238020	chr12:4616642	C/T	cg11146114	chr12:4671731	NA	0.57	6.06	0.31	3.63e-9	Phosphorus levels;
LUSC	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg20684491	chr1:25596433	NA	0.36	5.83	0.3	1.33e-8	Erythrocyte sedimentation rate;
LUSC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-1.03	-19.84	-0.74	2.02e-58	Height;
LUSC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.33	0.37	1.8e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10754283	0.934	rs1934043	chr1:90106645	C/T	cg21401794	chr1:90099060	LRRC8C	0.65	9.74	0.47	6.91e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg03929089	chr4:120376271	NA	0.67	6.17	0.32	1.97e-9	Intraocular pressure;
LUSC	trans	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg26811252	chr16:29126840	RRN3P2	0.58	9.22	0.45	3.51e-18	Menopause (age at onset);
LUSC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg04733989	chr22:42467013	NAGA	-0.62	-9.75	-0.47	6.31e-20	Schizophrenia;
LUSC	cis	rs7605827	0.930	rs6431709	chr2:15638296	T/C	cg19274914	chr2:15703543	NA	0.47	9.12	0.45	7.34e-18	Educational attainment (years of education);
LUSC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg17173187	chr15:85201210	NMB	0.35	7.06	0.36	9.55e-12	P wave terminal force;
LUSC	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg15448220	chr1:150897856	SETDB1	0.4	5.89	0.31	9.28e-9	Melanoma;
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	0.91	16.83	0.68	1.84e-46	Menarche (age at onset);
LUSC	cis	rs7809950	1.000	rs4727680	chr7:107087407	T/G	cg23024343	chr7:107201750	COG5	-0.55	-8.76	-0.43	1.01e-16	Coronary artery disease;
LUSC	trans	rs7939886	0.920	rs61887958	chr11:55938234	A/G	cg15704280	chr7:45808275	SEPT13	0.88	6.69	0.34	9.39e-11	Myopia (pathological);
LUSC	cis	rs6005807	0.719	rs73430179	chr22:28998821	T/C	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs68170813	0.559	rs17350182	chr7:106909637	T/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.92e-20	Coronary artery disease;
LUSC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.7	0.39	1.61e-13	Prudent dietary pattern;
LUSC	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg17830980	chr10:43048298	ZNF37B	-0.39	-6.28	-0.32	1.07e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1499972	0.941	rs73168378	chr3:117636234	G/T	cg07612923	chr3:117604196	NA	0.64	5.76	0.3	1.95e-8	Schizophrenia;
LUSC	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07636037	chr3:49044803	WDR6	0.7	9.08	0.44	9.83e-18	Menarche (age at onset);
LUSC	cis	rs240993	0.595	rs3777912	chr6:111902676	T/C	cg22127309	chr6:111907043	TRAF3IP2	0.34	6.12	0.32	2.69e-9	Inflammatory skin disease;Psoriasis;
LUSC	cis	rs3087591	0.922	rs11867284	chr17:29597464	G/A	cg24425628	chr17:29625626	OMG;NF1	0.56	8.13	0.41	8.47e-15	Hip circumference;
LUSC	cis	rs4363385	0.720	rs1338178	chr1:152981550	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.48e-13	Inflammatory skin disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22159387	chr7:117824075	NAA38	-0.42	-6.26	-0.32	1.16e-9	Electrocardiographic conduction measures;
LUSC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg05738196	chr6:26577821	NA	0.53	8.32	0.41	2.23e-15	Schizophrenia;
LUSC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg11366901	chr6:160182831	ACAT2	0.96	13.04	0.58	1.04e-31	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg15485101	chr11:133734466	NA	-0.35	-6.28	-0.33	1.04e-9	Childhood ear infection;
LUSC	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.3	0.45	1.94e-18	Coffee consumption (cups per day);
LUSC	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg20283391	chr11:68216788	NA	0.51	7.18	0.37	4.49e-12	Total body bone mineral density;
LUSC	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg07895657	chr22:50616420	PANX2	-0.36	-5.89	-0.31	9.41e-9	Obesity-related traits;
LUSC	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg03433033	chr1:76189801	ACADM	-0.39	-5.71	-0.3	2.55e-8	Daytime sleep phenotypes;
LUSC	cis	rs4629710	0.592	rs9492864	chr6:131531306	A/T	cg12606694	chr6:131520996	AKAP7	0.62	9.17	0.45	4.95e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06850241	chr22:41845214	NA	-0.3	-5.92	-0.31	7.83e-9	Vitiligo;
LUSC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg07424592	chr7:64974309	NA	0.69	5.99	0.31	5.45e-9	Diabetic kidney disease;
LUSC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03264133	chr6:25882463	NA	0.39	6.36	0.33	6.57e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10324419	chr4:175205038	FBXO8;KIAA1712	0.37	6.5	0.34	2.96e-10	Triglycerides;
LUSC	cis	rs2219968	1.000	rs13260890	chr8:78970064	G/A	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs4596713	0.568	rs7048937	chr9:71746253	A/G	cg25283916	chr1:242222868	NA	0.29	6.01	0.31	4.87e-9	Headache;
LUSC	trans	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg18187862	chr3:45730750	SACM1L	0.55	7.02	0.36	1.26e-11	Primary sclerosing cholangitis;
LUSC	cis	rs3105593	1.000	rs3109894	chr15:50878574	C/T	cg08437265	chr15:50716283	USP8	0.4	6.1	0.32	2.86e-9	QT interval;
LUSC	cis	rs6674970	0.932	rs12569193	chr1:151115186	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.44	-5.94	-0.31	7.23e-9	Childhood ear infection;
LUSC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.63	-0.34	1.32e-10	Aortic root size;
LUSC	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg20283391	chr11:68216788	NA	-0.61	-8.46	-0.42	8.4e-16	Total body bone mineral density;
LUSC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.91	0.44	3.4e-17	Lung cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03833794	chr17:78190983	SGSH	0.48	6.88	0.35	2.99e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg11645453	chr3:52864694	ITIH4	-0.36	-8.25	-0.41	3.81e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.56	0.46	2.75e-19	Prudent dietary pattern;
LUSC	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg05855489	chr10:104503620	C10orf26	-0.48	-7.29	-0.37	2.21e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs1376359	0.537	rs579478	chr1:103255084	G/A	cg17154563	chr19:40477487	PSMC4	0.48	6.04	0.31	4.22e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg00432049	chr6:150390894	ULBP3	-0.27	-5.7	-0.3	2.7e-8	Alopecia areata;
LUSC	cis	rs73200209	0.744	rs11614312	chr12:116694851	A/G	cg01776926	chr12:116560359	MED13L	0.48	5.79	0.3	1.62e-8	Total body bone mineral density;
LUSC	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07080220	chr10:102295463	HIF1AN	-0.67	-9.33	-0.45	1.47e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.76	-11.96	-0.55	1.14e-27	Tonsillectomy;
LUSC	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg17425144	chr1:10567563	PEX14	0.64	13.22	0.59	2.22e-32	Breast size;
LUSC	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.9	20.74	0.75	5.35e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11585357	0.671	rs2501776	chr1:17619279	C/T	cg08277548	chr1:17600880	PADI3	0.47	5.88	0.31	9.75e-9	Hair shape;
LUSC	cis	rs16910800	1.000	rs73479585	chr11:23197391	T/C	cg20040320	chr11:23191996	NA	-0.45	-6.59	-0.34	1.68e-10	Cancer;
LUSC	trans	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs921665	0.749	rs2368682	chr2:3197387	C/T	cg02624386	chr2:3182749	NA	0.59	6.6	0.34	1.59e-10	World class endurance athleticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06005309	chr2:202316239	STRADB;TRAK2	0.44	6.31	0.33	8.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg02527881	chr3:46936655	PTH1R	-0.41	-7.36	-0.37	1.42e-12	Colorectal cancer;
LUSC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg11645453	chr3:52864694	ITIH4	0.34	7.95	0.4	2.82e-14	Bipolar disorder;
LUSC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg16434002	chr17:42200994	HDAC5	0.44	5.86	0.31	1.12e-8	Total body bone mineral density;
LUSC	trans	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.95	-0.36	1.93e-11	Monocyte count;
LUSC	trans	rs7660760	1.000	rs7662146	chr4:177530793	C/T	cg14630032	chr3:148898124	CP	-0.25	-5.97	-0.31	6.13e-9	Left ventricle wall thickness;
LUSC	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.82	-0.35	4.34e-11	Response to antipsychotic treatment;
LUSC	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg04990556	chr1:26633338	UBXN11	-0.46	-6.11	-0.32	2.7e-9	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg13042288	chr15:90349979	ANPEP	-0.49	-6.93	-0.35	2.17e-11	Uric acid levels;
LUSC	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg17652424	chr22:38574118	PLA2G6	-0.3	-6.51	-0.34	2.69e-10	Cutaneous nevi;
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	10.68	0.5	4.34e-23	Lymphocyte counts;
LUSC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg06028605	chr16:24865363	SLC5A11	0.51	9.0	0.44	1.77e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.58	10.63	0.5	6.51e-23	Bone mineral density;
LUSC	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg13902645	chr11:5959945	NA	-0.62	-8.6	-0.43	3.19e-16	DNA methylation (variation);
LUSC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg11752832	chr7:134001865	SLC35B4	0.59	9.23	0.45	3.21e-18	Mean platelet volume;
LUSC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.27	-0.45	2.39e-18	Monocyte percentage of white cells;
LUSC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg05872129	chr22:39784769	NA	-0.61	-11.08	-0.52	1.59e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs10266483	0.921	rs653746	chr7:63744777	T/C	cg24201672	chr7:64023550	ZNF680	-0.43	-5.66	-0.3	3.2e-8	Response to statin therapy;
LUSC	trans	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg18335740	chr13:41363409	SLC25A15	0.48	6.9	0.35	2.58e-11	Lewy body disease;
LUSC	cis	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg26958806	chr6:27640298	NA	0.75	6.01	0.31	4.76e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg03806693	chr22:41940476	POLR3H	-0.54	-7.3	-0.37	2.11e-12	Neuroticism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21005948	chr18:46065258	KIAA0427	-0.55	-7.22	-0.37	3.47e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg04871131	chr7:94954202	PON1	-0.38	-6.12	-0.32	2.65e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg00310523	chr12:86230176	RASSF9	0.52	9.79	0.47	4.67e-20	Major depressive disorder;
LUSC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.33	5.71	0.3	2.5e-8	Obesity-related traits;
LUSC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	11.95	0.55	1.2e-27	Platelet count;
LUSC	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg03806693	chr22:41940476	POLR3H	-0.57	-7.86	-0.39	5.5e-14	Neuroticism;
LUSC	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg22676075	chr6:135203613	NA	0.58	9.21	0.45	3.6e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs8018808	0.935	rs4899654	chr14:77867314	A/C	cg18872420	chr14:78023429	SPTLC2	0.36	5.73	0.3	2.2e-8	Myeloid white cell count;
LUSC	cis	rs921665	1.000	rs7581068	chr2:3178831	T/C	cg16434511	chr2:3151078	NA	-0.53	-5.92	-0.31	8.05e-9	World class endurance athleticism;
LUSC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg01097406	chr16:89675127	NA	0.46	9.3	0.45	1.96e-18	Vitiligo;
LUSC	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg05082376	chr22:42548792	NA	-0.42	-7.04	-0.36	1.11e-11	Cognitive function;
LUSC	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.32	0.67	1.91e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22029157	chr1:209979665	IRF6	0.72	10.71	0.51	3.31e-23	Cleft lip with or without cleft palate;
LUSC	cis	rs12545109	0.842	rs2609975	chr8:57401667	T/C	cg09654669	chr8:57350985	NA	-0.52	-6.75	-0.35	6.57e-11	Obesity-related traits;
LUSC	cis	rs9644630	1.000	rs4921657	chr8:19370867	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.33	6.06	0.31	3.62e-9	Oropharynx cancer;
LUSC	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg14092571	chr14:90743983	NA	-0.36	-5.99	-0.31	5.48e-9	Mortality in heart failure;
LUSC	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg12002119	chr2:101014098	CHST10	0.37	6.27	0.32	1.12e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	11.99	0.55	8.38e-28	Platelet count;
LUSC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg21665744	chr7:39171113	POU6F2	0.43	6.66	0.34	1.11e-10	IgG glycosylation;
LUSC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06634786	chr22:41940651	POLR3H	0.53	6.19	0.32	1.79e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg25482853	chr8:67687455	SGK3	1.2	17.05	0.68	2.38e-47	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg06521331	chr12:34319734	NA	-0.4	-5.73	-0.3	2.26e-8	Resting heart rate;
LUSC	cis	rs2274273	0.901	rs68046603	chr14:55762803	T/A	cg04306507	chr14:55594613	LGALS3	0.54	12.17	0.55	1.88e-28	Protein biomarker;
LUSC	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg01304814	chr3:48885189	PRKAR2A	0.85	5.97	0.31	6.12e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg24829409	chr8:58192753	C8orf71	-0.48	-5.89	-0.31	9.28e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.6	9.74	0.47	6.75e-20	Body mass index;
LUSC	cis	rs6800768	0.663	rs7428009	chr3:24094151	A/C	cg10674438	chr3:24145617	LOC152024	-0.41	-6.4	-0.33	5.21e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18854424	chr1:2615690	NA	-0.49	-9.93	-0.48	1.54e-20	Ulcerative colitis;
LUSC	cis	rs7945718	0.967	rs10765989	chr11:12769397	A/G	cg25843174	chr11:12811716	TEAD1	-0.31	-6.98	-0.36	1.58e-11	Educational attainment (years of education);
LUSC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	0.87	14.83	0.63	1.38e-38	Tonsillectomy;
LUSC	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg11584989	chr19:19387371	SF4	0.64	7.2	0.37	3.92e-12	Bipolar disorder;
LUSC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg20573242	chr4:122745356	CCNA2	-0.44	-6.87	-0.35	3.23e-11	Type 2 diabetes;
LUSC	trans	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg17712092	chr4:129076599	LARP1B	-0.73	-10.28	-0.49	9.91e-22	Breast cancer;
LUSC	cis	rs701145	0.585	rs938989	chr3:153788222	A/G	cg17054900	chr3:154042577	DHX36	0.75	6.32	0.33	8.21e-10	Coronary artery disease;
LUSC	cis	rs10193935	1.000	rs10195776	chr2:42425098	G/A	cg27598129	chr2:42591480	NA	-0.64	-8.64	-0.43	2.28e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.75	-0.35	6.52e-11	Lung cancer;
LUSC	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.7	10.54	0.5	1.25e-22	Corneal astigmatism;
LUSC	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg05110241	chr16:68378359	PRMT7	-0.56	-6.31	-0.33	9.05e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9515201	0.787	rs9521734	chr13:111037289	A/T	cg05272587	chr13:111038400	COL4A2	-0.37	-6.05	-0.31	3.8e-9	White matter hyperintensity burden;
LUSC	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg05925327	chr15:68127851	NA	-0.43	-6.93	-0.35	2.22e-11	Restless legs syndrome;
LUSC	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg18232548	chr7:50535776	DDC	0.55	7.74	0.39	1.17e-13	Malaria;
LUSC	cis	rs701145	0.585	rs1629659	chr3:153798731	C/T	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	cis	rs6681460	0.898	rs1032634	chr1:67195192	C/G	cg02459107	chr1:67143332	SGIP1	-0.46	-8.6	-0.43	3.16e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg15448220	chr1:150897856	SETDB1	-0.4	-6.04	-0.31	4.06e-9	Melanoma;
LUSC	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg04155289	chr7:94953770	PON1	-0.34	-5.77	-0.3	1.77e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg07211511	chr3:129823064	LOC729375	-0.74	-9.59	-0.46	2.12e-19	Blood pressure (smoking interaction);
LUSC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg26338869	chr17:61819248	STRADA	0.41	5.87	0.31	1.05e-8	Prudent dietary pattern;
LUSC	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.81	-0.3	1.49e-8	Type 2 diabetes;
LUSC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.34	0.56	4.44e-29	Prudent dietary pattern;
LUSC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg23436779	chr17:56769830	TEX14;RAD51C	-0.47	-5.99	-0.31	5.49e-9	Cognitive test performance;
LUSC	cis	rs7712401	0.791	rs4835897	chr5:122121504	C/G	cg19077854	chr5:122220652	SNX24	0.33	7.29	0.37	2.2e-12	Mean platelet volume;
LUSC	cis	rs17828380	0.920	rs12902541	chr15:63615016	T/C	cg05507819	chr15:63340323	TPM1	-0.76	-6.13	-0.32	2.46e-9	Social communication problems;
LUSC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg00343986	chr7:65444356	GUSB	-0.42	-6.44	-0.33	4.24e-10	Aortic root size;
LUSC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg16434002	chr17:42200994	HDAC5	0.43	5.74	0.3	2.12e-8	Total body bone mineral density;
LUSC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg11812906	chr14:75593930	NEK9	-0.64	-10.65	-0.5	5.18e-23	Height;
LUSC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg06238570	chr21:40685208	BRWD1	-0.54	-8.41	-0.42	1.18e-15	Menarche (age at onset);
LUSC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.23	0.56	1.09e-28	Cognitive test performance;
LUSC	cis	rs9399401	0.961	rs2050157	chr6:142658162	C/T	cg03128060	chr6:142623767	GPR126	0.31	5.68	0.3	2.96e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg17168535	chr8:21777572	XPO7	0.84	15.26	0.64	2.93e-40	Mean corpuscular volume;
LUSC	cis	rs4363385	0.574	rs6671520	chr1:152944156	C/T	cg00922841	chr1:152955080	SPRR1A	-0.36	-6.05	-0.31	3.88e-9	Inflammatory skin disease;
LUSC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	trans	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-9.22	-0.45	3.34e-18	Depression;
LUSC	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg18721089	chr20:30220636	NA	-0.39	-6.34	-0.33	7.33e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg10840412	chr1:235813424	GNG4	0.67	8.97	0.44	2.19e-17	Bipolar disorder;
LUSC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg25767906	chr1:53392781	SCP2	-0.51	-9.52	-0.46	3.54e-19	Monocyte count;
LUSC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14298792	chr15:30685198	CHRFAM7A	-0.69	-8.93	-0.44	2.94e-17	Huntington's disease progression;
LUSC	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg18132916	chr6:79620363	NA	-0.37	-5.74	-0.3	2.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg21798802	chr22:38057573	PDXP	0.48	10.54	0.5	1.25e-22	Fat distribution (HIV);
LUSC	trans	rs12677056	0.735	rs72672881	chr8:113300247	G/A	cg12159992	chr12:102059490	MYBPC1	0.36	6.03	0.31	4.3e-9	Peripheral artery disease;
LUSC	cis	rs12220238	1.000	rs9665468	chr10:75938838	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.57	6.84	0.35	3.84e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.6	-0.47	1.92e-19	Gut microbiome composition (summer);
LUSC	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg05234568	chr11:5960015	NA	-0.57	-8.51	-0.42	5.84e-16	DNA methylation (variation);
LUSC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg06096015	chr1:231504339	EGLN1	0.56	9.73	0.47	7.59e-20	Hemoglobin concentration;
LUSC	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg07148914	chr20:33460835	GGT7	0.53	8.26	0.41	3.47e-15	Height;
LUSC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.66	0.34	1.13e-10	Platelet count;
LUSC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	13.27	0.59	1.42e-32	Mean platelet volume;
LUSC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg23711669	chr6:146136114	FBXO30	0.9	17.2	0.69	6.1e-48	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9815354	0.951	rs9850310	chr3:41891098	T/C	cg03022575	chr3:42003672	ULK4	0.63	6.85	0.35	3.49e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7177699	0.581	rs7181432	chr15:79123779	C/T	cg00540400	chr15:79124168	NA	0.43	7.5	0.38	5.63e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg23950597	chr19:37808831	NA	-0.64	-7.65	-0.39	2.23e-13	Coronary artery calcification;
LUSC	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg18721089	chr20:30220636	NA	-0.4	-6.56	-0.34	2.03e-10	Mean corpuscular hemoglobin;
LUSC	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg15704280	chr7:45808275	SEPT13	-0.76	-9.6	-0.47	2.01e-19	Coronary artery disease;
LUSC	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg10560079	chr2:191398806	TMEM194B	-0.71	-8.6	-0.43	3.09e-16	Diastolic blood pressure;
LUSC	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.8	0.3	1.51e-8	Cognitive test performance;
LUSC	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg12935359	chr14:103987150	CKB	0.65	10.48	0.5	2.01e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs4654899	1.000	rs7521675	chr1:21424070	T/C	cg01072550	chr1:21505969	NA	-0.53	-8.09	-0.4	1.11e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05776053	chr2:74358815	NA	0.45	7.13	0.36	6.06e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg05373962	chr22:49881684	NA	-0.43	-10.23	-0.49	1.53e-21	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.02	-0.31	4.54e-9	Triglycerides;
LUSC	cis	rs11785693	0.862	rs17351027	chr8:4987098	A/G	cg26367366	chr8:4980734	NA	-0.67	-8.07	-0.4	1.24e-14	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg15595755	chr5:1867978	NA	0.4	6.28	0.32	1.06e-9	Cardiovascular disease risk factors;
LUSC	cis	rs4786125	0.581	rs7194903	chr16:6918194	A/G	cg03623568	chr16:6915990	A2BP1	-0.43	-7.5	-0.38	5.74e-13	Heart rate variability traits (SDNN);
LUSC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.54	-0.42	4.92e-16	Aortic root size;
LUSC	trans	rs10511400	0.618	rs923728	chr3:119918149	C/T	cg02809009	chr19:50354510	PTOV1	0.65	6.3	0.33	9.19e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs926392	0.932	rs6124105	chr20:37686081	G/A	cg27552599	chr20:37590471	DHX35	0.33	5.75	0.3	2e-8	Dialysis-related mortality;
LUSC	cis	rs7189233	0.531	rs9921627	chr16:53482692	G/A	cg09728985	chr16:53543985	NA	-0.3	-5.78	-0.3	1.73e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	5.71	0.3	2.56e-8	Schizophrenia;
LUSC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24838063	chr12:130822603	PIWIL1	0.7	10.79	0.51	1.7e-23	Menopause (age at onset);
LUSC	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg21775007	chr8:11205619	TDH	0.54	8.0	0.4	2.08e-14	Retinal vascular caliber;
LUSC	trans	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg04995722	chr7:26192034	NFE2L3	-0.43	-6.67	-0.34	1.05e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg05072774	chr3:49840536	C3orf54	-0.42	-5.69	-0.3	2.71e-8	Resting heart rate;
LUSC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg06453172	chr10:134556979	INPP5A	-0.49	-6.18	-0.32	1.91e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg11062466	chr8:58055876	NA	0.68	8.12	0.41	8.95e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg01528321	chr10:82214614	TSPAN14	0.87	13.27	0.59	1.39e-32	Post bronchodilator FEV1;
LUSC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.73	-11.64	-0.54	1.67e-26	Body mass index;
LUSC	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.1	-0.32	2.92e-9	Myopia (pathological);
LUSC	cis	rs7246967	0.673	rs34342502	chr19:22881428	C/A	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs8030485	0.536	rs4778918	chr15:79434040	T/C	cg17916960	chr15:79447300	NA	0.4	7.29	0.37	2.27e-12	Left ventricle wall thickness;
LUSC	cis	rs243505	1.000	rs1019058	chr7:148424243	A/G	cg09806900	chr7:148480153	CUL1	-0.48	-6.84	-0.35	3.81e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg13010199	chr12:38710504	ALG10B	-0.49	-7.62	-0.39	2.56e-13	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-8.31	-0.41	2.37e-15	Alzheimer's disease;
LUSC	cis	rs2282300	0.653	rs67745574	chr11:30234839	C/T	cg25418670	chr11:30344373	C11orf46	-0.66	-9.48	-0.46	4.95e-19	Morning vs. evening chronotype;
LUSC	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg24375607	chr4:120327624	NA	0.79	12.05	0.55	5.19e-28	Corneal astigmatism;
LUSC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg22823121	chr1:150693482	HORMAD1	0.54	8.11	0.41	9.61e-15	Melanoma;
LUSC	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg15423357	chr2:25149977	NA	0.35	6.43	0.33	4.46e-10	Body mass index;
LUSC	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg02269571	chr22:50332266	NA	0.58	7.48	0.38	6.75e-13	Schizophrenia;
LUSC	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.82	-0.43	6.68e-17	Response to antipsychotic treatment;
LUSC	cis	rs7572644	0.656	rs12463914	chr2:28057359	C/T	cg27432699	chr2:27873401	GPN1	0.53	6.76	0.35	6.23e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-1.04	-20.21	-0.74	7.12e-60	Height;
LUSC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg25258033	chr6:167368657	RNASET2	0.36	5.66	0.3	3.2e-8	Primary biliary cholangitis;
LUSC	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.38e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.63	10.13	0.48	3.37e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6546550	0.935	rs13017134	chr2:70090579	C/G	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.17	-0.37	4.97e-12	Prevalent atrial fibrillation;
LUSC	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg12365402	chr11:9010492	NRIP3	-0.49	-9.43	-0.46	7.35e-19	Hemoglobin concentration;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg11408517	chr6:150039536	LATS1	0.41	6.02	0.31	4.62e-9	Triglycerides;
LUSC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.51	0.53	4.85e-26	Menopause (age at onset);
LUSC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	-0.5	-7.25	-0.37	2.91e-12	Resistin levels;
LUSC	cis	rs9815354	0.812	rs73071344	chr3:41827062	C/T	cg03022575	chr3:42003672	ULK4	0.83	8.43	0.42	1.06e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs68170813	0.559	rs12535081	chr7:106979291	C/T	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.69	-0.3	2.76e-8	Coronary artery disease;
LUSC	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg13010199	chr12:38710504	ALG10B	0.45	6.38	0.33	5.89e-10	Morning vs. evening chronotype;
LUSC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.65	-11.08	-0.52	1.63e-24	Blood protein levels;
LUSC	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg04176472	chr15:90893244	GABARAPL3	0.34	5.86	0.31	1.08e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-1.01	-14.28	-0.62	1.86e-36	Initial pursuit acceleration;
LUSC	cis	rs6484504	0.512	rs7940020	chr11:31366453	T/G	cg26647111	chr11:31128758	NA	0.4	5.65	0.3	3.36e-8	Red blood cell count;
LUSC	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg05072774	chr3:49840536	C3orf54	-0.43	-5.91	-0.31	8.3e-9	Resting heart rate;
LUSC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	22.9	0.78	1.85e-70	Height;
LUSC	cis	rs4363385	0.668	rs1933386	chr1:152959265	T/A	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.43	-0.38	9.41e-13	Inflammatory skin disease;
LUSC	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg22089800	chr15:90895588	ZNF774	0.53	7.56	0.38	3.96e-13	Rheumatoid arthritis;
LUSC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.1	-0.32	2.89e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs1941687	0.669	rs7243220	chr18:31408110	T/G	cg27147174	chr7:100797783	AP1S1	-0.44	-6.58	-0.34	1.87e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg04369109	chr6:150039330	LATS1	-0.57	-8.3	-0.41	2.65e-15	Lung cancer;
LUSC	trans	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.74	-0.35	7.03e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg10660136	chr2:232379107	C2orf52	0.46	6.05	0.31	3.81e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg10360139	chr7:1886902	MAD1L1	-0.47	-7.26	-0.37	2.67e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg23985595	chr17:80112537	CCDC57	-0.3	-5.71	-0.3	2.55e-8	Life satisfaction;
LUSC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg21770322	chr7:97807741	LMTK2	0.41	7.21	0.37	3.79e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg13010199	chr12:38710504	ALG10B	0.53	7.86	0.4	5.47e-14	Morning vs. evening chronotype;
LUSC	cis	rs12541635	0.639	rs10095827	chr8:106984403	A/G	cg10147462	chr8:107024639	NA	0.66	13.52	0.59	1.56e-33	Age of smoking initiation;
LUSC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg07424592	chr7:64974309	NA	0.7	6.15	0.32	2.24e-9	Diabetic kidney disease;
LUSC	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg04455712	chr21:45112962	RRP1B	0.45	8.45	0.42	8.82e-16	Mean corpuscular volume;
LUSC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg05025164	chr4:1340916	KIAA1530	0.42	6.34	0.33	7.29e-10	Obesity-related traits;
LUSC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg18402987	chr7:1209562	NA	0.7	7.58	0.38	3.42e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg04511125	chr2:88470314	THNSL2	0.72	6.83	0.35	3.94e-11	Plasma clusterin levels;
LUSC	cis	rs6847149	0.929	rs6839680	chr4:110765496	A/G	cg07850274	chr4:110748770	RRH	-0.52	-8.16	-0.41	6.87e-15	Exercise treadmill test traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22831313	chr6:125623058	HDDC2	-0.42	-6.37	-0.33	6.35e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg11751927	chr11:117857137	IL10RA	0.45	6.15	0.32	2.27e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg15790184	chr11:494944	RNH1	0.49	7.53	0.38	4.71e-13	Systemic lupus erythematosus;
LUSC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00339695	chr16:24857497	SLC5A11	0.59	8.78	0.43	8.37e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs6845621	0.901	rs11725069	chr4:18929324	G/T	cg12196642	chr4:18937545	NA	-0.36	-6.72	-0.34	8.04e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs60695258	0.517	rs867196	chr4:87971600	G/C	cg10685359	chr4:87814065	C4orf36	-0.35	-6.24	-0.32	1.3e-9	Hematocrit;
LUSC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21028142	chr17:79581711	NPLOC4	0.32	7.79	0.39	8.41e-14	Eye color traits;
LUSC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.29	-0.45	1.98e-18	Monocyte percentage of white cells;
LUSC	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.93	-0.35	2.15e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg08048268	chr3:133502702	NA	-0.4	-7.33	-0.37	1.71e-12	Iron status biomarkers;
LUSC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.83	-11.48	-0.53	6.28e-26	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg07810366	chr2:100720526	AFF3	0.45	7.6	0.38	2.95e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg03146154	chr1:46216737	IPP	0.52	7.67	0.39	1.95e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg13798780	chr7:105162888	PUS7	0.58	6.32	0.33	8.2e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6456156	0.742	rs2022000	chr6:167529611	A/G	cg07741184	chr6:167504864	NA	-0.36	-6.34	-0.33	7.42e-10	Primary biliary cholangitis;
LUSC	cis	rs4285028	0.898	rs12491991	chr3:121706021	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	9.4	0.46	9.18e-19	Multiple sclerosis;
LUSC	cis	rs11671005	0.735	rs45617039	chr19:58951096	G/A	cg13877915	chr19:58951672	ZNF132	0.44	5.68	0.3	2.96e-8	Mean platelet volume;
LUSC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg22535103	chr8:58192502	C8orf71	-0.74	-7.58	-0.38	3.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.8	-14.27	-0.62	2.07e-36	Dental caries;
LUSC	cis	rs7809950	1.000	rs17154104	chr7:107090698	C/T	cg23024343	chr7:107201750	COG5	-0.56	-8.81	-0.43	7.01e-17	Coronary artery disease;
LUSC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.77	0.3	1.8e-8	Life satisfaction;
LUSC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg06636001	chr8:8085503	FLJ10661	0.59	9.24	0.45	2.92e-18	Mood instability;
LUSC	cis	rs7599312	0.963	rs10184221	chr2:213409014	G/A	cg16329650	chr2:213403929	ERBB4	0.66	9.19	0.45	4.21e-18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-1.03	-19.86	-0.74	1.61e-58	Height;
LUSC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg06784218	chr1:46089804	CCDC17	-0.57	-11.25	-0.52	4.27e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9400467	0.508	rs456871	chr6:111687650	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg23093090	chr10:104574429	C10orf26	-0.38	-7.03	-0.36	1.14e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg23625390	chr15:77176239	SCAPER	0.39	5.65	0.3	3.36e-8	Blood metabolite levels;
LUSC	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg05925327	chr15:68127851	NA	-0.39	-5.98	-0.31	5.69e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11645453	chr3:52864694	ITIH4	-0.4	-10.04	-0.48	6.91e-21	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs4974559	0.947	rs10000797	chr4:1345647	G/A	cg02980000	chr4:1222292	CTBP1	0.73	7.22	0.37	3.59e-12	Systolic blood pressure;
LUSC	cis	rs6690583	0.623	rs12042018	chr1:85436937	T/C	cg22153463	chr1:85462885	MCOLN2	0.61	5.87	0.31	1.07e-8	Serum sulfate level;
LUSC	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.68	0.54	1.12e-26	Ileal carcinoids;
LUSC	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-8.77	-0.43	9.03e-17	Morning vs. evening chronotype;
LUSC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg25124228	chr12:125621409	AACS	-0.47	-7.14	-0.36	5.84e-12	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg21890820	chr11:65308645	LTBP3	0.5	7.33	0.37	1.77e-12	Bone mineral density;
LUSC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg01579765	chr21:45077557	HSF2BP	-0.49	-10.41	-0.49	3.67e-22	Mean corpuscular volume;
LUSC	cis	rs6469656	0.881	rs35338453	chr8:117791493	C/T	cg24004040	chr8:117650383	NA	0.41	5.79	0.3	1.63e-8	Colorectal cancer;
LUSC	cis	rs524023	0.756	rs475688	chr11:64364291	C/T	cg19131476	chr11:64387923	NRXN2	0.36	8.26	0.41	3.57e-15	Urate levels in obese individuals;
LUSC	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	-0.52	-6.91	-0.35	2.53e-11	Multiple sclerosis;
LUSC	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.4	-0.38	1.11e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1322512	0.713	rs75583601	chr6:152929264	C/T	cg27316956	chr6:152958899	SYNE1	-0.35	-5.87	-0.31	1.04e-8	Tonometry;
LUSC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.4	-5.81	-0.3	1.44e-8	Tonsillectomy;
LUSC	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg02423579	chr7:2872169	GNA12	-0.37	-5.68	-0.3	2.96e-8	Height;
LUSC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg11062466	chr8:58055876	NA	0.67	8.5	0.42	6.28e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs11971779	0.941	rs74299967	chr7:139043769	G/T	cg07862535	chr7:139043722	LUC7L2	0.74	8.31	0.41	2.47e-15	Diisocyanate-induced asthma;
LUSC	cis	rs4604732	0.642	rs7515859	chr1:247640057	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.36	5.82	0.3	1.38e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg15704280	chr7:45808275	SEPT13	-0.46	-6.36	-0.33	6.56e-10	HDL cholesterol;
LUSC	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg20734569	chr3:48348370	SPINK8	-0.41	-7.37	-0.37	1.37e-12	Coronary artery disease;
LUSC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg05754148	chr16:3507555	NAT15	0.53	7.99	0.4	2.2e-14	Tuberculosis;
LUSC	cis	rs6901250	0.655	rs9384990	chr6:117126941	A/G	cg12892004	chr6:117198278	RFX6	0.4	7.59	0.38	3.22e-13	C-reactive protein levels;
LUSC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16680214	chr1:154839983	KCNN3	-0.55	-10.74	-0.51	2.65e-23	Prostate cancer;
LUSC	trans	rs3857536	0.776	rs7765531	chr6:66932886	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.44e-9	Blood trace element (Cu levels);
LUSC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg12311346	chr5:56204834	C5orf35	-0.66	-10.18	-0.49	2.25e-21	Coronary artery disease;
LUSC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg05347473	chr6:146136440	FBXO30	0.57	9.83	0.47	3.39e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.16	-0.55	2.05e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg15848620	chr12:58087721	OS9	-0.57	-8.24	-0.41	4.01e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs3820928	0.709	rs10178202	chr2:227914561	C/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-6.67	-0.34	1.07e-10	Pulmonary function;
LUSC	cis	rs2262909	0.962	rs2017521	chr19:22126138	T/C	cg11619707	chr19:22235551	ZNF257	-0.39	-5.72	-0.3	2.32e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	trans	rs61931739	0.658	rs708142	chr12:33719872	G/A	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg11941060	chr3:133502564	NA	-0.52	-8.0	-0.4	2.11e-14	Iron status biomarkers;
LUSC	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg19812747	chr11:111475976	SIK2	-0.5	-7.04	-0.36	1.1e-11	Primary sclerosing cholangitis;
LUSC	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.49	16.86	0.68	1.38e-46	Opioid sensitivity;
LUSC	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.35	5.65	0.3	3.38e-8	Response to antipsychotic treatment;
LUSC	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg15704280	chr7:45808275	SEPT13	-0.63	-7.68	-0.39	1.83e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-7.45	-0.38	7.91e-13	Alzheimer's disease (late onset);
LUSC	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg23992470	chr4:843637	GAK	-0.54	-6.2	-0.32	1.62e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7712401	0.601	rs417268	chr5:122345012	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.25	-0.45	2.68e-18	Mean platelet volume;
LUSC	cis	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.29	-0.37	2.33e-12	Morning vs. evening chronotype;
LUSC	cis	rs10979	0.557	rs9403517	chr6:143909400	T/C	cg25407410	chr6:143891975	LOC285740	-0.65	-8.16	-0.41	6.7e-15	Hypospadias;
LUSC	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg17691542	chr6:26056736	HIST1H1C	0.55	7.79	0.39	8.71e-14	Iron status biomarkers;
LUSC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	0.99	18.41	0.71	9.28e-53	Menopause (age at onset);
LUSC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.29	-0.37	2.23e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01570182	chr17:44337453	NA	0.93	14.09	0.61	1.05e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg00012203	chr2:219082015	ARPC2	-0.79	-13.56	-0.6	1.08e-33	Colorectal cancer;
LUSC	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg04362960	chr10:104952993	NT5C2	0.62	9.83	0.47	3.35e-20	Arsenic metabolism;
LUSC	trans	rs1934953	0.556	rs4917678	chr10:96851966	A/G	cg08498836	chr3:149292366	WWTR1	0.35	6.0	0.31	5.13e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7707921	0.767	rs226196	chr5:81576965	C/A	cg15871215	chr5:81402204	ATG10	0.43	6.72	0.35	7.83e-11	Breast cancer;
LUSC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.82	0.39	7e-14	Parkinson's disease;
LUSC	cis	rs9650315	0.929	rs67565274	chr8:57165771	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.07	0.36	9.07e-12	Height;
LUSC	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg20703242	chr1:230279135	GALNT2	0.63	8.71	0.43	1.47e-16	Coronary artery disease;
LUSC	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.62	-0.57	4.01e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg26924012	chr15:45694286	SPATA5L1	1.13	20.47	0.75	6.15e-61	Homoarginine levels;
LUSC	cis	rs2857891	0.697	rs1004754	chr11:6946248	T/C	cg14883916	chr11:6947541	ZNF215	0.46	6.05	0.31	3.92e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.66	-0.39	2.06e-13	Schizophrenia;
LUSC	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg13010199	chr12:38710504	ALG10B	0.56	8.42	0.42	1.12e-15	Morning vs. evening chronotype;
LUSC	trans	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.36	0.49	5.35e-22	Mean corpuscular volume;
LUSC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg05835009	chr4:710272	PCGF3	0.57	8.73	0.43	1.25e-16	White blood cell count;
LUSC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.56e-24	Aortic root size;
LUSC	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg17507749	chr15:85114479	UBE2QP1	0.65	8.15	0.41	7.64e-15	Schizophrenia;
LUSC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg16606324	chr3:10149918	C3orf24	0.59	8.55	0.42	4.49e-16	Alzheimer's disease;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg07792738	chr5:148738024	PCYOX1L	0.36	5.98	0.31	5.66e-9	Schizophrenia;
LUSC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg05425664	chr17:57184151	TRIM37	-0.55	-8.25	-0.41	3.79e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs11030122	0.702	rs11030276	chr11:3946134	A/G	cg18678763	chr11:4115507	RRM1	-0.45	-5.77	-0.3	1.79e-8	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg05059571	chr16:84539110	KIAA1609	0.47	9.22	0.45	3.56e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg20793623	chr3:41236272	NA	-0.35	-6.24	-0.32	1.35e-9	Schizophrenia;
LUSC	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-6.53	-0.34	2.48e-10	Homocysteine levels;
LUSC	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg25206134	chr2:45395956	NA	-0.51	-6.08	-0.32	3.34e-9	Bipolar disorder;
LUSC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.92	0.77	1.24e-66	Prudent dietary pattern;
LUSC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg10117171	chr1:25599238	RHD	0.38	5.85	0.31	1.15e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg05373962	chr22:49881684	NA	-0.44	-10.7	-0.51	3.68e-23	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.92	0.31	7.86e-9	Menopause (age at onset);
LUSC	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg06484146	chr7:12443880	VWDE	-0.62	-6.24	-0.32	1.36e-9	Coronary artery disease;
LUSC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg24250549	chr1:154909240	PMVK	0.57	9.15	0.45	5.78e-18	Prostate cancer;
LUSC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	0.83	15.43	0.65	6.13e-41	Gestational age at birth (maternal effect);
LUSC	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23158103	chr7:148848205	ZNF398	-0.45	-7.25	-0.37	2.86e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg11812906	chr14:75593930	NEK9	-0.64	-10.75	-0.51	2.31e-23	Height;
LUSC	trans	rs2018683	0.707	rs917216	chr7:28971472	A/G	cg19402173	chr7:128379420	CALU	-0.46	-7.07	-0.36	9.25e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg16342193	chr10:102329863	NA	-0.36	-6.66	-0.34	1.15e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg08125401	chr15:74726457	SEMA7A	0.5	6.02	0.31	4.63e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs909341	0.629	rs3761124	chr20:62288752	T/C	cg16989086	chr20:62203971	PRIC285	-0.53	-7.36	-0.37	1.41e-12	Atopic dermatitis;
LUSC	trans	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg25482853	chr8:67687455	SGK3	1.11	15.42	0.64	6.91e-41	Obesity-related traits;
LUSC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.61	-0.43	2.98e-16	Lung cancer;
LUSC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg00310523	chr12:86230176	RASSF9	-0.43	-7.91	-0.4	3.85e-14	Major depressive disorder;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg13400516	chr1:2159040	SKI	0.37	6.29	0.33	9.71e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg02493740	chr2:85810744	VAMP5	0.52	9.12	0.45	6.97e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-9.64	-0.47	1.49e-19	Gut microbiome composition (summer);
LUSC	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.24	-0.37	3.08e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08677398	chr8:58056175	NA	0.55	6.95	0.36	1.94e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs877282	0.947	rs12358875	chr10:757531	T/C	cg17470449	chr10:769945	NA	0.52	6.97	0.36	1.72e-11	Uric acid levels;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg06475894	chr1:223567955	C1orf65	-0.38	-5.99	-0.31	5.28e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg06637938	chr14:75390232	RPS6KL1	0.52	8.37	0.42	1.6e-15	Height;
LUSC	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-18.39	-0.71	1.14e-52	Primary sclerosing cholangitis;
LUSC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg11812906	chr14:75593930	NEK9	-0.66	-11.23	-0.52	4.98e-25	Height;
LUSC	cis	rs17125944	0.686	rs7143400	chr14:53324891	A/C	cg00686598	chr14:53173677	PSMC6	-0.65	-5.82	-0.3	1.4e-8	Alzheimer's disease (late onset);
LUSC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.16	0.32	2.14e-9	Menopause (age at onset);
LUSC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg02782426	chr3:40428986	ENTPD3	0.37	7.0	0.36	1.43e-11	Renal cell carcinoma;
LUSC	cis	rs10740039	0.768	rs10821801	chr10:62371775	C/A	cg18175470	chr10:62150864	ANK3	-0.44	-6.6	-0.34	1.66e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02018176	chr4:1364513	KIAA1530	0.71	12.82	0.57	7.19e-31	Longevity;
LUSC	cis	rs16912285	0.688	rs7128427	chr11:24338598	C/T	ch.11.24196551F	chr11:24239977	NA	0.85	8.18	0.41	6.17e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg11871910	chr12:69753446	YEATS4	0.71	11.97	0.55	1.05e-27	Blood protein levels;
LUSC	cis	rs7572644	0.699	rs13400398	chr2:28162109	C/T	cg27432699	chr2:27873401	GPN1	-0.51	-6.86	-0.35	3.39e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.12	0.45	6.99e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.72	-10.11	-0.48	3.96e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg07936489	chr17:37558343	FBXL20	-0.7	-9.74	-0.47	6.83e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs934734	0.563	rs11126035	chr2:65597066	T/C	cg08085232	chr2:65598271	SPRED2	-0.43	-6.76	-0.35	6.04e-11	Rheumatoid arthritis;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg17949255	chr17:48942907	TOB1	0.41	6.24	0.32	1.34e-9	Mosquito bite size;
LUSC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.19	-0.37	4.4e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.23	0.45	3.24e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.41	-0.33	5.06e-10	Neuroticism;
LUSC	cis	rs250677	0.522	rs6872172	chr5:148359529	G/C	cg18129178	chr5:148520854	ABLIM3	0.52	7.36	0.37	1.41e-12	Breast cancer;
LUSC	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg21385522	chr1:16154831	NA	-0.55	-8.26	-0.41	3.55e-15	Systolic blood pressure;
LUSC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-8.57	-0.42	3.87e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg20607287	chr7:12443886	VWDE	-0.58	-5.97	-0.31	6.11e-9	Coronary artery disease;
LUSC	cis	rs17824933	0.836	rs2074233	chr11:60785464	G/A	cg16817237	chr11:60793675	NA	0.36	5.74	0.3	2.15e-8	Multiple sclerosis;
LUSC	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.86	-0.35	3.29e-11	Breast cancer;
LUSC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.99	14.11	0.61	8.99e-36	Platelet count;
LUSC	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg12935359	chr14:103987150	CKB	0.65	10.68	0.5	4.17e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24110177	chr3:50126178	RBM5	0.61	10.29	0.49	9.34e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg18681998	chr4:17616180	MED28	-0.88	-15.36	-0.64	1.19e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg26384229	chr12:38710491	ALG10B	0.72	11.4	0.53	1.24e-25	Morning vs. evening chronotype;
LUSC	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.2	0.49	1.84e-21	Lymphocyte counts;
LUSC	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.61	9.74	0.47	6.61e-20	Alcohol dependence;
LUSC	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg10840412	chr1:235813424	GNG4	0.57	7.39	0.37	1.17e-12	Bipolar disorder;
LUSC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg02931644	chr1:25747376	RHCE	0.34	6.19	0.32	1.81e-9	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg24558204	chr6:135376177	HBS1L	0.67	10.28	0.49	1.04e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg13798780	chr7:105162888	PUS7	0.56	6.15	0.32	2.23e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	6.04	0.31	4.19e-9	Cystic fibrosis severity;
LUSC	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.55	-7.44	-0.38	8.74e-13	Body mass index (adult);
LUSC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	0.92	16.06	0.66	2.14e-43	Menopause (age at onset);
LUSC	cis	rs72772090	0.539	rs11738115	chr5:96113072	A/T	cg17330273	chr5:96107758	CAST;ERAP1	0.66	7.36	0.37	1.43e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.49	-0.42	6.87e-16	Bone mineral density;
LUSC	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg05925327	chr15:68127851	NA	-0.43	-6.95	-0.36	1.91e-11	Restless legs syndrome;
LUSC	cis	rs1538970	0.962	rs2153609	chr1:45814058	A/G	cg05343316	chr1:45956843	TESK2	0.56	7.98	0.4	2.35e-14	Platelet count;
LUSC	cis	rs807669	0.557	rs712958	chr22:19167409	T/C	cg02655711	chr22:19163373	SLC25A1	0.7	12.27	0.56	8.16e-29	Metabolite levels;
LUSC	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg13010199	chr12:38710504	ALG10B	0.69	11.81	0.54	3.94e-27	Heart rate;
LUSC	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg26384229	chr12:38710491	ALG10B	0.68	10.62	0.5	7e-23	Morning vs. evening chronotype;
LUSC	cis	rs71403859	0.504	rs35203704	chr16:71959661	G/A	cg03805757	chr16:71968109	PKD1L3	-0.6	-6.37	-0.33	6.29e-10	Post bronchodilator FEV1;
LUSC	cis	rs8099014	0.906	rs4940692	chr18:56099715	A/G	cg12907477	chr18:56117327	MIR122	0.45	6.84	0.35	3.83e-11	Platelet count;
LUSC	cis	rs28785552	0.800	rs1971063	chr19:53232854	G/C	cg22067481	chr19:53234126	ZNF611	-0.5	-6.68	-0.34	9.76e-11	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg11812906	chr14:75593930	NEK9	0.65	11.2	0.52	6.3e-25	Height;
LUSC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg00206168	chr11:65308501	LTBP3	1.33	8.86	0.44	4.93e-17	Height;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16322655	chr11:31391333	DNAJC24;DCDC1	0.37	6.23	0.32	1.41e-9	Asthma;
LUSC	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	0.93	14.04	0.61	1.58e-35	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg04455712	chr21:45112962	RRP1B	-0.46	-8.9	-0.44	3.61e-17	Mean corpuscular volume;
LUSC	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg08330031	chr10:104623503	C10orf32	0.31	5.66	0.3	3.32e-8	Arsenic metabolism;
LUSC	cis	rs790123	0.541	rs12330293	chr3:122383035	G/A	cg00926285	chr3:122398533	PARP14	-0.47	-5.98	-0.31	5.79e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg21141812	chr3:48556323	PFKFB4	0.34	6.07	0.32	3.53e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg08213375	chr14:104286397	PPP1R13B	0.44	7.58	0.38	3.4e-13	Reticulocyte count;
LUSC	cis	rs2970818	0.731	rs10849089	chr12:4661387	A/T	cg11146114	chr12:4671731	NA	-0.59	-6.14	-0.32	2.32e-9	Phosphorus levels;
LUSC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.69	-0.57	2.24e-30	Platelet count;
LUSC	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs926938	0.527	rs360584	chr1:115463181	G/A	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.44	-0.33	4.23e-10	Autism;
LUSC	cis	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg21775007	chr8:11205619	TDH	-0.63	-9.61	-0.47	1.85e-19	Triglycerides;
LUSC	cis	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.48	6.48	0.33	3.23e-10	Coronary artery disease;
LUSC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg01652190	chr22:50026171	C22orf34	-0.3	-6.12	-0.32	2.64e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg16586182	chr3:47516702	SCAP	-0.51	-8.01	-0.4	1.91e-14	Colorectal cancer;
LUSC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	1.04	20.11	0.74	1.65e-59	Menopause (age at onset);
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-8.41	-0.42	1.25e-15	Lymphocyte counts;
LUSC	trans	rs800082	1.000	rs800084	chr3:144340494	C/T	cg24215973	chr2:240111563	HDAC4	0.46	6.89	0.35	2.87e-11	Smoking behavior;
LUSC	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg08000102	chr2:233561755	GIGYF2	-0.7	-11.58	-0.54	2.72e-26	Coronary artery disease;
LUSC	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.61e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs12530845	0.673	rs4269479	chr7:135332379	C/T	cg23117316	chr7:135346802	PL-5283	-0.62	-9.56	-0.46	2.64e-19	Red blood cell traits;
LUSC	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.2	0.37	3.98e-12	Bipolar disorder;
LUSC	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg17764715	chr19:33622953	WDR88	0.58	7.9	0.4	4.17e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg00376283	chr12:123451042	ABCB9	0.7	7.93	0.4	3.22e-14	Height;Educational attainment;Head circumference (infant);
LUSC	trans	rs4942242	0.663	rs9525815	chr13:44223692	T/C	cg19169023	chr15:41853346	TYRO3	-0.57	-8.71	-0.43	1.48e-16	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.49	-0.42	6.98e-16	Bladder cancer;
LUSC	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg15704280	chr7:45808275	SEPT13	-0.53	-7.34	-0.37	1.63e-12	HDL cholesterol;
LUSC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg15691649	chr6:25882328	NA	-0.36	-5.75	-0.3	1.96e-8	Blood metabolite levels;
LUSC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.06	15.23	0.64	3.66e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg02376097	chr19:46275166	DMPK	0.4	6.99	0.36	1.52e-11	Coronary artery disease;
LUSC	trans	rs11088226	0.581	rs2833862	chr21:33884390	A/G	cg09050820	chr6:167586206	TCP10L2	0.45	6.96	0.36	1.82e-11	Gastritis;
LUSC	cis	rs11614062	0.761	rs11107115	chr12:93972987	A/G	cg18151635	chr12:93972918	NA	-0.63	-8.68	-0.43	1.73e-16	Height;
LUSC	cis	rs2979489	0.945	rs13250272	chr8:30294942	A/G	cg26383811	chr8:30366931	RBPMS	0.48	7.33	0.37	1.75e-12	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg21174375	chr14:64681225	SYNE2	0.33	6.12	0.32	2.66e-9	Atrial fibrillation;
LUSC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10754283	0.967	rs10922680	chr1:90101326	C/T	cg21401794	chr1:90099060	LRRC8C	-0.64	-9.7	-0.47	9.36e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg09479241	chr17:27052676	TLCD1	-0.43	-6.04	-0.31	4.18e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7246967	0.551	rs6511367	chr19:22821270	G/A	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg00339695	chr16:24857497	SLC5A11	0.37	6.49	0.33	3.1e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01457413	chr19:9879603	ZNF846	0.49	7.54	0.38	4.37e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-6.79	-0.35	5.19e-11	Menarche (age at onset);
LUSC	cis	rs9403521	1.000	rs6915784	chr6:143984268	A/C	cg18240653	chr6:144019428	PHACTR2	-0.46	-5.73	-0.3	2.24e-8	Obesity-related traits;
LUSC	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg04374321	chr14:90722782	PSMC1	0.69	10.65	0.5	5.28e-23	Mortality in heart failure;
LUSC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.09	-0.61	1.06e-35	Eye color traits;
LUSC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg00343986	chr7:65444356	GUSB	0.43	6.55	0.34	2.22e-10	Aortic root size;
LUSC	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg17788362	chr6:86352627	SYNCRIP	0.47	6.99	0.36	1.54e-11	Smooth-surface caries;
LUSC	cis	rs10512488	1.000	rs10512488	chr17:40963904	C/T	cg05878104	chr17:40932452	WNK4	0.41	5.89	0.31	9.34e-9	Type 2 diabetes (age of onset);
LUSC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06634786	chr22:41940651	POLR3H	0.52	6.04	0.31	4.17e-9	Vitiligo;
LUSC	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg15556689	chr8:8085844	FLJ10661	0.55	8.51	0.42	5.94e-16	Retinal vascular caliber;
LUSC	cis	rs7712401	0.562	rs246267	chr5:122256104	A/T	cg19077854	chr5:122220652	SNX24	0.42	9.68	0.47	1.04e-19	Mean platelet volume;
LUSC	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.86	-12.5	-0.56	1.08e-29	Asthma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03361557	chr19:19774500	ATP13A1	-0.52	-6.79	-0.35	5.05e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg13010199	chr12:38710504	ALG10B	0.42	6.1	0.32	2.87e-9	Morning vs. evening chronotype;
LUSC	cis	rs1847202	0.592	rs13073005	chr3:72951007	C/T	cg25664220	chr3:72788482	NA	-0.42	-7.62	-0.38	2.6e-13	Motion sickness;
LUSC	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg05731713	chr7:157510257	PTPRN2	0.49	9.33	0.45	1.55e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg25797454	chr6:150327115	RAET1K	0.34	7.8	0.39	7.9e-14	Alopecia areata;
LUSC	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.61	11.53	0.53	4.2e-26	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg03732007	chr1:2071316	PRKCZ	0.57	10.53	0.5	1.41e-22	Height;
LUSC	cis	rs73206853	0.620	rs111354540	chr12:111150302	A/G	cg12870014	chr12:110450643	ANKRD13A	0.64	6.25	0.32	1.23e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg23711669	chr6:146136114	FBXO30	0.9	16.67	0.67	8.1e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3126085	0.935	rs4845750	chr1:152201217	A/G	cg26876637	chr1:152193138	HRNR	0.49	6.32	0.33	8.36e-10	Atopic dermatitis;
LUSC	cis	rs2274273	0.624	rs10141396	chr14:55816925	A/C	cg04306507	chr14:55594613	LGALS3	0.47	9.15	0.45	5.85e-18	Protein biomarker;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26693529	chr2:20101779	TTC32	-0.4	-6.03	-0.31	4.36e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg02782426	chr3:40428986	ENTPD3	0.41	7.6	0.38	3.09e-13	Renal cell carcinoma;
LUSC	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg02176678	chr2:219576539	TTLL4	0.61	11.03	0.52	2.41e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs17001868	0.568	rs73167007	chr22:40734241	G/C	cg07138101	chr22:40742427	ADSL	0.64	7.62	0.38	2.72e-13	Mammographic density (dense area);
LUSC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg04756594	chr16:24857601	SLC5A11	0.34	5.73	0.3	2.27e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs701145	0.938	rs2596630	chr3:153992586	A/G	cg17054900	chr3:154042577	DHX36	0.84	8.49	0.42	6.84e-16	Coronary artery disease;
LUSC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	12.59	0.57	5.16e-30	Cognitive test performance;
LUSC	cis	rs4950928	0.823	rs10920579	chr1:203158972	A/G	cg17014757	chr1:203156097	CHI3L1	-0.43	-7.6	-0.38	2.92e-13	YKL-40 levels;
LUSC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg05313129	chr8:58192883	C8orf71	-0.5	-5.71	-0.3	2.44e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-9.08	-0.44	9.63e-18	Morning vs. evening chronotype;
LUSC	cis	rs2219968	0.676	rs34077447	chr8:78839966	T/C	cg00738934	chr8:78996279	NA	-0.35	-5.94	-0.31	6.98e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22544720	chr18:61089873	VPS4B	-0.44	-6.64	-0.34	1.3e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3741151	1.000	rs75007932	chr11:73080336	G/A	cg17517138	chr11:73019481	ARHGEF17	1.11	9.05	0.44	1.23e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg23719950	chr11:63933701	MACROD1	-0.61	-7.94	-0.4	3.13e-14	Attention deficit hyperactivity disorder;
LUSC	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.82	-0.3	1.41e-8	Bipolar disorder;
LUSC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg05347473	chr6:146136440	FBXO30	-0.65	-11.19	-0.52	6.83e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg08000102	chr2:233561755	GIGYF2	0.68	11.29	0.53	2.97e-25	Coronary artery disease;
LUSC	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg24375607	chr4:120327624	NA	0.73	10.41	0.49	3.68e-22	Corneal astigmatism;
LUSC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.8	-0.39	7.87e-14	Gut microbiome composition (summer);
LUSC	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg04362960	chr10:104952993	NT5C2	0.6	9.4	0.46	9.06e-19	Arsenic metabolism;
LUSC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.47	-8.11	-0.41	9.79e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03934478	chr11:495069	RNH1	0.82	9.84	0.47	3.08e-20	Body mass index;
LUSC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg16624210	chr5:671434	TPPP	-0.5	-6.56	-0.34	2.06e-10	Obesity-related traits;
LUSC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-9.38	-0.46	1.01e-18	Gut microbiome composition (summer);
LUSC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.59	9.61	0.47	1.82e-19	Aortic root size;
LUSC	cis	rs2227930	0.506	rs953135	chr3:142121826	C/T	cg16271453	chr3:142027066	XRN1	-0.54	-9.69	-0.47	9.77e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg26441486	chr22:50317300	CRELD2	-0.52	-7.94	-0.4	3.14e-14	Schizophrenia;
LUSC	cis	rs4839827	1	rs4839827	chr6:96853967	C/T	cg06623918	chr6:96969491	KIAA0776	0.56	8.99	0.44	1.85e-17	Migraine;
LUSC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg00825309	chr19:58991885	ZNF446	-0.52	-7.72	-0.39	1.4e-13	Uric acid clearance;
LUSC	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg14019695	chr9:139328340	INPP5E	-0.47	-8.94	-0.44	2.75e-17	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg04691961	chr3:161091175	C3orf57	-0.35	-6.09	-0.32	3.03e-9	Morning vs. evening chronotype;
LUSC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg13902645	chr11:5959945	NA	-0.6	-8.44	-0.42	9.71e-16	DNA methylation (variation);
LUSC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.27	-0.32	1.1e-9	Extrinsic epigenetic age acceleration;
LUSC	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg15704280	chr7:45808275	SEPT13	0.71	6.75	0.35	6.59e-11	Intraocular pressure;
LUSC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.42	0.38	9.68e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28830936	0.966	rs1918310	chr15:42065253	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.26	-0.32	1.17e-9	Diastolic blood pressure;
LUSC	cis	rs77633900	0.614	rs113557153	chr15:76994445	A/G	cg21673338	chr15:77095150	SCAPER	-0.79	-6.87	-0.35	3.12e-11	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg20684491	chr1:25596433	NA	0.39	6.26	0.32	1.15e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.83	14.33	0.62	1.2e-36	Metabolic syndrome;
LUSC	cis	rs4588572	0.615	rs4143070	chr5:77769094	G/C	cg11547950	chr5:77652471	NA	-0.46	-6.91	-0.35	2.46e-11	Triglycerides;
LUSC	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg18833306	chr6:118973337	C6orf204	-0.44	-5.68	-0.3	2.89e-8	Diastolic blood pressure;
LUSC	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.85	14.85	0.63	1.22e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs28595532	0.546	rs17516389	chr4:119239267	T/C	cg21605333	chr4:119757512	SEC24D	0.77	6.5	0.34	2.93e-10	Cannabis dependence symptom count;
LUSC	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	1.07	17.26	0.69	3.57e-48	Testicular germ cell tumor;
LUSC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg10729496	chr3:10149963	C3orf24	0.55	7.21	0.37	3.79e-12	Alzheimer's disease;
LUSC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-13.14	-0.58	4.64e-32	Platelet count;
LUSC	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg09904177	chr6:26538194	HMGN4	-0.76	-6.02	-0.31	4.72e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2235649	0.833	rs55684627	chr16:1848817	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-6.04	-0.31	4.07e-9	Blood metabolite levels;
LUSC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.5	0.38	5.88e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs10016947	1.000	rs10028984	chr4:104249970	T/C	cg02356640	chr11:1501973	HCCA2	0.68	6.01	0.31	4.99e-9	Breast cancer;
LUSC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03576123	chr11:487126	PTDSS2	-1.03	-10.97	-0.51	4.09e-24	Body mass index;
LUSC	cis	rs710865	0.627	rs10799710	chr1:19483209	A/G	cg13387374	chr1:19411106	UBR4	0.53	8.34	0.42	1.92e-15	Brain structure;
LUSC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg18512352	chr11:47633146	NA	-0.47	-9.32	-0.45	1.58e-18	Subjective well-being;
LUSC	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg13385521	chr17:29058706	SUZ12P	0.59	5.7	0.3	2.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs174601	0.615	rs174534	chr11:61549458	C/T	cg19610905	chr11:61596333	FADS2	0.46	6.97	0.36	1.69e-11	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUSC	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg09876464	chr15:85330779	ZNF592	0.36	6.68	0.34	9.78e-11	P wave terminal force;
LUSC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.39	0.56	3.01e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg11812906	chr14:75593930	NEK9	-0.64	-11.08	-0.52	1.66e-24	Height;
LUSC	cis	rs240764	0.618	rs846778	chr6:101273147	T/C	cg09795085	chr6:101329169	ASCC3	0.47	6.64	0.34	1.26e-10	Neuroticism;
LUSC	cis	rs2970818	0.764	rs11063179	chr12:4580488	G/A	cg11146114	chr12:4671731	NA	-0.71	-6.77	-0.35	5.8e-11	Phosphorus levels;
LUSC	cis	rs55665837	1.000	rs3923294	chr11:14441402	T/G	cg05501817	chr11:14380813	RRAS2	-0.41	-6.61	-0.34	1.51e-10	Vitamin D levels;
LUSC	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04004882	chr2:215674386	BARD1	0.47	6.2	0.32	1.62e-9	Neuroblastoma;
LUSC	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg00677455	chr12:58241039	CTDSP2	0.5	7.53	0.38	4.79e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg12560992	chr17:57184187	TRIM37	-0.71	-12.61	-0.57	4.42e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs6690583	0.623	rs61768852	chr1:85454613	T/C	cg11262906	chr1:85462892	MCOLN2	0.68	6.56	0.34	2.02e-10	Serum sulfate level;
LUSC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.75	0.3	2.03e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12618769	0.597	rs17505326	chr2:99156807	T/A	cg10123293	chr2:99228465	UNC50	0.49	7.92	0.4	3.53e-14	Bipolar disorder;
LUSC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg17294928	chr15:75287854	SCAMP5	-0.75	-10.03	-0.48	7.03e-21	Blood trace element (Zn levels);
LUSC	cis	rs17095355	1.000	rs12244557	chr10:111746142	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.63	-8.02	-0.4	1.8e-14	Biliary atresia;
LUSC	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg21231944	chr12:82153410	PPFIA2	-0.38	-6.09	-0.32	3.07e-9	Resting heart rate;
LUSC	cis	rs113835537	0.529	rs74869459	chr11:66296569	T/C	cg24851651	chr11:66362959	CCS	0.55	8.06	0.4	1.33e-14	Airway imaging phenotypes;
LUSC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	7.76	0.39	1.05e-13	Electroencephalogram traits;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07396495	chr16:53468716	RBL2	-0.52	-6.5	-0.34	2.85e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22590775	chr19:49891494	CCDC155	0.55	8.03	0.4	1.66e-14	Multiple sclerosis;
LUSC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg05973401	chr12:123451056	ABCB9	0.53	6.59	0.34	1.73e-10	Neutrophil percentage of white cells;
LUSC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06022373	chr22:39101656	GTPBP1	0.88	14.59	0.62	1.24e-37	Menopause (age at onset);
LUSC	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.72	11.39	0.53	1.31e-25	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8032315	1.000	rs6227	chr15:91425232	C/T	cg05469396	chr15:91419421	FURIN	-0.44	-6.87	-0.35	3.07e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	1.14	19.67	0.73	9.55e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7953508	0.506	rs12425869	chr12:93961353	A/G	cg18151635	chr12:93972918	NA	-0.63	-9.16	-0.45	5.26e-18	Pubertal anthropometrics;
LUSC	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg06532163	chr17:45867833	NA	0.35	6.56	0.34	2.03e-10	IgG glycosylation;
LUSC	cis	rs981844	1.000	rs2606337	chr4:154656845	C/T	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs56399783	0.901	rs7803944	chr7:2809087	G/A	cg14895029	chr7:2775587	GNA12	0.48	5.95	0.31	6.61e-9	Childhood ear infection;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24739457	chr1:205821442	NA	0.36	6.21	0.32	1.57e-9	Menarche (age at onset);
LUSC	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg12935359	chr14:103987150	CKB	-0.52	-8.73	-0.43	1.24e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs16937	0.711	rs11240390	chr1:205179457	A/G	cg00857998	chr1:205179979	DSTYK	0.47	6.66	0.34	1.11e-10	Schizophrenia;
LUSC	cis	rs7336332	0.598	rs76790205	chr13:28002885	C/T	cg22138327	chr13:27999177	GTF3A	0.82	9.95	0.48	1.34e-20	Weight;
LUSC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg23711669	chr6:146136114	FBXO30	0.85	15.91	0.66	8.01e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg11632617	chr15:75315747	PPCDC	-0.5	-6.58	-0.34	1.86e-10	Blood trace element (Zn levels);
LUSC	cis	rs7712401	0.601	rs28892	chr5:122283826	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.69	-0.47	1.01e-19	Mean platelet volume;
LUSC	cis	rs113835537	0.877	rs2229456	chr11:66328741	A/C	cg24851651	chr11:66362959	CCS	0.46	5.96	0.31	6.58e-9	Airway imaging phenotypes;
LUSC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.65	-0.54	1.53e-26	Schizophrenia;
LUSC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg26061582	chr7:22766209	IL6	0.49	7.3	0.37	2.14e-12	Lung cancer;
LUSC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2625529	0.824	rs7182776	chr15:72462831	A/G	cg16672083	chr15:72433130	SENP8	0.49	7.36	0.37	1.46e-12	Red blood cell count;
LUSC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg10729496	chr3:10149963	C3orf24	0.55	7.21	0.37	3.79e-12	Alzheimer's disease;
LUSC	cis	rs832540	0.866	rs252894	chr5:56224339	A/C	cg12311346	chr5:56204834	C5orf35	0.45	5.7	0.3	2.69e-8	Coronary artery disease;
LUSC	cis	rs4595586	0.545	rs4142846	chr12:39395140	C/T	cg26384229	chr12:38710491	ALG10B	0.46	6.4	0.33	5.4e-10	Morning vs. evening chronotype;
LUSC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-6.81	-0.35	4.53e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2731664	0.792	rs2630764	chr5:176880085	C/T	cg23176889	chr5:176863531	GRK6	-0.65	-13.37	-0.59	5.84e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg21285383	chr16:89894308	SPIRE2	0.32	6.61	0.34	1.56e-10	Vitiligo;
LUSC	cis	rs11645898	0.748	rs3852785	chr16:72198642	G/A	cg14768367	chr16:72042858	DHODH	-0.64	-6.94	-0.35	2.08e-11	Blood protein levels;
LUSC	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.35	0.42	1.82e-15	Lung cancer;
LUSC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg12419862	chr22:24373484	LOC391322	0.8	9.97	0.48	1.11e-20	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg11189052	chr15:85197271	WDR73	-0.44	-6.37	-0.33	6.24e-10	P wave terminal force;
LUSC	cis	rs28830936	0.841	rs4923914	chr15:42119603	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.69	-0.3	2.82e-8	Diastolic blood pressure;
LUSC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06634786	chr22:41940651	POLR3H	0.52	6.04	0.31	4.17e-9	Vitiligo;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09504196	chr7:148823235	ZNF425;ZNF398	0.47	6.99	0.36	1.5e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.57	-0.38	3.59e-13	Glomerular filtration rate;
LUSC	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg01943577	chr7:158741284	NA	-0.41	-5.99	-0.31	5.38e-9	Height;
LUSC	cis	rs72802342	0.510	rs12932952	chr16:75365486	C/T	cg03315344	chr16:75512273	CHST6	0.42	6.22	0.32	1.49e-9	Advanced age-related macular degeneration;
LUSC	cis	rs9311676	0.656	rs11130638	chr3:58405947	A/G	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.3e-10	Systemic lupus erythematosus;
LUSC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg16060761	chr17:80687452	NA	-0.41	-6.61	-0.34	1.49e-10	Breast cancer;
LUSC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg11245181	chr6:149772854	ZC3H12D	-0.3	-6.51	-0.34	2.8e-10	Dupuytren's disease;
LUSC	cis	rs4654899	0.785	rs9426656	chr1:21505932	T/G	cg01072550	chr1:21505969	NA	-0.54	-8.22	-0.41	4.67e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.25	0.45	2.77e-18	Prudent dietary pattern;
LUSC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg10169327	chr19:45448959	APOC2	0.28	6.13	0.32	2.54e-9	Blood protein levels;
LUSC	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07988820	chr12:82153109	PPFIA2	-0.42	-6.21	-0.32	1.6e-9	Resting heart rate;
LUSC	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg21770322	chr7:97807741	LMTK2	0.55	10.12	0.48	3.46e-21	Breast cancer;
LUSC	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.29	-5.77	-0.3	1.84e-8	Schizophrenia;
LUSC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.54	-0.38	4.48e-13	Blood metabolite levels;
LUSC	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg20487152	chr13:99095054	FARP1	-0.41	-6.87	-0.35	3.11e-11	Longevity;
LUSC	cis	rs3806933	0.522	rs13186912	chr5:110456704	A/T	cg04022379	chr5:110408740	TSLP	-0.63	-9.7	-0.47	9e-20	Eosinophilic esophagitis;
LUSC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg03188948	chr7:1209495	NA	0.49	6.47	0.33	3.53e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg06552810	chr11:31128660	NA	-0.42	-7.42	-0.38	9.89e-13	Red blood cell count;
LUSC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.75	-11.7	-0.54	9.89e-27	Menarche (age at onset);
LUSC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg05973401	chr12:123451056	ABCB9	0.53	7.8	0.39	7.89e-14	Platelet count;
LUSC	cis	rs34779708	0.706	rs36027395	chr10:35550323	T/A	cg03585969	chr10:35415529	CREM	0.53	7.32	0.37	1.88e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg09092052	chr15:45571596	NA	-0.43	-6.03	-0.31	4.27e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg05507819	chr15:63340323	TPM1	0.64	8.94	0.44	2.8e-17	Platelet count;
LUSC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.49	-6.64	-0.34	1.28e-10	Tonsillectomy;
LUSC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg02187348	chr16:89574699	SPG7	-0.48	-7.61	-0.38	2.82e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg09307838	chr4:120376055	NA	-0.68	-9.98	-0.48	1.06e-20	Corneal astigmatism;
LUSC	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg23359895	chr10:1095482	IDI1	-0.66	-6.04	-0.31	4.08e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs68170813	0.523	rs7777976	chr7:106888594	C/T	cg02696742	chr7:106810147	HBP1	-0.64	-9.58	-0.46	2.35e-19	Coronary artery disease;
LUSC	cis	rs2559856	0.903	rs10128996	chr12:102081498	G/A	cg12924262	chr12:102091054	CHPT1	0.42	5.8	0.3	1.51e-8	Blood protein levels;
LUSC	cis	rs11997175	0.574	rs4370495	chr8:33654819	G/A	ch.8.33884649F	chr8:33765107	NA	0.52	8.57	0.42	3.94e-16	Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00841985	chr3:15901302	ANKRD28	0.54	7.58	0.38	3.4e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs113835537	0.529	rs10501397	chr11:66272976	G/T	cg24851651	chr11:66362959	CCS	0.54	8.19	0.41	5.76e-15	Airway imaging phenotypes;
LUSC	cis	rs7189233	0.911	rs72801854	chr16:53517242	G/A	cg04059762	chr16:53544020	NA	-0.32	-5.86	-0.31	1.09e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.19	-0.32	1.78e-9	Type 2 diabetes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04703749	chr11:64809102	SAC3D1	0.47	6.71	0.34	8.59e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6580649	0.941	rs11612970	chr12:48451009	T/C	cg24011408	chr12:48396354	COL2A1	-0.46	-6.17	-0.32	1.95e-9	Lung cancer;
LUSC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg00945038	chr17:61921165	SMARCD2	0.51	8.67	0.43	1.94e-16	Prudent dietary pattern;
LUSC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg13939156	chr17:80058883	NA	0.33	6.46	0.33	3.66e-10	Life satisfaction;
LUSC	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.65	-0.43	2.19e-16	Total cholesterol levels;
LUSC	cis	rs4654899	0.865	rs960564	chr1:21416435	G/T	cg01072550	chr1:21505969	NA	-0.48	-7.06	-0.36	9.63e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs11958404	0.789	rs78112793	chr5:157428226	A/G	cg05962755	chr5:157440814	NA	0.53	6.14	0.32	2.32e-9	IgG glycosylation;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23180600	chr3:10780722	NA	0.45	6.83	0.35	4.02e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg01416388	chr22:39784598	NA	-0.43	-6.5	-0.33	2.99e-10	Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg08219700	chr8:58056026	NA	0.43	5.68	0.3	2.94e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2599510	0.811	rs176413	chr2:32646847	G/A	cg02381751	chr2:32503542	YIPF4	-0.39	-5.68	-0.3	2.87e-8	Interleukin-18 levels;
LUSC	cis	rs477692	1.000	rs7475154	chr10:131440584	C/T	cg05714579	chr10:131428358	MGMT	-0.5	-7.41	-0.38	1.03e-12	Response to temozolomide;
LUSC	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg04725166	chr1:7887271	PER3	-0.45	-6.34	-0.33	7.27e-10	Crohn's disease;
LUSC	trans	rs2420915	0.749	rs7087772	chr10:122863793	A/G	cg06217504	chr4:147056211	NA	0.45	6.17	0.32	1.96e-9	Fibrinogen levels;
LUSC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg10207240	chr12:122356781	WDR66	0.46	6.47	0.33	3.5e-10	Mean corpuscular volume;
LUSC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06634786	chr22:41940651	POLR3H	-0.53	-6.47	-0.33	3.42e-10	Vitiligo;
LUSC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.81	-0.39	7.54e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg08807101	chr21:30365312	RNF160	-0.68	-10.44	-0.5	2.82e-22	Pancreatic cancer;
LUSC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.42	6.45	0.33	3.84e-10	Prudent dietary pattern;
LUSC	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.56	0.42	4.16e-16	Response to antipsychotic treatment;
LUSC	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg13852791	chr20:30311386	BCL2L1	0.72	8.29	0.41	2.73e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg07148914	chr20:33460835	GGT7	0.46	6.71	0.34	8.25e-11	Height;
LUSC	cis	rs6574644	0.958	rs7153613	chr14:81779725	C/T	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	0.93	9.46	0.46	5.65e-19	Nonalcoholic fatty liver disease;
LUSC	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg26395211	chr5:140044315	WDR55	-0.45	-7.1	-0.36	7.41e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	19.86	0.74	1.73e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2235649	0.789	rs9939680	chr16:1852720	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-6.05	-0.31	3.93e-9	Blood metabolite levels;
LUSC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.61	9.46	0.46	5.63e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.51	0.5	1.62e-22	Morning vs. evening chronotype;
LUSC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00149659	chr3:10157352	C3orf10	0.92	12.88	0.58	4.25e-31	Alzheimer's disease;
LUSC	cis	rs3806933	0.522	rs17553936	chr5:110454681	A/G	cg04022379	chr5:110408740	TSLP	0.62	9.37	0.46	1.09e-18	Eosinophilic esophagitis;
LUSC	trans	rs9929218	1.000	rs13334294	chr16:68809278	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.72	-0.54	8.62e-27	Colorectal cancer;
LUSC	cis	rs11958404	0.615	rs10044900	chr5:157451580	C/T	cg05962755	chr5:157440814	NA	-0.38	-5.76	-0.3	1.95e-8	IgG glycosylation;
LUSC	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg25319279	chr11:5960081	NA	-0.46	-6.51	-0.34	2.74e-10	DNA methylation (variation);
LUSC	cis	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg21775007	chr8:11205619	TDH	-0.45	-6.17	-0.32	2e-9	Morning vs. evening chronotype;
LUSC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg20135002	chr11:47629003	NA	-0.51	-7.98	-0.4	2.41e-14	Subjective well-being;
LUSC	cis	rs7428	0.520	rs7605890	chr2:85559525	A/C	cg24342717	chr2:85555507	TGOLN2	-0.75	-11.62	-0.54	1.93e-26	Ear protrusion;
LUSC	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.41	-0.42	1.23e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10979	0.597	rs9496691	chr6:143910970	T/C	cg25407410	chr6:143891975	LOC285740	-0.65	-8.3	-0.41	2.65e-15	Hypospadias;
LUSC	cis	rs2413583	0.591	rs115263847	chr22:39729777	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.64	5.77	0.3	1.79e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10822866	chr20:60982408	CABLES2	-0.41	-6.46	-0.33	3.73e-10	Electrocardiographic conduction measures;
LUSC	cis	rs6087990	0.865	rs6058859	chr20:31335157	A/G	cg13636640	chr20:31349939	DNMT3B	0.98	21.32	0.76	2.89e-64	Ulcerative colitis;
LUSC	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-5.95	-0.31	6.93e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg05785598	chr3:49045655	WDR6	0.35	5.81	0.3	1.43e-8	Parkinson's disease;
LUSC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08704250	chr15:31115839	NA	-0.47	-7.03	-0.36	1.17e-11	Huntington's disease progression;
LUSC	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.86	-10.74	-0.51	2.64e-23	Blood trace element (Cu levels);
LUSC	cis	rs2235544	0.565	rs605182	chr1:54466956	A/G	cg25741118	chr1:54482237	LDLRAD1	0.28	6.03	0.31	4.41e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11764359	chr7:65958608	NA	-0.62	-9.47	-0.46	5.39e-19	Aortic root size;
LUSC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	12.37	0.56	3.28e-29	Menopause (age at onset);
LUSC	trans	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.65	9.2	0.45	3.95e-18	Obesity-related traits;
LUSC	cis	rs34779708	0.733	rs4244997	chr10:35547254	T/C	cg03585969	chr10:35415529	CREM	0.53	7.38	0.37	1.3e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg19773385	chr1:10388646	KIF1B	-0.58	-9.66	-0.47	1.26e-19	Hepatocellular carcinoma;
LUSC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.57	-0.46	2.53e-19	Mood instability;
LUSC	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.62	0.54	1.97e-26	Ileal carcinoids;
LUSC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.49	8.19	0.41	5.46e-15	Lymphocyte counts;
LUSC	cis	rs422249	0.634	rs174617	chr11:61629166	A/G	cg06860612	chr11:61641270	FADS3	0.28	5.77	0.3	1.81e-8	Trans fatty acid levels;
LUSC	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.2e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg11861562	chr11:117069780	TAGLN	-0.4	-7.15	-0.36	5.62e-12	Blood protein levels;
LUSC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg01616529	chr11:638424	DRD4	-0.35	-5.82	-0.3	1.38e-8	Systemic lupus erythematosus;
LUSC	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg23598886	chr18:12777645	NA	-0.64	-6.29	-0.33	9.71e-10	Inflammatory skin disease;
LUSC	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg19508488	chr2:152266495	RIF1	0.53	7.65	0.39	2.23e-13	Lung cancer;
LUSC	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg11845111	chr2:191398756	TMEM194B	-0.83	-11.14	-0.52	1.04e-24	Diastolic blood pressure;
LUSC	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-6.16	-0.32	2.07e-9	Bladder cancer;
LUSC	trans	rs7628219	0.607	rs6778490	chr3:70762164	C/T	cg02919122	chr3:112109797	NA	0.41	6.07	0.32	3.38e-9	Insomnia (caffeine-induced);
LUSC	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg17385448	chr1:15911702	AGMAT	0.36	6.2	0.32	1.69e-9	Systolic blood pressure;
LUSC	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg24631222	chr15:78858424	CHRNA5	-0.8	-11.04	-0.52	2.34e-24	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg21293242	chr8:11204541	TDH	0.31	5.89	0.31	9.28e-9	Retinal vascular caliber;
LUSC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg03233332	chr7:66118400	NA	-0.4	-6.01	-0.31	4.74e-9	Aortic root size;
LUSC	cis	rs7246967	0.611	rs56271774	chr19:22831327	C/T	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg05373962	chr22:49881684	NA	-0.44	-10.55	-0.5	1.15e-22	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.39	7.62	0.38	2.67e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.64	-0.43	2.31e-16	Bipolar disorder;
LUSC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg21132104	chr15:45694354	SPATA5L1	0.59	8.14	0.41	8.1e-15	Homoarginine levels;
LUSC	cis	rs6977660	0.714	rs12536561	chr7:19816659	G/A	cg07541023	chr7:19748670	TWISTNB	0.63	6.84	0.35	3.87e-11	Thyroid stimulating hormone;
LUSC	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.79	12.94	0.58	2.49e-31	Bladder cancer;
LUSC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg16479474	chr6:28041457	NA	0.32	5.72	0.3	2.31e-8	Parkinson's disease;
LUSC	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.96	0.4	2.8e-14	Birth weight;
LUSC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-1.04	-20.21	-0.74	7.12e-60	Height;
LUSC	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg03859395	chr2:55845619	SMEK2	0.86	16.22	0.66	4.87e-44	Metabolic syndrome;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05793193	chr7:152161912	LOC100128822	-0.47	-6.19	-0.32	1.72e-9	Hepatitis;
LUSC	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg24130564	chr14:104152367	KLC1	0.46	6.39	0.33	5.65e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	0.64	13.37	0.59	5.97e-33	Prudent dietary pattern;
LUSC	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg24375607	chr4:120327624	NA	0.75	11.42	0.53	9.94e-26	Corneal astigmatism;
LUSC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00166722	chr3:10149974	C3orf24	0.62	8.47	0.42	8.07e-16	Alzheimer's disease;
LUSC	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg18200150	chr17:30822561	MYO1D	0.36	6.89	0.35	2.78e-11	Schizophrenia;
LUSC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg22166914	chr1:53195759	ZYG11B	0.69	11.66	0.54	1.39e-26	Monocyte count;
LUSC	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs12210905	1.000	rs72843611	chr6:27131382	C/T	cg11502198	chr6:26597334	ABT1	-0.78	-5.65	-0.3	3.43e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs7119038	0.580	rs7123726	chr11:118694547	T/C	cg19308663	chr11:118741387	NA	0.35	6.14	0.32	2.28e-9	Sjögren's syndrome;
LUSC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-6.66	-0.34	1.11e-10	Mean corpuscular volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20272604	chr1:231004631	C1orf198	-0.54	-6.87	-0.35	3.07e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg06454157	chr6:167490870	NA	-0.28	-6.88	-0.35	2.98e-11	Primary biliary cholangitis;
LUSC	cis	rs6430585	0.591	rs72970243	chr2:136484232	G/A	cg07169764	chr2:136633963	MCM6	0.83	10.63	0.5	6.49e-23	Corneal structure;
LUSC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	1.03	18.73	0.72	5.27e-54	Parkinson's disease;
LUSC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg17911788	chr17:44343683	NA	0.31	6.02	0.31	4.69e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00995911	chr19:45004602	ZNF180	-0.47	-6.12	-0.32	2.58e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	11.59	0.54	2.41e-26	Coronary artery disease;
LUSC	cis	rs929596	0.564	rs2602373	chr2:234561953	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-6.03	-0.31	4.27e-9	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs10754283	0.934	rs6428563	chr1:90111583	T/A	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs1422110	0.616	rs1862230	chr5:85444868	C/T	cg01787110	chr1:109008453	NBPF6	-0.52	-8.66	-0.43	1.98e-16	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg03340356	chr1:67600835	NA	0.44	6.82	0.35	4.39e-11	Psoriasis;
LUSC	trans	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg26043149	chr18:55253948	FECH	-0.54	-7.99	-0.4	2.25e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg17168535	chr8:21777572	XPO7	0.84	15.49	0.65	3.71e-41	Mean corpuscular volume;
LUSC	trans	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-12.17	-0.55	1.89e-28	Colorectal cancer;
LUSC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg06026331	chr20:60912101	LAMA5	0.63	7.49	0.38	6.15e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg04722914	chr2:242255165	HDLBP;SEPT2	0.44	6.33	0.33	7.94e-10	Mosquito bite size;
LUSC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg20573242	chr4:122745356	CCNA2	0.43	6.63	0.34	1.36e-10	Type 2 diabetes;
LUSC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.71	10.65	0.5	5.51e-23	Aortic root size;
LUSC	cis	rs11756438	0.547	rs2798327	chr6:119005353	C/T	cg18833306	chr6:118973337	C6orf204	0.36	5.69	0.3	2.8e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.34	-5.84	-0.3	1.24e-8	Rheumatoid arthritis;
LUSC	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg02187348	chr16:89574699	SPG7	0.4	5.91	0.31	8.6e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg21951975	chr1:209979733	IRF6	0.55	8.25	0.41	3.6e-15	Cleft lip with or without cleft palate;
LUSC	cis	rs11031096	0.702	rs183484	chr11:4141132	C/A	cg18678763	chr11:4115507	RRM1	0.38	5.75	0.3	2.07e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs240764	0.658	rs7451736	chr6:101189901	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-6.32	-0.33	8.51e-10	Neuroticism;
LUSC	trans	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.51	-0.34	2.82e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg11843238	chr5:131593191	PDLIM4	-0.34	-6.01	-0.31	4.75e-9	Breast cancer;
LUSC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg20821713	chr7:1055600	C7orf50	-0.48	-6.54	-0.34	2.29e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs6484504	0.817	rs67707190	chr11:31210500	A/G	cg06552810	chr11:31128660	NA	-0.41	-6.4	-0.33	5.13e-10	Red blood cell count;
LUSC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg23711669	chr6:146136114	FBXO30	0.92	18.09	0.7	1.88e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9359856	0.636	rs1980878	chr6:90314749	A/C	cg13799429	chr6:90582589	CASP8AP2	0.71	7.61	0.38	2.87e-13	Bipolar disorder;
LUSC	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.38	0.46	1.02e-18	Arsenic metabolism;
LUSC	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg05163923	chr11:71159392	DHCR7	0.74	10.94	0.51	5.36e-24	Vitamin D levels;
LUSC	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.46	-7.09	-0.36	7.79e-12	Height;
LUSC	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg06360820	chr2:242988706	NA	-0.84	-10.09	-0.48	4.42e-21	Obesity-related traits;
LUSC	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg02023728	chr11:77925099	USP35	0.44	6.72	0.35	7.74e-11	Testicular germ cell tumor;
LUSC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg27535305	chr1:53392650	SCP2	-0.43	-8.48	-0.42	7.58e-16	Monocyte count;
LUSC	trans	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg17675199	chr6:35436792	RPL10A	-0.45	-6.47	-0.33	3.45e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3755132	0.929	rs3770467	chr2:15762935	G/A	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg06454157	chr6:167490870	NA	-0.27	-6.64	-0.34	1.28e-10	Primary biliary cholangitis;
LUSC	cis	rs7267979	0.565	rs4815437	chr20:25584788	C/G	cg03522245	chr20:25566470	NINL	-0.4	-6.09	-0.32	3.11e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	6.59	0.34	1.71e-10	Height;
LUSC	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09026875	chr17:60501189	METTL2A	-0.42	-6.57	-0.34	1.98e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-9.26	-0.45	2.63e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.55	10.95	0.51	4.77e-24	Asthma (sex interaction);
LUSC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.38	-0.33	5.85e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg04691961	chr3:161091175	C3orf57	-0.34	-5.78	-0.3	1.7e-8	Morning vs. evening chronotype;
LUSC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg12935359	chr14:103987150	CKB	-0.51	-7.89	-0.4	4.39e-14	Body mass index;
LUSC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06481639	chr22:41940642	POLR3H	0.5	5.77	0.3	1.81e-8	Cannabis dependence symptom count;
LUSC	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.09	-0.4	1.12e-14	Total cholesterol levels;
LUSC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg13531842	chr10:38383804	ZNF37A	-0.43	-6.71	-0.34	8.54e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12542260	0.871	rs72713049	chr8:125484088	T/G	cg27038428	chr8:125485867	RNF139	0.34	6.77	0.35	5.8e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	7.94	0.4	3.06e-14	Total body bone mineral density;
LUSC	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.82	-0.43	6.67e-17	Monocyte percentage of white cells;
LUSC	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg22508957	chr16:3507546	NAT15	-0.39	-6.14	-0.32	2.38e-9	Body mass index (adult);
LUSC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.84	-15.3	-0.64	2.06e-40	Cognitive function;
LUSC	cis	rs4908769	0.624	rs3765971	chr1:8445360	C/T	cg00546117	chr1:8445545	RERE	0.31	6.33	0.33	7.83e-10	Allergy;
LUSC	cis	rs559928	1.000	rs559928	chr11:64150370	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.62	-7.1	-0.36	7.46e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs11608355	1.000	rs10774692	chr12:109862324	G/T	cg05360138	chr12:110035743	NA	0.47	6.43	0.33	4.52e-10	Neuroticism;
LUSC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25072359	chr17:41440525	NA	0.67	9.51	0.46	3.94e-19	Menopause (age at onset);
LUSC	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.65	-10.92	-0.51	5.98e-24	Caffeine consumption;
LUSC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.17	-0.32	1.95e-9	Neutrophil percentage of white cells;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02160419	chr7:75807660	NA	-0.48	-6.19	-0.32	1.75e-9	Hepatitis;
LUSC	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg16339924	chr4:17578868	LAP3	-0.56	-8.16	-0.41	7.01e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg02117656	chr17:79614917	TSPAN10	0.31	5.77	0.3	1.85e-8	Eye color traits;
LUSC	cis	rs243505	1.000	rs243519	chr7:148423624	G/A	cg09806900	chr7:148480153	CUL1	-0.48	-6.95	-0.36	1.94e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg00042356	chr1:8021962	PARK7	0.84	10.02	0.48	8.04e-21	Inflammatory bowel disease;
LUSC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	cis	rs6754311	0.551	rs313519	chr2:136439517	A/C	cg07169764	chr2:136633963	MCM6	0.55	7.29	0.37	2.32e-12	Mosquito bite size;
LUSC	cis	rs1775715	0.870	rs11008696	chr10:32218614	G/A	cg26784012	chr10:32216390	ARHGAP12	0.42	6.97	0.36	1.71e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.57	-0.5	1.04e-22	Alzheimer's disease;
LUSC	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	6.98	0.36	1.63e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs66823261	0.778	rs2906332	chr8:194943	C/T	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.53	-6.55	-0.34	2.23e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg21775007	chr8:11205619	TDH	-0.47	-6.66	-0.34	1.12e-10	Monocyte count;
LUSC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg03146154	chr1:46216737	IPP	0.56	8.23	0.41	4.12e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.27	-0.45	2.45e-18	Depression;
LUSC	cis	rs4356932	1.000	rs4593163	chr4:76976056	T/C	cg00809888	chr4:76862425	NAAA	0.34	5.7	0.3	2.6e-8	Blood protein levels;
LUSC	cis	rs7674212	0.539	rs7676041	chr4:104126421	T/A	cg16532752	chr4:104119610	CENPE	-0.46	-6.82	-0.35	4.25e-11	Type 2 diabetes;
LUSC	cis	rs2224391	0.910	rs2875979	chr6:5275243	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.42	6.23	0.32	1.38e-9	Height;
LUSC	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.85	14.78	0.63	2.23e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs28647808	0.786	rs4962137	chr9:136256826	G/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg13390004	chr1:15929781	NA	0.4	6.75	0.35	6.45e-11	Systolic blood pressure;
LUSC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.25	-0.32	1.26e-9	Personality dimensions;
LUSC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg01657329	chr11:68192670	LRP5	-0.43	-6.38	-0.33	5.86e-10	Total body bone mineral density;
LUSC	trans	rs2315885	0.808	rs9591672	chr13:56276768	A/G	cg14536096	chr20:58509298	NA	-0.4	-6.05	-0.31	3.84e-9	Blood pressure;
LUSC	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg09092052	chr15:45571596	NA	0.44	6.15	0.32	2.16e-9	Glomerular filtration rate;
LUSC	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg20026190	chr17:76395443	PGS1	0.33	5.72	0.3	2.32e-8	HDL cholesterol levels;
LUSC	cis	rs10761482	0.861	rs10761491	chr10:62108718	A/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.1	-0.36	7.67e-12	Schizophrenia;
LUSC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg04727924	chr7:799746	HEATR2	-0.55	-6.7	-0.34	8.94e-11	Cerebrospinal P-tau181p levels;
LUSC	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-7.07	-0.36	8.83e-12	Triglycerides;
LUSC	cis	rs12928939	0.911	rs77823468	chr16:71828616	C/T	cg03805757	chr16:71968109	PKD1L3	-0.46	-6.65	-0.34	1.23e-10	Post bronchodilator FEV1;
LUSC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-8.78	-0.43	8.85e-17	Breast cancer;
LUSC	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg04733989	chr22:42467013	NAGA	0.61	9.4	0.46	8.69e-19	Schizophrenia;
LUSC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.64	0.6	5.79e-34	Cognitive test performance;
LUSC	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg20487152	chr13:99095054	FARP1	-0.42	-7.12	-0.36	6.7e-12	Longevity;
LUSC	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg15423357	chr2:25149977	NA	0.37	7.36	0.37	1.43e-12	Body mass index in non-asthmatics;
LUSC	cis	rs2798269	0.789	rs3886357	chr13:22085965	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.39	-5.77	-0.3	1.8e-8	PR segment;
LUSC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg12963246	chr6:28129442	ZNF389	0.51	7.06	0.36	9.81e-12	Depression;
LUSC	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg18721089	chr20:30220636	NA	-0.37	-6.54	-0.34	2.35e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs7189233	0.531	rs1362429	chr16:53479084	G/C	cg09728985	chr16:53543985	NA	-0.31	-5.8	-0.3	1.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg21854759	chr1:92012499	NA	-0.54	-9.14	-0.45	6.07e-18	Breast cancer;
LUSC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-12.09	-0.55	3.73e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg24154853	chr7:158122151	PTPRN2	0.45	8.87	0.44	4.48e-17	Calcium levels;
LUSC	cis	rs7851660	0.967	rs4743135	chr9:100599493	C/T	cg13688889	chr9:100608707	NA	-0.61	-10.38	-0.49	4.54e-22	Strep throat;
LUSC	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg14092571	chr14:90743983	NA	-0.36	-5.99	-0.31	5.36e-9	Mortality in heart failure;
LUSC	cis	rs950881	0.867	rs72823641	chr2:102936159	T/A	cg20060108	chr2:102954350	IL1RL1	0.5	6.14	0.32	2.31e-9	Allergy;
LUSC	cis	rs2932538	0.922	rs6537744	chr1:113096746	C/G	cg22162597	chr1:113214053	CAPZA1	0.7	10.11	0.48	3.74e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7808935	0.958	rs67152137	chr7:27975919	G/C	cg22168087	chr7:27702803	HIBADH	0.52	6.54	0.34	2.29e-10	Prostate cancer;
LUSC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-5.86	-0.31	1.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-7.01	-0.36	1.31e-11	Lung cancer;
LUSC	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg06484146	chr7:12443880	VWDE	-0.73	-7.35	-0.37	1.58e-12	Coronary artery disease;
LUSC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg04414720	chr1:150670196	GOLPH3L	0.5	7.92	0.4	3.46e-14	Melanoma;
LUSC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg13607699	chr17:42295918	UBTF	-0.47	-7.5	-0.38	5.74e-13	Total body bone mineral density;
LUSC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-6.38	-0.33	5.87e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.5	0.38	5.82e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg25258033	chr6:167368657	RNASET2	0.4	6.02	0.31	4.59e-9	Primary biliary cholangitis;
LUSC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg08773314	chr2:239334832	ASB1	0.38	8.07	0.4	1.27e-14	Multiple system atrophy;
LUSC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08280861	chr8:58055591	NA	-0.56	-6.63	-0.34	1.37e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7851660	0.874	rs10122541	chr9:100628268	G/A	cg13688889	chr9:100608707	NA	-0.56	-8.94	-0.44	2.73e-17	Strep throat;
LUSC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg02153584	chr22:29168773	CCDC117	0.57	8.74	0.43	1.17e-16	Lymphocyte counts;
LUSC	cis	rs7712401	0.601	rs35157167	chr5:122318201	G/C	cg19077854	chr5:122220652	SNX24	-0.43	-9.53	-0.46	3.35e-19	Mean platelet volume;
LUSC	cis	rs7202877	0.706	rs4888375	chr16:75322356	T/C	cg04384234	chr16:75411784	CFDP1	-0.62	-8.63	-0.43	2.53e-16	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.39	-0.37	1.2e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg18302933	chr2:88491318	NA	-0.38	-7.48	-0.38	6.46e-13	Response to metformin (IC50);
LUSC	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg18196295	chr10:418757	DIP2C	0.39	6.15	0.32	2.22e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.37	-0.91	1.58e-130	Myeloid white cell count;
LUSC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg03188948	chr7:1209495	NA	0.68	7.14	0.36	5.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg05535760	chr7:792225	HEATR2	-0.78	-7.77	-0.39	1e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg11752832	chr7:134001865	SLC35B4	0.43	6.27	0.32	1.11e-9	Mean platelet volume;
LUSC	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg17168535	chr8:21777572	XPO7	0.68	10.43	0.5	3.15e-22	Mean corpuscular volume;
LUSC	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg27411982	chr8:10470053	RP1L1	-0.36	-5.75	-0.3	2.01e-8	Retinal vascular caliber;
LUSC	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg25643088	chr3:52874325	TMEM110	0.4	5.99	0.31	5.3e-9	Schizophrenia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10598428	chr7:134001208	SLC35B4	-0.47	-6.48	-0.33	3.27e-10	Hepatitis;
LUSC	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg12292205	chr6:26970375	C6orf41	-0.59	-7.36	-0.37	1.48e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs711244	0.846	rs2245109	chr2:37086197	G/C	cg14987922	chr2:37194071	STRN	-0.44	-6.41	-0.33	5.01e-10	Mean platelet volume;
LUSC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg22535103	chr8:58192502	C8orf71	-0.7	-7.45	-0.38	8.32e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg03233332	chr7:66118400	NA	0.42	6.16	0.32	2.11e-9	Aortic root size;
LUSC	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg17830980	chr10:43048298	ZNF37B	0.46	7.13	0.36	6.27e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg02493740	chr2:85810744	VAMP5	-0.51	-8.85	-0.44	5.2e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs72674100	0.881	rs72874647	chr4:97964813	A/G	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg02527881	chr3:46936655	PTH1R	-0.56	-8.22	-0.41	4.41e-15	Birth weight;
LUSC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg12257692	chr3:49977190	RBM6	-0.25	-7.05	-0.36	1.06e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg06784218	chr1:46089804	CCDC17	-0.5	-9.59	-0.46	2.2e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg22484793	chr3:52261325	TLR9	0.26	6.07	0.32	3.49e-9	Electroencephalogram traits;
LUSC	cis	rs9399401	0.845	rs263178	chr6:142865106	C/T	cg03128060	chr6:142623767	GPR126	0.32	5.88	0.31	9.92e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs4631830	0.863	rs6481329	chr10:51529746	G/A	cg20129853	chr10:51489980	NA	-0.34	-6.85	-0.35	3.57e-11	Prostate-specific antigen levels;
LUSC	cis	rs6516091	0.850	rs62199232	chr20:6050137	T/G	cg25325723	chr20:6104886	FERMT1	-0.67	-7.19	-0.37	4.38e-12	Abdominal aortic aneurysm;
LUSC	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg02569458	chr12:86230093	RASSF9	-0.49	-8.25	-0.41	3.64e-15	Major depressive disorder;
LUSC	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg19116668	chr7:99932089	PMS2L1	-0.33	-5.67	-0.3	3.17e-8	Coronary artery disease;
LUSC	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg26395211	chr5:140044315	WDR55	0.41	6.28	0.32	1.06e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg04998671	chr14:104000505	TRMT61A	-0.46	-7.29	-0.37	2.33e-12	Coronary artery disease;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg04895581	chr8:94753488	RBM12B	0.38	6.06	0.31	3.65e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.43e-12	Body mass index;
LUSC	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg20821713	chr7:1055600	C7orf50	-0.5	-6.2	-0.32	1.68e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg08601574	chr20:25228251	PYGB	0.43	6.57	0.34	1.94e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	0.95	16.45	0.67	5.73e-45	Cognitive function;
LUSC	cis	rs3106136	0.967	rs12499309	chr4:95171284	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.36	-6.36	-0.33	6.51e-10	Capecitabine sensitivity;
LUSC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg23630131	chr7:65973040	NA	-0.21	-5.75	-0.3	2e-8	Aortic root size;
LUSC	cis	rs17253792	0.822	rs74412558	chr14:56054311	C/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	8.91e-12	Putamen volume;
LUSC	cis	rs17824933	1.000	rs916813	chr11:60764028	A/G	cg16817237	chr11:60793675	NA	0.4	6.32	0.33	8.24e-10	Multiple sclerosis;
LUSC	cis	rs9309473	1.000	rs7580825	chr2:73635148	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.81	-0.35	4.53e-11	Metabolite levels;
LUSC	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg25173405	chr17:45401733	C17orf57	0.36	5.7	0.3	2.58e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-7.31	-0.37	2.01e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg20066347	chr14:69620129	DCAF5	0.4	6.15	0.32	2.26e-9	N-glycan levels;
LUSC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg27165867	chr14:105738592	BRF1	-0.52	-7.45	-0.38	8.05e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7180079	1.000	rs12148898	chr15:64643691	T/C	cg08069370	chr15:64387884	SNX1	0.54	5.91	0.31	8.34e-9	Monocyte count;
LUSC	cis	rs540254	0.619	rs1556517	chr1:160771761	C/A	cg20255094	chr1:160771763	LY9	0.55	6.55	0.34	2.17e-10	Blood protein levels;
LUSC	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg27124370	chr19:33622961	WDR88	-0.56	-7.26	-0.37	2.79e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.81	0.39	7.59e-14	Neuroticism;
LUSC	cis	rs136211	0.640	rs9610495	chr22:36760838	G/A	cg10790723	chr22:36903033	FOXRED2	0.4	5.83	0.3	1.3e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.42	6.45	0.33	3.9e-10	Dupuytren's disease;
LUSC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-1.19	-12.97	-0.58	2.03e-31	Diabetic kidney disease;
LUSC	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.92	11.07	0.52	1.81e-24	Bipolar disorder;
LUSC	cis	rs4704187	0.687	rs1477933	chr5:74437153	G/A	cg03227963	chr5:74354835	NA	0.31	6.77	0.35	5.75e-11	Response to amphetamines;
LUSC	cis	rs977987	0.742	rs34624768	chr16:75331572	G/A	cg03315344	chr16:75512273	CHST6	0.47	8.82	0.43	6.26e-17	Dupuytren's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23187103	chr8:128748481	MYC	-0.43	-6.24	-0.32	1.3e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg00310523	chr12:86230176	RASSF9	0.45	8.06	0.4	1.42e-14	Major depressive disorder;
LUSC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg08847533	chr14:75593920	NEK9	0.8	15.08	0.64	1.54e-39	Height;
LUSC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg13647721	chr17:30228624	UTP6	-0.58	-6.02	-0.31	4.64e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg05347473	chr6:146136440	FBXO30	0.45	7.79	0.39	8.26e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg15423357	chr2:25149977	NA	0.35	6.49	0.33	3.09e-10	Body mass index;
LUSC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-0.87	-17.63	-0.69	1.28e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg27284194	chr4:1044797	NA	0.48	7.84	0.39	6.24e-14	Recombination rate (males);
LUSC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.48	0.38	6.75e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg12365402	chr11:9010492	NRIP3	0.46	8.46	0.42	8.76e-16	Hemoglobin concentration;
LUSC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.45	5.88	0.31	1.01e-8	Renal function-related traits (BUN);
LUSC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg02951883	chr7:2050386	MAD1L1	-0.45	-7.8	-0.39	8e-14	Schizophrenia;
LUSC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg07703079	chr11:430292	ANO9	-0.63	-6.78	-0.35	5.53e-11	Body mass index;
LUSC	cis	rs7582720	0.943	rs114372659	chr2:203715514	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	8.17	0.41	6.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs12195417	0.524	rs1171106	chr6:84214735	T/G	cg08257003	chr6:84140564	ME1	-0.28	-6.34	-0.33	7.62e-10	Schizophrenia;
LUSC	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg21775007	chr8:11205619	TDH	-0.48	-7.05	-0.36	1.03e-11	Triglycerides;
LUSC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg15448220	chr1:150897856	SETDB1	0.41	6.1	0.32	2.95e-9	Melanoma;
LUSC	trans	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg25214090	chr10:38739885	LOC399744	-0.4	-6.42	-0.33	4.56e-10	Corneal astigmatism;
LUSC	trans	rs683250	0.701	rs11607886	chr11:83204132	T/C	cg26617787	chr11:123396133	GRAMD1B	0.29	5.97	0.31	5.95e-9	Subcortical brain region volumes;
LUSC	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12311346	chr5:56204834	C5orf35	-0.7	-10.75	-0.51	2.44e-23	Coronary artery disease;
LUSC	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs977987	0.778	rs11862719	chr16:75431708	T/A	cg03315344	chr16:75512273	CHST6	0.48	9.12	0.45	6.97e-18	Dupuytren's disease;
LUSC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg02569458	chr12:86230093	RASSF9	0.58	9.82	0.47	3.54e-20	Major depressive disorder;
LUSC	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg04851639	chr8:1020857	NA	-0.4	-8.05	-0.4	1.45e-14	Schizophrenia;
LUSC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg03609598	chr5:56110824	MAP3K1	-0.39	-5.67	-0.3	3.12e-8	Initial pursuit acceleration;
LUSC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.68	-0.3	2.93e-8	Tonsillectomy;
LUSC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg27494647	chr7:150038898	RARRES2	0.45	7.17	0.37	4.97e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg09517075	chr8:22133004	PIWIL2	0.43	8.46	0.42	8.31e-16	Hypertriglyceridemia;
LUSC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	1.06	20.2	0.74	7.16e-60	Menopause (age at onset);
LUSC	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg20991723	chr1:152506922	NA	-0.49	-9.28	-0.45	2.21e-18	Hair morphology;
LUSC	trans	rs3858145	0.588	rs115455464	chr10:70038498	T/C	cg04882175	chr6:131122610	NA	-0.65	-8.81	-0.43	7.04e-17	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LUSC	cis	rs2580764	0.565	rs2044291	chr2:55247954	A/G	cg09592903	chr2:55203963	RTN4	-0.5	-10.14	-0.49	2.98e-21	Mean platelet volume;
LUSC	cis	rs11112613	0.775	rs10861462	chr12:106019898	C/T	cg03607813	chr12:105948248	NA	-0.43	-6.09	-0.32	3.14e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.9	0.4	4.07e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.16	-0.32	2.12e-9	Total body bone mineral density;
LUSC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.35	0.56	3.96e-29	Prudent dietary pattern;
LUSC	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg21724239	chr8:58056113	NA	0.56	6.66	0.34	1.13e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg13798780	chr7:105162888	PUS7	0.56	6.15	0.32	2.23e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg13010199	chr12:38710504	ALG10B	0.56	8.62	0.43	2.75e-16	Morning vs. evening chronotype;
LUSC	trans	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg05714579	chr10:131428358	MGMT	-0.66	-10.73	-0.51	2.83e-23	Response to temozolomide;
LUSC	cis	rs858239	0.601	rs6962526	chr7:23158233	G/A	cg23682824	chr7:23144976	KLHL7	0.39	5.68	0.3	2.92e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.7	0.47	9.08e-20	Bipolar disorder;
LUSC	cis	rs977987	0.806	rs11149832	chr16:75462713	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.56	0.46	2.75e-19	Dupuytren's disease;
LUSC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg17724175	chr1:150552817	MCL1	0.36	6.5	0.34	2.95e-10	Melanoma;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg17168838	chr19:54663528	LENG1	0.38	6.33	0.33	7.85e-10	Triglycerides;
LUSC	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.88	14.29	0.62	1.69e-36	Coronary artery disease;
LUSC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg17143192	chr8:8559678	CLDN23	0.66	9.61	0.47	1.84e-19	Obesity-related traits;
LUSC	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg18232548	chr7:50535776	DDC	-0.53	-7.42	-0.38	9.56e-13	Malaria;
LUSC	cis	rs2996428	0.667	rs7511793	chr1:3744249	A/G	cg13057898	chr1:3703894	LRRC47	0.49	8.61	0.43	3.03e-16	Red cell distribution width;
LUSC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.94	0.31	7.28e-9	Menopause (age at onset);
LUSC	cis	rs977987	0.806	rs4888420	chr16:75462998	G/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.39e-11	Dupuytren's disease;
LUSC	cis	rs4409675	0.527	rs12067053	chr1:28227122	T/G	cg23691781	chr1:28212827	C1orf38	0.32	7.65	0.39	2.21e-13	Corneal astigmatism;
LUSC	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.92	12.02	0.55	6.84e-28	Exhaled nitric oxide output;
LUSC	cis	rs10193935	1.000	rs10171023	chr2:42407093	G/C	cg27598129	chr2:42591480	NA	-0.58	-7.86	-0.4	5.18e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	0.94	13.68	0.6	3.93e-34	Orofacial clefts;
LUSC	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg14092571	chr14:90743983	NA	-0.38	-6.33	-0.33	8.03e-10	Mortality in heart failure;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01145475	chr6:7313460	SSR1	0.76	6.43	0.33	4.51e-10	Cognitive performance;
LUSC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg14552801	chr7:65878734	NA	0.44	6.6	0.34	1.6e-10	Aortic root size;
LUSC	cis	rs4253772	0.938	rs45550937	chr22:46638128	C/G	cg18190219	chr22:46762943	CELSR1	-0.48	-5.81	-0.3	1.45e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs977987	0.806	rs4888425	chr16:75476363	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.5	0.46	4.32e-19	Dupuytren's disease;
LUSC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	0.7	15.06	0.64	1.7e-39	Prudent dietary pattern;
LUSC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03264133	chr6:25882463	NA	-0.39	-6.9	-0.35	2.67e-11	Height;
LUSC	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.35	0.37	1.58e-12	Electroencephalogram traits;
LUSC	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-6.88	-0.35	2.89e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.9	-15.03	-0.64	2.41e-39	Schizophrenia;
LUSC	cis	rs62400317	0.859	rs10948201	chr6:45093494	A/C	cg20913747	chr6:44695427	NA	0.46	7.32	0.37	1.89e-12	Total body bone mineral density;
LUSC	cis	rs7808935	0.628	rs9791862	chr7:27950760	G/A	cg22168087	chr7:27702803	HIBADH	0.68	8.08	0.4	1.23e-14	Prostate cancer;
LUSC	cis	rs3087591	0.879	rs12103564	chr17:29607243	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.63	-9.03	-0.44	1.43e-17	Hip circumference;
LUSC	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg17644776	chr2:200775616	C2orf69	0.42	5.83	0.3	1.32e-8	Schizophrenia;
LUSC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg15790184	chr11:494944	RNH1	0.61	6.51	0.34	2.82e-10	Body mass index;
LUSC	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg05855489	chr10:104503620	C10orf26	0.52	7.95	0.4	2.91e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.54	-8.53	-0.42	5.28e-16	Height;
LUSC	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg06484146	chr7:12443880	VWDE	-0.68	-7.23	-0.37	3.41e-12	Coronary artery disease;
LUSC	trans	rs7944735	0.690	rs7927682	chr11:47947658	T/C	cg15704280	chr7:45808275	SEPT13	0.61	6.22	0.32	1.48e-9	Intraocular pressure;
LUSC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.74	-12.66	-0.57	2.9e-30	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7712401	0.601	rs30054	chr5:122301999	A/G	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07080220	chr10:102295463	HIF1AN	0.67	8.74	0.43	1.13e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg07930552	chr6:133119739	C6orf192	0.79	10.32	0.49	7.22e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs4919087	0.962	rs10882883	chr10:99013312	A/G	cg25902810	chr10:99078978	FRAT1	0.46	6.72	0.35	7.82e-11	Monocyte count;
LUSC	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg23093090	chr10:104574429	C10orf26	-0.34	-6.25	-0.32	1.26e-9	Arsenic metabolism;
LUSC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg20684491	chr1:25596433	NA	0.39	6.19	0.32	1.79e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.64	-7.35	-0.37	1.57e-12	Iron status biomarkers;
LUSC	cis	rs10754283	0.967	rs4658302	chr1:90103336	A/G	cg21401794	chr1:90099060	LRRC8C	0.66	9.93	0.48	1.53e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg08508325	chr11:3079039	CARS	0.36	7.96	0.4	2.66e-14	Calcium levels;
LUSC	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.6	-8.06	-0.4	1.41e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4478858	0.718	rs10914329	chr1:31688441	T/A	cg00250761	chr1:31883323	NA	0.36	9.37	0.46	1.15e-18	Alcohol dependence;
LUSC	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg04546413	chr19:29218101	NA	-0.57	-7.42	-0.38	9.53e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.68	-12.0	-0.55	7.95e-28	White blood cell count (basophil);
LUSC	cis	rs8016982	0.662	rs1864169	chr14:81670033	G/T	cg01989461	chr14:81687754	GTF2A1	0.5	6.57	0.34	1.92e-10	Schizophrenia;
LUSC	cis	rs2637266	0.756	rs2245335	chr10:78553265	T/C	cg18941641	chr10:78392320	NA	0.37	6.7	0.34	8.79e-11	Pulmonary function;
LUSC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg00945038	chr17:61921165	SMARCD2	0.54	9.36	0.46	1.17e-18	Prudent dietary pattern;
LUSC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	1.05	20.03	0.74	3.41e-59	Menopause (age at onset);
LUSC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg10729496	chr3:10149963	C3orf24	0.54	7.18	0.37	4.44e-12	Alzheimer's disease;
LUSC	cis	rs4363385	0.747	rs1415961	chr1:152973464	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.83	-0.39	6.43e-14	Inflammatory skin disease;
LUSC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg13114125	chr14:105738426	BRF1	-0.9	-15.31	-0.64	1.85e-40	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-7.24	-0.37	3.05e-12	Blood metabolite levels;
LUSC	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg04733989	chr22:42467013	NAGA	0.4	6.44	0.33	4.08e-10	Cognitive function;
LUSC	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg00383909	chr3:49044727	WDR6	1.04	9.33	0.45	1.5e-18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg21775007	chr8:11205619	TDH	-0.68	-10.93	-0.51	5.46e-24	Retinal vascular caliber;
LUSC	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg18827107	chr12:86230957	RASSF9	0.4	5.89	0.31	9.32e-9	Major depressive disorder;
LUSC	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.71	-0.3	2.47e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08613594	chr2:201374742	KCTD18	-0.39	-6.12	-0.32	2.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7224314	1.000	rs62084078	chr17:65386886	T/C	cg01507342	chr17:65387096	PITPNC1	-0.45	-7.93	-0.4	3.28e-14	Diisocyanate-induced asthma;
LUSC	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg12863693	chr15:85201151	NMB	0.42	8.76	0.43	1.02e-16	Schizophrenia;
LUSC	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg09307838	chr4:120376055	NA	0.5	7.52	0.38	5.11e-13	Diastolic blood pressure;
LUSC	trans	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg26043149	chr18:55253948	FECH	-0.47	-7.37	-0.37	1.35e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg13939156	chr17:80058883	NA	-0.33	-6.39	-0.33	5.53e-10	Life satisfaction;
LUSC	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg10645314	chr2:3704589	ALLC	0.62	10.25	0.49	1.32e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-8.03	-0.4	1.63e-14	Response to antipsychotic treatment;
LUSC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-1.05	-15.66	-0.65	7.51e-42	Exhaled nitric oxide output;
LUSC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg11871910	chr12:69753446	YEATS4	0.6	7.9	0.4	4.06e-14	Response to diuretic therapy;
LUSC	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	1.5	13.43	0.59	3.43e-33	Atopic dermatitis;
LUSC	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg09092052	chr15:45571596	NA	-0.45	-6.59	-0.34	1.73e-10	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-6.36	-0.33	6.62e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.72	12.13	0.55	2.67e-28	Motion sickness;
LUSC	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	8.48	0.42	7.28e-16	Menarche (age at onset);
LUSC	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-7.71	-0.39	1.44e-13	Bladder cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13119284	chr22:32870628	FBXO7	0.76	6.25	0.32	1.23e-9	Cognitive performance;
LUSC	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg03060546	chr3:49711283	APEH	-0.59	-6.99	-0.36	1.49e-11	Menarche (age at onset);
LUSC	trans	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg26043149	chr18:55253948	FECH	0.46	6.81	0.35	4.6e-11	Bone mineral density;
LUSC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	0.88	14.77	0.63	2.32e-38	Cognitive function;
LUSC	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg13010199	chr12:38710504	ALG10B	0.64	9.83	0.47	3.29e-20	Bladder cancer;
LUSC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg01879757	chr17:41196368	BRCA1	-0.46	-6.92	-0.35	2.26e-11	Menopause (age at onset);
LUSC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg26597838	chr10:835615	NA	1.07	13.74	0.6	2.38e-34	Eosinophil percentage of granulocytes;
LUSC	cis	rs4285028	0.948	rs7640872	chr3:121697168	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.71	-9.16	-0.45	5.31e-18	Multiple sclerosis;
LUSC	cis	rs2294693	0.947	rs10155663	chr6:40994301	T/G	cg14769373	chr6:40998127	UNC5CL	-0.53	-7.89	-0.4	4.22e-14	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs9309473	1.000	rs11674602	chr2:73723185	A/T	cg20560298	chr2:73613845	ALMS1	-0.49	-7.02	-0.36	1.24e-11	Metabolite levels;
LUSC	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.51	8.41	0.42	1.19e-15	Alcohol dependence;
LUSC	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05901451	chr6:126070800	HEY2	-0.96	-18.88	-0.72	1.31e-54	Brugada syndrome;
LUSC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.75	11.96	0.55	1.07e-27	Neuroticism;
LUSC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg19318889	chr4:1322082	MAEA	0.45	7.28	0.37	2.42e-12	Obesity-related traits;
LUSC	trans	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg18187862	chr3:45730750	SACM1L	0.54	7.02	0.36	1.24e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9463078	0.547	rs2038557	chr6:44740471	G/A	cg25276700	chr6:44698697	NA	0.3	6.33	0.33	7.67e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg26354017	chr1:205819088	PM20D1	-0.48	-7.34	-0.37	1.69e-12	Menarche (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26316083	chr13:48808187	ITM2B	-0.42	-6.2	-0.32	1.67e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2237234	0.580	rs7763910	chr6:26472655	C/T	cg05738196	chr6:26577821	NA	-0.55	-8.52	-0.42	5.73e-16	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs68170813	0.559	rs3779498	chr7:106923158	C/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.79	-0.47	4.7e-20	Coronary artery disease;
LUSC	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg01677386	chr11:118938358	VPS11	0.49	7.01	0.36	1.35e-11	Coronary artery disease;
LUSC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07677032	chr17:61819896	STRADA	-0.51	-8.55	-0.42	4.47e-16	Prudent dietary pattern;
LUSC	cis	rs6977660	0.714	rs6977079	chr7:19818207	G/A	cg07541023	chr7:19748670	TWISTNB	0.6	6.51	0.34	2.7e-10	Thyroid stimulating hormone;
LUSC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00149659	chr3:10157352	C3orf10	0.98	14.19	0.61	4.3e-36	Alzheimer's disease;
LUSC	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg11019008	chr10:131425282	MGMT	0.39	5.84	0.3	1.26e-8	Response to temozolomide;
LUSC	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-7.01	-0.36	1.35e-11	Fear of minor pain;
LUSC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	ch.11.42038R	chr11:967971	AP2A2	0.43	6.42	0.33	4.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-17.0	-0.68	3.84e-47	Gut microbiome composition (summer);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09130549	chr8:97247213	UQCRB	-0.42	-6.09	-0.32	3.17e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg06521331	chr12:34319734	NA	-0.38	-6.65	-0.34	1.2e-10	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg08470875	chr2:26401718	FAM59B	-0.67	-8.83	-0.44	5.86e-17	Gut microbiome composition (summer);
LUSC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	0.93	15.91	0.66	7.9e-43	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg17366294	chr4:99064904	C4orf37	0.59	10.55	0.5	1.17e-22	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19436502	chr3:141944077	GK5	-0.44	-6.7	-0.34	8.92e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg20059928	chr15:40361485	NA	-0.51	-6.05	-0.31	3.94e-9	Corneal curvature;
LUSC	cis	rs7590368	0.715	rs56141717	chr2:10958989	C/T	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg08085267	chr17:45401833	C17orf57	0.54	8.83	0.44	6.01e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg09307838	chr4:120376055	NA	0.72	10.14	0.49	3.12e-21	Corneal astigmatism;
LUSC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg08270630	chr22:50330655	NA	-0.4	-6.07	-0.32	3.4e-9	Schizophrenia;
LUSC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg11843238	chr5:131593191	PDLIM4	0.37	6.45	0.33	3.91e-10	Breast cancer;
LUSC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg22907277	chr7:1156413	C7orf50	0.72	7.61	0.38	2.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	7.11	0.36	6.97e-12	Rheumatoid arthritis;
LUSC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg00149659	chr3:10157352	C3orf10	0.89	12.13	0.55	2.59e-28	Alzheimer's disease;
LUSC	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg18230493	chr5:56204884	C5orf35	-0.57	-8.95	-0.44	2.45e-17	Coronary artery disease;
LUSC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg02782426	chr3:40428986	ENTPD3	0.33	6.24	0.32	1.36e-9	Renal cell carcinoma;
LUSC	cis	rs71403859	0.730	rs17356206	chr16:71736359	G/C	cg08717414	chr16:71523259	ZNF19	-0.66	-7.26	-0.37	2.69e-12	Post bronchodilator FEV1;
LUSC	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg08680598	chr22:49984980	NA	-0.34	-6.36	-0.33	6.69e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11428934	1	rs11428934	chr19:49144245	T/TG	cg06677660	chr19:49140777	SEC1;DBP	0.46	6.02	0.31	4.59e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;
LUSC	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	0.7	11.18	0.52	7.2e-25	Blood metabolite ratios;
LUSC	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06636551	chr8:101224915	SPAG1	-0.45	-8.26	-0.41	3.54e-15	Atrioventricular conduction;
LUSC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-0.98	-14.24	-0.61	2.81e-36	Initial pursuit acceleration;
LUSC	cis	rs2041895	0.527	rs10861678	chr12:107319661	C/T	cg13944111	chr12:107296891	NA	0.36	6.44	0.33	4.24e-10	Glaucoma (low intraocular pressure);
LUSC	cis	rs4953404	0.588	rs1319499	chr2:46894846	T/A	cg09399716	chr2:46890238	NA	-0.31	-6.84	-0.35	3.82e-11	Pulse pressure (alcohol consumption interaction);
LUSC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg21724239	chr8:58056113	NA	0.78	8.01	0.4	1.89e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.23	-14.17	-0.61	5.08e-36	Gout;
LUSC	cis	rs9394159	0.583	rs6457738	chr6:33617464	C/T	cg14003231	chr6:33640908	ITPR3	-0.45	-8.94	-0.44	2.65e-17	Graves' disease;
LUSC	cis	rs3947	0.756	rs1613883	chr8:11699632	T/A	cg00262122	chr8:11665843	FDFT1	-0.48	-5.78	-0.3	1.69e-8	Blood protein levels;
LUSC	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.34	0.53	2.01e-25	Coffee consumption (cups per day);
LUSC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg18240062	chr17:79603768	NPLOC4	0.69	12.86	0.58	4.98e-31	Eye color traits;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg20546810	chr20:2489835	ZNF343	0.4	6.05	0.31	3.95e-9	Schizophrenia;
LUSC	cis	rs7937682	0.556	rs7108048	chr11:111352299	T/C	cg09085632	chr11:111637200	PPP2R1B	0.44	5.84	0.3	1.25e-8	Primary sclerosing cholangitis;
LUSC	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg05855489	chr10:104503620	C10orf26	0.47	7.21	0.37	3.8e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg14004847	chr7:1930337	MAD1L1	-0.47	-7.19	-0.37	4.38e-12	Bipolar disorder and schizophrenia;
LUSC	trans	rs4773505	0.745	rs9515619	chr13:90419085	C/G	cg07901206	chr2:129250690	NA	0.43	6.14	0.32	2.29e-9	Loneliness (multivariate analysis);
LUSC	cis	rs9811920	0.683	rs16841874	chr3:99720564	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.33	-6.16	-0.32	2.05e-9	Axial length;
LUSC	cis	rs9815354	1.000	rs1717024	chr3:41984888	G/T	cg03022575	chr3:42003672	ULK4	-0.51	-6.11	-0.32	2.82e-9	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9420	0.961	rs576859	chr11:57480623	A/C	cg02958346	chr11:57425731	CLP1	0.41	6.07	0.32	3.56e-9	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17079137	chr17:27070735	TRAF4	0.4	5.95	0.31	6.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.16e-9	Diabetic kidney disease;
LUSC	cis	rs12760731	0.720	rs12060844	chr1:178280816	T/C	cg00404053	chr1:178313656	RASAL2	0.57	6.56	0.34	2.07e-10	Obesity-related traits;
LUSC	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	1.01	20.96	0.75	7.7e-63	Platelet distribution width;
LUSC	cis	rs11603020	0.950	rs11229067	chr11:57374946	A/C	cg23127183	chr11:57508653	C11orf31	0.43	5.85	0.3	1.2e-8	Blood protein levels;
LUSC	cis	rs17092148	1.000	rs3787223	chr20:33331385	C/T	cg16810054	chr20:33298113	TP53INP2	0.4	6.38	0.33	5.99e-10	Neuroticism;
LUSC	trans	rs6600671	0.899	rs2319971	chr1:121226982	A/C	cg00646200	chr1:148855367	NA	0.46	7.47	0.38	6.89e-13	Hip geometry;
LUSC	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg17385448	chr1:15911702	AGMAT	0.35	5.89	0.31	9.59e-9	Systolic blood pressure;
LUSC	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.92	15.75	0.65	3.5e-42	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs17621444	0.522	rs4751761	chr10:121796742	A/C	cg02041677	chr10:121771263	NA	0.33	6.18	0.32	1.92e-9	IgG glycosylation;
LUSC	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg10857441	chr5:6722123	POLS	-0.44	-8.16	-0.41	7.07e-15	Menopause (age at onset);
LUSC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg03806693	chr22:41940476	POLR3H	-1.02	-13.77	-0.6	1.74e-34	Vitiligo;
LUSC	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg17366294	chr4:99064904	C4orf37	0.61	10.91	0.51	6.72e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg16434002	chr17:42200994	HDAC5	-0.45	-6.41	-0.33	5.09e-10	Total body bone mineral density;
LUSC	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.2	-0.32	1.7e-9	Resting heart rate;
LUSC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg26116260	chr4:7069785	GRPEL1	0.88	10.7	0.51	3.48e-23	Monocyte percentage of white cells;
LUSC	cis	rs225245	0.782	rs321601	chr17:33892087	A/C	cg05299278	chr17:33885742	SLFN14	-0.31	-6.8	-0.35	4.87e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg17279839	chr7:150038598	RARRES2	0.54	7.99	0.4	2.22e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg12935359	chr14:103987150	CKB	-0.52	-7.96	-0.4	2.78e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	7.01	0.36	1.34e-11	Renal cell carcinoma;
LUSC	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg22852734	chr6:133119734	C6orf192	1.22	14.19	0.61	4.37e-36	Type 2 diabetes nephropathy;
LUSC	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg20587970	chr11:113659929	NA	1.24	12.93	0.58	2.82e-31	Hip circumference adjusted for BMI;
LUSC	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.7	12.4	0.56	2.64e-29	White blood cell count (basophil);White blood cell count;
LUSC	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21984481	chr17:79567631	NPLOC4	-0.73	-15.53	-0.65	2.54e-41	Eye color traits;
LUSC	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.69	10.47	0.5	2.2e-22	Corneal astigmatism;
LUSC	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.8	-0.35	4.73e-11	Lung cancer;
LUSC	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.29e-21	Lymphocyte counts;
LUSC	cis	rs7584330	0.554	rs4420668	chr2:238444793	G/A	cg14458575	chr2:238380390	NA	0.43	5.73	0.3	2.3e-8	Prostate cancer;
LUSC	cis	rs17095355	0.605	rs58154613	chr10:111633966	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.58	-6.77	-0.35	5.95e-11	Biliary atresia;
LUSC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.08	0.36	8.42e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg12560992	chr17:57184187	TRIM37	0.83	15.1	0.64	1.19e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	1.04	16.82	0.68	2.06e-46	Testicular germ cell tumor;
LUSC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg14582100	chr15:45693742	SPATA5L1	0.59	10.64	0.5	5.61e-23	Homoarginine levels;
LUSC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg25643088	chr3:52874325	TMEM110	0.4	6.14	0.32	2.37e-9	Schizophrenia;
LUSC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg09263875	chr16:632152	PIGQ	0.71	13.2	0.59	2.71e-32	Height;
LUSC	cis	rs9457247	0.668	rs2236313	chr6:167360389	C/T	cg20406979	chr6:167373233	NA	0.29	6.79	0.35	4.99e-11	Crohn's disease;
LUSC	cis	rs12973672	0.812	rs10421096	chr19:35764559	C/T	cg12095397	chr19:35769544	USF2	0.44	6.67	0.34	1.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs12637928	0.560	rs7611910	chr3:110183949	G/T	cg17371621	chr15:61264283	RORA	0.36	6.08	0.32	3.3e-9	Neuroticism;
LUSC	cis	rs9929218	0.817	rs3114404	chr16:68722096	C/T	cg02972257	chr16:68554789	NA	0.44	5.67	0.3	3.14e-8	Colorectal cancer;
LUSC	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg07936489	chr17:37558343	FBXL20	-0.71	-10.03	-0.48	7.3e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs11828289	0.607	rs78341320	chr11:23188865	C/T	cg20040320	chr11:23191996	NA	-0.58	-6.1	-0.32	2.95e-9	Cancer;
LUSC	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg19554555	chr3:13937349	NA	-0.39	-5.84	-0.3	1.25e-8	Ovarian reserve;
LUSC	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg19875535	chr5:140030758	IK	0.47	7.57	0.38	3.6e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.58	-0.34	1.81e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-8.03	-0.4	1.67e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg24209194	chr3:40518798	ZNF619	0.41	5.95	0.31	6.7e-9	Renal cell carcinoma;
LUSC	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg11901034	chr3:128598214	ACAD9	-0.4	-6.24	-0.32	1.31e-9	IgG glycosylation;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.31	-5.79	-0.3	1.67e-8	Lymphocyte counts;
LUSC	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19096424	chr1:120255104	PHGDH	0.44	6.03	0.31	4.29e-9	Blood metabolite levels;
LUSC	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	11.11	0.52	1.29e-24	Lung cancer in ever smokers;
LUSC	cis	rs11209185	0.509	rs9326078	chr1:68452388	A/G	cg22082780	chr1:68452167	NA	0.48	8.76	0.43	9.77e-17	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg10377582	chr12:51612794	POU6F1	-0.34	-5.93	-0.31	7.52e-9	Cisplatin-induced ototoxicity;
LUSC	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg05768032	chr16:30646687	NA	0.38	5.71	0.3	2.47e-8	Multiple myeloma;
LUSC	cis	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg06521331	chr12:34319734	NA	-0.47	-7.68	-0.39	1.78e-13	Morning vs. evening chronotype;
LUSC	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg08523384	chr5:141488047	NDFIP1	-0.52	-7.48	-0.38	6.77e-13	Crohn's disease;
LUSC	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg08807101	chr21:30365312	RNF160	-0.66	-10.1	-0.48	4.14e-21	Pancreatic cancer;
LUSC	cis	rs9811920	0.809	rs793475	chr3:99543764	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-6.01	-0.31	4.84e-9	Axial length;
LUSC	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.59	8.23	0.41	4.16e-15	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	6.89	0.35	2.76e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg11812906	chr14:75593930	NEK9	0.65	11.13	0.52	1.1e-24	Height;
LUSC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg03146154	chr1:46216737	IPP	0.56	8.12	0.41	9.17e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2677744	0.719	rs2106673	chr15:91452595	A/G	cg23684204	chr15:91497937	RCCD1	0.39	5.7	0.3	2.69e-8	Attention deficit hyperactivity disorder;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg10296153	chr3:3168554	TRNT1	0.34	6.0	0.31	5.06e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	0.65	13.71	0.6	3.1e-34	Prudent dietary pattern;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg06877462	chr1:205807181	PM20D1	0.54	10.24	0.49	1.37e-21	Menarche (age at onset);
LUSC	cis	rs4654899	0.758	rs1354792	chr1:21391875	C/T	cg01072550	chr1:21505969	NA	0.54	8.6	0.43	3.2e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-7.57	-0.38	3.77e-13	Atrioventricular conduction;
LUSC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg21890820	chr11:65308645	LTBP3	0.49	7.41	0.38	1.07e-12	Bone mineral density;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg17514098	chr12:125302114	SCARB1	-0.41	-6.77	-0.35	5.94e-11	N-glycan levels;
LUSC	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg09835421	chr16:68378352	PRMT7	-0.54	-6.15	-0.32	2.18e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1113500	0.897	rs10785832	chr1:108638899	G/A	cg06207961	chr1:108661230	NA	0.41	7.64	0.39	2.27e-13	Growth-regulated protein alpha levels;
LUSC	trans	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.37	-6.01	-0.31	4.8e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg08975724	chr8:8085496	FLJ10661	0.45	6.73	0.35	7.58e-11	Retinal vascular caliber;
LUSC	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg13010199	chr12:38710504	ALG10B	0.67	10.38	0.49	4.53e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4363385	0.747	rs1415959	chr1:152973690	C/T	cg00922841	chr1:152955080	SPRR1A	0.45	7.99	0.4	2.15e-14	Inflammatory skin disease;
LUSC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.45	0.46	5.94e-19	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01687453	chr17:37026128	LASP1	-0.41	-6.09	-0.32	3.13e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6867913	0.709	rs891987	chr5:141467196	A/T	cg23435118	chr5:141488016	NDFIP1	0.45	7.24	0.37	3.16e-12	Asthma;
LUSC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg16325326	chr1:53192061	ZYG11B	-0.81	-14.15	-0.61	5.95e-36	Monocyte count;
LUSC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg21361702	chr7:150065534	REPIN1	0.47	6.26	0.32	1.16e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg24154853	chr7:158122151	PTPRN2	0.35	5.81	0.3	1.49e-8	Response to amphetamines;
LUSC	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg04719120	chr6:96025338	MANEA	0.46	5.81	0.3	1.45e-8	Behavioural disinhibition (generation interaction);
LUSC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg17971929	chr21:40555470	PSMG1	-0.64	-10.47	-0.5	2.19e-22	Cognitive function;
LUSC	cis	rs6542838	0.673	rs1949424	chr2:99468341	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.41	5.66	0.3	3.18e-8	Fear of minor pain;
LUSC	trans	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg07393940	chr7:158741817	NA	-0.54	-8.56	-0.42	4.27e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg12751644	chr20:60527061	NA	-0.35	-6.07	-0.32	3.43e-9	Body mass index;
LUSC	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg00310523	chr12:86230176	RASSF9	0.47	8.62	0.43	2.74e-16	Major depressive disorder;
LUSC	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.62	-10.3	-0.49	8.46e-22	Morning vs. evening chronotype;
LUSC	cis	rs7527798	0.592	rs10863461	chr1:207840776	C/T	cg09232269	chr1:207846808	CR1L	-0.29	-6.33	-0.33	7.78e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg16206743	chr13:37633760	FAM48A	0.38	6.15	0.32	2.2e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.49	5.84	0.3	1.27e-8	Renal function-related traits (BUN);
LUSC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg23758822	chr17:41437982	NA	1.0	18.97	0.72	5.5e-55	Menopause (age at onset);
LUSC	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg12940439	chr1:67600707	NA	0.35	5.86	0.31	1.12e-8	Psoriasis;
LUSC	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg18806716	chr10:30721971	MAP3K8	-0.71	-11.39	-0.53	1.31e-25	Inflammatory bowel disease;
LUSC	trans	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-12.07	-0.55	4.41e-28	Colorectal cancer;
LUSC	cis	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg21775007	chr8:11205619	TDH	0.49	6.82	0.35	4.37e-11	Retinal vascular caliber;
LUSC	cis	rs7719624	0.870	rs1990201	chr5:135395203	C/T	cg12897067	chr5:135418308	NA	-0.44	-6.4	-0.33	5.15e-10	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.74	0.35	6.99e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22590775	chr19:49891494	CCDC155	0.61	8.06	0.4	1.37e-14	Multiple sclerosis;
LUSC	cis	rs11785693	0.862	rs7009771	chr8:4990189	C/T	cg26367366	chr8:4980734	NA	0.75	8.77	0.43	9.41e-17	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg01879757	chr17:41196368	BRCA1	-0.47	-7.16	-0.36	5.11e-12	Menopause (age at onset);
LUSC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg00074818	chr8:8560427	CLDN23	0.58	9.87	0.48	2.57e-20	Obesity-related traits;
LUSC	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg26597838	chr10:835615	NA	0.78	9.16	0.45	5.21e-18	Eosinophil percentage of granulocytes;
LUSC	cis	rs601339	1.000	rs35683065	chr12:123164062	G/C	cg11919336	chr12:123188078	GPR109A	0.42	6.3	0.33	9.51e-10	Adiponectin levels;
LUSC	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg05855489	chr10:104503620	C10orf26	0.58	9.45	0.46	6.13e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg15896084	chr13:114927664	NA	0.37	6.72	0.35	7.87e-11	Schizophrenia;
LUSC	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.82	-0.39	6.81e-14	Blood metabolite levels;
LUSC	trans	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg25482853	chr8:67687455	SGK3	1.12	15.85	0.66	1.36e-42	Obesity-related traits;
LUSC	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg15556689	chr8:8085844	FLJ10661	-0.63	-9.74	-0.47	7.01e-20	Mood instability;
LUSC	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.98	19.14	0.72	1.17e-55	Diastolic blood pressure;
LUSC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg05973401	chr12:123451056	ABCB9	0.54	6.64	0.34	1.24e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6690583	0.562	rs76839162	chr1:85530021	A/G	cg11262906	chr1:85462892	MCOLN2	0.68	6.27	0.32	1.1e-9	Serum sulfate level;
LUSC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg14552801	chr7:65878734	NA	-0.46	-6.46	-0.33	3.72e-10	Aortic root size;
LUSC	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg12310025	chr6:25882481	NA	-0.35	-5.8	-0.3	1.57e-8	Height;
LUSC	cis	rs2820315	0.838	rs2819347	chr1:201884288	C/G	cg10061532	chr1:201886748	LMOD1	0.29	6.62	0.34	1.42e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.41	-0.42	1.23e-15	Height;
LUSC	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.75	-0.39	1.11e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10193935	0.901	rs1390609	chr2:42666230	G/T	cg27598129	chr2:42591480	NA	0.57	7.86	0.4	5.25e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg04998671	chr14:104000505	TRMT61A	-0.46	-7.25	-0.37	2.94e-12	Coronary artery disease;
LUSC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08280861	chr8:58055591	NA	0.54	6.3	0.33	9.15e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg06784218	chr1:46089804	CCDC17	0.55	10.78	0.51	1.85e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg15737290	chr11:93063684	CCDC67	0.87	13.37	0.59	6.07e-33	Pulmonary function decline;
LUSC	cis	rs62400317	0.859	rs62436780	chr6:45128261	A/T	cg18551225	chr6:44695536	NA	-0.42	-6.84	-0.35	3.81e-11	Total body bone mineral density;
LUSC	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg25237894	chr2:233734115	C2orf82	0.36	6.15	0.32	2.27e-9	Coronary artery disease;
LUSC	cis	rs968451	0.789	rs1569498	chr22:39714704	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.69	9.59	0.46	2.2e-19	Primary biliary cholangitis;
LUSC	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06544989	chr22:39130855	UNC84B	0.36	6.45	0.33	3.98e-10	Menopause (age at onset);
LUSC	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg01652190	chr22:50026171	C22orf34	-0.31	-6.32	-0.33	8.35e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg00049323	chr5:472564	LOC25845	-0.44	-6.8	-0.35	4.79e-11	Cystic fibrosis severity;
LUSC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg08847533	chr14:75593920	NEK9	0.85	15.82	0.65	1.78e-42	Height;
LUSC	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.74	-0.3	2.12e-8	Ileal carcinoids;
LUSC	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg00933542	chr6:150070202	PCMT1	0.33	6.91	0.35	2.48e-11	Lung cancer;
LUSC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg08601574	chr20:25228251	PYGB	-0.43	-6.62	-0.34	1.47e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg06521331	chr12:34319734	NA	-0.51	-8.35	-0.42	1.85e-15	Morning vs. evening chronotype;
LUSC	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg21775007	chr8:11205619	TDH	0.46	6.57	0.34	1.93e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs67072384	0.818	rs2291290	chr11:72465877	T/C	cg04827223	chr11:72435913	ARAP1	-0.74	-6.42	-0.33	4.6e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg00310523	chr12:86230176	RASSF9	0.41	7.22	0.37	3.47e-12	Major depressive disorder;
LUSC	cis	rs6977660	0.714	rs12334001	chr7:19814399	T/C	cg05791153	chr7:19748676	TWISTNB	0.7	7.45	0.38	8.29e-13	Thyroid stimulating hormone;
LUSC	cis	rs8114671	0.967	rs6142321	chr20:33788474	G/A	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.93	-0.31	7.56e-9	Height;
LUSC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg16586182	chr3:47516702	SCAP	-0.53	-7.5	-0.38	5.7e-13	Birth weight;
LUSC	cis	rs6901250	0.569	rs686708	chr6:117091683	A/G	cg12892004	chr6:117198278	RFX6	0.37	6.79	0.35	5.16e-11	C-reactive protein levels;
LUSC	cis	rs11229555	0.609	rs4598685	chr11:58216864	A/G	cg15696309	chr11:58395628	NA	-0.65	-7.92	-0.4	3.67e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08677398	chr8:58056175	NA	0.52	6.87	0.35	3.18e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7615316	1.000	rs2049326	chr3:142337672	C/T	cg16271453	chr3:142027066	XRN1	-0.36	-6.08	-0.32	3.26e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.64	0.47	1.43e-19	Coffee consumption (cups per day);
LUSC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.44	-5.88	-0.31	1.02e-8	Menarche (age at onset);
LUSC	cis	rs4974559	0.895	rs10018133	chr4:1338246	C/T	cg02980000	chr4:1222292	CTBP1	0.76	7.34	0.37	1.6e-12	Systolic blood pressure;
LUSC	cis	rs7615316	1.000	rs2049325	chr3:142337430	A/G	cg16271453	chr3:142027066	XRN1	-0.36	-6.08	-0.32	3.26e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7172677	1.000	rs4886422	chr15:75426723	C/T	cg14664628	chr15:75095509	CSK	-0.44	-5.81	-0.3	1.43e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.44	0.56	1.81e-29	Prudent dietary pattern;
LUSC	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg24675056	chr1:15929824	NA	0.48	8.27	0.41	3.15e-15	Systolic blood pressure;
LUSC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06634786	chr22:41940651	POLR3H	0.55	6.41	0.33	5.09e-10	Vitiligo;
LUSC	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg26441486	chr22:50317300	CRELD2	0.48	7.03	0.36	1.17e-11	Schizophrenia;
LUSC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg00999904	chr2:3704751	ALLC	-0.6	-9.24	-0.45	3.01e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg25703541	chr22:24373054	LOC391322	-0.84	-14.37	-0.62	8.7e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg21775007	chr8:11205619	TDH	0.42	6.02	0.31	4.66e-9	Neuroticism;
LUSC	cis	rs8102476	0.640	rs7247241	chr19:38747272	T/C	cg14131526	chr19:38747285	PPP1R14A	-0.34	-5.98	-0.31	5.75e-9	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg01765077	chr12:122356316	WDR66	0.49	6.73	0.35	7.26e-11	Mean corpuscular volume;
LUSC	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-5.73	-0.3	2.25e-8	Retinal vascular caliber;
LUSC	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg08847533	chr14:75593920	NEK9	-0.8	-14.71	-0.63	4.29e-38	Height;
LUSC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg22437258	chr11:111473054	SIK2	0.52	7.44	0.38	8.76e-13	Primary sclerosing cholangitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26665246	chr5:179105570	CBY3	-0.4	-6.18	-0.32	1.82e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs68170813	0.652	rs76924513	chr7:107205887	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.48	-5.89	-0.31	9.58e-9	Coronary artery disease;
LUSC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-10.22	-0.49	1.6e-21	Mood instability;
LUSC	cis	rs4776059	0.550	rs8036979	chr15:52947995	A/T	cg22715398	chr15:52968154	KIAA1370	0.73	8.28	0.41	2.91e-15	Schizophrenia;
LUSC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg06454157	chr6:167490870	NA	-0.3	-6.93	-0.35	2.21e-11	Crohn's disease;
LUSC	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg03690763	chr11:133734501	NA	-0.33	-5.87	-0.31	1.07e-8	Childhood ear infection;
LUSC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2219968	0.676	rs10156234	chr8:78835777	C/T	cg00738934	chr8:78996279	NA	-0.36	-6.09	-0.32	3.17e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2224391	0.628	rs2753237	chr6:5252675	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-7.01	-0.36	1.31e-11	Height;
LUSC	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-6.15	-0.32	2.19e-9	Menarche (age at onset);
LUSC	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg01256987	chr12:42539512	GXYLT1	-0.4	-7.38	-0.37	1.3e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg05234568	chr11:5960015	NA	0.43	6.54	0.34	2.37e-10	DNA methylation (variation);
LUSC	cis	rs35123781	1.000	rs589153	chr5:139057548	A/G	cg10513866	chr5:139070639	NA	0.46	8.87	0.44	4.44e-17	Schizophrenia;
LUSC	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.58	-9.13	-0.45	6.87e-18	Schizophrenia;
LUSC	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg11584989	chr19:19387371	SF4	0.6	7.31	0.37	1.93e-12	Bipolar disorder;
LUSC	cis	rs3774830	0.714	rs73212742	chr4:5464915	A/G	cg26943120	chr4:5472116	STK32B	0.29	5.77	0.3	1.84e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08726783	chr22:24199851	SLC2A11	-0.4	-5.96	-0.31	6.42e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg11645453	chr3:52864694	ITIH4	0.34	7.98	0.4	2.32e-14	Bipolar disorder;
LUSC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.04	0.36	1.09e-11	Platelet count;
LUSC	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.78	-0.63	2.22e-38	Schizophrenia;
LUSC	cis	rs12367572	0.663	rs1857926	chr12:45344524	C/T	cg04608330	chr12:45269318	NELL2	-0.4	-6.18	-0.32	1.83e-9	Gut microbiome composition (summer);
LUSC	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg16797656	chr11:68205561	LRP5	0.37	6.16	0.32	2.13e-9	Total body bone mineral density;
LUSC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21016266	chr12:122356598	WDR66	0.63	9.29	0.45	2.08e-18	Mean corpuscular volume;
LUSC	cis	rs4499344	0.622	rs7246407	chr19:33061209	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.62	-7.89	-0.4	4.23e-14	Mean platelet volume;
LUSC	cis	rs7178572	0.568	rs12913233	chr15:77543297	C/T	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.51e-14	Type 2 diabetes;
LUSC	cis	rs61990749	0.597	rs28534379	chr14:78172140	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.59	-6.4	-0.33	5.16e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.97	-0.61	2.98e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.58	0.38	3.49e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.87	0.35	3.19e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Parkinson's disease;
LUSC	cis	rs10392	0.543	rs16987679	chr20:37557185	G/C	cg27552599	chr20:37590471	DHX35	0.46	7.35	0.37	1.57e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	9.62	0.47	1.66e-19	Lung cancer in ever smokers;
LUSC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11645453	chr3:52864694	ITIH4	0.33	7.57	0.38	3.67e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.92e-10	Life satisfaction;
LUSC	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.6	-0.38	2.99e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-8.24	-0.41	3.99e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg21466736	chr12:48725269	NA	-0.31	-5.83	-0.3	1.3e-8	Glycated hemoglobin levels;
LUSC	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg01620082	chr3:125678407	NA	-0.75	-7.11	-0.36	6.89e-12	Depression;
LUSC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg03146154	chr1:46216737	IPP	0.55	8.16	0.41	7.02e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg03732007	chr1:2071316	PRKCZ	0.47	7.53	0.38	4.67e-13	Height;
LUSC	cis	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.33	-0.41	2.13e-15	Coronary artery disease;
LUSC	cis	rs17253792	0.915	rs78089630	chr14:56178584	G/C	cg01858014	chr14:56050164	KTN1	-0.85	-6.86	-0.35	3.35e-11	Putamen volume;
LUSC	trans	rs11625034	1.000	rs11625034	chr14:54349976	A/G	cg10394757	chr16:66879807	CA7	-0.24	-5.97	-0.31	6.17e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg27600084	chr12:12264075	NA	0.45	6.64	0.34	1.26e-10	Breast size;
LUSC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg04414720	chr1:150670196	GOLPH3L	0.54	8.51	0.42	5.79e-16	Melanoma;
LUSC	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg13798780	chr7:105162888	PUS7	0.55	5.95	0.31	6.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7524258	0.868	rs7538921	chr1:7267007	T/C	cg07173049	chr1:7289937	CAMTA1	0.35	7.2	0.37	3.89e-12	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg22117172	chr7:91764530	CYP51A1	0.33	5.81	0.3	1.49e-8	Breast cancer;
LUSC	trans	rs800082	0.539	rs1178897	chr3:144241161	A/C	cg24215973	chr2:240111563	HDAC4	-0.47	-7.27	-0.37	2.49e-12	Smoking behavior;
LUSC	cis	rs4474465	0.790	rs7106931	chr11:78229612	A/G	cg27205649	chr11:78285834	NARS2	0.53	6.06	0.31	3.69e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7615316	0.789	rs6440082	chr3:142114406	A/G	cg16271453	chr3:142027066	XRN1	0.37	6.72	0.34	8.04e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.54	-10.7	-0.51	3.69e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg17366294	chr4:99064904	C4orf37	0.57	9.91	0.48	1.76e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg05343316	chr1:45956843	TESK2	0.59	8.46	0.42	8.79e-16	Platelet count;
LUSC	cis	rs77633900	0.614	rs2468120	chr15:76909975	G/A	cg21673338	chr15:77095150	SCAPER	-0.72	-6.99	-0.36	1.48e-11	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs4919687	0.550	rs7907503	chr10:104440050	C/T	cg04362960	chr10:104952993	NT5C2	0.47	6.82	0.35	4.21e-11	Colorectal cancer;
LUSC	cis	rs11674184	0.525	rs4669755	chr2:11748585	A/C	cg07314298	chr2:11723111	GREB1	0.59	10.18	0.49	2.25e-21	Endometriosis;
LUSC	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg09876464	chr15:85330779	ZNF592	0.36	6.69	0.34	9.51e-11	P wave terminal force;
LUSC	trans	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07923666	chr12:49932857	KCNH3	-0.52	-6.74	-0.35	6.79e-11	Resting heart rate;
LUSC	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg21984481	chr17:79567631	NPLOC4	-0.59	-11.42	-0.53	1.03e-25	Eye color traits;
LUSC	cis	rs3820928	0.874	rs13393902	chr2:227880554	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.8	-0.39	7.97e-14	Pulmonary function;
LUSC	cis	rs3741151	0.773	rs73542952	chr11:73108556	A/G	cg17517138	chr11:73019481	ARHGEF17	0.98	8.42	0.42	1.13e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.56	0.34	2.01e-10	Retinal vascular caliber;
LUSC	trans	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg03886242	chr7:26192032	NFE2L3	-0.42	-6.7	-0.34	9.01e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18932078	chr1:2524107	MMEL1	-0.31	-6.89	-0.35	2.79e-11	Ulcerative colitis;
LUSC	cis	rs3741151	0.686	rs11828904	chr11:73139116	T/C	cg17517138	chr11:73019481	ARHGEF17	0.81	7.52	0.38	5.05e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.16	0.32	2.14e-9	Menopause (age at onset);
LUSC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	7.13	0.36	6.09e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.97e-10	Bipolar disorder;
LUSC	trans	rs3808502	0.534	rs1529858	chr8:11145662	G/T	cg15556689	chr8:8085844	FLJ10661	0.46	6.55	0.34	2.19e-10	Neuroticism;
LUSC	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.28	0.37	2.47e-12	Response to antipsychotic treatment;
LUSC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.42	-6.15	-0.32	2.21e-9	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16469426	chr7:19748791	TWISTNB	-0.46	-6.8	-0.35	4.79e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg16606324	chr3:10149918	C3orf24	0.64	9.23	0.45	3.29e-18	Alzheimer's disease;
LUSC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15664640	chr17:80829946	TBCD	-0.75	-13.55	-0.6	1.26e-33	Breast cancer;
LUSC	cis	rs7178572	0.568	rs4886515	chr15:77686886	G/A	cg22256960	chr15:77711686	NA	-0.5	-7.92	-0.4	3.57e-14	Type 2 diabetes;
LUSC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg14895029	chr7:2775587	GNA12	-0.37	-5.69	-0.3	2.8e-8	Height;
LUSC	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg24631222	chr15:78858424	CHRNA5	0.84	11.39	0.53	1.35e-25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs56399783	0.901	rs12540539	chr7:2873294	C/T	cg14895029	chr7:2775587	GNA12	0.5	6.0	0.31	5.02e-9	Childhood ear infection;
LUSC	cis	rs981844	1.000	rs55792703	chr4:154668278	C/A	cg14289246	chr4:154710475	SFRP2	0.48	6.1	0.32	2.87e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs11997175	0.624	rs4733460	chr8:33675169	T/C	ch.8.33884649F	chr8:33765107	NA	0.47	7.07	0.36	9.32e-12	Body mass index;
LUSC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg11871910	chr12:69753446	YEATS4	0.62	8.94	0.44	2.63e-17	Response to diuretic therapy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18454701	chr2:46844136	PIGF;CRIPT	-0.42	-6.25	-0.32	1.22e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg01125463	chr6:42946178	PEX6	-0.35	-5.67	-0.3	3.06e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18099408	chr3:52552593	STAB1	-0.4	-6.78	-0.35	5.35e-11	Bipolar disorder;
LUSC	cis	rs7336332	0.941	rs9579097	chr13:28084337	C/T	cg22138327	chr13:27999177	GTF3A	0.69	7.15	0.36	5.44e-12	Weight;
LUSC	cis	rs11166629	0.651	rs7818130	chr8:135641806	G/A	cg27224718	chr8:135614730	ZFAT	0.44	7.21	0.37	3.77e-12	Smoking quantity;
LUSC	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg05340658	chr4:99064831	C4orf37	0.44	6.91	0.35	2.39e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10979	0.571	rs7764231	chr6:143919151	C/G	cg25407410	chr6:143891975	LOC285740	-0.57	-6.87	-0.35	3.17e-11	Hypospadias;
LUSC	cis	rs1775715	0.737	rs1541260	chr10:32105570	C/T	cg26784012	chr10:32216390	ARHGAP12	0.44	7.39	0.37	1.21e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg16423285	chr20:60520624	NA	-0.47	-5.9	-0.31	8.91e-9	Body mass index;
LUSC	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.54	-0.5	1.32e-22	Monocyte count;
LUSC	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-8.26	-0.41	3.46e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs500891	0.525	rs12192277	chr6:84090641	G/C	cg08257003	chr6:84140564	ME1	0.32	7.35	0.37	1.49e-12	Platelet-derived growth factor BB levels;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg09617296	chr13:100153694	TM9SF2	0.38	6.18	0.32	1.9e-9	Asthma;
LUSC	cis	rs9815354	1.000	rs7646144	chr3:41853125	T/A	cg03022575	chr3:42003672	ULK4	0.56	6.25	0.32	1.24e-9	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg24642439	chr20:33292090	TP53INP2	0.47	7.24	0.37	3.04e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs9341808	0.586	rs3805869	chr6:81045917	T/C	cg08355045	chr6:80787529	NA	0.48	8.24	0.41	3.91e-15	Sitting height ratio;
LUSC	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg02018176	chr4:1364513	KIAA1530	0.45	6.12	0.32	2.68e-9	Recombination rate (females);
LUSC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.66	-0.43	2.06e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.03	-0.4	1.68e-14	Chronic sinus infection;
LUSC	cis	rs6977660	0.714	rs4721827	chr7:19825655	A/G	cg05791153	chr7:19748676	TWISTNB	0.67	6.93	0.35	2.24e-11	Thyroid stimulating hormone;
LUSC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	0.92	17.85	0.7	1.56e-50	Gestational age at birth (maternal effect);
LUSC	cis	rs1256061	0.654	rs1256033	chr14:64745399	A/G	cg23250157	chr14:64679961	SYNE2	0.32	5.83	0.3	1.31e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs11677370	0.574	rs12329183	chr2:3866943	G/A	cg17052675	chr2:3827356	NA	-0.63	-9.62	-0.47	1.72e-19	Type 2 diabetes;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg07962043	chr11:60691582	TMEM132A	0.49	6.06	0.31	3.73e-9	Cognitive function;Information processing speed;
LUSC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg06618935	chr21:46677482	NA	-0.38	-7.54	-0.38	4.34e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4629710	0.592	rs11759793	chr6:131546384	G/A	cg12700074	chr6:131571435	AKAP7	-0.36	-6.05	-0.31	3.92e-9	Multiple myeloma (IgH translocation);
LUSC	trans	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg25214090	chr10:38739885	LOC399744	0.43	6.51	0.34	2.73e-10	Corneal astigmatism;
LUSC	cis	rs17604090	1.000	rs114892953	chr7:29676298	G/A	cg19413766	chr7:29689036	LOC646762	-0.6	-6.77	-0.35	5.81e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg08798685	chr6:27730294	NA	-0.64	-6.01	-0.31	4.93e-9	Breast cancer;
LUSC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00149659	chr3:10157352	C3orf10	1.01	14.42	0.62	5.3e-37	Alzheimer's disease;
LUSC	cis	rs965604	1.000	rs1504549	chr15:78766629	C/T	cg18825076	chr15:78729989	IREB2	-0.42	-6.82	-0.35	4.25e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.39	-0.33	5.54e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs8099014	1.000	rs8092062	chr18:56127875	C/T	cg12907477	chr18:56117327	MIR122	0.44	6.99	0.36	1.52e-11	Platelet count;
LUSC	cis	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.75	0.47	6.48e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	12.12	0.55	2.99e-28	Height;
LUSC	cis	rs6912958	0.677	rs111990232	chr6:88022240	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.39	7.04	0.36	1.11e-11	Monocyte percentage of white cells;
LUSC	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg26384229	chr12:38710491	ALG10B	0.74	11.9	0.55	1.78e-27	Morning vs. evening chronotype;
LUSC	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg07382826	chr16:28625726	SULT1A1	0.29	6.19	0.32	1.73e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg14668632	chr7:2872130	GNA12	-0.45	-6.47	-0.33	3.53e-10	Height;
LUSC	trans	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1712517	0.844	rs1163074	chr10:105021762	C/T	cg05636881	chr10:105038444	INA	0.39	6.42	0.33	4.56e-10	Migraine;
LUSC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.08e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4974559	0.947	rs28437782	chr4:1355062	A/G	cg02980000	chr4:1222292	CTBP1	0.73	7.26	0.37	2.71e-12	Systolic blood pressure;
LUSC	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg08684580	chr7:98029266	BAIAP2L1	0.38	5.82	0.3	1.35e-8	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg13010199	chr12:38710504	ALG10B	0.64	9.82	0.47	3.8e-20	Bladder cancer;
LUSC	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.68	-10.91	-0.51	6.36e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17407555	0.697	rs73212840	chr4:10087458	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.25	-0.32	1.26e-9	Schizophrenia (age at onset);
LUSC	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg08461752	chr10:43522343	NA	0.58	7.15	0.36	5.43e-12	Pediatric bone mineral content (radius);
LUSC	cis	rs12973672	0.812	rs12986033	chr19:35748782	A/G	cg12095397	chr19:35769544	USF2	0.43	6.53	0.34	2.45e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7582720	1.000	rs72928608	chr2:203836507	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg15309053	chr8:964076	NA	0.33	6.84	0.35	3.73e-11	Schizophrenia;
LUSC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg09904177	chr6:26538194	HMGN4	0.42	6.19	0.32	1.74e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.79	-0.3	1.62e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg27535305	chr1:53392650	SCP2	0.36	6.82	0.35	4.3e-11	Monocyte count;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05420251	chr10:102133820	C10orf75	-0.39	-5.94	-0.31	7.05e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.7	-0.34	9.09e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg21798802	chr22:38057573	PDXP	0.35	7.22	0.37	3.45e-12	Fat distribution (HIV);
LUSC	trans	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg06521331	chr12:34319734	NA	-0.41	-6.38	-0.33	5.95e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg27471124	chr11:109292789	C11orf87	0.37	6.74	0.35	6.99e-11	Schizophrenia;
LUSC	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg20487152	chr13:99095054	FARP1	-0.44	-7.9	-0.4	3.99e-14	Longevity;
LUSC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.81	-14.3	-0.62	1.58e-36	Sudden cardiac arrest;
LUSC	cis	rs1062753	0.771	rs5751245	chr22:42620940	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.41	7.3	0.37	2.1e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs9341835	0.772	rs9294202	chr6:64138954	A/G	cg00787780	chr6:64151745	NA	-0.33	-5.77	-0.3	1.82e-8	Schizophrenia;
LUSC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg12463550	chr7:65579703	CRCP	-0.51	-7.49	-0.38	6.15e-13	Aortic root size;
LUSC	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg15934090	chr1:100435551	SLC35A3	0.48	8.29	0.41	2.72e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs739496	0.542	rs7306529	chr12:111780644	A/G	cg10833066	chr12:111807467	FAM109A	0.6	12.27	0.56	8.1e-29	Platelet count;
LUSC	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg08085267	chr17:45401833	C17orf57	-0.54	-8.67	-0.43	1.94e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg03146154	chr1:46216737	IPP	0.57	8.47	0.42	8e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6546537	1.000	rs6546535	chr2:69833382	G/T	cg10773587	chr2:69614142	GFPT1	-0.47	-7.34	-0.37	1.68e-12	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg27068330	chr11:65405492	SIPA1	0.61	9.23	0.45	3.18e-18	Acne (severe);
LUSC	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	17.64	0.69	1.13e-49	Body mass index (adult);
LUSC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg14895029	chr7:2775587	GNA12	-0.41	-6.11	-0.32	2.74e-9	Height;
LUSC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg14456004	chr13:21872349	NA	1.02	14.26	0.62	2.38e-36	White matter hyperintensity burden;
LUSC	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.53	0.38	4.72e-13	Iron status biomarkers;
LUSC	cis	rs9902453	0.967	rs11080121	chr17:28528842	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.44	0.42	9.61e-16	Coffee consumption (cups per day);
LUSC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg12257692	chr3:49977190	RBM6	0.24	6.67	0.34	1.06e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.86	16.72	0.68	4.85e-46	Body mass index (adult);
LUSC	trans	rs7538876	0.903	rs1324368	chr1:17752000	A/G	cg13009662	chr5:127419527	SLC12A2;FLJ33630	0.42	6.11	0.32	2.83e-9	Basal cell carcinoma;
LUSC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg06640241	chr16:89574553	SPG7	0.84	14.92	0.63	6.52e-39	Multiple myeloma (IgH translocation);
LUSC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg06784218	chr1:46089804	CCDC17	0.47	8.97	0.44	2.15e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.78	-12.8	-0.57	8.35e-31	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01325958	chr17:37793326	STARD3	-0.39	-6.09	-0.32	3.17e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg18230493	chr5:56204884	C5orf35	-0.54	-8.66	-0.43	1.99e-16	Coronary artery disease;
LUSC	cis	rs11195062	0.693	rs7912643	chr10:112027936	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.95	-0.31	6.69e-9	Multiple myeloma;
LUSC	cis	rs72792276	1.000	rs10519971	chr5:127379216	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.81	-7.3	-0.37	2.06e-12	Red cell distribution width;
LUSC	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.73	11.94	0.55	1.37e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs244293	0.931	rs244297	chr17:53241700	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.4	-5.8	-0.3	1.51e-8	Menarche (age at onset);
LUSC	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg08277548	chr1:17600880	PADI3	-0.66	-6.98	-0.36	1.58e-11	Hair shape;
LUSC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.64	0.63	7.44e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.38	-0.42	1.49e-15	Total cholesterol levels;
LUSC	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg20908204	chr19:46285434	DMPK	-0.45	-8.46	-0.42	8.49e-16	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09770904	chr12:6309613	CD9	-0.4	-6.3	-0.33	9.23e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.71	12.8	0.57	8.38e-31	Prudent dietary pattern;
LUSC	cis	rs6906287	0.647	rs12197337	chr6:118884092	C/T	cg21191810	chr6:118973309	C6orf204	0.33	6.05	0.31	3.83e-9	Electrocardiographic conduction measures;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00481081	chr10:74856747	P4HA1	-0.4	-5.97	-0.31	6.11e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg22153463	chr1:85462885	MCOLN2	-0.7	-8.81	-0.43	6.89e-17	Serum sulfate level;
LUSC	cis	rs9796	0.561	rs7173086	chr15:41509288	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.56	-0.42	4.14e-16	Menopause (age at onset);
LUSC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg19046167	chr17:80928561	B3GNTL1	-0.44	-6.33	-0.33	8.02e-10	Breast cancer;
LUSC	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-13.64	-0.6	5.43e-34	Coronary artery disease;
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05564831	chr3:52568323	NT5DC2	0.36	6.72	0.35	7.78e-11	Electroencephalogram traits;
LUSC	cis	rs12208915	0.848	rs12209635	chr6:79532215	C/T	cg05283184	chr6:79620031	NA	0.43	5.8	0.3	1.52e-8	Left atrial antero-posterior diameter;
LUSC	cis	rs911119	0.955	rs6036474	chr20:23604414	G/A	cg16589663	chr20:23618590	CST3	0.59	7.07	0.36	9.31e-12	Chronic kidney disease;
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.49	-6.66	-0.34	1.12e-10	Longevity;Endometriosis;
LUSC	cis	rs7903847	0.620	rs17112676	chr10:99122288	G/A	cg20016023	chr10:99160130	RRP12	-0.33	-7.98	-0.4	2.3e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg22777020	chr22:31556080	RNF185	-0.45	-5.76	-0.3	1.95e-8	Colorectal cancer;
LUSC	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg01528321	chr10:82214614	TSPAN14	0.95	14.57	0.62	1.42e-37	Post bronchodilator FEV1;
LUSC	cis	rs2580764	0.632	rs2588510	chr2:55199248	A/G	cg20993754	chr2:55226987	RTN4	0.33	5.66	0.3	3.29e-8	Mean platelet volume;
LUSC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.96	-15.13	-0.64	9.55e-40	Body mass index;
LUSC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.37	-0.33	6.23e-10	Total body bone mineral density;
LUSC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.03	-0.68	3.06e-47	Gut microbiome composition (summer);
LUSC	cis	rs6464929	0.910	rs12534095	chr7:148720705	C/T	cg23583168	chr7:148888333	NA	0.46	5.86	0.31	1.09e-8	Pediatric bone mineral content (hip);
LUSC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06634786	chr22:41940651	POLR3H	-0.52	-6.08	-0.32	3.25e-9	Vitiligo;
LUSC	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg08085267	chr17:45401833	C17orf57	0.54	8.83	0.44	6.01e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg18002602	chr11:66138449	SLC29A2	0.45	8.12	0.41	8.95e-15	Educational attainment (years of education);
LUSC	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg08200582	chr11:442649	ANO9	-0.53	-6.34	-0.33	7.31e-10	Body mass index;
LUSC	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-5.71	-0.3	2.54e-8	IgG glycosylation;
LUSC	cis	rs6693567	0.565	rs1260398	chr1:150279876	T/C	cg15654264	chr1:150340011	RPRD2	-0.45	-7.44	-0.38	8.64e-13	Migraine;
LUSC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg09796270	chr17:17721594	SREBF1	0.4	7.05	0.36	1.06e-11	Total body bone mineral density;
LUSC	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.14	-20.28	-0.74	3.45e-60	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.62	-0.34	1.46e-10	Lung cancer;
LUSC	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	0.59	9.25	0.45	2.65e-18	Breast cancer;
LUSC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg08493051	chr2:3487164	NA	-0.56	-8.6	-0.43	3.11e-16	Neurofibrillary tangles;
LUSC	cis	rs7833986	0.534	rs2458083	chr8:56898785	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	10.93	0.51	5.61e-24	Height;
LUSC	cis	rs2281845	0.533	rs10753891	chr1:201100482	A/G	cg22815214	chr1:201083145	CACNA1S	0.44	6.83	0.35	4.04e-11	Permanent tooth development;
LUSC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg06697600	chr4:7070879	GRPEL1	0.47	6.59	0.34	1.7e-10	Monocyte percentage of white cells;
LUSC	trans	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg25214090	chr10:38739885	LOC399744	0.52	7.7	0.39	1.51e-13	Corneal astigmatism;
LUSC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg26513180	chr16:89883248	FANCA	0.88	17.29	0.69	2.74e-48	Vitiligo;
LUSC	trans	rs6445525	0.967	rs2060022	chr3:65999755	A/G	cg12639933	chr12:57626296	SHMT2	0.33	5.97	0.31	6.07e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1729407	0.709	rs2098453	chr11:116696680	C/T	cg08985259	chr11:116699649	APOC3	-0.25	-5.83	-0.3	1.34e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs2235544	0.530	rs914720	chr1:54484482	C/T	cg25741118	chr1:54482237	LDLRAD1	-0.33	-7.63	-0.39	2.51e-13	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs231513	0.911	rs124722	chr17:41956002	T/G	cg26893861	chr17:41843967	DUSP3	-0.5	-5.94	-0.31	7.03e-9	Cognitive function;
LUSC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg05481257	chr2:20870211	GDF7	-0.37	-6.9	-0.35	2.59e-11	Abdominal aortic aneurysm;
LUSC	trans	rs514406	1.000	rs514406	chr1:53330458	A/G	cg24643429	chr1:3562429	WDR8	0.35	6.3	0.33	9.23e-10	Monocyte count;
LUSC	cis	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg26958806	chr6:27640298	NA	0.76	6.21	0.32	1.54e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg08807101	chr21:30365312	RNF160	0.66	10.35	0.49	5.88e-22	Pancreatic cancer;
LUSC	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.89	-14.98	-0.63	3.73e-39	Schizophrenia;
LUSC	cis	rs12369635	1.000	rs9645723	chr12:129554501	C/T	cg01909103	chr12:129572610	TMEM132D	-0.62	-5.93	-0.31	7.4e-9	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs2235544	0.565	rs637590	chr1:54461703	A/G	cg25741118	chr1:54482237	LDLRAD1	0.29	6.49	0.33	3.14e-10	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-1.05	-15.66	-0.65	7.51e-42	Exhaled nitric oxide output;
LUSC	cis	rs8016982	0.674	rs61980899	chr14:81676844	T/C	cg01989461	chr14:81687754	GTF2A1	0.72	12.73	0.57	1.6e-30	Schizophrenia;
LUSC	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg27124370	chr19:33622961	WDR88	0.53	6.69	0.34	9.21e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15266121	chr12:105630063	APPL2	-0.4	-6.26	-0.32	1.19e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	5.81	0.3	1.49e-8	Renal function-related traits (BUN);
LUSC	cis	rs4919694	0.572	rs4917995	chr10:104845443	A/T	cg05855489	chr10:104503620	C10orf26	-0.58	-6.79	-0.35	5.26e-11	Arsenic metabolism;
LUSC	trans	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.53	0.46	3.4e-19	Mean corpuscular volume;
LUSC	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg14458575	chr2:238380390	NA	0.46	5.76	0.3	1.95e-8	Prostate cancer;
LUSC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg04058563	chr4:185651563	MLF1IP	0.86	12.83	0.57	6.41e-31	Blood protein levels;
LUSC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg16850897	chr7:100343110	ZAN	-0.46	-5.87	-0.31	1.05e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.62	-0.38	2.71e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg11502198	chr6:26597334	ABT1	0.59	9.24	0.45	2.88e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs12210905	1.000	rs5030958	chr6:27214257	G/C	cg11837749	chr1:55047332	ACOT11	0.58	6.19	0.32	1.76e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.0	0.31	5.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg15549821	chr19:49342101	PLEKHA4	0.56	7.78	0.39	9.33e-14	Red cell distribution width;
LUSC	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg05347473	chr6:146136440	FBXO30	0.52	8.67	0.43	1.95e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg08125733	chr17:73851984	WBP2	0.47	6.56	0.34	2.04e-10	White matter hyperintensity burden;
LUSC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	8.92	0.44	3.02e-17	Motion sickness;
LUSC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	trans	rs1459104	0.866	rs28822225	chr11:54818606	C/G	cg03929089	chr4:120376271	NA	0.7	6.06	0.31	3.72e-9	Body mass index;
LUSC	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.52	7.99	0.4	2.24e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg21433313	chr16:3507492	NAT15	0.41	5.77	0.3	1.76e-8	Body mass index (adult);
LUSC	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	5.79	0.3	1.61e-8	Schizophrenia;
LUSC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg06784218	chr1:46089804	CCDC17	0.55	11.22	0.52	5.24e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg24733560	chr20:60626293	TAF4	0.43	6.92	0.35	2.25e-11	Body mass index;
LUSC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg03388025	chr16:89894329	SPIRE2	0.3	6.31	0.33	8.74e-10	Vitiligo;
LUSC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.79	14.9	0.63	7.6e-39	Dental caries;
LUSC	cis	rs7804356	1.000	rs12535784	chr7:26882067	G/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.12	-0.32	2.67e-9	Type 1 diabetes;
LUSC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg02117656	chr17:79614917	TSPAN10	0.3	5.67	0.3	3.16e-8	Eye color traits;
LUSC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg26587870	chr6:27730563	NA	-0.66	-5.98	-0.31	5.62e-9	Depression;
LUSC	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.12	-0.58	5.09e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1595825	0.838	rs73058854	chr2:198885060	G/A	cg10547527	chr2:198650123	BOLL	-0.53	-6.36	-0.33	6.65e-10	Ulcerative colitis;
LUSC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg18681998	chr4:17616180	MED28	0.81	14.81	0.63	1.74e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg08847533	chr14:75593920	NEK9	0.85	15.77	0.65	2.82e-42	Height;
LUSC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg15147215	chr3:52552868	STAB1	-0.31	-6.13	-0.32	2.54e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg09165964	chr15:75287851	SCAMP5	0.45	6.78	0.35	5.33e-11	Breast cancer;
LUSC	cis	rs3740713	1.000	rs73440625	chr11:18470800	A/G	cg07915343	chr11:18477680	LDHAL6A	-0.54	-6.74	-0.35	6.85e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs151234	0.741	rs151227	chr16:28549508	C/T	cg01378222	chr16:28622494	SULT1A1	-0.56	-8.26	-0.41	3.53e-15	Platelet distribution width;
LUSC	cis	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.28	-0.37	2.48e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	9.11	0.45	7.51e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg09165964	chr15:75287851	SCAMP5	0.45	6.71	0.34	8.36e-11	Breast cancer;
LUSC	trans	rs796395	0.664	rs2993047	chr1:218685055	G/A	cg05473648	chr11:79113178	MIR708;ODZ4	-0.34	-5.98	-0.31	5.64e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg02176678	chr2:219576539	TTLL4	0.6	10.67	0.5	4.48e-23	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg21775007	chr8:11205619	TDH	0.42	6.2	0.32	1.66e-9	Systolic blood pressure;
LUSC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg17143192	chr8:8559678	CLDN23	0.65	9.4	0.46	9.2e-19	Obesity-related traits;
LUSC	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg14583973	chr4:3374767	RGS12	0.29	6.31	0.33	8.66e-10	Parental longevity (mother's age at death);
LUSC	cis	rs2273669	0.667	rs12198088	chr6:109338433	C/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	8.89e-9	Prostate cancer;
LUSC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.01e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.59	9.61	0.47	1.82e-19	Aortic root size;
LUSC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.25	-0.52	4e-25	Mean corpuscular volume;
LUSC	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg19682013	chr15:45996608	NA	0.39	6.0	0.31	5.15e-9	Waist circumference;Weight;
LUSC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18876405	chr7:65276391	NA	0.54	8.47	0.42	8.18e-16	Aortic root size;
LUSC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4964805	0.657	rs11111787	chr12:104189499	C/T	cg02344784	chr12:104178138	NT5DC3	0.46	8.86	0.44	4.8e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.62	-0.34	1.42e-10	Lung cancer;
LUSC	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg20991723	chr1:152506922	NA	-0.54	-10.18	-0.49	2.29e-21	Hair morphology;
LUSC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg13010199	chr12:38710504	ALG10B	0.69	11.52	0.53	4.54e-26	Heart rate;
LUSC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg14895029	chr7:2775587	GNA12	-0.46	-7.02	-0.36	1.22e-11	Height;
LUSC	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.87	14.56	0.62	1.53e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg24733560	chr20:60626293	TAF4	0.37	6.11	0.32	2.83e-9	Body mass index;
LUSC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	7.93	0.4	3.4e-14	Total body bone mineral density;
LUSC	cis	rs6977660	0.714	rs12672320	chr7:19813594	G/T	cg05791153	chr7:19748676	TWISTNB	0.7	7.47	0.38	7.16e-13	Thyroid stimulating hormone;
LUSC	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg17470449	chr10:769945	NA	0.55	7.82	0.39	7.21e-14	Uric acid levels;
LUSC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg18402987	chr7:1209562	NA	0.69	7.41	0.38	1.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.88	-0.51	8.12e-24	Schizophrenia;
LUSC	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	12.45	0.56	1.67e-29	Mean platelet volume;
LUSC	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-0.97	-22.1	-0.77	2.49e-67	Urate levels in lean individuals;
LUSC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.57	-0.5	1e-22	Migraine;Coronary artery disease;
LUSC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg05552183	chr6:42928497	GNMT	0.47	7.66	0.39	1.99e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13076329	chr4:114682704	CAMK2D	-0.43	-5.96	-0.31	6.35e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.61	-0.6	7.34e-34	Chronic sinus infection;
LUSC	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	9.49	0.46	4.4e-19	Lung cancer in ever smokers;
LUSC	cis	rs73206853	0.841	rs73191851	chr12:111032305	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	6.54	0.34	2.3e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg04362960	chr10:104952993	NT5C2	0.58	9.18	0.45	4.58e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg02117656	chr17:79614917	TSPAN10	0.3	5.67	0.3	3.16e-8	Eye color traits;
LUSC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-8.71	-0.43	1.45e-16	Hemoglobin concentration;
LUSC	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	0.97	21.55	0.76	3.54e-65	Longevity;
LUSC	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg18209359	chr17:80159595	CCDC57	0.36	5.68	0.3	2.95e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs60154123	0.614	rs645890	chr1:210459801	A/C	cg22029157	chr1:209979665	IRF6	0.52	5.94	0.31	6.96e-9	Coronary artery disease;
LUSC	cis	rs9309473	0.606	rs79234109	chr2:73848354	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-5.79	-0.3	1.59e-8	Metabolite levels;
LUSC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	0.93	15.66	0.65	7.69e-42	Menopause (age at onset);
LUSC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.42	7.82	0.39	6.83e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg21141812	chr3:48556323	PFKFB4	0.33	5.85	0.3	1.19e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg08888203	chr3:10149979	C3orf24	0.48	7.06	0.36	9.82e-12	Alzheimer's disease;
LUSC	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg19717773	chr7:2847554	GNA12	-0.4	-7.22	-0.37	3.5e-12	Plateletcrit;
LUSC	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg24851651	chr11:66362959	CCS	-0.36	-5.68	-0.3	3.01e-8	Educational attainment (years of education);
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.59	-9.32	-0.45	1.58e-18	Lymphocyte counts;
LUSC	cis	rs1957429	0.808	rs4902325	chr14:65330843	A/G	cg23373153	chr14:65346875	NA	-0.94	-10.53	-0.5	1.46e-22	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg08345082	chr10:99160200	RRP12	-0.37	-7.11	-0.36	6.88e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg04218760	chr10:45406644	TMEM72	-0.29	-6.9	-0.35	2.6e-11	Mean corpuscular volume;
LUSC	cis	rs2227631	0.505	rs12530730	chr7:100758591	T/A	cg18465962	chr7:100767262	NA	0.39	6.25	0.32	1.26e-9	Plasminogen activator inhibitor type 1 levels (PAI-1);
LUSC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.07	-0.4	1.28e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg24006582	chr15:45444508	DUOX1	-0.55	-8.06	-0.4	1.4e-14	Uric acid levels;
LUSC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg03526776	chr6:41159608	TREML2	-0.32	-6.12	-0.32	2.59e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg18681998	chr4:17616180	MED28	0.86	15.82	0.65	1.84e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3092073	0.617	rs17448680	chr20:44594726	T/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.38	-5.95	-0.31	6.94e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg11843238	chr5:131593191	PDLIM4	-0.37	-6.03	-0.31	4.26e-9	Breast cancer;
LUSC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg15147215	chr3:52552868	STAB1	0.32	6.54	0.34	2.26e-10	Electroencephalogram traits;
LUSC	cis	rs4343996	0.870	rs4722708	chr7:3382563	A/T	cg21248987	chr7:3385318	SDK1	-0.4	-6.86	-0.35	3.25e-11	Motion sickness;
LUSC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.8	0.6	1.3600000000000001e-34	Chronic sinus infection;
LUSC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.86	-0.35	3.37e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4363385	0.747	rs6671524	chr1:152974247	C/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.78	-0.39	9.11e-14	Inflammatory skin disease;
LUSC	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg22705602	chr4:152727874	NA	-0.36	-7.61	-0.38	2.79e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.52	0.34	2.57e-10	Lung cancer;
LUSC	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	trans	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg26384229	chr12:38710491	ALG10B	0.55	8.8	0.43	7.24e-17	Morning vs. evening chronotype;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26434548	chr7:129074607	FAM40B	-0.46	-6.06	-0.31	3.61e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7188861	0.813	rs12596260	chr16:11398265	T/G	cg00044050	chr16:11439710	C16orf75	0.55	6.15	0.32	2.21e-9	HDL cholesterol;
LUSC	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.92	0.35	2.31e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.99	0.31	5.41e-9	Morning vs. evening chronotype;
LUSC	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.88	16.71	0.67	5.51e-46	Body mass index (adult);
LUSC	trans	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	8.12	0.41	9.4e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg20976159	chr1:228193529	WNT3A	-0.31	-6.19	-0.32	1.79e-9	Diastolic blood pressure;
LUSC	cis	rs8092503	1.000	rs8085272	chr18:52481583	A/G	cg12377874	chr18:52495404	RAB27B	-0.32	-5.72	-0.3	2.31e-8	Childhood body mass index;
LUSC	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg10434728	chr15:90938212	IQGAP1	-0.46	-9.23	-0.45	3.16e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs8073060	0.927	rs7502331	chr17:33868858	A/G	cg19694781	chr19:47549865	TMEM160	0.69	10.55	0.5	1.2e-22	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg21573476	chr21:45109991	RRP1B	-0.41	-6.74	-0.35	7.09e-11	Mean corpuscular volume;
LUSC	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00631329	chr6:26305371	NA	-0.45	-8.86	-0.44	4.68e-17	Educational attainment;
LUSC	cis	rs1595825	0.732	rs7577835	chr2:198378056	T/C	cg00982548	chr2:198649783	BOLL	-0.51	-6.19	-0.32	1.72e-9	Ulcerative colitis;
LUSC	cis	rs11605275	1.000	rs11605704	chr11:20032096	A/G	cg14835545	chr11:20032148	NAV2	0.86	6.61	0.34	1.54e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7539409	0.651	rs6576953	chr1:84316946	A/G	cg10977910	chr1:84465055	TTLL7	0.75	7.93	0.4	3.38e-14	Alzheimer's disease;
LUSC	cis	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-10.31	-0.49	7.72e-22	Bladder cancer;
LUSC	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.63	9.96	0.48	1.24e-20	Phospholipid levels (plasma);
LUSC	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.9	16.03	0.66	2.76e-43	Metabolic syndrome;
LUSC	cis	rs11997175	0.624	rs7016783	chr8:33696831	A/G	ch.8.33884649F	chr8:33765107	NA	0.45	6.77	0.35	5.67e-11	Body mass index;
LUSC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg04267008	chr7:1944627	MAD1L1	-0.47	-7.02	-0.36	1.24e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	0.94	17.45	0.69	6.2e-49	Headache;
LUSC	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.53	8.12	0.41	9.31e-15	Cognitive test performance;
LUSC	cis	rs7582720	1.000	rs72934556	chr2:203990789	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	8.71	0.43	1.44e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1595825	0.836	rs79748557	chr2:198567912	G/T	cg00982548	chr2:198649783	BOLL	-0.55	-7.01	-0.36	1.31e-11	Ulcerative colitis;
LUSC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg09417038	chr21:47716443	C21orf57	0.43	6.92	0.35	2.37e-11	Testicular germ cell tumor;
LUSC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg00031303	chr3:195681400	NA	0.68	9.77	0.47	5.42e-20	Pancreatic cancer;
LUSC	trans	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg27411982	chr8:10470053	RP1L1	0.45	7.51	0.38	5.53e-13	Mood instability;
LUSC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.66	-8.99	-0.44	1.88e-17	Glomerular filtration rate (creatinine);
LUSC	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg00757033	chr12:89920650	WDR51B	0.61	10.24	0.49	1.39e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.79	-0.47	4.49e-20	Gut microbiome composition (summer);
LUSC	cis	rs2303282	0.664	rs899242	chr16:56398585	C/G	cg00500540	chr16:56394104	NA	-0.4	-6.96	-0.36	1.76e-11	Breast cancer;
LUSC	cis	rs16917546	1.000	rs10995260	chr10:64410580	G/A	cg03961010	chr10:64397487	ZNF365	-0.43	-6.77	-0.35	5.63e-11	Basal cell carcinoma;
LUSC	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg18132916	chr6:79620363	NA	-0.38	-5.74	-0.3	2.18e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs34375054	0.558	rs67041765	chr12:125672913	T/G	cg00522288	chr12:125625016	AACS	-0.35	-6.45	-0.33	3.9e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.24	14.21	0.61	3.56e-36	Diabetic kidney disease;
LUSC	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.7	0.39	1.51e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg01065977	chr19:18549689	ISYNA1	-0.24	-6.01	-0.31	4.94e-9	Breast cancer;
LUSC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg24733560	chr20:60626293	TAF4	0.38	6.31	0.33	8.74e-10	Body mass index;
LUSC	cis	rs1322512	1.000	rs2250632	chr6:153011126	C/A	cg03415253	chr6:152958462	SYNE1	0.38	5.68	0.3	2.95e-8	Tonometry;
LUSC	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg15934090	chr1:100435551	SLC35A3	0.47	7.72	0.39	1.4e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10761482	0.813	rs10821727	chr10:62099113	C/T	cg18175470	chr10:62150864	ANK3	-0.51	-7.36	-0.37	1.48e-12	Schizophrenia;
LUSC	cis	rs9462027	0.628	rs3734268	chr6:34716028	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.9	-0.31	9.02e-9	Systemic lupus erythematosus;
LUSC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg11494091	chr17:61959527	GH2	0.39	6.77	0.35	5.68e-11	Height;
LUSC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.6	-5.66	-0.3	3.24e-8	Cerebrospinal P-tau181p levels;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg18883852	chr13:45965548	LOC100190939	-0.39	-6.3	-0.33	9.4e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.08	15.38	0.64	9.93e-41	Uric acid levels;
LUSC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.93	-0.51	5.65e-24	Alzheimer's disease;
LUSC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg02176678	chr2:219576539	TTLL4	-0.57	-9.99	-0.48	1.02e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6460942	0.915	rs2216051	chr7:12304054	G/A	cg06484146	chr7:12443880	VWDE	-0.52	-6.29	-0.33	9.98e-10	Coronary artery disease;
LUSC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg12365402	chr11:9010492	NRIP3	-0.42	-7.55	-0.38	4.2e-13	Hemoglobin concentration;
LUSC	cis	rs10266483	0.739	rs12665990	chr7:63865000	G/A	cg24201672	chr7:64023550	ZNF680	0.5	6.03	0.31	4.28e-9	Response to statin therapy;
LUSC	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.53	8.62	0.43	2.73e-16	Breast cancer;
LUSC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	6.57	0.34	1.88e-10	Menarche (age at onset);
LUSC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg05623727	chr3:50126028	RBM5	-0.35	-6.65	-0.34	1.21e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg25767906	chr1:53392781	SCP2	-0.48	-8.6	-0.43	3.12e-16	Monocyte count;
LUSC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.15	0.49	2.9e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9309473	0.607	rs7573719	chr2:73582986	G/A	cg20560298	chr2:73613845	ALMS1	-0.57	-8.3	-0.41	2.62e-15	Metabolite levels;
LUSC	cis	rs16854884	0.657	rs12107291	chr3:143739547	T/C	cg06585982	chr3:143692056	C3orf58	0.5	7.93	0.4	3.36e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.52	-6.99	-0.36	1.47e-11	Response to bleomycin (chromatid breaks);
LUSC	cis	rs3772130	1.000	rs3772130	chr3:121344140	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.66	9.47	0.46	5.11e-19	Cognitive performance;
LUSC	cis	rs921968	0.541	rs933994	chr2:219650616	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-10.22	-0.49	1.59e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.49	-9.12	-0.45	7.36e-18	Longevity;Endometriosis;
LUSC	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg02018176	chr4:1364513	KIAA1530	0.44	6.02	0.31	4.62e-9	Recombination rate (females);
LUSC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg11941060	chr3:133502564	NA	-0.52	-7.96	-0.4	2.68e-14	Iron status biomarkers;
LUSC	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg07541023	chr7:19748670	TWISTNB	0.67	7.09	0.36	8.25e-12	Thyroid stimulating hormone;
LUSC	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.55	9.7	0.47	9.47e-20	Birth weight;
LUSC	cis	rs9356171	0.572	rs62435477	chr6:164328670	C/T	cg25752492	chr6:164341247	NA	-0.39	-6.58	-0.34	1.79e-10	Diisocyanate-induced asthma;
LUSC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07677032	chr17:61819896	STRADA	0.54	9.03	0.44	1.36e-17	Prudent dietary pattern;
LUSC	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg06937882	chr20:24974362	C20orf3	-0.41	-6.94	-0.36	2.02e-11	Blood protein levels;
LUSC	trans	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg02113368	chr10:135107346	TUBGCP2	-0.34	-6.01	-0.31	4.92e-9	Dementia with Lewy bodies;
LUSC	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg00376283	chr12:123451042	ABCB9	0.69	9.71	0.47	8.23e-20	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg22356347	chr1:167427500	CD247	-0.29	-6.61	-0.34	1.54e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	6.86	0.35	3.25e-11	Platelet count;
LUSC	cis	rs1577917	0.958	rs1816937	chr6:86557251	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg01884057	chr2:25150051	NA	0.48	11.26	0.52	3.91e-25	Body mass index;
LUSC	cis	rs977987	0.836	rs7198873	chr16:75474754	G/A	cg03315344	chr16:75512273	CHST6	0.49	9.31	0.45	1.73e-18	Dupuytren's disease;
LUSC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25072359	chr17:41440525	NA	0.62	9.07	0.44	1.05e-17	Menopause (age at onset);
LUSC	cis	rs10886558	0.630	rs4237512	chr10:121810127	A/C	cg02041677	chr10:121771263	NA	-0.33	-6.35	-0.33	7.16e-10	Shingles;
LUSC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19717773	chr7:2847554	GNA12	0.43	6.72	0.35	7.81e-11	Height;
LUSC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.49	6.14	0.32	2.31e-9	Schizophrenia;
LUSC	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	8.0	0.4	2.03e-14	Multiple sclerosis;
LUSC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.17	-0.32	1.98e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg25173405	chr17:45401733	C17orf57	0.36	5.76	0.3	1.96e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg21770322	chr7:97807741	LMTK2	0.5	8.59	0.43	3.5e-16	Breast cancer;
LUSC	cis	rs6690583	0.623	rs12042018	chr1:85436937	T/C	cg11262906	chr1:85462892	MCOLN2	0.68	6.61	0.34	1.55e-10	Serum sulfate level;
LUSC	cis	rs6930083	0.737	rs13196885	chr6:36632688	C/T	cg08179530	chr6:36648295	CDKN1A	-0.49	-6.67	-0.34	1.05e-10	Coronary artery disease;
LUSC	cis	rs9300255	0.722	rs1060105	chr12:123806219	C/T	cg00376283	chr12:123451042	ABCB9	-0.71	-8.08	-0.4	1.17e-14	Neutrophil percentage of white cells;
LUSC	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs72772090	1.000	rs56116814	chr5:96048714	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.62	-6.91	-0.35	2.39e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6495367	0.803	rs2870111	chr15:79403585	C/T	cg17916960	chr15:79447300	NA	0.4	7.45	0.38	8.2e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg07460842	chr6:66804631	NA	0.7	8.69	0.43	1.68e-16	Type 2 diabetes;
LUSC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg09455208	chr3:40491958	NA	0.53	9.47	0.46	5.15e-19	Renal cell carcinoma;
LUSC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.39	6.01	0.31	4.93e-9	Total body bone mineral density;
LUSC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg08645402	chr16:4508243	NA	0.52	8.46	0.42	8.23e-16	Schizophrenia;
LUSC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	7.95	0.4	2.83e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg24397884	chr7:158709396	WDR60	0.79	8.86	0.44	4.84e-17	Height;
LUSC	cis	rs6845621	0.727	rs2110211	chr4:18917064	A/G	cg12196642	chr4:18937545	NA	-0.34	-6.34	-0.33	7.56e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg03676636	chr4:99064102	C4orf37	0.35	7.45	0.38	7.89e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg04369109	chr6:150039330	LATS1	-0.6	-8.71	-0.43	1.44e-16	Lung cancer;
LUSC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg11663144	chr21:46675770	NA	-0.41	-6.97	-0.36	1.66e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	1.05	17.3	0.69	2.5e-48	Testicular germ cell tumor;
LUSC	cis	rs62408225	1.000	rs1504215	chr6:91006227	G/A	cg06866423	chr6:90926672	BACH2	0.43	6.22	0.32	1.49e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg05283184	chr6:79620031	NA	-0.56	-11.8	-0.54	4.14e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-1.04	-20.22	-0.74	5.96e-60	Height;
LUSC	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.65	0.39	2.2e-13	Morning vs. evening chronotype;
LUSC	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg00857998	chr1:205179979	DSTYK	0.64	9.86	0.47	2.73e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.18	0.49	2.21e-21	Lymphocyte counts;
LUSC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg13395646	chr4:1353034	KIAA1530	-0.61	-9.42	-0.46	7.48e-19	Longevity;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg23244062	chr14:93799399	BTBD7;KIAA1409	0.38	5.96	0.31	6.53e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.96	-16.54	-0.67	2.55e-45	Body mass index;
LUSC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.09	0.77	2.83e-67	Prudent dietary pattern;
LUSC	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.6	-0.6	7.94e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg18252515	chr7:66147081	NA	-1.32	-8.8	-0.43	7.39e-17	Diabetic kidney disease;
LUSC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg04553112	chr3:125709451	NA	-0.48	-5.83	-0.3	1.29e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg01256987	chr12:42539512	GXYLT1	0.36	6.61	0.34	1.53e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7172677	0.732	rs2289583	chr15:75311036	C/A	cg14664628	chr15:75095509	CSK	0.61	7.94	0.4	3.18e-14	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg16393715	chr7:1948819	MAD1L1	0.36	6.25	0.32	1.23e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	13.21	0.59	2.45e-32	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg07606381	chr6:8435919	SLC35B3	0.72	12.17	0.55	1.89e-28	Motion sickness;
LUSC	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-8.31	-0.41	2.5e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs3760982	0.626	rs12463370	chr19:44292166	G/A	cg11993925	chr19:44307056	LYPD5	0.28	6.26	0.32	1.2e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9487051	0.768	rs427960	chr6:109524939	C/T	cg01475377	chr6:109611718	NA	-0.35	-5.69	-0.3	2.76e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.39	-5.74	-0.3	2.18e-8	Tonsillectomy;
LUSC	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.41	6.63	0.34	1.38e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-40.51	-0.91	6.17e-131	Myeloid white cell count;
LUSC	cis	rs4363385	0.818	rs12029168	chr1:152987993	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.74	-0.3	2.17e-8	Inflammatory skin disease;
LUSC	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg27068330	chr11:65405492	SIPA1	-0.79	-11.16	-0.52	8.64e-25	Acne (severe);
LUSC	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg04450456	chr4:17643702	FAM184B	-0.35	-5.87	-0.31	1.05e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.78	0.35	5.42e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs6700896	0.522	rs4655583	chr1:66155407	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	5.95	0.31	6.86e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.19	-0.32	1.76e-9	Neuroticism;
LUSC	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg16386425	chr10:429943	DIP2C	0.4	5.87	0.31	1.04e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg00012203	chr2:219082015	ARPC2	-0.58	-9.25	-0.45	2.73e-18	Ulcerative colitis;
LUSC	trans	rs9944715	0.954	rs1808946	chr18:43854860	A/G	cg01718231	chr17:29326311	RNF135	-0.54	-7.54	-0.38	4.52e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs372883	0.901	rs733610	chr21:30656199	G/A	cg08807101	chr21:30365312	RNF160	-0.41	-5.81	-0.3	1.46e-8	Pancreatic cancer;
LUSC	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg20503657	chr10:835505	NA	0.55	7.2	0.37	4.09e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg00105475	chr2:10696890	NA	0.38	6.27	0.32	1.11e-9	Prostate cancer;
LUSC	cis	rs9326248	0.861	rs4938352	chr11:117027481	G/A	cg26566898	chr11:117069891	TAGLN	0.38	6.06	0.31	3.6e-9	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00175859	chr6:138428631	PERP	-0.44	-6.7	-0.34	8.79e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg20129853	chr10:51489980	NA	0.36	7.4	0.38	1.14e-12	Prostate-specific antigen levels;
LUSC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	9.79	0.47	4.77e-20	Personality dimensions;
LUSC	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg00310523	chr12:86230176	RASSF9	0.44	7.91	0.4	3.74e-14	Major depressive disorder;
LUSC	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg08000102	chr2:233561755	GIGYF2	0.75	12.65	0.57	3.23e-30	Schizophrenia;
LUSC	cis	rs12464559	0.522	rs11676866	chr2:152628858	G/C	cg01189475	chr2:152685088	ARL5A	0.65	7.2	0.37	4.04e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg24881330	chr22:46731750	TRMU	0.85	8.4	0.42	1.28e-15	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.69	-6.61	-0.34	1.5e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	13.55	0.6	1.23e-33	Platelet count;
LUSC	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.58	9.62	0.47	1.68e-19	Breast cancer;
LUSC	cis	rs10887741	0.966	rs2077695	chr10:89435483	T/C	cg13926569	chr10:89418898	PAPSS2	0.34	6.7	0.34	8.88e-11	Exercise (leisure time);
LUSC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg02772935	chr3:125709198	NA	-0.49	-5.87	-0.31	1.04e-8	Blood pressure (smoking interaction);
LUSC	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.78	-13.06	-0.58	8.9e-32	Schizophrenia;
LUSC	cis	rs62408225	0.722	rs1319433	chr6:90921988	G/A	cg06866423	chr6:90926672	BACH2	0.4	6.24	0.32	1.31e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs71435601	0.628	rs560408	chr2:21398379	T/C	cg20757404	chr19:378427	NA	0.37	6.01	0.31	4.87e-9	Cholesterol, total;
LUSC	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.93	-0.44	3.01e-17	Total cholesterol levels;
LUSC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.9	16.2	0.66	5.81e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.76	12.04	0.55	5.5e-28	Squamous cell carcinoma;
LUSC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.34	6.45	0.33	3.86e-10	Platelet count;
LUSC	cis	rs9653442	0.545	rs1821827	chr2:100764717	T/C	cg22139774	chr2:100720529	AFF3	-0.42	-7.25	-0.37	2.9e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs870825	0.616	rs7674952	chr4:185622327	A/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	12.79	0.57	9.42e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg01879757	chr17:41196368	BRCA1	-0.51	-8.2	-0.41	5.4e-15	Menopause (age at onset);
LUSC	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.75	0.73	4.54e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg11244672	chr19:19639970	YJEFN3	-0.54	-6.56	-0.34	1.99e-10	Bipolar disorder;
LUSC	cis	rs1957429	0.522	rs73279816	chr14:65348375	G/A	cg23373153	chr14:65346875	NA	-1.02	-9.25	-0.45	2.73e-18	Pediatric areal bone mineral density (radius);
LUSC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.52	-0.42	5.37e-16	Type 2 diabetes;
LUSC	cis	rs9581857	0.547	rs9579094	chr13:28081495	G/A	cg22138327	chr13:27999177	GTF3A	0.7	7.16	0.36	5.16e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs73200209	0.703	rs17427025	chr12:116677033	C/G	cg01776926	chr12:116560359	MED13L	-0.46	-5.73	-0.3	2.3e-8	Total body bone mineral density;
LUSC	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg00310523	chr12:86230176	RASSF9	-0.42	-7.98	-0.4	2.35e-14	Major depressive disorder;
LUSC	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.68	-0.39	1.8e-13	Joint mobility (Beighton score);
LUSC	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg08847533	chr14:75593920	NEK9	-0.81	-13.85	-0.6	9.04e-35	Height;
LUSC	trans	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg04995722	chr7:26192034	NFE2L3	0.38	6.23	0.32	1.37e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9361491	0.657	rs9359344	chr6:79461033	G/A	cg05283184	chr6:79620031	NA	-0.32	-5.9	-0.31	9.16e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs17401966	0.537	rs3748575	chr1:10342352	C/T	cg19773385	chr1:10388646	KIF1B	-0.34	-6.12	-0.32	2.6e-9	Hepatocellular carcinoma;
LUSC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13770153	chr20:60521292	NA	-0.62	-8.16	-0.41	6.68e-15	Body mass index;
LUSC	cis	rs400736	0.930	rs226251	chr1:8024690	T/C	cg25007680	chr1:8021821	PARK7	0.61	9.56	0.46	2.59e-19	Response to antidepressants and depression;
LUSC	cis	rs72634258	0.945	rs28624	chr1:8084355	G/T	cg00042356	chr1:8021962	PARK7	-0.67	-8.72	-0.43	1.38e-16	Inflammatory bowel disease;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24473633	chr8:142138319	DENND3	-0.44	-5.98	-0.31	5.68e-9	Hepatitis;
LUSC	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg18129178	chr5:148520854	ABLIM3	0.61	9.26	0.45	2.59e-18	Breast cancer;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg15242686	chr22:24348715	GSTTP1	0.43	6.53	0.34	2.49e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs997295	0.713	rs12905509	chr15:67994108	A/G	cg08079166	chr15:68083412	MAP2K5	-0.32	-6.48	-0.33	3.24e-10	Motion sickness;
LUSC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	6.65	0.34	1.19e-10	Obesity-related traits;
LUSC	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg00677455	chr12:58241039	CTDSP2	0.69	10.48	0.5	2.07e-22	Intelligence (multi-trait analysis);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg09119797	chr1:35658164	SFPQ	0.34	5.98	0.31	5.88e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg12454169	chr2:30669597	LCLAT1	0.61	7.82	0.39	7.08e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs4072705	0.615	rs7028021	chr9:127249022	A/G	cg13476313	chr9:127244764	NR5A1	0.34	6.48	0.33	3.21e-10	Menarche (age at onset);
LUSC	cis	rs983392	0.868	rs7933202	chr11:59936926	A/C	cg20284999	chr11:59952153	MS4A6A	-0.36	-5.81	-0.3	1.49e-8	Alzheimer's disease (late onset);
LUSC	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg17410650	chr12:54324560	NA	-0.57	-10.25	-0.49	1.25e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg09491104	chr22:46646882	C22orf40	-0.67	-7.0	-0.36	1.42e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2637266	0.935	rs7921790	chr10:78368253	T/C	cg18941641	chr10:78392320	NA	0.39	7.06	0.36	9.56e-12	Pulmonary function;
LUSC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg06212747	chr3:49208901	KLHDC8B	0.45	5.99	0.31	5.28e-9	Parkinson's disease;
LUSC	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg23796481	chr11:64053134	BAD;GPR137	0.52	8.14	0.41	8.04e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.94	-0.31	7.28e-9	IgG glycosylation;
LUSC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	0.88	15.67	0.65	6.95e-42	Cognitive function;
LUSC	cis	rs6500395	1.000	rs1420701	chr16:48730873	C/T	cg04672837	chr16:48644449	N4BP1	-0.48	-7.11	-0.36	7.05e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs59698941	0.943	rs60545802	chr5:132204577	T/G	cg02081065	chr5:132209139	LEAP2	-0.65	-6.75	-0.35	6.57e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-10.68	-0.5	4.33e-23	Bipolar disorder;
LUSC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg11663144	chr21:46675770	NA	-0.4	-6.93	-0.35	2.19e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.67	10.12	0.48	3.54e-21	Breast cancer;
LUSC	cis	rs17490626	0.568	rs12413525	chr10:71211721	C/A	cg14388049	chr10:71211838	TSPAN15	-0.32	-5.81	-0.3	1.47e-8	Thrombosis;
LUSC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.71	0.54	9.03e-27	Prudent dietary pattern;
LUSC	cis	rs2235649	0.798	rs9932983	chr16:1848184	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.07	-0.32	3.56e-9	Blood metabolite levels;
LUSC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.81	13.83	0.6	1.03e-34	Blood protein levels;
LUSC	cis	rs1144713	0.686	rs1144715	chr12:32261435	A/G	cg01321189	chr12:32259338	BICD1	0.43	6.66	0.34	1.12e-10	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.78	0.39	9.12e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg27124370	chr19:33622961	WDR88	0.58	8.26	0.41	3.54e-15	Bone properties (heel);
LUSC	cis	rs3087591	1.000	rs8068801	chr17:29570587	G/T	cg24425628	chr17:29625626	OMG;NF1	-0.57	-8.26	-0.41	3.47e-15	Hip circumference;
LUSC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs7181230	0.885	rs3923235	chr15:40371121	A/G	cg22705835	chr10:65332833	REEP3	-0.4	-6.54	-0.34	2.34e-10	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg07424592	chr7:64974309	NA	0.63	5.69	0.3	2.81e-8	Diabetic kidney disease;
LUSC	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg25457927	chr22:38595422	NA	-0.34	-6.81	-0.35	4.62e-11	Cutaneous nevi;
LUSC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.12	0.66	1.24e-43	Platelet count;
LUSC	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg01629716	chr15:45996671	NA	0.4	5.87	0.31	1.05e-8	Waist circumference;Weight;
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23978390	chr7:1156363	C7orf50	0.48	6.82	0.35	4.33e-11	Longevity;Endometriosis;
LUSC	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg22508957	chr16:3507546	NAT15	-0.4	-6.35	-0.33	6.88e-10	Body mass index (adult);
LUSC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06221963	chr1:154839813	KCNN3	-0.61	-13.83	-0.6	1.03e-34	Prostate cancer;
LUSC	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.94	-0.31	7.31e-9	Neutrophil percentage of white cells;
LUSC	cis	rs10761482	0.861	rs10740027	chr10:62159661	T/C	cg18175470	chr10:62150864	ANK3	-0.57	-8.44	-0.42	9.48e-16	Schizophrenia;
LUSC	cis	rs7809950	0.678	rs13230144	chr7:106909172	T/C	cg23024343	chr7:107201750	COG5	-0.66	-10.06	-0.48	5.78e-21	Coronary artery disease;
LUSC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.1	0.48	4.14e-21	Electroencephalogram traits;
LUSC	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg08213375	chr14:104286397	PPP1R13B	0.54	10.89	0.51	7.59e-24	Schizophrenia;
LUSC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.79	-0.43	8.19e-17	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.9	0.48	2.05e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	0.93	12.54	0.57	7.95e-30	Primary sclerosing cholangitis;
LUSC	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.52	3.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03352830	chr11:487213	PTDSS2	0.71	8.83	0.43	6.13e-17	Body mass index;
LUSC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg22907277	chr7:1156413	C7orf50	0.51	7.68	0.39	1.74e-13	Longevity;Endometriosis;
LUSC	cis	rs722599	0.961	rs2359239	chr14:75326771	C/T	cg08847533	chr14:75593920	NEK9	-0.41	-5.99	-0.31	5.31e-9	IgG glycosylation;
LUSC	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg18132916	chr6:79620363	NA	-0.37	-5.74	-0.3	2.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	11.77	0.54	5.55e-27	Personality dimensions;
LUSC	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg11584989	chr19:19387371	SF4	0.58	6.97	0.36	1.74e-11	Bipolar disorder;
LUSC	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg04036182	chr15:45458818	NA	0.35	5.8	0.3	1.5e-8	Glomerular filtration rate;
LUSC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg02503808	chr4:7069936	GRPEL1	1.03	13.79	0.6	1.52e-34	Monocyte percentage of white cells;
LUSC	cis	rs9807841	0.592	rs1053007	chr19:10754400	A/G	cg17710535	chr19:10819994	QTRT1	0.44	7.27	0.37	2.57e-12	Inflammatory skin disease;
LUSC	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	8.56	0.42	4.33e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-18.03	-0.7	3.21e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-6.85	-0.35	3.57e-11	Menarche (age at onset);
LUSC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-8.59	-0.43	3.38e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg26338869	chr17:61819248	STRADA	0.41	5.94	0.31	7.17e-9	Prudent dietary pattern;
LUSC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	5.78	0.3	1.72e-8	Joint mobility (Beighton score);
LUSC	trans	rs3960554	0.808	rs112372188	chr7:75723376	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	9.32	0.45	1.63e-18	Eotaxin levels;
LUSC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg13939156	chr17:80058883	NA	0.34	6.72	0.35	7.89e-11	Life satisfaction;
LUSC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg27170947	chr2:26402098	FAM59B	0.61	9.28	0.45	2.16e-18	Gut microbiome composition (summer);
LUSC	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.91	-0.35	2.4e-11	Menopause (age at onset);
LUSC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	7.04	0.36	1.07e-11	Schizophrenia;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26356754	chr6:43325264	ZNF318	0.36	6.35	0.33	7.22e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg14440974	chr22:39074834	NA	-0.35	-5.93	-0.31	7.55e-9	Menopause (age at onset);
LUSC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg20818283	chr2:191399100	TMEM194B	0.43	6.72	0.35	7.81e-11	Pulse pressure;
LUSC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs2235649	0.828	rs9925354	chr16:1849866	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.1	-0.32	2.96e-9	Blood metabolite levels;
LUSC	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg03948781	chr1:205179583	DSTYK	0.3	5.67	0.3	3.04e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21659725	chr3:3221576	CRBN	0.6	7.99	0.4	2.2e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	trans	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg03886242	chr7:26192032	NFE2L3	0.37	6.07	0.32	3.42e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-7.52	-0.38	5.03e-13	Mood instability;
LUSC	cis	rs2274273	0.745	rs748017	chr14:55542300	A/G	cg04306507	chr14:55594613	LGALS3	0.51	10.72	0.51	3.06e-23	Protein biomarker;
LUSC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg16545954	chr1:2118288	C1orf86	0.31	5.92	0.31	7.79e-9	Height;
LUSC	cis	rs2708377	0.929	rs73053768	chr12:11155747	A/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.83	8.18	0.41	5.97e-15	Bitter taste perception;
LUSC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg08219700	chr8:58056026	NA	0.49	6.06	0.31	3.61e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6740322	0.644	rs11690918	chr2:43474112	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.47	-6.02	-0.31	4.72e-9	Coronary artery disease;
LUSC	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg25036284	chr2:26402008	FAM59B	-0.75	-10.98	-0.52	3.59e-24	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9400467	0.528	rs1989574	chr6:111728533	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.88	-0.35	3.05e-11	Blood metabolite levels;Amino acid levels;
LUSC	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg03929089	chr4:120376271	NA	0.68	7.58	0.38	3.49e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.46	-5.75	-0.3	2.02e-8	Schizophrenia;
LUSC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg15790184	chr11:494944	RNH1	0.52	5.98	0.31	5.62e-9	Body mass index;
LUSC	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.25	0.64	3.15e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg04310649	chr10:35416472	CREM	-0.43	-6.72	-0.35	7.83e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg04155289	chr7:94953770	PON1	-0.35	-5.9	-0.31	8.94e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.57	12.83	0.57	6.67e-31	Hemoglobin concentration;
LUSC	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg00631329	chr6:26305371	NA	-0.34	-6.31	-0.33	8.7e-10	Educational attainment;
LUSC	cis	rs12760731	0.565	rs10494511	chr1:178094265	A/G	cg00404053	chr1:178313656	RASAL2	0.6	6.06	0.31	3.6e-9	Obesity-related traits;
LUSC	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg23093090	chr10:104574429	C10orf26	-0.35	-6.46	-0.33	3.66e-10	Arsenic metabolism;
LUSC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg12463550	chr7:65579703	CRCP	0.5	7.02	0.36	1.22e-11	Aortic root size;
LUSC	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.45	-7.04	-0.36	1.13e-11	Tonsillectomy;
LUSC	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg00564555	chr16:1970112	NA	0.34	5.99	0.31	5.3300000000000004e-09	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs35374984	0.920	rs16930800	chr10:30234268	A/C	cg02747044	chr21:38639544	DSCR3	-0.72	-6.28	-0.32	1.08e-9	Emphysema distribution in smoking;
LUSC	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.43	6.69	0.34	9.59e-11	Dupuytren's disease;
LUSC	trans	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg13010199	chr12:38710504	ALG10B	0.48	7.33	0.37	1.73e-12	Morning vs. evening chronotype;
LUSC	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg21775007	chr8:11205619	TDH	-0.68	-10.44	-0.5	2.97e-22	Retinal vascular caliber;
LUSC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.16	-0.32	2.12e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.54	-0.42	4.8e-16	Personality dimensions;
LUSC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08677398	chr8:58056175	NA	0.54	6.63	0.34	1.35e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg03806693	chr22:41940476	POLR3H	0.98	14.25	0.61	2.56e-36	Vitiligo;
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.38	-6.27	-0.32	1.15e-9	Longevity;Endometriosis;
LUSC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg20283391	chr11:68216788	NA	0.52	7.74	0.39	1.18e-13	Total body bone mineral density;
LUSC	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg26876637	chr1:152193138	HRNR	0.46	6.82	0.35	4.21e-11	Atopic dermatitis;
LUSC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg13560548	chr3:10150139	C3orf24	0.52	7.14	0.36	5.82e-12	Alzheimer's disease;
LUSC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	cis	rs11168618	0.904	rs12366459	chr12:48930900	C/T	cg24011408	chr12:48396354	COL2A1	0.4	6.42	0.33	4.67e-10	Adiponectin levels;
LUSC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg13010199	chr12:38710504	ALG10B	-0.44	-6.57	-0.34	1.95e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6546550	0.869	rs6720498	chr2:70124805	T/C	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.24	-0.37	3.14e-12	Prevalent atrial fibrillation;
LUSC	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg24578937	chr1:2090814	PRKCZ	0.57	12.48	0.56	1.28e-29	Height;
LUSC	trans	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg06521331	chr12:34319734	NA	-0.39	-5.95	-0.31	6.77e-9	Bladder cancer;
LUSC	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg24375607	chr4:120327624	NA	0.75	12.08	0.55	4.2e-28	Corneal astigmatism;
LUSC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-10.8	-0.51	1.62e-23	Bipolar disorder;
LUSC	trans	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg07829597	chr10:77161705	C10orf41;ZNF503	0.66	6.16	0.32	2.03e-9	Sexual dysfunction (female);
LUSC	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.92	12.13	0.55	2.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg13175981	chr1:150552382	MCL1	0.49	6.96	0.36	1.83e-11	Tonsillectomy;
LUSC	cis	rs7903847	0.600	rs2275582	chr10:99128983	G/A	cg20016023	chr10:99160130	RRP12	-0.28	-6.26	-0.32	1.16e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2692947	0.770	rs2315421	chr2:96497516	G/C	cg22654517	chr2:96458247	NA	0.38	7.56	0.38	3.95e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg11062466	chr8:58055876	NA	0.71	8.53	0.42	5.07e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.46e-35	Breast cancer;
LUSC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.22	-14.55	-0.62	1.77e-37	Diabetic kidney disease;
LUSC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg02782426	chr3:40428986	ENTPD3	0.34	6.45	0.33	4.03e-10	Renal cell carcinoma;
LUSC	cis	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg06521852	chr22:38141419	TRIOBP	0.4	6.33	0.33	7.93e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs2652834	1.000	rs2652832	chr15:63396928	T/C	cg05507819	chr15:63340323	TPM1	0.67	8.13	0.41	8.72e-15	HDL cholesterol;
LUSC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-17.36	-0.69	1.4e-48	Primary sclerosing cholangitis;
LUSC	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg16989719	chr2:238392110	NA	-0.42	-7.45	-0.38	7.96e-13	Prostate cancer;
LUSC	cis	rs34779708	0.733	rs12777960	chr10:35541026	C/A	cg03585969	chr10:35415529	CREM	0.55	7.63	0.39	2.51e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg20016023	chr10:99160130	RRP12	0.31	7.78	0.39	8.89e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6429082	0.597	rs6683978	chr1:235541425	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.51	-6.89	-0.35	2.74e-11	Adiposity;
LUSC	cis	rs6494488	0.500	rs72741319	chr15:64716977	C/G	cg08069370	chr15:64387884	SNX1	-0.64	-5.67	-0.3	3.05e-8	Coronary artery disease;
LUSC	cis	rs6961069	0.671	rs28600997	chr7:80222539	C/T	cg04458919	chr7:80252533	CD36	-0.41	-7.16	-0.36	5.3e-12	Platelet count;
LUSC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.48	-0.53	6.18e-26	Mean corpuscular volume;
LUSC	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg06640241	chr16:89574553	SPG7	0.68	10.74	0.51	2.57e-23	Multiple myeloma (IgH translocation);
LUSC	cis	rs4356932	0.967	rs13128319	chr4:76975206	A/G	cg00809888	chr4:76862425	NAAA	-0.35	-5.91	-0.31	8.42e-9	Blood protein levels;
LUSC	cis	rs11958404	0.929	rs72816533	chr5:157413352	G/T	cg05962755	chr5:157440814	NA	0.51	6.25	0.32	1.28e-9	IgG glycosylation;
LUSC	cis	rs243505	0.559	rs734003	chr7:148505498	T/G	cg09806900	chr7:148480153	CUL1	0.67	9.97	0.48	1.14e-20	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg17127132	chr2:85788382	GGCX	0.45	7.08	0.36	8.53e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10779751	0.960	rs4845857	chr1:11285680	T/C	cg08854313	chr1:11322531	MTOR	0.89	14.58	0.62	1.27e-37	Body mass index;
LUSC	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.6	-0.43	3.16e-16	Total cholesterol levels;
LUSC	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.54	-0.42	4.9e-16	Systolic blood pressure;
LUSC	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg19920283	chr7:105172520	RINT1	0.6	6.35	0.33	7.01e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.55	-6.34	-0.33	7.33e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07169764	chr2:136633963	MCM6	0.98	13.72	0.6	2.83e-34	Corneal structure;
LUSC	cis	rs1832871	0.711	rs9459826	chr6:158680396	C/G	cg07165851	chr6:158734300	TULP4	-0.5	-7.67	-0.39	1.9e-13	Height;
LUSC	cis	rs9472414	0.771	rs720988	chr6:44765660	C/T	cg20913747	chr6:44695427	NA	0.4	5.74	0.3	2.17e-8	Height;
LUSC	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg04545296	chr12:48745243	ZNF641	0.34	6.26	0.32	1.2e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs6456156	0.806	rs11967165	chr6:167529936	T/C	cg07741184	chr6:167504864	NA	-0.35	-6.23	-0.32	1.37e-9	Primary biliary cholangitis;
LUSC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg11366901	chr6:160182831	ACAT2	0.81	11.23	0.52	4.73e-25	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg03146154	chr1:46216737	IPP	-0.56	-8.41	-0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9653442	0.900	rs1160544	chr2:100832218	A/C	cg22139774	chr2:100720529	AFF3	-0.47	-8.21	-0.41	4.89e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7621025	0.500	rs9845460	chr3:136587117	A/G	cg15507776	chr3:136538369	TMEM22	0.58	7.97	0.4	2.5e-14	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUSC	trans	rs7307780	0.703	rs7965922	chr12:76230735	C/T	cg05238905	chr6:149867353	PPIL4	0.63	5.97	0.31	6.14e-9	Sudden cardiac arrest;
LUSC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06634786	chr22:41940651	POLR3H	-0.5	-6.24	-0.32	1.29e-9	Vitiligo;
LUSC	cis	rs4631830	0.863	rs4554834	chr10:51530146	A/C	cg10326726	chr10:51549505	MSMB	-0.37	-6.32	-0.33	8.4e-10	Prostate-specific antigen levels;
LUSC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21862992	chr11:68658383	NA	0.51	8.11	0.41	9.88e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.42	-6.75	-0.35	6.54e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg06028605	chr16:24865363	SLC5A11	-0.4	-6.54	-0.34	2.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs733592	1.000	rs1859440	chr12:48427329	T/C	cg24011408	chr12:48396354	COL2A1	-0.46	-7.65	-0.39	2.1e-13	Plateletcrit;
LUSC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.83	0.35	3.91e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg00852783	chr1:26633632	UBXN11	0.6	9.58	0.46	2.23e-19	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9473147	0.516	rs9395286	chr6:47575332	T/C	cg12968598	chr6:47444699	CD2AP	0.53	8.08	0.4	1.24e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs11676348	0.808	rs4674267	chr2:219046437	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.39	-5.99	-0.31	5.37e-9	Ulcerative colitis;
LUSC	cis	rs72781680	1.000	rs72781663	chr2:24221694	C/G	cg20701182	chr2:24300061	SF3B14	0.59	6.26	0.32	1.18e-9	Lymphocyte counts;
LUSC	trans	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.86	0.47	2.69e-20	Mean corpuscular volume;
LUSC	cis	rs4919687	0.550	rs7904252	chr10:104456725	A/C	cg05855489	chr10:104503620	C10orf26	-0.66	-10.69	-0.5	3.91e-23	Colorectal cancer;
LUSC	cis	rs1577917	0.793	rs9362245	chr6:86496320	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-6.46	-0.33	3.63e-10	Response to antipsychotic treatment;
LUSC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24739457	chr1:205821442	NA	0.4	7.2	0.37	4.06e-12	Menarche (age at onset);
LUSC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg09323728	chr8:95962352	TP53INP1	-0.4	-7.93	-0.4	3.44e-14	Type 2 diabetes;
LUSC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.05	0.31	3.95e-9	Menopause (age at onset);
LUSC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.34	-0.49	6.17e-22	Gut microbiome composition (summer);
LUSC	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg13072238	chr3:49761600	GMPPB	0.64	8.2	0.41	5.24e-15	Menarche (age at onset);
LUSC	cis	rs17092148	1.000	rs2425004	chr20:33405956	G/T	cg16810054	chr20:33298113	TP53INP2	0.43	6.81	0.35	4.68e-11	Neuroticism;
LUSC	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg00012203	chr2:219082015	ARPC2	-0.57	-8.96	-0.44	2.39e-17	Ulcerative colitis;
LUSC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.22	-0.37	3.5e-12	Subjective well-being;
LUSC	cis	rs7202877	0.610	rs7202284	chr16:75374346	A/T	cg04384234	chr16:75411784	CFDP1	-0.61	-8.24	-0.41	4.07e-15	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg24006582	chr15:45444508	DUOX1	0.67	9.66	0.47	1.21e-19	Uric acid levels;
LUSC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.55	-0.34	2.15e-10	Breast cancer;
LUSC	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg21643547	chr1:205240462	TMCC2	-0.5	-9.28	-0.45	2.16e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7493	0.901	rs11767787	chr7:95026753	T/C	cg17330251	chr7:94953956	PON1	-0.35	-5.84	-0.3	1.22e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs12410462	0.581	rs6675521	chr1:227544702	C/T	cg23173402	chr1:227635558	NA	0.55	6.39	0.33	5.42e-10	Major depressive disorder;
LUSC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg07952391	chr2:88470173	THNSL2	-0.75	-6.49	-0.33	3.06e-10	Plasma clusterin levels;
LUSC	cis	rs8114671	0.967	rs4911476	chr20:33780768	A/C	cg07148914	chr20:33460835	GGT7	-0.43	-6.42	-0.33	4.55e-10	Height;
LUSC	trans	rs2794256	0.503	rs706858	chr6:120038177	C/T	cg07064544	chr20:43029994	HNF4A	0.32	6.09	0.32	3.15e-9	Spontaneous preterm birth (preterm birth);
LUSC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg22907277	chr7:1156413	C7orf50	0.4	6.27	0.32	1.12e-9	Longevity;Endometriosis;
LUSC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg26373071	chr5:1325741	CLPTM1L	0.43	8.09	0.4	1.14e-14	Lung cancer;
LUSC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.06e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.05	12.98	0.58	1.8e-31	Sexual dysfunction (female);
LUSC	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg25482853	chr8:67687455	SGK3	1.03	15.45	0.65	5.41e-41	Obesity-related traits;
LUSC	cis	rs4961252	0.505	rs4961327	chr8:142102053	C/T	cg13924514	chr8:142070760	NA	-0.34	-5.7	-0.3	2.59e-8	Isovolumetric relaxation time;Response to interferon beta therapy;
LUSC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.66	8.97	0.44	2.17e-17	Multiple sclerosis;
LUSC	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.88	14.29	0.62	1.69e-36	Coronary artery disease;
LUSC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg11343870	chr11:67888858	CHKA	0.43	6.04	0.31	4.12e-9	Mosquito bite size;
LUSC	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg08355456	chr11:67383691	NA	-0.37	-6.55	-0.34	2.19e-10	Mean corpuscular volume;
LUSC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.8	15.45	0.65	5.33e-41	Dental caries;
LUSC	cis	rs13089785	0.965	rs67028142	chr3:123635213	A/G	cg19611163	chr3:123411211	MYLK	0.34	5.72	0.3	2.4e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17507749	chr15:85114479	UBE2QP1	0.56	7.19	0.37	4.31e-12	Schizophrenia;
LUSC	cis	rs1549118	0.560	rs11848126	chr14:78318268	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.44	-5.79	-0.3	1.62e-8	Resting heart rate;
LUSC	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.66	0.34	1.1e-10	Retinal vascular caliber;
LUSC	cis	rs4764124	0.646	rs10846062	chr12:14965781	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.37	5.74	0.3	2.11e-8	Pubertal anthropometrics;
LUSC	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg05925327	chr15:68127851	NA	0.38	6.16	0.32	2.05e-9	Restless legs syndrome;
LUSC	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14442939	chr10:27389572	ANKRD26	0.85	9.51	0.46	3.89e-19	Breast cancer;
LUSC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg23649088	chr2:200775458	C2orf69	0.59	7.24	0.37	3.17e-12	Schizophrenia;
LUSC	cis	rs4343996	0.727	rs7797018	chr7:3386840	G/T	cg21248987	chr7:3385318	SDK1	-0.37	-6.23	-0.32	1.37e-9	Motion sickness;
LUSC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9323205	0.765	rs12232228	chr14:51658072	A/G	cg23942311	chr14:51606299	NA	0.3	6.27	0.32	1.14e-9	Cancer;
LUSC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-11.7	-0.54	1.01e-26	Chronic sinus infection;
LUSC	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg09904177	chr6:26538194	HMGN4	0.75	14.22	0.61	3.36e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg05084668	chr3:125655381	ALG1L	-0.49	-7.01	-0.36	1.33e-11	Blood pressure (smoking interaction);
LUSC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg20744362	chr22:50050164	C22orf34	0.41	8.48	0.42	7.37e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs427941	0.667	rs201436	chr7:101733576	T/C	cg06246474	chr7:101738831	CUX1	0.41	6.7	0.34	8.72e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg21211680	chr2:198530	NA	0.72	7.52	0.38	5.09e-13	Blood protein levels;
LUSC	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg17173187	chr15:85201210	NMB	0.48	8.78	0.43	8.71e-17	Schizophrenia;
LUSC	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg08645402	chr16:4508243	NA	0.51	8.11	0.41	9.7e-15	Schizophrenia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22605943	chr3:107243790	BBX	-0.45	-6.2	-0.32	1.69e-9	Hepatitis;
LUSC	cis	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg06521331	chr12:34319734	NA	-0.48	-7.77	-0.39	9.54e-14	Morning vs. evening chronotype;
LUSC	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg05985134	chr18:33552581	C18orf21	0.51	7.02	0.36	1.27e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg03676636	chr4:99064102	C4orf37	-0.35	-7.63	-0.39	2.5e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	0.93	18.29	0.71	2.88e-52	Cognitive function;
LUSC	cis	rs4356932	1.000	rs7670789	chr4:76940381	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.47e-8	Blood protein levels;
LUSC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg07741184	chr6:167504864	NA	0.4	7.07	0.36	9.16e-12	Crohn's disease;
LUSC	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg06937882	chr20:24974362	C20orf3	0.42	7.0	0.36	1.43e-11	Blood protein levels;
LUSC	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg04287289	chr16:89883240	FANCA	-0.51	-7.82	-0.39	6.78e-14	Vitiligo;
LUSC	cis	rs6977940	0.818	rs73033466	chr7:2902617	G/C	cg19731401	chr7:2775893	GNA12	0.68	7.79	0.39	8.66e-14	White matter integrity;
LUSC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.75	-12.49	-0.56	1.25e-29	Body mass index;
LUSC	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.44	-6.04	-0.31	4.09e-9	Neutrophil percentage of white cells;
LUSC	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.95	17.44	0.69	6.76e-49	Bone mineral density;
LUSC	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg13010199	chr12:38710504	ALG10B	0.69	10.77	0.51	2.01e-23	Morning vs. evening chronotype;
LUSC	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg19812747	chr11:111475976	SIK2	0.53	7.53	0.38	4.86e-13	Primary sclerosing cholangitis;
LUSC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg13685833	chr1:53393034	SCP2	-0.37	-5.67	-0.3	3.08e-8	Monocyte count;
LUSC	cis	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg17469321	chr7:55412551	NA	0.68	10.92	0.51	5.92e-24	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9399401	0.710	rs12197866	chr6:142706063	C/T	cg03128060	chr6:142623767	GPR126	0.61	9.98	0.48	1.1e-20	Chronic obstructive pulmonary disease;
LUSC	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg26384229	chr12:38710491	ALG10B	0.67	10.61	0.5	7.65e-23	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg20821713	chr7:1055600	C7orf50	-0.38	-6.11	-0.32	2.8e-9	Longevity;Endometriosis;
LUSC	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.52	11.17	0.52	8.18e-25	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg10621924	chr7:39171070	POU6F2	0.43	6.54	0.34	2.3e-10	IgG glycosylation;
LUSC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg14004847	chr7:1930337	MAD1L1	-0.57	-8.79	-0.43	8e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg05855489	chr10:104503620	C10orf26	-0.76	-12.93	-0.58	2.72e-31	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg04518342	chr5:131593106	PDLIM4	0.33	5.74	0.3	2.12e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs61935443	0.720	rs10859783	chr12:95285339	A/G	cg21533806	chr12:95267307	NA	0.5	6.24	0.32	1.29e-9	Schizophrenia;
LUSC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg21770322	chr7:97807741	LMTK2	0.41	7.28	0.37	2.36e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.6	-0.43	3.16e-16	Total cholesterol levels;
LUSC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.84	-0.35	3.9e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01881255	chr19:40950703	SERTAD3	-0.43	-6.42	-0.33	4.81e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg20734569	chr3:48348370	SPINK8	-0.47	-8.24	-0.41	3.9e-15	Coronary artery disease;
LUSC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg20608306	chr11:116969690	SIK3	0.38	6.27	0.32	1.12e-9	Blood protein levels;
LUSC	cis	rs8017423	0.935	rs11628906	chr14:90738002	C/T	cg04374321	chr14:90722782	PSMC1	-0.68	-10.45	-0.5	2.67e-22	Mortality in heart failure;
LUSC	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01256987	chr12:42539512	GXYLT1	-0.59	-12.38	-0.56	3.09e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg24578937	chr1:2090814	PRKCZ	-0.44	-9.79	-0.47	4.79e-20	Height;
LUSC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08736216	chr1:53307985	ZYG11A	0.3	6.16	0.32	2.04e-9	Monocyte count;
LUSC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.85	-0.35	3.67e-11	Schizophrenia;
LUSC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg13319975	chr6:146136371	FBXO30	0.49	7.34	0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs34421088	0.506	rs7813424	chr8:11144517	G/A	cg15556689	chr8:8085844	FLJ10661	0.46	6.7	0.34	8.78e-11	Neuroticism;
LUSC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.73	12.7	0.57	2e-30	Colorectal cancer;
LUSC	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.68	11.63	0.54	1.84e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9549260	0.753	rs9532563	chr13:41160270	T/C	cg21288729	chr13:41239152	FOXO1	0.51	6.09	0.32	3.17e-9	Red blood cell count;
LUSC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18595196	chr3:52726726	GNL3;SNORD69	0.29	5.71	0.3	2.5e-8	Bipolar disorder;
LUSC	cis	rs7493	0.851	rs11770903	chr7:95026327	A/G	cg17330251	chr7:94953956	PON1	-0.35	-5.73	-0.3	2.22e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.42	5.78	0.3	1.72e-8	Menopause (age at onset);
LUSC	cis	rs4746818	1.000	rs10733850	chr10:70959617	C/T	cg11621586	chr10:70884670	VPS26A	1.14	11.13	0.52	1.13e-24	Left atrial antero-posterior diameter;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg24747780	chr7:75072203	POM121C	0.39	6.09	0.32	3.1e-9	Asthma;
LUSC	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg27471124	chr11:109292789	C11orf87	0.55	9.78	0.47	4.89e-20	Schizophrenia;
LUSC	cis	rs965469	0.846	rs7271575	chr20:3333877	C/T	cg25506879	chr20:3388711	C20orf194	-0.51	-5.65	-0.3	3.4e-8	IFN-related cytopenia;
LUSC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg20135002	chr11:47629003	NA	-0.51	-8.11	-0.41	9.83e-15	Subjective well-being;
LUSC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-14.85	-0.63	1.22e-38	Total body bone mineral density;
LUSC	cis	rs6580649	0.941	rs17122612	chr12:48459488	C/G	cg24011408	chr12:48396354	COL2A1	-0.46	-6.17	-0.32	2.03e-9	Lung cancer;
LUSC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.79	0.35	5.03e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs11997175	0.603	rs4739381	chr8:33806892	C/A	ch.8.33884649F	chr8:33765107	NA	0.42	6.36	0.33	6.55e-10	Body mass index;
LUSC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg13319975	chr6:146136371	FBXO30	-0.54	-8.2	-0.41	5.37e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7180079	1.000	rs11633312	chr15:64594611	T/C	cg02848875	chr15:64387786	SNX1	0.4	5.67	0.3	3.17e-8	Monocyte count;
LUSC	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg07930552	chr6:133119739	C6orf192	0.95	8.49	0.42	7.03e-16	Type 2 diabetes nephropathy;
LUSC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg22535103	chr8:58192502	C8orf71	-0.65	-7.36	-0.37	1.44e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.25	-0.37	3e-12	Obesity-related traits;
LUSC	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg12292205	chr6:26970375	C6orf41	-0.39	-5.79	-0.3	1.61e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs868036	1.000	rs1871307	chr15:68100623	C/T	cg08079166	chr15:68083412	MAP2K5	0.4	8.28	0.41	3.04e-15	Restless legs syndrome;
LUSC	cis	rs10193935	0.901	rs871045	chr2:42609431	G/C	cg27598129	chr2:42591480	NA	-0.64	-8.59	-0.43	3.26e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-6.78	-0.35	5.32e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6542838	0.611	rs1878589	chr2:99517979	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-7.12	-0.36	6.46e-12	Fear of minor pain;
LUSC	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg16342193	chr10:102329863	NA	-0.35	-6.51	-0.34	2.83e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	9.05	0.44	1.25e-17	Total body bone mineral density;
LUSC	trans	rs11696501	0.739	rs6073815	chr20:44234615	A/T	cg03272292	chr12:48577362	C12orf68	0.51	5.99	0.31	5.36e-9	Brain structure;
LUSC	trans	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	12.16	0.55	2e-28	Exhaled nitric oxide output;
LUSC	cis	rs6484504	0.553	rs413067	chr11:31223497	T/C	cg26647111	chr11:31128758	NA	-0.42	-6.03	-0.31	4.44e-9	Red blood cell count;
LUSC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.18	0.37	4.43e-12	Platelet count;
LUSC	cis	rs10492096	0.947	rs61918020	chr12:6605514	C/T	cg13857086	chr12:6580257	VAMP1	0.61	7.25	0.37	2.89e-12	Hip geometry;
LUSC	cis	rs9341835	0.518	rs6939983	chr6:64173216	C/T	cg03326410	chr6:64151739	NA	-0.37	-6.01	-0.31	4.85e-9	Schizophrenia;
LUSC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg26380479	chr7:97908229	NA	-0.28	-6.23	-0.32	1.4e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg16482183	chr6:26056742	HIST1H1C	0.56	8.43	0.42	1.01e-15	Height;
LUSC	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg01966878	chr4:90757139	SNCA	-0.35	-6.12	-0.32	2.56e-9	Dementia with Lewy bodies;
LUSC	cis	rs45535039	1.000	rs45535039	chr11:119060963	T/C	cg16724696	chr11:118992527	HINFP	0.49	6.03	0.31	4.38e-9	Plateletcrit;
LUSC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.05	0.44	1.21e-17	Motion sickness;
LUSC	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg23649088	chr2:200775458	C2orf69	-0.52	-7.04	-0.36	1.13e-11	Schizophrenia;
LUSC	cis	rs1969253	0.632	rs865808	chr3:183858939	G/T	cg21665078	chr3:183852786	EIF2B5	-0.42	-7.04	-0.36	1.13e-11	Major depressive disorder;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg14016680	chr3:197687242	LMLN;IQCG	0.46	6.09	0.32	3.17e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs11690935	0.632	rs11690807	chr2:172628120	G/A	cg13550731	chr2:172543902	DYNC1I2	0.6	9.37	0.46	1.08e-18	Schizophrenia;
LUSC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	29.3	0.85	2.51e-94	Chronic sinus infection;
LUSC	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg24642439	chr20:33292090	TP53INP2	0.62	9.57	0.46	2.42e-19	Coronary artery disease;
LUSC	cis	rs7715806	0.500	rs72633983	chr5:75002845	C/T	cg19683494	chr5:74908142	NA	0.58	7.79	0.39	8.27e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg08200582	chr11:442649	ANO9	-0.52	-6.1	-0.32	3.02e-9	Body mass index;
LUSC	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg08668359	chr10:1443807	ADARB2	0.41	6.33	0.33	7.92e-10	Radiation response;
LUSC	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg05347473	chr6:146136440	FBXO30	0.38	6.17	0.32	2.01e-9	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg01620082	chr3:125678407	NA	-0.86	-7.42	-0.38	9.7e-13	Depression;
LUSC	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg14458575	chr2:238380390	NA	0.68	11.41	0.53	1.06e-25	Prostate cancer;
LUSC	trans	rs9929218	0.817	rs3114404	chr16:68722096	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-13.45	-0.59	2.87e-33	Colorectal cancer;
LUSC	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg20701182	chr2:24300061	SF3B14	-0.45	-5.72	-0.3	2.42e-8	Asthma;
LUSC	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg13615516	chr5:77269221	NA	0.38	6.43	0.33	4.39e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6840360	1.000	rs2840130	chr4:152600699	T/C	cg22705602	chr4:152727874	NA	-0.27	-5.64	-0.3	3.55e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg21951975	chr1:209979733	IRF6	0.41	6.82	0.35	4.31e-11	Monobrow;
LUSC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg08200582	chr11:442649	ANO9	-0.53	-6.13	-0.32	2.49e-9	Body mass index;
LUSC	cis	rs7953508	0.506	rs1316740	chr12:93968288	C/A	cg18151635	chr12:93972918	NA	-0.62	-8.89	-0.44	3.85e-17	Pubertal anthropometrics;
LUSC	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg06784218	chr1:46089804	CCDC17	0.31	5.72	0.3	2.38e-8	Platelet count;
LUSC	cis	rs8099014	0.954	rs4245271	chr18:56114063	A/G	cg12907477	chr18:56117327	MIR122	0.44	7.14	0.36	5.8e-12	Platelet count;
LUSC	cis	rs1448094	0.617	rs4842569	chr12:86468609	T/G	cg00310523	chr12:86230176	RASSF9	-0.34	-6.22	-0.32	1.5e-9	Major depressive disorder;
LUSC	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.41	6.14	0.32	2.3e-9	Response to bleomycin (chromatid breaks);
LUSC	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.04	-0.31	4.06e-9	Height;
LUSC	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg00277334	chr10:82204260	NA	-0.5	-7.95	-0.4	2.82e-14	Sarcoidosis;
LUSC	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg25664220	chr3:72788482	NA	-0.72	-11.55	-0.53	3.46e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7615952	0.605	rs34865555	chr3:125304134	C/T	cg05084668	chr3:125655381	ALG1L	-0.56	-6.53	-0.34	2.44e-10	Blood pressure (smoking interaction);
LUSC	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	cis	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg27411982	chr8:10470053	RP1L1	0.46	7.18	0.37	4.46e-12	Neuroticism;
LUSC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg11062466	chr8:58055876	NA	0.75	9.1	0.45	8.12e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.4	0.33	5.28e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7119	0.651	rs8041520	chr15:77839169	C/T	cg27398640	chr15:77910606	LINGO1	-0.32	-6.5	-0.34	2.87e-10	Type 2 diabetes;
LUSC	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs3857536	0.785	rs2157964	chr6:66938419	A/G	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.71	-12.4	-0.56	2.68e-29	White blood cell count (basophil);
LUSC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg11764359	chr7:65958608	NA	0.55	7.28	0.37	2.49e-12	Aortic root size;
LUSC	cis	rs35079168	0.661	rs3118529	chr9:137304915	C/T	cg14344989	chr9:137329237	RXRA	-0.4	-6.5	-0.34	2.86e-10	Intelligence;
LUSC	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.44e-17	Iron status biomarkers;
LUSC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.5	0.42	6.45e-16	Hemoglobin concentration;
LUSC	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg25554036	chr4:6271136	WFS1	-0.54	-10.23	-0.49	1.56e-21	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6681460	1.000	rs9662943	chr1:67121132	A/G	cg02459107	chr1:67143332	SGIP1	-0.48	-8.96	-0.44	2.33e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg19812747	chr11:111475976	SIK2	-0.45	-6.23	-0.32	1.38e-9	Primary sclerosing cholangitis;
LUSC	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg23985595	chr17:80112537	CCDC57	-0.31	-5.9	-0.31	9.1e-9	Life satisfaction;
LUSC	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	9.2	0.45	3.96e-18	Bipolar disorder;
LUSC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-9.5	-0.46	4.36e-19	Chronic sinus infection;
LUSC	cis	rs9462027	0.628	rs9462010	chr6:34716605	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.9	-0.31	9.02e-9	Systemic lupus erythematosus;
LUSC	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-21.2	-0.76	8.74e-64	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.46	7.13	0.36	6.38e-12	Response to antipsychotic treatment;
LUSC	cis	rs8060686	0.668	rs9932414	chr16:68219969	A/G	cg26727032	chr16:67993705	SLC12A4	-0.41	-6.36	-0.33	6.67e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg13798780	chr7:105162888	PUS7	0.58	6.32	0.33	8.2e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs73416724	1.000	rs17209379	chr6:43265231	A/C	cg26312998	chr6:43337775	ZNF318	0.56	6.32	0.33	8.29e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-22.15	-0.77	1.53e-67	Prudent dietary pattern;
LUSC	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg05855489	chr10:104503620	C10orf26	0.5	7.7	0.39	1.59e-13	Arsenic metabolism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06386278	chr11:86013177	C11orf73	-0.42	-6.04	-0.31	4.06e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.2	-0.32	1.7e-9	Resting heart rate;
LUSC	trans	rs877282	0.583	rs11595057	chr10:819203	A/C	cg22713356	chr15:30763199	NA	0.7	9.5	0.46	4.07e-19	Uric acid levels;
LUSC	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.32	-5.93	-0.31	7.69e-9	IgG glycosylation;
LUSC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08859206	chr1:53392774	SCP2	0.51	8.74	0.43	1.14e-16	Monocyte count;
LUSC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00166722	chr3:10149974	C3orf24	-0.61	-7.93	-0.4	3.25e-14	Alzheimer's disease;
LUSC	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg12826209	chr6:26865740	GUSBL1	0.79	7.84	0.39	6.12e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg17633681	chr16:88106987	BANP	0.53	10.15	0.49	2.88e-21	Menopause (age at onset);
LUSC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg00310523	chr12:86230176	RASSF9	0.52	9.8	0.47	4.35e-20	Major depressive disorder;
LUSC	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.28	-5.88	-0.31	9.81e-9	Lung cancer;
LUSC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.7	13.48	0.59	2.38e-33	Gestational age at birth (maternal effect);
LUSC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg07424592	chr7:64974309	NA	-0.63	-5.65	-0.3	3.53e-8	Diabetic kidney disease;
LUSC	cis	rs11716531	0.574	rs13075192	chr3:27279235	C/T	cg02860705	chr3:27208620	NA	0.62	10.21	0.49	1.72e-21	Diastolic blood pressure;
LUSC	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.32	-0.41	2.32e-15	Response to antipsychotic treatment;
LUSC	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.38	-0.42	1.49e-15	Response to antipsychotic treatment;
LUSC	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg20573242	chr4:122745356	CCNA2	-0.45	-6.49	-0.33	3.16e-10	Type 2 diabetes;
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg21951975	chr1:209979733	IRF6	0.77	16.58	0.67	1.8e-45	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.64	-10.82	-0.51	1.34e-23	Longevity;Endometriosis;
LUSC	cis	rs6496044	0.568	rs6496066	chr15:86075462	A/C	cg13263323	chr15:86062960	AKAP13	-0.37	-6.16	-0.32	2.06e-9	Interstitial lung disease;
LUSC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.68	-9.51	-0.46	4.05e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17282769	chr12:11802362	ETV6	-0.48	-5.96	-0.31	6.45e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg09365446	chr1:150670422	GOLPH3L	-0.42	-6.31	-0.33	8.88e-10	Lymphocyte counts;
LUSC	cis	rs2970818	0.831	rs10849086	chr12:4645400	G/A	cg11146114	chr12:4671731	NA	-0.57	-5.77	-0.3	1.82e-8	Phosphorus levels;
LUSC	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	1.13	17.52	0.69	3.45e-49	Blood pressure (smoking interaction);
LUSC	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.22	-0.32	1.45e-9	Response to antipsychotic treatment;
LUSC	cis	rs61931739	0.635	rs10772122	chr12:33964674	A/C	cg06521331	chr12:34319734	NA	-0.41	-6.88	-0.35	2.92e-11	Morning vs. evening chronotype;
LUSC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.71	6.68	0.34	9.92e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg01294253	chr9:136912663	BRD3	0.34	5.76	0.3	1.9e-8	Platelet distribution width;
LUSC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-0.78	-13.45	-0.59	2.9e-33	Cognitive function;
LUSC	cis	rs3126085	0.867	rs12027899	chr1:152253954	C/A	cg26876637	chr1:152193138	HRNR	0.45	6.08	0.32	3.31e-9	Atopic dermatitis;
LUSC	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg18721089	chr20:30220636	NA	-0.39	-6.12	-0.32	2.66e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs8028182	0.583	rs9944207	chr15:75912889	A/T	cg20655648	chr15:75932815	IMP3	0.44	5.94	0.31	7.34e-9	Sudden cardiac arrest;
LUSC	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg02275930	chr1:2372054	NA	-0.52	-7.81	-0.39	7.37e-14	Non-obstructive azoospermia;
LUSC	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg25809561	chr17:30822961	MYO1D	0.55	9.51	0.46	3.89e-19	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.69	12.61	0.57	4.56e-30	Prudent dietary pattern;
LUSC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg17264618	chr3:40429014	ENTPD3	0.3	6.27	0.32	1.11e-9	Renal cell carcinoma;
LUSC	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg01733217	chr16:74700730	RFWD3	0.75	12.24	0.56	1.05e-28	Testicular germ cell tumor;
LUSC	cis	rs975210	0.556	rs2291986	chr15:70368432	C/T	cg01666796	chr15:70364327	TLE3	0.43	5.96	0.31	6.49e-9	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LUSC	trans	rs7178375	1.000	rs12907055	chr15:31204294	C/G	cg04373760	chr16:53404718	NA	0.65	8.79	0.43	7.82e-17	Hypertriglyceridemia;
LUSC	cis	rs10193935	0.901	rs6544533	chr2:42516372	G/C	cg27598129	chr2:42591480	NA	-0.57	-7.83	-0.39	6.33e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg17971929	chr21:40555470	PSMG1	-0.6	-10.0	-0.48	8.96e-21	Cognitive function;
LUSC	cis	rs12760731	0.565	rs77024410	chr1:178164121	A/C	cg00404053	chr1:178313656	RASAL2	0.66	6.82	0.35	4.26e-11	Obesity-related traits;
LUSC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg03388025	chr16:89894329	SPIRE2	0.34	6.84	0.35	3.81e-11	Vitiligo;
LUSC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10802521	chr3:52805072	NEK4	-0.57	-9.17	-0.45	5.16e-18	Bipolar disorder;
LUSC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.45	6.68	0.34	9.88e-11	Systemic lupus erythematosus;
LUSC	cis	rs7408868	1.000	rs7247835	chr19:15262844	A/G	cg14696996	chr19:15285081	NOTCH3	0.98	9.06	0.44	1.11e-17	Pulse pressure;
LUSC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.49	6.17	0.32	1.95e-9	Mean platelet volume;
LUSC	cis	rs9837602	1.000	rs2291494	chr3:99781805	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.16	0.32	2.03e-9	Breast cancer;
LUSC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs7608623	0.773	rs1862900	chr2:23922315	C/A	cg08917208	chr2:24149416	ATAD2B	-0.42	-5.74	-0.3	2.12e-8	Obesity-related traits;
LUSC	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg23601095	chr6:26197514	HIST1H3D	0.71	7.35	0.37	1.57e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg14416269	chr4:6271139	WFS1	0.45	8.5	0.42	6.38e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg09033563	chr22:24373618	LOC391322	-0.49	-6.81	-0.35	4.54e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.08	15.86	0.66	1.23e-42	Uric acid levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03352409	chr22:21336370	LZTR1	0.49	6.76	0.35	6.16e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.47	6.63	0.34	1.37e-10	Lung function (FEV1/FVC);
LUSC	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg11789530	chr4:8429930	ACOX3	-0.41	-6.11	-0.32	2.78e-9	Response to antineoplastic agents;
LUSC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.53	-9.26	-0.45	2.52e-18	Menopause (age at onset);
LUSC	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.84	0.3	1.25e-8	Breast cancer;
LUSC	trans	rs4596713	0.508	rs4076287	chr9:71755333	A/G	cg25283916	chr1:242222868	NA	-0.32	-6.6	-0.34	1.64e-10	Headache;
LUSC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg18827107	chr12:86230957	RASSF9	-0.46	-6.96	-0.36	1.81e-11	Major depressive disorder;
LUSC	cis	rs7804356	1.000	rs73067456	chr7:26852998	G/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg01557791	chr16:72042693	DHODH	-0.46	-6.83	-0.35	4e-11	Fibrinogen levels;
LUSC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.26	0.45	2.6e-18	Prudent dietary pattern;
LUSC	cis	rs13082711	0.911	rs7650165	chr3:27462440	C/T	cg02860705	chr3:27208620	NA	0.5	8.51	0.42	6.09e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs28735056	0.660	rs12454454	chr18:77674634	C/T	cg20368463	chr18:77673604	PQLC1	-0.74	-11.65	-0.54	1.44e-26	Schizophrenia;
LUSC	cis	rs2235649	0.592	rs8051883	chr16:1958978	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.47	-5.69	-0.3	2.76e-8	Blood metabolite levels;
LUSC	cis	rs2692947	0.770	rs72823920	chr2:96430876	G/A	cg22654517	chr2:96458247	NA	0.37	7.01	0.36	1.36e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg22903471	chr2:27725779	GCKR	-0.4	-6.84	-0.35	3.67e-11	Total body bone mineral density;
LUSC	cis	rs6681460	0.966	rs10789214	chr1:67146817	C/T	cg02459107	chr1:67143332	SGIP1	0.48	8.9	0.44	3.53e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.72	-13.39	-0.59	5.04e-33	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg08470875	chr2:26401718	FAM59B	-0.69	-9.37	-0.46	1.16e-18	Gut microbiome composition (summer);
LUSC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	1.03	19.24	0.72	4.93e-56	Menopause (age at onset);
LUSC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg11344533	chr11:111475393	SIK2	-0.46	-6.35	-0.33	7.08e-10	Primary sclerosing cholangitis;
LUSC	cis	rs4948275	0.550	rs10994742	chr10:63132240	A/T	cg26296364	chr10:63212206	TMEM26	-0.36	-5.82	-0.3	1.35e-8	Night sleep phenotypes;
LUSC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.42	0.33	4.72e-10	Alzheimer's disease (late onset);
LUSC	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg13010199	chr12:38710504	ALG10B	0.58	9.16	0.45	5.51e-18	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.36e-8	Lung cancer;
LUSC	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg20991723	chr1:152506922	NA	0.51	9.77	0.47	5.58e-20	Hair morphology;
LUSC	cis	rs714027	1.000	rs4823074	chr22:30512478	G/A	cg11564601	chr22:30592435	NA	-0.37	-6.78	-0.35	5.4e-11	Lymphocyte counts;
LUSC	cis	rs5758511	0.573	rs2284082	chr22:42240797	C/T	cg03131358	chr22:42195972	CCDC134	-0.32	-5.74	-0.3	2.12e-8	Birth weight;
LUSC	cis	rs77633900	0.772	rs2460161	chr15:76640430	C/T	cg21673338	chr15:77095150	SCAPER	-0.69	-5.97	-0.31	5.98e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.37	5.69	0.3	2.73e-8	Longevity;Endometriosis;
LUSC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-10.29	-0.49	9.32e-22	Menarche (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06366937	chr1:74663927	TNNI3K;FPGT;LRRIQ3	0.65	6.04	0.31	4.21e-9	Cognitive performance;
LUSC	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	8.62	0.43	2.77e-16	Schizophrenia;
LUSC	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg20991723	chr1:152506922	NA	0.53	10.22	0.49	1.57e-21	Hair morphology;
LUSC	cis	rs807669	0.900	rs712964	chr22:19156117	T/C	cg02655711	chr22:19163373	SLC25A1	0.78	14.78	0.63	2.29e-38	Metabolite levels;
LUSC	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg11861562	chr11:117069780	TAGLN	0.32	6.2	0.32	1.64e-9	Blood protein levels;
LUSC	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg04310649	chr10:35416472	CREM	-0.42	-6.46	-0.33	3.77e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg27165867	chr14:105738592	BRF1	-0.5	-7.39	-0.37	1.19e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg02153584	chr22:29168773	CCDC117	0.55	8.29	0.41	2.87e-15	Lymphocyte counts;
LUSC	cis	rs16912285	0.688	rs12284649	chr11:24316260	T/A	ch.11.24196551F	chr11:24239977	NA	0.85	8.88	0.44	4.15e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg00310523	chr12:86230176	RASSF9	0.45	8.28	0.41	2.97e-15	Major depressive disorder;
LUSC	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg23711669	chr6:146136114	FBXO30	0.86	15.54	0.65	2.4e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg14500267	chr11:67383377	NA	0.34	6.51	0.34	2.75e-10	Mean corpuscular volume;
LUSC	cis	rs12681287	0.547	rs10087788	chr8:87544174	G/A	cg27223183	chr8:87520930	FAM82B	0.53	6.99	0.36	1.54e-11	Caudate activity during reward;
LUSC	cis	rs11264799	0.765	rs12128597	chr1:157623603	C/T	cg18268488	chr1:157545234	FCRL4	0.33	5.74	0.3	2.13e-8	IgA nephropathy;
LUSC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.68	10.68	0.5	4.27e-23	Aortic root size;
LUSC	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg09092052	chr15:45571596	NA	-0.48	-6.67	-0.34	1.04e-10	Glomerular filtration rate;
LUSC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.67	8.9	0.44	3.56e-17	Multiple sclerosis;
LUSC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.86	-0.4	5.32e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.51	-10.37	-0.49	5.03e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg09904177	chr6:26538194	HMGN4	-0.68	-11.36	-0.53	1.62e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg05985134	chr18:33552581	C18orf21	0.52	7.25	0.37	2.99e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs12760731	0.565	rs12034657	chr1:178099354	A/C	cg00404053	chr1:178313656	RASAL2	-0.63	-6.54	-0.34	2.28e-10	Obesity-related traits;
LUSC	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg25554036	chr4:6271136	WFS1	0.46	7.0	0.36	1.42e-11	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7617773	0.779	rs1045482	chr3:48312229	A/G	cg20734569	chr3:48348370	SPINK8	-0.44	-7.69	-0.39	1.68e-13	Coronary artery disease;
LUSC	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg04850211	chr1:228464232	OBSCN	-0.32	-5.7	-0.3	2.67e-8	Diastolic blood pressure;
LUSC	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg01528321	chr10:82214614	TSPAN14	0.62	9.3	0.45	1.9e-18	Post bronchodilator FEV1;
LUSC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg10523860	chr14:103875565	MARK3	-0.36	-6.18	-0.32	1.89e-9	Body mass index;
LUSC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.61	-8.13	-0.41	8.28e-15	High light scatter reticulocyte count;
LUSC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	12.95	0.58	2.37e-31	Alzheimer's disease;
LUSC	cis	rs9815354	1.000	rs2128835	chr3:41862873	A/G	cg03022575	chr3:42003672	ULK4	0.58	6.54	0.34	2.3e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs16937	0.711	rs6682400	chr1:205173519	T/G	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.36e-10	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg16339924	chr4:17578868	LAP3	-0.57	-8.44	-0.42	9.44e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17059575	chr17:33307583	LIG3	-0.46	-6.9	-0.35	2.62e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7851660	0.844	rs12342417	chr9:100639065	G/A	cg13688889	chr9:100608707	NA	-0.54	-8.44	-0.42	9.99e-16	Strep throat;
LUSC	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg08917208	chr2:24149416	ATAD2B	0.84	9.31	0.45	1.77e-18	Lymphocyte counts;
LUSC	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg02660097	chr11:68866761	NA	0.43	6.14	0.32	2.36e-9	Blond vs. brown hair color;
LUSC	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg11062466	chr8:58055876	NA	0.51	6.7	0.34	8.73e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	31.79	0.87	5.08e-103	Chronic sinus infection;
LUSC	cis	rs75920871	0.588	rs1871756	chr11:116953645	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.54	-6.9	-0.35	2.65e-11	Subjective well-being;
LUSC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg13395646	chr4:1353034	KIAA1530	-0.59	-9.26	-0.45	2.58e-18	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.48	0.53	6.2e-26	Prudent dietary pattern;
LUSC	cis	rs9362426	0.708	rs9342112	chr6:88092491	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	6.03	0.31	4.36e-9	Depressive episodes in bipolar disorder;
LUSC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg27494647	chr7:150038898	RARRES2	0.48	7.29	0.37	2.23e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg01028140	chr2:1542097	TPO	-0.52	-8.45	-0.42	9.07e-16	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs8056893	0.569	rs9937244	chr16:68307559	T/A	cg02226672	chr16:68398533	SMPD3	0.29	5.66	0.3	3.27e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg02153584	chr22:29168773	CCDC117	-0.57	-8.58	-0.43	3.58e-16	Lymphocyte counts;
LUSC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg11062466	chr8:58055876	NA	0.65	8.55	0.42	4.36e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg04727924	chr7:799746	HEATR2	-0.55	-6.71	-0.34	8.16e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs12530845	0.887	rs6948382	chr7:135323576	G/A	cg23117316	chr7:135346802	PL-5283	-0.57	-9.2	-0.45	3.85e-18	Red blood cell traits;
LUSC	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg09307838	chr4:120376055	NA	0.5	7.61	0.38	2.91e-13	Educational attainment;
LUSC	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg07169764	chr2:136633963	MCM6	1.18	17.49	0.69	4.22e-49	Corneal structure;
LUSC	cis	rs7119	0.604	rs2271397	chr15:77907775	T/C	cg27398640	chr15:77910606	LINGO1	0.38	8.91	0.44	3.25e-17	Type 2 diabetes;
LUSC	cis	rs9341808	0.539	rs2490253	chr6:80895870	T/C	cg08355045	chr6:80787529	NA	0.47	8.16	0.41	6.82e-15	Sitting height ratio;
LUSC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.93	15.93	0.66	6.79e-43	Bladder cancer;
LUSC	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg10426581	chr7:100472382	SRRT	0.86	12.37	0.56	3.44e-29	Resting heart rate;
LUSC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg00509249	chr6:109615579	CCDC162	-0.33	-5.9	-0.31	9.11e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg20243544	chr17:37824526	PNMT	-0.45	-5.69	-0.3	2.81e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs73206853	0.841	rs7959516	chr12:110622224	A/C	cg12870014	chr12:110450643	ANKRD13A	0.56	5.67	0.3	3.15e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05670192	chr19:56154902	ZNF581	-0.39	-6.34	-0.33	7.6e-10	Electrocardiographic conduction measures;
LUSC	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.69	11.15	0.52	9.34e-25	Body mass index (adult);
LUSC	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg00225070	chr15:80189496	MTHFS	0.42	6.09	0.32	3.07e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.74	-0.35	7.04e-11	Total body bone mineral density;
LUSC	cis	rs77633900	0.892	rs7180257	chr15:76632907	A/G	cg21673338	chr15:77095150	SCAPER	0.63	6.0	0.31	5.07e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2742417	1.000	rs2673039	chr3:45748435	A/G	cg09608765	chr3:45636137	LIMD1	-0.38	-7.48	-0.38	6.41e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.92	-0.35	2.39e-11	Response to antipsychotic treatment;
LUSC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-1.11	-24.8	-0.81	9.96e-78	Height;
LUSC	cis	rs9283706	0.608	rs10053537	chr5:66332543	T/C	cg11590213	chr5:66331682	MAST4	0.45	6.76	0.35	6.28e-11	Coronary artery disease;
LUSC	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg27411982	chr8:10470053	RP1L1	0.44	6.8	0.35	4.82e-11	Morning vs. evening chronotype;
LUSC	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg04906043	chr13:21280425	IL17D	0.4	6.74	0.35	6.85e-11	Dental caries;
LUSC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg04518342	chr5:131593106	PDLIM4	-0.33	-5.95	-0.31	6.83e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg26338869	chr17:61819248	STRADA	0.41	5.81	0.3	1.47e-8	Prudent dietary pattern;
LUSC	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg08085267	chr17:45401833	C17orf57	-0.64	-10.71	-0.51	3.26e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg21827317	chr3:136751795	NA	0.39	6.9	0.35	2.6e-11	Neuroticism;
LUSC	cis	rs2273669	0.667	rs6651000	chr6:109281411	G/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.76	-0.3	1.94e-8	Prostate cancer;
LUSC	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg04310649	chr10:35416472	CREM	-0.42	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg06064525	chr11:970664	AP2A2	-0.37	-7.29	-0.37	2.23e-12	Alzheimer's disease (late onset);
LUSC	cis	rs6714788	0.503	rs2309748	chr2:100681449	A/T	cg07810366	chr2:100720526	AFF3	-0.39	-6.18	-0.32	1.85e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4730250	0.554	rs112665932	chr7:106916121	A/G	cg02696742	chr7:106810147	HBP1	-0.56	-7.44	-0.38	8.44e-13	Osteoarthritis;
LUSC	cis	rs10986311	0.862	rs1408096	chr9:127107143	C/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.39	6.18	0.32	1.91e-9	Vitiligo;
LUSC	cis	rs11030122	0.702	rs10835406	chr11:3992954	G/T	cg18678763	chr11:4115507	RRM1	0.45	5.9	0.31	9.07e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11785693	0.817	rs62491199	chr8:4997878	G/A	cg26367366	chr8:4980734	NA	0.76	8.68	0.43	1.81e-16	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs2979489	0.891	rs4285443	chr8:30327317	A/G	cg26383811	chr8:30366931	RBPMS	-0.49	-7.91	-0.4	3.81e-14	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-11.98	-0.55	9.35e-28	Platelet count;
LUSC	cis	rs7246967	0.611	rs4933024	chr19:22867063	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	trans	rs7313075	0.639	rs34804904	chr12:102586795	A/C	cg03720887	chr8:101963845	YWHAZ	0.62	6.15	0.32	2.27e-9	Height;
LUSC	cis	rs17621444	0.522	rs1029154	chr10:121772614	G/T	cg02041677	chr10:121771263	NA	-0.34	-6.47	-0.33	3.53e-10	IgG glycosylation;
LUSC	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg08508325	chr11:3079039	CARS	0.37	8.28	0.41	2.98e-15	Calcium levels;
LUSC	trans	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.59	-0.34	1.71e-10	Endometrial cancer;
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.88	-15.71	-0.65	4.88e-42	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12891047	1.000	rs2295108	chr14:68250622	T/C	cg20999565	chr14:68265668	ZFYVE26	-0.39	-6.12	-0.32	2.58e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg02972257	chr16:68554789	NA	0.49	6.47	0.33	3.57e-10	Ulcerative colitis;
LUSC	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg07423050	chr13:99094983	FARP1	-0.54	-9.69	-0.47	9.98e-20	Longevity;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00414058	chr16:9185479	C16orf72	0.69	6.02	0.31	4.56e-9	Cognitive performance;
LUSC	cis	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg06521331	chr12:34319734	NA	-0.47	-7.56	-0.38	3.99e-13	Morning vs. evening chronotype;
LUSC	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg09184832	chr6:79620586	NA	-0.42	-6.79	-0.35	5.28e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg04317338	chr11:64019027	PLCB3	0.69	7.93	0.4	3.42e-14	Mean platelet volume;
LUSC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.76	0.35	5.99e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7712401	0.601	rs173480	chr5:122254131	C/A	cg19077854	chr5:122220652	SNX24	0.41	8.94	0.44	2.67e-17	Mean platelet volume;
LUSC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	6.74	0.35	6.91e-11	Menarche (age at onset);
LUSC	cis	rs738322	0.810	rs4820323	chr22:38599767	C/G	cg25457927	chr22:38595422	NA	0.48	10.07	0.48	5.46e-21	Cutaneous nevi;
LUSC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.54	-0.38	4.37e-13	Schizophrenia;
LUSC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2625529	0.668	rs12591338	chr15:72556847	T/A	cg16672083	chr15:72433130	SENP8	-0.49	-7.2	-0.37	4.02e-12	Red blood cell count;
LUSC	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg13010199	chr12:38710504	ALG10B	-0.62	-9.61	-0.47	1.87e-19	Bladder cancer;
LUSC	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg14458575	chr2:238380390	NA	-0.69	-12.19	-0.55	1.6e-28	Prostate cancer;
LUSC	trans	rs2392780	0.536	rs590574	chr8:128335715	A/G	cg10897648	chr18:56338258	MALT1	-0.41	-6.21	-0.32	1.56e-9	Breast cancer (early onset);
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg07138452	chr17:17141020	FLCN	-0.47	-6.03	-0.31	4.24e-9	Height;
LUSC	cis	rs1595825	0.891	rs7585709	chr2:198883682	C/T	cg10547527	chr2:198650123	BOLL	-0.52	-6.3	-0.33	9.56e-10	Ulcerative colitis;
LUSC	cis	rs4363385	0.647	rs4845513	chr1:152998066	T/C	cg00922841	chr1:152955080	SPRR1A	-0.42	-6.95	-0.36	1.92e-11	Inflammatory skin disease;
LUSC	cis	rs920590	0.717	rs62496675	chr8:19635733	A/T	cg03894339	chr8:19674705	INTS10	0.42	5.66	0.3	3.18e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg17911788	chr17:44343683	NA	0.3	5.82	0.3	1.35e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg03647239	chr10:116582469	FAM160B1	0.47	7.59	0.38	3.26e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg17366294	chr4:99064904	C4orf37	0.54	9.49	0.46	4.71e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg16359550	chr11:109292809	C11orf87	-0.47	-7.94	-0.4	3.16e-14	Schizophrenia;
LUSC	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg12863693	chr15:85201151	NMB	0.37	6.88	0.35	2.97e-11	Schizophrenia;
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg00024416	chr22:24240387	NA	-0.32	-5.9	-0.31	9.02e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg17515076	chr17:73810948	UNK	0.35	5.84	0.3	1.22e-8	White matter hyperintensity burden;
LUSC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg21724239	chr8:58056113	NA	0.66	7.4	0.38	1.14e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs62400317	0.826	rs17288327	chr6:45349877	A/G	cg20913747	chr6:44695427	NA	-0.47	-7.68	-0.39	1.82e-13	Total body bone mineral density;
LUSC	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.33	0.33	8.1e-10	Morning vs. evening chronotype;
LUSC	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg01528321	chr10:82214614	TSPAN14	1.03	15.99	0.66	3.98e-43	Post bronchodilator FEV1;
LUSC	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	0.68	6.69	0.34	9.24e-11	Prostate cancer;
LUSC	cis	rs6076065	0.723	rs6137949	chr20:23418217	T/G	cg11657817	chr20:23433608	CST11	0.41	7.28	0.37	2.37e-12	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg01579765	chr21:45077557	HSF2BP	-0.5	-10.53	-0.5	1.38e-22	Mean corpuscular volume;
LUSC	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg21827317	chr3:136751795	NA	0.39	6.95	0.36	1.98e-11	Neuroticism;
LUSC	cis	rs12956009	0.583	rs11662486	chr18:44868325	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.35	0.33	7.19e-10	Educational attainment (years of education);
LUSC	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg16797656	chr11:68205561	LRP5	-0.39	-6.37	-0.33	6.36e-10	Total body bone mineral density;
LUSC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg16339924	chr4:17578868	LAP3	0.61	9.34	0.46	1.38e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.92	0.31	7.84e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs77741769	0.507	rs11065264	chr12:121218380	T/G	cg02419362	chr12:121203948	SPPL3	0.46	8.61	0.43	2.9e-16	Mean corpuscular volume;
LUSC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg10556349	chr10:835070	NA	0.56	6.23	0.32	1.41e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg08684580	chr7:98029266	BAIAP2L1	0.39	5.85	0.3	1.16e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-9.68	-0.47	1.03e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg00405596	chr8:11794950	NA	0.36	5.98	0.31	5.83e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.24	0.45	3.04e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25764190	chr19:44037015	ZNF575	0.39	6.06	0.31	3.64e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs12367572	0.663	rs4561266	chr12:45415763	C/T	cg04608330	chr12:45269318	NELL2	-0.39	-5.87	-0.31	1.06e-8	Gut microbiome composition (summer);
LUSC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg13206674	chr6:150067644	NUP43	0.57	9.09	0.45	9.1e-18	Lung cancer;
LUSC	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.85	-12.22	-0.56	1.24e-28	Asthma;
LUSC	trans	rs6601327	0.606	rs7006985	chr8:9564437	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-6.16	-0.32	2.04e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg23630131	chr7:65973040	NA	-0.21	-5.83	-0.3	1.33e-8	Aortic root size;
LUSC	cis	rs9318086	0.712	rs3794339	chr13:24434065	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.41	6.19	0.32	1.75e-9	Myopia (pathological);
LUSC	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.46	-0.46	5.87e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg09975044	chr14:104007538	NA	0.37	5.84	0.3	1.27e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg13565492	chr6:43139072	SRF	-0.56	-6.21	-0.32	1.57e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg07703079	chr11:430292	ANO9	0.6	6.54	0.34	2.28e-10	Body mass index;
LUSC	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg12927641	chr6:109611667	NA	-0.35	-5.87	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs11971779	0.715	rs6467856	chr7:139127299	A/C	cg07862535	chr7:139043722	LUC7L2	0.57	7.14	0.36	6.02e-12	Diisocyanate-induced asthma;
LUSC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11764359	chr7:65958608	NA	0.61	9.19	0.45	4.15e-18	Aortic root size;
LUSC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg09826364	chr7:158789723	NA	-0.38	-5.91	-0.31	8.3e-9	Facial morphology (factor 20);
LUSC	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg18681998	chr4:17616180	MED28	0.84	14.92	0.63	6.27e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs977987	0.778	rs62059846	chr16:75430809	T/A	cg03315344	chr16:75512273	CHST6	0.48	9.12	0.45	6.97e-18	Dupuytren's disease;
LUSC	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg15654264	chr1:150340011	RPRD2	0.65	10.79	0.51	1.71e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11764359	chr7:65958608	NA	-0.68	-10.93	-0.51	5.47e-24	Aortic root size;
LUSC	trans	rs13011075	0.844	rs10174380	chr2:68596469	C/T	cg14221825	chr19:46271408	SIX5	0.43	6.18	0.32	1.82e-9	Mean corpuscular volume;
LUSC	cis	rs1030877	0.924	rs2250658	chr2:105889683	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.78	14.96	0.63	4.33e-39	Obesity-related traits;
LUSC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg15145296	chr3:125709740	NA	-0.56	-6.62	-0.34	1.44e-10	Blood pressure (smoking interaction);
LUSC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-6.52	-0.34	2.66e-10	Breast cancer;
LUSC	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg23750338	chr8:142222470	SLC45A4	0.58	11.3	0.53	2.76e-25	Immature fraction of reticulocytes;
LUSC	cis	rs6693567	0.516	rs3850844	chr1:150413940	G/T	cg15654264	chr1:150340011	RPRD2	0.44	7.11	0.36	7.28e-12	Migraine;
LUSC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg27266027	chr21:40555129	PSMG1	-0.41	-5.97	-0.31	5.92e-9	Cognitive function;
LUSC	cis	rs9309473	1.000	rs10169714	chr2:73808773	T/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.41	-0.33	4.86e-10	Metabolite levels;
LUSC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg06212747	chr3:49208901	KLHDC8B	0.43	5.76	0.3	1.94e-8	Parkinson's disease;
LUSC	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03517284	chr6:25882590	NA	-0.38	-6.8	-0.35	4.89e-11	Height;
LUSC	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg14346243	chr4:90757452	SNCA	-0.4	-5.78	-0.3	1.72e-8	Neuroticism;
LUSC	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18932078	chr1:2524107	MMEL1	0.32	7.12	0.36	6.68e-12	Ulcerative colitis;
LUSC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06850241	chr22:41845214	NA	0.34	6.06	0.31	3.71e-9	Vitiligo;
LUSC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.26	0.37	2.8e-12	Platelet count;
LUSC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	8.97	0.44	2.17e-17	Menopause (age at onset);
LUSC	trans	rs10511400	0.618	rs2319542	chr3:119905641	A/G	cg02809009	chr19:50354510	PTOV1	0.69	6.02	0.31	4.71e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg02117656	chr17:79614917	TSPAN10	0.31	5.76	0.3	1.88e-8	Eye color traits;
LUSC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg13395646	chr4:1353034	KIAA1530	0.63	10.34	0.49	6.46e-22	Obesity-related traits;
LUSC	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg22676075	chr6:135203613	NA	-0.46	-7.26	-0.37	2.74e-12	Red blood cell count;
LUSC	trans	rs6601327	0.571	rs7838571	chr8:9647796	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	7.56	0.38	3.91e-13	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg04455712	chr21:45112962	RRP1B	0.43	8.0	0.4	2e-14	Mean corpuscular volume;
LUSC	cis	rs6845621	0.901	rs1079811	chr4:18925941	G/A	cg12196642	chr4:18937545	NA	-0.33	-6.09	-0.32	3.08e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	9.13	0.45	6.88e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg03213289	chr20:61660250	NA	0.66	12.81	0.57	7.61e-31	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg24296786	chr1:45957014	TESK2	-0.51	-7.66	-0.39	2.01e-13	High light scatter reticulocyte count;
LUSC	cis	rs6940638	1.000	rs6940638	chr6:27046250	A/G	cg09904177	chr6:26538194	HMGN4	-0.5	-5.92	-0.31	7.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg18681998	chr4:17616180	MED28	0.85	15.8	0.65	2.14e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6429082	0.702	rs10802797	chr1:235705673	A/G	cg26050004	chr1:235667680	B3GALNT2	0.46	6.57	0.34	1.97e-10	Adiposity;
LUSC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg03579872	chr1:53393473	SCP2	-0.4	-5.93	-0.31	7.36e-9	Monocyte count;
LUSC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25072359	chr17:41440525	NA	0.65	9.38	0.46	1.06e-18	Menopause (age at onset);
LUSC	trans	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.32	-0.33	8.5e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg05738196	chr6:26577821	NA	-0.45	-6.94	-0.36	2.01e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs3916	0.794	rs3021337	chr12:121163261	C/T	cg21892295	chr12:121157589	UNC119B	-0.4	-6.62	-0.34	1.4e-10	Urinary metabolites (H-NMR features);
LUSC	cis	rs7264396	0.887	rs1570841	chr20:34048161	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.61	-0.34	1.5e-10	Total cholesterol levels;
LUSC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.38	0.33	5.82e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg00277334	chr10:82204260	NA	-0.48	-7.11	-0.36	7e-12	Post bronchodilator FEV1;
LUSC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg21153622	chr11:89784906	NA	-0.46	-7.16	-0.36	5.31e-12	Coronary artery disease;
LUSC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg02551604	chr5:131831745	NA	-0.42	-6.62	-0.34	1.39e-10	Asthma (sex interaction);
LUSC	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-9.49	-0.46	4.53e-19	Bone mineral density;
LUSC	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg21535247	chr6:8435926	SLC35B3	-0.57	-8.45	-0.42	9.16e-16	Motion sickness;
LUSC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg25036284	chr2:26402008	FAM59B	-0.69	-9.72	-0.47	7.82e-20	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg19230755	chr7:65878503	NA	0.42	5.89	0.31	9.35e-9	Aortic root size;
LUSC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg07578070	chr6:150326732	RAET1K	0.41	6.37	0.33	6.13e-10	Alopecia areata;
LUSC	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg07173049	chr1:7289937	CAMTA1	0.34	7.03	0.36	1.19e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7200543	1.000	rs16966953	chr16:15135854	A/G	cg03427771	chr16:15082598	PDXDC1	-0.42	-5.89	-0.31	9.58e-9	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg04691961	chr3:161091175	C3orf57	-0.35	-5.99	-0.31	5.34e-9	Morning vs. evening chronotype;
LUSC	cis	rs2289328	1.000	rs2289328	chr15:40705417	G/A	cg13931752	chr15:40660718	DISP2	0.46	6.11	0.32	2.83e-9	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.62	-0.38	2.64e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg16407604	chr1:40724172	ZMPSTE24	0.39	6.24	0.32	1.36e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-12.38	-0.56	3.13e-29	Alzheimer's disease;
LUSC	cis	rs3892630	0.588	rs1976501	chr19:33208155	C/T	cg22980127	chr19:33182716	NUDT19	0.9	12.93	0.58	2.68e-31	Red blood cell traits;
LUSC	cis	rs2692947	0.667	rs4144055	chr2:96647856	G/T	cg23100626	chr2:96804247	ASTL	0.26	6.33	0.33	8.04e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg11062466	chr8:58055876	NA	0.49	6.3	0.33	9.37e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	0.96	19.16	0.72	1.04e-55	Cognitive function;
LUSC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg20790798	chr5:1857306	NA	-0.51	-8.67	-0.43	1.94e-16	Cardiovascular disease risk factors;
LUSC	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-7.86	-0.4	5.16e-14	Neuroticism;
LUSC	cis	rs4144743	0.641	rs67696888	chr17:45355116	A/G	cg18085866	chr17:45331354	ITGB3	-0.64	-6.33	-0.33	7.69e-10	Body mass index;
LUSC	cis	rs28830936	1.000	rs17678767	chr15:42096422	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.69	-0.3	2.81e-8	Diastolic blood pressure;
LUSC	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg04455712	chr21:45112962	RRP1B	0.44	8.56	0.42	4.19e-16	Mean corpuscular volume;
LUSC	cis	rs1775715	0.835	rs1419169	chr10:32257204	C/G	cg18675610	chr10:32216311	ARHGAP12	0.28	5.93	0.31	7.38e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.5	0.5	1.75e-22	Colorectal cancer;
LUSC	cis	rs96067	0.711	rs272827	chr1:36627191	C/T	cg24686825	chr1:36642396	MAP7D1	0.7	10.88	0.51	8.09e-24	Corneal structure;
LUSC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg06618935	chr21:46677482	NA	-0.39	-7.81	-0.39	7.53e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg18479299	chr3:125709523	NA	-0.52	-5.92	-0.31	7.97e-9	Blood pressure (smoking interaction);
LUSC	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18854424	chr1:2615690	NA	0.49	9.84	0.47	3.06e-20	Ulcerative colitis;
LUSC	cis	rs67696533	0.711	rs6119897	chr20:31145415	A/G	cg13636640	chr20:31349939	DNMT3B	-0.49	-6.72	-0.35	7.72e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-1.03	-20.48	-0.75	5.94e-61	Height;
LUSC	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg26924012	chr15:45694286	SPATA5L1	0.73	11.02	0.52	2.74e-24	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.37	-0.42	1.66e-15	Schizophrenia;
LUSC	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	1.03	22.65	0.78	1.85e-69	Testicular germ cell tumor;
LUSC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg18230493	chr5:56204884	C5orf35	-0.88	-13.22	-0.59	2.3e-32	Initial pursuit acceleration;
LUSC	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg05925327	chr15:68127851	NA	-0.38	-5.95	-0.31	6.96e-9	Restless legs syndrome;
LUSC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.84	-14.79	-0.63	2.09e-38	Cognitive function;
LUSC	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg04310649	chr10:35416472	CREM	0.4	6.36	0.33	6.72e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg04287289	chr16:89883240	FANCA	0.78	13.34	0.59	7.98e-33	Vitiligo;
LUSC	cis	rs6700896	0.931	rs12035753	chr1:66116691	T/G	cg04111102	chr1:66153794	NA	0.32	7.1	0.36	7.54e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.43	0.42	1.08e-15	Prudent dietary pattern;
LUSC	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg08355456	chr11:67383691	NA	0.38	7.01	0.36	1.35e-11	Mean corpuscular volume;
LUSC	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.38e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg01652190	chr22:50026171	C22orf34	-0.31	-6.39	-0.33	5.51e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg09640425	chr7:158790006	NA	-0.42	-6.49	-0.33	3.09e-10	Facial morphology (factor 20);
LUSC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg07741184	chr6:167504864	NA	0.43	7.59	0.38	3.18e-13	Crohn's disease;
LUSC	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg17848003	chr1:3704513	LRRC47	0.34	6.15	0.32	2.18e-9	Red cell distribution width;
LUSC	cis	rs2219968	0.828	rs13248588	chr8:78880744	A/G	cg00738934	chr8:78996279	NA	-0.38	-6.71	-0.34	8.44e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg13010199	chr12:38710504	ALG10B	0.67	10.34	0.49	6.17e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg17986701	chr20:44574422	PCIF1	0.37	6.57	0.34	1.94e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.71	12.78	0.57	9.99e-31	Prudent dietary pattern;
LUSC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg07507251	chr3:52567010	NT5DC2	-0.32	-6.29	-0.33	9.86e-10	Bipolar disorder;
LUSC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg12463550	chr7:65579703	CRCP	0.55	8.22	0.41	4.5e-15	Aortic root size;
LUSC	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg20701182	chr2:24300061	SF3B14	0.75	7.62	0.38	2.73e-13	Lymphocyte counts;
LUSC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.09	-0.32	3.19e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg05738196	chr6:26577821	NA	-0.51	-6.08	-0.32	3.27e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.64	0.5	5.88e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg12639453	chr1:2035780	PRKCZ	-0.31	-6.54	-0.34	2.38e-10	Height;
LUSC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg07395648	chr5:131743802	NA	0.38	5.92	0.31	7.78e-9	Asthma (sex interaction);
LUSC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg03289416	chr15:75166202	SCAMP2	0.44	6.95	0.36	1.95e-11	Breast cancer;
LUSC	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg22356347	chr1:167427500	CD247	-0.35	-8.33	-0.41	2.07e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	trans	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg26043149	chr18:55253948	FECH	-0.52	-7.72	-0.39	1.37e-13	Bone mineral density;
LUSC	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg09307838	chr4:120376055	NA	0.69	9.72	0.47	7.6e-20	Corneal astigmatism;
LUSC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.84	-0.3	1.25e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12618769	0.543	rs58778964	chr2:99110599	G/C	cg10123293	chr2:99228465	UNC50	0.45	7.48	0.38	6.81e-13	Bipolar disorder;
LUSC	cis	rs12681287	0.571	rs13254675	chr8:87353594	C/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.17	-0.37	4.86e-12	Caudate activity during reward;
LUSC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-0.89	-13.28	-0.59	1.29e-32	Asthma;
LUSC	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.38	-0.53	1.35e-25	Mean corpuscular volume;
LUSC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg12463550	chr7:65579703	CRCP	-0.42	-6.04	-0.31	4.22e-9	Calcium levels;
LUSC	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg17470449	chr10:769945	NA	0.55	7.79	0.39	8.33e-14	Uric acid levels;
LUSC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.46	0.46	5.87e-19	Blood protein levels;
LUSC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.42	-6.15	-0.32	2.19e-9	Alzheimer's disease (late onset);
LUSC	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17467752	chr17:38218738	THRA	-0.7	-11.27	-0.52	3.54e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs1595825	0.891	rs114426561	chr2:198698891	A/G	cg00982548	chr2:198649783	BOLL	-0.58	-7.2	-0.37	3.9e-12	Ulcerative colitis;
LUSC	cis	rs17401966	0.931	rs12753426	chr1:10372110	T/C	cg19773385	chr1:10388646	KIF1B	-0.5	-8.39	-0.42	1.38e-15	Hepatocellular carcinoma;
LUSC	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.3	-0.37	2.1e-12	Bipolar disorder;
LUSC	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.6	-0.47	2.03e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.88e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs6960043	0.818	rs1974619	chr7:15065300	C/T	cg19272540	chr7:15055459	NA	-0.31	-7.64	-0.39	2.31e-13	Type 2 diabetes;
LUSC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg21724239	chr8:58056113	NA	-0.78	-8.35	-0.42	1.78e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg10547527	chr2:198650123	BOLL	-0.5	-5.9	-0.31	9.07e-9	Ulcerative colitis;
LUSC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg17366294	chr4:99064904	C4orf37	0.53	8.74	0.43	1.17e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-9.26	-0.45	2.56e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-10.01	-0.48	8.56e-21	Personality dimensions;
LUSC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg01420254	chr6:26195488	NA	0.63	7.08	0.36	8.45e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs8032315	1.000	rs2071410	chr15:91420940	C/G	cg05469396	chr15:91419421	FURIN	-0.42	-6.51	-0.34	2.72e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg00684032	chr4:1343700	KIAA1530	0.34	5.96	0.31	6.54e-9	Obesity-related traits;
LUSC	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg13010199	chr12:38710504	ALG10B	0.66	10.09	0.48	4.48e-21	Bladder cancer;
LUSC	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-6.9	-0.35	2.68e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg04756594	chr16:24857601	SLC5A11	0.37	6.18	0.32	1.9e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg12560992	chr17:57184187	TRIM37	0.59	9.47	0.46	5.35e-19	Testicular germ cell tumor;
LUSC	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg15997130	chr1:24165203	NA	0.52	8.62	0.43	2.63e-16	Immature fraction of reticulocytes;
LUSC	cis	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg21775007	chr8:11205619	TDH	0.46	5.87	0.31	1.05e-8	Neuroticism;
LUSC	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05901451	chr6:126070800	HEY2	0.58	8.91	0.44	3.42e-17	Endometrial cancer;
LUSC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg05729581	chr11:3078854	CARS	-0.53	-8.32	-0.41	2.19e-15	Longevity;
LUSC	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg14634687	chr17:47094252	IGF2BP1	0.31	6.54	0.34	2.26e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	trans	rs6445975	0.572	rs4320076	chr3:58405284	T/G	cg18950693	chr14:70346909	SMOC1	-0.4	-6.03	-0.31	4.25e-9	Systemic lupus erythematosus;
LUSC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	9.25	0.45	2.73e-18	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg17063962	chr7:91808500	NA	-0.51	-7.66	-0.39	1.97e-13	Breast cancer;
LUSC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg17420585	chr12:42539391	GXYLT1	0.4	7.79	0.39	8.36e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9473147	0.516	rs9349415	chr6:47551861	T/C	cg02130027	chr6:47444894	CD2AP	0.35	5.7	0.3	2.68e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7586879	0.789	rs13404163	chr2:25126616	A/G	cg01884057	chr2:25150051	NA	0.42	8.8	0.43	7.49e-17	Body mass index;
LUSC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-1.19	-12.83	-0.57	6.75e-31	Diabetic kidney disease;
LUSC	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg02903104	chr8:1507517	DLGAP2	0.39	7.6	0.38	3.11e-13	Lung cancer;
LUSC	cis	rs6942756	0.806	rs9641846	chr7:128873679	G/A	cg02491457	chr7:128862824	NA	0.52	7.83	0.39	6.39e-14	White matter hyperintensity burden;
LUSC	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg10950924	chr17:47092072	IGF2BP1	0.38	5.93	0.31	7.73e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUSC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg08859206	chr1:53392774	SCP2	-0.41	-6.62	-0.34	1.41e-10	Monocyte count;
LUSC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg07703079	chr11:430292	ANO9	0.57	6.27	0.32	1.14e-9	Body mass index;
LUSC	cis	rs9650315	0.929	rs35423308	chr8:57201836	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.31	0.37	1.93e-12	Height;
LUSC	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg24642439	chr20:33292090	TP53INP2	0.42	6.07	0.32	3.38e-9	Height;
LUSC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg21880101	chr17:80066754	CCDC57	0.31	5.85	0.3	1.17e-8	Life satisfaction;
LUSC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg21972741	chr5:435613	AHRR	0.37	6.99	0.36	1.47e-11	Cystic fibrosis severity;
LUSC	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg02428538	chr16:24856791	SLC5A11	0.6	6.85	0.35	3.59e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs12310956	0.510	rs10772109	chr12:33839548	A/C	cg26384229	chr12:38710491	ALG10B	-0.54	-8.24	-0.41	4.01e-15	Morning vs. evening chronotype;
LUSC	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg12310025	chr6:25882481	NA	-0.34	-5.69	-0.3	2.74e-8	Height;
LUSC	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg11211951	chr8:145729740	GPT	-0.58	-11.15	-0.52	9.59e-25	Age at first birth;
LUSC	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11585357	0.842	rs72633804	chr1:17617024	T/C	cg08277548	chr1:17600880	PADI3	-0.64	-6.62	-0.34	1.42e-10	Hair shape;
LUSC	trans	rs2786098	0.656	rs12028758	chr1:197522958	C/T	cg16005942	chr6:160526640	IGF2R	0.52	6.59	0.34	1.7e-10	Asthma;
LUSC	cis	rs9395066	0.527	rs12524069	chr6:44897973	C/A	cg25276700	chr6:44698697	NA	0.31	6.21	0.32	1.57e-9	Height;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg22745437	chr19:38397769	WDR87;SIPA1L3	0.75	5.95	0.31	6.94e-9	Cognitive performance;
LUSC	cis	rs2273669	0.667	rs76201299	chr6:109344975	T/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	9.1e-9	Prostate cancer;
LUSC	cis	rs4343996	1.000	rs6461994	chr7:3356483	C/G	cg21248987	chr7:3385318	SDK1	-0.35	-5.94	-0.31	7.05e-9	Motion sickness;
LUSC	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.16	0.41	6.97e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg17120908	chr11:65337727	SSSCA1	-0.55	-9.61	-0.47	1.78e-19	Bone mineral density;
LUSC	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-11.62	-0.54	1.99e-26	Personality dimensions;
LUSC	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg08975724	chr8:8085496	FLJ10661	0.42	6.0	0.31	5.18e-9	Neuroticism;
LUSC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg27165867	chr14:105738592	BRF1	-0.51	-7.42	-0.38	9.52e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg02176678	chr2:219576539	TTLL4	-0.58	-10.36	-0.49	5.62e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs78572108	0.858	rs10183814	chr2:42262064	T/C	cg00607755	chr2:42274082	PKDCC	0.35	6.24	0.32	1.34e-9	Total body bone mineral density;
LUSC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01570182	chr17:44337453	NA	0.7	10.6	0.5	8.01e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs290268	1.000	rs290271	chr9:93551619	G/A	cg02608019	chr9:93564028	SYK	0.55	9.13	0.45	6.57e-18	Platelet count;
LUSC	cis	rs9549260	0.755	rs2297627	chr13:41233931	A/G	cg21288729	chr13:41239152	FOXO1	0.6	9.24	0.45	3.02e-18	Red blood cell count;
LUSC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.7	10.86	0.51	9.8e-24	Aortic root size;
LUSC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg12639453	chr1:2035780	PRKCZ	0.28	5.88	0.31	1.01e-8	Height;
LUSC	trans	rs72674100	1.000	rs28630925	chr4:97991385	G/T	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4363385	0.658	rs426147	chr1:153045011	G/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.39	-0.37	1.19e-12	Inflammatory skin disease;
LUSC	cis	rs1775715	0.870	rs11008700	chr10:32236937	A/G	cg26784012	chr10:32216390	ARHGAP12	0.36	5.83	0.3	1.3e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24838063	chr12:130822603	PIWIL1	0.67	10.27	0.49	1.1e-21	Menopause (age at onset);
LUSC	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg21545522	chr1:205238299	TMCC2	0.46	8.6	0.43	3.05e-16	Red blood cell count;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg26828218	chr2:219264796	CTDSP1	0.53	7.05	0.36	1e-11	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg02175503	chr12:58329896	NA	0.55	8.79	0.43	7.88e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11645453	chr3:52864694	ITIH4	0.35	8.13	0.41	8.33e-15	Bipolar disorder;
LUSC	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg08000102	chr2:233561755	GIGYF2	0.81	14.03	0.61	1.85e-35	Schizophrenia;
LUSC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg19592336	chr6:28129416	ZNF389	0.48	6.3	0.33	9.46e-10	Depression;
LUSC	cis	rs3740713	1.000	rs16935432	chr11:18470487	G/A	cg07915343	chr11:18477680	LDHAL6A	-0.54	-6.74	-0.35	6.85e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs644148	0.500	rs2686773	chr19:44999802	G/A	cg15540054	chr19:45004280	ZNF180	-0.44	-6.05	-0.31	3.91e-9	Personality dimensions;
LUSC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.92	-0.31	8e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.45	0.38	7.82e-13	Morning vs. evening chronotype;
LUSC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg20135002	chr11:47629003	NA	-0.52	-8.12	-0.41	8.82e-15	Subjective well-being;
LUSC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.75	-13.36	-0.59	6.48e-33	Cognitive function;
LUSC	trans	rs7944735	0.671	rs7106731	chr11:48003392	T/G	cg15704280	chr7:45808275	SEPT13	0.55	6.6	0.34	1.64e-10	Intraocular pressure;
LUSC	cis	rs1595825	0.945	rs73058818	chr2:198862600	C/T	cg00982548	chr2:198649783	BOLL	-0.56	-7.15	-0.36	5.59e-12	Ulcerative colitis;
LUSC	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg10911889	chr6:126070802	HEY2	0.4	6.14	0.32	2.28e-9	Brugada syndrome;
LUSC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg09491104	chr22:46646882	C22orf40	-0.63	-7.26	-0.37	2.76e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg16342193	chr10:102329863	NA	-0.35	-6.42	-0.33	4.6e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg13010199	chr12:38710504	ALG10B	0.66	9.93	0.48	1.57e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7659604	0.540	rs9995322	chr4:122675642	G/A	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.91	-0.31	8.47e-9	Type 2 diabetes;
LUSC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg06784218	chr1:46089804	CCDC17	0.49	9.73	0.47	7.31e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs6600671	1.000	rs7532615	chr1:121172840	G/T	cg00646200	chr1:148855367	NA	-0.4	-6.39	-0.33	5.5e-10	Hip geometry;
LUSC	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03517284	chr6:25882590	NA	-0.39	-6.95	-0.36	1.89e-11	Height;
LUSC	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg04369109	chr6:150039330	LATS1	-0.41	-5.79	-0.3	1.64e-8	Testicular germ cell tumor;
LUSC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg20135002	chr11:47629003	NA	0.48	7.57	0.38	3.71e-13	Subjective well-being;
LUSC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12311346	chr5:56204834	C5orf35	-0.66	-10.07	-0.48	5.26e-21	Coronary artery disease;
LUSC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-12.07	-0.55	4.48e-28	Platelet count;
LUSC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg08470875	chr2:26401718	FAM59B	-0.71	-9.6	-0.47	1.92e-19	Gut microbiome composition (summer);
LUSC	cis	rs2629540	0.889	rs4962402	chr10:126459114	T/G	cg08799069	chr10:126477246	METTL10	-0.68	-10.11	-0.48	3.87e-21	Cocaine dependence;
LUSC	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg08999081	chr20:33150536	PIGU	0.33	5.7	0.3	2.59e-8	Height;
LUSC	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg24296786	chr1:45957014	TESK2	0.48	7.01	0.36	1.29e-11	High light scatter reticulocyte count;
LUSC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg11871910	chr12:69753446	YEATS4	0.83	14.58	0.62	1.34e-37	Blood protein levels;
LUSC	trans	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.87	0.35	3.16e-11	Endometrial cancer;
LUSC	trans	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg07211511	chr3:129823064	LOC729375	-0.75	-9.78	-0.47	4.94e-20	Blood pressure (smoking interaction);
LUSC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.72	-0.43	1.34e-16	Platelet count;
LUSC	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg10207240	chr12:122356781	WDR66	0.43	6.15	0.32	2.22e-9	Mean corpuscular volume;
LUSC	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg05738196	chr6:26577821	NA	0.81	15.2	0.64	4.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg12288994	chr5:1860383	NA	0.31	6.98	0.36	1.6e-11	Cardiovascular disease risk factors;
LUSC	cis	rs13315871	1.000	rs11708590	chr3:58336635	A/G	cg20936604	chr3:58311152	NA	0.66	6.71	0.34	8.57e-11	Cholesterol, total;
LUSC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg12257692	chr3:49977190	RBM6	-0.26	-7.13	-0.36	6.45e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2286885	0.965	rs4836548	chr9:129255456	G/A	cg15282417	chr9:129245246	FAM125B	0.41	6.82	0.35	4.27e-11	Intraocular pressure;
LUSC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg04518342	chr5:131593106	PDLIM4	0.44	7.66	0.39	2.04e-13	Breast cancer;
LUSC	trans	rs236907	0.814	rs6695933	chr1:171774239	A/C	cg13482142	chr2:234261155	NA	0.52	6.19	0.32	1.79e-9	Mean platelet volume;
LUSC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg13395646	chr4:1353034	KIAA1530	-0.62	-10.12	-0.48	3.66e-21	Obesity-related traits;
LUSC	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg13042288	chr15:90349979	ANPEP	-0.42	-6.51	-0.34	2.71e-10	Uric acid levels;
LUSC	cis	rs939658	0.683	rs8041222	chr15:79465549	A/G	cg17916960	chr15:79447300	NA	-0.39	-7.18	-0.37	4.52e-12	Refractive error;
LUSC	cis	rs4700695	0.719	rs27584	chr5:65445232	G/A	cg21114390	chr5:65439923	SFRS12	-0.64	-9.15	-0.45	5.85e-18	Facial morphology (factor 19);
LUSC	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg00191853	chr8:101177733	SPAG1	-0.36	-6.04	-0.31	4.05e-9	Atrioventricular conduction;
LUSC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Parkinson's disease;
LUSC	cis	rs1385374	0.858	rs10847697	chr12:129299385	C/T	cg09035930	chr12:129282057	SLC15A4	-0.58	-6.47	-0.33	3.41e-10	Systemic lupus erythematosus;
LUSC	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg23029597	chr12:123009494	RSRC2	-0.6	-8.51	-0.42	5.81e-16	Body mass index;
LUSC	cis	rs151234	0.676	rs554206	chr16:28576369	G/A	cg01378222	chr16:28622494	SULT1A1	-0.62	-8.34	-0.42	1.91e-15	Platelet distribution width;
LUSC	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg25482853	chr8:67687455	SGK3	1.2	16.99	0.68	4.47e-47	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-13.3	-0.59	1.08e-32	Bladder cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04130928	chr5:176449623	ZNF346	-0.4	-6.0	-0.31	5.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11971779	0.680	rs66491565	chr7:139088977	C/G	cg07862535	chr7:139043722	LUC7L2	0.59	7.37	0.37	1.32e-12	Diisocyanate-induced asthma;
LUSC	cis	rs3772130	0.962	rs9826473	chr3:121556219	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.72	10.43	0.5	3.12e-22	Cognitive performance;
LUSC	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg22681709	chr2:178499509	PDE11A	-0.42	-5.87	-0.31	1.04e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.52	10.27	0.49	1.14e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs3087591	0.801	rs2012535	chr17:29561391	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.55	-7.86	-0.4	5.37e-14	Hip circumference;
LUSC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11088226	0.709	rs55860967	chr21:33880018	G/A	cg09050820	chr6:167586206	TCP10L2	0.48	6.03	0.31	4.38e-9	Gastritis;
LUSC	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	9.07	0.44	1.01e-17	Iron status biomarkers;
LUSC	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.73	-13.36	-0.59	6.47e-33	Ulcerative colitis;
LUSC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg18240062	chr17:79603768	NPLOC4	0.71	12.97	0.58	1.96e-31	Eye color traits;
LUSC	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg08000102	chr2:233561755	GIGYF2	0.73	10.96	0.51	4.46e-24	Schizophrenia;
LUSC	trans	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.39	0.37	1.21e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs2018683	0.899	rs10479817	chr7:28978148	A/C	cg19402173	chr7:128379420	CALU	-0.53	-8.41	-0.42	1.21e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg19812747	chr11:111475976	SIK2	-0.55	-8.2	-0.41	5.19e-15	Primary sclerosing cholangitis;
LUSC	cis	rs7177699	0.557	rs7403714	chr15:79118650	C/T	cg00540400	chr15:79124168	NA	-0.47	-7.96	-0.4	2.75e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg03065625	chr11:46941490	LRP4	0.39	6.16	0.32	2.12e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-9.05	-0.44	1.24e-17	Bipolar disorder;
LUSC	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg02569458	chr12:86230093	RASSF9	0.49	8.2	0.41	5.16e-15	Major depressive disorder;
LUSC	cis	rs10754283	0.967	rs12058749	chr1:90105604	C/T	cg21401794	chr1:90099060	LRRC8C	0.67	10.02	0.48	7.75e-21	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg04865166	chr7:105162814	PUS7	-0.52	-5.79	-0.3	1.6e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg19773385	chr1:10388646	KIF1B	-0.57	-9.87	-0.48	2.58e-20	Hepatocellular carcinoma;
LUSC	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg22467129	chr15:76604101	ETFA	-0.42	-6.59	-0.34	1.72e-10	Blood metabolite levels;
LUSC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg02475777	chr4:1388615	CRIPAK	0.45	6.86	0.35	3.37e-11	Obesity-related traits;
LUSC	trans	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg18335740	chr13:41363409	SLC25A15	-0.46	-6.88	-0.35	2.95e-11	Lewy body disease;
LUSC	cis	rs6942756	1.000	rs4440569	chr7:128923907	T/A	cg02491457	chr7:128862824	NA	-0.49	-6.72	-0.35	7.96e-11	White matter hyperintensity burden;
LUSC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.84	-10.95	-0.51	4.73e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6704644	0.584	rs56336977	chr2:234357496	C/T	cg05711037	chr2:234359783	DGKD	0.62	6.54	0.34	2.27e-10	Bilirubin levels;
LUSC	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.69	-0.43	1.65e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg23795048	chr12:9217529	LOC144571	0.33	5.8	0.3	1.55e-8	Sjögren's syndrome;
LUSC	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg12935359	chr14:103987150	CKB	0.6	9.08	0.44	9.73e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13387677	chr22:38203802	GCAT	-0.39	-5.98	-0.31	5.61e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6498114	0.652	rs3087456	chr16:10970902	G/A	cg03103192	chr4:52917271	SPATA18	0.33	6.3	0.33	9.14e-10	Nasopharyngeal carcinoma;
LUSC	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg21798802	chr22:38057573	PDXP	0.35	7.43	0.38	9.29e-13	Fat distribution (HIV);
LUSC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08704250	chr15:31115839	NA	-0.59	-9.24	-0.45	2.97e-18	Huntington's disease progression;
LUSC	cis	rs10875746	0.951	rs61918826	chr12:48543978	T/C	cg13454099	chr12:49076203	C12orf41	-0.52	-6.15	-0.32	2.17e-9	Longevity (90 years and older);
LUSC	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.59	-0.34	1.73e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9811920	0.809	rs766778	chr3:99751480	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.44	-6.56	-0.34	2.07e-10	Axial length;
LUSC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg27170947	chr2:26402098	FAM59B	-0.69	-10.55	-0.5	1.2e-22	Gut microbiome composition (summer);
LUSC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.36	6.19	0.32	1.78e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg06637938	chr14:75390232	RPS6KL1	0.62	10.27	0.49	1.06e-21	Caffeine consumption;
LUSC	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg25828445	chr12:7781288	NA	0.62	6.45	0.33	3.88e-10	HDL cholesterol levels;
LUSC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.3	-0.41	2.62e-15	Mean platelet volume;
LUSC	cis	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg21775007	chr8:11205619	TDH	-0.44	-5.84	-0.3	1.27e-8	Neuroticism;
LUSC	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-6.69	-0.34	9.42e-11	Monocyte percentage of white cells;
LUSC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg13175981	chr1:150552382	MCL1	0.47	6.62	0.34	1.44e-10	Tonsillectomy;
LUSC	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.22	0.32	1.49e-9	Corneal astigmatism;
LUSC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg06784218	chr1:46089804	CCDC17	0.56	11.62	0.54	1.92e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02018176	chr4:1364513	KIAA1530	0.72	13.44	0.59	3.19e-33	Longevity;
LUSC	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg16989719	chr2:238392110	NA	-0.39	-6.62	-0.34	1.41e-10	Prostate cancer;
LUSC	cis	rs9359856	0.564	rs72917989	chr6:90470385	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.2	-0.41	5.08e-15	Bipolar disorder;
LUSC	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg23283495	chr1:209979779	IRF6	-0.68	-8.17	-0.41	6.3e-15	Cleft lip with or without cleft palate;
LUSC	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg22676075	chr6:135203613	NA	0.46	7.13	0.36	6.1e-12	Red blood cell count;
LUSC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.67	-0.3	3.01e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg18825076	chr15:78729989	IREB2	-0.59	-9.73	-0.47	7.2e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	trans	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.86	0.4	5.2e-14	Ulcerative colitis;
LUSC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg00074818	chr8:8560427	CLDN23	0.57	9.75	0.47	6.48e-20	Obesity-related traits;
LUSC	cis	rs6815814	0.904	rs7664239	chr4:38786304	T/C	cg06935464	chr4:38784597	TLR10	0.46	5.94	0.31	7.29e-9	Breast cancer;
LUSC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13126279	chr21:47581558	C21orf56	-0.54	-8.37	-0.42	1.63e-15	Testicular germ cell tumor;
LUSC	cis	rs9811920	0.809	rs7649349	chr3:99725629	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.35	5.9	0.31	9e-9	Axial length;
LUSC	cis	rs1568889	1.000	rs11602768	chr11:28351786	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	8.87	0.44	4.52e-17	Bipolar disorder;
LUSC	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-0.59	-12.15	-0.55	2.3e-28	Obesity-related traits;
LUSC	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.55	-8.18	-0.41	6.07e-15	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg05182265	chr7:156933206	UBE3C	0.59	9.5	0.46	4.17e-19	Body mass index;
LUSC	cis	rs2235649	0.623	rs8048162	chr16:1848918	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-5.92	-0.31	7.81e-9	Blood metabolite levels;
LUSC	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg26384229	chr12:38710491	ALG10B	0.85	13.54	0.6	1.3e-33	Bladder cancer;
LUSC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22433210	chr17:43662623	NA	-0.73	-10.65	-0.5	5.56e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.73	-0.3	2.25e-8	Tonsillectomy;
LUSC	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg01629716	chr15:45996671	NA	0.4	6.06	0.31	3.68e-9	Waist circumference;Weight;
LUSC	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg12552261	chr5:112820674	MCC	-0.44	-7.02	-0.36	1.25e-11	Type 2 diabetes;
LUSC	cis	rs2976388	1.000	rs2978982	chr8:143763490	T/C	cg17252645	chr8:143867129	LY6D	-0.36	-6.31	-0.33	9.04e-10	Urinary tract infection frequency;
LUSC	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg00864171	chr11:67383662	NA	0.34	6.02	0.31	4.72e-9	Mean corpuscular volume;
LUSC	cis	rs4631830	0.733	rs4512771	chr10:51540906	C/A	cg16070123	chr10:51489643	NA	-0.48	-7.4	-0.38	1.08e-12	Prostate-specific antigen levels;
LUSC	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.74	-14.3	-0.62	1.65e-36	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-7.01	-0.36	1.34e-11	Waist circumference;Hip circumference;
LUSC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18876405	chr7:65276391	NA	0.54	8.47	0.42	8.18e-16	Aortic root size;
LUSC	cis	rs1018836	0.637	rs6471113	chr8:91519735	A/G	cg16814680	chr8:91681699	NA	-0.64	-9.57	-0.46	2.4e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs28830936	0.966	rs2277535	chr15:42119711	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.92	-0.31	7.95e-9	Diastolic blood pressure;
LUSC	trans	rs7939886	0.920	rs60087290	chr11:55983527	C/G	cg03929089	chr4:120376271	NA	0.82	6.13	0.32	2.55e-9	Myopia (pathological);
LUSC	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.68	-0.39	1.74e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg05738196	chr6:26577821	NA	0.5	7.16	0.36	5.23e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg09365446	chr1:150670422	GOLPH3L	-0.5	-7.32	-0.37	1.86e-12	Urate levels;
LUSC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg18876405	chr7:65276391	NA	0.51	7.85	0.39	5.58e-14	Calcium levels;
LUSC	trans	rs9929218	1.000	rs9929218	chr16:68820946	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-11.06	-0.52	1.97e-24	Colorectal cancer;
LUSC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg15445000	chr17:37608096	MED1	0.4	6.74	0.35	6.92e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg06287003	chr12:125626642	AACS	-0.4	-7.18	-0.37	4.64e-12	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg14993813	chr1:46806288	NSUN4	-0.53	-7.39	-0.37	1.18e-12	Menopause (age at onset);
LUSC	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg09904177	chr6:26538194	HMGN4	0.65	11.67	0.54	1.3e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21028142	chr17:79581711	NPLOC4	0.32	7.79	0.39	8.42e-14	Eye color traits;
LUSC	cis	rs10950821	0.530	rs6950224	chr7:20688109	G/C	cg02470904	chr7:20686108	ABCB5	0.33	5.89	0.31	9.35e-9	Response to statin therapy;
LUSC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg27284194	chr4:1044797	NA	0.4	6.32	0.33	8.3e-10	Longevity;
LUSC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	0.92	15.33	0.64	1.58e-40	Breast cancer;
LUSC	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg06784218	chr1:46089804	CCDC17	0.31	5.98	0.31	5.76e-9	Red blood cell count;Reticulocyte count;
LUSC	trans	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.21	0.49	1.73e-21	Mean corpuscular volume;
LUSC	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg01475377	chr6:109611718	NA	-0.36	-6.4	-0.33	5.29e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg20811857	chr17:78079795	GAA	-0.32	-6.06	-0.31	3.59e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg04155289	chr7:94953770	PON1	-0.36	-6.16	-0.32	2.07e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6690583	0.623	rs2083284	chr1:85440023	C/T	cg11262906	chr1:85462892	MCOLN2	0.68	6.46	0.33	3.67e-10	Serum sulfate level;
LUSC	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg27068330	chr11:65405492	SIPA1	-0.68	-9.55	-0.46	2.82e-19	Non-alcoholic fatty liver disease histology (lobular);
LUSC	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00791764	chr4:53727839	RASL11B	0.58	7.98	0.4	2.42e-14	Optic nerve measurement (cup area);
LUSC	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.58	-0.43	3.56e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs3849570	0.615	rs35779564	chr3:81982771	G/A	cg07356753	chr3:81810745	GBE1	-0.52	-7.45	-0.38	8.07e-13	Waist circumference;Body mass index;
LUSC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg03289416	chr15:75166202	SCAMP2	0.45	6.88	0.35	2.9100000000000002e-11	Breast cancer;
LUSC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg06671706	chr8:8559999	CLDN23	-0.47	-6.2	-0.32	1.65e-9	Obesity-related traits;
LUSC	trans	rs72674100	1.000	rs28575922	chr4:97974891	C/A	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs61931739	0.635	rs1405024	chr12:33937939	A/T	cg26384229	chr12:38710491	ALG10B	-0.5	-7.63	-0.39	2.52e-13	Morning vs. evening chronotype;
LUSC	cis	rs4343996	0.542	rs6969267	chr7:3435750	T/C	cg21248987	chr7:3385318	SDK1	0.35	5.67	0.3	3.09e-8	Motion sickness;
LUSC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	0.8	14.01	0.61	2.13e-35	Cognitive function;
LUSC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg06784218	chr1:46089804	CCDC17	0.56	11.2	0.52	6.35e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.52	3.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4596713	0.568	rs7034303	chr9:71746871	A/G	cg25283916	chr1:242222868	NA	0.3	6.15	0.32	2.25e-9	Headache;
LUSC	cis	rs4654899	0.580	rs1977296	chr1:21091543	G/T	cg01072550	chr1:21505969	NA	-0.47	-7.05	-0.36	1.03e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.59	0.5	8.39e-23	Colorectal cancer;
LUSC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.78	-0.51	1.9e-23	Chronic sinus infection;
LUSC	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg07701084	chr6:150067640	NUP43	0.46	6.93	0.35	2.23e-11	Testicular germ cell tumor;
LUSC	cis	rs10203711	1.000	rs7590907	chr2:239550312	T/C	cg14580085	chr2:239553406	NA	0.37	6.08	0.32	3.32e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg22963979	chr7:1858916	MAD1L1	0.57	8.76	0.43	9.95e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.5	7.2	0.37	3.9e-12	Coronary heart disease;
LUSC	trans	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg19894588	chr14:64061835	NA	0.51	7.34	0.37	1.6e-12	Glioblastoma;Glioma;
LUSC	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg27471124	chr11:109292789	C11orf87	0.43	7.48	0.38	6.65e-13	Schizophrenia;
LUSC	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg02580895	chr19:2754563	NA	-0.48	-7.18	-0.37	4.57e-12	Total cholesterol levels;
LUSC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-9.41	-0.46	8.3e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg05082376	chr22:42548792	NA	0.43	6.59	0.34	1.73e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg06454157	chr6:167490870	NA	-0.25	-6.25	-0.32	1.28e-9	Crohn's disease;
LUSC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26314531	chr2:26401878	FAM59B	-0.69	-9.44	-0.46	6.76e-19	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.42	-7.18	-0.37	4.42e-12	Prudent dietary pattern;
LUSC	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg14631576	chr9:95140430	CENPP	-0.35	-6.2	-0.32	1.62e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9346649	0.583	rs4708642	chr6:168491500	G/A	cg02770688	chr6:168491649	NA	0.48	9.01	0.44	1.59e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg16132339	chr22:24313637	DDTL;DDT	-0.41	-6.55	-0.34	2.17e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg13072238	chr3:49761600	GMPPB	0.68	8.78	0.43	8.64e-17	Menarche (age at onset);
LUSC	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	0.88	13.93	0.61	4.47e-35	Pulmonary function decline;
LUSC	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg13390004	chr1:15929781	NA	0.42	7.1	0.36	7.7e-12	Systolic blood pressure;
LUSC	cis	rs4654899	0.758	rs6702331	chr1:21516107	A/T	cg01072550	chr1:21505969	NA	-0.54	-8.26	-0.41	3.44e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg17691542	chr6:26056736	HIST1H1C	0.48	7.16	0.36	5.26e-12	Height;
LUSC	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.67	-0.34	1.08e-10	Monocyte percentage of white cells;
LUSC	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg14196790	chr5:131705035	SLC22A5	0.49	8.43	0.42	1.08e-15	Blood metabolite levels;
LUSC	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg19743168	chr1:23544995	NA	0.41	7.96	0.4	2.75e-14	Height;
LUSC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	9.0	0.44	1.76e-17	Total body bone mineral density;
LUSC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7241530	0.662	rs72987826	chr18:75910795	T/C	cg14642773	chr18:75888474	NA	0.39	5.74	0.3	2.17e-8	Educational attainment (years of education);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg02400238	chr19:44507710	ZNF230	0.52	6.17	0.32	1.94e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs12493885	0.818	rs10935972	chr3:153774029	G/A	cg17054900	chr3:154042577	DHX36	-0.74	-7.55	-0.38	4.06e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg13560548	chr3:10150139	C3orf24	0.5	7.04	0.36	1.07e-11	Alzheimer's disease;
LUSC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg24829409	chr8:58192753	C8orf71	-0.53	-6.17	-0.32	2.03e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg08975724	chr8:8085496	FLJ10661	0.44	6.4	0.33	5.2e-10	Retinal vascular caliber;
LUSC	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg23093090	chr10:104574429	C10orf26	-0.37	-6.91	-0.35	2.51e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17916960	chr15:79447300	NA	-0.52	-10.31	-0.49	7.72e-22	Refractive error;
LUSC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7715806	0.500	rs17563610	chr5:74981322	A/T	cg19683494	chr5:74908142	NA	0.58	7.96	0.4	2.65e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14442939	chr10:27389572	ANKRD26	0.51	6.12	0.32	2.61e-9	Breast cancer;
LUSC	cis	rs1355223	1.000	rs12792532	chr11:34765782	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.84	-0.3	1.22e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.02	0.31	4.49e-9	Menopause (age at onset);
LUSC	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg06740227	chr12:86229804	RASSF9	0.39	6.15	0.32	2.22e-9	Major depressive disorder;
LUSC	cis	rs427941	0.632	rs201502	chr7:101759561	C/T	cg06246474	chr7:101738831	CUX1	-0.36	-5.92	-0.31	7.97e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg19592336	chr6:28129416	ZNF389	0.48	6.29	0.33	1.02e-9	Depression;
LUSC	cis	rs377070	1.000	rs377070	chr4:123629002	G/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.51	7.29	0.37	2.33e-12	Mosquito bite size;
LUSC	cis	rs9815354	0.680	rs73073288	chr3:42027637	G/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg23649088	chr2:200775458	C2orf69	-0.57	-7.01	-0.36	1.33e-11	Schizophrenia;
LUSC	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg25214090	chr10:38739885	LOC399744	0.58	8.45	0.42	9.1e-16	Corneal astigmatism;
LUSC	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg06360820	chr2:242988706	NA	-0.88	-9.7	-0.47	9.02e-20	Obesity-related traits;
LUSC	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg26441486	chr22:50317300	CRELD2	0.43	6.33	0.33	7.83e-10	Schizophrenia;
LUSC	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	1.1	17.23	0.69	4.59e-48	Exhaled nitric oxide output;
LUSC	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg09654669	chr8:57350985	NA	0.49	6.75	0.35	6.5500000000000006e-11	Obesity-related traits;
LUSC	cis	rs12545109	0.765	rs2438063	chr8:57384360	A/G	cg09654669	chr8:57350985	NA	0.58	7.95	0.4	2.92e-14	Obesity-related traits;
LUSC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg09365446	chr1:150670422	GOLPH3L	0.55	8.44	0.42	9.59e-16	Tonsillectomy;
LUSC	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg26536354	chr8:144654954	C8orf73	0.65	7.43	0.38	8.88e-13	Attention deficit hyperactivity disorder;
LUSC	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-10.45	-0.5	2.62e-22	Bladder cancer;
LUSC	cis	rs78572108	0.858	rs4952579	chr2:42264741	C/G	cg00607755	chr2:42274082	PKDCC	0.37	6.56	0.34	2.03e-10	Total body bone mineral density;
LUSC	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg17173187	chr15:85201210	NMB	0.37	6.37	0.33	6.23e-10	Schizophrenia;
LUSC	cis	rs4319547	0.688	rs10847415	chr12:123144293	T/C	cg23029597	chr12:123009494	RSRC2	-0.6	-8.09	-0.4	1.12e-14	Body mass index;
LUSC	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.85	-0.31	1.14e-8	Bipolar disorder;
LUSC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg05110241	chr16:68378359	PRMT7	-0.62	-6.65	-0.34	1.22e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	9.46	0.46	5.6e-19	Coronary artery disease;
LUSC	cis	rs9905704	0.918	rs430973	chr17:56709206	T/G	cg12560992	chr17:57184187	TRIM37	0.56	7.98	0.4	2.41e-14	Testicular germ cell tumor;
LUSC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-6.8	-0.35	4.8e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg02196730	chr15:80188777	MTHFS	0.41	6.18	0.32	1.84e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.67	10.69	0.5	3.99e-23	Body mass index (adult);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08158524	chr12:129308519	SLC15A4	-0.48	-6.47	-0.33	3.44e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg14552801	chr7:65878734	NA	0.44	6.02	0.31	4.68e-9	Aortic root size;
LUSC	trans	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg18187862	chr3:45730750	SACM1L	0.54	7.12	0.36	6.59e-12	Primary sclerosing cholangitis;
LUSC	cis	rs28655083	0.509	rs285024	chr16:77099844	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.38	6.15	0.32	2.24e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.53	-0.38	4.72e-13	Reticulocyte count;
LUSC	cis	rs12620999	0.941	rs10929213	chr2:238020637	A/G	cg23555395	chr2:238036564	NA	-0.54	-8.93	-0.44	2.88e-17	Systemic lupus erythematosus;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18080401	chr12:49365529	WNT10B	0.4	6.09	0.32	3.13e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg05347473	chr6:146136440	FBXO30	0.41	7.06	0.36	9.96e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11696501	0.539	rs6073849	chr20:44299385	A/T	cg03272292	chr12:48577362	C12orf68	0.5	6.1	0.32	2.93e-9	Brain structure;
LUSC	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg04374321	chr14:90722782	PSMC1	0.75	12.22	0.56	1.25e-28	Mortality in heart failure;
LUSC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	1.3	11.93	0.55	1.42e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg19812747	chr11:111475976	SIK2	0.45	6.0	0.31	5.27e-9	Primary sclerosing cholangitis;
LUSC	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg12573674	chr2:1569213	NA	-0.63	-8.74	-0.43	1.15e-16	IgG glycosylation;
LUSC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg02915803	chr1:1606292	LOC728661;CDK11B	-0.4	-6.32	-0.33	8.48e-10	Body mass index;
LUSC	trans	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg25214090	chr10:38739885	LOC399744	0.42	6.3	0.33	9.33e-10	Corneal astigmatism;
LUSC	trans	rs62387962	0.649	rs17055032	chr5:157269721	C/A	cg09066361	chr7:126890254	GRM8	0.48	6.3	0.33	9.58e-10	Platelet distribution width;
LUSC	cis	rs7215564	0.818	rs35059200	chr17:78661619	T/C	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg23711669	chr6:146136114	FBXO30	0.87	16.3	0.67	2.26e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg21609526	chr1:3105151	PRDM16	-0.29	-5.74	-0.3	2.16e-8	Migraine;
LUSC	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg09469691	chr10:81107165	PPIF	0.58	8.75	0.43	1.07e-16	Height;
LUSC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg06784218	chr1:46089804	CCDC17	0.55	11.09	0.52	1.49e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg21770322	chr7:97807741	LMTK2	0.43	7.31	0.37	1.95e-12	Breast cancer;
LUSC	trans	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.72	-0.35	7.69e-11	Endometrial cancer;
LUSC	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg05283184	chr6:79620031	NA	-0.57	-11.99	-0.55	8.45e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.19	0.41	5.48e-15	Axial length;
LUSC	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg05283184	chr6:79620031	NA	-0.58	-12.14	-0.55	2.34e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg11645453	chr3:52864694	ITIH4	0.34	7.92	0.4	3.46e-14	Bipolar disorder;
LUSC	cis	rs250677	0.522	rs4562031	chr5:148368451	A/G	cg18129178	chr5:148520854	ABLIM3	0.54	7.59	0.38	3.13e-13	Breast cancer;
LUSC	cis	rs138229	0.506	rs138233	chr22:50559953	G/A	cg16473166	chr22:50639996	SELO	0.47	5.66	0.3	3.22e-8	Behavioural disinhibition (generation interaction);
LUSC	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg05973401	chr12:123451056	ABCB9	0.53	6.59	0.34	1.73e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6700896	0.500	rs12043254	chr1:66131707	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.93	0.31	7.6e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1395	1.000	rs7593448	chr2:27449293	C/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.39	6.43	0.33	4.44e-10	Blood metabolite levels;
LUSC	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg24631222	chr15:78858424	CHRNA5	-0.65	-8.14	-0.41	7.95e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7589342	0.929	rs7590652	chr2:106440306	A/G	cg16077055	chr2:106428750	NCK2	0.36	6.82	0.35	4.29e-11	Addiction;
LUSC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg02951883	chr7:2050386	MAD1L1	-0.54	-9.83	-0.47	3.41e-20	Schizophrenia;
LUSC	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.32	0.33	8.39e-10	IgG glycosylation;
LUSC	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg03733263	chr8:22462867	KIAA1967	-0.87	-14.08	-0.61	1.11e-35	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.55	0.46	2.95e-19	Prudent dietary pattern;
LUSC	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.41	-5.98	-0.31	5.59e-9	Platelet distribution width;
LUSC	cis	rs11640533	1.000	rs11640533	chr16:53412862	A/G	cg02380802	chr16:53407808	NA	-0.42	-6.48	-0.33	3.32e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	5.84	0.3	1.23e-8	Breast cancer;
LUSC	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg16414030	chr3:133502952	NA	-0.42	-6.47	-0.33	3.44e-10	Iron status biomarkers;
LUSC	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg18753928	chr3:113234510	CCDC52	-0.51	-7.96	-0.4	2.8e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	0.87	13.97	0.61	2.9e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs3768617	0.811	rs12022720	chr1:183017223	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.57	0.42	3.97e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg11812906	chr14:75593930	NEK9	0.66	11.47	0.53	6.48e-26	Height;
LUSC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg23630131	chr7:65973040	NA	-0.21	-5.74	-0.3	2.13e-8	Aortic root size;
LUSC	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg15557168	chr22:42548783	NA	-0.42	-6.49	-0.33	3.16e-10	Schizophrenia;
LUSC	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg21643547	chr1:205240462	TMCC2	-0.39	-7.05	-0.36	1.02e-11	Red blood cell count;
LUSC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg12560992	chr17:57184187	TRIM37	0.81	15.09	0.64	1.3e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.61	-9.82	-0.47	3.67e-20	Longevity;
LUSC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.08	0.55	4.01e-28	Prudent dietary pattern;
LUSC	cis	rs6961069	0.901	rs13236689	chr7:80236014	T/G	cg04458919	chr7:80252533	CD36	-0.35	-6.53	-0.34	2.52e-10	Platelet count;
LUSC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	6.31	0.33	8.7e-10	Personality dimensions;
LUSC	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg00857998	chr1:205179979	DSTYK	0.61	9.23	0.45	3.19e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs12541635	0.677	rs61002083	chr8:106982132	A/G	cg10147462	chr8:107024639	NA	0.66	13.5	0.59	1.99e-33	Age of smoking initiation;
LUSC	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg09092052	chr15:45571596	NA	0.47	6.56	0.34	2.04e-10	Glomerular filtration rate;
LUSC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.5	7.21	0.37	3.75e-12	Coronary heart disease;
LUSC	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-10.52	-0.5	1.46e-22	Morning vs. evening chronotype;
LUSC	cis	rs12295403	0.964	rs61886869	chr11:18688508	C/T	cg09887367	chr11:18690185	NA	-0.34	-7.01	-0.36	1.33e-11	Ovarian reserve;
LUSC	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg09044154	chr16:88155775	NA	-0.55	-7.35	-0.37	1.54e-12	Menopause (age at onset);
LUSC	trans	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg10756647	chr7:56101905	PSPH	0.89	9.05	0.44	1.19e-17	Diabetic kidney disease;
LUSC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg11645453	chr3:52864694	ITIH4	0.37	8.61	0.43	2.99e-16	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03583524	chr22:38239812	ANKRD54	0.49	6.43	0.33	4.33e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.56	-0.42	4.24e-16	Total cholesterol levels;
LUSC	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-7.47	-0.38	7.26e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.61	-9.85	-0.47	2.99e-20	Dilated cardiomyopathy;
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg00024416	chr22:24240387	NA	0.33	5.79	0.3	1.66e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6469656	1.000	rs7007250	chr8:117801441	T/A	cg24004040	chr8:117650383	NA	0.42	5.68	0.3	2.89e-8	Colorectal cancer;
LUSC	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg06784218	chr1:46089804	CCDC17	0.33	6.01	0.31	4.8e-9	Platelet count;
LUSC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg13395646	chr4:1353034	KIAA1530	-0.6	-9.48	-0.46	4.73e-19	Longevity;
LUSC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg05347473	chr6:146136440	FBXO30	0.55	9.38	0.46	1.04e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-8.48	-0.42	7.41e-16	Menopause (age at onset);
LUSC	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.86	-0.44	4.94e-17	Metabolite levels;
LUSC	cis	rs2692947	0.695	rs12464148	chr2:96596710	G/C	cg23100626	chr2:96804247	ASTL	0.23	5.75	0.3	2.05e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg05283184	chr6:79620031	NA	-0.57	-11.99	-0.55	8.81e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs1018836	0.851	rs7014073	chr8:91618548	T/C	cg16814680	chr8:91681699	NA	-0.79	-13.33	-0.59	8.29e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1823874	0.924	rs4965542	chr15:100356619	A/G	cg16400843	chr15:100339927	C15orf51	0.41	8.29	0.41	2.75e-15	IgG glycosylation;
LUSC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25072359	chr17:41440525	NA	0.66	9.42	0.46	7.64e-19	Menopause (age at onset);
LUSC	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.4	-0.38	1.15e-12	Psoriasis;
LUSC	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.54	7.96	0.4	2.77e-14	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg05855489	chr10:104503620	C10orf26	-0.56	-8.63	-0.43	2.55e-16	Arsenic metabolism;
LUSC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	8.29	0.41	2.72e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg27147174	chr7:100797783	AP1S1	-0.56	-8.84	-0.44	5.71e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	trans	rs17807624	0.702	rs7815172	chr8:11453671	T/C	cg15556689	chr8:8085844	FLJ10661	0.47	6.82	0.35	4.39e-11	Systemic lupus erythematosus;
LUSC	cis	rs9503598	0.778	rs1328688	chr6:3468508	G/A	cg00476032	chr6:3446245	SLC22A23	0.39	7.72	0.39	1.38e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03646922	chr17:4167316	ANKFY1	-0.38	-6.65	-0.34	1.21e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	16.58	0.67	1.84e-45	Platelet count;
LUSC	cis	rs4654899	0.758	rs6689852	chr1:21341051	T/C	cg01072550	chr1:21505969	NA	-0.53	-8.16	-0.41	7.06e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.61	10.34	0.49	6.28e-22	Blood metabolite ratios;
LUSC	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.72	0.35	7.96e-11	Educational attainment;
LUSC	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg15133208	chr4:90757351	SNCA	-0.32	-5.66	-0.3	3.23e-8	Dementia with Lewy bodies;
LUSC	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.83	14.43	0.62	5.16e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23158103	chr7:148848205	ZNF398	-0.48	-7.98	-0.4	2.33e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6977660	1.000	rs6973890	chr7:19820497	T/C	cg07541023	chr7:19748670	TWISTNB	0.51	5.73	0.3	2.3e-8	Thyroid stimulating hormone;
LUSC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg24130564	chr14:104152367	KLC1	-0.43	-6.08	-0.32	3.34e-9	Body mass index;
LUSC	trans	rs2048656	0.635	rs7830613	chr8:9649769	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.16	-0.32	2.04e-9	Schizophrenia;
LUSC	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg26394196	chr10:1453818	ADARB2	-0.37	-6.35	-0.33	7.22e-10	Radiation response;
LUSC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg14440974	chr22:39074834	NA	-0.36	-5.96	-0.31	6.56e-9	Menopause (age at onset);
LUSC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.47	7.81	0.39	7.35e-14	Vitiligo;
LUSC	cis	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg06521331	chr12:34319734	NA	-0.47	-7.67	-0.39	1.89e-13	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	14.48	0.62	3.37e-37	Platelet count;
LUSC	cis	rs1485394	0.778	rs2280448	chr12:53896984	G/A	cg20730629	chr12:53886622	MAP3K12	-0.46	-5.91	-0.31	8.49e-9	Electroencephalogram traits;
LUSC	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.38	-0.37	1.27e-12	Bipolar disorder;
LUSC	cis	rs713477	0.967	rs34652660	chr14:55919480	C/A	cg13175173	chr14:55914753	NA	-0.3	-6.21	-0.32	1.59e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg12437481	chr16:420112	MRPL28	0.46	8.27	0.41	3.17e-15	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg23711669	chr6:146136114	FBXO30	0.89	16.81	0.68	2.18e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg14092571	chr14:90743983	NA	0.37	5.76	0.3	1.86e-8	Mortality in heart failure;
LUSC	trans	rs7538876	0.903	rs6681150	chr1:17750685	G/A	cg13009662	chr5:127419527	SLC12A2;FLJ33630	0.41	6.02	0.31	4.53e-9	Basal cell carcinoma;
LUSC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg00031303	chr3:195681400	NA	0.67	9.4	0.46	8.94e-19	Pancreatic cancer;
LUSC	cis	rs9372253	0.843	rs28721292	chr6:110719631	T/C	cg19196401	chr6:110721138	DDO	-0.46	-8.62	-0.43	2.78e-16	Platelet distribution width;
LUSC	cis	rs710216	0.917	rs710223	chr1:43411038	C/G	cg03128534	chr1:43423976	SLC2A1	0.51	6.45	0.33	3.9e-10	Red cell distribution width;
LUSC	cis	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.3	-0.33	9.13e-10	Morning vs. evening chronotype;
LUSC	cis	rs6460942	0.908	rs6948654	chr7:12418546	T/A	cg06484146	chr7:12443880	VWDE	-0.72	-7.24	-0.37	3.15e-12	Coronary artery disease;
LUSC	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg19743168	chr1:23544995	NA	0.39	7.14	0.36	5.75e-12	Height;
LUSC	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg06640241	chr16:89574553	SPG7	0.72	11.35	0.53	1.88e-25	Multiple myeloma (IgH translocation);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20798677	chr17:39968547	FKBP10;SC65	-0.48	-6.46	-0.33	3.63e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-9.64	-0.47	1.4e-19	Body mass index;
LUSC	cis	rs2742417	0.967	rs1534875	chr3:45741043	T/G	cg04837898	chr3:45731254	SACM1L	-0.34	-5.65	-0.3	3.43e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg05313129	chr8:58192883	C8orf71	-0.5	-6.51	-0.34	2.8e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.17	-0.41	6.57e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-1.12	-25.08	-0.81	8.21e-79	Height;
LUSC	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-7.78	-0.39	9.04e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	8.49	0.42	6.67e-16	Total cholesterol levels;
LUSC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg13395646	chr4:1353034	KIAA1530	-0.6	-9.4	-0.46	8.77e-19	Longevity;
LUSC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.83	11.47	0.53	6.46e-26	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg01616529	chr11:638424	DRD4	-0.35	-6.02	-0.31	4.64e-9	Systemic lupus erythematosus;
LUSC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08048268	chr3:133502702	NA	-0.46	-8.87	-0.44	4.36e-17	Iron status biomarkers;
LUSC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg02018176	chr4:1364513	KIAA1530	0.54	9.57	0.46	2.55e-19	Longevity;
LUSC	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg18721089	chr20:30220636	NA	-0.41	-6.06	-0.31	3.77e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10254974	chr17:16342133	NCRNA00188;SNORD49B;SNORD49A	0.41	6.02	0.31	4.67e-9	Triglycerides;
LUSC	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg05738196	chr6:26577821	NA	0.82	15.82	0.65	1.9e-42	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19970425	chr15:55581976	RAB27A	-0.42	-5.99	-0.31	5.52e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg22676075	chr6:135203613	NA	0.46	7.27	0.37	2.56e-12	Red blood cell count;
LUSC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.75	0.3	2.02e-8	Personality dimensions;
LUSC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg26659404	chr1:25747437	RHCE	-0.28	-5.74	-0.3	2.1e-8	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs2354432	0.556	rs2883319	chr1:146838177	A/G	cg25205988	chr1:146714368	CHD1L	-0.89	-7.57	-0.38	3.65e-13	Mitochondrial DNA levels;
LUSC	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg17168535	chr8:21777572	XPO7	0.85	15.69	0.65	5.73e-42	Mean corpuscular volume;
LUSC	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg23711669	chr6:146136114	FBXO30	0.85	15.11	0.64	1.11e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.12	-0.41	9.13e-15	Lung cancer;
LUSC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.16	0.55	2.09e-28	Prudent dietary pattern;
LUSC	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.37	6.16	0.32	2.11e-9	Cystic fibrosis severity;
LUSC	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26314531	chr2:26401878	FAM59B	-0.67	-9.29	-0.45	2.03e-18	Gut microbiome composition (summer);
LUSC	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.61	7.2	0.37	4.07e-12	Crohn's disease;
LUSC	cis	rs727505	1.000	rs10233385	chr7:124498707	C/G	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	trans	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg12856521	chr11:46389249	DGKZ	0.44	6.49	0.33	3.11e-10	Leprosy;
LUSC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.57	10.8	0.51	1.61e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8113142	0.614	rs73023299	chr19:29207298	T/G	cg04546413	chr19:29218101	NA	0.47	6.27	0.32	1.09e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg11845111	chr2:191398756	TMEM194B	-0.83	-11.14	-0.52	1e-24	Diastolic blood pressure;
LUSC	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg26408565	chr15:76604113	ETFA	0.46	7.32	0.37	1.84e-12	Blood metabolite levels;
LUSC	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg24209194	chr3:40518798	ZNF619	0.47	6.58	0.34	1.87e-10	Renal cell carcinoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22779477	chr10:127408223	C10orf137	-0.41	-6.09	-0.32	3.03e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg22907277	chr7:1156413	C7orf50	0.68	7.31	0.37	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg06194479	chr1:118472240	GDAP2;WDR3	0.36	5.94	0.31	7e-9	Asthma;
LUSC	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg08213375	chr14:104286397	PPP1R13B	0.43	8.28	0.41	3.05e-15	Schizophrenia;
LUSC	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg02017074	chr12:117425053	FBXW8	0.66	7.77	0.39	9.54e-14	Subcortical brain region volumes;Hippocampal volume;
LUSC	cis	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg02972257	chr16:68554789	NA	0.42	5.85	0.3	1.19e-8	Colorectal cancer;
LUSC	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg18099408	chr3:52552593	STAB1	0.36	6.04	0.31	4.2e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Colorectal cancer;
LUSC	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-5.96	-0.31	6.58e-9	Neutrophil percentage of white cells;
LUSC	cis	rs240110	0.525	rs6917195	chr6:101277926	C/T	cg09795085	chr6:101329169	ASCC3	0.44	6.18	0.32	1.82e-9	Neuroticism;
LUSC	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg21545522	chr1:205238299	TMCC2	0.46	8.52	0.42	5.56e-16	Red blood cell count;
LUSC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	10.47	0.5	2.27e-22	Monocyte percentage of white cells;
LUSC	cis	rs7552167	0.925	rs3932664	chr1:24511663	G/T	cg01960748	chr1:24522592	NA	-0.7	-10.87	-0.51	9.08e-24	Psoriasis vulgaris;
LUSC	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg01689657	chr7:91764605	CYP51A1	0.31	5.66	0.3	3.26e-8	Breast cancer;
LUSC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg17644776	chr2:200775616	C2orf69	0.49	7.97	0.4	2.55e-14	Osteoporosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20001219	chr13:99101692	FARP1	0.42	5.94	0.31	7.04e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26314531	chr2:26401878	FAM59B	-0.73	-10.21	-0.49	1.79e-21	Gut microbiome composition (summer);
LUSC	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.21	-0.49	1.74e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg05110241	chr16:68378359	PRMT7	-0.55	-6.05	-0.31	3.81e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg20243544	chr17:37824526	PNMT	0.49	6.88	0.35	3.02e-11	Asthma;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg23034840	chr1:205782522	SLC41A1	0.57	7.9	0.4	3.97e-14	Menarche (age at onset);
LUSC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6987853	0.761	rs2974356	chr8:42434633	C/T	cg09913449	chr8:42400586	C8orf40	0.53	9.23	0.45	3.26e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.52	-0.42	5.65e-16	Type 2 diabetes;
LUSC	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg04725166	chr1:7887271	PER3	-0.45	-6.4	-0.33	5.4e-10	Crohn's disease;
LUSC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-6.34	-0.33	7.64e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6545883	0.862	rs778141	chr2:61682178	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-6.41	-0.33	5.01e-10	Tuberculosis;
LUSC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg25039879	chr17:56429692	SUPT4H1	0.68	9.14	0.45	6.1e-18	Cognitive test performance;
LUSC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg25344623	chr2:136566232	LCT	0.39	5.94	0.31	6.99e-9	Mosquito bite size;
LUSC	trans	rs1998174	0.509	rs1118173	chr1:171830704	C/T	cg13482142	chr2:234261155	NA	0.42	6.09	0.32	3.11e-9	Platelet distribution width;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg06538774	chr22:24584247	SUSD2	-0.38	-6.1	-0.32	2.86e-9	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs488628	1.000	rs540615	chr3:118138699	A/C	cg06621744	chr14:37052470	NKX2-8	-0.29	-6.68	-0.34	1.02e-10	White matter integrity (bipolar disorder risk interaction);
LUSC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg06641503	chr3:48959341	ARIH2	-0.38	-5.77	-0.3	1.83e-8	Parkinson's disease;
LUSC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.47	-8.19	-0.41	5.67e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11644478	chr21:40555479	PSMG1	-0.62	-9.49	-0.46	4.7e-19	Menarche (age at onset);
LUSC	cis	rs5758511	0.773	rs12167978	chr22:42346475	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.49	-6.02	-0.31	4.65e-9	Birth weight;
LUSC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	1.04	16.52	0.67	3.21e-45	Testicular germ cell tumor;
LUSC	cis	rs9467160	0.734	rs35901848	chr6:24443640	G/A	cg20631270	chr6:24437470	GPLD1	0.44	6.1	0.32	2.99e-9	Liver enzyme levels;
LUSC	cis	rs941898	0.574	rs8006662	chr14:100577890	C/T	cg26002632	chr14:100625216	DEGS2	0.33	5.64	0.3	3.56e-8	White matter hyperintensity burden;
LUSC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg13607699	chr17:42295918	UBTF	0.56	8.53	0.42	5.32e-16	Total body bone mineral density;
LUSC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg23188684	chr11:67383651	NA	0.35	6.33	0.33	7.98e-10	Mean corpuscular volume;
LUSC	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg06484146	chr7:12443880	VWDE	-0.73	-7.34	-0.37	1.64e-12	Coronary artery disease;
LUSC	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg13010199	chr12:38710504	ALG10B	0.48	7.28	0.37	2.47e-12	Heart rate;
LUSC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg04287289	chr16:89883240	FANCA	0.77	6.21	0.32	1.57e-9	Skin colour saturation;
LUSC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg09323728	chr8:95962352	TP53INP1	-0.38	-7.71	-0.39	1.48e-13	Type 2 diabetes;
LUSC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg17376030	chr22:41985996	PMM1	-0.46	-5.73	-0.3	2.21e-8	Vitiligo;
LUSC	cis	rs55883249	1.000	rs62119429	chr2:9743585	G/C	cg23886495	chr2:9695866	ADAM17	0.49	5.78	0.3	1.71e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22105146	chr4:56262445	TMEM165	-0.42	-6.56	-0.34	2.06e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10144321	0.903	rs4905958	chr14:100924288	A/G	cg14882082	chr14:100845427	WDR25	-0.42	-8.11	-0.41	9.73e-15	Menarche (age at onset);
LUSC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	trans	rs7495211	0.529	rs11247366	chr15:98624159	T/A	cg08901157	chr15:56033728	PRTG	0.35	6.2	0.32	1.7e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs727505	0.754	rs55859595	chr7:124783083	G/T	cg23710748	chr7:124431027	NA	-0.41	-7.13	-0.36	6.25e-12	Lewy body disease;
LUSC	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.44	-7.03	-0.36	1.16e-11	Tonsillectomy;
LUSC	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg12002119	chr2:101014098	CHST10	0.38	6.39	0.33	5.68e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg16584290	chr5:462447	EXOC3	0.46	8.15	0.41	7.32e-15	Cystic fibrosis severity;
LUSC	cis	rs7424096	0.555	rs75219072	chr2:37225706	C/T	cg14987922	chr2:37194071	STRN	0.61	8.21	0.41	4.87e-15	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	10.8	0.51	1.65e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg03563238	chr19:33554763	RHPN2	-0.37	-6.34	-0.33	7.24e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg11530693	chr1:120165357	ZNF697	0.69	10.79	0.51	1.79e-23	Systemic lupus erythematosus;
LUSC	cis	rs6542838	0.641	rs6760065	chr2:99486318	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.36	-0.33	6.61e-10	Fear of minor pain;
LUSC	trans	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.02	-0.31	4.72e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs2261181	0.803	rs2612065	chr12:66172771	G/C	cg19918230	chr2:219745647	WNT10A	-0.54	-5.98	-0.31	5.88e-9	Type 2 diabetes;
LUSC	cis	rs870825	0.616	rs28375770	chr4:185647395	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.64	-8.16	-0.41	6.69e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.73	0.39	1.3e-13	Electroencephalogram traits;
LUSC	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg05043794	chr9:111880884	C9orf5	-0.34	-7.2	-0.37	3.89e-12	Menarche (age at onset);
LUSC	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg11812906	chr14:75593930	NEK9	0.39	5.76	0.3	1.91e-8	Caffeine consumption;
LUSC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.46	6.11	0.32	2.81e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg20503657	chr10:835505	NA	0.78	9.74	0.47	6.96e-20	Eosinophil percentage of granulocytes;
LUSC	trans	rs2562456	0.833	rs4644962	chr19:21520927	C/T	cg00806126	chr19:22604979	ZNF98	-0.43	-6.21	-0.32	1.6e-9	Pain;
LUSC	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg13072238	chr3:49761600	GMPPB	-0.63	-7.95	-0.4	2.93e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	10.77	0.51	2.08e-23	Hip circumference adjusted for BMI;
LUSC	cis	rs10276381	0.786	rs10281102	chr7:28243473	A/G	cg23620719	chr7:28220237	JAZF1	0.64	6.7	0.34	8.86e-11	Crohn's disease;
LUSC	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.45	-0.42	8.92e-16	Schizophrenia;
LUSC	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg04508216	chr1:11107452	MASP2	0.31	5.67	0.3	3.17e-8	Body mass index;
LUSC	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	7.04	0.36	1.07e-11	Schizophrenia;
LUSC	cis	rs9296092	0.517	rs7743445	chr6:33470600	G/T	cg13560919	chr6:33536144	NA	-0.78	-13.33	-0.59	8.65e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22618164	chr12:122356400	WDR66	-0.5	-7.22	-0.37	3.64e-12	Mean corpuscular volume;
LUSC	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg05973401	chr12:123451056	ABCB9	0.52	6.58	0.34	1.85e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.74	-12.09	-0.55	3.73e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg17366294	chr4:99064904	C4orf37	0.55	9.77	0.47	5.18e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg18402987	chr7:1209562	NA	0.7	8.02	0.4	1.78e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	0.99	14.2	0.61	3.83e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg00376283	chr12:123451042	ABCB9	0.69	9.71	0.47	8.35e-20	Height;Educational attainment;Head circumference (infant);
LUSC	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.35	-0.33	7.06e-10	Systolic blood pressure;
LUSC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg00945038	chr17:61921165	SMARCD2	0.4	6.03	0.31	4.3e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7216064	1.000	rs7221651	chr17:65832390	A/G	cg12091567	chr17:66097778	LOC651250	0.71	8.95	0.44	2.49e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.54	-0.38	4.33e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00415308	chr7:77427774	PHTF2;TMEM60	0.41	6.25	0.32	1.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10879418	chr16:81479272	CMIP	-0.46	-6.13	-0.32	2.43e-9	Hepatitis;
LUSC	cis	rs11971779	0.590	rs6467839	chr7:139062790	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.18	0.32	1.85e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg25233709	chr10:116636983	FAM160B1	0.37	6.18	0.32	1.87e-9	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9837602	1.000	rs9864437	chr3:99764754	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.09	-0.32	3.14e-9	Breast cancer;
LUSC	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg23241863	chr10:102295624	HIF1AN	0.47	5.71	0.3	2.49e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg15704280	chr7:45808275	SEPT13	0.74	8.4	0.42	1.26e-15	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg09904177	chr6:26538194	HMGN4	-0.78	-6.06	-0.31	3.58e-9	Depression;
LUSC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.47	0.33	3.44e-10	Platelet count;
LUSC	cis	rs1003719	0.715	rs2251952	chr21:38559711	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-9.99	-0.48	9.79e-21	Eye color traits;
LUSC	cis	rs16937	0.711	rs11240388	chr1:205177617	G/A	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.36e-10	Schizophrenia;
LUSC	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg09998033	chr7:158218633	PTPRN2	0.48	7.59	0.38	3.2e-13	Obesity-related traits;
LUSC	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg19773385	chr1:10388646	KIF1B	-0.58	-10.05	-0.48	6.12e-21	Hepatocellular carcinoma;
LUSC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg06238570	chr21:40685208	BRWD1	0.48	7.49	0.38	6.18e-13	Cognitive function;
LUSC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg11843238	chr5:131593191	PDLIM4	-0.38	-6.07	-0.32	3.54e-9	Breast cancer;
LUSC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	13.7	0.6	3.4e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.46	0.53	7.26e-26	Menopause (age at onset);
LUSC	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-5.97	-0.31	6.08e-9	Ulcerative colitis;
LUSC	cis	rs41271473	0.948	rs11585206	chr1:228824848	C/T	cg16512390	chr1:228756714	NA	0.54	6.22	0.32	1.5e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg13902645	chr11:5959945	NA	-0.6	-8.44	-0.42	9.71e-16	DNA methylation (variation);
LUSC	cis	rs10203711	1.000	rs13028091	chr2:239569723	C/T	cg14580085	chr2:239553406	NA	0.42	7.11	0.36	7.05e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1143633	0.579	rs3811042	chr2:113670834	G/A	cg06156847	chr2:113672199	IL1F7	0.28	6.02	0.31	4.65e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg24851651	chr11:66362959	CCS	-0.36	-5.73	-0.3	2.25e-8	Educational attainment (years of education);
LUSC	cis	rs2652834	1.000	rs2652833	chr15:63396885	C/A	cg05507819	chr15:63340323	TPM1	0.68	8.27	0.41	3.21e-15	HDL cholesterol;
LUSC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg18681998	chr4:17616180	MED28	0.84	15.29	0.64	2.27e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17604090	1.000	rs28591682	chr7:29690811	T/C	cg19413766	chr7:29689036	LOC646762	-0.64	-7.69	-0.39	1.69e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg06623918	chr6:96969491	KIAA0776	0.73	8.64	0.43	2.33e-16	Migraine;Coronary artery disease;
LUSC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg09796270	chr17:17721594	SREBF1	-0.4	-6.98	-0.36	1.55e-11	Total body bone mineral density;
LUSC	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg17507749	chr15:85114479	UBE2QP1	0.65	8.25	0.41	3.75e-15	Schizophrenia;
LUSC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.94	-12.67	-0.57	2.62e-30	Alzheimer's disease;
LUSC	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.36	-0.37	1.44e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg06627557	chr7:32535165	LSM5;AVL9	1.0	17.05	0.68	2.4e-47	Cognitive ability;
LUSC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg26335602	chr6:28129616	ZNF389	0.43	5.8	0.3	1.54e-8	Depression;
LUSC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.57	-8.8	-0.43	7.23e-17	Neurofibrillary tangles;
LUSC	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-0.88	-13.32	-0.59	9.52e-33	Asthma;
LUSC	cis	rs9398803	0.865	rs9401882	chr6:126755055	A/G	cg19875578	chr6:126661172	C6orf173	0.41	6.11	0.32	2.81e-9	Male-pattern baldness;
LUSC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg12386194	chr3:101231763	SENP7	-0.43	-6.33	-0.33	7.76e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs983392	0.678	rs1426253	chr11:59981218	A/C	cg02771260	chr11:59836817	MS4A3	-0.36	-5.96	-0.31	6.46e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	8.82	0.43	6.31e-17	Bipolar disorder;
LUSC	trans	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg26043149	chr18:55253948	FECH	0.42	6.42	0.33	4.78e-10	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs911119	1.000	rs13039536	chr20:23612305	A/G	cg16589663	chr20:23618590	CST3	0.59	6.87	0.35	3.15e-11	Chronic kidney disease;
LUSC	cis	rs1577917	0.916	rs12661611	chr6:86553835	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-6.17	-0.32	1.97e-9	Response to antipsychotic treatment;
LUSC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg01420254	chr6:26195488	NA	0.64	7.28	0.37	2.35e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg00825309	chr19:58991885	ZNF446	-0.5	-7.23	-0.37	3.37e-12	Uric acid clearance;
LUSC	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg14993813	chr1:46806288	NSUN4	-0.5	-6.91	-0.35	2.4e-11	Menopause (age at onset);
LUSC	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg20356878	chr3:121714668	ILDR1	-0.45	-6.31	-0.33	9.09e-10	Multiple sclerosis;
LUSC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26314531	chr2:26401878	FAM59B	0.74	10.13	0.48	3.38e-21	Gut microbiome composition (summer);
LUSC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg25214090	chr10:38739885	LOC399744	0.54	7.98	0.4	2.39e-14	Corneal astigmatism;
LUSC	cis	rs713477	0.967	rs7146170	chr14:55914054	G/C	cg13175173	chr14:55914753	NA	-0.31	-6.49	-0.33	3.05e-10	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.0	0.31	5.02e-9	Corneal astigmatism;
LUSC	cis	rs231513	0.954	rs231500	chr17:41973374	T/C	cg26893861	chr17:41843967	DUSP3	-0.5	-6.07	-0.32	3.42e-9	Cognitive function;
LUSC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg05623727	chr3:50126028	RBM5	0.31	5.82	0.3	1.37e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2235544	0.565	rs633315	chr1:54468689	G/A	cg25741118	chr1:54482237	LDLRAD1	0.28	5.98	0.31	5.61e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg03647239	chr10:116582469	FAM160B1	0.45	7.19	0.37	4.38e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg02423579	chr7:2872169	GNA12	-0.45	-6.62	-0.34	1.42e-10	Height;
LUSC	cis	rs7582720	1.000	rs72926796	chr2:203827480	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg05340658	chr4:99064831	C4orf37	0.43	6.71	0.34	8.57e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg16898833	chr6:26189333	HIST1H4D	0.78	6.03	0.31	4.37e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg09904177	chr6:26538194	HMGN4	-0.76	-5.7	-0.3	2.63e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11676348	0.772	rs6738953	chr2:218950036	C/A	cg00012203	chr2:219082015	ARPC2	-0.51	-7.88	-0.4	4.72e-14	Ulcerative colitis;
LUSC	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg11812906	chr14:75593930	NEK9	-0.53	-8.67	-0.43	1.94e-16	Coronary artery disease;
LUSC	cis	rs10193935	1.000	rs4048	chr2:42424595	A/C	cg27598129	chr2:42591480	NA	-0.66	-8.69	-0.43	1.7e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg13852791	chr20:30311386	BCL2L1	0.83	10.26	0.49	1.16e-21	Mean corpuscular hemoglobin;
LUSC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.69	10.66	0.5	5.11e-23	Coronary artery disease;
LUSC	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg02782426	chr3:40428986	ENTPD3	0.33	6.15	0.32	2.21e-9	Renal cell carcinoma;
LUSC	trans	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.79	-0.35	5.1e-11	Monocyte count;
LUSC	cis	rs4776059	0.958	rs35505902	chr15:52888493	A/G	cg22715398	chr15:52968154	KIAA1370	-0.71	-10.09	-0.48	4.56e-21	Schizophrenia;
LUSC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg11608241	chr8:8085544	FLJ10661	0.44	6.32	0.33	8.37e-10	Systolic blood pressure;
LUSC	cis	rs1697139	0.583	rs11739587	chr5:66540481	A/C	cg11553311	chr5:66541588	NA	-0.31	-5.86	-0.31	1.09e-8	Breast cancer;
LUSC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg10729496	chr3:10149963	C3orf24	0.56	7.55	0.38	4.22e-13	Alzheimer's disease;
LUSC	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg17385448	chr1:15911702	AGMAT	0.37	6.23	0.32	1.42e-9	Systolic blood pressure;
LUSC	cis	rs6460942	0.630	rs17671056	chr7:12390961	C/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.87	-0.31	1.05e-8	Coronary artery disease;
LUSC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08219700	chr8:58056026	NA	0.66	7.44	0.38	8.4e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg05340658	chr4:99064831	C4orf37	0.62	9.69	0.47	1.01e-19	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg25214090	chr10:38739885	LOC399744	0.53	7.71	0.39	1.46e-13	Corneal astigmatism;
LUSC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-0.87	-15.87	-0.66	1.17e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.64	0.63	8.06e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg24562669	chr7:97807699	LMTK2	0.35	6.11	0.32	2.75e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg15371732	chr17:78194151	SLC26A11;SGSH	0.41	6.27	0.32	1.13e-9	Cystic fibrosis severity;
LUSC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.8	0.35	4.94e-11	Depression;
LUSC	cis	rs17490626	0.568	rs12413525	chr10:71211721	C/A	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.43	-0.46	7e-19	Thrombosis;
LUSC	cis	rs11169552	0.510	rs4768899	chr12:51000666	T/A	cg12884762	chr12:50931848	DIP2B	-0.31	-5.66	-0.3	3.23e-8	Colorectal cancer;
LUSC	cis	rs2637266	0.783	rs10824437	chr10:78469493	C/T	cg18941641	chr10:78392320	NA	0.35	6.32	0.33	8.42e-10	Pulmonary function;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11513088	chr12:26111821	RASSF8	-0.42	-6.04	-0.31	4.12e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4474465	1.000	rs7124092	chr11:78155086	T/C	cg27205649	chr11:78285834	NARS2	-0.51	-6.08	-0.32	3.31e-9	Alzheimer's disease (survival time);
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg17541715	chr7:1216824	NA	-0.37	-5.88	-0.31	9.89e-9	Longevity;Endometriosis;
LUSC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-7.42	-0.38	9.48e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg14458575	chr2:238380390	NA	-0.64	-11.54	-0.53	3.64e-26	Prostate cancer;
LUSC	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg02023728	chr11:77925099	USP35	0.44	6.7	0.34	8.71e-11	Testicular germ cell tumor;
LUSC	cis	rs500891	0.574	rs3798891	chr6:84117293	C/A	cg08257003	chr6:84140564	ME1	0.36	8.74	0.43	1.14e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg21573476	chr21:45109991	RRP1B	-0.39	-6.26	-0.32	1.21e-9	Mean corpuscular volume;
LUSC	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg22029157	chr1:209979665	IRF6	0.73	8.97	0.44	2.23e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg02972257	chr16:68554789	NA	-0.5	-6.36	-0.33	6.76e-10	Ulcerative colitis;
LUSC	cis	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg02508848	chr16:68573721	ZFP90	-0.43	-5.75	-0.3	2e-8	Ulcerative colitis;
LUSC	cis	rs7605827	0.930	rs6722963	chr2:15527105	C/T	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg22705602	chr4:152727874	NA	-0.31	-6.19	-0.32	1.81e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg21775007	chr8:11205619	TDH	-0.54	-8.02	-0.4	1.82e-14	Retinal vascular caliber;
LUSC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg16797656	chr11:68205561	LRP5	-0.4	-7.29	-0.37	2.26e-12	Total body bone mineral density;
LUSC	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg04310649	chr10:35416472	CREM	-0.42	-6.43	-0.33	4.4e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7178572	0.568	rs11853460	chr15:77515319	C/T	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg11645453	chr3:52864694	ITIH4	0.35	8.1	0.41	1.07e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs500891	0.525	rs2096223	chr6:84077446	T/G	cg08257003	chr6:84140564	ME1	0.35	8.63	0.43	2.58e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs981844	1.000	rs56232929	chr4:154665700	A/G	cg14289246	chr4:154710475	SFRP2	0.47	5.86	0.31	1.14e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.45	9.46	0.46	5.89e-19	Airflow obstruction;
LUSC	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg03732007	chr1:2071316	PRKCZ	0.46	7.36	0.37	1.48e-12	Height;
LUSC	cis	rs3755132	0.852	rs56002839	chr2:15790440	G/A	cg12888861	chr2:15731646	DDX1	0.48	7.11	0.36	7.01e-12	Wilms tumor;
LUSC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-8.6	-0.43	3.13e-16	Hemoglobin concentration;
LUSC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16405210	chr4:1374714	KIAA1530	0.71	11.0	0.52	3.21e-24	Obesity-related traits;
LUSC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg05855489	chr10:104503620	C10orf26	-0.62	-8.09	-0.4	1.15e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.62	11.08	0.52	1.59e-24	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg14004847	chr7:1930337	MAD1L1	-0.56	-8.71	-0.43	1.46e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg26893861	chr17:41843967	DUSP3	0.86	13.17	0.58	3.36e-32	Triglycerides;
LUSC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10802521	chr3:52805072	NEK4	-0.48	-7.54	-0.38	4.41e-13	Cognitive function;
LUSC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-0.85	-15.6	-0.65	1.33e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg24397884	chr7:158709396	WDR60	0.8	9.04	0.44	1.31e-17	Height;
LUSC	cis	rs17818399	0.620	rs6544906	chr2:46863872	A/C	cg21493583	chr2:46842958	PIGF;CRIPT	0.34	6.12	0.32	2.63e-9	Height;
LUSC	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.82	-14.55	-0.62	1.77e-37	Sudden cardiac arrest;
LUSC	trans	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.99	-0.31	5.47e-9	Dementia with Lewy bodies;
LUSC	cis	rs8179	0.645	rs56201652	chr7:92278116	G/A	cg15732164	chr7:92237376	CDK6	-0.4	-6.01	-0.31	4.86e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.44	6.0	0.31	5.27e-9	Tonsillectomy;
LUSC	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05901451	chr6:126070800	HEY2	-0.59	-8.88	-0.44	4.04e-17	Endometrial cancer;
LUSC	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.5	-9.63	-0.47	1.52e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs977987	0.843	rs6564259	chr16:75447393	T/G	cg03315344	chr16:75512273	CHST6	0.48	8.92	0.44	3.16e-17	Dupuytren's disease;
LUSC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07234876	chr8:600039	NA	-0.9	-8.86	-0.44	4.9e-17	IgG glycosylation;
LUSC	cis	rs5771242	0.518	rs7290465	chr22:50679758	C/T	cg16473166	chr22:50639996	SELO	-0.7	-9.88	-0.48	2.28e-20	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LUSC	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg19196401	chr6:110721138	DDO	-0.41	-7.67	-0.39	1.88e-13	Platelet distribution width;
LUSC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg03526776	chr6:41159608	TREML2	0.34	6.65	0.34	1.19e-10	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-7.35	-0.37	1.5e-12	Aortic root size;
LUSC	cis	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg02972257	chr16:68554789	NA	-0.53	-6.6	-0.34	1.64e-10	Ulcerative colitis;
LUSC	cis	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg05901451	chr6:126070800	HEY2	0.57	8.76	0.43	1.03e-16	Endometrial cancer;
LUSC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg05082376	chr22:42548792	NA	-0.41	-6.32	-0.33	8.57e-10	Schizophrenia;
LUSC	cis	rs7241530	0.662	rs55745067	chr18:75902055	A/G	cg14642773	chr18:75888474	NA	0.41	6.27	0.32	1.14e-9	Educational attainment (years of education);
LUSC	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg23711669	chr6:146136114	FBXO30	0.73	12.89	0.58	3.92e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19717773	chr7:2847554	GNA12	0.41	6.91	0.35	2.51e-11	Height;
LUSC	cis	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.43	-0.42	1.05e-15	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.19	-29.28	-0.85	2.92e-94	Chronic sinus infection;
LUSC	cis	rs35306767	0.623	rs56201968	chr10:1141666	A/G	cg20503657	chr10:835505	NA	0.48	6.2	0.32	1.67e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs929596	0.564	rs2602364	chr2:234524229	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-6.41	-0.33	4.85e-10	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg26395211	chr5:140044315	WDR55	0.46	7.1	0.36	7.64e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg11843238	chr5:131593191	PDLIM4	0.4	6.67	0.34	1.04e-10	Breast cancer;
LUSC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg00945038	chr17:61921165	SMARCD2	0.53	8.91	0.44	3.28e-17	Prudent dietary pattern;
LUSC	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg11657440	chr19:46296263	DMWD	-0.73	-11.19	-0.52	6.89e-25	Coronary artery disease;
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.66	10.84	0.51	1.19e-23	Lymphocyte counts;
LUSC	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg24397884	chr7:158709396	WDR60	0.8	8.96	0.44	2.34e-17	Height;
LUSC	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.65	-0.3	3.46e-8	Ileal carcinoids;
LUSC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08677398	chr8:58056175	NA	0.53	7.05	0.36	1.04e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07741184	chr6:167504864	NA	-0.39	-6.94	-0.35	2.07e-11	Primary biliary cholangitis;
LUSC	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg13042288	chr15:90349979	ANPEP	-0.48	-6.77	-0.35	5.86e-11	Uric acid levels;
LUSC	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg00376283	chr12:123451042	ABCB9	0.65	8.3	0.41	2.63e-15	Neutrophil percentage of white cells;
LUSC	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg20701182	chr2:24300061	SF3B14	0.78	7.8	0.39	7.8500000000000006e-14	Lymphocyte counts;
LUSC	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg14530993	chr4:882597	GAK	0.72	7.41	0.38	1.07e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-6.87	-0.35	3.18e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg06046430	chr4:77819534	ANKRD56	0.48	6.88	0.35	2.88e-11	Emphysema distribution in smoking;
LUSC	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg00383909	chr3:49044727	WDR6	1.12	10.38	0.49	4.73e-22	Cognitive function;
LUSC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg12639453	chr1:2035780	PRKCZ	-0.3	-6.32	-0.33	8.39e-10	Height;
LUSC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.18	0.55	1.66e-28	Motion sickness;
LUSC	trans	rs11700980	0.551	rs11701783	chr21:30115629	C/G	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg23791538	chr6:167370224	RNASET2	-0.41	-6.54	-0.34	2.25e-10	Crohn's disease;
LUSC	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg09307838	chr4:120376055	NA	0.57	8.56	0.42	4.04e-16	Diastolic blood pressure;
LUSC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg06238570	chr21:40685208	BRWD1	-0.62	-10.31	-0.49	8e-22	Cognitive function;
LUSC	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	7.13	0.36	6.3e-12	IgG glycosylation;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg05700333	chr5:131892723	RAD50	-0.47	-6.27	-0.32	1.12e-9	Height;
LUSC	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.34	-0.42	1.98e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.14	-0.32	2.35e-9	Coronary artery disease;
LUSC	trans	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg02800362	chr5:177631904	HNRNPAB	0.87	12.81	0.57	8.07e-31	Obesity-related traits;
LUSC	cis	rs11214589	0.747	rs10891536	chr11:113209428	C/G	cg14159747	chr11:113255604	NA	0.24	5.8	0.3	1.51e-8	Neuroticism;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21744723	chr5:34839210	TTC23L	0.72	6.23	0.32	1.4e-9	Cognitive performance;
LUSC	cis	rs4561483	0.734	rs33655	chr16:11970381	C/T	cg08843971	chr16:11963173	GSPT1	-0.47	-7.03	-0.36	1.14e-11	Testicular germ cell tumor;
LUSC	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14019695	chr9:139328340	INPP5E	0.5	9.64	0.47	1.41e-19	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg23277830	chr1:3704460	LRRC47	0.3	5.73	0.3	2.22e-8	Red cell distribution width;
LUSC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.27	-0.62	2.03e-36	Eye color traits;
LUSC	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg23625390	chr15:77176239	SCAPER	0.46	6.87	0.35	3.09e-11	Blood metabolite levels;
LUSC	trans	rs12677056	0.746	rs61189440	chr8:113314753	T/G	cg12159992	chr12:102059490	MYBPC1	0.36	5.98	0.31	5.78e-9	Peripheral artery disease;
LUSC	cis	rs12145833	0.665	rs78871868	chr1:243422322	C/T	cg02356786	chr1:243265016	LOC731275	0.68	6.23	0.32	1.41e-9	Obesity (early onset extreme);
LUSC	cis	rs6543140	0.865	rs6760275	chr2:103079607	C/T	cg09003973	chr2:102972529	NA	0.54	6.87	0.35	3.16e-11	Blood protein levels;
LUSC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg23711669	chr6:146136114	FBXO30	0.89	17.09	0.68	1.64e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1018697	0.966	rs1953930	chr10:104549461	G/A	cg04362960	chr10:104952993	NT5C2	0.48	6.64	0.34	1.25e-10	Colorectal adenoma (advanced);
LUSC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg02269571	chr22:50332266	NA	0.59	8.72	0.43	1.32e-16	Schizophrenia;
LUSC	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg18753928	chr3:113234510	CCDC52	-0.5	-7.69	-0.39	1.66e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07741184	chr6:167504864	NA	0.5	8.84	0.44	5.46e-17	Crohn's disease;
LUSC	trans	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg07393940	chr7:158741817	NA	-0.36	-6.43	-0.33	4.3e-10	Life satisfaction;
LUSC	cis	rs617219	0.698	rs10514159	chr5:78596044	T/C	cg24856658	chr5:78533917	JMY	0.29	5.8	0.3	1.55e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs612683	0.518	rs660945	chr1:100831830	A/T	cg06223162	chr1:101003688	GPR88	-0.39	-7.25	-0.37	2.88e-12	Breast cancer;
LUSC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg11062466	chr8:58055876	NA	0.48	6.03	0.31	4.34e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg11663144	chr21:46675770	NA	-0.39	-6.76	-0.35	6.33e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg26102564	chr10:131424627	MGMT	0.37	5.88	0.31	9.79e-9	Response to temozolomide;
LUSC	trans	rs3857536	0.842	rs2188591	chr6:66939511	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs11955175	1.000	rs78426328	chr5:40673176	G/T	cg05478818	chr5:40835740	RPL37	0.72	5.95	0.31	6.65e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.36	-0.46	1.24e-18	Total cholesterol levels;
LUSC	cis	rs4851254	0.660	rs9784000	chr2:100697201	G/C	cg07810366	chr2:100720526	AFF3	-0.44	-5.9	-0.31	8.91e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg11812906	chr14:75593930	NEK9	0.63	11.22	0.52	5.32e-25	Height;
LUSC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg01448562	chr3:133502909	NA	-0.66	-10.9	-0.51	7.41e-24	Iron status biomarkers;
LUSC	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg21918786	chr6:109611834	NA	-0.37	-6.25	-0.32	1.28e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs11577318	0.528	rs11247935	chr1:26698622	G/C	cg00852783	chr1:26633632	UBXN11	-0.55	-7.54	-0.38	4.61e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11690462	0.528	rs1344734	chr2:26637068	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.48	6.11	0.32	2.78e-9	Coronary artery disease;
LUSC	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.9	-0.35	2.6e-11	Menopause (age at onset);
LUSC	trans	rs9929218	1.000	rs13334326	chr16:68809207	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.72	-0.54	8.62e-27	Colorectal cancer;
LUSC	cis	rs3755132	0.929	rs6743630	chr2:15768256	G/A	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	7.56	0.38	3.9e-13	Resting heart rate;
LUSC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg13535736	chr9:111863775	C9orf5	-0.4	-6.76	-0.35	6.01e-11	Menarche (age at onset);
LUSC	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg19052272	chr2:3704530	ALLC	0.59	10.68	0.5	4.17e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9341808	0.754	rs3805925	chr6:80883833	T/C	cg08355045	chr6:80787529	NA	0.58	10.07	0.48	5.31e-21	Sitting height ratio;
LUSC	cis	rs17155006	0.746	rs420753	chr7:107746253	A/G	cg05962710	chr7:107745446	LAMB4	-0.36	-6.52	-0.34	2.57e-10	Pneumococcal bacteremia;
LUSC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg04727924	chr7:799746	HEATR2	-0.59	-6.26	-0.32	1.15e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.46	0.5	2.54e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg00944433	chr1:107599041	PRMT6	-0.39	-7.06	-0.36	9.62e-12	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg23625390	chr15:77176239	SCAPER	0.47	7.23	0.37	3.25e-12	Blood metabolite levels;
LUSC	cis	rs870825	0.616	rs7678616	chr4:185648714	T/G	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.74	8.65	0.43	2.15e-16	Schizophrenia;
LUSC	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg06002616	chr8:101225028	SPAG1	-0.41	-6.82	-0.35	4.26e-11	Atrioventricular conduction;
LUSC	cis	rs9359856	1.000	rs9359856	chr6:90307985	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.59	-7.0	-0.36	1.4e-11	Bipolar disorder;
LUSC	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg04310649	chr10:35416472	CREM	-0.43	-6.59	-0.34	1.73e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg16606324	chr3:10149918	C3orf24	-0.67	-9.19	-0.45	4.26e-18	Alzheimer's disease;
LUSC	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.81	0.3	1.44e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1858037	0.867	rs4671658	chr2:65561392	A/G	cg08085232	chr2:65598271	SPRED2	0.41	6.18	0.32	1.83e-9	Rheumatoid arthritis;
LUSC	cis	rs2708977	0.966	rs749027	chr2:97203137	A/C	cg01950434	chr2:97203154	ARID5A	-0.57	-8.55	-0.42	4.5e-16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg25801113	chr15:45476975	SHF	0.35	7.09	0.36	8.23e-12	Uric acid levels;
LUSC	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg17252645	chr8:143867129	LY6D	0.38	6.62	0.34	1.41e-10	Urinary tract infection frequency;
LUSC	cis	rs9473147	0.543	rs9349417	chr6:47580657	A/G	cg12968598	chr6:47444699	CD2AP	0.53	8.1	0.41	1.06e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	13.78	0.6	1.66e-34	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.8	15.59	0.65	1.49e-41	Dental caries;
LUSC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.31	0.37	1.96e-12	Motion sickness;
LUSC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-9.5	-0.46	4.05e-19	Longevity;Endometriosis;
LUSC	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.81	-0.65	2.07e-42	Height;
LUSC	cis	rs1322512	0.917	rs2623956	chr6:152971617	G/A	cg27316956	chr6:152958899	SYNE1	-0.33	-5.91	-0.31	8.44e-9	Tonometry;
LUSC	cis	rs911119	0.908	rs8121147	chr20:23601708	T/C	cg16589663	chr20:23618590	CST3	0.59	7.08	0.36	8.56e-12	Chronic kidney disease;
LUSC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg24011408	chr12:48396354	COL2A1	-0.43	-7.22	-0.37	3.61e-12	Plateletcrit;
LUSC	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs17125944	0.773	rs1952089	chr14:53339777	C/T	cg00686598	chr14:53173677	PSMC6	-0.65	-6.01	-0.31	4.85e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg09904177	chr6:26538194	HMGN4	-0.53	-6.18	-0.32	1.91e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg02023728	chr11:77925099	USP35	0.52	6.91	0.35	2.52e-11	Testicular germ cell tumor;
LUSC	cis	rs477692	0.669	rs12265939	chr10:131445398	A/G	cg05714579	chr10:131428358	MGMT	-0.65	-10.25	-0.49	1.33e-21	Response to temozolomide;
LUSC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.13	0.32	2.46e-9	Menopause (age at onset);
LUSC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.24	0.45	3.06e-18	Motion sickness;
LUSC	trans	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg26043149	chr18:55253948	FECH	-0.45	-6.9	-0.35	2.59e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg01119278	chr6:110721349	DDO	-0.49	-8.76	-0.43	9.88e-17	Platelet distribution width;
LUSC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg12963246	chr6:28129442	ZNF389	0.51	7.07	0.36	9.01e-12	Depression;
LUSC	cis	rs6723226	0.572	rs176411	chr2:32643528	A/G	cg02381751	chr2:32503542	YIPF4	0.51	8.08	0.4	1.18e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs668210	0.793	rs506873	chr11:65767215	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.53	-7.12	-0.36	6.78e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs13006833	0.668	rs2664252	chr2:191148347	G/A	cg21644426	chr2:191273491	MFSD6	0.45	6.51	0.34	2.69e-10	Urinary metabolites;
LUSC	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg06917634	chr15:78832804	PSMA4	-0.58	-7.11	-0.36	7.01e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6494488	0.500	rs72742916	chr15:64850675	T/A	cg08069370	chr15:64387884	SNX1	-0.64	-5.73	-0.3	2.24e-8	Coronary artery disease;
LUSC	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.59	0.38	3.15e-13	Iron status biomarkers;
LUSC	trans	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg14791747	chr16:20752902	THUMPD1	0.73	9.55	0.46	2.84e-19	Cognitive test performance;
LUSC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg10253484	chr15:75165896	SCAMP2	0.5	7.47	0.38	7.21e-13	Breast cancer;
LUSC	cis	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg07988820	chr12:82153109	PPFIA2	-0.4	-5.72	-0.3	2.32e-8	Resting heart rate;
LUSC	cis	rs7804356	1.000	rs73065521	chr7:26831409	C/A	cg03456212	chr7:26904342	SKAP2	-0.55	-6.52	-0.34	2.66e-10	Type 1 diabetes;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg05131254	chr6:138188363	TNFAIP3	0.4	6.28	0.32	1.06e-9	Educational attainment (years of education);
LUSC	trans	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg21659725	chr3:3221576	CRBN	0.72	8.83	0.44	6.22e-17	Menarche (age at onset);
LUSC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	0.92	15.35	0.64	1.35e-40	Breast cancer;
LUSC	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-0.87	-15.45	-0.65	5.48e-41	Height;
LUSC	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg00990874	chr7:1149470	C7orf50	-0.56	-6.53	-0.34	2.43e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg11941060	chr3:133502564	NA	-0.52	-8.14	-0.41	7.76e-15	Iron status biomarkers;
LUSC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg08219700	chr8:58056026	NA	0.46	5.88	0.31	1e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	ch.11.42038R	chr11:967971	AP2A2	0.55	8.3	0.41	2.69e-15	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg14552801	chr7:65878734	NA	0.44	6.27	0.32	1.12e-9	Aortic root size;
LUSC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg14668632	chr7:2872130	GNA12	-0.5	-7.45	-0.38	7.99e-13	Height;
LUSC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg18512352	chr11:47633146	NA	-0.46	-9.22	-0.45	3.55e-18	Subjective well-being;
LUSC	cis	rs2688608	0.967	rs2675663	chr10:75660270	T/G	cg23231163	chr10:75533350	FUT11	-0.37	-5.96	-0.31	6.34e-9	Inflammatory bowel disease;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg15383120	chr6:291909	DUSP22	0.66	11.14	0.52	1.02e-24	Menopause (age at onset);
LUSC	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg01503450	chr10:980765	NA	-0.39	-5.79	-0.3	1.59e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg02972257	chr16:68554789	NA	0.41	5.74	0.3	2.13e-8	Colorectal cancer;
LUSC	cis	rs6681460	0.834	rs2916	chr1:67216697	G/A	cg02459107	chr1:67143332	SGIP1	-0.47	-8.35	-0.42	1.81e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs9653442	0.564	rs12992234	chr2:100767886	G/A	cg07810366	chr2:100720526	AFF3	-0.43	-7.31	-0.37	2.03e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg11871910	chr12:69753446	YEATS4	0.61	9.47	0.46	5.44e-19	Response to diuretic therapy;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23713156	chr17:80606235	WDR45L	-0.48	-6.22	-0.32	1.48e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg18827107	chr12:86230957	RASSF9	-0.42	-6.19	-0.32	1.78e-9	Major depressive disorder;
LUSC	cis	rs61612642	0.590	rs6931028	chr6:42193064	A/T	cg01092361	chr6:42185687	MRPS10	0.78	8.49	0.42	6.66e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg11965913	chr1:205819406	PM20D1	-0.55	-8.92	-0.44	3.23e-17	Menarche (age at onset);
LUSC	cis	rs2290159	0.800	rs56363132	chr3:12680403	T/C	cg23032965	chr3:12705835	RAF1	0.74	9.13	0.45	6.87e-18	Cholesterol, total;
LUSC	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg12927641	chr6:109611667	NA	-0.35	-5.9	-0.31	8.81e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs6545883	0.826	rs2694651	chr2:61588642	T/C	cg15711740	chr2:61764176	XPO1	0.42	6.28	0.33	1.04e-9	Tuberculosis;
LUSC	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg13789015	chr9:136890014	NCRNA00094	0.7	12.69	0.57	2.29e-30	Platelet distribution width;
LUSC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-25.08	-0.81	8.21e-79	Height;
LUSC	cis	rs1775715	0.737	rs1541260	chr10:32105570	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.75	0.35	6.68e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	0.6	9.55	0.46	2.87e-19	Breast cancer;
LUSC	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg26769984	chr7:1090371	C7orf50	0.69	9.94	0.48	1.44e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.15	-0.36	5.46e-12	Coronary artery disease;
LUSC	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg00310523	chr12:86230176	RASSF9	0.37	6.77	0.35	5.65e-11	Major depressive disorder;
LUSC	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.88	-0.31	9.9e-9	Ileal carcinoids;
LUSC	cis	rs1823874	0.720	rs7162911	chr15:100355050	A/G	cg16400843	chr15:100339927	C15orf51	0.35	7.02	0.36	1.25e-11	IgG glycosylation;
LUSC	cis	rs713587	0.571	rs564667	chr2:25310860	A/T	cg01884057	chr2:25150051	NA	-0.27	-5.84	-0.3	1.25e-8	Body mass index in non-asthmatics;
LUSC	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.85	-0.35	3.49e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.51e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-8.33	-0.41	2.14e-15	Body mass index;
LUSC	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg25206134	chr2:45395956	NA	0.62	7.23	0.37	3.24e-12	Bipolar disorder;
LUSC	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg08601574	chr20:25228251	PYGB	0.44	6.79	0.35	5.29e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs16937	0.711	rs3851284	chr1:205156080	A/T	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.36e-10	Schizophrenia;
LUSC	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg11584989	chr19:19387371	SF4	0.57	6.92	0.35	2.31e-11	Bipolar disorder;
LUSC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg25036284	chr2:26402008	FAM59B	0.77	11.11	0.52	1.34e-24	Gut microbiome composition (summer);
LUSC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.92	15.79	0.65	2.33e-42	Bladder cancer;
LUSC	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg16447950	chr5:562315	NA	-0.59	-7.08	-0.36	8.54e-12	Lung disease severity in cystic fibrosis;
LUSC	trans	rs1325195	0.840	rs2816177	chr1:179248952	A/G	cg11624085	chr17:8464688	MYH10	0.44	7.19	0.37	4.29e-12	IgE grass sensitization;
LUSC	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.71	11.44	0.53	8.57e-26	Eye color traits;
LUSC	cis	rs57590327	0.555	rs7634258	chr3:81799100	T/C	cg07356753	chr3:81810745	GBE1	-0.67	-10.65	-0.5	5.4e-23	Extraversion;
LUSC	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg22906224	chr7:99728672	NA	-0.42	-5.69	-0.3	2.79e-8	Coronary artery disease;
LUSC	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg07148914	chr20:33460835	GGT7	0.48	7.14	0.36	5.69e-12	Height;
LUSC	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg26384229	chr12:38710491	ALG10B	0.71	11.22	0.52	5.05e-25	Morning vs. evening chronotype;
LUSC	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07636037	chr3:49044803	WDR6	-0.67	-8.62	-0.43	2.79e-16	Menarche (age at onset);
LUSC	cis	rs35995292	0.500	rs28369620	chr7:38921872	C/T	cg19327137	chr7:38886074	VPS41	0.55	10.26	0.49	1.21e-21	Subjective well-being (multi-trait analysis);
LUSC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21545522	chr1:205238299	TMCC2	0.51	9.85	0.47	2.95e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.5	-0.38	5.8e-13	Bipolar disorder;
LUSC	trans	rs236907	0.812	rs55732843	chr1:171796962	A/G	cg13482142	chr2:234261155	NA	0.51	6.26	0.32	1.21e-9	Mean platelet volume;
LUSC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg08219700	chr8:58056026	NA	0.48	5.88	0.31	1e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-6.06	-0.31	3.58e-9	Height;
LUSC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg15352829	chr14:105391018	PLD4	-0.42	-8.79	-0.43	7.86e-17	Rheumatoid arthritis;
LUSC	cis	rs7605827	0.930	rs10164574	chr2:15677258	G/A	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.27e-17	Educational attainment (years of education);
LUSC	cis	rs6714710	0.580	rs57681139	chr2:98454473	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg00857998	chr1:205179979	DSTYK	0.62	9.41	0.46	8.36e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg05791153	chr7:19748676	TWISTNB	-0.77	-8.26	-0.41	3.36e-15	Thyroid stimulating hormone;
LUSC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg27170947	chr2:26402098	FAM59B	0.69	9.76	0.47	5.91e-20	Gut microbiome composition (summer);
LUSC	cis	rs977987	0.843	rs8056080	chr16:75410798	C/A	cg04384234	chr16:75411784	CFDP1	-0.45	-7.54	-0.38	4.4e-13	Dupuytren's disease;
LUSC	cis	rs9658691	0.607	rs9658788	chr10:90776486	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-6.23	-0.32	1.42e-9	Mosquito bite size;
LUSC	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg26408565	chr15:76604113	ETFA	0.43	6.1	0.32	2.96e-9	Blood metabolite levels;
LUSC	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg05373962	chr22:49881684	NA	-0.41	-8.55	-0.42	4.58e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.58	-0.42	3.72e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.28	0.59	1.28e-32	Cognitive test performance;
LUSC	cis	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.08	0.32	3.25e-9	Neuroticism;
LUSC	cis	rs6580649	0.882	rs59766465	chr12:48470169	G/A	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg20701182	chr2:24300061	SF3B14	0.9	11.53	0.53	4.11e-26	Lymphocyte counts;
LUSC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-6.06	-0.31	3.59e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg05863683	chr7:1912471	MAD1L1	0.3	5.93	0.31	7.68e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg09060275	chr22:27053596	MIAT	-0.4	-5.99	-0.31	5.46e-9	Height;
LUSC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.47	5.75	0.3	2.01e-8	Renal function-related traits (BUN);
LUSC	trans	rs10763170	0.608	rs11004722	chr10:56826608	G/A	cg10538533	chr12:53074328	KRT1	0.3	5.98	0.31	5.81e-9	Sporadic pituitary adenoma;
LUSC	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg26408565	chr15:76604113	ETFA	-0.43	-6.82	-0.35	4.4e-11	Blood metabolite levels;
LUSC	cis	rs7605827	0.930	rs13026732	chr2:15695429	G/A	cg19274914	chr2:15703543	NA	0.47	8.85	0.44	5.29e-17	Educational attainment (years of education);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02150654	chr10:122216378	PPAPDC1A	-0.5	-6.14	-0.32	2.38e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	0.93	16.01	0.66	3.23e-43	Menopause (age at onset);
LUSC	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	5.84	0.3	1.23e-8	Breast cancer;
LUSC	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg15704280	chr7:45808275	SEPT13	0.82	7.82	0.39	6.96e-14	Axial length;
LUSC	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg09904177	chr6:26538194	HMGN4	-0.47	-6.85	-0.35	3.58e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg27535305	chr1:53392650	SCP2	0.37	6.89	0.35	2.78e-11	Monocyte count;
LUSC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.72	-0.35	7.84e-11	Extrinsic epigenetic age acceleration;
LUSC	trans	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg26043149	chr18:55253948	FECH	0.49	7.28	0.37	2.43e-12	Bone mineral density;
LUSC	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg02527881	chr3:46936655	PTH1R	-0.42	-7.61	-0.38	2.88e-13	Colorectal cancer;
LUSC	cis	rs4474465	0.688	rs7940507	chr11:78284453	T/C	cg27205649	chr11:78285834	NARS2	0.59	7.2	0.37	4.05e-12	Alzheimer's disease (survival time);
LUSC	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg06917634	chr15:78832804	PSMA4	-0.44	-5.95	-0.31	6.67e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.57e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs7849782	0.935	rs724556	chr9:104425068	G/T	cg22914338	chr19:14376960	NA	0.26	6.37	0.33	6.38e-10	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.49	-9.28	-0.45	2.25e-18	Urinary metabolites;
LUSC	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg09307838	chr4:120376055	NA	0.65	9.87	0.48	2.43e-20	Corneal astigmatism;
LUSC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg21665744	chr7:39171113	POU6F2	-0.47	-7.27	-0.37	2.64e-12	IgG glycosylation;
LUSC	trans	rs4729127	1.000	rs57515158	chr7:94007842	T/G	cg16531660	chr3:141457093	RNF7	0.56	6.03	0.31	4.26e-9	Intelligence;
LUSC	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg18132916	chr6:79620363	NA	-0.4	-6.17	-0.32	1.99e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg03806693	chr22:41940476	POLR3H	-0.49	-6.78	-0.35	5.59e-11	Neuroticism;
LUSC	trans	rs1973993	1.000	rs1973993	chr1:96943994	A/G	cg10631902	chr5:14652156	NA	0.51	8.77	0.43	9.54e-17	Weight;
LUSC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.72	-10.54	-0.5	1.35e-22	Migraine;Coronary artery disease;
LUSC	cis	rs1190552	0.846	rs3783381	chr14:102965435	A/G	cg18135206	chr14:102964638	TECPR2	0.48	5.89	0.31	9.54e-9	Blood protein levels;
LUSC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg14433983	chr11:636460	DRD4	-0.35	-5.88	-0.31	9.78e-9	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08219700	chr8:58056026	NA	0.68	7.92	0.4	3.51e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7429990	0.965	rs319686	chr3:47930420	C/G	cg11946769	chr3:48343235	NME6	0.44	5.82	0.3	1.39e-8	Educational attainment (years of education);
LUSC	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg12863693	chr15:85201151	NMB	0.36	7.03	0.36	1.15e-11	Schizophrenia;
LUSC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2745967	0.791	rs11118957	chr1:208116590	C/T	cg15031826	chr1:208136952	NA	0.41	5.65	0.3	3.48e-8	Resting heart rate;
LUSC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.91	-0.51	6.79e-24	Alzheimer's disease;
LUSC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg21775007	chr8:11205619	TDH	-0.45	-6.3	-0.33	9.13e-10	Joint mobility (Beighton score);
LUSC	cis	rs12618769	0.597	rs17032870	chr2:99132786	C/T	cg10123293	chr2:99228465	UNC50	0.45	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.73	-12.82	-0.57	7.16e-31	Dental caries;
LUSC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg13319975	chr6:146136371	FBXO30	0.39	5.78	0.3	1.75e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-12.68	-0.57	2.45e-30	Total body bone mineral density;
LUSC	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg09998033	chr7:158218633	PTPRN2	-0.4	-6.38	-0.33	5.87e-10	Obesity-related traits;
LUSC	cis	rs7903847	0.642	rs11189175	chr10:99139609	T/C	cg08345082	chr10:99160200	RRP12	-0.37	-7.46	-0.38	7.51e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg06453172	chr10:134556979	INPP5A	-0.5	-6.31	-0.33	8.66e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7640424	0.620	rs71321252	chr3:107813107	A/C	cg09227934	chr3:107805635	CD47	-0.55	-7.78	-0.39	9.23e-14	Body mass index;
LUSC	trans	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-9.61	-0.47	1.87e-19	Brugada syndrome;
LUSC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg15147215	chr3:52552868	STAB1	-0.34	-6.67	-0.34	1.05e-10	Bipolar disorder;
LUSC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg17554472	chr22:41940697	POLR3H	-0.46	-5.72	-0.3	2.39e-8	Vitiligo;
LUSC	trans	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.59e-15	Diabetic kidney disease;
LUSC	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg15485101	chr11:133734466	NA	0.39	7.06	0.36	9.98e-12	Childhood ear infection;
LUSC	cis	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg06521331	chr12:34319734	NA	0.4	6.59	0.34	1.72e-10	Morning vs. evening chronotype;
LUSC	cis	rs2625529	0.730	rs8182011	chr15:72389948	C/T	cg16672083	chr15:72433130	SENP8	0.48	7.67	0.39	1.94e-13	Red blood cell count;
LUSC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg06064525	chr11:970664	AP2A2	0.34	6.95	0.36	1.92e-11	Alzheimer's disease (late onset);
LUSC	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.26	-0.41	3.57e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg05855489	chr10:104503620	C10orf26	-0.68	-10.0	-0.48	8.83e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg23260525	chr10:116636907	FAM160B1	0.42	9.08	0.44	9.59e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.32e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg08888203	chr3:10149979	C3orf24	0.56	8.12	0.41	9.08e-15	Alzheimer's disease;
LUSC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg05754148	chr16:3507555	NAT15	-0.57	-8.77	-0.43	9.55e-17	Tuberculosis;
LUSC	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg08079166	chr15:68083412	MAP2K5	0.41	7.5	0.38	5.85e-13	Restless legs syndrome;
LUSC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25072359	chr17:41440525	NA	0.65	9.39	0.46	9.7e-19	Menopause (age at onset);
LUSC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3087591	0.708	rs7350943	chr17:29684553	C/T	cg24425628	chr17:29625626	OMG;NF1	0.49	7.21	0.37	3.86e-12	Hip circumference;
LUSC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg24642439	chr20:33292090	TP53INP2	0.4	5.84	0.3	1.22e-8	Height;
LUSC	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg03585969	chr10:35415529	CREM	0.6	8.73	0.43	1.27e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9807989	0.839	rs1974675	chr2:102986375	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.66	0.3	3.23e-8	Asthma;
LUSC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.82	-0.3	1.42e-8	Depression;
LUSC	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.68	-0.47	1.07e-19	Multiple sclerosis;
LUSC	trans	rs1015291	0.708	rs10770561	chr12:19999041	C/T	cg01501474	chr7:55323552	NA	0.48	6.23	0.32	1.41e-9	Diastolic blood pressure;
LUSC	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg09835421	chr16:68378352	PRMT7	-0.7	-7.06	-0.36	9.98e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4843185	0.731	rs3815795	chr16:85712105	A/G	cg00168118	chr16:85669675	KIAA0182	-0.37	-5.75	-0.3	2.04e-8	Platelet distribution width;
LUSC	cis	rs11032090	1	rs11032090	chr11:4417129	A/G	cg08577913	chr11:4415193	TRIM21	0.44	7.01	0.36	1.34e-11	Lung cancer;
LUSC	cis	rs9815354	0.638	rs60525434	chr3:42044286	T/G	cg03022575	chr3:42003672	ULK4	0.6	6.43	0.33	4.44e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg07393940	chr7:158741817	NA	0.36	6.55	0.34	2.13e-10	Life satisfaction;
LUSC	cis	rs483180	0.531	rs541503	chr1:120208297	A/G	cg19096424	chr1:120255104	PHGDH	-0.44	-6.15	-0.32	2.16e-9	Macular telangiectasia type 2;
LUSC	cis	rs7615316	0.779	rs2086933	chr3:142039406	G/A	cg16271453	chr3:142027066	XRN1	-0.41	-7.12	-0.36	6.57e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.04	-14.0	-0.61	2.32e-35	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	0.93	17.43	0.69	7.74e-49	Heart rate;
LUSC	cis	rs4663866	0.901	rs71426512	chr2:239187128	C/T	cg16914508	chr2:239161102	PER2	0.69	7.31	0.37	1.94e-12	Irritable bowel syndrome;
LUSC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg21724239	chr8:58056113	NA	0.78	8.17	0.41	6.56e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.69	0.54	1.11e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg13535736	chr9:111863775	C9orf5	0.39	6.64	0.34	1.27e-10	Menarche (age at onset);
LUSC	cis	rs752010	0.619	rs10789406	chr1:42105182	G/T	cg06885757	chr1:42089581	HIVEP3	-0.47	-9.31	-0.45	1.72e-18	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg06238570	chr21:40685208	BRWD1	-0.64	-10.64	-0.5	5.72e-23	Cognitive function;
LUSC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg06008330	chr7:65541103	ASL	-0.4	-6.18	-0.32	1.84e-9	Aortic root size;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg19410738	chr19:39226868	CAPN12	0.37	6.16	0.32	2.1e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs240764	0.717	rs10872622	chr6:101165017	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-6.08	-0.32	3.25e-9	Neuroticism;
LUSC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10862848	chr6:42927986	GNMT	-0.28	-6.75	-0.35	6.42e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	11.08	0.52	1.71e-24	Alzheimer's disease;
LUSC	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg09904177	chr6:26538194	HMGN4	-0.44	-6.26	-0.32	1.17e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2953174	0.938	rs2975758	chr2:241530750	G/A	cg07929629	chr2:241523174	NA	0.45	5.98	0.31	5.87e-9	Bipolar disorder;
LUSC	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.57	-12.01	-0.55	7.37e-28	Sense of smell;
LUSC	trans	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Bladder cancer;
LUSC	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg11993925	chr19:44307056	LYPD5	0.36	7.75	0.39	1.08e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs2227564	0.700	rs2688612	chr10:75653205	G/T	cg23231163	chr10:75533350	FUT11	-0.41	-5.79	-0.3	1.59e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg15704280	chr7:45808275	SEPT13	0.75	8.45	0.42	9.35e-16	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg20887711	chr4:1340912	KIAA1530	0.44	6.57	0.34	1.97e-10	Obesity-related traits;
LUSC	cis	rs506338	0.517	rs490192	chr11:64471369	C/T	cg19131476	chr11:64387923	NRXN2	0.34	7.25	0.37	2.98e-12	Body mass index;Urate levels;
LUSC	cis	rs7580658	0.963	rs4233583	chr2:128060068	C/A	cg09760422	chr2:128146352	NA	-0.33	-7.27	-0.37	2.51e-12	Protein C levels;
LUSC	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.75	-0.35	6.36e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg04398451	chr17:18023971	MYO15A	0.46	7.35	0.37	1.57e-12	Total body bone mineral density;
LUSC	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg23241863	chr10:102295624	HIF1AN	0.48	5.74	0.3	2.18e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs666930	0.519	rs483180	chr1:120267505	C/G	cg19096424	chr1:120255104	PHGDH	-0.6	-8.34	-0.42	1.95e-15	Breast cancer;
LUSC	cis	rs7000551	0.751	rs2449348	chr8:22359572	C/T	cg12081754	chr8:22256438	SLC39A14	0.4	6.06	0.31	3.76e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg26816564	chr1:7831052	VAMP3	0.5	6.1	0.32	3e-9	Inflammatory bowel disease;
LUSC	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	12.64	0.57	3.44e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	0.9	13.45	0.59	2.91e-33	Breast cancer;
LUSC	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.79	11.12	0.52	1.2e-24	Corneal astigmatism;
LUSC	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg05082376	chr22:42548792	NA	-0.4	-6.56	-0.34	2.08e-10	Cognitive function;
LUSC	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg16006841	chr5:176797999	RGS14	0.65	10.58	0.5	9.59e-23	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs2455601	0.608	rs1368017	chr11:8867070	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-7.2	-0.37	4.05e-12	Schizophrenia;
LUSC	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.37	-0.46	1.15e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg05110241	chr16:68378359	PRMT7	-0.69	-7.31	-0.37	2.01e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.52	0.34	2.67e-10	Testicular germ cell tumor;
LUSC	cis	rs7577696	0.568	rs7574000	chr2:32342888	A/C	cg02381751	chr2:32503542	YIPF4	-0.53	-7.08	-0.36	8.79e-12	Inflammatory biomarkers;
LUSC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	0.96	13.11	0.58	5.87e-32	Eosinophil percentage of granulocytes;
LUSC	cis	rs7818345	0.845	rs17407039	chr8:19268056	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.32	6.06	0.31	3.6e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg06002616	chr8:101225028	SPAG1	-0.41	-6.85	-0.35	3.54e-11	Atrioventricular conduction;
LUSC	trans	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg03929089	chr4:120376271	NA	-0.55	-6.33	-0.33	8.09e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.84	12.83	0.57	6.74e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-8.02	-0.4	1.84e-14	Schizophrenia;
LUSC	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg12483005	chr1:23474871	LUZP1	0.44	6.86	0.35	3.39e-11	Height;
LUSC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg16797656	chr11:68205561	LRP5	0.4	7.19	0.37	4.25e-12	Total body bone mineral density;
LUSC	cis	rs1403694	0.515	rs1648722	chr3:186448989	C/T	cg12454167	chr3:186435060	KNG1	0.28	7.6	0.38	2.98e-13	Blood protein levels;
LUSC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg27535305	chr1:53392650	SCP2	0.39	7.31	0.37	1.96e-12	Monocyte count;
LUSC	cis	rs11158026	0.526	rs3825610	chr14:55347916	T/A	cg04306507	chr14:55594613	LGALS3	0.4	6.46	0.33	3.78e-10	Parkinson's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08701034	chr19:36001408	DMKN	0.43	6.51	0.34	2.82e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	15.18	0.64	6.12e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg01294253	chr9:136912663	BRD3	0.36	6.35	0.33	6.86e-10	Platelet distribution width;
LUSC	cis	rs4704187	0.687	rs4704179	chr5:74457273	C/T	cg03227963	chr5:74354835	NA	0.31	6.8	0.35	4.74e-11	Response to amphetamines;
LUSC	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22857025	chr5:266934	NA	-1.19	-14.03	-0.61	1.79e-35	Breast cancer;
LUSC	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg24642439	chr20:33292090	TP53INP2	0.41	5.88	0.31	9.72e-9	Height;
LUSC	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg24375607	chr4:120327624	NA	0.79	12.05	0.55	5.19e-28	Corneal astigmatism;
LUSC	trans	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg19894588	chr14:64061835	NA	0.47	6.72	0.35	7.86e-11	Glioblastoma;Glioma;
LUSC	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg09904177	chr6:26538194	HMGN4	0.66	11.7	0.54	1.01e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs72772090	0.539	rs72773922	chr5:96116660	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-6.73	-0.35	7.35e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg13319975	chr6:146136371	FBXO30	-0.46	-7.12	-0.36	6.54e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.17	-0.41	6.35e-15	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.71	0.39	1.43e-13	Prudent dietary pattern;
LUSC	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.49	0.42	7.05e-16	Lung cancer in ever smokers;
LUSC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg04450456	chr4:17643702	FAM184B	0.38	6.48	0.33	3.32e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10887741	0.546	rs4316430	chr10:89443649	G/A	cg13926569	chr10:89418898	PAPSS2	0.31	6.72	0.35	7.88e-11	Exercise (leisure time);
LUSC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.51e-14	Prudent dietary pattern;
LUSC	cis	rs1045714	0.895	rs73035504	chr7:2642878	G/A	cg24848437	chr7:2645542	IQCE	0.63	6.97	0.36	1.72e-11	Urate levels in lean individuals;
LUSC	cis	rs11971779	0.680	rs4398844	chr7:139043139	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.11	0.36	6.95e-12	Diisocyanate-induced asthma;
LUSC	cis	rs6060717	0.610	rs6060755	chr20:34606915	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-6.22	-0.32	1.5e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4474465	1.000	rs11237509	chr11:78173439	C/A	cg27205649	chr11:78285834	NARS2	-0.49	-5.79	-0.3	1.61e-8	Alzheimer's disease (survival time);
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg15242686	chr22:24348715	GSTTP1	0.42	6.23	0.32	1.44e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg24920358	chr1:40204285	PPIE	0.6	10.77	0.51	2.03e-23	Blood protein levels;
LUSC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg04733989	chr22:42467013	NAGA	0.54	8.35	0.42	1.88e-15	Schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02294249	chr13:34392492	RFC3	0.38	6.19	0.32	1.79e-9	Triglycerides;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18652121	chr3:179322868	MRPL47;NDUFB5	0.42	6.46	0.33	3.59e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs12541635	0.801	rs1429675	chr8:107101623	A/G	cg10147462	chr8:107024639	NA	-0.44	-7.77	-0.39	9.9e-14	Age of smoking initiation;
LUSC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg04166393	chr7:2884313	GNA12	0.45	5.98	0.31	5.7e-9	Height;
LUSC	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg00484396	chr16:3507460	NAT15	-0.45	-7.52	-0.38	5.25e-13	Body mass index (adult);
LUSC	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg02018176	chr4:1364513	KIAA1530	0.52	8.83	0.44	5.92e-17	Obesity-related traits;
LUSC	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg12863693	chr15:85201151	NMB	0.36	7.06	0.36	9.44e-12	Schizophrenia;
LUSC	cis	rs12137294	0.866	rs1078362	chr1:205209530	A/G	cg21643547	chr1:205240462	TMCC2	-0.35	-6.43	-0.33	4.48e-10	Red cell distribution width;
LUSC	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg00277334	chr10:82204260	NA	-0.49	-6.67	-0.34	1.09e-10	Post bronchodilator FEV1;
LUSC	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg23649088	chr2:200775458	C2orf69	-0.53	-7.09	-0.36	8.14e-12	Schizophrenia;
LUSC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.47	-7.12	-0.36	6.78e-12	Testicular germ cell tumor;
LUSC	trans	rs953492	0.731	rs10803133	chr1:243454014	A/G	cg25284624	chr1:224180302	NA	0.4	6.12	0.32	2.56e-9	Diastolic blood pressure;
LUSC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg22823121	chr1:150693482	HORMAD1	0.55	7.85	0.39	5.76e-14	Melanoma;
LUSC	cis	rs117623576	0.941	rs7924082	chr10:32429126	A/G	cg03047570	chr10:32398778	NA	0.54	5.97	0.31	6.05e-9	Anti-saccade response;
LUSC	cis	rs10754283	0.967	rs6663363	chr1:90116854	A/G	cg21401794	chr1:90099060	LRRC8C	0.62	9.05	0.44	1.18e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.29	-0.37	2.23e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	12.23	0.56	1.08e-28	Personality dimensions;
LUSC	cis	rs870825	0.616	rs28660669	chr4:185623312	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg06641503	chr3:48959341	ARIH2	-0.39	-5.88	-0.31	9.73e-9	Parkinson's disease;
LUSC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg15105969	chr2:36825350	FEZ2	0.47	6.32	0.33	8.46e-10	Height;
LUSC	trans	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg10756647	chr7:56101905	PSPH	-0.84	-8.42	-0.42	1.14e-15	Diabetic kidney disease;
LUSC	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-8.37	-0.42	1.64e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg05673287	chr15:77411982	SGK269	0.43	6.94	0.36	2.02e-11	Type 2 diabetes;
LUSC	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg10765909	chr12:53715428	AAAS	0.41	6.29	0.33	9.79e-10	Platelet distribution width;
LUSC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg04287289	chr16:89883240	FANCA	0.78	13.64	0.6	5.58e-34	Vitiligo;
LUSC	cis	rs6489882	0.902	rs4767040	chr12:113374017	C/G	cg20102336	chr12:113376681	OAS3	-0.41	-5.94	-0.31	7.09e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.79	-0.3	1.6e-8	Type 2 diabetes;
LUSC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.72	6.98	0.36	1.62e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2835872	0.758	rs1709821	chr21:39035622	T/C	cg20424643	chr21:39039972	KCNJ6	-0.44	-7.48	-0.38	6.79e-13	Electroencephalographic traits in alcoholism;
LUSC	trans	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg13798780	chr7:105162888	PUS7	0.56	6.22	0.32	1.45e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7903847	0.642	rs11189175	chr10:99139609	T/C	cg20016023	chr10:99160130	RRP12	-0.33	-8.17	-0.41	6.41e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg00750074	chr16:89608354	SPG7	-0.46	-7.79	-0.39	8.64e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-6.39	-0.33	5.43e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.97	-0.4	2.59e-14	Mood instability;
LUSC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg25767906	chr1:53392781	SCP2	0.39	6.78	0.35	5.63e-11	Monocyte count;
LUSC	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.89	15.25	0.64	3.17e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7246967	0.673	rs3951783	chr19:22839264	T/A	cg23217946	chr19:22817039	ZNF492	0.49	6.8	0.35	4.87e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs977987	0.806	rs17696696	chr16:75393352	G/T	cg04384234	chr16:75411784	CFDP1	0.41	6.94	0.35	2.06e-11	Dupuytren's disease;
LUSC	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg13010199	chr12:38710504	ALG10B	0.58	9.27	0.45	2.32e-18	Morning vs. evening chronotype;
LUSC	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.69	0.47	9.71e-20	Coffee consumption (cups per day);
LUSC	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs72960926	0.744	rs2352083	chr6:75023176	A/G	cg03266952	chr6:74778945	NA	-0.82	-7.01	-0.36	1.29e-11	Metabolite levels (MHPG);
LUSC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg13010344	chr12:123464640	ARL6IP4	0.49	6.44	0.33	4.06e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg02807482	chr3:125708958	NA	0.47	5.88	0.31	9.8e-9	Blood pressure (smoking interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14546714	chr17:73179300	SUMO2	0.45	6.46	0.33	3.68e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg15423357	chr2:25149977	NA	0.4	7.84	0.39	6.29e-14	Body mass index in non-asthmatics;
LUSC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.5	8.35	0.42	1.9e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg09035930	chr12:129282057	SLC15A4	-0.6	-10.22	-0.49	1.69e-21	Systemic lupus erythematosus;
LUSC	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	5.97	0.31	6.21e-9	Rheumatoid arthritis;
LUSC	cis	rs7605827	0.930	rs6716384	chr2:15608210	A/G	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.69	0.39	1.63e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.7	10.64	0.5	6.02e-23	Dilated cardiomyopathy;
LUSC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg25204440	chr1:209979598	IRF6	0.5	5.72	0.3	2.36e-8	Cleft lip with or without cleft palate;
LUSC	trans	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg13565492	chr6:43139072	SRF	-0.61	-6.39	-0.33	5.65e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg08999081	chr20:33150536	PIGU	0.44	8.2	0.41	5.25e-15	Coronary artery disease;
LUSC	cis	rs9359856	0.529	rs72915915	chr6:90430593	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.89	-0.44	4e-17	Bipolar disorder;
LUSC	cis	rs6558174	0.965	rs2404655	chr8:22490209	T/C	cg03733263	chr8:22462867	KIAA1967	0.47	6.41	0.33	4.84e-10	Breast cancer;
LUSC	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg07541023	chr7:19748670	TWISTNB	0.78	7.81	0.39	7.24e-14	Thyroid stimulating hormone;
LUSC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg08219700	chr8:58056026	NA	0.45	5.81	0.3	1.49e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg24675056	chr1:15929824	NA	0.49	8.47	0.42	7.99e-16	Systolic blood pressure;
LUSC	cis	rs62458065	0.640	rs10274556	chr7:32513947	A/G	cg20159608	chr7:32802032	NA	-0.74	-9.28	-0.45	2.15e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs62238980	0.614	rs4820061	chr22:32378359	G/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs12681287	0.604	rs34227066	chr8:87449366	C/T	cg27223183	chr8:87520930	FAM82B	-0.54	-7.47	-0.38	6.9e-13	Caudate activity during reward;
LUSC	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg24812749	chr6:127587940	RNF146	0.55	7.53	0.38	4.75e-13	Breast cancer;
LUSC	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg22676075	chr6:135203613	NA	0.5	7.71	0.39	1.46e-13	Red blood cell count;
LUSC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2835872	0.733	rs1787400	chr21:39038217	G/C	cg20424643	chr21:39039972	KCNJ6	-0.45	-7.33	-0.37	1.7e-12	Electroencephalographic traits in alcoholism;
LUSC	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg19610905	chr11:61596333	FADS2	-0.54	-8.32	-0.41	2.33e-15	Trans fatty acid levels;
LUSC	cis	rs4973397	0.509	rs10191571	chr2:232279975	C/A	cg09339159	chr2:232260559	B3GNT7	0.48	7.02	0.36	1.23e-11	Anti-saccade response;
LUSC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.58	-8.28	-0.41	2.93e-15	Diastolic blood pressure;
LUSC	cis	rs7570971	0.617	rs1869829	chr2:135877562	C/T	cg07169764	chr2:136633963	MCM6	-0.52	-6.99	-0.36	1.5e-11	Blood metabolite levels;Body mass index;Cholesterol, total;
LUSC	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg10978503	chr1:24200527	CNR2	-0.54	-12.67	-0.57	2.67e-30	Immature fraction of reticulocytes;
LUSC	cis	rs7267979	0.789	rs1983974	chr20:25530619	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-16.88	-0.68	1.13e-46	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs500891	0.953	rs1171101	chr6:84196539	A/C	cg08257003	chr6:84140564	ME1	-0.33	-6.76	-0.35	6.13e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg00012203	chr2:219082015	ARPC2	-0.7	-11.59	-0.54	2.53e-26	Colorectal cancer;
LUSC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg06096015	chr1:231504339	EGLN1	0.58	10.29	0.49	9.77e-22	Hemoglobin concentration;
LUSC	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg03563238	chr19:33554763	RHPN2	-0.41	-6.47	-0.33	3.5e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg27411982	chr8:10470053	RP1L1	0.38	5.99	0.31	5.32e-9	Retinal vascular caliber;
LUSC	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg08017756	chr2:100939284	LONRF2	-0.45	-8.49	-0.42	6.69e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7809950	0.678	rs3801966	chr7:106824580	G/A	cg23024343	chr7:107201750	COG5	-0.62	-8.67	-0.43	1.92e-16	Coronary artery disease;
LUSC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.74	-0.3	2.14e-8	Depression;
LUSC	cis	rs977987	0.806	rs11864102	chr16:75442360	C/T	cg03315344	chr16:75512273	CHST6	0.48	9.05	0.44	1.21e-17	Dupuytren's disease;
LUSC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.26	-0.32	1.18e-9	Joint mobility (Beighton score);
LUSC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08109568	chr15:31115862	NA	-0.59	-8.22	-0.41	4.55e-15	Huntington's disease progression;
LUSC	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.74	0.35	7.03e-11	Body mass index;
LUSC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg07395648	chr5:131743802	NA	0.39	5.84	0.3	1.24e-8	Breast cancer;
LUSC	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.75	9.94	0.48	1.49e-20	Gastritis;
LUSC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.1e-30	Aortic root size;
LUSC	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.59	11.07	0.52	1.82e-24	Metabolite levels;
LUSC	cis	rs9837602	1.000	rs793472	chr3:99546110	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-5.79	-0.3	1.61e-8	Breast cancer;
LUSC	trans	rs629535	0.547	rs72654095	chr8:70120770	A/G	cg21567404	chr3:27674614	NA	-0.92	-13.35	-0.59	6.83e-33	Dupuytren's disease;
LUSC	trans	rs877282	0.583	rs10904566	chr10:821662	C/G	cg22713356	chr15:30763199	NA	0.78	10.05	0.48	6.17e-21	Uric acid levels;
LUSC	cis	rs9487051	0.803	rs11153161	chr6:109541774	A/G	cg00509249	chr6:109615579	CCDC162	-0.34	-5.81	-0.3	1.42e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg17845761	chr1:175162550	KIAA0040	0.3	5.73	0.3	2.24e-8	Alcohol dependence;
LUSC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg00784671	chr22:46762841	CELSR1	-0.49	-6.67	-0.34	1.04e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg16558253	chr16:72132732	DHX38	-0.38	-6.07	-0.32	3.45e-9	Fibrinogen levels;
LUSC	cis	rs1322512	1.000	rs2800625	chr6:153006016	A/G	cg27316956	chr6:152958899	SYNE1	0.34	5.98	0.31	5.72e-9	Tonometry;
LUSC	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg26898376	chr11:64110657	CCDC88B	0.33	6.16	0.32	2.06e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.09	-0.45	8.85e-18	Monocyte percentage of white cells;
LUSC	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg05784532	chr1:230284198	GALNT2	0.55	8.07	0.4	1.29e-14	Coronary artery disease;
LUSC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg15704280	chr7:45808275	SEPT13	-1.08	-21.87	-0.77	1.98e-66	Height;
LUSC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg15147215	chr3:52552868	STAB1	-0.32	-6.21	-0.32	1.54e-9	Bipolar disorder;
LUSC	cis	rs2274273	0.805	rs28612464	chr14:55816411	T/C	cg04306507	chr14:55594613	LGALS3	0.53	11.62	0.54	1.95e-26	Protein biomarker;
LUSC	cis	rs7202877	0.610	rs11646418	chr16:75367585	G/C	cg04384234	chr16:75411784	CFDP1	-0.63	-8.46	-0.42	8.43e-16	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs2227564	0.649	rs2243610	chr10:75601653	A/T	cg23231163	chr10:75533350	FUT11	-0.43	-6.09	-0.32	3.08e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.38	6.01	0.31	4.72e-9	Electroencephalogram traits;
LUSC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg13114125	chr14:105738426	BRF1	-0.86	-14.6	-0.62	1.1e-37	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg21775007	chr8:11205619	TDH	0.42	6.31	0.33	8.74e-10	Mood instability;
LUSC	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg05775895	chr3:12838266	CAND2	0.51	8.8	0.43	7.4e-17	QRS complex (12-leadsum);
LUSC	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.74	7.74	0.39	1.17e-13	Yeast infection;
LUSC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg08470875	chr2:26401718	FAM59B	-0.69	-9.37	-0.46	1.16e-18	Gut microbiome composition (summer);
LUSC	cis	rs7589728	1.000	rs11893832	chr2:88507537	G/C	cg04511125	chr2:88470314	THNSL2	0.7	6.6	0.34	1.65e-10	Plasma clusterin levels;
LUSC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg19812747	chr11:111475976	SIK2	-0.55	-8.2	-0.41	5.19e-15	Primary sclerosing cholangitis;
LUSC	cis	rs1788820	0.917	rs1624695	chr18:21142992	A/T	cg14672496	chr18:21087552	C18orf8	0.42	6.89	0.35	2.86e-11	Body mass index;
LUSC	cis	rs9355610	0.609	rs3756838	chr6:167371251	G/A	cg23791538	chr6:167370224	RNASET2	0.41	5.9	0.31	8.99e-9	Graves' disease;
LUSC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg16240275	chr20:61666158	NCRNA00029	0.42	9.4	0.46	9.21e-19	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2742234	0.955	rs2075913	chr10:43622368	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.36	-6.68	-0.34	9.8e-11	Hirschsprung disease;
LUSC	cis	rs12760731	0.720	rs12691481	chr1:178392653	T/C	cg00404053	chr1:178313656	RASAL2	0.54	6.23	0.32	1.38e-9	Obesity-related traits;
LUSC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg15352829	chr14:105391018	PLD4	-0.43	-9.01	-0.44	1.62e-17	Rheumatoid arthritis;
LUSC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg09021430	chr5:549028	NA	-0.56	-7.48	-0.38	6.59e-13	Obesity-related traits;
LUSC	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg01677386	chr11:118938358	VPS11	-0.49	-6.96	-0.36	1.8e-11	Coronary artery disease;
LUSC	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg23598886	chr18:12777645	NA	-0.58	-5.75	-0.3	2.01e-8	Inflammatory skin disease;
LUSC	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg10518543	chr12:38710700	ALG10B	-0.42	-5.89	-0.31	9.47e-9	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2219968	0.728	rs1988920	chr8:78841080	G/T	cg00738934	chr8:78996279	NA	-0.36	-6.15	-0.32	2.16e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6977660	0.652	rs10267417	chr7:19843797	C/T	cg07541023	chr7:19748670	TWISTNB	0.61	6.02	0.31	4.56e-9	Thyroid stimulating hormone;
LUSC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg27398817	chr8:82754497	SNX16	0.47	6.38	0.33	5.89e-10	Diastolic blood pressure;
LUSC	cis	rs2625529	0.730	rs2929527	chr15:72282270	T/G	cg16672083	chr15:72433130	SENP8	0.49	8.05	0.4	1.43e-14	Red blood cell count;
LUSC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-1.03	-19.85	-0.74	1.79e-58	Height;
LUSC	cis	rs8114671	0.933	rs6142327	chr20:33793147	T/A	cg24642439	chr20:33292090	TP53INP2	-0.41	-6.02	-0.31	4.51e-9	Height;
LUSC	cis	rs7605827	0.930	rs11680044	chr2:15607103	T/G	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.67	0.6	4.11e-34	Platelet count;
LUSC	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg16339924	chr4:17578868	LAP3	0.48	7.11	0.36	7.16e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg10547527	chr2:198650123	BOLL	-0.5	-5.87	-0.31	1.04e-8	Ulcerative colitis;
LUSC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg04414720	chr1:150670196	GOLPH3L	0.56	9.1	0.45	8.47e-18	Tonsillectomy;
LUSC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg07395648	chr5:131743802	NA	0.37	5.83	0.3	1.29e-8	Asthma (sex interaction);
LUSC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg08219700	chr8:58056026	NA	0.5	5.93	0.31	7.63e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12410462	0.581	rs6675521	chr1:227544702	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.66	-6.47	-0.33	3.44e-10	Major depressive disorder;
LUSC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg04850211	chr1:228464232	OBSCN	-0.33	-6.15	-0.32	2.27e-9	Diastolic blood pressure;
LUSC	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.21	0.52	5.74e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs6688613	0.685	rs10918600	chr1:166919342	C/T	cg07049167	chr1:166818506	POGK	-0.43	-6.3	-0.33	9.33e-10	Refractive astigmatism;
LUSC	cis	rs4478858	0.684	rs16865957	chr1:31753353	G/A	cg00250761	chr1:31883323	NA	-0.34	-8.15	-0.41	7.26e-15	Alcohol dependence;
LUSC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.49	0.33	3.07e-10	Alzheimer's disease (late onset);
LUSC	trans	rs724744	0.742	rs1205931	chr6:22358551	T/A	cg13807341	chr11:118445984	ARCN1	-0.35	-5.95	-0.31	6.64e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg05234568	chr11:5960015	NA	-0.55	-8.66	-0.43	2.1e-16	DNA methylation (variation);
LUSC	cis	rs7189233	0.531	rs4783813	chr16:53518370	C/G	cg09728985	chr16:53543985	NA	-0.3	-5.68	-0.3	2.9e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg10523860	chr14:103875565	MARK3	-0.4	-6.32	-0.33	8.26e-10	Body mass index;
LUSC	cis	rs1784581	0.651	rs1784589	chr6:162389571	A/G	cg17173639	chr6:162384350	PARK2	-0.68	-12.19	-0.55	1.59e-28	Itch intensity from mosquito bite;
LUSC	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-0.93	-18.14	-0.7	1.14e-51	Brugada syndrome;
LUSC	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.5	-0.46	4.29e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg02167203	chr6:41068553	NFYA;LOC221442	0.39	5.85	0.3	1.17e-8	Alzheimer's disease (late onset);
LUSC	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg04362960	chr10:104952993	NT5C2	0.67	9.13	0.45	6.82e-18	Arsenic metabolism;
LUSC	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg15839431	chr19:19639596	YJEFN3	-0.66	-7.29	-0.37	2.33e-12	Bipolar disorder;
LUSC	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.47	-0.46	5.1e-19	Schizophrenia;
LUSC	trans	rs11088226	0.538	rs4816436	chr21:33880251	A/G	cg09050820	chr6:167586206	TCP10L2	0.47	7.1	0.36	7.49e-12	Gastritis;
LUSC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.37	0.53	1.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.29	-0.45	2.04e-18	Morning vs. evening chronotype;
LUSC	cis	rs1322512	0.958	rs12195158	chr6:153006544	T/C	cg27316956	chr6:152958899	SYNE1	0.35	6.09	0.32	3.07e-9	Tonometry;
LUSC	cis	rs2274273	0.934	rs2341621	chr14:55726425	C/T	cg04306507	chr14:55594613	LGALS3	0.56	13.15	0.58	4.03e-32	Protein biomarker;
LUSC	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	8.85	0.44	5.39e-17	Migraine;Coronary artery disease;
LUSC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.4	0.62	6.35e-37	Platelet count;
LUSC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg01884057	chr2:25150051	NA	0.48	11.37	0.53	1.53e-25	Body mass index;
LUSC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	0.59	9.36	0.46	1.22e-18	Breast cancer;
LUSC	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg21890820	chr11:65308645	LTBP3	0.48	7.17	0.37	4.81e-12	Bone mineral density;
LUSC	cis	rs12137294	0.866	rs1172153	chr1:205220661	T/C	cg21643547	chr1:205240462	TMCC2	-0.35	-6.4	-0.33	5.2e-10	Red cell distribution width;
LUSC	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg27471124	chr11:109292789	C11orf87	0.52	8.58	0.42	3.74e-16	Schizophrenia;
LUSC	trans	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg13565492	chr6:43139072	SRF	-0.63	-6.57	-0.34	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6546550	0.803	rs10165883	chr2:70117015	C/T	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.45	-0.38	7.85e-13	Prevalent atrial fibrillation;
LUSC	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.66	-10.39	-0.49	4.2e-22	Height;
LUSC	trans	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.7	0.51	3.71e-23	Mean corpuscular volume;
LUSC	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg01516881	chr6:292596	DUSP22	-0.52	-7.58	-0.38	3.53e-13	Menopause (age at onset);
LUSC	cis	rs11264799	0.539	rs2777968	chr1:157549325	T/G	cg18268488	chr1:157545234	FCRL4	0.39	7.61	0.38	2.88e-13	IgA nephropathy;
LUSC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg09165964	chr15:75287851	SCAMP5	0.5	7.38	0.37	1.26e-12	Breast cancer;
LUSC	cis	rs2070997	0.667	rs13295907	chr9:133718242	G/T	cg11464064	chr9:133710261	ABL1	0.48	5.65	0.3	3.47e-8	Response to amphetamines;
LUSC	cis	rs11030122	0.702	rs10835402	chr11:3990914	T/C	cg08557956	chr11:4115526	RRM1	-0.47	-5.95	-0.31	6.69e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg17264618	chr3:40429014	ENTPD3	0.32	6.7	0.34	8.83e-11	Renal cell carcinoma;
LUSC	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg25182066	chr10:30743637	MAP3K8	-0.48	-6.74	-0.35	6.94e-11	Inflammatory bowel disease;
LUSC	cis	rs6500395	0.928	rs12934788	chr16:48706343	C/A	cg04672837	chr16:48644449	N4BP1	-0.45	-6.74	-0.35	6.96e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.58e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.39	-7.96	-0.4	2.79e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs7707921	0.767	rs6894520	chr5:81594748	C/T	cg21483461	chr5:81570383	RPS23	-0.38	-5.72	-0.3	2.36e-8	Breast cancer;
LUSC	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg05738196	chr6:26577821	NA	0.77	13.72	0.6	2.75e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02187348	chr16:89574699	SPG7	0.62	10.37	0.49	4.87e-22	Multiple myeloma (IgH translocation);
LUSC	cis	rs4474465	1.000	rs11237500	chr11:78163636	G/A	cg27205649	chr11:78285834	NARS2	-0.52	-6.16	-0.32	2.11e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.6	-8.51	-0.42	5.97e-16	Diastolic blood pressure;
LUSC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg18827107	chr12:86230957	RASSF9	-0.48	-7.15	-0.36	5.49e-12	Major depressive disorder;
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.93	19.08	0.72	2.06e-55	Menarche (age at onset);
LUSC	cis	rs1355223	1.000	rs1355223	chr11:34764479	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-5.71	-0.3	2.54e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg24130564	chr14:104152367	KLC1	-0.48	-7.02	-0.36	1.24e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg21535247	chr6:8435926	SLC35B3	-0.59	-9.13	-0.45	6.77e-18	Motion sickness;
LUSC	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg15448220	chr1:150897856	SETDB1	0.43	6.2	0.32	1.63e-9	Melanoma;
LUSC	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.12	-0.32	2.64e-9	Joint mobility (Beighton score);
LUSC	cis	rs75804782	0.520	rs72987319	chr2:239351143	C/T	cg18131467	chr2:239335373	ASB1	-0.75	-6.67	-0.34	1.04e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs2708377	0.858	rs115781584	chr12:11304560	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.82	7.95	0.4	2.96e-14	Bitter taste perception;
LUSC	cis	rs7312774	0.609	rs2374656	chr12:107380411	A/C	cg16260113	chr12:107380972	MTERFD3	0.84	6.17	0.32	1.99e-9	Severe influenza A (H1N1) infection;
LUSC	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg23649088	chr2:200775458	C2orf69	-0.57	-7.43	-0.38	9.27e-13	Schizophrenia;
LUSC	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.38	7.51	0.38	5.28e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.65	-11.77	-0.54	5.47e-27	Aortic root size;
LUSC	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	0.6	9.45	0.46	5.98e-19	Breast cancer;
LUSC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	1.04	21.21	0.76	7.95e-64	Cognitive function;
LUSC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs2637266	0.783	rs846583	chr10:78495658	T/A	cg18941641	chr10:78392320	NA	0.4	7.25	0.37	2.91e-12	Pulmonary function;
LUSC	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14240646	chr10:27532245	ACBD5	0.88	8.42	0.42	1.16e-15	Breast cancer;
LUSC	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg07661805	chr8:143867942	LY6D	-0.26	-6.02	-0.31	4.54e-9	Urinary tract infection frequency;
LUSC	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-0.59	-9.34	-0.46	1.4e-18	Breast cancer;
LUSC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg16339924	chr4:17578868	LAP3	0.55	8.47	0.42	7.79e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-1.03	-20.48	-0.75	5.94e-61	Height;
LUSC	cis	rs6977660	1.000	rs6959889	chr7:19822024	A/C	cg05791153	chr7:19748676	TWISTNB	0.53	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LUSC	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg22491629	chr6:157744540	C6orf35	-0.88	-10.67	-0.5	4.68e-23	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs11165623	0.564	rs9887897	chr1:96996671	T/C	cg10631902	chr5:14652156	NA	-0.41	-6.08	-0.32	3.24e-9	Hip circumference;Waist circumference;
LUSC	cis	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg26958806	chr6:27640298	NA	0.84	6.6	0.34	1.66e-10	Depression;
LUSC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg09021430	chr5:549028	NA	-0.55	-7.55	-0.38	4.23e-13	Obesity-related traits;
LUSC	cis	rs1595825	0.891	rs74965164	chr2:198499162	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.67	-0.34	1.04e-10	Ulcerative colitis;
LUSC	cis	rs2742234	0.868	rs2505512	chr10:43633596	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.37	-6.51	-0.34	2.79e-10	Hirschsprung disease;
LUSC	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg25457927	chr22:38595422	NA	0.52	11.5	0.53	5.21e-26	Cutaneous nevi;
LUSC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-13.75	-0.6	2.07e-34	Extrinsic epigenetic age acceleration;
LUSC	cis	rs727505	1.000	rs67585224	chr7:124537476	A/C	cg23710748	chr7:124431027	NA	-0.42	-7.54	-0.38	4.53e-13	Lewy body disease;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg03043160	chr13:76056444	TBC1D4	-0.51	-6.21	-0.32	1.55e-9	Neuroticism;
LUSC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21016266	chr12:122356598	WDR66	-0.58	-8.66	-0.43	2.05e-16	Mean corpuscular volume;
LUSC	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg03676636	chr4:99064102	C4orf37	0.36	8.04	0.4	1.54e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01555853	chr2:18059744	KCNS3	0.41	6.06	0.31	3.76e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg11342453	chr6:26196699	NA	0.54	5.71	0.3	2.52e-8	Gout;Renal underexcretion gout;
LUSC	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg27411982	chr8:10470053	RP1L1	0.42	6.42	0.33	4.57e-10	Mood instability;
LUSC	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.59	-0.34	1.73e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg02569458	chr12:86230093	RASSF9	0.61	10.25	0.49	1.32e-21	Major depressive disorder;
LUSC	trans	rs1941687	0.702	rs1493924	chr18:31314721	T/C	cg27147174	chr7:100797783	AP1S1	-0.46	-6.69	-0.34	9.18e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs12266014	0.895	rs11014296	chr10:25202038	C/T	cg16316141	chr10:25305874	ENKUR;THNSL1	0.39	5.66	0.3	3.18e-8	Monocyte count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg08085267	chr17:45401833	C17orf57	0.53	8.61	0.43	2.88e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg12963246	chr6:28129442	ZNF389	0.45	6.19	0.32	1.79e-9	Parkinson's disease;
LUSC	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg04398451	chr17:18023971	MYO15A	0.44	6.96	0.36	1.79e-11	Total body bone mineral density;
LUSC	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg06623918	chr6:96969491	KIAA0776	0.73	8.64	0.43	2.33e-16	Migraine;Coronary artery disease;
LUSC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs16917546	1.000	rs10995248	chr10:64396042	A/G	cg03961010	chr10:64397487	ZNF365	0.41	6.65	0.34	1.2e-10	Basal cell carcinoma;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg09403165	chr15:90118814	C15orf42	0.51	6.34	0.33	7.66e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs3857536	0.740	rs9354392	chr6:66894555	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.36	-0.33	6.61e-10	Blood trace element (Cu levels);
LUSC	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/A	cg00631329	chr6:26305371	NA	-0.43	-6.09	-0.32	3.11e-9	Educational attainment;
LUSC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.25	0.49	1.34e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg04756594	chr16:24857601	SLC5A11	0.42	5.84	0.3	1.24e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.64	0.39	2.35e-13	Bipolar disorder;
LUSC	cis	rs6714710	0.580	rs57804205	chr2:98454472	G/A	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	6.6	0.34	1.62e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.67	11.87	0.54	2.37e-27	Aortic root size;
LUSC	cis	rs8141797	0.642	rs1004058	chr22:24482500	A/C	cg00411358	chr22:24577142	SUSD2	0.61	5.95	0.31	6.82e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg23649088	chr2:200775458	C2orf69	-0.57	-6.74	-0.35	7.11e-11	Schizophrenia;
LUSC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg04013166	chr16:89971882	TCF25	0.54	5.92	0.31	7.93e-9	Skin colour saturation;
LUSC	trans	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-7.54	-0.38	4.61e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.59e-9	Menopause (age at onset);
LUSC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg12463550	chr7:65579703	CRCP	-0.63	-5.68	-0.3	2.92e-8	Diabetic kidney disease;
LUSC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg07424592	chr7:64974309	NA	-0.64	-5.79	-0.3	1.61e-8	Diabetic kidney disease;
LUSC	trans	rs2288327	0.591	rs2562845	chr2:179514433	T/C	cg14011486	chr1:26737247	LIN28	0.51	6.43	0.33	4.3e-10	Atrial fibrillation;
LUSC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg20607287	chr7:12443886	VWDE	-0.58	-6.77	-0.35	5.96e-11	Coronary artery disease;
LUSC	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.61e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	13.27	0.59	1.39e-32	Post bronchodilator FEV1;
LUSC	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.9	0.4	4.05e-14	Corneal astigmatism;
LUSC	cis	rs4074961	0.527	rs10908356	chr1:38038388	G/A	cg02930200	chr1:38022384	DNALI1	0.29	5.9	0.31	8.81e-9	Axial length;
LUSC	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.63	0.47	1.59e-19	Menarche (age at onset);
LUSC	cis	rs11153306	0.515	rs3213575	chr6:111919271	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.35	-6.75	-0.35	6.65e-11	Tonsillectomy;
LUSC	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg25174290	chr11:3078921	CARS	-0.41	-6.12	-0.32	2.68e-9	Calcium levels;
LUSC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.22	-0.45	3.32e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	7.43	0.38	8.96e-13	Menarche (age at onset);
LUSC	cis	rs7267979	0.549	rs6138537	chr20:25184466	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.58	10.11	0.48	3.81e-21	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04565464	chr8:145669602	NFKBIL2	0.39	6.42	0.33	4.7e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg20368463	chr18:77673604	PQLC1	-0.54	-7.75	-0.39	1.15e-13	Schizophrenia;
LUSC	trans	rs11700980	0.551	rs2832014	chr21:30110966	T/A	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.41e-9	QRS complex (12-leadsum);
LUSC	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-9.81	-0.47	3.96e-20	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.85	0.3	1.18e-8	Breast cancer;
LUSC	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg01475377	chr6:109611718	NA	0.38	6.67	0.34	1.06e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs8071789	1.000	rs8071789	chr17:38006333	C/T	cg20243544	chr17:37824526	PNMT	0.4	5.93	0.31	7.54e-9	Selective IgA deficiency;
LUSC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.64	-10.74	-0.51	2.71e-23	Prudent dietary pattern;
LUSC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg04017836	chr7:65315216	NA	-0.37	-5.95	-0.31	6.75e-9	Height;
LUSC	trans	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg14895029	chr7:2775587	GNA12	-0.4	-5.95	-0.31	6.94e-9	Height;
LUSC	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg22029157	chr1:209979665	IRF6	0.78	9.85	0.47	2.93e-20	Cleft lip with or without cleft palate;
LUSC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg05026186	chr5:148520876	ABLIM3	-0.37	-6.01	-0.31	4.77e-9	Breast cancer;
LUSC	cis	rs250677	0.522	rs4431331	chr5:148353574	A/C	cg18129178	chr5:148520854	ABLIM3	-0.49	-6.95	-0.36	1.91e-11	Breast cancer;
LUSC	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.94	0.36	2.02e-11	Neuroticism;
LUSC	cis	rs116988415	0.584	rs17180497	chr14:65269707	A/C	cg25083366	chr14:65239357	SPTB	-0.65	-6.96	-0.36	1.75e-11	Daytime sleep phenotypes;
LUSC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg13560548	chr3:10150139	C3orf24	0.51	7.32	0.37	1.85e-12	Alzheimer's disease;
LUSC	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.71	-0.54	9.26e-27	Coffee consumption (cups per day);
LUSC	cis	rs9650657	0.770	rs9969626	chr8:10670801	A/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.34	-0.33	7.25e-10	Neuroticism;
LUSC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg12310025	chr6:25882481	NA	-0.45	-7.83	-0.39	6.42e-14	Height;
LUSC	cis	rs9649213	0.555	rs6955259	chr7:97892356	T/A	cg08684580	chr7:98029266	BAIAP2L1	-0.42	-7.39	-0.38	1.16e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	7.57	0.38	3.6e-13	Electroencephalogram traits;
LUSC	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg04310649	chr10:35416472	CREM	-0.42	-6.59	-0.34	1.71e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg01657329	chr11:68192670	LRP5	-0.43	-6.87	-0.35	3.14e-11	Total body bone mineral density;
LUSC	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg07930552	chr6:133119739	C6orf192	0.95	8.49	0.42	7.03e-16	Type 2 diabetes nephropathy;
LUSC	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg06612196	chr6:6737390	NA	0.56	11.11	0.52	1.32e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.31	-5.77	-0.3	1.84e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg05043794	chr9:111880884	C9orf5	-0.32	-6.75	-0.35	6.51e-11	Menarche (age at onset);
LUSC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-7.7	-0.39	1.6e-13	Personality dimensions;
LUSC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg24675658	chr1:53192096	ZYG11B	-0.53	-7.53	-0.38	4.89e-13	Monocyte count;
LUSC	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg19700328	chr14:106028568	NA	-0.41	-6.9	-0.35	2.58e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs2979489	0.945	rs12548554	chr8:30346544	G/A	cg26383811	chr8:30366931	RBPMS	-0.55	-8.63	-0.43	2.56e-16	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	trans	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.59	-0.34	1.71e-10	Endometrial cancer;
LUSC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-6.7	-0.34	8.72e-11	Tonsillectomy;
LUSC	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	0.86	11.38	0.53	1.4e-25	Coronary artery disease;
LUSC	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg11901034	chr3:128598214	ACAD9	-0.42	-6.67	-0.34	1.09e-10	IgG glycosylation;
LUSC	trans	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.32	-0.33	8.55e-10	Bladder cancer;
LUSC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07157834	chr1:205819609	PM20D1	0.52	8.38	0.42	1.5e-15	Menarche (age at onset);
LUSC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	1.22	16.34	0.67	1.68e-44	Eosinophil percentage of granulocytes;
LUSC	trans	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg14403583	chr14:105418241	AHNAK2	-0.57	-9.68	-0.47	1.1e-19	Rheumatoid arthritis;
LUSC	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg12011299	chr4:100065546	ADH4	-0.72	-10.42	-0.5	3.38e-22	Alcohol dependence;
LUSC	cis	rs7000551	0.619	rs2443506	chr8:22373383	T/C	cg12081754	chr8:22256438	SLC39A14	0.42	6.35	0.33	7.14e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs10905065	0.735	rs10795347	chr10:5742077	C/G	cg25171089	chr10:5708825	ASB13	-0.4	-5.73	-0.3	2.25e-8	Menopause (age at onset);
LUSC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	7.43	0.38	9.07e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07741184	chr6:167504864	NA	0.37	6.37	0.33	6.38e-10	Primary biliary cholangitis;
LUSC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg08392591	chr16:89556376	ANKRD11	0.47	7.27	0.37	2.59e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg08219700	chr8:58056026	NA	0.45	5.75	0.3	1.98e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06634786	chr22:41940651	POLR3H	-0.53	-6.47	-0.33	3.45e-10	Vitiligo;
LUSC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg06641503	chr3:48959341	ARIH2	-0.39	-5.88	-0.31	9.73e-9	Parkinson's disease;
LUSC	cis	rs9362426	0.708	rs7744793	chr6:88102040	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	5.98	0.31	5.67e-9	Depressive episodes in bipolar disorder;
LUSC	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.72	10.85	0.51	1.08e-23	Eosinophil percentage of white cells;
LUSC	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg03676636	chr4:99064102	C4orf37	0.37	7.68	0.39	1.8e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.63	-0.43	2.45e-16	Lung cancer;
LUSC	cis	rs72781680	0.752	rs72796114	chr2:23906133	C/G	cg08917208	chr2:24149416	ATAD2B	0.98	9.69	0.47	9.64e-20	Lymphocyte counts;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg01495663	chr14:21945285	RAB2B;TOX4	0.46	6.66	0.34	1.1e-10	Mosquito bite size;
LUSC	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg15819921	chr19:927150	ARID3A	0.44	6.53	0.34	2.48e-10	Life satisfaction;
LUSC	cis	rs4891159	0.790	rs8085133	chr18:74144083	A/C	cg24786174	chr18:74118243	ZNF516	-0.9	-18.48	-0.71	4.91e-53	Longevity;
LUSC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg15017067	chr4:17643749	FAM184B	0.34	5.66	0.3	3.25e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg11247378	chr22:39784982	NA	-0.63	-12.21	-0.56	1.34e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg17788362	chr6:86352627	SYNCRIP	0.48	7.17	0.37	4.95e-12	Smooth-surface caries;
LUSC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.6	-10.73	-0.51	2.85e-23	Longevity;Endometriosis;
LUSC	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg11473876	chr11:109292803	C11orf87	0.41	6.76	0.35	6.14e-11	Schizophrenia;
LUSC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Body mass index;
LUSC	cis	rs62400317	0.826	rs12194628	chr6:45329376	G/C	cg18551225	chr6:44695536	NA	-0.44	-7.22	-0.37	3.52e-12	Total body bone mineral density;
LUSC	trans	rs7939886	0.920	rs77391761	chr11:55814896	G/C	cg03929089	chr4:120376271	NA	0.77	6.33	0.33	8e-10	Myopia (pathological);
LUSC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs240764	0.658	rs7746961	chr6:101215244	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.26	-0.32	1.21e-9	Neuroticism;
LUSC	trans	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.35	0.37	1.5e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs13082711	0.911	rs4973769	chr3:27425746	T/C	cg02860705	chr3:27208620	NA	0.49	8.38	0.42	1.53e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg06713675	chr4:122721982	EXOSC9	0.38	6.24	0.32	1.3e-9	Type 2 diabetes;
LUSC	cis	rs7818345	0.967	rs4481612	chr8:19285336	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.7	0.34	8.83e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs308403	0.608	rs309368	chr4:123662997	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.83	10.96	0.51	4.31e-24	Blood protein levels;
LUSC	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg23093090	chr10:104574429	C10orf26	-0.36	-6.63	-0.34	1.33e-10	Arsenic metabolism;
LUSC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18876405	chr7:65276391	NA	0.54	8.46	0.42	8.32e-16	Aortic root size;
LUSC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg00339695	chr16:24857497	SLC5A11	-0.37	-6.46	-0.33	3.69e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3857067	1.000	rs3857067	chr4:95026434	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.3	-5.65	-0.3	3.47e-8	QT interval;
LUSC	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg12826209	chr6:26865740	GUSBL1	0.52	7.42	0.38	9.51e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01523759	chr16:89202603	ACSF3	-0.44	-6.94	-0.36	2.03e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg05896524	chr21:47604654	C21orf56	0.56	8.78	0.43	8.75e-17	Testicular germ cell tumor;
LUSC	cis	rs73198271	0.694	rs73201840	chr8:8647067	G/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.32	-0.33	8.29e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg13560548	chr3:10150139	C3orf24	0.49	6.89	0.35	2.82e-11	Alzheimer's disease;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg26243475	chr13:51484009	RNASEH2B	0.46	6.01	0.31	4.76e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9612	1.000	rs346527	chr19:44259361	A/G	cg08581076	chr19:44259116	C19orf61	0.53	6.66	0.34	1.1e-10	Exhaled nitric oxide output;
LUSC	trans	rs9650657	0.665	rs1897207	chr8:10615235	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.27	-0.32	1.14e-9	Neuroticism;
LUSC	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg17366294	chr4:99064904	C4orf37	0.58	9.89	0.48	2.08e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg13854012	chr2:162103682	NA	-0.45	-7.97	-0.4	2.53e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs1775715	0.737	rs2799015	chr10:32107712	C/T	cg18675610	chr10:32216311	ARHGAP12	0.31	6.58	0.34	1.8e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs11039100	0.607	rs11038946	chr11:5779859	C/T	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12541635	0.966	rs6469028	chr8:107014552	C/T	cg10147462	chr8:107024639	NA	0.55	9.85	0.47	3.01e-20	Age of smoking initiation;
LUSC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	5.92	0.31	8.08e-9	Parkinson's disease;
LUSC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg15494558	chr6:150152522	LRP11	0.34	5.77	0.3	1.77e-8	Lung cancer;
LUSC	cis	rs977987	0.843	rs4888372	chr16:75313485	G/A	cg04384234	chr16:75411784	CFDP1	-0.41	-6.82	-0.35	4.32e-11	Dupuytren's disease;
LUSC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-8.02	-0.4	1.8e-14	Height;
LUSC	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg10978503	chr1:24200527	CNR2	0.54	13.21	0.59	2.32e-32	Immature fraction of reticulocytes;
LUSC	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg02100629	chr10:71892760	AIFM2	-0.38	-6.07	-0.32	3.43e-9	Blood protein levels;
LUSC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg18758796	chr5:131593413	PDLIM4	0.34	5.83	0.3	1.31e-8	Blood metabolite levels;
LUSC	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg14345882	chr6:26364793	BTN3A2	0.6	5.69	0.3	2.81e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	9.0	0.44	1.8e-17	Schizophrenia;
LUSC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg13397359	chr6:42928475	GNMT	0.58	9.85	0.47	2.9e-20	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg04850017	chr11:63683019	RCOR2	0.37	7.56	0.38	3.92e-13	Schizophrenia;
LUSC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.01e-9	Life satisfaction;
LUSC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg05347473	chr6:146136440	FBXO30	-0.55	-9.43	-0.46	7.02e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.39	-6.02	-0.31	4.69e-9	Platelet count;
LUSC	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.5	-6.78	-0.35	5.4e-11	IgG glycosylation;
LUSC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	6.27	0.32	1.14e-9	Mean platelet volume;
LUSC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.71	-11.04	-0.52	2.31e-24	Aortic root size;
LUSC	cis	rs7605827	0.930	rs7602186	chr2:15510003	C/T	cg19274914	chr2:15703543	NA	0.45	8.77	0.43	9.38e-17	Educational attainment (years of education);
LUSC	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.44	-0.33	4.21e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18876405	chr7:65276391	NA	-0.56	-8.67	-0.43	1.96e-16	Aortic root size;
LUSC	cis	rs7809950	0.724	rs1858888	chr7:107046062	T/A	cg23024343	chr7:107201750	COG5	-0.7	-10.11	-0.48	3.99e-21	Coronary artery disease;
LUSC	cis	rs492146	0.740	rs1032418	chr6:52834957	A/T	cg24393602	chr6:52860404	GSTA4	0.4	5.82	0.3	1.36e-8	Epilepsy (remission after treatment);
LUSC	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.84	-0.3	1.21e-8	Testicular germ cell tumor;
LUSC	cis	rs6681460	0.932	rs4655640	chr1:67089220	T/C	cg02459107	chr1:67143332	SGIP1	0.46	8.42	0.42	1.15e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs6484504	0.600	rs2761593	chr11:31326752	G/T	cg06552810	chr11:31128660	NA	0.39	6.85	0.35	3.49e-11	Red blood cell count;
LUSC	cis	rs7560272	0.588	rs4852959	chr2:73880601	C/A	cg20560298	chr2:73613845	ALMS1	0.44	6.67	0.34	1.07e-10	Schizophrenia;
LUSC	trans	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17712092	chr4:129076599	LARP1B	-0.78	-11.91	-0.55	1.7e-27	Eosinophil percentage of white cells;
LUSC	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg16482183	chr6:26056742	HIST1H1C	0.7	8.3	0.41	2.61e-15	Iron status biomarkers;
LUSC	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg09941381	chr10:64027924	RTKN2	-0.38	-7.01	-0.36	1.31e-11	Rheumatoid arthritis;
LUSC	trans	rs10432489	0.708	rs3922471	chr2:181771937	T/C	cg11196870	chr8:41386826	GINS4	0.93	6.32	0.33	8.44e-10	QT interval;
LUSC	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg08355456	chr11:67383691	NA	-0.37	-6.55	-0.34	2.19e-10	Mean corpuscular volume;
LUSC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	10.0	0.48	8.85e-21	Personality dimensions;
LUSC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.47	5.68	0.3	2.87e-8	Renal function-related traits (BUN);
LUSC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg20887711	chr4:1340912	KIAA1530	0.44	6.62	0.34	1.46e-10	Obesity-related traits;
LUSC	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg26597838	chr10:835615	NA	0.78	9.46	0.46	5.75e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs6545883	0.868	rs6545887	chr2:61828818	C/G	cg15711740	chr2:61764176	XPO1	-0.46	-7.31	-0.37	1.98e-12	Tuberculosis;
LUSC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg17366294	chr4:99064904	C4orf37	0.56	9.96	0.48	1.2e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg11189052	chr15:85197271	WDR73	-0.46	-5.8	-0.3	1.57e-8	Schizophrenia;
LUSC	cis	rs1185460	1.000	rs1784305	chr11:118942048	G/A	cg23280166	chr11:118938394	VPS11	0.45	6.89	0.35	2.82e-11	Coronary artery disease;
LUSC	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg16240275	chr20:61666158	NCRNA00029	0.41	8.95	0.44	2.43e-17	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs4293296	0.525	rs28429558	chr14:54827875	A/G	cg02257953	chr14:54816093	NA	-0.44	-6.19	-0.32	1.78e-9	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	trans	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.48	0.42	7.16e-16	Diabetic kidney disease;
LUSC	cis	rs500891	0.645	rs1180189	chr6:83966928	A/T	cg08257003	chr6:84140564	ME1	0.3	6.7	0.34	8.8e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03934478	chr11:495069	RNH1	0.79	8.95	0.44	2.5e-17	Body mass index;
LUSC	trans	rs7939886	0.920	rs7946368	chr11:55804219	C/T	cg15704280	chr7:45808275	SEPT13	0.8	6.88	0.35	3.04e-11	Myopia (pathological);
LUSC	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg03806693	chr22:41940476	POLR3H	-0.54	-7.28	-0.37	2.4e-12	Neuroticism;
LUSC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.86	-0.31	1.11e-8	Tonsillectomy;
LUSC	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg19920283	chr7:105172520	RINT1	0.61	6.67	0.34	1.07e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg06627628	chr2:24431161	ITSN2	-0.61	-7.4	-0.38	1.09e-12	Lymphocyte counts;
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.47	7.27	0.37	2.58e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg11062466	chr8:58055876	NA	0.76	9.04	0.44	1.31e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg27494647	chr7:150038898	RARRES2	0.53	8.0	0.4	2e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12900413	0.562	rs28450767	chr15:90298228	A/G	cg24249390	chr15:90295951	MESP1	-0.38	-5.95	-0.31	6.73e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs939658	1.000	rs11072826	chr15:79461516	C/T	cg17916960	chr15:79447300	NA	0.52	10.5	0.5	1.8e-22	Refractive error;
LUSC	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg21427119	chr20:30132790	HM13	-0.39	-5.73	-0.3	2.25e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg18512352	chr11:47633146	NA	0.47	9.41	0.46	8.43e-19	Subjective well-being;
LUSC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.12	-0.72	1.42e-55	Height;
LUSC	cis	rs79387448	0.745	rs17027341	chr2:103136559	A/G	cg09003973	chr2:102972529	NA	0.86	8.61	0.43	3.03e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.53	-7.88	-0.4	4.6e-14	Lymphocyte counts;
LUSC	trans	rs57046232	0.552	rs1998971	chr20:6334912	G/A	cg17788362	chr6:86352627	SYNCRIP	0.42	6.1	0.32	2.95e-9	Colorectal cancer;
LUSC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg21573476	chr21:45109991	RRP1B	-0.4	-6.36	-0.33	6.5e-10	Mean corpuscular volume;
LUSC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22590775	chr19:49891494	CCDC155	0.61	8.9	0.44	3.74e-17	Multiple sclerosis;
LUSC	cis	rs12249377	0.519	rs10785972	chr10:92593800	C/T	cg14313238	chr10:92632228	RPP30	0.42	5.76	0.3	1.87e-8	White matter microstructure (global fractional anisotropy);
LUSC	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.61	11.41	0.53	1.09e-25	Obesity (extreme);
LUSC	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg15848620	chr12:58087721	OS9	0.45	6.28	0.33	1.05e-9	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs10986311	0.802	rs7045589	chr9:127110354	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.45	7.4	0.38	1.14e-12	Vitiligo;
LUSC	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg06028605	chr16:24865363	SLC5A11	0.46	8.2	0.41	5.17e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg14530993	chr4:882597	GAK	0.75	7.15	0.36	5.42e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	0.95	11.68	0.54	1.14e-26	Nonalcoholic fatty liver disease;
LUSC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.38	-0.37	1.23e-12	Psoriasis;
LUSC	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg06937882	chr20:24974362	C20orf3	-0.43	-7.41	-0.38	1.04e-12	Blood protein levels;
LUSC	cis	rs9309473	0.607	rs6546824	chr2:73587331	G/A	cg20560298	chr2:73613845	ALMS1	-0.56	-8.25	-0.41	3.61e-15	Metabolite levels;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg27588902	chr6:42928151	GNMT	-0.3	-6.66	-0.34	1.14e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09468767	chr5:159848851	PTTG1	-0.4	-6.02	-0.31	4.52e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.87	14.84	0.63	1.29e-38	Bladder cancer;
LUSC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.03	-19.85	-0.74	1.83e-58	Cognitive function;
LUSC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.81	13.52	0.59	1.62e-33	Aortic root size;
LUSC	cis	rs79387448	0.745	rs7583683	chr2:103113763	C/T	cg09003973	chr2:102972529	NA	-0.88	-8.77	-0.43	9.45e-17	Gut microbiota (bacterial taxa);
LUSC	cis	rs7181230	1.000	rs9972424	chr15:40365851	A/G	cg00868766	chr15:40364524	NA	0.34	5.92	0.31	7.8e-9	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg11764359	chr7:65958608	NA	0.52	6.71	0.34	8.37e-11	Aortic root size;
LUSC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-1.04	-24.31	-0.8	6.97e-76	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg06877462	chr1:205807181	PM20D1	0.34	6.19	0.32	1.81e-9	Monocyte percentage of white cells;
LUSC	cis	rs11690935	0.655	rs12997093	chr2:172564438	A/G	cg13550731	chr2:172543902	DYNC1I2	0.59	9.35	0.46	1.34e-18	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-0.82	-10.08	-0.48	4.74e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.77	-0.54	5.61e-27	Mean corpuscular volume;
LUSC	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg11473876	chr11:109292803	C11orf87	0.35	5.97	0.31	5.95e-9	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-8.31	-0.41	2.37e-15	Alzheimer's disease;
LUSC	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.6	-9.67	-0.47	1.11e-19	Body mass index;
LUSC	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.01e-14	Retinal vascular caliber;
LUSC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.52	-11.05	-0.52	2.05e-24	Type 2 diabetes;
LUSC	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.83	0.51	1.22e-23	Morning vs. evening chronotype;
LUSC	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg03264133	chr6:25882463	NA	-0.34	-5.7	-0.3	2.61e-8	Height;
LUSC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	cis	rs4072705	0.646	rs10120967	chr9:127244134	C/T	cg13476313	chr9:127244764	NR5A1	0.35	6.89	0.35	2.81e-11	Menarche (age at onset);
LUSC	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.67	0.6	4.14e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4363385	0.510	rs2068678	chr1:152906956	G/A	cg00922841	chr1:152955080	SPRR1A	-0.37	-5.95	-0.31	6.9e-9	Inflammatory skin disease;
LUSC	cis	rs6464929	0.911	rs6965276	chr7:148724505	G/A	cg23583168	chr7:148888333	NA	0.46	5.87	0.31	1.07e-8	Pediatric bone mineral content (hip);
LUSC	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.96	0.7	5.99e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg04455712	chr21:45112962	RRP1B	0.45	8.46	0.42	8.73e-16	Mean corpuscular volume;
LUSC	cis	rs997295	0.554	rs7180312	chr15:68105256	G/A	cg08079166	chr15:68083412	MAP2K5	0.37	7.65	0.39	2.19e-13	Motion sickness;
LUSC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-10.69	-0.5	4.05e-23	Schizophrenia;
LUSC	cis	rs12210905	0.614	rs12199685	chr6:27323486	G/A	cg08851530	chr6:28072375	NA	0.9	5.78	0.3	1.75e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18404041	chr3:52824283	ITIH1	-0.5	-9.39	-0.46	9.65e-19	Bipolar disorder;
LUSC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.04	-0.4	1.62e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg24531977	chr5:56204891	C5orf35	-0.57	-8.52	-0.42	5.73e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08048268	chr3:133502702	NA	-0.49	-9.55	-0.46	2.94e-19	Iron status biomarkers;
LUSC	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg00405596	chr8:11794950	NA	0.36	6.02	0.31	4.62e-9	Myopia (pathological);
LUSC	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.72	0.34	8.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	10.03	0.48	7.42e-21	Coffee consumption (cups per day);
LUSC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg13047869	chr3:10149882	C3orf24	-0.61	-8.12	-0.41	8.92e-15	Alzheimer's disease;
LUSC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg10207240	chr12:122356781	WDR66	0.47	6.64	0.34	1.29e-10	Mean corpuscular volume;
LUSC	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg26769984	chr7:1090371	C7orf50	0.67	9.94	0.48	1.4e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.71	-0.43	1.4e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.68	7.64	0.39	2.31e-13	Diabetic retinopathy;
LUSC	cis	rs7577696	0.925	rs7573543	chr2:32342508	A/T	cg02381751	chr2:32503542	YIPF4	-0.4	-5.7	-0.3	2.7e-8	Inflammatory biomarkers;
LUSC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg25072359	chr17:41440525	NA	0.65	9.35	0.46	1.28e-18	Menopause (age at onset);
LUSC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.87	14.68	0.63	5.27e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg11871910	chr12:69753446	YEATS4	0.45	5.83	0.3	1.3e-8	Response to diuretic therapy;
LUSC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.57	-10.3	-0.49	8.96e-22	Homoarginine levels;
LUSC	trans	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg12856521	chr11:46389249	DGKZ	0.39	6.34	0.33	7.44e-10	Leprosy;
LUSC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg02415014	chr8:143852576	LYNX1	0.32	7.59	0.38	3.22e-13	Urinary tract infection frequency;
LUSC	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg26924012	chr15:45694286	SPATA5L1	0.77	12.26	0.56	8.62e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs68170813	0.652	rs6958969	chr7:107197755	A/T	cg24556660	chr7:106842632	COG5;HBP1	-0.45	-5.66	-0.3	3.23e-8	Coronary artery disease;
LUSC	cis	rs738321	0.757	rs5750546	chr22:38542499	C/T	cg25457927	chr22:38595422	NA	-0.42	-8.01	-0.4	1.93e-14	Breast cancer;
LUSC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg18305652	chr10:134549665	INPP5A	0.46	6.83	0.35	4.01e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs3768617	0.811	rs34721094	chr1:183051521	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.75	0.43	1.08e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg06718696	chr17:78121285	EIF4A3	0.44	6.29	0.33	9.77e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs9815354	1.000	rs73079321	chr3:41863910	C/T	cg03022575	chr3:42003672	ULK4	0.58	6.52	0.34	2.6e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg01943577	chr7:158741284	NA	-0.44	-6.88	-0.35	2.96e-11	Height;
LUSC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg10546459	chr2:36825355	FEZ2	0.52	7.55	0.38	4.08e-13	Height;
LUSC	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg15445000	chr17:37608096	MED1	0.39	6.63	0.34	1.35e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg23711669	chr6:146136114	FBXO30	0.83	15.34	0.64	1.48e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg26597838	chr10:835615	NA	0.53	6.42	0.33	4.72e-10	Eosinophil percentage of granulocytes;
LUSC	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg11887960	chr12:57824829	NA	0.55	6.69	0.34	9.64e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4713675	0.565	rs9469566	chr6:33667605	G/T	cg14003231	chr6:33640908	ITPR3	0.31	5.93	0.31	7.5e-9	Plateletcrit;
LUSC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg16606324	chr3:10149918	C3orf24	-0.62	-9.58	-0.46	2.34e-19	Alzheimer's disease;
LUSC	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg04218760	chr10:45406644	TMEM72	-0.3	-7.35	-0.37	1.57e-12	Mean corpuscular volume;
LUSC	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.12	15.56	0.65	1.87e-41	Uric acid levels;
LUSC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg05347473	chr6:146136440	FBXO30	0.45	7.61	0.38	2.74e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16457196	chr5:176944438	DDX41	-0.46	-5.98	-0.31	5.75e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs56161922	0.818	rs111340461	chr1:207870682	A/C	cg11752769	chr1:207818423	CR1L	-0.7	-5.91	-0.31	8.43e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg25258033	chr6:167368657	RNASET2	0.36	5.73	0.3	2.28e-8	Primary biliary cholangitis;
LUSC	cis	rs59698941	0.943	rs17691542	chr5:132279227	T/C	cg02081065	chr5:132209139	LEAP2	-0.6	-5.82	-0.3	1.4e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg19812747	chr11:111475976	SIK2	-0.52	-7.26	-0.37	2.67e-12	Primary sclerosing cholangitis;
LUSC	cis	rs4343996	0.967	rs10260145	chr7:3345308	C/T	cg21248987	chr7:3385318	SDK1	0.4	6.8	0.35	4.77e-11	Motion sickness;
LUSC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.78	-11.09	-0.52	1.52e-24	Blood protein levels;
LUSC	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg04450456	chr4:17643702	FAM184B	0.41	6.98	0.36	1.62e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg12560992	chr17:57184187	TRIM37	-0.84	-15.48	-0.65	3.83e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg04414720	chr1:150670196	GOLPH3L	0.5	7.71	0.39	1.45e-13	Melanoma;
LUSC	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.49	0.75	5.16e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs17253792	0.555	rs17683626	chr14:56041112	G/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.04	-0.36	1.1e-11	Putamen volume;
LUSC	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg15737290	chr11:93063684	CCDC67	0.68	8.22	0.41	4.45e-15	Pulmonary function decline;
LUSC	cis	rs2617583	0.509	rs62331137	chr5:1459573	A/G	cg13982541	chr5:1466431	LPCAT1	0.43	6.17	0.32	1.94e-9	Breast cancer;
LUSC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.11	-0.36	6.96e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg24686825	chr1:36642396	MAP7D1	-0.6	-9.31	-0.45	1.73e-18	Corneal structure;
LUSC	cis	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg06521852	chr22:38141419	TRIOBP	0.39	5.9	0.31	9.05e-9	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.1	0.55	3.33e-28	Cognitive test performance;
LUSC	cis	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg17469321	chr7:55412551	NA	0.65	10.53	0.5	1.45e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg06191203	chr2:152266755	RIF1	0.41	5.64	0.3	3.58e-8	Lung cancer;
LUSC	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg05621596	chr22:47072043	GRAMD4	-0.54	-8.55	-0.42	4.43e-16	Urate levels in obese individuals;
LUSC	cis	rs9398803	0.965	rs6907898	chr6:126666416	C/T	cg19875578	chr6:126661172	C6orf173	0.41	6.12	0.32	2.66e-9	Male-pattern baldness;
LUSC	trans	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg08601574	chr20:25228251	PYGB	-0.44	-6.79	-0.35	5.29e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Smoking initiation;
LUSC	trans	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.4	0.42	1.29e-15	Ulcerative colitis;
LUSC	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg26102564	chr10:131424627	MGMT	0.41	6.34	0.33	7.38e-10	Response to temozolomide;
LUSC	cis	rs9359856	0.518	rs11965790	chr6:90261621	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.59	-6.19	-0.32	1.75e-9	Bipolar disorder;
LUSC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	6.02	0.31	4.7e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg14664628	chr15:75095509	CSK	-1.01	-17.32	-0.69	2.09e-48	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg01620082	chr3:125678407	NA	-0.83	-7.35	-0.37	1.56e-12	Depression;
LUSC	cis	rs7580658	0.926	rs4662725	chr2:128141320	G/A	cg09760422	chr2:128146352	NA	-0.33	-7.25	-0.37	2.91e-12	Protein C levels;
LUSC	cis	rs77741769	0.571	rs73415720	chr12:121344515	T/C	cg02419362	chr12:121203948	SPPL3	0.45	8.29	0.41	2.85e-15	Mean corpuscular volume;
LUSC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg10755058	chr3:40428713	ENTPD3	0.35	5.97	0.31	6.05e-9	Renal cell carcinoma;
LUSC	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07080220	chr10:102295463	HIF1AN	0.59	7.86	0.4	5.23e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08859206	chr1:53392774	SCP2	-0.48	-8.14	-0.41	7.75e-15	Monocyte count;
LUSC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg12963246	chr6:28129442	ZNF389	0.38	5.73	0.3	2.28e-8	Cardiac Troponin-T levels;
LUSC	cis	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-8.23	-0.41	4.13e-15	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1832871	0.965	rs861179	chr6:158712720	A/G	cg07165851	chr6:158734300	TULP4	0.37	6.37	0.33	6.31e-10	Height;
LUSC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.37	0.59	6.04e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9633740	0.578	rs11185982	chr10:82305627	C/T	cg01528321	chr10:82214614	TSPAN14	0.73	6.95	0.36	1.91e-11	Post bronchodilator FEV1;
LUSC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.65	-9.74	-0.47	6.74e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg22903657	chr4:1355424	KIAA1530	-0.36	-6.02	-0.31	4.68e-9	Obesity-related traits;
LUSC	trans	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.24	-0.37	3.17e-12	Neuroticism;
LUSC	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg12560992	chr17:57184187	TRIM37	0.85	15.26	0.64	3e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.37	0.37	1.39e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-0.88	-18.2	-0.71	6.32e-52	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg04362960	chr10:104952993	NT5C2	0.6	9.4	0.46	8.93e-19	Arsenic metabolism;
LUSC	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.53	10.57	0.5	1e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs62432291	0.681	rs420054	chr6:159655084	C/G	cg14500486	chr6:159655392	FNDC1	-0.52	-5.86	-0.31	1.09e-8	Joint mobility (Beighton score);
LUSC	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.84	-0.44	5.72e-17	Axial length;
LUSC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-8.02	-0.4	1.74e-14	Longevity;Endometriosis;
LUSC	trans	rs475616	1.000	rs2795863	chr10:30500267	C/T	cg02841571	chr6:169977833	WDR27	0.41	6.0	0.31	5.01e-9	Monocyte count;
LUSC	cis	rs78366141	0.649	rs61737091	chr4:89671721	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.96	7.68	0.39	1.82e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs12493885	0.725	rs61793489	chr3:153731156	T/C	cg17054900	chr3:154042577	DHX36	-0.7	-7.28	-0.37	2.4e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg15790184	chr11:494944	RNH1	0.5	7.82	0.39	6.93e-14	Systemic lupus erythematosus;
LUSC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.48	0.38	6.59e-13	Motion sickness;
LUSC	cis	rs12618769	0.597	rs12617721	chr2:99083892	G/T	cg10123293	chr2:99228465	UNC50	-0.46	-7.69	-0.39	1.7e-13	Bipolar disorder;
LUSC	cis	rs73206853	0.841	rs57726856	chr12:110961123	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	7.83e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg06784218	chr1:46089804	CCDC17	0.51	10.18	0.49	2.28e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2219968	0.828	rs10102662	chr8:78906075	C/T	cg00738934	chr8:78996279	NA	0.34	6.01	0.31	4.99e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg21770322	chr7:97807741	LMTK2	0.53	9.42	0.46	7.44e-19	Breast cancer;
LUSC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg00343986	chr7:65444356	GUSB	-0.39	-5.81	-0.3	1.48e-8	Calcium levels;
LUSC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.06	20.08	0.74	2.32e-59	Cognitive ability;
LUSC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-5.87	-0.31	1.06e-8	Major depressive disorder;
LUSC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08439880	chr3:133502540	NA	-0.4	-7.32	-0.37	1.83e-12	Iron status biomarkers;
LUSC	trans	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs10276303	0.519	rs11983447	chr7:3399423	T/A	cg21248987	chr7:3385318	SDK1	-0.39	-6.52	-0.34	2.6e-10	Dupuytren's disease;
LUSC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg17211192	chr8:82754475	SNX16	-0.76	-10.05	-0.48	6.13e-21	Diastolic blood pressure;
LUSC	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg03605463	chr16:89740564	NA	0.59	9.22	0.45	3.39e-18	Vitiligo;
LUSC	cis	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.92	-0.4	3.48e-14	Height;
LUSC	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg02403541	chr12:121454288	C12orf43	0.59	8.46	0.42	8.6e-16	N-glycan levels;
LUSC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.62	12.64	0.57	3.5e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg13206674	chr6:150067644	NUP43	0.6	9.62	0.47	1.67e-19	Lung cancer;
LUSC	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg11244672	chr19:19639970	YJEFN3	-0.52	-6.49	-0.33	3.05e-10	Bipolar disorder;
LUSC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg02951883	chr7:2050386	MAD1L1	-0.51	-9.03	-0.44	1.42e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07636037	chr3:49044803	WDR6	0.69	8.83	0.43	6.21e-17	Menarche (age at onset);
LUSC	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg00490450	chr3:139108681	COPB2	0.53	8.24	0.41	3.94e-15	Obesity-related traits;
LUSC	trans	rs800082	1.000	rs9849975	chr3:144294530	A/G	cg24215973	chr2:240111563	HDAC4	-0.47	-7.16	-0.36	5.28e-12	Smoking behavior;
LUSC	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	1.04	14.11	0.61	9.12e-36	Exhaled nitric oxide levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11818790	chr22:42196598	CCDC134	-0.42	-6.25	-0.32	1.23e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7586879	0.861	rs10164466	chr2:25114069	T/C	cg15423357	chr2:25149977	NA	0.32	5.77	0.3	1.82e-8	Body mass index;
LUSC	cis	rs56399783	0.614	rs55776032	chr7:2762255	T/C	cg14895029	chr7:2775587	GNA12	0.55	5.93	0.31	7.66e-9	Childhood ear infection;
LUSC	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.5	-6.77	-0.35	5.66e-11	Neutrophil percentage of white cells;
LUSC	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.52	-8.28	-0.41	2.91e-15	Platelet count;
LUSC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg24399712	chr22:39784796	NA	-0.62	-11.12	-0.52	1.19e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg05802129	chr4:122689817	NA	-0.37	-6.69	-0.34	9.68e-11	Type 2 diabetes;
LUSC	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.68	9.95	0.48	1.33e-20	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs6554196	0.508	rs2237038	chr4:55525833	C/T	cg18836493	chr4:55524333	KIT	0.43	7.01	0.36	1.36e-11	Monocyte count;
LUSC	cis	rs11608355	0.597	rs10850070	chr12:109793882	A/G	cg19025524	chr12:109796872	NA	-0.49	-9.19	-0.45	4.27e-18	Neuroticism;
LUSC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.69	-11.07	-0.52	1.76e-24	Prudent dietary pattern;
LUSC	cis	rs7597155	0.967	rs4852995	chr2:69983663	G/C	cg02498382	chr2:70120550	SNRNP27	-0.24	-5.69	-0.3	2.76e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.02	0.31	4.51e-9	Schizophrenia;
LUSC	trans	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg14227996	chr4:17616232	MED28	-0.54	-6.06	-0.31	3.69e-9	Opioid sensitivity;
LUSC	trans	rs10432489	0.708	rs6730421	chr2:181755815	A/G	cg25678491	chr13:101327172	TMTC4	-0.78	-6.38	-0.33	5.97e-10	QT interval;
LUSC	cis	rs6901250	0.788	rs591794	chr6:117089018	G/A	cg12892004	chr6:117198278	RFX6	0.41	7.42	0.38	9.5e-13	C-reactive protein levels;
LUSC	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg20587970	chr11:113659929	NA	-1.04	-13.97	-0.61	3.13e-35	Hip circumference adjusted for BMI;
LUSC	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg06671706	chr8:8559999	CLDN23	0.5	6.49	0.33	3.18e-10	Obesity-related traits;
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-8.09	-0.4	1.14e-14	Longevity;Endometriosis;
LUSC	cis	rs9790314	0.663	rs4557202	chr3:160820524	G/C	cg03342759	chr3:160939853	NMD3	-0.42	-6.78	-0.35	5.43e-11	Morning vs. evening chronotype;
LUSC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	13.04	0.58	1.03e-31	Platelet count;
LUSC	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.82	-0.43	6.58e-17	Response to antipsychotic treatment;
LUSC	trans	rs1941687	0.505	rs12605642	chr18:31313965	G/T	cg13755796	chr4:20253514	NA	-0.39	-6.06	-0.31	3.75e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs7106204	0.748	rs6484031	chr11:24237115	A/C	ch.11.24196551F	chr11:24239977	NA	1.16	14.62	0.62	8.9e-38	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg05802129	chr4:122689817	NA	-0.34	-5.98	-0.31	5.62e-9	Type 2 diabetes;
LUSC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg11344533	chr11:111475393	SIK2	-0.49	-6.89	-0.35	2.86e-11	Primary sclerosing cholangitis;
LUSC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg13628971	chr7:2884303	GNA12	0.49	7.24	0.37	3.12e-12	Height;
LUSC	cis	rs11608355	0.545	rs12819658	chr12:109907670	A/T	cg05360138	chr12:110035743	NA	0.89	11.55	0.53	3.47e-26	Neuroticism;
LUSC	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg19622623	chr12:86230825	RASSF9	-0.43	-6.03	-0.31	4.27e-9	Major depressive disorder;
LUSC	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg12257692	chr3:49977190	RBM6	-0.21	-5.68	-0.3	2.9e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg08332330	chr12:125549884	AACS	0.41	6.35	0.33	7.09e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg13390004	chr1:15929781	NA	0.4	6.81	0.35	4.66e-11	Systolic blood pressure;
LUSC	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg08000102	chr2:233561755	GIGYF2	-0.5	-7.76	-0.39	1.04e-13	Coronary artery disease;
LUSC	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg24642439	chr20:33292090	TP53INP2	0.42	6.06	0.31	3.62e-9	Height;
LUSC	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.56	-8.86	-0.44	4.74e-17	Schizophrenia;
LUSC	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg17385448	chr1:15911702	AGMAT	0.37	6.33	0.33	8.03e-10	Systolic blood pressure;
LUSC	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg00339695	chr16:24857497	SLC5A11	0.36	6.28	0.33	1.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26314531	chr2:26401878	FAM59B	-0.71	-9.41	-0.46	8.43e-19	Gut microbiome composition (summer);
LUSC	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg24313572	chr1:56050060	NA	0.32	6.8	0.35	4.94e-11	Morning vs. evening chronotype;
LUSC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg12963246	chr6:28129442	ZNF389	0.4	6.4	0.33	5.12e-10	Parkinson's disease;
LUSC	cis	rs9633740	0.685	rs10749608	chr10:82243986	A/G	cg01528321	chr10:82214614	TSPAN14	1.0	6.98	0.36	1.58e-11	Post bronchodilator FEV1;
LUSC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.41	-0.33	4.89e-10	Menopause (age at onset);
LUSC	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg16359550	chr11:109292809	C11orf87	0.37	6.19	0.32	1.77e-9	Schizophrenia;
LUSC	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg18675610	chr10:32216311	ARHGAP12	0.3	6.48	0.33	3.23e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.56	10.98	0.52	3.71e-24	Prostate cancer;
LUSC	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg02016764	chr4:38805732	TLR1	-0.54	-5.74	-0.3	2.17e-8	Breast cancer;
LUSC	cis	rs7759001	0.857	rs7754411	chr6:27359584	A/T	cg18711553	chr6:27366782	ZNF391	-0.39	-5.74	-0.3	2.07e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-12.91	-0.58	3.2e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg26028573	chr6:26043587	HIST1H2BB	0.39	5.74	0.3	2.08e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.44	5.92	0.31	8.01e-9	Renal function-related traits (BUN);
LUSC	cis	rs36405	0.500	rs2013781	chr14:72357320	T/C	cg23396177	chr14:72358413	NA	-0.38	-7.01	-0.36	1.32e-11	Yang-deficiency constitution;
LUSC	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg05738196	chr6:26577821	NA	0.83	16.12	0.66	1.2e-43	Intelligence (multi-trait analysis);
LUSC	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.39	-6.46	-0.33	3.61e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs806215	0.901	rs989100	chr7:127220918	T/C	cg25922125	chr7:127225783	GCC1	-0.61	-7.4	-0.38	1.12e-12	Type 2 diabetes;
LUSC	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg18129178	chr5:148520854	ABLIM3	-0.7	-10.64	-0.5	5.82e-23	Breast cancer;
LUSC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs7394190	0.748	rs2292307	chr10:75549916	C/A	cg07699608	chr10:75541558	CHCHD1	0.5	5.68	0.3	2.93e-8	Incident atrial fibrillation;
LUSC	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg27661571	chr11:113659931	NA	-0.6	-7.25	-0.37	2.83e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg19774624	chr17:42201019	HDAC5	0.71	10.36	0.49	5.25e-22	Total body bone mineral density;
LUSC	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg18904891	chr8:8559673	CLDN23	0.41	6.27	0.32	1.09e-9	Mood instability;
LUSC	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.48	10.18	0.49	2.2e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg15711740	chr2:61764176	XPO1	0.51	8.12	0.41	8.95e-15	Tuberculosis;
LUSC	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.28	0.53	3.17e-25	Eye color traits;
LUSC	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17467752	chr17:38218738	THRA	0.78	12.57	0.57	5.92e-30	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs909341	0.909	rs2257885	chr20:62334220	G/A	cg09650180	chr20:62225654	GMEB2	-0.46	-6.0	-0.31	5.12e-9	Atopic dermatitis;
LUSC	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg12927641	chr6:109611667	NA	-0.35	-6.0	-0.31	5.23e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7605827	0.930	rs7606850	chr2:15678250	T/C	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.77e-16	Educational attainment (years of education);
LUSC	cis	rs11191270	0.554	rs11191253	chr10:104066507	A/T	cg15320455	chr10:103880129	LDB1	0.58	5.9	0.31	8.78e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1595825	0.891	rs16866940	chr2:198509058	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.61	-0.34	1.52e-10	Ulcerative colitis;
LUSC	trans	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.65	10.31	0.49	7.85e-22	Endometrial cancer;
LUSC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.16	-0.36	5.25e-12	Blood metabolite levels;
LUSC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.94	15.17	0.64	6.76e-40	Coronary artery disease;
LUSC	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg02023728	chr11:77925099	USP35	0.49	6.88	0.35	3.02e-11	Testicular germ cell tumor;
LUSC	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg09479241	chr17:27052676	TLCD1	-0.42	-5.92	-0.31	8.13e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	9.51	0.46	3.89e-19	Lung cancer in ever smokers;
LUSC	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	0.82	12.44	0.56	1.96e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-6.48	-0.33	3.34e-10	Lung cancer;
LUSC	cis	rs7617773	0.963	rs9822496	chr3:48181333	T/C	cg20734569	chr3:48348370	SPINK8	-0.43	-7.73	-0.39	1.24e-13	Coronary artery disease;
LUSC	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.31	-0.33	8.95e-10	Bipolar disorder;
LUSC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg15445000	chr17:37608096	MED1	0.4	6.86	0.35	3.35e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg24060327	chr5:131705240	SLC22A5	-0.52	-8.76	-0.43	1.03e-16	Breast cancer;
LUSC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg10729496	chr3:10149963	C3orf24	0.53	7.11	0.36	7.27e-12	Alzheimer's disease;
LUSC	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg20333904	chr2:240724165	NA	-0.4	-7.3	-0.37	2.1e-12	Obesity-related traits;
LUSC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22307029	chr19:49891270	CCDC155	0.67	9.41	0.46	8.02e-19	Multiple sclerosis;
LUSC	cis	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg10665199	chr7:133106180	EXOC4	0.58	8.08	0.4	1.19e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17465697	chr1:228594029	TRIM11	-0.58	-7.42	-0.38	1.01e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg05973401	chr12:123451056	ABCB9	0.54	7.31	0.37	1.97e-12	Neutrophil percentage of white cells;
LUSC	cis	rs721399	0.568	rs13254811	chr8:18273018	A/G	cg18736775	chr8:18248649	NAT2	-0.55	-6.5	-0.33	3.01e-10	Blood metabolite levels;
LUSC	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-15.5	-0.65	3.41e-41	Heart rate;
LUSC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.5	6.65	0.34	1.2e-10	Multiple sclerosis;
LUSC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg02951883	chr7:2050386	MAD1L1	-0.52	-9.11	-0.45	7.68e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs981844	0.826	rs1545604	chr4:154682733	C/T	cg14289246	chr4:154710475	SFRP2	0.5	6.69	0.34	9.33e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs4343996	0.626	rs57952815	chr7:3395417	T/A	cg21248987	chr7:3385318	SDK1	-0.37	-6.28	-0.33	1.02e-9	Motion sickness;
LUSC	cis	rs4474465	0.646	rs10793337	chr11:78285875	A/T	cg27205649	chr11:78285834	NARS2	0.6	7.51	0.38	5.4e-13	Alzheimer's disease (survival time);
LUSC	cis	rs6494488	0.500	rs59684202	chr15:65018501	A/C	cg08069370	chr15:64387884	SNX1	-0.61	-5.8	-0.3	1.52e-8	Coronary artery disease;
LUSC	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.5	-0.42	6.28e-16	Bladder cancer;
LUSC	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg13609457	chr4:120235615	NA	0.4	6.15	0.32	2.27e-9	Diastolic blood pressure;
LUSC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg06212747	chr3:49208901	KLHDC8B	0.42	5.81	0.3	1.43e-8	Parkinson's disease;
LUSC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg26897989	chr16:1907736	C16orf73	-0.44	-6.36	-0.33	6.63e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg07068942	chr3:156806752	NA	0.4	6.0	0.31	5.1e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg25237894	chr2:233734115	C2orf82	-0.33	-6.05	-0.31	3.82e-9	Coronary artery disease;
LUSC	cis	rs929596	0.793	rs2602376	chr2:234582051	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-7.0	-0.36	1.4e-11	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11890956	chr21:40555474	PSMG1	-0.74	-11.95	-0.55	1.2e-27	Cognitive function;
LUSC	cis	rs4594175	0.962	rs7157823	chr14:51633170	C/T	cg23942311	chr14:51606299	NA	0.3	5.68	0.3	2.86e-8	Cancer;
LUSC	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.78e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.28	-0.53	3.1e-25	Bipolar disorder;
LUSC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg05585544	chr11:47624801	NA	-0.42	-7.37	-0.37	1.35e-12	Subjective well-being;
LUSC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg23630131	chr7:65973040	NA	-0.2	-5.73	-0.3	2.23e-8	Aortic root size;
LUSC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	12.02	0.55	6.57e-28	Prudent dietary pattern;
LUSC	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg27246729	chr12:121163418	ACADS	0.42	6.63	0.34	1.38e-10	Mean corpuscular volume;
LUSC	cis	rs243505	1.000	rs243520	chr7:148423560	C/T	cg09806900	chr7:148480153	CUL1	-0.49	-6.87	-0.35	3.09e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12423338	chr3:99944194	NA	-0.77	-6.04	-0.31	4.11e-9	Cognitive performance;
LUSC	cis	rs2303282	0.716	rs7192780	chr16:56467566	A/G	cg00500540	chr16:56394104	NA	-0.43	-7.38	-0.37	1.27e-12	Breast cancer;
LUSC	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg17279839	chr7:150038598	RARRES2	0.43	6.62	0.34	1.44e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02018176	chr4:1364513	KIAA1530	0.55	9.75	0.47	6.39e-20	Longevity;
LUSC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg26924012	chr15:45694286	SPATA5L1	1.12	19.83	0.74	2.12e-58	Homoarginine levels;
LUSC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg16049864	chr8:95962084	TP53INP1	-0.68	-13.49	-0.59	2e-33	Type 2 diabetes;
LUSC	trans	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg26384229	chr12:38710491	ALG10B	0.59	8.76	0.43	9.93e-17	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs12476592	1.000	rs12476592	chr2:63850098	G/C	cg10828910	chr2:63850056	LOC388955	-0.55	-6.1	-0.32	3e-9	Childhood ear infection;
LUSC	cis	rs2273669	0.588	rs78276890	chr6:109305299	G/A	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.86	-0.4	5.34e-14	Blood metabolite levels;
LUSC	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg11584989	chr19:19387371	SF4	0.58	7.02	0.36	1.22e-11	Bipolar disorder;
LUSC	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.85	-0.31	1.15e-8	Resting heart rate;
LUSC	cis	rs12681287	0.640	rs13267782	chr8:87481887	G/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.36	6.31e-12	Caudate activity during reward;
LUSC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.78	-0.3	1.71e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg22800045	chr5:56110881	MAP3K1	0.46	6.12	0.32	2.65e-9	Coronary artery disease;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg06145435	chr7:1022769	CYP2W1	0.33	6.86	0.35	3.28e-11	Longevity;Endometriosis;
LUSC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg23711669	chr6:146136114	FBXO30	0.88	16.13	0.66	1.12e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2970818	0.764	rs11063182	chr12:4581371	A/G	cg11146114	chr12:4671731	NA	-0.58	-6.0	-0.31	5.05e-9	Phosphorus levels;
LUSC	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg19789473	chr17:27170043	C17orf63	-0.31	-5.83	-0.3	1.34e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9398803	0.865	rs9398810	chr6:126815604	C/A	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	1.94e-9	Male-pattern baldness;
LUSC	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.85	-0.35	3.67e-11	Retinal vascular caliber;
LUSC	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg13319975	chr6:146136371	FBXO30	-0.41	-6.01	-0.31	4.79e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11209002	1.000	rs3762320	chr1:67588647	T/G	cg02640540	chr1:67518911	SLC35D1	0.64	7.05	0.36	1.05e-11	Crohn's disease;
LUSC	cis	rs2573652	1.000	rs2581365	chr15:100513318	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.4	-7.36	-0.37	1.48e-12	Height;
LUSC	cis	rs6087990	0.735	rs6058891	chr20:31386347	T/C	cg13636640	chr20:31349939	DNMT3B	0.91	18.58	0.71	2.11e-53	Ulcerative colitis;
LUSC	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.06	0.31	3.74e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg22903657	chr4:1355424	KIAA1530	-0.48	-8.01	-0.4	1.94e-14	Obesity-related traits;
LUSC	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg00792783	chr2:198669748	PLCL1	0.43	5.7	0.3	2.66e-8	Dermatomyositis;
LUSC	cis	rs1403694	0.515	rs710448	chr3:186452885	A/G	cg12454167	chr3:186435060	KNG1	0.29	7.56	0.38	3.97e-13	Blood protein levels;
LUSC	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg18827107	chr12:86230957	RASSF9	-0.49	-7.15	-0.36	5.47e-12	Major depressive disorder;
LUSC	cis	rs7091068	0.616	rs7901507	chr10:95505424	C/G	cg20715218	chr10:95462985	C10orf4	0.59	6.48	0.33	3.2e-10	Urinary tract infection frequency;
LUSC	trans	rs11782517	0.889	rs56730365	chr8:10109379	G/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.05	0.31	3.83e-9	Nose size;
LUSC	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg00484396	chr16:3507460	NAT15	-0.39	-6.52	-0.34	2.54e-10	Body mass index (adult);
LUSC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.67	-8.82	-0.43	6.53e-17	Menarche (age at onset);
LUSC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-7.63	-0.39	2.53e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg27129171	chr3:47204927	SETD2	0.58	8.26	0.41	3.51e-15	Birth weight;
LUSC	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg12473912	chr3:136751656	NA	0.39	6.74	0.35	6.82e-11	Neuroticism;
LUSC	cis	rs500891	0.574	rs12203860	chr6:84174401	C/T	cg08257003	chr6:84140564	ME1	-0.31	-7.15	-0.36	5.58e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs8062405	0.756	rs151182	chr16:28495752	C/T	cg16576597	chr16:28551801	NUPR1	0.28	5.7	0.3	2.69e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs11030122	0.702	rs10835312	chr11:3950253	G/A	cg18678763	chr11:4115507	RRM1	-0.45	-5.82	-0.3	1.38e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9650315	0.733	rs56127704	chr8:57206231	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.33	0.37	1.73e-12	Height;
LUSC	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg25456477	chr12:86230367	RASSF9	0.39	6.84	0.35	3.72e-11	Major depressive disorder;
LUSC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg08088566	chr11:430123	ANO9	0.64	7.47	0.38	7.09e-13	Body mass index;
LUSC	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.28	-0.37	2.44e-12	Retinal vascular caliber;
LUSC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg22920501	chr2:26401640	FAM59B	-0.79	-11.86	-0.54	2.53e-27	Gut microbiome composition (summer);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg25560363	chr15:77925481	LINGO1	0.46	6.17	0.32	1.99e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs240764	0.853	rs12191199	chr6:101008093	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-6.48	-0.33	3.35e-10	Neuroticism;
LUSC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.5	6.4	0.33	5.32e-10	Facial morphology (factor 23);
LUSC	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg25206134	chr2:45395956	NA	0.53	6.3	0.33	9.55e-10	Bipolar disorder;
LUSC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg27432699	chr2:27873401	GPN1	-0.57	-8.44	-0.42	9.56e-16	Total body bone mineral density;
LUSC	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg21293242	chr8:11204541	TDH	0.31	5.75	0.3	2.04e-8	Retinal vascular caliber;
LUSC	cis	rs6495367	1.000	rs13380109	chr15:79378775	G/A	cg17916960	chr15:79447300	NA	0.35	6.73	0.35	7.48e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2282300	0.739	rs34855782	chr11:30225470	G/A	cg25418670	chr11:30344373	C11orf46	-0.61	-8.81	-0.43	7.19e-17	Morning vs. evening chronotype;
LUSC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg22563815	chr15:78856949	CHRNA5	-0.25	-6.09	-0.32	3.11e-9	Sudden cardiac arrest;
LUSC	cis	rs2282802	0.685	rs2116790	chr5:139654115	G/A	cg26211634	chr5:139558579	C5orf32	0.44	8.14	0.41	8.05e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-1.13	-17.99	-0.7	4.71e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-1.01	-24.32	-0.8	6.36e-76	Urate levels in lean individuals;
LUSC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg12963246	chr6:28129442	ZNF389	0.4	6.22	0.32	1.53e-9	Parkinson's disease;
LUSC	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	10.18	0.49	2.2e-21	Lymphocyte counts;
LUSC	cis	rs57994353	0.568	rs10870166	chr9:139316916	C/G	cg14019695	chr9:139328340	INPP5E	0.36	5.65	0.3	3.42e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUSC	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg05738196	chr6:26577821	NA	0.54	6.4	0.33	5.3e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg13647721	chr17:30228624	UTP6	-0.65	-6.38	-0.33	5.81e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	6.68	0.34	9.91e-11	Lung cancer in ever smokers;
LUSC	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	ch.11.42038R	chr11:967971	AP2A2	0.47	6.99	0.36	1.49e-11	Alzheimer's disease (late onset);
LUSC	cis	rs983392	0.667	rs583791	chr11:59947252	C/T	cg20284999	chr11:59952153	MS4A6A	0.36	6.24	0.32	1.3e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.86	12.53	0.57	8.99e-30	Asthma;
LUSC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.03	-15.49	-0.65	3.76e-41	Primary sclerosing cholangitis;
LUSC	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg20243544	chr17:37824526	PNMT	0.52	7.41	0.38	1.02e-12	Asthma;
LUSC	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg24375607	chr4:120327624	NA	-0.77	-11.53	-0.53	4.12e-26	Corneal astigmatism;
LUSC	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.73	14.19	0.61	4.47e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg21175976	chr8:11421337	BLK	0.34	5.81	0.3	1.44e-8	Neuroticism;
LUSC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg25204440	chr1:209979598	IRF6	0.5	5.72	0.3	2.36e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs60154123	0.614	rs127043	chr1:210459011	T/G	cg22029157	chr1:209979665	IRF6	0.5	5.88	0.31	9.75e-9	Coronary artery disease;
LUSC	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg04398451	chr17:18023971	MYO15A	0.4	6.24	0.32	1.36e-9	Total body bone mineral density;
LUSC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg09655341	chr17:79618100	PDE6G	0.27	6.31	0.33	9.05e-10	Eye color traits;
LUSC	cis	rs6545883	0.718	rs6715259	chr2:61851845	G/T	cg15711740	chr2:61764176	XPO1	-0.37	-5.85	-0.3	1.17e-8	Tuberculosis;
LUSC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-8.37	-0.42	1.55e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs7980799	0.649	rs2220059	chr12:33648630	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.92	-0.4	3.67e-14	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs7939886	0.764	rs12282595	chr11:55933084	C/T	cg15704280	chr7:45808275	SEPT13	0.8	6.14	0.32	2.3e-9	Myopia (pathological);
LUSC	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg11244672	chr19:19639970	YJEFN3	-0.54	-6.56	-0.34	1.99e-10	Bipolar disorder;
LUSC	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.88	15.03	0.64	2.4e-39	Bladder cancer;
LUSC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg14019146	chr3:50243930	SLC38A3	-0.29	-6.31	-0.33	8.76e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs926938	0.527	rs360583	chr1:115462743	C/T	cg12756093	chr1:115239321	AMPD1	0.46	7.0	0.36	1.43e-11	Autism;
LUSC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg06454157	chr6:167490870	NA	-0.3	-6.94	-0.36	2.04e-11	Crohn's disease;
LUSC	cis	rs1163251	0.756	rs539799	chr1:120208472	C/T	cg19096424	chr1:120255104	PHGDH	0.43	6.01	0.31	4.78e-9	Blood metabolite levels;
LUSC	cis	rs9910055	0.550	rs850856	chr17:42157739	C/T	cg19774624	chr17:42201019	HDAC5	0.71	9.79	0.47	4.52e-20	Total body bone mineral density;
LUSC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-7.03	-0.36	1.2e-11	Total body bone mineral density;
LUSC	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg04362960	chr10:104952993	NT5C2	0.59	9.34	0.46	1.42e-18	Arsenic metabolism;
LUSC	cis	rs1499972	0.941	rs7631320	chr3:117650116	T/C	cg07612923	chr3:117604196	NA	0.65	5.87	0.31	1.03e-8	Schizophrenia;
LUSC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06221963	chr1:154839813	KCNN3	-0.61	-13.83	-0.6	1.03e-34	Prostate cancer;
LUSC	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.62	-0.34	1.39e-10	QT interval;
LUSC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg03036452	chr22:46663545	TTC38	0.54	5.82	0.3	1.41e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs859767	0.519	rs11688414	chr2:135420237	G/A	cg12500956	chr2:135428796	TMEM163	-0.26	-6.02	-0.31	4.55e-9	Neuroticism;
LUSC	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg22618164	chr12:122356400	WDR66	0.63	9.34	0.46	1.38e-18	Mean corpuscular volume;
LUSC	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg04586622	chr2:25135609	ADCY3	0.41	8.92	0.44	3.12e-17	Body mass index in non-asthmatics;
LUSC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg22638593	chr5:131593259	PDLIM4	0.43	5.67	0.3	3.15e-8	Breast cancer;
LUSC	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg13736514	chr6:26305472	NA	-0.46	-9.26	-0.45	2.64e-18	Educational attainment;
LUSC	cis	rs1550582	0.547	rs6991998	chr8:135580221	C/A	cg17885191	chr8:135476712	NA	0.58	7.49	0.38	6.04e-13	Educational attainment;
LUSC	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg01557791	chr16:72042693	DHODH	-0.52	-7.54	-0.38	4.61e-13	Fibrinogen levels;
LUSC	cis	rs926938	0.618	rs1286560	chr1:115375930	C/T	cg12756093	chr1:115239321	AMPD1	-0.53	-8.04	-0.4	1.59e-14	Autism;
LUSC	cis	rs7577851	0.716	rs55932708	chr2:69679197	G/A	cg10773587	chr2:69614142	GFPT1	0.55	6.23	0.32	1.39e-9	Parkinson's disease (age of onset);
LUSC	cis	rs921665	0.748	rs1869420	chr2:3202073	C/T	cg02624386	chr2:3182749	NA	0.62	6.61	0.34	1.55e-10	World class endurance athleticism;
LUSC	cis	rs7705502	1.000	rs75738222	chr5:173349404	C/T	cg18693985	chr5:173351052	CPEB4	-0.36	-5.84	-0.3	1.23e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg09835421	chr16:68378352	PRMT7	-0.59	-6.21	-0.32	1.59e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.7	0.34	8.88e-11	Personality dimensions;
LUSC	cis	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg06521331	chr12:34319734	NA	-0.48	-7.88	-0.4	4.7e-14	Morning vs. evening chronotype;
LUSC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg24733560	chr20:60626293	TAF4	0.41	6.65	0.34	1.17e-10	Body mass index;
LUSC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg01765077	chr12:122356316	WDR66	0.5	7.3	0.37	2.17e-12	Mean corpuscular volume;
LUSC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07256732	chr16:621771	PIGQ	-0.35	-6.47	-0.33	3.58e-10	Height;
LUSC	cis	rs9831754	1.000	rs9822043	chr3:78352113	T/C	cg06138941	chr3:78371609	NA	-0.77	-10.25	-0.49	1.29e-21	Calcium levels;
LUSC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.35	-0.33	7.14e-10	Personality dimensions;
LUSC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg11965913	chr1:205819406	PM20D1	-0.45	-6.5	-0.34	2.84e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.78	13.04	0.58	1.06e-31	Cognitive function;
LUSC	cis	rs12530845	1.000	rs73721606	chr7:135335678	C/T	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs17095355	1.000	rs17095355	chr10:111735750	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.52	-6.78	-0.35	5.34e-11	Biliary atresia;
LUSC	trans	rs7307780	0.703	rs12317066	chr12:76236777	C/T	cg05238905	chr6:149867353	PPIL4	0.61	5.96	0.31	6.37e-9	Sudden cardiac arrest;
LUSC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00339695	chr16:24857497	SLC5A11	-0.62	-9.73	-0.47	7.05e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg06462663	chr19:18546047	ISYNA1	0.45	7.63	0.39	2.54e-13	Breast cancer;
LUSC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg17173187	chr15:85201210	NMB	0.37	6.5	0.33	3e-10	Schizophrenia;
LUSC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg13683864	chr3:40499215	RPL14	-1.11	-21.81	-0.77	3.53e-66	Renal cell carcinoma;
LUSC	cis	rs2625529	0.824	rs12916951	chr15:72252498	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.66	-0.39	1.97e-13	Red blood cell count;
LUSC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06481639	chr22:41940642	POLR3H	-0.53	-6.19	-0.32	1.77e-9	Vitiligo;
LUSC	cis	rs870825	0.616	rs4256263	chr4:185622959	C/A	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	trans	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.67	-0.54	1.26e-26	Colorectal cancer;
LUSC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.67	-0.5	4.42e-23	Glomerular filtration rate;
LUSC	cis	rs2425143	0.818	rs7272684	chr20:34424692	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.12	-0.32	2.58e-9	Blood protein levels;
LUSC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.68	11.27	0.52	3.61e-25	Heart rate;
LUSC	cis	rs4805272	0.582	rs11083652	chr19:29231569	G/C	cg12756686	chr19:29218302	NA	-0.46	-7.05	-0.36	1.01e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9309473	0.687	rs6747145	chr2:73609177	C/T	cg20560298	chr2:73613845	ALMS1	-0.61	-8.8	-0.43	7.42e-17	Metabolite levels;
LUSC	cis	rs8099014	1.000	rs4464160	chr18:56111830	T/G	cg12907477	chr18:56117327	MIR122	0.47	7.45	0.38	8.12e-13	Platelet count;
LUSC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg19539972	chr4:7069911	GRPEL1	0.54	6.08	0.32	3.28e-9	Monocyte percentage of white cells;
LUSC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg06784218	chr1:46089804	CCDC17	0.47	9.26	0.45	2.6e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-7.62	-0.38	2.62e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05670192	chr19:56154902	ZNF581	0.4	6.02	0.31	4.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21028142	chr17:79581711	NPLOC4	0.35	8.24	0.41	4.03e-15	Eye color traits;
LUSC	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-9.39	-0.46	9.87e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg06287003	chr12:125626642	AACS	0.4	7.32	0.37	1.89e-12	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.39	0.42	1.36e-15	Lung cancer;
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.29	-7.43	-0.38	9.19e-13	Lymphocyte counts;
LUSC	cis	rs4704187	0.687	rs10462354	chr5:74453027	T/G	cg03227963	chr5:74354835	NA	0.31	6.8	0.35	4.74e-11	Response to amphetamines;
LUSC	cis	rs2708977	1.000	rs1011040	chr2:97212755	A/G	cg01950434	chr2:97203154	ARID5A	-0.53	-7.99	-0.4	2.28e-14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg20368463	chr18:77673604	PQLC1	0.48	6.78	0.35	5.39e-11	Schizophrenia;
LUSC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg19592336	chr6:28129416	ZNF389	0.53	7.05	0.36	1.02e-11	Parkinson's disease;
LUSC	cis	rs1979679	0.608	rs1581075	chr12:28723925	T/A	cg13890972	chr12:28721907	NA	-0.42	-6.0	-0.31	5.21e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg00343986	chr7:65444356	GUSB	0.45	6.92	0.35	2.33e-11	Aortic root size;
LUSC	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	7.23	0.37	3.41e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg09904177	chr6:26538194	HMGN4	-0.51	-5.71	-0.3	2.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg07541023	chr7:19748670	TWISTNB	0.68	7.31	0.37	1.98e-12	Thyroid stimulating hormone;
LUSC	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg05283184	chr6:79620031	NA	-0.57	-11.86	-0.54	2.54e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs2282032	1.000	rs2282032	chr14:90758891	G/T	cg14092571	chr14:90743983	NA	0.5	6.69	0.34	9.33e-11	Longevity;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02054479	chr16:20911997	LYRM1;DCUN1D3	0.39	6.32	0.33	8.6e-10	Triglycerides;
LUSC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	0.91	12.34	0.56	4.35e-29	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6681460	1.000	rs7532173	chr1:67086111	A/G	cg02459107	chr1:67143332	SGIP1	0.47	8.58	0.42	3.63e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12379764	chr21:47803548	PCNT	-0.49	-6.88	-0.35	2.96e-11	Testicular germ cell tumor;
LUSC	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg20701182	chr2:24300061	SF3B14	0.54	5.78	0.3	1.73e-8	Lymphocyte counts;
LUSC	cis	rs9549260	0.785	rs10507484	chr13:41218134	T/C	cg21288729	chr13:41239152	FOXO1	0.64	10.0	0.48	9.34e-21	Red blood cell count;
LUSC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.07	16.17	0.66	7.65e-44	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg02508848	chr16:68573721	ZFP90	-0.43	-5.73	-0.3	2.23e-8	Ulcerative colitis;
LUSC	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	0.86	12.77	0.57	1.08e-30	Obesity-related traits;
LUSC	trans	rs2188420	0.745	rs711440	chr7:106587964	T/C	cg04262465	chr14:101405693	SNORD113-6	-0.4	-6.11	-0.32	2.75e-9	Interferon gamma levels;
LUSC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg23283495	chr1:209979779	IRF6	0.69	9.03	0.44	1.43e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.97	13.83	0.6	1.05e-34	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg03342759	chr3:160939853	NMD3	0.44	6.26	0.32	1.15e-9	Parkinson's disease;
LUSC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg00376283	chr12:123451042	ABCB9	-0.65	-8.27	-0.41	3.33e-15	Neutrophil percentage of white cells;
LUSC	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.56	-0.38	3.89e-13	Neuroticism;
LUSC	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg20019720	chr6:154832845	CNKSR3	0.62	8.53	0.42	5.16e-16	Lipoprotein (a) levels;
LUSC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg00933542	chr6:150070202	PCMT1	-0.3	-6.2	-0.32	1.62e-9	Lung cancer;
LUSC	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg23958373	chr8:599963	NA	-0.68	-6.17	-0.32	1.92e-9	IgG glycosylation;
LUSC	cis	rs12956009	0.518	rs1434518	chr18:44833498	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.55	0.34	2.11e-10	Educational attainment (years of education);
LUSC	cis	rs7224314	1.000	rs62084077	chr17:65386837	G/A	cg01507342	chr17:65387096	PITPNC1	-0.45	-7.94	-0.4	3.06e-14	Diisocyanate-induced asthma;
LUSC	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg22852734	chr6:133119734	C6orf192	1.33	10.41	0.49	3.74e-22	Type 2 diabetes nephropathy;
LUSC	cis	rs8092503	1.000	rs12456067	chr18:52499448	C/T	cg12377874	chr18:52495404	RAB27B	0.32	5.67	0.3	3.12e-8	Childhood body mass index;
LUSC	cis	rs2230307	0.536	rs834277	chr1:100510855	T/G	cg24955406	chr1:100503596	HIAT1	0.57	6.15	0.32	2.23e-9	Carotid intima media thickness;
LUSC	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg11887960	chr12:57824829	NA	0.56	6.84	0.35	3.75e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	0.8	9.91	0.48	1.86e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg04851639	chr8:1020857	NA	-0.4	-8.05	-0.4	1.45e-14	Schizophrenia;
LUSC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11764359	chr7:65958608	NA	-0.62	-9.33	-0.45	1.47e-18	Calcium levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09700990	chr6:90122154	RRAGD	0.53	7.44	0.38	8.82e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4729127	1.000	rs78697521	chr7:94012938	G/C	cg14660007	chr13:78271894	SLAIN1	0.5	5.97	0.31	5.96e-9	Intelligence;
LUSC	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg24631222	chr15:78858424	CHRNA5	0.68	9.05	0.44	1.19e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg13206674	chr6:150067644	NUP43	0.6	9.26	0.45	2.6e-18	Lung cancer;
LUSC	cis	rs6500395	0.735	rs16946340	chr16:48667717	G/A	cg04672837	chr16:48644449	N4BP1	0.43	6.34	0.33	7.38e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg17294928	chr15:75287854	SCAMP5	-0.76	-10.13	-0.48	3.23e-21	Blood trace element (Zn levels);
LUSC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg04546413	chr19:29218101	NA	0.72	11.5	0.53	5.38e-26	Methadone dose in opioid dependence;
LUSC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.59e-9	Menopause (age at onset);
LUSC	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg10356904	chr22:49881777	NA	-0.3	-6.19	-0.32	1.74e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg06453172	chr10:134556979	INPP5A	-0.49	-6.11	-0.32	2.78e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.36	-6.25	-0.32	1.27e-9	Longevity;Endometriosis;
LUSC	cis	rs6987853	0.736	rs35295075	chr8:42428852	A/G	cg09913449	chr8:42400586	C8orf40	0.53	9.15	0.45	5.62e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg13798780	chr7:105162888	PUS7	0.53	5.96	0.31	6.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg07507251	chr3:52567010	NT5DC2	0.31	6.02	0.31	4.57e-9	Bipolar disorder;
LUSC	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg11189052	chr15:85197271	WDR73	0.5	6.45	0.33	3.81e-10	Schizophrenia;
LUSC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg22907277	chr7:1156413	C7orf50	0.7	8.15	0.41	7.16e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg23630131	chr7:65973040	NA	-0.22	-6.03	-0.31	4.39e-9	Aortic root size;
LUSC	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg14675211	chr2:100938903	LONRF2	0.37	5.76	0.3	1.94e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3125734	0.653	rs1007976	chr10:63970144	C/T	cg09941381	chr10:64027924	RTKN2	0.33	6.16	0.32	2.12e-9	Rheumatoid arthritis;
LUSC	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg12826209	chr6:26865740	GUSBL1	0.54	7.83	0.39	6.36e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13126279	chr21:47581558	C21orf56	-0.54	-8.14	-0.41	8.18e-15	Testicular germ cell tumor;
LUSC	cis	rs727505	0.551	rs2293346	chr7:124783849	C/T	cg23710748	chr7:124431027	NA	-0.38	-6.65	-0.34	1.22e-10	Lewy body disease;
LUSC	cis	rs9796	0.553	rs2925343	chr15:41306493	T/C	cg18705301	chr15:41695430	NDUFAF1	0.58	10.38	0.49	4.7e-22	Menopause (age at onset);
LUSC	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg19622623	chr12:86230825	RASSF9	-0.43	-6.0	-0.31	5.07e-9	Major depressive disorder;
LUSC	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg00982548	chr2:198649783	BOLL	-0.58	-7.21	-0.37	3.87e-12	Ulcerative colitis;
LUSC	cis	rs62400317	0.859	rs12191566	chr6:45160002	T/C	cg20913747	chr6:44695427	NA	-0.48	-7.67	-0.39	1.91e-13	Total body bone mineral density;
LUSC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg11693508	chr17:37793320	STARD3	0.59	7.39	0.37	1.21e-12	Bipolar disorder;
LUSC	cis	rs9837602	0.882	rs9875664	chr3:99729130	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.96	-0.31	6.33e-9	Breast cancer;
LUSC	cis	rs921665	0.831	rs7578217	chr2:3175376	A/G	cg16434511	chr2:3151078	NA	0.52	5.85	0.3	1.18e-8	World class endurance athleticism;
LUSC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg17330251	chr7:94953956	PON1	-0.37	-6.0	-0.31	5.2e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21028142	chr17:79581711	NPLOC4	0.32	7.79	0.39	8.41e-14	Eye color traits;
LUSC	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg05294307	chr14:35346193	BAZ1A	-0.62	-7.46	-0.38	7.55e-13	Psoriasis;
LUSC	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	0.88	13.23	0.59	1.97e-32	Obesity-related traits;
LUSC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg04025307	chr7:1156635	C7orf50	0.44	6.09	0.32	3.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg09915433	chr19:53449742	NA	-0.61	-9.67	-0.47	1.14e-19	Psoriasis;
LUSC	cis	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg06521331	chr12:34319734	NA	-0.47	-7.66	-0.39	2.08e-13	Morning vs. evening chronotype;
LUSC	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg15704280	chr7:45808275	SEPT13	-0.45	-6.23	-0.32	1.42e-9	HDL cholesterol;
LUSC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg11812906	chr14:75593930	NEK9	-0.67	-11.46	-0.53	7.4e-26	Height;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg19522332	chr3:178866004	PIK3CA	0.39	6.39	0.33	5.49e-10	Triglycerides;
LUSC	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.22	-0.32	1.51e-9	Retinal vascular caliber;
LUSC	cis	rs9532580	0.553	rs9549250	chr13:41225229	T/G	cg21288729	chr13:41239152	FOXO1	0.63	9.68	0.47	1.06e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs3820068	0.608	rs12091644	chr1:16044945	G/A	cg17385448	chr1:15911702	AGMAT	0.37	5.89	0.31	9.18e-9	Systolic blood pressure;
LUSC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg22166914	chr1:53195759	ZYG11B	0.68	11.27	0.53	3.38e-25	Monocyte count;
LUSC	cis	rs4343996	0.967	rs10224769	chr7:3347166	A/T	cg21248987	chr7:3385318	SDK1	0.4	6.68	0.34	1e-10	Motion sickness;
LUSC	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg16928487	chr17:17741425	SREBF1	0.47	9.21	0.45	3.57e-18	Total body bone mineral density;
LUSC	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.14	0.41	7.69e-15	Axial length;
LUSC	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg18512352	chr11:47633146	NA	-0.47	-9.04	-0.44	1.27e-17	Subjective well-being;
LUSC	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg27398640	chr15:77910606	LINGO1	-0.29	-5.85	-0.3	1.17e-8	Type 2 diabetes;
LUSC	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg14844989	chr11:31128820	NA	-0.37	-5.77	-0.3	1.83e-8	Red blood cell count;
LUSC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10802521	chr3:52805072	NEK4	0.52	8.56	0.42	4.18e-16	Bipolar disorder;
LUSC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg01557791	chr16:72042693	DHODH	0.52	7.47	0.38	6.98e-13	Fibrinogen levels;
LUSC	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg16512390	chr1:228756714	NA	0.7	8.78	0.43	8.79e-17	Chronic lymphocytic leukemia;
LUSC	cis	rs117623576	0.941	rs60146023	chr10:32411515	G/A	cg03047570	chr10:32398778	NA	-0.61	-6.61	-0.34	1.49e-10	Anti-saccade response;
LUSC	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	7.11	0.36	7.16e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg00701064	chr4:6280414	WFS1	0.59	14.2	0.61	3.93e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.49	6.71	0.34	8.43e-11	Blood protein levels;
LUSC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs6977940	0.818	rs73033490	chr7:2909730	C/T	cg19731401	chr7:2775893	GNA12	0.57	6.55	0.34	2.14e-10	White matter integrity;
LUSC	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg13798780	chr7:105162888	PUS7	0.56	5.91	0.31	8.51e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg05347473	chr6:146136440	FBXO30	0.49	8.24	0.41	4.05e-15	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg18187862	chr3:45730750	SACM1L	0.56	7.06	0.36	9.52e-12	Primary sclerosing cholangitis;
LUSC	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg05738196	chr6:26577821	NA	-0.55	-8.61	-0.43	2.88e-16	Schizophrenia;
LUSC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.39	-0.37	1.2e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1847202	0.859	rs4490296	chr3:72949197	C/A	cg25664220	chr3:72788482	NA	-0.41	-7.36	-0.37	1.44e-12	Motion sickness;
LUSC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.51	-0.46	4.02e-19	Chronic sinus infection;
LUSC	cis	rs4356932	1.000	rs6532093	chr4:76948032	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg05283184	chr6:79620031	NA	-0.52	-10.34	-0.49	6.44e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg00191853	chr8:101177733	SPAG1	-0.36	-6.03	-0.31	4.39e-9	Atrioventricular conduction;
LUSC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.58	-0.42	3.72e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg05717871	chr11:638507	DRD4	-0.35	-6.1	-0.32	3.01e-9	Systemic lupus erythematosus;
LUSC	cis	rs865483	0.828	rs1016680	chr17:35874385	G/T	cg06716730	chr17:35851459	DUSP14	-0.26	-5.85	-0.31	1.14e-8	Monocyte count;
LUSC	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg11812906	chr14:75593930	NEK9	-0.67	-11.46	-0.53	7.13e-26	Height;
LUSC	cis	rs12681287	0.640	rs7816275	chr8:87373404	A/G	cg27223183	chr8:87520930	FAM82B	0.55	7.38	0.37	1.27e-12	Caudate activity during reward;
LUSC	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg06197492	chr11:2016605	H19	0.41	6.65	0.34	1.2e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg11062466	chr8:58055876	NA	0.49	6.48	0.33	3.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.7	-0.34	8.67e-11	Blood metabolite levels;
LUSC	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.31	-0.37	2e-12	Bipolar disorder;
LUSC	cis	rs7605827	0.897	rs7567750	chr2:15690412	C/T	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.82e-16	Educational attainment (years of education);
LUSC	trans	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg18187862	chr3:45730750	SACM1L	-0.61	-7.52	-0.38	5.26e-13	Primary sclerosing cholangitis;
LUSC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg04287289	chr16:89883240	FANCA	0.78	13.77	0.6	1.85e-34	Vitiligo;
LUSC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg13319975	chr6:146136371	FBXO30	0.46	6.88	0.35	2.99e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs870825	0.549	rs7699919	chr4:185648610	A/C	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg24375607	chr4:120327624	NA	0.76	12.2	0.56	1.45e-28	Corneal astigmatism;
LUSC	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.6	-0.34	1.58e-10	Arsenic metabolism;
LUSC	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg24006582	chr15:45444508	DUOX1	-0.6	-8.69	-0.43	1.64e-16	Uric acid levels;
LUSC	cis	rs7503807	0.967	rs12947696	chr17:78596793	C/T	cg09596252	chr17:78655493	RPTOR	0.41	7.05	0.36	1.04e-11	Obesity;
LUSC	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.81	-0.43	7.12e-17	Breast cancer;
LUSC	cis	rs308403	0.506	rs309365	chr4:123659343	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	10.94	0.51	5.28e-24	Blood protein levels;
LUSC	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg04362960	chr10:104952993	NT5C2	0.58	9.19	0.45	4.29e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg24209194	chr3:40518798	ZNF619	0.47	6.51	0.34	2.72e-10	Renal cell carcinoma;
LUSC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg10609677	chr17:41278573	BRCA1;NBR2	0.36	5.9	0.31	8.96e-9	Menopause (age at onset);
LUSC	cis	rs909002	0.849	rs10914456	chr1:32088171	T/C	cg01639898	chr1:32083012	HCRTR1	0.28	6.39	0.33	5.49e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4842666	0.915	rs73437338	chr12:90054619	T/C	cg00757033	chr12:89920650	WDR51B	0.55	7.68	0.39	1.82e-13	Blood pressure;
LUSC	cis	rs2262909	0.962	rs11667209	chr19:22259467	A/G	cg11619707	chr19:22235551	ZNF257	0.39	5.83	0.3	1.29e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg27631724	chr1:11040367	C1orf127	0.54	9.4	0.46	8.69e-19	Ewing sarcoma;
LUSC	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	trans	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg14227996	chr4:17616232	MED28	-0.58	-6.47	-0.33	3.42e-10	Opioid sensitivity;
LUSC	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg25019033	chr10:957182	NA	-0.5	-6.66	-0.34	1.16e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg03060546	chr3:49711283	APEH	-0.63	-7.42	-0.38	9.68e-13	Menarche (age at onset);
LUSC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg00343986	chr7:65444356	GUSB	-0.43	-6.55	-0.34	2.22e-10	Aortic root size;
LUSC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg15445000	chr17:37608096	MED1	-0.35	-5.82	-0.3	1.38e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.52	0.53	4.58e-26	Menopause (age at onset);
LUSC	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	trans	rs9929218	1.000	rs8044058	chr16:68807088	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-12.09	-0.55	3.58e-28	Colorectal cancer;
LUSC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg14895029	chr7:2775587	GNA12	-0.41	-6.31	-0.33	9e-10	Height;
LUSC	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg20933634	chr6:27740509	NA	-0.42	-5.68	-0.3	2.87e-8	Parkinson's disease;
LUSC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.44	-0.5	2.87e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg24579218	chr15:68104479	NA	-0.37	-6.61	-0.34	1.55e-10	Restless legs syndrome;
LUSC	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg03647239	chr10:116582469	FAM160B1	0.44	7.15	0.36	5.58e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs2700987	0.692	rs2392494	chr7:37387207	T/C	cg26076750	chr5:98105150	RGMB	-0.36	-6.6	-0.34	1.62e-10	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.5	0.42	6.19e-16	Prudent dietary pattern;
LUSC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg22963979	chr7:1858916	MAD1L1	0.6	9.59	0.46	2.14e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs1178968	1.000	rs12539763	chr7:72762429	C/T	cg25889504	chr7:72793014	NA	0.56	7.49	0.38	6.01e-13	Triglyceride levels;
LUSC	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-9.85	-0.47	2.92e-20	Total cholesterol levels;
LUSC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg07703079	chr11:430292	ANO9	0.61	6.44	0.33	4.19e-10	Body mass index;
LUSC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.09	-0.4	1.08e-14	Lymphocyte counts;
LUSC	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg17173187	chr15:85201210	NMB	-0.37	-6.7	-0.34	8.96e-11	Schizophrenia;
LUSC	cis	rs6961069	0.585	rs2151916	chr7:80253383	T/C	cg04458919	chr7:80252533	CD36	-0.38	-6.75	-0.35	6.37e-11	Platelet count;
LUSC	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-8.25	-0.41	3.75e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-1.04	-20.37	-0.74	1.55e-60	Height;
LUSC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg19683494	chr5:74908142	NA	0.6	8.12	0.41	9.1e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg05585544	chr11:47624801	NA	-0.42	-7.36	-0.37	1.46e-12	Subjective well-being;
LUSC	cis	rs6688613	0.765	rs56229522	chr1:166816108	T/A	cg07049167	chr1:166818506	POGK	0.5	7.44	0.38	8.86e-13	Refractive astigmatism;
LUSC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg20406979	chr6:167373233	NA	0.26	5.95	0.31	6.94e-9	Crohn's disease;
LUSC	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg06096015	chr1:231504339	EGLN1	-0.54	-9.61	-0.47	1.82e-19	Hemoglobin concentration;
LUSC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg19318889	chr4:1322082	MAEA	0.6	10.43	0.5	3.06e-22	Longevity;
LUSC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03060546	chr3:49711283	APEH	0.67	7.81	0.39	7.22e-14	Menarche (age at onset);
LUSC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg27068330	chr11:65405492	SIPA1	-0.74	-10.23	-0.49	1.45e-21	Acne (severe);
LUSC	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg13575925	chr12:9217583	LOC144571	0.35	6.31	0.33	8.87e-10	Sjögren's syndrome;
LUSC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg16393715	chr7:1948819	MAD1L1	0.34	5.8	0.3	1.52e-8	Bipolar disorder and schizophrenia;
LUSC	trans	rs7951105	1.000	rs61886661	chr11:39244000	A/G	cg24085930	chr3:21832523	NA	0.49	6.06	0.31	3.58e-9	Free thyroxine concentration;
LUSC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg15017067	chr4:17643749	FAM184B	0.34	5.65	0.3	3.38e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs240110	0.570	rs966741	chr6:101218375	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.26	-0.32	1.18e-9	Neuroticism;
LUSC	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg20503657	chr10:835505	NA	0.77	9.17	0.45	4.8e-18	Eosinophil percentage of granulocytes;
LUSC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	1.04	19.88	0.74	1.41e-58	Menopause (age at onset);
LUSC	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg02176678	chr2:219576539	TTLL4	0.58	10.5	0.5	1.76e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-7.87	-0.4	4.86e-14	Prudent dietary pattern;
LUSC	trans	rs2665103	0.655	rs1501367	chr15:82522816	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.4	-0.33	5.18e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg00677455	chr12:58241039	CTDSP2	0.61	8.47	0.42	7.68e-16	Multiple sclerosis;
LUSC	cis	rs2279817	0.780	rs79923328	chr1:18008116	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.13	-0.32	2.54e-9	Neuroticism;
LUSC	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg19773385	chr1:10388646	KIF1B	-0.59	-10.09	-0.48	4.5e-21	Hepatocellular carcinoma;
LUSC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg24209194	chr3:40518798	ZNF619	-0.45	-6.3	-0.33	9.52e-10	Renal cell carcinoma;
LUSC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.97	19.48	0.73	5.37e-57	Height;
LUSC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg04369109	chr6:150039330	LATS1	0.55	7.5	0.38	5.65e-13	Lung cancer;
LUSC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg03526776	chr6:41159608	TREML2	0.32	6.07	0.32	3.44e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg16447950	chr5:562315	NA	-0.54	-6.76	-0.35	6.15e-11	Obesity-related traits;
LUSC	cis	rs11645898	0.872	rs72787070	chr16:72151101	T/C	cg14768367	chr16:72042858	DHODH	-0.66	-7.51	-0.38	5.44e-13	Blood protein levels;
LUSC	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg13072238	chr3:49761600	GMPPB	-0.39	-6.36	-0.33	6.55e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg26043149	chr18:55253948	FECH	0.49	7.47	0.38	7.27e-13	Bone mineral density;
LUSC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.95	-0.31	6.6e-9	Tonsillectomy;
LUSC	cis	rs7945705	0.846	rs4929912	chr11:8816695	A/G	cg12365402	chr11:9010492	NRIP3	-0.41	-7.37	-0.37	1.38e-12	Hemoglobin concentration;
LUSC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.46	0.38	7.35e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg12463550	chr7:65579703	CRCP	0.49	7.1	0.36	7.77e-12	Aortic root size;
LUSC	cis	rs7923609	0.841	rs10761786	chr10:65336207	T/C	cg01631684	chr10:65280961	REEP3	-0.41	-6.42	-0.33	4.76e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7605827	0.930	rs7596951	chr2:15513473	G/C	cg19274914	chr2:15703543	NA	0.46	8.89	0.44	3.76e-17	Educational attainment (years of education);
LUSC	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg02023728	chr11:77925099	USP35	0.43	6.6	0.34	1.64e-10	Testicular germ cell tumor;
LUSC	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg21643547	chr1:205240462	TMCC2	-0.41	-7.55	-0.38	4.08e-13	Red blood cell count;
LUSC	trans	rs853679	0.599	rs188015	chr6:27877446	T/A	cg06606381	chr12:133084897	FBRSL1	-0.71	-7.15	-0.36	5.52e-12	Depression;
LUSC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg25204440	chr1:209979598	IRF6	0.5	5.72	0.3	2.36e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs17095355	0.605	rs2274979	chr10:111631781	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.56	-6.46	-0.33	3.63e-10	Biliary atresia;
LUSC	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg17443473	chr1:3703550	LRRC47	0.32	5.68	0.3	2.96e-8	Red cell distribution width;
LUSC	cis	rs12681287	0.752	rs4310184	chr8:87245253	T/C	cg27223183	chr8:87520930	FAM82B	-0.46	-5.82	-0.3	1.4e-8	Caudate activity during reward;
LUSC	cis	rs4664308	0.810	rs59019419	chr2:161061287	G/A	cg03641300	chr2:160917029	PLA2R1	-0.62	-10.65	-0.5	5.47e-23	Idiopathic membranous nephropathy;
LUSC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.6	0.57	4.77e-30	Motion sickness;
LUSC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg14789911	chr21:47582049	C21orf56	-0.42	-6.59	-0.34	1.7e-10	Testicular germ cell tumor;
LUSC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.52e-9	Menopause (age at onset);
LUSC	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.24	-0.37	3.08e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs71403859	0.502	rs34766979	chr16:71475511	G/A	cg08717414	chr16:71523259	ZNF19	-0.72	-8.08	-0.4	1.17e-14	Post bronchodilator FEV1;
LUSC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.76	-0.35	6.33e-11	Alzheimer's disease (late onset);
LUSC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14829155	chr15:31115871	NA	-0.57	-7.92	-0.4	3.5e-14	Huntington's disease progression;
LUSC	cis	rs4704187	0.687	rs4324655	chr5:74373360	C/T	cg03227963	chr5:74354835	NA	0.33	7.11	0.36	7.31e-12	Response to amphetamines;
LUSC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.2	0.32	1.62e-9	Mean platelet volume;
LUSC	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26384229	chr12:38710491	ALG10B	0.9	15.53	0.65	2.54e-41	Morning vs. evening chronotype;
LUSC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg20887711	chr4:1340912	KIAA1530	0.44	6.6	0.34	1.63e-10	Obesity-related traits;
LUSC	cis	rs897080	0.552	rs1067318	chr2:44634509	A/C	cg00619915	chr2:44497795	NA	-0.41	-5.8	-0.3	1.54e-8	Height;
LUSC	cis	rs6084875	0.840	rs6052816	chr20:4725086	T/C	cg26097573	chr20:4721490	PRNT	-0.31	-5.76	-0.3	1.87e-8	Systemic lupus erythematosus;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18147309	chr17:65362822	PSMD12	-0.41	-6.05	-0.31	3.85e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21332495	chr17:41476307	ARL4D	-0.45	-6.84	-0.35	3.75e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-5.98	-0.31	5.71e-9	Morning vs. evening chronotype;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03672602	chr19:19754555	GMIP	0.46	6.5	0.34	2.96e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.64	-0.34	1.25e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9326248	0.530	rs11216171	chr11:116749113	T/A	cg11861562	chr11:117069780	TAGLN	0.37	6.34	0.33	7.54e-10	Blood protein levels;
LUSC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.89	18.73	0.72	4.89e-54	Intelligence (multi-trait analysis);
LUSC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg19468946	chr17:37922297	IKZF3	-0.44	-6.93	-0.35	2.22e-11	Self-reported allergy;
LUSC	trans	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	10.17	0.49	2.39e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg16339924	chr4:17578868	LAP3	0.58	8.85	0.44	5.14e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23615779	chr7:143077590	ZYX	0.5	6.85	0.35	3.52e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03264133	chr6:25882463	NA	-0.5	-9.04	-0.44	1.33e-17	Blood metabolite levels;
LUSC	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg08277548	chr1:17600880	PADI3	-0.68	-6.88	-0.35	2.88e-11	Hair shape;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00961003	chr20:3748878	C20orf27	0.42	5.95	0.31	6.71e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2041895	0.527	rs10861681	chr12:107334262	C/T	cg13944111	chr12:107296891	NA	0.36	6.7	0.34	8.74e-11	Glaucoma (low intraocular pressure);
LUSC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg00945038	chr17:61921165	SMARCD2	0.54	9.64	0.47	1.44e-19	Prudent dietary pattern;
LUSC	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg20701182	chr2:24300061	SF3B14	0.56	6.0	0.31	5.19e-9	Lymphocyte counts;
LUSC	cis	rs6960043	1.000	rs12113083	chr7:15051943	G/C	cg19272540	chr7:15055459	NA	-0.29	-6.94	-0.35	2.05e-11	Type 2 diabetes;
LUSC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	8.6	0.43	3.14e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs9309473	1.000	rs6755241	chr2:73641364	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-6.46	-0.33	3.74e-10	Metabolite levels;
LUSC	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.5e-8	Breast cancer;
LUSC	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg11502198	chr6:26597334	ABT1	0.73	12.27	0.56	7.72e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg13047869	chr3:10149882	C3orf24	0.57	8.41	0.42	1.22e-15	Alzheimer's disease;
LUSC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.51	7.89	0.4	4.33e-14	Eosinophil percentage of white cells;
LUSC	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg02750262	chr18:72916776	ZADH2	0.63	7.39	0.37	1.22e-12	Vascular endothelial growth factor levels;
LUSC	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.06	-0.36	9.46e-12	Coronary artery disease;
LUSC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.61	-12.25	-0.56	9.49e-29	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11642862	1.000	rs74483355	chr16:30836430	C/T	cg02466173	chr16:30829666	NA	-0.7	-7.33	-0.37	1.71e-12	Tonsillectomy;
LUSC	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg01579765	chr21:45077557	HSF2BP	-0.5	-10.49	-0.5	1.89e-22	Mean corpuscular volume;
LUSC	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	7.04	0.36	1.07e-11	Schizophrenia;
LUSC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-7.39	-0.37	1.22e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg13877915	chr19:58951672	ZNF132	0.46	7.39	0.38	1.16e-12	Uric acid clearance;
LUSC	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg09835421	chr16:68378352	PRMT7	-0.52	-6.35	-0.33	6.98e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06022373	chr22:39101656	GTPBP1	-0.68	-10.59	-0.5	8.37e-23	Menopause (age at onset);
LUSC	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg21545522	chr1:205238299	TMCC2	0.43	7.94	0.4	3.18e-14	Red blood cell count;
LUSC	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.69	-0.3	2.73e-8	Bipolar disorder;
LUSC	cis	rs877282	0.898	rs71489279	chr10:760510	T/C	cg17470449	chr10:769945	NA	0.52	7.36	0.37	1.42e-12	Uric acid levels;
LUSC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12379764	chr21:47803548	PCNT	-0.57	-7.85	-0.39	5.66e-14	Testicular germ cell tumor;
LUSC	trans	rs338389	0.586	rs338390	chr15:68259214	A/G	cg16317052	chr17:61678891	TACO1	0.38	5.99	0.31	5.4e-9	Survival in rectal cancer;
LUSC	cis	rs859767	0.741	rs4954156	chr2:135395863	T/C	cg12500956	chr2:135428796	TMEM163	-0.28	-6.24	-0.32	1.3e-9	Neuroticism;
LUSC	cis	rs7615316	0.844	rs7641330	chr3:142305638	T/C	cg16271453	chr3:142027066	XRN1	-0.36	-6.03	-0.31	4.41e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg14061069	chr19:46274453	DMPK	0.67	13.9	0.61	5.85e-35	Coronary artery disease;
LUSC	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg26384229	chr12:38710491	ALG10B	-0.62	-9.51	-0.46	3.84e-19	Morning vs. evening chronotype;
LUSC	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	0.82	12.44	0.56	1.96e-29	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.72	14.09	0.61	1e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12760731	0.623	rs10913539	chr1:178336682	T/C	cg00404053	chr1:178313656	RASAL2	0.47	5.67	0.3	3.02e-8	Obesity-related traits;
LUSC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.02	-0.36	1.22e-11	Lung cancer;
LUSC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg16339924	chr4:17578868	LAP3	0.59	9.27	0.45	2.38e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-0.81	-9.95	-0.48	1.35e-20	Refractive error;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg22907277	chr7:1156413	C7orf50	0.48	7.35	0.37	1.5e-12	Longevity;Endometriosis;
LUSC	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.46	6.81	0.35	4.61e-11	Schizophrenia;
LUSC	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.21	-0.37	3.87e-12	Schizophrenia;
LUSC	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-1.15	-18.43	-0.71	8.08e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.2	0.61	3.9e-36	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.68	-0.43	1.76e-16	Response to antipsychotic treatment;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg18493069	chr6:108582623	SNX3	0.37	6.38	0.33	5.76e-10	Triglycerides;
LUSC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg16524733	chr11:117070046	TAGLN	-0.39	-6.84	-0.35	3.67e-11	Blood protein levels;
LUSC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.95	0.36	1.97e-11	Cystic fibrosis severity;
LUSC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.55	0.46	2.98e-19	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	11.81	0.54	3.83e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg05872129	chr22:39784769	NA	0.6	11.56	0.53	3.15e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	1.11	19.03	0.72	3.14e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7119	0.667	rs907390	chr15:77902419	T/C	cg27398640	chr15:77910606	LINGO1	0.37	8.79	0.43	7.86e-17	Type 2 diabetes;
LUSC	trans	rs7916697	0.520	rs4745957	chr10:70044702	A/G	cg04882175	chr6:131122610	NA	0.47	6.12	0.32	2.56e-9	Optic disc area;
LUSC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.87	-0.35	3.19e-11	Total body bone mineral density;
LUSC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08470875	chr2:26401718	FAM59B	0.72	9.9	0.48	1.91e-20	Gut microbiome composition (summer);
LUSC	cis	rs9311676	0.656	rs7647184	chr3:58370046	C/T	cg26110898	chr3:58419937	PDHB	0.42	6.72	0.35	7.93e-11	Systemic lupus erythematosus;
LUSC	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.54	0.5	1.27e-22	Colorectal cancer;
LUSC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg04455712	chr21:45112962	RRP1B	0.46	8.78	0.43	8.54e-17	Mean corpuscular volume;
LUSC	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg13010344	chr12:123464640	ARL6IP4	0.49	6.27	0.32	1.11e-9	Neutrophil percentage of white cells;
LUSC	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg08645402	chr16:4508243	NA	0.51	8.61	0.43	3.01e-16	Schizophrenia;
LUSC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.74	-0.57	1.37e-30	Alzheimer's disease;
LUSC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.93	-0.4	3.36e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.77	12.87	0.58	4.52e-31	Schizophrenia;
LUSC	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg07167872	chr1:205819463	PM20D1	-0.43	-5.92	-0.31	8.16e-9	Menarche (age at onset);
LUSC	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg03128534	chr1:43423976	SLC2A1	-0.5	-6.54	-0.34	2.33e-10	Red cell distribution width;
LUSC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg21665744	chr7:39171113	POU6F2	0.5	7.85	0.39	5.53e-14	IgG glycosylation;
LUSC	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02176678	chr2:219576539	TTLL4	0.6	10.86	0.51	9.63e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.44e-17	Iron status biomarkers;
LUSC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg27165867	chr14:105738592	BRF1	-0.53	-7.91	-0.4	3.8e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg07703079	chr11:430292	ANO9	0.65	6.68	0.34	1.03e-10	Body mass index;
LUSC	cis	rs6500395	0.962	rs868792	chr16:48640632	T/C	cg04672837	chr16:48644449	N4BP1	0.47	6.99	0.36	1.48e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.38	0.46	1.04e-18	Monocyte percentage of white cells;
LUSC	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.37	0.46	1.13e-18	Arsenic metabolism;
LUSC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18402987	chr7:1209562	NA	0.43	5.69	0.3	2.73e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.67	10.29	0.49	9.56e-22	Colorectal cancer;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg01198024	chr21:33672713	MRAP	-0.41	-6.08	-0.32	3.36e-9	Neuroticism;
LUSC	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg08558340	chr7:100472263	SRRT	0.51	6.38	0.33	5.82e-10	Resting heart rate;
LUSC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg21724239	chr8:58056113	NA	0.57	6.58	0.34	1.84e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg25214090	chr10:38739885	LOC399744	0.48	7.02	0.36	1.28e-11	Corneal astigmatism;
LUSC	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.02	16.24	0.66	3.98e-44	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs1018836	0.631	rs61276517	chr8:91474406	A/G	cg16814680	chr8:91681699	NA	-0.58	-8.68	-0.43	1.84e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.53	-7.54	-0.38	4.5e-13	Menarche (age at onset);
LUSC	cis	rs4911259	0.533	rs6058931	chr20:31471012	C/T	cg13636640	chr20:31349939	DNMT3B	-0.82	-15.77	-0.65	2.83e-42	Inflammatory bowel disease;
LUSC	cis	rs10465746	0.746	rs6699501	chr1:84389993	A/G	cg10977910	chr1:84465055	TTLL7	0.44	6.36	0.33	6.81e-10	Obesity-related traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02667081	chr16:71880439	ATXN1L	0.46	6.75	0.35	6.61e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg19773385	chr1:10388646	KIF1B	-0.51	-9.04	-0.44	1.3e-17	Hepatocellular carcinoma;
LUSC	cis	rs9581857	0.556	rs1885991	chr13:28040470	G/A	cg22138327	chr13:27999177	GTF3A	0.7	9.5	0.46	4.1e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs4409675	0.576	rs6660899	chr1:28214281	G/C	cg23691781	chr1:28212827	C1orf38	0.32	7.59	0.38	3.28e-13	Corneal astigmatism;
LUSC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.67	11.39	0.53	1.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg25427524	chr10:38739819	LOC399744	-0.51	-7.05	-0.36	1.04e-11	Obesity (extreme);
LUSC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg25456477	chr12:86230367	RASSF9	0.33	5.82	0.3	1.39e-8	Major depressive disorder;
LUSC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg00701064	chr4:6280414	WFS1	-0.58	-14.0	-0.61	2.4e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2273669	0.667	rs12195728	chr6:109278873	A/G	cg05315195	chr6:109294784	ARMC2	-0.6	-6.58	-0.34	1.86e-10	Prostate cancer;
LUSC	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.84	0.44	5.42e-17	Coffee consumption (cups per day);
LUSC	cis	rs68170813	0.652	rs7807154	chr7:107161391	T/G	cg24556660	chr7:106842632	COG5;HBP1	-0.45	-5.65	-0.3	3.52e-8	Coronary artery disease;
LUSC	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17261708	chr5:176794207	RGS14	0.33	5.77	0.3	1.8e-8	Hemoglobin concentration;Hematocrit;
LUSC	trans	rs12637928	0.580	rs13088261	chr3:110256470	T/C	cg17371621	chr15:61264283	RORA	0.36	5.97	0.31	5.94e-9	Neuroticism;
LUSC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.43	6.79	0.35	5.1e-11	Blood metabolite levels;
LUSC	cis	rs7246967	0.673	rs7250343	chr19:22822845	A/G	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25072359	chr17:41440525	NA	0.57	8.33	0.41	2.08e-15	Menopause (age at onset);
LUSC	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg18904891	chr8:8559673	CLDN23	0.6	7.9	0.4	4.13e-14	Obesity-related traits;
LUSC	cis	rs4234798	0.500	rs10937793	chr4:7219614	C/T	cg18431297	chr4:7219810	SORCS2	0.33	6.21	0.32	1.55e-9	Insulin-like growth factors;
LUSC	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg23283495	chr1:209979779	IRF6	0.68	8.38	0.42	1.51e-15	Cleft lip with or without cleft palate;
LUSC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg01657329	chr11:68192670	LRP5	0.45	7.24	0.37	3.17e-12	Total body bone mineral density;
LUSC	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg09184832	chr6:79620586	NA	0.4	6.37	0.33	6.35e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg03247675	chr19:10812111	QTRT1	0.41	6.44	0.33	4.28e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg17470449	chr10:769945	NA	0.5	6.9	0.35	2.7e-11	Uric acid levels;
LUSC	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg25930673	chr12:123319894	HIP1R	-0.65	-6.67	-0.34	1.08e-10	Schizophrenia;
LUSC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg19912559	chr1:40204330	PPIE	0.54	8.26	0.41	3.35e-15	Blood protein levels;
LUSC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg08200582	chr11:442649	ANO9	-0.53	-5.74	-0.3	2.07e-8	Body mass index;
LUSC	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg26566898	chr11:117069891	TAGLN	0.34	6.4	0.33	5.37e-10	Blood protein levels;
LUSC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.38	-0.37	1.28e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg06238570	chr21:40685208	BRWD1	-0.61	-10.36	-0.49	5.54e-22	Cognitive function;
LUSC	cis	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg01251360	chr16:68772225	CDH1	-0.25	-5.96	-0.31	6.49e-9	Colorectal cancer;
LUSC	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg21573476	chr21:45109991	RRP1B	-0.41	-6.46	-0.33	3.77e-10	Mean corpuscular volume;
LUSC	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg04508216	chr1:11107452	MASP2	0.33	5.87	0.31	1.03e-8	Body mass index;
LUSC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg00509249	chr6:109615579	CCDC162	-0.34	-6.09	-0.32	3.11e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg12963246	chr6:28129442	ZNF389	0.4	5.99	0.31	5.44e-9	Cardiac Troponin-T levels;
LUSC	cis	rs600231	0.542	rs11227205	chr11:65256164	G/A	cg17120908	chr11:65337727	SSSCA1	-0.63	-9.12	-0.45	7.22e-18	Bone mineral density;
LUSC	trans	rs10432489	0.708	rs3922471	chr2:181771937	T/C	cg16818443	chr4:2965195	GRK4;NOP14	0.82	6.01	0.31	4.74e-9	QT interval;
LUSC	trans	rs11696501	0.688	rs6073862	chr20:44331705	T/C	cg03272292	chr12:48577362	C12orf68	0.51	6.05	0.31	3.87e-9	Brain structure;
LUSC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00166722	chr3:10149974	C3orf24	0.56	7.54	0.38	4.61e-13	Alzheimer's disease;
LUSC	cis	rs977987	0.843	rs10459859	chr16:75381950	T/C	cg04384234	chr16:75411784	CFDP1	-0.42	-6.82	-0.35	4.37e-11	Dupuytren's disease;
LUSC	cis	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.57	0.67	2.05e-45	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg11812906	chr14:75593930	NEK9	-0.66	-11.14	-0.52	1.03e-24	Height;
LUSC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg00857998	chr1:205179979	DSTYK	0.64	9.83	0.47	3.41e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg26816564	chr1:7831052	VAMP3	-0.92	-12.96	-0.58	2.13e-31	Inflammatory bowel disease;
LUSC	trans	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04565464	chr8:145669602	NFKBIL2	-0.36	-6.06	-0.31	3.74e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04579064	chr14:104029527	BAG5;C14orf153	-0.46	-6.06	-0.31	3.7e-9	Hepatitis;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg13987042	chr11:74660265	XRRA1;SPCS2	-0.49	-6.19	-0.32	1.8e-9	Cognitive function;Information processing speed;
LUSC	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg23711669	chr6:146136114	FBXO30	0.86	15.54	0.65	2.4e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9517320	1.000	rs9513430	chr13:99127252	C/G	cg07423050	chr13:99094983	FARP1	0.33	6.22	0.32	1.48e-9	Longevity;
LUSC	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg18827107	chr12:86230957	RASSF9	-0.44	-6.61	-0.34	1.48e-10	Major depressive disorder;
LUSC	cis	rs116988415	1.000	rs11622962	chr14:65299145	C/T	cg00114569	chr14:65239327	SPTB	0.54	5.75	0.3	1.98e-8	Daytime sleep phenotypes;
LUSC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.56	0.53	3.14e-26	Menopause (age at onset);
LUSC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg20090143	chr19:45452003	APOC2	-0.47	-8.87	-0.44	4.61e-17	Blood protein levels;
LUSC	cis	rs6736093	0.966	rs35189728	chr2:112720228	C/G	cg12686935	chr2:112915763	FBLN7	-0.37	-6.03	-0.31	4.39e-9	Coronary artery disease;
LUSC	cis	rs7953508	0.711	rs11107117	chr12:93979419	T/C	cg18151635	chr12:93972918	NA	-0.59	-8.12	-0.41	9.03e-15	Pubertal anthropometrics;
LUSC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.97	0.77	8.25e-67	Prudent dietary pattern;
LUSC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.56	9.16	0.45	5.5e-18	Aortic root size;
LUSC	cis	rs6743226	1.000	rs6743226	chr2:242236972	T/C	cg10021735	chr2:242295487	FARP2	0.36	5.67	0.3	3.17e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LUSC	cis	rs2710642	0.777	rs2539987	chr2:63142864	A/G	cg17519650	chr2:63277830	OTX1	0.52	7.31	0.37	1.93e-12	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg13397359	chr6:42928475	GNMT	0.64	10.68	0.5	4.16e-23	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7615316	0.902	rs6440092	chr3:142313987	T/A	cg16271453	chr3:142027066	XRN1	-0.36	-6.12	-0.32	2.58e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.75	11.25	0.52	4.01e-25	Multiple sclerosis;
LUSC	cis	rs79387448	0.638	rs11465670	chr2:103034440	A/G	cg09003973	chr2:102972529	NA	0.96	10.03	0.48	7.18e-21	Gut microbiota (bacterial taxa);
LUSC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	13.27	0.59	1.39e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg10729496	chr3:10149963	C3orf24	0.54	7.15	0.36	5.46e-12	Alzheimer's disease;
LUSC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg21770322	chr7:97807741	LMTK2	0.4	6.84	0.35	3.82e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7712401	0.791	rs6872932	chr5:122145636	A/G	cg19077854	chr5:122220652	SNX24	0.35	7.95	0.4	2.84e-14	Mean platelet volume;
LUSC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.73	-11.85	-0.54	2.87e-27	Body mass index;
LUSC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg25039879	chr17:56429692	SUPT4H1	0.66	8.73	0.43	1.23e-16	Cognitive test performance;
LUSC	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg01652190	chr22:50026171	C22orf34	-0.3	-6.21	-0.32	1.59e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg18964960	chr10:1102726	WDR37	0.44	6.01	0.31	4.94e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs2235649	0.833	rs9929185	chr16:1852070	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-6.02	-0.31	4.48e-9	Blood metabolite levels;
LUSC	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg10911889	chr6:126070802	HEY2	0.42	6.39	0.33	5.72e-10	Brugada syndrome;
LUSC	cis	rs12620999	0.838	rs13007071	chr2:238038755	A/G	cg23555395	chr2:238036564	NA	-0.53	-8.94	-0.44	2.77e-17	Systemic lupus erythematosus;
LUSC	trans	rs2188420	0.745	rs849395	chr7:106586497	T/C	cg04262465	chr14:101405693	SNORD113-6	-0.42	-6.37	-0.33	6.13e-10	Interferon gamma levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00996262	chr17:7554930	ATP1B2	0.63	5.96	0.31	6.42e-9	Cognitive performance;
LUSC	cis	rs7615316	0.902	rs6440093	chr3:142316036	A/G	cg16271453	chr3:142027066	XRN1	-0.36	-6.12	-0.32	2.58e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs16976116	0.901	rs73409853	chr15:55502681	A/T	cg11288833	chr15:55489084	RSL24D1	0.51	6.16	0.32	2.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03517284	chr6:25882590	NA	-0.46	-8.19	-0.41	5.6e-15	Blood metabolite levels;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg00576301	chr13:36920965	SPG20	0.47	6.08	0.32	3.35e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.82	-0.3	1.41e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg12927641	chr6:109611667	NA	-0.35	-5.9	-0.31	8.95e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.36	5.83	0.3	1.33e-8	Menopause (age at onset);
LUSC	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2.04e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg19629631	chr7:2060116	MAD1L1	-0.36	-5.68	-0.3	2.87e-8	Neuroticism;
LUSC	cis	rs2692947	0.759	rs2949885	chr2:96662415	A/G	cg22654517	chr2:96458247	NA	0.31	5.94	0.31	7.08e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg24675658	chr1:53192096	ZYG11B	-0.73	-12.49	-0.56	1.25e-29	Monocyte count;
LUSC	cis	rs9807989	0.507	rs7581119	chr2:103049865	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.06	0.36	9.98e-12	Asthma;
LUSC	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.6	-0.34	1.65e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg27068330	chr11:65405492	SIPA1	0.74	10.25	0.49	1.26e-21	Acne (severe);
LUSC	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg22508957	chr16:3507546	NAT15	0.43	6.32	0.33	8.2e-10	Body mass index (adult);
LUSC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs7712401	0.686	rs246305	chr5:122199606	A/T	cg19077854	chr5:122220652	SNX24	0.32	7.17	0.37	4.99e-12	Mean platelet volume;
LUSC	cis	rs11997175	0.625	rs953617	chr8:33599158	G/C	ch.8.33884649F	chr8:33765107	NA	0.42	6.78	0.35	5.33e-11	Body mass index;
LUSC	cis	rs7091068	0.518	rs726817	chr10:95459817	C/T	cg20715218	chr10:95462985	C10orf4	0.47	5.97	0.31	6.1e-9	Urinary tract infection frequency;
LUSC	cis	rs9549260	0.753	rs9532562	chr13:41153585	A/G	cg21288729	chr13:41239152	FOXO1	0.58	6.78	0.35	5.58e-11	Red blood cell count;
LUSC	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg02038168	chr22:39784481	NA	-0.48	-7.72	-0.39	1.35e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1322512	0.917	rs2038616	chr6:153022674	T/C	cg27316956	chr6:152958899	SYNE1	0.36	6.17	0.32	1.92e-9	Tonometry;
LUSC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg27170947	chr2:26402098	FAM59B	-0.69	-10.55	-0.5	1.2e-22	Gut microbiome composition (summer);
LUSC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.41	6.86	0.35	3.38e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg03060546	chr3:49711283	APEH	0.66	7.47	0.38	7.11e-13	Menarche (age at onset);
LUSC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg14552801	chr7:65878734	NA	0.38	5.84	0.3	1.25e-8	Aortic root size;
LUSC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08677398	chr8:58056175	NA	0.52	6.92	0.35	2.27e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg27284194	chr4:1044797	NA	0.58	8.52	0.42	5.71e-16	Recombination rate (females);
LUSC	cis	rs2219968	0.701	rs2200015	chr8:78990829	T/C	cg00738934	chr8:78996279	NA	0.43	7.88	0.4	4.51e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	9.98	0.48	1.04e-20	Coffee consumption (cups per day);
LUSC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg21724239	chr8:58056113	NA	0.56	6.86	0.35	3.37e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19726916	chr19:17420182	DDA1	0.41	5.97	0.31	6.19e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.7	0.51	3.69e-23	Bone mineral density;
LUSC	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg15485101	chr11:133734466	NA	0.38	7.17	0.37	4.98e-12	Childhood ear infection;
LUSC	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg13852791	chr20:30311386	BCL2L1	0.71	8.05	0.4	1.49e-14	Mean corpuscular hemoglobin;
LUSC	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg18209359	chr17:80159595	CCDC57	0.39	6.44	0.33	4.06e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg17366294	chr4:99064904	C4orf37	0.53	8.27	0.41	3.15e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs701145	0.938	rs355788	chr3:154000612	T/C	cg17054900	chr3:154042577	DHX36	0.84	8.49	0.42	6.84e-16	Coronary artery disease;
LUSC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.82	-13.01	-0.58	1.39e-31	Tonsillectomy;
LUSC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg22800045	chr5:56110881	MAP3K1	0.46	5.97	0.31	5.93e-9	Coronary artery disease;
LUSC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.2	0.32	1.69e-9	Obesity-related traits;
LUSC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.66	0.6	4.84e-34	Platelet count;
LUSC	cis	rs67366981	1.000	rs67366981	chr14:77703964	T/C	cg22824376	chr14:77648248	TMEM63C	0.68	6.38	0.33	5.76e-10	Obsessive-compulsive symptoms;
LUSC	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg03859395	chr2:55845619	SMEK2	-0.63	-8.79	-0.43	8.07e-17	Metabolic syndrome;
LUSC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.84	0.44	5.51e-17	Motion sickness;
LUSC	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.36	-0.42	1.71e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg22029157	chr1:209979665	IRF6	0.81	10.42	0.5	3.33e-22	Cleft lip with or without cleft palate;
LUSC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg07741184	chr6:167504864	NA	0.37	6.72	0.35	7.82e-11	Crohn's disease;
LUSC	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg24130564	chr14:104152367	KLC1	0.45	6.42	0.33	4.6e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs4650994	0.525	rs2493865	chr1:178545016	G/A	cg05059571	chr16:84539110	KIAA1609	0.48	9.18	0.45	4.59e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg09060608	chr5:178986726	RUFY1	0.63	10.93	0.51	5.56e-24	Lung cancer;
LUSC	cis	rs6556937	0.562	rs31250	chr5:96013441	G/C	cg07690455	chr5:95997198	CAST	0.48	6.6	0.34	1.62e-10	Blood protein levels;
LUSC	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22496380	chr5:211416	CCDC127	-0.85	-8.68	-0.43	1.72e-16	Breast cancer;
LUSC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg02487422	chr3:49467188	NICN1	-0.42	-5.88	-0.31	9.94e-9	Menarche (age at onset);
LUSC	cis	rs1178968	1.000	rs7802062	chr7:72757812	T/C	cg25889504	chr7:72793014	NA	0.58	7.54	0.38	4.5e-13	Triglyceride levels;
LUSC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.63	10.52	0.5	1.55e-22	Bone mineral density;
LUSC	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg24397884	chr7:158709396	WDR60	0.71	6.01	0.31	4.97e-9	Hippocampal volume;
LUSC	cis	rs9653442	0.545	rs11123810	chr2:100759285	T/C	cg22139774	chr2:100720529	AFF3	-0.43	-7.33	-0.37	1.73e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.76	-13.51	-0.59	1.73e-33	Brugada syndrome;
LUSC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg04414720	chr1:150670196	GOLPH3L	0.5	7.9	0.4	4.13e-14	Melanoma;
LUSC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-6.92	-0.35	2.31e-11	Aortic root size;
LUSC	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg25214090	chr10:38739885	LOC399744	0.54	7.9	0.4	4.18e-14	Corneal astigmatism;
LUSC	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg20503657	chr10:835505	NA	0.55	7.25	0.37	2.89e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg27411982	chr8:10470053	RP1L1	-0.49	-7.61	-0.38	2.84e-13	Neuroticism;
LUSC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg02569458	chr12:86230093	RASSF9	-0.52	-8.78	-0.43	8.37e-17	Major depressive disorder;
LUSC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg08219700	chr8:58056026	NA	0.49	6.19	0.32	1.77e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg02782426	chr3:40428986	ENTPD3	0.38	7.41	0.38	1.05e-12	Renal cell carcinoma;
LUSC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg08888203	chr3:10149979	C3orf24	0.59	8.11	0.41	9.88e-15	Alzheimer's disease;
LUSC	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg12002119	chr2:101014098	CHST10	-0.34	-5.71	-0.3	2.44e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-6.24	-0.32	1.33e-9	Neuroticism;
LUSC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.66	-0.5	5.13e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg13852791	chr20:30311386	BCL2L1	0.94	14.73	0.63	3.46e-38	Mean corpuscular hemoglobin;
LUSC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.11	-0.32	2.71e-9	Initial pursuit acceleration;
LUSC	cis	rs3741151	0.656	rs10501411	chr11:73292085	A/C	cg17517138	chr11:73019481	ARHGEF17	0.89	7.81	0.39	7.39e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg20608306	chr11:116969690	SIK3	0.37	6.97	0.36	1.73e-11	Blood protein levels;
LUSC	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg14696996	chr19:15285081	NOTCH3	0.99	9.07	0.44	1.06e-17	Pulse pressure;
LUSC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg05347473	chr6:146136440	FBXO30	0.53	8.89	0.44	3.86e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12190007	0.508	rs7452203	chr6:169741858	C/T	cg16388071	chr6:169726476	NA	-0.37	-6.07	-0.32	3.48e-9	Obesity-related traits;
LUSC	trans	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg25214090	chr10:38739885	LOC399744	0.42	6.29	0.33	1.02e-9	Corneal astigmatism;
LUSC	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg23791538	chr6:167370224	RNASET2	-0.47	-7.84	-0.39	6.19e-14	Crohn's disease;
LUSC	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg04362960	chr10:104952993	NT5C2	0.58	8.42	0.42	1.15e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs4478858	0.746	rs60073066	chr1:31689589	G/A	cg00250761	chr1:31883323	NA	0.37	9.4	0.46	8.95e-19	Alcohol dependence;
LUSC	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg18357645	chr12:58087776	OS9	0.59	9.0	0.44	1.73e-17	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg05059571	chr16:84539110	KIAA1609	-0.47	-8.93	-0.44	2.86e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	22.91	0.78	1.74e-70	Prudent dietary pattern;
LUSC	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg00105475	chr2:10696890	NA	0.35	5.92	0.31	7.8e-9	Prostate cancer;
LUSC	cis	rs231513	0.911	rs231515	chr17:41964083	A/G	cg26893861	chr17:41843967	DUSP3	-0.51	-6.19	-0.32	1.74e-9	Cognitive function;
LUSC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg10319629	chr12:132285459	NA	0.4	6.31	0.33	8.96e-10	Migraine;
LUSC	cis	rs3820928	0.874	rs7594505	chr2:227878562	C/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.96	-0.4	2.72e-14	Pulmonary function;
LUSC	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.05e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg13010199	chr12:38710504	ALG10B	0.58	9.27	0.45	2.32e-18	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.45	0.56	1.73e-29	Motion sickness;
LUSC	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg05340658	chr4:99064831	C4orf37	0.61	9.57	0.46	2.42e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.33	0.37	1.8e-12	Motion sickness;
LUSC	cis	rs11039100	0.850	rs11039164	chr11:5843138	C/T	cg13902645	chr11:5959945	NA	-0.52	-5.87	-0.31	1.07e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.21	-0.45	3.8e-18	Bipolar disorder and schizophrenia;
LUSC	trans	rs35847492	1.000	rs35847492	chr8:9276025	G/C	cg27411982	chr8:10470053	RP1L1	0.45	6.28	0.32	1.08e-9	Neuroticism;
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg24846343	chr22:24311635	DDTL	0.77	17.35	0.69	1.61e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg09839279	chr12:125627357	AACS	-0.31	-5.69	-0.3	2.71e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg24562669	chr7:97807699	LMTK2	0.34	6.0	0.31	5.27e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg13647721	chr17:30228624	UTP6	-0.67	-7.19	-0.37	4.33e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg03585969	chr10:35415529	CREM	0.6	8.86	0.44	4.85e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs62400317	0.859	rs10948205	chr6:45124585	T/C	cg20913747	chr6:44695427	NA	-0.47	-7.51	-0.38	5.31e-13	Total body bone mineral density;
LUSC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg05025164	chr4:1340916	KIAA1530	0.41	6.23	0.32	1.41e-9	Obesity-related traits;
LUSC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg21782813	chr7:2030301	MAD1L1	0.58	10.31	0.49	8.12e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	7.41	0.38	1.03e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg16405210	chr4:1374714	KIAA1530	0.72	11.05	0.52	2.04e-24	Obesity-related traits;
LUSC	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg00745463	chr17:30367425	LRRC37B	0.64	7.62	0.38	2.72e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs9649213	0.511	rs6950994	chr7:97887872	G/A	cg24562669	chr7:97807699	LMTK2	0.39	6.61	0.34	1.49e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg24829409	chr8:58192753	C8orf71	-0.46	-5.8	-0.3	1.5e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg03929089	chr4:120376271	NA	-0.5	-7.0	-0.36	1.41e-11	HDL cholesterol;
LUSC	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg15839431	chr19:19639596	YJEFN3	-0.58	-6.41	-0.33	5.02e-10	Bipolar disorder;
LUSC	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg10255544	chr17:80519551	FOXK2	0.36	5.8	0.3	1.56e-8	Reticulocyte fraction of red cells;
LUSC	trans	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.63	-0.39	2.43e-13	Menarche (age at onset);
LUSC	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg13072238	chr3:49761600	GMPPB	-0.64	-8.14	-0.41	8.05e-15	Menarche (age at onset);
LUSC	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg26727032	chr16:67993705	SLC12A4	-0.45	-5.89	-0.31	9.66e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4077515	0.870	rs11793497	chr9:139271850	A/G	cg14019695	chr9:139328340	INPP5E	0.44	8.29	0.41	2.87e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	0.6	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2224391	0.628	rs2773318	chr6:5258843	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.48	-6.13	-0.32	2.46e-9	Height;
LUSC	cis	rs6674970	0.933	rs11204772	chr1:151056305	C/T	cg11822372	chr1:151115635	SEMA6C	0.55	8.52	0.42	5.48e-16	Childhood ear infection;
LUSC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg00310523	chr12:86230176	RASSF9	0.49	9.26	0.45	2.64e-18	Major depressive disorder;
LUSC	cis	rs76793172	1.000	rs77756656	chr19:46320718	C/G	cg27118825	chr19:46318748	RSPH6A;SYMPK	0.46	5.66	0.3	3.21e-8	Eosinophil counts;
LUSC	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	8.04	0.4	1.53e-14	Coronary artery disease;
LUSC	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	10.72	0.51	3.01e-23	Eye color traits;
LUSC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg18350739	chr11:68623251	NA	-0.36	-6.33	-0.33	7.68e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01685246	chr16:30538016	ZNF768	-0.42	-6.19	-0.32	1.81e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs10788309	0.967	rs7898398	chr10:85793343	A/G	cg18063312	chr5:72740737	NA	-0.36	-6.02	-0.31	4.55e-9	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUSC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06481639	chr22:41940642	POLR3H	0.48	5.7	0.3	2.63e-8	Vitiligo;
LUSC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	trans	rs9944715	1.000	rs11082518	chr18:43842032	G/A	cg01718231	chr17:29326311	RNF135	-0.5	-6.95	-0.36	1.97e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg14993813	chr1:46806288	NSUN4	-0.52	-7.2	-0.37	4.05e-12	Menopause (age at onset);
LUSC	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21659725	chr3:3221576	CRBN	0.58	8.08	0.4	1.2e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg00033643	chr7:134001901	SLC35B4	0.47	7.3	0.37	2.15e-12	Mean platelet volume;
LUSC	cis	rs9372253	0.843	rs9386895	chr6:110719632	T/A	cg19196401	chr6:110721138	DDO	-0.46	-8.62	-0.43	2.78e-16	Platelet distribution width;
LUSC	cis	rs6546550	0.935	rs6546551	chr2:70073703	C/T	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.04	-0.36	1.08e-11	Prevalent atrial fibrillation;
LUSC	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg20135002	chr11:47629003	NA	-0.5	-7.97	-0.4	2.6e-14	Subjective well-being;
LUSC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6545883	0.894	rs12622458	chr2:61523554	A/C	cg15711740	chr2:61764176	XPO1	0.43	6.61	0.34	1.5e-10	Tuberculosis;
LUSC	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs895636	1.000	rs895636	chr2:45188353	A/G	cg19444027	chr12:57145625	PRIM1	-0.53	-6.64	-0.34	1.25e-10	Metabolite levels;Fasting plasma glucose;
LUSC	cis	rs13315871	1.000	rs13076951	chr3:58436703	C/T	cg12435725	chr3:58293450	RPP14	-0.7	-6.93	-0.35	2.21e-11	Cholesterol, total;
LUSC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg03433033	chr1:76189801	ACADM	0.73	9.58	0.46	2.23e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06108461	chr20:60628389	TAF4	-0.96	-16.37	-0.67	1.27e-44	Body mass index;
LUSC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.79	13.06	0.58	8.9e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2652834	0.851	rs6494391	chr15:63406785	T/C	cg05507819	chr15:63340323	TPM1	0.45	5.75	0.3	2e-8	HDL cholesterol;
LUSC	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.76	11.42	0.53	9.75e-26	Cognitive ability;
LUSC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg10729496	chr3:10149963	C3orf24	0.56	7.62	0.38	2.62e-13	Alzheimer's disease;
LUSC	cis	rs62400317	0.859	rs72869118	chr6:45064626	T/C	cg20913747	chr6:44695427	NA	-0.46	-7.45	-0.38	8.3e-13	Total body bone mineral density;
LUSC	cis	rs2455601	0.882	rs11042116	chr11:8928472	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.78	-0.35	5.48e-11	Schizophrenia;
LUSC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.17	0.45	5.15e-18	Motion sickness;
LUSC	cis	rs79911532	0.515	rs117892182	chr7:75805689	C/A	cg03592824	chr7:75666768	STYXL1	0.65	6.52	0.34	2.57e-10	Mononucleosis;
LUSC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg11965913	chr1:205819406	PM20D1	0.46	6.38	0.33	5.83e-10	Parkinson's disease;
LUSC	cis	rs240764	0.687	rs7754085	chr6:101220806	T/A	cg09795085	chr6:101329169	ASCC3	-0.44	-6.24	-0.32	1.29e-9	Neuroticism;
LUSC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg13939156	chr17:80058883	NA	-0.33	-6.52	-0.34	2.63e-10	Life satisfaction;
LUSC	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg23752985	chr2:85803571	VAMP8	0.33	6.46	0.33	3.68e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.92	0.31	8.06e-9	Morning vs. evening chronotype;
LUSC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg10729496	chr3:10149963	C3orf24	0.51	6.94	0.35	2.07e-11	Alzheimer's disease;
LUSC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.06	-0.48	5.7e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4400599	0.618	rs4845610	chr1:154205428	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.9	-0.31	8.9e-9	Platelet distribution width;
LUSC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg15556689	chr8:8085844	FLJ10661	0.66	10.64	0.5	6.05e-23	Mood instability;
LUSC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg15595755	chr5:1867978	NA	0.46	8.37	0.42	1.57e-15	Cardiovascular disease risk factors;
LUSC	cis	rs2303282	0.664	rs4238787	chr16:56442066	C/T	cg00500540	chr16:56394104	NA	-0.39	-6.7	-0.34	8.91e-11	Breast cancer;
LUSC	cis	rs56161922	1.000	rs4562622	chr1:207876577	A/C	cg11752769	chr1:207818423	CR1L	0.71	6.07	0.32	3.54e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07639963	chr12:77157760	ZDHHC17	-0.49	-6.13	-0.32	2.54e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.21	-0.49	1.83e-21	Eye color traits;
LUSC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-9.69	-0.47	9.62e-20	Gut microbiome composition (summer);
LUSC	trans	rs6126344	0.957	rs1018422	chr20:50404452	C/T	cg03643032	chr16:85954903	IRF8	0.3	6.06	0.31	3.63e-9	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs727505	0.607	rs66478705	chr7:124789211	C/G	cg23710748	chr7:124431027	NA	-0.4	-6.92	-0.35	2.31e-11	Lewy body disease;
LUSC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg23630131	chr7:65973040	NA	-0.21	-5.8	-0.3	1.55e-8	Aortic root size;
LUSC	cis	rs9534288	0.783	rs7987385	chr13:46634131	A/G	cg15192986	chr13:46630673	CPB2	-0.8	-12.65	-0.57	3.2e-30	Blood protein levels;
LUSC	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.76	-12.55	-0.57	7.19e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg22823121	chr1:150693482	HORMAD1	0.5	7.18	0.37	4.54e-12	Melanoma;
LUSC	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg09835421	chr16:68378352	PRMT7	-0.54	-5.92	-0.31	7.97e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg14664628	chr15:75095509	CSK	0.47	6.49	0.33	3.07e-10	Systemic lupus erythematosus;
LUSC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg26335602	chr6:28129616	ZNF389	0.43	5.77	0.3	1.79e-8	Depression;
LUSC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.45	0.33	3.86e-10	Menopause (age at onset);
LUSC	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg13575925	chr12:9217583	LOC144571	0.34	6.28	0.32	1.07e-9	Sjögren's syndrome;
LUSC	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg10018233	chr7:150070692	REPIN1	0.4	6.68	0.34	9.91e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg05896524	chr21:47604654	C21orf56	-0.59	-9.37	-0.46	1.08e-18	Testicular germ cell tumor;
LUSC	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg10909506	chr17:38081995	ORMDL3	0.34	6.11	0.32	2.71e-9	Self-reported allergy;
LUSC	cis	rs1256061	0.603	rs1269056	chr14:64743890	T/C	cg21174375	chr14:64681225	SYNE2	0.35	6.26	0.32	1.18e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs9503598	0.636	rs6596978	chr6:3468878	C/T	cg05722439	chr19:14072965	RFX1	-0.3	-6.03	-0.31	4.43e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.03	-0.31	4.28e-9	Platelet count;
LUSC	cis	rs3820928	0.967	rs12622456	chr2:227768868	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.96	-0.4	2.8e-14	Pulmonary function;
LUSC	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg15423357	chr2:25149977	NA	0.38	7.57	0.38	3.62e-13	Body mass index;
LUSC	cis	rs10779751	0.690	rs2791659	chr1:11126569	C/A	cg08854313	chr1:11322531	MTOR	0.81	12.1	0.55	3.52e-28	Body mass index;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg08682991	chr16:70557429	COG4;SF3B3	0.78	6.23	0.32	1.44e-9	Cognitive performance;
LUSC	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg21775007	chr8:11205619	TDH	-0.59	-9.25	-0.45	2.83e-18	Retinal vascular caliber;
LUSC	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-9.19	-0.45	4.26e-18	Retinal vascular caliber;
LUSC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg23601095	chr6:26197514	HIST1H3D	0.68	7.51	0.38	5.59e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg21775007	chr8:11205619	TDH	0.47	6.95	0.36	1.9e-11	Neuroticism;
LUSC	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.72e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg12473912	chr3:136751656	NA	0.39	6.74	0.35	6.82e-11	Neuroticism;
LUSC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg21724239	chr8:58056113	NA	0.76	8.31	0.41	2.37e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.9e-20	Migraine;Coronary artery disease;
LUSC	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg09526685	chr4:187126073	CYP4V2	0.62	5.99	0.31	5.41e-9	Blood protein levels;
LUSC	cis	rs6500395	0.962	rs9941336	chr16:48652769	G/A	cg04672837	chr16:48644449	N4BP1	0.47	6.73	0.35	7.28e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2067615	0.542	rs4346064	chr12:107081599	C/A	cg15890332	chr12:107067104	RFX4	0.35	6.27	0.32	1.08e-9	Heart rate;
LUSC	cis	rs6693567	0.507	rs863862	chr1:150352361	T/A	cg15654264	chr1:150340011	RPRD2	0.46	7.35	0.37	1.5e-12	Migraine;
LUSC	cis	rs2425143	1.000	rs7267759	chr20:34257284	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.56	-0.34	2.09e-10	Blood protein levels;
LUSC	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg23202291	chr11:1979235	NA	-0.42	-6.74	-0.35	7.07e-11	DNA methylation (variation);
LUSC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.15	-0.32	2.18e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs72634258	0.945	rs225132	chr1:8095500	A/C	cg26816564	chr1:7831052	VAMP3	0.5	6.52	0.34	2.64e-10	Inflammatory bowel disease;
LUSC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.44	0.53	8.49e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs62400317	0.859	rs12201005	chr6:45136922	A/T	cg18551225	chr6:44695536	NA	-0.42	-6.84	-0.35	3.81e-11	Total body bone mineral density;
LUSC	cis	rs4356932	0.967	rs4386624	chr4:76946139	G/C	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-11.68	-0.54	1.17e-26	Chronic sinus infection;
LUSC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-0.63	-13.37	-0.59	5.78e-33	Prudent dietary pattern;
LUSC	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.46	-6.08	-0.32	3.2e-9	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	0.59	9.28	0.45	2.19e-18	Breast cancer;
LUSC	cis	rs12973672	1.000	rs34832786	chr19:35769518	T/C	cg12095397	chr19:35769544	USF2	0.44	6.91	0.35	2.42e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg14844989	chr11:31128820	NA	-0.37	-5.85	-0.3	1.18e-8	Red blood cell count;
LUSC	cis	rs3755132	0.929	rs2302931	chr2:15737480	C/A	cg12888861	chr2:15731646	DDX1	0.5	7.34	0.37	1.68e-12	Wilms tumor;
LUSC	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07080220	chr10:102295463	HIF1AN	0.68	9.2	0.45	3.94e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg14458575	chr2:238380390	NA	0.65	11.53	0.53	3.96e-26	Prostate cancer;
LUSC	cis	rs4589502	1.000	rs80263963	chr15:67127228	C/T	cg09911534	chr15:67153556	NA	-0.64	-6.55	-0.34	2.16e-10	Lung cancer (smoking interaction);
LUSC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg00857998	chr1:205179979	DSTYK	0.66	10.29	0.49	9.24e-22	Red blood cell count;
LUSC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg22508957	chr16:3507546	NAT15	-0.61	-9.83	-0.47	3.31e-20	Tuberculosis;
LUSC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg05025164	chr4:1340916	KIAA1530	0.41	6.11	0.32	2.8e-9	Obesity-related traits;
LUSC	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-6.17	-0.32	1.97e-9	Testicular germ cell tumor;
LUSC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg23281280	chr6:28129359	ZNF389	0.45	5.7	0.3	2.65e-8	Depression;
LUSC	cis	rs17155006	0.561	rs22783	chr7:107743243	G/T	cg05962710	chr7:107745446	LAMB4	-0.34	-6.1	-0.32	2.87e-9	Pneumococcal bacteremia;
LUSC	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08645402	chr16:4508243	NA	0.52	8.78	0.43	8.49e-17	Schizophrenia;
LUSC	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg07828340	chr4:882639	GAK	-0.96	-10.94	-0.51	5.03e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg00012203	chr2:219082015	ARPC2	-0.82	-15.34	-0.64	1.4e-40	Colorectal cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00670742	chr2:87034831	CD8A	0.74	6.06	0.31	3.63e-9	Cognitive performance;
LUSC	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg19682013	chr15:45996608	NA	0.38	5.72	0.3	2.31e-8	Waist circumference;Weight;
LUSC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13126279	chr21:47581558	C21orf56	0.47	7.05	0.36	1e-11	Testicular germ cell tumor;
LUSC	cis	rs10489202	1.000	rs3767474	chr1:168062398	C/T	cg24449463	chr1:168025552	DCAF6	-0.57	-7.03	-0.36	1.17e-11	Schizophrenia;
LUSC	cis	rs3820928	0.874	rs10189579	chr2:227864876	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.31	-0.37	1.99e-12	Pulmonary function;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26401236	chr17:19881329	AKAP10	-0.49	-6.62	-0.34	1.46e-10	Hepatitis;
LUSC	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg15704280	chr7:45808275	SEPT13	-0.64	-7.08	-0.36	8.44e-12	Axial length;
LUSC	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg26924012	chr15:45694286	SPATA5L1	0.75	11.26	0.52	3.73e-25	Glomerular filtration rate;
LUSC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg20608306	chr11:116969690	SIK3	0.4	6.68	0.34	9.91e-11	Blood protein levels;
LUSC	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg18240062	chr17:79603768	NPLOC4	0.63	11.19	0.52	6.63e-25	Eye color traits;
LUSC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg23788917	chr6:8435910	SLC35B3	0.51	7.5	0.38	5.8e-13	Motion sickness;
LUSC	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.67	-0.39	1.88e-13	Height;
LUSC	cis	rs8099014	0.859	rs11152072	chr18:56098912	A/G	cg12907477	chr18:56117327	MIR122	0.46	6.95	0.36	1.91e-11	Platelet count;
LUSC	cis	rs793571	0.714	rs972801	chr15:58921198	C/T	cg05156742	chr15:59063176	FAM63B	-0.53	-7.62	-0.38	2.64e-13	Schizophrenia;
LUSC	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg19610905	chr11:61596333	FADS2	-0.51	-7.72	-0.39	1.39e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUSC	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg23173402	chr1:227635558	NA	0.69	7.52	0.38	5.16e-13	Major depressive disorder;
LUSC	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg08345082	chr10:99160200	RRP12	-0.32	-6.67	-0.34	1.08e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	15.66	0.65	7.7e-42	Lung cancer in ever smokers;
LUSC	cis	rs2274273	0.624	rs66464079	chr14:55766164	G/T	cg04306507	chr14:55594613	LGALS3	0.49	9.89	0.48	2.21e-20	Protein biomarker;
LUSC	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg24642439	chr20:33292090	TP53INP2	-0.48	-7.39	-0.37	1.2e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.57	-11.37	-0.53	1.53e-25	Asthma (sex interaction);
LUSC	cis	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg17469321	chr7:55412551	NA	0.68	10.97	0.51	4.06e-24	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs13315871	1.000	rs13315871	chr3:58381287	G/A	cg20936604	chr3:58311152	NA	-0.65	-6.09	-0.32	3.05e-9	Cholesterol, total;
LUSC	cis	rs76878669	0.561	rs11227465	chr11:66115879	T/A	cg18002602	chr11:66138449	SLC29A2	-0.48	-8.37	-0.42	1.55e-15	Educational attainment (years of education);
LUSC	trans	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.67	10.69	0.5	3.8e-23	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7586879	0.765	rs11683429	chr2:25120733	T/A	cg15423357	chr2:25149977	NA	0.32	5.77	0.3	1.8e-8	Body mass index;
LUSC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.21	-0.32	1.57e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.59	0.43	3.36e-16	Prudent dietary pattern;
LUSC	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.61	9.71	0.47	8.65e-20	Alcohol dependence;
LUSC	cis	rs55665837	1.000	rs10047457	chr11:14439459	T/A	cg19336497	chr11:14380999	RRAS2	-0.37	-7.53	-0.38	4.9e-13	Vitamin D levels;
LUSC	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg21880101	chr17:80066754	CCDC57	-0.31	-5.8	-0.3	1.54e-8	Life satisfaction;
LUSC	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg21132104	chr15:45694354	SPATA5L1	0.41	6.09	0.32	3.08e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg07936489	chr17:37558343	FBXL20	-0.7	-9.69	-0.47	1.01e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg14458575	chr2:238380390	NA	0.7	8.06	0.4	1.34e-14	Prostate cancer;
LUSC	cis	rs1044826	0.642	rs407958	chr3:139213632	T/C	cg15131784	chr3:139108705	COPB2	0.39	6.36	0.33	6.82e-10	Obesity-related traits;
LUSC	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg00191853	chr8:101177733	SPAG1	0.36	5.81	0.3	1.42e-8	Atrioventricular conduction;
LUSC	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg14552801	chr7:65878734	NA	0.44	6.27	0.32	1.12e-9	Aortic root size;
LUSC	cis	rs1506636	0.539	rs17701547	chr7:123383461	A/G	cg03229431	chr7:123269106	ASB15	-0.53	-7.22	-0.37	3.55e-12	Plateletcrit;Platelet count;
LUSC	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg24675056	chr1:15929824	NA	0.45	7.85	0.39	5.81e-14	Systolic blood pressure;
LUSC	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	11.4	0.53	1.21e-25	Colorectal cancer;
LUSC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06022373	chr22:39101656	GTPBP1	0.81	12.6	0.57	4.67e-30	Menopause (age at onset);
LUSC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.3	5.65	0.3	3.51e-8	Obesity-related traits;
LUSC	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-8.99	-0.44	1.89e-17	Bone mineral density;
LUSC	cis	rs16949788	0.793	rs12439706	chr15:66668004	C/T	cg08120210	chr15:66682733	MAP2K1	-0.58	-5.82	-0.3	1.41e-8	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.49	9.33	0.45	1.55e-18	Monocyte percentage of white cells;
LUSC	cis	rs11229555	0.645	rs12289985	chr11:58185436	C/G	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs2587949	0.615	rs1872414	chr3:4234154	T/C	cg15139668	chr4:4577005	NA	0.4	6.01	0.31	4.8e-9	Periodontitis (DPAL);
LUSC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg22920501	chr2:26401640	FAM59B	-0.79	-11.76	-0.54	5.97e-27	Gut microbiome composition (summer);
LUSC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.28	0.49	1.04e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg08917208	chr2:24149416	ATAD2B	0.51	5.76	0.3	1.88e-8	Lymphocyte counts;
LUSC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg03609598	chr5:56110824	MAP3K1	-0.43	-6.23	-0.32	1.44e-9	Initial pursuit acceleration;
LUSC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg20891558	chr2:74357851	NA	0.78	13.05	0.58	9.37e-32	Gestational age at birth (maternal effect);
LUSC	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.5	-6.77	-0.35	5.68e-11	Schizophrenia;
LUSC	trans	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg05926928	chr17:57297772	GDPD1	-0.9	-10.32	-0.49	7.2e-22	Opioid sensitivity;
LUSC	cis	rs963731	0.649	rs2278912	chr2:39199702	C/T	cg04010122	chr2:39346883	SOS1	-0.8	-5.84	-0.3	1.21e-8	Corticobasal degeneration;
LUSC	cis	rs877282	0.945	rs71489301	chr10:770191	A/G	cg17470449	chr10:769945	NA	0.53	7.48	0.38	6.8e-13	Uric acid levels;
LUSC	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg09976142	chr9:130955436	CIZ1	0.47	7.86	0.39	5.49e-14	Attention deficit hyperactivity disorder;
LUSC	cis	rs273573	0.816	rs605083	chr11:30853147	C/G	cg14844989	chr11:31128820	NA	0.36	5.74	0.3	2.18e-8	Total body bone mineral density;
LUSC	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg20848291	chr7:100343083	ZAN	-0.65	-8.69	-0.43	1.6e-16	Other erythrocyte phenotypes;
LUSC	cis	rs62400317	0.762	rs72865924	chr6:44878943	G/A	cg18551225	chr6:44695536	NA	-0.46	-7.44	-0.38	8.7e-13	Total body bone mineral density;
LUSC	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg09184832	chr6:79620586	NA	-0.43	-6.96	-0.36	1.76e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	1.06	12.72	0.57	1.69e-30	Schizophrenia;
LUSC	cis	rs897080	0.515	rs1067404	chr2:44675823	G/T	cg00619915	chr2:44497795	NA	0.42	6.01	0.31	4.83e-9	Height;
LUSC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-0.81	-11.07	-0.52	1.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg21775007	chr8:11205619	TDH	0.5	6.85	0.35	3.54e-11	Monocyte count;
LUSC	cis	rs28830936	0.966	rs17678552	chr15:42066190	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.27	-0.32	1.14e-9	Diastolic blood pressure;
LUSC	cis	rs2227564	0.678	rs2242256	chr10:75597546	C/G	cg23231163	chr10:75533350	FUT11	0.42	5.79	0.3	1.66e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg06521331	chr12:34319734	NA	-0.48	-7.85	-0.39	5.8e-14	Morning vs. evening chronotype;
LUSC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23158103	chr7:148848205	ZNF398	-0.46	-7.49	-0.38	6.07e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6499755	0.932	rs9302665	chr16:55340567	C/G	cg02859129	chr16:55357253	IRX6	-0.37	-6.17	-0.32	1.98e-9	Hypospadias;
LUSC	cis	rs921665	0.831	rs7596478	chr2:3176358	A/G	cg02624386	chr2:3182749	NA	0.57	6.44	0.33	4.26e-10	World class endurance athleticism;
LUSC	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg17385448	chr1:15911702	AGMAT	0.37	6.4	0.33	5.32e-10	Systolic blood pressure;
LUSC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg12963246	chr6:28129442	ZNF389	0.38	5.74	0.3	2.09e-8	Cardiac Troponin-T levels;
LUSC	cis	rs7191700	0.511	rs8058983	chr16:11360849	A/G	cg00044050	chr16:11439710	C16orf75	-0.7	-12.45	-0.56	1.77e-29	Multiple sclerosis;
LUSC	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg05340658	chr4:99064831	C4orf37	0.45	7.08	0.36	8.69e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg15212455	chr7:39170539	POU6F2	0.62	10.0	0.48	8.88e-21	IgG glycosylation;
LUSC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.71	12.58	0.57	5.56e-30	Prudent dietary pattern;
LUSC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.04	-0.4	1.62e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2637266	0.967	rs4979898	chr10:78355672	G/A	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg08085267	chr17:45401833	C17orf57	-0.51	-7.29	-0.37	2.22e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg00750074	chr16:89608354	SPG7	-0.57	-10.08	-0.48	4.76e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg24011408	chr12:48396354	COL2A1	0.56	7.59	0.38	3.21e-13	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07150314	chr2:27579984	GTF3C2	-0.42	-6.47	-0.33	3.55e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg01579765	chr21:45077557	HSF2BP	-0.45	-9.51	-0.46	3.98e-19	Mean corpuscular volume;
LUSC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg03060546	chr3:49711283	APEH	0.64	6.96	0.36	1.76e-11	Menarche (age at onset);
LUSC	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg13010199	chr12:38710504	ALG10B	0.52	7.81	0.39	7.56e-14	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg04025307	chr7:1156635	C7orf50	0.44	6.07	0.32	3.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.39	-6.88	-0.35	2.99e-11	Longevity;Endometriosis;
LUSC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.51	-7.67	-0.39	1.9e-13	Menarche (age at onset);
LUSC	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	0.98	14.93	0.63	5.84e-39	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg05738196	chr6:26577821	NA	0.81	15.71	0.65	4.89e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg20203395	chr5:56204925	C5orf35	-0.46	-7.01	-0.36	1.3e-11	Breast cancer;Breast cancer (early onset);
LUSC	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg26384229	chr12:38710491	ALG10B	-0.7	-11.03	-0.52	2.42e-24	Morning vs. evening chronotype;
LUSC	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg19508488	chr2:152266495	RIF1	0.39	5.77	0.3	1.77e-8	Lung cancer;
LUSC	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs7799006	0.606	rs34417375	chr7:2315105	C/T	cg12823233	chr7:2316876	SNX8	-0.45	-7.58	-0.38	3.49e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	5.84	0.3	1.22e-8	Schizophrenia;
LUSC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg16850897	chr7:100343110	ZAN	0.6	8.41	0.42	1.19e-15	Other erythrocyte phenotypes;
LUSC	cis	rs9677476	0.774	rs1973016	chr2:232117513	C/G	cg07929768	chr2:232055508	NA	0.33	6.1	0.32	2.87e-9	Food antigen IgG levels;
LUSC	trans	rs62238980	0.614	rs17682583	chr22:32401495	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg01879757	chr17:41196368	BRCA1	-0.5	-7.79	-0.39	8.44e-14	Menopause (age at onset);
LUSC	cis	rs11779988	0.545	rs448882	chr8:17794039	C/T	cg01800426	chr8:17659068	MTUS1	-0.5	-5.97	-0.31	5.95e-9	Breast cancer;
LUSC	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.44	6.19	0.32	1.78e-9	Blood metabolite levels;
LUSC	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg18721089	chr20:30220636	NA	-0.35	-6.01	-0.31	4.98e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg09021430	chr5:549028	NA	-0.56	-7.57	-0.38	3.61e-13	Obesity-related traits;
LUSC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg19266014	chr7:2183958	MAD1L1	-0.34	-5.68	-0.3	2.97e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	7.88	0.4	4.61e-14	Menarche (age at onset);
LUSC	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg14830002	chr1:247616686	OR2B11	0.64	7.25	0.37	2.89e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10504229	0.516	rs4361758	chr8:57990401	C/T	cg11062466	chr8:58055876	NA	0.39	5.79	0.3	1.58e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg19318889	chr4:1322082	MAEA	0.45	7.41	0.38	1.06e-12	Obesity-related traits;
LUSC	cis	rs3849570	1.000	rs2290081	chr3:81810725	C/T	cg07356753	chr3:81810745	GBE1	-0.67	-10.87	-0.51	9.3e-24	Waist circumference;Body mass index;
LUSC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.11	-0.48	3.92e-21	Monocyte count;
LUSC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08219700	chr8:58056026	NA	0.68	8.62	0.43	2.75e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg24642439	chr20:33292090	TP53INP2	-0.56	-8.51	-0.42	5.89e-16	Height;
LUSC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	1.05	18.06	0.7	2.28e-51	Testicular germ cell tumor;
LUSC	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	7.34	0.37	1.61e-12	Educational attainment;
LUSC	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	7.65	0.39	2.21e-13	Response to antipsychotic treatment;
LUSC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg13560548	chr3:10150139	C3orf24	-0.54	-6.62	-0.34	1.45e-10	Alzheimer's disease;
LUSC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg03579872	chr1:53393473	SCP2	-0.38	-5.71	-0.3	2.54e-8	Monocyte count;
LUSC	cis	rs4253772	0.938	rs45550937	chr22:46638128	C/G	cg24881330	chr22:46731750	TRMU	0.63	5.85	0.31	1.15e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7572733	0.534	rs4850815	chr2:198786167	G/T	cg00792783	chr2:198669748	PLCL1	-0.44	-5.96	-0.31	6.57e-9	Dermatomyositis;
LUSC	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14442939	chr10:27389572	ANKRD26	-0.88	-9.89	-0.48	2.06e-20	Breast cancer;
LUSC	cis	rs10992471	0.603	rs10116813	chr9:95090360	C/T	cg14631576	chr9:95140430	CENPP	-0.37	-6.23	-0.32	1.37e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12016809	chr21:47604291	C21orf56	-0.47	-7.02	-0.36	1.22e-11	Testicular germ cell tumor;
LUSC	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg04586622	chr2:25135609	ADCY3	0.32	6.18	0.32	1.92e-9	Body mass index;
LUSC	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg06606381	chr12:133084897	FBRSL1	-0.95	-9.13	-0.45	6.49e-18	Depression;
LUSC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg04450456	chr4:17643702	FAM184B	0.4	6.94	0.35	2.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06544989	chr22:39130855	UNC84B	0.32	5.75	0.3	2e-8	Menopause (age at onset);
LUSC	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg12002119	chr2:101014098	CHST10	0.35	5.88	0.31	9.71e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.17	-0.32	1.95e-9	Neutrophil percentage of white cells;
LUSC	cis	rs6901250	0.569	rs594940	chr6:117090358	C/T	cg12892004	chr6:117198278	RFX6	0.37	6.68	0.34	9.97e-11	C-reactive protein levels;
LUSC	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg19773385	chr1:10388646	KIF1B	-0.59	-10.01	-0.48	8.62e-21	Hepatocellular carcinoma;
LUSC	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg25809561	chr17:30822961	MYO1D	0.57	9.69	0.47	9.59e-20	Schizophrenia;
LUSC	cis	rs10465746	0.780	rs7529293	chr1:84331981	A/G	cg10977910	chr1:84465055	TTLL7	0.45	6.44	0.33	4.26e-10	Obesity-related traits;
LUSC	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg04450003	chr12:50355995	AQP5	0.78	13.3	0.59	1.11e-32	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04110109	chr17:39968849	FKBP10;SC65	0.46	6.58	0.34	1.79e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1185460	0.967	rs1177562	chr11:118949331	C/T	cg23280166	chr11:118938394	VPS11	0.48	7.33	0.37	1.76e-12	Coronary artery disease;
LUSC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg22907277	chr7:1156413	C7orf50	0.71	10.28	0.49	1.04e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06850241	chr22:41845214	NA	0.34	6.3	0.33	9.5e-10	Vitiligo;
LUSC	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.43	-0.33	4.41e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2708977	0.637	rs597420	chr2:97070353	T/C	cg01950434	chr2:97203154	ARID5A	-0.45	-6.18	-0.32	1.89e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-7.1	-0.36	7.36e-12	Aortic root size;
LUSC	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg13755796	chr4:20253514	NA	-0.44	-6.9	-0.35	2.56e-11	Life satisfaction;
LUSC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.79	-13.07	-0.58	8.16e-32	Aortic root size;
LUSC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg10018233	chr7:150070692	REPIN1	0.38	6.73	0.35	7.52e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg24562669	chr7:97807699	LMTK2	0.48	8.76	0.43	1e-16	Breast cancer;
LUSC	cis	rs4704187	0.687	rs6894048	chr5:74456838	A/G	cg03227963	chr5:74354835	NA	0.31	6.8	0.35	4.74e-11	Response to amphetamines;
LUSC	cis	rs6723226	0.803	rs387780	chr2:32502495	T/C	cg02381751	chr2:32503542	YIPF4	0.65	9.7	0.47	9.32e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs11051970	0.918	rs1055876	chr12:32536200	C/T	cg24626660	chr12:32551988	NA	0.38	6.14	0.32	2.31e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01341218	chr17:43662625	NA	0.77	11.31	0.53	2.49e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20491397	chr13:22177926	EFHA1	-0.42	-6.25	-0.32	1.23e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17255340	0.539	rs1144192	chr6:83980929	C/G	cg08257003	chr6:84140564	ME1	0.32	7.7	0.39	1.52e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs11676348	0.755	rs62183956	chr2:219046122	C/T	cg23569941	chr2:219139048	TMBIM1;PNKD	-0.36	-6.01	-0.31	4.85e-9	Ulcerative colitis;
LUSC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.43	-6.23	-0.32	1.4e-9	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26272893	chr1:41445793	CTPS	-0.42	-6.23	-0.32	1.42e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg04369109	chr6:150039330	LATS1	-0.57	-8.45	-0.42	9.43e-16	Lung cancer;
LUSC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg19318889	chr4:1322082	MAEA	-0.54	-8.8	-0.43	7.42e-17	Obesity-related traits;
LUSC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Depression;
LUSC	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg23093090	chr10:104574429	C10orf26	-0.46	-8.04	-0.4	1.52e-14	Arsenic metabolism;
LUSC	cis	rs2573652	1.000	rs2727198	chr15:100513722	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.42	-7.7	-0.39	1.52e-13	Height;
LUSC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg15557168	chr22:42548783	NA	0.48	7.39	0.38	1.16e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-8.49	-0.42	6.8e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg16576597	chr16:28551801	NUPR1	0.29	5.75	0.3	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	6.02	0.31	4.59e-9	Tonsillectomy;
LUSC	trans	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg10840412	chr1:235813424	GNG4	0.53	6.33	0.33	8.1e-10	Neuroticism;
LUSC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg25204440	chr1:209979598	IRF6	0.53	6.95	0.36	1.98e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11764359	chr7:65958608	NA	-0.68	-10.93	-0.51	5.62e-24	Aortic root size;
LUSC	cis	rs1775715	0.737	rs2151047	chr10:32102110	G/A	cg26784012	chr10:32216390	ARHGAP12	0.46	7.67	0.39	1.89e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.03	20.82	0.75	2.6e-62	Cognitive function;
LUSC	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg11530693	chr1:120165357	ZNF697	0.69	10.78	0.51	1.91e-23	Systemic lupus erythematosus;
LUSC	cis	rs702885	0.510	rs1641463	chr2:65782300	G/A	cg05136724	chr2:65793962	NA	-0.53	-5.75	-0.3	2.05e-8	Electroencephalogram traits;
LUSC	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg10255544	chr17:80519551	FOXK2	0.41	6.73	0.35	7.32e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs8114671	0.967	rs6142322	chr20:33788538	C/A	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.81	-0.3	1.45e-8	Height;
LUSC	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg19628046	chr18:33552617	C18orf21	0.5	6.25	0.32	1.26e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27636011	chr10:102746998	C10orf2;MRPL43	0.45	6.03	0.31	4.23e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10100465	0.961	rs13439042	chr8:118634613	A/T	cg09430518	chr8:118662568	NA	0.3	5.82	0.3	1.4e-8	Leprosy;
LUSC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg12463550	chr7:65579703	CRCP	-0.51	-7.33	-0.37	1.74e-12	Aortic root size;
LUSC	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	9.73	0.47	7.58e-20	Lung cancer in ever smokers;
LUSC	cis	rs886126	1.000	rs10774616	chr12:111662885	G/T	cg10833066	chr12:111807467	FAM109A	0.4	6.29	0.33	9.97e-10	Coronary heart disease;
LUSC	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.03	-0.4	1.66e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg14993813	chr1:46806288	NSUN4	-0.5	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg03676636	chr4:99064102	C4orf37	0.36	7.89	0.4	4.25e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg15445000	chr17:37608096	MED1	-0.38	-6.67	-0.34	1.06e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22980127	chr19:33182716	NUDT19	0.91	12.49	0.56	1.25e-29	Red blood cell traits;
LUSC	cis	rs662064	0.962	rs620405	chr1:10554794	T/C	cg17425144	chr1:10567563	PEX14	0.36	5.68	0.3	3e-8	Asthma;
LUSC	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg20991723	chr1:152506922	NA	0.51	9.74	0.47	6.76e-20	Hair morphology;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24777315	chr12:66135734	NA	-0.45	-6.09	-0.32	3.1e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs11700980	0.551	rs12481736	chr21:30113657	A/G	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs12210905	0.843	rs12208039	chr6:26984004	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.64e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg02931644	chr1:25747376	RHCE	0.37	6.82	0.35	4.41e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg06532163	chr17:45867833	NA	0.35	6.53	0.34	2.45e-10	IgG glycosylation;
LUSC	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg24631222	chr15:78858424	CHRNA5	0.66	8.75	0.43	1.09e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.22	0.32	1.45e-9	IgG glycosylation;
LUSC	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg15423357	chr2:25149977	NA	0.34	6.45	0.33	3.96e-10	Body mass index in non-asthmatics;
LUSC	cis	rs11785400	0.890	rs13279182	chr8:143720544	A/G	cg24634471	chr8:143751801	JRK	0.57	8.43	0.42	1.03e-15	Schizophrenia;
LUSC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs4363385	0.510	rs7531076	chr1:153039167	G/T	cg25856811	chr1:152973957	SPRR3	-0.37	-6.17	-0.32	1.99e-9	Inflammatory skin disease;
LUSC	cis	rs7131987	0.903	rs2194519	chr12:29423583	C/T	cg09582351	chr12:29534625	ERGIC2	0.32	6.64	0.34	1.25e-10	QT interval;
LUSC	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg23711669	chr6:146136114	FBXO30	0.87	16.13	0.66	1.09e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.71	-12.4	-0.56	2.68e-29	White blood cell count (basophil);
LUSC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.39	0.46	9.85e-19	Prudent dietary pattern;
LUSC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg11247378	chr22:39784982	NA	-0.6	-10.33	-0.49	6.74e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs10761482	0.600	rs72807911	chr10:62228288	T/C	cg18175470	chr10:62150864	ANK3	0.49	6.68	0.34	1.02e-10	Schizophrenia;
LUSC	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.43	6.33	0.33	7.95e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18402987	chr7:1209562	NA	0.44	5.83	0.3	1.3e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg17376030	chr22:41985996	PMM1	0.51	6.39	0.33	5.65e-10	Vitiligo;
LUSC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg00310523	chr12:86230176	RASSF9	0.51	9.45	0.46	6.23e-19	Major depressive disorder;
LUSC	cis	rs7582720	1.000	rs72932588	chr2:203883193	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	8.22	0.41	4.56e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg05738196	chr6:26577821	NA	-0.52	-5.76	-0.3	1.96e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs12210905	0.688	rs9393814	chr6:27372978	C/T	cg14616345	chr9:133901267	LAMC3	-0.65	-5.95	-0.31	6.6e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg25554036	chr4:6271136	WFS1	0.6	12.22	0.56	1.26e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2414856	0.510	rs72756981	chr15:64575487	G/T	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	7.65	0.39	2.14e-13	Height;
LUSC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs10979	1.000	rs9390112	chr6:143896147	G/A	cg25407410	chr6:143891975	LOC285740	-0.73	-11.8	-0.54	4.24e-27	Hypospadias;
LUSC	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg26668713	chr11:65405903	SIPA1	0.6	7.65	0.39	2.2e-13	Blood pressure (age interaction);
LUSC	cis	rs8103278	0.662	rs16980051	chr19:46345886	T/C	cg11657440	chr19:46296263	DMWD	-0.48	-7.03	-0.36	1.15e-11	Coronary artery disease;
LUSC	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg06623918	chr6:96969491	KIAA0776	0.73	8.64	0.43	2.33e-16	Migraine;Coronary artery disease;
LUSC	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg07080220	chr10:102295463	HIF1AN	0.6	7.77	0.39	9.77e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.66	-0.34	1.13e-10	Systolic blood pressure;
LUSC	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg05110241	chr16:68378359	PRMT7	-0.71	-7.36	-0.37	1.42e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.89	0.31	9.52e-9	Menopause (age at onset);
LUSC	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg14154082	chr13:112174009	NA	0.38	7.64	0.39	2.31e-13	Menarche (age at onset);
LUSC	cis	rs12618769	0.520	rs72821904	chr2:99084882	G/A	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg22482690	chr17:47019901	SNF8	0.35	6.45	0.33	3.88e-10	Type 2 diabetes;
LUSC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	15.59	0.65	1.52e-41	Platelet count;
LUSC	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg11845111	chr2:191398756	TMEM194B	-0.85	-10.65	-0.5	5.39e-23	Diastolic blood pressure;
LUSC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg22535103	chr8:58192502	C8orf71	-0.67	-7.5	-0.38	5.78e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs508970	0.518	rs10792301	chr11:60888519	A/G	cg27301655	chr11:60869634	CD5	-0.26	-5.8	-0.3	1.51e-8	Rheumatoid arthritis;
LUSC	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg09184832	chr6:79620586	NA	-0.44	-7.08	-0.36	8.31e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.34	-0.37	1.67e-12	Subjective well-being;
LUSC	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg02696742	chr7:106810147	HBP1	-0.64	-9.59	-0.46	2.08e-19	Coronary artery disease;
LUSC	cis	rs2455601	0.882	rs11042118	chr11:8928791	T/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.77	-0.35	5.71e-11	Schizophrenia;
LUSC	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-1.05	-14.2	-0.61	4.09e-36	Exhaled nitric oxide levels;
LUSC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg24642844	chr7:1081250	C7orf50	-0.79	-10.39	-0.49	4.39e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg05507819	chr15:63340323	TPM1	0.64	8.99	0.44	1.93e-17	Platelet count;
LUSC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.89	0.55	1.95e-27	Prudent dietary pattern;
LUSC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.13	0.48	3.24e-21	Electroencephalogram traits;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg26691175	chr1:229761129	URB2;TAF5L	0.46	6.43	0.33	4.45e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.46	-0.38	7.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg12564285	chr5:131593104	PDLIM4	0.43	8.42	0.42	1.09e-15	Blood metabolite levels;
LUSC	cis	rs2979489	0.838	rs2979513	chr8:30397925	G/C	cg26383811	chr8:30366931	RBPMS	-0.52	-8.19	-0.41	5.76e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.53	-10.02	-0.48	8e-21	Prostate cancer;
LUSC	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg01858014	chr14:56050164	KTN1	-0.89	-7.32	-0.37	1.9e-12	Putamen volume;
LUSC	cis	rs3741151	0.773	rs58564192	chr11:73228904	G/A	cg17517138	chr11:73019481	ARHGEF17	0.96	8.06	0.4	1.35e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.68	-12.74	-0.57	1.37e-30	Monocyte count;
LUSC	cis	rs2742234	0.590	rs2503863	chr10:43667398	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.03	-0.36	1.17e-11	Hirschsprung disease;
LUSC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg00745463	chr17:30367425	LRRC37B	0.53	7.11	0.36	7.07e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg15839431	chr19:19639596	YJEFN3	0.42	5.89	0.31	9.46e-9	Tonsillectomy;
LUSC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg25036284	chr2:26402008	FAM59B	-0.74	-10.79	-0.51	1.73e-23	Gut microbiome composition (summer);
LUSC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.68	-8.84	-0.44	5.66e-17	Menarche (age at onset);
LUSC	cis	rs7095944	0.582	rs10901823	chr10:126488660	C/T	cg08799069	chr10:126477246	METTL10	-0.39	-6.21	-0.32	1.55e-9	Asthma;
LUSC	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.72	9.89	0.48	2.09e-20	Gastritis;
LUSC	cis	rs11822910	0.911	rs11828218	chr11:57196223	C/G	cg00522883	chr11:57194120	SLC43A3	0.44	7.22	0.37	3.54e-12	Platelet distribution width;
LUSC	cis	rs7527798	0.614	rs11118253	chr1:207825469	G/C	cg09232269	chr1:207846808	CR1L	-0.3	-6.39	-0.33	5.46e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg07414643	chr4:187882934	NA	0.58	10.99	0.52	3.39e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg26513180	chr16:89883248	FANCA	0.63	9.79	0.47	4.45e-20	Vitiligo;
LUSC	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg20587970	chr11:113659929	NA	-1.12	-15.45	-0.65	5.26e-41	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg11764359	chr7:65958608	NA	-0.78	-12.7	-0.57	2.07e-30	Aortic root size;
LUSC	cis	rs4499344	0.622	rs10401677	chr19:33061120	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.61	7.81	0.39	7.43e-14	Mean platelet volume;
LUSC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.72	-0.3	2.37e-8	Tonsillectomy;
LUSC	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg04492858	chr10:133558786	NA	0.43	7.19	0.37	4.2e-12	Survival in rectal cancer;
LUSC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.38	-5.95	-0.31	6.96e-9	Vitiligo;
LUSC	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06002616	chr8:101225028	SPAG1	0.4	6.65	0.34	1.19e-10	Atrioventricular conduction;
LUSC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.82	0.78	3.9e-70	Prudent dietary pattern;
LUSC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.73	-12.48	-0.56	1.32e-29	Motion sickness;
LUSC	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.78	-11.66	-0.54	1.32e-26	Corneal astigmatism;
LUSC	cis	rs4776059	0.798	rs10851520	chr15:52912978	C/G	cg22715398	chr15:52968154	KIAA1370	0.63	8.06	0.4	1.41e-14	Schizophrenia;
LUSC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06634786	chr22:41940651	POLR3H	-0.56	-6.51	-0.34	2.73e-10	Vitiligo;
LUSC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-9.86	-0.47	2.62e-20	Bipolar disorder;
LUSC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg09699651	chr6:150184138	LRP11	0.37	5.79	0.3	1.61e-8	Lung cancer;
LUSC	cis	rs7000551	0.725	rs2469756	chr8:22360423	G/A	cg12081754	chr8:22256438	SLC39A14	0.46	6.97	0.36	1.72e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.32	-5.89	-0.31	9.24e-9	IgG glycosylation;
LUSC	trans	rs4729127	1.000	rs4729127	chr7:94008535	A/G	cg20086523	chr13:52378287	DHRS12	0.54	6.31	0.33	9.11e-10	Intelligence;
LUSC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs7147624	1.000	rs2898816	chr14:66008160	T/C	cg03016385	chr14:66212404	NA	-0.83	-9.08	-0.45	9.48e-18	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg11057378	chr10:81107060	PPIF	0.34	5.73	0.3	2.3e-8	Height;
LUSC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.1	-0.48	4.17e-21	Hemoglobin concentration;
LUSC	cis	rs34375054	0.558	rs67041765	chr12:125672913	T/G	cg25124228	chr12:125621409	AACS	-0.44	-6.54	-0.34	2.3e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.16	-0.52	8.53e-25	Bipolar disorder;
LUSC	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17916960	chr15:79447300	NA	-0.54	-11.0	-0.52	3.11e-24	Refractive error;
LUSC	cis	rs2637266	0.783	rs2588333	chr10:78538952	A/G	cg18941641	chr10:78392320	NA	0.37	6.58	0.34	1.83e-10	Pulmonary function;
LUSC	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.89	-0.31	9.19e-9	Birth weight;
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.3	6.01	0.31	4.83e-9	Lymphocyte counts;
LUSC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-8.07	-0.4	1.27e-14	Personality dimensions;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg27602981	chr16:89385820	ANKRD11	-0.38	-6.08	-0.32	3.27e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.18	-0.37	4.45e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10779751	0.690	rs743577	chr1:11119135	G/A	cg04508216	chr1:11107452	MASP2	0.33	5.87	0.31	1.08e-8	Body mass index;
LUSC	cis	rs12286929	0.583	rs10458966	chr11:115102758	T/C	cg04055981	chr11:115044050	NA	0.37	6.3	0.33	9.33e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10193935	0.901	rs13375	chr2:42559288	A/G	cg27598129	chr2:42591480	NA	-0.6	-8.46	-0.42	8.59e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg13047869	chr3:10149882	C3orf24	0.43	6.53	0.34	2.46e-10	Alzheimer's disease;
LUSC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8018967	0.622	rs2041073	chr14:73972535	C/T	cg19682024	chr14:74008259	HEATR4;ACOT1	0.39	5.79	0.3	1.59e-8	Blood metabolite ratios;
LUSC	cis	rs6942756	0.806	rs2566886	chr7:128917866	G/A	cg02491457	chr7:128862824	NA	0.49	7.23	0.37	3.26e-12	White matter hyperintensity burden;
LUSC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg25036284	chr2:26402008	FAM59B	-0.7	-9.88	-0.48	2.22e-20	Gut microbiome composition (summer);
LUSC	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg15839431	chr19:19639596	YJEFN3	0.44	6.14	0.32	2.36e-9	Tonsillectomy;
LUSC	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg15839431	chr19:19639596	YJEFN3	-0.64	-6.75	-0.35	6.5e-11	Bipolar disorder;
LUSC	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg12863693	chr15:85201151	NMB	0.34	6.81	0.35	4.58e-11	Schizophrenia;
LUSC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.86e-18	Tonsillectomy;
LUSC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg10596483	chr8:143751796	JRK	0.61	9.5	0.46	4.34e-19	Schizophrenia;
LUSC	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21984481	chr17:79567631	NPLOC4	0.73	15.43	0.65	6.24e-41	Eye color traits;
LUSC	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.74	-0.39	1.2e-13	Retinal vascular caliber;
LUSC	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg24375607	chr4:120327624	NA	0.78	11.31	0.53	2.61e-25	Corneal astigmatism;
LUSC	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg17031739	chr1:67600172	NA	0.36	5.7	0.3	2.57e-8	Psoriasis;
LUSC	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.87	0.51	9.15e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7945718	0.839	rs763373	chr11:12840342	C/G	cg25843174	chr11:12811716	TEAD1	-0.31	-7.15	-0.36	5.63e-12	Educational attainment (years of education);
LUSC	trans	rs1486139	1.000	rs111294851	chr7:46282965	C/T	cg17534202	chr9:96721102	NA	-0.37	-6.56	-0.34	2.01e-10	Select biomarker traits;
LUSC	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg19920283	chr7:105172520	RINT1	0.58	6.12	0.32	2.65e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs6496932	0.913	rs34896088	chr15:85821624	A/C	cg26334166	chr20:61950840	COL20A1	0.31	6.12	0.32	2.57e-9	Central corneal thickness;Corneal structure;
LUSC	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg02023728	chr11:77925099	USP35	0.47	7.06	0.36	9.75e-12	Testicular germ cell tumor;
LUSC	cis	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.37e-9	Ulcerative colitis;
LUSC	cis	rs6484504	0.600	rs972714	chr11:31358875	T/G	cg06552810	chr11:31128660	NA	0.39	6.68	0.34	1.02e-10	Red blood cell count;
LUSC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg00376283	chr12:123451042	ABCB9	0.71	10.83	0.51	1.3e-23	Platelet count;
LUSC	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.08	15.76	0.65	3.3e-42	Uric acid levels;
LUSC	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg00982548	chr2:198649783	BOLL	-0.6	-7.39	-0.37	1.19e-12	Ulcerative colitis;
LUSC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg23324259	chr8:82754387	SNX16	-0.42	-5.68	-0.3	2.98e-8	Diastolic blood pressure;
LUSC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.01	0.4	1.9e-14	Parkinson's disease;
LUSC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg20203395	chr5:56204925	C5orf35	-0.76	-10.15	-0.49	2.81e-21	Initial pursuit acceleration;
LUSC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.66	12.58	0.57	5.48e-30	Monocyte count;
LUSC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg10356904	chr22:49881777	NA	-0.31	-6.36	-0.33	6.58e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6541297	1.000	rs7543050	chr1:230278291	C/G	cg05784532	chr1:230284198	GALNT2	0.47	6.92	0.35	2.26e-11	Coronary artery disease;
LUSC	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg11584989	chr19:19387371	SF4	0.58	6.97	0.36	1.74e-11	Bipolar disorder;
LUSC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg09034736	chr1:150693464	HORMAD1	-0.41	-5.88	-0.31	9.86e-9	Melanoma;
LUSC	trans	rs1268789	0.545	rs959539	chr4:79372693	T/G	cg06112894	chr8:141469983	TRAPPC9	0.23	6.27	0.32	1.12e-9	Hair shape;Hair morphology;
LUSC	cis	rs7582720	1.000	rs74421437	chr2:203831252	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06634786	chr22:41940651	POLR3H	0.51	6.11	0.32	2.82e-9	Vitiligo;
LUSC	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg14092571	chr14:90743983	NA	-0.35	-5.71	-0.3	2.45e-8	Mortality in heart failure;
LUSC	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg13010199	chr12:38710504	ALG10B	-0.48	-7.56	-0.38	3.92e-13	Morning vs. evening chronotype;
LUSC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.38	0.33	5.95e-10	Menopause (age at onset);
LUSC	trans	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg07393940	chr7:158741817	NA	0.38	6.89	0.35	2.77e-11	Life satisfaction;
LUSC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg21951975	chr1:209979733	IRF6	0.6	7.73	0.39	1.24e-13	Cleft lip with or without cleft palate;
LUSC	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.36e-13	Type 2 diabetes;
LUSC	cis	rs941764	0.965	rs747159	chr14:91841030	A/C	cg10511902	chr14:91842949	CCDC88C	-0.43	-7.44	-0.38	8.45e-13	Breast cancer;
LUSC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg25039879	chr17:56429692	SUPT4H1	0.68	9.08	0.45	9.42e-18	Cognitive test performance;
LUSC	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg05714579	chr10:131428358	MGMT	0.53	7.86	0.4	5.38e-14	Response to temozolomide;
LUSC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18876405	chr7:65276391	NA	-0.55	-8.81	-0.43	6.92e-17	Aortic root size;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17482706	chr9:77643371	C9orf41	0.43	6.14	0.32	2.28e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg16325326	chr1:53192061	ZYG11B	0.69	11.17	0.52	7.98e-25	Monocyte count;
LUSC	cis	rs9992101	0.645	rs907446	chr4:77254804	C/T	cg17010112	chr4:77227123	STBD1	-0.32	-5.98	-0.31	5.84e-9	Creatinine levels;
LUSC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg04352962	chr1:209979756	IRF6	0.51	6.89	0.35	2.84e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.81	0.3	1.49e-8	Breast cancer;
LUSC	cis	rs2398893	0.924	rs11789837	chr9:96817369	T/G	cg14459158	chr9:96720562	NA	0.31	6.03	0.31	4.3e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg13685833	chr1:53393034	SCP2	-0.39	-5.86	-0.31	1.11e-8	Monocyte count;
LUSC	cis	rs240764	0.817	rs58266877	chr6:101156284	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-6.25	-0.32	1.22e-9	Neuroticism;
LUSC	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg03605463	chr16:89740564	NA	0.39	5.91	0.31	8.42e-9	Vitiligo;
LUSC	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-9.05	-0.44	1.22e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.66	8.95	0.44	2.43e-17	High light scatter reticulocyte count;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23860886	chr6:18155593	KDM1B;TPMT	0.38	6.14	0.32	2.36e-9	Asthma;
LUSC	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg07148914	chr20:33460835	GGT7	0.57	8.69	0.43	1.63e-16	Height;
LUSC	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg09307838	chr4:120376055	NA	0.73	10.49	0.5	1.93e-22	Corneal astigmatism;
LUSC	cis	rs4682868	0.552	rs6771233	chr3:42922697	G/T	cg21365077	chr3:42922735	NA	0.41	5.69	0.3	2.84e-8	Monocyte percentage of white cells;
LUSC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.28	6.29	0.33	9.75e-10	Electroencephalogram traits;
LUSC	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-7.8	-0.39	7.8500000000000006e-14	Schizophrenia;
LUSC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06850241	chr22:41845214	NA	-0.32	-6.01	-0.31	4.96e-9	Vitiligo;
LUSC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg14668632	chr7:2872130	GNA12	-0.47	-6.89	-0.35	2.73e-11	Height;
LUSC	cis	rs968451	0.789	rs1003643	chr22:39676494	T/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	9.19	0.45	4.31e-18	Primary biliary cholangitis;
LUSC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.65	-0.34	1.21e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg02389323	chr16:88786976	FAM38A	1.17	11.78	0.54	5.11e-27	Plateletcrit;
LUSC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-9.26	-0.45	2.59e-18	Chronic sinus infection;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23611233	chr1:249133059	ZNF672	0.38	5.98	0.31	5.69e-9	Asthma;
LUSC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg26924012	chr15:45694286	SPATA5L1	1.13	20.89	0.75	1.35e-62	Homoarginine levels;
LUSC	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	13.51	0.59	1.71e-33	Post bronchodilator FEV1;
LUSC	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs860295	0.812	rs3820594	chr1:155829511	C/T	cg08949192	chr1:155289623	RUSC1;FDPS	-0.35	-5.77	-0.3	1.79e-8	Body mass index;
LUSC	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg06612196	chr6:6737390	NA	0.56	11.11	0.52	1.32e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg07061783	chr6:25882402	NA	-0.39	-6.08	-0.32	3.22e-9	Blood metabolite levels;
LUSC	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg13514129	chr1:39547527	MACF1	0.72	11.86	0.54	2.49e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.83	14.71	0.63	4.25e-38	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	0.92	15.35	0.64	1.35e-40	Breast cancer;
LUSC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg08888203	chr3:10149979	C3orf24	-0.45	-6.24	-0.32	1.34e-9	Alzheimer's disease;
LUSC	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg13390004	chr1:15929781	NA	0.41	6.84	0.35	3.76e-11	Systolic blood pressure;
LUSC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21545522	chr1:205238299	TMCC2	0.51	9.81	0.47	3.88e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg04117972	chr1:227635322	NA	0.61	5.78	0.3	1.74e-8	Major depressive disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16290904	chr8:77912348	PXMP3	-0.42	-6.0	-0.31	5.03e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.73	-0.35	7.52e-11	Mood instability;
LUSC	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.39	7.68	0.39	1.81e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-10.46	-0.5	2.48e-22	Alzheimer's disease;
LUSC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg16545954	chr1:2118288	C1orf86	-0.29	-5.64	-0.3	3.54e-8	Height;
LUSC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.34	6.72	0.35	7.94e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1595825	0.891	rs75163179	chr2:198895402	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-6.23	-0.32	1.38e-9	Ulcerative colitis;
LUSC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.27	0.56	7.85e-29	Motion sickness;
LUSC	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg24562669	chr7:97807699	LMTK2	0.37	6.42	0.33	4.66e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.8	-14.33	-0.62	1.2e-36	Brugada syndrome;
LUSC	cis	rs6469656	0.667	rs11781970	chr8:117762990	G/T	cg24004040	chr8:117650383	NA	-0.4	-5.85	-0.31	1.14e-8	Colorectal cancer;
LUSC	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-6.94	-0.36	2.02e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs62458065	0.713	rs1597560	chr7:32493886	C/G	cg20159608	chr7:32802032	NA	-0.73	-9.12	-0.45	7.08e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs4474465	0.688	rs4367973	chr11:78284545	C/A	cg27205649	chr11:78285834	NARS2	0.55	6.6	0.34	1.61e-10	Alzheimer's disease (survival time);
LUSC	cis	rs10207628	0.601	rs6743470	chr2:127868435	G/T	cg06223080	chr2:127868745	NA	0.38	6.56	0.34	2.06e-10	Psychosis and Alzheimer's disease;
LUSC	cis	rs2540226	0.816	rs6719179	chr2:39981675	A/C	cg23576258	chr2:39999331	THUMPD2	0.34	5.82	0.3	1.37e-8	Personality dimensions;
LUSC	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-8.11	-0.41	9.71e-15	Neuroticism;
LUSC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg06636001	chr8:8085503	FLJ10661	0.69	11.33	0.53	2.12e-25	Systolic blood pressure;
LUSC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	6.46	0.33	3.69e-10	Bipolar disorder;
LUSC	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg09323728	chr8:95962352	TP53INP1	-0.32	-5.97	-0.31	6.15e-9	Type 2 diabetes;
LUSC	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg25801113	chr15:45476975	SHF	-0.36	-7.18	-0.37	4.43e-12	Uric acid levels;
LUSC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	5.79	0.3	1.65e-8	Personality dimensions;
LUSC	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.49	-7.04	-0.36	1.12e-11	Rheumatoid arthritis;
LUSC	cis	rs4776059	0.798	rs7167494	chr15:52928453	C/G	cg24008177	chr15:52972085	KIAA1370	-0.38	-6.86	-0.35	3.37e-11	Schizophrenia;
LUSC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-0.84	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg05340658	chr4:99064831	C4orf37	0.45	7.1	0.36	7.73e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg23791538	chr6:167370224	RNASET2	-0.42	-6.74	-0.35	6.85e-11	Crohn's disease;
LUSC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg14004847	chr7:1930337	MAD1L1	0.55	8.51	0.42	5.86e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg13647721	chr17:30228624	UTP6	0.6	5.93	0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs6542838	0.641	rs4553869	chr2:99505940	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.39	-0.33	5.71e-10	Fear of minor pain;
LUSC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg07424592	chr7:64974309	NA	0.7	6.15	0.32	2.24e-9	Diabetic kidney disease;
LUSC	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg19774624	chr17:42201019	HDAC5	-0.48	-6.97	-0.36	1.66e-11	Total body bone mineral density;
LUSC	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7674212	0.531	rs10006474	chr4:103928047	A/G	cg16532752	chr4:104119610	CENPE	-0.42	-5.87	-0.31	1.06e-8	Type 2 diabetes;
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.69	10.55	0.5	1.24e-22	Lymphocyte counts;
LUSC	cis	rs7091068	0.616	rs10748611	chr10:95482761	A/C	cg20715218	chr10:95462985	C10orf4	0.62	6.99	0.36	1.54e-11	Urinary tract infection frequency;
LUSC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	14.57	0.62	1.47e-37	Platelet count;
LUSC	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg02569458	chr12:86230093	RASSF9	0.42	6.77	0.35	5.89e-11	Major depressive disorder;
LUSC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg18479299	chr3:125709523	NA	-0.51	-5.83	-0.3	1.33e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6714710	0.580	rs55886305	chr2:98495661	T/G	cg26665480	chr2:98280029	ACTR1B	0.58	8.56	0.42	4.18e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg08213375	chr14:104286397	PPP1R13B	0.42	7.41	0.38	1.03e-12	Reticulocyte count;
LUSC	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	7.26	0.37	2.65e-12	Cognitive test performance;
LUSC	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.97	0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg27201871	chr17:79212816	C17orf56;C17orf89	0.37	6.22	0.32	1.47e-9	Tuberculosis;
LUSC	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg13010199	chr12:38710504	ALG10B	0.69	10.56	0.5	1.13e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7577851	0.715	rs6721259	chr2:69709919	A/G	cg10773587	chr2:69614142	GFPT1	0.48	5.67	0.3	3.03e-8	Parkinson's disease (age of onset);
LUSC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4776059	1.000	rs12914502	chr15:52911335	A/G	cg25063058	chr15:52860530	ARPP19	0.41	5.78	0.3	1.74e-8	Schizophrenia;
LUSC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-15.88	-0.66	1.05e-42	Gut microbiome composition (summer);
LUSC	trans	rs4942242	0.640	rs9533571	chr13:44230136	C/T	cg19169023	chr15:41853346	TYRO3	-0.58	-9.19	-0.45	4.41e-18	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg21724239	chr8:58056113	NA	0.59	7.11	0.36	6.93e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7572644	0.699	rs1506537	chr2:28181901	G/C	cg27432699	chr2:27873401	GPN1	-0.51	-6.86	-0.35	3.28e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	9.33	0.45	1.56e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg09904177	chr6:26538194	HMGN4	-0.51	-5.94	-0.31	6.98e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6542838	0.641	rs1581249	chr2:99500630	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-5.65	-0.3	3.42e-8	Fear of minor pain;
LUSC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg04025307	chr7:1156635	C7orf50	0.4	6.18	0.32	1.84e-9	Longevity;Endometriosis;
LUSC	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg04733989	chr22:42467013	NAGA	0.42	7.04	0.36	1.12e-11	Cognitive function;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14478806	chr15:80351979	ZFAND6	0.51	7.18	0.37	4.58e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.49	-8.32	-0.41	2.32e-15	Lymphocyte counts;
LUSC	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg11502198	chr6:26597334	ABT1	0.55	8.49	0.42	7.05e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg04117972	chr1:227635322	NA	0.61	6.54	0.34	2.3e-10	Major depressive disorder;
LUSC	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg21775007	chr8:11205619	TDH	0.52	7.09	0.36	8.13e-12	Neuroticism;
LUSC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	0.83	13.89	0.61	5.99e-35	Menopause (age at onset);
LUSC	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg08975724	chr8:8085496	FLJ10661	0.48	7.3	0.37	2.1e-12	Mood instability;
LUSC	cis	rs73200209	0.744	rs73200239	chr12:116684424	G/C	cg01776926	chr12:116560359	MED13L	-0.49	-5.98	-0.31	5.81e-9	Total body bone mineral density;
LUSC	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg25358565	chr5:93447407	FAM172A	0.8	11.39	0.53	1.34e-25	Diabetic retinopathy;
LUSC	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.97	-0.31	6.22e-9	IgG glycosylation;
LUSC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Parkinson's disease;
LUSC	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg09184832	chr6:79620586	NA	0.41	6.46	0.33	3.72e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-25.77	-0.82	2.2e-81	Exhaled nitric oxide output;
LUSC	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	8.67	0.43	1.92e-16	Mean corpuscular hemoglobin;
LUSC	trans	rs12210905	0.688	rs12195783	chr6:27444345	A/G	cg11837749	chr1:55047332	ACOT11	0.73	6.17	0.32	1.97e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.94	0.31	7.17e-9	Menopause (age at onset);
LUSC	cis	rs9902453	0.967	rs12450441	chr17:28495021	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.19	0.41	5.67e-15	Coffee consumption (cups per day);
LUSC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.69	-10.73	-0.51	2.75e-23	Aortic root size;
LUSC	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg26566898	chr11:117069891	TAGLN	0.34	6.46	0.33	3.77e-10	Blood protein levels;
LUSC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.69e-9	Aortic root size;
LUSC	cis	rs7264396	0.887	rs2236165	chr20:34096725	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.64	-0.34	1.3e-10	Total cholesterol levels;
LUSC	cis	rs9392556	0.829	rs2783073	chr6:4118674	T/C	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.36	-6.27	-0.32	1.12e-9	Blood metabolite levels;
LUSC	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg21100191	chr22:23484243	RTDR1	0.91	15.73	0.65	3.99e-42	Bone mineral density;
LUSC	cis	rs10792830	0.832	rs583162	chr11:85813817	A/G	cg07180834	chr11:85838833	NA	-0.3	-5.91	-0.31	8.55e-9	Psychosis and Alzheimer's disease;
LUSC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.74	-0.35	6.93e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg17757837	chr7:157058334	UBE3C	0.82	12.98	0.58	1.8e-31	Body mass index;
LUSC	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg04359828	chr10:32216031	ARHGAP12	0.38	6.36	0.33	6.58e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg11584989	chr19:19387371	SF4	0.57	6.92	0.35	2.31e-11	Bipolar disorder;
LUSC	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg02023728	chr11:77925099	USP35	0.5	7.27	0.37	2.53e-12	Testicular germ cell tumor;
LUSC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg22166914	chr1:53195759	ZYG11B	-0.62	-10.29	-0.49	9.65e-22	Monocyte count;
LUSC	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg03806693	chr22:41940476	POLR3H	-0.63	-9.21	-0.45	3.59e-18	Vitiligo;
LUSC	trans	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-5.97	-0.31	6.07e-9	Depression;
LUSC	trans	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg18335740	chr13:41363409	SLC25A15	0.6	8.85	0.44	5.33e-17	Lewy body disease;
LUSC	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg00745463	chr17:30367425	LRRC37B	-0.67	-7.92	-0.4	3.56e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.63	-9.29	-0.45	2.08e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg07169764	chr2:136633963	MCM6	-0.6	-8.05	-0.4	1.47e-14	Mosquito bite size;
LUSC	cis	rs7202877	0.706	rs467780	chr16:75437138	A/G	cg03315344	chr16:75512273	CHST6	-0.42	-6.0	-0.31	5.21e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	13.77	0.6	1.8e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs12891047	0.866	rs1810523	chr14:68266708	C/T	cg20999565	chr14:68265668	ZFYVE26	0.37	5.65	0.3	3.37e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg12573674	chr2:1569213	NA	-0.61	-7.39	-0.37	1.19e-12	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs10979	0.965	rs9403508	chr6:143887857	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-11.91	-0.55	1.66e-27	Hypospadias;
LUSC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	cis	rs6714710	0.580	rs1838797	chr2:98454572	G/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.36	5.72	0.3	2.41e-8	Lymphocyte counts;
LUSC	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg06917634	chr15:78832804	PSMA4	-0.49	-6.51	-0.34	2.74e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6546537	0.911	rs13027712	chr2:69891367	C/T	cg10773587	chr2:69614142	GFPT1	-0.53	-8.12	-0.41	9.2e-15	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs2289328	0.825	rs35777573	chr15:40644246	T/A	cg13931752	chr15:40660718	DISP2	0.45	5.89	0.31	9.38e-9	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-1.0	-23.93	-0.79	2.05e-74	Urate levels in lean individuals;
LUSC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg12432903	chr7:1882776	MAD1L1	-0.38	-5.94	-0.31	7.15e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs72781680	0.716	rs2551334	chr2:24000396	G/A	cg08917208	chr2:24149416	ATAD2B	0.6	6.91	0.35	2.44e-11	Lymphocyte counts;
LUSC	cis	rs259282	0.589	rs6510271	chr19:33117666	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	10.51	0.5	1.67e-22	Schizophrenia;
LUSC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg23630131	chr7:65973040	NA	0.21	5.94	0.31	7.16e-9	Aortic root size;
LUSC	cis	rs4460629	0.521	rs4361977	chr1:155076079	C/T	cg23973274	chr1:155060172	NA	-0.32	-6.22	-0.32	1.46e-9	Serum magnesium levels;
LUSC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.62	0.34	1.47e-10	Tonsillectomy;
LUSC	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg04545296	chr12:48745243	ZNF641	0.3	5.74	0.3	2.17e-8	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg12935359	chr14:103987150	CKB	0.53	8.38	0.42	1.46e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg19812747	chr11:111475976	SIK2	-0.56	-8.15	-0.41	7.2e-15	Primary sclerosing cholangitis;
LUSC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06481639	chr22:41940642	POLR3H	-0.52	-5.94	-0.31	7e-9	Vitiligo;
LUSC	cis	rs6541297	0.887	rs6541295	chr1:230281698	A/G	cg20703242	chr1:230279135	GALNT2	0.57	7.17	0.37	4.92e-12	Coronary artery disease;
LUSC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.53	0.5	1.45e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg08847533	chr14:75593920	NEK9	0.86	15.97	0.66	4.74e-43	Height;
LUSC	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs12618769	0.597	rs4850879	chr2:99113082	A/G	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	0.65	13.88	0.6	6.8000000000000005e-35	Prudent dietary pattern;
LUSC	cis	rs9682041	0.561	rs6444928	chr3:170147875	A/G	cg11886554	chr3:170076028	SKIL	0.63	7.32	0.37	1.83e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LUSC	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.3	-5.73	-0.3	2.2e-8	Schizophrenia;
LUSC	cis	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg21775007	chr8:11205619	TDH	-0.46	-5.87	-0.31	1.05e-8	Neuroticism;
LUSC	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.33e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.06	0.36	9.57e-12	Bipolar disorder;
LUSC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg16482183	chr6:26056742	HIST1H1C	0.5	7.28	0.37	2.43e-12	Height;
LUSC	cis	rs6087990	0.899	rs4911110	chr20:31392366	C/T	cg13636640	chr20:31349939	DNMT3B	-0.93	-19.79	-0.73	3.2e-58	Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08677398	chr8:58056175	NA	0.52	6.58	0.34	1.79e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.61	-9.8	-0.47	4.11e-20	Urinary electrolytes (magnesium/calcium ratio);
LUSC	cis	rs1832871	0.672	rs7745596	chr6:158732991	T/A	cg07165851	chr6:158734300	TULP4	0.46	6.89	0.35	2.81e-11	Height;
LUSC	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg02269571	chr22:50332266	NA	-0.6	-8.97	-0.44	2.2e-17	Schizophrenia;
LUSC	cis	rs593982	0.858	rs663797	chr11:65552740	A/G	cg08755490	chr11:65554678	OVOL1	1.43	16.36	0.67	1.36e-44	Atopic dermatitis;
LUSC	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg27471124	chr11:109292789	C11orf87	0.38	6.89	0.35	2.71e-11	Schizophrenia;
LUSC	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.64	9.64	0.47	1.49e-19	Corneal astigmatism;
LUSC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.91	-13.22	-0.59	2.25e-32	Initial pursuit acceleration;
LUSC	trans	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg02800362	chr5:177631904	HNRNPAB	0.88	13.11	0.58	5.56e-32	Obesity-related traits;
LUSC	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.33	-0.33	8.1e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg22903471	chr2:27725779	GCKR	-0.39	-6.68	-0.34	9.96e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs9309473	0.500	rs6546862	chr2:73860348	G/A	cg20560298	chr2:73613845	ALMS1	0.46	7.02	0.36	1.27e-11	Metabolite levels;
LUSC	trans	rs11039798	0.844	rs41431447	chr11:48983199	A/G	cg03929089	chr4:120376271	NA	0.73	6.22	0.32	1.46e-9	Axial length;
LUSC	trans	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.74	-0.35	6.89e-11	Life satisfaction;
LUSC	trans	rs12651329	1.000	rs12651329	chr4:36079594	A/G	cg13138952	chr17:236013	NA	-0.4	-6.25	-0.32	1.26e-9	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg09826364	chr7:158789723	NA	-0.39	-6.21	-0.32	1.6e-9	Facial morphology (factor 20);
LUSC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg25019033	chr10:957182	NA	0.57	7.8	0.39	8.07e-14	Eosinophil percentage of granulocytes;
LUSC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg17724175	chr1:150552817	MCL1	0.37	6.7	0.34	8.92e-11	Tonsillectomy;
LUSC	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg10356904	chr22:49881777	NA	-0.3	-5.99	-0.31	5.56e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1062746	0.777	rs34400756	chr16:87372078	A/G	cg02258303	chr16:87377426	FBXO31	-0.6	-10.08	-0.48	5.03e-21	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg15704280	chr7:45808275	SEPT13	0.82	7.82	0.39	6.96e-14	Axial length;
LUSC	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.16	-0.36	5.08e-12	Coronary artery disease;
LUSC	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-8.32	-0.41	2.29e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7560272	0.512	rs13015885	chr2:73920482	G/T	cg20560298	chr2:73613845	ALMS1	0.4	6.06	0.31	3.73e-9	Schizophrenia;
LUSC	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-1.04	-12.46	-0.56	1.56e-29	Schizophrenia;
LUSC	trans	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg12856521	chr11:46389249	DGKZ	0.42	6.75	0.35	6.52e-11	Leprosy;
LUSC	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.72	-12.06	-0.55	4.86e-28	Height;
LUSC	cis	rs7833986	0.501	rs9650314	chr8:56903610	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.68	10.98	0.51	3.87e-24	Height;
LUSC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.57	-9.38	-0.46	1.03e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.28	-5.76	-0.3	1.88e-8	Longevity;Endometriosis;
LUSC	cis	rs9398803	0.835	rs9321065	chr6:126744087	G/A	cg19875578	chr6:126661172	C6orf173	0.43	6.27	0.32	1.11e-9	Male-pattern baldness;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10308682	chr20:5931622	MCM8;TRMT6	0.45	6.06	0.31	3.63e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg17757837	chr7:157058334	UBE3C	0.82	13.26	0.59	1.5e-32	Body mass index;
LUSC	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.82	-0.47	3.7e-20	Total cholesterol levels;
LUSC	cis	rs1113500	0.862	rs11185264	chr1:108640506	T/C	cg11967332	chr1:108735228	SLC25A24	0.4	5.96	0.31	6.28e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs7584330	0.554	rs7598559	chr2:238435398	A/G	cg14458575	chr2:238380390	NA	-0.51	-6.05	-0.31	3.99e-9	Prostate cancer;
LUSC	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg27661571	chr11:113659931	NA	-0.67	-7.74	-0.39	1.16e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.9	0.55	1.81e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg01294253	chr9:136912663	BRD3	0.34	5.92	0.31	8.12e-9	Platelet distribution width;
LUSC	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg15485101	chr11:133734466	NA	0.42	7.68	0.39	1.82e-13	Childhood ear infection;
LUSC	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg15704280	chr7:45808275	SEPT13	-0.82	-11.57	-0.53	2.95e-26	Coronary artery disease;
LUSC	cis	rs722599	0.683	rs8022046	chr14:75278302	G/A	cg08847533	chr14:75593920	NEK9	0.45	6.3	0.33	9.61e-10	IgG glycosylation;
LUSC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg16339924	chr4:17578868	LAP3	0.64	9.62	0.47	1.73e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.66	-0.43	2.03e-16	Bipolar disorder;
LUSC	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-7.95	-0.4	2.99e-14	Schizophrenia;
LUSC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.89	-18.69	-0.71	7.45e-54	Intelligence (multi-trait analysis);
LUSC	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg00806126	chr19:22604979	ZNF98	0.37	5.75	0.3	2.05e-8	Pain;
LUSC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	1.03	19.23	0.72	5.24e-56	Menopause (age at onset);
LUSC	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg17830980	chr10:43048298	ZNF37B	0.42	6.21	0.32	1.54e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg07169764	chr2:136633963	MCM6	0.56	7.27	0.37	2.56e-12	Mosquito bite size;
LUSC	cis	rs727505	1.000	rs67552763	chr7:124517857	A/G	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg19508488	chr2:152266495	RIF1	0.5	7.11	0.36	7.19e-12	Lung cancer;
LUSC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg18681998	chr4:17616180	MED28	0.8	14.46	0.62	4.01e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.87	-0.68	1.34e-46	Exhaled nitric oxide output;
LUSC	cis	rs12620999	0.878	rs7593514	chr2:237980691	A/G	cg23555395	chr2:238036564	NA	0.47	8.45	0.42	9.37e-16	Systemic lupus erythematosus;
LUSC	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg12179176	chr11:130786555	SNX19	0.74	12.45	0.56	1.79e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg12310025	chr6:25882481	NA	-0.77	-12.94	-0.58	2.44e-31	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03264670	chr22:29196746	XBP1	0.78	6.05	0.31	3.78e-9	Cognitive performance;
LUSC	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg03128945	chr5:622914	CEP72	-0.47	-6.7	-0.34	8.81e-11	Obesity-related traits;
LUSC	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.17	-0.45	4.89e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs9359856	0.564	rs55722352	chr6:90365853	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.88	-8.96	-0.44	2.37e-17	Bipolar disorder;
LUSC	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg09835421	chr16:68378352	PRMT7	-0.44	-5.72	-0.3	2.4e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.83e-30	Motion sickness;
LUSC	cis	rs9296095	0.950	rs5745587	chr6:33545125	A/G	cg14003231	chr6:33640908	ITPR3	0.46	7.16	0.36	5.28e-12	Platelet count;
LUSC	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.96	21.5	0.76	5.45e-65	Longevity;
LUSC	cis	rs9948	0.786	rs56797569	chr2:97413555	G/T	cg01990225	chr2:97406019	LMAN2L	-0.78	-5.86	-0.31	1.1e-8	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg04310649	chr10:35416472	CREM	-0.42	-6.39	-0.33	5.6e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.54	0.6	1.33e-33	Cognitive test performance;
LUSC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg12615879	chr12:58013172	SLC26A10	-0.29	-6.1	-0.32	2.92e-9	Multiple sclerosis;
LUSC	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg11502198	chr6:26597334	ABT1	0.71	12.06	0.55	4.63e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg27266027	chr21:40555129	PSMG1	0.4	5.78	0.3	1.75e-8	Cognitive function;
LUSC	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	cis	rs2658782	0.724	rs2658770	chr11:93261886	A/G	cg15737290	chr11:93063684	CCDC67	0.61	7.33	0.37	1.7e-12	Pulmonary function decline;
LUSC	cis	rs2764208	0.860	rs205286	chr6:34551334	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.05	-0.31	3.85e-9	Systemic lupus erythematosus;
LUSC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	8.83	0.43	6.15e-17	Total body bone mineral density;
LUSC	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg02574844	chr11:5959923	NA	-0.43	-6.05	-0.31	3.8e-9	DNA methylation (variation);
LUSC	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg00579200	chr11:133705235	NA	-0.39	-5.72	-0.3	2.39e-8	Childhood ear infection;
LUSC	cis	rs7180079	0.563	rs7403103	chr15:65018526	C/T	cg08069370	chr15:64387884	SNX1	0.53	5.95	0.31	6.84e-9	Monocyte count;
LUSC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg10802521	chr3:52805072	NEK4	-0.46	-7.09	-0.36	7.8e-12	Electroencephalogram traits;
LUSC	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg00944433	chr1:107599041	PRMT6	0.39	7.15	0.36	5.48e-12	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg02951883	chr7:2050386	MAD1L1	-0.52	-9.06	-0.44	1.13e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.39e-22	Alzheimer's disease (late onset);
LUSC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg16928487	chr17:17741425	SREBF1	0.45	8.92	0.44	3.14e-17	Total body bone mineral density;
LUSC	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.79	-0.43	8.19e-17	Response to antipsychotic treatment;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03161075	chr14:51298083	NIN	-0.48	-7.06	-0.36	9.74e-12	Electrocardiographic conduction measures;
LUSC	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg27490568	chr2:178487706	NA	0.4	5.69	0.3	2.75e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg03563238	chr19:33554763	RHPN2	-0.4	-6.23	-0.32	1.43e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg07936489	chr17:37558343	FBXL20	-0.7	-9.54	-0.46	3.03e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs9831754	0.704	rs9836909	chr3:78451594	A/G	cg06138941	chr3:78371609	NA	-0.55	-7.12	-0.36	6.59e-12	Calcium levels;
LUSC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.59	-0.43	3.42e-16	Bipolar disorder;
LUSC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg11247378	chr22:39784982	NA	-0.63	-12.21	-0.56	1.34e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg23093090	chr10:104574429	C10orf26	-0.4	-6.7	-0.34	8.69e-11	Arsenic metabolism;
LUSC	cis	rs1957429	0.614	rs380741	chr14:65322027	C/T	cg23373153	chr14:65346875	NA	-0.81	-7.48	-0.38	6.66e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs3099143	1.000	rs3106375	chr15:77142243	T/C	cg21673338	chr15:77095150	SCAPER	-0.81	-7.52	-0.38	5.15e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-6.58	-0.34	1.79e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg09998033	chr7:158218633	PTPRN2	0.45	7.06	0.36	9.5e-12	Obesity-related traits;
LUSC	cis	rs6723108	0.591	rs13399952	chr2:135394404	A/G	cg12500956	chr2:135428796	TMEM163	-0.28	-6.59	-0.34	1.71e-10	Type 2 diabetes;
LUSC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg07777115	chr5:623756	CEP72	-0.45	-5.72	-0.3	2.35e-8	Obesity-related traits;
LUSC	cis	rs7719624	0.811	rs17689879	chr5:135393138	C/T	cg12897067	chr5:135418308	NA	-0.43	-6.31	-0.33	8.82e-10	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs9462027	0.583	rs2814995	chr6:34621171	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.09	-0.32	3.12e-9	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg11062466	chr8:58055876	NA	0.75	8.89	0.44	4e-17	Developmental language disorder (linguistic errors);
LUSC	trans	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg15556689	chr8:8085844	FLJ10661	0.49	7.27	0.37	2.64e-12	Triglycerides;
LUSC	cis	rs10097731	0.901	rs10464931	chr8:82042664	A/G	cg25230327	chr8:82042993	NA	0.45	6.65	0.34	1.21e-10	Serum total protein level;
LUSC	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.41	-0.42	1.23e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg05347473	chr6:146136440	FBXO30	0.56	9.55	0.46	2.83e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6545883	1.000	rs778762	chr2:61782921	G/T	cg15711740	chr2:61764176	XPO1	-0.5	-7.94	-0.4	3.14e-14	Tuberculosis;
LUSC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg04553112	chr3:125709451	NA	-0.5	-5.66	-0.3	3.27e-8	Blood pressure (smoking interaction);
LUSC	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg01884057	chr2:25150051	NA	0.39	8.54	0.42	4.78e-16	Body mass index in non-asthmatics;
LUSC	cis	rs7577851	0.625	rs66931274	chr2:69580970	C/T	cg10773587	chr2:69614142	GFPT1	0.56	6.2	0.32	1.64e-9	Parkinson's disease (age of onset);
LUSC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg03146154	chr1:46216737	IPP	0.56	8.23	0.41	4.12e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.12	-19.47	-0.73	6.08e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11857246	chr1:11741390	MAD2L2	-0.5	-6.12	-0.32	2.57e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg10018233	chr7:150070692	REPIN1	0.4	6.62	0.34	1.46e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg26408565	chr15:76604113	ETFA	-0.5	-8.05	-0.4	1.46e-14	Blood metabolite levels;
LUSC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg09904177	chr6:26538194	HMGN4	-0.39	-5.68	-0.3	2.93e-8	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg20587970	chr11:113659929	NA	1.25	13.53	0.6	1.41e-33	Hip circumference adjusted for BMI;
LUSC	trans	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs7615316	0.779	rs3816805	chr3:142076059	A/G	cg16271453	chr3:142027066	XRN1	-0.4	-6.99	-0.36	1.51e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06850241	chr22:41845214	NA	0.32	6.06	0.31	3.58e-9	Vitiligo;
LUSC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.72	-0.3	2.37e-8	Tonsillectomy;
LUSC	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.37	0.42	1.57e-15	Parkinson's disease;
LUSC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg26304593	chr6:42947056	PEX6	-0.54	-8.49	-0.42	6.8e-16	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs72949976	0.646	rs1441171	chr2:214033637	G/T	cg08319019	chr2:214017104	IKZF2	0.66	11.03	0.52	2.54e-24	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs7572644	0.782	rs10175826	chr2:28261384	G/A	cg27432699	chr2:27873401	GPN1	-0.53	-6.94	-0.36	2e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg14458575	chr2:238380390	NA	0.67	11.64	0.54	1.65e-26	Prostate cancer;
LUSC	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg22117172	chr7:91764530	CYP51A1	0.32	5.74	0.3	2.15e-8	Breast cancer;
LUSC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.85	-0.39	5.83e-14	Blood metabolite levels;
LUSC	cis	rs739496	0.947	rs1029388	chr12:111926901	A/G	cg10833066	chr12:111807467	FAM109A	0.33	6.15	0.32	2.17e-9	Platelet count;
LUSC	cis	rs7560272	0.669	rs13008860	chr2:73774019	G/A	cg20560298	chr2:73613845	ALMS1	-0.39	-5.94	-0.31	7.04e-9	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08280861	chr8:58055591	NA	0.54	6.3	0.33	9.15e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg18352616	chr4:3374830	RGS12	0.35	7.03	0.36	1.15e-11	Serum sulfate level;
LUSC	cis	rs921665	0.831	rs3887811	chr2:3182777	A/G	cg16434511	chr2:3151078	NA	-0.62	-6.74	-0.35	7.05e-11	World class endurance athleticism;
LUSC	cis	rs2067615	0.560	rs10467028	chr12:107076405	A/G	cg15890332	chr12:107067104	RFX4	0.34	6.2	0.32	1.69e-9	Heart rate;
LUSC	cis	rs3770081	1.000	rs56977454	chr2:86204014	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.08	-6.72	-0.35	7.64e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg13010199	chr12:38710504	ALG10B	-0.63	-10.7	-0.51	3.65e-23	Heart rate;
LUSC	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg24375607	chr4:120327624	NA	0.75	11.05	0.52	2.18e-24	Corneal astigmatism;
LUSC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg06238570	chr21:40685208	BRWD1	0.49	7.64	0.39	2.28e-13	Cognitive function;
LUSC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15664640	chr17:80829946	TBCD	0.63	11.19	0.52	6.99e-25	Breast cancer;
LUSC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg27165867	chr14:105738592	BRF1	-0.52	-7.6	-0.38	3.01e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	6.9	0.35	2.66e-11	Renal cell carcinoma;
LUSC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg16325326	chr1:53192061	ZYG11B	0.94	17.54	0.69	2.74e-49	Monocyte count;
LUSC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg00745463	chr17:30367425	LRRC37B	-0.79	-9.21	-0.45	3.67e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs963731	0.649	rs2278914	chr2:39218552	G/A	cg04010122	chr2:39346883	SOS1	-0.79	-5.73	-0.3	2.2e-8	Corticobasal degeneration;
LUSC	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.18	-0.32	1.84e-9	Type 2 diabetes;
LUSC	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.21	0.45	3.72e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs16937	0.662	rs10900456	chr1:205145005	C/T	cg00857998	chr1:205179979	DSTYK	0.47	6.55	0.34	2.13e-10	Schizophrenia;
LUSC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06544989	chr22:39130855	UNC84B	0.33	5.76	0.3	1.86e-8	Menopause (age at onset);
LUSC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg03060546	chr3:49711283	APEH	0.71	12.09	0.55	3.6e-28	Resting heart rate;
LUSC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg04369109	chr6:150039330	LATS1	-0.55	-8.09	-0.4	1.1e-14	Lung cancer;
LUSC	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg15423357	chr2:25149977	NA	0.35	6.43	0.33	4.46e-10	Body mass index;
LUSC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg16447950	chr5:562315	NA	-0.55	-7.1	-0.36	7.47e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2200578	1.000	rs72954221	chr2:99899445	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.61	7.16	0.36	5.11e-12	IgG glycosylation;
LUSC	cis	rs73206853	0.698	rs1018134	chr12:111121119	G/A	cg12870014	chr12:110450643	ANKRD13A	0.67	7.36	0.37	1.45e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4631830	0.896	rs7077830	chr10:51522276	C/G	cg20129853	chr10:51489980	NA	0.34	7.04	0.36	1.13e-11	Prostate-specific antigen levels;
LUSC	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg14036092	chr11:66035641	RAB1B	0.42	5.94	0.31	7.35e-9	Gout;
LUSC	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.93	15.74	0.65	3.8e-42	Bladder cancer;
LUSC	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg24011408	chr12:48396354	COL2A1	-0.53	-8.72	-0.43	1.33e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-6.89	-0.35	2.83e-11	Bipolar disorder;
LUSC	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg24631222	chr15:78858424	CHRNA5	0.67	9.23	0.45	3.08e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs921968	0.643	rs832806	chr2:219473914	A/T	cg02176678	chr2:219576539	TTLL4	0.6	10.54	0.5	1.34e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10493773	0.928	rs12751296	chr1:86176968	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.44	-9.35	-0.46	1.28e-18	Urate levels in overweight individuals;
LUSC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.34	-0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24531977	chr5:56204891	C5orf35	-0.83	-13.02	-0.58	1.22e-31	Coronary artery disease;
LUSC	cis	rs1712517	0.771	rs61871160	chr10:105144288	C/T	cg05636881	chr10:105038444	INA	0.4	6.67	0.34	1.09e-10	Migraine;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04314308	chr19:19336150	NCAN	-0.47	-6.32	-0.33	8.45e-10	Hepatitis;
LUSC	trans	rs62458065	0.568	rs62463963	chr7:32486691	C/T	cg00845942	chr12:64062724	DPY19L2	-0.56	-6.72	-0.35	7.64e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-0.99	-14.45	-0.62	4.26e-37	Initial pursuit acceleration;
LUSC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-1.09	-21.56	-0.76	3.12e-65	Height;
LUSC	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21659725	chr3:3221576	CRBN	0.61	8.63	0.43	2.6e-16	Resting heart rate;
LUSC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg01802117	chr1:53393560	SCP2	-0.39	-6.45	-0.33	3.94e-10	Monocyte count;
LUSC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg22920501	chr2:26401640	FAM59B	-0.78	-10.99	-0.52	3.46e-24	Gut microbiome composition (summer);
LUSC	trans	rs1998174	0.509	rs10753205	chr1:171839958	G/A	cg13482142	chr2:234261155	NA	0.42	6.11	0.32	2.81e-9	Platelet distribution width;
LUSC	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.47	-0.42	8.07e-16	Total cholesterol levels;
LUSC	cis	rs977987	0.843	rs11149820	chr16:75422760	G/A	cg03315344	chr16:75512273	CHST6	0.53	10.35	0.49	6.07e-22	Dupuytren's disease;
LUSC	cis	rs9814567	0.731	rs34797591	chr3:134192516	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	10.27	0.49	1.14e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg04586622	chr2:25135609	ADCY3	0.38	8.09	0.4	1.08e-14	Body mass index;
LUSC	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg05805236	chr11:65401703	PCNXL3	0.43	7.11	0.36	7.12e-12	Acne (severe);
LUSC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-1.24	-13.61	-0.6	7.43e-34	Diabetic kidney disease;
LUSC	cis	rs9902453	0.967	rs4429345	chr17:28458105	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-8.21	-0.41	5e-15	Coffee consumption (cups per day);
LUSC	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg03522245	chr20:25566470	NINL	-0.35	-5.68	-0.3	2.97e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	7.89	0.4	4.47e-14	Retinal vascular caliber;
LUSC	cis	rs751728	0.664	rs943478	chr6:33750940	T/A	cg25922239	chr6:33757077	LEMD2	0.42	6.29	0.33	9.76e-10	Crohn's disease;
LUSC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg05861140	chr6:150128134	PCMT1	-0.39	-6.1	-0.32	2.87e-9	Lung cancer;
LUSC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	12.46	0.56	1.59e-29	Total body bone mineral density;
LUSC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.25	0.41	3.79e-15	Melanoma;
LUSC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	18.98	0.72	5.41e-55	Chronic sinus infection;
LUSC	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17916960	chr15:79447300	NA	-0.53	-10.57	-0.5	1.05e-22	Refractive error;
LUSC	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg07810366	chr2:100720526	AFF3	0.5	8.74	0.43	1.12e-16	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg13319975	chr6:146136371	FBXO30	-0.53	-8.07	-0.4	1.27e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg20307385	chr11:47447363	PSMC3	-0.48	-6.26	-0.32	1.21e-9	Subjective well-being;
LUSC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg26668828	chr6:292823	DUSP22	-0.52	-7.78	-0.39	9.08e-14	Menopause (age at onset);
LUSC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-6.11	-0.32	2.82e-9	IgG glycosylation;
LUSC	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg05731713	chr7:157510257	PTPRN2	0.49	9.39	0.46	9.76e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.85	-0.3	1.17e-8	Bipolar disorder;
LUSC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	6.97	0.36	1.69e-11	Tonsillectomy;
LUSC	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	0.98	11.97	0.55	1.05e-27	Nonalcoholic fatty liver disease;
LUSC	cis	rs6599077	1.000	rs6808392	chr3:40096750	T/C	cg13683864	chr3:40499215	RPL14	-0.6	-7.64	-0.39	2.38e-13	Sleep-related phenotypes;
LUSC	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-10.08	-0.48	4.89e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.4	5.75	0.3	2.04e-8	Lung cancer;
LUSC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg11645453	chr3:52864694	ITIH4	0.36	8.32	0.41	2.33e-15	Bipolar disorder;
LUSC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.5	-8.28	-0.41	3.09e-15	IgG glycosylation;
LUSC	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	0.6	9.41	0.46	8.58e-19	Breast cancer;
LUSC	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	0.94	17.57	0.69	2.21e-49	Headache;
LUSC	cis	rs7202877	0.706	rs467780	chr16:75437138	A/G	cg04384234	chr16:75411784	CFDP1	0.66	9.06	0.44	1.14e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs10779751	0.770	rs7553827	chr1:11222393	C/T	cg08854313	chr1:11322531	MTOR	0.84	12.74	0.57	1.49e-30	Body mass index;
LUSC	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg01966878	chr4:90757139	SNCA	-0.43	-6.22	-0.32	1.49e-9	Neuroticism;
LUSC	trans	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg14791747	chr16:20752902	THUMPD1	-0.42	-6.42	-0.33	4.76e-10	Dental caries;
LUSC	cis	rs11785693	0.909	rs62489556	chr8:4968149	G/A	cg26367366	chr8:4980734	NA	0.84	8.69	0.43	1.6e-16	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs1950626	0.662	rs72700538	chr14:101441911	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.77	0.39	9.82e-14	Pelvic organ prolapse (moderate/severe);
LUSC	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	1.13	18.46	0.71	6.01e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9399401	0.925	rs1040526	chr6:142735816	A/G	cg03128060	chr6:142623767	GPR126	0.34	6.28	0.32	1.06e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg26566898	chr11:117069891	TAGLN	0.37	7.26	0.37	2.81e-12	Blood protein levels;
LUSC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg20476274	chr7:133979776	SLC35B4	0.87	16.89	0.68	1.02e-46	Mean platelet volume;
LUSC	trans	rs4714291	0.802	rs7759622	chr6:40114735	C/T	cg02267698	chr19:7991119	CTXN1	-0.55	-8.12	-0.41	9.13e-15	Strep throat;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.42	-6.89	-0.35	2.81e-11	Longevity;Endometriosis;
LUSC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.94	0.36	2.01e-11	Tonsillectomy;
LUSC	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg00495681	chr13:53174319	NA	0.79	15.17	0.64	6.69e-40	Lewy body disease;
LUSC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg14092988	chr3:52407081	DNAH1	-0.33	-6.46	-0.33	3.64e-10	Bipolar disorder;
LUSC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg24324837	chr19:49891574	CCDC155	0.49	6.25	0.32	1.23e-9	Multiple sclerosis;
LUSC	cis	rs2425143	1.000	rs11696527	chr20:34245379	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.21	-0.32	1.58e-9	Blood protein levels;
LUSC	cis	rs6563842	0.563	rs4575411	chr13:41277794	C/G	cg21288729	chr13:41239152	FOXO1	0.54	8.31	0.41	2.35e-15	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUSC	cis	rs73198271	0.694	rs115037021	chr8:8647080	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.32	-0.33	8.29e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7542375	0.507	rs2784270	chr1:221094967	C/T	cg16008148	chr1:221062819	NA	-0.42	-8.31	-0.41	2.49e-15	Obesity-related traits;
LUSC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.95	-17.65	-0.69	9.86e-50	Chronic sinus infection;
LUSC	trans	rs1486139	1.000	rs1385932	chr7:46268354	C/T	cg17534202	chr9:96721102	NA	-0.35	-6.11	-0.32	2.85e-9	Select biomarker traits;
LUSC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26314531	chr2:26401878	FAM59B	-0.73	-10.21	-0.49	1.79e-21	Gut microbiome composition (summer);
LUSC	trans	rs12987465	0.545	rs116021360	chr2:49708739	G/T	cg16509045	chr9:77502963	TRPM6	-0.3	-5.97	-0.31	6.06e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide);
LUSC	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg00484396	chr16:3507460	NAT15	-0.42	-6.85	-0.35	3.54e-11	Body mass index (adult);
LUSC	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg27147174	chr7:100797783	AP1S1	-0.65	-10.45	-0.5	2.58e-22	Life satisfaction;
LUSC	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg11161011	chr14:65562177	MAX	-0.81	-12.23	-0.56	1.1e-28	Obesity-related traits;
LUSC	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.69	-0.39	1.67e-13	Retinal vascular caliber;
LUSC	cis	rs478607	0.764	rs2666558	chr11:64481579	G/A	cg19131476	chr11:64387923	NRXN2	-0.31	-5.67	-0.3	3.05e-8	Urate levels;
LUSC	cis	rs3820928	1.000	rs6752707	chr2:227766822	C/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.73	-0.39	1.32e-13	Pulmonary function;
LUSC	trans	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.1	-0.32	2.97e-9	Depression;
LUSC	cis	rs12594515	1.000	rs11854554	chr15:45994546	C/G	cg19682013	chr15:45996608	NA	0.39	5.8	0.3	1.52e-8	Waist circumference;Weight;
LUSC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg24579218	chr15:68104479	NA	-0.39	-6.78	-0.35	5.39e-11	Restless legs syndrome;
LUSC	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23598886	chr18:12777645	NA	0.65	6.6	0.34	1.61e-10	Inflammatory skin disease;
LUSC	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg23649088	chr2:200775458	C2orf69	-0.58	-7.11	-0.36	7.05e-12	Schizophrenia;
LUSC	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg07148914	chr20:33460835	GGT7	0.46	6.9	0.35	2.59e-11	Height;
LUSC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	7.86	0.4	5.41e-14	Mean platelet volume;
LUSC	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg04733989	chr22:42467013	NAGA	0.4	6.41	0.33	4.89e-10	Cognitive function;
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg09033563	chr22:24373618	LOC391322	0.46	6.33	0.33	7.8e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs6600671	1.000	rs1832558	chr1:121177380	A/G	cg00646200	chr1:148855367	NA	0.47	7.52	0.38	5.11e-13	Hip geometry;
LUSC	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg13072238	chr3:49761600	GMPPB	0.41	6.73	0.35	7.48e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg05347473	chr6:146136440	FBXO30	0.47	7.68	0.39	1.75e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.19e-33	Morning vs. evening chronotype;
LUSC	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg11130432	chr3:121712080	ILDR1	-0.65	-9.77	-0.47	5.4e-20	Multiple sclerosis;
LUSC	cis	rs78572108	0.858	rs72613887	chr2:42267914	G/A	cg00607755	chr2:42274082	PKDCC	0.34	5.83	0.3	1.28e-8	Total body bone mineral density;
LUSC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg08847533	chr14:75593920	NEK9	-0.79	-13.67	-0.6	4.42e-34	Height;
LUSC	trans	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg03886242	chr7:26192032	NFE2L3	-0.39	-5.97	-0.31	6.05e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg00677455	chr12:58241039	CTDSP2	0.54	6.91	0.35	2.4e-11	Multiple sclerosis;
LUSC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg18350739	chr11:68623251	NA	-0.36	-6.33	-0.33	7.68e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11645453	chr3:52864694	ITIH4	-0.49	-10.4	-0.49	3.89e-22	Schizophrenia;
LUSC	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	9.13	0.45	6.77e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs6982636	1.000	rs2980871	chr8:126488930	A/G	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.34	-6.3	-0.33	9.35e-10	Lipid metabolism phenotypes;
LUSC	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg10253484	chr15:75165896	SCAMP2	0.41	5.8	0.3	1.52e-8	Systemic lupus erythematosus;
LUSC	trans	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.62	-0.34	1.46e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg24375607	chr4:120327624	NA	0.76	11.11	0.52	1.29e-24	Corneal astigmatism;
LUSC	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg18806716	chr10:30721971	MAP3K8	-0.7	-10.7	-0.51	3.51e-23	Inflammatory bowel disease;
LUSC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03352830	chr11:487213	PTDSS2	0.7	8.83	0.44	5.97e-17	Body mass index;
LUSC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg26513180	chr16:89883248	FANCA	0.78	6.39	0.33	5.68e-10	Skin colour saturation;
LUSC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.54	-7.74	-0.39	1.17e-13	Tuberculosis;
LUSC	cis	rs80130819	0.748	rs2634679	chr12:48735304	G/T	cg24011408	chr12:48396354	COL2A1	0.44	5.66	0.3	3.31e-8	Prostate cancer;
LUSC	cis	rs2932538	0.922	rs6659677	chr1:113087076	G/C	cg22162597	chr1:113214053	CAPZA1	0.7	9.98	0.48	1.03e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.34	-0.37	1.67e-12	Subjective well-being;
LUSC	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg26446133	chr18:72167187	CNDP2	-0.79	-10.96	-0.51	4.33e-24	Refractive error;
LUSC	cis	rs244293	0.760	rs12952166	chr17:53005586	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.84	-0.3	1.27e-8	Menarche (age at onset);
LUSC	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	12.73	0.57	1.55e-30	Total body bone mineral density;
LUSC	cis	rs9650315	0.866	rs11990562	chr8:57198214	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	-0.56	-6.77	-0.35	5.65e-11	Height;
LUSC	cis	rs62400317	0.859	rs62438863	chr6:45040592	C/T	cg18551225	chr6:44695536	NA	-0.42	-6.74	-0.35	7.02e-11	Total body bone mineral density;
LUSC	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg03929089	chr4:120376271	NA	-0.84	-11.49	-0.53	5.46e-26	Coronary artery disease;
LUSC	cis	rs2798269	1.000	rs1200046	chr13:22131160	C/A	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.13	-0.32	2.42e-9	PR segment;
LUSC	cis	rs10193935	0.901	rs10189710	chr2:42573102	C/G	cg27598129	chr2:42591480	NA	-0.6	-8.24	-0.41	3.96e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3126085	1.000	rs2338556	chr1:152309427	T/A	cg26876637	chr1:152193138	HRNR	-0.44	-5.67	-0.3	3.13e-8	Atopic dermatitis;
LUSC	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg03342759	chr3:160939853	NMD3	-0.51	-8.7	-0.43	1.59e-16	Morning vs. evening chronotype;
LUSC	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg27432699	chr2:27873401	GPN1	-0.57	-8.57	-0.42	3.87e-16	Total body bone mineral density;
LUSC	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12826209	chr6:26865740	GUSBL1	0.65	8.63	0.43	2.55e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.9	12.86	0.58	4.98e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.63	-10.68	-0.5	4.07e-23	Blood metabolite levels;
LUSC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg20587970	chr11:113659929	NA	1.06	13.37	0.59	6.16e-33	Hip circumference adjusted for BMI;
LUSC	cis	rs727505	1.000	rs113394869	chr7:124518172	G/C	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs9309473	0.583	rs6718864	chr2:73574591	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-7.29	-0.37	2.26e-12	Metabolite levels;
LUSC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.53	0.38	4.8e-13	Bipolar disorder;
LUSC	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs7119167	0.686	rs7933162	chr11:73044213	A/C	cg17517138	chr11:73019481	ARHGEF17	0.49	5.71	0.3	2.49e-8	Blood protein levels;
LUSC	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg13010199	chr12:38710504	ALG10B	0.65	9.9	0.48	1.96e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg17554472	chr22:41940697	POLR3H	0.47	5.72	0.3	2.42e-8	Vitiligo;
LUSC	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg10578777	chr12:7781093	NA	0.54	5.71	0.3	2.48e-8	HDL cholesterol levels;
LUSC	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg16447950	chr5:562315	NA	-0.59	-7.08	-0.36	8.54e-12	Lung disease severity in cystic fibrosis;
LUSC	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg15556689	chr8:8085844	FLJ10661	0.63	9.08	0.44	9.73e-18	Neuroticism;
LUSC	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg19824325	chr16:58548873	SETD6	0.94	9.13	0.45	6.5e-18	Schizophrenia;
LUSC	cis	rs11785693	0.862	rs17435605	chr8:4987302	A/G	cg26367366	chr8:4980734	NA	0.76	9.07	0.44	1e-17	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg15790184	chr11:494944	RNH1	0.42	6.4	0.33	5.37e-10	Systemic lupus erythematosus;
LUSC	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-9.66	-0.47	1.24e-19	Platelet distribution width;
LUSC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg06008330	chr7:65541103	ASL	-0.41	-6.3	-0.33	9.65e-10	Aortic root size;
LUSC	cis	rs16976116	0.901	rs28564077	chr15:55495151	G/A	cg11288833	chr15:55489084	RSL24D1	0.49	5.8	0.3	1.53e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg20243544	chr17:37824526	PNMT	0.39	5.96	0.31	6.31e-9	Self-reported allergy;
LUSC	cis	rs10203711	1.000	rs907102	chr2:239564503	G/A	cg14580085	chr2:239553406	NA	0.41	6.96	0.36	1.76e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2806561	0.780	rs12751560	chr1:23407081	C/A	cg19743168	chr1:23544995	NA	-0.44	-9.06	-0.44	1.15e-17	Height;
LUSC	trans	rs1922233	1.000	rs1997497	chr4:92365182	C/T	cg24250684	chr1:219729030	NA	-0.33	-6.54	-0.34	2.26e-10	Gut microbiome composition (summer and winter);
LUSC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	11.08	0.52	1.69e-24	Prudent dietary pattern;
LUSC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.58	-7.85	-0.39	5.82e-14	Renal function-related traits (BUN);
LUSC	cis	rs2734839	1.000	rs2734839	chr11:113286490	C/T	cg14159747	chr11:113255604	NA	0.26	6.56	0.34	2.1e-10	Information processing speed;
LUSC	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.88	0.31	9.93e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg01819759	chr13:79234251	RNF219	0.6	8.09	0.4	1.14e-14	Large artery stroke;
LUSC	cis	rs977987	0.771	rs12929673	chr16:75470295	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.11	-0.36	7.07e-12	Dupuytren's disease;
LUSC	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-6.08	-0.32	3.3e-9	Menarche (age at onset);
LUSC	cis	rs7011049	1.000	rs7011049	chr8:53834012	C/A	cg26025543	chr8:53854495	NA	0.51	6.3	0.33	9.53e-10	Systolic blood pressure;
LUSC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.59	9.68	0.47	1.06e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs1784581	0.588	rs6455789	chr6:162417948	C/T	cg17173639	chr6:162384350	PARK2	0.57	9.98	0.48	1.09e-20	Itch intensity from mosquito bite;
LUSC	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12016809	chr21:47604291	C21orf56	-0.43	-6.54	-0.34	2.27e-10	Testicular germ cell tumor;
LUSC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg03036452	chr22:46663545	TTC38	0.53	5.76	0.3	1.89e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs727505	0.789	rs4731233	chr7:124736291	C/T	cg23710748	chr7:124431027	NA	-0.4	-7.04	-0.36	1.08e-11	Lewy body disease;
LUSC	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg06784218	chr1:46089804	CCDC17	0.32	6.02	0.31	4.55e-9	Platelet count;
LUSC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.22	0.41	4.51e-15	Prudent dietary pattern;
LUSC	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.46	0.53	7.16e-26	Eye color traits;
LUSC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-0.73	-12.32	-0.56	5.16e-29	Height;
LUSC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg00750074	chr16:89608354	SPG7	-0.47	-8.18	-0.41	6.05e-15	Multiple myeloma (IgH translocation);
LUSC	cis	rs7246967	0.673	rs4932784	chr19:22874251	A/C	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.86	-0.35	3.4e-11	Monocyte percentage of white cells;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg17520314	chr17:79604207	NPLOC4	-0.48	-7.03	-0.36	1.18e-11	Cognitive function;Information processing speed;
LUSC	trans	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg21775007	chr8:11205619	TDH	-0.45	-6.36	-0.33	6.81e-10	Joint mobility (Beighton score);
LUSC	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.82	-0.91	6.98e-129	Myeloid white cell count;
LUSC	cis	rs7572644	0.679	rs4419196	chr2:28075298	A/G	cg27432699	chr2:27873401	GPN1	0.52	6.95	0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7582720	0.943	rs72926798	chr2:203827675	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg13395646	chr4:1353034	KIAA1530	-0.54	-8.58	-0.42	3.74e-16	Obesity-related traits;
LUSC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.44	-7.05	-0.36	1.05e-11	Tonsillectomy;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg07934232	chr19:36619082	NA	0.41	6.41	0.33	4.97e-10	Schizophrenia (age at onset);
LUSC	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.62	10.4	0.49	3.99e-22	Blood metabolite ratios;
LUSC	cis	rs7605827	0.930	rs2287264	chr2:15637592	C/G	cg19274914	chr2:15703543	NA	0.46	8.84	0.44	5.74e-17	Educational attainment (years of education);
LUSC	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-10.4	-0.49	3.86e-22	Migraine;Coronary artery disease;
LUSC	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg08422745	chr4:174089978	GALNT7	-0.73	-11.76	-0.54	5.78e-27	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg00757033	chr12:89920650	WDR51B	0.59	10.45	0.5	2.65e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs7980799	0.649	rs11052732	chr12:33657801	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.17	-0.32	1.99e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04565464	chr8:145669602	NFKBIL2	0.38	6.35	0.33	7.15e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.08	0.4	1.24e-14	Coffee consumption (cups per day);
LUSC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg05347473	chr6:146136440	FBXO30	0.46	7.99	0.4	2.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg23992470	chr4:843637	GAK	0.6	6.45	0.33	3.98e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs7094131	0.542	rs7071306	chr10:22867339	A/G	cg00377074	chr6:134159127	MGC34034	0.4	6.29	0.33	1e-9	Obesity-related traits;
LUSC	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg08085267	chr17:45401833	C17orf57	-0.46	-6.58	-0.34	1.82e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1577917	0.883	rs12214536	chr6:86790310	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.18e-11	Response to antipsychotic treatment;
LUSC	cis	rs7712401	0.642	rs17388251	chr5:122360403	C/T	cg19077854	chr5:122220652	SNX24	0.34	7.51	0.38	5.47e-13	Mean platelet volume;
LUSC	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg03806693	chr22:41940476	POLR3H	0.91	13.27	0.59	1.41e-32	Vitiligo;
LUSC	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg18357645	chr12:58087776	OS9	0.49	7.3	0.37	2.17e-12	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.19	-0.49	2.05e-21	Hemoglobin concentration;
LUSC	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.55	0.38	4.06e-13	Iron status biomarkers;
LUSC	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg26695010	chr11:65641043	EFEMP2	0.44	6.42	0.33	4.77e-10	Eosinophil percentage of white cells;
LUSC	trans	rs7939886	0.920	rs11231821	chr11:55777052	C/G	cg03929089	chr4:120376271	NA	0.79	6.79	0.35	5.1e-11	Myopia (pathological);
LUSC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg08886695	chr4:3369023	RGS12	-0.37	-6.08	-0.32	3.37e-9	Parental longevity (mother's age at death);
LUSC	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	7.79	0.39	8.39e-14	Eosinophil percentage of white cells;
LUSC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13012494	chr21:47604986	C21orf56	-0.51	-7.81	-0.39	7.43e-14	Testicular germ cell tumor;
LUSC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18404041	chr3:52824283	ITIH1	-0.56	-10.63	-0.5	6.41e-23	Bipolar disorder;
LUSC	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg23887609	chr12:130822674	PIWIL1	-0.48	-7.11	-0.36	6.92e-12	Menopause (age at onset);
LUSC	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg01966878	chr4:90757139	SNCA	-0.34	-5.85	-0.31	1.15e-8	Dementia with Lewy bodies;
LUSC	cis	rs59698941	0.943	rs67860107	chr5:132276825	G/C	cg02081065	chr5:132209139	LEAP2	-0.64	-6.66	-0.34	1.1e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.65	10.99	0.52	3.31e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg24375607	chr4:120327624	NA	0.79	11.44	0.53	8.43e-26	Corneal astigmatism;
LUSC	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	1.08	24.0	0.8	1.12e-74	Schizophrenia;
LUSC	cis	rs941898	0.836	rs7158754	chr14:100583349	A/G	cg26002632	chr14:100625216	DEGS2	-0.31	-5.69	-0.3	2.71e-8	White matter hyperintensity burden;
LUSC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.71	-6.79	-0.35	5.16e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg08601574	chr20:25228251	PYGB	-0.43	-6.66	-0.34	1.14e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.04	23.43	0.79	1.79e-72	Schizophrenia;
LUSC	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg21433313	chr16:3507492	NAT15	0.79	9.77	0.47	5.34e-20	Tuberculosis;
LUSC	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg20129853	chr10:51489980	NA	-0.34	-6.98	-0.36	1.58e-11	Prostate-specific antigen levels;
LUSC	cis	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg06521331	chr12:34319734	NA	-0.43	-7.07	-0.36	9.25e-12	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25634484	chr8:8559074	CLDN23	0.48	7.93	0.4	3.25e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs1864729	1.000	rs2853320	chr8:98283523	C/G	cg08679828	chr8:102218111	ZNF706	-0.85	-7.71	-0.39	1.45e-13	Estradiol plasma levels (breast cancer);
LUSC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg05082376	chr22:42548792	NA	0.43	6.89	0.35	2.85e-11	Schizophrenia;
LUSC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg18904891	chr8:8559673	CLDN23	0.58	8.07	0.4	1.25e-14	Obesity-related traits;
LUSC	cis	rs6733011	0.578	rs12712039	chr2:99497980	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-5.74	-0.3	2.17e-8	Bipolar disorder;
LUSC	trans	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg10756647	chr7:56101905	PSPH	0.85	8.45	0.42	8.99e-16	Gout;
LUSC	cis	rs1847202	1.000	rs6807627	chr3:72939767	C/T	cg25664220	chr3:72788482	NA	-0.35	-6.58	-0.34	1.8e-10	Motion sickness;
LUSC	trans	rs3960554	0.599	rs56090527	chr7:75762125	A/C	cg19862616	chr7:65841803	NCRNA00174	0.9	10.2	0.49	1.89e-21	Eotaxin levels;
LUSC	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.01e-12	Asthma;
LUSC	cis	rs909002	0.849	rs4949449	chr1:32088534	T/G	cg01639898	chr1:32083012	HCRTR1	0.28	6.41	0.33	5.05e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	9.86	0.47	2.6e-20	Lymphocyte counts;
LUSC	cis	rs1113500	0.787	rs10881502	chr1:108641819	C/T	cg06207961	chr1:108661230	NA	-0.31	-5.83	-0.3	1.32e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs73198271	0.601	rs11997731	chr8:8649848	C/T	cg01851573	chr8:8652454	MFHAS1	0.53	8.51	0.42	5.95e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg11693508	chr17:37793320	STARD3	0.66	8.19	0.41	5.46e-15	Bipolar disorder;
LUSC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07677032	chr17:61819896	STRADA	0.55	8.93	0.44	2.91e-17	Prudent dietary pattern;
LUSC	cis	rs4842666	0.765	rs4842675	chr12:90075243	C/T	cg00757033	chr12:89920650	WDR51B	0.49	7.05	0.36	1.02e-11	Blood pressure;
LUSC	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-7.27	-0.37	2.6e-12	Schizophrenia;
LUSC	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.79	0.35	5.23e-11	IgG glycosylation;
LUSC	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.73	11.86	0.54	2.66e-27	Monocyte count;
LUSC	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-8.17	-0.41	6.62e-15	Bladder cancer;
LUSC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg19920283	chr7:105172520	RINT1	0.61	6.62	0.34	1.42e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg04990556	chr1:26633338	UBXN11	-0.48	-6.12	-0.32	2.64e-9	Monocyte percentage of white cells;
LUSC	cis	rs9811920	0.809	rs793437	chr3:99559854	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-6.01	-0.31	4.77e-9	Axial length;
LUSC	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg10911889	chr6:126070802	HEY2	-0.38	-5.87	-0.31	1.04e-8	Brugada syndrome;
LUSC	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.8	-0.3	1.55e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	17.4	0.69	1.03e-48	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6120849	0.754	rs3746436	chr20:33586193	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	6.91	0.35	2.47e-11	Protein C levels;
LUSC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.28	0.56	7.44e-29	Motion sickness;
LUSC	cis	rs4363385	0.818	rs451939	chr1:153006877	C/T	cg00922841	chr1:152955080	SPRR1A	-0.4	-7.07	-0.36	9.08e-12	Inflammatory skin disease;
LUSC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-11.72	-0.54	8.13e-27	Longevity;Endometriosis;
LUSC	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	11.78	0.54	4.88e-27	Coronary artery disease;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg09184467	chr10:14995699	DCLRE1C	-0.48	-6.31	-0.33	8.62e-10	Height;
LUSC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-0.99	-14.45	-0.62	4.26e-37	Initial pursuit acceleration;
LUSC	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg24692254	chr21:30365293	RNF160	-0.73	-11.19	-0.52	6.62e-25	Pancreatic cancer;
LUSC	cis	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.26	-0.37	2.82e-12	Morning vs. evening chronotype;
LUSC	cis	rs9905704	0.681	rs887206	chr17:56575084	G/C	cg12560992	chr17:57184187	TRIM37	-0.5	-5.84	-0.3	1.21e-8	Testicular germ cell tumor;
LUSC	cis	rs16937	0.518	rs1172149	chr1:205224758	A/G	cg21643547	chr1:205240462	TMCC2	-0.37	-6.72	-0.34	8.05e-11	Schizophrenia;
LUSC	cis	rs7246967	0.673	rs2361021	chr19:22816324	T/G	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg11752832	chr7:134001865	SLC35B4	0.4	6.07	0.32	3.45e-9	Mean platelet volume;
LUSC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg20887711	chr4:1340912	KIAA1530	0.44	6.62	0.34	1.46e-10	Obesity-related traits;
LUSC	cis	rs3125734	0.633	rs1368157	chr10:64001114	T/C	cg19640130	chr10:64028056	RTKN2	-0.39	-7.02	-0.36	1.22e-11	Rheumatoid arthritis;
LUSC	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.36	0.37	1.42e-12	Morning vs. evening chronotype;
LUSC	cis	rs2573652	0.674	rs11630619	chr15:100543367	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.36	-6.32	-0.33	8.59e-10	Height;
LUSC	cis	rs7508	0.511	rs2237853	chr8:17877880	G/A	cg01800426	chr8:17659068	MTUS1	-0.57	-6.98	-0.36	1.61e-11	Atrial fibrillation;
LUSC	cis	rs73206853	0.563	rs56386451	chr12:111174516	A/G	cg12870014	chr12:110450643	ANKRD13A	0.69	6.67	0.34	1.08e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg10729496	chr3:10149963	C3orf24	0.55	7.42	0.38	9.54e-13	Alzheimer's disease;
LUSC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg05729581	chr11:3078854	CARS	-0.57	-8.85	-0.44	5.31e-17	Longevity;
LUSC	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	trans	rs9755467	0.665	rs57706556	chr3:127181579	T/A	cg22395942	chr19:2354559	SPPL2B	0.43	6.38	0.33	5.77e-10	Educational attainment (years of education);
LUSC	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg22532475	chr10:104410764	TRIM8	-0.26	-6.06	-0.31	3.67e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	8.87	0.44	4.63e-17	Exhaled nitric oxide output;
LUSC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.82	-0.3	1.42e-8	Depression;
LUSC	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.82	12.34	0.56	4.47e-29	Eosinophil percentage of white cells;
LUSC	trans	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.62	0.47	1.76e-19	Mean corpuscular volume;
LUSC	trans	rs6561151	0.681	rs17065161	chr13:44443723	A/T	cg12856521	chr11:46389249	DGKZ	0.73	9.82	0.47	3.73e-20	Crohn's disease;
LUSC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg12564285	chr5:131593104	PDLIM4	0.53	9.68	0.47	1.08e-19	Acylcarnitine levels;
LUSC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg22709100	chr7:91322751	NA	0.4	5.79	0.3	1.62e-8	Breast cancer;
LUSC	cis	rs6500395	1.000	rs12599744	chr16:48716729	G/A	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg24733560	chr20:60626293	TAF4	0.4	6.4	0.33	5.12e-10	Body mass index;
LUSC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.99	0.4	2.24e-14	Bipolar disorder;
LUSC	trans	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg06606381	chr12:133084897	FBRSL1	-1.08	-9.48	-0.46	5e-19	Depression;
LUSC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg06915202	chr7:98029285	BAIAP2L1	0.32	6.39	0.33	5.7e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg26597838	chr10:835615	NA	0.79	9.74	0.47	6.95e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg16576597	chr16:28551801	NUPR1	0.29	5.82	0.3	1.36e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg15934090	chr1:100435551	SLC35A3	0.49	8.32	0.41	2.32e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs113835537	0.529	rs3179961	chr11:66244454	A/G	cg24851651	chr11:66362959	CCS	0.53	8.15	0.41	7.43e-15	Airway imaging phenotypes;
LUSC	cis	rs12210905	0.925	rs12214640	chr6:26762080	G/A	cg11502198	chr6:26597334	ABT1	-0.74	-5.7	-0.3	2.59e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs9311676	0.656	rs62258127	chr3:58397102	G/A	cg26110898	chr3:58419937	PDHB	0.4	6.48	0.33	3.27e-10	Systemic lupus erythematosus;
LUSC	cis	rs701145	0.529	rs355759	chr3:154008078	G/C	cg17054900	chr3:154042577	DHX36	0.44	5.75	0.3	2.01e-8	Coronary artery disease;
LUSC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12667521	chr19:29218732	NA	0.59	9.0	0.44	1.77e-17	Methadone dose in opioid dependence;
LUSC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-9.45	-0.46	6.2800000000000005e-19	Gut microbiome composition (summer);
LUSC	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.62	-0.34	1.47e-10	Retinal vascular caliber;
LUSC	cis	rs12627970	0.565	rs2072872	chr22:39713128	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.82	15.16	0.64	7.52e-40	Inflammatory bowel disease;
LUSC	cis	rs2677744	1.000	rs1266489	chr15:91458485	G/A	cg00526711	chr15:91477898	UNC45A	0.31	6.18	0.32	1.87e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg05294307	chr14:35346193	BAZ1A	-0.57	-7.0	-0.36	1.39e-11	Psoriasis;
LUSC	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg11887960	chr12:57824829	NA	0.54	6.8	0.35	4.89e-11	Obesity-related traits;
LUSC	trans	rs2262909	1.000	rs2359821	chr19:22208314	C/T	cg05197062	chr11:11642011	GALNTL4	-0.51	-7.08	-0.36	8.34e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.66	9.7	0.47	9.19e-20	Menarche (age at onset);
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg15242686	chr22:24348715	GSTTP1	0.42	6.23	0.32	1.44e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs8040855	0.894	rs4843023	chr15:85705872	A/C	cg00988175	chr11:59481031	OR10V1	-0.3	-6.38	-0.33	5.96e-10	Bulimia nervosa;
LUSC	cis	rs4629180	0.651	rs9653468	chr2:102108403	A/G	cg01388757	chr2:102091195	RFX8	-0.34	-5.9	-0.31	8.84e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg08219700	chr8:58056026	NA	0.5	6.59	0.34	1.67e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.7	-6.62	-0.34	1.41e-10	Lung cancer in ever smokers;
LUSC	cis	rs13082711	0.911	rs2172298	chr3:27425611	T/C	cg02860705	chr3:27208620	NA	0.48	7.99	0.4	2.27e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg03161606	chr19:29218774	NA	0.56	6.85	0.35	3.64e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.54	-0.38	4.58e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.45	-8.34	-0.42	1.94e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	8.37	0.42	1.58e-15	Total body bone mineral density;
LUSC	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg16520312	chr17:43971471	MAPT;LOC100128977	0.38	6.51	0.34	2.7e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg00945038	chr17:61921165	SMARCD2	0.4	5.81	0.3	1.49e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg08807101	chr21:30365312	RNF160	-0.5	-7.39	-0.37	1.21e-12	Dental caries;
LUSC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg00383909	chr3:49044727	WDR6	0.42	5.71	0.3	2.51e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-0.8	-12.96	-0.58	2.11e-31	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.71	12.54	0.57	7.86e-30	Superior crus of antihelix expression;
LUSC	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg03806693	chr22:41940476	POLR3H	-0.72	-10.68	-0.5	4.22e-23	Vitiligo;
LUSC	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg18850127	chr7:39170497	POU6F2	0.68	11.0	0.52	3.13e-24	IgG glycosylation;
LUSC	cis	rs2901656	0.502	rs9425602	chr1:172383686	T/A	cg03748243	chr1:172413542	C1orf105;PIGC	-0.3	-5.79	-0.3	1.66e-8	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg09092052	chr15:45571596	NA	0.5	7.0	0.36	1.44e-11	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg11984989	chr7:158649758	WDR60	-1.01	-17.18	-0.68	7.65e-48	Height;
LUSC	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.92	-0.31	8.1e-9	Breast cancer;
LUSC	cis	rs9400467	0.508	rs12211763	chr6:111787156	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.32	-0.33	8.41e-10	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs12541635	0.639	rs6469030	chr8:107030321	C/T	cg10147462	chr8:107024639	NA	0.66	13.79	0.6	1.53e-34	Age of smoking initiation;
LUSC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg19318889	chr4:1322082	MAEA	0.58	9.99	0.48	9.81e-21	Longevity;
LUSC	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.08	-0.36	8.81e-12	Response to antipsychotic treatment;
LUSC	cis	rs11756438	0.572	rs1771756	chr6:119018502	C/T	cg18833306	chr6:118973337	C6orf204	0.38	6.0	0.31	5.25e-9	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2769264	0.649	rs9436029	chr1:151367378	C/T	cg18801370	chr1:151430492	POGZ	-0.96	-8.56	-0.42	4.05e-16	Blood trace element (Cu levels);
LUSC	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.64	0.39	2.25e-13	Iron status biomarkers;
LUSC	cis	rs1375194	0.606	rs2044644	chr2:33817559	A/G	cg04131969	chr2:33951647	MYADML	-0.61	-8.47	-0.42	7.87e-16	Response to antidepressants in depression;
LUSC	cis	rs3750965	1.000	rs731974	chr11:68847156	C/T	cg06818126	chr11:68850279	TPCN2	-0.45	-6.45	-0.33	3.92e-10	Hair color;
LUSC	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-18.0	-0.7	4.16e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs983392	0.709	rs4492839	chr11:59986399	T/A	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.16	-0.32	2.04e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.9	-0.4	4.02e-14	Glomerular filtration rate;
LUSC	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg25457927	chr22:38595422	NA	-0.37	-7.56	-0.38	3.8e-13	Breast cancer;
LUSC	cis	rs9612	1.000	rs346545	chr19:44256386	T/C	cg08581076	chr19:44259116	C19orf61	0.53	6.71	0.34	8.22e-11	Exhaled nitric oxide output;
LUSC	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg09796270	chr17:17721594	SREBF1	0.43	7.63	0.39	2.41e-13	Total body bone mineral density;
LUSC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.85	0.66	1.36e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg05084668	chr3:125655381	ALG1L	-0.45	-6.02	-0.31	4.67e-9	Blood pressure (smoking interaction);
LUSC	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg03929089	chr4:120376271	NA	0.64	6.06	0.31	3.65e-9	Intraocular pressure;
LUSC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg11843238	chr5:131593191	PDLIM4	0.44	7.73	0.39	1.28e-13	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.0	0.48	8.89e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg09307838	chr4:120376055	NA	0.76	11.09	0.52	1.5e-24	Corneal astigmatism;
LUSC	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg13334819	chr7:99746414	C7orf59	0.49	6.56	0.34	2.05e-10	Coronary artery disease;
LUSC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.63	-10.17	-0.49	2.48e-21	Menarche (age at onset);
LUSC	cis	rs1788820	0.917	rs1788819	chr18:21100504	G/A	cg14672496	chr18:21087552	C18orf8	0.44	6.92	0.35	2.33e-11	Body mass index;
LUSC	cis	rs75804782	0.521	rs72993065	chr2:239409001	C/T	cg18131467	chr2:239335373	ASB1	-0.72	-6.36	-0.33	6.59e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs3774830	0.743	rs11728680	chr4:5462247	A/G	cg26943120	chr4:5472116	STK32B	0.31	6.12	0.32	2.59e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg24130564	chr14:104152367	KLC1	0.45	6.53	0.34	2.43e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg22875332	chr1:76189707	ACADM	-0.4	-5.9	-0.31	8.71e-9	Daytime sleep phenotypes;
LUSC	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg02569458	chr12:86230093	RASSF9	-0.36	-5.76	-0.3	1.87e-8	Major depressive disorder;
LUSC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg05863683	chr7:1912471	MAD1L1	0.3	5.66	0.3	3.24e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg15660573	chr17:549704	VPS53	-0.68	-11.63	-0.54	1.74e-26	Prostate cancer;
LUSC	trans	rs72674100	1.000	rs61291954	chr4:97971955	C/T	cg09670535	chr1:18959427	PAX7	-0.56	-5.99	-0.31	5.44e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs28595532	0.748	rs72670249	chr4:119336823	G/T	cg21605333	chr4:119757512	SEC24D	1.02	8.31	0.41	2.47e-15	Cannabis dependence symptom count;
LUSC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg24634471	chr8:143751801	JRK	0.53	7.47	0.38	7.03e-13	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.08	0.32	3.34e-9	Menopause (age at onset);
LUSC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg17551891	chr7:1960795	MAD1L1	-0.31	-5.69	-0.3	2.79e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg01629716	chr15:45996671	NA	0.4	6.08	0.32	3.26e-9	Waist circumference;Weight;
LUSC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.52	0.76	4.6e-65	Prudent dietary pattern;
LUSC	cis	rs10979	0.838	rs12208649	chr6:143893321	G/T	cg25407410	chr6:143891975	LOC285740	-0.74	-12.23	-0.56	1.14e-28	Hypospadias;
LUSC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg04155289	chr7:94953770	PON1	-0.35	-6.07	-0.32	3.38e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg22117172	chr7:91764530	CYP51A1	-0.31	-5.65	-0.3	3.51e-8	Breast cancer;
LUSC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg21724239	chr8:58056113	NA	0.57	6.6	0.34	1.61e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg00800038	chr16:89945340	TCF25	-0.64	-6.72	-0.35	7.69e-11	Skin colour saturation;
LUSC	cis	rs662064	0.748	rs12375	chr1:10596341	C/T	cg20482658	chr1:10539492	PEX14	0.32	6.45	0.33	3.89e-10	Asthma;
LUSC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-9.91	-0.48	1.83e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg22482690	chr17:47019901	SNF8	0.41	7.7	0.39	1.56e-13	Type 2 diabetes;
LUSC	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg08085267	chr17:45401833	C17orf57	-0.5	-7.21	-0.37	3.76e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.35	-5.65	-0.3	3.38e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg06219351	chr7:158114137	PTPRN2	-0.52	-9.45	-0.46	5.96e-19	Calcium levels;
LUSC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg23985595	chr17:80112537	CCDC57	-0.31	-5.98	-0.31	5.8e-9	Life satisfaction;
LUSC	cis	rs10740039	0.810	rs10761528	chr10:62367660	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-7.08	-0.36	8.3e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs877282	0.755	rs1769242	chr10:787896	T/C	cg17470449	chr10:769945	NA	0.41	6.06	0.31	3.62e-9	Uric acid levels;
LUSC	cis	rs11608355	0.521	rs10850131	chr12:109837052	A/G	cg19025524	chr12:109796872	NA	0.39	7.25	0.37	2.99e-12	Neuroticism;
LUSC	cis	rs12474201	0.507	rs6714451	chr2:47017743	G/C	cg06386533	chr2:46925753	SOCS5	0.47	6.78	0.35	5.4e-11	Height;
LUSC	cis	rs7107174	0.901	rs2511162	chr11:77927101	A/G	cg02023728	chr11:77925099	USP35	0.46	6.73	0.35	7.19e-11	Testicular germ cell tumor;
LUSC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.78	14.38	0.62	7.93e-37	Osteoporosis;
LUSC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg21535247	chr6:8435926	SLC35B3	0.57	9.0	0.44	1.69e-17	Motion sickness;
LUSC	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg15309053	chr8:964076	NA	0.42	8.69	0.43	1.6e-16	Schizophrenia;
LUSC	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg04990556	chr1:26633338	UBXN11	0.85	11.14	0.52	9.76e-25	Obesity-related traits;
LUSC	cis	rs66716358	0.800	rs4755809	chr11:44323193	A/G	cg02785814	chr11:44338707	NA	-0.41	-6.26	-0.32	1.19e-9	Monobrow;
LUSC	cis	rs2273669	0.667	rs12206834	chr6:109303967	T/G	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.69	0.6	3.62e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg02782426	chr3:40428986	ENTPD3	0.34	6.44	0.33	4.16e-10	Renal cell carcinoma;
LUSC	trans	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg14227996	chr4:17616232	MED28	0.55	6.21	0.32	1.55e-9	Opioid sensitivity;
LUSC	cis	rs965469	0.895	rs6139123	chr20:3396634	C/T	cg25506879	chr20:3388711	C20orf194	-0.52	-5.64	-0.3	3.57e-8	IFN-related cytopenia;
LUSC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg24733560	chr20:60626293	TAF4	0.41	6.69	0.34	9.26e-11	Body mass index;
LUSC	cis	rs10779751	0.610	rs2486921	chr1:11124943	G/A	cg08854313	chr1:11322531	MTOR	0.81	12.1	0.55	3.52e-28	Body mass index;
LUSC	cis	rs1866706	0.896	rs7119811	chr11:12882376	T/G	cg25843174	chr11:12811716	TEAD1	0.28	5.82	0.3	1.37e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.04	-0.36	1.07e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4746822	0.815	rs10823318	chr10:70979924	A/T	cg14418922	chr10:70824840	NA	-0.38	-6.29	-0.33	1.01e-9	Glycemic traits (pregnancy);
LUSC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.54	-8.46	-0.42	8.33e-16	Personality dimensions;
LUSC	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg26528668	chr16:1614120	IFT140	0.42	7.2	0.37	3.97e-12	Coronary artery disease;
LUSC	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg16342193	chr10:102329863	NA	-0.41	-6.78	-0.35	5.57e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg05855489	chr10:104503620	C10orf26	-0.53	-8.07	-0.4	1.25e-14	Arsenic metabolism;
LUSC	cis	rs12286929	0.839	rs12790574	chr11:115009145	C/T	cg04055981	chr11:115044050	NA	0.34	5.78	0.3	1.76e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg15934090	chr1:100435551	SLC35A3	0.47	8.08	0.4	1.21e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.89	-18.73	-0.72	4.96e-54	Gut microbiota (bacterial taxa);
LUSC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.17	0.58	3.55e-32	Cognitive test performance;
LUSC	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.24	-0.37	3.19e-12	Waist circumference;Hip circumference;
LUSC	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg08213375	chr14:104286397	PPP1R13B	0.52	10.19	0.49	2.08e-21	Schizophrenia;
LUSC	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg00484396	chr16:3507460	NAT15	0.85	11.31	0.53	2.56e-25	Tuberculosis;
LUSC	trans	rs1997103	0.954	rs6593236	chr7:55410992	C/T	cg20935933	chr6:143382018	AIG1	0.51	7.38	0.37	1.26e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs240764	0.658	rs705584	chr6:101261553	C/T	cg09795085	chr6:101329169	ASCC3	0.43	6.26	0.32	1.18e-9	Neuroticism;
LUSC	cis	rs7493	0.950	rs7802171	chr7:95030321	A/G	cg21856205	chr7:94953877	PON1	-0.36	-5.71	-0.3	2.55e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs7939886	0.920	rs11227273	chr11:55893034	T/G	cg03929089	chr4:120376271	NA	0.74	6.01	0.31	4.95e-9	Myopia (pathological);
LUSC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.7	-10.76	-0.51	2.16e-23	Aortic root size;
LUSC	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg09953122	chr20:23471693	CST8	0.66	5.72	0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg06092702	chr1:163392909	NA	0.43	7.05	0.36	1.04e-11	Motion sickness;
LUSC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg11871910	chr12:69753446	YEATS4	0.84	15.2	0.64	5.09e-40	Blood protein levels;
LUSC	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg15997130	chr1:24165203	NA	0.52	8.62	0.43	2.75e-16	Immature fraction of reticulocytes;
LUSC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03934478	chr11:495069	RNH1	0.91	10.47	0.5	2.32e-22	Body mass index;
LUSC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg24562669	chr7:97807699	LMTK2	0.34	5.95	0.31	6.83e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.34	5.68	0.3	2.99e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs8114671	0.935	rs633198	chr20:33778434	T/C	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.14	-0.32	2.3e-9	Height;
LUSC	trans	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg07817883	chr1:32538562	TMEM39B	-0.61	-7.36	-0.37	1.41e-12	Monocyte percentage of white cells;
LUSC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06112835	chr11:68658793	MRPL21	-0.51	-8.0	-0.4	2.02e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs9392918	0.967	rs6927500	chr6:7706004	A/G	cg12631351	chr5:80256738	RASGRF2	-0.35	-5.99	-0.31	5.47e-9	Height;
LUSC	cis	rs3849570	0.673	rs9877408	chr3:81974558	A/G	cg07356753	chr3:81810745	GBE1	-0.5	-7.41	-0.38	1.04e-12	Waist circumference;Body mass index;
LUSC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg06238570	chr21:40685208	BRWD1	-0.65	-10.69	-0.5	3.9e-23	Cognitive function;
LUSC	cis	rs2898681	0.614	rs11947787	chr4:53705225	C/A	cg00338735	chr4:53728038	RASL11B	0.42	5.77	0.3	1.86e-8	Optic nerve measurement (cup area);
LUSC	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14829155	chr15:31115871	NA	-0.58	-7.93	-0.4	3.26e-14	Huntington's disease progression;
LUSC	cis	rs1045714	0.895	rs17833498	chr7:2647007	A/G	cg24848437	chr7:2645542	IQCE	-0.58	-6.95	-0.36	1.9e-11	Urate levels in lean individuals;
LUSC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg22549504	chr19:17448937	GTPBP3	0.55	7.06	0.36	9.83e-12	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-6.69	-0.34	9.17e-11	Homocysteine levels;
LUSC	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	12.09	0.55	3.72e-28	Ileal carcinoids;
LUSC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg01416388	chr22:39784598	NA	-0.41	-6.14	-0.32	2.32e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg00321850	chr1:175162397	KIAA0040	-0.41	-6.96	-0.36	1.86e-11	Alcohol dependence;
LUSC	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg24006582	chr15:45444508	DUOX1	-0.6	-8.67	-0.43	1.84e-16	Uric acid levels;
LUSC	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg03585969	chr10:35415529	CREM	0.61	8.92	0.44	3.24e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg00857998	chr1:205179979	DSTYK	0.64	9.87	0.48	2.44e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7818345	0.967	rs12679671	chr8:19270831	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.36	7.01	0.36	1.34e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg04545296	chr12:48745243	ZNF641	0.37	6.68	0.34	1.01e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs11031096	0.589	rs935130	chr11:4213530	A/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.81	-0.3	1.43e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg06637938	chr14:75390232	RPS6KL1	0.65	11.0	0.52	3.23e-24	Caffeine consumption;
LUSC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	7.43	0.38	9.25e-13	Personality dimensions;
LUSC	trans	rs10221833	0.602	rs355889	chr2:165634651	C/T	cg26993132	chr16:89239499	CDH15	0.31	5.99	0.31	5.47e-9	Response to statin therapy;
LUSC	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg02807482	chr3:125708958	NA	-0.48	-5.66	-0.3	3.18e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg16680214	chr1:154839983	KCNN3	-0.51	-9.7	-0.47	9.21e-20	Prostate cancer;
LUSC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-6.65	-0.34	1.22e-10	Blood pressure (smoking interaction);
LUSC	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	0.88	12.82	0.57	7.43e-31	Coronary artery disease;
LUSC	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.32	-0.41	2.25e-15	Response to antipsychotic treatment;
LUSC	cis	rs6961069	0.806	rs11770907	chr7:80258630	G/A	cg04458919	chr7:80252533	CD36	0.38	6.8	0.35	4.91e-11	Platelet count;
LUSC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	9.39	0.46	9.42e-19	Mean platelet volume;
LUSC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-0.93	-13.25	-0.59	1.69e-32	Vitiligo;
LUSC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg16434002	chr17:42200994	HDAC5	0.45	6.17	0.32	1.94e-9	Total body bone mineral density;
LUSC	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg12257692	chr3:49977190	RBM6	0.21	5.79	0.3	1.66e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	1.19	11.85	0.54	2.81e-27	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUSC	cis	rs4664308	0.810	rs62175552	chr2:160937220	T/G	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.62	-0.54	1.97e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg00791764	chr4:53727839	RASL11B	0.56	7.7	0.39	1.6e-13	Optic nerve measurement (cup area);
LUSC	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.01	-0.31	4.99e-9	Neuroticism;
LUSC	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14442939	chr10:27389572	ANKRD26	0.85	7.75	0.39	1.1e-13	Breast cancer;
LUSC	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg07424592	chr7:64974309	NA	1.12	6.76	0.35	6.14e-11	Diabetic kidney disease;
LUSC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg26408565	chr15:76604113	ETFA	-0.45	-7.02	-0.36	1.22e-11	Blood metabolite levels;
LUSC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg24675658	chr1:53192096	ZYG11B	0.6	9.54	0.46	3e-19	Monocyte count;
LUSC	trans	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-7.41	-0.38	1.01e-12	Morning vs. evening chronotype;
LUSC	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.15	0.52	9.34e-25	Coffee consumption (cups per day);
LUSC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg26528668	chr16:1614120	IFT140	0.4	6.43	0.33	4.5e-10	Coronary artery disease;
LUSC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg22029157	chr1:209979665	IRF6	-0.64	-10.86	-0.51	9.52e-24	Orofacial clefts;
LUSC	trans	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg22508957	chr16:3507546	NAT15	0.63	10.5	0.5	1.78e-22	Tuberculosis;
LUSC	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg12386194	chr3:101231763	SENP7	0.63	8.55	0.42	4.4e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg24375607	chr4:120327624	NA	0.78	11.54	0.53	3.88e-26	Corneal astigmatism;
LUSC	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg08917208	chr2:24149416	ATAD2B	0.98	9.81	0.47	4.02e-20	Lymphocyte counts;
LUSC	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	6.11	0.32	2.76e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.7	12.32	0.56	5.1e-29	Dental caries;
LUSC	trans	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg26043149	chr18:55253948	FECH	-0.44	-6.77	-0.35	5.75e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs981844	0.740	rs6815202	chr4:154682440	A/G	cg14289246	chr4:154710475	SFRP2	-0.52	-7.43	-0.38	9.09e-13	Response to statins (LDL cholesterol change);
LUSC	cis	rs708547	0.599	rs1718864	chr4:57887471	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	7.64	0.39	2.25e-13	Response to bleomycin (chromatid breaks);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12738349	chr22:24236284	MIF	-0.47	-6.31	-0.33	8.69e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04937561	chr11:57103057	SSRP1	0.41	6.57	0.34	1.96e-10	Asthma;
LUSC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2901656	0.604	rs5029890	chr1:172451753	T/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.3	5.88	0.31	1.02e-8	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	9.16	0.45	5.55e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg17376030	chr22:41985996	PMM1	-0.46	-5.72	-0.3	2.42e-8	Vitiligo;
LUSC	cis	rs9650657	0.665	rs1897207	chr8:10615235	C/T	cg27411982	chr8:10470053	RP1L1	-0.36	-5.77	-0.3	1.85e-8	Neuroticism;
LUSC	cis	rs714027	0.967	rs193477	chr22:30451486	C/T	cg11564601	chr22:30592435	NA	-0.36	-6.71	-0.34	8.55e-11	Lymphocyte counts;
LUSC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg21153622	chr11:89784906	NA	-0.4	-6.15	-0.32	2.16e-9	HDL cholesterol;
LUSC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18876405	chr7:65276391	NA	-0.55	-8.76	-0.43	9.78e-17	Aortic root size;
LUSC	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg07507251	chr3:52567010	NT5DC2	0.29	5.65	0.3	3.52e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.71	-0.34	8.18e-11	Breast cancer;
LUSC	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.77	0.51	2.06e-23	Morning vs. evening chronotype;
LUSC	cis	rs662064	0.962	rs683864	chr1:10561954	T/C	cg20482658	chr1:10539492	PEX14	0.33	6.79	0.35	5.27e-11	Asthma;
LUSC	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg00579200	chr11:133705235	NA	-0.39	-5.67	-0.3	3.03e-8	Childhood ear infection;
LUSC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg12365402	chr11:9010492	NRIP3	0.46	8.41	0.42	1.18e-15	Hemoglobin concentration;
LUSC	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg22709100	chr7:91322751	NA	-0.4	-5.78	-0.3	1.67e-8	Breast cancer;
LUSC	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00338735	chr4:53728038	RASL11B	0.49	5.67	0.3	3.11e-8	Optic nerve measurement (cup area);
LUSC	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.77	11.16	0.52	8.56e-25	Corneal astigmatism;
LUSC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.9	16.05	0.66	2.25e-43	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg15556689	chr8:8085844	FLJ10661	0.67	10.86	0.51	9.95e-24	Mood instability;
LUSC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg07701084	chr6:150067640	NUP43	0.58	8.92	0.44	3.05e-17	Lung cancer;
LUSC	cis	rs12956009	0.507	rs1560900	chr18:44866849	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	6.17	0.32	1.93e-9	Educational attainment (years of education);
LUSC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg03289416	chr15:75166202	SCAMP2	0.44	6.93	0.35	2.24e-11	Breast cancer;
LUSC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.74	-0.3	2.14e-8	Monocyte count;
LUSC	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.21	-0.32	1.59e-9	Neutrophil percentage of white cells;
LUSC	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.73	-0.43	1.21e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.82e-24	Hypertriglyceridemia;
LUSC	cis	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg06521331	chr12:34319734	NA	-0.49	-8.14	-0.41	8e-15	Morning vs. evening chronotype;
LUSC	cis	rs1113500	0.836	rs2801220	chr1:108584649	A/G	cg06207961	chr1:108661230	NA	-0.37	-6.7	-0.34	9.07e-11	Growth-regulated protein alpha levels;
LUSC	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.27	0.52	3.57e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs11625487	0.957	rs7156032	chr14:77951364	G/A	cg16049707	chr14:77965284	ISM2	-0.47	-6.2	-0.32	1.63e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs7843479	0.965	rs17581910	chr8:21799626	A/G	cg17168535	chr8:21777572	XPO7	0.68	10.6	0.5	7.91e-23	Mean corpuscular volume;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg14238478	chr2:219433113	RQCD1;USP37	0.47	6.14	0.32	2.28e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg15147215	chr3:52552868	STAB1	-0.32	-6.34	-0.33	7.59e-10	Bipolar disorder;
LUSC	cis	rs1044573	0.526	rs6050422	chr20:25177920	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	7.81	0.39	7.3e-14	Allergic rhinitis;
LUSC	trans	rs12439619	0.693	rs28689861	chr15:82498710	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.44	-6.26	-0.32	1.19e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.07	-0.32	3.53e-9	Resting heart rate;
LUSC	trans	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg18187862	chr3:45730750	SACM1L	-0.55	-7.31	-0.37	2.02e-12	Primary sclerosing cholangitis;
LUSC	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.53	-0.5	1.46e-22	Coffee consumption (cups per day);
LUSC	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg17127132	chr2:85788382	GGCX	0.44	6.28	0.33	1.03e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.57	0.67	2.02e-45	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.8	-0.3	1.53e-8	Total body bone mineral density;
LUSC	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg13114125	chr14:105738426	BRF1	-0.89	-15.51	-0.65	3e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg23815491	chr16:72088622	HP	0.33	5.69	0.3	2.71e-8	Fibrinogen levels;
LUSC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg13206674	chr6:150067644	NUP43	0.6	9.55	0.46	2.91e-19	Lung cancer;
LUSC	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-0.51	-7.8	-0.39	7.79e-14	Breast cancer;
LUSC	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg13789015	chr9:136890014	NCRNA00094	0.73	13.4	0.59	4.45e-33	Platelet distribution width;
LUSC	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.79	11.58	0.54	2.77e-26	Corneal astigmatism;
LUSC	trans	rs11696501	0.688	rs6130897	chr20:44330004	C/T	cg03272292	chr12:48577362	C12orf68	0.47	5.97	0.31	5.95e-9	Brain structure;
LUSC	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg11473876	chr11:109292803	C11orf87	-0.34	-5.69	-0.3	2.72e-8	Schizophrenia;
LUSC	cis	rs2279817	1.000	rs10888048	chr1:18019742	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.49	7.02	0.36	1.22e-11	Neuroticism;
LUSC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.07e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs240764	0.817	rs12201852	chr6:101149576	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.16	-0.32	2.04e-9	Neuroticism;
LUSC	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg25643088	chr3:52874325	TMEM110	-0.4	-6.07	-0.32	3.44e-9	Schizophrenia;
LUSC	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-12.14	-0.55	2.42e-28	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs870825	0.721	rs72703528	chr4:185607311	A/G	cg04058563	chr4:185651563	MLF1IP	0.81	10.65	0.5	5.57e-23	Blood protein levels;
LUSC	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg09092052	chr15:45571596	NA	0.48	6.61	0.34	1.56e-10	Glomerular filtration rate;
LUSC	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg08917208	chr2:24149416	ATAD2B	0.51	5.76	0.3	1.88e-8	Lymphocyte counts;
LUSC	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg03433033	chr1:76189801	ACADM	-0.48	-7.12	-0.36	6.61e-12	Daytime sleep phenotypes;
LUSC	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg05283184	chr6:79620031	NA	-0.58	-11.98	-0.55	9.46e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg20203395	chr5:56204925	C5orf35	0.53	7.62	0.38	2.58e-13	Initial pursuit acceleration;
LUSC	cis	rs9300255	0.664	rs7306755	chr12:123767929	G/A	cg00376283	chr12:123451042	ABCB9	-0.72	-7.84	-0.39	5.96e-14	Neutrophil percentage of white cells;
LUSC	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.75	-0.6	2.1e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg12595281	chr15:93633172	RGMA	0.45	7.29	0.37	2.2e-12	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.09	0.48	4.54e-21	Electroencephalogram traits;
LUSC	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg02493740	chr2:85810744	VAMP5	0.31	5.66	0.3	3.2e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs936229	0.813	rs4886629	chr15:75072558	G/C	cg10253484	chr15:75165896	SCAMP2	-0.5	-6.58	-0.34	1.84e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs12030196	0.788	rs10889125	chr1:59417116	A/G	cg21156790	chr22:29168647	CCDC117	0.46	6.23	0.32	1.44e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	0.82	9.99	0.48	9.51e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs3772130	0.527	rs2141614	chr3:121590173	G/A	cg20356878	chr3:121714668	ILDR1	0.61	9.9	0.48	2.05e-20	Cognitive performance;
LUSC	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.74	-0.39	1.22e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg16359550	chr11:109292809	C11orf87	0.36	6.27	0.32	1.14e-9	Schizophrenia;
LUSC	cis	rs4664308	0.618	rs55668231	chr2:160882066	A/G	cg03641300	chr2:160917029	PLA2R1	-0.48	-7.73	-0.39	1.27e-13	Idiopathic membranous nephropathy;
LUSC	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	6.93	0.35	2.2e-11	Height;
LUSC	cis	rs7189233	0.531	rs8062535	chr16:53512488	G/A	cg09728985	chr16:53543985	NA	-0.33	-6.25	-0.32	1.23e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg24459738	chr19:57751996	ZNF805	-0.51	-7.53	-0.38	4.85e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg21856205	chr7:94953877	PON1	-0.36	-5.73	-0.3	2.29e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg25214090	chr10:38739885	LOC399744	0.43	6.53	0.34	2.42e-10	Corneal astigmatism;
LUSC	cis	rs4664308	0.870	rs2305818	chr2:161029218	G/A	cg03641300	chr2:160917029	PLA2R1	-0.64	-10.9	-0.51	7.12e-24	Idiopathic membranous nephropathy;
LUSC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-11.65	-0.54	1.55e-26	Chronic sinus infection;
LUSC	cis	rs2279817	0.691	rs7543007	chr1:17990475	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.46	-6.09	-0.32	3.1e-9	Neuroticism;
LUSC	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.16	-0.49	2.57e-21	Eye color traits;
LUSC	cis	rs4843185	0.667	rs4143865	chr16:85716612	T/A	cg00168118	chr16:85669675	KIAA0182	0.38	5.76	0.3	1.88e-8	Platelet distribution width;
LUSC	cis	rs2230307	0.536	rs56215716	chr1:100447486	G/A	cg24955406	chr1:100503596	HIAT1	0.56	6.08	0.32	3.31e-9	Carotid intima media thickness;
LUSC	trans	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg07393940	chr7:158741817	NA	0.36	6.43	0.33	4.46e-10	Life satisfaction;
LUSC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.3	0.33	9.52e-10	Personality dimensions;
LUSC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-0.93	-13.21	-0.59	2.52e-32	Vitiligo;
LUSC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg11344533	chr11:111475393	SIK2	-0.49	-6.6	-0.34	1.59e-10	Primary sclerosing cholangitis;
LUSC	cis	rs72949976	0.606	rs1922797	chr2:214027642	G/A	cg08319019	chr2:214017104	IKZF2	0.68	11.42	0.53	9.95e-26	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs7809950	0.678	rs2395868	chr7:106897500	C/T	cg23024343	chr7:107201750	COG5	0.61	9.59	0.46	2.11e-19	Coronary artery disease;
LUSC	cis	rs7216064	0.906	rs8074644	chr17:65878217	G/C	cg12091567	chr17:66097778	LOC651250	-0.73	-9.37	-0.46	1.13e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	5.68	0.3	2.98e-8	Response to antipsychotic treatment;
LUSC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg13072238	chr3:49761600	GMPPB	-0.65	-7.74	-0.39	1.17e-13	Menarche (age at onset);
LUSC	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.75	-0.43	1.05e-16	Response to antipsychotic treatment;
LUSC	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.83	-18.14	-0.7	1.17e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6847149	0.929	rs6847467	chr4:110800020	G/A	cg07850274	chr4:110748770	RRH	0.5	7.18	0.37	4.51e-12	Exercise treadmill test traits;
LUSC	trans	rs2562456	0.754	rs11673234	chr19:21507602	A/C	cg00806126	chr19:22604979	ZNF98	-0.42	-5.99	-0.31	5.56e-9	Pain;
LUSC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.9	0.35	2.69e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg22907277	chr7:1156413	C7orf50	0.71	8.02	0.4	1.83e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg03804128	chr16:635623	NA	0.3	5.85	0.3	1.17e-8	Height;
LUSC	cis	rs2969070	0.674	rs2906149	chr7:2524359	C/T	cg03277898	chr7:2518824	NA	0.29	6.31	0.33	8.85e-10	Diastolic blood pressure;
LUSC	trans	rs1015291	0.836	rs951062	chr12:19988377	C/T	cg01501474	chr7:55323552	NA	-0.45	-6.15	-0.32	2.27e-9	Diastolic blood pressure;
LUSC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-8.69	-0.43	1.65e-16	Menarche (age at onset);
LUSC	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg17911788	chr17:44343683	NA	-0.32	-6.07	-0.32	3.55e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-0.87	-16.55	-0.67	2.41e-45	Urate levels;
LUSC	cis	rs9399401	0.921	rs9403387	chr6:142773210	G/T	cg03128060	chr6:142623767	GPR126	0.31	5.74	0.3	2.09e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg11941060	chr3:133502564	NA	-0.61	-9.82	-0.47	3.8e-20	Iron status biomarkers;
LUSC	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg05283184	chr6:79620031	NA	-0.56	-11.88	-0.54	2.27e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg26924012	chr15:45694286	SPATA5L1	0.77	11.89	0.55	1.94e-27	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9309473	0.607	rs1522926	chr2:73591241	T/C	cg20560298	chr2:73613845	ALMS1	-0.5	-7.31	-0.37	1.93e-12	Metabolite levels;
LUSC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg13047869	chr3:10149882	C3orf24	0.57	7.9	0.4	4.11e-14	Alzheimer's disease;
LUSC	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs1113500	0.565	rs1777455	chr1:108590288	C/A	cg11967332	chr1:108735228	SLC25A24	-0.43	-5.91	-0.31	8.58e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs2742234	0.541	rs60845448	chr10:43721462	C/T	cg02780029	chr10:43622663	RET	0.35	5.82	0.3	1.41e-8	Hirschsprung disease;
LUSC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.67	11.93	0.55	1.38e-27	Aortic root size;
LUSC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg11764359	chr7:65958608	NA	-0.5	-6.25	-0.32	1.26e-9	Aortic root size;
LUSC	cis	rs1322512	1.000	rs2800623	chr6:153003720	A/G	cg03415253	chr6:152958462	SYNE1	0.39	5.72	0.3	2.4e-8	Tonometry;
LUSC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg15445000	chr17:37608096	MED1	0.4	6.79	0.35	5.09e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-7.69	-0.39	1.62e-13	Bipolar disorder;
LUSC	cis	rs4930561	0.714	rs7130844	chr11:67927517	C/T	cg04465784	chr11:67976953	SUV420H1	-0.29	-5.81	-0.3	1.48e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg21724239	chr8:58056113	NA	0.78	8.56	0.42	4.04e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs116988415	1.000	rs116988415	chr14:65292145	C/T	cg00114569	chr14:65239327	SPTB	0.64	6.2	0.32	1.7e-9	Daytime sleep phenotypes;
LUSC	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg19920283	chr7:105172520	RINT1	0.57	6.08	0.32	3.34e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs16912285	0.688	rs12277966	chr11:24286633	G/A	ch.11.24196551F	chr11:24239977	NA	0.83	8.2	0.41	5.12e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	0.99	14.21	0.61	3.62e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg27535305	chr1:53392650	SCP2	0.38	7.08	0.36	8.63e-12	Monocyte count;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.38	-8.43	-0.42	1.02e-15	Longevity;Endometriosis;
LUSC	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg22138327	chr13:27999177	GTF3A	0.8	10.52	0.5	1.55e-22	Weight;
LUSC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.11	0.41	9.88e-15	Cognitive test performance;
LUSC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.7	0.34	8.92e-11	Tonsillectomy;
LUSC	cis	rs4423214	0.592	rs11233933	chr11:71210070	C/T	cg05163923	chr11:71159392	DHCR7	-0.63	-6.62	-0.34	1.41e-10	Vitamin D levels;
LUSC	trans	rs236907	0.859	rs35930163	chr1:171768184	G/A	cg13482142	chr2:234261155	NA	0.5	6.19	0.32	1.8e-9	Mean platelet volume;
LUSC	cis	rs6426558	0.537	rs2813969	chr1:227404082	T/C	cg10327440	chr1:227177885	CDC42BPA	0.54	7.28	0.37	2.36e-12	Neutrophil percentage of white cells;
LUSC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg06238570	chr21:40685208	BRWD1	-0.63	-10.68	-0.5	4.1000000000000003e-23	Cognitive function;
LUSC	cis	rs73200209	0.744	rs10507269	chr12:116560327	A/T	cg01776926	chr12:116560359	MED13L	-0.51	-6.07	-0.32	3.48e-9	Total body bone mineral density;
LUSC	cis	rs7809950	1.000	rs2253146	chr7:107200319	A/G	cg23024343	chr7:107201750	COG5	-0.56	-8.76	-0.43	9.82e-17	Coronary artery disease;
LUSC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg04518342	chr5:131593106	PDLIM4	0.45	8.31	0.41	2.47e-15	Breast cancer;
LUSC	cis	rs4363385	0.818	rs57311099	chr1:153005597	A/C	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.45e-8	Inflammatory skin disease;
LUSC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg15445000	chr17:37608096	MED1	0.38	6.61	0.34	1.53e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7814319	0.933	rs13261690	chr8:97238661	C/A	cg20787634	chr8:97240163	UQCRB	-0.35	-6.02	-0.31	4.5e-9	Lung function (FVC);
LUSC	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.27	0.52	3.59e-25	Colorectal cancer;
LUSC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg00105475	chr2:10696890	NA	0.38	6.27	0.32	1.11e-9	Prostate cancer;
LUSC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg22117172	chr7:91764530	CYP51A1	0.33	5.85	0.3	1.18e-8	Breast cancer;
LUSC	trans	rs1532331	0.864	rs6414900	chr5:43126528	G/A	cg02477305	chr13:23993013	SACS	0.35	5.97	0.31	5.96e-9	Menarche (age at onset);
LUSC	cis	rs2742417	1.000	rs2673037	chr3:45749094	A/T	cg09608765	chr3:45636137	LIMD1	-0.38	-7.51	-0.38	5.47e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg17279839	chr7:150038598	RARRES2	0.41	6.29	0.33	9.69e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs500891	0.621	rs62419328	chr6:84158736	A/G	cg08257003	chr6:84140564	ME1	0.37	9.12	0.45	7.43e-18	Platelet-derived growth factor BB levels;
LUSC	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.96	0.4	2.69e-14	Retinal vascular caliber;
LUSC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18854424	chr1:2615690	NA	-0.5	-9.95	-0.48	1.35e-20	Ulcerative colitis;
LUSC	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg01629716	chr15:45996671	NA	0.4	6.06	0.31	3.7e-9	Waist circumference;Weight;
LUSC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg25767906	chr1:53392781	SCP2	0.53	9.87	0.48	2.59e-20	Monocyte count;
LUSC	cis	rs2324229	0.828	rs1016242	chr6:83955571	A/T	cg08257003	chr6:84140564	ME1	0.26	5.97	0.31	5.94e-9	Platelet-derived growth factor BB levels;
LUSC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg08270630	chr22:50330655	NA	-0.4	-6.28	-0.33	1.02e-9	Schizophrenia;
LUSC	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-8.83	-0.43	6.17e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg05855489	chr10:104503620	C10orf26	0.58	7.81	0.39	7.28e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg08470875	chr2:26401718	FAM59B	-0.67	-8.89	-0.44	3.83e-17	Gut microbiome composition (summer);
LUSC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19346786	chr7:2764209	NA	-0.37	-6.54	-0.34	2.33e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24739457	chr1:205821442	NA	0.35	6.04	0.31	4.22e-9	Menarche (age at onset);
LUSC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg11663144	chr21:46675770	NA	-0.43	-7.39	-0.37	1.21e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.92	15.32	0.64	1.7e-40	Bladder cancer;
LUSC	cis	rs3087591	0.708	rs2525563	chr17:29647908	T/G	cg24425628	chr17:29625626	OMG;NF1	0.45	6.72	0.35	7.67e-11	Hip circumference;
LUSC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg02038168	chr22:39784481	NA	0.46	7.61	0.38	2.88e-13	IgG glycosylation;
LUSC	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs75804782	0.521	rs1123472	chr2:239414355	C/T	cg18131467	chr2:239335373	ASB1	0.61	6.25	0.32	1.22e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs9796	0.621	rs557864	chr15:41471358	T/C	cg18705301	chr15:41695430	NDUFAF1	0.48	8.53	0.42	5.24e-16	Menopause (age at onset);
LUSC	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg14345882	chr6:26364793	BTN3A2	0.61	5.65	0.3	3.4e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2236918	0.932	rs2526697	chr1:242040129	A/G	cg17736920	chr1:242011382	EXO1	-0.41	-6.47	-0.33	3.48e-10	Menopause (age at onset);
LUSC	cis	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg06521331	chr12:34319734	NA	-0.37	-6.07	-0.32	3.55e-9	Morning vs. evening chronotype;
LUSC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.81	-0.35	4.64e-11	Total body bone mineral density;
LUSC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg10018233	chr7:150070692	REPIN1	0.39	6.77	0.35	5.8e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs17092148	1.000	rs910872	chr20:33334540	T/C	cg16810054	chr20:33298113	TP53INP2	-0.41	-6.42	-0.33	4.77e-10	Neuroticism;
LUSC	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg22655196	chr4:3374909	RGS12	0.3	5.78	0.3	1.71e-8	Serum sulfate level;
LUSC	cis	rs600626	0.541	rs11236528	chr11:75469476	T/C	cg24262691	chr11:75473276	NA	0.51	6.64	0.34	1.3100000000000001e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs4601821	0.895	rs2155464	chr11:113242448	T/C	cg14159747	chr11:113255604	NA	0.26	6.03	0.31	4.42e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs2481665	0.608	rs2476194	chr1:62594593	C/T	cg18591186	chr1:62594603	INADL	-0.61	-11.29	-0.53	2.88e-25	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg12744634	chr1:26560303	CCDC21	0.38	5.66	0.3	3.33e-8	Obesity-related traits;
LUSC	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.43e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs860295	0.702	rs11264387	chr1:155563152	G/T	cg08949192	chr1:155289623	RUSC1;FDPS	-0.34	-5.74	-0.3	2.13e-8	Body mass index;
LUSC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg20701182	chr2:24300061	SF3B14	0.88	11.35	0.53	1.86e-25	Lymphocyte counts;
LUSC	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg20203395	chr5:56204925	C5orf35	-0.41	-6.15	-0.32	2.26e-9	Coronary artery disease;
LUSC	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.16e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg15242686	chr22:24348715	GSTTP1	0.43	6.38	0.33	5.87e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg09904177	chr6:26538194	HMGN4	-0.73	-6.89	-0.35	2.78e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg13010199	chr12:38710504	ALG10B	-0.45	-6.75	-0.35	6.46e-11	Heart rate;
LUSC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg16797656	chr11:68205561	LRP5	0.35	5.84	0.3	1.23e-8	Total body bone mineral density;
LUSC	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg16989719	chr2:238392110	NA	-0.38	-6.6	-0.34	1.61e-10	Prostate cancer;
LUSC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg02951883	chr7:2050386	MAD1L1	-0.45	-7.8	-0.39	7.97e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.79	0.35	5.2e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12292205	chr6:26970375	C6orf41	-0.58	-7.17	-0.37	4.88e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2425143	1.000	rs6060572	chr20:34294015	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.4	-0.33	5.31e-10	Blood protein levels;
LUSC	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg22563815	chr15:78856949	CHRNA5	0.27	6.41	0.33	4.96e-10	Sudden cardiac arrest;
LUSC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg18681998	chr4:17616180	MED28	0.86	15.62	0.65	1.1e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg11530693	chr1:120165357	ZNF697	0.69	10.79	0.51	1.79e-23	Systemic lupus erythematosus;
LUSC	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg08313168	chr12:7315531	NA	0.46	5.98	0.31	5.65e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11645453	chr3:52864694	ITIH4	0.31	7.25	0.37	2.85e-12	Bipolar disorder;
LUSC	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-19.84	-0.74	2.04e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg05340658	chr4:99064831	C4orf37	0.46	7.34	0.37	1.66e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg05347473	chr6:146136440	FBXO30	0.43	7.16	0.36	5.17e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.88	-0.35	2.88e-11	Triglycerides;
LUSC	cis	rs4363385	0.510	rs11812015	chr1:153045584	G/T	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.39	-0.33	5.43e-10	Inflammatory skin disease;
LUSC	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg11693508	chr17:37793320	STARD3	0.67	7.77	0.39	9.74e-14	Bipolar disorder;
LUSC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.73	9.54	0.46	3.05e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.52	8.15	0.41	7.24e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs6076960	0.713	rs3865568	chr20:6249339	A/G	cg21095983	chr6:86352623	SYNCRIP	0.51	7.68	0.39	1.8e-13	Smooth-surface caries;
LUSC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21016266	chr12:122356598	WDR66	-0.57	-8.69	-0.43	1.64e-16	Mean corpuscular volume;
LUSC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg15556689	chr8:8085844	FLJ10661	0.67	11.36	0.53	1.71e-25	Mood instability;
LUSC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg18477163	chr1:228402036	OBSCN	-0.56	-10.39	-0.49	4.2e-22	Diastolic blood pressure;
LUSC	trans	rs6030	0.871	rs1894694	chr1:169515381	T/C	cg16792071	chr10:134842795	NA	0.28	6.03	0.31	4.38e-9	Uric acid levels;
LUSC	trans	rs11933661	0.528	rs1022008	chr4:130966269	C/G	cg25019777	chr4:53525403	USP46	0.4	6.06	0.31	3.7e-9	Alcohol dependence;
LUSC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11645453	chr3:52864694	ITIH4	0.38	8.65	0.43	2.25e-16	Bipolar disorder;
LUSC	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg23587288	chr2:27483067	SLC30A3	-0.29	-5.7	-0.3	2.61e-8	Blood metabolite levels;
LUSC	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg15997130	chr1:24165203	NA	0.52	8.54	0.42	4.67e-16	Immature fraction of reticulocytes;
LUSC	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.75	-12.4	-0.56	2.68e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	16.2	0.66	5.64e-44	Platelet count;
LUSC	cis	rs4947962	0.525	rs28374832	chr7:55148817	C/T	cg23757825	chr7:55092271	EGFR	-0.46	-5.78	-0.3	1.7e-8	Subjective response to lithium treatment;
LUSC	trans	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg25214090	chr10:38739885	LOC399744	0.57	8.27	0.41	3.3e-15	Corneal astigmatism;
LUSC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.22	-14.19	-0.61	4.12e-36	Diabetic kidney disease;
LUSC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.79	-0.39	8.52e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg16342193	chr10:102329863	NA	-0.35	-6.3	-0.33	9.17e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.53	-8.16	-0.41	6.97e-15	Lymphocyte counts;
LUSC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg11843238	chr5:131593191	PDLIM4	0.51	9.06	0.44	1.14e-17	Acylcarnitine levels;
LUSC	cis	rs16910800	0.731	rs56768542	chr11:23191946	A/G	cg20040320	chr11:23191996	NA	-0.59	-7.63	-0.39	2.4e-13	Cancer;
LUSC	cis	rs1434579	0.572	rs926052	chr19:44952236	A/T	cg15540054	chr19:45004280	ZNF180	0.47	6.89	0.35	2.75e-11	Tuberculosis;
LUSC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21984481	chr17:79567631	NPLOC4	-0.67	-14.16	-0.61	5.79e-36	Eye color traits;
LUSC	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg24006582	chr15:45444508	DUOX1	-0.6	-8.82	-0.43	6.55e-17	Uric acid levels;
LUSC	cis	rs12986413	0.651	rs2238609	chr19:2146629	C/T	cg09261902	chr19:2140048	AP3D1	0.34	6.07	0.32	3.48e-9	Height;
LUSC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.39	-0.42	1.37e-15	Mood instability;
LUSC	trans	rs933117	1.000	rs933117	chr21:31100797	C/T	cg25856663	chr15:83317632	CPEB1	0.49	6.02	0.31	4.48e-9	Body mass index;
LUSC	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg13072238	chr3:49761600	GMPPB	-0.73	-8.34	-0.42	1.94e-15	Menarche (age at onset);
LUSC	cis	rs793571	0.503	rs1427281	chr15:58959273	T/C	cg05156742	chr15:59063176	FAM63B	0.5	6.68	0.34	9.81e-11	Schizophrenia;
LUSC	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg26618903	chr10:100175079	PYROXD2	0.47	9.04	0.44	1.34e-17	Metabolite levels;
LUSC	cis	rs9788682	0.948	rs905739	chr15:78845110	A/G	cg24631222	chr15:78858424	CHRNA5	0.81	10.91	0.51	6.59e-24	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg25174290	chr11:3078921	CARS	0.41	6.39	0.33	5.64e-10	Longevity;
LUSC	cis	rs4964805	1.000	rs11111792	chr12:104194857	C/G	cg02344784	chr12:104178138	NT5DC3	0.45	7.15	0.36	5.34e-12	Attention deficit hyperactivity disorder;
LUSC	trans	rs61931739	0.620	rs708141	chr12:33719664	G/A	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg14895029	chr7:2775587	GNA12	-0.42	-6.25	-0.32	1.26e-9	Height;
LUSC	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg04850211	chr1:228464232	OBSCN	-0.37	-6.22	-0.32	1.49e-9	Diastolic blood pressure;
LUSC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg26695010	chr11:65641043	EFEMP2	-0.48	-7.33	-0.37	1.75e-12	Eosinophil percentage of white cells;
LUSC	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg08645402	chr16:4508243	NA	0.52	8.95	0.44	2.59e-17	Schizophrenia;
LUSC	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg11189052	chr15:85197271	WDR73	0.48	6.09	0.32	3.15e-9	Schizophrenia;
LUSC	cis	rs926938	0.584	rs869990	chr1:115379614	A/G	cg12756093	chr1:115239321	AMPD1	-0.54	-8.13	-0.41	8.4e-15	Autism;
LUSC	cis	rs73198271	0.531	rs17154756	chr8:8652394	C/T	cg01851573	chr8:8652454	MFHAS1	0.58	7.72	0.39	1.34e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs72777070	0.627	rs13418911	chr2:9795857	A/G	cg14973360	chr2:9800511	NA	-0.39	-5.84	-0.3	1.21e-8	Platelet-derived growth factor BB levels;
LUSC	cis	rs12940923	1.000	rs12940923	chr17:56369849	A/T	cg19466818	chr17:56409534	MIR142	-0.38	-6.76	-0.35	6.25e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	0.6	9.43	0.46	7.09e-19	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25401754	chr6:153304305	FBXO5	-0.41	-6.14	-0.32	2.28e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg25214090	chr10:38739885	LOC399744	0.46	6.8	0.35	4.7e-11	Corneal astigmatism;
LUSC	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-7.04	-0.36	1.09e-11	Menarche (age at onset);
LUSC	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg23029597	chr12:123009494	RSRC2	-0.75	-9.47	-0.46	5.19e-19	Body mass index;
LUSC	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.64	-0.34	1.24e-10	Response to antipsychotic treatment;
LUSC	cis	rs12618769	0.597	rs72819986	chr2:99045867	G/C	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.14e-13	Bipolar disorder;
LUSC	cis	rs11997175	0.574	rs4446694	chr8:33654978	A/G	ch.8.33884649F	chr8:33765107	NA	0.52	8.57	0.42	3.94e-16	Body mass index;
LUSC	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg10518572	chr11:65560635	OVOL1	-0.25	-5.75	-0.3	1.97e-8	Acne (severe);
LUSC	cis	rs12136530	0.744	rs66932922	chr1:19776143	G/A	cg01832549	chr1:19774989	CAPZB	-0.33	-6.1	-0.32	2.92e-9	Lead levels in blood;
LUSC	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg04733989	chr22:42467013	NAGA	-0.42	-6.91	-0.35	2.52e-11	Cognitive function;
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg06263672	chr7:65235340	NA	-0.46	-6.73	-0.35	7.28e-11	Calcium levels;
LUSC	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg26384229	chr12:38710491	ALG10B	0.9	15.67	0.65	7.43e-42	Bladder cancer;
LUSC	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg01973587	chr1:228161476	NA	0.36	6.04	0.31	4.02e-9	Diastolic blood pressure;
LUSC	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.29	-0.33	1.02e-9	Bipolar disorder;
LUSC	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg06636551	chr8:101224915	SPAG1	-0.4	-7.42	-0.38	9.55e-13	Atrioventricular conduction;
LUSC	cis	rs17739794	0.517	rs35856917	chr8:774395	C/G	cg07178994	chr8:816998	NA	-0.39	-5.86	-0.31	1.11e-8	Clozapine-induced cytotoxicity;
LUSC	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg08645402	chr16:4508243	NA	0.48	7.63	0.39	2.49e-13	Schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20256097	chr20:3185301	DDRGK1	0.75	6.06	0.31	3.66e-9	Cognitive performance;
LUSC	cis	rs870825	0.616	rs28445002	chr4:185648977	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.76	-0.3	1.88e-8	Depression;
LUSC	cis	rs7165170	0.808	rs12915979	chr15:91199025	C/T	cg00756943	chr15:91208460	NA	-0.39	-5.72	-0.3	2.38e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg27218536	chr17:35969412	SYNRG	0.36	6.15	0.32	2.24e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs4664308	0.967	rs17831329	chr2:160915819	T/C	cg03641300	chr2:160917029	PLA2R1	-0.69	-11.49	-0.53	5.49e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg03665457	chr10:38645376	HSD17B7P2	-0.48	-6.83	-0.35	4.1e-11	Breast cancer;
LUSC	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg22029157	chr1:209979665	IRF6	0.73	8.97	0.44	2.23e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg06623918	chr6:96969491	KIAA0776	0.81	10.09	0.48	4.42e-21	Migraine;Coronary artery disease;
LUSC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.17	-0.32	1.98e-9	Total body bone mineral density;
LUSC	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs708547	1.000	rs708547	chr4:57821309	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.76	-0.3	1.87e-8	Response to bleomycin (chromatid breaks);
LUSC	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.91	15.7	0.65	5.65e-42	Morning vs. evening chronotype;
LUSC	cis	rs6681460	0.866	rs996123	chr1:67025343	T/C	cg02459107	chr1:67143332	SGIP1	0.48	8.66	0.43	2.04e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg21775007	chr8:11205619	TDH	-0.53	-7.17	-0.37	4.87e-12	Neuroticism;
LUSC	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg05234568	chr11:5960015	NA	-0.57	-8.33	-0.41	2.06e-15	DNA methylation (variation);
LUSC	cis	rs6942756	0.713	rs691807	chr7:129076203	G/C	cg02491457	chr7:128862824	NA	-0.43	-5.99	-0.31	5.36e-9	White matter hyperintensity burden;
LUSC	trans	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg13010199	chr12:38710504	ALG10B	0.4	6.21	0.32	1.55e-9	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11945604	chr12:6387873	NA	-0.4	-5.94	-0.31	7.05e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs977987	0.806	rs11648176	chr16:75456423	C/G	cg04384234	chr16:75411784	CFDP1	-0.43	-7.06	-0.36	9.49e-12	Dupuytren's disease;
LUSC	cis	rs8099014	0.911	rs4383234	chr18:56126247	C/G	cg12907477	chr18:56117327	MIR122	0.43	6.82	0.35	4.3e-11	Platelet count;
LUSC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg11218175	chr11:495084	RNH1	0.53	5.67	0.3	3.11e-8	Body mass index;
LUSC	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg03060546	chr3:49711283	APEH	-0.62	-7.22	-0.37	3.61e-12	Menarche (age at onset);
LUSC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg22800045	chr5:56110881	MAP3K1	0.79	10.3	0.49	8.51e-22	Initial pursuit acceleration;
LUSC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08219700	chr8:58056026	NA	0.65	7.63	0.39	2.51e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-8.53	-0.42	5.13e-16	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg16606324	chr3:10149918	C3orf24	0.68	9.9	0.48	2.05e-20	Alzheimer's disease;
LUSC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	0.92	13.73	0.6	2.47e-34	Breast cancer;
LUSC	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs13064411	0.696	rs7619913	chr3:113017503	A/G	cg18753928	chr3:113234510	CCDC52	-0.43	-6.19	-0.32	1.77e-9	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg21100191	chr22:23484243	RTDR1	0.87	14.62	0.62	9.22e-38	Bone mineral density;
LUSC	cis	rs4700695	0.640	rs27083	chr5:65435865	C/T	cg21114390	chr5:65439923	SFRS12	-0.63	-8.93	-0.44	2.93e-17	Facial morphology (factor 19);
LUSC	cis	rs3812762	0.833	rs10500705	chr11:8805261	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.36	-5.92	-0.31	8.14e-9	Hypospadias;
LUSC	cis	rs7674212	0.541	rs11727498	chr4:104100987	C/T	cg16532752	chr4:104119610	CENPE	-0.48	-6.75	-0.35	6.72e-11	Type 2 diabetes;
LUSC	trans	rs11700980	0.551	rs2832030	chr21:30114620	C/T	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs17407555	0.738	rs73212870	chr4:10111798	C/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.27	-0.32	1.15e-9	Schizophrenia (age at onset);
LUSC	cis	rs9653442	0.564	rs4851253	chr2:100762786	T/G	cg22139774	chr2:100720529	AFF3	-0.42	-7.01	-0.36	1.32e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg06108461	chr20:60628389	TAF4	-0.97	-16.57	-0.67	1.97e-45	Body mass index;
LUSC	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg00105475	chr2:10696890	NA	0.38	6.27	0.32	1.11e-9	Prostate cancer;
LUSC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg05872129	chr22:39784769	NA	-0.58	-9.85	-0.47	2.82e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.53	8.83	0.44	5.84e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12210905	0.925	rs11961179	chr6:26994157	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.95	-0.31	6.94e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs9394152	0.817	rs4428487	chr6:33468394	G/A	cg13560919	chr6:33536144	NA	0.6	10.56	0.5	1.11e-22	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9648716	0.515	rs801121	chr7:140745041	G/A	cg23214464	chr7:140373596	ADCK2	-0.72	-6.12	-0.32	2.66e-9	Type 2 diabetes;
LUSC	cis	rs1788820	0.843	rs1788821	chr18:21120869	A/G	cg14672496	chr18:21087552	C18orf8	0.43	6.72	0.35	7.83e-11	Body mass index;
LUSC	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg05501817	chr11:14380813	RRAS2	0.49	7.95	0.4	2.94e-14	Vitamin D levels;
LUSC	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	15.93	0.66	6.95e-43	Lung cancer in ever smokers;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	0.99	21.51	0.76	5.21e-65	Menarche (age at onset);
LUSC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.76	-0.39	1.05e-13	Height;
LUSC	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-5.92	-0.31	8.15e-9	Crohn's disease;
LUSC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	7.74	0.39	1.17e-13	Menarche (age at onset);
LUSC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg02038168	chr22:39784481	NA	-0.44	-6.68	-0.34	1.02e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg02951883	chr7:2050386	MAD1L1	-0.59	-10.72	-0.51	3.01e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg06808227	chr14:105710500	BRF1	-0.66	-10.39	-0.49	4.39e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg27284194	chr4:1044797	NA	0.48	6.88	0.35	2.99e-11	Recombination rate (females);
LUSC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg06600287	chr1:53387719	ECHDC2	-0.28	-5.74	-0.3	2.11e-8	Monocyte count;
LUSC	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg00105475	chr2:10696890	NA	0.36	5.81	0.3	1.46e-8	Prostate cancer;
LUSC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg22907277	chr7:1156413	C7orf50	0.68	7.31	0.37	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.11	0.32	2.8e-9	Corneal astigmatism;
LUSC	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	1.1	17.23	0.69	4.59e-48	Exhaled nitric oxide output;
LUSC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	7.0	0.36	1.45e-11	Platelet count;
LUSC	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18854424	chr1:2615690	NA	0.47	9.26	0.45	2.46e-18	Multiple sclerosis;
LUSC	cis	rs1863824	0.595	rs61859067	chr10:88159997	G/A	cg07322936	chr10:88137208	NA	-0.64	-9.01	-0.44	1.64e-17	Schizophrenia;
LUSC	cis	rs11031096	0.711	rs10835719	chr11:4203906	A/G	cg18678763	chr11:4115507	RRM1	0.39	5.7	0.3	2.57e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg24531977	chr5:56204891	C5orf35	0.56	8.35	0.42	1.8e-15	Coronary artery disease;
LUSC	cis	rs4285028	0.948	rs12488334	chr3:121702526	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-9.06	-0.44	1.11e-17	Multiple sclerosis;
LUSC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg27588902	chr6:42928151	GNMT	-0.29	-6.49	-0.33	3.11e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	0.92	17.72	0.7	5.45e-50	Menarche (age at onset);
LUSC	cis	rs57920188	0.535	rs4295855	chr1:4094993	C/T	cg20703997	chr1:4087676	NA	0.59	8.18	0.41	6.18e-15	Interleukin-17 levels;
LUSC	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg24375607	chr4:120327624	NA	0.78	11.59	0.54	2.37e-26	Corneal astigmatism;
LUSC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.94	0.36	2.04e-11	Cystic fibrosis severity;
LUSC	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.71	-0.34	8.13e-11	Joint mobility (Beighton score);
LUSC	cis	rs728616	0.558	rs61859215	chr10:82151148	G/A	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.8	-0.3	1.57e-8	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs79911532	0.515	rs75257637	chr7:75712848	C/T	cg03592824	chr7:75666768	STYXL1	0.67	6.41	0.33	4.98e-10	Mononucleosis;
LUSC	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg06092702	chr1:163392909	NA	-0.45	-7.37	-0.37	1.39e-12	Motion sickness;
LUSC	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08645402	chr16:4508243	NA	-0.45	-7.09	-0.36	8e-12	Schizophrenia;
LUSC	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg09904177	chr6:26538194	HMGN4	0.66	11.7	0.54	1.01e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs2668423	0.502	rs2074898	chr19:1391361	A/G	cg02639931	chr19:1387894	NDUFS7	-0.69	-14.98	-0.63	3.71e-39	Nonalcoholic fatty liver disease;
LUSC	cis	rs7089973	0.966	rs61867966	chr10:116584362	T/C	cg23260525	chr10:116636907	FAM160B1	0.37	7.06	0.36	9.48e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg19468946	chr17:37922297	IKZF3	-0.43	-6.79	-0.35	5.22e-11	Self-reported allergy;
LUSC	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg26566898	chr11:117069891	TAGLN	0.37	7.02	0.36	1.28e-11	Blood protein levels;
LUSC	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.16e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg15934090	chr1:100435551	SLC35A3	-0.43	-7.44	-0.38	8.6e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-0.78	-12.36	-0.56	3.58e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg18478394	chr8:109455254	TTC35	0.42	6.57	0.34	1.93e-10	Dupuytren's disease;
LUSC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg09074113	chr2:20870087	GDF7	-0.38	-7.85	-0.39	5.75e-14	Abdominal aortic aneurysm;
LUSC	cis	rs921665	0.748	rs1869420	chr2:3202073	C/T	cg16434511	chr2:3151078	NA	-0.58	-5.93	-0.31	7.76e-9	World class endurance athleticism;
LUSC	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg15501526	chr10:2543763	NA	0.55	10.24	0.49	1.44e-21	Age-related hearing impairment;
LUSC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg03609598	chr5:56110824	MAP3K1	-0.41	-5.84	-0.3	1.25e-8	Initial pursuit acceleration;
LUSC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg17911788	chr17:44343683	NA	-0.44	-8.01	-0.4	1.9e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs965604	1.000	rs8042238	chr15:78774271	C/T	cg18825076	chr15:78729989	IREB2	-0.43	-6.88	-0.35	3.03e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	6.04	0.31	4.11e-9	Parkinson's disease;
LUSC	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-7.21	-0.37	3.77e-12	Monocyte percentage of white cells;
LUSC	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg20302533	chr7:39170763	POU6F2	0.51	7.94	0.4	3.05e-14	IgG glycosylation;
LUSC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.92	-0.81	3.6e-78	Height;
LUSC	cis	rs4400599	0.618	rs2220390	chr1:154233016	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-6.08	-0.32	3.36e-9	Platelet distribution width;
LUSC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.17	-0.41	6.24e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg13010199	chr12:38710504	ALG10B	0.57	9.09	0.45	9.21e-18	Morning vs. evening chronotype;
LUSC	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg05110241	chr16:68378359	PRMT7	-0.52	-6.21	-0.32	1.6e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9462027	0.606	rs2815001	chr6:34634353	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.08	-0.32	3.24e-9	Systemic lupus erythematosus;
LUSC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.43	0.38	9.46e-13	Bipolar disorder;
LUSC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg14668632	chr7:2872130	GNA12	0.46	6.88	0.35	2.99e-11	Height;
LUSC	trans	rs7939886	0.920	rs1031978	chr11:55965641	G/T	cg03929089	chr4:120376271	NA	0.81	6.11	0.32	2.73e-9	Myopia (pathological);
LUSC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg18512352	chr11:47633146	NA	-0.46	-9.21	-0.45	3.73e-18	Subjective well-being;
LUSC	cis	rs6484504	0.600	rs1323738	chr11:31344898	T/C	cg06552810	chr11:31128660	NA	0.39	6.77	0.35	5.8e-11	Red blood cell count;
LUSC	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg15704280	chr7:45808275	SEPT13	0.77	8.54	0.42	4.87e-16	Axial length;
LUSC	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg08807101	chr21:30365312	RNF160	0.65	10.11	0.48	3.86e-21	Pancreatic cancer;
LUSC	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg25237894	chr2:233734115	C2orf82	0.35	6.55	0.34	2.23e-10	Coronary artery disease;
LUSC	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg06219351	chr7:158114137	PTPRN2	-0.53	-8.41	-0.42	1.21e-15	Response to amphetamines;
LUSC	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.25	-0.32	1.23e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs68092024	0.731	rs793479	chr3:99488232	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-6.14	-0.32	2.31e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs2274273	0.662	rs66476033	chr14:55660863	C/A	cg04306507	chr14:55594613	LGALS3	0.48	9.67	0.47	1.2e-19	Protein biomarker;
LUSC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg16049864	chr8:95962084	TP53INP1	-0.56	-10.15	-0.49	2.93e-21	Type 2 diabetes;
LUSC	cis	rs17155006	0.783	rs410286	chr7:107749257	A/T	cg05962710	chr7:107745446	LAMB4	-0.36	-6.52	-0.34	2.57e-10	Pneumococcal bacteremia;
LUSC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.65	-0.71	1.04e-53	Height;
LUSC	cis	rs11997175	0.545	rs66783231	chr8:33811467	A/T	ch.8.33884649F	chr8:33765107	NA	0.47	6.93	0.35	2.12e-11	Body mass index;
LUSC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs7246967	0.673	rs12978794	chr19:22812134	C/T	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg08798685	chr6:27730294	NA	-0.63	-5.93	-0.31	7.45e-9	Depression;
LUSC	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg05855489	chr10:104503620	C10orf26	0.6	9.68	0.47	1.11e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.69	-12.68	-0.57	2.3e-30	Extrinsic epigenetic age acceleration;
LUSC	trans	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.77	0.35	5.73e-11	Monocyte count;
LUSC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg21770322	chr7:97807741	LMTK2	0.4	7.0	0.36	1.44e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18854424	chr1:2615690	NA	0.51	10.5	0.5	1.82e-22	Ulcerative colitis;
LUSC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg21643547	chr1:205240462	TMCC2	-0.44	-7.93	-0.4	3.35e-14	Red blood cell count;
LUSC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg24642844	chr7:1081250	C7orf50	-0.69	-9.81	-0.47	3.94e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	12.92	0.58	3.05e-31	Platelet count;
LUSC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.75	0.39	1.11e-13	Bipolar disorder;
LUSC	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg05425664	chr17:57184151	TRIM37	-0.49	-7.35	-0.37	1.51e-12	Testicular germ cell tumor;
LUSC	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg12615879	chr12:58013172	SLC26A10	-0.26	-5.8	-0.3	1.54e-8	Multiple sclerosis;
LUSC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.79	14.5	0.62	2.72e-37	Gestational age at birth (maternal effect);
LUSC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg27529037	chr20:44575021	PCIF1	0.4	6.99	0.36	1.49e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6840360	1.000	rs4696111	chr4:152671405	T/C	cg22705602	chr4:152727874	NA	-0.27	-5.92	-0.31	8.09e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg10792982	chr14:105748885	BRF1	0.52	9.43	0.46	7.25e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs28655083	0.957	rs2171096	chr16:77079043	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-6.83	-0.35	3.99e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22496380	chr5:211416	CCDC127	-0.87	-8.95	-0.44	2.56e-17	Breast cancer;
LUSC	cis	rs4654899	0.758	rs6690574	chr1:21504279	G/A	cg01072550	chr1:21505969	NA	-0.54	-8.22	-0.41	4.67e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs225245	0.755	rs226441	chr17:34033072	C/T	cg05299278	chr17:33885742	SLFN14	0.3	6.67	0.34	1.08e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg06609049	chr19:2785107	THOP1	1.15	22.39	0.77	1.92e-68	Total cholesterol levels;
LUSC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-6.9	-0.35	2.59e-11	Alzheimer's disease (late onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02356872	chr19:49617495	LIN7B	-0.48	-6.6	-0.34	1.6e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21897817	chr19:50432804	NUP62;IL4I1;ATF5	-0.4	-6.12	-0.32	2.6e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.68	-0.43	1.83e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7674212	0.541	rs2623064	chr4:104030792	C/A	cg16532752	chr4:104119610	CENPE	-0.49	-6.82	-0.35	4.2e-11	Type 2 diabetes;
LUSC	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg05855489	chr10:104503620	C10orf26	0.6	9.56	0.46	2.74e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs61990749	0.544	rs8003979	chr14:78211290	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	6.59	0.34	1.76e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs55665837	0.539	rs10500804	chr11:14910273	A/C	cg19336497	chr11:14380999	RRAS2	-0.38	-6.91	-0.35	2.47e-11	Vitamin D levels;
LUSC	trans	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.27	-0.32	1.09e-9	Morning vs. evening chronotype;
LUSC	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17916960	chr15:79447300	NA	-0.52	-10.31	-0.49	8.12e-22	Refractive error;
LUSC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.38	0.42	1.53e-15	Bipolar disorder;
LUSC	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg21545522	chr1:205238299	TMCC2	0.48	8.99	0.44	1.83e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg05340658	chr4:99064831	C4orf37	-0.41	-6.48	-0.33	3.32e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.49	-0.42	6.81e-16	Platelet count;
LUSC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg07424592	chr7:64974309	NA	0.69	6.19	0.32	1.81e-9	Diabetic kidney disease;
LUSC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	0.93	15.94	0.66	6.18e-43	Menopause (age at onset);
LUSC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg21782813	chr7:2030301	MAD1L1	0.37	6.27	0.32	1.13e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg00750074	chr16:89608354	SPG7	-0.45	-7.75	-0.39	1.11e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.53	-10.58	-0.5	9.77e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs2070433	0.800	rs11702190	chr21:47877367	C/T	cg12379764	chr21:47803548	PCNT	0.78	9.92	0.48	1.67e-20	Lymphocyte counts;
LUSC	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg21643547	chr1:205240462	TMCC2	0.36	6.84	0.35	3.88e-11	Red blood cell count;
LUSC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg00945038	chr17:61921165	SMARCD2	-0.38	-5.85	-0.3	1.18e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg09021430	chr5:549028	NA	-0.55	-7.09	-0.36	7.87e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs11031096	0.711	rs11031156	chr11:4179021	C/T	cg18678763	chr11:4115507	RRM1	-0.4	-5.64	-0.3	3.54e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.33	0.53	2.12e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg21033440	chr11:65409861	SIPA1	-0.55	-7.54	-0.38	4.47e-13	Blood pressure (age interaction);
LUSC	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.33	-0.41	2.19e-15	Rheumatoid arthritis;
LUSC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.25	-0.41	3.75e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg09835421	chr16:68378352	PRMT7	-0.51	-6.28	-0.32	1.06e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg05552183	chr6:42928497	GNMT	0.48	8.2	0.41	5.1e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg06917634	chr15:78832804	PSMA4	-0.42	-5.88	-0.31	1.02e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	0.97	13.2	0.59	2.63e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg24375607	chr4:120327624	NA	0.7	11.42	0.53	1.04e-25	Corneal astigmatism;
LUSC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg20476274	chr7:133979776	SLC35B4	0.87	16.91	0.68	8.63e-47	Mean platelet volume;
LUSC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.96	0.77	8.44e-67	Prudent dietary pattern;
LUSC	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg06636001	chr8:8085503	FLJ10661	0.53	7.9	0.4	3.97e-14	Retinal vascular caliber;
LUSC	cis	rs12940923	1.000	rs11867412	chr17:56382512	C/T	cg19466818	chr17:56409534	MIR142	-0.38	-6.57	-0.34	1.92e-10	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-6.64	-0.34	1.27e-10	Total cholesterol levels;
LUSC	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.71	-11.17	-0.52	7.69e-25	Alcohol dependence;
LUSC	cis	rs7927771	0.524	rs6485763	chr11:47627302	C/T	cg20307385	chr11:47447363	PSMC3	0.45	6.5	0.34	2.89e-10	Subjective well-being;
LUSC	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg09835421	chr16:68378352	PRMT7	0.75	8.49	0.42	7.01e-16	Schizophrenia;
LUSC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg14440974	chr22:39074834	NA	-0.38	-6.31	-0.33	8.64e-10	Menopause (age at onset);
LUSC	cis	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.56	-0.34	2.01e-10	Morning vs. evening chronotype;
LUSC	cis	rs25645	0.502	rs7207600	chr17:38091660	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.53	-8.5	-0.42	6.25e-16	Myeloid white cell count;
LUSC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.73	-12.8	-0.57	8.73e-31	Personality dimensions;
LUSC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05665937	chr4:1216051	CTBP1	0.43	6.86	0.35	3.35e-11	Obesity-related traits;
LUSC	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.85	18.47	0.71	5.57e-53	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	0.82	12.42	0.56	2.16e-29	Gut microbiome composition (summer);
LUSC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg17420585	chr12:42539391	GXYLT1	-0.34	-6.5	-0.33	3e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg18512352	chr11:47633146	NA	-0.46	-9.22	-0.45	3.55e-18	Subjective well-being;
LUSC	cis	rs7043114	0.507	rs10992340	chr9:95209693	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.36	-0.33	6.67e-10	Height;
LUSC	cis	rs9311676	0.632	rs11130631	chr3:58366128	G/C	cg13750441	chr3:58318267	PXK	0.35	6.76	0.35	6.33e-11	Systemic lupus erythematosus;
LUSC	trans	rs9944715	0.954	rs12962307	chr18:43815420	A/T	cg01718231	chr17:29326311	RNF135	-0.5	-7.07	-0.36	9.28e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg04310649	chr10:35416472	CREM	-0.43	-6.64	-0.34	1.27e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg09877947	chr5:131593287	PDLIM4	-0.46	-7.01	-0.36	1.33e-11	Blood metabolite levels;
LUSC	cis	rs9323205	0.731	rs56024569	chr14:51697655	A/G	cg23942311	chr14:51606299	NA	-0.45	-8.52	-0.42	5.51e-16	Cancer;
LUSC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg22535103	chr8:58192502	C8orf71	-0.66	-7.36	-0.37	1.42e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs12681287	0.640	rs13252046	chr8:87477751	G/T	cg27223183	chr8:87520930	FAM82B	-0.53	-7.16	-0.36	5.04e-12	Caudate activity during reward;
LUSC	trans	rs2048656	0.523	rs1976673	chr8:9679780	T/A	cg15556689	chr8:8085844	FLJ10661	0.48	6.73	0.35	7.29e-11	Schizophrenia;
LUSC	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg17173187	chr15:85201210	NMB	0.44	8.08	0.4	1.23e-14	Schizophrenia;
LUSC	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg14458575	chr2:238380390	NA	0.59	6.95	0.36	1.94e-11	Prostate cancer;
LUSC	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05901451	chr6:126070800	HEY2	-0.5	-7.88	-0.4	4.65e-14	Endometrial cancer;
LUSC	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.41	-0.33	5.01e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg01966878	chr4:90757139	SNCA	-0.34	-5.85	-0.31	1.15e-8	Dementia with Lewy bodies;
LUSC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	6.07	0.32	3.48e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9925964	0.804	rs9926533	chr16:31014179	C/T	cg02466173	chr16:30829666	NA	0.32	5.8	0.3	1.55e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1712517	0.771	rs2008530	chr10:105058839	G/A	cg05636881	chr10:105038444	INA	0.38	6.21	0.32	1.61e-9	Migraine;
LUSC	cis	rs28830936	0.966	rs28680296	chr15:42121538	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.85	-0.31	1.15e-8	Diastolic blood pressure;
LUSC	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg23649088	chr2:200775458	C2orf69	0.52	8.12	0.41	9.23e-15	Osteoporosis;
LUSC	cis	rs2290159	0.747	rs6777175	chr3:12646255	A/T	cg23032965	chr3:12705835	RAF1	0.71	8.68	0.43	1.75e-16	Cholesterol, total;
LUSC	trans	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg24313572	chr1:56050060	NA	-0.31	-6.38	-0.33	5.9e-10	Morning vs. evening chronotype;
LUSC	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.33e-21	Lymphocyte counts;
LUSC	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.21	-13.94	-0.61	4.07e-35	Diabetic kidney disease;
LUSC	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.83	0.44	5.91e-17	Schizophrenia;
LUSC	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg06636551	chr8:101224915	SPAG1	-0.4	-7.41	-0.38	1.06e-12	Atrioventricular conduction;
LUSC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg11247378	chr22:39784982	NA	-0.62	-11.22	-0.52	5.2e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg21827317	chr3:136751795	NA	0.39	6.91	0.35	2.41e-11	Neuroticism;
LUSC	cis	rs7712401	0.686	rs154511	chr5:122195554	T/A	cg19077854	chr5:122220652	SNX24	0.32	7.19	0.37	4.32e-12	Mean platelet volume;
LUSC	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.55	-0.38	4.17e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg18187862	chr3:45730750	SACM1L	0.55	7.05	0.36	1.02e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg24110177	chr3:50126178	RBM5	-0.41	-6.08	-0.32	3.23e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00552226	chr2:70475288	TIA1	0.4	5.96	0.31	6.58e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs896854	0.573	rs13271375	chr8:95853907	A/G	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.57	-0.42	4e-16	Type 2 diabetes;
LUSC	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg19784903	chr17:45786737	TBKBP1	-0.46	-6.79	-0.35	5.19e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.98	0.36	1.57e-11	Lung cancer in ever smokers;
LUSC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg20203395	chr5:56204925	C5orf35	0.41	6.11	0.32	2.81e-9	Coronary artery disease;
LUSC	cis	rs6845621	0.901	rs1452553	chr4:18920030	C/G	cg12196642	chr4:18937545	NA	-0.33	-6.46	-0.33	3.69e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.17	14.79	0.63	1.99e-38	Lung cancer in ever smokers;
LUSC	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg04362960	chr10:104952993	NT5C2	0.61	9.53	0.46	3.35e-19	Arsenic metabolism;
LUSC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg23815491	chr16:72088622	HP	0.34	5.93	0.31	7.76e-9	Fibrinogen levels;
LUSC	cis	rs80130819	0.515	rs1793917	chr12:48384944	A/T	cg24011408	chr12:48396354	COL2A1	0.51	6.38	0.33	5.94e-10	Prostate cancer;
LUSC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-6.36	-0.33	6.49e-10	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08677398	chr8:58056175	NA	0.53	6.36	0.33	6.53e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00166722	chr3:10149974	C3orf24	0.6	8.39	0.42	1.4e-15	Alzheimer's disease;
LUSC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg21724239	chr8:58056113	NA	-0.54	-5.72	-0.3	2.31e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.45	0.53	7.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg05791153	chr7:19748676	TWISTNB	-1.1	-11.46	-0.53	7.04e-26	Thyroid stimulating hormone;
LUSC	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	1.1	14.47	0.62	3.47e-37	Nonalcoholic fatty liver disease;
LUSC	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.22	-0.41	4.66e-15	Neuroticism;
LUSC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.69	8.71	0.43	1.39e-16	Menarche (age at onset);
LUSC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg19773385	chr1:10388646	KIF1B	-0.5	-8.74	-0.43	1.19e-16	Hepatocellular carcinoma;
LUSC	trans	rs1941687	0.797	rs6507069	chr18:31393188	C/G	cg27147174	chr7:100797783	AP1S1	-0.44	-6.45	-0.33	3.83e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22269486	chr8:27630099	CCDC25	-0.42	-6.25	-0.32	1.26e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9660992	1.000	rs9660992	chr1:205249450	A/G	cg00857998	chr1:205179979	DSTYK	0.44	6.6	0.34	1.61e-10	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg09904177	chr6:26538194	HMGN4	0.66	11.72	0.54	8.26e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg00982548	chr2:198649783	BOLL	-0.56	-7.01	-0.36	1.36e-11	Ulcerative colitis;
LUSC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-0.8	-12.96	-0.58	2.11e-31	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg03929089	chr4:120376271	NA	0.54	6.59	0.34	1.68e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg13736514	chr6:26305472	NA	-0.47	-9.38	-0.46	1.07e-18	Educational attainment;
LUSC	trans	rs7581030	0.538	rs4852777	chr2:71534161	G/C	cg06465196	chr4:154387603	KIAA0922	0.42	6.03	0.31	4.3e-9	Testicular germ cell tumor;
LUSC	trans	rs61931739	0.591	rs1608907	chr12:33945435	A/G	cg26384229	chr12:38710491	ALG10B	0.52	7.77	0.39	1e-13	Morning vs. evening chronotype;
LUSC	cis	rs2179367	0.568	rs9498358	chr6:149779665	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.37	-6.13	-0.32	2.53e-9	Dupuytren's disease;
LUSC	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg05343316	chr1:45956843	TESK2	0.61	8.61	0.43	2.97e-16	Platelet count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06456258	chr22:39898429	SMCR7L	-0.42	-6.39	-0.33	5.49e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg08392591	chr16:89556376	ANKRD11	0.5	7.84	0.39	6.01e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg18357645	chr12:58087776	OS9	0.43	6.51	0.34	2.83e-10	Multiple sclerosis;
LUSC	cis	rs7202877	0.519	rs3743606	chr16:75335474	C/A	cg03315344	chr16:75512273	CHST6	0.44	6.07	0.32	3.46e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg26893861	chr17:41843967	DUSP3	0.88	13.71	0.6	3.12e-34	Triglycerides;
LUSC	cis	rs7241530	0.662	rs6506753	chr18:75904851	G/A	cg14642773	chr18:75888474	NA	0.39	6.0	0.31	5.05e-9	Educational attainment (years of education);
LUSC	cis	rs9818941	0.748	rs12634315	chr3:157728016	T/C	cg08654915	chr3:157813417	NA	-0.32	-7.39	-0.37	1.23e-12	Height;
LUSC	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	8.43	0.42	1.02e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg03342759	chr3:160939853	NMD3	-0.37	-5.65	-0.3	3.44e-8	Educational attainment (years of education);
LUSC	cis	rs7119038	0.731	rs28409215	chr11:118679304	G/A	cg19308663	chr11:118741387	NA	0.36	6.44	0.33	4.09e-10	Sjögren's syndrome;
LUSC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.35	0.37	1.5e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg06784218	chr1:46089804	CCDC17	0.48	9.35	0.46	1.3e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11997175	0.646	rs7005018	chr8:33700210	A/G	ch.8.33884649F	chr8:33765107	NA	0.45	6.65	0.34	1.2e-10	Body mass index;
LUSC	cis	rs2445762	0.642	rs8025191	chr15:51623785	A/G	cg07517944	chr15:51633816	GLDN	0.41	6.81	0.35	4.42e-11	Hormone measurements;
LUSC	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.29	-6.02	-0.31	4.48e-9	Cystic fibrosis severity;
LUSC	cis	rs983392	0.631	rs7107627	chr11:60041296	T/A	cg24026212	chr11:59952134	MS4A6A	0.37	6.36	0.33	6.66e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.06	20.5	0.75	4.82e-61	Cognitive ability;
LUSC	cis	rs9788721	0.640	rs1394371	chr15:78724469	C/T	cg18825076	chr15:78729989	IREB2	-0.55	-8.36	-0.42	1.72e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	0.71	11.46	0.53	7.19e-26	Blood metabolite ratios;
LUSC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg18132916	chr6:79620363	NA	-0.38	-5.83	-0.3	1.28e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg04998671	chr14:104000505	TRMT61A	0.4	5.88	0.31	1.01e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg09796270	chr17:17721594	SREBF1	-0.42	-7.27	-0.37	2.54e-12	Total body bone mineral density;
LUSC	trans	rs17133449	0.696	rs10904325	chr10:4751327	G/T	cg17844448	chr7:27782764	TAX1BP1	0.4	6.63	0.34	1.38e-10	Major depressive disorder;
LUSC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13721600	chr17:29151762	CRLF3	0.87	7.55	0.38	4.2e-13	Cognitive performance;
LUSC	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg16473166	chr22:50639996	SELO	0.66	9.31	0.45	1.72e-18	Obesity-related traits;
LUSC	cis	rs60154123	0.730	rs679042	chr1:210457122	A/G	cg22029157	chr1:209979665	IRF6	0.52	5.96	0.31	6.32e-9	Coronary artery disease;
LUSC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-7.1	-0.36	7.45e-12	Alzheimer's disease (late onset);
LUSC	cis	rs3849570	1.000	rs7638516	chr3:81826249	A/C	cg07356753	chr3:81810745	GBE1	-0.57	-9.04	-0.44	1.26e-17	Waist circumference;Body mass index;
LUSC	trans	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.38	-0.33	5.77e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4566357	1.000	rs3765192	chr2:227927536	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.79	-0.3	1.61e-8	Coronary artery disease;
LUSC	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg04607235	chr12:12878440	APOLD1	-0.56	-6.38	-0.33	5.81e-10	Systemic lupus erythematosus;
LUSC	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg04827223	chr11:72435913	ARAP1	-0.71	-8.97	-0.44	2.19e-17	Type 2 diabetes;
LUSC	cis	rs1971762	0.523	rs7135101	chr12:54080605	G/A	cg23533419	chr12:54090519	NA	-0.38	-6.2	-0.32	1.64e-9	Height;
LUSC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg18758796	chr5:131593413	PDLIM4	0.4	6.73	0.35	7.29e-11	Breast cancer;
LUSC	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg09365446	chr1:150670422	GOLPH3L	0.51	7.5	0.38	5.68e-13	Melanoma;
LUSC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.93	0.31	7.57e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg09184832	chr6:79620586	NA	-0.43	-6.97	-0.36	1.66e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08677398	chr8:58056175	NA	0.53	6.98	0.36	1.61e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs9811920	0.965	rs9849632	chr3:99867211	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	6.87	0.35	3.18e-11	Axial length;
LUSC	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg24692254	chr21:30365293	RNF160	-0.55	-6.79	-0.35	5.11e-11	Cognitive test performance;
LUSC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg24881330	chr22:46731750	TRMU	0.89	8.95	0.44	2.52e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg13010199	chr12:38710504	ALG10B	-0.4	-6.01	-0.31	4.99e-9	Morning vs. evening chronotype;
LUSC	cis	rs7246967	0.673	rs7254097	chr19:22865900	T/G	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20637919	chr8:12613290	LONRF1	0.74	6.59	0.34	1.73e-10	Cognitive performance;
LUSC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.25	-14.44	-0.62	4.77e-37	Gout;
LUSC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg26380479	chr7:97908229	NA	-0.28	-6.37	-0.33	6.43e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	trans	rs12210905	1.000	rs9348756	chr6:27228259	G/A	cg11837749	chr1:55047332	ACOT11	0.59	5.96	0.31	6.42e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.77	-10.43	-0.5	3.05e-22	Coronary artery disease;
LUSC	cis	rs76878669	0.561	rs11823140	chr11:66098322	G/T	cg18002602	chr11:66138449	SLC29A2	-0.44	-7.7	-0.39	1.51e-13	Educational attainment (years of education);
LUSC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg12463550	chr7:65579703	CRCP	0.51	7.37	0.37	1.33e-12	Aortic root size;
LUSC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.6	-7.53	-0.38	4.69e-13	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg15352829	chr14:105391018	PLD4	0.41	8.49	0.42	6.99e-16	Rheumatoid arthritis;
LUSC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg12463550	chr7:65579703	CRCP	0.46	6.79	0.35	5.29e-11	Aortic root size;
LUSC	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg24112000	chr20:60950667	NA	-0.48	-9.41	-0.46	8.19e-19	Colorectal cancer;
LUSC	cis	rs2667011	0.818	rs2715923	chr2:160845721	A/G	cg06573604	chr2:160760825	LY75	0.49	6.49	0.33	3.16e-10	Bilirubin levels;
LUSC	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.36	6.93	0.35	2.24e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	8.56	0.42	4.06e-16	Motion sickness;
LUSC	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg20607287	chr7:12443886	VWDE	-0.59	-6.06	-0.31	3.64e-9	Coronary artery disease;
LUSC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.24	-0.37	3.21e-12	Blood metabolite levels;
LUSC	trans	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg07393940	chr7:158741817	NA	0.37	6.7	0.34	8.88e-11	Life satisfaction;
LUSC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	13.69	0.6	3.45e-34	Alzheimer's disease;
LUSC	cis	rs3126085	0.935	rs12027807	chr1:152253726	C/G	cg26876637	chr1:152193138	HRNR	0.46	6.38	0.33	6.03e-10	Atopic dermatitis;
LUSC	cis	rs4474465	1.000	rs7929712	chr11:78158542	T/C	cg27205649	chr11:78285834	NARS2	-0.5	-5.94	-0.31	7.09e-9	Alzheimer's disease (survival time);
LUSC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg00129232	chr17:37814104	STARD3	-0.4	-5.83	-0.3	1.31e-8	Asthma;
LUSC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.6	0.47	1.97e-19	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg22535103	chr8:58192502	C8orf71	-0.75	-7.79	-0.39	8.27e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg23505145	chr19:12996616	KLF1	0.63	10.59	0.5	8.41e-23	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg04036182	chr15:45458818	NA	0.35	5.75	0.3	2.01e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg14835575	chr10:16859367	RSU1	0.72	9.38	0.46	1.06e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	trans	rs2700987	0.669	rs10279336	chr7:37389523	G/A	cg26076750	chr5:98105150	RGMB	-0.36	-6.58	-0.34	1.86e-10	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14169450	chr9:139327907	INPP5E	-0.46	-8.27	-0.41	3.29e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6500395	0.963	rs6500405	chr16:48690486	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	0.59	9.25	0.45	2.75e-18	Breast cancer;
LUSC	cis	rs2708977	0.842	rs10209780	chr2:97140142	T/G	cg01950434	chr2:97203154	ARID5A	-0.53	-7.8	-0.39	7.89e-14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs2073300	1.000	rs6048826	chr20:23458050	C/A	cg09953122	chr20:23471693	CST8	-0.69	-6.87	-0.35	3.24e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-10.37	-0.49	4.98e-22	Schizophrenia;
LUSC	trans	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.19	-0.45	4.27e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg14092988	chr3:52407081	DNAH1	0.33	5.86	0.31	1.1e-8	Bipolar disorder;
LUSC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11764359	chr7:65958608	NA	0.68	10.95	0.51	4.86e-24	Aortic root size;
LUSC	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg20821713	chr7:1055600	C7orf50	-0.55	-6.79	-0.35	5.2e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg09307838	chr4:120376055	NA	-0.45	-6.72	-0.34	8e-11	Diastolic blood pressure;
LUSC	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg03522245	chr20:25566470	NINL	0.36	5.75	0.3	2.05e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9467773	0.626	rs9379860	chr6:26370605	T/C	cg09904177	chr6:26538194	HMGN4	-0.49	-7.74	-0.39	1.19e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.98	0.31	5.72e-9	Menopause (age at onset);
LUSC	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg18190219	chr22:46762943	CELSR1	-0.55	-6.28	-0.33	1.05e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg24154853	chr7:158122151	PTPRN2	0.35	5.77	0.3	1.82e-8	Response to amphetamines;
LUSC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg16405210	chr4:1374714	KIAA1530	-0.53	-8.02	-0.4	1.84e-14	Obesity-related traits;
LUSC	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg09699651	chr6:150184138	LRP11	0.38	5.9	0.31	8.9e-9	Testicular germ cell tumor;
LUSC	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg01420254	chr6:26195488	NA	0.68	7.52	0.38	5.21e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg02493740	chr2:85810744	VAMP5	-0.52	-9.02	-0.44	1.49e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs11024102	1.000	rs10766368	chr11:17014882	G/C	cg15084286	chr11:17036142	PLEKHA7	0.45	6.08	0.32	3.22e-9	Glaucoma (primary angle closure);
LUSC	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg04362960	chr10:104952993	NT5C2	0.59	9.34	0.45	1.43e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7674212	0.541	rs4699051	chr4:104114394	T/C	cg16532752	chr4:104119610	CENPE	-0.49	-7.08	-0.36	8.68e-12	Type 2 diabetes;
LUSC	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.54	9.71	0.47	8.49e-20	Bone mineral density;
LUSC	cis	rs911119	1.000	rs67567111	chr20:23619075	G/T	cg16589663	chr20:23618590	CST3	0.6	7.08	0.36	8.36e-12	Chronic kidney disease;
LUSC	trans	rs7657257	1.000	rs16892283	chr4:15731534	A/G	cg17675199	chr6:35436792	RPL10A	-0.84	-6.08	-0.32	3.37e-9	Blood protein levels;
LUSC	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg02466173	chr16:30829666	NA	0.56	11.3	0.53	2.63e-25	Dementia with Lewy bodies;
LUSC	cis	rs17401966	0.540	rs4846219	chr1:10463888	C/A	cg19773385	chr1:10388646	KIF1B	-0.41	-7.1	-0.36	7.74e-12	Hepatocellular carcinoma;
LUSC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg26587870	chr6:27730563	NA	-0.66	-5.92	-0.31	8.07e-9	Depression;
LUSC	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg17145862	chr1:211918768	LPGAT1	0.23	6.1	0.32	2.97e-9	Leprosy;
LUSC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-6.93	-0.35	2.19e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg01973587	chr1:228161476	NA	-0.35	-5.65	-0.3	3.5e-8	Diastolic blood pressure;
LUSC	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg05373962	chr22:49881684	NA	-0.44	-10.74	-0.51	2.5e-23	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg11245181	chr6:149772854	ZC3H12D	-0.31	-6.66	-0.34	1.13e-10	Dupuytren's disease;
LUSC	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.21	-0.32	1.59e-9	Neutrophil percentage of white cells;
LUSC	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.25	0.32	1.25e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6537837	0.838	rs6663547	chr1:110114229	A/C	cg05049280	chr1:110155535	GNAT2	0.46	6.28	0.33	1.03e-9	Major depressive disorder;
LUSC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg04362960	chr10:104952993	NT5C2	0.53	6.5	0.34	2.92e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg12560992	chr17:57184187	TRIM37	0.83	15.3	0.64	2e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg23711669	chr6:146136114	FBXO30	0.86	16.1	0.66	1.47e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg06454157	chr6:167490870	NA	-0.27	-6.64	-0.34	1.28e-10	Primary biliary cholangitis;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg16671877	chr6:116421702	NT5DC1	0.39	6.18	0.32	1.88e-9	Triglycerides;
LUSC	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-9.69	-0.47	1.03e-19	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6722750	0.716	rs2037863	chr2:64416263	G/A	cg22352474	chr2:64371530	PELI1	-0.53	-7.96	-0.4	2.76e-14	Neuroticism;
LUSC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.81	13.73	0.6	2.53e-34	Monocyte count;
LUSC	cis	rs3818285	0.679	rs2475275	chr10:111633979	C/T	cg00817464	chr10:111662876	XPNPEP1	0.73	12.94	0.58	2.55e-31	Superior crus of antihelix expression;
LUSC	cis	rs7678296	0.649	rs60691639	chr4:37239925	T/C	cg06805348	chr4:37245195	KIAA1239	0.58	5.93	0.31	7.46e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg06671706	chr8:8559999	CLDN23	-0.44	-5.92	-0.31	7.81e-9	Obesity-related traits;
LUSC	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg20701182	chr2:24300061	SF3B14	0.57	6.01	0.31	4.78e-9	Lymphocyte counts;
LUSC	trans	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg25214090	chr10:38739885	LOC399744	0.49	7.53	0.38	4.82e-13	Corneal astigmatism;
LUSC	cis	rs7215564	0.908	rs35725122	chr17:78663275	A/T	cg09596252	chr17:78655493	RPTOR	0.53	5.85	0.31	1.15e-8	Myopia (pathological);
LUSC	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.83	10.76	0.51	2.28e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00631329	chr6:26305371	NA	-0.46	-9.18	-0.45	4.58e-18	Educational attainment;
LUSC	cis	rs9392556	0.829	rs649725	chr6:4109593	A/C	cg08342332	chr6:4079704	C6orf201;C6orf146	0.33	5.65	0.3	3.45e-8	Blood metabolite levels;
LUSC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg16797656	chr11:68205561	LRP5	0.4	7.25	0.37	2.99e-12	Total body bone mineral density;
LUSC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	0.87	14.83	0.63	1.38e-38	Tonsillectomy;
LUSC	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07636037	chr3:49044803	WDR6	-0.69	-9.2	-0.45	4.05e-18	Menarche (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13320518	chr10:114207009	VTI1A;ZDHHC6	0.79	6.68	0.34	1.02e-10	Cognitive performance;
LUSC	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg07382826	chr16:28625726	SULT1A1	0.28	6.0	0.31	5.11e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.19	16.51	0.67	3.48e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg03146154	chr1:46216737	IPP	-0.57	-8.28	-0.41	2.94e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	0.94	17.98	0.7	4.92e-51	Heart rate;
LUSC	cis	rs977987	0.806	rs2903033	chr16:75389606	T/A	cg04384234	chr16:75411784	CFDP1	-0.39	-6.17	-0.32	1.95e-9	Dupuytren's disease;
LUSC	cis	rs1256061	0.603	rs1256044	chr14:64734027	G/A	cg23250157	chr14:64679961	SYNE2	0.32	5.71	0.3	2.56e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.19	-0.32	1.74e-9	Bladder cancer;
LUSC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg09455208	chr3:40491958	NA	-0.54	-9.67	-0.47	1.13e-19	Renal cell carcinoma;
LUSC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg06784218	chr1:46089804	CCDC17	0.54	11.15	0.52	9.22e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-8.95	-0.44	2.55e-17	Neuroticism;
LUSC	cis	rs1775715	0.737	rs2799018	chr10:32202069	C/T	cg18675610	chr10:32216311	ARHGAP12	0.31	6.66	0.34	1.12e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	1.03	19.53	0.73	3.31e-57	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.93	0.55	1.49e-27	Prudent dietary pattern;
LUSC	cis	rs7828089	0.744	rs10108011	chr8:22320806	C/T	cg12081754	chr8:22256438	SLC39A14	0.42	6.37	0.33	6.4e-10	Verbal declarative memory;
LUSC	cis	rs1172822	0.665	rs897794	chr19:55831576	A/C	cg04391588	chr19:55832610	TMEM150B	0.29	5.79	0.3	1.65e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg26462404	chr19:2270807	OAZ1	0.43	5.98	0.31	5.68e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg16342193	chr10:102329863	NA	-0.35	-6.39	-0.33	5.63e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg03929089	chr4:120376271	NA	-0.93	-16.14	-0.66	9.76e-44	Height;
LUSC	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg19468946	chr17:37922297	IKZF3	-0.46	-7.32	-0.37	1.88e-12	Self-reported allergy;
LUSC	trans	rs9380880	0.826	rs2273062	chr6:39550935	C/A	cg09045552	chr2:169506620	LASS6	0.73	6.56	0.34	2.11e-10	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg08799069	chr10:126477246	METTL10	0.61	8.22	0.41	4.52e-15	Cocaine dependence;
LUSC	cis	rs7577696	0.962	rs212739	chr2:32404703	A/G	cg02381751	chr2:32503542	YIPF4	0.4	5.77	0.3	1.82e-8	Inflammatory biomarkers;
LUSC	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg21045802	chr8:109455806	TTC35	0.48	7.57	0.38	3.76e-13	Dupuytren's disease;
LUSC	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg17120908	chr11:65337727	SSSCA1	-0.53	-9.23	-0.45	3.22e-18	Bone mineral density;
LUSC	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.55	9.69	0.47	9.98e-20	Birth weight;
LUSC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.06e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg22532475	chr10:104410764	TRIM8	-0.35	-7.76	-0.39	1.01e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.69	-0.43	1.66e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.55	-8.28	-0.41	3.02e-15	Gut microbiome composition (summer);
LUSC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg06618935	chr21:46677482	NA	-0.39	-7.97	-0.4	2.6e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg21775007	chr8:11205619	TDH	-0.65	-10.36	-0.49	5.25e-22	Neuroticism;
LUSC	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg17757837	chr7:157058334	UBE3C	0.82	13.01	0.58	1.35e-31	Body mass index;
LUSC	trans	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg10840412	chr1:235813424	GNG4	0.53	6.39	0.33	5.55e-10	Neuroticism;
LUSC	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-8.1	-0.41	1.05e-14	Height;
LUSC	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg00745463	chr17:30367425	LRRC37B	-0.77	-9.18	-0.45	4.6e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg12463550	chr7:65579703	CRCP	0.5	7.28	0.37	2.41e-12	Aortic root size;
LUSC	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg00074818	chr8:8560427	CLDN23	0.59	9.56	0.46	2.63e-19	Obesity-related traits;
LUSC	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs7246967	0.551	rs56968124	chr19:22814449	T/C	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg23649088	chr2:200775458	C2orf69	-0.56	-6.78	-0.35	5.52e-11	Schizophrenia;
LUSC	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg20587970	chr11:113659929	NA	-1.04	-13.97	-0.61	3.13e-35	Hip circumference adjusted for BMI;
LUSC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg04733989	chr22:42467013	NAGA	0.59	9.16	0.45	5.24e-18	Schizophrenia;
LUSC	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg25024717	chr12:54324583	NA	0.41	6.61	0.34	1.56e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg25204440	chr1:209979598	IRF6	-0.39	-5.73	-0.3	2.2e-8	Monobrow;
LUSC	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.42	5.9	0.31	9.13e-9	Lung cancer;
LUSC	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg04310649	chr10:35416472	CREM	-0.41	-6.49	-0.33	3.13e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg11062466	chr8:58055876	NA	0.65	8.33	0.41	2.12e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22442454	chr1:209979470	IRF6	0.44	5.9	0.31	8.81e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg04287289	chr16:89883240	FANCA	0.77	13.48	0.59	2.32e-33	Vitiligo;
LUSC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-1.07	-25.94	-0.82	4.9e-82	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs73129298	0.515	rs4647955	chr20:48599561	G/C	cg25655593	chr20:48599521	SNAI1	0.59	6.27	0.32	1.11e-9	Inflammatory skin disease;
LUSC	cis	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg02972257	chr16:68554789	NA	-0.44	-5.76	-0.3	1.94e-8	Ulcerative colitis;
LUSC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.97	0.66	4.9e-43	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04643909	chr4:39640571	C4orf34	-0.44	-6.58	-0.34	1.79e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.63	-7.6	-0.38	3.06e-13	Yeast infection;
LUSC	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.08	-0.36	8.81e-12	Response to antipsychotic treatment;
LUSC	cis	rs12541635	1.000	rs1366965	chr8:107085224	T/A	cg10147462	chr8:107024639	NA	-0.47	-8.61	-0.43	2.99e-16	Age of smoking initiation;
LUSC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	0.64	13.57	0.6	1.06e-33	Prudent dietary pattern;
LUSC	cis	rs500891	0.525	rs12524172	chr6:84069668	C/T	cg08257003	chr6:84140564	ME1	0.35	8.62	0.43	2.8e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs2742234	0.541	rs11238476	chr10:43711436	G/T	cg02780029	chr10:43622663	RET	0.34	5.66	0.3	3.23e-8	Hirschsprung disease;
LUSC	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg17052675	chr2:3827356	NA	-0.58	-11.38	-0.53	1.42e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03576123	chr11:487126	PTDSS2	-1.13	-11.88	-0.55	2.18e-27	Body mass index;
LUSC	cis	rs7973719	0.833	rs7962563	chr12:7353514	G/A	cg07052231	chr12:7363540	PEX5	0.54	9.44	0.46	6.79e-19	IgG glycosylation;
LUSC	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.6	10.2	0.49	1.85e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7202877	0.706	rs247434	chr16:75445304	G/A	cg03315344	chr16:75512273	CHST6	-0.46	-6.34	-0.33	7.24e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.12e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.73	9.11	0.45	7.89e-18	Type 2 diabetes;
LUSC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.64	-10.28	-0.49	1.03e-21	Height;
LUSC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4845570	1.000	rs3811415	chr1:151763767	C/T	cg07092448	chr1:151763213	TDRKH	-1.28	-14.39	-0.62	7.46e-37	Coronary artery disease;
LUSC	cis	rs2637266	0.935	rs2579719	chr10:78400026	A/G	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.94e-13	Pulmonary function;
LUSC	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs16976116	0.951	rs6493768	chr15:55484294	T/A	cg11288833	chr15:55489084	RSL24D1	0.54	6.48	0.33	3.35e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-7.53	-0.38	4.65e-13	Fear of minor pain;
LUSC	cis	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg14019146	chr3:50243930	SLC38A3	-0.45	-10.56	-0.5	1.12e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg03351412	chr1:154909251	PMVK	0.51	8.03	0.4	1.7e-14	Prostate cancer;
LUSC	cis	rs11645898	0.504	rs75888697	chr16:71985222	A/C	cg14768367	chr16:72042858	DHODH	-0.59	-5.67	-0.3	3.05e-8	Blood protein levels;
LUSC	trans	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.76	-0.35	6.16e-11	Monocyte count;
LUSC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg05025164	chr4:1340916	KIAA1530	0.48	7.39	0.37	1.17e-12	Obesity-related traits;
LUSC	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg27539214	chr16:67997921	SLC12A4	-0.44	-5.74	-0.3	2.08e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg10018233	chr7:150070692	REPIN1	0.38	6.61	0.34	1.48e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08645402	chr16:4508243	NA	-0.53	-9.14	-0.45	6.15e-18	Schizophrenia;
LUSC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg04455712	chr21:45112962	RRP1B	0.47	8.96	0.44	2.42e-17	Mean corpuscular volume;
LUSC	trans	rs1864729	1.000	rs2583504	chr8:98283404	G/C	cg08679828	chr8:102218111	ZNF706	-0.85	-7.71	-0.39	1.45e-13	Estradiol plasma levels (breast cancer);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00772840	chr19:15490660	AKAP8	-0.41	-6.18	-0.32	1.91e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs75920871	0.528	rs12279066	chr11:116913909	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.37	-0.33	6.26e-10	Subjective well-being;
LUSC	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg27068330	chr11:65405492	SIPA1	0.64	9.66	0.47	1.28e-19	Acne (severe);
LUSC	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-5.97	-0.31	5.92e-9	Ulcerative colitis;
LUSC	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.6	-12.24	-0.56	1.02e-28	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.39	-0.42	1.41e-15	Schizophrenia;
LUSC	cis	rs4780401	0.728	rs8057398	chr16:11780629	G/T	cg01061890	chr16:11836724	TXNDC11	-0.43	-6.0	-0.31	5.21e-9	Rheumatoid arthritis;
LUSC	cis	rs7830933	0.780	rs1561105	chr8:23610799	T/G	cg04349084	chr8:23602677	NA	0.36	5.88	0.31	9.75e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUSC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg03790207	chr6:42947109	PEX6	-0.47	-7.17	-0.37	4.75e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg15423357	chr2:25149977	NA	0.45	9.13	0.45	6.59e-18	Body mass index;
LUSC	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.58	-5.72	-0.3	2.35e-8	Lung cancer in ever smokers;
LUSC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-7.3	-0.37	2.11e-12	Renal function-related traits (BUN);
LUSC	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.95	-18.88	-0.72	1.25e-54	Brugada syndrome;
LUSC	cis	rs7674212	0.507	rs223361	chr4:103769304	T/C	cg16532752	chr4:104119610	CENPE	-0.41	-5.7	-0.3	2.64e-8	Type 2 diabetes;
LUSC	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-0.56	-8.62	-0.43	2.7e-16	Breast cancer;
LUSC	cis	rs62408225	0.722	rs2064870	chr6:90903990	T/C	cg06866423	chr6:90926672	BACH2	0.41	6.49	0.33	3.01e-10	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10802521	chr3:52805072	NEK4	-0.52	-8.38	-0.42	1.51e-15	Bipolar disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01526870	chr12:12510070	LOH12CR1;LOH12CR2	0.81	6.26	0.32	1.21e-9	Cognitive performance;
LUSC	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg22676075	chr6:135203613	NA	0.57	8.91	0.44	3.27e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg04586622	chr2:25135609	ADCY3	0.42	8.96	0.44	2.27e-17	Body mass index;
LUSC	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg05855489	chr10:104503620	C10orf26	0.53	8.19	0.41	5.5e-15	Arsenic metabolism;
LUSC	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg20701182	chr2:24300061	SF3B14	0.88	11.57	0.53	3.02e-26	Lymphocyte counts;
LUSC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6599077	0.950	rs60037145	chr3:40102918	C/T	cg13683864	chr3:40499215	RPL14	-0.61	-7.6	-0.38	3.09e-13	Sleep-related phenotypes;
LUSC	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg22705602	chr4:152727874	NA	-0.37	-8.16	-0.41	6.99e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9815354	1.000	rs28702390	chr3:41889920	C/A	cg03022575	chr3:42003672	ULK4	0.63	6.85	0.35	3.49e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	5.67	0.3	3.15e-8	Schizophrenia;
LUSC	cis	rs11676855	1.000	rs11676855	chr2:235900171	C/T	cg14917874	chr2:235941519	SH3BP4	-0.49	-8.16	-0.41	7.07e-15	Dialysis-related mortality;
LUSC	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.9	12.15	0.55	2.14e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg01503450	chr10:980765	NA	-0.4	-5.81	-0.3	1.45e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg05343316	chr1:45956843	TESK2	0.71	9.62	0.47	1.68e-19	Platelet count;
LUSC	cis	rs6489882	0.867	rs4767031	chr12:113362751	C/G	cg20102336	chr12:113376681	OAS3	-0.41	-5.88	-0.31	9.9e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg24375607	chr4:120327624	NA	-0.72	-10.85	-0.51	1.04e-23	Corneal astigmatism;
LUSC	cis	rs7241530	0.662	rs4799261	chr18:75889293	G/A	cg14642773	chr18:75888474	NA	0.36	6.01	0.31	4.91e-9	Educational attainment (years of education);
LUSC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02034447	chr16:89574710	SPG7	0.44	6.5	0.34	2.89e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg22907277	chr7:1156413	C7orf50	0.68	7.31	0.37	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg25258033	chr6:167368657	RNASET2	0.49	8.1	0.41	1.04e-14	Crohn's disease;
LUSC	cis	rs12618769	0.597	rs3754880	chr2:99132215	G/C	cg10123293	chr2:99228465	UNC50	0.45	7.43	0.38	8.89e-13	Bipolar disorder;
LUSC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.62	-0.43	2.82e-16	Bipolar disorder;
LUSC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-6.13	-0.32	2.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	0.94	18.21	0.71	5.78e-52	Cognitive function;
LUSC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg16262614	chr3:133464971	TF	0.43	7.64	0.39	2.28e-13	Iron status biomarkers;
LUSC	cis	rs116988415	0.584	rs4902310	chr14:65241906	T/C	cg00114569	chr14:65239327	SPTB	0.66	6.4	0.33	5.23e-10	Daytime sleep phenotypes;
LUSC	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg16950941	chr11:66035639	RAB1B	0.48	7.1	0.36	7.32e-12	Gout;
LUSC	cis	rs9311676	0.609	rs62258080	chr3:58367493	G/A	cg13750441	chr3:58318267	PXK	0.36	6.86	0.35	3.33e-11	Systemic lupus erythematosus;
LUSC	cis	rs3772130	0.962	rs13061326	chr3:121493125	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.23	0.49	1.48e-21	Cognitive performance;
LUSC	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg08824895	chr13:115047677	UPF3A	0.54	8.2	0.41	5.38e-15	Schizophrenia;
LUSC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.73	0.35	7.47e-11	Depression;
LUSC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg02018176	chr4:1364513	KIAA1530	0.52	9.14	0.45	6.36e-18	Obesity-related traits;
LUSC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg23719950	chr11:63933701	MACROD1	-0.55	-7.48	-0.38	6.61e-13	Mean platelet volume;
LUSC	cis	rs4561483	0.583	rs11075030	chr16:11976414	C/A	cg08843971	chr16:11963173	GSPT1	0.41	6.25	0.32	1.22e-9	Testicular germ cell tumor;
LUSC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.06	0.58	9.04e-32	Chronic sinus infection;
LUSC	cis	rs4144027	0.791	rs66473563	chr14:104361871	C/T	cg12183467	chr14:104352244	NA	0.3	6.01	0.31	4.97e-9	Blood metabolite levels;
LUSC	cis	rs501916	0.634	rs61333299	chr15:48066806	G/A	cg16110827	chr15:48056943	SEMA6D	-0.38	-5.98	-0.31	5.89e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs3099143	0.908	rs6495222	chr15:77180015	A/C	cg21673338	chr15:77095150	SCAPER	0.81	7.7	0.39	1.56e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg09953122	chr20:23471693	CST8	-0.86	-7.29	-0.37	2.21e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.76	-12.44	-0.56	1.83e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg15448220	chr1:150897856	SETDB1	0.39	5.86	0.31	1.11e-8	Melanoma;
LUSC	cis	rs9650657	0.707	rs10098699	chr8:10676756	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.1	-0.32	2.85e-9	Neuroticism;
LUSC	trans	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg26043149	chr18:55253948	FECH	-0.46	-7.1	-0.36	7.46e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06850241	chr22:41845214	NA	0.34	6.14	0.32	2.38e-9	Vitiligo;
LUSC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-16.89	-0.68	1.11e-46	Monocyte count;
LUSC	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg17470449	chr10:769945	NA	0.48	6.78	0.35	5.58e-11	Uric acid levels;
LUSC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg13560548	chr3:10150139	C3orf24	0.48	6.6	0.34	1.6e-10	Alzheimer's disease;
LUSC	cis	rs11779988	0.545	rs4124900	chr8:17785266	A/G	cg01800426	chr8:17659068	MTUS1	-0.5	-6.12	-0.32	2.67e-9	Breast cancer;
LUSC	cis	rs11871801	0.560	rs8074296	chr17:40583421	A/G	cg16308533	chr17:40838983	CNTNAP1	0.37	5.8	0.3	1.52e-8	Crohn's disease;
LUSC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.64	9.18	0.45	4.63e-18	Diastolic blood pressure;
LUSC	cis	rs9715521	0.677	rs67500083	chr4:59862419	C/T	cg11281224	chr4:60001000	NA	-0.49	-6.84	-0.35	3.81e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg05187965	chr10:45406764	TMEM72	-0.36	-8.47	-0.42	8.17e-16	Mean corpuscular volume;
LUSC	cis	rs7712401	0.791	rs10063253	chr5:122128711	T/C	cg19077854	chr5:122220652	SNX24	0.35	7.85	0.39	5.87e-14	Mean platelet volume;
LUSC	cis	rs3820928	0.874	rs4675131	chr2:227836742	T/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.82	-0.39	6.77e-14	Pulmonary function;
LUSC	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg02466173	chr16:30829666	NA	0.53	9.04	0.44	1.29e-17	Dementia with Lewy bodies;
LUSC	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	9.35	0.46	1.31e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg21545522	chr1:205238299	TMCC2	0.45	8.55	0.42	4.64e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg00539368	chr18:74514137	NA	0.49	6.39	0.33	5.69e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LUSC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg18110333	chr6:292329	DUSP22	-0.51	-7.42	-0.38	9.73e-13	Menopause (age at onset);
LUSC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.03	20.73	0.75	5.92e-62	Cognitive function;
LUSC	cis	rs4363385	0.765	rs3806221	chr1:153002555	G/T	cg25856811	chr1:152973957	SPRR3	-0.36	-5.94	-0.31	6.97e-9	Inflammatory skin disease;
LUSC	cis	rs887829	0.641	rs10197460	chr2:234589190	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.41	-6.6	-0.34	1.6e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs6516091	0.850	rs62199228	chr20:6047655	G/A	cg25325723	chr20:6104886	FERMT1	-0.69	-7.21	-0.37	3.74e-12	Abdominal aortic aneurysm;
LUSC	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg22029157	chr1:209979665	IRF6	0.51	8.2	0.41	5.07e-15	Monobrow;
LUSC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.95	0.55	1.23e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg01528321	chr10:82214614	TSPAN14	1.01	15.25	0.64	3.34e-40	Post bronchodilator FEV1;
LUSC	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.66	-8.97	-0.44	2.15e-17	Large artery stroke;
LUSC	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg03929089	chr4:120376271	NA	-0.44	-6.15	-0.32	2.24e-9	HDL cholesterol;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05821866	chr1:167905319	DCAF6;BRP44	0.46	6.5	0.34	2.99e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2274273	1.000	rs3742566	chr14:55595839	T/A	cg04306507	chr14:55594613	LGALS3	0.53	11.37	0.53	1.48e-25	Protein biomarker;
LUSC	cis	rs2279817	0.820	rs12754031	chr1:18006619	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.12	-0.32	2.68e-9	Neuroticism;
LUSC	cis	rs10779751	1.000	rs11121706	chr1:11302065	C/T	cg08854313	chr1:11322531	MTOR	0.82	13.45	0.59	3.08e-33	Body mass index;
LUSC	cis	rs7572644	0.665	rs4493211	chr2:28039472	G/T	cg27432699	chr2:27873401	GPN1	0.57	7.28	0.37	2.47e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1971762	0.583	rs3852561	chr12:54085842	C/T	cg23533419	chr12:54090519	NA	-0.37	-6.12	-0.32	2.58e-9	Height;
LUSC	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	9.76	0.47	5.88e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg04450456	chr4:17643702	FAM184B	0.38	6.47	0.33	3.48e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.15	16.21	0.66	5.28e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg11494091	chr17:61959527	GH2	0.36	6.04	0.31	4.21e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7539409	0.651	rs7521788	chr1:84309320	G/T	cg10977910	chr1:84465055	TTLL7	0.71	7.55	0.38	4.31e-13	Alzheimer's disease;
LUSC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.2	30.95	0.86	3.89e-100	Testicular germ cell tumor;
LUSC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg24879335	chr3:133465180	TF	0.46	7.69	0.39	1.68e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg23601095	chr6:26197514	HIST1H3D	0.7	7.53	0.38	4.89e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs10737909	1.000	rs10803369	chr1:15550525	G/T	cg21012057	chr1:15538911	TMEM51	-0.34	-5.7	-0.3	2.61e-8	Migraine;
LUSC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.72	10.91	0.51	6.63e-24	Menarche (age at onset);
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg12419862	chr22:24373484	LOC391322	-0.97	-18.75	-0.72	4.18e-54	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-0.92	-17.05	-0.68	2.55e-47	Headache;
LUSC	cis	rs12410462	0.710	rs74140145	chr1:227423946	C/T	cg04117972	chr1:227635322	NA	0.48	5.76	0.3	1.86e-8	Major depressive disorder;
LUSC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	9.62	0.47	1.69e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg22903471	chr2:27725779	GCKR	-0.42	-7.26	-0.37	2.79e-12	Total body bone mineral density;
LUSC	cis	rs59698941	0.943	rs739863	chr5:132232315	C/T	cg02081065	chr5:132209139	LEAP2	-0.65	-7.18	-0.37	4.63e-12	Apolipoprotein A-IV levels;
LUSC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg24562669	chr7:97807699	LMTK2	0.34	5.95	0.31	6.88e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.69	10.25	0.49	1.25e-21	Corneal astigmatism;
LUSC	cis	rs4964805	0.913	rs35945096	chr12:104201929	G/A	cg02344784	chr12:104178138	NT5DC3	0.44	7.07	0.36	9.28e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg18402987	chr7:1209562	NA	0.71	7.53	0.38	4.64e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3784262	1.000	rs4646622	chr15:58257199	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.8	-0.3	1.58e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2271400	0.852	rs1450741	chr8:56792159	T/C	cg08894788	chr8:56792171	LYN	-0.43	-6.77	-0.35	5.8e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
LUSC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg08888203	chr3:10149979	C3orf24	0.64	8.7	0.43	1.49e-16	Alzheimer's disease;
LUSC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg00677455	chr12:58241039	CTDSP2	0.62	8.81	0.43	6.8e-17	Multiple sclerosis;
LUSC	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	14.02	0.61	1.89e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg25930673	chr12:123319894	HIP1R	-0.72	-7.24	-0.37	3.14e-12	Schizophrenia;
LUSC	cis	rs7789940	0.857	rs12532935	chr7:75939698	G/C	cg15798862	chr7:76129360	DTX2	-0.45	-7.24	-0.37	3.05e-12	Multiple sclerosis;
LUSC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05025164	chr4:1340916	KIAA1530	-0.67	-10.43	-0.5	3.15e-22	Longevity;
LUSC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg18681998	chr4:17616180	MED28	0.85	16.06	0.66	2.03e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs929596	0.597	rs10173355	chr2:234597321	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-7.82	-0.39	6.93e-14	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs6500395	1.000	rs3919552	chr16:48716328	C/T	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg00191853	chr8:101177733	SPAG1	-0.39	-6.47	-0.33	3.49e-10	Atrioventricular conduction;
LUSC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-6.6	-0.34	1.6e-10	High light scatter reticulocyte count;
LUSC	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg06547715	chr2:218990976	CXCR2	0.32	6.31	0.33	8.97e-10	Ulcerative colitis;
LUSC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg12658694	chr1:38397304	INPP5B	-0.49	-7.05	-0.36	1.05e-11	Coronary artery disease;
LUSC	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg13010199	chr12:38710504	ALG10B	0.61	9.55	0.46	2.89e-19	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg18681998	chr4:17616180	MED28	0.83	14.83	0.63	1.45e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11971779	0.793	rs4732366	chr7:139027845	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	6.7	0.34	8.68e-11	Diisocyanate-induced asthma;
LUSC	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.6	9.35	0.46	1.34e-18	Heart rate;
LUSC	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.88	-15.01	-0.63	2.86e-39	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.61	0.34	1.5e-10	Lung cancer;
LUSC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	7.18	0.37	4.56e-12	Renal cell carcinoma;
LUSC	cis	rs57590327	0.555	rs3772884	chr3:81802720	G/T	cg07356753	chr3:81810745	GBE1	-0.68	-10.66	-0.5	4.89e-23	Extraversion;
LUSC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg03146154	chr1:46216737	IPP	0.5	7.49	0.38	6.02e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg24375607	chr4:120327624	NA	0.81	12.01	0.55	7.59e-28	Corneal astigmatism;
LUSC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg20406979	chr6:167373233	NA	0.26	6.26	0.32	1.19e-9	Crohn's disease;
LUSC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg23172400	chr8:95962367	TP53INP1	-0.45	-9.4	-0.46	8.89e-19	Type 2 diabetes;
LUSC	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.44	-5.91	-0.31	8.63e-9	IgG glycosylation;
LUSC	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.58	-7.78	-0.39	9.21e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg05110241	chr16:68378359	PRMT7	-0.47	-6.07	-0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg20887711	chr4:1340912	KIAA1530	0.68	10.37	0.49	4.81e-22	Longevity;
LUSC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg04369109	chr6:150039330	LATS1	-0.6	-8.83	-0.43	6.2e-17	Lung cancer;
LUSC	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg08017756	chr2:100939284	LONRF2	-0.41	-7.61	-0.38	2.81e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.23	0.32	1.4e-9	Corneal astigmatism;
LUSC	cis	rs12760731	0.623	rs2295019	chr1:178451732	A/G	cg00404053	chr1:178313656	RASAL2	0.55	6.28	0.33	1.04e-9	Obesity-related traits;
LUSC	trans	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	9.19	0.45	4.34e-18	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg09658497	chr7:2847517	GNA12	-0.32	-5.72	-0.3	2.37e-8	Height;
LUSC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11302857	chr20:278071	ZCCHC3	0.76	6.17	0.32	1.93e-9	Cognitive performance;
LUSC	trans	rs853679	0.546	rs483143	chr6:27846744	G/C	cg06606381	chr12:133084897	FBRSL1	-0.75	-7.33	-0.37	1.79e-12	Depression;
LUSC	cis	rs360798	0.512	rs2430388	chr2:63106784	T/C	cg17519650	chr2:63277830	OTX1	0.51	7.06	0.36	9.79e-12	Coronary artery disease;
LUSC	cis	rs727505	1.000	rs55964341	chr7:124517280	A/G	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg18806716	chr10:30721971	MAP3K8	-0.59	-9.66	-0.47	1.22e-19	Itch intensity from mosquito bite;
LUSC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.26	0.37	2.67e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg23985595	chr17:80112537	CCDC57	-0.3	-5.71	-0.3	2.55e-8	Life satisfaction;
LUSC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg12011299	chr4:100065546	ADH4	0.64	10.14	0.49	3.04e-21	Alcohol dependence;
LUSC	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg09915433	chr19:53449742	NA	-0.61	-9.67	-0.47	1.14e-19	Psoriasis;
LUSC	cis	rs240764	0.658	rs4463266	chr6:101223997	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-6.34	-0.33	7.43e-10	Neuroticism;
LUSC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg04414720	chr1:150670196	GOLPH3L	0.57	9.25	0.45	2.68e-18	Tonsillectomy;
LUSC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08280861	chr8:58055591	NA	0.57	7.2	0.37	3.94e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs988712	0.537	rs10742179	chr11:27650524	A/G	cg15471856	chr13:19448839	NA	-0.45	-6.36	-0.33	6.51e-10	Obesity;
LUSC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg03188948	chr7:1209495	NA	0.64	7.29	0.37	2.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg15704280	chr7:45808275	SEPT13	0.87	12.61	0.57	4.33e-30	Coronary artery disease;
LUSC	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-0.88	-16.6	-0.67	1.54e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21643547	chr1:205240462	TMCC2	-0.51	-9.44	-0.46	6.64e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg12311346	chr5:56204834	C5orf35	-0.69	-9.75	-0.47	6.43e-20	Type 2 diabetes;
LUSC	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.7	0.75	7.91e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.99	0.31	5.28e-9	Schizophrenia;
LUSC	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.9e-20	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	0.96	13.28	0.59	1.29e-32	Primary sclerosing cholangitis;
LUSC	cis	rs17095355	1.000	rs12569906	chr10:111706856	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.62	-0.38	2.6e-13	Biliary atresia;
LUSC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	1.03	15.1	0.64	1.27e-39	Blood trace element (Zn levels);
LUSC	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg24397884	chr7:158709396	WDR60	0.7	8.25	0.41	3.64e-15	Height;
LUSC	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg05468064	chr22:46423449	NA	-0.39	-6.71	-0.34	8.15e-11	Dupuytren's disease;
LUSC	cis	rs7210086	0.768	rs4075985	chr17:70640873	C/G	cg04206342	chr17:70636940	NA	-0.35	-5.83	-0.3	1.28e-8	Ulcerative colitis;
LUSC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.82	11.63	0.54	1.79e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg14227996	chr4:17616232	MED28	0.82	7.87	0.4	4.98e-14	Opioid sensitivity;
LUSC	cis	rs9399401	0.593	rs262117	chr6:142807093	G/A	cg04461802	chr6:142623433	GPR126	0.44	5.72	0.3	2.41e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs1524927	1.000	rs12704873	chr7:96336279	G/C	cg03808172	chr7:96339361	SHFM1	0.43	6.66	0.34	1.12e-10	Total body bone mineral density;
LUSC	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.7	-0.47	8.88e-20	Coronary artery disease;
LUSC	cis	rs1160297	0.576	rs12617374	chr2:53107105	C/T	cg07782112	chr2:53107842	NA	0.4	6.64	0.34	1.26e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs68170813	0.641	rs77487103	chr7:107078793	T/C	cg02696742	chr7:106810147	HBP1	-0.67	-9.5	-0.46	4.29e-19	Coronary artery disease;
LUSC	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.76	-14.89	-0.63	8.28e-39	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.42	-0.38	1.01e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg15934090	chr1:100435551	SLC35A3	0.48	8.32	0.41	2.2e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs295140	0.546	rs295137	chr2:201150040	C/T	cg23649088	chr2:200775458	C2orf69	0.41	6.07	0.32	3.49e-9	QT interval;
LUSC	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg13010199	chr12:38710504	ALG10B	0.5	7.57	0.38	3.77e-13	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.32e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.47	-5.83	-0.3	1.3e-8	Schizophrenia;
LUSC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.46	-0.42	8.61e-16	Schizophrenia;
LUSC	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg25427524	chr10:38739819	LOC399744	0.45	5.9	0.31	8.86e-9	Obesity (extreme);
LUSC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.91	-0.48	1.84e-20	Gut microbiome composition (summer);
LUSC	cis	rs8040855	0.860	rs6496775	chr15:85708141	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.42	6.09	0.32	3.18e-9	Bulimia nervosa;
LUSC	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg27432699	chr2:27873401	GPN1	0.8	14.96	0.63	4.51e-39	Oral cavity cancer;
LUSC	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.56	0.5	1.09e-22	Schizophrenia;
LUSC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg16339924	chr4:17578868	LAP3	0.64	10.13	0.48	3.35e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13319049	chr4:39699555	UBE2K	-0.4	-6.17	-0.32	2.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs9944715	0.911	rs9945783	chr18:43782260	T/C	cg01718231	chr17:29326311	RNF135	-0.5	-7.11	-0.36	7.16e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs9886428	1.000	rs9886428	chr8:14113816	G/A	cg11959399	chr20:741723	C20orf54	-0.4	-6.45	-0.33	3.98e-10	IgG glycosylation;
LUSC	cis	rs6460942	0.908	rs6979124	chr7:12232551	G/T	cg06484146	chr7:12443880	VWDE	-0.56	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg22507989	chr22:21356069	FLJ39582;THAP7	0.4	6.06	0.31	3.63e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg03676636	chr4:99064102	C4orf37	-0.32	-7.2	-0.37	4.01e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12928939	0.517	rs8049508	chr16:71978313	C/T	cg03805757	chr16:71968109	PKD1L3	-0.62	-9.42	-0.46	7.57e-19	Post bronchodilator FEV1;
LUSC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03934478	chr11:495069	RNH1	0.91	10.47	0.5	2.32e-22	Body mass index;
LUSC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg22906224	chr7:99728672	NA	0.56	8.17	0.41	6.35e-15	Coronary artery disease;
LUSC	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg15737290	chr11:93063684	CCDC67	0.65	8.08	0.4	1.19e-14	Pulmonary function decline;
LUSC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.84	-0.3	1.26e-8	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg26043149	chr18:55253948	FECH	0.48	7.22	0.37	3.5e-12	Bone mineral density;
LUSC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg21226059	chr5:178986404	RUFY1	0.57	9.88	0.48	2.22e-20	Lung cancer;
LUSC	cis	rs17030434	0.654	rs10021631	chr4:154646675	A/G	cg14289246	chr4:154710475	SFRP2	-0.45	-6.3	-0.33	9.54e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg13385521	chr17:29058706	SUZ12P	0.59	5.7	0.3	2.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6076065	1.000	rs2405231	chr20:23342239	A/C	cg11657817	chr20:23433608	CST11	0.45	8.93	0.44	2.94e-17	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs243505	1.000	rs243510	chr7:148432534	A/G	cg09806900	chr7:148480153	CUL1	-0.5	-6.94	-0.36	2.02e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg21573476	chr21:45109991	RRP1B	-0.41	-6.74	-0.35	7.09e-11	Mean corpuscular volume;
LUSC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg10792982	chr14:105748885	BRF1	0.48	8.44	0.42	9.88e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg00310523	chr12:86230176	RASSF9	0.45	8.0	0.4	2.1e-14	Major depressive disorder;
LUSC	cis	rs9309473	0.500	rs11688718	chr2:73760939	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-7.84	-0.39	5.92e-14	Metabolite levels;
LUSC	trans	rs7078219	0.714	rs11190137	chr10:101287944	G/T	cg10182584	chr2:200776745	C2orf69	-0.4	-5.98	-0.31	5.75e-9	Dental caries;
LUSC	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg22532475	chr10:104410764	TRIM8	0.25	5.87	0.31	1.03e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs4950928	0.823	rs4950929	chr1:203160126	A/C	cg17014757	chr1:203156097	CHI3L1	0.42	7.67	0.39	1.89e-13	YKL-40 levels;
LUSC	cis	rs10992471	0.603	rs1980848	chr9:95248571	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.47	8.17	0.41	6.51e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg22437258	chr11:111473054	SIK2	0.53	7.53	0.38	4.93e-13	Primary sclerosing cholangitis;
LUSC	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg22571038	chr17:48585470	MYCBPAP	0.44	5.69	0.3	2.72e-8	Visceral fat;
LUSC	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg08601574	chr20:25228251	PYGB	0.42	6.43	0.33	4.36e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg23093090	chr10:104574429	C10orf26	-0.4	-6.79	-0.35	5.05e-11	Arsenic metabolism;
LUSC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	12.0	0.55	7.98e-28	Prudent dietary pattern;
LUSC	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg18232548	chr7:50535776	DDC	-0.51	-7.06	-0.36	9.5e-12	Malaria;
LUSC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg12927641	chr6:109611667	NA	-0.43	-7.47	-0.38	7.04e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg00815214	chr21:47717953	NA	-0.35	-5.72	-0.3	2.33e-8	Testicular germ cell tumor;
LUSC	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.78	10.8	0.51	1.66e-23	HIV-1 control;
LUSC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg25025879	chr12:53359317	NA	-0.57	-8.69	-0.43	1.63e-16	Cancer (pleiotropy);
LUSC	cis	rs1499972	0.941	rs56310214	chr3:117640127	G/A	cg07612923	chr3:117604196	NA	0.62	5.64	0.3	3.54e-8	Schizophrenia;
LUSC	cis	rs7759001	0.857	rs980960	chr6:27361042	A/G	cg18711553	chr6:27366782	ZNF391	0.39	5.65	0.3	3.44e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg22878388	chr2:105853796	NA	-0.33	-6.0	-0.31	5.2e-9	Type 2 diabetes;
LUSC	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.15	-0.32	2.26e-9	Neutrophil percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19559774	chr10:102747161	MRPL43;C10orf2	-0.42	-6.05	-0.31	3.87e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg00990874	chr7:1149470	C7orf50	-0.6	-7.77	-0.39	9.8e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg01125463	chr6:42946178	PEX6	0.36	6.03	0.31	4.24e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.75	-11.5	-0.53	5.35e-26	Menarche (age at onset);
LUSC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg13072238	chr3:49761600	GMPPB	-0.74	-9.17	-0.45	5.02e-18	Menarche (age at onset);
LUSC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.75	0.35	6.47e-11	Tonsillectomy;
LUSC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.88	13.49	0.59	2.11e-33	Alzheimer's disease;
LUSC	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg08000102	chr2:233561755	GIGYF2	-0.5	-7.77	-0.39	9.6e-14	Coronary artery disease;
LUSC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.17	0.49	2.37e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg05552183	chr6:42928497	GNMT	0.48	8.18	0.41	6.03e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3771570	1.000	rs56383420	chr2:242219281	A/G	cg21155796	chr2:242212141	HDLBP	0.67	7.46	0.38	7.42e-13	Prostate cancer;
LUSC	trans	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg01620082	chr3:125678407	NA	-0.51	-7.82	-0.39	7.07e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg18402987	chr7:1209562	NA	0.48	6.12	0.32	2.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.01	-0.31	4.99e-9	Retinal vascular caliber;
LUSC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.12	0.45	7.37e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg04733989	chr22:42467013	NAGA	-0.42	-7.2	-0.37	4.09e-12	Cognitive function;
LUSC	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg16482183	chr6:26056742	HIST1H1C	0.64	8.88	0.44	4.06e-17	Height;
LUSC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.2	22.43	0.78	1.32e-68	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg02591199	chr4:113066609	C4orf32	0.37	6.02	0.31	4.69e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs10779751	0.770	rs1148480	chr1:11172006	A/G	cg08854313	chr1:11322531	MTOR	0.84	13.76	0.6	1.87e-34	Body mass index;
LUSC	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-8.67	-0.43	1.93e-16	Response to antipsychotic treatment;
LUSC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg08392591	chr16:89556376	ANKRD11	0.47	7.24	0.37	3.16e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs1451375	0.669	rs4469404	chr7:50647062	C/T	cg18232548	chr7:50535776	DDC	-0.5	-7.58	-0.38	3.49e-13	Malaria;
LUSC	cis	rs9462027	0.588	rs13215181	chr6:34759881	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.92	-0.31	7.82e-9	Systemic lupus erythematosus;
LUSC	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg04310649	chr10:35416472	CREM	-0.43	-6.59	-0.34	1.73e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	trans	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg02030672	chr11:45687055	CHST1	0.45	6.75	0.35	6.61e-11	Obesity-related traits;
LUSC	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.73	-0.39	1.31e-13	Glomerular filtration rate;
LUSC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.86e-14	Melanoma;
LUSC	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg14036092	chr11:66035641	RAB1B	0.4	5.71	0.3	2.51e-8	Gout;
LUSC	cis	rs12760731	0.517	rs11587387	chr1:178229950	C/T	cg00404053	chr1:178313656	RASAL2	0.67	6.92	0.35	2.33e-11	Obesity-related traits;
LUSC	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.68	-11.7	-0.54	9.92e-27	Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11309891	chr11:73388802	RAB6A	0.5	6.49	0.33	3.16e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7106204	0.514	rs2099890	chr11:24255948	C/T	ch.11.24196551F	chr11:24239977	NA	0.93	10.34	0.49	6.32e-22	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs3784262	1.000	rs1372368	chr15:58297363	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.93	-0.31	7.51e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg16070123	chr10:51489643	NA	-0.56	-9.31	-0.45	1.72e-18	Prostate-specific antigen levels;
LUSC	trans	rs961253	0.556	rs6038446	chr20:6331883	G/A	cg21095983	chr6:86352623	SYNCRIP	0.45	6.79	0.35	5.12e-11	Colorectal cancer;
LUSC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.57	-8.43	-0.42	1.06e-15	Alzheimer's disease;
LUSC	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	0.85	13.38	0.59	5.28e-33	Blood protein levels;
LUSC	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg09408571	chr1:101003634	GPR88	0.29	5.67	0.3	3.12e-8	Monocyte count;
LUSC	cis	rs9473147	0.571	rs9369717	chr6:47554468	T/G	cg12968598	chr6:47444699	CD2AP	0.52	7.98	0.4	2.29e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg16359550	chr11:109292809	C11orf87	0.36	6.11	0.32	2.76e-9	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg16339924	chr4:17578868	LAP3	0.51	7.77	0.39	1.01e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg08048268	chr3:133502702	NA	0.35	6.41	0.33	4.94e-10	Iron status biomarkers;
LUSC	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg02825527	chr7:2087843	MAD1L1	-0.51	-5.73	-0.3	2.2e-8	Neuroticism;
LUSC	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-10.3	-0.49	8.86e-22	Body mass index;
LUSC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg08888203	chr3:10149979	C3orf24	0.59	8.11	0.41	9.88e-15	Alzheimer's disease;
LUSC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9369695	0.883	rs9473128	chr6:47505010	C/T	cg12968598	chr6:47444699	CD2AP	0.53	8.07	0.4	1.3e-14	Reticulocyte count;
LUSC	trans	rs8050260	0.500	rs4783650	chr16:68558528	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.55	-6.74	-0.35	6.86e-11	Plateletcrit;
LUSC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg02782426	chr3:40428986	ENTPD3	-0.33	-6.49	-0.33	3.13e-10	Renal cell carcinoma;
LUSC	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg17366294	chr4:99064904	C4orf37	0.61	10.92	0.51	6.22e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	0.549	rs11698185	chr20:25181998	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.64	11.81	0.54	4.02e-27	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg20701182	chr2:24300061	SF3B14	0.74	7.28	0.37	2.48e-12	Lymphocyte counts;
LUSC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.39e-22	Alzheimer's disease (late onset);
LUSC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	0.95	12.63	0.57	3.77e-30	Eosinophil percentage of granulocytes;
LUSC	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg18806716	chr10:30721971	MAP3K8	-0.56	-8.64	-0.43	2.33e-16	Inflammatory bowel disease;
LUSC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02187348	chr16:89574699	SPG7	0.58	9.23	0.45	3.18e-18	Multiple myeloma (IgH translocation);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24443054	chr6:157802504	ZDHHC14	0.44	6.04	0.31	4.22e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg01528321	chr10:82214614	TSPAN14	0.82	12.47	0.56	1.41e-29	Post bronchodilator FEV1;
LUSC	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg11845111	chr2:191398756	TMEM194B	-0.86	-11.5	-0.53	5.35e-26	Diastolic blood pressure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05971912	chr6:150185499	LRP11	-0.44	-6.7	-0.34	8.82e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg02999463	chr8:37707322	BRF2	0.4	6.15	0.32	2.24e-9	Schizophrenia;
LUSC	cis	rs9811920	0.535	rs704571	chr3:99481946	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.31	-5.85	-0.31	1.15e-8	Axial length;
LUSC	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg25319279	chr11:5960081	NA	-0.45	-6.27	-0.32	1.15e-9	DNA methylation (variation);
LUSC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg15445000	chr17:37608096	MED1	0.39	6.68	0.34	9.76e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg04362960	chr10:104952993	NT5C2	-0.6	-8.23	-0.41	4.2e-15	Arsenic metabolism;
LUSC	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-8.3	-0.41	2.64e-15	Schizophrenia;
LUSC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg24642439	chr20:33292090	TP53INP2	0.62	9.87	0.48	2.59e-20	Coronary artery disease;
LUSC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg12639453	chr1:2035780	PRKCZ	0.29	6.15	0.32	2.27e-9	Height;
LUSC	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg17376030	chr22:41985996	PMM1	-0.47	-5.91	-0.31	8.61e-9	Vitiligo;
LUSC	cis	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg21775007	chr8:11205619	TDH	0.47	6.67	0.34	1.05e-10	Neuroticism;
LUSC	cis	rs5771069	0.669	rs137879	chr22:50457041	C/T	cg27068297	chr22:50451975	IL17REL	0.38	7.96	0.4	2.71e-14	Ulcerative colitis;
LUSC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg09626299	chr10:82213104	TSPAN14	-0.21	-5.97	-0.31	6.12e-9	Post bronchodilator FEV1;
LUSC	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg15501526	chr10:2543763	NA	0.58	9.62	0.47	1.7e-19	Age-related hearing impairment;
LUSC	trans	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg10756647	chr7:56101905	PSPH	0.88	6.12	0.32	2.65e-9	Diabetic kidney disease;
LUSC	cis	rs427941	0.703	rs201456	chr7:101741059	C/G	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg21132104	chr15:45694354	SPATA5L1	0.56	7.65	0.39	2.19e-13	Homoarginine levels;
LUSC	cis	rs10276303	0.519	rs6947525	chr7:3396065	C/A	cg21248987	chr7:3385318	SDK1	-0.39	-6.61	-0.34	1.53e-10	Dupuytren's disease;
LUSC	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg17764715	chr19:33622953	WDR88	0.6	8.33	0.41	2.08e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg18721089	chr20:30220636	NA	-0.39	-6.15	-0.32	2.2e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg02380750	chr20:61661411	NA	0.35	6.08	0.32	3.23e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	7.8	0.39	7.99e-14	Cognitive test performance;
LUSC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg18538332	chr22:24372958	LOC391322	0.43	6.24	0.32	1.3e-9	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-8.27	-0.41	3.33e-15	Total cholesterol levels;
LUSC	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-7.7	-0.39	1.55e-13	Morning vs. evening chronotype;
LUSC	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	9.69	0.47	9.66e-20	Bone mineral density;
LUSC	cis	rs9311676	0.632	rs11130646	chr3:58447013	C/G	cg26110898	chr3:58419937	PDHB	0.41	6.78	0.35	5.63e-11	Systemic lupus erythematosus;
LUSC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	0.71	11.98	0.55	9.36e-28	Methadone dose in opioid dependence;
LUSC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	6.47	0.33	3.5e-10	Obesity-related traits;
LUSC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg27165867	chr14:105738592	BRF1	-0.53	-7.84	-0.39	6.15e-14	Platelet count;
LUSC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg11189052	chr15:85197271	WDR73	-0.66	-10.26	-0.49	1.2e-21	P wave terminal force;
LUSC	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.01	0.36	1.29e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg18350739	chr11:68623251	NA	-0.37	-6.62	-0.34	1.42e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg24578937	chr1:2090814	PRKCZ	-0.45	-10.07	-0.48	5.46e-21	Height;
LUSC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg00933542	chr6:150070202	PCMT1	0.32	6.7	0.34	8.68e-11	Lung cancer;
LUSC	cis	rs9323205	0.723	rs12587352	chr14:51739441	T/C	cg23942311	chr14:51606299	NA	-0.41	-7.84	-0.39	5.93e-14	Cancer;
LUSC	cis	rs2235544	0.554	rs605272	chr1:54467026	T/A	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	trans	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18876405	chr7:65276391	NA	0.5	6.95	0.36	1.97e-11	Corneal structure;
LUSC	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	0.87	14.46	0.62	3.8e-37	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00149659	chr3:10157352	C3orf10	-0.95	-14.42	-0.62	5.6e-37	Alzheimer's disease;
LUSC	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.62	9.57	0.46	2.54e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.94	-13.68	-0.6	3.9e-34	Initial pursuit acceleration;
LUSC	cis	rs7188861	0.768	rs497184	chr16:11389589	G/A	cg00044050	chr16:11439710	C16orf75	0.56	6.25	0.32	1.27e-9	HDL cholesterol;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12454419	chr4:77135195	SCARB2	-0.54	-6.35	-0.33	7e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.52	-0.34	2.58e-10	Lung cancer;
LUSC	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg20487152	chr13:99095054	FARP1	-0.42	-7.12	-0.36	6.61e-12	Neuroticism;
LUSC	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg02018176	chr4:1364513	KIAA1530	0.43	5.9	0.31	8.71e-9	Recombination rate (females);
LUSC	cis	rs17021463	0.872	rs11097417	chr4:95268071	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.37	-7.04	-0.36	1.12e-11	Testicular germ cell tumor;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13696300	chr17:18162128	FLII	0.49	6.48	0.33	3.23e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs2244503	1.000	rs1523452	chr3:64947340	C/T	cg08115371	chr11:79115706	ODZ4	-0.45	-6.25	-0.32	1.24e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05776053	chr2:74358815	NA	0.47	7.6	0.38	3.05e-13	Gestational age at birth (maternal effect);
LUSC	cis	rs7712401	0.658	rs4836203	chr5:122077077	A/T	cg19077854	chr5:122220652	SNX24	0.33	7.08	0.36	8.29e-12	Mean platelet volume;
LUSC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg16606324	chr3:10149918	C3orf24	0.64	9.21	0.45	3.73e-18	Alzheimer's disease;
LUSC	trans	rs4714291	0.802	rs1923465	chr6:39971376	A/T	cg02267698	chr19:7991119	CTXN1	-0.51	-7.59	-0.38	3.28e-13	Strep throat;
LUSC	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.78	11.78	0.54	5.03e-27	Morning vs. evening chronotype;
LUSC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg04450456	chr4:17643702	FAM184B	0.35	5.81	0.3	1.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg18187862	chr3:45730750	SACM1L	-0.59	-7.62	-0.38	2.69e-13	Primary sclerosing cholangitis;
LUSC	cis	rs1507153	0.851	rs9352610	chr6:79389398	A/G	cg05283184	chr6:79620031	NA	-0.39	-6.79	-0.35	5.27e-11	Sjögren's syndrome;
LUSC	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.36	-6.2	-0.32	1.63e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs710216	0.797	rs1770811	chr1:43400547	A/T	cg22176566	chr1:43424700	SLC2A1	0.45	5.75	0.3	2.01e-8	Red cell distribution width;
LUSC	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	12.63	0.57	3.83e-30	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg23260525	chr10:116636907	FAM160B1	0.47	10.25	0.49	1.26e-21	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.69	11.15	0.52	9.54e-25	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg27165867	chr14:105738592	BRF1	-0.53	-7.74	-0.39	1.16e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg19318889	chr4:1322082	MAEA	0.46	7.38	0.37	1.29e-12	Obesity-related traits;
LUSC	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18932078	chr1:2524107	MMEL1	0.29	6.26	0.32	1.18e-9	Ulcerative colitis;
LUSC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg05754148	chr16:3507555	NAT15	0.53	8.04	0.4	1.58e-14	Tuberculosis;
LUSC	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.88	15.06	0.64	1.82e-39	Bladder cancer;
LUSC	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg25024717	chr12:54324583	NA	-0.38	-6.63	-0.34	1.34e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	cis	rs13006833	0.668	rs2664253	chr2:191148558	G/A	cg21644426	chr2:191273491	MFSD6	0.45	6.52	0.34	2.66e-10	Urinary metabolites;
LUSC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg21770322	chr7:97807741	LMTK2	0.41	7.29	0.37	2.32e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7580658	0.680	rs6710535	chr2:128190960	C/G	cg09760422	chr2:128146352	NA	0.28	5.77	0.3	1.83e-8	Protein C levels;
LUSC	cis	rs601339	0.878	rs7956284	chr12:123183017	G/A	cg11919336	chr12:123188078	GPR109A	0.42	6.27	0.32	1.12e-9	Adiponectin levels;
LUSC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg00757033	chr12:89920650	WDR51B	0.59	10.16	0.49	2.54e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12396054	chr3:194354240	TMEM44	-0.41	-5.99	-0.31	5.31e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs250677	0.522	rs1432798	chr5:148383345	C/G	cg18129178	chr5:148520854	ABLIM3	-0.45	-6.81	-0.35	4.52e-11	Breast cancer;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg20264529	chr10:30638039	MTPAP	-0.55	-6.14	-0.32	2.33e-9	Height;
LUSC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg00149659	chr3:10157352	C3orf10	0.62	8.63	0.43	2.51e-16	Alzheimer's disease;
LUSC	cis	rs2688608	0.836	rs2675668	chr10:75636148	G/A	cg23231163	chr10:75533350	FUT11	-0.38	-6.06	-0.31	3.62e-9	Inflammatory bowel disease;
LUSC	cis	rs4363385	0.747	rs4314835	chr1:152984901	C/T	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.84	-0.39	6.12e-14	Inflammatory skin disease;
LUSC	cis	rs9469578	1.000	rs9469580	chr6:33715837	A/G	cg18708504	chr6:33715942	IP6K3	-0.71	-8.96	-0.44	2.39e-17	Phosphorus levels;
LUSC	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg06885757	chr1:42089581	HIVEP3	0.46	9.49	0.46	4.56e-19	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg15448220	chr1:150897856	SETDB1	0.4	5.87	0.31	1.02e-8	Melanoma;
LUSC	cis	rs6460942	0.915	rs10488158	chr7:12508894	C/T	cg06484146	chr7:12443880	VWDE	-0.64	-6.59	-0.34	1.73e-10	Coronary artery disease;
LUSC	cis	rs4285028	0.747	rs1463736	chr3:121400725	G/A	cg11130432	chr3:121712080	ILDR1	-0.56	-8.13	-0.41	8.7e-15	Multiple sclerosis;
LUSC	trans	rs9409565	0.826	rs2139189	chr9:97238538	A/G	cg05679027	chr9:99775184	HIATL2	-0.43	-6.32	-0.33	8.14e-10	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg27284194	chr4:1044797	NA	0.37	5.99	0.31	5.41e-9	Obesity-related traits;
LUSC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg12386194	chr3:101231763	SENP7	0.46	6.73	0.35	7.37e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	6.22	0.32	1.51e-9	Height;
LUSC	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg03342759	chr3:160939853	NMD3	-0.45	-5.95	-0.31	6.79e-9	Parkinson's disease;
LUSC	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg14582100	chr15:45693742	SPATA5L1	0.45	8.44	0.42	9.53e-16	Glomerular filtration rate;
LUSC	cis	rs9650315	0.929	rs13282345	chr8:57163708	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.07	0.36	9.07e-12	Height;
LUSC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg21016266	chr12:122356598	WDR66	0.44	6.36	0.33	6.8e-10	Mean corpuscular volume;
LUSC	cis	rs4363385	0.620	rs4388644	chr1:152983674	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-5.67	-0.3	3.17e-8	Inflammatory skin disease;
LUSC	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg00484396	chr16:3507460	NAT15	0.46	6.88	0.35	3e-11	Body mass index (adult);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11927827	chr4:89513619	HERC3	-0.44	-6.54	-0.34	2.35e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10761482	0.813	rs10821734	chr10:62103412	C/T	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs78366141	0.649	rs78114325	chr4:89682189	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.95	7.48	0.38	6.54e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs17125944	0.615	rs12590862	chr14:53297008	A/G	cg00686598	chr14:53173677	PSMC6	-0.73	-6.61	-0.34	1.52e-10	Alzheimer's disease (late onset);
LUSC	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	7.41	0.38	1.02e-12	Rheumatoid arthritis;
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg07332563	chr6:291687	DUSP22	-0.7	-11.77	-0.54	5.6e-27	Menopause (age at onset);
LUSC	cis	rs7173743	0.750	rs12903355	chr15:79129145	A/T	cg00540400	chr15:79124168	NA	0.35	6.15	0.32	2.17e-9	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg22907277	chr7:1156413	C7orf50	0.68	7.3	0.37	2.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg17507749	chr15:85114479	UBE2QP1	0.54	6.73	0.35	7.18e-11	Schizophrenia;
LUSC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.54	-0.8	9.72e-77	Height;
LUSC	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.52	-0.34	2.59e-10	Schizophrenia;
LUSC	cis	rs11051970	0.679	rs2651366	chr12:32560431	T/C	cg02745156	chr12:32552066	NA	0.38	6.82	0.35	4.37e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg02493740	chr2:85810744	VAMP5	-0.37	-6.53	-0.34	2.49e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg03522245	chr20:25566470	NINL	-0.36	-5.83	-0.3	1.33e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg17757837	chr7:157058334	UBE3C	-0.9	-14.63	-0.62	8.54e-38	Body mass index;
LUSC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg20135002	chr11:47629003	NA	-0.48	-7.4	-0.38	1.09e-12	Subjective well-being;
LUSC	cis	rs193541	0.507	rs7726172	chr5:122081200	C/T	cg19077854	chr5:122220652	SNX24	0.27	5.77	0.3	1.82e-8	Glucose homeostasis traits;
LUSC	cis	rs9400467	0.528	rs12214380	chr6:111796937	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.35	-6.57	-0.34	1.98e-10	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs2798269	0.966	rs2761914	chr13:22137130	T/A	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.04	-0.31	4.15e-9	PR segment;
LUSC	cis	rs722599	0.715	rs61978928	chr14:75321714	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.4	-5.89	-0.31	9.22e-9	IgG glycosylation;
LUSC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg14092988	chr3:52407081	DNAH1	0.31	6.12	0.32	2.57e-9	Bipolar disorder;
LUSC	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg00784671	chr22:46762841	CELSR1	0.41	6.03	0.31	4.38e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7973719	1.000	rs7973719	chr12:7334813	C/T	cg07052231	chr12:7363540	PEX5	0.51	8.82	0.43	6.3e-17	IgG glycosylation;
LUSC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg15790184	chr11:494944	RNH1	0.58	6.26	0.32	1.18e-9	Body mass index;
LUSC	cis	rs4953076	0.573	rs2053456	chr2:44448632	G/A	cg04920474	chr2:44395004	PPM1B	0.63	8.2	0.41	5.37e-15	Height;
LUSC	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.45	7.0	0.36	1.38e-11	Systolic blood pressure;
LUSC	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.67	0.54	1.25e-26	Ileal carcinoids;
LUSC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11890956	chr21:40555474	PSMG1	1.03	20.16	0.74	1.09e-59	Cognitive function;
LUSC	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-14.99	-0.63	3.36e-39	Lymphocyte percentage of white cells;
LUSC	trans	rs800082	0.668	rs7643301	chr3:144293612	G/A	cg24215973	chr2:240111563	HDAC4	-0.61	-9.81	-0.47	3.99e-20	Smoking behavior;
LUSC	cis	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg06521331	chr12:34319734	NA	-0.52	-8.45	-0.42	8.96e-16	Morning vs. evening chronotype;
LUSC	cis	rs977987	0.737	rs8046697	chr16:75442144	T/C	cg03315344	chr16:75512273	CHST6	0.49	8.99	0.44	1.91e-17	Dupuytren's disease;
LUSC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg22638593	chr5:131593259	PDLIM4	0.37	5.65	0.3	3.52e-8	Breast cancer;
LUSC	cis	rs7172677	1.000	rs1021382	chr15:75417398	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.84	-0.3	1.27e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	0.93	15.91	0.66	8.22e-43	Menopause (age at onset);
LUSC	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg24642439	chr20:33292090	TP53INP2	0.42	5.95	0.31	6.7e-9	Height;
LUSC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg11764359	chr7:65958608	NA	0.49	6.16	0.32	2.14e-9	Aortic root size;
LUSC	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.05	0.4	1.5e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg20783262	chr1:68152310	GADD45A	0.48	6.06	0.31	3.75e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg07460842	chr6:66804631	NA	0.46	6.46	0.33	3.81e-10	Blood trace element (Cu levels);
LUSC	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg00339695	chr16:24857497	SLC5A11	-0.36	-5.69	-0.3	2.85e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.03	-0.4	1.65e-14	Chronic sinus infection;
LUSC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.91	14.58	0.62	1.3e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.15	0.32	2.24e-9	Personality dimensions;
LUSC	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg19046167	chr17:80928561	B3GNTL1	-0.46	-6.89	-0.35	2.84e-11	Breast cancer;
LUSC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg13206674	chr6:150067644	NUP43	0.59	9.24	0.45	2.88e-18	Lung cancer;
LUSC	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg08027265	chr7:2291960	NA	-0.34	-5.77	-0.3	1.82e-8	Schizophrenia;
LUSC	cis	rs62400317	0.859	rs72869127	chr6:45071712	T/C	cg18551225	chr6:44695536	NA	-0.42	-6.84	-0.35	3.83e-11	Total body bone mineral density;
LUSC	trans	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg20935933	chr6:143382018	AIG1	0.51	7.47	0.38	6.96e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg11530693	chr1:120165357	ZNF697	0.69	10.79	0.51	1.79e-23	Systemic lupus erythematosus;
LUSC	trans	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg25214090	chr10:38739885	LOC399744	0.39	6.12	0.32	2.66e-9	Diastolic blood pressure;
LUSC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg16339924	chr4:17578868	LAP3	0.52	7.79	0.39	8.73e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.9	11.52	0.53	4.58e-26	Menarche (age at onset);
LUSC	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.56	-0.42	4.3e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs96067	0.805	rs4653162	chr1:36613704	G/T	cg24686825	chr1:36642396	MAP7D1	0.43	5.81	0.3	1.46e-8	Corneal structure;
LUSC	cis	rs1178968	0.748	rs10271751	chr7:72752062	T/C	cg25889504	chr7:72793014	NA	0.58	7.53	0.38	4.84e-13	Triglyceride levels;
LUSC	cis	rs4363385	0.818	rs532743	chr1:153011758	T/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg06521331	chr12:34319734	NA	-0.48	-8.04	-0.4	1.53e-14	Morning vs. evening chronotype;
LUSC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg02269571	chr22:50332266	NA	0.59	8.67	0.43	1.85e-16	Schizophrenia;
LUSC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg09555818	chr19:45449301	APOC2	0.43	8.31	0.41	2.41e-15	Blood protein levels;
LUSC	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.06	-0.36	9.55e-12	Bipolar disorder;
LUSC	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg08499158	chr17:42289980	UBTF	-0.47	-7.92	-0.4	3.44e-14	Total body bone mineral density;
LUSC	cis	rs6845621	0.745	rs4697168	chr4:18865249	G/T	cg12196642	chr4:18937545	NA	-0.32	-5.91	-0.31	8.59e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	9.67	0.47	1.13e-19	Lung cancer in ever smokers;
LUSC	cis	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg27411982	chr8:10470053	RP1L1	-0.51	-8.08	-0.4	1.2e-14	Neuroticism;
LUSC	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.51	-8.49	-0.42	6.92e-16	IgG glycosylation;
LUSC	trans	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg16487237	chr3:137487248	NA	0.37	5.97	0.31	5.92e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg18904891	chr8:8559673	CLDN23	0.61	8.18	0.41	5.89e-15	Obesity-related traits;
LUSC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg16393715	chr7:1948819	MAD1L1	0.38	6.43	0.33	4.36e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg02175503	chr12:58329896	NA	0.66	10.82	0.51	1.33e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-6.27	-0.32	1.13e-9	Tonsillectomy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22807378	chr6:170151601	TCTE3;C6orf70	-0.41	-6.21	-0.32	1.53e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.9	-14.05	-0.61	1.47e-35	Systemic lupus erythematosus;
LUSC	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg18105134	chr13:113819100	PROZ	0.68	9.66	0.47	1.24e-19	Platelet distribution width;
LUSC	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg03433033	chr1:76189801	ACADM	-0.44	-6.56	-0.34	2.02e-10	Daytime sleep phenotypes;
LUSC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.58	5.77	0.3	1.85e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9646944	0.501	rs13030675	chr2:103091618	C/A	cg20060108	chr2:102954350	IL1RL1	0.47	6.25	0.32	1.24e-9	Blood protein levels;
LUSC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.54	-0.34	2.36e-10	Bipolar disorder;
LUSC	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg04374321	chr14:90722782	PSMC1	0.47	7.11	0.36	7.08e-12	Mortality in heart failure;
LUSC	cis	rs1983170	0.808	rs4658229	chr1:92019171	G/A	cg25838465	chr1:92012736	NA	0.42	5.86	0.31	1.09e-8	Eosinophil percentage of white cells;
LUSC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	trans	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg19862616	chr7:65841803	NCRNA00174	0.87	10.19	0.49	2.13e-21	Eotaxin levels;
LUSC	cis	rs6500395	1.000	rs9933237	chr16:48676562	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.8	0.35	4.86e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9318086	0.935	rs9652080	chr13:24435426	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.4	-6.14	-0.32	2.3e-9	Myopia (pathological);
LUSC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.36e-10	Menopause (age at onset);
LUSC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.89	-18.74	-0.72	4.54e-54	Intelligence (multi-trait analysis);
LUSC	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.84	14.41	0.62	5.79e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg02018176	chr4:1364513	KIAA1530	0.52	8.87	0.44	4.63e-17	Obesity-related traits;
LUSC	trans	rs61931739	0.635	rs1486883	chr12:33908740	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.7	0.39	1.6e-13	Morning vs. evening chronotype;
LUSC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08564027	chr20:61660810	NA	0.9	17.26	0.69	3.72e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.76	10.44	0.5	2.84e-22	Corneal astigmatism;
LUSC	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs9581857	0.547	rs9579095	chr13:28082555	C/T	cg22138327	chr13:27999177	GTF3A	0.69	7.15	0.36	5.43e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs12541635	0.677	rs62527405	chr8:107058109	G/C	cg10147462	chr8:107024639	NA	0.66	13.77	0.6	1.77e-34	Age of smoking initiation;
LUSC	cis	rs2143950	0.512	rs62625038	chr14:35517017	A/G	cg16230307	chr14:35515116	FAM177A1	-0.42	-5.8	-0.3	1.5e-8	Atopic dermatitis;
LUSC	cis	rs4851254	0.584	rs56935201	chr2:100637788	G/A	cg22139774	chr2:100720529	AFF3	-0.44	-5.65	-0.3	3.39e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10193935	0.901	rs1044562	chr2:42516884	C/G	cg27598129	chr2:42591480	NA	-0.62	-8.55	-0.42	4.38e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	7.36	0.37	1.41e-12	Breast cancer;
LUSC	cis	rs7084402	1.000	rs12259315	chr10:60266152	T/C	cg07615347	chr10:60278583	BICC1	-0.35	-5.76	-0.3	1.95e-8	Refractive error;
LUSC	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg05347473	chr6:146136440	FBXO30	0.51	8.45	0.42	9.03e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.9	0.44	3.72e-17	Menopause (age at onset);
LUSC	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg12310025	chr6:25882481	NA	-0.42	-7.39	-0.37	1.21e-12	Height;
LUSC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg20684491	chr1:25596433	NA	0.37	5.67	0.3	3.08e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs4499344	0.633	rs259256	chr19:33151802	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.77	11.63	0.54	1.81e-26	Mean platelet volume;
LUSC	cis	rs1507153	0.775	rs9343780	chr6:79355335	T/C	cg05283184	chr6:79620031	NA	-0.42	-7.29	-0.37	2.29e-12	Sjögren's syndrome;
LUSC	cis	rs1881797	0.527	rs77059530	chr1:247648916	G/A	cg14830002	chr1:247616686	OR2B11	0.65	7.41	0.38	1.03e-12	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg26043149	chr18:55253948	FECH	0.52	7.81	0.39	7.46e-14	Bone mineral density;
LUSC	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg20573242	chr4:122745356	CCNA2	-0.44	-6.41	-0.33	5.1e-10	Type 2 diabetes;
LUSC	cis	rs11031096	0.502	rs4910875	chr11:4047855	C/G	cg08557956	chr11:4115526	RRM1	-0.48	-6.26	-0.32	1.2e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg17385448	chr1:15911702	AGMAT	0.37	6.23	0.32	1.41e-9	Systolic blood pressure;
LUSC	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	7.22	0.37	3.6e-12	Multiple sclerosis;
LUSC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg10207240	chr12:122356781	WDR66	0.44	6.16	0.32	2.05e-9	Mean corpuscular volume;
LUSC	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg12560992	chr17:57184187	TRIM37	0.58	9.32	0.45	1.65e-18	Testicular germ cell tumor;
LUSC	cis	rs7220711	0.934	rs8068071	chr17:41782779	C/T	cg26893861	chr17:41843967	DUSP3	-0.39	-5.65	-0.3	3.49e-8	Bone mineral density (spine);Bone mineral density (hip);
LUSC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18402987	chr7:1209562	NA	0.43	5.69	0.3	2.73e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg04508216	chr1:11107452	MASP2	0.31	5.67	0.3	3.17e-8	Body mass index;
LUSC	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.46	-8.83	-0.43	6.22e-17	Axial length;
LUSC	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.41	0.33	4.82e-10	Sudden cardiac arrest;
LUSC	cis	rs7799006	0.634	rs34502289	chr7:2311266	G/A	cg08027265	chr7:2291960	NA	-0.62	-11.11	-0.52	1.32e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg10253484	chr15:75165896	SCAMP2	-0.52	-6.73	-0.35	7.39e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06022373	chr22:39101656	GTPBP1	-0.8	-13.46	-0.59	2.71e-33	Menopause (age at onset);
LUSC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06505273	chr16:24850292	NA	0.39	5.69	0.3	2.8e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg03929089	chr4:120376271	NA	-0.94	-16.46	-0.67	5.66e-45	Height;
LUSC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.83	15.26	0.64	2.99e-40	Dental caries;
LUSC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg04352962	chr1:209979756	IRF6	0.5	6.74	0.35	7.02e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg06096015	chr1:231504339	EGLN1	-0.53	-9.19	-0.45	4.44e-18	Hemoglobin concentration;
LUSC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.42	-0.33	4.6e-10	Schizophrenia;
LUSC	cis	rs2857891	0.695	rs2248438	chr11:6985062	G/C	cg04053776	chr11:6947353	ZNF215	0.41	6.06	0.31	3.65e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs7766436	0.885	rs12111199	chr6:22578106	C/T	cg13666174	chr6:22585274	NA	-0.41	-5.73	-0.3	2.29e-8	Coronary artery disease;
LUSC	cis	rs7215564	0.908	rs35884143	chr17:78656043	A/G	cg09596252	chr17:78655493	RPTOR	0.55	5.92	0.31	7.92e-9	Myopia (pathological);
LUSC	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.12	-0.45	7.15e-18	Monocyte percentage of white cells;
LUSC	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg27005118	chr17:13972210	COX10	-0.32	-6.02	-0.31	4.59e-9	Temperament;
LUSC	cis	rs6901250	0.851	rs2175622	chr6:117149667	T/A	cg12892004	chr6:117198278	RFX6	0.44	8.18	0.41	6.14e-15	C-reactive protein levels;
LUSC	cis	rs9341808	0.519	rs3805878	chr6:81013855	A/G	cg08355045	chr6:80787529	NA	0.39	6.84	0.35	3.8e-11	Sitting height ratio;
LUSC	cis	rs3087591	0.659	rs8065496	chr17:29720140	T/C	cg24425628	chr17:29625626	OMG;NF1	0.46	6.77	0.35	5.98e-11	Hip circumference;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23456826	chr14:24912049	SDR39U1	0.39	6.32	0.33	8.59e-10	Triglycerides;
LUSC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.31	-0.37	1.96e-12	Menopause (age at onset);
LUSC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.68	0.34	9.99e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs55665837	1.000	rs12276938	chr11:14463488	C/G	cg19336497	chr11:14380999	RRAS2	-0.38	-7.54	-0.38	4.43e-13	Vitamin D levels;
LUSC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07677032	chr17:61819896	STRADA	0.54	9.03	0.44	1.36e-17	Prudent dietary pattern;
LUSC	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.56	-9.1	-0.45	8.07e-18	Breast cancer;
LUSC	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg05855489	chr10:104503620	C10orf26	0.72	11.11	0.52	1.28e-24	Colorectal cancer;
LUSC	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg04455712	chr21:45112962	RRP1B	0.46	8.88	0.44	4.26e-17	Mean corpuscular volume;
LUSC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg06618935	chr21:46677482	NA	-0.39	-7.46	-0.38	7.69e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6723226	0.881	rs10181198	chr2:32686582	A/G	cg02381751	chr2:32503542	YIPF4	0.63	9.45	0.46	6.01e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs1005224	0.926	rs7143743	chr14:76127805	G/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.68	-9.36	-0.46	1.18e-18	Large artery stroke;
LUSC	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	0.91	14.58	0.62	1.3e-37	Triglycerides;
LUSC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	15.73	0.65	4.3e-42	Platelet count;
LUSC	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.82	-0.3	1.34e-8	Resting heart rate;
LUSC	cis	rs699371	0.507	rs10149787	chr14:74925452	A/C	cg16374328	chr14:74960395	NPC2;ISCA2	-0.36	-5.8	-0.3	1.54e-8	Height;
LUSC	cis	rs17824933	1.000	rs929230	chr11:60760971	C/T	cg16817237	chr11:60793675	NA	0.39	6.19	0.32	1.73e-9	Multiple sclerosis;
LUSC	trans	rs1941687	0.797	rs12963024	chr18:31389547	A/G	cg27147174	chr7:100797783	AP1S1	-0.47	-6.84	-0.35	3.87e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg15839431	chr19:19639596	YJEFN3	-0.58	-6.62	-0.34	1.46e-10	Bipolar disorder;
LUSC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	10.77	0.51	2.09e-23	Homoarginine levels;
LUSC	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.15	-0.36	5.48e-12	Bipolar disorder;
LUSC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg11812906	chr14:75593930	NEK9	-0.63	-10.32	-0.49	7.18e-22	Height;
LUSC	trans	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg21659725	chr3:3221576	CRBN	0.71	8.58	0.42	3.58e-16	Menarche (age at onset);
LUSC	cis	rs73206853	0.563	rs11830452	chr12:111198576	A/T	cg12870014	chr12:110450643	ANKRD13A	0.65	6.92	0.35	2.32e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg12463550	chr7:65579703	CRCP	0.44	6.5	0.33	3.01e-10	Aortic root size;
LUSC	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.03	0.44	1.35e-17	Lung cancer in ever smokers;
LUSC	cis	rs2692947	0.644	rs1168970	chr2:96816606	C/T	cg23100626	chr2:96804247	ASTL	0.3	7.14	0.36	6.01e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg01884057	chr2:25150051	NA	-0.38	-8.58	-0.42	3.67e-16	Body mass index in non-asthmatics;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11905131	chr22:24372483	LOC391322	-0.59	-9.89	-0.48	2.06e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	0.95	18.98	0.72	5.3e-55	Cognitive function;
LUSC	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg02016764	chr4:38805732	TLR1	-0.53	-5.74	-0.3	2.16e-8	Breast cancer;
LUSC	cis	rs9534288	0.830	rs1548325	chr13:46635101	A/G	cg15192986	chr13:46630673	CPB2	-0.79	-12.65	-0.57	3.06e-30	Blood protein levels;
LUSC	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg05527609	chr1:210001259	C1orf107	-0.46	-6.96	-0.36	1.78e-11	Monobrow;
LUSC	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg14343924	chr8:8086146	FLJ10661	0.43	6.18	0.32	1.86e-9	Mood instability;
LUSC	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg00750074	chr16:89608354	SPG7	-0.45	-7.33	-0.37	1.71e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.74	-11.66	-0.54	1.39e-26	Menopause (age at onset);
LUSC	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg11861562	chr11:117069780	TAGLN	0.3	5.72	0.3	2.38e-8	Blood protein levels;
LUSC	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.54	0.42	4.94e-16	Response to antipsychotic treatment;
LUSC	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg24331049	chr13:111365604	ING1	0.63	8.2	0.41	5.4e-15	Coronary artery disease;
LUSC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg21285383	chr16:89894308	SPIRE2	-0.3	-5.8	-0.3	1.51e-8	Vitiligo;
LUSC	cis	rs6580649	0.941	rs17122613	chr12:48460016	T/C	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-17.02	-0.68	3.26e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.43	-0.46	6.97e-19	Chronic sinus infection;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06585708	chr5:3602413	NA	0.29	6.03	0.31	4.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg04756594	chr16:24857601	SLC5A11	-0.41	-5.65	-0.3	3.41e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-16.79	-0.68	2.69e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9905704	0.681	rs887206	chr17:56575084	G/C	cg19466818	chr17:56409534	MIR142	0.37	7.05	0.36	1.01e-11	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg04369109	chr6:150039330	LATS1	-0.54	-8.05	-0.4	1.51e-14	Lung cancer;
LUSC	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-1.02	-20.42	-0.75	1.04e-60	Dilated cardiomyopathy;
LUSC	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.79	-11.27	-0.52	3.47e-25	Exhaled nitric oxide output;
LUSC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.71	0.47	8.46e-20	Bipolar disorder;
LUSC	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.43	-7.11	-0.36	7.01e-12	Eosinophil percentage of white cells;
LUSC	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg26395211	chr5:140044315	WDR55	-0.38	-5.83	-0.3	1.28e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7524258	0.900	rs7514988	chr1:7271651	C/T	cg07173049	chr1:7289937	CAMTA1	0.31	6.51	0.34	2.73e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.84	-0.35	3.69e-11	Bipolar disorder;
LUSC	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.39	-5.65	-0.3	3.35e-8	Childhood ear infection;
LUSC	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-0.53	-8.24	-0.41	4.03e-15	Breast cancer;
LUSC	cis	rs12530845	0.945	rs12540273	chr7:135333854	T/G	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs308403	0.568	rs13146929	chr4:123671151	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.79	10.2	0.49	1.95e-21	Blood protein levels;
LUSC	cis	rs41271473	0.607	rs10916361	chr1:228859971	A/T	cg10167378	chr1:228756711	NA	0.48	6.89	0.35	2.82e-11	Chronic lymphocytic leukemia;
LUSC	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg05784532	chr1:230284198	GALNT2	0.54	8.04	0.4	1.57e-14	Coronary artery disease;
LUSC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg09165964	chr15:75287851	SCAMP5	-0.45	-6.78	-0.35	5.41e-11	Breast cancer;
LUSC	trans	rs12439619	1.000	rs12439619	chr15:82546946	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.54	-8.62	-0.43	2.7e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs11608355	0.515	rs11609921	chr12:109918405	A/G	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.78	-12.93	-0.58	2.79e-31	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23564255	chr14:24711932	TINF2	-0.44	-6.82	-0.35	4.3e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg26384229	chr12:38710491	ALG10B	0.78	11.72	0.54	8.25e-27	Morning vs. evening chronotype;
LUSC	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-13.61	-0.6	7.56e-34	Coronary artery disease;
LUSC	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg03647239	chr10:116582469	FAM160B1	0.46	7.35	0.37	1.52e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9308433	0.529	rs10465696	chr1:214499883	G/A	cg06198575	chr1:214491504	SMYD2	0.45	6.99	0.36	1.46e-11	IgG glycosylation;
LUSC	trans	rs1949829	1.000	rs1949829	chr7:51537887	C/T	cg20941110	chr15:83953819	BNC1	0.55	6.05	0.31	3.85e-9	Wegener's granulomatosis;
LUSC	cis	rs4654899	0.758	rs6694455	chr1:21352185	C/T	cg01072550	chr1:21505969	NA	-0.54	-8.29	-0.41	2.85e-15	Superior frontal gyrus grey matter volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17450446	chr1:160002111	PIGM	0.4	6.15	0.32	2.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-7.3	-0.37	2.07e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg02475777	chr4:1388615	CRIPAK	0.45	6.69	0.34	9.62e-11	Obesity-related traits;
LUSC	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	0.93	17.44	0.69	6.92e-49	Headache;
LUSC	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg22705602	chr4:152727874	NA	-0.38	-8.16	-0.41	6.96e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.03	0.31	4.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg24375607	chr4:120327624	NA	0.72	11.66	0.54	1.38e-26	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	cis	rs6120849	0.754	rs6120804	chr20:33623701	C/A	cg24642439	chr20:33292090	TP53INP2	0.61	6.74	0.35	6.84e-11	Protein C levels;
LUSC	cis	rs3087591	0.919	rs2952993	chr17:29539998	G/A	cg24425628	chr17:29625626	OMG;NF1	0.6	8.67	0.43	1.91e-16	Hip circumference;
LUSC	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.91	12.43	0.56	2.13e-29	Mean corpuscular hemoglobin;
LUSC	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg04034577	chr2:241836375	C2orf54	0.49	9.31	0.45	1.75e-18	Urinary metabolites;
LUSC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	9.0	0.44	1.77e-17	Prudent dietary pattern;
LUSC	cis	rs483180	0.512	rs594400	chr1:120214275	G/T	cg19096424	chr1:120255104	PHGDH	-0.46	-6.42	-0.33	4.6e-10	Macular telangiectasia type 2;
LUSC	cis	rs7264396	0.779	rs6087723	chr20:34175783	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.52	7.56	0.38	3.84e-13	Total cholesterol levels;
LUSC	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.59	0.5	8.44e-23	Bladder cancer;
LUSC	trans	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg21659725	chr3:3221576	CRBN	-0.65	-7.72	-0.39	1.36e-13	Menarche (age at onset);
LUSC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg06671706	chr8:8559999	CLDN23	0.5	6.68	0.34	9.98e-11	Obesity-related traits;
LUSC	cis	rs28655083	0.956	rs8060627	chr16:77077065	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.43	-6.72	-0.35	7.71e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.52	-7.52	-0.38	4.98e-13	Renal function-related traits (BUN);
LUSC	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg03342759	chr3:160939853	NMD3	-0.5	-8.49	-0.42	6.79e-16	Morning vs. evening chronotype;
LUSC	cis	rs3087591	0.708	rs3815154	chr17:29654974	G/A	cg24425628	chr17:29625626	OMG;NF1	0.46	6.86	0.35	3.37e-11	Hip circumference;
LUSC	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.57	9.61	0.47	1.86e-19	Breast cancer;
LUSC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.76	-12.48	-0.56	1.28e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.58	-9.25	-0.45	2.75e-18	Aortic root size;
LUSC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg21573476	chr21:45109991	RRP1B	0.39	6.49	0.33	3.07e-10	Mean corpuscular volume;
LUSC	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg22800045	chr5:56110881	MAP3K1	0.43	5.89	0.31	9.65e-9	Coronary artery disease;
LUSC	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg15790184	chr11:494944	RNH1	0.42	6.4	0.33	5.37e-10	Systemic lupus erythematosus;
LUSC	cis	rs2652834	1.000	rs2729788	chr15:63400378	G/C	cg05507819	chr15:63340323	TPM1	0.68	8.21	0.41	4.95e-15	HDL cholesterol;
LUSC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg18402987	chr7:1209562	NA	0.73	7.85	0.39	5.87e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6961069	0.837	rs1722505	chr7:80240689	T/C	cg04458919	chr7:80252533	CD36	-0.36	-6.63	-0.34	1.32e-10	Platelet count;
LUSC	cis	rs6692729	0.933	rs1046240	chr1:227071525	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.51	-7.32	-0.37	1.91e-12	Electrodermal activity;
LUSC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.68	12.02	0.55	6.91e-28	Aortic root size;
LUSC	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg00945038	chr17:61921165	SMARCD2	0.4	6.09	0.32	3.17e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4786125	0.639	rs7200754	chr16:6897636	A/G	cg03623568	chr16:6915990	A2BP1	0.35	6.31	0.33	8.99e-10	Heart rate variability traits (SDNN);
LUSC	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg06636001	chr8:8085503	FLJ10661	0.48	7.07	0.36	9.18e-12	Neuroticism;
LUSC	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.28	-0.45	2.21e-18	Joint mobility (Beighton score);
LUSC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg05347473	chr6:146136440	FBXO30	0.46	7.96	0.4	2.77e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.78	13.25	0.59	1.72e-32	Metabolic syndrome;
LUSC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg26338869	chr17:61819248	STRADA	0.42	6.18	0.32	1.88e-9	Prudent dietary pattern;
LUSC	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg17633681	chr16:88106987	BANP	0.47	8.38	0.42	1.51e-15	Menopause (age at onset);
LUSC	cis	rs1997103	0.954	rs6593235	chr7:55410986	A/G	cg17469321	chr7:55412551	NA	0.66	10.59	0.5	8.59e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.21	-0.32	1.59e-9	Retinal vascular caliber;
LUSC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg11764359	chr7:65958608	NA	0.55	7.2	0.37	3.94e-12	Aortic root size;
LUSC	cis	rs12367572	0.620	rs1857925	chr12:45344385	T/C	cg04608330	chr12:45269318	NELL2	-0.39	-6.01	-0.31	4.98e-9	Gut microbiome composition (summer);
LUSC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg20684491	chr1:25596433	NA	0.39	6.12	0.32	2.61e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg06238570	chr21:40685208	BRWD1	-0.56	-8.77	-0.43	9.03e-17	Menarche (age at onset);
LUSC	cis	rs897984	0.568	rs11862962	chr16:30909706	C/G	cg02466173	chr16:30829666	NA	-0.53	-8.56	-0.42	4.15e-16	Dementia with Lewy bodies;
LUSC	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg22705602	chr4:152727874	NA	0.38	7.85	0.39	5.54e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7903847	0.642	rs7924254	chr10:99120925	C/T	cg20016023	chr10:99160130	RRP12	-0.29	-6.2	-0.32	1.7e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs13082711	0.863	rs36055621	chr3:27436797	T/C	cg02860705	chr3:27208620	NA	0.46	7.66	0.39	2e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg27147174	chr7:100797783	AP1S1	-0.68	-10.87	-0.51	9.28e-24	Life satisfaction;
LUSC	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg02569458	chr12:86230093	RASSF9	0.54	8.83	0.44	5.86e-17	Major depressive disorder;
LUSC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.5	0.34	2.85e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg17385448	chr1:15911702	AGMAT	-0.38	-6.54	-0.34	2.27e-10	Systolic blood pressure;
LUSC	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg23950597	chr19:37808831	NA	-0.64	-7.56	-0.38	3.91e-13	Coronary artery calcification;
LUSC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg26513180	chr16:89883248	FANCA	0.9	17.06	0.68	2.16e-47	Vitiligo;
LUSC	cis	rs9322817	0.691	rs2499663	chr6:105300570	A/G	cg02098413	chr6:105308735	HACE1	-0.27	-5.84	-0.3	1.25e-8	Thyroid stimulating hormone;
LUSC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg17279839	chr7:150038598	RARRES2	-0.44	-6.81	-0.35	4.59e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg23630131	chr7:65973040	NA	0.21	5.81	0.3	1.45e-8	Aortic root size;
LUSC	cis	rs17407555	0.697	rs56079809	chr4:10102736	C/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-6.57	-0.34	1.9e-10	Schizophrenia (age at onset);
LUSC	cis	rs9341808	0.556	rs10455370	chr6:81040867	A/G	cg08355045	chr6:80787529	NA	-0.46	-7.86	-0.4	5.17e-14	Sitting height ratio;
LUSC	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg25554036	chr4:6271136	WFS1	0.59	12.15	0.55	2.29e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9650315	0.929	rs7829319	chr8:57172232	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.68	0.34	1.01e-10	Height;
LUSC	cis	rs4478137	0.931	rs4057797	chr4:164245053	T/A	cg06758707	chr4:164254230	NPY1R	0.63	9.92	0.48	1.7e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg17366294	chr4:99064904	C4orf37	0.59	10.39	0.49	4.12e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-7.21	-0.37	3.73e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg01733217	chr16:74700730	RFWD3	0.74	12.46	0.56	1.53e-29	Testicular germ cell tumor;
LUSC	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.77	11.09	0.52	1.49e-24	Corneal astigmatism;
LUSC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.02	0.58	1.28e-31	Chronic sinus infection;
LUSC	cis	rs273573	0.922	rs927224	chr11:30810665	T/C	cg06552810	chr11:31128660	NA	-0.33	-5.71	-0.3	2.43e-8	Total body bone mineral density;
LUSC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.45	0.33	3.9e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6580649	0.941	rs11612578	chr12:48414798	T/C	cg24011408	chr12:48396354	COL2A1	-0.49	-6.73	-0.35	7.51e-11	Lung cancer;
LUSC	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.71	11.07	0.52	1.75e-24	Alcohol dependence;
LUSC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg12564285	chr5:131593104	PDLIM4	-0.48	-8.3	-0.41	2.59e-15	Blood metabolite levels;
LUSC	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg27411982	chr8:10470053	RP1L1	0.43	6.63	0.34	1.36e-10	Triglycerides;
LUSC	cis	rs7408868	0.611	rs11671336	chr19:15294043	C/T	cg14696996	chr19:15285081	NOTCH3	0.64	6.76	0.35	6.09e-11	Pulse pressure;
LUSC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg09365446	chr1:150670422	GOLPH3L	0.52	8.07	0.4	1.29e-14	Tonsillectomy;
LUSC	cis	rs12980942	0.872	rs2053086	chr19:41799475	C/T	cg25627403	chr19:41769009	HNRNPUL1	-0.61	-6.54	-0.34	2.26e-10	Coronary artery disease;
LUSC	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.84	-0.3	1.26e-8	Total body bone mineral density;
LUSC	cis	rs4566357	0.615	rs2272202	chr2:227914625	C/T	cg11843606	chr2:227700838	RHBDD1	0.53	8.15	0.41	7.43e-15	Coronary artery disease;
LUSC	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg18302933	chr2:88491318	NA	-0.38	-7.54	-0.38	4.57e-13	Response to metformin (IC50);
LUSC	cis	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg02972257	chr16:68554789	NA	-0.53	-6.6	-0.34	1.64e-10	Ulcerative colitis;
LUSC	trans	rs34421088	0.506	rs4841518	chr8:11145963	G/C	cg06636001	chr8:8085503	FLJ10661	0.5	7.39	0.37	1.17e-12	Neuroticism;
LUSC	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-0.52	-8.03	-0.4	1.65e-14	Breast cancer;
LUSC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg23161317	chr6:28129485	ZNF389	0.44	5.69	0.3	2.71e-8	Parkinson's disease;
LUSC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg01416388	chr22:39784598	NA	-0.45	-6.95	-0.36	1.91e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.86	-15.28	-0.64	2.37e-40	Ulcerative colitis;
LUSC	cis	rs9297145	0.715	rs62473008	chr7:98751541	A/G	cg05967295	chr7:98741636	SMURF1	0.99	14.86	0.63	1.1e-38	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg12927641	chr6:109611667	NA	0.4	6.82	0.35	4.25e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.08	0.55	4.01e-28	Prudent dietary pattern;
LUSC	cis	rs12474201	0.619	rs17821827	chr2:46918682	C/T	cg09399716	chr2:46890238	NA	-0.43	-8.27	-0.41	3.32e-15	Height;
LUSC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.23	14.12	0.61	8.1e-36	Diabetic kidney disease;
LUSC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-1.01	-17.64	-0.69	1.14e-49	Body mass index;
LUSC	cis	rs9311676	0.656	rs11712213	chr3:58384995	G/A	cg13750441	chr3:58318267	PXK	0.35	6.72	0.35	7.86e-11	Systemic lupus erythematosus;
LUSC	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.77	11.2	0.52	6.24e-25	Corneal astigmatism;
LUSC	cis	rs2637266	1.000	rs7392737	chr10:78366059	C/T	cg18941641	chr10:78392320	NA	0.39	7.22	0.37	3.61e-12	Pulmonary function;
LUSC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg22903657	chr4:1355424	KIAA1530	-0.37	-6.3	-0.33	9.34e-10	Obesity-related traits;
LUSC	cis	rs506338	0.517	rs516117	chr11:64433444	T/C	cg19131476	chr11:64387923	NRXN2	0.36	7.81	0.39	7.34e-14	Body mass index;Urate levels;
LUSC	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg26384229	chr12:38710491	ALG10B	-0.8	-13.11	-0.58	5.6199999999999995e-32	Morning vs. evening chronotype;
LUSC	trans	rs67133203	1.000	rs67133203	chr12:51426657	A/T	cg17484237	chr5:156536107	HAVCR2	0.44	5.97	0.31	6.2e-9	Urinary tract infection frequency;
LUSC	cis	rs2236918	1.000	rs1635512	chr1:242024500	A/G	cg17736920	chr1:242011382	EXO1	-0.45	-7.13	-0.36	6.19e-12	Menopause (age at onset);
LUSC	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg05163923	chr11:71159392	DHCR7	-0.77	-10.02	-0.48	7.56e-21	Vitamin D levels;
LUSC	cis	rs4343996	0.901	rs1112428	chr7:3352512	T/C	cg21248987	chr7:3385318	SDK1	-0.36	-6.1	-0.32	2.93e-9	Motion sickness;
LUSC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg08736216	chr1:53307985	ZYG11A	0.28	5.74	0.3	2.12e-8	Monocyte count;
LUSC	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22857025	chr5:266934	NA	-1.2	-14.11	-0.61	8.51e-36	Breast cancer;
LUSC	cis	rs617219	0.819	rs6889156	chr5:78596919	T/C	cg24856658	chr5:78533917	JMY	0.31	5.99	0.31	5.44e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg20573242	chr4:122745356	CCNA2	0.64	9.44	0.46	6.7e-19	Type 2 diabetes;
LUSC	cis	rs4906332	0.782	rs7161305	chr14:104002234	G/A	cg04998671	chr14:104000505	TRMT61A	-0.58	-7.8	-0.39	7.99e-14	Coronary artery disease;
LUSC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	cis	rs11209185	0.509	rs9436790	chr1:68447044	G/A	cg22082780	chr1:68452167	NA	0.44	7.38	0.37	1.27e-12	Itch intensity from mosquito bite adjusted by bite size;
LUSC	trans	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg17567195	chr5:167378696	ODZ2	-0.4	-6.2	-0.32	1.68e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9395066	0.545	rs12526711	chr6:44883873	C/T	cg25276700	chr6:44698697	NA	0.3	6.11	0.32	2.76e-9	Height;
LUSC	cis	rs262150	0.625	rs55974535	chr7:158769145	C/G	cg09640425	chr7:158790006	NA	0.47	5.66	0.3	3.32e-8	Facial morphology (factor 20);
LUSC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.63	-0.34	1.33e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4499344	0.556	rs865659	chr19:33139967	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.94	13.87	0.6	7.32e-35	Mean platelet volume;
LUSC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg00933542	chr6:150070202	PCMT1	0.31	6.51	0.34	2.78e-10	Lung cancer;
LUSC	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.99	-0.4	2.22e-14	Glomerular filtration rate;
LUSC	cis	rs4842666	0.915	rs17249754	chr12:90060586	A/G	cg00757033	chr12:89920650	WDR51B	-0.47	-6.96	-0.36	1.79e-11	Blood pressure;
LUSC	cis	rs7119	0.666	rs2516302	chr15:77879842	C/G	cg27398640	chr15:77910606	LINGO1	0.36	8.37	0.42	1.61e-15	Type 2 diabetes;
LUSC	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.87	0.31	1.06e-8	Morning vs. evening chronotype;
LUSC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg27494647	chr7:150038898	RARRES2	0.48	7.29	0.37	2.23e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg05182265	chr7:156933206	UBE3C	-0.61	-10.08	-0.48	4.95e-21	Body mass index;
LUSC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18131467	chr2:239335373	ASB1	1.01	23.44	0.79	1.51e-72	Multiple system atrophy;
LUSC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg00677455	chr12:58241039	CTDSP2	0.62	8.65	0.43	2.18e-16	Multiple sclerosis;
LUSC	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg13010199	chr12:38710504	ALG10B	0.62	9.48	0.46	4.72e-19	Bladder cancer;
LUSC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.57	-0.34	1.98e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.6	-8.41	-0.42	1.23e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12483801	chr4:183727862	NA	0.42	5.88	0.31	1e-8	Pediatric autoimmune diseases;
LUSC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg05738196	chr6:26577821	NA	-0.6	-7.05	-0.36	1e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2625529	0.730	rs35713471	chr15:72459971	C/A	cg16672083	chr15:72433130	SENP8	-0.51	-7.33	-0.37	1.71e-12	Red blood cell count;
LUSC	trans	rs11088226	0.581	rs2016103	chr21:33878030	G/A	cg09050820	chr6:167586206	TCP10L2	0.49	7.73	0.39	1.24e-13	Gastritis;
LUSC	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.01	-0.31	4.97e-9	Retinal vascular caliber;
LUSC	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg22906224	chr7:99728672	NA	-0.56	-8.52	-0.42	5.57e-16	Coronary artery disease;
LUSC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg14343924	chr8:8086146	FLJ10661	0.42	5.97	0.31	5.9e-9	Mood instability;
LUSC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.59	0.34	1.76e-10	Lung cancer;
LUSC	cis	rs11630290	0.592	rs11634436	chr15:64158394	T/G	cg12036633	chr15:63758958	NA	0.53	6.83	0.35	4.13e-11	Iris characteristics;
LUSC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg04546413	chr19:29218101	NA	0.72	11.48	0.53	6.21e-26	Methadone dose in opioid dependence;
LUSC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg02038168	chr22:39784481	NA	-0.43	-6.55	-0.34	2.23e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg05872129	chr22:39784769	NA	-0.51	-7.27	-0.37	2.51e-12	IgG glycosylation;
LUSC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg15017067	chr4:17643749	FAM184B	0.34	5.76	0.3	1.96e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.61	-0.43	3.03e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-8.35	-0.42	1.85e-15	Morning vs. evening chronotype;
LUSC	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg23093090	chr10:104574429	C10orf26	-0.36	-6.62	-0.34	1.4e-10	Arsenic metabolism;
LUSC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg06784218	chr1:46089804	CCDC17	-0.48	-9.7	-0.47	9.43e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-1.11	-13.36	-0.59	6.33e-33	Type 2 diabetes nephropathy;
LUSC	cis	rs240764	0.817	rs239216	chr6:101147892	T/G	cg09795085	chr6:101329169	ASCC3	0.42	6.15	0.32	2.16e-9	Neuroticism;
LUSC	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg18681998	chr4:17616180	MED28	0.83	14.53	0.62	2.08e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17850984	chr19:4246870	CCDC94	-0.43	-6.36	-0.33	6.77e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg02800362	chr5:177631904	HNRNPAB	0.87	12.81	0.57	8.07e-31	Obesity-related traits;
LUSC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg09021430	chr5:549028	NA	-0.57	-7.7	-0.39	1.61e-13	Obesity-related traits;
LUSC	cis	rs7605827	0.897	rs10084390	chr2:15597662	C/A	cg19274914	chr2:15703543	NA	0.46	8.8	0.43	7.47e-17	Educational attainment (years of education);
LUSC	trans	rs2392780	0.536	rs452529	chr8:128333259	C/G	cg10195415	chr17:73887371	TRIM65	-0.37	-6.09	-0.32	3.16e-9	Breast cancer (early onset);
LUSC	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg05855489	chr10:104503620	C10orf26	0.52	8.08	0.4	1.19e-14	Arsenic metabolism;
LUSC	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg13813247	chr22:41461852	NA	-0.37	-6.75	-0.35	6.38e-11	Neuroticism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05076971	chr7:117824189	NAA38	-0.49	-5.97	-0.31	6.03e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13264059	chr10:129705415	PTPRE	-0.41	-6.31	-0.33	8.93e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1957429	0.634	rs7143541	chr14:65419777	G/T	cg23373153	chr14:65346875	NA	-0.87	-9.16	-0.45	5.54e-18	Pediatric areal bone mineral density (radius);
LUSC	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.7	-0.34	9.1e-11	Reticulocyte count;
LUSC	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg15654264	chr1:150340011	RPRD2	0.65	10.85	0.51	1.1e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg07741184	chr6:167504864	NA	0.36	6.53	0.34	2.52e-10	Crohn's disease;
LUSC	cis	rs354225	0.544	rs13386146	chr2:54802514	G/C	cg26097391	chr2:54893211	SPTBN1	0.45	6.82	0.35	4.21e-11	Schizophrenia;
LUSC	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.76	-13.67	-0.6	4.17e-34	Longevity;
LUSC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.57	0.38	3.73e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	13.16	0.58	3.88e-32	Lung cancer in ever smokers;
LUSC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg17366294	chr4:99064904	C4orf37	0.58	10.2	0.49	1.91e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4566357	0.615	rs12618793	chr2:227909552	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.37	-0.42	1.64e-15	Coronary artery disease;
LUSC	cis	rs34421088	0.585	rs6992190	chr8:11596549	A/C	cg13293535	chr8:11597251	GATA4	0.3	5.69	0.3	2.71e-8	Neuroticism;
LUSC	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg04865166	chr7:105162814	PUS7	0.51	5.65	0.3	3.36e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg02782426	chr3:40428986	ENTPD3	0.41	7.61	0.38	2.87e-13	Renal cell carcinoma;
LUSC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	12.32	0.56	5.3e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13315871	0.929	rs11130627	chr3:58315749	G/A	cg20936604	chr3:58311152	NA	-0.76	-6.96	-0.36	1.78e-11	Cholesterol, total;
LUSC	cis	rs4561483	0.801	rs40311	chr16:11963190	C/G	cg08843971	chr16:11963173	GSPT1	0.48	7.18	0.37	4.52e-12	Testicular germ cell tumor;
LUSC	cis	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.55	-0.38	4.09e-13	Morning vs. evening chronotype;
LUSC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg00684032	chr4:1343700	KIAA1530	-0.36	-6.11	-0.32	2.82e-9	Obesity-related traits;
LUSC	trans	rs6982636	0.967	rs2980860	chr8:126485337	A/G	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.32	-6.36	-0.33	6.73e-10	Lipid metabolism phenotypes;
LUSC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg20991723	chr1:152506922	NA	0.52	9.93	0.48	1.63e-20	Hair morphology;
LUSC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	1.04	19.18	0.72	7.95e-56	Menopause (age at onset);
LUSC	cis	rs9650315	0.866	rs13266192	chr8:57195456	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	7.13	0.36	6.25e-12	Height;
LUSC	cis	rs2236918	0.710	rs2797602	chr1:242029206	G/T	cg17736920	chr1:242011382	EXO1	0.4	6.35	0.33	7.03e-10	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	12.15	0.55	2.22e-28	Prudent dietary pattern;
LUSC	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	7.34	0.37	1.62e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg19773385	chr1:10388646	KIF1B	-0.57	-9.61	-0.47	1.81e-19	Hepatocellular carcinoma;
LUSC	cis	rs2274273	0.870	rs66696758	chr14:55766509	G/A	cg04306507	chr14:55594613	LGALS3	0.54	12.08	0.55	3.86e-28	Protein biomarker;
LUSC	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.7	-11.41	-0.53	1.06e-25	Morning vs. evening chronotype;
LUSC	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg21643547	chr1:205240462	TMCC2	-0.38	-7.04	-0.36	1.11e-11	Red blood cell count;
LUSC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	7.06	0.36	9.71e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg27170947	chr2:26402098	FAM59B	0.72	10.52	0.5	1.48e-22	Gut microbiome composition (summer);
LUSC	cis	rs7000551	0.725	rs2469757	chr8:22360938	C/T	cg12081754	chr8:22256438	SLC39A14	0.43	6.44	0.33	4.11e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.06	-26.47	-0.82	5.08e-84	Colorectal cancer;
LUSC	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-7.03	-0.36	1.21e-11	Height;
LUSC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg06221963	chr1:154839813	KCNN3	-0.44	-8.9	-0.44	3.67e-17	Schizophrenia;
LUSC	cis	rs2932538	0.961	rs2932534	chr1:113200797	A/G	cg22162597	chr1:113214053	CAPZA1	0.64	9.46	0.46	5.76e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs4443100	0.916	rs8139695	chr22:23373902	A/T	cg14186256	chr22:23484241	RTDR1	-0.48	-5.99	-0.31	5.39e-9	Serum parathyroid hormone levels;
LUSC	cis	rs57590327	0.528	rs4856346	chr3:81502655	T/G	cg07356753	chr3:81810745	GBE1	0.45	6.02	0.31	4.58e-9	Extraversion;
LUSC	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg13010199	chr12:38710504	ALG10B	0.48	7.28	0.37	2.47e-12	Heart rate;
LUSC	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	7.74	0.39	1.2e-13	Height;
LUSC	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-0.56	-8.69	-0.43	1.63e-16	Breast cancer;
LUSC	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.7	-0.43	1.5e-16	Uric acid levels;
LUSC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg15839431	chr19:19639596	YJEFN3	-0.4	-5.69	-0.3	2.76e-8	Tonsillectomy;
LUSC	cis	rs7202877	0.656	rs3851736	chr16:75387332	T/C	cg03315344	chr16:75512273	CHST6	0.45	6.67	0.34	1.07e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg18753928	chr3:113234510	CCDC52	-0.51	-7.63	-0.39	2.53e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg21285383	chr16:89894308	SPIRE2	-0.35	-7.33	-0.37	1.75e-12	Vitiligo;
LUSC	cis	rs56399783	0.901	rs73047393	chr7:2775879	C/T	cg19731401	chr7:2775893	GNA12	0.73	8.92	0.44	3.05e-17	Childhood ear infection;
LUSC	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.53	10.0	0.48	9.14e-21	Bone mineral density;
LUSC	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.55	-7.06	-0.36	9.48e-12	Body mass index;
LUSC	trans	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg10756647	chr7:56101905	PSPH	0.85	8.28	0.41	3.01e-15	Diabetic kidney disease;
LUSC	cis	rs6845621	0.901	rs9993984	chr4:18927087	G/A	cg12196642	chr4:18937545	NA	-0.35	-6.52	-0.34	2.55e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9925964	0.967	rs1978487	chr16:31129942	C/T	cg02466173	chr16:30829666	NA	-0.32	-5.85	-0.3	1.19e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9341808	0.530	rs3805877	chr6:81031529	T/A	cg08355045	chr6:80787529	NA	0.51	8.89	0.44	3.84e-17	Sitting height ratio;
LUSC	cis	rs2797160	1.000	rs2747725	chr6:126012397	A/C	cg05901451	chr6:126070800	HEY2	0.54	7.85	0.39	5.56e-14	Endometrial cancer;
LUSC	cis	rs3862435	0.764	rs12913819	chr15:91045928	T/C	cg22089800	chr15:90895588	ZNF774	-0.55	-5.9	-0.31	9.05e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg13852791	chr20:30311386	BCL2L1	0.93	14.15	0.61	6.1e-36	Mean corpuscular hemoglobin;
LUSC	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg18105134	chr13:113819100	PROZ	-0.75	-10.71	-0.51	3.38e-23	Platelet distribution width;
LUSC	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg10426581	chr7:100472382	SRRT	0.86	12.37	0.56	3.44e-29	Resting heart rate;
LUSC	cis	rs12549902	0.966	rs17659386	chr8:41513531	T/C	cg21772509	chr8:41503840	NKX6-3	0.64	10.42	0.5	3.4e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs2742234	0.590	rs2505553	chr10:43681251	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.03	-0.36	1.17e-11	Hirschsprung disease;
LUSC	cis	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.21	-0.32	1.56e-9	Resting heart rate;
LUSC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg08847533	chr14:75593920	NEK9	0.84	15.49	0.65	3.54e-41	Height;
LUSC	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg17366294	chr4:99064904	C4orf37	0.56	9.77	0.47	5.22e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg22532475	chr10:104410764	TRIM8	-0.25	-5.99	-0.31	5.4e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.02	0.63	2.56e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-10.97	-0.51	4.05e-24	Mean corpuscular volume;
LUSC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg12559939	chr2:27858050	GPN1	0.39	6.05	0.31	3.98e-9	Oral cavity cancer;
LUSC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg15448220	chr1:150897856	SETDB1	0.43	6.26	0.32	1.21e-9	Melanoma;
LUSC	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg06223162	chr1:101003688	GPR88	0.49	9.44	0.46	6.6e-19	Monocyte count;
LUSC	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	1.17	17.75	0.7	4.18e-50	Corneal structure;
LUSC	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg05868516	chr6:26286170	HIST1H4H	0.36	5.87	0.31	1.05e-8	Educational attainment;
LUSC	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.66	-12.34	-0.56	4.6e-29	Platelet distribution width;
LUSC	cis	rs1953600	0.521	rs7067644	chr10:81924245	A/G	cg00277334	chr10:82204260	NA	-0.43	-6.72	-0.35	7.72e-11	Sarcoidosis;
LUSC	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.84	0.51	1.15e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg00310523	chr12:86230176	RASSF9	0.47	8.63	0.43	2.61e-16	Major depressive disorder;
LUSC	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg08000102	chr2:233561755	GIGYF2	-0.52	-8.0	-0.4	2.13e-14	Coronary artery disease;
LUSC	cis	rs11039100	1.000	rs12798823	chr11:5826716	T/G	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg13531842	chr10:38383804	ZNF37A	-0.46	-7.23	-0.37	3.4e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg05313129	chr8:58192883	C8orf71	-0.55	-6.21	-0.32	1.55e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs997295	0.737	rs11631474	chr15:67934167	C/T	cg08079166	chr15:68083412	MAP2K5	0.31	6.14	0.32	2.32e-9	Motion sickness;
LUSC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.19	16.49	0.67	4.02e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.48	6.4	0.33	5.14e-10	Renal function-related traits (BUN);
LUSC	cis	rs8141797	0.901	rs738808	chr22:24488461	C/T	cg00411358	chr22:24577142	SUSD2	-0.61	-6.02	-0.31	4.6e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg06238570	chr21:40685208	BRWD1	0.47	7.3	0.37	2.08e-12	Cognitive function;
LUSC	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-15.02	-0.63	2.6e-39	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg24375607	chr4:120327624	NA	0.75	11.42	0.53	9.94e-26	Corneal astigmatism;
LUSC	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg05082376	chr22:42548792	NA	0.36	5.84	0.3	1.24e-8	Cognitive function;
LUSC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.71	-0.34	8.1e-11	Lung cancer;
LUSC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg24733560	chr20:60626293	TAF4	0.44	8.08	0.4	1.19e-14	Body mass index;
LUSC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	16.56	0.67	2.19e-45	Platelet count;
LUSC	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	trans	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg02030672	chr11:45687055	CHST1	0.45	6.74	0.35	6.79e-11	Obesity-related traits;
LUSC	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	6.14	0.32	2.4e-9	Lung cancer in ever smokers;
LUSC	cis	rs243505	0.632	rs887571	chr7:148505253	G/A	cg09806900	chr7:148480153	CUL1	0.57	8.44	0.42	1e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs73206853	0.609	rs12311902	chr12:110883799	T/C	cg12870014	chr12:110450643	ANKRD13A	0.5	5.9	0.31	9.03e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1891275	0.515	rs1418161	chr10:93484655	C/G	cg07889827	chr10:93443413	NA	-0.4	-9.1	-0.45	8.58e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25492241	chr3:159482591	SCHIP1	0.72	6.77	0.35	5.84e-11	Cognitive performance;
LUSC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	9.12	0.45	7.28e-18	Mean platelet volume;
LUSC	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg20503657	chr10:835505	NA	0.52	6.27	0.32	1.12e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.89	-0.4	4.34e-14	Glomerular filtration rate;
LUSC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg05347473	chr6:146136440	FBXO30	0.46	7.99	0.4	2.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5758511	0.514	rs9607882	chr22:42567451	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	9.8	0.47	4.25e-20	Birth weight;
LUSC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg02951883	chr7:2050386	MAD1L1	-0.45	-7.66	-0.39	2.07e-13	Bipolar disorder and schizophrenia;
LUSC	trans	rs7939886	0.920	rs7934132	chr11:55942463	T/A	cg15704280	chr7:45808275	SEPT13	0.88	6.69	0.34	9.39e-11	Myopia (pathological);
LUSC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg05347473	chr6:146136440	FBXO30	0.51	8.39	0.42	1.43e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2282300	1.000	rs12796693	chr11:30429583	A/C	cg25418670	chr11:30344373	C11orf46	-0.47	-6.28	-0.32	1.06e-9	Morning vs. evening chronotype;
LUSC	trans	rs1325195	0.920	rs2816167	chr1:179200657	T/G	cg11624085	chr17:8464688	MYH10	0.44	6.97	0.36	1.7e-11	IgE grass sensitization;
LUSC	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.43	-5.83	-0.3	1.29e-8	Coronary artery disease;
LUSC	cis	rs7523273	0.586	rs2796276	chr1:207951513	G/A	cg22525895	chr1:207977042	MIR29B2	0.42	6.71	0.34	8.25e-11	Schizophrenia;
LUSC	trans	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg18187862	chr3:45730750	SACM1L	0.53	6.62	0.34	1.46e-10	Primary sclerosing cholangitis;
LUSC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg06064525	chr11:970664	AP2A2	0.48	10.63	0.5	6.39e-23	Alzheimer's disease (late onset);
LUSC	cis	rs10979	1.000	rs1416207	chr6:143889275	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs9463078	0.547	rs764396	chr6:44710691	C/G	cg25276700	chr6:44698697	NA	0.3	6.2	0.32	1.66e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs753955	0.593	rs7982516	chr13:24410278	A/G	cg03803002	chr8:141110260	TRAPPC9	-0.34	-6.07	-0.32	3.45e-9	Lung cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00144817	chr8:17503298	MTUS1	-0.76	-6.28	-0.32	1.08e-9	Cognitive performance;
LUSC	cis	rs10744422	1.000	rs12255	chr12:123350204	C/T	cg25930673	chr12:123319894	HIP1R	-0.6	-6.06	-0.31	3.7e-9	Schizophrenia;
LUSC	cis	rs240764	0.658	rs7740006	chr6:101220432	T/C	cg09795085	chr6:101329169	ASCC3	-0.44	-6.24	-0.32	1.29e-9	Neuroticism;
LUSC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.35	-0.37	1.55e-12	Subjective well-being;
LUSC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg05347473	chr6:146136440	FBXO30	-0.6	-10.6	-0.5	7.93e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg00343986	chr7:65444356	GUSB	0.4	5.93	0.31	7.43e-9	Aortic root size;
LUSC	cis	rs11955175	1.000	rs77394428	chr5:40743517	A/G	cg05478818	chr5:40835740	RPL37	0.74	5.84	0.3	1.27e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg12365402	chr11:9010492	NRIP3	-0.47	-8.71	-0.43	1.39e-16	Hemoglobin concentration;
LUSC	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.13	0.41	8.35e-15	Prudent dietary pattern;
LUSC	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg09307838	chr4:120376055	NA	0.65	9.89	0.48	2.06e-20	Corneal astigmatism;
LUSC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg15556689	chr8:8085844	FLJ10661	0.67	10.39	0.49	4.1e-22	Neuroticism;
LUSC	cis	rs2249625	0.508	rs114505309	chr6:72892383	G/A	cg18830697	chr6:72922368	RIMS1	0.38	7.67	0.39	1.87e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	17.55	0.69	2.62e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4072705	0.616	rs915033	chr9:127245558	C/G	cg13476313	chr9:127244764	NR5A1	0.33	6.5	0.34	2.91e-10	Menarche (age at onset);
LUSC	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.74	-0.35	7e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg24733560	chr20:60626293	TAF4	0.41	6.77	0.35	5.69e-11	Body mass index;
LUSC	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg25251562	chr2:3704773	ALLC	0.56	9.28	0.45	2.13e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg14186256	chr22:23484241	RTDR1	0.96	17.5	0.69	4.01e-49	Bone mineral density;
LUSC	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg19920283	chr7:105172520	RINT1	0.64	7.1	0.36	7.7e-12	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.06	-0.48	5.7e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12541635	0.966	rs7819043	chr8:106989783	T/C	cg10147462	chr8:107024639	NA	0.56	10.1	0.48	4.04e-21	Age of smoking initiation;
LUSC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg21856205	chr7:94953877	PON1	-0.36	-5.94	-0.31	7.32e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg07507251	chr3:52567010	NT5DC2	0.33	6.38	0.33	5.76e-10	Bipolar disorder;
LUSC	cis	rs62400317	0.826	rs12205468	chr6:45310285	G/A	cg18551225	chr6:44695536	NA	-0.44	-7.41	-0.38	1.03e-12	Total body bone mineral density;
LUSC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.31	-7.8	-0.39	7.73e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg05347473	chr6:146136440	FBXO30	0.59	10.32	0.49	7.44e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg23625390	chr15:77176239	SCAPER	0.67	10.14	0.49	3.04e-21	Blood metabolite levels;
LUSC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg14019146	chr3:50243930	SLC38A3	-0.36	-8.19	-0.41	5.48e-15	Body mass index;
LUSC	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg19743168	chr1:23544995	NA	0.55	11.05	0.52	2.13e-24	Height;
LUSC	cis	rs983392	0.667	rs662196	chr11:59942757	C/T	cg02771260	chr11:59836817	MS4A3	0.37	6.28	0.33	1.03e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg18681998	chr4:17616180	MED28	0.84	15.61	0.65	1.21e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08280861	chr8:58055591	NA	0.57	6.2	0.32	1.67e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg07701084	chr6:150067640	NUP43	0.55	8.32	0.41	2.23e-15	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19467738	chr11:94823267	ENDOD1	-0.43	-6.4	-0.33	5.14e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	1.15	15.33	0.64	1.56e-40	Nonalcoholic fatty liver disease;
LUSC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	13.04	0.58	1.06e-31	Hip circumference adjusted for BMI;
LUSC	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg13010199	chr12:38710504	ALG10B	0.58	9.24	0.45	2.96e-18	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.66	-0.43	2.01e-16	Bipolar disorder;
LUSC	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg23029597	chr12:123009494	RSRC2	-0.72	-9.33	-0.45	1.51e-18	Body mass index;
LUSC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19748678	chr4:122722346	EXOSC9	0.66	9.94	0.48	1.44e-20	Type 2 diabetes;
LUSC	trans	rs9650657	0.682	rs6989160	chr8:10705360	A/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.13	-0.32	2.44e-9	Neuroticism;
LUSC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg04166393	chr7:2884313	GNA12	0.43	5.85	0.3	1.18e-8	Height;
LUSC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	8.72	0.43	1.29e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg23422044	chr7:1970798	MAD1L1	-0.59	-6.61	-0.34	1.52e-10	Bipolar disorder;
LUSC	cis	rs829883	0.659	rs11109520	chr12:98928646	C/T	cg25150519	chr12:98850993	NA	0.64	8.87	0.44	4.44e-17	Colorectal adenoma (advanced);
LUSC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg15649852	chr7:65879115	NA	-0.4	-5.65	-0.3	3.47e-8	Aortic root size;
LUSC	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg05283184	chr6:79620031	NA	-0.45	-8.61	-0.43	2.94e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.85	0.3	1.18e-8	Menopause (age at onset);
LUSC	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg14634687	chr17:47094252	IGF2BP1	0.31	6.59	0.34	1.75e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg09365446	chr1:150670422	GOLPH3L	0.48	7.07	0.36	9.1e-12	Melanoma;
LUSC	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg05791153	chr7:19748676	TWISTNB	0.75	7.89	0.4	4.47e-14	Thyroid stimulating hormone;
LUSC	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg16576597	chr16:28551801	NUPR1	0.3	6.02	0.31	4.57e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg09092052	chr15:45571596	NA	0.44	6.13	0.32	2.43e-9	Glomerular filtration rate;
LUSC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg06212747	chr3:49208901	KLHDC8B	0.59	8.35	0.42	1.89e-15	Menarche (age at onset);
LUSC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.98	0.44	2.03e-17	Motion sickness;
LUSC	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg24375607	chr4:120327624	NA	0.77	11.56	0.53	3.04e-26	Corneal astigmatism;
LUSC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg08773314	chr2:239334832	ASB1	-0.42	-9.06	-0.44	1.15e-17	Multiple system atrophy;
LUSC	cis	rs7804356	1.000	rs2030136	chr7:26891016	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.14	-0.32	2.39e-9	Type 1 diabetes;
LUSC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.31	-6.14	-0.32	2.32e-9	Total body bone mineral density;
LUSC	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg27005118	chr17:13972210	COX10	-0.49	-9.11	-0.45	7.82e-18	Temperament;
LUSC	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg21053147	chr12:120880522	NA	-0.48	-5.79	-0.3	1.61e-8	Type 1 diabetes nephropathy;
LUSC	cis	rs16854884	0.657	rs6778627	chr3:143720869	G/T	cg06585982	chr3:143692056	C3orf58	0.48	7.5	0.38	5.7e-13	Economic and political preferences (feminism/equality);
LUSC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg18681998	chr4:17616180	MED28	0.84	15.61	0.65	1.21e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs727505	0.789	rs66756015	chr7:124740641	C/A	cg23710748	chr7:124431027	NA	-0.4	-7.04	-0.36	1.08e-11	Lewy body disease;
LUSC	cis	rs9549260	0.564	rs9315784	chr13:41289166	G/A	cg21288729	chr13:41239152	FOXO1	0.55	8.3	0.41	2.7e-15	Red blood cell count;
LUSC	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg00376283	chr12:123451042	ABCB9	0.78	11.88	0.55	2.13e-27	Platelet count;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00451227	chr4:185975098	NA	-0.34	-6.08	-0.32	3.21e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg18352616	chr4:3374830	RGS12	0.28	5.79	0.3	1.61e-8	Parental longevity (mother's age at death);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg16655905	chr19:38755330	SPINT2	0.8	6.33	0.33	7.7e-10	Cognitive performance;
LUSC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.67	-0.47	1.13e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs12519773	0.502	rs67862943	chr5:92529268	G/A	cg18783429	chr5:92414398	NA	0.32	6.68	0.34	1.02e-10	Migraine;
LUSC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg08999081	chr20:33150536	PIGU	0.42	7.81	0.39	7.3e-14	Coronary artery disease;
LUSC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.02	0.4	1.82e-14	Parkinson's disease;
LUSC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.49e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1950626	0.833	rs72700524	chr14:101417309	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.46	0.38	7.73e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs11229555	0.645	rs34054511	chr11:58204943	A/C	cg15696309	chr11:58395628	NA	-0.6	-7.32	-0.37	1.87e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg23283495	chr1:209979779	IRF6	0.78	15.77	0.65	2.87e-42	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	trans	rs12637928	0.560	rs17726773	chr3:110151055	G/A	cg17371621	chr15:61264283	RORA	0.36	5.94	0.31	7.03e-9	Neuroticism;
LUSC	cis	rs1832871	0.643	rs112195967	chr6:158775695	C/T	cg07165851	chr6:158734300	TULP4	0.47	7.23	0.37	3.42e-12	Height;
LUSC	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg21775007	chr8:11205619	TDH	-0.51	-7.5	-0.38	5.89e-13	Retinal vascular caliber;
LUSC	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg27446573	chr6:127587934	RNF146	0.64	10.38	0.49	4.67e-22	Breast cancer;
LUSC	cis	rs2282300	0.637	rs1765131	chr11:30404538	G/C	cg25418670	chr11:30344373	C11orf46	-0.41	-6.35	-0.33	7.02e-10	Morning vs. evening chronotype;
LUSC	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18252515	chr7:66147081	NA	-0.4	-6.01	-0.31	4.93e-9	Corneal structure;
LUSC	cis	rs7809950	1.000	rs10234355	chr7:107086517	T/G	cg23024343	chr7:107201750	COG5	-0.55	-8.76	-0.43	1.01e-16	Coronary artery disease;
LUSC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.74	-0.35	7.1e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	0.85	13.9	0.61	5.48e-35	Tonsillectomy;
LUSC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg20573242	chr4:122745356	CCNA2	0.42	6.52	0.34	2.6200000000000003e-10	Type 2 diabetes;
LUSC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7605827	0.930	rs13016997	chr2:15699240	A/T	cg19274914	chr2:15703543	NA	0.47	9.14	0.45	6.29e-18	Educational attainment (years of education);
LUSC	trans	rs10432489	0.708	rs10178270	chr2:181773395	G/C	cg11196870	chr8:41386826	GINS4	0.93	6.32	0.33	8.44e-10	QT interval;
LUSC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg16989086	chr20:62203971	PRIC285	0.45	6.34	0.33	7.32e-10	Glioblastoma;
LUSC	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.64	-0.34	1.3e-10	Inflammatory bowel disease;
LUSC	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg06637938	chr14:75390232	RPS6KL1	0.65	10.68	0.5	4.38e-23	Caffeine consumption;
LUSC	cis	rs4919694	0.572	rs4917995	chr10:104845443	A/T	cg04362960	chr10:104952993	NT5C2	-0.87	-11.2	-0.52	6e-25	Arsenic metabolism;
LUSC	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.52	0.34	2.64e-10	Testicular germ cell tumor;
LUSC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.19	0.64	5.59e-40	Platelet count;
LUSC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs11608355	0.521	rs6606704	chr12:109814036	T/C	cg19025524	chr12:109796872	NA	-0.41	-7.71	-0.39	1.5e-13	Neuroticism;
LUSC	cis	rs713477	1.000	rs8014526	chr14:55885054	C/G	cg13175173	chr14:55914753	NA	-0.3	-6.19	-0.32	1.81e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg12963246	chr6:28129442	ZNF389	0.48	6.7	0.34	8.74e-11	Depression;
LUSC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.23	0.41	4.36e-15	Prudent dietary pattern;
LUSC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.65	11.94	0.55	1.34e-27	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg18964960	chr10:1102726	WDR37	-0.45	-6.13	-0.32	2.54e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg08999081	chr20:33150536	PIGU	-0.41	-7.56	-0.38	3.88e-13	Glomerular filtration rate (creatinine);
LUSC	trans	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs3772130	0.961	rs34667636	chr3:121353291	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.67	9.62	0.47	1.71e-19	Cognitive performance;
LUSC	cis	rs954108	0.809	rs1792023	chr13:29368502	G/A	cg11788234	chr13:29393811	NA	-0.38	-6.61	-0.34	1.49e-10	Obesity-related traits;
LUSC	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.17	0.32	2.01e-9	Corneal astigmatism;
LUSC	trans	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.03	21.4	0.76	1.41e-64	Colorectal cancer;
LUSC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg12257692	chr3:49977190	RBM6	0.25	6.88	0.35	2.97e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg20135002	chr11:47629003	NA	0.48	7.54	0.38	4.4e-13	Subjective well-being;
LUSC	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg25664220	chr3:72788482	NA	-0.69	-11.74	-0.54	6.79e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg08085267	chr17:45401833	C17orf57	-0.5	-7.25	-0.37	2.97e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg05855489	chr10:104503620	C10orf26	-0.69	-10.09	-0.48	4.4e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05760393	chr11:2466141	KCNQ1	0.41	6.49	0.33	3.19e-10	Asthma;
LUSC	cis	rs17621444	0.522	rs10788017	chr10:121805225	T/A	cg02041677	chr10:121771263	NA	-0.35	-6.59	-0.34	1.75e-10	IgG glycosylation;
LUSC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg21285383	chr16:89894308	SPIRE2	0.35	7.36	0.37	1.43e-12	Vitiligo;
LUSC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg03804128	chr16:635623	NA	0.3	5.84	0.3	1.26e-8	Height;
LUSC	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg03929089	chr4:120376271	NA	-0.44	-6.05	-0.31	3.92e-9	HDL cholesterol;
LUSC	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg26162295	chr17:38119207	GSDMA	-0.3	-7.07	-0.36	9.38e-12	Asthma;
LUSC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-14.06	-0.61	1.38e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg18129178	chr5:148520854	ABLIM3	-0.77	-10.83	-0.51	1.24e-23	Breast cancer;
LUSC	cis	rs983392	0.667	rs624663	chr11:59945065	C/T	cg02771260	chr11:59836817	MS4A3	0.37	6.28	0.33	1.03e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg19774624	chr17:42201019	HDAC5	0.67	9.6	0.47	1.98e-19	Total body bone mineral density;
LUSC	cis	rs11642862	0.901	rs76345698	chr16:30946165	G/A	cg02466173	chr16:30829666	NA	-0.65	-6.41	-0.33	5.04e-10	Tonsillectomy;
LUSC	cis	rs68170813	0.559	rs79543528	chr7:106891090	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.71	-0.47	8.54e-20	Coronary artery disease;
LUSC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg21573476	chr21:45109991	RRP1B	-0.38	-6.32	-0.33	8.38e-10	Mean corpuscular volume;
LUSC	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg00898013	chr13:113819073	PROZ	0.54	8.29	0.41	2.8e-15	Platelet distribution width;
LUSC	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg00321850	chr1:175162397	KIAA0040	-0.36	-5.95	-0.31	6.91e-9	Alcohol dependence;
LUSC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg26677194	chr12:130822605	PIWIL1	0.59	8.78	0.43	8.41e-17	Menopause (age at onset);
LUSC	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg16850897	chr7:100343110	ZAN	-0.57	-7.81	-0.39	7.66e-14	Other erythrocyte phenotypes;
LUSC	cis	rs9462027	0.585	rs2814974	chr6:34572028	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.15	-0.32	2.19e-9	Systemic lupus erythematosus;
LUSC	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03709012	chr19:19516395	GATAD2A	-0.51	-7.32	-0.37	1.84e-12	Tonsillectomy;
LUSC	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg03161606	chr19:29218774	NA	0.62	10.01	0.48	8.23e-21	Methadone dose in opioid dependence;
LUSC	cis	rs6546537	0.955	rs7590422	chr2:69883715	T/C	cg10773587	chr2:69614142	GFPT1	-0.47	-7.29	-0.37	2.26e-12	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs4343996	0.967	rs10250444	chr7:3350027	A/G	cg21248987	chr7:3385318	SDK1	-0.38	-6.43	-0.33	4.54e-10	Motion sickness;
LUSC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.62	10.88	0.51	8.36e-24	Type 2 diabetes;
LUSC	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs12594515	1.000	rs56412446	chr15:45996424	A/G	cg19682013	chr15:45996608	NA	0.39	5.8	0.3	1.51e-8	Waist circumference;Weight;
LUSC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg07217954	chr7:1067459	C7orf50	0.53	5.71	0.3	2.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.7	-9.52	-0.46	3.67e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7605378	1.000	rs797163	chr2:200696387	G/A	cg17644776	chr2:200775616	C2orf69	0.39	6.28	0.33	1.04e-9	Osteoporosis;
LUSC	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg08085267	chr17:45401833	C17orf57	-0.47	-6.62	-0.34	1.47e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9309473	0.583	rs6713196	chr2:73576405	T/C	cg20560298	chr2:73613845	ALMS1	-0.59	-8.83	-0.43	6.22e-17	Metabolite levels;
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-8.03	-0.4	1.71e-14	Lymphocyte counts;
LUSC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.6	-0.34	1.59e-10	Life satisfaction;
LUSC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg14668632	chr7:2872130	GNA12	-0.43	-6.76	-0.35	6.14e-11	Height;
LUSC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg11344533	chr11:111475393	SIK2	-0.49	-6.87	-0.35	3.18e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg21775007	chr8:11205619	TDH	-0.49	-6.82	-0.35	4.27e-11	Triglycerides;
LUSC	cis	rs2074585	0.560	rs1973537	chr15:91062901	T/C	cg22089800	chr15:90895588	ZNF774	-0.57	-8.1	-0.41	1.04e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs3106136	0.934	rs17376404	chr4:95224046	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.25	-0.32	1.29e-9	Capecitabine sensitivity;
LUSC	cis	rs36093844	0.898	rs80079882	chr11:85590955	T/C	cg25872744	chr11:85566296	CCDC83	-0.42	-6.2	-0.32	1.64e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs6693567	0.565	rs1262432	chr1:150371839	C/A	cg15654264	chr1:150340011	RPRD2	0.45	7.18	0.37	4.41e-12	Migraine;
LUSC	cis	rs56399783	0.901	rs7803944	chr7:2809087	G/A	cg19731401	chr7:2775893	GNA12	0.61	8.35	0.42	1.86e-15	Childhood ear infection;
LUSC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg14092988	chr3:52407081	DNAH1	0.33	6.4	0.33	5.38e-10	Bipolar disorder;
LUSC	cis	rs7043114	0.525	rs7869742	chr9:95256174	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.26	-0.32	1.18e-9	Height;
LUSC	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg20991723	chr1:152506922	NA	0.53	9.76	0.47	5.9e-20	Hair morphology;
LUSC	cis	rs860295	0.812	rs4278368	chr1:155722557	G/A	cg08949192	chr1:155289623	RUSC1;FDPS	-0.34	-5.72	-0.3	2.38e-8	Body mass index;
LUSC	trans	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg18187862	chr3:45730750	SACM1L	0.52	6.65	0.34	1.2e-10	Primary sclerosing cholangitis;
LUSC	cis	rs1018836	0.608	rs1033348	chr8:91464169	C/G	cg16814680	chr8:91681699	NA	-0.53	-7.67	-0.39	1.89e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg05187965	chr10:45406764	TMEM72	-0.37	-8.8	-0.43	7.41e-17	Mean corpuscular volume;
LUSC	cis	rs2282032	0.883	rs2094653	chr14:90784827	A/G	cg14092571	chr14:90743983	NA	0.5	6.53	0.34	2.49e-10	Longevity;
LUSC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.47	0.33	3.46e-10	Menopause (age at onset);
LUSC	cis	rs2346177	0.844	rs12991646	chr2:46643831	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.57	-0.38	3.57e-13	HDL cholesterol;
LUSC	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.82	-0.43	6.39e-17	Response to antipsychotic treatment;
LUSC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg26195577	chr20:24973756	C20orf3	1.11	18.4	0.71	1.06e-52	Blood protein levels;
LUSC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.88	-0.31	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs151234	0.741	rs11074908	chr16:28608356	C/T	cg01378222	chr16:28622494	SULT1A1	-0.63	-7.99	-0.4	2.17e-14	Platelet distribution width;
LUSC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg15335139	chr3:50242325	SLC38A3	-0.25	-5.71	-0.3	2.5e-8	Body mass index;
LUSC	cis	rs75229567	0.618	rs35394896	chr12:70188346	T/A	cg10114359	chr12:70132523	RAB3IP	1.0	9.94	0.48	1.4e-20	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs1775715	0.966	rs1639132	chr10:32301260	G/A	cg26784012	chr10:32216390	ARHGAP12	-0.37	-6.04	-0.31	4.18e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6977660	0.619	rs12530799	chr7:19782793	G/A	cg07541023	chr7:19748670	TWISTNB	0.63	6.65	0.34	1.23e-10	Thyroid stimulating hormone;
LUSC	cis	rs6693567	0.565	rs696615	chr1:150338988	A/C	cg15654264	chr1:150340011	RPRD2	0.44	6.92	0.35	2.34e-11	Migraine;
LUSC	cis	rs12760731	0.720	rs12026110	chr1:178410984	G/A	cg00404053	chr1:178313656	RASAL2	0.59	6.22	0.32	1.46e-9	Obesity-related traits;
LUSC	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg26384229	chr12:38710491	ALG10B	0.7	10.93	0.51	5.66e-24	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-11.01	-0.52	2.85e-24	Bipolar disorder;
LUSC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.44	-6.51	-0.34	2.83e-10	Breast cancer;
LUSC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg14689365	chr7:158441557	NCAPG2	0.53	8.31	0.41	2.4e-15	Height;
LUSC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	5.67	0.3	3.1e-8	Schizophrenia;
LUSC	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg22139774	chr2:100720529	AFF3	0.45	8.02	0.4	1.85e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg21770322	chr7:97807741	LMTK2	0.4	7.01	0.36	1.31e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg05861140	chr6:150128134	PCMT1	-0.37	-5.83	-0.3	1.32e-8	Lung cancer;
LUSC	cis	rs231513	0.954	rs231505	chr17:41970268	A/T	cg26893861	chr17:41843967	DUSP3	0.47	6.03	0.31	4.33e-9	Cognitive function;
LUSC	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg11901034	chr3:128598214	ACAD9	0.43	7.0	0.36	1.41e-11	IgG glycosylation;
LUSC	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg23460707	chr10:133558971	NA	0.35	6.01	0.31	4.86e-9	Survival in rectal cancer;
LUSC	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg05340658	chr4:99064831	C4orf37	0.45	7.22	0.37	3.57e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg09307838	chr4:120376055	NA	-0.47	-7.14	-0.36	5.8e-12	Diastolic blood pressure;
LUSC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.91	14.42	0.62	5.59e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg27124370	chr19:33622961	WDR88	0.53	6.8	0.35	4.84e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg11584989	chr19:19387371	SF4	0.58	6.97	0.36	1.74e-11	Bipolar disorder;
LUSC	trans	rs9392918	0.587	rs12212270	chr6:7709341	A/C	cg12631351	chr5:80256738	RASGRF2	-0.38	-6.04	-0.31	4.04e-9	Height;
LUSC	cis	rs12956009	0.518	rs3902716	chr18:44889441	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.4	0.33	5.4e-10	Educational attainment (years of education);
LUSC	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg20503657	chr10:835505	NA	0.79	9.84	0.47	3.22e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs1267303	0.798	rs1267304	chr1:46990426	C/T	cg25110126	chr1:46999211	NA	-0.69	-9.68	-0.47	1.05e-19	Monobrow;
LUSC	cis	rs3770081	1.000	rs2303340	chr2:86333193	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.02	-7.07	-0.36	9.18e-12	Facial emotion recognition (sad faces);
LUSC	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg05343316	chr1:45956843	TESK2	0.61	8.47	0.42	7.76e-16	Platelet count;
LUSC	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4363385	0.747	rs885096	chr1:152971313	T/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.74	-0.39	1.21e-13	Inflammatory skin disease;
LUSC	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.76e-12	Type 2 diabetes;
LUSC	cis	rs17401966	0.540	rs6541084	chr1:10285447	A/G	cg19773385	chr1:10388646	KIF1B	-0.36	-6.13	-0.32	2.51e-9	Hepatocellular carcinoma;
LUSC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg20135002	chr11:47629003	NA	-0.48	-7.55	-0.38	4.19e-13	Subjective well-being;
LUSC	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.39	-6.92	-0.35	2.32e-11	Ovarian reserve;
LUSC	cis	rs829883	0.622	rs4762498	chr12:98964737	A/G	cg25150519	chr12:98850993	NA	-0.63	-8.64	-0.43	2.44e-16	Colorectal adenoma (advanced);
LUSC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg21724239	chr8:58056113	NA	0.51	6.25	0.32	1.23e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs6561151	0.681	rs4942249	chr13:44426804	C/A	cg12856521	chr11:46389249	DGKZ	0.75	9.56	0.46	2.63e-19	Crohn's disease;
LUSC	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg01294253	chr9:136912663	BRD3	0.36	6.24	0.32	1.34e-9	Platelet distribution width;
LUSC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg13319975	chr6:146136371	FBXO30	0.72	11.13	0.52	1.11e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7580658	0.929	rs4662575	chr2:128022215	C/T	cg09760422	chr2:128146352	NA	-0.32	-7.05	-0.36	1.02e-11	Protein C levels;
LUSC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-7.16	-0.36	5.1e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg06718696	chr17:78121285	EIF4A3	0.62	9.09	0.45	9.2e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	trans	rs4596713	0.508	rs59620993	chr9:71771911	C/T	cg25283916	chr1:242222868	NA	-0.31	-6.3	-0.33	9.33e-10	Headache;
LUSC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.08	0.36	8.48e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg20243544	chr17:37824526	PNMT	0.48	6.1	0.32	3e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.49	-7.3	-0.37	2.19e-12	IgG glycosylation;
LUSC	cis	rs11229555	0.874	rs11229519	chr11:58310587	C/T	cg15696309	chr11:58395628	NA	-0.69	-8.94	-0.44	2.61e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg22963979	chr7:1858916	MAD1L1	-0.74	-12.73	-0.57	1.57e-30	Bipolar disorder and schizophrenia;
LUSC	cis	rs9311676	0.656	rs55964615	chr3:58389120	A/T	cg13750441	chr3:58318267	PXK	0.35	6.73	0.35	7.31e-11	Systemic lupus erythematosus;
LUSC	cis	rs17604090	0.887	rs850013	chr7:29666530	T/C	cg19413766	chr7:29689036	LOC646762	-0.55	-7.01	-0.36	1.31e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.64	-8.48	-0.42	7.18e-16	Alzheimer's disease;
LUSC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.56	-8.53	-0.42	5.35e-16	Lymphocyte counts;
LUSC	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg17757837	chr7:157058334	UBE3C	-0.84	-13.98	-0.61	2.87e-35	Body mass index;
LUSC	cis	rs3857536	0.730	rs7761295	chr6:66932532	G/A	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.56e-10	Blood trace element (Cu levels);
LUSC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg01879757	chr17:41196368	BRCA1	-0.39	-5.96	-0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs2413583	0.591	rs76449672	chr22:39696482	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	6.54	0.34	2.36e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.68	-10.73	-0.51	2.93e-23	Blood protein levels;
LUSC	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg23795048	chr12:9217529	LOC144571	0.34	5.77	0.3	1.84e-8	Sjögren's syndrome;
LUSC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00684032	chr4:1343700	KIAA1530	0.37	6.54	0.34	2.32e-10	Obesity-related traits;
LUSC	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg08916839	chr5:415575	AHRR	0.66	6.72	0.35	7.72e-11	Fat distribution (HIV);
LUSC	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg14346243	chr4:90757452	SNCA	-0.41	-5.83	-0.3	1.34e-8	Neuroticism;
LUSC	trans	rs724744	0.772	rs1737225	chr6:22353202	T/G	cg13807341	chr11:118445984	ARCN1	-0.36	-6.19	-0.32	1.77e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg11130432	chr3:121712080	ILDR1	-0.63	-9.49	-0.46	4.55e-19	Multiple sclerosis;
LUSC	trans	rs2262909	0.893	rs4244912	chr19:22203237	T/A	cg17074339	chr11:11642133	GALNTL4	-0.41	-6.2	-0.32	1.68e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.89	-0.31	9.19e-9	Birth weight;
LUSC	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-10.68	-0.5	4.17e-23	Monocyte percentage of white cells;
LUSC	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg09835421	chr16:68378352	PRMT7	-0.74	-8.26	-0.41	3.48e-15	Schizophrenia;
LUSC	cis	rs11264213	0.901	rs72661631	chr1:36417453	A/G	cg27506609	chr1:36549197	TEKT2	0.7	7.98	0.4	2.39e-14	Schizophrenia;
LUSC	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg02997394	chr19:33096574	ANKRD27	0.87	10.0	0.48	9.16e-21	Eosinophilic esophagitis;
LUSC	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg08213375	chr14:104286397	PPP1R13B	0.44	8.36	0.42	1.7e-15	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs3740713	1.000	rs12289603	chr11:18471370	T/C	cg15463284	chr11:18477534	LDHAL6A	-0.49	-5.79	-0.3	1.6e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg24375607	chr4:120327624	NA	0.76	12.15	0.55	2.25e-28	Corneal astigmatism;
LUSC	cis	rs8040855	0.756	rs12909477	chr15:85689875	C/A	cg04831495	chr15:85060580	GOLGA6L5	0.39	5.8	0.3	1.54e-8	Bulimia nervosa;
LUSC	cis	rs12541635	0.966	rs11782609	chr8:106967919	G/A	cg10147462	chr8:107024639	NA	0.56	9.76	0.47	5.99e-20	Age of smoking initiation;
LUSC	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg22482690	chr17:47019901	SNF8	0.38	7.28	0.37	2.4e-12	Type 2 diabetes;
LUSC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg20119798	chr7:94954144	PON1	0.36	7.01	0.36	1.31e-11	Paraoxonase activity;
LUSC	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg09911534	chr15:67153556	NA	-0.63	-7.29	-0.37	2.3e-12	Lung cancer (smoking interaction);
LUSC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.72	12.03	0.55	6.29e-28	Motion sickness;
LUSC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-0.89	-12.79	-0.57	9.15e-31	Initial pursuit acceleration;
LUSC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.85	15.92	0.66	7.31e-43	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.67	10.6	0.5	7.78e-23	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08704250	chr15:31115839	NA	0.58	9.4	0.46	9.12e-19	Huntington's disease progression;
LUSC	cis	rs6574644	1.000	rs6574644	chr14:81778644	G/A	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	10.48	0.5	2.1e-22	Monocyte percentage of white cells;
LUSC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.29	-5.76	-0.3	1.88e-8	Total body bone mineral density;
LUSC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg14343924	chr8:8086146	FLJ10661	0.41	5.94	0.31	7.35e-9	Mood instability;
LUSC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	trans	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	7.47	0.38	7.28e-13	Menarche (age at onset);
LUSC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg16447950	chr5:562315	NA	-0.55	-6.93	-0.35	2.12e-11	Obesity-related traits;
LUSC	cis	rs6076065	0.723	rs2424532	chr20:23373877	G/A	cg11657817	chr20:23433608	CST11	0.43	8.07	0.4	1.25e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg24690094	chr11:67383802	NA	0.38	7.28	0.37	2.48e-12	Mean corpuscular volume;
LUSC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.6	-9.48	-0.46	5.06e-19	Iron status biomarkers;
LUSC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.5	6.05	0.31	3.83e-9	Blood protein levels;
LUSC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.53	-0.34	2.44e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg13334819	chr7:99746414	C7orf59	0.5	6.73	0.35	7.37e-11	Coronary artery disease;
LUSC	trans	rs1998174	0.509	rs6683945	chr1:171840264	G/A	cg13482142	chr2:234261155	NA	0.42	6.11	0.32	2.81e-9	Platelet distribution width;
LUSC	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg16624210	chr5:671434	TPPP	0.49	6.1	0.32	2.89e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	5.86	0.31	1.12e-8	Personality dimensions;
LUSC	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg14696996	chr19:15285081	NOTCH3	1.02	9.38	0.46	1.03e-18	Pulse pressure;
LUSC	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	6.08	0.32	3.37e-9	Rheumatoid arthritis;
LUSC	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21643547	chr1:205240462	TMCC2	-0.49	-9.16	-0.45	5.24e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7553864	0.667	rs1886633	chr1:87610356	G/A	cg17420885	chr1:87600446	LOC339524	-0.5	-6.91	-0.35	2.52e-11	Smoking behavior;
LUSC	cis	rs4953318	0.619	rs10183887	chr2:46361808	T/A	cg12428440	chr2:46370979	PRKCE	0.46	7.73	0.39	1.29e-13	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg11693508	chr17:37793320	STARD3	0.56	6.67	0.34	1.04e-10	Bipolar disorder;
LUSC	cis	rs3809566	0.637	rs8026047	chr15:63323347	C/G	cg00520135	chr15:63333846	TPM1	0.33	6.13	0.32	2.46e-9	Platelet count;
LUSC	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg11344533	chr11:111475393	SIK2	0.45	5.91	0.31	8.68e-9	Primary sclerosing cholangitis;
LUSC	cis	rs4588572	0.644	rs891150	chr5:77761794	G/A	cg11547950	chr5:77652471	NA	-0.48	-7.01	-0.36	1.29e-11	Triglycerides;
LUSC	cis	rs2430307	0.556	rs3930019	chr7:76541610	C/T	cg15770687	chr7:76625569	PMS2L11	0.8	8.49	0.42	6.91e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs2908197	0.806	rs6465098	chr7:75972947	T/C	cg10167463	chr7:75959203	YWHAG	-0.43	-6.41	-0.33	4.87e-10	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.91	-14.76	-0.63	2.6e-38	Lymphocyte percentage of white cells;
LUSC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg06363034	chr20:62225388	GMEB2	-0.46	-7.7	-0.39	1.55e-13	Glioblastoma;
LUSC	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.39	-0.46	9.35e-19	Schizophrenia;
LUSC	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg00484396	chr16:3507460	NAT15	-0.38	-6.39	-0.33	5.47e-10	Body mass index (adult);
LUSC	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg18232548	chr7:50535776	DDC	0.5	7.69	0.39	1.66e-13	Malaria;
LUSC	cis	rs1506636	1.000	rs7357252	chr7:123369856	C/T	cg03229431	chr7:123269106	ASB15	-0.65	-10.57	-0.5	9.99e-23	Plateletcrit;Platelet count;
LUSC	cis	rs11676348	0.808	rs61700947	chr2:219046171	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.38	5.86	0.31	1.13e-8	Ulcerative colitis;
LUSC	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg09436375	chr6:42928200	GNMT	-0.29	-6.73	-0.35	7.57e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21963583	chr11:68658836	MRPL21	0.56	8.29	0.41	2.71e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs354225	0.544	rs10183867	chr2:54812722	C/G	cg01766943	chr2:54829624	SPTBN1	0.49	8.06	0.4	1.39e-14	Schizophrenia;
LUSC	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg05110241	chr16:68378359	PRMT7	-0.53	-6.55	-0.34	2.19e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg17294928	chr15:75287854	SCAMP5	0.43	6.21	0.32	1.57e-9	Breast cancer;
LUSC	trans	rs7181230	0.885	rs35781999	chr15:40355406	G/C	cg22705835	chr10:65332833	REEP3	-0.4	-6.43	-0.33	4.46e-10	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs56283067	0.847	rs62435999	chr6:44695273	T/G	cg20913747	chr6:44695427	NA	-0.48	-7.73	-0.39	1.24e-13	Total body bone mineral density;
LUSC	trans	rs1245541	0.508	rs748035	chr10:73833355	C/T	cg01042749	chr10:102672582	FAM178A	-0.46	-6.1	-0.32	2.87e-9	Insulin-like growth factors;
LUSC	cis	rs16912285	0.585	rs11027807	chr11:24346556	G/T	ch.11.24196551F	chr11:24239977	NA	0.87	8.38	0.42	1.5e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	8.25	0.41	3.71e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg20608306	chr11:116969690	SIK3	0.35	6.63	0.34	1.39e-10	Blood protein levels;
LUSC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.27	-0.62	2.03e-36	Eye color traits;
LUSC	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.65	0.34	1.19e-10	Height;
LUSC	trans	rs7939886	0.920	rs11227222	chr11:55876393	G/T	cg15704280	chr7:45808275	SEPT13	-0.77	-6.69	-0.34	9.49e-11	Myopia (pathological);
LUSC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg08270630	chr22:50330655	NA	-0.43	-6.42	-0.33	4.8e-10	Schizophrenia;
LUSC	cis	rs7914558	0.646	rs11191459	chr10:104662118	G/A	cg05855489	chr10:104503620	C10orf26	0.42	5.74	0.3	2.12e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.41	-0.33	4.92e-10	Menopause (age at onset);
LUSC	cis	rs7712401	0.601	rs246287	chr5:122245426	A/T	cg19077854	chr5:122220652	SNX24	0.4	8.85	0.44	5.38e-17	Mean platelet volume;
LUSC	cis	rs11039100	1.000	rs61875914	chr11:5828299	T/G	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02176678	chr2:219576539	TTLL4	0.64	11.79	0.54	4.45e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg18904891	chr8:8559673	CLDN23	0.6	7.87	0.4	4.84e-14	Obesity-related traits;
LUSC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06022373	chr22:39101656	GTPBP1	0.74	11.51	0.53	4.67e-26	Menopause (age at onset);
LUSC	cis	rs11630290	0.649	rs1036910	chr15:64157015	T/C	cg12036633	chr15:63758958	NA	0.53	6.83	0.35	4.13e-11	Iris characteristics;
LUSC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg04546413	chr19:29218101	NA	0.61	8.07	0.4	1.24e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9309473	0.615	rs62151562	chr2:73603540	T/G	cg20560298	chr2:73613845	ALMS1	-0.52	-6.19	-0.32	1.8e-9	Metabolite levels;
LUSC	cis	rs72960926	0.744	rs16884624	chr6:74998293	G/C	cg03266952	chr6:74778945	NA	-0.63	-5.96	-0.31	6.54e-9	Metabolite levels (MHPG);
LUSC	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg20701182	chr2:24300061	SF3B14	0.58	6.19	0.32	1.72e-9	Lymphocyte counts;
LUSC	cis	rs7927771	0.524	rs1056387	chr11:47681370	A/C	cg20307385	chr11:47447363	PSMC3	0.5	6.85	0.35	3.59e-11	Subjective well-being;
LUSC	trans	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.42	-0.33	4.79e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg20818283	chr2:191399100	TMEM194B	0.43	6.72	0.35	7.81e-11	Pulse pressure;
LUSC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg06740227	chr12:86229804	RASSF9	0.44	7.07	0.36	8.95e-12	Major depressive disorder;
LUSC	cis	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.09	-0.36	8.15e-12	Neuroticism;
LUSC	cis	rs2286885	1.000	rs4837093	chr9:129254443	G/A	cg15282417	chr9:129245246	FAM125B	0.42	7.01	0.36	1.35e-11	Intraocular pressure;
LUSC	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg13256891	chr4:100009986	ADH5	-0.5	-6.45	-0.33	4.01e-10	Alcohol dependence;
LUSC	cis	rs858239	0.539	rs6971673	chr7:23159523	C/G	cg23682824	chr7:23144976	KLHL7	0.39	5.68	0.3	2.92e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2124969	0.562	rs13393480	chr2:161058790	G/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-7.02	-0.36	1.21e-11	Waist circumference adjusted for body mass index;
LUSC	trans	rs4252134	0.959	rs4252090	chr6:161133544	A/T	cg00639886	chr12:54943102	PDE1B	-0.43	-6.21	-0.32	1.6e-9	Giant cell arteritis;
LUSC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg06074448	chr4:187884817	NA	-0.41	-6.82	-0.35	4.28e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg21775007	chr8:11205619	TDH	-0.61	-9.48	-0.46	4.95e-19	Retinal vascular caliber;
LUSC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.34	-0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg11584989	chr19:19387371	SF4	0.61	7.27	0.37	2.54e-12	Bipolar disorder;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg14668821	chr17:77704760	ENPP7	0.29	6.03	0.31	4.41e-9	Menopause (age at onset);
LUSC	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg20744362	chr22:50050164	C22orf34	0.37	6.85	0.35	3.59e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.65	10.35	0.49	5.97e-22	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg05855489	chr10:104503620	C10orf26	0.56	6.45	0.33	4.02e-10	Arsenic metabolism;
LUSC	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.53	0.53	4.12e-26	Chronic sinus infection;
LUSC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-6.84	-0.35	3.86e-11	Electroencephalogram traits;
LUSC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.58	10.76	0.51	2.21e-23	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.63	7.64	0.39	2.3e-13	Lung function (FEV1/FVC);
LUSC	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg13072238	chr3:49761600	GMPPB	-0.4	-6.44	-0.33	4.19e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.56	-0.46	2.61e-19	Subjective well-being;
LUSC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg26335602	chr6:28129616	ZNF389	0.42	5.7	0.3	2.63e-8	Parkinson's disease;
LUSC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg22800045	chr5:56110881	MAP3K1	-0.64	-8.92	-0.44	3.12e-17	Initial pursuit acceleration;
LUSC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.12	-0.48	3.71e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg27068330	chr11:65405492	SIPA1	-0.74	-10.3	-0.49	8.46e-22	Acne (severe);
LUSC	cis	rs73200209	0.701	rs11609930	chr12:116644670	A/G	cg01776926	chr12:116560359	MED13L	-0.5	-6.12	-0.32	2.63e-9	Total body bone mineral density;
LUSC	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg00745463	chr17:30367425	LRRC37B	-0.85	-9.92	-0.48	1.75e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg12288994	chr5:1860383	NA	0.32	7.05	0.36	1.04e-11	Cardiovascular disease risk factors;
LUSC	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg27411982	chr8:10470053	RP1L1	0.42	7.05	0.36	1e-11	Systolic blood pressure;
LUSC	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg24675658	chr1:53192096	ZYG11B	-0.54	-8.39	-0.42	1.38e-15	Monocyte count;
LUSC	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg22681709	chr2:178499509	PDE11A	-0.55	-10.98	-0.52	3.63e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg14440974	chr22:39074834	NA	-0.37	-6.14	-0.32	2.34e-9	Menopause (age at onset);
LUSC	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg24579218	chr15:68104479	NA	-0.37	-6.58	-0.34	1.79e-10	Restless legs syndrome;
LUSC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.71	11.1	0.52	1.35e-24	Menopause (age at onset);
LUSC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg16624210	chr5:671434	TPPP	0.49	6.39	0.33	5.59e-10	Obesity-related traits;
LUSC	cis	rs4363385	0.510	rs2339386	chr1:152892307	C/T	cg25856811	chr1:152973957	SPRR3	-0.38	-6.11	-0.32	2.74e-9	Inflammatory skin disease;
LUSC	cis	rs2625529	0.668	rs12591313	chr15:72556746	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-7.2	-0.37	4.02e-12	Red blood cell count;
LUSC	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg20016023	chr10:99160130	RRP12	-0.35	-8.3	-0.41	2.63e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg05253716	chr12:129299332	SLC15A4;MGC16384	-0.43	-5.69	-0.3	2.72e-8	Systemic lupus erythematosus;
LUSC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.06	15.61	0.65	1.2e-41	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg24250549	chr1:154909240	PMVK	0.65	10.87	0.51	9.05e-24	Prostate cancer;
LUSC	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg23172400	chr8:95962367	TP53INP1	-0.37	-7.4	-0.38	1.14e-12	Type 2 diabetes;
LUSC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.76	0.35	6.35e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs3820928	0.874	rs10933165	chr2:227883648	C/G	cg11843606	chr2:227700838	RHBDD1	0.54	7.98	0.4	2.33e-14	Pulmonary function;
LUSC	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.23	-0.32	1.39e-9	Retinal vascular caliber;
LUSC	cis	rs2688608	1.000	rs2688610	chr10:75654931	A/G	cg19442545	chr10:75533431	FUT11	0.37	5.74	0.3	2.07e-8	Inflammatory bowel disease;
LUSC	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.13	-0.36	6.31e-12	Neuroticism;
LUSC	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg23202291	chr11:1979235	NA	0.41	6.2	0.32	1.69e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg26384229	chr12:38710491	ALG10B	0.67	10.52	0.5	1.54e-22	Morning vs. evening chronotype;
LUSC	cis	rs10203711	0.966	rs7594129	chr2:239600686	G/T	cg14580085	chr2:239553406	NA	0.43	7.35	0.37	1.5e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	9.07	0.44	1.03e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2219968	0.962	rs4276683	chr8:78939763	T/G	cg00738934	chr8:78996279	NA	0.4	7.15	0.36	5.57e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1483121	0.808	rs11039482	chr11:48009074	C/T	cg20307385	chr11:47447363	PSMC3	0.65	5.74	0.3	2.1e-8	Fasting blood glucose (BMI interaction);Fasting blood glucose;
LUSC	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg01528321	chr10:82214614	TSPAN14	0.6	9.02	0.44	1.51e-17	Post bronchodilator FEV1;
LUSC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg12963246	chr6:28129442	ZNF389	0.48	6.73	0.35	7.46e-11	Depression;
LUSC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	10.84	0.51	1.21e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg16339924	chr4:17578868	LAP3	0.49	7.09	0.36	8.13e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7000551	0.689	rs2122878	chr8:22311916	T/C	cg12081754	chr8:22256438	SLC39A14	0.48	7.29	0.37	2.33e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg15103426	chr22:29168792	CCDC117	-0.5	-6.24	-0.32	1.32e-9	Lymphocyte counts;
LUSC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg02487422	chr3:49467188	NICN1	0.45	7.17	0.37	4.78e-12	Resting heart rate;
LUSC	cis	rs2708377	0.929	rs61931280	chr12:11300255	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg08508325	chr11:3079039	CARS	-0.53	-13.31	-0.59	1.01e-32	Longevity;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg04124316	chr13:42615242	NA	0.42	6.22	0.32	1.5e-9	N-glycan levels;
LUSC	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg00071950	chr4:10020882	SLC2A9	-0.57	-9.73	-0.47	7.51e-20	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg21918786	chr6:109611834	NA	-0.35	-6.02	-0.31	4.59e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14240646	chr10:27532245	ACBD5	0.65	7.49	0.38	6.41e-13	Breast cancer;
LUSC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg23102388	chr7:1867652	MAD1L1	-0.32	-5.81	-0.3	1.5e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs983392	0.667	rs583791	chr11:59947252	C/T	cg02771260	chr11:59836817	MS4A3	0.37	6.41	0.33	4.87e-10	Alzheimer's disease (late onset);
LUSC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.29	0.76	3.71e-64	Prudent dietary pattern;
LUSC	trans	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg25214090	chr10:38739885	LOC399744	0.54	7.88	0.4	4.8e-14	Corneal astigmatism;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05749855	chr16:89472771	ANKRD11	-0.84	-7.79	-0.39	8.73e-14	Cognitive performance;
LUSC	cis	rs9346649	0.654	rs35453512	chr6:168491906	C/G	cg02770688	chr6:168491649	NA	0.47	8.96	0.44	2.32e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg11764359	chr7:65958608	NA	-0.53	-6.93	-0.35	2.22e-11	Aortic root size;
LUSC	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.72	10.91	0.51	6.36e-24	Eosinophil percentage of white cells;
LUSC	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg26384229	chr12:38710491	ALG10B	0.75	11.9	0.55	1.83e-27	Morning vs. evening chronotype;
LUSC	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.66	10.76	0.51	2.28e-23	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg03461704	chr1:205818484	PM20D1	0.39	6.54	0.34	2.29e-10	Menarche (age at onset);
LUSC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.38	-5.8	-0.3	1.57e-8	Platelet count;
LUSC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg12463550	chr7:65579703	CRCP	0.45	6.73	0.35	7.31e-11	Aortic root size;
LUSC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg25258033	chr6:167368657	RNASET2	0.39	6.27	0.32	1.09e-9	Crohn's disease;
LUSC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-12.74	-0.57	1.37e-30	Alzheimer's disease;
LUSC	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg21153622	chr11:89784906	NA	-0.39	-6.04	-0.31	4.16e-9	HDL cholesterol;
LUSC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6494488	0.500	rs111737146	chr15:65004840	C/T	cg08069370	chr15:64387884	SNX1	-0.66	-5.77	-0.3	1.76e-8	Coronary artery disease;
LUSC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.6	0.54	2.33e-26	Prudent dietary pattern;
LUSC	cis	rs4629180	0.675	rs10195061	chr2:102093974	T/G	cg01388757	chr2:102091195	RFX8	-0.36	-6.13	-0.32	2.43e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	11.04	0.52	2.33e-24	Platelet count;
LUSC	trans	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg18187862	chr3:45730750	SACM1L	-0.49	-6.02	-0.31	4.71e-9	Primary sclerosing cholangitis;
LUSC	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg20487152	chr13:99095054	FARP1	-0.41	-6.89	-0.35	2.87e-11	Longevity;
LUSC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg00376283	chr12:123451042	ABCB9	0.67	8.44	0.42	9.73e-16	Neutrophil percentage of white cells;
LUSC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.46	-0.33	3.63e-10	Blood metabolite levels;
LUSC	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.99	-0.44	1.88e-17	Response to antipsychotic treatment;
LUSC	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg05110241	chr16:68378359	PRMT7	-0.63	-6.81	-0.35	4.42e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.08	0.32	3.32e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs617219	0.817	rs72764978	chr5:78491840	T/A	cg24856658	chr5:78533917	JMY	-0.3	-5.86	-0.31	1.13e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg19468946	chr17:37922297	IKZF3	-0.39	-6.17	-0.32	1.98e-9	Self-reported allergy;
LUSC	trans	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-13.65	-0.6	5.33e-34	Colorectal cancer;
LUSC	cis	rs2625529	0.668	rs35206011	chr15:72539494	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-7.25	-0.37	2.89e-12	Red blood cell count;
LUSC	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.54	-8.02	-0.4	1.81e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9311676	0.609	rs55845662	chr3:58424899	A/C	cg13750441	chr3:58318267	PXK	0.35	6.73	0.35	7.53e-11	Systemic lupus erythematosus;
LUSC	trans	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.02	-0.36	1.25e-11	Triglycerides;
LUSC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.47	-0.38	7.07e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.6	-0.38	3.04e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg14416269	chr4:6271139	WFS1	0.54	11.41	0.53	1.07e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.16	0.32	2.14e-9	Total body bone mineral density;
LUSC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg20406979	chr6:167373233	NA	0.26	6.22	0.32	1.48e-9	Crohn's disease;
LUSC	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg06917634	chr15:78832804	PSMA4	-0.48	-5.92	-0.31	7.82e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs11123259	0.830	rs6733911	chr2:115694295	G/C	cg00844339	chr9:138873417	NA	0.31	6.09	0.32	3.18e-9	Gut microbiome composition (winter);
LUSC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.07	-20.88	-0.75	1.59e-62	Cognitive ability;
LUSC	trans	rs6480314	0.542	rs79081413	chr10:70028503	A/G	cg04882175	chr6:131122610	NA	-0.53	-6.27	-0.32	1.09e-9	Optic nerve measurement (disc area);
LUSC	cis	rs7605827	0.897	rs7586068	chr2:15596747	T/A	cg19274914	chr2:15703543	NA	0.47	8.98	0.44	2.02e-17	Educational attainment (years of education);
LUSC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.21	0.32	1.54e-9	Menopause (age at onset);
LUSC	cis	rs6012953	0.934	rs2904269	chr20:49156331	C/A	cg13958625	chr20:49123093	NA	0.3	6.69	0.34	9.65e-11	Vitiligo;
LUSC	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	6.82	0.35	4.38e-11	Height;
LUSC	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.48	-9.07	-0.44	1.08e-17	Breast cancer;
LUSC	cis	rs12220238	1.000	rs2279648	chr10:75867193	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.67	7.62	0.38	2.65e-13	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg23262351	chr6:79576851	IRAK1BP1	-0.41	-6.12	-0.32	2.6e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg04036182	chr15:45458818	NA	-0.36	-5.94	-0.31	7.11e-9	Glomerular filtration rate;
LUSC	cis	rs701145	0.586	rs181443	chr3:153959028	G/T	cg17054900	chr3:154042577	DHX36	0.46	6.06	0.31	3.63e-9	Coronary artery disease;
LUSC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg05872129	chr22:39784769	NA	-0.61	-11.3	-0.53	2.64e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs11958404	1.000	rs72816532	chr5:157413130	C/T	cg05962755	chr5:157440814	NA	0.51	6.24	0.32	1.31e-9	IgG glycosylation;
LUSC	cis	rs599083	0.793	rs314750	chr11:68182028	G/A	cg20283391	chr11:68216788	NA	0.5	6.68	0.34	9.83e-11	Bone mineral density (spine);
LUSC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18854424	chr1:2615690	NA	-0.5	-10.01	-0.48	8.46e-21	Ulcerative colitis;
LUSC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.78	8.11	0.41	9.99e-15	Initial pursuit acceleration;
LUSC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg13206674	chr6:150067644	NUP43	0.62	10.05	0.48	6.22e-21	Lung cancer;
LUSC	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg05738196	chr6:26577821	NA	0.81	15.7	0.65	5.52e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs62400317	0.859	rs12212745	chr6:45166258	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.5	-0.38	5.86e-13	Total body bone mineral density;
LUSC	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg05707623	chr12:122985044	ZCCHC8	0.66	8.11	0.41	9.63e-15	Body mass index;
LUSC	cis	rs2040771	0.770	rs2518840	chr22:19255856	A/C	cg02655711	chr22:19163373	SLC25A1	0.49	8.8	0.43	7.41e-17	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg27284194	chr4:1044797	NA	0.59	8.84	0.44	5.65e-17	Recombination rate (females);
LUSC	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg16586182	chr3:47516702	SCAP	0.53	8.31	0.41	2.4e-15	Colorectal cancer;
LUSC	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-5.9	-0.31	8.99e-9	Neutrophil percentage of white cells;
LUSC	trans	rs75804782	0.641	rs1030786	chr2:239361150	A/G	cg01134436	chr17:81009848	B3GNTL1	0.64	6.17	0.32	1.93e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs8060686	0.516	rs8048365	chr16:68253326	T/A	cg05110241	chr16:68378359	PRMT7	-0.46	-5.95	-0.31	6.6e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.64	11.1	0.52	1.42e-24	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg18187862	chr3:45730750	SACM1L	0.57	7.42	0.38	9.59e-13	Primary sclerosing cholangitis;
LUSC	cis	rs2692947	0.832	rs2692954	chr2:96683378	T/G	cg23100626	chr2:96804247	ASTL	0.31	7.36	0.37	1.42e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.49	8.05	0.4	1.47e-14	Alcohol dependence;
LUSC	cis	rs6545883	0.630	rs12998475	chr2:61437487	T/C	cg15711740	chr2:61764176	XPO1	0.42	6.3	0.33	9.6e-10	Tuberculosis;
LUSC	cis	rs9549260	0.755	rs7317254	chr13:41217849	A/G	cg21288729	chr13:41239152	FOXO1	0.66	10.17	0.49	2.4e-21	Red blood cell count;
LUSC	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.06	-0.36	9.46e-12	Coronary artery disease;
LUSC	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.39	5.75	0.3	2.03e-8	Height;
LUSC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	0.88	15.63	0.65	1.05e-41	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg12963246	chr6:28129442	ZNF389	0.48	7.12	0.36	6.68e-12	Parkinson's disease;
LUSC	cis	rs3755132	0.778	rs4668455	chr2:15740177	G/A	cg12888861	chr2:15731646	DDX1	0.49	7.16	0.36	5.19e-12	Wilms tumor;
LUSC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg05802129	chr4:122689817	NA	-0.45	-7.32	-0.37	1.83e-12	Type 2 diabetes;
LUSC	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	6.06	0.31	3.73e-9	Rheumatoid arthritis;
LUSC	trans	rs330071	0.500	rs17662123	chr8:9246837	G/A	cg06636001	chr8:8085503	FLJ10661	0.52	8.03	0.4	1.69e-14	Acne (severe);
LUSC	cis	rs41271473	0.950	rs72750042	chr1:228854138	T/C	cg16512390	chr1:228756714	NA	0.55	6.5	0.34	2.89e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg19554555	chr3:13937349	NA	-0.38	-5.71	-0.3	2.47e-8	Ovarian reserve;
LUSC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg11062466	chr8:58055876	NA	0.56	7.36	0.37	1.48e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2273669	0.504	rs78123955	chr6:109434847	T/C	cg05315195	chr6:109294784	ARMC2	-0.55	-5.85	-0.3	1.18e-8	Prostate cancer;
LUSC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs11958404	0.932	rs72818108	chr5:157437883	A/T	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg08345082	chr10:99160200	RRP12	-0.35	-7.03	-0.36	1.16e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs59698941	0.943	rs12516596	chr5:132273608	C/G	cg02081065	chr5:132209139	LEAP2	-0.62	-6.22	-0.32	1.45e-9	Apolipoprotein A-IV levels;
LUSC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.64	9.83	0.47	3.45e-20	Lymphocyte counts;
LUSC	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg08668510	chr10:1095578	IDI1	0.63	6.04	0.31	4.07e-9	Glomerular filtration rate (creatinine);
LUSC	trans	rs7219451	0.655	rs8067028	chr17:38974029	G/A	cg11917579	chr10:2815429	NA	0.28	6.09	0.32	3.15e-9	Glucose homeostasis traits;
LUSC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg10523679	chr1:76189770	ACADM	-0.53	-7.98	-0.4	2.44e-14	Daytime sleep phenotypes;
LUSC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.17	0.41	6.44e-15	Prudent dietary pattern;
LUSC	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.84	-0.35	3.77e-11	Monocyte percentage of white cells;
LUSC	cis	rs453301	0.562	rs1038248	chr8:9040858	G/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.44	-0.33	4.14e-10	Joint mobility (Beighton score);
LUSC	cis	rs7769051	0.522	rs62424539	chr6:133173272	C/T	cg22852734	chr6:133119734	C6orf192	0.79	6.31	0.33	8.66e-10	Type 2 diabetes nephropathy;
LUSC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg17724175	chr1:150552817	MCL1	-0.46	-8.1	-0.41	1.02e-14	Urate levels;
LUSC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg07424592	chr7:64974309	NA	0.7	6.18	0.32	1.89e-9	Diabetic kidney disease;
LUSC	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg26647111	chr11:31128758	NA	-0.43	-6.22	-0.32	1.48e-9	Red blood cell count;
LUSC	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg23093090	chr10:104574429	C10orf26	-0.37	-6.86	-0.35	3.32e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg05855489	chr10:104503620	C10orf26	0.6	9.68	0.47	1.1e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg13206674	chr6:150067644	NUP43	0.56	8.73	0.43	1.2e-16	Lung cancer;
LUSC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg17971929	chr21:40555470	PSMG1	-0.68	-11.28	-0.53	3.31e-25	Cognitive function;
LUSC	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg25110126	chr1:46999211	NA	0.53	7.27	0.37	2.56e-12	Monobrow;
LUSC	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg27471124	chr11:109292789	C11orf87	0.42	7.5	0.38	5.67e-13	Schizophrenia;
LUSC	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg08000102	chr2:233561755	GIGYF2	0.66	10.89	0.51	7.79e-24	Coronary artery disease;
LUSC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.93	0.44	2.81e-17	Lung cancer;
LUSC	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg16797656	chr11:68205561	LRP5	0.42	5.78	0.3	1.72e-8	Bone mineral density (spine);
LUSC	cis	rs6433857	0.536	rs1542035	chr2:181351114	T/C	cg23363182	chr2:181467187	NA	-0.45	-7.29	-0.37	2.2e-12	Body mass index;
LUSC	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-9.96	-0.48	1.26e-20	Blood metabolite levels;
LUSC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	9.37	0.46	1.13e-18	Motion sickness;
LUSC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.52	0.38	5.06e-13	Electroencephalogram traits;
LUSC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.42	-0.42	1.16e-15	Aortic root size;
LUSC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	15.88	0.66	1.04e-42	Platelet count;
LUSC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.41	-6.68	-0.34	9.94e-11	Monocyte percentage of white cells;
LUSC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg08798685	chr6:27730294	NA	-0.61	-6.21	-0.32	1.61e-9	Breast cancer;
LUSC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg00431813	chr7:1051703	C7orf50	-0.45	-7.43	-0.38	9.23e-13	Longevity;Endometriosis;
LUSC	cis	rs11229555	0.645	rs4367960	chr11:58194961	C/G	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4363385	0.782	rs394859	chr1:153025704	T/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.48	-0.38	6.58e-13	Inflammatory skin disease;
LUSC	cis	rs9303542	0.625	rs6504340	chr17:46617019	A/G	cg09704116	chr17:46666958	LOC404266	0.29	5.75	0.3	2.01e-8	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg22681709	chr2:178499509	PDE11A	-0.52	-9.2	-0.45	3.97e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg22709100	chr7:91322751	NA	0.4	5.86	0.31	1.12e-8	Breast cancer;
LUSC	trans	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg18187862	chr3:45730750	SACM1L	-0.51	-6.18	-0.32	1.83e-9	Primary sclerosing cholangitis;
LUSC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg16584290	chr5:462447	EXOC3	-0.37	-6.43	-0.33	4.39e-10	Cystic fibrosis severity;
LUSC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.7	9.93	0.48	1.56e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg05313129	chr8:58192883	C8orf71	-0.5	-6.92	-0.35	2.28e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2346177	0.777	rs7587138	chr2:46657089	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.36	-6.07	-0.32	3.49e-9	HDL cholesterol;
LUSC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg25767906	chr1:53392781	SCP2	0.48	8.71	0.43	1.47e-16	Monocyte count;
LUSC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg20135002	chr11:47629003	NA	-0.51	-8.21	-0.41	4.85e-15	Subjective well-being;
LUSC	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg26924012	chr15:45694286	SPATA5L1	1.14	20.41	0.74	1.14e-60	Homoarginine levels;
LUSC	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg00982548	chr2:198649783	BOLL	0.58	7.3	0.37	2.06e-12	Ulcerative colitis;
LUSC	cis	rs6690583	0.623	rs12030730	chr1:85454109	C/G	cg11262906	chr1:85462892	MCOLN2	0.67	6.43	0.33	4.48e-10	Serum sulfate level;
LUSC	trans	rs1973993	0.745	rs7512263	chr1:96941158	C/A	cg10631902	chr5:14652156	NA	-0.53	-7.87	-0.4	4.97e-14	Weight;
LUSC	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.83	-0.35	3.95e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6977660	0.714	rs4721824	chr7:19785898	A/G	cg05791153	chr7:19748676	TWISTNB	0.75	7.42	0.38	1.01e-12	Thyroid stimulating hormone;
LUSC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg13010199	chr12:38710504	ALG10B	0.42	6.14	0.32	2.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg21433313	chr16:3507492	NAT15	0.44	5.99	0.31	5.44e-9	Body mass index (adult);
LUSC	cis	rs1775715	0.870	rs3847415	chr10:32219456	G/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.69	0.34	9.42e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg18512352	chr11:47633146	NA	-0.46	-9.22	-0.45	3.55e-18	Subjective well-being;
LUSC	cis	rs3849570	0.961	rs3772896	chr3:81751968	C/T	cg07356753	chr3:81810745	GBE1	-0.7	-11.15	-0.52	9.31e-25	Waist circumference;Body mass index;
LUSC	cis	rs12410462	0.581	rs12402691	chr1:227543693	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.67	-6.56	-0.34	2.02e-10	Major depressive disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10524192	chr9:34637478	SIGMAR1	-0.44	-6.68	-0.34	1e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg07173049	chr1:7289937	CAMTA1	0.33	6.95	0.36	1.97e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.1	0.45	8.28e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6967385	0.583	rs1116972	chr7:12348307	A/C	cg20607287	chr7:12443886	VWDE	0.39	5.9	0.31	8.87e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24110177	chr3:50126178	RBM5	-0.54	-8.8	-0.43	7.39e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2526882	0.562	rs12893492	chr14:71506775	T/C	cg15816911	chr14:71606274	NA	0.34	5.92	0.31	7.92e-9	Schizophrenia;
LUSC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg11062466	chr8:58055876	NA	0.59	7.34	0.37	1.65e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.8	-0.35	4.89e-11	Vitiligo;
LUSC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg23262073	chr20:60523788	NA	-0.43	-6.2	-0.32	1.69e-9	Body mass index;
LUSC	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.47	6.38	0.33	5.99e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg14552801	chr7:65878734	NA	0.38	5.92	0.31	7.97e-9	Aortic root size;
LUSC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs4903214	0.895	rs7161419	chr14:74695757	A/G	cg08255017	chr14:74727001	VSX2	-0.41	-5.92	-0.31	7.89e-9	Inflammatory bowel disease;
LUSC	cis	rs3820928	0.967	rs720501	chr2:227778445	C/T	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.98	-0.4	2.39e-14	Pulmonary function;
LUSC	trans	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg02800362	chr5:177631904	HNRNPAB	0.83	12.44	0.56	1.95e-29	Obesity-related traits;
LUSC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg19812747	chr11:111475976	SIK2	-0.55	-8.18	-0.41	5.92e-15	Primary sclerosing cholangitis;
LUSC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-0.82	-14.11	-0.61	8.92e-36	Longevity;
LUSC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.68	12.22	0.56	1.26e-28	Aortic root size;
LUSC	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg19875535	chr5:140030758	IK	0.5	8.24	0.41	3.98e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6545883	0.894	rs2121661	chr2:61561658	A/G	cg15711740	chr2:61764176	XPO1	0.43	6.59	0.34	1.76e-10	Tuberculosis;
LUSC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.49	7.69	0.39	1.68e-13	Colorectal cancer;
LUSC	cis	rs7598759	0.548	rs1823328	chr2:232355184	G/A	cg19187155	chr2:232395269	NMUR1	0.94	16.34	0.67	1.68e-44	Noise-induced hearing loss;
LUSC	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06850241	chr22:41845214	NA	-0.31	-5.76	-0.3	1.89e-8	Vitiligo;
LUSC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.85	16.12	0.66	1.25e-43	Mean platelet volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27007426	chr8:87354751	WWP1	-0.4	-5.94	-0.31	6.99e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.44	6.8	0.35	4.96e-11	Schizophrenia;
LUSC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	1.08	9.74	0.47	6.73e-20	Skin colour saturation;
LUSC	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg15848620	chr12:58087721	OS9	0.47	6.53	0.34	2.39e-10	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg02796970	chr10:39023768	NA	0.51	8.25	0.41	3.82e-15	Menopause (age at onset);
LUSC	cis	rs11779988	0.545	rs438873	chr8:17786516	G/A	cg01800426	chr8:17659068	MTUS1	-0.47	-5.8	-0.3	1.53e-8	Breast cancer;
LUSC	cis	rs1461503	0.966	rs4936764	chr11:122844492	G/A	cg27398637	chr11:122830231	C11orf63	-0.41	-6.54	-0.34	2.29e-10	Menarche (age at onset);
LUSC	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg03948781	chr1:205179583	DSTYK	0.3	5.65	0.3	3.5e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.6	-0.43	3.16e-16	Total cholesterol levels;
LUSC	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg15309053	chr8:964076	NA	0.3	5.89	0.31	9.29e-9	Schizophrenia;
LUSC	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg15556689	chr8:8085844	FLJ10661	0.63	8.76	0.43	1.02e-16	Neuroticism;
LUSC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg22963979	chr7:1858916	MAD1L1	-0.56	-8.58	-0.43	3.59e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-9.56	-0.46	2.74e-19	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23243902	chr11:117049849	SIDT2	0.42	6.2	0.32	1.7e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.06	0.48	5.93e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.33	0.77	3.16e-68	Prudent dietary pattern;
LUSC	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg09904177	chr6:26538194	HMGN4	-0.54	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg00945038	chr17:61921165	SMARCD2	0.51	8.73	0.43	1.23e-16	Prudent dietary pattern;
LUSC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-1.0	-18.3	-0.71	2.56e-52	Height;
LUSC	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg23625390	chr15:77176239	SCAPER	0.46	7.12	0.36	6.79e-12	Blood metabolite levels;
LUSC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.35	6.31	0.33	8.82e-10	Obesity-related traits;
LUSC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg11189052	chr15:85197271	WDR73	-0.65	-10.15	-0.49	2.83e-21	P wave terminal force;
LUSC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	0.93	18.29	0.71	2.79e-52	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13089785	1.000	rs35181974	chr3:123607884	C/A	cg02558132	chr3:123411198	MYLK	0.36	6.13	0.32	2.46e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12379764	chr21:47803548	PCNT	0.49	7.0	0.36	1.4e-11	Testicular germ cell tumor;
LUSC	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg19046167	chr17:80928561	B3GNTL1	-0.45	-6.62	-0.34	1.44e-10	Breast cancer;
LUSC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.79	0.47	4.58e-20	Bipolar disorder;
LUSC	cis	rs6594499	0.872	rs1379300	chr5:110441439	A/G	cg04022379	chr5:110408740	TSLP	0.43	6.5	0.33	2.96e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs62400317	0.859	rs12203558	chr6:45244423	C/G	cg18551225	chr6:44695536	NA	-0.44	-7.28	-0.37	2.46e-12	Total body bone mineral density;
LUSC	cis	rs10489202	1.000	rs10489202	chr1:167903079	A/C	cg24449463	chr1:168025552	DCAF6	0.56	6.99	0.36	1.5e-11	Schizophrenia;
LUSC	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg05585544	chr11:47624801	NA	-0.34	-6.17	-0.32	1.96e-9	Subjective well-being;
LUSC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg18758796	chr5:131593413	PDLIM4	0.4	7.06	0.36	9.82e-12	Blood metabolite levels;
LUSC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg16423285	chr20:60520624	NA	0.64	8.17	0.41	6.5e-15	Body mass index;
LUSC	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg14092571	chr14:90743983	NA	0.36	5.84	0.3	1.22e-8	Mortality in heart failure;
LUSC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-11.11	-0.52	1.25e-24	Chronic sinus infection;
LUSC	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg12856521	chr11:46389249	DGKZ	0.41	6.38	0.33	6.02e-10	Leprosy;
LUSC	cis	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg02972257	chr16:68554789	NA	-0.44	-5.99	-0.31	5.5e-9	Colorectal cancer;
LUSC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg13206674	chr6:150067644	NUP43	0.6	9.53	0.46	3.38e-19	Lung cancer;
LUSC	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg27661571	chr11:113659931	NA	-0.51	-6.24	-0.32	1.34e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.86	13.86	0.6	8.31e-35	Coronary artery disease;
LUSC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.44	-0.62	4.54e-37	Eye color traits;
LUSC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg03354898	chr7:1950403	MAD1L1	0.38	7.45	0.38	7.87e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg00792783	chr2:198669748	PLCL1	0.43	5.68	0.3	2.9e-8	Intracranial aneurysm;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00071408	chr8:22864908	RHOBTB2	0.44	6.09	0.32	3.06e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2274273	0.638	rs11622636	chr14:55647840	C/T	cg04306507	chr14:55594613	LGALS3	0.49	9.79	0.47	4.65e-20	Protein biomarker;
LUSC	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.66	-5.72	-0.3	2.34e-8	Major depressive disorder;
LUSC	cis	rs6977940	0.730	rs11766514	chr7:2896271	C/T	cg19731401	chr7:2775893	GNA12	0.63	7.3	0.37	2.17e-12	White matter integrity;
LUSC	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-8.18	-0.41	6.1e-15	Axial length;
LUSC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-1.11	-24.44	-0.8	2.38e-76	Height;
LUSC	cis	rs9378688	0.654	rs2505662	chr6:2326185	T/C	cg12303981	chr6:2244766	GMDS	-0.44	-6.12	-0.32	2.61e-9	Caudate nucleus volume;
LUSC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	9.65	0.47	1.34e-19	Height;
LUSC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg16584290	chr5:462447	EXOC3	0.46	8.15	0.41	7.32e-15	Cystic fibrosis severity;
LUSC	cis	rs72772090	0.539	rs72775817	chr5:96190709	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.88	-0.35	2.88e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg25019033	chr10:957182	NA	-0.51	-6.32	-0.33	8.28e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.82	-0.35	4.38e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg13206674	chr6:150067644	NUP43	0.56	8.7	0.43	1.51e-16	Lung cancer;
LUSC	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.62	-9.79	-0.47	4.52e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25072359	chr17:41440525	NA	0.65	9.26	0.45	2.46e-18	Menopause (age at onset);
LUSC	cis	rs1808579	0.935	rs4800493	chr18:21143932	T/C	cg14672496	chr18:21087552	C18orf8	0.34	5.69	0.3	2.83e-8	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs7173743	0.756	rs8032771	chr15:79126059	A/G	cg00540400	chr15:79124168	NA	0.36	6.18	0.32	1.84e-9	Coronary artery disease;
LUSC	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06002616	chr8:101225028	SPAG1	-0.46	-7.57	-0.38	3.77e-13	Atrioventricular conduction;
LUSC	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	1.3	11.92	0.55	1.51e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg00083206	chr6:110721305	DDO	-0.46	-8.29	-0.41	2.81e-15	Platelet distribution width;
LUSC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg06618935	chr21:46677482	NA	-0.38	-7.58	-0.38	3.51e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.56	-9.87	-0.48	2.51e-20	Bipolar disorder;
LUSC	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	0.91	17.84	0.7	1.74e-50	Metabolite levels;
LUSC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg03948781	chr1:205179583	DSTYK	0.3	5.66	0.3	3.31e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs7589561	0.602	rs10196773	chr2:106397496	G/A	cg26805882	chr4:174453287	NBLA00301	0.48	6.3	0.33	9.61e-10	Addiction;
LUSC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-9.91	-0.48	1.83e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg09085632	chr11:111637200	PPP2R1B	0.94	12.83	0.57	6.37e-31	Primary sclerosing cholangitis;
LUSC	cis	rs6570726	0.526	rs9403699	chr6:145730685	G/T	cg23711669	chr6:146136114	FBXO30	0.4	5.79	0.3	1.66e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.62	-0.38	2.62e-13	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg25767906	chr1:53392781	SCP2	-0.5	-9.21	-0.45	3.68e-18	Monocyte count;
LUSC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.4e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg04013093	chr6:42928303	GNMT	-0.27	-5.66	-0.3	3.34e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg22676075	chr6:135203613	NA	0.58	9.32	0.45	1.61e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs6601327	0.641	rs12542457	chr8:9564600	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.35	-0.33	6.9e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.14	0.41	8.16e-15	Axial length;
LUSC	cis	rs12681287	0.640	rs6992944	chr8:87419308	G/T	cg27223183	chr8:87520930	FAM82B	0.55	7.52	0.38	4.95e-13	Caudate activity during reward;
LUSC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg13609457	chr4:120235615	NA	0.41	5.64	0.3	3.55e-8	Corneal astigmatism;
LUSC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	7.22	0.37	3.53e-12	Renal cell carcinoma;
LUSC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.44	-9.3	-0.45	1.87e-18	Lymphocyte counts;
LUSC	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg23601095	chr6:26197514	HIST1H3D	0.68	7.51	0.38	5.59e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg05110241	chr16:68378359	PRMT7	-0.5	-6.01	-0.31	4.89e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg22491629	chr6:157744540	C6orf35	-0.9	-10.67	-0.5	4.68e-23	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06609250	chr11:85522094	SYTL2	-0.42	-6.17	-0.32	1.98e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg09904177	chr6:26538194	HMGN4	0.5	7.85	0.39	5.78e-14	Schizophrenia;
LUSC	cis	rs9840812	0.645	rs9883916	chr3:136208788	C/T	cg15507776	chr3:136538369	TMEM22	0.43	5.74	0.3	2.11e-8	Fibrinogen levels;
LUSC	cis	rs654351	0.543	rs622388	chr6:10387117	T/G	cg04978078	chr6:10383147	NA	-0.31	-5.82	-0.3	1.39e-8	Squamous cell lung carcinoma;
LUSC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg20203395	chr5:56204925	C5orf35	-0.79	-10.33	-0.49	6.78e-22	Initial pursuit acceleration;
LUSC	cis	rs10761482	0.861	rs10821737	chr10:62107802	A/G	cg18175470	chr10:62150864	ANK3	-0.51	-7.24	-0.37	3.06e-12	Schizophrenia;
LUSC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg08975724	chr8:8085496	FLJ10661	0.52	7.75	0.39	1.11e-13	Mood instability;
LUSC	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.2	-0.45	3.96e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4664308	1.000	rs4664308	chr2:160917497	A/G	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.31	-0.53	2.55e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs6574644	1.000	rs6574643	chr14:81774402	A/T	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.58	0.34	1.84e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4919087	1.000	rs12221430	chr10:99061386	C/G	cg25902810	chr10:99078978	FRAT1	0.5	7.24	0.37	3.05e-12	Monocyte count;
LUSC	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg14696996	chr19:15285081	NOTCH3	0.96	8.62	0.43	2.65e-16	Pulse pressure;
LUSC	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.51	6.13	0.32	2.44e-9	Cognitive ability;
LUSC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	1.19	16.28	0.67	2.87e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06873352	chr17:61820015	STRADA	0.71	12.3	0.56	6.28e-29	Prudent dietary pattern;
LUSC	cis	rs79349575	0.756	rs2291726	chr17:47039254	T/C	cg22482690	chr17:47019901	SNF8	-0.37	-6.88	-0.35	2.89e-11	Type 2 diabetes;
LUSC	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	0.69	6.92	0.35	2.32e-11	Prostate cancer;
LUSC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg07424592	chr7:64974309	NA	0.66	5.83	0.3	1.32e-8	Diabetic kidney disease;
LUSC	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg00277334	chr10:82204260	NA	-0.53	-7.33	-0.37	1.73e-12	Post bronchodilator FEV1;
LUSC	cis	rs460214	0.528	rs4817954	chr21:40023857	C/T	cg21578987	chr21:40029669	ERG	0.43	6.62	0.34	1.4e-10	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg00105475	chr2:10696890	NA	0.38	6.27	0.32	1.11e-9	Prostate cancer;
LUSC	cis	rs2637266	0.597	rs2583065	chr10:78555915	A/G	cg18941641	chr10:78392320	NA	0.38	7.03	0.36	1.19e-11	Pulmonary function;
LUSC	cis	rs11039100	0.681	rs11039170	chr11:5845187	T/G	cg05234568	chr11:5960015	NA	-0.52	-5.85	-0.31	1.14e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.34	-0.42	2.01e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9828933	0.938	rs2578011	chr3:64004819	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.56	-6.1	-0.32	2.91e-9	Type 2 diabetes;
LUSC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg06453172	chr10:134556979	INPP5A	0.49	6.46	0.33	3.63e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg02972257	chr16:68554789	NA	-0.5	-6.4	-0.33	5.31e-10	Ulcerative colitis;
LUSC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg14784868	chr12:69753453	YEATS4	0.61	8.9	0.44	3.54e-17	Response to diuretic therapy;
LUSC	cis	rs2580764	0.503	rs2972097	chr2:55267545	T/C	cg20993754	chr2:55226987	RTN4	-0.39	-6.5	-0.34	2.86e-10	Mean platelet volume;
LUSC	trans	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	10.03	0.48	7.23e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs4588572	0.643	rs1864173	chr5:77691158	C/T	cg11547950	chr5:77652471	NA	0.53	7.46	0.38	7.57e-13	Triglycerides;
LUSC	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg20283391	chr11:68216788	NA	-0.61	-8.48	-0.42	7.63e-16	Total body bone mineral density;
LUSC	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg06937882	chr20:24974362	C20orf3	-0.42	-7.0	-0.36	1.43e-11	Blood protein levels;
LUSC	trans	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg26043149	chr18:55253948	FECH	-0.46	-7.04	-0.36	1.07e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs35000415	0.938	rs12531054	chr7:128644251	A/C	cg19972273	chr7:128594194	NA	-0.6	-6.59	-0.34	1.67e-10	Systemic lupus erythematosus;
LUSC	cis	rs7681440	0.606	rs356184	chr4:90703233	A/G	cg06632027	chr4:90757378	SNCA	0.36	5.65	0.3	3.4e-8	Dementia with Lewy bodies;
LUSC	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg19418458	chr7:158789849	NA	0.5	7.75	0.39	1.09e-13	Facial morphology (factor 20);
LUSC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg27588902	chr6:42928151	GNMT	-0.3	-6.62	-0.34	1.45e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg17168535	chr8:21777572	XPO7	0.85	15.54	0.65	2.22e-41	Lung cancer in ever smokers;
LUSC	cis	rs7597155	0.935	rs10181122	chr2:69980910	C/T	cg02498382	chr2:70120550	SNRNP27	-0.25	-5.87	-0.31	1.04e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-5.97	-0.31	5.92e-9	Ulcerative colitis;
LUSC	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-7.61	-0.38	2.78e-13	Parkinson's disease;
LUSC	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg05340658	chr4:99064831	C4orf37	0.44	6.92	0.35	2.32e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg24585782	chr17:78113791	EIF4A3	-0.46	-7.21	-0.37	3.76e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.72	0.63	3.61e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg14121845	chr20:25566513	NINL	0.3	5.66	0.3	3.29e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-8.26	-0.41	3.46e-15	Lymphocyte counts;
LUSC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg12292205	chr6:26970375	C6orf41	0.51	8.57	0.42	3.88e-16	Schizophrenia;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg25703541	chr22:24373054	LOC391322	-0.86	-14.04	-0.61	1.69e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01488865	chr20:61569319	C20orf11;DIDO1	-0.4	-6.0	-0.31	5.28e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg20887711	chr4:1340912	KIAA1530	0.42	5.8	0.3	1.56e-8	Obesity-related traits;
LUSC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.99	0.55	8.55e-28	Chronic sinus infection;
LUSC	cis	rs4704187	0.687	rs6860441	chr5:74389799	G/A	cg03227963	chr5:74354835	NA	0.32	6.82	0.35	4.21e-11	Response to amphetamines;
LUSC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg24846343	chr22:24311635	DDTL	-0.59	-9.09	-0.45	9.09e-18	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg12667521	chr19:29218732	NA	0.53	6.14	0.32	2.32e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs11958404	0.932	rs6894528	chr5:157434788	A/G	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.29	0.37	2.29e-12	Platelet count;
LUSC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg22535103	chr8:58192502	C8orf71	-0.71	-7.68	-0.39	1.81e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs8056893	0.885	rs6499165	chr16:68326200	A/C	cg02226672	chr16:68398533	SMPD3	0.34	5.96	0.31	6.31e-9	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg05110241	chr16:68378359	PRMT7	-0.64	-8.15	-0.41	7.64e-15	Schizophrenia;
LUSC	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg05855489	chr10:104503620	C10orf26	-0.71	-10.15	-0.49	2.92e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg18230493	chr5:56204884	C5orf35	-0.92	-13.95	-0.61	3.52e-35	Initial pursuit acceleration;
LUSC	cis	rs13385	0.769	rs270166	chr5:139533279	A/C	cg26211634	chr5:139558579	C5orf32	-0.4	-5.94	-0.31	7.24e-9	Atrial fibrillation;
LUSC	cis	rs2637266	1.000	rs2130798	chr10:78329563	C/T	cg18941641	chr10:78392320	NA	0.38	6.83	0.35	4.09e-11	Pulmonary function;
LUSC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg03396347	chr1:1875803	NA	0.48	10.24	0.49	1.43e-21	Body mass index;
LUSC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.52	0.34	2.66e-10	Lung cancer;
LUSC	cis	rs73195822	0.667	rs60184376	chr12:111229975	T/C	cg12870014	chr12:110450643	ANKRD13A	0.69	6.75	0.35	6.65e-11	Itch intensity from mosquito bite;
LUSC	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg27661571	chr11:113659931	NA	-0.7	-7.96	-0.4	2.78e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs4363385	0.647	rs56412380	chr1:153000705	T/C	cg25856811	chr1:152973957	SPRR3	-0.4	-6.52	-0.34	2.64e-10	Inflammatory skin disease;
LUSC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25072359	chr17:41440525	NA	0.69	9.65	0.47	1.36e-19	Menopause (age at onset);
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.65	10.93	0.51	5.7e-24	Lymphocyte counts;
LUSC	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg08917208	chr2:24149416	ATAD2B	0.98	10.26	0.49	1.15e-21	Mean corpuscular hemoglobin;
LUSC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.56	8.64	0.43	2.35e-16	Methadone dose in opioid dependence;
LUSC	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg05805236	chr11:65401703	PCNXL3	-0.64	-10.61	-0.5	7.33e-23	Acne (severe);
LUSC	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg23625390	chr15:77176239	SCAPER	-0.67	-10.01	-0.48	8.51e-21	Blood metabolite levels;
LUSC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg18681998	chr4:17616180	MED28	0.81	14.59	0.62	1.22e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2692947	0.727	rs749459	chr2:96795714	G/A	cg23100626	chr2:96804247	ASTL	0.28	7.01	0.36	1.34e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9399401	0.633	rs262118	chr6:142843054	C/A	cg03128060	chr6:142623767	GPR126	0.51	7.89	0.4	4.44e-14	Chronic obstructive pulmonary disease;
LUSC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg18230493	chr5:56204884	C5orf35	-0.88	-13.39	-0.59	4.99e-33	Initial pursuit acceleration;
LUSC	trans	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg10756647	chr7:56101905	PSPH	0.85	8.31	0.41	2.5e-15	Diabetic kidney disease;
LUSC	cis	rs950881	0.867	rs10197862	chr2:102966549	A/G	cg20060108	chr2:102954350	IL1RL1	0.47	6.18	0.32	1.91e-9	Allergy;
LUSC	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.55	-0.42	4.55e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs603446	0.967	rs180370	chr11:116592365	C/T	cg08653369	chr3:150644434	CLRN1	-0.3	-6.0	-0.31	5e-9	Triglycerides;
LUSC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg07148914	chr20:33460835	GGT7	-0.55	-8.51	-0.42	5.81e-16	Height;
LUSC	trans	rs7615952	0.546	rs2979306	chr3:125312130	C/A	cg07211511	chr3:129823064	LOC729375	-0.51	-5.96	-0.31	6.32e-9	Blood pressure (smoking interaction);
LUSC	cis	rs61935443	0.666	rs11107780	chr12:95299142	G/A	cg21533806	chr12:95267307	NA	0.49	5.7	0.3	2.63e-8	Schizophrenia;
LUSC	cis	rs7712401	0.791	rs10059964	chr5:122118293	A/G	cg19077854	chr5:122220652	SNX24	0.35	7.83	0.39	6.55e-14	Mean platelet volume;
LUSC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg04369109	chr6:150039330	LATS1	-0.5	-7.24	-0.37	3.18e-12	Lung cancer;
LUSC	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	1.13	18.32	0.71	2.17e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg22906224	chr7:99728672	NA	-0.47	-6.6	-0.34	1.6e-10	Coronary artery disease;
LUSC	cis	rs1451375	1.000	rs10250513	chr7:50621488	T/G	cg18232548	chr7:50535776	DDC	0.51	7.83	0.39	6.32e-14	Malaria;
LUSC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03352830	chr11:487213	PTDSS2	0.75	8.72	0.43	1.34e-16	Body mass index;
LUSC	cis	rs73206853	0.764	rs7966591	chr12:110644045	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	7.97	0.4	2.56e-14	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7927771	0.524	rs10838784	chr11:47882341	G/A	cg20307385	chr11:47447363	PSMC3	0.48	6.99	0.36	1.46e-11	Subjective well-being;
LUSC	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.28	0.59	1.28e-32	Cognitive test performance;
LUSC	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg21211680	chr2:198530	NA	-0.6	-7.34	-0.37	1.68e-12	Blood protein levels;
LUSC	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.13	-0.91	8.02e-130	Myeloid white cell count;
LUSC	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg18806716	chr10:30721971	MAP3K8	-0.59	-9.13	-0.45	6.66e-18	Inflammatory bowel disease;
LUSC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg16584290	chr5:462447	EXOC3	-0.37	-6.43	-0.33	4.39e-10	Cystic fibrosis severity;
LUSC	cis	rs9309473	1.000	rs7558944	chr2:73810909	T/G	cg20560298	chr2:73613845	ALMS1	-0.46	-6.55	-0.34	2.17e-10	Metabolite levels;
LUSC	cis	rs2346177	0.844	rs4953371	chr2:46651143	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.37	6.51	0.34	2.69e-10	HDL cholesterol;
LUSC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11764359	chr7:65958608	NA	0.68	10.95	0.51	4.86e-24	Aortic root size;
LUSC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg15790184	chr11:494944	RNH1	0.58	6.31	0.33	8.97e-10	Body mass index;
LUSC	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.34	-6.6	-0.34	1.66e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.69	-11.36	-0.53	1.64e-25	Systemic lupus erythematosus;
LUSC	cis	rs9650657	0.812	rs11250072	chr8:10632121	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.42	-0.33	4.8e-10	Neuroticism;
LUSC	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.48	7.92	0.4	3.63e-14	Alcohol dependence;
LUSC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg22963979	chr7:1858916	MAD1L1	-0.68	-11.29	-0.53	2.9e-25	Bipolar disorder and schizophrenia;
LUSC	cis	rs6700896	0.864	rs12030956	chr1:66115298	G/T	cg04111102	chr1:66153794	NA	0.32	7.1	0.36	7.54e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg19610905	chr11:61596333	FADS2	0.52	7.72	0.39	1.34e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUSC	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.37e-33	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.67	0.34	1.05e-10	Lung cancer;
LUSC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg11062466	chr8:58055876	NA	0.65	8.33	0.41	2.12e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg01294253	chr9:136912663	BRD3	0.36	6.24	0.32	1.31e-9	Platelet distribution width;
LUSC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.38	0.46	1.07e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3736594	0.759	rs6753736	chr2:27958855	C/G	cg27432699	chr2:27873401	GPN1	-0.64	-9.0	-0.44	1.75e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.76	-0.3	1.93e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18004316	chr2:208634121	FZD5	0.77	6.7	0.34	9.05e-11	Cognitive performance;
LUSC	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg12002119	chr2:101014098	CHST10	0.34	5.71	0.3	2.48e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3849570	1.000	rs3860595	chr3:81811784	A/G	cg07356753	chr3:81810745	GBE1	-0.59	-9.38	-0.46	1.06e-18	Waist circumference;Body mass index;
LUSC	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg23795048	chr12:9217529	LOC144571	0.34	5.87	0.31	1.04e-8	Sjögren's syndrome;
LUSC	trans	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.61	-0.38	2.86e-13	Monocyte count;
LUSC	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.9	15.55	0.65	2.12e-41	Bladder cancer;
LUSC	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg19628046	chr18:33552617	C18orf21	-0.53	-6.62	-0.34	1.39e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg02487422	chr3:49467188	NICN1	0.48	7.63	0.39	2.46e-13	Resting heart rate;
LUSC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg14092988	chr3:52407081	DNAH1	0.3	5.97	0.31	6.02e-9	Bipolar disorder;
LUSC	cis	rs977987	0.806	rs11640473	chr16:75403289	C/A	cg03315344	chr16:75512273	CHST6	0.48	9.25	0.45	2.73e-18	Dupuytren's disease;
LUSC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg09359103	chr1:154839909	KCNN3	-0.69	-15.95	-0.66	5.7e-43	Prostate cancer;
LUSC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg09365446	chr1:150670422	GOLPH3L	0.48	7.02	0.36	1.21e-11	Melanoma;
LUSC	trans	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg21659725	chr3:3221576	CRBN	-0.71	-7.82	-0.39	7.08e-14	Menarche (age at onset);
LUSC	cis	rs7336332	0.569	rs57724994	chr13:28010389	T/C	cg22138327	chr13:27999177	GTF3A	0.68	9.24	0.45	2.98e-18	Weight;
LUSC	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg14582100	chr15:45693742	SPATA5L1	0.56	10.05	0.48	6.03e-21	Homoarginine levels;
LUSC	trans	rs11723530	0.538	rs13142537	chr4:170812339	C/T	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.17	-0.32	2.01e-9	Myopia (pathological);
LUSC	cis	rs7599312	0.586	rs7565257	chr2:213388276	G/A	cg16329650	chr2:213403929	ERBB4	0.51	7.38	0.37	1.31e-12	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg13175981	chr1:150552382	MCL1	-0.41	-5.67	-0.3	3.17e-8	Tonsillectomy;
LUSC	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg21892295	chr12:121157589	UNC119B	-0.52	-9.54	-0.46	3.07e-19	Mean corpuscular volume;
LUSC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.68	0.6	3.93e-34	Platelet count;
LUSC	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg14154082	chr13:112174009	NA	0.37	7.68	0.39	1.8e-13	Menarche (age at onset);
LUSC	cis	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg21775007	chr8:11205619	TDH	-0.49	-6.64	-0.34	1.3e-10	Neuroticism;
LUSC	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg07988820	chr12:82153109	PPFIA2	0.42	6.18	0.32	1.9e-9	Resting heart rate;
LUSC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg00745463	chr17:30367425	LRRC37B	-0.65	-8.07	-0.4	1.31e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg06951627	chr6:26196580	NA	0.53	5.72	0.3	2.39e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Depression;
LUSC	cis	rs73200209	0.665	rs17498599	chr12:116597253	C/T	cg01776926	chr12:116560359	MED13L	-0.51	-6.13	-0.32	2.45e-9	Total body bone mineral density;
LUSC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg04518342	chr5:131593106	PDLIM4	0.34	6.17	0.32	1.97e-9	Blood metabolite levels;
LUSC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.73	10.83	0.51	1.3e-23	Type 2 diabetes;
LUSC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg10253484	chr15:75165896	SCAMP2	-0.48	-7.23	-0.37	3.41e-12	Breast cancer;
LUSC	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Bladder cancer;
LUSC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-1.0	-18.3	-0.71	2.56e-52	Height;
LUSC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.21	0.32	1.62e-9	Schizophrenia;
LUSC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg16624210	chr5:671434	TPPP	0.5	6.34	0.33	7.27e-10	Obesity-related traits;
LUSC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg13397359	chr6:42928475	GNMT	0.62	10.29	0.49	9.19e-22	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.41	-0.42	1.24e-15	Retinal vascular caliber;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg20531166	chr11:82782814	RAB30	0.41	6.55	0.34	2.24e-10	Schizophrenia;
LUSC	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.65	-0.47	1.37e-19	Total cholesterol levels;
LUSC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg13939156	chr17:80058883	NA	0.34	6.7	0.34	8.7e-11	Life satisfaction;
LUSC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg18402987	chr7:1209562	NA	0.7	7.64	0.39	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg09655341	chr17:79618100	PDE6G	0.27	6.31	0.33	9.05e-10	Eye color traits;
LUSC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg11247378	chr22:39784982	NA	-0.66	-13.17	-0.58	3.35e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.78	-13.91	-0.61	5.29e-35	Dental caries;
LUSC	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg23625390	chr15:77176239	SCAPER	0.46	7.02	0.36	1.22e-11	Blood metabolite levels;
LUSC	cis	rs9318086	0.712	rs9510917	chr13:24442846	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.39	5.68	0.3	2.96e-8	Myopia (pathological);
LUSC	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg19169023	chr15:41853346	TYRO3	-0.57	-9.12	-0.45	7.42e-18	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00339695	chr16:24857497	SLC5A11	0.39	6.72	0.34	8.02e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00166722	chr3:10149974	C3orf24	0.6	7.97	0.4	2.62e-14	Alzheimer's disease;
LUSC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg02018176	chr4:1364513	KIAA1530	0.53	9.2	0.45	3.96e-18	Obesity-related traits;
LUSC	cis	rs6714016	0.744	rs2551347	chr2:23912401	C/T	cg08917208	chr2:24149416	ATAD2B	-0.56	-7.58	-0.38	3.41e-13	Plateletcrit;
LUSC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg17376030	chr22:41985996	PMM1	-0.46	-5.72	-0.3	2.42e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg06618935	chr21:46677482	NA	-0.37	-7.4	-0.38	1.09e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg15423357	chr2:25149977	NA	0.45	9.12	0.45	7.03e-18	Body mass index;
LUSC	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg05283184	chr6:79620031	NA	-0.44	-8.16	-0.41	6.98e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg06145435	chr7:1022769	CYP2W1	0.28	6.11	0.32	2.74e-9	Longevity;Endometriosis;
LUSC	cis	rs11229555	0.645	rs11601296	chr11:58423297	A/G	cg15696309	chr11:58395628	NA	-0.66	-7.01	-0.36	1.37e-11	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg27094323	chr7:1216898	NA	-0.45	-7.88	-0.4	4.66e-14	Longevity;Endometriosis;
LUSC	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg02527881	chr3:46936655	PTH1R	0.38	6.63	0.34	1.32e-10	Colorectal cancer;
LUSC	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg10909506	chr17:38081995	ORMDL3	0.32	5.75	0.3	2e-8	Self-reported allergy;
LUSC	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg14343924	chr8:8086146	FLJ10661	0.45	6.39	0.33	5.48e-10	Myopia (pathological);
LUSC	cis	rs11039100	0.607	rs34792182	chr11:5782874	G/C	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.82	0.54	3.63e-27	Mean corpuscular volume;
LUSC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.36	5.79	0.3	1.61e-8	Menopause (age at onset);
LUSC	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg00495681	chr13:53174319	NA	0.6	10.52	0.5	1.54e-22	Lewy body disease;
LUSC	trans	rs9860340	0.730	rs60936504	chr3:87640246	T/C	cg03644585	chr7:884825	UNC84A	0.42	5.99	0.31	5.4e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-8.79	-0.43	7.83e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6782228	0.606	rs2253144	chr3:128329920	C/T	cg16766828	chr3:128327626	NA	0.31	5.79	0.3	1.63e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg16989719	chr2:238392110	NA	-0.41	-7.25	-0.37	3e-12	Prostate cancer;
LUSC	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15557168	chr22:42548783	NA	-0.43	-7.24	-0.37	3.07e-12	Cognitive function;
LUSC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg01802117	chr1:53393560	SCP2	-0.36	-5.86	-0.31	1.1e-8	Monocyte count;
LUSC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.31	0.45	1.82e-18	Monocyte percentage of white cells;
LUSC	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg18721089	chr20:30220636	NA	-0.34	-5.89	-0.31	9.62e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg02018176	chr4:1364513	KIAA1530	0.53	9.24	0.45	2.99e-18	Obesity-related traits;
LUSC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg08470875	chr2:26401718	FAM59B	-0.71	-9.38	-0.46	1.05e-18	Gut microbiome composition (summer);
LUSC	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.06	0.31	3.59e-9	Recombination rate (females);
LUSC	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg17168535	chr8:21777572	XPO7	0.85	15.57	0.65	1.75e-41	Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.41	-7.85	-0.39	5.63e-14	Caffeine consumption;
LUSC	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-7.51	-0.38	5.43e-13	Fear of minor pain;
LUSC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg18825076	chr15:78729989	IREB2	0.47	6.4	0.33	5.32e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.57	9.86	0.47	2.63e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs231513	0.954	rs231506	chr17:41970191	A/G	cg26893861	chr17:41843967	DUSP3	-0.54	-6.58	-0.34	1.86e-10	Cognitive function;
LUSC	cis	rs10203711	0.933	rs12692238	chr2:239553940	T/C	cg14580085	chr2:239553406	NA	0.38	6.39	0.33	5.73e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg21951975	chr1:209979733	IRF6	0.58	7.24	0.37	3.05e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	10.62	0.5	6.98e-23	Mood instability;
LUSC	cis	rs12618769	0.597	rs3754888	chr2:99090674	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.54	0.38	4.41e-13	Bipolar disorder;
LUSC	cis	rs554111	0.656	rs17450813	chr1:21264308	T/C	cg01072550	chr1:21505969	NA	0.4	6.14	0.32	2.32e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg16647868	chr5:131706066	SLC22A5	0.4	6.29	0.33	1.01e-9	Breast cancer;
LUSC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg17420585	chr12:42539391	GXYLT1	-0.36	-7.02	-0.36	1.23e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.09e-30	Aortic root size;
LUSC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg26039829	chr8:22132926	PIWIL2	0.42	7.66	0.39	2.01e-13	Hypertriglyceridemia;
LUSC	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg07936489	chr17:37558343	FBXL20	-0.63	-8.9	-0.44	3.55e-17	Glomerular filtration rate (creatinine);
LUSC	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg24154853	chr7:158122151	PTPRN2	0.43	8.3	0.41	2.57e-15	Calcium levels;
LUSC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg13902645	chr11:5959945	NA	0.71	11.45	0.53	7.75e-26	DNA methylation (variation);
LUSC	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.54	-0.34	2.37e-10	Bipolar disorder;
LUSC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg20821713	chr7:1055600	C7orf50	-0.55	-6.8	-0.35	4.9e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.24e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11971779	0.680	rs7788777	chr7:139055193	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23583168	chr7:148888333	NA	-0.85	-14.74	-0.63	3.14e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg00101154	chr16:420108	MRPL28	-0.48	-8.38	-0.42	1.54e-15	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.06	0.36	9.53e-12	Bipolar disorder;
LUSC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.58	9.57	0.46	2.48e-19	Aortic root size;
LUSC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg06074448	chr4:187884817	NA	-0.47	-7.81	-0.39	7.42e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg17470449	chr10:769945	NA	0.56	7.62	0.38	2.72e-13	Uric acid levels;
LUSC	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg17366294	chr4:99064904	C4orf37	0.55	8.44	0.42	1.01e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2348418	0.864	rs6487689	chr12:28713034	C/T	cg13890972	chr12:28721907	NA	-0.34	-5.85	-0.3	1.18e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg06640241	chr16:89574553	SPG7	0.67	10.69	0.5	3.98e-23	Multiple myeloma (IgH translocation);
LUSC	trans	rs6991952	0.845	rs7822766	chr8:25742279	A/T	cg02047300	chr5:140208201	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.43	-5.97	-0.31	6.08e-9	Inguinal hernia;
LUSC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg25036284	chr2:26402008	FAM59B	-0.68	-9.64	-0.47	1.49e-19	Gut microbiome composition (summer);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08755283	chr5:118324104	DTWD2	-0.5	-6.89	-0.35	2.74e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs113835537	0.529	rs4542420	chr11:66277610	G/C	cg24851651	chr11:66362959	CCS	0.54	8.03	0.4	1.64e-14	Airway imaging phenotypes;
LUSC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg11764359	chr7:65958608	NA	-0.52	-6.83	-0.35	4e-11	Aortic root size;
LUSC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg27094323	chr7:1216898	NA	-0.36	-6.5	-0.33	3.01e-10	Longevity;Endometriosis;
LUSC	cis	rs4285028	0.948	rs34181646	chr3:121705373	T/A	cg11130432	chr3:121712080	ILDR1	-0.65	-10.05	-0.48	5.97e-21	Multiple sclerosis;
LUSC	cis	rs6977660	1.000	rs57916046	chr7:19800542	T/C	cg05791153	chr7:19748676	TWISTNB	0.63	6.79	0.35	5e-11	Thyroid stimulating hormone;
LUSC	cis	rs10871290	0.881	rs4099290	chr16:74468889	A/G	cg01733217	chr16:74700730	RFWD3	-0.62	-8.99	-0.44	1.92e-17	Breast cancer;
LUSC	cis	rs3741151	0.892	rs7105681	chr11:73059341	G/A	cg17517138	chr11:73019481	ARHGEF17	0.91	8.29	0.41	2.83e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs701145	0.585	rs1713811	chr3:153874566	G/A	cg17054900	chr3:154042577	DHX36	0.69	6.76	0.35	6.15e-11	Coronary artery disease;
LUSC	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg09526685	chr4:187126073	CYP4V2	-0.64	-6.36	-0.33	6.59e-10	Blood protein levels;
LUSC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.58	-8.24	-0.41	3.84e-15	Homoarginine levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16586152	chr7:106301062	FLJ36031	-0.45	-6.92	-0.35	2.32e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg06627628	chr2:24431161	ITSN2	0.61	8.75	0.43	1.08e-16	Asthma;
LUSC	cis	rs679087	0.932	rs7312697	chr12:29933069	T/C	cg14258853	chr12:29935411	TMTC1	0.9	15.97	0.66	4.5e-43	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs7760949	0.963	rs1467729	chr6:13911167	C/T	cg27413430	chr6:13925136	RNF182	-0.48	-7.39	-0.37	1.18e-12	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-13.47	-0.59	2.5e-33	Brugada syndrome;
LUSC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg04166393	chr7:2884313	GNA12	-0.47	-6.34	-0.33	7.56e-10	Height;
LUSC	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg23625390	chr15:77176239	SCAPER	-0.63	-9.44	-0.46	6.78e-19	Blood metabolite levels;
LUSC	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.05	0.31	3.83e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg24675658	chr1:53192096	ZYG11B	0.59	9.22	0.45	3.51e-18	Monocyte count;
LUSC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg04369109	chr6:150039330	LATS1	-0.58	-8.57	-0.42	4e-16	Lung cancer;
LUSC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.82	14.39	0.62	7.5e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs2219968	0.887	rs1947897	chr8:78946874	G/C	cg00738934	chr8:78996279	NA	0.34	5.73	0.3	2.23e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7659604	0.502	rs11098640	chr4:122675875	G/A	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.91	-0.31	8.47e-9	Type 2 diabetes;
LUSC	cis	rs4363385	0.747	rs6671414	chr1:152974119	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.88	-0.4	4.74e-14	Inflammatory skin disease;
LUSC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg07274523	chr3:49395745	GPX1	0.67	10.27	0.49	1.11e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg15704280	chr7:45808275	SEPT13	0.72	6.8	0.35	4.88e-11	Axial length;
LUSC	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	10.44	0.5	2.85e-22	Electrocardiographic conduction measures;
LUSC	cis	rs6484504	0.512	rs2761594	chr11:31318244	A/G	cg06552810	chr11:31128660	NA	0.42	7.24	0.37	3.07e-12	Red blood cell count;
LUSC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg18825076	chr15:78729989	IREB2	-0.53	-8.55	-0.42	4.42e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg11502198	chr6:26597334	ABT1	0.68	10.81	0.51	1.45e-23	Intelligence (multi-trait analysis);
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg14016074	chr11:809449	RPLP2	0.73	6.03	0.31	4.3e-9	Body mass index;
LUSC	cis	rs10779751	1.000	rs742824	chr1:11274022	G/A	cg08854313	chr1:11322531	MTOR	0.92	16.39	0.67	1.02e-44	Body mass index;
LUSC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.0	-0.31	5.12e-9	Testicular germ cell tumor;
LUSC	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.29	-0.33	1.02e-9	Bipolar disorder;
LUSC	cis	rs7674212	0.570	rs12501621	chr4:104095505	T/G	cg16532752	chr4:104119610	CENPE	-0.49	-7.2	-0.37	4.02e-12	Type 2 diabetes;
LUSC	trans	rs9929218	0.954	rs34530130	chr16:68827620	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-10.81	-0.51	1.44e-23	Colorectal cancer;
LUSC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg02951883	chr7:2050386	MAD1L1	-0.4	-7.01	-0.36	1.33e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg12573674	chr2:1569213	NA	-0.63	-8.74	-0.43	1.15e-16	IgG glycosylation;
LUSC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08736216	chr1:53307985	ZYG11A	-0.27	-5.66	-0.3	3.26e-8	Monocyte count;
LUSC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-6.99	-0.36	1.47e-11	Aortic root size;
LUSC	cis	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg21775007	chr8:11205619	TDH	-0.43	-5.92	-0.31	8.18e-9	Monocyte count;
LUSC	cis	rs12594515	1.000	rs12185095	chr15:45994635	G/T	cg19682013	chr15:45996608	NA	0.39	5.79	0.3	1.58e-8	Waist circumference;Weight;
LUSC	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.96	-0.44	2.34e-17	Retinal vascular caliber;
LUSC	cis	rs6484504	0.576	rs208067	chr11:31153578	C/T	cg14844989	chr11:31128820	NA	-0.39	-6.17	-0.32	1.97e-9	Red blood cell count;
LUSC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	6.92	0.35	2.31e-11	Prudent dietary pattern;
LUSC	cis	rs11166629	0.637	rs6578230	chr8:135564113	A/G	cg27224718	chr8:135614730	ZFAT	0.53	7.6	0.38	3.11e-13	Smoking quantity;
LUSC	trans	rs1997103	0.822	rs10273426	chr7:55417857	G/A	cg20935933	chr6:143382018	AIG1	0.48	6.48	0.33	3.36e-10	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg07716408	chr11:68623521	NA	-0.33	-6.18	-0.32	1.85e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6669072	0.967	rs4101233	chr1:91238773	C/T	cg08895590	chr1:91227319	NA	-0.39	-8.75	-0.43	1.09e-16	Cognitive function;
LUSC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18932078	chr1:2524107	MMEL1	-0.31	-6.84	-0.35	3.9e-11	Ulcerative colitis;
LUSC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs243505	0.762	rs933436	chr7:148487329	A/C	cg09806900	chr7:148480153	CUL1	-0.55	-8.27	-0.41	3.23e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs61931739	0.513	rs10844698	chr12:33890158	C/T	cg26384229	chr12:38710491	ALG10B	0.55	8.59	0.43	3.34e-16	Morning vs. evening chronotype;
LUSC	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05901451	chr6:126070800	HEY2	-0.94	-18.53	-0.71	3.23e-53	Brugada syndrome;
LUSC	cis	rs727505	0.721	rs56269941	chr7:124768732	T/A	cg23710748	chr7:124431027	NA	-0.39	-7.01	-0.36	1.29e-11	Lewy body disease;
LUSC	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg05343316	chr1:45956843	TESK2	0.74	9.96	0.48	1.27e-20	Platelet count;
LUSC	cis	rs2559856	1.000	rs2695299	chr12:102082664	G/A	cg12924262	chr12:102091054	CHPT1	0.42	5.82	0.3	1.38e-8	Blood protein levels;
LUSC	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg10978503	chr1:24200527	CNR2	0.5	11.46	0.53	7.02e-26	Immature fraction of reticulocytes;
LUSC	cis	rs239198	0.534	rs1813223	chr6:101331909	C/T	cg09795085	chr6:101329169	ASCC3	0.42	6.01	0.31	4.77e-9	Menarche (age at onset);
LUSC	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg24558204	chr6:135376177	HBS1L	0.68	10.82	0.51	1.32e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05700333	chr5:131892723	RAD50	0.43	7.01	0.36	1.31e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg03146154	chr1:46216737	IPP	-0.52	-7.71	-0.39	1.5e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs2786098	0.656	rs34261593	chr1:197530702	T/C	cg16005942	chr6:160526640	IGF2R	0.51	6.03	0.31	4.34e-9	Asthma;
LUSC	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg17143192	chr8:8559678	CLDN23	0.63	9.03	0.44	1.37e-17	Obesity-related traits;
LUSC	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg10434728	chr15:90938212	IQGAP1	0.43	8.51	0.42	6.14e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg20608306	chr11:116969690	SIK3	-0.36	-6.0	-0.31	5.09e-9	Blood protein levels;
LUSC	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg06363034	chr20:62225388	GMEB2	-0.46	-7.72	-0.39	1.4e-13	Glioblastoma;
LUSC	cis	rs870825	0.616	rs28666955	chr4:185631338	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.12	0.58	5.24e-32	Blood protein levels;
LUSC	cis	rs727505	1.000	rs56387611	chr7:124479180	G/A	cg23710748	chr7:124431027	NA	-0.42	-7.47	-0.38	6.9e-13	Lewy body disease;
LUSC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.11	-0.36	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg09365446	chr1:150670422	GOLPH3L	0.47	6.79	0.35	5.16e-11	Melanoma;
LUSC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.96	0.4	2.64e-14	Prudent dietary pattern;
LUSC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.48	-0.38	6.54e-13	Personality dimensions;
LUSC	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg08601574	chr20:25228251	PYGB	0.47	7.3	0.37	2.14e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6693567	0.526	rs3818978	chr1:150266338	T/A	cg15654264	chr1:150340011	RPRD2	-0.45	-7.23	-0.37	3.39e-12	Migraine;
LUSC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg18827107	chr12:86230957	RASSF9	-0.44	-6.56	-0.34	2.07e-10	Major depressive disorder;
LUSC	cis	rs6834538	0.577	rs10034556	chr4:113449650	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.35	5.71	0.3	2.5e-8	Free thyroxine concentration;
LUSC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg25036284	chr2:26402008	FAM59B	-0.71	-9.93	-0.48	1.55e-20	Gut microbiome composition (summer);
LUSC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.51	-7.14	-0.36	5.9e-12	Cognitive ability;
LUSC	cis	rs6574644	0.959	rs8003051	chr14:81780409	G/A	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg07169764	chr2:136633963	MCM6	1.04	13.89	0.6	6.38e-35	Corneal structure;
LUSC	cis	rs2969070	0.674	rs886630	chr7:2528126	G/T	cg03277898	chr7:2518824	NA	-0.29	-6.17	-0.32	2e-9	Diastolic blood pressure;
LUSC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg15649852	chr7:65879115	NA	0.41	5.78	0.3	1.67e-8	Aortic root size;
LUSC	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg22875332	chr1:76189707	ACADM	-0.39	-5.73	-0.3	2.2e-8	Daytime sleep phenotypes;
LUSC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.52	-6.62	-0.34	1.46e-10	Schizophrenia;
LUSC	cis	rs2692947	0.732	rs56847058	chr2:96406893	C/T	cg23100626	chr2:96804247	ASTL	0.29	6.89	0.35	2.78e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.54	0.5	1.25e-22	Morning vs. evening chronotype;
LUSC	cis	rs2637266	0.729	rs860166	chr10:78549111	C/T	cg18941641	chr10:78392320	NA	0.37	6.66	0.34	1.12e-10	Pulmonary function;
LUSC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg25039879	chr17:56429692	SUPT4H1	0.69	9.17	0.45	4.94e-18	Cognitive test performance;
LUSC	cis	rs9807841	0.592	rs3810155	chr19:10764867	C/G	cg09936142	chr19:10668400	KRI1	-0.41	-6.68	-0.34	9.95e-11	Inflammatory skin disease;
LUSC	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg18357645	chr12:58087776	OS9	0.42	6.31	0.33	9.11e-10	Multiple sclerosis;
LUSC	cis	rs35123781	1.000	rs34510678	chr5:139064835	C/T	cg10513866	chr5:139070639	NA	0.44	8.58	0.42	3.62e-16	Schizophrenia;
LUSC	cis	rs4253772	0.575	rs9615364	chr22:46797503	G/A	cg24881330	chr22:46731750	TRMU	0.72	5.72	0.3	2.43e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg12463550	chr7:65579703	CRCP	0.56	8.35	0.42	1.79e-15	Aortic root size;
LUSC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.95	0.36	1.9e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg22823121	chr1:150693482	HORMAD1	-0.57	-8.83	-0.44	6.01e-17	Tonsillectomy;
LUSC	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg03929089	chr4:120376271	NA	-0.75	-9.19	-0.45	4.36e-18	Coronary artery disease;
LUSC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.06	-0.31	3.72e-9	Total body bone mineral density;
LUSC	cis	rs11051970	0.918	rs11051969	chr12:32537123	T/C	cg24626660	chr12:32551988	NA	0.38	6.18	0.32	1.84e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg07424592	chr7:64974309	NA	0.67	5.88	0.31	9.86e-9	Diabetic kidney disease;
LUSC	cis	rs12530845	1.000	rs6979439	chr7:135329004	A/G	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs10761482	0.500	rs7906760	chr10:62286653	A/T	cg18175470	chr10:62150864	ANK3	-0.48	-7.19	-0.37	4.25e-12	Schizophrenia;
LUSC	trans	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg07393940	chr7:158741817	NA	-0.55	-8.51	-0.42	5.79e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.14	-0.32	2.32e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg03579872	chr1:53393473	SCP2	-0.39	-5.74	-0.3	2.09e-8	Monocyte count;
LUSC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.37	6.88	0.35	3e-11	Colorectal cancer;
LUSC	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg04374321	chr14:90722782	PSMC1	0.75	11.93	0.55	1.46e-27	Mortality in heart failure;
LUSC	cis	rs11608355	0.545	rs2302707	chr12:109893797	G/A	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.1e-26	Neuroticism;
LUSC	cis	rs9837602	1.000	rs9841186	chr3:99795651	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-6.36	-0.33	6.53e-10	Breast cancer;
LUSC	cis	rs12701220	0.597	rs10253153	chr7:1001974	G/A	cg26769984	chr7:1090371	C7orf50	0.44	6.27	0.32	1.13e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	10.34	0.49	6.33e-22	Lymphocyte counts;
LUSC	cis	rs1971762	0.521	rs5009146	chr12:54089297	A/C	cg23533419	chr12:54090519	NA	-0.37	-6.06	-0.31	3.76e-9	Height;
LUSC	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs360798	0.512	rs2539978	chr2:63195179	T/C	cg17519650	chr2:63277830	OTX1	0.51	7.04	0.36	1.08e-11	Coronary artery disease;
LUSC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg04036182	chr15:45458818	NA	-0.37	-6.01	-0.31	4.88e-9	Glomerular filtration rate;
LUSC	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg00677455	chr12:58241039	CTDSP2	0.7	10.55	0.5	1.21e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs9309473	0.948	rs7603647	chr2:73817238	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.56	-0.34	2.1e-10	Metabolite levels;
LUSC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	8.39	0.42	1.37e-15	Neuroticism;
LUSC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.23	-13.96	-0.61	3.2e-35	Diabetic kidney disease;
LUSC	cis	rs1160297	0.609	rs10164868	chr2:53095923	G/T	cg07782112	chr2:53107842	NA	0.43	6.99	0.36	1.51e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg01802117	chr1:53393560	SCP2	-0.35	-5.73	-0.3	2.22e-8	Monocyte count;
LUSC	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.56	0.6	1.12e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs1493916	0.748	rs1845386	chr18:31318256	C/G	cg27147174	chr7:100797783	AP1S1	-0.54	-8.44	-0.42	9.85e-16	Life satisfaction;
LUSC	cis	rs2294693	0.898	rs6458195	chr6:40972498	A/T	cg14769373	chr6:40998127	UNC5CL	0.42	6.25	0.32	1.26e-9	Gastric cancer;Non-cardia gastric cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01578996	chr19:57752011	ZNF805	-0.4	-5.99	-0.31	5.46e-9	Electrocardiographic conduction measures;
LUSC	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg25457927	chr22:38595422	NA	-0.41	-8.73	-0.43	1.24e-16	Cutaneous nevi;
LUSC	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg06360820	chr2:242988706	NA	-1.1	-11.29	-0.53	2.89e-25	Obesity-related traits;
LUSC	cis	rs7180079	1.000	rs3784381	chr15:64449839	G/T	cg08069370	chr15:64387884	SNX1	-0.55	-5.94	-0.31	7.33e-9	Monocyte count;
LUSC	trans	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.69	-0.43	1.69e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg03060546	chr3:49711283	APEH	0.71	11.85	0.54	2.69e-27	Resting heart rate;
LUSC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.61	-0.43	2.86e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg05738196	chr6:26577821	NA	0.47	6.8	0.35	4.7e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.02	0.31	4.49e-9	Menopause (age at onset);
LUSC	cis	rs752010	0.695	rs11210509	chr1:42109311	A/G	cg06885757	chr1:42089581	HIVEP3	0.44	8.31	0.41	2.37e-15	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-9.9	-0.48	2.04e-20	Mood instability;
LUSC	cis	rs7586879	0.964	rs13412941	chr2:25102709	C/T	cg01884057	chr2:25150051	NA	0.41	8.53	0.42	5.31e-16	Body mass index;
LUSC	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg19682013	chr15:45996608	NA	0.4	6.05	0.31	3.83e-9	Waist circumference;Weight;
LUSC	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg25828445	chr12:7781288	NA	0.61	6.46	0.33	3.65e-10	HDL cholesterol levels;
LUSC	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg10857441	chr5:6722123	POLS	-0.44	-8.67	-0.43	1.88e-16	Menopause (age at onset);
LUSC	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg05868516	chr6:26286170	HIST1H4H	0.37	6.09	0.32	3.03e-9	Educational attainment;
LUSC	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg09537434	chr19:41945824	ATP5SL	-0.59	-7.82	-0.39	7.13e-14	Colorectal cancer;
LUSC	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg26876637	chr1:152193138	HRNR	0.45	6.19	0.32	1.81e-9	Atopic dermatitis;
LUSC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg13560548	chr3:10150139	C3orf24	0.54	7.85	0.39	5.9e-14	Alzheimer's disease;
LUSC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg02951883	chr7:2050386	MAD1L1	-0.35	-5.95	-0.31	6.83e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs5760842	0.538	rs1076047	chr22:25495049	T/C	cg16733866	chr21:42792609	MX1	0.51	7.08	0.36	8.65e-12	Recurrent major depressive disorder;
LUSC	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg27471124	chr11:109292789	C11orf87	0.43	7.76	0.39	1.02e-13	Schizophrenia;
LUSC	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26384229	chr12:38710491	ALG10B	0.89	15.4	0.64	7.91e-41	Morning vs. evening chronotype;
LUSC	trans	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg09781936	chr22:19749961	TBX1	-0.33	-5.95	-0.31	6.85e-9	Inflammatory bowel disease;
LUSC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.73	0.39	1.26e-13	Electroencephalogram traits;
LUSC	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg24375607	chr4:120327624	NA	0.75	11.72	0.54	8.65e-27	Corneal astigmatism;
LUSC	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg12091567	chr17:66097778	LOC651250	0.9	13.86	0.6	7.75e-35	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.41	0.5	3.56e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7681440	0.647	rs1372508	chr4:90819786	C/G	cg15133208	chr4:90757351	SNCA	0.35	5.96	0.31	6.5e-9	Dementia with Lewy bodies;
LUSC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg17376030	chr22:41985996	PMM1	0.48	6.02	0.31	4.55e-9	Vitiligo;
LUSC	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg17691542	chr6:26056736	HIST1H1C	0.51	7.35	0.37	1.51e-12	Iron status biomarkers;
LUSC	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg05084668	chr3:125655381	ALG1L	-0.79	-11.93	-0.55	1.38e-27	Blood pressure (smoking interaction);
LUSC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.21	30.68	0.86	3.34e-99	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg17366294	chr4:99064904	C4orf37	0.58	9.63	0.47	1.59e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg05623727	chr3:50126028	RBM5	0.31	5.73	0.3	2.2e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07362569	chr17:61921086	SMARCD2	0.37	7.27	0.37	2.5e-12	Prudent dietary pattern;
LUSC	cis	rs934734	0.935	rs6711791	chr2:65579228	G/T	cg08085232	chr2:65598271	SPRED2	-0.37	-5.85	-0.3	1.16e-8	Rheumatoid arthritis;
LUSC	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg24687543	chr11:63912206	MACROD1	0.47	5.82	0.3	1.4e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs1045714	0.895	rs4721867	chr7:2643352	A/G	cg24848437	chr7:2645542	IQCE	-0.62	-7.08	-0.36	8.51e-12	Urate levels in lean individuals;
LUSC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24110177	chr3:50126178	RBM5	0.64	11.28	0.53	3.1e-25	Body mass index;
LUSC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-8.52	-0.42	5.74e-16	Bipolar disorder;
LUSC	cis	rs4423214	0.840	rs1792233	chr11:71182179	G/A	cg05163923	chr11:71159392	DHCR7	-0.77	-10.02	-0.48	7.56e-21	Vitamin D levels;
LUSC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.06e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs72634258	0.786	rs7537362	chr1:8177564	C/T	cg26816564	chr1:7831052	VAMP3	0.44	5.67	0.3	3.14e-8	Inflammatory bowel disease;
LUSC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg27170947	chr2:26402098	FAM59B	0.71	10.83	0.51	1.29e-23	Gut microbiome composition (summer);
LUSC	cis	rs9463078	0.605	rs7763421	chr6:44877313	A/G	cg25276700	chr6:44698697	NA	0.29	6.0	0.31	5.14e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.38	-5.8	-0.3	1.57e-8	Tonsillectomy;
LUSC	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg01528321	chr10:82214614	TSPAN14	0.91	14.37	0.62	8.53e-37	Post bronchodilator FEV1;
LUSC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg21132104	chr15:45694354	SPATA5L1	0.58	8.2	0.41	5.24e-15	Homoarginine levels;
LUSC	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg25233709	chr10:116636983	FAM160B1	0.38	6.77	0.35	5.76e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6736093	0.931	rs7578435	chr2:112714751	G/A	cg12686935	chr2:112915763	FBLN7	-0.36	-5.81	-0.3	1.45e-8	Coronary artery disease;
LUSC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg09034736	chr1:150693464	HORMAD1	0.49	7.0	0.36	1.39e-11	Tonsillectomy;
LUSC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4076764	0.522	rs10799914	chr1:163353205	A/G	cg06092702	chr1:163392909	NA	-0.35	-5.82	-0.3	1.35e-8	Motion sickness;
LUSC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg09359103	chr1:154839909	KCNN3	-0.7	-15.74	-0.65	3.87e-42	Prostate cancer;
LUSC	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg20503657	chr10:835505	NA	0.78	9.42	0.46	7.61e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs56283067	0.773	rs56115627	chr6:44683049	G/A	cg20913747	chr6:44695427	NA	-0.46	-7.68	-0.39	1.78e-13	Total body bone mineral density;
LUSC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg18479299	chr3:125709523	NA	-0.51	-5.74	-0.3	2.08e-8	Blood pressure (smoking interaction);
LUSC	cis	rs4737010	0.570	rs10112594	chr8:41645565	C/T	cg17182837	chr8:41585554	ANK1	-0.35	-6.29	-0.33	1.01e-9	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs983392	0.679	rs1026253	chr11:60030556	G/A	cg24026212	chr11:59952134	MS4A6A	0.36	6.15	0.32	2.27e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7809950	1.000	rs6976607	chr7:107223401	A/C	cg23024343	chr7:107201750	COG5	0.58	8.91	0.44	3.34e-17	Coronary artery disease;
LUSC	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg08807101	chr21:30365312	RNF160	-0.53	-6.68	-0.34	9.85e-11	Cognitive test performance;
LUSC	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.19	0.32	1.8e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.92	18.09	0.7	1.75e-51	Menarche (age at onset);
LUSC	cis	rs7246967	0.611	rs35355374	chr19:22837701	C/T	cg23217946	chr19:22817039	ZNF492	0.46	5.84	0.3	1.26e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-7.36	-0.37	1.4e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs11031096	0.711	rs10767881	chr11:4205122	C/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.89	-0.31	9.46e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.89	15.68	0.65	6.4e-42	Noise-induced hearing loss;
LUSC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg00933542	chr6:150070202	PCMT1	0.33	6.83	0.35	4.14e-11	Lung cancer;
LUSC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg22963979	chr7:1858916	MAD1L1	-0.47	-6.97	-0.36	1.71e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9929218	0.911	rs1075959	chr16:68832750	A/G	cg02972257	chr16:68554789	NA	0.41	5.67	0.3	3.06e-8	Colorectal cancer;
LUSC	cis	rs11608355	1.000	rs10774695	chr12:109868040	G/A	cg05360138	chr12:110035743	NA	0.47	6.36	0.33	6.68e-10	Neuroticism;
LUSC	trans	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-5.98	-0.31	5.88e-9	Mood instability;
LUSC	trans	rs800082	0.668	rs9856190	chr3:144288547	G/C	cg24215973	chr2:240111563	HDAC4	-0.61	-9.75	-0.47	6.19e-20	Smoking behavior;
LUSC	cis	rs7572644	0.782	rs10185472	chr2:28151354	G/A	cg27432699	chr2:27873401	GPN1	-0.53	-7.0	-0.36	1.41e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.36	-0.33	6.77e-10	Response to antipsychotic treatment;
LUSC	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg05925327	chr15:68127851	NA	-0.48	-7.2	-0.37	4.12e-12	Restless legs syndrome;
LUSC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg21280719	chr6:42927975	GNMT	-0.26	-5.71	-0.3	2.44e-8	Blood protein levels;
LUSC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg27170947	chr2:26402098	FAM59B	-0.62	-9.06	-0.44	1.13e-17	Gut microbiome composition (summer);
LUSC	cis	rs4964805	0.505	rs4981032	chr12:104165864	C/T	cg02344784	chr12:104178138	NT5DC3	0.38	6.05	0.31	3.94e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg02951883	chr7:2050386	MAD1L1	0.53	9.84	0.47	3.24e-20	Bipolar disorder and schizophrenia;
LUSC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.99	0.44	1.9e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg25036284	chr2:26402008	FAM59B	0.77	10.9	0.51	7.17e-24	Gut microbiome composition (summer);
LUSC	cis	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg09904177	chr6:26538194	HMGN4	-0.77	-5.92	-0.31	8.13e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-10.3	-0.49	8.75e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	1.06	23.26	0.79	7.47e-72	Schizophrenia;
LUSC	trans	rs11935423	0.778	rs28849180	chr4:100489995	C/T	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.07	-0.32	3.51e-9	Gut microbiome composition (summer);
LUSC	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg23950597	chr19:37808831	NA	-0.61	-6.99	-0.36	1.53e-11	Coronary artery calcification;
LUSC	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg05673287	chr15:77411982	SGK269	-0.45	-7.24	-0.37	3.19e-12	Type 2 diabetes;
LUSC	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg04283868	chr2:201171347	SPATS2L	0.4	5.99	0.31	5.32e-9	QT interval;
LUSC	cis	rs2219968	1.000	rs11783293	chr8:78958925	G/T	cg00738934	chr8:78996279	NA	0.34	6.19	0.32	1.81e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.43	6.35	0.33	6.96e-10	Longevity;Endometriosis;
LUSC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.07	-0.58	7.86e-32	Platelet count;
LUSC	trans	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg06521331	chr12:34319734	NA	-0.4	-6.0	-0.31	5.24e-9	Bladder cancer;
LUSC	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17957827	chr17:79895524	PYCR1	-0.5	-6.01	-0.31	4.85e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg02782426	chr3:40428986	ENTPD3	0.34	6.26	0.32	1.2e-9	Renal cell carcinoma;
LUSC	trans	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg11887960	chr12:57824829	NA	0.54	6.74	0.35	7.11e-11	Obesity-related traits;
LUSC	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg05187965	chr10:45406764	TMEM72	-0.36	-8.38	-0.42	1.49e-15	Mean corpuscular volume;
LUSC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.91	-14.23	-0.61	2.89e-36	Coronary artery disease;
LUSC	trans	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg25214090	chr10:38739885	LOC399744	0.42	6.47	0.33	3.43e-10	Corneal astigmatism;
LUSC	cis	rs7552167	0.925	rs4489498	chr1:24512055	A/G	cg01960748	chr1:24522592	NA	0.68	10.62	0.5	6.67e-23	Psoriasis vulgaris;
LUSC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.71	-11.97	-0.55	1.03e-27	Colorectal cancer;
LUSC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13126279	chr21:47581558	C21orf56	-0.48	-7.01	-0.36	1.32e-11	Testicular germ cell tumor;
LUSC	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg11608241	chr8:8085544	FLJ10661	-0.46	-6.48	-0.33	3.34e-10	Neuroticism;
LUSC	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	cg01733217	chr16:74700730	RFWD3	0.8	13.22	0.59	2.22e-32	Testicular germ cell tumor;
LUSC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg07395648	chr5:131743802	NA	0.37	5.8	0.3	1.52e-8	Asthma (sex interaction);
LUSC	trans	rs194045	0.609	rs252344	chr16:29184882	G/A	cg17334114	chr3:133646504	NA	0.54	6.76	0.35	6.05e-11	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs783147	0.500	rs9458016	chr6:161144800	A/G	cg15416064	chr12:49209402	NA	-0.43	-6.0	-0.31	5.11e-9	Lp (a) levels;
LUSC	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.87	14.92	0.63	6.18e-39	Bladder cancer;
LUSC	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.56	-0.38	3.95e-13	Joint mobility (Beighton score);
LUSC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg18512352	chr11:47633146	NA	-0.48	-10.02	-0.48	8.02e-21	Subjective well-being;
LUSC	cis	rs2273669	0.588	rs12205061	chr6:109338161	T/C	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	8.89e-9	Prostate cancer;
LUSC	cis	rs2324229	0.828	rs1180227	chr6:83951137	A/G	cg08257003	chr6:84140564	ME1	-0.29	-6.89	-0.35	2.78e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	16.89	0.68	1.07e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg13390004	chr1:15929781	NA	0.43	7.31	0.37	1.94e-12	Systolic blood pressure;
LUSC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg00933542	chr6:150070202	PCMT1	0.33	7.09	0.36	8.11e-12	Lung cancer;
LUSC	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.41	6.5	0.33	3e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	trans	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg11398623	chr21:37499189	NA	0.28	6.28	0.32	1.07e-9	Breast cancer;
LUSC	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg16512390	chr1:228756714	NA	0.7	8.82	0.43	6.67e-17	Chronic lymphocytic leukemia;
LUSC	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg14696996	chr19:15285081	NOTCH3	1.02	9.37	0.46	1.1e-18	Pulse pressure;
LUSC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	13.94	0.61	4.12e-35	Alzheimer's disease;
LUSC	cis	rs7605827	0.930	rs1549017	chr2:15617017	T/C	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.24	0.32	1.34e-9	Personality dimensions;
LUSC	cis	rs6681460	0.966	rs10889644	chr1:67145322	C/A	cg02459107	chr1:67143332	SGIP1	0.46	8.63	0.43	2.55e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg09904177	chr6:26538194	HMGN4	-0.66	-11.95	-0.55	1.2100000000000001e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs7119	0.637	rs2667775	chr15:77864802	T/G	cg27398640	chr15:77910606	LINGO1	0.35	7.87	0.4	5e-14	Type 2 diabetes;
LUSC	cis	rs727505	0.954	rs66871687	chr7:124670475	A/G	cg23710748	chr7:124431027	NA	-0.4	-7.06	-0.36	9.86e-12	Lewy body disease;
LUSC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.8	-17.21	-0.69	5.82e-48	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.83	-0.35	4.12e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12541635	0.966	rs6469031	chr8:107048095	T/C	cg10147462	chr8:107024639	NA	0.55	9.92	0.48	1.69e-20	Age of smoking initiation;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg00024416	chr22:24240387	NA	-0.33	-5.77	-0.3	1.84e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs16895831	0.519	rs12196290	chr6:42552548	G/A	cg10605015	chr6:42532144	UBR2	-0.49	-5.93	-0.31	7.49e-9	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs965469	1.000	rs6051762	chr20:3321590	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-5.69	-0.3	2.84e-8	IFN-related cytopenia;
LUSC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11764359	chr7:65958608	NA	-0.58	-8.99	-0.44	1.87e-17	Aortic root size;
LUSC	cis	rs72960926	0.744	rs11759133	chr6:74932518	A/G	cg03266952	chr6:74778945	NA	-0.77	-6.79	-0.35	5.08e-11	Metabolite levels (MHPG);
LUSC	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg24558204	chr6:135376177	HBS1L	0.68	10.47	0.5	2.25e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs17401966	0.522	rs17396973	chr1:10334924	C/T	cg19773385	chr1:10388646	KIF1B	-0.36	-6.3	-0.33	9.58e-10	Hepatocellular carcinoma;
LUSC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg02951883	chr7:2050386	MAD1L1	-0.5	-8.68	-0.43	1.74e-16	Schizophrenia;
LUSC	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.36	-0.46	1.24e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.29	5.79	0.3	1.64e-8	Cognitive function;
LUSC	cis	rs9815354	0.767	rs73081341	chr3:41900335	A/T	cg03022575	chr3:42003672	ULK4	0.64	6.93	0.35	2.12e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11209002	1.000	rs10749771	chr1:67573730	A/G	cg02640540	chr1:67518911	SLC35D1	0.69	7.6	0.38	3e-13	Crohn's disease;
LUSC	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg10840412	chr1:235813424	GNG4	0.45	6.01	0.31	4.74e-9	Bipolar disorder;
LUSC	cis	rs17621444	0.522	rs10749342	chr10:121816910	C/T	cg02041677	chr10:121771263	NA	0.34	6.42	0.33	4.61e-10	IgG glycosylation;
LUSC	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg21252483	chr19:49399788	TULP2	-0.48	-6.77	-0.35	5.81e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.71	-0.3	2.44e-8	Recombination rate (females);
LUSC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg07741184	chr6:167504864	NA	-0.35	-6.37	-0.33	6.35e-10	Crohn's disease;
LUSC	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg10253484	chr15:75165896	SCAMP2	-0.48	-7.0	-0.36	1.38e-11	Breast cancer;
LUSC	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg07549590	chr16:15018862	NA	-0.59	-9.89	-0.48	2.15e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg00277334	chr10:82204260	NA	-0.52	-7.33	-0.37	1.74e-12	Post bronchodilator FEV1;
LUSC	cis	rs4478137	0.501	rs28437702	chr4:164231410	C/T	cg06758707	chr4:164254230	NPY1R	-0.5	-6.79	-0.35	5.05e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs2652822	0.584	rs1017546	chr15:63566702	G/T	cg02713581	chr15:63449717	RPS27L	-0.38	-5.99	-0.31	5.41e-9	Metabolic traits;
LUSC	cis	rs1775715	0.870	rs1251400	chr10:32235145	A/G	cg26784012	chr10:32216390	ARHGAP12	0.41	6.81	0.35	4.47e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg17264618	chr3:40429014	ENTPD3	0.36	7.48	0.38	6.5e-13	Renal cell carcinoma;
LUSC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg25428297	chr7:1022841	CYP2W1	0.29	6.24	0.32	1.34e-9	Longevity;Endometriosis;
LUSC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.97	-0.68	4.92e-47	Monocyte count;
LUSC	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-0.54	-8.17	-0.41	6.28e-15	Breast cancer;
LUSC	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	6.01	0.31	4.76e-9	Rheumatoid arthritis;
LUSC	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg07701084	chr6:150067640	NUP43	-0.45	-6.9	-0.35	2.59e-11	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg11062466	chr8:58055876	NA	0.65	8.39	0.42	1.41e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg02899939	chr1:46016331	AKR1A1	0.46	6.16	0.32	2.05e-9	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09996156	chr7:86688487	KIAA1324L	-0.4	-5.95	-0.31	6.65e-9	Gut microbiome composition (summer);
LUSC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-0.83	-13.84	-0.6	9.33e-35	Tonsillectomy;
LUSC	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.69	0.34	9.14e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs965469	1.000	rs3310	chr20:3237232	C/T	cg25506879	chr20:3388711	C20orf194	-0.56	-6.46	-0.33	3.81e-10	IFN-related cytopenia;
LUSC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03517284	chr6:25882590	NA	0.39	6.54	0.34	2.33e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7903847	0.656	rs12218483	chr10:99141484	C/T	cg20016023	chr10:99160130	RRP12	-0.28	-6.15	-0.32	2.17e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6723226	0.750	rs1033751	chr2:32695759	T/C	cg02381751	chr2:32503542	YIPF4	0.54	8.29	0.41	2.78e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9463078	0.790	rs1324531	chr6:45136224	T/C	cg25276700	chr6:44698697	NA	-0.28	-5.68	-0.3	3e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg02079420	chr8:82753780	SNX16	0.38	5.77	0.3	1.8e-8	Diastolic blood pressure;
LUSC	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg20701182	chr2:24300061	SF3B14	0.58	6.2	0.32	1.71e-9	Lymphocyte counts;
LUSC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.73	0.35	7.5e-11	Aortic root size;
LUSC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.95	-13.5	-0.59	1.97e-33	Initial pursuit acceleration;
LUSC	cis	rs3770081	1.000	rs3810827	chr2:86334386	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.92	-0.35	2.37e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.6	0.57	4.6e-30	Menopause (age at onset);
LUSC	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg21643547	chr1:205240462	TMCC2	-0.41	-7.62	-0.38	2.7e-13	Red blood cell count;
LUSC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00166722	chr3:10149974	C3orf24	-0.57	-8.23	-0.41	4.28e-15	Alzheimer's disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02567981	chr12:50101354	FMNL3	-0.41	-6.36	-0.33	6.6e-10	Electrocardiographic conduction measures;
LUSC	cis	rs6681460	0.898	rs2483704	chr1:67195353	C/T	cg02459107	chr1:67143332	SGIP1	-0.45	-8.14	-0.41	7.93e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg00745463	chr17:30367425	LRRC37B	-0.62	-7.68	-0.39	1.76e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs9837602	1.000	rs1021103	chr3:99603230	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.47	0.33	3.39e-10	Breast cancer;
LUSC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.78	-12.99	-0.58	1.6e-31	Aortic root size;
LUSC	cis	rs727505	0.721	rs56069273	chr7:124768604	G/A	cg23710748	chr7:124431027	NA	-0.39	-6.96	-0.36	1.86e-11	Lewy body disease;
LUSC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	1.04	18.46	0.71	6.1e-53	Testicular germ cell tumor;
LUSC	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.66	-0.39	1.97e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg18350739	chr11:68623251	NA	0.4	7.15	0.36	5.43e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.57	-0.38	3.62e-13	Mood instability;
LUSC	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21659725	chr3:3221576	CRBN	0.63	10.51	0.5	1.62e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs1009647	1.000	rs1009647	chr14:55880047	G/A	cg04306507	chr14:55594613	LGALS3	0.44	7.31	0.37	2.04e-12	Testicular germ cell tumor;
LUSC	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg08079166	chr15:68083412	MAP2K5	0.49	8.04	0.4	1.59e-14	Restless legs syndrome;
LUSC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.82	-0.3	1.42e-8	Depression;
LUSC	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg27398640	chr15:77910606	LINGO1	0.29	5.88	0.31	1.01e-8	Type 2 diabetes;
LUSC	cis	rs17253792	0.732	rs79014965	chr14:56117551	T/G	cg01858014	chr14:56050164	KTN1	-0.8	-6.61	-0.34	1.56e-10	Putamen volume;
LUSC	cis	rs354225	0.584	rs6739140	chr2:54823502	C/G	cg01766943	chr2:54829624	SPTBN1	0.48	7.78	0.39	9.33e-14	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03933290	chr17:3717712	C17orf85	0.4	6.2	0.32	1.63e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.7	10.65	0.5	5.42e-23	Corneal astigmatism;
LUSC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6942756	1.000	rs66970518	chr7:128871006	G/A	cg02491457	chr7:128862824	NA	-0.56	-7.98	-0.4	2.31e-14	White matter hyperintensity burden;
LUSC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg22618164	chr12:122356400	WDR66	-0.57	-8.52	-0.42	5.6e-16	Mean corpuscular volume;
LUSC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06634786	chr22:41940651	POLR3H	0.53	6.19	0.32	1.79e-9	Cannabis dependence symptom count;
LUSC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11645453	chr3:52864694	ITIH4	0.3	7.28	0.37	2.37e-12	Bipolar disorder;
LUSC	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg13010344	chr12:123464640	ARL6IP4	-0.44	-6.04	-0.31	4.09e-9	Neutrophil percentage of white cells;
LUSC	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.26	11.09	0.52	1.56e-24	Alzheimer's disease (late onset);
LUSC	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.44	-6.75	-0.35	6.75e-11	Cognitive test performance;
LUSC	trans	rs10432489	0.708	rs4541220	chr2:181746466	A/G	cg04744134	chr19:8408128	KANK3	-0.87	-6.65	-0.34	1.19e-10	QT interval;
LUSC	trans	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg07923666	chr12:49932857	KCNH3	-0.5	-6.34	-0.33	7.66e-10	Resting heart rate;
LUSC	cis	rs9359856	0.564	rs56396054	chr6:90360406	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.86	-8.63	-0.43	2.5e-16	Bipolar disorder;
LUSC	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg14346243	chr4:90757452	SNCA	-0.42	-6.11	-0.32	2.78e-9	Neuroticism;
LUSC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg16928487	chr17:17741425	SREBF1	0.44	8.71	0.43	1.42e-16	Total body bone mineral density;
LUSC	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12908607	chr1:44402522	ARTN	-0.45	-7.22	-0.37	3.49e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs79911532	0.551	rs11553096	chr7:75677216	C/T	cg03592824	chr7:75666768	STYXL1	0.7	6.83	0.35	4e-11	Mononucleosis;
LUSC	cis	rs8018808	0.935	rs7146784	chr14:77932111	A/G	cg20045696	chr14:77926864	AHSA1	0.34	5.76	0.3	1.95e-8	Myeloid white cell count;
LUSC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06112835	chr11:68658793	MRPL21	0.53	8.32	0.41	2.29e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08045932	chr20:61659980	NA	-0.53	-9.2	-0.45	3.88e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg11244672	chr19:19639970	YJEFN3	-0.55	-6.91	-0.35	2.49e-11	Bipolar disorder;
LUSC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg13175981	chr1:150552382	MCL1	0.43	6.06	0.31	3.71e-9	Tonsillectomy;
LUSC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg11062466	chr8:58055876	NA	0.47	6.08	0.32	3.19e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg23630131	chr7:65973040	NA	-0.21	-6.0	-0.31	5.16e-9	Aortic root size;
LUSC	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg18002602	chr11:66138449	SLC29A2	0.46	8.28	0.41	3.04e-15	Educational attainment (years of education);
LUSC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg10253484	chr15:75165896	SCAMP2	-0.49	-7.37	-0.37	1.39e-12	Breast cancer;
LUSC	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.48	-0.46	5.04e-19	Schizophrenia;
LUSC	cis	rs4363385	0.510	rs11590835	chr1:153047166	T/C	cg25856811	chr1:152973957	SPRR3	-0.39	-6.45	-0.33	3.93e-10	Inflammatory skin disease;
LUSC	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg24634471	chr8:143751801	JRK	0.59	8.99	0.44	1.82e-17	Schizophrenia;
LUSC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.24	14.24	0.61	2.72e-36	Diabetic kidney disease;
LUSC	trans	rs4811340	0.600	rs1474793	chr20:51177744	T/C	cg15736553	chr3:11610338	VGLL4	-0.33	-5.96	-0.31	6.57e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	17.58	0.69	2.01e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.86	-0.35	3.27e-11	Lung cancer;
LUSC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.54	-7.96	-0.4	2.79e-14	Total body bone mineral density;
LUSC	cis	rs30380	0.632	rs27434	chr5:96129512	A/G	cg16492584	chr5:96139282	ERAP1	-0.53	-7.28	-0.37	2.44e-12	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs17039065	1.000	rs72889375	chr4:109387798	C/T	cg07444054	chr2:108107501	NA	0.44	6.43	0.33	4.35e-10	Gut microbiome composition (summer);
LUSC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg11050988	chr7:1952600	MAD1L1	-0.32	-6.1	-0.32	2.87e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg01028140	chr2:1542097	TPO	-0.46	-6.53	-0.34	2.47e-10	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs7572644	0.766	rs4665398	chr2:28094770	A/T	cg27432699	chr2:27873401	GPN1	0.52	6.47	0.33	3.5e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs926938	0.501	rs360686	chr1:115502524	C/T	cg12756093	chr1:115239321	AMPD1	0.43	6.28	0.32	1.08e-9	Autism;
LUSC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.4	-6.41	-0.33	4.92e-10	Systemic lupus erythematosus;
LUSC	cis	rs3126085	1.000	rs1858482	chr1:152306921	A/G	cg26876637	chr1:152193138	HRNR	0.43	5.72	0.3	2.39e-8	Atopic dermatitis;
LUSC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.85	-0.35	3.66e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg26924012	chr15:45694286	SPATA5L1	1.1	17.52	0.69	3.41e-49	Homoarginine levels;
LUSC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg23630131	chr7:65973040	NA	-0.21	-5.71	-0.3	2.52e-8	Aortic root size;
LUSC	trans	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.87	-0.35	3.12e-11	Neuroticism;
LUSC	cis	rs10875595	0.775	rs66998469	chr5:140659960	T/C	cg24830062	chr5:140700576	TAF7	-0.52	-6.39	-0.33	5.57e-10	Pulmonary function decline;
LUSC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.4	0.56	2.59e-29	Prudent dietary pattern;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06876892	chr16:833231	MSLNL	-0.26	-6.67	-0.34	1.09e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg26408565	chr15:76604113	ETFA	-0.5	-8.01	-0.4	1.88e-14	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.52	0.38	4.98e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	0.94	17.55	0.69	2.43e-49	Headache;
LUSC	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg08601574	chr20:25228251	PYGB	0.39	5.96	0.31	6.48e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs961253	0.501	rs6054145	chr20:6335730	T/C	cg17788362	chr6:86352627	SYNCRIP	0.44	6.16	0.32	2.05e-9	Colorectal cancer;
LUSC	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg21433313	chr16:3507492	NAT15	-0.39	-6.22	-0.32	1.48e-9	Body mass index (adult);
LUSC	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.11	-29.1	-0.85	1.35e-93	Myeloid white cell count;
LUSC	trans	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg03886242	chr7:26192032	NFE2L3	0.37	6.26	0.32	1.2e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg23029597	chr12:123009494	RSRC2	-0.72	-9.33	-0.45	1.51e-18	Body mass index;
LUSC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg03060546	chr3:49711283	APEH	0.7	11.75	0.54	6.43e-27	Resting heart rate;
LUSC	cis	rs834811	0.863	rs834821	chr7:135895713	A/T	cg01726295	chr7:135938950	NA	0.35	6.19	0.32	1.77e-9	Post-traumatic stress disorder;
LUSC	cis	rs713477	1.000	rs8014621	chr14:55906849	A/C	cg13175173	chr14:55914753	NA	-0.33	-6.84	-0.35	3.73e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs13385	0.769	rs28573694	chr5:139609951	T/G	cg26211634	chr5:139558579	C5orf32	0.46	6.96	0.36	1.78e-11	Atrial fibrillation;
LUSC	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	0.84	11.22	0.52	5.28e-25	Menopause (age at onset);
LUSC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg27398817	chr8:82754497	SNX16	-0.46	-6.17	-0.32	1.96e-9	Diastolic blood pressure;
LUSC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg16647868	chr5:131706066	SLC22A5	0.38	6.03	0.31	4.42e-9	Breast cancer;
LUSC	cis	rs4663866	1.000	rs34897410	chr2:239182123	T/C	cg16914508	chr2:239161102	PER2	0.68	7.21	0.37	3.7e-12	Irritable bowel syndrome;
LUSC	cis	rs10465746	0.967	rs12407641	chr1:84368115	T/C	cg10977910	chr1:84465055	TTLL7	0.43	6.16	0.32	2.07e-9	Obesity-related traits;
LUSC	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-11.0	-0.52	3.09e-24	Response to antipsychotic treatment;
LUSC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg04267008	chr7:1944627	MAD1L1	-0.46	-6.87	-0.35	3.08e-11	Schizophrenia;
LUSC	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg05973401	chr12:123451056	ABCB9	0.52	6.48	0.33	3.34e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg07395648	chr5:131743802	NA	-0.35	-5.77	-0.3	1.8e-8	Blood metabolite levels;
LUSC	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.79	0.43	7.99e-17	Lung cancer in ever smokers;
LUSC	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs68092024	0.731	rs792840	chr3:99471251	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	6.08	0.32	3.33e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs4423214	1.000	rs12419279	chr11:71139061	T/A	cg05163923	chr11:71159392	DHCR7	0.66	9.73	0.47	7.55e-20	Vitamin D levels;
LUSC	cis	rs78579285	0.544	rs11549835	chr16:88781073	G/A	cg01900006	chr16:88814613	FAM38A	0.54	5.86	0.31	1.11e-8	Joint mobility (Beighton score);
LUSC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg03713592	chr11:72463424	ARAP1	0.59	7.75	0.39	1.09e-13	Body mass index;
LUSC	cis	rs6840360	0.806	rs13149588	chr4:152717757	C/T	cg22705602	chr4:152727874	NA	0.27	5.71	0.3	2.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg13256891	chr4:100009986	ADH5	-0.41	-5.66	-0.3	3.32e-8	Alcohol dependence;
LUSC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25072359	chr17:41440525	NA	0.63	9.2	0.45	3.95e-18	Menopause (age at onset);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg12843872	chr7:90894352	FZD1	0.47	5.97	0.31	5.99e-9	Cognitive function;Information processing speed;
LUSC	cis	rs2273669	0.588	rs75995854	chr6:109325624	C/A	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.61	0.43	2.91e-16	Prudent dietary pattern;
LUSC	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg05182265	chr7:156933206	UBE3C	-0.59	-9.51	-0.46	3.83e-19	Body mass index;
LUSC	cis	rs6542838	0.644	rs7590596	chr2:99467938	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.43	-5.75	-0.3	2.01e-8	Fear of minor pain;
LUSC	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.9	-0.35	2.55e-11	Alcohol dependence;
LUSC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.9	14.45	0.62	4.05e-37	Developmental language disorder (linguistic errors);
LUSC	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-0.9	-16.03	-0.66	2.63e-43	Height;
LUSC	cis	rs7561273	0.586	rs11896092	chr2:24317827	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-6.84	-0.35	3.89e-11	Quantitative traits;
LUSC	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.87	13.75	0.6	2.09e-34	Coronary artery disease;
LUSC	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg09365446	chr1:150670422	GOLPH3L	0.45	6.72	0.34	8.04e-11	Melanoma;
LUSC	cis	rs9811920	0.965	rs9849632	chr3:99867211	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.38	5.74	0.3	2.17e-8	Axial length;
LUSC	cis	rs516243	0.807	rs578554	chr1:10741669	A/C	cg02903756	chr1:10750680	CASZ1	-0.47	-8.29	-0.41	2.88e-15	Migraine - clinic-based;
LUSC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg12463550	chr7:65579703	CRCP	0.47	6.96	0.36	1.86e-11	Aortic root size;
LUSC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg11062466	chr8:58055876	NA	0.7	8.6	0.43	3.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs12928939	0.723	rs71403864	chr16:71695030	C/T	cg03805757	chr16:71968109	PKD1L3	-0.39	-5.7	-0.3	2.68e-8	Post bronchodilator FEV1;
LUSC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg06742321	chr12:123595122	PITPNM2	0.38	5.7	0.3	2.69e-8	Platelet count;
LUSC	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg09654669	chr8:57350985	NA	-0.58	-7.88	-0.4	4.68e-14	Obesity-related traits;
LUSC	cis	rs7582720	1.000	rs114899426	chr2:203771652	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.66	0.43	2.06e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06766273	chr11:62521983	ZBTB3	0.44	6.27	0.32	1.13e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06850241	chr22:41845214	NA	-0.31	-5.94	-0.31	7.11e-9	Vitiligo;
LUSC	cis	rs9677476	0.818	rs62197333	chr2:232085049	G/C	cg07929768	chr2:232055508	NA	0.34	6.55	0.34	2.21e-10	Food antigen IgG levels;
LUSC	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.74	-10.9	-0.51	7.23e-24	Glomerular filtration rate;
LUSC	cis	rs3125734	0.534	rs10821973	chr10:64052337	G/A	cg09941381	chr10:64027924	RTKN2	-0.38	-6.96	-0.36	1.83e-11	Rheumatoid arthritis;
LUSC	cis	rs4141404	0.787	rs11913992	chr22:31585220	G/A	cg22777020	chr22:31556080	RNF185	-0.47	-6.8	-0.35	4.94e-11	Paclitaxel-induced neuropathy;
LUSC	cis	rs35123781	1.000	rs2336880	chr5:139063728	A/G	cg00976381	chr5:138713954	SLC23A1	0.39	6.03	0.31	4.44e-9	Schizophrenia;
LUSC	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg07741184	chr6:167504864	NA	-0.33	-5.88	-0.31	9.7e-9	Primary biliary cholangitis;
LUSC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg16447950	chr5:562315	NA	-0.52	-6.88	-0.35	3e-11	Obesity-related traits;
LUSC	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg24375607	chr4:120327624	NA	0.79	11.77	0.54	5.27e-27	Corneal astigmatism;
LUSC	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg16342193	chr10:102329863	NA	-0.35	-6.57	-0.34	1.98e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg16342193	chr10:102329863	NA	-0.36	-6.2	-0.32	1.64e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg24643429	chr1:3562429	WDR8	0.33	6.04	0.31	4.2e-9	Monocyte count;
LUSC	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg15017067	chr4:17643749	FAM184B	0.36	5.9	0.31	8.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.66	-11.14	-0.52	9.75e-25	Diastolic blood pressure;
LUSC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08219700	chr8:58056026	NA	0.65	7.64	0.39	2.34e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg07332563	chr6:291687	DUSP22	-0.47	-6.82	-0.35	4.36e-11	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.55	0.57	7.1e-30	Prudent dietary pattern;
LUSC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17916960	chr15:79447300	NA	-0.52	-10.31	-0.49	7.72e-22	Refractive error;
LUSC	cis	rs6545883	0.931	rs778756	chr2:61781994	A/G	cg15711740	chr2:61764176	XPO1	-0.44	-6.91	-0.35	2.47e-11	Tuberculosis;
LUSC	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-0.83	-15.21	-0.64	4.48e-40	Longevity;
LUSC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg17764715	chr19:33622953	WDR88	0.63	9.31	0.45	1.78e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg17691542	chr6:26056736	HIST1H1C	0.48	6.77	0.35	5.88e-11	Iron status biomarkers;
LUSC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08677398	chr8:58056175	NA	0.58	6.95	0.36	1.96e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg17633681	chr16:88106987	BANP	0.49	9.07	0.44	1.03e-17	Menopause (age at onset);
LUSC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.51	-0.38	5.35e-13	Aortic root size;
LUSC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.5	7.76	0.39	1.03e-13	Colorectal cancer;
LUSC	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-9.81	-0.47	4.11e-20	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.34	0.46	1.39e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.24	-0.37	3.09e-12	Bipolar disorder;
LUSC	cis	rs7927771	0.507	rs1483988	chr11:47899030	C/T	cg20307385	chr11:47447363	PSMC3	0.46	6.6	0.34	1.64e-10	Subjective well-being;
LUSC	cis	rs921665	0.831	rs2305491	chr2:3198175	C/T	cg16434511	chr2:3151078	NA	-0.61	-6.64	-0.34	1.29e-10	World class endurance athleticism;
LUSC	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg16359550	chr11:109292809	C11orf87	0.38	6.56	0.34	2e-10	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.0	0.52	3.07e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2996428	0.561	rs2275827	chr1:3746585	T/G	cg23277830	chr1:3704460	LRRC47	0.31	5.8	0.3	1.52e-8	Red cell distribution width;
LUSC	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.49	-5.76	-0.3	1.9e-8	Body mass index;
LUSC	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-5.71	-0.3	2.49e-8	Blood metabolite levels;
LUSC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	7.5	0.38	5.85e-13	Multiple sclerosis;
LUSC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg27170947	chr2:26402098	FAM59B	-0.71	-10.67	-0.5	4.58e-23	Gut microbiome composition (summer);
LUSC	cis	rs9467773	0.566	rs66972160	chr6:26359306	T/C	cg05738196	chr6:26577821	NA	-0.49	-7.55	-0.38	4.21e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg25258033	chr6:167368657	RNASET2	0.48	7.92	0.4	3.52e-14	Crohn's disease;
LUSC	trans	rs6480314	0.542	rs10998045	chr10:70029383	T/C	cg04882175	chr6:131122610	NA	-0.55	-6.32	-0.33	8.4e-10	Optic nerve measurement (disc area);
LUSC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg24060327	chr5:131705240	SLC22A5	-0.53	-8.78	-0.43	8.66e-17	Acylcarnitine levels;
LUSC	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21984481	chr17:79567631	NPLOC4	0.74	15.67	0.65	7.08e-42	Eye color traits;
LUSC	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.13	-0.36	6.41e-12	Menopause (age at onset);
LUSC	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg04545296	chr12:48745243	ZNF641	0.34	6.22	0.32	1.47e-9	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg10664184	chr19:17420304	DDA1	0.48	6.22	0.32	1.45e-9	Systemic lupus erythematosus;
LUSC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg12560992	chr17:57184187	TRIM37	-0.84	-15.4	-0.64	8.19e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg17507749	chr15:85114479	UBE2QP1	0.69	8.78	0.43	8.54e-17	Schizophrenia;
LUSC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.26	0.32	1.2e-9	Menopause (age at onset);
LUSC	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.14	10.28	0.49	1e-21	Alzheimer's disease (late onset);
LUSC	cis	rs9039	1.000	rs12924275	chr16:9191790	C/T	cg08831531	chr16:9218945	NA	-0.69	-10.39	-0.49	4.16e-22	Menopause (age at onset);
LUSC	trans	rs9375185	0.941	rs9401599	chr6:123120403	C/T	cg21773220	chr11:94883919	NA	-0.57	-6.42	-0.33	4.58e-10	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs13315871	0.929	rs9854438	chr3:58277327	G/A	cg20936604	chr3:58311152	NA	-0.7	-6.72	-0.35	7.91e-11	Cholesterol, total;
LUSC	trans	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg19694781	chr19:47549865	TMEM160	-0.41	-6.42	-0.33	4.71e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg22906224	chr7:99728672	NA	0.47	6.54	0.34	2.36e-10	Coronary artery disease;
LUSC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.28	0.53	3.18e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.25	-0.59	1.75e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg23887609	chr12:130822674	PIWIL1	0.49	7.25	0.37	2.87e-12	Menopause (age at onset);
LUSC	cis	rs12220238	1.000	rs12220238	chr10:75952670	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.61	0.34	1.48e-10	Soluble interleukin-2 receptor subunit alpha;
LUSC	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg15704280	chr7:45808275	SEPT13	-0.85	-14.27	-0.62	2.04e-36	Height;
LUSC	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg20608306	chr11:116969690	SIK3	0.34	6.33	0.33	7.77e-10	Blood protein levels;
LUSC	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.8	-13.22	-0.59	2.22e-32	Lymphocyte percentage of white cells;
LUSC	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg23950597	chr19:37808831	NA	-0.63	-7.56	-0.38	4.01e-13	Coronary artery calcification;
LUSC	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg13852791	chr20:30311386	BCL2L1	0.9	13.36	0.59	6.74e-33	Mean corpuscular hemoglobin;
LUSC	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg08000102	chr2:233561755	GIGYF2	0.75	11.78	0.54	4.88e-27	Coronary artery disease;
LUSC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.11	-0.41	1.01e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.99	0.44	1.9e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg15595755	chr5:1867978	NA	0.4	6.3	0.33	9.41e-10	Cardiovascular disease risk factors;
LUSC	cis	rs921665	0.831	rs2167961	chr2:3177617	C/G	cg16434511	chr2:3151078	NA	-0.63	-6.74	-0.35	7.07e-11	World class endurance athleticism;
LUSC	cis	rs3820928	0.874	rs4675128	chr2:227814757	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.0	-0.4	2.11e-14	Pulmonary function;
LUSC	cis	rs6840360	1.000	rs12331037	chr4:152663971	G/A	cg22705602	chr4:152727874	NA	-0.28	-6.0	-0.31	5.06e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg06238570	chr21:40685208	BRWD1	-0.53	-8.21	-0.41	4.79e-15	Menarche (age at onset);
LUSC	cis	rs2230307	0.536	rs564938	chr1:100592901	T/C	cg24955406	chr1:100503596	HIAT1	-0.59	-6.07	-0.32	3.47e-9	Carotid intima media thickness;
LUSC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08280861	chr8:58055591	NA	0.53	6.18	0.32	1.86e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.58	0.34	1.81e-10	Corneal astigmatism;
LUSC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.2	0.41	5.24e-15	Homoarginine levels;
LUSC	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.46	6.37	0.33	6.36e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs34891900	0.507	rs738133	chr22:18205557	C/T	cg08824373	chr22:18117835	NA	-0.41	-6.2	-0.32	1.66e-9	Sum neutrophil eosinophil counts;
LUSC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	6.29	0.33	1.01e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.02	-0.4	1.85e-14	Lung cancer;
LUSC	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.06	-0.48	5.7e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg11941060	chr3:133502564	NA	0.41	6.03	0.31	4.33e-9	Iron status biomarkers;
LUSC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.32	7.04	0.36	1.1e-11	Coronary artery disease;
LUSC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg24209194	chr3:40518798	ZNF619	0.45	5.94	0.31	7.21e-9	Renal cell carcinoma;
LUSC	trans	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg20587970	chr11:113659929	NA	-1.05	-14.68	-0.63	5.31e-38	Hip circumference adjusted for BMI;
LUSC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.28	-0.32	1.06e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	13.02	0.58	1.24e-31	Hip circumference adjusted for BMI;
LUSC	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg13852791	chr20:30311386	BCL2L1	0.59	6.41	0.33	4.99e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs9308433	0.529	rs4655244	chr1:214497580	A/G	cg06198575	chr1:214491504	SMYD2	0.45	7.06	0.36	9.75e-12	IgG glycosylation;
LUSC	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg02403541	chr12:121454288	C12orf43	-0.72	-11.01	-0.52	2.86e-24	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg16006841	chr5:176797999	RGS14	0.62	9.83	0.47	3.3e-20	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg20135002	chr11:47629003	NA	0.49	7.76	0.39	1.05e-13	Subjective well-being;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07332563	chr6:291687	DUSP22	0.71	12.0	0.55	7.99e-28	Menopause (age at onset);
LUSC	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg11584989	chr19:19387371	SF4	-0.52	-6.16	-0.32	2.05e-9	Bipolar disorder;
LUSC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.76	11.63	0.54	1.77e-26	Menopause (age at onset);
LUSC	cis	rs9650315	0.929	rs6474054	chr8:57169889	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.12	0.36	6.82e-12	Height;
LUSC	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg01689657	chr7:91764605	CYP51A1	0.31	5.8	0.3	1.57e-8	Breast cancer;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.51	-7.52	-0.38	5.06e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg06917634	chr15:78832804	PSMA4	0.82	14.78	0.63	2.27e-38	Sudden cardiac arrest;
LUSC	cis	rs939658	0.728	rs11637459	chr15:79413554	A/G	cg17916960	chr15:79447300	NA	-0.5	-9.52	-0.46	3.58e-19	Refractive error;
LUSC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg07741184	chr6:167504864	NA	0.4	7.01	0.36	1.3e-11	Primary biliary cholangitis;
LUSC	trans	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg24644049	chr4:85504048	CDS1	0.86	7.56	0.38	3.83e-13	Skin colour saturation;
LUSC	cis	rs6681460	0.934	rs10889635	chr1:67075575	G/A	cg02459107	chr1:67143332	SGIP1	0.48	8.82	0.43	6.45e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.76	-12.32	-0.56	5.16e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg16743903	chr16:89593216	SPG7	0.38	6.04	0.31	4.06e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs939658	1.000	rs8031504	chr15:79458589	G/T	cg17916960	chr15:79447300	NA	0.48	9.5	0.46	4.16e-19	Refractive error;
LUSC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg10729496	chr3:10149963	C3orf24	0.59	8.04	0.4	1.61e-14	Alzheimer's disease;
LUSC	cis	rs7539542	0.536	rs12091234	chr1:202855508	C/T	cg19681188	chr1:202830198	LOC148709	0.41	6.02	0.31	4.48e-9	Mean platelet volume;
LUSC	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.59	-9.63	-0.47	1.6e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg16342193	chr10:102329863	NA	-0.37	-6.77	-0.35	5.79e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.79	-0.39	8.48e-14	Chronic sinus infection;
LUSC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg24503407	chr1:205819492	PM20D1	0.53	8.56	0.42	4.3e-16	Menarche (age at onset);
LUSC	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg25838465	chr1:92012736	NA	-0.56	-10.12	-0.48	3.62e-21	Breast cancer;
LUSC	cis	rs793571	0.544	rs1427282	chr15:58914326	C/T	cg05156742	chr15:59063176	FAM63B	0.54	8.22	0.41	4.56e-15	Schizophrenia;
LUSC	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg18232548	chr7:50535776	DDC	0.54	7.63	0.39	2.51e-13	Malaria;
LUSC	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg01849466	chr14:104193079	ZFYVE21	0.57	8.93	0.44	2.83e-17	Schizophrenia;
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.18	0.41	5.81e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs116988415	0.584	rs4899145	chr14:65241867	G/A	cg00114569	chr14:65239327	SPTB	0.66	6.4	0.33	5.23e-10	Daytime sleep phenotypes;
LUSC	cis	rs2901656	0.583	rs6702667	chr1:172400484	A/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.3	6.25	0.32	1.28e-9	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs62408225	0.748	rs7744528	chr6:90916931	C/G	cg06866423	chr6:90926672	BACH2	0.4	6.32	0.33	8.41e-10	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.33	0.45	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.74	11.82	0.54	3.58e-27	Aortic root size;
LUSC	cis	rs2285947	1.000	rs2285950	chr7:21584432	C/T	cg04471919	chr7:21584483	DNAH11	-0.37	-8.55	-0.42	4.49e-16	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	cis	rs12545109	0.800	rs1371936	chr8:57422715	A/G	cg09654669	chr8:57350985	NA	-0.51	-6.6	-0.34	1.61e-10	Obesity-related traits;
LUSC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg06454157	chr6:167490870	NA	-0.27	-6.16	-0.32	2.06e-9	Crohn's disease;
LUSC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11645453	chr3:52864694	ITIH4	0.57	13.75	0.6	2.19e-34	Schizophrenia;
LUSC	cis	rs12618769	0.652	rs3769698	chr2:99233894	T/C	cg10123293	chr2:99228465	UNC50	0.47	7.57	0.38	3.62e-13	Bipolar disorder;
LUSC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.85	0.3	1.2e-8	Lung cancer;
LUSC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.85	-0.3	1.17e-8	Depression;
LUSC	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-10.94	-0.51	5.16e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4795519	0.569	rs2176132	chr17:22185887	T/C	cg22648282	chr17:21454238	C17orf51	-0.44	-5.92	-0.31	8.14e-9	Chronic myeloid leukemia;
LUSC	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg12826209	chr6:26865740	GUSBL1	0.48	6.17	0.32	1.97e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4285028	0.747	rs1127412	chr3:121414061	C/T	cg11130432	chr3:121712080	ILDR1	-0.56	-8.41	-0.42	1.18e-15	Multiple sclerosis;
LUSC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg09658497	chr7:2847517	GNA12	-0.37	-6.19	-0.32	1.74e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.88	0.6	6.55e-35	Cognitive test performance;
LUSC	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg26850624	chr5:429559	AHRR	-0.33	-5.88	-0.31	1.01e-8	Cystic fibrosis severity;
LUSC	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg26597838	chr10:835615	NA	0.74	8.74	0.43	1.18e-16	Eosinophil percentage of granulocytes;
LUSC	cis	rs7712401	0.715	rs6862366	chr5:122360158	G/C	cg19077854	chr5:122220652	SNX24	-0.41	-8.99	-0.44	1.9e-17	Mean platelet volume;
LUSC	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg09509183	chr1:209979624	IRF6	0.5	5.71	0.3	2.55e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg18305652	chr10:134549665	INPP5A	0.46	6.83	0.35	4.01e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7191700	0.509	rs415595	chr16:11363692	A/G	cg00044050	chr16:11439710	C16orf75	0.62	10.48	0.5	2.17e-22	Multiple sclerosis;
LUSC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02034447	chr16:89574710	SPG7	0.39	5.82	0.3	1.39e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18876405	chr7:65276391	NA	-0.55	-8.77	-0.43	9.25e-17	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17231661	chr11:119039801	NLRX1	-0.41	-6.41	-0.33	5.01e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg15423357	chr2:25149977	NA	0.33	6.36	0.33	6.73e-10	Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24616795	chr3:53032891	SFMBT1	0.42	6.29	0.33	9.84e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg04310649	chr10:35416472	CREM	-0.44	-6.84	-0.35	3.85e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4730250	0.707	rs257381	chr7:106803963	T/C	cg02696742	chr7:106810147	HBP1	-0.63	-8.89	-0.44	4.03e-17	Osteoarthritis;
LUSC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg02951883	chr7:2050386	MAD1L1	-0.4	-7.0	-0.36	1.45e-11	Schizophrenia;
LUSC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg12963246	chr6:28129442	ZNF389	0.52	7.16	0.36	5.3e-12	Depression;
LUSC	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	1.11	18.94	0.72	7.6e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	1.23	19.46	0.73	6.2e-57	Corneal structure;
LUSC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	0.84	14.17	0.61	5.3e-36	Tonsillectomy;
LUSC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg24675658	chr1:53192096	ZYG11B	-0.53	-8.33	-0.41	2.18e-15	Monocyte count;
LUSC	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20372048	chr12:82752172	CCDC59;C12orf26	0.43	6.02	0.31	4.69e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg11887960	chr12:57824829	NA	0.48	6.47	0.33	3.46e-10	Obesity-related traits;
LUSC	cis	rs240764	0.853	rs12190903	chr6:100983505	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-6.31	-0.33	8.88e-10	Neuroticism;
LUSC	cis	rs9549260	0.753	rs4943794	chr13:41173408	G/C	cg21288729	chr13:41239152	FOXO1	0.53	5.99	0.31	5.38e-9	Red blood cell count;
LUSC	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg13813247	chr22:41461852	NA	-0.34	-6.08	-0.32	3.28e-9	Neuroticism;
LUSC	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg20026190	chr17:76395443	PGS1	0.45	8.1	0.41	1.06e-14	HDL cholesterol levels;
LUSC	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg24375607	chr4:120327624	NA	-0.69	-10.9	-0.51	6.88e-24	Corneal astigmatism;
LUSC	cis	rs569214	0.763	rs484377	chr8:27477509	C/T	cg00839333	chr8:27504520	SCARA3	0.34	5.77	0.3	1.8e-8	Alzheimer's disease;
LUSC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg27427491	chr17:78079615	GAA	-0.36	-6.94	-0.36	2.03e-11	Yeast infection;
LUSC	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21545522	chr1:205238299	TMCC2	0.51	9.47	0.46	5.39e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.79	7.51	0.38	5.59e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-13.58	-0.6	9.78e-34	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2267137	0.868	rs174770	chr22:29766895	C/T	cg07256473	chr22:29710276	RASL10A	0.38	7.35	0.37	1.54e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.78	-0.35	5.59e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14765172	chr6:153304972	FBXO5	-0.42	-6.03	-0.31	4.29e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg26850624	chr5:429559	AHRR	-0.41	-8.0	-0.4	2.1e-14	Cystic fibrosis severity;
LUSC	cis	rs9311676	0.632	rs7624283	chr3:58369897	G/A	cg26110898	chr3:58419937	PDHB	0.42	6.72	0.35	7.93e-11	Systemic lupus erythematosus;
LUSC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.19	-0.41	5.8e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.3	-5.69	-0.3	2.76e-8	Schizophrenia;
LUSC	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg22437258	chr11:111473054	SIK2	-0.47	-6.06	-0.31	3.57e-9	Primary sclerosing cholangitis;
LUSC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg24690094	chr11:67383802	NA	0.54	11.24	0.52	4.64e-25	Mean corpuscular volume;
LUSC	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.14	-0.32	2.39e-9	Neuroticism;
LUSC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	7.33	0.37	1.75e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs16910800	1.000	rs2468647	chr11:23202054	C/T	cg20040320	chr11:23191996	NA	0.44	6.47	0.33	3.59e-10	Cancer;
LUSC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg02772935	chr3:125709198	NA	-0.48	-5.82	-0.3	1.36e-8	Blood pressure (smoking interaction);
LUSC	cis	rs9394152	0.781	rs9380362	chr6:33467734	T/C	cg13560919	chr6:33536144	NA	0.61	10.76	0.51	2.23e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22948335	chr2:70475902	TIA1	-0.43	-6.39	-0.33	5.56e-10	Electrocardiographic conduction measures;
LUSC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24110177	chr3:50126178	RBM5	-0.54	-8.74	-0.43	1.19e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-16.0	-0.66	3.52e-43	Gut microbiome composition (summer);
LUSC	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg03585969	chr10:35415529	CREM	0.6	8.53	0.42	5.07e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	4.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.88	14.94	0.63	5.21e-39	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01252224	chr16:83841660	HSBP1	-0.41	-5.97	-0.31	6.03e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg00105475	chr2:10696890	NA	0.38	6.27	0.32	1.11e-9	Prostate cancer;
LUSC	cis	rs11024102	0.962	rs12575487	chr11:17019317	C/T	cg15084286	chr11:17036142	PLEKHA7	0.46	6.16	0.32	2.09e-9	Glaucoma (primary angle closure);
LUSC	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg22117172	chr7:91764530	CYP51A1	0.31	5.7	0.3	2.7e-8	Breast cancer;
LUSC	cis	rs7582720	0.832	rs115194657	chr2:203829284	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg24675658	chr1:53192096	ZYG11B	0.72	11.91	0.55	1.75e-27	Monocyte count;
LUSC	cis	rs11828289	0.660	rs76379912	chr11:23182498	A/G	cg20040320	chr11:23191996	NA	-0.58	-6.09	-0.32	3.1e-9	Cancer;
LUSC	cis	rs3808502	0.527	rs2736389	chr8:11161310	C/A	cg21775007	chr8:11205619	TDH	0.48	6.85	0.35	3.49e-11	Neuroticism;
LUSC	cis	rs12928939	0.517	rs17358402	chr16:71967927	C/T	cg03805757	chr16:71968109	PKD1L3	-0.64	-9.8	-0.47	4.31e-20	Post bronchodilator FEV1;
LUSC	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg26394196	chr10:1453818	ADARB2	-0.38	-6.52	-0.34	2.63e-10	Radiation response;
LUSC	cis	rs3820928	0.874	rs10174073	chr2:227794944	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.98	-0.4	2.34e-14	Pulmonary function;
LUSC	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.24	0.52	4.42e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	0.92	15.52	0.65	2.79e-41	Menopause (age at onset);
LUSC	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-9.4	-0.46	9.12e-19	Chronic sinus infection;
LUSC	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23429847	chr5:128430259	ISOC1	0.53	7.33	0.37	1.78e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6504340	0.741	rs34490194	chr17:46648744	C/T	cg09704116	chr17:46666958	LOC404266	-0.37	-6.26	-0.32	1.22e-9	Primary tooth development (number of teeth);
LUSC	trans	rs7980799	0.649	rs2084391	chr12:33655419	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-8.01	-0.4	1.92e-14	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.01	-0.36	1.34e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9815354	0.812	rs58442057	chr3:41827209	G/A	cg03022575	chr3:42003672	ULK4	0.85	8.62	0.43	2.78e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg09877947	chr5:131593287	PDLIM4	-0.43	-6.76	-0.35	6.16e-11	Breast cancer;
LUSC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg03188948	chr7:1209495	NA	0.66	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg23950597	chr19:37808831	NA	-0.63	-7.68	-0.39	1.82e-13	Coronary artery calcification;
LUSC	cis	rs9816226	1.000	rs55835921	chr3:185831474	T/C	cg00760338	chr3:185826511	ETV5	-0.68	-8.79	-0.43	7.94e-17	Obesity;Body mass index;
LUSC	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg15309053	chr8:964076	NA	-0.34	-6.89	-0.35	2.86e-11	Schizophrenia;
LUSC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg05738196	chr6:26577821	NA	0.52	8.3	0.41	2.53e-15	Schizophrenia;
LUSC	trans	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-8.53	-0.42	5.13e-16	Obesity-related traits;
LUSC	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg22681709	chr2:178499509	PDE11A	-0.46	-6.8	-0.35	4.7e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg19468946	chr17:37922297	IKZF3	-0.43	-6.89	-0.35	2.82e-11	Self-reported allergy;
LUSC	cis	rs1178968	0.818	rs2528709	chr7:72788457	C/A	cg25889504	chr7:72793014	NA	0.57	7.43	0.38	9.39e-13	Triglyceride levels;
LUSC	cis	rs7246967	0.673	rs16999580	chr19:22923487	C/T	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.04e-8	Bronchopulmonary dysplasia;
LUSC	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	1.14	18.04	0.7	2.84e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	11.78	0.54	5.2e-27	Prudent dietary pattern;
LUSC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21862992	chr11:68658383	NA	0.48	7.74	0.39	1.17e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04362095	chr11:63592001	C11orf84	-0.58	-8.9	-0.44	3.5e-17	Pulse pressure;
LUSC	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05025164	chr4:1340916	KIAA1530	-0.67	-10.43	-0.5	3.15e-22	Longevity;
LUSC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg10356904	chr22:49881777	NA	-0.33	-7.52	-0.38	5.24e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.95	0.36	1.97e-11	Cystic fibrosis severity;
LUSC	cis	rs6722750	0.967	rs17754672	chr2:64400608	A/G	cg22352474	chr2:64371530	PELI1	-0.58	-8.77	-0.43	8.99e-17	Neuroticism;
LUSC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg12963246	chr6:28129442	ZNF389	0.55	7.74	0.39	1.17e-13	Parkinson's disease;
LUSC	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg26876637	chr1:152193138	HRNR	0.44	6.13	0.32	2.46e-9	Atopic dermatitis;
LUSC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg00933542	chr6:150070202	PCMT1	0.32	6.59	0.34	1.74e-10	Lung cancer;
LUSC	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg21775007	chr8:11205619	TDH	0.42	6.16	0.32	2.11e-9	Acne (severe);
LUSC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.6	9.89	0.48	2.12e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7527798	0.637	rs7515149	chr1:207838352	T/G	cg09232269	chr1:207846808	CR1L	-0.3	-6.3	-0.33	9.27e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.74	15.13	0.64	9.36e-40	Metabolite levels;
LUSC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg00033643	chr7:134001901	SLC35B4	0.43	6.35	0.33	7.2e-10	Mean platelet volume;
LUSC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	12.37	0.56	3.34e-29	Colorectal cancer;
LUSC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-9.39	-0.46	9.82e-19	Gut microbiome composition (summer);
LUSC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg05738196	chr6:26577821	NA	-0.47	-6.86	-0.35	3.27e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg21681030	chr2:46777652	RHOQ	0.45	6.34	0.33	7.36e-10	Height;
LUSC	cis	rs9326248	0.861	rs7120309	chr11:117042816	T/A	cg01368799	chr11:117014884	PAFAH1B2	0.46	5.66	0.3	3.2e-8	Blood protein levels;
LUSC	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg04310649	chr10:35416472	CREM	0.41	6.32	0.33	8.57e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg09904177	chr6:26538194	HMGN4	-0.74	-6.85	-0.35	3.47e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2274273	0.588	rs9919932	chr14:55814080	A/G	cg04306507	chr14:55594613	LGALS3	0.48	9.46	0.46	5.53e-19	Protein biomarker;
LUSC	cis	rs9902453	0.900	rs12451122	chr17:28486376	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.62	0.38	2.61e-13	Coffee consumption (cups per day);
LUSC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg21724239	chr8:58056113	NA	0.59	7.19	0.37	4.19e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg20291162	chr17:40259547	DHX58	0.57	7.59	0.38	3.26e-13	Fibrinogen levels;
LUSC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg00012203	chr2:219082015	ARPC2	-0.71	-11.57	-0.53	2.95e-26	Colorectal cancer;
LUSC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg06917634	chr15:78832804	PSMA4	-0.43	-5.94	-0.31	7.33e-9	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg17143192	chr8:8559678	CLDN23	0.65	9.0	0.44	1.8e-17	Obesity-related traits;
LUSC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.66	-11.92	-0.55	1.53e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6674176	0.542	rs803679	chr1:44349405	G/A	cg12908607	chr1:44402522	ARTN	-0.4	-5.83	-0.3	1.29e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2692947	0.832	rs2438972	chr2:96690873	T/C	cg23100626	chr2:96804247	ASTL	0.25	6.4	0.33	5.18e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9807989	0.839	rs3755276	chr2:102978459	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	5.74	0.3	2.08e-8	Asthma;
LUSC	cis	rs931127	0.719	rs2170082	chr11:65454795	A/G	cg05805236	chr11:65401703	PCNXL3	-0.41	-7.09	-0.36	8.22e-12	Systemic lupus erythematosus;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg27560182	chr1:26511621	CNKSR1	-0.39	-6.35	-0.33	7.18e-10	N-glycan levels;
LUSC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.75	-0.3	1.97e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg24829409	chr8:58192753	C8orf71	-0.47	-5.68	-0.3	2.89e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	0.93	15.77	0.65	2.76e-42	Menopause (age at onset);
LUSC	trans	rs9929218	0.954	rs17715762	chr16:68828250	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-10.8	-0.51	1.56e-23	Colorectal cancer;
LUSC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.03	0.36	1.14e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs977987	0.778	rs4888400	chr16:75425596	G/C	cg04384234	chr16:75411784	CFDP1	-0.42	-6.96	-0.36	1.81e-11	Dupuytren's disease;
LUSC	trans	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg19894588	chr14:64061835	NA	0.55	7.77	0.39	9.64e-14	Glioblastoma;Glioma;
LUSC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg13042288	chr15:90349979	ANPEP	-0.44	-6.26	-0.32	1.21e-9	Uric acid levels;
LUSC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.24	0.52	4.35e-25	Menopause (age at onset);
LUSC	cis	rs753955	0.567	rs11617286	chr13:24409348	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.36	-5.79	-0.3	1.64e-8	Lung cancer;
LUSC	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg18721089	chr20:30220636	NA	-0.35	-5.94	-0.31	7.09e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs12210905	0.920	rs72839451	chr6:27265437	G/C	cg11837749	chr1:55047332	ACOT11	0.66	6.3	0.33	9.13e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg14668632	chr7:2872130	GNA12	-0.42	-6.25	-0.32	1.27e-9	Height;
LUSC	cis	rs7091068	0.671	rs1096025	chr10:95404701	T/C	cg20715218	chr10:95462985	C10orf4	-0.6	-6.95	-0.36	1.94e-11	Urinary tract infection frequency;
LUSC	cis	rs80130819	0.515	rs1476608	chr12:48493731	C/T	cg24011408	chr12:48396354	COL2A1	0.44	5.96	0.31	6.48e-9	Prostate cancer;
LUSC	cis	rs6977660	1.000	rs10249989	chr7:19822296	A/G	cg07541023	chr7:19748670	TWISTNB	0.51	5.73	0.3	2.3e-8	Thyroid stimulating hormone;
LUSC	cis	rs2688419	0.527	rs1355740	chr3:23070957	C/T	cg00327796	chr3:23032191	NA	0.42	7.4	0.38	1.11e-12	Type 2 diabetes;
LUSC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.64	8.78	0.43	8.94e-17	High light scatter reticulocyte count;
LUSC	cis	rs8051149	0.688	rs12444670	chr16:87870312	C/T	cg01412419	chr16:87856264	NA	0.48	7.59	0.38	3.25e-13	Blood metabolite levels;
LUSC	cis	rs9583531	1.000	rs9583531	chr13:111385161	T/G	cg24331049	chr13:111365604	ING1	-0.54	-5.92	-0.31	8.15e-9	Coronary artery disease;
LUSC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg21535247	chr6:8435926	SLC35B3	0.57	8.67	0.43	1.96e-16	Motion sickness;
LUSC	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg05340658	chr4:99064831	C4orf37	0.45	7.09	0.36	8.1e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg15145296	chr3:125709740	NA	-0.55	-6.18	-0.32	1.88e-9	Blood pressure (smoking interaction);
LUSC	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg16950941	chr11:66035639	RAB1B	0.48	7.06	0.36	9.89e-12	Gout;
LUSC	cis	rs4566357	0.595	rs6707159	chr2:227909339	T/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.57	-0.42	3.97e-16	Coronary artery disease;
LUSC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg17724175	chr1:150552817	MCL1	0.38	6.82	0.35	4.17e-11	Tonsillectomy;
LUSC	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg15934090	chr1:100435551	SLC35A3	0.47	8.16	0.41	6.96e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs965469	0.625	rs1043159	chr20:3232031	C/T	cg25506879	chr20:3388711	C20orf194	-0.47	-6.47	-0.33	3.39e-10	IFN-related cytopenia;
LUSC	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg11019008	chr10:131425282	MGMT	0.4	6.2	0.32	1.68e-9	Response to temozolomide;
LUSC	trans	rs1456305	0.550	rs2392733	chr8:128100672	C/T	cg22517681	chr1:24995876	SRRM1	0.64	7.23	0.37	3.22e-12	Prostate cancer;
LUSC	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	10.16	0.49	2.58e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs2073300	1.000	rs61080017	chr20:23457569	A/G	cg09953122	chr20:23471693	CST8	-0.69	-6.86	-0.35	3.28e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7264396	0.832	rs224381	chr20:34097136	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.34	-0.33	7.6e-10	Total cholesterol levels;
LUSC	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg17507749	chr15:85114479	UBE2QP1	0.65	8.1	0.41	1.04e-14	Schizophrenia;
LUSC	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg16447950	chr5:562315	NA	-0.57	-6.9	-0.35	2.68e-11	Obesity-related traits;
LUSC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg06618935	chr21:46677482	NA	-0.39	-7.81	-0.39	7.65e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg26395211	chr5:140044315	WDR55	-0.37	-5.65	-0.3	3.4e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1298062	0.605	rs12327751	chr19:50968890	G/T	cg11430371	chr19:50961752	MYBPC2	0.29	5.83	0.3	1.34e-8	Age of smoking initiation;
LUSC	cis	rs6542838	0.641	rs1581249	chr2:99500630	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-5.79	-0.3	1.64e-8	Fear of minor pain;
LUSC	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.77	-0.43	9.39e-17	Depression;
LUSC	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg03474202	chr17:45855739	NA	-0.29	-6.69	-0.34	9.51e-11	IgG glycosylation;
LUSC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg15448220	chr1:150897856	SETDB1	-0.41	-5.99	-0.31	5.37e-9	Melanoma;
LUSC	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-0.88	-15.49	-0.65	3.56e-41	Height;
LUSC	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg23649088	chr2:200775458	C2orf69	-0.53	-6.82	-0.35	4.33e-11	Schizophrenia;
LUSC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs10979	0.557	rs9390120	chr6:143909411	A/G	cg25407410	chr6:143891975	LOC285740	-0.65	-8.16	-0.41	7e-15	Hypospadias;
LUSC	trans	rs3857536	0.785	rs2157964	chr6:66938419	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.61	12.58	0.57	5.62e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs12310956	0.510	rs11052882	chr12:33890017	T/C	cg06521331	chr12:34319734	NA	-0.36	-5.88	-0.31	1.02e-8	Morning vs. evening chronotype;
LUSC	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg16482183	chr6:26056742	HIST1H1C	0.65	9.14	0.45	6.04e-18	Iron status biomarkers;
LUSC	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg14835575	chr10:16859367	RSU1	0.72	9.22	0.45	3.31e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.87	-16.13	-0.66	1.12e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg01677386	chr11:118938358	VPS11	-0.48	-6.82	-0.35	4.41e-11	Coronary artery disease;
LUSC	trans	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.98	0.44	2.01e-17	Type 2 diabetes;
LUSC	cis	rs7000551	0.751	rs2100291	chr8:22374551	C/T	cg12081754	chr8:22256438	SLC39A14	0.45	6.88	0.35	2.88e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs8022179	0.566	rs959083	chr14:103822687	A/G	cg12935359	chr14:103987150	CKB	-0.54	-7.22	-0.37	3.47e-12	Monocyte count;
LUSC	cis	rs11153306	0.765	rs7740180	chr6:111944538	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.57	-0.34	1.91e-10	Tonsillectomy;
LUSC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.89	14.16	0.61	5.74e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7119167	0.901	rs10793060	chr11:73120653	A/G	cg17517138	chr11:73019481	ARHGEF17	0.52	5.93	0.31	7.51e-9	Blood protein levels;
LUSC	cis	rs9925964	0.748	rs11640961	chr16:30979818	C/T	cg02466173	chr16:30829666	NA	0.38	7.15	0.36	5.39e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.64	-10.06	-0.48	5.8e-21	Blood protein levels;
LUSC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs62027291	0.898	rs2404232	chr15:77260575	G/T	cg26408565	chr15:76604113	ETFA	0.56	6.48	0.33	3.26e-10	Plateletcrit;
LUSC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	7.82e-13	Motion sickness;
LUSC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	1.03	19.75	0.73	4.43e-58	Menopause (age at onset);
LUSC	cis	rs13223928	0.538	rs10951042	chr7:3139417	T/C	cg19214707	chr7:3157722	NA	-0.45	-8.92	-0.44	3.09e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	trans	rs10946292	0.706	rs3012450	chr6:170438131	A/G	cg17832364	chr10:94847294	NA	0.4	6.75	0.35	6.73e-11	Obesity-related traits;
LUSC	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	6.34	0.33	7.51e-10	Rheumatoid arthritis;
LUSC	cis	rs6845621	0.745	rs6449427	chr4:18865690	G/A	cg12196642	chr4:18937545	NA	-0.32	-5.91	-0.31	8.59e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs57920188	0.537	rs4440829	chr1:4080780	A/G	cg20703997	chr1:4087676	NA	-0.5	-6.79	-0.35	5.01e-11	Interleukin-17 levels;
LUSC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.94	-20.09	-0.74	2.03e-59	Post bronchodilator FEV1;
LUSC	cis	rs11112613	0.818	rs2374507	chr12:106009570	A/C	cg03607813	chr12:105948248	NA	0.73	8.73	0.43	1.25e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg26597838	chr10:835615	NA	-0.48	-6.58	-0.34	1.8e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs4285028	0.747	rs7648343	chr3:121426195	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.89	-12.06	-0.55	4.85e-28	Multiple sclerosis;
LUSC	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg27246729	chr12:121163418	ACADS	0.47	7.41	0.38	1.02e-12	Mean corpuscular volume;
LUSC	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.85	0.31	1.15e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.54	0.6	1.33e-33	Cognitive test performance;
LUSC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg02018176	chr4:1364513	KIAA1530	0.52	8.87	0.44	4.63e-17	Obesity-related traits;
LUSC	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg17127132	chr2:85788382	GGCX	0.42	6.07	0.32	3.48e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7608623	0.679	rs7561273	chr2:24247514	C/T	cg08917208	chr2:24149416	ATAD2B	0.44	5.93	0.31	7.73e-9	Obesity-related traits;
LUSC	cis	rs10904908	0.733	rs191693	chr10:17331115	G/A	cg01003015	chr10:17271136	VIM	0.4	5.8	0.3	1.53e-8	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg00376283	chr12:123451042	ABCB9	-0.65	-7.67	-0.39	1.91e-13	Neutrophil percentage of white cells;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg13678112	chr14:89029552	ZC3H14	0.41	6.2	0.32	1.65e-9	Schizophrenia (age at onset);
LUSC	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg02016764	chr4:38805732	TLR1	-0.54	-5.92	-0.31	7.93e-9	Breast cancer;
LUSC	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg23202291	chr11:1979235	NA	-0.36	-5.81	-0.3	1.44e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11645453	chr3:52864694	ITIH4	0.33	7.64	0.39	2.39e-13	Bipolar disorder;
LUSC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs2387326	0.717	rs11016101	chr10:129945003	C/T	cg16087940	chr10:129947807	NA	-0.38	-5.81	-0.3	1.42e-8	Select biomarker traits;
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	0.98	21.2	0.76	8.25e-64	Menarche (age at onset);
LUSC	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg25554036	chr4:6271136	WFS1	0.6	12.05	0.55	5.21e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg15242686	chr22:24348715	GSTTP1	0.41	6.1	0.32	2.94e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs17255340	0.577	rs12192297	chr6:84070966	T/C	cg08257003	chr6:84140564	ME1	0.35	8.49	0.42	6.69e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg13256891	chr4:100009986	ADH5	-0.44	-6.11	-0.32	2.83e-9	Alcohol dependence;
LUSC	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg25173405	chr17:45401733	C17orf57	-0.42	-6.76	-0.35	6.26e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs62408225	0.802	rs10806425	chr6:90926612	C/A	cg06866423	chr6:90926672	BACH2	0.42	6.45	0.33	3.89e-10	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs877282	0.898	rs10904546	chr10:757222	A/G	cg22713356	chr15:30763199	NA	1.03	13.61	0.6	7.56e-34	Uric acid levels;
LUSC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg06618935	chr21:46677482	NA	-0.29	-5.71	-0.3	2.47e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs981844	0.921	rs2606336	chr4:154656792	C/T	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg26668828	chr6:292823	DUSP22	-0.53	-7.97	-0.4	2.51e-14	Menopause (age at onset);
LUSC	cis	rs7202877	0.656	rs4888374	chr16:75322228	T/C	cg03315344	chr16:75512273	CHST6	0.41	6.02	0.31	4.59e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg06096015	chr1:231504339	EGLN1	0.54	9.31	0.45	1.7e-18	Hemoglobin concentration;
LUSC	cis	rs4938330	0.723	rs7931398	chr11:116879676	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-6.17	-0.32	1.96e-9	Blood protein levels;
LUSC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg01802117	chr1:53393560	SCP2	-0.43	-7.19	-0.37	4.19e-12	Monocyte count;
LUSC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg14949292	chr17:78079608	GAA	-0.31	-5.65	-0.3	3.39e-8	Yeast infection;
LUSC	cis	rs6456156	0.773	rs6456159	chr6:167529272	T/A	cg07741184	chr6:167504864	NA	-0.37	-6.66	-0.34	1.12e-10	Primary biliary cholangitis;
LUSC	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.95	0.36	1.93e-11	Morning vs. evening chronotype;
LUSC	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg20003494	chr4:90757398	SNCA	-0.33	-5.71	-0.3	2.5e-8	Dementia with Lewy bodies;
LUSC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.46	-7.29	-0.37	2.3e-12	Systemic lupus erythematosus;
LUSC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20307385	chr11:47447363	PSMC3	-0.44	-5.73	-0.3	2.23e-8	Subjective well-being;
LUSC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.25	0.32	1.28e-9	Personality dimensions;
LUSC	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.41	6.6	0.34	1.64e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg27411982	chr8:10470053	RP1L1	0.38	5.9	0.31	8.94e-9	Retinal vascular caliber;
LUSC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.02	14.9	0.63	7.22e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs440932	1.000	rs378974	chr8:9026639	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	6.4	0.33	5.19e-10	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg02269571	chr22:50332266	NA	-0.55	-8.2	-0.41	5.16e-15	Schizophrenia;
LUSC	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.93	15.76	0.65	3.11e-42	Bladder cancer;
LUSC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg16586182	chr3:47516702	SCAP	-0.47	-7.44	-0.38	8.45e-13	Colorectal cancer;
LUSC	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg15704280	chr7:45808275	SEPT13	-0.65	-6.89	-0.35	2.86e-11	D-dimer levels;
LUSC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg22638593	chr5:131593259	PDLIM4	0.36	5.79	0.3	1.61e-8	Blood metabolite levels;
LUSC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	16.57	0.67	2.06e-45	Platelet count;
LUSC	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg04362960	chr10:104952993	NT5C2	0.6	9.48	0.46	5e-19	Arsenic metabolism;
LUSC	trans	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.65	0.39	2.18e-13	Ulcerative colitis;
LUSC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	8.84	0.44	5.48e-17	Schizophrenia;
LUSC	cis	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg06521331	chr12:34319734	NA	-0.41	-6.74	-0.35	6.92e-11	Morning vs. evening chronotype;
LUSC	trans	rs9976767	0.637	rs2277799	chr21:43824123	G/C	cg19213045	chr13:40180622	NA	0.31	5.96	0.31	6.53e-9	Type 1 diabetes;
LUSC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg21435336	chr19:17392852	ANKLE1	-0.43	-5.87	-0.31	1.07e-8	Systemic lupus erythematosus;
LUSC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg15017067	chr4:17643749	FAM184B	0.36	5.96	0.31	6.28e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	0.92	15.23	0.64	3.94e-40	Breast cancer;
LUSC	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg10978503	chr1:24200527	CNR2	0.54	13.3	0.59	1.09e-32	Immature fraction of reticulocytes;
LUSC	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg17749961	chr2:30669863	LCLAT1	0.63	7.8	0.39	7.96e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	1.36	11.72	0.54	8.29e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg24375607	chr4:120327624	NA	0.77	11.3	0.53	2.73e-25	Corneal astigmatism;
LUSC	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg00277334	chr10:82204260	NA	0.52	7.29	0.37	2.32e-12	Post bronchodilator FEV1;
LUSC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08109568	chr15:31115862	NA	0.48	6.97	0.36	1.71e-11	Huntington's disease progression;
LUSC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg08493051	chr2:3487164	NA	0.53	8.3	0.41	2.52e-15	Neurofibrillary tangles;
LUSC	cis	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg06521331	chr12:34319734	NA	-0.51	-8.37	-0.42	1.55e-15	Morning vs. evening chronotype;
LUSC	trans	rs7939886	0.920	rs78769647	chr11:55965527	C/T	cg15704280	chr7:45808275	SEPT13	0.89	6.81	0.35	4.56e-11	Myopia (pathological);
LUSC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg16339924	chr4:17578868	LAP3	0.66	10.14	0.48	3.16e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg01256987	chr12:42539512	GXYLT1	0.35	6.37	0.33	6.16e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4713675	0.584	rs3818527	chr6:33661035	A/G	cg14003231	chr6:33640908	ITPR3	-0.31	-5.98	-0.31	5.86e-9	Plateletcrit;
LUSC	cis	rs3772130	0.961	rs13072618	chr3:121391833	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	10.06	0.48	5.63e-21	Cognitive performance;
LUSC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.9	0.4	4.21e-14	Prudent dietary pattern;
LUSC	cis	rs7119	0.717	rs12917314	chr15:77818285	T/C	cg27398640	chr15:77910606	LINGO1	-0.31	-6.61	-0.34	1.53e-10	Type 2 diabetes;
LUSC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg25019033	chr10:957182	NA	-0.51	-6.41	-0.33	5.04e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs7712401	0.601	rs154501	chr5:122211594	T/C	cg19077854	chr5:122220652	SNX24	0.41	9.2	0.45	3.93e-18	Mean platelet volume;
LUSC	cis	rs11031096	0.868	rs2920144	chr11:4060283	A/G	cg18678763	chr11:4115507	RRM1	0.4	5.89	0.31	9.38e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23705032	chr10:12237872	NUDT5;CDC123	-0.4	-6.0	-0.31	5.2e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg10167463	chr7:75959203	YWHAG	-0.66	-10.07	-0.48	5.33e-21	Multiple sclerosis;
LUSC	cis	rs7712401	0.601	rs246308	chr5:122270090	G/T	cg19077854	chr5:122220652	SNX24	0.41	8.94	0.44	2.64e-17	Mean platelet volume;
LUSC	cis	rs7103411	0.637	rs7116850	chr11:27645530	C/T	cg18117895	chr11:27722066	BDNF	-0.44	-5.87	-0.31	1.04e-8	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs11264799	0.765	rs12136747	chr1:157636930	C/G	cg18268488	chr1:157545234	FCRL4	-0.33	-5.91	-0.31	8.64e-9	IgA nephropathy;
LUSC	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.91e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg05973401	chr12:123451056	ABCB9	0.55	6.93	0.35	2.2e-11	Neutrophil percentage of white cells;
LUSC	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.47e-11	Response to antipsychotic treatment;
LUSC	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.27	-0.41	3.26e-15	Retinal vascular caliber;
LUSC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	15.74	0.65	3.76e-42	Platelet count;
LUSC	cis	rs12210905	0.688	rs114188783	chr6:27449604	T/C	cg08851530	chr6:28072375	NA	0.97	6.01	0.31	4.99e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05535760	chr7:792225	HEATR2	0.81	9.7	0.47	9.49e-20	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	13.55	0.6	1.2e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-7.9	-0.4	3.96e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00149659	chr3:10157352	C3orf10	1.0	14.77	0.63	2.33e-38	Alzheimer's disease;
LUSC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg20135002	chr11:47629003	NA	-0.51	-7.99	-0.4	2.16e-14	Subjective well-being;
LUSC	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg08048268	chr3:133502702	NA	-0.36	-6.46	-0.33	3.65e-10	Iron status biomarkers;
LUSC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg09034736	chr1:150693464	HORMAD1	0.45	6.44	0.33	4.28e-10	Melanoma;
LUSC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg11344533	chr11:111475393	SIK2	-0.49	-6.89	-0.35	2.86e-11	Primary sclerosing cholangitis;
LUSC	cis	rs113835537	0.529	rs79798028	chr11:66199362	T/G	cg24851651	chr11:66362959	CCS	0.54	8.29	0.41	2.71e-15	Airway imaging phenotypes;
LUSC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg23791538	chr6:167370224	RNASET2	-0.39	-6.07	-0.32	3.47e-9	Crohn's disease;
LUSC	cis	rs73200209	0.703	rs17498942	chr12:116686117	C/G	cg01776926	chr12:116560359	MED13L	-0.49	-5.98	-0.31	5.81e-9	Total body bone mineral density;
LUSC	cis	rs4144743	0.938	rs7225134	chr17:45326932	C/T	cg18085866	chr17:45331354	ITGB3	-0.75	-7.79	-0.39	8.26e-14	Body mass index;
LUSC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.48	0.46	4.78e-19	Prudent dietary pattern;
LUSC	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	9.93	0.48	1.56e-20	Lymphocyte counts;
LUSC	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.48	-0.69	4.87e-49	Exhaled nitric oxide output;
LUSC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg01973587	chr1:228161476	NA	0.34	5.97	0.31	6.03e-9	Diastolic blood pressure;
LUSC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg06060754	chr5:176797920	RGS14	-0.57	-9.05	-0.44	1.18e-17	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg23306229	chr2:178417860	TTC30B	0.53	6.1	0.32	2.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.46	-7.83	-0.39	6.55e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg22705602	chr4:152727874	NA	-0.3	-6.02	-0.31	4.55e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg08859206	chr1:53392774	SCP2	-0.41	-6.62	-0.34	1.42e-10	Monocyte count;
LUSC	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.87	0.66	1.16e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-9.18	-0.45	4.47e-18	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg22963979	chr7:1858916	MAD1L1	0.56	8.41	0.42	1.18e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.6	-0.43	3.16e-16	Total cholesterol levels;
LUSC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.81	14.62	0.62	9.49e-38	Blood protein levels;
LUSC	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg23649088	chr2:200775458	C2orf69	-0.47	-6.31	-0.33	8.98e-10	Schizophrenia;
LUSC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg11663144	chr21:46675770	NA	-0.38	-6.13	-0.32	2.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg24399712	chr22:39784796	NA	-0.41	-5.94	-0.31	6.97e-9	IgG glycosylation;
LUSC	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg23289794	chr7:2394357	EIF3B	-0.7	-9.6	-0.46	2.02e-19	Multiple sclerosis;
LUSC	cis	rs17253792	0.822	rs112374071	chr14:56061919	C/T	cg01858014	chr14:56050164	KTN1	-0.92	-7.5	-0.38	5.82e-13	Putamen volume;
LUSC	cis	rs9796	0.558	rs7166905	chr15:41514876	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.5	-8.88	-0.44	4.17e-17	Menopause (age at onset);
LUSC	trans	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg18187862	chr3:45730750	SACM1L	-0.55	-6.78	-0.35	5.52e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg03676636	chr4:99064102	C4orf37	0.36	7.7	0.39	1.5700000000000001e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2580764	0.566	rs2972072	chr2:55295370	G/T	cg09592903	chr2:55203963	RTN4	0.46	9.25	0.45	2.69e-18	Mean platelet volume;
LUSC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	0.62	13.31	0.59	1.01e-32	Prudent dietary pattern;
LUSC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-1.01	-14.23	-0.61	3.01e-36	Vitiligo;
LUSC	cis	rs950881	0.932	rs72823619	chr2:102924615	C/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.34	0.33	7.25e-10	Allergy;
LUSC	cis	rs9818941	0.824	rs4511848	chr3:157732021	A/C	cg08654915	chr3:157813417	NA	-0.31	-7.2	-0.37	4.1e-12	Height;
LUSC	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg09904177	chr6:26538194	HMGN4	0.75	14.34	0.62	1.18e-36	Intelligence (multi-trait analysis);
LUSC	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg27411982	chr8:10470053	RP1L1	0.41	6.32	0.33	8.43e-10	Neuroticism;
LUSC	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg10018233	chr7:150070692	REPIN1	0.46	9.44	0.46	6.86e-19	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.11e-11	Crohn's disease;
LUSC	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg15556689	chr8:8085844	FLJ10661	0.52	7.52	0.38	5.05e-13	Retinal vascular caliber;
LUSC	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg16586182	chr3:47516702	SCAP	-0.48	-7.64	-0.39	2.34e-13	Colorectal cancer;
LUSC	cis	rs870825	0.616	rs61539306	chr4:185650276	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	12.21	0.56	1.35e-28	Blood protein levels;
LUSC	cis	rs77633900	0.772	rs284903	chr15:76744813	G/A	cg21673338	chr15:77095150	SCAPER	-0.7	-6.03	-0.31	4.41e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg25258033	chr6:167368657	RNASET2	0.47	7.83	0.39	6.66e-14	Crohn's disease;
LUSC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg15440331	chr11:43380331	TTC17	0.45	6.25	0.32	1.22e-9	Triglyceride levels;
LUSC	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg24634471	chr8:143751801	JRK	0.5	7.13	0.36	6.36e-12	Schizophrenia;
LUSC	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg11502198	chr6:26597334	ABT1	0.62	9.65	0.47	1.34e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs240764	0.631	rs9386250	chr6:101204126	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.24	-0.32	1.32e-9	Neuroticism;
LUSC	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg11984989	chr7:158649758	WDR60	1.07	21.81	0.77	3.37e-66	Height;
LUSC	cis	rs7210086	0.948	rs17780256	chr17:70642923	A/C	cg04206342	chr17:70636940	NA	-0.37	-5.76	-0.3	1.86e-8	Ulcerative colitis;
LUSC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07677032	chr17:61819896	STRADA	0.52	8.79	0.43	7.84e-17	Prudent dietary pattern;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18679299	chr14:24664866	TM9SF1	0.44	6.01	0.31	4.88e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg25039879	chr17:56429692	SUPT4H1	0.7	9.16	0.45	5.34e-18	Cognitive test performance;
LUSC	cis	rs603424	0.551	rs525190	chr10:102087038	C/T	cg10365880	chr10:102089681	PKD2L1	-0.54	-6.88	-0.35	2.88e-11	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
LUSC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg03806693	chr22:41940476	POLR3H	-0.89	-12.81	-0.57	8.03e-31	Vitiligo;
LUSC	cis	rs17095355	1.000	rs61614979	chr10:111743994	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.56	-0.38	3.97e-13	Biliary atresia;
LUSC	cis	rs10744422	0.528	rs6489245	chr12:123360151	G/A	cg25930673	chr12:123319894	HIP1R	-0.63	-6.25	-0.32	1.28e-9	Schizophrenia;
LUSC	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.2	0.32	1.7e-9	Corneal astigmatism;
LUSC	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-1.18	-17.99	-0.7	4.68e-51	Blood pressure (smoking interaction);
LUSC	cis	rs2625529	0.824	rs35112434	chr15:72448326	G/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.42	-0.38	1.01e-12	Red blood cell count;
LUSC	cis	rs4631830	0.869	rs7896437	chr10:51529593	A/C	cg16070123	chr10:51489643	NA	-0.52	-8.08	-0.4	1.22e-14	Prostate-specific antigen levels;
LUSC	cis	rs7605827	0.930	rs2241237	chr2:15656157	A/T	cg19274914	chr2:15703543	NA	0.46	9.06	0.44	1.16e-17	Educational attainment (years of education);
LUSC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg16240275	chr20:61666158	NCRNA00029	0.42	9.26	0.45	2.55e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6545883	0.929	rs2421203	chr2:61669248	C/A	cg15711740	chr2:61764176	XPO1	-0.46	-7.2	-0.37	3.94e-12	Tuberculosis;
LUSC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg10664184	chr19:17420304	DDA1	0.47	6.13	0.32	2.53e-9	Systemic lupus erythematosus;
LUSC	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	10.26	0.49	1.23e-21	Psoriasis;
LUSC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.71	-12.31	-0.56	5.48e-29	Colorectal cancer;
LUSC	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.2	0.49	1.93e-21	Bladder cancer;
LUSC	trans	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg07393940	chr7:158741817	NA	-0.37	-6.58	-0.34	1.85e-10	Life satisfaction;
LUSC	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg03585969	chr10:35415529	CREM	0.62	9.07	0.44	1.04e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	trans	rs1147199	0.585	rs726433	chr9:87247336	C/T	cg18287975	chr5:88178977	MEF2C	-0.72	-6.29	-0.33	9.69e-10	Body mass index;
LUSC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.88	-0.35	3.05e-11	Lung cancer;
LUSC	trans	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg03929089	chr4:120376271	NA	0.64	6.03	0.31	4.42e-9	Axial length;
LUSC	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg08213375	chr14:104286397	PPP1R13B	0.54	10.89	0.51	7.59e-24	Schizophrenia;
LUSC	cis	rs2067615	0.560	rs2044304	chr12:107184363	T/G	cg15890332	chr12:107067104	RFX4	0.34	6.18	0.32	1.91e-9	Heart rate;
LUSC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	13.39	0.59	5.09e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08109568	chr15:31115862	NA	-0.74	-11.04	-0.52	2.25e-24	Huntington's disease progression;
LUSC	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	9.09	0.45	8.9e-18	Lung cancer in ever smokers;
LUSC	cis	rs5758511	0.773	rs62240997	chr22:42354567	T/G	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.98	-0.31	5.88e-9	Birth weight;
LUSC	cis	rs2387326	0.672	rs10829344	chr10:129944569	A/C	cg16087940	chr10:129947807	NA	-0.39	-6.0	-0.31	5.27e-9	Select biomarker traits;
LUSC	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg20908204	chr19:46285434	DMPK	-0.47	-8.82	-0.43	6.38e-17	Coronary artery disease;
LUSC	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg13319975	chr6:146136371	FBXO30	-0.4	-5.78	-0.3	1.72e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.5	8.1	0.41	1.04e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg21775007	chr8:11205619	TDH	0.43	6.13	0.32	2.46e-9	Mood instability;
LUSC	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg23093090	chr10:104574429	C10orf26	-0.37	-7.02	-0.36	1.23e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs5771242	0.518	rs5771258	chr22:50675648	C/A	cg08875078	chr22:50639485	SELO	0.46	5.94	0.31	7.04e-9	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LUSC	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.13e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7107174	0.901	rs2512525	chr11:77923019	T/C	cg02023728	chr11:77925099	USP35	0.52	6.93	0.35	2.15e-11	Testicular germ cell tumor;
LUSC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg12463550	chr7:65579703	CRCP	0.63	5.69	0.3	2.82e-8	Diabetic kidney disease;
LUSC	trans	rs61931739	0.583	rs1873010	chr12:33756375	T/C	cg26384229	chr12:38710491	ALG10B	0.43	6.24	0.32	1.31e-9	Morning vs. evening chronotype;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04210544	chr13:111806530	ARHGEF7	0.39	6.71	0.34	8.36e-11	Triglycerides;
LUSC	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg24631222	chr15:78858424	CHRNA5	0.83	11.54	0.53	3.73e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9612	1.000	rs347519	chr19:44273516	T/C	cg08581076	chr19:44259116	C19orf61	0.47	5.78	0.3	1.75e-8	Exhaled nitric oxide output;
LUSC	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg08000102	chr2:233561755	GIGYF2	-0.71	-11.76	-0.54	5.82e-27	Coronary artery disease;
LUSC	cis	rs12618769	0.520	rs4851135	chr2:99050705	T/A	cg10123293	chr2:99228465	UNC50	0.45	7.64	0.39	2.31e-13	Bipolar disorder;
LUSC	cis	rs1020064	0.895	rs2250659	chr2:105889684	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.65	8.65	0.43	2.25e-16	AIDS;
LUSC	cis	rs17407555	0.738	rs56143194	chr4:10067535	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.37	-0.33	6.3e-10	Schizophrenia (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13110711	chr17:27894392	ABHD15;TP53I13	-0.42	-6.21	-0.32	1.6e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.01	0.77	5.62e-67	Prudent dietary pattern;
LUSC	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg03676636	chr4:99064102	C4orf37	0.3	6.12	0.32	2.57e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4654899	1.000	rs7543126	chr1:21406088	T/G	cg01072550	chr1:21505969	NA	-0.51	-7.88	-0.4	4.75e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg05805236	chr11:65401703	PCNXL3	-0.63	-10.35	-0.49	5.99e-22	Acne (severe);
LUSC	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg08557956	chr11:4115526	RRM1	-0.42	-5.72	-0.3	2.34e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg03213289	chr20:61660250	NA	0.66	13.24	0.59	1.82e-32	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg21775007	chr8:11205619	TDH	-0.52	-7.37	-0.37	1.34e-12	Triglycerides;
LUSC	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg06885757	chr1:42089581	HIVEP3	0.48	10.38	0.49	4.7e-22	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-6.03	-0.31	4.24e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6460942	0.591	rs62451464	chr7:12363059	C/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.28	-0.33	1.02e-9	Coronary artery disease;
LUSC	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg22532475	chr10:104410764	TRIM8	-0.34	-7.4	-0.38	1.1e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.09	22.77	0.78	5.98e-70	Cognitive ability;
LUSC	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg21132104	chr15:45694354	SPATA5L1	0.4	5.68	0.3	2.87e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg11189052	chr15:85197271	WDR73	0.47	5.81	0.3	1.44e-8	Schizophrenia;
LUSC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-11.85	-0.54	2.69e-27	Hemoglobin concentration;
LUSC	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg26384229	chr12:38710491	ALG10B	0.5	7.09	0.36	7.95e-12	Morning vs. evening chronotype;
LUSC	cis	rs1355223	0.533	rs1597960	chr11:34726969	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.13	-0.32	2.55e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg10664184	chr19:17420304	DDA1	0.47	5.81	0.3	1.48e-8	Systemic lupus erythematosus;
LUSC	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg23992470	chr4:843637	GAK	0.6	6.41	0.33	5.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg15145296	chr3:125709740	NA	-0.59	-6.49	-0.33	3.19e-10	Blood pressure (smoking interaction);
LUSC	cis	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-6.76	-0.35	5.99e-11	Neuroticism;
LUSC	cis	rs6545883	0.868	rs7594191	chr2:61840018	A/G	cg15711740	chr2:61764176	XPO1	0.45	6.93	0.35	2.24e-11	Tuberculosis;
LUSC	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg00495681	chr13:53174319	NA	-0.46	-6.72	-0.35	7.95e-11	Lewy body disease;
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg06145435	chr7:1022769	CYP2W1	0.28	5.68	0.3	2.98e-8	Longevity;Endometriosis;
LUSC	cis	rs9807841	0.592	rs3810154	chr19:10764914	G/A	cg09936142	chr19:10668400	KRI1	-0.41	-6.68	-0.34	9.95e-11	Inflammatory skin disease;
LUSC	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	8.75	0.43	1.07e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.75	-12.55	-0.57	7.6e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg11845111	chr2:191398756	TMEM194B	-0.82	-10.91	-0.51	6.77e-24	Diastolic blood pressure;
LUSC	trans	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg03886242	chr7:26192032	NFE2L3	0.37	6.26	0.32	1.18e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.85	-11.68	-0.54	1.21e-26	Menarche (age at onset);
LUSC	cis	rs72634258	0.786	rs9434992	chr1:8179392	G/T	cg00042356	chr1:8021962	PARK7	0.54	6.59	0.34	1.72e-10	Inflammatory bowel disease;
LUSC	cis	rs1256061	0.603	rs10148269	chr14:64736924	A/G	cg21174375	chr14:64681225	SYNE2	0.35	6.26	0.32	1.18e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg22868518	chr11:507468	RNH1	-0.61	-5.97	-0.31	6.11e-9	Body mass index;
LUSC	cis	rs734999	0.869	rs1555791	chr1:2498862	G/C	cg18854424	chr1:2615690	NA	0.47	9.7	0.47	9.06e-20	Ulcerative colitis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22218058	chr3:32021831	OSBPL10;ZNF860	-0.45	-6.68	-0.34	1e-10	Hepatitis;
LUSC	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-1.13	-17.52	-0.69	3.44e-49	Exhaled nitric oxide output;
LUSC	cis	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.67	-0.34	1.04e-10	Cervical cancer;
LUSC	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg02176678	chr2:219576539	TTLL4	-0.58	-10.35	-0.49	5.77e-22	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg14458575	chr2:238380390	NA	0.78	8.81	0.43	7.09e-17	Prostate cancer;
LUSC	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg24558204	chr6:135376177	HBS1L	0.57	8.58	0.43	3.55e-16	Red blood cell count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12842013	chr14:23755227	HOMEZ	-0.44	-6.67	-0.34	1.04e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg19812747	chr11:111475976	SIK2	0.46	5.98	0.31	5.86e-9	Primary sclerosing cholangitis;
LUSC	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.38	-0.33	5.97e-10	Dupuytren's disease;
LUSC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg14668632	chr7:2872130	GNA12	-0.45	-6.31	-0.33	9.07e-10	Height;
LUSC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.0	-0.55	7.62e-28	Type 2 diabetes;
LUSC	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg05985134	chr18:33552581	C18orf21	-0.52	-7.24	-0.37	3.06e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs6500395	1.000	rs11640463	chr16:48644434	A/T	cg04672837	chr16:48644449	N4BP1	0.48	7.06	0.36	9.74e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12311346	chr5:56204834	C5orf35	0.74	12.28	0.56	7.38e-29	Initial pursuit acceleration;
LUSC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg06219351	chr7:158114137	PTPRN2	-0.53	-9.47	-0.46	5.14e-19	Calcium levels;
LUSC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg12463550	chr7:65579703	CRCP	0.41	5.93	0.31	7.36e-9	Aortic root size;
LUSC	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg02569458	chr12:86230093	RASSF9	0.47	7.52	0.38	5.13e-13	Major depressive disorder;
LUSC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg25258033	chr6:167368657	RNASET2	0.47	7.84	0.39	6.15e-14	Crohn's disease;
LUSC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	19.1	0.72	1.79e-55	Chronic sinus infection;
LUSC	trans	rs12705849	0.797	rs13230450	chr7:112754904	A/T	cg04564980	chr10:134974877	KNDC1	-0.35	-6.26	-0.32	1.18e-9	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg25214090	chr10:38739885	LOC399744	0.48	6.63	0.34	1.39e-10	Corneal astigmatism;
LUSC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg24154853	chr7:158122151	PTPRN2	0.45	8.87	0.44	4.48e-17	Calcium levels;
LUSC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg08601574	chr20:25228251	PYGB	-0.42	-6.5	-0.33	2.98e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.44	6.45	0.33	4.03e-10	Breast cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10577467	chr4:39183765	WDR19	0.39	5.97	0.31	6.18e-9	Triglycerides;
LUSC	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg06532163	chr17:45867833	NA	0.34	5.91	0.31	8.21e-9	IgG glycosylation;
LUSC	cis	rs10465746	0.905	rs12738214	chr1:84359050	C/A	cg10977910	chr1:84465055	TTLL7	0.42	5.99	0.31	5.39e-9	Obesity-related traits;
LUSC	cis	rs829883	0.573	rs73136486	chr12:98913727	T/A	cg25150519	chr12:98850993	NA	-0.63	-8.6	-0.43	3.08e-16	Colorectal adenoma (advanced);
LUSC	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg27219399	chr15:67835830	MAP2K5	0.37	5.76	0.3	1.9e-8	Restless legs syndrome;
LUSC	cis	rs7580658	0.895	rs62157549	chr2:128066007	A/G	cg09760422	chr2:128146352	NA	-0.29	-6.19	-0.32	1.76e-9	Protein C levels;
LUSC	cis	rs7528419	0.895	rs583104	chr1:109821307	G/T	cg00908766	chr1:109817496	CELSR2	0.64	10.05	0.48	6.39e-21	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUSC	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.55	-8.94	-0.44	2.71e-17	Post bronchodilator FEV1;
LUSC	trans	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg25174290	chr11:3078921	CARS	0.58	9.4	0.46	9.23e-19	Longevity;
LUSC	cis	rs7582180	0.845	rs7607676	chr2:100896966	G/A	cg08017756	chr2:100939284	LONRF2	-0.37	-6.18	-0.32	1.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.5	8.41	0.42	1.24e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg24558204	chr6:135376177	HBS1L	0.57	8.77	0.43	9.11e-17	Red blood cell count;
LUSC	cis	rs4363385	0.818	rs946096	chr1:153006529	T/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.43e-12	Inflammatory skin disease;
LUSC	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg08601574	chr20:25228251	PYGB	-0.44	-6.79	-0.35	5.29e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg01028140	chr2:1542097	TPO	-0.62	-8.38	-0.42	1.47e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	trans	rs10492201	0.529	rs4913269	chr12:68407845	C/G	cg21566642	chr2:233284661	NA	-0.38	-6.04	-0.31	4.05e-9	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-7.24	-0.37	3.11e-12	Mean platelet volume;
LUSC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg12564285	chr5:131593104	PDLIM4	0.32	5.7	0.3	2.68e-8	Blood metabolite levels;
LUSC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.45	-7.24	-0.37	3.05e-12	Blood metabolite levels;
LUSC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.43	-7.25	-0.37	2.9e-12	Alzheimer's disease (late onset);
LUSC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-0.88	-18.62	-0.71	1.43e-53	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg10167378	chr1:228756711	NA	-0.5	-7.01	-0.36	1.3e-11	Chronic lymphocytic leukemia;
LUSC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg23711669	chr6:146136114	FBXO30	0.87	15.63	0.65	1.03e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg07424592	chr7:64974309	NA	-0.4	-5.66	-0.3	3.23e-8	Calcium levels;
LUSC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg11645453	chr3:52864694	ITIH4	0.34	7.98	0.4	2.32e-14	Bipolar disorder;
LUSC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg00033643	chr7:134001901	SLC35B4	0.47	7.39	0.37	1.19e-12	Mean platelet volume;
LUSC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg06212747	chr3:49208901	KLHDC8B	0.44	5.96	0.31	6.46e-9	Parkinson's disease;
LUSC	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	6.8	0.35	4.84e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05901451	chr6:126070800	HEY2	0.57	8.55	0.42	4.43e-16	Endometrial cancer;
LUSC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.42	0.46	7.6e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg11586189	chr1:201857591	SHISA4	0.34	5.9	0.31	8.86e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg13683864	chr3:40499215	RPL14	-1.14	-21.28	-0.76	3.91e-64	Renal cell carcinoma;
LUSC	trans	rs6982636	1.000	rs2980869	chr8:126488250	C/T	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.33	-6.32	-0.33	8.36e-10	Lipid metabolism phenotypes;
LUSC	cis	rs12760731	0.668	rs12727134	chr1:178266794	T/C	cg00404053	chr1:178313656	RASAL2	0.49	5.92	0.31	7.85e-9	Obesity-related traits;
LUSC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg09034736	chr1:150693464	HORMAD1	-0.4	-5.69	-0.3	2.81e-8	Urate levels;
LUSC	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-7.45	-0.38	8.2e-13	Parkinson's disease;
LUSC	cis	rs259282	0.605	rs73028624	chr19:33111758	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.68	10.08	0.48	4.82e-21	Schizophrenia;
LUSC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08677398	chr8:58056175	NA	0.52	6.4	0.33	5.13e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.44	6.76	0.35	6.09e-11	Longevity;Endometriosis;
LUSC	cis	rs354225	0.584	rs17046097	chr2:54888075	A/G	cg26097391	chr2:54893211	SPTBN1	-0.44	-6.83	-0.35	4.03e-11	Schizophrenia;
LUSC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg05872129	chr22:39784769	NA	-0.57	-9.51	-0.46	3.85e-19	Post bronchodilator FEV1;
LUSC	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg13010199	chr12:38710504	ALG10B	0.55	8.36	0.42	1.74e-15	Morning vs. evening chronotype;
LUSC	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg11130432	chr3:121712080	ILDR1	-0.68	-10.36	-0.49	5.34e-22	Multiple sclerosis;
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.58	9.66	0.47	1.29e-19	Lymphocyte counts;
LUSC	cis	rs9815354	0.812	rs73077359	chr3:41850016	G/A	cg03022575	chr3:42003672	ULK4	0.86	8.66	0.43	2.07e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg18755752	chr8:142205143	DENND3	-0.54	-8.68	-0.43	1.72e-16	Immature fraction of reticulocytes;
LUSC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg24733560	chr20:60626293	TAF4	0.41	6.73	0.35	7.47e-11	Body mass index;
LUSC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.84	-0.3	1.23e-8	Tonsillectomy;
LUSC	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg05468064	chr22:46423449	NA	0.41	6.88	0.35	2.92e-11	Dupuytren's disease;
LUSC	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg10792982	chr14:105748885	BRF1	0.46	8.16	0.41	6.69e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.56	-9.21	-0.45	3.76e-18	Breast cancer;
LUSC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg25767906	chr1:53392781	SCP2	-0.36	-6.35	-0.33	7.15e-10	Monocyte count;
LUSC	trans	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg18187862	chr3:45730750	SACM1L	0.54	7.07	0.36	8.98e-12	Primary sclerosing cholangitis;
LUSC	cis	rs7075426	0.905	rs11202038	chr10:88204877	C/T	cg07322936	chr10:88137208	NA	0.54	8.22	0.41	4.65e-15	Migraine without aura;
LUSC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.19e-30	Aortic root size;
LUSC	cis	rs10908458	0.584	rs10908455	chr1:155067283	C/T	cg23973274	chr1:155060172	NA	0.32	6.39	0.33	5.65e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4704187	0.687	rs12653162	chr5:74391666	C/T	cg03227963	chr5:74354835	NA	0.32	6.82	0.35	4.21e-11	Response to amphetamines;
LUSC	cis	rs4948275	0.550	rs7904815	chr10:63136612	G/A	cg26296364	chr10:63212206	TMEM26	-0.35	-5.67	-0.3	3.09e-8	Night sleep phenotypes;
LUSC	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg13852791	chr20:30311386	BCL2L1	0.86	12.03	0.55	6.28e-28	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19748678	chr4:122722346	EXOSC9	-0.49	-7.29	-0.37	2.27e-12	Type 2 diabetes;
LUSC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg08968635	chr6:28129556	ZNF389	0.45	5.78	0.3	1.73e-8	Parkinson's disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25937148	chr3:43147320	C3orf39	-0.37	-6.49	-0.33	3.04e-10	Electrocardiographic conduction measures;
LUSC	cis	rs548987	0.529	rs1165164	chr6:25863481	G/A	cg03517284	chr6:25882590	NA	-0.39	-5.79	-0.3	1.58e-8	Homocysteine levels;
LUSC	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg05373962	chr22:49881684	NA	-0.39	-8.37	-0.42	1.58e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11864453	0.616	rs9938025	chr16:72022041	A/G	cg01557791	chr16:72042693	DHODH	0.45	5.94	0.31	7.05e-9	Fibrinogen levels;
LUSC	cis	rs7577851	0.625	rs12473304	chr2:69558112	C/T	cg10773587	chr2:69614142	GFPT1	0.59	6.41	0.33	5.08e-10	Parkinson's disease (age of onset);
LUSC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.68	-10.32	-0.49	7.46e-22	Monocyte percentage of white cells;
LUSC	cis	rs6987853	0.686	rs55837592	chr8:42359974	T/C	cg09913449	chr8:42400586	C8orf40	-0.44	-7.4	-0.38	1.13e-12	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	9.06	0.44	1.11e-17	Prudent dietary pattern;
LUSC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-11.88	-0.54	2.19e-27	Body mass index;
LUSC	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	11.55	0.53	3.55e-26	Ileal carcinoids;
LUSC	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.7	-11.27	-0.52	3.39e-25	Sudden cardiac arrest;
LUSC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg06238570	chr21:40685208	BRWD1	0.46	7.1	0.36	7.38e-12	Cognitive function;
LUSC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.4	-7.44	-0.38	8.48e-13	Longevity;Endometriosis;
LUSC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg07959070	chr22:50026188	C22orf34	-0.34	-6.92	-0.35	2.34e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4141404	0.818	rs6518737	chr22:31582662	A/G	cg22777020	chr22:31556080	RNF185	-0.47	-6.82	-0.35	4.36e-11	Paclitaxel-induced neuropathy;
LUSC	trans	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg05340658	chr4:99064831	C4orf37	0.65	10.82	0.51	1.34e-23	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs62238980	0.614	rs17682385	chr22:32387572	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5.04e-9	Childhood ear infection;
LUSC	cis	rs1322512	0.713	rs1028650	chr6:152938025	G/T	cg27316956	chr6:152958899	SYNE1	-0.36	-5.94	-0.31	7.06e-9	Tonometry;
LUSC	cis	rs4343996	0.747	rs1403158	chr7:3464896	A/G	cg21248987	chr7:3385318	SDK1	0.34	5.73	0.3	2.27e-8	Motion sickness;
LUSC	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg06606381	chr12:133084897	FBRSL1	-0.95	-8.61	-0.43	2.88e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	9.22	0.45	3.5e-18	Mood instability;
LUSC	cis	rs11997175	0.603	rs12234894	chr8:33699275	G/C	ch.8.33884649F	chr8:33765107	NA	0.45	6.65	0.34	1.2e-10	Body mass index;
LUSC	cis	rs5009270	0.512	rs75795332	chr7:112241690	G/A	cg23628563	chr7:112262597	NA	0.43	5.93	0.31	7.36e-9	Osteoarthritis (hip);
LUSC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg24675658	chr1:53192096	ZYG11B	0.58	9.15	0.45	5.79e-18	Monocyte count;
LUSC	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg21775007	chr8:11205619	TDH	-0.65	-10.26	-0.49	1.22e-21	Retinal vascular caliber;
LUSC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.23	0.56	1.14e-28	Prudent dietary pattern;
LUSC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	1.05	20.03	0.74	3.41e-59	Menopause (age at onset);
LUSC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg11608241	chr8:8085544	FLJ10661	0.39	5.64	0.3	3.55e-8	Joint mobility (Beighton score);
LUSC	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07636037	chr3:49044803	WDR6	0.68	8.94	0.44	2.74e-17	Menarche (age at onset);
LUSC	cis	rs10193935	0.901	rs72798529	chr2:42537471	C/T	cg27598129	chr2:42591480	NA	-0.6	-8.17	-0.41	6.36e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6686643	0.868	rs9333461	chr1:165618320	G/T	cg16553119	chr1:165599451	MGST3	-0.49	-7.65	-0.39	2.18e-13	Total ventricular volume;
LUSC	cis	rs7000551	0.505	rs13258195	chr8:22227271	A/G	cg12081754	chr8:22256438	SLC39A14	-0.87	-13.49	-0.59	2.12e-33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg09594475	chr20:60884601	LAMA5	0.4	6.11	0.32	2.7e-9	Pelvic organ prolapse;
LUSC	cis	rs7605827	0.930	rs10929372	chr2:15662434	A/G	cg19274914	chr2:15703543	NA	0.48	9.3	0.45	1.82e-18	Educational attainment (years of education);
LUSC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	0.9	15.72	0.65	4.75e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	trans	rs7572263	0.652	rs34575089	chr2:209047368	G/A	cg21778348	chr7:27194614	HOXA7	-0.44	-6.07	-0.32	3.52e-9	Glioma;Non-glioblastoma glioma;
LUSC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg11645453	chr3:52864694	ITIH4	0.35	8.21	0.41	4.87e-15	Bipolar disorder;
LUSC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg01802117	chr1:53393560	SCP2	-0.39	-6.54	-0.34	2.27e-10	Monocyte count;
LUSC	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg11608241	chr8:8085544	FLJ10661	0.4	5.78	0.3	1.69e-8	Mood instability;
LUSC	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg04998671	chr14:104000505	TRMT61A	-0.43	-6.32	-0.33	8.34e-10	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.6	8.69	0.43	1.65e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg20476274	chr7:133979776	SLC35B4	-0.81	-14.42	-0.62	5.37e-37	Mean platelet volume;
LUSC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.7	13.01	0.58	1.41e-31	Height;
LUSC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.9	11.61	0.54	2.01e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs6601327	0.641	rs11780399	chr8:9589167	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.43	-0.33	4.36e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs6977660	1.000	rs10279601	chr7:19822171	G/A	cg05791153	chr7:19748676	TWISTNB	0.53	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LUSC	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg05714579	chr10:131428358	MGMT	-0.48	-7.03	-0.36	1.18e-11	Response to temozolomide;
LUSC	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.57	-9.21	-0.45	3.73e-18	Body mass index;
LUSC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg06046430	chr4:77819534	ANKRD56	0.47	6.83	0.35	4.03e-11	Emphysema distribution in smoking;
LUSC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	0.94	13.75	0.6	2.15e-34	Vitiligo;
LUSC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg07274523	chr3:49395745	GPX1	0.63	10.42	0.5	3.38e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg12552261	chr5:112820674	MCC	0.45	7.0	0.36	1.37e-11	Type 2 diabetes;
LUSC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg12292205	chr6:26970375	C6orf41	0.51	8.56	0.42	4.11e-16	Schizophrenia;
LUSC	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg14769373	chr6:40998127	UNC5CL	-0.55	-7.99	-0.4	2.15e-14	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg18512352	chr11:47633146	NA	0.48	9.97	0.48	1.11e-20	Subjective well-being;
LUSC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg24209194	chr3:40518798	ZNF619	0.43	5.85	0.3	1.2e-8	Renal cell carcinoma;
LUSC	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg00376283	chr12:123451042	ABCB9	-0.65	-8.34	-0.42	1.97e-15	Neutrophil percentage of white cells;
LUSC	cis	rs12190007	0.547	rs3006178	chr6:169823936	G/A	ch.6.169577133F	chr6:169835210	NA	-0.38	-5.74	-0.3	2.15e-8	Obesity-related traits;
LUSC	trans	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04565464	chr8:145669602	NFKBIL2	-0.42	-7.09	-0.36	8.11e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.66	-0.34	1.1e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6076065	0.594	rs6048755	chr20:23337233	A/G	cg11657817	chr20:23433608	CST11	0.55	11.08	0.52	1.66e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs250677	0.522	rs4705301	chr5:148354902	C/G	cg12140854	chr5:148520817	ABLIM3	-0.38	-6.02	-0.31	4.68e-9	Breast cancer;
LUSC	cis	rs7911264	0.967	rs2497318	chr10:94432000	C/T	cg25093409	chr10:94429542	NA	-0.39	-6.52	-0.34	2.6e-10	Inflammatory bowel disease;
LUSC	cis	rs11018904	0.906	rs12793836	chr11:89953493	C/T	cg26834418	chr11:89957033	CHORDC1	-0.5	-6.24	-0.32	1.34e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg13010199	chr12:38710504	ALG10B	0.47	7.19	0.37	4.25e-12	Morning vs. evening chronotype;
LUSC	trans	rs3857536	0.813	rs9354404	chr6:66948408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs7402982	0.934	rs8028620	chr15:99202875	C/T	cg03437748	chr15:99193247	IGF1R	0.54	8.54	0.42	4.81e-16	Birth weight;
LUSC	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg00310523	chr12:86230176	RASSF9	0.38	6.96	0.36	1.79e-11	Major depressive disorder;
LUSC	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.28	-0.37	2.48e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg09904177	chr6:26538194	HMGN4	0.7	6.79	0.35	5.28e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg13047869	chr3:10149882	C3orf24	-0.6	-8.76	-0.43	9.71e-17	Alzheimer's disease;
LUSC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	13.21	0.59	2.51e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.64	-8.37	-0.42	1.56e-15	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg05313129	chr8:58192883	C8orf71	-0.51	-5.75	-0.3	1.99e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg13395646	chr4:1353034	KIAA1530	0.49	6.93	0.35	2.14e-11	Obesity-related traits;
LUSC	cis	rs7560272	0.588	rs4852965	chr2:73911169	T/C	cg20560298	chr2:73613845	ALMS1	0.42	6.41	0.33	4.85e-10	Schizophrenia;
LUSC	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg05868516	chr6:26286170	HIST1H4H	0.36	6.02	0.31	4.5e-9	Educational attainment;
LUSC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg19592336	chr6:28129416	ZNF389	0.5	6.57	0.34	1.94e-10	Parkinson's disease;
LUSC	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg01503450	chr10:980765	NA	-0.41	-5.81	-0.3	1.45e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.72	10.08	0.48	4.9e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs3849570	0.643	rs10779986	chr3:81970818	C/G	cg07356753	chr3:81810745	GBE1	0.55	8.33	0.41	2.06e-15	Waist circumference;Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02263479	chr16:2097837	NTHL1;TSC2	-0.41	-6.15	-0.32	2.26e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg17264618	chr3:40429014	ENTPD3	-0.34	-7.34	-0.37	1.6e-12	Renal cell carcinoma;
LUSC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.63	-14.32	-0.62	1.37e-36	Prostate cancer;
LUSC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg00343986	chr7:65444356	GUSB	-0.42	-6.33	-0.33	8.09e-10	Aortic root size;
LUSC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg13010199	chr12:38710504	ALG10B	0.69	11.51	0.53	4.95e-26	Heart rate;
LUSC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.8	-14.56	-0.62	1.51e-37	Longevity;
LUSC	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg21699342	chr2:239360505	ASB1	0.55	10.09	0.48	4.41e-21	Multiple system atrophy;
LUSC	cis	rs829883	0.932	rs249840	chr12:98871993	T/C	cg25150519	chr12:98850993	NA	0.65	10.19	0.49	2.13e-21	Colorectal adenoma (advanced);
LUSC	cis	rs397969	0.596	rs17605101	chr17:19877634	T/C	cg13482628	chr17:19912719	NA	0.47	5.82	0.3	1.35e-8	Platelet count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11950805	chr1:43824379	CDC20	-0.4	-6.14	-0.32	2.31e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg05472934	chr7:22766657	IL6	0.53	8.22	0.41	4.5e-15	Lung cancer;
LUSC	cis	rs67696533	0.600	rs4911237	chr20:31122344	C/T	cg13636640	chr20:31349939	DNMT3B	0.48	6.49	0.33	3.12e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-0.92	-13.56	-0.6	1.09e-33	Initial pursuit acceleration;
LUSC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.98	0.44	2.08e-17	Motion sickness;
LUSC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.72e-10	Crohn's disease;
LUSC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.88	0.31	9.69e-9	Menopause (age at onset);
LUSC	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg03342759	chr3:160939853	NMD3	-0.5	-8.32	-0.41	2.19e-15	Morning vs. evening chronotype;
LUSC	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg03929089	chr4:120376271	NA	0.66	6.16	0.32	2.06e-9	Axial length;
LUSC	cis	rs10186029	0.509	rs13426230	chr2:213940447	G/A	cg08319019	chr2:214017104	IKZF2	-0.42	-6.12	-0.32	2.64e-9	Systemic sclerosis;
LUSC	trans	rs11723530	0.538	rs7670130	chr4:170812566	C/T	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.16	-0.32	2.13e-9	Myopia (pathological);
LUSC	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg02176678	chr2:219576539	TTLL4	0.61	10.98	0.51	3.82e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg10518572	chr11:65560635	OVOL1	-0.26	-6.01	-0.31	4.88e-9	Acne (severe);
LUSC	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg16070123	chr10:51489643	NA	-0.51	-8.04	-0.4	1.58e-14	Prostate-specific antigen levels;
LUSC	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg02466173	chr16:30829666	NA	-0.53	-10.36	-0.49	5.3e-22	Dementia with Lewy bodies;
LUSC	cis	rs10911363	0.592	rs2702182	chr1:183516440	C/T	cg09173681	chr1:183549694	NCF2	0.6	10.57	0.5	9.95e-23	Systemic lupus erythematosus;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14704079	chr4:140222620	NAA15	-0.42	-6.09	-0.32	3.19e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg01657329	chr11:68192670	LRP5	-0.44	-6.59	-0.34	1.73e-10	Total body bone mineral density;
LUSC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	0.6	9.46	0.46	5.9e-19	Breast cancer;
LUSC	cis	rs6460942	0.556	rs10228123	chr7:12374025	A/C	cg06484146	chr7:12443880	VWDE	-0.5	-6.12	-0.32	2.62e-9	Coronary artery disease;
LUSC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg14552801	chr7:65878734	NA	-0.46	-6.54	-0.34	2.31e-10	Aortic root size;
LUSC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24549020	chr5:56110836	MAP3K1	0.49	5.67	0.3	3.12e-8	Initial pursuit acceleration;
LUSC	cis	rs11018904	0.817	rs11606060	chr11:89928597	T/C	cg26138821	chr11:89956704	CHORDC1	-0.6	-6.87	-0.35	3.24e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06850241	chr22:41845214	NA	-0.31	-5.71	-0.3	2.44e-8	Vitiligo;
LUSC	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg11189052	chr15:85197271	WDR73	0.47	5.83	0.3	1.28e-8	Schizophrenia;
LUSC	cis	rs4654899	1.000	rs6426669	chr1:21430584	C/A	cg01072550	chr1:21505969	NA	-0.51	-7.8	-0.39	7.8e-14	Superior frontal gyrus grey matter volume;
LUSC	trans	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.09	0.48	4.47e-21	Mean corpuscular volume;
LUSC	cis	rs7903847	0.673	rs61861870	chr10:99154339	G/T	cg20016023	chr10:99160130	RRP12	-0.28	-6.03	-0.31	4.26e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.91	12.42	0.56	2.22e-29	Mean corpuscular hemoglobin;
LUSC	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg22676075	chr6:135203613	NA	0.57	9.06	0.44	1.1e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-7.14	-0.36	5.69e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-9.14	-0.45	6.19e-18	Morning vs. evening chronotype;
LUSC	cis	rs8048589	0.615	rs34147612	chr16:12233188	G/A	cg02910054	chr16:12241554	SNX29	0.51	6.18	0.32	1.91e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs12545109	0.800	rs1913278	chr8:57403725	T/C	cg09654669	chr8:57350985	NA	-0.5	-6.48	-0.33	3.29e-10	Obesity-related traits;
LUSC	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg04117972	chr1:227635322	NA	0.6	6.78	0.35	5.48e-11	Major depressive disorder;
LUSC	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.61	-5.72	-0.3	2.43e-8	Narcolepsy;
LUSC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.81	-0.39	7.23e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-8.04	-0.4	1.55e-14	Lymphocyte counts;
LUSC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg10755058	chr3:40428713	ENTPD3	0.36	5.97	0.31	5.99e-9	Renal cell carcinoma;
LUSC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg08270630	chr22:50330655	NA	-0.43	-6.58	-0.34	1.8e-10	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg25036284	chr2:26402008	FAM59B	-0.69	-9.6	-0.47	1.93e-19	Gut microbiome composition (summer);
LUSC	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.55	8.69	0.43	1.65e-16	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs13315871	0.929	rs76226186	chr3:58318499	C/T	cg20936604	chr3:58311152	NA	-0.77	-7.1	-0.36	7.59e-12	Cholesterol, total;
LUSC	cis	rs1595825	1.000	rs73058829	chr2:198871145	G/A	cg00982548	chr2:198649783	BOLL	-0.49	-6.15	-0.32	2.15e-9	Ulcerative colitis;
LUSC	cis	rs7923609	0.811	rs7899657	chr10:65323265	G/A	cg01631684	chr10:65280961	REEP3	0.4	5.85	0.3	1.19e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg24558204	chr6:135376177	HBS1L	-0.46	-6.63	-0.34	1.34e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.65	-10.14	-0.49	3.06e-21	Menarche (age at onset);
LUSC	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.72	-13.34	-0.59	7.96e-33	Ulcerative colitis;
LUSC	cis	rs1499972	0.941	rs62263120	chr3:117630253	A/G	cg07612923	chr3:117604196	NA	0.64	5.76	0.3	1.95e-8	Schizophrenia;
LUSC	cis	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg21775007	chr8:11205619	TDH	0.53	7.51	0.38	5.6e-13	Monocyte count;
LUSC	cis	rs7903847	0.642	rs10882910	chr10:99138043	G/A	cg20016023	chr10:99160130	RRP12	-0.34	-8.25	-0.41	3.65e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg10326726	chr10:51549505	MSMB	-0.37	-6.42	-0.33	4.7e-10	Prostate-specific antigen levels;
LUSC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.7	0.3	2.6e-8	Self-reported allergy;
LUSC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg17173187	chr15:85201210	NMB	0.36	6.45	0.33	3.83e-10	Schizophrenia;
LUSC	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg17691542	chr6:26056736	HIST1H1C	0.4	6.03	0.31	4.38e-9	Schizophrenia;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg01517273	chr1:154599968	ADAR	0.48	6.36	0.33	6.48e-10	Cognitive function;Information processing speed;
LUSC	cis	rs4663866	1.000	rs4663868	chr2:239161091	C/T	cg16914508	chr2:239161102	PER2	0.68	7.14	0.36	5.87e-12	Irritable bowel syndrome;
LUSC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	5.89	0.31	9.6e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.24	-0.32	1.35e-9	Neutrophil percentage of white cells;
LUSC	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg11887960	chr12:57824829	NA	0.54	6.63	0.34	1.32e-10	Obesity-related traits;
LUSC	cis	rs11018904	0.906	rs35129016	chr11:89948689	T/C	cg26834418	chr11:89957033	CHORDC1	-0.53	-6.37	-0.33	6.08e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.64	-0.39	2.38e-13	Joint mobility (Beighton score);
LUSC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg11645453	chr3:52864694	ITIH4	0.34	7.68	0.39	1.76e-13	Bipolar disorder;
LUSC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.66	11.13	0.52	1.13e-24	Bone mineral density;
LUSC	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.67	0.54	1.25e-26	Ileal carcinoids;
LUSC	cis	rs7712401	0.584	rs4836382	chr5:122376641	G/A	cg19077854	chr5:122220652	SNX24	0.36	7.28	0.37	2.35e-12	Mean platelet volume;
LUSC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.59	7.8	0.39	7.87e-14	Response to diuretic therapy;
LUSC	cis	rs6696846	0.630	rs11240373	chr1:205135600	A/C	cg21643547	chr1:205240462	TMCC2	-0.39	-6.77	-0.35	5.96e-11	Red blood cell count;
LUSC	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03878208	chr11:72483293	STARD10	0.58	7.76	0.39	1.07e-13	Type 2 diabetes;
LUSC	trans	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.47	-7.03	-0.36	1.16e-11	Endometrial cancer;
LUSC	cis	rs593982	0.920	rs521678	chr11:65485727	T/G	cg08755490	chr11:65554678	OVOL1	1.5	13.22	0.59	2.31e-32	Atopic dermatitis;
LUSC	cis	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.69	-0.39	1.71e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg08854313	chr1:11322531	MTOR	0.86	14.27	0.62	2.14e-36	Body mass index;
LUSC	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg23942311	chr14:51606299	NA	0.49	10.96	0.51	4.45e-24	Cancer;
LUSC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs41271473	1.000	rs6665334	chr1:228868574	A/C	cg10167378	chr1:228756711	NA	0.55	6.58	0.34	1.84e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg02569458	chr12:86230093	RASSF9	0.59	9.96	0.48	1.28e-20	Major depressive disorder;
LUSC	cis	rs1160297	0.576	rs1376569	chr2:53087260	C/T	cg07782112	chr2:53107842	NA	0.4	6.5	0.34	2.87e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	1.05	18.99	0.72	4.92e-55	Parkinson's disease;
LUSC	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg01689657	chr7:91764605	CYP51A1	0.31	5.67	0.3	3.11e-8	Breast cancer;
LUSC	cis	rs7072216	0.652	rs11189600	chr10:100179274	A/G	cg26618903	chr10:100175079	PYROXD2	0.31	6.01	0.31	4.77e-9	Metabolite levels;
LUSC	cis	rs9395066	0.509	rs11967188	chr6:44956925	C/T	cg25276700	chr6:44698697	NA	0.28	5.8	0.3	1.55e-8	Height;
LUSC	cis	rs4889855	0.614	rs7221663	chr17:78484166	T/C	cg00066239	chr17:78472159	NA	-0.43	-7.23	-0.37	3.4e-12	Fractional excretion of uric acid;
LUSC	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg04450456	chr4:17643702	FAM184B	0.36	6.07	0.32	3.5e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg15839431	chr19:19639596	YJEFN3	-0.62	-6.32	-0.33	8.31e-10	Bipolar disorder;
LUSC	cis	rs57481061	1	rs57481061	chr12:90019178	C/G	cg00757033	chr12:89920650	WDR51B	0.51	6.73	0.35	7.41e-11	Coronary artery disease;
LUSC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	16.98	0.68	4.78e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1953600	0.668	rs7091565	chr10:81913561	A/G	cg00277334	chr10:82204260	NA	-0.39	-5.96	-0.31	6.55e-9	Sarcoidosis;
LUSC	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg10523679	chr1:76189770	ACADM	0.66	9.12	0.45	6.95e-18	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01439340	chr17:79369256	NA	-0.43	-6.35	-0.33	6.92e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7727544	0.557	rs715285	chr5:131485383	A/G	cg14196790	chr5:131705035	SLC22A5	0.44	7.58	0.38	3.49e-13	Blood metabolite levels;
LUSC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14893161	chr1:205819251	PM20D1	0.86	15.8	0.65	2.15e-42	Menarche (age at onset);
LUSC	cis	rs9341808	0.754	rs9343973	chr6:80913216	A/G	cg08355045	chr6:80787529	NA	0.58	10.2	0.49	1.97e-21	Sitting height ratio;
LUSC	cis	rs4356932	0.967	rs6835736	chr4:76962494	A/T	cg00809888	chr4:76862425	NAAA	0.36	6.12	0.32	2.68e-9	Blood protein levels;
LUSC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg00339695	chr16:24857497	SLC5A11	0.41	7.1	0.36	7.74e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs509477	0.662	rs273343	chr18:32604173	G/C	cg23791764	chr18:32556832	MAPRE2	0.39	5.65	0.3	3.42e-8	Cerebrospinal fluid AB1-42 levels;
LUSC	trans	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.0	-0.31	5.09e-9	Monocyte count;
LUSC	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg06360820	chr2:242988706	NA	-1.06	-10.79	-0.51	1.68e-23	Obesity-related traits;
LUSC	cis	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg20307385	chr11:47447363	PSMC3	0.5	5.81	0.3	1.49e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs897080	0.552	rs1067383	chr2:44645911	C/T	cg00619915	chr2:44497795	NA	-0.4	-5.83	-0.3	1.3e-8	Height;
LUSC	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.6	11.27	0.52	3.59e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs7584330	0.554	rs74001386	chr2:238425333	T/A	cg16989719	chr2:238392110	NA	-0.43	-6.15	-0.32	2.25e-9	Prostate cancer;
LUSC	trans	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg14791747	chr16:20752902	THUMPD1	-0.72	-9.74	-0.47	6.82e-20	Cognitive test performance;
LUSC	cis	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg00806126	chr19:22604979	ZNF98	0.37	5.98	0.31	5.78e-9	Pain;
LUSC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.79	14.9	0.63	7.27e-39	Dental caries;
LUSC	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg24006582	chr15:45444508	DUOX1	-0.61	-8.95	-0.44	2.5e-17	Uric acid levels;
LUSC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs57590327	0.555	rs6767749	chr3:81725513	G/A	cg07356753	chr3:81810745	GBE1	-0.67	-10.42	-0.5	3.49e-22	Extraversion;
LUSC	cis	rs2235649	0.663	rs6600167	chr16:1848912	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-5.92	-0.31	7.81e-9	Blood metabolite levels;
LUSC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg00012203	chr2:219082015	ARPC2	-0.7	-11.41	-0.53	1.08e-25	Colorectal cancer;
LUSC	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg05673287	chr15:77411982	SGK269	-0.44	-6.97	-0.36	1.7e-11	Type 2 diabetes;
LUSC	cis	rs977987	0.843	rs67409275	chr16:75457212	T/C	cg04384234	chr16:75411784	CFDP1	-0.45	-7.41	-0.38	1.07e-12	Dupuytren's disease;
LUSC	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg23625390	chr15:77176239	SCAPER	0.64	9.54	0.46	3.23e-19	Blood metabolite levels;
LUSC	cis	rs4144743	1.000	rs7218524	chr17:45326565	A/G	cg18085866	chr17:45331354	ITGB3	-0.75	-7.79	-0.39	8.26e-14	Body mass index;
LUSC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	10.64	0.5	5.72e-23	Homoarginine levels;
LUSC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg09367891	chr1:107599246	PRMT6	-0.48	-7.73	-0.39	1.27e-13	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg24375607	chr4:120327624	NA	0.71	11.07	0.52	1.74e-24	Corneal astigmatism;
LUSC	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg02023728	chr11:77925099	USP35	0.42	6.34	0.33	7.44e-10	Testicular germ cell tumor;
LUSC	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg01191920	chr7:158217561	PTPRN2	-0.52	-10.81	-0.51	1.5e-23	Obesity-related traits;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.86	-14.05	-0.61	1.5e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2667011	0.697	rs7584941	chr2:160831263	A/G	cg06573604	chr2:160760825	LY75	-0.5	-6.24	-0.32	1.3e-9	Bilirubin levels;
LUSC	cis	rs9811920	0.809	rs1387647	chr3:99826942	T/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	6.63	0.34	1.35e-10	Axial length;
LUSC	cis	rs57590327	0.503	rs9880844	chr3:81507217	C/T	cg07356753	chr3:81810745	GBE1	0.46	6.07	0.32	3.47e-9	Extraversion;
LUSC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg25767906	chr1:53392781	SCP2	0.53	9.75	0.47	6.33e-20	Monocyte count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14162034	chr15:78112026	NA	-0.48	-6.29	-0.33	1.01e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg16230307	chr14:35515116	FAM177A1	0.78	10.0	0.48	8.96e-21	Psoriasis;
LUSC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg03538708	chr1:25844672	NA	-0.39	-6.36	-0.33	6.76e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg16624210	chr5:671434	TPPP	0.49	6.25	0.32	1.23e-9	Obesity-related traits;
LUSC	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg04733989	chr22:42467013	NAGA	0.39	6.29	0.33	1e-9	Cognitive function;
LUSC	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg06532163	chr17:45867833	NA	0.34	6.41	0.33	4.93e-10	IgG glycosylation;
LUSC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.68	-11.35	-0.53	1.8e-25	Prudent dietary pattern;
LUSC	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	0.6	9.63	0.47	1.55e-19	Breast cancer;
LUSC	cis	rs714027	0.837	rs713875	chr22:30592487	C/G	cg11564601	chr22:30592435	NA	-0.41	-7.61	-0.38	2.85e-13	Lymphocyte counts;
LUSC	trans	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg06521331	chr12:34319734	NA	0.4	6.28	0.32	1.05e-9	Bladder cancer;
LUSC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-1.06	-15.03	-0.64	2.29e-39	Vitiligo;
LUSC	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg13072238	chr3:49761600	GMPPB	-0.64	-8.14	-0.41	8.05e-15	Menarche (age at onset);
LUSC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.67	-8.68	-0.43	1.83e-16	Schizophrenia;
LUSC	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg00540400	chr15:79124168	NA	-0.47	-7.97	-0.4	2.46e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg09904177	chr6:26538194	HMGN4	0.66	11.71	0.54	8.69e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-10.3	-0.49	8.75e-22	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.69	-8.87	-0.44	4.43e-17	Huntington's disease progression;
LUSC	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg05110241	chr16:68378359	PRMT7	-0.43	-5.69	-0.3	2.79e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.26	0.32	1.19e-9	Mean platelet volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17861791	chr1:113162073	ST7L;CAPZA1	0.42	6.29	0.33	1.01e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.03	-0.44	1.45e-17	Total cholesterol levels;
LUSC	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.66	-0.34	1.14e-10	Reticulocyte count;
LUSC	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg11019008	chr10:131425282	MGMT	0.4	5.86	0.31	1.11e-8	Response to temozolomide;
LUSC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg24829409	chr8:58192753	C8orf71	-0.62	-6.43	-0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.05	0.74	3.05e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg08999081	chr20:33150536	PIGU	-0.41	-7.58	-0.38	3.34e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg00757033	chr12:89920650	WDR51B	0.6	10.47	0.5	2.28e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg19773385	chr1:10388646	KIF1B	-0.54	-8.42	-0.42	1.11e-15	Hepatocellular carcinoma;
LUSC	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg23093090	chr10:104574429	C10orf26	-0.37	-6.82	-0.35	4.16e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg18305652	chr10:134549665	INPP5A	0.46	6.63	0.34	1.35e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.24	0.52	4.44e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg04546413	chr19:29218101	NA	0.71	11.45	0.53	7.79e-26	Methadone dose in opioid dependence;
LUSC	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg14092571	chr14:90743983	NA	-0.36	-5.82	-0.3	1.35e-8	Mortality in heart failure;
LUSC	cis	rs4631830	0.863	rs2611508	chr10:51518047	T/A	cg20129853	chr10:51489980	NA	-0.33	-6.44	-0.33	4.05e-10	Prostate-specific antigen levels;
LUSC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.4	-5.89	-0.31	9.45e-9	Platelet count;
LUSC	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg19773385	chr1:10388646	KIF1B	0.5	8.98	0.44	2.08e-17	Hepatocellular carcinoma;
LUSC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6460942	0.915	rs62447639	chr7:12486803	T/C	cg06484146	chr7:12443880	VWDE	-0.67	-6.91	-0.35	2.47e-11	Coronary artery disease;
LUSC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg16797656	chr11:68205561	LRP5	0.35	5.92	0.31	8.03e-9	Total body bone mineral density;
LUSC	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg02269571	chr22:50332266	NA	-0.55	-8.23	-0.41	4.28e-15	Schizophrenia;
LUSC	cis	rs9296092	0.538	rs9296094	chr6:33520064	A/G	cg13560919	chr6:33536144	NA	-0.82	-15.68	-0.65	6.77e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg04518342	chr5:131593106	PDLIM4	0.4	7.33	0.37	1.73e-12	Breast cancer;
LUSC	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.38	-0.46	1.07e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg24375607	chr4:120327624	NA	0.78	12.78	0.57	1e-30	Corneal astigmatism;
LUSC	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg06219351	chr7:158114137	PTPRN2	-0.53	-8.34	-0.42	1.93e-15	Response to amphetamines;
LUSC	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.37	-6.04	-0.31	4.01e-9	Total body bone mineral density;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11904960	chr17:35716418	ACACA	-0.45	-7.03	-0.36	1.17e-11	Electrocardiographic conduction measures;
LUSC	cis	rs7945718	0.806	rs11022507	chr11:12829753	A/T	cg25843174	chr11:12811716	TEAD1	0.29	6.51	0.34	2.76e-10	Educational attainment (years of education);
LUSC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg18681998	chr4:17616180	MED28	-0.86	-15.12	-0.64	1.08e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10489202	0.954	rs3820399	chr1:168062053	C/T	cg24449463	chr1:168025552	DCAF6	-0.57	-6.99	-0.36	1.51e-11	Schizophrenia;
LUSC	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg24558204	chr6:135376177	HBS1L	0.59	9.2	0.45	4.06e-18	Red blood cell count;
LUSC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg10220895	chr1:228464137	OBSCN	0.32	5.94	0.31	7.12e-9	Diastolic blood pressure;
LUSC	cis	rs6977660	0.507	rs4719580	chr7:19784847	G/T	cg07541023	chr7:19748670	TWISTNB	0.61	6.46	0.33	3.63e-10	Thyroid stimulating hormone;
LUSC	trans	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg21659725	chr3:3221576	CRBN	0.72	8.67	0.43	1.92e-16	Menarche (age at onset);
LUSC	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg20701182	chr2:24300061	SF3B14	0.55	5.65	0.3	3.47e-8	Lymphocyte counts;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23604961	chr13:108870525	LIG4;ABHD13	-0.44	-6.48	-0.33	3.26e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.4	-0.38	1.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7705502	1.000	rs7736263	chr5:173339222	G/T	cg18693985	chr5:173351052	CPEB4	-0.36	-5.75	-0.3	2.01e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.88e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg27284194	chr4:1044797	NA	0.54	7.66	0.39	1.98e-13	Recombination rate (females);
LUSC	cis	rs7809950	0.678	rs77395658	chr7:107000651	G/A	cg23024343	chr7:107201750	COG5	-0.66	-9.9	-0.48	1.99e-20	Coronary artery disease;
LUSC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg15103426	chr22:29168792	CCDC117	0.6	8.35	0.42	1.87e-15	Lymphocyte counts;
LUSC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg05585544	chr11:47624801	NA	-0.41	-7.22	-0.37	3.43e-12	Subjective well-being;
LUSC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg02269571	chr22:50332266	NA	-0.6	-8.95	-0.44	2.57e-17	Schizophrenia;
LUSC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg07507251	chr3:52567010	NT5DC2	0.36	6.94	0.36	2.04e-11	Bipolar disorder;
LUSC	cis	rs57920188	0.703	rs10915642	chr1:4089244	T/C	cg20703997	chr1:4087676	NA	0.54	8.16	0.41	7.11e-15	Interleukin-17 levels;
LUSC	cis	rs67696533	0.600	rs3746614	chr20:31108477	C/T	cg13636640	chr20:31349939	DNMT3B	0.49	6.74	0.35	6.83e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs1355223	0.573	rs7127169	chr11:34727846	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.13	-0.32	2.55e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs11605924	0.901	rs11038672	chr11:45846498	C/G	ch.11.939596F	chr11:45881766	CRY2	-0.5	-7.35	-0.37	1.54e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg21782813	chr7:2030301	MAD1L1	0.37	6.1	0.32	2.99e-9	Schizophrenia;
LUSC	cis	rs9660992	1.000	rs9660992	chr1:205249450	A/G	cg21545522	chr1:205238299	TMCC2	0.42	7.94	0.4	3.01e-14	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs3126085	0.935	rs3120660	chr1:152258701	G/T	cg26876637	chr1:152193138	HRNR	-0.46	-6.38	-0.33	6.03e-10	Atopic dermatitis;
LUSC	cis	rs7572644	0.621	rs4464229	chr2:28038080	C/T	cg27432699	chr2:27873401	GPN1	0.58	7.37	0.37	1.36e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.85	12.16	0.55	2.09e-28	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg21827317	chr3:136751795	NA	0.37	6.65	0.34	1.16e-10	Neuroticism;
LUSC	cis	rs6961069	0.621	rs6973242	chr7:80238793	C/T	cg04458919	chr7:80252533	CD36	-0.4	-7.15	-0.36	5.43e-12	Platelet count;
LUSC	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg17757837	chr7:157058334	UBE3C	0.82	13.2	0.59	2.61e-32	Body mass index;
LUSC	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.19	0.49	2.03e-21	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.66	0.5	4.85e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.27	-0.49	1.14e-21	Hemoglobin concentration;
LUSC	trans	rs6982636	0.967	rs2980854	chr8:126477497	C/T	cg13325919	chr3:181432053	SOX2;SOX2OT	-0.35	-6.68	-0.34	1e-10	Lipid metabolism phenotypes;
LUSC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	10.54	0.5	1.27e-22	Menopause (age at onset);
LUSC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg06784218	chr1:46089804	CCDC17	0.48	9.36	0.46	1.18e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg03036452	chr22:46663545	TTC38	0.53	5.78	0.3	1.72e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs240764	0.559	rs9404049	chr6:101237129	C/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.46	-0.33	3.75e-10	Neuroticism;
LUSC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	8.71	0.43	1.44e-16	Height;
LUSC	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg15704280	chr7:45808275	SEPT13	0.82	7.82	0.39	6.96e-14	Axial length;
LUSC	cis	rs10779751	0.734	rs2486920	chr1:11125050	T/C	cg04508216	chr1:11107452	MASP2	0.33	5.89	0.31	9.32e-9	Body mass index;
LUSC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg09877947	chr5:131593287	PDLIM4	0.49	8.45	0.42	9.13e-16	Blood metabolite levels;
LUSC	cis	rs7572644	0.699	rs7593127	chr2:28258027	G/A	cg27432699	chr2:27873401	GPN1	-0.52	-7.07	-0.36	9.22e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg10596483	chr8:143751796	JRK	0.61	9.41	0.46	8.19e-19	Schizophrenia;
LUSC	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg25173405	chr17:45401733	C17orf57	0.38	6.06	0.31	3.65e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs524023	0.914	rs2360873	chr11:64391157	G/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.39	-0.49	4.28e-22	Urate levels in obese individuals;
LUSC	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg01416388	chr22:39784598	NA	-0.43	-6.73	-0.35	7.48e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs1775715	0.966	rs1755066	chr10:32309160	C/G	cg26784012	chr10:32216390	ARHGAP12	-0.38	-6.15	-0.32	2.27e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.72	12.03	0.55	5.89e-28	Motion sickness;
LUSC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-6.88	-0.35	3.02e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg20307385	chr11:47447363	PSMC3	-0.46	-6.67	-0.34	1.09e-10	Subjective well-being;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21044797	chr8:142138325	DENND3	0.7	6.24	0.32	1.33e-9	Cognitive performance;
LUSC	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg13575925	chr12:9217583	LOC144571	0.35	6.43	0.33	4.51e-10	Sjögren's syndrome;
LUSC	cis	rs12984174	0.877	rs408484	chr19:18139771	C/T	cg21649277	chr19:18117794	ARRDC2	0.72	7.58	0.38	3.38e-13	Pulmonary function in asthmatics;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04789776	chr8:22462112	KIAA1967	0.76	6.65	0.34	1.21e-10	Cognitive performance;
LUSC	cis	rs2386661	0.547	rs11259582	chr10:5646767	C/T	cg17085576	chr10:5658249	NA	-0.43	-6.37	-0.33	6.09e-10	Breast cancer;
LUSC	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg27124370	chr19:33622961	WDR88	0.52	6.73	0.35	7.56e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01129155	chr16:33817129	NA	0.43	6.05	0.31	3.95e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg06636001	chr8:8085503	FLJ10661	0.5	7.18	0.37	4.49e-12	Morning vs. evening chronotype;
LUSC	cis	rs11030122	0.702	rs1452047	chr11:3991648	A/C	cg08557956	chr11:4115526	RRM1	-0.47	-5.91	-0.31	8.67e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9309473	0.519	rs2421586	chr2:73899719	C/T	cg20560298	chr2:73613845	ALMS1	0.47	7.06	0.36	9.61e-12	Metabolite levels;
LUSC	cis	rs922692	0.744	rs2277545	chr15:79083591	T/C	cg00540400	chr15:79124168	NA	-0.41	-7.1	-0.36	7.6e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg25319279	chr11:5960081	NA	-0.45	-6.32	-0.33	8.2e-10	DNA methylation (variation);
LUSC	cis	rs7712401	0.601	rs396941	chr5:122318265	G/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.53	-0.46	3.35e-19	Mean platelet volume;
LUSC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.76	13.72	0.6	2.85e-34	Aortic root size;
LUSC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18099408	chr3:52552593	STAB1	-0.4	-6.85	-0.35	3.62e-11	Bipolar disorder;
LUSC	cis	rs9309473	0.851	rs6546850	chr2:73831147	A/T	cg20560298	chr2:73613845	ALMS1	-0.47	-6.63	-0.34	1.37e-10	Metabolite levels;
LUSC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06634786	chr22:41940651	POLR3H	-0.57	-6.56	-0.34	2.08e-10	Vitiligo;
LUSC	cis	rs1595825	0.891	rs79845692	chr2:198523541	T/C	cg19156104	chr2:198669113	PLCL1	-0.45	-5.69	-0.3	2.74e-8	Ulcerative colitis;
LUSC	cis	rs240764	0.658	rs2132168	chr6:101178491	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.56	-0.34	2.04e-10	Neuroticism;
LUSC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.97	-0.68	4.92e-47	Monocyte count;
LUSC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg11062466	chr8:58055876	NA	0.75	9.1	0.45	8.12e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-0.87	-16.03	-0.66	2.6900000000000002e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.71	0.34	8.26e-11	Lung cancer;
LUSC	cis	rs6426558	0.524	rs2813948	chr1:227459621	A/T	cg10327440	chr1:227177885	CDC42BPA	0.55	7.43	0.38	8.94e-13	Neutrophil percentage of white cells;
LUSC	cis	rs2694528	0.844	rs9291696	chr5:60064385	C/T	cg11474532	chr5:59995715	DEPDC1B	0.86	7.9	0.4	3.98e-14	Parkinson's disease;
LUSC	cis	rs11756438	0.572	rs2638550	chr6:118998481	C/G	cg18833306	chr6:118973337	C6orf204	0.36	5.73	0.3	2.2e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16204370	chr22:41682343	RANGAP1	-0.44	-6.47	-0.33	3.53e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs4714291	0.722	rs9296320	chr6:40118298	C/G	cg02267698	chr19:7991119	CTXN1	0.52	8.21	0.41	4.97e-15	Strep throat;
LUSC	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg16482183	chr6:26056742	HIST1H1C	0.59	8.04	0.4	1.54e-14	Iron status biomarkers;
LUSC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08677398	chr8:58056175	NA	0.52	6.35	0.33	7.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9359856	0.517	rs112527288	chr6:90509141	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.84	-8.33	-0.41	2.13e-15	Bipolar disorder;
LUSC	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg01579765	chr21:45077557	HSF2BP	-0.46	-9.72	-0.47	8.01e-20	Mean corpuscular volume;
LUSC	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.09	-0.4	1.1e-14	Triglycerides;
LUSC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg13393036	chr8:95962371	TP53INP1	-0.44	-9.2	-0.45	3.88e-18	Type 2 diabetes;
LUSC	cis	rs4594175	0.926	rs4901084	chr14:51634131	G/A	cg23942311	chr14:51606299	NA	0.3	5.68	0.3	2.86e-8	Cancer;
LUSC	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg14993813	chr1:46806288	NSUN4	-0.5	-6.94	-0.36	2.02e-11	Menopause (age at onset);
LUSC	trans	rs12902680	0.706	rs12437760	chr15:46525644	T/C	cg04321580	chr8:143696133	ARC	-0.42	-6.0	-0.31	5e-9	Neuroticism;
LUSC	cis	rs790123	0.965	rs2133850	chr3:122381696	C/T	cg00926285	chr3:122398533	PARP14	-0.38	-5.84	-0.3	1.21e-8	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs11864453	0.645	rs7194668	chr16:72128207	G/C	cg01557791	chr16:72042693	DHODH	-0.44	-6.31	-0.33	8.75e-10	Fibrinogen levels;
LUSC	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg26893861	chr17:41843967	DUSP3	0.92	14.26	0.62	2.34e-36	Triglycerides;
LUSC	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg26162295	chr17:38119207	GSDMA	-0.28	-6.33	-0.33	8.07e-10	Myeloid white cell count;
LUSC	cis	rs432925	0.600	rs214249	chr16:348687	T/G	cg06233593	chr16:337645	AXIN1	0.45	8.5	0.42	6.51e-16	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg13010199	chr12:38710504	ALG10B	0.41	6.49	0.33	3.06e-10	Morning vs. evening chronotype;
LUSC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.71	-16.53	-0.67	2.9e-45	Prostate cancer;
LUSC	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg11473876	chr11:109292803	C11orf87	0.42	6.48	0.33	3.26e-10	Schizophrenia;
LUSC	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.3e-11	Uric acid levels;
LUSC	cis	rs1018836	0.608	rs2205150	chr8:91483232	G/A	cg16814680	chr8:91681699	NA	-0.59	-8.73	-0.43	1.27e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg01879757	chr17:41196368	BRCA1	-0.39	-5.95	-0.31	6.79e-9	Menopause (age at onset);
LUSC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.71	-9.64	-0.47	1.42e-19	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02034447	chr16:89574710	SPG7	0.43	6.28	0.32	1.07e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg01657329	chr11:68192670	LRP5	-0.42	-6.31	-0.33	8.78e-10	Total body bone mineral density;
LUSC	cis	rs1018836	0.923	rs12545726	chr8:91532087	T/A	cg16814680	chr8:91681699	NA	-0.75	-12.14	-0.55	2.47e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	8.28	0.41	2.98e-15	Monocyte count;
LUSC	cis	rs6681460	0.608	rs10889624	chr1:67005807	A/G	cg02459107	chr1:67143332	SGIP1	0.38	6.37	0.33	6.44e-10	Presence of antiphospholipid antibodies;
LUSC	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg12179176	chr11:130786555	SNX19	0.64	9.7	0.47	9.07e-20	Schizophrenia;
LUSC	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg01557791	chr16:72042693	DHODH	-0.45	-6.6	-0.34	1.6e-10	Fibrinogen levels;
LUSC	trans	rs961253	0.556	rs6038446	chr20:6331883	G/A	cg17788362	chr6:86352627	SYNCRIP	0.41	6.0	0.31	5.01e-9	Colorectal cancer;
LUSC	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg07701084	chr6:150067640	NUP43	0.47	6.99	0.36	1.52e-11	Testicular germ cell tumor;
LUSC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06634786	chr22:41940651	POLR3H	0.51	6.05	0.31	3.96e-9	Vitiligo;
LUSC	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg12432903	chr7:1882776	MAD1L1	0.51	6.25	0.32	1.23e-9	Bipolar disorder;
LUSC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.2e-28	Corneal astigmatism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05195750	chr11:31531557	ELP4;IMMP1L	0.44	6.21	0.32	1.53e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg14228332	chr4:119757509	SEC24D	0.74	5.65	0.3	3.39e-8	Cannabis dependence symptom count;
LUSC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg11871910	chr12:69753446	YEATS4	0.46	6.03	0.31	4.26e-9	Response to diuretic therapy;
LUSC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	0.91	16.11	0.66	1.33e-43	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.88	-0.31	9.93e-9	Eotaxin levels;
LUSC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.81	14.5	0.62	2.68e-37	Mean platelet volume;
LUSC	cis	rs67366981	1.000	rs8006732	chr14:77713070	T/G	cg22824376	chr14:77648248	TMEM63C	0.63	6.17	0.32	1.97e-9	Obsessive-compulsive symptoms;
LUSC	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg26513180	chr16:89883248	FANCA	0.58	8.9	0.44	3.62e-17	Vitiligo;
LUSC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	6.44	0.33	4.16e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs656319	0.513	rs17746227	chr8:9981654	T/C	cg21775007	chr8:11205619	TDH	-0.48	-6.56	-0.34	2.06e-10	Myopia (pathological);
LUSC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.04	0.52	2.31e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	9.58	0.46	2.29e-19	Mood instability;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	11.08	0.52	1.63e-24	Lymphocyte counts;
LUSC	cis	rs1538970	0.962	rs2298018	chr1:45813441	T/C	cg05343316	chr1:45956843	TESK2	0.59	8.2	0.41	5.17e-15	Platelet count;
LUSC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08219700	chr8:58056026	NA	0.66	7.44	0.38	8.4e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-5.97	-0.31	6.04e-9	IgG glycosylation;
LUSC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg27284194	chr4:1044797	NA	0.34	5.65	0.3	3.38e-8	Obesity-related traits;
LUSC	cis	rs35123781	0.502	rs261532	chr5:138949362	A/C	cg11459648	chr5:138714337	SLC23A1	0.49	7.57	0.38	3.66e-13	Schizophrenia;
LUSC	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg08079166	chr15:68083412	MAP2K5	-0.35	-6.08	-0.32	3.23e-9	Obesity;
LUSC	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.7	-0.3	2.61e-8	Coronary artery disease;
LUSC	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.71	10.85	0.51	1.08e-23	Smoking initiation;
LUSC	cis	rs7215564	0.908	rs34267318	chr17:78664619	G/A	cg23238734	chr17:78661607	RPTOR	0.48	6.12	0.32	2.63e-9	Myopia (pathological);
LUSC	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05731713	chr7:157510257	PTPRN2	0.48	9.29	0.45	1.99e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs1577917	0.796	rs12661231	chr6:86544471	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.35	-0.33	7.15e-10	Response to antipsychotic treatment;
LUSC	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg03676636	chr4:99064102	C4orf37	-0.27	-5.81	-0.3	1.45e-8	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4566357	0.790	rs4389330	chr2:227957483	C/G	cg11843606	chr2:227700838	RHBDD1	0.49	7.18	0.37	4.54e-12	Coronary artery disease;
LUSC	cis	rs7833787	1.000	rs7844375	chr8:18703258	A/G	cg17701159	chr8:18705777	PSD3	-0.38	-6.21	-0.32	1.55e-9	Obesity-related traits;
LUSC	cis	rs12042938	1.000	rs4366301	chr1:231806286	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.43	-6.29	-0.33	9.73e-10	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg08888203	chr3:10149979	C3orf24	-0.63	-9.14	-0.45	6.24e-18	Alzheimer's disease;
LUSC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.26	0.52	3.75e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2637266	1.000	rs1077916	chr10:78381951	G/A	cg18941641	chr10:78392320	NA	0.37	6.67	0.34	1.08e-10	Pulmonary function;
LUSC	cis	rs965513	0.932	rs10818050	chr9:100538923	A/G	cg13688889	chr9:100608707	NA	-0.57	-8.58	-0.42	3.68e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg00191853	chr8:101177733	SPAG1	0.36	5.82	0.3	1.39e-8	Atrioventricular conduction;
LUSC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg27284194	chr4:1044797	NA	0.36	5.87	0.31	1.07e-8	Obesity-related traits;
LUSC	cis	rs2235649	0.789	rs9939680	chr16:1852720	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-5.9	-0.31	9.08e-9	Blood metabolite levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21528620	chr1:110753221	KCNC4	-0.52	-6.85	-0.35	3.53e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.89	-0.44	3.87e-17	Response to antipsychotic treatment;
LUSC	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg09796270	chr17:17721594	SREBF1	-0.44	-7.77	-0.39	1.01e-13	Total body bone mineral density;
LUSC	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg23625390	chr15:77176239	SCAPER	0.45	6.9	0.35	2.55e-11	Blood metabolite levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27079446	chr18:3449844	TGIF1	-0.55	-7.27	-0.37	2.59e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg27539214	chr16:67997921	SLC12A4	0.55	6.57	0.34	1.96e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.63	0.39	2.55e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.14	-0.45	6.37e-18	Monocyte percentage of white cells;
LUSC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg25456477	chr12:86230367	RASSF9	0.39	6.86	0.35	3.45e-11	Major depressive disorder;
LUSC	trans	rs4714291	0.928	rs761799	chr6:39990050	T/A	cg02267698	chr19:7991119	CTXN1	0.53	7.48	0.38	6.51e-13	Strep throat;
LUSC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	11.72	0.54	8.33e-27	Prudent dietary pattern;
LUSC	trans	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg07211511	chr3:129823064	LOC729375	-0.62	-8.42	-0.42	1.1e-15	Blood pressure (smoking interaction);
LUSC	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg15711740	chr2:61764176	XPO1	-0.5	-7.84	-0.39	6.11e-14	Tuberculosis;
LUSC	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg18578876	chr12:123200353	GPR109B	-0.89	-7.07	-0.36	9.32e-12	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LUSC	trans	rs17807624	0.780	rs13277929	chr8:11453030	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	7.04	0.36	1.11e-11	Systemic lupus erythematosus;
LUSC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.6	8.49	0.42	6.68e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.86	14.37	0.62	8.39e-37	Bladder cancer;
LUSC	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.89	15.27	0.64	2.63e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg08270630	chr22:50330655	NA	-0.39	-5.79	-0.3	1.64e-8	Schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg00544901	chr19:49999417	RPS11	0.39	6.53	0.34	2.51e-10	Triglycerides;
LUSC	cis	rs3772130	0.583	rs4296627	chr3:121567684	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.83	13.54	0.6	1.29e-33	Cognitive performance;
LUSC	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.62	-0.43	2.8e-16	Neuroticism;
LUSC	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg07148914	chr20:33460835	GGT7	-0.44	-6.59	-0.34	1.68e-10	Height;
LUSC	cis	rs472402	0.580	rs11134173	chr5:6659696	C/A	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.43	-6.2	-0.32	1.66e-9	Response to amphetamines;
LUSC	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.99	0.66	3.88e-43	Morning vs. evening chronotype;
LUSC	cis	rs11690935	0.632	rs2292816	chr2:172586714	G/C	cg13550731	chr2:172543902	DYNC1I2	0.6	9.48	0.46	4.73e-19	Schizophrenia;
LUSC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg22549504	chr19:17448937	GTPBP3	0.56	7.36	0.37	1.42e-12	Systemic lupus erythematosus;
LUSC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg16482183	chr6:26056742	HIST1H1C	0.57	8.61	0.43	2.91e-16	Height;
LUSC	cis	rs6960043	0.818	rs13220985	chr7:15062694	A/G	cg19272540	chr7:15055459	NA	0.33	8.01	0.4	1.91e-14	Type 2 diabetes;
LUSC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg12863693	chr15:85201151	NMB	-0.27	-6.16	-0.32	2.06e-9	P wave terminal force;
LUSC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.1	-0.32	2.95e-9	Schizophrenia;
LUSC	cis	rs58785573	0.570	rs4833078	chr4:38646476	C/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.49	7.45	0.38	8.27e-13	Lymphocyte percentage of white cells;
LUSC	cis	rs7572644	0.713	rs4666020	chr2:28046028	A/G	cg27432699	chr2:27873401	GPN1	-0.58	-7.55	-0.38	4.12e-13	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs911119	0.913	rs6048929	chr20:23588855	T/C	cg16589663	chr20:23618590	CST3	0.56	6.77	0.35	5.68e-11	Chronic kidney disease;
LUSC	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.97	-0.31	5.96e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg23241863	chr10:102295624	HIF1AN	0.5	5.87	0.31	1.05e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.41	6.03	0.31	4.44e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg06238570	chr21:40685208	BRWD1	-0.46	-7.06	-0.36	9.46e-12	Cognitive function;
LUSC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs4654899	0.733	rs10442633	chr1:21265097	C/T	cg01072550	chr1:21505969	NA	-0.53	-7.99	-0.4	2.25e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg19592336	chr6:28129416	ZNF389	0.46	6.36	0.33	6.55e-10	Parkinson's disease;
LUSC	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg16989719	chr2:238392110	NA	-0.37	-6.42	-0.33	4.56e-10	Prostate cancer;
LUSC	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	8.19	0.41	5.73e-15	Coronary artery disease;
LUSC	cis	rs2637266	0.775	rs2579744	chr10:78311824	A/G	cg18941641	chr10:78392320	NA	0.4	7.07	0.36	9.2e-12	Pulmonary function;
LUSC	cis	rs2637266	0.935	rs2583055	chr10:78400029	C/T	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.94e-13	Pulmonary function;
LUSC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg08470875	chr2:26401718	FAM59B	-0.69	-9.34	-0.46	1.39e-18	Gut microbiome composition (summer);
LUSC	cis	rs10992471	0.627	rs10820980	chr9:95253342	C/T	cg14631576	chr9:95140430	CENPP	-0.33	-5.96	-0.31	6.48e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.71	0.39	1.49e-13	Vitiligo;
LUSC	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg04450456	chr4:17643702	FAM184B	0.4	6.7	0.34	8.68e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17401966	0.838	rs4529713	chr1:10307295	A/G	cg19773385	chr1:10388646	KIF1B	-0.53	-9.26	-0.45	2.63e-18	Hepatocellular carcinoma;
LUSC	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	13.29	0.59	1.19e-32	Blood protein levels;
LUSC	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs79387448	0.576	rs11902044	chr2:102972534	C/T	cg09003973	chr2:102972529	NA	1.21	12.76	0.57	1.2e-30	Gut microbiota (bacterial taxa);
LUSC	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg23950597	chr19:37808831	NA	-0.62	-7.43	-0.38	9.32e-13	Coronary artery calcification;
LUSC	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg26441486	chr22:50317300	CRELD2	0.53	8.0	0.4	2.07e-14	Schizophrenia;
LUSC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg06238570	chr21:40685208	BRWD1	-0.63	-10.61	-0.5	7.24e-23	Cognitive function;
LUSC	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg01475377	chr6:109611718	NA	-0.41	-7.38	-0.37	1.24e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-7.32	-0.37	1.85e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.27	0.37	2.64e-12	Cognitive ability;
LUSC	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.89	-0.35	2.75e-11	Menarche (age at onset);
LUSC	trans	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg10840412	chr1:235813424	GNG4	0.51	6.18	0.32	1.87e-9	Neuroticism;
LUSC	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg25182066	chr10:30743637	MAP3K8	-0.48	-6.63	-0.34	1.36e-10	Inflammatory bowel disease;
LUSC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg13072238	chr3:49761600	GMPPB	0.38	6.18	0.32	1.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.68	-10.71	-0.51	3.23e-23	Menarche (age at onset);
LUSC	cis	rs617219	0.889	rs1717565	chr5:78440369	T/C	cg24856658	chr5:78533917	JMY	-0.3	-5.76	-0.3	1.87e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg13206674	chr6:150067644	NUP43	0.49	7.53	0.38	4.88e-13	Lung cancer;
LUSC	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg07636037	chr3:49044803	WDR6	0.9	11.69	0.54	1.04e-26	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg24829409	chr8:58192753	C8orf71	-0.62	-7.56	-0.38	3.95e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.33	0.53	2.06e-25	Prudent dietary pattern;
LUSC	cis	rs1775715	0.677	rs2799034	chr10:32175896	A/G	cg04359828	chr10:32216031	ARHGAP12	0.39	6.66	0.34	1.14e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs886126	0.684	rs3809288	chr12:111652522	G/A	cg10833066	chr12:111807467	FAM109A	0.4	6.23	0.32	1.44e-9	Coronary heart disease;
LUSC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26314531	chr2:26401878	FAM59B	-0.69	-9.31	-0.45	1.74e-18	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.56e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg01475377	chr6:109611718	NA	0.46	8.43	0.42	1.03e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg20991723	chr1:152506922	NA	0.5	9.34	0.45	1.44e-18	Hair morphology;
LUSC	cis	rs1506636	0.646	rs805778	chr7:123214655	C/T	cg03229431	chr7:123269106	ASB15	-0.6	-9.11	-0.45	8.02e-18	Plateletcrit;Platelet count;
LUSC	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg01657329	chr11:68192670	LRP5	-0.39	-5.69	-0.3	2.82e-8	Total body bone mineral density;
LUSC	cis	rs6688613	0.685	rs2235184	chr1:166870528	A/G	cg07049167	chr1:166818506	POGK	-0.44	-6.12	-0.32	2.69e-9	Refractive astigmatism;
LUSC	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg12483005	chr1:23474871	LUZP1	0.42	6.59	0.34	1.71e-10	Height;
LUSC	cis	rs1662342	1.000	rs16944555	chr18:3252130	T/C	cg00760847	chr18:3262519	MYL12B	-0.59	-5.74	-0.3	2.16e-8	QRS duration;
LUSC	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	0.88	15.45	0.65	5.27e-41	Metabolic syndrome;
LUSC	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-8.6	-0.43	3.23e-16	Lymphocyte counts;
LUSC	cis	rs12760731	0.565	rs6701848	chr1:178156816	A/C	cg00404053	chr1:178313656	RASAL2	0.64	6.48	0.33	3.34e-10	Obesity-related traits;
LUSC	cis	rs9322817	0.691	rs6571207	chr6:105242161	A/C	cg02098413	chr6:105308735	HACE1	-0.28	-5.77	-0.3	1.79e-8	Thyroid stimulating hormone;
LUSC	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	8.87	0.44	4.6e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs9296092	0.538	rs35381461	chr6:33519751	T/C	cg13560919	chr6:33536144	NA	-0.82	-15.74	-0.65	3.89e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs1982963	0.613	rs2749885	chr14:52516567	T/G	cg05884192	chr14:52515736	NID2	-0.23	-5.94	-0.31	7.15e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7621025	0.599	rs13063987	chr3:136445397	C/G	cg15507776	chr3:136538369	TMEM22	-0.42	-5.77	-0.3	1.85e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUSC	cis	rs612683	0.524	rs479269	chr1:100887616	A/G	cg06223162	chr1:101003688	GPR88	0.43	7.85	0.39	5.71e-14	Breast cancer;
LUSC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs1371867	0.846	rs2083499	chr8:101230534	T/A	cg06636551	chr8:101224915	SPAG1	0.47	8.76	0.43	9.83e-17	Atrioventricular conduction;
LUSC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.64	-0.5	5.81e-23	Electroencephalogram traits;
LUSC	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg03859395	chr2:55845619	SMEK2	0.77	13.33	0.59	8.66e-33	Metabolic syndrome;
LUSC	cis	rs3754214	0.769	rs509345	chr1:150276022	A/G	cg15654264	chr1:150340011	RPRD2	-0.44	-7.29	-0.37	2.22e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.66	-6.31	-0.33	8.68e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs240764	0.658	rs705585	chr6:101262409	A/G	cg09795085	chr6:101329169	ASCC3	0.44	6.54	0.34	2.34e-10	Neuroticism;
LUSC	cis	rs17407555	0.606	rs73229818	chr4:10019884	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-6.25	-0.32	1.28e-9	Schizophrenia (age at onset);
LUSC	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg11984989	chr7:158649758	WDR60	1.12	13.38	0.59	5.62e-33	Height;
LUSC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg21699342	chr2:239360505	ASB1	0.43	6.61	0.34	1.56e-10	Multiple system atrophy;
LUSC	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.73	12.02	0.55	6.42e-28	Monocyte count;
LUSC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg24634471	chr8:143751801	JRK	0.6	9.08	0.45	9.55e-18	Schizophrenia;
LUSC	cis	rs7216064	1.000	rs7208663	chr17:65885171	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-9.37	-0.46	1.13e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.35e-33	Morning vs. evening chronotype;
LUSC	cis	rs244293	1.000	rs244296	chr17:53242878	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-5.9	-0.31	8.75e-9	Menarche (age at onset);
LUSC	cis	rs6690583	0.623	rs6672362	chr1:85454881	C/G	cg22153463	chr1:85462885	MCOLN2	0.62	6.0	0.31	5.12e-9	Serum sulfate level;
LUSC	cis	rs9650315	0.929	rs7001649	chr8:57169520	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.12	0.36	6.82e-12	Height;
LUSC	cis	rs858239	0.571	rs6953020	chr7:23172132	T/C	cg23682824	chr7:23144976	KLHL7	0.4	5.8	0.3	1.51e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.64	9.4	0.46	8.83e-19	Menarche (age at onset);
LUSC	cis	rs61990749	0.597	rs8016447	chr14:78222068	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.63	6.67	0.34	1.08e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg00310523	chr12:86230176	RASSF9	0.42	7.88	0.4	4.52e-14	Major depressive disorder;
LUSC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg08132940	chr7:1081526	C7orf50	-0.5	-5.98	-0.31	5.89e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7605827	0.930	rs12995776	chr2:15717131	T/A	cg19274914	chr2:15703543	NA	0.46	8.74	0.43	1.15e-16	Educational attainment (years of education);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg19945092	chr10:27149349	ABI1	0.78	6.11	0.32	2.72e-9	Cognitive performance;
LUSC	cis	rs2580764	0.540	rs2920893	chr2:55270629	C/T	cg09592903	chr2:55203963	RTN4	0.5	10.14	0.49	3.06e-21	Mean platelet volume;
LUSC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.99	0.55	8.74e-28	Ileal carcinoids;
LUSC	cis	rs7084921	0.533	rs12765091	chr10:101855231	G/C	cg11888571	chr10:102027403	CWF19L1	-0.43	-5.96	-0.31	6.29e-9	Bone mineral density;
LUSC	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.75	12.79	0.57	8.95e-31	Retinal vascular caliber;
LUSC	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.12	0.32	2.59e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg02475777	chr4:1388615	CRIPAK	0.42	6.38	0.33	5.76e-10	Obesity-related traits;
LUSC	cis	rs7903847	0.642	rs6584128	chr10:99171926	G/T	cg20016023	chr10:99160130	RRP12	0.31	7.6	0.38	3.02e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07690290	chr12:66524581	LLPH	0.72	6.09	0.32	3.05e-9	Cognitive performance;
LUSC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.01	-0.31	4.79e-9	Total body bone mineral density;
LUSC	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg02023728	chr11:77925099	USP35	0.48	7.13	0.36	6.4e-12	Testicular germ cell tumor;
LUSC	cis	rs9811920	0.516	rs793486	chr3:99493165	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.3	-5.7	-0.3	2.6e-8	Axial length;
LUSC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.56	5.92	0.31	7.82e-9	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-12.35	-0.56	3.9e-29	Colorectal cancer;
LUSC	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg03929089	chr4:120376271	NA	0.83	11.27	0.52	3.58e-25	Coronary artery disease;
LUSC	cis	rs1577917	0.883	rs2660575	chr6:86684995	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.24	-0.32	1.35e-9	Response to antipsychotic treatment;
LUSC	cis	rs4285028	0.747	rs1463736	chr3:121400725	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-12.81	-0.57	8.07e-31	Multiple sclerosis;
LUSC	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg06462663	chr19:18546047	ISYNA1	0.47	7.86	0.4	5.38e-14	Breast cancer;
LUSC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg08807101	chr21:30365312	RNF160	-0.53	-8.35	-0.42	1.88e-15	Cognitive test performance;
LUSC	cis	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.24	-0.32	1.29e-9	Morning vs. evening chronotype;
LUSC	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23158103	chr7:148848205	ZNF398	-0.51	-8.78	-0.43	8.7e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg14196790	chr5:131705035	SLC22A5	0.46	7.4	0.38	1.13e-12	Breast cancer;Mosquito bite size;
LUSC	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg24596788	chr1:163392923	NA	-0.43	-7.4	-0.38	1.13e-12	Motion sickness;
LUSC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg08132940	chr7:1081526	C7orf50	-0.52	-6.27	-0.32	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.86	13.87	0.6	7.36e-35	Coronary artery disease;
LUSC	cis	rs2236918	1.000	rs1635515	chr1:242017009	A/G	cg17736920	chr1:242011382	EXO1	0.45	7.12	0.36	6.71e-12	Menopause (age at onset);
LUSC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg01879757	chr17:41196368	BRCA1	-0.46	-6.96	-0.36	1.78e-11	Menopause (age at onset);
LUSC	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.56	-0.42	4.07e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	15.26	0.64	2.89e-40	Platelet count;
LUSC	cis	rs7246967	0.673	rs28787949	chr19:22830356	A/G	cg23217946	chr19:22817039	ZNF492	0.48	6.8	0.35	4.73e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.26e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg09365446	chr1:150670422	GOLPH3L	0.47	7.0	0.36	1.4e-11	Melanoma;
LUSC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.5	0.56	1.14e-29	Motion sickness;
LUSC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-13.52	-0.59	1.62e-33	Strep throat;
LUSC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg13047869	chr3:10149882	C3orf24	0.6	8.23	0.41	4.23e-15	Alzheimer's disease;
LUSC	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg20936604	chr3:58311152	NA	-0.73	-7.06	-0.36	9.42e-12	Cholesterol, total;
LUSC	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.12	26.67	0.82	9.47e-85	Schizophrenia;
LUSC	cis	rs9426691	1	rs9426691	chr1:23484904	A/G	cg12483005	chr1:23474871	LUZP1	0.47	6.58	0.34	1.86e-10	Coenzyme Q10 levels;
LUSC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	1.04	18.26	0.71	3.94e-52	Parkinson's disease;
LUSC	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg24375607	chr4:120327624	NA	0.78	11.41	0.53	1.14e-25	Corneal astigmatism;
LUSC	cis	rs9462027	0.628	rs6937132	chr6:34799221	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.79	-0.3	1.6e-8	Systemic lupus erythematosus;
LUSC	cis	rs6539288	0.803	rs7307895	chr12:107332126	A/C	cg26297688	chr12:107349093	C12orf23	-0.32	-5.74	-0.3	2.09e-8	Total body bone mineral density;
LUSC	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg16797656	chr11:68205561	LRP5	0.37	6.08	0.32	3.27e-9	Total body bone mineral density;
LUSC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.66	8.46	0.42	8.77e-16	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03946452	chr6:34393990	RPS10	-0.46	-6.87	-0.35	3.23e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	0.64	13.56	0.6	1.13e-33	Prudent dietary pattern;
LUSC	trans	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg27411982	chr8:10470053	RP1L1	0.42	6.33	0.33	7.88e-10	Monocyte count;
LUSC	cis	rs9372498	0.572	rs62422230	chr6:118959436	T/C	cg18833306	chr6:118973337	C6orf204	-0.46	-5.84	-0.3	1.24e-8	Diastolic blood pressure;
LUSC	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg00792783	chr2:198669748	PLCL1	0.43	5.68	0.3	2.9e-8	Dermatomyositis;
LUSC	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg19743168	chr1:23544995	NA	0.43	8.06	0.4	1.41e-14	Height;
LUSC	trans	rs11039798	1.000	rs6485908	chr11:48652198	C/T	cg15704280	chr7:45808275	SEPT13	-0.65	-6.15	-0.32	2.2e-9	Axial length;
LUSC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00149659	chr3:10157352	C3orf10	0.91	12.44	0.56	1.89e-29	Alzheimer's disease;
LUSC	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	0.83	11.85	0.54	2.7e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs10740039	0.883	rs7905018	chr10:62407343	T/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.91	-0.35	2.5e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs295140	0.903	rs7605146	chr2:201183888	A/G	cg04283868	chr2:201171347	SPATS2L	-0.41	-6.12	-0.32	2.57e-9	QT interval;
LUSC	cis	rs6426558	0.537	rs689094	chr1:227308909	G/A	cg10327440	chr1:227177885	CDC42BPA	0.55	7.48	0.38	6.75e-13	Neutrophil percentage of white cells;
LUSC	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.67	-11.83	-0.54	3.36e-27	White blood cell count (basophil);
LUSC	cis	rs9815354	1.000	rs73081364	chr3:41913616	G/C	cg03022575	chr3:42003672	ULK4	0.61	6.69	0.34	9.3e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg19773385	chr1:10388646	KIF1B	-0.53	-8.23	-0.41	4.24e-15	Hepatocellular carcinoma;
LUSC	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg01629716	chr15:45996671	NA	0.4	6.08	0.32	3.26e-9	Waist circumference;Weight;
LUSC	cis	rs6714710	0.603	rs17488897	chr2:98365164	G/C	cg26665480	chr2:98280029	ACTR1B	0.64	9.1	0.45	8.48e-18	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.88	-0.31	9.73e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg06046430	chr4:77819534	ANKRD56	0.48	7.24	0.37	3.15e-12	Emphysema distribution in smoking;
LUSC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21211367	chr2:162094118	NA	0.44	7.13	0.36	6.31e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.47	6.92	0.35	2.39e-11	Cognitive test performance;
LUSC	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg04998671	chr14:104000505	TRMT61A	0.43	6.81	0.35	4.53e-11	Coronary artery disease;
LUSC	cis	rs1113500	0.933	rs12132785	chr1:108633083	A/T	cg06207961	chr1:108661230	NA	0.4	7.45	0.38	8.18e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.61	-9.11	-0.45	7.91e-18	Corneal astigmatism;
LUSC	cis	rs16976116	0.951	rs28706531	chr15:55477072	G/A	cg11288833	chr15:55489084	RSL24D1	0.52	6.33	0.33	7.81e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-9.55	-0.46	2.85e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg04756594	chr16:24857601	SLC5A11	-0.49	-7.28	-0.37	2.37e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.98	-0.36	1.57e-11	Bipolar disorder;
LUSC	cis	rs240764	0.817	rs239247	chr6:101088350	T/C	cg09795085	chr6:101329169	ASCC3	0.41	6.04	0.31	4.01e-9	Neuroticism;
LUSC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24110177	chr3:50126178	RBM5	0.56	9.15	0.45	5.78e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	12.8	0.57	8.8e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg23093090	chr10:104574429	C10orf26	-0.4	-6.53	-0.34	2.47e-10	Arsenic metabolism;
LUSC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg11645453	chr3:52864694	ITIH4	0.38	7.9	0.4	4.13e-14	Bipolar disorder;
LUSC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg00990874	chr7:1149470	C7orf50	-0.61	-7.82	-0.39	6.96e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-7.78	-0.39	8.86e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.41	6.24	0.32	1.34e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg24812749	chr6:127587940	RNF146	0.73	10.48	0.5	2.02e-22	Breast cancer;
LUSC	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.02	0.31	4.62e-9	Recombination rate (females);
LUSC	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg27398640	chr15:77910606	LINGO1	-0.3	-7.04	-0.36	1.13e-11	Type 2 diabetes;
LUSC	cis	rs7131987	0.621	rs57803026	chr12:29497506	G/A	cg09582351	chr12:29534625	ERGIC2	-0.35	-7.13	-0.36	6.34e-12	QT interval;
LUSC	cis	rs4664304	0.900	rs17231993	chr2:160741415	C/T	cg03641300	chr2:160917029	PLA2R1	-0.38	-6.16	-0.32	2.09e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00321850	chr1:175162397	KIAA0040	0.45	7.69	0.39	1.7e-13	Alcohol dependence;
LUSC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg22676075	chr6:135203613	NA	0.47	7.33	0.37	1.72e-12	Red blood cell count;
LUSC	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg19682013	chr15:45996608	NA	0.38	5.88	0.31	1.02e-8	Waist circumference;Weight;
LUSC	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.58	-5.9	-0.31	8.89e-9	Lung cancer in ever smokers;
LUSC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.26	-0.32	1.22e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg21545522	chr1:205238299	TMCC2	0.45	8.5	0.42	6.56e-16	Red blood cell count;
LUSC	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg03806693	chr22:41940476	POLR3H	-0.91	-12.65	-0.57	3.07e-30	Vitiligo;
LUSC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg08470875	chr2:26401718	FAM59B	-0.68	-8.9	-0.44	3.59e-17	Gut microbiome composition (summer);
LUSC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	7.33	0.37	1.72e-12	Menarche (age at onset);
LUSC	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg04362960	chr10:104952993	NT5C2	0.61	9.63	0.47	1.61e-19	Arsenic metabolism;
LUSC	cis	rs4654899	0.758	rs2320826	chr1:21392096	A/C	cg01072550	chr1:21505969	NA	-0.5	-7.79	-0.39	8.58e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs3862435	0.572	rs2589967	chr15:90907876	T/C	cg22089800	chr15:90895588	ZNF774	0.58	6.36	0.33	6.51e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs7805747	0.961	rs17173238	chr7:151406220	A/G	cg17611936	chr7:151411526	PRKAG2	0.46	6.44	0.33	4.28e-10	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUSC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08048268	chr3:133502702	NA	-0.41	-7.84	-0.39	6.1e-14	Iron status biomarkers;
LUSC	cis	rs4737010	0.501	rs990174	chr8:41632230	A/G	cg17182837	chr8:41585554	ANK1	-0.36	-6.5	-0.34	2.87e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg13010199	chr12:38710504	ALG10B	0.5	7.53	0.38	4.69e-13	Morning vs. evening chronotype;
LUSC	trans	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg27411982	chr8:10470053	RP1L1	0.37	5.95	0.31	6.64e-9	Mood instability;
LUSC	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg22532475	chr10:104410764	TRIM8	-0.32	-7.26	-0.37	2.67e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-10.59	-0.5	8.96e-23	Blood trace element (Cu levels);
LUSC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-7.61	-0.38	2.77e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs72792276	1.000	rs72792279	chr5:127374404	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	7.44	0.38	8.76e-13	Red cell distribution width;
LUSC	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.74	-12.21	-0.56	1.33e-28	Body mass index;
LUSC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg01973587	chr1:228161476	NA	0.44	8.04	0.4	1.62e-14	Diastolic blood pressure;
LUSC	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.89	-0.31	9.64e-9	Reticulocyte count;
LUSC	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg16850897	chr7:100343110	ZAN	-0.57	-7.81	-0.39	7.66e-14	Other erythrocyte phenotypes;
LUSC	cis	rs10887741	0.690	rs10509410	chr10:89440001	C/T	cg13926569	chr10:89418898	PAPSS2	0.34	7.62	0.38	2.58e-13	Exercise (leisure time);
LUSC	cis	rs4631830	0.737	rs7071471	chr10:51503335	C/T	cg10326726	chr10:51549505	MSMB	0.36	6.04	0.31	4.02e-9	Prostate-specific antigen levels;
LUSC	trans	rs17685	0.961	rs41301394	chr7:75612803	C/T	cg19862616	chr7:65841803	NCRNA00174	0.87	12.74	0.57	1.38e-30	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg21782813	chr7:2030301	MAD1L1	-0.37	-6.15	-0.32	2.27e-9	Schizophrenia;
LUSC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg05872129	chr22:39784769	NA	-0.55	-8.97	-0.44	2.13e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg22143856	chr6:28129313	ZNF389	-0.41	-5.8	-0.3	1.55e-8	Depression;
LUSC	cis	rs941898	0.957	rs2181102	chr14:100583949	A/G	cg26002632	chr14:100625216	DEGS2	0.33	6.06	0.31	3.73e-9	White matter hyperintensity burden;
LUSC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.73	-10.08	-0.48	4.94e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21963583	chr11:68658836	MRPL21	0.55	8.08	0.4	1.22e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	3.98e-32	Post bronchodilator FEV1;
LUSC	trans	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.54	0.34	2.32e-10	Corneal astigmatism;
LUSC	cis	rs754466	0.957	rs61854183	chr10:79698077	T/C	cg17075019	chr10:79541650	NA	-0.64	-8.18	-0.41	5.81e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg11062466	chr8:58055876	NA	0.65	8.17	0.41	6.25e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs672059	1.000	rs1760621	chr1:183156006	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.05	0.4	1.44e-14	Hypertriglyceridemia;
LUSC	cis	rs9811920	0.683	rs793439	chr3:99637783	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.35	6.76	0.35	6.26e-11	Axial length;
LUSC	cis	rs9921192	1.000	rs251733	chr16:4321605	A/T	cg07945448	chr16:4304224	NA	0.44	6.3	0.33	9.61e-10	Prostate-specific antigen levels;
LUSC	cis	rs2455601	0.935	rs12049908	chr11:8919309	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.88	-0.35	2.9100000000000002e-11	Schizophrenia;
LUSC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg11168104	chr5:1857477	NA	-0.32	-5.71	-0.3	2.44e-8	Cardiovascular disease risk factors;
LUSC	cis	rs3770081	0.590	rs12622715	chr2:86453563	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.07	-7.19	-0.37	4.25e-12	Facial emotion recognition (sad faces);
LUSC	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-5.75	-0.3	2.03e-8	Recombination measurement;
LUSC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.3	-0.33	9.36e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg21782813	chr7:2030301	MAD1L1	0.4	6.58	0.34	1.82e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.73	-15.2	-0.64	4.89e-40	Systemic lupus erythematosus;
LUSC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg18512352	chr11:47633146	NA	-0.48	-9.57	-0.46	2.41e-19	Subjective well-being;
LUSC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg14784868	chr12:69753453	YEATS4	0.61	8.75	0.43	1.07e-16	Blood protein levels;
LUSC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	0.89	13.12	0.58	5.18e-32	Breast cancer;
LUSC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23158103	chr7:148848205	ZNF398	-0.47	-7.71	-0.39	1.5e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.61	-10.01	-0.48	8.38e-21	Post bronchodilator FEV1;
LUSC	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg20744362	chr22:50050164	C22orf34	0.39	7.31	0.37	1.98e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg16016176	chr3:119298513	ADPRH	0.39	5.97	0.31	5.96e-9	Educational attainment (years of education);
LUSC	cis	rs6998277	0.830	rs6468836	chr8:103602630	A/G	cg10187029	chr8:103597600	NA	0.8	12.41	0.56	2.47e-29	Migraine;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11788103	chr19:12833533	TNPO2	0.49	7.52	0.38	5.21e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.7	-0.34	8.84e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs4363385	0.818	rs574649	chr1:153008471	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-9.78	-0.47	4.8e-20	Morning vs. evening chronotype;
LUSC	cis	rs4948102	1.000	rs4948102	chr7:56097265	C/G	cg17215666	chr7:56131930	SUMF2	0.45	5.77	0.3	1.8e-8	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.7	-0.34	8.85e-11	Menopause (age at onset);
LUSC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.47e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg21775007	chr8:11205619	TDH	-0.43	-5.9	-0.31	9.14e-9	Neuroticism;
LUSC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs9399401	0.961	rs7774095	chr6:142670862	C/A	cg03128060	chr6:142623767	GPR126	0.31	5.69	0.3	2.8e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg10756475	chr4:1757242	NA	-0.38	-6.02	-0.31	4.57e-9	Bladder cancer;Urinary bladder cancer;
LUSC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg21643547	chr1:205240462	TMCC2	-0.43	-7.8	-0.39	8.02e-14	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs500891	0.525	rs3757011	chr6:84081069	G/C	cg08257003	chr6:84140564	ME1	0.35	8.63	0.43	2.58e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	trans	rs11743006	0.626	rs56066735	chr5:136506397	T/C	cg07379741	chr17:7311030	NLGN2	0.41	6.11	0.32	2.82e-9	Mathematical ability;
LUSC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg10792982	chr14:105748885	BRF1	0.52	9.5	0.46	4.24e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4253772	0.872	rs45552534	chr22:46638171	G/A	cg09491104	chr22:46646882	C22orf40	-0.59	-6.48	-0.33	3.23e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-10.29	-0.49	9.28e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs554111	0.656	rs17450586	chr1:21254593	T/G	cg01072550	chr1:21505969	NA	0.4	6.1	0.32	3e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs2463822	0.844	rs1919359	chr11:62055703	A/G	cg06239285	chr11:62104954	ASRGL1	0.91	8.38	0.42	1.45e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.6	-0.34	1.57e-10	Retinal vascular caliber;
LUSC	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg09877947	chr5:131593287	PDLIM4	0.43	7.1	0.36	7.66e-12	Blood metabolite levels;
LUSC	trans	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg01620082	chr3:125678407	NA	-0.85	-7.28	-0.37	2.42e-12	Depression;
LUSC	cis	rs4843185	0.576	rs381624	chr16:85728679	G/A	cg05245094	chr16:85669572	KIAA0182	0.41	6.11	0.32	2.73e-9	Platelet distribution width;
LUSC	cis	rs12980942	0.591	rs11879435	chr19:41757603	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.71	7.41	0.38	1.03e-12	Coronary artery disease;
LUSC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg19318889	chr4:1322082	MAEA	0.52	8.83	0.44	5.95e-17	Longevity;
LUSC	cis	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg21775007	chr8:11205619	TDH	-0.5	-6.92	-0.35	2.38e-11	Neuroticism;
LUSC	cis	rs1775715	0.737	rs2799012	chr10:32103077	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.75	0.35	6.68e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.86	-0.4	5.4e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs1865721	0.682	rs3745081	chr18:73142923	A/G	cg26385618	chr18:73139727	C18orf62	-0.47	-8.83	-0.44	5.92e-17	Intelligence;
LUSC	cis	rs12422267	0.609	rs10128884	chr12:132621624	C/T	cg09764611	chr12:132620959	NA	-0.58	-9.21	-0.45	3.71e-18	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14159672	chr1:205819179	PM20D1	0.86	15.35	0.64	1.34e-40	Menarche (age at onset);
LUSC	trans	rs72674100	1.000	rs28461859	chr4:97988033	T/A	cg09670535	chr1:18959427	PAX7	-0.56	-6.01	-0.31	4.76e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.31	-0.33	8.8e-10	Lung cancer;
LUSC	cis	rs9796	0.870	rs2925346	chr15:41315695	G/A	cg18705301	chr15:41695430	NDUFAF1	0.45	7.84	0.39	5.94e-14	Menopause (age at onset);
LUSC	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg21211680	chr2:198530	NA	-0.54	-6.69	-0.34	9.29e-11	Blood protein levels;
LUSC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.41	-7.64	-0.39	2.29e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs240768	1.000	rs240785	chr6:100973377	C/T	cg12253828	chr6:101329408	ASCC3	-0.82	-5.82	-0.3	1.4e-8	Economic and political preferences (immigration/crime);
LUSC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg07424592	chr7:64974309	NA	0.7	6.07	0.32	3.39e-9	Diabetic kidney disease;
LUSC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.59	0.38	3.29e-13	Prudent dietary pattern;
LUSC	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg23649088	chr2:200775458	C2orf69	0.6	8.03	0.4	1.67e-14	Schizophrenia;
LUSC	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.48	-9.07	-0.44	1.08e-17	Axial length;
LUSC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-0.86	-17.47	-0.69	5.36e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg18681998	chr4:17616180	MED28	0.78	13.54	0.6	1.34e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg13319975	chr6:146136371	FBXO30	0.48	7.25	0.37	2.88e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7131987	0.650	rs6487808	chr12:29463359	C/T	cg09582351	chr12:29534625	ERGIC2	0.35	7.04	0.36	1.07e-11	QT interval;
LUSC	cis	rs10992471	0.580	rs10992304	chr9:95085365	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-7.87	-0.4	5.08e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.44	-0.33	4.14e-10	Total body bone mineral density;
LUSC	cis	rs1113500	0.548	rs3853497	chr1:108657184	C/T	cg06207961	chr1:108661230	NA	0.38	6.27	0.32	1.12e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21545522	chr1:205238299	TMCC2	0.49	9.16	0.45	5.45e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg13609457	chr4:120235615	NA	0.38	5.77	0.3	1.81e-8	Diastolic blood pressure;
LUSC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23158103	chr7:148848205	ZNF398	-0.49	-7.99	-0.4	2.27e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	6.28	0.32	1.08e-9	Tonsillectomy;
LUSC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	12.26	0.56	8.48e-29	Alzheimer's disease;
LUSC	trans	rs2055729	0.813	rs55999429	chr8:9741185	G/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.72	-0.35	7.95e-11	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.72	-12.58	-0.57	5.73e-30	White blood cell count (basophil);
LUSC	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.5	-0.34	2.9e-10	Retinal vascular caliber;
LUSC	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg26647111	chr11:31128758	NA	0.43	6.16	0.32	2.13e-9	Red blood cell count;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24739457	chr1:205821442	NA	0.41	7.25	0.37	2.89e-12	Menarche (age at onset);
LUSC	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg27489772	chr12:121021490	NA	-0.61	-7.84	-0.39	6.05e-14	Type 1 diabetes nephropathy;
LUSC	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg26384229	chr12:38710491	ALG10B	0.65	10.52	0.5	1.55e-22	Morning vs. evening chronotype;
LUSC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.1	-0.41	1.02e-14	Personality dimensions;
LUSC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg16586182	chr3:47516702	SCAP	0.49	7.62	0.38	2.7e-13	Colorectal cancer;
LUSC	cis	rs7674212	0.581	rs11946020	chr4:103944742	T/C	cg16532752	chr4:104119610	CENPE	-0.45	-6.23	-0.32	1.42e-9	Type 2 diabetes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06157335	chr1:53164003	C1orf163	0.47	6.78	0.35	5.37e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.02	-0.44	1.5e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg16606324	chr3:10149918	C3orf24	0.58	8.23	0.41	4.27e-15	Alzheimer's disease;
LUSC	cis	rs7178375	0.607	rs7171212	chr15:31207711	C/T	cg01738805	chr15:31195741	MTMR15	0.86	7.05	0.36	1.03e-11	Hypertriglyceridemia;
LUSC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.84	0.39	5.94e-14	Prudent dietary pattern;
LUSC	cis	rs1904096	0.506	rs7697827	chr4:95184748	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.16	-0.41	6.72e-15	Type 2 diabetes;
LUSC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.05e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg21724239	chr8:58056113	NA	0.78	9.03	0.44	1.43e-17	Developmental language disorder (linguistic errors);
LUSC	trans	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg27411982	chr8:10470053	RP1L1	0.42	6.25	0.32	1.25e-9	Monocyte count;
LUSC	cis	rs9309473	1.000	rs7583255	chr2:73797996	T/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.48	-0.33	3.37e-10	Metabolite levels;
LUSC	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg08975724	chr8:8085496	FLJ10661	0.48	6.9	0.35	2.55e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg21433313	chr16:3507492	NAT15	-0.7	-8.81	-0.43	6.94e-17	Tuberculosis;
LUSC	cis	rs9807989	0.507	rs2287033	chr2:103011237	C/T	cg03938978	chr2:103052716	IL18RAP	-0.35	-6.55	-0.34	2.19e-10	Asthma;
LUSC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg14773178	chr5:1868261	NA	0.36	6.69	0.34	9.65e-11	Cardiovascular disease risk factors;
LUSC	cis	rs3087591	0.683	rs2525567	chr17:29675673	C/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.0	0.36	1.44e-11	Hip circumference;
LUSC	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg25251562	chr2:3704773	ALLC	-0.49	-7.44	-0.38	8.43e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-0.87	-7.7	-0.39	1.58e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg13531842	chr10:38383804	ZNF37A	0.49	7.52	0.38	5.08e-13	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9650315	0.866	rs35152040	chr8:57201462	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.31	0.37	1.93e-12	Height;
LUSC	cis	rs4363385	0.818	rs2879487	chr1:152985360	C/A	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.38	-0.37	1.25e-12	Inflammatory skin disease;
LUSC	trans	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg04995722	chr7:26192034	NFE2L3	0.38	6.32	0.33	8.6e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg26384229	chr12:38710491	ALG10B	0.73	11.94	0.55	1.27e-27	Morning vs. evening chronotype;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18604876	chr3:5164258	ARL8B	-0.52	-6.7	-0.34	9.04e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg04450456	chr4:17643702	FAM184B	0.4	6.73	0.35	7.5e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs59698941	0.943	rs66500331	chr5:132261693	G/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg16393715	chr7:1948819	MAD1L1	0.36	6.2	0.32	1.63e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg15556689	chr8:8085844	FLJ10661	0.57	8.3	0.41	2.64e-15	Monocyte count;
LUSC	cis	rs9479482	0.967	rs1543547	chr6:150346532	T/C	cg07578070	chr6:150326732	RAET1K	0.39	6.1	0.32	2.89e-9	Alopecia areata;
LUSC	cis	rs9326248	0.861	rs7120309	chr11:117042816	T/A	cg26566898	chr11:117069891	TAGLN	0.39	6.28	0.32	1.08e-9	Blood protein levels;
LUSC	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg24733560	chr20:60626293	TAF4	0.37	5.98	0.31	5.71e-9	Body mass index;
LUSC	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg15448220	chr1:150897856	SETDB1	0.42	6.11	0.32	2.75e-9	Melanoma;
LUSC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg25204440	chr1:209979598	IRF6	0.53	6.98	0.36	1.6e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	11.4	0.53	1.17e-25	Colorectal cancer;
LUSC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.91	-0.48	1.78e-20	Hemoglobin concentration;
LUSC	cis	rs909002	0.962	rs7537646	chr1:32135495	G/A	cg01639898	chr1:32083012	HCRTR1	0.26	5.94	0.31	7.1e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.5	-7.0	-0.36	1.4e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg27411982	chr8:10470053	RP1L1	-0.46	-6.82	-0.35	4.29e-11	Morning vs. evening chronotype;
LUSC	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg21100191	chr22:23484243	RTDR1	0.93	16.43	0.67	7.13e-45	Bone mineral density;
LUSC	cis	rs11630290	0.592	rs1039817	chr15:64155367	T/A	cg12036633	chr15:63758958	NA	0.52	6.63	0.34	1.37e-10	Iris characteristics;
LUSC	cis	rs6750795	0.518	rs1434519	chr2:232433761	A/G	cg19187155	chr2:232395269	NMUR1	0.76	11.16	0.52	8.85e-25	Height;
LUSC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4356932	0.967	rs28505472	chr4:76972727	C/T	cg00809888	chr4:76862425	NAAA	0.34	5.78	0.3	1.75e-8	Blood protein levels;
LUSC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg20607798	chr8:58055168	NA	0.57	5.78	0.3	1.7e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7589342	0.929	rs7590652	chr2:106440306	A/G	cg14210321	chr2:106509881	NCK2	-0.55	-8.42	-0.42	1.15e-15	Addiction;
LUSC	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg02466173	chr16:30829666	NA	-0.53	-8.61	-0.43	2.84e-16	Dementia with Lewy bodies;
LUSC	trans	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg00845942	chr12:64062724	DPY19L2	-0.62	-7.84	-0.39	6.14e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9534288	0.830	rs1126364	chr13:46633394	C/G	cg15192986	chr13:46630673	CPB2	-0.8	-12.69	-0.57	2.14e-30	Blood protein levels;
LUSC	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg00321850	chr1:175162397	KIAA0040	-0.43	-7.3	-0.37	2.06e-12	Alcohol dependence;
LUSC	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg23625390	chr15:77176239	SCAPER	-0.66	-9.95	-0.48	1.38e-20	Blood metabolite levels;
LUSC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg17279839	chr7:150038598	RARRES2	0.48	7.6	0.38	3.05e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg15212455	chr7:39170539	POU6F2	0.62	9.89	0.48	2.15e-20	IgG glycosylation;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19223106	chr19:58898630	RPS5	0.49	7.91	0.4	3.83e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4566357	0.930	rs6436647	chr2:227922958	G/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.75	-0.3	1.97e-8	Coronary artery disease;
LUSC	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08045932	chr20:61659980	NA	0.59	10.57	0.5	1.05e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg17366294	chr4:99064904	C4orf37	0.57	10.05	0.48	6.03e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.56	0.6	1.12e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg07211511	chr3:129823064	LOC729375	-1.24	-20.03	-0.74	3.4e-59	Blood pressure (smoking interaction);
LUSC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4843185	0.669	rs4843506	chr16:85715440	T/A	cg00168118	chr16:85669675	KIAA0182	0.37	5.73	0.3	2.25e-8	Platelet distribution width;
LUSC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg26924012	chr15:45694286	SPATA5L1	1.12	20.85	0.75	2.06e-62	Homoarginine levels;
LUSC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg00431813	chr7:1051703	C7orf50	-0.38	-6.11	-0.32	2.73e-9	Longevity;Endometriosis;
LUSC	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg19700328	chr14:106028568	NA	-0.41	-6.88	-0.35	2.95e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg24578937	chr1:2090814	PRKCZ	-0.41	-8.94	-0.44	2.65e-17	Height;
LUSC	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg01689657	chr7:91764605	CYP51A1	-0.32	-5.86	-0.31	1.14e-8	Breast cancer;
LUSC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg08027265	chr7:2291960	NA	-0.39	-6.45	-0.33	3.88e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6840360	0.642	rs2034061	chr4:152420756	C/T	cg20465933	chr4:152376761	FAM160A1	0.32	5.69	0.3	2.8e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg04691961	chr3:161091175	C3orf57	-0.35	-6.05	-0.31	3.9e-9	Morning vs. evening chronotype;
LUSC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg23791538	chr6:167370224	RNASET2	0.37	6.03	0.31	4.43e-9	Crohn's disease;
LUSC	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.87	13.96	0.61	3.36e-35	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.47	-6.08	-0.32	3.25e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs16848425	1.000	rs28608630	chr4:73526279	A/G	cg15289899	chr11:2397255	CD81	0.68	5.96	0.31	6.35e-9	Height;
LUSC	trans	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg01966878	chr4:90757139	SNCA	-0.43	-6.16	-0.32	2.13e-9	Neuroticism;
LUSC	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.71	-0.39	1.45e-13	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08327705	chr5:6756273	POLS	0.45	6.54	0.34	2.31e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs1568889	0.877	rs1384903	chr11:28124359	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.58	6.94	0.35	2.06e-11	Bipolar disorder;
LUSC	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg05360138	chr12:110035743	NA	-0.87	-10.68	-0.5	4.11e-23	Neuroticism;
LUSC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.71	-0.43	1.46e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg04267008	chr7:1944627	MAD1L1	-0.45	-6.61	-0.34	1.53e-10	Schizophrenia;
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.85	15.31	0.64	1.86e-40	Menarche (age at onset);
LUSC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03060546	chr3:49711283	APEH	0.67	7.7	0.39	1.51e-13	Menarche (age at onset);
LUSC	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg08807101	chr21:30365312	RNF160	0.62	9.93	0.48	1.59e-20	Pancreatic cancer;
LUSC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg26695010	chr11:65641043	EFEMP2	-0.47	-7.08	-0.36	8.68e-12	Eosinophil percentage of white cells;
LUSC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg06784218	chr1:46089804	CCDC17	0.55	11.17	0.52	7.91e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg18827107	chr12:86230957	RASSF9	0.47	7.07	0.36	9.01e-12	Major depressive disorder;
LUSC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-10.85	-0.51	1.06e-23	Gut microbiome composition (summer);
LUSC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg15147215	chr3:52552868	STAB1	-0.33	-6.37	-0.33	6.24e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06002616	chr8:101225028	SPAG1	-0.46	-7.47	-0.38	7.11e-13	Atrioventricular conduction;
LUSC	cis	rs4654899	0.931	rs4654880	chr1:21186608	C/A	cg01072550	chr1:21505969	NA	0.48	7.28	0.37	2.41e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4737010	0.570	rs6474364	chr8:41646997	T/G	cg17182837	chr8:41585554	ANK1	-0.36	-6.41	-0.33	4.92e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4629710	0.592	rs1885641	chr6:131553986	A/G	cg12606694	chr6:131520996	AKAP7	0.62	9.42	0.46	7.5e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg00814883	chr7:100076585	TSC22D4	-0.76	-10.49	-0.5	1.99e-22	Platelet count;
LUSC	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg02023728	chr11:77925099	USP35	0.48	6.76	0.35	6.33e-11	Testicular germ cell tumor;
LUSC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.56	-9.57	-0.46	2.5e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs12545109	0.800	rs2576599	chr8:57388410	G/A	cg09654669	chr8:57350985	NA	-0.51	-6.95	-0.36	1.98e-11	Obesity-related traits;
LUSC	cis	rs9473147	0.516	rs2151975	chr6:47515663	T/C	cg12968598	chr6:47444699	CD2AP	0.52	7.94	0.4	3.18e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs10465746	0.780	rs10874424	chr1:84424033	C/T	cg10977910	chr1:84465055	TTLL7	0.44	6.34	0.33	7.39e-10	Obesity-related traits;
LUSC	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg06606381	chr12:133084897	FBRSL1	-0.97	-8.52	-0.42	5.67e-16	Depression;
LUSC	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	6.66	0.34	1.13e-10	Breast cancer;
LUSC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg19318889	chr4:1322082	MAEA	0.43	6.98	0.36	1.58e-11	Obesity-related traits;
LUSC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.64	9.91	0.48	1.8899999999999998e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22433210	chr17:43662623	NA	-0.72	-10.4	-0.49	4.03e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg05283184	chr6:79620031	NA	-0.55	-11.23	-0.52	4.78e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs11030122	0.702	rs7102215	chr11:3943970	C/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.75	-0.3	2.06e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.34	-5.96	-0.31	6.45e-9	Hematocrit;
LUSC	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.0	0.52	3.23e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg05754148	chr16:3507555	NAT15	-0.48	-6.94	-0.36	2.01e-11	Tuberculosis;
LUSC	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-0.85	-14.8	-0.63	1.92e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23978390	chr7:1156363	C7orf50	0.47	6.62	0.34	1.44e-10	Longevity;Endometriosis;
LUSC	trans	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.94	0.55	1.29e-27	Exhaled nitric oxide output;
LUSC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg11062466	chr8:58055876	NA	0.65	8.48	0.42	7.17e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2274273	0.624	rs7150234	chr14:55802181	A/G	cg04306507	chr14:55594613	LGALS3	0.47	9.31	0.45	1.79e-18	Protein biomarker;
LUSC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.4	0.53	1.2e-25	Menopause (age at onset);
LUSC	trans	rs17039065	1.000	rs72889379	chr4:109390266	C/T	cg07444054	chr2:108107501	NA	0.42	6.17	0.32	1.93e-9	Gut microbiome composition (summer);
LUSC	cis	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.4e-10	Ulcerative colitis;
LUSC	cis	rs12541635	0.934	rs2115703	chr8:107045935	C/G	cg10147462	chr8:107024639	NA	0.55	9.92	0.48	1.72e-20	Age of smoking initiation;
LUSC	cis	rs2282300	0.739	rs6484478	chr11:30306440	A/G	cg25418670	chr11:30344373	C11orf46	0.64	9.15	0.45	5.83e-18	Morning vs. evening chronotype;
LUSC	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg05163923	chr11:71159392	DHCR7	0.74	10.94	0.51	5.38e-24	Vitamin D levels;
LUSC	cis	rs68170813	0.652	rs17482494	chr7:107168487	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.45	-5.65	-0.3	3.52e-8	Coronary artery disease;
LUSC	cis	rs1395	1.000	rs1275522	chr2:27426878	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.39	-6.47	-0.33	3.47e-10	Blood metabolite levels;
LUSC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg21724239	chr8:58056113	NA	0.78	9.27	0.45	2.34e-18	Developmental language disorder (linguistic errors);
LUSC	trans	rs72674100	1.000	rs28539607	chr4:97977256	T/G	cg09670535	chr1:18959427	PAX7	-0.56	-5.98	-0.31	5.64e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg05738196	chr6:26577821	NA	-0.52	-5.76	-0.3	1.92e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8114671	0.933	rs2103971	chr20:33786256	T/C	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.04	-0.31	4.17e-9	Height;
LUSC	cis	rs16949788	1.000	rs9672789	chr15:66713633	C/A	cg08120210	chr15:66682733	MAP2K1	-0.59	-5.95	-0.31	6.69e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.16	0.32	2.06e-9	Systolic blood pressure;
LUSC	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.92	-0.31	7.93e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.66	-0.3	3.35e-8	Coronary artery disease;
LUSC	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.27	-0.32	1.11e-9	Recombination measurement;
LUSC	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.93	0.35	2.19e-11	IgG glycosylation;
LUSC	cis	rs12618769	0.543	rs3769728	chr2:99103001	G/A	cg10123293	chr2:99228465	UNC50	0.46	7.64	0.39	2.35e-13	Bipolar disorder;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04511966	chr5:180618506	NA	0.47	6.35	0.33	7.11e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11748023	0.605	rs249616	chr5:139529656	C/T	cg26211634	chr5:139558579	C5orf32	0.31	5.68	0.3	2.96e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2842992	0.747	rs4709379	chr6:160227530	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	7.48	0.38	6.47e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg03060546	chr3:49711283	APEH	0.65	6.99	0.36	1.46e-11	Menarche (age at onset);
LUSC	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	15.06	0.64	1.82e-39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg04374321	chr14:90722782	PSMC1	0.74	11.76	0.54	5.76e-27	Mortality in heart failure;
LUSC	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg24375607	chr4:120327624	NA	0.79	11.91	0.55	1.72e-27	Corneal astigmatism;
LUSC	cis	rs2285947	0.901	rs2285943	chr7:21582963	G/T	cg04471919	chr7:21584483	DNAH11	0.35	7.75	0.39	1.1e-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg05110241	chr16:68378359	PRMT7	-0.82	-8.9	-0.44	3.6e-17	Magnesium levels;
LUSC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg01097406	chr16:89675127	NA	-0.35	-7.1	-0.36	7.44e-12	Vitiligo;
LUSC	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg13647721	chr17:30228624	UTP6	-0.67	-6.12	-0.32	2.58e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs12122100	0.837	rs12142004	chr1:146506676	T/C	cg03526459	chr1:146549940	NA	-0.41	-6.69	-0.34	9.32e-11	HIV-1 control;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26335459	chr4:2845453	ADD1	0.48	6.69	0.34	9.29e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-0.58	-9.18	-0.45	4.67e-18	Breast cancer;
LUSC	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	6.1	0.32	2.9e-9	Breast cancer;
LUSC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg19230755	chr7:65878503	NA	-0.43	-6.02	-0.31	4.48e-9	Aortic root size;
LUSC	cis	rs7572644	0.766	rs11127132	chr2:28236120	C/T	cg27432699	chr2:27873401	GPN1	0.53	6.46	0.33	3.79e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg13485126	chr2:43173341	NA	0.56	6.17	0.32	1.92e-9	Schizophrenia;
LUSC	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	6.99	0.36	1.5e-11	Ovarian reserve;
LUSC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-1.23	-13.28	-0.59	1.37e-32	Diabetic kidney disease;
LUSC	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg18352616	chr4:3374830	RGS12	0.28	5.79	0.3	1.59e-8	Parental longevity (mother's age at death);
LUSC	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.22	-0.37	3.45e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs76878669	0.561	rs1892940	chr11:66111251	A/G	cg18002602	chr11:66138449	SLC29A2	-0.47	-8.49	-0.42	6.83e-16	Educational attainment (years of education);
LUSC	cis	rs7945718	0.875	rs9888181	chr11:12782781	G/A	cg25843174	chr11:12811716	TEAD1	0.32	7.23	0.37	3.39e-12	Educational attainment (years of education);
LUSC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.27	0.56	7.72e-29	Cognitive test performance;
LUSC	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg20848291	chr7:100343083	ZAN	-0.62	-8.51	-0.42	5.96e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg19318889	chr4:1322082	MAEA	0.46	7.52	0.38	5.18e-13	Obesity-related traits;
LUSC	cis	rs2224391	0.628	rs2753233	chr6:5250982	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.48	-6.59	-0.34	1.75e-10	Height;
LUSC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-1.01	-17.26	-0.69	3.51e-48	Coronary artery disease;
LUSC	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg24531977	chr5:56204891	C5orf35	-0.55	-8.18	-0.41	6.19e-15	Coronary artery disease;
LUSC	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.2	-0.45	3.96e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg17757837	chr7:157058334	UBE3C	0.83	13.32	0.59	9.66e-33	Body mass index;
LUSC	cis	rs7267979	0.844	rs35735333	chr20:25337205	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.8	-17.01	-0.68	3.69e-47	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs9463078	0.587	rs1150806	chr6:44897787	C/T	cg25276700	chr6:44698697	NA	-0.28	-5.78	-0.3	1.76e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.72	-11.16	-0.52	8.31e-25	Bone mineral density;
LUSC	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg13010199	chr12:38710504	ALG10B	0.6	9.27	0.45	2.42e-18	Morning vs. evening chronotype;
LUSC	cis	rs17401966	0.540	rs6682868	chr1:10454773	C/T	cg17425144	chr1:10567563	PEX14	0.35	6.16	0.32	2.11e-9	Hepatocellular carcinoma;
LUSC	cis	rs11785693	0.862	rs73189843	chr8:5000915	C/T	cg26367366	chr8:4980734	NA	0.77	8.84	0.44	5.8e-17	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg07424592	chr7:64974309	NA	0.69	6.18	0.32	1.88e-9	Diabetic kidney disease;
LUSC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	6.07	0.32	3.45e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7572644	0.766	rs4666028	chr2:28088580	T/A	cg27432699	chr2:27873401	GPN1	0.51	6.42	0.33	4.57e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-1.23	-18.9	-0.72	1.08e-54	Blood pressure (smoking interaction);
LUSC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg24324837	chr19:49891574	CCDC155	0.49	6.92	0.35	2.31e-11	Multiple sclerosis;
LUSC	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg20587970	chr11:113659929	NA	-1.15	-15.6	-0.65	1.32e-41	Hip circumference adjusted for BMI;
LUSC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg24675658	chr1:53192096	ZYG11B	0.72	11.93	0.55	1.46e-27	Monocyte count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10367011	chr12:132434599	EP400	-0.52	-6.06	-0.31	3.57e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12872889	chr17:74137522	FOXJ1	-0.42	-6.1	-0.32	2.87e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2377585	0.524	rs10505736	chr12:8841834	T/C	cg03761649	chr12:8850719	RIMKLB	0.49	6.4	0.33	5.36e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06636551	chr8:101224915	SPAG1	-0.45	-8.17	-0.41	6.22e-15	Atrioventricular conduction;
LUSC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.82	-0.3	1.38e-8	Monocyte count;
LUSC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06028605	chr16:24865363	SLC5A11	0.65	10.29	0.49	9.3e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg12365402	chr11:9010492	NRIP3	0.48	8.94	0.44	2.77e-17	Hemoglobin concentration;
LUSC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08677398	chr8:58056175	NA	0.54	6.65	0.34	1.23e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.22e-14	Major depressive disorder;
LUSC	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	0.57	8.76	0.43	9.88e-17	Breast cancer;
LUSC	trans	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg25214090	chr10:38739885	LOC399744	0.45	6.6	0.34	1.61e-10	Corneal astigmatism;
LUSC	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg17173187	chr15:85201210	NMB	0.39	6.85	0.35	3.6e-11	Schizophrenia;
LUSC	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg11993925	chr19:44307056	LYPD5	0.45	9.98	0.48	1.06e-20	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs57590327	0.503	rs9874184	chr3:81505439	C/T	cg07356753	chr3:81810745	GBE1	0.46	6.07	0.32	3.47e-9	Extraversion;
LUSC	trans	rs1934953	0.556	rs7909236	chr10:96829430	A/C	cg08498836	chr3:149292366	WWTR1	-0.35	-6.18	-0.32	1.89e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg23711669	chr6:146136114	FBXO30	-0.83	-14.82	-0.63	1.54e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg05182265	chr7:156933206	UBE3C	0.48	7.25	0.37	2.99e-12	Body mass index;
LUSC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.68	-0.3	2.92e-8	Aortic root size;
LUSC	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg24829409	chr8:58192753	C8orf71	-0.48	-5.72	-0.3	2.42e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg11663144	chr21:46675770	NA	-0.41	-7.03	-0.36	1.15e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg26043149	chr18:55253948	FECH	-0.52	-7.53	-0.38	4.73e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg07393940	chr7:158741817	NA	0.37	6.78	0.35	5.58e-11	Life satisfaction;
LUSC	trans	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg07393940	chr7:158741817	NA	0.36	6.43	0.33	4.41e-10	Life satisfaction;
LUSC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg00933542	chr6:150070202	PCMT1	0.33	6.81	0.35	4.45e-11	Lung cancer;
LUSC	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.81	-13.99	-0.61	2.61e-35	Bladder cancer;
LUSC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg05738196	chr6:26577821	NA	0.82	15.84	0.66	1.47e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg27432699	chr2:27873401	GPN1	0.82	15.29	0.64	2.21e-40	Oral cavity cancer;
LUSC	cis	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg17469321	chr7:55412551	NA	0.64	10.23	0.49	1.54e-21	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27305525	chr1:154955752	FLAD1	0.44	6.56	0.34	2e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg09184832	chr6:79620586	NA	-0.45	-7.29	-0.37	2.27e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19748678	chr4:122722346	EXOSC9	-0.5	-7.39	-0.37	1.19e-12	Type 2 diabetes;
LUSC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.07	0.52	1.72e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.11	-0.48	3.98e-21	Hemoglobin concentration;
LUSC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-1.0	-14.74	-0.63	3.27e-38	Initial pursuit acceleration;
LUSC	cis	rs2692947	0.727	rs2692950	chr2:96673524	T/C	cg23100626	chr2:96804247	ASTL	0.25	6.2	0.32	1.66e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg24130564	chr14:104152367	KLC1	-0.54	-7.84	-0.39	6.08e-14	Body mass index;
LUSC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg27121462	chr16:89883253	FANCA	0.56	8.95	0.44	2.48e-17	Vitiligo;
LUSC	cis	rs9311676	0.632	rs4130877	chr3:58374893	T/C	cg13750441	chr3:58318267	PXK	0.36	6.86	0.35	3.29e-11	Systemic lupus erythematosus;
LUSC	cis	rs1775715	0.737	rs2808028	chr10:32101189	G/A	cg03015672	chr10:32216066	ARHGAP12	0.33	5.84	0.3	1.22e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg23093090	chr10:104574429	C10orf26	-0.38	-7.05	-0.36	1.05e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg06028605	chr16:24865363	SLC5A11	0.46	8.38	0.42	1.45e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg02018176	chr4:1364513	KIAA1530	0.42	5.75	0.3	2e-8	Recombination rate (females);
LUSC	cis	rs7084402	0.967	rs1658469	chr10:60292402	C/T	cg07615347	chr10:60278583	BICC1	-0.35	-5.7	-0.3	2.67e-8	Refractive error;
LUSC	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg05283184	chr6:79620031	NA	-0.57	-12.15	-0.55	2.25e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.747	rs3806219	chr1:152972522	C/T	cg00922841	chr1:152955080	SPRR1A	0.46	8.13	0.41	8.38e-15	Inflammatory skin disease;
LUSC	cis	rs4722585	0.764	rs4259314	chr7:26182214	A/G	cg07876897	chr7:26191696	NFE2L3	-0.42	-6.34	-0.33	7.43e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LUSC	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.76	-0.3	1.92e-8	IgG glycosylation;
LUSC	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg06627628	chr2:24431161	ITSN2	0.51	7.27	0.37	2.53e-12	Asthma;
LUSC	cis	rs9398803	0.865	rs1538172	chr6:126748493	A/G	cg19875578	chr6:126661172	C6orf173	0.42	6.27	0.32	1.09e-9	Male-pattern baldness;
LUSC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08470875	chr2:26401718	FAM59B	-0.72	-9.9	-0.48	1.91e-20	Gut microbiome composition (summer);
LUSC	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04004882	chr2:215674386	BARD1	0.47	6.21	0.32	1.54e-9	Neuroblastoma;
LUSC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08219700	chr8:58056026	NA	0.64	8.09	0.4	1.09e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs1009647	0.592	rs1045004	chr14:55819791	G/A	cg04306507	chr14:55594613	LGALS3	0.46	6.67	0.34	1.09e-10	Testicular germ cell tumor;
LUSC	cis	rs13223928	0.651	rs4722426	chr7:3150697	C/T	cg19214707	chr7:3157722	NA	0.44	8.91	0.44	3.37e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.74	11.3	0.53	2.7e-25	Tonsillectomy;
LUSC	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg16482183	chr6:26056742	HIST1H1C	0.44	6.59	0.34	1.72e-10	Height;
LUSC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg24296786	chr1:45957014	TESK2	0.54	8.24	0.41	4.09e-15	High light scatter reticulocyte count;
LUSC	cis	rs79387448	0.935	rs7567133	chr2:103253128	C/A	cg09003973	chr2:102972529	NA	0.66	6.6	0.34	1.61e-10	Gut microbiota (bacterial taxa);
LUSC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.49	8.02	0.4	1.76e-14	Bipolar disorder;
LUSC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg03929089	chr4:120376271	NA	0.83	12.35	0.56	4.02e-29	Height;
LUSC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg15448220	chr1:150897856	SETDB1	0.41	6.1	0.32	2.95e-9	Melanoma;
LUSC	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg11984989	chr7:158649758	WDR60	-1.0	-17.47	-0.69	5.16e-49	Height;
LUSC	cis	rs6543140	0.964	rs6543138	chr2:103066132	G/A	cg09003973	chr2:102972529	NA	0.51	6.68	0.34	1.02e-10	Blood protein levels;
LUSC	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg06552810	chr11:31128660	NA	-0.4	-7.13	-0.36	6.38e-12	Red blood cell count;
LUSC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg11632617	chr15:75315747	PPCDC	-0.52	-6.76	-0.35	6.32e-11	Blood trace element (Zn levels);
LUSC	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21659725	chr3:3221576	CRBN	0.64	10.6	0.5	7.9e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg12483005	chr1:23474871	LUZP1	0.41	6.46	0.33	3.62e-10	Height;
LUSC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg06640241	chr16:89574553	SPG7	0.91	17.02	0.68	3.34e-47	Multiple myeloma (IgH translocation);
LUSC	cis	rs2625529	0.652	rs2957750	chr15:72332258	C/T	cg16672083	chr15:72433130	SENP8	0.48	8.11	0.41	9.5e-15	Red blood cell count;
LUSC	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.58	8.72	0.43	1.37e-16	Blood protein levels;
LUSC	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg11502198	chr6:26597334	ABT1	0.59	9.24	0.45	2.88e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.39	0.46	9.37e-19	Bipolar disorder;
LUSC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg00990874	chr7:1149470	C7orf50	-0.62	-8.22	-0.41	4.6e-15	Bronchopulmonary dysplasia;
LUSC	cis	rs28647808	0.881	rs28625799	chr9:136264557	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg02176678	chr2:219576539	TTLL4	0.61	10.95	0.51	4.76e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1904096	0.506	rs28522293	chr4:95167087	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.08	-0.4	1.18e-14	Type 2 diabetes;
LUSC	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg03676636	chr4:99064102	C4orf37	0.32	6.27	0.32	1.12e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg16447950	chr5:562315	NA	-0.54	-6.69	-0.34	9.21e-11	Obesity-related traits;
LUSC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	0.93	15.91	0.66	7.9e-43	Menopause (age at onset);
LUSC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs12210905	0.920	rs9379975	chr6:27295808	T/A	cg11837749	chr1:55047332	ACOT11	0.66	6.3	0.33	9.13e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.27	0.32	1.14e-9	Corneal astigmatism;
LUSC	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg15744005	chr10:104629667	AS3MT	-0.39	-7.97	-0.4	2.58e-14	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs909341	0.909	rs2750480	chr20:62342654	G/A	cg09650180	chr20:62225654	GMEB2	-0.44	-5.67	-0.3	3.13e-8	Atopic dermatitis;
LUSC	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg24692254	chr21:30365293	RNF160	-0.51	-7.52	-0.38	5.09e-13	Dental caries;
LUSC	cis	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05901451	chr6:126070800	HEY2	0.57	8.71	0.43	1.38e-16	Endometrial cancer;
LUSC	trans	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg10756647	chr7:56101905	PSPH	-0.84	-8.39	-0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg24675658	chr1:53192096	ZYG11B	-0.63	-9.91	-0.48	1.78e-20	Monocyte count;
LUSC	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.97	-20.18	-0.74	8.73e-60	Ulcerative colitis;
LUSC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg03396347	chr1:1875803	NA	-0.55	-12.27	-0.56	8.21e-29	Body mass index;
LUSC	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.16	0.32	2.09e-9	Corneal astigmatism;
LUSC	cis	rs10266483	0.739	rs55747800	chr7:63870483	C/A	cg24201672	chr7:64023550	ZNF680	0.5	6.1	0.32	2.88e-9	Response to statin therapy;
LUSC	cis	rs7712401	0.580	rs42536	chr5:122276423	T/C	cg19077854	chr5:122220652	SNX24	0.42	9.41	0.46	8.49e-19	Mean platelet volume;
LUSC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg07701084	chr6:150067640	NUP43	0.54	8.23	0.41	4.16e-15	Lung cancer;
LUSC	cis	rs10050311	0.746	rs17454662	chr4:87673764	G/A	cg10685359	chr4:87814065	C4orf36	-0.43	-5.66	-0.3	3.19e-8	Insulin-related traits;
LUSC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.74	11.18	0.52	7.35e-25	Type 2 diabetes;
LUSC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.15	-0.36	5.49e-12	Major depressive disorder;
LUSC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg12615879	chr12:58013172	SLC26A10	0.27	5.76	0.3	1.86e-8	Multiple sclerosis;
LUSC	cis	rs6733011	0.519	rs12712034	chr2:99458933	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.33	-0.33	7.81e-10	Bipolar disorder;
LUSC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21545522	chr1:205238299	TMCC2	0.52	9.82	0.47	3.68e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg25258033	chr6:167368657	RNASET2	-0.47	-7.95	-0.4	2.87e-14	Crohn's disease;
LUSC	cis	rs4906332	0.782	rs12891288	chr14:103999750	C/T	cg04998671	chr14:104000505	TRMT61A	-0.56	-7.79	-0.39	8.43e-14	Coronary artery disease;
LUSC	cis	rs4253772	0.530	rs9615989	chr22:46803774	A/T	cg09491104	chr22:46646882	C22orf40	-0.65	-5.65	-0.3	3.5e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6960043	0.818	rs6947830	chr7:15064984	A/G	cg19272540	chr7:15055459	NA	0.3	7.42	0.38	1.01e-12	Type 2 diabetes;
LUSC	cis	rs1971762	0.563	rs10747679	chr12:54077750	C/T	cg23533419	chr12:54090519	NA	-0.37	-6.02	-0.31	4.64e-9	Height;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22308759	chr17:56064928	VEZF1	-0.42	-6.46	-0.33	3.61e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1595825	0.838	rs73058878	chr2:198895078	T/G	cg00982548	chr2:198649783	BOLL	-0.54	-6.89	-0.35	2.72e-11	Ulcerative colitis;
LUSC	cis	rs62432291	0.681	rs2932987	chr6:159655673	C/G	cg14500486	chr6:159655392	FNDC1	0.5	5.74	0.3	2.17e-8	Joint mobility (Beighton score);
LUSC	cis	rs4144027	0.791	rs67727470	chr14:104361996	A/G	cg12183467	chr14:104352244	NA	0.3	5.94	0.31	7.04e-9	Blood metabolite levels;
LUSC	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg03522245	chr20:25566470	NINL	-0.35	-5.77	-0.3	1.83e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	8.16	0.41	6.74e-15	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg18305652	chr10:134549665	INPP5A	0.45	6.57	0.34	1.94e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	cis	rs17661538	0.504	rs34295748	chr10:18470126	A/G	cg03634479	chr10:18430412	CACNB2	0.66	6.0	0.31	4.99e-9	Response to antipsychotic treatment;
LUSC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg04369109	chr6:150039330	LATS1	-0.54	-8.06	-0.4	1.4e-14	Lung cancer;
LUSC	cis	rs6545883	0.929	rs10173974	chr2:61748900	C/G	cg15711740	chr2:61764176	XPO1	-0.49	-7.82	-0.39	6.97e-14	Tuberculosis;
LUSC	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg06612196	chr6:6737390	NA	0.55	10.47	0.5	2.28e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.49	-6.91	-0.35	2.46e-11	Mean platelet volume;
LUSC	cis	rs13067593	1.000	rs11715620	chr3:188563772	T/G	cg17809494	chr3:188572244	LPP	0.45	6.26	0.32	1.18e-9	Immune reponse to smallpox (secreted IFN-alpha);
LUSC	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg24006582	chr15:45444508	DUOX1	-0.6	-8.75	-0.43	1.04e-16	Uric acid levels;
LUSC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	0.77	13.35	0.59	7.08e-33	Cognitive function;
LUSC	cis	rs6906287	0.609	rs767139	chr6:118884799	A/G	cg21191810	chr6:118973309	C6orf204	0.33	6.05	0.31	3.83e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg18827107	chr12:86230957	RASSF9	-0.5	-7.58	-0.38	3.49e-13	Major depressive disorder;
LUSC	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg22681709	chr2:178499509	PDE11A	-0.5	-9.02	-0.44	1.47e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06634786	chr22:41940651	POLR3H	0.49	6.05	0.31	3.88e-9	Vitiligo;
LUSC	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg15848620	chr12:58087721	OS9	0.48	6.58	0.34	1.87e-10	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs8099014	1.000	rs4940701	chr18:56110158	A/T	cg12907477	chr18:56117327	MIR122	0.44	7.02	0.36	1.28e-11	Platelet count;
LUSC	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg01557791	chr16:72042693	DHODH	-0.48	-6.96	-0.36	1.85e-11	Fibrinogen levels;
LUSC	cis	rs4343996	0.506	rs10274978	chr7:3433777	T/C	cg21248987	chr7:3385318	SDK1	0.36	5.98	0.31	5.8e-9	Motion sickness;
LUSC	cis	rs760794	0.729	rs2206033	chr6:19796878	A/C	cg02404759	chr6:19790362	NA	-0.41	-6.62	-0.34	1.42e-10	Endometriosis;
LUSC	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-8.44	-0.42	1e-15	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg09904177	chr6:26538194	HMGN4	-0.8	-6.0	-0.31	5.13e-9	Depression;
LUSC	cis	rs7095944	0.584	rs4962693	chr10:126424835	C/T	cg08799069	chr10:126477246	METTL10	-0.4	-6.08	-0.32	3.26e-9	Asthma;
LUSC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg02038168	chr22:39784481	NA	-0.5	-8.33	-0.41	2.18e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs4474465	0.920	rs7941889	chr11:78154401	T/G	cg27205649	chr11:78285834	NARS2	-0.5	-5.9	-0.31	9.04e-9	Alzheimer's disease (survival time);
LUSC	cis	rs10208940	0.920	rs34366735	chr2:68771995	A/G	cg12452813	chr2:68675892	NA	0.57	5.84	0.3	1.23e-8	Urate levels in lean individuals;
LUSC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg08493051	chr2:3487164	NA	0.48	7.46	0.38	7.55e-13	Neurofibrillary tangles;
LUSC	cis	rs2070433	0.756	rs2839295	chr21:47917871	A/T	cg12379764	chr21:47803548	PCNT	0.73	9.52	0.46	3.66e-19	Lymphocyte counts;
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.3	6.01	0.31	4.73e-9	Lymphocyte counts;
LUSC	cis	rs116139393	0.656	rs10244591	chr7:6771098	G/C	cg09896999	chr7:6746977	ZNF12	-0.53	-7.99	-0.4	2.23e-14	Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg13736514	chr6:26305472	NA	-0.48	-9.6	-0.46	1.99e-19	Educational attainment;
LUSC	cis	rs790123	0.965	rs2133850	chr3:122381696	C/T	cg17380795	chr3:122379686	NA	0.35	5.65	0.3	3.41e-8	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs12545109	0.837	rs6474063	chr8:57355545	C/T	cg09654669	chr8:57350985	NA	-0.54	-7.43	-0.38	9.23e-13	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.49e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.73	-10.3	-0.49	8.61e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	1.07	17.26	0.69	3.57e-48	Testicular germ cell tumor;
LUSC	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg20476274	chr7:133979776	SLC35B4	0.7	11.8	0.54	4.23e-27	Mean platelet volume;
LUSC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg20735989	chr4:730612	PCGF3	-0.45	-6.58	-0.34	1.81e-10	White blood cell count;
LUSC	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.4	-0.42	1.3e-15	Schizophrenia;
LUSC	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg03929089	chr4:120376271	NA	0.72	6.86	0.35	3.37e-11	Axial length;
LUSC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-6.97	-0.36	1.74e-11	Bipolar disorder;
LUSC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg09323728	chr8:95962352	TP53INP1	-0.34	-6.36	-0.33	6.56e-10	Type 2 diabetes;
LUSC	cis	rs9653442	0.545	rs4851252	chr2:100757280	C/T	cg07810366	chr2:100720526	AFF3	-0.43	-7.12	-0.36	6.55e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2729354	1.000	rs2729355	chr11:57353983	T/G	cg24343310	chr11:57249947	NA	0.36	6.5	0.34	2.89e-10	Blood protein levels;
LUSC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	0.9	16.42	0.67	7.71e-45	Cognitive function;
LUSC	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg17507749	chr15:85114479	UBE2QP1	0.56	6.91	0.35	2.45e-11	Schizophrenia;
LUSC	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07988820	chr12:82153109	PPFIA2	0.44	6.2	0.32	1.7e-9	Resting heart rate;
LUSC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg02018176	chr4:1364513	KIAA1530	0.52	9.14	0.45	6.17e-18	Obesity-related traits;
LUSC	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg13010199	chr12:38710504	ALG10B	0.55	8.36	0.42	1.74e-15	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg03806693	chr22:41940476	POLR3H	0.88	12.7	0.57	2e-30	Vitiligo;
LUSC	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg02023728	chr11:77925099	USP35	0.47	6.87	0.35	3.08e-11	Testicular germ cell tumor;
LUSC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-6.89	-0.35	2.72e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg12856521	chr11:46389249	DGKZ	0.4	6.16	0.32	2.1e-9	Leprosy;
LUSC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg17279839	chr7:150038598	RARRES2	0.47	7.33	0.37	1.79e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg14530993	chr4:882597	GAK	0.69	6.84	0.35	3.88e-11	Parkinson's disease;
LUSC	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.49e-20	Coronary artery disease;
LUSC	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.45	-8.25	-0.41	3.65e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01151686	chr17:33307622	LIG3	-0.46	-6.89	-0.35	2.83e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg07332563	chr6:291687	DUSP22	-0.7	-11.9	-0.55	1.84e-27	Menopause (age at onset);
LUSC	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	14.96	0.63	4.25e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.13	0.36	6.23e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg01475377	chr6:109611718	NA	-0.37	-6.46	-0.33	3.61e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg07169764	chr2:136633963	MCM6	-1.13	-16.99	-0.68	4.34e-47	Corneal structure;
LUSC	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.75	-12.37	-0.56	3.48e-29	Body mass index;
LUSC	cis	rs76878669	0.561	rs2236679	chr11:66108894	G/C	cg24851651	chr11:66362959	CCS	0.37	5.78	0.3	1.76e-8	Educational attainment (years of education);
LUSC	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	0.87	15.49	0.65	3.77e-41	Heart rate;
LUSC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	8.3	0.41	2.69e-15	Total body bone mineral density;
LUSC	cis	rs1018697	0.897	rs2150929	chr10:104550937	T/A	cg04362960	chr10:104952993	NT5C2	0.47	6.5	0.34	2.96e-10	Colorectal adenoma (advanced);
LUSC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.28e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg13393036	chr8:95962371	TP53INP1	0.34	6.81	0.35	4.44e-11	Type 2 diabetes;
LUSC	cis	rs6545883	0.831	rs9309336	chr2:61763165	T/C	cg15711740	chr2:61764176	XPO1	-0.5	-7.87	-0.4	5.05e-14	Tuberculosis;
LUSC	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg05973401	chr12:123451056	ABCB9	0.53	6.54	0.34	2.3e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg22963979	chr7:1858916	MAD1L1	0.57	9.1	0.45	8.32e-18	Bipolar disorder and schizophrenia;
LUSC	trans	rs11700980	0.591	rs73901413	chr21:30109304	T/C	cg14791747	chr16:20752902	THUMPD1	0.55	5.98	0.31	5.75e-9	QRS complex (12-leadsum);
LUSC	cis	rs9649213	0.574	rs7789440	chr7:97888798	G/T	cg26380479	chr7:97908229	NA	-0.27	-5.85	-0.3	1.16e-8	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs34421088	0.623	rs2572433	chr8:11101041	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	7.07	0.36	9.15e-12	Neuroticism;
LUSC	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg24675056	chr1:15929824	NA	0.46	7.96	0.4	2.79e-14	Systolic blood pressure;
LUSC	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg13010199	chr12:38710504	ALG10B	0.7	10.75	0.51	2.36e-23	Bladder cancer;
LUSC	cis	rs4654899	0.795	rs61309203	chr1:21118489	A/T	cg01072550	chr1:21505969	NA	-0.44	-6.53	-0.34	2.38e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.52	-7.55	-0.38	4.09e-13	Renal function-related traits (BUN);
LUSC	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg00074818	chr8:8560427	CLDN23	0.49	8.45	0.42	9.39e-16	Obesity-related traits;
LUSC	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.49	6.2	0.32	1.71e-9	Schizophrenia;
LUSC	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg16473166	chr22:50639996	SELO	0.68	9.65	0.47	1.34e-19	Obesity-related traits;
LUSC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-11.09	-0.52	1.5e-24	Alzheimer's disease;
LUSC	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17507749	chr15:85114479	UBE2QP1	0.5	6.2	0.32	1.67e-9	Schizophrenia;
LUSC	cis	rs7621025	0.500	rs71630059	chr3:136581611	G/A	cg15507776	chr3:136538369	TMEM22	-0.62	-8.29	-0.41	2.76e-15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
LUSC	cis	rs754133	1.000	rs754133	chr12:54418920	C/T	cg10005224	chr12:54424964	HOXC4;HOXC5	0.43	8.66	0.43	2.02e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
LUSC	cis	rs3087591	0.960	rs2905787	chr17:29482381	G/A	cg24425628	chr17:29625626	OMG;NF1	0.6	8.42	0.42	1.15e-15	Hip circumference;
LUSC	cis	rs8040855	0.627	rs11634975	chr15:85606478	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-5.74	-0.3	2.08e-8	Bulimia nervosa;
LUSC	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg14458575	chr2:238380390	NA	0.68	11.41	0.53	1.06e-25	Prostate cancer;
LUSC	cis	rs1003719	0.688	rs2000416	chr21:38540089	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-9.79	-0.47	4.62e-20	Eye color traits;
LUSC	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg24675056	chr1:15929824	NA	0.46	7.92	0.4	3.44e-14	Systolic blood pressure;
LUSC	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg02569458	chr12:86230093	RASSF9	-0.49	-8.25	-0.41	3.64e-15	Major depressive disorder;
LUSC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg26408565	chr15:76604113	ETFA	-0.5	-8.11	-0.41	9.51e-15	Blood metabolite levels;
LUSC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06481639	chr22:41940642	POLR3H	-0.53	-5.98	-0.31	5.59e-9	Vitiligo;
LUSC	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06002616	chr8:101225028	SPAG1	-0.46	-7.56	-0.38	3.93e-13	Atrioventricular conduction;
LUSC	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg08680598	chr22:49984980	NA	-0.34	-6.29	-0.33	1e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg20503657	chr10:835505	NA	0.82	11.75	0.54	6.55e-27	Eosinophil percentage of granulocytes;
LUSC	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.76	-0.43	9.87e-17	Response to antipsychotic treatment;
LUSC	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18854424	chr1:2615690	NA	0.52	10.79	0.51	1.71e-23	Ulcerative colitis;
LUSC	cis	rs710216	0.957	rs841563	chr1:43429520	C/T	cg03128534	chr1:43423976	SLC2A1	0.47	5.82	0.3	1.36e-8	Red cell distribution width;
LUSC	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg26816564	chr1:7831052	VAMP3	0.57	6.56	0.34	2.08e-10	Inflammatory bowel disease;
LUSC	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg24375607	chr4:120327624	NA	0.79	12.05	0.55	5.19e-28	Corneal astigmatism;
LUSC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg21972741	chr5:435613	AHRR	0.36	6.8	0.35	4.8e-11	Cystic fibrosis severity;
LUSC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg11366901	chr6:160182831	ACAT2	0.81	11.23	0.52	4.73e-25	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs113835537	0.935	rs76228630	chr11:66458676	T/C	cg24851651	chr11:66362959	CCS	0.52	6.42	0.33	4.69e-10	Airway imaging phenotypes;
LUSC	trans	rs4800353	0.929	rs4267422	chr18:19608303	C/T	cg01841828	chr16:69166849	CHTF8;CIRH1A	-0.58	-6.05	-0.31	3.85e-9	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs73206853	0.841	rs3026456	chr12:110748735	G/C	cg12870014	chr12:110450643	ANKRD13A	0.68	6.44	0.33	4.21e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4253772	0.938	rs14842	chr22:46639457	A/T	cg09491104	chr22:46646882	C22orf40	-0.63	-6.52	-0.34	2.57e-10	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs2562456	0.793	rs116057198	chr19:21508451	A/G	cg00806126	chr19:22604979	ZNF98	-0.42	-5.99	-0.31	5.56e-9	Pain;
LUSC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg04310649	chr10:35416472	CREM	0.4	6.15	0.32	2.17e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg22709100	chr7:91322751	NA	-0.39	-5.75	-0.3	2.06e-8	Breast cancer;
LUSC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03264133	chr6:25882463	NA	-0.5	-9.07	-0.44	1.04e-17	Blood metabolite levels;
LUSC	cis	rs9650657	0.836	rs2898252	chr8:10604164	T/C	cg27411982	chr8:10470053	RP1L1	-0.36	-5.78	-0.3	1.76e-8	Neuroticism;
LUSC	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.51	10.22	0.49	1.68e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs3736594	1.000	rs12477908	chr2:27987046	A/C	cg27432699	chr2:27873401	GPN1	-0.62	-8.98	-0.44	1.96e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.9	-14.4	-0.62	6.4e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	8.37	0.42	1.56e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs7818345	0.845	rs11785649	chr8:19268233	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.32	6.15	0.32	2.22e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg04990556	chr1:26633338	UBXN11	0.85	11.14	0.52	9.76e-25	Obesity-related traits;
LUSC	cis	rs75804782	0.521	rs56120037	chr2:239398464	G/A	cg18131467	chr2:239335373	ASB1	-0.67	-6.17	-0.32	2e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.37	-7.13	-0.36	6.33e-12	Type 2 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10566763	chr6:106773518	ATG5	-0.52	-6.6	-0.34	1.65e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6542838	0.611	rs1878589	chr2:99517979	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.49	-0.33	3.16e-10	Fear of minor pain;
LUSC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18252515	chr7:66147081	NA	-0.57	-7.86	-0.39	5.44e-14	Corneal structure;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16080015	chr7:5085479	RBAK	-0.48	-7.16	-0.36	5.12e-12	Electrocardiographic conduction measures;
LUSC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1358748	0.522	rs6687611	chr1:67558169	T/C	cg02640540	chr1:67518911	SLC35D1	0.66	6.61	0.34	1.5e-10	Tuberculosis;
LUSC	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg14019695	chr9:139328340	INPP5E	0.45	8.53	0.42	5.23e-16	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-0.54	-8.97	-0.44	2.23e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg17328964	chr8:145687451	CYHR1	0.47	7.45	0.38	8.17e-13	Age at first birth;
LUSC	trans	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg26384229	chr12:38710491	ALG10B	0.56	8.72	0.43	1.33e-16	Morning vs. evening chronotype;
LUSC	cis	rs11229555	0.609	rs12289198	chr11:58175057	T/C	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.47	7.06	0.36	9.69e-12	Asthma (bronchodilator response);
LUSC	cis	rs9473147	0.516	rs9381579	chr6:47556680	C/T	cg12968598	chr6:47444699	CD2AP	0.52	7.93	0.4	3.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21659725	chr3:3221576	CRBN	-0.61	-9.93	-0.48	1.58e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg21100191	chr22:23484243	RTDR1	0.92	16.16	0.66	8.69e-44	Bone mineral density;
LUSC	cis	rs11168618	0.567	rs56354789	chr12:48803943	C/A	cg24011408	chr12:48396354	COL2A1	0.42	6.6	0.34	1.6e-10	Adiponectin levels;
LUSC	cis	rs10992471	0.528	rs7031567	chr9:95241363	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.36	-6.22	-0.32	1.5e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2274273	0.870	rs1952087	chr14:55683211	A/C	cg04306507	chr14:55594613	LGALS3	0.57	12.96	0.58	2.1e-31	Protein biomarker;
LUSC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg15445000	chr17:37608096	MED1	0.39	6.63	0.34	1.37e-10	Urinary metabolites;
LUSC	cis	rs79387448	0.745	rs72993754	chr2:103151136	A/G	cg09003973	chr2:102972529	NA	0.75	7.41	0.38	1.01e-12	Gut microbiota (bacterial taxa);
LUSC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg03146154	chr1:46216737	IPP	0.5	7.51	0.38	5.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08470875	chr2:26401718	FAM59B	0.71	9.8	0.47	4.22e-20	Gut microbiome composition (summer);
LUSC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg18230493	chr5:56204884	C5orf35	-0.86	-12.98	-0.58	1.85e-31	Initial pursuit acceleration;
LUSC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.25	-0.41	3.75e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg05234568	chr11:5960015	NA	-0.63	-8.89	-0.44	3.96e-17	DNA methylation (variation);
LUSC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.82	14.39	0.62	7.5e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4964805	0.657	rs4964813	chr12:104189554	T/C	cg02344784	chr12:104178138	NT5DC3	0.46	8.86	0.44	4.8e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs952623	0.649	rs7801660	chr7:39072473	C/T	cg15212455	chr7:39170539	POU6F2	0.36	5.96	0.31	6.42e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.83	-0.3	1.31e-8	Crohn's disease;
LUSC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15664640	chr17:80829946	TBCD	-0.48	-8.86	-0.44	4.97e-17	Breast cancer;
LUSC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.25	0.32	1.28e-9	Menopause (age at onset);
LUSC	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg17623882	chr6:41773611	USP49	-0.58	-9.94	-0.48	1.46e-20	Menarche (age at onset);
LUSC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg07870213	chr5:140052090	DND1	0.99	14.68	0.63	5.57e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg24675056	chr1:15929824	NA	0.48	8.27	0.41	3.15e-15	Systolic blood pressure;
LUSC	cis	rs12900413	0.687	rs12913572	chr15:90319313	T/C	cg24249390	chr15:90295951	MESP1	-0.37	-5.85	-0.31	1.15e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg20307385	chr11:47447363	PSMC3	0.45	6.5	0.34	2.87e-10	Subjective well-being;
LUSC	cis	rs10979	1.000	rs9390107	chr6:143892721	A/T	cg25407410	chr6:143891975	LOC285740	-0.73	-11.95	-0.55	1.25e-27	Hypospadias;
LUSC	cis	rs4072705	1.000	rs10760372	chr9:127468816	T/C	cg13476313	chr9:127244764	NR5A1	0.29	5.66	0.3	3.21e-8	Menarche (age at onset);
LUSC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg06238570	chr21:40685208	BRWD1	0.46	7.12	0.36	6.54e-12	Cognitive function;
LUSC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg01879757	chr17:41196368	BRCA1	-0.39	-5.96	-0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg13560548	chr3:10150139	C3orf24	0.47	6.65	0.34	1.23e-10	Alzheimer's disease;
LUSC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg06784218	chr1:46089804	CCDC17	0.55	10.98	0.52	3.63e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.64	10.05	0.48	5.93e-21	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg14092988	chr3:52407081	DNAH1	0.33	6.3	0.33	9.43e-10	Bipolar disorder;
LUSC	cis	rs3741151	0.892	rs60078907	chr11:73085834	T/C	cg17517138	chr11:73019481	ARHGEF17	0.83	7.53	0.38	4.94e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg21211680	chr2:198530	NA	0.75	7.59	0.38	3.18e-13	Blood protein levels;
LUSC	trans	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.4	0.33	5.41e-10	Corneal astigmatism;
LUSC	cis	rs9420	0.925	rs10896636	chr11:57448032	C/G	cg02958346	chr11:57425731	CLP1	-0.45	-6.57	-0.34	1.98e-10	Schizophrenia;
LUSC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg13047869	chr3:10149882	C3orf24	0.43	6.53	0.34	2.46e-10	Alzheimer's disease;
LUSC	cis	rs977987	0.872	rs1559339	chr16:75318646	A/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.82	-0.35	4.28e-11	Dupuytren's disease;
LUSC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18099408	chr3:52552593	STAB1	-0.37	-6.18	-0.32	1.91e-9	Bipolar disorder;
LUSC	cis	rs10193935	0.901	rs10169411	chr2:42637749	G/A	cg27598129	chr2:42591480	NA	-0.61	-8.27	-0.41	3.18e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg17366294	chr4:99064904	C4orf37	0.61	10.86	0.51	1.01e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg15147215	chr3:52552868	STAB1	-0.32	-6.39	-0.33	5.73e-10	Electroencephalogram traits;
LUSC	cis	rs7814319	0.901	rs13253635	chr8:97240847	A/G	cg20787634	chr8:97240163	UQCRB	-0.34	-5.92	-0.31	7.93e-9	Lung function (FVC);
LUSC	cis	rs73001065	0.536	rs10408596	chr19:19512657	A/T	cg03709012	chr19:19516395	GATAD2A	0.95	8.75	0.43	1.11e-16	LDL cholesterol;
LUSC	cis	rs6969780	0.778	rs2465275	chr7:27145100	G/A	cg26364809	chr7:27145159	NA	-0.62	-6.21	-0.32	1.54e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19260500	chr3:133969278	RYK	-0.4	-6.16	-0.32	2.11e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg25036284	chr2:26402008	FAM59B	-0.71	-10.02	-0.48	7.79e-21	Gut microbiome composition (summer);
LUSC	cis	rs17095355	0.901	rs12240333	chr10:111743972	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.48	-0.38	6.7e-13	Biliary atresia;
LUSC	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg23933602	chr10:16859644	RSU1	0.58	6.75	0.35	6.52e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg21970626	chr13:21893289	NA	-0.4	-5.7	-0.3	2.7e-8	White matter hyperintensity burden;
LUSC	trans	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg25214090	chr10:38739885	LOC399744	0.53	7.94	0.4	3.08e-14	Corneal astigmatism;
LUSC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.21	-0.37	3.77e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg23711669	chr6:146136114	FBXO30	-0.92	-17.89	-0.7	1.16e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg11871910	chr12:69753446	YEATS4	0.95	17.8	0.7	2.59e-50	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.71	-16.35	-0.67	1.43e-44	Prostate cancer;
LUSC	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg24011408	chr12:48396354	COL2A1	0.49	8.18	0.41	5.86e-15	Plateletcrit;
LUSC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	0.93	13.08	0.58	7.49e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg05555928	chr11:63887634	MACROD1	-0.46	-5.81	-0.3	1.49e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4243830	1.000	rs12047931	chr1:6587614	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.95	8.93	0.44	2.84e-17	Body mass index;
LUSC	cis	rs4363385	0.747	rs7521181	chr1:152955223	G/A	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.54	-0.38	4.34e-13	Inflammatory skin disease;
LUSC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg07424592	chr7:64974309	NA	0.42	5.95	0.31	6.7e-9	Calcium levels;
LUSC	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg09904177	chr6:26538194	HMGN4	0.63	10.52	0.5	1.46e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg24558204	chr6:135376177	HBS1L	0.59	9.07	0.44	1.01e-17	Red blood cell count;
LUSC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg03709012	chr19:19516395	GATAD2A	0.76	11.7	0.54	1e-26	Tonsillectomy;
LUSC	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg07157834	chr1:205819609	PM20D1	0.42	5.67	0.3	3.1e-8	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg04539111	chr16:67997858	SLC12A4	-0.47	-6.3	-0.33	9.58e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg07061783	chr6:25882402	NA	0.43	6.11	0.32	2.71e-9	Blood metabolite levels;
LUSC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg16524733	chr11:117070046	TAGLN	0.43	7.42	0.38	9.88e-13	Blood protein levels;
LUSC	cis	rs6939532	0.522	rs9366652	chr6:26354219	C/G	cg09904177	chr6:26538194	HMGN4	-0.47	-6.87	-0.35	3.14e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14829155	chr15:31115871	NA	-0.58	-8.48	-0.42	7.45e-16	Huntington's disease progression;
LUSC	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.61	-12.26	-0.56	8.57e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11650494	0.710	rs77653195	chr17:47468868	A/T	cg08112188	chr17:47440006	ZNF652	1.07	8.75	0.43	1.07e-16	Prostate cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01247845	chr5:68513627	MRPS36	-0.43	-6.34	-0.33	7.65e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1808579	0.804	rs1652376	chr18:21109466	A/C	cg14672496	chr18:21087552	C18orf8	-0.4	-7.09	-0.36	7.98e-12	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs2239815	0.545	rs5762855	chr22:29246605	A/T	cg02153584	chr22:29168773	CCDC117	0.53	6.06	0.31	3.71e-9	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	cis	rs78545713	0.649	rs16891464	chr6:26235300	A/G	cg23601095	chr6:26197514	HIST1H3D	0.62	5.97	0.31	6.23e-9	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg25173405	chr17:45401733	C17orf57	-0.46	-6.74	-0.35	6.91e-11	Glaucoma (primary open-angle);
LUSC	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg27284194	chr4:1044797	NA	0.6	8.88	0.44	4.09e-17	Recombination rate (females);
LUSC	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-8.27	-0.41	3.31e-15	Axial length;
LUSC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg11693508	chr17:37793320	STARD3	0.56	6.7	0.34	8.71e-11	Bipolar disorder;
LUSC	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08645402	chr16:4508243	NA	-0.47	-7.43	-0.38	8.94e-13	Schizophrenia;
LUSC	cis	rs6546550	0.869	rs6712827	chr2:70156540	C/G	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.28	-0.37	2.34e-12	Prevalent atrial fibrillation;
LUSC	cis	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg27642588	chr6:29709602	LOC285830	0.49	7.91	0.4	3.76e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg03453431	chr7:157225567	NA	-0.59	-10.72	-0.51	3.12e-23	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs6460942	0.908	rs6979046	chr7:12232744	A/G	cg06484146	chr7:12443880	VWDE	-0.56	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	cis	rs9905704	0.718	rs62083527	chr17:56667853	T/C	cg12560992	chr17:57184187	TRIM37	0.51	5.91	0.31	8.67e-9	Testicular germ cell tumor;
LUSC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg17173187	chr15:85201210	NMB	-0.31	-6.37	-0.33	6.29e-10	P wave terminal force;
LUSC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg03676636	chr4:99064102	C4orf37	0.36	7.97	0.4	2.56e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg26811252	chr16:29126840	RRN3P2	0.6	9.5	0.46	4.09e-19	Menopause (age at onset);
LUSC	trans	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg02800362	chr5:177631904	HNRNPAB	0.87	12.81	0.57	8.07e-31	Obesity-related traits;
LUSC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08045932	chr20:61659980	NA	0.59	10.39	0.49	4.1e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6066835	1.000	rs6125446	chr20:47348161	C/G	cg18078177	chr20:47281410	PREX1	0.71	6.23	0.32	1.42e-9	Multiple myeloma;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11205200	chr9:131267365	GLE1	-0.49	-6.43	-0.33	4.47e-10	Hepatitis;
LUSC	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg05673287	chr15:77411982	SGK269	-0.44	-6.87	-0.35	3.09e-11	Type 2 diabetes;
LUSC	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.7	8.78	0.43	8.43e-17	Type 2 diabetes;
LUSC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.69	9.18	0.45	4.48e-18	Gut microbiome composition (summer);
LUSC	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.85	-13.92	-0.61	4.84e-35	Schizophrenia;
LUSC	cis	rs9837602	1.000	rs9833888	chr3:99723580	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.11	0.32	2.75e-9	Breast cancer;
LUSC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg05802129	chr4:122689817	NA	-0.37	-6.56	-0.34	2.06e-10	Type 2 diabetes;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg13453750	chr1:205783389	SLC41A1	-0.3	-5.9	-0.31	8.7e-9	Menarche (age at onset);
LUSC	cis	rs6998277	1.000	rs4734648	chr8:103635994	G/A	cg10187029	chr8:103597600	NA	0.65	8.22	0.41	4.41e-15	Migraine;
LUSC	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg24851651	chr11:66362959	CCS	-0.51	-8.01	-0.4	1.95e-14	Bipolar disorder;
LUSC	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg10840412	chr1:235813424	GNG4	0.7	9.47	0.46	5.13e-19	Bipolar disorder;
LUSC	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg05855489	chr10:104503620	C10orf26	0.52	8.08	0.4	1.19e-14	Arsenic metabolism;
LUSC	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg18190219	chr22:46762943	CELSR1	-0.55	-6.28	-0.33	1.05e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg22782873	chr19:19639568	YJEFN3	-0.48	-5.8	-0.3	1.53e-8	Bipolar disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09199072	chr6:116692265	DSE	-0.42	-6.0	-0.31	5.12e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-16.85	-0.68	1.61e-46	Coronary artery disease;
LUSC	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.72	-11.63	-0.54	1.79e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs9549260	0.755	rs2755216	chr13:41156938	G/A	cg21288729	chr13:41239152	FOXO1	0.6	9.35	0.46	1.26e-18	Red blood cell count;
LUSC	cis	rs2629540	0.855	rs12776722	chr10:126469833	G/A	cg08799069	chr10:126477246	METTL10	0.7	10.08	0.48	4.82e-21	Cocaine dependence;
LUSC	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg24375607	chr4:120327624	NA	-0.75	-11.45	-0.53	7.96e-26	Corneal astigmatism;
LUSC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg23711669	chr6:146136114	FBXO30	-0.7	-12.22	-0.56	1.23e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg26395211	chr5:140044315	WDR55	-0.37	-5.72	-0.3	2.43e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2997447	0.744	rs2997442	chr1:26403530	T/G	cg19633962	chr1:26362018	EXTL1	-0.48	-5.76	-0.3	1.89e-8	QRS complex (12-leadsum);
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg26690232	chr1:40506155	CAP1	0.68	6.4	0.33	5.37e-10	Body mass index;
LUSC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-12.61	-0.57	4.4e-30	Platelet count;
LUSC	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg23625390	chr15:77176239	SCAPER	0.63	9.56	0.46	2.7e-19	Blood metabolite levels;
LUSC	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg00191853	chr8:101177733	SPAG1	-0.38	-6.31	-0.33	9.08e-10	Atrioventricular conduction;
LUSC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg13397359	chr6:42928475	GNMT	0.57	9.58	0.46	2.25e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.55	7.58	0.38	3.38e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6545883	0.894	rs778148	chr2:61606866	G/A	cg15711740	chr2:61764176	XPO1	0.41	6.21	0.32	1.6e-9	Tuberculosis;
LUSC	cis	rs17433780	0.928	rs10922533	chr1:89456659	C/G	cg09516651	chr1:89888402	LOC400759	0.49	8.13	0.41	8.65e-15	Carotid intima media thickness;
LUSC	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	0.68	10.65	0.5	5.36e-23	Blood metabolite ratios;
LUSC	trans	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	9.54	0.46	3.1400000000000002e-19	Eotaxin levels;
LUSC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg05347473	chr6:146136440	FBXO30	0.49	8.16	0.41	6.84e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg16447950	chr5:562315	NA	-0.58	-7.11	-0.36	7.26e-12	Obesity-related traits;
LUSC	cis	rs4499344	0.556	rs259220	chr19:33137629	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.94	13.84	0.6	9.41e-35	Mean platelet volume;
LUSC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	15.47	0.65	4.22e-41	Platelet count;
LUSC	cis	rs983392	0.679	rs4938932	chr11:60033448	C/T	cg24026212	chr11:59952134	MS4A6A	0.36	6.2	0.32	1.71e-9	Alzheimer's disease (late onset);
LUSC	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.51	-7.65	-0.39	2.2e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3740713	1.000	rs75740864	chr11:18470689	C/G	cg23797887	chr11:18477753	LDHAL6A	-0.56	-6.77	-0.35	5.8e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg03804128	chr16:635623	NA	0.3	5.84	0.3	1.25e-8	Height;
LUSC	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg12884169	chr21:40033163	ERG	0.56	11.17	0.52	8.17e-25	Coronary artery disease;
LUSC	cis	rs6489785	0.735	rs12825746	chr12:121268033	A/C	cg02419362	chr12:121203948	SPPL3	0.4	7.21	0.37	3.86e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7212590	0.618	rs35806089	chr17:57943906	A/G	cg10252138	chr17:58120427	NA	-0.72	-7.02	-0.36	1.22e-11	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg16797656	chr11:68205561	LRP5	0.36	6.06	0.31	3.77e-9	Total body bone mineral density;
LUSC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg23262073	chr20:60523788	NA	-0.45	-6.52	-0.34	2.66e-10	Body mass index;
LUSC	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg22117172	chr7:91764530	CYP51A1	0.32	5.73	0.3	2.25e-8	Breast cancer;
LUSC	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg07167872	chr1:205819463	PM20D1	-0.43	-5.83	-0.3	1.31e-8	Menarche (age at onset);
LUSC	cis	rs740160	0.510	rs12112936	chr7:98899500	G/A	cg24650262	chr7:98904301	NA	0.61	6.84	0.35	3.73e-11	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs909674	0.734	rs1005522	chr22:39845898	C/A	cg24399712	chr22:39784796	NA	-0.55	-8.35	-0.42	1.85e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs1005224	0.895	rs11624114	chr14:76131800	A/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-5.84	-0.3	1.21e-8	Large artery stroke;
LUSC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg05043794	chr9:111880884	C9orf5	0.34	7.61	0.38	2.84e-13	Menarche (age at onset);
LUSC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-7.58	-0.38	3.35e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05901451	chr6:126070800	HEY2	0.57	8.64	0.43	2.36e-16	Endometrial cancer;
LUSC	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg24675056	chr1:15929824	NA	0.42	6.99	0.36	1.49e-11	Systolic blood pressure;
LUSC	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg05373962	chr22:49881684	NA	-0.39	-8.51	-0.42	6.05e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg12927641	chr6:109611667	NA	-0.43	-7.58	-0.38	3.41e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs34734847	0.787	rs658521	chr12:121162414	G/T	cg27246729	chr12:121163418	ACADS	0.41	6.51	0.34	2.75e-10	Mean corpuscular volume;
LUSC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17509989	chr5:176798049	RGS14	0.66	10.55	0.5	1.24e-22	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg10547527	chr2:198650123	BOLL	-0.49	-5.69	-0.3	2.76e-8	Ulcerative colitis;
LUSC	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	0.56	8.3	0.41	2.7e-15	Breast cancer;
LUSC	trans	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.68	0.39	1.77e-13	Ulcerative colitis;
LUSC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg11766577	chr21:47581405	C21orf56	-0.43	-6.35	-0.33	7e-10	Testicular germ cell tumor;
LUSC	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg15485101	chr11:133734466	NA	0.38	7.15	0.36	5.56e-12	Childhood ear infection;
LUSC	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.36	-0.56	3.81e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg06547715	chr2:218990976	CXCR2	0.33	6.34	0.33	7.44e-10	Ulcerative colitis;
LUSC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg02896835	chr1:92012615	NA	-0.65	-11.72	-0.54	8.22e-27	Breast cancer;
LUSC	cis	rs6577655	0.517	rs6999469	chr8:135577530	G/A	cg17885191	chr8:135476712	NA	0.59	7.62	0.38	2.61e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs72949976	0.898	rs6732233	chr2:214022834	C/T	cg08319019	chr2:214017104	IKZF2	-0.57	-8.34	-0.42	1.93e-15	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs2354432	0.607	rs59689207	chr1:146722484	G/A	cg25205988	chr1:146714368	CHD1L	-1.0	-9.42	-0.46	7.81e-19	Mitochondrial DNA levels;
LUSC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22618164	chr12:122356400	WDR66	0.58	8.57	0.42	3.94e-16	Mean corpuscular volume;
LUSC	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg04240660	chr16:89714849	CHMP1A	-0.4	-6.42	-0.33	4.6e-10	Hemoglobin concentration;
LUSC	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg26566898	chr11:117069891	TAGLN	0.34	6.46	0.33	3.75e-10	Blood protein levels;
LUSC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg24060327	chr5:131705240	SLC22A5	0.69	11.35	0.53	1.86e-25	Breast cancer;
LUSC	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg11887960	chr12:57824829	NA	0.52	6.61	0.34	1.55e-10	Obesity-related traits;
LUSC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg21535247	chr6:8435926	SLC35B3	0.56	8.39	0.42	1.42e-15	Motion sickness;
LUSC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg09365446	chr1:150670422	GOLPH3L	0.48	7.04	0.36	1.12e-11	Melanoma;
LUSC	cis	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg06521331	chr12:34319734	NA	0.4	6.7	0.34	8.72e-11	Morning vs. evening chronotype;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24788636	chr1:40562667	PPT1	0.36	6.18	0.32	1.87e-9	Triglycerides;
LUSC	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg01579765	chr21:45077557	HSF2BP	-0.46	-9.59	-0.46	2.06e-19	Mean corpuscular volume;
LUSC	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg08017756	chr2:100939284	LONRF2	-0.43	-8.0	-0.4	2.04e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs10788972	0.620	rs34764952	chr1:54483694	C/T	cg25741118	chr1:54482237	LDLRAD1	-0.3	-6.63	-0.34	1.32e-10	Parkinson disease and lewy body pathology;
LUSC	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.71	10.94	0.51	5.36e-24	Alcohol dependence;
LUSC	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg21665744	chr7:39171113	POU6F2	0.44	6.68	0.34	9.83e-11	IgG glycosylation;
LUSC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.72	13.43	0.59	3.41e-33	Height;
LUSC	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg03395511	chr6:291903	DUSP22	0.44	6.77	0.35	5.89e-11	Menopause (age at onset);
LUSC	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg21775007	chr8:11205619	TDH	-0.57	-8.37	-0.42	1.62e-15	Neuroticism;
LUSC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	0.92	15.47	0.65	4.21e-41	Menopause (age at onset);
LUSC	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg26195577	chr20:24973756	C20orf3	1.13	18.17	0.71	8.33e-52	Blood protein levels;
LUSC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	12.08	0.55	3.89e-28	Menopause (age at onset);
LUSC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg11845111	chr2:191398756	TMEM194B	0.54	9.31	0.45	1.71e-18	Pulse pressure;
LUSC	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg15485101	chr11:133734466	NA	0.42	7.69	0.39	1.71e-13	Childhood ear infection;
LUSC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg00343986	chr7:65444356	GUSB	-0.42	-6.28	-0.33	1.04e-9	Aortic root size;
LUSC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.29	0.53	2.88e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17467752	chr17:38218738	THRA	0.49	7.19	0.37	4.17e-12	Lymphocyte percentage of white cells;
LUSC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg13175981	chr1:150552382	MCL1	0.48	6.81	0.35	4.53e-11	Tonsillectomy;
LUSC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg18230493	chr5:56204884	C5orf35	0.83	12.47	0.56	1.44e-29	Initial pursuit acceleration;
LUSC	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg12552261	chr5:112820674	MCC	-0.44	-6.99	-0.36	1.48e-11	Type 2 diabetes;
LUSC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.38	7.41e-13	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.69	0.39	1.63e-13	Prudent dietary pattern;
LUSC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.39	-6.0	-0.31	5.25e-9	Platelet count;
LUSC	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.74	11.92	0.55	1.54e-27	Metabolic syndrome;
LUSC	cis	rs1461503	0.534	rs4293127	chr11:122804263	G/C	cg27398637	chr11:122830231	C11orf63	-0.38	-6.09	-0.32	3.16e-9	Menarche (age at onset);
LUSC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg17328964	chr8:145687451	CYHR1	0.46	7.44	0.38	8.33e-13	Age at first birth;
LUSC	cis	rs6469656	1.000	rs7820778	chr8:117666463	A/G	cg24004040	chr8:117650383	NA	-0.42	-6.26	-0.32	1.16e-9	Colorectal cancer;
LUSC	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg15309053	chr8:964076	NA	0.34	6.98	0.36	1.62e-11	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg26380479	chr7:97908229	NA	-0.27	-6.06	-0.31	3.64e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg23205692	chr1:25664452	TMEM50A	0.42	6.44	0.33	4.21e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs2625529	0.557	rs1000281	chr15:72553422	A/G	cg16672083	chr15:72433130	SENP8	0.45	7.63	0.39	2.47e-13	Red blood cell count;
LUSC	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg05925327	chr15:68127851	NA	-0.39	-6.07	-0.32	3.39e-9	Restless legs syndrome;
LUSC	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.57	-6.61	-0.34	1.57e-10	Iron status biomarkers;
LUSC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.86	14.08	0.61	1.19e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	1.23	12.51	0.56	1.05e-29	Plateletcrit;
LUSC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	7.7	0.39	1.6e-13	Menarche (age at onset);
LUSC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-1.01	-17.28	-0.69	2.91e-48	Body mass index;
LUSC	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg07828024	chr6:149772892	ZC3H12D	-0.32	-7.02	-0.36	1.25e-11	Dupuytren's disease;
LUSC	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg22852734	chr6:133119734	C6orf192	1.17	14.03	0.61	1.8e-35	Type 2 diabetes nephropathy;
LUSC	cis	rs4631830	0.733	rs4512771	chr10:51540906	C/A	cg20129853	chr10:51489980	NA	-0.33	-6.6	-0.34	1.63e-10	Prostate-specific antigen levels;
LUSC	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.61	8.33	0.41	2.06e-15	Adiposity;
LUSC	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg05925327	chr15:68127851	NA	-0.41	-6.46	-0.33	3.79e-10	Restless legs syndrome;
LUSC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.14	0.36	5.71e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg02403541	chr12:121454288	C12orf43	0.7	10.25	0.49	1.33e-21	N-glycan levels;
LUSC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg05084668	chr3:125655381	ALG1L	-0.48	-6.79	-0.35	5.17e-11	Blood pressure (smoking interaction);
LUSC	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg02012338	chr4:187126139	CYP4V2	0.62	5.68	0.3	2.96e-8	Blood protein levels;
LUSC	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg21770322	chr7:97807741	LMTK2	0.56	10.08	0.48	4.99e-21	Breast cancer;
LUSC	cis	rs12291225	0.839	rs4757244	chr11:14258655	A/G	cg19336497	chr11:14380999	RRAS2	0.47	9.08	0.45	9.45e-18	Sense of smell;
LUSC	cis	rs9921338	0.924	rs7202024	chr16:11440758	A/G	cg00044050	chr16:11439710	C16orf75	-0.51	-6.68	-0.34	9.91e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs6960043	0.905	rs2215381	chr7:15054935	G/T	cg19272540	chr7:15055459	NA	0.34	8.72	0.43	1.3e-16	Type 2 diabetes;
LUSC	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-9.02	-0.44	1.46e-17	Morning vs. evening chronotype;
LUSC	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg20701182	chr2:24300061	SF3B14	0.56	6.09	0.32	3.06e-9	Lymphocyte counts;
LUSC	cis	rs1953600	0.870	rs2573356	chr10:81949363	C/T	cg00277334	chr10:82204260	NA	0.45	7.08	0.36	8.35e-12	Sarcoidosis;
LUSC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.1e-30	Aortic root size;
LUSC	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.23	-0.69	4.77e-48	Exhaled nitric oxide output;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg09039689	chr11:46639039	KIAA0652;HARBI1	0.43	6.34	0.33	7.6e-10	Triglycerides;
LUSC	cis	rs240764	0.658	rs7753317	chr6:101220433	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-6.24	-0.32	1.29e-9	Neuroticism;
LUSC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg19230755	chr7:65878503	NA	-0.41	-5.81	-0.3	1.47e-8	Aortic root size;
LUSC	trans	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg26043149	chr18:55253948	FECH	0.49	7.24	0.37	3.14e-12	Bone mineral density;
LUSC	cis	rs9928842	0.823	rs889514	chr16:75272512	A/G	cg09066997	chr16:75300724	BCAR1	0.51	6.49	0.33	3.07e-10	Alcoholic chronic pancreatitis;
LUSC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg16606324	chr3:10149918	C3orf24	0.58	8.23	0.41	4.27e-15	Alzheimer's disease;
LUSC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg23985595	chr17:80112537	CCDC57	0.3	5.82	0.3	1.39e-8	Life satisfaction;
LUSC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg05738196	chr6:26577821	NA	0.53	8.33	0.41	2.14e-15	Schizophrenia;
LUSC	cis	rs9905704	0.671	rs2531733	chr17:56548811	A/G	cg12560992	chr17:57184187	TRIM37	-0.5	-5.7	-0.3	2.68e-8	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg13206674	chr6:150067644	NUP43	0.56	8.59	0.43	3.41e-16	Lung cancer;
LUSC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg05855489	chr10:104503620	C10orf26	0.62	8.22	0.41	4.66e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg04310649	chr10:35416472	CREM	0.4	6.33	0.33	7.85e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.9	-0.44	3.54e-17	Metabolite levels;
LUSC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg14552801	chr7:65878734	NA	0.38	5.92	0.31	7.97e-9	Aortic root size;
LUSC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg11632617	chr15:75315747	PPCDC	-0.54	-7.1	-0.36	7.37e-12	Blood trace element (Zn levels);
LUSC	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg22875332	chr1:76189707	ACADM	-0.41	-6.21	-0.32	1.61e-9	Daytime sleep phenotypes;
LUSC	cis	rs9341808	0.718	rs9443735	chr6:80820474	G/T	cg08355045	chr6:80787529	NA	0.56	9.59	0.46	2.06e-19	Sitting height ratio;
LUSC	trans	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg18335740	chr13:41363409	SLC25A15	0.78	14.17	0.61	5.29e-36	Lewy body disease;
LUSC	cis	rs1775715	1.000	rs1251363	chr10:32328526	G/C	cg04359828	chr10:32216031	ARHGAP12	-0.36	-5.85	-0.31	1.14e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg25801113	chr15:45476975	SHF	-0.34	-6.87	-0.35	3.13e-11	Uric acid levels;
LUSC	cis	rs2629540	0.824	rs10901809	chr10:126410804	C/T	cg08799069	chr10:126477246	METTL10	0.45	6.62	0.34	1.4e-10	Cocaine dependence;
LUSC	cis	rs977987	1.000	rs62060550	chr16:75502252	C/T	cg04384234	chr16:75411784	CFDP1	-0.49	-8.11	-0.41	9.52e-15	Dupuytren's disease;
LUSC	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg15103426	chr22:29168792	CCDC117	0.48	6.2	0.32	1.66e-9	Lymphocyte counts;
LUSC	cis	rs713477	1.000	rs713477	chr14:55904426	C/A	cg04306507	chr14:55594613	LGALS3	-0.33	-6.47	-0.33	3.46e-10	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs80346118	0.850	rs73609692	chr20:47464324	G/A	cg16950247	chr11:62911616	SLC22A24	0.49	5.96	0.31	6.47e-9	Diastolic blood pressure;
LUSC	cis	rs2219968	1.000	rs59541962	chr8:78964111	G/C	cg00738934	chr8:78996279	NA	0.34	6.18	0.32	1.89e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg03538708	chr1:25844672	NA	-0.35	-5.74	-0.3	2.11e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg01802117	chr1:53393560	SCP2	0.38	6.23	0.32	1.37e-9	Monocyte count;
LUSC	cis	rs1451375	0.572	rs68011952	chr7:50638128	C/T	cg18232548	chr7:50535776	DDC	0.47	6.16	0.32	2.12e-9	Malaria;
LUSC	cis	rs4073416	0.542	rs7147536	chr14:65874698	C/T	cg03016385	chr14:66212404	NA	-0.43	-6.9	-0.35	2.59e-11	N-glycan levels;
LUSC	trans	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-9.0	-0.44	1.77e-17	Obesity-related traits;
LUSC	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	10.83	0.51	1.25e-23	Lung cancer in ever smokers;
LUSC	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg01657329	chr11:68192670	LRP5	-0.39	-5.67	-0.3	3.17e-8	Total body bone mineral density;
LUSC	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	0.93	17.19	0.69	6.65e-48	Headache;
LUSC	trans	rs2587949	0.593	rs2587929	chr3:4238613	A/T	cg15139668	chr4:4577005	NA	-0.41	-6.13	-0.32	2.42e-9	Periodontitis (DPAL);
LUSC	trans	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg19894588	chr14:64061835	NA	0.45	6.54	0.34	2.25e-10	Glioblastoma;Glioma;
LUSC	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	-0.53	-6.93	-0.35	2.16e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2820315	1.000	rs2820313	chr1:201870221	A/G	cg10061532	chr1:201886748	LMOD1	0.27	6.25	0.32	1.28e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.79	-11.15	-0.52	9.5e-25	Cognitive test performance;
LUSC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg00484396	chr16:3507460	NAT15	-0.71	-12.38	-0.56	3.24e-29	Tuberculosis;
LUSC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25072359	chr17:41440525	NA	0.68	9.5	0.46	4.34e-19	Menopause (age at onset);
LUSC	cis	rs6750047	0.585	rs4670234	chr2:38272477	C/T	cg07380506	chr2:38303506	CYP1B1	0.45	6.26	0.32	1.2e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	trans	rs931812	0.557	rs4734498	chr8:101946548	T/G	cg20993868	chr7:22813445	NA	0.34	6.28	0.32	1.07e-9	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg25801113	chr15:45476975	SHF	0.35	7.17	0.37	4.84e-12	Uric acid levels;
LUSC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.25	-0.41	3.75e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg17366294	chr4:99064904	C4orf37	0.57	9.91	0.48	1.88e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg27446573	chr6:127587934	RNF146	0.71	11.7	0.54	9.48e-27	Breast cancer;
LUSC	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg23289794	chr7:2394357	EIF3B	-0.75	-9.76	-0.47	5.75e-20	Multiple sclerosis;
LUSC	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg26195577	chr20:24973756	C20orf3	1.1	18.4	0.71	1.05e-52	Blood protein levels;
LUSC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09263875	chr16:632152	PIGQ	0.71	12.79	0.57	9.63e-31	Height;
LUSC	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg16359550	chr11:109292809	C11orf87	0.34	5.78	0.3	1.72e-8	Schizophrenia;
LUSC	cis	rs295140	1.000	rs11696001	chr2:201162433	G/A	cg04283868	chr2:201171347	SPATS2L	0.43	6.55	0.34	2.24e-10	QT interval;
LUSC	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.65	-0.3	3.5e-8	Coronary artery disease;
LUSC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg21535942	chr1:75199100	CRYZ;TYW3	0.48	7.45	0.38	8.23e-13	Resistin levels;
LUSC	cis	rs16976116	0.901	rs1061822	chr15:55496058	A/C	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg13770153	chr20:60521292	NA	-0.61	-8.41	-0.42	1.23e-15	Body mass index;
LUSC	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.86	-15.2	-0.64	4.98e-40	Ulcerative colitis;
LUSC	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.45	-0.42	9.43e-16	Lung cancer;
LUSC	cis	rs2290159	0.800	rs57884385	chr3:12673551	G/C	cg23032965	chr3:12705835	RAF1	0.74	9.13	0.45	6.87e-18	Cholesterol, total;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19777900	chr20:56284917	PMEPA1	-0.41	-6.27	-0.32	1.11e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg06640241	chr16:89574553	SPG7	-0.71	-11.12	-0.52	1.18e-24	Multiple myeloma (IgH translocation);
LUSC	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg02016764	chr4:38805732	TLR1	-0.53	-5.74	-0.3	2.16e-8	Breast cancer;
LUSC	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg23029597	chr12:123009494	RSRC2	-0.74	-9.13	-0.45	6.67e-18	Body mass index;
LUSC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.86	-11.15	-0.52	9.63e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs72634258	0.699	rs2493214	chr1:7994420	A/G	cg26816564	chr1:7831052	VAMP3	0.48	6.72	0.34	8.02e-11	Inflammatory bowel disease;
LUSC	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg12292205	chr6:26970375	C6orf41	0.38	6.15	0.32	2.24e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4704187	0.663	rs9654428	chr5:74466884	A/C	cg03227963	chr5:74354835	NA	0.31	6.7	0.34	8.62e-11	Response to amphetamines;
LUSC	trans	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-8.31	-0.41	2.44e-15	Obesity-related traits;
LUSC	cis	rs6484504	0.576	rs286653	chr11:31227824	C/T	cg06552810	chr11:31128660	NA	-0.4	-7.1	-0.36	7.62e-12	Red blood cell count;
LUSC	trans	rs7680126	0.633	rs4698023	chr4:10304726	A/G	cg26043149	chr18:55253948	FECH	-0.49	-6.22	-0.32	1.45e-9	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
LUSC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2398893	0.889	rs7870790	chr9:96779553	G/A	cg14459158	chr9:96720562	NA	0.3	5.91	0.31	8.65e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25802871	chr7:2282184	FTSJ2;NUDT1	-0.47	-6.0	-0.31	5.07e-9	Hepatitis;
LUSC	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg26384229	chr12:38710491	ALG10B	0.72	11.08	0.52	1.6e-24	Morning vs. evening chronotype;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	0.85	15.51	0.65	2.99e-41	Menarche (age at onset);
LUSC	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg03585969	chr10:35415529	CREM	0.58	8.43	0.42	1.02e-15	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg13072238	chr3:49761600	GMPPB	-0.36	-5.8	-0.3	1.5e-8	Body mass index;
LUSC	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg17252645	chr8:143867129	LY6D	-0.37	-6.47	-0.33	3.51e-10	Urinary tract infection frequency;
LUSC	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg26102564	chr10:131424627	MGMT	0.41	6.07	0.32	3.52e-9	Response to temozolomide;
LUSC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-7.92	-0.4	3.55e-14	Acylcarnitine levels;
LUSC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg04944784	chr2:26401820	FAM59B	0.7	9.55	0.46	2.83e-19	Gut microbiome composition (summer);
LUSC	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg13073564	chr4:8508604	NA	-0.41	-7.98	-0.4	2.31e-14	Response to antineoplastic agents;
LUSC	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg11189052	chr15:85197271	WDR73	-0.41	-5.91	-0.31	8.47e-9	P wave terminal force;
LUSC	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg01028140	chr2:1542097	TPO	-0.5	-6.94	-0.36	2.01e-11	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs8008758	0.517	rs1620117	chr14:101696931	C/A	cg26224664	chr14:101693935	NA	-0.38	-9.67	-0.47	1.14e-19	Body mass index (alcohol intake interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25099438	chr2:207024027	EEF1B2;NDUFS1	-0.38	-6.02	-0.31	4.71e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs68170813	0.559	rs3823960	chr7:107009349	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.56	-0.46	2.74e-19	Coronary artery disease;
LUSC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg07806771	chr7:64541737	NA	0.42	5.98	0.31	5.6e-9	Calcium levels;
LUSC	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg09658497	chr7:2847517	GNA12	-0.33	-5.9	-0.31	8.69e-9	Height;
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.68	-11.25	-0.52	4.17e-25	Longevity;Endometriosis;
LUSC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg18904891	chr8:8559673	CLDN23	0.41	6.03	0.31	4.32e-9	Mood instability;
LUSC	cis	rs977987	0.778	rs4888426	chr16:75476451	G/A	cg03315344	chr16:75512273	CHST6	0.49	9.5	0.46	4.32e-19	Dupuytren's disease;
LUSC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg15212455	chr7:39170539	POU6F2	0.59	9.47	0.46	5.27e-19	IgG glycosylation;
LUSC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg13319975	chr6:146136371	FBXO30	0.48	7.31	0.37	1.98e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg26441486	chr22:50317300	CRELD2	0.48	7.13	0.36	6.28e-12	Schizophrenia;
LUSC	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg00383909	chr3:49044727	WDR6	1.14	10.58	0.5	9.36e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg12826209	chr6:26865740	GUSBL1	0.69	7.79	0.39	8.74e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.9	-0.35	2.55e-11	Alcohol dependence;
LUSC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-8.67	-0.43	1.85e-16	Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25405238	chr17:79254455	SLC38A10	0.44	6.02	0.31	4.72e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg04369109	chr6:150039330	LATS1	-0.55	-8.23	-0.41	4.32e-15	Lung cancer;
LUSC	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg08508325	chr11:3079039	CARS	0.38	8.51	0.42	6.01e-16	Calcium levels;
LUSC	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.24	-0.41	3.86e-15	Response to antipsychotic treatment;
LUSC	cis	rs7799006	0.895	rs3757437	chr7:2271980	C/T	cg08027265	chr7:2291960	NA	-0.46	-7.82	-0.39	7.13e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.78	0.3	1.74e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg23791538	chr6:167370224	RNASET2	-0.4	-6.41	-0.33	4.9e-10	Crohn's disease;
LUSC	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg19257562	chr1:2043853	PRKCZ	0.32	6.32	0.33	8.45e-10	Height;
LUSC	cis	rs225245	0.817	rs225269	chr17:33967931	G/T	cg05299278	chr17:33885742	SLFN14	0.31	6.88	0.35	3.04e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg25482853	chr8:67687455	SGK3	1.06	15.78	0.65	2.71e-42	Obesity-related traits;
LUSC	cis	rs13082711	0.863	rs35998108	chr3:27423427	G/A	cg02860705	chr3:27208620	NA	0.49	8.38	0.42	1.53e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	trans	rs17607347	0.542	rs62052891	chr16:72556434	C/T	cg12945194	chr11:64703312	GPHA2	0.37	5.99	0.31	5.52e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6460942	0.908	rs78682952	chr7:12284886	C/A	cg06484146	chr7:12443880	VWDE	-0.55	-5.85	-0.3	1.18e-8	Coronary artery disease;
LUSC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.99	-0.31	5.37e-9	Personality dimensions;
LUSC	cis	rs6442522	0.733	rs4143273	chr3:15501808	C/T	cg16303742	chr3:15540471	COLQ	-0.3	-5.9	-0.31	8.68e-9	Uric acid levels;
LUSC	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21171335	chr12:122356390	WDR66	-0.52	-7.73	-0.39	1.31e-13	Mean corpuscular volume;
LUSC	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-1.04	-21.92	-0.77	1.28e-66	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-10.19	-0.49	2e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.5	-0.42	6.45e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23493127	chr6:144164392	LTV1	-0.4	-7.1	-0.36	7.72e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.46	-7.04	-0.36	1.1e-11	Response to antipsychotic treatment;
LUSC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg21770322	chr7:97807741	LMTK2	0.41	7.25	0.37	2.92e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg13010199	chr12:38710504	ALG10B	0.41	6.02	0.31	4.71e-9	Morning vs. evening chronotype;
LUSC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg21745248	chr20:55926117	RAE1	0.72	6.69	0.34	9.41e-11	Myocardial infarction;
LUSC	trans	rs12210905	0.688	rs114157955	chr6:27329878	C/T	cg02699829	chr19:13216355	TRMT1	-0.56	-6.23	-0.32	1.39e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg03929089	chr4:120376271	NA	0.66	6.22	0.32	1.47e-9	Intraocular pressure;
LUSC	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg21869046	chr19:41225005	ITPKC	0.49	6.78	0.35	5.56e-11	Kawasaki disease;
LUSC	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg10523860	chr14:103875565	MARK3	0.41	6.81	0.35	4.52e-11	Body mass index;
LUSC	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.33	-0.56	4.74e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.52	0.38	5.17e-13	Motion sickness;
LUSC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg04455712	chr21:45112962	RRP1B	0.46	8.79	0.43	8.25e-17	Mean corpuscular volume;
LUSC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-7.85	-0.39	5.8e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg10167463	chr7:75959203	YWHAG	-0.64	-9.64	-0.47	1.45e-19	Multiple sclerosis;
LUSC	cis	rs7795096	0.806	rs1109277	chr7:151540959	C/G	cg17008978	chr7:151542804	PRKAG2	-0.34	-6.58	-0.34	1.8e-10	Bipolar disorder (age of onset and psychotic symptoms);
LUSC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg09877947	chr5:131593287	PDLIM4	0.44	6.68	0.34	1.03e-10	Breast cancer;
LUSC	cis	rs79387448	0.683	rs7571985	chr2:103147561	G/A	cg09003973	chr2:102972529	NA	0.88	8.61	0.43	2.99e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg14433983	chr11:636460	DRD4	-0.35	-5.88	-0.31	9.78e-9	Systemic lupus erythematosus;
LUSC	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg12454169	chr2:30669597	LCLAT1	0.62	8.45	0.42	9.14e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	10.02	0.48	7.83e-21	Lymphocyte counts;
LUSC	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09307838	chr4:120376055	NA	0.75	10.7	0.51	3.49e-23	Corneal astigmatism;
LUSC	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg18827107	chr12:86230957	RASSF9	-0.4	-5.95	-0.31	6.77e-9	Major depressive disorder;
LUSC	trans	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-9.58	-0.46	2.35e-19	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-6.25	-0.32	1.22e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg16240275	chr20:61666158	NCRNA00029	0.42	8.89	0.44	3.82e-17	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27110648	chr12:100378843	ANKS1B	0.39	5.94	0.31	7e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.84	-0.54	3.05e-27	Chronic sinus infection;
LUSC	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.89	-0.31	9.34e-9	Resting heart rate;
LUSC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.65	-0.34	1.2e-10	Menopause (age at onset);
LUSC	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg23260525	chr10:116636907	FAM160B1	0.4	8.18	0.41	5.96e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21643547	chr1:205240462	TMCC2	-0.51	-9.98	-0.48	1.09e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs72674100	1.000	rs28417914	chr4:97988227	G/T	cg16405019	chr1:18959625	PAX7	-0.58	-6.33	-0.33	7.76e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.49	-7.03	-0.36	1.14e-11	Mean platelet volume;
LUSC	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.71	11.1	0.52	1.44e-24	Alcohol dependence;
LUSC	cis	rs968451	0.865	rs12627761	chr22:39724137	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.63	-8.52	-0.42	5.65e-16	Primary biliary cholangitis;
LUSC	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg05738196	chr6:26577821	NA	-0.6	-7.21	-0.37	3.78e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg21772509	chr8:41503840	NKX6-3	0.69	11.49	0.53	5.84e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs757278	0.591	rs4727855	chr7:117305374	A/G	cg10524701	chr7:117356490	CTTNBP2	-0.4	-5.74	-0.3	2.11e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.7	10.7	0.51	3.47e-23	Aortic root size;
LUSC	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg22437258	chr11:111473054	SIK2	0.51	7.05	0.36	1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11031096	0.754	rs10835611	chr11:4117730	G/C	cg18678763	chr11:4115507	RRM1	-0.48	-7.1	-0.36	7.72e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6469656	0.730	rs1436766	chr8:117652598	T/C	cg24004040	chr8:117650383	NA	-0.45	-6.46	-0.33	3.68e-10	Colorectal cancer;
LUSC	cis	rs9650657	0.615	rs7818181	chr8:10696515	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.29	-0.33	1.01e-9	Neuroticism;
LUSC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.33	0.37	1.8e-12	Motion sickness;
LUSC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05535760	chr7:792225	HEATR2	0.78	9.17	0.45	5.01e-18	Cerebrospinal P-tau181p levels;
LUSC	cis	rs6692729	0.966	rs8383	chr1:227083550	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.5	-7.06	-0.36	9.96e-12	Electrodermal activity;
LUSC	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg23093090	chr10:104574429	C10orf26	-0.46	-5.74	-0.3	2.12e-8	Arsenic metabolism;
LUSC	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg05347473	chr6:146136440	FBXO30	-0.47	-7.8	-0.39	8.16e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4903214	0.895	rs7161419	chr14:74695757	A/G	cg17626009	chr17:80792113	TBCD;ZNF750	-0.46	-6.31	-0.33	8.77e-10	Inflammatory bowel disease;
LUSC	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg23795048	chr12:9217529	LOC144571	0.34	5.88	0.31	1.02e-8	Sjögren's syndrome;
LUSC	cis	rs7580658	0.857	rs11890187	chr2:128083738	T/C	cg09760422	chr2:128146352	NA	-0.3	-6.47	-0.33	3.52e-10	Protein C levels;
LUSC	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg05738196	chr6:26577821	NA	0.81	15.89	0.66	9.93e-43	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-11.29	-0.53	2.95e-25	Monocyte count;
LUSC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg00522288	chr12:125625016	AACS	-0.33	-5.99	-0.31	5.47e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.34	0.62	1.16e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-11.55	-0.53	3.51e-26	Schizophrenia;
LUSC	cis	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.43	6.5	0.33	2.98e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs59698941	0.943	rs67806898	chr5:132296771	A/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-9.14	-0.45	6.19e-18	Morning vs. evening chronotype;
LUSC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg16482183	chr6:26056742	HIST1H1C	0.52	7.79	0.39	8.41e-14	Height;
LUSC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg09455208	chr3:40491958	NA	0.58	10.27	0.49	1.07e-21	Renal cell carcinoma;
LUSC	trans	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg26043149	chr18:55253948	FECH	-0.45	-6.9	-0.35	2.59e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4561483	0.514	rs33639	chr16:11989499	A/C	cg08843971	chr16:11963173	GSPT1	-0.44	-6.63	-0.34	1.33e-10	Testicular germ cell tumor;
LUSC	cis	rs7809950	0.678	rs6949634	chr7:106984684	G/T	cg23024343	chr7:107201750	COG5	-0.64	-9.59	-0.46	2.06e-19	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	6.1	0.32	2.92e-9	IgG glycosylation;
LUSC	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs240764	0.658	rs9322182	chr6:101223295	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.34	-0.33	7.43e-10	Neuroticism;
LUSC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg23711669	chr6:146136114	FBXO30	-0.92	-17.89	-0.7	1.18e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-6.03	-0.31	4.39e-9	IgG glycosylation;
LUSC	cis	rs7705502	1.000	rs7705507	chr5:173358337	C/T	cg18693985	chr5:173351052	CPEB4	-0.37	-5.79	-0.3	1.65e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs1044826	0.597	rs6772199	chr3:139178133	C/T	cg15131784	chr3:139108705	COPB2	0.4	6.48	0.33	3.24e-10	Obesity-related traits;
LUSC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg02551604	chr5:131831745	NA	-0.42	-6.62	-0.34	1.39e-10	Asthma (sex interaction);
LUSC	cis	rs7582720	1.000	rs72934519	chr2:203939640	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.65	0.43	2.2e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03713592	chr11:72463424	ARAP1	0.82	9.59	0.46	2.19e-19	Type 2 diabetes;
LUSC	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg13852791	chr20:30311386	BCL2L1	0.7	8.01	0.4	1.97e-14	Mean corpuscular hemoglobin;
LUSC	cis	rs17095355	0.642	rs57822924	chr10:111702078	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.62	-7.61	-0.38	2.8e-13	Biliary atresia;
LUSC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg25019033	chr10:957182	NA	-0.5	-6.26	-0.32	1.18e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg02475777	chr4:1388615	CRIPAK	0.39	5.77	0.3	1.8e-8	Obesity-related traits;
LUSC	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg14664628	chr15:75095509	CSK	0.43	6.16	0.32	2.11e-9	Caffeine consumption;
LUSC	trans	rs1325195	0.881	rs2816208	chr1:179171248	G/A	cg11624085	chr17:8464688	MYH10	0.41	6.64	0.34	1.29e-10	IgE grass sensitization;
LUSC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg23711669	chr6:146136114	FBXO30	0.81	14.55	0.62	1.77e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2996428	0.561	rs2275833	chr1:3745721	C/T	cg23277830	chr1:3704460	LRRC47	0.31	5.87	0.31	1.05e-8	Red cell distribution width;
LUSC	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg15654264	chr1:150340011	RPRD2	0.64	10.58	0.5	9.37e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg02454025	chr1:11042201	C1orf127	1.03	18.59	0.71	1.77e-53	Ewing sarcoma;
LUSC	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg19773385	chr1:10388646	KIF1B	-0.58	-9.93	-0.48	1.59e-20	Hepatocellular carcinoma;
LUSC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg06582575	chr6:163149167	PACRG;PARK2	1.1	14.12	0.61	7.99e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17401966	1.000	rs11121532	chr1:10277898	G/T	cg19773385	chr1:10388646	KIF1B	-0.54	-8.31	-0.41	2.52e-15	Hepatocellular carcinoma;
LUSC	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg10518543	chr12:38710700	ALG10B	0.4	5.71	0.3	2.44e-8	Morning vs. evening chronotype;
LUSC	cis	rs2294693	0.945	rs9394755	chr6:41006680	C/T	cg14769373	chr6:40998127	UNC5CL	0.5	7.11	0.36	7.17e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs2742417	0.967	rs1609553	chr3:45735142	T/C	cg09608765	chr3:45636137	LIMD1	-0.38	-7.38	-0.37	1.24e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs62458065	0.513	rs10268803	chr7:32547835	A/G	cg00845942	chr12:64062724	DPY19L2	-0.61	-7.62	-0.38	2.63e-13	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs4729127	1.000	rs73426361	chr7:94012656	G/T	cg20086523	chr13:52378287	DHRS12	0.55	6.41	0.33	5.07e-10	Intelligence;
LUSC	cis	rs7760535	0.811	rs464401	chr6:111669007	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Metabolic traits;
LUSC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg25174290	chr11:3078921	CARS	0.59	9.14	0.45	6.32e-18	Longevity;
LUSC	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg07930552	chr6:133119739	C6orf192	0.71	6.89	0.35	2.76e-11	Type 2 diabetes nephropathy;
LUSC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg06637938	chr14:75390232	RPS6KL1	0.53	8.29	0.41	2.73e-15	Height;
LUSC	cis	rs1385374	0.642	rs10847691	chr12:129287449	G/A	cg09035930	chr12:129282057	SLC15A4	-0.63	-6.85	-0.35	3.63e-11	Systemic lupus erythematosus;
LUSC	cis	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg20368463	chr18:77673604	PQLC1	-0.53	-7.7	-0.39	1.58e-13	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.21	-0.37	3.86e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg24675658	chr1:53192096	ZYG11B	0.58	9.14	0.45	6.02e-18	Monocyte count;
LUSC	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg22117172	chr7:91764530	CYP51A1	0.32	5.68	0.3	2.9e-8	Breast cancer;
LUSC	cis	rs3087591	0.922	rs12950506	chr17:29598392	A/G	cg24425628	chr17:29625626	OMG;NF1	0.54	7.72	0.39	1.4e-13	Hip circumference;
LUSC	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.73	-0.43	1.23e-16	Response to antipsychotic treatment;
LUSC	trans	rs9929218	1.000	rs12448448	chr16:68802516	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.48	-0.53	6.2e-26	Colorectal cancer;
LUSC	cis	rs28647808	0.881	rs41316984	chr9:136259231	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg27471124	chr11:109292789	C11orf87	0.45	7.71	0.39	1.5e-13	Schizophrenia;
LUSC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-8.06	-0.4	1.41e-14	Personality dimensions;
LUSC	trans	rs12200782	1.000	rs12199239	chr6:26432570	G/C	cg11837749	chr1:55047332	ACOT11	0.58	6.23	0.32	1.41e-9	Small cell lung carcinoma;
LUSC	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.46	7.02	0.36	1.23e-11	Colorectal cancer;
LUSC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.55	-8.33	-0.41	2.15e-15	Rheumatoid arthritis;
LUSC	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.48	-7.21	-0.37	3.65e-12	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs4663866	1.000	rs4663866	chr2:239150815	A/C	cg16914508	chr2:239161102	PER2	0.65	6.88	0.35	3.03e-11	Irritable bowel syndrome;
LUSC	cis	rs7113850	0.512	rs11027747	chr11:24197995	A/G	ch.11.24196551F	chr11:24239977	NA	-0.55	-5.93	-0.31	7.49e-9	Bone fracture in osteoporosis;
LUSC	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg05925327	chr15:68127851	NA	0.43	6.8	0.35	4.8e-11	Obesity;
LUSC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.07	0.32	3.49e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg16586182	chr3:47516702	SCAP	-0.49	-7.71	-0.39	1.47e-13	Colorectal cancer;
LUSC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg24585782	chr17:78113791	EIF4A3	0.53	7.83	0.39	6.45e-14	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs911119	0.913	rs3810575	chr20:23583392	G/A	cg16589663	chr20:23618590	CST3	0.62	7.53	0.38	4.7e-13	Chronic kidney disease;
LUSC	cis	rs62400317	0.762	rs10456120	chr6:44900107	C/T	cg18551225	chr6:44695536	NA	-0.48	-7.85	-0.39	5.89e-14	Total body bone mineral density;
LUSC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.65	0.54	1.53e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg00792783	chr2:198669748	PLCL1	0.45	5.99	0.31	5.43e-9	Dermatomyositis;
LUSC	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg03585969	chr10:35415529	CREM	0.6	8.8	0.43	7.41e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22968622	chr17:43663579	NA	-0.77	-11.79	-0.54	4.49e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg00191853	chr8:101177733	SPAG1	-0.41	-6.56	-0.34	2.08e-10	Atrioventricular conduction;
LUSC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.81	0.39	7.4e-14	Prudent dietary pattern;
LUSC	cis	rs7760949	0.889	rs9396264	chr6:13930342	T/A	cg27413430	chr6:13925136	RNF182	0.61	8.97	0.44	2.17e-17	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.26	-0.41	3.33e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs2055729	0.710	rs10104236	chr8:9740292	G/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-5.96	-0.31	6.25e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9807989	0.839	rs1974675	chr2:102986375	G/A	cg09003973	chr2:102972529	NA	0.44	6.0	0.31	5.06e-9	Asthma;
LUSC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-7.46	-0.38	7.33e-13	Chronic sinus infection;
LUSC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg04317338	chr11:64019027	PLCB3	0.66	7.53	0.38	4.65e-13	Mean platelet volume;
LUSC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.79	0.43	8.13e-17	Prudent dietary pattern;
LUSC	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg21293242	chr8:11204541	TDH	0.31	5.75	0.3	2.04e-8	Retinal vascular caliber;
LUSC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg20406979	chr6:167373233	NA	0.26	6.12	0.32	2.68e-9	Crohn's disease;
LUSC	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg17425144	chr1:10567563	PEX14	0.64	13.28	0.59	1.27e-32	Breast size;
LUSC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg19748678	chr4:122722346	EXOSC9	0.5	7.54	0.38	4.37e-13	Type 2 diabetes;
LUSC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg18306943	chr3:40428807	ENTPD3	0.38	5.82	0.3	1.36e-8	Renal cell carcinoma;
LUSC	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg03342759	chr3:160939853	NMD3	-0.39	-6.41	-0.33	4.89e-10	Morning vs. evening chronotype;
LUSC	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.82	14.35	0.62	1.04e-36	Metabolic syndrome;
LUSC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg23649088	chr2:200775458	C2orf69	0.6	7.4	0.38	1.08e-12	Schizophrenia;
LUSC	cis	rs3931020	0.657	rs7522428	chr1:75178360	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.46	5.83	0.3	1.31e-8	Resistin levels;
LUSC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.19	-0.49	2.09e-21	Bipolar disorder;
LUSC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23158103	chr7:148848205	ZNF398	-0.46	-7.56	-0.38	3.84e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	1.06	23.43	0.79	1.74e-72	Schizophrenia;
LUSC	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg07148914	chr20:33460835	GGT7	-0.51	-7.94	-0.4	3.09e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-5.91	-0.31	8.63e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14548871	chr10:102505330	PAX2	-0.46	-6.26	-0.32	1.21e-9	Hepatitis;
LUSC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg02153584	chr22:29168773	CCDC117	0.68	10.95	0.51	4.85e-24	Lymphocyte counts;
LUSC	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg04362960	chr10:104952993	NT5C2	0.55	8.01	0.4	1.91e-14	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg23711669	chr6:146136114	FBXO30	-0.89	-16.79	-0.68	2.56e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.87	-16.56	-0.67	2.12e-45	Colorectal cancer;
LUSC	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.85	-14.98	-0.63	3.53e-39	Ulcerative colitis;
LUSC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18876405	chr7:65276391	NA	0.54	8.47	0.42	8.1e-16	Aortic root size;
LUSC	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.77	9.79	0.47	4.6e-20	Migraine;Coronary artery disease;
LUSC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.02	20.48	0.75	5.84e-61	Cognitive function;
LUSC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-6.41	-0.33	4.89e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg10434728	chr15:90938212	IQGAP1	0.39	8.2	0.41	5.23e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.45	-0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs738321	0.701	rs11703601	chr22:38598041	C/T	cg25457927	chr22:38595422	NA	-0.45	-8.44	-0.42	1.01e-15	Breast cancer;
LUSC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18404041	chr3:52824283	ITIH1	0.47	8.91	0.44	3.34e-17	Bipolar disorder;
LUSC	cis	rs599083	0.744	rs603129	chr11:68186669	A/T	cg01657329	chr11:68192670	LRP5	0.51	7.57	0.38	3.73e-13	Bone mineral density (spine);
LUSC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.59	0.46	2.2e-19	Mean platelet volume;
LUSC	cis	rs9549260	0.561	rs2297014	chr13:41372960	G/A	cg21288729	chr13:41239152	FOXO1	0.53	5.85	0.3	1.16e-8	Red blood cell count;
LUSC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-10.06	-0.48	5.49e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg10523679	chr1:76189770	ACADM	-0.46	-6.53	-0.34	2.38e-10	Daytime sleep phenotypes;
LUSC	cis	rs239198	0.602	rs9377240	chr6:101323752	C/T	cg09795085	chr6:101329169	ASCC3	0.45	6.35	0.33	6.95e-10	Menarche (age at onset);
LUSC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg21659725	chr3:3221576	CRBN	-0.68	-7.65	-0.39	2.13e-13	Menarche (age at onset);
LUSC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg07777115	chr5:623756	CEP72	-0.45	-5.7	-0.3	2.62e-8	Obesity-related traits;
LUSC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg23791538	chr6:167370224	RNASET2	0.41	6.7	0.34	8.84e-11	Crohn's disease;
LUSC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg13902645	chr11:5959945	NA	-0.58	-8.27	-0.41	3.14e-15	DNA methylation (variation);
LUSC	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg00129232	chr17:37814104	STARD3	-0.43	-6.25	-0.32	1.26e-9	Asthma;
LUSC	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg22980127	chr19:33182716	NUDT19	0.69	8.82	0.43	6.3e-17	Red blood cell traits;
LUSC	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg13010199	chr12:38710504	ALG10B	0.57	9.09	0.45	9.21e-18	Morning vs. evening chronotype;
LUSC	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-7.36	-0.37	1.45e-12	Testicular germ cell tumor;
LUSC	cis	rs9420	0.884	rs589914	chr11:57661032	A/G	cg02958346	chr11:57425731	CLP1	0.44	6.04	0.31	4.07e-9	Schizophrenia;
LUSC	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg18512352	chr11:47633146	NA	-0.48	-9.8	-0.47	4.44e-20	Subjective well-being;
LUSC	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.52	-13.94	-0.61	4.06e-35	Urate levels in overweight individuals;
LUSC	cis	rs9837602	1.000	rs2291494	chr3:99781805	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.82	-0.3	1.38e-8	Breast cancer;
LUSC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	6.03	0.31	4.44e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.57	11.42	0.53	9.72e-26	Monocyte percentage of white cells;
LUSC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg11645453	chr3:52864694	ITIH4	-0.36	-8.3	-0.41	2.64e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg04871131	chr7:94954202	PON1	-0.39	-6.18	-0.32	1.84e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg20406979	chr6:167373233	NA	-0.26	-6.11	-0.32	2.77e-9	Crohn's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00978910	chr1:172502140	C1orf9	-0.49	-6.17	-0.32	2e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg09365446	chr1:150670422	GOLPH3L	-0.44	-6.72	-0.35	7.86e-11	Tonsillectomy;
LUSC	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.54	0.57	8.04e-30	Lymphocyte percentage of white cells;
LUSC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg07741184	chr6:167504864	NA	0.37	6.72	0.35	7.82e-11	Crohn's disease;
LUSC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg14949292	chr17:78079608	GAA	0.4	6.89	0.35	2.79e-11	Yeast infection;
LUSC	cis	rs12760731	0.565	rs11583503	chr1:178169663	G/C	cg00404053	chr1:178313656	RASAL2	0.66	6.82	0.35	4.26e-11	Obesity-related traits;
LUSC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.47e-8	Life satisfaction;
LUSC	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg24147428	chr11:65409760	SIPA1	-0.52	-7.73	-0.39	1.25e-13	Blood pressure (age interaction);
LUSC	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.77	-12.99	-0.58	1.66e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg20991723	chr1:152506922	NA	0.5	9.28	0.45	2.18e-18	Hair morphology;
LUSC	cis	rs1030877	0.515	rs920217	chr2:105904662	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.66	-9.25	-0.45	2.65e-18	Obesity-related traits;
LUSC	cis	rs68170813	0.523	rs10253172	chr7:106786474	C/T	cg02696742	chr7:106810147	HBP1	0.65	9.18	0.45	4.72e-18	Coronary artery disease;
LUSC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg09034736	chr1:150693464	HORMAD1	0.51	7.51	0.38	5.57e-13	Tonsillectomy;
LUSC	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg25173405	chr17:45401733	C17orf57	-0.39	-6.19	-0.32	1.74e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg22920501	chr2:26401640	FAM59B	-0.67	-8.85	-0.44	5.39e-17	Gut microbiome composition (summer);
LUSC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.74	-0.43	1.19e-16	Coffee consumption (cups per day);
LUSC	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg01620082	chr3:125678407	NA	-0.75	-7.26	-0.37	2.81e-12	Depression;
LUSC	cis	rs7582180	0.903	rs13013891	chr2:100896110	T/C	cg08017756	chr2:100939284	LONRF2	-0.36	-5.97	-0.31	5.98e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	10.33	0.49	7.1e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs4363385	0.776	rs1415957	chr1:152948909	A/G	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.41	-0.38	1.03e-12	Inflammatory skin disease;
LUSC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-17.43	-0.69	7.53e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg20283391	chr11:68216788	NA	-0.61	-8.57	-0.42	3.81e-16	Total body bone mineral density;
LUSC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.72	-12.81	-0.57	7.8e-31	Dental caries;
LUSC	cis	rs12995849	0.676	rs934306	chr2:106459654	C/A	cg14210321	chr2:106509881	NCK2	-0.41	-5.94	-0.31	7.02e-9	Addiction;
LUSC	cis	rs1018836	0.892	rs4140680	chr8:91584157	G/A	cg16814680	chr8:91681699	NA	-0.65	-9.81	-0.47	3.95e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12911832	1.000	rs12911832	chr15:58985904	A/T	cg05156742	chr15:59063176	FAM63B	0.47	6.6	0.34	1.58e-10	Schizophrenia;
LUSC	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg15501526	chr10:2543763	NA	0.56	9.88	0.48	2.33e-20	Age-related hearing impairment;
LUSC	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs4363385	0.510	rs7532166	chr1:153046851	C/G	cg25856811	chr1:152973957	SPRR3	-0.37	-6.11	-0.32	2.78e-9	Inflammatory skin disease;
LUSC	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg26597838	chr10:835615	NA	0.88	11.69	0.54	1.09e-26	Eosinophil percentage of granulocytes;
LUSC	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg24881330	chr22:46731750	TRMU	0.91	7.17	0.37	4.85e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25427524	chr10:38739819	LOC399744	-0.65	-11.4	-0.53	1.19e-25	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.85	-14.37	-0.62	8.64e-37	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.16	-0.41	6.92e-15	Lung cancer;
LUSC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg01420254	chr6:26195488	NA	0.72	7.5	0.38	5.86e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg01475377	chr6:109611718	NA	0.42	7.51	0.38	5.35e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg20129853	chr10:51489980	NA	0.36	7.45	0.38	7.84e-13	Prostate-specific antigen levels;
LUSC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg12463550	chr7:65579703	CRCP	0.56	8.35	0.42	1.79e-15	Aortic root size;
LUSC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.51	0.34	2.83e-10	Lung cancer;
LUSC	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg25664220	chr3:72788482	NA	-0.72	-12.01	-0.55	7.08e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9399401	0.845	rs263189	chr6:142859724	T/C	cg03128060	chr6:142623767	GPR126	0.32	5.96	0.31	6.54e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg23387468	chr7:139079360	LUC7L2	-0.42	-6.44	-0.33	4.05e-10	Diisocyanate-induced asthma;
LUSC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	1.22	13.64	0.6	5.53e-34	Diabetic kidney disease;
LUSC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-10.7	-0.51	3.49e-23	Schizophrenia;
LUSC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-1.06	-15.01	-0.63	2.89e-39	Vitiligo;
LUSC	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg04850211	chr1:228464232	OBSCN	-0.37	-6.21	-0.32	1.58e-9	Diastolic blood pressure;
LUSC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg04155289	chr7:94953770	PON1	0.33	5.65	0.3	3.47e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg17764715	chr19:33622953	WDR88	0.61	8.36	0.42	1.67e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21659725	chr3:3221576	CRBN	0.59	8.0	0.4	2.05e-14	Resting heart rate;
LUSC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24549020	chr5:56110836	MAP3K1	-0.48	-5.85	-0.3	1.16e-8	Initial pursuit acceleration;
LUSC	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.9	15.6	0.65	1.31e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg11802864	chr11:65308245	LTBP3	0.85	5.86	0.31	1.11e-8	Height;
LUSC	cis	rs11153147	0.649	rs10456863	chr6:109299092	A/T	cg05315195	chr6:109294784	ARMC2	-0.56	-6.2	-0.32	1.66e-9	Mean corpuscular volume;
LUSC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg09034736	chr1:150693464	HORMAD1	0.46	6.73	0.35	7.26e-11	Tonsillectomy;
LUSC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg16325326	chr1:53192061	ZYG11B	0.86	15.37	0.64	1.05e-40	Monocyte count;
LUSC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg00255919	chr5:131827918	IRF1	-0.43	-8.25	-0.41	3.61e-15	Asthma (sex interaction);
LUSC	cis	rs79387448	0.745	rs17027428	chr2:103163175	G/A	cg09003973	chr2:102972529	NA	0.89	8.62	0.43	2.69e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs4363385	0.667	rs454186	chr1:153049149	C/T	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.24	-0.37	3.05e-12	Inflammatory skin disease;
LUSC	trans	rs9944715	0.734	rs9967220	chr18:43780059	C/T	cg01718231	chr17:29326311	RNF135	-0.55	-7.83	-0.39	6.7e-14	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg04733989	chr22:42467013	NAGA	0.38	6.47	0.33	3.58e-10	Cognitive function;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15985629	chr12:44199522	TWF1	-0.46	-6.13	-0.32	2.47e-9	Hepatitis;
LUSC	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg07541023	chr7:19748670	TWISTNB	0.78	8.21	0.41	4.98e-15	Thyroid stimulating hormone;
LUSC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg02487422	chr3:49467188	NICN1	0.47	7.38	0.37	1.27e-12	Resting heart rate;
LUSC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg06096015	chr1:231504339	EGLN1	0.56	9.82	0.47	3.68e-20	Hemoglobin concentration;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg00431813	chr7:1051703	C7orf50	-0.45	-7.36	-0.37	1.43e-12	Longevity;Endometriosis;
LUSC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.78	0.51	1.95e-23	Hypertriglyceridemia;
LUSC	cis	rs7804356	1.000	rs28404962	chr7:26860324	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.2	-0.32	1.66e-9	Type 1 diabetes;
LUSC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	13.25	0.59	1.72e-32	Alzheimer's disease;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg21483475	chr3:154042025	DHX36	0.38	6.71	0.34	8.44e-11	Triglycerides;
LUSC	cis	rs540254	0.578	rs12117689	chr1:160782100	C/T	cg20255094	chr1:160771763	LY9	0.56	6.75	0.35	6.45e-11	Blood protein levels;
LUSC	trans	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.35	-0.42	1.82e-15	Retinal vascular caliber;
LUSC	trans	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg10756647	chr7:56101905	PSPH	0.88	8.91	0.44	3.39e-17	Diabetic kidney disease;
LUSC	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg05294307	chr14:35346193	BAZ1A	-0.57	-6.58	-0.34	1.8e-10	Psoriasis;
LUSC	cis	rs2463822	0.583	rs17709552	chr11:62040519	A/G	cg06239285	chr11:62104954	ASRGL1	-0.62	-6.43	-0.33	4.49e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg11871910	chr12:69753446	YEATS4	0.84	14.61	0.62	1.03e-37	Blood protein levels;
LUSC	cis	rs965469	0.901	rs6037586	chr20:3368114	G/A	cg25506879	chr20:3388711	C20orf194	-0.52	-5.68	-0.3	2.97e-8	IFN-related cytopenia;
LUSC	trans	rs1422110	1.000	rs1422110	chr5:85466140	C/T	cg01787110	chr1:109008453	NBPF6	-0.42	-6.65	-0.34	1.16e-10	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs6722750	0.716	rs6546056	chr2:64414077	A/G	cg22352474	chr2:64371530	PELI1	-0.52	-7.64	-0.39	2.31e-13	Neuroticism;
LUSC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg05623727	chr3:50126028	RBM5	-0.33	-6.18	-0.32	1.86e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg04865166	chr7:105162814	PUS7	0.52	5.92	0.31	7.79e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg07157834	chr1:205819609	PM20D1	-0.43	-5.65	-0.3	3.52e-8	Menarche (age at onset);
LUSC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg04398451	chr17:18023971	MYO15A	-0.57	-9.44	-0.46	6.61e-19	Total body bone mineral density;
LUSC	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg23093090	chr10:104574429	C10orf26	-0.37	-6.76	-0.35	6.05e-11	Waist circumference;Hip circumference;
LUSC	cis	rs3744061	0.505	rs60239313	chr17:74647586	T/C	cg27546012	chr17:74684504	MXRA7	-0.36	-6.28	-0.32	1.07e-9	Retinal arteriolar caliber;
LUSC	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg09307838	chr4:120376055	NA	0.76	10.87	0.51	9.13e-24	Corneal astigmatism;
LUSC	cis	rs2692947	0.628	rs1997257	chr2:96429625	A/G	cg23100626	chr2:96804247	ASTL	0.24	5.88	0.31	9.81e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4589502	0.925	rs57729347	chr15:67136438	G/A	cg12317470	chr15:67143691	NA	0.63	7.15	0.36	5.53e-12	Lung cancer (smoking interaction);
LUSC	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg12823233	chr7:2316876	SNX8	-0.45	-7.64	-0.39	2.24e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11764359	chr7:65958608	NA	-0.68	-10.93	-0.51	5.47e-24	Aortic root size;
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg15242686	chr22:24348715	GSTTP1	0.55	8.94	0.44	2.74e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg24812749	chr6:127587940	RNF146	0.65	9.79	0.47	4.51e-20	Breast cancer;
LUSC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg02079420	chr8:82753780	SNX16	0.41	7.1	0.36	7.48e-12	Diastolic blood pressure;
LUSC	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.69	-10.8	-0.51	1.66e-23	Alcohol dependence;
LUSC	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg19743168	chr1:23544995	NA	-0.41	-8.73	-0.43	1.27e-16	Height;
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.34	-0.42	1.94e-15	Lymphocyte counts;
LUSC	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg27489772	chr12:121021490	NA	-0.6	-7.79	-0.39	8.71e-14	Type 1 diabetes nephropathy;
LUSC	trans	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg14791747	chr16:20752902	THUMPD1	-0.4	-6.13	-0.32	2.47e-9	Dental caries;
LUSC	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg16482183	chr6:26056742	HIST1H1C	0.56	7.92	0.4	3.6e-14	Iron status biomarkers;
LUSC	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg18477163	chr1:228402036	OBSCN	-0.56	-10.36	-0.49	5.35e-22	Diastolic blood pressure;
LUSC	cis	rs9467160	0.871	rs9461014	chr6:24449008	T/G	cg20631270	chr6:24437470	GPLD1	0.44	5.76	0.3	1.94e-8	Liver enzyme levels;
LUSC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.49	-6.6	-0.34	1.62e-10	Tonsillectomy;
LUSC	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg24375607	chr4:120327624	NA	0.75	11.06	0.52	2e-24	Corneal astigmatism;
LUSC	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg01420254	chr6:26195488	NA	0.63	7.08	0.36	8.38e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs12136530	0.744	rs16862798	chr1:19777837	A/G	cg01832549	chr1:19774989	CAPZB	-0.33	-6.1	-0.32	2.96e-9	Lead levels in blood;
LUSC	cis	rs4363385	0.818	rs382292	chr1:153006641	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.43e-12	Inflammatory skin disease;
LUSC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.18	0.45	4.46e-18	Prudent dietary pattern;
LUSC	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg26762873	chr11:5879799	OR52E8	0.31	6.03	0.31	4.38e-9	DNA methylation (variation);
LUSC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.73	-12.15	-0.55	2.3e-28	Coronary artery disease;
LUSC	cis	rs926938	0.527	rs360685	chr1:115499795	G/C	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.41	-0.33	5.01e-10	Autism;
LUSC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg24558204	chr6:135376177	HBS1L	0.6	9.42	0.46	7.41e-19	Red blood cell count;
LUSC	cis	rs4423214	0.592	rs11233977	chr11:71221605	C/T	cg05163923	chr11:71159392	DHCR7	-0.69	-7.06	-0.36	9.73e-12	Vitamin D levels;
LUSC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg18350739	chr11:68623251	NA	-0.38	-6.43	-0.33	4.36e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06544989	chr22:39130855	UNC84B	0.34	5.8	0.3	1.53e-8	Menopause (age at onset);
LUSC	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg26677194	chr12:130822605	PIWIL1	0.59	8.79	0.43	7.9e-17	Menopause (age at onset);
LUSC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg13047869	chr3:10149882	C3orf24	0.64	8.43	0.42	1.06e-15	Alzheimer's disease;
LUSC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg24642439	chr20:33292090	TP53INP2	-0.68	-10.85	-0.51	1.09e-23	Coronary artery disease;
LUSC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.81	-0.35	4.68e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg03340356	chr1:67600835	NA	-0.39	-6.2	-0.32	1.66e-9	Psoriasis;
LUSC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg00857998	chr1:205179979	DSTYK	-0.64	-10.13	-0.48	3.22e-21	Red blood cell count;
LUSC	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg22709100	chr7:91322751	NA	0.39	5.86	0.31	1.08e-8	Breast cancer;
LUSC	trans	rs17607347	0.542	rs1429071	chr16:72452277	A/G	cg22321522	chr19:15490619	AKAP8	-0.57	-5.96	-0.31	6.43e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6693567	0.565	rs6685252	chr1:150259945	T/A	cg15654264	chr1:150340011	RPRD2	-0.44	-7.08	-0.36	8.57e-12	Migraine;
LUSC	cis	rs4946717	0.740	rs9480634	chr6:106468486	C/T	cg02270332	chr6:106475062	NA	0.45	9.33	0.45	1.46e-18	Inflammatory bowel disease;
LUSC	cis	rs977987	0.806	rs4887818	chr16:75361995	T/C	cg04384234	chr16:75411784	CFDP1	-0.42	-6.91	-0.35	2.43e-11	Dupuytren's disease;
LUSC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg02423579	chr7:2872169	GNA12	-0.45	-6.69	-0.34	9.32e-11	Height;
LUSC	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg20608306	chr11:116969690	SIK3	0.37	6.96	0.36	1.8e-11	Blood protein levels;
LUSC	cis	rs10740039	1.000	rs10740039	chr10:62414682	C/G	cg18175470	chr10:62150864	ANK3	-0.39	-6.17	-0.32	1.93e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg21775007	chr8:11205619	TDH	0.46	6.57	0.34	1.93e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9394438	0.628	rs4714080	chr6:37544618	A/G	cg00985040	chr6:37553208	NA	0.39	8.75	0.43	1.11e-16	IgG glycosylation;
LUSC	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg07929629	chr2:241523174	NA	0.62	10.96	0.51	4.49e-24	Bipolar disorder;
LUSC	cis	rs3760982	1.000	rs60184524	chr19:44294215	A/G	cg11993925	chr19:44307056	LYPD5	0.28	6.21	0.32	1.59e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg20406979	chr6:167373233	NA	0.26	6.09	0.32	3.07e-9	Crohn's disease;
LUSC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.2	-0.32	1.62e-9	Life satisfaction;
LUSC	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.49	8.06	0.4	1.35e-14	IgG glycosylation;
LUSC	cis	rs354225	0.544	rs12713266	chr2:54805443	G/T	cg01766943	chr2:54829624	SPTBN1	0.48	7.61	0.38	2.89e-13	Schizophrenia;
LUSC	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg06092702	chr1:163392909	NA	0.42	6.96	0.36	1.86e-11	Motion sickness;
LUSC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	0.94	16.07	0.66	1.97e-43	Menopause (age at onset);
LUSC	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg05283184	chr6:79620031	NA	0.58	12.24	0.56	1.01e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg16989719	chr2:238392110	NA	-0.37	-6.45	-0.33	3.87e-10	Prostate cancer;
LUSC	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg08079166	chr15:68083412	MAP2K5	0.41	7.29	0.37	2.33e-12	Restless legs syndrome;
LUSC	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs2516839	0.652	rs2516841	chr1:161010774	A/G	cg11161846	chr1:160990452	F11R	-0.35	-6.38	-0.33	5.79e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg03585969	chr10:35415529	CREM	-0.63	-9.25	-0.45	2.65e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02119927	chr10:71078141	HK1	-0.41	-6.14	-0.32	2.29e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg12165864	chr7:66369176	NA	-0.51	-6.77	-0.35	5.64e-11	Corneal structure;
LUSC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	0.98	14.25	0.61	2.6e-36	Eosinophil percentage of granulocytes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04552940	chr2:27712630	IFT172	-0.42	-6.29	-0.33	1.02e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg27284194	chr4:1044797	NA	0.35	5.99	0.31	5.54e-9	Obesity-related traits;
LUSC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg00484396	chr16:3507460	NAT15	-0.91	-10.66	-0.5	5.13e-23	Tuberculosis;
LUSC	cis	rs2376015	1	rs2376015	chr1:66123774	A/G	cg04111102	chr1:66153794	NA	0.33	7.24	0.37	3.19e-12	Fibrinogen levels;
LUSC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg12463550	chr7:65579703	CRCP	0.45	6.62	0.34	1.44e-10	Aortic root size;
LUSC	cis	rs9865818	0.626	rs2889896	chr3:188102716	C/T	cg23651889	chr3:188115336	LPP	-0.38	-5.72	-0.3	2.33e-8	Allergic sensitization;
LUSC	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	7.12	0.36	6.54e-12	Ovarian reserve;
LUSC	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg12386194	chr3:101231763	SENP7	0.4	5.74	0.3	2.16e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg15556689	chr8:8085844	FLJ10661	0.42	6.12	0.32	2.69e-9	Platelet distribution width;
LUSC	cis	rs10489525	0.599	rs7526323	chr1:115604241	G/A	cg17147537	chr1:115611705	TSPAN2	0.3	6.07	0.32	3.53e-9	Autism;
LUSC	trans	rs10221833	0.636	rs355876	chr2:165632858	T/G	cg26993132	chr16:89239499	CDH15	0.31	5.99	0.31	5.4e-9	Response to statin therapy;
LUSC	cis	rs4594175	0.707	rs4901102	chr14:51746605	C/T	cg23942311	chr14:51606299	NA	-0.29	-6.01	-0.31	4.78e-9	Cancer;
LUSC	trans	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-7.63	-0.39	2.47e-13	Menarche (age at onset);
LUSC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg25797454	chr6:150327115	RAET1K	0.33	7.49	0.38	6.34e-13	Alopecia areata;
LUSC	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg04607235	chr12:12878440	APOLD1	-0.51	-5.81	-0.3	1.43e-8	Systemic lupus erythematosus;
LUSC	cis	rs17095355	1.000	rs17126902	chr10:111710381	A/G	cg00817464	chr10:111662876	XPNPEP1	0.67	8.4	0.42	1.26e-15	Biliary atresia;
LUSC	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg17470449	chr10:769945	NA	0.49	6.71	0.34	8.1e-11	Uric acid levels;
LUSC	cis	rs4704187	0.687	rs922390	chr5:74401269	A/G	cg03227963	chr5:74354835	NA	0.32	6.82	0.35	4.4e-11	Response to amphetamines;
LUSC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.79	11.34	0.53	1.97e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg04727924	chr7:799746	HEATR2	0.53	6.24	0.32	1.35e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg07507251	chr3:52567010	NT5DC2	0.34	6.54	0.34	2.27e-10	Bipolar disorder;
LUSC	cis	rs2273669	0.667	rs12204576	chr6:109318843	A/G	cg05315195	chr6:109294784	ARMC2	-0.53	-5.94	-0.31	7.15e-9	Prostate cancer;
LUSC	cis	rs4845459	0.967	rs10888503	chr1:152593549	C/T	cg08895932	chr1:152778580	LCE1C	-0.38	-6.49	-0.33	3.07e-10	Psoriasis;
LUSC	cis	rs4290604	0.748	rs12692198	chr2:238057391	C/A	cg23555395	chr2:238036564	NA	-0.52	-6.94	-0.35	2.07e-11	Asthma;
LUSC	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.23	0.45	3.29e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg19156104	chr2:198669113	PLCL1	0.46	5.64	0.3	3.54e-8	Ulcerative colitis;
LUSC	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-5.77	-0.3	1.84e-8	IgG glycosylation;
LUSC	cis	rs74181299	0.890	rs2723062	chr2:65280220	G/A	cg05010058	chr2:65284262	CEP68	0.31	6.14	0.32	2.3e-9	Pulse pressure;
LUSC	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg15485101	chr11:133734466	NA	-0.34	-6.26	-0.32	1.18e-9	Childhood ear infection;
LUSC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg01765077	chr12:122356316	WDR66	0.51	7.27	0.37	2.52e-12	Mean corpuscular volume;
LUSC	cis	rs17253792	0.822	rs77197405	chr14:56159662	T/A	cg01858014	chr14:56050164	KTN1	-0.84	-6.83	-0.35	4.13e-11	Putamen volume;
LUSC	cis	rs9362426	1.000	rs9362426	chr6:88089874	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.36	5.71	0.3	2.51e-8	Depressive episodes in bipolar disorder;
LUSC	cis	rs4566357	1.000	rs6705783	chr2:227923268	C/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.8	-0.3	1.57e-8	Coronary artery disease;
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.58	-11.06	-0.52	1.97e-24	Longevity;Endometriosis;
LUSC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.57	-0.34	1.94e-10	Schizophrenia;
LUSC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg13560548	chr3:10150139	C3orf24	0.49	6.89	0.35	2.82e-11	Alzheimer's disease;
LUSC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg06238570	chr21:40685208	BRWD1	0.46	7.13	0.36	6.22e-12	Cognitive function;
LUSC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg17173187	chr15:85201210	NMB	-0.31	-6.38	-0.33	6.01e-10	P wave terminal force;
LUSC	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21659725	chr3:3221576	CRBN	-0.64	-10.63	-0.5	6.13e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs6998277	0.830	rs7017839	chr8:103610769	G/C	cg10187029	chr8:103597600	NA	0.79	12.21	0.56	1.39e-28	Migraine;
LUSC	cis	rs7586879	0.828	rs2384056	chr2:25092649	G/A	cg01884057	chr2:25150051	NA	0.4	8.18	0.41	5.98e-15	Body mass index;
LUSC	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.26	0.64	2.81e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs7923609	0.756	rs7090758	chr10:65335315	T/C	cg01631684	chr10:65280961	REEP3	0.38	5.72	0.3	2.42e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7923609	0.869	rs10733792	chr10:65232539	A/G	cg01631684	chr10:65280961	REEP3	-0.42	-6.44	-0.33	4.1e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg20935933	chr6:143382018	AIG1	0.51	7.4	0.38	1.08e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.69	-10.67	-0.5	4.7e-23	Hypertriglyceridemia;
LUSC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg26513180	chr16:89883248	FANCA	0.63	5.86	0.31	1.11e-8	Skin colour saturation;
LUSC	cis	rs713477	0.935	rs4901564	chr14:55912409	G/T	cg13175173	chr14:55914753	NA	-0.32	-6.78	-0.35	5.42e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg04317338	chr11:64019027	PLCB3	0.66	7.41	0.38	1.06e-12	Mean platelet volume;
LUSC	cis	rs4343996	0.967	rs7803993	chr7:3353057	G/A	cg21248987	chr7:3385318	SDK1	-0.39	-6.61	-0.34	1.57e-10	Motion sickness;
LUSC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg01256987	chr12:42539512	GXYLT1	-0.44	-8.29	-0.41	2.74e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.57	7.97	0.4	2.59e-14	Chronic sinus infection;
LUSC	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-0.91	-17.45	-0.69	6.14e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.59	-0.54	2.5e-26	Schizophrenia;
LUSC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.07	-0.32	3.41e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs198712	0.505	rs198314	chr7:24191005	C/T	cg06529468	chr19:10676722	KRI1	0.38	6.1	0.32	2.89e-9	Aggressive periodontitis (sex interaction);
LUSC	cis	rs3087591	0.922	rs9892839	chr17:29618990	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.57	-8.21	-0.41	5.05e-15	Hip circumference;
LUSC	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg08601574	chr20:25228251	PYGB	0.41	6.2	0.32	1.65e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.82	0.6	1.14e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.17	0.55	1.95e-28	Colorectal cancer;
LUSC	cis	rs9914988	0.945	rs9279	chr17:27187636	G/T	cg09479241	chr17:27052676	TLCD1	-0.42	-5.68	-0.3	2.92e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg13010344	chr12:123464640	ARL6IP4	-0.44	-6.04	-0.31	4.09e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21643547	chr1:205240462	TMCC2	-0.5	-9.42	-0.46	7.85e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg04450456	chr4:17643702	FAM184B	-0.4	-6.55	-0.34	2.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.39	5.94	0.31	7.16e-9	Vitiligo;
LUSC	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.55	-6.81	-0.35	4.42e-11	Schizophrenia;
LUSC	cis	rs1018697	1.000	rs10748830	chr10:104548382	A/C	cg04362960	chr10:104952993	NT5C2	0.47	6.45	0.33	4e-10	Colorectal adenoma (advanced);
LUSC	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04362095	chr11:63592001	C11orf84	-0.57	-8.72	-0.43	1.32e-16	Pulse pressure;
LUSC	cis	rs2294693	0.891	rs1072119	chr6:40993072	G/A	cg14769373	chr6:40998127	UNC5CL	-0.51	-7.12	-0.36	6.84e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg17173187	chr15:85201210	NMB	0.47	8.86	0.44	4.87e-17	Schizophrenia;
LUSC	cis	rs506338	0.517	rs530775	chr11:64426933	A/G	cg19395706	chr11:64412079	NRXN2	0.29	5.92	0.31	7.91e-9	Body mass index;Urate levels;
LUSC	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	11.48	0.53	5.9e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg05926928	chr17:57297772	GDPD1	1.45	17.98	0.7	5.08e-51	Opioid sensitivity;
LUSC	cis	rs10097731	0.901	rs4398860	chr8:82041753	C/T	cg25230327	chr8:82042993	NA	-0.47	-6.66	-0.34	1.1e-10	Serum total protein level;
LUSC	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	12.47	0.56	1.45e-29	Primary sclerosing cholangitis;
LUSC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	0.91	15.15	0.64	7.89e-40	Breast cancer;
LUSC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08219700	chr8:58056026	NA	0.56	7.69	0.39	1.62e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1865721	0.755	rs3813081	chr18:73185096	A/G	cg26385618	chr18:73139727	C18orf62	-0.42	-7.13	-0.36	6.11e-12	Intelligence;
LUSC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg21951975	chr1:209979733	IRF6	0.61	7.89	0.4	4.43e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.33	-0.33	7.98e-10	Arsenic metabolism;
LUSC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.11	0.48	3.78e-21	Bipolar disorder;
LUSC	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	6.48	0.33	3.36e-10	Schizophrenia;
LUSC	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg15557168	chr22:42548783	NA	0.35	5.84	0.3	1.25e-8	Cognitive function;
LUSC	cis	rs10266483	0.774	rs4718067	chr7:63816396	A/G	cg24201672	chr7:64023550	ZNF680	-0.45	-5.86	-0.31	1.09e-8	Response to statin therapy;
LUSC	cis	rs6120849	0.707	rs6088690	chr20:33633326	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.58	0.34	1.8e-10	Protein C levels;
LUSC	cis	rs17014483	0.749	rs2924936	chr4:89641514	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.68	6.14	0.32	2.29e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4629710	0.545	rs3777477	chr6:131534374	T/C	cg12700074	chr6:131571435	AKAP7	-0.37	-6.13	-0.32	2.48e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.14e-35	Breast cancer;
LUSC	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg07167872	chr1:205819463	PM20D1	-0.44	-5.94	-0.31	7.24e-9	Menarche (age at onset);
LUSC	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg14582100	chr15:45693742	SPATA5L1	0.45	8.47	0.42	7.77e-16	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05653691	chr1:16175060	FLJ37453;SPEN	-0.41	-6.2	-0.32	1.71e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs55910451	0.732	rs2797496	chr10:5801232	A/C	cg11519256	chr10:5708881	ASB13	-0.5	-6.27	-0.32	1.1e-9	Breast cancer;
LUSC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05776053	chr2:74358815	NA	0.44	7.04	0.36	1.07e-11	Gestational age at birth (maternal effect);
LUSC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.76	14.05	0.61	1.54e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-8.49	-0.42	6.96e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.52e-11	Morning vs. evening chronotype;
LUSC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.78	7.71	0.39	1.47e-13	Initial pursuit acceleration;
LUSC	cis	rs1395	0.922	rs1561535	chr2:27471025	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.36	5.83	0.3	1.32e-8	Blood metabolite levels;
LUSC	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg03647239	chr10:116582469	FAM160B1	0.44	7.15	0.36	5.58e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs8038465	1.000	rs8032531	chr15:73977271	A/G	cg15420318	chr15:73925796	NPTN	0.42	6.61	0.34	1.54e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg18806716	chr10:30721971	MAP3K8	-0.57	-8.67	-0.43	1.9e-16	Itch intensity from mosquito bite;
LUSC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg07677032	chr17:61819896	STRADA	-0.56	-9.14	-0.45	6.16e-18	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg17366294	chr4:99064904	C4orf37	0.56	9.76	0.47	5.88e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg13385521	chr17:29058706	SUZ12P	0.58	5.68	0.3	2.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7119	0.651	rs34829483	chr15:77835986	C/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.41	-0.33	4.89e-10	Type 2 diabetes;
LUSC	cis	rs9395066	0.545	rs35357222	chr6:44940552	C/G	cg25276700	chr6:44698697	NA	0.29	5.86	0.31	1.08e-8	Height;
LUSC	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg00310523	chr12:86230176	RASSF9	0.44	8.25	0.41	3.7e-15	Major depressive disorder;
LUSC	cis	rs7929679	0.521	rs7122506	chr11:34786853	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.87	0.31	1.03e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg24829409	chr8:58192753	C8orf71	-0.62	-6.81	-0.35	4.59e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4474465	1.000	rs10899522	chr11:78190763	C/G	cg27205649	chr11:78285834	NARS2	0.49	5.97	0.31	5.95e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg24110177	chr3:50126178	RBM5	0.41	6.48	0.33	3.2e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.0	0.31	5.27e-9	Lung cancer;
LUSC	trans	rs28735056	0.660	rs12454454	chr18:77674634	C/T	cg05926928	chr17:57297772	GDPD1	-0.48	-6.78	-0.35	5.6e-11	Schizophrenia;
LUSC	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.07e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4654899	0.865	rs6664532	chr1:21515800	G/A	cg01072550	chr1:21505969	NA	-0.52	-7.89	-0.4	4.41e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg16545954	chr1:2118288	C1orf86	0.38	7.33	0.37	1.69e-12	Height;
LUSC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.71	0.7	5.75e-50	Chronic sinus infection;
LUSC	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	0.84	11.27	0.52	3.53e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs6714710	0.603	rs13008968	chr2:98435982	C/T	cg26665480	chr2:98280029	ACTR1B	0.59	8.65	0.43	2.26e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	1.03	19.58	0.73	2.08e-57	Menopause (age at onset);
LUSC	cis	rs7119	0.667	rs907393	chr15:77903447	T/C	cg27398640	chr15:77910606	LINGO1	0.38	8.86	0.44	4.7e-17	Type 2 diabetes;
LUSC	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg11645453	chr3:52864694	ITIH4	0.28	6.55	0.34	2.2e-10	Electroencephalogram traits;
LUSC	cis	rs9296092	0.560	rs9469506	chr6:33527897	A/G	cg13560919	chr6:33536144	NA	-0.85	-16.44	-0.67	6.54e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg21659725	chr3:3221576	CRBN	0.68	8.24	0.41	3.83e-15	Menarche (age at onset);
LUSC	cis	rs4851254	0.550	rs13402299	chr2:100659409	C/T	cg07810366	chr2:100720526	AFF3	-0.46	-5.95	-0.31	6.87e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9341808	0.718	rs3828754	chr6:80900640	C/G	cg08355045	chr6:80787529	NA	0.59	10.22	0.49	1.64e-21	Sitting height ratio;
LUSC	cis	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg06521331	chr12:34319734	NA	-0.47	-7.63	-0.39	2.47e-13	Morning vs. evening chronotype;
LUSC	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.55	-0.46	2.96e-19	Bone mineral density;
LUSC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.4	-5.9	-0.31	9.05e-9	Renal function-related traits (BUN);
LUSC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg04166393	chr7:2884313	GNA12	-0.43	-5.97	-0.31	6.2e-9	Height;
LUSC	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg05347473	chr6:146136440	FBXO30	0.49	8.23	0.41	4.25e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08048268	chr3:133502702	NA	-0.46	-8.98	-0.44	2.05e-17	Iron status biomarkers;
LUSC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg04267008	chr7:1944627	MAD1L1	-0.45	-6.46	-0.33	3.63e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg02187348	chr16:89574699	SPG7	0.5	7.77	0.39	9.64e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs1971762	0.583	rs12810378	chr12:54091838	G/T	cg23533419	chr12:54090519	NA	-0.37	-5.96	-0.31	6.52e-9	Height;
LUSC	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg19875535	chr5:140030758	IK	0.48	7.89	0.4	4.32e-14	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg18230493	chr5:56204884	C5orf35	-0.92	-14.05	-0.61	1.47e-35	Initial pursuit acceleration;
LUSC	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg24558204	chr6:135376177	HBS1L	0.57	8.77	0.43	9.11e-17	Red blood cell count;
LUSC	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.78	-0.43	8.95e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-6.9	-0.35	2.64e-11	Aortic root size;
LUSC	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.66	-0.3	3.35e-8	Coronary artery disease;
LUSC	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.5	-6.3	-0.33	9.26e-10	Menarche (age at onset);
LUSC	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg14809332	chr8:144654887	C8orf73	0.5	6.09	0.32	3.13e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	10.42	0.5	3.26e-22	Homoarginine levels;
LUSC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.55	0.42	4.56e-16	Motion sickness;
LUSC	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.72	-10.23	-0.49	1.5e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg05805236	chr11:65401703	PCNXL3	0.41	6.85	0.35	3.47e-11	Acne (severe);
LUSC	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg05373962	chr22:49881684	NA	-0.41	-8.64	-0.43	2.33e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg03388025	chr16:89894329	SPIRE2	0.31	6.47	0.33	3.52e-10	Vitiligo;
LUSC	cis	rs983392	0.709	rs2081547	chr11:59989430	C/T	cg02771260	chr11:59836817	MS4A3	-0.36	-5.92	-0.31	8.18e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.66	-0.43	2.09e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg11663144	chr21:46675770	NA	-0.41	-7.18	-0.37	4.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	14.27	0.62	2.12e-36	Exhaled nitric oxide levels;
LUSC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg16624210	chr5:671434	TPPP	0.49	6.19	0.32	1.76e-9	Obesity-related traits;
LUSC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.03	0.31	4.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg17173187	chr15:85201210	NMB	0.36	5.87	0.31	1.06e-8	Schizophrenia;
LUSC	cis	rs4704187	0.687	rs6862754	chr5:74427193	T/C	cg03227963	chr5:74354835	NA	0.32	6.89	0.35	2.81e-11	Response to amphetamines;
LUSC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg25036284	chr2:26402008	FAM59B	-0.77	-11.38	-0.53	1.46e-25	Gut microbiome composition (summer);
LUSC	cis	rs2997447	0.655	rs2275949	chr1:26385150	C/G	cg19633962	chr1:26362018	EXTL1	-0.61	-7.49	-0.38	6.15e-13	QRS complex (12-leadsum);
LUSC	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg05805236	chr11:65401703	PCNXL3	-0.64	-10.4	-0.49	3.8e-22	Acne (severe);
LUSC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08219700	chr8:58056026	NA	0.68	7.76	0.39	1.05e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg03806693	chr22:41940476	POLR3H	0.9	13.1	0.58	6.27e-32	Vitiligo;
LUSC	cis	rs9322817	0.691	rs9404586	chr6:105332814	A/G	cg02098413	chr6:105308735	HACE1	0.28	5.94	0.31	7.34e-9	Thyroid stimulating hormone;
LUSC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg24920358	chr1:40204285	PPIE	0.6	10.7	0.51	3.61e-23	Blood protein levels;
LUSC	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.71	0.3	2.51e-8	Platelet count;
LUSC	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg20487152	chr13:99095054	FARP1	-0.4	-6.9	-0.35	2.67e-11	Longevity;
LUSC	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg09307838	chr4:120376055	NA	0.71	10.34	0.49	6.26e-22	Corneal astigmatism;
LUSC	cis	rs897984	0.770	rs3813020	chr16:30934075	G/A	cg02466173	chr16:30829666	NA	0.56	11.19	0.52	6.77e-25	Dementia with Lewy bodies;
LUSC	cis	rs12541635	1.000	rs1864320	chr8:107088979	C/T	cg10147462	chr8:107024639	NA	0.48	8.98	0.44	1.96e-17	Age of smoking initiation;
LUSC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg14416269	chr4:6271139	WFS1	0.52	10.93	0.51	5.39e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg02030672	chr11:45687055	CHST1	0.44	6.65	0.34	1.19e-10	Obesity-related traits;
LUSC	cis	rs4253772	0.938	rs75977757	chr22:46641525	G/T	cg18190219	chr22:46762943	CELSR1	-0.52	-6.02	-0.31	4.71e-9	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11764359	chr7:65958608	NA	0.54	7.11	0.36	7.23e-12	Aortic root size;
LUSC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg22482690	chr17:47019901	SNF8	0.4	7.59	0.38	3.17e-13	Type 2 diabetes;
LUSC	cis	rs501916	0.602	rs472081	chr15:48058652	G/T	cg16110827	chr15:48056943	SEMA6D	-0.38	-5.93	-0.31	7.5e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg23625390	chr15:77176239	SCAPER	-0.42	-6.43	-0.33	4.54e-10	Blood metabolite levels;
LUSC	cis	rs27434	0.607	rs26654	chr5:96140367	C/T	cg16492584	chr5:96139282	ERAP1	-0.58	-7.9	-0.4	4.08e-14	Ankylosing spondylitis;
LUSC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.62	12.64	0.57	3.5e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg18753928	chr3:113234510	CCDC52	-0.44	-6.76	-0.35	6.31e-11	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg07148914	chr20:33460835	GGT7	-0.55	-8.35	-0.42	1.88e-15	Height;
LUSC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-1.18	-16.59	-0.67	1.59e-45	Breast cancer;
LUSC	cis	rs4604732	0.642	rs7549312	chr1:247640078	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.36	5.82	0.3	1.38e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg17279839	chr7:150038598	RARRES2	0.51	7.83	0.39	6.46e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg01448562	chr3:133502909	NA	-0.66	-10.66	-0.5	4.99e-23	Iron status biomarkers;
LUSC	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.81	-14.85	-0.63	1.19e-38	Ulcerative colitis;
LUSC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg13206674	chr6:150067644	NUP43	0.62	10.08	0.48	4.87e-21	Lung cancer;
LUSC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21963583	chr11:68658836	MRPL21	0.56	8.57	0.42	3.8e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.85	-0.3	1.19e-8	Personality dimensions;
LUSC	cis	rs9300255	0.679	rs4759420	chr12:123794871	G/C	cg00376283	chr12:123451042	ABCB9	0.66	7.74	0.39	1.2e-13	Neutrophil percentage of white cells;
LUSC	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg13736514	chr6:26305472	NA	-0.45	-8.75	-0.43	1.08e-16	Educational attainment;
LUSC	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	12.64	0.57	3.43e-30	Total body bone mineral density;
LUSC	cis	rs9503598	0.778	rs10155771	chr6:3465930	G/A	cg00476032	chr6:3446245	SLC22A23	0.38	7.52	0.38	5.25e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-9.64	-0.47	1.4e-19	Body mass index;
LUSC	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg07150166	chr2:30669952	LCLAT1	-0.52	-6.14	-0.32	2.33e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg19230755	chr7:65878503	NA	0.41	5.76	0.3	1.95e-8	Aortic root size;
LUSC	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg08219700	chr8:58056026	NA	0.49	6.0	0.31	5.05e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	1.04	15.89	0.66	9.39e-43	Primary sclerosing cholangitis;
LUSC	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg13042288	chr15:90349979	ANPEP	-0.5	-7.06	-0.36	9.79e-12	Uric acid levels;
LUSC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.9	-18.76	-0.72	3.77e-54	Intelligence (multi-trait analysis);
LUSC	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18932078	chr1:2524107	MMEL1	-0.32	-7.12	-0.36	6.57e-12	Ulcerative colitis;
LUSC	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg26875233	chr11:93583750	C11orf90	-0.31	-6.06	-0.31	3.76e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19006050	chr10:131904236	NA	-0.44	-6.43	-0.33	4.32e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg24060327	chr5:131705240	SLC22A5	-0.67	-11.67	-0.54	1.22e-26	Breast cancer;
LUSC	trans	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05039488	chr6:79577232	IRAK1BP1	0.43	6.34	0.33	7.63e-10	Endometrial cancer;
LUSC	cis	rs727505	1.000	rs10281582	chr7:124423688	A/G	cg23710748	chr7:124431027	NA	-0.4	-7.13	-0.36	6.15e-12	Lewy body disease;
LUSC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25072359	chr17:41440525	NA	0.66	9.5	0.46	4.09e-19	Menopause (age at onset);
LUSC	cis	rs834603	0.547	rs1704966	chr7:47469948	G/A	cg09696706	chr7:47479511	TNS3	0.33	5.9	0.31	8.81e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	12.91	0.58	3.43e-31	Lung cancer in ever smokers;
LUSC	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg00074818	chr8:8560427	CLDN23	0.59	9.54	0.46	3.07e-19	Obesity-related traits;
LUSC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	12.42	0.56	2.18e-29	Monocyte percentage of white cells;
LUSC	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg22705602	chr4:152727874	NA	0.34	7.14	0.36	5.92e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg02187348	chr16:89574699	SPG7	-0.37	-5.67	-0.3	3.08e-8	Multiple myeloma (IgH translocation);
LUSC	trans	rs1325195	0.920	rs380474	chr1:179217448	C/T	cg11624085	chr17:8464688	MYH10	0.44	7.1	0.36	7.36e-12	IgE grass sensitization;
LUSC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.48	7.5	0.38	5.74e-13	Schizophrenia;
LUSC	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg09165964	chr15:75287851	SCAMP5	-0.46	-6.76	-0.35	6.06e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg15242686	chr22:24348715	GSTTP1	0.53	8.39	0.42	1.35e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs13242816	1.000	rs17138708	chr7:116109062	T/G	cg16553024	chr7:116138462	CAV2	-0.54	-5.92	-0.31	7.84e-9	P wave duration;
LUSC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	8.5	0.42	6.61e-16	Menarche (age at onset);
LUSC	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg01448562	chr3:133502909	NA	0.52	7.85	0.39	5.57e-14	Iron status biomarkers;
LUSC	cis	rs7586879	0.609	rs7608976	chr2:25075281	G/A	cg04586622	chr2:25135609	ADCY3	0.39	8.04	0.4	1.58e-14	Body mass index;
LUSC	cis	rs9796	0.717	rs476633	chr15:41392134	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.27	-0.41	3.13e-15	Menopause (age at onset);
LUSC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.86	-0.4	5.2e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs2652834	1.000	rs11637852	chr15:63397151	G/A	cg05507819	chr15:63340323	TPM1	0.68	8.15	0.41	7.29e-15	HDL cholesterol;
LUSC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg12412775	chr1:25698385	RHCE	-0.29	-5.76	-0.3	1.86e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs12472274	0.941	rs4663861	chr2:239105203	C/T	cg17459225	chr2:239074497	NA	0.63	10.03	0.48	7.08e-21	Phospholipid levels (plasma);
LUSC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.5	-0.38	5.64e-13	Joint mobility (Beighton score);
LUSC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-1.23	-13.78	-0.6	1.62e-34	Diabetic kidney disease;
LUSC	cis	rs10743315	0.643	rs16915128	chr12:19304286	G/T	cg02471346	chr12:19282374	PLEKHA5	-0.68	-6.69	-0.34	9.42e-11	Gut microbiota (bacterial taxa);
LUSC	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-6.55	-0.34	2.12e-10	Monocyte percentage of white cells;
LUSC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00149659	chr3:10157352	C3orf10	0.99	14.17	0.61	5.01e-36	Alzheimer's disease;
LUSC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg22800045	chr5:56110881	MAP3K1	-0.6	-8.46	-0.42	8.76e-16	Initial pursuit acceleration;
LUSC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg15242686	chr22:24348715	GSTTP1	0.4	6.16	0.32	2.08e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3820928	0.845	rs13419076	chr2:227873028	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.61	-0.38	2.81e-13	Pulmonary function;
LUSC	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg15445000	chr17:37608096	MED1	-0.39	-6.77	-0.35	5.69e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg17845761	chr1:175162550	KIAA0040	-0.31	-5.95	-0.31	6.59e-9	Alcohol dependence;
LUSC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.54	-8.28	-0.41	2.98e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg10434728	chr15:90938212	IQGAP1	-0.46	-9.42	-0.46	7.61e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs12995849	0.905	rs12712218	chr2:106451751	G/T	cg14210321	chr2:106509881	NCK2	-0.39	-5.82	-0.3	1.36e-8	Addiction;
LUSC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg09359103	chr1:154839909	KCNN3	0.72	17.2	0.69	6.02e-48	Prostate cancer;
LUSC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-0.84	-10.15	-0.49	2.92e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.4	-6.19	-0.32	1.77e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg12863693	chr15:85201151	NMB	0.36	7.06	0.36	9.44e-12	Schizophrenia;
LUSC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg15448220	chr1:150897856	SETDB1	0.38	5.66	0.3	3.19e-8	Tonsillectomy;
LUSC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg14581129	chr12:53358946	NA	-0.71	-9.83	-0.47	3.26e-20	Cancer (pleiotropy);
LUSC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg26750617	chr12:132293702	NA	-0.36	-5.72	-0.3	2.37e-8	Migraine;
LUSC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	5.9e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4474465	0.688	rs10899553	chr11:78265210	A/G	cg27205649	chr11:78285834	NARS2	0.52	6.12	0.32	2.64e-9	Alzheimer's disease (survival time);
LUSC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02018176	chr4:1364513	KIAA1530	0.75	13.67	0.6	4.11e-34	Longevity;
LUSC	cis	rs2357013	0.725	rs13426096	chr2:53206582	A/G	cg07782112	chr2:53107842	NA	0.38	6.0	0.31	4.99e-9	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	1.14	12.61	0.57	4.36e-30	Arsenic metabolism;
LUSC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.68	0.39	1.77e-13	Parkinson's disease;
LUSC	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-6.89	-0.35	2.82e-11	Breast cancer;
LUSC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.19	-0.49	2.06e-21	Gut microbiome composition (summer);
LUSC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg22638593	chr5:131593259	PDLIM4	0.38	5.81	0.3	1.44e-8	Breast cancer;
LUSC	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg02187348	chr16:89574699	SPG7	0.6	9.46	0.46	5.8e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.78	0.3	1.69e-8	Breast cancer;
LUSC	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg00206168	chr11:65308501	LTBP3	1.32	8.84	0.44	5.6e-17	Height;
LUSC	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg12856521	chr11:46389249	DGKZ	0.43	6.44	0.33	4.28e-10	Leprosy;
LUSC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg17330251	chr7:94953956	PON1	-0.37	-5.96	-0.31	6.32e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg02807482	chr3:125708958	NA	-0.52	-6.5	-0.33	2.98e-10	Blood pressure (smoking interaction);
LUSC	cis	rs1886644	0.700	rs10493758	chr1:85349184	C/T	cg08479277	chr1:85350632	LPAR3	0.37	6.27	0.32	1.09e-9	Glucose homeostasis traits;
LUSC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg13256891	chr4:100009986	ADH5	0.51	7.03	0.36	1.21e-11	Smoking initiation;
LUSC	cis	rs4343996	1.000	rs4298408	chr7:3358731	T/C	cg21248987	chr7:3385318	SDK1	-0.38	-6.45	-0.33	3.93e-10	Motion sickness;
LUSC	cis	rs10193935	0.901	rs222469	chr2:42640235	T/C	cg27598129	chr2:42591480	NA	-0.62	-8.36	-0.42	1.76e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg13798780	chr7:105162888	PUS7	0.56	6.12	0.32	2.55e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg22508957	chr16:3507546	NAT15	-0.41	-6.5	-0.34	2.96e-10	Body mass index (adult);
LUSC	cis	rs1044826	0.597	rs1017468	chr3:139145778	A/G	cg00490450	chr3:139108681	COPB2	0.5	7.87	0.4	4.85e-14	Obesity-related traits;
LUSC	cis	rs701145	0.585	rs1727923	chr3:153786303	C/T	cg17054900	chr3:154042577	DHX36	-0.73	-7.44	-0.38	8.72e-13	Coronary artery disease;
LUSC	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg02176678	chr2:219576539	TTLL4	-0.58	-10.32	-0.49	7.34e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg22166914	chr1:53195759	ZYG11B	0.48	7.57	0.38	3.68e-13	Monocyte count;
LUSC	cis	rs62408225	0.962	rs6899623	chr6:90986559	A/G	cg06866423	chr6:90926672	BACH2	0.4	5.78	0.3	1.75e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	0.44	6.56	0.34	2e-10	Menarche (age at onset);
LUSC	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg13010199	chr12:38710504	ALG10B	0.55	8.44	0.42	9.84e-16	Morning vs. evening chronotype;
LUSC	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.16	0.36	5.11e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg20991723	chr1:152506922	NA	0.5	9.44	0.46	6.48e-19	Hair morphology;
LUSC	cis	rs8040855	0.794	rs4843024	chr15:85705900	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.41	5.94	0.31	7.16e-9	Bulimia nervosa;
LUSC	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.43	0.38	9.31e-13	Menarche (age at onset);
LUSC	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.72	-13.48	-0.59	2.36e-33	Ulcerative colitis;
LUSC	cis	rs12928939	0.769	rs12445161	chr16:71741928	C/T	cg08717414	chr16:71523259	ZNF19	-0.42	-5.91	-0.31	8.23e-9	Post bronchodilator FEV1;
LUSC	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg13010199	chr12:38710504	ALG10B	0.55	8.38	0.42	1.5e-15	Morning vs. evening chronotype;
LUSC	cis	rs7582720	1.000	rs72932566	chr2:203855342	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	8.37	0.42	1.63e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05901451	chr6:126070800	HEY2	0.57	8.58	0.43	3.59e-16	Endometrial cancer;
LUSC	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg27489772	chr12:121021490	NA	0.6	7.87	0.4	5.06e-14	Type 1 diabetes nephropathy;
LUSC	cis	rs6496044	0.568	rs2344436	chr15:86074906	C/T	cg13263323	chr15:86062960	AKAP13	-0.37	-6.16	-0.32	2.06e-9	Interstitial lung disease;
LUSC	cis	rs71403859	0.504	rs12926413	chr16:71972325	T/C	cg08717414	chr16:71523259	ZNF19	-0.56	-5.75	-0.3	2.02e-8	Post bronchodilator FEV1;
LUSC	cis	rs4953076	0.573	rs7593987	chr2:44393532	C/T	cg04920474	chr2:44395004	PPM1B	-0.64	-8.17	-0.41	6.34e-15	Height;
LUSC	cis	rs3736594	0.802	rs9678824	chr2:27964328	G/C	cg27432699	chr2:27873401	GPN1	0.66	9.21	0.45	3.58e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.51	6.38	0.33	5.79e-10	Renal function-related traits (BUN);
LUSC	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	6.56	0.34	2.04e-10	Response to antipsychotic treatment;
LUSC	cis	rs2816316	0.848	rs3011685	chr1:192524993	C/T	cg02586212	chr1:192544902	RGS1	0.31	5.71	0.3	2.55e-8	Celiac disease;
LUSC	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-5.69	-0.3	2.78e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07805730	chr1:85156430	SSX2IP	-0.43	-6.24	-0.32	1.34e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg20573242	chr4:122745356	CCNA2	0.43	6.65	0.34	1.19e-10	Type 2 diabetes;
LUSC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg21361702	chr7:150065534	REPIN1	0.5	6.87	0.35	3.09e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	0.68	6.84	0.35	3.85e-11	Prostate cancer;
LUSC	cis	rs225245	0.782	rs321618	chr17:33912404	A/G	cg05299278	chr17:33885742	SLFN14	0.31	6.9	0.35	2.68e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.71	-0.39	1.42e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9378688	1.000	rs72830184	chr6:2223930	T/C	cg12303981	chr6:2244766	GMDS	-0.54	-6.31	-0.33	8.88e-10	Caudate nucleus volume;
LUSC	cis	rs193541	0.507	rs1965900	chr5:122082786	T/C	cg19077854	chr5:122220652	SNX24	0.26	5.64	0.3	3.56e-8	Glucose homeostasis traits;
LUSC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00166722	chr3:10149974	C3orf24	0.58	7.42	0.38	9.7e-13	Alzheimer's disease;
LUSC	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.87	-0.44	4.34e-17	Total cholesterol levels;
LUSC	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg20607287	chr7:12443886	VWDE	-0.59	-6.14	-0.32	2.35e-9	Coronary artery disease;
LUSC	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg21665744	chr7:39171113	POU6F2	0.42	6.71	0.34	8.22e-11	IgG glycosylation;
LUSC	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg01884057	chr2:25150051	NA	0.47	10.68	0.5	4.12e-23	Body mass index in non-asthmatics;
LUSC	cis	rs500891	0.525	rs1539439	chr6:84078564	C/T	cg08257003	chr6:84140564	ME1	-0.35	-8.15	-0.41	7.26e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22857025	chr5:266934	NA	-1.19	-13.96	-0.61	3.19e-35	Breast cancer;
LUSC	cis	rs9399401	0.523	rs171915	chr6:142866845	C/T	cg03128060	chr6:142623767	GPR126	0.43	7.34	0.37	1.63e-12	Chronic obstructive pulmonary disease;
LUSC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg25174290	chr11:3078921	CARS	0.6	9.56	0.46	2.69e-19	Longevity;
LUSC	cis	rs4704187	0.663	rs4404659	chr5:74422119	T/C	cg03227963	chr5:74354835	NA	0.32	6.9	0.35	2.6e-11	Response to amphetamines;
LUSC	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.61	0.34	1.51e-10	Corneal astigmatism;
LUSC	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg06636001	chr8:8085503	FLJ10661	0.86	15.15	0.64	7.88e-40	Mood instability;
LUSC	cis	rs11997175	0.625	rs11991490	chr8:33595407	T/C	ch.8.33884649F	chr8:33765107	NA	0.41	6.51	0.34	2.81e-10	Body mass index;
LUSC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.04	21.37	0.76	1.82e-64	Cognitive function;
LUSC	trans	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg06636001	chr8:8085503	FLJ10661	0.42	6.14	0.32	2.37e-9	Retinal vascular caliber;
LUSC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg05802129	chr4:122689817	NA	-0.49	-8.72	-0.43	1.33e-16	Type 2 diabetes;
LUSC	trans	rs1532331	0.966	rs6451674	chr5:43110754	C/T	cg02477305	chr13:23993013	SACS	0.34	6.02	0.31	4.48e-9	Menarche (age at onset);
LUSC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg03388025	chr16:89894329	SPIRE2	0.3	6.15	0.32	2.16e-9	Vitiligo;
LUSC	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg22618164	chr12:122356400	WDR66	0.63	9.22	0.45	3.36e-18	Mean corpuscular volume;
LUSC	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg15997130	chr1:24165203	NA	0.53	8.67	0.43	1.86e-16	Immature fraction of reticulocytes;
LUSC	cis	rs955333	0.685	rs1022403	chr6:154899713	C/G	cg20019720	chr6:154832845	CNKSR3	-0.47	-6.67	-0.34	1.07e-10	Diabetic kidney disease;
LUSC	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.39	-6.83	-0.35	3.95e-11	Eosinophil percentage of white cells;
LUSC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg12564285	chr5:131593104	PDLIM4	0.44	8.0	0.4	2.03e-14	Breast cancer;
LUSC	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg05340658	chr4:99064831	C4orf37	0.46	7.29	0.37	2.3e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg23229984	chr5:148520753	ABLIM3	0.39	5.94	0.31	7.12e-9	Breast cancer;
LUSC	cis	rs55728055	0.661	rs16989334	chr22:32016092	A/G	cg01338084	chr22:32026380	PISD	0.86	6.39	0.33	5.67e-10	Age-related hearing impairment;
LUSC	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.81	13.63	0.6	6.36e-34	Mean corpuscular volume;
LUSC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg02423579	chr7:2872169	GNA12	-0.38	-5.84	-0.3	1.24e-8	Height;
LUSC	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg05283184	chr6:79620031	NA	-0.57	-11.83	-0.54	3.38e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs2019216	0.500	rs12946184	chr17:21944675	A/C	cg22648282	chr17:21454238	C17orf51	-0.5	-6.83	-0.35	4.12e-11	Pelvic organ prolapse;
LUSC	cis	rs6084875	0.840	rs2025118	chr20:4723691	C/T	cg26097573	chr20:4721490	PRNT	-0.31	-5.76	-0.3	1.87e-8	Systemic lupus erythematosus;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24430517	chr2:242673979	D2HGDH	-0.42	-6.37	-0.33	6.23e-10	Electrocardiographic conduction measures;
LUSC	cis	rs2387326	0.629	rs12261739	chr10:129945520	A/G	cg16087940	chr10:129947807	NA	-0.4	-6.12	-0.32	2.59e-9	Select biomarker traits;
LUSC	trans	rs6448119	0.541	rs17526294	chr4:22061205	C/T	cg02770672	chr6:164366085	NA	-0.49	-6.03	-0.31	4.3e-9	Rheumatoid arthritis;
LUSC	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18854424	chr1:2615690	NA	0.51	10.18	0.49	2.18e-21	Ulcerative colitis;
LUSC	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.25	-27.69	-0.83	1.64e-88	Exhaled nitric oxide output;
LUSC	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg12826209	chr6:26865740	GUSBL1	0.67	7.58	0.38	3.45e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg14092571	chr14:90743983	NA	0.38	6.47	0.33	3.59e-10	Mortality in heart failure;
LUSC	cis	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.45e-10	Ulcerative colitis;
LUSC	trans	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg25206134	chr2:45395956	NA	0.56	6.12	0.32	2.6e-9	Neuroticism;
LUSC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.47	6.98	0.36	1.62e-11	Schizophrenia;
LUSC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.73	-10.13	-0.48	3.42e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.28	-0.45	2.27e-18	Gut microbiome composition (summer);
LUSC	cis	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg06521331	chr12:34319734	NA	-0.48	-7.71	-0.39	1.43e-13	Morning vs. evening chronotype;
LUSC	cis	rs2274273	0.686	rs2182207	chr14:55589803	G/A	cg04306507	chr14:55594613	LGALS3	0.48	9.51	0.46	3.87e-19	Protein biomarker;
LUSC	cis	rs1784581	0.674	rs3016555	chr6:162391421	T/C	cg17173639	chr6:162384350	PARK2	-0.68	-12.1	-0.55	3.28e-28	Itch intensity from mosquito bite;
LUSC	trans	rs2729385	1.000	rs2729385	chr11:57262993	C/T	cg14304014	chr19:1625356	TCF3	-0.39	-6.06	-0.31	3.76e-9	Interleukin-18 levels;
LUSC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.33	0.62	1.18e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs7944735	0.671	rs1228044	chr11:48011180	A/G	cg15704280	chr7:45808275	SEPT13	0.55	6.68	0.34	1e-10	Intraocular pressure;
LUSC	cis	rs1808579	0.935	rs12964689	chr18:21116998	A/G	cg14672496	chr18:21087552	C18orf8	0.37	6.31	0.33	9.12e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg26597838	chr10:835615	NA	0.78	9.46	0.46	5.75e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg00484396	chr16:3507460	NAT15	-0.46	-6.96	-0.36	1.79e-11	Body mass index (adult);
LUSC	cis	rs17030434	0.954	rs79908936	chr4:154749305	C/T	cg14289246	chr4:154710475	SFRP2	-0.56	-7.36	-0.37	1.46e-12	Electrocardiographic conduction measures;
LUSC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg09509183	chr1:209979624	IRF6	0.53	6.42	0.33	4.67e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg04450456	chr4:17643702	FAM184B	0.39	6.54	0.34	2.34e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg14092571	chr14:90743983	NA	-0.36	-5.87	-0.31	1.04e-8	Mortality in heart failure;
LUSC	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg17757837	chr7:157058334	UBE3C	-0.81	-13.09	-0.58	6.75e-32	Body mass index;
LUSC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.95e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10476260	chr2:74682101	INO80B	-0.4	-6.04	-0.31	4.21e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10979	0.557	rs9285501	chr6:143915121	G/C	cg25407410	chr6:143891975	LOC285740	-0.61	-8.08	-0.4	1.2e-14	Hypospadias;
LUSC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg12463550	chr7:65579703	CRCP	0.43	6.1	0.32	2.92e-9	Aortic root size;
LUSC	cis	rs3087591	0.960	rs9898664	chr17:29567152	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.55	-7.91	-0.4	3.72e-14	Hip circumference;
LUSC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.27e-31	Prudent dietary pattern;
LUSC	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg05283184	chr6:79620031	NA	-0.57	-12.04	-0.55	5.59e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg10755058	chr3:40428713	ENTPD3	0.35	5.97	0.31	5.95e-9	Renal cell carcinoma;
LUSC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg27432699	chr2:27873401	GPN1	-0.79	-14.81	-0.63	1.62e-38	Oral cavity cancer;
LUSC	cis	rs6961069	0.745	rs3211839	chr7:80280462	G/A	cg04458919	chr7:80252533	CD36	-0.35	-6.26	-0.32	1.18e-9	Platelet count;
LUSC	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-0.85	-11.87	-0.54	2.38e-27	Corneal structure;
LUSC	cis	rs9976767	0.637	rs2277799	chr21:43824123	G/C	cg23042151	chr21:43824109	UBASH3A	-0.34	-6.47	-0.33	3.41e-10	Type 1 diabetes;
LUSC	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg11764359	chr7:65958608	NA	0.73	11.46	0.53	7.24e-26	Aortic root size;
LUSC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg03388025	chr16:89894329	SPIRE2	0.31	6.42	0.33	4.56e-10	Vitiligo;
LUSC	trans	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg18187862	chr3:45730750	SACM1L	-0.53	-6.51	-0.34	2.69e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1941023	0.584	rs950803	chr11:60152563	A/T	cg08716584	chr11:60157161	MS4A7	0.62	11.66	0.54	1.43e-26	Congenital heart disease (maternal effect);
LUSC	cis	rs4629180	1.000	rs4851457	chr2:102091220	C/T	cg01388757	chr2:102091195	RFX8	0.47	7.45	0.38	8.14e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.84	-15.15	-0.64	8.06e-40	Caffeine consumption;
LUSC	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg15103426	chr22:29168792	CCDC117	0.58	7.9	0.4	4.21e-14	Lymphocyte counts;
LUSC	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg26924012	chr15:45694286	SPATA5L1	0.78	12.38	0.56	3.09e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.95	0.7	6.41e-51	Chronic sinus infection;
LUSC	cis	rs4964805	0.606	rs7312606	chr12:104188385	C/G	cg02344784	chr12:104178138	NT5DC3	0.47	9.02	0.44	1.45e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg02569458	chr12:86230093	RASSF9	0.42	6.86	0.35	3.31e-11	Major depressive disorder;
LUSC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg22920501	chr2:26401640	FAM59B	0.83	12.04	0.55	5.72e-28	Gut microbiome composition (summer);
LUSC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg03351412	chr1:154909251	PMVK	0.54	8.4	0.42	1.29e-15	Prostate cancer;
LUSC	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-1.03	-9.27	-0.45	2.31e-18	Mitochondrial DNA levels;
LUSC	cis	rs61863818	0.521	rs7923907	chr10:99143499	C/T	cg20016023	chr10:99160130	RRP12	0.24	5.77	0.3	1.85e-8	Monocyte percentage of white cells;
LUSC	cis	rs1823874	0.581	rs9920347	chr15:100339331	C/T	cg16400843	chr15:100339927	C15orf51	-0.39	-7.3	-0.37	2.12e-12	IgG glycosylation;
LUSC	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg13902645	chr11:5959945	NA	-0.58	-8.16	-0.41	6.88e-15	DNA methylation (variation);
LUSC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg17800788	chr1:21766015	NBPF3	0.32	6.14	0.32	2.32e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs72634258	0.786	rs4405150	chr1:8173672	T/C	cg00042356	chr1:8021962	PARK7	-0.59	-7.11	-0.36	7.1e-12	Inflammatory bowel disease;
LUSC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg00343986	chr7:65444356	GUSB	-0.4	-6.33	-0.33	8.11e-10	Aortic root size;
LUSC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.68	0.39	1.81e-13	Prudent dietary pattern;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21975007	chr6:132128965	ENPP1	-0.5	-6.33	-0.33	7.83e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg00074818	chr8:8560427	CLDN23	0.58	9.78	0.47	4.93e-20	Obesity-related traits;
LUSC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg14983838	chr19:29218262	NA	0.65	8.85	0.44	5.33e-17	Methadone dose in opioid dependence;
LUSC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.31	0.53	2.51e-25	Menopause (age at onset);
LUSC	cis	rs3764021	0.870	rs7973638	chr12:9880441	T/C	cg20894963	chr12:9885564	CLECL1	0.33	6.76	0.35	5.99e-11	Type 1 diabetes;
LUSC	cis	rs9341808	0.618	rs6916507	chr6:80862265	T/C	cg08355045	chr6:80787529	NA	0.57	9.9	0.48	1.97e-20	Sitting height ratio;
LUSC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg09359103	chr1:154839909	KCNN3	-0.7	-16.49	-0.67	3.99e-45	Prostate cancer;
LUSC	cis	rs11166629	0.651	rs7842812	chr8:135641794	T/C	cg27224718	chr8:135614730	ZFAT	0.43	7.01	0.36	1.3e-11	Smoking quantity;
LUSC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.68	9.53	0.46	3.35e-19	Methadone dose in opioid dependence;
LUSC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-0.84	-14.34	-0.62	1.1e-36	Tonsillectomy;
LUSC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg10862848	chr6:42927986	GNMT	-0.29	-7.04	-0.36	1.08e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1869026	1.000	rs1869026	chr2:121341281	G/T	cg07218647	chr2:121338498	NA	-0.27	-5.76	-0.3	1.9e-8	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs8064299	0.597	rs9944506	chr17:72782726	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.93	19.1	0.72	1.72e-55	Monocyte count;
LUSC	cis	rs870825	0.616	rs10025167	chr4:185649551	A/C	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg08668510	chr10:1095578	IDI1	0.63	6.04	0.31	4.07e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.4	0.53	1.16e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg05343316	chr1:45956843	TESK2	0.62	8.76	0.43	9.69e-17	Platelet count;
LUSC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg17178900	chr1:205818956	PM20D1	-0.73	-13.26	-0.59	1.55e-32	Monocyte percentage of white cells;
LUSC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.66	0.76	1.38e-65	Prudent dietary pattern;
LUSC	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.03	0.31	4.41e-9	Corneal astigmatism;
LUSC	cis	rs2580764	0.598	rs6726158	chr2:55239202	G/T	cg09592903	chr2:55203963	RTN4	-0.47	-9.45	-0.46	6.2e-19	Mean platelet volume;
LUSC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-0.92	-13.6	-0.6	8.09e-34	Initial pursuit acceleration;
LUSC	cis	rs1881797	0.932	rs4551631	chr1:247667663	C/T	cg14830002	chr1:247616686	OR2B11	-0.54	-7.73	-0.39	1.28e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg11189052	chr15:85197271	WDR73	0.49	6.19	0.32	1.79e-9	Schizophrenia;
LUSC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg00277334	chr10:82204260	NA	-0.58	-8.8	-0.43	7.37e-17	Post bronchodilator FEV1;
LUSC	cis	rs1322512	1.000	rs2800631	chr6:153008631	T/C	cg03415253	chr6:152958462	SYNE1	0.38	5.66	0.3	3.19e-8	Tonometry;
LUSC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.64	0.6	5.79e-34	Cognitive test performance;
LUSC	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.63	11.29	0.53	2.94e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.55	-0.38	4.12e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs500891	0.525	rs6937193	chr6:84095331	C/T	cg08257003	chr6:84140564	ME1	0.34	8.28	0.41	2.92e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs4363385	0.510	rs11803710	chr1:153053096	C/G	cg00922841	chr1:152955080	SPRR1A	-0.39	-6.7	-0.34	8.9e-11	Inflammatory skin disease;
LUSC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.59	-9.2	-0.45	4.12e-18	Longevity;
LUSC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg23625390	chr15:77176239	SCAPER	0.46	6.93	0.35	2.11e-11	Blood metabolite levels;
LUSC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.67	8.17	0.41	6.62e-15	Lung function (FEV1/FVC);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21815882	chr7:26241064	CBX3;HNRNPA2B1	0.44	6.16	0.32	2.13e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.82	13.98	0.61	2.89e-35	Blood protein levels;
LUSC	trans	rs9409565	0.826	rs9409778	chr9:97242839	G/A	cg05679027	chr9:99775184	HIATL2	-0.46	-6.54	-0.34	2.33e-10	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs929596	0.564	rs2741024	chr2:234517745	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-6.37	-0.33	6.31e-10	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs10465746	0.714	rs12141272	chr1:84434517	C/T	cg10977910	chr1:84465055	TTLL7	0.44	6.42	0.33	4.72e-10	Obesity-related traits;
LUSC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.75	-0.47	6.13e-20	Gut microbiome composition (summer);
LUSC	cis	rs11792861	0.566	rs1003346	chr9:111815340	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.43	7.08	0.36	8.54e-12	Menarche (age at onset);
LUSC	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg10167378	chr1:228756711	NA	0.76	9.78	0.47	5.16e-20	Chronic lymphocytic leukemia;
LUSC	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg13010199	chr12:38710504	ALG10B	-0.5	-7.61	-0.38	2.85e-13	Morning vs. evening chronotype;
LUSC	cis	rs4845570	1.000	rs7542898	chr1:151753622	T/G	cg07092448	chr1:151763213	TDRKH	-1.28	-14.49	-0.62	3.02e-37	Coronary artery disease;
LUSC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	11.49	0.53	5.54e-26	Alzheimer's disease;
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg09033563	chr22:24373618	LOC391322	-0.47	-6.27	-0.32	1.11e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.14	-0.45	5.99e-18	Schizophrenia;
LUSC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15369054	chr17:80825471	TBCD	0.41	6.68	0.34	9.88e-11	Breast cancer;
LUSC	cis	rs9811920	0.683	rs10936003	chr3:99667565	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.34	-6.48	-0.33	3.23e-10	Axial length;
LUSC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17261708	chr5:176794207	RGS14	0.33	5.77	0.3	1.8e-8	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg24209194	chr3:40518798	ZNF619	-0.42	-6.01	-0.31	4.78e-9	Renal cell carcinoma;
LUSC	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg20276088	chr3:133502917	NA	-0.42	-6.11	-0.32	2.76e-9	Iron status biomarkers;
LUSC	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.5	-0.34	2.9e-10	Retinal vascular caliber;
LUSC	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg00325661	chr8:49890786	NA	0.66	10.52	0.5	1.46e-22	Blood metabolite ratios;
LUSC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg23791538	chr6:167370224	RNASET2	0.42	6.79	0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs76878669	0.561	rs7948058	chr11:66148111	T/A	cg24851651	chr11:66362959	CCS	0.38	5.88	0.31	9.79e-9	Educational attainment (years of education);
LUSC	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-39.91	-0.91	3.76e-129	Myeloid white cell count;
LUSC	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.58	-11.44	-0.53	8.75e-26	Monocyte percentage of white cells;
LUSC	cis	rs4654899	0.582	rs4654729	chr1:21224253	T/C	cg01072550	chr1:21505969	NA	0.5	7.56	0.38	3.82e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs400736	1.000	rs400736	chr1:8078309	T/C	cg25007680	chr1:8021821	PARK7	0.57	8.97	0.44	2.1e-17	Response to antidepressants and depression;
LUSC	cis	rs11630290	0.806	rs10519220	chr15:64047120	C/T	cg12036633	chr15:63758958	NA	0.65	7.39	0.37	1.19e-12	Iris characteristics;
LUSC	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-7.0	-0.36	1.41e-11	Schizophrenia;
LUSC	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.94	-0.31	7.1e-9	Breast cancer;
LUSC	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg06917634	chr15:78832804	PSMA4	-0.59	-7.22	-0.37	3.61e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg08132940	chr7:1081526	C7orf50	-0.43	-5.75	-0.3	2.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9309473	1.000	rs10184268	chr2:73627044	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-6.14	-0.32	2.33e-9	Metabolite levels;
LUSC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.52	0.5	1.48e-22	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg13042288	chr15:90349979	ANPEP	-0.42	-6.38	-0.33	6.05e-10	Uric acid levels;
LUSC	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg09835421	chr16:68378352	PRMT7	-0.59	-6.21	-0.32	1.59e-9	Schizophrenia;
LUSC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg21770322	chr7:97807741	LMTK2	0.41	7.06	0.36	9.5e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg12559939	chr2:27858050	GPN1	0.41	6.44	0.33	4.23e-10	Oral cavity cancer;
LUSC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg23205692	chr1:25664452	TMEM50A	0.45	6.72	0.34	8.02e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs4594175	0.926	rs10135534	chr14:51617970	C/A	cg23942311	chr14:51606299	NA	0.31	5.9	0.31	9.02e-9	Cancer;
LUSC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.28e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10193935	0.901	rs62142599	chr2:42548935	G/A	cg27598129	chr2:42591480	NA	-0.6	-8.52	-0.42	5.63e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs722599	0.748	rs7145173	chr14:75351647	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.42	-6.15	-0.32	2.18e-9	IgG glycosylation;
LUSC	cis	rs9359856	1.000	rs2026650	chr6:90311633	C/G	cg13799429	chr6:90582589	CASP8AP2	0.57	6.69	0.34	9.33e-11	Bipolar disorder;
LUSC	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg09835421	chr16:68378352	PRMT7	-0.51	-5.76	-0.3	1.93e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs7113850	0.541	rs7129631	chr11:24208560	A/G	ch.11.24196551F	chr11:24239977	NA	0.95	7.45	0.38	7.8e-13	Bone fracture in osteoporosis;
LUSC	trans	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07923666	chr12:49932857	KCNH3	-0.5	-6.41	-0.33	5.08e-10	Resting heart rate;
LUSC	cis	rs240764	0.853	rs12660725	chr6:100978570	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-5.91	-0.31	8.42e-9	Neuroticism;
LUSC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg22823121	chr1:150693482	HORMAD1	0.58	8.88	0.44	4.04e-17	Tonsillectomy;
LUSC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21984481	chr17:79567631	NPLOC4	-0.57	-11.07	-0.52	1.83e-24	Eye color traits;
LUSC	cis	rs12791968	0.649	rs3802785	chr11:44995441	C/T	cg11846598	chr11:44996168	LOC221122	-0.58	-8.11	-0.41	9.49e-15	Inhibitory control;
LUSC	cis	rs10743315	0.557	rs77194694	chr12:19354075	A/G	cg02471346	chr12:19282374	PLEKHA5	0.79	6.31	0.33	9e-10	Gut microbiota (bacterial taxa);
LUSC	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.8	-12.29	-0.56	6.98e-29	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg13206674	chr6:150067644	NUP43	0.63	10.35	0.49	5.66e-22	Lung cancer;
LUSC	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg23601095	chr6:26197514	HIST1H3D	0.47	5.67	0.3	3.03e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-8.78	-0.43	8.54e-17	Hemoglobin concentration;
LUSC	cis	rs17095355	1.000	rs11194941	chr10:111744810	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.48	-0.38	6.7e-13	Biliary atresia;
LUSC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg22800045	chr5:56110881	MAP3K1	0.47	6.19	0.32	1.78e-9	Coronary artery disease;
LUSC	cis	rs7123876	0.587	rs72962169	chr11:72365669	C/T	cg03713592	chr11:72463424	ARAP1	0.71	7.6	0.38	3.1e-13	Body mass index;
LUSC	cis	rs929596	0.583	rs77070100	chr2:234587847	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.19	-0.37	4.18e-12	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs6500395	1.000	rs2355297	chr16:48685338	T/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.84	-0.35	3.77e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06544989	chr22:39130855	UNC84B	0.37	6.41	0.33	5.04e-10	Menopause (age at onset);
LUSC	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg21775007	chr8:11205619	TDH	-0.44	-6.4	-0.33	5.33e-10	Mood instability;
LUSC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	9.52	0.46	3.6e-19	Menarche (age at onset);
LUSC	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21659725	chr3:3221576	CRBN	0.52	8.2	0.41	5.1e-15	Body mass index;
LUSC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg25237894	chr2:233734115	C2orf82	-0.37	-6.87	-0.35	3.16e-11	Coronary artery disease;
LUSC	trans	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.4	0.42	1.29e-15	Ulcerative colitis;
LUSC	cis	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg17469321	chr7:55412551	NA	0.66	10.63	0.5	6.09e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg03585969	chr10:35415529	CREM	0.59	8.65	0.43	2.24e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7043114	0.544	rs12335553	chr9:95297871	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.37	-6.56	-0.34	2.07e-10	Height;
LUSC	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg18232548	chr7:50535776	DDC	-0.54	-7.61	-0.38	2.83e-13	Malaria;
LUSC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg07424592	chr7:64974309	NA	0.63	5.69	0.3	2.81e-8	Diabetic kidney disease;
LUSC	cis	rs11168618	0.875	rs7972785	chr12:48877056	T/C	cg24011408	chr12:48396354	COL2A1	0.38	6.04	0.31	4.05e-9	Adiponectin levels;
LUSC	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg23260525	chr10:116636907	FAM160B1	0.48	10.46	0.5	2.49e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.54	0.46	3.08e-19	Mean platelet volume;
LUSC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg22431228	chr1:16359049	CLCNKA	-0.47	-9.1	-0.45	8.22e-18	Dilated cardiomyopathy;
LUSC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg02782426	chr3:40428986	ENTPD3	0.41	7.79	0.39	8.51e-14	Renal cell carcinoma;
LUSC	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg18352616	chr4:3374830	RGS12	0.32	6.35	0.33	7.16e-10	Serum sulfate level;
LUSC	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg00745463	chr17:30367425	LRRC37B	-0.72	-8.68	-0.43	1.71e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.49	-0.33	3.06e-10	Lung cancer;
LUSC	cis	rs7246967	0.673	rs62120313	chr19:22877183	G/C	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg18512352	chr11:47633146	NA	-0.48	-9.88	-0.48	2.38e-20	Subjective well-being;
LUSC	trans	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg18187862	chr3:45730750	SACM1L	0.53	6.9	0.35	2.6e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg15691649	chr6:25882328	NA	-0.37	-5.85	-0.3	1.19e-8	Blood metabolite levels;
LUSC	trans	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg13565492	chr6:43139072	SRF	-0.57	-6.06	-0.31	3.68e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.31	0.33	8.87e-10	Bipolar disorder;
LUSC	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg22705602	chr4:152727874	NA	-0.33	-6.62	-0.34	1.45e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2652834	0.950	rs2652815	chr15:63401345	T/C	cg05507819	chr15:63340323	TPM1	0.66	8.0	0.4	2.11e-14	HDL cholesterol;
LUSC	cis	rs2548003	0.565	rs2554899	chr5:28741116	C/T	cg22863700	chr5:28928346	NA	0.47	6.49	0.33	3.1e-10	Hip geometry;
LUSC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.31	-0.37	2e-12	Personality dimensions;
LUSC	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg15704280	chr7:45808275	SEPT13	0.73	8.39	0.42	1.38e-15	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs12439619	0.768	rs28694364	chr15:82500460	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.47	-6.44	-0.33	4.23e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg03146154	chr1:46216737	IPP	0.53	7.75	0.39	1.09e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg00066239	chr17:78472159	NA	0.42	7.25	0.37	2.83e-12	Fractional excretion of uric acid;
LUSC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08439880	chr3:133502540	NA	-0.36	-6.42	-0.33	4.76e-10	Iron status biomarkers;
LUSC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	1.03	19.24	0.72	4.93e-56	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07588614	chr3:113604183	GRAMD1C	0.44	6.05	0.31	3.85e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg00012203	chr2:219082015	ARPC2	-0.68	-11.04	-0.52	2.26e-24	Colorectal cancer;
LUSC	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg01528321	chr10:82214614	TSPAN14	1.01	15.68	0.65	6.26e-42	Post bronchodilator FEV1;
LUSC	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg04865166	chr7:105162814	PUS7	0.51	5.7	0.3	2.65e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.36	-0.37	1.45e-12	Bipolar disorder;
LUSC	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg02023728	chr11:77925099	USP35	0.46	6.65	0.34	1.23e-10	Testicular germ cell tumor;
LUSC	cis	rs10276381	1.000	rs10280937	chr7:28182306	T/C	cg23620719	chr7:28220237	JAZF1	0.58	6.27	0.32	1.11e-9	Crohn's disease;
LUSC	cis	rs6076065	0.748	rs6076055	chr20:23333917	G/C	cg11657817	chr20:23433608	CST11	0.53	10.68	0.5	4.37e-23	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2262909	0.925	rs73019900	chr19:22286680	G/A	cg11619707	chr19:22235551	ZNF257	0.39	5.86	0.31	1.08e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4664308	0.618	rs6722275	chr2:160893260	C/T	cg03641300	chr2:160917029	PLA2R1	-0.49	-8.0	-0.4	2.04e-14	Idiopathic membranous nephropathy;
LUSC	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg02176678	chr2:219576539	TTLL4	0.6	10.67	0.5	4.48e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.46	-6.89	-0.35	2.71e-11	Menarche (age at onset);
LUSC	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	0.93	12.47	0.56	1.46e-29	Primary sclerosing cholangitis;
LUSC	cis	rs7241530	0.569	rs12965943	chr18:75900225	T/G	cg14642773	chr18:75888474	NA	0.38	5.73	0.3	2.29e-8	Educational attainment (years of education);
LUSC	cis	rs12931792	0.712	rs2887799	chr16:30163833	G/A	cg17640201	chr16:30407289	ZNF48	0.57	8.92	0.44	3.23e-17	Tonsillectomy;
LUSC	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg13206674	chr6:150067644	NUP43	0.43	6.49	0.33	3.13e-10	Lung cancer;
LUSC	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg17366294	chr4:99064904	C4orf37	0.58	10.39	0.49	4.22e-22	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6924906	0.655	rs78763763	chr6:82238661	G/A	cg15052890	chr17:4636830	MED11;CXCL16	-0.58	-6.12	-0.32	2.57e-9	Blood pressure;
LUSC	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	0.58	9.24	0.45	2.94e-18	Breast cancer;
LUSC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07157834	chr1:205819609	PM20D1	0.53	8.74	0.43	1.13e-16	Menarche (age at onset);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09332974	chr1:113616366	LRIG2	-0.45	-6.79	-0.35	5.26e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg03877680	chr5:178157825	ZNF354A	0.52	6.43	0.33	4.31e-10	Neutrophil percentage of white cells;
LUSC	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.35e-13	Type 2 diabetes;
LUSC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.73	0.35	7.58e-11	Tonsillectomy;
LUSC	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg04362960	chr10:104952993	NT5C2	0.58	9.12	0.45	7.45e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg05082376	chr22:42548792	NA	-0.42	-6.46	-0.33	3.64e-10	Schizophrenia;
LUSC	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg26395211	chr5:140044315	WDR55	-0.37	-5.72	-0.3	2.43e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.69	-10.09	-0.48	4.5e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs2658782	0.789	rs3020073	chr11:93103830	T/C	cg15737290	chr11:93063684	CCDC67	0.62	7.64	0.39	2.34e-13	Pulmonary function decline;
LUSC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	0.92	15.89	0.66	9.31e-43	Heart rate;
LUSC	cis	rs62400317	0.762	rs12190313	chr6:44903902	T/G	cg20913747	chr6:44695427	NA	-0.47	-7.33	-0.37	1.72e-12	Total body bone mineral density;
LUSC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4713118	0.869	rs6901520	chr6:27714575	G/T	cg20933634	chr6:27740509	NA	0.41	5.88	0.31	9.8e-9	Parkinson's disease;
LUSC	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.1	-17.5	-0.69	3.98e-49	Primary sclerosing cholangitis;
LUSC	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg16482183	chr6:26056742	HIST1H1C	0.46	6.63	0.34	1.34e-10	Height;
LUSC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.84	0.44	5.54e-17	Diabetic kidney disease;
LUSC	cis	rs17401966	0.540	rs3748581	chr1:10441664	T/C	cg17425144	chr1:10567563	PEX14	-0.34	-6.07	-0.32	3.4e-9	Hepatocellular carcinoma;
LUSC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg22437258	chr11:111473054	SIK2	0.52	7.44	0.38	8.76e-13	Primary sclerosing cholangitis;
LUSC	cis	rs539096	0.692	rs6686238	chr1:44210253	C/G	cg15962314	chr1:44399869	ARTN	0.24	5.73	0.3	2.2e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4950928	0.823	rs2153101	chr1:203168474	A/T	cg17014757	chr1:203156097	CHI3L1	-0.44	-7.64	-0.39	2.31e-13	YKL-40 levels;
LUSC	cis	rs28719689	0.655	rs17063833	chr8:1275384	A/G	cg22761795	chr8:1265118	NA	0.53	6.55	0.34	2.18e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3784262	0.679	rs11071365	chr15:58334126	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-6.85	-0.35	3.59e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg14664628	chr15:75095509	CSK	-0.49	-7.01	-0.36	1.32e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg24130564	chr14:104152367	KLC1	-0.49	-6.97	-0.36	1.72e-11	Body mass index;
LUSC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-9.18	-0.45	4.77e-18	Gut microbiome composition (summer);
LUSC	cis	rs4700695	0.698	rs416369	chr5:65231058	C/T	cg21114390	chr5:65439923	SFRS12	0.51	6.13	0.32	2.54e-9	Facial morphology (factor 19);
LUSC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.27	0.59	1.45e-32	Chronic sinus infection;
LUSC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.53	-0.5	1.4e-22	Bipolar disorder;
LUSC	cis	rs1003719	0.715	rs58008706	chr21:38540506	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-9.79	-0.47	4.62e-20	Eye color traits;
LUSC	cis	rs9807989	0.708	rs6543124	chr2:102987459	T/A	cg03938978	chr2:103052716	IL18RAP	0.33	6.02	0.31	4.57e-9	Asthma;
LUSC	cis	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg21775007	chr8:11205619	TDH	-0.56	-7.53	-0.38	4.65e-13	Neuroticism;
LUSC	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-6.09	-0.32	3.17e-9	Systolic blood pressure;
LUSC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg17143192	chr8:8559678	CLDN23	-0.37	-5.76	-0.3	1.89e-8	Mood instability;
LUSC	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg17252645	chr8:143867129	LY6D	0.38	6.7	0.34	8.75e-11	Urinary tract infection frequency;
LUSC	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg20016023	chr10:99160130	RRP12	-0.32	-8.03	-0.4	1.74e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.86	0.54	2.49e-27	Chronic sinus infection;
LUSC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	7.77e-16	Aortic root size;
LUSC	cis	rs11645898	0.872	rs72791121	chr16:72225294	C/T	cg14768367	chr16:72042858	DHODH	-0.57	-6.25	-0.32	1.22e-9	Blood protein levels;
LUSC	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.8	-0.3	1.53e-8	Ileal carcinoids;
LUSC	cis	rs16976116	0.951	rs9300	chr15:55489065	G/A	cg11288833	chr15:55489084	RSL24D1	0.54	6.56	0.34	2.04e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1712517	0.873	rs7916056	chr10:104997914	T/C	cg05636881	chr10:105038444	INA	-0.4	-6.53	-0.34	2.43e-10	Migraine;
LUSC	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg12002119	chr2:101014098	CHST10	0.36	5.91	0.31	8.32e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg20302533	chr7:39170763	POU6F2	0.5	8.44	0.42	9.9e-16	IgG glycosylation;
LUSC	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg24631222	chr15:78858424	CHRNA5	0.85	11.44	0.53	8.6e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg09307838	chr4:120376055	NA	0.76	11.03	0.52	2.54e-24	Corneal astigmatism;
LUSC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.67	11.21	0.52	5.48e-25	Bone mineral density;
LUSC	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg23625390	chr15:77176239	SCAPER	-0.66	-10.06	-0.48	5.81e-21	Blood metabolite levels;
LUSC	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg27284194	chr4:1044797	NA	0.6	8.85	0.44	5.26e-17	Recombination rate (females);
LUSC	cis	rs2970818	0.831	rs11063187	chr12:4587910	G/T	cg11146114	chr12:4671731	NA	-0.6	-5.69	-0.3	2.83e-8	Phosphorus levels;
LUSC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg00106254	chr7:1943704	MAD1L1	0.42	6.08	0.32	3.27e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11583043	0.575	rs658861	chr1:101584241	G/A	cg11406453	chr1:101602562	NA	0.41	6.95	0.36	1.89e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg15654264	chr1:150340011	RPRD2	0.65	10.86	0.51	1.03e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg17330251	chr7:94953956	PON1	-0.37	-5.99	-0.31	5.35e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24826892	chr11:71159390	DHCR7	0.5	6.87	0.35	3.14e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg03647239	chr10:116582469	FAM160B1	0.44	7.15	0.36	5.46e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg05855489	chr10:104503620	C10orf26	0.55	6.27	0.32	1.1e-9	Arsenic metabolism;
LUSC	cis	rs73001065	0.818	rs12610185	chr19:19721722	G/A	cg03709012	chr19:19516395	GATAD2A	0.89	7.15	0.36	5.34e-12	LDL cholesterol;
LUSC	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	19.04	0.72	3.1e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg08847533	chr14:75593920	NEK9	0.85	16.03	0.66	2.81e-43	Height;
LUSC	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg23649088	chr2:200775458	C2orf69	0.54	8.3	0.41	2.54e-15	Schizophrenia;
LUSC	cis	rs7264396	1.000	rs224440	chr20:34159447	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-7.68	-0.39	1.73e-13	Total cholesterol levels;
LUSC	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-6.99	-0.36	1.49e-11	Total cholesterol levels;
LUSC	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-7.35	-0.37	1.5e-12	Morning vs. evening chronotype;
LUSC	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg06197492	chr11:2016605	H19	0.42	6.94	0.35	2.08e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	trans	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.47	-0.42	8.12e-16	Retinal vascular caliber;
LUSC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg06618935	chr21:46677482	NA	-0.37	-7.58	-0.38	3.42e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg24829409	chr8:58192753	C8orf71	-0.48	-5.89	-0.31	9.28e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs71403859	0.502	rs7195767	chr16:71464943	A/G	cg08717414	chr16:71523259	ZNF19	-0.71	-8.34	-0.41	2.04e-15	Post bronchodilator FEV1;
LUSC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg06808227	chr14:105710500	BRF1	-0.64	-9.74	-0.47	6.74e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg09835421	chr16:68378352	PRMT7	-0.54	-5.92	-0.31	7.97e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4631830	0.863	rs3123078	chr10:51524971	A/G	cg16070123	chr10:51489643	NA	0.5	8.03	0.4	1.73e-14	Prostate-specific antigen levels;
LUSC	cis	rs68170813	0.559	rs11764448	chr7:106924928	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.79	-0.47	4.7e-20	Coronary artery disease;
LUSC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg00310523	chr12:86230176	RASSF9	0.52	9.36	0.46	1.18e-18	Major depressive disorder;
LUSC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.83	-15.09	-0.64	1.3e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2798269	0.528	rs7322862	chr13:22108134	C/T	cg18095732	chr13:22033692	ZDHHC20	0.4	6.26	0.32	1.16e-9	PR segment;
LUSC	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg13628971	chr7:2884303	GNA12	0.37	5.83	0.3	1.33e-8	Height;
LUSC	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.55	-0.53	3.32e-26	Mean corpuscular volume;
LUSC	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg06637938	chr14:75390232	RPS6KL1	0.53	8.64	0.43	2.32e-16	Height;
LUSC	cis	rs4343996	1.000	rs13230698	chr7:3361125	T/C	cg21248987	chr7:3385318	SDK1	-0.39	-6.62	-0.34	1.39e-10	Motion sickness;
LUSC	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg18478394	chr8:109455254	TTC35	0.41	6.29	0.33	9.7e-10	Dupuytren's disease;
LUSC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg13206674	chr6:150067644	NUP43	0.63	10.35	0.49	5.66e-22	Lung cancer;
LUSC	cis	rs7432375	0.566	rs835636	chr3:136674500	A/C	cg15507776	chr3:136538369	TMEM22	0.45	7.58	0.38	3.43e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg14343924	chr8:8086146	FLJ10661	0.44	6.21	0.32	1.6e-9	Mood instability;
LUSC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg25173405	chr17:45401733	C17orf57	0.36	5.74	0.3	2.14e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg07414643	chr4:187882934	NA	0.53	10.06	0.48	5.68e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10740039	0.766	rs2119917	chr10:62437384	G/A	cg18175470	chr10:62150864	ANK3	-0.47	-7.15	-0.36	5.39e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg20283391	chr11:68216788	NA	-0.58	-8.21	-0.41	4.97e-15	Total body bone mineral density;
LUSC	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-10.25	-0.49	1.26e-21	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-0.95	-13.71	-0.6	3.07e-34	Vitiligo;
LUSC	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg19116668	chr7:99932089	PMS2L1	0.34	5.87	0.31	1.05e-8	Coronary artery disease;
LUSC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25072359	chr17:41440525	NA	0.65	9.38	0.46	1.06e-18	Menopause (age at onset);
LUSC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg00898013	chr13:113819073	PROZ	-0.64	-8.93	-0.44	2.89e-17	Platelet distribution width;
LUSC	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg18825076	chr15:78729989	IREB2	0.47	6.28	0.32	1.07e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg01448562	chr3:133502909	NA	-0.58	-8.69	-0.43	1.62e-16	Iron status biomarkers;
LUSC	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.95	-20.29	-0.74	3.17e-60	Ulcerative colitis;
LUSC	cis	rs11051970	0.679	rs2651377	chr12:32556919	A/C	cg24626660	chr12:32551988	NA	0.31	5.73	0.3	2.28e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg01879757	chr17:41196368	BRCA1	-0.46	-6.92	-0.35	2.26e-11	Menopause (age at onset);
LUSC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.83	-0.3	1.29e-8	Obesity-related traits;
LUSC	cis	rs9504361	0.808	rs2277096	chr6:564515	G/T	cg15781525	chr6:564561	EXOC2	-0.35	-5.69	-0.3	2.78e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Psoriasis;Pit-and-Fissure caries;Eosinophil counts;
LUSC	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg09911534	chr15:67153556	NA	0.68	7.78	0.39	9.27e-14	Lung cancer (smoking interaction);
LUSC	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg25206134	chr2:45395956	NA	0.59	6.91	0.35	2.4e-11	Bipolar disorder;
LUSC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg23073111	chr11:64073390	ESRRA	0.35	6.37	0.33	6.29e-10	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12379764	chr21:47803548	PCNT	-0.42	-5.91	-0.31	8.39e-9	Testicular germ cell tumor;
LUSC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-11.79	-0.54	4.5e-27	Colorectal cancer;
LUSC	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg23205692	chr1:25664452	TMEM50A	0.45	6.77	0.35	5.68e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg16362232	chr11:430036	ANO9	0.64	8.15	0.41	7.37e-15	Body mass index;
LUSC	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg06462663	chr19:18546047	ISYNA1	0.47	7.63	0.39	2.52e-13	Breast cancer;
LUSC	cis	rs2425143	1.000	rs56116518	chr20:34286251	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.32	-0.33	8.56e-10	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg17366294	chr4:99064904	C4orf37	0.56	9.9	0.48	1.95e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	1.1	26.31	0.82	2.03e-83	Testicular germ cell tumor;
LUSC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.16	0.32	2.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.84	-0.35	3.74e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg20703242	chr1:230279135	GALNT2	0.57	8.79	0.43	8.1e-17	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs12190007	0.514	rs2984462	chr6:169843903	A/T	ch.6.169577133F	chr6:169835210	NA	-0.41	-6.24	-0.32	1.34e-9	Obesity-related traits;
LUSC	cis	rs9513627	0.920	rs2390280	chr13:100208802	A/G	cg25919922	chr13:100150906	NA	0.83	6.72	0.35	7.8e-11	Obesity-related traits;
LUSC	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg25922239	chr6:33757077	LEMD2	0.53	7.88	0.4	4.68e-14	Crohn's disease;
LUSC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg07606381	chr6:8435919	SLC35B3	-0.72	-12.22	-0.56	1.21e-28	Motion sickness;
LUSC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg13073564	chr4:8508604	NA	0.47	8.76	0.43	1.01e-16	Response to antineoplastic agents;
LUSC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs240764	0.595	rs1039033	chr6:101191397	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-5.87	-0.31	1.03e-8	Neuroticism;
LUSC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08219700	chr8:58056026	NA	-0.66	-8.11	-0.41	9.82e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg21724239	chr8:58056113	NA	0.67	7.43	0.38	9.33e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg00074818	chr8:8560427	CLDN23	-0.58	-9.45	-0.46	6.19e-19	Obesity-related traits;
LUSC	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg19418458	chr7:158789849	NA	-0.63	-10.45	-0.5	2.7e-22	Facial morphology (factor 20);
LUSC	trans	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg25214090	chr10:38739885	LOC399744	0.54	7.92	0.4	3.56e-14	Corneal astigmatism;
LUSC	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-10.4	-0.49	3.84e-22	Body mass index;
LUSC	cis	rs2274273	0.624	rs67412516	chr14:55853237	A/T	cg04306507	chr14:55594613	LGALS3	0.47	9.43	0.46	6.91e-19	Protein biomarker;
LUSC	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg16576597	chr16:28551801	NUPR1	-0.33	-6.71	-0.34	8.24e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.99	-0.44	1.91e-17	Axial length;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09477292	chr4:6577027	MAN2B2	0.42	6.35	0.33	7e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4363385	0.588	rs6661059	chr1:153027257	A/T	cg00922841	chr1:152955080	SPRR1A	-0.37	-6.22	-0.32	1.51e-9	Inflammatory skin disease;
LUSC	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.64	-0.47	1.47e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7119	0.717	rs12902925	chr15:77819141	T/C	cg27398640	chr15:77910606	LINGO1	-0.31	-6.63	-0.34	1.34e-10	Type 2 diabetes;
LUSC	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.71	13.14	0.58	4.57e-32	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.17	0.58	3.33e-32	Chronic sinus infection;
LUSC	cis	rs6740322	0.696	rs11685054	chr2:43474295	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.49	-6.45	-0.33	3.83e-10	Coronary artery disease;
LUSC	cis	rs1178968	1.000	rs3108462	chr7:72739455	T/C	cg25889504	chr7:72793014	NA	0.58	7.53	0.38	4.84e-13	Triglyceride levels;
LUSC	cis	rs62158211	1.000	rs62158211	chr2:114106139	G/T	cg17784749	chr2:114082611	LOC440839	0.53	6.31	0.33	8.93e-10	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LUSC	cis	rs1476679	0.962	rs34995835	chr7:99990364	T/G	cg19116668	chr7:99932089	PMS2L1	0.45	8.1	0.41	1.02e-14	Alzheimer's disease (late onset);
LUSC	cis	rs9796	0.870	rs12905926	chr15:41283408	G/A	cg18705301	chr15:41695430	NDUFAF1	0.47	8.18	0.41	5.86e-15	Menopause (age at onset);
LUSC	cis	rs7799006	0.606	rs12669625	chr7:2315950	C/T	cg12823233	chr7:2316876	SNX8	-0.45	-7.63	-0.39	2.48e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg13072238	chr3:49761600	GMPPB	-0.4	-6.49	-0.33	3.1e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg06462663	chr19:18546047	ISYNA1	0.44	7.26	0.37	2.8e-12	Breast cancer;
LUSC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-13.39	-0.59	5.04e-33	Chronic sinus infection;
LUSC	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg01191920	chr7:158217561	PTPRN2	-0.52	-10.67	-0.5	4.73e-23	Obesity-related traits;
LUSC	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg20703242	chr1:230279135	GALNT2	-0.56	-8.04	-0.4	1.63e-14	Coronary artery disease;
LUSC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.9	17.15	0.68	1.03e-47	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04313601	chr11:10315759	SBF2	-0.4	-6.06	-0.31	3.61e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.8	0.6	1.3600000000000001e-34	Chronic sinus infection;
LUSC	cis	rs2637266	0.902	rs2583056	chr10:78399498	A/G	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.93e-13	Pulmonary function;
LUSC	cis	rs12493885	0.725	rs61791493	chr3:153743573	A/G	cg17054900	chr3:154042577	DHX36	-0.7	-7.37	-0.37	1.33e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg23093090	chr10:104574429	C10orf26	0.49	9.29	0.45	2.07e-18	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg00383909	chr3:49044727	WDR6	1.1	9.65	0.47	1.36e-19	Cognitive function;
LUSC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-10.22	-0.49	1.66e-21	Electroencephalogram traits;
LUSC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg16386425	chr10:429943	DIP2C	0.43	6.68	0.34	9.94e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg23758822	chr17:41437982	NA	1.02	19.52	0.73	3.82e-57	Menopause (age at onset);
LUSC	cis	rs12618769	0.597	rs2309390	chr2:99114310	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.48	0.38	6.81e-13	Bipolar disorder;
LUSC	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg20608306	chr11:116969690	SIK3	0.37	6.8	0.35	4.86e-11	Blood protein levels;
LUSC	cis	rs34734847	0.787	rs1814851	chr12:121128633	C/G	cg27246729	chr12:121163418	ACADS	0.41	6.47	0.33	3.41e-10	Mean corpuscular volume;
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg01238044	chr22:24384105	GSTT1	-0.64	-10.36	-0.49	5.46e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12478601	1.000	rs11888640	chr2:43806382	C/T	cg24650394	chr2:43863435	PLEKHH2	0.35	5.75	0.3	2.02e-8	Polycystic ovary syndrome;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13504215	chr3:30648325	TGFBR2	-0.4	-6.02	-0.31	4.62e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11785693	0.862	rs11774044	chr8:4988035	C/G	cg26367366	chr8:4980734	NA	0.83	9.67	0.47	1.2e-19	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03264133	chr6:25882463	NA	0.35	5.85	0.3	1.17e-8	Blood metabolite levels;
LUSC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg05973401	chr12:123451056	ABCB9	0.51	6.97	0.36	1.69e-11	Neutrophil percentage of white cells;
LUSC	trans	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.58	9.41	0.46	8.25e-19	Aortic root size;
LUSC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg11645453	chr3:52864694	ITIH4	0.29	6.57	0.34	1.91e-10	Electroencephalogram traits;
LUSC	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg15309053	chr8:964076	NA	0.42	8.72	0.43	1.33e-16	Schizophrenia;
LUSC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	14.74	0.63	3.08e-38	Platelet count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05655972	chr18:11908331	MPPE1	-0.42	-6.25	-0.32	1.27e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg10840412	chr1:235813424	GNG4	0.51	6.18	0.32	1.87e-9	Neuroticism;
LUSC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg21573476	chr21:45109991	RRP1B	-0.37	-5.96	-0.31	6.35e-9	Mean corpuscular volume;
LUSC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	8.24	0.41	3.88e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9625935	0.957	rs35705048	chr22:30270699	T/G	cg11564601	chr22:30592435	NA	-0.39	-5.85	-0.3	1.17e-8	Tonsillectomy;
LUSC	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg22529645	chr1:3704559	LRRC47	0.34	5.83	0.3	1.3e-8	Red cell distribution width;
LUSC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg06238570	chr21:40685208	BRWD1	0.47	7.16	0.36	5.21e-12	Cognitive function;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08393024	chr5:115177154	ATG12;AP3S1	0.42	5.95	0.31	6.74e-9	Neuroticism;
LUSC	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg24069376	chr3:38537580	EXOG	-0.37	-7.36	-0.37	1.44e-12	Electrocardiographic conduction measures;
LUSC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg14004847	chr7:1930337	MAD1L1	-0.54	-8.03	-0.4	1.72e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg08048268	chr3:133502702	NA	-0.35	-6.73	-0.35	7.25e-11	Iron status biomarkers (transferrin levels);
LUSC	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg05855489	chr10:104503620	C10orf26	0.6	9.79	0.47	4.58e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg04362960	chr10:104952993	NT5C2	0.49	7.37	0.37	1.33e-12	Waist circumference;Hip circumference;
LUSC	cis	rs17401966	0.558	rs4846218	chr1:10452040	G/T	cg19773385	chr1:10388646	KIF1B	-0.37	-6.58	-0.34	1.8e-10	Hepatocellular carcinoma;
LUSC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg03233332	chr7:66118400	NA	-0.43	-6.21	-0.32	1.6e-9	Aortic root size;
LUSC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15664640	chr17:80829946	TBCD	0.49	8.75	0.43	1.1e-16	Breast cancer;
LUSC	trans	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg25214090	chr10:38739885	LOC399744	-0.39	-6.11	-0.32	2.72e-9	Corneal astigmatism;
LUSC	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg08949735	chr16:89699720	DPEP1	-0.24	-5.79	-0.3	1.63e-8	Vitiligo;
LUSC	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.49	-7.01	-0.36	1.34e-11	Menarche (age at onset);
LUSC	cis	rs73198271	0.960	rs12155530	chr8:8610964	C/T	cg01851573	chr8:8652454	MFHAS1	0.57	8.21	0.41	4.91e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.06	-0.31	3.69e-9	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08377010	chr19:48673515	LIG1	-0.4	-5.96	-0.31	6.35e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9503598	1.000	rs9503598	chr6:3446263	A/G	cg00476032	chr6:3446245	SLC22A23	-0.41	-8.35	-0.42	1.85e-15	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs7177699	0.557	rs4389113	chr15:79121739	G/A	cg15571903	chr15:79123663	NA	-0.34	-6.2	-0.32	1.67e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs77633900	0.772	rs157761	chr15:76796078	C/A	cg21673338	chr15:77095150	SCAPER	-0.71	-6.05	-0.31	3.86e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg05347473	chr6:146136440	FBXO30	0.41	7.05	0.36	1.06e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.68	-9.08	-0.44	9.73e-18	Lymphocyte counts;Red cell distribution width;
LUSC	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg13042288	chr15:90349979	ANPEP	-0.4	-6.18	-0.32	1.86e-9	Uric acid levels;
LUSC	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.78e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.53	-0.5	1.4e-22	Electroencephalogram traits;
LUSC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg23262073	chr20:60523788	NA	-0.44	-6.48	-0.33	3.29e-10	Body mass index;
LUSC	cis	rs7615316	0.751	rs2862746	chr3:142042815	C/G	cg16271453	chr3:142027066	XRN1	-0.41	-7.23	-0.37	3.29e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg02158880	chr13:53174818	NA	-0.38	-5.87	-0.31	1.04e-8	Lewy body disease;
LUSC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg07741184	chr6:167504864	NA	0.49	8.49	0.42	7.09e-16	Crohn's disease;
LUSC	cis	rs7923609	0.967	rs2393986	chr10:65320006	A/T	cg01631684	chr10:65280961	REEP3	-0.43	-6.66	-0.34	1.1e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg03233332	chr7:66118400	NA	-0.41	-5.98	-0.31	5.79e-9	Aortic root size;
LUSC	cis	rs7011049	1.000	rs72640850	chr8:53836681	A/C	cg26025543	chr8:53854495	NA	0.51	6.1	0.32	2.97e-9	Systolic blood pressure;
LUSC	cis	rs778371	0.788	rs778355	chr2:233784749	T/G	cg08000102	chr2:233561755	GIGYF2	-0.59	-7.79	-0.39	8.38e-14	Schizophrenia;
LUSC	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.75	0.65	3.49e-42	Bladder cancer;
LUSC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg14019146	chr3:50243930	SLC38A3	0.31	6.97	0.36	1.73e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg23788917	chr6:8435910	SLC35B3	0.51	7.56	0.38	3.86e-13	Motion sickness;
LUSC	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg23625390	chr15:77176239	SCAPER	0.48	7.24	0.37	3.12e-12	Blood metabolite levels;
LUSC	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg26384229	chr12:38710491	ALG10B	0.74	12.08	0.55	4.07e-28	Morning vs. evening chronotype;
LUSC	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.58	0.34	1.81e-10	Corneal astigmatism;
LUSC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg04450456	chr4:17643702	FAM184B	0.37	6.26	0.32	1.16e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg17279839	chr7:150038598	RARRES2	0.4	6.2	0.32	1.7e-9	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg08975724	chr8:8085496	FLJ10661	0.49	6.89	0.35	2.83e-11	Retinal vascular caliber;
LUSC	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg16414030	chr3:133502952	NA	-0.42	-6.56	-0.34	2.11e-10	Iron status biomarkers;
LUSC	cis	rs240764	0.583	rs11155638	chr6:101203801	T/A	cg09795085	chr6:101329169	ASCC3	-0.44	-6.46	-0.33	3.67e-10	Neuroticism;
LUSC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg05973401	chr12:123451056	ABCB9	0.56	8.12	0.41	9.21e-15	Platelet count;
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg20849893	chr7:64541193	NA	-0.5	-7.27	-0.37	2.53e-12	Calcium levels;
LUSC	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg12927641	chr6:109611667	NA	-0.34	-5.81	-0.3	1.49e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs4786125	0.636	rs7192853	chr16:6918241	G/C	cg03623568	chr16:6915990	A2BP1	-0.49	-8.23	-0.41	4.15e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.76	-12.78	-0.57	1.03e-30	Schizophrenia;
LUSC	cis	rs4812048	1.000	rs6070696	chr20:57597645	A/G	cg14073986	chr20:57617431	SLMO2	0.59	7.04	0.36	1.07e-11	Mean platelet volume;
LUSC	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg01652190	chr22:50026171	C22orf34	-0.31	-6.32	-0.33	8.35e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-0.93	-15.56	-0.65	2.01e-41	Body mass index;
LUSC	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.45	9.52	0.46	3.71e-19	Airflow obstruction;
LUSC	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg09877947	chr5:131593287	PDLIM4	0.39	6.08	0.32	3.29e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg17971929	chr21:40555470	PSMG1	0.73	11.9	0.55	1.8e-27	Cognitive function;
LUSC	cis	rs8032158	1.000	rs60482539	chr15:56180297	A/C	cg02198044	chr15:56286336	NEDD4	-0.36	-5.69	-0.3	2.72e-8	Keloid;
LUSC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-6.44	-0.33	4.18e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-0.91	-17.5	-0.69	4e-49	Cognitive function;
LUSC	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg04586622	chr2:25135609	ADCY3	0.43	9.23	0.45	3.12e-18	Body mass index;
LUSC	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg14675211	chr2:100938903	LONRF2	0.37	5.78	0.3	1.76e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.53	-0.38	4.92e-13	Morning vs. evening chronotype;
LUSC	cis	rs2345546	1	rs2345546	chr16:25427472	C/T	cg08360281	chr16:25269390	ZKSCAN2	0.72	8.46	0.42	8.24e-16	Major depression and alcohol dependence;
LUSC	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg12927641	chr6:109611667	NA	-0.34	-5.77	-0.3	1.81e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.54	-10.67	-0.5	4.59e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg05340658	chr4:99064831	C4orf37	0.66	10.86	0.51	9.9899999999999993e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg21643547	chr1:205240462	TMCC2	-0.42	-7.65	-0.39	2.17e-13	Red blood cell count;
LUSC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg02951883	chr7:2050386	MAD1L1	-0.44	-7.61	-0.38	2.76e-13	Schizophrenia;
LUSC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.76	-0.3	1.96e-8	Lung cancer;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg10488340	chr16:67063589	CBFB	0.41	5.99	0.31	5.37e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.06	-0.55	4.92e-28	Mean corpuscular volume;
LUSC	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.7	10.65	0.5	5.42e-23	Corneal astigmatism;
LUSC	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg22029157	chr1:209979665	IRF6	0.72	8.77	0.43	9.3e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-6.98	-0.36	1.58e-11	Monocyte percentage of white cells;
LUSC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.16	-0.32	2.04e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	8.19e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs61990749	0.597	rs7142390	chr14:78232880	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.63	6.5	0.34	2.88e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg22800045	chr5:56110881	MAP3K1	0.59	7.83	0.39	6.39e-14	Type 2 diabetes;
LUSC	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.29	-21.04	-0.75	3.7e-63	Type 1 diabetes nephropathy;
LUSC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.31	-0.56	5.64e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10266483	0.661	rs608769	chr7:63753161	T/C	cg24201672	chr7:64023550	ZNF680	-0.46	-5.83	-0.3	1.32e-8	Response to statin therapy;
LUSC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.7e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2346177	0.967	rs4953374	chr2:46654401	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-9.26	-0.45	2.58e-18	HDL cholesterol;
LUSC	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg21775007	chr8:11205619	TDH	-0.54	-7.8	-0.39	8.18e-14	Triglycerides;
LUSC	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.38e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg26338869	chr17:61819248	STRADA	0.42	6.06	0.31	3.7e-9	Prudent dietary pattern;
LUSC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.27	0.45	2.31e-18	Prudent dietary pattern;
LUSC	cis	rs9473147	0.503	rs2171086	chr6:47590104	C/T	cg02130027	chr6:47444894	CD2AP	0.36	5.85	0.3	1.19e-8	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs10511400	0.618	rs9858566	chr3:119886548	G/C	cg02809009	chr19:50354510	PTOV1	-0.67	-6.11	-0.32	2.71e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.82	15.09	0.64	1.34e-39	Blood protein levels;
LUSC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06544989	chr22:39130855	UNC84B	0.34	5.94	0.31	6.98e-9	Menopause (age at onset);
LUSC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg18904891	chr8:8559673	CLDN23	0.61	8.18	0.41	6.04e-15	Obesity-related traits;
LUSC	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.82	-0.3	1.41e-8	Type 2 diabetes;
LUSC	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg08917208	chr2:24149416	ATAD2B	0.88	10.02	0.48	7.83e-21	Lymphocyte counts;
LUSC	cis	rs1691799	0.777	rs11176145	chr12:66719795	A/G	cg16791601	chr12:66731901	HELB	0.58	9.91	0.48	1.86e-20	White blood cell count (basophil);
LUSC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg19592336	chr6:28129416	ZNF389	0.46	6.01	0.31	4.81e-9	Depression;
LUSC	cis	rs10875746	0.551	rs2054904	chr12:48724354	C/G	cg13454099	chr12:49076203	C12orf41	-0.5	-5.79	-0.3	1.67e-8	Longevity (90 years and older);
LUSC	cis	rs4766566	0.694	rs1362006	chr12:111742222	A/G	cg10833066	chr12:111807467	FAM109A	0.55	10.56	0.5	1.06e-22	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUSC	cis	rs8018808	0.935	rs12436593	chr14:77928476	C/T	cg20045696	chr14:77926864	AHSA1	0.34	5.71	0.3	2.46e-8	Myeloid white cell count;
LUSC	cis	rs62432291	0.681	rs450538	chr6:159659523	A/G	cg14500486	chr6:159655392	FNDC1	-0.54	-6.06	-0.31	3.76e-9	Joint mobility (Beighton score);
LUSC	cis	rs7608623	0.679	rs4665652	chr2:24250023	G/A	cg08917208	chr2:24149416	ATAD2B	-0.45	-5.95	-0.31	6.63e-9	Obesity-related traits;
LUSC	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.64	9.7	0.47	9.23e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.13	0.41	8.35e-15	Prudent dietary pattern;
LUSC	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg05340658	chr4:99064831	C4orf37	-0.46	-7.28	-0.37	2.39e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9473147	0.543	rs7738044	chr6:47469273	A/G	cg12968598	chr6:47444699	CD2AP	0.53	7.97	0.4	2.49e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	10.63	0.5	6.27e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	10.8	0.51	1.67e-23	Mean corpuscular volume;
LUSC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.12	0.41	9.02e-15	Prudent dietary pattern;
LUSC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.63	-13.28	-0.59	1.31e-32	Monocyte percentage of white cells;
LUSC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg08200582	chr11:442649	ANO9	-0.58	-6.56	-0.34	2.09e-10	Body mass index;
LUSC	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg21849932	chr20:62369462	LIME1	-0.41	-6.1	-0.32	2.94e-9	Prostate cancer;
LUSC	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg16447950	chr5:562315	NA	-0.55	-7.69	-0.39	1.62e-13	Obesity-related traits;
LUSC	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.55	-0.46	2.81e-19	Coronary artery disease;
LUSC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg08847533	chr14:75593920	NEK9	0.86	16.11	0.66	1.35e-43	Height;
LUSC	trans	rs1470506	0.529	rs1374395	chr2:77302502	A/T	cg21390574	chr3:122675597	SEMA5B	-0.3	-6.11	-0.32	2.83e-9	IgG glycosylation;
LUSC	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg18681998	chr4:17616180	MED28	0.78	13.8	0.6	1.41e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg07169764	chr2:136633963	MCM6	-0.6	-8.04	-0.4	1.52e-14	Mosquito bite size;
LUSC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.24	0.32	1.3e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs17030434	1.000	rs732680	chr4:154725211	G/A	cg14289246	chr4:154710475	SFRP2	-0.5	-6.42	-0.33	4.61e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.16	0.32	2.05e-9	Retinal vascular caliber;
LUSC	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg04518342	chr5:131593106	PDLIM4	0.37	6.77	0.35	5.7e-11	Blood metabolite levels;
LUSC	trans	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg04995722	chr7:26192034	NFE2L3	-0.37	-6.07	-0.32	3.42e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08704250	chr15:31115839	NA	0.4	6.02	0.31	4.47e-9	Huntington's disease progression;
LUSC	cis	rs698813	0.674	rs7590224	chr2:44501209	T/G	cg00619915	chr2:44497795	NA	-0.53	-7.2	-0.37	3.91e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg02716173	chr4:95372836	PDLIM5	0.44	5.95	0.31	6.85e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg24846343	chr22:24311635	DDTL	0.56	11.47	0.53	6.61e-26	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9921338	1.000	rs8049173	chr16:11436882	G/A	cg00044050	chr16:11439710	C16orf75	-0.5	-6.67	-0.34	1.07e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs3820928	0.874	rs6706802	chr2:227850776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.61	-0.38	2.91e-13	Pulmonary function;
LUSC	cis	rs4363385	0.747	rs4845504	chr1:152960043	G/A	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.44	-0.38	8.86e-13	Inflammatory skin disease;
LUSC	cis	rs9815354	0.812	rs11129935	chr3:41985203	A/C	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.72e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.46	8.71	0.43	1.47e-16	Blood metabolite levels;
LUSC	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg15556689	chr8:8085844	FLJ10661	0.67	10.6	0.5	7.87e-23	Mood instability;
LUSC	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg00945038	chr17:61921165	SMARCD2	0.38	5.7	0.3	2.7e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg11766577	chr21:47581405	C21orf56	0.55	8.64	0.43	2.34e-16	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.48	0.38	6.59e-13	Motion sickness;
LUSC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg02487422	chr3:49467188	NICN1	0.47	7.48	0.38	6.58e-13	Resting heart rate;
LUSC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg26695010	chr11:65641043	EFEMP2	-0.47	-7.11	-0.36	7.05e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg10729496	chr3:10149963	C3orf24	0.58	7.26	0.37	2.69e-12	Alzheimer's disease;
LUSC	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg14583973	chr4:3374767	RGS12	0.34	7.46	0.38	7.62e-13	Serum sulfate level;
LUSC	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.73	0.35	7.21e-11	Systolic blood pressure;
LUSC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg10207240	chr12:122356781	WDR66	0.45	6.54	0.34	2.34e-10	Mean corpuscular volume;
LUSC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20887711	chr4:1340912	KIAA1530	0.68	10.58	0.5	9.47e-23	Longevity;
LUSC	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg10596483	chr8:143751796	JRK	0.61	9.4	0.46	9.11e-19	Schizophrenia;
LUSC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg22963979	chr7:1858916	MAD1L1	-0.54	-8.03	-0.4	1.64e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg11366901	chr6:160182831	ACAT2	0.81	11.23	0.52	4.73e-25	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg24006582	chr15:45444508	DUOX1	0.66	9.6	0.47	1.92e-19	Uric acid levels;
LUSC	cis	rs7523050	0.908	rs72697202	chr1:109398704	A/G	cg08274380	chr1:109419600	GPSM2	0.92	9.73	0.47	7.24e-20	Fat distribution (HIV);
LUSC	cis	rs738321	0.757	rs2284062	chr22:38544221	A/G	cg25457927	chr22:38595422	NA	-0.41	-8.02	-0.4	1.86e-14	Breast cancer;
LUSC	cis	rs9715521	0.589	rs11726451	chr4:59852381	A/C	cg11281224	chr4:60001000	NA	-0.46	-6.58	-0.34	1.83e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg02423579	chr7:2872169	GNA12	-0.41	-6.41	-0.33	5e-10	Height;
LUSC	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg01884057	chr2:25150051	NA	0.49	11.49	0.53	5.46e-26	Body mass index;
LUSC	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg02574844	chr11:5959923	NA	-0.4	-6.03	-0.31	4.45e-9	DNA methylation (variation);
LUSC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.48	-0.33	3.34e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg09876464	chr15:85330779	ZNF592	0.34	6.02	0.31	4.69e-9	P wave terminal force;
LUSC	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg03859395	chr2:55845619	SMEK2	0.87	16.06	0.66	1.99e-43	Metabolic syndrome;
LUSC	cis	rs7615316	0.779	rs9861997	chr3:142060862	T/A	cg16271453	chr3:142027066	XRN1	-0.4	-6.96	-0.36	1.82e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg07211511	chr3:129823064	LOC729375	-0.62	-8.21	-0.41	4.72e-15	Blood pressure (smoking interaction);
LUSC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg26769984	chr7:1090371	C7orf50	0.58	7.49	0.38	6.03e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg16325326	chr1:53192061	ZYG11B	-0.69	-10.75	-0.51	2.33e-23	Monocyte count;
LUSC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-1.1	-23.72	-0.79	1.27e-73	Height;
LUSC	cis	rs7215564	0.908	rs9908112	chr17:78753455	A/G	cg23238734	chr17:78661607	RPTOR	-0.51	-6.14	-0.32	2.31e-9	Myopia (pathological);
LUSC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.75	12.97	0.58	1.88e-31	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12997796	0.503	rs34492196	chr2:87021758	T/C	cg25203885	chr2:87302643	LOC285074	-0.58	-5.67	-0.3	3.16e-8	Schizophrenia;
LUSC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg12292205	chr6:26970375	C6orf41	0.51	8.56	0.42	4.13e-16	Schizophrenia;
LUSC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg04352962	chr1:209979756	IRF6	-0.49	-6.67	-0.34	1.05e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs4343996	0.558	rs11771359	chr7:3412515	C/T	cg21248987	chr7:3385318	SDK1	0.37	6.23	0.32	1.38e-9	Motion sickness;
LUSC	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg23711669	chr6:146136114	FBXO30	-0.82	-14.68	-0.63	5.49e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	10.78	0.51	1.84e-23	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07923666	chr12:49932857	KCNH3	-0.53	-6.48	-0.33	3.22e-10	Resting heart rate;
LUSC	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg04036182	chr15:45458818	NA	0.39	6.56	0.34	2.03e-10	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06850241	chr22:41845214	NA	0.3	5.76	0.3	1.88e-8	Vitiligo;
LUSC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg03146154	chr1:46216737	IPP	0.56	8.39	0.42	1.36e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08470875	chr2:26401718	FAM59B	0.72	9.9	0.48	1.91e-20	Gut microbiome composition (summer);
LUSC	cis	rs548181	1.000	rs548181	chr11:125461709	A/G	cg03464685	chr11:125439445	EI24	1.16	14.22	0.61	3.23e-36	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg13683864	chr3:40499215	RPL14	-0.96	-16.33	-0.67	1.72e-44	Renal cell carcinoma;
LUSC	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13789015	chr9:136890014	NCRNA00094	0.64	11.83	0.54	3.25e-27	Platelet distribution width;
LUSC	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg16070123	chr10:51489643	NA	0.57	9.38	0.46	1.07e-18	Prostate-specific antigen levels;
LUSC	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg12615879	chr12:58013172	SLC26A10	0.38	8.92	0.44	3.08e-17	Multiple sclerosis;
LUSC	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.48	0.46	4.82e-19	Coffee consumption (cups per day);
LUSC	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg21775007	chr8:11205619	TDH	0.45	6.41	0.33	4.88e-10	Neuroticism;
LUSC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18876405	chr7:65276391	NA	-0.54	-8.57	-0.42	3.82e-16	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25716846	chr3:42641998	NKTR	-0.41	-6.05	-0.31	3.87e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg06637938	chr14:75390232	RPS6KL1	0.66	11.04	0.52	2.38e-24	Caffeine consumption;
LUSC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.67	-6.08	-0.32	3.34e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.64	0.6	5.64e-34	Platelet count;
LUSC	cis	rs11583043	0.708	rs10493942	chr1:101545482	G/A	cg11406453	chr1:101602562	NA	-0.4	-6.65	-0.34	1.2e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg02931644	chr1:25747376	RHCE	0.34	6.33	0.33	7.69e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs6725041	0.547	rs59096325	chr2:213203853	C/T	cg16329650	chr2:213403929	ERBB4	-0.42	-6.67	-0.34	1.09e-10	QT interval (ambient particulate matter interaction);
LUSC	trans	rs4729127	1.000	rs17166229	chr7:94017673	A/G	cg19058453	chr19:9879420	ZNF846	0.62	6.17	0.32	1.99e-9	Intelligence;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg13848568	chr1:45965625	CCDC163P;MMACHC	0.39	6.0	0.31	5.26e-9	Asthma;
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.54	-8.12	-0.41	9.05e-15	Lymphocyte counts;
LUSC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.06	-0.55	4.73e-28	Type 2 diabetes;
LUSC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg17507749	chr15:85114479	UBE2QP1	0.69	8.71	0.43	1.38e-16	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg13206674	chr6:150067644	NUP43	0.63	10.29	0.49	9.36e-22	Lung cancer;
LUSC	cis	rs9462027	0.628	rs9462030	chr6:34831280	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.88	-0.31	9.86e-9	Systemic lupus erythematosus;
LUSC	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-15.07	-0.64	1.64e-39	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs73206853	0.841	rs56379265	chr12:110956370	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	7.83e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.95	-0.31	6.6e-9	Tonsillectomy;
LUSC	cis	rs12712073	0.837	rs11692867	chr2:100759477	G/A	cg22139774	chr2:100720529	AFF3	-0.41	-7.14	-0.36	6.02e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg23711669	chr6:146136114	FBXO30	0.78	14.12	0.61	7.9e-36	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg12062639	chr20:23401060	NAPB	0.97	7.94	0.4	3.07e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs62056376	0.646	rs7210639	chr17:32588628	C/T	cg19986872	chr5:131347773	ACSL6	-0.38	-5.94	-0.31	7.01e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs7712401	0.601	rs35847506	chr5:122327108	G/A	cg19077854	chr5:122220652	SNX24	-0.43	-9.48	-0.46	4.83e-19	Mean platelet volume;
LUSC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.5	7.81	0.39	7.53e-14	Colorectal cancer;
LUSC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.66	0.3	3.26e-8	Menopause (age at onset);
LUSC	cis	rs3820928	0.934	rs1366756	chr2:227772038	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.69	-0.39	1.66e-13	Pulmonary function;
LUSC	cis	rs11585357	1.000	rs72646785	chr1:17603472	G/T	cg08277548	chr1:17600880	PADI3	-0.65	-6.71	-0.34	8.45e-11	Hair shape;
LUSC	cis	rs738322	0.553	rs28718653	chr22:38570698	C/A	cg25457927	chr22:38595422	NA	-0.36	-7.13	-0.36	6.36e-12	Cutaneous nevi;
LUSC	cis	rs12210905	0.925	rs72838238	chr6:26971681	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08229018	chr4:119274133	PRSS12	-0.44	-5.98	-0.31	5.86e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6987853	0.966	rs2923439	chr8:42429122	A/G	cg09913449	chr8:42400586	C8orf40	0.49	8.16	0.41	7.05e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-7.84	-0.39	6.11e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs75920871	0.588	rs4548653	chr11:116903316	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-6.65	-0.34	1.17e-10	Subjective well-being;
LUSC	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg23260525	chr10:116636907	FAM160B1	0.4	8.18	0.41	6.12e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg24531977	chr5:56204891	C5orf35	-0.63	-9.36	-0.46	1.19e-18	Coronary artery disease;
LUSC	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg15432903	chr11:17409602	KCNJ11	0.61	10.83	0.51	1.26e-23	Type 2 diabetes;
LUSC	cis	rs1595825	0.891	rs7584475	chr2:198577424	A/C	cg19156104	chr2:198669113	PLCL1	-0.44	-5.7	-0.3	2.59e-8	Ulcerative colitis;
LUSC	cis	rs6942756	0.744	rs2718088	chr7:128927020	C/A	cg02491457	chr7:128862824	NA	0.49	7.3	0.37	2.13e-12	White matter hyperintensity burden;
LUSC	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	0.93	17.02	0.68	3.36e-47	Headache;
LUSC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg00677455	chr12:58241039	CTDSP2	0.59	8.48	0.42	7.35e-16	Multiple sclerosis;
LUSC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.19	-0.32	1.79e-9	Monocyte count;
LUSC	cis	rs4363385	0.791	rs11205177	chr1:153002502	G/A	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.9	-0.4	4e-14	Inflammatory skin disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03744954	chr7:23637556	CCDC126	-0.4	-6.3	-0.33	9.5e-10	Electrocardiographic conduction measures;
LUSC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	0.64	13.37	0.59	5.97e-33	Prudent dietary pattern;
LUSC	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg24579218	chr15:68104479	NA	-0.39	-6.78	-0.35	5.39e-11	Restless legs syndrome;
LUSC	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg18240062	chr17:79603768	NPLOC4	0.78	15.3	0.64	2.02e-40	Eye color traits;
LUSC	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg02696742	chr7:106810147	HBP1	0.65	9.75	0.47	6.45e-20	Coronary artery disease;
LUSC	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	6.07	0.32	3.52e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg04398451	chr17:18023971	MYO15A	0.45	7.11	0.36	6.97e-12	Total body bone mineral density;
LUSC	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg18323236	chr1:24743029	NIPAL3	-0.38	-6.56	-0.34	2.05e-10	Response to interferon beta in multiple sclerosis;
LUSC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.47	7.53	0.38	4.65e-13	Resistin levels;
LUSC	cis	rs7582180	0.903	rs7607170	chr2:100903008	C/G	cg08017756	chr2:100939284	LONRF2	-0.36	-6.15	-0.32	2.24e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg21918786	chr6:109611834	NA	-0.39	-6.7	-0.34	8.78e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs500891	0.504	rs976065	chr6:84092514	C/T	cg08257003	chr6:84140564	ME1	0.35	8.63	0.43	2.58e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs2219968	1.000	rs6473085	chr8:78974505	T/A	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg03732007	chr1:2071316	PRKCZ	0.58	10.6	0.5	8.14e-23	Height;
LUSC	trans	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg27275811	chr11:74457193	NA	-0.64	-6.22	-0.32	1.51e-9	Type 2 diabetes nephropathy;
LUSC	trans	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg25214090	chr10:38739885	LOC399744	0.54	7.93	0.4	3.3e-14	Corneal astigmatism;
LUSC	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg23029597	chr12:123009494	RSRC2	0.74	9.36	0.46	1.24e-18	Body mass index;
LUSC	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg23625390	chr15:77176239	SCAPER	-0.46	-7.15	-0.36	5.41e-12	Blood metabolite levels;
LUSC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg00933542	chr6:150070202	PCMT1	0.3	6.16	0.32	2.06e-9	Lung cancer;
LUSC	cis	rs2067615	0.579	rs10778502	chr12:107090201	T/C	cg15890332	chr12:107067104	RFX4	0.33	5.83	0.3	1.33e-8	Heart rate;
LUSC	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.58	-7.62	-0.38	2.72e-13	Body mass index (adult);
LUSC	cis	rs4478137	0.931	rs3967762	chr4:164244976	T/C	cg06758707	chr4:164254230	NPY1R	0.63	9.92	0.48	1.7e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg08132940	chr7:1081526	C7orf50	-0.52	-6.22	-0.32	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.5	6.22	0.32	1.45e-9	Gut microbiome composition (summer);
LUSC	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg17749961	chr2:30669863	LCLAT1	0.71	8.42	0.42	1.09e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg02423579	chr7:2872169	GNA12	-0.38	-5.99	-0.31	5.55e-9	Height;
LUSC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg14440974	chr22:39074834	NA	-0.36	-5.92	-0.31	7.79e-9	Menopause (age at onset);
LUSC	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg02176678	chr2:219576539	TTLL4	0.6	10.98	0.51	3.81e-24	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs1493916	0.905	rs10460051	chr18:31413679	C/T	cg13755796	chr4:20253514	NA	-0.43	-6.61	-0.34	1.5e-10	Life satisfaction;
LUSC	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg03709012	chr19:19516395	GATAD2A	0.75	11.59	0.54	2.52e-26	Tonsillectomy;
LUSC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.01	0.4	1.89e-14	Corneal astigmatism;
LUSC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.66	-0.67	8.4e-46	Monocyte count;
LUSC	cis	rs2346177	0.875	rs12986585	chr2:46644121	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.39	6.66	0.34	1.14e-10	HDL cholesterol;
LUSC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg16447950	chr5:562315	NA	-0.52	-6.88	-0.35	3e-11	Obesity-related traits;
LUSC	trans	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg14791747	chr16:20752902	THUMPD1	0.43	6.18	0.32	1.88e-9	Pancreatic cancer;
LUSC	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg03929089	chr4:120376271	NA	-0.57	-6.34	-0.33	7.48e-10	D-dimer levels;
LUSC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg13535736	chr9:111863775	C9orf5	-0.42	-6.69	-0.34	9.51e-11	Menarche (age at onset);
LUSC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg03526776	chr6:41159608	TREML2	0.29	5.7	0.3	2.62e-8	Alzheimer's disease (late onset);
LUSC	cis	rs11650494	0.710	rs76651802	chr17:47473785	A/G	cg08112188	chr17:47440006	ZNF652	0.93	7.93	0.4	3.3e-14	Prostate cancer;
LUSC	cis	rs9311676	0.609	rs11719450	chr3:58456811	A/G	cg26110898	chr3:58419937	PDHB	-0.39	-6.11	-0.32	2.7e-9	Systemic lupus erythematosus;
LUSC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg21918786	chr6:109611834	NA	-0.42	-7.28	-0.37	2.36e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg03146154	chr1:46216737	IPP	0.5	7.42	0.38	9.7e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-6.94	-0.36	2.04e-11	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.817	rs188588	chr12:34215277	G/A	cg13010199	chr12:38710504	ALG10B	0.4	6.25	0.32	1.25e-9	Morning vs. evening chronotype;
LUSC	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg07169764	chr2:136633963	MCM6	1.18	17.48	0.69	4.99e-49	Corneal structure;
LUSC	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg22089800	chr15:90895588	ZNF774	-0.64	-9.65	-0.47	1.3e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs1044826	0.642	rs6439860	chr3:139175797	A/G	cg00490450	chr3:139108681	COPB2	0.45	6.96	0.36	1.79e-11	Obesity-related traits;
LUSC	cis	rs1784581	0.588	rs7752870	chr6:162422510	T/C	cg17173639	chr6:162384350	PARK2	0.57	9.98	0.48	1.05e-20	Itch intensity from mosquito bite;
LUSC	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg05110241	chr16:68378359	PRMT7	-0.56	-6.32	-0.33	8.54e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg18402987	chr7:1209562	NA	0.7	7.64	0.39	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg06606381	chr12:133084897	FBRSL1	-0.67	-7.52	-0.38	5.13e-13	Depression;
LUSC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg18230493	chr5:56204884	C5orf35	0.77	12.79	0.57	9.26e-31	Initial pursuit acceleration;
LUSC	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg24642439	chr20:33292090	TP53INP2	0.49	7.34	0.37	1.62e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs4363385	0.818	rs368912	chr1:153016204	C/G	cg25856811	chr1:152973957	SPRR3	-0.34	-5.79	-0.3	1.62e-8	Inflammatory skin disease;
LUSC	cis	rs193541	0.632	rs415417	chr5:122322884	G/A	cg19077854	chr5:122220652	SNX24	-0.39	-8.35	-0.42	1.88e-15	Glucose homeostasis traits;
LUSC	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.17	0.55	1.95e-28	Colorectal cancer;
LUSC	cis	rs96067	0.652	rs274132	chr1:36581978	C/T	cg27506609	chr1:36549197	TEKT2	0.62	10.28	0.49	1.01e-21	Corneal structure;
LUSC	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg25233709	chr10:116636983	FAM160B1	0.37	6.59	0.34	1.69e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs929596	0.585	rs2018985	chr2:234648860	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-9.08	-0.44	9.94e-18	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14442939	chr10:27389572	ANKRD26	0.89	7.59	0.38	3.12e-13	Breast cancer;
LUSC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg08270630	chr22:50330655	NA	-0.44	-6.66	-0.34	1.1e-10	Schizophrenia;
LUSC	cis	rs7178572	0.568	rs11636554	chr15:77608747	C/T	cg22256960	chr15:77711686	NA	-0.48	-7.57	-0.38	3.57e-13	Type 2 diabetes;
LUSC	cis	rs10140922	0.966	rs10140133	chr14:35819834	C/G	cg07166546	chr14:35805898	NA	-0.26	-6.15	-0.32	2.19e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4891159	0.548	rs617823	chr18:74120233	A/G	cg24786174	chr18:74118243	ZNF516	0.97	21.18	0.76	1.03e-63	Longevity;
LUSC	cis	rs6967385	0.580	rs3902479	chr7:12329328	T/C	cg20607287	chr7:12443886	VWDE	0.37	5.79	0.3	1.64e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07167872	chr1:205819463	PM20D1	0.88	17.16	0.68	8.75e-48	Menarche (age at onset);
LUSC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18252515	chr7:66147081	NA	-0.39	-5.66	-0.3	3.22e-8	Aortic root size;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18976893	chr8:27168292	PTK2B;TRIM35	0.74	6.4	0.33	5.17e-10	Cognitive performance;
LUSC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg17264618	chr3:40429014	ENTPD3	0.34	6.92	0.35	2.37e-11	Renal cell carcinoma;
LUSC	cis	rs926938	0.527	rs360679	chr1:115494121	G/T	cg12756093	chr1:115239321	AMPD1	0.45	6.81	0.35	4.47e-11	Autism;
LUSC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg25039879	chr17:56429692	SUPT4H1	0.66	8.88	0.44	4.12e-17	Cognitive test performance;
LUSC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.18	0.88	4.53e-111	Chronic sinus infection;
LUSC	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg25427524	chr10:38739819	LOC399744	-0.55	-7.8	-0.39	7.86e-14	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.69	0.34	9.16e-11	Rheumatoid arthritis;
LUSC	cis	rs7247513	0.964	rs4804202	chr19:12718619	T/C	cg01871581	chr19:12707946	ZNF490	-0.56	-8.76	-0.43	9.82e-17	Bipolar disorder;
LUSC	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.56	9.15	0.45	5.91e-18	Bone mineral density;
LUSC	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg25214090	chr10:38739885	LOC399744	0.55	8.15	0.41	7.34e-15	Corneal astigmatism;
LUSC	cis	rs983392	0.709	rs1820428	chr11:59986333	A/T	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.16	-0.32	2.04e-9	Alzheimer's disease (late onset);
LUSC	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg02423579	chr7:2872169	GNA12	-0.37	-5.89	-0.31	9.44e-9	Height;
LUSC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22618164	chr12:122356400	WDR66	0.57	8.59	0.43	3.4e-16	Mean corpuscular volume;
LUSC	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.42	6.57	0.34	1.89e-10	Schizophrenia;
LUSC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg07424592	chr7:64974309	NA	-0.43	-6.18	-0.32	1.91e-9	Calcium levels;
LUSC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs7178375	0.607	rs34178381	chr15:31222585	G/C	cg01738805	chr15:31195741	MTMR15	0.86	7.03	0.36	1.19e-11	Hypertriglyceridemia;
LUSC	cis	rs477692	0.569	rs10764885	chr10:131310207	G/A	cg05714579	chr10:131428358	MGMT	0.42	5.99	0.31	5.47e-9	Response to temozolomide;
LUSC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.25	-0.32	1.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg19812747	chr11:111475976	SIK2	-0.57	-8.29	-0.41	2.72e-15	Primary sclerosing cholangitis;
LUSC	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg08508325	chr11:3079039	CARS	0.36	8.18	0.41	5.9e-15	Calcium levels;
LUSC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.28	0.59	1.28e-32	Cognitive test performance;
LUSC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg21770322	chr7:97807741	LMTK2	-0.41	-7.08	-0.36	8.48e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6960043	0.502	rs6461145	chr7:15026872	C/T	cg19272540	chr7:15055459	NA	0.24	5.69	0.3	2.79e-8	Type 2 diabetes;
LUSC	cis	rs7833986	0.941	rs13278255	chr8:57067975	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.63	9.6	0.47	1.98e-19	Height;
LUSC	trans	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg18335740	chr13:41363409	SLC25A15	-0.61	-10.68	-0.5	4.32e-23	Lewy body disease;
LUSC	cis	rs12044355	0.516	rs2356383	chr1:231742973	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-8.95	-0.44	2.52e-17	Alzheimer's disease;
LUSC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.24e-19	Prudent dietary pattern;
LUSC	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.81	0.57	7.83e-31	Lymphocyte percentage of white cells;
LUSC	cis	rs2274273	0.622	rs11846809	chr14:55401782	T/C	cg04306507	chr14:55594613	LGALS3	0.4	8.37	0.42	1.61e-15	Protein biomarker;
LUSC	cis	rs4363385	0.818	rs1415969	chr1:153006448	G/T	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.44e-8	Inflammatory skin disease;
LUSC	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg08601574	chr20:25228251	PYGB	0.42	6.41	0.33	4.9e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1538970	0.962	rs2153608	chr1:45813941	C/T	cg05343316	chr1:45956843	TESK2	-0.59	-8.07	-0.4	1.24e-14	Platelet count;
LUSC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg02423579	chr7:2872169	GNA12	-0.47	-7.03	-0.36	1.16e-11	Height;
LUSC	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	7.54	0.38	4.6e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18876405	chr7:65276391	NA	0.56	8.98	0.44	2e-17	Aortic root size;
LUSC	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.8	-0.35	4.79e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs1775715	0.707	rs2799019	chr10:32142850	C/T	cg04359828	chr10:32216031	ARHGAP12	0.4	6.91	0.35	2.52e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg05501817	chr11:14380813	RRAS2	-0.39	-5.8	-0.3	1.55e-8	Mitochondrial DNA levels;
LUSC	trans	rs71435601	0.574	rs487858	chr2:21400305	G/A	cg20757404	chr19:378427	NA	0.37	5.96	0.31	6.28e-9	Cholesterol, total;
LUSC	trans	rs8073060	0.963	rs11080354	chr17:33872407	A/G	cg19694781	chr19:47549865	TMEM160	-0.68	-10.11	-0.48	3.87e-21	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs1941687	0.563	rs1565784	chr18:31358491	G/T	cg27147174	chr7:100797783	AP1S1	0.53	8.41	0.42	1.2e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	trans	rs17507216	1.000	rs3850610	chr15:83221392	A/C	cg04831495	chr15:85060580	GOLGA6L5	0.46	6.69	0.34	9.39e-11	Excessive daytime sleepiness;
LUSC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11764359	chr7:65958608	NA	-0.58	-8.91	-0.44	3.25e-17	Aortic root size;
LUSC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg15704280	chr7:45808275	SEPT13	0.98	14.71	0.63	4.22e-38	Coronary artery disease;
LUSC	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg21775007	chr8:11205619	TDH	0.45	6.44	0.33	4.07e-10	Morning vs. evening chronotype;
LUSC	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.5	0.38	5.67e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1712517	0.524	rs4917384	chr10:104995788	T/C	cg04362960	chr10:104952993	NT5C2	0.53	7.19	0.37	4.29e-12	Migraine;
LUSC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg02475777	chr4:1388615	CRIPAK	-0.41	-6.07	-0.32	3.48e-9	Obesity-related traits;
LUSC	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg08085267	chr17:45401833	C17orf57	-0.52	-7.44	-0.38	8.47e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg00750074	chr16:89608354	SPG7	-0.45	-7.79	-0.39	8.37e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg04287289	chr16:89883240	FANCA	-0.43	-6.11	-0.32	2.74e-9	Vitiligo;
LUSC	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.83	14.38	0.62	7.74e-37	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg25019033	chr10:957182	NA	-0.5	-6.37	-0.33	6.33e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg16989086	chr20:62203971	PRIC285	0.47	6.7	0.34	8.79e-11	Glioblastoma;
LUSC	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19717773	chr7:2847554	GNA12	-0.38	-6.14	-0.32	2.41e-9	Height;
LUSC	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	11.23	0.52	5.01e-25	Lung cancer in ever smokers;
LUSC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg11629889	chr17:40839022	CNTNAP1	0.51	8.91	0.44	3.35e-17	Colorectal or endometrial cancer;
LUSC	cis	rs2235649	0.663	rs6600168	chr16:1848927	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-5.92	-0.31	7.81e-9	Blood metabolite levels;
LUSC	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg06623918	chr6:96969491	KIAA0776	0.77	9.96	0.48	1.21e-20	Migraine;Coronary artery disease;
LUSC	cis	rs1371867	0.846	rs2919471	chr8:101232701	T/C	cg06002616	chr8:101225028	SPAG1	0.47	7.66	0.39	1.97e-13	Atrioventricular conduction;
LUSC	cis	rs4629710	0.592	rs11759926	chr6:131571269	G/T	cg12606694	chr6:131520996	AKAP7	0.62	9.36	0.46	1.19e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg20608306	chr11:116969690	SIK3	0.39	6.48	0.33	3.24e-10	Blood protein levels;
LUSC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.81e-10	Bipolar disorder;
LUSC	cis	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg15711740	chr2:61764176	XPO1	-0.47	-7.36	-0.37	1.43e-12	Tuberculosis;
LUSC	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.14	-0.45	6.37e-18	Monocyte percentage of white cells;
LUSC	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg26924012	chr15:45694286	SPATA5L1	1.11	20.26	0.74	4.5e-60	Homoarginine levels;
LUSC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.66	-0.6	4.79e-34	Chronic sinus infection;
LUSC	cis	rs2708377	0.929	rs61928567	chr12:11304413	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	-0.39	-5.8	-0.3	1.55e-8	Resistin levels;
LUSC	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg11494091	chr17:61959527	GH2	0.37	6.11	0.32	2.8e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs367615	0.552	rs2416210	chr5:108741137	C/T	cg17395555	chr5:108820864	NA	-0.46	-7.97	-0.4	2.53e-14	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg05283184	chr6:79620031	NA	-0.57	-12.18	-0.55	1.67e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	10.31	0.49	8.33e-22	Bone mineral density;
LUSC	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg04539111	chr16:67997858	SLC12A4	-0.41	-5.8	-0.3	1.51e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16150798	chr11:61560092	MIR611;C11orf10;FEN1	-0.43	-6.35	-0.33	6.91e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg26043149	chr18:55253948	FECH	-0.47	-7.1	-0.36	7.71e-12	Bone mineral density;
LUSC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg03146154	chr1:46216737	IPP	-0.51	-7.46	-0.38	7.41e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.92	14.7	0.63	4.43e-38	Parkinson's disease;
LUSC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.84	0.3	1.21e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg09699651	chr6:150184138	LRP11	0.45	7.17	0.37	4.98e-12	Testicular germ cell tumor;
LUSC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg25811766	chr13:21894605	NA	0.64	10.11	0.48	3.98e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg23505145	chr19:12996616	KLF1	0.65	10.81	0.51	1.47e-23	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.35	6.24	0.32	1.33e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg21775007	chr8:11205619	TDH	-0.65	-10.21	-0.49	1.76e-21	Retinal vascular caliber;
LUSC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg07701084	chr6:150067640	NUP43	0.57	8.93	0.44	3e-17	Lung cancer;
LUSC	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg09904177	chr6:26538194	HMGN4	-0.78	-5.94	-0.31	6.98e-9	Depression;
LUSC	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg22437258	chr11:111473054	SIK2	0.46	6.22	0.32	1.5e-9	Primary sclerosing cholangitis;
LUSC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg06238570	chr21:40685208	BRWD1	0.49	7.51	0.38	5.59e-13	Cognitive function;
LUSC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg00701064	chr4:6280414	WFS1	0.59	14.24	0.61	2.82e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg17376030	chr22:41985996	PMM1	-0.48	-6.03	-0.31	4.35e-9	Vitiligo;
LUSC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.52	7.22	0.37	3.61e-12	Cognitive ability;
LUSC	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg01028140	chr2:1542097	TPO	-0.58	-8.07	-0.4	1.31e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13033626	chr12:7342228	PEX5	-0.42	-6.09	-0.32	3.13e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.68	11.04	0.52	2.29e-24	Schizophrenia;
LUSC	cis	rs4619890	0.510	rs7680747	chr4:7871623	G/A	cg24250820	chr4:7887609	AFAP1	0.36	6.16	0.32	2.11e-9	Glaucoma (primary open-angle);
LUSC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg15556689	chr8:8085844	FLJ10661	0.69	11.09	0.52	1.47e-24	Joint mobility (Beighton score);
LUSC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06544989	chr22:39130855	UNC84B	0.35	6.09	0.32	3.03e-9	Menopause (age at onset);
LUSC	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg08027265	chr7:2291960	NA	-0.43	-7.5	-0.38	5.9e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg23752985	chr2:85803571	VAMP8	0.34	7.07	0.36	8.94e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07362569	chr17:61921086	SMARCD2	0.37	7.63	0.39	2.5e-13	Prudent dietary pattern;
LUSC	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-0.96	-12.87	-0.58	4.54e-31	Exhaled nitric oxide output;
LUSC	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg09165964	chr15:75287851	SCAMP5	-0.93	-8.31	-0.41	2.51e-15	Lung cancer;
LUSC	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg17757837	chr7:157058334	UBE3C	0.83	13.32	0.59	9.66e-33	Body mass index;
LUSC	cis	rs12050794	0.671	rs2052713	chr15:72520392	G/C	cg16672083	chr15:72433130	SENP8	0.47	7.87	0.4	5.09e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.74	-10.22	-0.49	1.59e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.55	0.38	4.06e-13	Iron status biomarkers;
LUSC	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg15557168	chr22:42548783	NA	0.33	5.68	0.3	2.98e-8	Cognitive function;
LUSC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg24147428	chr11:65409760	SIPA1	-0.55	-7.89	-0.4	4.49e-14	Blood pressure (age interaction);
LUSC	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg06784218	chr1:46089804	CCDC17	0.31	6.02	0.31	4.56e-9	Red blood cell count;Reticulocyte count;
LUSC	trans	rs459571	0.959	rs455381	chr9:136905577	C/A	cg10765909	chr12:53715428	AAAS	-0.43	-6.19	-0.32	1.75e-9	Platelet distribution width;
LUSC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.76	13.53	0.59	1.5e-33	Aortic root size;
LUSC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.03	-0.31	4.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg17971929	chr21:40555470	PSMG1	-0.51	-7.56	-0.38	3.84e-13	Menarche (age at onset);
LUSC	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg24642439	chr20:33292090	TP53INP2	0.47	7.09	0.36	8.29e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs72960926	0.744	rs72964203	chr6:74858552	T/C	cg03266952	chr6:74778945	NA	-0.85	-7.25	-0.37	2.94e-12	Metabolite levels (MHPG);
LUSC	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.52	10.44	0.5	2.89e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg08017756	chr2:100939284	LONRF2	-0.44	-8.26	-0.41	3.38e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg13770153	chr20:60521292	NA	-0.41	-5.89	-0.31	9.33e-9	Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20094282	chr17:79369258	NA	-0.46	-6.92	-0.35	2.33e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg13047869	chr3:10149882	C3orf24	-0.54	-7.3	-0.37	2.17e-12	Alzheimer's disease;
LUSC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-5.97	-0.31	6.02e-9	Insulin-like growth factors;
LUSC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg07424592	chr7:64974309	NA	-0.64	-5.79	-0.3	1.65e-8	Diabetic kidney disease;
LUSC	cis	rs4925114	0.568	rs9900803	chr17:17650978	C/T	cg09796270	chr17:17721594	SREBF1	-0.43	-7.46	-0.38	7.37e-13	Body mass index;
LUSC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.12	15.13	0.64	9.18e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2120243	0.874	rs1840680	chr3:157156029	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	6.57	0.34	1.96e-10	Hepatocellular carcinoma in hepatitis B infection;
LUSC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg05347473	chr6:146136440	FBXO30	0.47	8.05	0.4	1.46e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.76	11.48	0.53	6.24e-26	Itch intensity from mosquito bite;
LUSC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg23711669	chr6:146136114	FBXO30	0.88	16.13	0.66	1.12e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.37	-0.33	6.25e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg15556689	chr8:8085844	FLJ10661	0.54	8.18	0.41	6.04e-15	Neuroticism;
LUSC	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg01119278	chr6:110721349	DDO	-0.49	-8.81	-0.43	6.81e-17	Platelet distribution width;
LUSC	cis	rs59698941	0.550	rs11748063	chr5:132200943	C/T	cg14825688	chr5:132208181	LEAP2	-0.4	-6.05	-0.31	3.91e-9	Apolipoprotein A-IV levels;
LUSC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg05802129	chr4:122689817	NA	-0.52	-8.67	-0.43	1.96e-16	Type 2 diabetes;
LUSC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-12.07	-0.55	4.5e-28	Platelet count;
LUSC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-7.95	-0.4	2.89e-14	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08817937	chr21:33651471	C21orf45	-0.42	-6.22	-0.32	1.48e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg05887092	chr17:76393375	PGS1	0.52	9.5	0.46	4.27e-19	HDL cholesterol levels;
LUSC	cis	rs10761482	0.861	rs2061492	chr10:62104016	G/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs6977660	0.652	rs10267417	chr7:19843797	C/T	cg05791153	chr7:19748676	TWISTNB	0.68	6.63	0.34	1.39e-10	Thyroid stimulating hormone;
LUSC	cis	rs6736093	0.966	rs11674226	chr2:112698388	G/A	cg12686935	chr2:112915763	FBLN7	-0.37	-5.9	-0.31	8.73e-9	Coronary artery disease;
LUSC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.87	-0.31	1.04e-8	Tonsillectomy;
LUSC	trans	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.57	0.38	3.56e-13	Ulcerative colitis;
LUSC	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg13010199	chr12:38710504	ALG10B	0.68	10.64	0.5	5.92e-23	Bladder cancer;
LUSC	cis	rs739496	0.542	rs12423926	chr12:111781055	C/T	cg10833066	chr12:111807467	FAM109A	-0.6	-11.26	-0.52	3.73e-25	Platelet count;
LUSC	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg22431228	chr1:16359049	CLCNKA	0.33	6.89	0.35	2.71e-11	Dilated cardiomyopathy;
LUSC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg16624210	chr5:671434	TPPP	0.49	6.39	0.33	5.59e-10	Obesity-related traits;
LUSC	cis	rs68170813	0.559	rs78079372	chr7:106934548	T/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.98	-0.48	1.09e-20	Coronary artery disease;
LUSC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	cis	rs7527798	0.571	rs7531923	chr1:207833336	T/G	cg09232269	chr1:207846808	CR1L	-0.29	-6.15	-0.32	2.16e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs9815354	0.627	rs115971784	chr3:42016146	T/C	cg03022575	chr3:42003672	ULK4	0.76	7.6	0.38	3e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg01256987	chr12:42539512	GXYLT1	-0.4	-7.24	-0.37	3.07e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4730250	0.670	rs9641380	chr7:106868151	C/G	cg02696742	chr7:106810147	HBP1	-0.64	-9.71	-0.47	8.5e-20	Osteoarthritis;
LUSC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-6.78	-0.35	5.32e-11	Bipolar disorder;
LUSC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg12463550	chr7:65579703	CRCP	0.42	5.99	0.31	5.37e-9	Calcium levels;
LUSC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-0.7	-10.91	-0.51	6.71e-24	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg09835421	chr16:68378352	PRMT7	-0.57	-6.38	-0.33	5.76e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs330071	0.500	rs17662123	chr8:9246837	G/A	cg14343924	chr8:8086146	FLJ10661	0.44	6.28	0.32	1.03e-9	Acne (severe);
LUSC	cis	rs9811920	0.965	rs10222474	chr3:99862551	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.38	5.72	0.3	2.4e-8	Axial length;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg26220528	chr12:57623348	SHMT2	0.47	7.38	0.37	1.24e-12	Triglycerides;
LUSC	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg24130564	chr14:104152367	KLC1	0.44	6.33	0.33	8.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-1.16	-16.37	-0.67	1.19e-44	Breast cancer;
LUSC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg01475377	chr6:109611718	NA	0.46	8.34	0.42	1.92e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg01884057	chr2:25150051	NA	-0.46	-10.67	-0.5	4.62e-23	Body mass index;
LUSC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7216064	1.000	rs60432293	chr17:65860407	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-9.37	-0.46	1.13e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs6542838	0.641	rs883773	chr2:99491635	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.08	-0.32	3.32e-9	Fear of minor pain;
LUSC	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.57	-7.22	-0.37	3.47e-12	Schizophrenia;
LUSC	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg04998671	chr14:104000505	TRMT61A	-0.44	-6.93	-0.35	2.17e-11	Coronary artery disease;
LUSC	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg04398451	chr17:18023971	MYO15A	0.43	6.75	0.35	6.57e-11	Total body bone mineral density;
LUSC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.97	0.31	6.05e-9	Menopause (age at onset);
LUSC	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg22906224	chr7:99728672	NA	-0.46	-6.5	-0.34	2.92e-10	Coronary artery disease;
LUSC	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg17173187	chr15:85201210	NMB	0.51	9.66	0.47	1.24e-19	Schizophrenia;
LUSC	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	8.55	0.42	4.47e-16	Lung cancer in ever smokers;
LUSC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.31	0.33	8.63e-10	Personality dimensions;
LUSC	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg10167378	chr1:228756711	NA	0.69	8.9	0.44	3.68e-17	Chronic lymphocytic leukemia;
LUSC	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg02023728	chr11:77925099	USP35	0.49	7.15	0.36	5.56e-12	Testicular germ cell tumor;
LUSC	cis	rs7804356	1.000	rs73069507	chr7:26877536	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.12	-0.32	2.58e-9	Type 1 diabetes;
LUSC	cis	rs4664308	0.692	rs4233681	chr2:160960058	T/C	cg03641300	chr2:160917029	PLA2R1	-0.62	-10.19	-0.49	2.01e-21	Idiopathic membranous nephropathy;
LUSC	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg03713592	chr11:72463424	ARAP1	0.74	8.55	0.42	4.38e-16	Type 2 diabetes;
LUSC	cis	rs12681287	0.752	rs12681438	chr8:87293089	G/A	cg27223183	chr8:87520930	FAM82B	-0.46	-5.86	-0.31	1.13e-8	Caudate activity during reward;
LUSC	cis	rs7804356	1.000	rs3801850	chr7:26820577	T/C	cg03456212	chr7:26904342	SKAP2	-0.55	-6.49	-0.33	3.17e-10	Type 1 diabetes;
LUSC	trans	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.36	0.33	6.64e-10	Corneal astigmatism;
LUSC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.27	0.56	7.85e-29	Motion sickness;
LUSC	cis	rs243505	1.000	rs243507	chr7:148434600	G/A	cg09806900	chr7:148480153	CUL1	-0.49	-6.89	-0.35	2.77e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg27165867	chr14:105738592	BRF1	-0.53	-7.97	-0.4	2.54e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6840360	1.000	rs28710456	chr4:152667171	T/C	cg22705602	chr4:152727874	NA	-0.28	-6.07	-0.32	3.49e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg22467129	chr15:76604101	ETFA	-0.51	-8.26	-0.41	3.38e-15	Blood metabolite levels;
LUSC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg00033643	chr7:134001901	SLC35B4	0.43	6.79	0.35	5.13e-11	Mean platelet volume;
LUSC	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.74	0.35	6.76e-11	Educational attainment;
LUSC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.45	-0.33	3.84e-10	Total body bone mineral density;
LUSC	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg25039879	chr17:56429692	SUPT4H1	0.66	8.88	0.44	4.12e-17	Cognitive test performance;
LUSC	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.52	8.45	0.42	9.1e-16	Immature fraction of reticulocytes;
LUSC	cis	rs2692947	0.673	rs1168965	chr2:96787899	C/G	cg23100626	chr2:96804247	ASTL	-0.31	-7.37	-0.37	1.33e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.8	10.5	0.5	1.74e-22	Schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20521125	chr10:103912151	NOLC1	-0.46	-6.67	-0.34	1.09e-10	Electrocardiographic conduction measures;
LUSC	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg13575925	chr12:9217583	LOC144571	0.35	6.38	0.33	5.81e-10	Sjögren's syndrome;
LUSC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	15.41	0.64	7.23e-41	Platelet count;
LUSC	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.7	-0.3	2.62e-8	Personality dimensions;
LUSC	cis	rs6939532	0.522	rs4712981	chr6:26361430	C/T	cg05738196	chr6:26577821	NA	-0.41	-5.66	-0.3	3.19e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10911363	0.659	rs7518244	chr1:183434807	C/T	cg09173681	chr1:183549694	NCF2	-0.63	-11.15	-0.52	9.35e-25	Systemic lupus erythematosus;
LUSC	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.37	-6.05	-0.31	3.98e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4474465	0.850	rs10793332	chr11:78270020	C/G	cg27205649	chr11:78285834	NARS2	0.51	6.08	0.32	3.26e-9	Alzheimer's disease (survival time);
LUSC	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg19052272	chr2:3704530	ALLC	0.45	7.37	0.37	1.37e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg21361702	chr7:150065534	REPIN1	0.58	9.21	0.45	3.6e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg23625390	chr15:77176239	SCAPER	-0.64	-9.92	-0.48	1.73e-20	Blood metabolite levels;
LUSC	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg06917634	chr15:78832804	PSMA4	0.48	5.97	0.31	6.07e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg05043794	chr9:111880884	C9orf5	-0.38	-7.93	-0.4	3.31e-14	Menarche (age at onset);
LUSC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01341218	chr17:43662625	NA	0.77	11.31	0.53	2.5e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7582720	1.000	rs72934715	chr2:203713280	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	8.17	0.41	6.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs17095355	0.792	rs61881587	chr10:111759710	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.31	-0.37	1.96e-12	Biliary atresia;
LUSC	cis	rs500891	0.597	rs4706998	chr6:84167277	A/G	cg08257003	chr6:84140564	ME1	0.35	8.43	0.42	1.05e-15	Platelet-derived growth factor BB levels;
LUSC	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg14227996	chr4:17616232	MED28	0.82	7.87	0.4	4.98e-14	Opioid sensitivity;
LUSC	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg16482183	chr6:26056742	HIST1H1C	0.64	9.08	0.44	9.81e-18	Iron status biomarkers;
LUSC	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.52e-8	Breast cancer;
LUSC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg06636551	chr8:101224915	SPAG1	-0.38	-7.13	-0.36	6.31e-12	Atrioventricular conduction;
LUSC	trans	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.32	0.53	2.26e-25	Mean corpuscular volume;
LUSC	cis	rs7264396	0.623	rs6060504	chr20:34197619	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.16	-0.36	5.13e-12	Total cholesterol levels;
LUSC	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	6.82	0.35	4.2e-11	Resting heart rate;
LUSC	cis	rs2637266	0.905	rs3923669	chr10:78375047	T/C	cg18941641	chr10:78392320	NA	0.38	6.94	0.36	2.04e-11	Pulmonary function;
LUSC	cis	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg06521852	chr22:38141419	TRIOBP	0.42	6.37	0.33	6.26e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs1124376	1.000	rs61138004	chr3:20145855	C/G	cg05072819	chr3:20081367	KAT2B	0.69	7.74	0.39	1.19e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg02931644	chr1:25747376	RHCE	0.32	5.82	0.3	1.41e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg00933542	chr6:150070202	PCMT1	0.34	6.96	0.36	1.82e-11	Lung cancer;
LUSC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg18758796	chr5:131593413	PDLIM4	0.43	7.5	0.38	5.82e-13	Breast cancer;
LUSC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg02153584	chr22:29168773	CCDC117	-0.55	-7.89	-0.4	4.43e-14	Lymphocyte counts;
LUSC	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg22681709	chr2:178499509	PDE11A	-0.49	-9.07	-0.44	1.02e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs117623576	0.941	rs211409	chr10:32393213	T/C	cg03047570	chr10:32398778	NA	0.74	7.92	0.4	3.45e-14	Anti-saccade response;
LUSC	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg05966235	chr16:28915196	ATP2A1	0.34	5.95	0.31	6.63e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	cis	rs3820928	0.845	rs7570869	chr2:227878818	A/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.78	-0.39	9.41e-14	Pulmonary function;
LUSC	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg10523679	chr1:76189770	ACADM	-0.48	-6.77	-0.35	5.73e-11	Daytime sleep phenotypes;
LUSC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08564027	chr20:61660810	NA	0.91	17.42	0.69	8.43e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7561273	0.609	rs2339945	chr2:24348096	G/A	cg06627628	chr2:24431161	ITSN2	-0.51	-6.8	-0.35	4.71e-11	Quantitative traits;
LUSC	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg20307385	chr11:47447363	PSMC3	-0.44	-6.61	-0.34	1.51e-10	Subjective well-being;
LUSC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg11871910	chr12:69753446	YEATS4	0.84	15.2	0.64	5.09e-40	Blood protein levels;
LUSC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg06784218	chr1:46089804	CCDC17	0.56	11.69	0.54	1.05e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs55665837	1.000	rs11023224	chr11:14457739	G/A	cg05501817	chr11:14380813	RRAS2	-0.41	-6.51	-0.34	2.72e-10	Vitamin D levels;
LUSC	cis	rs11958404	0.860	rs72818117	chr5:157441130	G/A	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg17724175	chr1:150552817	MCL1	0.32	5.67	0.3	3.05e-8	Melanoma;
LUSC	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg02153584	chr22:29168773	CCDC117	-0.45	-6.91	-0.35	2.4e-11	Red cell distribution width;
LUSC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06028605	chr16:24865363	SLC5A11	0.68	10.29	0.49	9.04e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg00074818	chr8:8560427	CLDN23	0.59	9.72	0.47	7.75e-20	Obesity-related traits;
LUSC	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.78	-12.79	-0.57	9.47e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg00504896	chr12:9437009	LOC642846	-0.4	-6.07	-0.32	3.49e-9	Breast size;
LUSC	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg05855489	chr10:104503620	C10orf26	0.53	7.97	0.4	2.6e-14	Arsenic metabolism;
LUSC	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg22437258	chr11:111473054	SIK2	-0.45	-5.91	-0.31	8.45e-9	Primary sclerosing cholangitis;
LUSC	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg08645402	chr16:4508243	NA	0.49	7.39	0.38	1.16e-12	Schizophrenia;
LUSC	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg16579770	chr16:72058938	DHODH	0.34	5.73	0.3	2.26e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs9473147	0.571	rs9395285	chr6:47554177	G/A	cg20196966	chr6:47445060	CD2AP	0.43	6.05	0.31	3.86e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg02951883	chr7:2050386	MAD1L1	-0.56	-10.46	-0.5	2.46e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.71	-0.3	2.53e-8	Testicular germ cell tumor;
LUSC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg10729496	chr3:10149963	C3orf24	0.56	7.52	0.38	5.16e-13	Alzheimer's disease;
LUSC	cis	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg06521331	chr12:34319734	NA	-0.48	-7.75	-0.39	1.11e-13	Morning vs. evening chronotype;
LUSC	cis	rs3790645	1.000	rs444482	chr1:26890648	C/G	cg17456097	chr1:26900765	RPS6KA1	0.42	6.07	0.32	3.44e-9	Glucose homeostasis traits;
LUSC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg01171360	chr6:293285	DUSP22	-0.53	-8.04	-0.4	1.57e-14	Menopause (age at onset);
LUSC	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	7.52	0.38	5.07e-13	Response to antipsychotic treatment;
LUSC	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.83	-0.44	5.99e-17	Morning vs. evening chronotype;
LUSC	cis	rs7818345	0.845	rs7821446	chr8:19268822	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.32	-6.14	-0.32	2.38e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg07936489	chr17:37558343	FBXL20	0.83	10.41	0.5	3.52e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg20135002	chr11:47629003	NA	0.48	7.4	0.38	1.1e-12	Subjective well-being;
LUSC	cis	rs3760982	0.967	rs12463346	chr19:44292244	A/G	cg11993925	chr19:44307056	LYPD5	0.28	6.04	0.31	4.06e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs6867032	0.527	rs9312971	chr5:2012888	C/A	cg26168224	chr5:2018326	NA	0.59	10.18	0.49	2.19e-21	Gut microbiome composition (winter);
LUSC	trans	rs2302464	1.000	rs10516291	chr4:15732791	C/T	cg17675199	chr6:35436792	RPL10A	-0.83	-6.11	-0.32	2.84e-9	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg13395646	chr4:1353034	KIAA1530	-0.59	-9.19	-0.45	4.18e-18	Obesity-related traits;
LUSC	cis	rs5769707	0.605	rs2071900	chr22:50052175	A/G	cg05373962	chr22:49881684	NA	-0.4	-8.54	-0.42	4.72e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12516959	chr21:47718080	NA	-0.4	-6.59	-0.34	1.75e-10	Testicular germ cell tumor;
LUSC	cis	rs9928842	0.679	rs4888361	chr16:75267676	A/G	cg09066997	chr16:75300724	BCAR1	0.46	5.81	0.3	1.48e-8	Alcoholic chronic pancreatitis;
LUSC	cis	rs476633	0.691	rs28568756	chr15:41539371	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.72	-0.43	1.37e-16	Glomerular filtration rate (creatinine);
LUSC	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	11.56	0.53	3.04e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-14.08	-0.61	1.14e-35	Bladder cancer;
LUSC	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg22906224	chr7:99728672	NA	-0.5	-6.94	-0.35	2.09e-11	Coronary artery disease;
LUSC	cis	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg09904177	chr6:26538194	HMGN4	-0.77	-5.72	-0.3	2.39e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg10609677	chr17:41278573	BRCA1;NBR2	0.35	5.71	0.3	2.48e-8	Menopause (age at onset);
LUSC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.92	0.35	2.31e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs10911251	0.528	rs10911263	chr1:183115018	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.64	0.5	5.92e-23	Colorectal cancer;
LUSC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.6	8.51	0.42	5.97e-16	Diastolic blood pressure;
LUSC	cis	rs6867913	0.709	rs2338874	chr5:141466926	G/A	cg08523384	chr5:141488047	NDFIP1	-0.41	-6.66	-0.34	1.11e-10	Asthma;
LUSC	cis	rs28785552	0.769	rs11669363	chr19:53232321	C/A	cg22067481	chr19:53234126	ZNF611	-0.51	-7.07	-0.36	9.02e-12	Response to paliperidone in schizophrenia (PANSS score);
LUSC	trans	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs4650994	0.507	rs56229230	chr1:178526563	G/A	cg05059571	chr16:84539110	KIAA1609	-0.48	-9.07	-0.44	1.07e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg02807482	chr3:125708958	NA	-0.46	-5.91	-0.31	8.58e-9	Blood pressure (smoking interaction);
LUSC	trans	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg18335740	chr13:41363409	SLC25A15	-0.53	-8.34	-0.42	1.91e-15	Lewy body disease;
LUSC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg24209194	chr3:40518798	ZNF619	-0.43	-6.05	-0.31	3.8e-9	Renal cell carcinoma;
LUSC	cis	rs1971762	0.522	rs10747680	chr12:54077776	T/G	cg23533419	chr12:54090519	NA	-0.37	-6.02	-0.31	4.7e-9	Height;
LUSC	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg23422044	chr7:1970798	MAD1L1	-0.46	-5.82	-0.3	1.39e-8	Bipolar disorder;
LUSC	cis	rs6840360	0.642	rs11726254	chr4:152438850	G/C	cg20465933	chr4:152376761	FAM160A1	0.33	5.97	0.31	6.02e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg18187862	chr3:45730750	SACM1L	0.52	6.79	0.35	5.18e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7123876	0.587	rs61895588	chr11:72360986	A/G	cg04827223	chr11:72435913	ARAP1	-0.59	-6.65	-0.34	1.22e-10	Body mass index;
LUSC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg06145435	chr7:1022769	CYP2W1	-0.33	-7.15	-0.36	5.44e-12	Longevity;Endometriosis;
LUSC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg12560992	chr17:57184187	TRIM37	0.84	15.44	0.65	5.6e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06634786	chr22:41940651	POLR3H	0.52	6.07	0.32	3.47e-9	Vitiligo;
LUSC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.73	0.6	2.62e-34	Platelet count;
LUSC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg26335602	chr6:28129616	ZNF389	0.42	5.68	0.3	2.87e-8	Depression;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04600299	chr7:149570367	ATP6V0E2;LOC401431	0.4	6.04	0.31	4.16e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05776053	chr2:74358815	NA	0.43	6.41	0.33	5.02e-10	Gestational age at birth (maternal effect);
LUSC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.61	8.14	0.41	8.02e-15	High light scatter reticulocyte count;
LUSC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg18827107	chr12:86230957	RASSF9	-0.46	-6.88	-0.35	3.04e-11	Major depressive disorder;
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg17372223	chr3:52568218	NT5DC2	0.39	6.37	0.33	6.23e-10	Electroencephalogram traits;
LUSC	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg25036284	chr2:26402008	FAM59B	0.69	9.36	0.46	1.17e-18	Gut microbiome composition (summer);
LUSC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg06134567	chr22:46658398	PKDREJ	-0.49	-5.84	-0.3	1.21e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg15556689	chr8:8085844	FLJ10661	0.56	8.61	0.43	2.89e-16	Retinal vascular caliber;
LUSC	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg00757033	chr12:89920650	WDR51B	0.59	10.22	0.49	1.69e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg13607699	chr17:42295918	UBTF	0.5	7.81	0.39	7.29e-14	Total body bone mineral density;
LUSC	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-9.6	-0.47	1.9e-19	Platelet distribution width;
LUSC	cis	rs9427116	0.875	rs11264233	chr1:154625632	C/T	cg17218026	chr1:154582156	ADAR	0.5	8.59	0.43	3.34e-16	Blood protein levels;
LUSC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.76	-12.09	-0.55	3.64e-28	Height;
LUSC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	14.36	0.62	9.42e-37	Platelet count;
LUSC	trans	rs4729127	1.000	rs17166205	chr7:94003841	T/A	cg20086523	chr13:52378287	DHRS12	0.56	6.38	0.33	6.03e-10	Intelligence;
LUSC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg23601095	chr6:26197514	HIST1H3D	0.68	7.36	0.37	1.48e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg23711669	chr6:146136114	FBXO30	-0.82	-14.71	-0.63	3.97e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg13560548	chr3:10150139	C3orf24	0.48	6.6	0.34	1.6e-10	Alzheimer's disease;
LUSC	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg16482183	chr6:26056742	HIST1H1C	0.8	10.21	0.49	1.77e-21	Iron status biomarkers;
LUSC	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg03264133	chr6:25882463	NA	-0.34	-5.69	-0.3	2.8e-8	Height;
LUSC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.81	-0.47	3.85e-20	Hemoglobin concentration;
LUSC	cis	rs2282802	0.685	rs2337138	chr5:139691664	A/C	cg26211634	chr5:139558579	C5orf32	0.42	8.17	0.41	6.46e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6429082	0.783	rs390539	chr1:235679690	A/C	cg26050004	chr1:235667680	B3GALNT2	0.63	8.71	0.43	1.42e-16	Adiposity;
LUSC	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg05714579	chr10:131428358	MGMT	0.5	7.11	0.36	6.88e-12	Response to temozolomide;
LUSC	cis	rs9840812	0.769	rs534944	chr3:135961031	T/G	cg15507776	chr3:136538369	TMEM22	0.43	5.93	0.31	7.5e-9	Fibrinogen levels;
LUSC	cis	rs7945718	0.967	rs11826129	chr11:12768883	G/A	cg25843174	chr11:12811716	TEAD1	0.31	6.92	0.35	2.3e-11	Educational attainment (years of education);
LUSC	cis	rs308403	0.568	rs309358	chr4:123653926	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.8	10.65	0.5	5.19e-23	Blood protein levels;
LUSC	cis	rs17255340	0.539	rs1144189	chr6:83982263	C/T	cg08257003	chr6:84140564	ME1	0.32	7.59	0.38	3.17e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs4702	0.611	rs2071382	chr15:91428197	T/C	cg05469396	chr15:91419421	FURIN	0.49	8.68	0.43	1.74e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg11502198	chr6:26597334	ABT1	0.7	11.72	0.54	8.63e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs9929218	0.871	rs1862748	chr16:68832943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-10.95	-0.51	4.85e-24	Colorectal cancer;
LUSC	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg27661571	chr11:113659931	NA	-0.6	-7.21	-0.37	3.85e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg00105475	chr2:10696890	NA	0.36	5.82	0.3	1.35e-8	Prostate cancer;
LUSC	cis	rs887829	0.570	rs45615240	chr2:234599296	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.4	-6.33	-0.33	7.73e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	trans	rs9662633	1.000	rs6695978	chr1:3648345	C/T	cg06237983	chr7:27187269	HOXA6	-0.65	-5.97	-0.31	6.01e-9	Visceral adipose tissue adjusted for BMI;
LUSC	trans	rs1147813	0.748	rs1023974	chr9:25864831	A/T	cg23362473	chr20:4680742	PRNP	0.38	6.03	0.31	4.27e-9	Morning vs. evening chronotype;
LUSC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.25	-0.32	1.26e-9	Personality dimensions;
LUSC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg06238570	chr21:40685208	BRWD1	-0.63	-10.76	-0.51	2.26e-23	Cognitive function;
LUSC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	14.6	0.62	1.14e-37	Platelet count;
LUSC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg03804128	chr16:635623	NA	0.32	6.42	0.33	4.63e-10	Height;
LUSC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg04287289	chr16:89883240	FANCA	0.79	13.89	0.61	6.18e-35	Vitiligo;
LUSC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	0.93	13.08	0.58	7.49e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg24562669	chr7:97807699	LMTK2	0.43	7.32	0.37	1.86e-12	Breast cancer;
LUSC	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg21827317	chr3:136751795	NA	0.39	6.95	0.36	1.98e-11	Neuroticism;
LUSC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg04756594	chr16:24857601	SLC5A11	-0.39	-5.96	-0.31	6.58e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg12463550	chr7:65579703	CRCP	-0.48	-7.09	-0.36	8.23e-12	Aortic root size;
LUSC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-10.25	-0.49	1.25e-21	Gut microbiome composition (summer);
LUSC	cis	rs1775715	0.870	rs3847414	chr10:32219176	A/G	cg18675610	chr10:32216311	ARHGAP12	0.27	5.91	0.31	8.27e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4780355	1.000	rs1111186	chr16:11347048	T/C	cg00044050	chr16:11439710	C16orf75	0.5	7.28	0.37	2.35e-12	Crohn's disease and psoriasis;
LUSC	trans	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.46	0.33	3.7e-10	Resting heart rate;
LUSC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.42	-6.24	-0.32	1.3e-9	Tonsillectomy;
LUSC	cis	rs829883	0.934	rs1641642	chr12:98898726	A/G	cg25150519	chr12:98850993	NA	0.64	9.72	0.47	8.06e-20	Colorectal adenoma (advanced);
LUSC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs500891	0.525	rs1170339	chr6:84031251	T/C	cg08257003	chr6:84140564	ME1	0.34	8.05	0.4	1.43e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs3087591	0.708	rs2189525	chr17:29668808	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.48	-7.4	-0.38	1.14e-12	Hip circumference;
LUSC	cis	rs3733418	0.929	rs12510464	chr4:165919040	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-5.94	-0.31	7.19e-9	Obesity-related traits;
LUSC	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg19622623	chr12:86230825	RASSF9	-0.41	-5.71	-0.3	2.44e-8	Major depressive disorder;
LUSC	cis	rs6426558	0.515	rs7543579	chr1:227377699	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.53	-7.22	-0.37	3.5e-12	Neutrophil percentage of white cells;
LUSC	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg17764715	chr19:33622953	WDR88	0.58	7.88	0.4	4.53e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg03342759	chr3:160939853	NMD3	-0.43	-5.65	-0.3	3.39e-8	Parkinson's disease;
LUSC	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg13575925	chr12:9217583	LOC144571	-0.34	-6.62	-0.34	1.44e-10	Sjögren's syndrome;
LUSC	cis	rs983392	0.679	rs1530914	chr11:60028940	C/T	cg20284999	chr11:59952153	MS4A6A	0.37	6.27	0.32	1.09e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.65	9.75	0.47	6.44e-20	Lymphocyte counts;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16249798	chr1:38325439	MTF1	-0.49	-7.43	-0.38	9.16e-13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg26162295	chr17:38119207	GSDMA	-0.24	-5.81	-0.3	1.47e-8	Self-reported allergy;
LUSC	cis	rs4919694	0.808	rs80020194	chr10:105035954	A/G	cg04362960	chr10:104952993	NT5C2	1.17	12.3	0.56	6.27e-29	Arsenic metabolism;
LUSC	cis	rs4478858	0.735	rs6676354	chr1:31800746	A/T	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg13628971	chr7:2884303	GNA12	0.45	6.45	0.33	3.9e-10	Height;
LUSC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-14.85	-0.63	1.22e-38	Total body bone mineral density;
LUSC	cis	rs77741769	0.571	rs11065324	chr12:121346795	C/G	cg02419362	chr12:121203948	SPPL3	-0.44	-8.18	-0.41	6.19e-15	Mean corpuscular volume;
LUSC	cis	rs10207628	0.698	rs13410629	chr2:127868733	C/T	cg06223080	chr2:127868745	NA	0.38	6.56	0.34	2.06e-10	Psychosis and Alzheimer's disease;
LUSC	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.17	0.32	1.97e-9	Systolic blood pressure;
LUSC	cis	rs2976388	1.000	rs2976388	chr8:143760256	G/A	cg17252645	chr8:143867129	LY6D	-0.38	-6.51	-0.34	2.8e-10	Urinary tract infection frequency;
LUSC	cis	rs1865721	0.755	rs3213875	chr18:73184048	C/T	cg26385618	chr18:73139727	C18orf62	-0.4	-7.22	-0.37	3.44e-12	Intelligence;
LUSC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg12463550	chr7:65579703	CRCP	-0.41	-5.91	-0.31	8.35e-9	Aortic root size;
LUSC	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg25237894	chr2:233734115	C2orf82	-0.35	-6.34	-0.33	7.45e-10	Coronary artery disease;
LUSC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg24829409	chr8:58192753	C8orf71	-0.45	-5.65	-0.3	3.37e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs6841433	0.615	rs57059575	chr4:115472393	C/G	cg01865118	chr8:29204221	DUSP4	-0.51	-5.97	-0.31	5.93e-9	Hemoglobin concentration;
LUSC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg11247378	chr22:39784982	NA	-0.62	-12.33	-0.56	4.86e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs7119	0.717	rs12902852	chr15:77809016	C/G	cg27398640	chr15:77910606	LINGO1	-0.3	-6.38	-0.33	5.83e-10	Type 2 diabetes;
LUSC	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.34	0.42	1.94e-15	Body mass index;
LUSC	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.43	-6.13	-0.32	2.47e-9	Platelet distribution width;
LUSC	cis	rs17255340	0.601	rs1144182	chr6:84023090	A/T	cg08257003	chr6:84140564	ME1	0.33	7.85	0.39	5.81e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg05343316	chr1:45956843	TESK2	0.59	6.17	0.32	1.96e-9	Platelet count;
LUSC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08439880	chr3:133502540	NA	-0.36	-6.41	-0.33	5.09e-10	Iron status biomarkers;
LUSC	cis	rs12891047	0.804	rs35272075	chr14:68317999	G/T	cg20999565	chr14:68265668	ZFYVE26	0.39	5.86	0.31	1.11e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg16482183	chr6:26056742	HIST1H1C	0.65	9.13	0.45	6.68e-18	Iron status biomarkers;
LUSC	cis	rs1322512	1.000	rs2800631	chr6:153008631	T/C	cg27316956	chr6:152958899	SYNE1	0.35	6.17	0.32	1.97e-9	Tonometry;
LUSC	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg22655196	chr4:3374909	RGS12	-0.32	-6.39	-0.33	5.44e-10	Serum sulfate level;
LUSC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.81	-11.16	-0.52	8.4e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs611744	0.806	rs2514846	chr8:109067105	C/G	cg18478394	chr8:109455254	TTC35	0.42	6.19	0.32	1.81e-9	Dupuytren's disease;
LUSC	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.5	-7.83	-0.39	6.35e-14	Blood metabolite levels;
LUSC	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	11.77	0.54	5.38e-27	Ileal carcinoids;
LUSC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg26335602	chr6:28129616	ZNF389	0.43	5.94	0.31	7.19e-9	Parkinson's disease;
LUSC	trans	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg10756647	chr7:56101905	PSPH	0.87	8.84	0.44	5.54e-17	Diabetic kidney disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25396640	chr7:64255131	ZNF138	0.47	7.18	0.37	4.63e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg06521331	chr12:34319734	NA	-0.42	-6.88	-0.35	2.98e-11	Morning vs. evening chronotype;
LUSC	trans	rs62103177	0.673	rs55852342	chr18:77594109	G/C	cg05926928	chr17:57297772	GDPD1	1.05	13.34	0.59	7.73e-33	Opioid sensitivity;
LUSC	cis	rs9815354	0.857	rs7652369	chr3:42020973	T/G	cg03022575	chr3:42003672	ULK4	0.54	5.77	0.3	1.81e-8	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	-0.38	-6.16	-0.32	2.09e-9	Menopause (age at onset);
LUSC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-5.93	-0.31	7.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg06640241	chr16:89574553	SPG7	0.7	11.42	0.53	9.98e-26	Multiple myeloma (IgH translocation);
LUSC	cis	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg06521331	chr12:34319734	NA	-0.36	-5.86	-0.31	1.09e-8	Morning vs. evening chronotype;
LUSC	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg10645314	chr2:3704589	ALLC	-0.49	-7.33	-0.37	1.72e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs11958404	0.615	rs10061079	chr5:157449968	G/C	cg05962755	chr5:157440814	NA	0.39	5.71	0.3	2.53e-8	IgG glycosylation;
LUSC	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg00334542	chr7:100209784	MOSPD3	-0.67	-7.51	-0.38	5.61e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg12935359	chr14:103987150	CKB	0.67	10.6	0.5	7.79e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg09839279	chr12:125627357	AACS	0.36	6.83	0.35	3.95e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	0.7	14.66	0.63	6.37e-38	Prudent dietary pattern;
LUSC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.52	7.27	0.37	2.56e-12	Gut microbiome composition (summer);
LUSC	cis	rs9925964	0.967	rs9936329	chr16:31140799	G/T	cg02466173	chr16:30829666	NA	0.33	6.06	0.31	3.7e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs73198271	0.653	rs3827811	chr8:8659038	C/T	cg01851573	chr8:8652454	MFHAS1	0.47	7.86	0.39	5.52e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg21724239	chr8:58056113	NA	0.61	6.68	0.34	1.03e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11645898	0.935	rs11640722	chr16:72172300	C/T	cg14768367	chr16:72042858	DHODH	-0.65	-7.11	-0.36	7.28e-12	Blood protein levels;
LUSC	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg16898833	chr6:26189333	HIST1H4D	0.65	6.1	0.32	3e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg14154082	chr13:112174009	NA	0.37	7.46	0.38	7.73e-13	Menarche (age at onset);
LUSC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.79	12.62	0.57	3.88e-30	Aortic root size;
LUSC	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg07080220	chr10:102295463	HIF1AN	0.61	7.51	0.38	5.47e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg01879757	chr17:41196368	BRCA1	-0.46	-6.97	-0.36	1.72e-11	Menopause (age at onset);
LUSC	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.32	0.45	1.64e-18	Coffee consumption (cups per day);
LUSC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.51	0.38	5.46e-13	Colorectal cancer;
LUSC	cis	rs3772130	1.000	rs11719458	chr3:121382005	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.65	9.65	0.47	1.37e-19	Cognitive performance;
LUSC	cis	rs2274273	0.837	rs10141552	chr14:55746091	C/T	cg04306507	chr14:55594613	LGALS3	-0.53	-11.79	-0.54	4.58e-27	Protein biomarker;
LUSC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13732083	chr21:47605072	C21orf56	-0.45	-6.7	-0.34	8.72e-11	Testicular germ cell tumor;
LUSC	cis	rs981844	0.816	rs56413502	chr4:154721784	T/A	cg14289246	chr4:154710475	SFRP2	0.48	6.08	0.32	3.27e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs12956009	0.518	rs10164267	chr18:44820032	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-7.24	-0.37	3.09e-12	Educational attainment (years of education);
LUSC	cis	rs11158026	0.603	rs56335168	chr14:55445132	C/A	cg04306507	chr14:55594613	LGALS3	0.4	7.28	0.37	2.37e-12	Parkinson's disease;
LUSC	cis	rs2413583	0.591	rs115038091	chr22:39728575	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.64	5.77	0.3	1.79e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7394190	0.748	rs60212594	chr10:75414344	G/C	cg07699608	chr10:75541558	CHCHD1	0.49	5.65	0.3	3.43e-8	Incident atrial fibrillation;
LUSC	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg17470723	chr8:74884337	TCEB1	0.5	7.38	0.37	1.23e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg13175981	chr1:150552382	MCL1	0.43	6.15	0.32	2.25e-9	Tonsillectomy;
LUSC	cis	rs9323205	0.634	rs56043194	chr14:51726066	A/C	cg23942311	chr14:51606299	NA	-0.39	-7.34	-0.37	1.69e-12	Cancer;
LUSC	trans	rs7581030	0.501	rs2542524	chr2:71611829	A/G	cg18809821	chr6:24403225	MRS2	-0.74	-6.5	-0.34	2.9e-10	Testicular germ cell tumor;
LUSC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg05585544	chr11:47624801	NA	-0.42	-7.26	-0.37	2.71e-12	Subjective well-being;
LUSC	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.26	-0.37	2.66e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	7.03	0.36	1.17e-11	Lung cancer in ever smokers;
LUSC	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg12935359	chr14:103987150	CKB	-0.52	-7.94	-0.4	3.12e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.91	-0.35	2.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg20243544	chr17:37824526	PNMT	0.39	5.89	0.31	9.61e-9	Self-reported allergy;
LUSC	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg03676636	chr4:99064102	C4orf37	0.35	7.46	0.38	7.32e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg14820908	chr5:178986412	RUFY1	-0.64	-12.12	-0.55	2.97e-28	Lung cancer;
LUSC	cis	rs4776059	1.000	rs12902679	chr15:52881317	C/T	cg25063058	chr15:52860530	ARPP19	-0.47	-6.24	-0.32	1.33e-9	Schizophrenia;
LUSC	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg03060546	chr3:49711283	APEH	0.67	7.7	0.39	1.51e-13	Menarche (age at onset);
LUSC	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg14583973	chr4:3374767	RGS12	0.33	6.92	0.35	2.38e-11	Serum sulfate level;
LUSC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-10.94	-0.51	5.28e-24	Cognitive function;
LUSC	trans	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg07393940	chr7:158741817	NA	0.36	6.47	0.33	3.58e-10	Life satisfaction;
LUSC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg27432699	chr2:27873401	GPN1	0.56	8.32	0.41	2.3e-15	Total body bone mineral density;
LUSC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02463440	chr8:22132932	PIWIL2	0.44	7.96	0.4	2.74e-14	Hypertriglyceridemia;
LUSC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg13902645	chr11:5959945	NA	-0.63	-9.03	-0.44	1.43e-17	DNA methylation (variation);
LUSC	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.12	-0.45	7.26e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg06917634	chr15:78832804	PSMA4	0.48	6.02	0.31	4.61e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg04362960	chr10:104952993	NT5C2	0.55	8.78	0.43	8.92e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg19622623	chr12:86230825	RASSF9	0.41	5.93	0.31	7.38e-9	Major depressive disorder;
LUSC	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg24011408	chr12:48396354	COL2A1	-0.53	-8.78	-0.43	8.53e-17	Plateletcrit;
LUSC	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg06484146	chr7:12443880	VWDE	-0.62	-6.23	-0.32	1.37e-9	Coronary artery disease;
LUSC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg13531842	chr10:38383804	ZNF37A	-0.43	-6.71	-0.34	8.54e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.91	-15.95	-0.66	5.82e-43	Cognitive function;
LUSC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19748678	chr4:122722346	EXOSC9	-0.49	-7.67	-0.39	1.93e-13	Type 2 diabetes;
LUSC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03352830	chr11:487213	PTDSS2	-0.7	-8.86	-0.44	4.74e-17	Body mass index;
LUSC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg06784218	chr1:46089804	CCDC17	0.48	9.63	0.47	1.62e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4343996	0.543	rs10224159	chr7:3420488	C/T	cg21248987	chr7:3385318	SDK1	0.36	6.07	0.32	3.52e-9	Motion sickness;
LUSC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg27189623	chr16:705930	WDR90	0.35	5.65	0.3	3.51e-8	Height;
LUSC	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg26944245	chr16:421049	TMEM8A;MRPL28	0.43	6.48	0.33	3.35e-10	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg15691649	chr6:25882328	NA	-0.41	-6.02	-0.31	4.57e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg05347473	chr6:146136440	FBXO30	0.53	9.04	0.44	1.3e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7107174	1.000	rs2510046	chr11:77988817	T/C	cg02023728	chr11:77925099	USP35	0.48	6.81	0.35	4.44e-11	Testicular germ cell tumor;
LUSC	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg09085632	chr11:111637200	PPP2R1B	0.94	12.83	0.57	6.32e-31	Primary sclerosing cholangitis;
LUSC	cis	rs73198271	0.595	rs11780672	chr8:8584153	A/C	cg01851573	chr8:8652454	MFHAS1	0.5	6.04	0.31	4.03e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	8.99	0.44	1.9e-17	Menarche (age at onset);
LUSC	cis	rs701145	0.938	rs813141	chr3:154066521	T/C	cg17054900	chr3:154042577	DHX36	0.79	8.25	0.41	3.74e-15	Coronary artery disease;
LUSC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg03351412	chr1:154909251	PMVK	0.53	8.39	0.42	1.42e-15	Prostate cancer;
LUSC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg10755058	chr3:40428713	ENTPD3	0.35	5.79	0.3	1.58e-8	Renal cell carcinoma;
LUSC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00149659	chr3:10157352	C3orf10	0.92	12.88	0.58	4.25e-31	Alzheimer's disease;
LUSC	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.88	14.7	0.63	4.61e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg21681030	chr2:46777652	RHOQ	0.47	6.44	0.33	4.12e-10	Height;
LUSC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg09165964	chr15:75287851	SCAMP5	-1.16	-19.53	-0.73	3.42e-57	Blood trace element (Zn levels);
LUSC	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg00071950	chr4:10020882	SLC2A9	-0.57	-9.21	-0.45	3.78e-18	Bone mineral density;
LUSC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.49	8.37	0.42	1.55e-15	Vitiligo;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07856758	chr19:37861652	ZNF527	0.34	6.36	0.33	6.61e-10	Triglycerides;
LUSC	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg09754948	chr16:28834200	ATXN2L	0.44	6.43	0.33	4.51e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg03522245	chr20:25566470	NINL	-0.36	-5.81	-0.3	1.43e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1775715	0.870	rs1251407	chr10:32238325	A/G	cg26784012	chr10:32216390	ARHGAP12	0.41	6.72	0.34	8e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.45	6.66	0.34	1.16e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.8	12.63	0.57	3.72e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs57920188	0.584	rs10915654	chr1:4091419	C/A	cg20703997	chr1:4087676	NA	0.57	8.34	0.42	1.96e-15	Interleukin-17 levels;
LUSC	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.28	-0.37	2.48e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg20203395	chr5:56204925	C5orf35	-0.76	-10.43	-0.5	3.03e-22	Initial pursuit acceleration;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11427898	chr15:38544983	SPRED1	-0.5	-6.72	-0.35	7.63e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg18683606	chr7:100471612	SRRT	0.46	6.12	0.32	2.56e-9	Resting heart rate;
LUSC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg11062466	chr8:58055876	NA	0.66	8.67	0.43	1.93e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7523050	0.908	rs12405585	chr1:109397229	C/A	cg08274380	chr1:109419600	GPSM2	0.88	9.59	0.46	2.07e-19	Fat distribution (HIV);
LUSC	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg05347473	chr6:146136440	FBXO30	0.54	9.31	0.45	1.71e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg11663144	chr21:46675770	NA	-0.4	-6.98	-0.36	1.56e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11229555	0.645	rs10896778	chr11:58193925	T/G	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-12.81	-0.57	8.14e-31	Total body bone mineral density;
LUSC	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg02993010	chr8:124780839	FAM91A1	-0.47	-5.65	-0.3	3.38e-8	Pancreatic cancer;
LUSC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg20587970	chr11:113659929	NA	-1.07	-14.2	-0.61	4.08e-36	Hip circumference adjusted for BMI;
LUSC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.49	0.42	7.07e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg18634211	chr1:26737262	LIN28	-0.54	-7.03	-0.36	1.15e-11	Atrial fibrillation;
LUSC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.62	8.23	0.41	4.34e-15	High light scatter reticulocyte count;
LUSC	trans	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg03886242	chr7:26192032	NFE2L3	0.37	6.26	0.32	1.18e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg20991723	chr1:152506922	NA	0.5	9.41	0.46	8.31e-19	Hair morphology;
LUSC	cis	rs829880	0.570	rs844205	chr12:98846053	A/G	cg25150519	chr12:98850993	NA	0.73	11.36	0.53	1.67e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.34	-0.42	1.92e-15	Triglycerides;
LUSC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg11663144	chr21:46675770	NA	-0.42	-7.27	-0.37	2.57e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs8022179	0.580	rs58153827	chr14:103844630	G/A	cg17675199	chr6:35436792	RPL10A	-0.49	-6.1	-0.32	2.88e-9	Monocyte count;
LUSC	cis	rs11229555	0.645	rs10896775	chr11:58175989	A/T	cg15696309	chr11:58395628	NA	-0.63	-7.81	-0.39	7.37e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12753569	1.000	rs12753569	chr1:76484014	G/T	cg00791851	chr1:76518896	NA	-0.32	-6.09	-0.32	3.09e-9	Personality dimensions;
LUSC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg00800038	chr16:89945340	TCF25	0.62	6.4	0.33	5.35e-10	Skin colour saturation;
LUSC	cis	rs6967385	0.934	rs17165850	chr7:12366064	G/C	cg20607287	chr7:12443886	VWDE	0.4	5.84	0.3	1.25e-8	Response to taxane treatment (placlitaxel);
LUSC	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21659725	chr3:3221576	CRBN	0.62	8.69	0.43	1.61e-16	Resting heart rate;
LUSC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.72	0.78	9.87e-70	Prudent dietary pattern;
LUSC	cis	rs4964805	0.594	rs4981036	chr12:104164344	C/G	cg02344784	chr12:104178138	NT5DC3	0.38	6.05	0.31	3.94e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg18721089	chr20:30220636	NA	-0.34	-5.68	-0.3	2.95e-8	Mean corpuscular hemoglobin;
LUSC	trans	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg26043149	chr18:55253948	FECH	-0.45	-6.85	-0.35	3.48e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg07703079	chr11:430292	ANO9	0.6	6.59	0.34	1.75e-10	Body mass index;
LUSC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.09	15.86	0.66	1.25e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg17252645	chr8:143867129	LY6D	0.36	6.29	0.33	1.02e-9	Urinary tract infection frequency;
LUSC	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg01028140	chr2:1542097	TPO	0.61	8.1	0.41	1.05e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.25	0.52	4.16e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg07212818	chr11:638076	DRD4	-0.49	-7.99	-0.4	2.21e-14	Systemic lupus erythematosus;
LUSC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg05347473	chr6:146136440	FBXO30	0.53	9.06	0.44	1.13e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1577917	0.917	rs2084293	chr6:86566002	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	cis	rs6901250	1.000	rs615199	chr6:117113653	T/C	cg12892004	chr6:117198278	RFX6	0.44	8.04	0.4	1.58e-14	C-reactive protein levels;
LUSC	cis	rs10779751	0.770	rs2015818	chr1:11170743	G/A	cg04508216	chr1:11107452	MASP2	0.31	5.7	0.3	2.58e-8	Body mass index;
LUSC	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	trans	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg07923666	chr12:49932857	KCNH3	-0.49	-6.14	-0.32	2.29e-9	Resting heart rate;
LUSC	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg15557168	chr22:42548783	NA	0.35	5.86	0.31	1.11e-8	Cognitive function;
LUSC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1950626	0.750	rs35820579	chr14:101435515	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.73	0.39	1.25e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg25039879	chr17:56429692	SUPT4H1	0.7	9.24	0.45	3.06e-18	Cognitive test performance;
LUSC	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg16989719	chr2:238392110	NA	-0.4	-6.89	-0.35	2.84e-11	Prostate cancer;
LUSC	cis	rs28647808	0.786	rs28590601	chr9:136256224	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg13789015	chr9:136890014	NCRNA00094	0.73	13.36	0.59	6.58e-33	Platelet distribution width;
LUSC	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg07169764	chr2:136633963	MCM6	1.03	16.47	0.67	4.8e-45	Corneal structure;
LUSC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	trans	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	10.17	0.49	2.49e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg09796270	chr17:17721594	SREBF1	0.43	7.45	0.38	8.14e-13	Total body bone mineral density;
LUSC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08704250	chr15:31115839	NA	0.4	6.02	0.31	4.47e-9	Huntington's disease progression;
LUSC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg08088566	chr11:430123	ANO9	0.61	7.11	0.36	7.06e-12	Body mass index;
LUSC	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg21827317	chr3:136751795	NA	0.52	9.52	0.46	3.62e-19	Schizophrenia;
LUSC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg18402987	chr7:1209562	NA	0.68	7.18	0.37	4.63e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10740039	0.883	rs2393676	chr10:62390258	A/G	cg18175470	chr10:62150864	ANK3	-0.47	-7.22	-0.37	3.57e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.33	5.73	0.3	2.23e-8	Menopause (age at onset);
LUSC	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13647721	chr17:30228624	UTP6	0.68	9.06	0.44	1.09e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg17366294	chr4:99064904	C4orf37	0.58	9.89	0.48	2.08e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs977987	0.843	rs4888415	chr16:75448921	C/T	cg04384234	chr16:75411784	CFDP1	-0.41	-6.73	-0.35	7.62e-11	Dupuytren's disease;
LUSC	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg02415014	chr8:143852576	LYNX1	0.26	5.88	0.31	9.95e-9	Urinary tract infection frequency;
LUSC	cis	rs950173	1.000	rs13000153	chr2:172586067	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.78	-7.59	-0.38	3.32e-13	Hippocampal volume;
LUSC	cis	rs16867321	0.950	rs12472841	chr2:181491840	C/A	cg23363182	chr2:181467187	NA	-0.44	-5.95	-0.31	6.72e-9	Obesity;
LUSC	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg05855489	chr10:104503620	C10orf26	0.52	8.02	0.4	1.85e-14	Arsenic metabolism;
LUSC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.24	-0.37	3.11e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg12002119	chr2:101014098	CHST10	0.35	5.85	0.3	1.18e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg15848620	chr12:58087721	OS9	-0.56	-8.04	-0.4	1.62e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg13319975	chr6:146136371	FBXO30	0.5	7.44	0.38	8.58e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg02153584	chr22:29168773	CCDC117	0.66	10.36	0.49	5.47e-22	Lymphocyte counts;
LUSC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.6e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg03060546	chr3:49711283	APEH	-0.62	-7.37	-0.37	1.37e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg16586182	chr3:47516702	SCAP	0.5	7.73	0.39	1.32e-13	Colorectal cancer;
LUSC	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg00105475	chr2:10696890	NA	0.38	6.29	0.33	1e-9	Prostate cancer;
LUSC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg20406979	chr6:167373233	NA	0.26	5.91	0.31	8.5e-9	Crohn's disease;
LUSC	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg23601095	chr6:26197514	HIST1H3D	0.72	7.41	0.38	1.04e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs11051970	0.545	rs2651374	chr12:32582858	G/A	cg02745156	chr12:32552066	NA	0.36	6.51	0.34	2.71e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg23985595	chr17:80112537	CCDC57	-0.31	-6.13	-0.32	2.41e-9	Life satisfaction;
LUSC	cis	rs1440410	0.835	rs11940580	chr4:144161525	C/G	cg01719995	chr4:144104893	USP38	0.34	5.88	0.31	1e-8	Ischemic stroke;
LUSC	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-8.24	-0.41	4.01e-15	Bladder cancer;
LUSC	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.43	6.72	0.35	7.64e-11	Height;
LUSC	cis	rs1506636	1.000	rs614645	chr7:123442349	T/C	cg03229431	chr7:123269106	ASB15	0.63	10.16	0.49	2.59e-21	Plateletcrit;Platelet count;
LUSC	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07080220	chr10:102295463	HIF1AN	0.69	9.22	0.45	3.53e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg26338869	chr17:61819248	STRADA	0.42	6.1	0.32	2.96e-9	Prudent dietary pattern;
LUSC	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg13010199	chr12:38710504	ALG10B	0.68	10.62	0.5	6.57e-23	Bladder cancer;
LUSC	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg16339924	chr4:17578868	LAP3	0.61	9.29	0.45	2.07e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3857536	0.813	rs6931701	chr6:66940905	T/C	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.45	-0.42	9.43e-16	Lung cancer;
LUSC	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg07274523	chr3:49395745	GPX1	0.65	10.3	0.49	8.85e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-9.59	-0.46	2.2e-19	Response to antipsychotic treatment;
LUSC	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.74	11.58	0.54	2.7e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-8.31	-0.41	2.51e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-9.05	-0.44	1.18e-17	Response to antipsychotic treatment;
LUSC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.94	0.36	2.01e-11	Tonsillectomy;
LUSC	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg21153622	chr11:89784906	NA	-0.4	-6.19	-0.32	1.73e-9	HDL cholesterol;
LUSC	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.19	-0.32	1.76e-9	Response to antipsychotic treatment;
LUSC	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg03342759	chr3:160939853	NMD3	-0.51	-8.42	-0.42	1.09e-15	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14155567	chr7:5540534	FBXL18	0.47	6.2	0.32	1.7e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.33	-0.33	7.7e-10	Morning vs. evening chronotype;
LUSC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg16743903	chr16:89593216	SPG7	-0.36	-5.66	-0.3	3.23e-8	Multiple myeloma (IgH translocation);
LUSC	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg13010199	chr12:38710504	ALG10B	0.58	9.27	0.45	2.32e-18	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.17	0.52	8.2e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.59	-7.57	-0.38	3.65e-13	Body mass index;
LUSC	cis	rs9549260	0.755	rs4943798	chr13:41202948	T/C	cg21288729	chr13:41239152	FOXO1	0.61	9.56	0.46	2.74e-19	Red blood cell count;
LUSC	cis	rs9287719	0.745	rs4997809	chr2:10755542	G/A	cg03983476	chr2:10830698	NOL10	-0.38	-5.77	-0.3	1.83e-8	Prostate cancer;
LUSC	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-6.4	-0.33	5.35e-10	Resting heart rate;
LUSC	trans	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg07211511	chr3:129823064	LOC729375	-1.23	-21.05	-0.76	3.19e-63	Blood pressure (smoking interaction);
LUSC	cis	rs7615316	0.779	rs6440077	chr3:142017527	A/G	cg16271453	chr3:142027066	XRN1	-0.41	-7.08	-0.36	8.42e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-6.3	-0.33	9.42e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2742417	0.624	rs2742394	chr3:45757591	C/T	cg04837898	chr3:45731254	SACM1L	-0.43	-6.96	-0.36	1.79e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9487051	0.768	rs9480910	chr6:109521707	T/C	cg00509249	chr6:109615579	CCDC162	-0.33	-5.79	-0.3	1.66e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs4343996	0.902	rs7798672	chr7:3342334	A/T	cg21248987	chr7:3385318	SDK1	0.41	6.96	0.36	1.78e-11	Motion sickness;
LUSC	cis	rs7432375	0.610	rs7633629	chr3:136517028	T/A	cg15507776	chr3:136538369	TMEM22	0.44	7.34	0.37	1.68e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg14893161	chr1:205819251	PM20D1	0.43	5.89	0.31	9.19e-9	Parkinson's disease;
LUSC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.82	11.9	0.55	1.85e-27	Chronic sinus infection;
LUSC	trans	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg21775007	chr8:11205619	TDH	-0.43	-6.08	-0.32	3.31e-9	Mood instability;
LUSC	cis	rs11158026	0.603	rs59323730	chr14:55439075	C/T	cg04306507	chr14:55594613	LGALS3	0.4	7.43	0.38	9.29e-13	Parkinson's disease;
LUSC	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.37	5.65	0.3	3.41e-8	Neutrophil percentage of white cells;
LUSC	cis	rs1413885	0.549	rs9436725	chr1:65852870	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	6.76	0.35	6.34e-11	Anticoagulant levels;
LUSC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg06808227	chr14:105710500	BRF1	-0.67	-10.53	-0.5	1.37e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.23	0.56	1.11e-28	Motion sickness;
LUSC	cis	rs1499972	0.941	rs62264762	chr3:117634443	C/A	cg07612923	chr3:117604196	NA	0.64	5.76	0.3	1.95e-8	Schizophrenia;
LUSC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg08125733	chr17:73851984	WBP2	-0.5	-7.1	-0.36	7.43e-12	White matter hyperintensity burden;
LUSC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.45	7.47	0.38	6.86e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6469656	0.892	rs10093551	chr8:117712821	T/C	cg24004040	chr8:117650383	NA	-0.42	-6.26	-0.32	1.16e-9	Colorectal cancer;
LUSC	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg17757837	chr7:157058334	UBE3C	-0.75	-10.52	-0.5	1.48e-22	Body mass index;
LUSC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.84	-0.35	3.69e-11	Crohn's disease;
LUSC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg22638593	chr5:131593259	PDLIM4	0.5	7.49	0.38	6.15e-13	Acylcarnitine levels;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.58	-9.09	-0.45	9.29e-18	Lymphocyte counts;
LUSC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	1.04	19.44	0.73	7.67e-57	Menopause (age at onset);
LUSC	cis	rs11676348	0.755	rs62183956	chr2:219046122	C/T	cg00012203	chr2:219082015	ARPC2	0.62	10.52	0.5	1.49e-22	Ulcerative colitis;
LUSC	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg25482853	chr8:67687455	SGK3	1.18	16.98	0.68	4.85e-47	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-8.91	-0.44	3.31e-17	Gut microbiome composition (summer);
LUSC	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg17845761	chr1:175162550	KIAA0040	0.33	6.29	0.33	1.02e-9	Alcohol dependence;
LUSC	cis	rs6545883	0.894	rs12615783	chr2:61440947	T/C	cg15711740	chr2:61764176	XPO1	0.45	6.7	0.34	8.64e-11	Tuberculosis;
LUSC	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	11.78	0.54	5.19e-27	Ileal carcinoids;
LUSC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg21782813	chr7:2030301	MAD1L1	0.37	6.03	0.31	4.46e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg07959070	chr22:50026188	C22orf34	-0.34	-7.08	-0.36	8.32e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg07810366	chr2:100720526	AFF3	0.41	7.1	0.36	7.68e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04791162	chr14:62331287	NA	0.5	5.97	0.31	6.16e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	0.89	16.68	0.67	7.5e-46	Heart rate;
LUSC	cis	rs1395	0.778	rs62128747	chr2:27412605	T/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.2	0.37	4.12e-12	Blood metabolite levels;
LUSC	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-5.96	-0.31	6.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.77	-0.3	1.77e-8	Neutrophil percentage of white cells;
LUSC	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg09034736	chr1:150693464	HORMAD1	-0.44	-6.05	-0.31	3.79e-9	Blood protein levels;
LUSC	cis	rs9296092	0.517	rs56043172	chr6:33522363	T/G	cg13560919	chr6:33536144	NA	-0.82	-15.86	-0.66	1.26e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg24342717	chr2:85555507	TGOLN2	-0.74	-12.32	-0.56	5.35e-29	Ear protrusion;
LUSC	cis	rs59104589	0.617	rs60132543	chr2:242344599	T/C	cg14842376	chr2:242211374	HDLBP	0.54	6.33	0.33	7.68e-10	Fibrinogen levels;
LUSC	cis	rs6815814	0.851	rs73235002	chr4:38769018	A/G	cg02016764	chr4:38805732	TLR1	-0.53	-5.79	-0.3	1.65e-8	Breast cancer;
LUSC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.53	-7.81	-0.39	7.49e-14	Platelet count;
LUSC	cis	rs929596	0.785	rs6714634	chr2:234664765	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.69	11.69	0.54	1.1e-26	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs62400317	0.859	rs10456121	chr6:45092545	G/A	cg20913747	chr6:44695427	NA	-0.46	-7.41	-0.38	1.06e-12	Total body bone mineral density;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09700085	chr3:45838028	SLC6A20	0.46	7.33	0.37	1.71e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs7659604	0.540	rs28615388	chr4:122678418	C/T	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.87	-0.31	1.06e-8	Type 2 diabetes;
LUSC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.07	-0.32	3.51e-9	Alzheimer's disease (late onset);
LUSC	cis	rs72634258	0.740	rs4489581	chr1:8174495	A/C	cg00042356	chr1:8021962	PARK7	-0.58	-7.11	-0.36	7.2e-12	Inflammatory bowel disease;
LUSC	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg16384552	chr7:74938386	SPDYE8P	0.48	7.02	0.36	1.22e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9549260	0.591	rs9577108	chr13:41271764	G/A	cg21288729	chr13:41239152	FOXO1	0.54	8.28	0.41	3.09e-15	Red blood cell count;
LUSC	cis	rs1775715	0.707	rs2778669	chr10:32161541	C/T	cg26784012	chr10:32216390	ARHGAP12	0.45	7.77	0.39	9.75e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg07856975	chr6:36356162	ETV7	0.34	6.21	0.32	1.61e-9	Platelet distribution width;
LUSC	cis	rs9549260	0.755	rs7328677	chr13:41229905	A/G	cg21288729	chr13:41239152	FOXO1	0.64	9.88	0.48	2.31e-20	Red blood cell count;
LUSC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg22823121	chr1:150693482	HORMAD1	-0.52	-7.69	-0.39	1.63e-13	Melanoma;
LUSC	trans	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg07663200	chr17:42030104	NA	0.36	6.01	0.31	4.74e-9	Post bronchodilator FEV1;
LUSC	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	7.4	0.38	1.11e-12	Colorectal cancer;
LUSC	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg01620082	chr3:125678407	NA	-0.83	-7.31	-0.37	1.98e-12	Depression;
LUSC	cis	rs644148	0.704	rs2686761	chr19:44989752	T/C	cg15540054	chr19:45004280	ZNF180	-0.52	-7.19	-0.37	4.19e-12	Personality dimensions;
LUSC	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg19812747	chr11:111475976	SIK2	0.5	6.88	0.35	2.96e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg23711669	chr6:146136114	FBXO30	0.88	15.92	0.66	7.5e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7818345	0.904	rs11780388	chr8:19271554	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.37	7.02	0.36	1.24e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.06	0.44	1.09e-17	Motion sickness;
LUSC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg24550644	chr17:30846204	MYO1D	-0.52	-9.11	-0.45	7.93e-18	Schizophrenia;
LUSC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03352830	chr11:487213	PTDSS2	0.69	8.57	0.42	3.78e-16	Body mass index;
LUSC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg14583973	chr4:3374767	RGS12	0.39	8.5	0.42	6.21e-16	Serum sulfate level;
LUSC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg12463550	chr7:65579703	CRCP	-0.46	-6.82	-0.35	4.21e-11	Aortic root size;
LUSC	cis	rs2377585	0.653	rs7299203	chr12:8849161	G/A	cg03761649	chr12:8850719	RIMKLB	0.46	6.47	0.33	3.52e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.99	-0.31	5.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg06359132	chr10:99160096	RRP12	-0.25	-5.74	-0.3	2.14e-8	Monocyte percentage of white cells;
LUSC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg25039879	chr17:56429692	SUPT4H1	0.66	8.88	0.44	4.09e-17	Cognitive test performance;
LUSC	cis	rs4804416	1.000	rs4804414	chr19:7223785	C/T	cg09779027	chr19:7224513	INSR	0.29	5.92	0.31	8.15e-9	Thyroid hormone levels;Hypothyroidism;
LUSC	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg07389463	chr12:132296394	NA	0.39	6.89	0.35	2.81e-11	Migraine;
LUSC	cis	rs752010	0.523	rs10890158	chr1:42117985	C/T	cg06885757	chr1:42089581	HIVEP3	0.5	10.17	0.49	2.36e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg19336497	chr11:14380999	RRAS2	-0.33	-6.04	-0.31	4.15e-9	Mitochondrial DNA levels;
LUSC	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.9	15.63	0.65	9.84e-42	Morning vs. evening chronotype;
LUSC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg16606324	chr3:10149918	C3orf24	-0.64	-9.68	-0.47	1.05e-19	Alzheimer's disease;
LUSC	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-9.04	-0.44	1.28e-17	Response to antipsychotic treatment;
LUSC	cis	rs5753037	0.838	rs140147	chr22:30184599	C/T	cg11564601	chr22:30592435	NA	0.34	5.7	0.3	2.62e-8	Type 1 diabetes;
LUSC	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg05360138	chr12:110035743	NA	0.58	7.44	0.38	8.78e-13	Neuroticism;
LUSC	trans	rs10946292	0.706	rs3012448	chr6:170434734	C/T	cg17832364	chr10:94847294	NA	0.39	6.44	0.33	4.2e-10	Obesity-related traits;
LUSC	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg20587970	chr11:113659929	NA	1.12	13.33	0.59	8.6e-33	Hip circumference adjusted for BMI;
LUSC	cis	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg09085632	chr11:111637200	PPP2R1B	0.53	6.94	0.35	2.07e-11	Primary sclerosing cholangitis;
LUSC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg19230755	chr7:65878503	NA	0.41	5.67	0.3	3.13e-8	Aortic root size;
LUSC	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg01629716	chr15:45996671	NA	0.4	6.12	0.32	2.57e-9	Waist circumference;Weight;
LUSC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.62	9.61	0.47	1.84e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2274273	0.588	rs17675223	chr14:55862236	G/A	cg04306507	chr14:55594613	LGALS3	0.48	9.47	0.46	5.32e-19	Protein biomarker;
LUSC	trans	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg05926928	chr17:57297772	GDPD1	0.5	7.19	0.37	4.18e-12	Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17042849	chr6:26104293	HIST1H4C	-0.5	-6.04	-0.31	4.1e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-8.91	-0.44	3.32e-17	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg21798802	chr22:38057573	PDXP	0.48	10.53	0.5	1.4e-22	Fat distribution (HIV);
LUSC	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg08079166	chr15:68083412	MAP2K5	0.41	7.29	0.37	2.33e-12	Restless legs syndrome;
LUSC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg18135555	chr8:22132992	PIWIL2	0.4	7.95	0.4	2.96e-14	Hypertriglyceridemia;
LUSC	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-7.51	-0.38	5.46e-13	Parkinson's disease;
LUSC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg13699009	chr12:122356056	WDR66	0.48	7.51	0.38	5.4e-13	Mean corpuscular volume;
LUSC	cis	rs9395066	0.545	rs10948185	chr6:44901727	C/T	cg25276700	chr6:44698697	NA	0.31	6.22	0.32	1.48e-9	Height;
LUSC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg00339695	chr16:24857497	SLC5A11	-0.42	-7.29	-0.37	2.31e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs8056893	0.714	rs1868159	chr16:68387496	G/T	cg02226672	chr16:68398533	SMPD3	-0.32	-5.68	-0.3	2.91e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.57	-9.45	-0.46	6.08e-19	Breast cancer;
LUSC	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.03e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg02527881	chr3:46936655	PTH1R	-0.4	-7.15	-0.36	5.37e-12	Colorectal cancer;
LUSC	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg08079166	chr15:68083412	MAP2K5	0.41	7.27	0.37	2.57e-12	Restless legs syndrome;
LUSC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg05347473	chr6:146136440	FBXO30	-0.56	-9.71	-0.47	8.3e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg23711669	chr6:146136114	FBXO30	0.81	14.15	0.61	5.9e-36	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg23601095	chr6:26197514	HIST1H3D	0.72	7.7	0.39	1.51e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg17623882	chr6:41773611	USP49	0.62	10.3	0.49	8.79e-22	Menarche (age at onset);
LUSC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.71	-11.04	-0.52	2.31e-24	Aortic root size;
LUSC	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg07856975	chr6:36356162	ETV7	0.34	6.2	0.32	1.69e-9	Platelet distribution width;
LUSC	cis	rs8099014	0.906	rs11152071	chr18:56087417	T/C	cg12907477	chr18:56117327	MIR122	0.44	6.9	0.35	2.61e-11	Platelet count;
LUSC	cis	rs12801636	0.512	rs2075660	chr11:65414709	C/A	cg24147428	chr11:65409760	SIPA1	-0.51	-5.89	-0.31	9.41e-9	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.71	-0.3	2.45e-8	Depression;
LUSC	cis	rs4363385	0.655	rs11205163	chr1:152983677	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.64	-0.39	2.38e-13	Inflammatory skin disease;
LUSC	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.14	0.36	5.87e-12	IgG glycosylation;
LUSC	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg27661571	chr11:113659931	NA	-0.61	-6.92	-0.35	2.35e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg01448562	chr3:133502909	NA	0.66	10.32	0.49	7.17e-22	Iron status biomarkers;
LUSC	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.33e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs16912285	0.688	rs12801367	chr11:24321827	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	9.55	0.46	2.86e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04175895	chr11:64851783	CDCA5;ZFPL1	-0.42	-6.29	-0.33	9.95e-10	Electrocardiographic conduction measures;
LUSC	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	0.6	9.43	0.46	7.12e-19	Breast cancer;
LUSC	cis	rs17621444	0.522	rs4752371	chr10:121792095	G/A	cg02041677	chr10:121771263	NA	-0.34	-6.34	-0.33	7.31e-10	IgG glycosylation;
LUSC	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg05347473	chr6:146136440	FBXO30	0.5	8.45	0.42	9.18e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg13010199	chr12:38710504	ALG10B	-0.5	-7.66	-0.39	2.08e-13	Morning vs. evening chronotype;
LUSC	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg14604444	chr12:130766091	NA	-0.33	-5.71	-0.3	2.49e-8	Menopause (age at onset);
LUSC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs10484885	0.514	rs10944450	chr6:90228498	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.56	-5.87	-0.31	1.06e-8	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg17469321	chr7:55412551	NA	0.66	10.63	0.5	6.09e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs7939886	0.920	rs12417606	chr11:55750479	C/T	cg15704280	chr7:45808275	SEPT13	0.84	7.06	0.36	9.96e-12	Myopia (pathological);
LUSC	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	cis	rs6901250	0.632	rs339355	chr6:117196503	A/T	cg12892004	chr6:117198278	RFX6	-0.39	-7.56	-0.38	4.01e-13	C-reactive protein levels;
LUSC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08048268	chr3:133502702	NA	0.46	8.94	0.44	2.67e-17	Iron status biomarkers;
LUSC	cis	rs8040855	0.599	rs1964724	chr15:85726500	G/C	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.89	0.35	2.72e-11	Bulimia nervosa;
LUSC	cis	rs13082711	0.911	rs11718991	chr3:27452944	A/G	cg02860705	chr3:27208620	NA	0.51	8.48	0.42	7.17e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg26513180	chr16:89883248	FANCA	-0.54	-8.05	-0.4	1.46e-14	Vitiligo;
LUSC	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg20026190	chr17:76395443	PGS1	0.45	8.02	0.4	1.82e-14	HDL cholesterol levels;
LUSC	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg24692254	chr21:30365293	RNF160	-0.7	-10.52	-0.5	1.56e-22	Pancreatic cancer;
LUSC	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	10.83	0.51	1.26e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg05347473	chr6:146136440	FBXO30	-0.6	-10.6	-0.5	7.93e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5753037	0.838	rs140149	chr22:30185613	C/T	cg11564601	chr22:30592435	NA	0.34	6.02	0.31	4.5e-9	Type 1 diabetes;
LUSC	cis	rs7804356	0.954	rs4722641	chr7:26838677	C/G	cg03456212	chr7:26904342	SKAP2	-0.55	-6.55	-0.34	2.18e-10	Type 1 diabetes;
LUSC	cis	rs9309711	0.961	rs35067331	chr2:3474085	C/T	cg10845886	chr2:3471009	TTC15	-0.64	-8.37	-0.42	1.63e-15	Neurofibrillary tangles;
LUSC	cis	rs9311676	0.656	rs11917591	chr3:58368449	C/T	cg26110898	chr3:58419937	PDHB	-0.42	-7.01	-0.36	1.29e-11	Systemic lupus erythematosus;
LUSC	cis	rs983392	0.679	rs10736700	chr11:60031399	T/C	cg20284999	chr11:59952153	MS4A6A	0.37	6.15	0.32	2.19e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg26856596	chr11:1961893	NA	0.35	6.91	0.35	2.47e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs12425451	0.544	rs1990330	chr12:3147462	A/C	cg05389053	chr12:3131226	TEAD4	0.44	5.93	0.31	7.62e-9	Narcolepsy with cataplexy;
LUSC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg06453172	chr10:134556979	INPP5A	-0.5	-6.2	-0.32	1.64e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	9.48	0.46	4.93e-19	Joint mobility (Beighton score);
LUSC	cis	rs72960926	0.744	rs72968273	chr6:74893673	C/A	cg03266952	chr6:74778945	NA	-0.8	-6.32	-0.33	8.53e-10	Metabolite levels (MHPG);
LUSC	cis	rs4700695	0.841	rs251305	chr5:65249859	C/T	cg21114390	chr5:65439923	SFRS12	0.5	5.93	0.31	7.61e-9	Facial morphology (factor 19);
LUSC	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg03599575	chr15:90893182	GABARAPL3	-0.34	-5.69	-0.3	2.8e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.36	-5.81	-0.3	1.44e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg00339695	chr16:24857497	SLC5A11	0.36	6.28	0.33	1.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-9.88	-0.48	2.22e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg23978390	chr7:1156363	C7orf50	0.42	5.7	0.3	2.63e-8	Longevity;Endometriosis;
LUSC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg05738196	chr6:26577821	NA	0.82	15.84	0.66	1.48e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg02423579	chr7:2872169	GNA12	-0.44	-6.33	-0.33	7.8e-10	Height;
LUSC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.98	-0.44	1.99e-17	Gut microbiome composition (summer);
LUSC	cis	rs965469	0.779	rs6037515	chr20:3233091	C/A	cg25506879	chr20:3388711	C20orf194	-0.49	-5.65	-0.3	3.46e-8	IFN-related cytopenia;
LUSC	cis	rs1028488	0.511	rs7762492	chr6:170704946	C/G	cg20370364	chr6:170703943	FAM120B	0.48	7.14	0.36	5.92e-12	Interferon alpha levels in systemic lupus erythematosus;
LUSC	cis	rs13089785	0.965	rs1920221	chr3:123606952	A/G	cg02558132	chr3:123411198	MYLK	0.33	5.72	0.3	2.36e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg19230755	chr7:65878503	NA	0.41	5.76	0.3	1.95e-8	Aortic root size;
LUSC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.55	7.48	0.38	6.49e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs4780401	0.703	rs3190321	chr16:11773662	C/G	cg01061890	chr16:11836724	TXNDC11	-0.44	-6.46	-0.33	3.78e-10	Rheumatoid arthritis;
LUSC	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg19508488	chr2:152266495	RIF1	0.4	5.8	0.3	1.51e-8	Lung cancer;
LUSC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-6.92	-0.35	2.26e-11	Bipolar disorder;
LUSC	cis	rs7215564	0.908	rs36077104	chr17:78661757	T/A	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg21293242	chr8:11204541	TDH	0.31	5.66	0.3	3.34e-8	Retinal vascular caliber;
LUSC	cis	rs11864453	0.645	rs7194668	chr16:72128207	G/C	cg16558253	chr16:72132732	DHX38	-0.37	-5.71	-0.3	2.46e-8	Fibrinogen levels;
LUSC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-1.02	-15.51	-0.65	3.14e-41	Obesity-related traits;
LUSC	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg12559939	chr2:27858050	GPN1	0.41	6.39	0.33	5.68e-10	Oral cavity cancer;
LUSC	cis	rs6545883	0.868	rs6748003	chr2:61806700	T/G	cg15711740	chr2:61764176	XPO1	-0.47	-7.44	-0.38	8.42e-13	Tuberculosis;
LUSC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.56	0.46	2.7e-19	Personality dimensions;
LUSC	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg04733989	chr22:42467013	NAGA	0.62	9.67	0.47	1.19e-19	Schizophrenia;
LUSC	cis	rs9420	0.884	rs644883	chr11:57663522	C/G	cg02958346	chr11:57425731	CLP1	0.43	6.01	0.31	4.98e-9	Schizophrenia;
LUSC	trans	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg05267876	chr1:229644265	NUP133	-0.48	-5.95	-0.31	6.91e-9	Parkinson's disease;
LUSC	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg23649088	chr2:200775458	C2orf69	-0.55	-6.51	-0.34	2.83e-10	Schizophrenia;
LUSC	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg05347473	chr6:146136440	FBXO30	0.49	8.09	0.4	1.14e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs931812	0.535	rs3105452	chr8:101943618	A/G	cg20993868	chr7:22813445	NA	0.34	6.26	0.32	1.17e-9	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg15790184	chr11:494944	RNH1	0.54	6.17	0.32	2e-9	Body mass index;
LUSC	cis	rs75804782	0.641	rs57080728	chr2:239350487	T/C	cg18131467	chr2:239335373	ASB1	-0.73	-6.63	-0.34	1.37e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7605827	0.930	rs11692646	chr2:15559198	C/G	cg19274914	chr2:15703543	NA	-0.47	-8.99	-0.44	1.91e-17	Educational attainment (years of education);
LUSC	trans	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg02800362	chr5:177631904	HNRNPAB	0.88	13.09	0.58	6.6e-32	Obesity-related traits;
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24739457	chr1:205821442	NA	0.35	6.07	0.32	3.56e-9	Menarche (age at onset);
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg25080152	chr8:128748155	MYC	0.45	6.21	0.32	1.53e-9	Neuroticism;
LUSC	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg08557956	chr11:4115526	RRM1	0.46	5.89	0.31	9.55e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg14433983	chr11:636460	DRD4	-0.37	-6.01	-0.31	4.77e-9	Systemic lupus erythematosus;
LUSC	cis	rs2040771	0.774	rs9604935	chr22:19211665	C/T	cg02655711	chr22:19163373	SLC25A1	0.47	8.4	0.42	1.32e-15	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg03060546	chr3:49711283	APEH	0.72	12.18	0.55	1.79e-28	Resting heart rate;
LUSC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06634786	chr22:41940651	POLR3H	0.52	6.13	0.32	2.55e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9309473	1.000	rs9653557	chr2:73795962	A/C	cg20560298	chr2:73613845	ALMS1	-0.46	-6.53	-0.34	2.47e-10	Metabolite levels;
LUSC	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg09997546	chr11:8931473	C11orf17;ST5	0.36	7.09	0.36	7.94e-12	Hemoglobin concentration;
LUSC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg24642844	chr7:1081250	C7orf50	-0.8	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg13114125	chr14:105738426	BRF1	-0.94	-16.05	-0.66	2.29e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	10.69	0.51	3.77e-23	Menopause (age at onset);
LUSC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg07507251	chr3:52567010	NT5DC2	0.33	6.54	0.34	2.28e-10	Bipolar disorder;
LUSC	cis	rs4722404	0.560	rs6975818	chr7:3115520	C/G	cg19214707	chr7:3157722	NA	-0.39	-6.63	-0.34	1.35e-10	Atopic dermatitis;
LUSC	cis	rs10740039	0.768	rs1372710	chr10:62362958	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.92	-0.35	2.3e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1178968	0.901	rs2528705	chr7:72791238	A/G	cg25889504	chr7:72793014	NA	0.59	7.35	0.37	1.59e-12	Triglyceride levels;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.7	10.71	0.51	3.4e-23	Lymphocyte counts;
LUSC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg06138931	chr13:21896616	NA	0.46	8.22	0.41	4.58e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg13660082	chr14:53194042	PSMC6	0.73	6.34	0.33	7.41e-10	Alzheimer's disease (late onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01297191	chr7:22396644	RAPGEF5	-0.39	-5.97	-0.31	6e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs16937	0.640	rs6664706	chr1:205182563	T/C	cg00857998	chr1:205179979	DSTYK	0.4	5.83	0.3	1.34e-8	Schizophrenia;
LUSC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	7.96	0.4	2.63e-14	Homoarginine levels;
LUSC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg02153584	chr22:29168773	CCDC117	0.65	10.51	0.5	1.59e-22	Lymphocyte counts;
LUSC	cis	rs711244	0.532	rs4670181	chr2:37226903	G/C	cg14987922	chr2:37194071	STRN	0.5	7.22	0.37	3.44e-12	Mean platelet volume;
LUSC	cis	rs4664304	0.658	rs2667016	chr2:160868855	C/T	cg03641300	chr2:160917029	PLA2R1	-0.36	-6.04	-0.31	4.03e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg07923666	chr12:49932857	KCNH3	-0.49	-6.14	-0.32	2.29e-9	Resting heart rate;
LUSC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.39	-0.37	1.2e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.45	-0.38	8.3e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.4	-6.64	-0.34	1.28e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9323205	0.677	rs12586581	chr14:51722938	G/A	cg23942311	chr14:51606299	NA	-0.39	-7.19	-0.37	4.34e-12	Cancer;
LUSC	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.71	0.34	8.15e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05351087	chr6:151773080	C6orf211;RMND1	-0.43	-6.45	-0.33	3.98e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg16482183	chr6:26056742	HIST1H1C	0.56	8.34	0.42	2.02e-15	Height;
LUSC	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.81	-0.43	6.75e-17	Total cholesterol levels;
LUSC	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.74	-0.39	1.2e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-7.99	-0.4	2.27e-14	Height;
LUSC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	12.72	0.57	1.68e-30	Cognitive test performance;
LUSC	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	11.91	0.55	1.75e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2692947	0.589	rs810057	chr2:97015073	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.21	0.32	1.6e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.56	0.38	3.9e-13	Colorectal cancer;
LUSC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg00074818	chr8:8560427	CLDN23	0.55	9.42	0.46	7.91e-19	Obesity-related traits;
LUSC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg22166914	chr1:53195759	ZYG11B	0.56	8.32	0.41	2.27e-15	Monocyte count;
LUSC	trans	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.47	8.33	0.41	2.19e-15	Obesity-related traits;
LUSC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg21782813	chr7:2030301	MAD1L1	0.34	5.67	0.3	3.08e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs4974559	0.641	rs28647383	chr4:1312908	G/C	cg02980000	chr4:1222292	CTBP1	1.04	9.52	0.46	3.61e-19	Systolic blood pressure;
LUSC	cis	rs4343996	0.558	rs7798141	chr7:3413024	A/G	cg21248987	chr7:3385318	SDK1	0.37	6.23	0.32	1.38e-9	Motion sickness;
LUSC	cis	rs13418410	0.715	rs10201046	chr2:33794438	A/G	cg04131969	chr2:33951647	MYADML	-0.45	-5.99	-0.31	5.32e-9	Non-response to antidepressants and depression;
LUSC	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg05163923	chr11:71159392	DHCR7	0.69	9.31	0.45	1.72e-18	Vitamin D levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04996852	chr16:3930112	CREBBP	-0.39	-5.96	-0.31	6.29e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2387326	0.671	rs12268728	chr10:129945897	G/A	cg16087940	chr10:129947807	NA	-0.4	-6.12	-0.32	2.59e-9	Select biomarker traits;
LUSC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg07716408	chr11:68623521	NA	-0.31	-5.86	-0.31	1.09e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg06671706	chr8:8559999	CLDN23	0.51	6.71	0.34	8.45e-11	Obesity-related traits;
LUSC	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg19920283	chr7:105172520	RINT1	0.57	6.08	0.32	3.34e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.45	-6.4	-0.33	5.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.78	-0.39	9e-14	Triglycerides;
LUSC	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg18721089	chr20:30220636	NA	0.35	5.91	0.31	8.53e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.67	8.69	0.43	1.71e-16	Schizophrenia;
LUSC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00149659	chr3:10157352	C3orf10	0.97	13.53	0.6	1.45e-33	Alzheimer's disease;
LUSC	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg04362960	chr10:104952993	NT5C2	1.15	13.48	0.59	2.28e-33	Arsenic metabolism;
LUSC	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg26395211	chr5:140044315	WDR55	0.41	6.37	0.33	6.09e-10	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs11209002	0.614	rs6670381	chr1:67562106	G/T	cg02640540	chr1:67518911	SLC35D1	0.64	9.11	0.45	7.99e-18	Crohn's disease;
LUSC	cis	rs9920506	0.536	rs12441998	chr15:78929372	G/A	cg24631222	chr15:78858424	CHRNA5	-0.55	-7.03	-0.36	1.17e-11	Post bronchodilator FEV1;
LUSC	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg07169764	chr2:136633963	MCM6	-1.04	-13.8	-0.6	1.35e-34	Corneal structure;
LUSC	cis	rs9650315	0.866	rs7825725	chr8:57172347	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.48	6.38	0.33	5.94e-10	Height;
LUSC	trans	rs800082	1.000	rs4681378	chr3:144308005	C/T	cg24215973	chr2:240111563	HDAC4	-0.47	-7.02	-0.36	1.21e-11	Smoking behavior;
LUSC	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	8.2	0.41	5.32e-15	Height;
LUSC	cis	rs12200560	0.505	rs11153095	chr6:97078592	T/C	cg06623918	chr6:96969491	KIAA0776	-0.48	-6.94	-0.35	2.09e-11	Coronary heart disease;
LUSC	cis	rs7572644	1.000	rs7581813	chr2:28319961	G/T	cg27432699	chr2:27873401	GPN1	0.51	6.19	0.32	1.72e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs4356932	1.000	rs7674409	chr4:76958334	C/G	cg00809888	chr4:76862425	NAAA	-0.35	-5.77	-0.3	1.79e-8	Blood protein levels;
LUSC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg02033258	chr5:131593261	PDLIM4	0.4	5.76	0.3	1.92e-8	Acylcarnitine levels;
LUSC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.61	0.47	1.83e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs62400317	0.859	rs12191262	chr6:45227016	G/A	cg18551225	chr6:44695536	NA	-0.45	-7.37	-0.37	1.38e-12	Total body bone mineral density;
LUSC	cis	rs73206853	0.841	rs3759382	chr12:110889483	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4776059	0.550	rs73396766	chr15:52911516	C/T	cg22715398	chr15:52968154	KIAA1370	0.71	7.8	0.39	8.14e-14	Schizophrenia;
LUSC	cis	rs698813	0.604	rs58667148	chr2:44481443	G/A	cg00619915	chr2:44497795	NA	-0.53	-7.52	-0.38	5e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.54	-7.31	-0.37	1.94e-12	Longevity;Endometriosis;
LUSC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.08	0.36	8.55e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24739457	chr1:205821442	NA	0.41	7.28	0.37	2.46e-12	Menarche (age at onset);
LUSC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg09365446	chr1:150670422	GOLPH3L	0.55	8.44	0.42	9.59e-16	Tonsillectomy;
LUSC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg12463550	chr7:65579703	CRCP	-0.42	-6.17	-0.32	1.98e-9	Aortic root size;
LUSC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg03605463	chr16:89740564	NA	0.6	9.57	0.46	2.5e-19	Vitiligo;
LUSC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.74	-11.24	-0.52	4.55e-25	Menarche (age at onset);
LUSC	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.55	-10.99	-0.52	3.55e-24	Paraoxonase activity;
LUSC	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14829155	chr15:31115871	NA	-0.57	-7.95	-0.4	2.98e-14	Huntington's disease progression;
LUSC	cis	rs9341808	0.519	rs607130	chr6:80999233	T/C	cg08355045	chr6:80787529	NA	-0.4	-6.92	-0.35	2.36e-11	Sitting height ratio;
LUSC	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg17168535	chr8:21777572	XPO7	0.67	10.34	0.49	6.11e-22	Mean corpuscular volume;
LUSC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg07777115	chr5:623756	CEP72	-0.45	-5.7	-0.3	2.62e-8	Obesity-related traits;
LUSC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.65	-10.17	-0.49	2.43e-21	Obesity-related traits;
LUSC	cis	rs2692947	0.644	rs1168968	chr2:96825363	C/T	cg23100626	chr2:96804247	ASTL	0.3	7.23	0.37	3.22e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg14133921	chr5:54831061	PPAP2A;RNF138P1	0.53	6.17	0.32	1.94e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11997175	0.704	rs11775534	chr8:33695232	G/A	ch.8.33884649F	chr8:33765107	NA	0.37	5.8	0.3	1.5e-8	Body mass index;
LUSC	cis	rs6690583	0.623	rs75918067	chr1:85453413	T/C	cg11262906	chr1:85462892	MCOLN2	0.68	6.56	0.34	2.02e-10	Serum sulfate level;
LUSC	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.64	-9.76	-0.47	5.61e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg14019146	chr3:50243930	SLC38A3	0.31	6.94	0.35	2.1e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11764359	chr7:65958608	NA	0.68	10.96	0.51	4.39e-24	Aortic root size;
LUSC	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.8	0.51	1.61e-23	Hypertriglyceridemia;
LUSC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg08975724	chr8:8085496	FLJ10661	0.53	8.1	0.41	1.02e-14	Mood instability;
LUSC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg01802117	chr1:53393560	SCP2	0.39	6.47	0.33	3.49e-10	Monocyte count;
LUSC	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg08601574	chr20:25228251	PYGB	0.49	7.53	0.38	4.75e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg18196295	chr10:418757	DIP2C	0.38	5.95	0.31	6.63e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs12618769	0.652	rs4851145	chr2:99222916	A/G	cg10123293	chr2:99228465	UNC50	-0.45	-7.25	-0.37	3e-12	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.82	0.39	7.02e-14	Prudent dietary pattern;
LUSC	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg20487152	chr13:99095054	FARP1	-0.41	-7.0	-0.36	1.45e-11	Neuroticism;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03146073	chr3:44519063	ZNF445	-0.42	-6.26	-0.32	1.15e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6750795	0.765	rs6742387	chr2:232354832	G/T	cg19187155	chr2:232395269	NMUR1	0.94	16.14	0.66	9.67e-44	Height;
LUSC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg25767906	chr1:53392781	SCP2	-0.54	-9.49	-0.46	4.52e-19	Monocyte count;
LUSC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg04450456	chr4:17643702	FAM184B	0.38	6.55	0.34	2.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.46	7.79	0.39	8.3e-14	Lymphocyte counts;
LUSC	trans	rs853679	0.599	rs149949	chr6:28011516	T/C	cg01620082	chr3:125678407	NA	-0.58	-6.62	-0.34	1.42e-10	Depression;
LUSC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg24209194	chr3:40518798	ZNF619	0.45	6.1	0.32	2.87e-9	Renal cell carcinoma;
LUSC	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg01097406	chr16:89675127	NA	-0.34	-6.52	-0.34	2.64e-10	Vitiligo;
LUSC	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg00898013	chr13:113819073	PROZ	-0.58	-8.23	-0.41	4.15e-15	Platelet distribution width;
LUSC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.32	5.81	0.3	1.43e-8	Bone mineral density (hip);Bone mineral density;
LUSC	cis	rs6669072	0.669	rs712031	chr1:91243395	A/G	cg08895590	chr1:91227319	NA	-0.39	-8.7	-0.43	1.56e-16	Cognitive function;
LUSC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	5.94	0.31	7.15e-9	Breast cancer;
LUSC	cis	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg24375607	chr4:120327624	NA	0.48	7.47	0.38	7.24e-13	Corneal astigmatism;
LUSC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg21427119	chr20:30132790	HM13	0.42	5.97	0.31	6.01e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg02023728	chr11:77925099	USP35	0.47	7.02	0.36	1.28e-11	Testicular germ cell tumor;
LUSC	cis	rs2386661	0.547	rs4747358	chr10:5650193	A/G	cg17085576	chr10:5658249	NA	0.43	6.22	0.32	1.46e-9	Breast cancer;
LUSC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg13047869	chr3:10149882	C3orf24	0.44	6.71	0.34	8.55e-11	Alzheimer's disease;
LUSC	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg05347473	chr6:146136440	FBXO30	0.54	9.27	0.45	2.34e-18	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg25206134	chr2:45395956	NA	0.59	6.79	0.35	5.05e-11	Bipolar disorder;
LUSC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg11843238	chr5:131593191	PDLIM4	0.38	6.6	0.34	1.62e-10	Breast cancer;
LUSC	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg17507749	chr15:85114479	UBE2QP1	0.56	6.91	0.35	2.45e-11	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg07701084	chr6:150067640	NUP43	0.57	8.87	0.44	4.47e-17	Lung cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25373372	chr6:82462656	FAM46A	-0.46	-6.33	-0.33	7.93e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg19812747	chr11:111475976	SIK2	-0.55	-8.18	-0.41	5.92e-15	Primary sclerosing cholangitis;
LUSC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg18681998	chr4:17616180	MED28	0.92	18.02	0.7	3.46e-51	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg04362960	chr10:104952993	NT5C2	0.6	9.35	0.46	1.32e-18	Arsenic metabolism;
LUSC	cis	rs2276314	0.857	rs28540805	chr18:33641975	T/G	cg05985134	chr18:33552581	C18orf21	0.49	6.68	0.34	1.03e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg13393036	chr8:95962371	TP53INP1	-0.46	-10.15	-0.49	2.77e-21	Type 2 diabetes;
LUSC	cis	rs1107366	1.000	rs1107364	chr3:125904263	G/A	cg01346077	chr3:125931526	NA	0.37	7.07	0.36	9.34e-12	Metabolite levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17144508	chr2:128283727	IWS1	-0.41	-6.08	-0.32	3.36e-9	Hepatitis;
LUSC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.92	-16.68	-0.67	7.22e-46	Cognitive function;
LUSC	cis	rs2281845	0.929	rs7549337	chr1:201097609	T/G	cg17810781	chr1:201082982	CACNA1S	0.32	5.74	0.3	2.1e-8	Permanent tooth development;
LUSC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.32	21.88	0.77	1.84e-66	Type 1 diabetes nephropathy;
LUSC	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg13010199	chr12:38710504	ALG10B	-0.53	-7.9	-0.4	3.98e-14	Morning vs. evening chronotype;
LUSC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg26850624	chr5:429559	AHRR	-0.43	-8.43	-0.42	1.08e-15	Cystic fibrosis severity;
LUSC	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs9818941	0.784	rs7614747	chr3:157750934	T/C	cg08654915	chr3:157813417	NA	-0.33	-7.51	-0.38	5.42e-13	Height;
LUSC	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg08847533	chr14:75593920	NEK9	0.86	15.55	0.65	2.15e-41	Height;
LUSC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.17	-0.32	1.96e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7071206	0.853	rs57420220	chr10:79428886	C/T	cg07817648	chr10:79422355	NA	-0.54	-7.46	-0.38	7.49e-13	Bone mineral density;
LUSC	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg16576597	chr16:28551801	NUPR1	0.28	5.73	0.3	2.23e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg20368463	chr18:77673604	PQLC1	0.79	13.99	0.61	2.53e-35	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUSC	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg21775007	chr8:11205619	TDH	0.46	6.53	0.34	2.4e-10	Neuroticism;
LUSC	cis	rs4363385	0.818	rs1334850	chr1:153004519	G/T	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.46e-8	Inflammatory skin disease;
LUSC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg04944784	chr2:26401820	FAM59B	0.73	9.85	0.47	2.93e-20	Gut microbiome composition (summer);
LUSC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.77	-0.8	1.22e-77	Height;
LUSC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg15691649	chr6:25882328	NA	-0.38	-6.11	-0.32	2.8e-9	Blood metabolite levels;
LUSC	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	6.53	0.34	2.43e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.34	-0.42	2e-15	Systolic blood pressure;
LUSC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.88	-18.04	-0.7	2.96e-51	Intelligence (multi-trait analysis);
LUSC	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg04287289	chr16:89883240	FANCA	0.76	6.26	0.32	1.19e-9	Skin colour saturation;
LUSC	cis	rs9831754	0.704	rs9882111	chr3:78470746	A/G	cg06138941	chr3:78371609	NA	-0.52	-6.94	-0.35	2.08e-11	Calcium levels;
LUSC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg20607798	chr8:58055168	NA	0.53	5.93	0.31	7.73e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg27411982	chr8:10470053	RP1L1	0.51	7.75	0.39	1.09e-13	Monocyte count;
LUSC	cis	rs2274273	0.840	rs17674463	chr14:55824863	A/T	cg04306507	chr14:55594613	LGALS3	0.53	11.91	0.55	1.69e-27	Protein biomarker;
LUSC	cis	rs2273669	0.667	rs11153154	chr6:109357324	G/T	cg05315195	chr6:109294784	ARMC2	-0.53	-5.84	-0.3	1.22e-8	Prostate cancer;
LUSC	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg24579218	chr15:68104479	NA	-0.35	-5.74	-0.3	2.12e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.73	12.34	0.56	4.47e-29	Menarche (age at onset);
LUSC	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg06671706	chr8:8559999	CLDN23	0.49	6.68	0.34	9.77e-11	Obesity-related traits;
LUSC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.94	0.48	1.4e-20	Bipolar disorder;
LUSC	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.23	-0.69	4.77e-48	Exhaled nitric oxide output;
LUSC	cis	rs2625529	0.824	rs10518979	chr15:72268986	A/G	cg16672083	chr15:72433130	SENP8	-0.51	-7.41	-0.38	1.02e-12	Red blood cell count;
LUSC	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07080220	chr10:102295463	HIF1AN	0.64	8.57	0.42	3.92e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6669072	0.967	rs12130887	chr1:91240696	G/T	cg08895590	chr1:91227319	NA	-0.38	-8.51	-0.42	5.8e-16	Cognitive function;
LUSC	cis	rs4423214	0.592	rs7114252	chr11:71237606	G/A	cg05163923	chr11:71159392	DHCR7	-0.69	-7.12	-0.36	6.62e-12	Vitamin D levels;
LUSC	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg22709100	chr7:91322751	NA	0.41	5.91	0.31	8.38e-9	Breast cancer;
LUSC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2820315	1.000	rs1517810	chr1:201850057	T/C	cg10061532	chr1:201886748	LMOD1	0.26	5.85	0.3	1.17e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs7315438	0.600	rs10850515	chr12:115873190	C/G	cg24172291	chr12:115889509	NA	-0.33	-5.72	-0.3	2.4e-8	Colorectal cancer;
LUSC	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	6.22	0.32	1.51e-9	Monocyte count;
LUSC	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg22529645	chr1:3704559	LRRC47	0.37	6.43	0.33	4.48e-10	Red cell distribution width;
LUSC	cis	rs6961069	0.713	rs1049654	chr7:80275455	A/C	cg04458919	chr7:80252533	CD36	0.34	6.01	0.31	4.74e-9	Platelet count;
LUSC	cis	rs9814567	0.762	rs13067564	chr3:134209956	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	12.1	0.55	3.54e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11971779	0.618	rs10085814	chr7:139064089	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg21775007	chr8:11205619	TDH	-0.43	-6.09	-0.32	3.09e-9	Monocyte count;
LUSC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.06	-0.58	8.6e-32	Alzheimer's disease;
LUSC	cis	rs9398803	0.835	rs4897182	chr6:126755642	A/C	cg19875578	chr6:126661172	C6orf173	0.42	6.26	0.32	1.18e-9	Male-pattern baldness;
LUSC	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26306683	chr17:18585705	ZNF286B	0.45	6.57	0.34	1.98e-10	Educational attainment (years of education);
LUSC	trans	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.11	-0.32	2.79e-9	Monocyte count;
LUSC	cis	rs4343996	0.811	rs6462030	chr7:3392526	G/A	cg21248987	chr7:3385318	SDK1	-0.4	-6.79	-0.35	5.07e-11	Motion sickness;
LUSC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.53	10.54	0.5	1.34e-22	Coronary artery disease;
LUSC	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg27147174	chr7:100797783	AP1S1	-0.63	-10.21	-0.49	1.8e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs6484504	0.532	rs10835757	chr11:31281902	C/T	cg14844989	chr11:31128820	NA	-0.37	-5.74	-0.3	2.16e-8	Red blood cell count;
LUSC	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	9.73	0.47	7.04e-20	Coffee consumption (cups per day);
LUSC	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg13010199	chr12:38710504	ALG10B	0.65	9.81	0.47	3.95e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8092503	1.000	rs12957162	chr18:52484299	T/A	cg12377874	chr18:52495404	RAB27B	0.33	5.83	0.3	1.32e-8	Childhood body mass index;
LUSC	cis	rs2908197	0.866	rs2961048	chr7:75935008	A/T	cg10167463	chr7:75959203	YWHAG	-0.39	-5.75	-0.3	1.96e-8	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg04025307	chr7:1156635	C7orf50	0.44	6.98	0.36	1.56e-11	Longevity;Endometriosis;
LUSC	cis	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg07460842	chr6:66804631	NA	0.75	9.35	0.46	1.34e-18	Exhaled nitric oxide output;
LUSC	cis	rs59698941	0.550	rs12652469	chr5:132182765	A/G	cg14825688	chr5:132208181	LEAP2	-0.43	-6.29	-0.33	9.85e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs240764	0.853	rs17303769	chr6:100967531	G/A	cg09795085	chr6:101329169	ASCC3	-0.41	-6.0	-0.31	5e-9	Neuroticism;
LUSC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg11764359	chr7:65958608	NA	0.49	6.09	0.32	3.19e-9	Aortic root size;
LUSC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg21918786	chr6:109611834	NA	-0.38	-6.47	-0.33	3.45e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.32	-0.33	8.21e-10	Bipolar disorder;
LUSC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg27398817	chr8:82754497	SNX16	0.5	6.75	0.35	6.75e-11	Diastolic blood pressure;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13077517	chr20:2082435	STK35	-0.39	-6.01	-0.31	4.74e-9	Hepatitis;
LUSC	cis	rs4629180	1.000	rs4629180	chr2:102088370	G/A	cg04415270	chr2:102091202	RFX8	-0.54	-8.66	-0.43	2e-16	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs11264213	0.901	rs72661623	chr1:36398368	G/A	cg27506609	chr1:36549197	TEKT2	0.68	7.88	0.4	4.58e-14	Schizophrenia;
LUSC	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg24531977	chr5:56204891	C5orf35	-0.65	-9.66	-0.47	1.27e-19	Coronary artery disease;
LUSC	cis	rs12594515	1.000	rs12592190	chr15:45994028	G/A	cg01629716	chr15:45996671	NA	0.39	5.76	0.3	1.89e-8	Waist circumference;Weight;
LUSC	cis	rs6460942	0.908	rs7781919	chr7:12235351	T/C	cg06484146	chr7:12443880	VWDE	-0.58	-6.09	-0.32	3.08e-9	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25072359	chr17:41440525	NA	-0.61	-8.55	-0.42	4.36e-16	Menopause (age at onset);
LUSC	cis	rs13720	0.722	rs163801	chr20:57578614	A/G	cg23907860	chr20:57583709	CTSZ	-0.49	-6.47	-0.33	3.5e-10	Platelet distribution width;
LUSC	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg17366294	chr4:99064904	C4orf37	0.57	8.69	0.43	1.59e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9420	0.961	rs79260745	chr11:57612960	T/C	cg02958346	chr11:57425731	CLP1	-0.43	-6.22	-0.32	1.51e-9	Schizophrenia;
LUSC	cis	rs10189230	0.967	rs12990760	chr2:222354725	G/T	cg14652038	chr2:222343519	EPHA4	0.32	5.72	0.3	2.35e-8	Urate levels in lean individuals;
LUSC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg25258033	chr6:167368657	RNASET2	0.4	6.06	0.31	3.7e-9	Primary biliary cholangitis;
LUSC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg24829409	chr8:58192753	C8orf71	-0.47	-5.9	-0.31	8.78e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg18477163	chr1:228402036	OBSCN	-0.46	-7.66	-0.39	1.98e-13	Parkinson's disease;
LUSC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg26695010	chr11:65641043	EFEMP2	0.53	7.9	0.4	4.12e-14	Eosinophil percentage of white cells;
LUSC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06634786	chr22:41940651	POLR3H	0.49	5.69	0.3	2.72e-8	Vitiligo;
LUSC	cis	rs2303282	0.664	rs67179399	chr16:56440201	G/A	cg00500540	chr16:56394104	NA	-0.39	-6.7	-0.34	8.98e-11	Breast cancer;
LUSC	cis	rs10463316	0.832	rs246482	chr5:150731857	C/G	cg03212797	chr5:150827313	SLC36A1	-0.52	-7.75	-0.39	1.13e-13	Metabolite levels (Pyroglutamine);
LUSC	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg20703242	chr1:230279135	GALNT2	0.57	8.88	0.44	4.15e-17	Coronary artery disease;
LUSC	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg02175503	chr12:58329896	NA	0.47	6.78	0.35	5.5e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs3862435	1.000	rs3862436	chr15:91082869	A/G	cg22089800	chr15:90895588	ZNF774	-0.6	-5.88	-0.31	1.01e-8	Response to exercise (triglyceride level interaction);
LUSC	cis	rs793571	0.544	rs383902	chr15:59034174	C/T	cg05156742	chr15:59063176	FAM63B	0.51	7.6	0.38	2.93e-13	Schizophrenia;
LUSC	trans	rs2285002	0.744	rs229673	chr14:65281944	A/G	cg15123499	chr10:636241	DIP2C	0.32	6.03	0.31	4.31e-9	Red cell distribution width;
LUSC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg22907277	chr7:1156413	C7orf50	0.72	10.27	0.49	1.06e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg23601095	chr6:26197514	HIST1H3D	0.68	7.42	0.38	9.69e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg05283184	chr6:79620031	NA	-0.5	-9.68	-0.47	1.09e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg25237894	chr2:233734115	C2orf82	0.35	6.54	0.34	2.32e-10	Coronary artery disease;
LUSC	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.35	0.33	7.22e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-5.72	-0.3	2.39e-8	Type 2 diabetes;
LUSC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg11941060	chr3:133502564	NA	-0.51	-7.94	-0.4	3.11e-14	Iron status biomarkers;
LUSC	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg17031739	chr1:67600172	NA	0.44	6.94	0.35	2.08e-11	Psoriasis;
LUSC	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg06636001	chr8:8085503	FLJ10661	0.43	6.53	0.34	2.52e-10	Myopia (pathological);
LUSC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg12257692	chr3:49977190	RBM6	-0.25	-6.99	-0.36	1.54e-11	Body mass index;
LUSC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06634786	chr22:41940651	POLR3H	0.49	5.73	0.3	2.21e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.4	0.38	1.14e-12	Motion sickness;
LUSC	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg01657329	chr11:68192670	LRP5	-0.4	-5.73	-0.3	2.28e-8	Total body bone mineral density;
LUSC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.24	0.37	3.18e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.8	-0.47	4.27e-20	Gut microbiome composition (summer);
LUSC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.07	20.64	0.75	1.34e-61	Cognitive ability;
LUSC	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg08085267	chr17:45401833	C17orf57	0.57	9.53	0.46	3.25e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg08557956	chr11:4115526	RRM1	-0.42	-5.67	-0.3	3.02e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs11587682	0.760	rs11205383	chr1:150455813	T/C	cg11822372	chr1:151115635	SEMA6C	-0.42	-5.71	-0.3	2.53e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06481639	chr22:41940642	POLR3H	-0.55	-6.24	-0.32	1.33e-9	Vitiligo;
LUSC	trans	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg03886242	chr7:26192032	NFE2L3	0.38	6.35	0.33	6.95e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14865585	chr21:45363474	AGPAT3	0.4	6.17	0.32	1.94e-9	Hepatitis;
LUSC	cis	rs9816226	0.618	rs1516728	chr3:185829891	A/T	cg00760338	chr3:185826511	ETV5	0.75	12.5	0.56	1.16e-29	Obesity;Body mass index;
LUSC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.92	0.31	7.86e-9	Menopause (age at onset);
LUSC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18876405	chr7:65276391	NA	0.57	9.31	0.45	1.82e-18	Aortic root size;
LUSC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.67	11.46	0.53	7.03e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg17173187	chr15:85201210	NMB	0.51	9.66	0.47	1.24e-19	Schizophrenia;
LUSC	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg11812906	chr14:75593930	NEK9	-0.63	-10.19	-0.49	2.14e-21	Height;
LUSC	cis	rs6736093	1.000	rs7604403	chr2:112656652	G/A	cg12686935	chr2:112915763	FBLN7	-0.39	-6.06	-0.31	3.58e-9	Coronary artery disease;
LUSC	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-9.79	-0.47	4.74e-20	Neuroticism;
LUSC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg00509249	chr6:109615579	CCDC162	0.31	5.66	0.3	3.28e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.49e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.7	11.84	0.54	2.97e-27	Heart rate;
LUSC	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg13119609	chr19:45449297	APOC2	0.33	5.75	0.3	2.05e-8	Blood protein levels;
LUSC	cis	rs12042938	0.935	rs1094657	chr1:231773407	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.43	6.28	0.33	1.05e-9	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg08742575	chr21:47604166	C21orf56	-0.44	-6.58	-0.34	1.83e-10	Testicular germ cell tumor;
LUSC	trans	rs12165098	0.673	rs4416086	chr18:36748710	C/T	cg23858286	chr9:138135095	NA	-0.42	-6.18	-0.32	1.84e-9	Sleep duration;
LUSC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.68	-10.57	-0.5	1.01e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.6	-0.34	1.65e-10	Blood metabolite levels;
LUSC	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg09626299	chr10:82213104	TSPAN14	-0.2	-5.8	-0.3	1.55e-8	Post bronchodilator FEV1;
LUSC	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00631329	chr6:26305371	NA	-0.44	-8.61	-0.43	2.92e-16	Educational attainment;
LUSC	cis	rs9807989	0.801	rs10173193	chr2:102975050	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.74	0.3	2.08e-8	Asthma;
LUSC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg00933542	chr6:150070202	PCMT1	0.34	6.95	0.36	1.89e-11	Lung cancer;
LUSC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg15110403	chr19:17392923	ANKLE1	-0.51	-6.96	-0.36	1.75e-11	Systemic lupus erythematosus;
LUSC	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg03585969	chr10:35415529	CREM	0.6	8.67	0.43	1.86e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	1.04	20.09	0.74	2.02e-59	Menopause (age at onset);
LUSC	cis	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1178127	0.580	rs1178175	chr7:18797629	C/T	cg02370815	chr7:18831390	HDAC9	-0.39	-5.82	-0.3	1.34e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
LUSC	cis	rs859767	0.741	rs1104802	chr2:135436366	A/C	cg12500956	chr2:135428796	TMEM163	-0.29	-6.48	-0.33	3.27e-10	Neuroticism;
LUSC	cis	rs11637445	0.677	rs3784716	chr15:68084450	G/T	cg08079166	chr15:68083412	MAP2K5	0.36	7.42	0.38	9.86e-13	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs9534288	0.797	rs2806922	chr13:46518059	A/G	cg15192986	chr13:46630673	CPB2	-0.61	-10.23	-0.49	1.52e-21	Blood protein levels;
LUSC	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg15309053	chr8:964076	NA	0.4	7.97	0.4	2.46e-14	Schizophrenia;
LUSC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg02951883	chr7:2050386	MAD1L1	-0.42	-7.2	-0.37	4.1e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg02403541	chr12:121454288	C12orf43	-0.74	-11.4	-0.53	1.21e-25	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg03676636	chr4:99064102	C4orf37	0.37	8.14	0.41	7.81e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08219700	chr8:58056026	NA	0.66	8.1	0.41	1.01e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs11158026	0.757	rs6572994	chr14:55427103	C/G	cg04306507	chr14:55594613	LGALS3	0.34	6.54	0.34	2.36e-10	Parkinson's disease;
LUSC	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg17127132	chr2:85788382	GGCX	0.44	6.41	0.33	5.1e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.66	-11.45	-0.53	7.59e-26	Age at first birth;
LUSC	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg19052272	chr2:3704530	ALLC	-0.46	-7.58	-0.38	3.35e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg09904177	chr6:26538194	HMGN4	-0.65	-10.61	-0.5	7.6e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-7.99	-0.4	2.26e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6574644	1.000	rs10138868	chr14:81776770	T/G	cg01989461	chr14:81687754	GTF2A1	0.47	5.68	0.3	2.9e-8	Obesity-related traits;
LUSC	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg17470449	chr10:769945	NA	0.51	7.07	0.36	9.06e-12	Uric acid levels;
LUSC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9549260	0.755	rs9549241	chr13:41210041	G/A	cg21288729	chr13:41239152	FOXO1	0.62	9.74	0.47	6.97e-20	Red blood cell count;
LUSC	trans	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg05926928	chr17:57297772	GDPD1	-0.83	-9.51	-0.46	3.82e-19	Opioid sensitivity;
LUSC	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.76	-0.35	6.13e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3820068	0.562	rs10927841	chr1:16045261	T/C	cg17385448	chr1:15911702	AGMAT	0.36	5.86	0.31	1.13e-8	Systolic blood pressure;
LUSC	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg00999904	chr2:3704751	ALLC	-0.43	-6.67	-0.34	1.06e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg04117972	chr1:227635322	NA	0.74	7.82	0.39	6.88e-14	Major depressive disorder;
LUSC	cis	rs2073300	1.000	rs6036424	chr20:23459976	A/C	cg09953122	chr20:23471693	CST8	0.65	6.65	0.34	1.18e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg21770322	chr7:97807741	LMTK2	0.56	9.93	0.48	1.51e-20	Breast cancer;
LUSC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.86	-0.54	2.57e-27	Chronic sinus infection;
LUSC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg21724239	chr8:58056113	NA	0.8	8.55	0.42	4.58e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg24687543	chr11:63912206	MACROD1	0.48	5.84	0.3	1.26e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg04511125	chr2:88470314	THNSL2	-0.44	-6.45	-0.33	4.02e-10	Response to metformin (IC50);
LUSC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg22638593	chr5:131593259	PDLIM4	0.43	6.25	0.32	1.28e-9	Acylcarnitine levels;
LUSC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.55	-8.97	-0.44	2.15e-17	Tonsillectomy;
LUSC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg03806693	chr22:41940476	POLR3H	0.99	13.49	0.59	2e-33	Vitiligo;
LUSC	cis	rs9346649	0.654	rs12527055	chr6:168492655	C/T	cg02770688	chr6:168491649	NA	0.51	9.71	0.47	8.45e-20	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs7571561	0.625	rs6712295	chr2:213275113	A/G	cg16329650	chr2:213403929	ERBB4	0.53	6.87	0.35	3.11e-11	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
LUSC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg02475777	chr4:1388615	CRIPAK	0.45	6.69	0.34	9.62e-11	Obesity-related traits;
LUSC	cis	rs7215564	0.908	rs34950888	chr17:78661779	T/G	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg06453172	chr10:134556979	INPP5A	-0.53	-6.51	-0.34	2.81e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2315504	1.000	rs916926	chr17:39030283	T/A	cg17985300	chr17:38952333	KRT28	-0.36	-7.37	-0.37	1.33e-12	Height;
LUSC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg02475777	chr4:1388615	CRIPAK	0.43	6.39	0.33	5.68e-10	Obesity-related traits;
LUSC	cis	rs2455601	0.638	rs2742478	chr11:8996099	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-6.4	-0.33	5.2e-10	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.93	0.31	7.57e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.64	8.74	0.43	1.15e-16	Multiple sclerosis;
LUSC	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg20628663	chr10:43360327	NA	0.73	10.96	0.51	4.51e-24	Blood protein levels;
LUSC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg01416388	chr22:39784598	NA	-0.44	-7.25	-0.37	3.01e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg24006582	chr15:45444508	DUOX1	-0.62	-9.45	-0.46	6.27e-19	Uric acid levels;
LUSC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg23711669	chr6:146136114	FBXO30	0.75	13.38	0.59	5.46e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg07148914	chr20:33460835	GGT7	-0.46	-6.74	-0.35	7.17e-11	Height;
LUSC	cis	rs4588572	0.643	rs7701154	chr5:77716621	G/A	cg11547950	chr5:77652471	NA	-0.52	-7.31	-0.37	2.05e-12	Triglycerides;
LUSC	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.27	-0.45	2.38e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.92	15.76	0.65	3.19e-42	Bladder cancer;
LUSC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg22834771	chr12:69754056	YEATS4	-0.55	-8.13	-0.41	8.34e-15	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.4	-5.71	-0.3	2.56e-8	Rheumatoid arthritis;
LUSC	cis	rs2289583	0.544	rs1867153	chr15:75271229	C/T	cg10253484	chr15:75165896	SCAMP2	0.43	5.75	0.3	2.07e-8	Systemic lupus erythematosus;
LUSC	cis	rs3820068	0.608	rs10927831	chr1:16028373	T/G	cg24675056	chr1:15929824	NA	0.4	6.58	0.34	1.87e-10	Systolic blood pressure;
LUSC	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.01	0.4	1.87e-14	Breast cancer;
LUSC	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	5.98	0.31	5.61e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10823500	0.549	rs10999204	chr10:72007306	G/A	cg02100629	chr10:71892760	AIFM2	-0.34	-5.92	-0.31	8.11e-9	Blood protein levels;
LUSC	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.21	-0.45	3.77e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg09877947	chr5:131593287	PDLIM4	0.37	6.13	0.32	2.5e-9	Blood metabolite levels;
LUSC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg13047869	chr3:10149882	C3orf24	0.66	9.71	0.47	8.63e-20	Alzheimer's disease;
LUSC	trans	rs41419946	1.000	rs12072131	chr1:165397025	G/A	cg00234446	chr18:74208345	NA	0.69	6.26	0.32	1.21e-9	Gut microbiome composition (winter);
LUSC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg10755058	chr3:40428713	ENTPD3	-0.33	-5.72	-0.3	2.36e-8	Renal cell carcinoma;
LUSC	cis	rs9815354	1.000	rs73079316	chr3:41863859	G/A	cg03022575	chr3:42003672	ULK4	0.64	7.04	0.36	1.1e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.86	13.15	0.58	4.26e-32	Asthma;
LUSC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg20887711	chr4:1340912	KIAA1530	0.47	7.15	0.36	5.57e-12	Obesity-related traits;
LUSC	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg20701182	chr2:24300061	SF3B14	0.55	5.83	0.3	1.32e-8	Lymphocyte counts;
LUSC	cis	rs2073300	1.000	rs6137983	chr20:23469465	C/A	cg09953122	chr20:23471693	CST8	-0.87	-6.99	-0.36	1.54e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg03579872	chr1:53393473	SCP2	-0.39	-5.74	-0.3	2.09e-8	Monocyte count;
LUSC	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.27	0.49	1.09e-21	Schizophrenia;
LUSC	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.67	10.29	0.49	9.56e-22	Colorectal cancer;
LUSC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg02423579	chr7:2872169	GNA12	-0.44	-6.35	-0.33	6.83e-10	Height;
LUSC	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg13647721	chr17:30228624	UTP6	0.64	6.43	0.33	4.46e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs9648716	0.515	rs38722	chr7:140695430	G/A	cg23214464	chr7:140373596	ADCK2	0.74	6.33	0.33	8.04e-10	Type 2 diabetes;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg00260888	chr20:30865478	KIF3B	0.48	6.28	0.32	1.06e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg08017634	chr8:144659831	NAPRT1	0.72	6.12	0.32	2.59e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs2274459	0.841	rs35698850	chr6:33700132	A/G	cg06253072	chr6:33679850	C6orf125	0.5	6.0	0.31	5.28e-9	Obesity (extreme);
LUSC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg01017244	chr2:74357527	NA	0.69	13.33	0.59	8.68e-33	Gestational age at birth (maternal effect);
LUSC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg07507251	chr3:52567010	NT5DC2	0.37	7.54	0.38	4.46e-13	Electroencephalogram traits;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg17291625	chr16:236080	NA	0.44	6.43	0.33	4.44e-10	Calcium levels;
LUSC	cis	rs7481584	0.962	rs11024759	chr11:2982092	T/C	cg08508325	chr11:3079039	CARS	0.3	5.84	0.3	1.27e-8	Calcium levels;
LUSC	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.46	9.54	0.46	3.07e-19	Airflow obstruction;
LUSC	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg01579765	chr21:45077557	HSF2BP	0.54	11.3	0.53	2.7e-25	Mean corpuscular volume;
LUSC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg04369109	chr6:150039330	LATS1	-0.56	-8.26	-0.41	3.39e-15	Lung cancer;
LUSC	cis	rs13315871	1.000	rs12330157	chr3:58364562	C/T	cg20936604	chr3:58311152	NA	-0.63	-5.85	-0.31	1.15e-8	Cholesterol, total;
LUSC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.59	-0.34	1.73e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.71	-13.2	-0.59	2.65e-32	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.17	0.37	4.94e-12	Cognitive ability;
LUSC	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg03929089	chr4:120376271	NA	0.5	6.18	0.32	1.87e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.74	10.31	0.49	7.79e-22	Corneal astigmatism;
LUSC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg06784218	chr1:46089804	CCDC17	-0.47	-9.14	-0.45	6.34e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg23093090	chr10:104574429	C10orf26	-0.39	-7.44	-0.38	8.66e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.86	13.87	0.6	7.36e-35	Coronary artery disease;
LUSC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg12560992	chr17:57184187	TRIM37	0.84	15.48	0.65	3.82e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg03859395	chr2:55845619	SMEK2	-0.69	-10.4	-0.49	4.02e-22	Metabolic syndrome;
LUSC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg06637938	chr14:75390232	RPS6KL1	0.53	8.5	0.42	6.22e-16	Height;
LUSC	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg01657329	chr11:68192670	LRP5	-0.47	-7.12	-0.36	6.78e-12	Total body bone mineral density;
LUSC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.68	-0.47	1.05e-19	Platelet count;
LUSC	cis	rs3925075	0.966	rs11645917	chr16:31359826	C/T	cg02846316	chr16:31340340	ITGAM	0.33	6.04	0.31	4.19e-9	IgA nephropathy;
LUSC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.53	0.34	2.48e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1322512	0.917	rs2758778	chr6:153007802	T/C	cg27316956	chr6:152958899	SYNE1	0.35	6.06	0.31	3.59e-9	Tonometry;
LUSC	cis	rs6574644	1.000	rs7153097	chr14:81772203	C/T	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08045932	chr20:61659980	NA	-0.58	-9.94	-0.48	1.47e-20	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg22777020	chr22:31556080	RNF185	-0.47	-5.96	-0.31	6.29e-9	Colorectal cancer;
LUSC	cis	rs9473147	0.516	rs6903331	chr6:47562915	A/G	cg20196966	chr6:47445060	CD2AP	0.42	5.91	0.31	8.6e-9	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.36	0.64	1.21e-40	Morning vs. evening chronotype;
LUSC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.4	-0.62	6.88e-37	Chronic sinus infection;
LUSC	cis	rs2109514	0.840	rs10228178	chr7:116132211	G/A	cg12739419	chr7:116140593	CAV2	-0.27	-5.84	-0.3	1.26e-8	Prevalent atrial fibrillation;
LUSC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg23281280	chr6:28129359	ZNF389	-0.44	-5.89	-0.31	9.47e-9	Depression;
LUSC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.56e-13	Motion sickness;
LUSC	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.63	8.33	0.41	2.13e-15	High light scatter reticulocyte count;
LUSC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08859206	chr1:53392774	SCP2	-0.55	-9.56	-0.46	2.58e-19	Monocyte count;
LUSC	cis	rs12712073	0.845	rs1370353	chr2:100764824	G/C	cg22139774	chr2:100720529	AFF3	-0.42	-7.25	-0.37	2.9e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg13010199	chr12:38710504	ALG10B	0.69	10.81	0.51	1.43e-23	Bladder cancer;
LUSC	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	11.15	0.52	9.43e-25	Lung cancer in ever smokers;
LUSC	cis	rs7640424	0.649	rs6795280	chr3:107876232	T/C	cg09227934	chr3:107805635	CD47	-0.36	-5.71	-0.3	2.51e-8	Body mass index;
LUSC	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg05738196	chr6:26577821	NA	0.79	15.0	0.63	2.98e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg04944784	chr2:26401820	FAM59B	0.78	11.16	0.52	8.66e-25	Gut microbiome composition (summer);
LUSC	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg05738196	chr6:26577821	NA	-0.6	-7.21	-0.37	3.78e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg04508216	chr1:11107452	MASP2	0.31	5.67	0.3	3.17e-8	Body mass index;
LUSC	trans	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg10756647	chr7:56101905	PSPH	-0.84	-8.42	-0.42	1.14e-15	Diabetic kidney disease;
LUSC	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg02389323	chr16:88786976	FAM38A	1.14	11.21	0.52	5.67e-25	Plateletcrit;
LUSC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg05195085	chr7:157951403	PTPRN2	0.31	5.8	0.3	1.54e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3764021	0.870	rs7307111	chr12:9877823	G/A	cg20894963	chr12:9885564	CLECL1	0.35	7.1	0.36	7.55e-12	Type 1 diabetes;
LUSC	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg15556689	chr8:8085844	FLJ10661	0.56	8.47	0.42	7.67e-16	Neuroticism;
LUSC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00339695	chr16:24857497	SLC5A11	0.59	8.98	0.44	2.04e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg05025164	chr4:1340916	KIAA1530	0.43	6.43	0.33	4.39e-10	Obesity-related traits;
LUSC	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg15556689	chr8:8085844	FLJ10661	0.57	8.53	0.42	5.11e-16	Neuroticism;
LUSC	cis	rs7254114	0.578	rs73506605	chr19:11307564	G/A	cg02815516	chr19:11306319	KANK2	-0.41	-8.63	-0.43	2.51e-16	Immature fraction of reticulocytes;
LUSC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg06675483	chr6:26987649	LOC100270746;C6orf41	-0.3	-6.02	-0.31	4.61e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs911119	0.908	rs6048950	chr20:23603252	A/G	cg16589663	chr20:23618590	CST3	0.57	6.82	0.35	4.18e-11	Chronic kidney disease;
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.61	-10.45	-0.5	2.74e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg13010199	chr12:38710504	ALG10B	0.41	6.41	0.33	4.96e-10	Morning vs. evening chronotype;
LUSC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg16434002	chr17:42200994	HDAC5	-0.45	-6.35	-0.33	6.83e-10	Total body bone mineral density;
LUSC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15664640	chr17:80829946	TBCD	-0.5	-8.86	-0.44	4.83e-17	Breast cancer;
LUSC	cis	rs11031096	0.711	rs10835723	chr11:4207566	G/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.77	-0.3	1.86e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25072359	chr17:41440525	NA	0.64	9.34	0.45	1.45e-18	Menopause (age at onset);
LUSC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.44	6.48	0.33	3.21e-10	Systemic lupus erythematosus;
LUSC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg22920501	chr2:26401640	FAM59B	0.83	12.04	0.55	5.72e-28	Gut microbiome composition (summer);
LUSC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.25	-0.41	3.72e-15	Longevity;
LUSC	cis	rs981844	1.000	rs72731674	chr4:154667447	C/A	cg14289246	chr4:154710475	SFRP2	0.48	6.03	0.31	4.26e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg25174290	chr11:3078921	CARS	-0.41	-6.15	-0.32	2.19e-9	Calcium levels;
LUSC	trans	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg26384229	chr12:38710491	ALG10B	-0.62	-8.6	-0.43	3.05e-16	Resting heart rate;
LUSC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7089973	0.966	rs17721283	chr10:116644141	A/G	cg23260525	chr10:116636907	FAM160B1	0.37	6.98	0.36	1.64e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02254798	chr10:74856984	P4HA1	-0.53	-7.18	-0.37	4.6e-12	Hepatitis;
LUSC	cis	rs3857536	0.776	rs1002764	chr6:66945760	C/A	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs8048589	0.615	rs12924889	chr16:12241768	A/G	cg02910054	chr16:12241554	SNX29	0.52	6.44	0.33	4.24e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg01475377	chr6:109611718	NA	-0.43	-7.65	-0.39	2.14e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs7241530	0.636	rs4799010	chr18:75910590	T/A	cg14642773	chr18:75888474	NA	0.39	5.74	0.3	2.17e-8	Educational attainment (years of education);
LUSC	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02176678	chr2:219576539	TTLL4	0.61	11.05	0.52	2.17e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg25019033	chr10:957182	NA	-0.5	-6.36	-0.33	6.72e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20916646	chr4:852691	GAK	0.44	6.87	0.35	3.09e-11	Sjögren's syndrome;
LUSC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-8.77	-0.43	9.02e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg01420254	chr6:26195488	NA	0.66	7.31	0.37	2.05e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg01251360	chr16:68772225	CDH1	-0.25	-5.9	-0.31	8.86e-9	Colorectal cancer;
LUSC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg20283391	chr11:68216788	NA	-0.57	-8.1	-0.41	1.03e-14	Total body bone mineral density;
LUSC	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg26384229	chr12:38710491	ALG10B	0.69	9.68	0.47	1.06e-19	Resting heart rate;
LUSC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.65	-10.98	-0.51	3.75e-24	Lung cancer;
LUSC	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg19773385	chr1:10388646	KIF1B	-0.53	-8.3	-0.41	2.57e-15	Hepatocellular carcinoma;
LUSC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.26	-0.37	2.73e-12	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10749792	chr7:56119218	PSPH;CCT6A	-0.45	-6.96	-0.36	1.76e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11676348	0.774	rs57545959	chr2:219047718	A/G	cg06547715	chr2:218990976	CXCR2	-0.32	-6.31	-0.33	8.77e-10	Ulcerative colitis;
LUSC	cis	rs3772130	0.564	rs35178434	chr3:121595936	G/A	cg11130432	chr3:121712080	ILDR1	0.36	5.71	0.3	2.47e-8	Cognitive performance;
LUSC	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg07701084	chr6:150067640	NUP43	0.51	7.26	0.37	2.75e-12	Lung cancer;
LUSC	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.44	0.5	2.94e-22	Colorectal cancer;
LUSC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.8	-0.47	4.27e-20	Gut microbiome composition (summer);
LUSC	trans	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg25214090	chr10:38739885	LOC399744	0.56	8.42	0.42	1.09e-15	Corneal astigmatism;
LUSC	cis	rs1113500	0.836	rs1122158	chr1:108588668	G/T	cg06207961	chr1:108661230	NA	0.38	6.91	0.35	2.49e-11	Growth-regulated protein alpha levels;
LUSC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	7.01	0.36	1.32e-11	Motion sickness;
LUSC	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg24375607	chr4:120327624	NA	0.75	11.1	0.52	1.35e-24	Corneal astigmatism;
LUSC	cis	rs701145	0.585	rs62276842	chr3:153784048	A/T	cg17054900	chr3:154042577	DHX36	-0.55	-5.92	-0.31	8.07e-9	Coronary artery disease;
LUSC	cis	rs354225	0.584	rs17046097	chr2:54888075	A/G	cg01766943	chr2:54829624	SPTBN1	-0.4	-6.43	-0.33	4.47e-10	Schizophrenia;
LUSC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.65	-8.99	-0.44	1.89e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg19318889	chr4:1322082	MAEA	0.45	7.13	0.36	6.31e-12	Obesity-related traits;
LUSC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg00310523	chr12:86230176	RASSF9	0.52	9.87	0.48	2.51e-20	Major depressive disorder;
LUSC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg23289794	chr7:2394357	EIF3B	-0.71	-9.35	-0.46	1.3e-18	Multiple sclerosis;
LUSC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg25036284	chr2:26402008	FAM59B	0.77	10.94	0.51	5.08e-24	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg21724239	chr8:58056113	NA	0.78	8.17	0.41	6.56e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg18002602	chr11:66138449	SLC29A2	0.46	8.08	0.4	1.17e-14	Educational attainment (years of education);
LUSC	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg01884057	chr2:25150051	NA	0.48	11.3	0.53	2.75e-25	Body mass index;
LUSC	cis	rs7927771	0.800	rs11039200	chr11:47379646	A/C	cg20135002	chr11:47629003	NA	-0.49	-7.36	-0.37	1.42e-12	Subjective well-being;
LUSC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg24257776	chr3:47051546	LOC100129354	0.33	5.88	0.31	1e-8	Colorectal cancer;
LUSC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg04111992	chr7:158790115	NA	-0.44	-7.0	-0.36	1.42e-11	Facial morphology (factor 20);
LUSC	cis	rs240764	0.817	rs240154	chr6:101065792	G/T	cg09795085	chr6:101329169	ASCC3	0.42	6.14	0.32	2.3e-9	Neuroticism;
LUSC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg25767906	chr1:53392781	SCP2	0.52	9.44	0.46	6.73e-19	Monocyte count;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg06642177	chr6:134496341	SGK1	0.36	6.61	0.34	1.51e-10	Triglycerides;
LUSC	cis	rs4654899	0.895	rs10916866	chr1:21137768	C/A	cg01072550	chr1:21505969	NA	0.46	6.85	0.35	3.5e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg06212747	chr3:49208901	KLHDC8B	0.58	8.04	0.4	1.55e-14	Menarche (age at onset);
LUSC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.43	-7.05	-0.36	1.02e-11	Longevity;Endometriosis;
LUSC	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg01966878	chr4:90757139	SNCA	-0.43	-6.22	-0.32	1.49e-9	Neuroticism;
LUSC	cis	rs7712401	0.601	rs438196	chr5:122263063	T/G	cg19077854	chr5:122220652	SNX24	0.41	8.93	0.44	2.84e-17	Mean platelet volume;
LUSC	cis	rs11229555	0.645	rs36019763	chr11:58232283	G/T	cg15696309	chr11:58395628	NA	-0.71	-8.54	-0.42	4.81e-16	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2729354	0.729	rs2848634	chr11:57252328	G/A	cg24343310	chr11:57249947	NA	0.44	8.52	0.42	5.43e-16	Blood protein levels;
LUSC	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg22532475	chr10:104410764	TRIM8	0.3	6.0	0.31	5.1e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.6	-0.43	3.16e-16	Total cholesterol levels;
LUSC	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg13902645	chr11:5959945	NA	-0.51	-6.85	-0.35	3.48e-11	DNA methylation (variation);
LUSC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.73	10.16	0.49	2.53e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs9818941	0.824	rs1123115	chr3:157813401	C/T	cg08654915	chr3:157813417	NA	0.34	7.88	0.4	4.62e-14	Height;
LUSC	cis	rs662735	0.515	rs507969	chr11:30830612	C/A	cg14844989	chr11:31128820	NA	0.37	5.86	0.31	1.11e-8	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02018176	chr4:1364513	KIAA1530	-0.67	-11.82	-0.54	3.52e-27	Obesity-related traits;
LUSC	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg19539972	chr4:7069911	GRPEL1	0.72	9.06	0.44	1.13e-17	Monocyte percentage of white cells;
LUSC	trans	rs7980799	0.649	rs11052732	chr12:33657801	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.21	-0.41	4.73e-15	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs1322512	0.874	rs1105902	chr6:152961448	A/T	cg27316956	chr6:152958899	SYNE1	-0.36	-6.22	-0.32	1.51e-9	Tonometry;
LUSC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg16447950	chr5:562315	NA	-0.54	-6.69	-0.34	9.26e-11	Obesity-related traits;
LUSC	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.19e-33	Morning vs. evening chronotype;
LUSC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	cis	rs8135665	0.600	rs6519096	chr22:38451389	C/T	cg13116946	chr22:38479732	SLC16A8	0.42	6.26	0.32	1.17e-9	Advanced age-related macular degeneration;Age-related macular degeneration;
LUSC	cis	rs2274273	0.905	rs2147961	chr14:55585381	T/C	cg04306507	chr14:55594613	LGALS3	0.56	12.95	0.58	2.27e-31	Protein biomarker;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09213347	chr11:105948576	AASDHPPT;KBTBD3	-0.48	-7.28	-0.37	2.44e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6750047	0.771	rs1056836	chr2:38298203	C/G	cg07380506	chr2:38303506	CYP1B1	-0.47	-6.46	-0.33	3.69e-10	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs16854884	0.802	rs6786460	chr3:143805895	A/G	cg06585982	chr3:143692056	C3orf58	0.45	6.83	0.35	4.14e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg22681709	chr2:178499509	PDE11A	-0.56	-10.64	-0.5	5.72e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs1325195	0.879	rs2793798	chr1:179094843	G/A	cg11624085	chr17:8464688	MYH10	-0.44	-7.37	-0.37	1.32e-12	IgE grass sensitization;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25878452	chr7:6746558	ZNF12	0.77	6.05	0.31	3.98e-9	Cognitive performance;
LUSC	cis	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg06521331	chr12:34319734	NA	-0.42	-6.47	-0.33	3.52e-10	Morning vs. evening chronotype;
LUSC	cis	rs10254118	0.730	rs6961517	chr7:133130940	G/T	cg10665199	chr7:133106180	EXOC4	0.52	7.02	0.36	1.23e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg07741184	chr6:167504864	NA	0.46	8.08	0.4	1.23e-14	Crohn's disease;
LUSC	cis	rs4964805	0.954	rs4964812	chr12:104189615	A/G	cg02344784	chr12:104178138	NT5DC3	0.45	7.15	0.36	5.34e-12	Attention deficit hyperactivity disorder;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg04568116	chr11:72353582	PDE2A	0.43	5.96	0.31	6.28e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg13010199	chr12:38710504	ALG10B	0.4	6.46	0.33	3.79e-10	Morning vs. evening chronotype;
LUSC	cis	rs2742234	0.541	rs7073849	chr10:43740474	G/C	cg15436174	chr10:43711423	RASGEF1A	0.43	7.0	0.36	1.43e-11	Hirschsprung disease;
LUSC	cis	rs3916	0.955	rs2066938	chr12:121160615	A/G	cg27246729	chr12:121163418	ACADS	0.5	7.38	0.37	1.27e-12	Urinary metabolites (H-NMR features);
LUSC	cis	rs4363385	0.835	rs431242	chr1:153050414	G/A	cg00922841	chr1:152955080	SPRR1A	-0.46	-7.74	-0.39	1.23e-13	Inflammatory skin disease;
LUSC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg06454157	chr6:167490870	NA	-0.29	-6.77	-0.35	5.66e-11	Rheumatoid arthritis;
LUSC	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg08798685	chr6:27730294	NA	-0.63	-5.74	-0.3	2.08e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg10172584	chr19:19639581	YJEFN3	-0.46	-5.65	-0.3	3.42e-8	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg16405210	chr4:1374714	KIAA1530	0.53	8.31	0.41	2.35e-15	Obesity-related traits;
LUSC	trans	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.85	-0.35	3.49e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg04756594	chr16:24857601	SLC5A11	0.46	6.86	0.35	3.34e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs3087591	0.922	rs2953013	chr17:29496343	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.6	-8.69	-0.43	1.63e-16	Hip circumference;
LUSC	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	0.79	13.19	0.59	2.85e-32	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs7561273	0.586	rs11892283	chr2:24317850	T/C	cg20701182	chr2:24300061	SF3B14	0.51	6.55	0.34	2.19e-10	Quantitative traits;
LUSC	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg22508957	chr16:3507546	NAT15	0.43	6.21	0.32	1.57e-9	Body mass index (adult);
LUSC	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg22681709	chr2:178499509	PDE11A	-0.46	-6.79	-0.35	5.2e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg13575925	chr12:9217583	LOC144571	0.35	6.31	0.33	8.87e-10	Sjögren's syndrome;
LUSC	cis	rs2970818	0.831	rs73037722	chr12:4573252	T/C	cg11146114	chr12:4671731	NA	-0.64	-6.12	-0.32	2.64e-9	Phosphorus levels;
LUSC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-6.13	-0.32	2.52e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7246967	0.611	rs12978511	chr19:22819216	C/T	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18876405	chr7:65276391	NA	-0.54	-8.52	-0.42	5.73e-16	Aortic root size;
LUSC	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg05738196	chr6:26577821	NA	0.52	8.24	0.41	3.96e-15	Schizophrenia;
LUSC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg17366294	chr4:99064904	C4orf37	0.55	9.59	0.46	2.1e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2742417	1.000	rs2673056	chr3:45737802	C/T	cg09608765	chr3:45636137	LIMD1	-0.37	-7.2	-0.37	4.14e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2346177	1.000	rs2346177	chr2:46642249	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.55	8.81	0.43	6.86e-17	HDL cholesterol;
LUSC	cis	rs9300255	0.739	rs6633	chr12:123745809	G/T	cg13010344	chr12:123464640	ARL6IP4	0.51	6.25	0.32	1.25e-9	Neutrophil percentage of white cells;
LUSC	cis	rs3815700	0.925	rs414496	chr19:33106761	A/G	cg02997394	chr19:33096574	ANKRD27	0.58	6.64	0.34	1.3100000000000001e-10	Eosinophilic esophagitis;
LUSC	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Body mass index;
LUSC	cis	rs7572644	0.679	rs4666012	chr2:28018293	A/G	cg27432699	chr2:27873401	GPN1	0.56	7.27	0.37	2.54e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	8.91	0.44	3.26e-17	Response to bleomycin (chromatid breaks);
LUSC	trans	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg17712092	chr4:129076599	LARP1B	-0.73	-10.28	-0.49	9.91e-22	Breast cancer;
LUSC	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12618769	0.625	rs72821955	chr2:99159792	G/A	cg10123293	chr2:99228465	UNC50	0.47	7.36	0.37	1.45e-12	Bipolar disorder;
LUSC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg17344932	chr17:38183730	MED24;SNORD124	0.37	6.03	0.31	4.26e-9	Self-reported allergy;
LUSC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg20607798	chr8:58055168	NA	0.54	6.22	0.32	1.5e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg11645453	chr3:52864694	ITIH4	0.32	7.46	0.38	7.55e-13	Electroencephalogram traits;
LUSC	cis	rs12210905	1.000	rs76889265	chr6:27008835	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-5.88	-0.31	1.02e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs10761482	0.861	rs10761489	chr10:62108604	G/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.1	-0.36	7.67e-12	Schizophrenia;
LUSC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.98	0.4	2.33e-14	Prudent dietary pattern;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26323130	chr2:149632683	KIF5C	0.48	7.26	0.37	2.69e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.11	-0.36	7.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg00012203	chr2:219082015	ARPC2	-0.7	-11.58	-0.54	2.78e-26	Colorectal cancer;
LUSC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg18827107	chr12:86230957	RASSF9	-0.47	-6.99	-0.36	1.55e-11	Major depressive disorder;
LUSC	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	0.95	11.68	0.54	1.14e-26	Nonalcoholic fatty liver disease;
LUSC	cis	rs7173743	0.816	rs11639335	chr15:79142307	A/G	cg00540400	chr15:79124168	NA	-0.35	-5.87	-0.31	1.03e-8	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18332849	chr19:45682064	BLOC1S3;TRAPPC6A	-0.41	-6.09	-0.32	3.08e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7193541	0.965	rs4402594	chr16:74701360	C/T	cg01733217	chr16:74700730	RFWD3	0.87	15.35	0.64	1.32e-40	Multiple myeloma;
LUSC	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg12927641	chr6:109611667	NA	-0.36	-6.03	-0.31	4.39e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg27205649	chr11:78285834	NARS2	0.48	5.95	0.31	6.88e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg06784218	chr1:46089804	CCDC17	-0.31	-6.08	-0.32	3.36e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg06915202	chr7:98029285	BAIAP2L1	-0.29	-5.71	-0.3	2.51e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6733011	0.559	rs6711022	chr2:99449536	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.4	-5.77	-0.3	1.82e-8	Bipolar disorder;
LUSC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.94	-17.38	-0.69	1.15e-48	Chronic sinus infection;
LUSC	cis	rs10207060	0.500	rs7600350	chr2:240716225	T/C	cg20333904	chr2:240724165	NA	-0.35	-6.08	-0.32	3.26e-9	Obesity-related traits;
LUSC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg23711669	chr6:146136114	FBXO30	0.76	13.58	0.6	9.51e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.12e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.54	-7.98	-0.4	2.36e-14	Response to antineoplastic agents;
LUSC	trans	rs853679	0.607	rs201002	chr6:27808192	A/G	cg06606381	chr12:133084897	FBRSL1	-0.73	-7.87	-0.4	5.09e-14	Depression;
LUSC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg02153584	chr22:29168773	CCDC117	0.64	10.32	0.49	7.61e-22	Lymphocyte counts;
LUSC	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg13010199	chr12:38710504	ALG10B	0.46	6.81	0.35	4.61e-11	Morning vs. evening chronotype;
LUSC	trans	rs62238980	0.614	rs117517889	chr22:32469452	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg01943577	chr7:158741284	NA	-0.4	-5.79	-0.3	1.62e-8	Height;
LUSC	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-15.94	-0.66	5.95e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.87	0.35	3.08e-11	Endometrial cancer;
LUSC	cis	rs62400317	0.859	rs11965706	chr6:45141441	T/A	cg20913747	chr6:44695427	NA	-0.47	-7.55	-0.38	4.28e-13	Total body bone mineral density;
LUSC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-9.7	-0.47	9.34e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg15448220	chr1:150897856	SETDB1	0.43	6.23	0.32	1.43e-9	Melanoma;
LUSC	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.51	-0.42	5.89e-16	Bone mineral density;
LUSC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg06784218	chr1:46089804	CCDC17	0.58	11.44	0.53	8.22e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg00945038	chr17:61921165	SMARCD2	0.54	9.27	0.45	2.34e-18	Prudent dietary pattern;
LUSC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.38	6.63	0.34	1.35e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11966583	chr1:166845478	TADA1	0.47	6.57	0.34	1.97e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg05805236	chr11:65401703	PCNXL3	0.41	6.89	0.35	2.78e-11	Acne (severe);
LUSC	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg19628046	chr18:33552617	C18orf21	0.52	6.34	0.33	7.36e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg26338869	chr17:61819248	STRADA	0.42	6.18	0.32	1.86e-9	Prudent dietary pattern;
LUSC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg07395648	chr5:131743802	NA	-0.42	-6.41	-0.33	5.06e-10	Breast cancer;
LUSC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg22963979	chr7:1858916	MAD1L1	-0.63	-10.22	-0.49	1.68e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs9929218	0.748	rs34592833	chr16:68739125	G/A	cg02972257	chr16:68554789	NA	0.45	5.79	0.3	1.64e-8	Colorectal cancer;
LUSC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg13047869	chr3:10149882	C3orf24	0.56	8.01	0.4	1.93e-14	Alzheimer's disease;
LUSC	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg27432699	chr2:27873401	GPN1	0.8	15.0	0.63	2.94e-39	Oral cavity cancer;
LUSC	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg24558204	chr6:135376177	HBS1L	0.68	10.52	0.5	1.57e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg06697600	chr4:7070879	GRPEL1	0.49	6.86	0.35	3.27e-11	Monocyte percentage of white cells;
LUSC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg19622623	chr12:86230825	RASSF9	-0.44	-6.09	-0.32	3.18e-9	Major depressive disorder;
LUSC	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg08213375	chr14:104286397	PPP1R13B	0.42	7.26	0.37	2.8e-12	Reticulocyte count;
LUSC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg27094323	chr7:1216898	NA	-0.37	-6.55	-0.34	2.21e-10	Longevity;Endometriosis;
LUSC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg16339924	chr4:17578868	LAP3	0.55	8.45	0.42	8.91e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg01256987	chr12:42539512	GXYLT1	0.35	6.4	0.33	5.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg24829409	chr8:58192753	C8orf71	-0.53	-6.17	-0.32	1.96e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00149659	chr3:10157352	C3orf10	0.91	12.44	0.56	1.89e-29	Alzheimer's disease;
LUSC	cis	rs8092503	0.953	rs2052326	chr18:52489444	G/C	cg12377874	chr18:52495404	RAB27B	-0.34	-6.29	-0.33	1.01e-9	Childhood body mass index;
LUSC	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	5.82	0.3	1.35e-8	Neuroticism;
LUSC	trans	rs961253	0.556	rs1160794	chr20:6330480	G/C	cg21095983	chr6:86352623	SYNCRIP	0.45	6.78	0.35	5.62e-11	Colorectal cancer;
LUSC	cis	rs12594711	1	rs12594711	chr15:78793921	C/T	cg18825076	chr15:78729989	IREB2	-0.43	-6.82	-0.35	4.31e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg05872129	chr22:39784769	NA	-0.61	-11.71	-0.54	9.43e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg18232548	chr7:50535776	DDC	-0.49	-6.79	-0.35	5.19e-11	Malaria;
LUSC	trans	rs1325195	0.537	rs61821690	chr1:179188006	C/T	cg11624085	chr17:8464688	MYH10	0.43	6.38	0.33	5.94e-10	IgE grass sensitization;
LUSC	cis	rs965469	0.895	rs6037592	chr20:3392950	T/G	cg25506879	chr20:3388711	C20orf194	-0.53	-5.76	-0.3	1.94e-8	IFN-related cytopenia;
LUSC	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg15654264	chr1:150340011	RPRD2	-0.65	-11.03	-0.52	2.44e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg24642844	chr7:1081250	C7orf50	-0.62	-6.14	-0.32	2.41e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-6.29	-0.33	9.76e-10	Electroencephalogram traits;
LUSC	cis	rs6540559	0.546	rs74991018	chr1:210033790	T/G	cg23283495	chr1:209979779	IRF6	0.67	7.92	0.4	3.5e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg14019146	chr3:50243930	SLC38A3	-0.37	-8.48	-0.42	7.13e-16	Body mass index;
LUSC	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg25664220	chr3:72788482	NA	-0.69	-11.54	-0.53	3.7e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg27398817	chr8:82754497	SNX16	-0.51	-6.79	-0.35	5.01e-11	Diastolic blood pressure;
LUSC	cis	rs4845459	0.967	rs1581803	chr1:152592281	A/C	cg08895932	chr1:152778580	LCE1C	0.36	6.28	0.32	1.08e-9	Psoriasis;
LUSC	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg00310523	chr12:86230176	RASSF9	0.43	7.73	0.39	1.24e-13	Major depressive disorder;
LUSC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg22166914	chr1:53195759	ZYG11B	0.69	11.84	0.54	2.93e-27	Monocyte count;
LUSC	cis	rs3820928	1.000	rs7579961	chr2:227776976	T/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.98	-0.4	2.36e-14	Pulmonary function;
LUSC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	11.85	0.54	2.86e-27	Cognitive test performance;
LUSC	cis	rs17661538	0.542	rs12779075	chr10:18427010	G/A	cg03634479	chr10:18430412	CACNB2	0.61	5.94	0.31	7.32e-9	Response to antipsychotic treatment;
LUSC	cis	rs10905065	1.000	rs10905065	chr10:5769827	C/T	cg11519256	chr10:5708881	ASB13	0.42	6.31	0.33	9.1e-10	Menopause (age at onset);
LUSC	trans	rs1375144	0.676	rs12711825	chr2:116168072	G/T	cg02581963	chr10:102133317	C10orf75	-0.38	-5.99	-0.31	5.44e-9	Bipolar disorder;
LUSC	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg26102564	chr10:131424627	MGMT	0.4	6.2	0.32	1.62e-9	Response to temozolomide;
LUSC	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg17252645	chr8:143867129	LY6D	-0.55	-10.25	-0.49	1.31e-21	Urinary tract infection frequency;
LUSC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg19302996	chr17:73780495	UNK	-0.51	-7.32	-0.37	1.83e-12	White matter hyperintensity burden;
LUSC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg10802521	chr3:52805072	NEK4	-0.54	-7.13	-0.36	6.22e-12	Bipolar disorder;
LUSC	trans	rs6841433	0.615	rs79776742	chr4:115471351	A/G	cg01865118	chr8:29204221	DUSP4	-0.51	-5.97	-0.31	5.93e-9	Hemoglobin concentration;
LUSC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-6.18	-0.32	1.89e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.35	-19.01	-0.72	3.8e-55	Hip circumference adjusted for BMI;
LUSC	cis	rs2567992	0.821	rs1169721	chr12:121641509	A/G	cg19357999	chr12:121661762	P2RX4	0.49	6.29	0.33	1.02e-9	Left ventricular obstructive tract defect (inherited effect);
LUSC	trans	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg10756647	chr7:56101905	PSPH	0.87	8.39	0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.69	0.34	9.48e-11	Schizophrenia;
LUSC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.78	0.35	5.46e-11	Tonsillectomy;
LUSC	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	1.16	18.4	0.71	1.09e-52	Primary sclerosing cholangitis;
LUSC	cis	rs6681460	0.966	rs2025595	chr1:67152499	G/A	cg02459107	chr1:67143332	SGIP1	0.5	9.17	0.45	5.14e-18	Presence of antiphospholipid antibodies;
LUSC	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg05738196	chr6:26577821	NA	0.78	14.77	0.63	2.49e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-5.65	-0.3	3.48e-8	IgG glycosylation;
LUSC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11764359	chr7:65958608	NA	0.61	9.19	0.45	4.28e-18	Aortic root size;
LUSC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg14440974	chr22:39074834	NA	0.37	6.22	0.32	1.53e-9	Menopause (age at onset);
LUSC	cis	rs56399783	0.901	rs11761804	chr7:2792524	C/T	cg19731401	chr7:2775893	GNA12	0.74	8.48	0.42	7.58e-16	Childhood ear infection;
LUSC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	10.0	0.48	8.85e-21	Personality dimensions;
LUSC	cis	rs9359856	0.564	rs10484885	chr6:90395016	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.53	-0.42	5.15e-16	Bipolar disorder;
LUSC	trans	rs9561329	0.528	rs1323986	chr13:93999772	A/G	cg25981597	chr2:197504344	CCDC150	0.47	6.2	0.32	1.68e-9	Neuroticism (age interaction);
LUSC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg25258033	chr6:167368657	RNASET2	0.43	6.91	0.35	2.52e-11	Crohn's disease;
LUSC	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg17411546	chr10:75410026	SYNPO2L	-0.51	-7.82	-0.39	7.12e-14	Inflammatory bowel disease;
LUSC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11764359	chr7:65958608	NA	-0.79	-12.98	-0.58	1.74e-31	Aortic root size;
LUSC	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	10.13	0.48	3.27e-21	Lymphocyte counts;
LUSC	cis	rs7106204	0.748	rs12273426	chr11:24212058	T/C	ch.11.24196551F	chr11:24239977	NA	1.11	12.47	0.56	1.48e-29	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	7.44	0.38	8.62e-13	Iron status biomarkers;
LUSC	cis	rs2658782	0.789	rs2605580	chr11:93147054	C/T	cg15737290	chr11:93063684	CCDC67	0.64	7.97	0.4	2.49e-14	Pulmonary function decline;
LUSC	trans	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg26043149	chr18:55253948	FECH	0.5	7.33	0.37	1.76e-12	Bone mineral density;
LUSC	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.22	-0.32	1.52e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg04865166	chr7:105162814	PUS7	0.52	5.67	0.3	3.03e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.38	-6.23	-0.32	1.39e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg24675056	chr1:15929824	NA	0.49	8.45	0.42	8.94e-16	Systolic blood pressure;
LUSC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg08499158	chr17:42289980	UBTF	-0.51	-8.28	-0.41	3.03e-15	Total body bone mineral density;
LUSC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.69	11.94	0.55	1.37e-27	Alcohol dependence;
LUSC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.9	16.97	0.68	5.35e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-0.56	-8.65	-0.43	2.28e-16	Breast cancer;
LUSC	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg10792982	chr14:105748885	BRF1	0.49	8.96	0.44	2.38e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	22.52	0.78	5.67e-69	Height;
LUSC	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg02569458	chr12:86230093	RASSF9	0.49	8.22	0.41	4.69e-15	Major depressive disorder;
LUSC	cis	rs10504073	0.669	rs11779189	chr8:50030592	C/G	cg00325661	chr8:49890786	NA	-0.56	-9.58	-0.46	2.38e-19	Blood metabolite ratios;
LUSC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg03929089	chr4:120376271	NA	-0.52	-5.95	-0.31	6.89e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg19266014	chr7:2183958	MAD1L1	-0.35	-5.88	-0.31	1e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg04317338	chr11:64019027	PLCB3	0.66	7.34	0.37	1.6e-12	Mean platelet volume;
LUSC	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.22	-0.32	1.52e-9	Sudden cardiac arrest;
LUSC	cis	rs9807989	0.507	rs10208196	chr2:102996345	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.11	0.36	7.27e-12	Asthma;
LUSC	cis	rs12579753	0.597	rs2244802	chr12:82153749	C/G	cg21231944	chr12:82153410	PPFIA2	0.35	5.84	0.3	1.21e-8	Resting heart rate;
LUSC	cis	rs17540621	1.000	rs116079162	chr2:47230808	C/T	cg23978866	chr2:47230407	TTC7A	-0.97	-6.63	-0.34	1.38e-10	Response to statin therapy;
LUSC	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	0.99	19.34	0.73	1.98e-56	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.78	-13.02	-0.58	1.25e-31	Aortic root size;
LUSC	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.43	0.53	9.68e-26	Eye color traits;
LUSC	trans	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg13010199	chr12:38710504	ALG10B	-0.4	-6.02	-0.31	4.52e-9	Morning vs. evening chronotype;
LUSC	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg10547527	chr2:198650123	BOLL	-0.49	-5.72	-0.3	2.4e-8	Ulcerative colitis;
LUSC	trans	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-13.16	-0.58	3.69e-32	Colorectal cancer;
LUSC	cis	rs6977660	0.714	rs4721824	chr7:19785898	A/G	cg07541023	chr7:19748670	TWISTNB	0.67	6.71	0.34	8.19e-11	Thyroid stimulating hormone;
LUSC	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg24881330	chr22:46731750	TRMU	0.67	8.01	0.4	1.94e-14	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg04586622	chr2:25135609	ADCY3	0.37	7.8	0.39	7.84e-14	Body mass index in non-asthmatics;
LUSC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.59	10.71	0.51	3.25e-23	Homoarginine levels;
LUSC	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg13010199	chr12:38710504	ALG10B	0.66	10.0	0.48	9.42e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg23630131	chr7:65973040	NA	-0.2	-5.67	-0.3	3.05e-8	Aortic root size;
LUSC	cis	rs6942756	1.000	rs66538149	chr7:128974061	G/A	cg02491457	chr7:128862824	NA	-0.47	-6.31	-0.33	9.1e-10	White matter hyperintensity burden;
LUSC	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.37	-0.37	1.38e-12	Neuroticism;
LUSC	cis	rs11608355	1.000	rs11066523	chr12:109851899	A/G	cg19025524	chr12:109796872	NA	0.39	6.22	0.32	1.53e-9	Neuroticism;
LUSC	cis	rs977987	0.866	rs17696831	chr16:75493298	C/G	cg04384234	chr16:75411784	CFDP1	-0.48	-7.87	-0.4	5.05e-14	Dupuytren's disease;
LUSC	cis	rs7605827	0.681	rs63106161	chr2:15537726	T/C	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs9815354	0.767	rs73073342	chr3:41839455	A/C	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.05	0.64	1.96e-39	Platelet count;
LUSC	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg01191920	chr7:158217561	PTPRN2	0.43	8.45	0.42	9.08e-16	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.35	0.76	2.22e-64	Prudent dietary pattern;
LUSC	cis	rs4654899	0.827	rs12564330	chr1:21207495	A/C	cg01072550	chr1:21505969	NA	0.5	7.64	0.39	2.27e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg02751453	chr18:77725136	HSBP1L1	0.41	5.65	0.3	3.41e-8	Opioid sensitivity;
LUSC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg06454157	chr6:167490870	NA	-0.25	-6.03	-0.31	4.28e-9	Crohn's disease;
LUSC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.99	-0.31	5.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs780094	0.500	rs74175068	chr2:27833502	T/C	cg27432699	chr2:27873401	GPN1	0.41	5.87	0.31	1.07e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.92	11.91	0.55	1.72e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg15848620	chr12:58087721	OS9	-0.52	-7.41	-0.38	1.02e-12	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg15534755	chr11:117069859	TAGLN	0.35	5.99	0.31	5.53e-9	Blood protein levels;
LUSC	cis	rs2227564	0.597	rs12256103	chr10:75545251	A/G	cg23231163	chr10:75533350	FUT11	-0.47	-6.93	-0.35	2.11e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs4942242	0.617	rs9590778	chr13:44199007	C/G	cg19169023	chr15:41853346	TYRO3	-0.61	-9.17	-0.45	4.87e-18	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg00540400	chr15:79124168	NA	-0.47	-8.15	-0.41	7.33e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9322817	0.691	rs2499664	chr6:105301484	C/G	cg02098413	chr6:105308735	HACE1	0.27	5.68	0.3	2.95e-8	Thyroid stimulating hormone;
LUSC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.54	-8.13	-0.41	8.35e-15	Lymphocyte counts;
LUSC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18252515	chr7:66147081	NA	-0.4	-5.73	-0.3	2.2e-8	Aortic root size;
LUSC	cis	rs9815354	0.680	rs17218936	chr3:42019392	C/T	cg03022575	chr3:42003672	ULK4	0.76	7.6	0.38	3e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	0.91	13.51	0.59	1.7e-33	Breast cancer;
LUSC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg25019033	chr10:957182	NA	-0.54	-6.9	-0.35	2.65e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg16342193	chr10:102329863	NA	-0.36	-6.76	-0.35	6.34e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.79	11.8	0.54	4.37e-27	Corneal astigmatism;
LUSC	trans	rs2229238	0.911	rs7551873	chr1:154505857	A/G	cg25273160	chr11:56955011	LRRC55	-0.31	-6.0	-0.31	5.19e-9	Coronary heart disease;
LUSC	cis	rs11158026	0.790	rs1107960	chr14:55384340	T/A	cg04306507	chr14:55594613	LGALS3	0.32	6.09	0.32	3.15e-9	Parkinson's disease;
LUSC	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	0.57	8.82	0.43	6.68e-17	Breast cancer;
LUSC	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.76	-0.39	1.07e-13	Blood metabolite levels;
LUSC	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-0.9	-17.81	-0.7	2.42e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg02023728	chr11:77925099	USP35	-0.43	-6.53	-0.34	2.41e-10	Testicular germ cell tumor;
LUSC	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg16744531	chr19:17905626	B3GNT3	0.46	6.8	0.35	4.74e-11	Tumor biomarkers;
LUSC	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg01620082	chr3:125678407	NA	-0.79	-7.53	-0.38	4.89e-13	Depression;
LUSC	cis	rs2029213	0.523	rs2035450	chr3:53269317	C/T	cg16894138	chr3:53270350	TKT	0.32	7.11	0.36	7.18e-12	Heart rate;
LUSC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	1.01	18.62	0.71	1.43e-53	Cognitive function;
LUSC	cis	rs6840360	1.000	rs6838966	chr4:152603475	C/T	cg22705602	chr4:152727874	NA	-0.27	-5.9	-0.31	8.83e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs4714291	0.698	rs9296321	chr6:40118352	C/T	cg02267698	chr19:7991119	CTXN1	-0.52	-7.9	-0.4	4.01e-14	Strep throat;
LUSC	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg21427119	chr20:30132790	HM13	-0.36	-5.67	-0.3	3.14e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12016809	chr21:47604291	C21orf56	0.47	6.89	0.35	2.79e-11	Testicular germ cell tumor;
LUSC	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	1.41	17.72	0.7	5.44e-50	Atopic dermatitis;
LUSC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.53	-7.18	-0.37	4.58e-12	Longevity;Endometriosis;
LUSC	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.0	-0.44	1.74e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2274273	0.840	rs10142448	chr14:55838108	G/T	cg04306507	chr14:55594613	LGALS3	-0.54	-11.71	-0.54	8.73e-27	Protein biomarker;
LUSC	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg24558204	chr6:135376177	HBS1L	0.69	10.73	0.51	2.87e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.42	-0.5	3.32e-22	Alzheimer's disease;
LUSC	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg13010199	chr12:38710504	ALG10B	0.55	8.49	0.42	6.68e-16	Morning vs. evening chronotype;
LUSC	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg27631724	chr1:11040367	C1orf127	0.52	9.04	0.44	1.31e-17	Ewing sarcoma;
LUSC	cis	rs7106204	0.514	rs11027789	chr11:24260906	T/C	ch.11.24196551F	chr11:24239977	NA	0.82	8.33	0.41	2.17e-15	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-17.65	-0.69	9.78e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg19508488	chr2:152266495	RIF1	0.54	7.73	0.39	1.23e-13	Lung cancer;
LUSC	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg14458575	chr2:238380390	NA	0.68	11.78	0.54	4.99e-27	Prostate cancer;
LUSC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg01448562	chr3:133502909	NA	-0.67	-10.96	-0.51	4.51e-24	Iron status biomarkers;
LUSC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg14668632	chr7:2872130	GNA12	-0.47	-7.43	-0.38	9.26e-13	Height;
LUSC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs2108225	0.714	rs929393	chr7:107437048	C/T	cg18560240	chr7:107437656	SLC26A3	-0.44	-6.88	-0.35	2.88e-11	Ulcerative colitis;
LUSC	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	7.23	0.37	3.22e-12	Monocyte count;
LUSC	cis	rs4953404	0.613	rs930853	chr2:46898849	A/G	cg09399716	chr2:46890238	NA	-0.3	-6.62	-0.34	1.42e-10	Pulse pressure (alcohol consumption interaction);
LUSC	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg24675056	chr1:15929824	NA	0.44	7.65	0.39	2.11e-13	Systolic blood pressure;
LUSC	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	1.08	14.54	0.62	1.95e-37	Nonalcoholic fatty liver disease;
LUSC	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg05283184	chr6:79620031	NA	-0.57	-12.03	-0.55	6.25e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg24558204	chr6:135376177	HBS1L	0.59	9.24	0.45	2.88e-18	Red blood cell count;
LUSC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg09021430	chr5:549028	NA	-0.53	-7.24	-0.37	3.18e-12	Obesity-related traits;
LUSC	cis	rs1595825	0.891	rs73058876	chr2:198895022	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-6.25	-0.32	1.23e-9	Ulcerative colitis;
LUSC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg05347473	chr6:146136440	FBXO30	0.57	10.03	0.48	7.41e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.48	-6.96	-0.36	1.86e-11	Iron status biomarkers;
LUSC	cis	rs6484504	0.576	rs158140	chr11:31212971	T/C	cg26647111	chr11:31128758	NA	-0.42	-6.03	-0.31	4.44e-9	Red blood cell count;
LUSC	cis	rs60154123	0.772	rs845452	chr1:210417861	C/T	cg22029157	chr1:209979665	IRF6	0.65	6.49	0.33	3.08e-10	Coronary artery disease;
LUSC	cis	rs28829049	0.566	rs59681755	chr1:19528985	G/A	cg13387374	chr1:19411106	UBR4	0.46	6.37	0.33	6.31e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	trans	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg14791747	chr16:20752902	THUMPD1	0.73	9.55	0.46	2.84e-19	Cognitive test performance;
LUSC	cis	rs7590368	0.715	rs7587453	chr2:10961390	A/G	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg26513180	chr16:89883248	FANCA	-0.53	-7.82	-0.39	7.21e-14	Vitiligo;
LUSC	cis	rs9831754	0.654	rs9837024	chr3:78451637	C/T	cg06138941	chr3:78371609	NA	0.55	7.18	0.37	4.47e-12	Calcium levels;
LUSC	cis	rs11971779	1.000	rs75919582	chr7:139054919	G/A	cg07862535	chr7:139043722	LUC7L2	0.73	8.06	0.4	1.39e-14	Diisocyanate-induced asthma;
LUSC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg09455208	chr3:40491958	NA	0.5	8.71	0.43	1.42e-16	Renal cell carcinoma;
LUSC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-1.05	-14.76	-0.63	2.55e-38	Vitiligo;
LUSC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg16414030	chr3:133502952	NA	-0.44	-6.99	-0.36	1.54e-11	Iron status biomarkers;
LUSC	trans	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg26043149	chr18:55253948	FECH	0.47	7.28	0.37	2.43e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.67	11.22	0.52	5.3e-25	Bone mineral density;
LUSC	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg21475434	chr5:93447410	FAM172A	-0.41	-5.65	-0.3	3.38e-8	Diabetic retinopathy;
LUSC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg20503657	chr10:835505	NA	0.46	6.26	0.32	1.19e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs79387448	0.745	rs1159509	chr2:103169073	T/A	cg09003973	chr2:102972529	NA	0.89	8.63	0.43	2.45e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg22532475	chr10:104410764	TRIM8	-0.35	-6.8	-0.35	4.95e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12760731	0.623	rs10913541	chr1:178347714	G/A	cg00404053	chr1:178313656	RASAL2	0.48	5.82	0.3	1.38e-8	Obesity-related traits;
LUSC	cis	rs365132	0.875	rs4976665	chr5:176352736	C/T	cg25401027	chr5:176370377	UIMC1	0.36	5.85	0.31	1.15e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	0.85	13.97	0.61	3.14e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	trans	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg26384229	chr12:38710491	ALG10B	0.68	10.67	0.5	4.61e-23	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10189605	chr6:58287430	GUSBL2	0.42	6.52	0.34	2.6200000000000003e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs72960926	0.744	rs952120	chr6:74917250	T/G	cg03266952	chr6:74778945	NA	-0.82	-6.74	-0.35	6.85e-11	Metabolite levels (MHPG);
LUSC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.08	-0.32	3.31e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs7838490	0.780	rs74584457	chr8:89691016	T/G	cg24558378	chr1:183589673	NA	0.34	6.27	0.32	1.09e-9	Body mass index and cholesterol (psychopharmacological treatment);
LUSC	cis	rs62400317	0.826	rs62438867	chr6:45049787	G/A	cg18551225	chr6:44695536	NA	-0.42	-6.82	-0.35	4.17e-11	Total body bone mineral density;
LUSC	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg27411982	chr8:10470053	RP1L1	0.42	6.48	0.33	3.29e-10	Neuroticism;
LUSC	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-1.13	-18.17	-0.71	8.74e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7804356	1.000	rs12537323	chr7:26854388	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg06718696	chr17:78121285	EIF4A3	0.44	6.34	0.33	7.44e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs9943753	0.508	rs7958071	chr12:109836089	G/A	cg19025524	chr12:109796872	NA	-0.38	-6.89	-0.35	2.77e-11	HDL cholesterol;
LUSC	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs713477	0.505	rs8019209	chr14:55891329	C/T	cg13175173	chr14:55914753	NA	-0.31	-6.0	-0.31	5.09e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.75	14.7	0.63	4.6e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg08213375	chr14:104286397	PPP1R13B	0.44	7.56	0.38	3.97e-13	Reticulocyte count;
LUSC	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26818010	chr10:134567672	INPP5A	-0.85	-11.2	-0.52	6.04e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg07828024	chr6:149772892	ZC3H12D	-0.33	-7.24	-0.37	3.16e-12	Dupuytren's disease;
LUSC	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg22563815	chr15:78856949	CHRNA5	0.27	6.41	0.33	4.82e-10	Sudden cardiac arrest;
LUSC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg14558114	chr2:88469736	THNSL2	0.78	7.07	0.36	9.21e-12	Plasma clusterin levels;
LUSC	cis	rs4930561	0.677	rs7946212	chr11:67982187	T/A	cg04465784	chr11:67976953	SUV420H1	-0.29	-5.78	-0.3	1.7e-8	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg23719950	chr11:63933701	MACROD1	-0.62	-8.08	-0.4	1.21e-14	Mean platelet volume;
LUSC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg21918786	chr6:109611834	NA	-0.38	-6.47	-0.33	3.45e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg10172584	chr19:19639581	YJEFN3	-0.5	-5.9	-0.31	8.98e-9	Bipolar disorder;
LUSC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.84	0.39	6.15e-14	Parkinson's disease;
LUSC	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.7	10.91	0.51	6.34e-24	Breast cancer;
LUSC	cis	rs8067287	0.762	rs11650981	chr17:16824038	A/G	cg26910001	chr17:16838321	NA	-0.48	-6.27	-0.32	1.11e-9	Diabetic kidney disease;
LUSC	cis	rs8113142	0.668	rs55933947	chr19:29104647	A/T	cg04546413	chr19:29218101	NA	0.43	5.9	0.31	8.86e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.73	12.11	0.55	3.07e-28	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7254114	0.578	rs4804574	chr19:11317482	G/A	cg02815516	chr19:11306319	KANK2	0.4	8.23	0.41	4.16e-15	Immature fraction of reticulocytes;
LUSC	cis	rs954108	0.809	rs1592059	chr13:29368961	G/A	cg11788234	chr13:29393811	NA	-0.38	-6.68	-0.34	1.01e-10	Obesity-related traits;
LUSC	cis	rs12760731	0.720	rs12039605	chr1:178433368	C/T	cg00404053	chr1:178313656	RASAL2	0.59	6.28	0.33	1.02e-9	Obesity-related traits;
LUSC	cis	rs3931020	0.688	rs455032	chr1:75196488	C/T	cg21906852	chr1:75198582	TYW3;CRYZ	-0.44	-5.78	-0.3	1.69e-8	Resistin levels;
LUSC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.48	0.53	6.19e-26	Prudent dietary pattern;
LUSC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06634786	chr22:41940651	POLR3H	0.51	6.1	0.32	2.91e-9	Vitiligo;
LUSC	cis	rs9535307	0.696	rs9535305	chr13:50290415	A/T	cg04663916	chr13:50265991	EBPL	0.49	5.71	0.3	2.44e-8	Obesity-related traits;
LUSC	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg21775007	chr8:11205619	TDH	0.71	11.47	0.53	6.73e-26	Retinal vascular caliber;
LUSC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.83	0.63	1.46e-38	Platelet count;
LUSC	cis	rs6845621	0.727	rs4697203	chr4:18920661	G/A	cg12196642	chr4:18937545	NA	-0.35	-6.55	-0.34	2.22e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9309473	0.615	rs11680965	chr2:73725916	G/T	cg20560298	chr2:73613845	ALMS1	-0.55	-6.53	-0.34	2.47e-10	Metabolite levels;
LUSC	cis	rs11997175	0.545	rs67960786	chr8:33668770	G/A	ch.8.33884649F	chr8:33765107	NA	0.5	7.17	0.37	4.86e-12	Body mass index;
LUSC	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg05855489	chr10:104503620	C10orf26	0.54	7.86	0.4	5.41e-14	Arsenic metabolism;
LUSC	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg18681998	chr4:17616180	MED28	0.84	15.56	0.65	1.86e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg13010199	chr12:38710504	ALG10B	0.46	6.46	0.33	3.7e-10	Resting heart rate;
LUSC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg12463550	chr7:65579703	CRCP	0.51	7.32	0.37	1.85e-12	Aortic root size;
LUSC	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg12552261	chr5:112820674	MCC	-0.44	-7.02	-0.36	1.25e-11	Type 2 diabetes;
LUSC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg22618164	chr12:122356400	WDR66	0.55	7.77	0.39	9.9e-14	Mean corpuscular volume;
LUSC	cis	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg06521331	chr12:34319734	NA	-0.45	-7.37	-0.37	1.36e-12	Morning vs. evening chronotype;
LUSC	cis	rs250677	0.522	rs919730	chr5:148352401	T/C	cg18129178	chr5:148520854	ABLIM3	0.51	7.14	0.36	5.79e-12	Breast cancer;
LUSC	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg12863693	chr15:85201151	NMB	0.42	8.43	0.42	1.05e-15	Schizophrenia;
LUSC	cis	rs2274273	1.000	rs8011834	chr14:55625977	A/C	cg04306507	chr14:55594613	LGALS3	0.57	13.54	0.6	1.36e-33	Protein biomarker;
LUSC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg13395646	chr4:1353034	KIAA1530	-0.59	-9.2	-0.45	4.06e-18	Obesity-related traits;
LUSC	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.86	14.6	0.62	1.12e-37	Bladder cancer;
LUSC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg21017887	chr14:105400489	NA	0.68	12.95	0.58	2.24e-31	Rheumatoid arthritis;
LUSC	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg00042356	chr1:8021962	PARK7	0.59	6.96	0.36	1.82e-11	Inflammatory bowel disease;
LUSC	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg13902645	chr11:5959945	NA	-0.54	-7.82	-0.39	6.85e-14	DNA methylation (variation);
LUSC	trans	rs6445525	1.000	rs9860098	chr3:65992808	A/G	cg12639933	chr12:57626296	SHMT2	0.34	6.12	0.32	2.65e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.52	-0.5	1.49e-22	Chronic sinus infection;
LUSC	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg22571038	chr17:48585470	MYCBPAP	0.51	6.42	0.33	4.75e-10	Visceral fat;
LUSC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg14092988	chr3:52407081	DNAH1	0.31	5.92	0.31	8.21e-9	Bipolar disorder;
LUSC	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-12.45	-0.56	1.77e-29	Electrocardiographic conduction measures;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15227275	chr13:49107436	RCBTB2	0.49	7.61	0.38	2.91e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	13.01	0.58	1.35e-31	Bipolar disorder;
LUSC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg16325326	chr1:53192061	ZYG11B	-0.97	-19.53	-0.73	3.44e-57	Monocyte count;
LUSC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.41	0.42	1.2e-15	Prudent dietary pattern;
LUSC	cis	rs9326248	0.861	rs7931335	chr11:117036805	C/T	cg26566898	chr11:117069891	TAGLN	0.38	6.09	0.32	3.16e-9	Blood protein levels;
LUSC	cis	rs10979	1.000	rs1416206	chr6:143889385	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs9788682	0.747	rs938682	chr15:78896547	A/G	cg06917634	chr15:78832804	PSMA4	-0.5	-6.47	-0.33	3.53e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg21211680	chr2:198530	NA	0.35	5.76	0.3	1.9e-8	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7572733	0.555	rs6729473	chr2:198763928	G/A	cg00792783	chr2:198669748	PLCL1	0.46	6.13	0.32	2.47e-9	Dermatomyositis;
LUSC	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg17691542	chr6:26056736	HIST1H1C	0.5	7.26	0.37	2.72e-12	Height;
LUSC	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.14	0.41	8.09e-15	Axial length;
LUSC	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg17376030	chr22:41985996	PMM1	-0.43	-5.82	-0.3	1.39e-8	Cannabis dependence symptom count;
LUSC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.67	-11.71	-0.54	8.94e-27	Lung cancer;
LUSC	cis	rs7809950	0.953	rs2237670	chr7:107131485	A/G	cg23024343	chr7:107201750	COG5	-0.55	-8.81	-0.43	7.13e-17	Coronary artery disease;
LUSC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.82	-0.3	1.38e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs981844	1.000	rs2118862	chr4:154657782	A/T	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.25	0.45	2.66e-18	Prudent dietary pattern;
LUSC	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.79	-12.43	-0.56	2.13e-29	Metabolic syndrome;
LUSC	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	14.96	0.63	4.25e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs4663866	1.000	rs2304668	chr2:239168448	G/A	cg16914508	chr2:239161102	PER2	0.65	6.76	0.35	6.17e-11	Irritable bowel syndrome;
LUSC	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg15704280	chr7:45808275	SEPT13	0.73	8.21	0.41	4.83e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.75	-0.35	6.52e-11	Lung cancer;
LUSC	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg27529037	chr20:44575021	PCIF1	0.42	7.36	0.37	1.43e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10679755	chr3:146262421	PLSCR1	-0.42	-6.23	-0.32	1.44e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4474465	0.646	rs10793334	chr11:78278792	C/T	cg27205649	chr11:78285834	NARS2	-0.59	-7.4	-0.38	1.14e-12	Alzheimer's disease (survival time);
LUSC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.94	-0.81	2.8e-78	Height;
LUSC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg09359103	chr1:154839909	KCNN3	0.58	11.93	0.55	1.48e-27	Prostate cancer;
LUSC	cis	rs13394619	1.000	rs13394619	chr2:11727507	A/G	cg07314298	chr2:11723111	GREB1	0.57	10.21	0.49	1.7e-21	Endometriosis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17913451	chr14:58619030	C14orf37	-0.47	-6.14	-0.32	2.29e-9	Hepatitis;
LUSC	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg21827317	chr3:136751795	NA	0.39	6.96	0.36	1.84e-11	Neuroticism;
LUSC	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg27411982	chr8:10470053	RP1L1	0.39	6.02	0.31	4.7e-9	Neuroticism;
LUSC	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-15.62	-0.65	1.1e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-1.13	-17.64	-0.69	1.06e-49	Exhaled nitric oxide output;
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	0.86	15.58	0.65	1.6e-41	Menarche (age at onset);
LUSC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg00049323	chr5:472564	LOC25845	-0.44	-6.8	-0.35	4.79e-11	Cystic fibrosis severity;
LUSC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.46	-0.38	7.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21023052	chr2:27009110	CENPA	-0.4	-5.96	-0.31	6.46e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08280861	chr8:58055591	NA	0.56	5.98	0.31	5.87e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6977660	1.000	rs5017193	chr7:19820103	G/A	cg05791153	chr7:19748676	TWISTNB	0.52	5.78	0.3	1.69e-8	Thyroid stimulating hormone;
LUSC	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg14092571	chr14:90743983	NA	-0.36	-5.95	-0.31	6.68e-9	Mortality in heart failure;
LUSC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22442454	chr1:209979470	IRF6	0.45	5.97	0.31	6.07e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs870825	0.616	rs28558715	chr4:185627761	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.77e-32	Blood protein levels;
LUSC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg16797656	chr11:68205561	LRP5	-0.38	-6.26	-0.32	1.18e-9	Total body bone mineral density;
LUSC	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-7.0	-0.36	1.44e-11	Axial length;
LUSC	cis	rs12973672	1.000	rs2280747	chr19:35770064	C/T	cg12095397	chr19:35769544	USF2	0.44	6.86	0.35	3.42e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.61	0.34	1.5e-10	Menopause (age at onset);
LUSC	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg14196790	chr5:131705035	SLC22A5	-0.41	-6.72	-0.34	8e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs939574	0.676	rs12694457	chr2:220134010	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.69	-6.74	-0.35	6.88e-11	Platelet distribution width;
LUSC	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	6.78	0.35	5.41e-11	Height;
LUSC	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg09165964	chr15:75287851	SCAMP5	0.54	7.92	0.4	3.53e-14	Breast cancer;
LUSC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.56	0.53	3.14e-26	Menopause (age at onset);
LUSC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17467752	chr17:38218738	THRA	-0.7	-11.21	-0.52	5.91e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.4	0.42	1.27e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg11861562	chr11:117069780	TAGLN	0.34	6.59	0.34	1.76e-10	Blood protein levels;
LUSC	cis	rs13089785	0.791	rs16834826	chr3:123584488	C/T	cg01860459	chr3:123419554	MYLK	-0.34	-5.73	-0.3	2.27e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg09034736	chr1:150693464	HORMAD1	0.51	7.51	0.38	5.57e-13	Tonsillectomy;
LUSC	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg08017756	chr2:100939284	LONRF2	-0.44	-8.33	-0.41	2.09e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.01	-0.36	1.36e-11	Triglycerides;
LUSC	cis	rs1003719	0.715	rs7277820	chr21:38580309	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-9.98	-0.48	1.08e-20	Eye color traits;
LUSC	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg23280166	chr11:118938394	VPS11	0.48	7.64	0.39	2.27e-13	Coronary artery disease;
LUSC	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg16482183	chr6:26056742	HIST1H1C	0.53	7.53	0.38	4.66e-13	Iron status biomarkers;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13630845	chr19:16682861	SLC35E1	0.77	6.92	0.35	2.32e-11	Cognitive performance;
LUSC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg09165964	chr15:75287851	SCAMP5	0.46	6.65	0.34	1.23e-10	Caffeine consumption;
LUSC	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.5	7.74	0.39	1.23e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.61	9.6	0.47	1.96e-19	Neuroticism;
LUSC	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06636551	chr8:101224915	SPAG1	-0.45	-8.26	-0.41	3.54e-15	Atrioventricular conduction;
LUSC	cis	rs909341	0.710	rs2297433	chr20:62293460	T/C	cg09650180	chr20:62225654	GMEB2	0.45	5.83	0.3	1.33e-8	Atopic dermatitis;
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg25703541	chr22:24373054	LOC391322	-0.89	-14.49	-0.62	2.87e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg15704280	chr7:45808275	SEPT13	-0.45	-6.38	-0.33	5.91e-10	HDL cholesterol;
LUSC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg07716408	chr11:68623521	NA	-0.3	-5.78	-0.3	1.69e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9359856	0.564	rs72915904	chr6:90421412	C/A	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.89	-0.44	4e-17	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.4	0.56	2.7e-29	Prudent dietary pattern;
LUSC	cis	rs9362426	1.000	rs406900	chr6:88085447	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	6.19	0.32	1.8e-9	Depressive episodes in bipolar disorder;
LUSC	cis	rs3931020	0.657	rs7522428	chr1:75178360	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.46	5.79	0.3	1.6e-8	Resistin levels;
LUSC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.2	-0.32	1.62e-9	Monocyte count;
LUSC	cis	rs6060717	0.610	rs2244883	chr20:34620896	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-6.37	-0.33	6.35e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs9905704	0.918	rs369184	chr17:56709086	C/T	cg12560992	chr17:57184187	TRIM37	0.55	7.78	0.39	9.1e-14	Testicular germ cell tumor;
LUSC	cis	rs72949976	1.000	rs6747328	chr2:214032156	C/G	cg08319019	chr2:214017104	IKZF2	-0.62	-9.68	-0.47	1.11e-19	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg19875535	chr5:140030758	IK	0.55	9.02	0.44	1.48e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg04374321	chr14:90722782	PSMC1	-0.74	-11.6	-0.54	2.34e-26	Mortality in heart failure;
LUSC	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.8	-0.35	4.81e-11	Menarche (age at onset);
LUSC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg04450456	chr4:17643702	FAM184B	0.39	6.6	0.34	1.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.67	9.99	0.48	1e-20	Chronic sinus infection;
LUSC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg06784218	chr1:46089804	CCDC17	0.48	9.5	0.46	4.15e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg13683864	chr3:40499215	RPL14	-1.01	-17.74	-0.7	4.38e-50	Renal cell carcinoma;
LUSC	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21659725	chr3:3221576	CRBN	0.54	8.6	0.43	3.15e-16	Body mass index;
LUSC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11764359	chr7:65958608	NA	-0.68	-10.93	-0.51	5.47e-24	Aortic root size;
LUSC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg12863693	chr15:85201151	NMB	0.34	6.78	0.35	5.49e-11	Schizophrenia;
LUSC	cis	rs7215564	0.818	rs1126064	chr17:78610388	A/G	cg09596252	chr17:78655493	RPTOR	0.56	6.19	0.32	1.81e-9	Myopia (pathological);
LUSC	cis	rs6484504	0.576	rs208066	chr11:31156206	C/G	cg14844989	chr11:31128820	NA	-0.39	-6.23	-0.32	1.39e-9	Red blood cell count;
LUSC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.04e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-1.25	-14.0	-0.61	2.4e-35	Diabetic kidney disease;
LUSC	cis	rs73198271	0.628	rs11780486	chr8:8589494	C/T	cg01851573	chr8:8652454	MFHAS1	-0.46	-5.76	-0.3	1.87e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6138458	0.626	rs6050261	chr20:25014206	C/T	cg06937882	chr20:24974362	C20orf3	-0.3	-5.71	-0.3	2.5e-8	Blood protein levels;
LUSC	cis	rs10865541	0.806	rs4971503	chr2:3417221	G/A	cg15807143	chr2:3452624	TTC15	0.32	5.66	0.3	3.24e-8	Obesity-related traits;
LUSC	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg08330031	chr10:104623503	C10orf32	0.32	5.68	0.3	2.86e-8	Arsenic metabolism;
LUSC	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	0.98	14.93	0.63	5.84e-39	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg24642439	chr20:33292090	TP53INP2	0.4	5.8	0.3	1.56e-8	Height;
LUSC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	13.27	0.59	1.42e-32	Mean platelet volume;
LUSC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06112835	chr11:68658793	MRPL21	0.5	7.74	0.39	1.22e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg01503450	chr10:980765	NA	-0.39	-5.79	-0.3	1.59e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-12.16	-0.55	2.05e-28	Platelet count;
LUSC	cis	rs6967385	0.560	rs10434998	chr7:12348375	C/T	cg06484146	chr7:12443880	VWDE	0.51	7.58	0.38	3.46e-13	Response to taxane treatment (placlitaxel);
LUSC	trans	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg06606381	chr12:133084897	FBRSL1	-1.06	-9.46	-0.46	5.85e-19	Depression;
LUSC	cis	rs858239	0.601	rs11982002	chr7:23163270	C/T	cg23682824	chr7:23144976	KLHL7	0.4	5.77	0.3	1.85e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg02153584	chr22:29168773	CCDC117	0.67	10.29	0.49	9.5e-22	Lymphocyte counts;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00119011	chr13:45694603	GTF2F2	0.44	5.95	0.31	6.69e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg07393940	chr7:158741817	NA	0.36	6.43	0.33	4.34e-10	Life satisfaction;
LUSC	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg16482183	chr6:26056742	HIST1H1C	0.56	7.66	0.39	2e-13	Iron status biomarkers;
LUSC	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.08	0.52	1.65e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg12963246	chr6:28129442	ZNF389	0.54	7.74	0.39	1.2e-13	Parkinson's disease;
LUSC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.66	-10.42	-0.5	3.4e-22	Prudent dietary pattern;
LUSC	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg08601574	chr20:25228251	PYGB	-0.45	-6.89	-0.35	2.83e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg12372898	chr4:77069563	NUP54	0.75	6.18	0.32	1.83e-9	Cognitive performance;
LUSC	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg24634471	chr8:143751801	JRK	-0.52	-7.52	-0.38	5e-13	Schizophrenia;
LUSC	cis	rs2414059	0.518	rs11070776	chr15:50735488	G/A	cg08437265	chr15:50716283	USP8	0.4	5.78	0.3	1.69e-8	QT interval;
LUSC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg21535247	chr6:8435926	SLC35B3	0.57	9.02	0.44	1.5e-17	Motion sickness;
LUSC	cis	rs10186029	0.509	rs13387516	chr2:213945341	T/C	cg08319019	chr2:214017104	IKZF2	-0.43	-6.31	-0.33	9.01e-10	Systemic sclerosis;
LUSC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg16325326	chr1:53192061	ZYG11B	-0.83	-14.56	-0.62	1.63e-37	Monocyte count;
LUSC	cis	rs36093844	0.800	rs76464398	chr11:85583898	C/T	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.42	16.71	0.67	5.66e-46	Opioid sensitivity;
LUSC	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg20734569	chr3:48348370	SPINK8	-0.47	-8.17	-0.41	6.44e-15	Coronary artery disease;
LUSC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.27e-31	Prudent dietary pattern;
LUSC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg25767906	chr1:53392781	SCP2	-0.57	-11.24	-0.52	4.57e-25	Monocyte count;
LUSC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-7.33	-0.37	1.77e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg05187965	chr10:45406764	TMEM72	-0.37	-8.68	-0.43	1.73e-16	Mean corpuscular volume;
LUSC	cis	rs96067	0.711	rs272833	chr1:36622870	C/G	cg24686825	chr1:36642396	MAP7D1	-0.72	-11.19	-0.52	6.85e-25	Corneal structure;
LUSC	cis	rs11893307	0.507	rs1465304	chr2:191585398	A/G	cg11845111	chr2:191398756	TMEM194B	-0.42	-5.7	-0.3	2.6e-8	Mean platelet volume;
LUSC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.44	-0.33	4.08e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4953076	0.533	rs10173126	chr2:44446492	T/C	cg04920474	chr2:44395004	PPM1B	0.63	8.13	0.41	8.32e-15	Height;
LUSC	cis	rs72781680	0.716	rs2712068	chr2:23984000	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	6.56	0.34	2.06e-10	Lymphocyte counts;
LUSC	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg05985134	chr18:33552581	C18orf21	0.51	7.03	0.36	1.17e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10979	0.931	rs9403509	chr6:143888691	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07162665	chr17:77020549	C1QTNF1	-0.42	-6.13	-0.32	2.44e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg27170947	chr2:26402098	FAM59B	-0.63	-9.08	-0.44	9.99e-18	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg05313129	chr8:58192883	C8orf71	-0.5	-6.92	-0.35	2.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg04362960	chr10:104952993	NT5C2	0.61	9.76	0.47	5.68e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08439880	chr3:133502540	NA	-0.33	-6.01	-0.31	4.89e-9	Iron status biomarkers;
LUSC	cis	rs12973672	0.812	rs13345192	chr19:35756155	A/C	cg12095397	chr19:35769544	USF2	-0.46	-6.92	-0.35	2.36e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.51	6.2	0.32	1.69e-9	Multiple sclerosis;
LUSC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg05585544	chr11:47624801	NA	-0.42	-7.31	-0.37	1.97e-12	Subjective well-being;
LUSC	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg16339924	chr4:17578868	LAP3	0.49	7.52	0.38	4.97e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7084921	0.549	rs9888058	chr10:101859205	C/T	cg02250046	chr10:101825185	CPN1	-0.34	-6.42	-0.33	4.77e-10	Bone mineral density;
LUSC	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg11845111	chr2:191398756	TMEM194B	-0.81	-10.66	-0.5	5.07e-23	Diastolic blood pressure;
LUSC	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg00825309	chr19:58991885	ZNF446	-0.5	-7.23	-0.37	3.27e-12	Uric acid clearance;
LUSC	trans	rs1998174	0.509	rs1076700	chr1:171826943	C/T	cg13482142	chr2:234261155	NA	0.42	6.09	0.32	3.11e-9	Platelet distribution width;
LUSC	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg22815214	chr1:201083145	CACNA1S	0.46	6.69	0.34	9.7e-11	Permanent tooth development;
LUSC	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.46	-0.5	2.51e-22	Eye color traits;
LUSC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.31	0.53	2.56e-25	Prudent dietary pattern;
LUSC	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg13010199	chr12:38710504	ALG10B	0.53	7.95	0.4	2.82e-14	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.36	0.42	1.76e-15	Hemoglobin concentration;
LUSC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg00814883	chr7:100076585	TSC22D4	-0.66	-8.64	-0.43	2.36e-16	Platelet count;
LUSC	cis	rs6687430	0.532	rs17035305	chr1:10616505	C/A	cg20482658	chr1:10539492	PEX14	0.28	5.67	0.3	3.1e-8	Hand grip strength;
LUSC	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	0.85	15.01	0.63	2.87e-39	Prostate cancer;
LUSC	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg19875535	chr5:140030758	IK	-0.53	-8.76	-0.43	1.02e-16	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18876405	chr7:65276391	NA	0.47	6.36	0.33	6.75e-10	Corneal structure;
LUSC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg10729496	chr3:10149963	C3orf24	0.54	7.17	0.37	4.98e-12	Alzheimer's disease;
LUSC	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg27426351	chr10:43362370	NA	0.46	6.27	0.32	1.12e-9	Blood protein levels;
LUSC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.3	-7.67	-0.39	1.89e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	0.96	15.11	0.64	1.15e-39	Dupuytren's disease;
LUSC	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.53	-8.44	-0.42	9.56e-16	Platelet count;
LUSC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.75	0.65	3.43e-42	Platelet count;
LUSC	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-8.1	-0.41	1.03e-14	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.06e-12	Motion sickness;
LUSC	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg02775129	chr4:119771670	NA	-0.81	-6.3	-0.33	9.24e-10	Cannabis dependence symptom count;
LUSC	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.84	13.8	0.6	1.32e-34	Bladder cancer;
LUSC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg02079420	chr8:82753780	SNX16	0.4	6.74	0.35	6.94e-11	Diastolic blood pressure;
LUSC	trans	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-8.1	-0.41	1.01e-14	Obesity-related traits;
LUSC	cis	rs9868809	0.881	rs13324142	chr3:48669447	C/T	cg01304814	chr3:48885189	PRKAR2A	0.6	5.65	0.3	3.45e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12776158	0.901	rs59145567	chr10:71217065	G/T	cg12610070	chr10:71211762	TSPAN15	-0.46	-5.91	-0.31	8.46e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04565464	chr8:145669602	NFKBIL2	0.36	6.03	0.31	4.33e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.88	-0.4	4.59e-14	Neuroticism;
LUSC	cis	rs16921914	0.559	rs2985140	chr11:31315886	C/T	cg14844989	chr11:31128820	NA	0.4	6.14	0.32	2.34e-9	Bone mineral density (spine);
LUSC	trans	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg26043149	chr18:55253948	FECH	0.51	7.59	0.38	3.26e-13	Bone mineral density;
LUSC	cis	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg21775007	chr8:11205619	TDH	0.47	6.67	0.34	1.09e-10	Neuroticism;
LUSC	cis	rs62400317	0.762	rs62436375	chr6:44875818	T/C	cg20913747	chr6:44695427	NA	-0.48	-7.44	-0.38	8.79e-13	Total body bone mineral density;
LUSC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg04282206	chr17:62833786	PLEKHM1P	-0.41	-6.01	-0.31	4.75e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg21905437	chr5:178450457	ZNF879	0.43	5.67	0.3	3.1e-8	Pubertal anthropometrics;
LUSC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg26958806	chr6:27640298	NA	0.59	5.68	0.3	2.86e-8	Depression;
LUSC	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg13852791	chr20:30311386	BCL2L1	0.82	10.75	0.51	2.37e-23	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg24375607	chr4:120327624	NA	0.77	12.51	0.56	1.08e-29	Corneal astigmatism;
LUSC	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-1.04	-12.46	-0.56	1.56e-29	Schizophrenia;
LUSC	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-7.29	-0.37	2.2e-12	Retinal vascular caliber;
LUSC	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg04117972	chr1:227635322	NA	0.53	6.22	0.32	1.46e-9	Major depressive disorder;
LUSC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg23711669	chr6:146136114	FBXO30	0.82	14.9	0.63	7.22e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg13628971	chr7:2884303	GNA12	-0.48	-6.92	-0.35	2.32e-11	Height;
LUSC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg09436375	chr6:42928200	GNMT	-0.29	-6.77	-0.35	5.94e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg13319975	chr6:146136371	FBXO30	0.48	7.25	0.37	3.01e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12931792	0.720	rs12102320	chr16:30178516	A/C	cg17640201	chr16:30407289	ZNF48	0.63	10.3	0.49	8.45e-22	Tonsillectomy;
LUSC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg09034736	chr1:150693464	HORMAD1	0.46	6.73	0.35	7.26e-11	Tonsillectomy;
LUSC	cis	rs1461503	0.548	rs7114175	chr11:122813983	A/T	cg27398637	chr11:122830231	C11orf63	-0.39	-6.44	-0.33	4.05e-10	Menarche (age at onset);
LUSC	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg27446573	chr6:127587934	RNF146	0.64	10.35	0.49	6.01e-22	Breast cancer;
LUSC	cis	rs12208915	0.731	rs9448581	chr6:79553378	A/G	cg05283184	chr6:79620031	NA	-0.46	-7.04	-0.36	1.07e-11	Left atrial antero-posterior diameter;
LUSC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.47	6.21	0.32	1.62e-9	Blood protein levels;
LUSC	cis	rs11676348	0.774	rs11683524	chr2:218984604	G/A	cg06547715	chr2:218990976	CXCR2	0.31	5.78	0.3	1.69e-8	Ulcerative colitis;
LUSC	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg18806716	chr10:30721971	MAP3K8	0.72	11.44	0.53	8.58e-26	Inflammatory bowel disease;
LUSC	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg24881330	chr22:46731750	TRMU	0.82	7.29	0.37	2.32e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg26924012	chr15:45694286	SPATA5L1	1.12	20.85	0.75	2.06e-62	Homoarginine levels;
LUSC	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.53	10.2	0.49	1.9e-21	Coronary artery disease;
LUSC	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.81	0.3	1.48e-8	Breast cancer;
LUSC	trans	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.54	-0.34	2.29e-10	Life satisfaction;
LUSC	cis	rs2282300	0.653	rs67745574	chr11:30234839	C/T	cg06241208	chr11:30344200	C11orf46	-0.45	-5.67	-0.3	3.12e-8	Morning vs. evening chronotype;
LUSC	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg21545522	chr1:205238299	TMCC2	0.42	7.99	0.4	2.22e-14	Red blood cell count;
LUSC	cis	rs3772130	0.962	rs9812137	chr3:121539103	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	10.13	0.48	3.31e-21	Cognitive performance;
LUSC	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg05294307	chr14:35346193	BAZ1A	-0.58	-6.94	-0.35	2.1e-11	Psoriasis;
LUSC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg00310523	chr12:86230176	RASSF9	0.54	10.15	0.49	2.75e-21	Major depressive disorder;
LUSC	trans	rs1325195	0.843	rs390018	chr1:179215747	T/C	cg11624085	chr17:8464688	MYH10	0.44	7.1	0.36	7.33e-12	IgE grass sensitization;
LUSC	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg09323728	chr8:95962352	TP53INP1	0.33	6.46	0.33	3.71e-10	Type 2 diabetes;
LUSC	cis	rs4478858	0.735	rs7523438	chr1:31788313	C/T	cg00250761	chr1:31883323	NA	0.37	8.78	0.43	8.83e-17	Alcohol dependence;
LUSC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24549020	chr5:56110836	MAP3K1	0.51	5.81	0.3	1.42e-8	Initial pursuit acceleration;
LUSC	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.76	-12.55	-0.57	7.08e-30	Lymphocyte percentage of white cells;
LUSC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg23093090	chr10:104574429	C10orf26	-0.34	-6.25	-0.32	1.25e-9	Arsenic metabolism;
LUSC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg16339924	chr4:17578868	LAP3	0.56	8.62	0.43	2.63e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg12927641	chr6:109611667	NA	-0.35	-5.88	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.29	-0.41	2.72e-15	Coronary artery disease;
LUSC	cis	rs1775715	0.870	rs7912121	chr10:32228995	T/G	cg04359828	chr10:32216031	ARHGAP12	0.39	6.7	0.34	9.02e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg03929089	chr4:120376271	NA	-0.6	-6.52	-0.34	2.61e-10	Axial length;
LUSC	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	9.12	0.45	7.31e-18	Response to antipsychotic treatment;
LUSC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg27284194	chr4:1044797	NA	-0.36	-5.86	-0.31	1.13e-8	Obesity-related traits;
LUSC	cis	rs9811920	0.931	rs7629487	chr3:99860401	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.35	-5.92	-0.31	7.84e-9	Axial length;
LUSC	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg03806693	chr22:41940476	POLR3H	0.86	12.76	0.57	1.23e-30	Vitiligo;
LUSC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06481639	chr22:41940642	POLR3H	-0.53	-5.9	-0.31	8.87e-9	Vitiligo;
LUSC	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg00982548	chr2:198649783	BOLL	-0.58	-7.15	-0.36	5.37e-12	Ulcerative colitis;
LUSC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.84	0.39	6.15e-14	Prudent dietary pattern;
LUSC	cis	rs6961069	0.585	rs1722507	chr7:80238710	C/T	cg04458919	chr7:80252533	CD36	0.4	7.32	0.37	1.91e-12	Platelet count;
LUSC	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg05985134	chr18:33552581	C18orf21	0.53	7.26	0.37	2.74e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.91	-0.44	3.44e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6445967	0.530	rs12495722	chr3:58401595	C/T	cg13705284	chr3:58523313	ACOX2	-0.27	-5.66	-0.3	3.28e-8	Platelet count;
LUSC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg01097406	chr16:89675127	NA	-0.34	-6.73	-0.35	7.39e-11	Vitiligo;
LUSC	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.1	0.41	1.02e-14	Body mass index;
LUSC	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg12179176	chr11:130786555	SNX19	0.73	11.42	0.53	1e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs11997175	0.624	rs4526317	chr8:33682936	T/A	ch.8.33884649F	chr8:33765107	NA	0.48	7.09	0.36	7.95e-12	Body mass index;
LUSC	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg25233709	chr10:116636983	FAM160B1	0.39	6.59	0.34	1.7e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs11690935	0.550	rs62183769	chr2:172838074	A/C	cg13550731	chr2:172543902	DYNC1I2	0.5	7.44	0.38	8.64e-13	Schizophrenia;
LUSC	cis	rs11608355	0.810	rs2217972	chr12:109857612	C/T	cg05360138	chr12:110035743	NA	0.6	8.06	0.4	1.34e-14	Neuroticism;
LUSC	cis	rs9549260	0.755	rs1923249	chr13:41143881	C/A	cg21288729	chr13:41239152	FOXO1	0.58	8.69	0.43	1.62e-16	Red blood cell count;
LUSC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg09455208	chr3:40491958	NA	0.53	9.45	0.46	6.16e-19	Renal cell carcinoma;
LUSC	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.17	-0.37	4.92e-12	Alzheimer's disease (late onset);
LUSC	cis	rs10144321	0.729	rs8018305	chr14:100829848	C/T	cg14882082	chr14:100845427	WDR25	-0.39	-7.47	-0.38	7.23e-13	Menarche (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06548519	chr17:34267111	LYZL6	-0.44	-6.72	-0.35	7.76e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg00376283	chr12:123451042	ABCB9	0.69	9.81	0.47	3.82e-20	Neutrophil percentage of white cells;
LUSC	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.7e-10	Corneal astigmatism;
LUSC	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.86	0.31	1.1e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg00290607	chr11:67383545	NA	0.37	6.88	0.35	3.04e-11	Mean corpuscular volume;
LUSC	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg21798802	chr22:38057573	PDXP	0.48	10.64	0.5	6.02e-23	Fat distribution (HIV);
LUSC	cis	rs4588572	0.644	rs10805920	chr5:77698222	G/A	cg11547950	chr5:77652471	NA	-0.41	-6.26	-0.32	1.19e-9	Triglycerides;
LUSC	cis	rs727505	0.954	rs28728448	chr7:124532938	T/A	cg23710748	chr7:124431027	NA	-0.41	-7.34	-0.37	1.61e-12	Lewy body disease;
LUSC	cis	rs136211	0.640	rs9610495	chr22:36760838	G/A	cg16924664	chr22:36878180	TXN2	0.4	5.97	0.31	6.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg21643547	chr1:205240462	TMCC2	-0.43	-7.82	-0.39	7.16e-14	Red blood cell count;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17866734	chr6:43484657	YIPF3;POLR1C	0.45	6.18	0.32	1.92e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg20607287	chr7:12443886	VWDE	-0.65	-6.59	-0.34	1.74e-10	Coronary artery disease;
LUSC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg26408565	chr15:76604113	ETFA	-0.52	-8.39	-0.42	1.4e-15	Blood metabolite levels;
LUSC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg06618935	chr21:46677482	NA	-0.4	-8.06	-0.4	1.41e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	5.99	0.31	5.3e-9	Height;
LUSC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24838063	chr12:130822603	PIWIL1	0.69	10.73	0.51	2.84e-23	Menopause (age at onset);
LUSC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg11663144	chr21:46675770	NA	-0.4	-7.32	-0.37	1.82e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg06552810	chr11:31128660	NA	-0.42	-7.39	-0.37	1.19e-12	Red blood cell count;
LUSC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg10130564	chr11:117069849	TAGLN	0.38	6.16	0.32	2.12e-9	Blood protein levels;
LUSC	cis	rs4253772	0.938	rs11704979	chr22:46632994	G/A	cg18190219	chr22:46762943	CELSR1	-0.51	-5.92	-0.31	7.92e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg10326726	chr10:51549505	MSMB	-0.37	-6.38	-0.33	5.76e-10	Prostate-specific antigen levels;
LUSC	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg15556689	chr8:8085844	FLJ10661	0.51	7.38	0.37	1.23e-12	Myopia (pathological);
LUSC	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg19773385	chr1:10388646	KIF1B	-0.5	-8.66	-0.43	2.11e-16	Hepatocellular carcinoma;
LUSC	trans	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17712092	chr4:129076599	LARP1B	0.74	11.11	0.52	1.3e-24	Eosinophil percentage of white cells;
LUSC	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg05373962	chr22:49881684	NA	-0.41	-8.5	-0.42	6.21e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2637266	0.935	rs2583054	chr10:78401442	A/G	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.94e-13	Pulmonary function;
LUSC	cis	rs4566357	0.576	rs10187255	chr2:227913442	T/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.27	-0.41	3.17e-15	Coronary artery disease;
LUSC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.52	-0.34	2.65e-10	Life satisfaction;
LUSC	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg09754948	chr16:28834200	ATXN2L	0.41	5.86	0.31	1.13e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9283706	0.676	rs6449842	chr5:66323159	C/G	cg11590213	chr5:66331682	MAST4	0.44	6.59	0.34	1.72e-10	Coronary artery disease;
LUSC	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg04362960	chr10:104952993	NT5C2	0.61	9.55	0.46	2.83e-19	Arsenic metabolism;
LUSC	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.47	-0.42	7.71e-16	Cystic fibrosis severity;
LUSC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.73	12.03	0.55	6.04e-28	Coronary artery disease;
LUSC	cis	rs7202877	0.610	rs10871307	chr16:75335114	G/T	cg04384234	chr16:75411784	CFDP1	-0.58	-7.44	-0.38	8.37e-13	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg14668632	chr7:2872130	GNA12	0.43	6.45	0.33	4.01e-10	Height;
LUSC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg00074818	chr8:8560427	CLDN23	0.56	9.41	0.46	8.06e-19	Obesity-related traits;
LUSC	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg27284194	chr4:1044797	NA	0.6	8.92	0.44	3.1e-17	Recombination rate (females);
LUSC	cis	rs8099014	1.000	rs8096440	chr18:56127985	T/A	cg12907477	chr18:56117327	MIR122	0.44	6.99	0.36	1.52e-11	Platelet count;
LUSC	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	20.48	0.75	5.81e-61	Prudent dietary pattern;
LUSC	cis	rs10489202	1.000	rs67600256	chr1:167972357	T/C	cg24449463	chr1:168025552	DCAF6	-0.58	-7.27	-0.37	2.56e-12	Schizophrenia;
LUSC	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.8	-0.51	1.62e-23	Glomerular filtration rate;
LUSC	cis	rs6901250	0.655	rs1398403	chr6:117122646	T/C	cg12892004	chr6:117198278	RFX6	0.4	7.59	0.38	3.13e-13	C-reactive protein levels;
LUSC	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg27427491	chr17:78079615	GAA	-0.34	-6.69	-0.34	9.27e-11	Yeast infection;
LUSC	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg00745463	chr17:30367425	LRRC37B	-0.77	-9.2	-0.45	3.98e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.31	-0.37	1.96e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg04111992	chr7:158790115	NA	-0.47	-7.47	-0.38	7.1e-13	Facial morphology (factor 20);
LUSC	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg13902645	chr11:5959945	NA	-0.6	-8.33	-0.41	2.16e-15	DNA methylation (variation);
LUSC	cis	rs3087591	1.000	rs2905795	chr17:29547601	A/G	cg24425628	chr17:29625626	OMG;NF1	0.59	8.82	0.43	6.48e-17	Hip circumference;
LUSC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18876405	chr7:65276391	NA	0.55	8.56	0.42	4.15e-16	Aortic root size;
LUSC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg21251018	chr6:28226885	NKAPL	0.32	6.03	0.31	4.39e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg13319975	chr6:146136371	FBXO30	0.51	7.67	0.39	1.94e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg06740227	chr12:86229804	RASSF9	0.37	5.82	0.3	1.39e-8	Major depressive disorder;
LUSC	cis	rs7131987	0.650	rs10843384	chr12:29472409	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.77	-0.35	5.69e-11	QT interval;
LUSC	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg20203395	chr5:56204925	C5orf35	-0.46	-6.74	-0.35	6.95e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg20243544	chr17:37824526	PNMT	0.5	7.13	0.36	6.18e-12	Asthma;
LUSC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg12963246	chr6:28129442	ZNF389	-0.55	-7.87	-0.4	5.14e-14	Parkinson's disease;
LUSC	trans	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg10756647	chr7:56101905	PSPH	0.85	8.31	0.41	2.5e-15	Diabetic kidney disease;
LUSC	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg00791764	chr4:53727839	RASL11B	0.56	7.7	0.39	1.6e-13	Optic nerve measurement (cup area);
LUSC	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg14459158	chr9:96720562	NA	0.33	6.64	0.34	1.3e-10	Esophageal adenocarcinoma;
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.6	-10.06	-0.48	5.67e-21	Lymphocyte counts;
LUSC	trans	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.22	-0.32	1.52e-9	Monocyte count;
LUSC	trans	rs7939886	0.920	rs11227273	chr11:55893034	T/G	cg15704280	chr7:45808275	SEPT13	0.81	6.68	0.34	9.89e-11	Myopia (pathological);
LUSC	cis	rs1957429	0.614	rs73279834	chr14:65352544	G/A	cg23373153	chr14:65346875	NA	-0.99	-8.98	-0.44	1.97e-17	Pediatric areal bone mineral density (radius);
LUSC	cis	rs9837602	1.000	rs9873878	chr3:99711816	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.17	0.32	1.96e-9	Breast cancer;
LUSC	cis	rs1413885	0.516	rs6588138	chr1:65838366	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	7.06	0.36	1e-11	Anticoagulant levels;
LUSC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg19266014	chr7:2183958	MAD1L1	-0.34	-5.69	-0.3	2.85e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.06	-0.4	1.37e-14	Type 2 diabetes;
LUSC	cis	rs10743315	0.547	rs7310796	chr12:19362390	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.46	-5.76	-0.3	1.95e-8	Gut microbiota (bacterial taxa);
LUSC	cis	rs12973672	0.812	rs2073899	chr19:35752917	C/T	cg12095397	chr19:35769544	USF2	0.43	6.63	0.34	1.32e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.74	14.43	0.62	5.06e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1950626	0.623	rs2295657	chr14:101430620	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.4	7.38	0.37	1.25e-12	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs11645898	0.935	rs11647125	chr16:72243277	T/C	cg14768367	chr16:72042858	DHODH	-0.57	-6.26	-0.32	1.15e-9	Blood protein levels;
LUSC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg11871910	chr12:69753446	YEATS4	0.83	14.58	0.62	1.34e-37	Blood protein levels;
LUSC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.53	-0.38	4.71e-13	Bipolar disorder;
LUSC	trans	rs12643440	0.526	rs10025799	chr4:17224345	A/G	cg03061682	chr15:28352098	NA	0.37	6.16	0.32	2.07e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg14893161	chr1:205819251	PM20D1	0.5	7.45	0.38	8.22e-13	Prostate-specific antigen levels;
LUSC	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	0.58	9.34	0.46	1.35e-18	Breast cancer;
LUSC	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg16928487	chr17:17741425	SREBF1	-0.47	-9.28	-0.45	2.15e-18	Total body bone mineral density;
LUSC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg13683864	chr3:40499215	RPL14	-0.97	-16.36	-0.67	1.35e-44	Renal cell carcinoma;
LUSC	cis	rs7851660	0.967	rs7049054	chr9:100599969	T/G	cg13688889	chr9:100608707	NA	-0.61	-10.38	-0.49	4.54e-22	Strep throat;
LUSC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg08742575	chr21:47604166	C21orf56	-0.42	-6.26	-0.32	1.2e-9	Testicular germ cell tumor;
LUSC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg07424592	chr7:64974309	NA	0.69	6.07	0.32	3.4e-9	Diabetic kidney disease;
LUSC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.61	-7.78	-0.39	9.36e-14	Systemic lupus erythematosus;
LUSC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg12310025	chr6:25882481	NA	-0.4	-7.12	-0.36	6.59e-12	Height;
LUSC	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg10326726	chr10:51549505	MSMB	-0.36	-6.09	-0.32	3.1e-9	Prostate-specific antigen levels;
LUSC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	0.64	13.56	0.6	1.13e-33	Prudent dietary pattern;
LUSC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.4	-5.73	-0.3	2.2e-8	Tonsillectomy;
LUSC	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg27087555	chr16:88793112	FAM38A	-1.49	-14.34	-0.62	1.11e-36	Plateletcrit;
LUSC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	1.06	17.27	0.69	3.28e-48	Testicular germ cell tumor;
LUSC	trans	rs12458462	0.851	rs60298379	chr18:77488422	C/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-6.36	-0.33	6.7e-10	Monocyte count;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08128228	chr1:167191360	POU2F1	-0.36	-6.43	-0.33	4.47e-10	Electrocardiographic conduction measures;
LUSC	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg05621596	chr22:47072043	GRAMD4	-0.4	-6.56	-0.34	2.06e-10	Urate levels in obese individuals;
LUSC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.23	0.61	3e-36	Platelet count;
LUSC	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg00310523	chr12:86230176	RASSF9	0.35	6.34	0.33	7.53e-10	Major depressive disorder;
LUSC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg15691649	chr6:25882328	NA	-0.39	-6.37	-0.33	6.13e-10	Blood metabolite levels;
LUSC	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg12615879	chr12:58013172	SLC26A10	0.37	8.46	0.42	8.33e-16	Multiple sclerosis;
LUSC	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	13.19	0.59	2.77e-32	Lung cancer in ever smokers;
LUSC	cis	rs6496667	0.509	rs2253419	chr15:90945875	A/G	cg10434728	chr15:90938212	IQGAP1	0.34	6.48	0.33	3.24e-10	Rheumatoid arthritis;
LUSC	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg17644776	chr2:200775616	C2orf69	-0.45	-6.88	-0.35	3.05e-11	LDL cholesterol to HDL cholesterol ratio;
LUSC	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.75	-11.04	-0.52	2.39e-24	Glomerular filtration rate;
LUSC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg05313129	chr8:58192883	C8orf71	-0.5	-6.52	-0.34	2.58e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg03732007	chr1:2071316	PRKCZ	-0.54	-9.76	-0.47	5.67e-20	Height;
LUSC	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.88	18.79	0.72	2.94e-54	Gut microbiota (bacterial taxa);
LUSC	cis	rs2637266	1.000	rs7897061	chr10:78366776	C/T	cg18941641	chr10:78392320	NA	0.4	7.24	0.37	3.05e-12	Pulmonary function;
LUSC	cis	rs243505	1.000	rs243514	chr7:148427873	A/G	cg09806900	chr7:148480153	CUL1	0.49	7.03	0.36	1.14e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	8.15	0.41	7.25e-15	Initial pursuit acceleration;
LUSC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg00310523	chr12:86230176	RASSF9	-0.53	-10.23	-0.49	1.5e-21	Major depressive disorder;
LUSC	cis	rs6484504	0.553	rs2183484	chr11:31259370	G/A	cg14844989	chr11:31128820	NA	-0.39	-6.02	-0.31	4.6e-9	Red blood cell count;
LUSC	cis	rs73001065	0.901	rs8107974	chr19:19388500	A/T	cg03709012	chr19:19516395	GATAD2A	0.84	6.26	0.32	1.17e-9	LDL cholesterol;
LUSC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg06784218	chr1:46089804	CCDC17	-0.5	-10.06	-0.48	5.91e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg12091567	chr17:66097778	LOC651250	-0.75	-9.36	-0.46	1.21e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	6.28	0.32	1.08e-9	Tonsillectomy;
LUSC	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-19.99	-0.74	4.99e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9419702	0.538	rs9419625	chr10:133534954	T/G	cg23460707	chr10:133558971	NA	0.36	6.2	0.32	1.67e-9	Survival in rectal cancer;
LUSC	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg21427119	chr20:30132790	HM13	-0.46	-6.65	-0.34	1.2e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26314531	chr2:26401878	FAM59B	-0.69	-9.39	-0.46	9.76e-19	Gut microbiome composition (summer);
LUSC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg19717773	chr7:2847554	GNA12	-0.33	-5.69	-0.3	2.77e-8	Height;
LUSC	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	7.2	0.37	3.89e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg12963246	chr6:28129442	ZNF389	0.43	5.92	0.31	8.05e-9	Depression;
LUSC	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.4	6.16	0.32	2.04e-9	Height;
LUSC	cis	rs9650657	0.812	rs7834466	chr8:10634805	G/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.2	-0.32	1.69e-9	Neuroticism;
LUSC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg01657329	chr11:68192670	LRP5	-0.45	-6.76	-0.35	6.35e-11	Total body bone mineral density;
LUSC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.17	0.58	3.43e-32	Chronic sinus infection;
LUSC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg19592336	chr6:28129416	ZNF389	0.47	6.36	0.33	6.45e-10	Parkinson's disease;
LUSC	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg26408565	chr15:76604113	ETFA	-0.47	-7.5	-0.38	5.79e-13	Blood metabolite levels;
LUSC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg06360820	chr2:242988706	NA	-0.9	-9.86	-0.47	2.7e-20	Obesity-related traits;
LUSC	cis	rs2559856	1.000	rs2251187	chr12:102081889	G/A	cg12924262	chr12:102091054	CHPT1	0.43	5.85	0.3	1.18e-8	Blood protein levels;
LUSC	cis	rs6695223	0.571	rs4907133	chr1:85538947	A/G	cg22153463	chr1:85462885	MCOLN2	-0.66	-7.55	-0.38	4.32e-13	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.9	0.51	7.26e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	5.97	0.31	6.12e-9	Breast cancer;
LUSC	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg26408565	chr15:76604113	ETFA	-0.49	-7.88	-0.4	4.81e-14	Blood metabolite levels;
LUSC	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg13057898	chr1:3703894	LRRC47	0.49	8.66	0.43	2.02e-16	Red cell distribution width;
LUSC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg12365402	chr11:9010492	NRIP3	-0.49	-9.44	-0.46	6.86e-19	Hemoglobin concentration;
LUSC	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg02403541	chr12:121454288	C12orf43	-0.73	-11.24	-0.52	4.35e-25	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs11153306	0.791	rs9387017	chr6:111944006	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.52	-0.34	2.54e-10	Tonsillectomy;
LUSC	cis	rs238295	0.805	rs6076852	chr20:5544502	A/G	cg15842884	chr20:5591925	RP5-1022P6.2	0.44	5.91	0.31	8.33e-9	Occipital cortical area (total cortical area interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05470666	chr10:74856828	P4HA1	-0.43	-6.38	-0.33	5.96e-10	Electrocardiographic conduction measures;
LUSC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg13119609	chr19:45449297	APOC2	0.51	10.16	0.49	2.67e-21	Blood protein levels;
LUSC	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg00191853	chr8:101177733	SPAG1	-0.4	-6.37	-0.33	6.42e-10	Atrioventricular conduction;
LUSC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg22800045	chr5:56110881	MAP3K1	0.46	6.56	0.34	2.1e-10	Coronary artery disease;
LUSC	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg00277334	chr10:82204260	NA	-0.53	-7.17	-0.37	4.8e-12	Post bronchodilator FEV1;
LUSC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00934597	chr7:893267	UNC84A	0.47	7.07	0.36	9.13e-12	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14893161	chr1:205819251	PM20D1	0.5	7.31	0.37	2e-12	Menarche (age at onset);
LUSC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg25019033	chr10:957182	NA	-0.52	-6.48	-0.33	3.29e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg16989719	chr2:238392110	NA	-0.4	-5.73	-0.3	2.21e-8	Prostate cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08567662	chr2:176867156	KIAA1715	-0.47	-7.13	-0.36	6.38e-12	Electrocardiographic conduction measures;
LUSC	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg26647111	chr11:31128758	NA	-0.42	-6.03	-0.31	4.23e-9	Red blood cell count;
LUSC	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg07701084	chr6:150067640	NUP43	0.54	8.09	0.4	1.09e-14	Lung cancer;
LUSC	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.54	-8.58	-0.43	3.59e-16	Schizophrenia;
LUSC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.56	-8.61	-0.43	2.87e-16	Lung disease severity in cystic fibrosis;
LUSC	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg13010199	chr12:38710504	ALG10B	0.54	8.05	0.4	1.48e-14	Morning vs. evening chronotype;
LUSC	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg02016764	chr4:38805732	TLR1	-0.54	-5.92	-0.31	7.93e-9	Breast cancer;
LUSC	cis	rs11229555	0.645	rs7116007	chr11:58218701	C/T	cg15696309	chr11:58395628	NA	-0.68	-8.26	-0.41	3.34e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg23029597	chr12:123009494	RSRC2	-0.74	-9.14	-0.45	6.4e-18	Body mass index;
LUSC	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg00225070	chr15:80189496	MTHFS	0.63	9.7	0.47	9.03e-20	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.77	13.41	0.59	4.13e-33	Aortic root size;
LUSC	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	9.46	0.46	5.61e-19	Lung cancer;
LUSC	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.9	15.19	0.64	5.67e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1775715	0.835	rs113450267	chr10:32223728	G/A	cg18675610	chr10:32216311	ARHGAP12	0.29	6.28	0.32	1.08e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs11677416	1.000	rs1304037	chr2:113532236	C/T	cg27083787	chr2:113543245	IL1A	-0.46	-7.14	-0.36	5.83e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg12641515	chr19:46296257	DMWD	0.48	7.17	0.37	4.76e-12	Coronary artery disease;
LUSC	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg08807101	chr21:30365312	RNF160	-0.66	-10.19	-0.49	2.03e-21	Pancreatic cancer;
LUSC	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg16342193	chr10:102329863	NA	-0.35	-6.2	-0.32	1.65e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs8099014	0.911	rs4940702	chr18:56110620	T/C	cg12907477	chr18:56117327	MIR122	0.43	6.72	0.35	7.88e-11	Platelet count;
LUSC	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg01028140	chr2:1542097	TPO	-0.37	-6.04	-0.31	4.05e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs6987853	0.686	rs7818789	chr8:42354257	A/G	cg09913449	chr8:42400586	C8orf40	0.42	7.18	0.37	4.44e-12	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg11161011	chr14:65562177	MAX	0.71	11.02	0.52	2.68e-24	Obesity-related traits;
LUSC	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg11845111	chr2:191398756	TMEM194B	-0.86	-11.5	-0.53	5.35e-26	Diastolic blood pressure;
LUSC	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg00784671	chr22:46762841	CELSR1	-0.58	-6.85	-0.35	3.6e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg13256891	chr4:100009986	ADH5	0.51	6.89	0.35	2.74e-11	Smoking initiation;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27367093	chr11:72145746	CLPB	-0.47	-6.14	-0.32	2.29e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg05861140	chr6:150128134	PCMT1	-0.39	-5.89	-0.31	9.58e-9	Lung cancer;
LUSC	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg08975724	chr8:8085496	FLJ10661	0.48	6.95	0.36	1.87e-11	Neuroticism;
LUSC	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg23625390	chr15:77176239	SCAPER	-0.64	-9.88	-0.48	2.35e-20	Blood metabolite levels;
LUSC	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg04374321	chr14:90722782	PSMC1	0.76	12.04	0.55	5.82e-28	Mortality in heart failure;
LUSC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.59	-0.67	1.64e-45	Height;
LUSC	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg17173187	chr15:85201210	NMB	0.36	6.45	0.33	3.99e-10	Schizophrenia;
LUSC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg08493051	chr2:3487164	NA	-0.53	-8.6	-0.43	3.11e-16	Neurofibrillary tangles;
LUSC	cis	rs6424115	0.557	rs35904775	chr1:24180623	T/C	cg15997130	chr1:24165203	NA	-0.49	-8.05	-0.4	1.42e-14	Immature fraction of reticulocytes;
LUSC	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg20283391	chr11:68216788	NA	-0.61	-8.42	-0.42	1.15e-15	Total body bone mineral density;
LUSC	cis	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs2625529	0.689	rs12898728	chr15:72112853	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-7.65	-0.39	2.14e-13	Red blood cell count;
LUSC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	11.55	0.53	3.31e-26	Personality dimensions;
LUSC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg07169764	chr2:136633963	MCM6	0.58	7.68	0.39	1.74e-13	Mosquito bite size;
LUSC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.61	0.57	4.22e-30	Prudent dietary pattern;
LUSC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.45	0.33	3.85e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg11502198	chr6:26597334	ABT1	0.59	8.93	0.44	2.98e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg24558204	chr6:135376177	HBS1L	0.59	8.97	0.44	2.15e-17	Red blood cell count;
LUSC	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.68	-11.44	-0.53	8.44e-26	Caffeine consumption;
LUSC	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.38	-0.37	1.27e-12	Bipolar disorder;
LUSC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg15103426	chr22:29168792	CCDC117	0.49	6.25	0.32	1.24e-9	Lymphocyte counts;
LUSC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18876405	chr7:65276391	NA	0.55	8.8	0.43	7.72e-17	Aortic root size;
LUSC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg22800045	chr5:56110881	MAP3K1	0.59	7.94	0.4	3.1e-14	Coronary artery disease;
LUSC	cis	rs7615316	0.872	rs7630130	chr3:142240934	G/C	cg16271453	chr3:142027066	XRN1	-0.4	-6.83	-0.35	3.93e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg18825076	chr15:78729989	IREB2	0.47	6.17	0.32	1.96e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg12081754	chr8:22256438	SLC39A14	0.69	10.69	0.5	3.98e-23	Verbal declarative memory;
LUSC	trans	rs488628	1.000	rs542459	chr3:118138927	T/C	cg06621744	chr14:37052470	NKX2-8	-0.28	-6.28	-0.32	1.07e-9	White matter integrity (bipolar disorder risk interaction);
LUSC	cis	rs997295	0.713	rs9302246	chr15:68021280	A/G	cg08079166	chr15:68083412	MAP2K5	-0.34	-6.67	-0.34	1.07e-10	Motion sickness;
LUSC	cis	rs4704187	0.687	rs4360021	chr5:74421962	A/G	cg03227963	chr5:74354835	NA	0.32	6.9	0.35	2.6e-11	Response to amphetamines;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08370718	chr15:49913307	DTWD1;C15orf33	-0.52	-6.6	-0.34	1.66e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg16031515	chr1:205743344	RAB7L1	-0.29	-6.14	-0.32	2.35e-9	Menarche (age at onset);
LUSC	trans	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg26043149	chr18:55253948	FECH	-0.45	-6.9	-0.35	2.59e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs6601327	0.635	rs10099122	chr8:9568003	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.29	-0.33	9.74e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs1549118	0.560	rs11848126	chr14:78318268	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.41	-5.65	-0.3	3.38e-8	Resting heart rate;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07134292	chr1:51702069	RNF11	-0.42	-6.6	-0.34	1.61e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-7.18	-0.37	4.62e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs72925845	0.525	rs72907478	chr17:76431015	C/T	cg03830375	chr17:76426088	DNAH17	0.52	6.02	0.31	4.6e-9	Triglycerides;
LUSC	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg05347473	chr6:146136440	FBXO30	0.48	7.89	0.4	4.3e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17604090	1.000	rs28420551	chr7:29685353	G/A	cg19413766	chr7:29689036	LOC646762	-0.58	-6.93	-0.35	2.12e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.3	-0.49	8.36e-22	Hemoglobin concentration;
LUSC	cis	rs10789491	0.588	rs2099766	chr1:47193987	T/C	cg15501359	chr1:47185051	KIAA0494	0.71	9.17	0.45	5.06e-18	Response to hepatitis C treatment;
LUSC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-0.55	-9.23	-0.45	3.18e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.94	0.31	7.02e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg01579765	chr21:45077557	HSF2BP	-0.46	-9.62	-0.47	1.65e-19	Mean corpuscular volume;
LUSC	trans	rs4714291	0.832	rs6917417	chr6:40104628	T/C	cg02267698	chr19:7991119	CTXN1	-0.52	-7.79	-0.39	8.3e-14	Strep throat;
LUSC	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg18209359	chr17:80159595	CCDC57	-0.39	-6.66	-0.34	1.15e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg07741184	chr6:167504864	NA	0.39	6.95	0.36	1.96e-11	Primary biliary cholangitis;
LUSC	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.67	-10.95	-0.51	4.71e-24	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	trans	rs10090774	0.965	rs11167007	chr8:141918181	G/C	cg16477744	chr7:157367142	PTPRN2;MIR153-2	0.28	5.99	0.31	5.4e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg13010199	chr12:38710504	ALG10B	0.54	8.43	0.42	1.05e-15	Morning vs. evening chronotype;
LUSC	trans	rs4674124	1.000	rs10181822	chr2:217761683	G/T	cg18563886	chr10:135203102	PAOX	0.45	6.24	0.32	1.31e-9	Breast cancer;
LUSC	cis	rs400736	0.562	rs12129505	chr1:8171734	T/C	cg25007680	chr1:8021821	PARK7	-0.48	-7.0	-0.36	1.38e-11	Response to antidepressants and depression;
LUSC	cis	rs5770917	1.000	rs2073604	chr22:51008925	G/A	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.6	-5.75	-0.3	2.05e-8	Narcolepsy;
LUSC	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg10104451	chr8:143696006	ARC	-0.64	-8.99	-0.44	1.86e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs10144321	0.644	rs10144242	chr14:100794404	C/T	cg14882082	chr14:100845427	WDR25	-0.41	-7.18	-0.37	4.66e-12	Menarche (age at onset);
LUSC	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg07701084	chr6:150067640	NUP43	0.47	7.13	0.36	6.29e-12	Testicular germ cell tumor;
LUSC	cis	rs7760949	0.963	rs4142889	chr6:13918461	T/A	cg27413430	chr6:13925136	RNF182	0.54	8.01	0.4	1.97e-14	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7095944	0.644	rs965484	chr10:126453481	T/C	cg08799069	chr10:126477246	METTL10	-0.41	-6.31	-0.33	8.77e-10	Asthma;
LUSC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg06784218	chr1:46089804	CCDC17	-0.58	-11.36	-0.53	1.65e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs35883536	0.587	rs2809799	chr1:101036516	A/G	cg09408571	chr1:101003634	GPR88	0.31	6.1	0.32	2.86e-9	Monocyte count;
LUSC	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.51	7.49	0.38	6.2800000000000005e-13	Axial length;
LUSC	cis	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg06521331	chr12:34319734	NA	-0.41	-6.69	-0.34	9.21e-11	Morning vs. evening chronotype;
LUSC	cis	rs6700896	0.931	rs11809906	chr1:66115064	C/T	cg04111102	chr1:66153794	NA	0.32	7.1	0.36	7.54e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.22	0.52	5.39e-25	Morning vs. evening chronotype;
LUSC	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg16070123	chr10:51489643	NA	0.57	9.38	0.46	1.07e-18	Prostate-specific antigen levels;
LUSC	cis	rs2668423	0.922	rs266805	chr19:1376723	C/T	cg02639931	chr19:1387894	NDUFS7	-0.52	-8.89	-0.44	3.78e-17	Nonalcoholic fatty liver disease;
LUSC	cis	rs61935443	0.832	rs11107771	chr12:95276844	A/G	cg21533806	chr12:95267307	NA	0.53	6.65	0.34	1.19e-10	Schizophrenia;
LUSC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.73	-13.2	-0.59	2.63e-32	Cognitive function;
LUSC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.21e-35	Breast cancer;
LUSC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg12615879	chr12:58013172	SLC26A10	-0.29	-6.11	-0.32	2.84e-9	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg10382835	chr6:42185730	MRPS10	0.68	6.53	0.34	2.52e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs6669072	0.647	rs814546	chr1:91239355	G/T	cg08895590	chr1:91227319	NA	-0.36	-8.22	-0.41	4.47e-15	Cognitive function;
LUSC	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg23241863	chr10:102295624	HIF1AN	0.5	5.71	0.3	2.53e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2860975	0.905	rs10786182	chr10:96789775	C/T	cg09036531	chr10:96991505	NA	-0.45	-6.33	-0.33	7.85e-10	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg01879757	chr17:41196368	BRCA1	-0.46	-6.58	-0.34	1.86e-10	Menopause (age at onset);
LUSC	cis	rs7577696	0.785	rs11683760	chr2:32364093	C/T	cg02381751	chr2:32503542	YIPF4	-0.42	-5.81	-0.3	1.48e-8	Inflammatory biomarkers;
LUSC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.82	0.39	7.02e-14	Prudent dietary pattern;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00834319	chr14:64970752	ZBTB25;ZBTB1	-0.42	-6.12	-0.32	2.64e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg07395648	chr5:131743802	NA	-0.37	-5.66	-0.3	3.32e-8	Breast cancer;
LUSC	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg18232548	chr7:50535776	DDC	-0.71	-11.09	-0.52	1.58e-24	Response to zileuton treatment in asthma (FEV1 change interaction);
LUSC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg22903471	chr2:27725779	GCKR	-0.39	-6.69	-0.34	9.58e-11	Total body bone mineral density;
LUSC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs68170813	0.641	rs6979368	chr7:107089009	C/G	cg02696742	chr7:106810147	HBP1	-0.66	-9.66	-0.47	1.21e-19	Coronary artery disease;
LUSC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	1.12	13.82	0.6	1.17e-34	Type 2 diabetes nephropathy;
LUSC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg04025307	chr7:1156635	C7orf50	0.44	5.95	0.31	6.78e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7605827	0.930	rs1997307	chr2:15512588	T/C	cg19274914	chr2:15703543	NA	0.46	8.89	0.44	3.98e-17	Educational attainment (years of education);
LUSC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06634786	chr22:41940651	POLR3H	-0.49	-6.14	-0.32	2.38e-9	Vitiligo;
LUSC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.11	-0.32	2.8e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.34	-6.29	-0.33	9.75e-10	Hirschsprung disease;
LUSC	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.9	-0.31	9.11e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg05973401	chr12:123451056	ABCB9	0.62	8.94	0.44	2.65e-17	Platelet count;
LUSC	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg04989706	chr14:50066350	PPIL5	-0.48	-6.26	-0.32	1.16e-9	Carotid intima media thickness;
LUSC	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Alcohol dependence;
LUSC	trans	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg07393940	chr7:158741817	NA	0.36	6.57	0.34	1.98e-10	Life satisfaction;
LUSC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg03732007	chr1:2071316	PRKCZ	-0.53	-9.36	-0.46	1.21e-18	Height;
LUSC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-1.2	-13.78	-0.6	1.67e-34	Diabetic kidney disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01073178	chr12:117537710	TESC	0.48	8.81	0.43	6.84e-17	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg07701084	chr6:150067640	NUP43	0.55	8.29	0.41	2.84e-15	Lung cancer;
LUSC	cis	rs36093844	0.800	rs76663264	chr11:85578455	C/G	cg25872744	chr11:85566296	CCDC83	-0.45	-5.88	-0.31	9.88e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg26876637	chr1:152193138	HRNR	0.45	6.61	0.34	1.54e-10	Atopic dermatitis;
LUSC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg02269571	chr22:50332266	NA	-0.57	-8.57	-0.42	3.92e-16	Schizophrenia;
LUSC	cis	rs870825	0.932	rs2696059	chr4:185575127	A/T	cg04058563	chr4:185651563	MLF1IP	-0.83	-11.36	-0.53	1.71e-25	Blood protein levels;
LUSC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs10432489	0.708	rs10189224	chr2:181764318	A/C	cg09897338	chr1:211849090	NEK2	-0.83	-6.1	-0.32	2.87e-9	QT interval;
LUSC	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.44	6.87	0.35	3.22e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg11608241	chr8:8085544	FLJ10661	0.42	6.27	0.32	1.14e-9	Neuroticism;
LUSC	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg13256891	chr4:100009986	ADH5	-0.44	-6.09	-0.32	3.05e-9	Alcohol dependence;
LUSC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg18240062	chr17:79603768	NPLOC4	0.7	13.1	0.58	6.19e-32	Eye color traits;
LUSC	cis	rs10248839	0.518	rs1317741	chr7:29711149	T/C	cg19413766	chr7:29689036	LOC646762	-0.54	-7.33	-0.37	1.75e-12	Facial emotion recognition (angry faces);
LUSC	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg15737290	chr11:93063684	CCDC67	0.64	8.12	0.41	9.11e-15	Pulmonary function decline;
LUSC	cis	rs2637266	1.000	rs7896831	chr10:78366649	A/T	cg18941641	chr10:78392320	NA	0.39	7.11	0.36	7.28e-12	Pulmonary function;
LUSC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg20476274	chr7:133979776	SLC35B4	0.87	16.7	0.67	6.08e-46	Mean platelet volume;
LUSC	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg23625390	chr15:77176239	SCAPER	-0.67	-10.04	-0.48	6.78e-21	Blood metabolite levels;
LUSC	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.96	13.5	0.59	1.85e-33	Initial pursuit acceleration;
LUSC	cis	rs4834770	1.000	rs6857641	chr4:120243511	T/C	cg24375607	chr4:120327624	NA	0.41	5.84	0.3	1.26e-8	Blood protein levels;
LUSC	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg23202291	chr11:1979235	NA	0.39	6.1	0.32	2.96e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20114781	chr15:43622253	ADAL;LCMT2	0.75	6.04	0.31	4.02e-9	Cognitive performance;
LUSC	cis	rs9311676	0.656	rs59643048	chr3:58390248	A/G	cg26110898	chr3:58419937	PDHB	0.4	6.42	0.33	4.56e-10	Systemic lupus erythematosus;
LUSC	cis	rs921943	0.957	rs6881725	chr5:78310754	T/C	cg16405876	chr5:78317871	DMGDH	0.28	5.7	0.3	2.69e-8	Blood and toenail selenium levels;Blood trace element (Se levels);
LUSC	cis	rs9311676	0.609	rs55797456	chr3:58378206	C/T	cg26110898	chr3:58419937	PDHB	0.42	6.77	0.35	5.85e-11	Systemic lupus erythematosus;
LUSC	trans	rs9409565	0.826	rs9409767	chr9:97228524	T/C	cg05679027	chr9:99775184	HIATL2	-0.49	-7.04	-0.36	1.09e-11	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg10523860	chr14:103875565	MARK3	-0.37	-6.07	-0.32	3.42e-9	Body mass index;
LUSC	trans	rs9393777	0.920	rs35716472	chr6:27406607	C/G	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.79	-0.43	8e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg25214090	chr10:38739885	LOC399744	0.5	7.57	0.38	3.58e-13	Corneal astigmatism;
LUSC	cis	rs9905704	0.918	rs304283	chr17:56785725	C/T	cg12560992	chr17:57184187	TRIM37	0.54	7.75	0.39	1.15e-13	Testicular germ cell tumor;
LUSC	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg15997130	chr1:24165203	NA	-0.52	-8.34	-0.42	1.99e-15	Immature fraction of reticulocytes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg15577575	chr1:145470249	ANKRD34A;POLR3GL	-0.45	-6.04	-0.31	4.15e-9	Hepatitis;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg01238044	chr22:24384105	GSTT1	-0.62	-9.96	-0.48	1.23e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-10.82	-0.51	1.36e-23	Monocyte percentage of white cells;
LUSC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-0.88	-16.85	-0.68	1.6e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.84	-0.3	1.23e-8	Total body bone mineral density;
LUSC	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg18721089	chr20:30220636	NA	-0.37	-5.75	-0.3	2.05e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg13736514	chr6:26305472	NA	0.46	8.96	0.44	2.37e-17	Educational attainment;
LUSC	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-1.47	-12.53	-0.57	8.61e-30	Plateletcrit;
LUSC	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg00564555	chr16:1970112	NA	-0.36	-6.39	-0.33	5.65e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs859767	0.704	rs1818614	chr2:135356351	A/G	cg12500956	chr2:135428796	TMEM163	-0.27	-6.18	-0.32	1.88e-9	Neuroticism;
LUSC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg22638593	chr5:131593259	PDLIM4	-0.48	-7.32	-0.37	1.88e-12	Acylcarnitine levels;
LUSC	cis	rs10911251	0.528	rs10911264	chr1:183115040	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.64	0.5	5.92e-23	Colorectal cancer;
LUSC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg24562669	chr7:97807699	LMTK2	0.35	6.16	0.32	2.07e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg22868518	chr11:507468	RNH1	-0.6	-5.92	-0.31	7.78e-9	Body mass index;
LUSC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg03388025	chr16:89894329	SPIRE2	0.35	7.55	0.38	4.21e-13	Vitiligo;
LUSC	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg05283184	chr6:79620031	NA	-0.57	-11.82	-0.54	3.53e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs7532866	0.885	rs7517224	chr1:26731029	A/G	cg17456097	chr1:26900765	RPS6KA1	-0.42	-6.11	-0.32	2.85e-9	Height;
LUSC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg21880101	chr17:80066754	CCDC57	-0.3	-5.72	-0.3	2.37e-8	Life satisfaction;
LUSC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg18240062	chr17:79603768	NPLOC4	0.61	10.28	0.49	1e-21	Eye color traits;
LUSC	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg21385522	chr1:16154831	NA	-0.98	-18.47	-0.71	5.65e-53	Dilated cardiomyopathy;
LUSC	cis	rs698813	0.674	rs6544753	chr2:44501895	A/T	cg00619915	chr2:44497795	NA	-0.53	-7.18	-0.37	4.66e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.58	9.41	0.46	8.25e-19	Aortic root size;
LUSC	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	10.76	0.51	2.24e-23	Ileal carcinoids;
LUSC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg12564285	chr5:131593104	PDLIM4	0.53	9.71	0.47	8.21e-20	Acylcarnitine levels;
LUSC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-6.84	-0.35	3.79e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.92e-20	Coronary artery disease;
LUSC	cis	rs295140	0.605	rs3769471	chr2:201195403	G/A	cg04283868	chr2:201171347	SPATS2L	0.41	6.03	0.31	4.41e-9	QT interval;
LUSC	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg12386194	chr3:101231763	SENP7	0.63	8.61	0.43	2.85e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg00290607	chr11:67383545	NA	0.37	6.88	0.35	3.04e-11	Mean corpuscular volume;
LUSC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg25036284	chr2:26402008	FAM59B	-0.68	-9.38	-0.46	1.06e-18	Gut microbiome composition (summer);
LUSC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-12.01	-0.55	7.05e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg22676075	chr6:135203613	NA	0.46	7.15	0.36	5.34e-12	Red blood cell count;
LUSC	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Colorectal cancer;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26355072	chr5:141674679	NA	-0.41	-6.76	-0.35	6.27e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.5	-0.38	5.79e-13	Personality dimensions;
LUSC	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	13.56	0.6	1.15e-33	Lymphocyte percentage of white cells;
LUSC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.21	0.32	1.62e-9	Schizophrenia;
LUSC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.38	0.69	1.15e-48	Chronic sinus infection;
LUSC	trans	rs2679649	1.000	rs2816128	chr6:122357203	G/A	cg00167820	chr8:131663355	NA	0.54	6.33	0.33	8.12e-10	Subcutaneous adipose tissue;
LUSC	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg03806693	chr22:41940476	POLR3H	-0.61	-9.01	-0.44	1.62e-17	Vitiligo;
LUSC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.88	-0.51	8.54e-24	Chronic sinus infection;
LUSC	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg11130432	chr3:121712080	ILDR1	-0.63	-9.59	-0.46	2.19e-19	Multiple sclerosis;
LUSC	trans	rs72674100	1.000	rs10016964	chr4:97989089	T/C	cg16405019	chr1:18959625	PAX7	-0.61	-6.44	-0.33	4.04e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg24060327	chr5:131705240	SLC22A5	-0.54	-8.89	-0.44	3.97e-17	Acylcarnitine levels;
LUSC	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.22	-0.32	1.52e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs8179	0.700	rs42040	chr7:92245927	C/T	cg15732164	chr7:92237376	CDK6	-0.5	-6.87	-0.35	3.11e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs7188861	0.681	rs6498184	chr16:11435990	A/G	cg00044050	chr16:11439710	C16orf75	-0.59	-6.47	-0.33	3.46e-10	HDL cholesterol;
LUSC	cis	rs4363385	0.510	rs55959888	chr1:152913490	A/G	cg00922841	chr1:152955080	SPRR1A	-0.36	-5.91	-0.31	8.57e-9	Inflammatory skin disease;
LUSC	cis	rs727505	0.954	rs989177	chr7:124412886	A/G	cg23710748	chr7:124431027	NA	-0.42	-7.53	-0.38	4.82e-13	Lewy body disease;
LUSC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg00343986	chr7:65444356	GUSB	0.45	6.9	0.35	2.64e-11	Aortic root size;
LUSC	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg13852791	chr20:30311386	BCL2L1	0.95	14.76	0.63	2.54e-38	Mean corpuscular hemoglobin;
LUSC	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg03929089	chr4:120376271	NA	-0.54	-6.15	-0.32	2.26e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9341808	1.000	rs1359239	chr6:80956146	G/A	cg08355045	chr6:80787529	NA	0.53	9.38	0.46	1.07e-18	Sitting height ratio;
LUSC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.72	-0.3	2.36e-8	Aortic root size;
LUSC	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.01	0.44	1.65e-17	Red blood cell count;
LUSC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03517284	chr6:25882590	NA	-0.42	-7.31	-0.37	1.94e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg19592336	chr6:28129416	ZNF389	-0.43	-6.01	-0.31	4.98e-9	Depression;
LUSC	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg26384229	chr12:38710491	ALG10B	0.73	11.89	0.55	2.05e-27	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.67	-10.53	-0.5	1.39e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.74	7.4	0.38	1.14e-12	Initial pursuit acceleration;
LUSC	trans	rs1486139	0.967	rs10229794	chr7:46295363	A/G	cg17534202	chr9:96721102	NA	-0.35	-6.3	-0.33	9.47e-10	Select biomarker traits;
LUSC	cis	rs11166629	1.000	rs4909332	chr8:135646340	T/C	cg21672855	chr8:135614777	ZFAT	0.35	5.65	0.3	3.46e-8	Smoking quantity;
LUSC	cis	rs11608355	0.545	rs7969313	chr12:109907303	A/G	cg05360138	chr12:110035743	NA	0.9	11.61	0.54	2.01e-26	Neuroticism;
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25192855	chr1:209979283	IRF6	0.33	7.01	0.36	1.36e-11	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg17187183	chr4:55093834	PDGFRA	0.39	5.78	0.3	1.72e-8	Corneal astigmatism;
LUSC	cis	rs17407555	0.601	rs73229828	chr4:10026833	A/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.24	-0.32	1.36e-9	Schizophrenia (age at onset);
LUSC	cis	rs11676348	0.805	rs13007219	chr2:218963859	C/A	cg00012203	chr2:219082015	ARPC2	-0.54	-8.44	-0.42	9.63e-16	Ulcerative colitis;
LUSC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	13.26	0.59	1.56e-32	Platelet count;
LUSC	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg26195577	chr20:24973756	C20orf3	1.12	18.1	0.7	1.58e-51	Blood protein levels;
LUSC	cis	rs7191700	0.836	rs10163410	chr16:11430615	G/C	cg00044050	chr16:11439710	C16orf75	0.57	8.34	0.42	1.98e-15	Multiple sclerosis;
LUSC	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg04906043	chr13:21280425	IL17D	-0.47	-8.54	-0.42	4.75e-16	Dental caries;
LUSC	cis	rs6076065	0.683	rs2424556	chr20:23419556	C/T	cg11657817	chr20:23433608	CST11	0.41	7.45	0.38	7.97e-13	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg05925327	chr15:68127851	NA	-0.43	-6.95	-0.36	1.91e-11	Restless legs syndrome;
LUSC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24110177	chr3:50126178	RBM5	0.65	11.69	0.54	1.1e-26	Body mass index;
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.24	-0.41	4.05e-15	Lymphocyte counts;
LUSC	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg19789473	chr17:27170043	C17orf63	-0.3	-5.69	-0.3	2.75e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs17407555	0.697	rs73212840	chr4:10087458	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-5.91	-0.31	8.4e-9	Schizophrenia (age at onset);
LUSC	trans	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg01620082	chr3:125678407	NA	0.51	5.99	0.31	5.49e-9	Depression;
LUSC	trans	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg05926928	chr17:57297772	GDPD1	0.51	7.2	0.37	4.04e-12	Schizophrenia;
LUSC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg15352829	chr14:105391018	PLD4	-0.39	-8.08	-0.4	1.2e-14	Rheumatoid arthritis;
LUSC	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg00540400	chr15:79124168	NA	0.46	8.1	0.41	1.06e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg17633681	chr16:88106987	BANP	-0.45	-8.04	-0.4	1.52e-14	Menopause (age at onset);
LUSC	cis	rs926938	0.527	rs360672	chr1:115483836	C/T	cg12756093	chr1:115239321	AMPD1	0.47	7.19	0.37	4.19e-12	Autism;
LUSC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-0.98	-17.61	-0.69	1.48e-49	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14731413	chr10:52833444	PRKG1	-0.34	-5.96	-0.31	6.28e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs61931739	0.583	rs1873011	chr12:33752808	T/C	cg26384229	chr12:38710491	ALG10B	0.44	6.38	0.33	5.95e-10	Morning vs. evening chronotype;
LUSC	cis	rs1385374	0.858	rs34888374	chr12:129296536	G/A	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.8	-0.35	4.96e-11	Systemic lupus erythematosus;
LUSC	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg24006582	chr15:45444508	DUOX1	-0.6	-8.88	-0.44	4.09e-17	Uric acid levels;
LUSC	cis	rs4474465	1.000	rs4945277	chr11:78166967	C/T	cg27205649	chr11:78285834	NARS2	-0.49	-5.8	-0.3	1.53e-8	Alzheimer's disease (survival time);
LUSC	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	0.87	14.4	0.62	6.61e-37	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs1775715	0.707	rs2808081	chr10:32162342	C/T	cg04359828	chr10:32216031	ARHGAP12	-0.35	-6.05	-0.31	3.95e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg10523860	chr14:103875565	MARK3	-0.36	-5.67	-0.3	3.08e-8	Body mass index;
LUSC	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14829155	chr15:31115871	NA	-0.57	-7.93	-0.4	3.23e-14	Huntington's disease progression;
LUSC	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	0.87	12.85	0.58	5.63e-31	Obesity-related traits;
LUSC	trans	rs7939886	0.920	rs7112815	chr11:55960104	T/C	cg03929089	chr4:120376271	NA	0.82	6.22	0.32	1.53e-9	Myopia (pathological);
LUSC	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg07169764	chr2:136633963	MCM6	-0.61	-8.02	-0.4	1.82e-14	Mosquito bite size;
LUSC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg18196295	chr10:418757	DIP2C	-0.42	-6.38	-0.33	6.03e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg23281280	chr6:28129359	ZNF389	0.45	5.86	0.31	1.14e-8	Parkinson's disease;
LUSC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.71	-10.78	-0.51	1.91e-23	Menarche (age at onset);
LUSC	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.78	11.21	0.52	5.63e-25	Corneal astigmatism;
LUSC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg14092988	chr3:52407081	DNAH1	0.31	6.12	0.32	2.57e-9	Bipolar disorder;
LUSC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.25	-0.49	1.28e-21	Hemoglobin concentration;
LUSC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg21724239	chr8:58056113	NA	0.83	9.77	0.47	5.21e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg06521331	chr12:34319734	NA	-0.43	-6.63	-0.34	1.37e-10	Morning vs. evening chronotype;
LUSC	cis	rs911119	0.955	rs6048946	chr20:23602307	G/T	cg16589663	chr20:23618590	CST3	0.59	7.08	0.36	8.56e-12	Chronic kidney disease;
LUSC	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg01657329	chr11:68192670	LRP5	0.48	6.35	0.33	7.17e-10	Bone mineral density (spine);
LUSC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg12863693	chr15:85201151	NMB	0.35	6.88	0.35	3.05e-11	Schizophrenia;
LUSC	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.31	-0.33	8.79e-10	Dupuytren's disease;
LUSC	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg14664628	chr15:75095509	CSK	-0.9	-14.04	-0.61	1.6e-35	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg05855489	chr10:104503620	C10orf26	-0.49	-7.47	-0.38	7.25e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg04310649	chr10:35416472	CREM	-0.41	-6.54	-0.34	2.32e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg15737290	chr11:93063684	CCDC67	-0.59	-7.05	-0.36	1.03e-11	Pulmonary function decline;
LUSC	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg01620082	chr3:125678407	NA	-0.8	-7.24	-0.37	3.11e-12	Depression;
LUSC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg16606324	chr3:10149918	C3orf24	-0.58	-7.94	-0.4	3.03e-14	Alzheimer's disease;
LUSC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg07424592	chr7:64974309	NA	0.7	6.2	0.32	1.67e-9	Diabetic kidney disease;
LUSC	trans	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg01620082	chr3:125678407	NA	-0.6	-6.63	-0.34	1.34e-10	Depression;
LUSC	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.87	0.51	9.1e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs68170813	0.652	rs79295036	chr7:107193669	C/A	cg02696742	chr7:106810147	HBP1	-0.64	-8.58	-0.42	3.72e-16	Coronary artery disease;
LUSC	cis	rs2797160	0.547	rs1418645	chr6:125946476	T/A	cg05901451	chr6:126070800	HEY2	-0.43	-6.08	-0.32	3.24e-9	Endometrial cancer;
LUSC	cis	rs67072384	0.748	rs6592484	chr11:72464470	C/T	cg04827223	chr11:72435913	ARAP1	-0.73	-6.35	-0.33	7.13e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg14383238	chr14:77647983	TMEM63C	0.51	6.35	0.33	6.85e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2692947	0.644	rs772154	chr2:97021664	G/T	cg23100626	chr2:96804247	ASTL	0.27	6.43	0.33	4.46e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs701145	0.585	rs357476	chr3:153892844	A/G	cg17054900	chr3:154042577	DHX36	-0.7	-7.14	-0.36	5.94e-12	Coronary artery disease;
LUSC	cis	rs17253792	0.822	rs77408754	chr14:56082047	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-6.27	-0.32	1.08e-9	Putamen volume;
LUSC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25072359	chr17:41440525	NA	0.65	9.39	0.46	9.33e-19	Menopause (age at onset);
LUSC	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg07382826	chr16:28625726	SULT1A1	0.28	5.81	0.3	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	1.1	16.97	0.68	5.24e-47	Gut microbiome composition (summer);
LUSC	trans	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	6.9	0.35	2.66e-11	Retinal vascular caliber;
LUSC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.69	0.63	4.85e-38	Menopause (age at onset);
LUSC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg22437258	chr11:111473054	SIK2	-0.48	-6.2	-0.32	1.65e-9	Primary sclerosing cholangitis;
LUSC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg04450456	chr4:17643702	FAM184B	0.4	6.92	0.35	2.25e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6433857	0.534	rs1157535	chr2:181361736	T/A	cg23363182	chr2:181467187	NA	-0.44	-7.16	-0.36	5.15e-12	Body mass index;
LUSC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.66	-11.47	-0.53	6.81e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.88	-0.48	2.32e-20	Joint mobility (Beighton score);
LUSC	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg15962314	chr1:44399869	ARTN	0.27	6.49	0.33	3.16e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs61774743	0.681	rs10889959	chr1:41849735	T/C	cg08462924	chr1:41848221	NA	0.47	7.93	0.4	3.33e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.51e-14	Prudent dietary pattern;
LUSC	cis	rs7520050	0.966	rs946529	chr1:46485548	G/T	cg06784218	chr1:46089804	CCDC17	-0.29	-5.67	-0.3	3.13e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg01557791	chr16:72042693	DHODH	-0.49	-6.28	-0.33	1.04e-9	Blood protein levels;
LUSC	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.35	-0.42	1.8e-15	Response to antipsychotic treatment;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02978827	chr13:48877687	RB1	0.51	7.02	0.36	1.26e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg16615211	chr3:44902933	MIR564;TMEM42	0.36	6.3	0.33	9.37e-10	Depressive symptoms;
LUSC	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.94	0.36	2.04e-11	Rheumatoid arthritis;
LUSC	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg05163923	chr11:71159392	DHCR7	-0.66	-8.52	-0.42	5.58e-16	Vitamin D levels;
LUSC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-1.03	-20.09	-0.74	2.01e-59	Height;
LUSC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-8.27	-0.41	3.14e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg06618935	chr21:46677482	NA	-0.39	-7.95	-0.4	2.88e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6693567	0.586	rs9661040	chr1:150483236	A/C	cg15654264	chr1:150340011	RPRD2	0.44	7.04	0.36	1.1e-11	Migraine;
LUSC	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg25319279	chr11:5960081	NA	-0.41	-5.79	-0.3	1.64e-8	DNA methylation (variation);
LUSC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.68	0.39	1.72e-13	Prudent dietary pattern;
LUSC	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02176678	chr2:219576539	TTLL4	-0.67	-13.25	-0.59	1.7e-32	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs77633900	0.614	rs2170998	chr15:77007159	C/T	cg21673338	chr15:77095150	SCAPER	0.73	7.9	0.4	3.95e-14	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg05555928	chr11:63887634	MACROD1	-0.48	-6.09	-0.32	3.08e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2749592	0.918	rs4934590	chr10:37877569	T/C	cg25427524	chr10:38739819	LOC399744	0.46	6.31	0.33	8.73e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg13798780	chr7:105162888	PUS7	0.56	6.04	0.31	4.04e-9	Bipolar disorder (body mass index interaction);
LUSC	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-12.05	-0.55	5.24e-28	Morning vs. evening chronotype;
LUSC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg01416388	chr22:39784598	NA	-0.39	-5.9	-0.31	8.75e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs10752881	0.505	rs35855069	chr1:183115341	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.32	0.49	7.22e-22	Colorectal cancer;
LUSC	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg24375607	chr4:120327624	NA	0.75	10.86	0.51	1.01e-23	Corneal astigmatism;
LUSC	trans	rs11989744	0.500	rs7844903	chr8:23568464	T/C	cg03492747	chr16:86543808	FOXF1	-0.66	-11.48	-0.53	6.29e-26	Waist-hip ratio;
LUSC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg04155289	chr7:94953770	PON1	0.47	9.51	0.46	3.82e-19	Paraoxonase activity;
LUSC	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg12223502	chr10:5658492	NA	-0.37	-5.77	-0.3	1.79e-8	Breast cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.43	6.05	0.31	3.97e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26354017	chr1:205819088	PM20D1	0.84	14.91	0.63	6.67e-39	Menarche (age at onset);
LUSC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg12463550	chr7:65579703	CRCP	-0.48	-7.11	-0.36	7.13e-12	Aortic root size;
LUSC	cis	rs2273669	0.667	rs11754955	chr6:109287459	A/G	cg05315195	chr6:109294784	ARMC2	-0.58	-6.41	-0.33	5.05e-10	Prostate cancer;
LUSC	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg09699651	chr6:150184138	LRP11	0.45	7.17	0.37	4.98e-12	Testicular germ cell tumor;
LUSC	cis	rs78761021	0.720	rs874307	chr17:9798074	C/G	cg26853458	chr17:9805074	RCVRN	0.34	5.9	0.31	9.08e-9	Type 2 diabetes;
LUSC	cis	rs11608355	0.846	rs35393419	chr12:109881809	C/T	cg05360138	chr12:110035743	NA	0.59	7.6	0.38	3.02e-13	Neuroticism;
LUSC	cis	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg21775007	chr8:11205619	TDH	-0.53	-7.54	-0.38	4.38e-13	Triglycerides;
LUSC	cis	rs13385	0.815	rs34386219	chr5:139561906	G/A	cg26211634	chr5:139558579	C5orf32	0.45	6.54	0.34	2.25e-10	Atrial fibrillation;
LUSC	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg02176678	chr2:219576539	TTLL4	-0.59	-10.45	-0.5	2.59e-22	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg07211511	chr3:129823064	LOC729375	-0.53	-6.08	-0.32	3.25e-9	Blood pressure (smoking interaction);
LUSC	cis	rs6060960	0.537	rs6089103	chr20:30464919	G/T	cg13852791	chr20:30311386	BCL2L1	0.56	6.21	0.32	1.57e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7215564	0.908	rs4889879	chr17:78662573	A/T	cg23238734	chr17:78661607	RPTOR	-0.44	-5.82	-0.3	1.35e-8	Myopia (pathological);
LUSC	cis	rs28830936	0.966	rs11635067	chr15:42124673	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.72	-0.3	2.37e-8	Diastolic blood pressure;
LUSC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg14895029	chr7:2775587	GNA12	0.39	6.08	0.32	3.22e-9	Height;
LUSC	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg02275930	chr1:2372054	NA	-0.54	-7.59	-0.38	3.1400000000000003e-13	Non-obstructive azoospermia;
LUSC	trans	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg18187862	chr3:45730750	SACM1L	-0.53	-6.57	-0.34	1.99e-10	Primary sclerosing cholangitis;
LUSC	trans	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg25815440	chr2:42134162	NA	-0.26	-6.02	-0.31	4.51e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg13607699	chr17:42295918	UBTF	0.55	8.34	0.42	1.93e-15	Total body bone mineral density;
LUSC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.5	0.56	1.14e-29	Motion sickness;
LUSC	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg03948781	chr1:205179583	DSTYK	0.33	6.46	0.33	3.63e-10	Red blood cell count;
LUSC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18854424	chr1:2615690	NA	0.5	10.34	0.49	6.33e-22	Ulcerative colitis;
LUSC	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg11861562	chr11:117069780	TAGLN	-0.33	-6.42	-0.33	4.56e-10	Blood protein levels;
LUSC	cis	rs7605827	0.897	rs7564514	chr2:15654808	G/A	cg19274914	chr2:15703543	NA	0.46	8.83	0.43	6.22e-17	Educational attainment (years of education);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23702945	chr17:62131694	ERN1	0.42	6.08	0.32	3.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs791888	0.929	rs791887	chr10:89411554	A/G	cg13926569	chr10:89418898	PAPSS2	-0.37	-7.31	-0.37	1.98e-12	Magnesium levels;
LUSC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.16	0.77	1.43e-67	Prudent dietary pattern;
LUSC	cis	rs55986470	0.817	rs72993054	chr2:239404244	C/T	cg18131467	chr2:239335373	ASB1	-0.66	-6.49	-0.33	3.19e-10	Chronotype;
LUSC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg17971929	chr21:40555470	PSMG1	-0.65	-10.61	-0.5	7.41e-23	Cognitive function;
LUSC	trans	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg01620082	chr3:125678407	NA	-0.64	-6.64	-0.34	1.24e-10	Breast cancer;
LUSC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg07169764	chr2:136633963	MCM6	1.18	18.03	0.7	3.01e-51	Corneal structure;
LUSC	cis	rs7523050	0.730	rs35100394	chr1:109433989	C/G	cg08274380	chr1:109419600	GPSM2	1.13	11.51	0.53	4.76e-26	Fat distribution (HIV);
LUSC	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg18683606	chr7:100471612	SRRT	0.44	5.95	0.31	6.75e-9	Resting heart rate;
LUSC	cis	rs67539049	1.000	rs68063127	chr8:11303726	G/C	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.41	-6.38	-0.33	5.98e-10	Itch intensity from mosquito bite;
LUSC	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	6.74	0.35	7.17e-11	Lung cancer in ever smokers;
LUSC	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg21100191	chr22:23484243	RTDR1	0.86	14.34	0.62	1.11e-36	Bone mineral density;
LUSC	cis	rs5770917	1.000	rs2073605	chr22:51008850	A/G	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.57	-5.67	-0.3	3.15e-8	Narcolepsy;
LUSC	cis	rs925255	0.747	rs6547850	chr2:28629343	G/T	cg01273330	chr2:28605224	NA	0.41	6.66	0.34	1.1e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-8.16	-0.41	6.74e-15	Type 2 diabetes;
LUSC	cis	rs7712401	0.645	rs246316	chr5:122266197	T/C	cg19077854	chr5:122220652	SNX24	0.42	9.36	0.46	1.18e-18	Mean platelet volume;
LUSC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg10360139	chr7:1886902	MAD1L1	-0.38	-5.66	-0.3	3.31e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg22907277	chr7:1156413	C7orf50	0.47	7.24	0.37	3.13e-12	Longevity;Endometriosis;
LUSC	cis	rs2742234	0.955	rs2435384	chr10:43673731	G/T	cg02780029	chr10:43622663	RET	-0.33	-5.99	-0.31	5.43e-9	Hirschsprung disease;
LUSC	cis	rs10779751	0.734	rs2261317	chr1:11124979	A/G	cg04508216	chr1:11107452	MASP2	0.33	5.87	0.31	1.03e-8	Body mass index;
LUSC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08109568	chr15:31115862	NA	-0.61	-8.44	-0.42	9.67e-16	Huntington's disease progression;
LUSC	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg27572855	chr1:25598939	RHD	-0.42	-7.45	-0.38	8.04e-13	Erythrocyte sedimentation rate;
LUSC	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg00321850	chr1:175162397	KIAA0040	-0.44	-7.62	-0.38	2.63e-13	Alcohol dependence;
LUSC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg22907277	chr7:1156413	C7orf50	0.41	6.17	0.32	2.01e-9	Longevity;Endometriosis;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg04534504	chr10:62704143	RHOBTB1	0.38	6.31	0.33	8.84e-10	Educational attainment (years of education);
LUSC	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg16386425	chr10:429943	DIP2C	-0.4	-6.34	-0.33	7.64e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg05147244	chr20:61493195	TCFL5	0.88	6.61	0.34	1.52e-10	Obesity-related traits;
LUSC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg05738196	chr6:26577821	NA	0.79	15.16	0.64	7.07e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs6681460	0.649	rs7540195	chr1:67002406	C/T	cg02459107	chr1:67143332	SGIP1	-0.37	-5.89	-0.31	9.44e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs71403859	0.502	rs8051974	chr16:71488771	C/T	cg08717414	chr16:71523259	ZNF19	-0.69	-8.51	-0.42	6.01e-16	Post bronchodilator FEV1;
LUSC	cis	rs12760731	0.641	rs11588490	chr1:178328139	T/A	cg00404053	chr1:178313656	RASAL2	0.57	6.07	0.32	3.44e-9	Obesity-related traits;
LUSC	trans	rs3857536	0.776	rs4710583	chr6:66940101	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.42	6.65	0.34	1.17e-10	Dupuytren's disease;
LUSC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-7.63	-0.39	2.47e-13	Bipolar disorder;
LUSC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.75	-0.35	6.7e-11	Menopause (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04522040	chr19:11039280	YIPF2;C19orf52	0.73	5.98	0.31	5.58e-9	Cognitive performance;
LUSC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.1	-0.36	7.4e-12	Bipolar disorder;
LUSC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg24399712	chr22:39784796	NA	-0.62	-11.46	-0.53	7.19e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18876405	chr7:65276391	NA	-0.55	-8.66	-0.43	2.09e-16	Aortic root size;
LUSC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg05896524	chr21:47604654	C21orf56	-0.53	-8.23	-0.41	4.26e-15	Testicular germ cell tumor;
LUSC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg16797656	chr11:68205561	LRP5	0.36	6.03	0.31	4.25e-9	Total body bone mineral density;
LUSC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.64	-9.39	-0.46	9.68e-19	Monocyte percentage of white cells;
LUSC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	0.83	14.2	0.61	4.02e-36	Menopause (age at onset);
LUSC	cis	rs4363385	0.626	rs1108410	chr1:153005662	T/C	cg25856811	chr1:152973957	SPRR3	-0.39	-6.44	-0.33	4.09e-10	Inflammatory skin disease;
LUSC	trans	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.45	6.88	0.35	3.03e-11	Endometrial cancer;
LUSC	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg23093090	chr10:104574429	C10orf26	-0.34	-6.28	-0.33	1.02e-9	Arsenic metabolism;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03591798	chr2:73404524	NA	0.44	6.3	0.33	9.14e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg01802117	chr1:53393560	SCP2	0.38	6.14	0.32	2.4e-9	Monocyte count;
LUSC	cis	rs9473147	0.571	rs9369717	chr6:47554468	T/G	cg20196966	chr6:47445060	CD2AP	0.43	6.04	0.31	4e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg08779649	chr13:50194554	NA	0.39	6.59	0.34	1.72e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs11264799	0.765	rs6427389	chr1:157632011	C/A	cg18268488	chr1:157545234	FCRL4	0.33	6.03	0.31	4.27e-9	IgA nephropathy;
LUSC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.22	0.59	2.22e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.42	6.05	0.31	3.9e-9	Breast cancer;
LUSC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.15	0.45	5.86e-18	Motion sickness;
LUSC	cis	rs62400317	0.762	rs10484625	chr6:44823449	G/A	cg20913747	chr6:44695427	NA	-0.47	-7.44	-0.38	8.51e-13	Total body bone mineral density;
LUSC	cis	rs2840044	0.534	rs321596	chr17:33885736	C/T	cg05299278	chr17:33885742	SLFN14	-0.33	-7.44	-0.38	8.86e-13	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg08601574	chr20:25228251	PYGB	-0.41	-6.32	-0.33	8.57e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg09035930	chr12:129282057	SLC15A4	-0.57	-9.84	-0.47	3.03e-20	Systemic lupus erythematosus;
LUSC	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg08601574	chr20:25228251	PYGB	0.46	6.98	0.36	1.62e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg17143192	chr8:8559678	CLDN23	0.56	7.83	0.39	6.51e-14	Obesity-related traits;
LUSC	cis	rs870825	0.929	rs1405941	chr4:185591518	A/C	cg04058563	chr4:185651563	MLF1IP	-0.82	-10.98	-0.51	3.75e-24	Blood protein levels;
LUSC	cis	rs4400599	0.618	rs10908751	chr1:154187305	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.92	-0.31	7.78e-9	Platelet distribution width;
LUSC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg11752832	chr7:134001865	SLC35B4	0.59	9.09	0.45	8.87e-18	Mean platelet volume;
LUSC	cis	rs7560272	0.538	rs6732812	chr2:73922475	T/C	cg20560298	chr2:73613845	ALMS1	0.4	6.26	0.32	1.16e-9	Schizophrenia;
LUSC	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg08999081	chr20:33150536	PIGU	0.32	5.68	0.3	2.91e-8	Height;
LUSC	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.77	-12.95	-0.58	2.23e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7180079	1.000	rs8034610	chr15:64628917	G/A	cg02848875	chr15:64387786	SNX1	0.41	5.84	0.3	1.27e-8	Monocyte count;
LUSC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg03354898	chr7:1950403	MAD1L1	-0.43	-8.61	-0.43	2.92e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	12.58	0.57	5.75e-30	Lung cancer in ever smokers;
LUSC	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg22875332	chr1:76189707	ACADM	-0.39	-5.8	-0.3	1.51e-8	Daytime sleep phenotypes;
LUSC	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg22356347	chr1:167427500	CD247	0.35	8.17	0.41	6.39e-15	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.15	0.32	2.16e-9	Morning vs. evening chronotype;
LUSC	trans	rs11264799	0.716	rs1113662	chr1:157635825	T/C	cg25498969	chr3:136062740	STAG1	-0.24	-5.98	-0.31	5.65e-9	IgA nephropathy;
LUSC	cis	rs716595	1.000	rs12416343	chr10:111992624	G/C	cg13996003	chr10:112034540	MXI1	-0.7	-5.81	-0.3	1.42e-8	Normalized brain volume;
LUSC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2354432	0.505	rs7551766	chr1:146858964	A/G	cg25205988	chr1:146714368	CHD1L	-0.92	-7.63	-0.39	2.44e-13	Mitochondrial DNA levels;
LUSC	trans	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg07393940	chr7:158741817	NA	0.38	6.88	0.35	2.9100000000000002e-11	Life satisfaction;
LUSC	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.46	6.29	0.33	1.02e-9	Multiple sclerosis;
LUSC	cis	rs62458065	0.713	rs28421905	chr7:32489501	G/A	cg20159608	chr7:32802032	NA	-0.73	-9.21	-0.45	3.77e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg27535305	chr1:53392650	SCP2	-0.4	-7.36	-0.37	1.44e-12	Monocyte count;
LUSC	cis	rs2070433	0.752	rs60290737	chr21:47837630	C/A	cg12379764	chr21:47803548	PCNT	0.76	8.92	0.44	3.04e-17	Lymphocyte counts;
LUSC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.31	0.37	2.03e-12	Motion sickness;
LUSC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22590775	chr19:49891494	CCDC155	0.57	7.48	0.38	6.73e-13	Multiple sclerosis;
LUSC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-17.76	-0.7	3.74e-50	Primary sclerosing cholangitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25401140	chr17:37558857	FBXL20	-0.41	-6.16	-0.32	2.11e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg17691542	chr6:26056736	HIST1H1C	0.39	5.88	0.31	9.87e-9	Schizophrenia;
LUSC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg25319279	chr11:5960081	NA	-0.37	-5.76	-0.3	1.88e-8	DNA methylation (variation);
LUSC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.28	0.37	2.47e-12	Mean platelet volume;
LUSC	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg17507749	chr15:85114479	UBE2QP1	0.52	6.3	0.33	9.57e-10	Schizophrenia;
LUSC	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg12165864	chr7:66369176	NA	-0.51	-6.75	-0.35	6.58e-11	Corneal structure;
LUSC	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.99	0.44	1.91e-17	Lung cancer;
LUSC	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg05855489	chr10:104503620	C10orf26	0.52	7.91	0.4	3.9e-14	Arsenic metabolism;
LUSC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg19592336	chr6:28129416	ZNF389	0.48	6.25	0.32	1.22e-9	Depression;
LUSC	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg13535736	chr9:111863775	C9orf5	-0.38	-6.1	-0.32	2.99e-9	Menarche (age at onset);
LUSC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11645453	chr3:52864694	ITIH4	0.33	7.6	0.38	3.08e-13	Electroencephalogram traits;
LUSC	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.13	0.64	9.04e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs10193935	0.901	rs2088281	chr2:42672731	A/G	cg27598129	chr2:42591480	NA	0.61	8.22	0.41	4.56e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10170846	0.626	rs9288575	chr2:223495133	A/C	cg25565276	chr2:223520875	FARSB	1.11	16.47	0.67	4.93e-45	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg10255544	chr17:80519551	FOXK2	0.38	6.24	0.32	1.33e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg22166914	chr1:53195759	ZYG11B	0.5	7.96	0.4	2.78e-14	Monocyte count;
LUSC	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg27471124	chr11:109292789	C11orf87	0.43	7.67	0.39	1.86e-13	Schizophrenia;
LUSC	cis	rs7759001	0.817	rs6920362	chr6:27351239	A/G	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	2.04e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg11062466	chr8:58055876	NA	0.5	6.45	0.33	3.85e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs3813948	0.543	rs2808468	chr1:207280703	A/G	cg23343680	chr15:51397292	TNFAIP8L3	-0.53	-6.09	-0.32	3.17e-9	C4b binding protein levels;
LUSC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg06238570	chr21:40685208	BRWD1	0.49	7.51	0.38	5.59e-13	Cognitive function;
LUSC	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.9	0.77	1.58e-66	Prudent dietary pattern;
LUSC	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.75	-0.35	6.46e-11	Heart rate;
LUSC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg23281280	chr6:28129359	ZNF389	-0.49	-6.35	-0.33	7.17e-10	Parkinson's disease;
LUSC	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg18681998	chr4:17616180	MED28	0.75	13.11	0.58	5.78e-32	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg06484146	chr7:12443880	VWDE	-0.68	-7.08	-0.36	8.67e-12	Coronary artery disease;
LUSC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg22963979	chr7:1858916	MAD1L1	-0.6	-9.52	-0.46	3.54e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00149659	chr3:10157352	C3orf10	0.88	12.2	0.56	1.44e-28	Alzheimer's disease;
LUSC	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg22508957	chr16:3507546	NAT15	-0.4	-5.74	-0.3	2.14e-8	Body mass index (adult);
LUSC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg17178900	chr1:205818956	PM20D1	0.52	8.2	0.41	5.18e-15	Menarche (age at onset);
LUSC	cis	rs3820928	0.874	rs1917127	chr2:227895125	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.57	-0.38	3.59e-13	Pulmonary function;
LUSC	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg14584255	chr6:163149320	PACRG;PARK2	-0.34	-6.6	-0.34	1.66e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs55883249	1.000	rs10495571	chr2:9736066	A/G	cg23886495	chr2:9695866	ADAM17	0.48	5.68	0.3	3e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg09904177	chr6:26538194	HMGN4	0.69	6.68	0.34	1.02e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg11062466	chr8:58055876	NA	0.75	9.12	0.45	7.24e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs9807841	0.555	rs6511708	chr19:10788813	A/G	cg09936142	chr19:10668400	KRI1	-0.44	-6.93	-0.35	2.23e-11	Inflammatory skin disease;
LUSC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg12963246	chr6:28129442	ZNF389	0.52	7.18	0.37	4.53e-12	Depression;
LUSC	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	0.96	13.57	0.6	1.08e-33	Primary sclerosing cholangitis;
LUSC	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.7	10.67	0.5	4.72e-23	Corneal astigmatism;
LUSC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11644478	chr21:40555479	PSMG1	0.64	10.63	0.5	6.41e-23	Cognitive function;
LUSC	cis	rs7759001	0.857	rs9468116	chr6:27366812	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg16342193	chr10:102329863	NA	-0.36	-6.37	-0.33	6.22e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6977660	0.714	rs10249635	chr7:19787090	A/G	cg07541023	chr7:19748670	TWISTNB	0.66	6.56	0.34	2.08e-10	Thyroid stimulating hormone;
LUSC	cis	rs10979	1.000	rs9496671	chr6:143884742	G/A	cg25407410	chr6:143891975	LOC285740	-0.73	-11.66	-0.54	1.35e-26	Hypospadias;
LUSC	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.38	-0.33	6.08e-10	Bipolar disorder;
LUSC	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.98	0.36	1.63e-11	Lung cancer;
LUSC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.41	0.33	4.97e-10	Personality dimensions;
LUSC	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg10018233	chr7:150070692	REPIN1	0.37	6.49	0.33	3.07e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg22482690	chr17:47019901	SNF8	0.38	7.18	0.37	4.44e-12	Type 2 diabetes;
LUSC	cis	rs10186029	0.548	rs4673728	chr2:214001997	C/G	cg08319019	chr2:214017104	IKZF2	0.49	7.51	0.38	5.55e-13	Systemic sclerosis;
LUSC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18932078	chr1:2524107	MMEL1	-0.3	-6.54	-0.34	2.37e-10	Ulcerative colitis;
LUSC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg16606324	chr3:10149918	C3orf24	0.68	9.78	0.47	4.89e-20	Alzheimer's disease;
LUSC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06634786	chr22:41940651	POLR3H	0.53	6.39	0.33	5.71e-10	Vitiligo;
LUSC	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08645402	chr16:4508243	NA	0.49	7.76	0.39	1.02e-13	Schizophrenia;
LUSC	cis	rs6733011	0.600	rs1568213	chr2:99432063	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.16	-0.32	2.07e-9	Bipolar disorder;
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg16132339	chr22:24313637	DDTL;DDT	0.38	5.79	0.3	1.62e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.46	6.49	0.33	3.08e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg24733560	chr20:60626293	TAF4	-0.43	-7.88	-0.4	4.78e-14	Body mass index;
LUSC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg12463550	chr7:65579703	CRCP	-0.48	-7.11	-0.36	7.13e-12	Aortic root size;
LUSC	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-0.76	-9.06	-0.44	1.11e-17	Refractive error;
LUSC	cis	rs62400317	0.859	rs10456546	chr6:45217424	C/T	cg20913747	chr6:44695427	NA	-0.48	-7.72	-0.39	1.36e-13	Total body bone mineral density;
LUSC	cis	rs9815354	0.812	rs60927633	chr3:41844010	C/T	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7508679	1.000	rs7248104	chr19:7224431	A/G	cg00428638	chr19:7224713	INSR	0.39	8.11	0.41	9.46e-15	Hypothyroidism;
LUSC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg13736514	chr6:26305472	NA	0.47	9.49	0.46	4.53e-19	Educational attainment;
LUSC	trans	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.28e-9	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg26043149	chr18:55253948	FECH	-0.43	-6.51	-0.34	2.83e-10	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4594175	0.926	rs10149006	chr14:51615265	A/C	cg23942311	chr14:51606299	NA	0.31	5.95	0.31	6.79e-9	Cancer;
LUSC	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg00129232	chr17:37814104	STARD3	-0.47	-7.0	-0.36	1.39e-11	Asthma;
LUSC	cis	rs12618769	0.520	rs11892744	chr2:99237792	C/T	cg10123293	chr2:99228465	UNC50	0.47	7.39	0.37	1.18e-12	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.88	0.48	2.35e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg07959070	chr22:50026188	C22orf34	-0.37	-7.58	-0.38	3.43e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg10978503	chr1:24200527	CNR2	0.53	13.1	0.58	6.34e-32	Immature fraction of reticulocytes;
LUSC	cis	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.41	-0.38	1.02e-12	Morning vs. evening chronotype;
LUSC	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.74	0.3	2.08e-8	Lung cancer;
LUSC	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg24006582	chr15:45444508	DUOX1	0.66	9.32	0.45	1.65e-18	Uric acid levels;
LUSC	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg09455208	chr3:40491958	NA	-0.48	-8.8	-0.43	7.25e-17	Renal cell carcinoma;
LUSC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg16339924	chr4:17578868	LAP3	0.6	9.3	0.45	1.94e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9473147	0.516	rs9395286	chr6:47575332	T/C	cg02130027	chr6:47444894	CD2AP	0.36	5.77	0.3	1.78e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs2710642	0.962	rs1828398	chr2:63034870	A/G	cg17519650	chr2:63277830	OTX1	-0.47	-6.64	-0.34	1.29e-10	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg25922239	chr6:33757077	LEMD2	0.43	6.44	0.33	4.21e-10	Crohn's disease;
LUSC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.82	0.51	1.4e-23	Menopause (age at onset);
LUSC	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg24399712	chr22:39784796	NA	-0.63	-11.38	-0.53	1.36e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.7	-0.43	1.5e-16	Uric acid levels;
LUSC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23158103	chr7:148848205	ZNF398	-0.43	-7.05	-0.36	1.01e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.99	0.36	1.49e-11	Resting heart rate;
LUSC	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.65	-0.3	3.46e-8	Ileal carcinoids;
LUSC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24591563	chr3:40498842	RPL14	0.37	6.18	0.32	1.89e-9	Triglycerides;
LUSC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg09455208	chr3:40491958	NA	0.59	10.09	0.48	4.36e-21	Renal cell carcinoma;
LUSC	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg14438399	chr17:27053147	TLCD1	0.52	5.75	0.3	2.05e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.06	-0.31	3.68e-9	Systolic blood pressure;
LUSC	cis	rs2354432	1.000	rs2120003	chr1:146690635	A/G	cg25205988	chr1:146714368	CHD1L	0.81	7.95	0.4	2.89e-14	Mitochondrial DNA levels;
LUSC	trans	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg21659725	chr3:3221576	CRBN	-0.67	-7.97	-0.4	2.5e-14	Menarche (age at onset);
LUSC	cis	rs3099143	1.000	rs3099138	chr15:77115524	G/A	cg21673338	chr15:77095150	SCAPER	-0.78	-7.25	-0.37	2.92e-12	Recalcitrant atopic dermatitis;
LUSC	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg24006582	chr15:45444508	DUOX1	-0.61	-8.87	-0.44	4.61e-17	Uric acid levels;
LUSC	trans	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.85	0.35	3.56e-11	Endometrial cancer;
LUSC	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg27005118	chr17:13972210	COX10	0.51	9.92	0.48	1.68e-20	Temperament;
LUSC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.87	0.4	4.95e-14	Prudent dietary pattern;
LUSC	cis	rs1775715	0.737	rs2808090	chr10:32143208	A/C	cg04359828	chr10:32216031	ARHGAP12	0.39	6.73	0.35	7.23e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.76	-8.64	-0.43	2.44e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg22143856	chr6:28129313	ZNF389	0.43	5.83	0.3	1.34e-8	Parkinson's disease;
LUSC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg24250549	chr1:154909240	PMVK	-0.65	-10.67	-0.5	4.63e-23	Prostate cancer;
LUSC	cis	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.65	-0.3	3.52e-8	Eotaxin levels;
LUSC	cis	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg07460842	chr6:66804631	NA	0.88	8.93	0.44	2.87e-17	Exhaled nitric oxide output;
LUSC	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg19812747	chr11:111475976	SIK2	0.49	6.76	0.35	6.35e-11	Primary sclerosing cholangitis;
LUSC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12667521	chr19:29218732	NA	0.61	8.81	0.43	7.07e-17	Methadone dose in opioid dependence;
LUSC	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg05738196	chr6:26577821	NA	-0.52	-5.76	-0.3	1.86e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg20368463	chr18:77673604	PQLC1	0.74	7.82	0.39	6.93e-14	Opioid sensitivity;
LUSC	cis	rs2190422	0.677	rs2190419	chr7:103073087	C/G	cg04218035	chr7:103086829	SLC26A5	0.32	6.25	0.32	1.23e-9	Morning vs. evening chronotype;
LUSC	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg22138327	chr13:27999177	GTF3A	0.8	10.51	0.5	1.6e-22	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.17	0.52	7.69e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.46	-6.81	-0.35	4.5e-11	Height;
LUSC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.9	-0.55	1.86e-27	Chronic sinus infection;
LUSC	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg07148914	chr20:33460835	GGT7	0.46	6.73	0.35	7.48e-11	Height;
LUSC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	0.92	18.12	0.7	1.36e-51	Cognitive function;
LUSC	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	12.59	0.57	5.09e-30	Primary sclerosing cholangitis;
LUSC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21016266	chr12:122356598	WDR66	0.62	9.52	0.46	3.53e-19	Mean platelet volume;
LUSC	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg19468946	chr17:37922297	IKZF3	-0.39	-6.15	-0.32	2.19e-9	Self-reported allergy;
LUSC	cis	rs2414856	0.510	rs72756984	chr15:64589419	T/C	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg05872129	chr22:39784769	NA	-0.61	-11.56	-0.53	3.28e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg20307385	chr11:47447363	PSMC3	-0.45	-6.69	-0.34	9.64e-11	Subjective well-being;
LUSC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg20573242	chr4:122745356	CCNA2	0.43	6.65	0.34	1.19e-10	Type 2 diabetes;
LUSC	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	6.65	0.34	1.19e-10	Iron status biomarkers;
LUSC	cis	rs13089785	1.000	rs2271969	chr3:123650432	A/G	cg01860459	chr3:123419554	MYLK	0.35	5.9	0.31	9.15e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg27432699	chr2:27873401	GPN1	-0.59	-9.0	-0.44	1.72e-17	Total body bone mineral density;
LUSC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.06	-0.55	4.59e-28	Type 2 diabetes;
LUSC	cis	rs1044826	0.956	rs7374385	chr3:139118544	A/C	cg00490450	chr3:139108681	COPB2	0.56	7.41	0.38	1.05e-12	Obesity-related traits;
LUSC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	9.0	0.44	1.77e-17	Prudent dietary pattern;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg10545536	chr3:45635693	LIMD1	0.73	6.28	0.32	1.03e-9	Cognitive performance;
LUSC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.68	12.34	0.56	4.54e-29	Extrinsic epigenetic age acceleration;
LUSC	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.74	-14.17	-0.61	4.95e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg24006582	chr15:45444508	DUOX1	-0.61	-8.75	-0.43	1.07e-16	Uric acid levels;
LUSC	cis	rs55728055	0.661	rs9619217	chr22:32043611	A/G	cg01338084	chr22:32026380	PISD	0.83	6.34	0.33	7.32e-10	Age-related hearing impairment;
LUSC	cis	rs2742234	0.541	rs7073849	chr10:43740474	G/C	cg02780029	chr10:43622663	RET	0.34	5.73	0.3	2.24e-8	Hirschsprung disease;
LUSC	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	6.98	0.36	1.64e-11	IgG glycosylation;
LUSC	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-10.49	-0.5	1.91e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs11166629	0.883	rs11778878	chr8:135599220	C/T	cg21672855	chr8:135614777	ZFAT	-0.37	-5.94	-0.31	7.16e-9	Smoking quantity;
LUSC	cis	rs2637266	1.000	rs12252604	chr10:78352591	T/C	cg18941641	chr10:78392320	NA	0.37	6.82	0.35	4.18e-11	Pulmonary function;
LUSC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.13	-0.41	8.39e-15	Lung cancer;
LUSC	cis	rs6939532	0.522	rs9358933	chr6:26363688	C/T	cg05738196	chr6:26577821	NA	-0.41	-5.66	-0.3	3.19e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17095355	0.818	rs57239324	chr10:111770871	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-6.82	-0.35	4.38e-11	Biliary atresia;
LUSC	cis	rs7202877	0.610	rs4536500	chr16:75343197	C/G	cg04384234	chr16:75411784	CFDP1	0.64	8.84	0.44	5.71e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg07507251	chr3:52567010	NT5DC2	0.32	6.3	0.33	9.33e-10	Bipolar disorder;
LUSC	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.65	10.03	0.48	7.21e-21	Sudden cardiac arrest;
LUSC	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg01966878	chr4:90757139	SNCA	-0.42	-5.92	-0.31	7.9e-9	Neuroticism;
LUSC	trans	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg26043149	chr18:55253948	FECH	0.48	7.07	0.36	9.06e-12	Bone mineral density;
LUSC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-8.72	-0.43	1.34e-16	Schizophrenia;
LUSC	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg19743168	chr1:23544995	NA	0.47	10.3	0.49	8.8e-22	Height;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg22331106	chr13:45563688	KIAA1704;NUFIP1	0.53	6.11	0.32	2.81e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg14789911	chr21:47582049	C21orf56	-0.37	-5.82	-0.3	1.42e-8	Testicular germ cell tumor;
LUSC	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6546550	0.743	rs6546548	chr2:70017022	A/G	cg02498382	chr2:70120550	SNRNP27	-0.25	-6.21	-0.32	1.57e-9	Prevalent atrial fibrillation;
LUSC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg00933542	chr6:150070202	PCMT1	0.31	6.53	0.34	2.48e-10	Lung cancer;
LUSC	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg08017756	chr2:100939284	LONRF2	0.47	8.68	0.43	1.71e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.61	0.6	7.09e-34	Cognitive test performance;
LUSC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.94	0.44	2.61e-17	Prudent dietary pattern;
LUSC	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg06207120	chr15:45996521	NA	0.39	5.9	0.31	8.8e-9	Waist circumference;Weight;
LUSC	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg23711669	chr6:146136114	FBXO30	-0.74	-13.05	-0.58	1.02e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4363385	0.818	rs426360	chr1:153014710	C/T	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.55	-0.38	4.26e-13	Inflammatory skin disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20404643	chr11:1492543	HCCA2	0.44	6.39	0.33	5.61e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg09307838	chr4:120376055	NA	-0.67	-10.1	-0.48	4.29e-21	Corneal astigmatism;
LUSC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg14552801	chr7:65878734	NA	0.38	5.91	0.31	8.41e-9	Aortic root size;
LUSC	cis	rs2078087	0.568	rs656664	chr1:183237940	G/A	cg13843938	chr1:183241246	NMNAT2	-0.42	-6.82	-0.35	4.2e-11	Obesity-related traits;
LUSC	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-9.73	-0.47	7.46e-20	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-9.54	-0.46	3.08e-19	Platelet count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03142856	chr1:45271752	TCTEX1D4	0.41	6.08	0.32	3.23e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg11843238	chr5:131593191	PDLIM4	0.37	6.33	0.33	7.7e-10	Breast cancer;
LUSC	cis	rs6500395	0.926	rs7192297	chr16:48670421	G/A	cg04672837	chr16:48644449	N4BP1	0.46	6.91	0.35	2.41e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25072359	chr17:41440525	NA	0.65	9.38	0.46	1.03e-18	Menopause (age at onset);
LUSC	cis	rs6688613	0.759	rs61815132	chr1:166920911	A/G	cg07049167	chr1:166818506	POGK	0.41	6.02	0.31	4.56e-9	Refractive astigmatism;
LUSC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg23711669	chr6:146136114	FBXO30	0.73	11.3	0.53	2.69e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7572644	0.766	rs6745379	chr2:28147541	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-6.49	-0.33	3.05e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.24	-0.37	3.09e-12	Alzheimer's disease (late onset);
LUSC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg27141850	chr2:20869434	GDF7	-0.34	-7.95	-0.4	2.85e-14	Abdominal aortic aneurysm;
LUSC	cis	rs6736093	0.933	rs4848229	chr2:112692650	C/A	cg12686935	chr2:112915763	FBLN7	-0.36	-5.84	-0.3	1.25e-8	Coronary artery disease;
LUSC	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg16989719	chr2:238392110	NA	-0.45	-6.03	-0.31	4.24e-9	Prostate cancer;
LUSC	cis	rs17253792	0.822	rs17832365	chr14:56153531	C/G	cg01858014	chr14:56050164	KTN1	-0.78	-6.43	-0.33	4.52e-10	Putamen volume;
LUSC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11645453	chr3:52864694	ITIH4	0.32	7.48	0.38	6.77e-13	Bipolar disorder;
LUSC	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg26162295	chr17:38119207	GSDMA	-0.29	-6.52	-0.34	2.64e-10	Asthma;
LUSC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg11632617	chr15:75315747	PPCDC	-0.54	-6.97	-0.36	1.67e-11	Blood trace element (Zn levels);
LUSC	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg15485101	chr11:133734466	NA	0.38	7.03	0.36	1.19e-11	Childhood ear infection;
LUSC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg07701084	chr6:150067640	NUP43	0.57	8.71	0.43	1.47e-16	Lung cancer;
LUSC	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-16.82	-0.68	2.02e-46	Exhaled nitric oxide output;
LUSC	cis	rs12760731	0.623	rs10913550	chr1:178408795	A/G	cg00404053	chr1:178313656	RASAL2	0.48	5.76	0.3	1.91e-8	Obesity-related traits;
LUSC	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg22709100	chr7:91322751	NA	-0.39	-5.66	-0.3	3.24e-8	Breast cancer;
LUSC	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg03929089	chr4:120376271	NA	0.72	6.86	0.35	3.37e-11	Axial length;
LUSC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.1	0.32	2.93e-9	Menopause (age at onset);
LUSC	cis	rs9815354	0.767	rs60943892	chr3:41852307	T/C	cg03022575	chr3:42003672	ULK4	0.85	8.74	0.43	1.16e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg13114125	chr14:105738426	BRF1	-0.92	-15.89	-0.66	9.54e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg22834771	chr12:69754056	YEATS4	-0.44	-6.63	-0.34	1.39e-10	Blood protein levels;
LUSC	cis	rs6484504	0.652	rs674035	chr11:31399014	G/A	cg06552810	chr11:31128660	NA	0.36	6.21	0.32	1.59e-9	Red blood cell count;
LUSC	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg11498726	chr8:26250323	BNIP3L	0.43	6.26	0.32	1.21e-9	Red cell distribution width;
LUSC	cis	rs9359856	0.564	rs72913921	chr6:90328692	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.16	-0.41	6.87e-15	Bipolar disorder;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26784348	chr1:67520192	SLC35D1	-0.46	-6.31	-0.33	8.83e-10	Hepatitis;
LUSC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-7.63	-0.39	2.48e-13	Hemoglobin concentration;
LUSC	cis	rs701145	0.617	rs7426835	chr3:154049539	C/T	cg10247383	chr3:153839028	SGEF	-0.44	-5.75	-0.3	2.04e-8	Coronary artery disease;
LUSC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.1	0.48	4.13e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg06808227	chr14:105710500	BRF1	-0.66	-10.29	-0.49	9.37e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs36093844	0.752	rs57534090	chr11:85573020	C/T	cg25872744	chr11:85566296	CCDC83	-0.45	-5.78	-0.3	1.69e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs929596	0.556	rs35984508	chr2:234587852	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.19	-0.37	4.18e-12	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg18232548	chr7:50535776	DDC	-0.56	-7.76	-0.39	1.05e-13	Systemic sclerosis;
LUSC	cis	rs7582720	1.000	rs72932776	chr2:203688300	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.98	0.4	2.35e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg03188948	chr7:1209495	NA	0.47	6.27	0.32	1.13e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg03351412	chr1:154909251	PMVK	0.56	8.87	0.44	4.52e-17	Prostate cancer;
LUSC	cis	rs6012953	1.000	rs6020560	chr20:49119419	T/C	cg13958625	chr20:49123093	NA	0.31	6.57	0.34	1.88e-10	Vitiligo;
LUSC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18099408	chr3:52552593	STAB1	-0.38	-6.5	-0.34	2.84e-10	Electroencephalogram traits;
LUSC	cis	rs1045714	0.895	rs2293405	chr7:2644607	G/T	cg24848437	chr7:2645542	IQCE	0.61	6.81	0.35	4.56e-11	Urate levels in lean individuals;
LUSC	cis	rs7712401	0.715	rs6859163	chr5:122354920	A/G	cg19077854	chr5:122220652	SNX24	-0.41	-8.71	-0.43	1.45e-16	Mean platelet volume;
LUSC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.39	6.0	0.31	5.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg02487422	chr3:49467188	NICN1	0.44	7.13	0.36	6.21e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs73001065	0.818	rs58847337	chr19:19726022	G/A	cg03709012	chr19:19516395	GATAD2A	0.89	7.12	0.36	6.51e-12	LDL cholesterol;
LUSC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg00431813	chr7:1051703	C7orf50	-0.41	-6.52	-0.34	2.64e-10	Longevity;Endometriosis;
LUSC	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.72	-0.43	1.34e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg04576048	chr1:205797593	PM20D1	0.33	5.91	0.31	8.26e-9	Menarche (age at onset);
LUSC	cis	rs4290604	0.748	rs4549025	chr2:238052911	C/T	cg23555395	chr2:238036564	NA	0.56	7.39	0.37	1.19e-12	Asthma;
LUSC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg27170947	chr2:26402098	FAM59B	0.66	9.0	0.44	1.74e-17	Gut microbiome composition (summer);
LUSC	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg05340658	chr4:99064831	C4orf37	0.44	6.92	0.35	2.25e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg13902645	chr11:5959945	NA	0.4	5.87	0.31	1.06e-8	DNA methylation (variation);
LUSC	cis	rs9503598	0.662	rs2326232	chr6:3451953	A/G	cg00476032	chr6:3446245	SLC22A23	0.31	6.1	0.32	2.94e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.51e-14	Prudent dietary pattern;
LUSC	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-0.53	-8.24	-0.41	3.87e-15	Breast cancer;
LUSC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	13.69	0.6	3.54e-34	Gut microbiome composition (summer);
LUSC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03264133	chr6:25882463	NA	-0.42	-7.25	-0.37	2.97e-12	Blood metabolite levels;
LUSC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-7.82	-0.39	7.04e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2667011	0.570	rs1397710	chr2:160860491	C/A	cg06573604	chr2:160760825	LY75	-0.45	-6.7	-0.34	8.99e-11	Bilirubin levels;
LUSC	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.89	15.27	0.64	2.63e-40	Bladder cancer;
LUSC	trans	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg07923666	chr12:49932857	KCNH3	-0.49	-6.12	-0.32	2.55e-9	Resting heart rate;
LUSC	cis	rs193541	0.632	rs30063	chr5:122295693	G/A	cg19077854	chr5:122220652	SNX24	0.4	8.56	0.42	4.32e-16	Glucose homeostasis traits;
LUSC	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg05855489	chr10:104503620	C10orf26	0.6	9.68	0.47	1.1e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg27411982	chr8:10470053	RP1L1	0.44	7.3	0.37	2.09e-12	Mood instability;
LUSC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg17971929	chr21:40555470	PSMG1	-0.64	-10.46	-0.5	2.44e-22	Cognitive function;
LUSC	cis	rs9318086	0.648	rs35449605	chr13:24472582	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.45	6.62	0.34	1.47e-10	Myopia (pathological);
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.74	-15.77	-0.65	3.01e-42	Longevity;Endometriosis;
LUSC	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.92	-0.58	3e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg07080220	chr10:102295463	HIF1AN	0.61	7.91	0.4	3.71e-14	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg08085267	chr17:45401833	C17orf57	-0.52	-8.2	-0.41	5.32e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.94	18.58	0.71	1.99e-53	Prudent dietary pattern;
LUSC	cis	rs911119	0.913	rs6048924	chr20:23578996	G/A	cg16589663	chr20:23618590	CST3	0.6	7.15	0.36	5.56e-12	Chronic kidney disease;
LUSC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg24813613	chr7:1882135	MAD1L1	-0.45	-7.33	-0.37	1.72e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12760731	0.623	rs1342849	chr1:178296692	A/G	cg00404053	chr1:178313656	RASAL2	0.47	5.81	0.3	1.48e-8	Obesity-related traits;
LUSC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.82	-14.39	-0.62	7.1e-37	Cognitive function;
LUSC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.77	-8.15	-0.41	7.49e-15	Initial pursuit acceleration;
LUSC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg23985595	chr17:80112537	CCDC57	-0.3	-5.75	-0.3	2.05e-8	Life satisfaction;
LUSC	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg08000102	chr2:233561755	GIGYF2	-0.51	-8.09	-0.4	1.13e-14	Coronary artery disease;
LUSC	trans	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg07393940	chr7:158741817	NA	0.54	8.75	0.43	1.06e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg00074818	chr8:8560427	CLDN23	0.58	9.88	0.48	2.23e-20	Obesity-related traits;
LUSC	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg12140854	chr5:148520817	ABLIM3	-0.36	-5.88	-0.31	9.93e-9	Breast cancer;
LUSC	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg18681998	chr4:17616180	MED28	-0.84	-14.22	-0.61	3.19e-36	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg11812906	chr14:75593930	NEK9	0.65	11.2	0.52	6.41e-25	Height;
LUSC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg14019146	chr3:50243930	SLC38A3	0.37	8.29	0.41	2.9e-15	Menarche (age at onset);
LUSC	cis	rs11030122	0.702	rs4910866	chr11:3950554	A/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.76	-0.3	1.86e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg08847533	chr14:75593920	NEK9	0.49	7.1	0.36	7.68e-12	Caffeine consumption;
LUSC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.9	17.15	0.68	1.03e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg06784218	chr1:46089804	CCDC17	0.53	10.97	0.51	3.94e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.6	8.45	0.42	9.09e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs67981189	0.634	rs221891	chr14:71611627	C/T	cg15816911	chr14:71606274	NA	-0.35	-6.19	-0.32	1.72e-9	Schizophrenia;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg03461704	chr1:205818484	PM20D1	-0.35	-5.67	-0.3	3.11e-8	Menarche (age at onset);
LUSC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	0.98	13.91	0.61	5.29e-35	Eosinophil percentage of granulocytes;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03646922	chr17:4167316	ANKFY1	-0.4	-6.83	-0.35	4.11e-11	Electrocardiographic conduction measures;
LUSC	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg08345082	chr10:99160200	RRP12	-0.36	-7.28	-0.37	2.45e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg22823121	chr1:150693482	HORMAD1	0.49	6.98	0.36	1.63e-11	Melanoma;
LUSC	cis	rs12931792	0.748	rs11150585	chr16:30184286	A/G	cg17640201	chr16:30407289	ZNF48	0.63	10.3	0.49	8.45e-22	Tonsillectomy;
LUSC	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.46	0.42	8.27e-16	Coffee consumption (cups per day);
LUSC	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg07828340	chr4:882639	GAK	1.07	11.34	0.53	1.99e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg22437258	chr11:111473054	SIK2	0.54	7.65	0.39	2.16e-13	Primary sclerosing cholangitis;
LUSC	cis	rs1385374	0.858	rs11059930	chr12:129297860	T/C	cg09035930	chr12:129282057	SLC15A4	-0.62	-6.66	-0.34	1.14e-10	Systemic lupus erythematosus;
LUSC	trans	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg11887960	chr12:57824829	NA	0.56	6.84	0.35	3.75e-11	Lung disease severity in cystic fibrosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26541027	chr1:110163313	AMPD2	0.42	6.36	0.33	6.72e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.5	-0.34	2.94e-10	Alzheimer's disease (late onset);
LUSC	cis	rs62400317	0.859	rs12205379	chr6:45215074	G/A	cg20913747	chr6:44695427	NA	-0.47	-7.7	-0.39	1.58e-13	Total body bone mineral density;
LUSC	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg11871910	chr12:69753446	YEATS4	0.44	5.74	0.3	2.18e-8	Response to diuretic therapy;
LUSC	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17467752	chr17:38218738	THRA	-0.54	-7.79	-0.39	8.48e-14	White blood cell count;
LUSC	cis	rs6142102	0.961	rs2284389	chr20:32656841	C/G	cg08999081	chr20:33150536	PIGU	0.34	5.87	0.31	1.07e-8	Skin pigmentation;
LUSC	cis	rs7173743	0.756	rs8030937	chr15:79129587	G/T	cg00540400	chr15:79124168	NA	0.35	5.94	0.31	7.12e-9	Coronary artery disease;
LUSC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	10.67	0.5	4.62e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25142702	chr5:6378806	MED10	-0.38	-6.17	-0.32	2.01e-9	Smoking initiation;
LUSC	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg17279839	chr7:150038598	RARRES2	0.43	6.78	0.35	5.58e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.26	-0.32	1.2e-9	Morning vs. evening chronotype;
LUSC	cis	rs4363385	0.530	rs11205181	chr1:153045728	C/T	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.32	-0.33	8.25e-10	Inflammatory skin disease;
LUSC	cis	rs17155006	0.718	rs370533	chr7:107746215	G/C	cg05962710	chr7:107745446	LAMB4	-0.35	-6.23	-0.32	1.43e-9	Pneumococcal bacteremia;
LUSC	cis	rs6977940	0.818	rs11770710	chr7:2896123	A/G	cg19731401	chr7:2775893	GNA12	0.59	6.81	0.35	4.69e-11	White matter integrity;
LUSC	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg13073564	chr4:8508604	NA	0.35	6.42	0.33	4.74e-10	Response to antineoplastic agents;
LUSC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg03060546	chr3:49711283	APEH	0.7	11.67	0.54	1.28e-26	Resting heart rate;
LUSC	cis	rs2249625	0.545	rs2496487	chr6:72875226	G/C	cg18830697	chr6:72922368	RIMS1	-0.36	-7.17	-0.37	4.81e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	6.69	0.34	9.53e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.73	0.51	2.88e-23	Colorectal cancer;
LUSC	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg20016023	chr10:99160130	RRP12	-0.33	-8.04	-0.4	1.57e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7759001	0.857	rs6934933	chr6:27354862	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.78	0.3	1.73e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg04017836	chr7:65315216	NA	-0.38	-6.0	-0.31	5.28e-9	Height;
LUSC	trans	rs61931739	0.635	rs1825746	chr12:33939984	C/T	cg26384229	chr12:38710491	ALG10B	0.51	7.64	0.39	2.36e-13	Morning vs. evening chronotype;
LUSC	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg02655711	chr22:19163373	SLC25A1	0.76	14.74	0.63	3.11e-38	Metabolite levels;
LUSC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg06740227	chr12:86229804	RASSF9	0.43	6.73	0.35	7.41e-11	Major depressive disorder;
LUSC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg04450456	chr4:17643702	FAM184B	-0.41	-6.64	-0.34	1.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21643547	chr1:205240462	TMCC2	-0.51	-9.46	-0.46	5.85e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1113500	0.548	rs11185271	chr1:108659933	A/G	cg11967332	chr1:108735228	SLC25A24	0.45	6.11	0.32	2.77e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	1.04	16.42	0.67	7.66e-45	Testicular germ cell tumor;
LUSC	cis	rs2835872	0.965	rs857973	chr21:39007498	A/G	cg20424643	chr21:39039972	KCNJ6	-0.39	-6.04	-0.31	4.1e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg22800045	chr5:56110881	MAP3K1	0.79	10.23	0.49	1.56e-21	Initial pursuit acceleration;
LUSC	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08048268	chr3:133502702	NA	-0.48	-9.32	-0.45	1.66e-18	Iron status biomarkers;
LUSC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.76	-0.35	6.1e-11	Extrinsic epigenetic age acceleration;
LUSC	trans	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg01134436	chr17:81009848	B3GNTL1	0.63	6.16	0.32	2.08e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26314531	chr2:26401878	FAM59B	0.7	9.35	0.46	1.34e-18	Gut microbiome composition (summer);
LUSC	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	13.03	0.58	1.14e-31	Post bronchodilator FEV1;
LUSC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.67	-10.47	-0.5	2.19e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.44	6.35	0.33	7.18e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg27311710	chr6:107349326	C6orf203	0.65	6.09	0.32	3.08e-9	Body mass index;
LUSC	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg21051086	chr3:73046214	PPP4R2	-0.52	-7.92	-0.4	3.52e-14	Pancreatic cancer;
LUSC	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.53	8.41	0.42	1.22e-15	Depressive symptoms;
LUSC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.83	-0.39	6.49e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-8.4	-0.42	1.28e-15	Total body bone mineral density;
LUSC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg06618935	chr21:46677482	NA	-0.41	-7.85	-0.39	5.79e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg21890820	chr11:65308645	LTBP3	1.28	9.7	0.47	9.09e-20	Height;
LUSC	cis	rs354225	0.544	rs12713267	chr2:54805607	T/C	cg01766943	chr2:54829624	SPTBN1	0.48	7.61	0.38	2.89e-13	Schizophrenia;
LUSC	cis	rs714027	0.605	rs5753037	chr22:30581722	C/T	cg11564601	chr22:30592435	NA	0.33	5.72	0.3	2.33e-8	Lymphocyte counts;
LUSC	cis	rs7000551	0.715	rs1879792	chr8:22314029	C/A	cg12081754	chr8:22256438	SLC39A14	0.48	7.21	0.37	3.65e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.85	-0.39	5.68e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6967385	0.934	rs17149915	chr7:12384899	G/A	cg06484146	chr7:12443880	VWDE	0.38	5.69	0.3	2.73e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7659604	0.521	rs4240263	chr4:122683623	C/T	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.88	-0.31	9.96e-9	Type 2 diabetes;
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.65	-0.47	1.32e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg23260525	chr10:116636907	FAM160B1	0.47	10.19	0.49	2.13e-21	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs735860	0.718	rs209488	chr6:53177540	A/T	cg10236188	chr6:53219634	NA	0.37	5.67	0.3	3.15e-8	Glaucoma;
LUSC	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg19682013	chr15:45996608	NA	0.38	5.8	0.3	1.5e-8	Waist circumference;Weight;
LUSC	cis	rs2637266	1.000	rs2395384	chr10:78335329	G/A	cg18941641	chr10:78392320	NA	0.38	6.9	0.35	2.66e-11	Pulmonary function;
LUSC	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg05347473	chr6:146136440	FBXO30	0.51	8.58	0.43	3.51e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.68	-9.51	-0.46	4.05e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg18306943	chr3:40428807	ENTPD3	0.38	5.82	0.3	1.41e-8	Renal cell carcinoma;
LUSC	cis	rs3007168	1.000	rs3007167	chr14:51613041	C/T	cg23942311	chr14:51606299	NA	0.36	5.79	0.3	1.61e-8	Cancer;
LUSC	cis	rs1941023	0.606	rs7946122	chr11:60172770	G/A	cg08716584	chr11:60157161	MS4A7	-0.62	-11.34	-0.53	2.02e-25	Congenital heart disease (maternal effect);
LUSC	trans	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg12856521	chr11:46389249	DGKZ	0.4	6.28	0.32	1.06e-9	Leprosy;
LUSC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	cis	rs7106204	0.609	rs11828535	chr11:24295565	G/C	ch.11.24196551F	chr11:24239977	NA	0.69	5.74	0.3	2.14e-8	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs4776059	0.916	rs2414161	chr15:52883285	T/C	cg22715398	chr15:52968154	KIAA1370	-0.73	-10.44	-0.5	2.78e-22	Schizophrenia;
LUSC	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg02023728	chr11:77925099	USP35	0.47	6.74	0.35	7.05e-11	Testicular germ cell tumor;
LUSC	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg00268967	chr12:58002603	GEFT;DTX3	-0.36	-5.74	-0.3	2.18e-8	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg03433033	chr1:76189801	ACADM	0.72	9.44	0.46	6.81e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7180079	1.000	rs11633312	chr15:64594611	T/C	cg08069370	chr15:64387884	SNX1	0.55	6.02	0.31	4.63e-9	Monocyte count;
LUSC	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg21775007	chr8:11205619	TDH	-0.65	-10.36	-0.49	5.25e-22	Retinal vascular caliber;
LUSC	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg27411982	chr8:10470053	RP1L1	-0.37	-5.93	-0.31	7.5e-9	Retinal vascular caliber;
LUSC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.7	-0.39	1.59e-13	Height;
LUSC	cis	rs500891	0.525	rs1144177	chr6:84029793	A/G	cg08257003	chr6:84140564	ME1	0.34	8.05	0.4	1.43e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs939574	0.799	rs1109867	chr2:220083453	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.94	-8.06	-0.4	1.42e-14	Platelet distribution width;
LUSC	trans	rs7726839	0.540	rs7558	chr5:660491	C/T	cg25482853	chr8:67687455	SGK3	1.09	15.46	0.65	4.65e-41	Obesity-related traits;
LUSC	cis	rs394563	0.602	rs409111	chr6:149766860	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.29	-5.95	-0.31	6.72e-9	Dupuytren's disease;
LUSC	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg02569458	chr12:86230093	RASSF9	0.42	6.86	0.35	3.31e-11	Major depressive disorder;
LUSC	cis	rs3007168	0.951	rs3007078	chr14:51612550	T/A	cg23942311	chr14:51606299	NA	0.35	5.74	0.3	2.09e-8	Cancer;
LUSC	cis	rs9309473	1.000	rs11893881	chr2:73824373	T/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.9	-0.35	2.65e-11	Metabolite levels;
LUSC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25072359	chr17:41440525	NA	0.65	9.26	0.45	2.46e-18	Menopause (age at onset);
LUSC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg09021430	chr5:549028	NA	0.74	17.25	0.69	3.99e-48	Obesity-related traits;
LUSC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	0.93	18.05	0.7	2.67e-51	Cognitive function;
LUSC	cis	rs72480748	0.509	rs3865457	chr19:41398969	C/T	cg04176888	chr19:41596066	CYP2A13	0.47	8.49	0.42	6.8e-16	Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LUSC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg07424592	chr7:64974309	NA	-0.64	-5.79	-0.3	1.61e-8	Diabetic kidney disease;
LUSC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg12639453	chr1:2035780	PRKCZ	-0.34	-7.29	-0.37	2.26e-12	Height;
LUSC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg08999081	chr20:33150536	PIGU	0.44	8.01	0.4	1.99e-14	Coronary artery disease;
LUSC	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg12292205	chr6:26970375	C6orf41	0.51	8.55	0.42	4.64e-16	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.86	-0.47	2.63e-20	Gut microbiome composition (summer);
LUSC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg25456477	chr12:86230367	RASSF9	0.44	7.88	0.4	4.75e-14	Major depressive disorder;
LUSC	cis	rs977987	0.806	rs12599361	chr16:75434973	A/T	cg04384234	chr16:75411784	CFDP1	-0.42	-6.84	-0.35	3.75e-11	Dupuytren's disease;
LUSC	cis	rs12980942	1.000	rs12972266	chr19:41810771	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.16	0.32	2.05e-9	Coronary artery disease;
LUSC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg20135002	chr11:47629003	NA	-0.52	-8.08	-0.4	1.17e-14	Subjective well-being;
LUSC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg17971929	chr21:40555470	PSMG1	0.53	8.35	0.42	1.85e-15	Cognitive function;
LUSC	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg27661571	chr11:113659931	NA	-0.66	-7.52	-0.38	5.2e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-12.37	-0.56	3.29e-29	Platelet count;
LUSC	cis	rs9921338	0.961	rs7193278	chr16:11445831	A/C	cg00044050	chr16:11439710	C16orf75	-0.51	-6.7	-0.34	9e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.18	0.58	3.19e-32	Cognitive test performance;
LUSC	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.35e-17	Iron status biomarkers;
LUSC	cis	rs1113500	0.933	rs3893034	chr1:108632178	G/A	cg11967332	chr1:108735228	SLC25A24	0.38	5.76	0.3	1.92e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1953600	0.870	rs2236557	chr10:81923961	A/G	cg00277334	chr10:82204260	NA	0.43	6.68	0.34	1.02e-10	Sarcoidosis;
LUSC	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg13390004	chr1:15929781	NA	0.4	6.89	0.35	2.72e-11	Systolic blood pressure;
LUSC	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg10326726	chr10:51549505	MSMB	-0.38	-6.57	-0.34	1.93e-10	Prostate-specific antigen levels;
LUSC	cis	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg06521331	chr12:34319734	NA	-0.37	-6.16	-0.32	2.06e-9	Morning vs. evening chronotype;
LUSC	cis	rs73129298	0.551	rs8125976	chr20:48599020	T/C	cg25655593	chr20:48599521	SNAI1	0.59	6.37	0.33	6.36e-10	Inflammatory skin disease;
LUSC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.29	0.49	9.44e-22	Monocyte percentage of white cells;
LUSC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg07806771	chr7:64541737	NA	-0.41	-5.87	-0.31	1.07e-8	Calcium levels;
LUSC	cis	rs7106204	0.748	rs12293729	chr11:24224679	A/G	ch.11.24196551F	chr11:24239977	NA	1.13	14.37	0.62	8.42e-37	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg04553112	chr3:125709451	NA	-0.51	-5.78	-0.3	1.76e-8	Blood pressure (smoking interaction);
LUSC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg22166914	chr1:53195759	ZYG11B	-0.49	-7.65	-0.39	2.23e-13	Monocyte count;
LUSC	cis	rs2857891	0.817	rs2638096	chr11:6977916	T/A	cg14883916	chr11:6947541	ZNF215	0.45	5.85	0.31	1.15e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs7546094	0.509	rs7415988	chr1:113159730	G/T	cg22162597	chr1:113214053	CAPZA1	-0.7	-10.0	-0.48	9.24e-21	Platelet distribution width;
LUSC	cis	rs501916	1.000	rs648627	chr15:48055738	C/T	cg16110827	chr15:48056943	SEMA6D	-0.34	-5.75	-0.3	1.99e-8	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26314531	chr2:26401878	FAM59B	0.75	10.15	0.49	2.9e-21	Mean corpuscular hemoglobin;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03342130	chr1:244211790	NA	-0.42	-6.08	-0.32	3.31e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg02527881	chr3:46936655	PTH1R	-0.43	-7.84	-0.39	6.16e-14	Colorectal cancer;
LUSC	cis	rs1775715	0.870	rs11008696	chr10:32218614	G/A	cg03015672	chr10:32216066	ARHGAP12	0.32	5.75	0.3	1.97e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	9.32	0.45	1.6e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.37	-0.42	1.6e-15	Systolic blood pressure;
LUSC	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24838063	chr12:130822603	PIWIL1	-0.7	-10.79	-0.51	1.7e-23	Menopause (age at onset);
LUSC	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg22676075	chr6:135203613	NA	0.59	9.48	0.46	5e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg23711669	chr6:146136114	FBXO30	0.82	14.67	0.63	6.12e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.12	0.32	2.56e-9	Platelet count;
LUSC	cis	rs11264799	0.603	rs12730818	chr1:157575630	T/A	cg18268488	chr1:157545234	FCRL4	0.36	6.44	0.33	4.18e-10	IgA nephropathy;
LUSC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	1.05	20.03	0.74	3.41e-59	Menopause (age at onset);
LUSC	cis	rs7091068	0.574	rs10748610	chr10:95462235	C/G	cg20715218	chr10:95462985	C10orf4	0.65	7.47	0.38	6.99e-13	Urinary tract infection frequency;
LUSC	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.98	-0.48	1.1e-20	Migraine;Coronary artery disease;
LUSC	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.36	-0.37	1.47e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg18827107	chr12:86230957	RASSF9	0.46	6.95	0.36	1.94e-11	Major depressive disorder;
LUSC	trans	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg07211511	chr3:129823064	LOC729375	-0.81	-10.7	-0.51	3.52e-23	Blood pressure (smoking interaction);
LUSC	cis	rs3126085	0.935	rs10888475	chr1:152226012	C/T	cg26876637	chr1:152193138	HRNR	0.44	6.38	0.33	5.75e-10	Atopic dermatitis;
LUSC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.63	-0.34	1.37e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg00339695	chr16:24857497	SLC5A11	0.34	5.81	0.3	1.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08564027	chr20:61660810	NA	0.9	17.04	0.68	2.82e-47	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6596100	0.500	rs58840150	chr5:132248041	A/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Breast cancer;
LUSC	cis	rs11031096	0.655	rs12275560	chr11:4211564	T/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.71	-0.3	2.5e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg23601095	chr6:26197514	HIST1H3D	0.7	7.6	0.38	2.96e-13	Gout;Renal underexcretion gout;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17937102	chr1:165667565	ALDH9A1	0.42	6.48	0.33	3.23e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs17125944	0.615	rs12586707	chr14:53298277	A/G	cg00686598	chr14:53173677	PSMC6	-0.68	-6.27	-0.32	1.12e-9	Alzheimer's disease (late onset);
LUSC	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg15785704	chr17:30669010	C17orf75	0.43	6.63	0.34	1.35e-10	Schizophrenia;
LUSC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	13.93	0.61	4.14e-35	Platelet count;
LUSC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg07395648	chr5:131743802	NA	0.42	6.01	0.31	4.97e-9	Breast cancer;
LUSC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg06618935	chr21:46677482	NA	-0.39	-7.91	-0.4	3.73e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg19676328	chr12:49525230	TUBA1B	-0.51	-8.28	-0.41	2.94e-15	Total cholesterol levels;
LUSC	cis	rs1577917	0.816	rs1838952	chr6:86601144	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.35	-0.33	7.09e-10	Response to antipsychotic treatment;
LUSC	cis	rs9309711	0.883	rs13429373	chr2:3477014	G/A	cg10845886	chr2:3471009	TTC15	-0.65	-8.32	-0.41	2.26e-15	Neurofibrillary tangles;
LUSC	cis	rs6723226	0.766	rs398290	chr2:32503526	T/C	cg02381751	chr2:32503542	YIPF4	0.65	9.58	0.46	2.29e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.14	-0.32	2.39e-9	Resting heart rate;
LUSC	cis	rs113835537	0.529	rs11550299	chr11:66254085	G/T	cg24851651	chr11:66362959	CCS	0.54	8.02	0.4	1.77e-14	Airway imaging phenotypes;
LUSC	cis	rs6714710	0.603	rs34503448	chr2:98587288	A/G	cg26665480	chr2:98280029	ACTR1B	0.61	8.79	0.43	8.12e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg17376030	chr22:41985996	PMM1	-0.46	-5.78	-0.3	1.71e-8	Vitiligo;
LUSC	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg27170947	chr2:26402098	FAM59B	-0.53	-7.54	-0.38	4.51e-13	Gut microbiome composition (summer);
LUSC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg16586182	chr3:47516702	SCAP	0.56	8.77	0.43	9.41e-17	Colorectal cancer;
LUSC	cis	rs10904908	0.733	rs359299	chr10:17334378	G/A	cg01003015	chr10:17271136	VIM	0.43	6.04	0.31	4.18e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg09184832	chr6:79620586	NA	-0.44	-7.17	-0.37	4.75e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6920965	0.509	rs575811	chr6:126162282	T/C	cg05901451	chr6:126070800	HEY2	0.4	5.65	0.3	3.46e-8	High light scatter reticulocyte count;
LUSC	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg12552261	chr5:112820674	MCC	-0.44	-7.02	-0.36	1.25e-11	Type 2 diabetes;
LUSC	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg18196295	chr10:418757	DIP2C	0.43	7.05	0.36	1e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs3764563	0.877	rs4019751	chr19:15740716	T/G	cg20725493	chr19:15740067	CYP4F8	-0.64	-6.62	-0.34	1.44e-10	Inflammatory biomarkers;
LUSC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg06238570	chr21:40685208	BRWD1	0.49	7.37	0.37	1.37e-12	Cognitive function;
LUSC	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg06223162	chr1:101003688	GPR88	0.48	8.92	0.44	3.02e-17	Monocyte count;
LUSC	cis	rs3733418	0.929	rs13149062	chr4:165905360	T/G	cg11630554	chr4:165878136	TRIM61;C4orf39	-0.51	-5.84	-0.3	1.25e-8	Obesity-related traits;
LUSC	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg05966235	chr16:28915196	ATP2A1	0.33	5.83	0.3	1.32e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg15744005	chr10:104629667	AS3MT	-0.27	-5.68	-0.3	2.93e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs701145	0.878	rs355753	chr3:153968846	T/C	cg17054900	chr3:154042577	DHX36	0.85	9.0	0.44	1.75e-17	Coronary artery disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26665246	chr5:179105570	CBY3	-0.6	-7.41	-0.38	1.05e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.95	-0.36	1.97e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg00745463	chr17:30367425	LRRC37B	0.78	8.66	0.43	2.06e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18252515	chr7:66147081	NA	-0.39	-5.66	-0.3	3.22e-8	Aortic root size;
LUSC	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	0.59	9.25	0.45	2.65e-18	Breast cancer;
LUSC	cis	rs5167	0.566	rs934427	chr19:45478816	T/G	cg13119609	chr19:45449297	APOC2	0.35	5.79	0.3	1.63e-8	Blood protein levels;
LUSC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg10360139	chr7:1886902	MAD1L1	-0.46	-7.14	-0.36	5.82e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.6	8.15	0.41	7.42e-15	High light scatter reticulocyte count;
LUSC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.89	0.31	9.34e-9	Menopause (age at onset);
LUSC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg10729496	chr3:10149963	C3orf24	0.52	6.96	0.36	1.76e-11	Alzheimer's disease;
LUSC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.14e-35	Breast cancer;
LUSC	cis	rs9341808	0.667	rs2490241	chr6:80846342	T/C	cg08355045	chr6:80787529	NA	0.47	8.18	0.41	5.96e-15	Sitting height ratio;
LUSC	cis	rs7940866	0.838	rs7122268	chr11:130892029	A/T	cg12179176	chr11:130786555	SNX19	0.61	9.72	0.47	7.8500000000000006e-20	Schizophrenia;
LUSC	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.09	15.23	0.64	3.79e-40	Lung cancer in ever smokers;
LUSC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg18190219	chr22:46762943	CELSR1	-0.54	-6.02	-0.31	4.61e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg11344533	chr11:111475393	SIK2	0.47	6.23	0.32	1.38e-9	Primary sclerosing cholangitis;
LUSC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06634786	chr22:41940651	POLR3H	-0.56	-6.54	-0.34	2.29e-10	Vitiligo;
LUSC	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg26395211	chr5:140044315	WDR55	0.46	7.16	0.36	5.08e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg05163923	chr11:71159392	DHCR7	0.78	11.49	0.53	5.51e-26	Vitamin D levels;
LUSC	cis	rs68170813	0.559	rs7807648	chr7:106965091	C/T	cg02696742	chr7:106810147	HBP1	-0.63	-9.1	-0.45	8.52e-18	Coronary artery disease;
LUSC	cis	rs2559856	1.000	rs2695298	chr12:102082589	G/A	cg12924262	chr12:102091054	CHPT1	0.42	5.84	0.3	1.24e-8	Blood protein levels;
LUSC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg24642844	chr7:1081250	C7orf50	-0.79	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10838798	0.584	rs1566732	chr11:48151494	A/C	cg18512352	chr11:47633146	NA	0.28	5.7	0.3	2.69e-8	Height;
LUSC	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg24642439	chr20:33292090	TP53INP2	-0.55	-8.21	-0.41	4.83e-15	Coronary artery disease;
LUSC	cis	rs2708977	0.933	rs6576972	chr2:97152446	C/T	cg01950434	chr2:97203154	ARID5A	-0.53	-8.06	-0.4	1.41e-14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.19	0.41	5.52e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.7	-10.95	-0.51	4.95e-24	Aortic root size;
LUSC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.54	0.6	1.33e-33	Cognitive test performance;
LUSC	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg00484396	chr16:3507460	NAT15	0.73	12.49	0.56	1.2e-29	Tuberculosis;
LUSC	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg09184832	chr6:79620586	NA	-0.42	-6.83	-0.35	3.96e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.38	-0.37	1.23e-12	Psoriasis;
LUSC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23158103	chr7:148848205	ZNF398	-0.42	-6.62	-0.34	1.46e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20891558	chr2:74357851	NA	0.79	14.33	0.62	1.24e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs9648716	0.515	rs75486053	chr7:140495583	A/C	cg23214464	chr7:140373596	ADCK2	0.67	5.65	0.3	3.41e-8	Type 2 diabetes;
LUSC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg12432903	chr7:1882776	MAD1L1	-0.39	-6.31	-0.33	8.83e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.95	0.61	3.51e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs338389	0.586	rs338402	chr15:68253951	C/T	cg16317052	chr17:61678891	TACO1	0.38	5.95	0.31	6.89e-9	Survival in rectal cancer;
LUSC	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg24375607	chr4:120327624	NA	0.79	11.99	0.55	8.46e-28	Corneal astigmatism;
LUSC	cis	rs9815354	1.000	rs1717020	chr3:41981490	A/C	cg03022575	chr3:42003672	ULK4	0.54	5.9	0.31	8.78e-9	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-0.76	-10.76	-0.51	2.21e-23	Platelet distribution width;
LUSC	cis	rs11648785	0.590	rs10431948	chr16:90099571	A/G	cg16611967	chr16:90144006	NA	-0.4	-5.79	-0.3	1.66e-8	Tanning;
LUSC	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg08999081	chr20:33150536	PIGU	-0.41	-7.68	-0.39	1.79e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg02380750	chr20:61661411	NA	-0.34	-5.91	-0.31	8.4e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg13010344	chr12:123464640	ARL6IP4	-0.48	-6.48	-0.33	3.22e-10	Neutrophil percentage of white cells;
LUSC	trans	rs9693857	0.520	rs4841163	chr8:9366178	C/G	cg06636001	chr8:8085503	FLJ10661	0.45	6.55	0.34	2.11e-10	Systolic blood pressure;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04407776	chr1:84465009	TTLL7	0.46	6.73	0.35	7.4e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3820928	0.839	rs4673174	chr2:227801316	A/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.75	-0.39	1.14e-13	Pulmonary function;
LUSC	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg01028140	chr2:1542097	TPO	-0.6	-8.23	-0.41	4.32e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg11189052	chr15:85197271	WDR73	0.54	6.13	0.32	2.42e-9	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21925064	chr5:148724958	GRPEL2	-0.41	-6.31	-0.33	8.81e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs981844	0.712	rs4616729	chr4:154746900	T/G	cg14289246	chr4:154710475	SFRP2	-0.46	-6.32	-0.33	8.22e-10	Response to statins (LDL cholesterol change);
LUSC	trans	rs7230711	1.000	rs17737030	chr18:48775644	C/T	cg03733578	chr1:18809059	KLHDC7A	0.48	6.07	0.32	3.54e-9	Immune response to anthrax vaccine;
LUSC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg24257776	chr3:47051546	LOC100129354	0.33	5.89	0.31	9.32e-9	Colorectal cancer;
LUSC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-6.78	-0.35	5.6e-11	Tonsillectomy;
LUSC	cis	rs4363385	0.818	rs6661791	chr1:152994113	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.79	-0.3	1.63e-8	Inflammatory skin disease;
LUSC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg07424592	chr7:64974309	NA	0.69	6.19	0.32	1.81e-9	Diabetic kidney disease;
LUSC	cis	rs137603	0.644	rs137635	chr22:39720656	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.52	-8.38	-0.42	1.54e-15	Primary biliary cholangitis;
LUSC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg11608241	chr8:8085544	FLJ10661	0.4	5.85	0.31	1.14e-8	Mood instability;
LUSC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00166722	chr3:10149974	C3orf24	0.62	8.64	0.43	2.36e-16	Alzheimer's disease;
LUSC	cis	rs2455601	0.882	rs11042118	chr11:8928791	T/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-7.8	-0.39	7.98e-14	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07677032	chr17:61819896	STRADA	0.54	9.06	0.44	1.15e-17	Prudent dietary pattern;
LUSC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg13607699	chr17:42295918	UBTF	0.49	7.64	0.39	2.39e-13	Total body bone mineral density;
LUSC	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.93	15.94	0.66	5.93e-43	Bladder cancer;
LUSC	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg26597838	chr10:835615	NA	-0.45	-6.12	-0.32	2.6e-9	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs2455601	0.507	rs2568044	chr11:9002477	T/C	cg09997546	chr11:8931473	C11orf17;ST5	0.35	6.15	0.32	2.18e-9	Schizophrenia;
LUSC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg26566898	chr11:117069891	TAGLN	-0.43	-7.49	-0.38	6.06e-13	Blood protein levels;
LUSC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg08888203	chr3:10149979	C3orf24	0.6	8.48	0.42	7.35e-16	Alzheimer's disease;
LUSC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.59	-9.55	-0.46	2.9e-19	Aortic root size;
LUSC	trans	rs9929218	1.000	rs4783570	chr16:68806539	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-11.75	-0.54	6.51e-27	Colorectal cancer;
LUSC	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg05855489	chr10:104503620	C10orf26	-0.68	-9.85	-0.47	2.9e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12368653	0.641	rs11172300	chr12:58076515	C/T	cg18357645	chr12:58087776	OS9	0.38	5.65	0.3	3.49e-8	Multiple sclerosis;
LUSC	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg18477163	chr1:228402036	OBSCN	0.57	9.59	0.46	2.12e-19	Diastolic blood pressure;
LUSC	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.1	25.33	0.81	9.63e-80	Schizophrenia;
LUSC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg12639453	chr1:2035780	PRKCZ	-0.31	-6.51	-0.34	2.75e-10	Height;
LUSC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08564027	chr20:61660810	NA	0.91	17.35	0.69	1.58e-48	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs524023	0.914	rs2666559	chr11:64439227	G/T	cg17873998	chr1:200117089	NR5A2	-0.39	-6.13	-0.32	2.54e-9	Urate levels in obese individuals;
LUSC	cis	rs11637445	0.677	rs4539549	chr15:68070619	C/T	cg08079166	chr15:68083412	MAP2K5	0.36	7.32	0.37	1.89e-12	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg02475777	chr4:1388615	CRIPAK	0.45	6.69	0.34	9.62e-11	Obesity-related traits;
LUSC	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg17127132	chr2:85788382	GGCX	0.42	6.03	0.31	4.3e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg00343986	chr7:65444356	GUSB	0.5	7.69	0.39	1.65e-13	Aortic root size;
LUSC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg08888203	chr3:10149979	C3orf24	0.63	9.09	0.45	8.92e-18	Alzheimer's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09418283	chr12:80084718	PAWR	-0.39	-6.05	-0.31	3.9e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2124969	0.562	rs4665164	chr2:161070078	T/G	cg03641300	chr2:160917029	PLA2R1	-0.44	-7.12	-0.36	6.75e-12	Waist circumference adjusted for body mass index;
LUSC	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	8.34	0.42	1.92e-15	Lung cancer in ever smokers;
LUSC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg06784218	chr1:46089804	CCDC17	-0.56	-11.07	-0.52	1.85e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg15790184	chr11:494944	RNH1	0.5	7.52	0.38	5.21e-13	Systemic lupus erythematosus;
LUSC	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.68	-9.23	-0.45	3.1e-18	Large artery stroke;
LUSC	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.03	-0.31	4.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg07703079	chr11:430292	ANO9	0.6	6.39	0.33	5.6e-10	Body mass index;
LUSC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.76	0.39	1.02e-13	Parkinson's disease;
LUSC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	0.83	14.72	0.63	3.75e-38	Blood protein levels;
LUSC	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg26408565	chr15:76604113	ETFA	-0.43	-6.82	-0.35	4.4e-11	Blood metabolite levels;
LUSC	cis	rs12618769	0.652	rs17513468	chr2:99235169	T/G	cg10123293	chr2:99228465	UNC50	0.47	7.55	0.38	4.22e-13	Bipolar disorder;
LUSC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg23788917	chr6:8435910	SLC35B3	0.51	7.57	0.38	3.75e-13	Motion sickness;
LUSC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.6	0.57	4.64e-30	Prudent dietary pattern;
LUSC	cis	rs174479	0.647	rs174457	chr11:61656975	T/C	cg01500311	chr11:61656094	FADS3	0.4	7.06	0.36	9.65e-12	Sphingolipid levels;
LUSC	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg04374321	chr14:90722782	PSMC1	-0.68	-10.3	-0.49	8.52e-22	Mortality in heart failure;
LUSC	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.88	16.04	0.66	2.51e-43	Neutrophil percentage of white cells;
LUSC	trans	rs747782	0.528	rs624348	chr11:48400795	G/A	cg15704280	chr7:45808275	SEPT13	-0.68	-6.43	-0.33	4.36e-10	Intraocular pressure;
LUSC	cis	rs1044826	0.642	rs9833307	chr3:139181370	G/A	cg00490450	chr3:139108681	COPB2	0.45	6.98	0.36	1.56e-11	Obesity-related traits;
LUSC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg02772935	chr3:125709198	NA	-0.5	-5.99	-0.31	5.3300000000000004e-09	Blood pressure (smoking interaction);
LUSC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg00033643	chr7:134001901	SLC35B4	0.47	7.28	0.37	2.36e-12	Mean platelet volume;
LUSC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg27535305	chr1:53392650	SCP2	0.33	5.95	0.31	6.6e-9	Monocyte count;
LUSC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg21535247	chr6:8435926	SLC35B3	0.55	8.48	0.42	7.63e-16	Motion sickness;
LUSC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg10755058	chr3:40428713	ENTPD3	0.36	5.97	0.31	5.99e-9	Renal cell carcinoma;
LUSC	cis	rs72960926	0.744	rs4282374	chr6:74899318	T/C	cg03266952	chr6:74778945	NA	-0.76	-6.05	-0.31	3.85e-9	Metabolite levels (MHPG);
LUSC	cis	rs939574	1.000	rs11552796	chr2:220108300	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.09	8.72	0.43	1.31e-16	Platelet distribution width;
LUSC	cis	rs6754311	0.593	rs313524	chr2:136444123	C/T	cg07169764	chr2:136633963	MCM6	0.55	7.29	0.37	2.32e-12	Mosquito bite size;
LUSC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg16325326	chr1:53192061	ZYG11B	0.7	11.49	0.53	5.47e-26	Monocyte count;
LUSC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg11247378	chr22:39784982	NA	-0.61	-10.94	-0.51	5.23e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg13010199	chr12:38710504	ALG10B	0.44	6.93	0.35	2.21e-11	Morning vs. evening chronotype;
LUSC	cis	rs11051970	0.611	rs10844197	chr12:32561015	A/C	cg02745156	chr12:32552066	NA	0.38	6.81	0.35	4.59e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2798269	0.966	rs17679426	chr13:22122477	A/T	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.09	-0.32	3.19e-9	PR segment;
LUSC	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg09462578	chr12:12878428	APOLD1	-0.68	-7.89	-0.4	4.41e-14	Systemic lupus erythematosus;
LUSC	trans	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg10756647	chr7:56101905	PSPH	-0.84	-8.39	-0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs1018836	0.923	rs2187982	chr8:91556317	G/T	cg16814680	chr8:91681699	NA	-0.75	-12.79	-0.57	9.26e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.59	-0.46	2.1e-19	Extrinsic epigenetic age acceleration;
LUSC	trans	rs62458065	0.850	rs62458099	chr7:32472395	C/T	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.08	-0.32	3.33e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17467752	chr17:38218738	THRA	-0.53	-7.87	-0.4	4.97e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg19592336	chr6:28129416	ZNF389	0.46	6.01	0.31	4.81e-9	Depression;
LUSC	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg05855489	chr10:104503620	C10orf26	0.49	7.36	0.37	1.48e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg22906224	chr7:99728672	NA	0.49	6.81	0.35	4.55e-11	Coronary artery disease;
LUSC	cis	rs77633900	0.772	rs157789	chr15:76805703	T/A	cg21673338	chr15:77095150	SCAPER	-0.71	-6.12	-0.32	2.65e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.5	-8.55	-0.42	4.36e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs59698941	0.943	rs67160603	chr5:132285618	G/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs12760731	0.720	rs3791023	chr1:178398092	A/C	cg00404053	chr1:178313656	RASAL2	0.57	6.23	0.32	1.39e-9	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00149659	chr3:10157352	C3orf10	0.98	14.19	0.61	4.3e-36	Alzheimer's disease;
LUSC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.94	-16.07	-0.66	1.96e-43	Coronary artery disease;
LUSC	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg05064044	chr6:292385	DUSP22	-0.51	-7.46	-0.38	7.57e-13	Menopause (age at onset);
LUSC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22968622	chr17:43663579	NA	0.8	12.25	0.56	9.6e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg04362960	chr10:104952993	NT5C2	0.59	9.34	0.45	1.43e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg24060327	chr5:131705240	SLC22A5	-0.47	-8.35	-0.42	1.87e-15	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.81	0.39	7.69e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2235649	0.833	rs7189070	chr16:1850813	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.44	-5.97	-0.31	6.06e-9	Blood metabolite levels;
LUSC	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-0.96	-12.87	-0.58	4.54e-31	Exhaled nitric oxide output;
LUSC	cis	rs72772090	0.908	rs17086588	chr5:96044914	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.62	7.29	0.37	2.28e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11229555	0.645	rs6591475	chr11:58193551	G/T	cg15696309	chr11:58395628	NA	0.64	7.9	0.4	3.97e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg05084668	chr3:125655381	ALG1L	-0.78	-11.57	-0.53	2.84e-26	Blood pressure (smoking interaction);
LUSC	cis	rs12220238	1.000	rs10824102	chr10:75948915	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.88	0.35	2.93e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs17014483	0.749	rs2972030	chr4:89631029	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.68	5.97	0.31	5.92e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	9.53	0.46	3.45e-19	Eotaxin levels;
LUSC	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg21775007	chr8:11205619	TDH	-0.54	-7.68	-0.39	1.74e-13	Neuroticism;
LUSC	cis	rs7572733	0.534	rs700688	chr2:198723833	A/G	cg00792783	chr2:198669748	PLCL1	-0.43	-5.88	-0.31	9.78e-9	Dermatomyositis;
LUSC	cis	rs35000415	0.938	rs17338998	chr7:128618559	C/T	cg19972273	chr7:128594194	NA	0.68	6.9	0.35	2.56e-11	Systemic lupus erythematosus;
LUSC	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg23649088	chr2:200775458	C2orf69	-0.59	-7.1	-0.36	7.73e-12	Chickenpox;
LUSC	cis	rs8048589	0.558	rs34565142	chr16:12231347	C/T	cg02910054	chr16:12241554	SNX29	0.45	5.82	0.3	1.42e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg12011299	chr4:100065546	ADH4	0.67	10.5	0.5	1.75e-22	Alcohol dependence;
LUSC	cis	rs2573652	1.000	rs11634977	chr15:100516472	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.47	-8.87	-0.44	4.46e-17	Height;
LUSC	cis	rs4478137	0.824	rs10857353	chr4:164215835	A/G	cg06758707	chr4:164254230	NPY1R	-0.59	-9.2	-0.45	4.04e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.76	-0.39	1.06e-13	Retinal vascular caliber;
LUSC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg19230755	chr7:65878503	NA	0.43	6.06	0.31	3.67e-9	Aortic root size;
LUSC	cis	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg17187183	chr4:55093834	PDGFRA	0.39	5.82	0.3	1.41e-8	Corneal astigmatism;
LUSC	cis	rs4845570	0.850	rs4618976	chr1:151766588	A/G	cg07092448	chr1:151763213	TDRKH	1.27	15.12	0.64	9.92e-40	Coronary artery disease;
LUSC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg07507251	chr3:52567010	NT5DC2	0.32	6.11	0.32	2.7e-9	Bipolar disorder;
LUSC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06112835	chr11:68658793	MRPL21	-0.48	-7.42	-0.38	9.57e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg06784218	chr1:46089804	CCDC17	0.54	10.93	0.51	5.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26496917	chr22:38668929	TMEM184B	0.44	6.17	0.32	1.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg22681709	chr2:178499509	PDE11A	-0.51	-9.15	-0.45	5.67e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9549260	0.564	rs8000965	chr13:41279488	C/T	cg21288729	chr13:41239152	FOXO1	0.55	8.42	0.42	1.12e-15	Red blood cell count;
LUSC	cis	rs4356932	1.000	rs4241579	chr4:76947284	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.72	-9.91	-0.48	1.9e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs1385374	0.841	rs11059929	chr12:129296893	G/A	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.57	-0.34	1.97e-10	Systemic lupus erythematosus;
LUSC	cis	rs4964805	0.954	rs10861104	chr12:104189923	A/C	cg02344784	chr12:104178138	NT5DC3	0.43	6.71	0.34	8.11e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg05855489	chr10:104503620	C10orf26	0.51	7.47	0.38	7.17e-13	Arsenic metabolism;
LUSC	cis	rs12681287	0.640	rs7007855	chr8:87429491	T/G	cg27223183	chr8:87520930	FAM82B	0.54	7.45	0.38	7.84e-13	Caudate activity during reward;
LUSC	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg25801113	chr15:45476975	SHF	-0.35	-6.9	-0.35	2.59e-11	Uric acid levels;
LUSC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg13397359	chr6:42928475	GNMT	0.68	12.0	0.55	7.83e-28	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg25019033	chr10:957182	NA	-0.46	-5.77	-0.3	1.79e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs977987	0.806	rs12051326	chr16:75437887	G/A	cg04384234	chr16:75411784	CFDP1	-0.41	-6.58	-0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.44	5.94	0.31	7.13e-9	Renal function-related traits (BUN);
LUSC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg26677194	chr12:130822605	PIWIL1	0.59	8.77	0.43	9.52e-17	Menopause (age at onset);
LUSC	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.84	14.43	0.62	5.19e-37	Bladder cancer;
LUSC	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg15704280	chr7:45808275	SEPT13	-0.46	-6.34	-0.33	7.57e-10	HDL cholesterol;
LUSC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.33	0.45	1.46e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18301423	chr5:131593218	PDLIM4	0.47	7.31	0.37	2.05e-12	Acylcarnitine levels;
LUSC	cis	rs2692947	0.644	rs1168974	chr2:96814928	G/A	cg23100626	chr2:96804247	ASTL	0.3	7.08	0.36	8.56e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.68	-11.29	-0.53	2.85e-25	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.52	0.5	1.48e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.27	-17.49	-0.69	4.55e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg07936489	chr17:37558343	FBXL20	-0.71	-9.75	-0.47	6.1e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg18099408	chr3:52552593	STAB1	-0.33	-5.65	-0.3	3.4e-8	Electroencephalogram traits;
LUSC	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-7.85	-0.39	5.59e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs590121	0.876	rs652054	chr11:75275532	C/A	cg26104986	chr11:75275303	SERPINH1	-0.28	-5.75	-0.3	2.01e-8	Coronary artery disease;
LUSC	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg11502198	chr6:26597334	ABT1	0.68	11.28	0.53	3.09e-25	Intelligence (multi-trait analysis);
LUSC	trans	rs4948088	1.000	rs2329566	chr7:51017655	G/A	cg26816907	chr1:197890812	LHX9	0.56	6.22	0.32	1.47e-9	Type 1 diabetes;
LUSC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg01616529	chr11:638424	DRD4	-0.34	-5.98	-0.31	5.7e-9	Systemic lupus erythematosus;
LUSC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg13319975	chr6:146136371	FBXO30	0.5	7.53	0.38	4.84e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg26587870	chr6:27730563	NA	0.54	5.96	0.31	6.41e-9	Depression;
LUSC	cis	rs9296092	0.517	rs55963187	chr6:33523778	G/C	cg13560919	chr6:33536144	NA	-0.83	-15.75	-0.65	3.39e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs3099143	0.901	rs78020233	chr15:77107050	T/G	cg21673338	chr15:77095150	SCAPER	-0.77	-6.53	-0.34	2.5e-10	Recalcitrant atopic dermatitis;
LUSC	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.11	-0.41	9.47e-15	Type 2 diabetes;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg23034840	chr1:205782522	SLC41A1	0.66	9.87	0.48	2.48e-20	Menarche (age at onset);
LUSC	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg24558204	chr6:135376177	HBS1L	-0.56	-8.14	-0.41	7.92e-15	Red blood cell count;
LUSC	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg23241863	chr10:102295624	HIF1AN	0.5	5.71	0.3	2.53e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg08132940	chr7:1081526	C7orf50	-0.51	-5.93	-0.31	7.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.57	-0.57	6.18e-30	Chronic sinus infection;
LUSC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.84	-12.41	-0.56	2.46e-29	Initial pursuit acceleration;
LUSC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg26695010	chr11:65641043	EFEMP2	0.41	5.75	0.3	2.03e-8	Breast cancer;
LUSC	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.09	-0.4	1.11e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg24733560	chr20:60626293	TAF4	0.41	6.6	0.34	1.63e-10	Body mass index;
LUSC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg22823121	chr1:150693482	HORMAD1	0.53	7.42	0.38	1.01e-12	Urate levels;
LUSC	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18876405	chr7:65276391	NA	0.48	6.53	0.34	2.49e-10	Corneal structure;
LUSC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg04871131	chr7:94954202	PON1	-0.36	-5.65	-0.3	3.45e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08859206	chr1:53392774	SCP2	-0.55	-9.56	-0.46	2.58e-19	Monocyte count;
LUSC	cis	rs9925964	0.933	rs9929899	chr16:31062701	C/A	cg02466173	chr16:30829666	NA	0.35	6.44	0.33	4.18e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.48e-28	Motion sickness;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg21157115	chr9:33001303	APTX	0.37	6.06	0.31	3.77e-9	Triglycerides;
LUSC	cis	rs7202877	0.706	rs37599	chr16:75502132	C/T	cg03315344	chr16:75512273	CHST6	-0.42	-5.95	-0.31	6.74e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg13642260	chr9:130955380	CIZ1	-0.48	-7.59	-0.38	3.27e-13	Attention deficit hyperactivity disorder;
LUSC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg15448220	chr1:150897856	SETDB1	0.4	5.87	0.31	1.02e-8	Melanoma;
LUSC	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-12.19	-0.55	1.62e-28	Migraine;Coronary artery disease;
LUSC	cis	rs2324229	0.828	rs1180226	chr6:83951709	G/A	cg08257003	chr6:84140564	ME1	0.27	6.31	0.33	8.98e-10	Platelet-derived growth factor BB levels;
LUSC	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.72	-13.56	-0.6	1.13e-33	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs469568	0.712	rs467604	chr5:178667984	A/G	cg08999896	chr5:178685787	ADAMTS2	-0.28	-5.7	-0.3	2.64e-8	Stroke (pediatric);
LUSC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11764359	chr7:65958608	NA	-0.68	-10.95	-0.51	4.81e-24	Aortic root size;
LUSC	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg06022373	chr22:39101656	GTPBP1	0.76	11.5	0.53	5.33e-26	Menopause (age at onset);
LUSC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg04733989	chr22:42467013	NAGA	0.39	6.62	0.34	1.45e-10	Cognitive function;
LUSC	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg04691961	chr3:161091175	C3orf57	-0.34	-5.81	-0.3	1.49e-8	Morning vs. evening chronotype;
LUSC	cis	rs427941	0.703	rs201452	chr7:101739663	C/T	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs4462272	0.503	rs12774352	chr10:101840960	A/G	cg02250046	chr10:101825185	CPN1	-0.3	-5.67	-0.3	3.14e-8	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2979489	0.891	rs4733495	chr8:30366883	A/G	cg26383811	chr8:30366931	RBPMS	0.5	7.71	0.39	1.45e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg27588902	chr6:42928151	GNMT	-0.29	-6.49	-0.33	3.11e-10	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg13114125	chr14:105738426	BRF1	-0.9	-15.79	-0.65	2.46e-42	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg04691961	chr3:161091175	C3orf57	-0.34	-5.83	-0.3	1.27e-8	Morning vs. evening chronotype;
LUSC	cis	rs427941	0.694	rs2529094	chr7:101739617	C/T	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs9815354	1.000	rs3774372	chr3:41877414	A/G	cg03022575	chr3:42003672	ULK4	0.66	7.17	0.37	4.77e-12	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg24631222	chr15:78858424	CHRNA5	0.85	11.44	0.53	8.6e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.3	0.49	8.36e-22	Schizophrenia;
LUSC	cis	rs7605827	0.897	rs2890488	chr2:15635439	T/A	cg19274914	chr2:15703543	NA	0.46	8.84	0.44	5.74e-17	Educational attainment (years of education);
LUSC	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18932078	chr1:2524107	MMEL1	-0.31	-6.83	-0.35	4.11e-11	Multiple sclerosis;
LUSC	cis	rs4555082	0.957	rs2816609	chr14:105720803	A/C	cg06808227	chr14:105710500	BRF1	-0.67	-9.99	-0.48	9.89e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4566357	1.000	rs1917129	chr2:227927951	A/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.91	-0.31	8.46e-9	Coronary artery disease;
LUSC	trans	rs12145833	0.538	rs12026408	chr1:243366805	G/A	cg01826367	chr1:224180288	NA	0.71	6.54	0.34	2.25e-10	Obesity (early onset extreme);
LUSC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg22618164	chr12:122356400	WDR66	-0.59	-8.77	-0.43	9.09e-17	Mean corpuscular volume;
LUSC	cis	rs3007168	1.000	rs3007076	chr14:51605352	G/T	cg23942311	chr14:51606299	NA	0.37	6.02	0.31	4.5e-9	Cancer;
LUSC	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.55	-9.12	-0.45	7.36e-18	Breast cancer;
LUSC	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	8.01	0.4	1.94e-14	Axial length;
LUSC	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg02569458	chr12:86230093	RASSF9	0.42	6.81	0.35	4.67e-11	Major depressive disorder;
LUSC	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg06064525	chr11:970664	AP2A2	-0.29	-5.68	-0.3	2.94e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14442939	chr10:27389572	ANKRD26	-0.88	-9.89	-0.48	2.12e-20	Breast cancer;
LUSC	trans	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg06521331	chr12:34319734	NA	0.4	6.29	0.33	1.02e-9	Bladder cancer;
LUSC	cis	rs1499972	0.941	rs62263123	chr3:117632263	G/A	cg07612923	chr3:117604196	NA	0.64	5.76	0.3	1.95e-8	Schizophrenia;
LUSC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.68	11.22	0.52	5.13e-25	Cognitive function;
LUSC	cis	rs6556937	0.597	rs7733671	chr5:96000269	A/G	cg07690455	chr5:95997198	CAST	-0.45	-6.14	-0.32	2.31e-9	Blood protein levels;
LUSC	cis	rs11690935	0.851	rs7573003	chr2:172741415	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.81	-13.03	-0.58	1.17e-31	Schizophrenia;
LUSC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg13319975	chr6:146136371	FBXO30	-0.39	-5.92	-0.31	8e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg23241863	chr10:102295624	HIF1AN	0.49	5.7	0.3	2.69e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg02016764	chr4:38805732	TLR1	-0.54	-5.69	-0.3	2.81e-8	Breast cancer;
LUSC	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs62400317	0.859	rs12153922	chr6:45256159	T/C	cg20913747	chr6:44695427	NA	-0.46	-7.47	-0.38	7.12e-13	Total body bone mineral density;
LUSC	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg23625390	chr15:77176239	SCAPER	-0.65	-9.95	-0.48	1.38e-20	Blood metabolite levels;
LUSC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg00814883	chr7:100076585	TSC22D4	-0.77	-9.7	-0.47	9.3e-20	Platelet count;
LUSC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	9.69	0.47	9.58e-20	Cognitive test performance;
LUSC	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg18755752	chr8:142205143	DENND3	-0.49	-7.44	-0.38	8.84e-13	Immature fraction of reticulocytes;
LUSC	cis	rs7123876	0.587	rs11601122	chr11:72362718	A/G	cg04827223	chr11:72435913	ARAP1	-0.63	-7.18	-0.37	4.57e-12	Body mass index;
LUSC	cis	rs11077815	0.815	rs394873	chr17:74413449	A/G	cg06840243	chr17:74442338	UBE2O	0.32	5.76	0.3	1.87e-8	Lymphocyte counts;
LUSC	cis	rs12050794	0.636	rs4506844	chr15:72509138	C/T	cg16672083	chr15:72433130	SENP8	0.47	7.9	0.4	4.11e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg00074818	chr8:8560427	CLDN23	0.59	9.8	0.47	4.21e-20	Obesity-related traits;
LUSC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.97	0.44	2.18e-17	Motion sickness;
LUSC	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg12463550	chr7:65579703	CRCP	-0.55	-8.36	-0.42	1.77e-15	Aortic root size;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02092906	chr6:83903419	PGM3;RWDD2A	-0.37	-5.98	-0.31	5.77e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs8017423	0.935	rs4643251	chr14:90669256	C/T	cg04374321	chr14:90722782	PSMC1	-0.67	-9.95	-0.48	1.32e-20	Mortality in heart failure;
LUSC	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg08888203	chr3:10149979	C3orf24	0.61	8.22	0.41	4.4e-15	Alzheimer's disease;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03909902	chr12:108154529	PRDM4	-0.35	-6.43	-0.33	4.46e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7539542	0.556	rs6662413	chr1:202888496	C/T	cg19681188	chr1:202830198	LOC148709	-0.39	-5.75	-0.3	2.06e-8	Mean platelet volume;
LUSC	cis	rs9517320	0.935	rs1886089	chr13:99124356	C/T	cg07423050	chr13:99094983	FARP1	0.33	6.23	0.32	1.41e-9	Longevity;
LUSC	cis	rs7771547	0.519	rs6917489	chr6:36368169	C/T	cg07856975	chr6:36356162	ETV7	0.41	6.03	0.31	4.4e-9	Platelet distribution width;
LUSC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg22709100	chr7:91322751	NA	0.4	5.81	0.3	1.48e-8	Breast cancer;
LUSC	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-0.97	-15.65	-0.65	8.2e-42	Dupuytren's disease;
LUSC	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg13256891	chr4:100009986	ADH5	0.45	6.24	0.32	1.3e-9	Alcohol dependence;
LUSC	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg22437258	chr11:111473054	SIK2	0.51	6.93	0.35	2.15e-11	Primary sclerosing cholangitis;
LUSC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.45	0.38	8.15e-13	Prudent dietary pattern;
LUSC	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	1.01	15.34	0.64	1.37e-40	Exhaled nitric oxide output;
LUSC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.29	-0.41	2.74e-15	Cystic fibrosis severity;
LUSC	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg08213375	chr14:104286397	PPP1R13B	0.43	8.25	0.41	3.62e-15	Schizophrenia;
LUSC	cis	rs3106136	0.967	rs8026	chr4:95212185	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.24	-0.32	1.33e-9	Capecitabine sensitivity;
LUSC	cis	rs7572644	0.699	rs4233719	chr2:28079344	C/A	cg27432699	chr2:27873401	GPN1	0.52	7.02	0.36	1.23e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs800082	0.768	rs2222702	chr3:144258814	T/A	cg24215973	chr2:240111563	HDAC4	0.41	6.11	0.32	2.74e-9	Smoking behavior;
LUSC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg27165867	chr14:105738592	BRF1	-0.51	-7.21	-0.37	3.83e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7586879	0.828	rs13428789	chr2:25087643	C/T	cg01884057	chr2:25150051	NA	0.39	8.22	0.41	4.45e-15	Body mass index;
LUSC	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg00898013	chr13:113819073	PROZ	-0.49	-7.08	-0.36	8.8e-12	Platelet distribution width;
LUSC	cis	rs2130392	0.503	rs2871418	chr4:185654723	A/G	cg21366198	chr4:185655624	MLF1IP	0.39	5.75	0.3	2e-8	Kawasaki disease;
LUSC	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-1.13	-17.99	-0.7	4.71e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg20701182	chr2:24300061	SF3B14	0.87	11.4	0.53	1.19e-25	Lymphocyte counts;
LUSC	cis	rs9341808	0.718	rs2322636	chr6:80897436	C/T	cg08355045	chr6:80787529	NA	0.59	10.22	0.49	1.58e-21	Sitting height ratio;
LUSC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg03804128	chr16:635623	NA	0.3	5.83	0.3	1.28e-8	Height;
LUSC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-1.05	-20.51	-0.75	4.34e-61	Height;
LUSC	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-9.08	-0.44	9.97e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg03676636	chr4:99064102	C4orf37	0.36	7.99	0.4	2.15e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11191270	0.590	rs12569901	chr10:104025410	C/G	cg15320455	chr10:103880129	LDB1	0.56	5.73	0.3	2.21e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	23.89	0.79	3e-74	Colorectal cancer;
LUSC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg14092988	chr3:52407081	DNAH1	0.31	6.17	0.32	2e-9	Bipolar disorder;
LUSC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg00701064	chr4:6280414	WFS1	0.61	14.8	0.63	1.85e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-13.04	-0.58	1.04e-31	Colorectal cancer;
LUSC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg04414720	chr1:150670196	GOLPH3L	0.56	9.1	0.45	8.47e-18	Tonsillectomy;
LUSC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg10729496	chr3:10149963	C3orf24	0.57	7.55	0.38	4.11e-13	Alzheimer's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20861091	chr8:144881744	SCRIB	0.55	6.82	0.35	4.27e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3820928	0.967	rs2396435	chr2:227778397	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.97	-0.4	2.57e-14	Pulmonary function;
LUSC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.67	-5.74	-0.3	2.17e-8	Major depressive disorder;
LUSC	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg04362960	chr10:104952993	NT5C2	0.58	9.16	0.45	5.32e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg00343986	chr7:65444356	GUSB	-0.43	-6.55	-0.34	2.22e-10	Aortic root size;
LUSC	cis	rs7719624	0.846	rs2237066	chr5:135367603	C/T	cg12897067	chr5:135418308	NA	-0.45	-6.53	-0.34	2.4e-10	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg25801113	chr15:45476975	SHF	-0.33	-6.43	-0.33	4.29e-10	Uric acid levels;
LUSC	cis	rs4478858	0.684	rs2062951	chr1:31762981	T/C	cg00250761	chr1:31883323	NA	-0.34	-8.15	-0.41	7.26e-15	Alcohol dependence;
LUSC	cis	rs6545883	0.860	rs777589	chr2:61425621	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-6.65	-0.34	1.21e-10	Tuberculosis;
LUSC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06028605	chr16:24865363	SLC5A11	0.64	9.68	0.47	1.08e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.39	-0.56	2.93e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.88	-14.74	-0.63	3.14e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg26597838	chr10:835615	NA	1.07	13.74	0.6	2.38e-34	Eosinophil percentage of granulocytes;
LUSC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg01802117	chr1:53393560	SCP2	-0.39	-6.44	-0.33	4.16e-10	Monocyte count;
LUSC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-12.2	-0.56	1.43e-28	Colorectal cancer;
LUSC	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg20703242	chr1:230279135	GALNT2	0.57	8.71	0.43	1.39e-16	Coronary artery disease;
LUSC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg13206674	chr6:150067644	NUP43	0.58	9.19	0.45	4.25e-18	Lung cancer;
LUSC	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg17366294	chr4:99064904	C4orf37	0.6	10.69	0.5	3.82e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1030268	0.505	rs77112963	chr7:133259399	G/A	cg10665199	chr7:133106180	EXOC4	0.64	7.15	0.36	5.68e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg02896835	chr1:92012615	NA	-0.53	-8.93	-0.44	2.88e-17	Breast cancer;
LUSC	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.24	-0.32	1.35e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-5.97	-0.31	6.07e-9	Mood instability;
LUSC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	0.98	13.57	0.6	1.03e-33	Vitiligo;
LUSC	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg26408565	chr15:76604113	ETFA	-0.42	-6.51	-0.34	2.82e-10	Blood metabolite levels;
LUSC	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17691542	chr6:26056736	HIST1H1C	1.0	12.67	0.57	2.59e-30	Iron status biomarkers;
LUSC	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06636551	chr8:101224915	SPAG1	0.43	7.88	0.4	4.8e-14	Atrioventricular conduction;
LUSC	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg25251562	chr2:3704773	ALLC	-0.48	-7.39	-0.38	1.15e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg04362960	chr10:104952993	NT5C2	0.59	9.51	0.46	3.97e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg01884057	chr2:25150051	NA	0.42	9.13	0.45	6.57e-18	Body mass index;
LUSC	cis	rs13006833	1.000	rs13006833	chr2:191205499	G/C	cg21644426	chr2:191273491	MFSD6	0.45	6.4	0.33	5.26e-10	Urinary metabolites;
LUSC	cis	rs529866	0.555	rs367569	chr16:11365500	C/T	cg00044050	chr16:11439710	C16orf75	0.56	7.83	0.39	6.35e-14	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg24130564	chr14:104152367	KLC1	-0.46	-6.38	-0.33	6.01e-10	Body mass index;
LUSC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.52e-24	Aortic root size;
LUSC	cis	rs834603	0.575	rs1612394	chr7:47467609	G/A	cg09696706	chr7:47479511	TNS3	0.32	5.75	0.3	2.01e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23319046	chr18:3247432	MYL12A	-0.42	-6.26	-0.32	1.18e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-17.54	-0.69	2.71e-49	Primary sclerosing cholangitis;
LUSC	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg24375607	chr4:120327624	NA	0.78	11.51	0.53	4.85e-26	Corneal astigmatism;
LUSC	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg18753928	chr3:113234510	CCDC52	-0.51	-7.96	-0.4	2.8e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-17.52	-0.69	3.22e-49	Exhaled nitric oxide output;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05431684	chr11:130781542	SNX19	0.42	6.15	0.32	2.2e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.91	16.24	0.66	4e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg02269571	chr22:50332266	NA	0.46	6.34	0.33	7.36e-10	Schizophrenia;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg21548813	chr6:291882	DUSP22	0.73	12.23	0.56	1.11e-28	Menopause (age at onset);
LUSC	cis	rs6977660	0.943	rs9639334	chr7:19838810	G/A	cg07541023	chr7:19748670	TWISTNB	0.54	6.16	0.32	2.06e-9	Thyroid stimulating hormone;
LUSC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg12432903	chr7:1882776	MAD1L1	-0.38	-5.97	-0.31	5.92e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg13390004	chr1:15929781	NA	0.42	7.13	0.36	6.1e-12	Systolic blood pressure;
LUSC	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg20607287	chr7:12443886	VWDE	-0.65	-6.59	-0.34	1.74e-10	Coronary artery disease;
LUSC	cis	rs796364	0.616	rs769956	chr2:200693720	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.5	-5.81	-0.3	1.46e-8	Schizophrenia;
LUSC	cis	rs10911251	0.528	rs10911266	chr1:183115097	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.66	0.5	5e-23	Colorectal cancer;
LUSC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg23791538	chr6:167370224	RNASET2	-0.39	-6.02	-0.31	4.72e-9	Crohn's disease;
LUSC	cis	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg00291366	chr1:12616550	NA	0.37	9.61	0.47	1.82e-19	Optic cup area;
LUSC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg21171335	chr12:122356390	WDR66	0.55	7.8	0.39	7.97e-14	Mean corpuscular volume;
LUSC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.35	-0.8	4.97e-76	Height;
LUSC	cis	rs977987	0.806	rs12930768	chr16:75464500	T/C	cg03315344	chr16:75512273	CHST6	0.5	9.55	0.46	2.98e-19	Dupuytren's disease;
LUSC	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.46	6.35	0.33	7.23e-10	Lung disease severity in cystic fibrosis;
LUSC	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg12856521	chr11:46389249	DGKZ	0.43	6.34	0.33	7.27e-10	Leprosy;
LUSC	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg11584989	chr19:19387371	SF4	0.57	6.82	0.35	4.18e-11	Bipolar disorder;
LUSC	cis	rs9650315	0.866	rs7815909	chr8:57200362	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.28	0.37	2.42e-12	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01122304	chr4:2845576	ADD1	-0.39	-6.21	-0.32	1.58e-9	Electrocardiographic conduction measures;
LUSC	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg08975724	chr8:8085496	FLJ10661	0.46	6.63	0.34	1.36e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg17279839	chr7:150038598	RARRES2	0.43	6.8	0.35	4.79e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2303282	1.000	rs2303282	chr16:56531185	C/G	cg00500540	chr16:56394104	NA	-0.44	-7.05	-0.36	1.04e-11	Breast cancer;
LUSC	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg24375607	chr4:120327624	NA	0.79	11.94	0.55	1.32e-27	Corneal astigmatism;
LUSC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg21535247	chr6:8435926	SLC35B3	0.62	9.72	0.47	7.79e-20	Motion sickness;
LUSC	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.48	-8.75	-0.43	1.11e-16	Total body bone mineral density;
LUSC	cis	rs16854884	0.683	rs2053211	chr3:143774592	C/T	cg06585982	chr3:143692056	C3orf58	-0.4	-6.13	-0.32	2.52e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs7681440	0.647	rs1372508	chr4:90819786	C/G	cg20003494	chr4:90757398	SNCA	0.35	5.81	0.3	1.48e-8	Dementia with Lewy bodies;
LUSC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg07703079	chr11:430292	ANO9	0.65	6.75	0.35	6.67e-11	Body mass index;
LUSC	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-1.08	-12.67	-0.57	2.61e-30	Mitochondrial DNA levels;
LUSC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg18225595	chr11:63971243	STIP1	0.61	10.33	0.49	6.88e-22	Platelet count;
LUSC	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	10.0	0.48	9.28e-21	Electrocardiographic conduction measures;
LUSC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg27535305	chr1:53392650	SCP2	0.36	6.78	0.35	5.43e-11	Monocyte count;
LUSC	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg04218760	chr10:45406644	TMEM72	-0.3	-7.14	-0.36	5.73e-12	Mean corpuscular volume;
LUSC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.39	-0.42	1.42e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs295140	0.526	rs295114	chr2:201195602	C/T	cg23649088	chr2:200775458	C2orf69	0.4	6.03	0.31	4.4e-9	QT interval;
LUSC	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.85	14.78	0.63	2.26e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs10392	0.543	rs4812332	chr20:37534665	C/T	cg27552599	chr20:37590471	DHX35	0.42	6.57	0.34	1.96e-10	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	trans	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	8.81	0.43	7.1e-17	Type 2 diabetes;
LUSC	cis	rs9311676	0.632	rs4228	chr3:58413669	G/T	cg13750441	chr3:58318267	PXK	0.35	6.86	0.35	3.41e-11	Systemic lupus erythematosus;
LUSC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-1.04	-20.09	-0.74	2.02e-59	Height;
LUSC	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg24130564	chr14:104152367	KLC1	-0.45	-6.2	-0.32	1.62e-9	Body mass index;
LUSC	cis	rs10779751	1.000	rs11121703	chr1:11293792	G/T	cg08854313	chr1:11322531	MTOR	-0.88	-15.01	-0.63	2.68e-39	Body mass index;
LUSC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg17333051	chr19:2783644	SGTA	0.49	7.38	0.37	1.26e-12	Total cholesterol levels;
LUSC	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	8.0	0.4	2.03e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg05855489	chr10:104503620	C10orf26	0.49	7.36	0.37	1.48e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	trans	rs1459104	0.866	rs66989058	chr11:54823043	C/A	cg03929089	chr4:120376271	NA	0.7	6.12	0.32	2.63e-9	Body mass index;
LUSC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7428496	0.528	rs2227931	chr3:142222284	A/G	cg16271453	chr3:142027066	XRN1	-0.51	-8.95	-0.44	2.6e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg23280166	chr11:118938394	VPS11	0.44	6.76	0.35	6.13e-11	Coronary artery disease;
LUSC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22442454	chr1:209979470	IRF6	0.43	5.81	0.3	1.46e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs6489882	0.867	rs6489866	chr12:113363408	A/G	cg20102336	chr12:113376681	OAS3	-0.42	-5.93	-0.31	7.36e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg09904177	chr6:26538194	HMGN4	0.42	6.15	0.32	2.16e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg20135002	chr11:47629003	NA	-0.52	-8.08	-0.4	1.17e-14	Subjective well-being;
LUSC	cis	rs239198	0.602	rs9390698	chr6:101296389	G/A	cg09795085	chr6:101329169	ASCC3	0.45	6.36	0.33	6.54e-10	Menarche (age at onset);
LUSC	cis	rs1322512	1.000	rs2800633	chr6:153010308	T/G	cg27316956	chr6:152958899	SYNE1	0.35	6.06	0.31	3.59e-9	Tonometry;
LUSC	cis	rs7759001	0.817	rs1883405	chr6:27350424	T/A	cg18711553	chr6:27366782	ZNF391	0.4	5.9	0.31	8.74e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs16912285	0.688	rs1899540	chr11:24339992	A/G	ch.11.24196551F	chr11:24239977	NA	0.81	7.79	0.39	8.47e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2652834	0.851	rs4775628	chr15:63426463	A/C	cg05507819	chr15:63340323	TPM1	0.45	5.82	0.3	1.37e-8	HDL cholesterol;
LUSC	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	1.14	19.67	0.73	9.55e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs11971779	0.616	rs6967932	chr7:139022381	C/T	cg07862535	chr7:139043722	LUC7L2	0.54	6.74	0.35	6.84e-11	Diisocyanate-induced asthma;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg23633666	chr10:44101845	ZNF485	0.47	6.12	0.32	2.65e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg03060546	chr3:49711283	APEH	-0.63	-7.6	-0.38	3.08e-13	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg03676636	chr4:99064102	C4orf37	0.36	8.07	0.4	1.3e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs524023	0.874	rs492175	chr11:64433078	A/G	cg19131476	chr11:64387923	NRXN2	0.37	10.07	0.48	5.2e-21	Urate levels in obese individuals;
LUSC	cis	rs10207060	0.500	rs28640956	chr2:240714001	G/C	cg20333904	chr2:240724165	NA	-0.35	-6.15	-0.32	2.26e-9	Obesity-related traits;
LUSC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg07701084	chr6:150067640	NUP43	-0.59	-9.26	-0.45	2.63e-18	Lung cancer;
LUSC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	0.93	15.69	0.65	5.75e-42	Menopause (age at onset);
LUSC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg22903657	chr4:1355424	KIAA1530	-0.36	-6.09	-0.32	3.11e-9	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.81	0.3	1.48e-8	Menopause (age at onset);
LUSC	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg08017634	chr8:144659831	NAPRT1	0.69	6.11	0.32	2.72e-9	Attention deficit hyperactivity disorder;
LUSC	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg20587970	chr11:113659929	NA	1.14	13.52	0.59	1.65e-33	Hip circumference adjusted for BMI;
LUSC	cis	rs34638657	0.872	rs6420436	chr16:82186719	C/G	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.06	-0.31	3.66e-9	Lung adenocarcinoma;
LUSC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg20684491	chr1:25596433	NA	-0.39	-6.33	-0.33	7.97e-10	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9811920	0.809	rs4928151	chr3:99767553	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.34	5.8	0.3	1.52e-8	Axial length;
LUSC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg17211192	chr8:82754475	SNX16	-0.81	-11.06	-0.52	1.89e-24	Diastolic blood pressure;
LUSC	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg16342193	chr10:102329863	NA	-0.36	-6.77	-0.35	5.77e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs9503598	0.636	rs6596974	chr6:3465833	C/T	cg05722439	chr19:14072965	RFX1	-0.31	-6.02	-0.31	4.72e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs4919687	0.550	rs10437480	chr10:104453024	C/G	cg04362960	chr10:104952993	NT5C2	0.47	6.9	0.35	2.62e-11	Colorectal cancer;
LUSC	cis	rs34638657	0.827	rs6564996	chr16:82207542	T/C	cg09439754	chr16:82129088	HSD17B2	-0.37	-5.68	-0.3	2.98e-8	Lung adenocarcinoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07284286	chr16:58662935	CNOT1	0.48	7.48	0.38	6.45e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1559088	0.744	rs12462426	chr19:33536683	A/C	cg27124370	chr19:33622961	WDR88	0.47	6.08	0.32	3.33e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs12973672	0.855	rs7256866	chr19:35771257	A/G	cg12095397	chr19:35769544	USF2	0.44	6.77	0.35	5.67e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs59104589	0.617	rs62193220	chr2:242353493	G/A	cg14842376	chr2:242211374	HDLBP	0.53	6.22	0.32	1.53e-9	Fibrinogen levels;
LUSC	trans	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.99	-0.31	5.47e-9	Dementia with Lewy bodies;
LUSC	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg21138405	chr5:131827807	IRF1	0.48	9.5	0.46	4.32e-19	Breast cancer;Mosquito bite size;
LUSC	cis	rs9309473	0.948	rs10173534	chr2:73813432	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.62	-0.34	1.4e-10	Metabolite levels;
LUSC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg09877947	chr5:131593287	PDLIM4	-0.45	-6.87	-0.35	3.19e-11	Breast cancer;
LUSC	cis	rs56283067	0.887	rs62437968	chr6:44729495	G/A	cg20913747	chr6:44695427	NA	-0.5	-8.25	-0.41	3.77e-15	Total body bone mineral density;
LUSC	trans	rs6590322	0.513	rs4937325	chr11:128222116	T/C	cg19073447	chr10:134024191	STK32C	-0.37	-6.21	-0.32	1.55e-9	Hippocampal atrophy;
LUSC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-8.18	-0.41	6.14e-15	Systemic lupus erythematosus;
LUSC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg04518342	chr5:131593106	PDLIM4	0.43	7.64	0.39	2.35e-13	Breast cancer;
LUSC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.34	0.33	7.28e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.61	8.41	0.42	1.24e-15	Resting heart rate;
LUSC	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg21724239	chr8:58056113	NA	0.56	6.71	0.34	8.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26314531	chr2:26401878	FAM59B	-0.68	-9.13	-0.45	6.62e-18	Gut microbiome composition (summer);
LUSC	trans	rs17278117	0.558	rs7675612	chr4:182596023	A/G	cg11957848	chr6:169575326	NA	0.64	6.08	0.32	3.31e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg15133208	chr4:90757351	SNCA	-0.5	-7.31	-0.37	2.03e-12	Neuroticism;
LUSC	cis	rs11610422	0.954	rs12830705	chr12:31415204	C/T	cg14306366	chr12:31406441	NA	-0.47	-5.77	-0.3	1.82e-8	Coronary artery disease;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg21966860	chr8:145538097	HSF1	-0.37	-6.1	-0.32	2.86e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-9.51	-0.46	3.79e-19	Platelet distribution width;
LUSC	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.39	-0.42	1.41e-15	Schizophrenia;
LUSC	cis	rs710216	0.843	rs844501	chr1:43440783	G/A	cg22176566	chr1:43424700	SLC2A1	0.47	5.71	0.3	2.47e-8	Red cell distribution width;
LUSC	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs731174	0.797	rs670692	chr1:38148124	G/A	cg14170840	chr1:38155120	C1orf109	-0.38	-5.97	-0.31	6.21e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.37	-0.33	6.38e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs9929218	1.000	rs2113199	chr16:68814502	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-11.78	-0.54	5.17e-27	Colorectal cancer;
LUSC	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg04607235	chr12:12878440	APOLD1	0.55	8.25	0.41	3.72e-15	Pulse pressure;
LUSC	cis	rs977987	0.931	rs7195161	chr16:75495572	T/C	cg03315344	chr16:75512273	CHST6	0.52	9.8	0.47	4.44e-20	Dupuytren's disease;
LUSC	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg04851639	chr8:1020857	NA	-0.39	-7.98	-0.4	2.3e-14	Schizophrenia;
LUSC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg24896697	chr17:25660093	NA	-0.46	-6.8	-0.35	4.96e-11	Cognitive function;
LUSC	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg09693106	chr22:46449821	C22orf26;LOC150381	-0.38	-5.87	-0.31	1.03e-8	Dupuytren's disease;
LUSC	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-0.76	-9.18	-0.45	4.79e-18	Refractive error;
LUSC	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg16070123	chr10:51489643	NA	0.57	9.38	0.46	1.07e-18	Prostate-specific antigen levels;
LUSC	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg26924012	chr15:45694286	SPATA5L1	1.11	19.72	0.73	5.85e-58	Homoarginine levels;
LUSC	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg12179176	chr11:130786555	SNX19	0.57	8.65	0.43	2.2e-16	Schizophrenia;
LUSC	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9811920	0.516	rs793485	chr3:99492383	C/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.3	-5.7	-0.3	2.58e-8	Axial length;
LUSC	cis	rs793571	0.523	rs7163162	chr15:58983588	T/A	cg05156742	chr15:59063176	FAM63B	0.52	7.56	0.38	3.85e-13	Schizophrenia;
LUSC	cis	rs10843647	1.000	rs1586281	chr12:30325631	G/C	cg12718339	chr12:29936407	TMTC1	-0.35	-5.89	-0.31	9.61e-9	Glucose homeostasis traits;
LUSC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	0.91	15.04	0.64	2.2e-39	Breast cancer;
LUSC	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg20503657	chr10:835505	NA	0.57	7.44	0.38	8.41e-13	Eosinophil percentage of granulocytes;
LUSC	cis	rs2652834	0.519	rs4075584	chr15:63340292	C/T	cg00520135	chr15:63333846	TPM1	-0.35	-5.75	-0.3	2e-8	HDL cholesterol;
LUSC	cis	rs9677476	0.863	rs16827863	chr2:232077670	C/T	cg07929768	chr2:232055508	NA	-0.34	-6.63	-0.34	1.36e-10	Food antigen IgG levels;
LUSC	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg15073853	chr19:18549131	ISYNA1	-0.31	-5.72	-0.3	2.37e-8	Breast cancer;
LUSC	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	1.1	14.57	0.62	1.44e-37	Nonalcoholic fatty liver disease;
LUSC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.62	0.38	2.68e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg07701084	chr6:150067640	NUP43	0.58	8.92	0.44	3.05e-17	Lung cancer;
LUSC	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg17691542	chr6:26056736	HIST1H1C	0.49	7.22	0.37	3.48e-12	Height;
LUSC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.19	-0.41	5.42e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6489785	0.643	rs2015462	chr12:121238204	G/C	cg02403541	chr12:121454288	C12orf43	0.39	5.86	0.31	1.09e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg09455208	chr3:40491958	NA	0.56	10.19	0.49	2.09e-21	Renal cell carcinoma;
LUSC	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.66	17.08	0.68	1.81e-47	Anterior chamber depth;
LUSC	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg14092571	chr14:90743983	NA	0.33	5.74	0.3	2.14e-8	Mortality in heart failure;
LUSC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg02951883	chr7:2050386	MAD1L1	-0.37	-6.37	-0.33	6.14e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg24953233	chr5:892707	TRIP13;BRD9	0.38	5.98	0.31	5.85e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.45	0.33	3.85e-10	Lung cancer;
LUSC	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg05110241	chr16:68378359	PRMT7	-0.45	-5.96	-0.31	6.5e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg12311346	chr5:56204834	C5orf35	-0.62	-9.05	-0.44	1.21e-17	Coronary artery disease;
LUSC	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3820928	1.000	rs4673173	chr2:227769493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.94	-0.4	3.07e-14	Pulmonary function;
LUSC	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg08975724	chr8:8085496	FLJ10661	0.49	7.19	0.37	4.18e-12	Myopia (pathological);
LUSC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	0.92	15.23	0.64	3.94e-40	Breast cancer;
LUSC	cis	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg06521331	chr12:34319734	NA	-0.39	-5.74	-0.3	2.14e-8	Resting heart rate;
LUSC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06634786	chr22:41940651	POLR3H	-0.48	-5.74	-0.3	2.11e-8	Vitiligo;
LUSC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05535760	chr7:792225	HEATR2	0.78	9.16	0.45	5.34e-18	Cerebrospinal P-tau181p levels;
LUSC	cis	rs11039100	0.607	rs61875872	chr11:5780615	T/A	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	1.03	25.05	0.81	1.11e-78	Multiple system atrophy;
LUSC	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg13609457	chr4:120235615	NA	0.37	5.84	0.3	1.24e-8	Diastolic blood pressure;
LUSC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg18479299	chr3:125709523	NA	-0.5	-6.02	-0.31	4.59e-9	Blood pressure (smoking interaction);
LUSC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg03233332	chr7:66118400	NA	0.4	5.92	0.31	8.07e-9	Aortic root size;
LUSC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg12365402	chr11:9010492	NRIP3	-0.41	-7.44	-0.38	8.57e-13	Hemoglobin concentration;
LUSC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-18.03	-0.7	3.22e-51	Coronary artery disease;
LUSC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg20203395	chr5:56204925	C5orf35	-0.72	-9.84	-0.47	3.21e-20	Initial pursuit acceleration;
LUSC	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg16928487	chr17:17741425	SREBF1	0.46	9.12	0.45	7.18e-18	Total body bone mineral density;
LUSC	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg23649088	chr2:200775458	C2orf69	-0.47	-7.1	-0.36	7.44e-12	QT interval;
LUSC	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg23711669	chr6:146136114	FBXO30	0.86	15.87	0.66	1.21e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4901869	0.966	rs60800733	chr14:59337778	A/G	cg02291164	chr14:59296302	NA	0.57	10.94	0.51	4.96e-24	Panic disorder;
LUSC	cis	rs10193935	0.792	rs7559001	chr2:42474301	C/T	cg27598129	chr2:42591480	NA	-0.6	-8.04	-0.4	1.63e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg03886242	chr7:26192032	NFE2L3	-0.37	-6.14	-0.32	2.4e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.09	16.34	0.67	1.65e-44	Gut microbiome composition (summer);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01959412	chr4:4861398	MSX1	-0.49	-7.13	-0.36	6.29e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs2637266	0.967	rs2395407	chr10:78380573	T/A	cg18941641	chr10:78392320	NA	0.4	7.31	0.37	1.97e-12	Pulmonary function;
LUSC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-0.82	-10.12	-0.48	3.61e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg04733989	chr22:42467013	NAGA	0.49	7.89	0.4	4.26e-14	Schizophrenia;
LUSC	trans	rs11039798	0.541	rs11040166	chr11:48965449	T/C	cg15704280	chr7:45808275	SEPT13	0.81	7.04	0.36	1.11e-11	Axial length;
LUSC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg05347473	chr6:146136440	FBXO30	0.59	10.32	0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg02782426	chr3:40428986	ENTPD3	0.32	6.16	0.32	2.12e-9	Renal cell carcinoma;
LUSC	cis	rs72960926	0.744	rs11754787	chr6:74915037	A/T	cg03266952	chr6:74778945	NA	-0.79	-6.43	-0.33	4.37e-10	Metabolite levels (MHPG);
LUSC	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs981844	0.775	rs62323979	chr4:154752935	T/C	cg14289246	chr4:154710475	SFRP2	0.48	6.43	0.33	4.46e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.12	0.64	1.05e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs6489785	0.522	rs1718188	chr12:121343893	T/A	cg02419362	chr12:121203948	SPPL3	-0.39	-6.78	-0.35	5.33e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg05714579	chr10:131428358	MGMT	0.49	7.44	0.38	8.62e-13	Response to temozolomide;
LUSC	cis	rs7432375	0.610	rs56163507	chr3:136516056	C/T	cg15507776	chr3:136538369	TMEM22	0.44	7.34	0.37	1.68e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs62458065	0.713	rs28421905	chr7:32489501	G/A	cg00845942	chr12:64062724	DPY19L2	-0.55	-6.67	-0.34	1.08e-10	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg21100191	chr22:23484243	RTDR1	0.68	10.05	0.48	6.23e-21	Bone mineral density;
LUSC	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg09835421	chr16:68378352	PRMT7	-0.59	-6.21	-0.32	1.55e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7246967	0.673	rs12979264	chr19:22865134	G/A	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.57e-11	Bronchopulmonary dysplasia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05704155	chr1:10459140	PGD	-0.38	-6.21	-0.32	1.59e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9948	0.521	rs62156207	chr2:97359236	C/A	cg01990225	chr2:97406019	LMAN2L	-1.07	-7.86	-0.4	5.2e-14	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs4356932	1.000	rs4580676	chr4:76953295	G/A	cg00809888	chr4:76862425	NAAA	0.34	5.71	0.3	2.44e-8	Blood protein levels;
LUSC	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.48	6.78	0.35	5.57e-11	Chronic sinus infection;
LUSC	cis	rs4363385	0.747	rs2339495	chr1:152975116	A/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.65	-0.3	3.43e-8	Inflammatory skin disease;
LUSC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg11062466	chr8:58055876	NA	0.51	6.48	0.33	3.36e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.82	0.35	4.4e-11	Heart rate;
LUSC	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg12564285	chr5:131593104	PDLIM4	-0.38	-7.02	-0.36	1.27e-11	Blood metabolite levels;
LUSC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg23283495	chr1:209979779	IRF6	0.64	7.9	0.4	4.2e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs2115630	0.764	rs11073716	chr15:85335774	C/T	cg17173187	chr15:85201210	NMB	-0.29	-5.81	-0.3	1.44e-8	P wave terminal force;
LUSC	cis	rs4343996	0.870	rs4443553	chr7:3378635	T/C	cg21248987	chr7:3385318	SDK1	-0.39	-6.86	-0.35	3.3e-11	Motion sickness;
LUSC	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-8.01	-0.4	1.87e-14	Dental caries;
LUSC	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg04607235	chr12:12878440	APOLD1	-0.47	-5.7	-0.3	2.61e-8	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18099408	chr3:52552593	STAB1	-0.41	-6.96	-0.36	1.84e-11	Bipolar disorder;
LUSC	cis	rs10865397	0.539	rs13414338	chr2:73383375	C/T	cg24220031	chr2:73402428	NA	-0.26	-6.12	-0.32	2.6e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.02	-0.48	7.56e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-5.82	-0.3	1.37e-8	Recombination measurement;
LUSC	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg02176678	chr2:219576539	TTLL4	-0.7	-13.45	-0.59	2.85e-33	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg10207240	chr12:122356781	WDR66	0.47	6.48	0.33	3.32e-10	Mean corpuscular volume;
LUSC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg21361702	chr7:150065534	REPIN1	0.45	6.28	0.33	1.03e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.61	9.71	0.47	8.65e-20	Alcohol dependence;
LUSC	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg19773385	chr1:10388646	KIF1B	-0.52	-8.79	-0.43	7.75e-17	Hepatocellular carcinoma;
LUSC	cis	rs2742234	0.955	rs1800861	chr10:43613843	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.37	-6.52	-0.34	2.66e-10	Hirschsprung disease;
LUSC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg04756594	chr16:24857601	SLC5A11	0.48	6.64	0.34	1.27e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg04865166	chr7:105162814	PUS7	0.52	5.92	0.31	7.79e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg17764715	chr19:33622953	WDR88	0.59	8.14	0.41	7.89e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg07157834	chr1:205819609	PM20D1	-0.44	-5.85	-0.3	1.17e-8	Menarche (age at onset);
LUSC	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-5.97	-0.31	6.07e-9	Retinal vascular caliber;
LUSC	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.61	-0.69	1.49e-49	Exhaled nitric oxide output;
LUSC	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg17127132	chr2:85788382	GGCX	-0.43	-6.22	-0.32	1.52e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.51e-14	Prudent dietary pattern;
LUSC	cis	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg02972257	chr16:68554789	NA	-0.54	-6.73	-0.35	7.29e-11	Ulcerative colitis;
LUSC	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg22676075	chr6:135203613	NA	0.53	8.02	0.4	1.78e-14	Red blood cell count;
LUSC	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.26	-0.37	2.65e-12	Bipolar disorder;
LUSC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-8.14	-0.41	7.78e-15	Longevity;
LUSC	cis	rs1784581	0.588	rs1789986	chr6:162409978	C/T	cg17173639	chr6:162384350	PARK2	-0.56	-9.76	-0.47	5.81e-20	Itch intensity from mosquito bite;
LUSC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg16325326	chr1:53192061	ZYG11B	-0.88	-16.23	-0.66	4.26e-44	Monocyte count;
LUSC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg15534755	chr11:117069859	TAGLN	0.35	6.11	0.32	2.75e-9	Blood protein levels;
LUSC	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg00677455	chr12:58241039	CTDSP2	0.71	10.92	0.51	6.17e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.41	-0.42	1.18e-15	Total cholesterol levels;
LUSC	cis	rs4970988	0.607	rs7548516	chr1:150980281	C/T	cg22823121	chr1:150693482	HORMAD1	-0.43	-5.83	-0.3	1.29e-8	Urate levels;
LUSC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg19748678	chr4:122722346	EXOSC9	0.5	7.61	0.38	2.9e-13	Type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05998513	chr10:97321375	SORBS1	-0.42	-6.43	-0.33	4.43e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg25319279	chr11:5960081	NA	-0.41	-5.79	-0.3	1.62e-8	DNA methylation (variation);
LUSC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.62	8.31	0.41	2.42e-15	High light scatter reticulocyte count;
LUSC	cis	rs6723226	1.000	rs6723226	chr2:32849207	C/T	cg02381751	chr2:32503542	YIPF4	0.55	8.28	0.41	2.92e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6500395	1.000	rs12598514	chr16:48689319	T/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg05234568	chr11:5960015	NA	-0.59	-8.47	-0.42	7.89e-16	DNA methylation (variation);
LUSC	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17159483	chr6:17600760	FAM8A1	-0.41	-6.08	-0.32	3.37e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03576123	chr11:487126	PTDSS2	-1.0	-10.66	-0.5	4.79e-23	Body mass index;
LUSC	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg15997130	chr1:24165203	NA	-0.48	-7.17	-0.37	4.97e-12	Immature fraction of reticulocytes;
LUSC	cis	rs9807841	0.592	rs3810154	chr19:10764914	G/A	cg17710535	chr19:10819994	QTRT1	0.41	6.78	0.35	5.45e-11	Inflammatory skin disease;
LUSC	cis	rs12195417	0.680	rs1170465	chr6:83987655	A/C	cg08257003	chr6:84140564	ME1	0.32	7.91	0.4	3.79e-14	Schizophrenia;
LUSC	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-0.92	-16.09	-0.66	1.58e-43	Height;
LUSC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg02079420	chr8:82753780	SNX16	-0.41	-7.1	-0.36	7.48e-12	Diastolic blood pressure;
LUSC	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg15704280	chr7:45808275	SEPT13	0.66	7.21	0.37	3.8e-12	Axial length;
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01516881	chr6:292596	DUSP22	-0.71	-11.37	-0.53	1.56e-25	Menopause (age at onset);
LUSC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg23161317	chr6:28129485	ZNF389	0.43	5.85	0.31	1.14e-8	Parkinson's disease;
LUSC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg08888203	chr3:10149979	C3orf24	0.59	8.19	0.41	5.59e-15	Alzheimer's disease;
LUSC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg12615879	chr12:58013172	SLC26A10	-0.28	-5.88	-0.31	9.9e-9	Multiple sclerosis;
LUSC	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.11	-0.32	2.85e-9	Resting heart rate;
LUSC	cis	rs9916302	0.821	rs4795386	chr17:37746847	A/G	cg07936489	chr17:37558343	FBXL20	-0.56	-7.36	-0.37	1.41e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00475322	chr7:917719	C7orf20	0.52	7.68	0.39	1.74e-13	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg00933542	chr6:150070202	PCMT1	0.33	7.03	0.36	1.19e-11	Lung cancer;
LUSC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg06074448	chr4:187884817	NA	-0.41	-6.82	-0.35	4.28e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2282300	0.637	rs10767841	chr11:30428275	G/A	cg25418670	chr11:30344373	C11orf46	-0.4	-6.24	-0.32	1.31e-9	Morning vs. evening chronotype;
LUSC	cis	rs12989701	0.825	rs4663097	chr2:127861906	C/G	cg08168897	chr2:127865431	BIN1	-0.55	-7.31	-0.37	2e-12	Alzheimer's disease (late onset);
LUSC	cis	rs9311676	0.609	rs62258133	chr3:58398318	C/G	cg26110898	chr3:58419937	PDHB	0.4	6.42	0.33	4.6e-10	Systemic lupus erythematosus;
LUSC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.9	16.19	0.66	6.09e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	0.92	15.58	0.65	1.65e-41	Menopause (age at onset);
LUSC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21963583	chr11:68658836	MRPL21	0.54	8.25	0.41	3.76e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg14440974	chr22:39074834	NA	-0.35	-5.93	-0.31	7.46e-9	Menopause (age at onset);
LUSC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.49	5.92	0.31	7.95e-9	Renal function-related traits (BUN);
LUSC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	7.99	0.4	2.28e-14	Personality dimensions;
LUSC	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg09754948	chr16:28834200	ATXN2L	0.42	6.11	0.32	2.78e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.58	10.76	0.51	2.21e-23	Bone mineral density;
LUSC	trans	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg22153745	chr1:153894579	GATAD2B	-0.53	-8.38	-0.42	1.47e-15	Total cholesterol levels;
LUSC	cis	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg24324837	chr19:49891574	CCDC155	0.5	6.35	0.33	6.84e-10	Multiple sclerosis;
LUSC	cis	rs6429082	0.713	rs867363	chr1:235579727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-7.94	-0.4	3.18e-14	Adiposity;
LUSC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg04025307	chr7:1156635	C7orf50	0.44	6.98	0.36	1.56e-11	Longevity;Endometriosis;
LUSC	cis	rs1729407	0.933	rs1729405	chr11:116678760	C/T	cg08985259	chr11:116699649	APOC3	-0.26	-5.84	-0.3	1.26e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs7584330	0.504	rs11890255	chr2:238434605	A/G	cg14458575	chr2:238380390	NA	0.42	5.83	0.3	1.3e-8	Prostate cancer;
LUSC	cis	rs6939532	0.522	rs13218591	chr6:26376832	T/C	cg09904177	chr6:26538194	HMGN4	-0.46	-6.72	-0.35	7.85e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg03585969	chr10:35415529	CREM	0.63	9.14	0.45	6.16e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs977987	0.778	rs4243112	chr16:75321031	T/C	cg03315344	chr16:75512273	CHST6	0.47	8.63	0.43	2.56e-16	Dupuytren's disease;
LUSC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.83	-0.39	6.33e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg11502198	chr6:26597334	ABT1	0.71	12.06	0.55	4.63e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg05714579	chr10:131428358	MGMT	-0.77	-12.3	-0.56	6.41e-29	Response to temozolomide;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23453437	chr7:148892747	ZNF282	0.47	7.15	0.36	5.61e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7973719	0.868	rs7315553	chr12:7353838	A/C	cg07052231	chr12:7363540	PEX5	0.54	9.42	0.46	7.85e-19	IgG glycosylation;
LUSC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-12.84	-0.57	5.91e-31	Alzheimer's disease;
LUSC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.52	-0.53	4.54e-26	Schizophrenia;
LUSC	cis	rs9473147	0.516	rs2151974	chr6:47515630	G/A	cg20196966	chr6:47445060	CD2AP	0.41	5.8	0.3	1.57e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg24631222	chr15:78858424	CHRNA5	0.54	6.11	0.32	2.73e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg09877947	chr5:131593287	PDLIM4	0.48	8.24	0.41	4.1e-15	Blood metabolite levels;
LUSC	cis	rs9650315	0.659	rs13253280	chr8:57206663	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.33	0.37	1.73e-12	Height;
LUSC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.1	-0.4	1.08e-14	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.45	-6.81	-0.35	4.66e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg03060546	chr3:49711283	APEH	-0.62	-7.28	-0.37	2.37e-12	Menarche (age at onset);
LUSC	cis	rs12681287	0.752	rs10085920	chr8:87252666	C/T	cg27223183	chr8:87520930	FAM82B	-0.45	-5.72	-0.3	2.33e-8	Caudate activity during reward;
LUSC	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg10978503	chr1:24200527	CNR2	0.49	11.48	0.53	5.91e-26	Immature fraction of reticulocytes;
LUSC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.34	-0.59	7.65e-33	Alzheimer's disease;
LUSC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.41	-0.38	1.03e-12	Aortic root size;
LUSC	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.59	-9.14	-0.45	6.07e-18	Corneal astigmatism;
LUSC	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg00012203	chr2:219082015	ARPC2	0.72	11.88	0.54	2.21e-27	Colorectal cancer;
LUSC	cis	rs9296092	0.521	rs56332659	chr6:33537887	T/C	cg13560919	chr6:33536144	NA	-0.88	-15.69	-0.65	5.8e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg26811252	chr16:29126840	RRN3P2	-0.65	-10.4	-0.49	3.84e-22	Menopause (age at onset);
LUSC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-17.68	-0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg12940439	chr1:67600707	NA	0.38	6.38	0.33	5.97e-10	Psoriasis;
LUSC	trans	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg22153745	chr1:153894579	GATAD2B	-0.49	-6.77	-0.35	5.65e-11	Total cholesterol levels;
LUSC	cis	rs10203711	0.933	rs11883643	chr2:239586885	A/G	cg14580085	chr2:239553406	NA	0.38	6.36	0.33	6.47e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1808579	0.904	rs1631685	chr18:21134239	C/T	cg14672496	chr18:21087552	C18orf8	0.37	6.57	0.34	1.88e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg10596483	chr8:143751796	JRK	0.61	9.41	0.46	8.19e-19	Schizophrenia;
LUSC	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	1.01	14.09	0.61	1.07e-35	Uric acid levels;
LUSC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg21724239	chr8:58056113	NA	0.56	6.63	0.34	1.35e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg04176472	chr15:90893244	GABARAPL3	0.35	6.21	0.32	1.54e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg06454157	chr6:167490870	NA	-0.27	-6.65	-0.34	1.22e-10	Primary biliary cholangitis;
LUSC	cis	rs3740713	1.000	rs73440636	chr11:18473556	C/T	cg15463284	chr11:18477534	LDHAL6A	-0.5	-5.84	-0.3	1.21e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs11700980	0.551	rs56263139	chr21:30109451	A/G	cg14791747	chr16:20752902	THUMPD1	0.55	5.98	0.31	5.75e-9	QRS complex (12-leadsum);
LUSC	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.76	11.15	0.52	8.96e-25	Corneal astigmatism;
LUSC	cis	rs8258	0.927	rs560355	chr11:117256384	C/G	cg15227623	chr11:117232454	CEP164	0.4	5.99	0.31	5.55e-9	Pulse pressure;
LUSC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg17294928	chr15:75287854	SCAMP5	-0.76	-10.07	-0.48	5.32e-21	Blood trace element (Zn levels);
LUSC	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.76	-11.94	-0.55	1.33e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs62027291	0.583	rs2469195	chr15:77259486	A/G	cg26408565	chr15:76604113	ETFA	0.4	5.76	0.3	1.88e-8	Plateletcrit;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14664575	chr19:40476624	PSMC4	0.37	6.09	0.32	3.18e-9	Triglycerides;
LUSC	cis	rs6977660	0.714	rs12334267	chr7:19810265	A/G	cg07541023	chr7:19748670	TWISTNB	0.61	6.6	0.34	1.61e-10	Thyroid stimulating hormone;
LUSC	cis	rs1595825	0.891	rs79745588	chr2:198516835	G/A	cg00982548	chr2:198649783	BOLL	-0.52	-6.57	-0.34	1.95e-10	Ulcerative colitis;
LUSC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg11062466	chr8:58055876	NA	0.51	6.96	0.36	1.84e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg08755490	chr11:65554678	OVOL1	0.4	5.82	0.3	1.4e-8	Acne (severe);
LUSC	cis	rs7937682	0.593	rs1944123	chr11:111356407	T/C	cg09085632	chr11:111637200	PPP2R1B	0.42	5.7	0.3	2.62e-8	Primary sclerosing cholangitis;
LUSC	cis	rs7805747	1.000	rs10480300	chr7:151406005	C/T	cg17611936	chr7:151411526	PRKAG2	0.44	5.81	0.3	1.48e-8	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUSC	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg17757837	chr7:157058334	UBE3C	0.82	13.21	0.59	2.34e-32	Body mass index;
LUSC	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg03733263	chr8:22462867	KIAA1967	0.9	15.5	0.65	3.3e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs2835872	1.000	rs1475839	chr21:39021941	C/T	cg20424643	chr21:39039972	KCNJ6	0.42	6.42	0.33	4.62e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7709377	0.595	rs37180	chr5:115630303	T/C	cg23108291	chr5:115420582	COMMD10	-0.4	-5.71	-0.3	2.55e-8	Metabolite levels  (X-11787);
LUSC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg19318889	chr4:1322082	MAEA	0.44	7.07	0.36	9.03e-12	Obesity-related traits;
LUSC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg07424592	chr7:64974309	NA	0.67	5.97	0.31	6.18e-9	Diabetic kidney disease;
LUSC	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-8.26	-0.41	3.42e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6484504	0.532	rs11031342	chr11:31309818	G/A	cg26647111	chr11:31128758	NA	-0.43	-6.16	-0.32	2.13e-9	Red blood cell count;
LUSC	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	9.29	0.45	1.98e-18	Total body bone mineral density;
LUSC	cis	rs7590720	1.000	rs1991533	chr2:216908910	T/C	cg12620499	chr2:216877984	MREG	0.91	13.45	0.59	2.9e-33	Alcohol dependence;
LUSC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18099408	chr3:52552593	STAB1	-0.45	-7.89	-0.4	4.5e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.53	8.31	0.41	2.36e-15	Response to antipsychotic treatment;
LUSC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.26	-0.32	1.2e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs73206853	0.563	rs7301623	chr12:111170903	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.51	0.38	5.32e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg13010199	chr12:38710504	ALG10B	0.66	10.17	0.49	2.5e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg08219700	chr8:58056026	NA	0.47	5.79	0.3	1.61e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg09904177	chr6:26538194	HMGN4	-0.75	-6.61	-0.34	1.51e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs983392	0.679	rs672399	chr11:60020112	T/G	cg02771260	chr11:59836817	MS4A3	0.38	6.2	0.32	1.7e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6722750	0.651	rs6751738	chr2:64418379	G/T	cg22352474	chr2:64371530	PELI1	-0.48	-7.19	-0.37	4.22e-12	Neuroticism;
LUSC	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg25427524	chr10:38739819	LOC399744	-0.5	-6.54	-0.34	2.26e-10	Obesity (extreme);
LUSC	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg22431228	chr1:16359049	CLCNKA	-0.56	-12.69	-0.57	2.19e-30	Systolic blood pressure;
LUSC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg05347473	chr6:146136440	FBXO30	0.45	7.68	0.39	1.73e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg19628046	chr18:33552617	C18orf21	0.51	6.13	0.32	2.47e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg09034736	chr1:150693464	HORMAD1	0.42	5.88	0.31	9.69e-9	Melanoma;
LUSC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg22907277	chr7:1156413	C7orf50	0.5	7.87	0.4	4.84e-14	Longevity;Endometriosis;
LUSC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg09044154	chr16:88155775	NA	-0.53	-6.94	-0.35	2.09e-11	Menopause (age at onset);
LUSC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.79	14.07	0.61	1.23e-35	Cognitive function;
LUSC	cis	rs11051970	0.636	rs2733703	chr12:32561794	C/T	cg02745156	chr12:32552066	NA	0.38	6.81	0.35	4.53e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08677398	chr8:58056175	NA	0.52	6.34	0.33	7.28e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg23422044	chr7:1970798	MAD1L1	-0.56	-6.32	-0.33	8.2e-10	Bipolar disorder;
LUSC	cis	rs9653442	1.000	rs7580200	chr2:100811903	G/T	cg07810366	chr2:100720526	AFF3	0.45	8.01	0.4	1.98e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10802521	chr3:52805072	NEK4	-0.53	-8.5	-0.42	6.56e-16	Bipolar disorder;
LUSC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg26513180	chr16:89883248	FANCA	-0.54	-8.05	-0.4	1.43e-14	Vitiligo;
LUSC	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.89	14.89	0.63	8.25e-39	Bladder cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27598656	chr16:81348532	GAN	0.43	5.95	0.31	6.66e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs800082	0.516	rs9811286	chr3:144230367	T/C	cg24215973	chr2:240111563	HDAC4	0.45	6.85	0.35	3.66e-11	Smoking behavior;
LUSC	cis	rs4947962	0.617	rs61160416	chr7:55128285	T/C	cg23757825	chr7:55092271	EGFR	-0.54	-6.43	-0.33	4.5e-10	Subjective response to lithium treatment;
LUSC	cis	rs6906287	0.609	rs11153759	chr6:118920860	T/A	cg21191810	chr6:118973309	C6orf204	0.32	5.96	0.31	6.53e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg23752985	chr2:85803571	VAMP8	0.31	6.59	0.34	1.75e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6545883	1.000	rs6545883	chr2:61772257	A/G	cg15711740	chr2:61764176	XPO1	-0.45	-7.02	-0.36	1.25e-11	Tuberculosis;
LUSC	trans	rs6601327	0.641	rs4840437	chr8:9606264	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.26	-0.32	1.16e-9	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14737592	chr12:57914238	DDIT3	0.51	7.27	0.37	2.53e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9311676	0.632	rs56288363	chr3:58374533	A/T	cg26110898	chr3:58419937	PDHB	0.42	6.74	0.35	7.17e-11	Systemic lupus erythematosus;
LUSC	trans	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.55	-0.38	4.06e-13	Depression;
LUSC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg12560992	chr17:57184187	TRIM37	0.84	15.17	0.64	6.64e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg23719950	chr11:63933701	MACROD1	-0.62	-8.08	-0.4	1.21e-14	Mean platelet volume;
LUSC	cis	rs9646944	0.501	rs10169676	chr2:103074919	G/A	cg20060108	chr2:102954350	IL1RL1	0.45	6.18	0.32	1.91e-9	Blood protein levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04879387	chr16:16043101	ABCC1	-0.43	-5.99	-0.31	5.35e-9	Hepatitis;
LUSC	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.23	0.49	1.52e-21	Birth weight;
LUSC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg11871910	chr12:69753446	YEATS4	0.61	9.45	0.46	6.18e-19	Response to diuretic therapy;
LUSC	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg17168535	chr8:21777572	XPO7	0.8	14.21	0.61	3.58e-36	Mean corpuscular volume;
LUSC	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg25237894	chr2:233734115	C2orf82	-0.34	-6.04	-0.31	4.22e-9	Coronary artery disease;
LUSC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg08200582	chr11:442649	ANO9	-0.5	-5.7	-0.3	2.7e-8	Body mass index;
LUSC	cis	rs3760982	1.000	rs10405457	chr19:44296582	G/T	cg11993925	chr19:44307056	LYPD5	0.29	6.37	0.33	6.41e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg24675056	chr1:15929824	NA	0.46	8.02	0.4	1.83e-14	Systolic blood pressure;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13965062	chr9:87284706	NTRK2	-0.57	-6.84	-0.35	3.74e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs68170813	0.617	rs12535761	chr7:107139275	A/C	cg02696742	chr7:106810147	HBP1	-0.64	-8.62	-0.43	2.66e-16	Coronary artery disease;
LUSC	cis	rs34421088	0.532	rs2736258	chr8:11170449	C/T	cg21775007	chr8:11205619	TDH	0.52	7.32	0.37	1.87e-12	Neuroticism;
LUSC	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg03342759	chr3:160939853	NMD3	-0.45	-6.4	-0.33	5.33e-10	Parkinson's disease;
LUSC	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg03929089	chr4:120376271	NA	0.69	7.78	0.39	9.14e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06634786	chr22:41940651	POLR3H	0.53	6.05	0.31	3.94e-9	Vitiligo;
LUSC	cis	rs4713675	0.584	rs9394163	chr6:33682414	A/G	cg14003231	chr6:33640908	ITPR3	0.3	5.92	0.31	8.11e-9	Plateletcrit;
LUSC	cis	rs7712401	0.601	rs446782	chr5:122341868	C/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.25	-0.45	2.68e-18	Mean platelet volume;
LUSC	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg12062639	chr20:23401060	NAPB	0.78	6.04	0.31	4.01e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-0.89	-13.28	-0.59	1.29e-32	Asthma;
LUSC	cis	rs12620999	0.941	rs4663240	chr2:238036632	G/T	cg23555395	chr2:238036564	NA	-0.53	-8.94	-0.44	2.77e-17	Systemic lupus erythematosus;
LUSC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.19	-0.49	2.05e-21	Hemoglobin concentration;
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.19	-0.45	4.44e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	0.67	10.44	0.5	2.97e-22	Height;
LUSC	trans	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg18187862	chr3:45730750	SACM1L	0.55	7.04	0.36	1.11e-11	Primary sclerosing cholangitis;
LUSC	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg17470723	chr8:74884337	TCEB1	0.52	8.19	0.41	5.71e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs62238980	0.614	rs77034034	chr22:32466661	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs1957429	0.901	rs1951490	chr14:65346957	G/T	cg23373153	chr14:65346875	NA	1.09	12.86	0.58	4.86e-31	Pediatric areal bone mineral density (radius);
LUSC	trans	rs2055729	0.677	rs10098618	chr8:9741478	A/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.38	0.33	6e-10	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg16724585	chr3:197361211	NA	-0.59	-8.25	-0.41	3.78e-15	Pancreatic cancer;
LUSC	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg13256891	chr4:100009986	ADH5	0.48	7.11	0.36	7.05e-12	Alcohol dependence;
LUSC	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg03929089	chr4:120376271	NA	0.57	7.32	0.37	1.91e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg08219700	chr8:58056026	NA	0.5	6.4	0.33	5.22e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs56283067	0.887	rs62437973	chr6:44761978	G/A	cg20913747	chr6:44695427	NA	-0.48	-7.48	-0.38	6.8e-13	Total body bone mineral density;
LUSC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.5	-0.38	5.71e-13	Retinal vascular caliber;
LUSC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg05043794	chr9:111880884	C9orf5	-0.35	-7.25	-0.37	2.91e-12	Menarche (age at onset);
LUSC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg16405210	chr4:1374714	KIAA1530	-0.56	-8.5	-0.42	6.57e-16	Obesity-related traits;
LUSC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg17747265	chr1:1875780	NA	-0.73	-16.93	-0.68	7.11e-47	Body mass index;
LUSC	cis	rs16949788	0.826	rs28723485	chr15:66624166	G/T	cg08120210	chr15:66682733	MAP2K1	-0.58	-5.87	-0.31	1.06e-8	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.88	-0.55	2.17e-27	Mean corpuscular volume;
LUSC	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-7.56	-0.38	3.93e-13	Atrioventricular conduction;
LUSC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07677032	chr17:61819896	STRADA	0.51	8.36	0.42	1.75e-15	Prudent dietary pattern;
LUSC	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-1.13	-17.64	-0.69	1.06e-49	Exhaled nitric oxide output;
LUSC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-7.45	-0.38	8.32e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg22437258	chr11:111473054	SIK2	-0.48	-6.24	-0.32	1.33e-9	Primary sclerosing cholangitis;
LUSC	cis	rs2688608	0.967	rs72814394	chr10:75656325	C/T	cg17411546	chr10:75410026	SYNPO2L	-0.47	-6.91	-0.35	2.4e-11	Inflammatory bowel disease;
LUSC	cis	rs9650657	0.812	rs6601522	chr8:10629061	G/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.34	-0.33	7.37e-10	Neuroticism;
LUSC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg19257562	chr1:2043853	PRKCZ	0.33	6.65	0.34	1.2e-10	Height;
LUSC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg27532560	chr4:187881888	NA	-0.39	-6.41	-0.33	5.1e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	1.04	20.66	0.75	1.15e-61	Menopause (age at onset);
LUSC	trans	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.97	0.48	1.18e-20	Mean corpuscular volume;
LUSC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg20476274	chr7:133979776	SLC35B4	0.84	15.13	0.64	9.69e-40	Mean platelet volume;
LUSC	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg17691542	chr6:26056736	HIST1H1C	0.45	6.87	0.35	3.11e-11	Height;
LUSC	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	8.08	0.4	1.22e-14	Lung cancer;
LUSC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg16928487	chr17:17741425	SREBF1	-0.45	-8.98	-0.44	1.95e-17	Total body bone mineral density;
LUSC	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.82	0.35	4.38e-11	Height;
LUSC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.78	-0.43	8.48e-17	Bipolar disorder;
LUSC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15506890	chr2:3487001	NA	-0.58	-9.66	-0.47	1.27e-19	Neurofibrillary tangles;
LUSC	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg16591659	chr17:78472290	NA	-0.46	-7.46	-0.38	7.41e-13	Fractional excretion of uric acid;
LUSC	cis	rs1568889	0.838	rs10835276	chr11:28167147	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.56	0.57	6.54e-30	Bipolar disorder;
LUSC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22968622	chr17:43663579	NA	0.8	12.27	0.56	7.9e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg06740227	chr12:86229804	RASSF9	0.38	6.11	0.32	2.83e-9	Major depressive disorder;
LUSC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.16	0.55	2.1e-28	Menopause (age at onset);
LUSC	trans	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg03886242	chr7:26192032	NFE2L3	0.37	6.18	0.32	1.83e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2271400	0.603	rs182832	chr8:56790861	G/T	cg08894788	chr8:56792171	LYN	0.45	6.0	0.31	5e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
LUSC	cis	rs2398893	0.855	rs11791859	chr9:96788758	G/A	cg14459158	chr9:96720562	NA	0.3	5.88	0.31	9.85e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg20887711	chr4:1340912	KIAA1530	0.46	7.16	0.36	5.1e-12	Obesity-related traits;
LUSC	cis	rs2219968	0.887	rs67368685	chr8:78966267	A/G	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.22	-0.32	1.48e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg26408565	chr15:76604113	ETFA	-0.5	-8.0	-0.4	2.04e-14	Blood metabolite levels;
LUSC	cis	rs7264396	0.836	rs2010565	chr20:34182517	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-7.56	-0.38	3.84e-13	Total cholesterol levels;
LUSC	cis	rs6901250	0.569	rs621486	chr6:117089143	T/C	cg12892004	chr6:117198278	RFX6	0.36	6.56	0.34	2.02e-10	C-reactive protein levels;
LUSC	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg03342759	chr3:160939853	NMD3	-0.43	-6.26	-0.32	1.17e-9	Parkinson's disease;
LUSC	cis	rs1322512	1.000	rs2800632	chr6:153008632	C/A	cg03415253	chr6:152958462	SYNE1	0.38	5.66	0.3	3.19e-8	Tonometry;
LUSC	cis	rs4654899	0.802	rs12401413	chr1:21236503	T/C	cg01072550	chr1:21505969	NA	-0.47	-6.81	-0.35	4.51e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg05896524	chr21:47604654	C21orf56	0.42	6.22	0.32	1.49e-9	Testicular germ cell tumor;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19648955	chr2:177134095	MTX2	-0.42	-6.3	-0.33	9.64e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg17366294	chr4:99064904	C4orf37	0.56	10.16	0.49	2.62e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg00484396	chr16:3507460	NAT15	0.48	7.15	0.36	5.34e-12	Body mass index (adult);
LUSC	cis	rs7605827	0.930	rs11694458	chr2:15530469	C/G	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg23752985	chr2:85803571	VAMP8	0.33	6.45	0.33	3.97e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2414856	0.510	rs72758907	chr15:64638559	G/A	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs13315871	0.932	rs35741271	chr3:58323091	A/G	cg12435725	chr3:58293450	RPP14	-0.72	-7.15	-0.36	5.35e-12	Cholesterol, total;
LUSC	cis	rs11039100	0.541	rs11038949	chr11:5780198	A/T	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.91	13.27	0.59	1.38e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg15445000	chr17:37608096	MED1	-0.39	-6.71	-0.34	8.49e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs13427251	0.692	rs10206082	chr2:100160024	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-6.75	-0.35	6.61e-11	Chronic sinus infection;
LUSC	cis	rs2220004	0.507	rs11231560	chr11:55689699	C/G	cg22937354	chr11:55606216	OR5D16	-0.37	-5.75	-0.3	2.07e-8	Odorant perception (&beta-damascenone);
LUSC	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg13628971	chr7:2884303	GNA12	0.39	6.09	0.32	3.05e-9	Height;
LUSC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.66	0.57	2.79e-30	Prudent dietary pattern;
LUSC	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg20701182	chr2:24300061	SF3B14	0.56	6.03	0.31	4.32e-9	Lymphocyte counts;
LUSC	cis	rs1982963	0.627	rs2073626	chr14:52488385	A/G	cg10843707	chr14:52510701	NID2	0.46	6.36	0.33	6.66e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	0.64	13.37	0.59	5.97e-33	Prudent dietary pattern;
LUSC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg14541582	chr5:601475	NA	-0.38	-5.93	-0.31	7.36e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs925550	0.627	rs1398559	chr4:123593320	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.48	-5.71	-0.3	2.53e-8	Primary biliary cholangitis;
LUSC	cis	rs9462027	0.561	rs2262245	chr6:34567694	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.9	-0.31	8.96e-9	Systemic lupus erythematosus;
LUSC	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.2	-0.37	4.06e-12	Schizophrenia;
LUSC	cis	rs7589342	0.507	rs6543338	chr2:106403911	C/G	cg09152813	chr2:106391379	NCK2	-0.37	-5.8	-0.3	1.58e-8	Addiction;
LUSC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.38	-0.37	1.29e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg18655438	chr5:1077845	SLC12A7	-0.35	-5.74	-0.3	2.15e-8	QT interval;
LUSC	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg17294928	chr15:75287854	SCAMP5	-0.75	-8.76	-0.43	9.88e-17	Blood trace element (Zn levels);
LUSC	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-10.82	-0.51	1.33e-23	Response to antipsychotic treatment;
LUSC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg09365446	chr1:150670422	GOLPH3L	0.46	6.67	0.34	1.07e-10	Melanoma;
LUSC	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.46	-6.2	-0.32	1.67e-9	Corneal astigmatism;
LUSC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg01448562	chr3:133502909	NA	-0.66	-10.66	-0.5	5.08e-23	Iron status biomarkers;
LUSC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06481639	chr22:41940642	POLR3H	-0.51	-6.17	-0.32	1.98e-9	Vitiligo;
LUSC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg00310523	chr12:86230176	RASSF9	-0.43	-7.93	-0.4	3.28e-14	Major depressive disorder;
LUSC	cis	rs9650657	0.665	rs7002117	chr8:10616169	A/G	cg27411982	chr8:10470053	RP1L1	0.4	6.28	0.32	1.07e-9	Neuroticism;
LUSC	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06481639	chr22:41940642	POLR3H	0.5	5.72	0.3	2.42e-8	Vitiligo;
LUSC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg03354898	chr7:1950403	MAD1L1	-0.44	-9.18	-0.45	4.67e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs2798269	0.867	rs11840168	chr13:22118302	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.23	-0.32	1.44e-9	PR segment;
LUSC	cis	rs78663649	0.708	rs79268770	chr19:16601411	A/T	cg10248733	chr19:16607483	C19orf44;CALR3	-0.88	-6.34	-0.33	7.41e-10	White blood cell count;
LUSC	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg07382826	chr16:28625726	SULT1A1	0.28	6.0	0.31	5.21e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg12432903	chr7:1882776	MAD1L1	0.51	6.24	0.32	1.34e-9	Bipolar disorder;
LUSC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg27494647	chr7:150038898	RARRES2	-0.48	-7.32	-0.37	1.82e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	8.34	0.42	1.92e-15	Lung cancer in ever smokers;
LUSC	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.19	16.51	0.67	3.48e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4343996	0.521	rs10278205	chr7:3424878	C/T	cg21248987	chr7:3385318	SDK1	0.37	6.3	0.33	9.65e-10	Motion sickness;
LUSC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15369054	chr17:80825471	TBCD	0.7	11.38	0.53	1.36e-25	Breast cancer;
LUSC	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.51	-6.63	-0.34	1.39e-10	Response to bleomycin (chromatid breaks);
LUSC	trans	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs11997175	0.624	rs7001604	chr8:33680979	T/C	ch.8.33884649F	chr8:33765107	NA	0.48	7.11	0.36	6.95e-12	Body mass index;
LUSC	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.92	14.18	0.61	4.64e-36	Testicular germ cell tumor;
LUSC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.84	0.39	6.15e-14	Prudent dietary pattern;
LUSC	cis	rs1113500	0.933	rs10881500	chr1:108638895	C/T	cg06207961	chr1:108661230	NA	0.41	7.64	0.39	2.27e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.79	-12.37	-0.56	3.46e-29	Pancreatic cancer;
LUSC	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.61	0.34	1.55e-10	Intraocular pressure;
LUSC	cis	rs2282300	0.956	rs1717779	chr11:30376698	A/T	cg25418670	chr11:30344373	C11orf46	-0.53	-7.47	-0.38	6.97e-13	Morning vs. evening chronotype;
LUSC	cis	rs2262909	0.962	rs73021832	chr19:22316144	G/C	cg11619707	chr19:22235551	ZNF257	0.41	6.13	0.32	2.48e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg22823121	chr1:150693482	HORMAD1	0.52	7.68	0.39	1.83e-13	Melanoma;
LUSC	cis	rs2425143	1.000	rs12479473	chr20:34398628	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.93	-0.31	7.7e-9	Blood protein levels;
LUSC	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs9463078	0.683	rs227850	chr6:44699068	C/T	cg25276700	chr6:44698697	NA	0.29	5.82	0.3	1.38e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs12367572	0.930	rs10880695	chr12:45233261	T/C	cg04608330	chr12:45269318	NELL2	-0.54	-8.49	-0.42	6.68e-16	Gut microbiome composition (summer);
LUSC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.63	-0.5	6.39e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.72	-0.3	2.42e-8	Coronary artery disease or large artery stroke;
LUSC	cis	rs73200209	0.744	rs7959347	chr12:116479781	A/G	cg01776926	chr12:116560359	MED13L	-0.5	-5.97	-0.31	6.1e-9	Total body bone mineral density;
LUSC	cis	rs7112043	0.838	rs11032839	chr11:34777725	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.41	5.96	0.31	6.46e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs16976116	0.901	rs1061870	chr15:55496769	G/T	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06544989	chr22:39130855	UNC84B	0.37	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg03522245	chr20:25566470	NINL	-0.36	-5.81	-0.3	1.43e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7189233	0.531	rs17801498	chr16:53513452	C/G	cg09728985	chr16:53543985	NA	-0.33	-6.31	-0.33	8.79e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg09835421	chr16:68378352	PRMT7	-0.7	-7.06	-0.36	9.98e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg15556689	chr8:8085844	FLJ10661	-0.63	-10.2	-0.49	1.93e-21	Joint mobility (Beighton score);
LUSC	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg18478394	chr8:109455254	TTC35	0.42	6.53	0.34	2.38e-10	Dupuytren's disease;
LUSC	cis	rs3849570	0.565	rs1851926	chr3:81977231	A/C	cg07356753	chr3:81810745	GBE1	-0.49	-7.25	-0.37	2.95e-12	Waist circumference;Body mass index;
LUSC	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	1.02	22.37	0.77	2.28e-68	Schizophrenia;
LUSC	cis	rs2742417	0.603	rs2253979	chr3:45773320	A/G	cg04837898	chr3:45731254	SACM1L	-0.45	-7.25	-0.37	2.97e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg04691961	chr3:161091175	C3orf57	-0.35	-5.97	-0.31	5.9e-9	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07677032	chr17:61819896	STRADA	0.55	9.09	0.45	9.21e-18	Prudent dietary pattern;
LUSC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg13047869	chr3:10149882	C3orf24	0.61	8.27	0.41	3.18e-15	Alzheimer's disease;
LUSC	cis	rs2692947	0.770	rs72492163	chr2:96417816	G/A	cg23100626	chr2:96804247	ASTL	0.29	6.89	0.35	2.78e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10740039	0.810	rs9415605	chr10:62376567	T/C	cg18175470	chr10:62150864	ANK3	0.46	6.57	0.34	1.98e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4629710	0.617	rs28360555	chr6:131538952	C/A	cg12606694	chr6:131520996	AKAP7	0.61	9.29	0.45	2.09e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	8.87	0.44	4.57e-17	Menopause (age at onset);
LUSC	cis	rs12900413	0.687	rs12913409	chr15:90319251	T/A	cg24249390	chr15:90295951	MESP1	-0.37	-5.85	-0.31	1.15e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs9463078	0.528	rs13211229	chr6:44912462	G/A	cg25276700	chr6:44698697	NA	0.29	5.9	0.31	8.99e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg15839431	chr19:19639596	YJEFN3	0.6	6.43	0.33	4.29e-10	Bipolar disorder;
LUSC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	1.13	12.77	0.57	1.1e-30	Diabetic kidney disease;
LUSC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg13707768	chr11:65081977	CDC42EP2	-0.55	-5.96	-0.31	6.49e-9	Schizophrenia;
LUSC	cis	rs12618769	0.597	rs11902825	chr2:99129137	T/C	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Smoking initiation;
LUSC	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg15571903	chr15:79123663	NA	0.32	5.9	0.31	9.02e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22455342	chr2:225449267	CUL3	0.46	6.13	0.32	2.41e-9	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg02415014	chr8:143852576	LYNX1	0.32	7.47	0.38	6.92e-13	Urinary tract infection frequency;
LUSC	cis	rs11828289	0.599	rs75341566	chr11:23186941	C/A	cg20040320	chr11:23191996	NA	-0.58	-6.1	-0.32	2.95e-9	Cancer;
LUSC	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg11584989	chr19:19387371	SF4	0.57	6.92	0.35	2.31e-11	Bipolar disorder;
LUSC	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.79	0.51	1.7e-23	Coffee consumption (cups per day);
LUSC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.84	10.52	0.5	1.54e-22	Gut microbiome composition (summer);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17660682	chr3:167452753	PDCD10;SERPINI1	-0.42	-6.02	-0.31	4.48e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11779988	0.545	rs208763	chr8:17806482	G/A	cg01800426	chr8:17659068	MTUS1	-0.47	-5.91	-0.31	8.27e-9	Breast cancer;
LUSC	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.22	-0.41	4.63e-15	Body mass index;
LUSC	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.92	17.88	0.7	1.26e-50	Ulcerative colitis;
LUSC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06544989	chr22:39130855	UNC84B	0.33	5.79	0.3	1.65e-8	Menopause (age at onset);
LUSC	cis	rs7681423	1.000	rs12644950	chr4:155537321	G/A	cg20735720	chr4:155535218	FGG	-0.47	-6.88	-0.35	2.92e-11	Fibrinogen;
LUSC	trans	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg27661571	chr11:113659931	NA	-0.64	-6.02	-0.31	4.61e-9	Height;
LUSC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.55e-8	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg08975724	chr8:8085496	FLJ10661	0.44	6.32	0.33	8.39e-10	Triglycerides;
LUSC	cis	rs4888262	0.545	rs4888270	chr16:74698576	A/G	cg01733217	chr16:74700730	RFWD3	0.78	13.23	0.59	2.08e-32	Testicular germ cell tumor;
LUSC	cis	rs6982240	0.514	rs11785274	chr8:142261541	G/A	cg00131261	chr8:142287264	NA	-0.37	-6.12	-0.32	2.59e-9	Tonsillectomy;
LUSC	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07636037	chr3:49044803	WDR6	0.7	9.5	0.46	4.11e-19	Menarche (age at onset);
LUSC	cis	rs2952156	0.916	rs903506	chr17:37879762	G/A	cg00129232	chr17:37814104	STARD3	-0.47	-6.84	-0.35	3.76e-11	Asthma;
LUSC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg05973401	chr12:123451056	ABCB9	0.65	9.49	0.46	4.49e-19	Platelet count;
LUSC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4704187	0.687	rs1600074	chr5:74436574	C/T	cg03227963	chr5:74354835	NA	0.3	6.48	0.33	3.2e-10	Response to amphetamines;
LUSC	cis	rs909341	0.678	rs6011018	chr20:62303622	T/G	cg09650180	chr20:62225654	GMEB2	0.45	5.9	0.31	8.83e-9	Atopic dermatitis;
LUSC	cis	rs73206853	0.764	rs73191817	chr12:110918673	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7267979	0.586	rs6050439	chr20:25192331	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	12.8	0.57	8.58e-31	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11158026	0.574	rs7152033	chr14:55392754	C/T	cg04306507	chr14:55594613	LGALS3	0.35	6.11	0.32	2.73e-9	Parkinson's disease;
LUSC	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg00564555	chr16:1970112	NA	0.37	6.12	0.32	2.64e-9	Insulin-like growth factors;
LUSC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg22532475	chr10:104410764	TRIM8	-0.32	-6.91	-0.35	2.48e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	11.84	0.54	3.05e-27	Colorectal cancer;
LUSC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg21724239	chr8:58056113	NA	0.61	7.07	0.36	8.99e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.96	0.36	1.76e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg05887092	chr17:76393375	PGS1	0.51	9.08	0.44	9.91e-18	HDL cholesterol levels;
LUSC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	1.04	19.49	0.73	4.77e-57	Menopause (age at onset);
LUSC	cis	rs7614311	0.681	rs73117042	chr3:63896543	T/C	cg22134162	chr3:63841271	THOC7	-0.5	-6.19	-0.32	1.79e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.44	0.53	8.39e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-8.1	-0.41	1.07e-14	Renal function-related traits (BUN);
LUSC	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-8.39	-0.42	1.43e-15	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg24675658	chr1:53192096	ZYG11B	-0.68	-11.0	-0.52	3.14e-24	Monocyte count;
LUSC	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg08917208	chr2:24149416	ATAD2B	0.95	10.6	0.5	8.16e-23	Lymphocyte counts;
LUSC	cis	rs3772130	0.564	rs9817555	chr3:121406327	G/A	cg20356878	chr3:121714668	ILDR1	0.55	8.9	0.44	3.7e-17	Cognitive performance;
LUSC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg13560548	chr3:10150139	C3orf24	0.46	6.6	0.34	1.61e-10	Alzheimer's disease;
LUSC	trans	rs2562456	0.520	rs582992	chr19:21449546	G/T	cg00806126	chr19:22604979	ZNF98	0.42	5.95	0.31	6.59e-9	Pain;
LUSC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg21770322	chr7:97807741	LMTK2	0.41	7.25	0.37	2.92e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.7	10.76	0.51	2.14e-23	Lymphocyte counts;
LUSC	cis	rs1950626	0.577	rs35097045	chr14:101454403	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.4	7.48	0.38	6.57e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.0	-0.36	1.37e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg21918786	chr6:109611834	NA	0.36	6.05	0.31	3.86e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg27165867	chr14:105738592	BRF1	-0.5	-7.3	-0.37	2.16e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	cis	rs62432291	0.681	rs2501177	chr6:159655593	C/T	cg14500486	chr6:159655392	FNDC1	-0.52	-5.84	-0.3	1.22e-8	Joint mobility (Beighton score);
LUSC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.72	-0.35	7.84e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg20684491	chr1:25596433	NA	0.37	5.79	0.3	1.61e-8	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs2692947	0.759	rs1917890	chr2:96672001	C/T	cg23100626	chr2:96804247	ASTL	0.26	6.46	0.33	3.66e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg06784218	chr1:46089804	CCDC17	0.56	11.2	0.52	6.35e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs10090774	0.965	rs11167016	chr8:141995180	A/G	cg16477744	chr7:157367142	PTPRN2;MIR153-2	0.28	5.98	0.31	5.63e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.51	7.31	0.37	1.94e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-6.07	-0.32	3.53e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg06784218	chr1:46089804	CCDC17	-0.54	-11.17	-0.52	8.04e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg05347473	chr6:146136440	FBXO30	0.49	8.23	0.41	4.25e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg04850211	chr1:228464232	OBSCN	-0.37	-6.2	-0.32	1.62e-9	Diastolic blood pressure;
LUSC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg00800038	chr16:89945340	TCF25	-0.75	-6.58	-0.34	1.83e-10	Skin colour saturation;
LUSC	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg02023728	chr11:77925099	USP35	0.51	7.06	0.36	9.76e-12	Testicular germ cell tumor;
LUSC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-12.17	-0.55	1.89e-28	Platelet count;
LUSC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	1.33	14.25	0.61	2.44e-36	Diabetic kidney disease;
LUSC	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.82	-0.39	6.86e-14	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1106634	0.748	rs79915075	chr8:20065641	A/G	cg17327115	chr8:20112950	LZTS1	0.56	5.65	0.3	3.38e-8	Bipolar disorder and schizophrenia;Major depressive disorder (broad);
LUSC	cis	rs4363385	0.747	rs6668215	chr1:152964498	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.65	-0.39	2.16e-13	Inflammatory skin disease;
LUSC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-1.22	-13.35	-0.59	7.04e-33	Diabetic kidney disease;
LUSC	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg24634471	chr8:143751801	JRK	0.51	7.25	0.37	2.97e-12	Schizophrenia;
LUSC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.14	-0.45	6.04e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.93	0.35	2.23e-11	Morning vs. evening chronotype;
LUSC	trans	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg25482853	chr8:67687455	SGK3	1.11	15.38	0.64	9.94e-41	Obesity-related traits;
LUSC	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg15556689	chr8:8085844	FLJ10661	0.52	7.78	0.39	9.42e-14	Neuroticism;
LUSC	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg00191853	chr8:101177733	SPAG1	0.34	5.78	0.3	1.74e-8	Atrioventricular conduction;
LUSC	cis	rs17621444	0.522	rs4237513	chr10:121810241	C/T	cg02041677	chr10:121771263	NA	-0.33	-6.35	-0.33	7.16e-10	IgG glycosylation;
LUSC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg08888203	chr3:10149979	C3orf24	0.63	8.8	0.43	7.4e-17	Alzheimer's disease;
LUSC	cis	rs7582720	1.000	rs72926802	chr2:203830228	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs11997175	0.625	rs4733172	chr8:33618049	T/C	ch.8.33884649F	chr8:33765107	NA	0.44	7.09	0.36	7.9e-12	Body mass index;
LUSC	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg03060546	chr3:49711283	APEH	0.68	7.67	0.39	1.84e-13	Menarche (age at onset);
LUSC	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg08755490	chr11:65554678	OVOL1	0.4	5.82	0.3	1.4e-8	Acne (severe);
LUSC	trans	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.59	-0.54	2.45e-26	Colorectal cancer;
LUSC	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	6.49	0.33	3.09e-10	Height;
LUSC	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.73	-0.47	7.36e-20	Hemoglobin concentration;
LUSC	cis	rs34779708	0.801	rs34592588	chr10:35540134	A/G	cg03585969	chr10:35415529	CREM	0.55	7.67	0.39	1.92e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs79911532	0.515	rs76760929	chr7:75625968	T/G	cg03592824	chr7:75666768	STYXL1	0.7	6.98	0.36	1.56e-11	Mononucleosis;
LUSC	cis	rs9865818	0.702	rs4686484	chr3:188118572	G/A	cg23651889	chr3:188115336	LPP	-0.39	-5.97	-0.31	6.18e-9	Allergic sensitization;
LUSC	cis	rs735860	0.726	rs209517	chr6:53206989	A/T	cg10236188	chr6:53219634	NA	0.39	5.91	0.31	8.47e-9	Glaucoma;
LUSC	cis	rs7072216	0.666	rs11598689	chr10:100156027	G/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-6.29	-0.33	1.02e-9	Metabolite levels;
LUSC	cis	rs12980942	0.872	rs12327659	chr19:41796472	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.58	6.43	0.33	4.53e-10	Coronary artery disease;
LUSC	trans	rs61931739	0.635	rs7979207	chr12:33910566	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.69	-0.39	1.66e-13	Morning vs. evening chronotype;
LUSC	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg01966878	chr4:90757139	SNCA	-0.36	-6.22	-0.32	1.48e-9	Dementia with Lewy bodies;
LUSC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	15.67	0.65	7.38e-42	Platelet count;
LUSC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.08	-0.36	8.51e-12	Electroencephalogram traits;
LUSC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg12963246	chr6:28129442	ZNF389	0.51	7.37	0.37	1.33e-12	Parkinson's disease;
LUSC	trans	rs61931739	0.613	rs4931773	chr12:33749131	G/A	cg26384229	chr12:38710491	ALG10B	0.43	6.28	0.32	1.03e-9	Morning vs. evening chronotype;
LUSC	cis	rs870825	0.929	rs72689260	chr4:185590656	G/T	cg04058563	chr4:185651563	MLF1IP	0.83	11.29	0.53	2.87e-25	Blood protein levels;
LUSC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg05347473	chr6:146136440	FBXO30	0.63	10.93	0.51	5.5e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.7	-0.47	9.21e-20	Coronary artery disease;
LUSC	trans	rs72674100	1.000	rs72882341	chr4:97993768	G/C	cg09670535	chr1:18959427	PAX7	-0.61	-6.23	-0.32	1.41e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg04998671	chr14:104000505	TRMT61A	-0.42	-6.11	-0.32	2.81e-9	Reticulocyte count;
LUSC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg18758796	chr5:131593413	PDLIM4	-0.4	-6.28	-0.33	1.04e-9	Breast cancer;
LUSC	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.04	-0.36	1.08e-11	Response to antipsychotic treatment;
LUSC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg20887711	chr4:1340912	KIAA1530	0.43	6.71	0.34	8.33e-11	Obesity-related traits;
LUSC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.61	10.19	0.49	2.08e-21	Blood metabolite levels;
LUSC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-9.71	-0.47	8.72e-20	Gut microbiome composition (summer);
LUSC	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg04998671	chr14:104000505	TRMT61A	-0.48	-6.71	-0.34	8.58e-11	Reticulocyte count;
LUSC	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg13010199	chr12:38710504	ALG10B	0.58	9.23	0.45	3.24e-18	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs149866169	1	rs149866169	chr6:27441723	T/A	cg08798685	chr6:27730294	NA	-0.64	-5.76	-0.3	1.92e-8	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs3772130	0.603	rs35489993	chr3:121411876	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	11.71	0.54	9.04e-27	Cognitive performance;
LUSC	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg03605463	chr16:89740564	NA	0.53	8.49	0.42	7.05e-16	Hemoglobin concentration;
LUSC	cis	rs2835872	0.737	rs1787404	chr21:39049362	C/T	cg20424643	chr21:39039972	KCNJ6	0.41	6.6	0.34	1.62e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg00647820	chr17:40259828	DHX58	0.47	6.54	0.34	2.27e-10	Fibrinogen levels;
LUSC	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg05234568	chr11:5960015	NA	-0.59	-8.46	-0.42	8.25e-16	DNA methylation (variation);
LUSC	cis	rs11971779	0.616	rs11771715	chr7:139027496	T/C	cg23387468	chr7:139079360	LUC7L2	0.4	6.01	0.31	4.77e-9	Diisocyanate-induced asthma;
LUSC	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg17385448	chr1:15911702	AGMAT	0.35	5.93	0.31	7.36e-9	Systolic blood pressure;
LUSC	trans	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg06606381	chr12:133084897	FBRSL1	-0.72	-7.47	-0.38	7.22e-13	Breast cancer;
LUSC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg11062466	chr8:58055876	NA	0.71	8.53	0.42	5.07e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg01620082	chr3:125678407	NA	-0.75	-6.29	-0.33	9.67e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs117352156	0.943	rs12411424	chr10:29214344	G/T	cg06394621	chr10:29236369	NA	-0.47	-6.34	-0.33	7.38e-10	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7072216	0.843	rs4400721	chr10:100147097	C/T	cg19567339	chr10:100142640	NA	0.36	5.67	0.3	3.07e-8	Metabolite levels;
LUSC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg00639195	chr15:79103007	ADAMTS7	0.46	6.87	0.35	3.19e-11	Diastolic blood pressure;
LUSC	cis	rs10779751	0.708	rs2746640	chr1:11292952	T/A	cg08854313	chr1:11322531	MTOR	0.87	14.02	0.61	1.91e-35	Body mass index;
LUSC	cis	rs1595825	0.636	rs111540926	chr2:198885578	G/A	cg00982548	chr2:198649783	BOLL	-0.54	-6.93	-0.35	2.2e-11	Ulcerative colitis;
LUSC	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg22705602	chr4:152727874	NA	-0.39	-8.43	-0.42	1.06e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.7	0.34	8.76e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg12560992	chr17:57184187	TRIM37	0.83	15.26	0.64	2.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg13206674	chr6:150067644	NUP43	0.45	6.28	0.33	1.03e-9	Testicular germ cell tumor;
LUSC	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05901451	chr6:126070800	HEY2	-0.59	-8.89	-0.44	3.97e-17	Endometrial cancer;
LUSC	cis	rs2445762	0.518	rs8043240	chr15:51635565	C/T	cg00184732	chr15:51633821	GLDN	0.3	5.9	0.31	8.99e-9	Hormone measurements;
LUSC	cis	rs61935443	0.720	rs10859780	chr12:95282601	T/C	cg21533806	chr12:95267307	NA	0.51	6.39	0.33	5.53e-10	Schizophrenia;
LUSC	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg25801113	chr15:45476975	SHF	0.36	7.32	0.37	1.82e-12	Uric acid levels;
LUSC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.67	-12.09	-0.55	3.73e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg12639453	chr1:2035780	PRKCZ	-0.3	-6.41	-0.33	5.06e-10	Height;
LUSC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg24209194	chr3:40518798	ZNF619	0.47	6.52	0.34	2.53e-10	Renal cell carcinoma;
LUSC	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg02269571	chr22:50332266	NA	0.59	7.55	0.38	4.13e-13	Schizophrenia;
LUSC	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg25427524	chr10:38739819	LOC399744	0.45	5.83	0.3	1.34e-8	Obesity (extreme);
LUSC	cis	rs6669072	0.647	rs814547	chr1:91238821	T/C	cg08895590	chr1:91227319	NA	-0.38	-8.6	-0.43	3.23e-16	Cognitive function;
LUSC	cis	rs11039100	0.850	rs11039168	chr11:5844723	C/A	cg05234568	chr11:5960015	NA	-0.52	-5.85	-0.31	1.14e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7818345	0.874	rs56298301	chr8:19305937	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.32	6.08	0.32	3.34e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	13.61	0.6	7.25e-34	Platelet count;
LUSC	cis	rs12618769	0.947	rs3769695	chr2:99259020	G/T	cg10123293	chr2:99228465	UNC50	0.43	5.99	0.31	5.36e-9	Bipolar disorder;
LUSC	cis	rs6426558	0.537	rs12139758	chr1:227260519	A/G	cg10327440	chr1:227177885	CDC42BPA	0.53	7.23	0.37	3.32e-12	Neutrophil percentage of white cells;
LUSC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg15595755	chr5:1867978	NA	0.46	8.49	0.42	6.64e-16	Cardiovascular disease risk factors;
LUSC	cis	rs73198271	0.562	rs11774860	chr8:8651879	C/T	cg01851573	chr8:8652454	MFHAS1	0.59	7.83	0.39	6.33e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs17253792	0.822	rs8006705	chr14:56171283	C/T	cg01858014	chr14:56050164	KTN1	-0.7	-6.2	-0.32	1.66e-9	Putamen volume;
LUSC	cis	rs367615	0.512	rs414724	chr5:108670421	A/G	cg17395555	chr5:108820864	NA	0.55	9.69	0.47	1e-19	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs12136530	0.774	rs11590840	chr1:19779673	A/G	cg01832549	chr1:19774989	CAPZB	-0.3	-5.73	-0.3	2.3e-8	Lead levels in blood;
LUSC	cis	rs12541635	0.966	rs7839239	chr8:107020406	C/T	cg10147462	chr8:107024639	NA	0.55	9.93	0.48	1.54e-20	Age of smoking initiation;
LUSC	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05962382	chr2:130345044	NA	-0.36	-6.34	-0.33	7.63e-10	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs28830936	0.934	rs2412641	chr15:42124399	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.72	-0.3	2.37e-8	Diastolic blood pressure;
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.54	8.71	0.43	1.45e-16	Longevity;Endometriosis;
LUSC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.45	-5.72	-0.3	2.38e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-15.09	-0.64	1.3e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9807841	0.545	rs4804514	chr19:10764203	G/T	cg17710535	chr19:10819994	QTRT1	0.41	6.78	0.35	5.45e-11	Inflammatory skin disease;
LUSC	cis	rs3771570	1.000	rs62193175	chr2:242284405	G/A	cg21155796	chr2:242212141	HDLBP	0.63	6.86	0.35	3.32e-11	Prostate cancer;
LUSC	cis	rs6494488	0.500	rs72742918	chr15:64852576	T/C	cg08069370	chr15:64387884	SNX1	-0.64	-5.74	-0.3	2.17e-8	Coronary artery disease;
LUSC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27297192	chr10:134578999	INPP5A	0.36	6.48	0.33	3.29e-10	Migraine;
LUSC	trans	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg10756647	chr7:56101905	PSPH	0.88	8.96	0.44	2.32e-17	Gout;
LUSC	cis	rs9341808	0.667	rs2505929	chr6:80834208	A/G	cg08355045	chr6:80787529	NA	0.47	8.24	0.41	3.89e-15	Sitting height ratio;
LUSC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14298792	chr15:30685198	CHRFAM7A	0.66	8.43	0.42	1.02e-15	Huntington's disease progression;
LUSC	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.67	11.4	0.53	1.15e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21659725	chr3:3221576	CRBN	-0.57	-7.91	-0.4	3.74e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg06521331	chr12:34319734	NA	-0.42	-6.56	-0.34	2.05e-10	Morning vs. evening chronotype;
LUSC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg12365402	chr11:9010492	NRIP3	-0.52	-10.14	-0.49	3.05e-21	Hemoglobin concentration;
LUSC	cis	rs1062746	0.502	rs11649601	chr16:87339220	G/C	cg02258303	chr16:87377426	FBXO31	-0.54	-8.4	-0.42	1.31e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs72700829	0.593	rs7526955	chr1:150990913	C/G	cg11822372	chr1:151115635	SEMA6C	-0.7	-6.7	-0.34	8.96e-11	Schizophrenia;
LUSC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.45	6.88	0.35	2.97e-11	Longevity;Endometriosis;
LUSC	trans	rs61931739	0.635	rs10772122	chr12:33964674	A/C	cg26384229	chr12:38710491	ALG10B	0.5	7.59	0.38	3.21e-13	Morning vs. evening chronotype;
LUSC	cis	rs9463078	0.753	rs3778507	chr6:44896803	G/A	cg25276700	chr6:44698697	NA	-0.3	-6.12	-0.32	2.66e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs931812	0.757	rs13251801	chr8:101902629	A/T	cg20993868	chr7:22813445	NA	0.52	9.7	0.47	9.55e-20	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09391979	chr2:86333508	PTCD3;POLR1A	0.8	6.57	0.34	1.99e-10	Cognitive performance;
LUSC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.47	-0.38	6.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6725041	0.547	rs1505353	chr2:213203057	C/A	cg16329650	chr2:213403929	ERBB4	-0.42	-6.67	-0.34	1.09e-10	QT interval (ambient particulate matter interaction);
LUSC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg24578937	chr1:2090814	PRKCZ	0.46	10.27	0.49	1.08e-21	Height;
LUSC	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg07828340	chr4:882639	GAK	0.91	9.31	0.45	1.74e-18	Parkinson's disease;
LUSC	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg08017756	chr2:100939284	LONRF2	-0.45	-8.44	-0.42	9.64e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg14019146	chr3:50243930	SLC38A3	0.31	6.84	0.35	3.72e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs5758511	0.773	rs62241023	chr22:42385429	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.15	0.36	5.36e-12	Birth weight;
LUSC	trans	rs62055045	0.528	rs62053065	chr16:71557806	G/A	cg21834679	chr15:96891026	NA	-0.4	-6.14	-0.32	2.31e-9	Schizophrenia;
LUSC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg05082376	chr22:42548792	NA	-0.45	-7.22	-0.37	3.54e-12	Schizophrenia;
LUSC	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.74	0.35	6.99e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14240646	chr10:27532245	ACBD5	-0.65	-7.75	-0.39	1.15e-13	Breast cancer;
LUSC	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg11568697	chr18:72916393	ZADH2	0.57	6.58	0.34	1.79e-10	Vascular endothelial growth factor levels;
LUSC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg13206674	chr6:150067644	NUP43	0.59	9.24	0.45	2.87e-18	Lung cancer;
LUSC	cis	rs9837602	1.000	rs13069311	chr3:99801628	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.91	-0.31	8.58e-9	Breast cancer;
LUSC	cis	rs17604090	0.878	rs4457221	chr7:29701774	C/T	cg19413766	chr7:29689036	LOC646762	-0.64	-7.7	-0.39	1.5700000000000001e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	10.24	0.49	1.4e-21	Lymphocyte counts;
LUSC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg12564285	chr5:131593104	PDLIM4	0.46	8.13	0.41	8.7e-15	Acylcarnitine levels;
LUSC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg22800045	chr5:56110881	MAP3K1	-0.75	-9.52	-0.46	3.59e-19	Initial pursuit acceleration;
LUSC	cis	rs11158026	0.757	rs7153937	chr14:55470875	A/G	cg04306507	chr14:55594613	LGALS3	0.37	7.31	0.37	1.99e-12	Parkinson's disease;
LUSC	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg02269571	chr22:50332266	NA	-0.55	-8.22	-0.41	4.59e-15	Schizophrenia;
LUSC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg08219700	chr8:58056026	NA	0.43	5.68	0.3	2.99e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.66	0.3	3.26e-8	Menopause (age at onset);
LUSC	cis	rs7827545	1.000	rs6992097	chr8:135565844	G/A	cg17885191	chr8:135476712	NA	0.56	8.35	0.42	1.87e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.9	0.48	2e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs977987	0.806	rs34021527	chr16:75474090	A/G	cg03315344	chr16:75512273	CHST6	0.49	9.38	0.46	1.03e-18	Dupuytren's disease;
LUSC	cis	rs4243830	1.000	rs12027598	chr1:6600804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.96	9.12	0.45	7.44e-18	Body mass index;
LUSC	cis	rs6120849	0.754	rs6088686	chr20:33623437	C/T	cg24642439	chr20:33292090	TP53INP2	0.62	6.78	0.35	5.4e-11	Protein C levels;
LUSC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg20135002	chr11:47629003	NA	0.48	7.54	0.38	4.4e-13	Subjective well-being;
LUSC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	12.48	0.56	1.3e-29	Platelet count;
LUSC	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg01819863	chr10:32635814	EPC1	0.91	10.71	0.51	3.27e-23	Sexual dysfunction (female);
LUSC	cis	rs886126	0.853	rs4766558	chr12:111664061	T/G	cg10833066	chr12:111807467	FAM109A	0.41	6.46	0.33	3.65e-10	Coronary heart disease;
LUSC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg03289416	chr15:75166202	SCAMP2	0.45	6.87	0.35	3.19e-11	Breast cancer;
LUSC	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg23625390	chr15:77176239	SCAPER	-0.62	-9.3	-0.45	1.95e-18	Blood metabolite levels;
LUSC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg23283495	chr1:209979779	IRF6	0.64	9.28	0.45	2.13e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs2835872	0.759	rs2835898	chr21:39071781	T/C	cg20424643	chr21:39039972	KCNJ6	0.4	6.05	0.31	3.88e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11764359	chr7:65958608	NA	-0.54	-7.11	-0.36	7.23e-12	Aortic root size;
LUSC	cis	rs6967385	0.560	rs7790370	chr7:12353523	G/C	cg10578991	chr7:12443926	VWDE	0.39	5.84	0.3	1.25e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg23711669	chr6:146136114	FBXO30	0.74	12.95	0.58	2.36e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7712401	0.580	rs4288111	chr5:122388182	A/G	cg19077854	chr5:122220652	SNX24	-0.3	-6.41	-0.33	5.03e-10	Mean platelet volume;
LUSC	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg25344623	chr2:136566232	LCT	-0.38	-5.65	-0.3	3.49e-8	Mosquito bite size;
LUSC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02018176	chr4:1364513	KIAA1530	0.72	13.9	0.61	5.85e-35	Longevity;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03828939	chr16:2525452	TBC1D24	-0.48	-6.65	-0.34	1.21e-10	Hepatitis;
LUSC	cis	rs708547	0.647	rs1626594	chr4:57878254	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	7.64	0.39	2.31e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.7	0.34	8.99e-11	Rheumatoid arthritis;
LUSC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18876405	chr7:65276391	NA	0.54	8.24	0.41	3.93e-15	Aortic root size;
LUSC	trans	rs12709013	0.636	rs4538000	chr16:58778410	A/C	cg19313373	chr1:162694184	DDR2	-0.35	-5.95	-0.31	6.74e-9	Blood metabolite ratios;
LUSC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg01879757	chr17:41196368	BRCA1	-0.44	-6.79	-0.35	5.15e-11	Menopause (age at onset);
LUSC	cis	rs6469656	1.000	rs35905748	chr8:117755248	A/G	cg24004040	chr8:117650383	NA	-0.43	-6.16	-0.32	2.15e-9	Colorectal cancer;
LUSC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg18402987	chr7:1209562	NA	0.51	5.66	0.3	3.31e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	20.09	0.74	2.07e-59	Prudent dietary pattern;
LUSC	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg26898376	chr11:64110657	CCDC88B	0.33	6.21	0.32	1.6e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01570182	chr17:44337453	NA	0.69	10.43	0.5	3.15e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg02807482	chr3:125708958	NA	-0.53	-6.62	-0.34	1.42e-10	Blood pressure (smoking interaction);
LUSC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-8.41	-0.42	1.24e-15	Schizophrenia;
LUSC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg15147215	chr3:52552868	STAB1	-0.29	-5.76	-0.3	1.93e-8	Electroencephalogram traits;
LUSC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.61	-0.38	2.74e-13	Joint mobility (Beighton score);
LUSC	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg06917634	chr15:78832804	PSMA4	-0.43	-5.84	-0.3	1.24e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.07	0.4	1.29e-14	Breast cancer;
LUSC	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.53	-8.59	-0.43	3.48e-16	Height;
LUSC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg13683864	chr3:40499215	RPL14	-1.14	-21.07	-0.76	2.71e-63	Renal cell carcinoma;
LUSC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19717773	chr7:2847554	GNA12	-0.37	-5.88	-0.31	9.82e-9	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15807973	chr10:88281572	WAPAL	-0.44	-6.71	-0.34	8.17e-11	Electrocardiographic conduction measures;
LUSC	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.76	-0.43	1.02e-16	Metabolite levels;
LUSC	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.54	-0.34	2.27e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg26043149	chr18:55253948	FECH	0.47	7.26	0.37	2.67e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs28595532	0.582	rs71608361	chr4:119224081	T/C	cg21605333	chr4:119757512	SEC24D	0.77	6.47	0.33	3.59e-10	Cannabis dependence symptom count;
LUSC	cis	rs7923609	0.905	rs7092784	chr10:65214749	C/T	cg01631684	chr10:65280961	REEP3	-0.41	-6.24	-0.32	1.31e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg01119278	chr6:110721349	DDO	-0.45	-7.96	-0.4	2.62e-14	Platelet distribution width;
LUSC	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs6750047	0.719	rs336035	chr2:38261467	A/G	cg07380506	chr2:38303506	CYP1B1	-0.44	-5.92	-0.31	8.15e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs6464929	0.956	rs3779039	chr7:148710576	C/T	cg23583168	chr7:148888333	NA	0.47	6.0	0.31	5.26e-9	Pediatric bone mineral content (hip);
LUSC	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg00540400	chr15:79124168	NA	-0.48	-8.43	-0.42	1.04e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9807989	0.507	rs1420097	chr2:103009354	C/G	cg03938978	chr2:103052716	IL18RAP	-0.33	-6.07	-0.32	3.42e-9	Asthma;
LUSC	cis	rs9796	0.717	rs2947494	chr15:41375741	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.27	-0.41	3.13e-15	Menopause (age at onset);
LUSC	cis	rs75229567	0.618	rs11177848	chr12:70180892	A/G	cg10114359	chr12:70132523	RAB3IP	1.43	12.91	0.58	3.43e-31	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg04398451	chr17:18023971	MYO15A	0.57	9.53	0.46	3.41e-19	Total body bone mineral density;
LUSC	cis	rs4654899	0.931	rs1152998	chr1:21124290	C/T	cg01072550	chr1:21505969	NA	-0.52	-7.88	-0.4	4.59e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg12292205	chr6:26970375	C6orf41	-0.5	-8.19	-0.41	5.49e-15	Schizophrenia;
LUSC	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.08e-17	Prudent dietary pattern;
LUSC	cis	rs1358748	0.522	rs4655671	chr1:67550763	C/T	cg02640540	chr1:67518911	SLC35D1	0.62	6.4	0.33	5.25e-10	Tuberculosis;
LUSC	cis	rs35079168	0.701	rs3132296	chr9:137302631	C/T	cg24164254	chr9:137329341	RXRA	-0.37	-5.97	-0.31	5.98e-9	Intelligence;
LUSC	cis	rs3916	0.911	rs34673751	chr12:121171891	G/A	cg27246729	chr12:121163418	ACADS	0.46	6.7	0.34	8.84e-11	Urinary metabolites (H-NMR features);
LUSC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg03790207	chr6:42947109	PEX6	0.4	5.81	0.3	1.42e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.53	-10.53	-0.5	1.4e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs10511400	0.618	rs2874023	chr3:119919544	T/C	cg02809009	chr19:50354510	PTOV1	-0.7	-6.22	-0.32	1.44e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg13263323	chr15:86062960	AKAP13	-0.35	-5.75	-0.3	2.02e-8	Coronary artery disease;
LUSC	cis	rs7177699	0.526	rs7166764	chr15:79123509	T/G	cg15571903	chr15:79123663	NA	0.34	6.31	0.33	8.74e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg03983476	chr2:10830698	NOL10	-0.37	-5.67	-0.3	3.05e-8	Prostate cancer;
LUSC	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg04586622	chr2:25135609	ADCY3	0.38	8.2	0.41	5.21e-15	Body mass index;
LUSC	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-0.76	-10.21	-0.49	1.76e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg06606381	chr12:133084897	FBRSL1	-1.0	-8.84	-0.44	5.76e-17	Lung cancer in ever smokers;
LUSC	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg02403541	chr12:121454288	C12orf43	0.7	10.2	0.49	1.88e-21	N-glycan levels;
LUSC	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg03161606	chr19:29218774	NA	0.51	5.96	0.31	6.3e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-8.73	-0.43	1.21e-16	Longevity;Endometriosis;
LUSC	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg13615516	chr5:77269221	NA	0.4	6.56	0.34	2.02e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg09835421	chr16:68378352	PRMT7	-0.55	-6.22	-0.32	1.45e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg20887711	chr4:1340912	KIAA1530	0.44	6.53	0.34	2.48e-10	Obesity-related traits;
LUSC	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.0	-0.36	1.39e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg09699651	chr6:150184138	LRP11	0.45	7.15	0.36	5.64e-12	Testicular germ cell tumor;
LUSC	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg00191853	chr8:101177733	SPAG1	-0.35	-5.71	-0.3	2.43e-8	Atrioventricular conduction;
LUSC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg01879757	chr17:41196368	BRCA1	-0.45	-6.83	-0.35	3.97e-11	Menopause (age at onset);
LUSC	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.58	-9.76	-0.47	5.93e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	2.04e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.6	-0.34	1.62e-10	Life satisfaction;
LUSC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.57	-8.38	-0.42	1.51e-15	Obesity-related traits;
LUSC	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg17640201	chr16:30407289	ZNF48	-0.89	-15.01	-0.63	2.88e-39	Tonsillectomy;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg05157912	chr14:75894395	JDP2	-0.49	-6.75	-0.35	6.38e-11	Cognitive function;Information processing speed;
LUSC	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg02403541	chr12:121454288	C12orf43	0.56	8.66	0.43	2.06e-16	Subjective well-being;Cardiovascular disease risk factors;
LUSC	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg09307838	chr4:120376055	NA	0.77	10.65	0.5	5.38e-23	Corneal astigmatism;
LUSC	cis	rs9323205	0.634	rs61985124	chr14:51712633	T/C	cg23942311	chr14:51606299	NA	-0.38	-6.88	-0.35	2.9e-11	Cancer;
LUSC	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	0.95	20.04	0.74	3.35e-59	Ulcerative colitis;
LUSC	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg02153584	chr22:29168773	CCDC117	0.52	7.48	0.38	6.55e-13	Lymphocyte counts;
LUSC	cis	rs5770917	1.000	rs2269385	chr22:51010939	G/A	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.61	-5.7	-0.3	2.69e-8	Narcolepsy;
LUSC	cis	rs1775715	0.870	rs1615256	chr10:32254101	T/C	cg18675610	chr10:32216311	ARHGAP12	0.29	6.06	0.31	3.63e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg09165964	chr15:75287851	SCAMP5	-0.87	-7.72	-0.39	1.36e-13	Lung cancer;
LUSC	cis	rs12286929	0.831	rs2507909	chr11:115010867	C/T	cg04055981	chr11:115044050	NA	0.36	6.02	0.31	4.52e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg19747945	chr6:42946146	PEX6	-0.34	-5.68	-0.3	2.94e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18357526	chr6:26021779	HIST1H4A	0.42	6.8	0.35	4.97e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg03676636	chr4:99064102	C4orf37	0.3	5.97	0.31	6.04e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17095355	1.000	rs17126931	chr10:111754633	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.66	-7.58	-0.38	3.36e-13	Biliary atresia;
LUSC	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.52	-6.81	-0.35	4.6e-11	Response to bleomycin (chromatid breaks);
LUSC	cis	rs4363385	0.574	rs4041402	chr1:152947397	T/C	cg25856811	chr1:152973957	SPRR3	-0.35	-5.76	-0.3	1.91e-8	Inflammatory skin disease;
LUSC	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg12573674	chr2:1569213	NA	-0.55	-6.16	-0.32	2.15e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs4589502	1.000	rs79390908	chr15:67130924	C/T	cg12317470	chr15:67143691	NA	0.67	6.01	0.31	4.76e-9	Lung cancer (smoking interaction);
LUSC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg05347473	chr6:146136440	FBXO30	0.56	9.49	0.46	4.63e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-14.97	-0.63	3.94e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28655083	0.529	rs4550465	chr16:77104785	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	7.11	0.36	7.24e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg21775007	chr8:11205619	TDH	-0.57	-8.39	-0.42	1.39e-15	Neuroticism;
LUSC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg14664628	chr15:75095509	CSK	-0.49	-7.01	-0.36	1.32e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs11030122	0.702	rs67300156	chr11:3953949	C/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.82	-0.3	1.34e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2282300	0.667	rs10734405	chr11:30273750	T/C	cg25418670	chr11:30344373	C11orf46	0.64	9.19	0.45	4.18e-18	Morning vs. evening chronotype;
LUSC	cis	rs2742234	0.915	rs2742233	chr10:43610558	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.37	-6.52	-0.34	2.6e-10	Hirschsprung disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24334803	chr1:249132834	ZNF672	0.42	6.03	0.31	4.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg23933602	chr10:16859644	RSU1	0.59	6.92	0.35	2.31e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg10547527	chr2:198650123	BOLL	-0.52	-6.15	-0.32	2.27e-9	Ulcerative colitis;
LUSC	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg00857998	chr1:205179979	DSTYK	-0.61	-9.57	-0.46	2.46e-19	Red blood cell count;
LUSC	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	1.08	16.37	0.67	1.22e-44	Primary sclerosing cholangitis;
LUSC	cis	rs354225	1.000	rs354225	chr2:54923766	G/A	cg26097391	chr2:54893211	SPTBN1	0.38	6.37	0.33	6.21e-10	Schizophrenia;
LUSC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg06494592	chr3:125709126	NA	-0.5	-5.77	-0.3	1.86e-8	Blood pressure (smoking interaction);
LUSC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg19046167	chr17:80928561	B3GNTL1	-0.43	-6.18	-0.32	1.86e-9	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22180410	chr4:187646446	FAT1	0.37	5.98	0.31	5.81e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7091068	0.550	rs7901909	chr10:95492508	C/T	cg20715218	chr10:95462985	C10orf4	0.64	8.72	0.43	1.33e-16	Urinary tract infection frequency;
LUSC	cis	rs13088645	0.532	rs12695612	chr3:134161824	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	5.89	0.31	9.29e-9	Coronary artery disease;
LUSC	cis	rs9473147	0.543	rs9381578	chr6:47556634	C/T	cg12968598	chr6:47444699	CD2AP	0.52	7.93	0.4	3.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg24375607	chr4:120327624	NA	0.77	11.32	0.53	2.32e-25	Corneal astigmatism;
LUSC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg23625390	chr15:77176239	SCAPER	0.46	7.0	0.36	1.44e-11	Blood metabolite levels;
LUSC	cis	rs11676348	0.774	rs57545959	chr2:219047718	A/G	cg00012203	chr2:219082015	ARPC2	0.58	9.47	0.46	5.32e-19	Ulcerative colitis;
LUSC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg06742321	chr12:123595122	PITPNM2	0.4	6.13	0.32	2.42e-9	Platelet count;
LUSC	cis	rs6087990	0.735	rs4911260	chr20:31376490	T/C	cg13636640	chr20:31349939	DNMT3B	0.9	18.21	0.71	5.77e-52	Ulcerative colitis;
LUSC	cis	rs11031096	0.503	rs67065286	chr11:4105273	A/C	cg18678763	chr11:4115507	RRM1	-0.5	-6.61	-0.34	1.5e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18932078	chr1:2524107	MMEL1	0.32	7.04	0.36	1.13e-11	Ulcerative colitis;
LUSC	cis	rs6736093	0.933	rs6754526	chr2:112729669	A/G	cg12686935	chr2:112915763	FBLN7	-0.37	-5.96	-0.31	6.32e-9	Coronary artery disease;
LUSC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.73	10.24	0.49	1.39e-21	Corneal astigmatism;
LUSC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.29	-5.81	-0.3	1.43e-8	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs11935423	0.778	rs1503778	chr4:100490688	G/A	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.07	-0.32	3.51e-9	Gut microbiome composition (summer);
LUSC	cis	rs16976116	0.901	rs28708989	chr15:55498934	C/T	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7581030	0.517	rs17743415	chr2:71562503	T/C	cg06465196	chr4:154387603	KIAA0922	0.42	5.95	0.31	6.95e-9	Testicular germ cell tumor;
LUSC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.44	-0.33	4.21e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10186029	0.648	rs13022006	chr2:213940309	A/C	cg08319019	chr2:214017104	IKZF2	0.6	8.9	0.44	3.71e-17	Systemic sclerosis;
LUSC	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg09654669	chr8:57350985	NA	-0.56	-7.78	-0.39	9.24e-14	Obesity-related traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18373552	chr10:76871314	SAMD8	-0.42	-6.32	-0.33	8.45e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	0.93	17.83	0.7	1.93e-50	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg26384229	chr12:38710491	ALG10B	0.57	8.85	0.44	5.35e-17	Morning vs. evening chronotype;
LUSC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg04450456	chr4:17643702	FAM184B	0.39	6.6	0.34	1.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.79	0.7	2.73e-50	Chronic sinus infection;
LUSC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg25258033	chr6:167368657	RNASET2	0.42	6.37	0.33	6.31e-10	Crohn's disease;
LUSC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg06784218	chr1:46089804	CCDC17	0.55	11.13	0.52	1.06e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg03233332	chr7:66118400	NA	-0.42	-6.08	-0.32	3.3e-9	Aortic root size;
LUSC	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.67	-11.86	-0.54	2.63e-27	Electrocardiographic conduction measures;
LUSC	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg15432903	chr11:17409602	KCNJ11	0.62	11.27	0.52	3.5e-25	Type 2 diabetes;
LUSC	cis	rs3781663	0.526	rs7936612	chr11:70019182	A/G	cg24276624	chr11:69982941	ANO1	-0.39	-5.94	-0.31	7.19e-9	Survival in rectal cancer;
LUSC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg18681998	chr4:17616180	MED28	0.91	17.58	0.69	1.92e-49	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.22	0.32	1.45e-9	IgG glycosylation;
LUSC	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.48	8.42	0.42	1.1e-15	HDL cholesterol;
LUSC	trans	rs433755	1.000	rs433755	chr5:9474946	A/C	cg05169988	chr15:99204912	IGF1R	-0.26	-6.17	-0.32	1.94e-9	Obesity-related traits;
LUSC	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg12935359	chr14:103987150	CKB	0.65	10.68	0.5	4.05e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs10746514	0.833	rs11122428	chr1:232261417	A/G	cg09506761	chr1:232265262	NA	-0.56	-9.56	-0.46	2.57e-19	Response to statin therapy;
LUSC	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg14343924	chr8:8086146	FLJ10661	0.43	5.97	0.31	6.11e-9	Myopia (pathological);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg27288268	chr19:14063180	PODNL1;DCAF15	0.67	5.97	0.31	6.18e-9	Cognitive performance;
LUSC	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg05163923	chr11:71159392	DHCR7	0.78	11.53	0.53	4e-26	Vitamin D levels;
LUSC	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.46	-0.38	7.3e-13	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg16423285	chr20:60520624	NA	-0.46	-5.86	-0.31	1.12e-8	Body mass index;
LUSC	cis	rs11166629	1.000	rs7003870	chr8:135616586	A/G	cg21672855	chr8:135614777	ZFAT	0.39	6.03	0.31	4.31e-9	Smoking quantity;
LUSC	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs12080794	1.000	rs12239200	chr1:9155963	A/T	cg11315153	chr6:62996299	KHDRBS2	-0.52	-6.16	-0.32	2.13e-9	Response to antidepressant treatment (citalopram);
LUSC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg20891283	chr12:69753455	YEATS4	0.66	10.45	0.5	2.68e-22	Blood protein levels;
LUSC	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg00383909	chr3:49044727	WDR6	-0.85	-7.51	-0.38	5.39e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg02380750	chr20:61661411	NA	0.34	5.92	0.31	8.1e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8014204	0.816	rs10144023	chr14:75291531	T/C	cg06637938	chr14:75390232	RPS6KL1	0.51	8.16	0.41	7.1e-15	Caffeine consumption;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02386183	chr20:13619553	TASP1	0.39	6.36	0.33	6.81e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7759001	0.857	rs6912091	chr6:27354852	C/G	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	1.97e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs6967330	0.584	rs73195679	chr7:105677321	C/A	cg07911171	chr1:7340656	CAMTA1	0.43	6.3	0.33	9.25e-10	Asthma (childhood onset);
LUSC	cis	rs932287	0.666	rs10840161	chr11:9053824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.47	9.07	0.44	1.03e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	0.780	rs2500413	chr20:25241155	T/C	cg08601574	chr20:25228251	PYGB	0.48	7.42	0.38	9.92e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	8.46	0.42	8.77e-16	Lung cancer in ever smokers;
LUSC	trans	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.55	-8.54	-0.42	4.78e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18876405	chr7:65276391	NA	0.56	8.78	0.43	8.88e-17	Aortic root size;
LUSC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg20135002	chr11:47629003	NA	-0.49	-7.69	-0.39	1.65e-13	Subjective well-being;
LUSC	trans	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg03886242	chr7:26192032	NFE2L3	0.39	6.51	0.34	2.68e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.86	13.71	0.6	2.99e-34	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg24558204	chr6:135376177	HBS1L	0.6	9.2	0.45	4.04e-18	Red blood cell count;
LUSC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg25258033	chr6:167368657	RNASET2	0.45	7.65	0.39	2.1e-13	Crohn's disease;
LUSC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.63	-14.63	-0.63	8.25e-38	Prostate cancer;
LUSC	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg21972741	chr5:435613	AHRR	0.33	6.26	0.32	1.18e-9	Cystic fibrosis severity;
LUSC	cis	rs6977660	1.000	rs34367208	chr7:19818811	T/G	cg07541023	chr7:19748670	TWISTNB	0.51	5.82	0.3	1.37e-8	Thyroid stimulating hormone;
LUSC	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg13072238	chr3:49761600	GMPPB	-0.67	-8.32	-0.41	2.34e-15	Menarche (age at onset);
LUSC	cis	rs7527798	0.571	rs12045913	chr1:207844625	A/G	cg09232269	chr1:207846808	CR1L	-0.28	-6.0	-0.31	5.05e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs7804356	1.000	rs3801844	chr7:26829759	C/T	cg03456212	chr7:26904342	SKAP2	0.52	6.21	0.32	1.53e-9	Type 1 diabetes;
LUSC	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg21827317	chr3:136751795	NA	0.37	6.67	0.34	1.06e-10	Neuroticism;
LUSC	cis	rs385076	0.503	rs212702	chr2:32444250	A/G	cg02381751	chr2:32503542	YIPF4	0.54	6.88	0.35	3.01e-11	Interleukin-18 levels;
LUSC	cis	rs9462027	0.628	rs1125340	chr6:34786408	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.74	-0.3	2.13e-8	Systemic lupus erythematosus;
LUSC	cis	rs6489882	0.807	rs1859333	chr12:113370966	T/C	cg20102336	chr12:113376681	OAS3	-0.42	-6.17	-0.32	1.98e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs11051970	0.879	rs73081911	chr12:32539124	C/G	cg24626660	chr12:32551988	NA	0.38	6.11	0.32	2.79e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg02018176	chr4:1364513	KIAA1530	0.43	5.91	0.31	8.37e-9	Recombination rate (females);
LUSC	cis	rs983392	0.755	rs1441586	chr11:59856028	T/C	cg20284999	chr11:59952153	MS4A6A	-0.33	-5.68	-0.3	2.98e-8	Alzheimer's disease (late onset);
LUSC	cis	rs10887741	0.966	rs2077695	chr10:89435483	T/C	cg24243914	chr10:89418206	PAPSS2	0.32	5.86	0.31	1.09e-8	Exercise (leisure time);
LUSC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.54	0.5	1.27e-22	Colorectal cancer;
LUSC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg13607699	chr17:42295918	UBTF	0.48	7.45	0.38	8.04e-13	Total body bone mineral density;
LUSC	cis	rs10207060	0.500	rs4365487	chr2:240706803	T/C	cg20333904	chr2:240724165	NA	-0.35	-6.1	-0.32	2.94e-9	Obesity-related traits;
LUSC	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg05519781	chr21:40033154	ERG	0.7	11.63	0.54	1.83e-26	Coronary artery disease;
LUSC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg00012203	chr2:219082015	ARPC2	0.7	11.64	0.54	1.61e-26	Colorectal cancer;
LUSC	cis	rs2239815	0.515	rs9625595	chr22:29238913	C/T	cg02153584	chr22:29168773	CCDC117	0.55	6.41	0.33	4.84e-10	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg24375607	chr4:120327624	NA	0.77	12.11	0.55	3.24e-28	Corneal astigmatism;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02528468	chr3:182510901	ATP11B	0.39	5.96	0.31	6.29e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg04352962	chr1:209979756	IRF6	-0.4	-5.98	-0.31	5.69e-9	Monobrow;
LUSC	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs7192380	0.964	rs55780735	chr16:69740374	A/G	cg00738113	chr16:70207722	CLEC18C	0.27	5.92	0.31	8.13e-9	Sjögren's syndrome;
LUSC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.04	-0.31	4.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg05347473	chr6:146136440	FBXO30	0.39	6.49	0.33	3.16e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-0.93	-13.27	-0.59	1.43e-32	Vitiligo;
LUSC	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg13010199	chr12:38710504	ALG10B	0.55	7.56	0.38	3.86e-13	Resting heart rate;
LUSC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg27572855	chr1:25598939	RHD	0.44	7.84	0.39	6.26e-14	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg19318889	chr4:1322082	MAEA	0.43	5.65	0.3	3.37e-8	Recombination rate (females);
LUSC	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.04	-21.96	-0.77	8.49e-67	Ulcerative colitis;
LUSC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11764359	chr7:65958608	NA	-0.63	-9.66	-0.47	1.24e-19	Aortic root size;
LUSC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg04414720	chr1:150670196	GOLPH3L	0.57	9.11	0.45	8.02e-18	Tonsillectomy;
LUSC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg07701084	chr6:150067640	NUP43	0.54	8.02	0.4	1.82e-14	Lung cancer;
LUSC	cis	rs7584330	0.554	rs13395743	chr2:238437554	C/T	cg16989719	chr2:238392110	NA	-0.42	-5.81	-0.3	1.47e-8	Prostate cancer;
LUSC	cis	rs1823874	0.653	rs12902823	chr15:100352218	G/A	cg16400843	chr15:100339927	C15orf51	0.34	6.7	0.34	9.1e-11	IgG glycosylation;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04290376	chr6:26056765	HIST1H1C	0.44	5.95	0.31	6.82e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg17425144	chr1:10567563	PEX14	0.65	13.39	0.59	5.04e-33	Breast size;
LUSC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg06740227	chr12:86229804	RASSF9	0.45	7.15	0.36	5.35e-12	Major depressive disorder;
LUSC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-9.47	-0.46	5.25e-19	Gut microbiome composition (summer);
LUSC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg07212818	chr11:638076	DRD4	-0.46	-7.29	-0.37	2.19e-12	Systemic lupus erythematosus;
LUSC	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.82	-0.3	1.41e-8	Bipolar disorder;
LUSC	cis	rs7923609	0.967	rs10761729	chr10:64995604	G/C	cg01631684	chr10:65280961	REEP3	-0.4	-6.26	-0.32	1.19e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-6.33	-0.33	8.09e-10	Aortic root size;
LUSC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	0.63	13.42	0.59	3.75e-33	Prudent dietary pattern;
LUSC	cis	rs2479724	0.636	rs41273794	chr6:41755708	C/T	cg17623882	chr6:41773611	USP49	0.5	6.51	0.34	2.81e-10	Menarche (age at onset);
LUSC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.89	-18.69	-0.71	7.45e-54	Intelligence (multi-trait analysis);
LUSC	trans	rs984440	0.524	rs10111139	chr8:139084283	C/T	cg03334052	chr1:168888044	NA	-0.38	-6.25	-0.32	1.24e-9	Obesity-related traits;
LUSC	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg13390004	chr1:15929781	NA	0.42	7.0	0.36	1.44e-11	Systolic blood pressure;
LUSC	cis	rs354225	0.544	rs3287	chr2:54807657	T/C	cg26097391	chr2:54893211	SPTBN1	0.42	6.31	0.33	8.77e-10	Schizophrenia;
LUSC	cis	rs4356932	1.000	rs4859598	chr4:76959828	C/T	cg00809888	chr4:76862425	NAAA	0.34	5.75	0.3	1.98e-8	Blood protein levels;
LUSC	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg16447950	chr5:562315	NA	-0.55	-6.69	-0.34	9.28e-11	Obesity-related traits;
LUSC	cis	rs4595586	0.679	rs7131749	chr12:39405462	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.65	-0.34	1.19e-10	Morning vs. evening chronotype;
LUSC	trans	rs877282	0.583	rs10904564	chr10:819459	C/G	cg22713356	chr15:30763199	NA	0.74	9.71	0.47	8.71e-20	Uric acid levels;
LUSC	cis	rs3125734	0.719	rs4529854	chr10:64043975	C/T	cg09941381	chr10:64027924	RTKN2	-0.35	-6.28	-0.32	1.08e-9	Rheumatoid arthritis;
LUSC	cis	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg20368463	chr18:77673604	PQLC1	0.61	9.47	0.46	5.4e-19	Schizophrenia;
LUSC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg02117656	chr17:79614917	TSPAN10	0.3	5.67	0.3	3.16e-8	Eye color traits;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg25428929	chr2:242606353	ATG4B	-0.41	-6.23	-0.32	1.43e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg06885757	chr1:42089581	HIVEP3	0.49	10.05	0.48	6.05e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg01483505	chr11:975446	AP2A2	0.4	5.76	0.3	1.92e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.58	0.38	3.39e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg15557168	chr22:42548783	NA	0.47	7.33	0.37	1.76e-12	Schizophrenia;
LUSC	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg23505145	chr19:12996616	KLF1	0.64	10.29	0.49	9.57e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg07636037	chr3:49044803	WDR6	0.43	6.26	0.32	1.21e-9	Resting heart rate;
LUSC	cis	rs4356932	1.000	rs13130221	chr4:76955617	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg10560079	chr2:191398806	TMEM194B	0.74	9.08	0.45	9.44e-18	Diastolic blood pressure;
LUSC	cis	rs4851254	0.579	rs78633727	chr2:100669457	T/C	cg22139774	chr2:100720529	AFF3	-0.46	-6.19	-0.32	1.81e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg01579765	chr21:45077557	HSF2BP	-0.56	-12.22	-0.56	1.26e-28	Mean corpuscular volume;
LUSC	cis	rs10904908	0.703	rs359287	chr10:17327791	A/T	cg01003015	chr10:17271136	VIM	0.42	6.0	0.31	5.12e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs72781680	0.821	rs2176265	chr2:24158638	C/G	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg26513180	chr16:89883248	FANCA	-0.53	-7.94	-0.4	3.1e-14	Vitiligo;
LUSC	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.7	-0.39	1.58e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs757081	0.667	rs476890	chr11:17209962	A/G	cg15432903	chr11:17409602	KCNJ11	-0.38	-5.94	-0.31	7.29e-9	Systolic blood pressure;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.64	-10.83	-0.51	1.22e-23	Longevity;Endometriosis;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg19444155	chr15:49338748	SECISBP2L	-0.37	-6.03	-0.31	4.26e-9	Triglycerides;
LUSC	cis	rs73206853	0.841	rs7967246	chr12:110756569	G/A	cg12870014	chr12:110450643	ANKRD13A	0.67	6.47	0.33	3.57e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.3	0.33	9.54e-10	Menopause (age at onset);
LUSC	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg16989719	chr2:238392110	NA	-0.49	-6.2	-0.32	1.69e-9	Prostate cancer;
LUSC	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	1.14	19.91	0.74	1.01e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs701145	0.585	rs1713804	chr3:153799122	A/G	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.39	0.46	9.85e-19	Prudent dietary pattern;
LUSC	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.42	-0.42	1.16e-15	Neuroticism;
LUSC	cis	rs240764	0.658	rs7746947	chr6:101188708	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-6.32	-0.33	8.51e-10	Neuroticism;
LUSC	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg13798780	chr7:105162888	PUS7	0.57	6.06	0.31	3.65e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	9.01	0.44	1.57e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg00012203	chr2:219082015	ARPC2	0.84	15.65	0.65	8.27e-42	Colorectal cancer;
LUSC	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.67	-11.13	-0.52	1.12e-24	Caffeine consumption;
LUSC	cis	rs11608355	0.846	rs4766598	chr12:109853306	A/G	cg05360138	chr12:110035743	NA	0.59	7.91	0.4	3.9e-14	Neuroticism;
LUSC	cis	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg21775007	chr8:11205619	TDH	-0.5	-7.18	-0.37	4.55e-12	Morning vs. evening chronotype;
LUSC	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg04176472	chr15:90893244	GABARAPL3	-0.33	-5.67	-0.3	3.03e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg09307838	chr4:120376055	NA	-0.58	-8.71	-0.43	1.42e-16	Corneal astigmatism;
LUSC	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.54	-10.51	-0.5	1.6e-22	Educational attainment;
LUSC	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.26	-0.32	1.19e-9	Acne (severe);
LUSC	cis	rs2414856	0.510	rs72758928	chr15:64657684	C/A	cg08069370	chr15:64387884	SNX1	-0.78	-6.58	-0.34	1.84e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs12220238	1.000	rs10824130	chr10:76008931	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.94	0.35	2.08e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs13253111	0.603	rs17058753	chr8:28090914	T/C	cg26534493	chr8:28060551	NA	0.4	7.16	0.36	5.05e-12	Childhood body mass index;
LUSC	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg10483660	chr13:112241077	NA	-0.31	-5.68	-0.3	2.99e-8	Hepatitis;
LUSC	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg15133208	chr4:90757351	SNCA	-0.57	-8.5	-0.42	6.46e-16	Neuroticism;
LUSC	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg09998033	chr7:158218633	PTPRN2	0.41	6.4	0.33	5.31e-10	Obesity-related traits;
LUSC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg24675658	chr1:53192096	ZYG11B	-0.61	-10.15	-0.49	2.93e-21	Monocyte count;
LUSC	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-7.28	-0.37	2.34e-12	Response to bleomycin (chromatid breaks);
LUSC	cis	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg06521331	chr12:34319734	NA	-0.38	-6.15	-0.32	2.19e-9	Morning vs. evening chronotype;
LUSC	cis	rs1775715	0.870	rs1775735	chr10:32255846	A/G	cg18675610	chr10:32216311	ARHGAP12	0.29	6.06	0.31	3.63e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg21775007	chr8:11205619	TDH	0.46	6.07	0.32	3.43e-9	Neuroticism;
LUSC	cis	rs9865818	0.702	rs6444285	chr3:188117786	C/T	cg23651889	chr3:188115336	LPP	-0.38	-5.85	-0.31	1.15e-8	Allergic sensitization;
LUSC	cis	rs243505	0.898	rs243541	chr7:148403243	A/T	cg09806900	chr7:148480153	CUL1	-0.48	-6.79	-0.35	5.23e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg14552801	chr7:65878734	NA	-0.42	-5.82	-0.3	1.37e-8	Aortic root size;
LUSC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg20243544	chr17:37824526	PNMT	0.39	5.89	0.31	9.46e-9	Self-reported allergy;
LUSC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg06271696	chr7:157225062	NA	-0.45	-8.97	-0.44	2.21e-17	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg02023728	chr11:77925099	USP35	-0.46	-6.67	-0.34	1.06e-10	Testicular germ cell tumor;
LUSC	cis	rs2274273	0.624	rs7151754	chr14:55788501	C/T	cg04306507	chr14:55594613	LGALS3	0.48	9.69	0.47	1e-19	Protein biomarker;
LUSC	trans	rs9860340	0.730	rs4859086	chr3:87636057	T/C	cg03644585	chr7:884825	UNC84A	0.42	6.09	0.32	3.17e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg02403541	chr12:121454288	C12orf43	0.7	10.07	0.48	5.15e-21	N-glycan levels;
LUSC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19717773	chr7:2847554	GNA12	-0.39	-6.13	-0.32	2.46e-9	Height;
LUSC	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg10840412	chr1:235813424	GNG4	0.46	6.16	0.32	2.05e-9	Bipolar disorder;
LUSC	cis	rs62027291	0.950	rs56293302	chr15:77286946	T/C	cg26408565	chr15:76604113	ETFA	0.54	6.64	0.34	1.3100000000000001e-10	Plateletcrit;
LUSC	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg16624210	chr5:671434	TPPP	0.49	6.07	0.32	3.49e-9	Obesity-related traits;
LUSC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg19592336	chr6:28129416	ZNF389	0.45	6.0	0.31	5.12e-9	Depression;
LUSC	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg27284194	chr4:1044797	NA	0.6	9.03	0.44	1.43e-17	Recombination rate (females);
LUSC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.41	5.85	0.3	1.19e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7709377	0.620	rs10066081	chr5:115488569	A/G	cg23108291	chr5:115420582	COMMD10	0.41	5.79	0.3	1.59e-8	Metabolite levels  (X-11787);
LUSC	cis	rs2282300	0.739	rs35883696	chr11:30246407	A/C	cg25418670	chr11:30344373	C11orf46	-0.66	-9.53	-0.46	3.4e-19	Morning vs. evening chronotype;
LUSC	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg08213375	chr14:104286397	PPP1R13B	0.38	6.26	0.32	1.19e-9	Reticulocyte count;
LUSC	trans	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.56	-7.86	-0.4	5.31e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs34779708	0.733	rs7086715	chr10:35541840	A/G	cg03585969	chr10:35415529	CREM	0.56	7.81	0.39	7.55e-14	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg13607699	chr17:42295918	UBTF	0.49	7.63	0.39	2.43e-13	Total body bone mineral density;
LUSC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.62	12.77	0.57	1.08e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs55883249	1.000	rs17453724	chr2:9764001	A/G	cg23886495	chr2:9695866	ADAM17	0.48	5.76	0.3	1.91e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs17621444	0.522	rs4614355	chr10:121811346	G/A	cg02041677	chr10:121771263	NA	-0.33	-6.21	-0.32	1.6e-9	IgG glycosylation;
LUSC	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg24558204	chr6:135376177	HBS1L	0.66	10.03	0.48	7.21e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg03929089	chr4:120376271	NA	0.57	6.29	0.33	9.77e-10	Axial length;
LUSC	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg12927641	chr6:109611667	NA	-0.37	-6.26	-0.32	1.17e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg09654669	chr8:57350985	NA	-0.59	-7.86	-0.4	5.41e-14	Obesity-related traits;
LUSC	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.21	0.49	1.77e-21	Lymphocyte counts;
LUSC	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15369054	chr17:80825471	TBCD	-0.58	-9.74	-0.47	6.79e-20	Breast cancer;
LUSC	cis	rs7712401	0.546	rs30021	chr5:122285894	G/A	cg19077854	chr5:122220652	SNX24	0.44	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	trans	rs1325195	1.000	rs1325195	chr1:179071756	G/A	cg11624085	chr17:8464688	MYH10	-0.46	-7.52	-0.38	5e-13	IgE grass sensitization;
LUSC	cis	rs9359856	0.957	rs9342201	chr6:90310356	G/T	cg13799429	chr6:90582589	CASP8AP2	0.58	6.87	0.35	3.11e-11	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.65	0.39	2.21e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg21775007	chr8:11205619	TDH	-0.65	-10.3	-0.49	9.02e-22	Retinal vascular caliber;
LUSC	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg25206134	chr2:45395956	NA	-0.6	-7.03	-0.36	1.15e-11	Bipolar disorder;
LUSC	cis	rs2050392	1.000	rs2480280	chr10:30696092	A/G	cg18806716	chr10:30721971	MAP3K8	-0.48	-7.84	-0.39	5.91e-14	Inflammatory bowel disease;
LUSC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs6120849	0.754	rs6087666	chr20:33640242	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.58	0.34	1.8e-10	Protein C levels;
LUSC	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.68	11.07	0.52	1.8e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-9.29	-0.45	2.04e-18	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg05855489	chr10:104503620	C10orf26	0.6	8.74	0.43	1.13e-16	Arsenic metabolism;
LUSC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg03733263	chr8:22462867	KIAA1967	0.97	16.8	0.68	2.35e-46	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg13206674	chr6:150067644	NUP43	0.58	8.99	0.44	1.93e-17	Lung cancer;
LUSC	cis	rs3733631	1.000	rs11943988	chr4:104654699	A/G	cg24090629	chr4:104641072	TACR3	-0.48	-5.99	-0.31	5.54e-9	Menarche (age at onset);
LUSC	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg02423579	chr7:2872169	GNA12	-0.49	-6.96	-0.36	1.8e-11	Height;
LUSC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg00074818	chr8:8560427	CLDN23	0.6	9.86	0.47	2.72e-20	Obesity-related traits;
LUSC	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.63	10.7	0.51	3.73e-23	Blood metabolite ratios;
LUSC	trans	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg17712092	chr4:129076599	LARP1B	-0.73	-10.22	-0.49	1.68e-21	Breast cancer;
LUSC	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg12863693	chr15:85201151	NMB	-0.35	-7.24	-0.37	3.1e-12	Schizophrenia;
LUSC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg17330251	chr7:94953956	PON1	-0.37	-5.94	-0.31	7.09e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.56	8.71	0.43	1.42e-16	Menopause (age at onset);
LUSC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	6.28	0.32	1.08e-9	Tonsillectomy;
LUSC	cis	rs7760535	0.811	rs1002475	chr6:111709589	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.36	2e-11	Metabolic traits;
LUSC	trans	rs72674100	1.000	rs28523751	chr4:97964750	T/A	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-6.13	-0.32	2.44e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.6	-8.51	-0.42	5.97e-16	Diastolic blood pressure;
LUSC	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg21775007	chr8:11205619	TDH	0.71	11.38	0.53	1.44e-25	Retinal vascular caliber;
LUSC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg14789911	chr21:47582049	C21orf56	-0.39	-6.12	-0.32	2.58e-9	Testicular germ cell tumor;
LUSC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.19	-0.41	5.54e-15	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg13010199	chr12:38710504	ALG10B	0.46	6.51	0.34	2.82e-10	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg25767906	chr1:53392781	SCP2	-0.66	-13.03	-0.58	1.13e-31	Monocyte count;
LUSC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg12403142	chr1:92012408	NA	-0.38	-6.08	-0.32	3.26e-9	Breast cancer;
LUSC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg01973587	chr1:228161476	NA	0.47	8.47	0.42	8.1e-16	Diastolic blood pressure;
LUSC	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg08601574	chr20:25228251	PYGB	0.45	6.81	0.35	4.41e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg18512352	chr11:47633146	NA	0.47	9.45	0.46	5.94e-19	Subjective well-being;
LUSC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg03146154	chr1:46216737	IPP	0.52	7.83	0.39	6.52e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.31	0.49	8.3e-22	Bladder cancer;
LUSC	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg16342193	chr10:102329863	NA	-0.36	-6.6	-0.34	1.66e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg05347473	chr6:146136440	FBXO30	0.53	9.17	0.45	5.12e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg23649088	chr2:200775458	C2orf69	-0.54	-6.96	-0.36	1.85e-11	Schizophrenia;
LUSC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	0.87	14.03	0.61	1.77e-35	Breast cancer;
LUSC	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg16989719	chr2:238392110	NA	-0.45	-6.93	-0.35	2.13e-11	Prostate cancer;
LUSC	cis	rs968451	0.547	rs738331	chr22:39714216	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.82	14.64	0.63	7.6e-38	Primary biliary cholangitis;
LUSC	cis	rs988712	0.705	rs4923461	chr11:27656910	A/G	cg10635145	chr11:27742435	BDNF	-0.48	-6.28	-0.33	1.04e-9	Obesity;
LUSC	cis	rs1322512	1.000	rs1290296	chr6:153010088	A/C	cg27316956	chr6:152958899	SYNE1	0.35	6.06	0.31	3.59e-9	Tonometry;
LUSC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg19046167	chr17:80928561	B3GNTL1	-0.46	-6.6	-0.34	1.66e-10	Breast cancer;
LUSC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg06671706	chr8:8559999	CLDN23	-0.45	-6.16	-0.32	2.04e-9	Obesity-related traits;
LUSC	cis	rs3126085	0.935	rs4534386	chr1:152251714	A/G	cg26876637	chr1:152193138	HRNR	0.46	6.38	0.33	6.03e-10	Atopic dermatitis;
LUSC	trans	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg04995722	chr7:26192034	NFE2L3	-0.36	-5.97	-0.31	5.96e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs727505	1.000	rs1541418	chr7:124448672	A/G	cg23710748	chr7:124431027	NA	-0.42	-7.5	-0.38	5.88e-13	Lewy body disease;
LUSC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.16	-0.41	6.93e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg13010199	chr12:38710504	ALG10B	0.42	6.12	0.32	2.66e-9	Morning vs. evening chronotype;
LUSC	cis	rs11264213	0.681	rs72659656	chr1:36176131	G/A	cg27506609	chr1:36549197	TEKT2	0.54	6.0	0.31	5.06e-9	Schizophrenia;
LUSC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg21361702	chr7:150065534	REPIN1	0.57	8.04	0.4	1.59e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg05855489	chr10:104503620	C10orf26	-0.48	-7.41	-0.38	1.04e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg24558204	chr6:135376177	HBS1L	0.68	10.65	0.5	5.24e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg26043149	chr18:55253948	FECH	0.48	7.33	0.37	1.77e-12	Bone mineral density;
LUSC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg20573242	chr4:122745356	CCNA2	0.56	8.25	0.41	3.75e-15	Type 2 diabetes;
LUSC	cis	rs983392	0.678	rs1562990	chr11:60023087	C/A	cg20284999	chr11:59952153	MS4A6A	0.39	6.51	0.34	2.82e-10	Alzheimer's disease (late onset);
LUSC	trans	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.66	7.94	0.4	3.07e-14	Type 2 diabetes;
LUSC	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg07856975	chr6:36356162	ETV7	0.34	6.21	0.32	1.61e-9	Platelet distribution width;
LUSC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	15.05	0.64	1.93e-39	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg13390004	chr1:15929781	NA	0.4	6.64	0.34	1.3100000000000001e-10	Systolic blood pressure;
LUSC	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.19	0.64	5.56e-40	Bladder cancer;
LUSC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg03146154	chr1:46216737	IPP	-0.6	-8.74	-0.43	1.15e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg23625390	chr15:77176239	SCAPER	0.46	6.99	0.36	1.46e-11	Blood metabolite levels;
LUSC	cis	rs59698941	0.943	rs72799498	chr5:132291157	G/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.31	-0.33	8.88e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.23	-0.49	1.51e-21	Monocyte count;
LUSC	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg18850127	chr7:39170497	POU6F2	0.59	9.11	0.45	7.84e-18	IgG glycosylation;
LUSC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg17724175	chr1:150552817	MCL1	0.37	6.73	0.35	7.38e-11	Melanoma;
LUSC	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg07936489	chr17:37558343	FBXL20	0.71	9.69	0.47	1e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg03676636	chr4:99064102	C4orf37	0.31	5.98	0.31	5.88e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg03342759	chr3:160939853	NMD3	-0.43	-6.26	-0.32	1.2e-9	Morning vs. evening chronotype;
LUSC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	7.54	0.38	4.62e-13	Resistin levels;
LUSC	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg13647721	chr17:30228624	UTP6	0.53	5.73	0.3	2.25e-8	Hip circumference adjusted for BMI;
LUSC	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.46	0.33	3.67e-10	Corneal astigmatism;
LUSC	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg23093090	chr10:104574429	C10orf26	-0.37	-6.93	-0.35	2.15e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg06627628	chr2:24431161	ITSN2	0.62	8.87	0.44	4.39e-17	Asthma;
LUSC	cis	rs7759001	0.817	rs4562132	chr6:27343285	C/A	cg18711553	chr6:27366782	ZNF391	0.42	6.03	0.31	4.37e-9	Glomerular filtration rate (creatinine);
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg07316298	chr16:32823289	NA	0.44	6.07	0.32	3.49e-9	Calcium levels;
LUSC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-14.85	-0.63	1.22e-38	Total body bone mineral density;
LUSC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-7.43	-0.38	9.25e-13	Personality dimensions;
LUSC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg23711669	chr6:146136114	FBXO30	-0.82	-14.7	-0.63	4.6e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.45	7.15	0.36	5.46e-12	Alzheimer's disease (late onset);
LUSC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	cis	rs983392	0.792	rs493692	chr11:59909610	A/G	cg24026212	chr11:59952134	MS4A6A	-0.31	-5.71	-0.3	2.45e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.27	-0.37	2.59e-12	Bipolar disorder;
LUSC	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg13798780	chr7:105162888	PUS7	0.56	6.15	0.32	2.23e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs1595825	0.891	rs41468149	chr2:198910107	C/G	cg00982548	chr2:198649783	BOLL	0.55	6.85	0.35	3.46e-11	Ulcerative colitis;
LUSC	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg23093090	chr10:104574429	C10orf26	-0.41	-6.9	-0.35	2.57e-11	Arsenic metabolism;
LUSC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg07061783	chr6:25882402	NA	0.39	6.22	0.32	1.46e-9	Blood metabolite levels;
LUSC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.83	0.6	1.02e-34	Platelet count;
LUSC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg05347473	chr6:146136440	FBXO30	0.53	9.28	0.45	2.26e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg13939156	chr17:80058883	NA	0.34	6.56	0.34	2.01e-10	Life satisfaction;
LUSC	cis	rs2625529	0.617	rs2957365	chr15:72348106	C/T	cg16672083	chr15:72433130	SENP8	0.49	8.19	0.41	5.72e-15	Red blood cell count;
LUSC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg16423285	chr20:60520624	NA	-0.47	-5.94	-0.31	6.99e-9	Body mass index;
LUSC	cis	rs6120849	0.754	rs6088691	chr20:33633758	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.58	0.34	1.8e-10	Protein C levels;
LUSC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.86	0.6	8.34e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg22166914	chr1:53195759	ZYG11B	-0.62	-10.29	-0.49	9.65e-22	Monocyte count;
LUSC	cis	rs3820928	0.845	rs4234065	chr2:227882006	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.8	-0.39	7.97e-14	Pulmonary function;
LUSC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg21724239	chr8:58056113	NA	0.74	8.15	0.41	7.47e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7113850	0.541	rs76005477	chr11:24233322	G/A	ch.11.24196551F	chr11:24239977	NA	1.01	9.09	0.45	8.71e-18	Bone fracture in osteoporosis;
LUSC	cis	rs7188861	0.681	rs12928822	chr16:11403893	C/T	cg00044050	chr16:11439710	C16orf75	0.59	6.55	0.34	2.15e-10	HDL cholesterol;
LUSC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg05738196	chr6:26577821	NA	-0.48	-7.11	-0.36	6.88e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.33	-0.33	7.98e-10	Neutrophil percentage of white cells;
LUSC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.53	-8.14	-0.41	7.97e-15	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9653442	0.527	rs12712064	chr2:100756548	C/T	cg07810366	chr2:100720526	AFF3	-0.45	-7.64	-0.39	2.32e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg17385448	chr1:15911702	AGMAT	0.34	5.68	0.3	2.97e-8	Systolic blood pressure;
LUSC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.08	0.55	4.01e-28	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.14e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg13866156	chr1:1669148	SLC35E2	-0.5	-8.05	-0.4	1.47e-14	Body mass index;
LUSC	trans	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg03886242	chr7:26192032	NFE2L3	0.38	6.29	0.33	1.02e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6894268	0.722	rs6422331	chr5:179002951	G/T	cg26135573	chr5:179059668	NA	0.54	6.59	0.34	1.71e-10	Eating disorders;
LUSC	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg07148914	chr20:33460835	GGT7	-0.52	-8.11	-0.41	1e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs698813	0.604	rs768006	chr2:44487612	C/G	cg00619915	chr2:44497795	NA	-0.53	-7.55	-0.38	4.09e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg16325326	chr1:53192061	ZYG11B	-0.7	-11.5	-0.53	5.18e-26	Monocyte count;
LUSC	cis	rs9392556	0.829	rs689308	chr6:4127730	A/C	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-6.48	-0.33	3.38e-10	Blood metabolite levels;
LUSC	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg05738196	chr6:26577821	NA	-0.79	-15.08	-0.64	1.47e-39	Intelligence (multi-trait analysis);
LUSC	trans	rs1997103	0.863	rs6956287	chr7:55415107	T/C	cg20935933	chr6:143382018	AIG1	0.5	6.92	0.35	2.28e-11	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs656319	0.580	rs13252589	chr8:10005526	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.38	-0.37	1.23e-12	Myopia (pathological);
LUSC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.77	-11.4	-0.53	1.22e-25	Vitiligo;
LUSC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.44	0.33	4.07e-10	Menopause (age at onset);
LUSC	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.03	-20.63	-0.75	1.46e-61	Ulcerative colitis;
LUSC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11039100	0.607	rs2133264	chr11:5781533	G/A	cg05234568	chr11:5960015	NA	-0.43	-5.7	-0.3	2.66e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs62400317	0.859	rs12201899	chr6:45298204	C/A	cg18551225	chr6:44695536	NA	-0.44	-7.35	-0.37	1.54e-12	Total body bone mineral density;
LUSC	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg01557791	chr16:72042693	DHODH	-0.52	-7.54	-0.38	4.42e-13	Fibrinogen levels;
LUSC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.76	-9.8	-0.47	4.38e-20	Iron status biomarkers;
LUSC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg10356904	chr22:49881777	NA	-0.35	-8.01	-0.4	1.92e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg11909976	chr19:59055696	TRIM28	-0.55	-6.09	-0.32	3.03e-9	Height;
LUSC	cis	rs738322	0.553	rs28565947	chr22:38570775	C/G	cg25457927	chr22:38595422	NA	-0.36	-7.13	-0.36	6.36e-12	Cutaneous nevi;
LUSC	trans	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg06521331	chr12:34319734	NA	-0.4	-6.24	-0.32	1.3e-9	Bladder cancer;
LUSC	cis	rs2976388	1.000	rs2585179	chr8:143774193	G/A	cg17252645	chr8:143867129	LY6D	-0.38	-6.5	-0.34	2.85e-10	Urinary tract infection frequency;
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg09033563	chr22:24373618	LOC391322	-0.57	-8.58	-0.43	3.57e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	8.86	0.44	4.86e-17	Prudent dietary pattern;
LUSC	trans	rs2490361	0.933	rs2490364	chr1:237322593	A/G	cg15653282	chr18:11689218	GNAL	0.4	6.24	0.32	1.29e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11971779	0.711	rs6961204	chr7:139047399	T/G	cg07862535	chr7:139043722	LUC7L2	0.69	8.08	0.4	1.19e-14	Diisocyanate-induced asthma;
LUSC	trans	rs1941687	0.797	rs7227708	chr18:31393091	A/G	cg27147174	chr7:100797783	AP1S1	-0.45	-6.56	-0.34	2.04e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.85	0.3	1.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg18755752	chr8:142205143	DENND3	-0.69	-12.24	-0.56	1.05e-28	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs497273	0.534	rs9431	chr12:121202664	A/C	cg02419362	chr12:121203948	SPPL3	0.43	7.95	0.4	2.9e-14	Systemic lupus erythematosus;
LUSC	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-10.45	-0.5	2.71e-22	Bladder cancer;
LUSC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg21724239	chr8:58056113	NA	0.8	8.55	0.42	4.58e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.89	-0.35	2.74e-11	Neuroticism;
LUSC	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg17385448	chr1:15911702	AGMAT	0.35	5.92	0.31	7.87e-9	Systolic blood pressure;
LUSC	cis	rs501916	1.000	rs565627	chr15:48056735	A/C	cg16110827	chr15:48056943	SEMA6D	-0.34	-5.66	-0.3	3.32e-8	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg15448220	chr1:150897856	SETDB1	0.42	6.06	0.31	3.68e-9	Melanoma;
LUSC	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg06627628	chr2:24431161	ITSN2	0.52	7.34	0.37	1.66e-12	Asthma;
LUSC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.45	-6.59	-0.34	1.73e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg00376283	chr12:123451042	ABCB9	0.67	8.44	0.42	9.73e-16	Neutrophil percentage of white cells;
LUSC	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg02007433	chr3:129722099	NA	-0.44	-5.99	-0.31	5.49e-9	Blood pressure (smoking interaction);
LUSC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg03146154	chr1:46216737	IPP	-0.5	-7.24	-0.37	3.08e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg26028573	chr6:26043587	HIST1H2BB	0.38	5.69	0.3	2.76e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg06618935	chr21:46677482	NA	-0.35	-7.06	-0.36	9.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.2	-0.37	4.13e-12	Bipolar disorder;
LUSC	cis	rs12478296	0.515	rs13412492	chr2:243000583	T/G	cg06360820	chr2:242988706	NA	-0.66	-8.26	-0.41	3.39e-15	Obesity-related traits;
LUSC	cis	rs6695223	1.000	rs4907132	chr1:85537522	T/C	cg22153463	chr1:85462885	MCOLN2	-0.58	-5.68	-0.3	2.97e-8	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg00864171	chr11:67383662	NA	0.34	6.01	0.31	4.84e-9	Mean corpuscular volume;
LUSC	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg13010199	chr12:38710504	ALG10B	0.55	8.38	0.42	1.44e-15	Morning vs. evening chronotype;
LUSC	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg04374321	chr14:90722782	PSMC1	0.72	11.42	0.53	1.05e-25	Mortality in heart failure;
LUSC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg13393036	chr8:95962371	TP53INP1	-0.45	-9.43	-0.46	7.28e-19	Type 2 diabetes;
LUSC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.13	15.81	0.65	2.04e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9837602	1.000	rs1688772	chr3:99503366	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-6.04	-0.31	4.08e-9	Breast cancer;
LUSC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	1.03	19.78	0.73	3.36e-58	Dilated cardiomyopathy;
LUSC	cis	rs7582720	1.000	rs72932780	chr2:203695826	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.78	0.43	8.49e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg11812906	chr14:75593930	NEK9	0.66	11.33	0.53	2.12e-25	Height;
LUSC	cis	rs68170813	0.559	rs6967638	chr7:106929356	T/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.78	-0.47	4.93e-20	Coronary artery disease;
LUSC	trans	rs11700980	0.551	rs2832022	chr21:30112718	G/A	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.31e-9	QRS complex (12-leadsum);
LUSC	trans	rs9473924	1.000	rs9473924	chr6:50834157	A/C	cg22375689	chr19:34175036	CHST8	-0.38	-6.08	-0.32	3.21e-9	Body mass index;
LUSC	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg22782873	chr19:19639568	YJEFN3	-0.53	-6.45	-0.33	3.94e-10	Bipolar disorder;
LUSC	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg09184832	chr6:79620586	NA	-0.44	-7.17	-0.37	4.8e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg06877462	chr1:205807181	PM20D1	0.48	8.57	0.42	3.94e-16	Menarche (age at onset);
LUSC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg14668632	chr7:2872130	GNA12	-0.47	-6.84	-0.35	3.89e-11	Height;
LUSC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg21782813	chr7:2030301	MAD1L1	0.49	8.47	0.42	7.92e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg17845761	chr1:175162550	KIAA0040	-0.3	-5.77	-0.3	1.76e-8	Alcohol dependence;
LUSC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg06008330	chr7:65541103	ASL	-0.4	-6.23	-0.32	1.43e-9	Aortic root size;
LUSC	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg06637938	chr14:75390232	RPS6KL1	0.64	10.52	0.5	1.47e-22	Caffeine consumption;
LUSC	cis	rs7597155	0.935	rs7567400	chr2:69981295	A/G	cg02498382	chr2:70120550	SNRNP27	0.24	5.69	0.3	2.74e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs524023	0.914	rs4930556	chr11:64377726	G/C	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.72	-0.3	2.3e-8	Urate levels in obese individuals;
LUSC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg27398817	chr8:82754497	SNX16	-0.65	-8.11	-0.41	9.85e-15	Diastolic blood pressure;
LUSC	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg15485101	chr11:133734466	NA	0.42	7.65	0.39	2.19e-13	Childhood ear infection;
LUSC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg10360139	chr7:1886902	MAD1L1	-0.38	-5.65	-0.3	3.35e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg19302996	chr17:73780495	UNK	-0.48	-7.01	-0.36	1.32e-11	White matter hyperintensity burden;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17822314	chr2:54198336	PSME4	-0.46	-6.56	-0.34	1.99e-10	Electrocardiographic conduction measures;
LUSC	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg06547715	chr2:218990976	CXCR2	-0.32	-6.42	-0.33	4.76e-10	Ulcerative colitis;
LUSC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg10351095	chr21:47802916	PCNT	0.43	6.12	0.32	2.64e-9	Testicular germ cell tumor;
LUSC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.59	-7.95	-0.4	2.93e-14	Systemic lupus erythematosus;
LUSC	cis	rs7017697	1.000	rs2410612	chr8:19681647	A/G	cg03894339	chr8:19674705	INTS10	0.43	6.2	0.32	1.68e-9	Breast cancer;
LUSC	cis	rs28647808	0.881	rs28461467	chr9:136261288	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs11229555	0.645	rs4517537	chr11:58213695	G/A	cg15696309	chr11:58395628	NA	-0.64	-7.7	-0.39	1.51e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg25036284	chr2:26402008	FAM59B	-0.74	-10.66	-0.5	4.96e-23	Gut microbiome composition (summer);
LUSC	cis	rs4950928	0.823	rs2494277	chr1:203168092	A/G	cg17014757	chr1:203156097	CHI3L1	-0.41	-7.28	-0.37	2.43e-12	YKL-40 levels;
LUSC	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.64	11.06	0.52	1.91e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7799006	0.691	rs10447541	chr7:2301578	T/G	cg08027265	chr7:2291960	NA	-0.63	-11.23	-0.52	4.8e-25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23279559	chr21:17101917	USP25	0.4	6.18	0.32	1.92e-9	Triglycerides;
LUSC	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.78e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs8067354	0.872	rs1295925	chr17:57910263	T/C	cg02344993	chr17:57696989	CLTC	-0.37	-5.65	-0.3	3.42e-8	Hemoglobin concentration;
LUSC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6426558	0.537	rs6662583	chr1:227383889	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.54	-7.55	-0.38	4.32e-13	Neutrophil percentage of white cells;
LUSC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24549020	chr5:56110836	MAP3K1	0.49	5.99	0.31	5.58e-9	Initial pursuit acceleration;
LUSC	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg07382826	chr16:28625726	SULT1A1	0.28	6.1	0.32	2.93e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs894344	0.650	rs11166592	chr8:135577008	A/C	cg17885191	chr8:135476712	NA	0.41	5.88	0.31	9.98e-9	Systolic blood pressure;
LUSC	trans	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.53	-0.34	2.48e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg07460842	chr6:66804631	NA	-0.48	-6.72	-0.35	7.74e-11	Blood trace element (Cu levels);
LUSC	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg05347473	chr6:146136440	FBXO30	0.52	8.69	0.43	1.64e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7605827	0.930	rs9287660	chr2:15595767	C/A	cg19274914	chr2:15703543	NA	0.46	8.76	0.43	1e-16	Educational attainment (years of education);
LUSC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg12365402	chr11:9010492	NRIP3	0.45	8.51	0.42	5.87e-16	Hemoglobin concentration;
LUSC	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg04450456	chr4:17643702	FAM184B	0.38	6.22	0.32	1.46e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg24642439	chr20:33292090	TP53INP2	-0.48	-7.33	-0.37	1.7e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg04374321	chr14:90722782	PSMC1	-0.68	-10.26	-0.49	1.17e-21	Mortality in heart failure;
LUSC	cis	rs16854884	0.657	rs6769910	chr3:143737830	C/G	cg06585982	chr3:143692056	C3orf58	0.5	7.93	0.4	3.36e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06112835	chr11:68658793	MRPL21	0.49	7.44	0.38	8.49e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg25258033	chr6:167368657	RNASET2	0.43	6.86	0.35	3.31e-11	Crohn's disease;
LUSC	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.16	-0.52	8.55e-25	Mean corpuscular volume;
LUSC	cis	rs1160297	0.585	rs2356681	chr2:53097750	C/T	cg07782112	chr2:53107842	NA	0.43	6.96	0.36	1.83e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.89	0.31	9.66e-9	Lung cancer;
LUSC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-7.01	-0.36	1.33e-11	Multiple sclerosis;
LUSC	trans	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg04775059	chr7:64541387	NA	0.44	6.35	0.33	6.86e-10	Aortic root size;
LUSC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	8.51	0.42	6.05e-16	Height;
LUSC	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg21643547	chr1:205240462	TMCC2	-0.48	-9.39	-0.46	9.37e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14893161	chr1:205819251	PM20D1	0.58	9.9	0.48	1.96e-20	Menarche (age at onset);
LUSC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.44	5.96	0.31	6.31e-9	Schizophrenia;
LUSC	cis	rs6684514	0.961	rs72710222	chr1:156285995	T/C	cg16558208	chr1:156270281	VHLL	0.36	5.76	0.3	1.9e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUSC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.75	0.77	5.71e-66	Prudent dietary pattern;
LUSC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg18681998	chr4:17616180	MED28	-0.84	-14.78	-0.63	2.26e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4919087	0.961	rs11189120	chr10:99069493	G/T	cg25902810	chr10:99078978	FRAT1	0.49	7.28	0.37	2.46e-12	Monocyte count;
LUSC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg22535103	chr8:58192502	C8orf71	-0.67	-7.23	-0.37	3.25e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	ch.11.42038R	chr11:967971	AP2A2	0.45	6.58	0.34	1.79e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg02569458	chr12:86230093	RASSF9	0.52	8.31	0.41	2.4e-15	Major depressive disorder;
LUSC	cis	rs28647808	0.881	rs41297211	chr9:136260721	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.88	0.58	4.32e-31	Platelet count;
LUSC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg12560992	chr17:57184187	TRIM37	0.85	15.35	0.64	1.26e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs735860	0.712	rs3736732	chr6:53160383	G/T	cg10236188	chr6:53219634	NA	-0.38	-5.93	-0.31	7.77e-9	Glaucoma;
LUSC	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg19622623	chr12:86230825	RASSF9	0.4	5.81	0.3	1.46e-8	Major depressive disorder;
LUSC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	8.93	0.44	2.98e-17	Prudent dietary pattern;
LUSC	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg23093090	chr10:104574429	C10orf26	-0.36	-6.5	-0.34	2.94e-10	Arsenic metabolism;
LUSC	cis	rs6733011	0.582	rs6757099	chr2:99415235	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.29	-0.33	1.01e-9	Bipolar disorder;
LUSC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg00106254	chr7:1943704	MAD1L1	-0.41	-5.89	-0.31	9.27e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg05872129	chr22:39784769	NA	-0.59	-9.99	-0.48	9.71e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6496667	0.510	rs7495784	chr15:91068882	T/C	cg22089800	chr15:90895588	ZNF774	-0.58	-8.12	-0.41	9e-15	Rheumatoid arthritis;
LUSC	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg00376283	chr12:123451042	ABCB9	0.83	13.0	0.58	1.47e-31	Platelet count;
LUSC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg04518342	chr5:131593106	PDLIM4	0.35	6.4	0.33	5.25e-10	Lung function (FEV1/FVC);
LUSC	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.88	12.77	0.57	1.12e-30	Coronary artery disease;
LUSC	cis	rs2348418	0.715	rs4931083	chr12:28721885	A/G	cg13890972	chr12:28721907	NA	0.38	6.73	0.35	7.52e-11	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg03678062	chr6:149772716	ZC3H12D	0.31	6.29	0.33	9.8e-10	Dupuytren's disease;
LUSC	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-6.11	-0.32	2.77e-9	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.4e-9	Ulcerative colitis;
LUSC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg20503657	chr10:835505	NA	1.01	14.17	0.61	4.98e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs6690583	0.623	rs61768853	chr1:85455707	T/C	cg22153463	chr1:85462885	MCOLN2	0.61	5.94	0.31	6.97e-9	Serum sulfate level;
LUSC	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg22563815	chr15:78856949	CHRNA5	0.25	6.24	0.32	1.36e-9	Sudden cardiac arrest;
LUSC	cis	rs1451375	0.698	rs1813214	chr7:50637525	A/G	cg18232548	chr7:50535776	DDC	0.5	7.6	0.38	3.11e-13	Malaria;
LUSC	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.77	11.09	0.52	1.49e-24	Corneal astigmatism;
LUSC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg25258033	chr6:167368657	RNASET2	0.46	7.32	0.37	1.85e-12	Crohn's disease;
LUSC	trans	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-5.95	-0.31	6.74e-9	Triglycerides;
LUSC	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg18827107	chr12:86230957	RASSF9	-0.41	-6.13	-0.32	2.54e-9	Major depressive disorder;
LUSC	cis	rs6546550	0.933	rs6546555	chr2:70135760	A/G	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.29	-0.37	2.2e-12	Prevalent atrial fibrillation;
LUSC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-1.09	-20.72	-0.75	6.29e-62	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23304886	chr14:102553823	HSP90AA1	-0.44	-6.6	-0.34	1.63e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6690583	0.562	rs11588919	chr1:85442813	A/T	cg11262906	chr1:85462892	MCOLN2	0.69	6.57	0.34	1.99e-10	Serum sulfate level;
LUSC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08859206	chr1:53392774	SCP2	0.51	8.65	0.43	2.13e-16	Monocyte count;
LUSC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg00509249	chr6:109615579	CCDC162	-0.32	-5.72	-0.3	2.33e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg15654264	chr1:150340011	RPRD2	0.59	9.73	0.47	7.52e-20	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2625529	0.586	rs2306489	chr15:72227471	G/A	cg16672083	chr15:72433130	SENP8	0.49	8.11	0.41	9.63e-15	Red blood cell count;
LUSC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.29	0.33	1.02e-9	Menopause (age at onset);
LUSC	cis	rs10740039	0.804	rs894384	chr10:62452293	C/G	cg18175470	chr10:62150864	ANK3	-0.44	-6.56	-0.34	2e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25072359	chr17:41440525	NA	0.69	9.65	0.47	1.36e-19	Menopause (age at onset);
LUSC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.86	11.76	0.54	5.81e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	trans	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.65	0.39	2.18e-13	Ulcerative colitis;
LUSC	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.75	-0.39	1.13e-13	Neuroticism;
LUSC	trans	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-8.19	-0.41	5.48e-15	Neuroticism;
LUSC	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg16482183	chr6:26056742	HIST1H1C	0.49	7.36	0.37	1.46e-12	Height;
LUSC	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	11.23	0.52	5.01e-25	Lung cancer in ever smokers;
LUSC	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	1.01	16.81	0.68	2.16e-46	Testicular germ cell tumor;
LUSC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg06600287	chr1:53387719	ECHDC2	0.29	5.94	0.31	7.17e-9	Monocyte count;
LUSC	cis	rs1413885	0.526	rs9728544	chr1:65847105	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	7.06	0.36	9.51e-12	Anticoagulant levels;
LUSC	trans	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg11244813	chr1:145039882	PDE4DIP	0.39	6.52	0.34	2.58e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg09904177	chr6:26538194	HMGN4	-0.75	-5.77	-0.3	1.76e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg08508325	chr11:3079039	CARS	0.39	8.81	0.43	6.97e-17	Calcium levels;
LUSC	cis	rs4704187	0.687	rs6891023	chr5:74500755	G/A	cg03227963	chr5:74354835	NA	0.31	6.76	0.35	6.31e-11	Response to amphetamines;
LUSC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg23262073	chr20:60523788	NA	-0.39	-6.23	-0.32	1.38e-9	Body mass index;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg08007338	chr1:180123948	QSOX1	0.67	6.05	0.31	3.95e-9	Cognitive performance;
LUSC	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg25251562	chr2:3704773	ALLC	0.54	8.89	0.44	3.77e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg16362232	chr11:430036	ANO9	0.57	7.59	0.38	3.18e-13	Body mass index;
LUSC	cis	rs9653442	0.545	rs13415465	chr2:100764004	T/G	cg22139774	chr2:100720529	AFF3	-0.43	-7.37	-0.37	1.32e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2708377	0.799	rs61928604	chr12:11311947	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-6.01	-0.31	4.82e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg16329650	chr2:213403929	ERBB4	0.86	18.45	0.71	6.91e-53	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg09307838	chr4:120376055	NA	0.75	10.89	0.51	7.5e-24	Corneal astigmatism;
LUSC	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.4	0.33	5.38e-10	Corneal astigmatism;
LUSC	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg23711669	chr6:146136114	FBXO30	0.75	12.94	0.58	2.6e-31	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.43	-0.46	7.11e-19	Depression;
LUSC	cis	rs62344088	1.000	rs10037843	chr5:120078	G/C	cg22857025	chr5:266934	NA	-0.99	-7.12	-0.36	6.61e-12	Asthma (childhood onset);
LUSC	cis	rs9815354	0.723	rs12152489	chr3:42060402	T/C	cg03022575	chr3:42003672	ULK4	0.78	7.85	0.39	5.64e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	1.09	12.99	0.58	1.62e-31	Mitochondrial DNA levels;
LUSC	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg26597838	chr10:835615	NA	-0.78	-9.69	-0.47	1.02e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg05855489	chr10:104503620	C10orf26	-0.68	-9.98	-0.48	1.09e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.79	-0.43	8.04e-17	Bipolar disorder;
LUSC	cis	rs699	0.556	rs2478520	chr1:230867197	G/A	cg07502417	chr1:230849801	AGT	0.27	6.38	0.33	5.92e-10	Coronary artery disease;
LUSC	cis	rs7615316	0.902	rs6440087	chr3:142247052	C/T	cg16271453	chr3:142027066	XRN1	-0.4	-6.83	-0.35	3.93e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7586879	0.639	rs6722022	chr2:25098859	A/G	cg01884057	chr2:25150051	NA	0.47	10.7	0.51	3.7e-23	Body mass index;
LUSC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg06096015	chr1:231504339	EGLN1	0.58	10.45	0.5	2.68e-22	Hemoglobin concentration;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg13582873	chr2:207024197	EEF1B2;NDUFS1	0.4	6.11	0.32	2.82e-9	Asthma;
LUSC	cis	rs7200543	1.000	rs55727637	chr16:15145252	C/T	cg03427771	chr16:15082598	PDXDC1	-0.42	-6.12	-0.32	2.56e-9	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg23649088	chr2:200775458	C2orf69	-0.48	-6.28	-0.33	1.02e-9	Schizophrenia;
LUSC	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg13615516	chr5:77269221	NA	0.4	6.56	0.34	2.02e-10	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11953916	chr17:11900692	ZNF18	0.41	6.14	0.32	2.33e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs953492	0.672	rs1766030	chr1:243314577	C/T	cg01826367	chr1:224180288	NA	-0.45	-6.69	-0.34	9.33e-11	Diastolic blood pressure;
LUSC	cis	rs36093844	0.747	rs11234420	chr11:85528580	G/A	cg25872744	chr11:85566296	CCDC83	-0.44	-6.02	-0.31	4.5e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.18	-0.52	7.13e-25	Mean corpuscular volume;
LUSC	cis	rs12200560	0.505	rs927271	chr6:97075910	T/G	cg06623918	chr6:96969491	KIAA0776	0.48	6.93	0.35	2.12e-11	Coronary heart disease;
LUSC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg21770322	chr7:97807741	LMTK2	0.4	7.03	0.36	1.19e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07377288	chr7:102004298	NA	0.45	6.08	0.32	3.21e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28595532	0.623	rs34082100	chr4:119220563	C/T	cg21605333	chr4:119757512	SEC24D	0.76	6.34	0.33	7.37e-10	Cannabis dependence symptom count;
LUSC	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg13852791	chr20:30311386	BCL2L1	0.94	14.26	0.62	2.29e-36	Mean corpuscular hemoglobin;
LUSC	cis	rs7147624	1.000	rs2411354	chr14:66062132	T/C	cg03016385	chr14:66212404	NA	-0.84	-9.37	-0.46	1.12e-18	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg09462578	chr12:12878428	APOLD1	-0.53	-6.5	-0.34	2.91e-10	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg01884057	chr2:25150051	NA	-0.38	-8.58	-0.42	3.67e-16	Body mass index in non-asthmatics;
LUSC	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	0.89	14.87	0.63	9.67e-39	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs28647808	0.881	rs28602295	chr9:136267471	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs2658782	0.694	rs3019221	chr11:93079700	C/G	cg15737290	chr11:93063684	CCDC67	0.71	8.83	0.44	6.04e-17	Pulmonary function decline;
LUSC	cis	rs2267681	0.603	rs12534299	chr7:139538522	A/G	cg14116596	chr7:139528673	TBXAS1	-0.35	-6.13	-0.32	2.55e-9	Cervical cancer;
LUSC	trans	rs7181230	1.000	rs11638521	chr15:40360314	T/C	cg22705835	chr10:65332833	REEP3	0.43	7.54	0.38	4.58e-13	Dehydroepiandrosterone sulphate levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12199165	chr10:103577593	MGEA5	-0.56	-6.45	-0.33	3.99e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg05623727	chr3:50126028	RBM5	-0.32	-6.08	-0.32	3.23e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4474465	0.920	rs10899532	chr11:78208470	T/G	cg27205649	chr11:78285834	NARS2	0.52	6.11	0.32	2.73e-9	Alzheimer's disease (survival time);
LUSC	cis	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg01251360	chr16:68772225	CDH1	-0.27	-6.51	-0.34	2.82e-10	Colorectal cancer;
LUSC	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg19628046	chr18:33552617	C18orf21	0.52	6.34	0.33	7.36e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs9309473	0.948	rs2421577	chr2:73840998	G/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.51	-0.34	2.77e-10	Metabolite levels;
LUSC	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg25233709	chr10:116636983	FAM160B1	-0.38	-6.63	-0.34	1.38e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg12963246	chr6:28129442	ZNF389	0.39	6.05	0.31	3.92e-9	Cardiac Troponin-T levels;
LUSC	cis	rs16949788	1.000	rs76623374	chr15:66767868	C/G	cg08120210	chr15:66682733	MAP2K1	-0.63	-6.52	-0.34	2.56e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6901250	0.819	rs9374623	chr6:117127312	C/A	cg12892004	chr6:117198278	RFX6	0.43	8.12	0.41	8.98e-15	C-reactive protein levels;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg18877635	chr1:229643817	NUP133	0.44	6.25	0.32	1.24e-9	Triglycerides;
LUSC	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg21053147	chr12:120880522	NA	-0.49	-6.13	-0.32	2.52e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9326248	0.813	rs588534	chr11:117068504	A/G	cg26566898	chr11:117069891	TAGLN	0.38	6.03	0.31	4.37e-9	Blood protein levels;
LUSC	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.88	0.31	1.02e-8	Lung cancer;
LUSC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05165339	chr4:1420672	NA	0.28	6.17	0.32	2.01e-9	Obesity-related traits;
LUSC	trans	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg25214090	chr10:38739885	LOC399744	0.46	7.39	0.37	1.2e-12	Corneal astigmatism;
LUSC	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg11812906	chr14:75593930	NEK9	-0.64	-10.45	-0.5	2.61e-22	Height;
LUSC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg09877947	chr5:131593287	PDLIM4	0.43	7.31	0.37	1.99e-12	Blood metabolite levels;
LUSC	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg17366294	chr4:99064904	C4orf37	0.53	9.1	0.45	8.59e-18	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7695732	0.752	rs1849597	chr4:89934550	A/G	cg08621624	chr12:2030223	NA	0.28	6.08	0.32	3.32e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg21724239	chr8:58056113	NA	0.8	8.46	0.42	8.32e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg13263323	chr15:86062960	AKAP13	-0.36	-5.9	-0.31	8.79e-9	Coronary artery disease;
LUSC	cis	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.4e-9	Ulcerative colitis;
LUSC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03576123	chr11:487126	PTDSS2	-0.95	-9.99	-0.48	1.02e-20	Body mass index;
LUSC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg11189052	chr15:85197271	WDR73	0.47	5.85	0.3	1.18e-8	Schizophrenia;
LUSC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	0.94	18.89	0.72	1.15e-54	Cognitive function;
LUSC	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg06552810	chr11:31128660	NA	-0.42	-7.37	-0.37	1.37e-12	Red blood cell count;
LUSC	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg10604040	chr11:65559109	OVOL1	0.31	5.72	0.3	2.34e-8	Acne (severe);
LUSC	cis	rs354225	0.544	rs7340302	chr2:54803671	A/C	cg01766943	chr2:54829624	SPTBN1	0.47	7.53	0.38	4.81e-13	Schizophrenia;
LUSC	cis	rs2249625	0.545	rs2463746	chr6:72876954	C/G	cg18830697	chr6:72922368	RIMS1	-0.36	-7.36	-0.37	1.45e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg21775007	chr8:11205619	TDH	-0.48	-6.69	-0.34	9.31e-11	Mood instability;
LUSC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.76	-0.47	5.98e-20	Bipolar disorder;
LUSC	trans	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-9.68	-0.47	1.1e-19	Blood pressure (smoking interaction);
LUSC	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.75	0.35	6.4e-11	Corneal astigmatism;
LUSC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.2e-9	Life satisfaction;
LUSC	cis	rs12681287	0.752	rs9283958	chr8:87253048	T/C	cg27223183	chr8:87520930	FAM82B	-0.47	-5.94	-0.31	7.1e-9	Caudate activity during reward;
LUSC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg02117656	chr17:79614917	TSPAN10	-0.3	-5.74	-0.3	2.15e-8	Eye color traits;
LUSC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.95	0.36	1.97e-11	Cystic fibrosis severity;
LUSC	cis	rs7589342	0.660	rs7571132	chr2:106398913	C/T	cg09152813	chr2:106391379	NCK2	-0.4	-6.31	-0.33	8.99e-10	Addiction;
LUSC	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg11189052	chr15:85197271	WDR73	0.48	5.97	0.31	6.23e-9	Schizophrenia;
LUSC	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg12473912	chr3:136751656	NA	0.39	6.77	0.35	5.97e-11	Neuroticism;
LUSC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	1.23	16.47	0.67	4.98e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs36093844	0.898	rs11234458	chr11:85591370	A/C	cg25872744	chr11:85566296	CCDC83	-0.42	-6.2	-0.32	1.64e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg20476274	chr7:133979776	SLC35B4	-0.8	-14.43	-0.62	5.08e-37	Mean platelet volume;
LUSC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg25456477	chr12:86230367	RASSF9	0.44	7.83	0.39	6.31e-14	Major depressive disorder;
LUSC	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg07148914	chr20:33460835	GGT7	0.39	5.69	0.3	2.82e-8	Coronary artery disease;
LUSC	cis	rs11608355	1.000	rs10774692	chr12:109862324	G/T	cg19025524	chr12:109796872	NA	-0.38	-5.94	-0.31	7.28e-9	Neuroticism;
LUSC	cis	rs981844	0.712	rs1456398	chr4:154738266	G/A	cg14289246	chr4:154710475	SFRP2	-0.44	-6.13	-0.32	2.46e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.56	0.42	4.1e-16	Prudent dietary pattern;
LUSC	cis	rs9398803	0.865	rs1361108	chr6:126767600	C/T	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	1.96e-9	Male-pattern baldness;
LUSC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg00990874	chr7:1149470	C7orf50	-0.49	-6.34	-0.33	7.39e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs3087591	0.960	rs8080679	chr17:29602610	A/G	cg24425628	chr17:29625626	OMG;NF1	0.55	7.95	0.4	2.97e-14	Hip circumference;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg02222234	chr2:208576132	CCNYL1	0.44	6.4	0.33	5.31e-10	Mosquito bite size;
LUSC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg00106254	chr7:1943704	MAD1L1	-0.42	-6.01	-0.31	4.91e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	0.64	13.62	0.6	6.82e-34	Prudent dietary pattern;
LUSC	cis	rs8064299	0.597	rs2053748	chr17:72775911	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.9	-17.03	-0.68	3.05e-47	Monocyte count;
LUSC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg06808227	chr14:105710500	BRF1	-0.6	-8.7	-0.43	1.58e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs17401966	0.522	rs6541085	chr1:10285709	A/G	cg19773385	chr1:10388646	KIF1B	-0.37	-6.39	-0.33	5.46e-10	Hepatocellular carcinoma;
LUSC	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-0.95	-18.47	-0.71	5.46e-53	Brugada syndrome;
LUSC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.7	11.4	0.53	1.18e-25	Heart rate;
LUSC	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.3	-0.37	2.18e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22307029	chr19:49891270	CCDC155	0.63	8.09	0.4	1.13e-14	Multiple sclerosis;
LUSC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.65	-8.31	-0.41	2.45e-15	Menarche (age at onset);
LUSC	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg08355456	chr11:67383691	NA	0.38	6.98	0.36	1.57e-11	Mean corpuscular volume;
LUSC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-5.89	-0.31	9.63e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg12560992	chr17:57184187	TRIM37	0.78	13.83	0.6	1.07e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs1847202	0.859	rs13075769	chr3:72939295	C/T	cg25664220	chr3:72788482	NA	-0.4	-7.11	-0.36	7.1e-12	Motion sickness;
LUSC	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg11812906	chr14:75593930	NEK9	-0.67	-11.32	-0.53	2.37e-25	Height;
LUSC	cis	rs3820068	0.822	rs11581917	chr1:15805722	G/A	cg17385448	chr1:15911702	AGMAT	0.41	5.7	0.3	2.57e-8	Systolic blood pressure;
LUSC	cis	rs2625529	0.652	rs9302260	chr15:72174611	T/C	cg16672083	chr15:72433130	SENP8	0.48	7.87	0.4	4.87e-14	Red blood cell count;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg03461704	chr1:205818484	PM20D1	0.35	5.78	0.3	1.75e-8	Menarche (age at onset);
LUSC	cis	rs6920965	0.507	rs7754833	chr6:126190894	A/G	cg05901451	chr6:126070800	HEY2	-0.54	-7.77	-0.39	1e-13	High light scatter reticulocyte count;
LUSC	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.75	-11.57	-0.54	2.81e-26	Testicular germ cell tumor;
LUSC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.83	0.39	6.56e-14	Colorectal cancer;
LUSC	cis	rs9811920	0.535	rs793481	chr3:99488742	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.3	-5.76	-0.3	1.87e-8	Axial length;
LUSC	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg05855489	chr10:104503620	C10orf26	0.59	8.76	0.43	9.78e-17	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg01097406	chr16:89675127	NA	-0.35	-7.04	-0.36	1.07e-11	Vitiligo;
LUSC	cis	rs34638657	0.687	rs2303261	chr16:82203768	G/T	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.58	-0.34	1.78e-10	Lung adenocarcinoma;
LUSC	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg02569458	chr12:86230093	RASSF9	0.52	8.72	0.43	1.32e-16	Major depressive disorder;
LUSC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg07703079	chr11:430292	ANO9	0.65	6.7	0.34	9.13e-11	Body mass index;
LUSC	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg02176678	chr2:219576539	TTLL4	0.56	9.63	0.47	1.51e-19	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.87	16.84	0.68	1.7e-46	Mean platelet volume;
LUSC	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.4	-0.38	1.15e-12	Psoriasis;
LUSC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg20090143	chr19:45452003	APOC2	0.49	9.56	0.46	2.6e-19	Blood protein levels;
LUSC	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg05729581	chr11:3078854	CARS	-0.53	-8.11	-0.41	9.45e-15	Longevity;
LUSC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg04155289	chr7:94953770	PON1	-0.35	-6.03	-0.31	4.4e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-7.43	-0.38	9.41e-13	Bipolar disorder;
LUSC	cis	rs952623	0.611	rs10435033	chr7:39054837	G/A	cg15212455	chr7:39170539	POU6F2	0.36	5.92	0.31	7.91e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg00268967	chr12:58002603	GEFT;DTX3	0.36	5.68	0.3	2.92e-8	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg08270630	chr22:50330655	NA	-0.42	-6.17	-0.32	1.94e-9	Schizophrenia;
LUSC	cis	rs2446066	0.659	rs11170566	chr12:53907067	C/T	cg20730629	chr12:53886622	MAP3K12	-0.45	-5.94	-0.31	7.17e-9	Red blood cell count;
LUSC	cis	rs10979	1.000	rs6570565	chr6:143899531	C/T	cg25407410	chr6:143891975	LOC285740	-0.69	-10.62	-0.5	6.71e-23	Hypospadias;
LUSC	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg21479132	chr6:26055353	NA	0.6	5.65	0.3	3.53e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg24812749	chr6:127587940	RNF146	0.73	10.48	0.5	2.02e-22	Breast cancer;
LUSC	trans	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg11887960	chr12:57824829	NA	0.48	6.52	0.34	2.57e-10	Obesity-related traits;
LUSC	cis	rs7072216	0.763	rs7911036	chr10:100167015	A/T	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	cis	rs9807989	0.765	rs6751967	chr2:102967413	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.85	0.3	1.19e-8	Asthma;
LUSC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg05234568	chr11:5960015	NA	-0.55	-8.69	-0.43	1.64e-16	DNA methylation (variation);
LUSC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.86	14.13	0.61	7.42e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4363385	0.600	rs10888532	chr1:153063407	C/A	cg00922841	chr1:152955080	SPRR1A	-0.34	-5.91	-0.31	8.64e-9	Inflammatory skin disease;
LUSC	trans	rs2562456	0.678	rs7260140	chr19:21523525	T/C	cg00806126	chr19:22604979	ZNF98	-0.43	-6.19	-0.32	1.78e-9	Pain;
LUSC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg01475377	chr6:109611718	NA	-0.45	-8.21	-0.41	4.87e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg03579872	chr1:53393473	SCP2	-0.39	-5.87	-0.31	1.05e-8	Monocyte count;
LUSC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg23630131	chr7:65973040	NA	0.21	5.94	0.31	7.16e-9	Aortic root size;
LUSC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-20.36	-0.74	1.77e-60	Coronary artery disease;
LUSC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.7	0.3	2.6e-8	Self-reported allergy;
LUSC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04267008	chr7:1944627	MAD1L1	-0.48	-7.03	-0.36	1.2e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.8	-0.39	7.87e-14	Gut microbiome composition (summer);
LUSC	trans	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.41	-0.33	4.93e-10	Neuroticism;
LUSC	cis	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg02972257	chr16:68554789	NA	-0.49	-6.53	-0.34	2.38e-10	Ulcerative colitis;
LUSC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.8	-0.35	4.73e-11	Lung cancer;
LUSC	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg18512352	chr11:47633146	NA	-0.43	-8.62	-0.43	2.82e-16	Subjective well-being;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03208016	chr1:180124071	QSOX1	-0.4	-6.01	-0.31	4.97e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg22549504	chr19:17448937	GTPBP3	0.53	6.64	0.34	1.29e-10	Systemic lupus erythematosus;
LUSC	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.34	-0.37	1.65e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	7.52	0.38	5.06e-13	Menarche (age at onset);
LUSC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg03929089	chr4:120376271	NA	-0.5	-7.01	-0.36	1.29e-11	HDL cholesterol;
LUSC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Depression;
LUSC	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-6.23	-0.32	1.44e-9	IgG glycosylation;
LUSC	cis	rs981844	0.775	rs10517580	chr4:154744128	T/G	cg14289246	chr4:154710475	SFRP2	0.46	6.2	0.32	1.66e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.72	-11.4	-0.53	1.17e-25	Breast size;
LUSC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg22834771	chr12:69754056	YEATS4	-0.49	-7.4	-0.38	1.13e-12	Blood protein levels;
LUSC	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg11245181	chr6:149772854	ZC3H12D	0.3	6.45	0.33	4.03e-10	Dupuytren's disease;
LUSC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.03	0.77	4.52e-67	Prudent dietary pattern;
LUSC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg23630131	chr7:65973040	NA	0.21	5.94	0.31	7.16e-9	Aortic root size;
LUSC	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg18827107	chr12:86230957	RASSF9	-0.45	-6.77	-0.35	5.7e-11	Major depressive disorder;
LUSC	cis	rs2692947	0.770	rs11689832	chr2:96554851	A/C	cg23100626	chr2:96804247	ASTL	0.3	7.03	0.36	1.18e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	14.18	0.61	4.69e-36	Monocyte count;
LUSC	cis	rs2279817	0.863	rs12023877	chr1:18025633	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.49	6.97	0.36	1.74e-11	Neuroticism;
LUSC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg20283391	chr11:68216788	NA	-0.53	-7.99	-0.4	2.17e-14	Total body bone mineral density;
LUSC	cis	rs1982963	0.950	rs1566132	chr14:52511836	C/T	cg10843707	chr14:52510701	NID2	-0.4	-7.17	-0.37	4.85e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg03036452	chr22:46663545	TTC38	0.53	5.7	0.3	2.59e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00281600	chr7:149322071	ZNF767	-0.49	-6.37	-0.33	6.31e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.43e-12	Body mass index;
LUSC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.0	0.58	1.45e-31	Platelet count;
LUSC	cis	rs7075426	0.646	rs4934210	chr10:88203667	G/A	cg07322936	chr10:88137208	NA	0.41	5.95	0.31	6.83e-9	Migraine without aura;
LUSC	cis	rs7091068	0.522	rs10748612	chr10:95494458	G/A	cg20715218	chr10:95462985	C10orf4	0.56	6.72	0.34	8e-11	Urinary tract infection frequency;
LUSC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.68	9.59	0.46	2.11e-19	Methadone dose in opioid dependence;
LUSC	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.87	14.93	0.63	5.75e-39	Morning vs. evening chronotype;
LUSC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg01657329	chr11:68192670	LRP5	0.45	7.15	0.36	5.67e-12	Total body bone mineral density;
LUSC	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg17143192	chr8:8559678	CLDN23	0.62	8.96	0.44	2.26e-17	Obesity-related traits;
LUSC	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg18232548	chr7:50535776	DDC	0.55	7.54	0.38	4.53e-13	Malaria;
LUSC	cis	rs59698941	0.943	rs67268447	chr5:132303194	G/A	cg14825688	chr5:132208181	LEAP2	-0.54	-5.75	-0.3	2.01e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs4629180	0.586	rs1509495	chr2:102134834	C/T	cg04415270	chr2:102091202	RFX8	-0.46	-7.88	-0.4	4.76e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg02038168	chr22:39784481	NA	-0.49	-7.89	-0.4	4.28e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg12292205	chr6:26970375	C6orf41	-0.52	-8.84	-0.44	5.51e-17	Schizophrenia;
LUSC	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.83	-0.43	6.13e-17	Monocyte percentage of white cells;
LUSC	trans	rs3857536	0.813	rs9294688	chr6:66945904	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	7.12	0.36	6.67e-12	Lung cancer in ever smokers;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg19573456	chr19:16607087	C19orf44;CALR3	0.68	5.98	0.31	5.85e-9	Cognitive performance;
LUSC	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg08085267	chr17:45401833	C17orf57	0.6	9.98	0.48	1.1e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs17095355	1.000	rs958086	chr10:111752548	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-8.04	-0.4	1.55e-14	Biliary atresia;
LUSC	cis	rs4285028	0.948	rs12493952	chr3:121708497	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.7	-9.18	-0.45	4.76e-18	Multiple sclerosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02084808	chr1:172413246	PIGC;C1orf105	-0.5	-7.44	-0.38	8.77e-13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2637266	0.716	rs2579734	chr10:78441306	A/G	cg18941641	chr10:78392320	NA	0.33	5.88	0.31	9.92e-9	Pulmonary function;
LUSC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08704250	chr15:31115839	NA	-0.47	-7.37	-0.37	1.32e-12	Huntington's disease progression;
LUSC	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg14416269	chr4:6271139	WFS1	0.56	12.08	0.55	3.96e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg13010344	chr12:123464640	ARL6IP4	0.46	6.28	0.33	1.03e-9	Neutrophil percentage of white cells;
LUSC	cis	rs4654899	0.802	rs12123910	chr1:21233316	C/T	cg01072550	chr1:21505969	NA	-0.52	-7.49	-0.38	6.09e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg11473876	chr11:109292803	C11orf87	0.39	6.3	0.33	9.31e-10	Schizophrenia;
LUSC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-7.77	-0.39	9.7e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg14092988	chr3:52407081	DNAH1	0.31	6.02	0.31	4.66e-9	Bipolar disorder;
LUSC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.02	20.28	0.74	3.65e-60	Cognitive function;
LUSC	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.45	0.33	3.82e-10	Corneal astigmatism;
LUSC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06505273	chr16:24850292	NA	0.42	5.76	0.3	1.95e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8077577	0.895	rs11871491	chr17:18105656	T/C	cg16794390	chr17:18148240	FLII	0.41	5.88	0.31	9.85e-9	Obesity-related traits;
LUSC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg06784218	chr1:46089804	CCDC17	0.49	9.84	0.47	3.04e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg14458575	chr2:238380390	NA	0.67	11.86	0.54	2.64e-27	Prostate cancer;
LUSC	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg13010199	chr12:38710504	ALG10B	0.58	9.13	0.45	6.73e-18	Morning vs. evening chronotype;
LUSC	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg10978503	chr1:24200527	CNR2	-0.49	-11.59	-0.54	2.39e-26	Immature fraction of reticulocytes;
LUSC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24110177	chr3:50126178	RBM5	0.57	9.36	0.46	1.18e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg20295408	chr7:1910781	MAD1L1	0.45	6.58	0.34	1.85e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg08017756	chr2:100939284	LONRF2	0.32	5.76	0.3	1.86e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg08999081	chr20:33150536	PIGU	0.45	8.09	0.4	1.11e-14	Coronary artery disease;
LUSC	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg09904177	chr6:26538194	HMGN4	-0.54	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg23752985	chr2:85803571	VAMP8	0.36	7.87	0.4	4.92e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.44	-0.46	6.64e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg14582100	chr15:45693742	SPATA5L1	0.6	10.95	0.51	4.7e-24	Homoarginine levels;
LUSC	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg13615516	chr5:77269221	NA	0.39	6.63	0.34	1.35e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11645453	chr3:52864694	ITIH4	0.32	7.41	0.38	1.06e-12	Bipolar disorder;
LUSC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	cis	rs9814567	0.752	rs9836401	chr3:134336897	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.12e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg09655341	chr17:79618100	PDE6G	-0.28	-6.59	-0.34	1.74e-10	Eye color traits;
LUSC	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg23601095	chr6:26197514	HIST1H3D	0.7	7.53	0.38	4.89e-13	Gout;Renal underexcretion gout;
LUSC	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10053473	chr17:62856997	LRRC37A3	0.64	10.08	0.48	5.06e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg14092571	chr14:90743983	NA	-0.36	-5.84	-0.3	1.24e-8	Mortality in heart failure;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04564312	chr5:102456179	GIN1	0.39	6.1	0.32	2.89e-9	Triglycerides;
LUSC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08219700	chr8:58056026	NA	-0.66	-8.58	-0.42	3.69e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-8.2	-0.41	5.33e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg11019008	chr10:131425282	MGMT	0.41	5.96	0.31	6.34e-9	Response to temozolomide;
LUSC	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg14829155	chr15:31115871	NA	-0.52	-7.22	-0.37	3.48e-12	Huntington's disease progression;
LUSC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg07741184	chr6:167504864	NA	0.49	8.62	0.43	2.75e-16	Crohn's disease;
LUSC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg14668632	chr7:2872130	GNA12	-0.45	-6.21	-0.32	1.59e-9	Height;
LUSC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg12463550	chr7:65579703	CRCP	0.42	6.07	0.32	3.45e-9	Calcium levels;
LUSC	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg03258749	chr1:151040405	MLLT11	-0.4	-5.99	-0.31	5.43e-9	Childhood ear infection;
LUSC	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.76	-0.43	9.87e-17	Response to antipsychotic treatment;
LUSC	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg17691542	chr6:26056736	HIST1H1C	0.49	7.19	0.37	4.26e-12	Height;
LUSC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg14552801	chr7:65878734	NA	-0.43	-5.87	-0.31	1.04e-8	Aortic root size;
LUSC	trans	rs984440	0.961	rs7813366	chr8:139080406	C/T	cg03334052	chr1:168888044	NA	0.42	5.98	0.31	5.68e-9	Obesity-related traits;
LUSC	cis	rs2398893	0.960	rs56335449	chr9:96748795	G/A	cg14459158	chr9:96720562	NA	0.32	5.81	0.3	1.44e-8	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.73	-12.34	-0.56	4.61e-29	White blood cell count (basophil);
LUSC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg22834771	chr12:69754056	YEATS4	-0.56	-8.33	-0.41	2.1e-15	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06221963	chr1:154839813	KCNN3	-0.6	-13.65	-0.6	5.11e-34	Prostate cancer;
LUSC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.69	-0.34	9.49e-11	Alzheimer's disease (late onset);
LUSC	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg19318889	chr4:1322082	MAEA	0.77	13.46	0.59	2.67e-33	Longevity;
LUSC	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg16797656	chr11:68205561	LRP5	0.45	7.81	0.39	7.47e-14	Total body bone mineral density;
LUSC	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg20991723	chr1:152506922	NA	0.48	8.81	0.43	7.05e-17	Hair morphology;
LUSC	cis	rs73198271	0.920	rs11781542	chr8:8617181	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.8	-0.3	1.58e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7189233	0.911	rs72801854	chr16:53517242	G/A	cg09728985	chr16:53543985	NA	-0.35	-6.37	-0.33	6.34e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7312122	0.557	rs4767008	chr12:113217468	C/T	cg00851732	chr12:113229793	RPH3A	0.49	5.74	0.3	2.12e-8	Methotrexate phramacokinetics (acute lymphoblastic leukemia);
LUSC	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.51	-0.42	5.99e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2354432	0.505	rs72691009	chr1:146708397	C/T	cg25205988	chr1:146714368	CHD1L	-1.02	-8.96	-0.44	2.35e-17	Mitochondrial DNA levels;
LUSC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	7.76	0.39	1.02e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.97	-0.36	1.67e-11	Colorectal cancer;
LUSC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.46	-6.21	-0.32	1.55e-9	Renal function-related traits (BUN);
LUSC	trans	rs12885221	0.542	rs7147339	chr14:33275672	T/C	cg10551270	chr5:892523	TRIP13;BRD9	-0.4	-6.06	-0.31	3.64e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs35883536	0.647	rs1335765	chr1:101048612	A/T	cg06223162	chr1:101003688	GPR88	-0.48	-8.83	-0.44	5.88e-17	Monocyte count;
LUSC	cis	rs7107174	1.000	rs7101429	chr11:77992967	A/G	cg02023728	chr11:77925099	USP35	0.49	6.84	0.35	3.83e-11	Testicular germ cell tumor;
LUSC	trans	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.39	-0.33	5.54e-10	Bladder cancer;
LUSC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg00166722	chr3:10149974	C3orf24	0.55	7.5	0.38	5.99e-13	Alzheimer's disease;
LUSC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg07703079	chr11:430292	ANO9	0.65	6.79	0.35	5.14e-11	Body mass index;
LUSC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg02038168	chr22:39784481	NA	-0.46	-6.89	-0.35	2.79e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2282300	0.739	rs34224414	chr11:30251041	T/G	cg06241208	chr11:30344200	C11orf46	-0.44	-5.65	-0.3	3.52e-8	Morning vs. evening chronotype;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21014120	chr2:203736523	ICA1L	-0.42	-6.37	-0.33	6.13e-10	Electrocardiographic conduction measures;
LUSC	cis	rs34638657	0.702	rs35865749	chr16:82199677	T/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.4	-0.33	5.4e-10	Lung adenocarcinoma;
LUSC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg25258033	chr6:167368657	RNASET2	-0.47	-7.95	-0.4	2.87e-14	Crohn's disease;
LUSC	trans	rs7939886	0.841	rs11231800	chr11:55770930	A/G	cg03929089	chr4:120376271	NA	0.79	6.24	0.32	1.32e-9	Myopia (pathological);
LUSC	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg04362960	chr10:104952993	NT5C2	0.63	9.85	0.47	2.92e-20	Arsenic metabolism;
LUSC	cis	rs7428	0.962	rs3637	chr2:85549874	A/G	cg24342717	chr2:85555507	TGOLN2	-0.6	-8.76	-0.43	1.03e-16	Ear protrusion;
LUSC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	0.66	10.27	0.49	1.14e-21	Height;
LUSC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	22.9	0.78	1.85e-70	Height;
LUSC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg07507251	chr3:52567010	NT5DC2	0.31	6.0	0.31	5.28e-9	Bipolar disorder;
LUSC	cis	rs7953508	0.506	rs10777530	chr12:93961110	C/T	cg18151635	chr12:93972918	NA	-0.6	-8.66	-0.43	1.99e-16	Pubertal anthropometrics;
LUSC	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg05347473	chr6:146136440	FBXO30	-0.37	-6.24	-0.32	1.3e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	0.91	12.24	0.56	1.04e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg08824895	chr13:115047677	UPF3A	0.55	8.35	0.42	1.84e-15	Schizophrenia;
LUSC	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg04586622	chr2:25135609	ADCY3	0.43	9.23	0.45	3.12e-18	Body mass index;
LUSC	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg10356904	chr22:49881777	NA	-0.29	-5.8	-0.3	1.55e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg24209194	chr3:40518798	ZNF619	0.47	6.35	0.33	7.15e-10	Renal cell carcinoma;
LUSC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-14.65	-0.63	7.01e-38	Vitiligo;
LUSC	cis	rs2200578	0.732	rs56271621	chr2:99658200	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.56	6.53	0.34	2.5e-10	IgG glycosylation;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05999005	chr2:152685246	ARL5A	-0.43	-6.63	-0.34	1.37e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.64	0.39	2.25e-13	Parkinson's disease;
LUSC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg00206168	chr11:65308501	LTBP3	1.16	8.45	0.42	9.36e-16	Height;
LUSC	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg00852783	chr1:26633632	UBXN11	0.6	8.92	0.44	3.24e-17	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.53	-10.48	-0.5	2.07e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs28829049	0.597	rs12740975	chr1:19437923	G/A	cg13387374	chr1:19411106	UBR4	0.42	5.78	0.3	1.71e-8	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.49	-6.79	-0.35	5e-11	Tonsillectomy;
LUSC	cis	rs2430307	0.556	rs3905501	chr7:76542080	C/T	cg15770687	chr7:76625569	PMS2L11	-0.77	-8.51	-0.42	5.79e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-21.97	-0.77	8.05e-67	Height;
LUSC	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.71	0.51	3.28e-23	Bladder cancer;
LUSC	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg26876637	chr1:152193138	HRNR	0.42	5.89	0.31	9.39e-9	Atopic dermatitis;
LUSC	cis	rs662735	0.515	rs686901	chr11:30854334	C/G	cg14844989	chr11:31128820	NA	0.38	6.08	0.32	3.34e-9	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	6.99	0.36	1.53e-11	Menarche (age at onset);
LUSC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22433210	chr17:43662623	NA	0.76	10.84	0.51	1.12e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg13072238	chr3:49761600	GMPPB	-0.71	-8.92	-0.44	3.03e-17	Menarche (age at onset);
LUSC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.25	0.49	1.34e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7949030	0.780	rs3017666	chr11:62404417	A/T	cg13298116	chr11:62369859	EML3;MTA2	-0.51	-8.73	-0.43	1.21e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg10018233	chr7:150070692	REPIN1	0.37	6.54	0.34	2.35e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6545883	0.772	rs1186709	chr2:61689380	G/A	cg15711740	chr2:61764176	XPO1	-0.44	-6.72	-0.34	8.05e-11	Tuberculosis;
LUSC	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg24375607	chr4:120327624	NA	0.69	10.99	0.52	3.39e-24	Corneal astigmatism;
LUSC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.41	-6.41	-0.33	4.95e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg18827107	chr12:86230957	RASSF9	-0.48	-7.12	-0.36	6.84e-12	Major depressive disorder;
LUSC	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg05855489	chr10:104503620	C10orf26	0.6	9.79	0.47	4.58e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2274273	0.840	rs6573014	chr14:55735892	C/T	cg04306507	chr14:55594613	LGALS3	-0.57	-13.26	-0.59	1.6e-32	Protein biomarker;
LUSC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.46	0.53	7.42e-26	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-7.7	-0.39	1.51e-13	Morning vs. evening chronotype;
LUSC	cis	rs7582720	1.000	rs72932786	chr2:203698737	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.73	0.43	1.22e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg27494647	chr7:150038898	RARRES2	0.47	7.21	0.37	3.88e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.23	-0.37	3.42e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6692729	0.966	rs6688068	chr1:227010730	A/T	cg10327440	chr1:227177885	CDC42BPA	0.48	6.9	0.35	2.63e-11	Electrodermal activity;
LUSC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11764359	chr7:65958608	NA	0.64	9.73	0.47	7.11e-20	Aortic root size;
LUSC	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.72	9.7	0.47	9.32e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	0.88	15.56	0.65	2.02e-41	Prostate cancer;
LUSC	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.69	11.54	0.53	3.8e-26	Colorectal cancer;
LUSC	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg02117656	chr17:79614917	TSPAN10	0.31	5.81	0.3	1.42e-8	Eye color traits;
LUSC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg15445000	chr17:37608096	MED1	0.4	6.78	0.35	5.36e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg02018176	chr4:1364513	KIAA1530	-0.5	-8.6	-0.43	3.07e-16	Obesity-related traits;
LUSC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg04896959	chr15:78267971	NA	-0.46	-9.09	-0.45	9.1e-18	Coronary artery disease or large artery stroke;
LUSC	cis	rs4629180	1.000	rs974374	chr2:102105846	C/T	cg01388757	chr2:102091195	RFX8	0.47	7.64	0.39	2.26e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg23093090	chr10:104574429	C10orf26	-0.37	-7.08	-0.36	8.73e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2279817	0.818	rs34304724	chr1:17994850	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.48	-5.92	-0.31	7.81e-9	Neuroticism;
LUSC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg22535103	chr8:58192502	C8orf71	-0.84	-8.32	-0.41	2.27e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.57	-9.33	-0.45	1.48e-18	Aortic root size;
LUSC	cis	rs77633900	0.772	rs283802	chr15:76791270	C/T	cg21673338	chr15:77095150	SCAPER	-0.71	-6.03	-0.31	4.33e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs983392	0.679	rs655231	chr11:60013857	A/G	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.34	-0.33	7.63e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4343996	0.837	rs6462105	chr7:3514512	C/T	cg21248987	chr7:3385318	SDK1	0.35	5.77	0.3	1.82e-8	Motion sickness;
LUSC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg17724175	chr1:150552817	MCL1	0.37	6.65	0.34	1.23e-10	Tonsillectomy;
LUSC	cis	rs9815354	0.812	rs73071341	chr3:41826211	C/T	cg03022575	chr3:42003672	ULK4	0.85	8.57	0.42	3.99e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.79	0.57	9.37e-31	Prudent dietary pattern;
LUSC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00149659	chr3:10157352	C3orf10	1.0	14.6	0.62	1.11e-37	Alzheimer's disease;
LUSC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	trans	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs4700695	0.668	rs253212	chr5:65497553	C/T	cg21114390	chr5:65439923	SFRS12	-0.5	-6.96	-0.36	1.81e-11	Facial morphology (factor 19);
LUSC	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg14696996	chr19:15285081	NOTCH3	0.99	9.07	0.44	1.06e-17	Pulse pressure;
LUSC	trans	rs6445975	0.572	rs12485999	chr3:58409763	C/T	cg18950693	chr14:70346909	SMOC1	-0.39	-5.96	-0.31	6.27e-9	Systemic lupus erythematosus;
LUSC	cis	rs62400317	0.723	rs12196188	chr6:44976426	G/C	cg18551225	chr6:44695536	NA	-0.43	-6.89	-0.35	2.83e-11	Total body bone mineral density;
LUSC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg27494647	chr7:150038898	RARRES2	0.57	8.36	0.42	1.67e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg19812747	chr11:111475976	SIK2	-0.55	-8.2	-0.41	5.19e-15	Primary sclerosing cholangitis;
LUSC	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg02100629	chr10:71892760	AIFM2	-0.4	-6.44	-0.33	4.16e-10	Blood protein levels;
LUSC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.47	7.46	0.38	7.33e-13	Menarche (age at onset);
LUSC	trans	rs2048656	0.600	rs1976671	chr8:9679634	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	6.7	0.34	8.61e-11	Schizophrenia;
LUSC	cis	rs12760731	0.720	rs10753178	chr1:178401000	A/T	cg00404053	chr1:178313656	RASAL2	0.54	6.23	0.32	1.38e-9	Obesity-related traits;
LUSC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg17366294	chr4:99064904	C4orf37	0.56	9.84	0.47	3.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg10572969	chr11:13690188	FAR1	0.72	5.94	0.31	7.06e-9	Cognitive performance;
LUSC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg06074448	chr4:187884817	NA	0.45	7.33	0.37	1.73e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06558623	chr16:89946397	TCF25	-0.96	-10.21	-0.49	1.79e-21	Skin colour saturation;
LUSC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	0.93	16.12	0.66	1.16e-43	Menopause (age at onset);
LUSC	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg05717871	chr11:638507	DRD4	-0.34	-5.9	-0.31	8.74e-9	Systemic lupus erythematosus;
LUSC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.35	6.36	0.33	6.77e-10	Obesity-related traits;
LUSC	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg06207120	chr15:45996521	NA	0.39	5.9	0.31	8.8e-9	Waist circumference;Weight;
LUSC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg20406979	chr6:167373233	NA	-0.25	-6.02	-0.31	4.58e-9	Crohn's disease;
LUSC	trans	rs57046232	0.552	rs6054166	chr20:6348251	A/C	cg21095983	chr6:86352623	SYNCRIP	0.48	7.18	0.37	4.67e-12	Colorectal cancer;
LUSC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	7.07	0.36	9.17e-12	Platelet count;
LUSC	cis	rs17286411	0.750	rs35619990	chr16:71949266	C/T	cg03805757	chr16:71968109	PKD1L3	0.42	6.96	0.36	1.83e-11	Blood protein levels;
LUSC	cis	rs6546886	0.912	rs60279245	chr2:74312743	T/G	cg14702570	chr2:74259524	NA	-0.3	-5.73	-0.3	2.2e-8	Dialysis-related mortality;
LUSC	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg15704280	chr7:45808275	SEPT13	-0.5	-6.88	-0.35	2.99e-11	Coronary artery disease;
LUSC	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg00631329	chr6:26305371	NA	-0.38	-7.28	-0.37	2.42e-12	Educational attainment;
LUSC	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	0.58	9.24	0.45	2.89e-18	Breast cancer;
LUSC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.9	-11.41	-0.53	1.12e-25	Gut microbiome composition (summer);
LUSC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.51	-0.5	1.61e-22	Alzheimer's disease;
LUSC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg07395648	chr5:131743802	NA	-0.4	-5.96	-0.31	6.36e-9	Breast cancer;
LUSC	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg03453431	chr7:157225567	NA	-0.63	-11.72	-0.54	8.31e-27	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-10.43	-0.5	3.17e-22	Hemoglobin concentration;
LUSC	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg25205988	chr1:146714368	CHD1L	-1.05	-8.61	-0.43	2.87e-16	Mitochondrial DNA levels;
LUSC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	7.43	0.38	9.47e-13	Electroencephalogram traits;
LUSC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg26924012	chr15:45694286	SPATA5L1	1.13	20.89	0.75	1.35e-62	Homoarginine levels;
LUSC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.77	-0.43	8.98e-17	Obesity-related traits;
LUSC	cis	rs6460942	0.915	rs62447642	chr7:12489147	T/C	cg06484146	chr7:12443880	VWDE	-0.67	-6.93	-0.35	2.12e-11	Coronary artery disease;
LUSC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg10729496	chr3:10149963	C3orf24	0.58	7.74	0.39	1.23e-13	Alzheimer's disease;
LUSC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg06618935	chr21:46677482	NA	-0.37	-7.33	-0.37	1.75e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.88	0.31	9.93e-9	Rheumatoid arthritis;
LUSC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-7.03	-0.36	1.18e-11	Electroencephalogram traits;
LUSC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	13.83	0.6	1.06e-34	Platelet count;
LUSC	cis	rs612683	0.862	rs12760924	chr1:100898600	A/T	cg06223162	chr1:101003688	GPR88	0.44	7.85	0.39	5.53e-14	Breast cancer;
LUSC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg09365446	chr1:150670422	GOLPH3L	0.49	7.04	0.36	1.09e-11	Melanoma;
LUSC	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg15704280	chr7:45808275	SEPT13	0.93	13.42	0.59	3.9e-33	Coronary artery disease;
LUSC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-8.98	-0.44	2e-17	Bipolar disorder;
LUSC	cis	rs8113142	0.614	rs4805261	chr19:29213292	T/C	cg04546413	chr19:29218101	NA	0.46	6.25	0.32	1.26e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02771843	chr3:69062953	C3orf64	-0.5	-6.17	-0.32	2.03e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs17095355	1.000	rs11194922	chr10:111695656	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.96	-0.36	1.81e-11	Biliary atresia;
LUSC	cis	rs12900413	0.603	rs12906832	chr15:90301314	C/G	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.56e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	0.42	6.0	0.31	5.18e-9	Platelet distribution width;
LUSC	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg09365446	chr1:150670422	GOLPH3L	0.45	6.59	0.34	1.66e-10	Melanoma;
LUSC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs500891	0.810	rs3812143	chr6:84141282	G/C	cg08257003	chr6:84140564	ME1	0.35	7.27	0.37	2.56e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.44	6.25	0.32	1.26e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-1.23	-13.29	-0.59	1.17e-32	Diabetic kidney disease;
LUSC	cis	rs2667011	0.818	rs7590560	chr2:160843043	C/G	cg06573604	chr2:160760825	LY75	0.49	6.19	0.32	1.77e-9	Bilirubin levels;
LUSC	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06002616	chr8:101225028	SPAG1	-0.4	-6.57	-0.34	1.93e-10	Atrioventricular conduction;
LUSC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg04166393	chr7:2884313	GNA12	0.43	5.76	0.3	1.94e-8	Height;
LUSC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg00990874	chr7:1149470	C7orf50	-0.53	-6.5	-0.34	2.94e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.25	0.37	2.91e-12	Motion sickness;
LUSC	cis	rs11650494	0.908	rs118099826	chr17:47447836	G/T	cg08112188	chr17:47440006	ZNF652	1.38	11.35	0.53	1.79e-25	Prostate cancer;
LUSC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-7.41	-0.38	1.03e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg08917208	chr2:24149416	ATAD2B	0.87	9.64	0.47	1.41e-19	Lymphocyte counts;
LUSC	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg19622623	chr12:86230825	RASSF9	-0.43	-6.08	-0.32	3.26e-9	Major depressive disorder;
LUSC	cis	rs7575217	0.588	rs11675221	chr2:101670937	C/T	cg23907051	chr2:101730305	TBC1D8	0.27	6.62	0.34	1.44e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.25	0.32	1.25e-9	Platelet count;
LUSC	cis	rs9356171	0.572	rs2281406	chr6:164325848	C/T	cg25752492	chr6:164341247	NA	-0.38	-6.6	-0.34	1.64e-10	Diisocyanate-induced asthma;
LUSC	cis	rs11971779	0.752	rs4732371	chr7:139077317	T/A	cg07862535	chr7:139043722	LUC7L2	0.59	7.31	0.37	2.01e-12	Diisocyanate-induced asthma;
LUSC	cis	rs2580764	0.573	rs13387751	chr2:55227375	C/G	cg20993754	chr2:55226987	RTN4	0.34	5.69	0.3	2.82e-8	Mean platelet volume;
LUSC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.3	-0.67	2.24e-44	Monocyte count;
LUSC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg26304593	chr6:42947056	PEX6	-0.54	-8.49	-0.42	6.8e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg05985134	chr18:33552581	C18orf21	0.5	6.73	0.35	7.22e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.27	0.37	2.54e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg19826802	chr17:26972212	KIAA0100	0.65	6.03	0.31	4.42e-9	Cognitive performance;
LUSC	trans	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg26043149	chr18:55253948	FECH	-0.54	-8.17	-0.41	6.46e-15	Bone mineral density;
LUSC	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg09184832	chr6:79620586	NA	-0.45	-7.43	-0.38	9.27e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg18904891	chr8:8559673	CLDN23	0.61	8.47	0.42	7.74e-16	Obesity-related traits;
LUSC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg00012203	chr2:219082015	ARPC2	-0.69	-11.35	-0.53	1.78e-25	Colorectal cancer;
LUSC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	6.33	0.33	8.03e-10	Mean platelet volume;
LUSC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg26380479	chr7:97908229	NA	-0.27	-6.04	-0.31	4.09e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4144743	0.877	rs7218773	chr17:45324211	C/T	cg18085866	chr17:45331354	ITGB3	-0.7	-7.62	-0.38	2.61e-13	Body mass index;
LUSC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Depression;
LUSC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.08	-0.36	8.53e-12	Extrinsic epigenetic age acceleration;
LUSC	trans	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg21659725	chr3:3221576	CRBN	-0.71	-8.18	-0.41	5.86e-15	Menarche (age at onset);
LUSC	cis	rs524023	1.000	rs10897518	chr11:64360705	A/G	cg07220939	chr11:64358617	SLC22A12	0.22	5.74	0.3	2.12e-8	Urate levels in obese individuals;
LUSC	cis	rs4356932	1.000	rs4543147	chr4:76976661	A/G	cg00809888	chr4:76862425	NAAA	0.36	5.95	0.31	6.91e-9	Blood protein levels;
LUSC	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg10523679	chr1:76189770	ACADM	-0.5	-7.31	-0.37	2.01e-12	Daytime sleep phenotypes;
LUSC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg18402987	chr7:1209562	NA	0.7	7.64	0.39	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18854424	chr1:2615690	NA	-0.49	-9.97	-0.48	1.18e-20	Ulcerative colitis;
LUSC	cis	rs2853333	0.622	rs2519962	chr19:35752691	A/G	cg12287945	chr19:35758300	LSR	-0.39	-5.7	-0.3	2.66e-8	Red blood cell count;
LUSC	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg22852734	chr6:133119734	C6orf192	0.83	6.71	0.34	8.22e-11	Type 2 diabetes nephropathy;
LUSC	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg05163923	chr11:71159392	DHCR7	0.74	10.94	0.51	5.36e-24	Vitamin D levels;
LUSC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg04944784	chr2:26401820	FAM59B	-0.48	-6.33	-0.33	7.96e-10	Gut microbiome composition (summer);
LUSC	trans	rs7939886	0.920	rs11227638	chr11:56019585	A/T	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg02773041	chr1:40204384	PPIE	0.55	8.26	0.41	3.47e-15	Blood protein levels;
LUSC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg06784218	chr1:46089804	CCDC17	-0.48	-9.31	-0.45	1.76e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	9.91e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.61	-7.75	-0.39	1.12e-13	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.77	-0.35	5.94e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7605827	0.930	rs12993042	chr2:15708218	A/T	cg19274914	chr2:15703543	NA	0.44	8.36	0.42	1.71e-15	Educational attainment (years of education);
LUSC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg12963246	chr6:28129442	ZNF389	0.48	6.55	0.34	2.12e-10	Depression;
LUSC	trans	rs7944735	1.000	rs7944735	chr11:47955608	G/C	cg03929089	chr4:120376271	NA	0.61	6.31	0.33	8.84e-10	Intraocular pressure;
LUSC	cis	rs11039100	1.000	rs1470872	chr11:5827540	T/C	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	6.85	0.35	3.64e-11	Eosinophil percentage of white cells;
LUSC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	15.85	0.66	1.37e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg18681998	chr4:17616180	MED28	0.85	15.99	0.66	3.99e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	trans	rs34421088	0.506	rs2572428	chr8:11146672	T/A	cg15556689	chr8:8085844	FLJ10661	0.46	6.96	0.36	1.79e-11	Neuroticism;
LUSC	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.71	-0.34	8.56e-11	Mood instability;
LUSC	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg19052272	chr2:3704530	ALLC	0.46	8.03	0.4	1.73e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	0.94	18.91	0.72	9.99e-55	Menarche (age at onset);
LUSC	cis	rs9341808	0.652	rs2505940	chr6:80851191	T/C	cg08355045	chr6:80787529	NA	0.47	8.07	0.4	1.24e-14	Sitting height ratio;
LUSC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-8.42	-0.42	1.14e-15	Menarche (age at onset);
LUSC	cis	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg20368463	chr18:77673604	PQLC1	0.76	12.74	0.57	1.46e-30	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUSC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19748678	chr4:122722346	EXOSC9	0.6	9.06	0.44	1.08e-17	Type 2 diabetes;
LUSC	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs2262909	1.000	rs765527	chr19:22129555	A/G	cg17074339	chr11:11642133	GALNTL4	0.4	6.07	0.32	3.49e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17030434	0.953	rs6535953	chr4:154728186	G/A	cg14289246	chr4:154710475	SFRP2	-0.51	-6.75	-0.35	6.73e-11	Electrocardiographic conduction measures;
LUSC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg06454157	chr6:167490870	NA	-0.28	-6.87	-0.35	3.1e-11	Primary biliary cholangitis;
LUSC	cis	rs10761750	1	rs10761750	chr10:65128619	G/A	cg01631684	chr10:65280961	REEP3	-0.4	-6.17	-0.32	1.96e-9	Vascular endothelial growth factor levels;
LUSC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg12310025	chr6:25882481	NA	-0.5	-8.97	-0.44	2.17e-17	Blood metabolite levels;
LUSC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.24	0.52	4.53e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg26380479	chr7:97908229	NA	-0.27	-6.11	-0.32	2.81e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-9.52	-0.46	3.51e-19	Morning vs. evening chronotype;
LUSC	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg10224037	chr5:178157518	ZNF354A	0.57	7.18	0.37	4.51e-12	Neutrophil percentage of white cells;
LUSC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg16339924	chr4:17578868	LAP3	0.58	8.8	0.43	7.66e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg24130564	chr14:104152367	KLC1	-0.45	-6.36	-0.33	6.5e-10	Body mass index;
LUSC	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg10560079	chr2:191398806	TMEM194B	-0.7	-8.8	-0.43	7.45e-17	Diastolic blood pressure;
LUSC	cis	rs8016982	0.662	rs7144005	chr14:81656437	C/T	cg01989461	chr14:81687754	GTF2A1	0.52	6.8	0.35	4.89e-11	Schizophrenia;
LUSC	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg25233709	chr10:116636983	FAM160B1	0.36	6.41	0.33	4.9e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2282802	0.651	rs6863474	chr5:139630862	C/T	cg26211634	chr5:139558579	C5orf32	0.44	8.22	0.41	4.71e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg01620082	chr3:125678407	NA	-0.82	-7.24	-0.37	3.06e-12	Breast cancer;
LUSC	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg05519781	chr21:40033154	ERG	0.77	13.35	0.59	7.23e-33	Coronary artery disease;
LUSC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg03929089	chr4:120376271	NA	-0.44	-6.11	-0.32	2.7e-9	HDL cholesterol;
LUSC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.5	0.56	1.1e-29	Motion sickness;
LUSC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.65	-0.47	1.36e-19	Mood instability;
LUSC	cis	rs12220238	1.000	rs7081350	chr10:75990328	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.79	0.35	5.26e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.55	-8.63	-0.43	2.49e-16	Personality dimensions;
LUSC	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg25575065	chr22:51066394	ARSA	-0.44	-6.07	-0.32	3.56e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg05347473	chr6:146136440	FBXO30	0.48	8.2	0.41	5.16e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8099014	0.814	rs9966765	chr18:56116790	C/G	cg12907477	chr18:56117327	MIR122	0.43	6.67	0.34	1.05e-10	Platelet count;
LUSC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg27170947	chr2:26402098	FAM59B	-0.69	-10.39	-0.49	4.13e-22	Gut microbiome composition (summer);
LUSC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06850241	chr22:41845214	NA	0.34	6.3	0.33	9.47e-10	Vitiligo;
LUSC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg21972741	chr5:435613	AHRR	0.37	6.99	0.36	1.47e-11	Cystic fibrosis severity;
LUSC	trans	rs3960554	0.932	rs11971220	chr7:75842792	C/T	cg19862616	chr7:65841803	NCRNA00174	0.89	9.56	0.46	2.71e-19	Eotaxin levels;
LUSC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg00343986	chr7:65444356	GUSB	-0.38	-5.73	-0.3	2.29e-8	Aortic root size;
LUSC	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg17173187	chr15:85201210	NMB	0.48	8.9	0.44	3.51e-17	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25444017	chr11:93475004	TAF1D;C11orf54	0.42	6.33	0.33	7.71e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg24006582	chr15:45444508	DUOX1	0.66	9.55	0.46	2.95e-19	Uric acid levels;
LUSC	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-7.12	-0.36	6.71e-12	Axial length;
LUSC	cis	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg06521331	chr12:34319734	NA	-0.49	-8.19	-0.41	5.73e-15	Morning vs. evening chronotype;
LUSC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg16339924	chr4:17578868	LAP3	0.71	11.34	0.53	2.02e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.39	-0.38	1.15e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg20503657	chr10:835505	NA	0.57	6.77	0.35	5.64e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg08807101	chr21:30365312	RNF160	0.51	6.64	0.34	1.25e-10	Cognitive test performance;
LUSC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.67	0.39	1.9e-13	Parkinson's disease;
LUSC	cis	rs10193935	0.901	rs6752455	chr2:42543577	A/C	cg27598129	chr2:42591480	NA	-0.61	-8.52	-0.42	5.73e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-7.08	-0.36	8.33e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.79	-0.39	8.44e-14	Type 2 diabetes;
LUSC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	6.65	0.34	1.22e-10	Obesity-related traits;
LUSC	cis	rs896543	0.702	rs6711119	chr2:237494334	C/T	cg25295825	chr2:237489920	CXCR7	0.52	6.36	0.33	6.67e-10	Alcohol dependence (age at onset);
LUSC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.77	7.65	0.39	2.1e-13	Initial pursuit acceleration;
LUSC	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.15	0.32	2.21e-9	Corneal astigmatism;
LUSC	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg17764715	chr19:33622953	WDR88	0.6	8.23	0.41	4.15e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.76	13.05	0.58	9.97e-32	Monocyte count;
LUSC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg17948913	chr5:572064	NA	0.38	6.29	0.33	9.68e-10	Obesity-related traits;
LUSC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg05347473	chr6:146136440	FBXO30	-0.47	-7.97	-0.4	2.54e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg06636001	chr8:8085503	FLJ10661	0.67	10.87	0.51	8.91e-24	Neuroticism;
LUSC	trans	rs4596713	0.568	rs7038833	chr9:71748097	C/T	cg25283916	chr1:242222868	NA	-0.32	-6.71	-0.34	8.25e-11	Headache;
LUSC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg13395646	chr4:1353034	KIAA1530	-0.59	-9.19	-0.45	4.14e-18	Obesity-related traits;
LUSC	cis	rs6692729	0.933	rs2855560	chr1:227081028	A/C	cg10327440	chr1:227177885	CDC42BPA	-0.5	-7.09	-0.36	7.94e-12	Electrodermal activity;
LUSC	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg19784903	chr17:45786737	TBKBP1	0.37	5.7	0.3	2.6e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg17127132	chr2:85788382	GGCX	0.43	6.21	0.32	1.56e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg25703541	chr22:24373054	LOC391322	-0.62	-7.82	-0.39	6.84e-14	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs4631830	0.863	rs2611489	chr10:51524889	C/T	cg16070123	chr10:51489643	NA	-0.52	-8.4	-0.42	1.27e-15	Prostate-specific antigen levels;
LUSC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-8.87	-0.44	4.58e-17	Obesity-related traits;
LUSC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.69	11.46	0.53	7.01e-26	Heart rate;
LUSC	trans	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg06606381	chr12:133084897	FBRSL1	0.57	6.49	0.33	3.17e-10	Depression;
LUSC	trans	rs61931739	0.591	rs10743834	chr12:33916129	A/C	cg26384229	chr12:38710491	ALG10B	0.52	7.77	0.39	9.66e-14	Morning vs. evening chronotype;
LUSC	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-7.03	-0.36	1.19e-11	Monocyte percentage of white cells;
LUSC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.74	-0.51	2.59e-23	Chronic sinus infection;
LUSC	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.28	0.53	3.13e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg23262073	chr20:60523788	NA	-0.44	-6.23	-0.32	1.4e-9	Body mass index;
LUSC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08439880	chr3:133502540	NA	0.35	6.46	0.33	3.61e-10	Iron status biomarkers;
LUSC	trans	rs61931739	0.621	rs843785	chr12:33729308	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-6.06	-0.31	3.59e-9	Morning vs. evening chronotype;
LUSC	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg15309053	chr8:964076	NA	0.4	8.11	0.41	9.83e-15	Schizophrenia;
LUSC	cis	rs865483	0.895	rs6607275	chr17:35833208	T/C	cg06716730	chr17:35851459	DUSP14	0.28	6.18	0.32	1.91e-9	Monocyte count;
LUSC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg03806693	chr22:41940476	POLR3H	1.01	13.99	0.61	2.56e-35	Cannabis dependence symptom count;
LUSC	cis	rs9322817	0.691	rs4946648	chr6:105329422	G/T	cg02098413	chr6:105308735	HACE1	0.27	5.8	0.3	1.52e-8	Thyroid stimulating hormone;
LUSC	cis	rs926938	0.560	rs360610	chr1:115393915	T/C	cg12756093	chr1:115239321	AMPD1	0.53	8.12	0.41	9.04e-15	Autism;
LUSC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg21238619	chr17:78079768	GAA	-0.38	-7.39	-0.37	1.21e-12	Yeast infection;
LUSC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg16624210	chr5:671434	TPPP	0.45	6.09	0.32	3.17e-9	Obesity-related traits;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg03172651	chr20:13201655	ISM1	0.4	6.21	0.32	1.55e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg05623727	chr3:50126028	RBM5	-0.32	-5.98	-0.31	5.87e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10754283	0.967	rs1953821	chr1:90107098	C/G	cg21401794	chr1:90099060	LRRC8C	0.63	8.91	0.44	3.47e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11645453	chr3:52864694	ITIH4	0.34	8.09	0.4	1.13e-14	Bipolar disorder;
LUSC	trans	rs1922233	1.000	rs6851215	chr4:92377632	T/C	cg24250684	chr1:219729030	NA	-0.34	-6.26	-0.32	1.19e-9	Gut microbiome composition (summer and winter);
LUSC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.56	11.98	0.55	9.47e-28	Hemoglobin concentration;
LUSC	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.97	-0.36	1.71e-11	Blood metabolite levels;
LUSC	cis	rs12618769	0.625	rs17034241	chr2:99224998	C/G	cg10123293	chr2:99228465	UNC50	0.47	7.71	0.39	1.48e-13	Bipolar disorder;
LUSC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg26338869	chr17:61819248	STRADA	0.41	5.94	0.31	7.15e-9	Prudent dietary pattern;
LUSC	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg24642439	chr20:33292090	TP53INP2	0.47	7.17	0.37	4.84e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.5	8.06	0.4	1.37e-14	Schizophrenia;
LUSC	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg04369109	chr6:150039330	LATS1	-0.4	-5.78	-0.3	1.67e-8	Testicular germ cell tumor;
LUSC	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg20019720	chr6:154832845	CNKSR3	0.63	8.79	0.43	8.09e-17	Lipoprotein (a) levels;
LUSC	trans	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg27661571	chr11:113659931	NA	-0.56	-6.61	-0.34	1.52e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs9944715	1.000	rs8099202	chr18:43834634	G/T	cg01718231	chr17:29326311	RNF135	0.52	7.44	0.38	8.81e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.61	-0.43	2.92e-16	Retinal vascular caliber;
LUSC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg01879757	chr17:41196368	BRCA1	-0.39	-5.96	-0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25072359	chr17:41440525	NA	0.69	9.65	0.47	1.36e-19	Menopause (age at onset);
LUSC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg25258033	chr6:167368657	RNASET2	0.39	6.3	0.33	9.49e-10	Crohn's disease;
LUSC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.57	-0.46	2.49e-19	Type 2 diabetes;
LUSC	cis	rs1784581	0.599	rs1789992	chr6:162401854	A/G	cg17173639	chr6:162384350	PARK2	-0.66	-11.67	-0.54	1.25e-26	Itch intensity from mosquito bite;
LUSC	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg04613313	chr13:79183823	NA	0.42	6.2	0.32	1.7e-9	Large artery stroke;
LUSC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg13319975	chr6:146136371	FBXO30	-0.53	-7.94	-0.4	3.06e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg16624210	chr5:671434	TPPP	0.5	6.38	0.33	6.07e-10	Obesity-related traits;
LUSC	cis	rs75229567	0.618	rs11177819	chr12:70134836	T/G	cg10114359	chr12:70132523	RAB3IP	1.28	11.11	0.52	1.31e-24	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.73	0.35	7.6e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05025164	chr4:1340916	KIAA1530	-0.63	-9.89	-0.48	2.2e-20	Obesity-related traits;
LUSC	trans	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg19676328	chr12:49525230	TUBA1B	-0.51	-7.94	-0.4	3.02e-14	Total cholesterol levels;
LUSC	trans	rs2587949	0.615	rs1385487	chr3:4228738	G/A	cg15139668	chr4:4577005	NA	-0.41	-5.96	-0.31	6.47e-9	Periodontitis (DPAL);
LUSC	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg03676636	chr4:99064102	C4orf37	0.33	7.31	0.37	2e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg16325326	chr1:53192061	ZYG11B	-0.7	-10.86	-0.51	1.01e-23	Monocyte count;
LUSC	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg20026190	chr17:76395443	PGS1	0.46	8.2	0.41	5.28e-15	HDL cholesterol levels;
LUSC	cis	rs1832871	0.711	rs7747669	chr6:158664345	A/G	cg07165851	chr6:158734300	TULP4	0.5	7.61	0.38	2.81e-13	Height;
LUSC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.24	0.59	1.94e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg06212747	chr3:49208901	KLHDC8B	0.44	5.94	0.31	7.24e-9	Parkinson's disease;
LUSC	trans	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg07393940	chr7:158741817	NA	0.37	6.78	0.35	5.58e-11	Life satisfaction;
LUSC	trans	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg24675658	chr1:53192096	ZYG11B	0.58	9.11	0.45	7.72e-18	Monocyte count;
LUSC	cis	rs7536201	1.000	rs10794667	chr1:25304552	C/T	cg23273869	chr1:25296894	NA	-0.28	-6.23	-0.32	1.43e-9	Psoriasis vulgaris;
LUSC	trans	rs4468007	0.553	rs4307413	chr9:124576430	A/G	cg21642649	chr21:34144118	C21orf66;C21orf49	0.41	5.97	0.31	5.9e-9	Educational attainment;
LUSC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg11812906	chr14:75593930	NEK9	-0.63	-10.34	-0.49	6.12e-22	Height;
LUSC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06544989	chr22:39130855	UNC84B	0.34	5.8	0.3	1.53e-8	Menopause (age at onset);
LUSC	cis	rs4601821	0.823	rs4938013	chr11:113264470	A/C	cg14159747	chr11:113255604	NA	0.26	6.17	0.32	2e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.47e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg18512352	chr11:47633146	NA	-0.46	-9.23	-0.45	3.25e-18	Subjective well-being;
LUSC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg01879757	chr17:41196368	BRCA1	-0.47	-7.16	-0.36	5.11e-12	Menopause (age at onset);
LUSC	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg19792802	chr11:65647270	CTSW	-0.41	-6.31	-0.33	8.84e-10	Crohn's disease;
LUSC	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs890448	0.796	rs2114365	chr4:102345646	G/A	cg05120309	chr14:100485494	NA	-0.37	-6.1	-0.32	2.97e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs3755132	0.929	rs4668948	chr2:15771586	A/C	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg26384229	chr12:38710491	ALG10B	0.7	11.03	0.52	2.5e-24	Morning vs. evening chronotype;
LUSC	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-6.7	-0.34	8.78e-11	Mean platelet volume;
LUSC	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg00745463	chr17:30367425	LRRC37B	0.63	7.52	0.38	5e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	6.95	0.36	1.91e-11	Response to antipsychotic treatment;
LUSC	cis	rs55871839	0.708	rs12114218	chr8:59817454	T/C	cg07426533	chr8:59803705	TOX	-0.36	-5.76	-0.3	1.91e-8	Pneumonia;
LUSC	cis	rs9399401	0.845	rs155259	chr6:142846565	G/A	cg03128060	chr6:142623767	GPR126	0.3	5.7	0.3	2.7e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg17328964	chr8:145687451	CYHR1	-0.68	-11.75	-0.54	6.65e-27	Age at first birth;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg25253773	chr2:74942436	NA	0.39	6.13	0.32	2.53e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs10416265	0.516	rs1270252	chr19:33623604	G/A	cg17764715	chr19:33622953	WDR88	-0.58	-6.4	-0.33	5.23e-10	Bone properties (heel);
LUSC	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg12292205	chr6:26970375	C6orf41	-0.39	-5.73	-0.3	2.26e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8102476	0.743	rs8100395	chr19:38747117	A/G	cg14131526	chr19:38747285	PPP1R14A	-0.34	-5.98	-0.31	5.75e-9	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.34	-0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.4	0.38	1.11e-12	Lung cancer in ever smokers;
LUSC	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06022373	chr22:39101656	GTPBP1	0.82	13.39	0.59	5.21e-33	Menopause (age at onset);
LUSC	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs4964805	0.559	rs1469999	chr12:104208111	A/G	cg02344784	chr12:104178138	NT5DC3	-0.44	-6.52	-0.34	2.66e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-6.3	-0.33	9.22e-10	Morning vs. evening chronotype;
LUSC	cis	rs11645898	0.748	rs72791112	chr16:72204069	T/A	cg14768367	chr16:72042858	DHODH	-0.63	-6.92	-0.35	2.31e-11	Blood protein levels;
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg00106254	chr7:1943704	MAD1L1	-0.4	-5.91	-0.31	8.29e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.6	0.38	3.12e-13	Electroencephalogram traits;
LUSC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	0.8	14.1	0.61	9.16e-36	Cognitive function;
LUSC	cis	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg17325771	chr7:75508891	RHBDD2	-0.41	-6.06	-0.31	3.73e-9	Eotaxin levels;
LUSC	cis	rs2274459	0.841	rs12205398	chr6:33701543	C/T	cg06253072	chr6:33679850	C6orf125	0.5	5.92	0.31	7.8e-9	Obesity (extreme);
LUSC	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg01884057	chr2:25150051	NA	-0.38	-8.49	-0.42	7.11e-16	Body mass index in non-asthmatics;
LUSC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.7	9.84	0.47	3.09e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.72	12.97	0.58	1.89e-31	Prudent dietary pattern;
LUSC	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Bladder cancer;
LUSC	cis	rs6500395	1.000	rs4517800	chr16:48677404	T/A	cg04672837	chr16:48644449	N4BP1	0.45	6.8	0.35	4.86e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2708377	0.929	rs61931269	chr12:11296418	C/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg05623727	chr3:50126028	RBM5	0.31	5.7	0.3	2.61e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs710216	0.912	rs11537640	chr1:43424519	T/G	cg03128534	chr1:43423976	SLC2A1	0.45	5.79	0.3	1.67e-8	Red cell distribution width;
LUSC	trans	rs8030485	0.571	rs1402760	chr15:79439159	G/A	cg16586880	chr8:140854244	TRAPPC9	-0.39	-6.36	-0.33	6.68e-10	Left ventricle wall thickness;
LUSC	cis	rs354225	0.544	rs10205410	chr2:54799599	G/T	cg26097391	chr2:54893211	SPTBN1	0.45	6.49	0.33	3.02e-10	Schizophrenia;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg03776034	chr3:154042375	DHX36	0.32	6.02	0.31	4.69e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.28	-0.45	2.27e-18	Gut microbiome composition (summer);
LUSC	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg23093090	chr10:104574429	C10orf26	-0.46	-5.73	-0.3	2.22e-8	Arsenic metabolism;
LUSC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.9	0.31	9.03e-9	Menopause (age at onset);
LUSC	cis	rs1322512	0.917	rs2057399	chr6:152950053	C/T	cg27316956	chr6:152958899	SYNE1	-0.36	-6.11	-0.32	2.72e-9	Tonometry;
LUSC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg11764359	chr7:65958608	NA	0.4	5.67	0.3	3.03e-8	Calcium levels;
LUSC	cis	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg06521331	chr12:34319734	NA	0.39	6.05	0.31	3.84e-9	Morning vs. evening chronotype;
LUSC	cis	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg09307838	chr4:120376055	NA	-0.41	-6.32	-0.33	8.26e-10	Diastolic blood pressure;
LUSC	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.82	0.35	4.2e-11	IgG glycosylation;
LUSC	cis	rs8067545	0.750	rs34290687	chr17:19991211	G/A	cg13482628	chr17:19912719	NA	0.46	7.57	0.38	3.79e-13	Schizophrenia;
LUSC	cis	rs2413583	0.591	rs17000979	chr22:39700758	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.64	6.32	0.33	8.23e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6005807	0.719	rs12165715	chr22:29005595	T/C	cg12565055	chr22:29076175	TTC28	0.54	5.79	0.3	1.62e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs12220238	1.000	rs7897778	chr10:75916105	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.57	6.78	0.35	5.33e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.54	-0.38	4.58e-13	Response to antipsychotic treatment;
LUSC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg07217954	chr7:1067459	C7orf50	0.54	5.85	0.3	1.17e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.53	-8.82	-0.43	6.41e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg06640241	chr16:89574553	SPG7	0.91	16.62	0.67	1.26e-45	Multiple myeloma (IgH translocation);
LUSC	cis	rs6138458	0.701	rs6138474	chr20:25012427	T/A	cg26195577	chr20:24973756	C20orf3	0.71	10.8	0.51	1.62e-23	Blood protein levels;
LUSC	cis	rs920590	0.560	rs7823457	chr8:19671334	G/A	cg03894339	chr8:19674705	INTS10	-0.46	-6.53	-0.34	2.52e-10	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg17173187	chr15:85201210	NMB	0.36	6.41	0.33	5.06e-10	Schizophrenia;
LUSC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg00012203	chr2:219082015	ARPC2	0.87	16.56	0.67	2.26e-45	Colorectal cancer;
LUSC	cis	rs1144713	0.600	rs2683489	chr12:32251181	A/G	cg01321189	chr12:32259338	BICD1	0.41	6.99	0.36	1.51e-11	Obesity-related traits;
LUSC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.67	11.93	0.55	1.38e-27	Aortic root size;
LUSC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.23	0.32	1.37e-9	Menopause (age at onset);
LUSC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.86	0.31	1.11e-8	Menopause (age at onset);
LUSC	trans	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg19894588	chr14:64061835	NA	0.54	7.68	0.39	1.75e-13	Glioblastoma;Glioma;
LUSC	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.88	-0.4	4.56e-14	Neuroticism;
LUSC	trans	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg10756647	chr7:56101905	PSPH	0.89	9.05	0.44	1.19e-17	Diabetic kidney disease;
LUSC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg27068330	chr11:65405492	SIPA1	-0.44	-5.73	-0.3	2.28e-8	Breast cancer;
LUSC	cis	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg09307838	chr4:120376055	NA	-0.48	-7.34	-0.37	1.62e-12	Diastolic blood pressure;
LUSC	cis	rs17818399	0.597	rs12104572	chr2:46862466	C/G	cg21493583	chr2:46842958	PIGF;CRIPT	0.31	5.67	0.3	3.11e-8	Height;
LUSC	cis	rs2370759	0.891	rs77706860	chr10:32628537	C/T	cg01819863	chr10:32635814	EPC1	1.06	10.88	0.51	8.44e-24	Sexual dysfunction (female);
LUSC	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	7.29	0.37	2.25e-12	Schizophrenia;
LUSC	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg11161011	chr14:65562177	MAX	-0.72	-11.07	-0.52	1.85e-24	Obesity-related traits;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07805240	chr7:8008383	GLCCI1	-0.52	-6.43	-0.33	4.5e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg24450063	chr1:156163899	SLC25A44	1.09	20.87	0.75	1.69e-62	Intracerebral hemorrhage;White matter hyperintensity burden;
LUSC	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg16434002	chr17:42200994	HDAC5	-0.45	-6.39	-0.33	5.66e-10	Total body bone mineral density;
LUSC	cis	rs7246967	0.673	rs2915932	chr19:22843701	C/T	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg22823121	chr1:150693482	HORMAD1	0.51	7.44	0.38	8.39e-13	Melanoma;
LUSC	cis	rs13418410	0.539	rs11695597	chr2:33840024	A/G	cg04131969	chr2:33951647	MYADML	0.73	10.88	0.51	8.35e-24	Non-response to antidepressants and depression;
LUSC	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg09904177	chr6:26538194	HMGN4	0.71	6.89	0.35	2.78e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4901869	0.966	rs4901870	chr14:59334221	A/T	cg02291164	chr14:59296302	NA	-0.58	-11.28	-0.53	3.17e-25	Panic disorder;
LUSC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs4986172	0.539	rs3744760	chr17:43195981	C/T	cg10701640	chr17:43249399	NA	-0.29	-5.95	-0.31	6.69e-9	Height;
LUSC	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	1.11	19.36	0.73	1.65e-56	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg12856521	chr11:46389249	DGKZ	0.41	6.33	0.33	8.12e-10	Leprosy;
LUSC	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg12823233	chr7:2316876	SNX8	-0.35	-5.97	-0.31	6.01e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs6942756	1.000	rs67820265	chr7:128887925	A/G	cg02491457	chr7:128862824	NA	-0.52	-7.39	-0.38	1.15e-12	White matter hyperintensity burden;
LUSC	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.78	0.35	5.37e-11	Rheumatoid arthritis;
LUSC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg07936489	chr17:37558343	FBXL20	-0.72	-9.84	-0.47	3.07e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs7074356	0.915	rs17680103	chr10:82207618	T/C	cg00277334	chr10:82204260	NA	0.66	6.26	0.32	1.19e-9	Borderline personality disorder;
LUSC	cis	rs2274273	0.712	rs7144652	chr14:55537718	G/A	cg04306507	chr14:55594613	LGALS3	0.49	10.67	0.5	4.55e-23	Protein biomarker;
LUSC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg19230755	chr7:65878503	NA	-0.43	-6.0	-0.31	5.04e-9	Aortic root size;
LUSC	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg20744362	chr22:50050164	C22orf34	0.36	6.64	0.34	1.29e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs656319	0.625	rs34427895	chr8:9875221	G/C	cg21775007	chr8:11205619	TDH	-0.47	-6.53	-0.34	2.44e-10	Myopia (pathological);
LUSC	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.67	-0.34	1.08e-10	Monocyte percentage of white cells;
LUSC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18404041	chr3:52824283	ITIH1	-0.52	-9.81	-0.47	4.05e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs6714710	0.603	rs34373359	chr2:98442202	G/A	cg26665480	chr2:98280029	ACTR1B	0.63	9.43	0.46	7.27e-19	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.09	0.4	1.08e-14	Homoarginine levels;
LUSC	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	8.03	0.4	1.68e-14	Iron status biomarkers;
LUSC	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.02e-14	Corneal astigmatism;
LUSC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.55	7.2	0.37	4.06e-12	Multiple sclerosis;
LUSC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg22166914	chr1:53195759	ZYG11B	0.69	12.52	0.57	9.17e-30	Monocyte count;
LUSC	cis	rs10266483	0.774	rs1404678	chr7:63802516	A/G	cg24201672	chr7:64023550	ZNF680	0.44	5.8	0.3	1.53e-8	Response to statin therapy;
LUSC	cis	rs12912251	0.947	rs7177621	chr15:38999394	C/G	cg01338139	chr15:38987640	C15orf53	-0.45	-6.27	-0.32	1.09e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg07741184	chr6:167504864	NA	0.38	6.95	0.36	1.98e-11	Crohn's disease;
LUSC	cis	rs3736594	0.513	rs62131881	chr2:27764781	G/T	cg27432699	chr2:27873401	GPN1	0.67	8.86	0.44	4.69e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	trans	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg10756647	chr7:56101905	PSPH	0.87	8.88	0.44	4.33e-17	Diabetic kidney disease;
LUSC	cis	rs11051970	0.566	rs2651372	chr12:32583199	A/G	cg02745156	chr12:32552066	NA	0.36	6.51	0.34	2.71e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg12935359	chr14:103987150	CKB	-0.54	-8.48	-0.42	7.37e-16	Body mass index;
LUSC	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg00376283	chr12:123451042	ABCB9	-0.65	-7.42	-0.38	9.57e-13	Neutrophil percentage of white cells;
LUSC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg16482183	chr6:26056742	HIST1H1C	0.55	8.12	0.41	9.06e-15	Height;
LUSC	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg04539111	chr16:67997858	SLC12A4	-0.47	-6.3	-0.33	9.58e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.82	-13.77	-0.6	1.83e-34	Morning vs. evening chronotype;
LUSC	cis	rs17253792	0.822	rs74720318	chr14:56099828	G/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.29e-10	Putamen volume;
LUSC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08048268	chr3:133502702	NA	-0.5	-9.91	-0.48	1.87e-20	Iron status biomarkers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14089512	chr10:102106757	SCD	-0.47	-6.15	-0.32	2.23e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9650657	0.615	rs6601534	chr8:10691993	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.01	-0.31	4.73e-9	Neuroticism;
LUSC	cis	rs12541635	0.966	rs2132471	chr8:107000963	G/A	cg10147462	chr8:107024639	NA	0.55	9.96	0.48	1.27e-20	Age of smoking initiation;
LUSC	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg09904177	chr6:26538194	HMGN4	-0.54	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg23093090	chr10:104574429	C10orf26	-0.43	-7.62	-0.38	2.72e-13	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg24733560	chr20:60626293	TAF4	0.35	5.81	0.3	1.47e-8	Body mass index;
LUSC	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.6	-0.54	2.32e-26	Mean corpuscular volume;
LUSC	cis	rs1044826	0.597	rs6803593	chr3:139193987	T/C	cg00490450	chr3:139108681	COPB2	0.46	6.96	0.36	1.79e-11	Obesity-related traits;
LUSC	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg21856205	chr7:94953877	PON1	-0.36	-5.76	-0.3	1.95e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg05776053	chr2:74358815	NA	0.4	6.07	0.32	3.47e-9	Gestational age at birth (maternal effect);
LUSC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22496380	chr5:211416	CCDC127	0.81	9.45	0.46	6.34e-19	Breast cancer;
LUSC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg00033643	chr7:134001901	SLC35B4	0.47	7.28	0.37	2.41e-12	Mean platelet volume;
LUSC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg19592336	chr6:28129416	ZNF389	-0.49	-6.47	-0.33	3.44e-10	Depression;
LUSC	trans	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg13010199	chr12:38710504	ALG10B	0.51	7.06	0.36	9.47e-12	Resting heart rate;
LUSC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg26441486	chr22:50317300	CRELD2	0.48	7.1	0.36	7.5e-12	Schizophrenia;
LUSC	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.96	-0.36	1.77e-11	Retinal vascular caliber;
LUSC	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.7	-11.2	-0.52	6.4e-25	Inhibitory control;
LUSC	trans	rs4811340	0.600	rs2869657	chr20:51190821	A/G	cg15736553	chr3:11610338	VGLL4	-0.33	-5.99	-0.31	5.4e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg20848291	chr7:100343083	ZAN	-0.68	-9.32	-0.45	1.68e-18	Other erythrocyte phenotypes;
LUSC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg17264618	chr3:40429014	ENTPD3	-0.36	-7.32	-0.37	1.9e-12	Renal cell carcinoma;
LUSC	cis	rs1904096	0.506	rs10028613	chr4:95223698	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-6.99	-0.36	1.48e-11	Type 2 diabetes;
LUSC	trans	rs13424581	1.000	rs11903344	chr2:225733342	G/T	cg25639566	chr4:40539823	RBM47	-0.68	-6.03	-0.31	4.4e-9	Platelet distribution width;
LUSC	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg04374321	chr14:90722782	PSMC1	0.72	11.47	0.53	6.92e-26	Mortality in heart failure;
LUSC	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.27	-0.41	3.18e-15	Body mass index;
LUSC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg25036284	chr2:26402008	FAM59B	-0.73	-10.66	-0.5	4.85e-23	Gut microbiome composition (summer);
LUSC	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	5.8	0.3	1.5e-8	Response to antipsychotic treatment;
LUSC	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	0.87	13.35	0.59	7.36e-33	Pulmonary function decline;
LUSC	cis	rs950881	0.808	rs72823677	chr2:102997051	C/T	cg20060108	chr2:102954350	IL1RL1	0.47	5.71	0.3	2.53e-8	Allergy;
LUSC	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg17173187	chr15:85201210	NMB	0.44	8.03	0.4	1.68e-14	Schizophrenia;
LUSC	cis	rs231513	0.954	rs231514	chr17:41964516	C/T	cg26893861	chr17:41843967	DUSP3	-0.55	-6.18	-0.32	1.82e-9	Cognitive function;
LUSC	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	7.38	0.37	1.23e-12	Height;
LUSC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg17279839	chr7:150038598	RARRES2	0.44	6.96	0.36	1.78e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg18477163	chr1:228402036	OBSCN	0.52	8.97	0.44	2.17e-17	Diastolic blood pressure;
LUSC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.92	0.44	3.02e-17	Motion sickness;
LUSC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg01416388	chr22:39784598	NA	0.44	7.3	0.37	2.08e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg27129171	chr3:47204927	SETD2	-0.5	-7.38	-0.37	1.23e-12	Birth weight;
LUSC	cis	rs193541	0.632	rs152038	chr5:122195846	G/A	cg19077854	chr5:122220652	SNX24	0.37	7.69	0.39	1.63e-13	Glucose homeostasis traits;
LUSC	trans	rs10946292	0.706	rs11754516	chr6:170434459	T/C	cg17832364	chr10:94847294	NA	0.38	6.26	0.32	1.17e-9	Obesity-related traits;
LUSC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg22875332	chr1:76189707	ACADM	0.77	10.36	0.49	5.22e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg04691961	chr3:161091175	C3orf57	-0.35	-5.99	-0.31	5.34e-9	Morning vs. evening chronotype;
LUSC	cis	rs9311676	0.656	rs11917529	chr3:58382158	C/T	cg13750441	chr3:58318267	PXK	0.34	6.66	0.34	1.15e-10	Systemic lupus erythematosus;
LUSC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.39	-7.63	-0.39	2.46e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg25174290	chr11:3078921	CARS	0.62	9.89	0.48	2.14e-20	Longevity;
LUSC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg01657329	chr11:68192670	LRP5	-0.44	-6.54	-0.34	2.35e-10	Total body bone mineral density;
LUSC	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-9.48	-0.46	4.97e-19	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7091068	0.566	rs7082701	chr10:95501042	G/T	cg20715218	chr10:95462985	C10orf4	0.61	6.54	0.34	2.31e-10	Urinary tract infection frequency;
LUSC	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.86	-0.4	5.45e-14	Neuroticism;
LUSC	cis	rs7188861	0.681	rs9932855	chr16:11406544	G/C	cg00044050	chr16:11439710	C16orf75	0.55	5.65	0.3	3.35e-8	HDL cholesterol;
LUSC	cis	rs73206853	0.764	rs7960988	chr12:110749918	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7106204	0.514	rs2099889	chr11:24255971	A/G	ch.11.24196551F	chr11:24239977	NA	0.93	10.34	0.49	6.32e-22	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7599312	0.532	rs1531788	chr2:213394320	C/T	cg16329650	chr2:213403929	ERBB4	0.47	7.09	0.36	8.24e-12	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	9.07	0.44	1.01e-17	Iron status biomarkers;
LUSC	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.8	-14.87	-0.63	9.73e-39	Obesity-related traits;
LUSC	cis	rs9309473	1.000	rs11899740	chr2:73631212	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-6.91	-0.35	2.44e-11	Metabolite levels;
LUSC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	6.45	0.33	3.87e-10	Electroencephalogram traits;
LUSC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg25019033	chr10:957182	NA	-0.49	-6.37	-0.33	6.38e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs6681460	0.932	rs492109	chr1:67187133	C/A	cg02459107	chr1:67143332	SGIP1	-0.46	-8.53	-0.42	5.01e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs713477	0.967	rs4243600	chr14:55910679	A/G	cg13175173	chr14:55914753	NA	-0.32	-6.74	-0.35	7.01e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08859206	chr1:53392774	SCP2	-0.55	-9.55	-0.46	2.86e-19	Monocyte count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17864206	chr1:43855683	C1orf84;MED8	-0.49	-5.98	-0.31	5.63e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs67366981	1.000	rs425310	chr14:77711497	C/T	cg22824376	chr14:77648248	TMEM63C	0.65	6.42	0.33	4.57e-10	Obsessive-compulsive symptoms;
LUSC	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	8.21	0.41	4.76e-15	Coffee consumption (cups per day);
LUSC	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg13647721	chr17:30228624	UTP6	0.63	6.22	0.32	1.49e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg00730023	chr19:17420725	DDA1	0.75	6.26	0.32	1.15e-9	Cognitive performance;
LUSC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.12	0.41	9.34e-15	Lung cancer;
LUSC	cis	rs10887741	0.646	rs2077773	chr10:89435501	G/A	cg13926569	chr10:89418898	PAPSS2	0.32	6.86	0.35	3.27e-11	Exercise (leisure time);
LUSC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.89	17.01	0.68	3.67e-47	Colorectal cancer;
LUSC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.33	0.53	2.21e-25	Menopause (age at onset);
LUSC	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg26102564	chr10:131424627	MGMT	0.42	6.56	0.34	2.1e-10	Response to temozolomide;
LUSC	cis	rs2857891	0.659	rs2638110	chr11:6993922	C/T	cg04053776	chr11:6947353	ZNF215	0.43	6.21	0.32	1.57e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18082322	chr5:148725041	GRPEL2	0.76	6.17	0.32	1.92e-9	Cognitive performance;
LUSC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-1.05	-15.46	-0.65	4.78e-41	Initial pursuit acceleration;
LUSC	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg12552261	chr5:112820674	MCC	0.44	7.11	0.36	7.19e-12	Type 2 diabetes;
LUSC	cis	rs1957429	0.808	rs7149922	chr14:65334541	C/T	cg23373153	chr14:65346875	NA	0.97	11.0	0.52	3.19e-24	Pediatric areal bone mineral density (radius);
LUSC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.38	7.74	0.39	1.23e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs75804782	0.521	rs56121087	chr2:239435766	A/G	cg18131467	chr2:239335373	ASB1	-0.67	-6.01	-0.31	4.73e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg23711669	chr6:146136114	FBXO30	0.91	17.7	0.7	6.39e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg13319975	chr6:146136371	FBXO30	0.47	7.24	0.37	3.19e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.96	0.36	1.86e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	5.78	0.3	1.75e-8	Schizophrenia;
LUSC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg13047869	chr3:10149882	C3orf24	0.66	8.9	0.44	3.62e-17	Alzheimer's disease;
LUSC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg25036284	chr2:26402008	FAM59B	-0.77	-11.38	-0.53	1.46e-25	Gut microbiome composition (summer);
LUSC	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg19682013	chr15:45996608	NA	0.38	5.88	0.31	1.02e-8	Waist circumference;Weight;
LUSC	cis	rs7215564	0.908	rs4889879	chr17:78662573	A/T	cg09596252	chr17:78655493	RPTOR	-0.57	-6.57	-0.34	1.88e-10	Myopia (pathological);
LUSC	trans	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg10756647	chr7:56101905	PSPH	0.85	8.47	0.42	7.94e-16	Gout;
LUSC	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg22431228	chr1:16359049	CLCNKA	0.33	6.19	0.32	1.74e-9	Dilated cardiomyopathy;
LUSC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg21132104	chr15:45694354	SPATA5L1	0.42	6.13	0.32	2.45e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg03146154	chr1:46216737	IPP	0.5	7.51	0.38	5.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9463078	0.764	rs2396370	chr6:44946472	A/G	cg25276700	chr6:44698697	NA	-0.29	-5.86	-0.31	1.11e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs793571	0.502	rs421829	chr15:59079902	G/C	cg05156742	chr15:59063176	FAM63B	0.55	8.79	0.43	8e-17	Schizophrenia;
LUSC	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg14004847	chr7:1930337	MAD1L1	0.56	8.66	0.43	2.04e-16	Schizophrenia;
LUSC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.88	-0.31	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg22467129	chr15:76604101	ETFA	-0.51	-8.26	-0.41	3.38e-15	Blood metabolite levels;
LUSC	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.74	0.68	4.02e-46	Exhaled nitric oxide output;
LUSC	trans	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.25	-0.32	1.25e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.57	-0.46	2.49e-19	Joint mobility (Beighton score);
LUSC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.11	-0.32	2.71e-9	Initial pursuit acceleration;
LUSC	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg17294928	chr15:75287854	SCAMP5	0.65	6.17	0.32	1.96e-9	Lung cancer;
LUSC	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg06784218	chr1:46089804	CCDC17	-0.31	-6.07	-0.32	3.47e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg24687543	chr11:63912206	MACROD1	0.47	5.96	0.31	6.34e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg15445000	chr17:37608096	MED1	-0.39	-6.94	-0.35	2.07e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg12863693	chr15:85201151	NMB	0.35	6.25	0.32	1.25e-9	Schizophrenia;
LUSC	cis	rs4947962	0.585	rs56659219	chr7:55155849	G/T	cg23757825	chr7:55092271	EGFR	-0.46	-5.67	-0.3	3.08e-8	Subjective response to lithium treatment;
LUSC	cis	rs394563	0.601	rs382720	chr6:149795261	C/T	cg11245181	chr6:149772854	ZC3H12D	0.34	6.99	0.36	1.5e-11	Dupuytren's disease;
LUSC	cis	rs9473147	0.516	rs9381575	chr6:47528764	C/G	cg20196966	chr6:47445060	CD2AP	0.41	5.73	0.3	2.24e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	9.46	0.46	5.52e-19	Bipolar disorder;
LUSC	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.28	-0.37	2.48e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs11039100	0.850	rs11039115	chr11:5831379	T/C	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs4720118	1.000	rs758780	chr7:33478460	A/G	cg23247845	chr10:3679085	NA	-0.34	-6.0	-0.31	5.07e-9	Leprosy;
LUSC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg20476274	chr7:133979776	SLC35B4	0.83	14.82	0.63	1.55e-38	Mean platelet volume;
LUSC	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg04851639	chr8:1020857	NA	-0.39	-8.19	-0.41	5.55e-15	Schizophrenia;
LUSC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg26373071	chr5:1325741	CLPTM1L	0.42	7.91	0.4	3.84e-14	Lung cancer;
LUSC	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg13010199	chr12:38710504	ALG10B	0.56	8.45	0.42	9.2e-16	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06634786	chr22:41940651	POLR3H	-0.55	-6.46	-0.33	3.75e-10	Vitiligo;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23961059	chr19:57874869	ZNF547;TRAPPC2P1	0.47	6.45	0.33	3.85e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.42	-5.92	-0.31	8.14e-9	Platelet count;
LUSC	trans	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-12.18	-0.55	1.8e-28	Platelet distribution width;
LUSC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg01416388	chr22:39784598	NA	-0.44	-6.84	-0.35	3.85e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg20701182	chr2:24300061	SF3B14	0.55	5.85	0.3	1.2e-8	Lymphocyte counts;
LUSC	cis	rs11587682	0.714	rs74127616	chr1:150459324	G/A	cg11822372	chr1:151115635	SEMA6C	-0.42	-5.71	-0.3	2.53e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg22563815	chr15:78856949	CHRNA5	0.25	6.24	0.32	1.36e-9	Sudden cardiac arrest;
LUSC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.7	0.51	3.69e-23	Bone mineral density;
LUSC	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg18721089	chr20:30220636	NA	-0.37	-5.75	-0.3	2.05e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs9888739	1.000	rs11860650	chr16:31326706	C/T	cg15817542	chr16:31343056	ITGAM	-0.51	-6.12	-0.32	2.58e-9	Systemic lupus erythematosus;
LUSC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-9.61	-0.47	1.87e-19	Mood instability;
LUSC	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.77	-12.46	-0.56	1.53e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg04455712	chr21:45112962	RRP1B	0.44	8.35	0.42	1.9e-15	Mean corpuscular volume;
LUSC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24838063	chr12:130822603	PIWIL1	0.68	10.69	0.51	3.78e-23	Menopause (age at onset);
LUSC	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg27426351	chr10:43362370	NA	-0.43	-5.92	-0.31	8.17e-9	Blood protein levels;
LUSC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.12e-18	Menopause (age at onset);
LUSC	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg06002616	chr8:101225028	SPAG1	-0.41	-6.93	-0.35	2.21e-11	Atrioventricular conduction;
LUSC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.54	-0.38	4.49e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-6.4	-0.33	5.27e-10	Reticulocyte count;
LUSC	cis	rs7202877	0.561	rs9933956	chr16:75362813	T/C	cg03315344	chr16:75512273	CHST6	0.42	6.14	0.32	2.39e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg04362960	chr10:104952993	NT5C2	0.57	8.97	0.44	2.18e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg24375607	chr4:120327624	NA	0.77	11.32	0.53	2.32e-25	Corneal astigmatism;
LUSC	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	trans	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg01620082	chr3:125678407	NA	-0.54	-6.56	-0.34	2.07e-10	Depression;
LUSC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.65	0.34	1.17e-10	Menopause (age at onset);
LUSC	cis	rs977987	0.843	rs12928036	chr16:75483132	G/A	cg04384234	chr16:75411784	CFDP1	-0.44	-7.34	-0.37	1.6e-12	Dupuytren's disease;
LUSC	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg22705602	chr4:152727874	NA	-0.31	-6.19	-0.32	1.81e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg18357645	chr12:58087776	OS9	-0.53	-7.65	-0.39	2.1e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.43	-6.83	-0.35	4.1e-11	Vitiligo;
LUSC	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg23422044	chr7:1970798	MAD1L1	-0.53	-5.72	-0.3	2.36e-8	Bipolar disorder;
LUSC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.71	11.17	0.52	7.93e-25	Longevity;
LUSC	cis	rs7719624	0.792	rs4976459	chr5:135362573	C/G	cg12897067	chr5:135418308	NA	-0.41	-5.85	-0.3	1.18e-8	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs7246967	0.673	rs62120125	chr19:22955099	T/A	cg23217946	chr19:22817039	ZNF492	0.43	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg20887711	chr4:1340912	KIAA1530	0.7	10.84	0.51	1.2e-23	Longevity;
LUSC	cis	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg25039879	chr17:56429692	SUPT4H1	0.71	9.61	0.47	1.77e-19	Cognitive test performance;
LUSC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.96	-0.4	2.7e-14	Aortic root size;
LUSC	cis	rs3760982	0.845	rs62116962	chr19:44287234	A/G	cg11993925	chr19:44307056	LYPD5	-0.28	-6.25	-0.32	1.25e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	trans	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.37	-0.33	6.25e-10	Monocyte count;
LUSC	cis	rs7911264	0.739	rs6583827	chr10:94358023	A/T	cg25093409	chr10:94429542	NA	0.36	6.21	0.32	1.59e-9	Inflammatory bowel disease;
LUSC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	11.75	0.54	6.64e-27	Personality dimensions;
LUSC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg06784218	chr1:46089804	CCDC17	0.47	9.26	0.45	2.6e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg10857441	chr5:6722123	POLS	-0.45	-8.31	-0.41	2.44e-15	Menopause (age at onset);
LUSC	cis	rs362296	0.661	rs3095077	chr4:3265710	A/G	cg14583973	chr4:3374767	RGS12	0.29	5.66	0.3	3.34e-8	Parental longevity (mother's age at death);
LUSC	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21701354	chr7:129592850	UBE2H	-0.58	-6.88	-0.35	2.96e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	12.44	0.56	1.93e-29	Ileal carcinoids;
LUSC	cis	rs10761482	0.906	rs7093702	chr10:62093709	A/C	cg18175470	chr10:62150864	ANK3	-0.49	-6.95	-0.36	1.98e-11	Schizophrenia;
LUSC	cis	rs10979	0.931	rs12191837	chr6:143898200	T/G	cg25407410	chr6:143891975	LOC285740	-0.75	-12.1	-0.55	3.36e-28	Hypospadias;
LUSC	cis	rs1832871	0.672	rs111782080	chr6:158765385	G/A	cg07165851	chr6:158734300	TULP4	0.46	6.95	0.36	1.98e-11	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27109827	chr16:28936530	RABEP2	-0.41	-6.31	-0.33	8.82e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg20406979	chr6:167373233	NA	0.26	6.15	0.32	2.25e-9	Crohn's disease;
LUSC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg02269571	chr22:50332266	NA	-0.6	-9.04	-0.44	1.35e-17	Schizophrenia;
LUSC	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg05738196	chr6:26577821	NA	0.83	16.11	0.66	1.29e-43	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06634786	chr22:41940651	POLR3H	0.48	5.84	0.3	1.21e-8	Vitiligo;
LUSC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.4	-5.68	-0.3	2.88e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.79	-0.57	9.23e-31	Platelet count;
LUSC	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.61	9.52	0.46	3.51e-19	Blood metabolite ratios;
LUSC	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	15.44	0.65	5.93e-41	Lung cancer in ever smokers;
LUSC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00166722	chr3:10149974	C3orf24	0.61	8.64	0.43	2.44e-16	Alzheimer's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15473325	chr12:133137087	FBRSL1	0.45	6.11	0.32	2.78e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg23625390	chr15:77176239	SCAPER	-0.62	-9.58	-0.46	2.23e-19	Blood metabolite levels;
LUSC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs11989744	0.500	rs7826966	chr8:23569106	G/T	cg03492747	chr16:86543808	FOXF1	-0.64	-11.12	-0.52	1.23e-24	Waist-hip ratio;
LUSC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg20607798	chr8:58055168	NA	0.53	5.85	0.3	1.2e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.41	-0.42	1.23e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg15704280	chr7:45808275	SEPT13	-0.46	-6.34	-0.33	7.64e-10	HDL cholesterol;
LUSC	cis	rs611744	0.870	rs685358	chr8:109161413	T/C	cg18478394	chr8:109455254	TTC35	0.41	6.19	0.32	1.75e-9	Dupuytren's disease;
LUSC	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg13683864	chr3:40499215	RPL14	-0.82	-13.29	-0.59	1.18e-32	Renal cell carcinoma;
LUSC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg11871910	chr12:69753446	YEATS4	0.83	14.55	0.62	1.67e-37	Blood protein levels;
LUSC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg21972741	chr5:435613	AHRR	0.36	6.8	0.35	4.8e-11	Cystic fibrosis severity;
LUSC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06481639	chr22:41940642	POLR3H	0.49	5.81	0.3	1.48e-8	Vitiligo;
LUSC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg22618164	chr12:122356400	WDR66	0.6	8.87	0.44	4.53e-17	Mean corpuscular volume;
LUSC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg14403583	chr14:105418241	AHNAK2	-0.57	-9.62	-0.47	1.66e-19	Rheumatoid arthritis;
LUSC	cis	rs12210905	0.688	rs12189640	chr6:27474657	T/C	cg08851530	chr6:28072375	NA	0.95	6.15	0.32	2.21e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.59	-0.43	3.36e-16	Mood instability;
LUSC	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg14343924	chr8:8086146	FLJ10661	-0.42	-5.81	-0.3	1.42e-8	Myopia (pathological);
LUSC	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.64	7.85	0.39	5.57e-14	Post bronchodilator FEV1;
LUSC	cis	rs11690462	0.528	rs11691698	chr2:26642190	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.51	6.57	0.34	1.96e-10	Coronary artery disease;
LUSC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg27588902	chr6:42928151	GNMT	-0.29	-6.59	-0.34	1.71e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg00484396	chr16:3507460	NAT15	0.49	7.25	0.37	2.84e-12	Body mass index (adult);
LUSC	cis	rs9473147	0.516	rs9463342	chr6:47585106	A/T	cg12968598	chr6:47444699	CD2AP	0.53	8.1	0.41	1.06e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg18230493	chr5:56204884	C5orf35	-0.94	-14.17	-0.61	5.14e-36	Initial pursuit acceleration;
LUSC	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.64	-10.03	-0.48	7.26e-21	Type 2 diabetes;
LUSC	cis	rs6076065	0.692	rs2424549	chr20:23394563	C/A	cg11657817	chr20:23433608	CST11	0.44	8.19	0.41	5.54e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs67397200	0.632	rs11666308	chr19:17437744	T/C	cg04248312	chr19:17393744	ANKLE1	-0.42	-6.16	-0.32	2.13e-9	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
LUSC	trans	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg26043149	chr18:55253948	FECH	-0.53	-7.64	-0.39	2.26e-13	Bone mineral density;
LUSC	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	0.83	12.97	0.58	2.03e-31	Blood protein levels;
LUSC	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg20790798	chr5:1857306	NA	-0.39	-5.76	-0.3	1.86e-8	Cardiovascular disease risk factors;
LUSC	cis	rs6076065	0.723	rs2424544	chr20:23390314	C/T	cg11657817	chr20:23433608	CST11	0.42	8.01	0.4	1.94e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg26566898	chr11:117069891	TAGLN	-0.46	-8.21	-0.41	4.76e-15	Blood protein levels;
LUSC	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg21361702	chr7:150065534	REPIN1	0.47	6.17	0.32	1.94e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	7.45	0.38	7.96e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs859767	0.741	rs13432068	chr2:135382914	G/A	cg12500956	chr2:135428796	TMEM163	-0.28	-6.28	-0.32	1.07e-9	Neuroticism;
LUSC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg14092988	chr3:52407081	DNAH1	0.32	6.28	0.33	1.04e-9	Bipolar disorder;
LUSC	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04004882	chr2:215674386	BARD1	0.47	6.2	0.32	1.62e-9	Neuroblastoma;
LUSC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.1	0.55	3.3e-28	Motion sickness;
LUSC	trans	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg10756647	chr7:56101905	PSPH	0.88	8.95	0.44	2.46e-17	Diabetic kidney disease;
LUSC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg17376030	chr22:41985996	PMM1	-0.48	-6.04	-0.31	4.06e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg04545296	chr12:48745243	ZNF641	0.33	6.14	0.32	2.4e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg25214090	chr10:38739885	LOC399744	0.54	7.82	0.39	6.86e-14	Corneal astigmatism;
LUSC	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.87	-0.31	1.05e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg18478394	chr8:109455254	TTC35	0.41	6.29	0.33	9.7e-10	Dupuytren's disease;
LUSC	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg01125463	chr6:42946178	PEX6	-0.36	-6.0	-0.31	5.07e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	1.08	15.88	0.66	1.05e-42	Primary sclerosing cholangitis;
LUSC	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.64	14.3	0.62	1.64e-36	Hemoglobin concentration;
LUSC	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg15595755	chr5:1867978	NA	0.44	7.73	0.39	1.24e-13	Cardiovascular disease risk factors;
LUSC	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg05283184	chr6:79620031	NA	-0.57	-12.04	-0.55	5.76e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs4842666	0.915	rs11105353	chr12:90026463	C/A	cg00757033	chr12:89920650	WDR51B	0.48	6.39	0.33	5.49e-10	Blood pressure;
LUSC	trans	rs2288327	0.673	rs6723399	chr2:179381715	G/C	cg14011486	chr1:26737247	LIN28	0.55	7.43	0.38	9e-13	Atrial fibrillation;
LUSC	cis	rs9888739	1.000	rs36055763	chr16:31299775	C/T	cg15817542	chr16:31343056	ITGAM	-0.51	-5.99	-0.31	5.3300000000000004e-09	Systemic lupus erythematosus;
LUSC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg25258033	chr6:167368657	RNASET2	0.38	5.86	0.31	1.11e-8	Primary biliary cholangitis;
LUSC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg06808227	chr14:105710500	BRF1	-0.64	-9.5	-0.46	4.19e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs921665	0.831	rs11682390	chr2:3187698	G/A	cg16434511	chr2:3151078	NA	-0.62	-6.62	-0.34	1.43e-10	World class endurance athleticism;
LUSC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg14004847	chr7:1930337	MAD1L1	-0.44	-6.41	-0.33	4.94e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg05187965	chr10:45406764	TMEM72	-0.38	-9.01	-0.44	1.62e-17	Mean corpuscular volume;
LUSC	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg13010199	chr12:38710504	ALG10B	0.54	8.18	0.41	5.97e-15	Morning vs. evening chronotype;
LUSC	cis	rs9309473	0.528	rs79799178	chr2:73791235	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.47	-0.33	3.51e-10	Metabolite levels;
LUSC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg07828024	chr6:149772892	ZC3H12D	0.34	7.3	0.37	2.13e-12	Dupuytren's disease;
LUSC	trans	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg18335740	chr13:41363409	SLC25A15	0.6	9.05	0.44	1.16e-17	Lewy body disease;
LUSC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg15848620	chr12:58087721	OS9	-0.57	-8.04	-0.4	1.56e-14	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs1493935	0.545	rs3134079	chr8:119839850	C/T	cg21751525	chr12:120910288	DYNLL1	0.41	6.27	0.32	1.09e-9	Eosinophil percentage of white cells;
LUSC	cis	rs4363385	0.747	rs4323653	chr1:152983359	T/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.67	-0.39	1.9e-13	Inflammatory skin disease;
LUSC	cis	rs4660306	0.614	rs1765711	chr1:45936285	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.42	5.8	0.3	1.55e-8	Homocysteine levels;
LUSC	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	11.06	0.52	2e-24	Lung cancer in ever smokers;
LUSC	cis	rs11785693	0.862	rs1156861	chr8:4984434	G/C	cg26367366	chr8:4980734	NA	0.8	9.47	0.46	5.19e-19	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg03929089	chr4:120376271	NA	0.69	7.57	0.38	3.76e-13	Axial length;
LUSC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg09307838	chr4:120376055	NA	0.64	9.67	0.47	1.19e-19	Corneal astigmatism;
LUSC	cis	rs7809950	1.000	rs2520249	chr7:107146748	A/G	cg23024343	chr7:107201750	COG5	-0.54	-8.65	-0.43	2.15e-16	Coronary artery disease;
LUSC	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg05855489	chr10:104503620	C10orf26	0.48	7.35	0.37	1.55e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.74	7.42	0.38	9.87e-13	Initial pursuit acceleration;
LUSC	cis	rs17401966	0.522	rs10492969	chr1:10286358	T/C	cg19773385	chr1:10388646	KIF1B	-0.36	-6.13	-0.32	2.51e-9	Hepatocellular carcinoma;
LUSC	cis	rs73206853	0.841	rs73206883	chr12:110849549	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	6.97	0.36	1.71e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg17385448	chr1:15911702	AGMAT	0.36	6.18	0.32	1.82e-9	Systolic blood pressure;
LUSC	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21640587	chr11:117668038	DSCAML1	0.65	9.43	0.46	6.91e-19	Myopia;
LUSC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg04518342	chr5:131593106	PDLIM4	-0.43	-7.5	-0.38	5.77e-13	Breast cancer;
LUSC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg07061783	chr6:25882402	NA	-0.38	-5.94	-0.31	7.17e-9	Blood metabolite levels;
LUSC	cis	rs7527798	0.544	rs11118354	chr1:207856868	A/G	cg09232269	chr1:207846808	CR1L	-0.31	-6.71	-0.34	8.55e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.85	-0.35	3.55e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-0.87	-11.96	-0.55	1.13e-27	Initial pursuit acceleration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16563178	chr3:50358443	HYAL2	0.44	6.51	0.34	2.74e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg02508848	chr16:68573721	ZFP90	-0.42	-5.68	-0.3	2.96e-8	Ulcerative colitis;
LUSC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.84	-0.39	6.14e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg08499158	chr17:42289980	UBTF	-0.51	-8.14	-0.41	7.79e-15	Total body bone mineral density;
LUSC	trans	rs17685	0.925	rs1057868	chr7:75615006	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	12.34	0.56	4.48e-29	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6120849	0.518	rs11696652	chr20:33637060	T/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.58	0.34	1.8e-10	Protein C levels;
LUSC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg21361702	chr7:150065534	REPIN1	0.45	6.28	0.33	1.03e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg05283184	chr6:79620031	NA	-0.57	-12.33	-0.56	4.63e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs5758511	0.573	rs4501042	chr22:42245763	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-7.46	-0.38	7.45e-13	Birth weight;
LUSC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg09307838	chr4:120376055	NA	0.5	7.53	0.38	4.84e-13	Diastolic blood pressure;
LUSC	cis	rs2607426	1.000	rs2607423	chr19:41275487	A/G	cg05508168	chr19:41255947	C19orf54;SNRPA	0.63	5.7	0.3	2.68e-8	Blood protein levels;
LUSC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg13683864	chr3:40499215	RPL14	-0.93	-16.27	-0.66	3.02e-44	Renal cell carcinoma;
LUSC	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.36	-6.12	-0.32	2.56e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg25258033	chr6:167368657	RNASET2	0.44	7.05	0.36	1.04e-11	Crohn's disease;
LUSC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.76	7.33	0.37	1.77e-12	Cerebrospinal P-tau181p levels;
LUSC	trans	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg19894588	chr14:64061835	NA	0.5	7.26	0.37	2.78e-12	Glioblastoma;Glioma;
LUSC	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg11812906	chr14:75593930	NEK9	-0.62	-10.45	-0.5	2.6e-22	Height;
LUSC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg06618935	chr21:46677482	NA	-0.37	-7.52	-0.38	5.25e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10992471	0.528	rs10992347	chr9:95220633	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.35	-6.14	-0.32	2.33e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg18512352	chr11:47633146	NA	-0.46	-9.21	-0.45	3.59e-18	Subjective well-being;
LUSC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08859206	chr1:53392774	SCP2	0.51	8.65	0.43	2.13e-16	Monocyte count;
LUSC	cis	rs469568	0.673	rs338876	chr5:178669870	A/G	cg08999896	chr5:178685787	ADAMTS2	0.29	5.78	0.3	1.69e-8	Stroke (pediatric);
LUSC	cis	rs7705502	1.000	rs55924019	chr5:173375257	A/G	cg18693985	chr5:173351052	CPEB4	-0.37	-5.83	-0.3	1.33e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01230929	chr5:133706738	UBE2B	-0.42	-5.95	-0.31	6.95e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg00945038	chr17:61921165	SMARCD2	0.4	5.76	0.3	1.95e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg24154853	chr7:158122151	PTPRN2	-0.41	-7.93	-0.4	3.38e-14	Calcium levels;
LUSC	cis	rs7572644	0.603	rs7580274	chr2:28266069	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-7.07	-0.36	8.88e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.72	0.47	8.03e-20	Personality dimensions;
LUSC	cis	rs41271951	0.512	rs12070256	chr1:151070090	C/T	cg11822372	chr1:151115635	SEMA6C	-0.76	-6.95	-0.36	1.98e-11	Blood protein levels;
LUSC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.04	21.22	0.76	6.93e-64	Cognitive function;
LUSC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-19.14	-0.72	1.16e-55	Height;
LUSC	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg13393036	chr8:95962371	TP53INP1	-0.35	-6.67	-0.34	1.04e-10	Type 2 diabetes;
LUSC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.38	6.6	0.34	1.62e-10	Obesity-related traits;
LUSC	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.83	-0.3	1.3e-8	Bipolar disorder;
LUSC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg16606324	chr3:10149918	C3orf24	0.58	8.23	0.41	4.27e-15	Alzheimer's disease;
LUSC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg18876405	chr7:65276391	NA	0.49	7.68	0.39	1.76e-13	Calcium levels;
LUSC	cis	rs10072221	0.836	rs11740038	chr5:75692003	G/T	cg03132911	chr5:75698732	IQGAP2	-0.38	-6.15	-0.32	2.27e-9	Mean platelet volume;
LUSC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg08888203	chr3:10149979	C3orf24	0.45	6.79	0.35	5.25e-11	Alzheimer's disease;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg16031515	chr1:205743344	RAB7L1	0.27	5.83	0.3	1.32e-8	Menarche (age at onset);
LUSC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.58	0.38	3.46e-13	Bipolar disorder;
LUSC	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg09365446	chr1:150670422	GOLPH3L	0.44	6.76	0.35	6.23e-11	Melanoma;
LUSC	cis	rs11229555	0.645	rs7947248	chr11:58197750	C/T	cg15696309	chr11:58395628	NA	-0.67	-8.13	-0.41	8.64e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4730250	0.707	rs257385	chr7:106807448	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-9.21	-0.45	3.62e-18	Osteoarthritis;
LUSC	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg09699651	chr6:150184138	LRP11	0.45	7.08	0.36	8.5e-12	Testicular germ cell tumor;
LUSC	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg23260525	chr10:116636907	FAM160B1	0.4	8.11	0.41	9.5e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg19257562	chr1:2043853	PRKCZ	0.32	6.46	0.33	3.77e-10	Height;
LUSC	cis	rs3740713	1.000	rs35593189	chr11:18468378	C/T	cg15463284	chr11:18477534	LDHAL6A	-0.52	-6.01	-0.31	4.79e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg10556349	chr10:835070	NA	0.57	6.32	0.33	8.28e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg09238746	chr17:78121135	EIF4A3	-0.97	-14.4	-0.62	6.71e-37	Yeast infection;
LUSC	cis	rs7903847	0.642	rs11817875	chr10:99158414	G/A	cg08345082	chr10:99160200	RRP12	-0.35	-6.99	-0.36	1.53e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg23752985	chr2:85803571	VAMP8	0.33	7.06	0.36	9.48e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.39	0.46	9.81e-19	Coffee consumption (cups per day);
LUSC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg10523860	chr14:103875565	MARK3	-0.36	-5.66	-0.3	3.25e-8	Body mass index;
LUSC	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.66	9.09	0.45	9.32e-18	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7709377	0.620	rs12054994	chr5:115477172	A/C	cg23108291	chr5:115420582	COMMD10	0.4	5.71	0.3	2.48e-8	Metabolite levels  (X-11787);
LUSC	cis	rs7923609	0.841	rs7920036	chr10:65293860	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.46	-0.33	3.74e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.72	-0.35	7.73e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg26395211	chr5:140044315	WDR55	-0.39	-6.0	-0.31	5.07e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg05501817	chr11:14380813	RRAS2	-0.57	-8.9	-0.44	3.72e-17	Sense of smell;
LUSC	cis	rs7223966	1.000	rs8075273	chr17:61728881	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.92	0.35	2.25e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	13.98	0.61	2.73e-35	Platelet count;
LUSC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg03929089	chr4:120376271	NA	0.83	11.28	0.53	3.15e-25	Height;
LUSC	cis	rs3764563	1.000	rs4646530	chr19:15735238	A/T	cg20725493	chr19:15740067	CYP4F8	0.64	6.91	0.35	2.43e-11	Inflammatory biomarkers;
LUSC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs3820928	0.874	rs10166456	chr2:227900113	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.8	-0.39	7.86e-14	Pulmonary function;
LUSC	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg09640425	chr7:158790006	NA	-0.41	-6.08	-0.32	3.31e-9	Facial morphology (factor 20);
LUSC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.67	-0.39	1.89e-13	Joint mobility (Beighton score);
LUSC	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg17366294	chr4:99064904	C4orf37	0.55	9.03	0.44	1.42e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg17173187	chr15:85201210	NMB	0.37	6.4	0.33	5.31e-10	Schizophrenia;
LUSC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg05738196	chr6:26577821	NA	-0.56	-6.9	-0.35	2.58e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.42	0.53	9.8e-26	Prudent dietary pattern;
LUSC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	7.03	0.36	1.16e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs62400317	0.859	rs6919873	chr6:45159336	A/G	cg20913747	chr6:44695427	NA	-0.47	-7.62	-0.38	2.69e-13	Total body bone mineral density;
LUSC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg05082376	chr22:42548792	NA	-0.4	-6.04	-0.31	4.1e-9	Schizophrenia;
LUSC	cis	rs11955175	1.000	rs75929994	chr5:40821816	T/C	cg17351974	chr5:40835760	RPL37	0.67	5.67	0.3	3.03e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs4654899	0.931	rs12723255	chr1:21233570	C/T	cg01072550	chr1:21505969	NA	0.51	7.67	0.39	1.94e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg12179176	chr11:130786555	SNX19	0.62	9.33	0.45	1.5e-18	Schizophrenia;
LUSC	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg17691542	chr6:26056736	HIST1H1C	0.47	7.01	0.36	1.29e-11	Height;
LUSC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg25643088	chr3:52874325	TMEM110	0.41	6.3	0.33	9.6e-10	Schizophrenia;
LUSC	cis	rs7202877	0.656	rs4888394	chr16:75413709	T/C	cg03315344	chr16:75512273	CHST6	0.44	6.48	0.33	3.35e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs11030122	0.702	rs17279635	chr11:3973083	A/C	cg18678763	chr11:4115507	RRM1	0.44	5.81	0.3	1.44e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	7.13	0.36	6.21e-12	Parkinson's disease;
LUSC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	8.12	0.41	9.06e-15	Height;
LUSC	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02176678	chr2:219576539	TTLL4	0.64	11.72	0.54	8.56e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12292205	chr6:26970375	C6orf41	-0.58	-7.39	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg08601574	chr20:25228251	PYGB	-0.44	-6.69	-0.34	9.36e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10740039	0.883	rs7476720	chr10:62410368	C/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.89	-0.35	2.79e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10276381	0.892	rs7786444	chr7:28154384	C/T	cg23620719	chr7:28220237	JAZF1	0.53	5.69	0.3	2.84e-8	Crohn's disease;
LUSC	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg13755796	chr4:20253514	NA	-0.45	-6.98	-0.36	1.55e-11	Life satisfaction;
LUSC	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.06	-0.36	9.78e-12	Coronary artery disease;
LUSC	trans	rs931812	0.757	rs34988706	chr8:101907062	C/T	cg20993868	chr7:22813445	NA	0.53	9.66	0.47	1.2e-19	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	trans	rs7605827	0.893	rs4668929	chr2:15719044	C/A	cg02506360	chr16:46963989	GPT2	-0.4	-5.94	-0.31	7.04e-9	Educational attainment (years of education);
LUSC	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg20243544	chr17:37824526	PNMT	0.5	7.04	0.36	1.09e-11	Asthma;
LUSC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19346786	chr7:2764209	NA	-0.4	-7.01	-0.36	1.36e-11	Height;
LUSC	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg08807101	chr21:30365312	RNF160	-0.51	-6.63	-0.34	1.32e-10	Cognitive test performance;
LUSC	trans	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg06521331	chr12:34319734	NA	-0.39	-5.95	-0.31	6.67e-9	Bladder cancer;
LUSC	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg05472934	chr7:22766657	IL6	0.5	7.8	0.39	7.86e-14	Lung cancer;
LUSC	cis	rs253664	1.000	rs253664	chr3:138113353	A/G	cg25188949	chr3:137893707	DBR1	-0.47	-5.82	-0.3	1.38e-8	Body mass index;
LUSC	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg21132104	chr15:45694354	SPATA5L1	0.41	6.04	0.31	4.09e-9	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs1325195	0.734	rs2791942	chr1:179108081	A/G	cg11624085	chr17:8464688	MYH10	0.42	6.96	0.36	1.78e-11	IgE grass sensitization;
LUSC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg04414720	chr1:150670196	GOLPH3L	0.55	9.02	0.44	1.56e-17	Tonsillectomy;
LUSC	cis	rs11577318	0.579	rs58034207	chr1:26683575	C/T	cg00852783	chr1:26633632	UBXN11	-0.5	-7.01	-0.36	1.31e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs10927875	0.619	rs7546589	chr1:16129530	A/G	cg22431228	chr1:16359049	CLCNKA	0.31	6.19	0.32	1.76e-9	Dilated cardiomyopathy;
LUSC	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.89	14.89	0.63	8.25e-39	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg02508848	chr16:68573721	ZFP90	-0.44	-5.66	-0.3	3.27e-8	Ulcerative colitis;
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg18538332	chr22:24372958	LOC391322	-0.37	-6.53	-0.34	2.4e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg03146154	chr1:46216737	IPP	0.51	7.73	0.39	1.28e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3812762	0.826	rs2292045	chr11:8806709	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-6.41	-0.33	4.84e-10	Hypospadias;
LUSC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg05802129	chr4:122689817	NA	-0.37	-6.56	-0.34	2.06e-10	Type 2 diabetes;
LUSC	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg22782873	chr19:19639568	YJEFN3	-0.48	-6.11	-0.32	2.7e-9	Bipolar disorder;
LUSC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.15	-0.49	2.88e-21	Obesity-related traits;
LUSC	cis	rs9472414	0.510	rs609643	chr6:44705303	A/G	cg20913747	chr6:44695427	NA	-0.39	-5.9	-0.31	8.87e-9	Height;
LUSC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg15445000	chr17:37608096	MED1	0.33	5.99	0.31	5.3300000000000004e-09	Glomerular filtration rate (creatinine);
LUSC	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg07169764	chr2:136633963	MCM6	-0.74	-10.01	-0.48	8.55e-21	Mosquito bite size;
LUSC	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.74	14.82	0.63	1.58e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs2979489	0.891	rs2979504	chr8:30386641	C/T	cg26383811	chr8:30366931	RBPMS	-0.51	-8.14	-0.41	7.96e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.69	-9.09	-0.45	8.97e-18	Gut microbiome composition (summer);
LUSC	cis	rs6489882	0.867	rs6489877	chr12:113368079	A/G	cg20102336	chr12:113376681	OAS3	-0.4	-5.74	-0.3	2.17e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg08999081	chr20:33150536	PIGU	0.42	7.21	0.37	3.87e-12	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg17366294	chr4:99064904	C4orf37	0.6	10.44	0.5	2.76e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7605827	0.930	rs6723148	chr2:15592019	G/T	cg19274914	chr2:15703543	NA	0.46	9.01	0.44	1.66e-17	Educational attainment (years of education);
LUSC	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg18932078	chr1:2524107	MMEL1	0.33	7.16	0.36	5.3e-12	Ulcerative colitis;
LUSC	cis	rs11229555	1.000	rs12808544	chr11:58373221	C/A	cg15696309	chr11:58395628	NA	-0.7	-9.29	-0.45	2.07e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg21775007	chr8:11205619	TDH	0.46	6.62	0.34	1.41e-10	Mood instability;
LUSC	cis	rs36051895	0.589	rs6476946	chr9:5195275	C/G	cg02405213	chr9:5042618	JAK2	0.51	7.17	0.37	4.92e-12	Pediatric autoimmune diseases;
LUSC	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg12002119	chr2:101014098	CHST10	0.36	5.93	0.31	7.72e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg02023728	chr11:77925099	USP35	0.47	6.93	0.35	2.21e-11	Testicular germ cell tumor;
LUSC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	10.7	0.51	3.61e-23	Homoarginine levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16440638	chr2:11887120	LPIN1	-0.41	-6.14	-0.32	2.39e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg05855489	chr10:104503620	C10orf26	0.53	8.2	0.41	5.35e-15	Arsenic metabolism;
LUSC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.68	-11.28	-0.53	3.18e-25	Cognitive function;
LUSC	cis	rs3743266	0.593	rs4775276	chr15:60806185	C/T	cg21667061	chr15:60772094	NARG2	0.37	6.11	0.32	2.7e-9	Menarche (age at onset);
LUSC	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg24558204	chr6:135376177	HBS1L	0.57	8.77	0.43	9.11e-17	Red blood cell count;
LUSC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg05084668	chr3:125655381	ALG1L	-0.47	-6.65	-0.34	1.22e-10	Blood pressure (smoking interaction);
LUSC	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg03585969	chr10:35415529	CREM	0.64	9.52	0.46	3.56e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg00745463	chr17:30367425	LRRC37B	-0.46	-6.32	-0.33	8.15e-10	Height;
LUSC	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-1.14	-17.81	-0.7	2.27e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.81	-15.27	-0.64	2.78e-40	Prudent dietary pattern;
LUSC	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg19418458	chr7:158789849	NA	0.52	6.68	0.34	1.01e-10	Facial morphology (factor 20);
LUSC	cis	rs11229555	0.609	rs34133416	chr11:58184720	T/C	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg27535305	chr1:53392650	SCP2	0.36	6.71	0.34	8.29e-11	Monocyte count;
LUSC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg20399509	chr21:47717575	C21orf57	-0.43	-6.29	-0.33	9.7e-10	Testicular germ cell tumor;
LUSC	cis	rs1538970	1.000	rs1417578	chr1:45850590	A/G	cg05343316	chr1:45956843	TESK2	0.6	8.57	0.42	3.93e-16	Platelet count;
LUSC	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg15571903	chr15:79123663	NA	-0.33	-5.94	-0.31	7.06e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.4	-6.61	-0.34	1.55e-10	Monocyte percentage of white cells;
LUSC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg18402987	chr7:1209562	NA	0.71	7.53	0.38	4.64e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg14895029	chr7:2775587	GNA12	-0.38	-6.1	-0.32	2.86e-9	Height;
LUSC	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-1.03	-14.29	-0.62	1.74e-36	Exhaled nitric oxide output;
LUSC	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	trans	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg24644049	chr4:85504048	CDS1	0.9	7.72	0.39	1.39e-13	Skin colour saturation;
LUSC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-5.99	-0.31	5.57e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs240764	0.853	rs2062635	chr6:101002659	G/A	cg09795085	chr6:101329169	ASCC3	-0.41	-5.9	-0.31	9.04e-9	Neuroticism;
LUSC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.78	9.98	0.48	1.08e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10489525	0.560	rs10858062	chr1:115602563	A/G	cg17147537	chr1:115611705	TSPAN2	0.29	5.98	0.31	5.77e-9	Autism;
LUSC	trans	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs469568	0.543	rs12153128	chr5:178668714	A/G	cg08999896	chr5:178685787	ADAMTS2	-0.36	-7.18	-0.37	4.6e-12	Stroke (pediatric);
LUSC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.84	13.51	0.59	1.72e-33	Breast cancer;
LUSC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg06238570	chr21:40685208	BRWD1	0.48	7.49	0.38	6.36e-13	Cognitive function;
LUSC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg07716408	chr11:68623521	NA	-0.32	-6.16	-0.32	2.1e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	14.42	0.62	5.58e-37	Total body bone mineral density;
LUSC	cis	rs7094131	0.523	rs10764343	chr10:22882655	G/C	cg19500236	chr10:22911537	PIP4K2A	0.35	6.24	0.32	1.31e-9	Obesity-related traits;
LUSC	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg00383909	chr3:49044727	WDR6	1.16	10.81	0.51	1.45e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg20090143	chr19:45452003	APOC2	0.47	9.14	0.45	6.27e-18	Blood protein levels;
LUSC	cis	rs35995292	0.500	rs8180877	chr7:38931258	G/A	cg19327137	chr7:38886074	VPS41	0.55	10.26	0.49	1.18e-21	Subjective well-being (multi-trait analysis);
LUSC	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg23711669	chr6:146136114	FBXO30	0.85	15.21	0.64	4.62e-40	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg21775007	chr8:11205619	TDH	-0.45	-6.6	-0.34	1.57e-10	Neuroticism;
LUSC	cis	rs6690583	0.623	rs2083283	chr1:85439996	C/A	cg11262906	chr1:85462892	MCOLN2	0.69	6.69	0.34	9.24e-11	Serum sulfate level;
LUSC	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg22482690	chr17:47019901	SNF8	0.4	7.47	0.38	6.92e-13	Type 2 diabetes;
LUSC	trans	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg05926928	chr17:57297772	GDPD1	0.6	9.25	0.45	2.77e-18	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUSC	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg22823121	chr1:150693482	HORMAD1	0.5	7.21	0.37	3.67e-12	Melanoma;
LUSC	cis	rs597583	0.806	rs1940039	chr11:117393102	C/T	cg27161313	chr11:117392002	DSCAML1	-0.43	-7.32	-0.37	1.85e-12	Putamen volume;
LUSC	cis	rs62400317	0.859	rs17209636	chr6:45142517	T/G	cg20913747	chr6:44695427	NA	-0.47	-7.55	-0.38	4.28e-13	Total body bone mineral density;
LUSC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg16797656	chr11:68205561	LRP5	-0.43	-7.86	-0.4	5.26e-14	Total body bone mineral density;
LUSC	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08645402	chr16:4508243	NA	0.54	9.13	0.45	6.81e-18	Schizophrenia;
LUSC	cis	rs6426558	0.537	rs7523167	chr1:227365304	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.53	-7.32	-0.37	1.91e-12	Neutrophil percentage of white cells;
LUSC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.75	-13.58	-0.6	9.72e-34	Calcium levels;
LUSC	cis	rs2274273	0.870	rs3783650	chr14:55848972	A/C	cg04306507	chr14:55594613	LGALS3	0.56	12.83	0.57	6.51e-31	Protein biomarker;
LUSC	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg12002119	chr2:101014098	CHST10	0.37	6.17	0.32	1.99e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg03342759	chr3:160939853	NMD3	-0.52	-8.77	-0.43	9.03e-17	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.72	12.16	0.55	2.03e-28	Motion sickness;
LUSC	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg22508957	chr16:3507546	NAT15	0.42	6.1	0.32	2.93e-9	Body mass index (adult);
LUSC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.49	-0.33	3.17e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg20991723	chr1:152506922	NA	-0.47	-8.42	-0.42	1.09e-15	Hair morphology;
LUSC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	0.98	10.97	0.51	4.05e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3740713	1.000	rs73440634	chr11:18473546	T/A	cg07915343	chr11:18477680	LDHAL6A	-0.56	-7.08	-0.36	8.47e-12	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs6977660	0.943	rs10227692	chr7:19850199	T/C	cg05791153	chr7:19748676	TWISTNB	0.5	5.68	0.3	2.89e-8	Thyroid stimulating hormone;
LUSC	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.59	-0.43	3.4e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg06212747	chr3:49208901	KLHDC8B	0.45	6.07	0.32	3.45e-9	Parkinson's disease;
LUSC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.99	-0.31	5.36e-9	Personality dimensions;
LUSC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.73	-10.0	-0.48	8.94e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg13939156	chr17:80058883	NA	-0.34	-6.73	-0.35	7.53e-11	Life satisfaction;
LUSC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg06637938	chr14:75390232	RPS6KL1	0.53	8.42	0.42	1.11e-15	Height;
LUSC	trans	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg10756647	chr7:56101905	PSPH	0.85	8.47	0.42	7.94e-16	Gout;
LUSC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg06060754	chr5:176797920	RGS14	0.61	9.67	0.47	1.14e-19	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg09904177	chr6:26538194	HMGN4	-0.76	-5.7	-0.3	2.63e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	8.37	0.42	1.64e-15	Colorectal cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20703240	chr5:177659585	AGXT2L2	-0.41	-5.99	-0.31	5.52e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs71435601	0.657	rs12712923	chr2:21421782	C/A	cg20757404	chr19:378427	NA	-0.41	-6.32	-0.33	8.46e-10	Cholesterol, total;
LUSC	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21659725	chr3:3221576	CRBN	-0.54	-8.62	-0.43	2.78e-16	Body mass index;
LUSC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg09455208	chr3:40491958	NA	0.59	10.68	0.5	4.25e-23	Renal cell carcinoma;
LUSC	cis	rs4363385	0.510	rs6693927	chr1:153044009	G/A	cg25856811	chr1:152973957	SPRR3	-0.38	-6.23	-0.32	1.43e-9	Inflammatory skin disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12447188	chr16:4743522	NUDT16L1	0.42	6.02	0.31	4.55e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4964805	0.913	rs12830701	chr12:104201682	A/C	cg02344784	chr12:104178138	NT5DC3	0.43	6.96	0.36	1.85e-11	Attention deficit hyperactivity disorder;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	ch.2.3405933F	chr2:168679352	B3GALT1	0.41	6.02	0.31	4.7e-9	Mosquito bite size;
LUSC	cis	rs73200209	0.744	rs2304460	chr12:116408538	A/G	cg01776926	chr12:116560359	MED13L	-0.52	-5.89	-0.31	9.19e-9	Total body bone mineral density;
LUSC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg20887711	chr4:1340912	KIAA1530	0.44	6.53	0.34	2.48e-10	Obesity-related traits;
LUSC	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	1.18	13.93	0.61	4.45e-35	Arsenic metabolism;
LUSC	cis	rs6076065	0.755	rs3746734	chr20:23349765	C/T	cg11657817	chr20:23433608	CST11	0.42	7.83	0.39	6.47e-14	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs1927790	0.727	rs6491285	chr13:96944930	T/A	cg03198741	chr6:1003969	LOC285768	-0.39	-6.04	-0.31	4.21e-9	Body mass index;
LUSC	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg12756686	chr19:29218302	NA	0.57	6.35	0.33	7.04e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg00933542	chr6:150070202	PCMT1	0.3	6.0	0.31	5.27e-9	Lung cancer;
LUSC	trans	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg07393940	chr7:158741817	NA	-0.38	-6.75	-0.35	6.48e-11	Life satisfaction;
LUSC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg22907277	chr7:1156413	C7orf50	0.48	7.27	0.37	2.6e-12	Longevity;Endometriosis;
LUSC	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11058730	chr11:34937778	PDHX;APIP	0.43	5.77	0.3	1.79e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.66	0.34	1.15e-10	Menopause (age at onset);
LUSC	cis	rs2190422	0.677	rs2382693	chr7:103076969	A/G	cg04218035	chr7:103086829	SLC26A5	-0.32	-6.21	-0.32	1.61e-9	Morning vs. evening chronotype;
LUSC	cis	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg07460842	chr6:66804631	NA	0.48	5.91	0.31	8.42e-9	Metabolite levels;
LUSC	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.79	0.51	1.7e-23	Coffee consumption (cups per day);
LUSC	cis	rs2637266	0.628	rs846632	chr10:78535759	C/A	cg18941641	chr10:78392320	NA	0.39	7.12	0.36	6.58e-12	Pulmonary function;
LUSC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg16339924	chr4:17578868	LAP3	0.55	8.38	0.42	1.46e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12618769	0.625	rs12618524	chr2:99064029	T/A	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.14e-13	Bipolar disorder;
LUSC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg00376283	chr12:123451042	ABCB9	0.66	8.29	0.41	2.85e-15	Neutrophil percentage of white cells;
LUSC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg23625390	chr15:77176239	SCAPER	-0.42	-6.43	-0.33	4.54e-10	Blood metabolite levels;
LUSC	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg14186256	chr22:23484241	RTDR1	0.76	11.78	0.54	4.86e-27	Bone mineral density;
LUSC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.18	0.52	7.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1322512	0.917	rs2758805	chr6:152959301	A/G	cg27316956	chr6:152958899	SYNE1	-0.37	-6.2	-0.32	1.62e-9	Tonometry;
LUSC	cis	rs11039100	1.000	rs1470872	chr11:5827540	T/C	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-8.63	-0.43	2.5e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs2039659	0.719	rs1538049	chr13:86276135	A/G	cg22803222	chr6:76636725	IMPG1	0.37	6.04	0.31	4.15e-9	Blood osmolality (transformed sodium);
LUSC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg05729581	chr11:3078854	CARS	-0.57	-8.5	-0.42	6.58e-16	Longevity;
LUSC	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg03929089	chr4:120376271	NA	-0.58	-7.05	-0.36	1.02e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs5167	0.566	rs2075620	chr19:45480037	C/T	cg10169327	chr19:45448959	APOC2	-0.3	-5.73	-0.3	2.29e-8	Blood protein levels;
LUSC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.16	0.61	5.72e-36	Platelet count;
LUSC	cis	rs7119038	0.818	rs73003215	chr11:118649512	G/A	cg19308663	chr11:118741387	NA	0.36	6.38	0.33	5.85e-10	Sjögren's syndrome;
LUSC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg12751644	chr20:60527061	NA	-0.33	-5.91	-0.31	8.33e-9	Body mass index;
LUSC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg23985595	chr17:80112537	CCDC57	-0.31	-5.91	-0.31	8.39e-9	Life satisfaction;
LUSC	trans	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg14791747	chr16:20752902	THUMPD1	-0.41	-6.17	-0.32	1.97e-9	Dental caries;
LUSC	cis	rs7759001	0.857	rs10946914	chr6:27369892	C/T	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg26441486	chr22:50317300	CRELD2	0.48	7.07	0.36	9.37e-12	Schizophrenia;
LUSC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg00677455	chr12:58241039	CTDSP2	0.54	6.91	0.35	2.4e-11	Multiple sclerosis;
LUSC	cis	rs72634258	0.945	rs161802	chr1:8042826	G/T	cg00042356	chr1:8021962	PARK7	0.64	8.37	0.42	1.65e-15	Inflammatory bowel disease;
LUSC	cis	rs9612	1.000	rs346544	chr19:44256205	A/G	cg08581076	chr19:44259116	C19orf61	0.51	6.43	0.33	4.38e-10	Exhaled nitric oxide output;
LUSC	cis	rs870825	0.698	rs66462315	chr4:185623917	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs1559088	0.501	rs8100568	chr19:33567565	T/C	cg17764715	chr19:33622953	WDR88	0.6	6.69	0.34	9.28e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs71403859	0.504	rs35203704	chr16:71959661	G/A	cg08717414	chr16:71523259	ZNF19	-0.56	-5.76	-0.3	1.87e-8	Post bronchodilator FEV1;
LUSC	trans	rs656319	0.605	rs60278284	chr8:10003210	G/C	cg21775007	chr8:11205619	TDH	-0.45	-6.25	-0.32	1.26e-9	Myopia (pathological);
LUSC	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	7.23	0.37	3.41e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.44	-0.42	9.63e-16	Total cholesterol levels;
LUSC	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg20302533	chr7:39170763	POU6F2	0.41	6.23	0.32	1.41e-9	IgG glycosylation;
LUSC	cis	rs10875746	0.903	rs989144	chr12:48483973	T/C	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.6	0.43	3.1e-16	Neutrophil percentage of white cells;
LUSC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	6.01	0.31	4.91e-9	Menopause (age at onset);
LUSC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.38	0.46	1.01e-18	Monocyte percentage of white cells;
LUSC	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg00504896	chr12:9437009	LOC642846	-0.48	-7.63	-0.39	2.41e-13	Breast size;
LUSC	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg03342759	chr3:160939853	NMD3	-0.45	-6.09	-0.32	3.1e-9	Parkinson's disease;
LUSC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg16423285	chr20:60520624	NA	-0.47	-5.92	-0.31	8.15e-9	Body mass index;
LUSC	trans	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg07393940	chr7:158741817	NA	0.54	8.76	0.43	1.03e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2354432	0.556	rs72710311	chr1:146698256	A/G	cg25205988	chr1:146714368	CHD1L	-0.99	-8.71	-0.43	1.43e-16	Mitochondrial DNA levels;
LUSC	cis	rs11622475	1.000	rs34964872	chr14:104448435	T/A	cg12183467	chr14:104352244	NA	-0.42	-7.49	-0.38	6.22e-13	Bipolar disorder;
LUSC	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg22508957	chr16:3507546	NAT15	-0.37	-6.11	-0.32	2.7e-9	Body mass index (adult);
LUSC	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg05110241	chr16:68378359	PRMT7	-0.44	-5.89	-0.31	9.24e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs253664	0.897	rs1199336	chr3:138088221	T/A	cg25188949	chr3:137893707	DBR1	-0.5	-5.94	-0.31	7.29e-9	Body mass index;
LUSC	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg17366294	chr4:99064904	C4orf37	0.57	9.97	0.48	1.14e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3770081	1.000	rs73947314	chr2:86273116	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.94	-6.51	-0.34	2.82e-10	Facial emotion recognition (sad faces);
LUSC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.4	-0.33	5.37e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.62	7.69	0.39	1.69e-13	Lung function (FEV1/FVC);
LUSC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg09367891	chr1:107599246	PRMT6	0.48	7.68	0.39	1.83e-13	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg03605463	chr16:89740564	NA	0.53	8.26	0.41	3.41e-15	Hemoglobin concentration;
LUSC	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	1.13	17.53	0.69	2.98e-49	Corneal structure;
LUSC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg24675658	chr1:53192096	ZYG11B	0.58	9.11	0.45	7.92e-18	Monocyte count;
LUSC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.66	-6.43	-0.33	4.49e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7119	0.634	rs2682922	chr15:77865006	A/C	cg27398640	chr15:77910606	LINGO1	0.36	7.96	0.4	2.67e-14	Type 2 diabetes;
LUSC	cis	rs7851660	0.874	rs1955144	chr9:100634589	A/G	cg13688889	chr9:100608707	NA	-0.56	-8.94	-0.44	2.78e-17	Strep throat;
LUSC	trans	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg18187862	chr3:45730750	SACM1L	0.6	7.68	0.39	1.72e-13	Primary sclerosing cholangitis;
LUSC	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg14769373	chr6:40998127	UNC5CL	-0.56	-8.12	-0.41	8.99e-15	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg27170947	chr2:26402098	FAM59B	-0.65	-9.7	-0.47	9.25e-20	Gut microbiome composition (summer);
LUSC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg22638593	chr5:131593259	PDLIM4	0.42	6.07	0.32	3.45e-9	Acylcarnitine levels;
LUSC	cis	rs67072384	1.000	rs67809272	chr11:72450941	T/A	cg04827223	chr11:72435913	ARAP1	-0.78	-6.71	-0.34	8.4e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.81	13.54	0.6	1.31e-33	Aortic root size;
LUSC	cis	rs2637266	0.935	rs4353214	chr10:78393149	C/T	cg18941641	chr10:78392320	NA	-0.41	-7.51	-0.38	5.41e-13	Pulmonary function;
LUSC	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.28	-18.08	-0.7	1.91e-51	Hip circumference adjusted for BMI;
LUSC	cis	rs1113500	0.548	rs11185269	chr1:108647636	T/C	cg06207961	chr1:108661230	NA	0.35	5.74	0.3	2.17e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs9311676	0.618	rs62258135	chr3:58403330	C/T	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.11e-10	Systemic lupus erythematosus;
LUSC	trans	rs17039065	0.920	rs58424294	chr4:109420427	C/T	cg07444054	chr2:108107501	NA	0.45	6.29	0.33	1.01e-9	Gut microbiome composition (summer);
LUSC	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	5.68	0.3	2.92e-8	Schizophrenia;
LUSC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.02	0.36	1.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg16325326	chr1:53192061	ZYG11B	0.85	15.13	0.64	9.25e-40	Monocyte count;
LUSC	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg02023728	chr11:77925099	USP35	0.5	7.11	0.36	7.17e-12	Testicular germ cell tumor;
LUSC	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg04586622	chr2:25135609	ADCY3	0.32	6.18	0.32	1.92e-9	Body mass index;
LUSC	cis	rs1775715	0.737	rs2151047	chr10:32102110	G/A	cg18675610	chr10:32216311	ARHGAP12	0.31	6.58	0.34	1.8e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.78	0.6	1.67e-34	Chronic sinus infection;
LUSC	cis	rs7075426	0.669	rs4934220	chr10:88288206	A/G	cg07322936	chr10:88137208	NA	-0.45	-6.53	-0.34	2.45e-10	Migraine without aura;
LUSC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.63	8.57	0.42	3.93e-16	High light scatter reticulocyte count;
LUSC	cis	rs4400599	0.901	rs2494671	chr1:154100779	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.37	6.01	0.31	4.87e-9	Platelet distribution width;
LUSC	cis	rs7113850	0.541	rs75347910	chr11:24213815	G/A	ch.11.24196551F	chr11:24239977	NA	0.97	7.41	0.38	1.05e-12	Bone fracture in osteoporosis;
LUSC	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-12.83	-0.57	6.33e-31	Total body bone mineral density;
LUSC	cis	rs56283067	0.887	rs10948171	chr6:44761028	C/T	cg20913747	chr6:44695427	NA	-0.49	-7.55	-0.38	4.27e-13	Total body bone mineral density;
LUSC	cis	rs56161922	0.818	rs4437879	chr1:207875977	G/A	cg11752769	chr1:207818423	CR1L	-0.71	-5.93	-0.31	7.62e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.42	-5.89	-0.31	9.46e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg00012203	chr2:219082015	ARPC2	0.87	16.15	0.66	9.37e-44	Colorectal cancer;
LUSC	cis	rs4363385	0.693	rs582345	chr1:153033406	G/A	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.2	-0.37	4.13e-12	Inflammatory skin disease;
LUSC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.59	9.72	0.47	8.16e-20	Aortic root size;
LUSC	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.75	-0.65	3.38e-42	Height;
LUSC	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg12935359	chr14:103987150	CKB	-0.57	-8.83	-0.44	5.8e-17	Body mass index;
LUSC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10862848	chr6:42927986	GNMT	-0.28	-6.73	-0.35	7.26e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg07810366	chr2:100720526	AFF3	-0.44	-7.34	-0.37	1.66e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.68	-0.43	1.83e-16	Bipolar disorder;
LUSC	cis	rs983392	0.805	rs7926729	chr11:59961786	C/T	cg20284999	chr11:59952153	MS4A6A	-0.39	-6.39	-0.33	5.55e-10	Alzheimer's disease (late onset);
LUSC	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg01652190	chr22:50026171	C22orf34	-0.31	-6.25	-0.32	1.24e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg18099408	chr3:52552593	STAB1	0.37	6.17	0.32	1.93e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs240764	0.717	rs6907444	chr6:101163606	G/T	cg09795085	chr6:101329169	ASCC3	-0.42	-6.08	-0.32	3.25e-9	Neuroticism;
LUSC	cis	rs56804039	1.000	rs17616779	chr8:8382374	A/G	cg15556689	chr8:8085844	FLJ10661	0.59	7.73	0.39	1.29e-13	Cervical cancer;
LUSC	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg02167203	chr6:41068553	NFYA;LOC221442	0.4	5.98	0.31	5.89e-9	Alzheimer's disease (late onset);
LUSC	cis	rs11031096	0.678	rs61899754	chr11:4201312	A/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.77	-0.3	1.85e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg24006582	chr15:45444508	DUOX1	0.57	8.17	0.41	6.5e-15	Uric acid levels;
LUSC	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.35	6.14	0.32	2.31e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.36	-0.33	6.81e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.6	9.19	0.45	4.26e-18	Blood protein levels;
LUSC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg27165867	chr14:105738592	BRF1	-0.52	-7.65	-0.39	2.17e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7608623	0.773	rs11679039	chr2:23921565	A/C	cg08917208	chr2:24149416	ATAD2B	-0.42	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg20744362	chr22:50050164	C22orf34	0.35	6.29	0.33	9.69e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.51	7.2	0.37	4.08e-12	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.63	10.91	0.51	6.56e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg04545296	chr12:48745243	ZNF641	0.33	6.21	0.32	1.57e-9	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	14.34	0.62	1.16e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	7.08	0.36	8.38e-12	Platelet count;
LUSC	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.48	-5.9	-0.31	8.74e-9	Neutrophil percentage of white cells;
LUSC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg07395648	chr5:131743802	NA	0.47	7.67	0.39	1.85e-13	Breast cancer;Mosquito bite size;
LUSC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg25019033	chr10:957182	NA	-0.53	-6.95	-0.36	1.88e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg17173187	chr15:85201210	NMB	0.36	6.08	0.32	3.27e-9	Schizophrenia;
LUSC	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	trans	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.92	0.48	1.72e-20	Mean corpuscular volume;
LUSC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg06238570	chr21:40685208	BRWD1	0.5	7.51	0.38	5.29e-13	Cognitive function;
LUSC	cis	rs12681287	0.547	rs9942823	chr8:87509177	A/G	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.56	-0.5	1.13e-22	Coffee consumption (cups per day);
LUSC	cis	rs7147624	1.000	rs7147624	chr14:65865625	G/T	cg03016385	chr14:66212404	NA	0.8	9.57	0.46	2.54e-19	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg07541023	chr7:19748670	TWISTNB	0.68	7.31	0.37	2.03e-12	Thyroid stimulating hormone;
LUSC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.59	10.64	0.5	5.79e-23	Bone mineral density;
LUSC	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg06026331	chr20:60912101	LAMA5	-0.42	-5.72	-0.3	2.41e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12292205	chr6:26970375	C6orf41	-0.63	-7.62	-0.38	2.66e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08677398	chr8:58056175	NA	0.52	6.87	0.35	3.18e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs67981189	0.574	rs2526884	chr14:71367967	G/A	cg15816911	chr14:71606274	NA	-0.32	-5.64	-0.3	3.55e-8	Schizophrenia;
LUSC	cis	rs4629180	1.000	rs974374	chr2:102105846	C/T	cg04415270	chr2:102091202	RFX8	0.58	9.66	0.47	1.27e-19	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs9653442	0.527	rs12712064	chr2:100756548	C/T	cg22139774	chr2:100720529	AFF3	-0.42	-7.25	-0.37	3e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg09654669	chr8:57350985	NA	-0.58	-8.08	-0.4	1.18e-14	Obesity-related traits;
LUSC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03934478	chr11:495069	RNH1	0.86	9.78	0.47	5.09e-20	Body mass index;
LUSC	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg24375607	chr4:120327624	NA	0.75	11.4	0.53	1.21e-25	Corneal astigmatism;
LUSC	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg01191920	chr7:158217561	PTPRN2	-0.5	-10.29	-0.49	9.19e-22	Obesity-related traits;
LUSC	cis	rs7715806	0.500	rs4703676	chr5:74979866	G/C	cg19683494	chr5:74908142	NA	0.58	7.92	0.4	3.64e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg16434002	chr17:42200994	HDAC5	-0.45	-6.35	-0.33	6.84e-10	Total body bone mineral density;
LUSC	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.19	0.32	1.77e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.49	-0.33	3.15e-10	Triglycerides;
LUSC	cis	rs710216	0.571	rs11210772	chr1:43448499	A/G	cg03128534	chr1:43423976	SLC2A1	-0.44	-6.48	-0.33	3.27e-10	Red cell distribution width;
LUSC	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-7.21	-0.37	3.8e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg01879757	chr17:41196368	BRCA1	-0.46	-7.03	-0.36	1.14e-11	Menopause (age at onset);
LUSC	cis	rs62408225	1.000	rs62408224	chr6:90955995	A/G	cg06866423	chr6:90926672	BACH2	0.41	5.86	0.31	1.08e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14591386	chr6:97345725	NDUFAF4	-0.44	-6.25	-0.32	1.25e-9	Hepatitis;
LUSC	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg23711669	chr6:146136114	FBXO30	0.87	15.84	0.65	1.59e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg08668359	chr10:1443807	ADARB2	0.41	6.23	0.32	1.43e-9	Radiation response;
LUSC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-5.99	-0.31	5.34e-9	Total body bone mineral density;
LUSC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-6.13	-0.32	2.44e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2067615	0.524	rs10861646	chr12:107071182	C/T	cg15890332	chr12:107067104	RFX4	0.36	6.33	0.33	7.72e-10	Heart rate;
LUSC	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Bladder cancer;
LUSC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.07	-0.32	3.51e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3772130	0.923	rs34865234	chr3:121560995	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	9.62	0.47	1.7e-19	Cognitive performance;
LUSC	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.76	-0.43	9.87e-17	Response to antipsychotic treatment;
LUSC	cis	rs2398893	0.924	rs1539282	chr9:96827424	T/C	cg14459158	chr9:96720562	NA	0.32	6.07	0.32	3.52e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg11965913	chr1:205819406	PM20D1	-0.47	-7.26	-0.37	2.77e-12	Menarche (age at onset);
LUSC	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg16473166	chr22:50639996	SELO	-0.58	-8.11	-0.41	9.69e-15	Obesity-related traits;
LUSC	cis	rs4812048	0.689	rs151357	chr20:57609055	A/G	cg14073986	chr20:57617431	SLMO2	0.5	5.76	0.3	1.91e-8	Mean platelet volume;
LUSC	cis	rs317865	0.737	rs73234644	chr4:16190661	T/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.61	5.83	0.3	1.3e-8	Kidney disease (early stage) in type 1 diabetes;
LUSC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg25456477	chr12:86230367	RASSF9	0.44	7.87	0.4	4.98e-14	Major depressive disorder;
LUSC	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.59	-9.63	-0.47	1.6e-19	Schizophrenia;
LUSC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	13.24	0.59	1.94e-32	Monocyte percentage of white cells;
LUSC	trans	rs4596713	0.538	rs7029627	chr9:71745687	C/T	cg25283916	chr1:242222868	NA	-0.29	-6.04	-0.31	4.19e-9	Headache;
LUSC	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg06219351	chr7:158114137	PTPRN2	0.51	9.13	0.45	6.75e-18	Calcium levels;
LUSC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.66	-11.66	-0.54	1.34e-26	Aortic root size;
LUSC	cis	rs55675132	0.620	rs2335721	chr1:115637248	C/G	cg01522456	chr1:115632236	TSPAN2	-0.44	-6.14	-0.32	2.39e-9	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.96	0.31	6.36e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21545522	chr1:205238299	TMCC2	0.49	8.99	0.44	1.91e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg16586182	chr3:47516702	SCAP	0.58	8.98	0.44	2.03e-17	Colorectal cancer;
LUSC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg12863693	chr15:85201151	NMB	0.35	6.85	0.35	3.61e-11	Schizophrenia;
LUSC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.92	0.4	3.53e-14	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04174309	chr11:117102980	RNF214;PCSK7	0.42	6.58	0.34	1.78e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg07741184	chr6:167504864	NA	0.39	6.84	0.35	3.88e-11	Primary biliary cholangitis;
LUSC	cis	rs932287	0.858	rs7109896	chr11:9054522	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.41	7.57	0.38	3.74e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg00376283	chr12:123451042	ABCB9	0.72	10.99	0.52	3.54e-24	Platelet count;
LUSC	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	8.32	0.41	2.34e-15	Menarche (age at onset);
LUSC	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg00376283	chr12:123451042	ABCB9	0.65	7.24	0.37	3.19e-12	Neutrophil percentage of white cells;
LUSC	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg19592336	chr6:28129416	ZNF389	0.45	5.94	0.31	7.18e-9	Depression;
LUSC	cis	rs72634258	0.842	rs7545745	chr1:8165667	T/A	cg26816564	chr1:7831052	VAMP3	-0.43	-5.81	-0.3	1.47e-8	Inflammatory bowel disease;
LUSC	cis	rs2224391	0.628	rs6913120	chr6:5260505	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.46	-5.75	-0.3	2.02e-8	Height;
LUSC	trans	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg12856521	chr11:46389249	DGKZ	0.39	6.25	0.32	1.27e-9	Leprosy;
LUSC	cis	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg06521331	chr12:34319734	NA	-0.38	-6.33	-0.33	8.13e-10	Morning vs. evening chronotype;
LUSC	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg01770232	chr7:22766155	IL6	0.4	5.76	0.3	1.93e-8	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
LUSC	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg04058563	chr4:185651563	MLF1IP	-0.39	-6.36	-0.33	6.72e-10	Kawasaki disease;
LUSC	trans	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.56	-0.42	4.08e-16	Depression;
LUSC	cis	rs2607426	0.681	rs2254326	chr19:41255889	G/T	cg05508168	chr19:41255947	C19orf54;SNRPA	0.87	6.05	0.31	3.81e-9	Blood protein levels;
LUSC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs3931020	0.688	rs968358	chr1:75193989	G/T	cg21906852	chr1:75198582	TYW3;CRYZ	0.45	5.82	0.3	1.37e-8	Resistin levels;
LUSC	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.7	-0.39	1.58e-13	Mood instability;
LUSC	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg02696742	chr7:106810147	HBP1	-0.64	-9.67	-0.47	1.2e-19	Osteoarthritis;
LUSC	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg06219351	chr7:158114137	PTPRN2	-0.54	-9.85	-0.47	2.89e-20	Calcium levels;
LUSC	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.11	-0.45	7.57e-18	Monocyte percentage of white cells;
LUSC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg12257692	chr3:49977190	RBM6	-0.25	-6.95	-0.36	1.96e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs35123781	1.000	rs2336880	chr5:139063728	A/G	cg10513866	chr5:139070639	NA	-0.42	-8.37	-0.42	1.65e-15	Schizophrenia;
LUSC	cis	rs113835537	1.000	rs113835537	chr11:66339639	A/G	cg24851651	chr11:66362959	CCS	0.53	6.79	0.35	5.28e-11	Airway imaging phenotypes;
LUSC	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.35	-5.8	-0.3	1.51e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-8.29	-0.41	2.86e-15	Lung cancer;
LUSC	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg07395648	chr5:131743802	NA	0.56	8.98	0.44	2.07e-17	Blood metabolite levels;
LUSC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10802521	chr3:52805072	NEK4	-0.47	-7.36	-0.37	1.44e-12	Bipolar disorder;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	ch.5.3315058R	chr5:173165015	NA	0.43	6.11	0.32	2.72e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg17788362	chr6:86352627	SYNCRIP	0.5	7.57	0.38	3.79e-13	Smooth-surface caries;
LUSC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.65	-8.69	-0.43	1.68e-16	Body mass index;
LUSC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-7.92	-0.4	3.46e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4604732	0.536	rs12074913	chr1:247631607	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.45	6.87	0.35	3.13e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9487051	0.735	rs459956	chr6:109524760	A/G	cg00509249	chr6:109615579	CCDC162	-0.33	-5.74	-0.3	2.15e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.63	9.97	0.48	1.15e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.02	-0.4	1.76e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs2431623	0.752	rs2431637	chr10:12875263	G/A	cg08415853	chr5:87979005	LOC645323	-0.38	-6.09	-0.32	3.05e-9	Asymmetrical dimethylarginine levels;
LUSC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.89	0.61	6.08e-35	Platelet count;
LUSC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg23436779	chr17:56769830	TEX14;RAD51C	-0.46	-5.66	-0.3	3.27e-8	Cognitive test performance;
LUSC	cis	rs6541297	0.645	rs4846920	chr1:230301574	A/G	cg05784532	chr1:230284198	GALNT2	0.52	6.16	0.32	2.07e-9	Coronary artery disease;
LUSC	cis	rs3845702	0.736	rs259810	chr2:180787821	T/C	cg01881094	chr2:180872142	CWC22	-0.96	-10.83	-0.51	1.28e-23	Schizophrenia;
LUSC	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg00129232	chr17:37814104	STARD3	-0.43	-6.31	-0.33	8.92e-10	Asthma;
LUSC	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg07211511	chr3:129823064	LOC729375	-1.24	-20.31	-0.74	2.85e-60	Blood pressure (smoking interaction);
LUSC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.23	-0.52	4.74e-25	Bipolar disorder;
LUSC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg17252645	chr8:143867129	LY6D	0.54	10.24	0.49	1.38e-21	Urinary tract infection frequency;
LUSC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-7.29	-0.37	2.26e-12	Renal function-related traits (BUN);
LUSC	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg16447950	chr5:562315	NA	-0.57	-6.95	-0.36	1.97e-11	Lung disease severity in cystic fibrosis;
LUSC	trans	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg23291145	chr4:41648620	LIMCH1	-0.38	-5.97	-0.31	6.17e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs240764	0.717	rs180963	chr6:101127213	T/C	cg09795085	chr6:101329169	ASCC3	0.4	5.83	0.3	1.34e-8	Neuroticism;
LUSC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4280164	0.551	rs3212260	chr14:24804088	A/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.62	-7.69	-0.39	1.67e-13	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23281280	chr6:28129359	ZNF389	0.44	5.7	0.3	2.58e-8	Depression;
LUSC	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg03474202	chr17:45855739	NA	-0.29	-6.7	-0.34	8.99e-11	IgG glycosylation;
LUSC	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.63	0.34	1.33e-10	Corneal astigmatism;
LUSC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg22963979	chr7:1858916	MAD1L1	-0.73	-11.88	-0.54	2.22e-27	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg06145435	chr7:1022769	CYP2W1	0.38	6.71	0.34	8.34e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.94	-0.35	2.1e-11	Monocyte percentage of white cells;
LUSC	cis	rs4380275	1.000	rs4854376	chr2:763683	A/T	cg21665850	chr2:731073	NA	0.36	5.66	0.3	3.19e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg26384229	chr12:38710491	ALG10B	-0.79	-13.28	-0.59	1.33e-32	Morning vs. evening chronotype;
LUSC	cis	rs4654899	1.000	rs10916937	chr1:21439785	A/G	cg01072550	chr1:21505969	NA	-0.53	-8.1	-0.41	1.06e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg22535103	chr8:58192502	C8orf71	-0.72	-7.42	-0.38	9.98e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7216064	0.906	rs1976052	chr17:65830578	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-8.56	-0.42	4.17e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.25e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg13009365	chr22:24093455	ZNF70	0.4	6.12	0.32	2.67e-9	Triglyceride levels;
LUSC	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg23283495	chr1:209979779	IRF6	0.68	7.91	0.4	3.77e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg24503407	chr1:205819492	PM20D1	0.52	7.55	0.38	4.09e-13	Prostate-specific antigen levels;
LUSC	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg05855489	chr10:104503620	C10orf26	-0.68	-10.19	-0.49	2.08e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1018836	0.631	rs2205158	chr8:91472515	C/T	cg16814680	chr8:91681699	NA	-0.56	-8.24	-0.41	4.09e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.48	7.13	0.36	6.05e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.37	-0.62	8.79e-37	Schizophrenia;
LUSC	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg14664628	chr15:75095509	CSK	-0.42	-6.19	-0.32	1.78e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.98	0.31	5.83e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	8.16	0.41	6.88e-15	Height;
LUSC	cis	rs78579285	0.584	rs35265318	chr16:88800785	C/T	cg01900006	chr16:88814613	FAM38A	0.61	6.83	0.35	4.14e-11	Joint mobility (Beighton score);
LUSC	cis	rs4654899	0.931	rs10753506	chr1:21141022	A/G	cg01072550	chr1:21505969	NA	0.48	7.2	0.37	4.09e-12	Superior frontal gyrus grey matter volume;
LUSC	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	6.49	0.33	3.03e-10	Retinal vascular caliber;
LUSC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.72	-12.84	-0.57	6e-31	Aortic root size;
LUSC	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg01966878	chr4:90757139	SNCA	-0.46	-6.66	-0.34	1.15e-10	Neuroticism;
LUSC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg07936489	chr17:37558343	FBXL20	-0.68	-9.0	-0.44	1.8e-17	Glomerular filtration rate (creatinine);
LUSC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg00509249	chr6:109615579	CCDC162	0.33	5.94	0.31	7.06e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg13010344	chr12:123464640	ARL6IP4	0.51	6.57	0.34	1.96e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	9.24	0.45	2.94e-18	Total body bone mineral density;
LUSC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.18	0.61	4.59e-36	Platelet count;
LUSC	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.8	13.2	0.59	2.74e-32	Morning vs. evening chronotype;
LUSC	cis	rs8077577	0.945	rs8069094	chr17:18096528	C/T	cg16794390	chr17:18148240	FLII	0.4	5.76	0.3	1.9e-8	Obesity-related traits;
LUSC	cis	rs6750047	0.625	rs336037	chr2:38261124	T/C	cg07380506	chr2:38303506	CYP1B1	-0.44	-6.09	-0.32	3.09e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.02	0.52	2.63e-24	Ileal carcinoids;
LUSC	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg03733263	chr8:22462867	KIAA1967	0.77	12.49	0.56	1.25e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg08999081	chr20:33150536	PIGU	-0.39	-7.15	-0.36	5.45e-12	Height;
LUSC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg12560992	chr17:57184187	TRIM37	-0.9	-17.62	-0.69	1.35e-49	Intelligence (multi-trait analysis);
LUSC	cis	rs1953600	0.645	rs7071579	chr10:81910278	A/G	cg00277334	chr10:82204260	NA	0.42	6.42	0.33	4.72e-10	Sarcoidosis;
LUSC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg00149659	chr3:10157352	C3orf10	0.62	8.57	0.42	3.84e-16	Alzheimer's disease;
LUSC	cis	rs36051895	0.623	rs7027871	chr9:5236822	C/G	cg02405213	chr9:5042618	JAK2	0.48	6.57	0.34	1.97e-10	Pediatric autoimmune diseases;
LUSC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.44	-6.04	-0.31	4.12e-9	Longevity;Endometriosis;
LUSC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	1.04	20.08	0.74	2.21e-59	Menopause (age at onset);
LUSC	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg08824895	chr13:115047677	UPF3A	-0.55	-8.56	-0.42	4.09e-16	Schizophrenia;
LUSC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.92	13.28	0.59	1.37e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6496044	0.634	rs4843066	chr15:86062911	C/T	cg13263323	chr15:86062960	AKAP13	-0.39	-6.38	-0.33	5.88e-10	Interstitial lung disease;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg18882576	chr2:191184621	HIBCH	0.41	6.75	0.35	6.66e-11	Triglycerides;
LUSC	cis	rs6736093	0.733	rs34974772	chr2:112810011	T/C	cg12686935	chr2:112915763	FBLN7	-0.4	-6.35	-0.33	7.04e-10	Coronary artery disease;
LUSC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	trans	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg19894588	chr14:64061835	NA	-0.56	-7.42	-0.38	9.85e-13	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg01629716	chr15:45996671	NA	0.39	5.96	0.31	6.31e-9	Waist circumference;Weight;
LUSC	cis	rs12476592	0.602	rs6546018	chr2:63817422	G/T	cg10828910	chr2:63850056	LOC388955	0.5	5.81	0.3	1.49e-8	Childhood ear infection;
LUSC	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg26395211	chr5:140044315	WDR55	-0.4	-6.15	-0.32	2.25e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.46	-0.33	3.61e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs9612	1.000	rs346528	chr19:44259232	G/T	cg08581076	chr19:44259116	C19orf61	0.53	6.66	0.34	1.1e-10	Exhaled nitric oxide output;
LUSC	cis	rs3768617	0.510	rs729819	chr1:183109034	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.64	0.5	5.6e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-6.8	-0.35	4.95e-11	Breast cancer;
LUSC	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg24578937	chr1:2090814	PRKCZ	0.6	13.94	0.61	3.84e-35	Height;
LUSC	cis	rs6681460	0.966	rs7542924	chr1:67143055	C/T	cg02459107	chr1:67143332	SGIP1	0.49	9.3	0.45	1.87e-18	Presence of antiphospholipid antibodies;
LUSC	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg26408565	chr15:76604113	ETFA	-0.49	-7.72	-0.39	1.38e-13	Blood metabolite levels;
LUSC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg06387496	chr7:2775674	GNA12	-0.36	-5.84	-0.3	1.21e-8	Height;
LUSC	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg24531977	chr5:56204891	C5orf35	-0.58	-8.63	-0.43	2.62e-16	Breast cancer;Breast cancer (early onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24357026	chr19:36705589	ZNF565;ZNF146	0.47	6.8	0.35	4.81e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-20.57	-0.75	2.54e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg18209359	chr17:80159595	CCDC57	-0.36	-5.82	-0.3	1.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.79	14.92	0.63	6.05e-39	Dental caries;
LUSC	cis	rs12318506	1.000	rs35383953	chr12:75660182	A/G	cg04728562	chr12:75699417	CAPS2	-0.75	-5.73	-0.3	2.28e-8	Coronary artery calcification;
LUSC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg26441486	chr22:50317300	CRELD2	0.46	6.95	0.36	1.93e-11	Schizophrenia;
LUSC	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg24375607	chr4:120327624	NA	0.71	11.47	0.53	6.7e-26	Corneal astigmatism;
LUSC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	14.86	0.63	1.07e-38	Platelet count;
LUSC	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.39	-0.33	5.71e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9811920	0.625	rs9868170	chr3:99914139	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.33	6.24	0.32	1.31e-9	Axial length;
LUSC	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-8.94	-0.44	2.62e-17	HDL cholesterol;
LUSC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.3	-0.49	8.6e-22	Monocyte count;
LUSC	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg14154082	chr13:112174009	NA	0.37	7.63	0.39	2.53e-13	Menarche (age at onset);
LUSC	cis	rs6977660	0.619	rs10271639	chr7:19779604	G/A	cg05791153	chr7:19748676	TWISTNB	0.63	6.77	0.35	5.64e-11	Thyroid stimulating hormone;
LUSC	cis	rs4654899	1.000	rs10799685	chr1:21465930	A/C	cg02927042	chr1:21476669	EIF4G3	0.35	5.67	0.3	3.11e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25072359	chr17:41440525	NA	0.67	9.53	0.46	3.28e-19	Menopause (age at onset);
LUSC	cis	rs16867335	1.000	rs6739798	chr2:181465853	T/C	cg23363182	chr2:181467187	NA	-0.46	-5.87	-0.31	1.05e-8	Survival in rectal cancer;
LUSC	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.59	-0.38	3.32e-13	Type 2 diabetes;
LUSC	cis	rs4499344	0.633	rs259282	chr19:33163043	C/T	cg22980127	chr19:33182716	NUDT19	-0.45	-6.7	-0.34	8.81e-11	Mean platelet volume;
LUSC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg25566285	chr7:158114605	PTPRN2	0.31	5.85	0.3	1.2e-8	Calcium levels;
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg06815965	chr1:205818668	PM20D1	0.39	5.99	0.31	5.5e-9	Menarche (age at onset);
LUSC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg06640241	chr16:89574553	SPG7	0.9	16.97	0.68	5.16e-47	Multiple myeloma (IgH translocation);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg12939436	chr13:29233288	POMP	0.38	6.11	0.32	2.71e-9	Asthma;
LUSC	trans	rs7709909	0.967	rs7712332	chr5:79957835	C/T	cg05588111	chr10:112678594	NCRNA00081;SHOC2	-0.45	-6.01	-0.31	4.97e-9	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	trans	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg03886242	chr7:26192032	NFE2L3	0.38	6.28	0.32	1.04e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.52	0.5	1.5e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11608355	0.545	rs6606724	chr12:109905179	T/C	cg05360138	chr12:110035743	NA	0.89	11.55	0.53	3.47e-26	Neuroticism;
LUSC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg11843238	chr5:131593191	PDLIM4	0.38	6.63	0.34	1.36e-10	Breast cancer;
LUSC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03517284	chr6:25882590	NA	0.45	8.04	0.4	1.56e-14	Blood metabolite levels;
LUSC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg03161606	chr19:29218774	NA	0.54	6.66	0.34	1.13e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg02951883	chr7:2050386	MAD1L1	-0.46	-8.0	-0.4	2.06e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs6845621	0.901	rs7694311	chr4:18924948	G/C	cg12196642	chr4:18937545	NA	-0.35	-6.6	-0.34	1.66e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg08079166	chr15:68083412	MAP2K5	-0.42	-8.6	-0.43	3.1e-16	Restless legs syndrome;
LUSC	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.27	0.37	2.55e-12	Educational attainment;
LUSC	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17467752	chr17:38218738	THRA	-0.71	-11.39	-0.53	1.31e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg16434002	chr17:42200994	HDAC5	-0.42	-5.67	-0.3	3.04e-8	Total body bone mineral density;
LUSC	cis	rs738321	0.757	rs12329956	chr22:38535946	G/A	cg25457927	chr22:38595422	NA	-0.33	-6.22	-0.32	1.48e-9	Breast cancer;
LUSC	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg15704280	chr7:45808275	SEPT13	0.78	7.55	0.38	4.31e-13	Axial length;
LUSC	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg22431228	chr1:16359049	CLCNKA	0.44	8.76	0.43	1.03e-16	Dilated cardiomyopathy;
LUSC	cis	rs10492096	1.000	rs10849462	chr12:6575992	C/T	cg13857086	chr12:6580257	VAMP1	0.83	9.32	0.45	1.66e-18	Hip geometry;
LUSC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25072359	chr17:41440525	NA	-0.68	-9.74	-0.47	6.96e-20	Menopause (age at onset);
LUSC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg20818283	chr2:191399100	TMEM194B	-0.43	-6.55	-0.34	2.21e-10	Pulse pressure;
LUSC	cis	rs1775715	0.707	rs2808073	chr10:32179275	A/G	cg26784012	chr10:32216390	ARHGAP12	0.46	7.85	0.39	5.77e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg17757837	chr7:157058334	UBE3C	-0.82	-13.3	-0.59	1.14e-32	Body mass index;
LUSC	cis	rs3106136	0.967	rs2129595	chr4:95224454	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.25	-0.32	1.29e-9	Capecitabine sensitivity;
LUSC	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs721399	0.719	rs4646254	chr8:18262059	A/G	cg18736775	chr8:18248649	NAT2	-0.59	-7.43	-0.38	9.05e-13	Blood metabolite levels;
LUSC	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg24375607	chr4:120327624	NA	0.77	11.37	0.53	1.59e-25	Corneal astigmatism;
LUSC	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg17420585	chr12:42539391	GXYLT1	-0.38	-7.16	-0.36	5.33e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.32	0.41	2.28e-15	Resting heart rate;
LUSC	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg02569458	chr12:86230093	RASSF9	0.48	7.63	0.39	2.55e-13	Major depressive disorder;
LUSC	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg25214090	chr10:38739885	LOC399744	0.53	7.63	0.39	2.55e-13	Corneal astigmatism;
LUSC	cis	rs7267979	0.668	rs2387977	chr20:25599776	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.67	-12.44	-0.56	1.81e-29	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11608355	1.000	rs10774690	chr12:109859682	G/A	cg05360138	chr12:110035743	NA	0.47	6.38	0.33	6.03e-10	Neuroticism;
LUSC	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg15997130	chr1:24165203	NA	0.52	8.54	0.42	4.67e-16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
LUSC	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg03433033	chr1:76189801	ACADM	0.39	5.65	0.3	3.5e-8	Daytime sleep phenotypes;
LUSC	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.71	-0.39	1.42e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg19196401	chr6:110721138	DDO	0.45	8.46	0.42	8.65e-16	Platelet distribution width;
LUSC	cis	rs11610422	1.000	rs12824459	chr12:31414435	C/T	cg14306366	chr12:31406441	NA	-0.51	-6.25	-0.32	1.25e-9	Coronary artery disease;
LUSC	cis	rs4664304	0.966	rs7601374	chr2:160754050	T/C	cg23995753	chr2:160760732	LY75	-0.31	-5.75	-0.3	2.05e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24631450	chr2:234262952	DGKD	0.41	6.47	0.33	3.56e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7605827	0.897	rs1919292	chr2:15567236	A/G	cg19274914	chr2:15703543	NA	0.46	8.68	0.43	1.77e-16	Educational attainment (years of education);
LUSC	cis	rs4077468	1.000	rs11801695	chr1:205916175	A/C	cg07167872	chr1:205819463	PM20D1	0.44	6.66	0.34	1.16e-10	Cystic fibrosis-related diabetes;
LUSC	trans	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.09	-0.32	3.17e-9	Monocyte count;
LUSC	cis	rs13082711	0.911	rs35262121	chr3:27508277	G/A	cg02860705	chr3:27208620	NA	0.48	8.05	0.4	1.48e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	0.67	10.44	0.5	2.97e-22	Height;
LUSC	cis	rs6714788	0.565	rs9308833	chr2:100662618	C/T	cg22139774	chr2:100720529	AFF3	-0.38	-6.23	-0.32	1.43e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg11764359	chr7:65958608	NA	0.52	6.97	0.36	1.71e-11	Aortic root size;
LUSC	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-15.62	-0.65	1.1e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg01475377	chr6:109611718	NA	-0.45	-8.21	-0.41	4.87e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs4073416	0.542	rs6573614	chr14:65958703	G/A	cg03016385	chr14:66212404	NA	-0.38	-5.78	-0.3	1.73e-8	N-glycan levels;
LUSC	cis	rs4474465	0.915	rs7128449	chr11:78206760	G/A	cg27205649	chr11:78285834	NARS2	0.51	5.91	0.31	8.55e-9	Alzheimer's disease (survival time);
LUSC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg14440974	chr22:39074834	NA	-0.39	-6.35	-0.33	7.01e-10	Menopause (age at onset);
LUSC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg01616529	chr11:638424	DRD4	-0.35	-6.02	-0.31	4.64e-9	Systemic lupus erythematosus;
LUSC	trans	rs7567288	0.636	rs6726463	chr2:134465009	G/T	cg12381416	chr3:14359266	NA	0.53	5.99	0.31	5.3e-9	Height;
LUSC	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg04362960	chr10:104952993	NT5C2	0.61	9.69	0.47	1.01e-19	Arsenic metabolism;
LUSC	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.7	0.67	6.27e-46	Exhaled nitric oxide output;
LUSC	cis	rs3741151	0.686	rs2298469	chr11:73133030	T/C	cg17517138	chr11:73019481	ARHGEF17	0.8	7.35	0.37	1.56e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-8.3	-0.41	2.62e-15	Personality dimensions;
LUSC	cis	rs4820539	1.000	rs1051875	chr22:23466031	G/A	cg21100191	chr22:23484243	RTDR1	0.89	15.1	0.64	1.25e-39	Bone mineral density;
LUSC	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg12927641	chr6:109611667	NA	-0.37	-6.38	-0.33	5.82e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg13535736	chr9:111863775	C9orf5	-0.39	-6.4	-0.33	5.2e-10	Menarche (age at onset);
LUSC	cis	rs6920965	0.583	rs9388456	chr6:126147197	C/T	cg05901451	chr6:126070800	HEY2	-0.55	-8.12	-0.41	9.07e-15	High light scatter reticulocyte count;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg04159381	chr1:53018615	ZCCHC11	0.45	6.36	0.33	6.61e-10	Mosquito bite size;
LUSC	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg00012203	chr2:219082015	ARPC2	-0.5	-7.74	-0.39	1.18e-13	Ulcerative colitis;
LUSC	cis	rs1981331	0.867	rs76188425	chr21:48002207	C/T	cg23283320	chr21:48055893	PRMT2	1.12	8.14	0.41	7.72e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-6.85	-0.35	3.46e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg14634687	chr17:47094252	IGF2BP1	0.33	7.13	0.36	6.33e-12	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.43	0.53	8.95e-26	Prudent dietary pattern;
LUSC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.79	0.35	5.21e-11	Tonsillectomy;
LUSC	cis	rs4561483	0.667	rs3743590	chr16:11930337	A/C	cg08843971	chr16:11963173	GSPT1	-0.42	-6.17	-0.32	1.98e-9	Testicular germ cell tumor;
LUSC	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.74	14.55	0.62	1.7e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs68170813	0.559	rs4730226	chr7:106887274	A/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.27e-20	Coronary artery disease;
LUSC	cis	rs75920871	0.528	rs1531706	chr11:116943952	C/A	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.48	-0.33	3.25e-10	Subjective well-being;
LUSC	cis	rs9318086	0.712	rs1886970	chr13:24440498	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.42	6.28	0.32	1.08e-9	Myopia (pathological);
LUSC	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22029157	chr1:209979665	IRF6	0.74	10.99	0.52	3.49e-24	Cleft lip with or without cleft palate;
LUSC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg05425664	chr17:57184151	TRIM37	0.54	7.98	0.4	2.31e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.53e-9	Bladder cancer;
LUSC	cis	rs11039100	1.000	rs1470873	chr11:5827395	A/C	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.57	-0.5	1.04e-22	Alzheimer's disease;
LUSC	cis	rs28830936	1.000	rs2004162	chr15:41965542	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.1	-0.32	2.87e-9	Diastolic blood pressure;
LUSC	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg05709478	chr1:6581295	PLEKHG5	-0.51	-6.03	-0.31	4.3e-9	Body mass index;
LUSC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg26924012	chr15:45694286	SPATA5L1	1.12	19.83	0.74	2.12e-58	Homoarginine levels;
LUSC	cis	rs1979679	0.573	rs2348417	chr12:28735596	G/A	cg13890972	chr12:28721907	NA	-0.42	-5.93	-0.31	7.61e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg11843238	chr5:131593191	PDLIM4	0.34	5.93	0.31	7.38e-9	Breast cancer;
LUSC	cis	rs12220238	1.000	rs11000941	chr10:76018301	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	6.79	0.35	5.22e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.6	-9.63	-0.47	1.63e-19	Body mass index;
LUSC	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg10596483	chr8:143751796	JRK	0.52	7.57	0.38	3.79e-13	Schizophrenia;
LUSC	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.6	8.25	0.41	3.6e-15	Body mass index (adult);
LUSC	cis	rs4363385	0.818	rs12085426	chr1:153003074	C/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.71	-0.39	1.49e-13	Inflammatory skin disease;
LUSC	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.33	0.56	4.92e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg16240275	chr20:61666158	NCRNA00029	0.42	9.12	0.45	7.45e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7709377	0.595	rs41271	chr5:115629354	T/C	cg23108291	chr5:115420582	COMMD10	-0.42	-6.03	-0.31	4.29e-9	Metabolite levels  (X-11787);
LUSC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.44	7.24	0.37	3.12e-12	Hip circumference adjusted for BMI;
LUSC	trans	rs75804782	0.690	rs56198112	chr2:239348887	A/G	cg01134436	chr17:81009848	B3GNTL1	0.66	6.4	0.33	5.11e-10	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs2254546	0.516	rs35451117	chr8:11398335	C/A	cg22980483	chr2:80023725	CTNNA2	0.37	6.02	0.31	4.61e-9	Systemic lupus erythematosus;Kawasaki disease;
LUSC	trans	rs979233	0.502	rs276252	chr5:42062822	G/A	cg07010552	chr17:7358735	CHRNB1	-0.42	-6.02	-0.31	4.47e-9	Systemic lupus erythematosus;
LUSC	cis	rs9308433	0.553	rs11120299	chr1:214509407	C/A	cg06198575	chr1:214491504	SMYD2	0.44	6.91	0.35	2.44e-11	IgG glycosylation;
LUSC	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg24375607	chr4:120327624	NA	0.75	11.05	0.52	2.18e-24	Corneal astigmatism;
LUSC	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg09877947	chr5:131593287	PDLIM4	0.48	7.95	0.4	2.96e-14	Breast cancer;
LUSC	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.74	-0.39	1.21e-13	Chronic sinus infection;
LUSC	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg08213375	chr14:104286397	PPP1R13B	0.4	7.07	0.36	9.18e-12	Reticulocyte count;
LUSC	cis	rs12295403	1.000	rs12789252	chr11:18690389	C/T	cg09887367	chr11:18690185	NA	-0.37	-7.75	-0.39	1.12e-13	Ovarian reserve;
LUSC	trans	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.28	-0.32	1.04e-9	Neuroticism;
LUSC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	7.04	0.36	1.09e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	1.04	19.44	0.73	7.67e-57	Menopause (age at onset);
LUSC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg16393715	chr7:1948819	MAD1L1	0.4	6.8	0.35	4.9e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg14765337	chr11:45931715	PEX16	-0.4	-6.71	-0.34	8.35e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg12257692	chr3:49977190	RBM6	0.26	7.26	0.37	2.74e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs981844	0.645	rs72731677	chr4:154671475	C/G	cg14289246	chr4:154710475	SFRP2	0.51	6.57	0.34	1.98e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs11997175	0.713	rs4327826	chr8:33654807	T/G	ch.8.33884649F	chr8:33765107	NA	0.48	7.72	0.39	1.38e-13	Body mass index;
LUSC	cis	rs1113500	0.933	rs4593854	chr1:108638519	A/G	cg06207961	chr1:108661230	NA	0.39	7.16	0.36	5.22e-12	Growth-regulated protein alpha levels;
LUSC	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg27411982	chr8:10470053	RP1L1	-0.49	-8.28	-0.41	2.9e-15	Neuroticism;
LUSC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.66	-10.95	-0.51	4.9e-24	Systemic lupus erythematosus;
LUSC	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg06637938	chr14:75390232	RPS6KL1	0.61	9.88	0.48	2.32e-20	Caffeine consumption;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	10.05	0.48	6.22e-21	Lymphocyte counts;
LUSC	cis	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg17469321	chr7:55412551	NA	0.66	10.62	0.5	6.87e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg24733560	chr20:60626293	TAF4	0.35	5.74	0.3	2.17e-8	Body mass index;
LUSC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.37	-5.72	-0.3	2.42e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg23093090	chr10:104574429	C10orf26	-0.36	-6.66	-0.34	1.12e-10	Arsenic metabolism;
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.72	-10.94	-0.51	5.17e-24	Lymphocyte counts;
LUSC	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg19767477	chr5:127420684	SLC12A2	-0.43	-5.7	-0.3	2.58e-8	Ileal carcinoids;
LUSC	trans	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg05197062	chr11:11642011	GALNTL4	0.57	7.92	0.4	3.5e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7106204	0.748	rs6484024	chr11:24210079	T/C	ch.11.24196551F	chr11:24239977	NA	1.13	12.74	0.57	1.39e-30	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg10172584	chr19:19639581	YJEFN3	0.47	5.72	0.3	2.42e-8	Bipolar disorder;
LUSC	trans	rs1268789	0.545	rs4975067	chr4:79369767	C/A	cg06112894	chr8:141469983	TRAPPC9	0.22	5.96	0.31	6.33e-9	Hair shape;Hair morphology;
LUSC	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.88	0.31	1.02e-8	Breast cancer;
LUSC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-14.06	-0.61	1.38e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg07507251	chr3:52567010	NT5DC2	0.3	5.93	0.31	7.47e-9	Cognitive function;
LUSC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg07167872	chr1:205819463	PM20D1	-0.46	-6.66	-0.34	1.11e-10	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.76e-12	Type 2 diabetes;
LUSC	cis	rs1808579	0.935	rs57440424	chr18:21108614	G/A	cg14672496	chr18:21087552	C18orf8	0.36	6.23	0.32	1.43e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	trans	rs12692738	0.526	rs355874	chr2:165632668	G/A	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4363385	0.588	rs1577960	chr1:153025687	G/A	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.53	-0.34	2.42e-10	Inflammatory skin disease;
LUSC	cis	rs9296092	0.538	rs62405941	chr6:33517297	G/A	cg13560919	chr6:33536144	NA	-0.84	-15.62	-0.65	1.08e-41	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg05855489	chr10:104503620	C10orf26	0.58	9.29	0.45	2e-18	Reticulocyte count;
LUSC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.72	-9.62	-0.47	1.67e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00260888	chr20:30865478	KIF3B	-0.39	-6.07	-0.32	3.38e-9	Hepatitis;
LUSC	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg03806693	chr22:41940476	POLR3H	0.99	14.32	0.62	1.31e-36	Vitiligo;
LUSC	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg07148914	chr20:33460835	GGT7	-0.52	-8.12	-0.41	8.94e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs714027	0.605	rs1989870	chr22:30472254	A/G	cg11564601	chr22:30592435	NA	0.33	5.78	0.3	1.73e-8	Lymphocyte counts;
LUSC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg21475434	chr5:93447410	FAM172A	-0.86	-9.45	-0.46	6.2800000000000005e-19	Diabetic retinopathy;
LUSC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.11	-0.48	3.97e-21	Obesity-related traits;
LUSC	cis	rs72772090	0.539	rs56213813	chr5:96112284	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-7.27	-0.37	2.59e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.19	0.52	6.63e-25	Menopause (age at onset);
LUSC	cis	rs13401104	0.796	rs72620810	chr2:237117697	A/G	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg24692254	chr21:30365293	RNF160	0.75	11.86	0.54	2.66e-27	Pancreatic cancer;
LUSC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg00074818	chr8:8560427	CLDN23	0.57	9.66	0.47	1.29e-19	Obesity-related traits;
LUSC	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg09835421	chr16:68378352	PRMT7	-0.67	-7.05	-0.36	1.03e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	0.58	9.28	0.45	2.15e-18	Breast cancer;
LUSC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg07424592	chr7:64974309	NA	0.68	6.05	0.31	3.8e-9	Diabetic kidney disease;
LUSC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg03213289	chr20:61660250	NA	0.67	13.65	0.6	5.25e-34	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2834081	0.536	rs11702285	chr21:34474294	G/A	cg00274965	chr21:34405681	NA	0.4	6.72	0.34	8.01e-11	Sum eosinophil basophil counts;
LUSC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg21681030	chr2:46777652	RHOQ	0.52	7.45	0.38	8.06e-13	Height;
LUSC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08219700	chr8:58056026	NA	0.65	7.21	0.37	3.67e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1953600	0.870	rs12770550	chr10:81953451	G/T	cg00277334	chr10:82204260	NA	0.45	7.03	0.36	1.2e-11	Sarcoidosis;
LUSC	cis	rs4478858	0.735	rs11576621	chr1:31795460	A/G	cg00250761	chr1:31883323	NA	-0.35	-8.75	-0.43	1.09e-16	Alcohol dependence;
LUSC	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	0.78	11.89	0.55	1.96e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.86	-0.31	1.13e-8	Alzheimer's disease (late onset);
LUSC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-18.85	-0.72	1.63e-54	Renal cell carcinoma;
LUSC	cis	rs10193935	0.901	rs6544529	chr2:42510652	A/T	cg27598129	chr2:42591480	NA	-0.64	-8.71	-0.43	1.39e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg18240062	chr17:79603768	NPLOC4	-0.69	-12.86	-0.58	4.98e-31	Eye color traits;
LUSC	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.93	-0.35	2.15e-11	Fear of minor pain;
LUSC	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg07895657	chr22:50616420	PANX2	0.34	5.96	0.31	6.26e-9	Obesity-related traits;
LUSC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg06618935	chr21:46677482	NA	-0.39	-7.74	-0.39	1.16e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	11.88	0.55	2.16e-27	Electrocardiographic conduction measures;
LUSC	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.68	0.65	6.55e-42	Morning vs. evening chronotype;
LUSC	trans	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg18187862	chr3:45730750	SACM1L	-0.58	-7.47	-0.38	7.1e-13	Primary sclerosing cholangitis;
LUSC	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.7	-9.91	-0.48	1.9e-20	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg24631222	chr15:78858424	CHRNA5	0.84	11.42	0.53	1.05e-25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg22029157	chr1:209979665	IRF6	0.52	8.37	0.42	1.6e-15	Monobrow;
LUSC	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	12.65	0.57	3.08e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg14343924	chr8:8086146	FLJ10661	-0.4	-5.71	-0.3	2.52e-8	Mood instability;
LUSC	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg17077180	chr1:38461687	NA	-0.54	-9.43	-0.46	6.96e-19	Coronary artery disease;
LUSC	cis	rs1256061	0.603	rs1256036	chr14:64743332	C/T	cg21174375	chr14:64681225	SYNE2	0.35	6.26	0.32	1.18e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.7	-0.43	1.53e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg18209359	chr17:80159595	CCDC57	-0.39	-6.66	-0.34	1.15e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg05084668	chr3:125655381	ALG1L	-0.45	-6.02	-0.31	4.67e-9	Blood pressure (smoking interaction);
LUSC	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg09491104	chr22:46646882	C22orf40	-0.74	-6.78	-0.35	5.44e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7705502	1.000	rs56197583	chr5:173336792	G/A	cg18693985	chr5:173351052	CPEB4	-0.37	-5.98	-0.31	5.85e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.48	6.51	0.34	2.82e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg06454157	chr6:167490870	NA	-0.25	-6.07	-0.31	3.57e-9	Crohn's disease;
LUSC	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg10018233	chr7:150070692	REPIN1	0.4	6.67	0.34	1.04e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6722750	0.901	rs7567728	chr2:64411932	A/C	cg22352474	chr2:64371530	PELI1	-0.53	-7.84	-0.39	6.25e-14	Neuroticism;
LUSC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	7.5	0.38	5.7e-13	Tonsillectomy;
LUSC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg25566285	chr7:158114605	PTPRN2	-0.33	-6.06	-0.31	3.61e-9	Calcium levels;
LUSC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg02269571	chr22:50332266	NA	-0.48	-7.16	-0.36	5.04e-12	Schizophrenia;
LUSC	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg05234568	chr11:5960015	NA	-0.53	-8.19	-0.41	5.78e-15	DNA methylation (variation);
LUSC	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	0.81	11.23	0.52	4.75e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg07741184	chr6:167504864	NA	-0.38	-6.93	-0.35	2.13e-11	Crohn's disease;
LUSC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg11663144	chr21:46675770	NA	-0.41	-7.17	-0.37	4.73e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4746818	0.892	rs10823298	chr10:70867083	T/C	cg11621586	chr10:70884670	VPS26A	1.05	11.71	0.54	9.17e-27	Left atrial antero-posterior diameter;
LUSC	cis	rs6681460	0.649	rs1856315	chr1:67005229	A/G	cg02459107	chr1:67143332	SGIP1	0.37	6.27	0.32	1.11e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21963583	chr11:68658836	MRPL21	0.56	8.55	0.42	4.63e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg05872129	chr22:39784769	NA	-0.6	-11.18	-0.52	7.36e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.26	-0.37	2.74e-12	Triglycerides;
LUSC	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17467752	chr17:38218738	THRA	0.77	12.45	0.56	1.7e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	trans	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg11887960	chr12:57824829	NA	0.53	6.64	0.34	1.23e-10	Obesity-related traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19139554	chr3:50126253	RBM5	-0.44	-6.21	-0.32	1.56e-9	Electrocardiographic conduction measures;
LUSC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg18225595	chr11:63971243	STIP1	0.51	6.33	0.33	7.83e-10	Mean platelet volume;
LUSC	cis	rs2652834	0.904	rs7175602	chr15:63367032	T/C	cg05507819	chr15:63340323	TPM1	-0.72	-9.24	-0.45	2.93e-18	HDL cholesterol;
LUSC	cis	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg20307385	chr11:47447363	PSMC3	0.55	6.42	0.33	4.77e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg06484146	chr7:12443880	VWDE	-0.73	-7.35	-0.37	1.58e-12	Coronary artery disease;
LUSC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.56	0.46	2.65e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg10130564	chr11:117069849	TAGLN	0.31	5.75	0.3	2.01e-8	Blood protein levels;
LUSC	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg00757033	chr12:89920650	WDR51B	-0.51	-8.97	-0.44	2.15e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26880961	chr2:92231224	NA	-0.45	-7.4	-0.38	1.14e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg07541023	chr7:19748670	TWISTNB	0.65	6.89	0.35	2.82e-11	Thyroid stimulating hormone;
LUSC	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg03983476	chr2:10830698	NOL10	0.37	5.7	0.3	2.7e-8	Prostate cancer;
LUSC	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.34	0.37	1.62e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg05373962	chr22:49881684	NA	-0.41	-8.71	-0.43	1.39e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg07148914	chr20:33460835	GGT7	-0.46	-6.8	-0.35	4.88e-11	Height;
LUSC	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg17127132	chr2:85788382	GGCX	0.42	5.9	0.31	9.03e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg04508216	chr1:11107452	MASP2	0.31	5.65	0.3	3.43e-8	Body mass index;
LUSC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.51	0.65	3.1e-41	Platelet count;
LUSC	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg11189052	chr15:85197271	WDR73	-0.44	-6.42	-0.33	4.63e-10	P wave terminal force;
LUSC	cis	rs17095355	1.000	rs55717725	chr10:111666629	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.57	-7.27	-0.37	2.51e-12	Biliary atresia;
LUSC	trans	rs1459104	0.866	rs34179570	chr11:54823141	C/T	cg15704280	chr7:45808275	SEPT13	0.71	6.25	0.32	1.22e-9	Body mass index;
LUSC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg02569458	chr12:86230093	RASSF9	0.52	8.61	0.43	2.94e-16	Major depressive disorder;
LUSC	cis	rs2798269	0.933	rs2315545	chr13:22076491	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.38	-5.71	-0.3	2.49e-8	PR segment;
LUSC	cis	rs7809950	1.000	rs3801944	chr7:107255548	T/C	cg23024343	chr7:107201750	COG5	0.54	8.33	0.41	2.17e-15	Coronary artery disease;
LUSC	cis	rs6725041	0.532	rs12623803	chr2:213201642	G/C	cg16329650	chr2:213403929	ERBB4	-0.42	-6.67	-0.34	1.06e-10	QT interval (ambient particulate matter interaction);
LUSC	cis	rs2273669	0.667	rs12200531	chr6:109320441	T/C	cg05315195	chr6:109294784	ARMC2	-0.53	-5.94	-0.31	7.15e-9	Prostate cancer;
LUSC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18876405	chr7:65276391	NA	0.54	8.47	0.42	7.77e-16	Aortic root size;
LUSC	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.65	16.67	0.67	8.27e-46	Anterior chamber depth;
LUSC	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg16586182	chr3:47516702	SCAP	-0.52	-8.11	-0.41	1e-14	Colorectal cancer;
LUSC	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12292205	chr6:26970375	C6orf41	-0.64	-9.18	-0.45	4.53e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg03929089	chr4:120376271	NA	0.77	8.48	0.42	7.34e-16	Axial length;
LUSC	cis	rs7707921	0.881	rs112355050	chr5:81386035	C/T	cg15871215	chr5:81402204	ATG10	-0.44	-6.39	-0.33	5.69e-10	Breast cancer;
LUSC	cis	rs9303542	0.694	rs4793854	chr17:46572133	A/G	cg09704116	chr17:46666958	LOC404266	0.32	6.01	0.31	4.88e-9	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg25174290	chr11:3078921	CARS	-0.41	-6.08	-0.32	3.28e-9	Calcium levels;
LUSC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06558623	chr16:89946397	TCF25	1.11	9.73	0.47	7.07e-20	Skin colour saturation;
LUSC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg12927641	chr6:109611667	NA	-0.4	-6.81	-0.35	4.61e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg11812906	chr14:75593930	NEK9	0.65	11.16	0.52	8.82e-25	Height;
LUSC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg16606324	chr3:10149918	C3orf24	0.68	9.98	0.48	1.06e-20	Alzheimer's disease;
LUSC	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-7.51	-0.38	5.27e-13	Schizophrenia;
LUSC	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg11812906	chr14:75593930	NEK9	-0.64	-10.89	-0.51	7.59e-24	Height;
LUSC	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg04166393	chr7:2884313	GNA12	0.44	6.11	0.32	2.74e-9	Height;
LUSC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg23260525	chr10:116636907	FAM160B1	0.48	10.32	0.49	7.3e-22	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg13319975	chr6:146136371	FBXO30	-0.4	-5.78	-0.3	1.72e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05776053	chr2:74358815	NA	-0.43	-6.76	-0.35	6.04e-11	Gestational age at birth (maternal effect);
LUSC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.71	-13.26	-0.59	1.53e-32	Extrinsic epigenetic age acceleration;
LUSC	cis	rs13401104	0.796	rs72620803	chr2:237110460	T/C	cg19324714	chr2:237145437	ASB18	0.42	5.65	0.3	3.43e-8	Educational attainment;
LUSC	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.24	-0.37	3.09e-12	Bipolar disorder;
LUSC	trans	rs12200782	0.872	rs41266837	chr6:26409729	G/A	cg11837749	chr1:55047332	ACOT11	0.52	6.28	0.32	1.06e-9	Small cell lung carcinoma;
LUSC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg09165964	chr15:75287851	SCAMP5	-1.05	-15.08	-0.64	1.5e-39	Blood trace element (Zn levels);
LUSC	cis	rs2625529	0.824	rs4777475	chr15:72218206	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.49	-0.38	6.37e-13	Red blood cell count;
LUSC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.69	-12.36	-0.56	3.74e-29	Prudent dietary pattern;
LUSC	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.45	-0.42	9.25e-16	Response to antipsychotic treatment;
LUSC	cis	rs7091068	0.536	rs7893369	chr10:95410147	A/G	cg20715218	chr10:95462985	C10orf4	0.62	8.33	0.41	2.1e-15	Urinary tract infection frequency;
LUSC	cis	rs7577851	0.627	rs112826171	chr2:69672871	A/G	cg10773587	chr2:69614142	GFPT1	0.55	6.61	0.34	1.49e-10	Parkinson's disease (age of onset);
LUSC	cis	rs2046867	0.818	rs17010204	chr3:72879099	G/A	cg25664220	chr3:72788482	NA	-0.67	-11.58	-0.54	2.61e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs8180991	0.955	rs55921265	chr8:126503915	G/A	cg24553815	chr6:147728235	NA	-0.44	-6.11	-0.32	2.81e-9	C-reactive protein levels or LDL-cholesterol levels (pleiotropy);
LUSC	cis	rs10465746	0.901	rs17534614	chr1:84383079	G/A	cg10977910	chr1:84465055	TTLL7	0.42	6.08	0.32	3.29e-9	Obesity-related traits;
LUSC	trans	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg10756647	chr7:56101905	PSPH	0.86	8.39	0.42	1.36e-15	Diabetic kidney disease;
LUSC	cis	rs28595532	0.748	rs115651241	chr4:119363509	C/T	cg21605333	chr4:119757512	SEC24D	1.02	8.29	0.41	2.73e-15	Cannabis dependence symptom count;
LUSC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.73	0.6	2.61e-34	Breast cancer;
LUSC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08280861	chr8:58055591	NA	0.54	5.66	0.3	3.23e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21028142	chr17:79581711	NPLOC4	-0.32	-7.6	-0.38	2.93e-13	Eye color traits;
LUSC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg09491104	chr22:46646882	C22orf40	-0.64	-7.29	-0.37	2.28e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs870825	0.655	rs2310104	chr4:185619967	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg11752832	chr7:134001865	SLC35B4	0.55	8.65	0.43	2.28e-16	Mean platelet volume;
LUSC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg05896524	chr21:47604654	C21orf56	0.4	5.84	0.3	1.24e-8	Testicular germ cell tumor;
LUSC	cis	rs7588746	0.571	rs4673891	chr2:201156362	C/G	cg23649088	chr2:200775458	C2orf69	-0.42	-6.05	-0.31	3.91e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs4478858	0.735	rs6681286	chr1:31799384	G/C	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg15556689	chr8:8085844	FLJ10661	0.68	9.88	0.48	2.3e-20	Red cell distribution width;
LUSC	cis	rs17255340	0.539	rs12214015	chr6:84107124	C/T	cg08257003	chr6:84140564	ME1	0.34	8.48	0.42	7.31e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg01881094	chr2:180872142	CWC22	-0.82	-10.74	-0.51	2.66e-23	Schizophrenia;
LUSC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg05896524	chr21:47604654	C21orf56	-0.53	-8.09	-0.4	1.1e-14	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg17366294	chr4:99064904	C4orf37	0.53	9.16	0.45	5.41e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.84	0.35	3.81e-11	Tonsillectomy;
LUSC	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg06636001	chr8:8085503	FLJ10661	0.65	9.89	0.48	2.17e-20	Mood instability;
LUSC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1395	1.000	rs1141313	chr2:27460968	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.38	6.2	0.32	1.7e-9	Blood metabolite levels;
LUSC	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg00484396	chr16:3507460	NAT15	0.87	11.38	0.53	1.46e-25	Tuberculosis;
LUSC	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg26816564	chr1:7831052	VAMP3	0.92	13.32	0.59	9.06e-33	Inflammatory bowel disease;
LUSC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.13	0.36	6.41e-12	Platelet count;
LUSC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg26441486	chr22:50317300	CRELD2	-0.54	-8.21	-0.41	4.86e-15	Schizophrenia;
LUSC	cis	rs6942756	0.806	rs68184415	chr7:128988862	C/T	cg02491457	chr7:128862824	NA	-0.51	-7.74	-0.39	1.23e-13	White matter hyperintensity burden;
LUSC	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg05754148	chr16:3507555	NAT15	0.79	9.61	0.47	1.9e-19	Tuberculosis;
LUSC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.43	-5.72	-0.3	2.32e-8	Gut microbiome composition (summer);
LUSC	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	8.92	0.44	3.12e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-6.32	-0.33	8.16e-10	Menopause (age at onset);
LUSC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg24209194	chr3:40518798	ZNF619	0.44	5.82	0.3	1.36e-8	Renal cell carcinoma;
LUSC	cis	rs2652834	0.808	rs6494393	chr15:63426435	A/C	cg05507819	chr15:63340323	TPM1	0.45	5.82	0.3	1.37e-8	HDL cholesterol;
LUSC	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-7.07	-0.36	9.11e-12	Axial length;
LUSC	cis	rs9815354	0.812	rs17218103	chr3:41943724	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.49	0.42	6.81e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.03	-0.36	1.2e-11	Bipolar disorder;
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.47	-6.21	-0.32	1.56e-9	Longevity;Endometriosis;
LUSC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs34779708	0.931	rs12261654	chr10:35322024	G/A	cg04310649	chr10:35416472	CREM	-0.4	-6.07	-0.32	3.45e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2191566	1.000	rs384544	chr19:44505255	A/T	cg03039196	chr19:44506973	ZNF230	-0.37	-5.86	-0.31	1.14e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg08847533	chr14:75593920	NEK9	0.84	14.5	0.62	2.61e-37	Height;
LUSC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.59	-0.38	3.19e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg24759859	chr6:86352639	SYNCRIP	0.41	5.97	0.31	6.06e-9	Smooth-surface caries;
LUSC	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg16070123	chr10:51489643	NA	0.55	9.19	0.45	4.36e-18	Prostate-specific antigen levels;
LUSC	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-13.93	-0.61	4.39e-35	Exhaled nitric oxide output;
LUSC	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg16386425	chr10:429943	DIP2C	0.41	5.92	0.31	8.21e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	11.4	0.53	1.17e-25	Colorectal cancer;
LUSC	cis	rs11997175	0.624	rs79944133	chr8:33730588	A/G	ch.8.33884649F	chr8:33765107	NA	0.47	6.58	0.34	1.82e-10	Body mass index;
LUSC	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg18232548	chr7:50535776	DDC	0.5	7.49	0.38	6.04e-13	Malaria;
LUSC	trans	rs7980799	0.682	rs1601006	chr12:33629519	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.75	-0.43	1.07e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs2046867	0.628	rs61159664	chr3:72916958	C/G	cg25664220	chr3:72788482	NA	-0.55	-9.69	-0.47	1.01e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2932538	0.922	rs999923	chr1:113110548	T/C	cg22162597	chr1:113214053	CAPZA1	0.7	10.0	0.48	9.16e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7584330	0.737	rs6758246	chr2:238359891	G/C	cg16989719	chr2:238392110	NA	-0.35	-5.97	-0.31	6.11e-9	Prostate cancer;
LUSC	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg12863693	chr15:85201151	NMB	0.41	8.42	0.42	1.11e-15	Schizophrenia;
LUSC	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-13.42	-0.59	3.98e-33	Brugada syndrome;
LUSC	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg14092571	chr14:90743983	NA	-0.35	-5.71	-0.3	2.45e-8	Mortality in heart failure;
LUSC	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg26875233	chr11:93583750	C11orf90	-0.31	-6.04	-0.31	4e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg14092988	chr3:52407081	DNAH1	0.3	5.86	0.31	1.1e-8	Bipolar disorder;
LUSC	cis	rs7408868	1.000	rs10416389	chr19:15278674	G/C	cg14696996	chr19:15285081	NOTCH3	0.97	9.33	0.45	1.56e-18	Pulse pressure;
LUSC	trans	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.94	0.4	3.18e-14	Ulcerative colitis;
LUSC	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.87	-0.44	4.51e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-5.93	-0.31	7.51e-9	Vitiligo;
LUSC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-6.98	-0.36	1.55e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs11031096	0.655	rs35898891	chr11:4211112	G/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.72	-0.3	2.41e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.36	-0.33	6.77e-10	Response to antipsychotic treatment;
LUSC	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg04352962	chr1:209979756	IRF6	0.53	6.2	0.32	1.68e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg04850211	chr1:228464232	OBSCN	0.31	5.68	0.3	2.95e-8	Diastolic blood pressure;
LUSC	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.69	-0.3	2.78e-8	Reticulocyte count;
LUSC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.91	0.35	2.41e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg02423579	chr7:2872169	GNA12	-0.44	-6.44	-0.33	4.19e-10	Height;
LUSC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg10117171	chr1:25599238	RHD	-0.37	-5.69	-0.3	2.85e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg24503407	chr1:205819492	PM20D1	0.56	9.29	0.45	2.05e-18	Menarche (age at onset);
LUSC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.39	-6.0	-0.31	5.25e-9	Platelet count;
LUSC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg00409905	chr10:38381863	ZNF37A	-0.34	-6.0	-0.31	5.18e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg17127132	chr2:85788382	GGCX	0.45	6.98	0.36	1.55e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs5758511	0.689	rs62240864	chr22:42563889	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.62	-7.0	-0.36	1.38e-11	Birth weight;
LUSC	cis	rs8016982	0.559	rs10133562	chr14:81732758	C/T	cg01989461	chr14:81687754	GTF2A1	-0.49	-6.19	-0.32	1.78e-9	Schizophrenia;
LUSC	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg06207120	chr15:45996521	NA	0.39	6.03	0.31	4.28e-9	Waist circumference;Weight;
LUSC	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg27432699	chr2:27873401	GPN1	0.79	14.85	0.63	1.19e-38	Oral cavity cancer;
LUSC	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.58	10.21	0.49	1.7e-21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.69	0.34	9.51e-11	Intraocular pressure;
LUSC	trans	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.37	-0.33	6.25e-10	Monocyte count;
LUSC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00684032	chr4:1343700	KIAA1530	0.37	6.51	0.34	2.82e-10	Obesity-related traits;
LUSC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14829155	chr15:31115871	NA	-0.55	-7.64	-0.39	2.26e-13	Huntington's disease progression;
LUSC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	trans	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg24644049	chr4:85504048	CDS1	0.69	7.03	0.36	1.15e-11	Skin colour saturation;
LUSC	cis	rs3772130	0.540	rs11717089	chr3:121563271	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.83	13.54	0.6	1.29e-33	Cognitive performance;
LUSC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg24399712	chr22:39784796	NA	-0.63	-10.5	-0.5	1.73e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.19	-0.37	4.31e-12	Neuroticism;
LUSC	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19748678	chr4:122722346	EXOSC9	-0.5	-7.4	-0.38	1.09e-12	Type 2 diabetes;
LUSC	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg24642439	chr20:33292090	TP53INP2	0.41	5.93	0.31	7.46e-9	Height;
LUSC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.95	0.44	2.56e-17	Menopause (age at onset);
LUSC	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg05360138	chr12:110035743	NA	0.93	10.92	0.51	6.12e-24	Neuroticism;
LUSC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.63	-5.96	-0.31	6.45e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg24060327	chr5:131705240	SLC22A5	-0.66	-11.6	-0.54	2.26e-26	Breast cancer;
LUSC	cis	rs9807989	0.839	rs10192157	chr2:102968356	C/T	cg03938978	chr2:103052716	IL18RAP	0.32	5.91	0.31	8.63e-9	Asthma;
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	5.8	0.3	1.55e-8	Electroencephalogram traits;
LUSC	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs9549260	0.755	rs3892360	chr13:41184078	C/G	cg21288729	chr13:41239152	FOXO1	0.6	9.15	0.45	5.98e-18	Red blood cell count;
LUSC	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg08807101	chr21:30365312	RNF160	-0.69	-10.67	-0.5	4.74e-23	Pancreatic cancer;
LUSC	cis	rs12493885	0.725	rs11707232	chr3:153742077	T/A	cg17054900	chr3:154042577	DHX36	-0.7	-7.37	-0.37	1.33e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9399401	0.626	rs6906468	chr6:142769386	A/G	cg03128060	chr6:142623767	GPR126	0.54	9.51	0.46	3.83e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs16958440	0.581	rs11872531	chr18:44689234	C/A	cg17192377	chr18:44677553	HDHD2	0.52	6.12	0.32	2.6e-9	Sitting height ratio;
LUSC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg22638593	chr5:131593259	PDLIM4	-0.41	-5.89	-0.31	9.42e-9	Breast cancer;
LUSC	cis	rs1044826	0.642	rs176983	chr3:139213755	G/A	cg15131784	chr3:139108705	COPB2	0.4	6.4	0.33	5.34e-10	Obesity-related traits;
LUSC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg02772935	chr3:125709198	NA	-0.48	-5.86	-0.31	1.12e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.0	-15.99	-0.66	3.98e-43	Platelet count;
LUSC	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg05925327	chr15:68127851	NA	-0.4	-6.42	-0.33	4.63e-10	Restless legs syndrome;
LUSC	cis	rs17689437	0.647	rs820799	chr16:68559537	C/A	cg02508848	chr16:68573721	ZFP90	-0.38	-5.95	-0.31	6.71e-9	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LUSC	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.13	-0.36	6.32e-12	Menopause (age at onset);
LUSC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg24813613	chr7:1882135	MAD1L1	-0.41	-6.81	-0.35	4.42e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg02997394	chr19:33096574	ANKRD27	0.79	8.95	0.44	2.44e-17	Eosinophilic esophagitis;
LUSC	trans	rs311904	0.793	rs10775200	chr15:69331758	G/A	cg07092097	chr10:88720025	SNCG	-0.64	-6.15	-0.32	2.2e-9	Obesity-related traits;
LUSC	trans	rs7939886	0.920	rs58405266	chr11:55863225	G/A	cg03929089	chr4:120376271	NA	0.73	6.06	0.31	3.65e-9	Myopia (pathological);
LUSC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg05527609	chr1:210001259	C1orf107	0.88	11.72	0.54	8.63e-27	Orofacial clefts;
LUSC	cis	rs17540621	1.000	rs116131523	chr2:47198516	G/A	cg23978866	chr2:47230407	TTC7A	-0.92	-6.91	-0.35	2.44e-11	Response to statin therapy;
LUSC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg06454157	chr6:167490870	NA	-0.25	-6.06	-0.31	3.65e-9	Crohn's disease;
LUSC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg17366294	chr4:99064904	C4orf37	-0.56	-10.04	-0.48	6.75e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.55	7.61	0.38	2.91e-13	Systemic lupus erythematosus;
LUSC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg23711669	chr6:146136114	FBXO30	-0.83	-15.28	-0.64	2.38e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4499344	0.768	rs10411319	chr19:33102805	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.86	13.3	0.59	1.12e-32	Mean platelet volume;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg15222563	chr19:7745491	TRAPPC5	0.42	5.97	0.31	6.13e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg22437258	chr11:111473054	SIK2	0.48	6.51	0.34	2.69e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.83	-0.44	5.87e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.55	-0.42	4.52e-16	Lung cancer;
LUSC	cis	rs11971779	0.941	rs28395455	chr7:139035986	A/G	cg07862535	chr7:139043722	LUC7L2	0.63	7.07	0.36	9.04e-12	Diisocyanate-induced asthma;
LUSC	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg20701182	chr2:24300061	SF3B14	0.52	6.74	0.35	6.86e-11	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs28595532	0.668	rs56410164	chr4:119331625	A/G	cg21605333	chr4:119757512	SEC24D	1.01	8.28	0.41	3.09e-15	Cannabis dependence symptom count;
LUSC	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg03340356	chr1:67600835	NA	0.39	6.45	0.33	3.81e-10	Psoriasis;
LUSC	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg22089800	chr15:90895588	ZNF774	0.53	7.56	0.38	3.96e-13	Rheumatoid arthritis;
LUSC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.66	-10.87	-0.51	8.99e-24	Type 2 diabetes;
LUSC	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg08807101	chr21:30365312	RNF160	-0.67	-10.34	-0.49	6.11e-22	Pancreatic cancer;
LUSC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16680214	chr1:154839983	KCNN3	-0.56	-10.94	-0.51	5.23e-24	Prostate cancer;
LUSC	cis	rs57590327	0.503	rs13079104	chr3:81886039	A/T	cg07356753	chr3:81810745	GBE1	-0.65	-10.05	-0.48	6.11e-21	Extraversion;
LUSC	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg08601574	chr20:25228251	PYGB	0.42	6.41	0.33	4.9e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg01973587	chr1:228161476	NA	-0.41	-7.15	-0.36	5.48e-12	Diastolic blood pressure;
LUSC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08280861	chr8:58055591	NA	0.57	6.79	0.35	5.08e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg09754948	chr16:28834200	ATXN2L	0.41	6.13	0.32	2.5e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg13736514	chr6:26305472	NA	-0.36	-6.71	-0.34	8.54e-11	Educational attainment;
LUSC	cis	rs977987	0.872	rs4887816	chr16:75319716	T/C	cg04384234	chr16:75411784	CFDP1	-0.38	-6.01	-0.31	4.85e-9	Dupuytren's disease;
LUSC	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg03732007	chr1:2071316	PRKCZ	0.48	7.71	0.39	1.48e-13	Height;
LUSC	cis	rs17125944	0.556	rs12588482	chr14:53311552	G/A	cg00686598	chr14:53173677	PSMC6	-0.61	-5.66	-0.3	3.27e-8	Alzheimer's disease (late onset);
LUSC	cis	rs8053891	0.614	rs34235351	chr16:71987875	G/A	cg04254540	chr16:71951199	KIAA0174	-0.48	-6.65	-0.34	1.22e-10	Coronary artery disease;
LUSC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg10556349	chr10:835070	NA	0.53	6.35	0.33	7.02e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg05234568	chr11:5960015	NA	-0.6	-8.66	-0.43	2.01e-16	DNA methylation (variation);
LUSC	cis	rs6684514	0.885	rs12036837	chr1:156283895	A/C	cg16558208	chr1:156270281	VHLL	0.39	6.03	0.31	4.43e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUSC	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg26395211	chr5:140044315	WDR55	-0.37	-5.77	-0.3	1.78e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg18758796	chr5:131593413	PDLIM4	0.45	7.62	0.38	2.72e-13	Breast cancer;
LUSC	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg11584989	chr19:19387371	SF4	0.55	6.75	0.35	6.39e-11	Bipolar disorder;
LUSC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg13206674	chr6:150067644	NUP43	0.6	9.53	0.46	3.38e-19	Lung cancer;
LUSC	cis	rs7827545	0.545	rs6998092	chr8:135557449	A/G	cg17885191	chr8:135476712	NA	0.62	7.9	0.4	4.19e-14	Hypertension (SNP x SNP interaction);
LUSC	cis	rs36405	0.500	rs17178883	chr14:72355591	C/T	cg23396177	chr14:72358413	NA	0.37	7.01	0.36	1.36e-11	Yang-deficiency constitution;
LUSC	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg13755796	chr4:20253514	NA	-0.43	-6.67	-0.34	1.07e-10	Life satisfaction;
LUSC	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.14	-0.41	7.97e-15	Retinal vascular caliber;
LUSC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21724239	chr8:58056113	NA	0.85	9.53	0.46	3.26e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.3	-0.45	1.93e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7241530	0.662	rs55841218	chr18:75902133	G/A	cg14642773	chr18:75888474	NA	0.41	6.27	0.32	1.14e-9	Educational attainment (years of education);
LUSC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	0.95	12.87	0.58	4.49e-31	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.76	0.39	1.01e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg20891283	chr12:69753455	YEATS4	0.68	10.76	0.51	2.27e-23	Blood protein levels;
LUSC	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg01620082	chr3:125678407	NA	-0.72	-6.85	-0.35	3.64e-11	Urinary tract infection frequency;
LUSC	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg14530993	chr4:882597	GAK	0.69	6.84	0.35	3.88e-11	Parkinson's disease;
LUSC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg06238570	chr21:40685208	BRWD1	0.49	7.41	0.38	1.01e-12	Cognitive function;
LUSC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.06	0.58	9.27e-32	Alzheimer's disease;
LUSC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg09491104	chr22:46646882	C22orf40	-0.64	-7.39	-0.37	1.22e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.04	-0.31	4.21e-9	Resting heart rate;
LUSC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg12751644	chr20:60527061	NA	0.36	6.25	0.32	1.24e-9	Body mass index;
LUSC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.44e-15	Total body bone mineral density;
LUSC	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	1.12	19.01	0.72	3.91e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2979489	0.891	rs3824107	chr8:30353412	A/G	cg26383811	chr8:30366931	RBPMS	0.51	7.45	0.38	8.02e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg11502198	chr6:26597334	ABT1	0.71	11.81	0.54	3.94e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg17830980	chr10:43048298	ZNF37B	-0.39	-6.09	-0.32	3.12e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs12519773	0.526	rs4632783	chr5:92528309	A/G	cg18783429	chr5:92414398	NA	0.33	7.03	0.36	1.18e-11	Migraine;
LUSC	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg00982548	chr2:198649783	BOLL	-0.58	-7.21	-0.37	3.87e-12	Ulcerative colitis;
LUSC	cis	rs3126085	0.935	rs3126046	chr1:152256925	G/A	cg26876637	chr1:152193138	HRNR	-0.46	-6.38	-0.33	6.03e-10	Atopic dermatitis;
LUSC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg05234568	chr11:5960015	NA	-0.53	-8.23	-0.41	4.35e-15	DNA methylation (variation);
LUSC	cis	rs4601821	0.823	rs10891546	chr11:113265292	C/T	cg14159747	chr11:113255604	NA	-0.25	-6.15	-0.32	2.17e-9	Alcoholic chronic pancreatitis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16003500	chr20:49547260	ADNP	0.47	6.42	0.33	4.7e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs796825	0.530	rs7612000	chr3:119965914	C/T	cg21790991	chr3:120137480	FSTL1	-0.33	-5.93	-0.31	7.5e-9	HIV-1 susceptibility;
LUSC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.6	0.38	3.11e-13	Prudent dietary pattern;
LUSC	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg24558204	chr6:135376177	HBS1L	0.57	8.81	0.43	6.87e-17	Red blood cell count;
LUSC	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg01966878	chr4:90757139	SNCA	-0.37	-6.38	-0.33	6.04e-10	Dementia with Lewy bodies;
LUSC	trans	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.41	-6.0	-0.31	5.25e-9	Platelet distribution width;
LUSC	cis	rs7598759	0.548	rs11693738	chr2:232360484	C/T	cg19187155	chr2:232395269	NMUR1	0.93	16.15	0.66	9.37e-44	Noise-induced hearing loss;
LUSC	cis	rs7605827	0.675	rs2111449	chr2:15616215	C/T	cg19274914	chr2:15703543	NA	0.44	7.89	0.4	4.46e-14	Educational attainment (years of education);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg17397135	chr2:28789816	PLB1	0.37	5.96	0.31	6.46e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.68	-11.44	-0.53	8.82e-26	Caffeine consumption;
LUSC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg09323728	chr8:95962352	TP53INP1	0.38	7.25	0.37	2.98e-12	Type 2 diabetes;
LUSC	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg16230307	chr14:35515116	FAM177A1	0.5	6.31	0.33	8.95e-10	Psoriasis;
LUSC	cis	rs6429082	0.608	rs903348	chr1:235571343	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.5	-6.82	-0.35	4.3e-11	Adiposity;
LUSC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs5771069	0.931	rs5771222	chr22:50445704	C/T	cg27467552	chr22:50353597	PIM3	0.43	7.28	0.37	2.45e-12	Ulcerative colitis;
LUSC	cis	rs7241530	0.636	rs12456531	chr18:75899668	G/C	cg14642773	chr18:75888474	NA	0.38	5.69	0.3	2.75e-8	Educational attainment (years of education);
LUSC	cis	rs738321	0.756	rs11089863	chr22:38512402	G/A	cg25457927	chr22:38595422	NA	-0.33	-6.16	-0.32	2.04e-9	Breast cancer;
LUSC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	cis	rs56283067	0.578	rs1321079	chr6:45358403	T/A	cg18551225	chr6:44695536	NA	-0.41	-6.33	-0.33	7.88e-10	Total body bone mineral density;
LUSC	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg27124370	chr19:33622961	WDR88	0.57	7.41	0.38	1.03e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9309473	0.500	rs2421664	chr2:73858881	C/T	cg20560298	chr2:73613845	ALMS1	0.43	6.51	0.34	2.82e-10	Metabolite levels;
LUSC	cis	rs7584330	0.554	rs9646713	chr2:238443542	T/C	cg16989719	chr2:238392110	NA	-0.41	-5.96	-0.31	6.3e-9	Prostate cancer;
LUSC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.64	0.47	1.43e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg13256891	chr4:100009986	ADH5	-0.45	-6.23	-0.32	1.43e-9	Alcohol dependence;
LUSC	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01570182	chr17:44337453	NA	-0.67	-10.07	-0.48	5.08e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg15423357	chr2:25149977	NA	0.4	7.89	0.4	4.4e-14	Body mass index in non-asthmatics;
LUSC	cis	rs7712401	0.601	rs35256179	chr5:122334255	C/A	cg19077854	chr5:122220652	SNX24	-0.43	-9.18	-0.45	4.76e-18	Mean platelet volume;
LUSC	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	6.85	0.35	3.59e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs6545883	0.562	rs777588	chr2:61426820	G/A	cg15711740	chr2:61764176	XPO1	-0.4	-6.28	-0.32	1.05e-9	Tuberculosis;
LUSC	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg18132916	chr6:79620363	NA	-0.38	-5.81	-0.3	1.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg02038168	chr22:39784481	NA	-0.5	-8.2	-0.41	5.34e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs2230307	0.536	rs580678	chr1:100483009	C/A	cg24955406	chr1:100503596	HIAT1	0.56	6.1	0.32	2.86e-9	Carotid intima media thickness;
LUSC	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg05340658	chr4:99064831	C4orf37	0.59	8.75	0.43	1.04e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	trans	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg09904177	chr6:26538194	HMGN4	-0.8	-6.02	-0.31	4.48e-9	Depression;
LUSC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg05064044	chr6:292385	DUSP22	-0.51	-7.6	-0.38	3.07e-13	Menopause (age at onset);
LUSC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg03188948	chr7:1209495	NA	0.68	7.2	0.37	4.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg16926213	chr1:1841314	NA	0.31	5.81	0.3	1.44e-8	Body mass index;
LUSC	cis	rs540254	0.551	rs1961611	chr1:160773029	G/A	cg20255094	chr1:160771763	LY9	0.55	6.6	0.34	1.64e-10	Blood protein levels;
LUSC	cis	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg24375607	chr4:120327624	NA	0.46	7.08	0.36	8.4e-12	Diastolic blood pressure;
LUSC	cis	rs1577917	0.958	rs1838958	chr6:86563968	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-1.13	-18.23	-0.71	5.2e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg27661571	chr11:113659931	NA	-0.56	-6.33	-0.33	8.02e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg24130564	chr14:104152367	KLC1	-0.48	-7.41	-0.38	1.01e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-9.47	-0.46	5.18e-19	Chronic sinus infection;
LUSC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg20016023	chr10:99160130	RRP12	-0.33	-8.07	-0.4	1.26e-14	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg26559250	chr6:158074478	ZDHHC14	0.48	6.26	0.32	1.2e-9	Neuroticism;
LUSC	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg08213375	chr14:104286397	PPP1R13B	0.52	10.25	0.49	1.29e-21	Schizophrenia;
LUSC	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg27411982	chr8:10470053	RP1L1	0.44	6.78	0.35	5.56e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.96	-0.31	6.49e-9	Dementia with Lewy bodies;
LUSC	cis	rs9650315	0.929	rs72656021	chr8:57166381	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.07	0.36	9.07e-12	Height;
LUSC	cis	rs9868809	0.881	rs3821876	chr3:48668394	G/T	cg00383909	chr3:49044727	WDR6	1.0	8.42	0.42	1.14e-15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg08798685	chr6:27730294	NA	-0.69	-6.14	-0.32	2.4e-9	Depression;
LUSC	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg03289416	chr15:75166202	SCAMP2	0.41	5.98	0.31	5.78e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg04034577	chr2:241836375	C2orf54	-0.48	-8.73	-0.43	1.27e-16	Urinary metabolites;
LUSC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg02079420	chr8:82753780	SNX16	-0.37	-5.66	-0.3	3.3e-8	Diastolic blood pressure;
LUSC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg00945038	chr17:61921165	SMARCD2	0.39	5.94	0.31	7.26e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.35	5.95	0.31	6.96e-9	Breast cancer;
LUSC	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg05283184	chr6:79620031	NA	-0.45	-8.5	-0.42	6.3e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.07	0.44	1.05e-17	Red blood cell count;
LUSC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.27	-0.32	1.1e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg16989719	chr2:238392110	NA	-0.43	-7.33	-0.37	1.74e-12	Prostate cancer;
LUSC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-11.0	-0.52	3.2e-24	Mean corpuscular volume;
LUSC	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg06623918	chr6:96969491	KIAA0776	-0.83	-10.35	-0.49	5.66e-22	Migraine;Coronary artery disease;
LUSC	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.83	-20.1	-0.74	1.83e-59	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs57590327	0.503	rs6800295	chr3:81593011	A/G	cg07356753	chr3:81810745	GBE1	-0.49	-6.61	-0.34	1.5e-10	Extraversion;
LUSC	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12826209	chr6:26865740	GUSBL1	0.74	9.08	0.44	9.64e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.83	0.63	1.46e-38	Platelet count;
LUSC	cis	rs16912285	0.786	rs76326641	chr11:24253072	G/A	ch.11.24196551F	chr11:24239977	NA	0.72	6.09	0.32	3.05e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4654899	0.931	rs4654727	chr1:21214735	C/T	cg01072550	chr1:21505969	NA	0.5	7.49	0.38	6.24e-13	Superior frontal gyrus grey matter volume;
LUSC	trans	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg06521331	chr12:34319734	NA	-0.4	-6.09	-0.32	3.07e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg06937882	chr20:24974362	C20orf3	0.42	7.0	0.36	1.43e-11	Blood protein levels;
LUSC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg05347473	chr6:146136440	FBXO30	0.45	7.7	0.39	1.61e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg25237894	chr2:233734115	C2orf82	-0.36	-7.06	-0.36	9.61e-12	Coronary artery disease;
LUSC	cis	rs1712517	0.836	rs11191649	chr10:105067037	T/C	cg05636881	chr10:105038444	INA	0.38	6.22	0.32	1.47e-9	Migraine;
LUSC	trans	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg10756647	chr7:56101905	PSPH	0.89	9.05	0.44	1.19e-17	Diabetic kidney disease;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08393024	chr5:115177154	ATG12;AP3S1	-0.4	-6.13	-0.32	2.51e-9	Hepatitis;
LUSC	cis	rs4077468	1.000	rs11801695	chr1:205916175	A/C	cg24503407	chr1:205819492	PM20D1	0.44	6.31	0.33	8.95e-10	Cystic fibrosis-related diabetes;
LUSC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg21724239	chr8:58056113	NA	0.56	6.63	0.34	1.35e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2637266	0.714	rs7895605	chr10:78454207	G/A	cg18941641	chr10:78392320	NA	0.33	5.97	0.31	5.95e-9	Pulmonary function;
LUSC	cis	rs713477	0.967	rs6573029	chr14:55913550	A/C	cg13175173	chr14:55914753	NA	-0.3	-6.28	-0.32	1.08e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.77	11.14	0.52	9.92e-25	Corneal astigmatism;
LUSC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.85	-14.98	-0.63	3.53e-39	Ulcerative colitis;
LUSC	cis	rs2677744	0.626	rs3743452	chr15:91497515	C/T	cg22570213	chr15:91497863	RCCD1	-0.38	-5.77	-0.3	1.81e-8	Attention deficit hyperactivity disorder;
LUSC	cis	rs4588572	0.644	rs1159930	chr5:77768943	C/T	cg11547950	chr5:77652471	NA	0.46	6.77	0.35	5.72e-11	Triglycerides;
LUSC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg01097406	chr16:89675127	NA	-0.37	-7.34	-0.37	1.63e-12	Vitiligo;
LUSC	cis	rs400736	0.894	rs226242	chr1:8033468	G/A	cg25007680	chr1:8021821	PARK7	0.59	9.3	0.45	1.95e-18	Response to antidepressants and depression;
LUSC	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg03678062	chr6:149772716	ZC3H12D	0.31	6.32	0.33	8.59e-10	Dupuytren's disease;
LUSC	cis	rs1775715	0.707	rs1541262	chr10:32179771	A/G	cg03015672	chr10:32216066	ARHGAP12	0.34	6.12	0.32	2.65e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	13.91	0.61	5.25e-35	Platelet count;
LUSC	trans	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg25214090	chr10:38739885	LOC399744	0.5	7.6	0.38	2.98e-13	Corneal astigmatism;
LUSC	cis	rs3741151	0.773	rs7925226	chr11:73137362	A/G	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9311171	0.689	rs6775702	chr3:37972794	A/T	cg12605080	chr3:37966887	CTDSPL	0.33	6.06	0.31	3.72e-9	Prostate cancer;
LUSC	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.46	0.38	7.56e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg04374321	chr14:90722782	PSMC1	-0.44	-6.63	-0.34	1.34e-10	Mortality in heart failure;
LUSC	cis	rs931127	0.666	rs7932857	chr11:65457493	A/C	cg05805236	chr11:65401703	PCNXL3	-0.42	-7.3	-0.37	2.13e-12	Systemic lupus erythematosus;
LUSC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.04	21.37	0.76	1.82e-64	Cognitive function;
LUSC	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg23387468	chr7:139079360	LUC7L2	-0.45	-6.71	-0.34	8.3e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2637266	0.655	rs10824436	chr10:78457848	T/C	cg18941641	chr10:78392320	NA	0.33	5.85	0.3	1.2e-8	Pulmonary function;
LUSC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.16	0.32	2.11e-9	Mean platelet volume;
LUSC	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg21466736	chr12:48725269	NA	-0.33	-5.75	-0.3	2.06e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg26924012	chr15:45694286	SPATA5L1	-1.06	-18.71	-0.72	6.31e-54	Homoarginine levels;
LUSC	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	11.1	0.52	1.4e-24	Lung cancer in ever smokers;
LUSC	cis	rs1847202	0.717	rs13063437	chr3:72952388	A/G	cg25664220	chr3:72788482	NA	-0.44	-7.94	-0.4	3.04e-14	Motion sickness;
LUSC	cis	rs721399	0.568	rs7816847	chr8:18275189	A/C	cg18736775	chr8:18248649	NAT2	-0.54	-6.54	-0.34	2.36e-10	Blood metabolite levels;
LUSC	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg10523679	chr1:76189770	ACADM	-0.49	-7.25	-0.37	2.94e-12	Daytime sleep phenotypes;
LUSC	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg13010199	chr12:38710504	ALG10B	-0.51	-7.67	-0.39	1.87e-13	Morning vs. evening chronotype;
LUSC	cis	rs9581857	0.556	rs9581863	chr13:28040171	A/G	cg22138327	chr13:27999177	GTF3A	0.7	9.5	0.46	4.1e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg13902645	chr11:5959945	NA	-0.67	-10.81	-0.51	1.49e-23	DNA methylation (variation);
LUSC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg27170947	chr2:26402098	FAM59B	-0.66	-9.54	-0.46	3.21e-19	Gut microbiome composition (summer);
LUSC	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg18681998	chr4:17616180	MED28	0.77	13.73	0.6	2.53e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.28	-0.37	2.35e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs11603020	0.950	rs28362949	chr11:57371911	G/T	cg23127183	chr11:57508653	C11orf31	-0.46	-6.39	-0.33	5.63e-10	Blood protein levels;
LUSC	cis	rs2637266	0.846	rs2637260	chr10:78320346	C/T	cg18941641	chr10:78392320	NA	-0.4	-7.6	-0.38	2.98e-13	Pulmonary function;
LUSC	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg14343924	chr8:8086146	FLJ10661	0.43	6.14	0.32	2.41e-9	Mood instability;
LUSC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.9	-13.87	-0.6	7.52e-35	Coronary artery disease;
LUSC	cis	rs7493	0.950	rs7802171	chr7:95030321	A/G	cg04871131	chr7:94954202	PON1	-0.4	-6.16	-0.32	2.07e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs710216	0.957	rs710215	chr1:43429105	T/C	cg03128534	chr1:43423976	SLC2A1	0.47	5.86	0.31	1.13e-8	Red cell distribution width;
LUSC	trans	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Bladder cancer;
LUSC	trans	rs1493916	0.748	rs4799355	chr18:31313124	G/T	cg13755796	chr4:20253514	NA	-0.38	-6.01	-0.31	4.92e-9	Life satisfaction;
LUSC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg22800045	chr5:56110881	MAP3K1	0.76	9.84	0.47	3.24e-20	Initial pursuit acceleration;
LUSC	cis	rs1832871	0.711	rs76962726	chr6:158674041	C/T	cg07165851	chr6:158734300	TULP4	0.52	7.89	0.4	4.29e-14	Height;
LUSC	cis	rs9633740	0.945	rs6586030	chr10:82254047	C/T	cg01528321	chr10:82214614	TSPAN14	-1.05	-10.84	-0.51	1.12e-23	Post bronchodilator FEV1;
LUSC	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg26395211	chr5:140044315	WDR55	-0.39	-6.0	-0.31	5.16e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	0.57	9.07	0.44	1.02e-17	Breast cancer;
LUSC	cis	rs11608355	0.846	rs4766472	chr12:109853602	C/G	cg19025524	chr12:109796872	NA	-0.39	-5.72	-0.3	2.35e-8	Neuroticism;
LUSC	cis	rs10979	1.000	rs9386034	chr6:143890572	T/G	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg18964960	chr10:1102726	WDR37	-0.47	-6.29	-0.33	9.85e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg11062466	chr8:58055876	NA	0.51	6.9	0.35	2.67e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg05714579	chr10:131428358	MGMT	0.49	7.32	0.37	1.82e-12	Response to temozolomide;
LUSC	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg11993925	chr19:44307056	LYPD5	0.35	7.56	0.38	4.02e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs8032315	0.965	rs12906125	chr15:91427612	G/A	cg05469396	chr15:91419421	FURIN	-0.43	-6.69	-0.34	9.7e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg12179176	chr11:130786555	SNX19	0.65	9.99	0.48	9.51e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg27147174	chr7:100797783	AP1S1	-0.64	-10.28	-0.49	1.02e-21	Life satisfaction;
LUSC	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.63	11.42	0.53	9.71e-26	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs7474896	0.559	rs1208645	chr10:38132087	C/T	cg25427524	chr10:38739819	LOC399744	0.42	5.68	0.3	2.93e-8	Obesity (extreme);
LUSC	trans	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg26043149	chr18:55253948	FECH	-0.46	-7.1	-0.36	7.46e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	cis	rs3733418	0.929	rs4690797	chr4:165908505	G/C	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-5.92	-0.31	7.89e-9	Obesity-related traits;
LUSC	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg07959070	chr22:50026188	C22orf34	-0.34	-6.97	-0.36	1.7e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg15423357	chr2:25149977	NA	0.35	6.43	0.33	4.46e-10	Body mass index;
LUSC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg25036284	chr2:26402008	FAM59B	-0.71	-10.02	-0.48	7.79e-21	Gut microbiome composition (summer);
LUSC	cis	rs2115536	0.692	rs6495451	chr15:80164053	C/T	cg00225070	chr15:80189496	MTHFS	0.43	6.23	0.32	1.41e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg05861140	chr6:150128134	PCMT1	-0.39	-6.03	-0.31	4.46e-9	Lung cancer;
LUSC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03352830	chr11:487213	PTDSS2	0.72	8.67	0.43	1.85e-16	Body mass index;
LUSC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.9	0.44	3.66e-17	Schizophrenia;
LUSC	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg21466736	chr12:48725269	NA	-0.33	-5.76	-0.3	1.92e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.96	-0.48	1.29e-20	Hemoglobin concentration;
LUSC	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg17757837	chr7:157058334	UBE3C	0.82	13.08	0.58	7.24e-32	Body mass index;
LUSC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	1.03	20.61	0.75	1.8e-61	Cognitive function;
LUSC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg06238570	chr21:40685208	BRWD1	-0.59	-9.22	-0.45	3.36e-18	Menarche (age at onset);
LUSC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg14416269	chr4:6271139	WFS1	0.54	11.47	0.53	6.87e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.76	10.15	0.49	2.73e-21	Type 2 diabetes nephropathy;
LUSC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	0.93	16.21	0.66	5.4e-44	Menopause (age at onset);
LUSC	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg04362960	chr10:104952993	NT5C2	0.6	9.47	0.46	5.21e-19	Arsenic metabolism;
LUSC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg06742321	chr12:123595122	PITPNM2	0.39	5.83	0.3	1.28e-8	Platelet count;
LUSC	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.02	0.31	4.61e-9	Neuroticism;
LUSC	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.69	0.5	3.96e-23	Schizophrenia;
LUSC	cis	rs858239	0.539	rs1358442	chr7:23189739	C/T	cg23682824	chr7:23144976	KLHL7	0.4	5.71	0.3	2.52e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.78	-12.94	-0.58	2.46e-31	Aortic root size;
LUSC	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg17385448	chr1:15911702	AGMAT	-0.38	-5.91	-0.31	8.36e-9	Systolic blood pressure;
LUSC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7605827	0.836	rs1549016	chr2:15616859	G/A	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.37e-17	Educational attainment (years of education);
LUSC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg24562669	chr7:97807699	LMTK2	0.34	5.95	0.31	6.83e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg22029157	chr1:209979665	IRF6	-0.68	-11.68	-0.54	1.15e-26	Monobrow;
LUSC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs12318506	0.826	rs13377894	chr12:75661825	A/G	cg04728562	chr12:75699417	CAPS2	-0.77	-5.93	-0.31	7.49e-9	Coronary artery calcification;
LUSC	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg15704280	chr7:45808275	SEPT13	0.73	8.29	0.41	2.88e-15	Axial length;
LUSC	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg13256891	chr4:100009986	ADH5	0.46	6.84	0.35	3.78e-11	Alcohol dependence;
LUSC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4655582	0.510	rs12022410	chr1:66153933	A/G	cg04111102	chr1:66153794	NA	0.27	5.79	0.3	1.65e-8	Fibrinogen levels;
LUSC	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg08017756	chr2:100939284	LONRF2	-0.4	-7.35	-0.37	1.51e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs16912285	0.591	rs7929025	chr11:24363324	A/C	ch.11.24196551F	chr11:24239977	NA	0.78	8.16	0.41	6.79e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs244293	0.730	rs9303362	chr17:53062553	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.38	-5.71	-0.3	2.54e-8	Menarche (age at onset);
LUSC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	9.02	0.44	1.54e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.79	-0.35	5.14e-11	Response to antipsychotic treatment;
LUSC	cis	rs2625529	0.730	rs982752	chr15:72145937	C/T	cg16672083	chr15:72433130	SENP8	-0.48	-7.72	-0.39	1.38e-13	Red blood cell count;
LUSC	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05901451	chr6:126070800	HEY2	-0.6	-9.07	-0.44	1.03e-17	Endometrial cancer;
LUSC	cis	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg06521331	chr12:34319734	NA	-0.37	-6.22	-0.32	1.46e-9	Morning vs. evening chronotype;
LUSC	cis	rs500891	0.553	rs7758546	chr6:84135023	G/C	cg08257003	chr6:84140564	ME1	0.37	9.17	0.45	5.06e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs7561273	0.586	rs6545264	chr2:24310105	A/G	cg06627628	chr2:24431161	ITSN2	-0.51	-6.84	-0.35	3.85e-11	Quantitative traits;
LUSC	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg05472934	chr7:22766657	IL6	0.44	6.99	0.36	1.49e-11	Lung cancer;
LUSC	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.87	0.35	3.15e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg26335602	chr6:28129616	ZNF389	-0.42	-5.73	-0.3	2.21e-8	Depression;
LUSC	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg11244672	chr19:19639970	YJEFN3	0.58	7.31	0.37	2.04e-12	Bipolar disorder;
LUSC	cis	rs897984	0.806	rs11640534	chr16:30949515	G/A	cg02466173	chr16:30829666	NA	0.57	11.43	0.53	9.44e-26	Dementia with Lewy bodies;
LUSC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.52	0.34	2.54e-10	Schizophrenia;
LUSC	cis	rs12210905	0.925	rs9467965	chr6:26992539	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.99	-0.31	5.28e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.76	-10.33	-0.49	6.8e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.5	0.53	5.21e-26	Prudent dietary pattern;
LUSC	cis	rs56283067	0.887	rs12200892	chr6:44768925	T/C	cg20913747	chr6:44695427	NA	-0.48	-7.43	-0.38	9.45e-13	Total body bone mineral density;
LUSC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg19230755	chr7:65878503	NA	0.41	5.75	0.3	2e-8	Aortic root size;
LUSC	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg05855489	chr10:104503620	C10orf26	-0.69	-10.09	-0.48	4.4e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg17264618	chr3:40429014	ENTPD3	0.37	7.77	0.39	9.49e-14	Renal cell carcinoma;
LUSC	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg02466173	chr16:30829666	NA	0.56	10.92	0.51	5.93e-24	Dementia with Lewy bodies;
LUSC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.63	-0.39	2.43e-13	Aortic root size;
LUSC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-1.06	-20.02	-0.74	3.96e-59	Menopause (age at onset);
LUSC	trans	rs724744	0.740	rs1772077	chr6:22353749	G/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.19	-0.32	1.77e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg06671706	chr8:8559999	CLDN23	0.5	6.86	0.35	3.37e-11	Obesity-related traits;
LUSC	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg26597838	chr10:835615	NA	0.91	12.54	0.57	8.07e-30	Eosinophil percentage of granulocytes;
LUSC	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg15704280	chr7:45808275	SEPT13	0.56	6.89	0.35	2.71e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg12292205	chr6:26970375	C6orf41	-0.63	-7.57	-0.38	3.72e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg05872129	chr22:39784769	NA	-0.59	-10.34	-0.49	6.14e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg15017067	chr4:17643749	FAM184B	0.35	5.81	0.3	1.49e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.26	11.09	0.52	1.56e-24	Alzheimer's disease (late onset);
LUSC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg16325326	chr1:53192061	ZYG11B	0.81	14.0	0.61	2.39e-35	Monocyte count;
LUSC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.6	-9.32	-0.45	1.69e-18	Longevity;
LUSC	trans	rs67539049	1.000	rs67350204	chr8:11300293	A/G	cg26241650	chr22:40417538	FAM83F	0.45	6.02	0.31	4.71e-9	Itch intensity from mosquito bite;
LUSC	cis	rs7809950	0.817	rs2237671	chr7:107131528	A/T	cg23024343	chr7:107201750	COG5	-0.69	-10.34	-0.49	6.28e-22	Coronary artery disease;
LUSC	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.89	-0.31	9.23e-9	Height;
LUSC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.08	0.55	4.01e-28	Prudent dietary pattern;
LUSC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg03146154	chr1:46216737	IPP	0.56	8.35	0.42	1.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.07	-0.48	5.1e-21	Obesity-related traits;
LUSC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.38	-0.42	1.54e-15	Longevity;
LUSC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	9.42	0.46	7.79e-19	Eosinophil percentage of white cells;
LUSC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg23625390	chr15:77176239	SCAPER	0.47	7.2	0.37	4.11e-12	Blood metabolite levels;
LUSC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg03060546	chr3:49711283	APEH	0.71	11.95	0.55	1.23e-27	Resting heart rate;
LUSC	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg17691542	chr6:26056736	HIST1H1C	0.53	7.38	0.37	1.26e-12	Iron status biomarkers;
LUSC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg09904177	chr6:26538194	HMGN4	-0.71	-12.37	-0.56	3.45e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs7131987	0.934	rs2216854	chr12:29423460	G/A	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.37	-0.33	6.43e-10	QT interval;
LUSC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.79	-0.39	8.52e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg23950597	chr19:37808831	NA	-0.63	-7.41	-0.38	1.05e-12	Coronary artery calcification;
LUSC	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg19773385	chr1:10388646	KIF1B	-0.57	-9.86	-0.47	2.77e-20	Hepatocellular carcinoma;
LUSC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg15103426	chr22:29168792	CCDC117	0.45	5.84	0.3	1.26e-8	Lymphocyte counts;
LUSC	cis	rs8044868	0.561	rs3909542	chr16:72183505	C/T	cg16579770	chr16:72058938	DHODH	0.35	5.84	0.3	1.25e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg10018233	chr7:150070692	REPIN1	0.4	7.08	0.36	8.65e-12	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.64	-10.51	-0.5	1.7e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23621158	chr4:83206416	NA	-0.39	-5.96	-0.31	6.36e-9	Electrocardiographic conduction measures;
LUSC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg12615879	chr12:58013172	SLC26A10	-0.28	-5.93	-0.31	7.62e-9	Multiple sclerosis;
LUSC	cis	rs6577655	0.501	rs879104	chr8:135609537	G/A	cg17885191	chr8:135476712	NA	0.42	5.76	0.3	1.91e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg08017756	chr2:100939284	LONRF2	0.42	7.78	0.39	8.95e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6537837	1.000	rs7355157	chr1:110129835	T/C	cg05049280	chr1:110155535	GNAT2	0.51	6.94	0.36	2e-11	Major depressive disorder;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13099106	chr12:120525172	CCDC64	0.46	6.64	0.34	1.3e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-16.25	-0.66	3.52e-44	Exhaled nitric oxide output;
LUSC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20592700	chr7:5230083	WIPI2	-0.5	-6.75	-0.35	6.49e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg13175981	chr1:150552382	MCL1	0.54	7.64	0.39	2.37e-13	Tonsillectomy;
LUSC	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.47	7.81	0.39	7.33e-14	Alcohol dependence;
LUSC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg07716408	chr11:68623521	NA	0.32	6.13	0.32	2.5e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg24375607	chr4:120327624	NA	0.79	11.78	0.54	5.25e-27	Corneal astigmatism;
LUSC	cis	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.75	-0.35	6.42e-11	Morning vs. evening chronotype;
LUSC	trans	rs1864729	1.000	rs1431891	chr8:98282716	A/G	cg08679828	chr8:102218111	ZNF706	-0.87	-7.9	-0.4	3.95e-14	Estradiol plasma levels (breast cancer);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04830409	chr12:64615927	C12orf66	0.4	5.99	0.31	5.41e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03878208	chr11:72483293	STARD10	0.57	7.28	0.37	2.33e-12	Type 2 diabetes;
LUSC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs10266483	0.739	rs12538943	chr7:63856368	G/A	cg24201672	chr7:64023550	ZNF680	0.49	5.89	0.31	9.36e-9	Response to statin therapy;
LUSC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg24209194	chr3:40518798	ZNF619	-0.45	-6.33	-0.33	7.78e-10	Renal cell carcinoma;
LUSC	cis	rs9469578	0.710	rs73743330	chr6:33713971	G/A	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg06008330	chr7:65541103	ASL	0.4	6.18	0.32	1.85e-9	Aortic root size;
LUSC	cis	rs727505	0.819	rs4142718	chr7:124731688	T/A	cg23710748	chr7:124431027	NA	-0.4	-6.97	-0.36	1.73e-11	Lewy body disease;
LUSC	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg05340658	chr4:99064831	C4orf37	0.58	9.5	0.46	4.19e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs62400317	0.859	rs12198376	chr6:45153681	G/C	cg20913747	chr6:44695427	NA	-0.47	-7.46	-0.38	7.32e-13	Total body bone mineral density;
LUSC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18758796	chr5:131593413	PDLIM4	0.53	9.2	0.45	3.99e-18	Acylcarnitine levels;
LUSC	cis	rs113835537	0.559	rs11227497	chr11:66269464	T/C	cg24851651	chr11:66362959	CCS	0.55	8.26	0.41	3.47e-15	Airway imaging phenotypes;
LUSC	cis	rs2219968	0.961	rs2128016	chr8:78964507	C/T	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg16482183	chr6:26056742	HIST1H1C	0.64	9.23	0.45	3.26e-18	Iron status biomarkers;
LUSC	cis	rs911119	0.779	rs3761280	chr20:23620076	A/G	cg16589663	chr20:23618590	CST3	0.6	7.08	0.36	8.36e-12	Chronic kidney disease;
LUSC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	9.51	0.46	3.94e-19	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.27	-0.37	2.51e-12	Bipolar disorder;
LUSC	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-9.6	-0.47	1.98e-19	Schizophrenia;
LUSC	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg13390004	chr1:15929781	NA	0.4	6.46	0.33	3.61e-10	Systolic blood pressure;
LUSC	cis	rs782590	0.574	rs12991445	chr2:55675939	C/T	cg03859395	chr2:55845619	SMEK2	0.66	9.94	0.48	1.51e-20	Metabolic syndrome;
LUSC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg12935359	chr14:103987150	CKB	0.52	8.12	0.41	8.93e-15	Body mass index;
LUSC	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg16230307	chr14:35515116	FAM177A1	0.78	10.0	0.48	8.96e-21	Psoriasis;
LUSC	cis	rs4499344	0.805	rs12978075	chr19:33067852	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.61	-7.75	-0.39	1.12e-13	Mean platelet volume;
LUSC	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg11845111	chr2:191398756	TMEM194B	-0.89	-11.0	-0.52	3.1e-24	Diastolic blood pressure;
LUSC	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.98	0.4	2.31e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg09359103	chr1:154839909	KCNN3	0.68	15.29	0.64	2.2e-40	Prostate cancer;
LUSC	cis	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg06521331	chr12:34319734	NA	-0.45	-7.28	-0.37	2.4e-12	Morning vs. evening chronotype;
LUSC	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg24585782	chr17:78113791	EIF4A3	-0.44	-6.65	-0.34	1.18e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs427941	0.703	rs10953358	chr7:101738226	T/C	cg06246474	chr7:101738831	CUX1	-0.41	-6.71	-0.34	8.45e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg14835575	chr10:16859367	RSU1	0.39	5.79	0.3	1.6e-8	Platelet distribution width;
LUSC	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg22709100	chr7:91322751	NA	0.4	5.9	0.31	8.7e-9	Breast cancer;
LUSC	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.29	0.53	2.92e-25	Morning vs. evening chronotype;
LUSC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg25258033	chr6:167368657	RNASET2	0.47	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	cis	rs6500395	0.735	rs74017013	chr16:48664120	G/A	cg04672837	chr16:48644449	N4BP1	0.47	7.02	0.36	1.22e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25072359	chr17:41440525	NA	0.62	8.88	0.44	4.23e-17	Menopause (age at onset);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg13325330	chr6:44355541	CDC5L	0.49	5.98	0.31	5.86e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.11	-0.45	7.8e-18	Monocyte percentage of white cells;
LUSC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg26566898	chr11:117069891	TAGLN	-0.47	-8.33	-0.41	2.06e-15	Blood protein levels;
LUSC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg18825076	chr15:78729989	IREB2	-0.63	-10.36	-0.49	5.6e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.93	15.0	0.63	2.96e-39	Multiple sclerosis;
LUSC	cis	rs4423214	0.559	rs10898201	chr11:71201527	C/A	cg05163923	chr11:71159392	DHCR7	-0.65	-7.1	-0.36	7.41e-12	Vitamin D levels;
LUSC	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg05472934	chr7:22766657	IL6	0.54	8.41	0.42	1.2e-15	Lung cancer;
LUSC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg04025307	chr7:1156635	C7orf50	0.44	6.06	0.31	3.75e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1346	0.580	rs7937415	chr11:65363958	A/G	cg17120908	chr11:65337727	SSSCA1	-0.4	-5.7	-0.3	2.62e-8	Vertical cup-disc ratio;Optic cup area;
LUSC	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg03465714	chr1:152285911	FLG	-0.43	-5.94	-0.31	7.27e-9	Atopic dermatitis;
LUSC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg06008330	chr7:65541103	ASL	-0.41	-6.45	-0.33	3.81e-10	Aortic root size;
LUSC	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.6	-9.91	-0.48	1.82e-20	Schizophrenia;
LUSC	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg05973401	chr12:123451056	ABCB9	0.54	6.77	0.35	5.69e-11	Neutrophil percentage of white cells;
LUSC	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg11887960	chr12:57824829	NA	0.55	7.21	0.37	3.7e-12	Lung disease severity in cystic fibrosis;
LUSC	trans	rs3857536	0.813	rs7757118	chr6:66946661	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs7799006	0.606	rs34262822	chr7:2304275	C/T	cg12823233	chr7:2316876	SNX8	-0.44	-7.49	-0.38	6.02e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.71	-0.39	1.41e-13	Triglycerides;
LUSC	trans	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.84	0.47	3.04e-20	Mean corpuscular volume;
LUSC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.65	0.76	1.42e-65	Prudent dietary pattern;
LUSC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg22437258	chr11:111473054	SIK2	0.5	6.83	0.35	4.12e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	13.55	0.6	1.22e-33	Platelet count;
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.34	-7.22	-0.37	3.43e-12	Longevity;Endometriosis;
LUSC	cis	rs6489882	0.779	rs57484342	chr12:113371973	A/G	cg20102336	chr12:113376681	OAS3	-0.42	-6.1	-0.32	2.9e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg04398451	chr17:18023971	MYO15A	-0.54	-9.06	-0.44	1.13e-17	Total body bone mineral density;
LUSC	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg24006582	chr15:45444508	DUOX1	-0.61	-8.97	-0.44	2.25e-17	Uric acid levels;
LUSC	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg01256987	chr12:42539512	GXYLT1	0.36	6.69	0.34	9.16e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.77	0.3	1.81e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.2	0.37	4.1e-12	Asthma (childhood onset);
LUSC	cis	rs7577851	0.716	rs66641893	chr2:69677296	T/G	cg10773587	chr2:69614142	GFPT1	0.56	6.66	0.34	1.13e-10	Parkinson's disease (age of onset);
LUSC	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg21775007	chr8:11205619	TDH	0.77	12.07	0.55	4.53e-28	Retinal vascular caliber;
LUSC	trans	rs6601327	0.670	rs6990418	chr8:9422006	C/G	cg15556689	chr8:8085844	FLJ10661	0.46	6.51	0.34	2.83e-10	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.74	0.35	6.95e-11	Retinal vascular caliber;
LUSC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21582582	chr3:182698605	DCUN1D1	0.47	8.11	0.41	9.55e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs117352156	1.000	rs10826546	chr10:29237462	C/T	cg06394621	chr10:29236369	NA	0.46	5.75	0.3	2.06e-8	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-16.09	-0.66	1.58e-43	Height;
LUSC	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg26395211	chr5:140044315	WDR55	-0.39	-5.95	-0.31	6.92e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg11764359	chr7:65958608	NA	-0.69	-10.44	-0.5	2.96e-22	Aortic root size;
LUSC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg19046167	chr17:80928561	B3GNTL1	0.49	6.96	0.36	1.77e-11	Glycated hemoglobin levels;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg10506160	chr16:11762778	SNN	0.48	5.99	0.31	5.58e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2086824	0.702	rs3114896	chr16:89393562	C/T	cg02187348	chr16:89574699	SPG7	-0.4	-6.09	-0.32	3.19e-9	Multiple myeloma (IgH translocation);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22886512	chr19:8408083	KANK3	-0.48	-6.2	-0.32	1.63e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg18850127	chr7:39170497	POU6F2	0.64	9.83	0.47	3.28e-20	IgG glycosylation;
LUSC	cis	rs7598759	0.604	rs4973407	chr2:232311639	G/A	cg19187155	chr2:232395269	NMUR1	0.4	5.73	0.3	2.28e-8	Noise-induced hearing loss;
LUSC	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg07578070	chr6:150326732	RAET1K	0.38	5.84	0.3	1.24e-8	Alopecia areata;
LUSC	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06636551	chr8:101224915	SPAG1	0.43	8.14	0.41	8.19e-15	Atrioventricular conduction;
LUSC	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg09904177	chr6:26538194	HMGN4	-0.51	-5.71	-0.3	2.54e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg05100916	chr7:112090586	IFRD1	0.5	7.16	0.36	5.33e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg21643547	chr1:205240462	TMCC2	-0.42	-7.65	-0.39	2.17e-13	Red blood cell count;
LUSC	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg09904177	chr6:26538194	HMGN4	0.5	8.04	0.4	1.61e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.44	-6.73	-0.35	7.61e-11	Height;
LUSC	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg02023728	chr11:77925099	USP35	0.51	7.27	0.37	2.59e-12	Testicular germ cell tumor;
LUSC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.9	-14.81	-0.63	1.62e-38	Platelet count;
LUSC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.27	-0.37	2.55e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg02569458	chr12:86230093	RASSF9	0.49	8.22	0.41	4.69e-15	Major depressive disorder;
LUSC	trans	rs4714291	0.802	rs2983140	chr6:40017224	A/G	cg02267698	chr19:7991119	CTXN1	-0.54	-7.88	-0.4	4.79e-14	Strep throat;
LUSC	cis	rs6076065	0.723	rs2424531	chr20:23372754	C/T	cg11657817	chr20:23433608	CST11	-0.42	-8.06	-0.4	1.34e-14	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg13010199	chr12:38710504	ALG10B	0.55	8.48	0.42	7.35e-16	Morning vs. evening chronotype;
LUSC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg15445000	chr17:37608096	MED1	-0.38	-6.55	-0.34	2.15e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg26162295	chr17:38119207	GSDMA	0.29	7.06	0.36	9.85e-12	Asthma and hay fever;
LUSC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg23887609	chr12:130822674	PIWIL1	0.48	7.1	0.36	7.75e-12	Menopause (age at onset);
LUSC	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs6700896	0.864	rs56274111	chr1:66128511	A/C	cg04111102	chr1:66153794	NA	0.33	7.26	0.37	2.81e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.32	-6.62	-0.34	1.41e-10	Longevity;Endometriosis;
LUSC	cis	rs9399401	0.626	rs4304190	chr6:142778912	A/G	cg03128060	chr6:142623767	GPR126	0.58	9.63	0.47	1.55e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg10117171	chr1:25599238	RHD	-0.39	-6.02	-0.31	4.57e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.46	7.04	0.36	1.09e-11	Colorectal cancer;
LUSC	cis	rs7605827	0.930	rs7596969	chr2:15513615	C/G	cg19274914	chr2:15703543	NA	-0.46	-8.84	-0.44	5.43e-17	Educational attainment (years of education);
LUSC	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.42	-0.38	1.01e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg00701064	chr4:6280414	WFS1	0.59	14.09	0.61	1.05e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs10266483	0.774	rs7796802	chr7:63784122	G/A	cg24201672	chr7:64023550	ZNF680	0.45	5.82	0.3	1.34e-8	Response to statin therapy;
LUSC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg12927641	chr6:109611667	NA	-0.43	-7.59	-0.38	3.21e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.83	-20.1	-0.74	1.83e-59	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg14186256	chr22:23484241	RTDR1	0.96	18.0	0.7	4.08e-51	Bone mineral density;
LUSC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg03188948	chr7:1209495	NA	0.65	6.89	0.35	2.73e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg02403541	chr12:121454288	C12orf43	-0.71	-10.82	-0.51	1.4e-23	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.96	-0.4	2.74e-14	Systolic blood pressure;
LUSC	cis	rs1009647	0.645	rs67773067	chr14:55697207	G/T	cg04306507	chr14:55594613	LGALS3	0.43	5.76	0.3	1.94e-8	Testicular germ cell tumor;
LUSC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Depression;
LUSC	cis	rs2273669	0.667	rs11153153	chr6:109356104	A/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	9.1e-9	Prostate cancer;
LUSC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	5.69	0.3	2.81e-8	Aortic root size;
LUSC	trans	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg06606381	chr12:133084897	FBRSL1	-0.96	-8.38	-0.42	1.53e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05062854	chr22:32435553	NA	0.44	6.77	0.35	5.63e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg00701064	chr4:6280414	WFS1	0.59	14.2	0.61	3.93e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10163222	chr19:45004637	ZNF180	-0.43	-6.58	-0.34	1.86e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg21775007	chr8:11205619	TDH	-0.41	-6.15	-0.32	2.16e-9	Mood instability;
LUSC	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15561356	chr20:61904111	ARFGAP1	-0.41	-6.19	-0.32	1.72e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs240768	1.000	rs240782	chr6:100965257	G/C	cg12253828	chr6:101329408	ASCC3	0.84	5.86	0.31	1.13e-8	Economic and political preferences (immigration/crime);
LUSC	trans	rs11700980	1.000	rs73898414	chr21:30125196	C/T	cg05609335	chr17:75789393	NA	0.41	6.32	0.33	8.58e-10	QRS complex (12-leadsum);
LUSC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18404041	chr3:52824283	ITIH1	-0.46	-8.49	-0.42	7.02e-16	Electroencephalogram traits;
LUSC	cis	rs7572644	0.766	rs13003383	chr2:28235763	C/T	cg27432699	chr2:27873401	GPN1	0.53	6.55	0.34	2.19e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg24692254	chr21:30365293	RNF160	-0.67	-10.06	-0.48	5.91e-21	Pancreatic cancer;
LUSC	cis	rs4285028	0.747	rs9850439	chr3:121393075	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-12.81	-0.57	8.07e-31	Multiple sclerosis;
LUSC	cis	rs12989701	0.877	rs71414738	chr2:127876242	C/T	cg08168897	chr2:127865431	BIN1	0.73	9.32	0.45	1.65e-18	Alzheimer's disease (late onset);
LUSC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg02753203	chr1:228287806	NA	0.68	11.6	0.54	2.24e-26	Diastolic blood pressure;
LUSC	cis	rs34779708	0.733	rs16935945	chr10:35540320	A/C	cg03585969	chr10:35415529	CREM	0.55	7.63	0.39	2.51e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg00677455	chr12:58241039	CTDSP2	0.7	10.53	0.5	1.45e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg08499158	chr17:42289980	UBTF	0.41	6.34	0.33	7.43e-10	Total body bone mineral density;
LUSC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg20476274	chr7:133979776	SLC35B4	0.88	17.02	0.68	3.21e-47	Mean platelet volume;
LUSC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-0.88	-12.74	-0.57	1.45e-30	Vitiligo;
LUSC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg24399712	chr22:39784796	NA	-0.62	-11.12	-0.52	1.19e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs1322512	1.000	rs2758812	chr6:152965908	C/T	cg27316956	chr6:152958899	SYNE1	-0.34	-6.05	-0.31	3.84e-9	Tonometry;
LUSC	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.59	-11.4	-0.53	1.15e-25	Longevity;Endometriosis;
LUSC	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg00083206	chr6:110721305	DDO	-0.45	-8.25	-0.41	3.77e-15	Platelet distribution width;
LUSC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg25258033	chr6:167368657	RNASET2	0.44	6.69	0.34	9.54e-11	Crohn's disease;
LUSC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg19318889	chr4:1322082	MAEA	0.48	7.88	0.4	4.54e-14	Obesity-related traits;
LUSC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg18305652	chr10:134549665	INPP5A	0.46	6.83	0.35	4.01e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs12541635	0.966	rs56352125	chr8:107041831	G/T	cg10147462	chr8:107024639	NA	0.55	9.92	0.48	1.72e-20	Age of smoking initiation;
LUSC	cis	rs7590368	0.715	rs55770944	chr2:10959384	A/G	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg08392591	chr16:89556376	ANKRD11	0.44	6.65	0.34	1.19e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg13010199	chr12:38710504	ALG10B	-0.47	-7.23	-0.37	3.3e-12	Morning vs. evening chronotype;
LUSC	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21643547	chr1:205240462	TMCC2	-0.5	-9.34	-0.46	1.37e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg00825309	chr19:58991885	ZNF446	-0.52	-7.65	-0.39	2.1e-13	Uric acid clearance;
LUSC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08677398	chr8:58056175	NA	0.58	7.13	0.36	6.42e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg23711669	chr6:146136114	FBXO30	0.76	13.6	0.6	7.96e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg15556689	chr8:8085844	FLJ10661	0.67	10.6	0.5	7.87e-23	Mood instability;
LUSC	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.83	-0.35	4.12e-11	Lung cancer;
LUSC	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg23093090	chr10:104574429	C10orf26	-0.37	-6.94	-0.35	2.06e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.52	-7.83	-0.39	6.7e-14	Urate levels;
LUSC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.83	-12.9	-0.58	3.66e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07636037	chr3:49044803	WDR6	0.67	8.65	0.43	2.22e-16	Menarche (age at onset);
LUSC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15369054	chr17:80825471	TBCD	0.65	10.31	0.49	7.9e-22	Breast cancer;
LUSC	cis	rs7589342	0.566	rs11895542	chr2:106390429	G/A	cg09152813	chr2:106391379	NCK2	-0.38	-6.16	-0.32	2.12e-9	Addiction;
LUSC	cis	rs3820068	0.608	rs12760450	chr1:16037282	G/A	cg13390004	chr1:15929781	NA	0.42	6.86	0.35	3.29e-11	Systolic blood pressure;
LUSC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06558623	chr16:89946397	TCF25	1.11	9.73	0.47	7.08e-20	Skin colour saturation;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20002729	chr12:110318525	GLTP	-0.44	-6.43	-0.33	4.44e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	7.24	0.37	3.2e-12	Monocyte count;
LUSC	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg00792783	chr2:198669748	PLCL1	0.42	5.67	0.3	3.09e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg22676075	chr6:135203613	NA	0.47	7.37	0.37	1.32e-12	Red blood cell count;
LUSC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg23711669	chr6:146136114	FBXO30	0.89	16.79	0.68	2.69e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg05425664	chr17:57184151	TRIM37	-0.52	-7.73	-0.39	1.31e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14298792	chr15:30685198	CHRFAM7A	0.59	7.72	0.39	1.41e-13	Huntington's disease progression;
LUSC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.63	-0.34	1.32e-10	Fear of minor pain;
LUSC	cis	rs1775715	0.737	rs2799012	chr10:32103077	C/T	cg18675610	chr10:32216311	ARHGAP12	0.29	6.34	0.33	7.56e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg10645314	chr2:3704589	ALLC	-0.38	-6.67	-0.34	1.04e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg05347473	chr6:146136440	FBXO30	-0.38	-6.3	-0.33	9.2e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6987853	0.712	rs56220385	chr8:42428862	A/T	cg09913449	chr8:42400586	C8orf40	0.52	9.01	0.44	1.57e-17	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg09650180	chr20:62225654	GMEB2	-0.67	-9.59	-0.46	2.11e-19	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUSC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg12564285	chr5:131593104	PDLIM4	0.38	6.99	0.36	1.53e-11	Breast cancer;
LUSC	cis	rs4474465	0.790	rs7481910	chr11:78264202	G/C	cg27205649	chr11:78285834	NARS2	0.51	6.05	0.31	3.99e-9	Alzheimer's disease (survival time);
LUSC	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg24692254	chr21:30365293	RNF160	-0.55	-6.74	-0.35	6.98e-11	Cognitive test performance;
LUSC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.56	-0.38	3.83e-13	Aortic root size;
LUSC	cis	rs55728055	0.661	rs62237765	chr22:31956981	A/G	cg01338084	chr22:32026380	PISD	0.93	6.78	0.35	5.4e-11	Age-related hearing impairment;
LUSC	trans	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg25214090	chr10:38739885	LOC399744	0.4	6.31	0.33	8.77e-10	Corneal astigmatism;
LUSC	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg18512352	chr11:47633146	NA	-0.46	-9.31	-0.45	1.73e-18	Subjective well-being;
LUSC	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg11984989	chr7:158649758	WDR60	-1.05	-12.11	-0.55	3.2e-28	Height;
LUSC	trans	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg01620082	chr3:125678407	NA	-0.85	-7.31	-0.37	1.99e-12	Depression;
LUSC	cis	rs12931792	0.846	rs9924308	chr16:30154740	C/T	cg17640201	chr16:30407289	ZNF48	-0.55	-8.91	-0.44	3.45e-17	Tonsillectomy;
LUSC	trans	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.47	-0.38	7e-13	Menarche (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26904215	chr21:47823096	PCNT	-0.75	-6.05	-0.31	3.8e-9	Cognitive performance;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00929050	chr14:50359216	ARF6	0.47	6.73	0.35	7.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs2587949	0.577	rs2629245	chr3:4236036	G/A	cg15139668	chr4:4577005	NA	0.39	6.01	0.31	4.88e-9	Periodontitis (DPAL);
LUSC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.88	-14.16	-0.61	5.75e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-1.11	-17.38	-0.69	1.16e-48	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg24848339	chr3:12840334	CAND2	0.36	8.03	0.4	1.74e-14	P wave duration;
LUSC	cis	rs738322	0.775	rs4820324	chr22:38599857	G/C	cg17652424	chr22:38574118	PLA2G6	0.28	5.69	0.3	2.79e-8	Cutaneous nevi;
LUSC	cis	rs113835537	0.529	rs4930183	chr11:66255732	C/T	cg24851651	chr11:66362959	CCS	0.54	8.02	0.4	1.77e-14	Airway imaging phenotypes;
LUSC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.65	10.2	0.49	1.94e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05901451	chr6:126070800	HEY2	-0.59	-8.83	-0.44	5.91e-17	Endometrial cancer;
LUSC	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14019695	chr9:139328340	INPP5E	0.49	9.38	0.46	1.06e-18	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4862307	0.836	rs4507404	chr4:185003767	C/T	cg06737308	chr4:185021514	ENPP6	-0.48	-7.52	-0.38	5.23e-13	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUSC	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg18230493	chr5:56204884	C5orf35	-0.55	-8.85	-0.44	5.12e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.7	11.56	0.53	3.27e-26	Heart rate;
LUSC	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	6.82	0.35	4.38e-11	Height;
LUSC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.63	-11.75	-0.54	6.52e-27	Type 2 diabetes;
LUSC	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-16.69	-0.67	6.84e-46	Primary sclerosing cholangitis;
LUSC	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-7.47	-0.38	7.11e-13	Atrioventricular conduction;
LUSC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21028142	chr17:79581711	NPLOC4	-0.32	-7.81	-0.39	7.47e-14	Eye color traits;
LUSC	cis	rs11997175	0.599	rs66474258	chr8:33640225	A/T	ch.8.33884649F	chr8:33765107	NA	0.53	8.56	0.42	4.33e-16	Body mass index;
LUSC	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg09654669	chr8:57350985	NA	-0.56	-7.78	-0.39	9.24e-14	Obesity-related traits;
LUSC	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg20991723	chr1:152506922	NA	0.49	9.21	0.45	3.74e-18	Hair morphology;
LUSC	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg04850211	chr1:228464232	OBSCN	0.32	5.67	0.3	3.08e-8	Diastolic blood pressure;
LUSC	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg25205988	chr1:146714368	CHD1L	1.05	8.62	0.43	2.81e-16	Mitochondrial DNA levels;
LUSC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-0.87	-16.18	-0.66	7.13e-44	Cognitive function;
LUSC	cis	rs7615316	0.807	rs7623524	chr3:142245984	A/T	cg16271453	chr3:142027066	XRN1	-0.4	-6.83	-0.35	3.93e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs921968	0.565	rs2059717	chr2:219600316	A/T	cg02176678	chr2:219576539	TTLL4	-0.54	-9.4	-0.46	8.84e-19	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.62	-0.34	1.44e-10	Monocyte percentage of white cells;
LUSC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-14.29	-0.62	1.69e-36	Height;
LUSC	trans	rs11700980	1.000	rs7283800	chr21:30107787	C/T	cg05609335	chr17:75789393	NA	-0.41	-6.55	-0.34	2.11e-10	QRS complex (12-leadsum);
LUSC	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	9.18	0.45	4.68e-18	Menopause (age at onset);
LUSC	trans	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg15556689	chr8:8085844	FLJ10661	0.63	8.84	0.44	5.45e-17	Neuroticism;
LUSC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg02772935	chr3:125709198	NA	-0.47	-6.1	-0.32	2.99e-9	Blood pressure (smoking interaction);
LUSC	cis	rs6688613	0.729	rs7545806	chr1:166938555	T/C	cg07049167	chr1:166818506	POGK	0.43	5.77	0.3	1.79e-8	Refractive astigmatism;
LUSC	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.07	14.26	0.62	2.27e-36	Uric acid levels;
LUSC	cis	rs2658782	0.789	rs3020076	chr11:93141058	C/T	cg15737290	chr11:93063684	CCDC67	0.64	7.97	0.4	2.62e-14	Pulmonary function decline;
LUSC	cis	rs7084921	0.578	rs11190393	chr10:101869988	C/T	cg11888571	chr10:102027403	CWF19L1	-0.42	-5.73	-0.3	2.3e-8	Bone mineral density;
LUSC	trans	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg26384229	chr12:38710491	ALG10B	0.56	9.1	0.45	8.21e-18	Morning vs. evening chronotype;
LUSC	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg19812747	chr11:111475976	SIK2	-0.48	-6.84	-0.35	3.87e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg01879757	chr17:41196368	BRCA1	-0.46	-7.0	-0.36	1.44e-11	Menopause (age at onset);
LUSC	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-7.12	-0.36	6.54e-12	Menopause (age at onset);
LUSC	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg23711669	chr6:146136114	FBXO30	0.88	16.36	0.67	1.35e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28493229	0.786	rs73546894	chr19:41189203	C/T	cg21869046	chr19:41225005	ITPKC	0.57	7.5	0.38	5.85e-13	Kawasaki disease;
LUSC	cis	rs7215564	0.818	rs112155856	chr17:78594573	A/T	cg09596252	chr17:78655493	RPTOR	0.56	6.15	0.32	2.21e-9	Myopia (pathological);
LUSC	cis	rs59698941	0.943	rs60042606	chr5:132248170	G/T	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-7.48	-0.38	6.55e-13	Chronic sinus infection;
LUSC	cis	rs897984	0.542	rs750952	chr16:31093954	C/T	cg02466173	chr16:30829666	NA	-0.51	-9.48	-0.46	4.85e-19	Dementia with Lewy bodies;
LUSC	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg25456477	chr12:86230367	RASSF9	0.37	6.43	0.33	4.34e-10	Major depressive disorder;
LUSC	cis	rs2742417	1.000	rs2673057	chr3:45735730	A/T	cg09608765	chr3:45636137	LIMD1	-0.35	-6.94	-0.36	2.05e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs6961069	0.837	rs1761662	chr7:80238463	C/T	cg04458919	chr7:80252533	CD36	-0.37	-6.76	-0.35	6.03e-11	Platelet count;
LUSC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.08	-0.32	3.31e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg19747945	chr6:42946146	PEX6	-0.35	-5.85	-0.3	1.16e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg27572855	chr1:25598939	RHD	0.41	7.23	0.37	3.22e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg04455712	chr21:45112962	RRP1B	0.5	9.6	0.47	1.92e-19	Mean corpuscular volume;
LUSC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg05552183	chr6:42928497	GNMT	0.48	8.07	0.4	1.3e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3768617	0.706	rs8179460	chr1:183056222	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.57	0.42	3.79e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs3755132	0.929	rs16862823	chr2:15775210	T/C	cg12888861	chr2:15731646	DDX1	0.52	7.43	0.38	9.29e-13	Wilms tumor;
LUSC	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg03859395	chr2:55845619	SMEK2	0.88	16.19	0.66	6.22e-44	Metabolic syndrome;
LUSC	cis	rs2063714	0.532	rs2063713	chr6:157196299	G/T	cg23222435	chr6:157204239	ARID1B	-0.71	-11.91	-0.55	1.62e-27	Sitting height ratio;
LUSC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.65	10.78	0.51	1.96e-23	Mood instability;
LUSC	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.47	-7.07	-0.36	9.37e-12	Alzheimer's disease (late onset);
LUSC	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	11.45	0.53	7.93e-26	Ileal carcinoids;
LUSC	cis	rs7605827	0.930	rs6740183	chr2:15692583	T/C	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.82e-16	Educational attainment (years of education);
LUSC	cis	rs240764	0.658	rs9390679	chr6:101216102	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-6.26	-0.32	1.21e-9	Neuroticism;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg00431813	chr7:1051703	C7orf50	-0.42	-6.62	-0.34	1.42e-10	Longevity;Endometriosis;
LUSC	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	0.97	10.96	0.51	4.58e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg26043149	chr18:55253948	FECH	0.49	7.05	0.36	1.05e-11	Bone mineral density;
LUSC	trans	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg09050820	chr6:167586206	TCP10L2	0.74	9.61	0.47	1.89e-19	Gastritis;
LUSC	trans	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg14791747	chr16:20752902	THUMPD1	-0.42	-6.12	-0.32	2.67e-9	Pancreatic cancer;
LUSC	trans	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg25214090	chr10:38739885	LOC399744	0.56	8.23	0.41	4.16e-15	Corneal astigmatism;
LUSC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00166722	chr3:10149974	C3orf24	0.63	8.77	0.43	9.36e-17	Alzheimer's disease;
LUSC	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg13256891	chr4:100009986	ADH5	0.48	7.08	0.36	8.67e-12	Alcohol dependence;
LUSC	cis	rs11229555	0.645	rs12785578	chr11:58206432	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6546886	0.912	rs4331526	chr2:74294449	A/C	cg14702570	chr2:74259524	NA	-0.3	-5.73	-0.3	2.26e-8	Dialysis-related mortality;
LUSC	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg22482690	chr17:47019901	SNF8	0.32	5.74	0.3	2.09e-8	Type 2 diabetes;
LUSC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg26695010	chr11:65641043	EFEMP2	-0.46	-7.01	-0.36	1.32e-11	Eosinophil percentage of white cells;
LUSC	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.78	-13.43	-0.59	3.56e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7000551	0.680	rs28546543	chr8:22314872	A/C	cg12081754	chr8:22256438	SLC39A14	0.46	6.99	0.36	1.46e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg11663144	chr21:46675770	NA	-0.32	-5.67	-0.3	3.04e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg09655341	chr17:79618100	PDE6G	-0.29	-6.64	-0.34	1.29e-10	Eye color traits;
LUSC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg00310523	chr12:86230176	RASSF9	0.53	10.0	0.48	9.39e-21	Major depressive disorder;
LUSC	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg21573476	chr21:45109991	RRP1B	-0.38	-6.22	-0.32	1.47e-9	Mean corpuscular volume;
LUSC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg18827107	chr12:86230957	RASSF9	-0.47	-7.06	-0.36	9.99e-12	Major depressive disorder;
LUSC	cis	rs17401966	0.522	rs12133617	chr1:10288463	C/T	cg19773385	chr1:10388646	KIF1B	-0.36	-6.13	-0.32	2.51e-9	Hepatocellular carcinoma;
LUSC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg25456477	chr12:86230367	RASSF9	-0.44	-7.97	-0.4	2.57e-14	Major depressive disorder;
LUSC	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-11.98	-0.55	9.08e-28	Body mass index;
LUSC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg14949292	chr17:78079608	GAA	-0.3	-5.74	-0.3	2.15e-8	Yeast infection;
LUSC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg13114125	chr14:105738426	BRF1	-0.92	-15.61	-0.65	1.22e-41	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs57046232	0.552	rs6139968	chr20:6319606	A/C	cg17788362	chr6:86352627	SYNCRIP	0.45	6.23	0.32	1.38e-9	Colorectal cancer;
LUSC	trans	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.41	0.33	4.84e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.78	0.47	4.89e-20	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	trans	rs208520	1.000	rs208523	chr6:66954195	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-12.34	-0.56	4.42e-29	Exhaled nitric oxide output;
LUSC	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg03676636	chr4:99064102	C4orf37	0.3	5.96	0.31	6.35e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg27426351	chr10:43362370	NA	-0.43	-5.99	-0.31	5.54e-9	Blood protein levels;
LUSC	cis	rs9473147	0.543	rs9381578	chr6:47556634	C/T	cg02130027	chr6:47444894	CD2AP	0.35	5.7	0.3	2.68e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg13390004	chr1:15929781	NA	0.42	6.9	0.35	2.55e-11	Systolic blood pressure;
LUSC	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.69e-9	Response to antipsychotic treatment;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26297968	chr2:211035960	C2orf67	0.45	7.23	0.37	3.28e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.83	-10.57	-0.5	1.04e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs500891	0.525	rs2875343	chr6:84101327	G/C	cg08257003	chr6:84140564	ME1	0.33	8.05	0.4	1.46e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.68e-10	Depression;
LUSC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.15	-0.49	2.92e-21	Platelet count;
LUSC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	13.55	0.6	1.18e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-10.33	-0.49	6.65e-22	Schizophrenia;
LUSC	cis	rs1160297	0.609	rs12618983	chr2:53091691	C/T	cg07782112	chr2:53107842	NA	-0.4	-6.43	-0.33	4.51e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs10746514	1.000	rs1576618	chr1:232244331	A/G	cg09506761	chr1:232265262	NA	-0.43	-7.05	-0.36	1.01e-11	Response to statin therapy;
LUSC	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03517284	chr6:25882590	NA	-0.4	-7.01	-0.36	1.35e-11	Height;
LUSC	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.74	12.09	0.55	3.67e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg17294928	chr15:75287854	SCAMP5	0.82	10.82	0.51	1.36e-23	Blood trace element (Zn levels);
LUSC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg27532560	chr4:187881888	NA	-0.39	-6.41	-0.33	5.1e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.76	7.33	0.37	1.77e-12	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg15448220	chr1:150897856	SETDB1	0.43	6.1	0.32	2.86e-9	Melanoma;
LUSC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg15744005	chr10:104629667	AS3MT	-0.29	-6.28	-0.32	1.05e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg21280719	chr6:42927975	GNMT	-0.3	-7.27	-0.37	2.49e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.23	-0.69	4.77e-48	Exhaled nitric oxide output;
LUSC	cis	rs6542838	0.641	rs12478574	chr2:99476369	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-6.02	-0.31	4.5e-9	Fear of minor pain;
LUSC	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg24642439	chr20:33292090	TP53INP2	0.4	5.84	0.3	1.22e-8	Height;
LUSC	cis	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg05299278	chr17:33885742	SLFN14	0.28	5.95	0.31	6.84e-9	Response to radiotherapy in cancer (late toxicity);
LUSC	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-1.04	-16.14	-0.66	1.05e-43	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	13.98	0.61	2.73e-35	Platelet count;
LUSC	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	11.98	0.55	9.48e-28	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.14e-21	Bladder cancer;
LUSC	cis	rs4903604	0.581	rs11850485	chr14:78033863	A/G	cg18872420	chr14:78023429	SPTLC2	0.4	6.06	0.31	3.75e-9	Gut microbiome composition (winter);
LUSC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.14	-0.32	2.3e-9	Personality dimensions;
LUSC	cis	rs11642862	1.000	rs111954099	chr16:30789623	A/G	cg02466173	chr16:30829666	NA	-0.66	-7.14	-0.36	5.79e-12	Tonsillectomy;
LUSC	cis	rs9638182	0.522	rs61010704	chr7:73019975	A/G	cg07452164	chr7:72993570	TBL2	0.47	6.45	0.33	3.86e-10	Triglycerides;
LUSC	cis	rs2625529	0.824	rs7183749	chr15:72377278	G/A	cg16672083	chr15:72433130	SENP8	-0.52	-7.63	-0.39	2.45e-13	Red blood cell count;
LUSC	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg23625390	chr15:77176239	SCAPER	-0.66	-10.01	-0.48	8.54e-21	Blood metabolite levels;
LUSC	cis	rs7180079	1.000	rs62021599	chr15:64535177	G/A	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.64	10.99	0.52	3.39e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg11663144	chr21:46675770	NA	-0.4	-6.86	-0.35	3.36e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.41	-0.42	1.23e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs11792861	0.525	rs2417975	chr9:111860185	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.42	6.86	0.35	3.32e-11	Menarche (age at onset);
LUSC	cis	rs4444235	0.564	rs9323252	chr14:54404121	G/A	cg16720578	chr14:54410717	NA	0.36	6.82	0.35	4.39e-11	Colorectal cancer;
LUSC	cis	rs4478858	0.735	rs12134484	chr1:31823741	G/A	cg00250761	chr1:31883323	NA	-0.35	-8.66	-0.43	1.99e-16	Alcohol dependence;
LUSC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg01657329	chr11:68192670	LRP5	-0.47	-7.59	-0.38	3.12e-13	Total body bone mineral density;
LUSC	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg00999904	chr2:3704751	ALLC	-0.41	-7.14	-0.36	5.82e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.54	-9.36	-0.46	1.23e-18	Bipolar disorder;
LUSC	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.62	9.16	0.45	5.44e-18	Squamous cell carcinoma;
LUSC	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg23933602	chr10:16859644	RSU1	0.58	6.79	0.35	4.99e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.55	9.35	0.46	1.28e-18	IgG glycosylation;
LUSC	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.8e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2298450	0.512	rs2245474	chr21:37612407	C/G	cg02919814	chr21:37666008	DOPEY2	0.42	6.31	0.33	8.96e-10	Schizophrenia;
LUSC	trans	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-6.74	-0.35	6.9e-11	Endometrial cancer;
LUSC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	9.31	0.45	1.75e-18	Total body bone mineral density;
LUSC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	10.81	0.51	1.49e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg07777115	chr5:623756	CEP72	-0.47	-5.96	-0.31	6.52e-9	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg13206674	chr6:150067644	NUP43	0.59	9.47	0.46	5.14e-19	Lung cancer;
LUSC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg04369109	chr6:150039330	LATS1	-0.58	-8.43	-0.42	1.02e-15	Lung cancer;
LUSC	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg23942311	chr14:51606299	NA	0.48	10.51	0.5	1.58e-22	Cancer;
LUSC	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg17294928	chr15:75287854	SCAMP5	-0.84	-11.42	-0.53	1.01e-25	Blood trace element (Zn levels);
LUSC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg07701084	chr6:150067640	NUP43	0.48	6.74	0.35	7.17e-11	Lung cancer;
LUSC	cis	rs7605827	0.930	rs1019358	chr2:15524042	A/G	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg04166393	chr7:2884313	GNA12	0.45	5.87	0.31	1.05e-8	Height;
LUSC	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg22705602	chr4:152727874	NA	-0.37	-7.93	-0.4	3.32e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.86	0.4	5.17e-14	Parkinson's disease;
LUSC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg14582100	chr15:45693742	SPATA5L1	0.59	10.78	0.51	1.84e-23	Homoarginine levels;
LUSC	cis	rs4253772	0.872	rs45576734	chr22:46638365	A/G	cg18190219	chr22:46762943	CELSR1	-0.48	-5.81	-0.3	1.45e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg27411982	chr8:10470053	RP1L1	0.37	5.86	0.31	1.13e-8	Retinal vascular caliber;
LUSC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07677032	chr17:61819896	STRADA	0.54	9.03	0.44	1.36e-17	Prudent dietary pattern;
LUSC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	1.05	19.08	0.72	1.98e-55	Parkinson's disease;
LUSC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg16447950	chr5:562315	NA	-0.57	-7.18	-0.37	4.58e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	7.0	0.36	1.44e-11	Height;
LUSC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24904631	chr17:17875305	TOM1L2;LRRC48	0.37	5.85	0.3	1.18e-8	Total body bone mineral density;
LUSC	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.55	9.89	0.48	2.07e-20	Bone mineral density;
LUSC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg06008330	chr7:65541103	ASL	0.4	6.17	0.32	1.96e-9	Aortic root size;
LUSC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.77	9.92	0.48	1.68e-20	Gut microbiome composition (summer);
LUSC	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg09491104	chr22:46646882	C22orf40	-0.68	-6.76	-0.35	6.1e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs593982	1.000	rs74638829	chr11:65495571	C/T	cg08755490	chr11:65554678	OVOL1	-1.45	-15.28	-0.64	2.39e-40	Atopic dermatitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25539011	chr4:139936823	CCRN4L	-0.41	-6.07	-0.32	3.38e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg05425664	chr17:57184151	TRIM37	-0.45	-6.76	-0.35	6.2e-11	Testicular germ cell tumor;
LUSC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg23630131	chr7:65973040	NA	0.21	5.88	0.31	9.83e-9	Aortic root size;
LUSC	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs4629710	0.592	rs11154622	chr6:131547578	C/T	cg12606694	chr6:131520996	AKAP7	0.62	9.44	0.46	6.45e-19	Multiple myeloma (IgH translocation);
LUSC	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.35e-33	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg05313129	chr8:58192883	C8orf71	-0.51	-5.99	-0.31	5.57e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg08270630	chr22:50330655	NA	0.41	6.05	0.31	3.98e-9	Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26547359	chr10:16859530	RSU1	-0.51	-6.5	-0.34	2.99e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4919087	0.590	rs2861877	chr10:99053316	C/A	cg25902810	chr10:99078978	FRAT1	-0.42	-5.73	-0.3	2.3e-8	Monocyte count;
LUSC	cis	rs12541635	0.967	rs11997513	chr8:107093325	C/T	cg10147462	chr8:107024639	NA	-0.49	-8.99	-0.44	1.89e-17	Age of smoking initiation;
LUSC	cis	rs11630290	0.592	rs12232261	chr15:64153302	A/G	cg12036633	chr15:63758958	NA	0.52	6.67	0.34	1.05e-10	Iris characteristics;
LUSC	cis	rs981844	0.712	rs4434231	chr4:154746293	G/T	cg14289246	chr4:154710475	SFRP2	-0.49	-6.61	-0.34	1.52e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs4704187	0.687	rs4404660	chr5:74422210	T/C	cg03227963	chr5:74354835	NA	0.32	6.9	0.35	2.6e-11	Response to amphetamines;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20994686	chr17:71306668	CDC42EP4	0.49	7.44	0.38	8.33e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg08270630	chr22:50330655	NA	0.41	6.06	0.31	3.64e-9	Schizophrenia;
LUSC	cis	rs3791556	0.501	rs3791536	chr2:240101713	G/A	cg03281426	chr2:240109471	HDAC4	0.43	6.21	0.32	1.58e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg17366294	chr4:99064904	C4orf37	-0.56	-9.59	-0.46	2.07e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.2	0.37	4.13e-12	Cognitive ability;
LUSC	cis	rs4363385	0.818	rs11205174	chr1:153001230	C/T	cg25856811	chr1:152973957	SPRR3	0.35	5.86	0.31	1.12e-8	Inflammatory skin disease;
LUSC	cis	rs6460942	0.908	rs967126	chr7:12237300	G/C	cg06484146	chr7:12443880	VWDE	-0.59	-6.17	-0.32	1.94e-9	Coronary artery disease;
LUSC	cis	rs317865	0.609	rs73234660	chr4:16221047	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.61	5.94	0.31	7.13e-9	Kidney disease (early stage) in type 1 diabetes;
LUSC	cis	rs1775715	0.737	rs2799031	chr10:32173168	C/T	cg18675610	chr10:32216311	ARHGAP12	0.3	6.56	0.34	2.04e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs13418410	0.715	rs4670209	chr2:33802956	G/A	cg04131969	chr2:33951647	MYADML	-0.45	-5.95	-0.31	6.64e-9	Non-response to antidepressants and depression;
LUSC	cis	rs9359856	0.564	rs1036853	chr6:90499502	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.17	-0.41	6.64e-15	Bipolar disorder;
LUSC	cis	rs926392	0.589	rs2019032	chr20:37680326	C/A	cg16355469	chr20:37678765	NA	0.53	7.16	0.36	5.21e-12	Dialysis-related mortality;
LUSC	cis	rs10489202	1.000	rs2272911	chr1:167936302	C/T	cg24449463	chr1:168025552	DCAF6	-0.58	-7.37	-0.37	1.32e-12	Schizophrenia;
LUSC	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg13334819	chr7:99746414	C7orf59	0.5	6.76	0.35	6.07e-11	Coronary artery disease;
LUSC	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg06636551	chr8:101224915	SPAG1	-0.4	-7.41	-0.38	1.06e-12	Atrioventricular conduction;
LUSC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-12.32	-0.56	5.32e-29	Bipolar disorder and schizophrenia;
LUSC	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg08330031	chr10:104623503	C10orf32	0.32	5.7	0.3	2.61e-8	Arsenic metabolism;
LUSC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01341218	chr17:43662625	NA	-0.76	-11.1	-0.52	1.45e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.48	-8.61	-0.43	3.01e-16	Longevity;Endometriosis;
LUSC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg13607699	chr17:42295918	UBTF	0.61	10.3	0.49	8.56e-22	Total body bone mineral density;
LUSC	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.32	-0.37	1.9e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	10.56	0.5	1.11e-22	Homoarginine levels;
LUSC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg03233332	chr7:66118400	NA	-0.43	-6.21	-0.32	1.6e-9	Aortic root size;
LUSC	cis	rs4713675	0.584	rs7739505	chr6:33670370	G/A	cg14003231	chr6:33640908	ITPR3	0.31	5.97	0.31	5.95e-9	Plateletcrit;
LUSC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg02807482	chr3:125708958	NA	-0.52	-6.5	-0.33	2.98e-10	Blood pressure (smoking interaction);
LUSC	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.45	-0.46	6.32e-19	Body mass index;
LUSC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg04315214	chr1:2043799	PRKCZ	0.47	9.92	0.48	1.65e-20	Height;
LUSC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg27170947	chr2:26402098	FAM59B	-0.69	-10.54	-0.5	1.32e-22	Gut microbiome composition (summer);
LUSC	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg22681709	chr2:178499509	PDE11A	-0.51	-9.49	-0.46	4.7e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg10207240	chr12:122356781	WDR66	0.44	6.31	0.33	8.64e-10	Mean corpuscular volume;
LUSC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg17211192	chr8:82754475	SNX16	-0.64	-9.11	-0.45	7.56e-18	Diastolic blood pressure;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18295930	chr20:46130624	NCOA3	-0.48	-7.05	-0.36	1.04e-11	Electrocardiographic conduction measures;
LUSC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23158103	chr7:148848205	ZNF398	-0.49	-8.01	-0.4	1.98e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs17253792	0.822	rs76612185	chr14:56037706	T/C	cg01858014	chr14:56050164	KTN1	-0.89	-7.04	-0.36	1.1e-11	Putamen volume;
LUSC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	0.93	15.69	0.65	5.75e-42	Menopause (age at onset);
LUSC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06221963	chr1:154839813	KCNN3	0.66	16.08	0.66	1.74e-43	Prostate cancer;
LUSC	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg04369109	chr6:150039330	LATS1	-0.56	-8.25	-0.41	3.74e-15	Lung cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19628164	chr3:143689916	C3orf58	-0.54	-7.16	-0.36	5.21e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg05738196	chr6:26577821	NA	0.52	8.3	0.41	2.53e-15	Schizophrenia;
LUSC	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg00784671	chr22:46762841	CELSR1	-0.56	-6.87	-0.35	3.09e-11	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	1.14	18.04	0.7	2.84e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg19678392	chr7:94953810	PON1	-0.36	-5.65	-0.3	3.47e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg07211511	chr3:129823064	LOC729375	-0.76	-10.11	-0.48	3.98e-21	Blood pressure (smoking interaction);
LUSC	cis	rs9309473	1.000	rs6705489	chr2:73648811	G/T	cg20560298	chr2:73613845	ALMS1	-0.43	-6.16	-0.32	2.03e-9	Metabolite levels;
LUSC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg24642844	chr7:1081250	C7orf50	-0.5	-7.99	-0.4	2.26e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg20283391	chr11:68216788	NA	0.5	6.78	0.35	5.4e-11	Bone mineral density (spine);
LUSC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg01879757	chr17:41196368	BRCA1	-0.4	-6.08	-0.32	3.23e-9	Menopause (age at onset);
LUSC	cis	rs243505	0.559	rs10215159	chr7:148479071	G/C	cg09806900	chr7:148480153	CUL1	0.68	10.09	0.48	4.52e-21	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg15468180	chr1:107600409	PRMT6	-0.4	-6.38	-0.33	5.78e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	1.11	14.4	0.62	6.72e-37	Nonalcoholic fatty liver disease;
LUSC	cis	rs9311676	0.656	rs11917591	chr3:58368449	C/T	cg13750441	chr3:58318267	PXK	-0.33	-6.59	-0.34	1.74e-10	Systemic lupus erythematosus;
LUSC	cis	rs78579285	0.583	rs77376965	chr16:88800477	G/A	cg01900006	chr16:88814613	FAM38A	0.61	6.77	0.35	5.7e-11	Joint mobility (Beighton score);
LUSC	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg00105475	chr2:10696890	NA	0.38	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg05084668	chr3:125655381	ALG1L	-0.49	-6.86	-0.35	3.34e-11	Blood pressure (smoking interaction);
LUSC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-1.03	-20.11	-0.74	1.74e-59	Height;
LUSC	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg25930673	chr12:123319894	HIP1R	0.6	6.2	0.32	1.65e-9	Schizophrenia;
LUSC	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg06191203	chr2:152266755	RIF1	-0.43	-5.91	-0.31	8.53e-9	Lung cancer;
LUSC	cis	rs7923609	0.846	rs7075901	chr10:65280994	C/A	cg01631684	chr10:65280961	REEP3	-0.41	-6.39	-0.33	5.66e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12472274	0.617	rs7568705	chr2:239081808	C/T	cg17459225	chr2:239074497	NA	0.52	8.62	0.43	2.72e-16	Phospholipid levels (plasma);
LUSC	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg15605315	chr1:45957053	TESK2	0.46	7.19	0.37	4.38e-12	High light scatter reticulocyte count;
LUSC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25072359	chr17:41440525	NA	0.6	8.64	0.43	2.33e-16	Menopause (age at onset);
LUSC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.88	-16.8	-0.68	2.41e-46	Cognitive function;
LUSC	cis	rs2677744	0.626	rs3743452	chr15:91497515	C/T	cg23684204	chr15:91497937	RCCD1	-0.6	-8.44	-0.42	9.54e-16	Attention deficit hyperactivity disorder;
LUSC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg24250549	chr1:154909240	PMVK	0.64	10.43	0.5	3.19e-22	Prostate cancer;
LUSC	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg25214090	chr10:38739885	LOC399744	0.53	7.72	0.39	1.33e-13	Corneal astigmatism;
LUSC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg11062466	chr8:58055876	NA	0.5	6.32	0.33	8.39e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg21775007	chr8:11205619	TDH	0.74	12.67	0.57	2.71e-30	Retinal vascular caliber;
LUSC	cis	rs597583	0.806	rs11603366	chr11:117396505	G/T	cg27161313	chr11:117392002	DSCAML1	-0.43	-7.19	-0.37	4.33e-12	Putamen volume;
LUSC	cis	rs920590	0.643	rs13280085	chr8:19669959	G/T	cg03894339	chr8:19674705	INTS10	-0.43	-6.28	-0.32	1.05e-9	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.9	-15.62	-0.65	1.1e-41	Morning vs. evening chronotype;
LUSC	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg00173435	chr12:106696525	TCP11L2	-0.61	-8.97	-0.44	2.1e-17	Tourette syndrome;
LUSC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg02487422	chr3:49467188	NICN1	0.44	7.09	0.36	7.95e-12	Resting heart rate;
LUSC	trans	rs931812	0.895	rs965625	chr8:101909749	T/C	cg20993868	chr7:22813445	NA	0.64	11.75	0.54	6.73e-27	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.11	16.49	0.67	4.22e-45	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4629710	0.592	rs13206776	chr6:131576679	T/G	cg12606694	chr6:131520996	AKAP7	0.62	9.46	0.46	5.64e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg15073853	chr19:18549131	ISYNA1	-0.33	-5.92	-0.31	8.14e-9	Breast cancer;
LUSC	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg23093090	chr10:104574429	C10orf26	-0.49	-5.86	-0.31	1.12e-8	Arsenic metabolism;
LUSC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg11764359	chr7:65958608	NA	0.49	6.09	0.32	3.19e-9	Aortic root size;
LUSC	cis	rs7246967	0.673	rs2361023	chr19:22816867	C/T	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13732083	chr21:47605072	C21orf56	0.43	6.25	0.32	1.27e-9	Testicular germ cell tumor;
LUSC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg21880101	chr17:80066754	CCDC57	-0.31	-5.91	-0.31	8.41e-9	Life satisfaction;
LUSC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.82	0.57	7.03e-31	Chronic sinus infection;
LUSC	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.28	0.71	3.22e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6690583	0.623	rs12033900	chr1:85478559	T/C	cg11262906	chr1:85462892	MCOLN2	0.67	6.34	0.33	7.32e-10	Serum sulfate level;
LUSC	cis	rs727505	0.866	rs17327181	chr7:124720303	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.71	-0.34	8.35e-11	Lewy body disease;
LUSC	cis	rs55665837	1.000	rs12295723	chr11:14450201	T/C	cg19336497	chr11:14380999	RRAS2	-0.37	-7.53	-0.38	4.9e-13	Vitamin D levels;
LUSC	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg06484146	chr7:12443880	VWDE	-0.75	-7.52	-0.38	4.97e-13	Coronary artery disease;
LUSC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg16606324	chr3:10149918	C3orf24	0.6	8.66	0.43	2.03e-16	Alzheimer's disease;
LUSC	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg16989719	chr2:238392110	NA	-0.5	-6.41	-0.33	4.87e-10	Prostate cancer;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg16274148	chr9:100684771	C9orf156	0.54	6.71	0.34	8.14e-11	Cognitive function;Information processing speed;
LUSC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.76	-13.45	-0.59	2.85e-33	Dental caries;
LUSC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.73	12.77	0.57	1.1e-30	Colorectal cancer;
LUSC	cis	rs2859741	0.546	rs10489413	chr1:37513906	C/T	cg09363841	chr1:37513479	NA	-0.37	-7.3	-0.37	2.13e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs7567389	0.600	rs7590030	chr2:128055967	G/A	cg09760422	chr2:128146352	NA	-0.28	-5.66	-0.3	3.28e-8	Self-rated health;
LUSC	trans	rs62458065	0.850	rs10239812	chr7:32460348	A/G	cg00845942	chr12:64062724	DPY19L2	-0.54	-6.09	-0.32	3.14e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.63	11.23	0.52	4.99e-25	Extrinsic epigenetic age acceleration;
LUSC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg12463550	chr7:65579703	CRCP	-0.42	-6.04	-0.31	4.22e-9	Calcium levels;
LUSC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.88	0.6	6.55e-35	Cognitive test performance;
LUSC	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg14690467	chr7:148917905	ZNF282	-0.26	-5.69	-0.3	2.82e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg11845111	chr2:191398756	TMEM194B	-0.87	-10.5	-0.5	1.79e-22	Diastolic blood pressure;
LUSC	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg17507749	chr15:85114479	UBE2QP1	0.53	6.58	0.34	1.87e-10	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22557350	chr10:126432983	FAM53B	-0.42	-6.2	-0.32	1.64e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg09877947	chr5:131593287	PDLIM4	0.42	6.98	0.36	1.57e-11	Blood metabolite levels;
LUSC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg15103426	chr22:29168792	CCDC117	0.59	8.32	0.41	2.28e-15	Lymphocyte counts;
LUSC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	0.91	12.91	0.58	3.36e-31	Vitiligo;
LUSC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg20135002	chr11:47629003	NA	-0.51	-7.92	-0.4	3.59e-14	Subjective well-being;
LUSC	cis	rs7178572	0.849	rs12901503	chr15:77819056	A/G	cg22256960	chr15:77711686	NA	-0.52	-8.47	-0.42	8.1e-16	Type 2 diabetes;
LUSC	cis	rs911119	0.909	rs111360484	chr20:23618984	G/C	cg16589663	chr20:23618590	CST3	0.6	7.08	0.36	8.36e-12	Chronic kidney disease;
LUSC	cis	rs7809950	0.678	rs7788330	chr7:106985648	G/T	cg23024343	chr7:107201750	COG5	-0.66	-9.9	-0.48	1.99e-20	Coronary artery disease;
LUSC	cis	rs6599077	0.950	rs4676561	chr3:40101286	G/T	cg13683864	chr3:40499215	RPL14	-0.59	-7.4	-0.38	1.11e-12	Sleep-related phenotypes;
LUSC	cis	rs597583	0.760	rs688968	chr11:117406739	C/G	cg27161313	chr11:117392002	DSCAML1	-0.49	-7.65	-0.39	2.14e-13	Putamen volume;
LUSC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg14552801	chr7:65878734	NA	-0.43	-5.86	-0.31	1.09e-8	Aortic root size;
LUSC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	8.61	0.43	2.89e-16	Alzheimer's disease;
LUSC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.6	0.38	3.07e-13	Prudent dietary pattern;
LUSC	cis	rs1564271	0.506	rs1148163	chr10:26929671	G/C	cg13837822	chr10:26931731	LOC731789	0.51	11.42	0.53	9.83e-26	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUSC	cis	rs921665	0.831	rs2167962	chr2:3192427	G/A	cg02624386	chr2:3182749	NA	0.51	5.84	0.3	1.26e-8	World class endurance athleticism;
LUSC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.21	-0.41	4.91e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.23	-0.49	1.51e-21	Monocyte count;
LUSC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03352830	chr11:487213	PTDSS2	0.68	8.61	0.43	2.91e-16	Body mass index;
LUSC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4478858	0.684	rs4949374	chr1:31754511	G/C	cg00250761	chr1:31883323	NA	-0.33	-7.95	-0.4	2.9e-14	Alcohol dependence;
LUSC	cis	rs4499344	0.693	rs8106944	chr19:33097783	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	12.66	0.57	2.92e-30	Mean platelet volume;
LUSC	cis	rs7851660	0.809	rs10818241	chr9:100661972	A/G	cg13688889	chr9:100608707	NA	-0.54	-8.44	-0.42	9.53e-16	Strep throat;
LUSC	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg01657329	chr11:68192670	LRP5	-0.45	-6.59	-0.34	1.68e-10	Total body bone mineral density;
LUSC	cis	rs7615316	0.934	rs6440088	chr3:142270359	T/C	cg16271453	chr3:142027066	XRN1	-0.37	-6.43	-0.33	4.53e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg03476357	chr21:30257390	N6AMT1	0.77	8.12	0.41	8.89e-15	Cognitive test performance;
LUSC	trans	rs61931739	0.649	rs12424056	chr12:33714314	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-6.17	-0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg22638593	chr5:131593259	PDLIM4	0.4	5.91	0.31	8.41e-9	Breast cancer;
LUSC	cis	rs1950626	0.750	rs35683125	chr14:101454750	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.8	0.39	8.17e-14	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs6120849	0.754	rs6120813	chr20:33642112	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.58	0.34	1.8e-10	Protein C levels;
LUSC	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg21775007	chr8:11205619	TDH	-0.65	-10.23	-0.49	1.51e-21	Retinal vascular caliber;
LUSC	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg04374321	chr14:90722782	PSMC1	-0.68	-10.15	-0.49	2.72e-21	Mortality in heart failure;
LUSC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs11229555	0.874	rs17567523	chr11:58354081	G/A	cg15696309	chr11:58395628	NA	-0.71	-9.19	-0.45	4.43e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg15691649	chr6:25882328	NA	-0.39	-6.37	-0.33	6.13e-10	Blood metabolite levels;
LUSC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg04398451	chr17:18023971	MYO15A	0.5	7.97	0.4	2.45e-14	Total body bone mineral density;
LUSC	cis	rs6782228	0.527	rs2712371	chr3:128346214	G/A	cg16766828	chr3:128327626	NA	-0.31	-5.66	-0.3	3.3e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.84	0.44	5.57e-17	Motion sickness;
LUSC	cis	rs7953249	0.935	rs7135337	chr12:121404155	A/C	cg02403541	chr12:121454288	C12orf43	-0.6	-9.28	-0.45	2.24e-18	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-7.21	-0.37	3.75e-12	Mood instability;
LUSC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg23985595	chr17:80112537	CCDC57	-0.31	-5.94	-0.31	7.03e-9	Life satisfaction;
LUSC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03576123	chr11:487126	PTDSS2	-0.97	-10.78	-0.51	1.95e-23	Body mass index;
LUSC	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg01689657	chr7:91764605	CYP51A1	-0.32	-5.88	-0.31	9.85e-9	Breast cancer;
LUSC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg13047869	chr3:10149882	C3orf24	0.61	8.24	0.41	3.97e-15	Alzheimer's disease;
LUSC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.9	0.31	9.03e-9	Menopause (age at onset);
LUSC	trans	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg25214090	chr10:38739885	LOC399744	0.52	7.87	0.4	4.87e-14	Corneal astigmatism;
LUSC	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.93	-0.31	7.65e-9	Type 2 diabetes;
LUSC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg06784218	chr1:46089804	CCDC17	-0.47	-8.92	-0.44	3.06e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9807841	0.592	rs10415961	chr19:10759981	G/C	cg09936142	chr19:10668400	KRI1	-0.44	-7.08	-0.36	8.76e-12	Inflammatory skin disease;
LUSC	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg16928487	chr17:17741425	SREBF1	-0.43	-8.55	-0.42	4.5e-16	Total body bone mineral density;
LUSC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.03	12.78	0.57	1.0500000000000001e-30	Sexual dysfunction (female);
LUSC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg25456477	chr12:86230367	RASSF9	-0.32	-5.69	-0.3	2.83e-8	Major depressive disorder;
LUSC	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.31	-0.41	2.36e-15	Schizophrenia;
LUSC	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.79	11.5	0.53	5.34e-26	Corneal astigmatism;
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg17541715	chr7:1216824	NA	-0.39	-6.16	-0.32	2.09e-9	Longevity;Endometriosis;
LUSC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.04	-0.44	1.32e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.61	-9.56	-0.46	2.66e-19	Height;
LUSC	cis	rs2200578	1.000	rs116648076	chr2:99882347	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.57	6.61	0.34	1.53e-10	IgG glycosylation;
LUSC	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.3	-0.37	2.1e-12	Bipolar disorder;
LUSC	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg00495681	chr13:53174319	NA	0.79	15.67	0.65	7.42e-42	Lewy body disease;
LUSC	trans	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg01596870	chr19:55963115	NA	-0.54	-7.16	-0.36	5.31e-12	Obesity-related traits;
LUSC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06221963	chr1:154839813	KCNN3	-0.61	-13.87	-0.6	7.21e-35	Prostate cancer;
LUSC	trans	rs3794271	0.706	rs9971816	chr12:20826911	C/T	cg25453430	chr21:37433068	SETD4	0.41	6.33	0.33	7.83e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
LUSC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg27432699	chr2:27873401	GPN1	-0.58	-8.91	-0.44	3.47e-17	Total body bone mineral density;
LUSC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.87	13.84	0.6	9.42e-35	Multiple system atrophy;
LUSC	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg17385448	chr1:15911702	AGMAT	0.37	6.31	0.33	8.9e-10	Systolic blood pressure;
LUSC	cis	rs3770081	1.000	rs2241435	chr2:86360916	C/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.83	5.88	0.31	9.86e-9	Facial emotion recognition (sad faces);
LUSC	cis	rs4700695	0.668	rs20768	chr5:65484805	C/T	cg21114390	chr5:65439923	SFRS12	-0.5	-6.93	-0.35	2.12e-11	Facial morphology (factor 19);
LUSC	cis	rs7937682	0.564	rs1944116	chr11:111366792	A/C	cg09085632	chr11:111637200	PPP2R1B	0.44	5.84	0.3	1.24e-8	Primary sclerosing cholangitis;
LUSC	cis	rs1144713	0.686	rs1144714	chr12:32261252	A/C	cg01321189	chr12:32259338	BICD1	0.43	6.63	0.34	1.37e-10	Obesity-related traits;
LUSC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.91	11.53	0.53	3.98e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6693567	0.565	rs1260457	chr1:150347374	G/A	cg15654264	chr1:150340011	RPRD2	0.46	7.36	0.37	1.42e-12	Migraine;
LUSC	trans	rs2048656	0.605	rs7837008	chr8:9646506	T/C	cg15556689	chr8:8085844	FLJ10661	0.46	6.47	0.33	3.55e-10	Schizophrenia;
LUSC	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg24596788	chr1:163392923	NA	-0.38	-6.48	-0.33	3.3e-10	Motion sickness;
LUSC	cis	rs965469	1.000	rs6051709	chr20:3263685	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-5.93	-0.31	7.54e-9	IFN-related cytopenia;
LUSC	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg17143192	chr8:8559678	CLDN23	0.67	9.31	0.45	1.75e-18	Obesity-related traits;
LUSC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg27532560	chr4:187881888	NA	-0.39	-6.34	-0.33	7.63e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg25801113	chr15:45476975	SHF	-0.35	-6.98	-0.36	1.58e-11	Uric acid levels;
LUSC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.94	0.44	2.75e-17	Prudent dietary pattern;
LUSC	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg03060546	chr3:49711283	APEH	-0.61	-7.2	-0.37	3.89e-12	Menarche (age at onset);
LUSC	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23544223	chr18:12777786	NA	0.59	6.27	0.32	1.15e-9	Inflammatory skin disease;
LUSC	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.03	-20.36	-0.74	1.76e-60	Ulcerative colitis;
LUSC	cis	rs1018836	0.608	rs10111060	chr8:91491152	T/C	cg16814680	chr8:91681699	NA	-0.63	-9.43	-0.46	7.18e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4144743	0.938	rs35439279	chr17:45321694	C/T	cg18085866	chr17:45331354	ITGB3	-0.75	-8.07	-0.4	1.26e-14	Body mass index;
LUSC	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg05347473	chr6:146136440	FBXO30	0.51	8.46	0.42	8.73e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg10253484	chr15:75165896	SCAMP2	-0.39	-5.65	-0.3	3.48e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs9921338	0.961	rs72773829	chr16:11412623	G/A	cg00044050	chr16:11439710	C16orf75	-0.5	-6.75	-0.35	6.73e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.22	0.37	3.63e-12	Mean platelet volume;
LUSC	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg10426581	chr7:100472382	SRRT	0.86	12.47	0.56	1.43e-29	Resting heart rate;
LUSC	cis	rs897984	0.806	rs12928852	chr16:30943988	C/T	cg02466173	chr16:30829666	NA	0.56	11.3	0.53	2.68e-25	Dementia with Lewy bodies;
LUSC	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.71	11.64	0.54	1.63e-26	Eye color traits;
LUSC	cis	rs9650315	0.866	rs28538240	chr8:57182945	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.88	0.35	3.01e-11	Height;
LUSC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.48	0.42	7.57e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg26513180	chr16:89883248	FANCA	0.89	16.17	0.66	7.53e-44	Vitiligo;
LUSC	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg08807101	chr21:30365312	RNF160	-0.53	-6.68	-0.34	9.85e-11	Cognitive test performance;
LUSC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg05754148	chr16:3507555	NAT15	0.52	7.85	0.39	5.54e-14	Tuberculosis;
LUSC	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.21	0.74	6.52e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg13318129	chr22:45737514	FAM118A	0.7	8.48	0.42	7.4e-16	Tonsillectomy;
LUSC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg22166914	chr1:53195759	ZYG11B	-0.62	-10.26	-0.49	1.21e-21	Monocyte count;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg08771429	chr7:91876374	KRIT1;ANKIB1	0.41	6.03	0.31	4.43e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2625529	0.775	rs12913042	chr15:72202309	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-7.24	-0.37	3.18e-12	Red blood cell count;
LUSC	trans	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg05926928	chr17:57297772	GDPD1	-0.9	-10.33	-0.49	6.63e-22	Opioid sensitivity;
LUSC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg26958806	chr6:27640298	NA	0.69	5.91	0.31	8.22e-9	Depression;
LUSC	trans	rs9944715	1.000	rs4890628	chr18:43788045	T/C	cg01718231	chr17:29326311	RNF135	-0.5	-7.06	-0.36	9.81e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg03233332	chr7:66118400	NA	-0.41	-5.97	-0.31	6.03e-9	Aortic root size;
LUSC	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg13736514	chr6:26305472	NA	-0.48	-9.6	-0.46	1.99e-19	Educational attainment;
LUSC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.46	-0.38	7.39e-13	Bipolar disorder;
LUSC	cis	rs2307022	0.586	rs3785126	chr16:68388661	C/T	cg02226672	chr16:68398533	SMPD3	0.33	6.15	0.32	2.25e-9	Body mass index;
LUSC	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg20701182	chr2:24300061	SF3B14	0.82	8.15	0.41	7.36e-15	Lymphocyte counts;
LUSC	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg24596788	chr1:163392923	NA	-0.45	-7.62	-0.38	2.6e-13	Motion sickness;
LUSC	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg24851651	chr11:66362959	CCS	-0.38	-6.06	-0.31	3.72e-9	Educational attainment (years of education);
LUSC	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg23752985	chr2:85803571	VAMP8	0.37	8.19	0.41	5.69e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs11165623	0.740	rs11165638	chr1:96921357	C/A	cg10631902	chr5:14652156	NA	-0.55	-8.98	-0.44	1.97e-17	Hip circumference;Waist circumference;
LUSC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24110177	chr3:50126178	RBM5	-0.55	-9.05	-0.44	1.22e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2303282	0.716	rs12445699	chr16:56452584	A/G	cg00500540	chr16:56394104	NA	-0.43	-7.37	-0.37	1.37e-12	Breast cancer;
LUSC	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg20734569	chr3:48348370	SPINK8	0.46	8.19	0.41	5.74e-15	Coronary artery disease;
LUSC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg04733989	chr22:42467013	NAGA	0.53	8.18	0.41	5.88e-15	Schizophrenia;
LUSC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.36	-8.21	-0.41	4.76e-15	Cystic fibrosis severity;
LUSC	cis	rs3087591	0.664	rs2854308	chr17:29666539	A/G	cg24425628	chr17:29625626	OMG;NF1	0.47	7.23	0.37	3.33e-12	Hip circumference;
LUSC	trans	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.3	-0.33	9.43e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3820928	1.000	rs1835158	chr2:227763993	C/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.77	-0.39	9.77e-14	Pulmonary function;
LUSC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg12365402	chr11:9010492	NRIP3	0.47	8.79	0.43	8.12e-17	Hemoglobin concentration;
LUSC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg01879757	chr17:41196368	BRCA1	-0.47	-7.16	-0.36	5.11e-12	Menopause (age at onset);
LUSC	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg03342759	chr3:160939853	NMD3	-0.51	-8.44	-0.42	9.48e-16	Morning vs. evening chronotype;
LUSC	cis	rs6961069	0.806	rs10499859	chr7:80258810	A/G	cg04458919	chr7:80252533	CD36	0.37	6.74	0.35	7.09e-11	Platelet count;
LUSC	cis	rs7590368	0.683	rs72779445	chr2:10957707	G/C	cg15705551	chr2:10952987	PDIA6	0.57	6.12	0.32	2.64e-9	Educational attainment (years of education);
LUSC	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.49	9.87	0.48	2.5e-20	Anterior chamber depth;
LUSC	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.23	-0.37	3.29e-12	Major depressive disorder;
LUSC	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg04362960	chr10:104952993	NT5C2	0.45	6.75	0.35	6.5500000000000006e-11	Waist circumference;Hip circumference;
LUSC	cis	rs11809207	0.723	rs57653638	chr1:26524401	A/G	cg00300879	chr1:26503847	CNKSR1	0.3	5.75	0.3	2.01e-8	Height;
LUSC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg08822215	chr16:89438651	ANKRD11	0.38	5.89	0.31	9.26e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg05340658	chr4:99064831	C4orf37	0.41	6.24	0.32	1.31e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg24675658	chr1:53192096	ZYG11B	0.61	9.78	0.47	4.83e-20	Monocyte count;
LUSC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.83	-0.54	3.32e-27	Chronic sinus infection;
LUSC	cis	rs11997175	0.603	rs12156112	chr8:33791598	T/C	ch.8.33884649F	chr8:33765107	NA	0.42	6.37	0.33	6.35e-10	Body mass index;
LUSC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-5.8	-0.3	1.55e-8	Tonsillectomy;
LUSC	cis	rs2236918	1.000	rs851782	chr1:242033783	A/G	cg17736920	chr1:242011382	EXO1	0.44	6.81	0.35	4.48e-11	Menopause (age at onset);
LUSC	cis	rs4285028	0.948	rs13089878	chr3:121703895	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.71	-9.24	-0.45	3.07e-18	Multiple sclerosis;
LUSC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg08200582	chr11:442649	ANO9	-0.51	-5.98	-0.31	5.68e-9	Body mass index;
LUSC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg16339924	chr4:17578868	LAP3	0.56	8.67	0.43	1.94e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2540226	0.550	rs13401182	chr2:39932807	G/A	cg23576258	chr2:39999331	THUMPD2	0.38	6.38	0.33	5.82e-10	Personality dimensions;
LUSC	cis	rs6005807	0.719	rs9625513	chr22:29022172	C/T	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	trans	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg22328901	chr2:86333256	PTCD3;POLR1A	0.41	5.98	0.31	5.75e-9	Metabolic syndrome;
LUSC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg17554472	chr22:41940697	POLR3H	0.48	5.9	0.31	8.76e-9	Vitiligo;
LUSC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg03036452	chr22:46663545	TTC38	0.58	5.76	0.3	1.88e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg12310025	chr6:25882481	NA	0.4	6.88	0.35	2.92e-11	Blood metabolite levels;
LUSC	trans	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.38	-0.33	5.95e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	0.94	18.89	0.72	1.15e-54	Cognitive function;
LUSC	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg00083206	chr6:110721305	DDO	0.45	8.27	0.41	3.22e-15	Platelet distribution width;
LUSC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg23172400	chr8:95962367	TP53INP1	0.31	6.25	0.32	1.28e-9	Type 2 diabetes;
LUSC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.74	-12.75	-0.57	1.29e-30	Sudden cardiac arrest;
LUSC	cis	rs6961069	0.585	rs10265780	chr7:80255369	A/G	cg04458919	chr7:80252533	CD36	-0.38	-6.75	-0.35	6.37e-11	Platelet count;
LUSC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg12292205	chr6:26970375	C6orf41	-0.69	-12.15	-0.55	2.25e-28	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7428496	0.528	rs13085261	chr3:142242287	G/A	cg16271453	chr3:142027066	XRN1	-0.51	-8.77	-0.43	9.61e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.38	-0.42	1.45e-15	Lymphocyte counts;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07148880	chr1:200992788	KIF21B	0.47	6.3	0.33	9.62e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg16434002	chr17:42200994	HDAC5	-0.49	-6.9	-0.35	2.66e-11	Total body bone mineral density;
LUSC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg09365446	chr1:150670422	GOLPH3L	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.08	0.55	4.01e-28	Prudent dietary pattern;
LUSC	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg11502198	chr6:26597334	ABT1	0.59	9.08	0.44	9.8e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6500395	1.000	rs2129243	chr16:48646852	A/T	cg04672837	chr16:48644449	N4BP1	0.43	6.17	0.32	1.93e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg24558204	chr6:135376177	HBS1L	0.59	9.11	0.45	7.58e-18	Red blood cell count;
LUSC	cis	rs4499344	0.526	rs11084655	chr19:33034698	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	10.28	0.49	1.02e-21	Mean platelet volume;
LUSC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.03	-0.31	4.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20360273	chr2:70056711	GMCL1	-0.48	-7.42	-0.38	9.65e-13	Electrocardiographic conduction measures;
LUSC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg04518342	chr5:131593106	PDLIM4	0.55	10.37	0.49	4.93e-22	Acylcarnitine levels;
LUSC	trans	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg16660971	chr17:78860029	RPTOR	0.37	6.01	0.31	4.78e-9	Major depressive disorder;
LUSC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg11608241	chr8:8085544	FLJ10661	-0.42	-6.07	-0.32	3.52e-9	Mood instability;
LUSC	cis	rs7216064	1.000	rs73352808	chr17:65875157	G/A	cg12091567	chr17:66097778	LOC651250	-0.74	-9.32	-0.45	1.62e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg02972257	chr16:68554789	NA	-0.47	-6.13	-0.32	2.46e-9	Ulcerative colitis;
LUSC	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg01652190	chr22:50026171	C22orf34	-0.28	-5.92	-0.31	7.95e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-1.01	-14.2	-0.61	3.96e-36	Exhaled nitric oxide output;
LUSC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg22823121	chr1:150693482	HORMAD1	0.54	7.74	0.39	1.17e-13	Melanoma;
LUSC	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.39	5.96	0.31	6.41e-9	Height;
LUSC	cis	rs73198271	0.681	rs35457364	chr8:8649790	T/A	cg01851573	chr8:8652454	MFHAS1	0.53	8.49	0.42	7.11e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg20406979	chr6:167373233	NA	0.25	6.03	0.31	4.37e-9	Crohn's disease;
LUSC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-5.86	-0.31	1.09e-8	Tonsillectomy;
LUSC	cis	rs4356932	1.000	rs6857372	chr4:76974727	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.83	0.3	1.33e-8	Blood protein levels;
LUSC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.73	0.35	7.49e-11	Tonsillectomy;
LUSC	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.31	0.53	2.41e-25	Eye color traits;
LUSC	cis	rs10992471	0.603	rs10116813	chr9:95090360	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-8.38	-0.42	1.46e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.91	16.38	0.67	1.09e-44	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg00484396	chr16:3507460	NAT15	-0.45	-7.31	-0.37	2.03e-12	Body mass index (adult);
LUSC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	5.72	0.3	2.39e-8	Renal function-related traits (BUN);
LUSC	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	5.97	0.31	6.2e-9	Schizophrenia;
LUSC	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.47	-0.42	7.8e-16	Response to antipsychotic treatment;
LUSC	trans	rs9944275	0.860	rs34169909	chr15:97189563	T/C	cg18834029	chr10:103349097	POLL;RP11-529I10.4	-0.6	-5.97	-0.31	6.23e-9	Depressive symptoms (multi-trait analysis);Neuroticism (multi-trait analysis);
LUSC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-9.89	-0.48	2.17e-20	Schizophrenia;
LUSC	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg10845886	chr2:3471009	TTC15	-0.63	-8.24	-0.41	4.09e-15	Neurofibrillary tangles;
LUSC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg05347473	chr6:146136440	FBXO30	0.45	7.7	0.39	1.61e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12220238	0.730	rs11000899	chr10:75913055	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.92	0.35	2.36e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07256732	chr16:621771	PIGQ	-0.37	-6.5	-0.34	2.89e-10	Height;
LUSC	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg05911100	chr12:8333192	FAM66C	-0.36	-6.16	-0.32	2.12e-9	Neuroticism;
LUSC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg24250549	chr1:154909240	PMVK	0.6	9.76	0.47	5.94e-20	Prostate cancer;
LUSC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs244293	0.965	rs244305	chr17:53237843	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-5.93	-0.31	7.63e-9	Menarche (age at onset);
LUSC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.7	9.84	0.47	3.06e-20	Bronchopulmonary dysplasia;
LUSC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-6.43	-0.33	4.31e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg13560548	chr3:10150139	C3orf24	0.51	7.05	0.36	1.04e-11	Alzheimer's disease;
LUSC	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.85	14.85	0.63	1.22e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00376283	chr12:123451042	ABCB9	-0.69	-9.82	-0.47	3.77e-20	Neutrophil percentage of white cells;
LUSC	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg08000102	chr2:233561755	GIGYF2	-0.69	-11.5	-0.53	5.13e-26	Coronary artery disease;
LUSC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.65	8.76	0.43	1.01e-16	High light scatter reticulocyte count;
LUSC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg16586182	chr3:47516702	SCAP	-0.49	-7.71	-0.39	1.43e-13	Colorectal cancer;
LUSC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg06671706	chr8:8559999	CLDN23	0.51	6.71	0.34	8.45e-11	Obesity-related traits;
LUSC	cis	rs6987853	0.814	rs2923415	chr8:42455577	A/G	cg09913449	chr8:42400586	C8orf40	0.42	6.91	0.35	2.47e-11	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg15147215	chr3:52552868	STAB1	-0.31	-6.11	-0.32	2.79e-9	Bipolar disorder;
LUSC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg22709100	chr7:91322751	NA	0.38	5.64	0.3	3.57e-8	Breast cancer;
LUSC	cis	rs2637266	1.000	rs2894339	chr10:78354104	G/A	cg18941641	chr10:78392320	NA	0.39	7.17	0.37	4.97e-12	Pulmonary function;
LUSC	cis	rs1044826	0.667	rs2083336	chr3:139201272	T/G	cg00490450	chr3:139108681	COPB2	0.46	6.96	0.36	1.86e-11	Obesity-related traits;
LUSC	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg07148914	chr20:33460835	GGT7	0.54	8.25	0.41	3.63e-15	Height;
LUSC	trans	rs17133449	0.718	rs2167695	chr10:4753980	G/C	cg17844448	chr7:27782764	TAX1BP1	-0.38	-6.2	-0.32	1.68e-9	Major depressive disorder;
LUSC	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.27	-17.1	-0.68	1.53e-47	Hip circumference adjusted for BMI;
LUSC	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg23422044	chr7:1970798	MAD1L1	-0.66	-7.51	-0.38	5.6e-13	Bipolar disorder;
LUSC	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg02117656	chr17:79614917	TSPAN10	-0.31	-5.67	-0.3	3.13e-8	Eye color traits;
LUSC	trans	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.59e-15	Diabetic kidney disease;
LUSC	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.86e-12	Blood metabolite levels;
LUSC	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg17333051	chr19:2783644	SGTA	0.46	6.81	0.35	4.44e-11	Total cholesterol levels;
LUSC	cis	rs7113850	0.541	rs80031332	chr11:24211553	A/G	ch.11.24196551F	chr11:24239977	NA	0.95	7.4	0.38	1.14e-12	Bone fracture in osteoporosis;
LUSC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11645453	chr3:52864694	ITIH4	-0.37	-8.1	-0.41	1.07e-14	Bipolar disorder;
LUSC	trans	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg20935933	chr6:143382018	AIG1	0.51	7.38	0.37	1.26e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-9.55	-0.46	2.86e-19	Gut microbiome composition (summer);
LUSC	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg02423579	chr7:2872169	GNA12	-0.37	-5.68	-0.3	2.96e-8	Height;
LUSC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg23630131	chr7:65973040	NA	-0.21	-5.84	-0.3	1.27e-8	Aortic root size;
LUSC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.74	12.05	0.55	5.08e-28	Coronary artery disease;
LUSC	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	8.85	0.44	5.34e-17	Schizophrenia;
LUSC	cis	rs672059	1.000	rs3120034	chr1:183167051	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.72	0.43	1.36e-16	Hypertriglyceridemia;
LUSC	cis	rs6120849	0.951	rs6120848	chr20:33728678	T/C	cg24642439	chr20:33292090	TP53INP2	0.56	6.19	0.32	1.78e-9	Protein C levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07542287	chr2:240046312	HDAC4	-0.77	-6.48	-0.33	3.28e-10	Cognitive performance;
LUSC	cis	rs3764563	1.000	rs4371280	chr19:15715768	A/C	cg20725493	chr19:15740067	CYP4F8	-0.67	-6.55	-0.34	2.2e-10	Inflammatory biomarkers;
LUSC	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg27661571	chr11:113659931	NA	0.64	6.14	0.32	2.4e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4423214	0.592	rs3829251	chr11:71194559	G/A	cg05163923	chr11:71159392	DHCR7	-0.65	-6.94	-0.35	2.1e-11	Vitamin D levels;
LUSC	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.67	-0.43	1.84e-16	Uric acid levels;
LUSC	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg17764715	chr19:33622953	WDR88	0.59	7.9	0.4	4.06e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.45	-0.46	6.09e-19	Bipolar disorder;
LUSC	trans	rs262741	0.538	rs7728710	chr5:165186172	C/T	cg02631838	chr1:33358788	HPCA	0.34	6.03	0.31	4.43e-9	Lewy body disease;
LUSC	cis	rs12042938	0.600	rs823163	chr1:231771108	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.43	6.45	0.33	3.87e-10	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg23625390	chr15:77176239	SCAPER	0.46	7.01	0.36	1.35e-11	Blood metabolite levels;
LUSC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg02187348	chr16:89574699	SPG7	0.5	7.94	0.4	3.09e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg14416269	chr4:6271139	WFS1	0.41	6.65	0.34	1.22e-10	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg25214090	chr10:38739885	LOC399744	0.4	6.18	0.32	1.89e-9	Diastolic blood pressure;
LUSC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg04800585	chr6:26043546	HIST1H2BB	0.42	6.02	0.31	4.51e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6500395	1.000	rs6500398	chr16:48650332	C/T	cg04672837	chr16:48644449	N4BP1	0.48	6.98	0.36	1.56e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.8	13.17	0.58	3.4e-32	Aortic root size;
LUSC	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg18105134	chr13:113819100	PROZ	0.64	9.75	0.47	6.36e-20	Platelet distribution width;
LUSC	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg01256987	chr12:42539512	GXYLT1	-0.39	-7.11	-0.36	7.2e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.09	0.4	1.15e-14	Axial length;
LUSC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.82	-14.17	-0.61	5.01e-36	Cognitive function;
LUSC	cis	rs9951602	0.607	rs3017651	chr18:76668622	T/C	cg00806245	chr18:76673096	NA	-0.43	-6.74	-0.35	6.83e-11	Obesity-related traits;
LUSC	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg22681709	chr2:178499509	PDE11A	-0.48	-8.8	-0.43	7.7e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.21	0.52	5.66e-25	Coffee consumption (cups per day);
LUSC	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.43	17.37	0.69	1.32e-48	Opioid sensitivity;
LUSC	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg05147244	chr20:61493195	TCFL5	-0.88	-7.99	-0.4	2.15e-14	Obesity-related traits;
LUSC	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg13628971	chr7:2884303	GNA12	0.41	6.31	0.33	8.92e-10	Height;
LUSC	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.33	-0.37	1.78e-12	HDL cholesterol;
LUSC	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.83	12.19	0.55	1.6e-28	Cognitive ability;
LUSC	cis	rs922692	0.715	rs11632102	chr15:79086057	G/A	cg00540400	chr15:79124168	NA	-0.42	-7.25	-0.37	2.94e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg00376283	chr12:123451042	ABCB9	0.81	12.52	0.57	9.78e-30	Platelet count;
LUSC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.79	-0.39	8.75e-14	Tonsillectomy;
LUSC	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg27284194	chr4:1044797	NA	0.57	8.42	0.42	1.12e-15	Recombination rate (females);
LUSC	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg00944433	chr1:107599041	PRMT6	0.34	6.22	0.32	1.53e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs1943345	0.830	rs571055	chr11:82898829	G/C	cg07047830	chr11:82868014	PCF11	0.52	6.42	0.33	4.57e-10	Obesity-related traits;
LUSC	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg22906224	chr7:99728672	NA	0.53	7.68	0.39	1.83e-13	Coronary artery disease;
LUSC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.42	-0.42	1.12e-15	Type 2 diabetes;
LUSC	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg19610905	chr11:61596333	FADS2	-0.54	-8.19	-0.41	5.58e-15	Trans fatty acid levels;
LUSC	cis	rs2742417	0.603	rs2742371	chr3:45782763	G/A	cg04837898	chr3:45731254	SACM1L	-0.45	-7.45	-0.38	8.27e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.77	-0.35	5.85e-11	Retinal vascular caliber;
LUSC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs1957429	0.520	rs77606588	chr14:65356268	G/A	cg23373153	chr14:65346875	NA	-1.01	-8.51	-0.42	6.09e-16	Pediatric areal bone mineral density (radius);
LUSC	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg16006841	chr5:176797999	RGS14	-0.66	-9.25	-0.45	2.82e-18	Urate levels in lean individuals;
LUSC	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg24130564	chr14:104152367	KLC1	-0.46	-6.36	-0.33	6.47e-10	Body mass index;
LUSC	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.57	-0.38	3.57e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.85	-14.33	-0.62	1.22e-36	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg05294307	chr14:35346193	BAZ1A	-0.56	-6.74	-0.35	6.84e-11	Psoriasis;
LUSC	cis	rs11958404	0.932	rs72816542	chr5:157416402	C/T	cg05962755	chr5:157440814	NA	0.56	6.55	0.34	2.22e-10	IgG glycosylation;
LUSC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	22.51	0.78	6.26e-69	Height;
LUSC	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg08917208	chr2:24149416	ATAD2B	0.53	5.97	0.31	6e-9	Lymphocyte counts;
LUSC	cis	rs72960926	0.744	rs72953763	chr6:74983753	G/C	cg03266952	chr6:74778945	NA	-0.82	-6.99	-0.36	1.49e-11	Metabolite levels (MHPG);
LUSC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23158103	chr7:148848205	ZNF398	-0.5	-8.35	-0.42	1.88e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs13082711	0.911	rs6777272	chr3:27488310	T/G	cg02860705	chr3:27208620	NA	0.5	8.11	0.41	1e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg05082376	chr22:42548792	NA	0.43	6.59	0.34	1.73e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg20003494	chr4:90757398	SNCA	-0.34	-5.71	-0.3	2.55e-8	Dementia with Lewy bodies;
LUSC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.07	-0.48	5.1e-21	Obesity-related traits;
LUSC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.66	6.33	0.33	7.76e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.42	-0.46	7.9e-19	Chronic sinus infection;
LUSC	cis	rs10779751	0.686	rs2791656	chr1:11128329	A/G	cg08854313	chr1:11322531	MTOR	0.84	12.47	0.56	1.51e-29	Body mass index;
LUSC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg05340658	chr4:99064831	C4orf37	-0.46	-7.26	-0.37	2.68e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4704187	0.687	rs6864324	chr5:74497885	C/T	cg03227963	chr5:74354835	NA	-0.32	-6.91	-0.35	2.43e-11	Response to amphetamines;
LUSC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg04166393	chr7:2884313	GNA12	0.44	6.05	0.31	3.86e-9	Height;
LUSC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg06212747	chr3:49208901	KLHDC8B	0.43	5.86	0.31	1.1e-8	Parkinson's disease;
LUSC	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.85	9.88	0.48	2.24e-20	Breast cancer;
LUSC	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg20587970	chr11:113659929	NA	-1.22	-16.33	-0.67	1.76e-44	Hip circumference adjusted for BMI;
LUSC	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg00383909	chr3:49044727	WDR6	1.5	10.72	0.51	3.09e-23	Cognitive function;
LUSC	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs4343996	0.869	rs4719944	chr7:3496032	A/G	cg21248987	chr7:3385318	SDK1	0.37	6.1	0.32	2.86e-9	Motion sickness;
LUSC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-6.78	-0.35	5.34e-11	Aortic root size;
LUSC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg18240062	chr17:79603768	NPLOC4	0.69	12.86	0.58	4.98e-31	Eye color traits;
LUSC	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg04117972	chr1:227635322	NA	-0.69	-7.56	-0.38	3.89e-13	Major depressive disorder;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19527946	chr21:46293646	PTTG1IP	-0.44	-6.32	-0.33	8.37e-10	Electrocardiographic conduction measures;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14103574	chr5:162932455	MAT2B	0.48	7.39	0.37	1.19e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.84	9.5	0.46	4.31e-19	Yeast infection;
LUSC	trans	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg11197913	chr1:145054779	PDE4DIP	0.33	6.01	0.31	4.91e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg10577346	chr11:8704225	RPL27A	-0.44	-6.53	-0.34	2.42e-10	Cognitive function;
LUSC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg12935359	chr14:103987150	CKB	-0.52	-8.03	-0.4	1.66e-14	Body mass index;
LUSC	cis	rs62432291	0.681	rs2932988	chr6:159655402	A/G	cg14500486	chr6:159655392	FNDC1	-0.52	-5.86	-0.31	1.14e-8	Joint mobility (Beighton score);
LUSC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg20203395	chr5:56204925	C5orf35	-0.57	-8.3	-0.41	2.59e-15	Coronary artery disease;
LUSC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg18350739	chr11:68623251	NA	-0.37	-6.67	-0.34	1.09e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs611744	0.743	rs2514843	chr8:109063434	C/T	cg18478394	chr8:109455254	TTC35	0.42	6.13	0.32	2.54e-9	Dupuytren's disease;
LUSC	cis	rs4144743	1.000	rs35704663	chr17:45327321	T/G	cg18085866	chr17:45331354	ITGB3	-0.75	-7.79	-0.39	8.26e-14	Body mass index;
LUSC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg14416269	chr4:6271139	WFS1	0.52	11.11	0.52	1.3e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs36093844	0.898	rs12363602	chr11:85596401	T/A	cg25872744	chr11:85566296	CCDC83	-0.41	-5.87	-0.31	1.03e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs907612	0.638	rs11041476	chr11:1875067	C/T	cg05305434	chr11:1874049	LSP1	0.32	5.99	0.31	5.55e-9	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LUSC	trans	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.11	-0.32	2.77e-9	Parkinson's disease;
LUSC	cis	rs7000551	0.751	rs2443505	chr8:22375341	G/A	cg12081754	chr8:22256438	SLC39A14	0.46	6.92	0.35	2.37e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg07959070	chr22:50026188	C22orf34	-0.36	-7.26	-0.37	2.79e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26817334	chr2:119613580	NA	0.43	6.22	0.32	1.45e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9581857	0.685	rs9319368	chr13:28042275	T/G	cg22138327	chr13:27999177	GTF3A	0.74	8.04	0.4	1.53e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs16912285	0.748	rs7104550	chr11:24345162	A/G	ch.11.24196551F	chr11:24239977	NA	0.77	7.01	0.36	1.32e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg13042288	chr15:90349979	ANPEP	-0.48	-7.1	-0.36	7.58e-12	Uric acid levels;
LUSC	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.92	15.81	0.65	1.92e-42	Bladder cancer;
LUSC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.38	7.6	0.38	3e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg02751453	chr18:77725136	HSBP1L1	0.44	5.99	0.31	5.48e-9	Opioid sensitivity;
LUSC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg22166914	chr1:53195759	ZYG11B	-0.67	-11.3	-0.53	2.74e-25	Monocyte count;
LUSC	trans	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg08975724	chr8:8085496	FLJ10661	0.42	6.06	0.31	3.61e-9	Retinal vascular caliber;
LUSC	cis	rs3755132	0.929	rs6743036	chr2:15767761	G/A	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg02018176	chr4:1364513	KIAA1530	-0.56	-9.76	-0.47	5.87e-20	Obesity-related traits;
LUSC	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-7.8	-0.39	8.18e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs500891	0.504	rs1145897	chr6:84040440	C/T	cg08257003	chr6:84140564	ME1	0.34	8.09	0.4	1.08e-14	Platelet-derived growth factor BB levels;
LUSC	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.34	-0.46	1.42e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg06060754	chr5:176797920	RGS14	0.56	8.53	0.42	5.16e-16	Urinary electrolytes (magnesium/calcium ratio);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg27378424	chr22:31795766	DRG1	0.47	6.1	0.32	2.86e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg13319975	chr6:146136371	FBXO30	0.47	7.24	0.37	3.19e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.91	15.7	0.65	5.46e-42	Morning vs. evening chronotype;
LUSC	trans	rs9944715	0.954	rs4890319	chr18:43812644	T/A	cg01718231	chr17:29326311	RNF135	-0.54	-7.64	-0.39	2.38e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs9831754	1.000	rs9831754	chr3:78353591	A/C	cg06138941	chr3:78371609	NA	-0.74	-10.48	-0.5	2.11e-22	Calcium levels;
LUSC	trans	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg26043149	chr18:55253948	FECH	-0.45	-7.02	-0.36	1.23e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg24675056	chr1:15929824	NA	0.45	7.65	0.39	2.12e-13	Systolic blood pressure;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg02370978	chr2:86333167	PTCD3;POLR1A	0.42	5.98	0.31	5.67e-9	Mosquito bite size;
LUSC	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.55	-0.38	4.25e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg05973401	chr12:123451056	ABCB9	0.54	6.77	0.35	5.67e-11	Neutrophil percentage of white cells;
LUSC	cis	rs1358748	0.555	rs2093331	chr1:67531967	G/C	cg02640540	chr1:67518911	SLC35D1	0.62	6.52	0.34	2.6e-10	Tuberculosis;
LUSC	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg03474202	chr17:45855739	NA	-0.29	-6.48	-0.33	3.26e-10	IgG glycosylation;
LUSC	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg25204440	chr1:209979598	IRF6	0.47	5.94	0.31	7.17e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs7523050	0.643	rs7551142	chr1:109399710	G/T	cg08274380	chr1:109419600	GPSM2	1.1	10.69	0.51	3.76e-23	Fat distribution (HIV);
LUSC	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg03948781	chr1:205179583	DSTYK	0.32	6.25	0.32	1.26e-9	Red blood cell count;
LUSC	cis	rs7923609	0.871	rs6479905	chr10:65315231	A/G	cg01631684	chr10:65280961	REEP3	0.41	6.05	0.31	3.84e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs2648875	1.000	rs1472483	chr8:129070781	G/T	cg14550066	chr19:55417500	NCR1	0.34	6.03	0.31	4.46e-9	End-stage renal disease;
LUSC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg25258033	chr6:167368657	RNASET2	0.44	6.61	0.34	1.53e-10	Crohn's disease;
LUSC	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg02415014	chr8:143852576	LYNX1	0.33	7.66	0.39	1.97e-13	Urinary tract infection frequency;
LUSC	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg13206674	chr6:150067644	NUP43	0.43	6.48	0.33	3.26e-10	Testicular germ cell tumor;
LUSC	cis	rs1950626	0.623	rs3742401	chr14:101453344	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.4	7.44	0.38	8.78e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.42	-7.35	-0.37	1.51e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19717773	chr7:2847554	GNA12	-0.38	-5.99	-0.31	5.34e-9	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11223367	chr3:101497980	FAM55C	-0.44	-6.39	-0.33	5.65e-10	Electrocardiographic conduction measures;
LUSC	cis	rs6496044	0.568	rs6496039	chr15:86061963	A/T	cg13263323	chr15:86062960	AKAP13	-0.38	-6.23	-0.32	1.39e-9	Interstitial lung disease;
LUSC	cis	rs722599	0.748	rs731165	chr14:75352555	T/C	cg08847533	chr14:75593920	NEK9	-0.48	-6.88	-0.35	3e-11	IgG glycosylation;
LUSC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-7.24	-0.37	3.11e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg14664628	chr15:75095509	CSK	-0.67	-10.27	-0.49	1.14e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	trans	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg02030672	chr11:45687055	CHST1	-0.42	-6.33	-0.33	7.7e-10	Obesity-related traits;
LUSC	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.69	0.34	9.17e-11	Intraocular pressure;
LUSC	cis	rs981844	0.740	rs10009844	chr4:154681576	C/T	cg14289246	chr4:154710475	SFRP2	-0.49	-6.97	-0.36	1.73e-11	Response to statins (LDL cholesterol change);
LUSC	trans	rs961253	0.522	rs2225115	chr20:6360465	C/T	cg21095983	chr6:86352623	SYNCRIP	0.49	7.2	0.37	4.09e-12	Colorectal cancer;
LUSC	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg25319279	chr11:5960081	NA	-0.45	-7.03	-0.36	1.18e-11	DNA methylation (variation);
LUSC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg06221963	chr1:154839813	KCNN3	-0.6	-13.05	-0.58	9.49e-32	Prostate cancer;
LUSC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.11	0.32	2.74e-9	Personality dimensions;
LUSC	cis	rs8046696	1	rs8046696	chr16:75442143	T/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.48	-0.33	3.37e-10	Coronary artery disease;
LUSC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg05313129	chr8:58192883	C8orf71	-0.53	-6.85	-0.35	3.6e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.81	-13.47	-0.59	2.57e-33	Morning vs. evening chronotype;
LUSC	cis	rs71403859	0.502	rs71403847	chr16:71468226	T/C	cg08717414	chr16:71523259	ZNF19	-0.69	-7.92	-0.4	3.65e-14	Post bronchodilator FEV1;
LUSC	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-39.35	-0.91	1.8e-127	Myeloid white cell count;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg00047844	chr17:77752442	CBX2	0.56	7.54	0.38	4.52e-13	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.62	12.64	0.57	3.5e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9581857	0.547	rs9581871	chr13:28085767	G/A	cg22138327	chr13:27999177	GTF3A	0.69	7.14	0.36	5.86e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-7.97	-0.4	2.52e-14	Lymphocyte counts;
LUSC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg18681998	chr4:17616180	MED28	0.83	15.06	0.64	1.76e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg16606324	chr3:10149918	C3orf24	0.67	9.74	0.47	6.66e-20	Alzheimer's disease;
LUSC	cis	rs1775715	0.870	rs1755084	chr10:32253709	C/T	cg26784012	chr10:32216390	ARHGAP12	0.41	6.5	0.33	3.01e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs740160	0.510	rs6958704	chr7:98898358	G/A	cg24650262	chr7:98904301	NA	0.62	6.9	0.35	2.68e-11	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs67072384	0.901	rs7936972	chr11:72479692	T/C	cg04827223	chr11:72435913	ARAP1	-0.87	-6.44	-0.33	4.27e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg07701084	chr6:150067640	NUP43	0.57	8.93	0.44	2.83e-17	Lung cancer;
LUSC	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg25214090	chr10:38739885	LOC399744	0.5	7.4	0.38	1.11e-12	Corneal astigmatism;
LUSC	cis	rs9463078	0.764	rs9367211	chr6:44885305	T/C	cg25276700	chr6:44698697	NA	-0.3	-6.08	-0.32	3.32e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg04995722	chr7:26192034	NFE2L3	-0.39	-6.33	-0.33	7.75e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12541635	0.677	rs10808408	chr8:107005034	C/T	cg10147462	chr8:107024639	NA	0.65	13.57	0.6	1.06e-33	Age of smoking initiation;
LUSC	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	6.28	0.32	1.08e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6445975	0.578	rs6782218	chr3:58408765	T/C	cg18950693	chr14:70346909	SMOC1	-0.39	-5.96	-0.31	6.27e-9	Systemic lupus erythematosus;
LUSC	cis	rs1712517	1.000	rs1712517	chr10:105033015	C/T	cg05636881	chr10:105038444	INA	0.39	6.61	0.34	1.51e-10	Migraine;
LUSC	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.81	13.18	0.58	3.16e-32	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.11	-0.36	7.15e-12	Bipolar disorder;
LUSC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06634786	chr22:41940651	POLR3H	-0.53	-6.43	-0.33	4.33e-10	Vitiligo;
LUSC	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg15744005	chr10:104629667	AS3MT	-0.29	-6.25	-0.32	1.22e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs909341	0.716	rs71325463	chr20:62362834	G/A	cg09650180	chr20:62225654	GMEB2	-0.45	-5.85	-0.31	1.14e-8	Atopic dermatitis;
LUSC	cis	rs4285028	1.000	rs4285028	chr3:121660664	A/C	cg11130432	chr3:121712080	ILDR1	-0.63	-9.81	-0.47	4.04e-20	Multiple sclerosis;
LUSC	trans	rs17086172	0.630	rs1432076	chr18:70273041	G/A	cg02919422	chr8:55370544	SOX17	-0.59	-6.12	-0.32	2.69e-9	Airflow obstruction;
LUSC	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg15557168	chr22:42548783	NA	0.35	5.82	0.3	1.36e-8	Cognitive function;
LUSC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg06145435	chr7:1022769	CYP2W1	0.28	6.12	0.32	2.55e-9	Longevity;Endometriosis;
LUSC	cis	rs427941	0.967	rs6970036	chr7:101841824	A/G	cg06246474	chr7:101738831	CUX1	0.35	5.65	0.3	3.37e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs62400317	0.826	rs11970412	chr6:45037516	C/T	cg20913747	chr6:44695427	NA	-0.46	-7.42	-0.38	9.73e-13	Total body bone mineral density;
LUSC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-14.03	-0.61	1.75e-35	Hemoglobin concentration;
LUSC	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg15557168	chr22:42548783	NA	-0.41	-6.18	-0.32	1.88e-9	Schizophrenia;
LUSC	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg08601574	chr20:25228251	PYGB	0.42	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.51	7.87	0.4	5.03e-14	Depressive symptoms;
LUSC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	1.0	13.9	0.61	5.86e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg05973401	chr12:123451056	ABCB9	0.51	7.06	0.36	9.93e-12	Neutrophil percentage of white cells;
LUSC	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg26816564	chr1:7831052	VAMP3	1.04	14.18	0.61	4.77e-36	Inflammatory bowel disease;
LUSC	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg01657329	chr11:68192670	LRP5	-0.39	-5.67	-0.3	3.17e-8	Total body bone mineral density;
LUSC	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg00745463	chr17:30367425	LRRC37B	0.79	8.96	0.44	2.27e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.56	-7.78	-0.39	9.2e-14	Inhibitory control;
LUSC	cis	rs6489882	0.867	rs4766674	chr12:113365201	A/C	cg20102336	chr12:113376681	OAS3	0.43	6.22	0.32	1.51e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg12483005	chr1:23474871	LUZP1	0.42	6.62	0.34	1.4e-10	Height;
LUSC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg00990874	chr7:1149470	C7orf50	-0.53	-6.87	-0.35	3.09e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.63	10.68	0.5	4.18e-23	Blood metabolite levels;
LUSC	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-6.82	-0.35	4.4e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.42	6.65	0.34	1.18e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs8113142	0.651	rs73026091	chr19:29107018	T/C	cg04546413	chr19:29218101	NA	0.42	5.76	0.3	1.96e-8	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs8032315	1.000	rs8032315	chr15:91418297	A/T	cg06330618	chr15:91428456	FES	0.28	5.8	0.3	1.51e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08392591	chr16:89556376	ANKRD11	0.47	7.19	0.37	4.28e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	ch.11.42038R	chr11:967971	AP2A2	0.54	7.86	0.4	5.22e-14	Alzheimer's disease (late onset);
LUSC	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg00757033	chr12:89920650	WDR51B	0.61	10.88	0.51	8.3e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg04553112	chr3:125709451	NA	-0.47	-5.69	-0.3	2.76e-8	Blood pressure (smoking interaction);
LUSC	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg03585969	chr10:35415529	CREM	0.61	8.92	0.44	3.24e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg17691542	chr6:26056736	HIST1H1C	0.4	5.97	0.31	5.97e-9	Schizophrenia;
LUSC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23248424	chr5:179741104	GFPT2	-0.57	-8.97	-0.44	2.12e-17	Height;
LUSC	trans	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg07211511	chr3:129823064	LOC729375	-0.83	-11.86	-0.54	2.64e-27	Blood pressure (smoking interaction);
LUSC	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg02782426	chr3:40428986	ENTPD3	0.33	5.94	0.31	7e-9	Renal cell carcinoma;
LUSC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg23711669	chr6:146136114	FBXO30	0.71	12.32	0.56	5.36e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.38	-0.37	1.29e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.93	-17.64	-0.69	1.13e-49	Bone mineral density;
LUSC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg10729496	chr3:10149963	C3orf24	0.52	6.88	0.35	2.9100000000000002e-11	Alzheimer's disease;
LUSC	trans	rs12439619	0.508	rs8032033	chr15:82457896	G/C	cg04831495	chr15:85060580	GOLGA6L5	-0.48	-7.84	-0.39	6.29e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.77	11.37	0.53	1.57e-25	Corneal astigmatism;
LUSC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs4737010	0.501	rs55694640	chr8:41649439	T/G	cg17182837	chr8:41585554	ANK1	-0.39	-6.91	-0.35	2.44e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.82	-14.09	-0.61	1.03e-35	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7180079	0.925	rs4776447	chr15:64643067	C/T	cg08069370	chr15:64387884	SNX1	0.54	5.91	0.31	8.34e-9	Monocyte count;
LUSC	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg12615879	chr12:58013172	SLC26A10	0.37	8.55	0.42	4.47e-16	Multiple sclerosis;
LUSC	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg21053147	chr12:120880522	NA	0.55	6.62	0.34	1.41e-10	Type 1 diabetes nephropathy;
LUSC	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg15819921	chr19:927150	ARID3A	-0.44	-6.54	-0.34	2.29e-10	Life satisfaction;
LUSC	cis	rs2294693	0.945	rs10947944	chr6:41004657	T/C	cg14769373	chr6:40998127	UNC5CL	-0.52	-6.93	-0.35	2.12e-11	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg03146154	chr1:46216737	IPP	-0.54	-8.3	-0.41	2.65e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg26816564	chr1:7831052	VAMP3	0.96	13.23	0.59	1.99e-32	Inflammatory bowel disease;
LUSC	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg20503657	chr10:835505	NA	0.89	12.3	0.56	6.15e-29	Eosinophil percentage of granulocytes;
LUSC	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg15105969	chr2:36825350	FEZ2	0.45	5.91	0.31	8.56e-9	Height;
LUSC	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg23422044	chr7:1970798	MAD1L1	-0.6	-7.22	-0.37	3.44e-12	Bipolar disorder;
LUSC	cis	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg06521331	chr12:34319734	NA	0.4	6.56	0.34	2.11e-10	Morning vs. evening chronotype;
LUSC	cis	rs193541	0.545	rs12518979	chr5:122181787	G/T	cg19077854	chr5:122220652	SNX24	-0.35	-7.47	-0.38	7.17e-13	Glucose homeostasis traits;
LUSC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.8	-0.65	2.29e-42	Gut microbiome composition (summer);
LUSC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.44	-0.33	4.08e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.7	-0.34	9.06e-11	Lung cancer;
LUSC	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg04586622	chr2:25135609	ADCY3	0.42	9.0	0.44	1.8e-17	Body mass index;
LUSC	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.91	15.38	0.64	9.57e-41	Bladder cancer;
LUSC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.15	16.22	0.66	4.64e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg07701084	chr6:150067640	NUP43	0.57	8.84	0.44	5.56e-17	Lung cancer;
LUSC	cis	rs56283067	0.887	rs7765371	chr6:44777204	G/A	cg18551225	chr6:44695536	NA	-0.47	-7.3	-0.37	2.18e-12	Total body bone mineral density;
LUSC	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg01579765	chr21:45077557	HSF2BP	0.47	9.4	0.46	9.14e-19	Mean corpuscular volume;
LUSC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-1.07	-24.87	-0.81	5.49e-78	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	trans	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg13698153	chr12:118541722	VSIG10	-0.35	-5.96	-0.31	6.28e-9	Vitiligo;
LUSC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-7.51	-0.38	5.46e-13	Bipolar disorder;
LUSC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg07936489	chr17:37558343	FBXL20	-0.68	-9.56	-0.46	2.75e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.93	12.09	0.55	3.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs965513	1.000	rs7847663	chr9:100544868	C/T	cg13688889	chr9:100608707	NA	-0.56	-8.45	-0.42	9.41e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg15649852	chr7:65879115	NA	-0.41	-5.83	-0.3	1.31e-8	Aortic root size;
LUSC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-1.18	-13.0	-0.58	1.52e-31	Diabetic kidney disease;
LUSC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.32	0.37	1.82e-12	Motion sickness;
LUSC	cis	rs8099014	0.911	rs8092394	chr18:56127755	A/T	cg12907477	chr18:56117327	MIR122	0.43	6.69	0.34	9.48e-11	Platelet count;
LUSC	cis	rs6484504	0.576	rs11031323	chr11:31245413	T/G	cg26647111	chr11:31128758	NA	-0.41	-5.98	-0.31	5.75e-9	Red blood cell count;
LUSC	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.22	0.32	1.49e-9	Corneal astigmatism;
LUSC	cis	rs8141797	0.748	rs3788368	chr22:24577986	T/C	cg00411358	chr22:24577142	SUSD2	-0.5	-5.84	-0.3	1.23e-8	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.29	6.45	0.33	3.95e-10	Coronary artery disease;
LUSC	cis	rs13418410	0.715	rs7571269	chr2:33797271	C/A	cg04131969	chr2:33951647	MYADML	-0.46	-6.1	-0.32	2.9e-9	Non-response to antidepressants and depression;
LUSC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08677398	chr8:58056175	NA	0.54	6.63	0.34	1.35e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12760731	0.565	rs7536856	chr1:178057927	A/G	cg00404053	chr1:178313656	RASAL2	0.69	6.77	0.35	5.79e-11	Obesity-related traits;
LUSC	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg17031739	chr1:67600172	NA	0.37	5.71	0.3	2.5e-8	Psoriasis;
LUSC	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg27661571	chr11:113659931	NA	-0.61	-7.31	-0.37	1.96e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.97	-0.36	1.74e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg06207120	chr15:45996521	NA	0.39	5.9	0.31	8.8e-9	Waist circumference;Weight;
LUSC	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs12681287	0.752	rs12675974	chr8:87247845	T/C	cg27223183	chr8:87520930	FAM82B	-0.45	-5.72	-0.3	2.35e-8	Caudate activity during reward;
LUSC	cis	rs977987	0.737	rs8046697	chr16:75442144	T/C	cg04384234	chr16:75411784	CFDP1	-0.41	-6.48	-0.33	3.37e-10	Dupuytren's disease;
LUSC	cis	rs7833986	0.501	rs72651502	chr8:56875533	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	9.92	0.48	1.7e-20	Height;
LUSC	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.76	-0.3	1.92e-8	Height;
LUSC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg07424592	chr7:64974309	NA	0.69	6.08	0.32	3.28e-9	Diabetic kidney disease;
LUSC	cis	rs9653442	0.545	rs13415465	chr2:100764004	T/G	cg07810366	chr2:100720526	AFF3	-0.46	-7.79	-0.39	8.33e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.6	8.1	0.41	1.02e-14	High light scatter reticulocyte count;
LUSC	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg07169764	chr2:136633963	MCM6	-0.59	-7.76	-0.39	1.05e-13	Cholesterol, total;
LUSC	cis	rs10193935	0.901	rs13429697	chr2:42529818	C/T	cg27598129	chr2:42591480	NA	-0.61	-8.32	-0.41	2.25e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.67	-0.39	1.84e-13	Blood metabolite levels;
LUSC	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-7.63	-0.39	2.54e-13	Schizophrenia;
LUSC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.71	-0.43	1.43e-16	Bipolar disorder;
LUSC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.71	10.69	0.5	3.95e-23	Aortic root size;
LUSC	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.07	0.36	9.39e-12	Asthma;
LUSC	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14159747	chr11:113255604	NA	0.27	7.12	0.36	6.67e-12	Information processing speed;
LUSC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg06454157	chr6:167490870	NA	-0.29	-6.79	-0.35	5.15e-11	Crohn's disease;
LUSC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg06713675	chr4:122721982	EXOSC9	-0.45	-8.02	-0.4	1.86e-14	Type 2 diabetes;
LUSC	cis	rs1775715	0.737	rs2808072	chr10:32205504	A/T	cg03015672	chr10:32216066	ARHGAP12	0.34	6.12	0.32	2.59e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg24829409	chr8:58192753	C8orf71	-0.61	-7.49	-0.38	6.09e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21724239	chr8:58056113	NA	0.88	9.73	0.47	7.33e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs9928842	0.824	rs12924999	chr16:75262425	T/G	cg09066997	chr16:75300724	BCAR1	0.52	6.39	0.33	5.5e-10	Alcoholic chronic pancreatitis;
LUSC	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg13010199	chr12:38710504	ALG10B	0.52	7.89	0.4	4.32e-14	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg06092702	chr1:163392909	NA	-0.39	-6.55	-0.34	2.21e-10	Motion sickness;
LUSC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.43	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08280861	chr8:58055591	NA	0.55	6.51	0.34	2.73e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.41	7.96	0.4	2.71e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg24069376	chr3:38537580	EXOG	0.51	10.51	0.5	1.63e-22	Electrocardiographic conduction measures;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11226328	chr1:29213367	EPB41	0.44	6.35	0.33	6.99e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.14e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-10.05	-0.48	6.09e-21	Joint mobility (Beighton score);
LUSC	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg21724239	chr8:58056113	NA	0.59	7.31	0.37	1.97e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.86	-15.28	-0.64	2.37e-40	Ulcerative colitis;
LUSC	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs7503807	0.905	rs9909449	chr17:78614393	A/G	cg09596252	chr17:78655493	RPTOR	0.44	7.53	0.38	4.77e-13	Obesity;
LUSC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.73	0.35	7.58e-11	Tonsillectomy;
LUSC	cis	rs3790645	0.958	rs2278979	chr1:26877708	G/A	cg17456097	chr1:26900765	RPS6KA1	0.46	6.7	0.34	8.87e-11	Glucose homeostasis traits;
LUSC	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg09975044	chr14:104007538	NA	0.36	5.7	0.3	2.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg17554472	chr22:41940697	POLR3H	-0.45	-5.76	-0.3	1.86e-8	Vitiligo;
LUSC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg09509183	chr1:209979624	IRF6	0.53	6.29	0.33	9.68e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11141652	chr22:24348549	GSTTP1	0.39	5.83	0.3	1.29e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg20243544	chr17:37824526	PNMT	0.4	6.03	0.31	4.26e-9	Self-reported allergy;
LUSC	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg15704280	chr7:45808275	SEPT13	0.67	7.36	0.37	1.46e-12	Axial length;
LUSC	cis	rs9309473	1.000	rs10190219	chr2:73658331	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-6.46	-0.33	3.62e-10	Metabolite levels;
LUSC	trans	rs9650657	0.740	rs6980805	chr8:10679842	G/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.07	-0.32	3.56e-9	Neuroticism;
LUSC	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg09876464	chr15:85330779	ZNF592	0.36	6.67	0.34	1.07e-10	P wave terminal force;
LUSC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	trans	rs12080794	1.000	rs12239637	chr1:9155711	C/T	cg11315153	chr6:62996299	KHDRBS2	-0.52	-6.11	-0.32	2.76e-9	Response to antidepressant treatment (citalopram);
LUSC	cis	rs34375054	0.624	rs12832525	chr12:125680366	T/C	cg06287003	chr12:125626642	AACS	-0.36	-5.7	-0.3	2.6e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg23711669	chr6:146136114	FBXO30	-0.83	-15.28	-0.64	2.37e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg23649088	chr2:200775458	C2orf69	-0.37	-5.69	-0.3	2.72e-8	QT interval;
LUSC	cis	rs4588572	0.686	rs67689570	chr5:77676843	T/C	cg11547950	chr5:77652471	NA	0.54	7.76	0.39	1.04e-13	Triglycerides;
LUSC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg09904177	chr6:26538194	HMGN4	0.47	7.48	0.38	6.76e-13	Schizophrenia;
LUSC	cis	rs2282300	0.956	rs1222212	chr11:30374643	C/T	cg25418670	chr11:30344373	C11orf46	-0.53	-7.39	-0.37	1.19e-12	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15539901	chr8:124084814	WDR67	0.5	7.34	0.37	1.6e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.86	-0.35	3.36e-11	Monocyte count;
LUSC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg01256987	chr12:42539512	GXYLT1	-0.44	-8.5	-0.42	6.62e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg26677194	chr12:130822605	PIWIL1	0.6	8.96	0.44	2.29e-17	Menopause (age at onset);
LUSC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	8.4	0.42	1.28e-15	Mood instability;
LUSC	cis	rs6754311	0.593	rs4954279	chr2:136409073	G/A	cg07169764	chr2:136633963	MCM6	0.55	7.25	0.37	2.94e-12	Mosquito bite size;
LUSC	cis	rs9341808	0.667	rs583426	chr6:80946687	G/A	cg08355045	chr6:80787529	NA	-0.4	-6.82	-0.35	4.37e-11	Sitting height ratio;
LUSC	cis	rs2354432	0.607	rs6689243	chr1:146710559	A/T	cg25205988	chr1:146714368	CHD1L	-1.01	-9.27	-0.45	2.33e-18	Mitochondrial DNA levels;
LUSC	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg06392426	chr19:10676186	KRI1	0.48	5.78	0.3	1.74e-8	Red cell distribution width;
LUSC	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg13010199	chr12:38710504	ALG10B	0.52	7.89	0.4	4.44e-14	Morning vs. evening chronotype;
LUSC	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-5.77	-0.3	1.85e-8	Neutrophil percentage of white cells;
LUSC	cis	rs4363385	0.588	rs12079087	chr1:153023888	T/C	cg25856811	chr1:152973957	SPRR3	-0.35	-5.8	-0.3	1.54e-8	Inflammatory skin disease;
LUSC	trans	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg20935933	chr6:143382018	AIG1	0.45	6.06	0.31	3.62e-9	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs422249	0.634	rs174615	chr11:61628964	T/A	cg06860612	chr11:61641270	FADS3	0.28	5.86	0.31	1.09e-8	Trans fatty acid levels;
LUSC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17261708	chr5:176794207	RGS14	-0.36	-6.07	-0.32	3.5e-9	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	0.59	9.15	0.45	5.84e-18	Breast cancer;
LUSC	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg08847533	chr14:75593920	NEK9	-0.83	-15.44	-0.65	5.91e-41	Height;
LUSC	cis	rs73200209	0.744	rs17426718	chr12:116599676	A/C	cg01776926	chr12:116560359	MED13L	-0.51	-6.12	-0.32	2.68e-9	Total body bone mineral density;
LUSC	cis	rs977987	0.742	rs12928898	chr16:75462081	G/A	cg03315344	chr16:75512273	CHST6	0.5	9.56	0.46	2.75e-19	Dupuytren's disease;
LUSC	cis	rs4964805	1.000	rs73192052	chr12:104190854	C/T	cg02344784	chr12:104178138	NT5DC3	0.43	6.71	0.34	8.11e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-7.38	-0.37	1.29e-12	Aortic root size;
LUSC	cis	rs6847149	1.000	rs6847149	chr4:110800097	C/T	cg07850274	chr4:110748770	RRH	-0.57	-8.02	-0.4	1.84e-14	Exercise treadmill test traits;
LUSC	cis	rs12530845	0.943	rs60858457	chr7:135336918	T/C	cg23117316	chr7:135346802	PL-5283	-0.57	-9.06	-0.44	1.1e-17	Red blood cell traits;
LUSC	cis	rs11674184	0.564	rs746579	chr2:11744694	C/T	cg07314298	chr2:11723111	GREB1	-0.63	-10.07	-0.48	5.2e-21	Endometriosis;
LUSC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg02487422	chr3:49467188	NICN1	0.44	7.04	0.36	1.12e-11	Resting heart rate;
LUSC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.63	-5.9	-0.31	8.74e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.23	14.1	0.61	9.75e-36	Diabetic kidney disease;
LUSC	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg17173187	chr15:85201210	NMB	0.35	6.28	0.32	1.07e-9	Schizophrenia;
LUSC	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg02176678	chr2:219576539	TTLL4	-0.6	-10.7	-0.51	3.66e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.77	0.35	5.63e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.96	-19.24	-0.73	4.75e-56	Brugada syndrome;
LUSC	trans	rs1459104	0.759	rs7939392	chr11:55257285	C/T	cg03929089	chr4:120376271	NA	0.58	6.12	0.32	2.63e-9	Body mass index;
LUSC	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.83	-12.58	-0.57	5.67e-30	Body mass index;
LUSC	cis	rs4077468	1.000	rs9661504	chr1:205915667	A/T	cg11965913	chr1:205819406	PM20D1	-0.39	-5.74	-0.3	2.1e-8	Cystic fibrosis-related diabetes;
LUSC	cis	rs77741769	0.571	rs1542859	chr12:121336766	A/G	cg02419362	chr12:121203948	SPPL3	0.46	8.44	0.42	9.89e-16	Mean corpuscular volume;
LUSC	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.87	14.76	0.63	2.57e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg14440974	chr22:39074834	NA	-0.36	-6.05	-0.31	3.83e-9	Menopause (age at onset);
LUSC	cis	rs4674676	1	rs4674676	chr2:223529112	A/G	cg25565276	chr2:223520875	FARSB	1.1	15.63	0.65	1.05e-41	Chin dimples;
LUSC	cis	rs1595825	0.891	rs7584475	chr2:198577424	A/C	cg00982548	chr2:198649783	BOLL	-0.5	-6.45	-0.33	3.93e-10	Ulcerative colitis;
LUSC	cis	rs698813	0.543	rs12468824	chr2:44482448	G/T	cg00619915	chr2:44497795	NA	-0.53	-7.52	-0.38	5e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs1358748	0.522	rs2092911	chr1:67574319	T/G	cg02640540	chr1:67518911	SLC35D1	0.62	6.06	0.31	3.71e-9	Tuberculosis;
LUSC	cis	rs713587	0.935	rs4430895	chr2:25161386	C/T	cg15423357	chr2:25149977	NA	0.42	8.35	0.42	1.89e-15	Body mass index in non-asthmatics;
LUSC	cis	rs7192380	0.964	rs11075729	chr16:69620278	G/A	cg26679644	chr16:69762563	NA	0.36	6.39	0.33	5.66e-10	Sjögren's syndrome;
LUSC	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.73	-13.71	-0.6	3.05e-34	Ulcerative colitis;
LUSC	cis	rs2562456	0.833	rs62110428	chr19:21613656	C/T	cg00806126	chr19:22604979	ZNF98	-0.4	-5.71	-0.3	2.53e-8	Pain;
LUSC	trans	rs2983496	1.000	rs12525763	chr6:166037281	C/T	cg20192747	chr18:44774846	NA	-0.46	-5.95	-0.31	6.79e-9	Cortisol levels (saliva);
LUSC	cis	rs73058052	1.000	rs2288920	chr19:50091798	G/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.53	6.07	0.32	3.43e-9	Fibrinogen levels;
LUSC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg06454157	chr6:167490870	NA	-0.29	-6.78	-0.35	5.52e-11	Crohn's disease;
LUSC	trans	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg01620082	chr3:125678407	NA	-0.82	-7.32	-0.37	1.84e-12	Depression;
LUSC	cis	rs12681287	0.547	rs6985066	chr8:87526439	A/C	cg27223183	chr8:87520930	FAM82B	-0.54	-7.15	-0.36	5.67e-12	Caudate activity during reward;
LUSC	cis	rs7945718	0.967	rs4415740	chr11:12783911	C/T	cg25843174	chr11:12811716	TEAD1	0.32	7.15	0.36	5.54e-12	Educational attainment (years of education);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25734572	chr19:9896597	NA	0.39	6.48	0.33	3.27e-10	Schizophrenia;
LUSC	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.52	0.38	5.17e-13	Menarche (age at onset);
LUSC	cis	rs654950	0.875	rs632166	chr1:41995681	T/C	cg06885757	chr1:42089581	HIVEP3	-0.33	-6.34	-0.33	7.57e-10	Airway imaging phenotypes;
LUSC	cis	rs2637266	0.875	rs12783253	chr10:78378108	A/G	cg18941641	chr10:78392320	NA	0.39	7.03	0.36	1.14e-11	Pulmonary function;
LUSC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.42	6.51	0.34	2.73e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg26395211	chr5:140044315	WDR55	0.45	7.08	0.36	8.31e-12	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.43	-0.46	6.9e-19	Extrinsic epigenetic age acceleration;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05533744	chr16:67226368	E2F4	0.4	5.99	0.31	5.43e-9	Asthma;
LUSC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg21535247	chr6:8435926	SLC35B3	0.57	8.67	0.43	1.96e-16	Motion sickness;
LUSC	cis	rs858239	0.539	rs10280815	chr7:23188370	A/C	cg23682824	chr7:23144976	KLHL7	0.4	5.71	0.3	2.52e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg21100191	chr22:23484243	RTDR1	0.92	16.16	0.66	8.64e-44	Bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12732805	chr8:146078479	COMMD5	-0.43	-6.31	-0.33	8.88e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg03678062	chr6:149772716	ZC3H12D	-0.3	-6.15	-0.32	2.24e-9	Dupuytren's disease;
LUSC	cis	rs2637266	1.000	rs2395410	chr10:78381767	C/T	cg18941641	chr10:78392320	NA	0.39	7.16	0.36	5.33e-12	Pulmonary function;
LUSC	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg22782873	chr19:19639568	YJEFN3	0.49	6.16	0.32	2.05e-9	Bipolar disorder;
LUSC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg06096015	chr1:231504339	EGLN1	-0.48	-8.28	-0.41	2.96e-15	Hemoglobin concentration;
LUSC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg20849893	chr7:64541193	NA	-0.65	-5.68	-0.3	2.99e-8	Diabetic kidney disease;
LUSC	cis	rs3857536	0.813	rs6455091	chr6:66949127	C/G	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg00982548	chr2:198649783	BOLL	-0.58	-7.2	-0.37	4.13e-12	Ulcerative colitis;
LUSC	cis	rs2109514	0.870	rs6976316	chr7:116122943	G/A	cg12739419	chr7:116140593	CAV2	-0.27	-5.86	-0.31	1.14e-8	Prevalent atrial fibrillation;
LUSC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-17.49	-0.69	4.27e-49	Height;
LUSC	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg18110333	chr6:292329	DUSP22	0.5	7.64	0.39	2.28e-13	Menopause (age at onset);
LUSC	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg22705602	chr4:152727874	NA	-0.31	-6.19	-0.32	1.81e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.04	-0.31	4.13e-9	Resting heart rate;
LUSC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.61	-8.12	-0.41	8.85e-15	Huntington's disease progression;
LUSC	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.66e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.15	0.36	5.64e-12	IgG glycosylation;
LUSC	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg01966878	chr4:90757139	SNCA	-0.33	-5.7	-0.3	2.67e-8	Dementia with Lewy bodies;
LUSC	cis	rs6580649	0.598	rs1793913	chr12:48387025	T/A	cg05342945	chr12:48394962	COL2A1	-0.44	-5.71	-0.3	2.54e-8	Lung cancer;
LUSC	trans	rs2727943	0.688	rs4589912	chr3:1878635	G/A	cg09243576	chr3:46850588	NA	0.51	6.12	0.32	2.58e-9	Bipolar disorder;
LUSC	cis	rs73001065	0.818	rs12610191	chr19:19721976	C/T	cg03709012	chr19:19516395	GATAD2A	0.89	7.15	0.36	5.34e-12	LDL cholesterol;
LUSC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg13319975	chr6:146136371	FBXO30	0.51	7.87	0.4	4.96e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10843647	0.967	rs1485406	chr12:30324053	T/G	cg12718339	chr12:29936407	TMTC1	-0.36	-5.89	-0.31	9.41e-9	Glucose homeostasis traits;
LUSC	cis	rs4285028	0.699	rs1920297	chr3:121598000	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.79	-10.77	-0.51	2.03e-23	Multiple sclerosis;
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-8.13	-0.41	8.56e-15	Lymphocyte counts;
LUSC	cis	rs10208940	0.920	rs28361349	chr2:68785579	G/A	cg12452813	chr2:68675892	NA	0.57	5.92	0.31	7.99e-9	Urate levels in lean individuals;
LUSC	cis	rs11039100	1.000	rs35863965	chr11:5824256	G/T	cg13902645	chr11:5959945	NA	-0.53	-5.84	-0.3	1.21e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg06742321	chr12:123595122	PITPNM2	0.39	5.85	0.3	1.17e-8	Platelet count;
LUSC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.68	-11.09	-0.52	1.48e-24	Prudent dietary pattern;
LUSC	cis	rs2086824	0.702	rs3114891	chr16:89399455	A/G	cg06640241	chr16:89574553	SPG7	0.52	7.74	0.39	1.22e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs6693567	0.565	rs11205373	chr1:150404708	A/G	cg15654264	chr1:150340011	RPRD2	0.43	6.8	0.35	4.74e-11	Migraine;
LUSC	cis	rs911119	0.913	rs6036465	chr20:23588003	G/T	cg16589663	chr20:23618590	CST3	0.56	6.83	0.35	3.91e-11	Chronic kidney disease;
LUSC	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.98	-0.36	1.63e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs642803	1.000	rs557675	chr11:65566719	G/T	cg27068330	chr11:65405492	SIPA1	-0.53	-7.53	-0.38	4.92e-13	Urate levels;
LUSC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg06238570	chr21:40685208	BRWD1	0.54	8.14	0.41	7.97e-15	Cognitive function;
LUSC	cis	rs7246967	0.551	rs8102812	chr19:22879243	A/T	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg22906224	chr7:99728672	NA	0.63	8.67	0.43	1.85e-16	Coronary artery disease;
LUSC	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg02176678	chr2:219576539	TTLL4	-0.57	-10.08	-0.48	5.06e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg27411982	chr8:10470053	RP1L1	0.44	6.63	0.34	1.34e-10	Neuroticism;
LUSC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg22823121	chr1:150693482	HORMAD1	0.51	7.47	0.38	7.01e-13	Tonsillectomy;
LUSC	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg22491629	chr6:157744540	C6orf35	-0.91	-10.85	-0.51	1.06e-23	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs2262909	0.925	rs56073035	chr19:22276298	C/G	cg05197062	chr11:11642011	GALNTL4	0.54	7.58	0.38	3.39e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2067615	0.599	rs12369214	chr12:107198611	G/A	cg15890332	chr12:107067104	RFX4	0.34	6.34	0.33	7.4e-10	Heart rate;
LUSC	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs7264396	0.836	rs4911183	chr20:34181553	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.55	8.01	0.4	1.89e-14	Total cholesterol levels;
LUSC	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.79	-0.43	8.32e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg12365402	chr11:9010492	NRIP3	-0.49	-9.32	-0.45	1.61e-18	Hemoglobin concentration;
LUSC	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.82	17.31	0.69	2.27e-48	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.8	-12.57	-0.57	6.06e-30	Menopause (age at onset);
LUSC	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg18230493	chr5:56204884	C5orf35	-0.55	-8.43	-0.42	1.07e-15	Coronary artery disease;
LUSC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg01802117	chr1:53393560	SCP2	-0.37	-5.95	-0.31	6.66e-9	Monocyte count;
LUSC	cis	rs9534288	0.702	rs7331472	chr13:46644173	C/T	cg15192986	chr13:46630673	CPB2	-0.78	-11.82	-0.54	3.5e-27	Blood protein levels;
LUSC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg11766577	chr21:47581405	C21orf56	-0.4	-5.74	-0.3	2.14e-8	Testicular germ cell tumor;
LUSC	cis	rs2067615	0.579	rs10778509	chr12:107162918	G/A	cg15890332	chr12:107067104	RFX4	0.35	6.28	0.33	1.03e-9	Heart rate;
LUSC	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg24006582	chr15:45444508	DUOX1	-0.61	-8.95	-0.44	2.5e-17	Uric acid levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26640895	chr4:71859472	DCK	-0.41	-6.0	-0.31	5.17e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.31	-0.37	2.03e-12	Myopia (pathological);
LUSC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg08088566	chr11:430123	ANO9	0.58	6.87	0.35	3.21e-11	Body mass index;
LUSC	trans	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg04995722	chr7:26192034	NFE2L3	-0.4	-6.56	-0.34	2.08e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.07	14.92	0.63	6.04e-39	Uric acid levels;
LUSC	cis	rs7580658	0.550	rs62160290	chr2:128200695	C/T	cg09760422	chr2:128146352	NA	-0.27	-5.68	-0.3	2.87e-8	Protein C levels;
LUSC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg23093090	chr10:104574429	C10orf26	0.45	8.52	0.42	5.63e-16	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6500395	0.735	rs2883641	chr16:48664446	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.48	0.33	3.38e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg26408565	chr15:76604113	ETFA	-0.49	-8.09	-0.4	1.14e-14	Blood metabolite levels;
LUSC	trans	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg13852791	chr20:30311386	BCL2L1	0.69	7.15	0.36	5.35e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-6.43	-0.33	4.54e-10	Longevity;Endometriosis;
LUSC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-10.41	-0.49	3.68e-22	Schizophrenia;
LUSC	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.51	0.42	5.77e-16	Response to antipsychotic treatment;
LUSC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg20573242	chr4:122745356	CCNA2	0.54	7.94	0.4	3.1e-14	Type 2 diabetes;
LUSC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-16.89	-0.68	1.11e-46	Monocyte count;
LUSC	cis	rs2970818	0.831	rs10849090	chr12:4669954	A/G	cg11146114	chr12:4671731	NA	-0.59	-5.96	-0.31	6.57e-9	Phosphorus levels;
LUSC	cis	rs6987853	0.787	rs2974346	chr8:42401205	T/C	cg09913449	chr8:42400586	C8orf40	0.54	9.31	0.45	1.7e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg16928487	chr17:17741425	SREBF1	-0.32	-5.96	-0.31	6.51e-9	Total body bone mineral density;
LUSC	cis	rs11608355	0.960	rs11066526	chr12:109854476	G/C	cg05360138	chr12:110035743	NA	0.46	6.34	0.33	7.41e-10	Neuroticism;
LUSC	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg20908204	chr19:46285434	DMPK	0.41	8.24	0.41	3.93e-15	Coronary artery disease;
LUSC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.75	10.49	0.5	1.9e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg02931644	chr1:25747376	RHCE	0.37	6.8	0.35	4.82e-11	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg13010199	chr12:38710504	ALG10B	0.61	9.53	0.46	3.3e-19	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.67	11.29	0.53	2.85e-25	Colorectal cancer;
LUSC	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg13057898	chr1:3703894	LRRC47	0.49	8.42	0.42	1.14e-15	Red cell distribution width;
LUSC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12220238	1.000	rs7073432	chr10:75953350	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.8	0.35	4.73e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg00982548	chr2:198649783	BOLL	-0.56	-7.03	-0.36	1.14e-11	Ulcerative colitis;
LUSC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg01125463	chr6:42946178	PEX6	-0.37	-6.07	-0.32	3.5e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3806933	0.522	rs11241095	chr5:110439509	A/G	cg04022379	chr5:110408740	TSLP	0.66	9.58	0.46	2.3e-19	Eosinophilic esophagitis;
LUSC	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.51	-6.7	-0.34	8.75e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs62400317	0.787	rs10456547	chr6:45219526	T/C	cg20913747	chr6:44695427	NA	-0.48	-7.55	-0.38	4.08e-13	Total body bone mineral density;
LUSC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg04850211	chr1:228464232	OBSCN	-0.33	-6.07	-0.32	3.44e-9	Diastolic blood pressure;
LUSC	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg25922239	chr6:33757077	LEMD2	0.43	6.53	0.34	2.49e-10	Crohn's disease;
LUSC	cis	rs5850	0.557	rs10270788	chr7:23189000	T/C	cg23682824	chr7:23144976	KLHL7	0.4	5.71	0.3	2.52e-8	Blood protein levels;
LUSC	cis	rs1971762	0.563	rs7975862	chr12:54078427	A/C	cg23533419	chr12:54090519	NA	0.35	5.9	0.31	9.11e-9	Height;
LUSC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg14416269	chr4:6271139	WFS1	0.54	11.47	0.53	6.87e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg22105103	chr4:187893119	NA	-0.51	-8.0	-0.4	2.13e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg24296786	chr1:45957014	TESK2	0.53	8.37	0.42	1.57e-15	High light scatter reticulocyte count;
LUSC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	0.95	13.57	0.6	1.01e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs6076065	0.723	rs4815199	chr20:23347169	G/A	cg11657817	chr20:23433608	CST11	0.43	8.14	0.41	7.67e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg27494647	chr7:150038898	RARRES2	-0.46	-7.04	-0.36	1.08e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.1	0.64	1.26e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg04166393	chr7:2884313	GNA12	0.43	5.65	0.3	3.42e-8	Height;
LUSC	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.01	-15.59	-0.65	1.42e-41	Primary sclerosing cholangitis;
LUSC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.51	-0.42	5.88e-16	Longevity;
LUSC	cis	rs9815354	0.812	rs4264702	chr3:41952539	T/A	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.55e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-7.41	-0.38	1.02e-12	Height;
LUSC	cis	rs4730250	0.707	rs6946931	chr7:106788621	G/T	cg02696742	chr7:106810147	HBP1	-0.63	-9.06	-0.44	1.15e-17	Osteoarthritis;
LUSC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-1.03	-20.48	-0.75	5.94e-61	Height;
LUSC	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg04756594	chr16:24857601	SLC5A11	0.46	6.62	0.34	1.47e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs2262909	0.962	rs422344	chr19:22230956	C/G	cg17074339	chr11:11642133	GALNTL4	0.45	6.93	0.35	2.15e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg03060546	chr3:49711283	APEH	0.7	11.51	0.53	4.69e-26	Resting heart rate;
LUSC	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.88	0.31	1.02e-8	Lung cancer;
LUSC	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-14.46	-0.62	3.81e-37	Headache;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23359173	chr7:56119384	PSPH;CCT6A	-0.41	-6.15	-0.32	2.16e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	11.11	0.52	1.3e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg14440974	chr22:39074834	NA	-0.36	-5.96	-0.31	6.56e-9	Menopause (age at onset);
LUSC	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.62	9.36	0.46	1.19e-18	QT interval;
LUSC	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.39	-0.56	2.93e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.81	-0.51	1.47e-23	Chronic sinus infection;
LUSC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg07636037	chr3:49044803	WDR6	0.44	6.39	0.33	5.44e-10	Resting heart rate;
LUSC	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg03676636	chr4:99064102	C4orf37	0.37	7.65	0.39	2.14e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg13175981	chr1:150552382	MCL1	0.46	6.52	0.34	2.67e-10	Tonsillectomy;
LUSC	cis	rs7575217	0.961	rs11691031	chr2:101779358	A/G	cg23907051	chr2:101730305	TBC1D8	0.27	6.76	0.35	6.29e-11	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg22437258	chr11:111473054	SIK2	0.51	7.05	0.36	1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg11766577	chr21:47581405	C21orf56	-0.48	-7.12	-0.36	6.67e-12	Testicular germ cell tumor;
LUSC	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg08085267	chr17:45401833	C17orf57	-0.54	-8.66	-0.43	2e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg01802117	chr1:53393560	SCP2	0.39	6.42	0.33	4.59e-10	Monocyte count;
LUSC	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.86	14.35	0.62	1.04e-36	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.31	-6.8	-0.35	4.97e-11	Cystic fibrosis severity;
LUSC	trans	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg10840412	chr1:235813424	GNG4	0.51	6.12	0.32	2.63e-9	Neuroticism;
LUSC	cis	rs877282	0.583	rs10904562	chr10:819058	T/C	cg13775593	chr10:823151	NA	0.29	5.84	0.3	1.26e-8	Uric acid levels;
LUSC	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg00898013	chr13:113819073	PROZ	0.52	7.91	0.4	3.69e-14	Platelet distribution width;
LUSC	cis	rs601339	0.938	rs1696345	chr12:123183060	T/G	cg11919336	chr12:123188078	GPR109A	0.44	6.58	0.34	1.87e-10	Adiponectin levels;
LUSC	cis	rs977987	0.806	rs11864102	chr16:75442360	C/T	cg04384234	chr16:75411784	CFDP1	-0.42	-6.83	-0.35	4.03e-11	Dupuytren's disease;
LUSC	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.72	-0.3	2.42e-8	Alzheimer's disease (survival time);
LUSC	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg17366294	chr4:99064904	C4orf37	0.52	8.55	0.42	4.5e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-9.25	-0.45	2.68e-18	Gut microbiome composition (summer);
LUSC	cis	rs4704187	0.687	rs6453112	chr5:74389901	A/C	cg03227963	chr5:74354835	NA	0.32	6.82	0.35	4.21e-11	Response to amphetamines;
LUSC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.88	-12.73	-0.57	1.55e-30	Initial pursuit acceleration;
LUSC	trans	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg07211511	chr3:129823064	LOC729375	-0.99	-12.34	-0.56	4.37e-29	Blood pressure (smoking interaction);
LUSC	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21293242	chr8:11204541	TDH	0.32	5.91	0.31	8.66e-9	Retinal vascular caliber;
LUSC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.76	7.3	0.37	2.09e-12	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9341808	0.538	rs620147	chr6:80992090	G/A	cg08355045	chr6:80787529	NA	-0.4	-6.87	-0.35	3.06e-11	Sitting height ratio;
LUSC	cis	rs7607369	0.536	rs12990447	chr2:219667413	T/C	cg02176678	chr2:219576539	TTLL4	-0.52	-9.15	-0.45	5.72e-18	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.53	-6.38	-0.33	5.98e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs240764	0.548	rs12206838	chr6:101180128	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-6.32	-0.33	8.54e-10	Neuroticism;
LUSC	cis	rs8010715	0.636	rs2277480	chr14:24587515	G/A	cg23112188	chr14:24563095	PCK2	-0.32	-5.96	-0.31	6.29e-9	IgG glycosylation;
LUSC	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.73	0.51	2.93e-23	Monocyte percentage of white cells;
LUSC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg00166722	chr3:10149974	C3orf24	0.42	6.21	0.32	1.56e-9	Alzheimer's disease;
LUSC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg05738196	chr6:26577821	NA	0.79	14.12	0.61	7.83e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs400736	0.859	rs379920	chr1:8028865	G/C	cg25007680	chr1:8021821	PARK7	0.6	9.45	0.46	6.26e-19	Response to antidepressants and depression;
LUSC	cis	rs13720	0.673	rs163802	chr20:57578852	C/G	cg23907860	chr20:57583709	CTSZ	-0.48	-6.34	-0.33	7.34e-10	Platelet distribution width;
LUSC	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg06917634	chr15:78832804	PSMA4	0.5	7.02	0.36	1.22e-11	Sudden cardiac arrest;
LUSC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg07212818	chr11:638076	DRD4	-0.45	-7.51	-0.38	5.29e-13	Systemic lupus erythematosus;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04094723	chr17:73717212	ITGB4	-0.4	-6.07	-0.32	3.54e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg17173187	chr15:85201210	NMB	0.38	6.62	0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.91	0.51	6.39e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg22676075	chr6:135203613	NA	0.59	9.41	0.46	8.54e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg04352962	chr1:209979756	IRF6	-0.52	-6.19	-0.32	1.77e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs12618769	0.597	rs3754892	chr2:99063318	T/A	cg10123293	chr2:99228465	UNC50	0.46	7.04	0.36	1.08e-11	Bipolar disorder;
LUSC	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.63	10.09	0.48	4.6e-21	Phospholipid levels (plasma);
LUSC	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg13770153	chr20:60521292	NA	-0.6	-8.35	-0.42	1.79e-15	Body mass index;
LUSC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.09	0.45	9.17e-18	Prudent dietary pattern;
LUSC	cis	rs9420	0.961	rs11604333	chr11:57467035	C/G	cg23127183	chr11:57508653	C11orf31	-0.58	-9.06	-0.44	1.08e-17	Schizophrenia;
LUSC	cis	rs4253772	0.872	rs78864133	chr22:46638486	C/T	cg09491104	chr22:46646882	C22orf40	-0.59	-6.52	-0.34	2.6200000000000003e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs354225	0.544	rs1137645	chr2:54807592	C/G	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg00129232	chr17:37814104	STARD3	-0.4	-5.82	-0.3	1.39e-8	Asthma;
LUSC	cis	rs8114671	0.967	rs4911478	chr20:33782625	A/C	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.92	-0.31	7.84e-9	Height;
LUSC	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg03676636	chr4:99064102	C4orf37	0.29	6.23	0.32	1.38e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs983392	0.617	rs667897	chr11:59936979	C/T	cg24026212	chr11:59952134	MS4A6A	0.34	6.43	0.33	4.29e-10	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg14830002	chr1:247616686	OR2B11	0.5	7.81	0.39	7.23e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs16910800	0.953	rs7122949	chr11:23203530	C/T	cg20040320	chr11:23191996	NA	0.43	6.28	0.32	1.06e-9	Cancer;
LUSC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.87	0.31	1.03e-8	Menopause (age at onset);
LUSC	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg02187348	chr16:89574699	SPG7	-0.49	-6.72	-0.34	8.02e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs3770081	1.000	rs3770090	chr2:86263288	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.8	-5.68	-0.3	2.96e-8	Facial emotion recognition (sad faces);
LUSC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.82e-10	Bipolar disorder;
LUSC	cis	rs360798	0.512	rs2710640	chr2:63144305	A/G	cg17519650	chr2:63277830	OTX1	0.52	7.24	0.37	3.06e-12	Coronary artery disease;
LUSC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg16447950	chr5:562315	NA	-0.53	-6.97	-0.36	1.69e-11	Obesity-related traits;
LUSC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg03188948	chr7:1209495	NA	0.67	7.1	0.36	7.38e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21528273	chr1:44056889	PTPRF	0.4	6.11	0.32	2.7e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg06156847	chr2:113672199	IL1F7	-0.28	-5.96	-0.31	6.58e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2074585	0.560	rs12903058	chr15:91061121	G/T	cg10434728	chr15:90938212	IQGAP1	-0.35	-6.53	-0.34	2.4e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs7131987	0.903	rs2194518	chr12:29419460	C/T	cg09582351	chr12:29534625	ERGIC2	-0.31	-6.52	-0.34	2.67e-10	QT interval;
LUSC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg19774624	chr17:42201019	HDAC5	-0.81	-13.25	-0.59	1.7e-32	Total body bone mineral density;
LUSC	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg03975922	chr5:140080575	ZMAT2	0.33	5.97	0.31	6.2e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg12639453	chr1:2035780	PRKCZ	-0.3	-6.42	-0.33	4.66e-10	Height;
LUSC	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.84	0.39	6.15e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs338389	0.586	rs338400	chr15:68254156	C/T	cg16317052	chr17:61678891	TACO1	0.38	5.95	0.31	6.89e-9	Survival in rectal cancer;
LUSC	cis	rs7463659	0.935	rs7844624	chr8:135433894	T/C	cg17885191	chr8:135476712	NA	-0.4	-5.66	-0.3	3.19e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7605827	0.930	rs4668909	chr2:15607842	T/C	cg19274914	chr2:15703543	NA	0.45	8.55	0.42	4.36e-16	Educational attainment (years of education);
LUSC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg06060754	chr5:176797920	RGS14	0.56	8.94	0.44	2.78e-17	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.72	-0.3	2.34e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.85	-0.3	1.18e-8	Testicular germ cell tumor;
LUSC	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.28	-0.41	3.1e-15	Bladder cancer;
LUSC	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg10172584	chr19:19639581	YJEFN3	-0.52	-6.15	-0.32	2.26e-9	Bipolar disorder;
LUSC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.75	-0.51	2.45e-23	Chronic sinus infection;
LUSC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.5	6.16	0.32	2.15e-9	Multiple sclerosis;
LUSC	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg25214090	chr10:38739885	LOC399744	0.57	8.37	0.42	1.56e-15	Corneal astigmatism;
LUSC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs804280	0.662	rs11784764	chr8:11610874	C/T	cg26752888	chr8:11627280	NEIL2	0.54	6.93	0.35	2.23e-11	Myopia (pathological);
LUSC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.99	0.44	1.91e-17	Lung cancer;
LUSC	cis	rs432925	0.529	rs9925945	chr16:393564	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.39	5.98	0.31	5.73e-9	Morning vs. evening chronotype;
LUSC	trans	rs1325195	0.881	rs400976	chr1:179217582	T/C	cg11624085	chr17:8464688	MYH10	0.44	7.1	0.36	7.36e-12	IgE grass sensitization;
LUSC	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.69	-0.3	2.8e-8	Bipolar disorder;
LUSC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	0.94	16.31	0.67	2.19e-44	Menopause (age at onset);
LUSC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg09491104	chr22:46646882	C22orf40	-0.7	-7.3	-0.37	2.14e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg05784532	chr1:230284198	GALNT2	0.52	7.79	0.39	8.67e-14	Coronary artery disease;
LUSC	cis	rs9362426	0.943	rs7744338	chr6:88101999	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.41	6.27	0.32	1.12e-9	Depressive episodes in bipolar disorder;
LUSC	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg14696996	chr19:15285081	NOTCH3	0.96	9.25	0.45	2.69e-18	Pulse pressure;
LUSC	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg22875332	chr1:76189707	ACADM	-0.43	-6.46	-0.33	3.8e-10	Daytime sleep phenotypes;
LUSC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg03804128	chr16:635623	NA	0.3	5.85	0.3	1.17e-8	Height;
LUSC	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg18753928	chr3:113234510	CCDC52	-0.5	-7.74	-0.39	1.2e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg17366294	chr4:99064904	C4orf37	0.54	9.48	0.46	4.75e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07256732	chr16:621771	PIGQ	-0.35	-6.31	-0.33	8.62e-10	Height;
LUSC	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg04362960	chr10:104952993	NT5C2	0.52	6.54	0.34	2.35e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg20891283	chr12:69753455	YEATS4	0.45	6.17	0.32	1.98e-9	Response to diuretic therapy;
LUSC	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg15556689	chr8:8085844	FLJ10661	0.58	8.63	0.43	2.48e-16	Neuroticism;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10292851	chr8:101572103	ANKRD46	-0.43	-6.25	-0.32	1.23e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7084921	0.578	rs12776318	chr10:101868677	T/G	cg02250046	chr10:101825185	CPN1	-0.34	-6.16	-0.32	2.05e-9	Bone mineral density;
LUSC	cis	rs11997175	0.545	rs7388496	chr8:33667898	A/G	ch.8.33884649F	chr8:33765107	NA	0.44	6.31	0.33	8.83e-10	Body mass index;
LUSC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	7.33	0.37	1.69e-12	Prudent dietary pattern;
LUSC	cis	rs3007168	1.000	rs2999362	chr14:51605265	A/G	cg23942311	chr14:51606299	NA	0.37	6.02	0.31	4.5e-9	Cancer;
LUSC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg22535103	chr8:58192502	C8orf71	-0.74	-7.39	-0.37	1.22e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.76	-11.92	-0.55	1.62e-27	Tonsillectomy;
LUSC	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.17	0.55	1.88e-28	Ileal carcinoids;
LUSC	cis	rs11971779	0.555	rs6950143	chr7:139054418	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg16362232	chr11:430036	ANO9	0.58	7.69	0.39	1.71e-13	Body mass index;
LUSC	cis	rs354225	0.586	rs966003	chr2:54884870	C/T	cg26097391	chr2:54893211	SPTBN1	0.43	7.22	0.37	3.56e-12	Schizophrenia;
LUSC	cis	rs9905704	0.846	rs302861	chr17:56697040	G/C	cg12560992	chr17:57184187	TRIM37	0.58	8.38	0.42	1.49e-15	Testicular germ cell tumor;
LUSC	cis	rs524023	0.957	rs893007	chr11:64365668	C/A	cg19131476	chr11:64387923	NRXN2	-0.38	-10.24	-0.49	1.44e-21	Urate levels in obese individuals;
LUSC	trans	rs9380880	0.826	rs12175102	chr6:39554898	C/T	cg09045552	chr2:169506620	LASS6	-0.67	-6.26	-0.32	1.18e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs9311676	0.656	rs12495490	chr3:58373251	A/G	cg13750441	chr3:58318267	PXK	0.35	6.7	0.34	9.04e-11	Systemic lupus erythematosus;
LUSC	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg06637938	chr14:75390232	RPS6KL1	0.63	10.57	0.5	9.79e-23	Caffeine consumption;
LUSC	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg05754148	chr16:3507555	NAT15	0.81	9.78	0.47	5.12e-20	Tuberculosis;
LUSC	cis	rs2742234	0.590	rs2505557	chr10:43666016	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.06	-0.36	9.87e-12	Hirschsprung disease;
LUSC	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07080220	chr10:102295463	HIF1AN	-0.61	-8.51	-0.42	6.12e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.73	-0.43	1.23e-16	Response to antipsychotic treatment;
LUSC	trans	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.09	-0.32	3.08e-9	Bladder cancer;
LUSC	cis	rs7202877	0.706	rs247425	chr16:75460402	C/T	cg03315344	chr16:75512273	CHST6	-0.42	-6.03	-0.31	4.42e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.4	6.52	0.34	2.53e-10	Blood metabolite levels;
LUSC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg15103426	chr22:29168792	CCDC117	0.58	8.02	0.4	1.86e-14	Lymphocyte counts;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.77	-17.76	-0.7	3.62e-50	Longevity;Endometriosis;
LUSC	cis	rs6750047	0.546	rs2082255	chr2:38273758	C/A	cg07380506	chr2:38303506	CYP1B1	0.45	6.18	0.32	1.88e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7712401	0.601	rs2126935	chr5:122313571	A/G	cg19077854	chr5:122220652	SNX24	-0.39	-8.52	-0.42	5.65e-16	Mean platelet volume;
LUSC	cis	rs9309473	0.519	rs4852950	chr2:73864670	C/T	cg20560298	chr2:73613845	ALMS1	0.43	6.6	0.34	1.64e-10	Metabolite levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20088535	chr4:128802013	PLK4	0.48	6.59	0.34	1.68e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.72	-12.81	-0.57	7.8e-31	Dental caries;
LUSC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg20891283	chr12:69753455	YEATS4	0.65	9.74	0.47	7.01e-20	Response to diuretic therapy;
LUSC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg03354898	chr7:1950403	MAD1L1	-0.31	-5.93	-0.31	7.65e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg22681709	chr2:178499509	PDE11A	0.51	9.54	0.46	3.12e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.48	-8.27	-0.41	3.31e-15	Axial length;
LUSC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.23	-0.32	1.41e-9	Joint mobility (Beighton score);
LUSC	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg27411982	chr8:10470053	RP1L1	0.41	6.38	0.33	5.93e-10	Mood instability;
LUSC	cis	rs7523050	0.558	rs35926243	chr1:109407712	T/A	cg08274380	chr1:109419600	GPSM2	1.12	10.7	0.51	3.48e-23	Fat distribution (HIV);
LUSC	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-6.33	-0.33	7.89e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4253772	0.550	rs9615347	chr22:46728153	A/G	cg24881330	chr22:46731750	TRMU	0.8	6.64	0.34	1.25e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg16339924	chr4:17578868	LAP3	0.57	8.63	0.43	2.51e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4917833	0.789	rs10883099	chr10:100219314	G/A	cg19043522	chr10:100227446	HPSE2	0.4	5.71	0.3	2.53e-8	Pediatric bone mineral density (femoral neck);
LUSC	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.75	-0.3	2.01e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	1.07	18.05	0.7	2.65e-51	Parkinson's disease;
LUSC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg12463550	chr7:65579703	CRCP	-0.63	-5.68	-0.3	2.92e-8	Diabetic kidney disease;
LUSC	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	1.07	16.23	0.66	4.41e-44	Primary sclerosing cholangitis;
LUSC	cis	rs9392556	0.765	rs613709	chr6:4120683	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.36	-6.21	-0.32	1.55e-9	Blood metabolite levels;
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg06145435	chr7:1022769	CYP2W1	0.32	6.58	0.34	1.82e-10	Longevity;Endometriosis;
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.51	7.45	0.38	7.88e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.39	-0.37	1.19e-12	Triglycerides;
LUSC	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg05985134	chr18:33552581	C18orf21	0.5	6.87	0.35	3.19e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.44	-6.63	-0.34	1.35e-10	Colorectal cancer;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg24357026	chr19:36705589	ZNF565;ZNF146	-0.51	-6.05	-0.31	3.93e-9	Height;
LUSC	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.24	-0.37	3.09e-12	Bipolar disorder;
LUSC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.45	0.33	3.89e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs35883536	0.647	rs945329	chr1:101084273	C/T	cg06223162	chr1:101003688	GPR88	-0.44	-7.71	-0.39	1.46e-13	Monocyte count;
LUSC	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg12744634	chr1:26560303	CCDC21	0.39	5.8	0.3	1.53e-8	Obesity-related traits;
LUSC	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.61	0.5	7.47e-23	Morning vs. evening chronotype;
LUSC	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg04455712	chr21:45112962	RRP1B	0.44	8.37	0.42	1.61e-15	Mean corpuscular volume;
LUSC	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg08999081	chr20:33150536	PIGU	0.38	6.8	0.35	4.87e-11	Height;
LUSC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg01802117	chr1:53393560	SCP2	-0.37	-6.18	-0.32	1.83e-9	Monocyte count;
LUSC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.69	0.43	1.62e-16	Motion sickness;
LUSC	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg14196790	chr5:131705035	SLC22A5	-0.43	-6.97	-0.36	1.69e-11	Breast cancer;Mosquito bite size;
LUSC	trans	rs11782517	0.924	rs35222693	chr8:10108790	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.25	0.32	1.26e-9	Nose size;
LUSC	cis	rs62400317	0.859	rs62400326	chr6:45287465	T/C	cg18551225	chr6:44695536	NA	-0.42	-7.1	-0.36	7.71e-12	Total body bone mineral density;
LUSC	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.89	-0.35	2.73e-11	Neuroticism;
LUSC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg25894440	chr7:65020034	NA	-0.38	-6.02	-0.31	4.69e-9	Calcium levels;
LUSC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg05347473	chr6:146136440	FBXO30	-0.58	-10.06	-0.48	5.68e-21	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22433210	chr17:43662623	NA	0.69	9.91	0.48	1.87e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.29	0.33	9.99e-10	Menopause (age at onset);
LUSC	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg25182066	chr10:30743637	MAP3K8	-0.47	-6.71	-0.34	8.56e-11	Inflammatory bowel disease;
LUSC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg04369109	chr6:150039330	LATS1	-0.56	-8.35	-0.42	1.84e-15	Lung cancer;
LUSC	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.12	-0.55	2.76e-28	Rheumatoid arthritis;
LUSC	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.79	-11.61	-0.54	2.07e-26	Corneal astigmatism;
LUSC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg04414720	chr1:150670196	GOLPH3L	0.56	9.09	0.45	8.97e-18	Tonsillectomy;
LUSC	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg13010199	chr12:38710504	ALG10B	0.66	10.16	0.49	2.57e-21	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg25214090	chr10:38739885	LOC399744	0.57	8.27	0.41	3.3e-15	Corneal astigmatism;
LUSC	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg10247383	chr3:153839028	SGEF	-0.47	-5.78	-0.3	1.72e-8	Coronary artery disease;
LUSC	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg09003973	chr2:102972529	NA	1.21	12.76	0.57	1.2e-30	Gut microbiota (bacterial taxa);
LUSC	trans	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg06640241	chr16:89574553	SPG7	-0.67	-10.76	-0.51	2.2e-23	Multiple myeloma (IgH translocation);
LUSC	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg04733989	chr22:42467013	NAGA	0.39	6.2	0.32	1.67e-9	Cognitive function;
LUSC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.74	12.09	0.55	3.55e-28	Coronary artery disease;
LUSC	trans	rs12692738	0.526	rs355867	chr2:165631057	C/T	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.91	11.26	0.52	3.64e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs4280164	0.836	rs4981504	chr14:24791136	A/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.59	6.99	0.36	1.53e-11	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	11.26	0.52	3.82e-25	Coronary artery disease;
LUSC	cis	rs9303542	0.559	rs2326012	chr17:46618581	C/T	cg09704116	chr17:46666958	LOC404266	-0.39	-7.14	-0.36	5.92e-12	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg12863693	chr15:85201151	NMB	0.39	8.2	0.41	5.1e-15	Schizophrenia;
LUSC	cis	rs12956009	0.518	rs983095	chr18:44899258	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.42	0.33	4.56e-10	Educational attainment (years of education);
LUSC	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg01579765	chr21:45077557	HSF2BP	-0.5	-10.38	-0.49	4.45e-22	Mean corpuscular volume;
LUSC	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-13.93	-0.61	4.39e-35	Exhaled nitric oxide output;
LUSC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.95	-0.31	6.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs748404	0.697	rs567357	chr15:43571390	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.43	5.99	0.31	5.34e-9	Lung cancer;
LUSC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	16.76	0.68	3.58e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.32	-0.33	8.46e-10	Neuroticism;
LUSC	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg07148914	chr20:33460835	GGT7	0.53	8.12	0.41	8.96e-15	Height;
LUSC	cis	rs6714710	0.603	rs11684749	chr2:98420142	G/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.52	0.42	5.7e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg17712092	chr4:129076599	LARP1B	-0.8	-11.77	-0.54	5.56e-27	Eosinophil percentage of white cells;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg03284175	chr1:146643471	PRKAB2	0.35	6.18	0.32	1.89e-9	Triglycerides;
LUSC	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-6.32	-0.33	8.56e-10	Height;
LUSC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg16325326	chr1:53192061	ZYG11B	0.81	14.3	0.62	1.62e-36	Monocyte count;
LUSC	trans	rs750134	1.000	rs12582815	chr12:109117378	C/A	cg23338993	chr2:234600423	UGT1A10;UGT1A6;UGT1A9;UGT1A7;UGT1A8	0.48	6.05	0.31	3.94e-9	Low high density lipoprotein cholesterol levels;
LUSC	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg25427524	chr10:38739819	LOC399744	-0.48	-6.39	-0.33	5.62e-10	Obesity (extreme);
LUSC	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-9.02	-0.44	1.49e-17	Hip circumference adjusted for BMI;
LUSC	trans	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg25214090	chr10:38739885	LOC399744	0.43	6.53	0.34	2.51e-10	Corneal astigmatism;
LUSC	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.53	-10.47	-0.5	2.26e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg07393940	chr7:158741817	NA	0.38	6.88	0.35	2.92e-11	Life satisfaction;
LUSC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg09033563	chr22:24373618	LOC391322	0.53	8.38	0.42	1.46e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg00810483	chr4:3375144	RGS12	0.31	5.75	0.3	2.05e-8	Serum sulfate level;
LUSC	cis	rs10207060	0.500	rs7600350	chr2:240716225	T/C	cg07506560	chr2:240697449	NA	0.45	6.98	0.36	1.58e-11	Obesity-related traits;
LUSC	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	5.93	0.31	7.74e-9	Personality dimensions;
LUSC	cis	rs2463822	0.925	rs72923272	chr11:62166832	G/A	cg06239285	chr11:62104954	ASRGL1	-0.97	-10.05	-0.48	6.38e-21	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.75e-14	Melanoma;
LUSC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg03579872	chr1:53393473	SCP2	-0.39	-5.7	-0.3	2.6e-8	Monocyte count;
LUSC	cis	rs887829	0.570	rs6759892	chr2:234601669	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.39	6.31	0.33	8.84e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	12.39	0.56	2.78e-29	Colorectal cancer;
LUSC	cis	rs17604090	0.941	rs114036198	chr7:29676300	C/T	cg19413766	chr7:29689036	LOC646762	-0.6	-6.77	-0.35	5.81e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs4077515	0.874	rs35670379	chr9:139270606	T/C	cg14169450	chr9:139327907	INPP5E	0.42	7.62	0.39	2.56e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6977660	1.000	rs10279525	chr7:19822305	C/T	cg05791153	chr7:19748676	TWISTNB	0.54	6.03	0.31	4.33e-9	Thyroid stimulating hormone;
LUSC	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg24011408	chr12:48396354	COL2A1	-0.54	-8.92	-0.44	3.13e-17	Plateletcrit;
LUSC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg05373962	chr22:49881684	NA	0.42	10.2	0.49	1.94e-21	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.7	-10.93	-0.51	5.53e-24	Longevity;
LUSC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20307385	chr11:47447363	PSMC3	0.44	5.8	0.3	1.58e-8	Subjective well-being;
LUSC	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg05805236	chr11:65401703	PCNXL3	-0.5	-8.15	-0.41	7.34e-15	Acne (severe);
LUSC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.39	-0.33	5.51e-10	Mood instability;
LUSC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07677032	chr17:61819896	STRADA	0.52	8.64	0.43	2.42e-16	Prudent dietary pattern;
LUSC	cis	rs10489202	0.908	rs6692861	chr1:168079553	G/C	cg24449463	chr1:168025552	DCAF6	-0.55	-6.8	-0.35	4.97e-11	Schizophrenia;
LUSC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.78	-0.35	5.61e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg24631222	chr15:78858424	CHRNA5	-0.67	-8.86	-0.44	4.69e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs136211	0.577	rs9610498	chr22:36777739	C/T	cg16924664	chr22:36878180	TXN2	0.38	5.76	0.3	1.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg22638593	chr5:131593259	PDLIM4	0.49	7.46	0.38	7.65e-13	Acylcarnitine levels;
LUSC	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg13180566	chr4:1052158	NA	-0.34	-5.66	-0.3	3.2e-8	Recombination rate (females);
LUSC	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg15073853	chr19:18549131	ISYNA1	0.3	5.72	0.3	2.33e-8	Breast cancer;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg06877462	chr1:205807181	PM20D1	0.54	10.18	0.49	2.2e-21	Menarche (age at onset);
LUSC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25072359	chr17:41440525	NA	0.65	9.29	0.45	2e-18	Menopause (age at onset);
LUSC	cis	rs926938	0.618	rs360675	chr1:115490918	T/C	cg12756093	chr1:115239321	AMPD1	0.49	7.58	0.38	3.53e-13	Autism;
LUSC	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	9.07	0.44	1.06e-17	Menopause (age at onset);
LUSC	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.43	-6.06	-0.31	3.63e-9	Lung cancer;
LUSC	cis	rs55728055	0.661	rs7293143	chr22:32013365	A/G	cg01338084	chr22:32026380	PISD	-0.84	-6.23	-0.32	1.39e-9	Age-related hearing impairment;
LUSC	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg17279839	chr7:150038598	RARRES2	0.4	6.11	0.32	2.75e-9	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs2587949	0.615	rs1485247	chr3:4238196	C/T	cg15139668	chr4:4577005	NA	-0.41	-6.26	-0.32	1.19e-9	Periodontitis (DPAL);
LUSC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.59	-0.38	3.21e-13	Personality dimensions;
LUSC	cis	rs3126085	0.877	rs3120672	chr1:152255575	A/G	cg26876637	chr1:152193138	HRNR	0.45	6.08	0.32	3.31e-9	Atopic dermatitis;
LUSC	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg25664220	chr3:72788482	NA	0.65	10.8	0.51	1.57e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07113562	chr10:52834093	PRKG1	0.46	6.97	0.36	1.74e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg07835181	chr16:1525278	CLCN7	0.73	12.44	0.56	1.84e-29	Bone mineral density;
LUSC	cis	rs3740713	1.000	rs12289603	chr11:18471370	T/C	cg23797887	chr11:18477753	LDHAL6A	-0.54	-6.59	-0.34	1.69e-10	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg15704280	chr7:45808275	SEPT13	0.77	7.41	0.38	1.01e-12	Axial length;
LUSC	cis	rs17828380	0.920	rs17762822	chr15:63601379	G/A	cg05507819	chr15:63340323	TPM1	-0.75	-6.12	-0.32	2.59e-9	Social communication problems;
LUSC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23158103	chr7:148848205	ZNF398	-0.5	-8.33	-0.41	2.05e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs656319	0.580	rs13272793	chr8:10002027	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.88	-0.35	3.02e-11	Myopia (pathological);
LUSC	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs11690935	0.610	rs3770458	chr2:172651287	C/T	cg13550731	chr2:172543902	DYNC1I2	0.57	8.75	0.43	1.04e-16	Schizophrenia;
LUSC	cis	rs909341	0.909	rs1291210	chr20:62335293	A/C	cg09650180	chr20:62225654	GMEB2	-0.45	-5.9	-0.31	8.8e-9	Atopic dermatitis;
LUSC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg08859206	chr1:53392774	SCP2	-0.43	-7.04	-0.36	1.09e-11	Monocyte count;
LUSC	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg24069376	chr3:38537580	EXOG	0.42	8.2	0.41	5.24e-15	Electrocardiographic conduction measures;
LUSC	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-1.14	-18.19	-0.71	7.14e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg25214090	chr10:38739885	LOC399744	0.54	7.98	0.4	2.39e-14	Corneal astigmatism;
LUSC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.67	11.76	0.54	6.2e-27	Aortic root size;
LUSC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.56	11.17	0.52	7.79e-25	Asthma (sex interaction);
LUSC	trans	rs12210905	1.000	rs9357034	chr6:27243425	C/G	cg11837749	chr1:55047332	ACOT11	0.6	6.17	0.32	2.01e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6545883	0.859	rs2600661	chr2:61543081	T/C	cg15711740	chr2:61764176	XPO1	0.47	7.57	0.38	3.78e-13	Tuberculosis;
LUSC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg16506815	chr2:162101123	NA	0.42	6.28	0.32	1.07e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs1178968	0.901	rs757937	chr7:72750159	C/T	cg25889504	chr7:72793014	NA	0.59	7.96	0.4	2.69e-14	Triglyceride levels;
LUSC	cis	rs7923609	0.812	rs10822155	chr10:65071215	C/A	cg01631684	chr10:65280961	REEP3	-0.38	-5.65	-0.3	3.49e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg09034736	chr1:150693464	HORMAD1	-0.39	-5.67	-0.3	3.12e-8	Tonsillectomy;
LUSC	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.67	-7.88	-0.4	4.68e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.33	0.67	1.73e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg17252645	chr8:143867129	LY6D	0.38	6.68	0.34	1.01e-10	Urinary tract infection frequency;
LUSC	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg05784532	chr1:230284198	GALNT2	0.55	8.19	0.41	5.67e-15	Coronary artery disease;
LUSC	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg21775007	chr8:11205619	TDH	0.79	13.35	0.59	7.08e-33	Retinal vascular caliber;
LUSC	trans	rs12210905	0.541	rs62617138	chr6:27463766	C/A	cg14616345	chr9:133901267	LAMC3	-0.7	-5.99	-0.31	5.54e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.45e-9	Menopause (age at onset);
LUSC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg13047869	chr3:10149882	C3orf24	0.6	8.12	0.41	9.19e-15	Alzheimer's disease;
LUSC	trans	rs7567288	0.636	rs12998809	chr2:134466883	T/C	cg12381416	chr3:14359266	NA	0.53	5.99	0.31	5.3e-9	Height;
LUSC	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg05890377	chr2:74357713	NA	0.75	14.26	0.62	2.24e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg25174290	chr11:3078921	CARS	0.6	9.17	0.45	4.85e-18	Longevity;
LUSC	cis	rs6714710	0.603	rs2305143	chr2:98413781	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.47	-6.79	-0.35	5.2e-11	Longevity;Endometriosis;
LUSC	cis	rs3106136	0.527	rs2664872	chr4:95146952	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.35	-0.42	1.88e-15	Capecitabine sensitivity;
LUSC	cis	rs2692947	0.794	rs2692949	chr2:96673525	G/A	cg23100626	chr2:96804247	ASTL	0.25	6.2	0.32	1.66e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.96	0.31	6.37e-9	Rheumatoid arthritis;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26808979	chr11:16759946	C11orf58	-0.43	-6.25	-0.32	1.24e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg23283495	chr1:209979779	IRF6	0.44	7.16	0.36	5.23e-12	Monobrow;
LUSC	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg24675056	chr1:15929824	NA	0.45	7.81	0.39	7.42e-14	Systolic blood pressure;
LUSC	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg08355456	chr11:67383691	NA	0.37	6.87	0.35	3.21e-11	Mean corpuscular volume;
LUSC	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg24375607	chr4:120327624	NA	0.77	11.4	0.53	1.19e-25	Corneal astigmatism;
LUSC	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg13319975	chr6:146136371	FBXO30	0.49	7.42	0.38	9.93e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-10.88	-0.51	8.15e-24	Response to antipsychotic treatment;
LUSC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13732083	chr21:47605072	C21orf56	0.43	6.22	0.32	1.52e-9	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg04369109	chr6:150039330	LATS1	-0.57	-8.3	-0.41	2.62e-15	Lung cancer;
LUSC	cis	rs11039100	0.920	rs11038963	chr11:5781361	A/G	cg05234568	chr11:5960015	NA	-0.52	-5.76	-0.3	1.88e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg14458575	chr2:238380390	NA	0.69	11.79	0.54	4.67e-27	Prostate cancer;
LUSC	cis	rs965469	1.000	rs1331215	chr20:3376565	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-5.77	-0.3	1.78e-8	IFN-related cytopenia;
LUSC	cis	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg10665199	chr7:133106180	EXOC4	0.59	8.33	0.41	2.12e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05535760	chr7:792225	HEATR2	0.94	9.96	0.48	1.29e-20	Cerebrospinal P-tau181p levels;
LUSC	cis	rs72960926	0.744	rs56004196	chr6:74880673	G/A	cg03266952	chr6:74778945	NA	-0.8	-6.35	-0.33	7.23e-10	Metabolite levels (MHPG);
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.29	-5.87	-0.31	1.06e-8	Longevity;Endometriosis;
LUSC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.55	-9.09	-0.45	8.82e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.77	-13.26	-0.59	1.62e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg07817883	chr1:32538562	TMEM39B	0.6	5.97	0.31	5.92e-9	Monocyte percentage of white cells;
LUSC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.82	0.3	1.37e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14240646	chr10:27532245	ACBD5	-0.65	-7.75	-0.39	1.15e-13	Breast cancer;
LUSC	cis	rs2425143	0.547	rs6141583	chr20:34572834	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.01	-0.31	4.74e-9	Blood protein levels;
LUSC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.58	7.85	0.39	5.73e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg09888156	chr4:140222272	NAA15	0.43	7.09	0.36	8.19e-12	Triglycerides;
LUSC	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg07169764	chr2:136633963	MCM6	1.15	16.94	0.68	7.04e-47	Corneal structure;
LUSC	cis	rs3784262	0.934	rs7164408	chr15:58259336	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.66	-0.3	3.24e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg15309053	chr8:964076	NA	0.39	7.94	0.4	3.15e-14	Schizophrenia;
LUSC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.68	12.19	0.55	1.65e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg21427119	chr20:30132790	HM13	-0.44	-6.25	-0.32	1.23e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg17173187	chr15:85201210	NMB	0.37	6.31	0.33	9.02e-10	Schizophrenia;
LUSC	cis	rs6500395	1.000	rs9933329	chr16:48646572	T/C	cg04672837	chr16:48644449	N4BP1	0.48	7.15	0.36	5.54e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7851660	0.874	rs10120412	chr9:100628238	T/C	cg13688889	chr9:100608707	NA	-0.56	-8.89	-0.44	3.89e-17	Strep throat;
LUSC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg23758822	chr17:41437982	NA	1.02	18.36	0.71	1.55e-52	Menopause (age at onset);
LUSC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg10792982	chr14:105748885	BRF1	0.5	9.08	0.44	9.76e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg16342193	chr10:102329863	NA	-0.38	-6.43	-0.33	4.33e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6840360	0.967	rs7695162	chr4:152510541	G/A	cg22705602	chr4:152727874	NA	-0.28	-5.99	-0.31	5.3300000000000004e-09	Intelligence (multi-trait analysis);
LUSC	trans	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.65	-0.34	1.19e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg02018176	chr4:1364513	KIAA1530	0.45	7.73	0.39	1.3e-13	Obesity-related traits;
LUSC	cis	rs12618769	0.597	rs3769738	chr2:99078367	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.68	0.39	1.72e-13	Bipolar disorder;
LUSC	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.41	5.88	0.31	1e-8	Lung cancer;
LUSC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg22963979	chr7:1858916	MAD1L1	-0.61	-9.58	-0.46	2.24e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg17507749	chr15:85114479	UBE2QP1	0.71	9.38	0.46	1.02e-18	Schizophrenia;
LUSC	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg15704280	chr7:45808275	SEPT13	-0.59	-6.38	-0.33	6e-10	Axial length;
LUSC	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg21385522	chr1:16154831	NA	0.56	8.53	0.42	5.15e-16	Systolic blood pressure;
LUSC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06634786	chr22:41940651	POLR3H	0.49	5.72	0.3	2.34e-8	Vitiligo;
LUSC	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg06547715	chr2:218990976	CXCR2	0.34	6.55	0.34	2.2e-10	Ulcerative colitis;
LUSC	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07741184	chr6:167504864	NA	0.37	6.45	0.33	3.82e-10	Primary biliary cholangitis;
LUSC	cis	rs41271951	0.512	rs12068365	chr1:151015868	G/A	cg11822372	chr1:151115635	SEMA6C	-0.8	-7.4	-0.38	1.09e-12	Blood protein levels;
LUSC	trans	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg26384229	chr12:38710491	ALG10B	0.56	8.69	0.43	1.69e-16	Morning vs. evening chronotype;
LUSC	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg20129853	chr10:51489980	NA	0.36	7.53	0.38	4.63e-13	Prostate-specific antigen levels;
LUSC	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg02175503	chr12:58329896	NA	0.45	6.6	0.34	1.63e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg02503808	chr4:7069936	GRPEL1	1.04	14.24	0.61	2.84e-36	Monocyte percentage of white cells;
LUSC	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg18876405	chr7:65276391	NA	0.71	12.42	0.56	2.14e-29	Aortic root size;
LUSC	cis	rs11264799	0.765	rs7531547	chr1:157623267	G/T	cg18268488	chr1:157545234	FCRL4	0.33	5.74	0.3	2.13e-8	IgA nephropathy;
LUSC	cis	rs55882075	0.583	rs9637934	chr5:179114025	G/C	cg14593053	chr5:179126677	CANX	0.39	6.08	0.32	3.24e-9	Monocyte percentage of white cells;
LUSC	cis	rs10465746	0.780	rs4907190	chr1:84409168	T/C	cg10977910	chr1:84465055	TTLL7	0.45	6.61	0.34	1.48e-10	Obesity-related traits;
LUSC	cis	rs9648716	0.515	rs38740	chr7:140711275	G/A	cg23214464	chr7:140373596	ADCK2	0.72	6.24	0.32	1.29e-9	Type 2 diabetes;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22227058	chr5:159846119	SLU7	-0.42	-6.29	-0.33	9.99e-10	Electrocardiographic conduction measures;
LUSC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg24324837	chr19:49891574	CCDC155	0.49	6.25	0.32	1.23e-9	Multiple sclerosis;
LUSC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg11062466	chr8:58055876	NA	0.68	7.85	0.39	5.73e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs4499344	0.633	rs259282	chr19:33163043	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.77	11.79	0.54	4.82e-27	Mean platelet volume;
LUSC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.69	11.11	0.52	1.27e-24	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg17143192	chr8:8559678	CLDN23	0.63	9.03	0.44	1.37e-17	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg07741184	chr6:167504864	NA	0.39	7.04	0.36	1.12e-11	Crohn's disease;
LUSC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.6	-9.75	-0.47	6.36e-20	Aortic root size;
LUSC	trans	rs10763170	0.646	rs11004720	chr10:56824723	G/A	cg10538533	chr12:53074328	KRT1	0.3	6.05	0.31	3.91e-9	Sporadic pituitary adenoma;
LUSC	cis	rs11779988	0.545	rs398806	chr8:17786226	T/C	cg01800426	chr8:17659068	MTUS1	-0.47	-5.8	-0.3	1.53e-8	Breast cancer;
LUSC	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg22709100	chr7:91322751	NA	0.41	5.98	0.31	5.75e-9	Breast cancer;
LUSC	trans	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg18187862	chr3:45730750	SACM1L	0.53	7.03	0.36	1.16e-11	Primary sclerosing cholangitis;
LUSC	cis	rs3087591	0.960	rs2066736	chr17:29559932	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.66	-9.85	-0.47	2.85e-20	Hip circumference;
LUSC	cis	rs6714710	0.603	rs2278700	chr2:98427382	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg04374321	chr14:90722782	PSMC1	0.74	11.68	0.54	1.12e-26	Mortality in heart failure;
LUSC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg18904891	chr8:8559673	CLDN23	0.58	8.18	0.41	6.1e-15	Obesity-related traits;
LUSC	cis	rs6754311	0.593	rs313522	chr2:136430866	T/A	cg07169764	chr2:136633963	MCM6	0.55	7.29	0.37	2.32e-12	Mosquito bite size;
LUSC	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg07169764	chr2:136633963	MCM6	1.2	17.53	0.69	3.07e-49	Corneal structure;
LUSC	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg09307838	chr4:120376055	NA	0.71	10.61	0.5	7.43e-23	Corneal astigmatism;
LUSC	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.27	-0.41	3.16e-15	Schizophrenia;
LUSC	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg23093090	chr10:104574429	C10orf26	-0.37	-6.77	-0.35	5.8200000000000003e-11	Arsenic metabolism;
LUSC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg21724239	chr8:58056113	NA	0.79	9.39	0.46	9.94e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg20243544	chr17:37824526	PNMT	0.49	6.9	0.35	2.55e-11	Asthma;
LUSC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg04553112	chr3:125709451	NA	-0.5	-5.7	-0.3	2.7e-8	Blood pressure (smoking interaction);
LUSC	cis	rs896543	0.702	rs6711222	chr2:237494444	C/T	cg25295825	chr2:237489920	CXCR7	0.52	6.38	0.33	5.74e-10	Alcohol dependence (age at onset);
LUSC	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg18200150	chr17:30822561	MYO1D	0.51	10.29	0.49	9.6e-22	Schizophrenia;
LUSC	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg09034736	chr1:150693464	HORMAD1	0.42	5.91	0.31	8.53e-9	Melanoma;
LUSC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.72	12.18	0.55	1.76e-28	Motion sickness;
LUSC	trans	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg10756647	chr7:56101905	PSPH	-0.8	-8.22	-0.41	4.61e-15	Diabetic kidney disease;
LUSC	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg16482183	chr6:26056742	HIST1H1C	0.63	9.07	0.44	1.01e-17	Iron status biomarkers;
LUSC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.0	-18.84	-0.72	1.94e-54	Chronic sinus infection;
LUSC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg12463550	chr7:65579703	CRCP	-0.58	-8.61	-0.43	2.93e-16	Aortic root size;
LUSC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.47	0.33	3.59e-10	Lung cancer;
LUSC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg03676636	chr4:99064102	C4orf37	0.33	7.24	0.37	3.11e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7188861	0.626	rs7193871	chr16:11455606	C/G	cg00044050	chr16:11439710	C16orf75	0.66	10.21	0.49	1.82e-21	HDL cholesterol;
LUSC	cis	rs929596	0.639	rs7571915	chr2:234586574	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-7.87	-0.4	4.9e-14	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	1.14	18.04	0.7	2.84e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg22823121	chr1:150693482	HORMAD1	0.58	8.81	0.43	7.13e-17	Tonsillectomy;
LUSC	cis	rs7180079	1.000	rs59190688	chr15:64516669	G/A	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs2996428	0.667	rs11576900	chr1:3770914	A/G	cg17848003	chr1:3704513	LRRC47	0.31	5.75	0.3	2.03e-8	Red cell distribution width;
LUSC	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg08017634	chr8:144659831	NAPRT1	0.72	6.17	0.32	2.03e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg22166914	chr1:53195759	ZYG11B	0.42	6.88	0.35	3.02e-11	Monocyte count;
LUSC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg26380479	chr7:97908229	NA	-0.27	-6.14	-0.32	2.28e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21643547	chr1:205240462	TMCC2	-0.51	-9.75	-0.47	6.39e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.88	0.31	1.02e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9311676	0.632	rs11924677	chr3:58420542	T/C	cg13750441	chr3:58318267	PXK	0.35	6.83	0.35	4.14e-11	Systemic lupus erythematosus;
LUSC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02788857	chr8:22132959	PIWIL2	0.39	7.8	0.39	7.87e-14	Hypertriglyceridemia;
LUSC	cis	rs62103177	0.564	rs1864529	chr18:77748975	G/A	cg20368463	chr18:77673604	PQLC1	-0.63	-6.67	-0.34	1.09e-10	Opioid sensitivity;
LUSC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs243505	0.965	rs243503	chr7:148436106	G/C	cg09806900	chr7:148480153	CUL1	-0.48	-6.84	-0.35	3.71e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4343996	0.692	rs10258501	chr7:3460355	A/C	cg21248987	chr7:3385318	SDK1	0.37	6.13	0.32	2.49e-9	Motion sickness;
LUSC	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg08873628	chr1:175162347	KIAA0040	0.39	5.67	0.3	3.14e-8	Alcohol dependence;
LUSC	trans	rs9944715	0.871	rs4890632	chr18:43826293	G/A	cg01718231	chr17:29326311	RNF135	-0.48	-6.81	-0.35	4.41e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs77633900	0.772	rs506000	chr15:76817788	T/C	cg21673338	chr15:77095150	SCAPER	-0.71	-6.07	-0.32	3.44e-9	Non-glioblastoma glioma;Glioma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21830413	chr10:70884251	VPS26A	-0.43	-6.33	-0.33	7.72e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.14	0.55	2.51e-28	Prudent dietary pattern;
LUSC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg04352962	chr1:209979756	IRF6	0.53	6.46	0.33	3.78e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg24130564	chr14:104152367	KLC1	0.44	6.33	0.33	8.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	0.91	15.04	0.64	2.2e-39	Breast cancer;
LUSC	trans	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.45	-0.33	3.95e-10	Bladder cancer;
LUSC	cis	rs10792830	0.706	rs565031	chr11:85671501	A/T	cg07180834	chr11:85838833	NA	-0.3	-5.76	-0.3	1.94e-8	Psychosis and Alzheimer's disease;
LUSC	cis	rs7246967	0.673	rs73022713	chr19:22876222	G/C	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs16976116	0.901	rs28508034	chr15:55499010	T/C	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6445797	0.603	rs11130536	chr3:56668522	C/T	cg13792233	chr3:56591045	CCDC66	0.41	5.72	0.3	2.33e-8	Gastritis;
LUSC	cis	rs4363385	0.747	rs6671414	chr1:152974119	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.67	-0.3	3.15e-8	Inflammatory skin disease;
LUSC	cis	rs7572644	0.766	rs6727432	chr2:28250990	T/G	cg27432699	chr2:27873401	GPN1	-0.53	-6.58	-0.34	1.86e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs75518195	0.504	rs1449191	chr4:64881166	C/T	cg01709288	chr16:81111226	C16orf46	-0.41	-6.02	-0.31	4.56e-9	Triptolide cytotoxicity;
LUSC	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17173187	chr15:85201210	NMB	0.48	9.22	0.45	3.42e-18	Schizophrenia;
LUSC	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg16230307	chr14:35515116	FAM177A1	0.78	9.88	0.48	2.39e-20	Psoriasis;
LUSC	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.54	0.42	4.94e-16	Lung cancer in ever smokers;
LUSC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.74	-10.5	-0.5	1.83e-22	Gut microbiome composition (summer);
LUSC	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.83	-15.88	-0.66	1.1e-42	Heart rate;
LUSC	cis	rs10779751	0.770	rs4845853	chr1:11243470	A/G	cg08854313	chr1:11322531	MTOR	0.87	14.1	0.61	9.84e-36	Body mass index;
LUSC	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg03522245	chr20:25566470	NINL	0.36	5.84	0.3	1.24e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.28	0.59	1.28e-32	Cognitive test performance;
LUSC	cis	rs56399783	0.901	rs73049380	chr7:2832845	C/T	cg14895029	chr7:2775587	GNA12	0.47	5.86	0.31	1.11e-8	Childhood ear infection;
LUSC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg06877462	chr1:205807181	PM20D1	0.36	6.72	0.34	8.02e-11	Menarche (age at onset);
LUSC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	5.66	0.3	3.34e-8	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11831004	chr1:52834260	NA	-0.4	-6.12	-0.32	2.69e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg11887960	chr12:57824829	NA	0.52	6.65	0.34	1.17e-10	Obesity-related traits;
LUSC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.46	-6.11	-0.32	2.72e-9	Longevity;Endometriosis;
LUSC	cis	rs4285028	0.699	rs12637968	chr3:121599976	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.81	-10.84	-0.51	1.19e-23	Multiple sclerosis;
LUSC	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg04369109	chr6:150039330	LATS1	-0.52	-7.38	-0.37	1.27e-12	Lung cancer;
LUSC	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.7	-10.48	-0.5	2.13e-22	Colorectal cancer;
LUSC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg06074448	chr4:187884817	NA	-0.46	-7.68	-0.39	1.76e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1982963	1.000	rs904061	chr14:52504624	T/C	cg10843707	chr14:52510701	NID2	-0.41	-6.57	-0.34	1.94e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg24675658	chr1:53192096	ZYG11B	-0.75	-12.75	-0.57	1.31e-30	Monocyte count;
LUSC	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg22852734	chr6:133119734	C6orf192	1.23	10.2	0.49	1.92e-21	Type 2 diabetes nephropathy;
LUSC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg03395511	chr6:291903	DUSP22	-0.48	-7.32	-0.37	1.82e-12	Menopause (age at onset);
LUSC	cis	rs10908458	0.743	rs7367207	chr1:155079477	C/T	cg23973274	chr1:155060172	NA	-0.32	-6.24	-0.32	1.3e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4948102	0.961	rs7776550	chr7:56092391	T/C	cg17215666	chr7:56131930	SUMF2	0.45	5.8	0.3	1.52e-8	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25072359	chr17:41440525	NA	0.65	9.39	0.46	9.33e-19	Menopause (age at onset);
LUSC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10740039	0.516	rs10740035	chr10:62352606	A/C	cg18175470	chr10:62150864	ANK3	0.47	6.77	0.35	5.75e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7605827	0.930	rs7601661	chr2:15597409	A/G	cg19274914	chr2:15703543	NA	0.47	9.08	0.45	9.55e-18	Educational attainment (years of education);
LUSC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg18681998	chr4:17616180	MED28	0.8	14.37	0.62	8.88e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg17691542	chr6:26056736	HIST1H1C	0.62	8.86	0.44	4.89e-17	Iron status biomarkers;
LUSC	cis	rs6545883	0.894	rs6739427	chr2:61452879	T/C	cg15711740	chr2:61764176	XPO1	0.43	6.74	0.35	7.14e-11	Tuberculosis;
LUSC	cis	rs757081	0.667	rs17561348	chr11:17161615	C/T	cg15432903	chr11:17409602	KCNJ11	0.36	5.67	0.3	3.14e-8	Systolic blood pressure;
LUSC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg21782813	chr7:2030301	MAD1L1	0.49	8.32	0.41	2.34e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs2282802	0.685	rs12188849	chr5:139621570	G/A	cg26211634	chr5:139558579	C5orf32	0.44	8.27	0.41	3.12e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg17168535	chr8:21777572	XPO7	0.84	15.18	0.64	6.22e-40	Mean corpuscular volume;
LUSC	trans	rs4714291	0.832	rs9471247	chr6:40105318	A/G	cg02267698	chr19:7991119	CTXN1	-0.52	-7.65	-0.39	2.11e-13	Strep throat;
LUSC	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.15	0.32	2.27e-9	Corneal astigmatism;
LUSC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg06219351	chr7:158114137	PTPRN2	-0.52	-9.51	-0.46	3.88e-19	Calcium levels;
LUSC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg16586182	chr3:47516702	SCAP	-0.5	-7.91	-0.4	3.84e-14	Colorectal cancer;
LUSC	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.83	13.52	0.59	1.59e-33	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg16928487	chr17:17741425	SREBF1	-0.44	-8.59	-0.43	3.27e-16	Total body bone mineral density;
LUSC	trans	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg02030672	chr11:45687055	CHST1	0.44	6.69	0.34	9.42e-11	Obesity-related traits;
LUSC	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14442939	chr10:27389572	ANKRD26	-0.88	-9.91	-0.48	1.85e-20	Breast cancer;
LUSC	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.84	0.51	1.15e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg23992470	chr4:843637	GAK	0.58	6.21	0.32	1.56e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	9.78	0.47	5.03e-20	Height;
LUSC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg25039879	chr17:56429692	SUPT4H1	0.5	7.02	0.36	1.22e-11	Cognitive test performance;
LUSC	cis	rs6987853	0.761	rs2923391	chr8:42415942	G/A	cg09913449	chr8:42400586	C8orf40	0.53	9.21	0.45	3.73e-18	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg02030672	chr11:45687055	CHST1	0.55	8.95	0.44	2.6e-17	Obesity-related traits;
LUSC	cis	rs4889855	0.614	rs9892081	chr17:78484484	A/C	cg00066239	chr17:78472159	NA	0.39	6.77	0.35	5.76e-11	Fractional excretion of uric acid;
LUSC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.63	10.47	0.5	2.19e-22	Age at first birth;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10150615	chr22:24372951	LOC391322	-0.42	-6.98	-0.36	1.61e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg03676636	chr4:99064102	C4orf37	0.36	7.94	0.4	3.02e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7605827	0.930	rs10189180	chr2:15685949	T/C	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.82e-16	Educational attainment (years of education);
LUSC	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.47	-0.38	7.29e-13	Retinal vascular caliber;
LUSC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.41	-0.38	1.06e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7399018	0.739	rs7953955	chr12:51608467	A/G	cg25754956	chr12:51612065	POU6F1	1.02	16.58	0.67	1.74e-45	Cisplatin-induced ototoxicity;
LUSC	cis	rs11229555	1.000	rs10896795	chr11:58366561	A/G	cg15696309	chr11:58395628	NA	-0.69	-9.24	-0.45	2.95e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg18187862	chr3:45730750	SACM1L	0.52	6.65	0.34	1.2e-10	Primary sclerosing cholangitis;
LUSC	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg05738196	chr6:26577821	NA	0.83	16.08	0.66	1.69e-43	Intelligence (multi-trait analysis);
LUSC	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg15704280	chr7:45808275	SEPT13	0.78	7.55	0.38	4.31e-13	Axial length;
LUSC	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.38	0.37	1.26e-12	Iron status biomarkers;
LUSC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.69	11.32	0.53	2.36e-25	Longevity;
LUSC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg01851573	chr8:8652454	MFHAS1	-0.35	-5.96	-0.31	6.33e-9	Mood instability;
LUSC	cis	rs2235544	0.565	rs664848	chr1:54468321	C/T	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs4594175	0.926	rs4243570	chr14:51624243	C/T	cg23942311	chr14:51606299	NA	0.31	5.88	0.31	1.01e-8	Cancer;
LUSC	cis	rs6580649	0.883	rs4075913	chr12:48537624	A/G	cg24011408	chr12:48396354	COL2A1	0.46	6.3	0.33	9.31e-10	Lung cancer;
LUSC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-17.6	-0.69	1.62e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg13010199	chr12:38710504	ALG10B	0.68	11.24	0.52	4.28e-25	Heart rate;
LUSC	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg17366294	chr4:99064904	C4orf37	0.53	8.39	0.42	1.38e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg09165964	chr15:75287851	SCAMP5	-1.07	-16.47	-0.67	4.95e-45	Blood trace element (Zn levels);
LUSC	cis	rs870825	0.616	rs28579226	chr4:185650458	A/C	cg04058563	chr4:185651563	MLF1IP	0.81	12.19	0.56	1.52e-28	Blood protein levels;
LUSC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg21854759	chr1:92012499	NA	-0.54	-9.07	-0.44	1.07e-17	Breast cancer;
LUSC	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.57	-7.61	-0.38	2.76e-13	Longevity;Endometriosis;
LUSC	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg06623918	chr6:96969491	KIAA0776	-0.83	-10.13	-0.48	3.27e-21	Migraine;Coronary artery disease;
LUSC	cis	rs870825	0.655	rs72703561	chr4:185630890	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.12	0.58	5.24e-32	Blood protein levels;
LUSC	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.36e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.83	-0.3	1.32e-8	Coronary artery disease;
LUSC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.11	-0.48	3.92e-21	Monocyte count;
LUSC	trans	rs7103411	0.637	rs7116850	chr11:27645530	C/T	cg15471856	chr13:19448839	NA	-0.43	-6.29	-0.33	9.86e-10	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg26384229	chr12:38710491	ALG10B	0.7	10.77	0.51	2.06e-23	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg03354898	chr7:1950403	MAD1L1	-0.32	-6.3	-0.33	9.32e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg22782873	chr19:19639568	YJEFN3	0.5	6.11	0.32	2.84e-9	Bipolar disorder;
LUSC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg01448562	chr3:133502909	NA	-0.54	-7.94	-0.4	3.16e-14	Iron status biomarkers;
LUSC	cis	rs354225	0.584	rs13432302	chr2:54813938	A/C	cg01766943	chr2:54829624	SPTBN1	0.54	8.71	0.43	1.45e-16	Schizophrenia;
LUSC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg02423579	chr7:2872169	GNA12	0.44	6.29	0.33	1.01e-9	Height;
LUSC	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	9.53	0.46	3.48e-19	Menarche (age at onset);
LUSC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16680214	chr1:154839983	KCNN3	0.51	9.6	0.46	2.02e-19	Prostate cancer;
LUSC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg14558114	chr2:88469736	THNSL2	-0.64	-8.79	-0.43	8.24e-17	Response to metformin (IC50);
LUSC	cis	rs193541	0.632	rs30023	chr5:122285299	T/G	cg19077854	chr5:122220652	SNX24	0.4	8.57	0.42	3.96e-16	Glucose homeostasis traits;
LUSC	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.07	0.52	1.86e-24	Colorectal cancer;
LUSC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg12463550	chr7:65579703	CRCP	-0.45	-6.78	-0.35	5.38e-11	Cotinine glucuronidation;
LUSC	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg04414720	chr1:150670196	GOLPH3L	-0.43	-6.89	-0.35	2.86e-11	Tonsillectomy;
LUSC	cis	rs6489882	0.703	rs10850095	chr12:113360575	T/C	cg20102336	chr12:113376681	OAS3	-0.4	-5.71	-0.3	2.46e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg06238570	chr21:40685208	BRWD1	-0.56	-8.55	-0.42	4.47e-16	Menarche (age at onset);
LUSC	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg21775007	chr8:11205619	TDH	0.46	6.4	0.33	5.19e-10	Neuroticism;
LUSC	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	7.26	0.37	2.66e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05165339	chr4:1420672	NA	0.28	6.19	0.32	1.74e-9	Obesity-related traits;
LUSC	trans	rs4518370	0.926	rs10061374	chr5:82173912	T/C	cg14564229	chr9:119748106	ASTN2	-0.38	-5.97	-0.31	6.05e-9	Osteoarthritis biomarkers;
LUSC	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg06219351	chr7:158114137	PTPRN2	-0.51	-9.1	-0.45	8.56e-18	Calcium levels;
LUSC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12016809	chr21:47604291	C21orf56	-0.45	-6.71	-0.34	8.23e-11	Testicular germ cell tumor;
LUSC	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg16339924	chr4:17578868	LAP3	-0.55	-7.95	-0.4	2.87e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-7.09	-0.36	8.28e-12	Bipolar disorder;
LUSC	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg00982548	chr2:198649783	BOLL	-0.58	-7.25	-0.37	2.87e-12	Ulcerative colitis;
LUSC	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg05340658	chr4:99064831	C4orf37	0.44	6.92	0.35	2.25e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg04990556	chr1:26633338	UBXN11	0.85	11.14	0.52	9.76e-25	Obesity-related traits;
LUSC	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08645402	chr16:4508243	NA	0.48	7.34	0.37	1.66e-12	Schizophrenia;
LUSC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg20701182	chr2:24300061	SF3B14	-0.88	-11.39	-0.53	1.31e-25	Lymphocyte counts;
LUSC	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	8.14	0.41	7.88e-15	Triglycerides;
LUSC	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.03	-0.31	4.41e-9	Alcohol dependence;
LUSC	cis	rs1891275	0.515	rs2421694	chr10:93516104	A/G	cg07889827	chr10:93443413	NA	-0.4	-9.18	-0.45	4.78e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.28	-0.32	1.03e-9	Mood instability;
LUSC	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg09835421	chr16:68378352	PRMT7	-0.54	-5.92	-0.31	7.97e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11166629	1.000	rs7003870	chr8:135616586	A/G	cg27224718	chr8:135614730	ZFAT	0.68	11.0	0.52	3.28e-24	Smoking quantity;
LUSC	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.51	7.91	0.4	3.75e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs1325195	0.920	rs2816203	chr1:179163857	T/C	cg11624085	chr17:8464688	MYH10	0.41	6.64	0.34	1.29e-10	IgE grass sensitization;
LUSC	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.1	-0.32	3.01e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs3740713	1.000	rs2643872	chr11:18450444	A/T	cg23797887	chr11:18477753	LDHAL6A	-0.58	-7.16	-0.36	5.04e-12	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg22138327	chr13:27999177	GTF3A	0.71	9.63	0.47	1.58e-19	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg01802117	chr1:53393560	SCP2	-0.39	-6.43	-0.33	4.29e-10	Monocyte count;
LUSC	cis	rs1784581	0.588	rs7765624	chr6:162427462	C/A	cg17173639	chr6:162384350	PARK2	0.57	9.89	0.48	2.12e-20	Itch intensity from mosquito bite;
LUSC	cis	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg06521331	chr12:34319734	NA	-0.38	-6.64	-0.34	1.3e-10	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23186422	chr6:139013826	NA	-0.41	-6.13	-0.32	2.52e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs259282	0.692	rs17693106	chr19:33125055	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.67	-10.31	-0.49	8.08e-22	Schizophrenia;
LUSC	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.54	-7.55	-0.38	4.15e-13	Coronary artery disease;
LUSC	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.53	-0.42	5.22e-16	Response to antipsychotic treatment;
LUSC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg21724239	chr8:58056113	NA	0.8	8.59	0.43	3.29e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs11782517	0.920	rs4295669	chr8:10105427	C/A	cg15556689	chr8:8085844	FLJ10661	0.49	5.95	0.31	6.62e-9	Nose size;
LUSC	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg23942311	chr14:51606299	NA	0.49	11.44	0.53	8.92e-26	Cancer;
LUSC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg03929089	chr4:120376271	NA	-0.93	-16.14	-0.66	9.76e-44	Height;
LUSC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg18681998	chr4:17616180	MED28	0.86	15.74	0.65	3.96e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg06637938	chr14:75390232	RPS6KL1	0.65	10.68	0.5	4.38e-23	Caffeine consumption;
LUSC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14829155	chr15:31115871	NA	0.72	10.75	0.51	2.45e-23	Huntington's disease progression;
LUSC	trans	rs1908814	0.510	rs7819276	chr8:11755804	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.28	-0.32	1.03e-9	Neuroticism;
LUSC	cis	rs2274273	0.686	rs11624679	chr14:55624244	G/A	cg04306507	chr14:55594613	LGALS3	0.48	9.7	0.47	9.24e-20	Protein biomarker;
LUSC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg20821713	chr7:1055600	C7orf50	-0.57	-7.34	-0.37	1.59e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.78	0.39	8.95e-14	Electroencephalogram traits;
LUSC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.67	12.24	0.56	1.07e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg18681998	chr4:17616180	MED28	0.89	17.28	0.69	3.06e-48	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17255340	0.539	rs1170519	chr6:84011961	C/G	cg08257003	chr6:84140564	ME1	0.32	7.76	0.39	1.03e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg22800045	chr5:56110881	MAP3K1	0.78	9.56	0.46	2.72e-19	Initial pursuit acceleration;
LUSC	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg19116668	chr7:99932089	PMS2L1	0.33	5.83	0.3	1.28e-8	Coronary artery disease;
LUSC	cis	rs988712	0.672	rs35038967	chr11:27703480	T/A	cg10635145	chr11:27742435	BDNF	-0.46	-6.06	-0.31	3.67e-9	Obesity;
LUSC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg16447950	chr5:562315	NA	-0.56	-6.9	-0.35	2.63e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	0.57	7.68	0.39	1.81e-13	Childhood ear infection;
LUSC	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.11	-0.52	1.32e-24	Coffee consumption (cups per day);
LUSC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	0.64	13.45	0.59	3.06e-33	Prudent dietary pattern;
LUSC	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg18854424	chr1:2615690	NA	0.47	9.77	0.47	5.59e-20	Ulcerative colitis;
LUSC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg20406979	chr6:167373233	NA	0.26	6.13	0.32	2.5e-9	Crohn's disease;
LUSC	cis	rs907612	0.638	rs907611	chr11:1874072	G/A	cg05305434	chr11:1874049	LSP1	0.34	6.17	0.32	1.95e-9	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg00316803	chr15:76480434	C15orf27	0.4	7.09	0.36	7.81e-12	Blood metabolite levels;
LUSC	cis	rs2658782	0.789	rs1456238	chr11:93117370	G/C	cg15737290	chr11:93063684	CCDC67	0.61	7.46	0.38	7.34e-13	Pulmonary function decline;
LUSC	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg00825309	chr19:58991885	ZNF446	-0.5	-7.23	-0.37	3.27e-12	Uric acid clearance;
LUSC	cis	rs9369695	0.842	rs2396825	chr6:47568696	A/G	cg20196966	chr6:47445060	CD2AP	0.42	5.91	0.31	8.6e-9	Reticulocyte count;
LUSC	cis	rs10979	0.965	rs9390111	chr6:143894272	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-12.25	-0.56	9.15e-29	Hypospadias;
LUSC	cis	rs6545977	0.531	rs2539982	chr2:63111004	G/A	cg17519650	chr2:63277830	OTX1	0.7	10.19	0.49	2.13e-21	Prostate cancer;
LUSC	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg09904177	chr6:26538194	HMGN4	-0.8	-6.0	-0.31	5.13e-9	Depression;
LUSC	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg15744005	chr10:104629667	AS3MT	-0.28	-5.95	-0.31	6.91e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4561483	0.549	rs6498251	chr16:11952290	A/G	cg08843971	chr16:11963173	GSPT1	0.44	6.66	0.34	1.1e-10	Testicular germ cell tumor;
LUSC	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg15704280	chr7:45808275	SEPT13	0.78	7.46	0.38	7.71e-13	Axial length;
LUSC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg03146154	chr1:46216737	IPP	0.55	8.26	0.41	3.39e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg09365446	chr1:150670422	GOLPH3L	0.52	8.07	0.4	1.29e-14	Tonsillectomy;
LUSC	cis	rs4780401	0.782	rs933573	chr16:11793395	A/G	cg01061890	chr16:11836724	TXNDC11	0.42	6.06	0.31	3.63e-9	Rheumatoid arthritis;
LUSC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg23590916	chr17:43697445	MGC57346	0.5	6.69	0.34	9.18e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg13660082	chr14:53194042	PSMC6	-0.74	-6.4	-0.33	5.22e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.85	0.3	1.2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg19467586	chr17:45266599	CDC27	0.39	5.97	0.31	6.01e-9	Calcium levels;
LUSC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg05347473	chr6:146136440	FBXO30	0.59	10.32	0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg14458575	chr2:238380390	NA	0.69	8.36	0.42	1.7e-15	Prostate cancer;
LUSC	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg20487152	chr13:99095054	FARP1	-0.36	-6.33	-0.33	8.12e-10	Longevity;
LUSC	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg05738196	chr6:26577821	NA	0.82	15.82	0.65	1.78e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.818	rs407103	chr1:153007106	C/T	cg25856811	chr1:152973957	SPRR3	0.34	5.68	0.3	2.9e-8	Inflammatory skin disease;
LUSC	cis	rs7523273	0.548	rs2724381	chr1:207949017	T/C	cg22525895	chr1:207977042	MIR29B2	0.42	6.77	0.35	5.95e-11	Schizophrenia;
LUSC	cis	rs9815354	0.812	rs55916855	chr3:42002761	A/G	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.21e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	9.56	0.46	2.72e-19	Post bronchodilator FEV1;
LUSC	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.23	-0.37	3.34e-12	Mood instability;
LUSC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg04450456	chr4:17643702	FAM184B	0.42	7.04	0.36	1.07e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg11764359	chr7:65958608	NA	0.55	7.04	0.36	1.07e-11	Aortic root size;
LUSC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg05313129	chr8:58192883	C8orf71	-0.48	-5.76	-0.3	1.89e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9837602	1.000	rs704582	chr3:99571926	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.52	6.71	0.34	8.27e-11	Breast cancer;
LUSC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.62	10.14	0.49	3.07e-21	Lymphocyte counts;
LUSC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.66	-10.21	-0.49	1.71e-21	Menarche (age at onset);
LUSC	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.61	10.9	0.51	7.43e-24	Weight;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg13397359	chr6:42928475	GNMT	0.67	11.61	0.54	2.06e-26	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11785693	0.862	rs62491196	chr8:4995690	C/T	cg26367366	chr8:4980734	NA	0.73	8.62	0.43	2.77e-16	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	10.3	0.49	8.47e-22	Monocyte percentage of white cells;
LUSC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg01879757	chr17:41196368	BRCA1	-0.45	-6.98	-0.36	1.58e-11	Menopause (age at onset);
LUSC	cis	rs12136530	0.744	rs12090885	chr1:19779781	G/A	cg01832549	chr1:19774989	CAPZB	-0.32	-5.85	-0.31	1.14e-8	Lead levels in blood;
LUSC	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.41	-6.47	-0.33	3.45e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.9	-0.35	2.54e-11	Platelet count;
LUSC	trans	rs1998174	0.509	rs742509	chr1:171826694	G/A	cg13482142	chr2:234261155	NA	0.42	6.07	0.32	3.47e-9	Platelet distribution width;
LUSC	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg00277334	chr10:82204260	NA	-0.58	-8.65	-0.43	2.21e-16	Post bronchodilator FEV1;
LUSC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg07424592	chr7:64974309	NA	0.67	5.88	0.31	9.74e-9	Diabetic kidney disease;
LUSC	cis	rs698813	0.674	rs713447	chr2:44505185	T/G	cg00619915	chr2:44497795	NA	-0.5	-6.66	-0.34	1.1e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs1909881	1.000	rs3104903	chr8:96509113	C/T	cg04203453	chr8:96504381	NA	-0.32	-5.66	-0.3	3.3e-8	Obesity-related traits;
LUSC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	0.96	16.31	0.67	2.17e-44	Menopause (age at onset);
LUSC	cis	rs2227930	0.506	rs13082648	chr3:142129008	C/T	cg16271453	chr3:142027066	XRN1	-0.55	-9.72	-0.47	7.86e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs6977660	1.000	rs35784097	chr7:19818848	A/G	cg07541023	chr7:19748670	TWISTNB	0.51	5.82	0.3	1.37e-8	Thyroid stimulating hormone;
LUSC	trans	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07923666	chr12:49932857	KCNH3	-0.48	-5.96	-0.31	6.3e-9	Resting heart rate;
LUSC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg06600287	chr1:53387719	ECHDC2	-0.29	-6.1	-0.32	3.01e-9	Monocyte count;
LUSC	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.82	14.27	0.62	2.17e-36	Metabolic syndrome;
LUSC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-11.77	-0.54	5.5e-27	Extrinsic epigenetic age acceleration;
LUSC	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	7.58	0.38	3.38e-13	Body mass index;
LUSC	cis	rs9309473	1.000	rs7585004	chr2:73666645	C/G	cg20560298	chr2:73613845	ALMS1	-0.47	-6.63	-0.34	1.34e-10	Metabolite levels;
LUSC	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg25019033	chr10:957182	NA	0.53	8.55	0.42	4.61e-16	Eosinophil percentage of granulocytes;
LUSC	cis	rs9311676	0.656	rs62258140	chr3:58407083	C/T	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.1e-10	Systemic lupus erythematosus;
LUSC	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg24631222	chr15:78858424	CHRNA5	0.68	9.07	0.44	1.02e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.72	-10.04	-0.48	6.81e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.27	-0.37	2.65e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12190007	0.512	rs2984464	chr6:169837242	T/C	ch.6.169577133F	chr6:169835210	NA	-0.4	-6.08	-0.32	3.33e-9	Obesity-related traits;
LUSC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg05425664	chr17:57184151	TRIM37	-0.56	-8.29	-0.41	2.82e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg05347473	chr6:146136440	FBXO30	0.56	9.63	0.47	1.59e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17095355	0.818	rs2501575	chr10:111849864	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.69	-0.39	1.72e-13	Biliary atresia;
LUSC	cis	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	trans	rs6076960	0.684	rs3909041	chr20:6249598	C/G	cg21095983	chr6:86352623	SYNCRIP	0.49	7.39	0.37	1.16e-12	Smooth-surface caries;
LUSC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-1.24	-13.99	-0.61	2.59e-35	Diabetic kidney disease;
LUSC	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg25214090	chr10:38739885	LOC399744	0.6	8.81	0.43	6.84e-17	Corneal astigmatism;
LUSC	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg12863693	chr15:85201151	NMB	0.4	8.02	0.4	1.79e-14	Schizophrenia;
LUSC	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg10840412	chr1:235813424	GNG4	0.68	9.13	0.45	6.93e-18	Bipolar disorder;
LUSC	cis	rs10089	0.953	rs2190797	chr5:127352875	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	11.98	0.55	9.02e-28	Ileal carcinoids;
LUSC	cis	rs9462027	0.628	rs6925623	chr6:34800896	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.03	-0.31	4.26e-9	Systemic lupus erythematosus;
LUSC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.65	0.57	3.19e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg11344533	chr11:111475393	SIK2	-0.46	-6.35	-0.33	6.87e-10	Primary sclerosing cholangitis;
LUSC	trans	rs1325195	0.920	rs434283	chr1:179224180	T/C	cg11624085	chr17:8464688	MYH10	0.41	6.68	0.34	9.91e-11	IgE grass sensitization;
LUSC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.72	14.07	0.61	1.2e-35	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	7.1	0.36	7.44e-12	Menarche (age at onset);
LUSC	cis	rs1577917	0.917	rs1838959	chr6:86556804	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.35	0.56	3.96e-29	Prudent dietary pattern;
LUSC	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.65	9.84	0.47	3.09e-20	Educational attainment;
LUSC	cis	rs9341808	0.718	rs9443734	chr6:80820293	C/T	cg08355045	chr6:80787529	NA	0.56	9.59	0.46	2.06e-19	Sitting height ratio;
LUSC	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg26924012	chr15:45694286	SPATA5L1	1.1	19.11	0.72	1.62e-55	Homoarginine levels;
LUSC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.68	11.49	0.53	5.71e-26	Heart rate;
LUSC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg08200582	chr11:442649	ANO9	0.53	6.09	0.32	3.1e-9	Body mass index;
LUSC	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg27147174	chr7:100797783	AP1S1	-0.66	-10.66	-0.5	4.82e-23	Life satisfaction;
LUSC	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.83	0.68	1.9e-46	Exhaled nitric oxide output;
LUSC	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg02176678	chr2:219576539	TTLL4	-0.57	-10.14	-0.48	3.18e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs11264799	0.765	rs66931510	chr1:157635085	C/T	cg18268488	chr1:157545234	FCRL4	0.33	5.8	0.3	1.51e-8	IgA nephropathy;
LUSC	trans	rs77724872	0.655	rs7137145	chr12:104780482	C/G	cg10940549	chr15:45494721	SHF	-0.67	-6.11	-0.32	2.79e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg04058563	chr4:185651563	MLF1IP	0.47	7.81	0.39	7.71e-14	Kawasaki disease;
LUSC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.14	-0.32	2.39e-9	Initial pursuit acceleration;
LUSC	cis	rs7580658	0.929	rs11886231	chr2:128028130	G/A	cg09760422	chr2:128146352	NA	-0.32	-7.05	-0.36	1.02e-11	Protein C levels;
LUSC	cis	rs6845621	0.700	rs2215762	chr4:18910602	A/G	cg12196642	chr4:18937545	NA	-0.33	-6.27	-0.32	1.1e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg10596483	chr8:143751796	JRK	0.52	7.41	0.38	1.04e-12	Schizophrenia;
LUSC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg09034736	chr1:150693464	HORMAD1	0.46	6.74	0.35	6.78e-11	Tonsillectomy;
LUSC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18876405	chr7:65276391	NA	0.52	7.8	0.39	8e-14	Aortic root size;
LUSC	cis	rs6845621	0.835	rs10030640	chr4:18943713	A/C	cg12196642	chr4:18937545	NA	0.34	6.7	0.34	8.89e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg24838063	chr12:130822603	PIWIL1	0.68	10.48	0.5	2.08e-22	Menopause (age at onset);
LUSC	cis	rs2282032	1.000	rs56015111	chr14:90768946	G/A	cg14092571	chr14:90743983	NA	0.53	6.85	0.35	3.54e-11	Longevity;
LUSC	cis	rs9311676	0.656	rs11917567	chr3:58382254	C/T	cg13750441	chr3:58318267	PXK	0.35	6.67	0.34	1.07e-10	Systemic lupus erythematosus;
LUSC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg17264618	chr3:40429014	ENTPD3	0.29	6.46	0.33	3.61e-10	Renal cell carcinoma;
LUSC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.07	-0.36	9.23e-12	Bipolar disorder;
LUSC	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.93	15.88	0.66	1.1e-42	Bladder cancer;
LUSC	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.31	-0.33	8.95e-10	Bipolar disorder;
LUSC	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg13010199	chr12:38710504	ALG10B	0.55	8.29	0.41	2.82e-15	Morning vs. evening chronotype;
LUSC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg26304593	chr6:42947056	PEX6	-0.49	-7.42	-0.38	9.65e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg16339924	chr4:17578868	LAP3	0.53	8.13	0.41	8.2e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg03806693	chr22:41940476	POLR3H	0.82	12.06	0.55	4.79e-28	Vitiligo;
LUSC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg21573476	chr21:45109991	RRP1B	-0.36	-5.83	-0.3	1.31e-8	Mean corpuscular volume;
LUSC	trans	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.53	-0.34	2.48e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg15848620	chr12:58087721	OS9	-0.56	-7.94	-0.4	3.09e-14	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	6.68	0.34	9.71e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg11965913	chr1:205819406	PM20D1	0.45	6.57	0.34	1.98e-10	Parkinson's disease;
LUSC	cis	rs10419226	0.555	rs757350	chr19:18774810	G/A	cg22001208	chr19:18782374	NA	-0.37	-6.14	-0.32	2.37e-9	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	trans	rs4596713	0.568	rs10122932	chr9:71746053	C/G	cg25283916	chr1:242222868	NA	-0.3	-6.31	-0.33	8.74e-10	Headache;
LUSC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg02079420	chr8:82753780	SNX16	-0.38	-5.79	-0.3	1.64e-8	Diastolic blood pressure;
LUSC	trans	rs2262909	0.962	rs408687	chr19:22231123	T/C	cg05197062	chr11:11642011	GALNTL4	-0.56	-7.81	-0.39	7.34e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg04287289	chr16:89883240	FANCA	-0.78	-13.72	-0.6	2.85e-34	Vitiligo;
LUSC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.49	5.98	0.31	5.7e-9	Renal function-related traits (BUN);
LUSC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg21724239	chr8:58056113	NA	0.77	7.96	0.4	2.67e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs895636	1.000	rs895636	chr2:45188353	A/G	cg03867797	chr12:110939833	VPS29;RAD9B	-0.46	-6.05	-0.31	3.86e-9	Metabolite levels;Fasting plasma glucose;
LUSC	cis	rs2901656	0.544	rs6658843	chr1:172399082	G/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.31	6.27	0.32	1.15e-9	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg01028140	chr2:1542097	TPO	-0.62	-7.98	-0.4	2.43e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg10857441	chr5:6722123	POLS	-0.43	-7.79	-0.39	8.4e-14	Menopause (age at onset);
LUSC	trans	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07923666	chr12:49932857	KCNH3	-0.47	-6.27	-0.32	1.14e-9	Resting heart rate;
LUSC	cis	rs1483890	0.851	rs6762186	chr3:69402923	T/G	cg22125112	chr3:69402811	FRMD4B	0.39	5.85	0.3	1.18e-8	Resting heart rate;
LUSC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	1.04	19.44	0.73	7.67e-57	Menopause (age at onset);
LUSC	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg04545296	chr12:48745243	ZNF641	0.33	6.02	0.31	4.65e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg21573476	chr21:45109991	RRP1B	-0.42	-6.68	-0.34	1.03e-10	Coronary artery disease;
LUSC	cis	rs829883	0.902	rs1620317	chr12:98890566	T/C	cg25150519	chr12:98850993	NA	0.64	9.84	0.47	3.15e-20	Colorectal adenoma (advanced);
LUSC	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg05182265	chr7:156933206	UBE3C	-0.49	-7.37	-0.37	1.37e-12	Body mass index;
LUSC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.56	-0.38	3.87e-13	Aortic root size;
LUSC	cis	rs79387448	0.745	rs72993760	chr2:103151704	G/A	cg09003973	chr2:102972529	NA	0.86	8.44	0.42	9.66e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs4664304	0.620	rs4665125	chr2:160714314	C/G	cg23995753	chr2:160760732	LY75	0.3	5.64	0.3	3.56e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.2	22.43	0.78	1.32e-68	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs427941	1.000	rs423452	chr7:101848790	G/A	cg06246474	chr7:101738831	CUX1	-0.35	-5.65	-0.3	3.45e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs11018904	0.906	rs61903722	chr11:89967042	C/T	cg26138821	chr11:89956704	CHORDC1	-0.6	-7.3	-0.37	2.15e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg03342759	chr3:160939853	NMD3	0.52	8.74	0.43	1.15e-16	Morning vs. evening chronotype;
LUSC	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.69	8.47	0.42	7.83e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg07741184	chr6:167504864	NA	0.42	7.54	0.38	4.41e-13	Crohn's disease;
LUSC	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	0.58	9.14	0.45	6.01e-18	Breast cancer;
LUSC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg18230493	chr5:56204884	C5orf35	-0.96	-14.17	-0.61	4.9e-36	Initial pursuit acceleration;
LUSC	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg05527609	chr1:210001259	C1orf107	0.94	12.15	0.55	2.3e-28	Orofacial clefts;
LUSC	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg13514129	chr1:39547527	MACF1	0.71	11.79	0.54	4.48e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	7.28	0.37	2.43e-12	Height;
LUSC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg12463550	chr7:65579703	CRCP	0.57	8.52	0.42	5.72e-16	Aortic root size;
LUSC	trans	rs8040855	0.894	rs6496770	chr15:85705121	T/A	cg00988175	chr11:59481031	OR10V1	-0.28	-5.96	-0.31	6.57e-9	Bulimia nervosa;
LUSC	cis	rs17767294	0.708	rs34957169	chr6:27879397	T/C	cg08851530	chr6:28072375	NA	1.3	8.14	0.41	7.69e-15	Parkinson's disease;
LUSC	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.43	-6.7	-0.34	9.04e-11	Systemic lupus erythematosus;
LUSC	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg21361702	chr7:150065534	REPIN1	0.57	8.15	0.41	7.39e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.45	-0.42	9.36e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg13319975	chr6:146136371	FBXO30	0.46	7.11	0.36	7.11e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.79	-0.51	1.7e-23	Aortic root size;
LUSC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg09509183	chr1:209979624	IRF6	0.43	5.73	0.3	2.25e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg18854424	chr1:2615690	NA	0.49	10.32	0.49	7.46e-22	Ulcerative colitis;
LUSC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.66	-10.25	-0.49	1.27e-21	Menarche (age at onset);
LUSC	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg24642439	chr20:33292090	TP53INP2	0.48	7.33	0.37	1.8e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs9868809	0.881	rs2276850	chr3:48669648	G/A	cg00383909	chr3:49044727	WDR6	1.07	9.61	0.47	1.86e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	trans	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg05059571	chr16:84539110	KIAA1609	0.47	8.95	0.44	2.49e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	trans	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg27411982	chr8:10470053	RP1L1	-0.42	-6.6	-0.34	1.64e-10	Joint mobility (Beighton score);
LUSC	cis	rs7655841	0.504	rs10028974	chr4:129871442	C/A	cg26347359	chr4:129759716	PHF17	0.53	7.78	0.39	8.91e-14	Chronic obstructive pulmonary disease (moderate to severe);
LUSC	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg10978503	chr1:24200527	CNR2	0.53	13.1	0.58	6.34e-32	Immature fraction of reticulocytes;
LUSC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.69	-12.08	-0.55	3.97e-28	Dental caries;
LUSC	trans	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg26384229	chr12:38710491	ALG10B	-0.58	-8.59	-0.43	3.29e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg00074818	chr8:8560427	CLDN23	0.59	9.71	0.47	8.72e-20	Obesity-related traits;
LUSC	trans	rs4650994	0.505	rs2811291	chr1:178574217	C/T	cg05059571	chr16:84539110	KIAA1609	0.45	8.6	0.43	3.16e-16	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs2625529	0.652	rs2957734	chr15:72261385	A/G	cg16672083	chr15:72433130	SENP8	0.49	8.07	0.4	1.26e-14	Red blood cell count;
LUSC	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.75	-13.58	-0.6	9.72e-34	Calcium levels;
LUSC	cis	rs7553864	0.614	rs10493796	chr1:87614175	A/G	cg17420885	chr1:87600446	LOC339524	0.5	7.05	0.36	1.04e-11	Smoking behavior;
LUSC	cis	rs7580658	0.680	rs2069931	chr2:128185569	C/T	cg09760422	chr2:128146352	NA	-0.27	-5.86	-0.31	1.09e-8	Protein C levels;
LUSC	cis	rs3916	1.000	rs34708625	chr12:121180019	T/C	cg02419362	chr12:121203948	SPPL3	0.38	5.9	0.31	8.85e-9	Urinary metabolites (H-NMR features);
LUSC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7474896	0.559	rs1212108	chr10:38094322	A/C	cg25427524	chr10:38739819	LOC399744	-0.45	-5.76	-0.3	1.89e-8	Obesity (extreme);
LUSC	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg00071950	chr4:10020882	SLC2A9	0.51	8.48	0.42	7.41e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9403521	1.000	rs9403523	chr6:144004981	T/C	cg18240653	chr6:144019428	PHACTR2	-0.48	-5.93	-0.31	7.7e-9	Obesity-related traits;
LUSC	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.63	-9.89	-0.48	2.07e-20	Alcohol dependence;
LUSC	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	7.17	0.37	4.93e-12	Schizophrenia;
LUSC	trans	rs10432489	0.708	rs4290619	chr2:181766959	G/T	cg11196870	chr8:41386826	GINS4	-0.9	-5.99	-0.31	5.46e-9	QT interval;
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg00431813	chr7:1051703	C7orf50	-0.37	-5.73	-0.3	2.21e-8	Longevity;Endometriosis;
LUSC	cis	rs983392	0.679	rs7128450	chr11:60031270	G/C	cg02771260	chr11:59836817	MS4A3	0.37	6.11	0.32	2.83e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg00750074	chr16:89608354	SPG7	-0.43	-7.42	-0.38	9.66e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.38	-0.33	5.75e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg27588902	chr6:42928151	GNMT	0.29	6.32	0.33	8.54e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg08798685	chr6:27730294	NA	-0.69	-6.12	-0.32	2.55e-9	Depression;
LUSC	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg19789473	chr17:27170043	C17orf63	0.31	5.95	0.31	6.6e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4774899	0.837	rs12900038	chr15:57409449	G/T	cg21617494	chr15:57618479	NA	-0.36	-6.0	-0.31	5.23e-9	Urinary tract infection frequency;
LUSC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.7	0.34	8.92e-11	Tonsillectomy;
LUSC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg11861562	chr11:117069780	TAGLN	0.47	8.6	0.43	3.2e-16	Blood protein levels;
LUSC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg23625390	chr15:77176239	SCAPER	0.5	7.73	0.39	1.25e-13	Blood metabolite levels;
LUSC	cis	rs2278426	1.000	rs17699030	chr19:11330942	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	-0.68	-5.86	-0.31	1.13e-8	HDL cholesterol;
LUSC	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg25301532	chr20:43378953	KCNK15	0.37	6.55	0.34	2.12e-10	Obesity-related traits;
LUSC	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.56	-9.25	-0.45	2.75e-18	Breast cancer;
LUSC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg05555928	chr11:63887634	MACROD1	0.48	9.15	0.45	5.85e-18	Platelet count;
LUSC	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg24631222	chr15:78858424	CHRNA5	0.67	8.85	0.44	5.05e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg16325326	chr1:53192061	ZYG11B	0.74	12.93	0.58	2.75e-31	Monocyte count;
LUSC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg19774624	chr17:42201019	HDAC5	0.79	11.89	0.55	2.08e-27	Total body bone mineral density;
LUSC	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg12386194	chr3:101231763	SENP7	0.55	7.58	0.38	3.5e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05776053	chr2:74358815	NA	0.45	7.12	0.36	6.54e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg09359103	chr1:154839909	KCNN3	-0.72	-17.47	-0.69	5.45e-49	Prostate cancer;
LUSC	cis	rs2625529	0.590	rs12904652	chr15:72548765	T/C	cg16672083	chr15:72433130	SENP8	-0.46	-7.18	-0.37	4.44e-12	Red blood cell count;
LUSC	cis	rs34638657	0.500	rs1056675	chr16:82181934	T/C	cg09439754	chr16:82129088	HSD17B2	-0.35	-6.47	-0.33	3.47e-10	Lung adenocarcinoma;
LUSC	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg10253484	chr15:75165896	SCAMP2	-0.46	-6.58	-0.34	1.87e-10	Breast cancer;
LUSC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg22907277	chr7:1156413	C7orf50	0.62	9.69	0.47	1.01e-19	Longevity;Endometriosis;
LUSC	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg21045802	chr8:109455806	TTC35	0.48	7.55	0.38	4.19e-13	Dupuytren's disease;
LUSC	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.47	-5.76	-0.3	1.94e-8	Iron status biomarkers;
LUSC	cis	rs62408225	1.000	rs17513415	chr6:90947867	C/T	cg06866423	chr6:90926672	BACH2	0.4	5.7	0.3	2.59e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg06096015	chr1:231504339	EGLN1	-0.58	-10.38	-0.49	4.56e-22	Hemoglobin concentration;
LUSC	cis	rs4604732	0.631	rs12038880	chr1:247624603	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.43	6.15	0.32	2.21e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs3087591	0.708	rs2854305	chr17:29647003	G/A	cg24425628	chr17:29625626	OMG;NF1	0.46	6.85	0.35	3.48e-11	Hip circumference;
LUSC	cis	rs2860975	0.967	rs7902572	chr10:96772717	C/A	cg09036531	chr10:96991505	NA	-0.42	-5.8	-0.3	1.51e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg10360139	chr7:1886902	MAD1L1	-0.38	-5.67	-0.3	3.17e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20307385	chr11:47447363	PSMC3	-0.46	-5.89	-0.31	9.27e-9	Subjective well-being;
LUSC	trans	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg02800362	chr5:177631904	HNRNPAB	0.88	13.05	0.58	9.85e-32	Obesity-related traits;
LUSC	cis	rs6942756	1.000	rs6949950	chr7:128914818	G/A	cg02491457	chr7:128862824	NA	-0.5	-7.1	-0.36	7.68e-12	White matter hyperintensity burden;
LUSC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	1.02	17.89	0.7	1.1e-50	Parkinson's disease;
LUSC	trans	rs2244503	0.945	rs17071864	chr3:64939606	C/T	cg08115371	chr11:79115706	ODZ4	-0.45	-6.06	-0.31	3.65e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg00999904	chr2:3704751	ALLC	-0.33	-6.2	-0.32	1.67e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7172677	1.000	rs2029519	chr15:75415962	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.84	-0.3	1.27e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	trans	rs3857536	0.740	rs9360191	chr6:66942454	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.58	8.94	0.44	2.74e-17	Blood protein levels;
LUSC	cis	rs727505	0.865	rs10253613	chr7:124508929	G/A	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg20283391	chr11:68216788	NA	-0.57	-8.1	-0.41	1.04e-14	Total body bone mineral density;
LUSC	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg10621924	chr7:39171070	POU6F2	0.48	7.58	0.38	3.36e-13	IgG glycosylation;
LUSC	cis	rs7659604	0.540	rs7676867	chr4:122671315	T/C	cg19748678	chr4:122722346	EXOSC9	-0.43	-6.37	-0.33	6.36e-10	Type 2 diabetes;
LUSC	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.72	12.25	0.56	9.12e-29	White blood cell count (basophil);
LUSC	cis	rs2239815	0.515	rs5762848	chr22:29236308	A/G	cg02153584	chr22:29168773	CCDC117	0.54	6.24	0.32	1.29e-9	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	7.78	0.39	9.32e-14	Longevity;
LUSC	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg05714579	chr10:131428358	MGMT	-0.77	-11.67	-0.54	1.23e-26	Response to temozolomide;
LUSC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-1.1	-22.16	-0.77	1.46e-67	Coronary artery disease;
LUSC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.8	-0.35	4.82e-11	Total body bone mineral density;
LUSC	cis	rs7215564	0.908	rs8076854	chr17:78663962	A/G	cg23238734	chr17:78661607	RPTOR	0.48	6.12	0.32	2.63e-9	Myopia (pathological);
LUSC	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	7.66	0.39	2.05e-13	Response to antipsychotic treatment;
LUSC	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg04111992	chr7:158790115	NA	-0.45	-7.25	-0.37	2.94e-12	Facial morphology (factor 20);
LUSC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	trans	rs9929218	0.559	rs55907909	chr16:68805805	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.96	19.14	0.72	1.15e-55	Colorectal cancer;
LUSC	trans	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg05059571	chr16:84539110	KIAA1609	-0.48	-9.14	-0.45	6.21e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.25	-5.73	-0.3	2.27e-8	Electroencephalogram traits;
LUSC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.43	5.77	0.3	1.85e-8	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg07211511	chr3:129823064	LOC729375	-0.99	-12.34	-0.56	4.37e-29	Blood pressure (smoking interaction);
LUSC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-6.08	-0.32	3.35e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3741151	0.773	rs61345051	chr11:73112305	T/C	cg17517138	chr11:73019481	ARHGEF17	0.98	8.39	0.42	1.34e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg22676075	chr6:135203613	NA	0.48	7.49	0.38	6.19e-13	Red blood cell count;
LUSC	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.66	-8.33	-0.41	2.08e-15	Huntington's disease progression;
LUSC	cis	rs68170813	0.562	rs17429825	chr7:107050731	C/T	cg02696742	chr7:106810147	HBP1	-0.64	-9.09	-0.45	8.97e-18	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.26	-0.41	3.45e-15	Lung cancer;
LUSC	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	1.17	22.83	0.78	3.47e-70	Exhaled nitric oxide output;
LUSC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg10729496	chr3:10149963	C3orf24	0.56	7.5	0.38	5.84e-13	Alzheimer's disease;
LUSC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg08088566	chr11:430123	ANO9	0.6	7.04	0.36	1.09e-11	Body mass index;
LUSC	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg17691542	chr6:26056736	HIST1H1C	0.47	7.01	0.36	1.3e-11	Height;
LUSC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.03	-0.4	1.69e-14	Chronic sinus infection;
LUSC	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.37	6.46	0.33	3.62e-10	Primary biliary cholangitis;
LUSC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg18225595	chr11:63971243	STIP1	0.43	6.99	0.36	1.47e-11	Platelet count;
LUSC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.05	-0.48	6.23e-21	Hemoglobin concentration;
LUSC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18404041	chr3:52824283	ITIH1	-0.62	-11.96	-0.55	1.13e-27	Bipolar disorder;
LUSC	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg19743168	chr1:23544995	NA	0.4	8.04	0.4	1.58e-14	Height;
LUSC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg12463550	chr7:65579703	CRCP	0.63	5.77	0.3	1.81e-8	Diabetic kidney disease;
LUSC	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg19554555	chr3:13937349	NA	-0.37	-5.69	-0.3	2.82e-8	Ovarian reserve;
LUSC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg05082376	chr22:42548792	NA	0.43	6.46	0.33	3.79e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00290607	chr11:67383545	NA	0.37	7.01	0.36	1.3e-11	Mean corpuscular volume;
LUSC	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg24579218	chr15:68104479	NA	-0.38	-6.56	-0.34	2.03e-10	Obesity;
LUSC	trans	rs8040855	0.931	rs11855471	chr15:85719207	T/C	cg00988175	chr11:59481031	OR10V1	-0.3	-6.5	-0.34	2.89e-10	Bulimia nervosa;
LUSC	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg01733217	chr16:74700730	RFWD3	0.8	13.43	0.59	3.48e-33	Testicular germ cell tumor;
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	8.42	0.42	1.12e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg01475377	chr6:109611718	NA	-0.41	-7.2	-0.37	4.08e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs9534288	0.699	rs1467665	chr13:46662919	C/T	cg15192986	chr13:46630673	CPB2	-0.76	-11.24	-0.52	4.42e-25	Blood protein levels;
LUSC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg04756594	chr16:24857601	SLC5A11	0.47	6.4	0.33	5.23e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	8.06	0.4	1.41e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg24110177	chr3:50126178	RBM5	-0.42	-6.6	-0.34	1.63e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg13798780	chr7:105162888	PUS7	0.56	5.83	0.3	1.28e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.85	-0.47	2.93e-20	Hemoglobin concentration;
LUSC	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-0.59	-9.28	-0.45	2.13e-18	Breast cancer;
LUSC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-9.92	-0.48	1.73e-20	Longevity;Endometriosis;
LUSC	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	7.56	0.38	4.05e-13	Multiple sclerosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26528255	chr1:27652089	TMEM222	0.57	7.08	0.36	8.66e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg12863693	chr15:85201151	NMB	0.42	8.76	0.43	1.02e-16	Schizophrenia;
LUSC	cis	rs9398803	0.835	rs1602278	chr6:126838605	A/C	cg19875578	chr6:126661172	C6orf173	0.4	5.81	0.3	1.5e-8	Male-pattern baldness;
LUSC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18876405	chr7:65276391	NA	-0.53	-8.43	-0.42	1.06e-15	Aortic root size;
LUSC	trans	rs11057841	1.000	rs11057840	chr12:125316055	A/C	cg02981208	chr16:1575201	IFT140	0.51	5.94	0.31	7.04e-9	Lipoprotein-associated phospholipase A2 activity and mass;
LUSC	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg10604040	chr11:65559109	OVOL1	-0.31	-5.82	-0.3	1.41e-8	Acne (severe);
LUSC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.88	-0.35	2.97e-11	Alzheimer's disease (late onset);
LUSC	cis	rs12295403	1.000	rs12295403	chr11:18689653	G/T	cg09887367	chr11:18690185	NA	-0.34	-6.99	-0.36	1.5e-11	Ovarian reserve;
LUSC	cis	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg07988820	chr12:82153109	PPFIA2	-0.42	-6.05	-0.31	3.81e-9	Resting heart rate;
LUSC	cis	rs10875746	0.855	rs17122620	chr12:48464475	A/G	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs13394619	0.935	rs6746291	chr2:11728381	T/C	cg07314298	chr2:11723111	GREB1	-0.61	-11.17	-0.52	7.95e-25	Endometriosis;
LUSC	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-9.45	-0.46	6.11e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg02153584	chr22:29168773	CCDC117	0.68	11.01	0.52	3e-24	Lymphocyte counts;
LUSC	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.35	-6.63	-0.34	1.35e-10	Coronary artery disease;
LUSC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.7	10.18	0.49	2.21e-21	Menarche (age at onset);
LUSC	cis	rs9420	0.925	rs78587207	chr11:57654991	T/G	cg23127183	chr11:57508653	C11orf31	-0.53	-7.54	-0.38	4.59e-13	Schizophrenia;
LUSC	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg13010199	chr12:38710504	ALG10B	0.63	9.55	0.46	2.97e-19	Bladder cancer;
LUSC	cis	rs6469656	0.892	rs4278180	chr8:117726681	C/T	cg24004040	chr8:117650383	NA	-0.45	-6.48	-0.33	3.3e-10	Colorectal cancer;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg20273774	chr5:180671298	GNB2L1;SNORD95	0.33	6.24	0.32	1.36e-9	Tuberculosis;
LUSC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.13	-0.41	8.71e-15	Chronic sinus infection;
LUSC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg15017067	chr4:17643749	FAM184B	0.35	5.75	0.3	2.02e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.8	8.21	0.41	5.03e-15	Initial pursuit acceleration;
LUSC	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg27411982	chr8:10470053	RP1L1	0.43	6.84	0.35	3.87e-11	Mood instability;
LUSC	cis	rs2742234	0.518	rs1254967	chr10:43690391	G/A	cg15436174	chr10:43711423	RASGEF1A	0.44	7.0	0.36	1.4e-11	Hirschsprung disease;
LUSC	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.34	-7.29	-0.37	2.22e-12	Dupuytren's disease;
LUSC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg13047869	chr3:10149882	C3orf24	0.56	7.63	0.39	2.55e-13	Alzheimer's disease;
LUSC	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg02012338	chr4:187126139	CYP4V2	0.62	6.3	0.33	9.52e-10	Blood protein levels;
LUSC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg08508325	chr11:3079039	CARS	0.42	9.47	0.46	5.09e-19	Longevity;
LUSC	cis	rs1595825	0.679	rs7590697	chr2:198378546	A/G	cg00982548	chr2:198649783	BOLL	-0.52	-6.16	-0.32	2.13e-9	Ulcerative colitis;
LUSC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.01	-0.36	1.35e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg25019033	chr10:957182	NA	-0.51	-6.29	-0.33	9.84e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs12530845	0.561	rs73725182	chr7:135291001	C/T	cg23117316	chr7:135346802	PL-5283	-0.57	-8.57	-0.42	3.93e-16	Red blood cell traits;
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.37	-6.05	-0.31	3.95e-9	Longevity;Endometriosis;
LUSC	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg27284194	chr4:1044797	NA	0.6	8.85	0.44	5.26e-17	Recombination rate (females);
LUSC	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg17366294	chr4:99064904	C4orf37	0.55	9.64	0.47	1.46e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.12	0.52	1.17e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg16606324	chr3:10149918	C3orf24	-0.63	-9.42	-0.46	7.44e-19	Alzheimer's disease;
LUSC	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.95	0.31	6.75e-9	Rheumatoid arthritis;
LUSC	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.15	-0.32	2.19e-9	Neutrophil percentage of white cells;
LUSC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.75	0.35	6.45e-11	Menarche (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17942371	chr19:796826	PTBP1	0.43	5.97	0.31	6.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02176678	chr2:219576539	TTLL4	-0.7	-13.3	-0.59	1.08e-32	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs62400317	0.859	rs10948223	chr6:45273921	A/C	cg18551225	chr6:44695536	NA	-0.42	-7.0	-0.36	1.39e-11	Total body bone mineral density;
LUSC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10802521	chr3:52805072	NEK4	-0.54	-8.89	-0.44	3.84e-17	Bipolar disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15722731	chr6:122720674	HSF2	-0.51	-6.07	-0.32	3.38e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg04995722	chr7:26192034	NFE2L3	-0.43	-6.7	-0.34	8.8e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4073416	0.542	rs7143318	chr14:65940689	G/A	cg03016385	chr14:66212404	NA	-0.39	-5.83	-0.3	1.3e-8	N-glycan levels;
LUSC	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg11657440	chr19:46296263	DMWD	-0.54	-7.68	-0.39	1.75e-13	Coronary artery disease;
LUSC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg14004847	chr7:1930337	MAD1L1	0.44	6.63	0.34	1.32e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.18	-30.57	-0.86	8.33e-99	Testicular germ cell tumor;
LUSC	cis	rs4629710	0.592	rs1885641	chr6:131553986	A/G	cg12700074	chr6:131571435	AKAP7	-0.35	-5.9	-0.31	8.89e-9	Multiple myeloma (IgH translocation);
LUSC	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	7.3	0.37	2.15e-12	Neuroticism;
LUSC	cis	rs4664308	0.905	rs62175518	chr2:160915149	C/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-10.62	-0.5	6.75e-23	Idiopathic membranous nephropathy;
LUSC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg23034840	chr1:205782522	SLC41A1	0.68	9.55	0.46	2.97e-19	Prostate-specific antigen levels;
LUSC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.77	-0.35	5.93e-11	Menopause (age at onset);
LUSC	cis	rs7178375	0.607	rs71474639	chr15:31213257	A/G	cg15020726	chr15:31196382	MTMR15	0.84	7.7	0.39	1.59e-13	Hypertriglyceridemia;
LUSC	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg07148914	chr20:33460835	GGT7	0.53	7.98	0.4	2.41e-14	Height;
LUSC	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg13939156	chr17:80058883	NA	-0.35	-7.03	-0.36	1.18e-11	Life satisfaction;
LUSC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg16606324	chr3:10149918	C3orf24	0.68	9.9	0.48	2.05e-20	Alzheimer's disease;
LUSC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg25036284	chr2:26402008	FAM59B	-0.68	-9.27	-0.45	2.41e-18	Gut microbiome composition (summer);
LUSC	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg23260525	chr10:116636907	FAM160B1	0.4	8.26	0.41	3.54e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	6.41	0.33	4.88e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-9.75	-0.47	6.14e-20	Neuroticism;
LUSC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg18827107	chr12:86230957	RASSF9	-0.48	-7.19	-0.37	4.16e-12	Major depressive disorder;
LUSC	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.57	0.42	3.85e-16	Response to antipsychotic treatment;
LUSC	cis	rs12474201	0.928	rs35825831	chr2:46932544	T/G	cg06386533	chr2:46925753	SOCS5	0.77	11.6	0.54	2.19e-26	Height;
LUSC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg20203395	chr5:56204925	C5orf35	-0.58	-8.14	-0.41	7.93e-15	Initial pursuit acceleration;
LUSC	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg25809561	chr17:30822961	MYO1D	0.57	10.04	0.48	6.7e-21	Schizophrenia;
LUSC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg06145435	chr7:1022769	CYP2W1	0.29	5.96	0.31	6.51e-9	Longevity;Endometriosis;
LUSC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg05313129	chr8:58192883	C8orf71	-0.5	-6.51	-0.34	2.72e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg09455208	chr3:40491958	NA	0.52	9.16	0.45	5.22e-18	Renal cell carcinoma;
LUSC	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg26195577	chr20:24973756	C20orf3	1.11	18.4	0.71	1.06e-52	Blood protein levels;
LUSC	cis	rs2271400	1.000	rs2271400	chr8:56791244	C/T	cg08894788	chr8:56792171	LYN	-0.44	-6.97	-0.36	1.74e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
LUSC	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg07173049	chr1:7289937	CAMTA1	0.37	7.6	0.38	3.01e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	trans	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.59	-0.34	1.71e-10	Endometrial cancer;
LUSC	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-13.42	-0.59	3.73e-33	Total body bone mineral density;
LUSC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg06212747	chr3:49208901	KLHDC8B	0.45	6.11	0.32	2.77e-9	Parkinson's disease;
LUSC	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	6.87	0.35	3.1e-11	Response to antipsychotic treatment;
LUSC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	7.1	0.36	7.55e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg07741184	chr6:167504864	NA	0.35	6.23	0.32	1.41e-9	Crohn's disease;
LUSC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg11871910	chr12:69753446	YEATS4	0.63	9.63	0.47	1.52e-19	Blood protein levels;
LUSC	cis	rs548181	0.673	rs12288034	chr11:125570941	A/T	cg03464685	chr11:125439445	EI24	-1.09	-12.93	-0.58	2.86e-31	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01176458	chr3:27763828	EOMES	0.46	7.0	0.36	1.4e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.79	0.35	5.03e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	8.35	0.42	1.86e-15	Schizophrenia;
LUSC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg05025164	chr4:1340916	KIAA1530	0.42	6.64	0.34	1.29e-10	Longevity;
LUSC	cis	rs35883536	0.967	rs1582091	chr1:101177133	G/T	cg06223162	chr1:101003688	GPR88	0.33	5.93	0.31	7.72e-9	Monocyte count;
LUSC	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg23649088	chr2:200775458	C2orf69	-0.57	-6.73	-0.35	7.26e-11	Schizophrenia;
LUSC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08677398	chr8:58056175	NA	0.53	6.47	0.33	3.43e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.75	13.53	0.59	1.51e-33	Menarche (age at onset);
LUSC	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg05973401	chr12:123451056	ABCB9	0.52	6.43	0.33	4.29e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.88	-0.35	3.04e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs28647808	0.881	rs41316982	chr9:136259117	C/T	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg25428297	chr7:1022841	CYP2W1	0.28	5.98	0.31	5.59e-9	Longevity;Endometriosis;
LUSC	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg11608241	chr8:8085544	FLJ10661	-0.47	-6.7	-0.34	8.86e-11	Neuroticism;
LUSC	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg03709012	chr19:19516395	GATAD2A	1.05	12.98	0.58	1.73e-31	Nonalcoholic fatty liver disease;
LUSC	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg13852791	chr20:30311386	BCL2L1	0.72	8.29	0.41	2.73e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg06917634	chr15:78832804	PSMA4	-0.59	-7.1	-0.36	7.43e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg17127132	chr2:85788382	GGCX	0.46	7.35	0.37	1.52e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg09997546	chr11:8931473	C11orf17;ST5	0.39	8.36	0.42	1.75e-15	Hemoglobin concentration;
LUSC	trans	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.34e-10	Corneal astigmatism;
LUSC	cis	rs10875746	0.903	rs12304476	chr12:48482153	T/C	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg11494091	chr17:61959527	GH2	0.37	6.07	0.32	3.47e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2857891	0.695	rs2857896	chr11:6982825	A/T	cg14883916	chr11:6947541	ZNF215	0.41	5.71	0.3	2.51e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs981844	1.000	rs56331473	chr4:154668052	C/A	cg14289246	chr4:154710475	SFRP2	0.48	6.1	0.32	2.87e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.68	-0.39	1.82e-13	Height;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg12188830	chr3:57741926	SLMAP	0.35	6.11	0.32	2.77e-9	Triglycerides;
LUSC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg01181863	chr3:195395398	SDHAP2	-0.59	-8.04	-0.4	1.53e-14	Pancreatic cancer;
LUSC	cis	rs6433857	0.536	rs12474658	chr2:181352992	G/T	cg23363182	chr2:181467187	NA	-0.41	-6.51	-0.34	2.71e-10	Body mass index;
LUSC	cis	rs72781680	0.716	rs17045975	chr2:24099611	A/T	cg08917208	chr2:24149416	ATAD2B	-0.58	-6.84	-0.35	3.74e-11	Lymphocyte counts;
LUSC	cis	rs7215564	1.000	rs7215564	chr17:78737287	A/G	cg23238734	chr17:78661607	RPTOR	0.44	5.71	0.3	2.53e-8	Myopia (pathological);
LUSC	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg01765077	chr12:122356316	WDR66	0.5	6.97	0.36	1.75e-11	Mean corpuscular volume;
LUSC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs3812762	0.833	rs35670750	chr11:8782444	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-6.28	-0.32	1.08e-9	Hypospadias;
LUSC	cis	rs354225	0.544	rs12713266	chr2:54805443	G/T	cg26097391	chr2:54893211	SPTBN1	0.46	6.95	0.36	1.88e-11	Schizophrenia;
LUSC	cis	rs2734839	0.964	rs1800498	chr11:113291588	G/A	cg14159747	chr11:113255604	NA	0.23	5.75	0.3	1.98e-8	Information processing speed;
LUSC	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg05855489	chr10:104503620	C10orf26	0.51	7.26	0.37	2.67e-12	Arsenic metabolism;
LUSC	cis	rs4964805	0.913	rs11111793	chr12:104198118	G/T	cg02344784	chr12:104178138	NT5DC3	0.4	6.34	0.33	7.52e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg02016764	chr4:38805732	TLR1	-0.55	-5.99	-0.31	5.38e-9	Breast cancer;
LUSC	trans	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.44	6.58	0.34	1.83e-10	Endometrial cancer;
LUSC	cis	rs1957429	0.731	rs1951495	chr14:65336690	T/C	cg23373153	chr14:65346875	NA	0.94	10.29	0.49	9.2e-22	Pediatric areal bone mineral density (radius);
LUSC	trans	rs7181230	0.885	rs28444847	chr15:40356604	C/T	cg22705835	chr10:65332833	REEP3	-0.4	-6.43	-0.33	4.46e-10	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg12516959	chr21:47718080	NA	-0.38	-6.15	-0.32	2.25e-9	Testicular germ cell tumor;
LUSC	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.81	12.57	0.57	5.97e-30	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs7315438	0.599	rs7955092	chr12:115875881	T/C	cg24172291	chr12:115889509	NA	-0.35	-5.96	-0.31	6.27e-9	Colorectal cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24082730	chr3:126076366	KLF15	-0.41	-6.26	-0.32	1.16e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg16928487	chr17:17741425	SREBF1	0.33	6.07	0.32	3.55e-9	Total body bone mineral density;
LUSC	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.49	-6.88	-0.35	3e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9612	1.000	rs1058	chr19:44268325	C/G	cg08581076	chr19:44259116	C19orf61	0.49	5.96	0.31	6.39e-9	Exhaled nitric oxide output;
LUSC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.07	-0.32	3.41e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg10224037	chr5:178157518	ZNF354A	0.8	12.3	0.56	6.38e-29	Neutrophil percentage of white cells;
LUSC	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.66	9.44	0.46	6.8e-19	Adiposity;
LUSC	cis	rs17407555	0.647	rs55811736	chr4:10014221	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-6.24	-0.32	1.3e-9	Schizophrenia (age at onset);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg08020177	chr16:19535130	CP110	0.51	6.19	0.32	1.76e-9	Cognitive function;Information processing speed;
LUSC	cis	rs2688608	0.967	rs1815076	chr10:75659886	C/T	cg17411546	chr10:75410026	SYNPO2L	-0.43	-6.3	-0.33	9.58e-10	Inflammatory bowel disease;
LUSC	cis	rs13401104	0.796	rs57900956	chr2:237119214	C/A	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs6546550	0.867	rs726920	chr2:70152027	G/C	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.4	-0.38	1.09e-12	Prevalent atrial fibrillation;
LUSC	cis	rs7799006	0.606	rs878534	chr7:2314652	G/A	cg08027265	chr7:2291960	NA	-0.62	-11.08	-0.52	1.61e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4499344	0.730	rs259279	chr19:33161274	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.95	-16.03	-0.66	2.68e-43	Mean platelet volume;
LUSC	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.41	0.33	4.82e-10	Sudden cardiac arrest;
LUSC	cis	rs66887589	0.870	rs2389875	chr4:120557014	G/T	cg24375607	chr4:120327624	NA	-0.46	-6.91	-0.35	2.46e-11	Diastolic blood pressure;
LUSC	trans	rs13011075	0.919	rs62143899	chr2:68604553	C/T	cg14221825	chr19:46271408	SIX5	0.43	6.19	0.32	1.75e-9	Mean corpuscular volume;
LUSC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.68	12.02	0.55	6.86e-28	Aortic root size;
LUSC	cis	rs7927771	0.524	rs12785949	chr11:47729770	C/T	cg20307385	chr11:47447363	PSMC3	0.44	6.41	0.33	4.83e-10	Subjective well-being;
LUSC	cis	rs11779988	0.545	rs411531	chr8:17795934	A/G	cg01800426	chr8:17659068	MTUS1	-0.49	-5.93	-0.31	7.44e-9	Breast cancer;
LUSC	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg02696742	chr7:106810147	HBP1	-0.63	-9.54	-0.46	3.16e-19	Coronary artery disease;
LUSC	cis	rs2884670	1.000	rs2884670	chr12:4675218	C/T	cg11146114	chr12:4671731	NA	-0.38	-6.11	-0.32	2.72e-9	Allergic rhinitis;
LUSC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-8.29	-0.41	2.8e-15	Hemoglobin concentration;
LUSC	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg12940439	chr1:67600707	NA	-0.35	-5.83	-0.3	1.3e-8	Psoriasis;
LUSC	cis	rs2871473	0.951	rs1030025	chr2:103105611	A/T	cg09003973	chr2:102972529	NA	0.64	7.34	0.37	1.65e-12	Blood protein levels;
LUSC	cis	rs1595825	0.891	rs73061069	chr2:198908825	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-6.09	-0.32	3.14e-9	Ulcerative colitis;
LUSC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.28	-0.33	1.03e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs17102423	0.559	rs7160037	chr14:65490948	T/C	cg11161011	chr14:65562177	MAX	-0.73	-10.06	-0.48	5.59e-21	Obesity-related traits;
LUSC	cis	rs79387448	0.745	rs7572284	chr2:103119423	C/A	cg09003973	chr2:102972529	NA	0.86	8.6	0.43	3.07e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.14	0.36	5.87e-12	IgG glycosylation;
LUSC	cis	rs6060717	0.702	rs6060756	chr20:34608479	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.44	6.36	0.33	6.61e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.74	7.72	0.39	1.39e-13	Yeast infection;
LUSC	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg04310649	chr10:35416472	CREM	-0.4	-6.04	-0.31	4.2e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05901451	chr6:126070800	HEY2	0.56	8.46	0.42	8.35e-16	Endometrial cancer;
LUSC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg11632617	chr15:75315747	PPCDC	-0.48	-6.38	-0.33	6.02e-10	Blood trace element (Zn levels);
LUSC	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg19508488	chr2:152266495	RIF1	0.45	6.51	0.34	2.81e-10	Lung cancer;
LUSC	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.15	0.32	2.22e-9	Corneal astigmatism;
LUSC	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg03676636	chr4:99064102	C4orf37	0.35	7.65	0.39	2.21e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.36	-0.37	1.45e-12	Schizophrenia;
LUSC	cis	rs7577851	1.000	rs72837952	chr2:69742989	C/A	cg10773587	chr2:69614142	GFPT1	0.49	5.67	0.3	3.04e-8	Parkinson's disease (age of onset);
LUSC	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg11342453	chr6:26196699	NA	0.54	5.71	0.3	2.52e-8	Gout;Renal underexcretion gout;
LUSC	trans	rs2262909	0.719	rs12461632	chr19:22245089	G/A	cg17074339	chr11:11642133	GALNTL4	0.47	7.14	0.36	5.86e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg06640241	chr16:89574553	SPG7	0.87	16.22	0.66	4.75e-44	Multiple myeloma (IgH translocation);
LUSC	cis	rs7539409	0.915	rs1977119	chr1:84275509	A/G	cg10977910	chr1:84465055	TTLL7	0.64	6.05	0.31	3.84e-9	Alzheimer's disease;
LUSC	trans	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.1	-0.32	2.95e-9	Morning vs. evening chronotype;
LUSC	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg25214090	chr10:38739885	LOC399744	0.58	8.48	0.42	7.42e-16	Corneal astigmatism;
LUSC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg05084668	chr3:125655381	ALG1L	-0.48	-6.86	-0.35	3.28e-11	Blood pressure (smoking interaction);
LUSC	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-8.17	-0.41	6.38e-15	Axial length;
LUSC	cis	rs62400317	0.762	rs62436374	chr6:44874785	C/G	cg18551225	chr6:44695536	NA	-0.46	-7.44	-0.38	8.7e-13	Total body bone mineral density;
LUSC	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	1.05	23.86	0.79	3.67e-74	Schizophrenia;
LUSC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg05802129	chr4:122689817	NA	-0.5	-8.12	-0.41	9.17e-15	Type 2 diabetes;
LUSC	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg23752985	chr2:85803571	VAMP8	0.34	6.67	0.34	1.05e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg23950597	chr19:37808831	NA	0.61	7.24	0.37	3.18e-12	Coronary artery calcification;
LUSC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg06640241	chr16:89574553	SPG7	0.88	15.83	0.65	1.64e-42	Multiple myeloma (IgH translocation);
LUSC	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg02574844	chr11:5959923	NA	-0.43	-6.55	-0.34	2.15e-10	DNA methylation (variation);
LUSC	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg27411982	chr8:10470053	RP1L1	0.37	5.79	0.3	1.59e-8	Retinal vascular caliber;
LUSC	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg22815214	chr1:201083145	CACNA1S	0.6	10.41	0.49	3.67e-22	Permanent tooth development;
LUSC	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.06	-0.4	1.39e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08280861	chr8:58055591	NA	0.57	6.2	0.32	1.67e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg04450456	chr4:17643702	FAM184B	0.38	6.45	0.33	3.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs9976767	0.686	rs11203203	chr21:43836186	A/G	cg19517470	chr6:98488842	NA	-0.28	-6.02	-0.31	4.62e-9	Type 1 diabetes;
LUSC	cis	rs73198271	0.603	rs546606	chr8:8595843	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.74	-0.3	2.18e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4911253	0.509	rs66499347	chr20:31448696	C/T	cg13636640	chr20:31349939	DNMT3B	-0.81	-14.37	-0.62	8.49e-37	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.45	0.53	7.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg00546932	chr16:1947055	NA	0.37	5.68	0.3	2.97e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs10144321	0.810	rs2273800	chr14:100847707	C/T	cg14882082	chr14:100845427	WDR25	-0.42	-8.21	-0.41	4.73e-15	Menarche (age at onset);
LUSC	trans	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Depression;
LUSC	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.4	-0.38	1.12e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11828289	0.660	rs17306426	chr11:23222079	G/T	cg20040320	chr11:23191996	NA	0.59	6.28	0.33	1.05e-9	Cancer;
LUSC	cis	rs113835537	0.529	rs7943327	chr11:66256581	G/C	cg24851651	chr11:66362959	CCS	0.54	8.15	0.41	7.38e-15	Airway imaging phenotypes;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg18765479	chr12:132426275	PUS1	-0.38	-6.01	-0.31	4.94e-9	N-glycan levels;
LUSC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg26513180	chr16:89883248	FANCA	0.64	10.21	0.49	1.72e-21	Vitiligo;
LUSC	cis	rs7851660	0.809	rs10739526	chr9:100662671	T/C	cg13688889	chr9:100608707	NA	-0.54	-8.43	-0.42	1.05e-15	Strep throat;
LUSC	cis	rs926938	0.608	rs360612	chr1:115394747	G/A	cg12756093	chr1:115239321	AMPD1	0.53	8.12	0.41	9.04e-15	Autism;
LUSC	cis	rs12824058	0.737	rs2398508	chr12:130816460	G/A	cg24838063	chr12:130822603	PIWIL1	0.7	10.3	0.49	8.96e-22	Menopause (age at onset);
LUSC	cis	rs12541635	0.639	rs1032545	chr8:107005825	C/T	cg10147462	chr8:107024639	NA	0.68	14.29	0.62	1.73e-36	Age of smoking initiation;
LUSC	cis	rs7503807	0.967	rs12940622	chr17:78615571	G/A	cg09596252	chr17:78655493	RPTOR	0.44	7.43	0.38	9.4e-13	Obesity;
LUSC	cis	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg17411546	chr10:75410026	SYNPO2L	-0.42	-5.97	-0.31	6.03e-9	Inflammatory bowel disease;
LUSC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.39	-6.91	-0.35	2.42e-11	Eosinophil percentage of white cells;
LUSC	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg05625103	chr10:2543513	NA	0.42	6.38	0.33	6.06e-10	Age-related hearing impairment;
LUSC	cis	rs9473147	0.543	rs7738044	chr6:47469273	A/G	cg20196966	chr6:47445060	CD2AP	0.42	5.83	0.3	1.31e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.57	-11.56	-0.53	3.17e-26	Sense of smell;
LUSC	trans	rs2392780	0.536	rs2691039	chr8:128334662	A/G	cg10195415	chr17:73887371	TRIM65	0.41	6.51	0.34	2.68e-10	Breast cancer (early onset);
LUSC	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg24687543	chr11:63912206	MACROD1	0.47	5.96	0.31	6.34e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	1.04	14.11	0.61	9.12e-36	Exhaled nitric oxide levels;
LUSC	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg06627628	chr2:24431161	ITSN2	0.6	8.76	0.43	1.03e-16	Asthma;
LUSC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg22963979	chr7:1858916	MAD1L1	-0.74	-12.54	-0.57	7.99e-30	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	8.12e-16	Aortic root size;
LUSC	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg00677455	chr12:58241039	CTDSP2	0.57	7.62	0.38	2.6e-13	Multiple sclerosis;
LUSC	cis	rs11671005	0.693	rs11668821	chr19:58955813	G/A	cg13877915	chr19:58951672	ZNF132	0.45	5.78	0.3	1.71e-8	Mean platelet volume;
LUSC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg23711669	chr6:146136114	FBXO30	0.76	12.35	0.56	4.01e-29	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10132348	chr4:6784379	KIAA0232	-0.5	-6.45	-0.33	3.91e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg11245181	chr6:149772854	ZC3H12D	0.29	6.29	0.33	9.75e-10	Dupuytren's disease;
LUSC	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-11.0	-0.52	3.09e-24	Response to antipsychotic treatment;
LUSC	cis	rs1152591	0.505	rs1152593	chr14:64675895	C/T	cg21174375	chr14:64681225	SYNE2	0.33	5.74	0.3	2.11e-8	Atrial fibrillation;
LUSC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	0.92	13.9	0.61	5.47e-35	Breast cancer;
LUSC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg03233332	chr7:66118400	NA	-0.43	-6.17	-0.32	1.92e-9	Aortic root size;
LUSC	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg01097406	chr16:89675127	NA	-0.34	-6.64	-0.34	1.27e-10	Vitiligo;
LUSC	trans	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.02	-0.31	4.47e-9	Monocyte count;
LUSC	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg22431228	chr1:16359049	CLCNKA	-0.52	-10.41	-0.5	3.54e-22	Dilated cardiomyopathy;
LUSC	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg05163923	chr11:71159392	DHCR7	0.74	10.98	0.52	3.66e-24	Vitamin D levels;
LUSC	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg06532163	chr17:45867833	NA	0.34	6.41	0.33	4.93e-10	IgG glycosylation;
LUSC	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.37	-0.33	6.44e-10	Breast cancer;
LUSC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.91	-0.35	2.49e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.7	-0.39	1.6e-13	Glomerular filtration rate;
LUSC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.58	-12.04	-0.55	5.54e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.8	15.45	0.65	5.01e-41	Dental caries;
LUSC	cis	rs73206853	0.563	rs74869743	chr12:111204031	T/C	cg12870014	chr12:110450643	ANKRD13A	0.65	6.91	0.35	2.49e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.26	0.52	3.83e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg20129853	chr10:51489980	NA	-0.34	-6.77	-0.35	5.84e-11	Prostate-specific antigen levels;
LUSC	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19748678	chr4:122722346	EXOSC9	-0.44	-6.39	-0.33	5.73e-10	Type 2 diabetes;
LUSC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.65	9.87	0.48	2.53e-20	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20676401	chr10:5726466	C10orf18	-0.4	-6.02	-0.31	4.5e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg09365446	chr1:150670422	GOLPH3L	0.53	8.02	0.4	1.75e-14	Tonsillectomy;
LUSC	cis	rs62432291	0.681	rs420137	chr6:159652931	G/C	cg14500486	chr6:159655392	FNDC1	-0.52	-5.84	-0.3	1.22e-8	Joint mobility (Beighton score);
LUSC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.28	0.32	1.08e-9	Menarche (age at onset);
LUSC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg22868518	chr11:507468	RNH1	-0.64	-5.85	-0.3	1.19e-8	Body mass index;
LUSC	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg15644404	chr18:77186268	NFATC1	-0.67	-7.59	-0.38	3.25e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg11247378	chr22:39784982	NA	0.42	7.45	0.38	8.29e-13	IgG glycosylation;
LUSC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15664640	chr17:80829946	TBCD	-0.51	-8.89	-0.44	3.99e-17	Breast cancer;
LUSC	cis	rs7577696	0.554	rs34835885	chr2:32325414	G/A	cg02381751	chr2:32503542	YIPF4	-0.52	-6.66	-0.34	1.14e-10	Inflammatory biomarkers;
LUSC	cis	rs4132509	0.649	rs12038981	chr1:243866855	G/A	cg21452805	chr1:244014465	NA	0.65	6.91	0.35	2.45e-11	RR interval (heart rate);
LUSC	cis	rs12618769	0.597	rs11901568	chr2:99128621	C/T	cg10123293	chr2:99228465	UNC50	-0.46	-7.6	-0.38	2.97e-13	Bipolar disorder;
LUSC	cis	rs60695258	0.572	rs375795	chr4:87972465	C/T	cg10685359	chr4:87814065	C4orf36	-0.35	-6.24	-0.32	1.3e-9	Hematocrit;
LUSC	cis	rs4654899	0.643	rs651538	chr1:21097866	A/G	cg01072550	chr1:21505969	NA	-0.45	-6.75	-0.35	6.58e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg03461704	chr1:205818484	PM20D1	0.38	6.29	0.33	9.72e-10	Menarche (age at onset);
LUSC	cis	rs17621444	0.522	rs1117218	chr10:121817723	G/A	cg02041677	chr10:121771263	NA	-0.34	-6.39	-0.33	5.72e-10	IgG glycosylation;
LUSC	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg24955406	chr1:100503596	HIAT1	-0.55	-5.88	-0.31	9.8e-9	Carotid intima media thickness;
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.61	-10.03	-0.48	7.11e-21	Lymphocyte counts;
LUSC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03264133	chr6:25882463	NA	-0.42	-7.25	-0.37	2.86e-12	Blood metabolite levels;
LUSC	cis	rs6733011	0.538	rs10175560	chr2:99465418	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-6.17	-0.32	2.01e-9	Bipolar disorder;
LUSC	cis	rs4629180	0.586	rs2048252	chr2:102138384	C/T	cg01388757	chr2:102091195	RFX8	-0.35	-6.05	-0.31	3.82e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7605827	0.551	rs4668897	chr2:15480441	C/G	cg19274914	chr2:15703543	NA	0.41	7.46	0.38	7.4e-13	Educational attainment (years of education);
LUSC	cis	rs9837602	1.000	rs1038294	chr3:99503728	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.37	-6.02	-0.31	4.66e-9	Breast cancer;
LUSC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg12463550	chr7:65579703	CRCP	0.45	6.56	0.34	2.05e-10	Aortic root size;
LUSC	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg05360138	chr12:110035743	NA	0.54	7.06	0.36	9.55e-12	Neuroticism;
LUSC	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg22491629	chr6:157744540	C6orf35	-0.87	-10.69	-0.5	3.83e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs926392	0.896	rs4812357	chr20:37683071	C/T	cg27552599	chr20:37590471	DHX35	-0.33	-5.69	-0.3	2.73e-8	Dialysis-related mortality;
LUSC	cis	rs1950500	0.509	rs12882558	chr14:24819233	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.55	8.88	0.44	4.09e-17	Height;
LUSC	cis	rs2742234	0.955	rs2435384	chr10:43673731	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.36	-6.34	-0.33	7.61e-10	Hirschsprung disease;
LUSC	trans	rs7572263	0.528	rs13387151	chr2:209074635	A/C	cg15570148	chr3:61235985	FHIT	-0.48	-6.02	-0.31	4.52e-9	Glioma;Non-glioblastoma glioma;
LUSC	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg20991723	chr1:152506922	NA	0.51	9.74	0.47	6.76e-20	Hair morphology;
LUSC	trans	rs2392780	0.536	rs594154	chr8:128334911	G/A	cg10195415	chr17:73887371	TRIM65	0.41	6.49	0.33	3.12e-10	Breast cancer (early onset);
LUSC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.31	-0.37	1.97e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs1178968	0.901	rs6949855	chr7:72728130	A/G	cg25889504	chr7:72793014	NA	0.58	7.53	0.38	4.84e-13	Triglyceride levels;
LUSC	trans	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.43	-0.46	7.11e-19	Depression;
LUSC	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.88	-0.35	3.05e-11	Total body bone mineral density;
LUSC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18099408	chr3:52552593	STAB1	-0.44	-7.78	-0.39	9.25e-14	Bipolar disorder;
LUSC	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg01475377	chr6:109611718	NA	-0.38	-6.75	-0.35	6.74e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs10193935	0.792	rs13430031	chr2:42499968	C/T	cg27598129	chr2:42591480	NA	-0.59	-8.04	-0.4	1.59e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	5.9	0.31	9.03e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg26335602	chr6:28129616	ZNF389	0.49	6.56	0.34	2e-10	Parkinson's disease;
LUSC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg04362960	chr10:104952993	NT5C2	0.58	8.45	0.42	9e-16	Immature fraction of reticulocytes;Schizophrenia;
LUSC	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg23649088	chr2:200775458	C2orf69	-0.55	-6.98	-0.36	1.64e-11	Schizophrenia;
LUSC	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg26647111	chr11:31128758	NA	-0.41	-5.89	-0.31	9.29e-9	Red blood cell count;
LUSC	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.94	0.48	1.47e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17095355	1.000	rs11194926	chr10:111700922	A/G	cg00817464	chr10:111662876	XPNPEP1	0.61	7.48	0.38	6.76e-13	Biliary atresia;
LUSC	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg14092571	chr14:90743983	NA	-0.36	-5.98	-0.31	5.76e-9	Mortality in heart failure;
LUSC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.95	-0.31	6.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg04117972	chr1:227635322	NA	0.61	6.54	0.34	2.3e-10	Major depressive disorder;
LUSC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-10.51	-0.5	1.69e-22	Gut microbiome composition (summer);
LUSC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-12.16	-0.55	1.99e-28	Chronic sinus infection;
LUSC	cis	rs3106136	0.527	rs4235050	chr4:95157156	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.41	-0.42	1.2e-15	Capecitabine sensitivity;
LUSC	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg23601095	chr6:26197514	HIST1H3D	0.69	7.46	0.38	7.54e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.77	-12.16	-0.55	2.12e-28	Tonsillectomy;
LUSC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.39	-7.81	-0.39	7.63e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	0.93	18.13	0.7	1.26e-51	Cognitive function;
LUSC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg11645453	chr3:52864694	ITIH4	0.34	7.9	0.4	4.07e-14	Bipolar disorder;
LUSC	trans	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg21659725	chr3:3221576	CRBN	-0.71	-7.8	-0.39	7.78e-14	Menarche (age at onset);
LUSC	cis	rs7582720	1.000	rs7582720	chr2:203753072	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg02951883	chr7:2050386	MAD1L1	-0.57	-10.31	-0.49	8.07e-22	Schizophrenia;
LUSC	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.49	-6.21	-0.32	1.55e-9	Schizophrenia;
LUSC	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg13902645	chr11:5959945	NA	-0.55	-7.96	-0.4	2.74e-14	DNA methylation (variation);
LUSC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25072359	chr17:41440525	NA	0.62	9.05	0.44	1.2e-17	Menopause (age at onset);
LUSC	cis	rs9341835	0.772	rs9449233	chr6:64138234	G/T	cg03326410	chr6:64151739	NA	-0.38	-6.26	-0.32	1.15e-9	Schizophrenia;
LUSC	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg24562669	chr7:97807699	LMTK2	0.48	8.76	0.43	1.01e-16	Breast cancer;
LUSC	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-12.0	-0.55	8.2e-28	Total body bone mineral density;
LUSC	cis	rs9831754	0.906	rs2102601	chr3:78410536	G/A	cg06138941	chr3:78371609	NA	-0.65	-9.4	-0.46	8.73e-19	Calcium levels;
LUSC	cis	rs9788721	0.967	rs72740955	chr15:78849779	C/T	cg06917634	chr15:78832804	PSMA4	-0.47	-6.31	-0.33	9.05e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg07636037	chr3:49044803	WDR6	0.44	6.37	0.33	6.4e-10	Resting heart rate;
LUSC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.98	0.55	9.29e-28	Chronic sinus infection;
LUSC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg05872129	chr22:39784769	NA	-0.58	-9.97	-0.48	1.18e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	trans	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg18187862	chr3:45730750	SACM1L	-0.53	-6.45	-0.33	3.92e-10	Primary sclerosing cholangitis;
LUSC	trans	rs11935423	0.778	rs11943031	chr4:100489204	G/A	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.01	-0.31	4.77e-9	Gut microbiome composition (summer);
LUSC	cis	rs6674970	1.000	rs6656450	chr1:151089602	A/T	cg11822372	chr1:151115635	SEMA6C	0.53	8.11	0.41	9.8e-15	Childhood ear infection;
LUSC	cis	rs981844	0.712	rs6535957	chr4:154749862	C/A	cg14289246	chr4:154710475	SFRP2	-0.46	-6.32	-0.33	8.22e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18932078	chr1:2524107	MMEL1	-0.3	-6.44	-0.33	4.23e-10	Ulcerative colitis;
LUSC	cis	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg02972257	chr16:68554789	NA	-0.52	-6.62	-0.34	1.45e-10	Ulcerative colitis;
LUSC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg27165867	chr14:105738592	BRF1	-0.56	-8.49	-0.42	6.9e-16	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	7.08	0.36	8.4e-12	Retinal vascular caliber;
LUSC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg21770322	chr7:97807741	LMTK2	-0.41	-7.15	-0.36	5.52e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17661538	0.542	rs71497233	chr10:18423082	G/A	cg03634479	chr10:18430412	CACNB2	0.59	5.78	0.3	1.7e-8	Response to antipsychotic treatment;
LUSC	cis	rs7927771	0.524	rs11039431	chr11:47872012	G/T	cg20307385	chr11:47447363	PSMC3	0.46	6.77	0.35	5.93e-11	Subjective well-being;
LUSC	cis	rs10905065	0.965	rs7100576	chr10:5784649	G/A	cg11519256	chr10:5708881	ASB13	0.4	5.83	0.3	1.33e-8	Menopause (age at onset);
LUSC	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg00999904	chr2:3704751	ALLC	0.45	7.48	0.38	6.49e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg19743168	chr1:23544995	NA	0.47	10.23	0.49	1.53e-21	Height;
LUSC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg26769984	chr7:1090371	C7orf50	0.57	7.85	0.39	5.89e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs3820068	0.608	rs7514858	chr1:16035246	G/A	cg13390004	chr1:15929781	NA	0.42	6.82	0.35	4.38e-11	Systolic blood pressure;
LUSC	cis	rs778371	0.723	rs1078323	chr2:233681512	T/G	cg08000102	chr2:233561755	GIGYF2	-0.77	-12.53	-0.57	8.92e-30	Schizophrenia;
LUSC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.59	8.92	0.44	3.07e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.65	10.09	0.48	4.41e-21	Bladder cancer;
LUSC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.38	-0.33	5.89e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs834603	0.541	rs1704965	chr7:47470215	C/T	cg09696706	chr7:47479511	TNS3	0.32	5.75	0.3	2.01e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg00982548	chr2:198649783	BOLL	-0.58	-7.15	-0.36	5.37e-12	Ulcerative colitis;
LUSC	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg04176472	chr15:90893244	GABARAPL3	0.33	5.91	0.31	8.26e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg25922239	chr6:33757077	LEMD2	-0.41	-6.25	-0.32	1.25e-9	Crohn's disease;
LUSC	cis	rs7582720	1.000	rs72926783	chr2:203815740	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.67	9.65	0.47	1.39e-19	Educational attainment;
LUSC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg22800045	chr5:56110881	MAP3K1	0.58	7.97	0.4	2.48e-14	Coronary artery disease;
LUSC	cis	rs6540559	0.673	rs17015361	chr1:210018901	C/G	cg21951975	chr1:209979733	IRF6	0.55	6.88	0.35	2.95e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg26380479	chr7:97908229	NA	-0.27	-6.08	-0.32	3.2e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4077515	0.901	rs11791262	chr9:139271919	C/T	cg14019695	chr9:139328340	INPP5E	0.44	8.29	0.41	2.87e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs17401966	0.522	rs12133617	chr1:10288463	C/T	cg17425144	chr1:10567563	PEX14	-0.34	-6.05	-0.31	3.83e-9	Hepatocellular carcinoma;
LUSC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg17724175	chr1:150552817	MCL1	-0.47	-8.36	-0.42	1.76e-15	Blood protein levels;
LUSC	trans	rs2587949	0.593	rs2587931	chr3:4237523	T/C	cg15139668	chr4:4577005	NA	-0.4	-6.17	-0.32	1.96e-9	Periodontitis (DPAL);
LUSC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg21433313	chr16:3507492	NAT15	-0.78	-9.37	-0.46	1.09e-18	Tuberculosis;
LUSC	cis	rs11250464	0.794	rs11250487	chr10:1434168	C/A	cg26394196	chr10:1453818	ADARB2	-0.37	-6.31	-0.33	8.76e-10	Radiation response;
LUSC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.43	5.78	0.3	1.71e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs308403	0.533	rs309377	chr4:123676353	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	1.0	18.39	0.71	1.11e-52	Blood protein levels;
LUSC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg06640241	chr16:89574553	SPG7	0.74	10.22	0.49	1.68e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg09165964	chr15:75287851	SCAMP5	-0.94	-9.09	-0.45	9.01e-18	Lung cancer;
LUSC	cis	rs7246657	0.551	rs4806413	chr19:37617716	A/T	cg23950597	chr19:37808831	NA	-0.54	-5.86	-0.31	1.11e-8	Coronary artery calcification;
LUSC	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs600231	0.542	rs12360896	chr11:65238306	G/T	cg17120908	chr11:65337727	SSSCA1	-0.62	-8.95	-0.44	2.47e-17	Bone mineral density;
LUSC	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg17410650	chr12:54324560	NA	-0.6	-10.04	-0.48	6.44e-21	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg18681998	chr4:17616180	MED28	0.86	15.83	0.65	1.74e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4285028	0.747	rs6791882	chr3:121373058	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-12.8	-0.57	8.41e-31	Multiple sclerosis;
LUSC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	14.01	0.61	2.15e-35	Platelet count;
LUSC	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg17252645	chr8:143867129	LY6D	0.38	6.68	0.34	1.01e-10	Urinary tract infection frequency;
LUSC	cis	rs6772849	0.708	rs12491942	chr3:128421469	C/G	cg08795948	chr3:128337044	NA	0.4	5.73	0.3	2.26e-8	Monocyte percentage of white cells;Monocyte count;
LUSC	cis	rs2219968	0.676	rs2879369	chr8:78839710	C/T	cg00738934	chr8:78996279	NA	-0.35	-5.9	-0.31	8.72e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg13010199	chr12:38710504	ALG10B	0.47	7.14	0.36	6e-12	Bladder cancer;
LUSC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.84	15.1	0.64	1.28e-39	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.65	10.02	0.48	7.79e-21	Corneal astigmatism;
LUSC	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.51	7.91	0.4	3.75e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7605827	0.930	rs722328	chr2:15657164	T/C	cg19274914	chr2:15703543	NA	0.46	8.83	0.43	6.22e-17	Educational attainment (years of education);
LUSC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg18827107	chr12:86230957	RASSF9	-0.46	-6.97	-0.36	1.74e-11	Major depressive disorder;
LUSC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	10.85	0.51	1.1e-23	Total body bone mineral density;
LUSC	cis	rs7759001	0.817	rs4711149	chr6:27365845	C/A	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg20016023	chr10:99160130	RRP12	-0.33	-8.07	-0.4	1.26e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg04369109	chr6:150039330	LATS1	-0.58	-8.62	-0.43	2.72e-16	Lung cancer;
LUSC	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg27489772	chr12:121021490	NA	-0.56	-7.39	-0.38	1.16e-12	Type 1 diabetes nephropathy;
LUSC	cis	rs2857891	0.695	rs2346002	chr11:6987741	T/C	cg14883916	chr11:6947541	ZNF215	0.42	5.65	0.3	3.39e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg24690094	chr11:67383802	NA	-0.38	-7.41	-0.38	1.07e-12	Mean corpuscular volume;
LUSC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.38	0.64	9.74e-41	Platelet count;
LUSC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg15790184	chr11:494944	RNH1	0.53	5.75	0.3	1.97e-8	Body mass index;
LUSC	trans	rs459571	0.959	rs408307	chr9:136892523	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.73	11.87	0.54	2.37e-27	Platelet distribution width;
LUSC	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg17757837	chr7:157058334	UBE3C	0.8	12.16	0.55	2.12e-28	Body mass index;
LUSC	cis	rs5770917	1.000	rs12627787	chr22:51012381	C/T	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.61	-5.67	-0.3	3.03e-8	Narcolepsy;
LUSC	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg22431228	chr1:16359049	CLCNKA	0.44	8.83	0.43	6.09e-17	Dilated cardiomyopathy;
LUSC	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.39	-6.91	-0.35	2.42e-11	Eosinophil percentage of white cells;
LUSC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-6.18	-0.32	1.82e-9	Total body bone mineral density;
LUSC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18876405	chr7:65276391	NA	-0.53	-8.44	-0.42	9.69e-16	Aortic root size;
LUSC	cis	rs877282	0.898	rs36064821	chr10:760952	C/T	cg17470449	chr10:769945	NA	0.52	7.39	0.38	1.16e-12	Uric acid levels;
LUSC	cis	rs6028335	0.674	rs66513266	chr20:37597410	G/T	cg27552599	chr20:37590471	DHX35	0.45	5.66	0.3	3.21e-8	Alcohol and nicotine co-dependence;
LUSC	cis	rs7560272	0.723	rs1083919	chr2:73713863	C/G	cg20560298	chr2:73613845	ALMS1	0.46	7.19	0.37	4.17e-12	Schizophrenia;
LUSC	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg03433033	chr1:76189801	ACADM	-0.46	-6.88	-0.35	2.95e-11	Daytime sleep phenotypes;
LUSC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.77	0.3	1.83e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4925114	0.532	rs11655029	chr17:17649172	T/C	cg09796270	chr17:17721594	SREBF1	-0.43	-7.24	-0.37	3.15e-12	Body mass index;
LUSC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg26335602	chr6:28129616	ZNF389	0.46	6.06	0.31	3.64e-9	Parkinson's disease;
LUSC	trans	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg21659725	chr3:3221576	CRBN	-0.67	-7.77	-0.39	9.81e-14	Menarche (age at onset);
LUSC	cis	rs9687065	1.000	rs78013255	chr5:148397622	T/C	cg23229984	chr5:148520753	ABLIM3	-0.39	-5.8	-0.3	1.58e-8	Diastolic blood pressure;
LUSC	cis	rs6005807	0.719	rs9625524	chr22:29052951	C/T	cg12565055	chr22:29076175	TTC28	0.52	5.7	0.3	2.63e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs7291412	0.540	rs9627391	chr22:46447097	C/T	cg00785112	chr22:46450059	C22orf26;LOC150381	0.34	5.7	0.3	2.57e-8	Dupuytren's disease;Subjective well-being;
LUSC	cis	rs912057	0.932	rs1294404	chr6:6735022	G/A	cg06612196	chr6:6737390	NA	0.52	9.7	0.47	9.06e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs55871839	0.708	rs4738732	chr8:59809943	A/G	cg07426533	chr8:59803705	TOX	0.36	5.82	0.3	1.36e-8	Pneumonia;
LUSC	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg21138405	chr5:131827807	IRF1	0.35	6.24	0.32	1.34e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg12863693	chr15:85201151	NMB	0.36	7.35	0.37	1.56e-12	Schizophrenia;
LUSC	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg00484396	chr16:3507460	NAT15	-0.42	-6.79	-0.35	5.25e-11	Body mass index (adult);
LUSC	cis	rs11153147	0.730	rs2798646	chr6:109310596	C/A	cg05315195	chr6:109294784	ARMC2	0.51	5.65	0.3	3.43e-8	Mean corpuscular volume;
LUSC	cis	rs6460942	0.643	rs80264734	chr7:12233800	T/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.09	-0.32	3.08e-9	Coronary artery disease;
LUSC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg07507251	chr3:52567010	NT5DC2	0.33	6.37	0.33	6.25e-10	Bipolar disorder;
LUSC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg18180107	chr4:99064573	C4orf37	0.42	5.88	0.31	1.02e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4343996	0.727	rs7798418	chr7:3387048	C/G	cg21248987	chr7:3385318	SDK1	-0.35	-5.91	-0.31	8.23e-9	Motion sickness;
LUSC	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg06462663	chr19:18546047	ISYNA1	0.44	7.47	0.38	6.97e-13	Breast cancer;
LUSC	cis	rs155346	1.000	rs7728075	chr5:139382353	G/A	cg01090482	chr5:139365336	NRG2	-0.38	-6.21	-0.32	1.55e-9	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg05855489	chr10:104503620	C10orf26	0.72	11.27	0.52	3.51e-25	Waist circumference;Hip circumference;
LUSC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.21	0.37	3.76e-12	Platelet count;
LUSC	cis	rs4363385	0.626	rs6664183	chr1:153064002	A/G	cg07796016	chr1:152779584	LCE1C	-0.4	-6.25	-0.32	1.27e-9	Inflammatory skin disease;
LUSC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg26338869	chr17:61819248	STRADA	0.41	6.02	0.31	4.68e-9	Prudent dietary pattern;
LUSC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs877282	0.583	rs11253424	chr10:813426	C/T	cg13775593	chr10:823151	NA	0.26	5.78	0.3	1.68e-8	Uric acid levels;
LUSC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg22496339	chr2:162101262	NA	0.73	11.88	0.54	2.23e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg19748678	chr4:122722346	EXOSC9	0.5	7.67	0.39	1.86e-13	Type 2 diabetes;
LUSC	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg12863693	chr15:85201151	NMB	0.36	7.09	0.36	8e-12	Schizophrenia;
LUSC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.18	0.37	4.5e-12	Bipolar disorder;
LUSC	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg26195577	chr20:24973756	C20orf3	-1.12	-18.25	-0.71	4.21e-52	Blood protein levels;
LUSC	cis	rs4631830	0.863	rs7081532	chr10:51526093	A/G	cg20129853	chr10:51489980	NA	-0.33	-6.72	-0.35	7.66e-11	Prostate-specific antigen levels;
LUSC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11644478	chr21:40555479	PSMG1	-0.65	-10.18	-0.49	2.24e-21	Menarche (age at onset);
LUSC	cis	rs11630290	0.736	rs4777370	chr15:64160104	G/A	cg12036633	chr15:63758958	NA	0.59	6.4	0.33	5.39e-10	Iris characteristics;
LUSC	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg00898013	chr13:113819073	PROZ	-0.57	-8.09	-0.4	1.12e-14	Platelet distribution width;
LUSC	cis	rs4474465	1.000	rs10899508	chr11:78170708	T/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.74	-0.3	2.14e-8	Alzheimer's disease (survival time);
LUSC	cis	rs1996152	0.543	rs4789658	chr17:72389526	A/T	cg23221732	chr17:72383708	NA	0.32	6.25	0.32	1.24e-9	Interleukin-12p70 levels;
LUSC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02187348	chr16:89574699	SPG7	-0.55	-8.91	-0.44	3.36e-17	Multiple myeloma (IgH translocation);
LUSC	cis	rs9392556	0.829	rs853417	chr6:4113123	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.37	-6.46	-0.33	3.68e-10	Blood metabolite levels;
LUSC	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg10523860	chr14:103875565	MARK3	-0.37	-5.82	-0.3	1.37e-8	Body mass index;
LUSC	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg17411546	chr10:75410026	SYNPO2L	0.52	7.98	0.4	2.41e-14	Inflammatory bowel disease;
LUSC	trans	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg26043149	chr18:55253948	FECH	-0.49	-7.32	-0.37	1.92e-12	Bone mineral density;
LUSC	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-9.0	-0.44	1.76e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg21775007	chr8:11205619	TDH	0.81	13.85	0.6	8.77e-35	Retinal vascular caliber;
LUSC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg23711669	chr6:146136114	FBXO30	0.74	12.62	0.57	3.96e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs66887589	0.934	rs2389873	chr4:120554714	A/G	cg09307838	chr4:120376055	NA	-0.49	-7.48	-0.38	6.83e-13	Diastolic blood pressure;
LUSC	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg05283184	chr6:79620031	NA	-0.56	-11.74	-0.54	7.3e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg15448220	chr1:150897856	SETDB1	0.43	6.22	0.32	1.45e-9	Melanoma;
LUSC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	11.27	0.52	3.5e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg25019033	chr10:957182	NA	-0.53	-6.81	-0.35	4.62e-11	Eosinophil percentage of granulocytes;
LUSC	trans	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg15556689	chr8:8085844	FLJ10661	0.49	7.18	0.37	4.43e-12	Retinal vascular caliber;
LUSC	cis	rs6594499	0.872	rs7723819	chr5:110427347	A/G	cg04022379	chr5:110408740	TSLP	-0.52	-7.77	-0.39	9.99e-14	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg01879757	chr17:41196368	BRCA1	-0.46	-6.92	-0.35	2.26e-11	Menopause (age at onset);
LUSC	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-9.64	-0.47	1.4e-19	Body mass index;
LUSC	cis	rs1044826	0.642	rs6771831	chr3:139177585	C/T	cg00490450	chr3:139108681	COPB2	0.46	6.98	0.36	1.63e-11	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg10523679	chr1:76189770	ACADM	-0.49	-7.06	-0.36	9.81e-12	Daytime sleep phenotypes;
LUSC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.93	0.31	7.45e-9	Lung cancer;
LUSC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg10729496	chr3:10149963	C3orf24	0.54	7.17	0.37	4.98e-12	Alzheimer's disease;
LUSC	cis	rs12044355	0.896	rs12723735	chr1:231860372	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.4	5.69	0.3	2.74e-8	Alzheimer's disease;
LUSC	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.41	-0.38	1.04e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg09323728	chr8:95962352	TP53INP1	0.37	7.08	0.36	8.39e-12	Type 2 diabetes;
LUSC	trans	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg07393940	chr7:158741817	NA	0.38	6.89	0.35	2.77e-11	Life satisfaction;
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.57	-9.55	-0.46	2.94e-19	Lymphocyte counts;
LUSC	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg26395211	chr5:140044315	WDR55	-0.37	-5.7	-0.3	2.69e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg08601574	chr20:25228251	PYGB	0.44	6.76	0.35	6.18e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.89	17.23	0.69	4.95e-48	Colorectal cancer;
LUSC	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg25566285	chr7:158114605	PTPRN2	0.33	6.07	0.32	3.43e-9	Calcium levels;
LUSC	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg00898013	chr13:113819073	PROZ	0.55	7.96	0.4	2.76e-14	Platelet distribution width;
LUSC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.16e-9	Diabetic kidney disease;
LUSC	cis	rs58950470	0.927	rs1193851	chr11:65386206	C/G	cg05805236	chr11:65401703	PCNXL3	0.35	5.7	0.3	2.66e-8	Schizophrenia;
LUSC	cis	rs4363385	0.773	rs310122	chr1:153064288	C/T	cg00922841	chr1:152955080	SPRR1A	0.38	6.49	0.33	3.11e-10	Inflammatory skin disease;
LUSC	cis	rs7106204	0.764	rs11821644	chr11:24212686	T/C	ch.11.24196551F	chr11:24239977	NA	0.93	7.86	0.39	5.41e-14	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2979489	0.945	rs34960391	chr8:30332723	G/A	cg26383811	chr8:30366931	RBPMS	-0.51	-8.03	-0.4	1.66e-14	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs11031096	0.502	rs4910598	chr11:4101368	C/T	cg18678763	chr11:4115507	RRM1	-0.48	-6.27	-0.32	1.09e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg09699651	chr6:150184138	LRP11	0.45	7.17	0.37	4.98e-12	Testicular germ cell tumor;
LUSC	trans	rs2262909	1.000	rs2078089	chr19:22209753	A/T	cg05197062	chr11:11642011	GALNTL4	-0.51	-7.08	-0.36	8.34e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4654899	0.606	rs651085	chr1:21097783	A/G	cg01072550	chr1:21505969	NA	0.42	6.37	0.33	6.09e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg09904177	chr6:26538194	HMGN4	0.76	14.42	0.62	5.75e-37	Intelligence (multi-trait analysis);
LUSC	trans	rs72674100	1.000	rs2865754	chr4:97992711	T/C	cg09670535	chr1:18959427	PAX7	-0.61	-6.27	-0.32	1.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.3e-11	Uric acid levels;
LUSC	cis	rs7000551	0.751	rs2461482	chr8:22382898	C/T	cg12081754	chr8:22256438	SLC39A14	0.46	6.82	0.35	4.23e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg24375607	chr4:120327624	NA	0.76	12.17	0.55	1.85e-28	Corneal astigmatism;
LUSC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.65	-11.16	-0.52	8.28e-25	Diastolic blood pressure;
LUSC	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	trans	rs4734806	0.579	rs72677051	chr8:105873452	C/G	cg19267248	chr12:98849532	NA	0.39	6.06	0.31	3.58e-9	Periodontitis (DPAL);
LUSC	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.1	-0.32	2.98e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs62400317	0.859	rs12205379	chr6:45215074	G/A	cg18551225	chr6:44695536	NA	-0.44	-7.31	-0.37	2.04e-12	Total body bone mineral density;
LUSC	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg17031739	chr1:67600172	NA	0.46	7.21	0.37	3.76e-12	Psoriasis;
LUSC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg16447950	chr5:562315	NA	-0.55	-6.79	-0.35	5.23e-11	Obesity-related traits;
LUSC	cis	rs17227506	0.679	rs34216318	chr8:13444780	T/C	cg03566418	chr8:13424080	C8orf48	0.4	6.13	0.32	2.52e-9	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg27427491	chr17:78079615	GAA	-0.36	-6.58	-0.34	1.83e-10	Yeast infection;
LUSC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06544989	chr22:39130855	UNC84B	0.34	5.81	0.3	1.45e-8	Menopause (age at onset);
LUSC	cis	rs11031096	0.678	rs11031219	chr11:4197578	G/A	cg18678763	chr11:4115507	RRM1	-0.4	-5.69	-0.3	2.75e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08704250	chr15:31115839	NA	0.59	9.23	0.45	3.08e-18	Huntington's disease progression;
LUSC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.63	-0.43	2.45e-16	Lung cancer;
LUSC	cis	rs67072384	0.818	rs1872128	chr11:72465526	C/T	cg04827223	chr11:72435913	ARAP1	-0.73	-6.35	-0.33	7.13e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg20936604	chr3:58311152	NA	-0.73	-7.06	-0.36	9.42e-12	Cholesterol, total;
LUSC	cis	rs60154123	0.505	rs77990373	chr1:210041111	T/C	cg23283495	chr1:209979779	IRF6	0.66	7.9	0.4	4.2e-14	Coronary artery disease;
LUSC	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg12473912	chr3:136751656	NA	0.38	6.75	0.35	6.7e-11	Neuroticism;
LUSC	cis	rs4072705	0.646	rs2416933	chr9:127245529	C/T	cg13476313	chr9:127244764	NR5A1	-0.32	-6.43	-0.33	4.48e-10	Menarche (age at onset);
LUSC	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg03465714	chr1:152285911	FLG	-0.42	-5.85	-0.3	1.17e-8	Atopic dermatitis;
LUSC	cis	rs662064	1.000	rs662064	chr1:10557251	T/C	cg17425144	chr1:10567563	PEX14	0.35	5.69	0.3	2.85e-8	Asthma;
LUSC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg03732007	chr1:2071316	PRKCZ	0.45	7.1	0.36	7.69e-12	Height;
LUSC	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg21681030	chr2:46777652	RHOQ	0.46	6.35	0.33	7.24e-10	Height;
LUSC	cis	rs9649465	0.551	rs10255400	chr7:123388036	G/A	cg03229431	chr7:123269106	ASB15	-0.53	-8.58	-0.42	3.67e-16	Migraine;
LUSC	cis	rs4253772	0.872	rs79700435	chr22:46638211	G/A	cg09491104	chr22:46646882	C22orf40	-0.59	-6.44	-0.33	4.09e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg05868516	chr6:26286170	HIST1H4H	-0.35	-5.78	-0.3	1.73e-8	Educational attainment;
LUSC	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg25205988	chr1:146714368	CHD1L	-1.09	-8.8	-0.43	7.74e-17	Mitochondrial DNA levels;
LUSC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.81	-0.3	1.43e-8	Platelet count;
LUSC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	-0.46	-6.99	-0.36	1.5e-11	Systemic lupus erythematosus;
LUSC	cis	rs12760731	0.668	rs4573483	chr1:178268075	C/A	cg00404053	chr1:178313656	RASAL2	0.49	6.05	0.31	3.89e-9	Obesity-related traits;
LUSC	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.59	8.12	0.41	9.28e-15	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg10018233	chr7:150070692	REPIN1	0.38	6.54	0.34	2.32e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg12463550	chr7:65579703	CRCP	0.47	6.78	0.35	5.51e-11	Aortic root size;
LUSC	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.24	0.52	4.48e-25	Eye color traits;
LUSC	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	8.12	0.41	9.26e-15	Response to antipsychotic treatment;
LUSC	trans	rs4942242	0.663	rs34595450	chr13:44221245	A/G	cg19169023	chr15:41853346	TYRO3	-0.6	-8.99	-0.44	1.81e-17	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9513627	1.000	rs9582302	chr13:100125985	A/T	cg25919922	chr13:100150906	NA	-0.74	-6.46	-0.33	3.69e-10	Obesity-related traits;
LUSC	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.19	-0.37	4.36e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg21053147	chr12:120880522	NA	-0.49	-6.11	-0.32	2.77e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs55665837	1.000	rs3923294	chr11:14441402	T/G	cg19336497	chr11:14380999	RRAS2	-0.37	-7.53	-0.38	4.9e-13	Vitamin D levels;
LUSC	cis	rs6066835	1.000	rs73138221	chr20:47349525	T/C	cg18078177	chr20:47281410	PREX1	0.75	6.33	0.33	7.83e-10	Multiple myeloma;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg26035463	chr12:117627651	FBXO21	0.44	6.09	0.32	3.05e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg21775007	chr8:11205619	TDH	-0.5	-6.8	-0.35	4.83e-11	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.31	0.49	8.09e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg25039879	chr17:56429692	SUPT4H1	0.72	9.27	0.45	2.35e-18	Cognitive test performance;
LUSC	cis	rs1160297	0.517	rs1451462	chr2:53123412	C/T	cg07782112	chr2:53107842	NA	-0.34	-5.74	-0.3	2.08e-8	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21984481	chr17:79567631	NPLOC4	-0.73	-15.54	-0.65	2.39e-41	Eye color traits;
LUSC	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg18755752	chr8:142205143	DENND3	-0.68	-12.3	-0.56	6.23e-29	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg04267008	chr7:1944627	MAD1L1	0.45	6.48	0.33	3.28e-10	Schizophrenia;
LUSC	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.73	-0.35	7.4e-11	Mood instability;
LUSC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.82	14.68	0.63	5.55e-38	Blood protein levels;
LUSC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-7.93	-0.4	3.37e-14	Chronic sinus infection;
LUSC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg24675658	chr1:53192096	ZYG11B	-0.68	-11.06	-0.52	1.93e-24	Monocyte count;
LUSC	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg21466736	chr12:48725269	NA	-0.32	-5.65	-0.3	3.49e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg21775007	chr8:11205619	TDH	-0.43	-6.15	-0.32	2.26e-9	Myopia (pathological);
LUSC	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg13010199	chr12:38710504	ALG10B	0.56	7.58	0.38	3.45e-13	Resting heart rate;
LUSC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.13	0.48	3.24e-21	Bipolar disorder;
LUSC	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg05294307	chr14:35346193	BAZ1A	-0.57	-6.58	-0.34	1.82e-10	Psoriasis;
LUSC	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs9875589	0.509	rs11718142	chr3:14018793	G/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	6.83	0.35	3.91e-11	Ovarian reserve;
LUSC	cis	rs7561273	0.586	rs13418279	chr2:24349218	G/T	cg20701182	chr2:24300061	SF3B14	0.46	5.87	0.31	1.05e-8	Quantitative traits;
LUSC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg09796270	chr17:17721594	SREBF1	-0.34	-5.97	-0.31	5.92e-9	Total body bone mineral density;
LUSC	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg25024717	chr12:54324583	NA	-0.38	-6.43	-0.33	4.51e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg25174290	chr11:3078921	CARS	-0.42	-6.32	-0.33	8.33e-10	Calcium levels;
LUSC	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg04369109	chr6:150039330	LATS1	-0.54	-7.5	-0.38	5.75e-13	Lung cancer;
LUSC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg11645453	chr3:52864694	ITIH4	-0.37	-8.11	-0.41	9.81e-15	Bipolar disorder;
LUSC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.99	0.36	1.53e-11	Bipolar disorder;
LUSC	cis	rs4974559	0.501	rs1250129	chr4:1254930	C/T	cg02980000	chr4:1222292	CTBP1	0.62	6.98	0.36	1.6e-11	Systolic blood pressure;
LUSC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg04369109	chr6:150039330	LATS1	-0.58	-8.42	-0.42	1.14e-15	Lung cancer;
LUSC	cis	rs7945718	0.905	rs7124484	chr11:12745271	G/A	cg25843174	chr11:12811716	TEAD1	0.33	7.31	0.37	2.03e-12	Educational attainment (years of education);
LUSC	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg18721089	chr20:30220636	NA	-0.39	-6.08	-0.32	3.28e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs926392	0.572	rs6129156	chr20:37672209	A/C	cg16355469	chr20:37678765	NA	0.54	7.38	0.37	1.27e-12	Dialysis-related mortality;
LUSC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg06784218	chr1:46089804	CCDC17	0.51	10.03	0.48	7.26e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9467773	0.550	rs9379874	chr6:26440429	A/T	cg09904177	chr6:26538194	HMGN4	-0.56	-8.68	-0.43	1.81e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.06e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg03474202	chr17:45855739	NA	-0.3	-6.93	-0.35	2.14e-11	IgG glycosylation;
LUSC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.99	-0.48	9.74e-21	Platelet count;
LUSC	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg13010199	chr12:38710504	ALG10B	0.52	7.89	0.4	4.44e-14	Morning vs. evening chronotype;
LUSC	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-7.46	-0.38	7.67e-13	Schizophrenia;
LUSC	trans	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg06521331	chr12:34319734	NA	-0.39	-6.1	-0.32	2.98e-9	Bladder cancer;
LUSC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg09904177	chr6:26538194	HMGN4	-0.43	-6.69	-0.34	9.67e-11	Schizophrenia;
LUSC	cis	rs713477	0.712	rs72717779	chr14:55893440	A/G	cg13175173	chr14:55914753	NA	-0.29	-5.97	-0.31	6.14e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg22705602	chr4:152727874	NA	-0.32	-6.51	-0.34	2.76e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6500395	1.000	rs7196823	chr16:48616278	G/A	cg04672837	chr16:48644449	N4BP1	0.5	7.48	0.38	6.46e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs10843647	1.000	rs6416250	chr12:30325443	T/C	cg12718339	chr12:29936407	TMTC1	-0.36	-5.94	-0.31	7.29e-9	Glucose homeostasis traits;
LUSC	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg09835421	chr16:68378352	PRMT7	-0.48	-5.95	-0.31	6.7e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg05481257	chr2:20870211	GDF7	-0.37	-6.93	-0.35	2.12e-11	Abdominal aortic aneurysm;
LUSC	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg16482183	chr6:26056742	HIST1H1C	0.46	6.89	0.35	2.72e-11	Height;
LUSC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.79	-0.47	4.69e-20	Gut microbiome composition (summer);
LUSC	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg19743168	chr1:23544995	NA	0.43	9.3	0.45	1.9e-18	Height;
LUSC	cis	rs4494114	1.000	rs9439082	chr1:39344055	G/A	cg25970120	chr1:39325951	RRAGC	-0.41	-6.47	-0.33	3.56e-10	Blood protein levels;
LUSC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg16680214	chr1:154839983	KCNN3	-0.37	-6.51	-0.34	2.82e-10	Schizophrenia;
LUSC	cis	rs4629180	0.586	rs1995826	chr2:102129420	A/G	cg01388757	chr2:102091195	RFX8	0.34	5.79	0.3	1.63e-8	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg05110241	chr16:68378359	PRMT7	-0.59	-6.73	-0.35	7.4e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4751006	0.543	rs7899778	chr10:128780419	A/C	cg05702161	chr10:128779687	DOCK1	-0.78	-6.45	-0.33	3.87e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg06917634	chr15:78832804	PSMA4	-0.48	-5.99	-0.31	5.45e-9	Post bronchodilator FEV1;
LUSC	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg05855489	chr10:104503620	C10orf26	-0.71	-10.34	-0.49	6.51e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7949030	0.929	rs11231173	chr11:62418921	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.49	7.81	0.39	7.3e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17540621	1.000	rs10193261	chr2:47239142	G/T	cg23978866	chr2:47230407	TTC7A	-0.76	-5.93	-0.31	7.55e-9	Response to statin therapy;
LUSC	cis	rs7202877	0.706	rs1074961	chr16:75389484	C/T	cg04384234	chr16:75411784	CFDP1	-0.63	-8.82	-0.43	6.31e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-11.03	-0.52	2.41e-24	Bipolar disorder;
LUSC	cis	rs1595825	0.838	rs73058883	chr2:198896255	C/T	cg10547527	chr2:198650123	BOLL	-0.52	-6.25	-0.32	1.23e-9	Ulcerative colitis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23994917	chr2:232791126	NPPC	-0.56	-6.54	-0.34	2.38e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs79387448	0.745	rs72995658	chr2:103176773	A/G	cg09003973	chr2:102972529	NA	0.87	8.27	0.41	3.3e-15	Gut microbiota (bacterial taxa);
LUSC	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg04362960	chr10:104952993	NT5C2	-0.61	-9.39	-0.46	9.32e-19	Waist circumference;Hip circumference;
LUSC	cis	rs2762353	0.526	rs3936052	chr6:25715534	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	6.11	0.32	2.7e-9	Blood metabolite levels;
LUSC	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-14.05	-0.61	1.51e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg26441486	chr22:50317300	CRELD2	0.43	6.6	0.34	1.63e-10	Schizophrenia;
LUSC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg21963583	chr11:68658836	MRPL21	0.6	8.93	0.44	2.86e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg21951975	chr1:209979733	IRF6	0.57	8.52	0.42	5.74e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg08523384	chr5:141488047	NDFIP1	-0.51	-7.45	-0.38	8.09e-13	Crohn's disease;
LUSC	cis	rs2559856	1.000	rs10860771	chr12:102087242	A/G	cg12924262	chr12:102091054	CHPT1	0.43	6.04	0.31	4e-9	Blood protein levels;
LUSC	cis	rs2692947	0.628	rs1997257	chr2:96429625	A/G	cg22654517	chr2:96458247	NA	0.38	7.64	0.39	2.34e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg05973401	chr12:123451056	ABCB9	0.53	6.51	0.34	2.82e-10	Neutrophil percentage of white cells;
LUSC	cis	rs9427116	0.532	rs9426828	chr1:154591489	G/A	cg17218026	chr1:154582156	ADAR	0.57	10.26	0.49	1.18e-21	Blood protein levels;
LUSC	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg04310649	chr10:35416472	CREM	-0.41	-6.42	-0.33	4.65e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs1325195	0.537	rs931441	chr1:179189845	C/G	cg11624085	chr17:8464688	MYH10	0.44	6.35	0.33	6.94e-10	IgE grass sensitization;
LUSC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	0.71	15.15	0.64	7.61e-40	Prudent dietary pattern;
LUSC	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg15744005	chr10:104629667	AS3MT	-0.35	-7.13	-0.36	6.22e-12	Arsenic metabolism;
LUSC	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg20848291	chr7:100343083	ZAN	-0.6	-8.03	-0.4	1.73e-14	Other erythrocyte phenotypes;
LUSC	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg18105134	chr13:113819100	PROZ	-0.71	-10.49	-0.5	1.89e-22	Platelet distribution width;
LUSC	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg22963979	chr7:1858916	MAD1L1	0.49	7.3	0.37	2.08e-12	Schizophrenia;
LUSC	cis	rs3824867	0.920	rs7105122	chr11:47449544	A/G	cg20307385	chr11:47447363	PSMC3	0.64	9.54	0.46	3.12e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg17757837	chr7:157058334	UBE3C	0.83	13.32	0.59	9.66e-33	Body mass index;
LUSC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.08	21.02	0.75	4.3e-63	Cognitive ability;
LUSC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.92	-0.31	8e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg14416269	chr4:6271139	WFS1	0.54	11.41	0.53	1.08e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg08677398	chr8:58056175	NA	0.47	5.94	0.31	7.29e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg13939156	chr17:80058883	NA	0.38	7.34	0.37	1.65e-12	Life satisfaction;
LUSC	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg17507749	chr15:85114479	UBE2QP1	0.56	6.96	0.36	1.8e-11	Schizophrenia;
LUSC	cis	rs2996428	0.504	rs3765780	chr1:3767696	C/T	cg13057898	chr1:3703894	LRRC47	-0.35	-6.68	-0.34	1.01e-10	Red cell distribution width;
LUSC	trans	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg25214090	chr10:38739885	LOC399744	0.42	6.49	0.33	3.18e-10	Corneal astigmatism;
LUSC	trans	rs62238980	0.614	rs76161060	chr22:32383153	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	trans	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02176678	chr2:219576539	TTLL4	0.64	11.53	0.53	4.11e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg22868518	chr11:507468	RNH1	-0.59	-5.8	-0.3	1.56e-8	Body mass index;
LUSC	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	8.44	0.42	9.48e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg17385448	chr1:15911702	AGMAT	0.37	6.15	0.32	2.19e-9	Systolic blood pressure;
LUSC	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg04455712	chr21:45112962	RRP1B	0.46	8.72	0.43	1.31e-16	Mean corpuscular volume;
LUSC	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg19774624	chr17:42201019	HDAC5	-0.81	-13.61	-0.6	7.03e-34	Total body bone mineral density;
LUSC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.76	-0.35	6.19e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg13390004	chr1:15929781	NA	0.42	6.96	0.36	1.77e-11	Systolic blood pressure;
LUSC	cis	rs1712517	0.771	rs59744322	chr10:105146692	G/T	cg05636881	chr10:105038444	INA	0.4	6.71	0.34	8.14e-11	Migraine;
LUSC	trans	rs10090774	0.965	rs11777839	chr8:141917894	G/T	cg16477744	chr7:157367142	PTPRN2;MIR153-2	0.28	5.99	0.31	5.53e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg08392591	chr16:89556376	ANKRD11	0.44	6.58	0.34	1.86e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg03713592	chr11:72463424	ARAP1	0.49	7.0	0.36	1.38e-11	Body mass index;
LUSC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg06784218	chr1:46089804	CCDC17	0.54	10.6	0.5	8.22e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg03146154	chr1:46216737	IPP	0.55	8.35	0.42	1.78e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg16049864	chr8:95962084	TP53INP1	-0.5	-8.17	-0.41	6.32e-15	Type 2 diabetes;
LUSC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs60154123	0.614	rs645311	chr1:210459984	A/C	cg22029157	chr1:209979665	IRF6	0.52	5.93	0.31	7.46e-9	Coronary artery disease;
LUSC	cis	rs4740619	0.875	rs6474966	chr9:15757537	G/A	cg14451791	chr9:16040625	NA	-0.3	-5.73	-0.3	2.28e-8	Body mass index;
LUSC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg23281280	chr6:28129359	ZNF389	0.45	5.86	0.31	1.14e-8	Parkinson's disease;
LUSC	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg20744362	chr22:50050164	C22orf34	0.39	7.11	0.36	6.99e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	10.97	0.51	4.21e-24	Cognitive test performance;
LUSC	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg00792783	chr2:198669748	PLCL1	0.44	5.84	0.3	1.21e-8	Dermatomyositis;
LUSC	cis	rs955333	0.850	rs12525852	chr6:154917060	A/G	cg20019720	chr6:154832845	CNKSR3	0.49	6.2	0.32	1.68e-9	Diabetic kidney disease;
LUSC	cis	rs4654899	0.865	rs61779065	chr1:21356474	A/T	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.41	-0.33	4.83e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9549260	0.609	rs9315781	chr13:41264053	T/C	cg21288729	chr13:41239152	FOXO1	0.56	8.31	0.41	2.36e-15	Red blood cell count;
LUSC	cis	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg17187183	chr4:55093834	PDGFRA	0.39	5.89	0.31	9.61e-9	Corneal astigmatism;
LUSC	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg01528321	chr10:82214614	TSPAN14	1.07	16.88	0.68	1.16e-46	Post bronchodilator FEV1;
LUSC	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg07959070	chr22:50026188	C22orf34	-0.36	-7.39	-0.37	1.18e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg23505145	chr19:12996616	KLF1	0.64	10.81	0.51	1.51e-23	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg09323728	chr8:95962352	TP53INP1	-0.38	-7.58	-0.38	3.46e-13	Type 2 diabetes;
LUSC	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg15744005	chr10:104629667	AS3MT	-0.34	-6.96	-0.36	1.83e-11	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4363385	0.679	rs6686286	chr1:152984562	T/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.48	-0.38	6.47e-13	Inflammatory skin disease;
LUSC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg06713675	chr4:122721982	EXOSC9	-0.66	-11.39	-0.53	1.32e-25	Type 2 diabetes;
LUSC	cis	rs727505	0.754	rs55905546	chr7:124783064	A/C	cg23710748	chr7:124431027	NA	-0.41	-7.13	-0.36	6.4e-12	Lewy body disease;
LUSC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg18827107	chr12:86230957	RASSF9	-0.47	-7.07	-0.36	8.84e-12	Major depressive disorder;
LUSC	cis	rs10072221	0.836	rs13357820	chr5:75698761	G/T	cg03132911	chr5:75698732	IQGAP2	0.38	6.35	0.33	6.89e-10	Mean platelet volume;
LUSC	cis	rs1062746	0.502	rs76128303	chr16:87339236	T/C	cg02258303	chr16:87377426	FBXO31	-0.53	-8.07	-0.4	1.24e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs2625529	0.938	rs4238447	chr15:72131880	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.43	-0.38	9.31e-13	Red blood cell count;
LUSC	cis	rs7605827	0.893	rs4668929	chr2:15719044	C/A	cg19274914	chr2:15703543	NA	0.45	8.41	0.42	1.24e-15	Educational attainment (years of education);
LUSC	cis	rs10754283	0.901	rs10047070	chr1:90098715	G/C	cg21401794	chr1:90099060	LRRC8C	0.66	10.03	0.48	7.43e-21	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg14582100	chr15:45693742	SPATA5L1	0.44	8.43	0.42	1.07e-15	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs62400317	0.762	rs12212190	chr6:44926271	T/C	cg20913747	chr6:44695427	NA	-0.46	-7.3	-0.37	2.16e-12	Total body bone mineral density;
LUSC	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg09835421	chr16:68378352	PRMT7	-0.59	-6.21	-0.32	1.55e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.73	-11.01	-0.52	2.85e-24	Menarche (age at onset);
LUSC	cis	rs3931020	0.657	rs277369	chr1:75234661	T/C	cg21535942	chr1:75199100	CRYZ;TYW3	-0.46	-5.78	-0.3	1.7e-8	Resistin levels;
LUSC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg01256987	chr12:42539512	GXYLT1	-0.41	-7.6	-0.38	3.08e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg24692254	chr21:30365293	RNF160	0.67	10.28	0.49	1e-21	Selective IgA deficiency;
LUSC	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.66	0.34	1.15e-10	Schizophrenia;
LUSC	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg14416269	chr4:6271139	WFS1	0.54	11.72	0.54	8.55e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg13453750	chr1:205783389	SLC41A1	-0.33	-6.51	-0.34	2.82e-10	Menarche (age at onset);
LUSC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.64	0.57	3.36e-30	Motion sickness;
LUSC	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-1.06	-12.75	-0.57	1.28e-30	Schizophrenia;
LUSC	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg16230307	chr14:35515116	FAM177A1	0.74	8.83	0.43	6.15e-17	Psoriasis;
LUSC	trans	rs953492	0.701	rs1796846	chr1:243306924	A/G	cg25284624	chr1:224180302	NA	-0.47	-7.55	-0.38	4.33e-13	Diastolic blood pressure;
LUSC	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.75	0.65	3.58e-42	Morning vs. evening chronotype;
LUSC	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg05182265	chr7:156933206	UBE3C	0.45	6.84	0.35	3.68e-11	Body mass index;
LUSC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16405210	chr4:1374714	KIAA1530	-0.6	-9.42	-0.46	7.56e-19	Obesity-related traits;
LUSC	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg08645402	chr16:4508243	NA	-0.5	-8.46	-0.42	8.63e-16	Schizophrenia;
LUSC	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg19468946	chr17:37922297	IKZF3	-0.44	-6.86	-0.35	3.33e-11	Self-reported allergy;
LUSC	cis	rs7903847	0.612	rs9887994	chr10:99159815	T/G	cg20016023	chr10:99160130	RRP12	-0.25	-5.73	-0.3	2.25e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.3	-5.73	-0.3	2.2e-8	Lymphocyte counts;
LUSC	cis	rs2274273	0.837	rs8008119	chr14:55831228	T/C	cg04306507	chr14:55594613	LGALS3	0.53	11.91	0.55	1.69e-27	Protein biomarker;
LUSC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08704250	chr15:31115839	NA	-0.47	-7.07	-0.36	9.16e-12	Huntington's disease progression;
LUSC	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg14036092	chr11:66035641	RAB1B	0.4	5.67	0.3	3.09e-8	Gout;
LUSC	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08645402	chr16:4508243	NA	0.46	7.25	0.37	2.89e-12	Schizophrenia;
LUSC	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	1.1	10.29	0.49	9.08e-22	Alzheimer's disease (late onset);
LUSC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg24399712	chr22:39784796	NA	0.59	10.59	0.5	8.47e-23	IgG glycosylation;
LUSC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg06074448	chr4:187884817	NA	-0.38	-6.42	-0.33	4.77e-10	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.77	-10.43	-0.5	3.05e-22	Coronary artery disease;
LUSC	cis	rs77741769	0.571	rs12822123	chr12:121298644	C/T	cg02419362	chr12:121203948	SPPL3	0.46	8.57	0.42	3.87e-16	Mean corpuscular volume;
LUSC	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	6.07	0.32	3.53e-9	Schizophrenia;
LUSC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg16393715	chr7:1948819	MAD1L1	0.35	5.98	0.31	5.68e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg19694781	chr19:47549865	TMEM160	-0.58	-9.38	-0.46	1.03e-18	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.54	0.57	8.04e-30	Lymphocyte percentage of white cells;
LUSC	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg03522245	chr20:25566470	NINL	-0.35	-5.7	-0.3	2.58e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7678296	0.649	rs4585313	chr4:37240236	C/T	cg06805348	chr4:37245195	KIAA1239	-0.55	-5.82	-0.3	1.4e-8	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.42	-6.42	-0.33	4.8e-10	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg13072238	chr3:49761600	GMPPB	0.69	8.74	0.43	1.18e-16	Menarche (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18594562	chr20:57797677	ZNF831	0.4	6.19	0.32	1.72e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.92	12.05	0.55	5.3e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs2717463	1.000	rs10862109	chr12:80816877	C/T	cg24988884	chr13:30424332	UBL3	-0.48	-5.96	-0.31	6.46e-9	Positive affect;
LUSC	trans	rs2975734	0.736	rs4841300	chr8:10112595	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.33	-0.33	7.9e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18854424	chr1:2615690	NA	-0.52	-10.74	-0.51	2.56e-23	Ulcerative colitis;
LUSC	cis	rs9283706	0.562	rs6881240	chr5:66331471	G/A	cg11590213	chr5:66331682	MAST4	0.45	6.81	0.35	4.55e-11	Coronary artery disease;
LUSC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00166722	chr3:10149974	C3orf24	0.63	8.63	0.43	2.63e-16	Alzheimer's disease;
LUSC	cis	rs11785693	0.862	rs62491171	chr8:4987177	G/A	cg26367366	chr8:4980734	NA	0.75	8.88	0.44	4.3e-17	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg21951975	chr1:209979733	IRF6	0.58	7.24	0.37	3.05e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg19230755	chr7:65878503	NA	-0.43	-5.96	-0.31	6.34e-9	Aortic root size;
LUSC	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg02175503	chr12:58329896	NA	0.6	8.9	0.44	3.53e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	11.71	0.54	9.32e-27	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.57	0.38	3.75e-13	Blood metabolite levels;
LUSC	cis	rs2970818	0.831	rs2970808	chr12:4640362	C/T	cg11146114	chr12:4671731	NA	-0.56	-5.82	-0.3	1.39e-8	Phosphorus levels;
LUSC	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.5	7.21	0.37	3.75e-12	Coronary heart disease;
LUSC	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg20734569	chr3:48348370	SPINK8	-0.48	-8.34	-0.42	2.01e-15	Coronary artery disease;
LUSC	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg00999904	chr2:3704751	ALLC	-0.33	-5.98	-0.31	5.68e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2019216	0.500	rs12450390	chr17:21910636	G/T	cg22648282	chr17:21454238	C17orf51	-0.51	-7.51	-0.38	5.52e-13	Pelvic organ prolapse;
LUSC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.06	20.42	0.75	9.92e-61	Cognitive ability;
LUSC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg24130564	chr14:104152367	KLC1	-0.42	-6.08	-0.32	3.38e-9	Body mass index;
LUSC	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg10560079	chr2:191398806	TMEM194B	-0.67	-7.99	-0.4	2.25e-14	Diastolic blood pressure;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26606899	chr16:1802252	MAPK8IP3	-0.74	-6.05	-0.31	3.87e-9	Cognitive performance;
LUSC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.29	6.52	0.34	2.6200000000000003e-10	Electroencephalogram traits;
LUSC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg03233332	chr7:66118400	NA	0.4	5.91	0.31	8.36e-9	Aortic root size;
LUSC	cis	rs10779751	0.960	rs12739368	chr1:11288247	T/C	cg08854313	chr1:11322531	MTOR	0.88	14.87	0.63	9.44e-39	Body mass index;
LUSC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06112835	chr11:68658793	MRPL21	0.52	7.93	0.4	3.43e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	9.05	0.44	1.17e-17	Bone mineral density;
LUSC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-14.65	-0.63	7.34e-38	Vitiligo;
LUSC	cis	rs7605827	0.930	rs6431706	chr2:15600019	C/T	cg19274914	chr2:15703543	NA	0.47	9.08	0.45	9.55e-18	Educational attainment (years of education);
LUSC	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg08085267	chr17:45401833	C17orf57	-0.46	-6.66	-0.34	1.15e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6960043	0.738	rs7798360	chr7:15055972	A/G	cg19272540	chr7:15055459	NA	0.35	8.57	0.42	3.95e-16	Type 2 diabetes;
LUSC	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg13395646	chr4:1353034	KIAA1530	-0.62	-9.81	-0.47	3.86e-20	Obesity-related traits;
LUSC	cis	rs4654899	0.680	rs3125160	chr1:21127803	G/C	cg01072550	chr1:21505969	NA	0.46	6.83	0.35	4.01e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22590775	chr19:49891494	CCDC155	0.61	8.79	0.43	8.23e-17	Multiple sclerosis;
LUSC	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg06064525	chr11:970664	AP2A2	-0.37	-7.16	-0.36	5.31e-12	Alzheimer's disease (late onset);
LUSC	cis	rs7119167	0.686	rs1894076	chr11:73035296	C/T	cg17517138	chr11:73019481	ARHGEF17	0.49	5.73	0.3	2.3e-8	Blood protein levels;
LUSC	trans	rs10432489	0.708	rs4290619	chr2:181766959	G/T	cg04744134	chr19:8408128	KANK3	-0.84	-6.25	-0.32	1.24e-9	QT interval;
LUSC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06221963	chr1:154839813	KCNN3	-0.63	-14.35	-0.62	1.03e-36	Prostate cancer;
LUSC	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg19680485	chr15:31195859	MTMR15	0.5	6.58	0.34	1.86e-10	Huntington's disease progression;
LUSC	cis	rs537626	0.767	rs680618	chr11:69316881	T/C	cg08353955	chr11:69289746	NA	-0.39	-5.97	-0.31	6.18e-9	Breast cancer (early onset);
LUSC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.72	-0.57	1.7e-30	Bipolar disorder and schizophrenia;
LUSC	trans	rs1325195	0.920	rs1858551	chr1:179089213	C/T	cg11624085	chr17:8464688	MYH10	-0.44	-7.38	-0.37	1.25e-12	IgE grass sensitization;
LUSC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs497273	0.552	rs1179939	chr12:121326876	G/C	cg02419362	chr12:121203948	SPPL3	-0.43	-7.83	-0.39	6.7e-14	Systemic lupus erythematosus;
LUSC	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.79	11.93	0.55	1.47e-27	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18402987	chr7:1209562	NA	0.42	5.67	0.3	3.03e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg06521331	chr12:34319734	NA	-0.35	-5.75	-0.3	2.06e-8	Morning vs. evening chronotype;
LUSC	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg14530993	chr4:882597	GAK	0.72	7.41	0.38	1.07e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs41271473	0.948	rs11585206	chr1:228824848	C/T	cg10167378	chr1:228756711	NA	0.6	7.05	0.36	1.05e-11	Chronic lymphocytic leukemia;
LUSC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	7.98	0.4	2.33e-14	Mood instability;
LUSC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg03806693	chr22:41940476	POLR3H	-1.04	-13.97	-0.61	2.92e-35	Vitiligo;
LUSC	trans	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	cis	rs2708977	0.933	rs2708976	chr2:97184532	C/G	cg01950434	chr2:97203154	ARID5A	-0.54	-8.05	-0.4	1.47e-14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg03647239	chr10:116582469	FAM160B1	0.43	6.56	0.34	2.09e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg21427119	chr20:30132790	HM13	-0.44	-6.17	-0.32	1.96e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg05714579	chr10:131428358	MGMT	-0.53	-8.06	-0.4	1.33e-14	Response to temozolomide;
LUSC	cis	rs2742417	1.000	rs2742368	chr3:45752293	C/A	cg09608765	chr3:45636137	LIMD1	-0.38	-7.53	-0.38	4.87e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18000306	chr6:288505	NA	0.33	6.38	0.33	6.04e-10	Menopause (age at onset);
LUSC	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.57	-9.29	-0.45	2e-18	Breast cancer;
LUSC	cis	rs1568889	0.838	rs7952717	chr11:28261658	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	12.81	0.57	7.89e-31	Bipolar disorder;
LUSC	cis	rs1538970	1.000	rs2492840	chr1:45849792	C/A	cg05343316	chr1:45956843	TESK2	0.6	8.57	0.42	3.93e-16	Platelet count;
LUSC	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg04310649	chr10:35416472	CREM	-0.41	-6.44	-0.33	4.26e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7246967	0.673	rs12985825	chr19:22953451	A/C	cg23217946	chr19:22817039	ZNF492	0.43	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs9584850	0.834	rs745638	chr13:99119307	C/G	cg20487152	chr13:99095054	FARP1	-0.39	-6.44	-0.33	4.24e-10	Neuroticism;
LUSC	cis	rs7428496	0.528	rs1129391	chr3:142283766	T/C	cg16271453	chr3:142027066	XRN1	-0.5	-8.72	-0.43	1.33e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs9462027	0.606	rs4624858	chr6:34802301	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.07	-0.32	3.46e-9	Systemic lupus erythematosus;
LUSC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.42	-0.46	7.83e-19	Type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11971478	chr17:38375459	WIPF2	-0.4	-6.04	-0.31	4.09e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7084402	1.000	rs1863664	chr10:60266839	A/G	cg07615347	chr10:60278583	BICC1	-0.35	-5.76	-0.3	1.95e-8	Refractive error;
LUSC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-17.16	-0.68	8.97e-48	Primary sclerosing cholangitis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01813165	chr2:202646406	ALS2	0.44	6.51	0.34	2.81e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	0.87	17.74	0.7	4.6e-50	Ulcerative colitis;
LUSC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	-0.5	-6.42	-0.33	4.8e-10	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.7	10.54	0.5	1.25e-22	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06830555	chr3:18486241	NA	-0.4	-5.95	-0.31	6.87e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9473147	0.543	rs9369716	chr6:47552180	A/T	cg02130027	chr6:47444894	CD2AP	0.35	5.7	0.3	2.67e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs72781680	0.821	rs17046004	chr2:24144873	A/G	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg16928487	chr17:17741425	SREBF1	0.37	7.11	0.36	6.87e-12	Total body bone mineral density;
LUSC	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-0.58	-9.02	-0.44	1.53e-17	Breast cancer;
LUSC	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg19508488	chr2:152266495	RIF1	0.45	6.38	0.33	5.89e-10	Lung cancer;
LUSC	cis	rs13315871	1.000	rs9850717	chr3:58351875	C/T	cg12435725	chr3:58293450	RPP14	-0.6	-6.35	-0.33	6.95e-10	Cholesterol, total;
LUSC	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.56	8.68	0.43	1.73e-16	Total body bone mineral density;
LUSC	cis	rs68170813	0.617	rs7797791	chr7:107197222	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.47	-5.71	-0.3	2.43e-8	Coronary artery disease;
LUSC	cis	rs2637266	0.756	rs2583064	chr10:78557708	A/G	cg18941641	chr10:78392320	NA	0.37	6.7	0.34	8.79e-11	Pulmonary function;
LUSC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg06134567	chr22:46658398	PKDREJ	-0.46	-5.65	-0.3	3.37e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg01657329	chr11:68192670	LRP5	-0.45	-7.17	-0.37	4.75e-12	Total body bone mineral density;
LUSC	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg08601574	chr20:25228251	PYGB	0.39	5.96	0.31	6.48e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg05347473	chr6:146136440	FBXO30	-0.57	-9.83	-0.47	3.34e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg04310649	chr10:35416472	CREM	-0.4	-6.19	-0.32	1.72e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.48e-24	Aortic root size;
LUSC	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.45	6.65	0.34	1.18e-10	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg05855489	chr10:104503620	C10orf26	0.49	7.57	0.38	3.79e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.51	-0.46	3.89e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	0.9	17.09	0.68	1.69e-47	Metabolite levels;
LUSC	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.94	-0.44	2.75e-17	Breast cancer;
LUSC	cis	rs17824933	0.848	rs11230564	chr11:60776465	A/G	cg16817237	chr11:60793675	NA	0.39	6.17	0.32	1.98e-9	Multiple sclerosis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25104457	chr1:26201866	NA	-0.43	-6.18	-0.32	1.91e-9	Hepatitis;
LUSC	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg00509249	chr6:109615579	CCDC162	-0.33	-6.04	-0.31	4.17e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-1.13	-24.37	-0.8	4.1e-76	Height;
LUSC	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	0.97	11.75	0.54	6.71e-27	Nonalcoholic fatty liver disease;
LUSC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.95	-0.31	6.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12824058	0.816	rs1874522	chr12:130816536	C/T	cg23887609	chr12:130822674	PIWIL1	-0.45	-6.89	-0.35	2.83e-11	Menopause (age at onset);
LUSC	cis	rs7178572	1.000	rs8024485	chr15:77718368	C/A	cg22256960	chr15:77711686	NA	-0.54	-9.02	-0.44	1.51e-17	Type 2 diabetes;
LUSC	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.65	-10.85	-0.51	1.06e-23	Dilated cardiomyopathy;
LUSC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	7.06	0.36	9.77e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg10104451	chr8:143696006	ARC	-0.64	-8.88	-0.44	4.34e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg23281280	chr6:28129359	ZNF389	0.45	5.86	0.31	1.14e-8	Parkinson's disease;
LUSC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg12143784	chr7:64541923	NA	0.39	6.01	0.31	4.99e-9	Calcium levels;
LUSC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.89	-0.44	3.84e-17	Bipolar disorder;
LUSC	cis	rs829883	1.000	rs249837	chr12:98876535	A/G	cg25150519	chr12:98850993	NA	0.64	10.02	0.48	7.74e-21	Colorectal adenoma (advanced);
LUSC	trans	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg07393940	chr7:158741817	NA	0.36	6.52	0.34	2.56e-10	Life satisfaction;
LUSC	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-11.08	-0.52	1.59e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.67	-11.0	-0.52	3.25e-24	Longevity;Endometriosis;
LUSC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg02475777	chr4:1388615	CRIPAK	0.44	6.5	0.34	2.92e-10	Obesity-related traits;
LUSC	cis	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg27411982	chr8:10470053	RP1L1	-0.45	-6.71	-0.34	8.15e-11	Morning vs. evening chronotype;
LUSC	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg12863693	chr15:85201151	NMB	0.36	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg08917208	chr2:24149416	ATAD2B	0.88	9.86	0.47	2.7e-20	Lymphocyte counts;
LUSC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg01765077	chr12:122356316	WDR66	0.49	6.73	0.35	7.26e-11	Mean corpuscular volume;
LUSC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.53	-0.38	4.71e-13	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.29	0.33	9.99e-10	Menopause (age at onset);
LUSC	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg14844989	chr11:31128820	NA	-0.37	-5.79	-0.3	1.67e-8	Red blood cell count;
LUSC	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg13256891	chr4:100009986	ADH5	0.48	7.12	0.36	6.62e-12	Alcohol dependence;
LUSC	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	6.74	0.35	7.02e-11	Retinal vascular caliber;
LUSC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07677032	chr17:61819896	STRADA	-0.51	-8.6	-0.43	3.08e-16	Prudent dietary pattern;
LUSC	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.8	11.87	0.54	2.4e-27	Corneal astigmatism;
LUSC	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	7.84	0.39	6.1e-14	Menarche (age at onset);
LUSC	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg16482183	chr6:26056742	HIST1H1C	0.62	8.37	0.42	1.55e-15	Iron status biomarkers;
LUSC	cis	rs6942756	1.000	rs68076553	chr7:128959632	A/G	cg02491457	chr7:128862824	NA	-0.48	-6.51	-0.34	2.75e-10	White matter hyperintensity burden;
LUSC	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.05	0.31	3.83e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg23985595	chr17:80112537	CCDC57	-0.3	-5.69	-0.3	2.77e-8	Life satisfaction;
LUSC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg08508325	chr11:3079039	CARS	-0.43	-10.6	-0.5	8.3e-23	Longevity;
LUSC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg04800585	chr6:26043546	HIST1H2BB	0.43	6.12	0.32	2.56e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg10360139	chr7:1886902	MAD1L1	-0.39	-5.86	-0.31	1.09e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.8e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs4969178	0.965	rs8071884	chr17:76398058	C/G	cg05887092	chr17:76393375	PGS1	0.52	8.99	0.44	1.85e-17	HDL cholesterol levels;
LUSC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg03388025	chr16:89894329	SPIRE2	0.36	7.61	0.38	2.91e-13	Vitiligo;
LUSC	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.32	0.33	8.34e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9296092	0.517	rs56069946	chr6:33511136	G/A	cg13560919	chr6:33536144	NA	-0.85	-15.07	-0.64	1.59e-39	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.35	-0.42	1.87e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg15691649	chr6:25882328	NA	0.51	7.58	0.38	3.4e-13	Blood metabolite levels;
LUSC	cis	rs965513	0.965	rs10759944	chr9:100556972	A/G	cg13688889	chr9:100608707	NA	-0.54	-8.16	-0.41	6.68e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg18512352	chr11:47633146	NA	-0.44	-8.97	-0.44	2.1e-17	Subjective well-being;
LUSC	trans	rs7951870	0.673	rs13448	chr11:46695414	T/C	cg04198581	chr6:146289477	NA	0.31	6.08	0.32	3.34e-9	Schizophrenia;
LUSC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15369054	chr17:80825471	TBCD	-0.42	-6.85	-0.35	3.49e-11	Breast cancer;
LUSC	trans	rs12439619	1.000	rs35152457	chr15:82546548	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.52	-8.14	-0.41	7.89e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12826209	chr6:26865740	GUSBL1	0.75	9.08	0.45	9.54e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05191825	chr12:108956318	ISCU;SART3	0.69	5.98	0.31	5.81e-9	Cognitive performance;
LUSC	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg23992470	chr4:843637	GAK	-0.55	-6.42	-0.33	4.63e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11644478	chr21:40555479	PSMG1	0.91	16.83	0.68	1.84e-46	Cognitive function;
LUSC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg17143192	chr8:8559678	CLDN23	0.66	9.61	0.47	1.84e-19	Obesity-related traits;
LUSC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.36	-5.8	-0.3	1.56e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.9	-0.31	8.73e-9	Platelet count;
LUSC	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.65	-0.39	2.11e-13	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg11530693	chr1:120165357	ZNF697	0.67	10.55	0.5	1.18e-22	Systemic lupus erythematosus;
LUSC	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg00982548	chr2:198649783	BOLL	-0.59	-7.38	-0.37	1.3e-12	Ulcerative colitis;
LUSC	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg24634471	chr8:143751801	JRK	0.59	9.01	0.44	1.66e-17	Schizophrenia;
LUSC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-0.87	-14.56	-0.62	1.56e-37	Tonsillectomy;
LUSC	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	0.89	14.74	0.63	3.23e-38	Schizophrenia;
LUSC	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.78	7.05	0.36	1.04e-11	Lung cancer in ever smokers;
LUSC	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	0.85	13.71	0.6	3.13e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.33	-0.33	8.06e-10	Response to antipsychotic treatment;
LUSC	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg04733989	chr22:42467013	NAGA	0.38	6.27	0.32	1.1e-9	Cognitive function;
LUSC	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg03806693	chr22:41940476	POLR3H	-0.6	-8.87	-0.44	4.55e-17	Vitiligo;
LUSC	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.38e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12020437	chr14:77924595	C14orf133;AHSA1	0.46	6.29	0.33	9.92e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-12.76	-0.57	1.19e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7538876	0.903	rs1324367	chr1:17752451	C/G	cg07965774	chr1:17746286	RCC2	0.32	6.02	0.31	4.57e-9	Basal cell carcinoma;
LUSC	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.47	6.32	0.33	8.2e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg03233332	chr7:66118400	NA	-0.43	-6.18	-0.32	1.85e-9	Aortic root size;
LUSC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg08270630	chr22:50330655	NA	-0.43	-6.48	-0.33	3.36e-10	Schizophrenia;
LUSC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-10.92	-0.51	6.32e-24	Schizophrenia;
LUSC	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	7.16	0.36	5.01e-12	Triglycerides;
LUSC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg01879757	chr17:41196368	BRCA1	-0.46	-6.92	-0.35	2.26e-11	Menopause (age at onset);
LUSC	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.03	0.44	1.37e-17	Lung cancer in ever smokers;
LUSC	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg27411982	chr8:10470053	RP1L1	-0.45	-6.92	-0.35	2.25e-11	Neuroticism;
LUSC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg00334542	chr7:100209784	MOSPD3	-0.6	-7.02	-0.36	1.23e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.78	0.39	8.95e-14	Electroencephalogram traits;
LUSC	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg23950597	chr19:37808831	NA	-0.62	-7.3	-0.37	2.09e-12	Coronary artery calcification;
LUSC	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg07701084	chr6:150067640	NUP43	0.47	6.91	0.35	2.41e-11	Lung cancer;
LUSC	cis	rs3125734	0.633	rs3852412	chr10:64050288	C/T	cg19640130	chr10:64028056	RTKN2	-0.38	-6.63	-0.34	1.35e-10	Rheumatoid arthritis;
LUSC	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00631329	chr6:26305371	NA	-0.45	-8.62	-0.43	2.78e-16	Educational attainment;
LUSC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.15	-0.36	5.6e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.11	0.55	3.12e-28	Prudent dietary pattern;
LUSC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg06713675	chr4:122721982	EXOSC9	-0.72	-12.31	-0.56	5.85e-29	Type 2 diabetes;
LUSC	cis	rs791888	0.767	rs2255684	chr10:89419971	C/T	cg13926569	chr10:89418898	PAPSS2	-0.36	-6.96	-0.36	1.79e-11	Magnesium levels;
LUSC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg06074448	chr4:187884817	NA	0.41	6.87	0.35	3.15e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9650657	0.615	rs2271355	chr8:10692158	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.19	-0.32	1.8e-9	Neuroticism;
LUSC	trans	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg22153745	chr1:153894579	GATAD2B	-0.58	-9.12	-0.45	7.35e-18	Total cholesterol levels;
LUSC	cis	rs3750965	1.000	rs1466222	chr11:68832848	G/A	cg06818126	chr11:68850279	TPCN2	-0.44	-6.29	-0.33	9.88e-10	Hair color;
LUSC	cis	rs921665	0.748	rs1869419	chr2:3202080	C/T	cg16434511	chr2:3151078	NA	-0.58	-5.93	-0.31	7.76e-9	World class endurance athleticism;
LUSC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21963583	chr11:68658836	MRPL21	0.57	8.67	0.43	1.9e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26221243	chr8:128747973	MYC	-0.45	-5.98	-0.31	5.84e-9	Hepatitis;
LUSC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg14552801	chr7:65878734	NA	0.37	5.78	0.3	1.75e-8	Aortic root size;
LUSC	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-8.2	-0.41	5.2e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7246967	0.611	rs34806882	chr19:22880104	T/C	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7582180	1.000	rs7588623	chr2:100913361	A/G	cg08017756	chr2:100939284	LONRF2	-0.35	-5.85	-0.3	1.19e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg08975724	chr8:8085496	FLJ10661	0.48	7.02	0.36	1.24e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg13010199	chr12:38710504	ALG10B	0.58	9.31	0.45	1.79e-18	Morning vs. evening chronotype;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg05950485	chr8:101733214	PABPC1	0.41	6.15	0.32	2.27e-9	Schizophrenia;
LUSC	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg17507749	chr15:85114479	UBE2QP1	0.65	8.1	0.41	1.04e-14	Schizophrenia;
LUSC	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg04310649	chr10:35416472	CREM	-0.4	-6.22	-0.32	1.53e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7923609	0.812	rs10822184	chr10:65337153	C/T	cg01631684	chr10:65280961	REEP3	0.39	6.18	0.32	1.9e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	0.9	17.93	0.7	7.5400000000000006e-51	Metabolite levels;
LUSC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg21285383	chr16:89894308	SPIRE2	0.36	7.78	0.39	9.1e-14	Vitiligo;
LUSC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.1	0.55	3.33e-28	Cognitive test performance;
LUSC	cis	rs12530845	0.623	rs7798256	chr7:135344211	C/A	cg23117316	chr7:135346802	PL-5283	-0.65	-9.81	-0.47	4.03e-20	Red blood cell traits;
LUSC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	10.78	0.51	1.84e-23	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg13206674	chr6:150067644	NUP43	0.5	7.53	0.38	4.76e-13	Lung cancer;
LUSC	trans	rs3857536	0.776	rs9363560	chr6:66949686	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs1440410	0.835	rs4594668	chr4:144050446	A/T	cg01719995	chr4:144104893	USP38	-0.32	-5.68	-0.3	2.9e-8	Ischemic stroke;
LUSC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg03060546	chr3:49711283	APEH	-0.51	-6.98	-0.36	1.6e-11	Menarche (age at onset);
LUSC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	0.93	18.05	0.7	2.67e-51	Cognitive function;
LUSC	cis	rs66716358	0.744	rs1869480	chr11:44319657	C/G	cg16977035	chr11:44330474	ALX4	-0.35	-5.94	-0.31	7.27e-9	Monobrow;
LUSC	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.99	-0.36	1.47e-11	Blood metabolite levels;
LUSC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg12365402	chr11:9010492	NRIP3	-0.51	-9.81	-0.47	4.04e-20	Hemoglobin concentration;
LUSC	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg14416269	chr4:6271139	WFS1	0.44	8.25	0.41	3.82e-15	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1577917	0.958	rs12202188	chr6:86562700	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.57	8.71	0.43	1.41e-16	Blood protein levels;
LUSC	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg07169764	chr2:136633963	MCM6	-0.59	-7.85	-0.39	5.75e-14	Mosquito bite size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18416022	chr19:58089961	ZNF416	-0.41	-6.17	-0.32	1.93e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.61	9.8	0.47	4.24e-20	Response to diuretic therapy;
LUSC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg22834771	chr12:69754056	YEATS4	-0.56	-8.42	-0.42	1.11e-15	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	8.51	0.42	6.1e-16	Menopause (age at onset);
LUSC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg12463550	chr7:65579703	CRCP	0.52	7.46	0.38	7.59e-13	Aortic root size;
LUSC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg21699342	chr2:239360505	ASB1	0.56	10.33	0.49	6.79e-22	Multiple system atrophy;
LUSC	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg15423357	chr2:25149977	NA	-0.37	-7.29	-0.37	2.3e-12	Body mass index in non-asthmatics;
LUSC	cis	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg21775007	chr8:11205619	TDH	-0.41	-5.79	-0.3	1.62e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs3755132	0.929	rs7579604	chr2:15746975	A/T	cg12888861	chr2:15731646	DDX1	0.5	7.27	0.37	2.55e-12	Wilms tumor;
LUSC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg05855489	chr10:104503620	C10orf26	-0.62	-7.62	-0.38	2.59e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs59104589	0.617	rs3771567	chr2:242358619	G/A	cg14842376	chr2:242211374	HDLBP	0.51	5.92	0.31	8e-9	Fibrinogen levels;
LUSC	cis	rs7927771	0.524	rs10838732	chr11:47607940	C/G	cg20307385	chr11:47447363	PSMC3	0.44	6.43	0.33	4.53e-10	Subjective well-being;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg21728825	chr2:128568322	WDR33	0.39	6.11	0.32	2.79e-9	Triglycerides;
LUSC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg09904177	chr6:26538194	HMGN4	-0.39	-5.69	-0.3	2.76e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3771570	1.000	rs62186400	chr2:242226700	A/G	cg21155796	chr2:242212141	HDLBP	0.68	7.51	0.38	5.46e-13	Prostate cancer;
LUSC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.97	0.44	2.22e-17	Prudent dietary pattern;
LUSC	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg23029597	chr12:123009494	RSRC2	-0.7	-9.67	-0.47	1.18e-19	Body mass index;
LUSC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.73	11.98	0.55	9.43e-28	Cognitive function;
LUSC	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg04455712	chr21:45112962	RRP1B	0.46	8.75	0.43	1.07e-16	Mean corpuscular volume;
LUSC	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-6.34	-0.33	7.64e-10	Height;
LUSC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.59	-10.07	-0.48	5.37e-21	Prudent dietary pattern;
LUSC	cis	rs4786125	0.573	rs7201500	chr16:6897659	A/G	cg03623568	chr16:6915990	A2BP1	-0.36	-6.36	-0.33	6.52e-10	Heart rate variability traits (SDNN);
LUSC	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg03433033	chr1:76189801	ACADM	-0.43	-6.35	-0.33	7.05e-10	Daytime sleep phenotypes;
LUSC	cis	rs3087591	0.920	rs2905881	chr17:29547862	T/C	cg24425628	chr17:29625626	OMG;NF1	0.56	8.28	0.41	3.07e-15	Hip circumference;
LUSC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg01416388	chr22:39784598	NA	-0.42	-6.94	-0.35	2.11e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9612	1.000	rs16976747	chr19:44238152	G/A	cg08581076	chr19:44259116	C19orf61	0.52	6.32	0.33	8.18e-10	Exhaled nitric oxide output;
LUSC	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg15556689	chr8:8085844	FLJ10661	0.56	8.78	0.43	8.62e-17	Retinal vascular caliber;
LUSC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg12292205	chr6:26970375	C6orf41	-0.69	-12.16	-0.55	2.12e-28	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg17173187	chr15:85201210	NMB	0.49	9.32	0.45	1.67e-18	Schizophrenia;
LUSC	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg21361702	chr7:150065534	REPIN1	0.57	8.0	0.4	2.14e-14	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.19	-0.32	1.74e-9	Bladder cancer;
LUSC	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg08847533	chr14:75593920	NEK9	0.85	15.68	0.65	6.62e-42	Height;
LUSC	trans	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg17675199	chr6:35436792	RPL10A	-0.4	-5.95	-0.31	6.75e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-8.64	-0.43	2.28e-16	Menarche (age at onset);
LUSC	cis	rs7582720	0.943	rs72934550	chr2:203983940	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.61	0.43	2.86e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs72960926	0.744	rs72967284	chr6:75024375	C/T	cg03266952	chr6:74778945	NA	-0.82	-7.01	-0.36	1.29e-11	Metabolite levels (MHPG);
LUSC	cis	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg06521331	chr12:34319734	NA	-0.4	-5.69	-0.3	2.76e-8	Resting heart rate;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24357026	chr19:36705589	ZNF565;ZNF146	-0.41	-6.37	-0.33	6.34e-10	Electrocardiographic conduction measures;
LUSC	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg05855489	chr10:104503620	C10orf26	0.53	8.19	0.41	5.43e-15	Arsenic metabolism;
LUSC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg00825309	chr19:58991885	ZNF446	-0.41	-6.11	-0.32	2.77e-9	Uric acid clearance;
LUSC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.24	0.52	4.42e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg23625390	chr15:77176239	SCAPER	0.62	9.75	0.47	6.47e-20	Blood metabolite levels;
LUSC	trans	rs61931739	0.635	rs6488185	chr12:33933127	G/C	cg26384229	chr12:38710491	ALG10B	0.51	7.63	0.39	2.51e-13	Morning vs. evening chronotype;
LUSC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.69	-0.34	9.63e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg03146154	chr1:46216737	IPP	-0.51	-7.46	-0.38	7.41e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs77741769	0.591	rs73413868	chr12:121301732	T/C	cg02419362	chr12:121203948	SPPL3	0.46	8.64	0.43	2.42e-16	Mean corpuscular volume;
LUSC	cis	rs4974559	0.947	rs7659916	chr4:1361013	C/T	cg02980000	chr4:1222292	CTBP1	0.72	6.75	0.35	6.52e-11	Systolic blood pressure;
LUSC	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	9.47	0.46	5.4e-19	Intelligence (multi-trait analysis);
LUSC	trans	rs9929218	0.954	rs60302411	chr16:68824220	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.09	-0.52	1.52e-24	Colorectal cancer;
LUSC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg22800045	chr5:56110881	MAP3K1	-0.52	-7.56	-0.38	4.01e-13	Initial pursuit acceleration;
LUSC	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg00012203	chr2:219082015	ARPC2	-0.54	-8.47	-0.42	8.15e-16	Ulcerative colitis;
LUSC	cis	rs4077468	1.000	rs9661504	chr1:205915667	A/T	cg07167872	chr1:205819463	PM20D1	-0.39	-5.78	-0.3	1.7e-8	Cystic fibrosis-related diabetes;
LUSC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	0.93	17.52	0.69	3.28e-49	Heart rate;
LUSC	cis	rs7712401	0.584	rs28373879	chr5:122372402	G/C	cg19077854	chr5:122220652	SNX24	0.36	7.32	0.37	1.81e-12	Mean platelet volume;
LUSC	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17173187	chr15:85201210	NMB	0.48	9.21	0.45	3.74e-18	Schizophrenia;
LUSC	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg06462663	chr19:18546047	ISYNA1	0.47	7.81	0.39	7.61e-14	Breast cancer;
LUSC	cis	rs8016982	0.962	rs8007841	chr14:81647878	C/T	cg01989461	chr14:81687754	GTF2A1	-0.45	-6.64	-0.34	1.26e-10	Schizophrenia;
LUSC	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg04374321	chr14:90722782	PSMC1	0.71	11.25	0.52	3.96e-25	Mortality in heart failure;
LUSC	cis	rs1256061	0.603	rs1256045	chr14:64729760	A/C	cg23250157	chr14:64679961	SYNE2	0.32	5.7	0.3	2.68e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06481639	chr22:41940642	POLR3H	0.48	5.8	0.3	1.57e-8	Vitiligo;
LUSC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	0.91	17.02	0.68	3.17e-47	Heart rate;
LUSC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg10018233	chr7:150070692	REPIN1	0.39	6.74	0.35	6.82e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg04362960	chr10:104952993	NT5C2	0.64	9.38	0.46	1.02e-18	Arsenic metabolism;
LUSC	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg05373962	chr22:49881684	NA	-0.42	-10.05	-0.48	6.2e-21	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg09904177	chr6:26538194	HMGN4	-0.79	-6.14	-0.32	2.29e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.92	0.31	7.86e-9	Menopause (age at onset);
LUSC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-0.99	-14.41	-0.62	5.84e-37	Initial pursuit acceleration;
LUSC	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg02466173	chr16:30829666	NA	-0.58	-10.78	-0.51	1.9e-23	Multiple myeloma;
LUSC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg07716408	chr11:68623521	NA	-0.32	-6.13	-0.32	2.48e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9549260	0.709	rs9549247	chr13:41220777	G/C	cg21288729	chr13:41239152	FOXO1	0.65	10.06	0.48	5.76e-21	Red blood cell count;
LUSC	cis	rs9311676	0.632	rs62258139	chr3:58406836	C/T	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.3e-10	Systemic lupus erythematosus;
LUSC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-0.85	-16.73	-0.68	4.42e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8040855	0.627	rs2304418	chr15:85640983	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-5.81	-0.3	1.45e-8	Bulimia nervosa;
LUSC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg06221963	chr1:154839813	KCNN3	0.5	10.3	0.49	8.58e-22	Prostate cancer;
LUSC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg17554472	chr22:41940697	POLR3H	-0.48	-5.94	-0.31	7.14e-9	Vitiligo;
LUSC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg05347473	chr6:146136440	FBXO30	0.54	9.33	0.45	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg06454157	chr6:167490870	NA	-0.23	-5.76	-0.3	1.87e-8	Crohn's disease;
LUSC	cis	rs427941	0.632	rs201522	chr7:101771546	C/T	cg06246474	chr7:101738831	CUX1	0.37	6.21	0.32	1.59e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs6066835	1.000	rs6066837	chr20:47357337	A/C	cg18078177	chr20:47281410	PREX1	0.75	6.44	0.33	4.14e-10	Multiple myeloma;
LUSC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg26380479	chr7:97908229	NA	-0.26	-5.77	-0.3	1.78e-8	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg17830980	chr10:43048298	ZNF37B	0.42	6.51	0.34	2.72e-10	Extrinsic epigenetic age acceleration;
LUSC	trans	rs72674100	1.000	rs28368230	chr4:97970611	G/A	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2282300	0.637	rs7942037	chr11:30430332	G/C	cg25418670	chr11:30344373	C11orf46	-0.4	-6.29	-0.33	1.01e-9	Morning vs. evening chronotype;
LUSC	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg00310523	chr12:86230176	RASSF9	0.4	7.18	0.37	4.67e-12	Major depressive disorder;
LUSC	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg08085267	chr17:45401833	C17orf57	-0.51	-7.31	-0.37	2.02e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.21	-0.49	1.83e-21	Eye color traits;
LUSC	cis	rs870825	0.616	rs7692367	chr4:185651056	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	12.42	0.56	2.15e-29	Blood protein levels;
LUSC	trans	rs931812	0.964	rs2102290	chr8:101919844	G/C	cg20993868	chr7:22813445	NA	0.59	10.82	0.51	1.36e-23	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg10729496	chr3:10149963	C3orf24	0.59	7.62	0.38	2.67e-13	Alzheimer's disease;
LUSC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg25072359	chr17:41440525	NA	0.6	7.8	0.39	7.91e-14	Menopause (age at onset);
LUSC	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg11965913	chr1:205819406	PM20D1	-0.42	-6.39	-0.33	5.72e-10	Prostate-specific antigen levels;
LUSC	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg22529645	chr1:3704559	LRRC47	0.33	5.72	0.3	2.32e-8	Red cell distribution width;
LUSC	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg13535736	chr9:111863775	C9orf5	-0.37	-5.9	-0.31	8.82e-9	Menarche (age at onset);
LUSC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg26695010	chr11:65641043	EFEMP2	-0.47	-7.09	-0.36	7.82e-12	Eosinophil percentage of white cells;
LUSC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg09877947	chr5:131593287	PDLIM4	-0.55	-8.5	-0.42	6.28e-16	Acylcarnitine levels;
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg00024416	chr22:24240387	NA	-0.34	-6.04	-0.31	4.03e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg14458575	chr2:238380390	NA	0.86	15.19	0.64	5.38e-40	Prostate cancer;
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.28	-7.29	-0.37	2.21e-12	Lymphocyte counts;
LUSC	cis	rs12940923	1.000	rs11867689	chr17:56370355	G/C	cg19466818	chr17:56409534	MIR142	-0.38	-6.76	-0.35	6.25e-11	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.33	-0.37	1.74e-12	Aortic root size;
LUSC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21643547	chr1:205240462	TMCC2	-0.5	-9.3	-0.45	1.95e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg16482183	chr6:26056742	HIST1H1C	0.59	8.2	0.41	5.31e-15	Iron status biomarkers;
LUSC	trans	rs7939886	0.841	rs79902631	chr11:55995241	A/C	cg03929089	chr4:120376271	NA	0.82	6.13	0.32	2.55e-9	Myopia (pathological);
LUSC	cis	rs1808579	0.874	rs1788817	chr18:21097460	A/G	cg14672496	chr18:21087552	C18orf8	0.39	6.97	0.36	1.69e-11	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05890377	chr2:74357713	NA	0.74	13.68	0.6	3.91e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs6076065	0.723	rs1419009	chr20:23365094	G/A	cg11657817	chr20:23433608	CST11	0.43	8.07	0.4	1.25e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	1.04	25.8	0.82	1.72e-81	Multiple system atrophy;
LUSC	trans	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.28	0.32	1.07e-9	Neuroticism;
LUSC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg06600287	chr1:53387719	ECHDC2	-0.29	-5.7	-0.3	2.59e-8	Monocyte count;
LUSC	cis	rs13006833	0.634	rs1876877	chr2:191145274	G/A	cg21644426	chr2:191273491	MFSD6	0.44	6.28	0.33	1.03e-9	Urinary metabolites;
LUSC	cis	rs7953508	0.506	rs10859532	chr12:93960917	G/C	cg18151635	chr12:93972918	NA	-0.61	-8.85	-0.44	5.17e-17	Pubertal anthropometrics;
LUSC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg24634471	chr8:143751801	JRK	0.59	8.98	0.44	1.97e-17	Schizophrenia;
LUSC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg06238570	chr21:40685208	BRWD1	-0.64	-10.79	-0.51	1.73e-23	Cognitive function;
LUSC	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg27068330	chr11:65405492	SIPA1	-0.61	-9.25	-0.45	2.78e-18	Acne (severe);
LUSC	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg26408565	chr15:76604113	ETFA	0.47	7.61	0.38	2.85e-13	Blood metabolite levels;
LUSC	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg26384229	chr12:38710491	ALG10B	0.72	11.29	0.53	2.92e-25	Morning vs. evening chronotype;
LUSC	cis	rs55882075	0.535	rs67484565	chr5:179110574	G/T	cg14593053	chr5:179126677	CANX	0.38	5.96	0.31	6.29e-9	Monocyte percentage of white cells;
LUSC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.74	0.35	6.98e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9888739	0.800	rs1143678	chr16:31343005	C/T	cg15817542	chr16:31343056	ITGAM	-0.53	-7.13	-0.36	6.08e-12	Systemic lupus erythematosus;
LUSC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg18512352	chr11:47633146	NA	-0.46	-9.25	-0.45	2.83e-18	Subjective well-being;
LUSC	cis	rs9361491	0.657	rs9343798	chr6:79455282	A/G	cg05283184	chr6:79620031	NA	-0.32	-5.87	-0.31	1.04e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg06026331	chr20:60912101	LAMA5	-0.61	-7.29	-0.37	2.29e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.38e-9	Bladder cancer;
LUSC	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg22782873	chr19:19639568	YJEFN3	0.53	6.36	0.33	6.46e-10	Bipolar disorder;
LUSC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.55	0.5	1.17e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg08085267	chr17:45401833	C17orf57	-0.47	-6.66	-0.34	1.11e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg05025164	chr4:1340916	KIAA1530	0.54	8.4	0.42	1.29e-15	Obesity-related traits;
LUSC	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg03676636	chr4:99064102	C4orf37	0.3	6.36	0.33	6.6e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg09085632	chr11:111637200	PPP2R1B	0.95	13.23	0.59	2.02e-32	Primary sclerosing cholangitis;
LUSC	cis	rs7759001	0.817	rs2393929	chr6:27351931	A/C	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	2.04e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.49	-7.64	-0.39	2.35e-13	Alzheimer's disease (late onset);
LUSC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.42	-5.82	-0.3	1.4e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs713477	0.505	rs8019080	chr14:55891372	C/T	cg13175173	chr14:55914753	NA	-0.31	-5.94	-0.31	7.31e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs7582180	0.817	rs2309820	chr2:100899676	T/C	cg08017756	chr2:100939284	LONRF2	-0.37	-6.23	-0.32	1.41e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	10.49	0.5	1.91e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg08392591	chr16:89556376	ANKRD11	0.4	6.01	0.31	4.85e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg19318889	chr4:1322082	MAEA	0.45	7.13	0.36	6.31e-12	Obesity-related traits;
LUSC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.89	-16.74	-0.68	4.09e-46	Colorectal cancer;
LUSC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.18	0.37	4.56e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2067615	0.524	rs9804754	chr12:107083031	G/A	cg15890332	chr12:107067104	RFX4	0.36	6.24	0.32	1.35e-9	Heart rate;
LUSC	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.54	8.32	0.41	2.32e-15	Colorectal cancer;
LUSC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg14668632	chr7:2872130	GNA12	0.41	6.0	0.31	5.02e-9	Height;
LUSC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10743315	0.643	rs58663385	chr12:19337070	T/C	cg02471346	chr12:19282374	PLEKHA5	0.59	5.81	0.3	1.47e-8	Gut microbiota (bacterial taxa);
LUSC	cis	rs7561273	0.586	rs9309225	chr2:24292863	T/C	cg06627628	chr2:24431161	ITSN2	-0.51	-6.83	-0.35	3.93e-11	Quantitative traits;
LUSC	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg09796270	chr17:17721594	SREBF1	0.45	7.37	0.37	1.34e-12	Total body bone mineral density;
LUSC	cis	rs6840360	1.000	rs6823002	chr4:152604467	T/G	cg22705602	chr4:152727874	NA	-0.28	-5.86	-0.31	1.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.47	6.91	0.35	2.45e-11	Schizophrenia;
LUSC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg05347473	chr6:146136440	FBXO30	0.58	10.06	0.48	5.49e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.56	1.53e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3099143	1.000	rs4583202	chr15:77161676	G/A	cg21673338	chr15:77095150	SCAPER	0.78	7.34	0.37	1.64e-12	Recalcitrant atopic dermatitis;
LUSC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg17971929	chr21:40555470	PSMG1	0.77	13.29	0.59	1.16e-32	Cognitive function;
LUSC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08219700	chr8:58056026	NA	0.64	7.88	0.4	4.52e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs4654899	0.772	rs951805	chr1:21060356	A/G	cg01072550	chr1:21505969	NA	0.47	6.96	0.36	1.85e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-8.49	-0.42	6.77e-16	Total body bone mineral density;
LUSC	cis	rs73206853	0.841	rs28404862	chr12:110850241	C/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg08270630	chr22:50330655	NA	-0.43	-6.5	-0.33	2.98e-10	Schizophrenia;
LUSC	cis	rs7247513	0.790	rs17476839	chr19:12762783	C/T	cg01871581	chr19:12707946	ZNF490	0.51	7.52	0.38	5.17e-13	Bipolar disorder;
LUSC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03576123	chr11:487126	PTDSS2	-0.91	-10.25	-0.49	1.24e-21	Body mass index;
LUSC	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25214090	chr10:38739885	LOC399744	0.52	7.55	0.38	4.24e-13	Corneal astigmatism;
LUSC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	0.96	19.27	0.73	3.81e-56	Cognitive function;
LUSC	cis	rs6693567	0.565	rs834234	chr1:150352494	C/G	cg15654264	chr1:150340011	RPRD2	-0.43	-6.81	-0.35	4.48e-11	Migraine;
LUSC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs2742417	0.967	rs2742439	chr3:45744248	G/A	cg04837898	chr3:45731254	SACM1L	-0.35	-5.66	-0.3	3.28e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-10.45	-0.5	2.62e-22	Bladder cancer;
LUSC	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-9.98	-0.48	1.09e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6809651	0.524	rs12638263	chr3:185795855	A/C	cg00760338	chr3:185826511	ETV5	-0.62	-8.92	-0.44	3.16e-17	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LUSC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg15448220	chr1:150897856	SETDB1	0.43	6.23	0.32	1.43e-9	Melanoma;
LUSC	cis	rs240764	0.853	rs108422	chr6:101039279	G/C	cg09795085	chr6:101329169	ASCC3	0.4	5.76	0.3	1.87e-8	Neuroticism;
LUSC	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg05373962	chr22:49881684	NA	-0.4	-8.61	-0.43	2.85e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg24558204	chr6:135376177	HBS1L	0.68	10.65	0.5	5.18e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs6484504	0.532	rs1475558	chr11:31263428	A/G	cg06552810	chr11:31128660	NA	-0.41	-7.13	-0.36	6.32e-12	Red blood cell count;
LUSC	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg21775007	chr8:11205619	TDH	-0.5	-6.81	-0.35	4.68e-11	Morning vs. evening chronotype;
LUSC	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.66	-10.12	-0.48	3.51e-21	Glaucoma (primary open-angle);
LUSC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.61	8.56	0.42	4.2e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2901656	0.627	rs7528296	chr1:172381383	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.35	6.74	0.35	7.09e-11	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.28	-5.83	-0.3	1.33e-8	Crohn's disease;
LUSC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-7.24	-0.37	3.2e-12	Mean platelet volume;
LUSC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg23630131	chr7:65973040	NA	0.2	5.71	0.3	2.54e-8	Aortic root size;
LUSC	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg03036452	chr22:46663545	TTC38	0.59	5.95	0.31	6.85e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg01689657	chr7:91764605	CYP51A1	-0.32	-5.77	-0.3	1.79e-8	Breast cancer;
LUSC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg16325326	chr1:53192061	ZYG11B	0.96	17.99	0.7	4.36e-51	Monocyte count;
LUSC	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg06636001	chr8:8085503	FLJ10661	0.53	7.8	0.39	7.95e-14	Neuroticism;
LUSC	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg08773314	chr2:239334832	ASB1	0.43	9.34	0.46	1.42e-18	Multiple system atrophy;
LUSC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.64	-9.11	-0.45	7.89e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg11062466	chr8:58055876	NA	0.51	5.81	0.3	1.44e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs11030122	0.702	rs10835399	chr11:3989182	G/A	cg08557956	chr11:4115526	RRM1	-0.46	-5.81	-0.3	1.42e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11605924	0.934	rs7945565	chr11:45878992	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.58	-9.07	-0.44	1.02e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg26395211	chr5:140044315	WDR55	-0.4	-6.24	-0.32	1.33e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9392556	0.829	rs629362	chr6:4121831	A/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.37	-6.62	-0.34	1.44e-10	Blood metabolite levels;
LUSC	cis	rs9473147	0.543	rs4711878	chr6:47456118	A/G	cg20196966	chr6:47445060	CD2AP	0.41	5.78	0.3	1.7e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.94	-18.67	-0.71	8.71e-54	Ulcerative colitis;
LUSC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02475777	chr4:1388615	CRIPAK	-0.58	-8.55	-0.42	4.51e-16	Obesity-related traits;
LUSC	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg14829155	chr15:31115871	NA	-0.56	-7.67	-0.39	1.85e-13	Huntington's disease progression;
LUSC	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.84	-15.98	-0.66	4.2e-43	Heart rate;
LUSC	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-7.06	-0.36	9.99e-12	Neuroticism;
LUSC	trans	rs12200782	0.932	rs12189841	chr6:26544798	A/T	cg11837749	chr1:55047332	ACOT11	0.58	6.31	0.33	8.85e-10	Small cell lung carcinoma;
LUSC	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg00191853	chr8:101177733	SPAG1	-0.39	-6.47	-0.33	3.49e-10	Atrioventricular conduction;
LUSC	cis	rs4964805	0.549	rs1976256	chr12:104156899	G/C	cg02344784	chr12:104178138	NT5DC3	0.41	6.47	0.33	3.42e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg10253484	chr15:75165896	SCAMP2	-0.44	-6.26	-0.32	1.21e-9	Breast cancer;
LUSC	cis	rs11191270	0.554	rs11191265	chr10:104102118	G/A	cg15320455	chr10:103880129	LDB1	0.58	5.97	0.31	6.12e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1941023	0.568	rs1373064	chr11:60168200	C/T	cg08716584	chr11:60157161	MS4A7	-0.62	-11.34	-0.53	1.9e-25	Congenital heart disease (maternal effect);
LUSC	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	10.76	0.51	2.3e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg00933542	chr6:150070202	PCMT1	0.34	7.03	0.36	1.14e-11	Lung cancer;
LUSC	cis	rs72781680	0.652	rs12618900	chr2:23910775	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	9.65	0.47	1.39e-19	Lymphocyte counts;
LUSC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg21643547	chr1:205240462	TMCC2	-0.44	-8.01	-0.4	1.87e-14	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg23791538	chr6:167370224	RNASET2	-0.37	-5.87	-0.31	1.05e-8	Crohn's disease;
LUSC	cis	rs56146971	0.763	rs11160005	chr14:91872587	G/C	cg10511902	chr14:91842949	CCDC88C	0.44	5.69	0.3	2.74e-8	Alzheimer disease and age of onset;
LUSC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg06287003	chr12:125626642	AACS	-0.41	-6.87	-0.35	3.1e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.95	-15.16	-0.64	7.47e-40	Coronary artery disease;
LUSC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.73	10.46	0.5	2.42e-22	Response to bleomycin (chromatid breaks);
LUSC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21963583	chr11:68658836	MRPL21	0.54	8.24	0.41	4e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6546550	0.900	rs897122	chr2:70140271	C/T	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.59	-5.66	-0.3	3.2e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg08601574	chr20:25228251	PYGB	-0.43	-6.56	-0.34	2.06e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg13736514	chr6:26305472	NA	-0.45	-8.94	-0.44	2.72e-17	Educational attainment;
LUSC	cis	rs2292864	0.764	rs1969269	chr17:45335537	C/A	cg18085866	chr17:45331354	ITGB3	-0.71	-6.07	-0.32	3.46e-9	Left atrial antero-posterior diameter;
LUSC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg09035930	chr12:129282057	SLC15A4	0.73	15.47	0.65	4.48e-41	Systemic lupus erythematosus;
LUSC	cis	rs68170813	0.559	rs12535081	chr7:106979291	C/T	cg02696742	chr7:106810147	HBP1	-0.66	-9.77	-0.47	5.56e-20	Coronary artery disease;
LUSC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22968622	chr17:43663579	NA	0.8	12.38	0.56	3.25e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg05082376	chr22:42548792	NA	-0.43	-6.87	-0.35	3.23e-11	Schizophrenia;
LUSC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18404041	chr3:52824283	ITIH1	-0.47	-8.84	-0.44	5.48e-17	Bipolar disorder;
LUSC	cis	rs13315871	1.000	rs11710058	chr3:58383048	G/A	cg12435725	chr3:58293450	RPP14	-0.73	-7.19	-0.37	4.4e-12	Cholesterol, total;
LUSC	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg03909863	chr11:638404	DRD4	-0.41	-6.19	-0.32	1.81e-9	Systemic lupus erythematosus;
LUSC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg08888203	chr3:10149979	C3orf24	0.59	8.1	0.41	1.08e-14	Alzheimer's disease;
LUSC	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg26384229	chr12:38710491	ALG10B	0.72	11.31	0.53	2.59e-25	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	0.63	13.39	0.59	4.87e-33	Prudent dietary pattern;
LUSC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg07701084	chr6:150067640	NUP43	0.57	8.96	0.44	2.41e-17	Lung cancer;
LUSC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.67	-0.3	3.01e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg00033643	chr7:134001901	SLC35B4	0.45	7.05	0.36	1.02e-11	Mean platelet volume;
LUSC	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg08975724	chr8:8085496	FLJ10661	0.47	6.85	0.35	3.59e-11	Retinal vascular caliber;
LUSC	cis	rs4654899	0.680	rs12407731	chr1:21254789	C/T	cg01072550	chr1:21505969	NA	-0.54	-8.08	-0.4	1.21e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.65	10.85	0.51	1.07e-23	Systemic lupus erythematosus;
LUSC	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.05	-0.4	1.42e-14	Neuroticism;
LUSC	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg00310523	chr12:86230176	RASSF9	0.44	8.25	0.41	3.7e-15	Major depressive disorder;
LUSC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.67	0.34	1.07e-10	Menopause (age at onset);
LUSC	cis	rs6674970	0.933	rs11204772	chr1:151056305	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.46	-6.14	-0.32	2.4e-9	Childhood ear infection;
LUSC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.68	11.44	0.53	8.42e-26	Cognitive function;
LUSC	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-9.59	-0.46	2.08e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs6500395	1.000	rs7184144	chr16:48606077	C/T	cg04672837	chr16:48644449	N4BP1	0.43	6.47	0.33	3.47e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	1.22	16.56	0.67	2.15e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg19318889	chr4:1322082	MAEA	0.47	7.8	0.39	8.25e-14	Obesity-related traits;
LUSC	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg07167872	chr1:205819463	PM20D1	0.52	7.94	0.4	3.11e-14	Prostate-specific antigen levels;
LUSC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-0.82	-10.08	-0.48	4.74e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg22963979	chr7:1858916	MAD1L1	-0.73	-12.55	-0.57	7.22e-30	Bipolar disorder and schizophrenia;
LUSC	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg04827223	chr11:72435913	ARAP1	-0.73	-9.23	-0.45	3.17e-18	Type 2 diabetes;
LUSC	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-15.94	-0.66	6.34e-43	Height;
LUSC	cis	rs7605827	0.860	rs6760297	chr2:15632472	T/C	cg19274914	chr2:15703543	NA	0.47	9.15	0.45	5.75e-18	Educational attainment (years of education);
LUSC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.6	-0.38	3.03e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg25456477	chr12:86230367	RASSF9	0.38	6.83	0.35	4.07e-11	Major depressive disorder;
LUSC	cis	rs926938	0.563	rs360642	chr1:115425429	C/G	cg12756093	chr1:115239321	AMPD1	0.4	5.89	0.31	9.21e-9	Autism;
LUSC	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	0.99	12.02	0.55	6.89e-28	Nonalcoholic fatty liver disease;
LUSC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	11.52	0.53	4.54e-26	Menarche (age at onset);
LUSC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg05623727	chr3:50126028	RBM5	0.32	5.92	0.31	7.9e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg02466173	chr16:30829666	NA	-0.59	-10.69	-0.5	3.88e-23	Multiple myeloma;
LUSC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg00945038	chr17:61921165	SMARCD2	0.39	5.99	0.31	5.57e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09649245	chr11:44332195	ALX4	0.38	6.01	0.31	4.99e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9419702	0.538	rs9419625	chr10:133534954	T/G	cg04492858	chr10:133558786	NA	0.44	7.17	0.37	4.96e-12	Survival in rectal cancer;
LUSC	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.84	-0.35	3.68e-11	Response to antipsychotic treatment;
LUSC	cis	rs3741151	0.764	rs79892955	chr11:73096280	G/T	cg17517138	chr11:73019481	ARHGEF17	0.99	8.33	0.41	2.16e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.6	0.38	2.95e-13	Prudent dietary pattern;
LUSC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg12310025	chr6:25882481	NA	-0.43	-7.4	-0.38	1.12e-12	Blood metabolite levels;
LUSC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.65	0.34	1.19e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.58	10.66	0.5	4.78e-23	Homoarginine levels;
LUSC	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.32	0.53	2.36e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-7.64	-0.39	2.26e-13	Renal function-related traits (BUN);
LUSC	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg17127132	chr2:85788382	GGCX	0.44	6.26	0.32	1.17e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg12826209	chr6:26865740	GUSBL1	0.68	7.85	0.39	5.75e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg27170947	chr2:26402098	FAM59B	-0.65	-9.52	-0.46	3.75e-19	Gut microbiome composition (summer);
LUSC	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg06484146	chr7:12443880	VWDE	-0.68	-7.08	-0.36	8.67e-12	Coronary artery disease;
LUSC	cis	rs9504361	0.808	rs3765437	chr6:563013	C/T	cg15781525	chr6:564561	EXOC2	-0.36	-5.87	-0.31	1.03e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Psoriasis;Pit-and-Fissure caries;Eosinophil counts;
LUSC	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	1.11	18.39	0.71	1.19e-52	Primary sclerosing cholangitis;
LUSC	cis	rs3741151	0.773	rs17244596	chr11:73179236	A/G	cg17517138	chr11:73019481	ARHGEF17	0.97	8.24	0.41	3.9e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg11901034	chr3:128598214	ACAD9	-0.39	-6.0	-0.31	5.1e-9	IgG glycosylation;
LUSC	trans	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.79	0.47	4.54e-20	Mean corpuscular volume;
LUSC	trans	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg06606381	chr12:133084897	FBRSL1	-0.45	-5.97	-0.31	6.07e-9	Depression;
LUSC	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-6.03	-0.31	4.32e-9	Ulcerative colitis;
LUSC	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg14227996	chr4:17616232	MED28	0.82	7.87	0.4	4.98e-14	Opioid sensitivity;
LUSC	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg03929089	chr4:120376271	NA	0.72	6.86	0.35	3.37e-11	Axial length;
LUSC	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg13852791	chr20:30311386	BCL2L1	0.77	8.74	0.43	1.15e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg21782813	chr7:2030301	MAD1L1	0.35	5.89	0.31	9.53e-9	Schizophrenia;
LUSC	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg26727032	chr16:67993705	SLC12A4	-0.45	-5.96	-0.31	6.44e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg02176678	chr2:219576539	TTLL4	-0.55	-9.78	-0.47	4.92e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1950626	0.615	rs12893486	chr14:101463800	C/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.36	5.9	0.31	9.05e-9	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg20573242	chr4:122745356	CCNA2	0.58	8.45	0.42	8.9e-16	Type 2 diabetes;
LUSC	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg18290981	chr11:63789520	MACROD1	0.29	6.12	0.32	2.62e-9	Pulse pressure;
LUSC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11764359	chr7:65958608	NA	0.54	7.05	0.36	1.04e-11	Aortic root size;
LUSC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg12386194	chr3:101231763	SENP7	0.56	7.81	0.39	7.26e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg23093090	chr10:104574429	C10orf26	-0.36	-6.59	-0.34	1.71e-10	Arsenic metabolism;
LUSC	cis	rs7605827	0.930	rs13030859	chr2:15701038	G/A	cg19274914	chr2:15703543	NA	0.46	8.64	0.43	2.33e-16	Educational attainment (years of education);
LUSC	cis	rs669446	0.533	rs3791042	chr1:44219275	T/C	cg15962314	chr1:44399869	ARTN	0.24	5.81	0.3	1.49e-8	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	4.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg03161606	chr19:29218774	NA	0.61	9.03	0.44	1.38e-17	Methadone dose in opioid dependence;
LUSC	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg02073558	chr3:44770973	ZNF501	0.56	9.16	0.45	5.55e-18	Depressive symptoms;
LUSC	cis	rs4363385	0.626	rs6667103	chr1:153064438	A/G	cg00922841	chr1:152955080	SPRR1A	-0.35	-6.0	-0.31	5.06e-9	Inflammatory skin disease;
LUSC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg14440974	chr22:39074834	NA	-0.4	-6.47	-0.33	3.53e-10	Menopause (age at onset);
LUSC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg20243544	chr17:37824526	PNMT	0.38	5.65	0.3	3.45e-8	Self-reported allergy;
LUSC	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-5.94	-0.31	7.24e-9	Fear of minor pain;
LUSC	cis	rs11997175	0.766	rs4733178	chr8:33691899	A/T	ch.8.33884649F	chr8:33765107	NA	0.37	5.81	0.3	1.47e-8	Body mass index;
LUSC	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.63	6.94	0.35	2.09e-11	Crohn's disease;
LUSC	cis	rs56283067	0.887	rs4644056	chr6:44776136	G/T	cg18551225	chr6:44695536	NA	0.47	7.38	0.37	1.29e-12	Total body bone mineral density;
LUSC	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg02086790	chr16:375327	AXIN1	-0.37	-5.8	-0.3	1.53e-8	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg04865166	chr7:105162814	PUS7	0.51	5.74	0.3	2.17e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs3106136	0.901	rs17623135	chr4:95213091	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.24	-0.32	1.33e-9	Capecitabine sensitivity;
LUSC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11229555	0.598	rs7930623	chr11:58197641	A/G	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg07031243	chr17:40976230	BECN1	0.38	6.06	0.31	3.6e-9	Schizophrenia (age at onset);
LUSC	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-9.59	-0.46	2.08e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg20734569	chr3:48348370	SPINK8	-0.46	-7.81	-0.39	7.43e-14	Coronary artery disease;
LUSC	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.64	-10.68	-0.5	4.22e-23	Caffeine consumption;
LUSC	cis	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg06521852	chr22:38141419	TRIOBP	-0.35	-5.64	-0.3	3.57e-8	Glioblastoma;Glioma;
LUSC	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg09034736	chr1:150693464	HORMAD1	0.5	7.42	0.38	9.93e-13	Melanoma;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15190599	chr6:26156487	HIST1H1E	0.41	6.47	0.33	3.39e-10	Calcium levels;
LUSC	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14442939	chr10:27389572	ANKRD26	0.49	5.85	0.3	1.17e-8	Breast cancer;
LUSC	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg17385448	chr1:15911702	AGMAT	0.38	6.42	0.33	4.64e-10	Systolic blood pressure;
LUSC	cis	rs874628	0.703	rs72999449	chr19:18237050	A/T	cg00493341	chr19:18228948	MAST3	0.45	5.94	0.31	7.09e-9	Multiple sclerosis;
LUSC	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg11266682	chr4:10021025	SLC2A9	-0.55	-9.93	-0.48	1.53e-20	Bone mineral density;
LUSC	cis	rs4713675	0.565	rs1555965	chr6:33677400	A/G	cg14003231	chr6:33640908	ITPR3	0.29	5.69	0.3	2.82e-8	Plateletcrit;
LUSC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg14552801	chr7:65878734	NA	-0.46	-6.53	-0.34	2.45e-10	Aortic root size;
LUSC	cis	rs7424096	0.613	rs111805423	chr2:37248924	G/T	cg14987922	chr2:37194071	STRN	0.61	8.27	0.41	3.18e-15	High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg05926928	chr17:57297772	GDPD1	-0.89	-10.31	-0.49	8.13e-22	Opioid sensitivity;
LUSC	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg02886208	chr11:14281011	SPON1	0.33	5.9	0.31	8.91e-9	Mitochondrial DNA levels;
LUSC	cis	rs7000551	0.751	rs2449329	chr8:22374794	G/T	cg12081754	chr8:22256438	SLC39A14	0.45	6.86	0.35	3.3e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg11693508	chr17:37793320	STARD3	0.56	6.7	0.34	8.71e-11	Bipolar disorder;
LUSC	trans	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg01483505	chr11:975446	AP2A2	0.41	5.9	0.31	8.84e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg11344533	chr11:111475393	SIK2	-0.48	-6.49	-0.33	3.11e-10	Primary sclerosing cholangitis;
LUSC	cis	rs2562456	0.754	rs11666213	chr19:21605645	G/A	cg00806126	chr19:22604979	ZNF98	-0.4	-5.71	-0.3	2.43e-8	Pain;
LUSC	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg01657329	chr11:68192670	LRP5	0.48	6.32	0.33	8.42e-10	Bone mineral density (spine);
LUSC	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg11189052	chr15:85197271	WDR73	-0.59	-8.95	-0.44	2.5e-17	P wave terminal force;
LUSC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	8.27	0.41	3.32e-15	Mood instability;
LUSC	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.68	10.96	0.51	4.37e-24	Alcohol dependence;
LUSC	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg19508488	chr2:152266495	RIF1	0.39	5.71	0.3	2.54e-8	Lung cancer;
LUSC	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg21053147	chr12:120880522	NA	-0.49	-6.11	-0.32	2.77e-9	Type 1 diabetes nephropathy;
LUSC	trans	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.76	0.47	5.95e-20	Mean corpuscular volume;
LUSC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.64	12.29	0.56	6.94e-29	Pulse pressure;
LUSC	cis	rs7615316	0.902	rs6775718	chr3:142203235	G/T	cg16271453	chr3:142027066	XRN1	-0.39	-6.68	-0.34	9.95e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg24459738	chr19:57751996	ZNF805	-0.52	-7.69	-0.39	1.66e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs7605827	0.897	rs11892720	chr2:15674267	T/C	cg19274914	chr2:15703543	NA	0.45	8.44	0.42	9.88e-16	Educational attainment (years of education);
LUSC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg06740227	chr12:86229804	RASSF9	0.45	7.14	0.36	5.83e-12	Major depressive disorder;
LUSC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.52	-7.31	-0.37	2.03e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg20744362	chr22:50050164	C22orf34	0.38	8.05	0.4	1.44e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg21545522	chr1:205238299	TMCC2	0.45	8.44	0.42	9.5e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.27	0.52	3.49e-25	Menopause (age at onset);
LUSC	cis	rs6484504	0.600	rs1323738	chr11:31344898	T/C	cg26647111	chr11:31128758	NA	0.4	5.75	0.3	1.99e-8	Red blood cell count;
LUSC	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg00310523	chr12:86230176	RASSF9	0.47	8.52	0.42	5.52e-16	Major depressive disorder;
LUSC	cis	rs4938330	0.608	rs2277287	chr11:117096652	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-6.18	-0.32	1.83e-9	Blood protein levels;
LUSC	trans	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.2	0.49	1.86e-21	Mean corpuscular volume;
LUSC	cis	rs13315871	0.858	rs78946071	chr3:58318523	G/T	cg12435725	chr3:58293450	RPP14	-0.74	-7.16	-0.36	5.15e-12	Cholesterol, total;
LUSC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg00343986	chr7:65444356	GUSB	0.43	6.52	0.34	2.61e-10	Aortic root size;
LUSC	cis	rs1595825	0.891	rs59938443	chr2:198497105	C/T	cg19156104	chr2:198669113	PLCL1	-0.46	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg00944433	chr1:107599041	PRMT6	-0.38	-7.07	-0.36	9.07e-12	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg04727924	chr7:799746	HEATR2	-0.57	-6.02	-0.31	4.67e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg14675211	chr2:100938903	LONRF2	0.37	5.72	0.3	2.38e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1044826	0.692	rs169824	chr3:139235006	G/C	cg15131784	chr3:139108705	COPB2	-0.4	-6.43	-0.33	4.38e-10	Obesity-related traits;
LUSC	cis	rs3803170	0.513	rs10849941	chr12:111818487	A/T	cg10833066	chr12:111807467	FAM109A	0.41	7.9	0.4	3.98e-14	Mean corpuscular hemoglobin;
LUSC	cis	rs11039100	0.564	rs2047461	chr11:5783226	A/G	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg04374321	chr14:90722782	PSMC1	0.76	12.09	0.55	3.56e-28	Mortality in heart failure;
LUSC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg12963246	chr6:28129442	ZNF389	0.52	7.53	0.38	4.84e-13	Parkinson's disease;
LUSC	cis	rs9297145	0.585	rs4729521	chr7:98780520	G/T	cg05967295	chr7:98741636	SMURF1	-0.64	-10.06	-0.48	5.78e-21	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs73198271	0.710	rs7837843	chr8:8656485	A/G	cg01851573	chr8:8652454	MFHAS1	0.47	7.74	0.39	1.22e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs796364	0.616	rs6718118	chr2:200691852	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-5.97	-0.31	6.12e-9	Schizophrenia;
LUSC	cis	rs62458065	0.640	rs6950077	chr7:32502895	A/G	cg20159608	chr7:32802032	NA	0.72	9.29	0.45	1.96e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg14530993	chr4:882597	GAK	-0.65	-7.16	-0.36	5.14e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg04455712	chr21:45112962	RRP1B	-0.48	-8.85	-0.44	5.03e-17	Mean corpuscular volume;
LUSC	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg00129232	chr17:37814104	STARD3	-0.43	-6.36	-0.33	6.5e-10	Asthma;
LUSC	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg18478394	chr8:109455254	TTC35	0.44	6.81	0.35	4.63e-11	Dupuytren's disease;
LUSC	cis	rs9677476	0.863	rs57199832	chr2:232069083	T/G	cg07929768	chr2:232055508	NA	0.36	6.99	0.36	1.48e-11	Food antigen IgG levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24412469	chr1:200590040	KIF14	0.4	6.06	0.31	3.66e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg21880101	chr17:80066754	CCDC57	-0.31	-5.85	-0.31	1.15e-8	Life satisfaction;
LUSC	cis	rs4144743	0.938	rs55677902	chr17:45322572	G/T	cg18085866	chr17:45331354	ITGB3	-0.75	-7.99	-0.4	2.18e-14	Body mass index;
LUSC	cis	rs16912285	0.688	rs7109312	chr11:24338974	G/A	ch.11.24196551F	chr11:24239977	NA	0.85	8.08	0.4	1.18e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg02931644	chr1:25747376	RHCE	-0.32	-5.76	-0.3	1.89e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg13206674	chr6:150067644	NUP43	-0.57	-9.09	-0.45	8.66e-18	Lung cancer;
LUSC	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-0.51	-7.81	-0.39	7.54e-14	Breast cancer;
LUSC	cis	rs1160297	0.609	rs1828338	chr2:53096951	T/C	cg07782112	chr2:53107842	NA	0.41	6.58	0.34	1.79e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.55	-8.2	-0.41	5.16e-15	Gut microbiome composition (summer);
LUSC	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg24881330	chr22:46731750	TRMU	0.68	6.52	0.34	2.56e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.2	0.32	1.67e-9	Systolic blood pressure;
LUSC	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs1524927	0.966	rs11772629	chr7:96332857	C/G	cg03808172	chr7:96339361	SHFM1	0.45	6.88	0.35	3.01e-11	Total body bone mineral density;
LUSC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg03709012	chr19:19516395	GATAD2A	0.74	11.31	0.53	2.46e-25	Tonsillectomy;
LUSC	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.54	0.5	1.27e-22	Colorectal cancer;
LUSC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.02	-0.4	1.76e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs17597773	0.638	rs12145674	chr1:221000273	C/T	cg25786136	chr2:222575520	NA	-0.4	-6.16	-0.32	2.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg13206674	chr6:150067644	NUP43	0.56	8.91	0.44	3.36e-17	Lung cancer;
LUSC	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg21775007	chr8:11205619	TDH	-0.47	-6.64	-0.34	1.29e-10	Neuroticism;
LUSC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.33	0.56	4.75e-29	Prudent dietary pattern;
LUSC	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-7.18	-0.37	4.63e-12	Fear of minor pain;
LUSC	cis	rs2637266	0.935	rs12772269	chr10:78394292	C/A	cg18941641	chr10:78392320	NA	0.42	7.62	0.38	2.59e-13	Pulmonary function;
LUSC	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg05855489	chr10:104503620	C10orf26	-0.67	-9.52	-0.46	3.64e-19	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7818345	0.967	rs13255677	chr8:19288985	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.9	0.35	2.59e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.72	-17.35	-0.69	1.58e-48	Prostate cancer;
LUSC	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg13535736	chr9:111863775	C9orf5	-0.41	-6.77	-0.35	5.83e-11	Menarche (age at onset);
LUSC	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg16743903	chr16:89593216	SPG7	0.36	5.67	0.3	3.08e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	0.64	7.9	0.4	4.07e-14	Pulmonary function decline;
LUSC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg08859206	chr1:53392774	SCP2	0.49	8.26	0.41	3.56e-15	Monocyte count;
LUSC	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg13256891	chr4:100009986	ADH5	0.44	5.86	0.31	1.1e-8	Alcohol dependence;
LUSC	cis	rs138544659	1	rs138544659	chr15:78900701	T/G	cg06917634	chr15:78832804	PSMA4	-0.44	-5.91	-0.31	8.24e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg09904177	chr6:26538194	HMGN4	-0.74	-6.83	-0.35	4.11e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10193935	0.901	rs10200000	chr2:42442212	A/G	cg27598129	chr2:42591480	NA	-0.64	-8.68	-0.43	1.83e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg01097406	chr16:89675127	NA	0.32	5.67	0.3	3.08e-8	Vitiligo;
LUSC	cis	rs60154123	0.730	rs4844987	chr1:210458190	G/T	cg22029157	chr1:209979665	IRF6	0.51	5.84	0.3	1.23e-8	Coronary artery disease;
LUSC	cis	rs4622329	0.636	rs4764665	chr12:102287929	G/T	cg23541617	chr12:102225335	GNPTAB	0.27	6.39	0.33	5.47e-10	Systemic lupus erythematosus;
LUSC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.36	-0.33	6.55e-10	Extrinsic epigenetic age acceleration;
LUSC	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs10740039	0.883	rs10821809	chr10:62397370	A/G	cg18175470	chr10:62150864	ANK3	-0.46	-6.85	-0.35	3.59e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg05738196	chr6:26577821	NA	0.47	7.0	0.36	1.39e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg00825309	chr19:58991885	ZNF446	0.48	7.1	0.36	7.55e-12	Uric acid clearance;
LUSC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.73	12.05	0.55	5.05e-28	Coronary artery disease;
LUSC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	ch.11.42038R	chr11:967971	AP2A2	0.43	6.49	0.33	3.1e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.44	-0.33	4.15e-10	Arsenic metabolism;
LUSC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.24	0.52	4.29e-25	Eye color traits;
LUSC	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg10130564	chr11:117069849	TAGLN	0.3	5.79	0.3	1.65e-8	Blood protein levels;
LUSC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg03146154	chr1:46216737	IPP	0.51	7.67	0.39	1.84e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.26	0.41	3.44e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg18232548	chr7:50535776	DDC	-0.65	-9.65	-0.47	1.3e-19	Systemic sclerosis;
LUSC	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	7.59	0.38	3.33e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10140922	0.966	rs10083387	chr14:35823669	G/A	cg07166546	chr14:35805898	NA	-0.26	-6.31	-0.33	8.77e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg00757033	chr12:89920650	WDR51B	0.61	10.59	0.5	8.76e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-7.99	-0.4	2.19e-14	Chronic sinus infection;
LUSC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.84	0.3	1.21e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg19875535	chr5:140030758	IK	0.52	8.43	0.42	1.04e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg16405210	chr4:1374714	KIAA1530	0.55	8.21	0.41	4.9e-15	Obesity-related traits;
LUSC	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg04374321	chr14:90722782	PSMC1	-0.47	-7.25	-0.37	2.99e-12	Mortality in heart failure;
LUSC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.52	-7.15	-0.36	5.4e-12	Mean platelet volume;
LUSC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg06640241	chr16:89574553	SPG7	0.71	11.25	0.52	4.02e-25	Multiple myeloma (IgH translocation);
LUSC	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg20991723	chr1:152506922	NA	0.51	9.59	0.46	2.12e-19	Hair morphology;
LUSC	cis	rs79387448	0.745	rs6742433	chr2:103175360	C/T	cg09003973	chr2:102972529	NA	0.88	8.38	0.42	1.52e-15	Gut microbiota (bacterial taxa);
LUSC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.49	-0.38	6.39e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18099408	chr3:52552593	STAB1	-0.4	-7.03	-0.36	1.19e-11	Electroencephalogram traits;
LUSC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg01176363	chr20:62369445	LIME1	-0.47	-7.14	-0.36	5.85e-12	Prostate cancer;
LUSC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-7.98	-0.4	2.29e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1775715	0.737	rs2808090	chr10:32143208	A/C	cg03015672	chr10:32216066	ARHGAP12	0.33	6.02	0.31	4.59e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg00993799	chr7:104653126	LOC100216545	0.41	7.39	0.37	1.15e-12	Triglycerides;
LUSC	cis	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg09307838	chr4:120376055	NA	0.46	6.93	0.35	2.18e-11	Diastolic blood pressure;
LUSC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg17340268	chr14:105411764	AHNAK2	-0.38	-6.07	-0.32	3.45e-9	Rheumatoid arthritis;
LUSC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-11.46	-0.53	6.98e-26	Mood instability;
LUSC	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.09	-0.4	1.14e-14	Morning vs. evening chronotype;
LUSC	cis	rs13385	0.769	rs59443048	chr5:139602802	C/A	cg26211634	chr5:139558579	C5orf32	0.45	6.57	0.34	1.96e-10	Atrial fibrillation;
LUSC	trans	rs2162440	0.571	rs1427042	chr18:35208228	T/C	cg00460916	chr17:3698239	ITGAE	0.53	6.01	0.31	4.95e-9	Telomere length;
LUSC	cis	rs981844	0.775	rs17371261	chr4:154738479	G/T	cg14289246	chr4:154710475	SFRP2	-0.47	-6.46	-0.33	3.69e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg18190219	chr22:46762943	CELSR1	-0.48	-5.94	-0.31	7.32e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs698813	0.637	rs4952706	chr2:44500536	T/C	cg00619915	chr2:44497795	NA	-0.52	-6.99	-0.36	1.54e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.19	0.52	6.7e-25	Ileal carcinoids;
LUSC	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg11845111	chr2:191398756	TMEM194B	-0.88	-10.76	-0.51	2.31e-23	Diastolic blood pressure;
LUSC	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg12927641	chr6:109611667	NA	-0.35	-5.9	-0.31	8.95e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25072359	chr17:41440525	NA	0.65	9.39	0.46	9.33e-19	Menopause (age at onset);
LUSC	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg07701084	chr6:150067640	NUP43	0.52	7.78	0.39	8.84e-14	Lung cancer;
LUSC	cis	rs9905704	0.914	rs2611777	chr17:56826958	A/G	cg12560992	chr17:57184187	TRIM37	0.56	7.89	0.4	4.39e-14	Testicular germ cell tumor;
LUSC	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.75	-0.43	1.08e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7215564	0.908	rs7501674	chr17:78662177	C/T	cg23238734	chr17:78661607	RPTOR	0.46	5.95	0.31	6.75e-9	Myopia (pathological);
LUSC	cis	rs6580649	0.941	rs57380031	chr12:48452237	C/T	cg24011408	chr12:48396354	COL2A1	-0.46	-6.17	-0.32	1.95e-9	Lung cancer;
LUSC	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.45	6.01	0.31	4.94e-9	Renal function-related traits (BUN);
LUSC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg22920501	chr2:26401640	FAM59B	0.71	8.66	0.43	2.02e-16	Gut microbiome composition (summer);
LUSC	cis	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg06521331	chr12:34319734	NA	-0.36	-6.11	-0.32	2.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs2236918	0.687	rs1776176	chr1:242012554	C/T	cg17736920	chr1:242011382	EXO1	0.43	6.85	0.35	3.52e-11	Menopause (age at onset);
LUSC	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg05527609	chr1:210001259	C1orf107	0.71	10.3	0.49	8.45e-22	Orofacial clefts;
LUSC	trans	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	7.51	0.38	5.4e-13	Menarche (age at onset);
LUSC	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg12573674	chr2:1569213	NA	-0.46	-5.96	-0.31	6.26e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg23982607	chr1:1823379	GNB1	0.54	9.98	0.48	1.07e-20	Body mass index;
LUSC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.25	0.59	1.67e-32	Chronic sinus infection;
LUSC	cis	rs6840360	0.642	rs1443088	chr4:152450126	G/A	cg20465933	chr4:152376761	FAM160A1	0.32	5.77	0.3	1.85e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg17724175	chr1:150552817	MCL1	0.37	6.79	0.35	5.02e-11	Tonsillectomy;
LUSC	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.16	0.52	8.94e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg25922239	chr6:33757077	LEMD2	0.55	8.24	0.41	4.05e-15	Crohn's disease;
LUSC	trans	rs1325195	0.881	rs2791941	chr1:179112435	G/A	cg11624085	chr17:8464688	MYH10	0.43	7.11	0.36	6.97e-12	IgE grass sensitization;
LUSC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.06	-0.36	9.67e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.94	0.4	3.06e-14	Bipolar disorder;
LUSC	cis	rs9818941	0.824	rs12632906	chr3:157726384	T/A	cg08654915	chr3:157813417	NA	-0.32	-7.39	-0.37	1.23e-12	Height;
LUSC	cis	rs11048434	0.736	rs2377672	chr12:9112414	A/G	cg04155231	chr12:9217510	LOC144571	0.3	5.66	0.3	3.26e-8	Sjögren's syndrome;
LUSC	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg23422044	chr7:1970798	MAD1L1	-0.62	-7.23	-0.37	3.36e-12	Bipolar disorder;
LUSC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg23711669	chr6:146136114	FBXO30	-0.92	-17.68	-0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg10845886	chr2:3471009	TTC15	-0.62	-7.95	-0.4	2.92e-14	Neurofibrillary tangles;
LUSC	cis	rs1775715	0.707	rs2778669	chr10:32161541	C/T	cg03015672	chr10:32216066	ARHGAP12	0.33	6.01	0.31	4.87e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg23229984	chr5:148520753	ABLIM3	0.41	6.01	0.31	4.94e-9	Breast cancer;
LUSC	cis	rs9361491	0.543	rs1507153	chr6:79484386	C/A	cg05283184	chr6:79620031	NA	-0.44	-8.04	-0.4	1.55e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg16230307	chr14:35515116	FAM177A1	0.81	10.35	0.49	5.97e-22	Psoriasis;
LUSC	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.3e-11	Uric acid levels;
LUSC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.64	10.49	0.5	1.86e-22	Bone mineral density;
LUSC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg16584290	chr5:462447	EXOC3	-0.36	-6.24	-0.32	1.34e-9	Cystic fibrosis severity;
LUSC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg24375607	chr4:120327624	NA	0.78	11.58	0.54	2.65e-26	Corneal astigmatism;
LUSC	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05901451	chr6:126070800	HEY2	-0.76	-12.96	-0.58	2.07e-31	Brugada syndrome;
LUSC	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.55	-7.4	-0.38	1.12e-12	Schizophrenia;
LUSC	cis	rs113835537	0.935	rs1127145	chr11:66373305	G/A	cg24851651	chr11:66362959	CCS	0.52	6.4	0.33	5.11e-10	Airway imaging phenotypes;
LUSC	cis	rs4280164	0.945	rs1131941	chr14:24760808	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.58	-6.73	-0.35	7.18e-11	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs1346	0.552	rs10791820	chr11:65366847	C/T	cg17120908	chr11:65337727	SSSCA1	-0.41	-5.72	-0.3	2.31e-8	Vertical cup-disc ratio;Optic cup area;
LUSC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg25036284	chr2:26402008	FAM59B	-0.72	-9.87	-0.48	2.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg23625390	chr15:77176239	SCAPER	0.46	7.0	0.36	1.44e-11	Blood metabolite levels;
LUSC	cis	rs2579519	0.547	rs11683523	chr2:96544855	T/C	cg22654517	chr2:96458247	NA	0.37	6.92	0.35	2.33e-11	Diastolic blood pressure;
LUSC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.75e-14	Melanoma;
LUSC	cis	rs4964805	0.594	rs10861096	chr12:104169356	C/T	cg02344784	chr12:104178138	NT5DC3	0.37	6.01	0.31	4.95e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg19729930	chr2:74357872	NA	0.89	16.74	0.68	4.36e-46	Gestational age at birth (maternal effect);
LUSC	cis	rs8014204	0.762	rs973879	chr14:75297727	T/C	cg06637938	chr14:75390232	RPS6KL1	0.51	8.09	0.4	1.14e-14	Caffeine consumption;
LUSC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg12463550	chr7:65579703	CRCP	-0.52	-7.63	-0.39	2.44e-13	Aortic root size;
LUSC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06022373	chr22:39101656	GTPBP1	0.8	12.4	0.56	2.59e-29	Menopause (age at onset);
LUSC	cis	rs500891	1.000	rs13205618	chr6:84177713	C/T	cg08257003	chr6:84140564	ME1	0.34	7.12	0.36	6.55e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg20283391	chr11:68216788	NA	-0.57	-8.1	-0.41	1.03e-14	Total body bone mineral density;
LUSC	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg14092988	chr3:52407081	DNAH1	0.43	7.47	0.38	7.05e-13	Bipolar disorder;
LUSC	cis	rs870825	0.929	rs10015218	chr4:185589789	T/C	cg04058563	chr4:185651563	MLF1IP	0.81	10.66	0.5	4.96e-23	Blood protein levels;
LUSC	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg22508957	chr16:3507546	NAT15	-0.39	-6.12	-0.32	2.68e-9	Body mass index (adult);
LUSC	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg06917634	chr15:78832804	PSMA4	-0.8	-14.02	-0.61	1.89e-35	Sudden cardiac arrest;
LUSC	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.67	-0.39	1.9e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg03929089	chr4:120376271	NA	0.69	7.78	0.39	9.14e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2236918	0.687	rs1776136	chr1:242026845	G/A	cg17736920	chr1:242011382	EXO1	0.42	6.76	0.35	5.99e-11	Menopause (age at onset);
LUSC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.29	-0.33	9.68e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg24692254	chr21:30365293	RNF160	0.51	6.72	0.35	7.9e-11	Cognitive test performance;
LUSC	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs920590	0.573	rs4392917	chr8:19680635	G/C	cg03894339	chr8:19674705	INTS10	-0.43	-6.07	-0.32	3.53e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.9	-0.4	4.01e-14	Glomerular filtration rate;
LUSC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	8.51	0.42	5.86e-16	Colorectal cancer;
LUSC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06544989	chr22:39130855	UNC84B	0.37	6.61	0.34	1.49e-10	Menopause (age at onset);
LUSC	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg13057898	chr1:3703894	LRRC47	0.52	9.03	0.44	1.45e-17	Red cell distribution width;
LUSC	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	8.15	0.41	7.42e-15	Homoarginine levels;
LUSC	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg01629716	chr15:45996671	NA	0.39	5.96	0.31	6.31e-9	Waist circumference;Weight;
LUSC	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg10172584	chr19:19639581	YJEFN3	-0.46	-5.65	-0.3	3.42e-8	Bipolar disorder;
LUSC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-1.03	-11.43	-0.53	9.01e-26	Diabetic kidney disease;
LUSC	cis	rs6076065	0.676	rs4813490	chr20:23325150	A/G	cg11657817	chr20:23433608	CST11	0.45	8.36	0.42	1.71e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-5.67	-0.3	3.16e-8	Obesity-related traits;
LUSC	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.98	-0.36	1.58e-11	Bladder cancer;
LUSC	cis	rs240764	0.817	rs239226	chr6:101107969	G/C	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.69e-9	Neuroticism;
LUSC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg06008330	chr7:65541103	ASL	-0.41	-6.44	-0.33	4.23e-10	Aortic root size;
LUSC	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg03585969	chr10:35415529	CREM	0.6	8.79	0.43	8.31e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.55	-0.42	4.55e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg07211511	chr3:129823064	LOC729375	-0.78	-10.66	-0.5	5.09e-23	Blood pressure (smoking interaction);
LUSC	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg09904177	chr6:26538194	HMGN4	0.65	11.67	0.54	1.3e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg20026190	chr17:76395443	PGS1	0.45	7.82	0.39	7.14e-14	HDL cholesterol levels;
LUSC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs62458065	0.713	rs3801329	chr7:32496956	A/C	cg20159608	chr7:32802032	NA	-0.73	-9.16	-0.45	5.55e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs17401966	0.838	rs12141246	chr1:10327407	A/T	cg19773385	chr1:10388646	KIF1B	-0.49	-8.48	-0.42	7.19e-16	Hepatocellular carcinoma;
LUSC	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg27539214	chr16:67997921	SLC12A4	-0.58	-6.92	-0.35	2.3e-11	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs6030	0.957	rs2239852	chr1:169512524	C/T	cg16792071	chr10:134842795	NA	0.29	6.19	0.32	1.79e-9	Uric acid levels;
LUSC	cis	rs4343996	0.754	rs4327753	chr7:3372249	C/G	cg21248987	chr7:3385318	SDK1	-0.37	-6.34	-0.33	7.33e-10	Motion sickness;
LUSC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.68	11.57	0.53	2.84e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg01238044	chr22:24384105	GSTT1	0.5	7.03	0.36	1.14e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg21285383	chr16:89894308	SPIRE2	0.3	5.83	0.3	1.31e-8	Vitiligo;
LUSC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg21782813	chr7:2030301	MAD1L1	0.38	6.17	0.32	1.95e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.87	0.35	3.08e-11	IgG glycosylation;
LUSC	cis	rs9398803	0.830	rs2039735	chr6:126745076	T/C	cg19875578	chr6:126661172	C6orf173	0.43	6.27	0.32	1.11e-9	Male-pattern baldness;
LUSC	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg15133208	chr4:90757351	SNCA	-0.53	-8.19	-0.41	5.53e-15	Neuroticism;
LUSC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg18758796	chr5:131593413	PDLIM4	0.44	7.41	0.38	1.04e-12	Blood metabolite levels;
LUSC	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.51	6.84	0.35	3.71e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg15571903	chr15:79123663	NA	-0.34	-6.26	-0.32	1.16e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg00784671	chr22:46762841	CELSR1	-0.49	-6.7	-0.34	9.04e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg12935359	chr14:103987150	CKB	-0.56	-8.6	-0.43	3.13e-16	Body mass index;
LUSC	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg05805236	chr11:65401703	PCNXL3	-0.65	-10.68	-0.5	4.33e-23	Acne (severe);
LUSC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg23758822	chr17:41437982	NA	1.0	15.85	0.66	1.34e-42	Menopause (age at onset);
LUSC	cis	rs10465746	0.967	rs6576956	chr1:84343885	T/G	cg10977910	chr1:84465055	TTLL7	0.45	6.39	0.33	5.52e-10	Obesity-related traits;
LUSC	trans	rs2288327	0.915	rs2303838	chr2:179444939	C/T	cg14011486	chr1:26737247	LIN28	0.47	5.95	0.31	6.87e-9	Atrial fibrillation;
LUSC	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg03929089	chr4:120376271	NA	-0.53	-7.43	-0.38	9.25e-13	Coronary artery disease;
LUSC	trans	rs7939886	0.920	rs10501343	chr11:55759573	G/T	cg15704280	chr7:45808275	SEPT13	0.84	7.06	0.36	9.96e-12	Myopia (pathological);
LUSC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg15782153	chr7:917662	C7orf20	0.43	6.49	0.33	3.09e-10	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.83	0.75	2.5e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs977987	0.806	rs12917651	chr16:75466696	G/T	cg03315344	chr16:75512273	CHST6	0.5	9.52	0.46	3.5e-19	Dupuytren's disease;
LUSC	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.12	-0.32	2.61e-9	Resting heart rate;
LUSC	cis	rs17828380	0.920	rs71394508	chr15:63603615	C/T	cg05507819	chr15:63340323	TPM1	-0.77	-6.31	-0.33	8.71e-10	Social communication problems;
LUSC	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg06917634	chr15:78832804	PSMA4	0.47	5.97	0.31	5.95e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.94	0.31	7.17e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.75	0.35	6.45e-11	Menarche (age at onset);
LUSC	trans	rs2736345	0.516	rs9657551	chr8:11398183	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	6.38	0.33	5.77e-10	Sjögren's syndrome;Systemic lupus erythematosus;
LUSC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg23719950	chr11:63933701	MACROD1	0.6	8.04	0.4	1.55e-14	Mean platelet volume;
LUSC	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg01119278	chr6:110721349	DDO	-0.44	-7.8	-0.39	7.79e-14	Platelet distribution width;
LUSC	cis	rs7927771	0.800	rs11039200	chr11:47379646	A/C	cg20307385	chr11:47447363	PSMC3	-0.5	-6.3	-0.33	9.36e-10	Subjective well-being;
LUSC	cis	rs7577696	0.962	rs212679	chr2:32431107	C/A	cg02381751	chr2:32503542	YIPF4	0.41	5.92	0.31	8.06e-9	Inflammatory biomarkers;
LUSC	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg18099408	chr3:52552593	STAB1	0.36	5.98	0.31	5.74e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-11.17	-0.52	7.7e-25	Coronary artery disease;
LUSC	cis	rs7178572	0.568	rs12908262	chr15:77493256	G/A	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	8.02	0.4	1.76e-14	Retinal vascular caliber;
LUSC	cis	rs11583043	0.546	rs6688545	chr1:101590335	G/A	cg11406453	chr1:101602562	NA	-0.41	-6.82	-0.35	4.4e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs2267137	0.903	rs2283850	chr22:29772391	G/C	cg07256473	chr22:29710276	RASL10A	0.38	7.37	0.37	1.38e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg13798780	chr7:105162888	PUS7	0.55	6.08	0.32	3.27e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg00509249	chr6:109615579	CCDC162	-0.33	-5.77	-0.3	1.78e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.37	-6.25	-0.32	1.23e-9	Breast cancer;
LUSC	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	6.07	0.32	3.5e-9	Schizophrenia;
LUSC	cis	rs2652834	0.851	rs9888735	chr15:63410141	G/A	cg05507819	chr15:63340323	TPM1	0.46	5.94	0.31	7.3e-9	HDL cholesterol;
LUSC	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg05340658	chr4:99064831	C4orf37	0.63	9.84	0.47	3.15e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg04518342	chr5:131593106	PDLIM4	0.34	6.33	0.33	7.73e-10	Blood metabolite levels;
LUSC	trans	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.84	-0.35	3.85e-11	Neuroticism;
LUSC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg08132940	chr7:1081526	C7orf50	-0.47	-6.0	-0.31	5.24e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.51	-6.84	-0.35	3.68e-11	Tonsillectomy;
LUSC	cis	rs6906287	0.647	rs12206329	chr6:118863789	G/T	cg21191810	chr6:118973309	C6orf204	0.33	5.95	0.31	6.92e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.82	0.3	1.4e-8	Tonsillectomy;
LUSC	cis	rs2742417	0.603	rs2673075	chr3:45778288	C/A	cg10512202	chr3:45649293	LIMD1	0.36	6.06	0.31	3.57e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs4478858	0.735	rs10914368	chr1:31847937	A/G	cg00250761	chr1:31883323	NA	-0.36	-8.52	-0.42	5.4e-16	Alcohol dependence;
LUSC	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.54	-14.73	-0.63	3.31e-38	Urate levels in overweight individuals;
LUSC	cis	rs4595586	0.655	rs4142847	chr12:39395128	C/T	cg26384229	chr12:38710491	ALG10B	0.43	5.93	0.31	7.46e-9	Morning vs. evening chronotype;
LUSC	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg27219399	chr15:67835830	MAP2K5	0.36	5.95	0.31	6.94e-9	Restless legs syndrome;
LUSC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.52	-0.34	2.63e-10	Total body bone mineral density;
LUSC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.46	-0.38	7.79e-13	Aortic root size;
LUSC	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg20701182	chr2:24300061	SF3B14	0.59	6.26	0.32	1.21e-9	Lymphocyte counts;
LUSC	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg16989719	chr2:238392110	NA	-0.37	-6.51	-0.34	2.78e-10	Prostate cancer;
LUSC	cis	rs7605827	0.930	rs2058869	chr2:15679700	T/C	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.77e-16	Educational attainment (years of education);
LUSC	cis	rs1971762	0.563	rs7958775	chr12:54077556	T/C	cg23533419	chr12:54090519	NA	-0.37	-6.02	-0.31	4.6e-9	Height;
LUSC	cis	rs1451375	0.698	rs56766899	chr7:50648938	T/C	cg18232548	chr7:50535776	DDC	0.5	7.58	0.38	3.49e-13	Malaria;
LUSC	trans	rs10518128	1.000	rs10011543	chr4:75711122	C/T	cg04432875	chr13:113411561	ATP11A	0.54	6.02	0.31	4.5e-9	Electroencephalogram traits;
LUSC	cis	rs3087591	0.659	rs2214538	chr17:29636570	C/T	cg24425628	chr17:29625626	OMG;NF1	0.48	7.2	0.37	4.09e-12	Hip circumference;
LUSC	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg10356904	chr22:49881777	NA	-0.29	-5.91	-0.31	8.54e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg03342759	chr3:160939853	NMD3	-0.56	-9.5	-0.46	4.15e-19	Morning vs. evening chronotype;
LUSC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	0.6	9.29	0.45	2.11e-18	Breast cancer;
LUSC	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.13	-0.41	8.75e-15	Neuroticism;
LUSC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-1.01	-17.18	-0.68	7.55e-48	Body mass index;
LUSC	cis	rs3741151	0.773	rs7115055	chr11:73227827	T/C	cg17517138	chr11:73019481	ARHGEF17	0.96	8.06	0.4	1.35e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00149659	chr3:10157352	C3orf10	1.0	14.11	0.61	8.69e-36	Alzheimer's disease;
LUSC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-16.79	-0.68	2.69e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06634786	chr22:41940651	POLR3H	0.49	5.73	0.3	2.21e-8	Vitiligo;
LUSC	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg10596483	chr8:143751796	JRK	0.53	7.59	0.38	3.21e-13	Schizophrenia;
LUSC	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.31	0.37	1.98e-12	Motion sickness;
LUSC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg09034736	chr1:150693464	HORMAD1	0.44	6.26	0.32	1.18e-9	Melanoma;
LUSC	trans	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.23	0.52	4.84e-25	Mean corpuscular volume;
LUSC	cis	rs6669072	1.000	rs6669072	chr1:91247345	C/T	cg08895590	chr1:91227319	NA	-0.37	-8.25	-0.41	3.6e-15	Cognitive function;
LUSC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg06618935	chr21:46677482	NA	-0.38	-7.52	-0.38	5.23e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg21775007	chr8:11205619	TDH	-0.44	-6.08	-0.32	3.32e-9	Neuroticism;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg10891507	chr20:56285236	PMEPA1	0.7	6.24	0.32	1.31e-9	Cognitive performance;
LUSC	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg04374321	chr14:90722782	PSMC1	-0.43	-6.51	-0.34	2.72e-10	Mortality in heart failure;
LUSC	cis	rs62400317	0.859	rs12193720	chr6:45103362	A/G	cg20913747	chr6:44695427	NA	-0.46	-7.41	-0.38	1.05e-12	Total body bone mineral density;
LUSC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg06238570	chr21:40685208	BRWD1	0.47	7.25	0.37	2.94e-12	Cognitive function;
LUSC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg14061069	chr19:46274453	DMPK	0.67	13.86	0.6	8.31e-35	Coronary artery disease;
LUSC	trans	rs12210905	0.925	rs9467965	chr6:26992539	G/C	cg11837749	chr1:55047332	ACOT11	0.55	6.0	0.31	5.25e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs2540226	0.844	rs12624217	chr2:39997694	C/T	cg23576258	chr2:39999331	THUMPD2	0.34	5.75	0.3	1.99e-8	Personality dimensions;
LUSC	cis	rs4888262	0.508	rs6564153	chr16:74658723	A/C	cg01733217	chr16:74700730	RFWD3	0.77	12.34	0.56	4.38e-29	Testicular germ cell tumor;
LUSC	cis	rs9646944	0.501	rs10202813	chr2:103019740	A/C	cg20060108	chr2:102954350	IL1RL1	-0.44	-6.7	-0.34	9.12e-11	Blood protein levels;
LUSC	cis	rs4663866	1.000	rs4663867	chr2:239159964	G/C	cg16914508	chr2:239161102	PER2	0.68	7.14	0.36	5.87e-12	Irritable bowel syndrome;
LUSC	trans	rs7939886	0.920	rs7107736	chr11:55987980	C/G	cg03929089	chr4:120376271	NA	0.82	6.13	0.32	2.55e-9	Myopia (pathological);
LUSC	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg18305652	chr10:134549665	INPP5A	0.44	6.66	0.34	1.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.58	8.69	0.43	1.67e-16	Gut microbiome composition (summer);
LUSC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg17376030	chr22:41985996	PMM1	-0.47	-5.84	-0.3	1.25e-8	Vitiligo;
LUSC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg16325326	chr1:53192061	ZYG11B	0.82	14.09	0.61	1.07e-35	Monocyte count;
LUSC	cis	rs1950500	0.509	rs12888965	chr14:24834291	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.53	8.14	0.41	7.9e-15	Height;
LUSC	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-10.08	-0.48	4.89e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs61774743	0.636	rs1892423	chr1:41849340	A/C	cg08462924	chr1:41848221	NA	0.47	7.93	0.4	3.33e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08470875	chr2:26401718	FAM59B	-0.68	-9.27	-0.45	2.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg00343986	chr7:65444356	GUSB	-0.42	-6.46	-0.33	3.7e-10	Aortic root size;
LUSC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg25767906	chr1:53392781	SCP2	-0.36	-6.1	-0.32	2.89e-9	Monocyte count;
LUSC	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg23791538	chr6:167370224	RNASET2	0.5	8.21	0.41	4.88e-15	Crohn's disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg24603235	chr6:33588219	ITPR3	0.8	6.41	0.33	4.86e-10	Cognitive performance;
LUSC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	trans	rs6982636	1.000	rs2980856	chr8:126476379	C/G	cg13325919	chr3:181432053	SOX2;SOX2OT	0.35	6.69	0.34	9.62e-11	Lipid metabolism phenotypes;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07832834	chr1:2457954	PANK4	-0.33	-6.03	-0.31	4.37e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs12900413	0.687	rs28465116	chr15:90310152	T/C	cg24249390	chr15:90295951	MESP1	-0.37	-5.91	-0.31	8.6e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.7	0.34	8.68e-11	Lung cancer;
LUSC	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02176678	chr2:219576539	TTLL4	0.64	11.85	0.54	2.83e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4478858	0.684	rs7528066	chr1:31749092	C/G	cg00250761	chr1:31883323	NA	-0.34	-8.15	-0.41	7.26e-15	Alcohol dependence;
LUSC	cis	rs6460942	0.505	rs73055515	chr7:12328804	A/G	cg06484146	chr7:12443880	VWDE	-0.57	-5.94	-0.31	7.05e-9	Coronary artery disease;
LUSC	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg25019033	chr10:957182	NA	-0.56	-7.15	-0.36	5.35e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg00383909	chr3:49044727	WDR6	1.14	10.08	0.48	5.06e-21	Cognitive ability (multi-trait analysis);
LUSC	cis	rs701145	0.938	rs355769	chr3:154042550	T/C	cg17054900	chr3:154042577	DHX36	0.81	8.73	0.43	1.2e-16	Coronary artery disease;
LUSC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg06026331	chr20:60912101	LAMA5	0.57	7.07	0.36	8.85e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg24011408	chr12:48396354	COL2A1	-0.39	-5.74	-0.3	2.18e-8	Glycated hemoglobin levels;
LUSC	cis	rs7809950	0.678	rs2237660	chr7:106862963	T/A	cg23024343	chr7:107201750	COG5	-0.66	-9.38	-0.46	1.03e-18	Coronary artery disease;
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24739457	chr1:205821442	NA	0.36	6.12	0.32	2.68e-9	Menarche (age at onset);
LUSC	cis	rs17095355	1.000	rs7905306	chr10:111712902	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.64	-8.08	-0.4	1.16e-14	Biliary atresia;
LUSC	cis	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg06521331	chr12:34319734	NA	-0.47	-7.68	-0.39	1.78e-13	Morning vs. evening chronotype;
LUSC	cis	rs67072384	0.901	rs11235585	chr11:72476007	G/A	cg04827223	chr11:72435913	ARAP1	-0.8	-5.98	-0.31	5.58e-9	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg21433313	chr16:3507492	NAT15	-0.37	-5.86	-0.31	1.09e-8	Body mass index (adult);
LUSC	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg22732515	chr19:44031385	ETHE1	0.63	10.48	0.5	2.07e-22	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg07636037	chr3:49044803	WDR6	0.9	11.71	0.54	9.27e-27	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg18240062	chr17:79603768	NPLOC4	0.72	13.38	0.59	5.65e-33	Eye color traits;
LUSC	cis	rs4845570	1.000	rs17568246	chr1:151736456	A/G	cg07092448	chr1:151763213	TDRKH	-1.14	-11.46	-0.53	7.11e-26	Coronary artery disease;
LUSC	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg04511125	chr2:88470314	THNSL2	-0.44	-6.62	-0.34	1.41e-10	Response to metformin (IC50);
LUSC	cis	rs10744422	0.925	rs2061098	chr12:123349410	T/C	cg25930673	chr12:123319894	HIP1R	-0.6	-5.96	-0.31	6.34e-9	Schizophrenia;
LUSC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-7.31	-0.37	2.02e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.43	-0.42	1.03e-15	Body mass index;
LUSC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg03354898	chr7:1950403	MAD1L1	-0.32	-6.12	-0.32	2.66e-9	Schizophrenia;
LUSC	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.83	-0.43	6.1e-17	Total cholesterol levels;
LUSC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.44	6.45	0.33	3.93e-10	Breast cancer;
LUSC	cis	rs4474465	1.000	rs966456	chr11:78168603	T/A	cg27205649	chr11:78285834	NARS2	-0.52	-6.06	-0.31	3.77e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg22834771	chr12:69754056	YEATS4	-0.5	-7.45	-0.38	8.09e-13	Blood protein levels;
LUSC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg16339924	chr4:17578868	LAP3	0.56	8.6	0.43	3.21e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7527798	0.592	rs7539772	chr1:207833301	G/A	cg09232269	chr1:207846808	CR1L	-0.29	-6.15	-0.32	2.17e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs651907	0.640	rs771575	chr3:101619359	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.47	6.2	0.32	1.65e-9	Colorectal cancer;
LUSC	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg10523679	chr1:76189770	ACADM	-0.49	-7.08	-0.36	8.69e-12	Daytime sleep phenotypes;
LUSC	cis	rs934734	0.544	rs4671127	chr2:65562970	C/G	cg08085232	chr2:65598271	SPRED2	-0.44	-6.87	-0.35	3.12e-11	Rheumatoid arthritis;
LUSC	cis	rs983392	0.678	rs1426253	chr11:59981218	A/C	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.07	-0.32	3.51e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-0.77	-12.27	-0.56	8.26e-29	Height;
LUSC	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	5.83	0.3	1.34e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg11218175	chr11:495084	RNH1	0.53	5.71	0.3	2.51e-8	Body mass index;
LUSC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.16	-0.41	6.68e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	cis	rs1524927	0.566	rs12704876	chr7:96366342	C/T	cg03808172	chr7:96339361	SHFM1	0.41	6.57	0.34	1.9e-10	Total body bone mineral density;
LUSC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	0.54	8.16	0.41	6.98e-15	Breast cancer;
LUSC	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg20243544	chr17:37824526	PNMT	0.53	7.53	0.38	4.77e-13	Asthma;
LUSC	cis	rs198426	0.506	rs11230767	chr11:61426932	G/A	cg19838087	chr11:61442541	NA	0.3	5.99	0.31	5.47e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
LUSC	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00290607	chr11:67383545	NA	0.37	6.98	0.36	1.58e-11	Mean corpuscular volume;
LUSC	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg13256891	chr4:100009986	ADH5	0.47	6.46	0.33	3.62e-10	Alcohol dependence;
LUSC	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg06219351	chr7:158114137	PTPRN2	-0.54	-9.85	-0.47	2.89e-20	Calcium levels;
LUSC	trans	rs7230711	1.000	rs11663585	chr18:48687098	G/A	cg07422195	chr1:23894874	NA	-0.6	-6.03	-0.31	4.24e-9	Immune response to anthrax vaccine;
LUSC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-10.3	-0.49	8.65e-22	Bipolar disorder;
LUSC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.5	7.81	0.39	7.71e-14	Colorectal cancer;
LUSC	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg14675211	chr2:100938903	LONRF2	0.37	5.75	0.3	2.03e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03769349	chr8:95565789	KIAA1429	0.49	6.94	0.36	2.09e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg27129171	chr3:47204927	SETD2	-0.69	-10.53	-0.5	1.41e-22	Colorectal cancer;
LUSC	cis	rs7903847	0.619	rs10786336	chr10:99134953	A/C	cg08345082	chr10:99160200	RRP12	-0.38	-7.76	-0.39	1.06e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg21770322	chr7:97807741	LMTK2	0.4	6.87	0.35	3.1e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07080220	chr10:102295463	HIF1AN	0.67	8.64	0.43	2.38e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	6.37	0.33	6.13e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs2742234	0.910	rs2503866	chr10:43646261	T/A	cg02780029	chr10:43622663	RET	-0.36	-6.87	-0.35	3.07e-11	Hirschsprung disease;
LUSC	cis	rs644148	0.836	rs2686770	chr19:44998773	A/G	cg15540054	chr19:45004280	ZNF180	-0.62	-9.22	-0.45	3.37e-18	Personality dimensions;
LUSC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13770153	chr20:60521292	NA	-0.63	-8.55	-0.42	4.57e-16	Body mass index;
LUSC	cis	rs4974559	0.895	rs28493051	chr4:1331030	A/C	cg02980000	chr4:1222292	CTBP1	0.67	7.83	0.39	6.68e-14	Systolic blood pressure;
LUSC	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg26384229	chr12:38710491	ALG10B	0.7	10.74	0.51	2.52e-23	Morning vs. evening chronotype;
LUSC	cis	rs9650315	0.852	rs7830176	chr8:57172974	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	6.82	0.35	4.17e-11	Height;
LUSC	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.95	0.31	6.61e-9	Rheumatoid arthritis;
LUSC	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg03684893	chr10:554711	DIP2C	0.36	6.4	0.33	5.3e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg04155289	chr7:94953770	PON1	-0.34	-5.75	-0.3	2.02e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg13628971	chr7:2884303	GNA12	0.37	5.73	0.3	2.3e-8	Height;
LUSC	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg01652190	chr22:50026171	C22orf34	-0.3	-6.16	-0.32	2.1e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg09549848	chr9:113800279	LPAR1	-0.49	-6.21	-0.32	1.53e-9	Cognitive function;Information processing speed;
LUSC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg11752832	chr7:134001865	SLC35B4	0.53	8.03	0.4	1.74e-14	Mean platelet volume;
LUSC	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg05714579	chr10:131428358	MGMT	0.54	8.22	0.41	4.4e-15	Response to temozolomide;
LUSC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg15147215	chr3:52552868	STAB1	-0.34	-6.67	-0.34	1.06e-10	Bipolar disorder;
LUSC	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg24851651	chr11:66362959	CCS	-0.55	-9.85	-0.47	2.85e-20	HIV-1 susceptibility;
LUSC	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg18240062	chr17:79603768	NPLOC4	0.79	15.24	0.64	3.35e-40	Eye color traits;
LUSC	cis	rs7605827	0.930	rs3796002	chr2:15567649	T/C	cg19274914	chr2:15703543	NA	0.47	8.94	0.44	2.79e-17	Educational attainment (years of education);
LUSC	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg13010199	chr12:38710504	ALG10B	0.56	8.51	0.42	5.94e-16	Morning vs. evening chronotype;
LUSC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.79	0.35	5.25e-11	Tonsillectomy;
LUSC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg24375607	chr4:120327624	NA	0.71	10.81	0.51	1.5e-23	Corneal astigmatism;
LUSC	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg08847533	chr14:75593920	NEK9	-0.81	-13.69	-0.6	3.5e-34	Height;
LUSC	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg26395211	chr5:140044315	WDR55	-0.38	-5.89	-0.31	9.53e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg14664628	chr15:75095509	CSK	-0.77	-12.05	-0.55	5.36e-28	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs2736345	0.516	rs9657551	chr8:11398183	A/G	cg21775007	chr8:11205619	TDH	0.42	5.91	0.31	8.35e-9	Sjögren's syndrome;Systemic lupus erythematosus;
LUSC	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg27489772	chr12:121021490	NA	-0.51	-6.6	-0.34	1.64e-10	Type 1 diabetes nephropathy;
LUSC	cis	rs789859	0.869	rs1773225	chr3:194403578	A/G	cg02072170	chr3:194406190	FAM43A	0.39	8.16	0.41	7e-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	trans	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	6.69	0.34	9.44e-11	Retinal vascular caliber;
LUSC	cis	rs9905704	0.881	rs2611774	chr17:56732304	G/A	cg12560992	chr17:57184187	TRIM37	0.53	7.49	0.38	6.3e-13	Testicular germ cell tumor;
LUSC	cis	rs7561273	0.586	rs6545302	chr2:24364557	G/T	cg06627628	chr2:24431161	ITSN2	-0.55	-7.17	-0.37	4.85e-12	Quantitative traits;
LUSC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.72	0.35	7.83e-11	Lung cancer;
LUSC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg15145296	chr3:125709740	NA	-0.56	-6.31	-0.33	9e-10	Blood pressure (smoking interaction);
LUSC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.49	5.96	0.31	6.44e-9	Renal function-related traits (BUN);
LUSC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg07507251	chr3:52567010	NT5DC2	0.31	6.12	0.32	2.64e-9	Bipolar disorder;
LUSC	cis	rs12493885	0.818	rs73158489	chr3:153757862	C/T	cg17054900	chr3:154042577	DHX36	-0.55	-6.01	-0.31	4.76e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg08270630	chr22:50330655	NA	-0.43	-6.58	-0.34	1.8e-10	Schizophrenia;
LUSC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.95	-16.23	-0.66	4.32e-44	Coronary artery disease;
LUSC	cis	rs11971779	0.616	rs6967932	chr7:139022381	C/T	cg23387468	chr7:139079360	LUC7L2	0.42	6.28	0.33	1.04e-9	Diisocyanate-induced asthma;
LUSC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.3	-0.45	1.91e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9815354	1.000	rs73081353	chr3:41906448	T/A	cg03022575	chr3:42003672	ULK4	0.61	6.69	0.34	9.3e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2274459	1.000	rs12189725	chr6:33703394	G/T	cg06253072	chr6:33679850	C6orf125	0.5	5.67	0.3	3.03e-8	Obesity (extreme);
LUSC	cis	rs9905704	0.723	rs71372848	chr17:56736598	G/C	cg12560992	chr17:57184187	TRIM37	0.54	7.72	0.39	1.36e-13	Testicular germ cell tumor;
LUSC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg06238570	chr21:40685208	BRWD1	0.52	7.92	0.4	3.58e-14	Cognitive function;
LUSC	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg16797656	chr11:68205561	LRP5	0.38	6.25	0.32	1.27e-9	Total body bone mineral density;
LUSC	cis	rs7830933	0.780	rs11986562	chr8:23609098	T/C	cg04349084	chr8:23602677	NA	0.35	5.71	0.3	2.47e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
LUSC	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg22437258	chr11:111473054	SIK2	-0.43	-5.66	-0.3	3.21e-8	Primary sclerosing cholangitis;
LUSC	cis	rs35883536	0.609	rs1577513	chr1:101044402	C/A	cg09408571	chr1:101003634	GPR88	0.29	5.73	0.3	2.25e-8	Monocyte count;
LUSC	trans	rs9747201	0.609	rs9303022	chr17:80170651	C/G	cg07393940	chr7:158741817	NA	0.53	8.4	0.42	1.3e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg09849774	chr21:43526787	UMODL1;C21orf128	-0.42	-6.15	-0.32	2.17e-9	IgG glycosylation;
LUSC	cis	rs11809207	1.000	rs11247867	chr1:26517891	C/T	cg00147160	chr1:26503991	CNKSR1	0.41	6.77	0.35	5.87e-11	Height;
LUSC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg13498757	chr1:152161927	NA	0.35	5.81	0.3	1.46e-8	Inflammatory skin disease;
LUSC	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg11244672	chr19:19639970	YJEFN3	0.55	6.79	0.35	5.18e-11	Bipolar disorder;
LUSC	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.57	-10.16	-0.49	2.69e-21	Longevity;Endometriosis;
LUSC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.46	-8.13	-0.41	8.35e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg05347473	chr6:146136440	FBXO30	-0.59	-10.32	-0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg26516362	chr5:178986906	RUFY1	-0.52	-8.81	-0.43	6.96e-17	Lung cancer;
LUSC	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-1.13	-18.04	-0.7	2.96e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11645453	chr3:52864694	ITIH4	0.34	7.84	0.39	6.2e-14	Electroencephalogram traits;
LUSC	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.56	8.95	0.44	2.55e-17	Schizophrenia;
LUSC	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg10645314	chr2:3704589	ALLC	0.46	7.4	0.38	1.09e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg06360820	chr2:242988706	NA	-1.01	-10.5	-0.5	1.82e-22	Obesity-related traits;
LUSC	cis	rs6987853	0.787	rs2923448	chr8:42406008	G/A	cg09913449	chr8:42400586	C8orf40	0.53	9.22	0.45	3.48e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1080500	1.000	rs1080500	chr3:53175017	C/T	cg11645453	chr3:52864694	ITIH4	0.34	7.41	0.38	1.01e-12	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.6	-0.34	1.64e-10	Neuroticism;
LUSC	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.48	0.59	2.28e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg22089800	chr15:90895588	ZNF774	-0.65	-9.83	-0.47	3.47e-20	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg14668632	chr7:2872130	GNA12	-0.5	-7.11	-0.36	6.96e-12	Height;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg00628130	chr8:95908808	CCNE2	0.37	6.12	0.32	2.62e-9	Calcium levels;
LUSC	trans	rs961253	0.556	rs6054138	chr20:6327700	G/A	cg21095983	chr6:86352623	SYNCRIP	0.45	6.78	0.35	5.62e-11	Colorectal cancer;
LUSC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18357526	chr6:26021779	HIST1H4A	0.37	5.81	0.3	1.42e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg25173405	chr17:45401733	C17orf57	0.36	5.72	0.3	2.35e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-1.04	-13.0	-0.58	1.44e-31	Lung cancer in ever smokers;
LUSC	cis	rs9925964	0.933	rs10871454	chr16:31048079	C/T	cg02466173	chr16:30829666	NA	0.36	6.57	0.34	1.91e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4774899	0.932	rs1867641	chr15:57527722	A/G	cg08128148	chr15:57256372	TCF12	-0.35	-5.69	-0.3	2.77e-8	Urinary tract infection frequency;
LUSC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg08027265	chr7:2291960	NA	-0.39	-6.28	-0.32	1.05e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.13	0.45	6.62e-18	Height;
LUSC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg13866156	chr1:1669148	SLC35E2	-0.53	-8.86	-0.44	4.9e-17	Body mass index;
LUSC	cis	rs1595825	0.891	rs16823148	chr2:198584209	G/A	cg00982548	chr2:198649783	BOLL	-0.52	-6.77	-0.35	5.87e-11	Ulcerative colitis;
LUSC	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	11.98	0.55	9.49e-28	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg13636640	chr20:31349939	DNMT3B	-0.81	-15.5	-0.65	3.37e-41	Inflammatory bowel disease;
LUSC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg06713675	chr4:122721982	EXOSC9	-0.7	-12.04	-0.55	5.88e-28	Type 2 diabetes;
LUSC	cis	rs8032315	0.965	rs8027450	chr15:91418394	C/T	cg06330618	chr15:91428456	FES	0.28	5.65	0.3	3.5e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08109568	chr15:31115862	NA	-0.73	-10.64	-0.5	5.71e-23	Huntington's disease progression;
LUSC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg24829409	chr8:58192753	C8orf71	-0.61	-7.49	-0.38	6.09e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg11843238	chr5:131593191	PDLIM4	0.46	7.8	0.39	8e-14	Acylcarnitine levels;
LUSC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.08	0.32	3.32e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.77	11.44	0.53	8.25e-26	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.72	11.99	0.55	8.29e-28	Motion sickness;
LUSC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg07424592	chr7:64974309	NA	0.67	5.97	0.31	6.18e-9	Diabetic kidney disease;
LUSC	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg06917634	chr15:78832804	PSMA4	-0.43	-5.94	-0.31	7.33e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg00318621	chr2:106887213	NA	-0.37	-6.84	-0.35	3.76e-11	Facial morphology (factor 23);
LUSC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.37	5.96	0.31	6.51e-9	Menopause (age at onset);
LUSC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg00944433	chr1:107599041	PRMT6	0.36	6.7	0.34	8.99e-11	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.96	0.36	1.86e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg22676075	chr6:135203613	NA	0.46	7.24	0.37	3.06e-12	Red blood cell count;
LUSC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02463440	chr8:22132932	PIWIL2	0.41	7.43	0.38	9.43e-13	Hypertriglyceridemia;
LUSC	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg15704280	chr7:45808275	SEPT13	-0.63	-7.62	-0.38	2.63e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.51	-8.13	-0.41	8.2e-15	Platelet count;
LUSC	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg15654264	chr1:150340011	RPRD2	0.66	11.01	0.52	2.84e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	0.85	15.07	0.64	1.61e-39	Prostate cancer;
LUSC	cis	rs10186029	0.680	rs10179508	chr2:213978526	C/T	cg08319019	chr2:214017104	IKZF2	-0.57	-8.2	-0.41	5.25e-15	Systemic sclerosis;
LUSC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg11645453	chr3:52864694	ITIH4	0.34	7.7	0.39	1.59e-13	Bipolar disorder;
LUSC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.37	-0.42	1.56e-15	Mean platelet volume;
LUSC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg22117172	chr7:91764530	CYP51A1	0.33	5.84	0.3	1.24e-8	Breast cancer;
LUSC	cis	rs6980507	0.523	rs2974293	chr8:42369455	C/T	cg09913449	chr8:42400586	C8orf40	-0.45	-7.89	-0.4	4.42e-14	Glycated hemoglobin levels;
LUSC	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg05340658	chr4:99064831	C4orf37	0.44	6.88	0.35	3.05e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg23231163	chr10:75533350	FUT11	-0.43	-6.85	-0.35	3.62e-11	Inflammatory bowel disease;
LUSC	trans	rs10432489	0.708	rs10178270	chr2:181773395	G/C	cg16818443	chr4:2965195	GRK4;NOP14	0.82	6.01	0.31	4.74e-9	QT interval;
LUSC	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg00310523	chr12:86230176	RASSF9	0.39	6.95	0.36	1.9e-11	Major depressive disorder;
LUSC	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs7202877	0.656	rs6564245	chr16:75308899	A/G	cg03315344	chr16:75512273	CHST6	-0.46	-6.53	-0.34	2.46e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg13852791	chr20:30311386	BCL2L1	0.93	14.15	0.61	6.1e-36	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23544223	chr18:12777786	NA	0.59	6.27	0.32	1.15e-9	Inflammatory skin disease;
LUSC	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.47	-6.21	-0.32	1.53e-9	Corneal astigmatism;
LUSC	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg22356347	chr1:167427500	CD247	0.33	7.84	0.39	6.27e-14	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.41	0.33	4.84e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04565464	chr8:145669602	NFKBIL2	-0.37	-6.02	-0.31	4.56e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	13.73	0.6	2.57e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg25151919	chr3:44754333	ZNF502	-0.38	-6.1	-0.32	2.92e-9	Depressive symptoms;
LUSC	trans	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg18187862	chr3:45730750	SACM1L	0.52	6.83	0.35	4e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg18402987	chr7:1209562	NA	0.73	8.42	0.42	1.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6489882	0.703	rs2285934	chr12:113351520	A/C	cg20102336	chr12:113376681	OAS3	-0.38	-5.88	-0.31	9.82e-9	Chronic lymphocytic leukemia;
LUSC	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg15704280	chr7:45808275	SEPT13	-0.63	-7.68	-0.39	1.83e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg23601095	chr6:26197514	HIST1H3D	-0.71	-7.31	-0.37	1.95e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.58	-11.42	-0.53	1.04e-25	Monocyte percentage of white cells;
LUSC	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg24011408	chr12:48396354	COL2A1	0.41	5.87	0.31	1.03e-8	Glycated hemoglobin levels;
LUSC	cis	rs6433857	0.505	rs7561255	chr2:181369216	A/G	cg23363182	chr2:181467187	NA	-0.45	-7.22	-0.37	3.5e-12	Body mass index;
LUSC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	0.92	13.97	0.61	3.03e-35	Breast cancer;
LUSC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08219700	chr8:58056026	NA	0.66	7.82	0.39	7.08e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg08079166	chr15:68083412	MAP2K5	0.49	8.34	0.42	2e-15	Restless legs syndrome;
LUSC	cis	rs9323205	0.798	rs11157805	chr14:51658390	C/G	cg23942311	chr14:51606299	NA	0.36	7.38	0.37	1.26e-12	Cancer;
LUSC	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg03526776	chr6:41159608	TREML2	0.33	6.12	0.32	2.67e-9	Alzheimer's disease (late onset);
LUSC	trans	rs7833787	0.644	rs4921965	chr8:18679866	C/T	cg25885280	chr11:70760166	SHANK2	-0.24	-6.13	-0.32	2.46e-9	Obesity-related traits;
LUSC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.71	10.27	0.49	1.06e-21	Red cell distribution width;
LUSC	cis	rs16895831	0.531	rs12195803	chr6:42527571	G/A	cg10605015	chr6:42532144	UBR2	-0.5	-6.08	-0.32	3.3e-9	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.74	-11.55	-0.53	3.37e-26	Menarche (age at onset);
LUSC	trans	rs9473924	1.000	rs9463656	chr6:50859655	A/G	cg22375689	chr19:34175036	CHST8	0.38	6.14	0.32	2.35e-9	Body mass index;
LUSC	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-9.31	-0.45	1.73e-18	Morning vs. evening chronotype;
LUSC	cis	rs9395066	0.545	rs3799976	chr6:44835622	T/G	cg25276700	chr6:44698697	NA	0.3	6.05	0.31	3.87e-9	Height;
LUSC	trans	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg19862616	chr7:65841803	NCRNA00174	0.9	10.15	0.49	2.85e-21	Eotaxin levels;
LUSC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg12310025	chr6:25882481	NA	-0.5	-8.99	-0.44	1.82e-17	Blood metabolite levels;
LUSC	cis	rs12042938	0.600	rs1865225	chr1:231763004	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.45	-6.55	-0.34	2.15e-10	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg18357645	chr12:58087776	OS9	0.54	8.3	0.41	2.58e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.06	-0.31	3.58e-9	Breast cancer;
LUSC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	14.11	0.61	8.82e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg19610905	chr11:61596333	FADS2	0.51	7.97	0.4	2.45e-14	Trans fatty acid levels;
LUSC	cis	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg06521331	chr12:34319734	NA	-0.47	-7.82	-0.39	7.04e-14	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14970666	chr5:2038989	NA	0.43	6.77	0.35	5.87e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.74	-0.39	1.22e-13	Neuroticism;
LUSC	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.48	-0.33	3.39e-10	Mood instability;
LUSC	cis	rs2273669	0.667	rs2145763	chr6:109306963	C/A	cg05315195	chr6:109294784	ARMC2	-0.56	-6.21	-0.32	1.54e-9	Prostate cancer;
LUSC	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg24375607	chr4:120327624	NA	-0.69	-10.97	-0.51	3.92e-24	Corneal astigmatism;
LUSC	cis	rs5167	0.533	rs11083755	chr19:45490065	C/T	cg25746394	chr19:45450501	APOC2	0.32	6.07	0.32	3.55e-9	Blood protein levels;
LUSC	cis	rs2637266	1.000	rs7081214	chr10:78361134	G/A	cg18941641	chr10:78392320	NA	0.4	7.46	0.38	7.78e-13	Pulmonary function;
LUSC	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg04362960	chr10:104952993	NT5C2	-0.62	-9.5	-0.46	4.19e-19	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs4642101	0.561	rs9812144	chr3:12805910	G/A	cg05775895	chr3:12838266	CAND2	0.48	7.42	0.38	9.9e-13	QRS complex (12-leadsum);
LUSC	cis	rs35995292	0.534	rs917322	chr7:38943165	A/T	cg19327137	chr7:38886074	VPS41	-0.54	-10.15	-0.49	2.75e-21	Subjective well-being (multi-trait analysis);
LUSC	cis	rs2120019	0.507	rs4886642	chr15:75228846	T/C	cg09165964	chr15:75287851	SCAMP5	-0.97	-12.02	-0.55	6.78e-28	Blood trace element (Zn levels);
LUSC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	1.07	20.77	0.75	4.02e-62	Menopause (age at onset);
LUSC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07167872	chr1:205819463	PM20D1	0.54	9.22	0.45	3.45e-18	Menarche (age at onset);
LUSC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg20307385	chr11:47447363	PSMC3	-0.42	-5.7	-0.3	2.61e-8	Subjective well-being;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03508908	chr6:91005117	BACH2	-0.48	-6.39	-0.33	5.59e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg00431813	chr7:1051703	C7orf50	-0.39	-6.11	-0.32	2.72e-9	Longevity;Endometriosis;
LUSC	cis	rs13223928	0.621	rs4722440	chr7:3155901	C/T	cg19214707	chr7:3157722	NA	0.42	8.44	0.42	9.95e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs11608355	0.521	rs6606703	chr12:109813665	C/T	cg19025524	chr12:109796872	NA	-0.41	-7.73	-0.39	1.25e-13	Neuroticism;
LUSC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg22907277	chr7:1156413	C7orf50	0.71	7.56	0.38	3.84e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg27219399	chr15:67835830	MAP2K5	0.35	5.76	0.3	1.91e-8	Restless legs syndrome;
LUSC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs2274273	0.840	rs2009291	chr14:55838230	A/C	cg04306507	chr14:55594613	LGALS3	-0.57	-13.71	-0.6	3.04e-34	Protein biomarker;
LUSC	cis	rs4594175	0.886	rs11157801	chr14:51622918	C/T	cg23942311	chr14:51606299	NA	0.32	6.09	0.32	3.11e-9	Cancer;
LUSC	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.07	0.48	5.08e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6961069	0.722	rs13438282	chr7:80262224	C/T	cg04458919	chr7:80252533	CD36	0.37	6.66	0.34	1.1e-10	Platelet count;
LUSC	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg12379764	chr21:47803548	PCNT	0.79	12.07	0.55	4.46e-28	Lymphocyte counts;
LUSC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg13319975	chr6:146136371	FBXO30	0.4	6.08	0.32	3.33e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6429082	0.702	rs7532018	chr1:235706290	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.46	-6.21	-0.32	1.6e-9	Adiposity;
LUSC	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg09307838	chr4:120376055	NA	0.76	11.04	0.52	2.31e-24	Corneal astigmatism;
LUSC	trans	rs13314892	1.000	rs13314892	chr3:69795052	A/G	cg25117505	chr11:66313529	ZDHHC24;ACTN3	0.44	6.2	0.32	1.67e-9	QRS complex (12-leadsum);
LUSC	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg15556689	chr8:8085844	FLJ10661	0.57	8.52	0.42	5.57e-16	Myopia (pathological);
LUSC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg04450456	chr4:17643702	FAM184B	0.39	6.89	0.35	2.71e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12286929	0.609	rs12417740	chr11:115098436	A/G	cg04055981	chr11:115044050	NA	-0.36	-6.39	-0.33	5.63e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06634786	chr22:41940651	POLR3H	0.49	5.72	0.3	2.34e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs1044826	0.642	rs4607068	chr3:139162994	A/G	cg00490450	chr3:139108681	COPB2	0.49	7.74	0.39	1.18e-13	Obesity-related traits;
LUSC	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg26876637	chr1:152193138	HRNR	-0.46	-6.34	-0.33	7.49e-10	Atopic dermatitis;
LUSC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18404041	chr3:52824283	ITIH1	-0.47	-8.6	-0.43	3.23e-16	Bipolar disorder;
LUSC	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-7.13	-0.36	6.2e-12	Breast cancer;
LUSC	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg19592336	chr6:28129416	ZNF389	0.41	5.7	0.3	2.65e-8	Parkinson's disease;
LUSC	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg14458575	chr2:238380390	NA	0.55	6.49	0.33	3.15e-10	Prostate cancer;
LUSC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.28	0.59	1.28e-32	Hip circumference adjusted for BMI;
LUSC	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-13.42	-0.59	3.84e-33	Brugada syndrome;
LUSC	trans	rs800082	0.505	rs920148	chr3:144246677	A/C	cg24215973	chr2:240111563	HDAC4	0.46	7.02	0.36	1.28e-11	Smoking behavior;
LUSC	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg23887609	chr12:130822674	PIWIL1	0.47	6.97	0.36	1.67e-11	Menopause (age at onset);
LUSC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg11062466	chr8:58055876	NA	0.66	8.52	0.42	5.58e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs67460515	0.500	rs1868105	chr3:160645335	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-6.09	-0.32	3.05e-9	Parkinson's disease;
LUSC	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg13072238	chr3:49761600	GMPPB	-0.69	-8.19	-0.41	5.44e-15	Menarche (age at onset);
LUSC	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg04352962	chr1:209979756	IRF6	0.54	6.19	0.32	1.73e-9	Cleft lip with or without cleft palate;
LUSC	trans	rs8023715	1.000	rs34169613	chr15:97613156	C/T	cg09939392	chr16:90068365	NA	0.52	6.0	0.31	5.09e-9	Systemic lupus erythematosus;
LUSC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg01802117	chr1:53393560	SCP2	-0.41	-6.74	-0.35	6.84e-11	Monocyte count;
LUSC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg25019033	chr10:957182	NA	-0.51	-6.52	-0.34	2.67e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs921665	0.680	rs7571242	chr2:3199025	A/G	cg02624386	chr2:3182749	NA	0.59	6.41	0.33	4.82e-10	World class endurance athleticism;
LUSC	trans	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg07393940	chr7:158741817	NA	0.51	8.04	0.4	1.56e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg06784218	chr1:46089804	CCDC17	0.47	9.26	0.45	2.6e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08736216	chr1:53307985	ZYG11A	-0.29	-5.99	-0.31	5.41e-9	Monocyte count;
LUSC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.39	0.37	1.22e-12	Bipolar disorder;
LUSC	cis	rs4072705	0.586	rs7855247	chr9:127246644	T/C	cg13476313	chr9:127244764	NR5A1	-0.31	-6.04	-0.31	4.13e-9	Menarche (age at onset);
LUSC	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	cis	rs524023	0.629	rs480617	chr11:64478320	C/T	cg19131476	chr11:64387923	NRXN2	-0.36	-8.52	-0.42	5.45e-16	Urate levels in obese individuals;
LUSC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.78	0.43	8.4e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg12257692	chr3:49977190	RBM6	-0.24	-6.63	-0.34	1.38e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03614189	chr8:82598326	IMPA1	-0.45	-6.1	-0.32	2.87e-9	Hepatitis;
LUSC	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.65	0.34	1.19e-10	IgG glycosylation;
LUSC	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.15	-0.32	2.19e-9	Alcohol dependence;
LUSC	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg01966878	chr4:90757139	SNCA	-0.35	-6.12	-0.32	2.56e-9	Dementia with Lewy bodies;
LUSC	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.66	0.43	1.98e-16	Menarche (age at onset);
LUSC	cis	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg06521331	chr12:34319734	NA	-0.48	-7.69	-0.39	1.65e-13	Morning vs. evening chronotype;
LUSC	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg24375607	chr4:120327624	NA	0.76	11.23	0.52	4.89e-25	Corneal astigmatism;
LUSC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18876405	chr7:65276391	NA	-0.5	-8.04	-0.4	1.61e-14	Aortic root size;
LUSC	cis	rs4700695	0.841	rs152996	chr5:65256506	A/G	cg21114390	chr5:65439923	SFRS12	0.49	5.64	0.3	3.56e-8	Facial morphology (factor 19);
LUSC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.7	12.65	0.57	3.19e-30	Aortic root size;
LUSC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02353165	chr6:42928485	GNMT	0.66	11.14	0.52	1e-24	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.59	-0.34	1.71e-10	Schizophrenia;
LUSC	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-0.76	-11.83	-0.54	3.22e-27	Height;
LUSC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-9.46	-0.46	5.58e-19	Gut microbiome composition (summer);
LUSC	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg03342759	chr3:160939853	NMD3	-0.42	-6.38	-0.33	6.08e-10	Morning vs. evening chronotype;
LUSC	trans	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg02800362	chr5:177631904	HNRNPAB	0.88	13.05	0.58	9.85e-32	Obesity-related traits;
LUSC	cis	rs6469656	0.730	rs1529945	chr8:117660112	C/T	cg24004040	chr8:117650383	NA	-0.42	-6.26	-0.32	1.16e-9	Colorectal cancer;
LUSC	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg09835421	chr16:68378352	PRMT7	-0.53	-6.16	-0.32	2.08e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-6.22	-0.32	1.52e-9	IgG glycosylation;
LUSC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.47	-7.93	-0.4	3.43e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19596435	chr1:11741483	MAD2L2	-0.42	-6.7	-0.34	8.77e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6546537	0.714	rs17036759	chr2:69767029	C/T	cg10773587	chr2:69614142	GFPT1	-0.61	-10.22	-0.49	1.6e-21	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg19116668	chr7:99932089	PMS2L1	0.35	6.12	0.32	2.68e-9	Coronary artery disease;
LUSC	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg20608306	chr11:116969690	SIK3	0.39	7.29	0.37	2.27e-12	Blood protein levels;
LUSC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.57	9.09	0.45	9.27e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg27535305	chr1:53392650	SCP2	-0.4	-7.57	-0.38	3.57e-13	Monocyte count;
LUSC	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg25110126	chr1:46999211	NA	0.73	10.57	0.5	1.04e-22	Monobrow;
LUSC	cis	rs4494114	0.967	rs6696437	chr1:39348165	G/A	cg25970120	chr1:39325951	RRAGC	-0.4	-6.2	-0.32	1.7e-9	Blood protein levels;
LUSC	cis	rs12210905	0.688	rs12196452	chr6:27344415	A/T	cg08851530	chr6:28072375	NA	0.9	5.84	0.3	1.21e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg04155289	chr7:94953770	PON1	-0.33	-5.69	-0.3	2.78e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg04586622	chr2:25135609	ADCY3	0.37	7.51	0.38	5.56e-13	Body mass index in non-asthmatics;
LUSC	cis	rs3820928	0.618	rs2141828	chr2:227922470	T/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-6.92	-0.35	2.33e-11	Pulmonary function;
LUSC	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg10518543	chr12:38710700	ALG10B	-0.4	-5.65	-0.3	3.43e-8	Morning vs. evening chronotype;
LUSC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06022373	chr22:39101656	GTPBP1	0.78	12.16	0.55	2.1e-28	Menopause (age at onset);
LUSC	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg05043794	chr9:111880884	C9orf5	-0.34	-7.32	-0.37	1.91e-12	Menarche (age at onset);
LUSC	cis	rs4144743	0.528	rs2292866	chr17:45356782	T/C	cg18085866	chr17:45331354	ITGB3	-0.78	-6.68	-0.34	9.76e-11	Body mass index;
LUSC	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.89	11.95	0.55	1.2e-27	Mean corpuscular hemoglobin;
LUSC	trans	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg19249749	chr1:223853145	CAPN8	0.54	6.59	0.34	1.72e-10	Gut microbiome composition (summer);
LUSC	cis	rs7589342	0.839	rs10192144	chr2:106439854	A/G	cg14210321	chr2:106509881	NCK2	-0.53	-7.96	-0.4	2.69e-14	Addiction;
LUSC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg13047869	chr3:10149882	C3orf24	0.6	8.52	0.42	5.73e-16	Alzheimer's disease;
LUSC	cis	rs4853525	0.884	rs34303278	chr2:191731470	G/C	cg11845111	chr2:191398756	TMEM194B	-0.41	-5.97	-0.31	6.12e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg01416388	chr22:39784598	NA	0.42	7.14	0.36	5.98e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg14169450	chr9:139327907	INPP5E	0.4	6.87	0.35	3.24e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.39	-0.42	1.35e-15	Coffee consumption (cups per day);
LUSC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.6	-10.11	-0.48	3.86e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg22676075	chr6:135203613	NA	0.46	7.19	0.37	4.41e-12	Red blood cell count;
LUSC	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.24	-18.79	-0.72	3.08e-54	Type 1 diabetes nephropathy;
LUSC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg22166914	chr1:53195759	ZYG11B	0.68	11.69	0.54	1.08e-26	Monocyte count;
LUSC	cis	rs2386661	0.547	rs72781996	chr10:5646485	C/G	cg17085576	chr10:5658249	NA	-0.43	-6.3	-0.33	9.3e-10	Breast cancer;
LUSC	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg02569458	chr12:86230093	RASSF9	0.36	5.79	0.3	1.66e-8	Major depressive disorder;
LUSC	cis	rs8064299	0.574	rs1879455	chr17:72774738	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.91	17.46	0.69	5.81e-49	Monocyte count;
LUSC	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.67	-9.92	-0.48	1.73e-20	Metabolic syndrome;
LUSC	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.4	-5.83	-0.3	1.29e-8	Response to bleomycin (chromatid breaks);
LUSC	trans	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07923666	chr12:49932857	KCNH3	-0.51	-6.3	-0.33	9.31e-10	Resting heart rate;
LUSC	cis	rs9467160	0.871	rs13191455	chr6:24448459	T/C	cg20631270	chr6:24437470	GPLD1	0.45	5.98	0.31	5.83e-9	Liver enzyme levels;
LUSC	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg27411982	chr8:10470053	RP1L1	0.39	6.0	0.31	5.18e-9	Retinal vascular caliber;
LUSC	cis	rs231513	0.954	rs231494	chr17:41976928	G/C	cg26893861	chr17:41843967	DUSP3	-0.51	-6.06	-0.31	3.74e-9	Cognitive function;
LUSC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26314531	chr2:26401878	FAM59B	-0.68	-9.08	-0.44	9.58e-18	Gut microbiome composition (summer);
LUSC	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg23277830	chr1:3704460	LRRC47	0.35	6.66	0.34	1.11e-10	Red cell distribution width;
LUSC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-1.1	-22.29	-0.77	4.45e-68	Coronary artery disease;
LUSC	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.58	8.32	0.41	2.31e-15	Hip circumference;
LUSC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	11.11	0.52	1.25e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg10788674	chr12:133214645	POLE	-0.69	-6.05	-0.31	3.86e-9	Cognitive performance;
LUSC	cis	rs7605827	0.930	rs11903302	chr2:15706286	C/T	cg19274914	chr2:15703543	NA	0.47	8.8	0.43	7.28e-17	Educational attainment (years of education);
LUSC	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg24634471	chr8:143751801	JRK	0.59	8.99	0.44	1.82e-17	Schizophrenia;
LUSC	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg10596483	chr8:143751796	JRK	0.53	7.59	0.38	3.17e-13	Schizophrenia;
LUSC	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	0.61	9.61	0.47	1.78e-19	Breast cancer;
LUSC	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg03733263	chr8:22462867	KIAA1967	0.76	12.36	0.56	3.78e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	trans	rs11039798	1.000	rs11530232	chr11:48622376	C/T	cg15704280	chr7:45808275	SEPT13	0.74	6.33	0.33	7.95e-10	Axial length;
LUSC	cis	rs16949788	1.000	rs10468036	chr15:66710276	C/T	cg08120210	chr15:66682733	MAP2K1	-0.6	-5.97	-0.31	6.22e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	14.79	0.63	1.97e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg18538332	chr22:24372958	LOC391322	-0.4	-7.32	-0.37	1.83e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2235649	0.666	rs2076429	chr16:1817935	A/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.49	6.31	0.33	8.67e-10	Blood metabolite levels;
LUSC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08280861	chr8:58055591	NA	0.54	5.66	0.3	3.23e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg11941060	chr3:133502564	NA	-0.48	-7.41	-0.38	1.04e-12	Iron status biomarkers;
LUSC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	0.83	10.99	0.52	3.51e-24	Breast cancer;
LUSC	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.14	-0.64	8.9e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg00191853	chr8:101177733	SPAG1	-0.41	-6.53	-0.34	2.46e-10	Atrioventricular conduction;
LUSC	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg01733217	chr16:74700730	RFWD3	-0.79	-13.24	-0.59	1.87e-32	Testicular germ cell tumor;
LUSC	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg24147428	chr11:65409760	SIPA1	0.39	6.2	0.32	1.66e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg05234568	chr11:5960015	NA	0.63	9.82	0.47	3.7e-20	DNA methylation (variation);
LUSC	trans	rs9929218	0.954	rs35794312	chr16:68827785	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-10.81	-0.51	1.44e-23	Colorectal cancer;
LUSC	cis	rs921665	0.831	rs921666	chr2:3192141	G/C	cg16434511	chr2:3151078	NA	-0.63	-6.83	-0.35	3.92e-11	World class endurance athleticism;
LUSC	cis	rs796825	0.530	rs34829073	chr3:119943371	C/T	cg21790991	chr3:120137480	FSTL1	-0.33	-5.83	-0.3	1.32e-8	HIV-1 susceptibility;
LUSC	cis	rs751728	1.000	rs4342423	chr6:33732679	C/T	cg25922239	chr6:33757077	LEMD2	0.52	7.63	0.39	2.46e-13	Crohn's disease;
LUSC	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg06606381	chr12:133084897	FBRSL1	-0.77	-7.55	-0.38	4.28e-13	Depression;
LUSC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg06713675	chr4:122721982	EXOSC9	-0.47	-8.24	-0.41	3.92e-15	Type 2 diabetes;
LUSC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.77	10.47	0.5	2.27e-22	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.84	-20.22	-0.74	6.49e-60	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06634786	chr22:41940651	POLR3H	-0.53	-6.1	-0.32	3e-9	Vitiligo;
LUSC	cis	rs380904	0.552	rs10099003	chr8:144645460	C/T	cg13399544	chr8:144649678	C8orf73	-0.46	-7.59	-0.38	3.25e-13	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg26043149	chr18:55253948	FECH	-0.46	-7.06	-0.36	9.81e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg02753203	chr1:228287806	NA	-0.65	-11.04	-0.52	2.33e-24	Diastolic blood pressure;
LUSC	cis	rs11229555	0.645	rs7116847	chr11:58178478	C/A	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7202877	0.572	rs4888371	chr16:75308781	G/A	cg04384234	chr16:75411784	CFDP1	-0.66	-9.62	-0.47	1.71e-19	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-1.0	-19.18	-0.72	8.48e-56	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg24692254	chr21:30365293	RNF160	-0.57	-7.14	-0.36	6.03e-12	Cognitive test performance;
LUSC	trans	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg09904177	chr6:26538194	HMGN4	-0.8	-6.0	-0.31	5.13e-9	Depression;
LUSC	cis	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg05084668	chr3:125655381	ALG1L	-0.42	-5.66	-0.3	3.33e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-6.66	-0.34	1.15e-10	Blood metabolite levels;
LUSC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg09021430	chr5:549028	NA	-0.56	-7.67	-0.39	1.96e-13	Obesity-related traits;
LUSC	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg10483660	chr13:112241077	NA	-0.31	-5.68	-0.3	2.99e-8	Hepatitis;
LUSC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.03e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg00343986	chr7:65444356	GUSB	0.4	5.84	0.3	1.23e-8	Aortic root size;
LUSC	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg19554555	chr3:13937349	NA	-0.38	-5.75	-0.3	2e-8	Ovarian reserve;
LUSC	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.47	-7.03	-0.36	1.17e-11	Melanoma;
LUSC	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg22906224	chr7:99728672	NA	0.46	6.45	0.33	4.02e-10	Coronary artery disease;
LUSC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg00684032	chr4:1343700	KIAA1530	-0.36	-6.29	-0.33	9.86e-10	Obesity-related traits;
LUSC	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg06937882	chr20:24974362	C20orf3	-0.42	-7.0	-0.36	1.43e-11	Blood protein levels;
LUSC	cis	rs9815354	0.812	rs114034165	chr3:41823297	G/A	cg03022575	chr3:42003672	ULK4	0.85	8.66	0.43	2.12e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	6.5	0.33	2.98e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg06917634	chr15:78832804	PSMA4	-0.48	-5.97	-0.31	6.23e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg22377939	chr1:150208607	ANP32E	0.42	6.34	0.33	7.64e-10	Triglycerides;
LUSC	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg18681998	chr4:17616180	MED28	0.82	14.82	0.63	1.55e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg00042356	chr1:8021962	PARK7	0.58	6.71	0.34	8.12e-11	Inflammatory bowel disease;
LUSC	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg24130564	chr14:104152367	KLC1	-0.48	-6.78	-0.35	5.63e-11	Body mass index;
LUSC	cis	rs8179	0.700	rs42044	chr7:92250140	T/G	cg15732164	chr7:92237376	CDK6	-0.42	-5.98	-0.31	5.62e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs4975709	0.758	rs4975756	chr5:1882443	T/C	cg15595755	chr5:1867978	NA	0.4	6.36	0.33	6.76e-10	Cardiovascular disease risk factors;
LUSC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05025164	chr4:1340916	KIAA1530	-0.51	-7.8	-0.39	7.8e-14	Obesity-related traits;
LUSC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-7.8	-0.39	7.8500000000000006e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg26924012	chr15:45694286	SPATA5L1	0.77	12.26	0.56	8.62e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.58	10.79	0.51	1.7e-23	Bone mineral density;
LUSC	cis	rs7188861	0.813	rs1794021	chr16:11377234	G/A	cg00044050	chr16:11439710	C16orf75	0.54	6.19	0.32	1.77e-9	HDL cholesterol;
LUSC	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg26597838	chr10:835615	NA	0.77	8.9	0.44	3.72e-17	Eosinophil percentage of granulocytes;
LUSC	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg03585969	chr10:35415529	CREM	0.61	8.85	0.44	5.02e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.88	-0.35	2.99e-11	Retinal vascular caliber;
LUSC	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg00579200	chr11:133705235	NA	-0.41	-5.94	-0.31	7.25e-9	Childhood ear infection;
LUSC	cis	rs41271473	1.000	rs11578216	chr1:228880098	A/T	cg10167378	chr1:228756711	NA	-0.54	-6.56	-0.34	2.06e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs10761482	0.861	rs10994309	chr10:62105197	A/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.12	-0.36	6.69e-12	Schizophrenia;
LUSC	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg16339924	chr4:17578868	LAP3	0.49	7.29	0.37	2.22e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg06219351	chr7:158114137	PTPRN2	0.49	7.94	0.4	3.03e-14	Response to amphetamines;
LUSC	trans	rs9929218	1.000	rs9936621	chr16:68798682	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-11.48	-0.53	6.38e-26	Colorectal cancer;
LUSC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg07716408	chr11:68623521	NA	-0.32	-6.19	-0.32	1.8e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	7.13	0.36	6.2e-12	Colorectal cancer;
LUSC	cis	rs16937	0.711	rs12142514	chr1:205122529	A/G	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.24e-10	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.36	-0.46	1.25e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg06002616	chr8:101225028	SPAG1	-0.41	-6.83	-0.35	4.11e-11	Atrioventricular conduction;
LUSC	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.79	0.43	7.96e-17	Menarche (age at onset);
LUSC	cis	rs13089785	1.000	rs35181974	chr3:123607884	C/A	cg02012769	chr3:123398346	MYLK	0.32	5.79	0.3	1.66e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.86	-0.44	4.92e-17	Triglycerides;
LUSC	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.43	-0.33	4.34e-10	Neuroticism;
LUSC	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg00277334	chr10:82204260	NA	-0.4	-5.75	-0.3	1.98e-8	Post bronchodilator FEV1;
LUSC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	7.49	0.38	6.31e-13	Initial pursuit acceleration;
LUSC	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg06740227	chr12:86229804	RASSF9	0.36	5.69	0.3	2.71e-8	Major depressive disorder;
LUSC	trans	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg22153745	chr1:153894579	GATAD2B	-0.49	-6.75	-0.35	6.6e-11	Total cholesterol levels;
LUSC	cis	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.69	-0.34	9.21e-11	Morning vs. evening chronotype;
LUSC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	1.04	20.11	0.74	1.65e-59	Menopause (age at onset);
LUSC	cis	rs12422267	0.609	rs11246940	chr12:132623473	A/G	cg09764611	chr12:132620959	NA	-0.6	-9.3	-0.45	1.88e-18	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg03396347	chr1:1875803	NA	-0.53	-11.67	-0.54	1.31e-26	Body mass index;
LUSC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.43	7.54	0.38	4.39e-13	Obesity-related traits;
LUSC	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg12002119	chr2:101014098	CHST10	0.34	5.74	0.3	2.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.72	-0.47	7.9e-20	Coronary artery disease;
LUSC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg19622623	chr12:86230825	RASSF9	0.44	6.27	0.32	1.11e-9	Major depressive disorder;
LUSC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg13206674	chr6:150067644	NUP43	0.61	9.8	0.47	4.31e-20	Lung cancer;
LUSC	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg12454169	chr2:30669597	LCLAT1	-0.62	-8.54	-0.42	4.8e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs6960043	0.818	rs10228066	chr7:15063569	C/T	cg19272540	chr7:15055459	NA	-0.32	-7.79	-0.39	8.77e-14	Type 2 diabetes;
LUSC	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg11789530	chr4:8429930	ACOX3	-0.42	-6.07	-0.32	3.5e-9	Response to antineoplastic agents;
LUSC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.69	9.14	0.45	6.17e-18	Menarche (age at onset);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg13033626	chr12:7342228	PEX5	0.49	6.82	0.35	4.18e-11	Mosquito bite size;
LUSC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg03806693	chr22:41940476	POLR3H	0.95	12.89	0.58	3.76e-31	Vitiligo;
LUSC	cis	rs41271473	0.750	rs72751931	chr1:228887129	G/T	cg16512390	chr1:228756714	NA	0.47	5.71	0.3	2.5e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	6.52	0.34	2.54e-10	Lung cancer;
LUSC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg03929089	chr4:120376271	NA	0.82	11.14	0.52	9.93e-25	Coronary artery disease;
LUSC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	0.91	16.11	0.66	1.33e-43	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg21224049	chr4:668623	ATP5I	0.44	6.26	0.32	1.18e-9	Cognitive function;Information processing speed;
LUSC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg09165964	chr15:75287851	SCAMP5	-1.15	-18.88	-0.72	1.33e-54	Blood trace element (Zn levels);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08616760	chr5:178157801	ZNF354A	-0.38	-6.3	-0.33	9.63e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7188861	0.813	rs2867937	chr16:11398798	A/T	cg00044050	chr16:11439710	C16orf75	0.55	6.15	0.32	2.21e-9	HDL cholesterol;
LUSC	cis	rs240764	0.817	rs240145	chr6:101079610	A/C	cg09795085	chr6:101329169	ASCC3	0.42	6.04	0.31	4.03e-9	Neuroticism;
LUSC	trans	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg06606381	chr12:133084897	FBRSL1	0.83	7.5	0.38	5.77e-13	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg15704280	chr7:45808275	SEPT13	-0.44	-6.01	-0.31	4.86e-9	HDL cholesterol;
LUSC	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg17366294	chr4:99064904	C4orf37	0.5	8.64	0.43	2.42e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	6.56	0.34	2.1e-10	Lung cancer in ever smokers;
LUSC	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.5	7.83	0.39	6.39e-14	Depressive symptoms;
LUSC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06850241	chr22:41845214	NA	-0.33	-6.01	-0.31	4.81e-9	Vitiligo;
LUSC	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg17333051	chr19:2783644	SGTA	0.51	7.58	0.38	3.52e-13	Total cholesterol levels;
LUSC	cis	rs4629710	0.563	rs9483238	chr6:131567196	A/T	cg12606694	chr6:131520996	AKAP7	0.6	9.22	0.45	3.5e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	8.09e-13	Motion sickness;
LUSC	cis	rs116988415	0.584	rs4902309	chr14:65238171	A/G	cg25083366	chr14:65239357	SPTB	-0.64	-6.42	-0.33	4.71e-10	Daytime sleep phenotypes;
LUSC	cis	rs12681287	0.546	rs12546802	chr8:87499335	T/A	cg00550725	chr8:87521180	FAM82B	0.45	5.87	0.31	1.07e-8	Caudate activity during reward;
LUSC	cis	rs55871839	0.684	rs10108037	chr8:59812337	A/C	cg07426533	chr8:59803705	TOX	-0.36	-5.93	-0.31	7.66e-9	Pneumonia;
LUSC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg02018176	chr4:1364513	KIAA1530	0.57	10.06	0.48	5.77e-21	Obesity-related traits;
LUSC	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg09876464	chr15:85330779	ZNF592	0.36	6.55	0.34	2.21e-10	P wave terminal force;
LUSC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg05294307	chr14:35346193	BAZ1A	-0.58	-7.14	-0.36	5.92e-12	Psoriasis;
LUSC	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg19812747	chr11:111475976	SIK2	-0.46	-6.5	-0.34	2.93e-10	Primary sclerosing cholangitis;
LUSC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.9	0.44	3.55e-17	Prudent dietary pattern;
LUSC	cis	rs1113500	0.933	rs10785834	chr1:108639101	A/C	cg06207961	chr1:108661230	NA	0.41	7.46	0.38	7.43e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg23649088	chr2:200775458	C2orf69	0.54	7.46	0.38	7.54e-13	Schizophrenia;
LUSC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg19077165	chr18:44547161	KATNAL2	0.43	6.47	0.33	3.45e-10	Personality dimensions;
LUSC	cis	rs929596	0.755	rs4148325	chr2:234673309	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.65	-11.04	-0.52	2.35e-24	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.63	0.57	3.66e-30	Motion sickness;
LUSC	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg27165867	chr14:105738592	BRF1	-0.55	-8.03	-0.4	1.7e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4363385	0.791	rs11205177	chr1:153002502	G/A	cg25856811	chr1:152973957	SPRR3	-0.36	-5.94	-0.31	6.97e-9	Inflammatory skin disease;
LUSC	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg15839431	chr19:19639596	YJEFN3	0.66	7.28	0.37	2.39e-12	Bipolar disorder;
LUSC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg18681998	chr4:17616180	MED28	0.89	17.33	0.69	1.87e-48	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg09699651	chr6:150184138	LRP11	0.45	6.92	0.35	2.33e-11	Lung cancer;
LUSC	cis	rs9300255	0.664	rs28636834	chr12:123871070	A/C	cg13010344	chr12:123464640	ARL6IP4	0.49	6.22	0.32	1.48e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7572644	0.699	rs12470614	chr2:28217327	C/T	cg27432699	chr2:27873401	GPN1	0.5	6.84	0.35	3.78e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-7.0	-0.36	1.39e-11	Psoriasis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24923975	chr12:101801647	ARL1	-0.46	-6.01	-0.31	4.83e-9	Hepatitis;
LUSC	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg04450456	chr4:17643702	FAM184B	0.4	6.45	0.33	4e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg17507749	chr15:85114479	UBE2QP1	0.7	9.14	0.45	6.29e-18	Schizophrenia;
LUSC	cis	rs68092024	0.704	rs704576	chr3:99487154	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.36	-7.02	-0.36	1.28e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.68	-13.09	-0.58	7.08e-32	Monocyte count;
LUSC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.92	-0.31	8e-9	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg12027761	chr17:38279750	MSL1	-0.44	-6.32	-0.33	8.48e-10	Hepatitis;
LUSC	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.78	-0.35	5.36e-11	Monocyte percentage of white cells;
LUSC	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.84	-0.51	1.2e-23	Glomerular filtration rate;
LUSC	cis	rs12912251	1.000	rs12903120	chr15:38988097	G/T	cg01338139	chr15:38987640	C15orf53	-0.5	-6.79	-0.35	5.12e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg24881330	chr22:46731750	TRMU	-0.69	-7.27	-0.37	2.5e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg24375607	chr4:120327624	NA	0.76	12.17	0.55	1.85e-28	Corneal astigmatism;
LUSC	trans	rs2018683	0.707	rs7799357	chr7:28970118	A/G	cg19402173	chr7:128379420	CALU	-0.47	-7.18	-0.37	4.42e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-0.97	-14.49	-0.62	2.86e-37	Eosinophil percentage of white cells;
LUSC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg05347473	chr6:146136440	FBXO30	0.46	7.66	0.39	1.98e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs896854	0.573	rs11996455	chr8:95853708	G/A	cg16049864	chr8:95962084	TP53INP1	-0.55	-10.08	-0.48	4.73e-21	Type 2 diabetes;
LUSC	cis	rs13082711	0.522	rs569960	chr3:27329540	C/T	cg02860705	chr3:27208620	NA	0.48	8.93	0.44	2.93e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.62	0.47	1.63e-19	Bipolar disorder;
LUSC	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg04352962	chr1:209979756	IRF6	0.52	5.79	0.3	1.65e-8	Coronary artery disease;
LUSC	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg01256987	chr12:42539512	GXYLT1	0.36	6.61	0.34	1.53e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.68	-0.7	7.51e-50	Exhaled nitric oxide output;
LUSC	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	6.0	0.31	5.02e-9	Rheumatoid arthritis;
LUSC	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg23173402	chr1:227635558	NA	0.56	6.26	0.32	1.15e-9	Major depressive disorder;
LUSC	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg18209359	chr17:80159595	CCDC57	-0.37	-6.28	-0.32	1.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg11608241	chr8:8085544	FLJ10661	-0.46	-7.01	-0.36	1.35e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21171335	chr12:122356390	WDR66	0.55	7.8	0.39	7.97e-14	Mean corpuscular volume;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14428862	chr20:814736	FAM110A	0.48	6.48	0.33	3.36e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg09092052	chr15:45571596	NA	0.49	6.81	0.35	4.55e-11	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg03340356	chr1:67600835	NA	0.42	6.64	0.34	1.27e-10	Psoriasis;
LUSC	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg16230307	chr14:35515116	FAM177A1	0.73	8.45	0.42	8.86e-16	Psoriasis;
LUSC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.46	5.95	0.31	6.83e-9	Renal function-related traits (BUN);
LUSC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-7.36	-0.37	1.47e-12	Menopause (age at onset);
LUSC	trans	rs7939886	0.920	rs4612826	chr11:55948005	C/A	cg15704280	chr7:45808275	SEPT13	0.89	6.88	0.35	3e-11	Myopia (pathological);
LUSC	cis	rs3820928	0.874	rs4675132	chr2:227841792	A/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.83	-0.39	6.69e-14	Pulmonary function;
LUSC	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg26384229	chr12:38710491	ALG10B	0.7	10.84	0.51	1.12e-23	Morning vs. evening chronotype;
LUSC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	0.59	9.36	0.46	1.22e-18	Breast cancer;
LUSC	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.18	-0.49	2.18e-21	Eye color traits;
LUSC	trans	rs225245	0.817	rs225255	chr17:33955243	A/G	cg19694781	chr19:47549865	TMEM160	0.44	7.08	0.36	8.68e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs17401966	0.838	rs11580854	chr1:10293565	G/A	cg19773385	chr1:10388646	KIF1B	-0.53	-9.04	-0.44	1.31e-17	Hepatocellular carcinoma;
LUSC	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg08975724	chr8:8085496	FLJ10661	0.51	7.48	0.38	6.64e-13	Joint mobility (Beighton score);
LUSC	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg25206134	chr2:45395956	NA	0.57	6.52	0.34	2.6200000000000003e-10	Bipolar disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22302626	chr19:10196930	C19orf66	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg07926092	chr13:79233506	RNF219	0.55	7.0	0.36	1.44e-11	Large artery stroke;
LUSC	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg25214090	chr10:38739885	LOC399744	-0.51	-7.58	-0.38	3.54e-13	Corneal astigmatism;
LUSC	cis	rs909002	0.800	rs10914459	chr1:32096918	T/C	cg01639898	chr1:32083012	HCRTR1	0.31	7.36	0.37	1.48e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05694382	chr6:133136015	RPS12;SNORD101	-0.44	-6.01	-0.31	4.89e-9	Hepatitis;
LUSC	cis	rs7809950	1.000	rs7809950	chr7:107237807	T/C	cg23024343	chr7:107201750	COG5	0.57	8.94	0.44	2.64e-17	Coronary artery disease;
LUSC	trans	rs6601327	0.641	rs11778555	chr8:9587574	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.4	-0.33	5.21e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg02493740	chr2:85810744	VAMP5	-0.53	-9.26	-0.45	2.59e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.85	-14.94	-0.63	5.4300000000000003e-39	Cognitive function;
LUSC	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg18105134	chr13:113819100	PROZ	-0.76	-10.68	-0.5	4.38e-23	Platelet distribution width;
LUSC	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg24069376	chr3:38537580	EXOG	0.36	6.41	0.33	5.01e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.39	6.14	0.32	2.3e-9	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.62	-10.94	-0.51	5.3e-24	Menopause (age at onset);
LUSC	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg04450456	chr4:17643702	FAM184B	0.38	6.5	0.34	2.88e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg15038512	chr6:170123185	PHF10	0.53	7.08	0.36	8.47e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs6546550	0.901	rs13015457	chr2:70125763	G/T	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.87	0.4	4.97e-14	Prudent dietary pattern;
LUSC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.19	0.32	1.81e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs61935443	0.614	rs61935662	chr12:95313296	A/G	cg21533806	chr12:95267307	NA	0.49	5.75	0.3	2.04e-8	Schizophrenia;
LUSC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.52	0.34	2.59e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7804356	0.953	rs10242572	chr7:26895065	T/C	cg03456212	chr7:26904342	SKAP2	-0.52	-6.04	-0.31	4.16e-9	Type 1 diabetes;
LUSC	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.67	-0.34	1.07e-10	Bladder cancer;
LUSC	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg21573476	chr21:45109991	RRP1B	0.39	6.04	0.31	4.22e-9	Mean corpuscular volume;
LUSC	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg11502198	chr6:26597334	ABT1	0.59	9.37	0.46	1.15e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs71435601	0.628	rs532225	chr2:21397637	T/C	cg20757404	chr19:378427	NA	0.37	5.95	0.31	6.74e-9	Cholesterol, total;
LUSC	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.39	7.78	0.39	9.34e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs6700896	0.500	rs6693842	chr1:66078405	T/C	cg04111102	chr1:66153794	NA	0.31	6.83	0.35	4.14e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg23093090	chr10:104574429	C10orf26	-0.36	-6.65	-0.34	1.17e-10	Arsenic metabolism;
LUSC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08280861	chr8:58055591	NA	0.54	6.46	0.33	3.73e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg05527609	chr1:210001259	C1orf107	0.45	6.71	0.34	8.4e-11	Monobrow;
LUSC	cis	rs9905704	0.633	rs2632518	chr17:56512236	T/C	cg19466818	chr17:56409534	MIR142	-0.32	-6.1	-0.32	2.98e-9	Testicular germ cell tumor;
LUSC	cis	rs17155006	0.746	rs425623	chr7:107747465	C/T	cg05962710	chr7:107745446	LAMB4	-0.36	-6.52	-0.34	2.57e-10	Pneumococcal bacteremia;
LUSC	cis	rs1564271	0.553	rs2489583	chr10:26987698	A/G	cg13837822	chr10:26931731	LOC731789	0.46	9.31	0.45	1.78e-18	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUSC	cis	rs7760535	0.764	rs2343614	chr6:111705158	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.35	-6.45	-0.33	3.82e-10	Metabolic traits;
LUSC	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg00982548	chr2:198649783	BOLL	-0.58	-7.21	-0.37	3.87e-12	Ulcerative colitis;
LUSC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg02951883	chr7:2050386	MAD1L1	0.46	8.15	0.41	7.59e-15	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg00376283	chr12:123451042	ABCB9	0.66	8.34	0.42	2e-15	Neutrophil percentage of white cells;
LUSC	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs1371867	0.846	rs2919471	chr8:101232701	T/C	cg06636551	chr8:101224915	SPAG1	0.48	8.79	0.43	7.75e-17	Atrioventricular conduction;
LUSC	cis	rs4494114	1.000	rs880303	chr1:39340282	C/T	cg25970120	chr1:39325951	RRAGC	-0.41	-6.44	-0.33	4.15e-10	Blood protein levels;
LUSC	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg14092571	chr14:90743983	NA	-0.36	-5.86	-0.31	1.11e-8	Mortality in heart failure;
LUSC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg01475377	chr6:109611718	NA	-0.45	-8.21	-0.41	4.87e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg21782813	chr7:2030301	MAD1L1	0.44	7.17	0.37	4.73e-12	Schizophrenia;
LUSC	cis	rs12760731	0.720	rs12741848	chr1:178334941	A/G	cg00404053	chr1:178313656	RASAL2	0.53	6.09	0.32	3.06e-9	Obesity-related traits;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg01219382	chr4:184328462	NA	0.37	6.13	0.32	2.45e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg22903657	chr4:1355424	KIAA1530	-0.5	-8.36	-0.42	1.74e-15	Obesity-related traits;
LUSC	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg27284194	chr4:1044797	NA	0.59	8.79	0.43	7.77e-17	Recombination rate (females);
LUSC	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00684032	chr4:1343700	KIAA1530	0.37	6.51	0.34	2.82e-10	Obesity-related traits;
LUSC	cis	rs10203711	0.933	rs907110	chr2:239566391	C/T	cg14580085	chr2:239553406	NA	0.41	6.93	0.35	2.24e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg13010199	chr12:38710504	ALG10B	0.71	10.99	0.52	3.48e-24	Bladder cancer;
LUSC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.5	-0.38	5.8e-13	Bipolar disorder;
LUSC	cis	rs7681440	0.626	rs1372510	chr4:90817259	G/A	cg15133208	chr4:90757351	SNCA	-0.33	-5.69	-0.3	2.75e-8	Dementia with Lewy bodies;
LUSC	trans	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg04995722	chr7:26192034	NFE2L3	0.37	6.15	0.32	2.21e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs754466	0.874	rs61855849	chr10:79659934	G/A	cg17075019	chr10:79541650	NA	-0.64	-8.3	-0.41	2.54e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs757278	0.591	rs6980032	chr7:117303145	G/T	cg10524701	chr7:117356490	CTTNBP2	0.41	5.92	0.31	8.15e-9	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg21573476	chr21:45109991	RRP1B	-0.36	-5.84	-0.3	1.21e-8	Mean corpuscular volume;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22618350	chr1:91487603	ZNF644	-0.42	-6.18	-0.32	1.9e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	0.58	9.24	0.45	2.94e-18	Breast cancer;
LUSC	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.65	-0.43	2.27e-16	Mood instability;
LUSC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22307029	chr19:49891270	CCDC155	0.61	8.68	0.43	1.81e-16	Multiple sclerosis;
LUSC	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.81	-0.35	4.57e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.99	-0.44	1.91e-17	Axial length;
LUSC	cis	rs1524927	0.966	rs12704871	chr7:96334274	C/T	cg03808172	chr7:96339361	SHFM1	-0.45	-6.94	-0.35	2.07e-11	Total body bone mineral density;
LUSC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	6.92	0.35	2.27e-11	Multiple sclerosis;
LUSC	cis	rs4851254	0.961	rs7583067	chr2:100796850	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.73	-0.3	2.27e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2078087	0.568	rs504895	chr1:183215522	G/C	cg13843938	chr1:183241246	NMNAT2	0.41	6.77	0.35	5.85e-11	Obesity-related traits;
LUSC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg10645314	chr2:3704589	ALLC	-0.68	-10.35	-0.49	5.83e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs1322512	0.917	rs2250013	chr6:153006539	A/T	cg03415253	chr6:152958462	SYNE1	0.38	5.65	0.3	3.38e-8	Tonometry;
LUSC	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg13852791	chr20:30311386	BCL2L1	0.94	14.29	0.62	1.81e-36	Mean corpuscular hemoglobin;
LUSC	cis	rs9487051	0.735	rs1260595	chr6:109519873	T/G	cg01475377	chr6:109611718	NA	-0.36	-6.18	-0.32	1.9e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	7.01	0.36	1.29e-11	Height;
LUSC	cis	rs68149176	0.772	rs997761	chr16:87879522	A/C	cg03553613	chr16:87879502	SLC7A5	0.45	6.13	0.32	2.47e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21545522	chr1:205238299	TMCC2	0.49	9.21	0.45	3.82e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg18512352	chr11:47633146	NA	-0.46	-9.2	-0.45	3.88e-18	Subjective well-being;
LUSC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.66	8.93	0.44	2.9e-17	High light scatter reticulocyte count;
LUSC	cis	rs3099143	1.000	rs3099143	chr15:77104856	A/C	cg21673338	chr15:77095150	SCAPER	-0.76	-7.17	-0.37	4.88e-12	Recalcitrant atopic dermatitis;
LUSC	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg26816564	chr1:7831052	VAMP3	0.49	6.53	0.34	2.41e-10	Inflammatory bowel disease;
LUSC	cis	rs113835537	0.935	rs75863187	chr11:66443461	G/A	cg24851651	chr11:66362959	CCS	0.53	6.56	0.34	2.05e-10	Airway imaging phenotypes;
LUSC	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg05791153	chr7:19748676	TWISTNB	0.67	7.2	0.37	4.03e-12	Thyroid stimulating hormone;
LUSC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg18190219	chr22:46762943	CELSR1	-0.48	-6.0	-0.31	5.01e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10843647	0.967	rs1485411	chr12:30331167	G/T	cg12718339	chr12:29936407	TMTC1	-0.34	-5.69	-0.3	2.73e-8	Glucose homeostasis traits;
LUSC	cis	rs73200209	0.744	rs2392967	chr12:116531742	T/C	cg01776926	chr12:116560359	MED13L	-0.49	-5.98	-0.31	5.86e-9	Total body bone mineral density;
LUSC	cis	rs4663866	0.901	rs4663298	chr2:239139907	G/A	cg16914508	chr2:239161102	PER2	0.61	6.59	0.34	1.7e-10	Irritable bowel syndrome;
LUSC	cis	rs4144743	0.941	rs7211563	chr17:45324061	T/C	cg18085866	chr17:45331354	ITGB3	-0.7	-7.62	-0.38	2.61e-13	Body mass index;
LUSC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg03233332	chr7:66118400	NA	0.4	5.91	0.31	8.36e-9	Aortic root size;
LUSC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg07395648	chr5:131743802	NA	0.39	6.12	0.32	2.55e-9	Asthma (sex interaction);
LUSC	cis	rs10979	1.000	rs9399447	chr6:143896163	T/A	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg11062466	chr8:58055876	NA	0.47	6.3	0.33	9.47e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg27494647	chr7:150038898	RARRES2	0.47	7.29	0.37	2.19e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs66716358	0.710	rs10838256	chr11:44321199	T/C	cg16977035	chr11:44330474	ALX4	-0.36	-5.91	-0.31	8.29e-9	Monobrow;
LUSC	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg07382826	chr16:28625726	SULT1A1	0.28	5.98	0.31	5.77e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg21659725	chr3:3221576	CRBN	0.69	8.17	0.41	6.29e-15	Menarche (age at onset);
LUSC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg21017887	chr14:105400489	NA	0.7	13.52	0.59	1.63e-33	Rheumatoid arthritis;
LUSC	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05901451	chr6:126070800	HEY2	-0.59	-8.83	-0.43	6.14e-17	Endometrial cancer;
LUSC	cis	rs4899554	0.640	rs1569328	chr14:75741751	A/G	cg18117039	chr14:75741733	NA	-0.55	-7.62	-0.38	2.59e-13	Inflammatory bowel disease;
LUSC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19346786	chr7:2764209	NA	-0.48	-8.05	-0.4	1.52e-14	Height;
LUSC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.41	0.46	8.02e-19	Monocyte percentage of white cells;
LUSC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg18357645	chr12:58087776	OS9	0.55	8.23	0.41	4.17e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg11608241	chr8:8085544	FLJ10661	0.4	5.73	0.3	2.25e-8	Mood instability;
LUSC	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg04851639	chr8:1020857	NA	-0.35	-7.0	-0.36	1.4e-11	Schizophrenia;
LUSC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg16928487	chr17:17741425	SREBF1	0.45	8.92	0.44	3.14e-17	Total body bone mineral density;
LUSC	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg04539111	chr16:67997858	SLC12A4	-0.47	-6.3	-0.33	9.58e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg12463550	chr7:65579703	CRCP	-0.63	-5.68	-0.3	2.92e-8	Diabetic kidney disease;
LUSC	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg23260525	chr10:116636907	FAM160B1	0.4	8.12	0.41	8.78e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg16989719	chr2:238392110	NA	-0.5	-6.41	-0.33	4.87e-10	Prostate cancer;
LUSC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg22800045	chr5:56110881	MAP3K1	0.8	10.13	0.48	3.33e-21	Initial pursuit acceleration;
LUSC	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg17845761	chr1:175162550	KIAA0040	-0.3	-5.88	-0.31	1.02e-8	Alcohol dependence;
LUSC	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.37	-0.46	1.09e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg09436375	chr6:42928200	GNMT	-0.3	-6.89	-0.35	2.75e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-0.88	-18.29	-0.71	2.99e-52	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg20016023	chr10:99160130	RRP12	0.29	7.35	0.37	1.57e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4660306	0.677	rs781059	chr1:45934562	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-5.67	-0.3	3.07e-8	Homocysteine levels;
LUSC	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg00701064	chr4:6280414	WFS1	0.6	14.49	0.62	3.05e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	10.39	0.49	4.42e-22	Hemoglobin concentration;
LUSC	cis	rs2274273	0.638	rs3825614	chr14:55729387	G/A	cg04306507	chr14:55594613	LGALS3	0.48	9.66	0.47	1.26e-19	Protein biomarker;
LUSC	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg02018176	chr4:1364513	KIAA1530	-0.42	-6.05	-0.31	3.81e-9	Recombination rate (females);
LUSC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.53	10.25	0.49	1.29e-21	Monocyte count;
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg16031515	chr1:205743344	RAB7L1	-0.28	-6.11	-0.32	2.81e-9	Menarche (age at onset);
LUSC	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg17120908	chr11:65337727	SSSCA1	-0.53	-9.31	-0.45	1.78e-18	Bone mineral density;
LUSC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg11845111	chr2:191398756	TMEM194B	-0.54	-9.31	-0.45	1.79e-18	Pulse pressure;
LUSC	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.26	-0.32	1.21e-9	Response to antipsychotic treatment;
LUSC	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg17252645	chr8:143867129	LY6D	-0.36	-6.28	-0.32	1.07e-9	Urinary tract infection frequency;
LUSC	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg13736514	chr6:26305472	NA	-0.45	-8.98	-0.44	2.05e-17	Educational attainment;
LUSC	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg23625390	chr15:77176239	SCAPER	-0.66	-10.19	-0.49	2.03e-21	Blood metabolite levels;
LUSC	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg19875535	chr5:140030758	IK	-0.54	-8.91	-0.44	3.39e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6445797	0.632	rs6805469	chr3:56631235	G/T	cg13792233	chr3:56591045	CCDC66	0.4	5.72	0.3	2.41e-8	Gastritis;
LUSC	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	6.48	0.33	3.24e-10	Depressive symptoms;
LUSC	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg26566898	chr11:117069891	TAGLN	0.39	7.57	0.38	3.74e-13	Blood protein levels;
LUSC	cis	rs911119	1.000	rs6114206	chr20:23611789	A/G	cg16589663	chr20:23618590	CST3	0.59	6.95	0.36	1.88e-11	Chronic kidney disease;
LUSC	cis	rs9463078	0.605	rs13216116	chr6:44936681	C/T	cg25276700	chr6:44698697	NA	0.28	5.85	0.3	1.17e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs3740393	0.562	rs11191393	chr10:104527430	C/G	cg05855489	chr10:104503620	C10orf26	-0.57	-5.76	-0.3	1.89e-8	Microalbuminuria;
LUSC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	7.74	0.39	1.16e-13	Obesity-related traits;
LUSC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20307385	chr11:47447363	PSMC3	-0.46	-5.97	-0.31	6.16e-9	Subjective well-being;
LUSC	cis	rs9612	1.000	rs346524	chr19:44260572	T/C	cg08581076	chr19:44259116	C19orf61	0.53	6.71	0.34	8.22e-11	Exhaled nitric oxide output;
LUSC	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.49	0.75	5.16e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25072359	chr17:41440525	NA	-0.6	-8.68	-0.43	1.72e-16	Menopause (age at onset);
LUSC	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.42	6.05	0.31	3.98e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7246967	0.673	rs4627499	chr19:22832633	T/C	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs2820315	1.000	rs2820314	chr1:201872209	A/C	cg10061532	chr1:201886748	LMOD1	0.27	5.95	0.31	6.82e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs894734	0.535	rs10783613	chr12:54321966	G/T	cg25024717	chr12:54324583	NA	-0.38	-6.62	-0.34	1.47e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg11218175	chr11:495084	RNH1	0.53	5.66	0.3	3.31e-8	Body mass index;
LUSC	cis	rs9660992	0.967	rs1172135	chr1:205247160	G/C	cg21545522	chr1:205238299	TMCC2	0.44	8.18	0.41	5.86e-15	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs3862435	0.764	rs16944523	chr15:91038294	A/G	cg22089800	chr15:90895588	ZNF774	0.52	5.65	0.3	3.45e-8	Response to exercise (triglyceride level interaction);
LUSC	cis	rs34734847	1.000	rs56273049	chr12:121156041	A/T	cg27246729	chr12:121163418	ACADS	0.47	7.49	0.38	6.33e-13	Mean corpuscular volume;
LUSC	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg20790798	chr5:1857306	NA	-0.38	-5.78	-0.3	1.71e-8	Cardiovascular disease risk factors;
LUSC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg06784218	chr1:46089804	CCDC17	0.55	11.25	0.52	3.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.57	0.67	2.02e-45	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg04310649	chr10:35416472	CREM	-0.41	-6.14	-0.32	2.29e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs926938	0.606	rs6537844	chr1:115289295	G/A	cg12756093	chr1:115239321	AMPD1	-0.5	-7.09	-0.36	8.1e-12	Autism;
LUSC	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg17470723	chr8:74884337	TCEB1	0.5	7.38	0.37	1.23e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg11632617	chr15:75315747	PPCDC	-0.54	-7.01	-0.36	1.29e-11	Blood trace element (Zn levels);
LUSC	cis	rs12545109	0.571	rs7002482	chr8:57295200	C/T	cg09654669	chr8:57350985	NA	-0.45	-5.98	-0.31	5.7e-9	Obesity-related traits;
LUSC	cis	rs4629710	0.592	rs35017713	chr6:131581212	G/A	cg12700074	chr6:131571435	AKAP7	-0.34	-5.66	-0.3	3.19e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg24130564	chr14:104152367	KLC1	-0.51	-7.41	-0.38	1.04e-12	Body mass index;
LUSC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	11.4	0.53	1.17e-25	Alzheimer's disease;
LUSC	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg03522245	chr20:25566470	NINL	0.36	5.85	0.3	1.16e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs977987	0.806	rs4887818	chr16:75361995	T/C	cg03315344	chr16:75512273	CHST6	0.53	10.22	0.49	1.57e-21	Dupuytren's disease;
LUSC	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.93	-0.4	3.38e-14	Lymphocyte counts;
LUSC	cis	rs9653442	0.564	rs11123809	chr2:100758137	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-7.05	-0.36	1.06e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs34734847	0.933	rs998727	chr12:121149064	T/G	cg21892295	chr12:121157589	UNC119B	-0.46	-8.15	-0.41	7.24e-15	Mean corpuscular volume;
LUSC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	1.0	10.72	0.51	2.96e-23	Skin colour saturation;
LUSC	cis	rs9815354	0.812	rs56994465	chr3:42061606	A/G	cg03022575	chr3:42003672	ULK4	0.59	6.35	0.33	7.17e-10	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg21775007	chr8:11205619	TDH	-0.45	-6.45	-0.33	3.9e-10	Mood instability;
LUSC	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg14530993	chr4:882597	GAK	0.74	7.27	0.37	2.57e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs79911532	0.551	rs74999892	chr7:75756464	T/C	cg03592824	chr7:75666768	STYXL1	0.67	6.37	0.33	6.32e-10	Mononucleosis;
LUSC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg23950597	chr19:37808831	NA	-0.64	-7.59	-0.38	3.16e-13	Coronary artery calcification;
LUSC	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-5.92	-0.31	7.78e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg04234412	chr22:24373322	LOC391322	-0.59	-7.43	-0.38	9.17e-13	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg05347473	chr6:146136440	FBXO30	0.65	11.4	0.53	1.16e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.81	-0.43	6.8e-17	Lung cancer;
LUSC	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.86	-11.29	-0.53	2.89e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs1044826	0.647	rs4683463	chr3:139196946	T/G	cg00490450	chr3:139108681	COPB2	0.46	6.96	0.36	1.79e-11	Obesity-related traits;
LUSC	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg11019008	chr10:131425282	MGMT	0.41	5.91	0.31	8.46e-9	Response to temozolomide;
LUSC	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg26384229	chr12:38710491	ALG10B	0.5	7.24	0.37	3.07e-12	Morning vs. evening chronotype;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg24846343	chr22:24311635	DDTL	0.78	17.9	0.7	1.06e-50	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.76	-0.51	2.23e-23	Chronic sinus infection;
LUSC	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg13902645	chr11:5959945	NA	-0.59	-8.28	-0.41	3.07e-15	DNA methylation (variation);
LUSC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg11859384	chr17:80120422	CCDC57	0.36	5.71	0.3	2.46e-8	Life satisfaction;
LUSC	cis	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg26958806	chr6:27640298	NA	0.76	5.72	0.3	2.39e-8	Depression;
LUSC	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	11.27	0.53	3.35e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg23289794	chr7:2394357	EIF3B	-0.76	-9.99	-0.48	9.5e-21	Multiple sclerosis;
LUSC	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.32	6.54	0.34	2.25e-10	Schizophrenia;
LUSC	trans	rs8073060	0.586	rs225307	chr17:33918311	A/G	cg19694781	chr19:47549865	TMEM160	1.12	17.91	0.7	9.17e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.68	-0.63	5.51e-38	Schizophrenia;
LUSC	cis	rs10144321	0.644	rs11160580	chr14:100794314	T/C	cg14882082	chr14:100845427	WDR25	-0.41	-7.24	-0.37	3.14e-12	Menarche (age at onset);
LUSC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs11608355	0.545	rs11612500	chr12:109897136	T/C	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg12935359	chr14:103987150	CKB	0.67	10.87	0.51	9.08e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg20283391	chr11:68216788	NA	-0.52	-7.74	-0.39	1.18e-13	Total body bone mineral density;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08086221	chr19:48112482	GLTSCR1	-0.44	-6.0	-0.31	5.23e-9	Hepatitis;
LUSC	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg23752985	chr2:85803571	VAMP8	0.37	8.0	0.4	2.03e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.4	-0.42	1.33e-15	Body mass index;
LUSC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg08470875	chr2:26401718	FAM59B	-0.69	-9.37	-0.46	1.16e-18	Gut microbiome composition (summer);
LUSC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-12.63	-0.57	3.75e-30	Alzheimer's disease;
LUSC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg05082376	chr22:42548792	NA	-0.43	-6.83	-0.35	4.02e-11	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg16339924	chr4:17578868	LAP3	0.54	8.27	0.41	3.24e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg07424592	chr7:64974309	NA	0.69	5.99	0.31	5.45e-9	Diabetic kidney disease;
LUSC	trans	rs71435601	0.628	rs531380	chr2:21397561	C/G	cg20757404	chr19:378427	NA	0.37	6.01	0.31	4.87e-9	Cholesterol, total;
LUSC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs9653442	0.510	rs11891046	chr2:100794402	C/G	cg22139774	chr2:100720529	AFF3	-0.4	-6.95	-0.36	1.96e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6867913	0.709	rs891987	chr5:141467196	A/T	cg08523384	chr5:141488047	NDFIP1	0.42	7.0	0.36	1.4e-11	Asthma;
LUSC	cis	rs1368882	1.000	rs1368882	chr1:55107019	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.5	-8.12	-0.41	9.32e-15	Non-substance related behavioral disinhibition;
LUSC	cis	rs9311676	0.656	rs62258134	chr3:58398447	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.42	0.33	4.6e-10	Systemic lupus erythematosus;
LUSC	cis	rs2979489	0.580	rs73245347	chr8:30448213	T/G	cg26383811	chr8:30366931	RBPMS	-0.46	-7.39	-0.37	1.19e-12	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.79	0.6	1.44e-34	Platelet count;
LUSC	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.67	-0.34	1.06e-10	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg06521331	chr12:34319734	NA	-0.4	-6.21	-0.32	1.6e-9	Bladder cancer;
LUSC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23158103	chr7:148848205	ZNF398	-0.44	-6.8	-0.35	4.78e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg21033440	chr11:65409861	SIPA1	0.38	5.8	0.3	1.57e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg01256987	chr12:42539512	GXYLT1	-0.42	-7.7	-0.39	1.56e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.73	-0.39	1.24e-13	Blood metabolite levels;
LUSC	trans	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs2573652	1.000	rs2581362	chr15:100513524	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.4	-7.38	-0.37	1.23e-12	Height;
LUSC	cis	rs1891275	0.515	rs2153653	chr10:93495926	T/A	cg07889827	chr10:93443413	NA	-0.41	-9.28	-0.45	2.19e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.63	0.5	6.12e-23	Hip circumference adjusted for BMI;
LUSC	cis	rs1003719	0.591	rs9636914	chr21:38589732	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.52	7.66	0.39	2.08e-13	Eye color traits;
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01171360	chr6:293285	DUSP22	-0.69	-11.24	-0.52	4.47e-25	Menopause (age at onset);
LUSC	trans	rs73019876	0.869	rs10417673	chr19:22148101	A/T	cg16204205	chr18:19753432	GATA6	0.33	6.32	0.33	8.2e-10	Testicular germ cell tumor;
LUSC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg21854759	chr1:92012499	NA	-0.53	-8.91	-0.44	3.34e-17	Breast cancer;
LUSC	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	6.26	0.32	1.2e-9	Height;
LUSC	cis	rs4666002	0.789	rs13030973	chr2:27928797	T/C	cg27432699	chr2:27873401	GPN1	0.5	6.54	0.34	2.34e-10	Phospholipid levels (plasma);
LUSC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-10.75	-0.51	2.32e-23	Chronic sinus infection;
LUSC	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg20891283	chr12:69753455	YEATS4	0.44	5.82	0.3	1.38e-8	Response to diuretic therapy;
LUSC	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg21775007	chr8:11205619	TDH	-0.65	-10.36	-0.49	5.25e-22	Retinal vascular caliber;
LUSC	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg09904177	chr6:26538194	HMGN4	0.76	14.41	0.62	5.82e-37	Intelligence (multi-trait analysis);
LUSC	cis	rs17102423	0.963	rs35002541	chr14:65598704	G/A	cg11161011	chr14:65562177	MAX	-0.61	-9.45	-0.46	5.99e-19	Obesity-related traits;
LUSC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.98	-0.31	5.82e-9	Tonsillectomy;
LUSC	cis	rs11906854	0.636	rs3171389	chr20:34636281	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-6.08	-0.32	3.27e-9	Migraine - clinic-based;
LUSC	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg23625390	chr15:77176239	SCAPER	-0.61	-9.61	-0.47	1.82e-19	Blood metabolite levels;
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.32	-5.85	-0.31	1.14e-8	Lymphocyte counts;
LUSC	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg05283184	chr6:79620031	NA	0.57	12.15	0.55	2.21e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-11.25	-0.52	3.95e-25	Joint mobility (Beighton score);
LUSC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.4	-5.91	-0.31	8.65e-9	Menarche (age at onset);
LUSC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	0.6	9.38	0.46	1.03e-18	Breast cancer;
LUSC	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg14696996	chr19:15285081	NOTCH3	1.02	9.37	0.46	1.1e-18	Pulse pressure;
LUSC	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05962382	chr2:130345044	NA	-0.33	-5.65	-0.3	3.5e-8	Response to cytidine analogues (gemcitabine);
LUSC	trans	rs1478897	0.898	rs2248932	chr8:11391650	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.37	-0.33	6.22e-10	Systemic lupus erythematosus;
LUSC	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg13010199	chr12:38710504	ALG10B	0.66	10.22	0.49	1.67e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg11843238	chr5:131593191	PDLIM4	-0.39	-6.37	-0.33	6.18e-10	Breast cancer;
LUSC	cis	rs4954585	0.762	rs12986776	chr2:136991517	C/G	cg05194412	chr2:137003533	NA	0.4	7.35	0.37	1.5e-12	Colorectal cancer;
LUSC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.63	0.39	2.5e-13	Prudent dietary pattern;
LUSC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg22823121	chr1:150693482	HORMAD1	0.46	6.6	0.34	1.64e-10	Melanoma;
LUSC	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-8.5	-0.42	6.18e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg22532475	chr10:104410764	TRIM8	-0.33	-7.24	-0.37	3.03e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.45	6.75	0.35	6.52e-11	Systemic lupus erythematosus;
LUSC	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.8	-0.54	4.42e-27	Type 2 diabetes;
LUSC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26314531	chr2:26401878	FAM59B	-0.68	-9.01	-0.44	1.56e-17	Gut microbiome composition (summer);
LUSC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	0.83	11.25	0.52	3.97e-25	Eosinophil percentage of granulocytes;
LUSC	cis	rs6961069	0.585	rs1949818	chr7:80237059	C/T	cg04458919	chr7:80252533	CD36	-0.4	-7.27	-0.37	2.53e-12	Platelet count;
LUSC	cis	rs116988415	0.584	rs4902309	chr14:65238171	A/G	cg00114569	chr14:65239327	SPTB	-0.66	-6.73	-0.35	7.55e-11	Daytime sleep phenotypes;
LUSC	cis	rs4629180	0.586	rs1159902	chr2:102133641	G/A	cg01388757	chr2:102091195	RFX8	-0.37	-6.43	-0.33	4.37e-10	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7072216	0.770	rs1061123	chr10:100176997	A/G	cg26618903	chr10:100175079	PYROXD2	-0.35	-6.81	-0.35	4.66e-11	Metabolite levels;
LUSC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg06600287	chr1:53387719	ECHDC2	0.32	6.33	0.33	7.97e-10	Monocyte count;
LUSC	cis	rs4356932	1.000	rs4859415	chr4:76956528	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg09904177	chr6:26538194	HMGN4	0.76	14.41	0.62	5.82e-37	Intelligence (multi-trait analysis);
LUSC	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg13010199	chr12:38710504	ALG10B	0.66	10.16	0.49	2.52e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg06627628	chr2:24431161	ITSN2	-0.59	-7.24	-0.37	3.06e-12	Lymphocyte counts;
LUSC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.57	-0.38	3.58e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg22532475	chr10:104410764	TRIM8	-0.35	-7.78	-0.39	9.35e-14	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg27411982	chr8:10470053	RP1L1	0.38	5.95	0.31	6.79e-9	Retinal vascular caliber;
LUSC	cis	rs1595825	0.891	rs74265511	chr2:198494782	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.38	-0.33	5.85e-10	Ulcerative colitis;
LUSC	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.94	-0.44	2.7e-17	Total cholesterol levels;
LUSC	cis	rs17030434	1.000	rs6853522	chr4:154706220	A/C	cg14289246	chr4:154710475	SFRP2	0.53	7.11	0.36	7.28e-12	Electrocardiographic conduction measures;
LUSC	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg04837898	chr3:45731254	SACM1L	-0.39	-6.35	-0.33	7.1e-10	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2262909	0.962	rs12610034	chr19:22314528	G/A	cg11619707	chr19:22235551	ZNF257	0.39	5.92	0.31	7.9e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07741184	chr6:167504864	NA	0.37	6.45	0.33	3.82e-10	Primary biliary cholangitis;
LUSC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg18165381	chr3:44552316	NA	-0.37	-5.87	-0.31	1.04e-8	Depressive symptoms;
LUSC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.93	0.35	2.24e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg14196790	chr5:131705035	SLC22A5	0.42	6.78	0.35	5.61e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.83	-0.43	6.12e-17	Monocyte percentage of white cells;
LUSC	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg19773385	chr1:10388646	KIF1B	0.58	9.83	0.47	3.48e-20	Hepatocellular carcinoma;
LUSC	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg11050988	chr7:1952600	MAD1L1	-0.31	-5.95	-0.31	6.93e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-1.14	-17.81	-0.7	2.27e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06634786	chr22:41940651	POLR3H	0.48	5.85	0.3	1.17e-8	Vitiligo;
LUSC	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg22431228	chr1:16359049	CLCNKA	0.4	8.34	0.42	1.93e-15	Systolic blood pressure;
LUSC	cis	rs72792276	1.000	rs72794361	chr5:127435188	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	7.82	0.39	7.2e-14	Red cell distribution width;
LUSC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg06454157	chr6:167490870	NA	-0.25	-6.06	-0.31	3.71e-9	Crohn's disease;
LUSC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg23281280	chr6:28129359	ZNF389	0.49	6.35	0.33	7.06e-10	Parkinson's disease;
LUSC	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.7	0.75	7.91e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs28647808	0.748	rs28502181	chr9:136257792	T/G	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs41271473	0.948	rs12082771	chr1:228830777	C/T	cg10167378	chr1:228756711	NA	0.63	7.67	0.39	1.84e-13	Chronic lymphocytic leukemia;
LUSC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.28	6.02	0.31	4.49e-9	Electroencephalogram traits;
LUSC	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg04310649	chr10:35416472	CREM	-0.4	-6.21	-0.32	1.58e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs977987	0.843	rs4146810	chr16:75415831	A/G	cg04384234	chr16:75411784	CFDP1	-0.44	-7.38	-0.37	1.25e-12	Dupuytren's disease;
LUSC	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg23029597	chr12:123009494	RSRC2	0.75	9.55	0.46	2.84e-19	Body mass index;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17088247	chr6:28048961	ZNF165	-0.42	-6.2	-0.32	1.71e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10779751	0.770	rs2261434	chr1:11170131	A/C	cg08854313	chr1:11322531	MTOR	0.85	13.82	0.6	1.1e-34	Body mass index;
LUSC	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.81	0.51	1.49e-23	Morning vs. evening chronotype;
LUSC	trans	rs895636	0.898	rs10205310	chr2:45188646	A/G	cg03867797	chr12:110939833	VPS29;RAD9B	0.49	6.26	0.32	1.17e-9	Metabolite levels;Fasting plasma glucose;
LUSC	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg07936489	chr17:37558343	FBXL20	0.81	9.86	0.47	2.7e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg09238746	chr17:78121135	EIF4A3	-0.65	-10.13	-0.48	3.28e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs72700829	0.593	rs4418603	chr1:150989274	A/G	cg11822372	chr1:151115635	SEMA6C	-0.75	-6.7	-0.34	9e-11	Schizophrenia;
LUSC	cis	rs72634258	0.945	rs17367289	chr1:8053135	C/T	cg00042356	chr1:8021962	PARK7	-0.59	-8.15	-0.41	7.28e-15	Inflammatory bowel disease;
LUSC	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg05805236	chr11:65401703	PCNXL3	0.4	6.84	0.35	3.82e-11	Acne (severe);
LUSC	cis	rs1577917	0.681	rs4348284	chr6:86350394	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-7.56	-0.38	3.95e-13	Response to antipsychotic treatment;
LUSC	cis	rs7605827	0.930	rs2111451	chr2:15654483	T/C	cg19274914	chr2:15703543	NA	0.45	8.56	0.42	4.19e-16	Educational attainment (years of education);
LUSC	cis	rs7189233	0.550	rs9938788	chr16:53481422	G/C	cg09728985	chr16:53543985	NA	-0.31	-5.86	-0.31	1.14e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg01966878	chr4:90757139	SNCA	-0.36	-6.24	-0.32	1.31e-9	Dementia with Lewy bodies;
LUSC	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg05985134	chr18:33552581	C18orf21	0.51	7.05	0.36	1.01e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.25	0.37	3e-12	Platelet count;
LUSC	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg18854424	chr1:2615690	NA	0.49	10.38	0.49	4.55e-22	Ulcerative colitis;
LUSC	trans	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg18335740	chr13:41363409	SLC25A15	0.76	13.53	0.6	1.44e-33	Lewy body disease;
LUSC	cis	rs3812111	0.510	rs9372456	chr6:116592956	A/G	cg18828861	chr6:116576566	TSPYL4	0.38	6.72	0.35	7.97e-11	Age-related macular degeneration;
LUSC	cis	rs4919687	0.550	rs17784294	chr10:104479385	G/T	cg05855489	chr10:104503620	C10orf26	0.71	11.7	0.54	9.47e-27	Colorectal cancer;
LUSC	cis	rs9837602	1.000	rs793499	chr3:99565576	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	5.86	0.31	1.13e-8	Breast cancer;
LUSC	cis	rs7241530	0.662	rs8088204	chr18:75901055	C/T	cg14642773	chr18:75888474	NA	0.4	6.08	0.32	3.37e-9	Educational attainment (years of education);
LUSC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24110177	chr3:50126178	RBM5	-0.55	-9.1	-0.45	8.15e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	6.83	0.35	3.98e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.85	0.6	8.65e-35	Chronic sinus infection;
LUSC	cis	rs2479724	0.901	rs10947987	chr6:41754370	C/T	cg17623882	chr6:41773611	USP49	0.67	10.63	0.5	6.17e-23	Menarche (age at onset);
LUSC	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	7.13	0.36	6.3e-12	IgG glycosylation;
LUSC	cis	rs9311676	0.656	rs12497250	chr3:58399399	T/C	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.11e-10	Systemic lupus erythematosus;
LUSC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg10523860	chr14:103875565	MARK3	-0.37	-5.82	-0.3	1.35e-8	Body mass index;
LUSC	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg21827317	chr3:136751795	NA	0.39	6.93	0.35	2.23e-11	Neuroticism;
LUSC	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	13.19	0.59	2.77e-32	Lung cancer in ever smokers;
LUSC	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg05044414	chr3:183734942	ABCC5	0.2	7.02	0.36	1.27e-11	Anterior chamber depth;
LUSC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08280861	chr8:58055591	NA	0.52	6.81	0.35	4.54e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg05805236	chr11:65401703	PCNXL3	-0.63	-10.33	-0.49	6.71e-22	Acne (severe);
LUSC	cis	rs4664308	0.935	rs4665148	chr2:160917901	A/G	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.31	-0.53	2.55e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.63	-0.39	2.49e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg25214090	chr10:38739885	LOC399744	0.5	7.39	0.37	1.19e-12	Corneal astigmatism;
LUSC	cis	rs7707921	1.000	rs749401	chr5:81561369	T/C	cg15871215	chr5:81402204	ATG10	-0.43	-6.24	-0.32	1.3e-9	Breast cancer;
LUSC	cis	rs75804782	0.641	rs55844289	chr2:239323207	C/T	cg18131467	chr2:239335373	ASB1	-0.71	-6.47	-0.33	3.41e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-10.37	-0.49	4.97e-22	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg11019008	chr10:131425282	MGMT	0.45	6.61	0.34	1.52e-10	Response to temozolomide;
LUSC	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.36	0.42	1.7e-15	Lung cancer;
LUSC	cis	rs2274273	0.870	rs4496026	chr14:55790512	A/G	cg04306507	chr14:55594613	LGALS3	0.54	11.81	0.54	3.98e-27	Protein biomarker;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20428342	chr10:102820768	KAZALD1	-0.4	-5.98	-0.31	5.8e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg11845111	chr2:191398756	TMEM194B	-0.87	-11.22	-0.52	5.25e-25	Diastolic blood pressure;
LUSC	cis	rs7178572	0.568	rs7175674	chr15:77670910	C/T	cg22256960	chr15:77711686	NA	-0.51	-8.09	-0.4	1.11e-14	Type 2 diabetes;
LUSC	cis	rs9395066	0.545	rs10484627	chr6:44884267	A/T	cg25276700	chr6:44698697	NA	0.3	6.12	0.32	2.63e-9	Height;
LUSC	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	trans	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg21659725	chr3:3221576	CRBN	0.69	7.99	0.4	2.28e-14	Menarche (age at onset);
LUSC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.72	11.82	0.54	3.51e-27	Coronary artery disease;
LUSC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06634786	chr22:41940651	POLR3H	0.52	6.16	0.32	2.11e-9	Vitiligo;
LUSC	cis	rs13082711	0.911	rs3816881	chr3:27432888	T/C	cg02860705	chr3:27208620	NA	0.46	7.66	0.39	2e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg21573476	chr21:45109991	RRP1B	-0.42	-6.75	-0.35	6.5500000000000006e-11	Mean corpuscular volume;
LUSC	trans	rs7944735	0.567	rs76477746	chr11:48103368	G/C	cg15704280	chr7:45808275	SEPT13	0.71	5.96	0.31	6.48e-9	Intraocular pressure;
LUSC	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-7.1	-0.36	7.73e-12	Axial length;
LUSC	trans	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-8.84	-0.44	5.5e-17	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg19694781	chr19:47549865	TMEM160	-0.59	-9.41	-0.46	8.5e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26314531	chr2:26401878	FAM59B	-0.69	-9.28	-0.45	2.12e-18	Gut microbiome composition (summer);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03988675	chr1:14075428	PRDM2	-0.37	-6.13	-0.32	2.41e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.53	8.97	0.44	2.23e-17	IgG glycosylation;
LUSC	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg05941027	chr17:61774174	LIMD2	-0.22	-5.82	-0.3	1.36e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg06713675	chr4:122721982	EXOSC9	-0.69	-12.02	-0.55	6.45e-28	Type 2 diabetes;
LUSC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg04414720	chr1:150670196	GOLPH3L	0.5	7.76	0.39	1.07e-13	Melanoma;
LUSC	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.65	-0.47	1.39e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg21535247	chr6:8435926	SLC35B3	-0.56	-8.6	-0.43	3.16e-16	Motion sickness;
LUSC	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg00898013	chr13:113819073	PROZ	-0.58	-8.36	-0.42	1.76e-15	Platelet distribution width;
LUSC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08677398	chr8:58056175	NA	0.5	5.83	0.3	1.28e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7804356	1.000	rs3801821	chr7:26861206	C/T	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.05e-9	Type 1 diabetes;
LUSC	cis	rs6570726	0.533	rs1832374	chr6:145717752	A/G	cg23711669	chr6:146136114	FBXO30	0.46	7.08	0.36	8.66e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg14664628	chr15:75095509	CSK	0.44	6.27	0.32	1.1e-9	Systemic lupus erythematosus;
LUSC	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.31	21.44	0.76	9.83e-65	Type 1 diabetes nephropathy;
LUSC	cis	rs1461503	0.932	rs6589962	chr11:122843535	G/A	cg27398637	chr11:122830231	C11orf63	-0.4	-6.5	-0.34	2.93e-10	Menarche (age at onset);
LUSC	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg02466173	chr16:30829666	NA	-0.59	-10.83	-0.51	1.28e-23	Multiple myeloma;
LUSC	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.18	0.52	7.29e-25	Eye color traits;
LUSC	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.5	-0.46	4.14e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs28655083	0.828	rs7190227	chr16:77119568	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.52	7.75	0.39	1.13e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg03646922	chr17:4167316	ANKFY1	0.39	6.24	0.32	1.36e-9	Calcium levels;
LUSC	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg23587288	chr2:27483067	SLC30A3	0.3	5.86	0.31	1.13e-8	Blood metabolite levels;
LUSC	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg03585969	chr10:35415529	CREM	0.64	9.54	0.46	3.08e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg07507251	chr3:52567010	NT5DC2	0.34	6.45	0.33	4e-10	Bipolar disorder;
LUSC	trans	rs656319	0.580	rs17690549	chr8:9998538	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.63	-0.39	2.47e-13	Myopia (pathological);
LUSC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg24578937	chr1:2090814	PRKCZ	-0.44	-9.61	-0.47	1.78e-19	Height;
LUSC	cis	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.4e-9	Ulcerative colitis;
LUSC	cis	rs644148	0.738	rs2686768	chr19:44995990	C/T	cg15540054	chr19:45004280	ZNF180	-0.5	-7.02	-0.36	1.26e-11	Personality dimensions;
LUSC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.15	-0.32	2.21e-9	Initial pursuit acceleration;
LUSC	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14240646	chr10:27532245	ACBD5	-0.71	-7.65	-0.39	2.13e-13	Breast cancer;
LUSC	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.76	-0.35	6.24e-11	Heart rate;
LUSC	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg13615516	chr5:77269221	NA	0.4	6.76	0.35	6.09e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg23601095	chr6:26197514	HIST1H3D	0.73	7.97	0.4	2.52e-14	Gout;Renal underexcretion gout;
LUSC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00149659	chr3:10157352	C3orf10	-0.95	-14.2	-0.61	3.76e-36	Alzheimer's disease;
LUSC	cis	rs11645898	0.688	rs437638	chr16:72095452	C/T	cg14768367	chr16:72042858	DHODH	-0.73	-7.93	-0.4	3.22e-14	Blood protein levels;
LUSC	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	8.7	0.43	1.5e-16	Response to antipsychotic treatment;
LUSC	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg09876464	chr15:85330779	ZNF592	0.36	6.85	0.35	3.5e-11	P wave terminal force;
LUSC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.46e-35	Breast cancer;
LUSC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.7	11.13	0.52	1.11e-24	Cognitive function;
LUSC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg06808227	chr14:105710500	BRF1	-0.69	-10.97	-0.51	4.19e-24	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs3126085	0.825	rs7535078	chr1:152222915	T/C	cg26876637	chr1:152193138	HRNR	0.44	6.35	0.33	7.09e-10	Atopic dermatitis;
LUSC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg25767906	chr1:53392781	SCP2	0.49	8.74	0.43	1.13e-16	Monocyte count;
LUSC	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg12863693	chr15:85201151	NMB	0.36	7.15	0.36	5.61e-12	Schizophrenia;
LUSC	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg24375607	chr4:120327624	NA	0.76	11.87	0.54	2.32e-27	Corneal astigmatism;
LUSC	cis	rs12210905	0.687	rs12191649	chr6:27421208	A/T	cg08851530	chr6:28072375	NA	0.93	5.77	0.3	1.77e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs500891	0.525	rs7768550	chr6:84075810	T/G	cg08257003	chr6:84140564	ME1	0.34	8.16	0.41	6.84e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg13390004	chr1:15929781	NA	0.4	6.68	0.34	1e-10	Systolic blood pressure;
LUSC	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg19743168	chr1:23544995	NA	0.43	8.21	0.41	4.9e-15	Height;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16109953	chr14:24701739	GMPR2;NEDD8	0.49	6.74	0.35	6.83e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg01620082	chr3:125678407	NA	-0.85	-7.28	-0.37	2.42e-12	Depression;
LUSC	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg04998671	chr14:104000505	TRMT61A	-0.42	-6.0	-0.31	5e-9	Reticulocyte count;
LUSC	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg13010199	chr12:38710504	ALG10B	0.59	8.84	0.44	5.46e-17	Heart rate;
LUSC	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.38	-0.42	1.49e-15	Blood protein levels;
LUSC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-6.01	-0.31	4.75e-9	IgG glycosylation;
LUSC	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg15212455	chr7:39170539	POU6F2	0.38	5.97	0.31	5.92e-9	IgG glycosylation;
LUSC	trans	rs7739264	0.602	rs1121384	chr6:19771507	A/G	cg13431028	chr2:169073609	STK39	0.38	6.39	0.33	5.62e-10	Endometriosis;
LUSC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.79	0.6	1.47e-34	Alzheimer's disease;
LUSC	cis	rs1865721	0.771	rs7231277	chr18:73136724	A/G	cg26385618	chr18:73139727	C18orf62	-0.55	-10.1	-0.48	4.25e-21	Intelligence;
LUSC	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg04455712	chr21:45112962	RRP1B	0.43	7.39	0.38	1.16e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg14893161	chr1:205819251	PM20D1	0.89	17.69	0.7	7.09e-50	Menarche (age at onset);
LUSC	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg00631329	chr6:26305371	NA	-0.34	-6.31	-0.33	8.7e-10	Educational attainment;
LUSC	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.0	-0.4	2.14e-14	Glomerular filtration rate;
LUSC	cis	rs4654899	0.897	rs59537090	chr1:21498737	C/T	cg01072550	chr1:21505969	NA	-0.55	-8.49	-0.42	7e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10802521	chr3:52805072	NEK4	-0.47	-7.46	-0.38	7.66e-13	Electroencephalogram traits;
LUSC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.31	0.41	2.4e-15	Prudent dietary pattern;
LUSC	cis	rs6060717	0.536	rs8125966	chr20:34511823	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.74	-0.3	2.13e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg26195577	chr20:24973756	C20orf3	1.12	18.1	0.7	1.58e-51	Blood protein levels;
LUSC	cis	rs17818399	0.597	rs13385693	chr2:46867158	C/T	cg21493583	chr2:46842958	PIGF;CRIPT	0.34	6.12	0.32	2.69e-9	Height;
LUSC	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg21775007	chr8:11205619	TDH	-0.65	-10.36	-0.49	5.25e-22	Retinal vascular caliber;
LUSC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21016266	chr12:122356598	WDR66	0.62	9.42	0.46	7.45e-19	Mean corpuscular volume;
LUSC	trans	rs9886428	1.000	rs34062482	chr8:14115734	A/C	cg11959399	chr20:741723	C20orf54	-0.42	-6.66	-0.34	1.14e-10	IgG glycosylation;
LUSC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.48	-7.72	-0.39	1.33e-13	Alzheimer's disease (late onset);
LUSC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.35	-5.75	-0.3	2.04e-8	Total body bone mineral density;
LUSC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg20406979	chr6:167373233	NA	0.25	5.96	0.31	6.39e-9	Crohn's disease;
LUSC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.77	7.67	0.39	1.91e-13	Initial pursuit acceleration;
LUSC	cis	rs11585357	0.947	rs6684387	chr1:17611519	T/C	cg08277548	chr1:17600880	PADI3	0.63	6.8	0.35	4.74e-11	Hair shape;
LUSC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-0.88	-18.62	-0.71	1.43e-53	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11158026	0.518	rs878944	chr14:55443602	A/G	cg04306507	chr14:55594613	LGALS3	0.38	6.37	0.33	6.41e-10	Parkinson's disease;
LUSC	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs1507153	0.775	rs12210702	chr6:79369333	A/G	cg05283184	chr6:79620031	NA	-0.43	-7.63	-0.39	2.42e-13	Sjögren's syndrome;
LUSC	cis	rs4478137	0.501	rs9764	chr4:164245405	A/G	cg06758707	chr4:164254230	NPY1R	-0.51	-6.85	-0.35	3.58e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs4423214	0.610	rs12793607	chr11:71129316	C/T	cg05163923	chr11:71159392	DHCR7	-0.52	-7.79	-0.39	8.39e-14	Vitamin D levels;
LUSC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg19230755	chr7:65878503	NA	-0.38	-5.74	-0.3	2.17e-8	Aortic root size;
LUSC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg18230493	chr5:56204884	C5orf35	-0.66	-9.94	-0.48	1.5e-20	Coronary artery disease;
LUSC	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.62	-10.4	-0.49	4.07e-22	Schizophrenia;
LUSC	cis	rs2762353	0.526	rs9461203	chr6:25710555	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.41	-5.83	-0.3	1.3e-8	Blood metabolite levels;
LUSC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg20908204	chr19:46285434	DMPK	0.41	8.18	0.41	6.07e-15	Coronary artery disease;
LUSC	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.08	0.52	1.71e-24	Hypertriglyceridemia;
LUSC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg27535305	chr1:53392650	SCP2	-0.48	-9.36	-0.46	1.21e-18	Monocyte count;
LUSC	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg00206168	chr11:65308501	LTBP3	1.32	8.84	0.44	5.6e-17	Height;
LUSC	cis	rs1403694	0.695	rs13095338	chr3:186435583	T/C	cg12454167	chr3:186435060	KNG1	0.33	8.17	0.41	6.57e-15	Blood protein levels;
LUSC	cis	rs6009527	0.752	rs7286232	chr22:49568490	A/G	cg12746016	chr22:49560550	NA	0.48	8.74	0.43	1.19e-16	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01485046	chr19:46498389	CCDC61	-0.4	-5.99	-0.31	5.53e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg15485101	chr11:133734466	NA	0.39	7.13	0.36	6.18e-12	Childhood ear infection;
LUSC	cis	rs7614311	0.636	rs73117041	chr3:63896266	A/T	cg22134162	chr3:63841271	THOC7	-0.49	-6.17	-0.32	1.95e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg15103426	chr22:29168792	CCDC117	-0.44	-5.66	-0.3	3.26e-8	Lymphocyte counts;
LUSC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg12560992	chr17:57184187	TRIM37	-0.83	-15.13	-0.64	9.27e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs10887741	0.690	rs11202503	chr10:89440749	T/G	cg24243914	chr10:89418206	PAPSS2	0.34	6.72	0.35	7.86e-11	Exercise (leisure time);
LUSC	cis	rs12760731	0.565	rs35038893	chr1:178168417	C/T	cg00404053	chr1:178313656	RASAL2	0.66	6.82	0.35	4.26e-11	Obesity-related traits;
LUSC	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.08	0.55	4.06e-28	Ileal carcinoids;
LUSC	cis	rs6500395	0.832	rs8052733	chr16:48691978	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.47	7.04	0.36	1.11e-11	Testicular germ cell tumor;
LUSC	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg26924012	chr15:45694286	SPATA5L1	1.1	19.11	0.72	1.62e-55	Homoarginine levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08857478	chr17:74722826	JMJD6;C17orf95	0.41	6.44	0.33	4.25e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.09	-17.73	-0.7	4.82e-50	Primary sclerosing cholangitis;
LUSC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08677398	chr8:58056175	NA	-0.52	-6.85	-0.35	3.5e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4478858	0.709	rs7514640	chr1:31752316	G/A	cg00250761	chr1:31883323	NA	-0.34	-8.15	-0.41	7.26e-15	Alcohol dependence;
LUSC	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg18512352	chr11:47633146	NA	-0.48	-9.73	-0.47	7.1e-20	Subjective well-being;
LUSC	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.36	0.53	1.6e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg21854759	chr1:92012499	NA	0.51	8.57	0.42	4.02e-16	Breast cancer;
LUSC	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg27432699	chr2:27873401	GPN1	-0.51	-7.63	-0.39	2.43e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.77	12.76	0.57	1.2e-30	Metabolic syndrome;
LUSC	cis	rs6500395	1.000	rs1486412	chr16:48651750	A/T	cg04672837	chr16:48644449	N4BP1	0.48	6.98	0.36	1.56e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7589342	0.831	rs34554853	chr2:106448931	G/A	cg14210321	chr2:106509881	NCK2	-0.54	-8.16	-0.41	7.13e-15	Addiction;
LUSC	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	10.61	0.5	7.66e-23	Blood protein levels;
LUSC	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.16	0.49	2.61e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs41271473	1.000	rs11587994	chr1:228860072	A/C	cg16512390	chr1:228756714	NA	0.55	6.56	0.34	2.08e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs56399783	0.614	rs55776032	chr7:2762255	T/C	cg19731401	chr7:2775893	GNA12	0.73	8.59	0.43	3.46e-16	Childhood ear infection;
LUSC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.64	-9.19	-0.45	4.28e-18	Homoarginine levels;
LUSC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03517284	chr6:25882590	NA	-0.52	-9.71	-0.47	8.33e-20	Blood metabolite levels;
LUSC	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg09092052	chr15:45571596	NA	0.46	6.34	0.33	7.51e-10	Glomerular filtration rate;
LUSC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg06064525	chr11:970664	AP2A2	-0.29	-5.83	-0.3	1.33e-8	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7605827	0.897	rs7572509	chr2:15597288	C/T	cg19274914	chr2:15703543	NA	0.45	8.52	0.42	5.61e-16	Educational attainment (years of education);
LUSC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg13395646	chr4:1353034	KIAA1530	-0.55	-8.69	-0.43	1.64e-16	Obesity-related traits;
LUSC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.34	-0.33	7.54e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.79	0.57	9.25e-31	Platelet count;
LUSC	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.11	-0.36	7.15e-12	Bipolar disorder;
LUSC	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.45	-0.42	9.13e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs11971779	0.680	rs4398844	chr7:139043139	G/A	cg23387468	chr7:139079360	LUC7L2	0.42	6.35	0.33	7.03e-10	Diisocyanate-induced asthma;
LUSC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg09904177	chr6:26538194	HMGN4	-0.39	-5.71	-0.3	2.52e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs73206853	0.614	rs57154770	chr12:110814415	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.28	0.32	1.08e-9	Height;
LUSC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg22800045	chr5:56110881	MAP3K1	0.79	10.02	0.48	7.93e-21	Initial pursuit acceleration;
LUSC	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg06671706	chr8:8559999	CLDN23	0.45	6.33	0.33	7.81e-10	Obesity-related traits;
LUSC	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg13010199	chr12:38710504	ALG10B	0.61	9.44	0.46	6.49e-19	Bladder cancer;
LUSC	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	1.2	35.99	0.89	5.4800000000000004e-117	Myeloid white cell count;
LUSC	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg01579765	chr21:45077557	HSF2BP	-0.54	-11.5	-0.53	5.31e-26	Mean corpuscular volume;
LUSC	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg27432699	chr2:27873401	GPN1	0.71	11.94	0.55	1.33e-27	Oral cavity cancer;
LUSC	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02176678	chr2:219576539	TTLL4	0.6	11.19	0.52	6.86e-25	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg19077165	chr18:44547161	KATNAL2	0.41	6.3	0.33	9.21e-10	Personality dimensions;
LUSC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg16339924	chr4:17578868	LAP3	0.53	8.24	0.41	4.02e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.57	0.6	1e-33	Cognitive test performance;
LUSC	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg09307838	chr4:120376055	NA	0.75	11.0	0.52	3.27e-24	Corneal astigmatism;
LUSC	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg22681709	chr2:178499509	PDE11A	0.48	8.56	0.42	4.18e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-12.43	-0.56	2.12e-29	Colorectal cancer;
LUSC	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg23029597	chr12:123009494	RSRC2	0.74	9.66	0.47	1.24e-19	Body mass index;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg17133724	chr18:22932450	ZNF521	0.72	6.3	0.33	9.58e-10	Cognitive performance;
LUSC	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.61	0.34	1.48e-10	Corneal astigmatism;
LUSC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg03579872	chr1:53393473	SCP2	-0.39	-5.78	-0.3	1.74e-8	Monocyte count;
LUSC	cis	rs10266483	0.774	rs10239221	chr7:63813230	G/A	cg24201672	chr7:64023550	ZNF680	0.45	5.86	0.31	1.11e-8	Response to statin therapy;
LUSC	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg16342193	chr10:102329863	NA	-0.35	-6.28	-0.32	1.08e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2303282	0.716	rs2920702	chr16:56461511	C/G	cg00500540	chr16:56394104	NA	-0.43	-7.35	-0.37	1.52e-12	Breast cancer;
LUSC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg23630131	chr7:65973040	NA	0.21	5.78	0.3	1.76e-8	Aortic root size;
LUSC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.4	-0.46	8.96e-19	Bipolar disorder and schizophrenia;
LUSC	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg25214090	chr10:38739885	LOC399744	0.53	7.64	0.39	2.36e-13	Corneal astigmatism;
LUSC	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg25643088	chr3:52874325	TMEM110	0.39	6.0	0.31	5.11e-9	Schizophrenia;
LUSC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.73	-0.43	1.27e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs965469	0.779	rs6037516	chr20:3233142	C/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.65	-0.3	3.46e-8	IFN-related cytopenia;
LUSC	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-0.89	-13.18	-0.58	3.29e-32	Asthma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22717607	chr5:10353969	MARCH6	-0.46	-6.1	-0.32	2.94e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.41	-0.33	5.01e-10	Lung cancer;
LUSC	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg05973401	chr12:123451056	ABCB9	-0.54	-6.77	-0.35	5.72e-11	Neutrophil percentage of white cells;
LUSC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.52	-0.42	5.73e-16	Lung cancer;
LUSC	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg15556689	chr8:8085844	FLJ10661	0.54	7.44	0.38	8.52e-13	Neuroticism;
LUSC	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg07169764	chr2:136633963	MCM6	1.04	13.85	0.6	8.62e-35	Corneal structure;
LUSC	cis	rs2191566	0.664	rs7255512	chr19:44574700	C/T	cg03039196	chr19:44506973	ZNF230	0.35	5.82	0.3	1.4e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg05347473	chr6:146136440	FBXO30	-0.47	-7.97	-0.4	2.54e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg08125733	chr17:73851984	WBP2	0.46	6.44	0.33	4.14e-10	White matter hyperintensity burden;
LUSC	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.24e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6940638	0.956	rs10946899	chr6:27023694	T/A	cg09904177	chr6:26538194	HMGN4	-0.51	-6.41	-0.33	5.08e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.81	0.39	7.4e-14	Bipolar disorder;
LUSC	cis	rs12681287	0.927	rs7003059	chr8:87330713	C/T	cg27223183	chr8:87520930	FAM82B	-0.45	-6.0	-0.31	5.24e-9	Caudate activity during reward;
LUSC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg13531842	chr10:38383804	ZNF37A	-0.48	-7.42	-0.38	9.51e-13	Extrinsic epigenetic age acceleration;
LUSC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07167872	chr1:205819463	PM20D1	-0.74	-14.77	-0.63	2.42e-38	Monocyte percentage of white cells;
LUSC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg04111992	chr7:158790115	NA	-0.37	-5.94	-0.31	7.35e-9	Facial morphology (factor 20);
LUSC	cis	rs7577851	0.669	rs72826571	chr2:69564580	A/G	cg10773587	chr2:69614142	GFPT1	0.58	6.2	0.32	1.67e-9	Parkinson's disease (age of onset);
LUSC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg01073479	chr16:3509474	NAT15	-0.31	-5.91	-0.31	8.21e-9	Tuberculosis;
LUSC	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg07828024	chr6:149772892	ZC3H12D	0.34	7.32	0.37	1.9e-12	Dupuytren's disease;
LUSC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.34	5.85	0.3	1.2e-8	Obesity-related traits;
LUSC	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg08085267	chr17:45401833	C17orf57	0.54	8.78	0.43	8.52e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.58	-11.36	-0.53	1.63e-25	Educational attainment;
LUSC	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg14668632	chr7:2872130	GNA12	-0.4	-5.98	-0.31	5.77e-9	Height;
LUSC	cis	rs4950928	0.823	rs946262	chr1:203158229	C/T	cg17014757	chr1:203156097	CHI3L1	0.41	7.01	0.36	1.31e-11	YKL-40 levels;
LUSC	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	13.41	0.59	4.32e-33	Post bronchodilator FEV1;
LUSC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg18477163	chr1:228402036	OBSCN	-0.55	-10.27	-0.49	1.12e-21	Diastolic blood pressure;
LUSC	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg03647239	chr10:116582469	FAM160B1	0.46	7.32	0.37	1.9e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.17	-0.41	6.51e-15	Chronic sinus infection;
LUSC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg02221750	chr19:17393354	ANKLE1	-0.91	-14.25	-0.61	2.46e-36	Systemic lupus erythematosus;
LUSC	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg07148914	chr20:33460835	GGT7	-0.52	-7.94	-0.4	3.09e-14	Glomerular filtration rate (creatinine);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14514174	chr9:99181512	ZNF367	0.41	6.16	0.32	2.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6009527	0.762	rs2318940	chr22:49573394	G/A	cg12746016	chr22:49560550	NA	0.44	6.95	0.36	1.91e-11	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg19077165	chr18:44547161	KATNAL2	-0.41	-5.89	-0.31	9.19e-9	Personality dimensions;
LUSC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg01176363	chr20:62369445	LIME1	-0.47	-7.01	-0.36	1.29e-11	Prostate cancer;
LUSC	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.57	10.64	0.5	5.82e-23	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18436758	chr1:21113190	HP1BP3	-0.45	-6.12	-0.32	2.62e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg01620082	chr3:125678407	NA	-0.85	-7.37	-0.37	1.31e-12	Depression;
LUSC	cis	rs7586879	0.828	rs1968482	chr2:25086858	T/C	cg01884057	chr2:25150051	NA	0.4	8.18	0.41	5.86e-15	Body mass index;
LUSC	cis	rs7795096	0.806	rs10277544	chr7:151540633	T/C	cg17008978	chr7:151542804	PRKAG2	0.35	6.65	0.34	1.19e-10	Bipolar disorder (age of onset and psychotic symptoms);
LUSC	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg13852791	chr20:30311386	BCL2L1	0.94	14.79	0.63	1.95e-38	Mean corpuscular hemoglobin;
LUSC	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.35	-0.33	6.84e-10	Dupuytren's disease;
LUSC	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-10.1	-0.48	4.29e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg15133208	chr4:90757351	SNCA	0.32	5.68	0.3	2.95e-8	Dementia with Lewy bodies;
LUSC	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.7	-10.7	-0.51	3.54e-23	Alcohol dependence;
LUSC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.49	6.05	0.31	3.98e-9	Mean platelet volume;
LUSC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.4	-0.33	5.2e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs656319	0.513	rs17746227	chr8:9981654	T/C	cg27411982	chr8:10470053	RP1L1	-0.39	-5.81	-0.3	1.49e-8	Myopia (pathological);
LUSC	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg19875535	chr5:140030758	IK	-0.53	-8.78	-0.43	8.59e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg06740227	chr12:86229804	RASSF9	0.38	6.06	0.31	3.64e-9	Major depressive disorder;
LUSC	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg02153584	chr22:29168773	CCDC117	-0.56	-8.25	-0.41	3.67e-15	Lymphocyte counts;
LUSC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.46e-35	Breast cancer;
LUSC	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg06484146	chr7:12443880	VWDE	-0.74	-7.32	-0.37	1.86e-12	Coronary artery disease;
LUSC	trans	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-12.14	-0.55	2.47e-28	Colorectal cancer;
LUSC	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs1568889	0.838	rs7121937	chr11:28359858	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.87	0.58	4.52e-31	Bipolar disorder;
LUSC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg07701084	chr6:150067640	NUP43	0.57	8.96	0.44	2.36e-17	Lung cancer;
LUSC	trans	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.9	0.35	2.62e-11	Endometrial cancer;
LUSC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg18230493	chr5:56204884	C5orf35	-0.69	-10.56	-0.5	1.13e-22	Coronary artery disease;
LUSC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg06238570	chr21:40685208	BRWD1	0.48	7.54	0.38	4.41e-13	Cognitive function;
LUSC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg17211192	chr8:82754475	SNX16	0.76	10.09	0.48	4.45e-21	Diastolic blood pressure;
LUSC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg16624210	chr5:671434	TPPP	-0.48	-6.36	-0.33	6.6e-10	Obesity-related traits;
LUSC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg17330251	chr7:94953956	PON1	-0.36	-5.84	-0.3	1.22e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg25801113	chr15:45476975	SHF	0.36	7.35	0.37	1.52e-12	Uric acid levels;
LUSC	cis	rs1865721	1.000	rs62089508	chr18:73193344	C/T	cg26385618	chr18:73139727	C18orf62	-0.48	-8.1	-0.41	1.04e-14	Intelligence;
LUSC	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg00540400	chr15:79124168	NA	-0.48	-8.43	-0.42	1.04e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg15017067	chr4:17643749	FAM184B	0.34	5.66	0.3	3.25e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg13390004	chr1:15929781	NA	0.39	6.75	0.35	6.49e-11	Systolic blood pressure;
LUSC	cis	rs2629540	0.737	rs10901821	chr10:126480556	T/C	cg08799069	chr10:126477246	METTL10	-0.57	-8.68	-0.43	1.78e-16	Cocaine dependence;
LUSC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg24829409	chr8:58192753	C8orf71	-0.54	-6.12	-0.32	2.63e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	6.29	0.33	9.72e-10	Electroencephalogram traits;
LUSC	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg22705602	chr4:152727874	NA	-0.31	-6.16	-0.32	2.13e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg12560992	chr17:57184187	TRIM37	0.84	15.48	0.65	3.82e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs6700896	0.522	rs12030543	chr1:66155027	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	5.95	0.31	6.67e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7180079	1.000	rs2306974	chr15:64486527	A/G	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.05	0.31	3.88e-9	Height;
LUSC	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg12927641	chr6:109611667	NA	-0.35	-5.85	-0.3	1.19e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg20908204	chr19:46285434	DMPK	-0.45	-8.4	-0.42	1.26e-15	Coronary artery disease;
LUSC	cis	rs17255340	0.539	rs6908259	chr6:84050283	C/G	cg08257003	chr6:84140564	ME1	0.34	8.26	0.41	3.45e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	1.11	22.93	0.78	1.43e-70	Triglycerides;
LUSC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21984481	chr17:79567631	NPLOC4	-0.68	-13.95	-0.61	3.49e-35	Eye color traits;
LUSC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.16	0.32	2.12e-9	Menopause (age at onset);
LUSC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg07636037	chr3:49044803	WDR6	0.47	6.65	0.34	1.17e-10	Resting heart rate;
LUSC	cis	rs12760731	0.720	rs6702625	chr1:178339206	G/A	cg00404053	chr1:178313656	RASAL2	0.58	6.46	0.33	3.79e-10	Obesity-related traits;
LUSC	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.14	-0.45	6.2e-18	Monocyte percentage of white cells;
LUSC	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg09307838	chr4:120376055	NA	0.72	10.46	0.5	2.45e-22	Corneal astigmatism;
LUSC	cis	rs6669008	1.000	rs1891969	chr1:114185855	C/A	cg26035817	chr1:114414802	PTPN22	0.43	6.54	0.34	2.29e-10	Bacteremia;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04296578	chr1:45671659	ZSWIM5	0.33	5.95	0.31	6.91e-9	Asthma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05210131	chr2:182757482	SSFA2	-0.44	-6.52	-0.34	2.54e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.76	0.35	6.32e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs61869271	0.805	rs769119	chr10:116778675	A/G	cg23260525	chr10:116636907	FAM160B1	0.33	6.4	0.33	5.32e-10	Tonsillectomy;
LUSC	cis	rs1832871	0.672	rs11751081	chr6:158761505	G/A	cg07165851	chr6:158734300	TULP4	0.46	6.95	0.36	1.94e-11	Height;
LUSC	trans	rs13189969	0.967	rs10071546	chr5:105285578	C/T	cg17534029	chr20:62318426	RTEL1	0.32	5.99	0.31	5.37e-9	Obesity-related traits;
LUSC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg09877947	chr5:131593287	PDLIM4	-0.39	-6.45	-0.33	3.99e-10	Blood metabolite levels;
LUSC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg00750074	chr16:89608354	SPG7	-0.57	-10.34	-0.49	6.46e-22	Multiple myeloma (IgH translocation);
LUSC	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg05340658	chr4:99064831	C4orf37	0.59	9.09	0.45	8.8e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.2	0.32	1.66e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.84	11.24	0.52	4.62e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg20476274	chr7:133979776	SLC35B4	0.85	15.4	0.64	8.52e-41	Mean platelet volume;
LUSC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.65	-11.52	-0.53	4.51e-26	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-8.23	-0.41	4.35e-15	Mood instability;
LUSC	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg05110241	chr16:68378359	PRMT7	-0.56	-6.27	-0.32	1.13e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.2	-0.32	1.68e-9	Breast cancer;
LUSC	cis	rs16949788	1.000	rs76847935	chr15:66769613	G/A	cg08120210	chr15:66682733	MAP2K1	-0.63	-6.52	-0.34	2.56e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs240764	0.578	rs1414734	chr6:101201823	T/C	cg09795085	chr6:101329169	ASCC3	0.43	6.13	0.32	2.47e-9	Neuroticism;
LUSC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg08859206	chr1:53392774	SCP2	-0.4	-6.49	-0.33	3.06e-10	Monocyte count;
LUSC	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg10560079	chr2:191398806	TMEM194B	-0.63	-8.04	-0.4	1.55e-14	Diastolic blood pressure;
LUSC	cis	rs4363385	0.597	rs55667413	chr1:152976849	G/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.7	-0.3	2.69e-8	Inflammatory skin disease;
LUSC	cis	rs925550	0.526	rs62322204	chr4:123629089	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.51	-6.67	-0.34	1.08e-10	Primary biliary cholangitis;
LUSC	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.38	-0.33	5.85e-10	Dupuytren's disease;
LUSC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.95	0.36	1.93e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg16606324	chr3:10149918	C3orf24	-0.62	-9.31	-0.45	1.82e-18	Alzheimer's disease;
LUSC	trans	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg26384229	chr12:38710491	ALG10B	0.59	9.42	0.46	7.54e-19	Morning vs. evening chronotype;
LUSC	cis	rs1322512	1.000	rs2758779	chr6:153008022	T/A	cg27316956	chr6:152958899	SYNE1	0.35	6.06	0.31	3.59e-9	Tonometry;
LUSC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg25039879	chr17:56429692	SUPT4H1	0.72	9.75	0.47	6.09e-20	Cognitive test performance;
LUSC	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg13042288	chr15:90349979	ANPEP	-0.44	-6.38	-0.33	6.08e-10	Uric acid levels;
LUSC	cis	rs3087591	0.708	rs35109242	chr17:29649223	A/G	cg24425628	chr17:29625626	OMG;NF1	0.46	6.87	0.35	3.09e-11	Hip circumference;
LUSC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg20821713	chr7:1055600	C7orf50	-0.57	-7.38	-0.37	1.29e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	trans	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg13565492	chr6:43139072	SRF	-0.56	-6.01	-0.31	4.81e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg00701064	chr4:6280414	WFS1	0.59	14.45	0.62	4.21e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26748024	chr6:42420298	TRERF1	0.51	8.09	0.4	1.09e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6681460	0.932	rs523132	chr1:67174440	A/G	cg02459107	chr1:67143332	SGIP1	-0.47	-8.83	-0.44	5.96e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs193541	0.555	rs2438151	chr5:122199197	A/G	cg19077854	chr5:122220652	SNX24	0.37	7.87	0.4	4.89e-14	Glucose homeostasis traits;
LUSC	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.69	10.35	0.49	5.71e-22	Corneal astigmatism;
LUSC	cis	rs12681287	0.640	rs7841690	chr8:87365359	T/C	cg00550725	chr8:87521180	FAM82B	-0.42	-5.66	-0.3	3.3e-8	Caudate activity during reward;
LUSC	cis	rs6500395	0.928	rs4553627	chr16:48708801	A/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.74	-0.35	6.78e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg12924262	chr12:102091054	CHPT1	0.43	6.12	0.32	2.57e-9	Blood protein levels;
LUSC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg21724239	chr8:58056113	NA	0.74	8.15	0.41	7.47e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg00945038	chr17:61921165	SMARCD2	0.54	9.47	0.46	5.13e-19	Prudent dietary pattern;
LUSC	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg20991723	chr1:152506922	NA	0.51	9.6	0.47	1.93e-19	Hair morphology;
LUSC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08280861	chr8:58055591	NA	0.55	6.63	0.34	1.38e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.83	-0.3	1.33e-8	Platelet count;
LUSC	trans	rs12080794	1.000	rs56234523	chr1:9156034	T/C	cg11315153	chr6:62996299	KHDRBS2	-0.52	-6.16	-0.32	2.13e-9	Response to antidepressant treatment (citalopram);
LUSC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.82	-0.3	1.42e-8	Depression;
LUSC	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg18478394	chr8:109455254	TTC35	0.4	6.21	0.32	1.55e-9	Dupuytren's disease;
LUSC	cis	rs9653442	0.564	rs7593261	chr2:100789907	A/G	cg22139774	chr2:100720529	AFF3	-0.38	-6.46	-0.33	3.69e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg01657329	chr11:68192670	LRP5	0.42	6.26	0.32	1.16e-9	Total body bone mineral density;
LUSC	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.7	8.63	0.43	2.62e-16	Type 2 diabetes;
LUSC	trans	rs459571	1.000	rs459571	chr9:136912626	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.74	-12.34	-0.56	4.4e-29	Platelet distribution width;
LUSC	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.67e-24	Hypertriglyceridemia;
LUSC	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg13660082	chr14:53194042	PSMC6	-0.78	-6.43	-0.33	4.36e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02176678	chr2:219576539	TTLL4	-0.71	-13.66	-0.6	4.59e-34	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1044826	0.642	rs7652860	chr3:139205818	T/A	cg15131784	chr3:139108705	COPB2	0.4	6.38	0.33	5.94e-10	Obesity-related traits;
LUSC	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.73	12.26	0.56	8.75e-29	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg04352962	chr1:209979756	IRF6	0.48	6.29	0.33	1e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02187348	chr16:89574699	SPG7	0.59	9.72	0.47	8.1e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg08179530	chr6:36648295	CDKN1A	-0.55	-7.95	-0.4	2.95e-14	Coronary artery disease;
LUSC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7289126	1.000	rs7290372	chr22:38628388	T/G	cg25457927	chr22:38595422	NA	-0.29	-5.78	-0.3	1.71e-8	Mammographic density (dense area);Percent mammographic density;
LUSC	trans	rs2790216	0.526	rs1199093	chr10:59896794	C/G	cg08644993	chr1:153508755	S100A6	-0.37	-6.1	-0.32	2.96e-9	Inflammatory bowel disease;
LUSC	cis	rs16976116	0.901	rs113679855	chr15:55502428	C/T	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg20283391	chr11:68216788	NA	-0.61	-8.43	-0.42	1.02e-15	Total body bone mineral density;
LUSC	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	1.09	17.24	0.69	4.32e-48	Exhaled nitric oxide output;
LUSC	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg05872129	chr22:39784769	NA	-0.58	-9.89	-0.48	2.22e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6942756	1.000	rs6980385	chr7:128943615	G/A	cg02491457	chr7:128862824	NA	-0.48	-6.69	-0.34	9.62e-11	White matter hyperintensity burden;
LUSC	trans	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg10756647	chr7:56101905	PSPH	0.88	8.45	0.42	8.8e-16	Diabetic kidney disease;
LUSC	cis	rs6460942	0.591	rs6942432	chr7:12338393	A/G	cg06484146	chr7:12443880	VWDE	-0.59	-6.29	-0.33	9.69e-10	Coronary artery disease;
LUSC	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.97	-0.44	2.24e-17	Total cholesterol levels;
LUSC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg08999081	chr20:33150536	PIGU	0.4	7.43	0.38	8.92e-13	Height;
LUSC	cis	rs1044826	1.000	rs13089052	chr3:139227472	C/T	cg00490450	chr3:139108681	COPB2	0.51	6.8	0.35	4.8e-11	Obesity-related traits;
LUSC	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg09654669	chr8:57350985	NA	-0.62	-8.4	-0.42	1.3e-15	Obesity-related traits;
LUSC	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg24505687	chr6:33548425	BAK1	0.36	5.99	0.31	5.46e-9	Platelet count;
LUSC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg24250549	chr1:154909240	PMVK	0.64	10.36	0.49	5.26e-22	Prostate cancer;
LUSC	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.13	-20.08	-0.74	2.19e-59	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg16584290	chr5:462447	EXOC3	0.44	7.95	0.4	2.99e-14	Cystic fibrosis severity;
LUSC	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.14e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg08079166	chr15:68083412	MAP2K5	0.4	8.21	0.41	5.02e-15	Restless legs syndrome;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26720427	chr11:85780129	PICALM	-0.39	-6.0	-0.31	5.12e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.69	-8.93	-0.44	2.94e-17	Huntington's disease progression;
LUSC	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg24459738	chr19:57751996	ZNF805	-0.52	-7.85	-0.39	5.72e-14	Hyperactive-impulsive symptoms;
LUSC	cis	rs6740322	0.895	rs9309098	chr2:43554972	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.56	7.62	0.38	2.71e-13	Coronary artery disease;
LUSC	cis	rs727505	0.909	rs1031958	chr7:124627309	C/T	cg23710748	chr7:124431027	NA	-0.36	-6.25	-0.32	1.28e-9	Lewy body disease;
LUSC	cis	rs11637445	0.677	rs11631864	chr15:68067762	T/C	cg08079166	chr15:68083412	MAP2K5	-0.37	-7.65	-0.39	2.17e-13	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg06758649	chr12:107381105	MTERFD3	-0.44	-5.97	-0.31	6.11e-9	Neuroticism;
LUSC	trans	rs7567288	0.636	rs4256007	chr2:134464434	G/A	cg12381416	chr3:14359266	NA	0.53	5.99	0.31	5.3e-9	Height;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg24991452	chr6:35996059	MAPK14	0.49	6.65	0.34	1.22e-10	Cognitive function;Information processing speed;
LUSC	cis	rs7615316	0.902	rs7428496	chr3:142320532	A/T	cg16271453	chr3:142027066	XRN1	-0.36	-6.11	-0.32	2.81e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	6.65	0.34	1.19e-10	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10127479	chr1:147624510	NA	0.45	6.17	0.32	1.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.74	-12.51	-0.56	9.93e-30	White blood cell count (basophil);
LUSC	cis	rs9303542	0.571	rs2202895	chr17:46584657	T/C	cg09704116	chr17:46666958	LOC404266	0.31	5.95	0.31	6.69e-9	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.89	-10.61	-0.5	7.27e-23	Lung cancer in ever smokers;
LUSC	cis	rs17125944	0.686	rs8003683	chr14:53366605	G/T	cg00686598	chr14:53173677	PSMC6	0.65	6.19	0.32	1.77e-9	Alzheimer's disease (late onset);
LUSC	cis	rs243505	0.898	rs243540	chr7:148403312	A/G	cg09806900	chr7:148480153	CUL1	-0.44	-6.37	-0.33	6.13e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2692947	0.702	rs2312955	chr2:96777168	T/G	cg23100626	chr2:96804247	ASTL	-0.31	-7.28	-0.37	2.44e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg26647111	chr11:31128758	NA	-0.41	-6.0	-0.31	5.27e-9	Red blood cell count;
LUSC	cis	rs9937943	0.615	rs12925346	chr16:74492495	G/C	cg01733217	chr16:74700730	RFWD3	0.57	6.45	0.33	3.92e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25072359	chr17:41440525	NA	0.65	9.38	0.46	1.06e-18	Menopause (age at onset);
LUSC	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-7.07	-0.36	8.94e-12	Obesity-related traits;
LUSC	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg20302533	chr7:39170763	POU6F2	0.51	8.01	0.4	1.98e-14	IgG glycosylation;
LUSC	trans	rs2055729	0.645	rs12543996	chr8:9742666	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.97	-0.31	6.2e-9	Multiple myeloma (hyperdiploidy);
LUSC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-1.12	-24.77	-0.8	1.22e-77	Height;
LUSC	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg19875535	chr5:140030758	IK	0.49	7.89	0.4	4.41e-14	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg16414030	chr3:133502952	NA	-0.52	-8.11	-0.41	9.72e-15	Iron status biomarkers;
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg06877462	chr1:205807181	PM20D1	0.49	8.82	0.43	6.26e-17	Menarche (age at onset);
LUSC	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg18806716	chr10:30721971	MAP3K8	-0.58	-8.91	-0.44	3.45e-17	Inflammatory bowel disease;
LUSC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.58	10.61	0.5	7.61e-23	Bone mineral density;
LUSC	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg19920283	chr7:105172520	RINT1	0.59	5.85	0.3	1.16e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9359856	0.529	rs72919916	chr6:90489773	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.84	-8.36	-0.42	1.74e-15	Bipolar disorder;
LUSC	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg19628046	chr18:33552617	C18orf21	0.53	6.74	0.35	6.93e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs4654899	0.833	rs12135548	chr1:21084367	G/A	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.36	9.91e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg07148914	chr20:33460835	GGT7	-0.46	-6.81	-0.35	4.43e-11	Height;
LUSC	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg06623918	chr6:96969491	KIAA0776	-0.83	-10.02	-0.48	7.57e-21	Migraine;Coronary artery disease;
LUSC	cis	rs7582720	1.000	rs76461893	chr2:203865515	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	8.37	0.42	1.63e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.6	0.6	8.13e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6756513	0.520	rs6546560	chr2:70173690	A/G	cg02498382	chr2:70120550	SNRNP27	-0.26	-6.45	-0.33	3.89e-10	Breast cancer;Platelet count;
LUSC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg18479299	chr3:125709523	NA	-0.5	-5.79	-0.3	1.66e-8	Blood pressure (smoking interaction);
LUSC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-8.84	-0.44	5.48e-17	Chronic sinus infection;
LUSC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08280861	chr8:58055591	NA	0.54	5.89	0.31	9.6e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.6	0.5	8.19e-23	Bone mineral density;
LUSC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	1.22	16.41	0.67	8.56e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg27205649	chr11:78285834	NARS2	0.53	6.46	0.33	3.72e-10	Alzheimer's disease (survival time);
LUSC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06634786	chr22:41940651	POLR3H	-0.49	-6.15	-0.32	2.16e-9	Vitiligo;
LUSC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-1.17	-16.86	-0.68	1.46e-46	Breast cancer;
LUSC	trans	rs58873874	0.737	rs76634949	chr5:156890399	C/T	cg18122419	chr1:50882446	NA	-0.68	-5.98	-0.31	5.68e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg14440974	chr22:39074834	NA	-0.37	-6.12	-0.32	2.66e-9	Menopause (age at onset);
LUSC	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.65	-5.7	-0.3	2.7e-8	Narcolepsy;
LUSC	cis	rs11958404	0.932	rs72816579	chr5:157431877	T/C	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs965469	1.000	rs6037562	chr20:3326141	A/C	cg25506879	chr20:3388711	C20orf194	-0.51	-5.65	-0.3	3.48e-8	IFN-related cytopenia;
LUSC	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg07636037	chr3:49044803	WDR6	0.76	9.85	0.47	2.94e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg27489772	chr12:121021490	NA	0.58	7.66	0.39	1.99e-13	Type 1 diabetes nephropathy;
LUSC	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	cis	rs10493773	0.649	rs17398321	chr1:86084493	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.38	-7.73	-0.39	1.31e-13	Urate levels in overweight individuals;
LUSC	cis	rs12618769	0.597	rs10514774	chr2:99028695	A/G	cg10123293	chr2:99228465	UNC50	0.47	7.9	0.4	4.19e-14	Bipolar disorder;
LUSC	cis	rs155346	1.000	rs265145	chr5:139397332	A/G	cg01090482	chr5:139365336	NRG2	0.33	5.78	0.3	1.74e-8	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg24130564	chr14:104152367	KLC1	-0.46	-6.36	-0.33	6.47e-10	Body mass index;
LUSC	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg20283391	chr11:68216788	NA	-0.61	-8.57	-0.42	3.81e-16	Total body bone mineral density;
LUSC	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg06671706	chr8:8559999	CLDN23	0.49	6.52	0.34	2.66e-10	Obesity-related traits;
LUSC	cis	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.61	9.0	0.44	1.72e-17	Eye color traits;
LUSC	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.45	6.27	0.32	1.1e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4654899	0.772	rs61778530	chr1:21087363	G/C	cg01072550	chr1:21505969	NA	-0.48	-7.11	-0.36	6.95e-12	Superior frontal gyrus grey matter volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24430517	chr2:242673979	D2HGDH	0.44	6.29	0.33	1.01e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg05347473	chr6:146136440	FBXO30	0.47	7.77	0.39	9.97e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg14552801	chr7:65878734	NA	0.38	5.9	0.31	8.97e-9	Aortic root size;
LUSC	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg08085267	chr17:45401833	C17orf57	-0.55	-8.99	-0.44	1.86e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg16680214	chr1:154839983	KCNN3	-0.35	-6.26	-0.32	1.18e-9	Schizophrenia;
LUSC	cis	rs4629180	0.630	rs10188189	chr2:102127926	A/G	cg01388757	chr2:102091195	RFX8	-0.36	-6.23	-0.32	1.4e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.77	-12.22	-0.56	1.19e-28	Height;
LUSC	cis	rs16917546	1.000	rs10995251	chr10:64398466	C/T	cg03961010	chr10:64397487	ZNF365	-0.42	-6.58	-0.34	1.81e-10	Basal cell carcinoma;
LUSC	cis	rs17401966	0.540	rs1536262	chr1:10438687	C/T	cg17425144	chr1:10567563	PEX14	-0.35	-6.26	-0.32	1.18e-9	Hepatocellular carcinoma;
LUSC	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.77e-22	Eye color traits;
LUSC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg00684032	chr4:1343700	KIAA1530	0.34	5.8	0.3	1.58e-8	Obesity-related traits;
LUSC	cis	rs16854884	0.770	rs6784938	chr3:143817528	C/T	cg06585982	chr3:143692056	C3orf58	0.4	5.94	0.31	7.13e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-5.92	-0.31	7.95e-9	Recombination measurement;
LUSC	cis	rs4974559	1.000	rs10006789	chr4:1330333	T/C	cg02980000	chr4:1222292	CTBP1	0.68	7.94	0.4	3.14e-14	Systolic blood pressure;
LUSC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg20243544	chr17:37824526	PNMT	0.52	7.43	0.38	9.33e-13	Asthma;
LUSC	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs7945718	0.810	rs7930282	chr11:12835941	C/T	cg25843174	chr11:12811716	TEAD1	0.3	6.87	0.35	3.23e-11	Educational attainment (years of education);
LUSC	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg10523860	chr14:103875565	MARK3	-0.37	-5.94	-0.31	7.11e-9	Body mass index;
LUSC	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14240646	chr10:27532245	ACBD5	-0.65	-7.75	-0.39	1.15e-13	Breast cancer;
LUSC	cis	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg01251360	chr16:68772225	CDH1	-0.27	-6.3	-0.33	9.13e-10	Colorectal cancer;
LUSC	trans	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg10426581	chr7:100472382	SRRT	0.86	12.47	0.56	1.43e-29	Resting heart rate;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02737830	chr12:64616354	C12orf66	0.42	6.51	0.34	2.82e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.8	0.3	1.5e-8	Menopause (age at onset);
LUSC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg26958806	chr6:27640298	NA	0.63	5.65	0.3	3.39e-8	Depression;
LUSC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18876405	chr7:65276391	NA	0.5	6.88	0.35	2.9e-11	Corneal structure;
LUSC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs7605827	0.930	rs13033762	chr2:15592295	T/C	cg19274914	chr2:15703543	NA	0.46	8.66	0.43	1.98e-16	Educational attainment (years of education);
LUSC	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg05887092	chr17:76393375	PGS1	0.51	9.42	0.46	7.73e-19	HDL cholesterol levels;
LUSC	cis	rs8017423	0.608	rs12588149	chr14:90822676	G/A	cg04374321	chr14:90722782	PSMC1	-0.42	-6.34	-0.33	7.59e-10	Mortality in heart failure;
LUSC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg19077165	chr18:44547161	KATNAL2	-0.37	-5.65	-0.3	3.43e-8	Personality dimensions;
LUSC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg25344623	chr2:136566232	LCT	-0.38	-5.7	-0.3	2.7e-8	Mosquito bite size;
LUSC	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg10018233	chr7:150070692	REPIN1	0.35	6.24	0.32	1.32e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg24296786	chr1:45957014	TESK2	0.48	7.36	0.37	1.45e-12	High light scatter reticulocyte count;
LUSC	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg26384229	chr12:38710491	ALG10B	0.72	11.29	0.53	3.03e-25	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg25767906	chr1:53392781	SCP2	-0.49	-8.81	-0.43	7.08e-17	Monocyte count;
LUSC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg02569458	chr12:86230093	RASSF9	0.52	8.64	0.43	2.29e-16	Major depressive disorder;
LUSC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.46	0.38	7.73e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.6	-0.5	8.24e-23	Glomerular filtration rate;
LUSC	cis	rs3740713	0.669	rs61736803	chr11:18422487	C/A	cg07915343	chr11:18477680	LDHAL6A	-0.47	-5.87	-0.31	1.03e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg06521331	chr12:34319734	NA	0.37	6.34	0.33	7.6e-10	Morning vs. evening chronotype;
LUSC	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg00857998	chr1:205179979	DSTYK	-0.53	-8.02	-0.4	1.79e-14	Platelet count;
LUSC	cis	rs240764	0.817	rs239232	chr6:101103038	G/A	cg09795085	chr6:101329169	ASCC3	0.4	5.85	0.31	1.14e-8	Neuroticism;
LUSC	cis	rs7605827	0.897	rs11901455	chr2:15623888	C/T	cg19274914	chr2:15703543	NA	0.45	8.57	0.42	3.81e-16	Educational attainment (years of education);
LUSC	cis	rs2901656	0.502	rs9425308	chr1:172383265	A/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.3	5.78	0.3	1.68e-8	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg02176678	chr2:219576539	TTLL4	-0.58	-10.3	-0.49	8.75e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg26039829	chr8:22132926	PIWIL2	0.42	7.76	0.39	1.07e-13	Hypertriglyceridemia;
LUSC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.46	7.82	0.39	7.03e-14	Primary biliary cholangitis;
LUSC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg14416269	chr4:6271139	WFS1	0.54	11.39	0.53	1.32e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg22705602	chr4:152727874	NA	0.34	7.14	0.36	5.92e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.63	9.49	0.46	4.62e-19	Corneal astigmatism;
LUSC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.7	0.39	1.52e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg13072238	chr3:49761600	GMPPB	-0.71	-8.92	-0.44	3.03e-17	Menarche (age at onset);
LUSC	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg15839431	chr19:19639596	YJEFN3	-0.61	-6.79	-0.35	5.08e-11	Bipolar disorder;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg22696982	chr2:177502905	NA	0.39	6.53	0.34	2.51e-10	Schizophrenia;
LUSC	cis	rs2425143	1.000	rs6060557	chr20:34270266	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.37	-0.33	6.32e-10	Blood protein levels;
LUSC	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.79	-13.21	-0.59	2.49e-32	Platelet distribution width;
LUSC	trans	rs9910292	0.591	rs12602361	chr17:31362864	T/C	cg03789507	chr8:136667083	NA	0.5	6.27	0.32	1.13e-9	Mosquito bite size;
LUSC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.81	14.74	0.63	3.04e-38	Blood protein levels;
LUSC	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg04369109	chr6:150039330	LATS1	-0.59	-8.61	-0.43	2.98e-16	Lung cancer;
LUSC	cis	rs6740322	0.843	rs6727237	chr2:43562000	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.41	-5.75	-0.3	1.99e-8	Coronary artery disease;
LUSC	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg13535736	chr9:111863775	C9orf5	-0.39	-6.13	-0.32	2.46e-9	Menarche (age at onset);
LUSC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg24829409	chr8:58192753	C8orf71	-0.58	-6.24	-0.32	1.33e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-9.76	-0.47	5.6e-20	Mood instability;
LUSC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg15790184	chr11:494944	RNH1	0.49	7.53	0.38	4.71e-13	Systemic lupus erythematosus;
LUSC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg27129171	chr3:47204927	SETD2	0.74	12.88	0.58	4.37e-31	Colorectal cancer;
LUSC	cis	rs2607426	1.000	rs2607419	chr19:41279395	A/G	cg05508168	chr19:41255947	C19orf54;SNRPA	0.72	6.3	0.33	9.42e-10	Blood protein levels;
LUSC	cis	rs11645898	0.872	rs55955726	chr16:72213691	G/C	cg14768367	chr16:72042858	DHODH	-0.58	-6.37	-0.33	6.41e-10	Blood protein levels;
LUSC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00149659	chr3:10157352	C3orf10	0.96	13.92	0.61	4.8e-35	Alzheimer's disease;
LUSC	cis	rs12155623	0.504	rs10808736	chr8:49873039	C/A	cg22283653	chr8:49824208	NA	0.39	7.97	0.4	2.57e-14	Sudden cardiac arrest;
LUSC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg20135002	chr11:47629003	NA	-0.51	-7.97	-0.4	2.54e-14	Subjective well-being;
LUSC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg06784218	chr1:46089804	CCDC17	0.48	9.5	0.46	4.33e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7168353	0.948	rs10520720	chr15:93634724	A/G	cg04697454	chr15:93633408	RGMA	-0.36	-5.99	-0.31	5.43e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg18357645	chr12:58087776	OS9	-0.52	-7.65	-0.39	2.22e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.1	0.52	1.41e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg00321850	chr1:175162397	KIAA0040	0.44	7.15	0.36	5.55e-12	Alcohol dependence;
LUSC	cis	rs7582720	1.000	rs72936869	chr2:203788950	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs4077515	0.874	rs35670379	chr9:139270606	T/C	cg14019695	chr9:139328340	INPP5E	0.43	8.21	0.41	4.87e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-1.13	-17.91	-0.7	9.52e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg05313129	chr8:58192883	C8orf71	-0.51	-5.99	-0.31	5.57e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9473147	0.543	rs9296558	chr6:47451883	C/T	cg20196966	chr6:47445060	CD2AP	0.43	6.05	0.31	3.8e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg22963979	chr7:1858916	MAD1L1	-0.7	-11.43	-0.53	8.94e-26	Bipolar disorder and schizophrenia;
LUSC	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg24812749	chr6:127587940	RNF146	0.65	9.76	0.47	5.91e-20	Breast cancer;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg24105280	chr12:6797846	ZNF384	0.53	6.3	0.33	9.17e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg01448562	chr3:133502909	NA	-0.53	-7.97	-0.4	2.62e-14	Iron status biomarkers;
LUSC	cis	rs6681460	0.549	rs7537440	chr1:67031907	A/C	cg02459107	chr1:67143332	SGIP1	0.31	5.69	0.3	2.74e-8	Presence of antiphospholipid antibodies;
LUSC	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg22431228	chr1:16359049	CLCNKA	-0.39	-8.25	-0.41	3.79e-15	Systolic blood pressure;
LUSC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.15	-0.32	2.18e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9921338	0.961	rs4781069	chr16:11428762	G/A	cg00044050	chr16:11439710	C16orf75	-0.5	-6.66	-0.34	1.14e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.79	0.43	7.9e-17	Prudent dietary pattern;
LUSC	cis	rs4654899	0.772	rs12145203	chr1:21086127	C/T	cg01072550	chr1:21505969	NA	-0.44	-6.53	-0.34	2.41e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs41271951	0.512	rs76649628	chr1:151041851	A/G	cg11822372	chr1:151115635	SEMA6C	-0.76	-6.95	-0.36	1.98e-11	Blood protein levels;
LUSC	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.63	-9.83	-0.47	3.34e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.69	0.3	2.74e-8	Life satisfaction;
LUSC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg24675658	chr1:53192096	ZYG11B	0.62	9.91	0.48	1.78e-20	Monocyte count;
LUSC	cis	rs500891	1.000	rs35442758	chr6:84183607	G/A	cg08257003	chr6:84140564	ME1	0.34	7.02	0.36	1.26e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	15.74	0.65	3.76e-42	Platelet count;
LUSC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs6484504	0.576	rs286649	chr11:31230468	C/T	cg26647111	chr11:31128758	NA	-0.42	-5.98	-0.31	5.6e-9	Red blood cell count;
LUSC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	0.67	10.41	0.5	3.54e-22	Height;
LUSC	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg06637938	chr14:75390232	RPS6KL1	0.84	15.57	0.65	1.71e-41	Caffeine consumption;
LUSC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg02428538	chr16:24856791	SLC5A11	-0.52	-5.98	-0.31	5.74e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg12292205	chr6:26970375	C6orf41	-0.41	-6.23	-0.32	1.41e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg13010199	chr12:38710504	ALG10B	0.53	8.26	0.41	3.43e-15	Morning vs. evening chronotype;
LUSC	cis	rs6542838	0.641	rs6542841	chr2:99489039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.36	-0.33	6.68e-10	Fear of minor pain;
LUSC	cis	rs11756438	0.572	rs2798328	chr6:119005378	C/T	cg18833306	chr6:118973337	C6orf204	0.36	5.69	0.3	2.8e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg17376030	chr22:41985996	PMM1	-0.46	-5.72	-0.3	2.42e-8	Vitiligo;
LUSC	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg22709100	chr7:91322751	NA	-0.4	-5.94	-0.31	6.99e-9	Breast cancer;
LUSC	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-10.3	-0.49	8.49e-22	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.74	-0.43	1.17e-16	Monocyte percentage of white cells;
LUSC	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	5.78	0.3	1.72e-8	Schizophrenia;
LUSC	cis	rs11039100	0.850	rs11039115	chr11:5831379	T/C	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	trans	rs2700987	0.545	rs2717953	chr7:37390545	A/T	cg26076750	chr5:98105150	RGMB	-0.33	-6.04	-0.31	4.21e-9	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg21573476	chr21:45109991	RRP1B	-0.41	-6.77	-0.35	5.76e-11	Mean corpuscular volume;
LUSC	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.81e-12	Blood metabolite levels;
LUSC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg01097406	chr16:89675127	NA	0.32	6.37	0.33	6.28e-10	Vitiligo;
LUSC	trans	rs17641971	1.000	rs73579360	chr8:49920586	C/T	cg15678142	chr1:167411538	CD247	0.42	5.97	0.31	6.09e-9	Blood metabolite levels;
LUSC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg12863693	chr15:85201151	NMB	0.35	6.93	0.35	2.15e-11	Bipolar disorder lithium response (categorical) or schizophrenia;
LUSC	trans	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg26043149	chr18:55253948	FECH	0.46	7.09	0.36	8.28e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg09626299	chr10:82213104	TSPAN14	-0.2	-5.87	-0.31	1.06e-8	Post bronchodilator FEV1;
LUSC	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg15423357	chr2:25149977	NA	0.45	9.15	0.45	5.98e-18	Body mass index;
LUSC	cis	rs7493	0.950	rs11981299	chr7:95029701	T/A	cg17330251	chr7:94953956	PON1	-0.36	-5.74	-0.3	2.11e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6489882	0.807	rs1859334	chr12:113367332	C/T	cg20102336	chr12:113376681	OAS3	-0.42	-5.96	-0.31	6.39e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg24006582	chr15:45444508	DUOX1	0.65	9.23	0.45	3.13e-18	Uric acid levels;
LUSC	trans	rs769111	0.812	rs2908734	chr7:12070537	A/G	cg02081925	chr5:176931394	DOK3	0.38	6.17	0.32	1.96e-9	Tourette syndrome;
LUSC	cis	rs12542260	0.871	rs7834203	chr8:125482896	A/G	cg27038428	chr8:125485867	RNF139	0.33	6.71	0.34	8.12e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23158103	chr7:148848205	ZNF398	0.49	8.41	0.42	1.25e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25072359	chr17:41440525	NA	0.66	9.44	0.46	6.54e-19	Menopause (age at onset);
LUSC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg12365402	chr11:9010492	NRIP3	-0.47	-8.91	-0.44	3.27e-17	Hemoglobin concentration;
LUSC	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg18678763	chr11:4115507	RRM1	-0.54	-7.64	-0.39	2.31e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg21770322	chr7:97807741	LMTK2	0.56	10.08	0.48	4.97e-21	Breast cancer;
LUSC	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg25930673	chr12:123319894	HIP1R	-0.64	-6.39	-0.33	5.68e-10	Schizophrenia;
LUSC	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg25110126	chr1:46999211	NA	0.77	10.96	0.51	4.35e-24	Monobrow;
LUSC	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.74	-0.3	2.12e-8	Ileal carcinoids;
LUSC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21028142	chr17:79581711	NPLOC4	0.34	8.2	0.41	5.32e-15	Eye color traits;
LUSC	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.5e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.55	-0.38	4.09e-13	Morning vs. evening chronotype;
LUSC	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	0.7	11.14	0.52	9.84e-25	Blood metabolite ratios;
LUSC	trans	rs2357013	0.574	rs66762357	chr2:53155017	C/G	cg24904739	chr17:77959804	TBC1D16	-0.37	-6.0	-0.31	5e-9	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.09	-0.4	1.15e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs754133	0.963	rs12319419	chr12:54420776	G/C	cg10005224	chr12:54424964	HOXC4;HOXC5	0.43	8.48	0.42	7.6e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
LUSC	cis	rs698813	0.604	rs1596010	chr2:44491804	A/C	cg00619915	chr2:44497795	NA	-0.53	-7.48	-0.38	6.41e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.92	0.35	2.29e-11	Height;
LUSC	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg09904177	chr6:26538194	HMGN4	0.75	14.27	0.62	2.07e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs7220401	0.515	rs8080772	chr17:28413129	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-7.46	-0.38	7.69e-13	Coronary artery disease;
LUSC	cis	rs2070433	0.559	rs11089057	chr21:47721228	T/A	cg12379764	chr21:47803548	PCNT	0.73	8.46	0.42	8.55e-16	Lymphocyte counts;
LUSC	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg27147174	chr7:100797783	AP1S1	-0.65	-10.53	-0.5	1.45e-22	Life satisfaction;
LUSC	cis	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg05084668	chr3:125655381	ALG1L	-0.45	-6.02	-0.31	4.67e-9	Blood pressure (smoking interaction);
LUSC	cis	rs72792276	1.000	rs72794370	chr5:127444907	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	7.84	0.39	5.98e-14	Red cell distribution width;
LUSC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg12560992	chr17:57184187	TRIM37	0.53	7.81	0.39	7.29e-14	Cognitive test performance;
LUSC	cis	rs2625529	0.530	rs2959930	chr15:72598614	A/G	cg16672083	chr15:72433130	SENP8	-0.43	-6.63	-0.34	1.35e-10	Red blood cell count;
LUSC	trans	rs1994135	0.594	rs10772096	chr12:33732869	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.01	0.36	1.32e-11	Resting heart rate;
LUSC	cis	rs3770081	1.000	rs2241437	chr2:86360573	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.01	-6.72	-0.34	8.1e-11	Facial emotion recognition (sad faces);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04531794	chr10:99609860	GOLGA7B	-0.5	-6.51	-0.34	2.75e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs617219	0.853	rs55868416	chr5:78463527	C/T	cg24856658	chr5:78533917	JMY	-0.29	-5.67	-0.3	3.1e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs6977660	0.941	rs5017192	chr7:19820114	C/T	cg07541023	chr7:19748670	TWISTNB	0.5	5.69	0.3	2.79e-8	Thyroid stimulating hormone;
LUSC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.17	0.55	1.93e-28	Motion sickness;
LUSC	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg23711669	chr6:146136114	FBXO30	0.86	15.52	0.65	2.69e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg19318889	chr4:1322082	MAEA	0.49	8.06	0.4	1.4e-14	Obesity-related traits;
LUSC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.95	-14.92	-0.63	6.45e-39	Platelet count;
LUSC	trans	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg03886242	chr7:26192032	NFE2L3	0.38	6.29	0.33	9.81e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs34375054	0.641	rs34624329	chr12:125608028	T/G	cg00522288	chr12:125625016	AACS	-0.29	-5.68	-0.3	2.89e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg04374321	chr14:90722782	PSMC1	0.67	10.43	0.5	3.13e-22	Mortality in heart failure;
LUSC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg20406979	chr6:167373233	NA	0.25	5.96	0.31	6.39e-9	Crohn's disease;
LUSC	cis	rs9309473	0.660	rs10496192	chr2:73679866	T/C	cg20560298	chr2:73613845	ALMS1	-0.55	-6.56	-0.34	2.07e-10	Metabolite levels;
LUSC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg10360139	chr7:1886902	MAD1L1	-0.46	-7.08	-0.36	8.61e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg09904177	chr6:26538194	HMGN4	-0.76	-5.64	-0.3	3.57e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.47	7.89	0.4	4.49e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg23795048	chr12:9217529	LOC144571	0.33	5.7	0.3	2.67e-8	Sjögren's syndrome;
LUSC	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.41	-0.46	8.23e-19	Neuroticism;
LUSC	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg21573476	chr21:45109991	RRP1B	0.37	5.81	0.3	1.45e-8	Mean corpuscular volume;
LUSC	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg21100191	chr22:23484243	RTDR1	0.89	14.98	0.63	3.54e-39	Bone mineral density;
LUSC	cis	rs922692	0.715	rs2277546	chr15:79083376	C/A	cg00540400	chr15:79124168	NA	-0.41	-7.11	-0.36	7.2e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg00769240	chr8:12517080	NA	-0.48	-6.31	-0.33	8.66e-10	Blood pressure (smoking interaction);
LUSC	trans	rs890100	0.801	rs10189319	chr2:56706672	C/G	cg01657744	chr10:88471748	LDB3	0.44	6.09	0.32	3.05e-9	Gut microbiome composition (summer);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04631804	chr4:110624697	CASP6	-0.43	-6.18	-0.32	1.86e-9	Hepatitis;
LUSC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg20406979	chr6:167373233	NA	-0.26	-6.0	-0.31	5.04e-9	Lung cancer;
LUSC	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.61	-10.64	-0.5	5.77e-23	Lymphocyte percentage of white cells;
LUSC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg06784218	chr1:46089804	CCDC17	-0.29	-5.65	-0.3	3.48e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs6062509	0.732	rs6062304	chr20:62351539	A/T	cg21849932	chr20:62369462	LIME1	-0.4	-5.93	-0.31	7.59e-9	Prostate cancer;
LUSC	cis	rs2625529	0.730	rs12912771	chr15:72162928	A/T	cg16672083	chr15:72433130	SENP8	-0.47	-8.11	-0.41	9.79e-15	Red blood cell count;
LUSC	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg06028605	chr16:24865363	SLC5A11	0.46	8.1	0.41	1.03e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	1.11	15.86	0.66	1.27e-42	Uric acid levels;
LUSC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg26513180	chr16:89883248	FANCA	0.66	10.63	0.5	6.17e-23	Vitiligo;
LUSC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg26769984	chr7:1090371	C7orf50	0.59	8.26	0.41	3.43e-15	Bronchopulmonary dysplasia;
LUSC	cis	rs877282	0.853	rs7083589	chr10:754494	G/A	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg07701084	chr6:150067640	NUP43	0.53	7.94	0.4	3.18e-14	Lung cancer;
LUSC	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg02023728	chr11:77925099	USP35	0.48	6.4	0.33	5.13e-10	Testicular germ cell tumor;
LUSC	cis	rs4680	0.712	rs740601	chr22:19950763	T/G	cg23601416	chr22:19950040	COMT	-0.44	-9.17	-0.45	5.16e-18	Blood metabolite levels;
LUSC	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg04374321	chr14:90722782	PSMC1	-0.69	-10.44	-0.5	2.94e-22	Mortality in heart failure;
LUSC	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg06627628	chr2:24431161	ITSN2	-0.63	-9.58	-0.46	2.23e-19	Asthma;
LUSC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg21972741	chr5:435613	AHRR	0.36	6.8	0.35	4.8e-11	Cystic fibrosis severity;
LUSC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg12560992	chr17:57184187	TRIM37	0.84	15.43	0.65	6.21e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg15848620	chr12:58087721	OS9	-0.55	-7.87	-0.4	4.88e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg07148914	chr20:33460835	GGT7	-0.45	-6.67	-0.34	1.07e-10	Height;
LUSC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.54e-10	Menopause (age at onset);
LUSC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.99	0.55	8.64e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	8.25	0.41	3.71e-15	Height;
LUSC	cis	rs8099014	0.911	rs4331413	chr18:56133165	T/C	cg12907477	chr18:56117327	MIR122	0.4	6.02	0.31	4.69e-9	Platelet count;
LUSC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg05347473	chr6:146136440	FBXO30	0.47	7.92	0.4	3.57e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7809950	1.000	rs1544336	chr7:107082415	G/C	cg23024343	chr7:107201750	COG5	-0.54	-8.71	-0.43	1.38e-16	Coronary artery disease;
LUSC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.66	-11.35	-0.53	1.83e-25	Lung cancer;
LUSC	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg24375607	chr4:120327624	NA	-0.73	-11.2	-0.52	6.12e-25	Corneal astigmatism;
LUSC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.82	-14.86	-0.63	1.03e-38	Cognitive function;
LUSC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg15352829	chr14:105391018	PLD4	-0.39	-8.28	-0.41	3.09e-15	Rheumatoid arthritis;
LUSC	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg16797656	chr11:68205561	LRP5	0.45	7.8	0.39	8.18e-14	Total body bone mineral density;
LUSC	cis	rs7503807	1.000	rs901064	chr17:78596040	C/T	cg09596252	chr17:78655493	RPTOR	-0.43	-7.45	-0.38	7.82e-13	Obesity;
LUSC	cis	rs7043114	0.525	rs9299404	chr9:95170338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.38	6.63	0.34	1.32e-10	Height;
LUSC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-8.09	-0.4	1.09e-14	Body mass index;
LUSC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg27121462	chr16:89883253	FANCA	0.57	9.25	0.45	2.66e-18	Vitiligo;
LUSC	cis	rs981844	0.775	rs56101345	chr4:154764261	C/T	cg14289246	chr4:154710475	SFRP2	0.5	6.77	0.35	5.94e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.36	1.12e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg16049864	chr8:95962084	TP53INP1	-0.48	-8.02	-0.4	1.82e-14	Type 2 diabetes;
LUSC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg26373071	chr5:1325741	CLPTM1L	0.41	7.69	0.39	1.72e-13	Lung cancer;
LUSC	cis	rs7707921	0.958	rs4703870	chr5:81492643	G/A	cg15871215	chr5:81402204	ATG10	0.44	6.34	0.33	7.5e-10	Breast cancer;
LUSC	cis	rs6967385	0.560	rs12539290	chr7:12344101	T/G	cg20607287	chr7:12443886	VWDE	0.44	6.59	0.34	1.71e-10	Response to taxane treatment (placlitaxel);
LUSC	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg05527609	chr1:210001259	C1orf107	0.68	9.67	0.47	1.12e-19	Orofacial clefts;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08749455	chr11:72492538	STARD10	0.44	6.24	0.32	1.35e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg19812747	chr11:111475976	SIK2	-0.55	-8.18	-0.41	5.92e-15	Primary sclerosing cholangitis;
LUSC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg27121462	chr16:89883253	FANCA	-0.55	-8.9	-0.44	3.55e-17	Vitiligo;
LUSC	cis	rs4343996	0.659	rs9986894	chr7:3335346	A/C	cg21248987	chr7:3385318	SDK1	0.35	6.09	0.32	3.08e-9	Motion sickness;
LUSC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg09436375	chr6:42928200	GNMT	-0.29	-6.82	-0.35	4.33e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs28647808	0.748	rs28502181	chr9:136257792	T/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg27114661	chr2:242255285	SEPT2;HDLBP	0.42	6.11	0.32	2.82e-9	N-glycan levels;
LUSC	trans	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-6.8	-0.35	4.93e-11	Monocyte count;
LUSC	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.62	10.39	0.49	4.27e-22	Blood metabolite ratios;
LUSC	cis	rs12530845	0.887	rs73725434	chr7:135313657	T/C	cg23117316	chr7:135346802	PL-5283	-0.58	-9.31	-0.45	1.82e-18	Red blood cell traits;
LUSC	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.6	9.74	0.47	6.75e-20	Body mass index;
LUSC	cis	rs3820068	0.608	rs12091326	chr1:16048005	A/G	cg17385448	chr1:15911702	AGMAT	0.36	5.87	0.31	1.05e-8	Systolic blood pressure;
LUSC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg16386425	chr10:429943	DIP2C	-0.44	-7.11	-0.36	7.08e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.73e-23	Bladder cancer;
LUSC	cis	rs17401966	0.522	rs2027330	chr1:10275592	C/T	cg17425144	chr1:10567563	PEX14	-0.33	-5.78	-0.3	1.69e-8	Hepatocellular carcinoma;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04619838	chr16:67515103	ATP6V0D1	0.77	6.15	0.32	2.17e-9	Cognitive performance;
LUSC	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08219700	chr8:58056026	NA	0.62	6.81	0.35	4.55e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg13206674	chr6:150067644	NUP43	0.63	10.35	0.49	5.98e-22	Lung cancer;
LUSC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg10253484	chr15:75165896	SCAMP2	-0.47	-6.61	-0.34	1.52e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	11.03	0.52	2.5e-24	Hemoglobin concentration;
LUSC	cis	rs9921338	0.961	rs7191093	chr16:11442279	A/G	cg00044050	chr16:11439710	C16orf75	-0.51	-6.81	-0.35	4.58e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-15.8	-0.65	2.22e-42	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg13575925	chr12:9217583	LOC144571	0.35	6.36	0.33	6.77e-10	Sjögren's syndrome;
LUSC	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.82	0.51	1.41e-23	Morning vs. evening chronotype;
LUSC	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg09307838	chr4:120376055	NA	0.69	10.4	0.49	3.96e-22	Corneal astigmatism;
LUSC	cis	rs1979679	0.608	rs4931084	chr12:28722311	C/G	cg13890972	chr12:28721907	NA	-0.43	-6.11	-0.32	2.79e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg20203395	chr5:56204925	C5orf35	-0.46	-6.72	-0.35	7.67e-11	Coronary artery disease;
LUSC	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.16	0.32	2.05e-9	Corneal astigmatism;
LUSC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.22	0.37	3.45e-12	Motion sickness;
LUSC	cis	rs1062746	0.544	rs17770933	chr16:87325729	C/T	cg02258303	chr16:87377426	FBXO31	-0.51	-7.54	-0.38	4.35e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.71	0.3	2.51e-8	Platelet count;
LUSC	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg04455712	chr21:45112962	RRP1B	0.48	8.88	0.44	4.18e-17	Mean corpuscular volume;
LUSC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg09365446	chr1:150670422	GOLPH3L	-0.52	-7.57	-0.38	3.76e-13	Blood protein levels;
LUSC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg20243544	chr17:37824526	PNMT	0.38	5.67	0.3	3.11e-8	Self-reported allergy;
LUSC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.87	-14.25	-0.61	2.61e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg18721089	chr20:30220636	NA	-0.36	-6.2	-0.32	1.71e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg21017887	chr14:105400489	NA	0.69	13.26	0.59	1.5e-32	Rheumatoid arthritis;
LUSC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	1.03	17.76	0.7	3.6e-50	Height;
LUSC	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.9	12.12	0.55	2.84e-28	Mean corpuscular hemoglobin;
LUSC	trans	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg06606381	chr12:133084897	FBRSL1	-0.52	-6.26	-0.32	1.18e-9	Depression;
LUSC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	12.06	0.55	4.64e-28	Prudent dietary pattern;
LUSC	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg05283184	chr6:79620031	NA	-0.54	-11.17	-0.52	7.97e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg05665937	chr4:1216051	CTBP1	-0.37	-5.73	-0.3	2.19e-8	Obesity-related traits;
LUSC	cis	rs1160297	0.609	rs1376563	chr2:53104749	C/G	cg07782112	chr2:53107842	NA	0.39	6.59	0.34	1.76e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	0.94	13.17	0.58	3.5e-32	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08729914	chr12:64845936	TBK1	-0.49	-6.27	-0.32	1.13e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg07157834	chr1:205819609	PM20D1	-0.41	-5.81	-0.3	1.43e-8	Parkinson's disease;
LUSC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7043114	0.525	rs7020874	chr9:95112560	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.72	-0.35	7.86e-11	Height;
LUSC	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.5	-5.74	-0.3	2.15e-8	Schizophrenia;
LUSC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.48	-7.0	-0.36	1.44e-11	Melanoma;
LUSC	cis	rs963731	0.737	rs10194374	chr2:39244914	G/A	cg04010122	chr2:39346883	SOS1	-0.82	-5.74	-0.3	2.11e-8	Corticobasal degeneration;
LUSC	cis	rs4654899	0.802	rs10493004	chr1:21442736	T/C	cg01072550	chr1:21505969	NA	-0.5	-7.51	-0.38	5.6e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg02153584	chr22:29168773	CCDC117	0.54	7.94	0.4	3.05e-14	Lymphocyte counts;
LUSC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	11.45	0.53	7.9e-26	Colorectal cancer;
LUSC	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg24558204	chr6:135376177	HBS1L	0.58	8.97	0.44	2.14e-17	Red blood cell count;
LUSC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg15605315	chr1:45957053	TESK2	0.51	8.44	0.42	9.79e-16	High light scatter reticulocyte count;
LUSC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16744862	chr16:1823033	MRPS34;NME3;EME2	-0.42	-6.24	-0.32	1.36e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs116988415	0.539	rs11623956	chr14:65270391	G/A	cg00114569	chr14:65239327	SPTB	0.69	7.64	0.39	2.28e-13	Daytime sleep phenotypes;
LUSC	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg05347473	chr6:146136440	FBXO30	-0.46	-7.64	-0.39	2.35e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg05784532	chr1:230284198	GALNT2	0.49	7.39	0.38	1.16e-12	Coronary artery disease;
LUSC	cis	rs9399401	0.626	rs1928528	chr6:142779109	T/G	cg03128060	chr6:142623767	GPR126	0.58	9.63	0.47	1.55e-19	Chronic obstructive pulmonary disease;
LUSC	trans	rs1325195	0.879	rs9729199	chr1:179092613	G/C	cg11624085	chr17:8464688	MYH10	-0.43	-7.2	-0.37	4.05e-12	IgE grass sensitization;
LUSC	cis	rs4343996	0.967	rs7811244	chr7:3342276	G/A	cg21248987	chr7:3385318	SDK1	0.39	6.56	0.34	2.08e-10	Motion sickness;
LUSC	cis	rs4363385	0.553	rs1415972	chr1:152953552	A/G	cg25856811	chr1:152973957	SPRR3	0.35	6.01	0.31	4.97e-9	Inflammatory skin disease;
LUSC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11890956	chr21:40555474	PSMG1	1.03	19.71	0.73	6.47e-58	Cognitive function;
LUSC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg08847533	chr14:75593920	NEK9	0.85	15.55	0.65	2.07e-41	Height;
LUSC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.56e-10	Menopause (age at onset);
LUSC	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg04374321	chr14:90722782	PSMC1	0.67	10.55	0.5	1.15e-22	Mortality in heart failure;
LUSC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg05802129	chr4:122689817	NA	-0.5	-8.12	-0.41	9.17e-15	Type 2 diabetes;
LUSC	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg00339695	chr16:24857497	SLC5A11	0.37	6.5	0.34	2.96e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4588572	0.643	rs10068686	chr5:77795220	C/T	cg11547950	chr5:77652471	NA	-0.57	-8.06	-0.4	1.34e-14	Triglycerides;
LUSC	cis	rs11031096	0.655	rs10835695	chr11:4178962	G/T	cg18678763	chr11:4115507	RRM1	-0.4	-5.64	-0.3	3.54e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs12200782	1.000	rs72843802	chr6:26517515	C/T	cg11837749	chr1:55047332	ACOT11	0.58	6.31	0.33	8.85e-10	Small cell lung carcinoma;
LUSC	cis	rs1775715	0.707	rs2799024	chr10:32166922	A/G	cg03015672	chr10:32216066	ARHGAP12	0.34	6.22	0.32	1.49e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs870825	1.000	rs72689245	chr4:185579788	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	11.46	0.53	7e-26	Blood protein levels;
LUSC	cis	rs6967385	0.560	rs10279958	chr7:12350593	T/C	cg06484146	chr7:12443880	VWDE	0.42	6.25	0.32	1.25e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg14664628	chr15:75095509	CSK	-0.55	-8.46	-0.42	8.72e-16	Breast cancer;
LUSC	cis	rs9473147	0.516	rs10456570	chr6:47559451	A/G	cg20196966	chr6:47445060	CD2AP	0.41	5.75	0.3	2.07e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg12257692	chr3:49977190	RBM6	0.26	7.05	0.36	1.05e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg23093090	chr10:104574429	C10orf26	-0.4	-6.39	-0.33	5.44e-10	Arsenic metabolism;
LUSC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg16680214	chr1:154839983	KCNN3	0.36	6.42	0.33	4.7e-10	Schizophrenia;
LUSC	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg13647721	chr17:30228624	UTP6	-0.62	-5.93	-0.31	7.76e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg08219700	chr8:58056026	NA	0.49	6.06	0.31	3.61e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	-1.05	-16.05	-0.66	2.22e-43	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06873352	chr17:61820015	STRADA	0.57	8.85	0.44	5.07e-17	Height;
LUSC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.9	14.18	0.61	4.9e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2997447	0.655	rs11247852	chr1:26383125	C/G	cg19633962	chr1:26362018	EXTL1	0.54	6.39	0.33	5.55e-10	QRS complex (12-leadsum);
LUSC	cis	rs4746818	0.892	rs12437	chr10:70864065	T/C	cg11621586	chr10:70884670	VPS26A	1.04	11.74	0.54	6.76e-27	Left atrial antero-posterior diameter;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11808746	chr10:95256359	CEP55	-0.43	-6.6	-0.34	1.62e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs877282	0.533	rs10904565	chr10:819991	G/T	cg13775593	chr10:823151	NA	0.28	5.76	0.3	1.91e-8	Uric acid levels;
LUSC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.83	0.39	6.5e-14	Bipolar disorder;
LUSC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg09555818	chr19:45449301	APOC2	0.46	8.84	0.44	5.73e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg01629716	chr15:45996671	NA	0.4	6.02	0.31	4.54e-9	Waist circumference;Weight;
LUSC	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg24578937	chr1:2090814	PRKCZ	0.38	8.21	0.41	4.9e-15	Coronary artery disease;
LUSC	trans	rs724744	0.875	rs1205893	chr6:22344369	A/G	cg13807341	chr11:118445984	ARCN1	-0.38	-6.28	-0.32	1.03e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.7	12.23	0.56	1.17e-28	White blood cell count;
LUSC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.04	15.66	0.65	8.17e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg07507251	chr3:52567010	NT5DC2	0.34	6.61	0.34	1.5e-10	Bipolar disorder;
LUSC	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.64	9.95	0.48	1.38e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.72	10.69	0.5	4.02e-23	Smoking initiation;
LUSC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg22907277	chr7:1156413	C7orf50	0.39	6.01	0.31	4.85e-9	Longevity;Endometriosis;
LUSC	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg02753203	chr1:228287806	NA	0.72	12.56	0.57	6.61e-30	Diastolic blood pressure;
LUSC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg11247378	chr22:39784982	NA	-0.64	-11.46	-0.53	6.98e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6700559	0.740	rs10919997	chr1:200646650	C/T	cg07804481	chr1:200639085	DDX59	0.41	5.77	0.3	1.85e-8	Coronary artery disease;
LUSC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg13114125	chr14:105738426	BRF1	-0.9	-14.9	-0.63	7.45e-39	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-1.13	-18.15	-0.7	1.04e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg05926928	chr17:57297772	GDPD1	-0.43	-6.28	-0.32	1.04e-9	Schizophrenia;
LUSC	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	9.21	0.45	3.65e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	0.99	23.37	0.79	2.92e-72	Menarche (age at onset);
LUSC	cis	rs11718455	0.548	rs11918413	chr3:43902518	C/A	cg08738300	chr3:44038990	NA	-0.59	-8.64	-0.43	2.44e-16	Coronary artery disease;
LUSC	cis	rs6554196	0.525	rs12504135	chr4:55505933	A/T	cg18836493	chr4:55524333	KIT	-0.43	-7.58	-0.38	3.37e-13	Monocyte count;
LUSC	cis	rs9341808	0.667	rs3805913	chr6:80927322	A/G	cg08355045	chr6:80787529	NA	0.48	8.12	0.41	9.06e-15	Sitting height ratio;
LUSC	cis	rs587080	0.624	rs512715	chr11:65191208	C/G	cg17120908	chr11:65337727	SSSCA1	0.44	6.9	0.35	2.61e-11	Plateletcrit;
LUSC	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg04733989	chr22:42467013	NAGA	0.4	6.41	0.33	5.09e-10	Cognitive function;
LUSC	trans	rs12210905	0.920	rs9366690	chr6:27291079	T/C	cg11837749	chr1:55047332	ACOT11	0.66	6.3	0.33	9.13e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-9.97	-0.48	1.12e-20	Blood metabolite levels;
LUSC	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.49	-0.62	2.85e-37	Schizophrenia;
LUSC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg21433313	chr16:3507492	NAT15	-0.67	-11.23	-0.52	4.68e-25	Tuberculosis;
LUSC	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg20135002	chr11:47629003	NA	-0.41	-6.61	-0.34	1.5e-10	Subjective well-being;
LUSC	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg06223162	chr1:101003688	GPR88	0.5	9.47	0.46	5.25e-19	Monocyte count;
LUSC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03934478	chr11:495069	RNH1	0.91	10.53	0.5	1.39e-22	Body mass index;
LUSC	cis	rs612683	0.764	rs558035	chr1:100939777	T/C	cg06223162	chr1:101003688	GPR88	-0.47	-8.48	-0.42	7.34e-16	Breast cancer;
LUSC	cis	rs11018904	0.861	rs61903723	chr11:89968246	C/T	cg26834418	chr11:89957033	CHORDC1	-0.49	-6.01	-0.31	4.8e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg24558204	chr6:135376177	HBS1L	0.58	8.81	0.43	6.87e-17	Red blood cell count;
LUSC	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg26395211	chr5:140044315	WDR55	0.45	7.0	0.36	1.39e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg22907277	chr7:1156413	C7orf50	0.64	6.74	0.35	6.9e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9311676	0.656	rs11923253	chr3:58376992	G/A	cg13750441	chr3:58318267	PXK	0.36	6.95	0.36	1.91e-11	Systemic lupus erythematosus;
LUSC	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg16482183	chr6:26056742	HIST1H1C	0.45	6.58	0.34	1.81e-10	Height;
LUSC	cis	rs12908161	0.959	rs61074241	chr15:85333396	C/T	cg11189052	chr15:85197271	WDR73	0.54	6.43	0.33	4.5e-10	Schizophrenia;
LUSC	cis	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg26958806	chr6:27640298	NA	0.83	6.57	0.34	1.94e-10	Depression;
LUSC	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg13256891	chr4:100009986	ADH5	0.5	7.3	0.37	2.18e-12	Alcohol dependence;
LUSC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05535760	chr7:792225	HEATR2	0.79	9.46	0.46	5.56e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs4843185	0.733	rs1049868	chr16:85706633	A/G	cg26571870	chr16:85723150	GINS2	-0.32	-5.88	-0.31	1e-8	Platelet distribution width;
LUSC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24838063	chr12:130822603	PIWIL1	0.71	11.02	0.52	2.71e-24	Menopause (age at onset);
LUSC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21984481	chr17:79567631	NPLOC4	0.58	11.22	0.52	5.07e-25	Eye color traits;
LUSC	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg16850897	chr7:100343110	ZAN	0.37	5.81	0.3	1.46e-8	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs73198271	0.603	rs557892	chr8:8596048	A/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.82	-0.3	1.4e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.79	11.9	0.55	1.79e-27	Cognitive ability;
LUSC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08677398	chr8:58056175	NA	0.61	6.96	0.36	1.81e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs17253792	0.732	rs75796044	chr14:56034128	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-6.41	-0.33	4.87e-10	Putamen volume;
LUSC	cis	rs9900972	0.918	rs4789940	chr17:76877671	G/T	cg20937029	chr17:76870563	TIMP2	0.38	5.96	0.31	6.38e-9	Obesity-related traits;
LUSC	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.77	-11.51	-0.53	4.93e-26	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.78e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg00149659	chr3:10157352	C3orf10	0.64	9.07	0.44	1.04e-17	Alzheimer's disease;
LUSC	cis	rs9322817	0.691	rs56075147	chr6:105337494	T/A	cg02098413	chr6:105308735	HACE1	0.28	5.96	0.31	6.53e-9	Thyroid stimulating hormone;
LUSC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg13206674	chr6:150067644	NUP43	0.6	9.37	0.46	1.12e-18	Lung cancer;
LUSC	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg05043794	chr9:111880884	C9orf5	0.35	7.48	0.38	6.81e-13	Menarche (age at onset);
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg03188948	chr7:1209495	NA	0.44	6.44	0.33	4.19e-10	Longevity;Endometriosis;
LUSC	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.13	9.68	0.47	1.06e-19	Alzheimer's disease (late onset);
LUSC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg07837209	chr13:79184101	NA	-0.44	-6.55	-0.34	2.16e-10	Large artery stroke;
LUSC	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.36	-0.33	6.46e-10	Total body bone mineral density;
LUSC	cis	rs7189233	0.531	rs13337544	chr16:53519035	T/C	cg09728985	chr16:53543985	NA	-0.3	-5.67	-0.3	3.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs6500395	1.000	rs9930199	chr16:48571263	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.69	0.34	9.38e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6574644	1.000	rs12588160	chr14:81776666	T/G	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05901451	chr6:126070800	HEY2	0.57	8.61	0.43	2.83e-16	Endometrial cancer;
LUSC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.48	-0.42	7.41e-16	Obesity-related traits;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg03461704	chr1:205818484	PM20D1	0.41	6.93	0.35	2.23e-11	Menarche (age at onset);
LUSC	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg03342759	chr3:160939853	NMD3	-0.45	-6.22	-0.32	1.53e-9	Parkinson's disease;
LUSC	cis	rs1451375	1.000	rs1451375	chr7:50622712	A/C	cg18232548	chr7:50535776	DDC	-0.53	-8.32	-0.41	2.33e-15	Malaria;
LUSC	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg02100629	chr10:71892760	AIFM2	-0.4	-6.44	-0.33	4.16e-10	Blood protein levels;
LUSC	cis	rs983392	0.680	rs56357056	chr11:59986817	A/G	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.14	-0.32	2.38e-9	Alzheimer's disease (late onset);
LUSC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg08859206	chr1:53392774	SCP2	0.4	6.5	0.34	2.96e-10	Monocyte count;
LUSC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.93	0.35	2.24e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1568889	0.838	rs7125749	chr11:28154692	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.66	0.57	2.85e-30	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.24	0.52	4.35e-25	Menopause (age at onset);
LUSC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg08470875	chr2:26401718	FAM59B	-0.68	-9.16	-0.45	5.3e-18	Gut microbiome composition (summer);
LUSC	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg02023728	chr11:77925099	USP35	0.49	6.87	0.35	3.11e-11	Testicular germ cell tumor;
LUSC	cis	rs4285028	0.699	rs1574115	chr3:121469225	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-12.24	-0.56	1.02e-28	Multiple sclerosis;
LUSC	cis	rs300890	0.651	rs300917	chr4:144269849	C/G	cg01601573	chr4:144256835	GAB1	-0.29	-5.68	-0.3	2.87e-8	Nasopharyngeal carcinoma;
LUSC	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	0.97	12.18	0.55	1.66e-28	Nonalcoholic fatty liver disease;
LUSC	cis	rs35883536	0.967	rs1055044	chr1:101171354	A/G	cg06223162	chr1:101003688	GPR88	0.31	5.64	0.3	3.57e-8	Monocyte count;
LUSC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg12564285	chr5:131593104	PDLIM4	0.56	10.79	0.51	1.81e-23	Acylcarnitine levels;
LUSC	cis	rs9296092	0.538	rs75082458	chr6:33524792	C/T	cg13560919	chr6:33536144	NA	-0.83	-15.86	-0.66	1.3e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg25427524	chr10:38739819	LOC399744	0.45	5.9	0.31	8.86e-9	Obesity (extreme);
LUSC	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg04990556	chr1:26633338	UBXN11	0.85	11.14	0.52	9.76e-25	Obesity-related traits;
LUSC	cis	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05901451	chr6:126070800	HEY2	-0.6	-9.24	-0.45	3.07e-18	Endometrial cancer;
LUSC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg20818283	chr2:191399100	TMEM194B	0.46	7.02	0.36	1.26e-11	Pulse pressure;
LUSC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg08088566	chr11:430123	ANO9	-0.64	-7.44	-0.38	8.51e-13	Body mass index;
LUSC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg13395646	chr4:1353034	KIAA1530	-0.63	-9.84	-0.47	3.24e-20	Obesity-related traits;
LUSC	cis	rs2729354	0.768	rs2848640	chr11:57262680	A/G	cg24343310	chr11:57249947	NA	0.46	8.49	0.42	6.92e-16	Blood protein levels;
LUSC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20887711	chr4:1340912	KIAA1530	0.54	8.51	0.42	5.91e-16	Longevity;
LUSC	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.19	-0.41	5.58e-15	Response to antipsychotic treatment;
LUSC	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.56	-0.42	4.24e-16	Total cholesterol levels;
LUSC	trans	rs1493916	0.837	rs10401087	chr18:31320716	A/G	cg27147174	chr7:100797783	AP1S1	-0.54	-8.41	-0.42	1.2e-15	Life satisfaction;
LUSC	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg23625390	chr15:77176239	SCAPER	-0.61	-8.72	-0.43	1.31e-16	Blood metabolite levels;
LUSC	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg23173402	chr1:227635558	NA	0.59	7.08	0.36	8.53e-12	Major depressive disorder;
LUSC	cis	rs9837602	1.000	rs2291495	chr3:99782227	T/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.82	-0.3	1.38e-8	Breast cancer;
LUSC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.36	-0.37	1.47e-12	Menopause (age at onset);
LUSC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg04871131	chr7:94954202	PON1	-0.37	-5.97	-0.31	6.14e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg09904177	chr6:26538194	HMGN4	0.42	6.14	0.32	2.41e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg10356904	chr22:49881777	NA	-0.29	-5.86	-0.31	1.12e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg16797656	chr11:68205561	LRP5	0.4	7.26	0.37	2.67e-12	Total body bone mineral density;
LUSC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg11062466	chr8:58055876	NA	0.67	7.68	0.39	1.81e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9815354	0.680	rs78402272	chr3:42028425	G/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg09998033	chr7:158218633	PTPRN2	-0.62	-9.87	-0.48	2.57e-20	Obesity-related traits;
LUSC	cis	rs6138458	0.546	rs6050118	chr20:24891895	C/T	cg06937882	chr20:24974362	C20orf3	0.47	6.46	0.33	3.8e-10	Blood protein levels;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg01366246	chr3:193852768	HES1	0.44	6.2	0.32	1.64e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg25258033	chr6:167368657	RNASET2	0.44	7.05	0.36	1.06e-11	Crohn's disease;
LUSC	trans	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.51	8.01	0.4	1.94e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg02176678	chr2:219576539	TTLL4	-0.59	-10.42	-0.5	3.24e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg18827107	chr12:86230957	RASSF9	-0.4	-5.99	-0.31	5.56e-9	Major depressive disorder;
LUSC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg27494647	chr7:150038898	RARRES2	0.58	8.37	0.42	1.55e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg24375607	chr4:120327624	NA	0.79	12.03	0.55	6.08e-28	Corneal astigmatism;
LUSC	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg04586622	chr2:25135609	ADCY3	0.32	6.24	0.32	1.35e-9	Body mass index;
LUSC	cis	rs9311676	0.609	rs1126551	chr3:58416535	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.4	0.33	5.22e-10	Systemic lupus erythematosus;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg08219531	chr3:72495966	RYBP	0.42	6.37	0.33	6.13e-10	N-glycan levels;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg13646470	chr14:89291237	TTC8	0.52	6.48	0.33	3.25e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg15605315	chr1:45957053	TESK2	0.4	6.03	0.31	4.41e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg16414030	chr3:133502952	NA	-0.42	-6.51	-0.34	2.69e-10	Iron status biomarkers;
LUSC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg14196790	chr5:131705035	SLC22A5	0.49	8.4	0.42	1.28e-15	Blood metabolite levels;
LUSC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	29.35	0.85	1.65e-94	Chronic sinus infection;
LUSC	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg05855489	chr10:104503620	C10orf26	0.51	7.9	0.4	3.95e-14	Arsenic metabolism;
LUSC	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg03585969	chr10:35415529	CREM	0.61	8.85	0.44	5.02e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.48	-9.01	-0.44	1.61e-17	Longevity;Endometriosis;
LUSC	trans	rs17685	0.535	rs41296542	chr7:75600008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.46	6.18	0.32	1.85e-9	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1982963	0.627	rs8013745	chr14:52496745	G/T	cg10843707	chr14:52510701	NID2	0.47	6.3	0.33	9.55e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.36	0.53	1.6e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg08270630	chr22:50330655	NA	-0.41	-6.2	-0.32	1.71e-9	Schizophrenia;
LUSC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.7	10.74	0.51	2.63e-23	Aortic root size;
LUSC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg03477792	chr4:77819574	ANKRD56	0.62	8.86	0.44	4.88e-17	Emphysema distribution in smoking;
LUSC	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg05347473	chr6:146136440	FBXO30	-0.49	-8.27	-0.41	3.14e-15	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22433210	chr17:43662623	NA	0.94	13.36	0.59	6.3e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg06207120	chr15:45996521	NA	0.39	5.99	0.31	5.51e-9	Waist circumference;Weight;
LUSC	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.63	-0.34	1.38e-10	Retinal vascular caliber;
LUSC	cis	rs6967385	0.580	rs10258717	chr7:12331651	A/G	cg20607287	chr7:12443886	VWDE	0.36	5.75	0.3	2.02e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs1560104	0.665	rs4381587	chr16:12702904	G/C	cg02946846	chr16:12632861	SNX29	0.32	5.88	0.31	1.02e-8	Obesity-related traits;
LUSC	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg15073853	chr19:18549131	ISYNA1	-0.32	-5.66	-0.3	3.26e-8	Breast cancer;
LUSC	cis	rs6906287	0.647	rs11153753	chr6:118836153	T/C	cg21191810	chr6:118973309	C6orf204	0.32	5.83	0.3	1.27e-8	Electrocardiographic conduction measures;
LUSC	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg01657329	chr11:68192670	LRP5	0.5	6.64	0.34	1.24e-10	Bone mineral density (spine);
LUSC	cis	rs55910451	0.723	rs72774078	chr10:5768140	A/G	cg11519256	chr10:5708881	ASB13	-0.48	-5.81	-0.3	1.47e-8	Breast cancer;
LUSC	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg17691542	chr6:26056736	HIST1H1C	0.41	6.08	0.32	3.25e-9	Schizophrenia;
LUSC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg15445000	chr17:37608096	MED1	-0.39	-6.72	-0.35	7.97e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg16797656	chr11:68205561	LRP5	0.36	6.08	0.32	3.36e-9	Total body bone mineral density;
LUSC	trans	rs2514895	0.660	rs7925233	chr11:127113327	C/A	cg22738642	chr12:43137977	NA	0.5	6.26	0.32	1.17e-9	IgG glycosylation;
LUSC	cis	rs1775715	0.677	rs2808074	chr10:32179184	A/C	cg03015672	chr10:32216066	ARHGAP12	0.34	6.12	0.32	2.65e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00631329	chr6:26305371	NA	-0.46	-8.95	-0.44	2.49e-17	Educational attainment;
LUSC	cis	rs4363385	0.669	rs4845519	chr1:153003916	G/T	cg25856811	chr1:152973957	SPRR3	0.34	5.76	0.3	1.87e-8	Inflammatory skin disease;
LUSC	cis	rs10740039	0.516	rs2393675	chr10:62350748	T/G	cg18175470	chr10:62150864	ANK3	-0.47	-6.82	-0.35	4.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11650494	0.710	rs16948078	chr17:47474800	C/T	cg08112188	chr17:47440006	ZNF652	-0.83	-7.59	-0.38	3.15e-13	Prostate cancer;
LUSC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.51	-0.46	4.02e-19	Chronic sinus infection;
LUSC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg14416269	chr4:6271139	WFS1	0.5	10.62	0.5	6.83e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2658782	0.756	rs3019205	chr11:93109553	A/G	cg15737290	chr11:93063684	CCDC67	0.63	7.77	0.39	9.47e-14	Pulmonary function decline;
LUSC	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg26068271	chr17:76253126	NA	-0.59	-10.55	-0.5	1.17e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg21775007	chr8:11205619	TDH	-0.5	-7.04	-0.36	1.08e-11	Neuroticism;
LUSC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.66	-11.1	-0.52	1.36e-24	Diastolic blood pressure;
LUSC	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg22713356	chr15:30763199	NA	1.03	13.58	0.6	9.8e-34	Uric acid levels;
LUSC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg20406979	chr6:167373233	NA	0.26	6.02	0.31	4.59e-9	Crohn's disease;
LUSC	cis	rs4285028	0.580	rs1523519	chr3:121631841	C/T	cg20356878	chr3:121714668	ILDR1	-0.44	-6.7	-0.34	8.97e-11	Multiple sclerosis;
LUSC	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.07	-0.32	3.46e-9	Joint mobility (Beighton score);
LUSC	cis	rs9653442	0.564	rs4851256	chr2:100775045	A/G	cg07810366	chr2:100720526	AFF3	-0.41	-6.96	-0.36	1.81e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs9341835	0.772	rs9294197	chr6:64135648	A/G	cg00787780	chr6:64151745	NA	-0.33	-5.77	-0.3	1.82e-8	Schizophrenia;
LUSC	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.6	13.84	0.6	9.47e-35	Height;
LUSC	cis	rs2274273	0.934	rs17740741	chr14:55762712	G/C	cg04306507	chr14:55594613	LGALS3	0.54	12.17	0.55	1.88e-28	Protein biomarker;
LUSC	cis	rs6977660	0.714	rs4719586	chr7:19825548	T/C	cg05791153	chr7:19748676	TWISTNB	0.67	6.93	0.35	2.24e-11	Thyroid stimulating hormone;
LUSC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg15704280	chr7:45808275	SEPT13	0.66	7.26	0.37	2.77e-12	Axial length;
LUSC	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg09955084	chr16:413813	NA	0.27	5.86	0.31	1.1e-8	Bone mineral density (spine);Bone mineral density;
LUSC	trans	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	11.83	0.54	3.22e-27	Exhaled nitric oxide output;
LUSC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.71	12.79	0.57	9.66e-31	Prudent dietary pattern;
LUSC	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.19	-0.32	1.79e-9	IgG glycosylation;
LUSC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg11764359	chr7:65958608	NA	-0.53	-6.9	-0.35	2.67e-11	Aortic root size;
LUSC	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg05855489	chr10:104503620	C10orf26	0.51	7.85	0.39	5.62e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs9341808	0.718	rs3812121	chr6:80968727	A/G	cg08355045	chr6:80787529	NA	0.56	9.62	0.47	1.64e-19	Sitting height ratio;
LUSC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg27398817	chr8:82754497	SNX16	-0.45	-5.99	-0.31	5.29e-9	Diastolic blood pressure;
LUSC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.71	9.09	0.45	8.67e-18	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs921665	0.831	rs2368672	chr2:3188893	A/C	cg02624386	chr2:3182749	NA	0.59	6.59	0.34	1.68e-10	World class endurance athleticism;
LUSC	cis	rs34638657	0.656	rs1134847	chr16:82203742	C/T	cg09439754	chr16:82129088	HSD17B2	0.39	6.53	0.34	2.4e-10	Lung adenocarcinoma;
LUSC	cis	rs10423674	0.526	rs2023878	chr19:18834124	A/G	cg14292368	chr19:18793705	CRTC1	0.44	6.73	0.35	7.54e-11	Menarche (age at onset);
LUSC	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg12549451	chr6:135224345	NA	0.35	5.78	0.3	1.71e-8	Red blood cell count;
LUSC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.4	5.95	0.31	6.93e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1506636	0.512	rs1035015	chr7:123309842	G/C	cg03229431	chr7:123269106	ASB15	0.59	7.97	0.4	2.52e-14	Plateletcrit;Platelet count;
LUSC	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg17168535	chr8:21777572	XPO7	0.69	11.68	0.54	1.12e-26	Mean corpuscular volume;
LUSC	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg25214090	chr10:38739885	LOC399744	0.54	8.06	0.4	1.42e-14	Corneal astigmatism;
LUSC	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg08085267	chr17:45401833	C17orf57	-0.45	-6.49	-0.33	3.19e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg14791747	chr16:20752902	THUMPD1	-0.41	-6.2	-0.32	1.65e-9	Dental caries;
LUSC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9309473	0.519	rs4852951	chr2:73869796	C/G	cg20560298	chr2:73613845	ALMS1	0.46	6.96	0.36	1.84e-11	Metabolite levels;
LUSC	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg06677660	chr19:49140777	SEC1;DBP	-0.46	-6.0	-0.31	5e-9	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	8.0	0.4	2.1e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg00262122	chr8:11665843	FDFT1	0.4	5.9	0.31	8.84e-9	Neuroticism;
LUSC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.47	-0.38	6.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-7.26	-0.37	2.74e-12	Schizophrenia;
LUSC	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.93	-0.35	2.18e-11	Lung cancer;
LUSC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-5.69	-0.3	2.76e-8	Vitiligo;
LUSC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.73	0.51	2.84e-23	Menopause (age at onset);
LUSC	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.32	0.33	8.57e-10	Rheumatoid arthritis;
LUSC	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg00990874	chr7:1149470	C7orf50	-0.49	-6.19	-0.32	1.72e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg02475777	chr4:1388615	CRIPAK	0.45	6.86	0.35	3.37e-11	Obesity-related traits;
LUSC	cis	rs806215	1.000	rs2106187	chr7:127241353	C/T	cg25922125	chr7:127225783	GCC1	0.57	7.16	0.36	5.26e-12	Type 2 diabetes;
LUSC	cis	rs977987	0.815	rs4887829	chr16:75488935	C/T	cg03315344	chr16:75512273	CHST6	0.54	10.63	0.5	6.49e-23	Dupuytren's disease;
LUSC	cis	rs11030122	0.733	rs10835331	chr11:3957365	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.73	-0.3	2.23e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg03342759	chr3:160939853	NMD3	-0.54	-7.75	-0.39	1.09e-13	Parkinson's disease;
LUSC	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.69	-0.3	2.8e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg17168535	chr8:21777572	XPO7	0.84	15.66	0.65	7.57e-42	Mean corpuscular volume;
LUSC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg25039879	chr17:56429692	SUPT4H1	0.64	8.67	0.43	1.92e-16	Cognitive test performance;
LUSC	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg21132104	chr15:45694354	SPATA5L1	0.39	5.72	0.3	2.36e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg13010199	chr12:38710504	ALG10B	-0.45	-6.75	-0.35	6.46e-11	Heart rate;
LUSC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg02018176	chr4:1364513	KIAA1530	0.53	9.24	0.45	2.99e-18	Obesity-related traits;
LUSC	cis	rs7827545	0.545	rs6578228	chr8:135562422	G/A	cg17885191	chr8:135476712	NA	0.61	7.79	0.39	8.69e-14	Hypertension (SNP x SNP interaction);
LUSC	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg10434728	chr15:90938212	IQGAP1	0.43	8.78	0.43	8.7e-17	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs711244	0.783	rs2252032	chr2:37099339	C/T	cg14987922	chr2:37194071	STRN	0.46	6.65	0.34	1.18e-10	Mean platelet volume;
LUSC	trans	rs10877945	0.522	rs7297754	chr12:63443521	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.43	-6.99	-0.36	1.55e-11	Obesity-related traits;
LUSC	cis	rs17155006	0.664	rs1735499	chr7:107738882	G/A	cg05962710	chr7:107745446	LAMB4	-0.36	-6.3	-0.33	9.63e-10	Pneumococcal bacteremia;
LUSC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg01652190	chr22:50026171	C22orf34	-0.3	-6.2	-0.32	1.71e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2594714	0.515	rs10411270	chr19:13940838	A/T	cg18576835	chr19:13944261	NA	-0.46	-7.21	-0.37	3.7e-12	Breast cancer;
LUSC	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg05855489	chr10:104503620	C10orf26	-0.51	-7.68	-0.39	1.82e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg05872129	chr22:39784769	NA	-0.61	-11.46	-0.53	7.48e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs76793172	1.000	rs7257342	chr19:46356418	C/T	cg00442267	chr19:46317840	RSPH6A	-0.5	-5.69	-0.3	2.77e-8	Eosinophil counts;
LUSC	cis	rs12618769	0.597	rs1587835	chr2:99041269	A/C	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.14e-13	Bipolar disorder;
LUSC	trans	rs7567288	0.636	rs7574116	chr2:134466301	T/C	cg12381416	chr3:14359266	NA	0.53	5.99	0.31	5.3e-9	Height;
LUSC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.06	-0.31	3.67e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08645402	chr16:4508243	NA	0.52	8.86	0.44	4.72e-17	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08991391	chr14:60716504	PPM1A	-0.4	-5.98	-0.31	5.61e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07491203	chr7:155089714	INSIG1	-0.38	-6.23	-0.32	1.43e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.07	0.4	1.27e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	1.1	17.15	0.68	9.89e-48	Exhaled nitric oxide output;
LUSC	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg22117172	chr7:91764530	CYP51A1	0.31	5.7	0.3	2.7e-8	Breast cancer;
LUSC	trans	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.6	0.38	3.08e-13	Ulcerative colitis;
LUSC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg00717180	chr2:96193071	NA	-0.37	-5.98	-0.31	5.78e-9	HDL cholesterol;
LUSC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.77	-13.83	-0.6	1.06e-34	Aortic root size;
LUSC	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg04586622	chr2:25135609	ADCY3	0.42	8.74	0.43	1.16e-16	Body mass index;
LUSC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg07777115	chr5:623756	CEP72	-0.45	-5.77	-0.3	1.79e-8	Obesity-related traits;
LUSC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg07507251	chr3:52567010	NT5DC2	0.37	7.49	0.38	6.36e-13	Electroencephalogram traits;
LUSC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg00106254	chr7:1943704	MAD1L1	-0.44	-6.34	-0.33	7.42e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg27165867	chr14:105738592	BRF1	-0.51	-7.42	-0.38	9.52e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-0.58	-9.19	-0.45	4.34e-18	Breast cancer;
LUSC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg21724239	chr8:58056113	NA	0.78	9.03	0.44	1.43e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg03585969	chr10:35415529	CREM	0.62	8.91	0.44	3.28e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg17807903	chr1:86174739	ZNHIT6	0.41	9.64	0.47	1.48e-19	Urate levels in overweight individuals;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg03068637	chr8:87521094	FAM82B	0.4	6.11	0.32	2.74e-9	Schizophrenia;
LUSC	cis	rs807669	0.933	rs712959	chr22:19159015	C/T	cg02655711	chr22:19163373	SLC25A1	0.78	15.3	0.64	1.97e-40	Metabolite levels;
LUSC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg12615879	chr12:58013172	SLC26A10	-0.29	-5.94	-0.31	7.18e-9	Multiple sclerosis;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg02796970	chr10:39023768	NA	-0.48	-7.82	-0.39	6.93e-14	Menopause (age at onset);
LUSC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg12257692	chr3:49977190	RBM6	-0.25	-6.85	-0.35	3.54e-11	Body mass index;
LUSC	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs7927771	0.524	rs11039377	chr11:47789776	C/T	cg20307385	chr11:47447363	PSMC3	0.44	6.47	0.33	3.4e-10	Subjective well-being;
LUSC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg13319975	chr6:146136371	FBXO30	0.48	7.23	0.37	3.33e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.63	-10.4	-0.49	3.93e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg05887092	chr17:76393375	PGS1	0.51	9.14	0.45	6.11e-18	HDL cholesterol levels;
LUSC	cis	rs66887589	0.934	rs2389873	chr4:120554714	A/G	cg24375607	chr4:120327624	NA	-0.47	-7.24	-0.37	3.1e-12	Diastolic blood pressure;
LUSC	cis	rs4588572	0.643	rs10043027	chr5:77792707	T/C	cg11547950	chr5:77652471	NA	-0.58	-8.21	-0.41	4.91e-15	Triglycerides;
LUSC	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg05805236	chr11:65401703	PCNXL3	-0.64	-10.47	-0.5	2.24e-22	Acne (severe);
LUSC	cis	rs2242663	0.798	rs1791679	chr11:66337874	C/A	cg24851651	chr11:66362959	CCS	0.37	5.9	0.31	8.71e-9	Bipolar disorder;
LUSC	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg05738196	chr6:26577821	NA	0.52	7.57	0.38	3.64e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21862992	chr11:68658383	NA	0.49	7.83	0.39	6.45e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11650494	0.516	rs13341862	chr17:47494203	A/G	cg08112188	chr17:47440006	ZNF652	-1.0	-8.2	-0.41	5.2e-15	Prostate cancer;
LUSC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.18	-0.37	4.65e-12	Electroencephalogram traits;
LUSC	cis	rs11716531	0.573	rs642570	chr3:27342595	C/G	cg02860705	chr3:27208620	NA	0.47	8.55	0.42	4.33e-16	Diastolic blood pressure;
LUSC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.07e-17	Prudent dietary pattern;
LUSC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.59	9.62	0.47	1.67e-19	Aortic root size;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15531788	chr10:38146671	ZNF248	-0.51	-6.63	-0.34	1.36e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.79	14.38	0.62	7.6e-37	Osteoporosis;
LUSC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg13126279	chr21:47581558	C21orf56	-0.41	-5.8	-0.3	1.54e-8	Testicular germ cell tumor;
LUSC	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg16850897	chr7:100343110	ZAN	-0.47	-5.82	-0.3	1.37e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.44	-0.53	8.89e-26	Mean corpuscular volume;
LUSC	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg22709100	chr7:91322751	NA	0.42	6.2	0.32	1.71e-9	Breast cancer;
LUSC	cis	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg06521331	chr12:34319734	NA	-0.45	-7.3	-0.37	2.13e-12	Morning vs. evening chronotype;
LUSC	cis	rs9747201	0.609	rs9303022	chr17:80170651	C/G	cg18209359	chr17:80159595	CCDC57	-0.36	-5.83	-0.3	1.3e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg05347473	chr6:146136440	FBXO30	0.43	7.49	0.38	6.01e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9378688	1.000	rs3800187	chr6:2222253	C/T	cg12303981	chr6:2244766	GMDS	-0.49	-5.83	-0.3	1.31e-8	Caudate nucleus volume;
LUSC	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg10172584	chr19:19639581	YJEFN3	-0.46	-5.74	-0.3	2.18e-8	Bipolar disorder;
LUSC	cis	rs11997175	0.583	rs34540455	chr8:33799300	C/T	ch.8.33884649F	chr8:33765107	NA	0.49	7.31	0.37	1.97e-12	Body mass index;
LUSC	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg21064579	chr19:49206444	FUT2	0.45	8.68	0.43	1.74e-16	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
LUSC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.25	-14.44	-0.62	4.77e-37	Gout;
LUSC	cis	rs1322512	0.834	rs1744383	chr6:152941476	G/A	cg27316956	chr6:152958899	SYNE1	-0.36	-5.9	-0.31	8.86e-9	Tonometry;
LUSC	cis	rs1729407	0.565	rs2849173	chr11:116697321	G/C	cg08985259	chr11:116699649	APOC3	-0.25	-5.67	-0.3	3.05e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg08645402	chr16:4508243	NA	0.5	7.62	0.38	2.59e-13	Schizophrenia;
LUSC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.01	0.77	5.62e-67	Prudent dietary pattern;
LUSC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	0.92	16.04	0.66	2.4e-43	Menopause (age at onset);
LUSC	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.71	-12.52	-0.57	9.7e-30	White blood cell count (basophil);
LUSC	cis	rs7192380	0.756	rs12596945	chr16:69780819	C/A	cg00738113	chr16:70207722	CLEC18C	0.28	5.75	0.3	2.02e-8	Sjögren's syndrome;
LUSC	cis	rs4481887	0.646	rs28421649	chr1:248548122	G/C	cg26353448	chr1:248524236	OR2T4	-0.3	-5.66	-0.3	3.24e-8	Common traits (Other);
LUSC	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg04990556	chr1:26633338	UBXN11	0.85	11.14	0.52	9.76e-25	Obesity-related traits;
LUSC	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg05468064	chr22:46423449	NA	0.37	6.45	0.33	4.03e-10	Dupuytren's disease;
LUSC	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	cis	rs6963495	0.818	rs73192144	chr7:105203535	C/T	cg19920283	chr7:105172520	RINT1	0.57	5.89	0.31	9.54e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg02017074	chr12:117425053	FBXW8	0.62	7.19	0.37	4.24e-12	Subcortical brain region volumes;Hippocampal volume;
LUSC	cis	rs116139393	1.000	rs116139393	chr7:6771660	C/G	cg09896999	chr7:6746977	ZNF12	-0.5	-7.02	-0.36	1.22e-11	Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.66	-12.19	-0.55	1.62e-28	Type 2 diabetes;
LUSC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg18230493	chr5:56204884	C5orf35	-0.64	-9.81	-0.47	4.08e-20	Coronary artery disease;
LUSC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.54	0.38	4.62e-13	Obesity-related traits;
LUSC	cis	rs6700896	0.931	rs12043644	chr1:66147348	A/G	cg04111102	chr1:66153794	NA	0.33	7.38	0.37	1.24e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg06612196	chr6:6737390	NA	0.63	13.14	0.58	4.4e-32	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs9682041	0.627	rs34392658	chr3:170091584	C/T	cg11886554	chr3:170076028	SKIL	0.7	9.43	0.46	7.29e-19	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LUSC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05165339	chr4:1420672	NA	0.26	5.94	0.31	6.98e-9	Obesity-related traits;
LUSC	cis	rs2050392	1.000	rs2050392	chr10:30691503	G/A	cg18806716	chr10:30721971	MAP3K8	-0.45	-7.25	-0.37	2.84e-12	Inflammatory bowel disease;
LUSC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.99	0.36	1.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg21724239	chr8:58056113	NA	0.78	9.45	0.46	6.03e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg09877947	chr5:131593287	PDLIM4	0.44	6.92	0.35	2.26e-11	Breast cancer;
LUSC	trans	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg03886242	chr7:26192032	NFE2L3	-0.4	-6.54	-0.34	2.31e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg01973587	chr1:228161476	NA	0.45	8.3	0.41	2.53e-15	Diastolic blood pressure;
LUSC	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg16414030	chr3:133502952	NA	-0.42	-6.56	-0.34	2.11e-10	Iron status biomarkers;
LUSC	trans	rs1486139	1.000	rs10267081	chr7:46296931	C/T	cg17534202	chr9:96721102	NA	-0.36	-6.41	-0.33	5.09e-10	Select biomarker traits;
LUSC	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg05861140	chr6:150128134	PCMT1	0.45	7.13	0.36	6.13e-12	Lung cancer;
LUSC	cis	rs6681460	0.837	rs6669023	chr1:67171868	G/T	cg02459107	chr1:67143332	SGIP1	0.45	8.3	0.41	2.57e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	8.49	0.42	6.75e-16	Schizophrenia;
LUSC	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg04310649	chr10:35416472	CREM	-0.41	-6.43	-0.33	4.53e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.79	0.47	4.66e-20	Mean platelet volume;
LUSC	cis	rs7119	0.717	rs12904254	chr15:77802585	C/A	cg27398640	chr15:77910606	LINGO1	-0.3	-6.22	-0.32	1.47e-9	Type 2 diabetes;
LUSC	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg00944433	chr1:107599041	PRMT6	0.35	6.55	0.34	2.24e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg16049864	chr8:95962084	TP53INP1	-0.68	-13.49	-0.59	2.08e-33	Type 2 diabetes;
LUSC	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg13010199	chr12:38710504	ALG10B	0.56	8.58	0.42	3.73e-16	Morning vs. evening chronotype;
LUSC	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg08997352	chr12:9597637	DDX12	-0.7	-11.05	-0.52	2.1e-24	Breast size;
LUSC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.91	-17.54	-0.69	2.75e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4499344	0.604	rs259275	chr19:33159693	A/G	cg22980127	chr19:33182716	NUDT19	-0.45	-6.66	-0.34	1.11e-10	Mean platelet volume;
LUSC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.39	5.87	0.31	1.08e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg09911534	chr15:67153556	NA	0.49	6.48	0.33	3.3e-10	Lung cancer (smoking interaction);
LUSC	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg13206674	chr6:150067644	NUP43	0.5	7.53	0.38	4.76e-13	Lung cancer;
LUSC	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	7.15	0.36	5.44e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg14767165	chr6:160183909	ACAT2	0.43	5.95	0.31	6.89e-9	Iron status biomarkers;
LUSC	cis	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg24375607	chr4:120327624	NA	0.5	7.77	0.39	9.66e-14	Diastolic blood pressure;
LUSC	cis	rs308447	0.522	rs309363	chr4:123658169	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.83	11.53	0.53	3.9e-26	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs501916	0.605	rs8031169	chr15:48080330	G/C	cg16110827	chr15:48056943	SEMA6D	-0.37	-5.69	-0.3	2.75e-8	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg23950597	chr19:37808831	NA	-0.6	-7.26	-0.37	2.73e-12	Coronary artery calcification;
LUSC	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.89	-16.03	-0.66	2.76e-43	Metabolic syndrome;
LUSC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg09359103	chr1:154839909	KCNN3	0.68	15.43	0.64	6.57e-41	Prostate cancer;
LUSC	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg13390004	chr1:15929781	NA	0.43	7.11	0.36	7.16e-12	Systolic blood pressure;
LUSC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.18	29.13	0.85	1.04e-93	Testicular germ cell tumor;
LUSC	cis	rs4692589	0.581	rs62344679	chr4:170963591	G/A	cg19918862	chr4:170955249	NA	0.36	6.59	0.34	1.73e-10	Anxiety disorder;
LUSC	cis	rs1044826	0.642	rs7624321	chr3:139220159	C/A	cg00490450	chr3:139108681	COPB2	0.46	7.02	0.36	1.27e-11	Obesity-related traits;
LUSC	cis	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg17469321	chr7:55412551	NA	0.68	10.68	0.5	4.35e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg17462356	chr17:80056334	FASN	0.46	6.21	0.32	1.56e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs3743162	1.000	rs12917429	chr15:85425097	A/C	cg12863693	chr15:85201151	NMB	-0.32	-5.91	-0.31	8.38e-9	Alzheimer's disease (age of onset);
LUSC	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	0.99	17.94	0.7	7.17e-51	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs4664308	1.000	rs4665147	chr2:160917062	A/G	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.31	-0.53	2.55e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs2953174	1.000	rs2975754	chr2:241522634	G/A	cg07929629	chr2:241523174	NA	0.46	6.2	0.32	1.71e-9	Bipolar disorder;
LUSC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg14500267	chr11:67383377	NA	0.32	6.1	0.32	3e-9	Mean corpuscular volume;
LUSC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08736216	chr1:53307985	ZYG11A	-0.29	-6.07	-0.32	3.51e-9	Monocyte count;
LUSC	cis	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.44	6.64	0.34	1.29e-10	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-6.3	-0.33	9.4e-10	Fear of minor pain;
LUSC	trans	rs1347297	0.614	rs4894017	chr2:179281062	C/T	cg14011486	chr1:26737247	LIN28	0.46	7.14	0.36	5.96e-12	Alzheimer disease and age of onset;
LUSC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	0.9	17.25	0.69	3.85e-48	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.84	0.3	1.25e-8	Tonsillectomy;
LUSC	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.73e-23	Bladder cancer;
LUSC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg06238570	chr21:40685208	BRWD1	0.49	7.6	0.38	2.98e-13	Menarche (age at onset);
LUSC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.51	-0.46	3.89e-19	Extrinsic epigenetic age acceleration;
LUSC	trans	rs12210905	0.688	rs72839471	chr6:27316959	C/T	cg02699829	chr19:13216355	TRMT1	-0.56	-6.23	-0.32	1.39e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg23505145	chr19:12996616	KLF1	0.65	11.05	0.52	2.17e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg18404041	chr3:52824283	ITIH1	0.6	10.3	0.49	8.46e-22	Schizophrenia;
LUSC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.6	9.79	0.47	4.48e-20	Bone mineral density;
LUSC	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.48	-0.42	7.54e-16	Response to antipsychotic treatment;
LUSC	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.36	0.53	1.67e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg08738300	chr3:44038990	NA	0.63	9.12	0.45	7.18e-18	Coronary artery disease;
LUSC	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9650315	0.810	rs13262665	chr8:57188282	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	6.41	0.33	4.87e-10	Height;
LUSC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg16434002	chr17:42200994	HDAC5	-0.45	-6.35	-0.33	6.97e-10	Total body bone mineral density;
LUSC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.79	-0.39	8.52e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg07870213	chr5:140052090	DND1	-0.75	-11.23	-0.52	4.69e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg03808351	chr9:123631620	PHF19	-0.48	-6.01	-0.31	4.96e-9	Birth weight;
LUSC	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg18404041	chr3:52824283	ITIH1	0.4	6.94	0.35	2.07e-11	Body mass index;
LUSC	trans	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg26384229	chr12:38710491	ALG10B	0.62	8.6	0.43	3.05e-16	Resting heart rate;
LUSC	cis	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg02508848	chr16:68573721	ZFP90	-0.43	-5.82	-0.3	1.42e-8	Ulcerative colitis;
LUSC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg20135002	chr11:47629003	NA	0.48	7.55	0.38	4.28e-13	Subjective well-being;
LUSC	cis	rs67366981	1.000	rs17105594	chr14:77713146	C/T	cg22824376	chr14:77648248	TMEM63C	0.65	6.19	0.32	1.75e-9	Obsessive-compulsive symptoms;
LUSC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg23711669	chr6:146136114	FBXO30	0.86	16.1	0.66	1.47e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.65	-0.39	2.15e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs6740322	0.748	rs13420649	chr2:43463637	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-6.87	-0.35	3.21e-11	Coronary artery disease;
LUSC	cis	rs8038465	0.615	rs8024862	chr15:73958290	C/T	cg15420318	chr15:73925796	NPTN	0.62	10.72	0.51	3.11e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg09184832	chr6:79620586	NA	-0.44	-6.91	-0.35	2.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg10523679	chr1:76189770	ACADM	-0.49	-7.26	-0.37	2.71e-12	Daytime sleep phenotypes;
LUSC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg05872129	chr22:39784769	NA	0.61	11.12	0.52	1.19e-24	Intelligence (multi-trait analysis);
LUSC	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg15704280	chr7:45808275	SEPT13	0.67	6.31	0.33	8.99e-10	Axial length;
LUSC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg16624210	chr5:671434	TPPP	0.49	6.04	0.31	4.06e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-8.86	-0.44	4.7e-17	Response to antipsychotic treatment;
LUSC	cis	rs13315871	1.000	rs11706420	chr3:58392411	C/T	cg12435725	chr3:58293450	RPP14	0.59	6.21	0.32	1.57e-9	Cholesterol, total;
LUSC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg14773178	chr5:1868261	NA	0.33	6.24	0.32	1.32e-9	Cardiovascular disease risk factors;
LUSC	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg03676636	chr4:99064102	C4orf37	0.37	7.65	0.39	2.14e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg16031515	chr1:205743344	RAB7L1	-0.28	-6.11	-0.32	2.73e-9	Menarche (age at onset);
LUSC	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg20307385	chr11:47447363	PSMC3	-0.46	-5.94	-0.31	7.15e-9	Subjective well-being;
LUSC	cis	rs75920871	0.528	rs2513097	chr11:116836212	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.26	-0.32	1.16e-9	Subjective well-being;
LUSC	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg03894339	chr8:19674705	INTS10	0.8	9.9	0.48	1.92e-20	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9296092	0.517	rs78978280	chr6:33520747	T/A	cg13560919	chr6:33536144	NA	-0.82	-15.68	-0.65	6.77e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	12.4	0.56	2.75e-29	Mean corpuscular volume;
LUSC	cis	rs3760982	1.000	rs11669175	chr19:44289824	A/G	cg11993925	chr19:44307056	LYPD5	0.28	6.26	0.32	1.18e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs13385	0.769	rs13175916	chr5:139611508	T/C	cg26211634	chr5:139558579	C5orf32	0.45	6.65	0.34	1.23e-10	Atrial fibrillation;
LUSC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg11812906	chr14:75593930	NEK9	-0.63	-10.42	-0.5	3.34e-22	Height;
LUSC	cis	rs7575217	0.767	rs13386749	chr2:101746592	C/T	cg23907051	chr2:101730305	TBC1D8	-0.28	-7.39	-0.37	1.17e-12	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-9.27	-0.45	2.34e-18	Monocyte percentage of white cells;
LUSC	trans	rs877282	0.947	rs12358875	chr10:757531	T/C	cg22713356	chr15:30763199	NA	1.03	13.61	0.6	7.56e-34	Uric acid levels;
LUSC	cis	rs977987	0.806	rs8050059	chr16:75388731	C/T	cg04384234	chr16:75411784	CFDP1	-0.4	-6.33	-0.33	8.12e-10	Dupuytren's disease;
LUSC	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg27411982	chr8:10470053	RP1L1	0.4	6.14	0.32	2.3e-9	Myopia (pathological);
LUSC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11764359	chr7:65958608	NA	-0.59	-8.73	-0.43	1.27e-16	Aortic root size;
LUSC	cis	rs6840360	1.000	rs6823421	chr4:152604719	T/C	cg22705602	chr4:152727874	NA	-0.28	-5.96	-0.31	6.43e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs17828380	1.000	rs71393136	chr15:63492776	C/G	cg05507819	chr15:63340323	TPM1	-0.7	-5.92	-0.31	8.01e-9	Social communication problems;
LUSC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg04518342	chr5:131593106	PDLIM4	0.55	10.34	0.49	6.47e-22	Acylcarnitine levels;
LUSC	cis	rs7804356	1.000	rs7785918	chr7:26861959	C/T	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.05e-9	Type 1 diabetes;
LUSC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg20887711	chr4:1340912	KIAA1530	0.42	6.52	0.34	2.67e-10	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12620342	chr12:56522011	ESYT1	0.45	6.79	0.35	5.08e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg09307838	chr4:120376055	NA	0.6	8.58	0.42	3.63e-16	Educational attainment;
LUSC	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg09085632	chr11:111637200	PPP2R1B	0.95	13.24	0.59	1.82e-32	Primary sclerosing cholangitis;
LUSC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.7	10.83	0.51	1.22e-23	Aortic root size;
LUSC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08736216	chr1:53307985	ZYG11A	0.3	6.07	0.32	3.55e-9	Monocyte count;
LUSC	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg21775007	chr8:11205619	TDH	-0.65	-10.15	-0.49	2.75e-21	Retinal vascular caliber;
LUSC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg06453172	chr10:134556979	INPP5A	-0.53	-6.47	-0.33	3.42e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg11584989	chr19:19387371	SF4	0.61	7.27	0.37	2.54e-12	Bipolar disorder;
LUSC	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg09165964	chr15:75287851	SCAMP5	-1.15	-18.88	-0.72	1.33e-54	Blood trace element (Zn levels);
LUSC	cis	rs4363385	0.510	rs6689510	chr1:153048039	G/A	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.39	-0.33	5.43e-10	Inflammatory skin disease;
LUSC	cis	rs9039	1.000	rs9039	chr16:9205363	A/G	cg08831531	chr16:9218945	NA	-0.67	-10.13	-0.48	3.4e-21	Menopause (age at onset);
LUSC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg21770322	chr7:97807741	LMTK2	-0.41	-7.2	-0.37	4.05e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg07393940	chr7:158741817	NA	0.36	6.52	0.34	2.66e-10	Life satisfaction;
LUSC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg02569458	chr12:86230093	RASSF9	0.58	9.8	0.47	4.13e-20	Major depressive disorder;
LUSC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg03146154	chr1:46216737	IPP	0.57	8.47	0.42	7.65e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.17	-0.32	1.95e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7597155	1.000	rs7597155	chr2:69985435	G/A	cg02498382	chr2:70120550	SNRNP27	-0.24	-5.82	-0.3	1.37e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs76878669	0.561	rs10791876	chr11:66169646	C/T	cg24851651	chr11:66362959	CCS	0.38	6.0	0.31	5.15e-9	Educational attainment (years of education);
LUSC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.3	-0.41	2.63e-15	Obesity-related traits;
LUSC	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.15	0.64	7.62e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg07389463	chr12:132296394	NA	0.43	8.03	0.4	1.73e-14	Migraine;
LUSC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7264396	0.887	rs2281849	chr20:34060286	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.15	-0.32	2.23e-9	Total cholesterol levels;
LUSC	trans	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg04995722	chr7:26192034	NFE2L3	-0.4	-6.56	-0.34	2.08e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg00857998	chr1:205179979	DSTYK	0.58	8.94	0.44	2.64e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18854424	chr1:2615690	NA	0.49	9.91	0.48	1.84e-20	Ulcerative colitis;
LUSC	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg23093090	chr10:104574429	C10orf26	-0.38	-7.22	-0.37	3.46e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg24642439	chr20:33292090	TP53INP2	0.47	7.04	0.36	1.07e-11	Coronary artery disease;
LUSC	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	8.65	0.43	2.22e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.95	-12.69	-0.57	2.26e-30	Platelet count;
LUSC	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg03929089	chr4:120376271	NA	-0.45	-6.18	-0.32	1.92e-9	HDL cholesterol;
LUSC	trans	rs1171606	0.731	rs1171648	chr10:61450932	C/T	cg14119616	chr11:17099403	RPS13	-0.39	-5.96	-0.31	6.46e-9	Acylcarnitine levels;
LUSC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg04414720	chr1:150670196	GOLPH3L	0.57	9.22	0.45	3.31e-18	Tonsillectomy;
LUSC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12667521	chr19:29218732	NA	0.61	8.78	0.43	8.57e-17	Methadone dose in opioid dependence;
LUSC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg21782813	chr7:2030301	MAD1L1	0.58	10.31	0.49	8.12e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs4343996	0.727	rs12537113	chr7:3370274	C/G	cg21248987	chr7:3385318	SDK1	-0.35	-6.06	-0.31	3.62e-9	Motion sickness;
LUSC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.66	11.42	0.53	9.92e-26	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg23205692	chr1:25664452	TMEM50A	-0.38	-5.69	-0.3	2.85e-8	Erythrocyte sedimentation rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11316592	chr17:63556608	AXIN2	0.43	6.36	0.33	6.74e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.73	-12.68	-0.57	2.43e-30	Cognitive function;
LUSC	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.79	-0.35	5.04e-11	Monocyte percentage of white cells;
LUSC	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.81	-0.47	4.08e-20	Hemoglobin concentration;
LUSC	cis	rs4786125	0.801	rs8057091	chr16:6902148	A/G	cg03623568	chr16:6915990	A2BP1	-0.44	-7.78	-0.39	9.37e-14	Heart rate variability traits (SDNN);
LUSC	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg00898013	chr13:113819073	PROZ	-0.57	-8.13	-0.41	8.59e-15	Platelet distribution width;
LUSC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.49	-8.96	-0.44	2.3e-17	Urinary metabolites;
LUSC	cis	rs2273669	0.667	rs76249006	chr6:109366740	G/A	cg05315195	chr6:109294784	ARMC2	-0.52	-5.75	-0.3	2.07e-8	Prostate cancer;
LUSC	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.76	11.5	0.53	5.39e-26	Itch intensity from mosquito bite;
LUSC	cis	rs2969070	1.000	rs1548594	chr7:2513281	G/C	cg03277898	chr7:2518824	NA	-0.26	-5.67	-0.3	3.17e-8	Diastolic blood pressure;
LUSC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg03676636	chr4:99064102	C4orf37	0.34	7.44	0.38	8.44e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.61	0.34	1.53e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	8.22	0.41	4.59e-15	Menarche (age at onset);
LUSC	cis	rs9549260	0.755	rs9549255	chr13:41235213	C/T	cg21288729	chr13:41239152	FOXO1	0.63	9.82	0.47	3.79e-20	Red blood cell count;
LUSC	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg02423579	chr7:2872169	GNA12	-0.38	-5.83	-0.3	1.31e-8	Height;
LUSC	cis	rs12618769	0.625	rs56240302	chr2:99148970	C/T	cg10123293	chr2:99228465	UNC50	0.47	7.76	0.39	1.04e-13	Bipolar disorder;
LUSC	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-12.08	-0.55	4.08e-28	Hemoglobin concentration;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14298577	chr7:100272703	GNB2	-0.53	-6.55	-0.34	2.23e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg07636037	chr3:49044803	WDR6	0.77	10.09	0.48	4.54e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg14507445	chr22:49886340	NA	-0.3	-5.82	-0.3	1.35e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	ch.11.42038R	chr11:967971	AP2A2	0.54	7.86	0.4	5.22e-14	Alzheimer's disease (late onset);
LUSC	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06544989	chr22:39130855	UNC84B	0.35	6.14	0.32	2.36e-9	Menopause (age at onset);
LUSC	cis	rs9283706	0.608	rs1428408	chr5:66331203	T/C	cg11590213	chr5:66331682	MAST4	0.47	7.13	0.36	6.3e-12	Coronary artery disease;
LUSC	trans	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg18187862	chr3:45730750	SACM1L	-0.51	-6.56	-0.34	2.09e-10	Primary sclerosing cholangitis;
LUSC	cis	rs9369695	0.883	rs9381581	chr6:47580695	G/A	cg12968598	chr6:47444699	CD2AP	0.53	8.1	0.41	1.06e-14	Reticulocyte count;
LUSC	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg10523679	chr1:76189770	ACADM	-0.48	-6.93	-0.35	2.15e-11	Daytime sleep phenotypes;
LUSC	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg06096015	chr1:231504339	EGLN1	0.55	9.74	0.47	6.87e-20	Hemoglobin concentration;
LUSC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg01802117	chr1:53393560	SCP2	-0.39	-6.45	-0.33	3.94e-10	Monocyte count;
LUSC	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg12081754	chr8:22256438	SLC39A14	0.78	12.45	0.56	1.66e-29	Verbal declarative memory;
LUSC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06544989	chr22:39130855	UNC84B	0.34	5.74	0.3	2.1e-8	Menopause (age at onset);
LUSC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08439880	chr3:133502540	NA	-0.35	-6.23	-0.32	1.42e-9	Iron status biomarkers;
LUSC	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.57	-0.34	1.89e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	0.58	9.25	0.45	2.71e-18	Breast cancer;
LUSC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg09021430	chr5:549028	NA	-0.53	-7.47	-0.38	7.23e-13	Lung disease severity in cystic fibrosis;
LUSC	trans	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg19694781	chr19:47549865	TMEM160	-0.4	-6.31	-0.33	8.84e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04867738	chr17:42298359	UBTF	-0.53	-6.43	-0.33	4.51e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17467752	chr17:38218738	THRA	-0.51	-7.2	-0.37	4.05e-12	White blood cell count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08127293	chr16:14379328	NA	-0.44	-6.5	-0.34	2.93e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg21285383	chr16:89894308	SPIRE2	0.32	6.62	0.34	1.45e-10	Vitiligo;
LUSC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.52	0.34	2.54e-10	Schizophrenia;
LUSC	cis	rs9400467	0.509	rs463853	chr6:111673211	C/G	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg19622623	chr12:86230825	RASSF9	0.4	5.78	0.3	1.72e-8	Major depressive disorder;
LUSC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg08470875	chr2:26401718	FAM59B	-0.64	-8.73	-0.43	1.2e-16	Gut microbiome composition (summer);
LUSC	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg10560079	chr2:191398806	TMEM194B	-0.73	-9.11	-0.45	7.89e-18	Diastolic blood pressure;
LUSC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs847577	0.609	rs705308	chr7:97695363	C/A	cg24562669	chr7:97807699	LMTK2	-0.48	-8.52	-0.42	5.53e-16	Breast cancer;
LUSC	cis	rs7192380	0.928	rs12933210	chr16:69742048	A/T	cg26679644	chr16:69762563	NA	-0.36	-6.24	-0.32	1.3e-9	Sjögren's syndrome;
LUSC	cis	rs7577696	0.785	rs12611678	chr2:32347785	G/A	cg02381751	chr2:32503542	YIPF4	-0.44	-6.23	-0.32	1.4e-9	Inflammatory biomarkers;
LUSC	cis	rs295140	0.967	rs4673906	chr2:201163812	G/T	cg04283868	chr2:201171347	SPATS2L	0.43	6.52	0.34	2.67e-10	QT interval;
LUSC	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg18478394	chr8:109455254	TTC35	0.42	6.53	0.34	2.38e-10	Dupuytren's disease;
LUSC	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg09904177	chr6:26538194	HMGN4	-0.75	-7.17	-0.37	4.8e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.74	-11.88	-0.55	2.11e-27	Lymphocyte percentage of white cells;
LUSC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg13683864	chr3:40499215	RPL14	0.95	17.12	0.68	1.34e-47	Renal cell carcinoma;
LUSC	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.6	-9.84	-0.47	3.03e-20	Body mass index;
LUSC	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.49	8.05	0.4	1.47e-14	Alcohol dependence;
LUSC	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg07959070	chr22:50026188	C22orf34	-0.36	-7.36	-0.37	1.46e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7614311	0.731	rs6445387	chr3:63962678	C/G	cg22134162	chr3:63841271	THOC7	-0.46	-5.82	-0.3	1.41e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg04310649	chr10:35416472	CREM	0.4	6.14	0.32	2.33e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg24110177	chr3:50126178	RBM5	0.39	6.23	0.32	1.41e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-7.9	-0.4	4.16e-14	Renal function-related traits (BUN);
LUSC	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg10327440	chr1:227177885	CDC42BPA	-0.62	-5.79	-0.3	1.59e-8	Major depressive disorder;
LUSC	cis	rs6547741	0.816	rs7560847	chr2:27882700	A/G	cg12559939	chr2:27858050	GPN1	-0.4	-6.25	-0.32	1.29e-9	Oral cavity cancer;
LUSC	cis	rs1107366	0.637	rs2044575	chr3:125976368	A/C	cg01346077	chr3:125931526	NA	0.34	6.37	0.33	6.24e-10	Metabolite levels;
LUSC	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg27411982	chr8:10470053	RP1L1	0.37	5.67	0.3	3.13e-8	Retinal vascular caliber;
LUSC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg02487422	chr3:49467188	NICN1	0.46	7.39	0.37	1.22e-12	Resting heart rate;
LUSC	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg25173405	chr17:45401733	C17orf57	-0.39	-6.22	-0.32	1.5e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.05e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg24375607	chr4:120327624	NA	0.76	11.3	0.53	2.66e-25	Corneal astigmatism;
LUSC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg10130564	chr11:117069849	TAGLN	0.37	6.41	0.33	4.88e-10	Blood protein levels;
LUSC	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs9549260	0.591	rs9577115	chr13:41276553	T/C	cg21288729	chr13:41239152	FOXO1	0.54	8.28	0.41	3.09e-15	Red blood cell count;
LUSC	cis	rs9815354	0.638	rs113496706	chr3:42028574	G/T	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg04545296	chr12:48745243	ZNF641	0.33	6.17	0.32	2e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs926938	0.563	rs360655	chr1:115447867	T/C	cg12756093	chr1:115239321	AMPD1	0.41	6.16	0.32	2.04e-9	Autism;
LUSC	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg05283184	chr6:79620031	NA	-0.57	-11.67	-0.54	1.22e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg13685833	chr1:53393034	SCP2	0.44	6.53	0.34	2.49e-10	Monocyte count;
LUSC	trans	rs7715474	0.707	rs1816980	chr5:120095414	C/A	cg16756389	chr13:21834314	NA	0.36	6.06	0.31	3.61e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	1.02	22.38	0.77	2.1e-68	Schizophrenia;
LUSC	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg10167463	chr7:75959203	YWHAG	-0.66	-10.07	-0.48	5.33e-21	Multiple sclerosis;
LUSC	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg12826209	chr6:26865740	GUSBL1	-0.68	-8.21	-0.41	4.83e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7707921	0.690	rs6870335	chr5:81590070	A/T	cg15871215	chr5:81402204	ATG10	-0.46	-7.18	-0.37	4.66e-12	Breast cancer;
LUSC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	7.21	0.37	3.81e-12	Personality dimensions;
LUSC	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg06636001	chr8:8085503	FLJ10661	0.53	7.88	0.4	4.76e-14	Mood instability;
LUSC	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg11473876	chr11:109292803	C11orf87	0.34	5.74	0.3	2.15e-8	Schizophrenia;
LUSC	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg13256891	chr4:100009986	ADH5	0.45	6.24	0.32	1.3e-9	Alcohol dependence;
LUSC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg02487422	chr3:49467188	NICN1	0.4	5.67	0.3	3.15e-8	Parkinson's disease;
LUSC	cis	rs8114671	0.967	rs6142324	chr20:33789043	C/T	cg07148914	chr20:33460835	GGT7	-0.44	-6.55	-0.34	2.12e-10	Height;
LUSC	cis	rs6545883	0.825	rs4672426	chr2:61457148	G/A	cg15711740	chr2:61764176	XPO1	0.44	6.83	0.35	4.04e-11	Tuberculosis;
LUSC	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg08000102	chr2:233561755	GIGYF2	0.74	11.02	0.52	2.65e-24	Schizophrenia;
LUSC	cis	rs679087	0.932	rs10843507	chr12:29931056	C/A	cg14258853	chr12:29935411	TMTC1	0.85	14.64	0.63	7.49e-38	Schizophrenia;
LUSC	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.36e-13	Type 2 diabetes;
LUSC	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.2	0.49	1.93e-21	Resting heart rate;
LUSC	cis	rs738321	0.756	rs12167576	chr22:38512562	G/A	cg25457927	chr22:38595422	NA	-0.33	-6.16	-0.32	2.04e-9	Breast cancer;
LUSC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	20.42	0.75	1.05e-60	Prudent dietary pattern;
LUSC	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.17	-0.32	1.96e-9	Response to antipsychotic treatment;
LUSC	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.97	-0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.72	12.68	0.57	2.46e-30	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.4	-0.38	1.1e-12	Breast cancer;
LUSC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg06238570	chr21:40685208	BRWD1	-0.63	-10.89	-0.51	8.06e-24	Cognitive function;
LUSC	cis	rs113835537	0.660	rs7116940	chr11:66303895	T/C	cg24851651	chr11:66362959	CCS	0.54	7.87	0.4	5.04e-14	Airway imaging phenotypes;
LUSC	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.77	-13.27	-0.59	1.4e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02475777	chr4:1388615	CRIPAK	0.62	9.24	0.45	3.02e-18	Longevity;
LUSC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg04369109	chr6:150039330	LATS1	-0.58	-8.44	-0.42	9.96e-16	Lung cancer;
LUSC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.47	-7.29	-0.37	2.27e-12	Alzheimer's disease (late onset);
LUSC	cis	rs11677416	1.000	rs6542091	chr2:113525311	G/A	cg27083787	chr2:113543245	IL1A	0.44	6.78	0.35	5.4e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs7799006	0.895	rs3757437	chr7:2271980	C/T	cg12823233	chr7:2316876	SNX8	-0.37	-6.32	-0.33	8.36e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21942256	chr3:156892528	NA	0.48	7.5	0.38	5.99e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10761482	0.906	rs991405	chr10:62094202	C/T	cg18175470	chr10:62150864	ANK3	0.49	7.13	0.36	6.24e-12	Schizophrenia;
LUSC	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg15557168	chr22:42548783	NA	-0.33	-5.72	-0.3	2.43e-8	Cognitive function;
LUSC	cis	rs909341	0.763	rs1291209	chr20:62330439	T/C	cg09650180	chr20:62225654	GMEB2	-0.44	-5.79	-0.3	1.63e-8	Atopic dermatitis;
LUSC	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg05527609	chr1:210001259	C1orf107	0.89	13.17	0.58	3.37e-32	Orofacial clefts;
LUSC	cis	rs968451	0.789	rs5757603	chr22:39677128	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	9.17	0.45	4.9e-18	Primary biliary cholangitis;
LUSC	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg25457927	chr22:38595422	NA	0.36	7.2	0.37	4.14e-12	Cutaneous nevi;
LUSC	cis	rs7833787	1.000	rs7844500	chr8:18703343	A/G	cg17701159	chr8:18705777	PSD3	-0.38	-6.17	-0.32	1.93e-9	Obesity-related traits;
LUSC	cis	rs12760731	0.641	rs12036834	chr1:178236583	G/A	cg00404053	chr1:178313656	RASAL2	0.63	6.65	0.34	1.19e-10	Obesity-related traits;
LUSC	cis	rs7336332	0.598	rs7669	chr13:28009851	C/T	cg22138327	chr13:27999177	GTF3A	0.87	9.66	0.47	1.2e-19	Weight;
LUSC	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg19230755	chr7:65878503	NA	-0.43	-5.93	-0.31	7.67e-9	Aortic root size;
LUSC	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.58	8.71	0.43	1.48e-16	Blood protein levels;
LUSC	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.5	-0.46	4.09e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3770081	1.000	rs60649958	chr2:86283000	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.84	-0.35	3.84e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.22	-0.32	1.48e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.18	-0.41	6.18e-15	Axial length;
LUSC	cis	rs16912285	0.892	rs80332091	chr11:24255248	T/A	ch.11.24196551F	chr11:24239977	NA	0.72	6.09	0.32	3.05e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs981844	1.000	rs2251997	chr4:154654067	A/G	cg14289246	chr4:154710475	SFRP2	-0.48	-6.25	-0.32	1.22e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg25208724	chr1:156163844	SLC25A44	1.02	20.47	0.75	6.66e-61	Testicular germ cell tumor;
LUSC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg14668632	chr7:2872130	GNA12	-0.49	-7.31	-0.37	2e-12	Height;
LUSC	cis	rs75920871	0.528	rs4388921	chr11:116976778	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.46	-0.33	3.6e-10	Subjective well-being;
LUSC	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.26	-0.37	2.66e-12	Bipolar disorder;
LUSC	cis	rs10392	0.543	rs3752290	chr20:37555116	G/C	cg27552599	chr20:37590471	DHX35	0.45	7.37	0.37	1.31e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24377330	chr3:149375961	WWTR1	0.47	7.01	0.36	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9650315	0.866	rs3924847	chr8:57197009	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	7.13	0.36	6.25e-12	Height;
LUSC	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-0.46	-7.49	-0.38	6.38e-13	Uric acid clearance;
LUSC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg25767906	chr1:53392781	SCP2	0.43	7.72	0.39	1.4e-13	Monocyte count;
LUSC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg22681709	chr2:178499509	PDE11A	-0.6	-12.1	-0.55	3.39e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg06521331	chr12:34319734	NA	0.38	6.11	0.32	2.77e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs968451	0.951	rs5750789	chr22:39725280	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	8.63	0.43	2.62e-16	Primary biliary cholangitis;
LUSC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg06784218	chr1:46089804	CCDC17	0.47	9.26	0.45	2.6e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18854424	chr1:2615690	NA	0.52	10.81	0.51	1.52e-23	Ulcerative colitis;
LUSC	cis	rs977987	0.806	rs11865004	chr16:75395777	C/T	cg03315344	chr16:75512273	CHST6	0.48	9.2	0.45	4.05e-18	Dupuytren's disease;
LUSC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	cis	rs73206853	0.841	rs73206847	chr12:110672353	G/A	cg12870014	chr12:110450643	ANKRD13A	0.66	6.45	0.33	3.99e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs926938	0.584	rs6689326	chr1:115369112	T/A	cg12756093	chr1:115239321	AMPD1	-0.53	-8.07	-0.4	1.31e-14	Autism;
LUSC	cis	rs10045504	0.502	rs17456482	chr5:38737783	G/C	cg15396434	chr5:38725168	NA	-0.51	-5.65	-0.3	3.39e-8	Night sleep phenotypes;
LUSC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06481639	chr22:41940642	POLR3H	0.5	5.77	0.3	1.81e-8	Vitiligo;
LUSC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-6.11	-0.32	2.74e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7923609	1.000	rs10822161	chr10:65118203	G/A	cg01631684	chr10:65280961	REEP3	-0.39	-6.11	-0.32	2.83e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	11.36	0.53	1.64e-25	Colorectal cancer;
LUSC	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg19920283	chr7:105172520	RINT1	0.58	6.21	0.32	1.61e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.82	0.57	7.03e-31	Chronic sinus infection;
LUSC	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg17757837	chr7:157058334	UBE3C	0.83	13.22	0.59	2.23e-32	Body mass index;
LUSC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07677032	chr17:61819896	STRADA	0.53	8.99	0.44	1.89e-17	Prudent dietary pattern;
LUSC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.91	16.29	0.67	2.61e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg12667521	chr19:29218732	NA	0.51	6.19	0.32	1.73e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg00343986	chr7:65444356	GUSB	-0.43	-6.55	-0.34	2.17e-10	Aortic root size;
LUSC	cis	rs977987	0.806	rs12924920	chr16:75440133	G/A	cg03315344	chr16:75512273	CHST6	0.48	8.94	0.44	2.8e-17	Dupuytren's disease;
LUSC	trans	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg10840412	chr1:235813424	GNG4	0.51	6.21	0.32	1.54e-9	Neuroticism;
LUSC	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg00083937	chr22:51039805	MAPK8IP2	0.52	9.04	0.44	1.31e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg23791538	chr6:167370224	RNASET2	-0.39	-6.27	-0.32	1.09e-9	Crohn's disease;
LUSC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg13047869	chr3:10149882	C3orf24	0.57	7.9	0.4	4.11e-14	Alzheimer's disease;
LUSC	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-8.46	-0.42	8.53e-16	Menopause (age at onset);
LUSC	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg05347473	chr6:146136440	FBXO30	0.54	9.16	0.45	5.44e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9323205	0.677	rs113612692	chr14:51709461	C/A	cg23942311	chr14:51606299	NA	-0.44	-8.41	-0.42	1.22e-15	Cancer;
LUSC	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg00750074	chr16:89608354	SPG7	-0.57	-10.34	-0.49	6.46e-22	Multiple myeloma (IgH translocation);
LUSC	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg08999081	chr20:33150536	PIGU	0.39	7.07	0.36	8.94e-12	Height;
LUSC	cis	rs7804356	1.000	rs3801814	chr7:26881302	T/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.12	-0.32	2.58e-9	Type 1 diabetes;
LUSC	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg15997130	chr1:24165203	NA	0.52	8.58	0.42	3.67e-16	Immature fraction of reticulocytes;
LUSC	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.31	-0.41	2.43e-15	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg24881330	chr22:46731750	TRMU	0.81	6.7	0.34	8.97e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9650315	0.929	rs7840181	chr8:57168032	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.12	0.36	6.82e-12	Height;
LUSC	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.48	-6.67	-0.34	1.04e-10	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg08773314	chr2:239334832	ASB1	0.43	9.26	0.45	2.59e-18	Multiple system atrophy;
LUSC	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg22705602	chr4:152727874	NA	-0.32	-6.31	-0.33	8.76e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2692947	0.644	rs2969491	chr2:96794982	C/T	cg23100626	chr2:96804247	ASTL	0.3	7.17	0.37	4.93e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs789859	1.000	rs789862	chr3:194404522	C/T	cg02072170	chr3:194406190	FAM43A	-0.35	-7.53	-0.38	4.68e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg04455712	chr21:45112962	RRP1B	0.45	8.24	0.41	4.1e-15	Mean corpuscular volume;
LUSC	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg11189052	chr15:85197271	WDR73	0.49	5.98	0.31	5.78e-9	Schizophrenia;
LUSC	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.69	12.12	0.55	2.86e-28	White blood cell count (basophil);
LUSC	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.66	16.69	0.67	6.79e-46	Anterior chamber depth;
LUSC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-7.03	-0.36	1.13e-11	Blood metabolite levels;
LUSC	cis	rs1950626	0.833	rs1951025	chr14:101406022	T/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.46	0.38	7.73e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs554111	0.613	rs10753510	chr1:21412248	G/A	cg01072550	chr1:21505969	NA	0.38	5.8	0.3	1.57e-8	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs6540559	0.673	rs7511996	chr1:210018473	C/A	cg21951975	chr1:209979733	IRF6	0.55	6.88	0.35	2.95e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg05585544	chr11:47624801	NA	-0.42	-7.26	-0.37	2.71e-12	Subjective well-being;
LUSC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00149659	chr3:10157352	C3orf10	0.92	11.72	0.54	8.44e-27	Alzheimer's disease;
LUSC	trans	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.32	0.41	2.28e-15	Resting heart rate;
LUSC	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg04036182	chr15:45458818	NA	0.34	5.69	0.3	2.78e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs34734847	1.000	rs55730005	chr12:121157536	C/A	cg21892295	chr12:121157589	UNC119B	-0.52	-9.54	-0.46	3.07e-19	Mean corpuscular volume;
LUSC	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.72	0.35	8.08e-11	Corneal astigmatism;
LUSC	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg24375607	chr4:120327624	NA	0.67	10.33	0.49	7e-22	Corneal astigmatism;
LUSC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg21724239	chr8:58056113	NA	0.56	6.52	0.34	2.52e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1044826	1.000	rs9289577	chr3:139200327	C/G	cg00490450	chr3:139108681	COPB2	0.51	6.74	0.35	6.96e-11	Obesity-related traits;
LUSC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg26335602	chr6:28129616	ZNF389	0.46	6.5	0.34	2.9e-10	Parkinson's disease;
LUSC	cis	rs6076065	0.962	rs2424529	chr20:23369317	A/G	cg11657817	chr20:23433608	CST11	0.43	8.68	0.43	1.79e-16	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg17279839	chr7:150038598	RARRES2	0.55	8.18	0.41	6.01e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg25039879	chr17:56429692	SUPT4H1	0.71	9.47	0.46	5.43e-19	Cognitive test performance;
LUSC	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg27471124	chr11:109292789	C11orf87	0.41	7.09	0.36	8.05e-12	Schizophrenia;
LUSC	cis	rs701145	0.585	rs1527799	chr3:153811226	A/G	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg02018176	chr4:1364513	KIAA1530	0.44	6.11	0.32	2.78e-9	Recombination rate (females);
LUSC	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg23625390	chr15:77176239	SCAPER	-0.65	-9.66	-0.47	1.29e-19	Blood metabolite levels;
LUSC	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg03264133	chr6:25882463	NA	-0.34	-5.69	-0.3	2.8e-8	Height;
LUSC	trans	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.66	-0.34	1.13e-10	Neuroticism;
LUSC	cis	rs77633900	0.772	rs284897	chr15:76750722	T/C	cg21673338	chr15:77095150	SCAPER	-0.7	-6.1	-0.32	2.9e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.83	-0.57	6.66e-31	Chronic sinus infection;
LUSC	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg27284194	chr4:1044797	NA	0.48	7.65	0.39	2.21e-13	Recombination rate (males);
LUSC	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg24069376	chr3:38537580	EXOG	0.41	8.01	0.4	1.95e-14	Electrocardiographic conduction measures;
LUSC	cis	rs748404	0.697	rs513970	chr15:43579566	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.43	6.02	0.31	4.66e-9	Lung cancer;
LUSC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	12.43	0.56	2.1e-29	Personality dimensions;
LUSC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.28e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.4	-0.33	5.3e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg10756647	chr7:56101905	PSPH	-0.87	-8.68	-0.43	1.74e-16	Diabetic kidney disease;
LUSC	cis	rs9359856	0.636	rs6454767	chr6:90317335	G/A	cg13799429	chr6:90582589	CASP8AP2	0.76	8.14	0.41	8.07e-15	Bipolar disorder;
LUSC	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg01528321	chr10:82214614	TSPAN14	0.78	11.84	0.54	2.94e-27	Post bronchodilator FEV1;
LUSC	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg06742321	chr12:123595122	PITPNM2	0.39	5.74	0.3	2.17e-8	Platelet count;
LUSC	cis	rs56283067	0.578	rs1321078	chr6:45368214	G/T	cg18551225	chr6:44695536	NA	-0.43	-6.41	-0.33	4.92e-10	Total body bone mineral density;
LUSC	cis	rs4363385	0.747	rs2225919	chr1:152969603	A/G	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.59	-0.38	3.32e-13	Inflammatory skin disease;
LUSC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-0.89	-12.81	-0.57	7.52e-31	Initial pursuit acceleration;
LUSC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.78	-0.47	4.81e-20	Migraine;Coronary artery disease;
LUSC	trans	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.97	-0.31	6.18e-9	Dementia with Lewy bodies;
LUSC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	1.04	20.17	0.74	1.03e-59	Menopause (age at onset);
LUSC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.88	15.53	0.65	2.59e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg04117972	chr1:227635322	NA	0.76	7.27	0.37	2.65e-12	Major depressive disorder;
LUSC	trans	rs12210905	1.000	rs72843629	chr6:27175215	G/T	cg11837749	chr1:55047332	ACOT11	0.57	6.08	0.32	3.31e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg13010199	chr12:38710504	ALG10B	0.56	8.56	0.42	4.16e-16	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.69	-0.57	2.24e-30	Platelet count;
LUSC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-14.21	-0.61	3.52e-36	Hemoglobin concentration;
LUSC	cis	rs68170813	0.559	rs79564258	chr7:107059803	C/A	cg02696742	chr7:106810147	HBP1	-0.64	-9.11	-0.45	8.03e-18	Coronary artery disease;
LUSC	cis	rs9359856	0.913	rs9362663	chr6:90307550	A/C	cg13799429	chr6:90582589	CASP8AP2	0.55	6.41	0.33	4.94e-10	Bipolar disorder;
LUSC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg01802117	chr1:53393560	SCP2	0.38	6.18	0.32	1.82e-9	Monocyte count;
LUSC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg15105969	chr2:36825350	FEZ2	0.58	8.72	0.43	1.33e-16	Height;
LUSC	cis	rs9807841	0.568	rs3859514	chr19:10748820	T/C	cg17710535	chr19:10819994	QTRT1	0.4	6.59	0.34	1.69e-10	Inflammatory skin disease;
LUSC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg06885757	chr1:42089581	HIVEP3	0.5	10.17	0.49	2.41e-21	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg05527609	chr1:210001259	C1orf107	0.9	11.74	0.54	6.9e-27	Orofacial clefts;
LUSC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	12.77	0.57	1.09e-30	Cognitive test performance;
LUSC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.09	0.52	1.58e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg24375607	chr4:120327624	NA	0.81	12.0	0.55	8.02e-28	Corneal astigmatism;
LUSC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg14895029	chr7:2775587	GNA12	-0.37	-5.91	-0.31	8.27e-9	Height;
LUSC	cis	rs3784262	1.000	rs7165247	chr15:58251786	C/T	cg12031962	chr15:58353849	ALDH1A2	0.33	6.15	0.32	2.16e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs72781680	0.716	rs7564732	chr2:24034178	C/T	cg08917208	chr2:24149416	ATAD2B	0.59	6.78	0.35	5.32e-11	Lymphocyte counts;
LUSC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg06671706	chr8:8559999	CLDN23	0.48	6.58	0.34	1.84e-10	Obesity-related traits;
LUSC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.94	0.36	2.04e-11	Tonsillectomy;
LUSC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.67	11.39	0.53	1.33e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4240897	0.935	rs1474868	chr1:12044164	A/G	cg13216073	chr1:12042593	MFN2	-0.38	-6.67	-0.34	1.05e-10	Tuberculosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07458712	chr4:1769731	NA	0.48	7.21	0.37	3.8e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs2262909	0.924	rs11085509	chr19:22204573	T/C	cg17074339	chr11:11642133	GALNTL4	-0.41	-6.2	-0.32	1.68e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs478607	0.915	rs521793	chr11:64482947	G/C	cg19131476	chr11:64387923	NRXN2	-0.31	-5.68	-0.3	2.9e-8	Urate levels;
LUSC	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg05887092	chr17:76393375	PGS1	0.51	9.05	0.44	1.2e-17	HDL cholesterol levels;
LUSC	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg26395211	chr5:140044315	WDR55	-0.38	-5.74	-0.3	2.14e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10635789	chr4:668276	ATP5I	-0.4	-6.03	-0.31	4.36e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4853525	0.859	rs1894775	chr2:191716706	T/C	cg11845111	chr2:191398756	TMEM194B	-0.42	-6.18	-0.32	1.91e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg08345082	chr10:99160200	RRP12	-0.35	-7.18	-0.37	4.61e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4919087	0.923	rs12357266	chr10:98978045	G/A	cg25902810	chr10:99078978	FRAT1	0.51	7.28	0.37	2.48e-12	Monocyte count;
LUSC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg03526776	chr6:41159608	TREML2	0.33	6.19	0.32	1.74e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg13010199	chr12:38710504	ALG10B	0.45	6.4	0.33	5.12e-10	Morning vs. evening chronotype;
LUSC	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.16e-10	Subjective well-being;
LUSC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-6.74	-0.35	6.76e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg11019008	chr10:131425282	MGMT	0.4	5.79	0.3	1.66e-8	Response to temozolomide;
LUSC	trans	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.81e-10	Life satisfaction;
LUSC	cis	rs1359582	0.736	rs1980813	chr10:90354888	A/T	cg15661332	chr10:90342814	RNLS	-0.47	-5.78	-0.3	1.75e-8	Depressive and manic episodes in bipolar disorder;
LUSC	cis	rs7808935	0.628	rs72598552	chr7:27939961	G/A	cg22168087	chr7:27702803	HIBADH	0.7	8.29	0.41	2.84e-15	Prostate cancer;
LUSC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg08470875	chr2:26401718	FAM59B	-0.69	-9.18	-0.45	4.5e-18	Gut microbiome composition (summer);
LUSC	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.59	-0.43	3.31e-16	Response to antipsychotic treatment;
LUSC	cis	rs2932538	0.883	rs6696991	chr1:113095661	C/T	cg22162597	chr1:113214053	CAPZA1	0.55	7.89	0.4	4.48e-14	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg26695010	chr11:65641043	EFEMP2	-0.46	-7.0	-0.36	1.37e-11	Eosinophil percentage of white cells;
LUSC	cis	rs7577696	0.539	rs13010405	chr2:32338204	A/T	cg02381751	chr2:32503542	YIPF4	-0.5	-6.73	-0.35	7.48e-11	Inflammatory biomarkers;
LUSC	trans	rs2392780	0.536	rs430693	chr8:128338594	G/T	cg10897648	chr18:56338258	MALT1	-0.42	-6.35	-0.33	6.95e-10	Breast cancer (early onset);
LUSC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	8.16	0.41	7.05e-15	Bipolar disorder;
LUSC	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg16359550	chr11:109292809	C11orf87	-0.48	-8.27	-0.41	3.26e-15	Schizophrenia;
LUSC	cis	rs16895831	0.519	rs16895863	chr6:42571346	A/T	cg10605015	chr6:42532144	UBR2	-0.47	-5.8	-0.3	1.56e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Neutrophil count;Sum basophil neutrophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg11645453	chr3:52864694	ITIH4	-0.56	-13.23	-0.59	2.09e-32	Schizophrenia;
LUSC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-0.92	-13.6	-0.6	7.64e-34	Initial pursuit acceleration;
LUSC	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20307385	chr11:47447363	PSMC3	-0.44	-5.82	-0.3	1.36e-8	Subjective well-being;
LUSC	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg09796270	chr17:17721594	SREBF1	-0.43	-7.64	-0.39	2.25e-13	Total body bone mineral density;
LUSC	cis	rs7119167	0.851	rs3741148	chr11:73114723	A/G	cg17517138	chr11:73019481	ARHGEF17	0.53	6.19	0.32	1.81e-9	Blood protein levels;
LUSC	trans	rs41433250	1	rs41433250	chr13:31495835	A/G	cg06944693	chr11:130299298	ADAMTS8	-0.57	-6.21	-0.32	1.54e-9	Influenza A (H1N1) infection;Mild influenza (H1N1) infection;
LUSC	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg22732515	chr19:44031385	ETHE1	0.62	10.32	0.49	7.17e-22	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg02569458	chr12:86230093	RASSF9	0.52	8.57	0.42	3.81e-16	Major depressive disorder;
LUSC	cis	rs4285028	0.747	rs58367397	chr3:121451700	A/G	cg11130432	chr3:121712080	ILDR1	-0.53	-7.76	-0.39	1.02e-13	Multiple sclerosis;
LUSC	cis	rs870825	0.616	rs57316663	chr4:185630011	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.05	0.58	9.8e-32	Blood protein levels;
LUSC	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.46	-8.31	-0.41	2.51e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18876405	chr7:65276391	NA	0.49	6.68	0.34	9.84e-11	Corneal structure;
LUSC	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-7.41	-0.38	1.06e-12	Schizophrenia;
LUSC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg18306943	chr3:40428807	ENTPD3	0.36	5.82	0.3	1.42e-8	Renal cell carcinoma;
LUSC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.65	-0.34	1.21e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg12863693	chr15:85201151	NMB	0.34	6.81	0.35	4.58e-11	Schizophrenia;
LUSC	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.79	-0.3	1.67e-8	Bipolar disorder;
LUSC	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg21827317	chr3:136751795	NA	0.39	7.09	0.36	8.25e-12	Neuroticism;
LUSC	cis	rs9372498	0.536	rs62422236	chr6:118972633	G/T	cg18833306	chr6:118973337	C6orf204	-0.46	-5.85	-0.3	1.2e-8	Diastolic blood pressure;
LUSC	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg00898013	chr13:113819073	PROZ	-0.56	-8.11	-0.41	1.01e-14	Platelet distribution width;
LUSC	cis	rs12530845	1.000	rs60179239	chr7:135333028	A/G	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg27532560	chr4:187881888	NA	-0.43	-7.05	-0.36	1.05e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.53	-0.5	1.46e-22	Coffee consumption (cups per day);
LUSC	cis	rs7212590	0.748	rs73315252	chr17:57854855	A/G	cg10252138	chr17:58120427	NA	-0.73	-6.91	-0.35	2.44e-11	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	14.52	0.62	2.32e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs62400317	0.859	rs56337964	chr6:45039786	G/A	cg20913747	chr6:44695427	NA	-0.46	-7.43	-0.38	9.41e-13	Total body bone mineral density;
LUSC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg08847533	chr14:75593920	NEK9	0.85	16.03	0.66	2.81e-43	Height;
LUSC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg23262073	chr20:60523788	NA	-0.39	-6.11	-0.32	2.72e-9	Body mass index;
LUSC	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg02258303	chr16:87377426	FBXO31	-0.55	-9.44	-0.46	6.81e-19	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs4764124	0.646	rs10744078	chr12:14978535	T/G	cg19759883	chr12:14956454	WBP11;C12orf60	-0.37	-5.73	-0.3	2.3e-8	Pubertal anthropometrics;
LUSC	cis	rs9549260	0.564	rs9646110	chr13:41308301	A/T	cg21288729	chr13:41239152	FOXO1	-0.52	-7.88	-0.4	4.77e-14	Red blood cell count;
LUSC	cis	rs4363385	1.000	rs4363385	chr1:152989321	A/G	cg00922841	chr1:152955080	SPRR1A	-0.47	-7.88	-0.4	4.64e-14	Inflammatory skin disease;
LUSC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04565464	chr8:145669602	NFKBIL2	0.37	6.14	0.32	2.38e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs72674100	0.867	rs7656650	chr4:97964570	A/G	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg11247378	chr22:39784982	NA	0.57	9.97	0.48	1.19e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg02775129	chr4:119771670	NA	0.93	7.34	0.37	1.66e-12	Cannabis dependence symptom count;
LUSC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg16680214	chr1:154839983	KCNN3	0.41	7.14	0.36	5.99e-12	Prostate cancer;
LUSC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.72	-11.61	-0.54	2.12e-26	Body mass index;
LUSC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg04398451	chr17:18023971	MYO15A	0.57	9.53	0.46	3.41e-19	Total body bone mineral density;
LUSC	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg15556689	chr8:8085844	FLJ10661	0.55	8.46	0.42	8.4e-16	Retinal vascular caliber;
LUSC	cis	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg06521331	chr12:34319734	NA	-0.39	-5.81	-0.3	1.43e-8	Resting heart rate;
LUSC	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg00757033	chr12:89920650	WDR51B	0.59	10.19	0.49	2.14e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg24579218	chr15:68104479	NA	-0.38	-6.59	-0.34	1.69e-10	Obesity;
LUSC	cis	rs4845459	0.967	rs4845452	chr1:152591647	A/G	cg08895932	chr1:152778580	LCE1C	-0.37	-6.39	-0.33	5.71e-10	Psoriasis;
LUSC	cis	rs9653442	0.564	rs12712071	chr2:100793876	G/A	cg22139774	chr2:100720529	AFF3	-0.42	-7.28	-0.37	2.47e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.77	0.51	2.01e-23	Morning vs. evening chronotype;
LUSC	cis	rs6725041	0.547	rs61696052	chr2:213201295	G/C	cg16329650	chr2:213403929	ERBB4	-0.42	-6.67	-0.34	1.06e-10	QT interval (ambient particulate matter interaction);
LUSC	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg07148914	chr20:33460835	GGT7	0.54	8.21	0.41	4.99e-15	Height;
LUSC	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg24375607	chr4:120327624	NA	0.77	12.51	0.56	1.08e-29	Corneal astigmatism;
LUSC	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg06784218	chr1:46089804	CCDC17	0.34	6.08	0.32	3.27e-9	Platelet count;
LUSC	cis	rs73416724	1.000	rs17209400	chr6:43328062	A/G	cg26312998	chr6:43337775	ZNF318	0.57	6.66	0.34	1.16e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.29e-31	Prudent dietary pattern;
LUSC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.78	-0.51	1.83e-23	Chronic sinus infection;
LUSC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg12257692	chr3:49977190	RBM6	-0.25	-6.87	-0.35	3.08e-11	Body mass index;
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg01238044	chr22:24384105	GSTT1	-0.52	-7.59	-0.38	3.15e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs3744061	0.520	rs4322697	chr17:74648642	C/T	cg27546012	chr17:74684504	MXRA7	-0.38	-6.73	-0.35	7.23e-11	Retinal arteriolar caliber;
LUSC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.54	-7.69	-0.39	1.71e-13	Cognitive ability;
LUSC	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.44	6.46	0.33	3.75e-10	Height;
LUSC	cis	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg21775007	chr8:11205619	TDH	-0.49	-6.65	-0.34	1.22e-10	Morning vs. evening chronotype;
LUSC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg08847533	chr14:75593920	NEK9	0.84	15.6	0.65	1.29e-41	Height;
LUSC	cis	rs977987	0.815	rs1364078	chr16:75396881	T/C	cg03315344	chr16:75512273	CHST6	0.53	10.37	0.49	5.15e-22	Dupuytren's disease;
LUSC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6906287	0.647	rs7746778	chr6:118725871	C/A	cg21191810	chr6:118973309	C6orf204	0.33	6.05	0.31	3.93e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg16049864	chr8:95962084	TP53INP1	0.5	9.15	0.45	5.59e-18	Type 2 diabetes;
LUSC	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg04036182	chr15:45458818	NA	0.36	5.89	0.31	9.21e-9	Glomerular filtration rate;
LUSC	cis	rs7246657	0.678	rs2927740	chr19:38140966	A/G	cg23950597	chr19:37808831	NA	0.49	5.81	0.3	1.47e-8	Coronary artery calcification;
LUSC	cis	rs1044826	0.642	rs186103	chr3:139211942	C/A	cg00490450	chr3:139108681	COPB2	0.46	6.96	0.36	1.82e-11	Obesity-related traits;
LUSC	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg02569458	chr12:86230093	RASSF9	0.43	6.72	0.34	8e-11	Major depressive disorder;
LUSC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg13683864	chr3:40499215	RPL14	-0.98	-16.53	-0.67	2.78e-45	Renal cell carcinoma;
LUSC	cis	rs9653442	0.593	rs7597861	chr2:100853187	G/A	cg07810366	chr2:100720526	AFF3	-0.39	-6.37	-0.33	6.41e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg14440974	chr22:39074834	NA	-0.36	-5.98	-0.31	5.74e-9	Menopause (age at onset);
LUSC	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg11812906	chr14:75593930	NEK9	-0.58	-9.54	-0.46	3.13e-19	Height;
LUSC	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.78	11.26	0.52	3.88e-25	Corneal astigmatism;
LUSC	trans	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg17712092	chr4:129076599	LARP1B	-0.7	-9.81	-0.47	4.1e-20	Breast cancer;
LUSC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06634786	chr22:41940651	POLR3H	0.53	6.05	0.31	3.94e-9	Vitiligo;
LUSC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.34	0.53	1.97e-25	Prudent dietary pattern;
LUSC	cis	rs12928939	0.911	rs12919271	chr16:71792696	C/A	cg03805757	chr16:71968109	PKD1L3	-0.43	-6.29	-0.33	1.01e-9	Post bronchodilator FEV1;
LUSC	cis	rs7605827	0.930	rs2890487	chr2:15594938	A/G	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.26e-17	Educational attainment (years of education);
LUSC	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg11846333	chr4:119757529	SEC24D	-0.96	-6.85	-0.35	3.55e-11	Cannabis dependence symptom count;
LUSC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg02782426	chr3:40428986	ENTPD3	-0.42	-7.81	-0.39	7.49e-14	Renal cell carcinoma;
LUSC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.09	-0.32	3.07e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg20243544	chr17:37824526	PNMT	0.48	6.79	0.35	5.08e-11	Asthma;
LUSC	trans	rs6600671	0.934	rs12131379	chr1:121293437	T/C	cg00646200	chr1:148855367	NA	0.47	7.35	0.37	1.58e-12	Hip geometry;
LUSC	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-9.84	-0.47	3.12e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg17691542	chr6:26056736	HIST1H1C	0.46	6.95	0.36	1.95e-11	Height;
LUSC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	8.82	0.43	6.5e-17	Prudent dietary pattern;
LUSC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.82	0.39	7.02e-14	Prudent dietary pattern;
LUSC	cis	rs62400317	0.723	rs1329709	chr6:44974956	G/T	cg20913747	chr6:44695427	NA	-0.46	-7.23	-0.37	3.41e-12	Total body bone mineral density;
LUSC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-6.18	-0.32	1.82e-9	Total body bone mineral density;
LUSC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg04414720	chr1:150670196	GOLPH3L	0.53	8.33	0.41	2.16e-15	Melanoma;
LUSC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg13397359	chr6:42928475	GNMT	-0.55	-9.39	-0.46	9.7e-19	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.15	-0.36	5.65e-12	Body mass index;
LUSC	cis	rs35995292	0.534	rs2392607	chr7:38930380	G/A	cg19327137	chr7:38886074	VPS41	0.55	10.38	0.49	4.47e-22	Subjective well-being (multi-trait analysis);
LUSC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg25036284	chr2:26402008	FAM59B	-0.67	-9.29	-0.45	2.09e-18	Gut microbiome composition (summer);
LUSC	cis	rs926938	0.584	rs360607	chr1:115392401	C/A	cg12756093	chr1:115239321	AMPD1	0.46	7.05	0.36	1.01e-11	Autism;
LUSC	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg03929089	chr4:120376271	NA	0.82	11.14	0.52	9.93e-25	Coronary artery disease;
LUSC	trans	rs28647808	0.881	rs7029386	chr9:136263736	T/C	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs5744897	1.000	rs5744897	chr12:133226831	C/T	cg26621607	chr12:133180238	NA	0.43	5.72	0.3	2.37e-8	Urate levels in overweight individuals;
LUSC	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg02023728	chr11:77925099	USP35	0.46	6.78	0.35	5.58e-11	Testicular germ cell tumor;
LUSC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.61	8.11	0.41	9.99e-15	High light scatter reticulocyte count;
LUSC	cis	rs55665837	1.000	rs10832269	chr11:14465069	C/A	cg05501817	chr11:14380813	RRAS2	-0.4	-6.54	-0.34	2.3e-10	Vitamin D levels;
LUSC	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg02466173	chr16:30829666	NA	-0.49	-9.55	-0.46	2.86e-19	Dementia with Lewy bodies;
LUSC	cis	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg06521331	chr12:34319734	NA	-0.37	-6.07	-0.32	3.51e-9	Morning vs. evening chronotype;
LUSC	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg27661571	chr11:113659931	NA	-0.73	-8.05	-0.4	1.47e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg11632617	chr15:75315747	PPCDC	-0.55	-7.1	-0.36	7.61e-12	Blood trace element (Zn levels);
LUSC	cis	rs2109514	1.000	rs4727833	chr7:116147908	C/G	cg12739419	chr7:116140593	CAV2	-0.29	-6.54	-0.34	2.33e-10	Prevalent atrial fibrillation;
LUSC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.94	0.55	1.28e-27	Prudent dietary pattern;
LUSC	cis	rs7188861	0.813	rs34787601	chr16:11399538	T/A	cg00044050	chr16:11439710	C16orf75	0.51	5.83	0.3	1.32e-8	HDL cholesterol;
LUSC	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.93	-0.35	2.15e-11	Bipolar disorder;
LUSC	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg06092702	chr1:163392909	NA	-0.45	-7.42	-0.38	9.62e-13	Motion sickness;
LUSC	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg23029597	chr12:123009494	RSRC2	0.75	9.51	0.46	3.94e-19	Body mass index;
LUSC	cis	rs367615	0.552	rs7720036	chr5:108710699	A/G	cg17395555	chr5:108820864	NA	-0.52	-9.03	-0.44	1.43e-17	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.61	0.62	1.05e-37	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4129585	0.928	rs13262595	chr8:143316970	A/G	cg16886403	chr8:143471632	TSNARE1	0.43	6.15	0.32	2.16e-9	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7119	0.651	rs35657172	chr15:77847813	T/C	cg27398640	chr15:77910606	LINGO1	-0.33	-7.04	-0.36	1.12e-11	Type 2 diabetes;
LUSC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg07703079	chr11:430292	ANO9	0.6	6.51	0.34	2.79e-10	Body mass index;
LUSC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.17	-0.32	2.02e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7538876	0.903	rs6681150	chr1:17750685	G/A	cg07965774	chr1:17746286	RCC2	0.32	6.05	0.31	3.94e-9	Basal cell carcinoma;
LUSC	cis	rs12220238	1.000	rs10824114	chr10:75970503	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.22	0.37	3.42e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg21770322	chr7:97807741	LMTK2	-0.49	-7.97	-0.4	2.58e-14	Breast cancer;
LUSC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg22549504	chr19:17448937	GTPBP3	0.53	6.91	0.35	2.41e-11	Systemic lupus erythematosus;
LUSC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.63	8.75	0.43	1.07e-16	Menarche (age at onset);
LUSC	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg27432699	chr2:27873401	GPN1	-0.81	-15.22	-0.64	4.05e-40	Oral cavity cancer;
LUSC	cis	rs1832871	0.683	rs11752399	chr6:158711188	G/A	cg07165851	chr6:158734300	TULP4	0.5	7.66	0.39	2.05e-13	Height;
LUSC	cis	rs3931020	0.688	rs525487	chr1:75217420	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	-0.48	-6.0	-0.31	5.12e-9	Resistin levels;
LUSC	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg23277830	chr1:3704460	LRRC47	0.32	6.05	0.31	3.97e-9	Red cell distribution width;
LUSC	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs400736	0.930	rs370812	chr1:8075894	C/T	cg25007680	chr1:8021821	PARK7	0.57	9.11	0.45	7.79e-18	Response to antidepressants and depression;
LUSC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.78	0.6	1.56e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs7011049	0.908	rs72640860	chr8:53840500	G/A	cg26025543	chr8:53854495	NA	0.52	6.3	0.33	9.5e-10	Systolic blood pressure;
LUSC	cis	rs12291225	0.839	rs4757244	chr11:14258655	A/G	cg05501817	chr11:14380813	RRAS2	0.42	6.3	0.33	9.17e-10	Sense of smell;
LUSC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16405210	chr4:1374714	KIAA1530	-0.6	-9.23	-0.45	3.25e-18	Longevity;
LUSC	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg26384229	chr12:38710491	ALG10B	-0.56	-8.46	-0.42	8.29e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg23093090	chr10:104574429	C10orf26	-0.44	-7.85	-0.39	5.76e-14	Arsenic metabolism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13512204	chr9:78506874	PCSK5	0.41	6.29	0.33	9.93e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.44	0.33	4.14e-10	Lung cancer;
LUSC	cis	rs73198271	0.531	rs3748142	chr8:8655355	G/A	cg01851573	chr8:8652454	MFHAS1	0.71	9.08	0.44	9.6e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22433210	chr17:43662623	NA	0.75	10.84	0.51	1.13e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs12220238	0.818	rs10824082	chr10:75904080	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.6	7.01	0.36	1.29e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs3803170	0.513	rs4766572	chr12:111830765	G/A	cg10833066	chr12:111807467	FAM109A	0.38	7.17	0.37	4.88e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg24631222	chr15:78858424	CHRNA5	0.61	8.69	0.43	1.6e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2274459	0.841	rs12203688	chr6:33693624	G/T	cg06253072	chr6:33679850	C6orf125	-0.49	-5.92	-0.31	7.84e-9	Obesity (extreme);
LUSC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg12311346	chr5:56204834	C5orf35	-0.58	-8.88	-0.44	4.06e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg05340658	chr4:99064831	C4orf37	0.57	9.48	0.46	4.88e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3925075	0.966	rs7195915	chr16:31344455	A/G	cg02846316	chr16:31340340	ITGAM	0.35	6.53	0.34	2.48e-10	IgA nephropathy;
LUSC	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg03563238	chr19:33554763	RHPN2	-0.4	-6.38	-0.33	5.85e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	7.76	0.39	1.06e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.71	0.39	1.41e-13	Lung cancer in ever smokers;
LUSC	trans	rs2229238	0.911	rs73020246	chr1:154485640	A/G	cg25273160	chr11:56955011	LRRC55	0.31	5.96	0.31	6.37e-9	Coronary heart disease;
LUSC	trans	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg14791747	chr16:20752902	THUMPD1	0.42	6.45	0.33	3.86e-10	Dental caries;
LUSC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg15744005	chr10:104629667	AS3MT	0.31	6.4	0.33	5.33e-10	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	8.96	0.44	2.3e-17	Schizophrenia;
LUSC	cis	rs981844	0.712	rs4632640	chr4:154742389	G/C	cg14289246	chr4:154710475	SFRP2	-0.44	-6.13	-0.32	2.5e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg27284194	chr4:1044797	NA	0.57	8.46	0.42	8.22e-16	Recombination rate (females);
LUSC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.52	-0.38	5.1e-13	Electroencephalogram traits;
LUSC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg08125733	chr17:73851984	WBP2	0.47	6.64	0.34	1.26e-10	White matter hyperintensity burden;
LUSC	cis	rs35883536	0.605	rs2133118	chr1:101034337	C/T	cg06223162	chr1:101003688	GPR88	-0.47	-8.88	-0.44	4.29e-17	Monocyte count;
LUSC	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg01119278	chr6:110721349	DDO	-0.47	-8.47	-0.42	7.89e-16	Platelet distribution width;
LUSC	cis	rs9311676	0.632	rs6774357	chr3:58361530	A/C	cg13750441	chr3:58318267	PXK	0.34	6.66	0.34	1.1e-10	Systemic lupus erythematosus;
LUSC	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg14634687	chr17:47094252	IGF2BP1	0.31	6.57	0.34	1.93e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg20528787	chr7:158032352	PTPRN2	0.33	6.09	0.32	3.02e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg01629716	chr15:45996671	NA	0.39	5.89	0.31	9.27e-9	Waist circumference;Weight;
LUSC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg24250549	chr1:154909240	PMVK	0.64	10.42	0.5	3.32e-22	Prostate cancer;
LUSC	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg05805236	chr11:65401703	PCNXL3	-0.63	-10.33	-0.49	6.71e-22	Acne (severe);
LUSC	cis	rs2898681	0.581	rs730246	chr4:53680719	T/C	cg00338735	chr4:53728038	RASL11B	0.43	5.81	0.3	1.46e-8	Optic nerve measurement (cup area);
LUSC	cis	rs4499344	0.633	rs166311	chr19:33161246	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.74	11.49	0.53	5.76e-26	Mean platelet volume;
LUSC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg15691649	chr6:25882328	NA	-0.39	-6.29	-0.33	1.01e-9	Blood metabolite levels;
LUSC	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg24675056	chr1:15929824	NA	0.41	6.85	0.35	3.55e-11	Systolic blood pressure;
LUSC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg03060546	chr3:49711283	APEH	0.66	7.33	0.37	1.74e-12	Menarche (age at onset);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg14385122	chr9:71320671	PIP5K1B	0.39	5.95	0.31	6.72e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg24578937	chr1:2090814	PRKCZ	0.46	10.43	0.5	3.12e-22	Height;
LUSC	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	0.97	13.72	0.6	2.68e-34	Primary sclerosing cholangitis;
LUSC	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.87	0.31	1.05e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs10203711	1.000	rs12692239	chr2:239553947	T/C	cg14580085	chr2:239553406	NA	0.41	6.9	0.35	2.64e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg01733217	chr16:74700730	RFWD3	0.75	12.24	0.56	1.05e-28	Testicular germ cell tumor;
LUSC	cis	rs6494488	0.500	rs56095421	chr15:64911405	C/T	cg08069370	chr15:64387884	SNX1	-0.65	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	cis	rs7804356	1.000	rs6948657	chr7:26855943	C/T	cg03456212	chr7:26904342	SKAP2	-0.53	-6.14	-0.32	2.4e-9	Type 1 diabetes;
LUSC	cis	rs897080	0.552	rs1067389	chr2:44642290	G/A	cg00619915	chr2:44497795	NA	-0.41	-5.8	-0.3	1.51e-8	Height;
LUSC	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg12463550	chr7:65579703	CRCP	0.48	6.89	0.35	2.73e-11	Aortic root size;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26291818	chr8:61429582	RAB2A	-0.44	-6.04	-0.31	4.15e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17015704	chr6:119400380	FAM184A	0.47	7.28	0.37	2.39e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs868036	0.918	rs4776967	chr15:68033922	T/C	cg08079166	chr15:68083412	MAP2K5	0.4	8.06	0.4	1.38e-14	Restless legs syndrome;
LUSC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06544989	chr22:39130855	UNC84B	0.33	5.65	0.3	3.51e-8	Menopause (age at onset);
LUSC	trans	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg21775007	chr8:11205619	TDH	0.45	6.21	0.32	1.6e-9	Neuroticism;
LUSC	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg19628046	chr18:33552617	C18orf21	0.5	6.02	0.31	4.72e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg07507251	chr3:52567010	NT5DC2	-0.31	-6.13	-0.32	2.43e-9	Bipolar disorder;
LUSC	cis	rs8114671	0.967	rs34515766	chr20:33785221	C/G	cg07148914	chr20:33460835	GGT7	-0.44	-6.58	-0.34	1.82e-10	Height;
LUSC	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg14696996	chr19:15285081	NOTCH3	1.02	9.37	0.46	1.1e-18	Pulse pressure;
LUSC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.2	-0.41	5.09e-15	Lung cancer;
LUSC	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg11843606	chr2:227700838	RHBDD1	-0.64	-10.05	-0.48	6.37e-21	Pulmonary function;
LUSC	trans	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg19116668	chr7:99932089	PMS2L1	0.34	5.87	0.31	1.05e-8	Coronary artery disease;
LUSC	cis	rs2820315	0.964	rs2820311	chr1:201841476	A/G	cg10061532	chr1:201886748	LMOD1	0.26	5.86	0.31	1.09e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs360798	0.512	rs2710642	chr2:63149557	G/A	cg17519650	chr2:63277830	OTX1	0.52	7.21	0.37	3.87e-12	Coronary artery disease;
LUSC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.8	12.78	0.57	1.04e-30	Breast cancer;
LUSC	cis	rs4845570	1.000	rs1054479	chr1:151746079	A/T	cg07092448	chr1:151763213	TDRKH	-1.27	-14.41	-0.62	5.93e-37	Coronary artery disease;
LUSC	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.65	-10.92	-0.51	6.06e-24	Lung cancer;
LUSC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.79	-0.43	8.04e-17	Bipolar disorder;
LUSC	cis	rs7615316	0.934	rs13085998	chr3:142263812	C/T	cg16271453	chr3:142027066	XRN1	0.37	6.45	0.33	3.84e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs75920871	0.528	rs723955	chr11:116925042	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.42	-0.33	4.69e-10	Subjective well-being;
LUSC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	6.29	0.33	1.01e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg01528321	chr10:82214614	TSPAN14	0.82	12.36	0.56	3.74e-29	Post bronchodilator FEV1;
LUSC	cis	rs6977660	1.000	rs10260527	chr7:19801930	G/A	cg05791153	chr7:19748676	TWISTNB	0.59	6.47	0.33	3.52e-10	Thyroid stimulating hormone;
LUSC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg25019033	chr10:957182	NA	-0.52	-5.79	-0.3	1.62e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs1979679	0.541	rs7956757	chr12:28723004	C/T	cg13890972	chr12:28721907	NA	-0.42	-6.07	-0.32	3.45e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs2637266	0.756	rs846609	chr10:78551718	A/G	cg18941641	chr10:78392320	NA	0.38	6.81	0.35	4.57e-11	Pulmonary function;
LUSC	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg19318889	chr4:1322082	MAEA	0.43	5.66	0.3	3.22e-8	Recombination rate (females);
LUSC	trans	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg05926928	chr17:57297772	GDPD1	1.06	13.32	0.59	9.15e-33	Opioid sensitivity;
LUSC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.81	13.64	0.6	5.83e-34	Aortic root size;
LUSC	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg02569458	chr12:86230093	RASSF9	0.41	6.53	0.34	2.52e-10	Major depressive disorder;
LUSC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.57	-9.09	-0.45	8.8e-18	Aortic root size;
LUSC	cis	rs7178572	0.568	rs3743478	chr15:77400388	T/C	cg22256960	chr15:77711686	NA	-0.5	-7.88	-0.4	4.56e-14	Type 2 diabetes;
LUSC	trans	rs17035310	0.618	rs4464576	chr4:106177882	C/T	cg19865523	chr12:132537749	EP400	0.49	6.03	0.31	4.25e-9	Colorectal or endometrial cancer;
LUSC	cis	rs7572644	0.541	rs2839791	chr2:28232279	A/C	cg27432699	chr2:27873401	GPN1	-0.51	-6.95	-0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20382932	chr2:71357258	MCEE;MPHOSPH10	-0.33	-5.97	-0.31	6.04e-9	Electrocardiographic conduction measures;
LUSC	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg04539111	chr16:67997858	SLC12A4	-0.43	-5.71	-0.3	2.51e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg07424592	chr7:64974309	NA	0.67	5.97	0.31	6.18e-9	Diabetic kidney disease;
LUSC	trans	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg11887960	chr12:57824829	NA	0.57	6.83	0.35	4.12e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg26893861	chr17:41843967	DUSP3	0.87	13.45	0.59	2.87e-33	Triglycerides;
LUSC	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg13813247	chr22:41461852	NA	-0.37	-6.68	-0.34	9.83e-11	Neuroticism;
LUSC	cis	rs6840360	0.642	rs7676493	chr4:152426765	C/T	cg20465933	chr4:152376761	FAM160A1	0.33	5.94	0.31	7.18e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.32	-0.33	8.28e-10	Myopia (pathological);
LUSC	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	6.63	0.34	1.36e-10	Lung cancer in ever smokers;
LUSC	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.2	-0.32	1.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-9.07	-0.44	1.03e-17	Hip circumference adjusted for BMI;
LUSC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.57	0.5	9.83e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg20243544	chr17:37824526	PNMT	0.4	6.07	0.32	3.51e-9	Self-reported allergy;
LUSC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.08	-0.36	8.76e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs1124376	1.000	rs9828701	chr3:20149203	A/G	cg05072819	chr3:20081367	KAT2B	0.66	7.55	0.38	4.18e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs9653442	0.932	rs893245	chr2:100814893	C/T	cg07810366	chr2:100720526	AFF3	-0.46	-7.86	-0.4	5.2e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs12210905	0.688	rs12199806	chr6:27435943	A/C	cg08851530	chr6:28072375	NA	0.95	5.82	0.3	1.37e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs427941	0.703	rs201441	chr7:101737327	A/C	cg06246474	chr7:101738831	CUX1	0.41	6.79	0.35	5.02e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg07507251	chr3:52567010	NT5DC2	0.33	6.42	0.33	4.79e-10	Bipolar disorder;
LUSC	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg05673287	chr15:77411982	SGK269	-0.44	-7.11	-0.36	7.14e-12	Type 2 diabetes;
LUSC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs2303282	0.716	rs2550303	chr16:56395610	G/A	cg00500540	chr16:56394104	NA	-0.44	-7.55	-0.38	4.1e-13	Breast cancer;
LUSC	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-7.09	-0.36	7.98e-12	Homocysteine levels;
LUSC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.48	0.38	6.51e-13	Bipolar disorder;
LUSC	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.71	-0.43	1.46e-16	Mood instability;
LUSC	cis	rs8099014	1.000	rs4940710	chr18:56135390	C/G	cg12907477	chr18:56117327	MIR122	0.4	6.09	0.32	3.17e-9	Platelet count;
LUSC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.59	0.43	3.4e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.86	-0.35	3.35e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg02931644	chr1:25747376	RHCE	0.37	6.76	0.35	6.06e-11	Erythrocyte sedimentation rate;
LUSC	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg25482853	chr8:67687455	SGK3	1.1	15.91	0.66	8.06e-43	Obesity-related traits;
LUSC	cis	rs80130819	0.688	rs4760698	chr12:48592872	C/T	cg24011408	chr12:48396354	COL2A1	0.45	5.82	0.3	1.39e-8	Prostate cancer;
LUSC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg13047869	chr3:10149882	C3orf24	0.61	8.74	0.43	1.18e-16	Alzheimer's disease;
LUSC	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.71	10.91	0.51	6.5e-24	Breast cancer;
LUSC	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg14092571	chr14:90743983	NA	0.37	6.08	0.32	3.3e-9	Mortality in heart failure;
LUSC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg06212747	chr3:49208901	KLHDC8B	0.44	6.01	0.31	4.94e-9	Parkinson's disease;
LUSC	trans	rs7170930	0.541	rs67543551	chr15:66535599	T/G	cg06396762	chr16:3202609	NA	-0.72	-5.97	-0.31	6.08e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg03036452	chr22:46663545	TTC38	0.53	5.76	0.3	1.94e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg06618935	chr21:46677482	NA	-0.39	-7.95	-0.4	2.83e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg25258033	chr6:167368657	RNASET2	-0.47	-7.95	-0.4	2.87e-14	Crohn's disease;
LUSC	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.81	-0.35	4.49e-11	Response to antipsychotic treatment;
LUSC	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg17366294	chr4:99064904	C4orf37	0.6	10.58	0.5	9.38e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.6	5.83	0.3	1.3e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-6.42	-0.33	4.56e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-11.02	-0.52	2.62e-24	Response to antipsychotic treatment;
LUSC	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg05043794	chr9:111880884	C9orf5	-0.38	-7.85	-0.39	5.79e-14	Menarche (age at onset);
LUSC	cis	rs6960043	0.818	rs2358158	chr7:15054063	T/C	cg19272540	chr7:15055459	NA	0.35	8.72	0.43	1.33e-16	Type 2 diabetes;
LUSC	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg26566898	chr11:117069891	TAGLN	0.35	6.69	0.34	9.68e-11	Blood protein levels;
LUSC	cis	rs6500395	0.963	rs2111242	chr16:48708300	T/C	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg18132916	chr6:79620363	NA	0.38	5.88	0.31	1.02e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg20203395	chr5:56204925	C5orf35	0.58	8.6	0.43	3.13e-16	Initial pursuit acceleration;
LUSC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.03	-16.29	-0.67	2.44e-44	Primary sclerosing cholangitis;
LUSC	cis	rs1413885	0.516	rs716592	chr1:65843982	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.5	-7.41	-0.38	1.05e-12	Anticoagulant levels;
LUSC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg18230493	chr5:56204884	C5orf35	-0.92	-14.02	-0.61	1.94e-35	Initial pursuit acceleration;
LUSC	cis	rs193541	0.585	rs4546376	chr5:122089106	C/A	cg19077854	chr5:122220652	SNX24	0.28	6.26	0.32	1.18e-9	Glucose homeostasis traits;
LUSC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg22963979	chr7:1858916	MAD1L1	-0.7	-11.67	-0.54	1.28e-26	Bipolar disorder and schizophrenia;
LUSC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.49	-8.11	-0.41	9.9e-15	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg17366294	chr4:99064904	C4orf37	0.59	10.55	0.5	1.18e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg08493051	chr2:3487164	NA	-0.53	-8.06	-0.4	1.42e-14	Neurofibrillary tangles;
LUSC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg06287003	chr12:125626642	AACS	-0.39	-6.48	-0.33	3.26e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs926938	0.505	rs360629	chr1:115414733	A/G	cg01522456	chr1:115632236	TSPAN2	-0.38	-5.77	-0.3	1.82e-8	Autism;
LUSC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18404041	chr3:52824283	ITIH1	-0.5	-9.51	-0.46	4.04e-19	Bipolar disorder;
LUSC	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.16	0.41	6.79e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg21724239	chr8:58056113	NA	0.58	7.15	0.36	5.42e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19717773	chr7:2847554	GNA12	-0.37	-5.95	-0.31	6.8e-9	Height;
LUSC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.84	0.3	1.25e-8	Menopause (age at onset);
LUSC	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs3947	1.000	rs1736081	chr8:11702840	T/G	cg00262122	chr8:11665843	FDFT1	-0.48	-5.77	-0.3	1.79e-8	Blood protein levels;
LUSC	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	8.73	0.43	1.2e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg13535736	chr9:111863775	C9orf5	-0.41	-6.81	-0.35	4.48e-11	Menarche (age at onset);
LUSC	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg19875535	chr5:140030758	IK	0.47	7.56	0.38	4.05e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7605827	0.930	rs11893303	chr2:15613715	G/A	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg26897989	chr16:1907736	C16orf73	-0.44	-6.86	-0.35	3.32e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs17572109	0.666	rs11696005	chr2:219229641	T/C	cg00012203	chr2:219082015	ARPC2	-0.47	-6.1	-0.32	2.9e-9	Platelet count;Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg14664628	chr15:75095509	CSK	-0.49	-7.01	-0.36	1.32e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs3771570	0.681	rs12151655	chr2:242281438	T/A	cg21155796	chr2:242212141	HDLBP	0.63	6.86	0.35	3.32e-11	Prostate cancer;
LUSC	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg18357645	chr12:58087776	OS9	-0.55	-8.24	-0.41	3.86e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg14582100	chr15:45693742	SPATA5L1	0.44	7.79	0.39	8.31e-14	Glomerular filtration rate;
LUSC	trans	rs7939886	0.920	rs11227463	chr11:55955447	C/T	cg15704280	chr7:45808275	SEPT13	0.89	6.88	0.35	3e-11	Myopia (pathological);
LUSC	trans	rs28647808	0.881	rs71483207	chr9:136258698	A/G	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg21427119	chr20:30132790	HM13	-0.37	-5.98	-0.31	5.71e-9	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs17818399	0.502	rs1451152	chr2:46800150	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.35	5.71	0.3	2.49e-8	Height;
LUSC	cis	rs12541635	0.966	rs16873989	chr8:106966381	C/T	cg10147462	chr8:107024639	NA	0.56	9.76	0.47	5.99e-20	Age of smoking initiation;
LUSC	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg02176678	chr2:219576539	TTLL4	-0.57	-10.0	-0.48	9.34e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7818345	0.967	rs12678336	chr8:19280552	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	7.48	0.38	6.63e-13	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs5753037	0.629	rs140138	chr22:30164628	T/G	cg11564601	chr22:30592435	NA	0.33	5.76	0.3	1.92e-8	Type 1 diabetes;
LUSC	cis	rs7582180	0.903	rs13033057	chr2:100896415	C/T	cg08017756	chr2:100939284	LONRF2	-0.36	-6.01	-0.31	4.77e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg11062466	chr8:58055876	NA	0.49	6.77	0.35	5.65e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg03146154	chr1:46216737	IPP	0.5	7.41	0.38	1.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.63	13.14	0.58	4.41e-32	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg21045802	chr8:109455806	TTC35	0.46	7.07	0.36	9.34e-12	Dupuytren's disease;
LUSC	trans	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg21659725	chr3:3221576	CRBN	0.71	8.64	0.43	2.41e-16	Menarche (age at onset);
LUSC	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg00310523	chr12:86230176	RASSF9	0.47	8.39	0.42	1.37e-15	Major depressive disorder;
LUSC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg15448220	chr1:150897856	SETDB1	0.42	6.13	0.32	2.51e-9	Melanoma;
LUSC	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	11.4	0.53	1.17e-25	Colorectal cancer;
LUSC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg06713675	chr4:122721982	EXOSC9	-0.46	-8.15	-0.41	7.48e-15	Type 2 diabetes;
LUSC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg14668632	chr7:2872130	GNA12	-0.41	-6.22	-0.32	1.5e-9	Height;
LUSC	trans	rs7045881	0.735	rs10967594	chr9:26910951	G/T	cg10990997	chr6:39873526	MOCS1	-0.38	-6.06	-0.31	3.59e-9	Schizophrenia;
LUSC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.64	-0.34	1.3e-10	Blood protein levels;
LUSC	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg05855489	chr10:104503620	C10orf26	0.67	10.29	0.49	9.39e-22	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs3741151	0.656	rs11544311	chr11:73106237	A/C	cg17517138	chr11:73019481	ARHGEF17	0.97	8.28	0.41	3.08e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-10.2	-0.49	1.97e-21	Electroencephalogram traits;
LUSC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.94	13.56	0.6	1.1e-33	Chronic sinus infection;
LUSC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.3	0.49	8.56e-22	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg05855489	chr10:104503620	C10orf26	-0.51	-7.64	-0.39	2.33e-13	Arsenic metabolism;
LUSC	cis	rs12986413	0.967	rs1015670	chr19:2171490	G/A	cg09261902	chr19:2140048	AP3D1	0.31	5.93	0.31	7.5e-9	Height;
LUSC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg12560992	chr17:57184187	TRIM37	0.84	15.48	0.65	3.82e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs6693567	0.565	rs10888578	chr1:150260993	A/G	cg15654264	chr1:150340011	RPRD2	-0.46	-7.44	-0.38	8.38e-13	Migraine;
LUSC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18854424	chr1:2615690	NA	0.51	10.34	0.49	6.28e-22	Ulcerative colitis;
LUSC	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.55	-0.34	2.21e-10	Fear of minor pain;
LUSC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg25258033	chr6:167368657	RNASET2	-0.47	-7.82	-0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.77	0.3	1.77e-8	Breast cancer;
LUSC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg13119609	chr19:45449297	APOC2	0.5	9.92	0.48	1.65e-20	Blood protein levels;
LUSC	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	1.17	13.66	0.6	4.72e-34	Arsenic metabolism;
LUSC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	0.6	9.38	0.46	1.02e-18	Breast cancer;
LUSC	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg11812906	chr14:75593930	NEK9	-0.66	-11.18	-0.52	7.19e-25	Height;
LUSC	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg10547527	chr2:198650123	BOLL	-0.52	-6.07	-0.31	3.57e-9	Ulcerative colitis;
LUSC	cis	rs10419226	0.577	rs7257812	chr19:18787372	A/G	cg22001208	chr19:18782374	NA	-0.38	-6.45	-0.33	3.85e-10	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg17294928	chr15:75287854	SCAMP5	0.64	7.16	0.36	5.22e-12	Blood trace element (Zn levels);
LUSC	cis	rs10186029	0.616	rs12616255	chr2:213978895	T/A	cg08319019	chr2:214017104	IKZF2	0.57	8.28	0.41	2.97e-15	Systemic sclerosis;
LUSC	cis	rs17621444	0.522	rs10788020	chr10:121808870	A/G	cg02041677	chr10:121771263	NA	-0.34	-6.4	-0.33	5.35e-10	IgG glycosylation;
LUSC	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.21	-0.49	1.74e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg03732007	chr1:2071316	PRKCZ	0.47	7.62	0.38	2.68e-13	Height;
LUSC	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg12863693	chr15:85201151	NMB	0.41	8.48	0.42	7.34e-16	Schizophrenia;
LUSC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg03538708	chr1:25844672	NA	-0.37	-6.08	-0.32	3.23e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	7.81	0.39	7.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.68	-10.63	-0.5	6.1e-23	Menarche (age at onset);
LUSC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	-0.46	-6.06	-0.31	3.6e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05535760	chr7:792225	HEATR2	0.81	9.7	0.47	9.49e-20	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1044826	0.642	rs167187	chr3:139237008	C/T	cg15131784	chr3:139108705	COPB2	-0.41	-6.5	-0.34	2.86e-10	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.31	-0.37	2.04e-12	Subjective well-being;
LUSC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	0.93	17.4	0.69	1.02e-48	Heart rate;
LUSC	cis	rs7553864	0.614	rs4559475	chr1:87614236	T/C	cg17420885	chr1:87600446	LOC339524	-0.5	-6.98	-0.36	1.6e-11	Smoking behavior;
LUSC	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17916960	chr15:79447300	NA	-0.53	-10.71	-0.51	3.31e-23	Refractive error;
LUSC	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06022373	chr22:39101656	GTPBP1	0.75	12.1	0.55	3.37e-28	Menopause (age at onset);
LUSC	cis	rs965469	1.000	rs6051672	chr20:3224819	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-6.02	-0.31	4.62e-9	IFN-related cytopenia;
LUSC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	12.03	0.55	6.07e-28	Chronic sinus infection;
LUSC	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg00191853	chr8:101177733	SPAG1	-0.41	-6.59	-0.34	1.68e-10	Atrioventricular conduction;
LUSC	cis	rs2425143	0.512	rs11699653	chr20:34622916	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-6.16	-0.32	2.11e-9	Blood protein levels;
LUSC	cis	rs2073300	1.000	rs6048810	chr20:23446429	G/A	cg09953122	chr20:23471693	CST8	-0.75	-6.87	-0.35	3.15e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg06742321	chr12:123595122	PITPNM2	0.39	5.75	0.3	2.07e-8	Platelet count;
LUSC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	8.85	0.44	5.33e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs17253792	0.915	rs79894275	chr14:56180285	C/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.86	-0.35	3.35e-11	Putamen volume;
LUSC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.64	9.71	0.47	8.77e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.19	0.37	4.3e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.85	-0.35	3.61e-11	Neuroticism;
LUSC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.84	-15.3	-0.64	2.06e-40	Cognitive function;
LUSC	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.15	0.32	2.22e-9	Corneal astigmatism;
LUSC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.7	11.4	0.53	1.15e-25	Menarche (age at onset);
LUSC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08280861	chr8:58055591	NA	0.55	6.51	0.34	2.73e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg20203395	chr5:56204925	C5orf35	-0.56	-8.05	-0.4	1.49e-14	Coronary artery disease;
LUSC	cis	rs8103278	0.662	rs16980051	chr19:46345886	T/C	cg14061069	chr19:46274453	DMPK	-0.38	-6.41	-0.33	4.89e-10	Coronary artery disease;
LUSC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg17279839	chr7:150038598	RARRES2	0.43	7.1	0.36	7.76e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12220238	0.558	rs76330316	chr10:76002291	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.6	7.05	0.36	1.04e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs963731	0.649	rs4670903	chr2:39220975	G/A	cg04010122	chr2:39346883	SOS1	-0.77	-5.7	-0.3	2.64e-8	Corticobasal degeneration;
LUSC	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg22431228	chr1:16359049	CLCNKA	0.35	7.29	0.37	2.31e-12	Dilated cardiomyopathy;
LUSC	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.56	8.71	0.43	1.42e-16	Menopause (age at onset);
LUSC	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg06552810	chr11:31128660	NA	-0.41	-7.25	-0.37	2.89e-12	Red blood cell count;
LUSC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.75	-16.47	-0.67	4.96e-45	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9653442	0.564	rs6707067	chr2:100767232	G/A	cg22139774	chr2:100720529	AFF3	-0.42	-7.07	-0.36	9.09e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg20991723	chr1:152506922	NA	0.5	9.21	0.45	3.71e-18	Hair morphology;
LUSC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg27124370	chr19:33622961	WDR88	-0.58	-8.31	-0.41	2.4e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.86	-0.47	2.63e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.81	-13.07	-0.58	8.52e-32	Platelet count;
LUSC	trans	rs11700980	0.551	rs2832008	chr21:30109998	T/C	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.31e-9	QRS complex (12-leadsum);
LUSC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg19774624	chr17:42201019	HDAC5	-0.8	-13.02	-0.58	1.22e-31	Total body bone mineral density;
LUSC	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7605827	0.930	rs6431711	chr2:15683930	G/T	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.77e-16	Educational attainment (years of education);
LUSC	cis	rs10193935	0.818	rs2374428	chr2:42667961	T/C	cg27598129	chr2:42591480	NA	0.59	8.02	0.4	1.79e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg23601095	chr6:26197514	HIST1H3D	0.67	7.29	0.37	2.26e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg19743168	chr1:23544995	NA	0.4	7.81	0.39	7.42e-14	Height;
LUSC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg13206674	chr6:150067644	NUP43	0.61	9.72	0.47	8.16e-20	Lung cancer;
LUSC	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-7.56	-0.38	3.93e-13	Atrioventricular conduction;
LUSC	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg23173402	chr1:227635558	NA	-0.64	-7.37	-0.37	1.35e-12	Major depressive disorder;
LUSC	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg08219700	chr8:58056026	NA	0.44	5.75	0.3	2.01e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg18681998	chr4:17616180	MED28	-0.79	-13.6	-0.6	7.62e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2692947	0.770	rs2579552	chr2:96737083	A/G	cg22654517	chr2:96458247	NA	0.33	6.21	0.32	1.58e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs2652834	0.851	rs4238370	chr15:63347363	T/G	cg05507819	chr15:63340323	TPM1	0.69	8.7	0.43	1.54e-16	HDL cholesterol;
LUSC	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg19508488	chr2:152266495	RIF1	-0.45	-6.53	-0.34	2.52e-10	Lung cancer;
LUSC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.08	20.92	0.75	1.06e-62	Cognitive ability;
LUSC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg03676636	chr4:99064102	C4orf37	0.34	7.57	0.38	3.71e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg07694864	chr17:40700509	NA	-0.37	-5.96	-0.31	6.54e-9	Colorectal or endometrial cancer;
LUSC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg00750074	chr16:89608354	SPG7	-0.53	-9.63	-0.47	1.54e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.81	15.55	0.65	2.07e-41	Dental caries;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05994294	chr4:1374658	KIAA1530	0.48	6.24	0.32	1.29e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14453326	chr12:124086472	DDX55	-0.43	-6.31	-0.33	9e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg03146154	chr1:46216737	IPP	0.52	7.67	0.39	1.94e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9463078	0.547	rs4711798	chr6:44750777	A/G	cg25276700	chr6:44698697	NA	-0.28	-5.96	-0.31	6.26e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg04733989	chr22:42467013	NAGA	0.61	9.48	0.46	4.84e-19	Schizophrenia;
LUSC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg18230493	chr5:56204884	C5orf35	-0.66	-10.27	-0.49	1.07e-21	Coronary artery disease;
LUSC	cis	rs4594175	0.926	rs4318127	chr14:51624897	G/C	cg23942311	chr14:51606299	NA	0.31	5.86	0.31	1.11e-8	Cancer;
LUSC	cis	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.62	-0.43	2.69e-16	Morning vs. evening chronotype;
LUSC	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg20701182	chr2:24300061	SF3B14	0.87	11.34	0.53	1.97e-25	Lymphocyte counts;
LUSC	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg20059928	chr15:40361485	NA	-0.49	-5.96	-0.31	6.34e-9	Corneal curvature;
LUSC	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.75	12.59	0.57	5.28e-30	Multiple myeloma;
LUSC	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.7	-8.33	-0.41	2.15e-15	Refractive error;
LUSC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg19230755	chr7:65878503	NA	0.41	5.76	0.3	1.95e-8	Aortic root size;
LUSC	cis	rs1891275	0.515	rs4244930	chr10:93466849	T/C	cg07889827	chr10:93443413	NA	-0.38	-8.57	-0.42	3.97e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg08975724	chr8:8085496	FLJ10661	0.52	7.83	0.39	6.39e-14	Neuroticism;
LUSC	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.71	-0.34	8.3e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg27068330	chr11:65405492	SIPA1	-0.74	-10.3	-0.49	8.46e-22	Acne (severe);
LUSC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-20.86	-0.75	1.78e-62	Prudent dietary pattern;
LUSC	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.19	0.37	4.2e-12	Blood metabolite levels;
LUSC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg20891283	chr12:69753455	YEATS4	0.52	8.4	0.42	1.34e-15	Blood protein levels;
LUSC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-8.1	-0.41	1.05e-14	Electroencephalogram traits;
LUSC	cis	rs7572644	0.699	rs898034	chr2:28090820	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-6.72	-0.35	7.73e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg02711726	chr17:80685570	FN3KRP	0.4	6.21	0.32	1.61e-9	Glycated hemoglobin levels;
LUSC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.54	8.87	0.44	4.41e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg08470875	chr2:26401718	FAM59B	0.71	9.62	0.47	1.68e-19	Gut microbiome composition (summer);
LUSC	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg27539214	chr16:67997921	SLC12A4	-0.46	-5.95	-0.31	6.59e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs931812	0.895	rs4236763	chr8:101913022	G/A	cg20993868	chr7:22813445	NA	0.63	11.25	0.52	4.03e-25	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs2235649	0.789	rs4567715	chr16:1849363	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.06	-0.31	3.76e-9	Blood metabolite levels;
LUSC	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg08645402	chr16:4508243	NA	-0.39	-6.24	-0.32	1.35e-9	Schizophrenia;
LUSC	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.65	-10.67	-0.5	4.66e-23	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg06454157	chr6:167490870	NA	-0.28	-6.71	-0.34	8.57e-11	Primary biliary cholangitis;
LUSC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	12.33	0.56	4.97e-29	Chronic sinus infection;
LUSC	trans	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.63	0.39	2.44e-13	Ulcerative colitis;
LUSC	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg13010199	chr12:38710504	ALG10B	0.67	10.37	0.49	4.91e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2463822	0.583	rs72919477	chr11:62042403	G/C	cg06239285	chr11:62104954	ASRGL1	-0.65	-6.65	-0.34	1.19e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg05313129	chr8:58192883	C8orf71	-0.5	-5.71	-0.3	2.44e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2274273	1.000	rs4644	chr14:55604935	C/A	cg04306507	chr14:55594613	LGALS3	0.54	11.53	0.53	3.94e-26	Protein biomarker;
LUSC	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.48	-6.81	-0.35	4.55e-11	Iron status biomarkers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12810560	chr5:130500164	HINT1	-0.42	-6.36	-0.33	6.61e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg07936489	chr17:37558343	FBXL20	-0.7	-9.44	-0.46	6.37e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg10978503	chr1:24200527	CNR2	0.51	11.64	0.54	1.66e-26	Immature fraction of reticulocytes;
LUSC	cis	rs11112613	0.680	rs12231332	chr12:106046030	G/A	cg03607813	chr12:105948248	NA	0.41	5.9	0.31	8.85e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.59e-9	Menopause (age at onset);
LUSC	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.78	-14.59	-0.62	1.26e-37	Obesity-related traits;
LUSC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg12257692	chr3:49977190	RBM6	-0.26	-7.41	-0.38	1.02e-12	Body mass index;
LUSC	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg02569458	chr12:86230093	RASSF9	0.41	6.54	0.34	2.35e-10	Major depressive disorder;
LUSC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4786125	0.587	rs12709158	chr16:6925056	A/G	cg03623568	chr16:6915990	A2BP1	-0.5	-8.22	-0.41	4.41e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg17366294	chr4:99064904	C4orf37	0.51	8.8	0.43	7.36e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg01966878	chr4:90757139	SNCA	-0.34	-5.94	-0.31	7.11e-9	Dementia with Lewy bodies;
LUSC	trans	rs7339349	0.605	rs4885139	chr13:74542950	A/T	cg25826913	chr13:45885329	NA	0.59	6.21	0.32	1.61e-9	Neurofibrillary tangles;
LUSC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	1.04	19.44	0.73	7.67e-57	Menopause (age at onset);
LUSC	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.63	-0.39	2.46e-13	Blood metabolite levels;
LUSC	cis	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg06521331	chr12:34319734	NA	-0.35	-5.94	-0.31	7.11e-9	Morning vs. evening chronotype;
LUSC	trans	rs7615952	0.546	rs16836896	chr3:125311262	A/T	cg07211511	chr3:129823064	LOC729375	-0.56	-6.49	-0.33	3.15e-10	Blood pressure (smoking interaction);
LUSC	cis	rs9807989	0.839	rs4988956	chr2:102968007	G/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.91	0.31	8.63e-9	Asthma;
LUSC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg04317338	chr11:64019027	PLCB3	0.68	7.75	0.39	1.12e-13	Mean platelet volume;
LUSC	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg00277334	chr10:82204260	NA	-0.58	-8.65	-0.43	2.21e-16	Post bronchodilator FEV1;
LUSC	cis	rs4363385	0.747	rs3964619	chr1:152972811	A/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.83	-0.39	6.43e-14	Inflammatory skin disease;
LUSC	trans	rs2840044	1.000	rs225262	chr17:33959697	A/G	cg19694781	chr19:47549865	TMEM160	-0.58	-9.31	-0.45	1.71e-18	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.86	-0.35	3.45e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10783615	0.719	rs1975471	chr12:54336981	A/G	cg17410650	chr12:54324560	NA	-0.47	-6.26	-0.32	1.16e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg19773385	chr1:10388646	KIF1B	-0.53	-8.25	-0.41	3.6e-15	Hepatocellular carcinoma;
LUSC	cis	rs7188861	0.768	rs12922733	chr16:11380670	C/G	cg00044050	chr16:11439710	C16orf75	0.58	6.41	0.33	4.96e-10	HDL cholesterol;
LUSC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg02951883	chr7:2050386	MAD1L1	-0.59	-10.61	-0.5	7.48e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg15691649	chr6:25882328	NA	0.39	6.44	0.33	4.09e-10	Blood metabolite levels;
LUSC	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06850241	chr22:41845214	NA	-0.31	-6.01	-0.31	4.93e-9	Vitiligo;
LUSC	cis	rs3087591	1.000	rs2040791	chr17:29627297	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.55	-7.89	-0.4	4.22e-14	Hip circumference;
LUSC	trans	rs4714291	0.963	rs1923489	chr6:40023088	T/C	cg02267698	chr19:7991119	CTXN1	0.52	7.25	0.37	2.91e-12	Strep throat;
LUSC	cis	rs2455601	0.744	rs11042107	chr11:8905871	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-7.4	-0.38	1.11e-12	Schizophrenia;
LUSC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	12.24	0.56	1.03e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	12.25	0.56	9.46e-29	Colorectal cancer;
LUSC	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg26384229	chr12:38710491	ALG10B	-0.67	-10.46	-0.5	2.39e-22	Bladder cancer;
LUSC	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg22431228	chr1:16359049	CLCNKA	0.34	6.5	0.34	2.94e-10	Dilated cardiomyopathy;
LUSC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.18	27.62	0.83	2.92e-88	Chronic sinus infection;
LUSC	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg05855489	chr10:104503620	C10orf26	0.52	7.96	0.4	2.72e-14	Arsenic metabolism;
LUSC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg04871131	chr7:94954202	PON1	-0.38	-6.12	-0.32	2.68e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg11812906	chr14:75593930	NEK9	0.67	11.56	0.53	3.11e-26	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04402966	chr7:87505783	SLC25A40;DBF4	-0.43	-6.4	-0.33	5.28e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9811920	0.625	rs7631174	chr3:99913902	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.33	6.28	0.33	1.03e-9	Axial length;
LUSC	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Colorectal cancer;
LUSC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1034435	0.547	rs5767174	chr22:48898857	A/G	cg05992904	chr22:48892994	FAM19A5	-0.38	-6.69	-0.34	9.6e-11	Late-onset Alzheimer's disease;
LUSC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.72	-0.35	7.84e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.14	0.41	8.18e-15	Prudent dietary pattern;
LUSC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.77	0.63	2.41e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.21	0.32	1.6e-9	Corneal astigmatism;
LUSC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.76	-0.47	5.72e-20	Gut microbiome composition (summer);
LUSC	cis	rs2348418	0.715	rs11049719	chr12:28720379	A/T	cg13890972	chr12:28721907	NA	-0.39	-6.87	-0.35	3.24e-11	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.12	0.58	5.34e-32	Cognitive test performance;
LUSC	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	7.59	0.38	3.26e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg09904177	chr6:26538194	HMGN4	0.42	6.1	0.32	2.86e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg00012203	chr2:219082015	ARPC2	0.74	12.72	0.57	1.65e-30	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs2219968	1.000	rs1073444	chr8:78959671	T/C	cg00738934	chr8:78996279	NA	0.34	6.19	0.32	1.81e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg17507749	chr15:85114479	UBE2QP1	0.71	9.38	0.46	1.02e-18	Schizophrenia;
LUSC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02187348	chr16:89574699	SPG7	0.53	8.44	0.42	1.01e-15	Multiple myeloma (IgH translocation);
LUSC	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg21545522	chr1:205238299	TMCC2	0.42	8.06	0.4	1.34e-14	Red blood cell count;
LUSC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg23791538	chr6:167370224	RNASET2	0.41	6.65	0.34	1.2e-10	Crohn's disease;
LUSC	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg06092702	chr1:163392909	NA	-0.4	-6.91	-0.35	2.45e-11	Motion sickness;
LUSC	cis	rs1808579	0.874	rs1367083	chr18:21100240	C/T	cg14672496	chr18:21087552	C18orf8	0.4	7.11	0.36	7.23e-12	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs4792901	0.759	rs2271957	chr17:41598940	A/G	cg22562494	chr17:41607896	ETV4	-0.32	-6.05	-0.31	3.96e-9	Dupuytren's disease;
LUSC	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg00898013	chr13:113819073	PROZ	-0.53	-7.88	-0.4	4.77e-14	Platelet distribution width;
LUSC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg16586182	chr3:47516702	SCAP	-0.5	-7.98	-0.4	2.45e-14	Colorectal cancer;
LUSC	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg09003973	chr2:102972529	NA	1.21	12.76	0.57	1.2e-30	Gut microbiota (bacterial taxa);
LUSC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg13119609	chr19:45449297	APOC2	0.49	10.0	0.48	9.11e-21	Blood protein levels;
LUSC	cis	rs2769264	0.505	rs11801791	chr1:151387508	C/T	cg18801370	chr1:151430492	POGZ	0.68	8.29	0.41	2.88e-15	Blood trace element (Cu levels);
LUSC	cis	rs2731664	0.792	rs337374	chr5:176890416	A/G	cg23176889	chr5:176863531	GRK6	0.66	13.34	0.59	7.81e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs12618769	0.597	rs72819981	chr2:99040696	T/C	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.14e-13	Bipolar disorder;
LUSC	cis	rs7536201	1.000	rs12036815	chr1:25300632	C/T	cg23273869	chr1:25296894	NA	-0.27	-5.78	-0.3	1.74e-8	Psoriasis vulgaris;
LUSC	cis	rs9341835	0.772	rs9294196	chr6:64135193	A/G	cg03326410	chr6:64151739	NA	0.38	6.18	0.32	1.88e-9	Schizophrenia;
LUSC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-9.46	-0.46	5.56e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg15445000	chr17:37608096	MED1	-0.38	-6.46	-0.33	3.79e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.34	0.67	1.6e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.2e-40	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14514174	chr9:99181512	ZNF367	-0.39	-6.2	-0.32	1.66e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg17187183	chr4:55093834	PDGFRA	0.4	6.11	0.32	2.83e-9	Corneal astigmatism;
LUSC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg03146154	chr1:46216737	IPP	0.54	7.84	0.39	6.19e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.54	8.08	0.4	1.2e-14	Lymphocyte counts;
LUSC	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg02493740	chr2:85810744	VAMP5	-0.38	-6.67	-0.34	1.04e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2067615	0.524	rs754184	chr12:107117521	A/G	cg19260189	chr12:106995001	RFX4	0.23	5.8	0.3	1.57e-8	Heart rate;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03183882	chr3:15373315	SH3BP5	-0.48	-6.26	-0.32	1.16e-9	Hepatitis;
LUSC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.46	-8.46	-0.42	8.23e-16	Longevity;Endometriosis;
LUSC	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.43	-6.44	-0.33	4.05e-10	Tonsillectomy;
LUSC	cis	rs4280164	0.945	rs4366641	chr14:24771101	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.57	-6.73	-0.35	7.49e-11	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs7408868	1.000	rs7408868	chr19:15285679	G/C	cg14696996	chr19:15285081	NOTCH3	0.92	8.92	0.44	3.06e-17	Pulse pressure;
LUSC	cis	rs16976116	0.803	rs9920136	chr15:55504102	A/G	cg11288833	chr15:55489084	RSL24D1	0.5	5.95	0.31	6.81e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs56399783	0.901	rs6967664	chr7:2816384	A/G	cg14895029	chr7:2775587	GNA12	0.49	5.92	0.31	7.99e-9	Childhood ear infection;
LUSC	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.67	0.39	1.91e-13	Iron status biomarkers;
LUSC	cis	rs4423214	0.798	rs1894100	chr11:71130343	G/T	cg05163923	chr11:71159392	DHCR7	-0.71	-9.09	-0.45	9.05e-18	Vitamin D levels;
LUSC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24838063	chr12:130822603	PIWIL1	0.69	10.37	0.49	4.84e-22	Menopause (age at onset);
LUSC	cis	rs981844	1.000	rs2405431	chr4:154656396	A/G	cg14289246	chr4:154710475	SFRP2	0.5	6.26	0.32	1.2e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.19	-0.41	5.46e-15	Personality dimensions;
LUSC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg13047869	chr3:10149882	C3orf24	0.6	8.42	0.42	1.14e-15	Alzheimer's disease;
LUSC	cis	rs7289126	0.966	rs4820329	chr22:38646063	G/A	cg25457927	chr22:38595422	NA	-0.29	-5.75	-0.3	1.99e-8	Mammographic density (dense area);Percent mammographic density;
LUSC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.56	8.93	0.44	2.9e-17	Longevity;
LUSC	cis	rs73198271	0.515	rs78600128	chr8:8628706	C/A	cg01851573	chr8:8652454	MFHAS1	0.61	7.0	0.36	1.39e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg06606381	chr12:133084897	FBRSL1	-1.08	-9.45	-0.46	6.26e-19	Depression;
LUSC	cis	rs11018904	0.906	rs61903722	chr11:89967042	C/T	cg26028595	chr11:89956573	CHORDC1	-0.52	-6.17	-0.32	2.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.43	-6.22	-0.32	1.48e-9	Platelet count;
LUSC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg22800045	chr5:56110881	MAP3K1	0.44	5.95	0.31	6.73e-9	Coronary artery disease;
LUSC	cis	rs472402	0.580	rs10060745	chr5:6658003	T/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.54	-7.76	-0.39	1.02e-13	Response to amphetamines;
LUSC	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg26898376	chr11:64110657	CCDC88B	0.33	6.18	0.32	1.85e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs5758659	0.512	rs4822072	chr22:42360833	G/C	cg15557168	chr22:42548783	NA	-0.36	-5.97	-0.31	6.18e-9	Cognitive function;
LUSC	cis	rs2235649	0.833	rs9929264	chr16:1851934	T/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.43	-5.96	-0.31	6.47e-9	Blood metabolite levels;
LUSC	cis	rs7131987	0.683	rs3782511	chr12:29496224	G/A	cg09582351	chr12:29534625	ERGIC2	-0.35	-6.96	-0.36	1.8e-11	QT interval;
LUSC	cis	rs11031096	0.782	rs2165728	chr11:4147004	T/C	cg18678763	chr11:4115507	RRM1	-0.52	-7.46	-0.38	7.53e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	10.58	0.5	9.48e-23	Eye color traits;
LUSC	cis	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.52	6.31	0.33	9.05e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.4	5.93	0.31	7.51e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	13.46	0.59	2.77e-33	Alzheimer's disease;
LUSC	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg09365446	chr1:150670422	GOLPH3L	0.48	6.96	0.36	1.81e-11	Melanoma;
LUSC	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg17385448	chr1:15911702	AGMAT	0.36	6.09	0.32	3.12e-9	Systolic blood pressure;
LUSC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg01097406	chr16:89675127	NA	-0.34	-6.72	-0.35	7.75e-11	Vitiligo;
LUSC	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg00310523	chr12:86230176	RASSF9	0.45	8.0	0.4	2.1e-14	Major depressive disorder;
LUSC	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg07506560	chr2:240697449	NA	-0.49	-8.18	-0.41	6.08e-15	Obesity-related traits;
LUSC	cis	rs524023	0.914	rs80841	chr11:64437490	T/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.49	-0.5	1.96e-22	Urate levels in obese individuals;
LUSC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg06640241	chr16:89574553	SPG7	0.91	16.34	0.67	1.64e-44	Multiple myeloma (IgH translocation);
LUSC	cis	rs7106204	0.609	rs16912359	chr11:24290818	C/T	ch.11.24196551F	chr11:24239977	NA	0.7	5.86	0.31	1.1e-8	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg10547527	chr2:198650123	BOLL	-0.5	-5.91	-0.31	8.58e-9	Ulcerative colitis;
LUSC	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg14675211	chr2:100938903	LONRF2	0.37	5.77	0.3	1.78e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	1.03	15.48	0.65	3.89e-41	Obesity-related traits;
LUSC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg02487422	chr3:49467188	NICN1	0.46	7.12	0.36	6.79e-12	Resting heart rate;
LUSC	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg10857441	chr5:6722123	POLS	-0.43	-7.93	-0.4	3.33e-14	Menopause (age at onset);
LUSC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg02772935	chr3:125709198	NA	-0.48	-5.79	-0.3	1.63e-8	Blood pressure (smoking interaction);
LUSC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.23	0.32	1.42e-9	Height;
LUSC	trans	rs2386661	0.516	rs61832676	chr10:5646337	G/A	cg11398623	chr21:37499189	NA	0.27	6.16	0.32	2.11e-9	Breast cancer;
LUSC	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	8.73	0.43	1.26e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.37	5.89	0.31	9.21e-9	Primary tooth development (time to first tooth eruption);
LUSC	trans	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-6.04	-0.31	4.19e-9	Morning vs. evening chronotype;
LUSC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg21724239	chr8:58056113	NA	0.61	6.68	0.34	1.03e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg13560548	chr3:10150139	C3orf24	0.54	7.12	0.36	6.45e-12	Alzheimer's disease;
LUSC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.34	-0.56	4.44e-29	Rheumatoid arthritis;
LUSC	trans	rs1335645	1.000	rs56273250	chr1:111675762	G/A	cg26007445	chr17:62287566	TEX2	0.51	6.4	0.33	5.19e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg19743168	chr1:23544995	NA	-0.46	-10.0	-0.48	9.46e-21	Height;
LUSC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.73	10.94	0.51	5.1900000000000004e-24	Menarche (age at onset);
LUSC	cis	rs59698941	0.943	rs67074969	chr5:132251063	T/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	trans	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg07393940	chr7:158741817	NA	0.36	6.43	0.33	4.46e-10	Life satisfaction;
LUSC	cis	rs12928939	0.815	rs11648483	chr16:71707398	T/C	cg08717414	chr16:71523259	ZNF19	-0.41	-5.76	-0.3	1.87e-8	Post bronchodilator FEV1;
LUSC	cis	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg20368463	chr18:77673604	PQLC1	0.63	6.28	0.33	1.03e-9	Opioid sensitivity;
LUSC	cis	rs72627509	0.904	rs781663	chr4:57781754	A/G	cg26694713	chr4:57773883	REST	0.5	6.12	0.32	2.57e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-6.76	-0.35	6.14e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.93	-0.51	5.64e-24	Alzheimer's disease (late onset);
LUSC	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg16342193	chr10:102329863	NA	-0.38	-6.66	-0.34	1.1e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg01448562	chr3:133502909	NA	0.67	10.93	0.51	5.67e-24	Iron status biomarkers;
LUSC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg02475777	chr4:1388615	CRIPAK	0.37	5.68	0.3	2.96e-8	Obesity-related traits;
LUSC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg13628971	chr7:2884303	GNA12	0.5	7.03	0.36	1.17e-11	Height;
LUSC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg22437258	chr11:111473054	SIK2	0.53	7.5	0.38	5.65e-13	Primary sclerosing cholangitis;
LUSC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg00603274	chr11:61596626	FADS2	-0.58	-8.03	-0.4	1.74e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg22532475	chr10:104410764	TRIM8	-0.34	-7.52	-0.38	4.99e-13	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10769966	0.515	rs2568069	chr11:8977707	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.36	6.47	0.33	3.51e-10	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg06627628	chr2:24431161	ITSN2	0.51	7.27	0.37	2.53e-12	Asthma;
LUSC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	8.39	0.42	1.42e-15	Schizophrenia;
LUSC	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg15423357	chr2:25149977	NA	0.44	8.91	0.44	3.33e-17	Body mass index;
LUSC	cis	rs1178968	1.000	rs1178969	chr7:72759114	A/G	cg25889504	chr7:72793014	NA	0.58	7.49	0.38	6.02e-13	Triglyceride levels;
LUSC	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg16989719	chr2:238392110	NA	-0.36	-6.8	-0.35	4.86e-11	Prostate cancer;
LUSC	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.48	-0.33	3.2e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg05855489	chr10:104503620	C10orf26	0.58	9.35	0.46	1.29e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.75	0.35	6.59e-11	Personality dimensions;
LUSC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg11941060	chr3:133502564	NA	-0.47	-6.79	-0.35	5.27e-11	Iron status biomarkers;
LUSC	trans	rs1422110	0.543	rs10035841	chr5:85419597	T/C	cg01787110	chr1:109008453	NBPF6	0.5	8.97	0.44	2.16e-17	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg13010344	chr12:123464640	ARL6IP4	-0.48	-6.44	-0.33	4.12e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	10.83	0.51	1.23e-23	Menopause (age at onset);
LUSC	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg05855489	chr10:104503620	C10orf26	0.65	9.65	0.47	1.38e-19	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg16434002	chr17:42200994	HDAC5	-0.46	-6.43	-0.33	4.32e-10	Total body bone mineral density;
LUSC	cis	rs6669072	1.000	rs3856228	chr1:91247029	T/G	cg08895590	chr1:91227319	NA	-0.36	-8.22	-0.41	4.59e-15	Cognitive function;
LUSC	cis	rs4654899	0.865	rs6665549	chr1:21475884	G/C	cg01072550	chr1:21505969	NA	-0.5	-7.49	-0.38	6.19e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg07395648	chr5:131743802	NA	0.44	7.13	0.36	6.08e-12	Blood metabolite levels;
LUSC	cis	rs877282	0.853	rs11253332	chr10:755262	G/C	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg17366294	chr4:99064904	C4orf37	0.57	8.75	0.43	1.05e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12493885	0.769	rs61791507	chr3:153748886	C/A	cg17054900	chr3:154042577	DHX36	-0.67	-7.06	-0.36	9.76e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4851254	0.660	rs10209201	chr2:100672808	C/T	cg22139774	chr2:100720529	AFF3	-0.43	-5.71	-0.3	2.55e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs1223397	0.938	rs3817737	chr6:13279082	A/G	cg13974761	chr1:152670598	LCE2A	0.36	6.03	0.31	4.31e-9	Blood pressure;
LUSC	cis	rs2835872	0.793	rs2835833	chr21:38987897	A/G	cg20424643	chr21:39039972	KCNJ6	-0.37	-5.8	-0.3	1.57e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs4595586	0.632	rs1356266	chr12:39403581	A/G	cg26384229	chr12:38710491	ALG10B	-0.43	-5.96	-0.31	6.26e-9	Morning vs. evening chronotype;
LUSC	cis	rs10979	0.557	rs9376768	chr6:143909492	C/T	cg25407410	chr6:143891975	LOC285740	-0.65	-8.3	-0.41	2.65e-15	Hypospadias;
LUSC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg15691649	chr6:25882328	NA	-0.38	-6.22	-0.32	1.49e-9	Blood metabolite levels;
LUSC	cis	rs757081	0.667	rs17641418	chr11:17161341	T/C	cg15432903	chr11:17409602	KCNJ11	-0.39	-6.04	-0.31	4e-9	Systolic blood pressure;
LUSC	cis	rs870825	0.616	rs61653735	chr4:185630025	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	13.12	0.58	5.24e-32	Blood protein levels;
LUSC	cis	rs73001065	0.551	rs10424702	chr19:19508013	A/G	cg03709012	chr19:19516395	GATAD2A	0.97	9.18	0.45	4.5e-18	LDL cholesterol;
LUSC	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg15557168	chr22:42548783	NA	-0.38	-5.76	-0.3	1.93e-8	Schizophrenia;
LUSC	cis	rs10140922	0.966	rs10083375	chr14:35823531	C/T	cg07166546	chr14:35805898	NA	-0.26	-6.4	-0.33	5.37e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs9929218	1.000	rs35069703	chr16:68789445	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-11.95	-0.55	1.23e-27	Colorectal cancer;
LUSC	cis	rs4499344	0.504	rs259248	chr19:33148041	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.7	10.44	0.5	2.84e-22	Mean platelet volume;
LUSC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg01879757	chr17:41196368	BRCA1	-0.45	-6.85	-0.35	3.63e-11	Menopause (age at onset);
LUSC	cis	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg21775007	chr8:11205619	TDH	0.47	6.69	0.34	9.25e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg13390004	chr1:15929781	NA	0.41	6.76	0.35	6.35e-11	Systolic blood pressure;
LUSC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg04155289	chr7:94953770	PON1	-0.34	-5.76	-0.3	1.9e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg18187862	chr3:45730750	SACM1L	0.53	7.03	0.36	1.16e-11	Primary sclerosing cholangitis;
LUSC	cis	rs73206853	0.841	rs73206882	chr12:110840515	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs72634258	0.945	rs17523802	chr1:8021740	G/A	cg00042356	chr1:8021962	PARK7	0.85	10.4	0.49	3.8e-22	Inflammatory bowel disease;
LUSC	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.79	0.51	1.7e-23	Coffee consumption (cups per day);
LUSC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg05283184	chr6:79620031	NA	-0.46	-8.73	-0.43	1.21e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg06784218	chr1:46089804	CCDC17	-0.51	-10.05	-0.48	6.2e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg17515076	chr17:73810948	UNK	0.35	5.99	0.31	5.29e-9	White matter hyperintensity burden;
LUSC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg12288994	chr5:1860383	NA	0.29	6.42	0.33	4.77e-10	Cardiovascular disease risk factors;
LUSC	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg00982548	chr2:198649783	BOLL	-0.57	-7.13	-0.36	6.43e-12	Ulcerative colitis;
LUSC	trans	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	5.99	0.31	5.35e-9	Corneal astigmatism;
LUSC	trans	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.08	-0.44	9.93e-18	Depression;
LUSC	cis	rs4776059	0.550	rs8032394	chr15:52868032	G/A	cg22715398	chr15:52968154	KIAA1370	-0.57	-6.71	-0.34	8.48e-11	Schizophrenia;
LUSC	cis	rs3820928	1.000	rs10210763	chr2:227776029	G/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.85	-0.39	5.89e-14	Pulmonary function;
LUSC	trans	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg02030672	chr11:45687055	CHST1	0.43	6.49	0.33	3.18e-10	Obesity-related traits;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17823076	chr12:53574937	ZNF740;CSAD	-0.52	-6.99	-0.36	1.51e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs911119	0.955	rs8121283	chr20:23605002	G/C	cg16589663	chr20:23618590	CST3	0.57	6.82	0.35	4.18e-11	Chronic kidney disease;
LUSC	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg08668510	chr10:1095578	IDI1	0.74	6.62	0.34	1.47e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs6546886	0.912	rs13387010	chr2:74294654	A/G	cg14702570	chr2:74259524	NA	-0.31	-5.83	-0.3	1.33e-8	Dialysis-related mortality;
LUSC	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg14844989	chr11:31128820	NA	0.37	5.77	0.3	1.81e-8	Red blood cell count;
LUSC	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.53	-0.38	4.91e-13	Retinal vascular caliber;
LUSC	cis	rs1507153	0.614	rs236882	chr6:79316113	A/G	cg05283184	chr6:79620031	NA	0.38	7.0	0.36	1.37e-11	Sjögren's syndrome;
LUSC	cis	rs983392	0.709	rs7928895	chr11:59975165	G/A	cg20284999	chr11:59952153	MS4A6A	-0.38	-6.28	-0.32	1.06e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10203711	0.673	rs9677610	chr2:239621531	G/A	cg14580085	chr2:239553406	NA	0.42	6.98	0.36	1.61e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.66	10.93	0.51	5.5e-24	Schizophrenia;
LUSC	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg24130564	chr14:104152367	KLC1	-0.73	-11.75	-0.54	6.45e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.47	6.8	0.35	4.74e-11	Menarche (age at onset);
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg25719132	chr2:70520671	SNRPG	0.43	6.84	0.35	3.69e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs16937	0.711	rs4333898	chr1:205169613	C/T	cg00857998	chr1:205179979	DSTYK	0.46	6.54	0.34	2.36e-10	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.77	0.47	5.18e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg04369109	chr6:150039330	LATS1	-0.55	-8.2	-0.41	5.09e-15	Lung cancer;
LUSC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg17211192	chr8:82754475	SNX16	-0.78	-10.68	-0.5	4.1000000000000003e-23	Diastolic blood pressure;
LUSC	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg15445000	chr17:37608096	MED1	-0.4	-6.79	-0.35	5.25e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.65	-10.87	-0.51	9.03e-24	Caffeine consumption;
LUSC	cis	rs9395066	0.545	rs12525009	chr6:44875843	C/T	cg25276700	chr6:44698697	NA	0.3	5.99	0.31	5.45e-9	Height;
LUSC	trans	rs11751618	0.532	rs9450467	chr6:87193382	T/C	cg10525134	chr8:58191969	C8orf71	0.43	6.03	0.31	4.36e-9	Gut microbiome composition (winter);
LUSC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24110177	chr3:50126178	RBM5	-0.6	-9.73	-0.47	7.5599999999999994e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg05872129	chr22:39784769	NA	-0.59	-10.78	-0.51	1.82e-23	Intelligence (multi-trait analysis);
LUSC	trans	rs72674100	1.000	rs72882341	chr4:97993768	G/C	cg16405019	chr1:18959625	PAX7	-0.61	-6.41	-0.33	5.09e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6690583	0.623	rs75918067	chr1:85453413	T/C	cg22153463	chr1:85462885	MCOLN2	0.62	6.0	0.31	5.12e-9	Serum sulfate level;
LUSC	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg03474202	chr17:45855739	NA	-0.29	-6.83	-0.35	4.06e-11	IgG glycosylation;
LUSC	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.37	0.64	1.04e-40	Morning vs. evening chronotype;
LUSC	cis	rs7589342	0.862	rs6745887	chr2:106468039	G/A	cg14210321	chr2:106509881	NCK2	-0.5	-7.26	-0.37	2.75e-12	Addiction;
LUSC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-8.93	-0.44	2.9e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.59	-6.41	-0.33	4.99e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs28595532	0.623	rs34284204	chr4:119227672	C/T	cg21605333	chr4:119757512	SEC24D	0.73	6.13	0.32	2.46e-9	Cannabis dependence symptom count;
LUSC	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg14696996	chr19:15285081	NOTCH3	0.96	9.25	0.45	2.69e-18	Pulse pressure;
LUSC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-0.91	-15.95	-0.66	5.46e-43	Cognitive function;
LUSC	trans	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg14227996	chr4:17616232	MED28	0.57	6.4	0.33	5.22e-10	Opioid sensitivity;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21721210	chr19:39574878	PAPL	-0.44	-6.01	-0.31	4.94e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs417096	0.929	rs455396	chr6:39734557	A/G	cg17457912	chr17:1617102	C17orf91	-0.33	-6.4	-0.33	5.3e-10	Hypospadias;
LUSC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs12980942	1.000	rs12984160	chr19:41815713	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.57	6.16	0.32	2.05e-9	Coronary artery disease;
LUSC	cis	rs9378688	0.654	rs2505659	chr6:2326637	G/A	cg12303981	chr6:2244766	GMDS	-0.44	-6.12	-0.32	2.61e-9	Caudate nucleus volume;
LUSC	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg22431228	chr1:16359049	CLCNKA	0.32	5.84	0.3	1.23e-8	Dilated cardiomyopathy;
LUSC	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.91	15.54	0.65	2.38e-41	Bladder cancer;
LUSC	cis	rs6076065	0.723	rs6137908	chr20:23344590	G/A	cg11657817	chr20:23433608	CST11	0.44	8.18	0.41	6.2e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.6	-9.78	-0.47	4.89e-20	Body mass index;
LUSC	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.72e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg26043149	chr18:55253948	FECH	0.56	8.79	0.43	8.09e-17	Bone mineral density;
LUSC	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.5	-7.41	-0.38	1.03e-12	Coronary heart disease;
LUSC	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg15704280	chr7:45808275	SEPT13	0.93	13.42	0.59	3.7e-33	Coronary artery disease;
LUSC	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg11887960	chr12:57824829	NA	0.55	7.21	0.37	3.7e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg23262073	chr20:60523788	NA	-0.39	-5.95	-0.31	6.89e-9	Body mass index;
LUSC	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg13010199	chr12:38710504	ALG10B	0.54	8.45	0.42	9.36e-16	Morning vs. evening chronotype;
LUSC	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg06627628	chr2:24431161	ITSN2	-0.59	-7.16	-0.36	5.28e-12	Lymphocyte counts;
LUSC	cis	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg24375607	chr4:120327624	NA	-0.47	-7.32	-0.37	1.85e-12	Diastolic blood pressure;
LUSC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg13683864	chr3:40499215	RPL14	1.12	19.99	0.74	5.25e-59	Renal cell carcinoma;
LUSC	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.88	-0.31	9.79e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9400467	0.528	rs11153292	chr6:111722379	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.98	-0.36	1.56e-11	Blood metabolite levels;Amino acid levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07117119	chr16:68119705	NFATC3	-0.46	-7.09	-0.36	8.23e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg14458575	chr2:238380390	NA	0.71	12.4	0.56	2.54e-29	Prostate cancer;
LUSC	cis	rs721399	0.719	rs12674710	chr8:18263663	A/C	cg18736775	chr8:18248649	NAT2	-0.56	-6.94	-0.36	2e-11	Blood metabolite levels;
LUSC	cis	rs377070	0.934	rs309411	chr4:123620150	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.45	6.67	0.34	1.05e-10	Mosquito bite size;
LUSC	cis	rs524023	0.915	rs531763	chr11:64352063	A/G	cg07220939	chr11:64358617	SLC22A12	0.23	5.9	0.31	8.69e-9	Urate levels in obese individuals;
LUSC	cis	rs6500395	1.000	rs1420704	chr16:48716902	C/T	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg24558204	chr6:135376177	HBS1L	0.68	10.82	0.51	1.32e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00152838	chr16:24741724	TNRC6A	-0.46	-5.69	-0.3	2.74e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	0.91	13.5	0.59	1.98e-33	Breast cancer;
LUSC	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg22681709	chr2:178499509	PDE11A	0.46	8.49	0.42	6.84e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4666002	0.956	rs10169065	chr2:27778560	A/G	cg27432699	chr2:27873401	GPN1	0.41	5.7	0.3	2.69e-8	Phospholipid levels (plasma);
LUSC	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.42	6.56	0.34	2.1e-10	Dupuytren's disease;
LUSC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg08470875	chr2:26401718	FAM59B	-0.66	-8.99	-0.44	1.91e-17	Gut microbiome composition (summer);
LUSC	cis	rs1014246	0.807	rs10886003	chr10:118461226	G/A	cg14919929	chr10:118506882	NA	0.47	7.24	0.37	3.19e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12195820	chr8:42698243	THAP1	0.44	6.63	0.34	1.36e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg09365446	chr1:150670422	GOLPH3L	-0.42	-6.12	-0.32	2.56e-9	Tonsillectomy;
LUSC	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg17507749	chr15:85114479	UBE2QP1	0.71	9.36	0.46	1.2e-18	Schizophrenia;
LUSC	trans	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.37	0.49	4.82e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1014246	0.784	rs4751610	chr10:118473730	T/C	cg14919929	chr10:118506882	NA	-0.42	-6.71	-0.34	8.24e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg09365446	chr1:150670422	GOLPH3L	0.49	7.22	0.37	3.63e-12	Melanoma;
LUSC	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg27284194	chr4:1044797	NA	0.59	8.8	0.43	7.59e-17	Recombination rate (females);
LUSC	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.47	-7.18	-0.37	4.48e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg25319279	chr11:5960081	NA	-0.45	-6.25	-0.32	1.24e-9	DNA methylation (variation);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13411962	chr8:28243934	ZNF395	-0.54	-6.41	-0.33	5.03e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02018176	chr4:1364513	KIAA1530	0.74	14.1	0.61	9.53e-36	Longevity;
LUSC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg00933542	chr6:150070202	PCMT1	0.32	6.7	0.34	8.68e-11	Lung cancer;
LUSC	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg24642439	chr20:33292090	TP53INP2	-0.39	-5.67	-0.3	3.14e-8	Height;
LUSC	cis	rs2637266	0.967	rs12254242	chr10:78352934	T/C	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	trans	rs5747327	0.557	rs2895951	chr22:18232368	C/T	cg13083436	chr11:24518414	LUZP2	0.31	5.96	0.31	6.5e-9	Myeloid white cell count;Granulocyte count;
LUSC	cis	rs9653442	0.900	rs2309837	chr2:100837567	T/C	cg07810366	chr2:100720526	AFF3	-0.47	-8.03	-0.4	1.68e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-6.59	-0.34	1.69e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.95	0.31	6.76e-9	Self-reported allergy;
LUSC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.8	12.79	0.57	9.2e-31	Breast cancer;
LUSC	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg05768032	chr16:30646687	NA	0.38	5.67	0.3	3.07e-8	Multiple myeloma;
LUSC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26314531	chr2:26401878	FAM59B	-0.71	-10.02	-0.48	7.96e-21	Gut microbiome composition (summer);
LUSC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg23711669	chr6:146136114	FBXO30	0.73	12.89	0.58	3.92e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2348418	0.715	rs12307612	chr12:28719646	C/T	cg13890972	chr12:28721907	NA	-0.39	-6.87	-0.35	3.24e-11	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg06640241	chr16:89574553	SPG7	0.89	16.03	0.66	2.65e-43	Multiple myeloma (IgH translocation);
LUSC	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg05805236	chr11:65401703	PCNXL3	-0.63	-10.33	-0.49	6.71e-22	Acne (severe);
LUSC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg03354898	chr7:1950403	MAD1L1	-0.42	-8.57	-0.42	3.93e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.68	11.06	0.52	2e-24	Total cholesterol levels;
LUSC	cis	rs4629180	0.675	rs6707298	chr2:102089738	A/G	cg04415270	chr2:102091202	RFX8	0.46	7.99	0.4	2.27e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7582720	1.000	rs6723704	chr2:203738664	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.56	0.42	4.25e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs1927790	0.759	rs12585563	chr13:96991847	A/G	cg03198741	chr6:1003969	LOC285768	-0.4	-5.97	-0.31	5.97e-9	Body mass index;
LUSC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg06008330	chr7:65541103	ASL	0.4	6.21	0.32	1.57e-9	Aortic root size;
LUSC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.57	0.34	1.95e-10	Tonsillectomy;
LUSC	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.51	-8.47	-0.42	7.66e-16	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06544989	chr22:39130855	UNC84B	0.38	6.77	0.35	5.8200000000000003e-11	Menopause (age at onset);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08052428	chr9:135996421	RALGDS	0.43	6.14	0.32	2.29e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg11062466	chr8:58055876	NA	0.66	8.56	0.42	4.33e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-7.86	-0.4	5.38e-14	Dental caries;
LUSC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg20135002	chr11:47629003	NA	-0.51	-8.14	-0.41	8.16e-15	Subjective well-being;
LUSC	cis	rs6893300	0.524	rs12374446	chr5:179131143	A/G	cg14593053	chr5:179126677	CANX	0.48	7.43	0.38	9.08e-13	Resting heart rate;
LUSC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg22166914	chr1:53195759	ZYG11B	0.52	8.64	0.43	2.29e-16	Monocyte count;
LUSC	cis	rs4474465	0.850	rs10751292	chr11:78242201	C/G	cg27205649	chr11:78285834	NARS2	0.54	6.39	0.33	5.5e-10	Alzheimer's disease (survival time);
LUSC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg04155289	chr7:94953770	PON1	-0.36	-5.96	-0.31	6.54e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-6.56	-0.34	2.1e-10	Fear of minor pain;
LUSC	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg04719120	chr6:96025338	MANEA	0.46	5.78	0.3	1.72e-8	Behavioural disinhibition (generation interaction);
LUSC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00166722	chr3:10149974	C3orf24	0.55	7.54	0.38	4.57e-13	Alzheimer's disease;
LUSC	cis	rs11209002	0.522	rs2224502	chr1:67539439	A/G	cg02640540	chr1:67518911	SLC35D1	0.62	8.53	0.42	5.27e-16	Crohn's disease;
LUSC	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg05187965	chr10:45406764	TMEM72	-0.37	-8.71	-0.43	1.4e-16	Mean corpuscular volume;
LUSC	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg04998671	chr14:104000505	TRMT61A	0.43	6.18	0.32	1.83e-9	Reticulocyte count;
LUSC	trans	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg18187862	chr3:45730750	SACM1L	-0.55	-6.78	-0.35	5.52e-11	Primary sclerosing cholangitis;
LUSC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	8.0	0.4	2.05e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg16797656	chr11:68205561	LRP5	0.38	6.22	0.32	1.47e-9	Total body bone mineral density;
LUSC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg08270630	chr22:50330655	NA	-0.61	-7.72	-0.39	1.37e-13	Schizophrenia;
LUSC	cis	rs240764	0.817	rs239201	chr6:101123993	T/A	cg09795085	chr6:101329169	ASCC3	0.42	6.11	0.32	2.83e-9	Neuroticism;
LUSC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg02574844	chr11:5959923	NA	-0.46	-7.47	-0.38	6.95e-13	DNA methylation (variation);
LUSC	cis	rs3099143	1.000	rs3099137	chr15:77123626	G/A	cg21673338	chr15:77095150	SCAPER	-0.81	-7.62	-0.38	2.59e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.48	-8.93	-0.44	2.94e-17	Urinary metabolites;
LUSC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg03213289	chr20:61660250	NA	0.67	13.65	0.6	5.25e-34	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05901451	chr6:126070800	HEY2	0.57	8.57	0.42	3.96e-16	Endometrial cancer;
LUSC	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg25233709	chr10:116636983	FAM160B1	0.39	6.66	0.34	1.14e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg25036284	chr2:26402008	FAM59B	-0.74	-10.51	-0.5	1.66e-22	Gut microbiome composition (summer);
LUSC	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg16230307	chr14:35515116	FAM177A1	0.5	6.37	0.33	6.28e-10	Psoriasis;
LUSC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18876405	chr7:65276391	NA	0.54	8.23	0.41	4.27e-15	Aortic root size;
LUSC	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.04	0.31	4.1e-9	Schizophrenia;
LUSC	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-6.05	-0.31	3.84e-9	Resting heart rate;
LUSC	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.85	-0.44	5.12e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2742234	0.578	rs2435354	chr10:43652445	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.42	-7.06	-0.36	9.54e-12	Hirschsprung disease;
LUSC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg03538708	chr1:25844672	NA	-0.35	-5.76	-0.3	1.9e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs35883536	0.967	rs2050471	chr1:101175651	C/T	cg06223162	chr1:101003688	GPR88	0.32	5.85	0.3	1.17e-8	Monocyte count;
LUSC	trans	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	6.7	0.34	9.03e-11	Retinal vascular caliber;
LUSC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg14403583	chr14:105418241	AHNAK2	0.56	9.32	0.45	1.67e-18	Rheumatoid arthritis;
LUSC	cis	rs17095355	1.000	rs734165	chr10:111697789	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.65	-7.81	-0.39	7.6e-14	Biliary atresia;
LUSC	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.7	-0.39	1.5700000000000001e-13	Testicular germ cell tumor;
LUSC	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg24634471	chr8:143751801	JRK	0.58	8.75	0.43	1.07e-16	Schizophrenia;
LUSC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.84	15.42	0.64	6.99e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg07148914	chr20:33460835	GGT7	-0.52	-8.1	-0.41	1.02e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.98	-0.36	1.57e-11	Bipolar disorder;
LUSC	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.75	-11.64	-0.54	1.58e-26	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs6429082	0.521	rs291390	chr1:235649678	T/C	cg26050004	chr1:235667680	B3GALNT2	0.8	13.86	0.6	8.36e-35	Adiposity;
LUSC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-1.01	-17.07	-0.68	2.08e-47	Body mass index;
LUSC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg24690094	chr11:67383802	NA	0.44	8.21	0.41	4.77e-15	Mean corpuscular volume;
LUSC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg01516881	chr6:292596	DUSP22	-0.51	-7.19	-0.37	4.31e-12	Menopause (age at onset);
LUSC	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg04677158	chr5:78279841	ARSB	-0.46	-7.16	-0.36	5.11e-12	Blood and toenail selenium levels;Blood trace element (Se levels);
LUSC	cis	rs7538876	0.935	rs11577822	chr1:17754608	T/G	cg07965774	chr1:17746286	RCC2	0.31	5.83	0.3	1.34e-8	Basal cell carcinoma;
LUSC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg21951975	chr1:209979733	IRF6	0.58	7.61	0.38	2.76e-13	Cleft lip with or without cleft palate;
LUSC	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg24449463	chr1:168025552	DCAF6	-0.63	-9.66	-0.47	1.27e-19	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.18	0.45	4.54e-18	Motion sickness;
LUSC	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg09307838	chr4:120376055	NA	0.75	10.74	0.51	2.58e-23	Corneal astigmatism;
LUSC	cis	rs7113850	0.541	rs4451727	chr11:24216855	G/C	ch.11.24196551F	chr11:24239977	NA	0.96	8.77	0.43	9.54e-17	Bone fracture in osteoporosis;
LUSC	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg09754948	chr16:28834200	ATXN2L	0.44	6.43	0.33	4.51e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg14092571	chr14:90743983	NA	-0.35	-5.68	-0.3	2.89e-8	Mortality in heart failure;
LUSC	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.45	-0.42	9.13e-16	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	trans	rs7939886	0.920	rs12223248	chr11:55887633	A/C	cg03929089	chr4:120376271	NA	0.75	6.17	0.32	2.02e-9	Myopia (pathological);
LUSC	trans	rs2262909	0.962	rs73019844	chr19:22249925	T/C	cg05197062	chr11:11642011	GALNTL4	0.56	7.88	0.4	4.75e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7605827	0.930	rs6750232	chr2:15714958	C/T	cg19274914	chr2:15703543	NA	0.46	8.9	0.44	3.68e-17	Educational attainment (years of education);
LUSC	cis	rs981844	0.775	rs17371336	chr4:154749525	A/G	cg14289246	chr4:154710475	SFRP2	0.48	6.43	0.33	4.46e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg17279839	chr7:150038598	RARRES2	0.49	7.49	0.38	6.18e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12542260	0.817	rs117952028	chr8:125471390	C/A	cg27038428	chr8:125485867	RNF139	0.33	6.66	0.34	1.15e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.94	0.31	7.17e-9	Menopause (age at onset);
LUSC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs11997175	0.572	rs7836230	chr8:33623250	T/C	ch.8.33884649F	chr8:33765107	NA	0.51	8.15	0.41	7.39e-15	Body mass index;
LUSC	cis	rs2348418	0.864	rs7295120	chr12:28718108	C/A	cg13890972	chr12:28721907	NA	-0.34	-5.92	-0.31	7.94e-9	Lung function (FVC);Lung function (FEV1);
LUSC	trans	rs8073060	0.586	rs35542792	chr17:33903886	A/G	cg19694781	chr19:47549865	TMEM160	1.12	18.02	0.7	3.55e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg27661571	chr11:113659931	NA	0.67	6.6	0.34	1.59e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg20203395	chr5:56204925	C5orf35	0.46	6.83	0.35	4.09e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg25801113	chr15:45476975	SHF	0.34	7.0	0.36	1.37e-11	Uric acid levels;
LUSC	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg07701084	chr6:150067640	NUP43	0.54	8.09	0.4	1.12e-14	Lung cancer;
LUSC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg02551604	chr5:131831745	NA	-0.42	-6.62	-0.34	1.39e-10	Asthma (sex interaction);
LUSC	cis	rs227833	0.955	rs227836	chr6:44682740	C/G	cg20913747	chr6:44695427	NA	0.38	5.75	0.3	1.98e-8	Monobrow;
LUSC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	0.64	13.57	0.6	1e-33	Prudent dietary pattern;
LUSC	cis	rs17095355	1.000	rs12242642	chr10:111724213	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.49	-0.38	6.22e-13	Biliary atresia;
LUSC	cis	rs11051970	0.553	rs325419	chr12:32572460	A/G	cg02745156	chr12:32552066	NA	0.38	6.9	0.35	2.67e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.35	0.53	1.86e-25	Mean corpuscular volume;
LUSC	trans	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg25482853	chr8:67687455	SGK3	1.1	15.29	0.64	2.28e-40	Obesity-related traits;
LUSC	cis	rs4919687	0.550	rs11191372	chr10:104462187	T/C	cg04362960	chr10:104952993	NT5C2	0.47	6.85	0.35	3.52e-11	Colorectal cancer;
LUSC	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-1.24	-18.99	-0.72	4.75e-55	Blood pressure (smoking interaction);
LUSC	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.77	0.39	9.81e-14	Iron status biomarkers;
LUSC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22029157	chr1:209979665	IRF6	0.74	10.99	0.52	3.49e-24	Cleft lip with or without cleft palate;
LUSC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg12463550	chr7:65579703	CRCP	-0.47	-7.1	-0.36	7.5e-12	Aortic root size;
LUSC	cis	rs6546537	0.826	rs2704443	chr2:69889338	A/C	cg10773587	chr2:69614142	GFPT1	-0.53	-8.12	-0.41	9.2e-15	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01570182	chr17:44337453	NA	0.7	10.59	0.5	8.79e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.93	-0.4	3.36e-14	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg13010199	chr12:38710504	ALG10B	0.43	6.2	0.32	1.62e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs8060598	0.866	rs3135499	chr16:50766127	G/T	ch.13.721274R	chr13:51955414	INTS6	-0.4	-6.2	-0.32	1.62e-9	Leprosy;
LUSC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03576123	chr11:487126	PTDSS2	-1.12	-11.87	-0.54	2.31e-27	Body mass index;
LUSC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg04775059	chr7:64541387	NA	0.53	7.7	0.39	1.54e-13	Calcium levels;
LUSC	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.09	0.32	3.12e-9	Corneal astigmatism;
LUSC	cis	rs662064	0.962	rs2506901	chr1:10563492	A/G	cg20482658	chr1:10539492	PEX14	0.33	6.74	0.35	6.98e-11	Asthma;
LUSC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.52	0.38	4.99e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4704187	0.640	rs1600075	chr5:74418304	G/A	cg03227963	chr5:74354835	NA	0.32	6.81	0.35	4.62e-11	Response to amphetamines;
LUSC	cis	rs16958440	0.708	rs57468764	chr18:44624856	T/C	cg17192377	chr18:44677553	HDHD2	0.43	5.67	0.3	3.06e-8	Sitting height ratio;
LUSC	cis	rs2658782	0.654	rs2605622	chr11:93248242	A/G	cg15737290	chr11:93063684	CCDC67	0.61	7.65	0.39	2.18e-13	Pulmonary function decline;
LUSC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	trans	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg01620082	chr3:125678407	NA	-0.87	-7.72	-0.39	1.34e-13	Depression;
LUSC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg06740227	chr12:86229804	RASSF9	0.45	7.15	0.36	5.35e-12	Major depressive disorder;
LUSC	cis	rs7000551	0.532	rs55726237	chr8:22252985	C/T	cg12081754	chr8:22256438	SLC39A14	0.97	15.29	0.64	2.15e-40	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.53	8.5	0.42	6.22e-16	Bone mineral density;
LUSC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg04025307	chr7:1156635	C7orf50	0.43	6.26	0.32	1.21e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4889855	0.556	rs4278795	chr17:78533189	A/T	cg16591659	chr17:78472290	NA	0.32	6.14	0.32	2.39e-9	Fractional excretion of uric acid;
LUSC	cis	rs9653442	0.510	rs11891046	chr2:100794402	C/G	cg07810366	chr2:100720526	AFF3	-0.42	-7.18	-0.37	4.46e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs350251	0.524	rs350250	chr16:12202524	C/G	cg00459119	chr16:12172834	SNX29	-0.37	-6.06	-0.31	3.71e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg02176678	chr2:219576539	TTLL4	-0.59	-10.42	-0.5	3.24e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg27094323	chr7:1216898	NA	-0.39	-6.65	-0.34	1.21e-10	Longevity;Endometriosis;
LUSC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.76	-13.6	-0.6	7.84e-34	Dental caries;
LUSC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.94	-0.36	2.04e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.53e-12	Motion sickness;
LUSC	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg19773385	chr1:10388646	KIF1B	-0.49	-8.54	-0.42	4.68e-16	Hepatocellular carcinoma;
LUSC	trans	rs34421088	0.576	rs2572437	chr8:11098441	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.95	-0.31	6.67e-9	Neuroticism;
LUSC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg26338869	chr17:61819248	STRADA	0.4	5.77	0.3	1.81e-8	Prudent dietary pattern;
LUSC	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-6.93	-0.35	2.18e-11	Bladder cancer;
LUSC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.58	10.65	0.5	5.52e-23	Homoarginine levels;
LUSC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg25036284	chr2:26402008	FAM59B	-0.67	-9.38	-0.46	1.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08045932	chr20:61659980	NA	0.55	9.23	0.45	3.17e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg05861140	chr6:150128134	PCMT1	-0.38	-5.94	-0.31	7.1e-9	Lung cancer;
LUSC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.86	14.12	0.61	7.7e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg25036284	chr2:26402008	FAM59B	-0.71	-10.34	-0.49	6.12e-22	Gut microbiome composition (summer);
LUSC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	0.92	15.35	0.64	1.26e-40	Menopause (age at onset);
LUSC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg25019033	chr10:957182	NA	-0.53	-6.93	-0.35	2.15e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.66	-10.2	-0.49	1.89e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9296095	0.747	rs12206050	chr6:33564296	A/T	cg14003231	chr6:33640908	ITPR3	0.51	8.04	0.4	1.54e-14	Platelet count;
LUSC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	0.94	17.87	0.7	1.34e-50	Heart rate;
LUSC	cis	rs11971779	0.715	rs7787398	chr7:139061846	A/G	cg07862535	chr7:139043722	LUC7L2	0.6	7.47	0.38	6.89e-13	Diisocyanate-induced asthma;
LUSC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.38	-8.49	-0.42	6.67e-16	Longevity;Endometriosis;
LUSC	trans	rs11743006	0.626	rs11748042	chr5:136497231	T/A	cg07379741	chr17:7311030	NLGN2	0.4	5.97	0.31	6.15e-9	Mathematical ability;
LUSC	cis	rs10992471	0.603	rs10820968	chr9:95106443	A/G	cg14631576	chr9:95140430	CENPP	-0.38	-6.68	-0.34	1.03e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg05941027	chr17:61774174	LIMD2	0.22	5.82	0.3	1.4e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg06636551	chr8:101224915	SPAG1	-0.38	-7.13	-0.36	6.31e-12	Atrioventricular conduction;
LUSC	trans	rs62238980	0.614	rs734092	chr22:32462167	C/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.52	-6.06	-0.31	3.6e-9	Childhood ear infection;
LUSC	cis	rs9905704	0.671	rs2068710	chr17:56594535	C/G	cg19466818	chr17:56409534	MIR142	0.36	6.82	0.35	4.32e-11	Testicular germ cell tumor;
LUSC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.9	-0.35	2.58e-11	Menopause (age at onset);
LUSC	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg07741184	chr6:167504864	NA	-0.39	-7.07	-0.36	8.84e-12	Primary biliary cholangitis;
LUSC	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg04990556	chr1:26633338	UBXN11	0.88	11.64	0.54	1.61e-26	Obesity-related traits;
LUSC	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-7.11	-0.36	7.25e-12	Colorectal cancer;
LUSC	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg09835421	chr16:68378352	PRMT7	-0.47	-5.88	-0.31	9.72e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20185145	chr6:7230113	RREB1	0.48	6.81	0.35	4.57e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.78	0.43	8.85e-17	Prudent dietary pattern;
LUSC	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg24006582	chr15:45444508	DUOX1	-0.6	-8.75	-0.43	1.04e-16	Uric acid levels;
LUSC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs10789491	0.767	rs1595898	chr1:47193577	G/A	cg15501359	chr1:47185051	KIAA0494	0.78	10.2	0.49	1.91e-21	Response to hepatitis C treatment;
LUSC	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg26384229	chr12:38710491	ALG10B	0.57	8.58	0.42	3.71e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	6.9	0.35	2.68e-11	Height;
LUSC	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-0.76	-12.13	-0.55	2.63e-28	Height;
LUSC	trans	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21659725	chr3:3221576	CRBN	0.64	9.29	0.45	2.04e-18	Resting heart rate;
LUSC	cis	rs977987	0.835	rs3863445	chr16:75371744	C/G	cg04384234	chr16:75411784	CFDP1	-0.43	-6.89	-0.35	2.74e-11	Dupuytren's disease;
LUSC	cis	rs17407555	0.738	rs56143194	chr4:10067535	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-6.62	-0.34	1.45e-10	Schizophrenia (age at onset);
LUSC	cis	rs11264799	0.765	rs2152710	chr1:157626964	A/G	cg18268488	chr1:157545234	FCRL4	0.33	5.8	0.3	1.57e-8	IgA nephropathy;
LUSC	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.55	0.62	1.76e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg12454169	chr2:30669597	LCLAT1	0.7	9.06	0.44	1.11e-17	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg00316803	chr15:76480434	C15orf27	-0.4	-6.8	-0.35	4.95e-11	Blood metabolite levels;
LUSC	cis	rs240764	0.578	rs9322216	chr6:101251720	A/C	cg09795085	chr6:101329169	ASCC3	-0.45	-6.55	-0.34	2.14e-10	Neuroticism;
LUSC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.4	6.06	0.31	3.57e-9	Menopause (age at onset);
LUSC	cis	rs7582720	1.000	rs3845800	chr2:203734365	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.68	-7.76	-0.39	1.05e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1044826	1.000	rs3821544	chr3:139190188	C/T	cg00490450	chr3:139108681	COPB2	0.52	6.78	0.35	5.37e-11	Obesity-related traits;
LUSC	cis	rs308403	0.533	rs12644866	chr4:123667604	T/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.95	17.16	0.68	9.27e-48	Blood protein levels;
LUSC	cis	rs60154123	0.614	rs12069491	chr1:210460899	A/G	cg22029157	chr1:209979665	IRF6	0.51	5.8	0.3	1.56e-8	Coronary artery disease;
LUSC	cis	rs354225	0.626	rs6740893	chr2:54834380	G/A	cg26097391	chr2:54893211	SPTBN1	0.39	5.64	0.3	3.54e-8	Schizophrenia;
LUSC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-1.12	-25.14	-0.81	4.96e-79	Height;
LUSC	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.72	0.35	8.08e-11	Corneal astigmatism;
LUSC	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg08132940	chr7:1081526	C7orf50	-0.52	-6.07	-0.32	3.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2540226	0.935	rs7591347	chr2:39955465	C/T	cg23576258	chr2:39999331	THUMPD2	0.34	5.68	0.3	2.91e-8	Personality dimensions;
LUSC	cis	rs12594515	1.000	rs8029209	chr15:45993489	A/G	cg01629716	chr15:45996671	NA	0.38	5.72	0.3	2.31e-8	Waist circumference;Weight;
LUSC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg00784671	chr22:46762841	CELSR1	-0.49	-6.06	-0.31	3.75e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.64	-0.39	2.31e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg15445000	chr17:37608096	MED1	0.4	6.74	0.35	6.92e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs8099014	0.954	rs6566971	chr18:56123702	C/G	cg12907477	chr18:56117327	MIR122	0.44	7.04	0.36	1.07e-11	Platelet count;
LUSC	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	7.68	0.39	1.78e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg13010344	chr12:123464640	ARL6IP4	-0.44	-5.92	-0.31	7.93e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg17330251	chr7:94953956	PON1	-0.39	-6.51	-0.34	2.83e-10	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06873352	chr17:61820015	STRADA	0.56	8.9	0.44	3.5e-17	Height;
LUSC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg23172400	chr8:95962367	TP53INP1	-0.47	-9.59	-0.46	2.13e-19	Type 2 diabetes;
LUSC	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg02569458	chr12:86230093	RASSF9	0.42	6.85	0.35	3.49e-11	Major depressive disorder;
LUSC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.54	7.71	0.39	1.5e-13	Alzheimer's disease (late onset);
LUSC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg18876405	chr7:65276391	NA	-0.58	-9.31	-0.45	1.8e-18	Aortic root size;
LUSC	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg18825076	chr15:78729989	IREB2	-0.45	-6.1	-0.32	2.87e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.72	-11.25	-0.52	4.13e-25	Alcohol dependence;
LUSC	trans	rs28647808	0.748	rs114667516	chr9:136258537	A/G	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg02931644	chr1:25747376	RHCE	0.33	5.94	0.31	7.1e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg16447950	chr5:562315	NA	-0.47	-6.36	-0.33	6.51e-10	Obesity-related traits;
LUSC	cis	rs4786125	0.581	rs1967404	chr16:6921483	G/A	cg03623568	chr16:6915990	A2BP1	-0.46	-7.82	-0.39	6.88e-14	Heart rate variability traits (SDNN);
LUSC	cis	rs3755132	0.633	rs16862856	chr2:15794281	C/G	cg12888861	chr2:15731646	DDX1	0.53	7.63	0.39	2.41e-13	Wilms tumor;
LUSC	cis	rs9549260	0.651	rs9549251	chr13:41228650	A/G	cg21288729	chr13:41239152	FOXO1	0.64	9.95	0.48	1.38e-20	Red blood cell count;
LUSC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg19266014	chr7:2183958	MAD1L1	-0.34	-5.64	-0.3	3.57e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.24	0.52	4.42e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.86	-0.31	1.13e-8	Alzheimer's disease (late onset);
LUSC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg02428538	chr16:24856791	SLC5A11	0.51	5.97	0.31	6.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg13628971	chr7:2884303	GNA12	0.47	6.76	0.35	6.34e-11	Height;
LUSC	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg23093090	chr10:104574429	C10orf26	-0.35	-6.4	-0.33	5.2e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1451375	0.698	rs11238226	chr7:50645827	A/G	cg18232548	chr7:50535776	DDC	0.5	7.58	0.38	3.49e-13	Malaria;
LUSC	cis	rs11209185	0.509	rs1938424	chr1:68431722	A/G	cg22082780	chr1:68452167	NA	-0.44	-7.16	-0.36	5.29e-12	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs3812762	0.957	rs6484008	chr11:8754148	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.37	6.5	0.34	2.95e-10	Hypospadias;
LUSC	cis	rs4654899	0.680	rs3890762	chr1:21198265	G/A	cg01072550	chr1:21505969	NA	0.48	7.39	0.37	1.21e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9395066	0.545	rs10456119	chr6:44889045	C/T	cg25276700	chr6:44698697	NA	0.31	6.25	0.32	1.25e-9	Height;
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.71	-14.51	-0.62	2.57e-37	Longevity;Endometriosis;
LUSC	cis	rs2798269	1.000	rs12430739	chr13:22146413	A/T	cg18095732	chr13:22033692	ZDHHC20	-0.39	-5.94	-0.31	7.18e-9	PR segment;
LUSC	cis	rs7216064	0.531	rs6504573	chr17:66015963	C/T	cg12091567	chr17:66097778	LOC651250	-0.71	-10.86	-0.51	1.03e-23	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg00409905	chr10:38381863	ZNF37A	-0.34	-5.97	-0.31	6.09e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg06784218	chr1:46089804	CCDC17	-0.55	-11.14	-0.52	1.01e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg14036092	chr11:66035641	RAB1B	0.45	6.51	0.34	2.75e-10	Gout;
LUSC	cis	rs6906287	0.647	rs7772921	chr6:118964623	C/G	cg21191810	chr6:118973309	C6orf204	0.32	5.94	0.31	7.14e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg04450456	chr4:17643702	FAM184B	0.4	6.85	0.35	3.63e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08677398	chr8:58056175	NA	0.52	6.37	0.33	6.16e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg23711669	chr6:146136114	FBXO30	0.88	16.35	0.67	1.45e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-10.44	-0.5	2.98e-22	Electroencephalogram traits;
LUSC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg02475777	chr4:1388615	CRIPAK	0.37	5.67	0.3	3.06e-8	Obesity-related traits;
LUSC	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg00677455	chr12:58241039	CTDSP2	0.48	6.38	0.33	5.74e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg23887609	chr12:130822674	PIWIL1	0.47	7.1	0.36	7.61e-12	Menopause (age at onset);
LUSC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.31	-0.33	8.87e-10	Personality dimensions;
LUSC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	6.73	0.35	7.22e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg25206134	chr2:45395956	NA	0.57	6.5	0.34	2.92e-10	Bipolar disorder;
LUSC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.4	-6.63	-0.34	1.38e-10	Longevity;Endometriosis;
LUSC	cis	rs983392	0.679	rs1026252	chr11:60030559	C/T	cg20284999	chr11:59952153	MS4A6A	0.37	6.09	0.32	3.02e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg23625390	chr15:77176239	SCAPER	-0.66	-10.01	-0.48	8.54e-21	Blood metabolite levels;
LUSC	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg26876637	chr1:152193138	HRNR	-0.47	-6.6	-0.34	1.65e-10	Atopic dermatitis;
LUSC	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.46	7.52	0.38	5.02e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs79387448	0.745	rs1880000	chr2:103099953	T/C	cg09003973	chr2:102972529	NA	0.92	9.12	0.45	7.05e-18	Gut microbiota (bacterial taxa);
LUSC	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.03	0.36	1.18e-11	Multiple sclerosis;
LUSC	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.15	10.48	0.5	2.05e-22	Alzheimer's disease (late onset);
LUSC	cis	rs7267979	0.565	rs958075	chr20:25595123	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.69	-12.63	-0.57	3.81e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs701145	0.585	rs1713852	chr3:153795487	C/G	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.15	10.47	0.5	2.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg02079420	chr8:82753780	SNX16	0.43	7.37	0.37	1.39e-12	Diastolic blood pressure;
LUSC	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.95	0.36	1.93e-11	Morning vs. evening chronotype;
LUSC	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg06191203	chr2:152266755	RIF1	-0.43	-5.92	-0.31	8.12e-9	Lung cancer;
LUSC	cis	rs2637266	0.714	rs1965156	chr10:78450559	G/A	cg18941641	chr10:78392320	NA	0.33	5.98	0.31	5.67e-9	Pulmonary function;
LUSC	cis	rs4400599	1.000	rs4845364	chr1:154141908	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.35	-5.73	-0.3	2.29e-8	Platelet distribution width;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg19889152	chr6:33588278	ITPR3	0.78	6.25	0.32	1.22e-9	Cognitive performance;
LUSC	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg11062466	chr8:58055876	NA	0.49	6.45	0.33	3.88e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg05110241	chr16:68378359	PRMT7	-0.51	-6.12	-0.32	2.69e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	7.66	0.39	2.07e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-6.29	-0.33	9.73e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.7	0.43	1.52e-16	Prudent dietary pattern;
LUSC	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg23711669	chr6:146136114	FBXO30	0.87	15.55	0.65	2.07e-41	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg21548813	chr6:291882	DUSP22	-0.52	-7.85	-0.39	5.71e-14	Menopause (age at onset);
LUSC	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.5	7.39	0.37	1.18e-12	Breast cancer;
LUSC	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg24579218	chr15:68104479	NA	-0.36	-6.37	-0.33	6.26e-10	Restless legs syndrome;
LUSC	cis	rs12760731	0.641	rs10798605	chr1:178294872	G/A	cg00404053	chr1:178313656	RASAL2	0.57	6.56	0.34	2.07e-10	Obesity-related traits;
LUSC	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	0.89	14.31	0.62	1.49e-36	Pulmonary function decline;
LUSC	cis	rs17255340	0.520	rs1170501	chr6:83991861	C/A	cg08257003	chr6:84140564	ME1	0.32	7.89	0.4	4.39e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs3790645	0.958	rs2290589	chr1:26880288	C/T	cg17456097	chr1:26900765	RPS6KA1	0.43	6.2	0.32	1.71e-9	Glucose homeostasis traits;
LUSC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-1.03	-14.26	-0.62	2.36e-36	Vitiligo;
LUSC	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.77	12.75	0.57	1.31e-30	Metabolic syndrome;
LUSC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-14.08	-0.61	1.14e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4400599	0.618	rs9943097	chr1:154205823	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.9	-0.31	9.07e-9	Platelet distribution width;
LUSC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg22823121	chr1:150693482	HORMAD1	0.58	8.9	0.44	3.61e-17	Tonsillectomy;
LUSC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	14.06	0.61	1.37e-35	Platelet count;
LUSC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.86	0.58	5.23e-31	Prudent dietary pattern;
LUSC	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg16482183	chr6:26056742	HIST1H1C	0.66	9.16	0.45	5.55e-18	Iron status biomarkers;
LUSC	cis	rs10097731	0.908	rs28550260	chr8:82025584	T/C	cg25230327	chr8:82042993	NA	-0.49	-7.15	-0.36	5.46e-12	Serum total protein level;
LUSC	cis	rs977987	0.835	rs7200616	chr16:75366089	G/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.1	-0.36	7.41e-12	Dupuytren's disease;
LUSC	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.88	14.84	0.63	1.28e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg17757837	chr7:157058334	UBE3C	0.81	13.02	0.58	1.3e-31	Body mass index;
LUSC	cis	rs7236492	0.532	rs8090536	chr18:77195553	C/T	cg15644404	chr18:77186268	NFATC1	-0.51	-7.02	-0.36	1.27e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg14522847	chr3:15919537	NA	-0.77	-6.39	-0.33	5.52e-10	Cognitive performance;
LUSC	cis	rs28647808	0.881	rs4246171	chr9:136264731	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs8017423	1.000	rs4904644	chr14:90665689	A/G	cg04374321	chr14:90722782	PSMC1	-0.65	-9.38	-0.46	1.01e-18	Mortality in heart failure;
LUSC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg17366294	chr4:99064904	C4orf37	0.6	10.61	0.5	7.4e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg06238570	chr21:40685208	BRWD1	0.47	7.21	0.37	3.81e-12	Cognitive function;
LUSC	trans	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.4	-0.38	1.1e-12	Breast cancer;
LUSC	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg21211680	chr2:198530	NA	0.72	7.52	0.38	4.95e-13	Blood protein levels;
LUSC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.02	20.48	0.75	5.84e-61	Cognitive function;
LUSC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.89	14.2	0.61	4.04e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10489202	0.632	rs12401555	chr1:168069473	G/C	cg24449463	chr1:168025552	DCAF6	-0.68	-10.19	-0.49	2.04e-21	Schizophrenia;
LUSC	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg08355456	chr11:67383691	NA	0.38	7.01	0.36	1.35e-11	Mean corpuscular volume;
LUSC	cis	rs2742234	0.541	rs871763	chr10:43734188	C/T	cg02780029	chr10:43622663	RET	0.34	5.68	0.3	2.97e-8	Hirschsprung disease;
LUSC	cis	rs926938	0.552	rs360613	chr1:115394864	C/G	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.53	-0.34	2.47e-10	Autism;
LUSC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg07061783	chr6:25882402	NA	-0.38	-5.94	-0.31	7.35e-9	Blood metabolite levels;
LUSC	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg17788362	chr6:86352627	SYNCRIP	0.48	7.23	0.37	3.35e-12	Smooth-surface caries;
LUSC	cis	rs7808935	0.914	rs11971132	chr7:27985867	G/C	cg22168087	chr7:27702803	HIBADH	0.57	6.77	0.35	5.87e-11	Prostate cancer;
LUSC	cis	rs9921338	0.961	rs9936093	chr16:11437316	C/G	cg00044050	chr16:11439710	C16orf75	-0.5	-6.67	-0.34	1.07e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05901451	chr6:126070800	HEY2	0.57	8.71	0.43	1.38e-16	Endometrial cancer;
LUSC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg21724239	chr8:58056113	NA	0.79	9.68	0.47	1.07e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg23649088	chr2:200775458	C2orf69	0.53	6.45	0.33	3.97e-10	Schizophrenia;
LUSC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.64	11.0	0.52	3.11e-24	Bone mineral density;
LUSC	cis	rs9914988	0.613	rs1873477	chr17:27311532	A/G	cg10538030	chr17:27276405	PHF12	-0.56	-5.66	-0.3	3.28e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7264396	1.000	rs224434	chr20:34153856	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.21	-0.37	3.65e-12	Total cholesterol levels;
LUSC	trans	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.44	6.06	0.31	3.69e-9	Corneal astigmatism;
LUSC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	8.08	0.4	1.17e-14	Systolic blood pressure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22387939	chr2:71175719	ATP6V1B1	-0.38	-5.97	-0.31	5.97e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9341808	0.622	rs682482	chr6:80961139	A/G	cg08355045	chr6:80787529	NA	-0.41	-6.87	-0.35	3.2e-11	Sitting height ratio;
LUSC	trans	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg07211511	chr3:129823064	LOC729375	-1.03	-12.92	-0.58	3.13e-31	Blood pressure (smoking interaction);
LUSC	cis	rs9815354	0.812	rs967619	chr3:41876710	C/G	cg03022575	chr3:42003672	ULK4	0.84	8.86	0.44	4.79e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg22782873	chr19:19639568	YJEFN3	0.49	6.17	0.32	2e-9	Bipolar disorder;
LUSC	cis	rs4964805	0.710	rs1866296	chr12:104187092	G/A	cg02344784	chr12:104178138	NT5DC3	0.46	8.86	0.44	4.96e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs28830936	0.966	rs1107858	chr15:41968226	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.23	-0.32	1.43e-9	Diastolic blood pressure;
LUSC	trans	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.62	-10.97	-0.51	3.94e-24	Mean corpuscular volume;
LUSC	trans	rs12145833	0.596	rs12043646	chr1:243281992	G/A	cg25284624	chr1:224180302	NA	0.65	6.27	0.32	1.11e-9	Obesity (early onset extreme);
LUSC	cis	rs10193935	1.000	rs13421289	chr2:42412808	T/C	cg27598129	chr2:42591480	NA	-0.61	-8.05	-0.4	1.48e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7246967	0.673	rs8106215	chr19:22879446	G/A	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9341808	0.935	rs942381	chr6:80880150	T/G	cg08355045	chr6:80787529	NA	0.52	9.2	0.45	3.94e-18	Sitting height ratio;
LUSC	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg03465714	chr1:152285911	FLG	-0.42	-5.88	-0.31	9.75e-9	Atopic dermatitis;
LUSC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24110177	chr3:50126178	RBM5	0.65	11.69	0.54	1.1e-26	Body mass index;
LUSC	cis	rs72781680	0.611	rs74661620	chr2:24365260	C/A	cg20701182	chr2:24300061	SF3B14	0.83	10.2	0.49	1.89e-21	Lymphocyte counts;
LUSC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg03146154	chr1:46216737	IPP	0.52	7.83	0.39	6.52e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg13390004	chr1:15929781	NA	0.42	6.95	0.36	1.92e-11	Systolic blood pressure;
LUSC	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg20608306	chr11:116969690	SIK3	0.37	6.95	0.36	1.9e-11	Blood protein levels;
LUSC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.45	-8.57	-0.42	3.94e-16	Paraoxonase activity;
LUSC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.1	15.88	0.66	1.04e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg03676636	chr4:99064102	C4orf37	0.29	5.67	0.3	3.13e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9311676	0.632	rs4130877	chr3:58374893	T/C	cg26110898	chr3:58419937	PDHB	0.41	6.65	0.34	1.17e-10	Systemic lupus erythematosus;
LUSC	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.57	-10.4	-0.49	4.06e-22	Homoarginine levels;
LUSC	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg18357645	chr12:58087776	OS9	0.6	9.0	0.44	1.68e-17	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg15133208	chr4:90757351	SNCA	-0.53	-8.24	-0.41	3.95e-15	Neuroticism;
LUSC	trans	rs3891355	1.000	rs3851637	chr12:106951107	A/C	cg18191209	chr2:795478	NA	0.45	6.17	0.32	1.97e-9	Cognitive test performance;
LUSC	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg02034447	chr16:89574710	SPG7	0.4	5.91	0.31	8.5e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.72	-9.87	-0.48	2.59e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.53	-0.46	3.25e-19	Coronary artery disease;
LUSC	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg20503657	chr10:835505	NA	-0.52	-6.96	-0.36	1.86e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18404041	chr3:52824283	ITIH1	-0.58	-11.25	-0.52	4.15e-25	Bipolar disorder;
LUSC	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg16584290	chr5:462447	EXOC3	-0.34	-6.02	-0.31	4.7e-9	Cystic fibrosis severity;
LUSC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg17507749	chr15:85114479	UBE2QP1	0.69	9.22	0.45	3.35e-18	Schizophrenia;
LUSC	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg13010199	chr12:38710504	ALG10B	-0.47	-7.02	-0.36	1.24e-11	Bladder cancer;
LUSC	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.34	-0.33	7.57e-10	Retinal vascular caliber;
LUSC	cis	rs7149337	0.836	rs12588488	chr14:51660217	C/A	cg23942311	chr14:51606299	NA	0.47	10.32	0.49	7.45e-22	Cancer;
LUSC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg27432699	chr2:27873401	GPN1	-0.63	-9.7	-0.47	9.31e-20	Total body bone mineral density;
LUSC	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg20744362	chr22:50050164	C22orf34	0.39	7.11	0.36	6.99e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg11766577	chr21:47581405	C21orf56	0.42	6.4	0.33	5.22e-10	Testicular germ cell tumor;
LUSC	trans	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg21659725	chr3:3221576	CRBN	0.7	8.6	0.43	3.17e-16	Menarche (age at onset);
LUSC	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg00990874	chr7:1149470	C7orf50	-0.51	-6.09	-0.32	3.17e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg20219074	chr11:18656078	SPTY2D1	0.72	10.68	0.5	4.17e-23	Breast cancer;
LUSC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11645453	chr3:52864694	ITIH4	0.31	7.22	0.37	3.6e-12	Bipolar disorder;
LUSC	cis	rs501916	0.796	rs55961203	chr15:48050518	G/T	cg16110827	chr15:48056943	SEMA6D	-0.44	-6.84	-0.35	3.83e-11	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs7598759	0.617	rs6437017	chr2:232327584	C/A	cg19187155	chr2:232395269	NMUR1	0.49	7.16	0.36	5.16e-12	Noise-induced hearing loss;
LUSC	cis	rs727505	0.954	rs1383748	chr7:124638201	A/T	cg23710748	chr7:124431027	NA	-0.37	-6.46	-0.33	3.71e-10	Lewy body disease;
LUSC	trans	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.99	-0.4	2.18e-14	Neuroticism;
LUSC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg05941027	chr17:61774174	LIMD2	0.21	5.7	0.3	2.66e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.78	0.43	8.47e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg14004847	chr7:1930337	MAD1L1	-0.59	-9.2	-0.45	3.95e-18	Schizophrenia;
LUSC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-9.8	-0.47	4.36e-20	Blood metabolite levels;
LUSC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.72	11.9	0.55	1.79e-27	Motion sickness;
LUSC	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg05714579	chr10:131428358	MGMT	0.46	6.48	0.33	3.29e-10	Response to temozolomide;
LUSC	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg23260525	chr10:116636907	FAM160B1	0.45	9.6	0.47	1.91e-19	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg19622623	chr12:86230825	RASSF9	-0.46	-6.43	-0.33	4.47e-10	Major depressive disorder;
LUSC	trans	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.99	-0.31	5.47e-9	Dementia with Lewy bodies;
LUSC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.55	0.38	4.11e-13	Motion sickness;
LUSC	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg04310649	chr10:35416472	CREM	0.4	6.23	0.32	1.43e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	8.84	0.44	5.63e-17	Total body bone mineral density;
LUSC	cis	rs6683071	0.601	rs3002129	chr1:222855335	C/G	cg09820183	chr1:222886073	C1orf58;AIDA	0.5	5.73	0.3	2.3e-8	Cognitive performance;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg02603726	chr16:18812963	ARL6IP1	0.42	5.96	0.31	6.56e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.8	-13.18	-0.58	3.28e-32	Cognitive function;
LUSC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.81	13.64	0.6	5.83e-34	Aortic root size;
LUSC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.52	-0.42	5.68e-16	Aortic root size;
LUSC	cis	rs13242816	1.000	rs62471189	chr7:116101588	G/A	cg16553024	chr7:116138462	CAV2	-0.54	-5.87	-0.31	1.05e-8	P wave duration;
LUSC	trans	rs11696501	0.688	rs6104247	chr20:44244938	C/T	cg03272292	chr12:48577362	C12orf68	0.54	6.49	0.33	3.1e-10	Brain structure;
LUSC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg27284194	chr4:1044797	NA	-0.36	-5.86	-0.31	1.11e-8	Obesity-related traits;
LUSC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	0.63	13.36	0.59	6.42e-33	Prudent dietary pattern;
LUSC	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg22089800	chr15:90895588	ZNF774	0.53	7.68	0.39	1.82e-13	Rheumatoid arthritis;
LUSC	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg10172584	chr19:19639581	YJEFN3	0.47	5.74	0.3	2.1e-8	Bipolar disorder;
LUSC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg17279839	chr7:150038598	RARRES2	0.4	6.44	0.33	4.21e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg06219351	chr7:158114137	PTPRN2	-0.53	-8.41	-0.42	1.24e-15	Response to amphetamines;
LUSC	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg17376030	chr22:41985996	PMM1	-0.46	-6.07	-0.32	3.54e-9	Vitiligo;
LUSC	cis	rs4780355	0.918	rs1646019	chr16:11359680	C/T	cg00044050	chr16:11439710	C16orf75	0.56	8.39	0.42	1.35e-15	Crohn's disease and psoriasis;
LUSC	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.99	-17.15	-0.68	1e-47	Myeloid white cell count;
LUSC	trans	rs7567288	0.636	rs13007239	chr2:134461484	A/C	cg12381416	chr3:14359266	NA	0.56	6.29	0.33	1.02e-9	Height;
LUSC	cis	rs117352156	0.800	rs2887379	chr10:29214731	T/C	cg06394621	chr10:29236369	NA	-0.47	-6.34	-0.33	7.38e-10	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	13.04	0.58	1.07e-31	Total body bone mineral density;
LUSC	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.42	6.13	0.32	2.51e-9	Bipolar disorder;
LUSC	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.91	-0.44	3.31e-17	Monocyte percentage of white cells;
LUSC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6494488	0.500	rs113645218	chr15:64843582	C/T	cg08069370	chr15:64387884	SNX1	-0.64	-5.65	-0.3	3.48e-8	Coronary artery disease;
LUSC	cis	rs654950	0.901	rs1885654	chr1:42007188	C/A	cg06885757	chr1:42089581	HIVEP3	-0.44	-8.56	-0.42	4.05e-16	Airway imaging phenotypes;
LUSC	cis	rs77741769	0.571	rs10849807	chr12:121314056	T/C	cg02419362	chr12:121203948	SPPL3	0.46	8.57	0.42	3.84e-16	Mean corpuscular volume;
LUSC	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.77	11.2	0.52	6.24e-25	Corneal astigmatism;
LUSC	cis	rs11229555	1.000	rs3168135	chr11:58386177	G/A	cg15696309	chr11:58395628	NA	-0.69	-9.27	-0.45	2.43e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs600626	0.636	rs11236515	chr11:75451411	A/G	cg24262691	chr11:75473276	NA	0.47	5.89	0.31	9.55e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs3931020	0.688	rs525487	chr1:75217420	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	-0.49	-6.17	-0.32	2e-9	Resistin levels;
LUSC	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.33	0.56	5.01e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs4919687	0.550	rs10437480	chr10:104453024	C/G	cg05855489	chr10:104503620	C10orf26	0.7	11.37	0.53	1.55e-25	Colorectal cancer;
LUSC	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg00310523	chr12:86230176	RASSF9	0.37	6.83	0.35	4e-11	Major depressive disorder;
LUSC	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg14092571	chr14:90743983	NA	-0.9	-18.88	-0.72	1.33e-54	Gut microbiota (bacterial taxa);
LUSC	trans	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg26043149	chr18:55253948	FECH	-0.53	-7.87	-0.4	5.02e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.62	0.5	6.57e-23	Bladder cancer;
LUSC	cis	rs7582720	0.667	rs114863726	chr2:204158375	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	7.72	0.39	1.35e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17467752	chr17:38218738	THRA	-0.8	-13.04	-0.58	1.03e-31	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.47	7.34	0.37	1.62e-12	Colorectal cancer;
LUSC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06505273	chr16:24850292	NA	0.4	5.83	0.3	1.33e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6942756	0.956	rs13235668	chr7:128879710	A/G	cg02491457	chr7:128862824	NA	-0.53	-7.66	-0.39	2.01e-13	White matter hyperintensity burden;
LUSC	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg17143192	chr8:8559678	CLDN23	0.64	8.85	0.44	5.26e-17	Obesity-related traits;
LUSC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-1.11	-24.8	-0.81	9.96e-78	Height;
LUSC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg01802117	chr1:53393560	SCP2	-0.37	-6.13	-0.32	2.52e-9	Monocyte count;
LUSC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07362569	chr17:61921086	SMARCD2	0.37	7.63	0.39	2.5e-13	Prudent dietary pattern;
LUSC	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.06	-22.67	-0.78	1.45e-69	Ulcerative colitis;
LUSC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg26513180	chr16:89883248	FANCA	-0.52	-7.83	-0.39	6.42e-14	Vitiligo;
LUSC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.7	11.0	0.52	3.29e-24	Aortic root size;
LUSC	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg07959070	chr22:50026188	C22orf34	-0.33	-6.3	-0.33	9.33e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg19266034	chr7:108210536	THAP5;DNAJB9	0.38	6.05	0.31	3.92e-9	Mosquito bite size;
LUSC	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.94	15.99	0.66	4.04e-43	Bladder cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg22975147	chr17:8021903	ALOXE3	0.43	6.14	0.32	2.34e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-7.1	-0.36	7.7e-12	Blood metabolite levels;
LUSC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg22709100	chr7:91322751	NA	0.4	5.81	0.3	1.48e-8	Breast cancer;
LUSC	cis	rs3772130	0.775	rs6781857	chr3:121560721	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	9.91	0.48	1.88e-20	Cognitive performance;
LUSC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg26408565	chr15:76604113	ETFA	-0.52	-8.32	-0.41	2.23e-15	Blood metabolite levels;
LUSC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.11	-0.41	9.78e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg12463550	chr7:65579703	CRCP	0.51	7.52	0.38	5.19e-13	Aortic root size;
LUSC	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg08048268	chr3:133502702	NA	-0.33	-6.27	-0.32	1.09e-9	Iron status biomarkers;
LUSC	cis	rs6669072	0.647	rs814543	chr1:91241709	C/T	cg08895590	chr1:91227319	NA	0.38	8.57	0.42	3.86e-16	Cognitive function;
LUSC	cis	rs4343996	1.000	rs6461993	chr7:3356463	G/A	cg21248987	chr7:3385318	SDK1	-0.36	-6.16	-0.32	2.04e-9	Motion sickness;
LUSC	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.8	-0.35	4.73e-11	Lung cancer;
LUSC	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.53	-0.62	2.1e-37	Schizophrenia;
LUSC	cis	rs2354432	0.556	rs57388899	chr1:146773422	T/C	cg25205988	chr1:146714368	CHD1L	-0.99	-10.48	-0.5	2.15e-22	Mitochondrial DNA levels;
LUSC	cis	rs965513	1.000	rs4743131	chr9:100554907	C/G	cg13688889	chr9:100608707	NA	-0.54	-8.16	-0.41	6.68e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18099408	chr3:52552593	STAB1	-0.41	-7.0	-0.36	1.38e-11	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23791442	chr22:43010704	POLDIP3;RNU12	-0.39	-5.95	-0.31	6.65e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg15654264	chr1:150340011	RPRD2	0.63	10.29	0.49	9.21e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13012494	chr21:47604986	C21orf56	0.47	7.15	0.36	5.45e-12	Testicular germ cell tumor;
LUSC	trans	rs12651329	1.000	rs12651329	chr4:36079594	A/G	cg03693601	chr16:46655349	SHCBP1	-0.37	-5.95	-0.31	6.72e-9	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg08330031	chr10:104623503	C10orf32	-0.32	-5.78	-0.3	1.68e-8	Arsenic metabolism;
LUSC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg18350739	chr11:68623251	NA	-0.38	-6.74	-0.35	7.09e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs17152411	1.000	rs17152433	chr10:126670356	G/A	cg07906193	chr10:126599966	NA	0.37	5.69	0.3	2.84e-8	Height;
LUSC	trans	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg25214090	chr10:38739885	LOC399744	-0.4	-6.42	-0.33	4.56e-10	Corneal astigmatism;
LUSC	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg00857998	chr1:205179979	DSTYK	0.59	8.8	0.43	7.22e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6740322	0.895	rs10166994	chr2:43557977	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-7.52	-0.38	5.27e-13	Coronary artery disease;
LUSC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.83	-14.41	-0.62	5.88e-37	Monocyte count;
LUSC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg17294928	chr15:75287854	SCAMP5	-0.85	-11.07	-0.52	1.83e-24	Blood trace element (Zn levels);
LUSC	cis	rs870825	0.518	rs12512933	chr4:185665055	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	10.61	0.5	7.24e-23	Blood protein levels;
LUSC	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg06951627	chr6:26196580	NA	0.54	5.84	0.3	1.27e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg18827107	chr12:86230957	RASSF9	-0.41	-5.99	-0.31	5.43e-9	Major depressive disorder;
LUSC	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg23711669	chr6:146136114	FBXO30	0.89	16.27	0.66	3.05e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg19875535	chr5:140030758	IK	0.49	7.87	0.4	5.04e-14	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.72	-11.06	-0.52	1.95e-24	Lymphocyte counts;
LUSC	cis	rs9584850	0.834	rs7985565	chr13:99113471	C/G	cg20487152	chr13:99095054	FARP1	0.4	6.3	0.33	9.31e-10	Neuroticism;
LUSC	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg09033563	chr22:24373618	LOC391322	0.49	5.91	0.31	8.55e-9	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs4561483	0.583	rs12149833	chr16:12003723	C/T	cg08843971	chr16:11963173	GSPT1	0.42	6.32	0.33	8.53e-10	Testicular germ cell tumor;
LUSC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.21	-0.41	4.77e-15	Bladder cancer;
LUSC	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg03806693	chr22:41940476	POLR3H	-0.78	-11.16	-0.52	8.55e-25	Vitiligo;
LUSC	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.21	-0.49	1.7e-21	Eye color traits;
LUSC	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg01733217	chr16:74700730	RFWD3	0.8	13.42	0.59	3.86e-33	Testicular germ cell tumor;
LUSC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg27494647	chr7:150038898	RARRES2	0.51	7.86	0.4	5.3e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-11.1	-0.52	1.36e-24	Response to antipsychotic treatment;
LUSC	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg21479132	chr6:26055353	NA	0.59	5.74	0.3	2.09e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.73	-12.5	-0.56	1.14e-29	Lung cancer;
LUSC	cis	rs1624802	0.966	rs1707933	chr12:130497813	T/G	cg15444478	chr12:130494697	NA	-0.24	-5.73	-0.3	2.26e-8	Obesity-related traits;
LUSC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.57	-0.5	1.04e-22	Alzheimer's disease;
LUSC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg14458575	chr2:238380390	NA	0.74	13.16	0.58	3.79e-32	Prostate cancer;
LUSC	trans	rs867371	0.717	rs3858954	chr15:82558034	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.48	-7.01	-0.36	1.35e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-6.21	-0.32	1.58e-9	Height;
LUSC	cis	rs10207060	0.500	rs4380264	chr2:240699378	G/T	cg07506560	chr2:240697449	NA	0.46	6.81	0.35	4.45e-11	Obesity-related traits;
LUSC	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg23277830	chr1:3704460	LRRC47	0.36	6.84	0.35	3.9e-11	Red cell distribution width;
LUSC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	trans	rs7155454	0.935	rs4466998	chr14:65475540	C/A	cg18497238	chr14:75083495	NA	-0.25	-6.0	-0.31	5.04e-9	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LUSC	cis	rs240768	0.655	rs72939355	chr6:101005363	A/C	cg12253828	chr6:101329408	ASCC3	0.84	5.74	0.3	2.11e-8	Economic and political preferences (immigration/crime);
LUSC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg04414720	chr1:150670196	GOLPH3L	0.54	8.57	0.42	4.03e-16	Tonsillectomy;
LUSC	cis	rs7707921	0.881	rs2629744	chr5:81381997	A/T	cg15871215	chr5:81402204	ATG10	-0.45	-6.6	-0.34	1.64e-10	Breast cancer;
LUSC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg21724239	chr8:58056113	NA	0.54	6.64	0.34	1.27e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg05340658	chr4:99064831	C4orf37	0.63	10.01	0.48	8.32e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.62	0.38	2.72e-13	Neuroticism;
LUSC	cis	rs4654899	0.897	rs10799668	chr1:21169385	T/C	cg01072550	chr1:21505969	NA	0.48	7.28	0.37	2.44e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg22903471	chr2:27725779	GCKR	-0.41	-6.95	-0.36	1.98e-11	Menopause (age at onset);
LUSC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-7.88	-0.4	4.68e-14	Lymphocyte counts;
LUSC	cis	rs7106204	0.920	rs7946615	chr11:24221036	T/C	ch.11.24196551F	chr11:24239977	NA	0.99	9.97	0.48	1.12e-20	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg05368731	chr17:41323189	NBR1	0.83	13.45	0.59	2.99e-33	Menopause (age at onset);
LUSC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.28	-0.45	2.26e-18	Gut microbiome composition (summer);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02386183	chr20:13619553	TASP1	-0.33	-5.97	-0.31	6.03e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1018697	1.000	rs1018697	chr10:104549224	C/A	cg04362960	chr10:104952993	NT5C2	0.47	6.45	0.33	4.04e-10	Colorectal adenoma (advanced);
LUSC	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	1.13	17.53	0.69	2.98e-49	Corneal structure;
LUSC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg06808227	chr14:105710500	BRF1	-0.68	-10.69	-0.51	3.77e-23	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.93	-0.35	2.22e-11	Response to antipsychotic treatment;
LUSC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg12560992	chr17:57184187	TRIM37	-0.82	-14.77	-0.63	2.33e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs4888378	0.535	rs9319483	chr16:75345791	T/C	cg07303275	chr16:75499416	TMEM170A	-0.44	-5.67	-0.3	3.04e-8	Coronary artery disease;
LUSC	cis	rs2658782	0.688	rs2658768	chr11:93250827	T/C	cg15737290	chr11:93063684	CCDC67	0.6	7.2	0.37	4.06e-12	Pulmonary function decline;
LUSC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg26677194	chr12:130822605	PIWIL1	0.6	8.98	0.44	1.97e-17	Menopause (age at onset);
LUSC	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg16339924	chr4:17578868	LAP3	0.51	7.6	0.38	2.92e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10203711	0.966	rs10167210	chr2:239601726	A/C	cg14580085	chr2:239553406	NA	-0.41	-6.92	-0.35	2.25e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7575217	0.767	rs62152486	chr2:101745835	A/C	cg23907051	chr2:101730305	TBC1D8	-0.28	-7.39	-0.37	1.17e-12	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg18721089	chr20:30220636	NA	-0.35	-6.01	-0.31	4.78e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.23	-0.37	3.36e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03705284	chr1:1051907	C1orf159	-0.4	-6.07	-0.32	3.44e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2976388	0.692	rs1435453	chr8:143780775	C/T	cg17252645	chr8:143867129	LY6D	0.39	6.74	0.35	7.09e-11	Urinary tract infection frequency;
LUSC	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg00277334	chr10:82204260	NA	-0.54	-7.38	-0.37	1.3e-12	Post bronchodilator FEV1;
LUSC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.66	-13.18	-0.58	3.28e-32	Bipolar disorder;
LUSC	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg07382826	chr16:28625726	SULT1A1	0.28	5.86	0.31	1.11e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.84	14.61	0.62	1.02e-37	Metabolic syndrome;
LUSC	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.43	-0.42	1.02e-15	Response to antipsychotic treatment;
LUSC	cis	rs3772130	0.583	rs28497949	chr3:121448675	T/A	cg20356878	chr3:121714668	ILDR1	0.51	8.26	0.41	3.43e-15	Cognitive performance;
LUSC	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg00757033	chr12:89920650	WDR51B	0.59	10.15	0.49	2.74e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg11993925	chr19:44307056	LYPD5	0.35	7.63	0.39	2.55e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg18721089	chr20:30220636	NA	-0.39	-6.12	-0.32	2.66e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	9.15	0.45	5.79e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.31	-0.37	2e-12	Colorectal cancer;
LUSC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18876405	chr7:65276391	NA	-0.55	-8.65	-0.43	2.15e-16	Aortic root size;
LUSC	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg25110126	chr1:46999211	NA	-0.56	-7.51	-0.38	5.48e-13	Monobrow;
LUSC	cis	rs71403859	0.730	rs12923781	chr16:71653464	G/A	cg08717414	chr16:71523259	ZNF19	-0.71	-7.7	-0.39	1.54e-13	Post bronchodilator FEV1;
LUSC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg07936489	chr17:37558343	FBXL20	0.72	10.05	0.48	5.95e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs2688608	0.933	rs2633307	chr10:75653881	G/A	cg23231163	chr10:75533350	FUT11	-0.39	-6.26	-0.32	1.19e-9	Inflammatory bowel disease;
LUSC	cis	rs738322	0.600	rs6001030	chr22:38555904	T/G	cg25457927	chr22:38595422	NA	-0.33	-6.37	-0.33	6.36e-10	Cutaneous nevi;
LUSC	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.05	-0.44	1.24e-17	Neuroticism;
LUSC	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg01191920	chr7:158217561	PTPRN2	-0.42	-8.44	-0.42	9.69e-16	Obesity-related traits;
LUSC	cis	rs8067287	0.762	rs11651352	chr17:16824909	A/G	cg26910001	chr17:16838321	NA	0.43	5.68	0.3	2.97e-8	Diabetic kidney disease;
LUSC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg26441486	chr22:50317300	CRELD2	0.48	7.21	0.37	3.88e-12	Schizophrenia;
LUSC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11293355	chr13:103249041	TPP2	-0.48	-6.29	-0.33	9.85e-10	Hepatitis;
LUSC	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg01966878	chr4:90757139	SNCA	-0.36	-6.11	-0.32	2.82e-9	Dementia with Lewy bodies;
LUSC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg00522288	chr12:125625016	AACS	-0.32	-5.85	-0.3	1.16e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg02423579	chr7:2872169	GNA12	-0.37	-5.87	-0.31	1.07e-8	Height;
LUSC	cis	rs2692947	0.795	rs2252697	chr2:96778190	G/C	cg23100626	chr2:96804247	ASTL	-0.26	-6.49	-0.33	3.1e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg13256891	chr4:100009986	ADH5	0.51	6.95	0.36	1.91e-11	Smoking initiation;
LUSC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	8.5	0.42	6.34e-16	Mean platelet volume;
LUSC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg03354898	chr7:1950403	MAD1L1	0.42	8.42	0.42	1.12e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg09092052	chr15:45571596	NA	0.45	6.31	0.33	9.03e-10	Glomerular filtration rate;
LUSC	cis	rs9400467	0.508	rs1676863	chr6:111641590	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.33	-0.33	7.87e-10	Blood metabolite levels;Amino acid levels;
LUSC	trans	rs1325195	0.920	rs2816198	chr1:179158736	A/G	cg11624085	chr17:8464688	MYH10	0.4	6.53	0.34	2.44e-10	IgE grass sensitization;
LUSC	trans	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.17	0.45	5.01e-18	Mean corpuscular volume;
LUSC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg00431813	chr7:1051703	C7orf50	-0.41	-6.9	-0.35	2.68e-11	Longevity;Endometriosis;
LUSC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07677032	chr17:61819896	STRADA	0.52	8.7	0.43	1.55e-16	Prudent dietary pattern;
LUSC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	ch.11.42038R	chr11:967971	AP2A2	0.55	8.37	0.42	1.65e-15	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg03676636	chr4:99064102	C4orf37	0.38	8.06	0.4	1.4e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg24642439	chr20:33292090	TP53INP2	0.39	5.65	0.3	3.46e-8	Height;
LUSC	cis	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.79	0.43	8.03e-17	Endometrial cancer;
LUSC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg08677398	chr8:58056175	NA	0.52	6.28	0.32	1.08e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg07701084	chr6:150067640	NUP43	0.47	6.92	0.35	2.31e-11	Testicular germ cell tumor;
LUSC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.23	0.45	3.2e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	8.54	0.42	4.72e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg20368463	chr18:77673604	PQLC1	0.63	6.75	0.35	6.53e-11	Opioid sensitivity;
LUSC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg00990874	chr7:1149470	C7orf50	-0.6	-7.86	-0.4	5.2e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-6.05	-0.31	3.92e-9	Huntington's disease progression;
LUSC	cis	rs2425143	1.000	rs2295356	chr20:34252856	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.56	-0.34	2.09e-10	Blood protein levels;
LUSC	cis	rs10165862	0.572	rs11674212	chr2:73911180	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-6.94	-0.35	2.08e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg05340658	chr4:99064831	C4orf37	0.63	10.01	0.48	8.32e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg14458575	chr2:238380390	NA	0.68	12.04	0.55	5.7e-28	Prostate cancer;
LUSC	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg27471124	chr11:109292789	C11orf87	0.54	9.45	0.46	6.12e-19	Schizophrenia;
LUSC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	14.05	0.61	1.44e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs80282103	0.618	rs2387299	chr10:1163427	A/G	cg18964960	chr10:1102726	WDR37	0.71	5.86	0.31	1.11e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg24130564	chr14:104152367	KLC1	0.46	6.55	0.34	2.17e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.52	7.3	0.37	2.13e-12	Cognitive ability;
LUSC	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg06484146	chr7:12443880	VWDE	-0.57	-6.07	-0.31	3.57e-9	Coronary artery disease;
LUSC	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg15423357	chr2:25149977	NA	0.4	7.83	0.39	6.73e-14	Body mass index;
LUSC	cis	rs4363385	0.720	rs1970328	chr1:152975829	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.76	-0.39	1.05e-13	Inflammatory skin disease;
LUSC	cis	rs2282300	0.739	rs1616223	chr11:30338783	A/C	cg25418670	chr11:30344373	C11orf46	-0.64	-9.23	-0.45	3.29e-18	Morning vs. evening chronotype;
LUSC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.71	-0.3	2.45e-8	Depression;
LUSC	cis	rs7707921	0.914	rs4081859	chr5:81466669	G/A	cg15871215	chr5:81402204	ATG10	0.45	6.59	0.34	1.69e-10	Breast cancer;
LUSC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg03676636	chr4:99064102	C4orf37	0.34	7.56	0.38	3.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10186029	0.582	rs1992395	chr2:214003871	G/T	cg08319019	chr2:214017104	IKZF2	-0.47	-7.16	-0.36	5.24e-12	Systemic sclerosis;
LUSC	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg07959070	chr22:50026188	C22orf34	-0.36	-7.34	-0.37	1.69e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg23283495	chr1:209979779	IRF6	0.73	9.53	0.46	3.3e-19	Cleft lip with or without cleft palate;
LUSC	cis	rs394563	0.601	rs391875	chr6:149795136	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.34	-6.97	-0.36	1.7e-11	Dupuytren's disease;
LUSC	cis	rs62400317	0.859	rs56283067	chr6:45100330	T/C	cg18551225	chr6:44695536	NA	-0.42	-6.87	-0.35	3.15e-11	Total body bone mineral density;
LUSC	cis	rs308403	0.568	rs13101575	chr4:123617561	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.73	9.46	0.46	5.87e-19	Blood protein levels;
LUSC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.73	12.88	0.58	4.42e-31	Aortic root size;
LUSC	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg12002119	chr2:101014098	CHST10	0.35	5.99	0.31	5.42e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg17168535	chr8:21777572	XPO7	0.64	9.88	0.48	2.37e-20	Mean corpuscular volume;
LUSC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg04518342	chr5:131593106	PDLIM4	0.4	7.56	0.38	3.91e-13	Blood metabolite levels;
LUSC	cis	rs941898	0.957	rs941900	chr14:100603399	C/A	cg26002632	chr14:100625216	DEGS2	-0.31	-5.71	-0.3	2.46e-8	White matter hyperintensity burden;
LUSC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.83	-11.19	-0.52	6.49e-25	Alzheimer's disease;
LUSC	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.56	7.73	0.39	1.3e-13	Response to diuretic therapy;
LUSC	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.32	-0.37	1.86e-12	Putamen volume;
LUSC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.59	0.34	1.74e-10	Lung cancer;
LUSC	cis	rs17253792	0.822	rs112739186	chr14:56065167	A/T	cg01858014	chr14:56050164	KTN1	-0.86	-6.83	-0.35	4.12e-11	Putamen volume;
LUSC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg25258033	chr6:167368657	RNASET2	0.43	7.03	0.36	1.15e-11	Crohn's disease;
LUSC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08219700	chr8:58056026	NA	0.66	7.82	0.39	7.08e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg26898376	chr11:64110657	CCDC88B	0.31	5.71	0.3	2.54e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg13385521	chr17:29058706	SUZ12P	-0.67	-6.48	-0.33	3.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01045612	chr14:100438192	NA	-0.49	-6.11	-0.32	2.7e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21057228	chr5:122372722	PPIC	-0.37	-6.35	-0.33	6.91e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7215564	0.908	rs55886624	chr17:78658657	G/A	cg23238734	chr17:78661607	RPTOR	0.48	6.16	0.32	2.07e-9	Myopia (pathological);
LUSC	cis	rs72781680	0.706	rs72796108	chr2:23904990	C/A	cg08917208	chr2:24149416	ATAD2B	0.95	9.48	0.46	5.05e-19	Lymphocyte counts;
LUSC	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg16339924	chr4:17578868	LAP3	0.65	9.84	0.47	3.21e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21659725	chr3:3221576	CRBN	-0.52	-8.37	-0.42	1.61e-15	Body mass index;
LUSC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.38	0.33	5.95e-10	Menopause (age at onset);
LUSC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.66	-0.39	2.06e-13	Tonsillectomy;
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.67	-11.22	-0.52	5.24e-25	Longevity;Endometriosis;
LUSC	trans	rs11989744	0.500	rs1438456	chr8:23566909	T/C	cg03492747	chr16:86543808	FOXF1	-0.67	-11.58	-0.54	2.76e-26	Waist-hip ratio;
LUSC	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg13010199	chr12:38710504	ALG10B	-0.5	-7.72	-0.39	1.36e-13	Morning vs. evening chronotype;
LUSC	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22455342	chr2:225449267	CUL3	0.48	6.38	0.33	6.02e-10	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.43	-7.45	-0.38	7.97e-13	Menopause (age at onset);
LUSC	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.27	0.49	1.14e-21	Morning vs. evening chronotype;
LUSC	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-1.02	-12.31	-0.56	5.68e-29	Schizophrenia;
LUSC	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg03690763	chr11:133734501	NA	-0.32	-5.64	-0.3	3.57e-8	Childhood ear infection;
LUSC	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.55	-0.34	2.18e-10	Reticulocyte fraction of red cells;
LUSC	trans	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.74	0.35	6.9e-11	Corneal astigmatism;
LUSC	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg22089800	chr15:90895588	ZNF774	-0.64	-9.49	-0.46	4.41e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs977987	0.806	rs1895490	chr16:75392806	G/A	cg03315344	chr16:75512273	CHST6	0.5	9.52	0.46	3.51e-19	Dupuytren's disease;
LUSC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg23262073	chr20:60523788	NA	-0.41	-5.89	-0.31	9.62e-9	Body mass index;
LUSC	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	0.8	9.85	0.47	2.9e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.03	-0.31	4.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.22	0.37	3.57e-12	Educational attainment;
LUSC	cis	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg06521331	chr12:34319734	NA	0.4	6.61	0.34	1.48e-10	Morning vs. evening chronotype;
LUSC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08704250	chr15:31115839	NA	0.39	5.95	0.31	6.69e-9	Huntington's disease progression;
LUSC	cis	rs1507153	0.523	rs236886	chr6:79321534	A/C	cg05283184	chr6:79620031	NA	0.38	6.95	0.36	1.94e-11	Sjögren's syndrome;
LUSC	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.31	0.53	2.56e-25	Coffee consumption (cups per day);
LUSC	cis	rs2078087	0.831	rs12024028	chr1:183232982	T/C	cg13843938	chr1:183241246	NMNAT2	0.44	5.89	0.31	9.45e-9	Obesity-related traits;
LUSC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.4	-6.56	-0.34	2.03e-10	Longevity;Endometriosis;
LUSC	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg14582100	chr15:45693742	SPATA5L1	0.56	10.16	0.49	2.69e-21	Homoarginine levels;
LUSC	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg09003973	chr2:102972529	NA	1.2	12.53	0.57	8.64e-30	Gut microbiota (bacterial taxa);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17791867	chr7:112579927	C7orf60	0.42	6.26	0.32	1.15e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23544223	chr18:12777786	NA	0.59	6.27	0.32	1.15e-9	Inflammatory skin disease;
LUSC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.73	-11.2	-0.52	6.06e-25	Menarche (age at onset);
LUSC	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg18105134	chr13:113819100	PROZ	-0.69	-9.82	-0.47	3.79e-20	Platelet distribution width;
LUSC	cis	rs6977660	0.714	rs10244210	chr7:19823972	T/C	cg07541023	chr7:19748670	TWISTNB	0.6	6.3	0.33	9.45e-10	Thyroid stimulating hormone;
LUSC	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08645402	chr16:4508243	NA	0.48	7.4	0.38	1.09e-12	Schizophrenia;
LUSC	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg06363034	chr20:62225388	GMEB2	-0.46	-7.72	-0.39	1.4e-13	Glioblastoma;
LUSC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11764359	chr7:65958608	NA	0.54	7.11	0.36	7.23e-12	Aortic root size;
LUSC	trans	rs6725041	0.805	rs6745249	chr2:213130571	A/G	cg16357287	chr18:12947517	SEH1L	-0.39	-6.15	-0.32	2.25e-9	QT interval (ambient particulate matter interaction);
LUSC	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg08079166	chr15:68083412	MAP2K5	0.41	7.5	0.38	5.85e-13	Restless legs syndrome;
LUSC	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg11189052	chr15:85197271	WDR73	-0.49	-5.75	-0.3	2e-8	Schizophrenia;
LUSC	cis	rs13072153	0.793	rs9841477	chr3:123157477	A/C	cg13384396	chr3:123167677	ADCY5	0.26	5.82	0.3	1.4e-8	Chronic kidney disease;
LUSC	cis	rs9811920	0.965	rs6767441	chr3:99863183	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.38	5.7	0.3	2.71e-8	Axial length;
LUSC	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg21775007	chr8:11205619	TDH	-0.57	-8.39	-0.42	1.36e-15	Neuroticism;
LUSC	cis	rs9463078	0.683	rs227848	chr6:44698499	G/A	cg25276700	chr6:44698697	NA	0.3	5.93	0.31	7.5e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg12310025	chr6:25882481	NA	0.43	7.36	0.37	1.49e-12	Blood metabolite levels;
LUSC	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg08484992	chr16:88977278	CBFA2T3	0.32	5.84	0.3	1.26e-8	Social autistic-like traits;
LUSC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg13628971	chr7:2884303	GNA12	-0.49	-7.02	-0.36	1.28e-11	Height;
LUSC	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg20019720	chr6:154832845	CNKSR3	0.62	8.65	0.43	2.17e-16	Lipoprotein (a) levels;
LUSC	cis	rs10489202	1.000	rs12727036	chr1:167972147	A/G	cg24449463	chr1:168025552	DCAF6	-0.58	-7.27	-0.37	2.56e-12	Schizophrenia;
LUSC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg02269571	chr22:50332266	NA	-0.58	-8.83	-0.43	6.13e-17	Schizophrenia;
LUSC	cis	rs9815354	0.680	rs79239400	chr3:42030249	C/A	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg24450063	chr1:156163899	SLC25A44	1.06	20.26	0.74	4.47e-60	Testicular germ cell tumor;
LUSC	cis	rs1018836	0.663	rs2205152	chr8:91483618	C/T	cg16814680	chr8:91681699	NA	0.63	9.51	0.46	3.77e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14165241	chr9:131315156	SPTAN1	-0.47	-5.96	-0.31	6.53e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs981844	1.000	rs10517579	chr4:154666321	T/C	cg14289246	chr4:154710475	SFRP2	0.46	5.72	0.3	2.36e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs3101457	0.530	rs10754827	chr1:244528390	A/G	cg09033006	chr1:244517177	C1orf100	-0.4	-5.81	-0.3	1.46e-8	Smoking behavior;
LUSC	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-7.09	-0.36	7.82e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs4478858	0.698	rs4949204	chr1:31800415	A/G	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.84	-0.39	6.03e-14	Mood instability;
LUSC	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.84	-0.51	1.2e-23	Glomerular filtration rate;
LUSC	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-7.96	-0.4	2.65e-14	Schizophrenia;
LUSC	cis	rs62432291	0.681	rs429339	chr6:159660148	C/T	cg14500486	chr6:159655392	FNDC1	-0.54	-6.06	-0.31	3.76e-9	Joint mobility (Beighton score);
LUSC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	8.96	0.44	2.3e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7123876	0.587	rs55765314	chr11:72360935	C/A	cg04827223	chr11:72435913	ARAP1	-0.59	-6.65	-0.34	1.22e-10	Body mass index;
LUSC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg17554472	chr22:41940697	POLR3H	0.47	5.84	0.3	1.27e-8	Vitiligo;
LUSC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25072359	chr17:41440525	NA	0.65	9.33	0.45	1.48e-18	Menopause (age at onset);
LUSC	cis	rs11018904	0.861	rs12786959	chr11:89943676	A/T	cg26138821	chr11:89956704	CHORDC1	-0.58	-6.64	-0.34	1.3100000000000001e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7589342	0.862	rs6745887	chr2:106468039	G/A	cg16077055	chr2:106428750	NCK2	0.35	6.32	0.33	8.18e-10	Addiction;
LUSC	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg07506560	chr2:240697449	NA	0.47	7.71	0.39	1.45e-13	Obesity-related traits;
LUSC	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.59	-7.42	-0.38	1e-12	Body mass index (adult);
LUSC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-8.3	-0.41	2.67e-15	Aortic root size;
LUSC	trans	rs796395	0.650	rs675763	chr1:218682119	A/G	cg05473648	chr11:79113178	MIR708;ODZ4	-0.35	-5.95	-0.31	6.86e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg19678392	chr7:94953810	PON1	0.49	9.29	0.45	2.1e-18	Paraoxonase activity;
LUSC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg22868518	chr11:507468	RNH1	-0.65	-6.07	-0.32	3.46e-9	Body mass index;
LUSC	cis	rs722599	0.748	rs929579	chr14:75330697	C/T	cg08847533	chr14:75593920	NEK9	-0.45	-6.48	-0.33	3.25e-10	IgG glycosylation;
LUSC	cis	rs5753618	0.504	rs5749295	chr22:31932895	A/T	cg02404636	chr22:31891804	SFI1	0.43	6.25	0.32	1.25e-9	Colorectal cancer;
LUSC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg07395648	chr5:131743802	NA	0.42	5.76	0.3	1.94e-8	Breast cancer;
LUSC	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg10167378	chr1:228756711	NA	0.49	7.06	0.36	9.53e-12	Chronic lymphocytic leukemia;
LUSC	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.79	0.43	8.04e-17	Menopause (age at onset);
LUSC	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg00745463	chr17:30367425	LRRC37B	-0.54	-6.96	-0.36	1.84e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg21918786	chr6:109611834	NA	-0.37	-6.25	-0.32	1.22e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg21724239	chr8:58056113	NA	0.58	6.67	0.34	1.08e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3733631	1.000	rs17034046	chr4:104659604	C/T	cg24090629	chr4:104641072	TACR3	-0.47	-5.8	-0.3	1.51e-8	Menarche (age at onset);
LUSC	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg08677398	chr8:58056175	NA	0.41	5.65	0.3	3.37e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-10.4	-0.49	4.08e-22	Morning vs. evening chronotype;
LUSC	trans	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.26	-0.32	1.19e-9	Blood trace element (Cu levels);
LUSC	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg05855489	chr10:104503620	C10orf26	0.48	7.03	0.36	1.17e-11	Arsenic metabolism;
LUSC	cis	rs78545713	0.649	rs113407109	chr6:26224403	T/G	cg23601095	chr6:26197514	HIST1H3D	0.67	5.68	0.3	2.87e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12667521	chr19:29218732	NA	0.56	7.28	0.37	2.48e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs2677744	0.626	rs867468	chr15:91498127	G/A	cg20750528	chr15:91474456	HDDC3;UNC45A	-0.32	-5.64	-0.3	3.58e-8	Attention deficit hyperactivity disorder;
LUSC	cis	rs12493885	0.818	rs61791543	chr3:153766797	C/G	cg17054900	chr3:154042577	DHX36	-0.75	-7.66	-0.39	2.06e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs548181	0.536	rs503287	chr11:125461788	C/T	cg03464685	chr11:125439445	EI24	1.16	14.13	0.61	7.04e-36	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg09904177	chr6:26538194	HMGN4	0.7	12.48	0.56	1.34e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg08888203	chr3:10149979	C3orf24	0.63	8.88	0.44	4.16e-17	Alzheimer's disease;
LUSC	trans	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg18187862	chr3:45730750	SACM1L	-0.55	-6.65	-0.34	1.16e-10	Primary sclerosing cholangitis;
LUSC	cis	rs9649213	0.511	rs6950994	chr7:97887872	G/A	cg21770322	chr7:97807741	LMTK2	0.46	7.74	0.39	1.19e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7583236	0.500	rs7565597	chr2:70336070	T/G	cg19638749	chr2:70312615	NA	0.54	6.01	0.31	4.83e-9	Obesity-related traits;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04977109	chr17:46125622	NFE2L1	0.42	6.05	0.31	3.87e-9	Triglycerides;
LUSC	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg27446573	chr6:127587934	RNF146	0.46	7.02	0.36	1.24e-11	Breast cancer;
LUSC	trans	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg10756647	chr7:56101905	PSPH	-0.87	-8.66	-0.43	2.02e-16	Diabetic kidney disease;
LUSC	cis	rs11971779	0.616	rs1862878	chr7:139019914	C/G	cg23387468	chr7:139079360	LUC7L2	0.42	6.25	0.32	1.26e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6500395	1.000	rs12597569	chr16:48693342	C/T	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg01879757	chr17:41196368	BRCA1	-0.46	-7.09	-0.36	8.16e-12	Menopause (age at onset);
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg26354017	chr1:205819088	PM20D1	0.81	14.59	0.62	1.19e-37	Menarche (age at onset);
LUSC	cis	rs6969780	0.778	rs2428434	chr7:27145735	T/A	cg26364809	chr7:27145159	NA	-0.59	-5.98	-0.31	5.69e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs394563	0.663	rs415434	chr6:149772645	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.35	-7.73	-0.39	1.25e-13	Dupuytren's disease;
LUSC	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-10.58	-0.5	9.56e-23	Bladder cancer;
LUSC	cis	rs2274273	0.686	rs66782529	chr14:55587867	C/T	cg04306507	chr14:55594613	LGALS3	0.48	9.58	0.46	2.26e-19	Protein biomarker;
LUSC	cis	rs9300255	0.782	rs12809602	chr12:123768916	T/G	cg00376283	chr12:123451042	ABCB9	-0.68	-7.57	-0.38	3.68e-13	Neutrophil percentage of white cells;
LUSC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.06	-0.52	1.96e-24	Alzheimer's disease;
LUSC	cis	rs7929679	0.521	rs1509667	chr11:34791303	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.91	0.31	8.29e-9	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12620999	0.555	rs4078064	chr2:238110296	C/T	cg23555395	chr2:238036564	NA	-0.33	-6.12	-0.32	2.6e-9	Systemic lupus erythematosus;
LUSC	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg20203395	chr5:56204925	C5orf35	-0.44	-6.39	-0.33	5.45e-10	Coronary artery disease;
LUSC	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg02187348	chr16:89574699	SPG7	0.54	8.56	0.42	4.1e-16	Multiple myeloma (IgH translocation);
LUSC	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg21775007	chr8:11205619	TDH	0.65	10.85	0.51	1.1e-23	Retinal vascular caliber;
LUSC	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg19628046	chr18:33552617	C18orf21	0.5	6.15	0.32	2.16e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg08601574	chr20:25228251	PYGB	0.44	6.67	0.34	1.04e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg23260525	chr10:116636907	FAM160B1	0.43	9.23	0.45	3.24e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg23992470	chr4:843637	GAK	-0.54	-5.91	-0.31	8.42e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4809219	1	rs4809219	chr20:62303115	C/A	cg09650180	chr20:62225654	GMEB2	0.45	5.9	0.31	8.83e-9	Atopic dermatitis;
LUSC	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-0.74	-13.08	-0.58	7.31e-32	Gut microbiome composition (winter);
LUSC	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-7.02	-0.36	1.24e-11	Bladder cancer;
LUSC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.96	-15.51	-0.65	3.14e-41	Coronary artery disease;
LUSC	cis	rs9920506	0.536	rs11636605	chr15:78928878	A/G	cg05914723	chr15:78953907	NA	-0.35	-5.69	-0.3	2.79e-8	Post bronchodilator FEV1;
LUSC	cis	rs644148	0.748	rs542150	chr19:44967453	T/C	cg15540054	chr19:45004280	ZNF180	0.46	6.28	0.33	1.03e-9	Personality dimensions;
LUSC	cis	rs9400467	0.528	rs465796	chr6:111619725	T/G	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.25	-0.32	1.25e-9	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.85	15.28	0.64	2.52e-40	Menarche (age at onset);
LUSC	cis	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.55	-5.94	-0.31	7.2e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-10.03	-0.48	7.45e-21	Gut microbiome composition (summer);
LUSC	cis	rs9948	0.655	rs7568206	chr2:97393108	A/C	cg01990225	chr2:97406019	LMAN2L	-1.09	-8.15	-0.41	7.59e-15	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-5.83	-0.3	1.28e-8	Tonsillectomy;
LUSC	cis	rs4474465	0.915	rs10899512	chr11:78171338	G/A	cg27205649	chr11:78285834	NARS2	-0.49	-5.79	-0.3	1.61e-8	Alzheimer's disease (survival time);
LUSC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.18	0.45	4.55e-18	Prudent dietary pattern;
LUSC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19717773	chr7:2847554	GNA12	-0.38	-6.14	-0.32	2.29e-9	Height;
LUSC	cis	rs701145	0.585	rs1470663	chr3:153870883	A/G	cg17054900	chr3:154042577	DHX36	0.69	6.76	0.35	6.15e-11	Coronary artery disease;
LUSC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.28	0.53	3.21e-25	Prudent dietary pattern;
LUSC	cis	rs8027181	1.000	rs8027181	chr15:73088869	A/T	cg25632853	chr15:73088954	NA	0.35	7.13	0.36	6.16e-12	Triglyceride levels;
LUSC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.9	0.48	2.05e-20	Bipolar disorder;
LUSC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00376283	chr12:123451042	ABCB9	0.68	8.54	0.42	4.8e-16	Neutrophil percentage of white cells;
LUSC	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg24011408	chr12:48396354	COL2A1	0.53	7.38	0.37	1.27e-12	Lung cancer;
LUSC	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg01657329	chr11:68192670	LRP5	-0.4	-5.87	-0.31	1.07e-8	Total body bone mineral density;
LUSC	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg16482183	chr6:26056742	HIST1H1C	-0.53	-7.53	-0.38	4.66e-13	Iron status biomarkers;
LUSC	trans	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg07393940	chr7:158741817	NA	0.38	6.86	0.35	3.29e-11	Life satisfaction;
LUSC	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg22823121	chr1:150693482	HORMAD1	0.49	7.0	0.36	1.37e-11	Melanoma;
LUSC	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.63	-0.47	1.55e-19	Multiple sclerosis;
LUSC	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.85	-16.35	-0.67	1.53e-44	Body mass index (adult);
LUSC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg22800045	chr5:56110881	MAP3K1	0.82	10.17	0.49	2.35e-21	Initial pursuit acceleration;
LUSC	cis	rs4948102	0.924	rs13240915	chr7:56090752	G/C	cg17215666	chr7:56131930	SUMF2	0.48	6.22	0.32	1.48e-9	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.75e-14	Melanoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11614622	chr11:66623681	LRFN4;PC	0.41	6.08	0.32	3.21e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.5	-0.46	4.09e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.82	-0.43	6.4e-17	Total cholesterol levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22091798	chr11:62446605	UBXN1	-0.44	-6.1	-0.32	2.96e-9	Hepatitis;
LUSC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg22823121	chr1:150693482	HORMAD1	-0.61	-9.45	-0.46	6.14e-19	Tonsillectomy;
LUSC	trans	rs3857536	0.842	rs2188590	chr6:66939534	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs7580658	0.929	rs2276583	chr2:128014684	G/A	cg09760422	chr2:128146352	NA	-0.32	-7.05	-0.36	1.02e-11	Protein C levels;
LUSC	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg04352962	chr1:209979756	IRF6	0.49	5.76	0.3	1.94e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg14092571	chr14:90743983	NA	-0.36	-5.99	-0.31	5.46e-9	Mortality in heart failure;
LUSC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	cis	rs12137294	0.866	rs896320	chr1:205205347	T/C	cg00857998	chr1:205179979	DSTYK	0.4	5.77	0.3	1.77e-8	Red cell distribution width;
LUSC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg04121214	chr22:50244548	NA	-0.34	-5.74	-0.3	2.14e-8	Schizophrenia;
LUSC	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg13902645	chr11:5959945	NA	-0.58	-8.2	-0.41	5.23e-15	DNA methylation (variation);
LUSC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.83	-0.3	1.27e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg26958806	chr6:27640298	NA	0.66	5.66	0.3	3.22e-8	Depression;
LUSC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	15.13	0.64	9.56e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07636037	chr3:49044803	WDR6	0.7	9.43	0.46	6.91e-19	Menarche (age at onset);
LUSC	cis	rs500891	1.000	rs6910291	chr6:84185995	A/T	cg08257003	chr6:84140564	ME1	0.34	7.02	0.36	1.26e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.76	-0.3	1.92e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg00579200	chr11:133705235	NA	-0.39	-5.92	-0.31	8.19e-9	Childhood ear infection;
LUSC	cis	rs7605827	0.856	rs35549453	chr2:15527220	C/T	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg12927641	chr6:109611667	NA	-0.34	-5.77	-0.3	1.81e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs62400317	0.859	rs17209741	chr6:45292438	A/T	cg18551225	chr6:44695536	NA	-0.41	-6.94	-0.36	2.01e-11	Total body bone mineral density;
LUSC	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg01528321	chr10:82214614	TSPAN14	1.09	17.06	0.68	2.33e-47	Post bronchodilator FEV1;
LUSC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg24562669	chr7:97807699	LMTK2	0.37	6.45	0.33	3.99e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2236918	1.000	rs2526699	chr1:242022130	T/C	cg17736920	chr1:242011382	EXO1	0.46	7.26	0.37	2.8e-12	Menopause (age at onset);
LUSC	cis	rs4700695	0.719	rs27086	chr5:65453185	A/G	cg21114390	chr5:65439923	SFRS12	-0.63	-8.98	-0.44	2.07e-17	Facial morphology (factor 19);
LUSC	cis	rs10892173	0.765	rs1892903	chr11:117669619	A/G	cg21640587	chr11:117668038	DSCAML1	0.35	5.73	0.3	2.2e-8	Myopia;
LUSC	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.28	-0.37	2.48e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18404041	chr3:52824283	ITIH1	-0.56	-10.64	-0.5	6.05e-23	Bipolar disorder;
LUSC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg12463550	chr7:65579703	CRCP	-0.57	-8.62	-0.43	2.65e-16	Aortic root size;
LUSC	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.52	-7.1	-0.36	7.78e-12	Mean platelet volume;
LUSC	trans	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg03886242	chr7:26192032	NFE2L3	0.38	6.32	0.33	8.36e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg18129178	chr5:148520854	ABLIM3	-0.65	-10.24	-0.49	1.38e-21	Breast cancer;
LUSC	cis	rs4356932	1.000	rs11097222	chr4:76987451	A/G	cg00809888	chr4:76862425	NAAA	0.34	5.67	0.3	3.12e-8	Blood protein levels;
LUSC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg00933542	chr6:150070202	PCMT1	0.31	6.52	0.34	2.67e-10	Lung cancer;
LUSC	cis	rs193541	0.632	rs154504	chr5:122204086	A/T	cg19077854	chr5:122220652	SNX24	0.42	8.48	0.42	7.62e-16	Glucose homeostasis traits;
LUSC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg15557168	chr22:42548783	NA	-0.47	-7.33	-0.37	1.73e-12	Schizophrenia;
LUSC	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.42	-0.38	9.62e-13	Height;
LUSC	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg00757033	chr12:89920650	WDR51B	0.59	10.45	0.5	2.65e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.36	5.78	0.3	1.69e-8	Self-reported allergy;
LUSC	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg01557791	chr16:72042693	DHODH	-0.46	-6.84	-0.35	3.81e-11	Fibrinogen levels;
LUSC	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.38	-6.33	-0.33	8.04e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg09365446	chr1:150670422	GOLPH3L	0.55	8.44	0.42	9.59e-16	Tonsillectomy;
LUSC	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg04851639	chr8:1020857	NA	-0.37	-7.85	-0.39	5.87e-14	Schizophrenia;
LUSC	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg12935359	chr14:103987150	CKB	-0.57	-8.68	-0.43	1.73e-16	Body mass index;
LUSC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14159672	chr1:205819179	PM20D1	0.47	7.45	0.38	7.97e-13	Menarche (age at onset);
LUSC	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg04455712	chr21:45112962	RRP1B	0.46	8.72	0.43	1.37e-16	Mean corpuscular volume;
LUSC	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.99	0.55	8.74e-28	Ileal carcinoids;
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg15242686	chr22:24348715	GSTTP1	-0.41	-6.04	-0.31	4.11e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12304921	0.639	rs2306732	chr12:51455739	G/T	cg02675652	chr12:51477739	CSRNP2	-0.28	-5.8	-0.3	1.57e-8	Type 2 diabetes;
LUSC	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.64	10.04	0.48	6.8e-21	Hemoglobin concentration;
LUSC	cis	rs4700695	0.841	rs152994	chr5:65262989	A/G	cg21114390	chr5:65439923	SFRS12	0.49	5.64	0.3	3.56e-8	Facial morphology (factor 19);
LUSC	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg24642844	chr7:1081250	C7orf50	-0.52	-7.9	-0.4	4.07e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs4794665	0.874	rs9908159	chr17:54841961	T/C	cg18503679	chr3:21792543	ZNF385D	0.37	5.95	0.31	6.7e-9	Height;
LUSC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg08601574	chr20:25228251	PYGB	0.55	8.83	0.43	6.23e-17	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24838063	chr12:130822603	PIWIL1	0.7	10.75	0.51	2.38e-23	Menopause (age at onset);
LUSC	cis	rs9462027	0.606	rs2814984	chr6:34597513	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.03	-0.31	4.39e-9	Systemic lupus erythematosus;
LUSC	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	0.3	5.96	0.31	6.27e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg07930552	chr6:133119739	C6orf192	0.84	10.61	0.5	7.57e-23	Type 2 diabetes nephropathy;
LUSC	trans	rs1819054	0.806	rs1528351	chr7:121167875	C/T	cg18897345	chr22:38885348	DDX17	-0.41	-6.17	-0.32	2.03e-9	Hand grip strength;
LUSC	cis	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg21775007	chr8:11205619	TDH	0.49	6.62	0.34	1.43e-10	Neuroticism;
LUSC	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg07211511	chr3:129823064	LOC729375	-0.62	-8.21	-0.41	4.72e-15	Blood pressure (smoking interaction);
LUSC	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg22676075	chr6:135203613	NA	0.47	7.27	0.37	2.62e-12	Red blood cell count;
LUSC	cis	rs9807989	0.507	rs2110659	chr2:103043867	G/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.06	0.36	9.92e-12	Asthma;
LUSC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg05425664	chr17:57184151	TRIM37	0.52	7.8	0.39	8.19e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg23758822	chr17:41437982	NA	0.87	16.08	0.66	1.68e-43	Menopause (age at onset);
LUSC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg11062466	chr8:58055876	NA	0.68	7.85	0.39	5.73e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg09034736	chr1:150693464	HORMAD1	0.44	6.11	0.32	2.79e-9	Melanoma;
LUSC	trans	rs72674100	0.867	rs4615177	chr4:97963798	G/A	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	9.16	0.45	5.39e-18	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-9.06	-0.44	1.11e-17	Response to antipsychotic treatment;
LUSC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19717773	chr7:2847554	GNA12	0.42	6.86	0.35	3.26e-11	Height;
LUSC	trans	rs9944715	0.954	rs62096526	chr18:43745639	G/A	cg01718231	chr17:29326311	RNF135	0.51	7.16	0.36	5.11e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs4356932	1.000	rs1554013	chr4:76933484	T/C	cg00809888	chr4:76862425	NAAA	0.34	5.65	0.3	3.5e-8	Blood protein levels;
LUSC	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	8.39	0.42	1.35e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg00376283	chr12:123451042	ABCB9	0.84	13.24	0.59	1.88e-32	Platelet count;
LUSC	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg22029157	chr1:209979665	IRF6	0.55	6.18	0.32	1.9e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs1451375	0.755	rs3829897	chr7:50629764	G/T	cg18232548	chr7:50535776	DDC	0.53	8.01	0.4	1.91e-14	Malaria;
LUSC	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg21285383	chr16:89894308	SPIRE2	0.35	7.19	0.37	4.39e-12	Vitiligo;
LUSC	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg19622623	chr12:86230825	RASSF9	-0.43	-5.98	-0.31	5.85e-9	Major depressive disorder;
LUSC	cis	rs10140922	0.966	rs28589517	chr14:35820643	G/A	cg07166546	chr14:35805898	NA	-0.25	-6.08	-0.32	3.24e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg05472934	chr7:22766657	IL6	0.5	7.76	0.39	1.03e-13	Lung cancer;
LUSC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06634786	chr22:41940651	POLR3H	0.49	5.72	0.3	2.34e-8	Vitiligo;
LUSC	cis	rs17373728	0.739	rs6472896	chr8:76190315	A/C	cg07016329	chr8:76221503	NA	-0.49	-7.0	-0.36	1.44e-11	Diabetic kidney disease;
LUSC	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.49	7.0	0.36	1.41e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg02931644	chr1:25747376	RHCE	0.4	7.46	0.38	7.36e-13	Erythrocyte sedimentation rate;
LUSC	cis	rs7091068	0.518	rs1543580	chr10:95446811	C/T	cg20715218	chr10:95462985	C10orf4	0.51	6.47	0.33	3.4e-10	Urinary tract infection frequency;
LUSC	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg25482853	chr8:67687455	SGK3	1.2	17.16	0.68	9.11e-48	Lung disease severity in cystic fibrosis;
LUSC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg02153584	chr22:29168773	CCDC117	0.66	10.72	0.51	3.16e-23	Lymphocyte counts;
LUSC	cis	rs9625935	0.957	rs36606	chr22:30340410	A/T	cg11564601	chr22:30592435	NA	0.38	5.66	0.3	3.18e-8	Tonsillectomy;
LUSC	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg01557791	chr16:72042693	DHODH	-0.47	-6.05	-0.31	3.94e-9	Blood protein levels;
LUSC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	1.05	19.12	0.72	1.42e-55	Menopause (age at onset);
LUSC	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg21141812	chr3:48556323	PFKFB4	0.35	6.24	0.32	1.32e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg27490568	chr2:178487706	NA	0.45	6.45	0.33	3.99e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.83	-0.35	4.11e-11	Crohn's disease;
LUSC	cis	rs1891275	0.515	rs11186666	chr10:93477919	T/C	cg07889827	chr10:93443413	NA	-0.38	-8.53	-0.42	5.08e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg03806693	chr22:41940476	POLR3H	1.0	14.26	0.62	2.35e-36	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs929596	0.564	rs2741029	chr2:234530160	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-6.4	-0.33	5.13e-10	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg11657440	chr19:46296263	DMWD	-0.73	-11.2	-0.52	6.19e-25	Coronary artery disease;
LUSC	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.98	-0.48	1.1e-20	Migraine;Coronary artery disease;
LUSC	cis	rs7091068	0.550	rs7079013	chr10:95487878	A/C	cg20715218	chr10:95462985	C10orf4	0.66	9.35	0.46	1.29e-18	Urinary tract infection frequency;
LUSC	cis	rs6500395	0.962	rs1115759	chr16:48599530	A/G	cg04672837	chr16:48644449	N4BP1	0.42	6.01	0.31	4.91e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg00129232	chr17:37814104	STARD3	-0.5	-7.49	-0.38	6.21e-13	Asthma;
LUSC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg09555818	chr19:45449301	APOC2	0.47	8.77	0.43	9.14e-17	Blood protein levels;
LUSC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg11752832	chr7:134001865	SLC35B4	0.56	8.8	0.43	7.57e-17	Mean platelet volume;
LUSC	cis	rs4474465	1.000	rs10899505	chr11:78165343	T/C	cg27205649	chr11:78285834	NARS2	-0.49	-5.91	-0.31	8.5e-9	Alzheimer's disease (survival time);
LUSC	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg24596788	chr1:163392923	NA	-0.39	-6.69	-0.34	9.69e-11	Motion sickness;
LUSC	trans	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg09050820	chr6:167586206	TCP10L2	0.73	9.47	0.46	5.31e-19	Gastritis;
LUSC	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg21141812	chr3:48556323	PFKFB4	0.33	5.74	0.3	2.13e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg06521331	chr12:34319734	NA	-0.4	-5.76	-0.3	1.87e-8	Resting heart rate;
LUSC	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.75	-0.68	3.68e-46	Exhaled nitric oxide output;
LUSC	cis	rs981844	0.796	rs17030437	chr4:154704225	A/C	cg14289246	chr4:154710475	SFRP2	-0.45	-5.89	-0.31	9.63e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	6.84	0.35	3.84e-11	Bipolar disorder;
LUSC	cis	rs9650315	0.789	rs13261678	chr8:57188333	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.88	0.35	3.01e-11	Height;
LUSC	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg13397359	chr6:42928475	GNMT	0.43	5.9	0.31	8.84e-9	Blood protein levels;
LUSC	trans	rs62238980	0.614	rs77324143	chr22:32401957	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.01	-0.31	4.82e-9	Childhood ear infection;
LUSC	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg23093090	chr10:104574429	C10orf26	-0.36	-6.62	-0.34	1.42e-10	Arsenic metabolism;
LUSC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-8.04	-0.4	1.62e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-10.59	-0.5	8.99e-23	Pancreatic cancer;
LUSC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.46	-7.27	-0.37	2.59e-12	Bipolar disorder;
LUSC	cis	rs4786125	0.516	rs7203888	chr16:6915483	T/C	cg03623568	chr16:6915990	A2BP1	-0.49	-8.16	-0.41	7.04e-15	Heart rate variability traits (SDNN);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22380059	chr17:33307512	LIG3	-0.4	-6.06	-0.31	3.77e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	0.98	19.07	0.72	2.26e-55	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs4919087	1.000	rs7078288	chr10:99086361	C/T	cg25902810	chr10:99078978	FRAT1	-0.47	-6.78	-0.35	5.5e-11	Monocyte count;
LUSC	cis	rs10193935	0.818	rs10221927	chr2:42546680	A/C	cg27598129	chr2:42591480	NA	-0.63	-8.81	-0.43	6.7e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4363385	0.818	rs559236	chr1:153010510	T/C	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg22875332	chr1:76189707	ACADM	0.77	10.32	0.49	7.56e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg00750074	chr16:89608354	SPG7	-0.53	-9.57	-0.46	2.41e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.43	-0.42	1.08e-15	Lung cancer;
LUSC	cis	rs28655083	0.529	rs285022	chr16:77099730	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.38	6.15	0.32	2.24e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg22153799	chr7:158819822	NA	-0.33	-5.77	-0.3	1.83e-8	Facial morphology (factor 20);
LUSC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg07741184	chr6:167504864	NA	0.36	6.42	0.33	4.61e-10	Crohn's disease;
LUSC	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.78	11.53	0.53	4.06e-26	Corneal astigmatism;
LUSC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg19046167	chr17:80928561	B3GNTL1	0.5	7.08	0.36	8.79e-12	Glycated hemoglobin levels;
LUSC	cis	rs28647808	0.881	rs28461467	chr9:136261288	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-0.86	-17.21	-0.69	5.96e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950776	0.642	rs61630816	chr15:78965866	T/C	cg06917634	chr15:78832804	PSMA4	0.49	6.81	0.35	4.58e-11	Sudden cardiac arrest;
LUSC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03264133	chr6:25882463	NA	-0.39	-6.82	-0.35	4.2e-11	Height;
LUSC	cis	rs4588572	0.601	rs10070202	chr5:77792462	A/C	cg11547950	chr5:77652471	NA	-0.59	-8.31	-0.41	2.44e-15	Triglycerides;
LUSC	cis	rs62408225	0.962	rs1604830	chr6:90969221	T/C	cg06866423	chr6:90926672	BACH2	0.41	5.85	0.31	1.15e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs3736485	0.934	rs4775955	chr15:51873449	C/T	cg09125779	chr4:57547999	HOPX	-0.34	-6.01	-0.31	4.96e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-17.09	-0.68	1.69e-47	Exhaled nitric oxide output;
LUSC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg26335602	chr6:28129616	ZNF389	-0.45	-6.19	-0.32	1.74e-9	Depression;
LUSC	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg25456477	chr12:86230367	RASSF9	0.43	7.44	0.38	8.43e-13	Major depressive disorder;
LUSC	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg08847533	chr14:75593920	NEK9	-0.78	-13.21	-0.59	2.4e-32	Height;
LUSC	cis	rs7605827	0.930	rs918157	chr2:15657729	G/A	cg19274914	chr2:15703543	NA	0.46	8.83	0.43	6.22e-17	Educational attainment (years of education);
LUSC	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg16230307	chr14:35515116	FAM177A1	0.81	10.3	0.49	8.93e-22	Psoriasis;
LUSC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	11.15	0.52	8.96e-25	Prudent dietary pattern;
LUSC	cis	rs757278	0.591	rs1800136	chr7:117307108	G/A	cg10524701	chr7:117356490	CTTNBP2	0.4	5.76	0.3	1.9e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs6545883	0.929	rs2592352	chr2:61665336	C/T	cg15711740	chr2:61764176	XPO1	-0.46	-7.12	-0.36	6.47e-12	Tuberculosis;
LUSC	cis	rs8141797	0.901	rs176161	chr22:24516291	C/T	cg00411358	chr22:24577142	SUSD2	-0.61	-6.07	-0.32	3.43e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs3125734	0.633	rs6479792	chr10:63983264	T/G	cg19640130	chr10:64028056	RTKN2	-0.4	-7.07	-0.36	8.92e-12	Rheumatoid arthritis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08334199	chr2:178128998	NFE2L2	-0.4	-5.96	-0.31	6.5e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg08798685	chr6:27730294	NA	-0.64	-6.01	-0.31	4.93e-9	Breast cancer;
LUSC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.42	-6.52	-0.34	2.6200000000000003e-10	Bipolar disorder;
LUSC	cis	rs11597390	0.865	rs12781812	chr10:101891222	G/T	cg02250046	chr10:101825185	CPN1	-0.33	-6.0	-0.31	5.04e-9	Liver enzyme levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04900785	chr2:44589279	PREPL;C2orf34	0.41	5.96	0.31	6.52e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4363385	0.818	rs3795382	chr1:153004853	C/T	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.46e-8	Inflammatory skin disease;
LUSC	trans	rs1927790	0.727	rs9556550	chr13:96947034	A/C	cg03198741	chr6:1003969	LOC285768	-0.4	-6.09	-0.32	3.08e-9	Body mass index;
LUSC	cis	rs12541635	0.932	rs1835267	chr8:107044435	C/T	cg10147462	chr8:107024639	NA	0.55	9.92	0.48	1.72e-20	Age of smoking initiation;
LUSC	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg17366294	chr4:99064904	C4orf37	0.56	9.92	0.48	1.69e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg02158880	chr13:53174818	NA	0.57	9.84	0.47	3.16e-20	Lewy body disease;
LUSC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg06784218	chr1:46089804	CCDC17	0.48	9.47	0.46	5.16e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3936840	1.000	rs3936840	chr14:102984274	G/C	cg18135206	chr14:102964638	TECPR2	0.59	8.82	0.43	6.42e-17	Plateletcrit;
LUSC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg09877947	chr5:131593287	PDLIM4	0.46	7.56	0.38	3.84e-13	Breast cancer;
LUSC	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg17541715	chr7:1216824	NA	-0.43	-6.58	-0.34	1.78e-10	Longevity;Endometriosis;
LUSC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg04267008	chr7:1944627	MAD1L1	0.59	9.0	0.44	1.75e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.36	-0.37	1.48e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-1.24	-13.61	-0.6	7.43e-34	Diabetic kidney disease;
LUSC	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg13073564	chr4:8508604	NA	0.36	6.53	0.34	2.5e-10	Response to antineoplastic agents;
LUSC	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	5.74	0.3	2.12e-8	Neutrophil percentage of white cells;
LUSC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22307029	chr19:49891270	CCDC155	0.62	7.96	0.4	2.64e-14	Multiple sclerosis;
LUSC	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.74	0.3	2.08e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg10426581	chr7:100472382	SRRT	0.86	12.47	0.56	1.43e-29	Resting heart rate;
LUSC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26314531	chr2:26401878	FAM59B	-0.71	-9.41	-0.46	8.43e-19	Gut microbiome composition (summer);
LUSC	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg09365446	chr1:150670422	GOLPH3L	0.48	7.21	0.37	3.71e-12	Melanoma;
LUSC	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-11.79	-0.54	4.52e-27	Monocyte count;
LUSC	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.39	-5.73	-0.3	2.23e-8	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.69	0.39	1.63e-13	Prudent dietary pattern;
LUSC	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.61	0.34	1.48e-10	Corneal astigmatism;
LUSC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg16447950	chr5:562315	NA	-0.58	-7.3	-0.37	2.1e-12	Obesity-related traits;
LUSC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg15212455	chr7:39170539	POU6F2	0.59	9.42	0.46	7.64e-19	IgG glycosylation;
LUSC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg23630131	chr7:65973040	NA	0.21	5.79	0.3	1.6e-8	Aortic root size;
LUSC	cis	rs4363385	0.667	rs78426057	chr1:152964528	T/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.55	-0.38	4.06e-13	Inflammatory skin disease;
LUSC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs131777	0.576	rs131758	chr22:51017082	T/A	cg00083937	chr22:51039805	MAPK8IP2	0.56	9.56	0.46	2.6e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	0.7	7.02	0.36	1.26e-11	Prostate cancer;
LUSC	cis	rs1018836	0.700	rs7824511	chr8:91521545	T/C	cg16814680	chr8:91681699	NA	-0.73	-11.41	-0.53	1.05e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg13010199	chr12:38710504	ALG10B	0.45	6.38	0.33	5.87e-10	Morning vs. evening chronotype;
LUSC	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg07148914	chr20:33460835	GGT7	-0.46	-6.8	-0.35	4.88e-11	Height;
LUSC	cis	rs36093844	0.752	rs80193798	chr11:85577529	C/T	cg25872744	chr11:85566296	CCDC83	-0.45	-5.88	-0.31	1.01e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg08219700	chr8:58056026	NA	0.43	5.72	0.3	2.37e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.41	6.06	0.31	3.65e-9	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg22532475	chr10:104410764	TRIM8	-0.36	-7.89	-0.4	4.31e-14	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg04989706	chr14:50066350	PPIL5	-0.46	-6.28	-0.33	1.04e-9	Carotid intima media thickness;
LUSC	cis	rs9888739	0.920	rs12102768	chr16:31303950	G/A	cg15817542	chr16:31343056	ITGAM	-0.5	-6.05	-0.31	3.93e-9	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg03676636	chr4:99064102	C4orf37	0.37	8.12	0.41	9.37e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg07777115	chr5:623756	CEP72	-0.45	-5.7	-0.3	2.62e-8	Obesity-related traits;
LUSC	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg00982548	chr2:198649783	BOLL	-0.6	-7.44	-0.38	8.52e-13	Ulcerative colitis;
LUSC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg22903471	chr2:27725779	GCKR	-0.4	-6.79	-0.35	5.14e-11	Total body bone mineral density;
LUSC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg03563238	chr19:33554763	RHPN2	-0.35	-6.04	-0.31	4.03e-9	Bone properties (heel);
LUSC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg04733989	chr22:42467013	NAGA	0.61	9.3	0.45	1.92e-18	Schizophrenia;
LUSC	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg11812906	chr14:75593930	NEK9	0.66	11.25	0.52	3.96e-25	Height;
LUSC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.7	0.6	3.15e-34	Cognitive test performance;
LUSC	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg23649088	chr2:200775458	C2orf69	-0.53	-6.82	-0.35	4.37e-11	Schizophrenia;
LUSC	cis	rs67696533	0.600	rs910891	chr20:31111505	G/C	cg13636640	chr20:31349939	DNMT3B	0.47	6.21	0.32	1.55e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg03929089	chr4:120376271	NA	0.59	6.44	0.33	4.04e-10	Axial length;
LUSC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg02475777	chr4:1388615	CRIPAK	0.45	6.65	0.34	1.2e-10	Obesity-related traits;
LUSC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.53	0.38	4.69e-13	Bipolar disorder;
LUSC	cis	rs9715521	0.677	rs4490528	chr4:59854572	T/G	cg11281224	chr4:60001000	NA	-0.5	-7.02	-0.36	1.25e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03278965	chr3:141595308	ATP1B3	0.4	6.03	0.31	4.41e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.85	0.54	2.8e-27	Prudent dietary pattern;
LUSC	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg13206674	chr6:150067644	NUP43	0.55	8.45	0.42	9.43e-16	Lung cancer;
LUSC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg15352829	chr14:105391018	PLD4	-0.35	-7.35	-0.37	1.51e-12	Rheumatoid arthritis;
LUSC	cis	rs9039	0.921	rs9929699	chr16:9218270	A/G	cg08831531	chr16:9218945	NA	-0.54	-8.58	-0.43	3.59e-16	Menopause (age at onset);
LUSC	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.78	-14.11	-0.61	8.68e-36	Brugada syndrome;
LUSC	cis	rs981844	1.000	rs1116636	chr4:154657151	C/T	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg00409905	chr10:38381863	ZNF37A	0.37	6.32	0.33	8.2e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.7	-0.39	1.58e-13	Height;
LUSC	trans	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	2.03e-12	Bone mineral density;
LUSC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg05420251	chr10:102133820	C10orf75	0.44	6.44	0.33	4.25e-10	Mosquito bite size;
LUSC	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	0.9	16.12	0.66	1.15e-43	Bone mineral density;
LUSC	cis	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg06521331	chr12:34319734	NA	0.4	6.61	0.34	1.48e-10	Morning vs. evening chronotype;
LUSC	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg01028140	chr2:1542097	TPO	-0.61	-8.17	-0.41	6.41e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg21770322	chr7:97807741	LMTK2	-0.4	-7.0	-0.36	1.37e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg06191203	chr2:152266755	RIF1	-0.42	-5.73	-0.3	2.2e-8	Lung cancer;
LUSC	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg16558253	chr16:72132732	DHX38	-0.41	-6.26	-0.32	1.19e-9	Fibrinogen levels;
LUSC	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg11861562	chr11:117069780	TAGLN	0.33	6.38	0.33	5.8e-10	Blood protein levels;
LUSC	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.66	11.35	0.53	1.82e-25	Schizophrenia;
LUSC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg08847533	chr14:75593920	NEK9	0.85	15.78	0.65	2.64e-42	Height;
LUSC	cis	rs13202913	0.709	rs11965449	chr6:151830598	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.52	-5.88	-0.31	9.95e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg09904177	chr6:26538194	HMGN4	-0.65	-6.27	-0.32	1.14e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg26061582	chr7:22766209	IL6	0.52	7.63	0.39	2.56e-13	Lung cancer;
LUSC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.37	-0.33	6.14e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12210905	0.925	rs72838228	chr6:26945920	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.67	-5.96	-0.31	6.27e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06558623	chr16:89946397	TCF25	1.11	9.73	0.47	7.08e-20	Skin colour saturation;
LUSC	cis	rs10207060	0.500	rs10177457	chr2:240708067	G/A	cg20333904	chr2:240724165	NA	-0.36	-6.12	-0.32	2.56e-9	Obesity-related traits;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	ch.5.67026991F	chr5:66991235	NA	0.41	6.46	0.33	3.7e-10	Schizophrenia;
LUSC	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg11211951	chr8:145729740	GPT	0.45	8.28	0.41	3.08e-15	Age at first birth;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg01238044	chr22:24384105	GSTT1	-0.52	-7.58	-0.38	3.51e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg06521331	chr12:34319734	NA	-0.37	-6.18	-0.32	1.88e-9	Morning vs. evening chronotype;
LUSC	trans	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg01134436	chr17:81009848	B3GNTL1	0.66	6.08	0.32	3.31e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg27535305	chr1:53392650	SCP2	-0.4	-7.43	-0.38	9.16e-13	Monocyte count;
LUSC	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14240646	chr10:27532245	ACBD5	-0.91	-8.4	-0.42	1.29e-15	Breast cancer;
LUSC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg04362960	chr10:104952993	NT5C2	-0.61	-9.36	-0.46	1.19e-18	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg08179530	chr6:36648295	CDKN1A	0.61	8.77	0.43	9.24e-17	Coronary artery disease;
LUSC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	0.63	13.47	0.59	2.59e-33	Prudent dietary pattern;
LUSC	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg22875332	chr1:76189707	ACADM	-0.41	-6.07	-0.32	3.39e-9	Daytime sleep phenotypes;
LUSC	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	6.93	0.35	2.15e-11	Multiple sclerosis;
LUSC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg22834771	chr12:69754056	YEATS4	-0.56	-8.33	-0.41	2.1e-15	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02862674	chr6:44238426	TMEM151B	-0.45	-5.97	-0.31	6.12e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3947	1.000	rs3947	chr8:11702375	G/A	cg00262122	chr8:11665843	FDFT1	-0.5	-6.0	-0.31	5.13e-9	Blood protein levels;
LUSC	cis	rs12410462	0.581	rs77430808	chr1:227540880	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.66	-6.56	-0.34	2.09e-10	Major depressive disorder;
LUSC	cis	rs7582720	0.943	rs115827549	chr2:203725678	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	8.17	0.41	6.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg21132104	chr15:45694354	SPATA5L1	0.56	7.77	0.39	1.01e-13	Homoarginine levels;
LUSC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg01879757	chr17:41196368	BRCA1	-0.39	-5.96	-0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg26769984	chr7:1090371	C7orf50	0.46	6.64	0.34	1.27e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg05855489	chr10:104503620	C10orf26	0.59	9.39	0.46	9.82e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg17366294	chr4:99064904	C4orf37	0.55	9.77	0.47	5.18e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg15896084	chr13:114927664	NA	0.38	6.85	0.35	3.46e-11	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg13206674	chr6:150067644	NUP43	0.5	7.82	0.39	7.16e-14	Lung cancer;
LUSC	cis	rs11153730	0.503	rs283046	chr6:118627503	T/C	cg21191810	chr6:118973309	C6orf204	0.34	5.72	0.3	2.35e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUSC	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg17691542	chr6:26056736	HIST1H1C	0.45	6.75	0.35	6.45e-11	Height;
LUSC	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.41	5.74	0.3	2.16e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg03340356	chr1:67600835	NA	0.44	6.77	0.35	5.75e-11	Psoriasis;
LUSC	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg18232548	chr7:50535776	DDC	-0.58	-8.67	-0.43	1.88e-16	Systemic sclerosis;
LUSC	cis	rs3771570	0.901	rs62190410	chr2:242410621	C/T	cg21155796	chr2:242212141	HDLBP	0.61	6.86	0.35	3.35e-11	Prostate cancer;
LUSC	cis	rs9653442	0.545	rs12712067	chr2:100763900	A/C	cg22139774	chr2:100720529	AFF3	0.41	6.78	0.35	5.51e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4654899	0.802	rs6426648	chr1:21179527	A/G	cg01072550	chr1:21505969	NA	-0.47	-7.08	-0.36	8.56e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08470875	chr2:26401718	FAM59B	0.71	9.74	0.47	6.55e-20	Gut microbiome composition (summer);
LUSC	cis	rs17095355	0.901	rs12572168	chr10:111764786	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.12	-0.36	6.69e-12	Biliary atresia;
LUSC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg27170947	chr2:26402098	FAM59B	0.71	10.96	0.51	4.41e-24	Gut microbiome composition (summer);
LUSC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.9	0.61	5.47e-35	Breast cancer;
LUSC	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg20744362	chr22:50050164	C22orf34	0.38	7.93	0.4	3.42e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg15147215	chr3:52552868	STAB1	0.35	6.86	0.35	3.35e-11	Electroencephalogram traits;
LUSC	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg09365446	chr1:150670422	GOLPH3L	0.49	7.17	0.37	4.8e-12	Melanoma;
LUSC	cis	rs7804356	1.000	rs3801842	chr7:26830263	C/T	cg03456212	chr7:26904342	SKAP2	-0.56	-6.62	-0.34	1.47e-10	Type 1 diabetes;
LUSC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.24e-19	Prudent dietary pattern;
LUSC	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg24675056	chr1:15929824	NA	-0.41	-7.1	-0.36	7.46e-12	Systolic blood pressure;
LUSC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.9	16.97	0.68	5.1e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg05340658	chr4:99064831	C4orf37	0.68	11.35	0.53	1.73e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg21775007	chr8:11205619	TDH	-0.42	-6.33	-0.33	8e-10	Neuroticism;
LUSC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg16606324	chr3:10149918	C3orf24	0.58	8.44	0.42	1e-15	Alzheimer's disease;
LUSC	cis	rs1696756	0.638	rs1290396	chr17:77830767	C/T	cg00646381	chr17:77835854	NA	0.6	9.75	0.47	6.38e-20	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUSC	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg00784671	chr22:46762841	CELSR1	-0.54	-6.94	-0.35	2.07e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9300255	0.679	rs28583837	chr12:123863620	G/A	cg00376283	chr12:123451042	ABCB9	-0.66	-7.39	-0.37	1.2e-12	Neutrophil percentage of white cells;
LUSC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg09655341	chr17:79618100	PDE6G	-0.28	-6.36	-0.33	6.81e-10	Eye color traits;
LUSC	cis	rs4144743	0.702	rs7208055	chr17:45330827	C/A	cg18085866	chr17:45331354	ITGB3	-0.71	-6.85	-0.35	3.57e-11	Body mass index;
LUSC	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg03859395	chr2:55845619	SMEK2	0.81	14.18	0.61	4.69e-36	Metabolic syndrome;
LUSC	cis	rs9815354	0.812	rs73081383	chr3:41920614	A/G	cg03022575	chr3:42003672	ULK4	0.83	8.57	0.42	3.85e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7523050	0.643	rs35526993	chr1:109405107	A/T	cg08274380	chr1:109419600	GPSM2	1.07	10.65	0.5	5.34e-23	Fat distribution (HIV);
LUSC	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg23625390	chr15:77176239	SCAPER	-0.65	-10.12	-0.48	3.65e-21	Blood metabolite levels;
LUSC	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg21100191	chr22:23484243	RTDR1	0.92	15.74	0.65	3.76e-42	Bone mineral density;
LUSC	cis	rs9682041	0.877	rs9682908	chr3:170072010	C/T	cg11886554	chr3:170076028	SKIL	0.69	8.54	0.42	4.81e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LUSC	cis	rs7577696	0.568	rs177082	chr2:32438350	A/T	cg02381751	chr2:32503542	YIPF4	0.53	6.84	0.35	3.76e-11	Inflammatory biomarkers;
LUSC	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.26e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg01689657	chr7:91764605	CYP51A1	0.31	5.71	0.3	2.55e-8	Breast cancer;
LUSC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg00945038	chr17:61921165	SMARCD2	-0.52	-8.86	-0.44	4.88e-17	Prudent dietary pattern;
LUSC	cis	rs6489882	0.867	rs6489874	chr12:113367895	A/G	cg20102336	chr12:113376681	OAS3	-0.4	-5.74	-0.3	2.17e-8	Chronic lymphocytic leukemia;
LUSC	trans	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg26384229	chr12:38710491	ALG10B	0.66	9.51	0.46	3.77e-19	Resting heart rate;
LUSC	cis	rs73198271	0.565	rs575920	chr8:8594254	C/T	cg01851573	chr8:8652454	MFHAS1	0.41	6.28	0.33	1.04e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg20701182	chr2:24300061	SF3B14	0.57	6.11	0.32	2.75e-9	Lymphocyte counts;
LUSC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg16339924	chr4:17578868	LAP3	0.59	9.27	0.45	2.45e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.94	-0.36	2.04e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg04998671	chr14:104000505	TRMT61A	-0.48	-7.63	-0.39	2.42e-13	Coronary artery disease;
LUSC	cis	rs10465746	0.967	rs11163868	chr1:84397013	T/G	cg10977910	chr1:84465055	TTLL7	0.44	6.42	0.33	4.58e-10	Obesity-related traits;
LUSC	cis	rs12760731	0.623	rs6701584	chr1:178290509	C/T	cg00404053	chr1:178313656	RASAL2	0.48	5.93	0.31	7.58e-9	Obesity-related traits;
LUSC	cis	rs6845621	0.745	rs7356391	chr4:18865600	C/T	cg12196642	chr4:18937545	NA	-0.32	-5.94	-0.31	7.15e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg10596483	chr8:143751796	JRK	-0.52	-7.52	-0.38	5.08e-13	Schizophrenia;
LUSC	cis	rs2629540	0.889	rs10901815	chr10:126435598	G/A	cg08799069	chr10:126477246	METTL10	-0.68	-10.11	-0.48	3.87e-21	Cocaine dependence;
LUSC	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-7.69	-0.39	1.72e-13	Bone mineral density;
LUSC	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg07169764	chr2:136633963	MCM6	0.51	6.99	0.36	1.51e-11	Mosquito bite size;
LUSC	cis	rs10193935	0.901	rs10200353	chr2:42509554	A/G	cg27598129	chr2:42591480	NA	-0.64	-8.69	-0.43	1.65e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1011108	0.561	rs1053807	chr2:26800422	G/A	cg18742855	chr2:26800399	C2orf70	0.53	10.31	0.49	8.17e-22	Periodontal microbiota;
LUSC	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg07423050	chr13:99094983	FARP1	-0.55	-9.98	-0.48	1.09e-20	Neuroticism;
LUSC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.34	-0.42	1.94e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9815354	1.000	rs56158380	chr3:41885588	G/A	cg03022575	chr3:42003672	ULK4	0.64	7.02	0.36	1.21e-11	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs10411161	0.752	rs10404812	chr19:52400691	T/C	cg22319618	chr22:45562946	NUP50	-0.55	-6.18	-0.32	1.82e-9	Breast cancer;
LUSC	cis	rs6058796	1.000	rs35220493	chr20:31267831	G/A	cg13636640	chr20:31349939	DNMT3B	0.54	5.75	0.3	1.99e-8	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg13433942	chr9:4679784	CDC37L1	0.47	6.09	0.32	3.12e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg26384229	chr12:38710491	ALG10B	0.52	7.35	0.37	1.52e-12	Morning vs. evening chronotype;
LUSC	trans	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.07	-0.32	3.54e-9	Monocyte count;
LUSC	trans	rs9296949	1.000	rs6939631	chr6:14572428	C/T	cg00081417	chr6:140400137	NA	0.58	6.2	0.32	1.68e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.66	-0.3	3.26e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg03676636	chr4:99064102	C4orf37	0.36	8.06	0.4	1.33e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg05347473	chr6:146136440	FBXO30	0.46	7.7	0.39	1.51e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg00484396	chr16:3507460	NAT15	0.7	12.26	0.56	8.62e-29	Tuberculosis;
LUSC	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.61	10.66	0.5	4.85e-23	Birth weight;
LUSC	cis	rs7789940	0.904	rs12531348	chr7:75937191	G/C	cg15798862	chr7:76129360	DTX2	-0.45	-7.15	-0.36	5.43e-12	Multiple sclerosis;
LUSC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg18402987	chr7:1209562	NA	0.69	7.41	0.38	1.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg10172584	chr19:19639581	YJEFN3	-0.46	-5.68	-0.3	2.95e-8	Bipolar disorder;
LUSC	cis	rs11955175	1.000	rs78426328	chr5:40673176	G/T	cg04002187	chr5:40835754	RPL37	0.67	5.87	0.31	1.04e-8	Bipolar disorder and schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25622597	chr3:49449489	RHOA;TCTA	0.48	6.48	0.33	3.22e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.7	12.55	0.57	7.07e-30	Prudent dietary pattern;
LUSC	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.74	-0.35	7.14e-11	Monocyte percentage of white cells;
LUSC	trans	rs970548	0.738	rs61854113	chr10:46004815	C/T	cg20477318	chr10:51623047	TIMM23	0.59	6.02	0.31	4.5e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg25110126	chr1:46999211	NA	0.78	11.16	0.52	8.32e-25	Monobrow;
LUSC	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg19773385	chr1:10388646	KIF1B	-0.48	-8.47	-0.42	7.64e-16	Hepatocellular carcinoma;
LUSC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg05132306	chr1:1846340	CALML6	-0.35	-8.9	-0.44	3.61e-17	Body mass index;
LUSC	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.15	-0.41	7.24e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg11941060	chr3:133502564	NA	-0.51	-7.92	-0.4	3.5e-14	Iron status biomarkers;
LUSC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.96	-0.31	6.56e-9	Longevity;
LUSC	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg00484396	chr16:3507460	NAT15	-0.38	-6.32	-0.33	8.23e-10	Body mass index (adult);
LUSC	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	1.01	22.45	0.78	1.11e-68	Multiple myeloma;
LUSC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02187348	chr16:89574699	SPG7	0.64	10.93	0.51	5.63e-24	Multiple myeloma (IgH translocation);
LUSC	cis	rs2652822	0.933	rs7170846	chr15:63449543	A/C	cg02713581	chr15:63449717	RPS27L	0.43	6.72	0.35	7.69e-11	Metabolic traits;
LUSC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	0.92	15.94	0.66	5.93e-43	Menopause (age at onset);
LUSC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-6.48	-0.33	3.22e-10	Lung cancer;
LUSC	cis	rs1499972	0.941	rs62263122	chr3:117630669	T/C	cg07612923	chr3:117604196	NA	0.64	5.76	0.3	1.95e-8	Schizophrenia;
LUSC	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg18451016	chr1:38461880	NA	0.41	6.26	0.32	1.16e-9	Coronary artery disease;
LUSC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.76	-0.47	5.91e-20	Joint mobility (Beighton score);
LUSC	cis	rs77633900	0.772	rs284902	chr15:76745687	G/C	cg21673338	chr15:77095150	SCAPER	-0.68	-5.84	-0.3	1.22e-8	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs4363385	0.818	rs436621	chr1:153005492	A/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.43e-12	Inflammatory skin disease;
LUSC	cis	rs9341808	0.754	rs6916405	chr6:81024188	C/T	cg08355045	chr6:80787529	NA	0.56	9.73	0.47	7.43e-20	Sitting height ratio;
LUSC	cis	rs11676348	0.741	rs12694425	chr2:218942313	A/G	cg00012203	chr2:219082015	ARPC2	0.49	7.34	0.37	1.62e-12	Ulcerative colitis;
LUSC	cis	rs7129727	1	rs7129727	chr11:57484660	G/A	cg23127183	chr11:57508653	C11orf31	-0.53	-8.13	-0.41	8.55e-15	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15891076	chr10:65930618	NA	-0.72	-6.16	-0.32	2.14e-9	Cognitive performance;
LUSC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.81	14.74	0.63	3.04e-38	Blood protein levels;
LUSC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-7.96	-0.4	2.67e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.14	0.64	8.26e-40	Platelet count;
LUSC	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg01503450	chr10:980765	NA	-0.39	-5.77	-0.3	1.82e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs877282	0.583	rs10904566	chr10:821662	C/G	cg13775593	chr10:823151	NA	0.31	6.09	0.32	3.05e-9	Uric acid levels;
LUSC	cis	rs7106204	0.748	rs7122986	chr11:24224634	G/A	ch.11.24196551F	chr11:24239977	NA	1.13	14.81	0.63	1.67e-38	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7809950	0.678	rs2395869	chr7:106940098	C/A	cg23024343	chr7:107201750	COG5	-0.66	-9.81	-0.47	3.95e-20	Coronary artery disease;
LUSC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21862992	chr11:68658383	NA	0.47	7.21	0.37	3.72e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs3931020	0.657	rs277368	chr1:75230606	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	-0.45	-5.65	-0.3	3.38e-8	Resistin levels;
LUSC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.52	-9.0	-0.44	1.73e-17	Prudent dietary pattern;
LUSC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg12463550	chr7:65579703	CRCP	0.5	6.99	0.36	1.46e-11	Aortic root size;
LUSC	cis	rs7795096	0.806	rs10277655	chr7:151540697	T/C	cg17008978	chr7:151542804	PRKAG2	0.35	6.64	0.34	1.25e-10	Bipolar disorder (age of onset and psychotic symptoms);
LUSC	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg00105475	chr2:10696890	NA	0.38	6.27	0.32	1.11e-9	Prostate cancer;
LUSC	trans	rs7726558	0.731	rs73251672	chr5:118862735	T/C	cg14402224	chr7:50570049	DDC	-0.49	-6.5	-0.34	2.99e-10	QT interval (sulfonylurea treatment interaction);
LUSC	cis	rs4654899	0.932	rs10916943	chr1:21472429	T/C	cg02927042	chr1:21476669	EIF4G3	0.35	5.67	0.3	3.08e-8	Superior frontal gyrus grey matter volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15736296	chr11:57335454	UBE2L6	-0.43	-6.12	-0.32	2.69e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3007168	0.744	rs7147129	chr14:51640496	C/T	cg23942311	chr14:51606299	NA	-0.35	-6.31	-0.33	8.63e-10	Cancer;
LUSC	cis	rs1461503	0.966	rs1461504	chr11:122845129	T/C	cg27398637	chr11:122830231	C11orf63	-0.41	-6.54	-0.34	2.29e-10	Menarche (age at onset);
LUSC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg07507251	chr3:52567010	NT5DC2	0.34	6.74	0.35	7.17e-11	Bipolar disorder;
LUSC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.57	-11.09	-0.52	1.47e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4588572	0.570	rs6453389	chr5:77727003	T/G	cg11547950	chr5:77652471	NA	-0.48	-7.24	-0.37	3.19e-12	Triglycerides;
LUSC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg04998671	chr14:104000505	TRMT61A	-0.44	-6.24	-0.32	1.35e-9	Reticulocyte count;
LUSC	cis	rs3925075	0.584	rs12600286	chr16:31360679	G/C	cg02846316	chr16:31340340	ITGAM	0.38	6.92	0.35	2.29e-11	IgA nephropathy;
LUSC	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg09238746	chr17:78121135	EIF4A3	-0.65	-10.14	-0.49	3e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09047471	chr8:56792345	LYN	0.43	6.23	0.32	1.39e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg14552801	chr7:65878734	NA	0.37	5.66	0.3	3.2e-8	Aortic root size;
LUSC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.84	0.47	3.11e-20	Bipolar disorder;
LUSC	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.19	-0.49	2.09e-21	Bipolar disorder;
LUSC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-0.81	-15.31	-0.64	1.86e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7572733	0.534	rs734037	chr2:198749269	G/A	cg00792783	chr2:198669748	PLCL1	0.46	6.15	0.32	2.17e-9	Dermatomyositis;
LUSC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.39	0.56	3e-29	Motion sickness;
LUSC	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-7.81	-0.39	7.53e-14	Height;
LUSC	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	cis	rs9311676	0.618	rs12152336	chr3:58365146	T/A	cg13750441	chr3:58318267	PXK	0.35	6.76	0.35	6.33e-11	Systemic lupus erythematosus;
LUSC	cis	rs4132509	0.744	rs12031994	chr1:243917309	T/C	cg21452805	chr1:244014465	NA	0.56	5.69	0.3	2.78e-8	RR interval (heart rate);
LUSC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.48	-7.31	-0.37	2e-12	Height;
LUSC	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.84	-0.39	6.26e-14	Retinal vascular caliber;
LUSC	cis	rs12760731	0.565	rs16852576	chr1:178192371	C/T	cg00404053	chr1:178313656	RASAL2	0.66	6.86	0.35	3.32e-11	Obesity-related traits;
LUSC	cis	rs73416724	1.000	rs70953680	chr6:43267831	G/A	cg26312998	chr6:43337775	ZNF318	0.56	6.32	0.33	8.29e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs36093844	0.752	rs17744675	chr11:85593906	C/T	cg25872744	chr11:85566296	CCDC83	0.47	6.27	0.32	1.15e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg26876637	chr1:152193138	HRNR	0.46	6.57	0.34	1.89e-10	Atopic dermatitis;
LUSC	cis	rs9503598	0.636	rs6596978	chr6:3468878	C/T	cg00476032	chr6:3446245	SLC22A23	0.31	6.08	0.32	3.36e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs11828289	0.660	rs17306384	chr11:23189320	T/C	cg20040320	chr11:23191996	NA	-0.58	-6.1	-0.32	2.95e-9	Cancer;
LUSC	cis	rs4604732	0.536	rs12049066	chr1:247642655	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.49	7.44	0.38	8.79e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.79	-0.43	8.32e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-15.15	-0.64	7.76e-40	Exhaled nitric oxide output;
LUSC	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg27124370	chr19:33622961	WDR88	0.56	7.43	0.38	9.38e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2289328	0.882	rs7164581	chr15:40645098	C/G	cg13931752	chr15:40660718	DISP2	-0.49	-6.7	-0.34	8.8e-11	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs2652834	0.799	rs2729837	chr15:63430330	C/A	cg05507819	chr15:63340323	TPM1	0.47	6.01	0.31	4.98e-9	HDL cholesterol;
LUSC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06634786	chr22:41940651	POLR3H	0.51	6.12	0.32	2.69e-9	Vitiligo;
LUSC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.7	10.83	0.51	1.22e-23	Aortic root size;
LUSC	cis	rs7809950	1.000	rs12667527	chr7:107086969	T/C	cg23024343	chr7:107201750	COG5	-0.56	-8.8	-0.43	7.42e-17	Coronary artery disease;
LUSC	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-5.91	-0.31	8.41e-9	Joint mobility (Beighton score);
LUSC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	16.44	0.67	6.3e-45	Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07918776	chr15:49170303	SHC4;EID1	0.48	7.04	0.36	1.1e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09326324	chr1:161123937	UFC1	0.43	6.39	0.33	5.61e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg10482532	chr10:96946522	NA	-0.29	-5.99	-0.31	5.28e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg12091567	chr17:66097778	LOC651250	-0.74	-9.32	-0.45	1.62e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg24459738	chr19:57751996	ZNF805	-0.51	-7.53	-0.38	4.65e-13	Hyperactive-impulsive symptoms;
LUSC	trans	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.12	-0.32	2.6e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7072216	0.922	rs2296438	chr10:100146895	T/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-5.68	-0.3	2.92e-8	Metabolite levels;
LUSC	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.04	-0.36	1.1e-11	Menopause (age at onset);
LUSC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg16362232	chr11:430036	ANO9	0.65	8.11	0.41	9.98e-15	Body mass index;
LUSC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg06064525	chr11:970664	AP2A2	0.5	11.02	0.52	2.71e-24	Alzheimer's disease (late onset);
LUSC	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg15541040	chr2:3486749	NA	-0.51	-7.65	-0.39	2.17e-13	Neurofibrillary tangles;
LUSC	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.37	-0.56	3.42e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs13315871	0.929	rs13080508	chr3:58300116	G/A	cg20936604	chr3:58311152	NA	-0.67	-6.67	-0.34	1.08e-10	Cholesterol, total;
LUSC	trans	rs4729127	1.000	rs55921499	chr7:93975569	T/G	cg20086523	chr13:52378287	DHRS12	0.56	5.94	0.31	7e-9	Intelligence;
LUSC	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg17524180	chr13:113633600	MCF2L	-0.32	-6.3	-0.33	9.56e-10	Systolic blood pressure;
LUSC	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg11244672	chr19:19639970	YJEFN3	-0.61	-7.29	-0.37	2.25e-12	Bipolar disorder;
LUSC	cis	rs9398803	0.835	rs59698523	chr6:126733094	T/C	cg19875578	chr6:126661172	C6orf173	0.41	6.01	0.31	4.77e-9	Male-pattern baldness;
LUSC	cis	rs9399401	0.626	rs12664563	chr6:142785201	A/G	cg04461802	chr6:142623433	GPR126	0.46	5.9	0.31	8.97e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.88	-15.57	-0.65	1.76e-41	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs16937	0.503	rs76939335	chr1:205178610	T/C	cg21643547	chr1:205240462	TMCC2	-0.33	-5.7	-0.3	2.69e-8	Schizophrenia;
LUSC	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg00933542	chr6:150070202	PCMT1	0.33	6.78	0.35	5.31e-11	Lung cancer;
LUSC	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg02175503	chr12:58329896	NA	0.61	9.99	0.48	1.01e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg06494592	chr3:125709126	NA	-0.53	-5.92	-0.31	8.19e-9	Blood pressure (smoking interaction);
LUSC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.45	0.38	7.93e-13	Parkinson's disease;
LUSC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg18402987	chr7:1209562	NA	0.72	7.69	0.39	1.67e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg09915433	chr19:53449742	NA	-0.63	-10.21	-0.49	1.79e-21	Psoriasis;
LUSC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg06915202	chr7:98029285	BAIAP2L1	0.3	6.02	0.31	4.71e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg14154082	chr13:112174009	NA	0.37	7.7	0.39	1.54e-13	Menarche (age at onset);
LUSC	trans	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.4	0.42	1.29e-15	Ulcerative colitis;
LUSC	cis	rs9359856	0.564	rs3818133	chr6:90374456	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.89	-8.67	-0.43	1.94e-16	Bipolar disorder;
LUSC	cis	rs778371	0.723	rs12993791	chr2:233690082	C/T	cg08000102	chr2:233561755	GIGYF2	-0.77	-12.2	-0.56	1.46e-28	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg27170947	chr2:26402098	FAM59B	-0.65	-9.42	-0.46	7.77e-19	Gut microbiome composition (summer);
LUSC	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.66	10.68	0.5	4.08e-23	Phospholipid levels (plasma);
LUSC	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3743162	0.553	rs4842994	chr15:85415799	A/G	cg12863693	chr15:85201151	NMB	-0.3	-5.77	-0.3	1.81e-8	Alzheimer's disease (age of onset);
LUSC	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg15445000	chr17:37608096	MED1	0.4	6.82	0.35	4.25e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs6845621	0.901	rs1452552	chr4:18919979	G/A	cg12196642	chr4:18937545	NA	-0.33	-6.41	-0.33	5.05e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.81	-0.39	7.4e-14	Height;
LUSC	cis	rs3733418	0.929	rs13149738	chr4:165905697	T/C	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-5.92	-0.31	8.03e-9	Obesity-related traits;
LUSC	trans	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg18187862	chr3:45730750	SACM1L	-0.53	-6.42	-0.33	4.73e-10	Primary sclerosing cholangitis;
LUSC	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.67	-10.2	-0.49	1.94e-21	Colorectal cancer;
LUSC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg17279839	chr7:150038598	RARRES2	0.45	6.9	0.35	2.68e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg05874882	chr4:1763078	NA	0.51	8.21	0.41	4.74e-15	Bladder cancer;Urinary bladder cancer;
LUSC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg22823121	chr1:150693482	HORMAD1	-0.52	-7.67	-0.39	1.94e-13	Urate levels;
LUSC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.89	0.31	9.64e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg21361702	chr7:150065534	REPIN1	-0.5	-6.93	-0.35	2.21e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs295140	1.000	rs295140	chr2:201160699	T/C	cg04283868	chr2:201171347	SPATS2L	-0.44	-6.85	-0.35	3.62e-11	QT interval;
LUSC	cis	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg09307838	chr4:120376055	NA	0.51	7.82	0.39	7.13e-14	Diastolic blood pressure;
LUSC	cis	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg05084668	chr3:125655381	ALG1L	-0.42	-5.66	-0.3	3.33e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg01966878	chr4:90757139	SNCA	-0.41	-5.89	-0.31	9.29e-9	Neuroticism;
LUSC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.83	12.42	0.56	2.32e-29	Cognitive test performance;
LUSC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	0.92	13.9	0.61	5.47e-35	Breast cancer;
LUSC	cis	rs7605827	0.930	rs7593184	chr2:15598461	T/G	cg19274914	chr2:15703543	NA	0.47	9.08	0.45	9.55e-18	Educational attainment (years of education);
LUSC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg08270630	chr22:50330655	NA	-0.42	-6.19	-0.32	1.73e-9	Schizophrenia;
LUSC	cis	rs2354432	0.607	rs55918563	chr1:146718973	G/C	cg25205988	chr1:146714368	CHD1L	-1.01	-9.45	-0.46	6.1e-19	Mitochondrial DNA levels;
LUSC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg21724239	chr8:58056113	NA	0.78	9.39	0.46	1e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00339695	chr16:24857497	SLC5A11	-0.6	-9.22	-0.45	3.44e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg23887609	chr12:130822674	PIWIL1	0.48	7.05	0.36	1.04e-11	Menopause (age at onset);
LUSC	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg27661571	chr11:113659931	NA	-0.62	-7.43	-0.38	9.12e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.64	-10.58	-0.5	9.41e-23	Facial morphology (factor 20);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07116312	chr16:89173855	ACSF3	-0.74	-6.22	-0.32	1.5e-9	Cognitive performance;
LUSC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg02782426	chr3:40428986	ENTPD3	0.39	7.46	0.38	7.6e-13	Renal cell carcinoma;
LUSC	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg05373962	chr22:49881684	NA	-0.41	-8.6	-0.43	3.13e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.33	0.62	1.18e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.63	8.35	0.42	1.89e-15	High light scatter reticulocyte count;
LUSC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.39	0.33	5.42e-10	Sudden cardiac arrest;
LUSC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08470875	chr2:26401718	FAM59B	0.74	9.9	0.48	1.99e-20	Gut microbiome composition (summer);
LUSC	cis	rs6426558	0.537	rs10799381	chr1:227239746	G/T	cg10327440	chr1:227177885	CDC42BPA	0.53	7.19	0.37	4.2e-12	Neutrophil percentage of white cells;
LUSC	cis	rs2046867	0.818	rs11929144	chr3:72868234	T/C	cg25664220	chr3:72788482	NA	-0.69	-12.41	-0.56	2.44e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7903847	0.642	rs7084654	chr10:99135262	G/A	cg08345082	chr10:99160200	RRP12	-0.38	-7.76	-0.39	1.06e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3784262	1.000	rs9325	chr15:58245986	A/T	cg12031962	chr15:58353849	ALDH1A2	0.33	6.25	0.32	1.22e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.3	-0.33	9.2e-10	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	15.58	0.65	1.61e-41	Platelet count;
LUSC	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18301423	chr5:131593218	PDLIM4	0.47	7.46	0.38	7.75e-13	Acylcarnitine levels;
LUSC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10862848	chr6:42927986	GNMT	-0.28	-6.86	-0.35	3.36e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg01528321	chr10:82214614	TSPAN14	-1.03	-16.38	-0.67	1.16e-44	Post bronchodilator FEV1;
LUSC	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg04310649	chr10:35416472	CREM	-0.41	-6.48	-0.33	3.22e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.73	-0.35	7.25e-11	Response to antipsychotic treatment;
LUSC	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.54	-10.42	-0.5	3.45e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	9.08	0.44	9.71e-18	Total cholesterol levels;
LUSC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.92	-0.48	1.67e-20	Hemoglobin concentration;
LUSC	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg06740227	chr12:86229804	RASSF9	-0.37	-6.0	-0.31	5.01e-9	Major depressive disorder;
LUSC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg07636037	chr3:49044803	WDR6	0.44	6.38	0.33	5.9e-10	Resting heart rate;
LUSC	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-9.21	-0.45	3.78e-18	Morning vs. evening chronotype;
LUSC	cis	rs11605924	0.967	rs7121611	chr11:45864142	A/T	ch.11.939596F	chr11:45881766	CRY2	-0.5	-7.36	-0.37	1.4e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg22535103	chr8:58192502	C8orf71	-0.73	-7.44	-0.38	8.49e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg26566898	chr11:117069891	TAGLN	0.47	8.18	0.41	5.88e-15	Blood protein levels;
LUSC	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.21	-0.41	4.86e-15	Retinal vascular caliber;
LUSC	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg15571903	chr15:79123663	NA	0.32	5.9	0.31	9.02e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2742417	0.603	rs2673062	chr3:45763635	A/G	cg04837898	chr3:45731254	SACM1L	-0.46	-7.39	-0.37	1.22e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1499972	0.941	rs6807173	chr3:117642281	T/G	cg07612923	chr3:117604196	NA	0.64	5.76	0.3	1.93e-8	Schizophrenia;
LUSC	cis	rs2580764	0.565	rs35631428	chr2:55244438	G/A	cg20993754	chr2:55226987	RTN4	0.36	6.05	0.31	3.98e-9	Mean platelet volume;
LUSC	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-6.51	-0.34	2.81e-10	Response to antipsychotic treatment;
LUSC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.29	6.39	0.33	5.67e-10	Electroencephalogram traits;
LUSC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg27535305	chr1:53392650	SCP2	-0.4	-7.62	-0.38	2.66e-13	Monocyte count;
LUSC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.79	12.72	0.57	1.76e-30	Aortic root size;
LUSC	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg10255544	chr17:80519551	FOXK2	0.36	5.8	0.3	1.56e-8	Reticulocyte count;
LUSC	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg22875332	chr1:76189707	ACADM	-0.43	-6.31	-0.33	8.65e-10	Daytime sleep phenotypes;
LUSC	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.83e-12	Blood metabolite levels;
LUSC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg23590916	chr17:43697445	MGC57346	0.49	6.64	0.34	1.28e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs10208940	0.920	rs13400155	chr2:68723636	G/A	cg12452813	chr2:68675892	NA	0.58	5.95	0.31	6.61e-9	Urate levels in lean individuals;
LUSC	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg20734569	chr3:48348370	SPINK8	-0.48	-8.12	-0.41	8.91e-15	Coronary artery disease;
LUSC	cis	rs4363385	0.747	rs946101	chr1:152972032	C/T	cg00922841	chr1:152955080	SPRR1A	0.43	7.52	0.38	5.12e-13	Inflammatory skin disease;
LUSC	cis	rs4700695	0.719	rs27078	chr5:65445331	G/C	cg21114390	chr5:65439923	SFRS12	-0.64	-9.15	-0.45	5.85e-18	Facial morphology (factor 19);
LUSC	cis	rs977987	0.815	rs11149821	chr16:75422817	C/T	cg03315344	chr16:75512273	CHST6	0.48	9.1	0.45	8.27e-18	Dupuytren's disease;
LUSC	cis	rs790123	0.933	rs812596	chr3:122382301	A/T	cg17380795	chr3:122379686	NA	0.39	6.59	0.34	1.71e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg24631222	chr15:78858424	CHRNA5	0.8	11.19	0.52	6.59e-25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg13852791	chr20:30311386	BCL2L1	0.72	8.29	0.41	2.73e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg05855489	chr10:104503620	C10orf26	0.53	7.96	0.4	2.78e-14	Arsenic metabolism;
LUSC	cis	rs7119	0.717	rs12916682	chr15:77807937	A/T	cg27398640	chr15:77910606	LINGO1	-0.3	-6.36	-0.33	6.74e-10	Type 2 diabetes;
LUSC	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg27446573	chr6:127587934	RNF146	0.64	10.3	0.49	8.68e-22	Breast cancer;
LUSC	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg23173402	chr1:227635558	NA	0.64	5.78	0.3	1.75e-8	Major depressive disorder;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg23267160	chr1:87794116	LMO4	0.41	6.39	0.33	5.47e-10	Asthma;
LUSC	trans	rs10432489	0.708	rs12693263	chr2:181740210	A/G	cg04744134	chr19:8408128	KANK3	-0.83	-6.39	-0.33	5.52e-10	QT interval;
LUSC	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	0.98	18.41	0.71	9.42e-53	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.95e-8	Blood protein levels;
LUSC	cis	rs3136441	1.000	rs2290883	chr11:46890197	A/G	cg01183595	chr11:46746236	F2	-0.39	-5.94	-0.31	7.24e-9	HDL cholesterol;
LUSC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg26752657	chr1:75199075	CRYZ;TYW3	0.42	6.44	0.33	4.05e-10	Resistin levels;
LUSC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg08888203	chr3:10149979	C3orf24	0.66	9.07	0.44	1.06e-17	Alzheimer's disease;
LUSC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg05861140	chr6:150128134	PCMT1	-0.4	-6.32	-0.33	8.54e-10	Lung cancer;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01516881	chr6:292596	DUSP22	-0.7	-11.24	-0.52	4.54e-25	Menopause (age at onset);
LUSC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	14.05	0.61	1.44e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg05253716	chr12:129299332	SLC15A4;MGC16384	-0.43	-6.53	-0.34	2.45e-10	Systemic lupus erythematosus;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08467108	chr19:41304898	EGLN2	-0.42	-6.11	-0.32	2.78e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-6.33	-0.33	7.93e-10	Skin colour saturation;
LUSC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg17968037	chr7:100024898	ZCWPW1	-0.39	-6.05	-0.31	3.89e-9	Platelet count;
LUSC	cis	rs6599077	0.802	rs17075542	chr3:40128458	A/G	cg09455208	chr3:40491958	NA	-0.34	-5.7	-0.3	2.61e-8	Sleep-related phenotypes;
LUSC	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-10.03	-0.48	7.07e-21	Blood metabolite levels;
LUSC	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg17810781	chr1:201082982	CACNA1S	0.31	5.98	0.31	5.67e-9	Permanent tooth development;
LUSC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg21724239	chr8:58056113	NA	0.78	8.41	0.42	1.19e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs35883536	0.647	rs17411209	chr1:101046734	A/G	cg06223162	chr1:101003688	GPR88	-0.47	-8.62	-0.43	2.66e-16	Monocyte count;
LUSC	cis	rs932287	1.000	rs932287	chr11:9044767	A/G	cg12365402	chr11:9010492	NRIP3	-0.35	-5.84	-0.3	1.25e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg23630131	chr7:65973040	NA	0.2	5.71	0.3	2.54e-8	Aortic root size;
LUSC	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg08917208	chr2:24149416	ATAD2B	0.98	10.4	0.49	3.97e-22	Lymphocyte counts;
LUSC	cis	rs13401104	0.531	rs12469569	chr2:237113376	T/C	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.35e-8	Educational attainment;
LUSC	cis	rs1775715	0.835	rs12266771	chr10:32231380	G/A	cg18675610	chr10:32216311	ARHGAP12	0.28	6.17	0.32	2e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1904096	0.506	rs114312933	chr4:95216802	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.4	-0.42	1.25e-15	Type 2 diabetes;
LUSC	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg04240660	chr16:89714849	CHMP1A	0.42	6.69	0.34	9.64e-11	Hemoglobin concentration;
LUSC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg24813613	chr7:1882135	MAD1L1	-0.46	-7.8	-0.39	7.93e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs73416724	1.000	rs75473868	chr6:43352623	A/G	cg26312998	chr6:43337775	ZNF318	0.55	6.53	0.34	2.51e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs11700980	1.000	rs56923832	chr21:30035592	T/A	cg05609335	chr17:75789393	NA	0.43	6.24	0.32	1.35e-9	QRS complex (12-leadsum);
LUSC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg15445000	chr17:37608096	MED1	-0.39	-6.86	-0.35	3.28e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs6445967	0.530	rs12486031	chr3:58409679	G/A	cg13705284	chr3:58523313	ACOX2	-0.27	-5.71	-0.3	2.46e-8	Platelet count;
LUSC	cis	rs308403	0.640	rs13128246	chr4:123721306	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.82	10.23	0.49	1.5e-21	Blood protein levels;
LUSC	cis	rs11688816	0.904	rs360791	chr2:62917256	G/A	cg17519650	chr2:63277830	OTX1	-0.42	-5.84	-0.3	1.22e-8	Body mass index;
LUSC	trans	rs11818462	0.584	rs10884181	chr10:107334608	A/G	cg03755177	chr7:44349389	CAMK2B	-0.66	-5.95	-0.31	6.83e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6736093	0.966	rs11681063	chr2:112743342	G/A	cg12686935	chr2:112915763	FBLN7	-0.35	-5.66	-0.3	3.34e-8	Coronary artery disease;
LUSC	cis	rs35995292	0.500	rs6955677	chr7:38933942	C/T	cg19327137	chr7:38886074	VPS41	0.55	10.26	0.49	1.15e-21	Subjective well-being (multi-trait analysis);
LUSC	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg04455712	chr21:45112962	RRP1B	0.49	9.36	0.46	1.18e-18	Mean corpuscular volume;
LUSC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg15147215	chr3:52552868	STAB1	0.31	6.15	0.32	2.21e-9	Bipolar disorder;
LUSC	cis	rs4363385	0.818	rs11205167	chr1:152989727	T/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.49	-0.38	6.06e-13	Inflammatory skin disease;
LUSC	cis	rs225245	0.817	rs225284	chr17:33933006	A/C	cg05299278	chr17:33885742	SLFN14	0.31	6.71	0.34	8.11e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs11039100	1.000	rs12792952	chr11:5826813	C/G	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg06636001	chr8:8085503	FLJ10661	0.48	7.29	0.37	2.2e-12	Joint mobility (Beighton score);
LUSC	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg02569458	chr12:86230093	RASSF9	0.53	8.68	0.43	1.79e-16	Major depressive disorder;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03693601	chr16:46655349	SHCBP1	0.39	6.21	0.32	1.54e-9	Asthma;
LUSC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg06074448	chr4:187884817	NA	-0.46	-7.68	-0.39	1.76e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1395	0.925	rs1659696	chr2:27407831	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	-0.4	-6.62	-0.34	1.42e-10	Blood metabolite levels;
LUSC	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.34	-0.37	1.65e-12	Psoriasis;
LUSC	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.63	9.7	0.47	9.39e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg27284194	chr4:1044797	NA	0.37	6.07	0.32	3.51e-9	Longevity;
LUSC	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg22117172	chr7:91764530	CYP51A1	0.32	5.73	0.3	2.25e-8	Breast cancer;
LUSC	cis	rs17253792	0.822	rs78429067	chr14:56092551	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs11997175	0.550	rs6468206	chr8:33780878	A/C	ch.8.33884649F	chr8:33765107	NA	0.44	6.77	0.35	5.69e-11	Body mass index;
LUSC	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg22681709	chr2:178499509	PDE11A	0.44	6.43	0.33	4.42e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01422129	chr2:677375	TMEM18	-0.45	-6.71	-0.34	8.2e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg10811474	chr19:8428787	ANGPTL4	-0.39	-5.97	-0.31	6.07e-9	HDL cholesterol;
LUSC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	0.64	13.56	0.6	1.12e-33	Prudent dietary pattern;
LUSC	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg19875535	chr5:140030758	IK	0.5	8.28	0.41	3.06e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg05729581	chr11:3078854	CARS	0.4	5.96	0.31	6.27e-9	Calcium levels;
LUSC	cis	rs17253792	0.822	rs8007065	chr14:56081272	A/G	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg17294928	chr15:75287854	SCAMP5	-0.83	-11.27	-0.52	3.6e-25	Blood trace element (Zn levels);
LUSC	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.65	-0.34	1.23e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg13560548	chr3:10150139	C3orf24	0.52	7.18	0.37	4.45e-12	Alzheimer's disease;
LUSC	cis	rs2637266	1.000	rs755824	chr10:78381348	A/G	cg18941641	chr10:78392320	NA	0.41	7.43	0.38	9.3e-13	Pulmonary function;
LUSC	cis	rs61931739	0.635	rs1405025	chr12:33908491	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.69	-0.34	9.21e-11	Morning vs. evening chronotype;
LUSC	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-7.25	-0.37	2.98e-12	Bone mineral density;
LUSC	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg13575925	chr12:9217583	LOC144571	0.35	6.43	0.33	4.51e-10	Sjögren's syndrome;
LUSC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-0.88	-16.71	-0.67	5.51e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg01448562	chr3:133502909	NA	-0.66	-10.6	-0.5	7.79e-23	Iron status biomarkers;
LUSC	cis	rs6977660	1.000	rs10260360	chr7:19792824	T/C	cg07541023	chr7:19748670	TWISTNB	0.57	6.39	0.33	5.59e-10	Thyroid stimulating hormone;
LUSC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs9612	0.664	rs164069	chr19:44260199	T/C	cg08581076	chr19:44259116	C19orf61	0.53	6.75	0.35	6.5500000000000006e-11	Exhaled nitric oxide output;
LUSC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg22920501	chr2:26401640	FAM59B	-0.79	-11.86	-0.54	2.53e-27	Gut microbiome composition (summer);
LUSC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg19302996	chr17:73780495	UNK	-0.48	-7.01	-0.36	1.36e-11	White matter hyperintensity burden;
LUSC	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg17691542	chr6:26056736	HIST1H1C	0.53	7.38	0.37	1.26e-12	Iron status biomarkers;
LUSC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs9815354	0.638	rs73073258	chr3:42017894	G/A	cg03022575	chr3:42003672	ULK4	0.76	7.6	0.38	3e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.51	0.59	1.77e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9807989	0.811	rs11689730	chr2:102969984	C/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.79	0.3	1.58e-8	Asthma;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26386643	chr15:74753645	UBL7	0.82	6.43	0.33	4.5e-10	Cognitive performance;
LUSC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.02	0.31	4.62e-9	Recombination rate (females);
LUSC	trans	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg12856521	chr11:46389249	DGKZ	0.45	6.67	0.34	1.04e-10	Leprosy;
LUSC	trans	rs7178375	1.000	rs10163148	chr15:31212684	C/G	cg04373760	chr16:53404718	NA	0.62	8.0	0.4	2.04e-14	Hypertriglyceridemia;
LUSC	cis	rs778371	0.676	rs7560115	chr2:233709465	T/G	cg08000102	chr2:233561755	GIGYF2	-0.78	-12.19	-0.55	1.57e-28	Schizophrenia;
LUSC	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg12257692	chr3:49977190	RBM6	-0.21	-5.7	-0.3	2.69e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs308403	0.509	rs13122636	chr4:123671045	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.94	16.72	0.68	5.04e-46	Blood protein levels;
LUSC	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	0.96	13.57	0.6	1.08e-33	Primary sclerosing cholangitis;
LUSC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg04756594	chr16:24857601	SLC5A11	0.34	5.7	0.3	2.59e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg18827107	chr12:86230957	RASSF9	-0.5	-7.46	-0.38	7.71e-13	Major depressive disorder;
LUSC	cis	rs62408225	1.000	rs2875584	chr6:90950628	C/T	cg06866423	chr6:90926672	BACH2	0.4	5.71	0.3	2.47e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg07148914	chr20:33460835	GGT7	-0.52	-8.06	-0.4	1.33e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg07701084	chr6:150067640	NUP43	0.53	7.92	0.4	3.48e-14	Lung cancer;
LUSC	cis	rs9361491	0.534	rs10943568	chr6:79404207	G/T	cg05283184	chr6:79620031	NA	-0.39	-6.89	-0.35	2.79e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10045504	0.502	rs17456198	chr5:38732005	A/G	cg15396434	chr5:38725168	NA	-0.52	-5.94	-0.31	7.04e-9	Night sleep phenotypes;
LUSC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.07	0.52	1.76e-24	Alzheimer's disease;
LUSC	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg19653624	chr11:20408972	PRMT3	-0.69	-8.74	-0.43	1.17e-16	Pursuit maintenance gain;
LUSC	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg18850127	chr7:39170497	POU6F2	-0.51	-7.24	-0.37	3.06e-12	IgG glycosylation;
LUSC	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.57	-7.73	-0.39	1.26e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg25258033	chr6:167368657	RNASET2	0.38	6.21	0.32	1.61e-9	Crohn's disease;
LUSC	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg06612196	chr6:6737390	NA	0.56	11.11	0.52	1.31e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg11921908	chr5:153825219	SAP30L	0.35	5.99	0.31	5.35e-9	Schizophrenia;
LUSC	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg15704280	chr7:45808275	SEPT13	-0.45	-6.17	-0.32	1.94e-9	Height;
LUSC	cis	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg05299278	chr17:33885742	SLFN14	-0.3	-6.38	-0.33	6.03e-10	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-8.78	-0.43	8.73e-17	Response to antipsychotic treatment;
LUSC	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg17462356	chr17:80056334	FASN	0.46	6.23	0.32	1.44e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs500891	0.645	rs1180190	chr6:83966335	G/A	cg08257003	chr6:84140564	ME1	0.3	6.66	0.34	1.09e-10	Platelet-derived growth factor BB levels;
LUSC	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg04374321	chr14:90722782	PSMC1	-0.42	-6.39	-0.33	5.65e-10	Mortality in heart failure;
LUSC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg18827107	chr12:86230957	RASSF9	0.46	6.92	0.35	2.29e-11	Major depressive disorder;
LUSC	cis	rs3916	0.955	rs35525135	chr12:121140064	T/C	cg27246729	chr12:121163418	ACADS	0.49	7.11	0.36	7.22e-12	Urinary metabolites (H-NMR features);
LUSC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg05802129	chr4:122689817	NA	-0.37	-6.62	-0.34	1.44e-10	Type 2 diabetes;
LUSC	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg09307838	chr4:120376055	NA	0.75	10.98	0.51	3.78e-24	Corneal astigmatism;
LUSC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	11.85	0.54	2.77e-27	Colorectal cancer;
LUSC	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg16928487	chr17:17741425	SREBF1	0.48	9.55	0.46	2.81e-19	Total body bone mineral density;
LUSC	cis	rs5758659	0.692	rs5751251	chr22:42640606	G/C	cg00645731	chr22:42541494	CYP2D7P1	-0.31	-6.57	-0.34	1.98e-10	Cognitive function;
LUSC	cis	rs7408868	0.831	rs11672004	chr19:15277282	T/A	cg14696996	chr19:15285081	NOTCH3	0.8	7.71	0.39	1.41e-13	Pulse pressure;
LUSC	cis	rs3741151	0.656	rs12290785	chr11:73259012	G/T	cg17517138	chr11:73019481	ARHGEF17	0.92	7.8	0.39	8.22e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs55871839	0.708	rs6651298	chr8:59808307	C/G	cg07426533	chr8:59803705	TOX	-0.37	-6.01	-0.31	4.92e-9	Pneumonia;
LUSC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg25019033	chr10:957182	NA	-0.52	-6.6	-0.34	1.59e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg17127132	chr2:85788382	GGCX	-0.46	-7.25	-0.37	2.86e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs8135665	0.600	rs8142379	chr22:38450971	G/A	cg13116946	chr22:38479732	SLC16A8	0.42	6.24	0.32	1.32e-9	Advanced age-related macular degeneration;Age-related macular degeneration;
LUSC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg26380479	chr7:97908229	NA	-0.28	-6.2	-0.32	1.67e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.96	0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.67	-10.3	-0.49	8.67e-22	Brugada syndrome;
LUSC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18876405	chr7:65276391	NA	-0.55	-8.78	-0.43	8.51e-17	Aortic root size;
LUSC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21862992	chr11:68658383	NA	0.51	7.94	0.4	3.06e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg02524346	chr8:600233	NA	0.82	8.3	0.41	2.62e-15	IgG glycosylation;
LUSC	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg09904177	chr6:26538194	HMGN4	-0.76	-6.9	-0.35	2.61e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.51	6.68	0.34	9.94e-11	Blood protein levels;
LUSC	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg15704280	chr7:45808275	SEPT13	0.77	7.43	0.38	9.41e-13	Axial length;
LUSC	cis	rs16976116	0.901	rs1061875	chr15:55496278	C/T	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg00945038	chr17:61921165	SMARCD2	0.51	8.41	0.42	1.2e-15	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.41	5.78	0.3	1.69e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg18538332	chr22:24372958	LOC391322	-0.42	-7.74	-0.39	1.22e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg06808227	chr14:105710500	BRF1	-0.66	-9.9	-0.48	1.9e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.63	8.11	0.41	9.88e-15	Schizophrenia;
LUSC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg12560992	chr17:57184187	TRIM37	0.84	15.4	0.64	8.58e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs9361491	0.508	rs10943567	chr6:79402451	A/G	cg05283184	chr6:79620031	NA	-0.39	-7.12	-0.36	6.7e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg19338460	chr6:170058176	WDR27	-0.88	-7.29	-0.37	2.22e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs3741151	0.881	rs73542929	chr11:73094539	G/T	cg17517138	chr11:73019481	ARHGEF17	1.04	8.76	0.43	1.02e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-8.21	-0.41	4.72e-15	Blood pressure (smoking interaction);
LUSC	cis	rs4964805	0.632	rs9706225	chr12:104188086	T/C	cg02344784	chr12:104178138	NT5DC3	0.46	8.86	0.44	4.73e-17	Attention deficit hyperactivity disorder;
LUSC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-7.37	-0.37	1.33e-12	Mean platelet volume;
LUSC	cis	rs10203711	1.000	rs4663328	chr2:239574103	A/G	cg14580085	chr2:239553406	NA	-0.41	-7.0	-0.36	1.41e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.72	-12.45	-0.56	1.76e-29	Sudden cardiac arrest;
LUSC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	7.74	0.39	1.21e-13	Vitiligo;
LUSC	cis	rs4144743	1.000	rs11871251	chr17:45331427	G/A	cg18085866	chr17:45331354	ITGB3	-0.77	-8.01	-0.4	1.91e-14	Body mass index;
LUSC	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.45	0.75	7.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg22166914	chr1:53195759	ZYG11B	0.67	11.34	0.53	1.92e-25	Monocyte count;
LUSC	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.4	-7.07	-0.36	9.31e-12	HDL cholesterol;
LUSC	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg04586622	chr2:25135609	ADCY3	0.4	8.3	0.41	2.59e-15	Body mass index in non-asthmatics;
LUSC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg05754148	chr16:3507555	NAT15	-0.65	-7.83	-0.39	6.64e-14	Tuberculosis;
LUSC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.86	15.03	0.64	2.29e-39	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg09034736	chr1:150693464	HORMAD1	0.45	6.48	0.33	3.36e-10	Melanoma;
LUSC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg03146154	chr1:46216737	IPP	0.51	7.51	0.38	5.39e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7241530	0.662	rs6506734	chr18:75888374	A/G	cg14642773	chr18:75888474	NA	0.36	5.92	0.31	8.19e-9	Educational attainment (years of education);
LUSC	cis	rs911555	0.576	rs8015723	chr14:103895909	A/G	cg12935359	chr14:103987150	CKB	0.56	8.76	0.43	1e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg08888203	chr3:10149979	C3orf24	0.65	8.79	0.43	8.22e-17	Alzheimer's disease;
LUSC	cis	rs4746822	0.539	rs10998646	chr10:70976702	G/T	cg14418922	chr10:70824840	NA	-0.42	-7.28	-0.37	2.35e-12	Glycemic traits (pregnancy);
LUSC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26314531	chr2:26401878	FAM59B	0.67	9.64	0.47	1.42e-19	Gut microbiome composition (summer);
LUSC	cis	rs12220238	1.000	rs11000912	chr10:75948477	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.77	0.35	5.76e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg12863693	chr15:85201151	NMB	0.43	8.71	0.43	1.45e-16	Schizophrenia;
LUSC	cis	rs8141797	0.748	rs5760186	chr22:24435954	G/A	cg00411358	chr22:24577142	SUSD2	0.62	6.08	0.32	3.31e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.61	7.83	0.39	6.33e-14	Schizophrenia;
LUSC	cis	rs7760535	0.763	rs9487666	chr6:111869024	A/C	cg22127309	chr6:111907043	TRAF3IP2	-0.39	-7.39	-0.38	1.15e-12	Metabolic traits;
LUSC	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg24069376	chr3:38537580	EXOG	0.38	7.22	0.37	3.52e-12	Electrocardiographic conduction measures;
LUSC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.63	9.1	0.45	8.37e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg20476274	chr7:133979776	SLC35B4	0.87	16.91	0.68	8.63e-47	Mean platelet volume;
LUSC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg07395648	chr5:131743802	NA	-0.45	-7.16	-0.36	5.21e-12	Breast cancer;Mosquito bite size;
LUSC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg03806693	chr22:41940476	POLR3H	1.0	14.25	0.62	2.41e-36	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg03146154	chr1:46216737	IPP	-0.52	-7.39	-0.37	1.21e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	10.09	0.48	4.62e-21	Electrocardiographic conduction measures;
LUSC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg17807903	chr1:86174739	ZNHIT6	0.43	9.12	0.45	7.06e-18	Urate levels in overweight individuals;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01066274	chr16:75019182	WDR59	-0.42	-6.19	-0.32	1.76e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg10621924	chr7:39171070	POU6F2	0.5	7.81	0.39	7.37e-14	IgG glycosylation;
LUSC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	9.03	0.44	1.4e-17	Prudent dietary pattern;
LUSC	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.15	-0.49	2.75e-21	Hemoglobin concentration;
LUSC	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.73	-0.43	1.2e-16	Neuroticism;
LUSC	cis	rs55871839	0.684	rs13271523	chr8:59806664	T/C	cg07426533	chr8:59803705	TOX	-0.37	-6.05	-0.31	3.86e-9	Pneumonia;
LUSC	cis	rs870825	0.616	rs10006828	chr4:185651416	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	12.36	0.56	3.65e-29	Blood protein levels;
LUSC	cis	rs244293	0.760	rs4794547	chr17:53011172	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.42	-6.26	-0.32	1.19e-9	Menarche (age at onset);
LUSC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12292205	chr6:26970375	C6orf41	-0.55	-6.73	-0.35	7.22e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.55	0.34	2.13e-10	Corneal astigmatism;
LUSC	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg08601574	chr20:25228251	PYGB	-0.45	-6.89	-0.35	2.83e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11677416	1.000	rs4848303	chr2:113552698	A/G	cg27083787	chr2:113543245	IL1A	0.47	7.33	0.37	1.79e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg03258749	chr1:151040405	MLLT11	-0.43	-6.59	-0.34	1.76e-10	Childhood ear infection;
LUSC	trans	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg02030672	chr11:45687055	CHST1	0.47	7.0	0.36	1.45e-11	Obesity-related traits;
LUSC	cis	rs12776158	0.901	rs12413873	chr10:71212091	C/G	cg12610070	chr10:71211762	TSPAN15	-0.49	-7.22	-0.37	3.52e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6700896	0.931	rs11208715	chr1:66154414	G/T	cg04111102	chr1:66153794	NA	0.33	7.24	0.37	3.17e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg07936489	chr17:37558343	FBXL20	-0.69	-9.54	-0.46	3.22e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg10729496	chr3:10149963	C3orf24	0.54	7.18	0.37	4.44e-12	Alzheimer's disease;
LUSC	cis	rs12753569	0.967	rs6696116	chr1:76483732	C/T	cg00791851	chr1:76518896	NA	-0.33	-6.33	-0.33	7.94e-10	Personality dimensions;
LUSC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg09877947	chr5:131593287	PDLIM4	0.48	7.87	0.4	4.99e-14	Breast cancer;
LUSC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.6	0.69	1.6e-49	Chronic sinus infection;
LUSC	cis	rs72960926	0.744	rs72950579	chr6:74915560	G/A	cg03266952	chr6:74778945	NA	-0.79	-6.42	-0.33	4.65e-10	Metabolite levels (MHPG);
LUSC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.67	0.34	1.06e-10	Platelet count;
LUSC	cis	rs2692947	0.631	rs2312954	chr2:96772447	C/T	cg22654517	chr2:96458247	NA	-0.32	-5.98	-0.31	5.85e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9341808	0.718	rs6910201	chr6:80904938	G/C	cg08355045	chr6:80787529	NA	0.59	10.22	0.49	1.64e-21	Sitting height ratio;
LUSC	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg08917208	chr2:24149416	ATAD2B	0.87	10.02	0.48	7.9e-21	Lymphocyte counts;
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.41	6.06	0.31	3.69e-9	Longevity;Endometriosis;
LUSC	cis	rs4077468	1.000	rs11801695	chr1:205916175	A/C	cg07157834	chr1:205819609	PM20D1	0.42	5.99	0.31	5.49e-9	Cystic fibrosis-related diabetes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14121103	chr3:43731973	ABHD5	0.41	6.15	0.32	2.24e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-6.06	-0.31	3.66e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.24	-0.32	1.35e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg02972257	chr16:68554789	NA	-0.53	-6.68	-0.34	1e-10	Ulcerative colitis;
LUSC	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg10523860	chr14:103875565	MARK3	0.39	6.12	0.32	2.56e-9	Body mass index;
LUSC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.91	0.35	2.49e-11	Parkinson's disease;
LUSC	cis	rs8141797	0.901	rs5751804	chr22:24490105	A/C	cg00411358	chr22:24577142	SUSD2	0.61	6.32	0.33	8.56e-10	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg11189052	chr15:85197271	WDR73	0.48	5.91	0.31	8.56e-9	Schizophrenia;
LUSC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg22166914	chr1:53195759	ZYG11B	0.6	9.8	0.47	4.26e-20	Monocyte count;
LUSC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg08508325	chr11:3079039	CARS	-0.51	-12.55	-0.57	7.33e-30	Longevity;
LUSC	cis	rs4499344	0.730	rs35098593	chr19:33103939	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs9677476	0.863	rs12465438	chr2:232073106	G/A	cg07929768	chr2:232055508	NA	0.37	7.11	0.36	7.15e-12	Food antigen IgG levels;
LUSC	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.57	8.09	0.4	1.09e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8112211	0.911	rs2270095	chr19:38840896	A/G	cg14299480	chr19:38876666	GGN	-0.35	-6.19	-0.32	1.74e-9	Blood protein levels;
LUSC	cis	rs6463523	0.933	rs79984239	chr7:766220	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.99	20.6	0.75	1.97e-61	Subjective well-being;
LUSC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.26	0.37	2.67e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg17366294	chr4:99064904	C4orf37	0.61	10.89	0.51	7.87e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg06612196	chr6:6737390	NA	0.56	10.74	0.51	2.55e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg26395211	chr5:140044315	WDR55	0.45	6.99	0.36	1.5e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.33	-0.49	6.9e-22	Platelet count;
LUSC	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg13010199	chr12:38710504	ALG10B	0.66	10.16	0.49	2.52e-21	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs1015291	0.680	rs1352903	chr12:19994758	A/G	cg01501474	chr7:55323552	NA	-0.45	-5.97	-0.31	6.09e-9	Diastolic blood pressure;
LUSC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs2737618	0.674	rs2260033	chr1:200086074	G/A	cg21825944	chr1:200113062	NR5A2	-0.3	-5.76	-0.3	1.95e-8	Uric acid levels;
LUSC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-8.3	-0.41	2.6e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs12681287	0.570	rs4961188	chr8:87383033	T/C	cg00550725	chr8:87521180	FAM82B	-0.43	-5.71	-0.3	2.51e-8	Caudate activity during reward;
LUSC	cis	rs6494488	0.500	rs72741320	chr15:64721745	C/A	cg08069370	chr15:64387884	SNX1	-0.64	-5.67	-0.3	3.05e-8	Coronary artery disease;
LUSC	cis	rs6445967	0.569	rs7622497	chr3:58282673	A/C	cg23715586	chr3:58305044	RPP14	0.45	7.62	0.39	2.57e-13	Platelet count;
LUSC	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg20607287	chr7:12443886	VWDE	-0.56	-6.55	-0.34	2.15e-10	Coronary artery disease;
LUSC	cis	rs4842666	0.915	rs117742247	chr12:89991313	C/T	cg00757033	chr12:89920650	WDR51B	0.51	6.68	0.34	9.94e-11	Blood pressure;
LUSC	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg24324837	chr19:49891574	CCDC155	0.5	6.41	0.33	5.07e-10	Multiple sclerosis;
LUSC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.16	-0.36	5.16e-12	Colorectal cancer;
LUSC	cis	rs5997397	0.720	rs132549	chr22:29318724	C/T	cg02153584	chr22:29168773	CCDC117	-0.44	-7.01	-0.36	1.32e-11	Red cell distribution width;
LUSC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg05347473	chr6:146136440	FBXO30	0.46	7.96	0.4	2.72e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1003719	0.667	rs2835606	chr21:38490851	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.59	9.07	0.44	1.05e-17	Eye color traits;
LUSC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg05802129	chr4:122689817	NA	-0.37	-6.72	-0.34	8e-11	Type 2 diabetes;
LUSC	cis	rs4947962	0.618	rs12538489	chr7:55099836	C/T	cg23757825	chr7:55092271	EGFR	-0.66	-8.69	-0.43	1.69e-16	Subjective response to lithium treatment;
LUSC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7809950	1.000	rs67982599	chr7:107100104	T/G	cg23024343	chr7:107201750	COG5	-0.54	-8.71	-0.43	1.42e-16	Coronary artery disease;
LUSC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg06238570	chr21:40685208	BRWD1	0.48	7.27	0.37	2.5e-12	Cognitive function;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg17811310	chr19:34012326	PEPD	0.34	5.96	0.31	6.55e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17916960	chr15:79447300	NA	0.53	10.75	0.51	2.33e-23	Refractive error;
LUSC	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg16414030	chr3:133502952	NA	-0.4	-5.93	-0.31	7.45e-9	Iron status biomarkers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19877921	chr17:61904685	PSMC5;FTSJ3	-0.38	-6.13	-0.32	2.42e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2420915	0.642	rs7071645	chr10:122863589	T/C	cg06217504	chr4:147056211	NA	0.45	6.17	0.32	1.96e-9	Fibrinogen levels;
LUSC	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg09904177	chr6:26538194	HMGN4	0.75	14.21	0.61	3.52e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg00684032	chr4:1343700	KIAA1530	-0.37	-6.34	-0.33	7.44e-10	Obesity-related traits;
LUSC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg23630131	chr7:65973040	NA	-0.21	-5.8	-0.3	1.55e-8	Aortic root size;
LUSC	cis	rs735539	0.609	rs7332034	chr13:21214943	T/C	cg04906043	chr13:21280425	IL17D	-0.44	-6.73	-0.35	7.42e-11	Dental caries;
LUSC	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.78	-13.23	-0.59	1.96e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.65	10.99	0.52	3.31e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg12560992	chr17:57184187	TRIM37	0.89	16.27	0.67	2.93e-44	Intelligence (multi-trait analysis);
LUSC	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg16797656	chr11:68205561	LRP5	0.35	5.9	0.31	8.96e-9	Total body bone mineral density;
LUSC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-6.63	-0.34	1.32e-10	Aortic root size;
LUSC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg05025164	chr4:1340916	KIAA1530	0.42	6.3	0.33	9.36e-10	Obesity-related traits;
LUSC	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg11266682	chr4:10021025	SLC2A9	0.43	7.67	0.39	1.91e-13	Bone mineral density;
LUSC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03352830	chr11:487213	PTDSS2	0.7	8.83	0.44	5.97e-17	Body mass index;
LUSC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg27398817	chr8:82754497	SNX16	-0.66	-8.41	-0.42	1.2e-15	Diastolic blood pressure;
LUSC	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	1.03	12.16	0.55	2.04e-28	Schizophrenia;
LUSC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06634786	chr22:41940651	POLR3H	0.52	5.89	0.31	9.62e-9	Vitiligo;
LUSC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.64	7.96	0.4	2.65e-14	Lung function (FEV1/FVC);
LUSC	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg20608306	chr11:116969690	SIK3	0.37	6.97	0.36	1.66e-11	Blood protein levels;
LUSC	cis	rs4363385	0.782	rs310126	chr1:153019416	A/C	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.3	-0.37	2.11e-12	Inflammatory skin disease;
LUSC	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg12573674	chr2:1569213	NA	-0.49	-5.74	-0.3	2.16e-8	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.14e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg24375607	chr4:120327624	NA	0.67	10.54	0.5	1.33e-22	Corneal astigmatism;
LUSC	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg24558204	chr6:135376177	HBS1L	0.67	10.4	0.49	4.01e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg03188948	chr7:1209495	NA	0.62	7.04	0.36	1.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg03676636	chr4:99064102	C4orf37	0.3	6.51	0.34	2.82e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg02475777	chr4:1388615	CRIPAK	0.39	5.97	0.31	6.06e-9	Obesity-related traits;
LUSC	cis	rs2191566	0.960	rs56171514	chr19:44506110	G/C	cg03039196	chr19:44506973	ZNF230	0.34	5.64	0.3	3.54e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg05861140	chr6:150128134	PCMT1	-0.41	-6.43	-0.33	4.34e-10	Lung cancer;
LUSC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	1.88e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg26441486	chr22:50317300	CRELD2	0.51	7.7	0.39	1.52e-13	Schizophrenia;
LUSC	cis	rs72792276	1.000	rs78529289	chr5:127405378	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	7.75	0.39	1.11e-13	Red cell distribution width;
LUSC	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.7	-8.73	-0.43	1.21e-16	Type 2 diabetes;
LUSC	cis	rs9649465	0.561	rs2429618	chr7:123421662	G/A	cg03229431	chr7:123269106	ASB15	0.48	7.69	0.39	1.66e-13	Migraine;
LUSC	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg00677455	chr12:58241039	CTDSP2	0.72	11.47	0.53	6.72e-26	Multiple sclerosis;
LUSC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21862992	chr11:68658383	NA	0.5	7.79	0.39	8.77e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg03161606	chr19:29218774	NA	0.61	9.38	0.46	1.01e-18	Methadone dose in opioid dependence;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24658452	chr6:133134754	RPS12	-0.42	-6.09	-0.32	3.09e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	11.28	0.53	3.19e-25	Personality dimensions;
LUSC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg23791442	chr22:43010704	POLDIP3;RNU12	0.55	6.23	0.32	1.43e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg22431228	chr1:16359049	CLCNKA	-0.51	-10.18	-0.49	2.27e-21	Dilated cardiomyopathy;
LUSC	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.56	7.9	0.4	3.96e-14	Lung cancer;
LUSC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.67	8.49	0.42	7.08e-16	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg19046167	chr17:80928561	B3GNTL1	0.48	7.23	0.37	3.31e-12	Breast cancer;
LUSC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg00599273	chr12:58146742	CDK4	0.3	5.73	0.3	2.25e-8	Multiple sclerosis;
LUSC	trans	rs7939886	0.841	rs10501349	chr11:56021284	G/A	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg24060327	chr5:131705240	SLC22A5	-0.68	-11.76	-0.54	6.2e-27	Breast cancer;
LUSC	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg12292205	chr6:26970375	C6orf41	-0.39	-5.83	-0.3	1.29e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3768617	0.811	rs12066082	chr1:183054863	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.69	0.43	1.65e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs1005224	0.853	rs2360035	chr14:76297093	A/T	cg25116370	chr14:76127843	TTLL5;C14orf1	0.39	5.89	0.31	9.35e-9	Large artery stroke;
LUSC	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg05855489	chr10:104503620	C10orf26	0.52	8.09	0.4	1.13e-14	Arsenic metabolism;
LUSC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.98	-0.36	1.57e-11	Lung cancer;
LUSC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.03	0.31	4.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12658694	chr1:38397304	INPP5B	0.58	10.03	0.48	7.48e-21	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	0.93	16.05	0.66	2.27e-43	Menopause (age at onset);
LUSC	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.59	-8.05	-0.4	1.45e-14	Red cell distribution width;
LUSC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.49	-7.95	-0.4	2.97e-14	Total body bone mineral density;
LUSC	trans	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.46	0.42	8.65e-16	Ulcerative colitis;
LUSC	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg17127132	chr2:85788382	GGCX	0.45	7.11	0.36	7.29e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg15534755	chr11:117069859	TAGLN	0.35	6.15	0.32	2.25e-9	Blood protein levels;
LUSC	cis	rs3803170	0.513	rs10849946	chr12:111830485	C/G	cg10833066	chr12:111807467	FAM109A	-0.39	-7.38	-0.37	1.29e-12	Mean corpuscular hemoglobin;
LUSC	cis	rs7241530	0.610	rs7243831	chr18:75906420	T/C	cg14642773	chr18:75888474	NA	0.39	5.96	0.31	6.32e-9	Educational attainment (years of education);
LUSC	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg18721089	chr20:30220636	NA	-0.37	-6.3	-0.33	9.5e-10	Mean corpuscular hemoglobin;
LUSC	trans	rs1941687	0.702	rs9956636	chr18:31304974	C/T	cg27147174	chr7:100797783	AP1S1	-0.43	-6.33	-0.33	7.82e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs4356932	0.875	rs6826408	chr4:76973564	A/C	cg00809888	chr4:76862425	NAAA	0.35	5.82	0.3	1.37e-8	Blood protein levels;
LUSC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.55	0.34	2.22e-10	Schizophrenia;
LUSC	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg05163923	chr11:71159392	DHCR7	-0.66	-8.52	-0.42	5.58e-16	Vitamin D levels;
LUSC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg13683864	chr3:40499215	RPL14	-0.93	-15.21	-0.64	4.75e-40	Renal cell carcinoma;
LUSC	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-13.7	-0.6	3.26e-34	Lymphocyte percentage of white cells;
LUSC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg25174290	chr11:3078921	CARS	-0.41	-6.1	-0.32	2.97e-9	Longevity;
LUSC	cis	rs981844	0.714	rs6822142	chr4:154683524	C/T	cg14289246	chr4:154710475	SFRP2	-0.52	-7.43	-0.38	9.38e-13	Response to statins (LDL cholesterol change);
LUSC	cis	rs662064	0.962	rs620405	chr1:10554794	T/C	cg20482658	chr1:10539492	PEX14	-0.32	-6.6	-0.34	1.62e-10	Asthma;
LUSC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-17.47	-0.69	5.27e-49	Coronary artery disease;
LUSC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg18512352	chr11:47633146	NA	-0.44	-9.04	-0.44	1.34e-17	Subjective well-being;
LUSC	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg08000102	chr2:233561755	GIGYF2	-0.68	-11.13	-0.52	1.12e-24	Coronary artery disease;
LUSC	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.03	0.52	2.51e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg26924012	chr15:45694286	SPATA5L1	-1.08	-17.25	-0.69	4.04e-48	Homoarginine levels;
LUSC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08280861	chr8:58055591	NA	0.56	6.05	0.31	3.96e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg26958806	chr6:27640298	NA	0.74	6.68	0.34	1.02e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9311676	0.632	rs7610312	chr3:58374029	A/G	cg26110898	chr3:58419937	PDHB	0.42	6.75	0.35	6.62e-11	Systemic lupus erythematosus;
LUSC	trans	rs800082	0.516	rs2889043	chr3:144231238	C/T	cg24215973	chr2:240111563	HDAC4	0.45	6.85	0.35	3.66e-11	Smoking behavior;
LUSC	cis	rs612683	0.694	rs6688364	chr1:101000874	G/A	cg06223162	chr1:101003688	GPR88	0.52	9.57	0.46	2.52e-19	Breast cancer;
LUSC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg21963583	chr11:68658836	MRPL21	0.58	9.17	0.45	4.86e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg27535305	chr1:53392650	SCP2	-0.4	-7.49	-0.38	6.15e-13	Monocyte count;
LUSC	cis	rs6961069	0.708	rs2030710	chr7:80220026	A/C	cg04458919	chr7:80252533	CD36	-0.41	-7.23	-0.37	3.36e-12	Platelet count;
LUSC	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg22875332	chr1:76189707	ACADM	-0.41	-6.09	-0.32	3.07e-9	Daytime sleep phenotypes;
LUSC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg19318889	chr4:1322082	MAEA	0.8	14.13	0.61	7.35e-36	Longevity;
LUSC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg21856205	chr7:94953877	PON1	-0.35	-5.74	-0.3	2.09e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	0.87	14.92	0.63	6.45e-39	Tonsillectomy;
LUSC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.79	14.38	0.62	7.99e-37	Dental caries;
LUSC	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.87	0.4	4.86e-14	Coffee consumption (cups per day);
LUSC	trans	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg13565492	chr6:43139072	SRF	-0.63	-6.63	-0.34	1.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg08085267	chr17:45401833	C17orf57	0.54	8.82	0.43	6.58e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg09904177	chr6:26538194	HMGN4	-0.75	-6.61	-0.34	1.51e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg17652424	chr22:38574118	PLA2G6	-0.31	-6.73	-0.35	7.49e-11	Cutaneous nevi;
LUSC	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg18225595	chr11:63971243	STIP1	0.52	6.05	0.31	3.95e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg09003973	chr2:102972529	NA	0.56	7.29	0.37	2.2e-12	Blood protein levels;
LUSC	cis	rs6693567	0.586	rs875514	chr1:150484555	C/G	cg15654264	chr1:150340011	RPRD2	0.45	7.26	0.37	2.72e-12	Migraine;
LUSC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg01557791	chr16:72042693	DHODH	0.49	6.94	0.36	2.02e-11	Fibrinogen levels;
LUSC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg09365446	chr1:150670422	GOLPH3L	0.55	8.46	0.42	8.21e-16	Tonsillectomy;
LUSC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg16423285	chr20:60520624	NA	0.88	11.76	0.54	5.8e-27	Obesity-related traits;
LUSC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg07424592	chr7:64974309	NA	0.59	5.93	0.31	7.53e-9	Diabetic kidney disease;
LUSC	cis	rs2742234	0.541	rs61845684	chr10:43744983	T/C	cg15436174	chr10:43711423	RASGEF1A	0.43	6.72	0.34	8.04e-11	Hirschsprung disease;
LUSC	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg08847533	chr14:75593920	NEK9	-0.75	-13.14	-0.58	4.47e-32	Height;
LUSC	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.52	-0.34	2.59e-10	Inflammatory bowel disease;
LUSC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg23630131	chr7:65973040	NA	0.21	5.79	0.3	1.6e-8	Aortic root size;
LUSC	cis	rs9549260	0.755	rs12585277	chr13:41224813	C/T	cg21288729	chr13:41239152	FOXO1	0.65	10.04	0.48	6.48e-21	Red blood cell count;
LUSC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg04944784	chr2:26401820	FAM59B	0.79	11.29	0.53	2.95e-25	Gut microbiome composition (summer);
LUSC	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.34	5.93	0.31	7.58e-9	Height;
LUSC	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg01579765	chr21:45077557	HSF2BP	-0.47	-9.78	-0.47	5.04e-20	Mean corpuscular volume;
LUSC	cis	rs56804039	1.000	rs11780966	chr8:8383396	T/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.33	-0.37	1.8e-12	Cervical cancer;
LUSC	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.68	-0.34	9.75e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs11700980	0.551	rs2832023	chr21:30112996	A/G	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.31e-9	QRS complex (12-leadsum);
LUSC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg10207240	chr12:122356781	WDR66	0.44	6.5	0.33	3.01e-10	Mean corpuscular volume;
LUSC	trans	rs9784649	1.000	rs56004901	chr5:24998968	A/G	cg08600765	chr20:34638493	LOC647979	-0.53	-6.35	-0.33	6.94e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.66	-9.31	-0.45	1.82e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg08975724	chr8:8085496	FLJ10661	0.47	6.88	0.35	2.88e-11	Mood instability;
LUSC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg22638593	chr5:131593259	PDLIM4	0.38	5.79	0.3	1.62e-8	Breast cancer;
LUSC	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.77	-0.43	9.54e-17	Response to antipsychotic treatment;
LUSC	cis	rs2245368	0.523	rs67814714	chr7:76517422	T/C	cg15770687	chr7:76625569	PMS2L11	0.85	8.85	0.44	5.3e-17	Body mass index in physically inactive individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg12292205	chr6:26970375	C6orf41	-0.7	-12.22	-0.56	1.23e-28	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg12615879	chr12:58013172	SLC26A10	-0.27	-5.72	-0.3	2.31e-8	Multiple sclerosis;
LUSC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg16647868	chr5:131706066	SLC22A5	0.38	6.03	0.31	4.42e-9	Breast cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10586042	chr5:36152206	SKP2;LMBRD2	-0.39	-5.98	-0.31	5.85e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg11247378	chr22:39784982	NA	-0.64	-12.82	-0.57	6.95e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.510	rs2068678	chr1:152906956	G/A	cg25856811	chr1:152973957	SPRR3	-0.38	-6.05	-0.31	3.98e-9	Inflammatory skin disease;
LUSC	cis	rs1005224	0.864	rs11625011	chr14:76144828	G/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.63	-8.57	-0.42	3.91e-16	Large artery stroke;
LUSC	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.55	0.5	1.21e-22	Hypertriglyceridemia;
LUSC	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.03	0.74	3.52e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg20503657	chr10:835505	NA	1.05	13.48	0.59	2.19e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg08684580	chr7:98029266	BAIAP2L1	0.38	5.81	0.3	1.46e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg00012203	chr2:219082015	ARPC2	-0.56	-8.97	-0.44	2.11e-17	Ulcerative colitis;
LUSC	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg24642844	chr7:1081250	C7orf50	-0.68	-6.5	-0.34	2.94e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg05985134	chr18:33552581	C18orf21	0.51	6.83	0.35	4.01e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.52	-8.02	-0.4	1.8e-14	Menarche (age at onset);
LUSC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18099408	chr3:52552593	STAB1	-0.43	-7.53	-0.38	4.66e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4474465	0.850	rs10899552	chr11:78262262	G/A	cg27205649	chr11:78285834	NARS2	0.5	5.96	0.31	6.56e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7000551	0.751	rs2469775	chr8:22373238	T/C	cg12081754	chr8:22256438	SLC39A14	0.42	6.37	0.33	6.35e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	7.99	0.4	2.28e-14	Schizophrenia;
LUSC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.52	-8.65	-0.43	2.24e-16	Immature fraction of reticulocytes;
LUSC	cis	rs7590368	0.961	rs12474895	chr2:10957848	A/C	cg15705551	chr2:10952987	PDIA6	0.58	7.95	0.4	2.95e-14	Educational attainment (years of education);
LUSC	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg07741184	chr6:167504864	NA	0.33	5.81	0.3	1.42e-8	Primary biliary cholangitis;
LUSC	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-5.93	-0.31	7.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.29	-0.33	9.77e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2425143	0.908	rs12480111	chr20:34423186	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-5.96	-0.31	6.26e-9	Blood protein levels;
LUSC	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.72	11.91	0.55	1.68e-27	Monocyte count;
LUSC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg20587970	chr11:113659929	NA	-1.18	-16.31	-0.67	2.13e-44	Hip circumference adjusted for BMI;
LUSC	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg07936489	chr17:37558343	FBXL20	0.69	9.66	0.47	1.27e-19	Glomerular filtration rate (creatinine);
LUSC	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg13615516	chr5:77269221	NA	0.39	6.66	0.34	1.16e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg09365446	chr1:150670422	GOLPH3L	0.47	7.07	0.36	9.18e-12	Melanoma;
LUSC	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg01858014	chr14:56050164	KTN1	-0.79	-7.71	-0.39	1.5e-13	Putamen volume;
LUSC	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	8.73	0.43	1.25e-16	Mean corpuscular hemoglobin;
LUSC	trans	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg07393940	chr7:158741817	NA	0.37	6.61	0.34	1.5e-10	Life satisfaction;
LUSC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg14583973	chr4:3374767	RGS12	0.4	8.57	0.42	3.96e-16	Serum sulfate level;
LUSC	trans	rs429017	0.541	rs400896	chr5:41273955	A/T	cg17064250	chr6:45388500	RUNX2	0.32	6.15	0.32	2.23e-9	Blood protein levels;
LUSC	trans	rs2562456	0.833	rs4429400	chr19:21520965	T/C	cg00806126	chr19:22604979	ZNF98	-0.43	-6.0	-0.31	5.12e-9	Pain;
LUSC	cis	rs2652834	0.718	rs2729831	chr15:63396039	A/T	cg05507819	chr15:63340323	TPM1	0.55	7.11	0.36	7.22e-12	HDL cholesterol;
LUSC	cis	rs9311676	0.618	rs12152337	chr3:58365271	T/C	cg13750441	chr3:58318267	PXK	0.35	6.76	0.35	6.33e-11	Systemic lupus erythematosus;
LUSC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg11859384	chr17:80120422	CCDC57	-0.36	-5.66	-0.3	3.31e-8	Life satisfaction;
LUSC	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07080220	chr10:102295463	HIF1AN	0.65	8.51	0.42	6.11e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg09904177	chr6:26538194	HMGN4	0.65	11.1	0.52	1.4e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-6.89	-0.35	2.86e-11	Self-reported allergy;
LUSC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.25	0.41	3.79e-15	Tonsillectomy;
LUSC	cis	rs2798269	1.000	rs2761916	chr13:22148286	A/C	cg18095732	chr13:22033692	ZDHHC20	-0.39	-5.95	-0.31	6.92e-9	PR segment;
LUSC	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg26893861	chr17:41843967	DUSP3	0.86	13.17	0.58	3.36e-32	Triglycerides;
LUSC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	1.06	17.85	0.7	1.59e-50	Parkinson's disease;
LUSC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.53	-0.38	4.71e-13	Bipolar disorder;
LUSC	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg22467129	chr15:76604101	ETFA	-0.43	-6.72	-0.35	7.94e-11	Blood metabolite levels;
LUSC	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg13010199	chr12:38710504	ALG10B	0.63	9.87	0.48	2.49e-20	Bladder cancer;
LUSC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.51	-0.46	3.81e-19	Gut microbiome composition (summer);
LUSC	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg16006841	chr5:176797999	RGS14	-0.59	-8.54	-0.42	4.8e-16	Urate levels in lean individuals;
LUSC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg26395211	chr5:140044315	WDR55	0.38	5.77	0.3	1.77e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9395066	0.545	rs2396372	chr6:44966867	T/C	cg25276700	chr6:44698697	NA	0.29	5.81	0.3	1.48e-8	Height;
LUSC	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-7.34	-0.37	1.65e-12	Retinal vascular caliber;
LUSC	cis	rs6693567	0.507	rs828784	chr1:150335240	T/A	cg15654264	chr1:150340011	RPRD2	0.46	7.35	0.37	1.5e-12	Migraine;
LUSC	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg25801113	chr15:45476975	SHF	0.35	7.17	0.37	4.84e-12	Uric acid levels;
LUSC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	15.84	0.65	1.57e-42	Platelet count;
LUSC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06505273	chr16:24850292	NA	-0.41	-5.74	-0.3	2.16e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg03474202	chr17:45855739	NA	-0.28	-6.27	-0.32	1.12e-9	IgG glycosylation;
LUSC	cis	rs9304742	0.683	rs10402714	chr19:53463680	G/A	cg09503522	chr19:53445286	ZNF321	-0.35	-5.67	-0.3	3.06e-8	Psoriasis;
LUSC	trans	rs7715474	0.629	rs6863440	chr5:120084621	G/C	cg12284098	chr8:1993893	MYOM2	0.33	6.1	0.32	2.92e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg00376283	chr12:123451042	ABCB9	-0.66	-7.74	-0.39	1.18e-13	Neutrophil percentage of white cells;
LUSC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg06219351	chr7:158114137	PTPRN2	0.5	9.02	0.44	1.46e-17	Calcium levels;
LUSC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg04362960	chr10:104952993	NT5C2	-0.6	-9.31	-0.45	1.74e-18	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg06784218	chr1:46089804	CCDC17	-0.57	-11.33	-0.53	2.11e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg10553204	chr2:20871195	GDF7	-0.34	-5.9	-0.31	8.83e-9	Abdominal aortic aneurysm;
LUSC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	0.92	17.78	0.7	2.98e-50	Heart rate;
LUSC	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg04455712	chr21:45112962	RRP1B	0.45	8.53	0.42	5.06e-16	Mean corpuscular volume;
LUSC	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.96	0.7	5.99e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.48	-7.19	-0.37	4.15e-12	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs17255340	0.559	rs1143796	chr6:84005867	T/C	cg08257003	chr6:84140564	ME1	0.31	7.78	0.39	9.43e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg05729581	chr11:3078854	CARS	0.5	7.48	0.38	6.66e-13	Longevity;
LUSC	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg22496339	chr2:162101262	NA	-0.45	-6.5	-0.34	2.95e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg09796270	chr17:17721594	SREBF1	0.46	7.97	0.4	2.53e-14	Total body bone mineral density;
LUSC	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg24558204	chr6:135376177	HBS1L	-0.6	-8.73	-0.43	1.23e-16	High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg13010199	chr12:38710504	ALG10B	-0.64	-9.99	-0.48	9.53e-21	Morning vs. evening chronotype;
LUSC	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg24579218	chr15:68104479	NA	-0.39	-6.81	-0.35	4.68e-11	Restless legs syndrome;
LUSC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.27e-31	Prudent dietary pattern;
LUSC	trans	rs61931739	0.533	rs7970871	chr12:33917301	G/A	cg26384229	chr12:38710491	ALG10B	0.51	7.63	0.39	2.51e-13	Morning vs. evening chronotype;
LUSC	cis	rs11997175	0.625	rs7460540	chr8:33597907	A/G	ch.8.33884649F	chr8:33765107	NA	0.42	6.66	0.34	1.15e-10	Body mass index;
LUSC	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg24324837	chr19:49891574	CCDC155	0.49	6.25	0.32	1.23e-9	Multiple sclerosis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06527153	chr1:109289113	STXBP3	0.42	6.29	0.33	1.02e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg00343986	chr7:65444356	GUSB	0.43	6.4	0.33	5.34e-10	Aortic root size;
LUSC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-25.08	-0.81	8.21e-79	Height;
LUSC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.32	0.77	3.6e-68	Prudent dietary pattern;
LUSC	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg05973401	chr12:123451056	ABCB9	-0.52	-7.71	-0.39	1.5e-13	Platelet count;
LUSC	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-20.56	-0.75	2.79e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2274273	0.624	rs66551709	chr14:55791022	A/T	cg04306507	chr14:55594613	LGALS3	0.48	9.69	0.47	9.94e-20	Protein biomarker;
LUSC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg11062466	chr8:58055876	NA	0.49	6.45	0.33	3.88e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9788721	0.836	rs72738718	chr15:78735438	G/C	cg18825076	chr15:78729989	IREB2	-0.59	-9.76	-0.47	5.72e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06850241	chr22:41845214	NA	-0.31	-5.85	-0.3	1.18e-8	Vitiligo;
LUSC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.79	-0.51	1.7e-23	Aortic root size;
LUSC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg22963979	chr7:1858916	MAD1L1	0.55	8.54	0.42	4.83e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs911555	0.755	rs2756122	chr14:103983033	C/G	cg12935359	chr14:103987150	CKB	-0.46	-7.46	-0.38	7.56e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg16797656	chr11:68205561	LRP5	0.36	6.08	0.32	3.22e-9	Total body bone mineral density;
LUSC	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg13010199	chr12:38710504	ALG10B	0.65	10.07	0.48	5.45e-21	Bladder cancer;
LUSC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg01416388	chr22:39784598	NA	-0.44	-7.44	-0.38	8.8e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg00343986	chr7:65444356	GUSB	-0.48	-7.2	-0.37	3.98e-12	Aortic root size;
LUSC	cis	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg00806126	chr19:22604979	ZNF98	0.37	5.87	0.31	1.05e-8	Pain;
LUSC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19346786	chr7:2764209	NA	-0.49	-8.1	-0.41	1.04e-14	Height;
LUSC	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08645402	chr16:4508243	NA	0.47	7.34	0.37	1.66e-12	Schizophrenia;
LUSC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-8.22	-0.41	4.62e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg23630131	chr7:65973040	NA	-0.2	-5.67	-0.3	3.05e-8	Aortic root size;
LUSC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg03678062	chr6:149772716	ZC3H12D	-0.33	-6.9	-0.35	2.62e-11	Dupuytren's disease;
LUSC	cis	rs2742234	0.541	rs10899786	chr10:43744583	G/A	cg07801480	chr10:43725741	RASGEF1A	-0.39	-5.68	-0.3	2.93e-8	Hirschsprung disease;
LUSC	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4730250	0.707	rs257387	chr7:106808480	G/A	cg02696742	chr7:106810147	HBP1	-0.66	-9.21	-0.45	3.62e-18	Osteoarthritis;
LUSC	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg05887092	chr17:76393375	PGS1	0.52	9.5	0.46	4.27e-19	HDL cholesterol levels;
LUSC	cis	rs4988958	0.565	rs12712146	chr2:103008714	C/T	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.65e-12	Asthma (childhood onset);
LUSC	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg11244672	chr19:19639970	YJEFN3	0.59	7.05	0.36	1.06e-11	Bipolar disorder;
LUSC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-10.29	-0.49	9.28e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs2708377	0.656	rs116607079	chr12:11262044	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.81	7.88	0.4	4.71e-14	Bitter taste perception;
LUSC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.8	14.43	0.62	4.94e-37	Blood protein levels;
LUSC	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-8.18	-0.41	6.18e-15	Neuroticism;
LUSC	cis	rs11935103	0.569	rs10022988	chr4:187291021	T/C	cg24610901	chr4:187293114	NA	-0.42	-5.84	-0.3	1.21e-8	Response to citalopram treatment;
LUSC	trans	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.43	-0.33	4.39e-10	Mood instability;
LUSC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg20476274	chr7:133979776	SLC35B4	0.8	13.71	0.6	2.91e-34	Mean platelet volume;
LUSC	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg08048268	chr3:133502702	NA	0.35	6.34	0.33	7.31e-10	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg11871910	chr12:69753446	YEATS4	0.47	6.32	0.33	8.44e-10	Response to diuretic therapy;
LUSC	cis	rs4654899	0.802	rs7519685	chr1:21192623	G/A	cg01072550	chr1:21505969	NA	-0.48	-7.23	-0.37	3.26e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg14440974	chr22:39074834	NA	-0.37	-6.14	-0.32	2.34e-9	Menopause (age at onset);
LUSC	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18932078	chr1:2524107	MMEL1	0.32	7.2	0.37	4e-12	Ulcerative colitis;
LUSC	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg06223162	chr1:101003688	GPR88	-0.48	-9.42	-0.46	7.63e-19	Breast cancer;
LUSC	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg26384229	chr12:38710491	ALG10B	0.73	11.43	0.53	9.6e-26	Morning vs. evening chronotype;
LUSC	cis	rs4363385	0.818	rs370162	chr1:153005488	G/A	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.45e-8	Inflammatory skin disease;
LUSC	trans	rs11782517	0.924	rs58868895	chr8:10109343	T/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.07	0.32	3.54e-9	Nose size;
LUSC	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.16	-23.24	-0.79	9.33e-72	Exhaled nitric oxide output;
LUSC	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg07936489	chr17:37558343	FBXL20	0.87	12.1	0.55	3.54e-28	Glomerular filtration rate (creatinine);
LUSC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16680214	chr1:154839983	KCNN3	-0.51	-9.38	-0.46	1.05e-18	Prostate cancer;
LUSC	trans	rs1486139	0.905	rs9639004	chr7:46282865	G/A	cg17534202	chr9:96721102	NA	-0.37	-6.56	-0.34	2.01e-10	Select biomarker traits;
LUSC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-7.87	-0.4	5.01e-14	Hemoglobin concentration;
LUSC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.84	-0.3	1.23e-8	Total body bone mineral density;
LUSC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg16850897	chr7:100343110	ZAN	-0.45	-5.75	-0.3	2.01e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9807989	0.765	rs13424006	chr2:102967236	T/C	cg09003973	chr2:102972529	NA	0.45	6.19	0.32	1.8e-9	Asthma;
LUSC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg22618164	chr12:122356400	WDR66	0.6	8.76	0.43	9.63e-17	Mean corpuscular volume;
LUSC	cis	rs2637266	1.000	rs10219021	chr10:78364516	C/T	cg18941641	chr10:78392320	NA	0.39	7.22	0.37	3.62e-12	Pulmonary function;
LUSC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.6	0.38	2.92e-13	Prudent dietary pattern;
LUSC	cis	rs10465746	0.935	rs11580836	chr1:84333310	C/T	cg10977910	chr1:84465055	TTLL7	0.45	6.38	0.33	5.91e-10	Obesity-related traits;
LUSC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg08027265	chr7:2291960	NA	-0.37	-5.9	-0.31	8.83e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg17462356	chr17:80056334	FASN	0.46	6.21	0.32	1.56e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.87	-15.39	-0.64	8.72e-41	Cognitive function;
LUSC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23158103	chr7:148848205	ZNF398	0.47	7.7	0.39	1.55e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg12218747	chr21:37451666	NA	-0.38	-5.67	-0.3	3.08e-8	Mitral valve prolapse;
LUSC	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg14631576	chr9:95140430	CENPP	-0.32	-5.66	-0.3	3.23e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg13319975	chr6:146136371	FBXO30	-0.66	-9.86	-0.47	2.74e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg07636037	chr3:49044803	WDR6	0.43	6.26	0.32	1.21e-9	Resting heart rate;
LUSC	cis	rs17095355	0.901	rs17126938	chr10:111761351	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.16	-0.36	5.31e-12	Biliary atresia;
LUSC	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.74	-11.6	-0.54	2.18e-26	Schizophrenia;
LUSC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg08680598	chr22:49984980	NA	-0.34	-6.37	-0.33	6.22e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6469656	1.000	rs10105610	chr8:117654088	C/G	cg24004040	chr8:117650383	NA	-0.41	-6.03	-0.31	4.39e-9	Colorectal cancer;
LUSC	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg08085267	chr17:45401833	C17orf57	-0.5	-7.25	-0.37	2.97e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg22089800	chr15:90895588	ZNF774	0.65	9.79	0.47	4.74e-20	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22029157	chr1:209979665	IRF6	0.74	11.02	0.52	2.73e-24	Cleft lip with or without cleft palate;
LUSC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06221963	chr1:154839813	KCNN3	-0.65	-15.56	-0.65	1.89e-41	Prostate cancer;
LUSC	cis	rs73198271	0.740	rs67766414	chr8:8649533	C/T	cg01851573	chr8:8652454	MFHAS1	0.53	8.52	0.42	5.36e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg09796270	chr17:17721594	SREBF1	-0.45	-7.8	-0.39	7.78e-14	Total body bone mineral density;
LUSC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-9.64	-0.47	1.42e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4594175	0.707	rs4901096	chr14:51722826	G/C	cg23942311	chr14:51606299	NA	0.29	5.72	0.3	2.34e-8	Cancer;
LUSC	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg07741184	chr6:167504864	NA	0.34	6.18	0.32	1.86e-9	Crohn's disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01956158	chr8:132916947	EFR3A	0.42	6.28	0.32	1.08e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg25258033	chr6:167368657	RNASET2	0.39	6.28	0.32	1.07e-9	Crohn's disease;
LUSC	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg13575925	chr12:9217583	LOC144571	0.35	6.43	0.33	4.51e-10	Sjögren's syndrome;
LUSC	trans	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.53	-0.42	5.13e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.47	-8.36	-0.42	1.72e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.58	-0.38	3.48e-13	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11031096	0.502	rs4910875	chr11:4047855	C/G	cg18678763	chr11:4115507	RRM1	-0.48	-6.37	-0.33	6.37e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg16362232	chr11:430036	ANO9	0.67	8.36	0.42	1.67e-15	Body mass index;
LUSC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-0.82	-14.94	-0.63	5.27e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs934734	0.563	rs11673956	chr2:65597657	A/G	cg08085232	chr2:65598271	SPRED2	-0.45	-6.9	-0.35	2.62e-11	Rheumatoid arthritis;
LUSC	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg05738196	chr6:26577821	NA	-0.48	-6.79	-0.35	5.24e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg02569458	chr12:86230093	RASSF9	0.42	6.81	0.35	4.67e-11	Major depressive disorder;
LUSC	cis	rs10492096	0.945	rs2041386	chr12:6562538	C/T	cg13857086	chr12:6580257	VAMP1	0.82	9.17	0.45	4.96e-18	Hip geometry;
LUSC	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg10172584	chr19:19639581	YJEFN3	-0.5	-5.91	-0.31	8.47e-9	Bipolar disorder;
LUSC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.69	-10.5	-0.5	1.75e-22	Aortic root size;
LUSC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02475777	chr4:1388615	CRIPAK	-0.57	-8.96	-0.44	2.41e-17	Longevity;
LUSC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg06454157	chr6:167490870	NA	-0.27	-6.64	-0.34	1.28e-10	Primary biliary cholangitis;
LUSC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	6.49	0.33	3.18e-10	Obesity-related traits;
LUSC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg18350739	chr11:68623251	NA	-0.38	-6.47	-0.33	3.43e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06634786	chr22:41940651	POLR3H	-0.5	-6.19	-0.32	1.8e-9	Vitiligo;
LUSC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.46	-0.38	7.78e-13	Aortic root size;
LUSC	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg22535103	chr8:58192502	C8orf71	-0.56	-6.71	-0.34	8.29e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg00982548	chr2:198649783	BOLL	-0.59	-7.35	-0.37	1.51e-12	Ulcerative colitis;
LUSC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg23711669	chr6:146136114	FBXO30	-0.92	-17.56	-0.69	2.31e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9581857	0.685	rs9319367	chr13:28042197	T/C	cg22138327	chr13:27999177	GTF3A	0.74	8.02	0.4	1.84e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-0.94	-15.88	-0.66	1.06e-42	Menopause (age at onset);
LUSC	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg03709012	chr19:19516395	GATAD2A	-0.49	-7.12	-0.36	6.85e-12	Tonsillectomy;
LUSC	cis	rs35096708	1.000	rs35096708	chr16:89887249	G/A	cg26513180	chr16:89883248	FANCA	-0.53	-6.25	-0.32	1.28e-9	Skin aging (microtopography measurement);
LUSC	cis	rs2742234	0.590	rs2505506	chr10:43645854	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.41	-7.04	-0.36	1.07e-11	Hirschsprung disease;
LUSC	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg03859395	chr2:55845619	SMEK2	-0.75	-11.87	-0.54	2.45e-27	Metabolic syndrome;
LUSC	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg00579200	chr11:133705235	NA	-0.41	-6.16	-0.32	2.12e-9	Childhood ear infection;
LUSC	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.69	9.22	0.45	3.44e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg19230755	chr7:65878503	NA	-0.4	-5.79	-0.3	1.64e-8	Aortic root size;
LUSC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg21017887	chr14:105400489	NA	0.68	13.09	0.58	7.04e-32	Rheumatoid arthritis;
LUSC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.61	-0.47	1.79e-19	Bipolar disorder;
LUSC	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg19920283	chr7:105172520	RINT1	0.58	6.11	0.32	2.71e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08859206	chr1:53392774	SCP2	-0.55	-9.41	-0.46	8.02e-19	Monocyte count;
LUSC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.2	0.52	6.31e-25	Prudent dietary pattern;
LUSC	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg17168535	chr8:21777572	XPO7	0.84	15.44	0.65	5.65e-41	Mean corpuscular volume;
LUSC	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg26597838	chr10:835615	NA	-0.48	-6.53	-0.34	2.45e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg04944784	chr2:26401820	FAM59B	0.65	9.3	0.45	1.85e-18	Gut microbiome composition (summer);
LUSC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg12963246	chr6:28129442	ZNF389	0.5	6.8	0.35	4.94e-11	Depression;
LUSC	cis	rs7640424	0.721	rs326356	chr3:107824563	C/T	cg09227934	chr3:107805635	CD47	-0.37	-6.0	-0.31	5.28e-9	Body mass index;
LUSC	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg24631222	chr15:78858424	CHRNA5	0.84	11.36	0.53	1.71e-25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg25174290	chr11:3078921	CARS	-0.41	-6.15	-0.32	2.27e-9	Calcium levels;
LUSC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06850241	chr22:41845214	NA	-0.3	-5.88	-0.31	9.71e-9	Vitiligo;
LUSC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08736216	chr1:53307985	ZYG11A	0.29	6.06	0.31	3.68e-9	Monocyte count;
LUSC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg26597838	chr10:835615	NA	1.22	16.83	0.68	1.8e-46	Eosinophil percentage of granulocytes;
LUSC	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.66	-0.34	1.12e-10	QT interval;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09826306	chr16:89990300	TUBB3	0.68	5.97	0.31	5.9e-9	Cognitive performance;
LUSC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg13939156	chr17:80058883	NA	-0.33	-6.41	-0.33	4.96e-10	Life satisfaction;
LUSC	cis	rs7113850	0.541	rs7131336	chr11:24219418	C/T	ch.11.24196551F	chr11:24239977	NA	0.96	9.08	0.44	9.71e-18	Bone fracture in osteoporosis;
LUSC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg06784218	chr1:46089804	CCDC17	0.48	9.35	0.46	1.3e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs427941	0.703	rs201435	chr7:101732865	G/C	cg06246474	chr7:101738831	CUX1	0.42	6.82	0.35	4.28e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19717773	chr7:2847554	GNA12	-0.39	-6.14	-0.32	2.38e-9	Height;
LUSC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg00074818	chr8:8560427	CLDN23	0.6	9.79	0.47	4.46e-20	Obesity-related traits;
LUSC	trans	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.42	0.33	4.58e-10	Mood instability;
LUSC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.46	7.56	0.38	3.98e-13	Pulse pressure;
LUSC	cis	rs5009270	0.512	rs75795332	chr7:112241690	G/A	cg27282281	chr7:112262583	NA	0.43	5.75	0.3	1.98e-8	Osteoarthritis (hip);
LUSC	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04850017	chr11:63683019	RCOR2	0.29	5.78	0.3	1.67e-8	Pulse pressure;
LUSC	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.8	-0.47	4.35e-20	Systolic blood pressure;
LUSC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.47	-6.21	-0.32	1.59e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg13628971	chr7:2884303	GNA12	-0.46	-6.29	-0.33	9.85e-10	Height;
LUSC	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.49	-6.82	-0.35	4.33e-11	Corneal astigmatism;
LUSC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.91	-0.4	3.82e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7674212	0.539	rs6850461	chr4:104120041	C/T	cg16532752	chr4:104119610	CENPE	-0.47	-6.8	-0.35	4.81e-11	Type 2 diabetes;
LUSC	cis	rs4730250	0.707	rs61014091	chr7:106810107	A/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.36	-0.46	1.18e-18	Osteoarthritis;
LUSC	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg00343986	chr7:65444356	GUSB	-0.39	-5.88	-0.31	1.02e-8	Aortic root size;
LUSC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg09455208	chr3:40491958	NA	0.6	10.6	0.5	7.95e-23	Renal cell carcinoma;
LUSC	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg00071950	chr4:10020882	SLC2A9	0.54	9.08	0.44	9.94e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg26695010	chr11:65641043	EFEMP2	0.59	8.83	0.43	6.1e-17	Eosinophil percentage of white cells;
LUSC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg13628971	chr7:2884303	GNA12	0.5	6.82	0.35	4.23e-11	Height;
LUSC	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17467752	chr17:38218738	THRA	-0.7	-11.27	-0.52	3.54e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.48	0.38	6.59e-13	Motion sickness;
LUSC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg02117656	chr17:79614917	TSPAN10	-0.3	-5.67	-0.3	3.16e-8	Eye color traits;
LUSC	cis	rs6500395	1.000	rs871903	chr16:48593643	A/C	cg04672837	chr16:48644449	N4BP1	0.43	6.34	0.33	7.56e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs117623576	0.887	rs211411	chr10:32394992	T/C	cg03047570	chr10:32398778	NA	0.71	7.9	0.4	4.12e-14	Anti-saccade response;
LUSC	cis	rs7923609	0.934	rs10822153	chr10:65056813	C/A	cg01631684	chr10:65280961	REEP3	-0.42	-6.42	-0.33	4.76e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.55	-0.38	4.17e-13	Aortic root size;
LUSC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18099408	chr3:52552593	STAB1	-0.41	-6.96	-0.36	1.84e-11	Bipolar disorder;
LUSC	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg01528321	chr10:82214614	TSPAN14	0.84	12.47	0.56	1.42e-29	Post bronchodilator FEV1;
LUSC	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg04851639	chr8:1020857	NA	-0.39	-8.4	-0.42	1.33e-15	Schizophrenia;
LUSC	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg19508488	chr2:152266495	RIF1	0.54	7.63	0.39	2.47e-13	Lung cancer;
LUSC	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.54	0.75	3.49e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg24375607	chr4:120327624	NA	-0.5	-7.93	-0.4	3.28e-14	Diastolic blood pressure;
LUSC	cis	rs1953600	0.729	rs2819872	chr10:81906269	A/G	cg00277334	chr10:82204260	NA	0.46	7.45	0.38	8.09e-13	Sarcoidosis;
LUSC	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg11843238	chr5:131593191	PDLIM4	0.37	6.45	0.33	3.91e-10	Breast cancer;
LUSC	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	0.88	14.51	0.62	2.49e-37	Schizophrenia;
LUSC	cis	rs10193935	0.901	rs6544549	chr2:42693056	C/T	cg27598129	chr2:42591480	NA	0.62	7.78	0.39	9.16e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg06096015	chr1:231504339	EGLN1	0.56	9.95	0.48	1.33e-20	Hemoglobin concentration;
LUSC	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg26384229	chr12:38710491	ALG10B	0.5	7.23	0.37	3.24e-12	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.28	0.45	2.23e-18	Prudent dietary pattern;
LUSC	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.22	-0.37	3.61e-12	Type 2 diabetes;
LUSC	trans	rs75804782	0.641	rs72983853	chr2:239324210	C/T	cg01134436	chr17:81009848	B3GNTL1	0.65	6.42	0.33	4.55e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg23985595	chr17:80112537	CCDC57	0.31	5.95	0.31	6.87e-9	Life satisfaction;
LUSC	trans	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-12.45	-0.56	1.76e-29	Colorectal cancer;
LUSC	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18075040	chr12:96337100	AMDHD1;CCDC38	-0.41	-6.2	-0.32	1.67e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg10360323	chr17:41437877	NA	0.4	5.71	0.3	2.44e-8	Menopause (age at onset);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09720372	chr3:108308234	KIAA1524;DZIP3	-0.49	-6.63	-0.34	1.34e-10	Hepatitis;
LUSC	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.06	-0.36	9.7e-12	Total cholesterol levels;
LUSC	cis	rs2573652	0.722	rs8041337	chr15:100541808	T/C	cg00587665	chr15:100533223	ADAMTS17	-0.39	-7.06	-0.36	9.69e-12	Height;
LUSC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24110177	chr3:50126178	RBM5	-0.54	-8.8	-0.43	7.39e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	9.69	0.47	1.02e-19	Personality dimensions;
LUSC	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg25124228	chr12:125621409	AACS	0.41	5.81	0.3	1.43e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08048268	chr3:133502702	NA	-0.49	-9.75	-0.47	6.27e-20	Iron status biomarkers;
LUSC	trans	rs9860340	0.652	rs17024791	chr3:87637975	C/G	cg03644585	chr7:884825	UNC84A	0.42	6.03	0.31	4.35e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg00376283	chr12:123451042	ABCB9	0.72	11.05	0.52	2.03e-24	Platelet count;
LUSC	cis	rs113835537	0.529	rs11227514	chr11:66286627	G/A	cg24851651	chr11:66362959	CCS	0.53	7.92	0.4	3.52e-14	Airway imaging phenotypes;
LUSC	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg16558253	chr16:72132732	DHX38	-0.37	-5.92	-0.31	8.15e-9	Fibrinogen levels;
LUSC	cis	rs354225	0.584	rs6739140	chr2:54823502	C/G	cg26097391	chr2:54893211	SPTBN1	0.44	6.62	0.34	1.41e-10	Schizophrenia;
LUSC	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg14582100	chr15:45693742	SPATA5L1	0.46	8.62	0.43	2.7e-16	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg06606381	chr12:133084897	FBRSL1	-0.56	-6.99	-0.36	1.5e-11	Depression;
LUSC	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg13256891	chr4:100009986	ADH5	-0.49	-6.37	-0.33	6.11e-10	Alcohol dependence;
LUSC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.14	0.41	8.18e-15	Prudent dietary pattern;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg27249304	chr10:71906591	TYSND1	0.48	6.24	0.32	1.31e-9	Neuroticism;
LUSC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg24813613	chr7:1882135	MAD1L1	-0.43	-7.22	-0.37	3.48e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.1	-0.32	2.93e-9	Alcohol dependence;
LUSC	cis	rs12541635	0.966	rs12550587	chr8:106978289	C/T	cg10147462	chr8:107024639	NA	0.55	9.54	0.46	3.08e-19	Age of smoking initiation;
LUSC	cis	rs1413885	0.516	rs10789183	chr1:65856779	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	6.89	0.35	2.73e-11	Anticoagulant levels;
LUSC	trans	rs2018683	0.707	rs10279610	chr7:28975696	C/G	cg19402173	chr7:128379420	CALU	0.46	7.16	0.36	5.21e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11764359	chr7:65958608	NA	-0.69	-11.18	-0.52	7.06e-25	Aortic root size;
LUSC	cis	rs7903847	0.656	rs74729163	chr10:99137287	A/C	cg08345082	chr10:99160200	RRP12	-0.32	-5.65	-0.3	3.36e-8	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg21575078	chr14:105956409	C14orf80	0.4	6.1	0.32	2.9e-9	Mosquito bite size;
LUSC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg20283391	chr11:68216788	NA	-0.53	-7.95	-0.4	2.97e-14	Total body bone mineral density;
LUSC	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.23e-8	Breast cancer;
LUSC	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg04374321	chr14:90722782	PSMC1	0.76	12.04	0.55	5.82e-28	Mortality in heart failure;
LUSC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg01971132	chr11:72492946	STARD10	0.54	6.29	0.33	9.76e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9837602	1.000	rs4075038	chr3:99680086	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-6.1	-0.32	2.88e-9	Breast cancer;
LUSC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00339695	chr16:24857497	SLC5A11	0.39	6.63	0.34	1.36e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg27631724	chr1:11040367	C1orf127	0.56	10.92	0.51	6.1e-24	Ewing sarcoma;
LUSC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg26354017	chr1:205819088	PM20D1	0.8	13.77	0.6	1.75e-34	Menarche (age at onset);
LUSC	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg10978503	chr1:24200527	CNR2	-0.45	-9.45	-0.46	5.93e-19	Immature fraction of reticulocytes;
LUSC	cis	rs73198271	0.562	rs79296712	chr8:8659978	G/A	cg01851573	chr8:8652454	MFHAS1	0.66	8.94	0.44	2.73e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg17120908	chr11:65337727	SSSCA1	0.53	9.49	0.46	4.53e-19	Bone mineral density;
LUSC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.9	0.31	9.03e-9	Renal function-related traits (BUN);
LUSC	cis	rs1840108	0.529	rs35192399	chr2:181492583	T/C	cg23363182	chr2:181467187	NA	-0.46	-5.82	-0.3	1.39e-8	Anti-saccade response;
LUSC	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg10978503	chr1:24200527	CNR2	-0.46	-9.52	-0.46	3.6e-19	Immature fraction of reticulocytes;
LUSC	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg02176678	chr2:219576539	TTLL4	0.6	10.82	0.51	1.34e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs11153306	0.818	rs1476043	chr6:111944979	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.57	-0.34	1.91e-10	Tonsillectomy;
LUSC	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	16.96	0.68	5.75e-47	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg06713675	chr4:122721982	EXOSC9	-0.46	-8.04	-0.4	1.62e-14	Type 2 diabetes;
LUSC	cis	rs1014246	0.848	rs10787714	chr10:118459384	G/T	cg14919929	chr10:118506882	NA	0.46	7.17	0.37	4.93e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.93	15.82	0.65	1.76e-42	Bladder cancer;
LUSC	cis	rs12618769	0.543	rs6753380	chr2:99129040	A/G	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.12e-13	Bipolar disorder;
LUSC	cis	rs4285028	0.699	rs2689290	chr3:121585146	C/T	cg11130432	chr3:121712080	ILDR1	-0.57	-9.01	-0.44	1.63e-17	Multiple sclerosis;
LUSC	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	8.76	0.43	9.9900000000000006e-17	Total body bone mineral density;
LUSC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg15145296	chr3:125709740	NA	-0.56	-6.66	-0.34	1.1e-10	Blood pressure (smoking interaction);
LUSC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.69	-12.08	-0.55	3.97e-28	Dental caries;
LUSC	cis	rs1595825	0.891	rs16867018	chr2:198521490	C/T	cg19156104	chr2:198669113	PLCL1	-0.45	-5.69	-0.3	2.74e-8	Ulcerative colitis;
LUSC	cis	rs71403859	0.502	rs34380814	chr16:71488175	C/T	cg08717414	chr16:71523259	ZNF19	-0.7	-8.56	-0.42	4.22e-16	Post bronchodilator FEV1;
LUSC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.94	-0.36	2.04e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg13565492	chr6:43139072	SRF	-0.72	-10.08	-0.48	4.93e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1964356	0.524	rs7839585	chr8:8854235	C/G	cg11995313	chr8:8860691	ERI1	0.35	5.73	0.3	2.2e-8	Mean corpuscular volume;
LUSC	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg19748678	chr4:122722346	EXOSC9	0.48	7.29	0.37	2.22e-12	Type 2 diabetes;
LUSC	cis	rs656319	0.513	rs6985941	chr8:9983179	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-5.8	-0.3	1.54e-8	Myopia (pathological);
LUSC	cis	rs367615	0.537	rs1965670	chr5:108649798	A/T	cg17395555	chr5:108820864	NA	-0.45	-8.17	-0.41	6.58e-15	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs500891	0.547	rs1144178	chr6:84029716	A/G	cg08257003	chr6:84140564	ME1	0.34	8.05	0.4	1.43e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg21775007	chr8:11205619	TDH	-0.48	-6.62	-0.34	1.44e-10	Monocyte count;
LUSC	trans	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17712092	chr4:129076599	LARP1B	0.73	10.83	0.51	1.25e-23	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02067639	chr14:71067412	MED6	-0.41	-6.1	-0.32	2.85e-9	Electrocardiographic conduction measures;
LUSC	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg09307838	chr4:120376055	NA	0.65	9.89	0.48	2.06e-20	Corneal astigmatism;
LUSC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-9.73	-0.47	7.1e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg21361702	chr7:150065534	REPIN1	0.46	6.18	0.32	1.9e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs17255340	0.539	rs4706990	chr6:84108065	A/T	cg08257003	chr6:84140564	ME1	-0.34	-8.32	-0.41	2.23e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg14675211	chr2:100938903	LONRF2	0.37	5.77	0.3	1.78e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg23649088	chr2:200775458	C2orf69	-0.47	-6.31	-0.33	8.98e-10	Schizophrenia;
LUSC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.62	-7.82	-0.39	6.87e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	0.89	16.73	0.68	4.41e-46	Heart rate;
LUSC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	12.92	0.58	3.1e-31	Cognitive test performance;
LUSC	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg03342759	chr3:160939853	NMD3	-0.51	-8.7	-0.43	1.59e-16	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	trans	rs7939886	0.841	rs79902631	chr11:55995241	A/C	cg15704280	chr7:45808275	SEPT13	0.9	6.77	0.35	5.92e-11	Myopia (pathological);
LUSC	cis	rs1981331	1.000	rs118078026	chr21:48012129	T/C	cg17243659	chr21:48055224	PRMT2	0.86	6.24	0.32	1.31e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg11984989	chr7:158649758	WDR60	1.13	13.89	0.6	6.42e-35	Height;
LUSC	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg06028605	chr16:24865363	SLC5A11	0.48	8.67	0.43	1.97e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4974559	0.739	rs28573879	chr4:1285910	C/T	cg02980000	chr4:1222292	CTBP1	1.02	9.35	0.46	1.28e-18	Systolic blood pressure;
LUSC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg02782426	chr3:40428986	ENTPD3	-0.35	-6.91	-0.35	2.48e-11	Renal cell carcinoma;
LUSC	cis	rs1413885	0.502	rs7545397	chr1:65856282	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	7.0	0.36	1.37e-11	Anticoagulant levels;
LUSC	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg03433033	chr1:76189801	ACADM	-0.44	-6.7	-0.34	9.05e-11	Daytime sleep phenotypes;
LUSC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg15921436	chr17:44337874	NA	-0.7	-10.6	-0.5	7.91e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.62	0.43	2.69e-16	Prudent dietary pattern;
LUSC	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg08484992	chr16:88977278	CBFA2T3	-0.4	-7.28	-0.37	2.36e-12	Social autistic-like traits;
LUSC	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg04310649	chr10:35416472	CREM	-0.43	-6.56	-0.34	2.09e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg03859395	chr2:55845619	SMEK2	-0.63	-8.85	-0.44	5.26e-17	Metabolic syndrome;
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	6.88	0.35	2.93e-11	Renal function-related traits (BUN);
LUSC	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.66	10.48	0.5	2.06e-22	Morning vs. evening chronotype;
LUSC	cis	rs9677476	1.000	rs6724253	chr2:232121998	A/G	cg07929768	chr2:232055508	NA	0.3	5.7	0.3	2.69e-8	Food antigen IgG levels;
LUSC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg18402987	chr7:1209562	NA	0.7	7.64	0.39	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25152348	chr22:50946712	NCAPH2;LMF2	0.39	6.51	0.34	2.77e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg04362960	chr10:104952993	NT5C2	0.61	9.35	0.46	1.27e-18	Arsenic metabolism;
LUSC	trans	rs75804782	0.641	rs3769124	chr2:239349362	G/A	cg01134436	chr17:81009848	B3GNTL1	0.66	6.4	0.33	5.11e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg16423285	chr20:60520624	NA	-0.47	-5.94	-0.31	6.99e-9	Body mass index;
LUSC	cis	rs3135063	0.504	rs78139882	chr4:3287361	C/T	cg08817983	chr4:3391423	RGS12	-0.45	-6.42	-0.33	4.67e-10	Blood protein levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09512322	chr16:31085976	ZNF668;ZNF646	-0.44	-6.72	-0.35	7.89e-11	Electrocardiographic conduction measures;
LUSC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.71	10.77	0.51	1.99e-23	Aortic root size;
LUSC	cis	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.96	-0.31	6.24e-9	Neuroticism;
LUSC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg02018176	chr4:1364513	KIAA1530	0.47	8.21	0.41	4.75e-15	Obesity-related traits;
LUSC	cis	rs5167	0.536	rs1882752	chr19:45461342	G/C	cg25746394	chr19:45450501	APOC2	0.33	6.03	0.31	4.29e-9	Blood protein levels;
LUSC	cis	rs3764021	1.000	rs3764021	chr12:9833628	C/T	cg20894963	chr12:9885564	CLECL1	0.3	6.2	0.32	1.63e-9	Type 1 diabetes;
LUSC	cis	rs79911532	0.515	rs8509	chr7:75616577	G/A	cg03592824	chr7:75666768	STYXL1	0.64	6.4	0.33	5.28e-10	Mononucleosis;
LUSC	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg13642260	chr9:130955380	CIZ1	0.51	8.1	0.41	1.01e-14	Attention deficit hyperactivity disorder;
LUSC	cis	rs10208940	0.920	rs13417100	chr2:68821725	C/T	cg12452813	chr2:68675892	NA	-0.55	-5.75	-0.3	2.03e-8	Urate levels in lean individuals;
LUSC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.27	0.52	3.44e-25	Menopause (age at onset);
LUSC	cis	rs12900413	0.687	rs12902809	chr15:90305617	C/G	cg24249390	chr15:90295951	MESP1	-0.36	-5.81	-0.3	1.45e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	trans	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg06521331	chr12:34319734	NA	-0.4	-6.02	-0.31	4.48e-9	Morning vs. evening chronotype;
LUSC	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg14458575	chr2:238380390	NA	0.58	6.82	0.35	4.36e-11	Prostate cancer;
LUSC	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg22709100	chr7:91322751	NA	0.4	5.9	0.31	8.7e-9	Breast cancer;
LUSC	cis	rs2637266	0.783	rs860165	chr10:78492807	A/G	cg18941641	chr10:78392320	NA	0.39	7.1	0.36	7.32e-12	Pulmonary function;
LUSC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	11.02	0.52	2.78e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.96	0.51	4.32e-24	Hypertriglyceridemia;
LUSC	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg17788362	chr6:86352627	SYNCRIP	0.46	6.79	0.35	5e-11	Smooth-surface caries;
LUSC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg13866156	chr1:1669148	SLC35E2	0.53	8.7	0.43	1.59e-16	Body mass index;
LUSC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg13319975	chr6:146136371	FBXO30	-0.53	-7.95	-0.4	2.94e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg05347473	chr6:146136440	FBXO30	-0.59	-10.32	-0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg21535247	chr6:8435926	SLC35B3	0.58	9.02	0.44	1.46e-17	Motion sickness;
LUSC	cis	rs10492096	1.000	rs12422771	chr12:6580273	G/T	cg13857086	chr12:6580257	VAMP1	0.84	9.31	0.45	1.73e-18	Hip geometry;
LUSC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg12751644	chr20:60527061	NA	-0.33	-6.0	-0.31	5.13e-9	Body mass index;
LUSC	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg26513180	chr16:89883248	FANCA	-0.55	-8.53	-0.42	5.07e-16	Vitiligo;
LUSC	cis	rs3125734	0.582	rs7904465	chr10:64002393	G/A	cg19640130	chr10:64028056	RTKN2	-0.41	-7.25	-0.37	2.9e-12	Rheumatoid arthritis;
LUSC	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg20713898	chr8:124780851	FAM91A1	-0.54	-7.62	-0.38	2.65e-13	Pancreatic cancer;
LUSC	cis	rs12681287	0.605	rs13262672	chr8:87355812	T/C	cg27223183	chr8:87520930	FAM82B	-0.54	-7.15	-0.36	5.47e-12	Caudate activity during reward;
LUSC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.6	0.46	2.02e-19	Bipolar disorder;
LUSC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.61	9.26	0.45	2.5e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg03948781	chr1:205179583	DSTYK	0.33	6.32	0.33	8.42e-10	Red blood cell count;
LUSC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.14	-0.32	2.35e-9	Life satisfaction;
LUSC	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg14895029	chr7:2775587	GNA12	-0.42	-6.37	-0.33	6.42e-10	Height;
LUSC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg00012203	chr2:219082015	ARPC2	0.7	11.55	0.53	3.58e-26	Colorectal cancer;
LUSC	cis	rs12286929	0.637	rs3802858	chr11:115078492	T/C	cg04055981	chr11:115044050	NA	-0.39	-6.61	-0.34	1.55e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.16	-14.37	-0.62	8.82e-37	Breast cancer;
LUSC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06634786	chr22:41940651	POLR3H	-0.53	-6.43	-0.33	4.33e-10	Vitiligo;
LUSC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg21724239	chr8:58056113	NA	0.59	6.83	0.35	3.92e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg17211192	chr8:82754475	SNX16	-0.75	-9.94	-0.48	1.47e-20	Diastolic blood pressure;
LUSC	cis	rs603446	0.678	rs664059	chr11:116642137	C/T	cg08985259	chr11:116699649	APOC3	-0.27	-6.1	-0.32	2.87e-9	Triglycerides;
LUSC	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg05925327	chr15:68127851	NA	-0.4	-6.24	-0.32	1.35e-9	Obesity;
LUSC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg12963246	chr6:28129442	ZNF389	0.51	7.06	0.36	9.81e-12	Depression;
LUSC	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg01528321	chr10:82214614	TSPAN14	0.98	14.61	0.62	1.03e-37	Post bronchodilator FEV1;
LUSC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg26695010	chr11:65641043	EFEMP2	-0.46	-7.09	-0.36	7.8e-12	Eosinophil percentage of white cells;
LUSC	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg27608139	chr16:2294856	DCI	-0.32	-5.66	-0.3	3.31e-8	Height;
LUSC	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg01294253	chr9:136912663	BRD3	0.38	6.73	0.35	7.26e-11	Platelet distribution width;
LUSC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg13114125	chr14:105738426	BRF1	-0.95	-16.26	-0.66	3.36e-44	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-8.39	-0.42	1.36e-15	Height;
LUSC	trans	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.55	0.46	2.86e-19	Mean corpuscular volume;
LUSC	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg24812749	chr6:127587940	RNF146	0.68	9.68	0.47	1.07e-19	Breast cancer;
LUSC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06634786	chr22:41940651	POLR3H	-0.54	-6.98	-0.36	1.57e-11	Vitiligo;
LUSC	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg15556689	chr8:8085844	FLJ10661	0.63	9.88	0.48	2.28e-20	Neuroticism;
LUSC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07677032	chr17:61819896	STRADA	0.54	8.97	0.44	2.22e-17	Prudent dietary pattern;
LUSC	cis	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg06521331	chr12:34319734	NA	0.37	6.27	0.32	1.09e-9	Morning vs. evening chronotype;
LUSC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.19	-0.52	6.61e-25	Alzheimer's disease;
LUSC	cis	rs4917300	0.605	rs1388800	chr8:143106264	C/T	cg25363559	chr8:143086065	NA	0.27	6.16	0.32	2.12e-9	Amyotrophic lateral sclerosis;
LUSC	cis	rs7119167	0.636	rs56397594	chr11:73038579	T/C	cg17517138	chr11:73019481	ARHGEF17	0.5	5.85	0.3	1.16e-8	Blood protein levels;
LUSC	cis	rs7584330	0.518	rs11884238	chr2:238424671	T/G	cg14458575	chr2:238380390	NA	0.44	5.77	0.3	1.78e-8	Prostate cancer;
LUSC	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.44	-6.96	-0.36	1.77e-11	Tonsillectomy;
LUSC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg01416388	chr22:39784598	NA	-0.4	-6.05	-0.31	3.8e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg15485101	chr11:133734466	NA	-0.42	-7.46	-0.38	7.73e-13	Childhood ear infection;
LUSC	cis	rs754133	0.964	rs736825	chr12:54417576	C/G	cg10005224	chr12:54424964	HOXC4;HOXC5	0.41	8.07	0.4	1.28e-14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
LUSC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg22920501	chr2:26401640	FAM59B	0.79	11.46	0.53	7.3e-26	Gut microbiome composition (summer);
LUSC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg16049864	chr8:95962084	TP53INP1	-0.64	-12.62	-0.57	4.06e-30	Type 2 diabetes;
LUSC	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg12935359	chr14:103987150	CKB	-0.65	-10.61	-0.5	7.5e-23	Intelligence (multi-trait analysis);
LUSC	trans	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg04995722	chr7:26192034	NFE2L3	-0.42	-6.46	-0.33	3.79e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg05585544	chr11:47624801	NA	-0.41	-7.13	-0.36	6.4e-12	Subjective well-being;
LUSC	cis	rs16912285	0.535	rs6484040	chr11:24309809	C/A	ch.11.24196551F	chr11:24239977	NA	0.91	10.13	0.48	3.43e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs12677618	1.000	rs10092931	chr8:142307201	A/G	cg00131261	chr8:142287264	NA	-0.34	-5.78	-0.3	1.74e-8	Plateletcrit;
LUSC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.63	-9.58	-0.46	2.28e-19	Menarche (age at onset);
LUSC	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg08000102	chr2:233561755	GIGYF2	0.7	11.59	0.54	2.41e-26	Coronary artery disease;
LUSC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	0.84	14.22	0.61	3.22e-36	Menopause (age at onset);
LUSC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg06028605	chr16:24865363	SLC5A11	-0.45	-8.15	-0.41	7.19e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg00898013	chr13:113819073	PROZ	0.56	8.08	0.4	1.2e-14	Platelet distribution width;
LUSC	cis	rs2290159	0.800	rs2290162	chr3:12647457	A/G	cg23032965	chr3:12705835	RAF1	0.71	8.68	0.43	1.75e-16	Cholesterol, total;
LUSC	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg14696996	chr19:15285081	NOTCH3	0.99	9.07	0.44	1.06e-17	Pulse pressure;
LUSC	cis	rs35000415	0.938	rs12539476	chr7:128657483	T/C	cg19972273	chr7:128594194	NA	0.68	6.9	0.35	2.56e-11	Systemic lupus erythematosus;
LUSC	cis	rs9462027	0.628	rs2814992	chr6:34617144	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.98	-0.31	5.85e-9	Systemic lupus erythematosus;
LUSC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg23978390	chr7:1156363	C7orf50	0.48	5.7	0.3	2.68e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05901451	chr6:126070800	HEY2	0.57	8.65	0.43	2.22e-16	Endometrial cancer;
LUSC	cis	rs4845570	1.000	rs6681093	chr1:151755284	C/G	cg07092448	chr1:151763213	TDRKH	-1.02	-10.24	-0.49	1.41e-21	Coronary artery disease;
LUSC	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.78	11.21	0.52	5.56e-25	Corneal astigmatism;
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.42	6.21	0.32	1.57e-9	Longevity;Endometriosis;
LUSC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg16405210	chr4:1374714	KIAA1530	0.55	8.35	0.42	1.86e-15	Obesity-related traits;
LUSC	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.84	12.36	0.56	3.71e-29	Cognitive ability;
LUSC	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.91	0.31	8.61e-9	Breast cancer;
LUSC	cis	rs6906287	0.647	rs6902812	chr6:118936294	A/G	cg21191810	chr6:118973309	C6orf204	0.32	5.91	0.31	8.23e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg11752832	chr7:134001865	SLC35B4	0.51	7.74	0.39	1.22e-13	Mean platelet volume;
LUSC	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg03806693	chr22:41940476	POLR3H	-0.96	-13.04	-0.58	1.08e-31	Vitiligo;
LUSC	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg05925327	chr15:68127851	NA	-0.38	-6.04	-0.31	4.22e-9	Restless legs syndrome;
LUSC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg26373071	chr5:1325741	CLPTM1L	0.43	8.08	0.4	1.17e-14	Lung cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22654626	chr19:18699620	C19orf60	0.49	7.93	0.4	3.38e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	18.9	0.72	1.12e-54	Chronic sinus infection;
LUSC	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg17509989	chr5:176798049	RGS14	-0.67	-9.28	-0.45	2.18e-18	Urate levels in lean individuals;
LUSC	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg25930673	chr12:123319894	HIP1R	-0.72	-7.24	-0.37	3.14e-12	Schizophrenia;
LUSC	cis	rs500891	0.574	rs10485147	chr6:84123350	A/T	cg08257003	chr6:84140564	ME1	0.37	9.02	0.44	1.56e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg07148914	chr20:33460835	GGT7	0.55	8.35	0.42	1.79e-15	Height;
LUSC	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-7.85	-0.39	5.54e-14	Chronic sinus infection;
LUSC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg06008330	chr7:65541103	ASL	0.39	6.06	0.31	3.62e-9	Aortic root size;
LUSC	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg19628046	chr18:33552617	C18orf21	-0.52	-6.36	-0.33	6.55e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg24642439	chr20:33292090	TP53INP2	-0.51	-7.69	-0.39	1.69e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg13334819	chr7:99746414	C7orf59	-0.5	-6.73	-0.35	7.41e-11	Coronary artery disease;
LUSC	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg26061582	chr7:22766209	IL6	0.49	7.45	0.38	7.86e-13	Lung cancer;
LUSC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg02079420	chr8:82753780	SNX16	-0.38	-5.79	-0.3	1.64e-8	Diastolic blood pressure;
LUSC	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.84	-0.35	3.68e-11	Response to antipsychotic treatment;
LUSC	cis	rs9308433	0.529	rs4655246	chr1:214502898	G/C	cg06198575	chr1:214491504	SMYD2	0.45	7.09	0.36	8.16e-12	IgG glycosylation;
LUSC	cis	rs8114671	0.967	rs6142321	chr20:33788474	G/A	cg07148914	chr20:33460835	GGT7	-0.44	-6.52	-0.34	2.66e-10	Height;
LUSC	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.18	0.41	5.99e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg03585969	chr10:35415529	CREM	0.64	9.51	0.46	4e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg06145435	chr7:1022769	CYP2W1	0.29	5.96	0.31	6.5e-9	Longevity;Endometriosis;
LUSC	cis	rs1595825	0.786	rs74484541	chr2:198894223	T/C	cg00982548	chr2:198649783	BOLL	-0.54	-6.89	-0.35	2.72e-11	Ulcerative colitis;
LUSC	cis	rs6987853	0.933	rs6980507	chr8:42383084	A/G	cg09913449	chr8:42400586	C8orf40	0.44	7.35	0.37	1.51e-12	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.77	-12.69	-0.57	2.12e-30	Aortic root size;
LUSC	cis	rs1408224	0.688	rs1773122	chr13:47222433	A/G	cg19833103	chr13:47126551	LRCH1	-0.4	-5.77	-0.3	1.79e-8	QRS complex (12-leadsum);
LUSC	trans	rs2018683	0.621	rs10261556	chr7:28976636	G/T	cg19402173	chr7:128379420	CALU	-0.52	-7.91	-0.4	3.89e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12145833	0.538	rs4658547	chr1:243391131	T/G	cg02356786	chr1:243265016	LOC731275	-0.63	-5.7	-0.3	2.66e-8	Obesity (early onset extreme);
LUSC	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg17173187	chr15:85201210	NMB	0.53	9.87	0.48	2.46e-20	Schizophrenia;
LUSC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg22800045	chr5:56110881	MAP3K1	-0.61	-8.51	-0.42	5.91e-16	Initial pursuit acceleration;
LUSC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg19920283	chr7:105172520	RINT1	-0.58	-6.24	-0.32	1.36e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg05555928	chr11:63887634	MACROD1	0.47	9.0	0.44	1.8e-17	Platelet count;
LUSC	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg04055107	chr11:65626734	MUS81;CFL1	0.52	6.31	0.33	9.12e-10	Crohn's disease;
LUSC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg09034736	chr1:150693464	HORMAD1	0.46	6.49	0.33	3.13e-10	Melanoma;
LUSC	cis	rs9308433	0.643	rs955920	chr1:214464309	G/A	cg06198575	chr1:214491504	SMYD2	0.44	6.73	0.35	7.55e-11	IgG glycosylation;
LUSC	cis	rs4851254	0.626	rs13001783	chr2:100689652	A/T	cg07810366	chr2:100720526	AFF3	-0.45	-6.06	-0.31	3.7e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg12559939	chr2:27858050	GPN1	0.39	6.03	0.31	4.3e-9	Oral cavity cancer;
LUSC	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.35	5.98	0.31	5.84e-9	Coronary artery disease;
LUSC	cis	rs6500395	1.000	rs8058362	chr16:48645316	T/C	cg04672837	chr16:48644449	N4BP1	0.48	7.06	0.36	9.74e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.88	14.52	0.62	2.28e-37	Bladder cancer;
LUSC	cis	rs975210	0.652	rs4777230	chr15:70365762	A/G	cg01666796	chr15:70364327	TLE3	-0.66	-7.42	-0.38	9.78e-13	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LUSC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg12463550	chr7:65579703	CRCP	-0.44	-6.55	-0.34	2.18e-10	Aortic root size;
LUSC	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg26850624	chr5:429559	AHRR	-0.37	-6.76	-0.35	6.09e-11	Cystic fibrosis severity;
LUSC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.19	15.61	0.65	1.22e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs977987	0.815	rs11149821	chr16:75422817	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.2	-0.37	4.07e-12	Dupuytren's disease;
LUSC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.73	12.12	0.55	2.84e-28	Coronary artery disease;
LUSC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg11062466	chr8:58055876	NA	0.49	6.49	0.33	3.19e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg23093090	chr10:104574429	C10orf26	-0.47	-5.76	-0.3	1.94e-8	Arsenic metabolism;
LUSC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg11247378	chr22:39784982	NA	-0.67	-13.68	-0.6	3.81e-34	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.87	-14.28	-0.62	1.84e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg27661571	chr11:113659931	NA	-0.62	-7.45	-0.38	8.21e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg17031739	chr1:67600172	NA	0.49	7.59	0.38	3.26e-13	Psoriasis;
LUSC	trans	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg27411982	chr8:10470053	RP1L1	0.43	6.49	0.33	3.05e-10	Neuroticism;
LUSC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	0.92	13.86	0.6	7.98e-35	Breast cancer;
LUSC	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg11473876	chr11:109292803	C11orf87	0.39	6.32	0.33	8.41e-10	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg04450456	chr4:17643702	FAM184B	0.39	6.65	0.34	1.18e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.37	5.67	0.3	3.02e-8	Educational attainment;
LUSC	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg15704280	chr7:45808275	SEPT13	-0.46	-6.35	-0.33	6.87e-10	HDL cholesterol;
LUSC	cis	rs7246967	0.611	rs62118780	chr19:22831114	C/G	cg23217946	chr19:22817039	ZNF492	0.45	6.04	0.31	4.09e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg00990874	chr7:1149470	C7orf50	-0.6	-7.7	-0.39	1.56e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs3931020	0.688	rs277375	chr1:75204143	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.58	7.87	0.4	4.88e-14	Resistin levels;
LUSC	cis	rs7119	0.635	rs2667767	chr15:77876031	T/C	cg27398640	chr15:77910606	LINGO1	0.37	8.52	0.42	5.44e-16	Type 2 diabetes;
LUSC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg18681998	chr4:17616180	MED28	0.81	13.89	0.61	5.89e-35	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg23555395	chr2:238036564	NA	-0.47	-8.25	-0.41	3.6e-15	Systemic lupus erythematosus;
LUSC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg16362232	chr11:430036	ANO9	0.66	8.14	0.41	7.98e-15	Body mass index;
LUSC	cis	rs1568889	1.000	rs16917689	chr11:28064466	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.51	0.46	3.95e-19	Bipolar disorder;
LUSC	cis	rs7615316	1.000	rs9862919	chr3:142341146	G/A	cg16271453	chr3:142027066	XRN1	-0.36	-6.2	-0.32	1.64e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.8	11.8	0.54	4.09e-27	Corneal astigmatism;
LUSC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg12463550	chr7:65579703	CRCP	-0.55	-8.16	-0.41	6.86e-15	Aortic root size;
LUSC	cis	rs500891	0.574	rs13214484	chr6:84133338	T/C	cg08257003	chr6:84140564	ME1	0.36	8.59	0.43	3.3e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.79	-13.4	-0.59	4.64e-33	Schizophrenia;
LUSC	trans	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg25206134	chr2:45395956	NA	0.6	6.51	0.34	2.73e-10	Neuroticism;
LUSC	trans	rs9409565	0.826	rs9409546	chr9:97209066	T/C	cg05679027	chr9:99775184	HIATL2	-0.49	-7.07	-0.36	9.02e-12	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg12863693	chr15:85201151	NMB	0.35	7.57	0.38	3.56e-13	Schizophrenia;
LUSC	cis	rs6076065	0.723	rs6137922	chr20:23363773	G/A	cg11657817	chr20:23433608	CST11	0.43	8.09	0.4	1.11e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1355223	0.752	rs286893	chr11:34674882	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.43	6.08	0.32	3.22e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.82	-12.89	-0.58	3.76e-31	Cognitive test performance;
LUSC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-6.1	-0.32	2.9e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg17971929	chr21:40555470	PSMG1	0.74	12.6	0.57	4.88e-30	Cognitive function;
LUSC	cis	rs17604090	0.756	rs10249388	chr7:29729135	G/T	cg19413766	chr7:29689036	LOC646762	-0.66	-7.92	-0.4	3.48e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	8.63	0.43	2.47e-16	Mood instability;
LUSC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg12463550	chr7:65579703	CRCP	0.42	6.01	0.31	4.78e-9	Calcium levels;
LUSC	cis	rs10992471	0.528	rs10514815	chr9:95256695	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.35	-6.02	-0.31	4.68e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.6	-9.92	-0.48	1.64e-20	Post bronchodilator FEV1;
LUSC	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg08085267	chr17:45401833	C17orf57	0.5	6.99	0.36	1.54e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.46	6.33	0.33	7.7e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg26446133	chr18:72167187	CNDP2	-0.77	-9.1	-0.45	8.32e-18	Refractive error;
LUSC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.74	-0.3	2.14e-8	Parkinson's disease;
LUSC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.4	0.38	1.12e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	trans	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg10756647	chr7:56101905	PSPH	0.87	8.84	0.44	5.54e-17	Diabetic kidney disease;
LUSC	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-8.52	-0.42	5.74e-16	Hepatocellular carcinoma;
LUSC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg25124228	chr12:125621409	AACS	0.46	7.64	0.39	2.3e-13	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-0.89	-12.86	-0.58	5.17e-31	Asthma;
LUSC	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.7	0.39	1.6e-13	Iron status biomarkers;
LUSC	cis	rs9547692	0.938	rs55639205	chr13:37469994	A/C	cg01493522	chr13:37497338	NA	-0.44	-6.28	-0.32	1.07e-9	Coronary artery disease;
LUSC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg03146154	chr1:46216737	IPP	-0.5	-7.19	-0.37	4.3e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	0.89	13.09	0.58	7.03e-32	Triglycerides;
LUSC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg12463550	chr7:65579703	CRCP	0.52	7.46	0.38	7.59e-13	Aortic root size;
LUSC	trans	rs3857536	0.813	rs7771716	chr6:66946769	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg21681030	chr2:46777652	RHOQ	0.49	6.84	0.35	3.84e-11	Height;
LUSC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg04727924	chr7:799746	HEATR2	-0.57	-5.98	-0.31	5.74e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg25703541	chr22:24373054	LOC391322	-0.92	-16.67	-0.67	7.97e-46	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	0.9	14.1	0.61	9.62e-36	Bladder cancer;
LUSC	cis	rs28830936	0.966	rs17733613	chr15:41917585	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.27	-0.32	1.13e-9	Diastolic blood pressure;
LUSC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.57	-9.66	-0.47	1.29e-19	Lung cancer;
LUSC	trans	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.76	-0.35	6.14e-11	Endometrial cancer;
LUSC	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg24375607	chr4:120327624	NA	0.79	11.68	0.54	1.17e-26	Corneal astigmatism;
LUSC	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06022373	chr22:39101656	GTPBP1	0.79	13.25	0.59	1.76e-32	Menopause (age at onset);
LUSC	cis	rs716316	0.590	rs6135309	chr20:14902522	C/T	cg04470754	chr20:14904432	MACROD2	-0.5	-8.08	-0.4	1.19e-14	Advanced glycation end-product levels;
LUSC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg03354898	chr7:1950403	MAD1L1	-0.45	-8.92	-0.44	3.02e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs909341	0.909	rs1295810	chr20:62330484	G/A	cg09650180	chr20:62225654	GMEB2	-0.44	-5.72	-0.3	2.35e-8	Atopic dermatitis;
LUSC	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg22676075	chr6:135203613	NA	0.58	9.02	0.44	1.46e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.13	-0.36	6.08e-12	Longevity;Endometriosis;
LUSC	cis	rs4566357	1.000	rs10933167	chr2:227925969	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.89	-0.31	9.43e-9	Coronary artery disease;
LUSC	cis	rs7523050	0.643	rs34096625	chr1:109401101	G/A	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	cis	rs6740322	0.748	rs6756625	chr2:43489313	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.49	6.52	0.34	2.54e-10	Coronary artery disease;
LUSC	trans	rs13130787	0.966	rs13105254	chr4:94842776	C/T	cg00867694	chr14:91884854	CCDC88C	-0.4	-6.29	-0.33	9.99e-10	Colorectal cancer;
LUSC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg22117172	chr7:91764530	CYP51A1	0.32	5.71	0.3	2.53e-8	Breast cancer;
LUSC	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg03894339	chr8:19674705	INTS10	0.58	7.84	0.39	5.95e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3931020	0.688	rs405445	chr1:75221150	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.63	-8.61	-0.43	2.95e-16	Resistin levels;
LUSC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.43	-6.18	-0.32	1.89e-9	Longevity;Endometriosis;
LUSC	trans	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg26043149	chr18:55253948	FECH	0.48	7.14	0.36	5.91e-12	Bone mineral density;
LUSC	cis	rs9831754	0.906	rs7611939	chr3:78392751	A/C	cg06138941	chr3:78371609	NA	-0.66	-8.99	-0.44	1.87e-17	Calcium levels;
LUSC	cis	rs838147	0.760	rs281408	chr19:49233406	A/C	cg21064579	chr19:49206444	FUT2	0.33	5.7	0.3	2.7e-8	Dietary macronutrient intake;
LUSC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg24733560	chr20:60626293	TAF4	0.38	6.26	0.32	1.18e-9	Body mass index;
LUSC	trans	rs7916697	0.626	rs61854803	chr10:70014638	T/C	cg04882175	chr6:131122610	NA	-0.51	-6.84	-0.35	3.83e-11	Optic disc area;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00435006	chr16:1877199	HAGH;FAHD1	-0.46	-6.32	-0.33	8.14e-10	Hepatitis;
LUSC	cis	rs501916	0.796	rs75186419	chr15:48043934	G/A	cg16110827	chr15:48056943	SEMA6D	-0.46	-7.05	-0.36	1.03e-11	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21724239	chr8:58056113	NA	-0.88	-9.74	-0.47	6.52e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	8.97	0.44	2.12e-17	Monocyte count;
LUSC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-5.75	-0.3	2.03e-8	Vitiligo;
LUSC	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.74	13.97	0.61	3.11e-35	Multiple sclerosis;
LUSC	cis	rs2637266	0.935	rs2579727	chr10:78395497	A/C	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.95e-13	Pulmonary function;
LUSC	trans	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg10756647	chr7:56101905	PSPH	-0.86	-8.52	-0.42	5.52e-16	Diabetic kidney disease;
LUSC	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg07701084	chr6:150067640	NUP43	0.5	7.44	0.38	8.36e-13	Lung cancer;
LUSC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg00522288	chr12:125625016	AACS	-0.31	-5.74	-0.3	2.14e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg04207045	chr7:99647562	ZSCAN21	0.41	6.35	0.33	7.21e-10	Mosquito bite size;
LUSC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	0.97	14.15	0.61	6.21e-36	Vitiligo;
LUSC	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg20026190	chr17:76395443	PGS1	0.44	7.75	0.39	1.11e-13	HDL cholesterol levels;
LUSC	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg15997130	chr1:24165203	NA	0.52	8.58	0.43	3.6e-16	Immature fraction of reticulocytes;
LUSC	cis	rs2235544	0.565	rs635059	chr1:54469120	G/C	cg25741118	chr1:54482237	LDLRAD1	0.28	6.04	0.31	4.04e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs6460942	0.591	rs10262667	chr7:12385391	C/T	cg06484146	chr7:12443880	VWDE	-0.52	-6.38	-0.33	5.87e-10	Coronary artery disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11686214	chr19:59084984	MZF1;LOC100131691	-0.45	-6.93	-0.35	2.11e-11	Electrocardiographic conduction measures;
LUSC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.09	-0.45	8.97e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg13126279	chr21:47581558	C21orf56	0.43	6.4	0.33	5.27e-10	Testicular germ cell tumor;
LUSC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg06784218	chr1:46089804	CCDC17	0.56	11.13	0.52	1.11e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg00603717	chr13:46039090	COG3	0.42	6.08	0.32	3.31e-9	Eotaxin levels;
LUSC	cis	rs6430585	0.527	rs961360	chr2:136393658	A/G	cg07169764	chr2:136633963	MCM6	1.07	13.98	0.61	2.71e-35	Corneal structure;
LUSC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.07	-0.32	3.47e-9	Personality dimensions;
LUSC	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg18132916	chr6:79620363	NA	-0.41	-6.3	-0.33	9.63e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs5758511	0.731	rs5751186	chr22:42349710	G/A	cg12850546	chr22:42539477	CYP2D7P1	0.47	5.85	0.31	1.14e-8	Birth weight;
LUSC	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	0.96	15.1	0.64	1.2e-39	Dupuytren's disease;
LUSC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg12463550	chr7:65579703	CRCP	-0.43	-6.36	-0.33	6.61e-10	Aortic root size;
LUSC	cis	rs3771570	1.000	rs62186422	chr2:242249499	A/G	cg21155796	chr2:242212141	HDLBP	0.67	7.52	0.38	5.23e-13	Prostate cancer;
LUSC	cis	rs2637266	0.783	rs1660908	chr10:78494856	T/C	cg18941641	chr10:78392320	NA	0.39	7.2	0.37	4.13e-12	Pulmonary function;
LUSC	cis	rs3741151	0.686	rs11823913	chr11:73141627	C/G	cg17517138	chr11:73019481	ARHGEF17	0.8	7.35	0.37	1.56e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg18230493	chr5:56204884	C5orf35	-0.89	-13.64	-0.6	5.59e-34	Initial pursuit acceleration;
LUSC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg09904177	chr6:26538194	HMGN4	0.65	11.28	0.53	3.25e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg26924012	chr15:45694286	SPATA5L1	1.14	20.79	0.75	3.36e-62	Homoarginine levels;
LUSC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18099408	chr3:52552593	STAB1	-0.37	-6.47	-0.33	3.49e-10	Electroencephalogram traits;
LUSC	cis	rs7586879	0.828	rs13012304	chr2:25122246	C/T	cg01884057	chr2:25150051	NA	0.42	8.8	0.43	7.49e-17	Body mass index;
LUSC	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg20701182	chr2:24300061	SF3B14	0.58	6.18	0.32	1.82e-9	Lymphocyte counts;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg21577260	chr17:73285714	SLC25A19	0.49	6.44	0.33	4.11e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7107174	0.901	rs1046780	chr11:77926769	A/G	cg02023728	chr11:77925099	USP35	0.5	7.24	0.37	3.18e-12	Testicular germ cell tumor;
LUSC	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg09367891	chr1:107599246	PRMT6	0.46	6.8	0.35	4.93e-11	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg07828024	chr6:149772892	ZC3H12D	0.34	7.31	0.37	1.93e-12	Dupuytren's disease;
LUSC	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.85	0.68	1.53e-46	Exhaled nitric oxide output;
LUSC	cis	rs2979489	0.891	rs2979511	chr8:30394968	G/A	cg26383811	chr8:30366931	RBPMS	-0.52	-8.16	-0.41	6.8e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg26752003	chr8:145688521	CYHR1	-0.59	-10.03	-0.48	7.31e-21	Age at first birth;
LUSC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg16325326	chr1:53192061	ZYG11B	0.69	11.18	0.52	7.53e-25	Monocyte count;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04297258	chr16:88772664	RNF166;CTU2	0.43	6.19	0.32	1.74e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg20701182	chr2:24300061	SF3B14	0.54	5.73	0.3	2.2e-8	Lymphocyte counts;
LUSC	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.72	9.63	0.47	1.56e-19	Migraine;Coronary artery disease;
LUSC	cis	rs57590327	0.555	rs13072957	chr3:81776242	A/G	cg07356753	chr3:81810745	GBE1	0.67	10.71	0.51	3.32e-23	Extraversion;
LUSC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg15335139	chr3:50242325	SLC38A3	-0.25	-5.71	-0.3	2.5e-8	Body mass index;
LUSC	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg17764715	chr19:33622953	WDR88	0.6	8.81	0.43	6.93e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg01733217	chr16:74700730	RFWD3	0.97	22.15	0.77	1.61e-67	Multiple myeloma;
LUSC	cis	rs354225	0.608	rs168505	chr2:54920968	C/T	cg26097391	chr2:54893211	SPTBN1	0.34	5.68	0.3	2.88e-8	Schizophrenia;
LUSC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg13560548	chr3:10150139	C3orf24	0.53	7.55	0.38	4.21e-13	Alzheimer's disease;
LUSC	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17467752	chr17:38218738	THRA	0.77	12.45	0.56	1.7e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg00898013	chr13:113819073	PROZ	0.55	8.28	0.41	3.02e-15	Platelet distribution width;
LUSC	trans	rs2229238	0.911	rs59838898	chr1:154466301	C/T	cg25273160	chr11:56955011	LRRC55	0.31	6.05	0.31	3.81e-9	Coronary heart disease;
LUSC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.57	-0.46	2.51e-19	Gut microbiome composition (summer);
LUSC	cis	rs977987	0.806	rs4888420	chr16:75462998	G/C	cg03315344	chr16:75512273	CHST6	0.5	9.56	0.46	2.75e-19	Dupuytren's disease;
LUSC	cis	rs7523273	0.606	rs2281289	chr1:207978916	C/T	cg22525895	chr1:207977042	MIR29B2	-0.39	-6.27	-0.32	1.09e-9	Schizophrenia;
LUSC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg09034736	chr1:150693464	HORMAD1	-0.5	-7.28	-0.37	2.38e-12	Tonsillectomy;
LUSC	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg02018176	chr4:1364513	KIAA1530	0.45	6.34	0.33	7.29e-10	Recombination rate (females);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25783469	chr7:73256908	WBSCR27	0.43	6.7	0.34	9.05e-11	Schizophrenia;
LUSC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.11	-0.48	3.98e-21	Hemoglobin concentration;
LUSC	cis	rs2692947	0.726	rs13019188	chr2:96774199	A/G	cg23100626	chr2:96804247	ASTL	-0.26	-6.48	-0.33	3.3e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-0.87	-12.57	-0.57	6.19e-30	Dilated cardiomyopathy;
LUSC	trans	rs1864729	1.000	rs2439702	chr8:98272647	C/T	cg08679828	chr8:102218111	ZNF706	-0.83	-7.54	-0.38	4.47e-13	Estradiol plasma levels (breast cancer);
LUSC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg11663144	chr21:46675770	NA	-0.41	-7.03	-0.36	1.15e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg21770322	chr7:97807741	LMTK2	0.44	7.61	0.38	2.79e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs939574	1.000	rs908196	chr2:220088248	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.96	-8.43	-0.42	1.05e-15	Platelet distribution width;
LUSC	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg17845761	chr1:175162550	KIAA0040	-0.31	-6.0	-0.31	5.07e-9	Alcohol dependence;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg01219670	chr7:76054755	ZP3	0.39	5.97	0.31	6.06e-9	Cognitive function;Information processing speed;
LUSC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	8.93	0.44	2.98e-17	Prudent dietary pattern;
LUSC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	0.95	18.98	0.72	5.3e-55	Cognitive function;
LUSC	cis	rs3755132	0.568	rs876718	chr2:15808935	A/G	cg12888861	chr2:15731646	DDX1	-0.5	-5.68	-0.3	2.86e-8	Wilms tumor;
LUSC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg20573242	chr4:122745356	CCNA2	0.43	6.65	0.34	1.19e-10	Type 2 diabetes;
LUSC	cis	rs1018697	0.518	rs284846	chr10:104557290	T/C	cg04362960	chr10:104952993	NT5C2	-0.65	-7.73	-0.39	1.31e-13	Colorectal adenoma (advanced);
LUSC	cis	rs17095355	0.584	rs12243027	chr10:111924817	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.65	-0.34	1.19e-10	Biliary atresia;
LUSC	cis	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg06521331	chr12:34319734	NA	0.4	6.5	0.34	2.87e-10	Morning vs. evening chronotype;
LUSC	cis	rs2932538	0.961	rs10745332	chr1:113189053	G/A	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.75	-0.47	6.14e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-1.09	-26.84	-0.83	2.17e-85	Testicular germ cell tumor;
LUSC	trans	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07923666	chr12:49932857	KCNH3	-0.5	-6.36	-0.33	6.67e-10	Resting heart rate;
LUSC	cis	rs4776059	0.916	rs4774636	chr15:52968193	A/C	cg22715398	chr15:52968154	KIAA1370	-0.66	-9.09	-0.45	9.04e-18	Schizophrenia;
LUSC	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.02	-22.11	-0.77	2.3e-67	Ulcerative colitis;
LUSC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg23978390	chr7:1156363	C7orf50	0.44	6.29	0.33	1.02e-9	Longevity;Endometriosis;
LUSC	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.9	-0.4	4.1e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg18187862	chr3:45730750	SACM1L	0.54	6.86	0.35	3.4e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg00857998	chr1:205179979	DSTYK	-0.61	-9.48	-0.46	4.87e-19	Red blood cell count;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg12026095	chr19:49468461	FTL	-0.5	-7.36	-0.37	1.48e-12	Cognitive function;Information processing speed;
LUSC	cis	rs7584330	0.666	rs1574530	chr2:238395708	A/T	cg14458575	chr2:238380390	NA	0.45	5.84	0.3	1.24e-8	Prostate cancer;
LUSC	cis	rs9837602	0.872	rs35154249	chr3:99738230	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.72	-0.3	2.37e-8	Breast cancer;
LUSC	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg00745463	chr17:30367425	LRRC37B	-0.75	-9.11	-0.45	8.01e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg24631222	chr15:78858424	CHRNA5	-0.66	-8.64	-0.43	2.3e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.37	-5.66	-0.3	3.3e-8	Ulcerative colitis;
LUSC	trans	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg21775007	chr8:11205619	TDH	0.41	6.04	0.31	4.05e-9	Mood instability;
LUSC	cis	rs73206853	0.563	rs73194040	chr12:111181106	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	7.37	0.37	1.38e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg03180552	chr7:157981849	PTPRN2	0.41	7.39	0.37	1.18e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg12826209	chr6:26865740	GUSBL1	0.67	5.84	0.3	1.27e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2898681	0.561	rs2200225	chr4:53738411	A/G	cg00791764	chr4:53727839	RASL11B	0.47	7.0	0.36	1.45e-11	Optic nerve measurement (cup area);
LUSC	cis	rs141518190	1	rs141518190	chr15:78900647	A/G	cg06917634	chr15:78832804	PSMA4	-0.44	-5.91	-0.31	8.24e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.19	-0.41	5.43e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg24060327	chr5:131705240	SLC22A5	0.67	11.21	0.52	5.78e-25	Blood metabolite levels;
LUSC	cis	rs3768617	0.966	rs6669796	chr1:183082825	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.48	0.42	7.3e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs193541	0.507	rs2407400	chr5:122080600	C/G	cg19077854	chr5:122220652	SNX24	-0.27	-6.25	-0.32	1.26e-9	Glucose homeostasis traits;
LUSC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-6.31	-0.33	9.06e-10	Monocyte count;
LUSC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06112835	chr11:68658793	MRPL21	0.51	7.81	0.39	7.24e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-7.9	-0.4	3.96e-14	Personality dimensions;
LUSC	cis	rs977987	0.654	rs8054194	chr16:75497160	G/T	cg04384234	chr16:75411784	CFDP1	-0.49	-7.93	-0.4	3.27e-14	Dupuytren's disease;
LUSC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg06454157	chr6:167490870	NA	-0.24	-6.04	-0.31	4.19e-9	Crohn's disease;
LUSC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.62	-8.21	-0.41	4.89e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg25566285	chr7:158114605	PTPRN2	0.32	5.8	0.3	1.56e-8	Calcium levels;
LUSC	cis	rs6733011	0.518	rs12992214	chr2:99466337	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-5.9	-0.31	8.96e-9	Bipolar disorder;
LUSC	cis	rs2970818	0.831	rs11063214	chr12:4635045	A/G	cg11146114	chr12:4671731	NA	-0.59	-5.88	-0.31	1.01e-8	Phosphorus levels;
LUSC	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg02493740	chr2:85810744	VAMP5	-0.38	-6.67	-0.34	1.04e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00166722	chr3:10149974	C3orf24	0.58	7.8	0.39	8.09e-14	Alzheimer's disease;
LUSC	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg14809332	chr8:144654887	C8orf73	0.56	6.64	0.34	1.25e-10	Attention deficit hyperactivity disorder;
LUSC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21582582	chr3:182698605	DCUN1D1	0.48	8.4	0.42	1.29e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg22676075	chr6:135203613	NA	0.59	9.4	0.46	9.14e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg00409905	chr10:38381863	ZNF37A	-0.34	-5.65	-0.3	3.53e-8	Breast cancer;
LUSC	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg05294307	chr14:35346193	BAZ1A	-0.56	-6.74	-0.35	6.84e-11	Psoriasis;
LUSC	cis	rs4786125	0.587	rs12920700	chr16:6926397	C/T	cg03623568	chr16:6915990	A2BP1	-0.48	-8.15	-0.41	7.63e-15	Heart rate variability traits (SDNN);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg11618704	chr10:43904553	HNRNPF	0.45	6.57	0.34	1.98e-10	Triglycerides;
LUSC	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.68	-0.3	2.93e-8	Alzheimer's disease (survival time);
LUSC	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg21251018	chr6:28226885	NKAPL	-0.31	-5.77	-0.3	1.82e-8	Pubertal anthropometrics;
LUSC	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg15485101	chr11:133734466	NA	0.35	6.2	0.32	1.66e-9	Childhood ear infection;
LUSC	cis	rs2290159	0.948	rs9852128	chr3:12635623	A/G	cg23032965	chr3:12705835	RAF1	0.54	7.03	0.36	1.2e-11	Cholesterol, total;
LUSC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg16099169	chr2:106886729	NA	-0.51	-6.55	-0.34	2.19e-10	Facial morphology (factor 23);
LUSC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06850241	chr22:41845214	NA	-0.3	-5.83	-0.3	1.28e-8	Vitiligo;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg14524403	chr9:136325208	C9orf7	0.42	6.04	0.31	4.03e-9	Mosquito bite size;
LUSC	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg22496339	chr2:162101262	NA	0.52	7.54	0.38	4.48e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg09238746	chr17:78121135	EIF4A3	-0.6	-8.95	-0.44	2.44e-17	Yeast infection;
LUSC	cis	rs79911532	0.515	rs112615204	chr7:75760909	C/T	cg03592824	chr7:75666768	STYXL1	0.67	6.37	0.33	6.32e-10	Mononucleosis;
LUSC	cis	rs9650315	0.866	rs11992729	chr8:57188153	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.88	0.35	3.01e-11	Height;
LUSC	cis	rs983392	0.679	rs654415	chr11:60013674	G/A	cg24026212	chr11:59952134	MS4A6A	0.36	6.3	0.33	9.17e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg17507749	chr15:85114479	UBE2QP1	0.54	5.99	0.31	5.56e-9	Schizophrenia;
LUSC	cis	rs7570971	0.500	rs13413101	chr2:135859371	A/T	cg07169764	chr2:136633963	MCM6	0.5	6.57	0.34	1.92e-10	Blood metabolite levels;Body mass index;Cholesterol, total;
LUSC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.85	-13.16	-0.58	3.91e-32	Systemic lupus erythematosus;
LUSC	cis	rs80282103	0.764	rs10047383	chr10:1103095	A/G	cg08668510	chr10:1095578	IDI1	0.67	5.91	0.31	8.35e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg14696996	chr19:15285081	NOTCH3	1.02	9.37	0.46	1.15e-18	Pulse pressure;
LUSC	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg05472934	chr7:22766657	IL6	0.52	8.08	0.4	1.2e-14	Lung cancer;
LUSC	cis	rs701145	0.878	rs355774	chr3:154036196	A/G	cg17054900	chr3:154042577	DHX36	0.84	8.81	0.43	7.07e-17	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg13206674	chr6:150067644	NUP43	0.6	9.49	0.46	4.58e-19	Lung cancer;
LUSC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22442454	chr1:209979470	IRF6	0.45	6.13	0.32	2.48e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs7712401	0.562	rs62377399	chr5:122324679	G/A	cg19077854	chr5:122220652	SNX24	-0.43	-9.48	-0.46	4.83e-19	Mean platelet volume;
LUSC	cis	rs5758511	0.514	rs5758626	chr22:42572363	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.57	9.7	0.47	8.94e-20	Birth weight;
LUSC	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg12559939	chr2:27858050	GPN1	0.4	6.32	0.33	8.49e-10	Oral cavity cancer;
LUSC	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg06636001	chr8:8085503	FLJ10661	0.63	9.66	0.47	1.22e-19	Joint mobility (Beighton score);
LUSC	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg15445000	chr17:37608096	MED1	0.39	6.58	0.34	1.86e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg20368463	chr18:77673604	PQLC1	-0.72	-11.43	-0.53	8.93e-26	Schizophrenia;
LUSC	cis	rs7539542	0.516	rs10732291	chr1:202891168	G/A	cg19681188	chr1:202830198	LOC148709	0.41	6.12	0.32	2.64e-9	Mean platelet volume;
LUSC	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg24562669	chr7:97807699	LMTK2	0.45	8.09	0.4	1.1e-14	Breast cancer;
LUSC	cis	rs1775715	0.737	rs2799031	chr10:32173168	C/T	cg26784012	chr10:32216390	ARHGAP12	0.46	7.86	0.4	5.38e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.12	-0.32	2.57e-9	Monocyte count;
LUSC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	8.71	0.43	1.45e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.27	0.37	2.54e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12756686	chr19:29218302	NA	0.68	9.28	0.45	2.12e-18	Methadone dose in opioid dependence;
LUSC	cis	rs11958404	0.932	rs12514557	chr5:157418954	T/C	cg05962755	chr5:157440814	NA	0.51	6.21	0.32	1.58e-9	IgG glycosylation;
LUSC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg04398451	chr17:18023971	MYO15A	-0.48	-7.71	-0.39	1.44e-13	Total body bone mineral density;
LUSC	cis	rs7577851	0.715	rs67340771	chr2:69615794	G/C	cg10773587	chr2:69614142	GFPT1	0.58	6.43	0.33	4.53e-10	Parkinson's disease (age of onset);
LUSC	cis	rs11023332	0.832	rs10832289	chr11:14669496	A/T	cg19336497	chr11:14380999	RRAS2	0.36	7.05	0.36	1.04e-11	Adiponectin levels;Vitamin D levels;
LUSC	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	7.15	0.36	5.58e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs3772130	0.564	rs28620947	chr3:121585631	G/A	cg20356878	chr3:121714668	ILDR1	0.61	9.89	0.48	2.07e-20	Cognitive performance;
LUSC	cis	rs7605827	0.930	rs3755129	chr2:15523549	T/C	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg09904177	chr6:26538194	HMGN4	-0.5	-5.95	-0.31	6.62e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9815354	1.000	rs1994157	chr3:41897482	G/A	cg03022575	chr3:42003672	ULK4	0.63	6.85	0.35	3.49e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	1.06	14.42	0.62	5.65e-37	Exhaled nitric oxide levels;
LUSC	cis	rs4919087	1.000	rs11189122	chr10:99072595	G/A	cg25902810	chr10:99078978	FRAT1	0.48	7.16	0.36	5.23e-12	Monocyte count;
LUSC	cis	rs1018836	0.851	rs7004287	chr8:91620842	G/C	cg16814680	chr8:91681699	NA	-0.79	-13.33	-0.59	8.69e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7264396	0.943	rs224395	chr20:34109427	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.46	-0.33	3.72e-10	Total cholesterol levels;
LUSC	cis	rs3931020	0.688	rs455032	chr1:75196488	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	-0.46	-5.93	-0.31	7.75e-9	Resistin levels;
LUSC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg23711669	chr6:146136114	FBXO30	0.77	13.91	0.61	5.36e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1957429	0.808	rs8009510	chr14:65351338	T/G	cg23373153	chr14:65346875	NA	1.07	12.89	0.58	3.85e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.03	-20.68	-0.75	9.41e-62	Cognitive function;
LUSC	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.52	-0.34	2.66e-10	Bladder cancer;
LUSC	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg20243544	chr17:37824526	PNMT	0.49	6.88	0.35	2.98e-11	Asthma;
LUSC	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg21798802	chr22:38057573	PDXP	0.32	6.64	0.34	1.29e-10	Fat distribution (HIV);
LUSC	cis	rs11229555	0.574	rs72919749	chr11:58323467	T/C	cg15696309	chr11:58395628	NA	-0.69	-7.23	-0.37	3.32e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	1.13	17.53	0.69	2.98e-49	Corneal structure;
LUSC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.5	0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07169764	chr2:136633963	MCM6	1.19	18.2	0.71	6.36e-52	Corneal structure;
LUSC	trans	rs7044246	0.924	rs9411424	chr9:134864382	C/T	cg03562770	chr12:39538604	NA	-0.37	-6.21	-0.32	1.54e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.23	-0.32	1.37e-9	Morning vs. evening chronotype;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23375948	chr7:2105870	MAD1L1	0.48	6.18	0.32	1.89e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.62e-10	Tonsillectomy;
LUSC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14829155	chr15:31115871	NA	-0.58	-7.79	-0.39	8.28e-14	Huntington's disease progression;
LUSC	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg00530320	chr1:46809349	NSUN4	0.56	8.67	0.43	1.91e-16	Menopause (age at onset);
LUSC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.9	0.44	3.49e-17	Prudent dietary pattern;
LUSC	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg00206168	chr11:65308501	LTBP3	1.28	8.47	0.42	7.99e-16	Height;
LUSC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.48	7.54	0.38	4.54e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg06885757	chr1:42089581	HIVEP3	0.47	9.64	0.47	1.41e-19	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs7605827	0.897	rs10166429	chr2:15514472	A/C	cg19274914	chr2:15703543	NA	0.46	8.86	0.44	4.71e-17	Educational attainment (years of education);
LUSC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.48	5.72	0.3	2.31e-8	Renal function-related traits (BUN);
LUSC	cis	rs10193935	1.000	rs10210866	chr2:42387879	A/G	cg27598129	chr2:42591480	NA	-0.57	-7.97	-0.4	2.56e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	12.73	0.57	1.5e-30	Platelet count;
LUSC	cis	rs7605827	0.930	rs11679632	chr2:15605659	G/A	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg15423357	chr2:25149977	NA	0.4	7.83	0.39	6.45e-14	Body mass index;
LUSC	cis	rs360798	0.532	rs360799	chr2:62953166	G/A	cg17519650	chr2:63277830	OTX1	-0.52	-7.39	-0.38	1.16e-12	Coronary artery disease;
LUSC	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.8	-11.73	-0.54	7.43e-27	Coronary artery disease;
LUSC	cis	rs2637266	0.935	rs2579728	chr10:78395598	A/G	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.95e-13	Pulmonary function;
LUSC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.74	-0.35	7.07e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs10193935	0.786	rs13399052	chr2:42385151	G/A	cg27598129	chr2:42591480	NA	-0.57	-7.97	-0.4	2.56e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg26384229	chr12:38710491	ALG10B	0.69	10.81	0.51	1.51e-23	Morning vs. evening chronotype;
LUSC	cis	rs7072216	0.881	rs2274247	chr10:100150148	G/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-5.68	-0.3	2.88e-8	Metabolite levels;
LUSC	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	11.27	0.52	3.59e-25	Lung cancer in ever smokers;
LUSC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg05025164	chr4:1340916	KIAA1530	0.41	6.12	0.32	2.59e-9	Obesity-related traits;
LUSC	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	0.83	15.08	0.64	1.46e-39	Sudden cardiac arrest;
LUSC	cis	rs7084921	0.608	rs11596211	chr10:101840119	T/A	cg02250046	chr10:101825185	CPN1	-0.33	-5.98	-0.31	5.63e-9	Bone mineral density;
LUSC	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg08779649	chr13:50194554	NA	0.41	6.92	0.35	2.27e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg07274523	chr3:49395745	GPX1	0.68	10.47	0.5	2.28e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg24531977	chr5:56204891	C5orf35	-0.55	-8.12	-0.41	9.25e-15	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg04851639	chr8:1020857	NA	-0.4	-8.05	-0.4	1.45e-14	Schizophrenia;
LUSC	cis	rs2970818	0.665	rs11063169	chr12:4573791	T/G	cg11146114	chr12:4671731	NA	-0.64	-6.25	-0.32	1.24e-9	Phosphorus levels;
LUSC	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg18904891	chr8:8559673	CLDN23	-0.38	-5.87	-0.31	1.06e-8	Mood instability;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04841346	chr1:145096723	SEC22B	0.49	7.38	0.37	1.25e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10193935	0.901	rs6733464	chr2:42563597	A/G	cg27598129	chr2:42591480	NA	-0.61	-8.26	-0.41	3.47e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.78	10.03	0.48	7.15e-21	Gut microbiome composition (summer);
LUSC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18099408	chr3:52552593	STAB1	-0.39	-6.86	-0.35	3.41e-11	Bipolar disorder;
LUSC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05776053	chr2:74358815	NA	0.48	7.69	0.39	1.7e-13	Gestational age at birth (maternal effect);
LUSC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg05855489	chr10:104503620	C10orf26	-0.62	-8.09	-0.4	1.15e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.64	-15.08	-0.64	1.54e-39	Prostate cancer;
LUSC	cis	rs1014246	0.848	rs2420330	chr10:118457481	C/T	cg14919929	chr10:118506882	NA	0.43	6.84	0.35	3.68e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs793571	0.590	rs673813	chr15:59077171	A/T	cg05156742	chr15:59063176	FAM63B	0.55	8.46	0.42	8.42e-16	Schizophrenia;
LUSC	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.56	-9.22	-0.45	3.33e-18	Breast cancer;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg09315468	chr8:38089562	DDHD2	0.39	5.98	0.31	5.66e-9	Schizophrenia;
LUSC	cis	rs7178572	0.568	rs10152181	chr15:77678346	A/G	cg22256960	chr15:77711686	NA	-0.5	-7.92	-0.4	3.57e-14	Type 2 diabetes;
LUSC	trans	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg25214090	chr10:38739885	LOC399744	0.54	7.89	0.4	4.22e-14	Corneal astigmatism;
LUSC	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.5	7.63	0.39	2.52e-13	Coffee consumption (cups per day);
LUSC	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg15704280	chr7:45808275	SEPT13	0.78	7.55	0.38	4.31e-13	Axial length;
LUSC	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.17	-0.41	6.57e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2267137	0.903	rs5752903	chr22:29769306	G/T	cg07256473	chr22:29710276	RASL10A	0.38	7.49	0.38	6.37e-13	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs9650315	0.929	rs57626491	chr8:57170336	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.12	0.36	6.82e-12	Height;
LUSC	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	0.57	8.8	0.43	7.52e-17	Breast cancer;
LUSC	trans	rs28588043	0.550	rs9426921	chr1:170951864	C/A	cg07135042	chr19:56905152	ZNF582	-0.61	-6.16	-0.32	2.08e-9	Number of children (6+ vs. 0 or 1);
LUSC	cis	rs13088318	0.504	rs9828111	chr3:101197777	C/T	cg12386194	chr3:101231763	SENP7	0.38	5.77	0.3	1.78e-8	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.83	0.6	1.04e-34	Platelet count;
LUSC	cis	rs68092024	0.731	rs793479	chr3:99488232	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.36	-7.02	-0.36	1.28e-11	Cleft lip with or without cleft palate;
LUSC	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg15704280	chr7:45808275	SEPT13	0.93	13.51	0.59	1.78e-33	Height;
LUSC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg05234568	chr11:5960015	NA	-0.63	-9.86	-0.47	2.75e-20	DNA methylation (variation);
LUSC	cis	rs7189233	0.955	rs11540358	chr16:53503943	C/G	cg09728985	chr16:53543985	NA	-0.34	-6.07	-0.32	3.5e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.41	-5.83	-0.3	1.28e-8	Platelet count;
LUSC	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.47	7.65	0.39	2.19e-13	Alcohol dependence;
LUSC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg02711726	chr17:80685570	FN3KRP	-0.41	-6.17	-0.32	1.96e-9	Glycated hemoglobin levels;
LUSC	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.05	-23.79	-0.79	7e-74	Colorectal cancer;
LUSC	cis	rs7107174	0.688	rs11237490	chr11:78135229	C/T	cg02023728	chr11:77925099	USP35	0.42	6.46	0.33	3.75e-10	Testicular germ cell tumor;
LUSC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg04733989	chr22:42467013	NAGA	0.54	8.42	0.42	1.15e-15	Schizophrenia;
LUSC	cis	rs11690935	0.843	rs9784070	chr2:172785007	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.79	-12.19	-0.55	1.55e-28	Schizophrenia;
LUSC	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg21775007	chr8:11205619	TDH	0.74	12.22	0.56	1.25e-28	Retinal vascular caliber;
LUSC	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	0.91	19.16	0.72	9.72e-56	Ulcerative colitis;
LUSC	cis	rs9796	0.558	rs4445868	chr15:41531991	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.54	-0.42	4.87e-16	Menopause (age at onset);
LUSC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg18230493	chr5:56204884	C5orf35	-0.55	-8.79	-0.43	8.22e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.75	11.95	0.55	1.22e-27	Coronary artery disease;
LUSC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.15	-0.36	5.41e-12	Urate levels;
LUSC	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg11344533	chr11:111475393	SIK2	-0.46	-6.35	-0.33	6.87e-10	Primary sclerosing cholangitis;
LUSC	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-0.95	-18.42	-0.71	8.69e-53	Headache;
LUSC	trans	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.6	0.38	3.08e-13	Ulcerative colitis;
LUSC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg05368731	chr17:41323189	NBR1	0.81	13.21	0.59	2.46e-32	Menopause (age at onset);
LUSC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.46	-0.42	8.4e-16	Chronic sinus infection;
LUSC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.63	13.88	0.6	6.84e-35	Hemoglobin concentration;
LUSC	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg02153584	chr22:29168773	CCDC117	0.66	10.32	0.49	7.36e-22	Lymphocyte counts;
LUSC	cis	rs10743315	0.557	rs77344887	chr12:19312751	C/T	cg02471346	chr12:19282374	PLEKHA5	0.8	6.4	0.33	5.14e-10	Gut microbiota (bacterial taxa);
LUSC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg14993813	chr1:46806288	NSUN4	-0.52	-7.31	-0.37	1.96e-12	Menopause (age at onset);
LUSC	cis	rs11264799	0.501	rs849827	chr1:157545231	G/T	cg18268488	chr1:157545234	FCRL4	0.39	7.69	0.39	1.62e-13	IgA nephropathy;
LUSC	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg20129853	chr10:51489980	NA	-0.35	-7.17	-0.37	4.88e-12	Prostate-specific antigen levels;
LUSC	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg24642439	chr20:33292090	TP53INP2	0.45	6.48	0.33	3.38e-10	Height;
LUSC	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg22705602	chr4:152727874	NA	-0.34	-7.57	-0.38	3.75e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-9.33	-0.45	1.53e-18	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg00343986	chr7:65444356	GUSB	-0.43	-6.26	-0.32	1.19e-9	Aortic root size;
LUSC	cis	rs2658782	0.724	rs1869914	chr11:93112492	C/G	cg15737290	chr11:93063684	CCDC67	0.63	7.65	0.39	2.2e-13	Pulmonary function decline;
LUSC	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg16928487	chr17:17741425	SREBF1	0.46	9.03	0.44	1.4e-17	Total body bone mineral density;
LUSC	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.68	-0.34	1.01e-10	Response to antipsychotic treatment;
LUSC	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg22709100	chr7:91322751	NA	0.47	6.93	0.35	2.21e-11	Breast cancer;
LUSC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg14552801	chr7:65878734	NA	0.45	6.39	0.33	5.71e-10	Aortic root size;
LUSC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg24733560	chr20:60626293	TAF4	0.36	5.89	0.31	9.44e-9	Body mass index;
LUSC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.7	12.23	0.56	1.17e-28	Aortic root size;
LUSC	trans	rs236907	0.859	rs3891278	chr1:171756248	A/C	cg13482142	chr2:234261155	NA	0.48	5.96	0.31	6.35e-9	Mean platelet volume;
LUSC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.11	0.32	2.72e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg02972257	chr16:68554789	NA	-0.5	-6.18	-0.32	1.91e-9	Ulcerative colitis;
LUSC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.71	0.47	8.56e-20	Bipolar disorder;
LUSC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03517284	chr6:25882590	NA	-0.4	-6.81	-0.35	4.47e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	1.02	18.06	0.7	2.44e-51	Eosinophil percentage of white cells;
LUSC	trans	rs9910292	0.591	rs12944197	chr17:31353532	G/A	cg03789507	chr8:136667083	NA	0.48	6.13	0.32	2.44e-9	Mosquito bite size;
LUSC	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg11993925	chr19:44307056	LYPD5	0.35	7.57	0.38	3.76e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg10253484	chr15:75165896	SCAMP2	-0.49	-6.91	-0.35	2.4e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg06363034	chr20:62225388	GMEB2	-0.45	-7.71	-0.39	1.47e-13	Glioblastoma;
LUSC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	cis	rs3736594	0.527	rs62141279	chr2:27771415	C/T	cg27432699	chr2:27873401	GPN1	0.69	9.11	0.45	7.55e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg07661805	chr8:143867942	LY6D	-0.26	-6.01	-0.31	4.78e-9	Urinary tract infection frequency;
LUSC	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.57	-11.78	-0.54	5.12e-27	Sense of smell;
LUSC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg02782426	chr3:40428986	ENTPD3	0.43	7.93	0.4	3.31e-14	Renal cell carcinoma;
LUSC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.72	-9.53	-0.46	3.32e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg09184832	chr6:79620586	NA	-0.42	-6.79	-0.35	5.28e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs240768	1.000	rs240165	chr6:101043226	T/G	cg12253828	chr6:101329408	ASCC3	0.84	5.74	0.3	2.11e-8	Economic and political preferences (immigration/crime);
LUSC	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg11941060	chr3:133502564	NA	0.38	5.96	0.31	6.37e-9	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs6546550	0.901	rs4144081	chr2:70155482	G/A	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.17e-12	Prevalent atrial fibrillation;
LUSC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg18850127	chr7:39170497	POU6F2	0.61	9.34	0.46	1.4e-18	IgG glycosylation;
LUSC	cis	rs3733418	0.929	rs13120990	chr4:165905118	A/G	cg11630554	chr4:165878136	TRIM61;C4orf39	-0.51	-5.84	-0.3	1.25e-8	Obesity-related traits;
LUSC	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg09754948	chr16:28834200	ATXN2L	-0.44	-6.42	-0.33	4.58e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	trans	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg09050820	chr6:167586206	TCP10L2	0.73	9.47	0.46	5.31e-19	Gastritis;
LUSC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg18190219	chr22:46762943	CELSR1	-0.49	-6.08	-0.32	3.2e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.59	-8.04	-0.4	1.6e-14	Red cell distribution width;
LUSC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg01879757	chr17:41196368	BRCA1	-0.46	-7.0	-0.36	1.42e-11	Menopause (age at onset);
LUSC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	7.51	0.38	5.5e-13	Multiple sclerosis;
LUSC	trans	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg07393940	chr7:158741817	NA	0.52	8.6	0.43	3.15e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-10.52	-0.5	1.56e-22	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg26811252	chr16:29126840	RRN3P2	0.61	9.64	0.47	1.46e-19	Menopause (age at onset);
LUSC	trans	rs7939886	0.920	rs11231885	chr11:55804022	T/A	cg15704280	chr7:45808275	SEPT13	0.8	6.88	0.35	3.04e-11	Myopia (pathological);
LUSC	cis	rs9905704	0.918	rs302852	chr17:56685214	C/T	cg12560992	chr17:57184187	TRIM37	0.55	7.87	0.4	4.98e-14	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.28	0.45	2.14e-18	Motion sickness;
LUSC	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-9.97	-0.48	1.18e-20	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg00106254	chr7:1943704	MAD1L1	-0.39	-5.81	-0.3	1.45e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-7.69	-0.39	1.69e-13	Hemoglobin concentration;
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg22907277	chr7:1156413	C7orf50	0.63	9.78	0.47	4.82e-20	Longevity;Endometriosis;
LUSC	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg00745463	chr17:30367425	LRRC37B	-0.67	-7.89	-0.4	4.47e-14	Hip circumference adjusted for BMI;
LUSC	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg11887960	chr12:57824829	NA	0.58	7.05	0.36	1.05e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg16606324	chr3:10149918	C3orf24	0.58	8.23	0.41	4.27e-15	Alzheimer's disease;
LUSC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18854424	chr1:2615690	NA	0.5	10.05	0.48	6.38e-21	Ulcerative colitis;
LUSC	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.23e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg23029597	chr12:123009494	RSRC2	-0.74	-9.26	-0.45	2.62e-18	Body mass index;
LUSC	cis	rs2742234	0.910	rs2505505	chr10:43648221	G/T	cg02780029	chr10:43622663	RET	-0.36	-7.11	-0.36	7.03e-12	Hirschsprung disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05164514	chr4:148605397	PRMT10	-0.39	-5.96	-0.31	6.26e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs72674100	1.000	rs6849450	chr4:97986017	C/A	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.61	0.47	1.78e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.6	-8.65	-0.43	2.21e-16	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg12002119	chr2:101014098	CHST10	0.38	6.38	0.33	6.04e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.47	-6.04	-0.31	4.08e-9	Huntington's disease progression;
LUSC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg04369109	chr6:150039330	LATS1	-0.54	-8.03	-0.4	1.7e-14	Lung cancer;
LUSC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg05347473	chr6:146136440	FBXO30	-0.6	-10.67	-0.5	4.62e-23	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.09	-0.4	1.15e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs77372450	0.636	rs77291311	chr5:157018650	T/C	cg25387487	chr5:157003181	ADAM19	-0.5	-5.83	-0.3	1.28e-8	Bipolar disorder (body mass index interaction);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg19388017	chr19:15285100	NOTCH3	-0.4	-6.12	-0.32	2.56e-9	Asthma;
LUSC	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg18404041	chr3:52824283	ITIH1	-0.37	-6.42	-0.33	4.62e-10	Electroencephalogram traits;
LUSC	cis	rs10193935	0.901	rs17029344	chr2:42444287	T/C	cg27598129	chr2:42591480	NA	-0.63	-8.38	-0.42	1.44e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg22089800	chr15:90895588	ZNF774	0.66	10.32	0.49	7.21e-22	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08859206	chr1:53392774	SCP2	-0.6	-11.28	-0.53	3.11e-25	Monocyte count;
LUSC	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.89	15.25	0.64	3.11e-40	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg19862616	chr7:65841803	NCRNA00174	0.83	9.74	0.47	6.94e-20	Eotaxin levels;
LUSC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg22800045	chr5:56110881	MAP3K1	0.77	9.42	0.46	7.46e-19	Initial pursuit acceleration;
LUSC	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg24375607	chr4:120327624	NA	0.72	11.1	0.52	1.45e-24	Corneal astigmatism;
LUSC	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg03161606	chr19:29218774	NA	0.48	5.88	0.31	9.72e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs4363385	0.747	rs6689609	chr1:152967588	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.64	-0.39	2.28e-13	Inflammatory skin disease;
LUSC	cis	rs1950626	0.833	rs12891189	chr14:101415523	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.42	7.46	0.38	7.73e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs9462027	0.651	rs9469884	chr6:34758703	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.82	-0.3	1.38e-8	Systemic lupus erythematosus;
LUSC	cis	rs2439831	1.000	rs2467426	chr15:43989518	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	7.24	0.37	3.13e-12	Lung cancer in ever smokers;
LUSC	cis	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg06521331	chr12:34319734	NA	-0.37	-6.32	-0.33	8.26e-10	Morning vs. evening chronotype;
LUSC	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg07936489	chr17:37558343	FBXL20	0.72	9.96	0.48	1.28e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	11.15	0.52	9.43e-25	Lung cancer in ever smokers;
LUSC	cis	rs7759001	0.857	rs3734574	chr6:27371193	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.73	0.3	2.25e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg16359550	chr11:109292809	C11orf87	0.37	6.38	0.33	5.9e-10	Schizophrenia;
LUSC	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-39.91	-0.91	3.76e-129	Myeloid white cell count;
LUSC	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg23950597	chr19:37808831	NA	-0.52	-5.82	-0.3	1.42e-8	Coronary artery calcification;
LUSC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-6.64	-0.34	1.27e-10	Blood metabolite levels;
LUSC	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg12863693	chr15:85201151	NMB	0.36	7.06	0.36	9.44e-12	Schizophrenia;
LUSC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.94	-15.02	-0.63	2.46e-39	Coronary artery disease;
LUSC	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg03342759	chr3:160939853	NMD3	-0.42	-6.23	-0.32	1.43e-9	Morning vs. evening chronotype;
LUSC	cis	rs12760731	0.565	rs6701832	chr1:178156775	A/G	cg00404053	chr1:178313656	RASAL2	0.66	6.8	0.35	4.85e-11	Obesity-related traits;
LUSC	cis	rs7577851	0.762	rs41285955	chr2:69709079	A/T	cg10773587	chr2:69614142	GFPT1	0.48	5.67	0.3	3.03e-8	Parkinson's disease (age of onset);
LUSC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05535760	chr7:792225	HEATR2	-0.78	-7.87	-0.4	4.83e-14	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.24	-0.32	1.3e-9	Bipolar disorder;
LUSC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.41	-6.53	-0.34	2.46e-10	Mean platelet volume;
LUSC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.89	15.49	0.65	3.73e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	10.81	0.51	1.45e-23	Alzheimer's disease;
LUSC	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg11946769	chr3:48343235	NME6	0.71	11.35	0.53	1.84e-25	Coronary artery disease;
LUSC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg13395646	chr4:1353034	KIAA1530	-0.6	-9.39	-0.46	9.66e-19	Longevity;
LUSC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg07701084	chr6:150067640	NUP43	0.53	7.85	0.39	5.88e-14	Lung cancer;
LUSC	cis	rs5758511	0.573	rs2267439	chr22:42237769	C/T	cg03131358	chr22:42195972	CCDC134	-0.33	-5.75	-0.3	2.01e-8	Birth weight;
LUSC	cis	rs7582720	1.000	rs72932777	chr2:203689914	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.98	0.4	2.35e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg01557791	chr16:72042693	DHODH	-0.52	-7.54	-0.38	4.42e-13	Fibrinogen levels;
LUSC	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-9.55	-0.46	2.88e-19	Platelet distribution width;
LUSC	cis	rs2625529	0.938	rs4777464	chr15:72131763	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.53	-0.38	4.92e-13	Red blood cell count;
LUSC	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg20744362	chr22:50050164	C22orf34	0.39	7.16	0.36	5.13e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg23241863	chr10:102295624	HIF1AN	0.49	6.12	0.32	2.64e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg03340356	chr1:67600835	NA	0.44	7.03	0.36	1.18e-11	Psoriasis;
LUSC	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg07169764	chr2:136633963	MCM6	-0.74	-9.84	-0.47	3.17e-20	Mosquito bite size;
LUSC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03264133	chr6:25882463	NA	-0.44	-7.74	-0.39	1.16e-13	Blood metabolite levels;
LUSC	cis	rs2625529	1.000	rs2625529	chr15:72118777	C/G	cg16672083	chr15:72433130	SENP8	0.39	6.07	0.31	3.56e-9	Red blood cell count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26039424	chr1:46154040	TMEM69	-0.44	-6.66	-0.34	1.12e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2274273	0.662	rs2094436	chr14:55661495	C/G	cg04306507	chr14:55594613	LGALS3	0.48	9.67	0.47	1.2e-19	Protein biomarker;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12197573	chr18:14470687	NA	-0.29	-6.64	-0.34	1.27e-10	Electrocardiographic conduction measures;
LUSC	cis	rs4812048	1.000	rs6070697	chr20:57599402	G/A	cg14073986	chr20:57617431	SLMO2	0.62	6.81	0.35	4.54e-11	Mean platelet volume;
LUSC	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg04374321	chr14:90722782	PSMC1	0.75	12.08	0.55	4e-28	Mortality in heart failure;
LUSC	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg17252645	chr8:143867129	LY6D	-0.37	-6.43	-0.33	4.42e-10	Urinary tract infection frequency;
LUSC	trans	rs7939886	0.920	rs11227428	chr11:55941972	C/G	cg03929089	chr4:120376271	NA	0.8	6.07	0.32	3.54e-9	Myopia (pathological);
LUSC	cis	rs4622329	0.615	rs7306175	chr12:102294618	G/T	cg23541617	chr12:102225335	GNPTAB	0.28	6.35	0.33	7.16e-10	Systemic lupus erythematosus;
LUSC	cis	rs10979	0.597	rs9390118	chr6:143907610	A/G	cg25407410	chr6:143891975	LOC285740	-0.65	-8.19	-0.41	5.6e-15	Hypospadias;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19853194	chr18:9913725	VAPA	0.42	6.49	0.33	3.16e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg02117656	chr17:79614917	TSPAN10	-0.31	-5.69	-0.3	2.75e-8	Eye color traits;
LUSC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11060661	chr22:24314208	DDT;DDTL	0.48	7.89	0.4	4.42e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.8	13.32	0.59	8.93e-33	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4953404	0.613	rs897532	chr2:46893225	G/A	cg09399716	chr2:46890238	NA	-0.32	-7.17	-0.37	4.93e-12	Pulse pressure (alcohol consumption interaction);
LUSC	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg04362960	chr10:104952993	NT5C2	0.59	9.3	0.45	1.91e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg06096015	chr1:231504339	EGLN1	0.56	9.9	0.48	1.99e-20	Hemoglobin concentration;
LUSC	cis	rs3744061	0.505	rs9915915	chr17:74652274	A/G	cg27546012	chr17:74684504	MXRA7	-0.38	-6.6	-0.34	1.63e-10	Retinal arteriolar caliber;
LUSC	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg22852734	chr6:133119734	C6orf192	1.22	14.16	0.61	5.69e-36	Type 2 diabetes nephropathy;
LUSC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg16434002	chr17:42200994	HDAC5	0.46	6.79	0.35	5.28e-11	Total body bone mineral density;
LUSC	cis	rs7973719	0.865	rs12228393	chr12:7368182	A/G	cg07052231	chr12:7363540	PEX5	-0.52	-9.1	-0.45	8.41e-18	IgG glycosylation;
LUSC	cis	rs9815354	0.812	rs77732985	chr3:41945872	G/A	cg03022575	chr3:42003672	ULK4	0.82	8.57	0.42	3.94e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg03233332	chr7:66118400	NA	0.4	5.89	0.31	9.29e-9	Aortic root size;
LUSC	cis	rs13242816	1.000	rs35595472	chr7:116122306	G/A	cg16553024	chr7:116138462	CAV2	-0.52	-5.68	-0.3	2.89e-8	P wave duration;
LUSC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg16049864	chr8:95962084	TP53INP1	0.47	7.5	0.38	5.81e-13	Type 2 diabetes;
LUSC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg12963246	chr6:28129442	ZNF389	-0.56	-8.07	-0.4	1.31e-14	Depression;
LUSC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23158103	chr7:148848205	ZNF398	-0.47	-7.52	-0.38	5.05e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.17	0.52	7.73e-25	Prudent dietary pattern;
LUSC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	6.59	0.34	1.7e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22307029	chr19:49891270	CCDC155	0.68	9.47	0.46	5.35e-19	Multiple sclerosis;
LUSC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	13.28	0.59	1.37e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg05234568	chr11:5960015	NA	-0.58	-9.54	-0.46	3.1400000000000002e-19	DNA methylation (variation);
LUSC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.44	-6.89	-0.35	2.76e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg08219700	chr8:58056026	NA	0.5	5.93	0.31	7.63e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg12091567	chr17:66097778	LOC651250	-0.75	-9.35	-0.46	1.27e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2463822	0.583	rs72919472	chr11:62040655	C/T	cg06239285	chr11:62104954	ASRGL1	-0.66	-6.8	-0.35	4.87e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs983392	0.709	rs4492839	chr11:59986399	T/A	cg02771260	chr11:59836817	MS4A3	-0.36	-5.93	-0.31	7.71e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.52	-0.34	2.53e-10	High light scatter reticulocyte count;
LUSC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg06212747	chr3:49208901	KLHDC8B	0.44	5.98	0.31	5.79e-9	Parkinson's disease;
LUSC	cis	rs9811920	0.535	rs792835	chr3:99476295	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.31	-5.85	-0.31	1.15e-8	Axial length;
LUSC	cis	rs34638657	0.732	rs7206093	chr16:82201884	G/A	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.45	-0.33	3.97e-10	Lung adenocarcinoma;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg01238044	chr22:24384105	GSTT1	-0.53	-7.69	-0.39	1.7e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg10057126	chr4:77819792	ANKRD56	0.5	7.6	0.38	3.03e-13	Emphysema distribution in smoking;
LUSC	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg08601574	chr20:25228251	PYGB	0.45	6.81	0.35	4.56e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg14222797	chr10:16859974	RSU1	0.59	6.14	0.32	2.38e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg20608306	chr11:116969690	SIK3	0.37	6.8	0.35	4.86e-11	Blood protein levels;
LUSC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-1.03	-16.75	-0.68	3.86e-46	Systemic lupus erythematosus;
LUSC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.82	-0.39	7.15e-14	Neuroticism;
LUSC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg04369109	chr6:150039330	LATS1	0.53	7.73	0.39	1.25e-13	Lung cancer;
LUSC	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg23601416	chr22:19950040	COMT	-0.45	-9.27	-0.45	2.39e-18	Blood metabolite levels;
LUSC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg06784218	chr1:46089804	CCDC17	0.55	11.09	0.52	1.49e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.67	0.6	4.46e-34	Cognitive test performance;
LUSC	trans	rs7495211	0.509	rs11247363	chr15:98623942	C/T	cg08901157	chr15:56033728	PRTG	0.35	6.12	0.32	2.63e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg08079166	chr15:68083412	MAP2K5	0.46	7.87	0.4	4.85e-14	Restless legs syndrome;
LUSC	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.55	-8.63	-0.43	2.61e-16	Schizophrenia;
LUSC	cis	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.66	-0.39	2.06e-13	Morning vs. evening chronotype;
LUSC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg16049864	chr8:95962084	TP53INP1	-0.63	-12.41	-0.56	2.49e-29	Type 2 diabetes;
LUSC	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg20607287	chr7:12443886	VWDE	-0.61	-6.34	-0.33	7.27e-10	Coronary artery disease;
LUSC	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg08601574	chr20:25228251	PYGB	0.42	6.33	0.33	7.89e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7192380	0.928	rs12933210	chr16:69742048	A/T	cg00738113	chr16:70207722	CLEC18C	0.27	5.92	0.31	7.83e-9	Sjögren's syndrome;
LUSC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06022373	chr22:39101656	GTPBP1	0.84	14.0	0.61	2.38e-35	Menopause (age at onset);
LUSC	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.74	-6.54	-0.34	2.32e-10	Lung cancer in ever smokers;
LUSC	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.55	-10.66	-0.5	4.87e-23	Educational attainment;
LUSC	cis	rs2073300	1.000	rs6106669	chr20:23460328	C/T	cg09953122	chr20:23471693	CST8	-0.76	-7.01	-0.36	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7236492	0.748	rs11663658	chr18:77197555	T/C	cg15644404	chr18:77186268	NFATC1	-0.68	-7.6	-0.38	2.97e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg05163923	chr11:71159392	DHCR7	0.66	9.82	0.47	3.7799999999999997e-20	Vitamin D levels;
LUSC	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg20476274	chr7:133979776	SLC35B4	0.88	16.9	0.68	1.01e-46	Mean platelet volume;
LUSC	cis	rs57994353	0.568	rs3812581	chr9:139311471	C/T	cg14019695	chr9:139328340	INPP5E	0.37	5.79	0.3	1.67e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
LUSC	cis	rs983392	0.649	rs7936120	chr11:60000574	T/A	cg20284999	chr11:59952153	MS4A6A	-0.36	-6.09	-0.32	3.14e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg17168535	chr8:21777572	XPO7	0.67	10.21	0.49	1.71e-21	Mean corpuscular volume;
LUSC	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	6.24	0.32	1.33e-9	Schizophrenia;
LUSC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.34e-12	Tonsillectomy;
LUSC	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg26384229	chr12:38710491	ALG10B	0.69	10.73	0.51	2.8e-23	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09918929	chr12:92540332	BTG1	0.49	6.93	0.35	2.13e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg01629716	chr15:45996671	NA	0.39	5.96	0.31	6.31e-9	Waist circumference;Weight;
LUSC	cis	rs4787491	0.729	rs7191849	chr16:30023157	T/C	cg06326092	chr16:30034487	C16orf92	0.23	5.68	0.3	2.89e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.36	0.37	1.47e-12	Bipolar disorder;
LUSC	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg08680598	chr22:49984980	NA	-0.36	-6.52	-0.34	2.6200000000000003e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11031096	0.678	rs17284356	chr11:4189232	G/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.76	-0.3	1.96e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.82	-15.1	-0.64	1.19e-39	Dental caries;
LUSC	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg00495681	chr13:53174319	NA	0.78	14.66	0.63	6.17e-38	Lewy body disease;
LUSC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg09655341	chr17:79618100	PDE6G	-0.28	-6.26	-0.32	1.18e-9	Eye color traits;
LUSC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg04369109	chr6:150039330	LATS1	-0.58	-8.44	-0.42	9.96e-16	Lung cancer;
LUSC	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg06197492	chr11:2016605	H19	0.44	7.14	0.36	5.79e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16263627	chr15:100339283	C15orf51	0.49	6.45	0.33	3.83e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs867371	0.826	rs2047678	chr15:82498198	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.11	-0.32	2.84e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg11663144	chr21:46675770	NA	-0.4	-7.16	-0.36	5.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7589342	0.536	rs10173137	chr2:106388049	A/C	cg09152813	chr2:106391379	NCK2	-0.38	-6.24	-0.32	1.31e-9	Addiction;
LUSC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.55	-8.8	-0.43	7.42e-17	Height;
LUSC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg22709100	chr7:91322751	NA	0.4	5.8	0.3	1.56e-8	Breast cancer;
LUSC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.67	0.6	4.46e-34	Cognitive test performance;
LUSC	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-9.39	-0.46	9.89e-19	Type 2 diabetes;
LUSC	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.98	16.91	0.68	8.98e-47	Alcohol dependence;
LUSC	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.08	0.4	1.17e-14	Lung cancer;
LUSC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.73	-14.1	-0.61	9.54e-36	Type 2 diabetes;
LUSC	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.35	-6.67	-0.34	1.09e-10	Coronary artery disease;
LUSC	cis	rs193541	0.632	rs2910135	chr5:122229790	C/T	cg19077854	chr5:122220652	SNX24	0.38	7.92	0.4	3.5e-14	Glucose homeostasis traits;
LUSC	trans	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.71e-10	Life satisfaction;
LUSC	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg15617548	chr2:171785815	GORASP2	-0.39	-6.12	-0.32	2.58e-9	Vertical cup-disc ratio;
LUSC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.8	10.5	0.5	1.74e-22	Schizophrenia;
LUSC	cis	rs10193935	0.901	rs222488	chr2:42648570	T/G	cg27598129	chr2:42591480	NA	-0.6	-8.25	-0.41	3.7e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg02176678	chr2:219576539	TTLL4	0.57	10.06	0.48	5.77e-21	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg09006514	chr2:127800616	NA	-0.34	-6.2	-0.32	1.62e-9	N-glycan levels;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg23034840	chr1:205782522	SLC41A1	0.61	8.66	0.43	2.05e-16	Menarche (age at onset);
LUSC	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg25801113	chr15:45476975	SHF	-0.34	-6.71	-0.34	8.19e-11	Uric acid levels;
LUSC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg21724239	chr8:58056113	NA	0.59	7.2	0.37	4.05e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.44	6.62	0.34	1.43e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg00530320	chr1:46809349	NSUN4	0.55	8.49	0.42	6.7e-16	Menopause (age at onset);
LUSC	cis	rs2070997	0.667	rs13287613	chr9:133715291	T/C	cg11464064	chr9:133710261	ABL1	0.48	5.65	0.3	3.47e-8	Response to amphetamines;
LUSC	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg14664628	chr15:75095509	CSK	0.42	6.02	0.31	4.53e-9	Caffeine consumption;
LUSC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg24692254	chr21:30365293	RNF160	-0.9	-17.62	-0.69	1.32e-49	Dental caries;
LUSC	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg25427524	chr10:38739819	LOC399744	-0.49	-6.94	-0.36	2.01e-11	Obesity (extreme);
LUSC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg12751644	chr20:60527061	NA	-0.34	-6.04	-0.31	4.13e-9	Body mass index;
LUSC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg23985595	chr17:80112537	CCDC57	-0.31	-5.98	-0.31	5.8e-9	Life satisfaction;
LUSC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.2	0.41	5.41e-15	Electroencephalogram traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21715212	chr22:45406639	PHF21B	0.44	7.38	0.37	1.29e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.73	0.39	1.27e-13	Ulcerative colitis;
LUSC	cis	rs62458065	0.925	rs10243243	chr7:32460709	A/G	cg20159608	chr7:32802032	NA	-0.59	-7.1	-0.36	7.58e-12	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00573355	chr2:74730266	LBX2;LOC151534	-0.39	-6.09	-0.32	3.07e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg26647111	chr11:31128758	NA	-0.43	-6.12	-0.32	2.58e-9	Red blood cell count;
LUSC	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg03929089	chr4:120376271	NA	0.71	6.57	0.34	1.9e-10	Axial length;
LUSC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.88	-14.1	-0.61	9.21e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.94	-0.31	7.12e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg14159672	chr1:205819179	PM20D1	-0.41	-5.93	-0.31	7.61e-9	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05654422	chr17:80709806	TBCD	-0.41	-6.13	-0.32	2.44e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg17420585	chr12:42539391	GXYLT1	-0.36	-6.92	-0.35	2.26e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg07041428	chr4:1763019	NA	0.38	5.66	0.3	3.29e-8	Bladder cancer;Urinary bladder cancer;
LUSC	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.93e-12	Blood metabolite levels;
LUSC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg00343986	chr7:65444356	GUSB	-0.42	-6.44	-0.33	4.05e-10	Aortic root size;
LUSC	cis	rs4132509	0.793	rs7538011	chr1:243703344	A/G	cg21452805	chr1:244014465	NA	0.6	6.14	0.32	2.34e-9	RR interval (heart rate);
LUSC	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.84	-0.44	5.72e-17	Axial length;
LUSC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22442454	chr1:209979470	IRF6	0.43	5.88	0.31	9.86e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg22963979	chr7:1858916	MAD1L1	-0.58	-8.85	-0.44	5.12e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg26695010	chr11:65641043	EFEMP2	-0.47	-7.08	-0.36	8.8e-12	Breast cancer;
LUSC	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	12.61	0.57	4.47e-30	Total body bone mineral density;
LUSC	cis	rs9807989	1.000	rs9807989	chr2:102971200	T/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.88	0.31	9.76e-9	Asthma;
LUSC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg17554472	chr22:41940697	POLR3H	0.48	5.91	0.31	8.32e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.9	0.44	3.72e-17	Menopause (age at onset);
LUSC	cis	rs4356932	1.000	rs4859588	chr4:76943677	C/T	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg05855489	chr10:104503620	C10orf26	0.61	8.98	0.44	1.99e-17	Arsenic metabolism;
LUSC	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg13256891	chr4:100009986	ADH5	-0.45	-6.26	-0.32	1.18e-9	Alcohol dependence;
LUSC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg03477792	chr4:77819574	ANKRD56	0.61	8.87	0.44	4.5e-17	Emphysema distribution in smoking;
LUSC	cis	rs300703	0.935	rs10193882	chr2:246301	A/T	cg21211680	chr2:198530	NA	-0.66	-6.77	-0.35	5.92e-11	Blood protein levels;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg12307764	chr15:40861449	RPUSD2	0.44	7.1	0.36	7.73e-12	Triglycerides;
LUSC	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg11473876	chr11:109292803	C11orf87	0.39	6.32	0.33	8.41e-10	Schizophrenia;
LUSC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.37	-0.91	1.58e-130	Myeloid white cell count;
LUSC	cis	rs3743266	0.507	rs10162677	chr15:60748568	C/T	cg21667061	chr15:60772094	NARG2	0.5	6.91	0.35	2.44e-11	Menarche (age at onset);
LUSC	trans	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg22705602	chr4:152727874	NA	-0.33	-6.65	-0.34	1.23e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.74	-0.35	6.93e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg19339932	chr22:20004356	ARVCF	0.37	6.09	0.32	3.08e-9	Metabolite levels (Pyroglutamine);
LUSC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-1.03	-20.48	-0.75	5.94e-61	Height;
LUSC	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg10604040	chr11:65559109	OVOL1	0.31	5.72	0.3	2.34e-8	Acne (severe);
LUSC	cis	rs9581857	0.547	rs76435345	chr13:28107638	G/A	cg22138327	chr13:27999177	GTF3A	0.66	7.23	0.37	3.26e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg13256891	chr4:100009986	ADH5	0.51	6.89	0.35	2.74e-11	Smoking initiation;
LUSC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.52	-7.25	-0.37	2.85e-12	Tuberculosis;
LUSC	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg25233709	chr10:116636983	FAM160B1	-0.4	-6.97	-0.36	1.7e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg20487152	chr13:99095054	FARP1	-0.42	-6.96	-0.36	1.8e-11	Longevity;
LUSC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-7.15	-0.36	5.53e-12	Alzheimer's disease (late onset);
LUSC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.64	0.6	5.64e-34	Platelet count;
LUSC	cis	rs9837602	1.000	rs13069311	chr3:99801628	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.28	0.33	1.03e-9	Breast cancer;
LUSC	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-9.41	-0.46	8.25e-19	Hemoglobin concentration;
LUSC	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.42	0.69	8.19e-49	Chronic sinus infection;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18056097	chr20:32441571	CHMP4B	0.44	6.02	0.31	4.6e-9	Neuroticism;
LUSC	trans	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg10756647	chr7:56101905	PSPH	-0.85	-8.35	-0.42	1.87e-15	Diabetic kidney disease;
LUSC	cis	rs7202877	0.706	rs247443	chr16:75465073	G/C	cg03315344	chr16:75512273	CHST6	-0.45	-6.46	-0.33	3.69e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg24130564	chr14:104152367	KLC1	-0.43	-6.05	-0.31	3.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg17173187	chr15:85201210	NMB	0.37	6.56	0.34	2.08e-10	Schizophrenia;
LUSC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-7.65	-0.39	2.16e-13	Chronic sinus infection;
LUSC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg03146154	chr1:46216737	IPP	0.51	7.68	0.39	1.8e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg01802117	chr1:53393560	SCP2	0.38	6.2	0.32	1.67e-9	Monocyte count;
LUSC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.13	0.55	2.54e-28	Cognitive test performance;
LUSC	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	7.62	0.38	2.62e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg13010199	chr12:38710504	ALG10B	0.44	6.95	0.36	1.9e-11	Morning vs. evening chronotype;
LUSC	cis	rs4478037	1.000	rs59229836	chr3:33162622	T/C	cg19404215	chr3:33155277	CRTAP	0.95	9.99	0.48	9.87e-21	Major depressive disorder;
LUSC	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg00432049	chr6:150390894	ULBP3	0.29	6.08	0.32	3.25e-9	Alopecia areata;
LUSC	trans	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg18187862	chr3:45730750	SACM1L	0.54	7.07	0.36	8.98e-12	Primary sclerosing cholangitis;
LUSC	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg08213375	chr14:104286397	PPP1R13B	0.44	7.57	0.38	3.77e-13	Reticulocyte count;
LUSC	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.56	7.96	0.4	2.75e-14	Iron status biomarkers;
LUSC	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg22089800	chr15:90895588	ZNF774	-0.59	-9.23	-0.45	3.11e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg06636001	chr8:8085503	FLJ10661	0.6	9.05	0.44	1.23e-17	Mood instability;
LUSC	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23583168	chr7:148888333	NA	-0.92	-16.88	-0.68	1.19e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg06521331	chr12:34319734	NA	0.43	6.8	0.35	4.75e-11	Morning vs. evening chronotype;
LUSC	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.76	-0.51	2.18e-23	Glomerular filtration rate;
LUSC	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg21433313	chr16:3507492	NAT15	-0.62	-9.43	-0.46	6.91e-19	Tuberculosis;
LUSC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.79	-13.28	-0.59	1.29e-32	Aortic root size;
LUSC	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.49	16.86	0.68	1.38e-46	Opioid sensitivity;
LUSC	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.71	6.99	0.36	1.47e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7523273	0.606	rs1970530	chr1:207924066	G/A	cg22525895	chr1:207977042	MIR29B2	0.4	6.44	0.33	4.18e-10	Schizophrenia;
LUSC	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.73	11.94	0.55	1.37e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.09	-0.48	4.6e-21	Hemoglobin concentration;
LUSC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.18	0.52	7.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs877282	0.629	rs78997110	chr10:764388	A/G	cg13042288	chr15:90349979	ANPEP	-0.46	-6.26	-0.32	1.21e-9	Uric acid levels;
LUSC	trans	rs13390641	0.614	rs72932428	chr2:104095235	G/C	cg03260781	chr1:16346299	HSPB7	-0.46	-6.09	-0.32	3.14e-9	Blood pressure;Blood pressure (anthropometric measures interaction);
LUSC	cis	rs11971779	0.680	rs10229249	chr7:139052510	A/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	trans	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg18187862	chr3:45730750	SACM1L	0.56	7.06	0.36	9.52e-12	Primary sclerosing cholangitis;
LUSC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	8.54	0.42	4.67e-16	Multiple sclerosis;
LUSC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg23711669	chr6:146136114	FBXO30	0.82	14.38	0.62	8.11e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg07803811	chr1:43423981	SLC2A1	0.43	6.47	0.33	3.45e-10	Red cell distribution width;
LUSC	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg01528321	chr10:82214614	TSPAN14	0.84	12.81	0.57	7.92e-31	Post bronchodilator FEV1;
LUSC	cis	rs9815354	0.556	rs113213296	chr3:41873097	G/A	cg03022575	chr3:42003672	ULK4	0.84	8.86	0.44	4.79e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.32	0.53	2.37e-25	Prudent dietary pattern;
LUSC	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg07930552	chr6:133119739	C6orf192	0.95	9.42	0.46	7.64e-19	Type 2 diabetes nephropathy;
LUSC	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-6.73	-0.35	7.26e-11	Schizophrenia;
LUSC	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg17211192	chr8:82754475	SNX16	-0.76	-10.02	-0.48	7.93e-21	Diastolic blood pressure;
LUSC	cis	rs2742417	1.000	rs2742452	chr3:45765708	C/T	cg04837898	chr3:45731254	SACM1L	-0.38	-6.33	-0.33	7.89e-10	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs9905704	0.633	rs2531731	chr17:56546524	A/C	cg12560992	chr17:57184187	TRIM37	-0.5	-5.69	-0.3	2.83e-8	Testicular germ cell tumor;
LUSC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.58	0.42	3.71e-16	Bipolar disorder;
LUSC	cis	rs11605924	0.934	rs7945689	chr11:45879006	C/T	ch.11.939596F	chr11:45881766	CRY2	-0.55	-8.39	-0.42	1.38e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs2857891	0.778	rs7118671	chr11:6934002	C/G	cg04053776	chr11:6947353	ZNF215	0.47	6.93	0.35	2.15e-11	Response to cytadine analogues (cytosine arabinoside);
LUSC	trans	rs4714291	0.963	rs9369159	chr6:39998853	T/C	cg02267698	chr19:7991119	CTXN1	0.51	7.25	0.37	2.85e-12	Strep throat;
LUSC	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.32	-6.33	-0.33	7.74e-10	Schizophrenia;
LUSC	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg08645402	chr16:4508243	NA	0.45	7.48	0.38	6.46e-13	Schizophrenia;
LUSC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-0.79	-11.6	-0.54	2.22e-26	Vitiligo;
LUSC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg09904177	chr6:26538194	HMGN4	-0.75	-13.43	-0.59	3.53e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg08859206	chr1:53392774	SCP2	-0.41	-6.62	-0.34	1.4e-10	Monocyte count;
LUSC	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg00509249	chr6:109615579	CCDC162	0.34	6.03	0.31	4.4e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg26898376	chr11:64110657	CCDC88B	0.36	6.71	0.34	8.36e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs9784649	1.000	rs11738315	chr5:24967891	T/C	cg08600765	chr20:34638493	LOC647979	-0.57	-6.51	-0.34	2.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.27e-8	Breast cancer;
LUSC	cis	rs6138458	0.620	rs914314	chr20:24897355	C/T	cg06937882	chr20:24974362	C20orf3	0.49	6.12	0.32	2.61e-9	Blood protein levels;
LUSC	trans	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg18335740	chr13:41363409	SLC25A15	-0.58	-9.13	-0.45	6.52e-18	Lewy body disease;
LUSC	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	8.71	0.43	1.46e-16	Retinal vascular caliber;
LUSC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.44	0.53	8.75e-26	Prudent dietary pattern;
LUSC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	10.89	0.51	8.04e-24	Bone mineral density;
LUSC	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg11584989	chr19:19387371	SF4	0.66	7.6	0.38	3e-13	Bipolar disorder;
LUSC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg05785598	chr3:49045655	WDR6	0.36	6.0	0.31	5.28e-9	Parkinson's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00300090	chr3:4345167	SETMAR	-0.49	-6.61	-0.34	1.55e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21984481	chr17:79567631	NPLOC4	-0.56	-10.73	-0.51	2.91e-23	Eye color traits;
LUSC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg03605463	chr16:89740564	NA	-0.57	-9.01	-0.44	1.67e-17	Vitiligo;
LUSC	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.52	-0.46	3.61e-19	Extrinsic epigenetic age acceleration;
LUSC	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21659725	chr3:3221576	CRBN	-0.58	-8.2	-0.41	5.33e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg06784218	chr1:46089804	CCDC17	-0.31	-5.93	-0.31	7.54e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-0.76	-11.97	-0.55	1e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.64	-5.78	-0.3	1.73e-8	Major depressive disorder;
LUSC	cis	rs10100465	0.924	rs1021014	chr8:118661891	G/A	cg09430518	chr8:118662568	NA	-0.29	-5.64	-0.3	3.57e-8	Leprosy;
LUSC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.81	0.39	7.63e-14	Major depressive disorder;
LUSC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.58	0.38	3.42e-13	Calcium levels;
LUSC	cis	rs6545883	0.826	rs1186697	chr2:61661417	G/A	cg15711740	chr2:61764176	XPO1	-0.44	-6.56	-0.34	2.11e-10	Tuberculosis;
LUSC	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	8.78	0.43	8.38e-17	Lung cancer in ever smokers;
LUSC	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.91	15.71	0.65	4.91e-42	Morning vs. evening chronotype;
LUSC	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg08917208	chr2:24149416	ATAD2B	0.56	6.27	0.32	1.12e-9	Lymphocyte counts;
LUSC	cis	rs78545713	0.649	rs77362785	chr6:26232351	G/A	cg23601095	chr6:26197514	HIST1H3D	0.67	5.68	0.3	2.87e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs9650315	0.586	rs35798072	chr8:57207926	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.8	0.39	7.83e-14	Height;
LUSC	cis	rs2273669	0.667	rs7767882	chr6:109334971	C/A	cg05315195	chr6:109294784	ARMC2	-0.53	-5.89	-0.31	9.28e-9	Prostate cancer;
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	1.01	22.71	0.78	1.06e-69	Menarche (age at onset);
LUSC	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg18827107	chr12:86230957	RASSF9	0.46	6.92	0.35	2.3e-11	Major depressive disorder;
LUSC	cis	rs6545883	0.894	rs6709441	chr2:61436930	A/T	cg15711740	chr2:61764176	XPO1	0.45	6.64	0.34	1.3e-10	Tuberculosis;
LUSC	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg13628971	chr7:2884303	GNA12	0.39	5.92	0.31	8.06e-9	Height;
LUSC	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg01966878	chr4:90757139	SNCA	-0.42	-6.05	-0.31	3.86e-9	Neuroticism;
LUSC	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.19	-0.45	4.23e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4499344	0.633	rs259251	chr19:33149768	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	11.42	0.53	1.02e-25	Mean platelet volume;
LUSC	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17507749	chr15:85114479	UBE2QP1	0.57	7.25	0.37	2.99e-12	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.03	0.52	2.57e-24	Menopause (age at onset);
LUSC	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-7.57	-0.38	3.74e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg18681998	chr4:17616180	MED28	0.84	15.44	0.65	5.89e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14016680	chr3:197687242	LMLN;IQCG	-0.4	-6.03	-0.31	4.33e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7589342	0.536	rs7563690	chr2:106396935	C/T	cg09152813	chr2:106391379	NCK2	-0.39	-6.3	-0.33	9.19e-10	Addiction;
LUSC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg13319975	chr6:146136371	FBXO30	0.49	7.34	0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7572644	0.608	rs75429814	chr2:27961614	T/C	cg27432699	chr2:27873401	GPN1	0.6	7.37	0.37	1.36e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.44	-0.38	8.62e-13	Mood instability;
LUSC	cis	rs3126085	0.935	rs10788824	chr1:152161694	A/G	cg26876637	chr1:152193138	HRNR	0.48	6.58	0.34	1.81e-10	Atopic dermatitis;
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.61	-0.47	1.88e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs72960926	0.744	rs72954314	chr6:74939737	A/G	cg03266952	chr6:74778945	NA	-0.84	-6.98	-0.36	1.57e-11	Metabolite levels (MHPG);
LUSC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg27284194	chr4:1044797	NA	0.35	5.83	0.3	1.32e-8	Obesity-related traits;
LUSC	cis	rs2108225	0.934	rs4730269	chr7:107455719	T/G	cg18560240	chr7:107437656	SLC26A3	-0.43	-6.43	-0.33	4.3e-10	Ulcerative colitis;
LUSC	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.69	-10.55	-0.5	1.2e-22	Colorectal cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12593303	chr2:54785406	SPTBN1	0.43	6.04	0.31	4.11e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs28830936	0.966	rs4924576	chr15:42119593	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.78	-0.3	1.75e-8	Diastolic blood pressure;
LUSC	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg26924012	chr15:45694286	SPATA5L1	0.8	12.45	0.56	1.8e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg21775007	chr8:11205619	TDH	-0.51	-7.0	-0.36	1.41e-11	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg26384229	chr12:38710491	ALG10B	0.72	11.29	0.53	2.92e-25	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg11764359	chr7:65958608	NA	0.49	6.15	0.32	2.16e-9	Aortic root size;
LUSC	cis	rs7617773	0.925	rs6442105	chr3:48182326	A/G	cg20734569	chr3:48348370	SPINK8	0.46	8.13	0.41	8.54e-15	Coronary artery disease;
LUSC	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg11764359	chr7:65958608	NA	-0.69	-10.46	-0.5	2.43e-22	Aortic root size;
LUSC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg19230755	chr7:65878503	NA	-0.44	-6.03	-0.31	4.39e-9	Aortic root size;
LUSC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg00033643	chr7:134001901	SLC35B4	0.45	7.05	0.36	1.02e-11	Mean platelet volume;
LUSC	cis	rs28647808	0.881	rs4549850	chr9:136265239	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.93	-0.31	7.37e-9	Blood protein levels;
LUSC	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.71	10.85	0.51	1.08e-23	Smoking initiation;
LUSC	cis	rs17155006	0.746	rs370495	chr7:107746246	T/C	cg05962710	chr7:107745446	LAMB4	-0.36	-6.43	-0.33	4.42e-10	Pneumococcal bacteremia;
LUSC	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg21775007	chr8:11205619	TDH	-0.47	-6.93	-0.35	2.2e-11	Neuroticism;
LUSC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-11.62	-0.54	1.88e-26	Schizophrenia;
LUSC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	9.72	0.47	7.69e-20	Personality dimensions;
LUSC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg11645453	chr3:52864694	ITIH4	0.35	8.05	0.4	1.44e-14	Bipolar disorder;
LUSC	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg20991723	chr1:152506922	NA	0.51	9.74	0.47	6.76e-20	Hair morphology;
LUSC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg27535305	chr1:53392650	SCP2	-0.41	-7.49	-0.38	6.38e-13	Monocyte count;
LUSC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg07701084	chr6:150067640	NUP43	0.55	8.42	0.42	1.09e-15	Lung cancer;
LUSC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.48	0.53	5.96e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13089785	1.000	rs13071800	chr3:123626813	C/A	cg02012769	chr3:123398346	MYLK	0.32	5.88	0.31	1.02e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-6.95	-0.36	1.91e-11	Arsenic metabolism;
LUSC	cis	rs73198271	0.515	rs78790772	chr8:8634367	A/G	cg01851573	chr8:8652454	MFHAS1	0.58	6.54	0.34	2.28e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7131987	0.621	rs11050181	chr12:29467669	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.72	-0.34	7.98e-11	QT interval;
LUSC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06022373	chr22:39101656	GTPBP1	0.78	12.16	0.55	2.1e-28	Menopause (age at onset);
LUSC	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg20628663	chr10:43360327	NA	-0.76	-11.4	-0.53	1.23e-25	Blood protein levels;
LUSC	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg13010199	chr12:38710504	ALG10B	0.68	10.71	0.51	3.28e-23	Bladder cancer;
LUSC	cis	rs240764	0.782	rs239223	chr6:101112345	A/G	cg09795085	chr6:101329169	ASCC3	0.41	5.98	0.31	5.69e-9	Neuroticism;
LUSC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06505273	chr16:24850292	NA	0.41	5.75	0.3	2e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21643547	chr1:205240462	TMCC2	-0.49	-9.28	-0.45	2.14e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg05555928	chr11:63887634	MACROD1	-0.48	-6.03	-0.31	4.41e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2282802	0.685	rs6867870	chr5:139641896	C/A	cg26211634	chr5:139558579	C5orf32	0.44	8.3	0.41	2.59e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg23188684	chr11:67383651	NA	0.34	6.05	0.31	3.94e-9	Mean corpuscular volume;
LUSC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg04727924	chr7:799746	HEATR2	-0.57	-6.81	-0.35	4.69e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.6	0.54	2.33e-26	Prudent dietary pattern;
LUSC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg22535103	chr8:58192502	C8orf71	-0.66	-7.41	-0.38	1.02e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs10511400	0.764	rs1259457	chr3:120200667	A/G	cg13423759	chr1:37937403	NA	-0.41	-6.01	-0.31	4.95e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg10523679	chr1:76189770	ACADM	-0.53	-7.85	-0.39	5.89e-14	Daytime sleep phenotypes;
LUSC	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg17168535	chr8:21777572	XPO7	0.79	13.95	0.61	3.5e-35	Mean corpuscular volume;
LUSC	trans	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg16011800	chr17:1958478	HIC1	0.45	6.14	0.32	2.37e-9	Lymphocyte counts;Red cell distribution width;
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	11.09	0.52	1.51e-24	Lymphocyte counts;
LUSC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg21724239	chr8:58056113	NA	0.8	8.46	0.42	8.32e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg00033643	chr7:134001901	SLC35B4	0.47	7.28	0.37	2.36e-12	Mean platelet volume;
LUSC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.62	10.23	0.49	1.54e-21	Height;
LUSC	cis	rs977987	0.778	rs1109341	chr16:75445605	G/A	cg03315344	chr16:75512273	CHST6	0.47	8.63	0.43	2.48e-16	Dupuytren's disease;
LUSC	cis	rs4363385	0.818	rs946095	chr1:153006470	T/C	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.44e-8	Inflammatory skin disease;
LUSC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9584850	0.834	rs7334078	chr13:99120484	C/T	cg07423050	chr13:99094983	FARP1	-0.37	-6.38	-0.33	5.93e-10	Neuroticism;
LUSC	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg25036284	chr2:26402008	FAM59B	-0.61	-7.86	-0.4	5.38e-14	Gut microbiome composition (summer);
LUSC	cis	rs4343996	0.521	rs10233684	chr7:3424405	A/G	cg21248987	chr7:3385318	SDK1	0.37	6.3	0.33	9.65e-10	Motion sickness;
LUSC	cis	rs12602901	0.519	rs238238	chr17:4856376	A/G	cg19427746	chr17:4889932	CAMTA2	-0.35	-6.31	-0.33	9e-10	Blood metabolite levels;
LUSC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.6	9.69	0.47	1.02e-19	Aortic root size;
LUSC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15369054	chr17:80825471	TBCD	0.72	12.44	0.56	1.9e-29	Breast cancer;
LUSC	cis	rs2835872	0.758	rs1709817	chr21:39036349	T/A	cg20424643	chr21:39039972	KCNJ6	-0.44	-7.43	-0.38	8.98e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg11879182	chr18:77439856	CTDP1	0.72	11.91	0.55	1.68e-27	Monocyte count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10667969	chr3:149181941	NA	0.5	7.42	0.38	9.64e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21643547	chr1:205240462	TMCC2	-0.5	-9.3	-0.45	1.95e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs73198271	0.628	rs11776981	chr8:8589459	C/T	cg01851573	chr8:8652454	MFHAS1	0.48	6.02	0.31	4.52e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.71	0.43	1.4e-16	Prudent dietary pattern;
LUSC	cis	rs6429082	0.660	rs10737818	chr1:235542023	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.5	-6.87	-0.35	3.11e-11	Adiposity;
LUSC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg09699651	chr6:150184138	LRP11	0.37	5.7	0.3	2.61e-8	Lung cancer;
LUSC	cis	rs5167	0.533	rs55778858	chr19:45485465	G/A	cg25746394	chr19:45450501	APOC2	0.32	6.07	0.32	3.55e-9	Blood protein levels;
LUSC	cis	rs699	0.545	rs2478524	chr1:230836276	G/C	cg07502417	chr1:230849801	AGT	-0.28	-6.19	-0.32	1.78e-9	Coronary artery disease;
LUSC	cis	rs54211	1.000	rs137608	chr22:39696887	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.6	5.78	0.3	1.72e-8	Sudden cardiac arrest;
LUSC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg17633681	chr16:88106987	BANP	0.52	9.86	0.47	2.63e-20	Menopause (age at onset);
LUSC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg00343986	chr7:65444356	GUSB	-0.38	-5.73	-0.3	2.29e-8	Aortic root size;
LUSC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.06	-0.36	9.67e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs240764	0.631	rs12195369	chr6:101204106	G/A	cg09795085	chr6:101329169	ASCC3	-0.41	-6.03	-0.31	4.43e-9	Neuroticism;
LUSC	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	11.51	0.53	4.63e-26	Coronary artery disease;
LUSC	cis	rs11971779	0.588	rs2003531	chr7:139126578	A/G	cg07862535	chr7:139043722	LUC7L2	0.57	7.15	0.36	5.57e-12	Diisocyanate-induced asthma;
LUSC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg00343986	chr7:65444356	GUSB	0.47	7.14	0.36	5.91e-12	Aortic root size;
LUSC	cis	rs62229266	0.804	rs62230821	chr21:37425116	C/T	cg12218747	chr21:37451666	NA	-0.38	-5.67	-0.3	3.14e-8	Mitral valve prolapse;
LUSC	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.73	-11.52	-0.53	4.39e-26	Schizophrenia;
LUSC	cis	rs72700829	0.531	rs955955	chr1:151011543	G/A	cg11822372	chr1:151115635	SEMA6C	-0.74	-6.7	-0.34	8.74e-11	Schizophrenia;
LUSC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.55	6.48	0.33	3.26e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.47	7.4	0.38	1.14e-12	Schizophrenia;
LUSC	cis	rs6977660	0.714	rs1468287	chr7:19784210	T/A	cg05791153	chr7:19748676	TWISTNB	0.76	7.49	0.38	6.33e-13	Thyroid stimulating hormone;
LUSC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg16240275	chr20:61666158	NCRNA00029	0.41	9.04	0.44	1.27e-17	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg23719950	chr11:63933701	MACROD1	-0.62	-8.07	-0.4	1.29e-14	Mean platelet volume;
LUSC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs72634258	0.945	rs225120	chr1:8046378	C/T	cg26816564	chr1:7831052	VAMP3	0.43	5.85	0.3	1.16e-8	Inflammatory bowel disease;
LUSC	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg10645314	chr2:3704589	ALLC	-0.47	-7.18	-0.37	4.47e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg27266060	chr8:22091797	NA	0.4	7.24	0.37	3.1e-12	Hypertriglyceridemia;
LUSC	trans	rs4714291	0.928	rs1923461	chr6:39984670	A/T	cg02267698	chr19:7991119	CTXN1	0.52	7.28	0.37	2.34e-12	Strep throat;
LUSC	cis	rs10484885	0.887	rs2273246	chr6:90453263	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.91	-10.67	-0.5	4.44e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7940866	0.903	rs7130842	chr11:130836269	A/G	cg12179176	chr11:130786555	SNX19	0.57	8.91	0.44	3.31e-17	Schizophrenia;
LUSC	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.68	-12.01	-0.55	7.53e-28	White blood cell count (basophil);
LUSC	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg04539111	chr16:67997858	SLC12A4	-0.41	-5.66	-0.3	3.28e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.56	-0.34	2.06e-10	Systolic blood pressure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26243254	chr12:132434651	EP400	-0.44	-6.61	-0.34	1.51e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-6.2	-0.32	1.71e-9	Response to antipsychotic treatment;
LUSC	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	9.43	0.46	7.41e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.61	-0.34	1.54e-10	Fear of minor pain;
LUSC	cis	rs11971779	0.680	rs7783619	chr7:139061437	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.2	0.32	1.67e-9	Diisocyanate-induced asthma;
LUSC	trans	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07923666	chr12:49932857	KCNH3	-0.52	-6.75	-0.35	6.56e-11	Resting heart rate;
LUSC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.33	0.45	1.54e-18	Prudent dietary pattern;
LUSC	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg09238746	chr17:78121135	EIF4A3	-0.44	-6.15	-0.32	2.16e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs72949976	0.564	rs4673730	chr2:214024836	G/T	cg08319019	chr2:214017104	IKZF2	0.68	11.5	0.53	5.01e-26	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs4423214	0.879	rs1792282	chr11:71135166	G/A	cg05163923	chr11:71159392	DHCR7	-0.66	-8.63	-0.43	2.56e-16	Vitamin D levels;
LUSC	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.74	12.09	0.55	3.79e-28	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg02782426	chr3:40428986	ENTPD3	0.37	7.0	0.36	1.4e-11	Renal cell carcinoma;
LUSC	cis	rs11030122	0.673	rs11030660	chr11:4043268	T/C	cg18678763	chr11:4115507	RRM1	-0.45	-6.0	-0.31	5.12e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs701145	0.585	rs1470662	chr3:153870997	T/G	cg17054900	chr3:154042577	DHX36	0.69	6.76	0.35	6.15e-11	Coronary artery disease;
LUSC	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs7428	1.000	rs7428	chr2:85545490	C/T	cg24342717	chr2:85555507	TGOLN2	0.6	8.79	0.43	7.98e-17	Ear protrusion;
LUSC	cis	rs17824933	0.943	rs11230562	chr11:60776186	C/T	cg16817237	chr11:60793675	NA	0.41	6.46	0.33	3.75e-10	Multiple sclerosis;
LUSC	trans	rs4714291	0.963	rs1767672	chr6:40104107	G/T	cg02267698	chr19:7991119	CTXN1	0.51	7.06	0.36	9.79e-12	Strep throat;
LUSC	cis	rs9547692	0.938	rs7333607	chr13:37462010	A/G	cg01493522	chr13:37497338	NA	-0.4	-5.92	-0.31	7.92e-9	Coronary artery disease;
LUSC	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2274273	0.870	rs7160523	chr14:55594560	G/T	cg04306507	chr14:55594613	LGALS3	0.58	13.33	0.59	8.58e-33	Protein biomarker;
LUSC	cis	rs7084921	0.608	rs12780514	chr10:101865884	T/C	cg11888571	chr10:102027403	CWF19L1	-0.42	-5.84	-0.3	1.27e-8	Bone mineral density;
LUSC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	1.0	13.8	0.6	1.32e-34	Vitiligo;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg08843538	chr2:210288784	MAP2	-0.44	-6.14	-0.32	2.29e-9	Height;
LUSC	cis	rs11997175	0.625	rs4268088	chr8:33599343	A/T	ch.8.33884649F	chr8:33765107	NA	0.42	6.63	0.34	1.38e-10	Body mass index;
LUSC	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg17507749	chr15:85114479	UBE2QP1	0.65	8.1	0.41	1.04e-14	Schizophrenia;
LUSC	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg03605463	chr16:89740564	NA	0.52	8.36	0.42	1.75e-15	Hemoglobin concentration;
LUSC	cis	rs10484885	0.757	rs12215741	chr6:90154845	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.62	-5.92	-0.31	8.02e-9	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1335645	0.502	rs646734	chr1:111628733	A/G	cg00321911	chr1:111669324	DRAM2	0.57	6.41	0.33	5.03e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.73	11.28	0.53	3.17e-25	Retinal vascular caliber;
LUSC	cis	rs8040855	0.557	rs9744503	chr15:85724217	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.4	6.68	0.34	1.03e-10	Bulimia nervosa;
LUSC	trans	rs11165623	0.624	rs11165665	chr1:97007925	T/C	cg10631902	chr5:14652156	NA	-0.4	-6.06	-0.31	3.64e-9	Hip circumference;Waist circumference;
LUSC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg11645453	chr3:52864694	ITIH4	-0.39	-9.0	-0.44	1.73e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg22834771	chr12:69754056	YEATS4	0.51	7.68	0.39	1.77e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-8.93	-0.44	2.81e-17	Gut microbiome composition (summer);
LUSC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg08888203	chr3:10149979	C3orf24	0.66	9.2	0.45	4.01e-18	Alzheimer's disease;
LUSC	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg00012203	chr2:219082015	ARPC2	0.81	13.75	0.6	2.12e-34	Colorectal cancer;
LUSC	cis	rs4073416	0.542	rs8010726	chr14:65932597	C/T	cg03016385	chr14:66212404	NA	-0.41	-6.42	-0.33	4.65e-10	N-glycan levels;
LUSC	cis	rs12594515	1.000	rs35182335	chr15:45995184	C/G	cg01629716	chr15:45996671	NA	0.39	5.87	0.31	1.08e-8	Waist circumference;Weight;
LUSC	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	7.67	0.39	1.95e-13	Educational attainment;
LUSC	trans	rs804280	0.662	rs11784764	chr8:11610874	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.4	-0.33	5.3e-10	Myopia (pathological);
LUSC	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.88	0.6	6.88e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg24829409	chr8:58192753	C8orf71	-0.55	-5.82	-0.3	1.38e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2274273	0.638	rs9919921	chr14:55695505	A/G	cg04306507	chr14:55594613	LGALS3	0.48	9.57	0.46	2.43e-19	Protein biomarker;
LUSC	cis	rs11168618	0.846	rs11168577	chr12:48842592	C/T	cg24011408	chr12:48396354	COL2A1	0.38	6.07	0.32	3.48e-9	Adiponectin levels;
LUSC	trans	rs7849782	0.967	rs7038036	chr9:104414233	T/G	cg22914338	chr19:14376960	NA	0.26	6.48	0.33	3.2e-10	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg20701182	chr2:24300061	SF3B14	0.55	5.83	0.3	1.32e-8	Lymphocyte counts;
LUSC	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg04398451	chr17:18023971	MYO15A	0.44	6.96	0.36	1.77e-11	Total body bone mineral density;
LUSC	cis	rs10887741	0.646	rs12257469	chr10:89437129	G/A	cg13926569	chr10:89418898	PAPSS2	0.32	6.79	0.35	5.26e-11	Exercise (leisure time);
LUSC	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg17366294	chr4:99064904	C4orf37	0.55	9.51	0.46	3.92e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.72	10.2	0.49	1.85e-21	Corneal astigmatism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15367106	chr12:96184558	NTN4	0.48	6.49	0.33	3.1e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg01989461	chr14:81687754	GTF2A1	-0.68	-12.07	-0.55	4.34e-28	Schizophrenia;
LUSC	cis	rs35000415	0.938	rs10488631	chr7:128594183	T/C	cg19972273	chr7:128594194	NA	0.67	6.79	0.35	5.17e-11	Systemic lupus erythematosus;
LUSC	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg26850624	chr5:429559	AHRR	-0.43	-8.44	-0.42	1.01e-15	Cystic fibrosis severity;
LUSC	trans	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg25214090	chr10:38739885	LOC399744	0.42	6.53	0.34	2.38e-10	Corneal astigmatism;
LUSC	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg24558204	chr6:135376177	HBS1L	0.68	10.65	0.5	5.52e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs2414059	0.518	rs2289108	chr15:50782335	G/A	cg06848185	chr17:75368902	SEPT9	0.37	6.18	0.32	1.88e-9	QT interval;
LUSC	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12200560	0.505	rs211183	chr6:97074723	G/T	cg06623918	chr6:96969491	KIAA0776	-0.49	-7.18	-0.37	4.6e-12	Coronary heart disease;
LUSC	trans	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-8.86	-0.44	4.74e-17	Obesity-related traits;
LUSC	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg08000102	chr2:233561755	GIGYF2	0.81	14.02	0.61	2.01e-35	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	0.58	9.25	0.45	2.71e-18	Breast cancer;
LUSC	cis	rs41271951	0.512	rs12090246	chr1:151107496	G/A	cg11822372	chr1:151115635	SEMA6C	-0.74	-6.73	-0.35	7.24e-11	Blood protein levels;
LUSC	cis	rs7011049	1.000	rs4521776	chr8:53838833	G/C	cg26025543	chr8:53854495	NA	0.52	6.3	0.33	9.5e-10	Systolic blood pressure;
LUSC	cis	rs56283067	0.578	rs72862930	chr6:45361883	C/T	cg20913747	chr6:44695427	NA	-0.44	-6.42	-0.33	4.68e-10	Total body bone mineral density;
LUSC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg07507251	chr3:52567010	NT5DC2	0.33	6.19	0.32	1.72e-9	Bipolar disorder;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.84	-15.2	-0.64	5.24e-40	Menarche (age at onset);
LUSC	cis	rs2224391	0.911	rs9504368	chr6:5261460	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.47	-6.74	-0.35	7.14e-11	Height;
LUSC	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.88	17.08	0.68	1.87e-47	Diastolic blood pressure;
LUSC	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03878208	chr11:72483293	STARD10	-0.56	-7.58	-0.38	3.37e-13	Type 2 diabetes;
LUSC	trans	rs89107	0.688	rs372237	chr6:118608979	G/T	cg11574620	chr4:80246899	NAA11	-0.36	-5.95	-0.31	6.73e-9	Cardiac structure and function;
LUSC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-9.69	-0.47	9.62e-20	Gut microbiome composition (summer);
LUSC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.57e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.45	0.38	8.3e-13	Bipolar disorder;
LUSC	cis	rs113835537	0.597	rs7116921	chr11:66303854	T/C	cg24851651	chr11:66362959	CCS	0.53	7.97	0.4	2.52e-14	Airway imaging phenotypes;
LUSC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg00074818	chr8:8560427	CLDN23	0.57	9.86	0.47	2.6e-20	Obesity-related traits;
LUSC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00149659	chr3:10157352	C3orf10	0.91	12.44	0.56	1.89e-29	Alzheimer's disease;
LUSC	cis	rs6901250	0.759	rs9489040	chr6:117131740	G/A	cg12892004	chr6:117198278	RFX6	0.39	7.17	0.37	4.71e-12	C-reactive protein levels;
LUSC	cis	rs75804782	0.521	rs66477197	chr2:239403832	C/T	cg18131467	chr2:239335373	ASB1	-0.68	-6.24	-0.32	1.29e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-6.69	-0.34	9.46e-11	Monocyte percentage of white cells;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17605604	chr5:102612899	C5orf30	-0.45	-6.76	-0.35	6.09e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg08508325	chr11:3079039	CARS	0.37	8.27	0.41	3.18e-15	Calcium levels;
LUSC	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg02569458	chr12:86230093	RASSF9	0.42	6.71	0.34	8.49e-11	Major depressive disorder;
LUSC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05890377	chr2:74357713	NA	0.72	13.68	0.6	3.83e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg05872129	chr22:39784769	NA	-0.61	-11.26	-0.52	3.86e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-0.95	-10.27	-0.49	1.11e-21	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg23625390	chr15:77176239	SCAPER	0.5	7.83	0.39	6.38e-14	Blood metabolite levels;
LUSC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg06808227	chr14:105710500	BRF1	-0.66	-10.08	-0.48	4.97e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg19610905	chr11:61596333	FADS2	0.55	8.06	0.4	1.41e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs4919087	1.000	rs10786326	chr10:99070377	G/A	cg25902810	chr10:99078978	FRAT1	0.49	7.22	0.37	3.57e-12	Monocyte count;
LUSC	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.13	0.45	6.54e-18	Coffee consumption (cups per day);
LUSC	cis	rs4363385	0.776	rs2879490	chr1:152947163	A/G	cg00922841	chr1:152955080	SPRR1A	-0.46	-7.55	-0.38	4.21e-13	Inflammatory skin disease;
LUSC	cis	rs2404602	0.735	rs4886800	chr15:76678692	A/G	cg23625390	chr15:77176239	SCAPER	-0.57	-8.62	-0.43	2.76e-16	Blood metabolite levels;
LUSC	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg08508325	chr11:3079039	CARS	0.38	8.44	0.42	1e-15	Calcium levels;
LUSC	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.44e-17	Iron status biomarkers;
LUSC	cis	rs8028313	0.504	rs2899730	chr15:68172520	G/T	cg08079166	chr15:68083412	MAP2K5	-0.34	-6.07	-0.32	3.52e-9	Obesity;
LUSC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23281280	chr6:28129359	ZNF389	0.43	5.71	0.3	2.47e-8	Depression;
LUSC	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg11887960	chr12:57824829	NA	0.56	6.84	0.35	3.75e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg14019146	chr3:50243930	SLC38A3	-0.36	-8.24	-0.41	4.02e-15	Body mass index;
LUSC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.76	-17.37	-0.69	1.31e-48	Longevity;Endometriosis;
LUSC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.68	-0.3	2.99e-8	Personality dimensions;
LUSC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-11.28	-0.53	3.26e-25	Alzheimer's disease;
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.5	-7.3	-0.37	2.06e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	0.92	15.33	0.64	1.58e-40	Breast cancer;
LUSC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg09904177	chr6:26538194	HMGN4	0.76	14.14	0.61	6.7e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs9311676	0.632	rs1126722	chr3:58413518	T/G	cg13750441	chr3:58318267	PXK	0.35	6.86	0.35	3.41e-11	Systemic lupus erythematosus;
LUSC	cis	rs2742234	0.955	rs2075910	chr10:43614230	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.37	-6.52	-0.34	2.66e-10	Hirschsprung disease;
LUSC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg15448220	chr1:150897856	SETDB1	0.41	5.91	0.31	8.67e-9	Melanoma;
LUSC	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg05855489	chr10:104503620	C10orf26	0.61	8.87	0.44	4.4e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg09835421	chr16:68378352	PRMT7	-0.54	-5.92	-0.31	7.97e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18552940	chr12:109490386	USP30	-0.43	-6.08	-0.32	3.24e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg16482183	chr6:26056742	HIST1H1C	0.45	6.8	0.35	4.91e-11	Height;
LUSC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg06713675	chr4:122721982	EXOSC9	-0.44	-7.77	-0.39	9.93e-14	Type 2 diabetes;
LUSC	cis	rs3741151	0.686	rs11822984	chr11:73261467	A/C	cg17517138	chr11:73019481	ARHGEF17	0.92	7.8	0.39	8.22e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9905704	0.918	rs304282	chr17:56785571	T/C	cg12560992	chr17:57184187	TRIM37	0.56	8.01	0.4	1.92e-14	Testicular germ cell tumor;
LUSC	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg01065977	chr19:18549689	ISYNA1	-0.23	-5.89	-0.31	9.22e-9	Breast cancer;
LUSC	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.64	0.63	8.06e-38	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg08680598	chr22:49984980	NA	-0.34	-6.25	-0.32	1.24e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.3	0.53	2.75e-25	Menopause (age at onset);
LUSC	cis	rs6942756	0.806	rs6967464	chr7:128909727	T/C	cg02491457	chr7:128862824	NA	0.48	7.23	0.37	3.26e-12	White matter hyperintensity burden;
LUSC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.52	-0.38	5.22e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.59	11.98	0.55	9.34e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2463822	0.583	rs7129536	chr11:62030829	C/T	cg06239285	chr11:62104954	ASRGL1	-0.59	-6.01	-0.31	4.85e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg07148914	chr20:33460835	GGT7	-0.53	-8.1	-0.41	1.05e-14	Glomerular filtration rate (creatinine);
LUSC	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.48	-0.33	3.28e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2219968	0.746	rs10957878	chr8:78910939	A/C	cg00738934	chr8:78996279	NA	-0.4	-7.22	-0.37	3.45e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg06521331	chr12:34319734	NA	-0.46	-7.33	-0.37	1.72e-12	Morning vs. evening chronotype;
LUSC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg05738196	chr6:26577821	NA	-0.61	-7.05	-0.36	1.06e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6542838	0.641	rs6542841	chr2:99489039	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.09	-0.32	3.1e-9	Fear of minor pain;
LUSC	cis	rs68170813	0.562	rs78181351	chr7:106999301	A/G	cg02696742	chr7:106810147	HBP1	-0.63	-9.36	-0.46	1.24e-18	Coronary artery disease;
LUSC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.35	0.46	1.28e-18	Monocyte percentage of white cells;
LUSC	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.88	0.35	2.95e-11	Height;
LUSC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg14416269	chr4:6271139	WFS1	0.54	11.38	0.53	1.35e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	11.77	0.54	5.5e-27	Hip circumference adjusted for BMI;
LUSC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs6686643	0.630	rs7554034	chr1:165610464	G/A	cg16553119	chr1:165599451	MGST3	-0.44	-5.84	-0.3	1.23e-8	Total ventricular volume;
LUSC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg09034736	chr1:150693464	HORMAD1	0.51	7.45	0.38	8.22e-13	Urate levels;
LUSC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg09626299	chr10:82213104	TSPAN14	-0.2	-5.92	-0.31	8.16e-9	Post bronchodilator FEV1;
LUSC	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	trans	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg21659725	chr3:3221576	CRBN	0.68	8.24	0.41	3.83e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs60154123	0.730	rs10863818	chr1:210458007	C/T	cg22029157	chr1:209979665	IRF6	0.51	5.84	0.3	1.23e-8	Coronary artery disease;
LUSC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg06096015	chr1:231504339	EGLN1	0.57	9.97	0.48	1.17e-20	Hemoglobin concentration;
LUSC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	9.73e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6426558	0.559	rs485234	chr1:227317747	A/G	cg10327440	chr1:227177885	CDC42BPA	0.55	7.41	0.38	1.02e-12	Neutrophil percentage of white cells;
LUSC	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.07	0.48	5.24e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15604682	chr7:102105781	ALKBH4;LRWD1	0.51	8.33	0.41	2.16e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05901451	chr6:126070800	HEY2	-0.57	-8.75	-0.43	1.11e-16	Endometrial cancer;
LUSC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.55	-0.34	2.23e-10	Life satisfaction;
LUSC	cis	rs17767294	0.708	rs9380018	chr6:27740646	A/G	cg08851530	chr6:28072375	NA	1.03	7.2	0.37	3.99e-12	Parkinson's disease;
LUSC	cis	rs73206853	0.563	rs55885633	chr12:111189251	C/T	cg12870014	chr12:110450643	ANKRD13A	0.66	6.54	0.34	2.34e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2303282	0.664	rs2440468	chr16:56420594	G/A	cg00500540	chr16:56394104	NA	-0.39	-6.67	-0.34	1.09e-10	Breast cancer;
LUSC	cis	rs2710642	0.927	rs2539980	chr2:63208460	T/C	cg17519650	chr2:63277830	OTX1	0.6	8.34	0.42	1.94e-15	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs1550582	1.000	rs1550582	chr8:135542084	A/G	cg17885191	chr8:135476712	NA	-0.66	-9.17	-0.45	4.81e-18	Educational attainment;
LUSC	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.84	0.44	5.47e-17	Coffee consumption (cups per day);
LUSC	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg07148914	chr20:33460835	GGT7	-0.45	-6.59	-0.34	1.67e-10	Height;
LUSC	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.42	-0.56	2.29e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1847202	0.793	rs11918132	chr3:72952144	C/T	cg25664220	chr3:72788482	NA	-0.44	-7.94	-0.4	3.01e-14	Motion sickness;
LUSC	cis	rs62400317	0.859	rs11965520	chr6:45259431	T/A	cg18551225	chr6:44695536	NA	-0.42	-7.01	-0.36	1.33e-11	Total body bone mineral density;
LUSC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg09455208	chr3:40491958	NA	0.53	9.3	0.45	1.91e-18	Renal cell carcinoma;
LUSC	cis	rs1775715	0.737	rs2778661	chr10:32159191	C/T	cg26784012	chr10:32216390	ARHGAP12	0.46	7.87	0.4	4.88e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs13242816	1.000	rs36011826	chr7:116118336	G/A	cg16553024	chr7:116138462	CAV2	-0.52	-5.71	-0.3	2.44e-8	P wave duration;
LUSC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg11632617	chr15:75315747	PPCDC	-0.52	-6.76	-0.35	6.32e-11	Blood trace element (Zn levels);
LUSC	trans	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04565464	chr8:145669602	NFKBIL2	0.38	6.35	0.33	7.15e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg04518342	chr5:131593106	PDLIM4	0.43	7.7	0.39	1.6e-13	Breast cancer;
LUSC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08677398	chr8:58056175	NA	0.53	6.36	0.33	6.53e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg00857998	chr1:205179979	DSTYK	0.6	9.1	0.45	8.62e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs2262909	0.962	rs1526884	chr19:22303651	A/G	cg05197062	chr11:11642011	GALNTL4	0.54	7.62	0.38	2.72e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg09904177	chr6:26538194	HMGN4	-0.5	-5.95	-0.31	6.62e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11785693	0.862	rs62491168	chr8:4982290	A/T	cg26367366	chr8:4980734	NA	0.81	9.55	0.46	2.81e-19	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs644148	0.933	rs565819	chr19:44967714	A/G	cg15540054	chr19:45004280	ZNF180	0.55	7.84	0.39	6.17e-14	Personality dimensions;
LUSC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	0.98	13.48	0.59	2.19e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg23791538	chr6:167370224	RNASET2	0.42	6.79	0.35	5.09e-11	Crohn's disease;
LUSC	trans	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg06521331	chr12:34319734	NA	-0.4	-6.09	-0.32	3.07e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.46	-0.33	3.63e-10	Blood metabolite levels;
LUSC	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg26395211	chr5:140044315	WDR55	0.45	7.0	0.36	1.39e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg25457927	chr22:38595422	NA	-0.38	-7.67	-0.39	1.93e-13	Cutaneous nevi;
LUSC	trans	rs7939886	0.920	rs12223067	chr11:55915420	C/A	cg15704280	chr7:45808275	SEPT13	0.83	6.64	0.34	1.27e-10	Myopia (pathological);
LUSC	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg26677194	chr12:130822605	PIWIL1	0.59	8.77	0.43	9.52e-17	Menopause (age at onset);
LUSC	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	16.76	0.68	3.52e-46	Exhaled nitric oxide output;
LUSC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.85	-0.35	3.66e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7809950	0.817	rs62483725	chr7:107201575	G/A	cg23024343	chr7:107201750	COG5	-0.71	-10.26	-0.49	1.19e-21	Coronary artery disease;
LUSC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.67	14.94	0.63	5.16e-39	Hemoglobin concentration;
LUSC	cis	rs6674970	0.933	rs11204772	chr1:151056305	C/T	cg03258749	chr1:151040405	MLLT11	-0.45	-6.76	-0.35	6.12e-11	Childhood ear infection;
LUSC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg23283495	chr1:209979779	IRF6	-0.66	-8.39	-0.42	1.4e-15	Cleft lip with or without cleft palate;
LUSC	cis	rs17401966	0.522	rs10492969	chr1:10286358	T/C	cg17425144	chr1:10567563	PEX14	-0.34	-6.05	-0.31	3.83e-9	Hepatocellular carcinoma;
LUSC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-7.5	-0.38	5.7e-13	Alzheimer's disease (late onset);
LUSC	cis	rs35883536	0.551	rs6666607	chr1:101032368	A/G	cg06223162	chr1:101003688	GPR88	-0.49	-9.1	-0.45	8.3e-18	Monocyte count;
LUSC	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.6	0.38	3.03e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg12560992	chr17:57184187	TRIM37	-0.83	-14.94	-0.63	5.1e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs1256061	0.564	rs1256043	chr14:64734282	A/G	cg21174375	chr14:64681225	SYNE2	0.35	6.26	0.32	1.19e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg14004847	chr7:1930337	MAD1L1	-0.56	-8.66	-0.43	2.04e-16	Schizophrenia;
LUSC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg13395646	chr4:1353034	KIAA1530	-0.63	-10.16	-0.49	2.66e-21	Obesity-related traits;
LUSC	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg21051086	chr3:73046214	PPP4R2	-0.52	-7.83	-0.39	6.62e-14	Pancreatic cancer;
LUSC	cis	rs897984	0.762	rs7204459	chr16:30984212	G/A	cg02466173	chr16:30829666	NA	0.55	10.91	0.51	6.58e-24	Dementia with Lewy bodies;
LUSC	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	6.95	0.36	1.87e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9341808	0.791	rs1324122	chr6:80946061	G/A	cg08355045	chr6:80787529	NA	0.56	9.58	0.46	2.37e-19	Sitting height ratio;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03309838	chr22:41215494	SLC25A17	-0.41	-6.89	-0.35	2.74e-11	Electrocardiographic conduction measures;
LUSC	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.72	-0.47	8.18e-20	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03264133	chr6:25882463	NA	-0.75	-12.42	-0.56	2.2e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.51	8.03	0.4	1.68e-14	Colorectal cancer;
LUSC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg09904177	chr6:26538194	HMGN4	0.47	7.48	0.38	6.76e-13	Schizophrenia;
LUSC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg17971929	chr21:40555470	PSMG1	-0.53	-7.75	-0.39	1.15e-13	Menarche (age at onset);
LUSC	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg06781209	chr11:61594997	FADS2	-0.44	-6.56	-0.34	2.09e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs11039100	0.920	rs12792905	chr11:5821544	G/C	cg05234568	chr11:5960015	NA	-0.51	-5.76	-0.3	1.87e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg00982548	chr2:198649783	BOLL	-0.59	-7.27	-0.37	2.62e-12	Ulcerative colitis;
LUSC	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	1.53	13.68	0.6	3.88e-34	Atopic dermatitis;
LUSC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg24829409	chr8:58192753	C8orf71	-0.61	-6.44	-0.33	4.18e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.59	-9.33	-0.45	1.57e-18	HDL cholesterol;
LUSC	trans	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-12.48	-0.56	1.37e-29	Colorectal cancer;
LUSC	cis	rs9608946	0.515	rs3804078	chr22:30853882	T/C	cg03868770	chr22:30783737	RNF215	-0.34	-5.67	-0.3	3.17e-8	Red cell distribution width;
LUSC	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg23093090	chr10:104574429	C10orf26	-0.37	-6.84	-0.35	3.81e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12541635	0.833	rs4734130	chr8:107096458	A/G	cg10147462	chr8:107024639	NA	-0.43	-7.56	-0.38	4.01e-13	Age of smoking initiation;
LUSC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.05	-0.31	3.93e-9	Platelet count;
LUSC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg12615879	chr12:58013172	SLC26A10	-0.26	-5.88	-0.31	9.8e-9	Multiple sclerosis;
LUSC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg12463550	chr7:65579703	CRCP	0.51	7.38	0.37	1.26e-12	Aortic root size;
LUSC	cis	rs36093844	0.800	rs1445504	chr11:85584879	G/A	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs4566357	1.000	rs2141829	chr2:227922454	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.91	-0.31	8.3e-9	Coronary artery disease;
LUSC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7681440	0.647	rs11941110	chr4:90819569	T/C	cg01966878	chr4:90757139	SNCA	-0.35	-5.67	-0.3	3.15e-8	Dementia with Lewy bodies;
LUSC	cis	rs4803468	1.000	rs55986560	chr19:41939835	C/T	cg09537434	chr19:41945824	ATP5SL	0.96	16.32	0.67	1.86e-44	Height;
LUSC	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg24881330	chr22:46731750	TRMU	0.57	6.53	0.34	2.46e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs77633900	0.614	rs280012	chr15:76974854	G/T	cg21673338	chr15:77095150	SCAPER	-0.8	-8.15	-0.41	7.48e-15	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-6.34	-0.33	7.49e-10	Psoriasis;
LUSC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg13683864	chr3:40499215	RPL14	-1.11	-18.36	-0.71	1.5e-52	Renal cell carcinoma;
LUSC	cis	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg09307838	chr4:120376055	NA	0.49	7.45	0.38	8.28e-13	Diastolic blood pressure;
LUSC	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg08975724	chr8:8085496	FLJ10661	0.46	7.07	0.36	8.95e-12	Retinal vascular caliber;
LUSC	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg13010199	chr12:38710504	ALG10B	0.49	7.53	0.38	4.89e-13	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8064299	0.597	rs4789098	chr17:72781292	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.91	18.0	0.7	4.29e-51	Monocyte count;
LUSC	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg23029597	chr12:123009494	RSRC2	-0.72	-9.5	-0.46	4.17e-19	Body mass index;
LUSC	trans	rs12200782	0.674	rs12207224	chr6:26519280	A/T	cg11837749	chr1:55047332	ACOT11	0.58	6.31	0.33	8.85e-10	Small cell lung carcinoma;
LUSC	cis	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg05299278	chr17:33885742	SLFN14	0.29	6.35	0.33	7.12e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs6596100	0.538	rs4705972	chr5:132179237	T/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.16	-0.32	2.14e-9	Breast cancer;
LUSC	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg13575925	chr12:9217583	LOC144571	0.35	6.44	0.33	4.27e-10	Sjögren's syndrome;
LUSC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.03	0.31	4.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg03806693	chr22:41940476	POLR3H	0.85	12.11	0.55	3.09e-28	Vitiligo;
LUSC	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg05805236	chr11:65401703	PCNXL3	-0.64	-10.71	-0.51	3.43e-23	Acne (severe);
LUSC	cis	rs3125734	0.633	rs7088891	chr10:64034019	G/T	cg09941381	chr10:64027924	RTKN2	-0.4	-7.21	-0.37	3.77e-12	Rheumatoid arthritis;
LUSC	cis	rs4891159	0.790	rs8098821	chr18:74140345	T/C	cg24786174	chr18:74118243	ZNF516	-0.84	-15.44	-0.65	5.61e-41	Longevity;
LUSC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24110177	chr3:50126178	RBM5	0.59	9.65	0.47	1.31e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg23752985	chr2:85803571	VAMP8	0.29	6.22	0.32	1.52e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2667011	0.759	rs1567537	chr2:160857568	T/C	cg06573604	chr2:160760825	LY75	-0.49	-6.23	-0.32	1.42e-9	Bilirubin levels;
LUSC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.88e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg26751094	chr13:95954534	ABCC4	-0.43	-7.68	-0.39	1.77e-13	Blood metabolite levels;
LUSC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-11.88	-0.54	2.19e-27	Body mass index;
LUSC	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg08085267	chr17:45401833	C17orf57	0.6	9.97	0.48	1.12e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg24920358	chr1:40204285	PPIE	0.6	10.61	0.5	7.42e-23	Blood protein levels;
LUSC	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.69	-0.3	2.8e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg10523679	chr1:76189770	ACADM	0.64	8.96	0.44	2.27e-17	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.84	-11.24	-0.52	4.63e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs330071	0.500	rs17662123	chr8:9246837	G/A	cg21775007	chr8:11205619	TDH	0.44	6.44	0.33	4.27e-10	Acne (severe);
LUSC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg25809561	chr17:30822961	MYO1D	0.39	6.44	0.33	4.09e-10	Schizophrenia;
LUSC	cis	rs240764	0.817	rs6907240	chr6:101153782	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.17	-0.32	2.03e-9	Neuroticism;
LUSC	cis	rs8126001	0.626	rs4337532	chr20:62715089	G/A	cg03642690	chr20:62727907	OPRL1	-0.32	-5.78	-0.3	1.68e-8	Pulse pressure;Mean corpuscular volume;
LUSC	trans	rs4650994	0.544	rs6682815	chr1:178501109	T/C	cg05059571	chr16:84539110	KIAA1609	-0.47	-9.1	-0.45	8.55e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs968451	0.547	rs11704319	chr22:39722886	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.74	-12.1	-0.55	3.42e-28	Primary biliary cholangitis;
LUSC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07167872	chr1:205819463	PM20D1	-0.75	-14.67	-0.63	6.03e-38	Monocyte percentage of white cells;
LUSC	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg01557791	chr16:72042693	DHODH	-0.5	-6.43	-0.33	4.45e-10	Blood protein levels;
LUSC	cis	rs714027	0.585	rs73162764	chr22:30358745	G/A	cg11564601	chr22:30592435	NA	0.34	5.86	0.31	1.14e-8	Lymphocyte counts;
LUSC	cis	rs4478858	0.746	rs10914328	chr1:31688406	A/G	cg00250761	chr1:31883323	NA	0.36	9.23	0.45	3.3e-18	Alcohol dependence;
LUSC	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs11209002	0.956	rs11209000	chr1:67578514	C/G	cg02640540	chr1:67518911	SLC35D1	0.69	7.58	0.38	3.42e-13	Crohn's disease;
LUSC	cis	rs9341808	0.690	rs3805926	chr6:80879280	C/G	cg08355045	chr6:80787529	NA	0.58	10.05	0.48	6.06e-21	Sitting height ratio;
LUSC	cis	rs36093844	1.000	rs11234452	chr11:85576801	C/T	cg25872744	chr11:85566296	CCDC83	-0.5	-7.76	-0.39	1.05e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.41	-6.58	-0.34	1.81e-10	Longevity;Endometriosis;
LUSC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg22467129	chr15:76604101	ETFA	-0.44	-6.95	-0.36	1.9e-11	Blood metabolite levels;
LUSC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg25204440	chr1:209979598	IRF6	0.5	6.63	0.34	1.36e-10	Cleft lip with or without cleft palate;
LUSC	trans	rs7939886	0.920	rs1482009	chr11:55884690	T/G	cg03929089	chr4:120376271	NA	0.75	6.11	0.32	2.77e-9	Myopia (pathological);
LUSC	cis	rs7106204	0.609	rs16912391	chr11:24310637	G/A	ch.11.24196551F	chr11:24239977	NA	0.69	5.68	0.3	2.86e-8	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg16512390	chr1:228756714	NA	0.7	8.89	0.44	4.03e-17	Chronic lymphocytic leukemia;
LUSC	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	0.57	9.09	0.45	8.73e-18	Breast cancer;
LUSC	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg16558253	chr16:72132732	DHX38	-0.42	-6.41	-0.33	5e-10	Fibrinogen levels;
LUSC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg07741184	chr6:167504864	NA	0.39	6.95	0.36	1.96e-11	Primary biliary cholangitis;
LUSC	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg10792982	chr14:105748885	BRF1	0.46	8.16	0.41	6.69e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.17	0.58	3.33e-32	Chronic sinus infection;
LUSC	cis	rs2282802	0.651	rs13353827	chr5:139654537	T/C	cg26211634	chr5:139558579	C5orf32	0.44	8.34	0.41	2.04e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.45	-0.46	6.1e-19	Type 2 diabetes;
LUSC	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg08601574	chr20:25228251	PYGB	0.43	6.55	0.34	2.15e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg26395211	chr5:140044315	WDR55	0.41	6.41	0.33	5.09e-10	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg20019720	chr6:154832845	CNKSR3	0.62	8.69	0.43	1.63e-16	Lipoprotein (a) levels;
LUSC	cis	rs886126	1.000	rs4766451	chr12:111670682	G/T	cg10833066	chr12:111807467	FAM109A	0.4	6.45	0.33	4.02e-10	Coronary heart disease;
LUSC	cis	rs4704187	0.687	rs9654429	chr5:74466925	C/G	cg03227963	chr5:74354835	NA	0.31	6.7	0.34	8.62e-11	Response to amphetamines;
LUSC	cis	rs9400467	0.528	rs7750792	chr6:111783759	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.46	-0.33	3.79e-10	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg03433033	chr1:76189801	ACADM	-0.46	-6.92	-0.35	2.27e-11	Daytime sleep phenotypes;
LUSC	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg06484146	chr7:12443880	VWDE	-0.67	-6.99	-0.36	1.51e-11	Coronary artery disease;
LUSC	cis	rs7202877	0.706	rs247447	chr16:75486648	A/G	cg04384234	chr16:75411784	CFDP1	0.63	8.34	0.42	2e-15	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.46	-0.5	2.51e-22	Eye color traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10139443	chr6:99963249	USP45	-0.38	-6.09	-0.32	3.05e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg15691649	chr6:25882328	NA	-0.4	-5.74	-0.3	2.18e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7943203	0.525	rs665293	chr11:108142617	G/A	cg04873221	chr11:107992290	ACAT1	-0.4	-5.87	-0.31	1.06e-8	Red blood cell count;Mean corpuscular volume;
LUSC	cis	rs8038465	0.615	rs6495076	chr15:73982965	G/A	cg15420318	chr15:73925796	NPTN	0.56	9.47	0.46	5.15e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs55871839	0.708	rs7000535	chr8:59804351	T/C	cg07426533	chr8:59803705	TOX	-0.36	-5.81	-0.3	1.44e-8	Pneumonia;
LUSC	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.16	-0.32	2.09e-9	Neutrophil percentage of white cells;
LUSC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs68170813	0.559	rs76208112	chr7:106964222	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.62	-0.47	1.71e-19	Coronary artery disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20471045	chr19:49568214	NTF4	-0.55	-7.58	-0.38	3.36e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-8.78	-0.43	8.37e-17	Bipolar disorder;
LUSC	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg03676636	chr4:99064102	C4orf37	0.32	6.05	0.31	3.8e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg23625390	chr15:77176239	SCAPER	0.59	9.36	0.46	1.25e-18	Blood metabolite levels;
LUSC	cis	rs6542838	0.597	rs35107109	chr2:99386210	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-5.9	-0.31	9.11e-9	Fear of minor pain;
LUSC	cis	rs921665	0.749	rs4854133	chr2:3199626	C/T	cg16434511	chr2:3151078	NA	-0.61	-6.49	-0.33	3.11e-10	World class endurance athleticism;
LUSC	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg02018176	chr4:1364513	KIAA1530	0.43	6.15	0.32	2.24e-9	Recombination rate (females);
LUSC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg23649088	chr2:200775458	C2orf69	0.54	7.35	0.37	1.58e-12	Schizophrenia;
LUSC	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg06637938	chr14:75390232	RPS6KL1	0.67	11.26	0.52	3.78e-25	Caffeine consumption;
LUSC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.8	-0.35	4.92e-11	Lung cancer;
LUSC	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg20734569	chr3:48348370	SPINK8	-0.47	-8.34	-0.42	1.93e-15	Coronary artery disease;
LUSC	cis	rs6693567	0.874	rs698915	chr1:150388318	C/T	cg15654264	chr1:150340011	RPRD2	-0.43	-6.08	-0.32	3.3e-9	Migraine;
LUSC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21016266	chr12:122356598	WDR66	0.61	9.04	0.44	1.33e-17	Mean corpuscular volume;
LUSC	cis	rs7814319	0.840	rs10504961	chr8:97240129	C/T	cg20787634	chr8:97240163	UQCRB	-0.34	-5.92	-0.31	7.92e-9	Lung function (FVC);
LUSC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06634786	chr22:41940651	POLR3H	0.53	6.19	0.32	1.79e-9	Vitiligo;
LUSC	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg10434728	chr15:90938212	IQGAP1	0.41	8.61	0.43	2.89e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg25214090	chr10:38739885	LOC399744	-0.41	-6.43	-0.33	4.44e-10	Corneal astigmatism;
LUSC	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg14019146	chr3:50243930	SLC38A3	0.48	11.43	0.53	9.38e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.21	0.59	2.51e-32	Cognitive test performance;
LUSC	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.51	6.62	0.34	1.44e-10	HIV-1 control;
LUSC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg12560992	chr17:57184187	TRIM37	0.83	15.26	0.64	2.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs9399401	0.710	rs6900087	chr6:142717303	A/T	cg03128060	chr6:142623767	GPR126	0.57	9.48	0.46	4.8e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg19046167	chr17:80928561	B3GNTL1	0.44	7.17	0.37	4.89e-12	Breast cancer;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01774158	chr5:133562094	PPP2CA	-0.35	-6.38	-0.33	6e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs3857536	0.813	rs7768944	chr6:66951088	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	trans	rs4729127	1.000	rs17166206	chr7:94004197	C/T	cg14660007	chr13:78271894	SLAIN1	0.49	6.22	0.32	1.52e-9	Intelligence;
LUSC	cis	rs501916	0.833	rs3809486	chr15:48051549	G/T	cg16110827	chr15:48056943	SEMA6D	-0.47	-7.28	-0.37	2.35e-12	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.36	0.37	1.47e-12	Mean platelet volume;
LUSC	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg22535103	chr8:58192502	C8orf71	-0.55	-6.65	-0.34	1.19e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs151234	0.612	rs11641853	chr16:28589719	A/G	cg01378222	chr16:28622494	SULT1A1	-0.63	-8.53	-0.42	5.08e-16	Platelet distribution width;
LUSC	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-10.55	-0.5	1.17e-22	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20263435	chr8:41435469	AGPAT6	-0.4	-6.01	-0.31	4.97e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs1995809	0.793	rs76475338	chr4:147758842	C/A	cg04587220	chr19:1071208	HMHA1	0.54	6.03	0.31	4.27e-9	Plasma amyloid beta peptide concentrations (ABx-40);
LUSC	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg13902645	chr11:5959945	NA	-0.59	-8.28	-0.41	2.95e-15	DNA methylation (variation);
LUSC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.01	0.58	1.44e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17467752	chr17:38218738	THRA	-0.77	-12.38	-0.56	3.22e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg23711669	chr6:146136114	FBXO30	0.91	17.74	0.7	4.59e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg26818010	chr10:134567672	INPP5A	-0.43	-6.5	-0.34	2.88e-10	Gait speed in old age;
LUSC	cis	rs9395066	0.545	rs10948197	chr6:44967490	C/T	cg25276700	chr6:44698697	NA	-0.27	-5.65	-0.3	3.46e-8	Height;
LUSC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26314531	chr2:26401878	FAM59B	0.72	10.0	0.48	9.4499999999999992e-21	Gut microbiome composition (summer);
LUSC	cis	rs4654899	0.865	rs61779120	chr1:21481230	T/C	cg01072550	chr1:21505969	NA	-0.53	-7.81	-0.39	7.38e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg08742575	chr21:47604166	C21orf56	-0.42	-6.26	-0.32	1.2e-9	Testicular germ cell tumor;
LUSC	cis	rs4363385	0.747	rs6668696	chr1:152964910	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.56	-0.38	3.85e-13	Inflammatory skin disease;
LUSC	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg24324837	chr19:49891574	CCDC155	0.49	6.25	0.32	1.23e-9	Multiple sclerosis;
LUSC	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.63	0.43	2.61e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.62	-10.42	-0.5	3.35e-22	Breast cancer;
LUSC	cis	rs2729354	0.817	rs2649667	chr11:57270509	A/C	cg24343310	chr11:57249947	NA	0.46	9.01	0.44	1.67e-17	Blood protein levels;
LUSC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	1.01	14.27	0.62	2.06e-36	Eosinophil percentage of granulocytes;
LUSC	trans	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg01826367	chr1:224180288	NA	-0.68	-6.61	-0.34	1.54e-10	Obesity (early onset extreme);
LUSC	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg12935359	chr14:103987150	CKB	0.54	8.47	0.42	7.69e-16	Body mass index;
LUSC	cis	rs7582720	0.943	rs72932560	chr2:203847417	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.35	0.42	1.88e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1113500	0.730	rs1777457	chr1:108588195	G/T	cg06207961	chr1:108661230	NA	-0.31	-5.88	-0.31	9.84e-9	Growth-regulated protein alpha levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20400718	chr8:42940792	FNTA	0.49	6.14	0.32	2.33e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg11161011	chr14:65562177	MAX	-0.74	-11.59	-0.54	2.37e-26	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	cis	rs10779751	0.762	rs6540965	chr1:11325521	C/G	cg08854313	chr1:11322531	MTOR	-0.68	-11.73	-0.54	7.75e-27	Body mass index;
LUSC	cis	rs6845621	0.727	rs4434248	chr4:18905576	C/T	cg12196642	chr4:18937545	NA	0.33	6.28	0.32	1.06e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2798269	0.966	rs11148158	chr13:22137743	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.04	-0.31	4.15e-9	PR segment;
LUSC	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg13160058	chr8:26243215	BNIP3L	-0.43	-7.61	-0.38	2.76e-13	Red cell distribution width;
LUSC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg01420254	chr6:26195488	NA	0.68	7.52	0.38	5.21e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.09	-0.36	7.97e-12	Colorectal cancer;
LUSC	cis	rs11714574	0.557	rs6787467	chr3:58377888	G/A	cg13750441	chr3:58318267	PXK	-0.3	-5.85	-0.3	1.16e-8	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);
LUSC	cis	rs983392	0.591	rs3132886	chr11:60016387	T/A	cg02771260	chr11:59836817	MS4A3	0.38	6.16	0.32	2.14e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9649465	0.561	rs688242	chr7:123420442	C/A	cg03229431	chr7:123269106	ASB15	0.48	7.79	0.39	8.83e-14	Migraine;
LUSC	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg03563238	chr19:33554763	RHPN2	-0.4	-6.43	-0.33	4.3e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg20406979	chr6:167373233	NA	0.27	6.34	0.33	7.5e-10	Crohn's disease;
LUSC	trans	rs2011013	0.957	rs61378395	chr15:84607934	A/G	cg17006413	chr1:942451	NA	0.26	6.01	0.31	4.74e-9	Sitting height ratio;
LUSC	cis	rs4561483	0.831	rs2075158	chr16:11945231	T/C	cg08843971	chr16:11963173	GSPT1	0.45	6.36	0.33	6.73e-10	Testicular germ cell tumor;
LUSC	trans	rs2729385	1.000	rs2729385	chr11:57262993	C/T	cg20818191	chr4:866154	GAK	-0.46	-6.2	-0.32	1.63e-9	Interleukin-18 levels;
LUSC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg03806693	chr22:41940476	POLR3H	0.99	13.85	0.6	9.09e-35	Vitiligo;
LUSC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg04775059	chr7:64541387	NA	0.48	7.03	0.36	1.2e-11	Calcium levels;
LUSC	trans	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	6.14	0.32	2.28e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg06238570	chr21:40685208	BRWD1	0.48	7.41	0.38	1.05e-12	Cognitive function;
LUSC	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg16342193	chr10:102329863	NA	-0.36	-6.56	-0.34	2.02e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	15.94	0.66	5.94e-43	Platelet count;
LUSC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00149659	chr3:10157352	C3orf10	0.98	14.52	0.62	2.16e-37	Alzheimer's disease;
LUSC	trans	rs2363709	0.881	rs17805405	chr3:67361963	A/G	cg23062198	chr2:14774063	FAM84A	0.56	6.09	0.32	3.09e-9	IgE levels;
LUSC	trans	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	7.36	0.37	1.43e-12	Menarche (age at onset);
LUSC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-1.18	-13.0	-0.58	1.52e-31	Diabetic kidney disease;
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg24846343	chr22:24311635	DDTL	0.66	14.02	0.61	2.03e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9815354	0.680	rs73073301	chr3:42028777	T/C	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg09365446	chr1:150670422	GOLPH3L	0.51	8.06	0.4	1.39e-14	Tonsillectomy;
LUSC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.06	13.3	0.59	1.06e-32	Sexual dysfunction (female);
LUSC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg08888203	chr3:10149979	C3orf24	0.59	8.11	0.41	9.88e-15	Alzheimer's disease;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg22927510	chr22:50968328	TYMP	0.42	6.05	0.31	3.93e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.51	-0.53	4.8e-26	Mean corpuscular volume;
LUSC	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg07080220	chr10:102295463	HIF1AN	0.59	7.67	0.39	1.94e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg16586182	chr3:47516702	SCAP	-0.52	-7.43	-0.38	9.45e-13	Birth weight;
LUSC	cis	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg21775007	chr8:11205619	TDH	0.46	6.46	0.33	3.63e-10	Neuroticism;
LUSC	cis	rs9560113	0.580	rs9560116	chr13:112193731	G/A	cg10483660	chr13:112241077	NA	0.38	6.85	0.35	3.46e-11	Menarche (age at onset);
LUSC	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg02997394	chr19:33096574	ANKRD27	0.79	8.95	0.44	2.49e-17	Eosinophilic esophagitis;
LUSC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg01283332	chr5:1856932	NA	-0.32	-5.98	-0.31	5.75e-9	Cardiovascular disease risk factors;
LUSC	trans	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.58e-15	Diabetic kidney disease;
LUSC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.46	-0.33	3.73e-10	Longevity;Endometriosis;
LUSC	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	7.63	0.39	2.51e-13	Height;
LUSC	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg20283391	chr11:68216788	NA	-0.61	-8.57	-0.42	3.81e-16	Total body bone mineral density;
LUSC	cis	rs713477	0.967	rs8009706	chr14:55914756	A/G	cg13175173	chr14:55914753	NA	-0.3	-6.4	-0.33	5.2e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03264133	chr6:25882463	NA	-0.5	-9.11	-0.45	7.57e-18	Blood metabolite levels;
LUSC	cis	rs68170813	0.559	rs59782202	chr7:107032766	G/T	cg02696742	chr7:106810147	HBP1	-0.61	-8.98	-0.44	1.96e-17	Coronary artery disease;
LUSC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-1.04	-20.32	-0.74	2.46e-60	Height;
LUSC	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-13.39	-0.59	5.12e-33	Morning vs. evening chronotype;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03911494	chr16:71660463	MARVELD3	-0.5	-6.11	-0.32	2.74e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg11161011	chr14:65562177	MAX	-0.69	-10.81	-0.51	1.53e-23	Obesity-related traits;
LUSC	cis	rs11587682	0.760	rs7542068	chr1:150463772	C/G	cg11822372	chr1:151115635	SEMA6C	0.42	5.67	0.3	3.13e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.73	-0.3	2.25e-8	Depression;
LUSC	cis	rs7512552	0.839	rs2794684	chr1:150320571	C/T	cg15654264	chr1:150340011	RPRD2	0.69	11.59	0.54	2.51e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg02493740	chr2:85810744	VAMP5	-0.49	-8.62	-0.43	2.68e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7178572	1.000	rs62007299	chr15:77711719	G/A	cg22256960	chr15:77711686	NA	-0.54	-9.11	-0.45	7.85e-18	Type 2 diabetes;
LUSC	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg23306229	chr2:178417860	TTC30B	0.55	6.13	0.32	2.52e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7560272	0.723	rs6743576	chr2:73814333	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-7.41	-0.38	1.02e-12	Schizophrenia;
LUSC	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.43	6.66	0.34	1.13e-10	Dupuytren's disease;
LUSC	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg00857998	chr1:205179979	DSTYK	-0.55	-8.5	-0.42	6.44e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.89	0.51	7.63e-24	Colorectal cancer;
LUSC	cis	rs13385	0.769	rs12717954	chr5:139595299	C/T	cg26211634	chr5:139558579	C5orf32	0.45	6.73	0.35	7.44e-11	Atrial fibrillation;
LUSC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg20203395	chr5:56204925	C5orf35	-0.45	-6.77	-0.35	5.92e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08170757	chr19:48867271	TMEM143;SYNGR4	-0.44	-6.4	-0.33	5.13e-10	Electrocardiographic conduction measures;
LUSC	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg21918786	chr6:109611834	NA	-0.38	-6.45	-0.33	3.86e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg18479299	chr3:125709523	NA	-0.51	-5.83	-0.3	1.33e-8	Blood pressure (smoking interaction);
LUSC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.72	-10.11	-0.48	3.96e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs4964805	0.626	rs11111767	chr12:104176246	A/G	cg02344784	chr12:104178138	NT5DC3	-0.43	-7.01	-0.36	1.34e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-7.88	-0.4	4.8e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs926938	0.563	rs360586	chr1:115467489	A/G	cg12756093	chr1:115239321	AMPD1	0.44	6.5	0.34	2.96e-10	Autism;
LUSC	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg00083937	chr22:51039805	MAPK8IP2	0.52	8.8	0.43	7.39e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs394563	0.810	rs480870	chr6:149784818	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.32	-6.39	-0.33	5.66e-10	Dupuytren's disease;
LUSC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-12.28	-0.56	7.17e-29	Personality dimensions;
LUSC	cis	rs2637266	1.000	rs7476937	chr10:78357692	A/T	cg18941641	chr10:78392320	NA	0.39	7.0	0.36	1.4e-11	Pulmonary function;
LUSC	trans	rs7044246	0.889	rs9411433	chr9:134921485	C/T	cg03562770	chr12:39538604	NA	-0.36	-6.29	-0.33	1.01e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg17366294	chr4:99064904	C4orf37	0.5	8.17	0.41	6.33e-15	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg26043149	chr18:55253948	FECH	-0.46	-7.09	-0.36	7.93e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg17470723	chr8:74884337	TCEB1	0.52	7.94	0.4	3.05e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg01966878	chr4:90757139	SNCA	-0.42	-6.0	-0.31	5.18e-9	Neuroticism;
LUSC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg21361702	chr7:150065534	REPIN1	0.58	9.16	0.45	5.54e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-1.06	-15.56	-0.65	1.88e-41	Vitiligo;
LUSC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.78	-10.48	-0.5	2.04e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-12.59	-0.57	5.17e-30	Platelet count;
LUSC	cis	rs6669072	0.565	rs1997155	chr1:91265543	G/T	cg08895590	chr1:91227319	NA	-0.27	-5.84	-0.3	1.21e-8	Cognitive function;
LUSC	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg16359550	chr11:109292809	C11orf87	0.34	5.99	0.31	5.43e-9	Schizophrenia;
LUSC	cis	rs9837602	1.000	rs62285462	chr3:99769834	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-5.97	-0.31	6.22e-9	Breast cancer;
LUSC	cis	rs4478858	0.735	rs1566961	chr1:31772450	G/A	cg00250761	chr1:31883323	NA	-0.34	-8.46	-0.42	8.39e-16	Alcohol dependence;
LUSC	trans	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.54	-0.34	2.36e-10	Endometrial cancer;
LUSC	cis	rs12928939	0.774	rs7192860	chr16:71643622	G/A	cg03805757	chr16:71968109	PKD1L3	-0.43	-6.25	-0.32	1.23e-9	Post bronchodilator FEV1;
LUSC	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg14092571	chr14:90743983	NA	-0.35	-5.67	-0.3	3.12e-8	Mortality in heart failure;
LUSC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15506890	chr2:3487001	NA	0.56	9.28	0.45	2.13e-18	Neurofibrillary tangles;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10518340	chr6:97731094	MIR548H3;C6orf167	-0.42	-6.05	-0.31	3.97e-9	Electrocardiographic conduction measures;
LUSC	trans	rs8040855	1.000	rs6496768	chr15:85702932	A/G	cg00988175	chr11:59481031	OR10V1	-0.29	-6.21	-0.32	1.53e-9	Bulimia nervosa;
LUSC	cis	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg02972257	chr16:68554789	NA	-0.5	-6.35	-0.33	7.04e-10	Ulcerative colitis;
LUSC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg02079420	chr8:82753780	SNX16	0.43	7.37	0.37	1.39e-12	Diastolic blood pressure;
LUSC	cis	rs75804782	0.521	rs72982596	chr2:239454919	G/C	cg18131467	chr2:239335373	ASB1	-0.63	-5.87	-0.31	1.03e-8	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21171335	chr12:122356390	WDR66	0.61	9.05	0.44	1.22e-17	Mean corpuscular volume;
LUSC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.06e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg26304593	chr6:42947056	PEX6	-0.52	-8.19	-0.41	5.67e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg17168535	chr8:21777572	XPO7	0.64	9.87	0.48	2.46e-20	Mean corpuscular volume;
LUSC	cis	rs17125944	0.615	rs6572867	chr14:53319283	C/T	cg00686598	chr14:53173677	PSMC6	-0.61	-5.67	-0.3	3.04e-8	Alzheimer's disease (late onset);
LUSC	trans	rs1941687	0.797	rs8096533	chr18:31383889	A/C	cg27147174	chr7:100797783	AP1S1	-0.46	-6.81	-0.35	4.54e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg21905437	chr5:178450457	ZNF879	0.43	5.7	0.3	2.65e-8	Pubertal anthropometrics;
LUSC	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg06917634	chr15:78832804	PSMA4	-0.43	-5.94	-0.31	7.33e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.07	-0.36	9.36e-12	Response to antipsychotic treatment;
LUSC	cis	rs30380	0.632	rs26496	chr5:96137882	A/G	cg16492584	chr5:96139282	ERAP1	-0.57	-7.71	-0.39	1.46e-13	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26807643	chr1:11741683	MAD2L2	-0.43	-6.27	-0.32	1.1e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6496667	0.509	rs2253419	chr15:90945875	A/G	cg22089800	chr15:90895588	ZNF774	0.54	7.81	0.39	7.5e-14	Rheumatoid arthritis;
LUSC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs7605827	0.930	rs2287635	chr2:15704410	C/G	cg19274914	chr2:15703543	NA	0.46	8.64	0.43	2.43e-16	Educational attainment (years of education);
LUSC	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg09835421	chr16:68378352	PRMT7	-0.55	-6.16	-0.32	2.09e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.75	-12.16	-0.55	1.97e-28	Body mass index;
LUSC	cis	rs907612	0.638	rs907611	chr11:1874072	G/A	cg26158194	chr11:1874320	LSP1	0.37	6.76	0.35	6.02e-11	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11603020	0.950	rs78624400	chr11:57375463	G/C	cg23127183	chr11:57508653	C11orf31	-0.46	-6.28	-0.32	1.06e-9	Blood protein levels;
LUSC	cis	rs6120849	0.707	rs6120826	chr20:33671831	G/A	cg24642439	chr20:33292090	TP53INP2	0.58	6.52	0.34	2.65e-10	Protein C levels;
LUSC	cis	rs9796	0.870	rs11855248	chr15:41276158	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.42	-7.24	-0.37	3.12e-12	Menopause (age at onset);
LUSC	cis	rs9361491	0.508	rs9352613	chr6:79424433	C/T	cg05283184	chr6:79620031	NA	0.38	6.92	0.35	2.3e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg20243544	chr17:37824526	PNMT	0.52	7.44	0.38	8.47e-13	Asthma;
LUSC	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg13010199	chr12:38710504	ALG10B	0.68	10.59	0.5	8.41e-23	Bladder cancer;
LUSC	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs662064	0.962	rs607941	chr1:10539543	C/T	cg20482658	chr1:10539492	PEX14	-0.33	-6.69	-0.34	9.27e-11	Asthma;
LUSC	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg08999081	chr20:33150536	PIGU	0.37	6.76	0.35	6.31e-11	Height;
LUSC	cis	rs11039100	0.681	rs11039120	chr11:5833096	A/G	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12016809	chr21:47604291	C21orf56	-0.46	-6.97	-0.36	1.68e-11	Testicular germ cell tumor;
LUSC	cis	rs679087	0.932	rs721617	chr12:29934586	C/T	cg14258853	chr12:29935411	TMTC1	0.96	16.53	0.67	2.88e-45	Schizophrenia;
LUSC	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg24690094	chr11:67383802	NA	-0.45	-8.33	-0.41	2.14e-15	Mean corpuscular volume;
LUSC	cis	rs12618769	0.625	rs76362434	chr2:99118005	C/T	cg10123293	chr2:99228465	UNC50	0.5	7.92	0.4	3.67e-14	Bipolar disorder;
LUSC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg16606324	chr3:10149918	C3orf24	0.67	9.71	0.47	8.57e-20	Alzheimer's disease;
LUSC	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg18833306	chr6:118973337	C6orf204	-0.46	-5.83	-0.3	1.34e-8	Renal cell carcinoma;
LUSC	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg19187155	chr2:232395269	NMUR1	0.93	18.3	0.71	2.66e-52	Height;
LUSC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26314531	chr2:26401878	FAM59B	0.72	10.1	0.48	4.02e-21	Gut microbiome composition (summer);
LUSC	cis	rs6961069	0.585	rs10265215	chr7:80257204	G/C	cg04458919	chr7:80252533	CD36	-0.41	-7.28	-0.37	2.49e-12	Platelet count;
LUSC	cis	rs9905704	0.918	rs36071323	chr17:56916804	C/T	cg12560992	chr17:57184187	TRIM37	0.57	8.05	0.4	1.47e-14	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg15839431	chr19:19639596	YJEFN3	-0.7	-7.58	-0.38	3.43e-13	Bipolar disorder;
LUSC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.73	0.6	2.42e-34	Alzheimer's disease;
LUSC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.59	9.72	0.47	8.16e-20	Aortic root size;
LUSC	cis	rs3936840	0.548	rs1190545	chr14:102904179	G/C	cg18135206	chr14:102964638	TECPR2	-0.46	-6.09	-0.32	3.06e-9	Plateletcrit;
LUSC	trans	rs57046232	0.552	rs6054147	chr20:6336002	A/G	cg21095983	chr6:86352623	SYNCRIP	-0.47	-7.01	-0.36	1.33e-11	Colorectal cancer;
LUSC	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg00334542	chr7:100209784	MOSPD3	-0.48	-5.69	-0.3	2.82e-8	Other erythrocyte phenotypes;
LUSC	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg06713675	chr4:122721982	EXOSC9	0.37	6.07	0.32	3.39e-9	Type 2 diabetes;
LUSC	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg07862535	chr7:139043722	LUC7L2	0.55	6.89	0.35	2.8e-11	Diisocyanate-induced asthma;
LUSC	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	0.87	14.3	0.62	1.57e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs965513	1.000	rs10983700	chr9:100537455	T/C	cg13688889	chr9:100608707	NA	-0.57	-8.62	-0.43	2.68e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg25214090	chr10:38739885	LOC399744	0.56	8.18	0.41	5.96e-15	Corneal astigmatism;
LUSC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg23281280	chr6:28129359	ZNF389	0.42	5.65	0.3	3.39e-8	Parkinson's disease;
LUSC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.83	-0.39	6.71e-14	Height;
LUSC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.33	-0.41	2.16e-15	Joint mobility (Beighton score);
LUSC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.07	-0.44	1.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg02773041	chr1:40204384	PPIE	0.52	7.91	0.4	3.78e-14	Blood protein levels;
LUSC	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14442939	chr10:27389572	ANKRD26	-0.9	-10.38	-0.49	4.59e-22	Breast cancer;
LUSC	cis	rs925255	0.776	rs2279990	chr2:28636740	C/T	cg01273330	chr2:28605224	NA	-0.44	-7.29	-0.37	2.29e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg13256891	chr4:100009986	ADH5	0.46	6.24	0.32	1.35e-9	Alcohol dependence;
LUSC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	0.96	13.34	0.59	7.57e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg09650180	chr20:62225654	GMEB2	-0.67	-9.54	-0.46	3e-19	Glioblastoma;
LUSC	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg02023728	chr11:77925099	USP35	0.48	6.47	0.33	3.54e-10	Testicular germ cell tumor;
LUSC	cis	rs422421	1.000	rs396007	chr5:176518426	T/C	cg00618323	chr5:176515533	FGFR4	0.37	5.98	0.31	5.89e-9	Height;
LUSC	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg00277334	chr10:82204260	NA	-0.55	-8.94	-0.44	2.71e-17	Post bronchodilator FEV1;
LUSC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg17173187	chr15:85201210	NMB	0.37	6.51	0.34	2.83e-10	Schizophrenia;
LUSC	cis	rs3087591	0.708	rs2854311	chr17:29671327	C/T	cg24425628	chr17:29625626	OMG;NF1	0.48	7.18	0.37	4.52e-12	Hip circumference;
LUSC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.68	8.84	0.44	5.48e-17	Schizophrenia;
LUSC	trans	rs9944715	0.954	rs13381525	chr18:43747538	G/A	cg01718231	chr17:29326311	RNF135	0.51	7.19	0.37	4.3e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg03676636	chr4:99064102	C4orf37	0.32	7.05	0.36	1.06e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs68170813	0.652	rs7784906	chr7:107148386	C/T	cg24556660	chr7:106842632	COG5;HBP1	-0.46	-5.69	-0.3	2.79e-8	Coronary artery disease;
LUSC	cis	rs6464929	0.956	rs66691097	chr7:148705943	C/G	cg23583168	chr7:148888333	NA	0.47	5.99	0.31	5.41e-9	Pediatric bone mineral content (hip);
LUSC	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg04545296	chr12:48745243	ZNF641	0.33	6.14	0.32	2.4e-9	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs6460942	0.818	rs7780083	chr7:12233647	C/T	cg06484146	chr7:12443880	VWDE	-0.58	-6.09	-0.32	3.08e-9	Coronary artery disease;
LUSC	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg17376030	chr22:41985996	PMM1	-0.44	-5.91	-0.31	8.5e-9	Vitiligo;
LUSC	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg08557956	chr11:4115526	RRM1	-0.45	-5.69	-0.3	2.81e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg26395211	chr5:140044315	WDR55	0.37	5.66	0.3	3.21e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2742417	0.603	rs2531755	chr3:45772742	T/C	cg10512202	chr3:45649293	LIMD1	0.36	5.94	0.31	7.3e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08280861	chr8:58055591	NA	0.57	6.03	0.31	4.4e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.84	14.12	0.61	8.06e-36	Coronary artery disease;
LUSC	cis	rs7575217	0.767	rs796056	chr2:101735276	A/C	cg23907051	chr2:101730305	TBC1D8	-0.28	-7.59	-0.38	3.24e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.7	-10.79	-0.51	1.7e-23	Aortic root size;
LUSC	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs2637266	0.599	rs2395425	chr10:78461920	C/T	cg18941641	chr10:78392320	NA	0.33	5.86	0.31	1.09e-8	Pulmonary function;
LUSC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.63	-0.34	1.33e-10	Alzheimer's disease (late onset);
LUSC	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg04398451	chr17:18023971	MYO15A	-0.48	-7.65	-0.39	2.12e-13	Total body bone mineral density;
LUSC	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg09998033	chr7:158218633	PTPRN2	0.49	7.89	0.4	4.3e-14	Obesity-related traits;
LUSC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg19318889	chr4:1322082	MAEA	0.48	7.69	0.39	1.68e-13	Obesity-related traits;
LUSC	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg15556689	chr8:8085844	FLJ10661	0.55	8.08	0.4	1.18e-14	Retinal vascular caliber;
LUSC	cis	rs2227564	0.649	rs2688626	chr10:75611090	G/A	cg23231163	chr10:75533350	FUT11	-0.42	-5.74	-0.3	2.08e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg24503407	chr1:205819492	PM20D1	0.43	5.65	0.3	3.5e-8	Parkinson's disease;
LUSC	cis	rs240764	0.746	rs240153	chr6:101067135	A/C	cg09795085	chr6:101329169	ASCC3	0.4	5.82	0.3	1.36e-8	Neuroticism;
LUSC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg05738196	chr6:26577821	NA	0.48	7.17	0.37	4.79e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg00745463	chr17:30367425	LRRC37B	-0.83	-9.75	-0.47	6.44e-20	Hip circumference adjusted for BMI;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg13997278	chr17:40118587	CNP	0.41	6.35	0.33	7.21e-10	Triglycerides;
LUSC	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg05973401	chr12:123451056	ABCB9	0.53	6.52	0.34	2.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.59	9.59	0.46	2.09e-19	Aortic root size;
LUSC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg24531977	chr5:56204891	C5orf35	-0.76	-10.76	-0.51	2.17e-23	Type 2 diabetes;
LUSC	cis	rs72772090	0.539	rs11747148	chr5:96112863	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-7.27	-0.37	2.59e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	1.23	16.23	0.66	4.34e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.09e-18	Menopause (age at onset);
LUSC	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-0.81	-8.54	-0.42	4.82e-16	Breast cancer;
LUSC	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg00321850	chr1:175162397	KIAA0040	-0.4	-6.89	-0.35	2.81e-11	Alcohol dependence;
LUSC	trans	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg09365446	chr1:150670422	GOLPH3L	0.47	7.02	0.36	1.24e-11	Melanoma;
LUSC	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg08847533	chr14:75593920	NEK9	-0.49	-7.08	-0.36	8.7e-12	IgG glycosylation;
LUSC	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-0.65	-9.8	-0.47	4.21e-20	Platelet distribution width;
LUSC	trans	rs11610422	0.953	rs12824490	chr12:31414490	C/T	cg02734259	chr12:9559402	NA	-0.61	-6.48	-0.33	3.38e-10	Coronary artery disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13635462	chr11:77790613	NDUFC2	0.73	5.95	0.31	6.92e-9	Cognitive performance;
LUSC	cis	rs1322512	0.917	rs2758818	chr6:152980753	G/C	cg27316956	chr6:152958899	SYNE1	0.37	6.25	0.32	1.25e-9	Tonometry;
LUSC	trans	rs1325195	0.920	rs12130276	chr1:179082525	C/T	cg11624085	chr17:8464688	MYH10	-0.44	-7.29	-0.37	2.2e-12	IgE grass sensitization;
LUSC	cis	rs887829	0.570	rs6753569	chr2:234595817	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.38	-6.12	-0.32	2.56e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg25643088	chr3:52874325	TMEM110	0.39	5.82	0.3	1.4e-8	Schizophrenia;
LUSC	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg04990556	chr1:26633338	UBXN11	0.88	11.8	0.54	4.15e-27	Obesity-related traits;
LUSC	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg06453172	chr10:134556979	INPP5A	-0.5	-6.0	-0.31	5.21e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs17039065	1.000	rs72889372	chr4:109387298	A/G	cg07444054	chr2:108107501	NA	0.43	6.3	0.33	9.24e-10	Gut microbiome composition (summer);
LUSC	cis	rs12618769	0.597	rs2278208	chr2:99154229	C/T	cg10123293	chr2:99228465	UNC50	0.5	8.12	0.41	9.4e-15	Bipolar disorder;
LUSC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.59	-0.38	3.21e-13	Personality dimensions;
LUSC	cis	rs6882046	0.513	rs35148765	chr5:88046158	C/A	cg22951263	chr5:87985283	NA	-0.47	-7.72	-0.39	1.39e-13	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LUSC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.61	-8.13	-0.41	8.71e-15	Systemic lupus erythematosus;
LUSC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg11766577	chr21:47581405	C21orf56	-0.56	-8.78	-0.43	8.84e-17	Testicular germ cell tumor;
LUSC	trans	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.75	0.54	6.59e-27	Mean corpuscular volume;
LUSC	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.66	9.44	0.46	6.8e-19	Adiposity;
LUSC	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg05340658	chr4:99064831	C4orf37	0.44	6.92	0.35	2.25e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg09238746	chr17:78121135	EIF4A3	-0.63	-9.53	-0.46	3.47e-19	Yeast infection;
LUSC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg27165867	chr14:105738592	BRF1	-0.53	-7.3	-0.37	2.17e-12	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs12902680	0.641	rs7162533	chr15:46586095	T/C	cg04321580	chr8:143696133	ARC	-0.4	-6.04	-0.31	4.18e-9	Neuroticism;
LUSC	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg11019008	chr10:131425282	MGMT	-0.4	-6.07	-0.31	3.57e-9	Response to temozolomide;
LUSC	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg23260525	chr10:116636907	FAM160B1	0.39	7.98	0.4	2.37e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg06219351	chr7:158114137	PTPRN2	0.47	7.41	0.38	1.02e-12	Calcium levels;
LUSC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06544989	chr22:39130855	UNC84B	0.35	6.35	0.33	6.84e-10	Menopause (age at onset);
LUSC	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.73	11.13	0.52	1.14e-24	Eosinophil percentage of white cells;
LUSC	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg17691542	chr6:26056736	HIST1H1C	0.46	6.51	0.34	2.78e-10	Iron status biomarkers;
LUSC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg14552801	chr7:65878734	NA	-0.43	-6.06	-0.31	3.77e-9	Aortic root size;
LUSC	cis	rs7973719	0.773	rs6486911	chr12:7356494	G/C	cg07052231	chr12:7363540	PEX5	0.54	9.42	0.46	7.85e-19	IgG glycosylation;
LUSC	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg15744005	chr10:104629667	AS3MT	-0.29	-6.26	-0.32	1.15e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9807989	0.811	rs67088699	chr2:102968751	C/T	cg03938978	chr2:103052716	IL18RAP	0.32	5.91	0.31	8.63e-9	Asthma;
LUSC	cis	rs239198	0.555	rs9386258	chr6:101286336	C/G	cg09795085	chr6:101329169	ASCC3	0.44	5.94	0.31	7.13e-9	Menarche (age at onset);
LUSC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg06618935	chr21:46677482	NA	-0.37	-7.26	-0.37	2.7e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1981331	1.000	rs79694455	chr21:47983979	C/T	cg17243659	chr21:48055224	PRMT2	0.84	6.04	0.31	4.14e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14829155	chr15:31115871	NA	-0.72	-10.71	-0.51	3.4e-23	Huntington's disease progression;
LUSC	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg08847533	chr14:75593920	NEK9	-0.81	-13.69	-0.6	3.48e-34	Height;
LUSC	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg08470875	chr2:26401718	FAM59B	0.66	8.54	0.42	4.71e-16	Gut microbiome composition (summer);
LUSC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.52	10.36	0.49	5.48e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24110177	chr3:50126178	RBM5	0.64	11.16	0.52	8.8e-25	Body mass index;
LUSC	cis	rs6961069	0.774	rs1413661	chr7:80243003	G/C	cg04458919	chr7:80252533	CD36	-0.36	-6.63	-0.34	1.32e-10	Platelet count;
LUSC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs28541881	0.536	rs60061147	chr19:34804420	G/C	cg00351152	chr3:12837017	CAND2	-0.67	-6.16	-0.32	2.08e-9	Colorectal cancer;
LUSC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg16339924	chr4:17578868	LAP3	0.55	8.33	0.41	2.08e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6120849	0.754	rs6088682	chr20:33615702	A/C	cg24642439	chr20:33292090	TP53INP2	0.61	6.74	0.35	6.84e-11	Protein C levels;
LUSC	cis	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg03522245	chr20:25566470	NINL	0.35	5.74	0.3	2.15e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	11.18	0.52	7.3e-25	Bone mineral density;
LUSC	cis	rs2084898	0.506	rs531260	chr11:120050515	C/T	cg07435449	chr11:120005650	TRIM29	0.37	6.62	0.34	1.41e-10	Stroke (pediatric);
LUSC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg16339924	chr4:17578868	LAP3	0.58	8.99	0.44	1.91e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06481639	chr22:41940642	POLR3H	0.49	5.82	0.3	1.38e-8	Vitiligo;
LUSC	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg04359828	chr10:32216031	ARHGAP12	0.39	6.63	0.34	1.39e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg23625390	chr15:77176239	SCAPER	0.51	7.91	0.4	3.79e-14	Blood metabolite levels;
LUSC	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg05234568	chr11:5960015	NA	-0.57	-8.22	-0.41	4.69e-15	DNA methylation (variation);
LUSC	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.06	-0.36	9.71e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7568458	0.516	rs62166769	chr2:85812784	T/A	cg23752985	chr2:85803571	VAMP8	0.3	5.97	0.31	5.97e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg11871910	chr12:69753446	YEATS4	0.92	17.37	0.69	1.28e-48	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg16576597	chr16:28551801	NUPR1	0.29	5.85	0.3	1.18e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1775715	0.835	rs12266771	chr10:32231380	G/A	cg03015672	chr10:32216066	ARHGAP12	0.32	5.79	0.3	1.63e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.38	0.53	1.43e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg17554472	chr22:41940697	POLR3H	-0.46	-5.8	-0.3	1.53e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.49	5.84	0.3	1.23e-8	Renal function-related traits (BUN);
LUSC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs2414856	0.510	rs77109323	chr15:64704941	G/A	cg08069370	chr15:64387884	SNX1	-0.64	-5.67	-0.3	3.05e-8	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-6.54	-0.34	2.36e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.22	-0.37	3.56e-12	Bipolar disorder;
LUSC	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.08	-0.32	3.36e-9	Neuroticism;
LUSC	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg07701084	chr6:150067640	NUP43	0.47	7.03	0.36	1.15e-11	Testicular germ cell tumor;
LUSC	cis	rs6845621	0.727	rs10026502	chr4:18910167	T/C	cg12196642	chr4:18937545	NA	-0.33	-6.22	-0.32	1.45e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.78	-0.43	8.6e-17	Response to antipsychotic treatment;
LUSC	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.36	-0.33	6.79e-10	Response to antipsychotic treatment;
LUSC	trans	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg01620082	chr3:125678407	NA	0.51	6.44	0.33	4.28e-10	Depression;
LUSC	cis	rs72772090	0.539	rs72775818	chr5:96193215	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-6.88	-0.35	2.88e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg22709100	chr7:91322751	NA	0.41	6.07	0.32	3.44e-9	Breast cancer;
LUSC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg18512352	chr11:47633146	NA	-0.47	-9.41	-0.46	8.03e-19	Subjective well-being;
LUSC	cis	rs1506636	0.889	rs619075	chr7:123426317	A/T	cg03229431	chr7:123269106	ASB15	0.65	10.64	0.5	6.03e-23	Plateletcrit;Platelet count;
LUSC	cis	rs7651511	0.611	rs1582875	chr3:141192125	A/T	cg00789793	chr3:141329863	RASA2	0.38	5.82	0.3	1.41e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.82	-0.47	3.69e-20	Chronic sinus infection;
LUSC	cis	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.57	-0.38	3.58e-13	Morning vs. evening chronotype;
LUSC	cis	rs6545883	0.860	rs13023037	chr2:61620989	C/T	cg15711740	chr2:61764176	XPO1	0.44	6.89	0.35	2.82e-11	Tuberculosis;
LUSC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.72	-13.31	-0.59	1.04e-32	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.63	10.16	0.49	2.59e-21	Type 2 diabetes;
LUSC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.4	5.72	0.3	2.33e-8	Menopause (age at onset);
LUSC	cis	rs2573652	1.000	rs2581363	chr15:100513364	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.4	-7.2	-0.37	4.07e-12	Height;
LUSC	cis	rs11785693	0.862	rs17350978	chr8:4983418	G/C	cg26367366	chr8:4980734	NA	0.81	9.58	0.46	2.36e-19	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs4908769	0.624	rs301790	chr1:8469284	G/C	cg00546117	chr1:8445545	RERE	-0.28	-5.65	-0.3	3.37e-8	Allergy;
LUSC	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg20991723	chr1:152506922	NA	0.5	9.54	0.46	3.1e-19	Hair morphology;
LUSC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg18350739	chr11:68623251	NA	-0.34	-5.95	-0.31	6.79e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg05347473	chr6:146136440	FBXO30	0.49	8.32	0.41	2.22e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg02176678	chr2:219576539	TTLL4	-0.58	-10.35	-0.49	5.81e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.57	-11.32	-0.53	2.22e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs853679	0.505	rs200992	chr6:27814677	A/G	cg01620082	chr3:125678407	NA	-0.74	-7.22	-0.37	3.44e-12	Depression;
LUSC	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.85	-0.3	1.18e-8	Lung cancer;
LUSC	cis	rs524023	0.914	rs2277311	chr11:64387932	G/A	cg19131476	chr11:64387923	NRXN2	-0.38	-10.37	-0.49	4.87e-22	Urate levels in obese individuals;
LUSC	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg00792783	chr2:198669748	PLCL1	0.43	5.7	0.3	2.66e-8	Dermatomyositis;
LUSC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.88	13.48	0.59	2.35e-33	Menarche (age at onset);
LUSC	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg24375607	chr4:120327624	NA	0.75	11.83	0.54	3.24e-27	Corneal astigmatism;
LUSC	cis	rs6460942	0.915	rs2192842	chr7:12315752	C/G	cg06484146	chr7:12443880	VWDE	-0.49	-5.84	-0.3	1.27e-8	Coronary artery disease;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg11596580	chr12:3600764	PRMT8	0.49	6.17	0.32	1.97e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.54	0.38	4.59e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.82	12.93	0.58	2.84e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.45	-0.46	6.09e-19	Electroencephalogram traits;
LUSC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg02079420	chr8:82753780	SNX16	-0.38	-5.7	-0.3	2.64e-8	Diastolic blood pressure;
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.51	-7.81	-0.39	7.37e-14	Lymphocyte counts;
LUSC	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg08392591	chr16:89556376	ANKRD11	0.39	5.75	0.3	1.97e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-7.09	-0.36	8.25e-12	Alzheimer's disease (late onset);
LUSC	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg06108461	chr20:60628389	TAF4	-0.76	-12.44	-0.56	1.85e-29	Body mass index;
LUSC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg06740227	chr12:86229804	RASSF9	0.39	6.15	0.32	2.22e-9	Major depressive disorder;
LUSC	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.27	-0.32	1.1e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1178968	0.901	rs1178953	chr7:72781277	A/G	cg25889504	chr7:72793014	NA	0.61	7.94	0.4	3.08e-14	Triglyceride levels;
LUSC	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg15557168	chr22:42548783	NA	-0.41	-6.22	-0.32	1.52e-9	Schizophrenia;
LUSC	trans	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	0.45	6.53	0.34	2.42e-10	Monocyte count;
LUSC	cis	rs4478858	0.806	rs6686845	chr1:31708796	A/T	cg00250761	chr1:31883323	NA	-0.38	-9.94	-0.48	1.44e-20	Alcohol dependence;
LUSC	trans	rs6600671	1.000	rs10903161	chr1:121178741	A/T	cg08727972	chr1:148025634	NBPF14	0.45	6.28	0.32	1.08e-9	Hip geometry;
LUSC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	9.28	0.45	2.13e-18	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg02527881	chr3:46936655	PTH1R	-0.44	-7.93	-0.4	3.24e-14	Colorectal cancer;
LUSC	trans	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg26043149	chr18:55253948	FECH	0.49	7.28	0.37	2.43e-12	Bone mineral density;
LUSC	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	10.95	0.51	4.95e-24	Menarche (age at onset);
LUSC	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.93	-17.73	-0.7	4.75e-50	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6693567	0.565	rs832621	chr1:150392909	G/C	cg15654264	chr1:150340011	RPRD2	0.43	6.81	0.35	4.55e-11	Migraine;
LUSC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg01483505	chr11:975446	AP2A2	-0.43	-6.24	-0.32	1.29e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg05585544	chr11:47624801	NA	-0.41	-7.23	-0.37	3.22e-12	Subjective well-being;
LUSC	trans	rs2950393	0.804	rs7967600	chr12:57161992	A/G	cg14367344	chr1:146644336	PRKAB2	-0.42	-5.98	-0.31	5.65e-9	Platelet distribution width;
LUSC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg21280719	chr6:42927975	GNMT	-0.31	-7.66	-0.39	1.97e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg18350739	chr11:68623251	NA	0.36	6.57	0.34	1.95e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg03188948	chr7:1209495	NA	0.45	6.02	0.31	4.64e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs874628	0.576	rs72999466	chr19:18248499	C/T	cg00493341	chr19:18228948	MAST3	0.44	6.16	0.32	2.14e-9	Multiple sclerosis;
LUSC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21724239	chr8:58056113	NA	0.81	8.84	0.44	5.66e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs3925075	1.000	rs4411512	chr16:31347445	C/T	cg02846316	chr16:31340340	ITGAM	0.36	6.66	0.34	1.11e-10	IgA nephropathy;
LUSC	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg11584989	chr19:19387371	SF4	0.58	7.02	0.36	1.22e-11	Bipolar disorder;
LUSC	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg13334819	chr7:99746414	C7orf59	-0.5	-6.73	-0.35	7.41e-11	Coronary artery disease;
LUSC	cis	rs2742417	0.603	rs2673032	chr3:45756927	C/T	cg10512202	chr3:45649293	LIMD1	0.36	6.06	0.31	3.65e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg00074818	chr8:8560427	CLDN23	0.58	9.91	0.48	1.88e-20	Obesity-related traits;
LUSC	cis	rs4629180	0.586	rs1509494	chr2:102134862	G/T	cg01388757	chr2:102091195	RFX8	-0.37	-6.47	-0.33	3.39e-10	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06505273	chr16:24850292	NA	-0.4	-5.7	-0.3	2.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10769945	0.679	rs7105710	chr11:1918083	T/C	cg06197492	chr11:2016605	H19	0.41	6.98	0.36	1.55e-11	DNA methylation (variation);
LUSC	trans	rs61931739	0.529	rs1525900	chr12:33976652	T/G	cg26384229	chr12:38710491	ALG10B	0.5	7.68	0.39	1.78e-13	Morning vs. evening chronotype;
LUSC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.18	-0.41	6.16e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg04450456	chr4:17643702	FAM184B	0.35	5.81	0.3	1.47e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.42	0.53	9.8e-26	Prudent dietary pattern;
LUSC	cis	rs8113142	0.651	rs56293350	chr19:29109841	C/T	cg04546413	chr19:29218101	NA	0.43	5.88	0.31	1.02e-8	Femoral neck bone geometry and menarche (age at onset);
LUSC	trans	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg07393940	chr7:158741817	NA	0.54	8.75	0.43	1.06e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs11051970	0.918	rs1055876	chr12:32536200	C/T	cg02745156	chr12:32552066	NA	0.43	6.89	0.35	2.84e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg15921436	chr17:44337874	NA	0.64	9.63	0.47	1.52e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg08219700	chr8:58056026	NA	0.54	6.56	0.34	2.05e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.9	20.92	0.75	1.07e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.45	17.66	0.69	9.33e-50	Opioid sensitivity;
LUSC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg07716408	chr11:68623521	NA	-0.3	-5.85	-0.3	1.2e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg23590916	chr17:43697445	MGC57346	0.5	6.64	0.34	1.26e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg15744005	chr10:104629667	AS3MT	-0.35	-6.57	-0.34	1.99e-10	Arsenic metabolism;
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg07507251	chr3:52567010	NT5DC2	0.36	7.32	0.37	1.89e-12	Electroencephalogram traits;
LUSC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23750338	chr8:142222470	SLC45A4	-0.59	-11.47	-0.53	6.9e-26	Immature fraction of reticulocytes;
LUSC	cis	rs12541635	0.966	rs11786829	chr8:107023752	C/G	cg10147462	chr8:107024639	NA	0.56	10.17	0.49	2.33e-21	Age of smoking initiation;
LUSC	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	11.45	0.53	7.83e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg21724239	chr8:58056113	NA	0.55	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg25237894	chr2:233734115	C2orf82	0.35	6.5	0.34	2.92e-10	Coronary artery disease;
LUSC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg00271210	chr6:167070053	RPS6KA2	0.28	5.7	0.3	2.62e-8	Crohn's disease;
LUSC	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.75	-12.44	-0.56	1.93e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg22907277	chr7:1156413	C7orf50	0.71	7.56	0.38	3.84e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg16797656	chr11:68205561	LRP5	0.37	6.09	0.32	3.02e-9	Total body bone mineral density;
LUSC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	1.09	17.16	0.68	9.45e-48	Monocyte percentage of white cells;
LUSC	cis	rs2742234	0.541	rs1317214	chr10:43733531	C/G	cg02780029	chr10:43622663	RET	0.34	5.68	0.3	2.97e-8	Hirschsprung disease;
LUSC	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.47	6.74	0.35	7.02e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs16854884	0.606	rs60676654	chr3:143734937	A/G	cg06585982	chr3:143692056	C3orf58	0.5	8.13	0.41	8.55e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg00579200	chr11:133705235	NA	-0.39	-5.86	-0.31	1.14e-8	Childhood ear infection;
LUSC	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17467752	chr17:38218738	THRA	0.78	12.48	0.56	1.34e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg21775007	chr8:11205619	TDH	-0.4	-5.7	-0.3	2.61e-8	Systolic blood pressure;
LUSC	cis	rs506338	0.517	rs17146216	chr11:64451281	C/G	cg19395706	chr11:64412079	NRXN2	0.29	5.82	0.3	1.38e-8	Body mass index;Urate levels;
LUSC	cis	rs6084875	0.840	rs1999665	chr20:4720988	C/T	cg07258627	chr20:4721683	PRNT	-0.34	-6.2	-0.32	1.69e-9	Systemic lupus erythematosus;
LUSC	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-6.81	-0.35	4.53e-11	Blood metabolite levels;
LUSC	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg06671660	chr6:41068741	NFYA;LOC221442	-0.46	-6.36	-0.33	6.73e-10	Alzheimer's disease (late onset);
LUSC	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg14668632	chr7:2872130	GNA12	0.41	6.27	0.32	1.13e-9	Height;
LUSC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg06454157	chr6:167490870	NA	-0.27	-6.64	-0.34	1.28e-10	Primary biliary cholangitis;
LUSC	cis	rs10740039	0.516	rs10740034	chr10:62352382	C/T	cg18175470	chr10:62150864	ANK3	-0.45	-6.78	-0.35	5.55e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg00982548	chr2:198649783	BOLL	-0.58	-7.29	-0.37	2.32e-12	Ulcerative colitis;
LUSC	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg03676636	chr4:99064102	C4orf37	0.36	7.99	0.4	2.22e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg12935359	chr14:103987150	CKB	-0.53	-8.12	-0.41	9.2e-15	Body mass index;
LUSC	cis	rs6693567	0.565	rs834242	chr1:150379858	G/A	cg15654264	chr1:150340011	RPRD2	0.43	6.88	0.35	2.96e-11	Migraine;
LUSC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	0.96	16.31	0.67	2.17e-44	Menopause (age at onset);
LUSC	cis	rs80130819	0.636	rs2732470	chr12:48664757	T/G	cg24011408	chr12:48396354	COL2A1	0.46	5.84	0.3	1.22e-8	Prostate cancer;
LUSC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg21285383	chr16:89894308	SPIRE2	0.33	6.98	0.36	1.63e-11	Vitiligo;
LUSC	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg10978503	chr1:24200527	CNR2	0.54	13.24	0.59	1.85e-32	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
LUSC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.41	-6.26	-0.32	1.2e-9	Tonsillectomy;
LUSC	cis	rs1609391	0.543	rs9859810	chr3:136629986	A/G	cg15507776	chr3:136538369	TMEM22	0.51	8.36	0.42	1.71e-15	Neuroticism;
LUSC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-14.28	-0.62	1.95e-36	Chronic sinus infection;
LUSC	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg05373962	chr22:49881684	NA	-0.4	-8.46	-0.42	8.69e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg04260516	chr14:24630327	IRF9	0.51	6.44	0.33	4.09e-10	Cognitive function;Information processing speed;
LUSC	cis	rs4690686	0.500	rs7683662	chr4:177272004	A/T	cg17059388	chr4:177262070	NA	0.49	9.05	0.44	1.17e-17	Essential tremor;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.58	-9.37	-0.46	1.14e-18	Lymphocyte counts;
LUSC	cis	rs3812762	0.879	rs10743089	chr11:8788168	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-7.07	-0.36	9.12e-12	Hypospadias;
LUSC	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg23711669	chr6:146136114	FBXO30	0.86	15.87	0.66	1.21e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.22	0.49	1.68e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg25214090	chr10:38739885	LOC399744	-0.54	-8.03	-0.4	1.64e-14	Corneal astigmatism;
LUSC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg12257692	chr3:49977190	RBM6	-0.25	-6.8	-0.35	4.84e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9646944	0.501	rs17027246	chr2:103080055	C/G	cg20060108	chr2:102954350	IL1RL1	0.45	6.08	0.32	3.22e-9	Blood protein levels;
LUSC	cis	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg06521331	chr12:34319734	NA	-0.49	-8.13	-0.41	8.54e-15	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg05313129	chr8:58192883	C8orf71	-0.51	-6.61	-0.34	1.52e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg00277334	chr10:82204260	NA	-0.57	-8.67	-0.43	1.9e-16	Post bronchodilator FEV1;
LUSC	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.39	-0.38	1.15e-12	Joint mobility (Beighton score);
LUSC	cis	rs35883536	0.588	rs12568329	chr1:101104588	A/G	cg06223162	chr1:101003688	GPR88	-0.36	-6.38	-0.33	6.07e-10	Monocyte count;
LUSC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg07395648	chr5:131743802	NA	0.37	5.8	0.3	1.52e-8	Asthma (sex interaction);
LUSC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-0.81	-16.05	-0.66	2.25e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9644630	0.841	rs3185	chr8:19328959	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.32	-5.81	-0.3	1.42e-8	Oropharynx cancer;
LUSC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	9.18	0.45	4.77e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg02825527	chr7:2087843	MAD1L1	-0.48	-5.78	-0.3	1.75e-8	Neuroticism;
LUSC	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg13319975	chr6:146136371	FBXO30	0.49	7.26	0.37	2.7e-12	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1325195	0.920	rs2816211	chr1:179192238	C/T	cg11624085	chr17:8464688	MYH10	0.41	6.69	0.34	9.35e-11	IgE grass sensitization;
LUSC	cis	rs8038465	0.638	rs62004615	chr15:73957799	C/A	cg15420318	chr15:73925796	NPTN	0.59	9.89	0.48	2.22e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	1.11	19.03	0.72	3.14e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg18132916	chr6:79620363	NA	-0.38	-5.77	-0.3	1.85e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs890100	0.739	rs987575	chr2:56752041	C/G	cg01657744	chr10:88471748	LDB3	0.45	6.11	0.32	2.75e-9	Gut microbiome composition (summer);
LUSC	trans	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg02030672	chr11:45687055	CHST1	0.45	6.74	0.35	6.79e-11	Obesity-related traits;
LUSC	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.28	-0.59	1.35e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg02073558	chr3:44770973	ZNF501	0.57	9.41	0.46	8.29e-19	Depressive symptoms;
LUSC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg26043149	chr18:55253948	FECH	0.49	7.42	0.38	9.52e-13	Bone mineral density;
LUSC	cis	rs10740039	0.516	rs958852	chr10:62322618	T/A	cg18175470	chr10:62150864	ANK3	-0.45	-6.89	-0.35	2.87e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs367943	0.730	rs2914174	chr5:112978531	C/T	cg12552261	chr5:112820674	MCC	-0.4	-6.13	-0.32	2.51e-9	Type 2 diabetes;
LUSC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.08	-0.32	3.31e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg08601574	chr20:25228251	PYGB	0.44	6.75	0.35	6.5e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg01973587	chr1:228161476	NA	0.45	8.02	0.4	1.8e-14	Diastolic blood pressure;
LUSC	trans	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg08499158	chr17:42289980	UBTF	0.38	6.03	0.31	4.39e-9	Red cell distribution width;Reticulocyte count;
LUSC	trans	rs6030	0.872	rs6686805	chr1:169512643	A/C	cg16792071	chr10:134842795	NA	0.28	5.97	0.31	6.18e-9	Uric acid levels;
LUSC	cis	rs4604732	0.631	rs12031721	chr1:247623773	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.31	0.33	9.08e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.52	-0.38	4.96e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg25173405	chr17:45401733	C17orf57	-0.41	-6.44	-0.33	4.2e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg05163923	chr11:71159392	DHCR7	0.74	11.0	0.52	3.15e-24	Vitamin D levels;
LUSC	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg14343924	chr8:8086146	FLJ10661	0.42	5.93	0.31	7.42e-9	Mood instability;
LUSC	trans	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg21775007	chr8:11205619	TDH	0.45	6.26	0.32	1.17e-9	Neuroticism;
LUSC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.7	-0.3	2.61e-8	Tonsillectomy;
LUSC	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg23127183	chr11:57508653	C11orf31	-0.52	-7.83	-0.39	6.7e-14	Schizophrenia;
LUSC	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg15848620	chr12:58087721	OS9	-0.55	-7.85	-0.39	5.64e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.45	0.5	2.62e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs4443100	0.837	rs6003490	chr22:23388447	G/A	cg21100191	chr22:23484243	RTDR1	0.54	6.45	0.33	3.88e-10	Serum parathyroid hormone levels;
LUSC	trans	rs6507022	0.934	rs6507038	chr18:31030946	A/G	cg19867917	chr2:3642629	COLEC11	0.3	6.02	0.31	4.7e-9	Metabolite levels  (X-11787);
LUSC	cis	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg06360820	chr2:242988706	NA	0.61	7.68	0.39	1.78e-13	Obesity-related traits;
LUSC	cis	rs6460942	0.556	rs2287067	chr7:12370533	T/C	cg20607287	chr7:12443886	VWDE	-0.47	-5.75	-0.3	1.99e-8	Coronary artery disease;
LUSC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.67	11.29	0.53	2.84e-25	Blood protein levels;
LUSC	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg25801113	chr15:45476975	SHF	0.35	7.17	0.37	4.84e-12	Uric acid levels;
LUSC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg21016266	chr12:122356598	WDR66	0.54	7.69	0.39	1.62e-13	Mean corpuscular volume;
LUSC	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg02527881	chr3:46936655	PTH1R	-0.38	-6.71	-0.34	8.33e-11	Colorectal cancer;
LUSC	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-7.04	-0.36	1.1e-11	Bipolar disorder;
LUSC	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg04369109	chr6:150039330	LATS1	-0.58	-8.78	-0.43	8.37e-17	Lung cancer;
LUSC	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg24558204	chr6:135376177	HBS1L	0.58	9.03	0.44	1.39e-17	Red blood cell count;
LUSC	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg00944433	chr1:107599041	PRMT6	0.38	7.07	0.36	9.36e-12	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg11062466	chr8:58055876	NA	0.71	8.53	0.42	5.07e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08843538	chr2:210288784	MAP2	0.46	7.94	0.4	3.2e-14	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg05347473	chr6:146136440	FBXO30	-0.47	-7.87	-0.4	5.09e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg24060327	chr5:131705240	SLC22A5	-0.67	-11.36	-0.53	1.61e-25	Breast cancer;
LUSC	cis	rs7605827	0.930	rs11893272	chr2:15613796	C/T	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.37e-17	Educational attainment (years of education);
LUSC	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg19789473	chr17:27170043	C17orf63	-0.31	-5.74	-0.3	2.13e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs9693857	0.520	rs4841163	chr8:9366178	C/G	cg08975724	chr8:8085496	FLJ10661	0.42	5.98	0.31	5.68e-9	Systolic blood pressure;
LUSC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.84	-0.35	3.88e-11	Monocyte percentage of white cells;
LUSC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg21285383	chr16:89894308	SPIRE2	0.31	6.58	0.34	1.79e-10	Vitiligo;
LUSC	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg26195577	chr20:24973756	C20orf3	1.12	18.1	0.7	1.58e-51	Blood protein levels;
LUSC	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg23093090	chr10:104574429	C10orf26	-0.41	-7.36	-0.37	1.42e-12	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs4921915	0.526	rs13277738	chr8:18241507	C/T	cg18736775	chr8:18248649	NAT2	-0.58	-6.55	-0.34	2.18e-10	Iron status biomarkers (transferrin levels);
LUSC	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg24558204	chr6:135376177	HBS1L	0.58	9.03	0.44	1.38e-17	Red blood cell count;
LUSC	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg22823121	chr1:150693482	HORMAD1	0.48	7.06	0.36	9.78e-12	Melanoma;
LUSC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	0.71	11.6	0.54	2.34e-26	Gestational age at birth (maternal effect);
LUSC	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg18232548	chr7:50535776	DDC	-0.54	-7.45	-0.38	8.23e-13	Malaria;
LUSC	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.7e-10	Corneal astigmatism;
LUSC	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg24631222	chr15:78858424	CHRNA5	0.83	11.27	0.52	3.54e-25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg13072238	chr3:49761600	GMPPB	-0.36	-5.84	-0.3	1.27e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1662342	1.000	rs1791107	chr18:3251861	T/C	cg00760847	chr18:3262519	MYL12B	-0.58	-5.68	-0.3	2.97e-8	QRS duration;
LUSC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.6	0.54	2.33e-26	Prudent dietary pattern;
LUSC	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg20701182	chr2:24300061	SF3B14	0.88	11.42	0.53	1.05e-25	Lymphocyte counts;
LUSC	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg13010199	chr12:38710504	ALG10B	0.57	9.05	0.44	1.2e-17	Morning vs. evening chronotype;
LUSC	trans	rs28647808	0.881	rs28602295	chr9:136267471	G/A	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg17507749	chr15:85114479	UBE2QP1	0.53	6.58	0.34	1.87e-10	Schizophrenia;
LUSC	cis	rs8179	0.645	rs11764331	chr7:92282624	C/T	cg15732164	chr7:92237376	CDK6	-0.4	-5.71	-0.3	2.46e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg08132940	chr7:1081526	C7orf50	-0.52	-6.15	-0.32	2.27e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs72634258	0.838	rs10489450	chr1:8079301	C/T	cg00042356	chr1:8021962	PARK7	0.77	9.68	0.47	1.1e-19	Inflammatory bowel disease;
LUSC	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg00290607	chr11:67383545	NA	0.37	6.88	0.35	3.04e-11	Mean corpuscular volume;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.92	-18.14	-0.7	1.17e-51	Menarche (age at onset);
LUSC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg22638593	chr5:131593259	PDLIM4	0.49	7.47	0.38	7e-13	Acylcarnitine levels;
LUSC	cis	rs3924048	0.559	rs4075304	chr1:12626803	C/T	cg00291366	chr1:12616550	NA	0.32	7.23	0.37	3.42e-12	Optic cup area;
LUSC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg05347473	chr6:146136440	FBXO30	0.57	9.78	0.47	5.04e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7808935	0.914	rs11982766	chr7:27983781	C/T	cg22168087	chr7:27702803	HIBADH	0.54	6.49	0.33	3.09e-10	Prostate cancer;
LUSC	cis	rs62400317	0.826	rs17288327	chr6:45349877	A/G	cg18551225	chr6:44695536	NA	-0.42	-7.02	-0.36	1.28e-11	Total body bone mineral density;
LUSC	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg22705602	chr4:152727874	NA	-0.33	-6.58	-0.34	1.84e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.67	-0.34	1.08e-10	Monocyte percentage of white cells;
LUSC	cis	rs34375054	0.525	rs12316499	chr12:125593318	G/A	cg06287003	chr12:125626642	AACS	-0.39	-6.84	-0.35	3.89e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.76	17.05	0.68	2.37e-47	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg24250549	chr1:154909240	PMVK	0.64	10.42	0.5	3.35e-22	Prostate cancer;
LUSC	cis	rs10992471	0.580	rs7030920	chr9:95122952	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-7.94	-0.4	3.15e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4654899	0.785	rs10916911	chr1:21290061	C/T	cg01072550	chr1:21505969	NA	-0.53	-8.08	-0.4	1.23e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg15448220	chr1:150897856	SETDB1	0.38	5.66	0.3	3.19e-8	Tonsillectomy;
LUSC	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg15704280	chr7:45808275	SEPT13	0.78	7.55	0.38	4.31e-13	Axial length;
LUSC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.44	-0.5	2.85e-22	Electroencephalogram traits;
LUSC	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	6.16	0.32	2.1e-9	Blood metabolite levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21370986	chr7:6145114	USP42	-0.4	-6.31	-0.33	9.02e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs926938	0.527	rs360684	chr1:115499001	A/G	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.31	-0.33	8.63e-10	Autism;
LUSC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg27121462	chr16:89883253	FANCA	-0.42	-6.49	-0.33	3.14e-10	Vitiligo;
LUSC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.52	0.38	5.03e-13	Bipolar disorder;
LUSC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13770153	chr20:60521292	NA	0.73	9.97	0.48	1.11e-20	Body mass index;
LUSC	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg04374321	chr14:90722782	PSMC1	-0.75	-11.88	-0.55	2.15e-27	Mortality in heart failure;
LUSC	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg18827107	chr12:86230957	RASSF9	-0.39	-5.83	-0.3	1.3e-8	Major depressive disorder;
LUSC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg01657329	chr11:68192670	LRP5	-0.44	-6.55	-0.34	2.19e-10	Total body bone mineral density;
LUSC	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg25039879	chr17:56429692	SUPT4H1	0.68	9.11	0.45	7.7e-18	Cognitive test performance;
LUSC	cis	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg15737290	chr11:93063684	CCDC67	-0.67	-7.97	-0.4	2.55e-14	Pulmonary function decline;
LUSC	trans	rs10221833	1.000	rs355829	chr2:165616315	G/T	cg17870553	chr6:144292355	PLAGL1	0.64	6.61	0.34	1.55e-10	Response to statin therapy;
LUSC	cis	rs644148	0.803	rs2686771	chr19:44999494	T/C	cg15540054	chr19:45004280	ZNF180	-0.63	-9.36	-0.46	1.18e-18	Personality dimensions;
LUSC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.68	-0.34	1.02e-10	Lung cancer;
LUSC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.98	0.31	5.68e-9	Menopause (age at onset);
LUSC	cis	rs4363385	0.693	rs56347903	chr1:152932175	T/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-6.68	-0.34	1.03e-10	Inflammatory skin disease;
LUSC	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg20703242	chr1:230279135	GALNT2	-0.55	-8.76	-0.43	1.02e-16	Coronary artery disease;
LUSC	cis	rs738322	0.805	rs2235344	chr22:38518083	G/A	cg25457927	chr22:38595422	NA	-0.39	-7.74	-0.39	1.23e-13	Cutaneous nevi;
LUSC	cis	rs3087591	0.960	rs12943508	chr17:29599954	C/G	cg24425628	chr17:29625626	OMG;NF1	0.57	8.29	0.41	2.75e-15	Hip circumference;
LUSC	cis	rs738321	0.757	rs4820315	chr22:38518731	C/T	cg25457927	chr22:38595422	NA	-0.38	-7.09	-0.36	8.09e-12	Breast cancer;
LUSC	trans	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.27	0.32	1.09e-9	Corneal astigmatism;
LUSC	cis	rs57920188	0.640	rs4378174	chr1:4080885	C/T	cg20703997	chr1:4087676	NA	0.58	8.17	0.41	6.6e-15	Interleukin-17 levels;
LUSC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg12751644	chr20:60527061	NA	-0.35	-6.22	-0.32	1.52e-9	Body mass index;
LUSC	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	6.26	0.32	1.2e-9	Height;
LUSC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg02503808	chr4:7069936	GRPEL1	1.01	14.64	0.63	8.04e-38	Monocyte percentage of white cells;
LUSC	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg24634471	chr8:143751801	JRK	0.51	7.34	0.37	1.59e-12	Schizophrenia;
LUSC	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.71	-0.65	5.14e-42	Height;
LUSC	cis	rs983392	0.679	rs4938932	chr11:60033448	C/T	cg20284999	chr11:59952153	MS4A6A	0.37	6.15	0.32	2.19e-9	Alzheimer's disease (late onset);
LUSC	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	0.88	13.56	0.6	1.16e-33	Triglycerides;
LUSC	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg12002119	chr2:101014098	CHST10	0.35	5.65	0.3	3.48e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs11039798	1.000	rs34044596	chr11:48527936	T/C	cg15704280	chr7:45808275	SEPT13	0.7	6.63	0.34	1.36e-10	Axial length;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26970905	chr8:8175877	PRAGMIN	-0.81	-6.42	-0.33	4.8e-10	Cognitive performance;
LUSC	cis	rs6987853	0.527	rs3935700	chr8:42364121	T/C	cg09913449	chr8:42400586	C8orf40	-0.44	-7.68	-0.39	1.82e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.69	10.16	0.49	2.54e-21	Corneal astigmatism;
LUSC	trans	rs1325195	0.920	rs2793793	chr1:179140145	C/G	cg11624085	chr17:8464688	MYH10	0.4	6.53	0.34	2.44e-10	IgE grass sensitization;
LUSC	cis	rs9811920	0.742	rs2316263	chr3:99900096	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.32	6.21	0.32	1.61e-9	Axial length;
LUSC	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg03563238	chr19:33554763	RHPN2	-0.38	-6.56	-0.34	2.09e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17412528	chr7:76178955	LOC100133091	-0.41	-6.11	-0.32	2.77e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15104702	chr7:106685023	PRKAR2B	-0.4	-5.98	-0.31	5.78e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.62	0.43	2.64e-16	Menarche (age at onset);
LUSC	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg17173187	chr15:85201210	NMB	0.37	6.4	0.33	5.31e-10	Schizophrenia;
LUSC	cis	rs17094222	0.504	rs4917904	chr10:102447292	G/A	cg26540559	chr10:102447443	NA	0.52	8.9	0.44	3.72e-17	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13041975	chr2:99952790	EIF5B;TXNDC9	-0.41	-6.04	-0.31	4.12e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4664308	0.691	rs1877196	chr2:160915150	G/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-10.62	-0.5	6.75e-23	Idiopathic membranous nephropathy;
LUSC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.52	-8.32	-0.41	2.3e-15	Menarche (age at onset);
LUSC	trans	rs890100	0.902	rs1155883	chr2:56738467	G/A	cg08299783	chr2:48920986	GTF2A1L;LHCGR	-0.32	-6.17	-0.32	1.95e-9	Gut microbiome composition (summer);
LUSC	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg05855489	chr10:104503620	C10orf26	-0.69	-10.2	-0.49	1.86e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.49	-6.71	-0.34	8.55e-11	Corneal astigmatism;
LUSC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.27	-0.62	2.03e-36	Eye color traits;
LUSC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	14.39	0.62	7.35e-37	Platelet count;
LUSC	cis	rs9905704	0.633	rs2021733	chr17:56489168	C/T	cg12560992	chr17:57184187	TRIM37	-0.49	-5.8	-0.3	1.51e-8	Testicular germ cell tumor;
LUSC	cis	rs2692947	0.732	rs56847058	chr2:96406893	C/T	cg22654517	chr2:96458247	NA	0.35	6.65	0.34	1.21e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18404041	chr3:52824283	ITIH1	-0.44	-8.07	-0.4	1.28e-14	Electroencephalogram traits;
LUSC	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg04310649	chr10:35416472	CREM	-0.43	-6.64	-0.34	1.27e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.59	-10.55	-0.5	1.24e-22	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-29.0	-0.85	3.1e-93	Myeloid white cell count;
LUSC	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	9.48	0.46	5e-19	Lymphocyte counts;
LUSC	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	0.81	11.34	0.53	1.99e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	trans	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-9.6	-0.47	1.91e-19	Morning vs. evening chronotype;
LUSC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.75	14.67	0.63	6.07e-38	Lung cancer;
LUSC	cis	rs2236918	0.643	rs3121389	chr1:242020264	C/T	cg17736920	chr1:242011382	EXO1	0.4	6.22	0.32	1.5e-9	Menopause (age at onset);
LUSC	cis	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05901451	chr6:126070800	HEY2	-0.57	-8.56	-0.42	4.29e-16	Endometrial cancer;
LUSC	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg25214090	chr10:38739885	LOC399744	0.53	7.59	0.38	3.3e-13	Corneal astigmatism;
LUSC	cis	rs4561483	0.743	rs28653099	chr16:12009150	C/A	cg08843971	chr16:11963173	GSPT1	0.43	6.58	0.34	1.83e-10	Testicular germ cell tumor;
LUSC	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg18404041	chr3:52824283	ITIH1	0.47	8.43	0.42	1.08e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.86	16.11	0.66	1.27e-43	Mean platelet volume;
LUSC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.59e-9	Menopause (age at onset);
LUSC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02187348	chr16:89574699	SPG7	0.57	9.15	0.45	5.89e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg03233332	chr7:66118400	NA	-0.42	-6.1	-0.32	2.88e-9	Aortic root size;
LUSC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18131467	chr2:239335373	ASB1	1.05	25.09	0.81	7.84e-79	Multiple system atrophy;
LUSC	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	11.51	0.53	4.93e-26	Ileal carcinoids;
LUSC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.8	0.35	4.74e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg18230493	chr5:56204884	C5orf35	-0.86	-13.06	-0.58	8.73e-32	Initial pursuit acceleration;
LUSC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-9.71	-0.47	8.3e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4343996	0.506	rs7790430	chr7:3432943	G/C	cg21248987	chr7:3385318	SDK1	0.37	6.1	0.32	2.87e-9	Motion sickness;
LUSC	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg00129232	chr17:37814104	STARD3	-0.49	-7.29	-0.37	2.24e-12	Asthma;
LUSC	cis	rs7903847	0.642	rs10882911	chr10:99138064	A/C	cg20016023	chr10:99160130	RRP12	-0.34	-8.25	-0.41	3.65e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6750047	0.546	rs985257	chr2:38283228	A/T	cg07380506	chr2:38303506	CYP1B1	-0.5	-6.85	-0.35	3.5e-11	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg05110241	chr16:68378359	PRMT7	-0.53	-6.16	-0.32	2.11e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg11871910	chr12:69753446	YEATS4	0.47	6.33	0.33	7.74e-10	Response to diuretic therapy;
LUSC	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg13010199	chr12:38710504	ALG10B	-0.62	-9.46	-0.46	5.77e-19	Morning vs. evening chronotype;
LUSC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.91	0.61	5.12e-35	Cognitive test performance;
LUSC	cis	rs858239	0.601	rs6971002	chr7:23172304	C/G	cg23682824	chr7:23144976	KLHL7	0.39	5.67	0.3	3.16e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg20398880	chr6:41068722	NFYA;LOC221442	-0.38	-6.03	-0.31	4.26e-9	Alzheimer's disease (late onset);
LUSC	cis	rs11662586	1.000	rs7243921	chr18:77695237	G/A	cg20368463	chr18:77673604	PQLC1	0.62	8.36	0.42	1.69e-15	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUSC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.27	-0.32	1.09e-9	Lung cancer;
LUSC	cis	rs7809950	0.954	rs62482543	chr7:107080656	G/A	cg23024343	chr7:107201750	COG5	-0.55	-8.73	-0.43	1.21e-16	Coronary artery disease;
LUSC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg22467129	chr15:76604101	ETFA	-0.42	-6.64	-0.34	1.28e-10	Blood metabolite levels;
LUSC	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg17507749	chr15:85114479	UBE2QP1	0.56	6.96	0.36	1.8e-11	Schizophrenia;
LUSC	cis	rs73206853	0.841	rs73191818	chr12:110918721	T/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg18306943	chr3:40428807	ENTPD3	0.4	5.98	0.31	5.73e-9	Renal cell carcinoma;
LUSC	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg13385521	chr17:29058706	SUZ12P	0.65	6.53	0.34	2.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs62400317	0.762	rs62436411	chr6:44940706	T/G	cg18551225	chr6:44695536	NA	-0.44	-7.16	-0.36	5.08e-12	Total body bone mineral density;
LUSC	trans	rs12210905	0.925	rs12192502	chr6:26995720	A/C	cg01357846	chr2:79252794	REG3G	-0.34	-6.08	-0.32	3.27e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.57	11.13	0.52	1.12e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg03188948	chr7:1209495	NA	0.66	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg18512352	chr11:47633146	NA	-0.46	-9.19	-0.45	4.42e-18	Body mass index;
LUSC	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg15556689	chr8:8085844	FLJ10661	0.58	8.82	0.43	6.5e-17	Neuroticism;
LUSC	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22455342	chr2:225449267	CUL3	0.46	6.14	0.32	2.32e-9	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg13114125	chr14:105738426	BRF1	-0.91	-16.03	-0.66	2.8e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.52	-7.11	-0.36	7.25e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg09092052	chr15:45571596	NA	0.46	6.37	0.33	6.18e-10	Glomerular filtration rate;
LUSC	cis	rs71391092	1	rs71391092	chr16:74567075	C/G	cg01733217	chr16:74700730	RFWD3	-0.72	-7.61	-0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs2607426	1.000	rs2607421	chr19:41277077	A/G	cg05508168	chr19:41255947	C19orf54;SNRPA	0.63	5.72	0.3	2.32e-8	Blood protein levels;
LUSC	cis	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg26958806	chr6:27640298	NA	0.76	5.72	0.3	2.39e-8	Depression;
LUSC	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg19700328	chr14:106028568	NA	-0.42	-7.08	-0.36	8.65e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg03465714	chr1:152285911	FLG	-0.41	-5.66	-0.3	3.21e-8	Atopic dermatitis;
LUSC	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg17757837	chr7:157058334	UBE3C	0.82	13.21	0.59	2.39e-32	Body mass index;
LUSC	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.14	-0.36	5.96e-12	Mood instability;
LUSC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06637938	chr14:75390232	RPS6KL1	0.86	16.1	0.66	1.4e-43	Caffeine consumption;
LUSC	cis	rs870825	0.616	rs28524599	chr4:185647414	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-0.65	-9.59	-0.46	2.1e-19	Platelet distribution width;
LUSC	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg00376283	chr12:123451042	ABCB9	0.67	8.36	0.42	1.68e-15	Neutrophil percentage of white cells;
LUSC	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg06484146	chr7:12443880	VWDE	-0.66	-7.17	-0.37	4.87e-12	Coronary artery disease;
LUSC	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg10518572	chr11:65560635	OVOL1	-0.25	-5.66	-0.3	3.25e-8	Acne (severe);
LUSC	cis	rs6584202	0.589	rs10883094	chr10:100188106	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-6.82	-0.35	4.17e-11	Obesity-related traits;
LUSC	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg12927641	chr6:109611667	NA	-0.36	-6.15	-0.32	2.19e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.28	0.32	1.08e-9	Height;
LUSC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.67	-0.43	1.89e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg13395646	chr4:1353034	KIAA1530	-0.59	-8.44	-0.42	9.78e-16	Longevity;
LUSC	cis	rs1595825	0.891	rs73058876	chr2:198895022	A/G	cg00982548	chr2:198649783	BOLL	-0.54	-6.89	-0.35	2.72e-11	Ulcerative colitis;
LUSC	trans	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg25214090	chr10:38739885	LOC399744	0.49	7.53	0.38	4.82e-13	Corneal astigmatism;
LUSC	trans	rs17266958	1.000	rs62576990	chr9:83298644	G/A	cg01905489	chr1:26616534	UBXN11	-0.58	-6.38	-0.33	6.04e-10	Preschool internalizing problems;
LUSC	cis	rs977987	0.843	rs8056080	chr16:75410798	C/A	cg03315344	chr16:75512273	CHST6	0.53	10.37	0.49	4.96e-22	Dupuytren's disease;
LUSC	trans	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg25214090	chr10:38739885	LOC399744	-0.5	-7.35	-0.37	1.51e-12	Corneal astigmatism;
LUSC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg11871910	chr12:69753446	YEATS4	-0.7	-11.87	-0.54	2.28e-27	Blood protein levels;
LUSC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg02187348	chr16:89574699	SPG7	0.49	7.5	0.38	5.65e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11764359	chr7:65958608	NA	0.67	10.44	0.5	2.93e-22	Aortic root size;
LUSC	cis	rs17621444	0.522	rs4373838	chr10:121809445	A/G	cg02041677	chr10:121771263	NA	-0.36	-6.82	-0.35	4.22e-11	IgG glycosylation;
LUSC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg06784218	chr1:46089804	CCDC17	0.54	11.06	0.52	1.88e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.91	0.48	1.8899999999999998e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg11984989	chr7:158649758	WDR60	1.13	13.89	0.6	6.42e-35	Height;
LUSC	cis	rs5771069	0.933	rs137848	chr22:50440296	A/G	cg03721641	chr22:50451245	IL17REL	0.28	5.97	0.31	6.11e-9	Ulcerative colitis;
LUSC	trans	rs13259667	0.500	rs4554442	chr8:78092543	A/G	cg04164058	chr15:89949694	NA	-0.48	-6.48	-0.33	3.22e-10	Behavioural disinhibition (generation interaction);
LUSC	cis	rs926938	0.521	rs360649	chr1:115439668	G/C	cg01522456	chr1:115632236	TSPAN2	-0.39	-5.85	-0.31	1.15e-8	Autism;
LUSC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg02018176	chr4:1364513	KIAA1530	0.5	8.83	0.44	5.87e-17	Obesity-related traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07097636	chr17:26646373	TMEM97	-0.41	-5.98	-0.31	5.6e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg09184832	chr6:79620586	NA	-0.44	-7.24	-0.37	3.16e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2688608	0.868	rs2688625	chr10:75631548	T/C	cg23231163	chr10:75533350	FUT11	-0.41	-6.43	-0.33	4.45e-10	Inflammatory bowel disease;
LUSC	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg18681998	chr4:17616180	MED28	0.74	13.43	0.59	3.44e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs62380364	0.542	rs2247885	chr5:88047999	T/C	cg22951263	chr5:87985283	NA	-0.48	-7.89	-0.4	4.43e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg23711669	chr6:146136114	FBXO30	0.75	13.38	0.59	5.42e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10150615	chr22:24372951	LOC391322	0.38	6.42	0.33	4.63e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.15	-0.32	2.19e-9	Depression;
LUSC	cis	rs17253792	0.822	rs74968702	chr14:56076818	A/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.15	-0.36	5.56e-12	Putamen volume;
LUSC	cis	rs5770917	1.000	rs2269385	chr22:51010939	G/A	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.62	-5.73	-0.3	2.26e-8	Narcolepsy;
LUSC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg20135002	chr11:47629003	NA	-0.46	-7.54	-0.38	4.41e-13	Subjective well-being;
LUSC	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.61	-12.63	-0.57	3.64e-30	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03352830	chr11:487213	PTDSS2	0.74	8.83	0.43	6.22e-17	Body mass index;
LUSC	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.52	-0.42	5.65e-16	Total cholesterol levels;
LUSC	cis	rs701145	0.585	rs62276839	chr3:153780407	C/T	cg17054900	chr3:154042577	DHX36	-0.74	-7.56	-0.38	4.04e-13	Coronary artery disease;
LUSC	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.55e-13	Putamen volume;
LUSC	cis	rs7289126	1.000	rs4820328	chr22:38635679	C/T	cg25457927	chr22:38595422	NA	-0.3	-6.0	-0.31	5.19e-9	Mammographic density (dense area);Percent mammographic density;
LUSC	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	0.58	9.26	0.45	2.59e-18	Breast cancer;
LUSC	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg06462663	chr19:18546047	ISYNA1	0.44	7.27	0.37	2.6e-12	Breast cancer;
LUSC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg02269571	chr22:50332266	NA	0.73	9.41	0.46	8.12e-19	Schizophrenia;
LUSC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg23711669	chr6:146136114	FBXO30	0.92	17.68	0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.69	11.24	0.52	4.33e-25	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs2041895	0.565	rs10861679	chr12:107322915	T/C	cg13944111	chr12:107296891	NA	0.35	6.69	0.34	9.3e-11	Glaucoma (low intraocular pressure);
LUSC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg04287289	chr16:89883240	FANCA	0.77	6.23	0.32	1.42e-9	Skin colour saturation;
LUSC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg11752832	chr7:134001865	SLC35B4	0.5	7.22	0.37	3.62e-12	Mean platelet volume;
LUSC	cis	rs7705502	1.000	rs72812811	chr5:173350990	G/A	cg18693985	chr5:173351052	CPEB4	-0.38	-5.97	-0.31	6.06e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs17095355	1.000	rs13377169	chr10:111729414	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.44	-0.38	8.8e-13	Biliary atresia;
LUSC	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg22029157	chr1:209979665	IRF6	0.51	8.27	0.41	3.33e-15	Monobrow;
LUSC	cis	rs6681460	0.800	rs539014	chr1:67211887	C/T	cg02459107	chr1:67143332	SGIP1	-0.47	-8.33	-0.41	2.14e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg18681998	chr4:17616180	MED28	0.74	13.59	0.6	8.62e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	1.0	15.05	0.64	1.96e-39	Primary sclerosing cholangitis;
LUSC	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.9	0.35	2.64e-11	IgG glycosylation;
LUSC	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.67	-11.16	-0.52	8.79e-25	Caffeine consumption;
LUSC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg04287289	chr16:89883240	FANCA	0.79	14.01	0.61	2.06e-35	Vitiligo;
LUSC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg11406453	chr1:101602562	NA	-0.33	-5.68	-0.3	2.9e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.39	0.33	5.53e-10	Corneal astigmatism;
LUSC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.75	12.78	0.57	1.0500000000000001e-30	Developmental language disorder (linguistic errors);
LUSC	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg24375607	chr4:120327624	NA	0.75	11.05	0.52	2.18e-24	Corneal astigmatism;
LUSC	cis	rs7923609	0.967	rs10740126	chr10:65210935	A/G	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.03e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.08	-0.4	1.2e-14	Mood instability;
LUSC	trans	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg11887960	chr12:57824829	NA	0.53	6.54	0.34	2.35e-10	Obesity-related traits;
LUSC	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg08000102	chr2:233561755	GIGYF2	0.72	11.87	0.54	2.43e-27	Coronary artery disease;
LUSC	trans	rs62056376	0.736	rs2215185	chr17:32633902	C/T	cg19986872	chr5:131347773	ACSL6	-0.38	-5.98	-0.31	5.73e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs3755132	0.929	rs7594193	chr2:15750640	C/T	cg12888861	chr2:15731646	DDX1	-0.53	-7.71	-0.39	1.47e-13	Wilms tumor;
LUSC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.94	0.48	1.4e-20	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.79	0.51	1.7e-23	Menopause (age at onset);
LUSC	cis	rs3099143	1.000	rs4886832	chr15:77121196	G/A	cg21673338	chr15:77095150	SCAPER	0.77	7.47	0.38	7.08e-13	Recalcitrant atopic dermatitis;
LUSC	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.59	-0.34	1.73e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg24675658	chr1:53192096	ZYG11B	0.64	10.07	0.48	5.11e-21	Monocyte count;
LUSC	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-6.85	-0.35	3.53e-11	Parkinson's disease;
LUSC	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg00310523	chr12:86230176	RASSF9	-0.37	-6.71	-0.34	8.16e-11	Major depressive disorder;
LUSC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	1.0	17.96	0.7	5.97e-51	Cognitive function;
LUSC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-12.87	-0.58	4.63e-31	Platelet count;
LUSC	cis	rs427941	0.703	rs1734879	chr7:101740610	C/A	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs597583	0.715	rs4938399	chr11:117398399	C/T	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.19	-0.41	5.58e-15	Putamen volume;
LUSC	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26224664	chr14:101693935	NA	0.39	10.18	0.49	2.29e-21	Body mass index (alcohol intake interaction);
LUSC	cis	rs17401966	1.000	rs4845934	chr1:10468946	G/A	cg19773385	chr1:10388646	KIF1B	-0.53	-8.23	-0.41	4.39e-15	Hepatocellular carcinoma;
LUSC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	10.64	0.5	5.62e-23	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1595825	0.786	rs77773624	chr2:198514845	G/A	cg00982548	chr2:198649783	BOLL	-0.52	-6.57	-0.34	1.95e-10	Ulcerative colitis;
LUSC	cis	rs4356932	0.817	rs6826398	chr4:76973546	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.82	0.3	1.37e-8	Blood protein levels;
LUSC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.11	-0.48	3.97e-21	Obesity-related traits;
LUSC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	12.63	0.57	3.84e-30	Personality dimensions;
LUSC	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg11584989	chr19:19387371	SF4	0.6	7.31	0.37	1.93e-12	Bipolar disorder;
LUSC	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg19875535	chr5:140030758	IK	0.47	7.66	0.39	2.01e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6142102	0.602	rs932388	chr20:32657378	C/T	cg24642439	chr20:33292090	TP53INP2	0.4	5.71	0.3	2.49e-8	Skin pigmentation;
LUSC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg06784218	chr1:46089804	CCDC17	-0.48	-9.23	-0.45	3.17e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg23205692	chr1:25664452	TMEM50A	0.45	6.71	0.34	8.39e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg04554929	chr8:105342491	NA	-0.41	-7.37	-0.37	1.33e-12	Paget's disease;
LUSC	cis	rs1775715	0.513	rs2808089	chr10:32145112	A/T	cg18675610	chr10:32216311	ARHGAP12	0.31	6.84	0.35	3.81e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.69	-0.39	1.68e-13	Triglycerides;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10012627	chr15:38545011	SPRED1	-0.35	-5.95	-0.31	6.82e-9	Triglycerides;
LUSC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07157834	chr1:205819609	PM20D1	0.75	13.88	0.6	6.43e-35	Monocyte percentage of white cells;
LUSC	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg02018176	chr4:1364513	KIAA1530	-0.47	-6.45	-0.33	4.03e-10	Recombination rate (females);
LUSC	cis	rs7169223	0.653	rs8042170	chr15:79096599	G/A	cg21242079	chr15:79101063	ADAMTS7	0.39	5.88	0.31	9.81e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9296092	0.538	rs76589475	chr6:33519517	G/C	cg13560919	chr6:33536144	NA	-0.82	-15.68	-0.65	6.59e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg15309053	chr8:964076	NA	0.4	8.05	0.4	1.46e-14	Schizophrenia;
LUSC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg13397359	chr6:42928475	GNMT	0.58	9.85	0.47	2.9e-20	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11866815	0.857	rs2361988	chr16:398151	T/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.39	5.97	0.31	6.22e-9	Body mass index;
LUSC	trans	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg25214090	chr10:38739885	LOC399744	-0.46	-6.79	-0.35	5.02e-11	Corneal astigmatism;
LUSC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.37	6.07	0.32	3.39e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg23093090	chr10:104574429	C10orf26	0.37	6.76	0.35	6.35e-11	Arsenic metabolism;
LUSC	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.53	6.28	0.32	1.07e-9	Schizophrenia;
LUSC	cis	rs427941	0.610	rs201489	chr7:101749901	C/T	cg06246474	chr7:101738831	CUX1	0.39	6.33	0.33	7.88e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg09035930	chr12:129282057	SLC15A4	0.73	16.0	0.66	3.52e-43	Systemic lupus erythematosus;
LUSC	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg13010199	chr12:38710504	ALG10B	0.47	7.34	0.37	1.69e-12	Morning vs. evening chronotype;
LUSC	cis	rs3087591	1.000	rs3087591	chr17:29630970	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.6	-8.59	-0.43	3.35e-16	Hip circumference;
LUSC	cis	rs2282300	0.739	rs34234618	chr11:30241701	T/C	cg06241208	chr11:30344200	C11orf46	-0.44	-5.65	-0.3	3.52e-8	Morning vs. evening chronotype;
LUSC	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg05283184	chr6:79620031	NA	-0.45	-8.61	-0.43	2.94e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg12463550	chr7:65579703	CRCP	0.5	7.25	0.37	2.97e-12	Aortic root size;
LUSC	cis	rs72949976	0.606	rs2178756	chr2:214031423	A/G	cg08319019	chr2:214017104	IKZF2	0.67	11.13	0.52	1.08e-24	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.61	8.9	0.44	3.69e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg00945038	chr17:61921165	SMARCD2	0.54	9.36	0.46	1.17e-18	Prudent dietary pattern;
LUSC	cis	rs11229555	1.000	rs2275993	chr11:58379987	A/G	cg15696309	chr11:58395628	NA	-0.69	-9.27	-0.45	2.43e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs897080	0.515	rs1067359	chr2:44661997	G/T	cg00619915	chr2:44497795	NA	-0.39	-5.69	-0.3	2.85e-8	Height;
LUSC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg04369109	chr6:150039330	LATS1	-0.52	-7.5	-0.38	5.72e-13	Lung cancer;
LUSC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.64	-14.79	-0.63	2.03e-38	Prostate cancer;
LUSC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.71	-11.65	-0.54	1.47e-26	Prudent dietary pattern;
LUSC	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.02	0.63	2.62e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.89	-0.35	2.72e-11	Lung cancer;
LUSC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.34	0.49	6.29e-22	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg15704280	chr7:45808275	SEPT13	-0.62	-8.17	-0.41	6.36e-15	Height;
LUSC	cis	rs540254	0.551	rs2271967	chr1:160787705	T/C	cg20255094	chr1:160771763	LY9	0.57	6.79	0.35	5.07e-11	Blood protein levels;
LUSC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg18904891	chr8:8559673	CLDN23	0.61	8.43	0.42	1.02e-15	Obesity-related traits;
LUSC	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg26116260	chr4:7069785	GRPEL1	1.16	18.16	0.7	9.53e-52	Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-5.9	-0.31	9.1e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg23711669	chr6:146136114	FBXO30	0.84	15.05	0.64	1.97e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1113500	0.614	rs11185243	chr1:108597141	T/C	cg06207961	chr1:108661230	NA	0.36	6.04	0.31	4.11e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg21775007	chr8:11205619	TDH	0.46	6.51	0.34	2.72e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg18904891	chr8:8559673	CLDN23	0.61	8.18	0.41	6.04e-15	Obesity-related traits;
LUSC	cis	rs7640424	0.620	rs7637244	chr3:107815763	T/A	cg09227934	chr3:107805635	CD47	-0.54	-7.83	-0.39	6.71e-14	Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01494303	chr16:3508002	NAT15	-0.44	-6.58	-0.34	1.81e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1712517	0.526	rs113528138	chr10:105125451	C/A	cg04362960	chr10:104952993	NT5C2	-0.5	-6.65	-0.34	1.21e-10	Migraine;
LUSC	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	7.7	0.39	1.52e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-0.92	-16.09	-0.66	1.58e-43	Height;
LUSC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.75	-0.54	6.51e-27	Mean corpuscular volume;
LUSC	cis	rs4654899	0.865	rs12130664	chr1:21332812	G/T	cg01072550	chr1:21505969	NA	-0.5	-7.41	-0.38	1.03e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1322512	0.917	rs2758817	chr6:152973270	G/C	cg27316956	chr6:152958899	SYNE1	-0.37	-6.3	-0.33	9.2e-10	Tonometry;
LUSC	cis	rs7180079	1.000	rs1117087	chr15:64598823	T/G	cg02848875	chr15:64387786	SNX1	0.41	5.76	0.3	1.95e-8	Monocyte count;
LUSC	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.68	-11.69	-0.54	1.07e-26	Colorectal cancer;
LUSC	cis	rs997295	0.713	rs8042567	chr15:67975599	G/A	cg08079166	chr15:68083412	MAP2K5	-0.33	-6.56	-0.34	2.06e-10	Motion sickness;
LUSC	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.49	0.5	1.96e-22	Lymphocyte counts;
LUSC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg08270630	chr22:50330655	NA	-0.43	-6.58	-0.34	1.79e-10	Schizophrenia;
LUSC	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.75	-11.65	-0.54	1.47e-26	Menarche (age at onset);
LUSC	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg24130564	chr14:104152367	KLC1	-0.48	-7.09	-0.36	8.15e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs11776272	0.623	rs11992609	chr8:21895146	C/T	cg17168535	chr8:21777572	XPO7	0.48	6.77	0.35	5.8200000000000003e-11	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	ch.1.28801127F	chr1:28928540	NA	0.45	6.14	0.32	2.36e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg00757033	chr12:89920650	WDR51B	0.6	10.35	0.49	5.9e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.52	10.29	0.49	9.11e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	9.07	0.44	1.02e-17	Mean platelet volume;
LUSC	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg02569458	chr12:86230093	RASSF9	0.41	6.64	0.34	1.25e-10	Major depressive disorder;
LUSC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9324022	0.929	rs9635298	chr14:101172542	C/T	cg18089426	chr14:101175970	NA	0.48	5.74	0.3	2.1e-8	Plateletcrit;
LUSC	cis	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg02972257	chr16:68554789	NA	-0.54	-6.73	-0.35	7.29e-11	Ulcerative colitis;
LUSC	cis	rs13315871	0.932	rs35741271	chr3:58323091	A/G	cg20936604	chr3:58311152	NA	-0.77	-7.27	-0.37	2.56e-12	Cholesterol, total;
LUSC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19717773	chr7:2847554	GNA12	-0.39	-6.4	-0.33	5.35e-10	Height;
LUSC	cis	rs1595825	0.891	rs77946222	chr2:198533251	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.61	-0.34	1.51e-10	Ulcerative colitis;
LUSC	cis	rs7759001	0.857	rs4713085	chr6:27349964	C/T	cg18711553	chr6:27366782	ZNF391	0.4	5.81	0.3	1.48e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.55	0.38	4.23e-13	Ulcerative colitis;
LUSC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-5.83	-0.3	1.28e-8	Tonsillectomy;
LUSC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.56	7.08	0.36	8.3e-12	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6494488	0.500	rs55881719	chr15:64714903	T/G	cg08069370	chr15:64387884	SNX1	-0.64	-5.67	-0.3	3.05e-8	Coronary artery disease;
LUSC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg12639453	chr1:2035780	PRKCZ	-0.31	-6.47	-0.33	3.4e-10	Height;
LUSC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.22	-0.45	3.47e-18	Bipolar disorder and schizophrenia;
LUSC	trans	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg02800362	chr5:177631904	HNRNPAB	0.88	13.16	0.58	3.72e-32	Obesity-related traits;
LUSC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg07703079	chr11:430292	ANO9	0.7	7.12	0.36	6.72e-12	Body mass index;
LUSC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg26335602	chr6:28129616	ZNF389	0.42	5.7	0.3	2.63e-8	Depression;
LUSC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.97	0.4	2.6e-14	Prudent dietary pattern;
LUSC	cis	rs6546537	0.562	rs1985342	chr2:69758927	C/T	cg10773587	chr2:69614142	GFPT1	-0.59	-9.74	-0.47	6.99e-20	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.21	-0.37	3.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg26217441	chr16:89643414	CPNE7	-0.52	-5.68	-0.3	2.93e-8	Plateletcrit;
LUSC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.63	10.63	0.5	6.2e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6424115	0.867	rs4649119	chr1:24171543	C/G	cg10978503	chr1:24200527	CNR2	-0.53	-12.49	-0.56	1.18e-29	Immature fraction of reticulocytes;
LUSC	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg10523679	chr1:76189770	ACADM	0.45	6.44	0.33	4.09e-10	Daytime sleep phenotypes;
LUSC	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg15133208	chr4:90757351	SNCA	-0.55	-8.64	-0.43	2.31e-16	Neuroticism;
LUSC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.62	0.43	2.69e-16	Prudent dietary pattern;
LUSC	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg22532475	chr10:104410764	TRIM8	0.26	6.15	0.32	2.21e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg04517722	chr19:17905589	B3GNT3	0.41	6.04	0.31	4.07e-9	Tumor biomarkers;
LUSC	trans	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg06521331	chr12:34319734	NA	0.41	6.45	0.33	3.83e-10	Morning vs. evening chronotype;
LUSC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg20891283	chr12:69753455	YEATS4	0.66	10.32	0.49	7.26e-22	Blood protein levels;
LUSC	cis	rs2708377	0.860	rs2597975	chr12:11252797	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs1784581	0.588	rs9458428	chr6:162424579	A/G	cg17173639	chr6:162384350	PARK2	-0.57	-9.9	-0.48	1.98e-20	Itch intensity from mosquito bite;
LUSC	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg03676636	chr4:99064102	C4orf37	0.33	7.11	0.36	7.01e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg26536354	chr8:144654954	C8orf73	0.65	7.23	0.37	3.27e-12	Attention deficit hyperactivity disorder;
LUSC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.94	15.17	0.64	6.65e-40	Coronary artery disease;
LUSC	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.79	-0.6	1.45e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	5.95	0.31	6.6e-9	Cystic fibrosis severity;
LUSC	cis	rs7759001	0.857	rs4713084	chr6:27349863	G/A	cg18711553	chr6:27366782	ZNF391	0.4	5.81	0.3	1.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	0.93	12.58	0.57	5.56e-30	Primary sclerosing cholangitis;
LUSC	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg15839431	chr19:19639596	YJEFN3	-0.57	-6.87	-0.35	3.12e-11	Bipolar disorder;
LUSC	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg18357645	chr12:58087776	OS9	0.51	7.6	0.38	3.05e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg12940923	chr8:10282607	MSRA	0.35	6.7	0.34	8.61e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg09365446	chr1:150670422	GOLPH3L	0.52	7.97	0.4	2.52e-14	Tonsillectomy;
LUSC	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs6756513	0.501	rs7581977	chr2:70174054	C/T	cg02498382	chr2:70120550	SNRNP27	0.26	6.47	0.33	3.48e-10	Breast cancer;Platelet count;
LUSC	cis	rs926938	0.527	rs360670	chr1:115482386	G/A	cg12756093	chr1:115239321	AMPD1	0.47	7.19	0.37	4.19e-12	Autism;
LUSC	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg03599575	chr15:90893182	GABARAPL3	-0.33	-5.82	-0.3	1.41e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg09904177	chr6:26538194	HMGN4	-0.64	-6.38	-0.33	5.78e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12594515	1.000	rs8043291	chr15:45996247	T/A	cg19682013	chr15:45996608	NA	0.39	5.8	0.3	1.51e-8	Waist circumference;Weight;
LUSC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	7.44	0.38	8.69e-13	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs12493885	0.818	rs7641039	chr3:153768638	A/C	cg17054900	chr3:154042577	DHX36	0.51	5.85	0.3	1.18e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs7939886	0.920	rs77344682	chr11:55999358	A/G	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg06462663	chr19:18546047	ISYNA1	0.47	8.02	0.4	1.76e-14	Breast cancer;
LUSC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg04450456	chr4:17643702	FAM184B	-0.4	-6.61	-0.34	1.57e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg20744362	chr22:50050164	C22orf34	0.4	8.24	0.41	3.94e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1832871	0.672	rs9457361	chr6:158771750	G/A	cg07165851	chr6:158734300	TULP4	0.47	7.08	0.36	8.77e-12	Height;
LUSC	cis	rs17253792	0.687	rs10137995	chr14:56173687	A/G	cg01858014	chr14:56050164	KTN1	-0.58	-5.71	-0.3	2.43e-8	Putamen volume;
LUSC	cis	rs11023332	0.617	rs1879888	chr11:14679247	A/G	cg19336497	chr11:14380999	RRAS2	-0.32	-6.02	-0.31	4.58e-9	Adiponectin levels;Vitamin D levels;
LUSC	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg25456477	chr12:86230367	RASSF9	0.39	6.88	0.35	2.96e-11	Major depressive disorder;
LUSC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	0.79	13.99	0.61	2.52e-35	Cognitive function;
LUSC	cis	rs2267137	0.776	rs2267145	chr22:29805407	C/T	cg07256473	chr22:29710276	RASL10A	-0.37	-7.32	-0.37	1.83e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs858239	0.600	rs10233039	chr7:23143113	G/A	cg05407003	chr7:23246146	NA	-0.39	-5.73	-0.3	2.21e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.66	-9.22	-0.45	3.51e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	1.01	19.41	0.73	9.83e-57	Menopause (age at onset);
LUSC	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.69	-0.39	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs3770081	1.000	rs77309268	chr2:86293294	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.84	-0.35	3.84e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg25237894	chr2:233734115	C2orf82	0.36	6.74	0.35	7.17e-11	Coronary artery disease;
LUSC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg24296786	chr1:45957014	TESK2	0.49	7.19	0.37	4.16e-12	High light scatter reticulocyte count;
LUSC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg24399712	chr22:39784796	NA	-0.65	-11.99	-0.55	8.41e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg19680485	chr15:31195859	MTMR15	0.49	6.54	0.34	2.31e-10	Huntington's disease progression;
LUSC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.45	-0.33	3.85e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-0.74	-10.88	-0.51	8.18e-24	Platelet distribution width;
LUSC	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg10356904	chr22:49881777	NA	-0.29	-5.82	-0.3	1.39e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg22431228	chr1:16359049	CLCNKA	0.4	8.32	0.41	2.3e-15	Systolic blood pressure;
LUSC	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg22705602	chr4:152727874	NA	-0.34	-6.92	-0.35	2.27e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg22906224	chr7:99728672	NA	-0.47	-6.59	-0.34	1.67e-10	Coronary artery disease;
LUSC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg20476274	chr7:133979776	SLC35B4	0.8	14.15	0.61	6.06e-36	Mean platelet volume;
LUSC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg26587870	chr6:27730563	NA	-0.66	-5.92	-0.31	8.07e-9	Depression;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15816013	chr14:102606074	WDR20;HSP90AA1	-0.41	-6.07	-0.32	3.48e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	1.21	16.39	0.67	1.07e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg18758796	chr5:131593413	PDLIM4	0.43	7.41	0.38	1.06e-12	Breast cancer;
LUSC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg16434002	chr17:42200994	HDAC5	-0.45	-6.41	-0.33	5.09e-10	Total body bone mineral density;
LUSC	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg21827317	chr3:136751795	NA	0.39	6.92	0.35	2.25e-11	Neuroticism;
LUSC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg10130564	chr11:117069849	TAGLN	0.37	6.68	0.34	9.73e-11	Blood protein levels;
LUSC	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.81	12.57	0.57	5.97e-30	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.52	8.43	0.42	1.07e-15	Longevity;Endometriosis;
LUSC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg23625390	chr15:77176239	SCAPER	0.51	7.83	0.39	6.53e-14	Blood metabolite levels;
LUSC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.64	-0.39	2.31e-13	Personality dimensions;
LUSC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg06494592	chr3:125709126	NA	-0.51	-6.16	-0.32	2.06e-9	Blood pressure (smoking interaction);
LUSC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg02187348	chr16:89574699	SPG7	0.48	7.41	0.38	1.06e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs7180079	0.620	rs8036775	chr15:64844372	G/T	cg08069370	chr15:64387884	SNX1	-0.52	-5.76	-0.3	1.87e-8	Monocyte count;
LUSC	cis	rs2249625	0.564	rs2496496	chr6:72884053	A/G	cg18830697	chr6:72922368	RIMS1	-0.37	-7.38	-0.37	1.25e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs6669072	0.647	rs1335727	chr1:91238652	C/T	cg08895590	chr1:91227319	NA	-0.39	-8.84	-0.44	5.45e-17	Cognitive function;
LUSC	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg12564285	chr5:131593104	PDLIM4	0.42	7.55	0.38	4.1e-13	Breast cancer;
LUSC	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg00757033	chr12:89920650	WDR51B	0.6	10.33	0.49	7.01e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg04218760	chr10:45406644	TMEM72	-0.29	-7.05	-0.36	1.03e-11	Mean corpuscular volume;
LUSC	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg00852783	chr1:26633632	UBXN11	0.6	8.97	0.44	2.16e-17	Monocyte percentage of white cells;
LUSC	cis	rs2667011	0.503	rs3792165	chr2:160837369	G/A	cg06573604	chr2:160760825	LY75	-0.48	-7.2	-0.37	3.99e-12	Bilirubin levels;
LUSC	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.62	9.46	0.46	5.51e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg01475377	chr6:109611718	NA	-0.45	-8.27	-0.41	3.26e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.73	-0.39	1.3e-13	Morning vs. evening chronotype;
LUSC	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg02023728	chr11:77925099	USP35	0.49	7.02	0.36	1.24e-11	Testicular germ cell tumor;
LUSC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.95	-13.07	-0.58	8.13e-32	Initial pursuit acceleration;
LUSC	cis	rs116988415	0.584	rs4902314	chr14:65254415	T/C	cg00114569	chr14:65239327	SPTB	0.68	7.16	0.36	5.31e-12	Daytime sleep phenotypes;
LUSC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg05082376	chr22:42548792	NA	0.43	6.59	0.34	1.67e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	0.96	13.38	0.59	5.31e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg18306943	chr3:40428807	ENTPD3	0.37	5.98	0.31	5.69e-9	Renal cell carcinoma;
LUSC	cis	rs2200578	0.786	rs62158261	chr2:99563210	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.54	6.33	0.33	7.95e-10	IgG glycosylation;
LUSC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.74	0.43	1.16e-16	Lung cancer;
LUSC	cis	rs7241530	0.662	rs924889	chr18:75900770	A/G	cg14642773	chr18:75888474	NA	0.4	5.97	0.31	6.06e-9	Educational attainment (years of education);
LUSC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18404041	chr3:52824283	ITIH1	-0.58	-11.27	-0.52	3.48e-25	Bipolar disorder;
LUSC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.47e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.67	12.48	0.56	1.31e-29	Metabolite levels;
LUSC	cis	rs7771547	0.519	rs58153398	chr6:36370394	A/C	cg07856975	chr6:36356162	ETV7	0.44	6.51	0.34	2.83e-10	Platelet distribution width;
LUSC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg23758822	chr17:41437982	NA	1.04	19.91	0.74	1.09e-58	Menopause (age at onset);
LUSC	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg24375607	chr4:120327624	NA	0.73	10.75	0.51	2.35e-23	Corneal astigmatism;
LUSC	cis	rs12681287	0.547	rs7459877	chr8:87505660	G/A	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06112835	chr11:68658793	MRPL21	0.52	8.07	0.4	1.29e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg12705353	chr12:122356852	WDR66	0.39	5.75	0.3	2.06e-8	Mean platelet volume;
LUSC	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	11.02	0.52	2.78e-24	Colorectal cancer;
LUSC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg20283391	chr11:68216788	NA	-0.57	-8.08	-0.4	1.16e-14	Total body bone mineral density;
LUSC	cis	rs9469578	1.000	rs9469581	chr6:33715904	C/A	cg18708504	chr6:33715942	IP6K3	0.7	8.84	0.44	5.53e-17	Phosphorus levels;
LUSC	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.58	-0.42	3.75e-16	Rheumatoid arthritis;
LUSC	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg10172584	chr19:19639581	YJEFN3	0.49	5.8	0.3	1.5e-8	Bipolar disorder;
LUSC	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg09491104	chr22:46646882	C22orf40	-0.73	-6.61	-0.34	1.56e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-6.1	-0.32	2.9e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06850241	chr22:41845214	NA	0.34	6.3	0.33	9.5e-10	Vitiligo;
LUSC	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg23241863	chr10:102295624	HIF1AN	0.48	5.74	0.3	2.18e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg06060754	chr5:176797920	RGS14	-0.61	-9.06	-0.44	1.1e-17	Urate levels in lean individuals;
LUSC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg23711669	chr6:146136114	FBXO30	0.86	16.1	0.66	1.47e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06481639	chr22:41940642	POLR3H	0.51	5.82	0.3	1.39e-8	Vitiligo;
LUSC	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.76	-10.26	-0.49	1.19e-21	Coronary artery disease;
LUSC	cis	rs4363385	0.818	rs454993	chr1:153008992	C/G	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.78	-0.35	5.39e-11	Neuroticism;
LUSC	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg03732007	chr1:2071316	PRKCZ	0.6	11.24	0.52	4.53e-25	Height;
LUSC	cis	rs7202877	0.610	rs3784936	chr16:75337583	C/G	cg03315344	chr16:75512273	CHST6	0.46	6.27	0.32	1.09e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2797160	1.000	rs77678056	chr6:126019738	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.86	0.35	3.43e-11	Endometrial cancer;
LUSC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg22549504	chr19:17448937	GTPBP3	0.54	6.7	0.34	8.78e-11	Systemic lupus erythematosus;
LUSC	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg11498726	chr8:26250323	BNIP3L	0.46	6.74	0.35	7.08e-11	Red cell distribution width;
LUSC	trans	rs6445975	0.666	rs9822328	chr3:58407837	T/C	cg18950693	chr14:70346909	SMOC1	-0.4	-6.06	-0.31	3.75e-9	Systemic lupus erythematosus;
LUSC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	10.89	0.51	7.73e-24	Cognitive test performance;
LUSC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg17554472	chr22:41940697	POLR3H	0.48	5.91	0.31	8.32e-9	Vitiligo;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06268701	chr1:110091083	GNAI3	-0.39	-5.99	-0.31	5.34e-9	Electrocardiographic conduction measures;
LUSC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	1.02	17.49	0.69	4.44e-49	Coronary artery disease;
LUSC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24549020	chr5:56110836	MAP3K1	-0.44	-5.88	-0.31	9.82e-9	Initial pursuit acceleration;
LUSC	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg17075019	chr10:79541650	NA	-0.76	-12.22	-0.56	1.18e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11051970	1.000	rs1872829	chr12:32535100	C/T	cg24626660	chr12:32551988	NA	0.4	6.75	0.35	6.62e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg14196790	chr5:131705035	SLC22A5	0.41	6.95	0.36	1.98e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs61863818	0.533	rs954148	chr10:99123006	T/C	cg20016023	chr10:99160130	RRP12	-0.27	-6.63	-0.34	1.33e-10	Monocyte percentage of white cells;
LUSC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	7.78	0.39	9.16e-14	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04565464	chr8:145669602	NFKBIL2	0.39	6.37	0.33	6.41e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg20701182	chr2:24300061	SF3B14	0.73	7.39	0.37	1.2e-12	Lymphocyte counts;
LUSC	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg21775007	chr8:11205619	TDH	-0.48	-6.9	-0.35	2.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs3733418	1.000	rs3733419	chr4:165878170	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.46	-6.1	-0.32	2.98e-9	Obesity-related traits;
LUSC	cis	rs2573652	0.722	rs11852383	chr15:100542765	C/T	cg00587665	chr15:100533223	ADAMTS17	-0.36	-6.51	-0.34	2.74e-10	Height;
LUSC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg07741184	chr6:167504864	NA	0.36	6.5	0.34	2.9e-10	Crohn's disease;
LUSC	cis	rs11756438	0.572	rs2798326	chr6:119005226	C/T	cg18833306	chr6:118973337	C6orf204	0.36	5.82	0.3	1.39e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg04362960	chr10:104952993	NT5C2	0.61	9.52	0.46	3.52e-19	Arsenic metabolism;
LUSC	trans	rs11039798	1.000	rs34044596	chr11:48527936	T/C	cg03929089	chr4:120376271	NA	0.64	5.99	0.31	5.58e-9	Axial length;
LUSC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.8e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs72949976	0.966	rs6752061	chr2:214027818	C/T	cg08319019	chr2:214017104	IKZF2	-0.64	-9.95	-0.48	1.39e-20	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	0.58	9.29	0.45	2.01e-18	Breast cancer;
LUSC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg08917208	chr2:24149416	ATAD2B	0.53	5.87	0.31	1.03e-8	Lymphocyte counts;
LUSC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.72	0.43	1.33e-16	Cognitive test performance;
LUSC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-1.24	-13.61	-0.6	7.37e-34	Diabetic kidney disease;
LUSC	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-7.37	-0.37	1.38e-12	Fear of minor pain;
LUSC	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.51	17.05	0.68	2.46e-47	Opioid sensitivity;
LUSC	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg08085267	chr17:45401833	C17orf57	-0.5	-8.01	-0.4	1.99e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6961069	0.708	rs10240336	chr7:80218674	T/C	cg04458919	chr7:80252533	CD36	-0.4	-7.0	-0.36	1.41e-11	Platelet count;
LUSC	cis	rs12458462	0.851	rs2169249	chr18:77489649	G/A	cg11879182	chr18:77439856	CTDP1	0.69	10.4	0.49	4.09e-22	Monocyte count;
LUSC	cis	rs68170813	0.652	rs6947674	chr7:107193504	T/C	cg02696742	chr7:106810147	HBP1	-0.62	-8.31	-0.41	2.42e-15	Coronary artery disease;
LUSC	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.78	-11.66	-0.54	1.4e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-11.57	-0.53	2.91e-26	Bipolar disorder;
LUSC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.35	-0.42	1.78e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.26	-0.32	1.17e-9	Reticulocyte count;
LUSC	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg13390004	chr1:15929781	NA	0.39	6.64	0.34	1.28e-10	Systolic blood pressure;
LUSC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg06145435	chr7:1022769	CYP2W1	0.3	6.21	0.32	1.56e-9	Longevity;Endometriosis;
LUSC	cis	rs243505	1.000	rs243522	chr7:148420509	A/G	cg09806900	chr7:148480153	CUL1	-0.48	-6.94	-0.35	2.08e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs500891	0.547	rs12191369	chr6:84102550	A/C	cg08257003	chr6:84140564	ME1	0.32	7.26	0.37	2.82e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.85	-13.63	-0.6	6.18e-34	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.77	-12.47	-0.56	1.44e-29	Aortic root size;
LUSC	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg24069376	chr3:38537580	EXOG	-0.39	-7.61	-0.38	2.84e-13	Electrocardiographic conduction measures;
LUSC	cis	rs72634258	0.786	rs6682709	chr1:8173796	A/C	cg00042356	chr1:8021962	PARK7	-0.53	-6.4	-0.33	5.31e-10	Inflammatory bowel disease;
LUSC	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg04608330	chr12:45269318	NELL2	-0.56	-8.87	-0.44	4.65e-17	Gut microbiome composition (summer);
LUSC	cis	rs13394619	0.655	rs7578132	chr2:11718858	C/T	cg07314298	chr2:11723111	GREB1	-0.46	-7.45	-0.38	8.05e-13	Endometriosis;
LUSC	trans	rs475616	0.959	rs1360550	chr10:30487760	G/A	cg02841571	chr6:169977833	WDR27	0.42	6.14	0.32	2.33e-9	Monocyte count;
LUSC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	0.92	18.06	0.7	2.35e-51	Cognitive function;
LUSC	cis	rs4776059	0.798	rs58018557	chr15:52901284	T/C	cg22715398	chr15:52968154	KIAA1370	0.69	9.08	0.44	9.74e-18	Schizophrenia;
LUSC	trans	rs656319	0.669	rs56279061	chr8:9873980	T/C	cg21775007	chr8:11205619	TDH	-0.47	-6.53	-0.34	2.44e-10	Myopia (pathological);
LUSC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg26380479	chr7:97908229	NA	-0.28	-6.13	-0.32	2.47e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7264396	0.943	rs224431	chr20:34153599	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.19	-0.37	4.16e-12	Total cholesterol levels;
LUSC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.67	-11.21	-0.52	5.48e-25	Heart rate;
LUSC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.06e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg15147215	chr3:52552868	STAB1	-0.3	-5.84	-0.3	1.24e-8	Electroencephalogram traits;
LUSC	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg17764715	chr19:33622953	WDR88	-0.58	-8.14	-0.41	7.69e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7582720	1.000	rs72928605	chr2:203832120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.23	0.41	4.13e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1775715	0.675	rs2808085	chr10:32148599	C/T	cg03015672	chr10:32216066	ARHGAP12	0.34	6.12	0.32	2.6e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg27275811	chr11:74457193	NA	0.61	6.0	0.31	5.02e-9	Type 2 diabetes nephropathy;
LUSC	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg09307838	chr4:120376055	NA	0.5	7.5	0.38	5.8e-13	Diastolic blood pressure;
LUSC	cis	rs7605827	0.930	rs2380652	chr2:15594926	T/C	cg19274914	chr2:15703543	NA	0.46	8.76	0.43	1e-16	Educational attainment (years of education);
LUSC	cis	rs400736	0.729	rs2493216	chr1:8008366	C/A	cg25007680	chr1:8021821	PARK7	-0.5	-7.36	-0.37	1.44e-12	Response to antidepressants and depression;
LUSC	cis	rs7789940	0.810	rs12533978	chr7:75943352	T/C	cg15798862	chr7:76129360	DTX2	-0.47	-7.67	-0.39	1.92e-13	Multiple sclerosis;
LUSC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08677398	chr8:58056175	NA	-0.57	-6.94	-0.36	2.04e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.18	0.77	1.27e-67	Prudent dietary pattern;
LUSC	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg13263323	chr15:86062960	AKAP13	-0.35	-5.72	-0.3	2.42e-8	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.26	0.52	3.75e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg06287003	chr12:125626642	AACS	-0.39	-6.39	-0.33	5.59e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg06064525	chr11:970664	AP2A2	-0.48	-10.63	-0.5	6.1e-23	Alzheimer's disease (late onset);
LUSC	cis	rs9677476	0.909	rs7573577	chr2:232104079	C/T	cg07929768	chr2:232055508	NA	0.35	6.49	0.33	3.16e-10	Food antigen IgG levels;
LUSC	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg25801113	chr15:45476975	SHF	0.34	7.12	0.36	6.56e-12	Uric acid levels;
LUSC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg06671706	chr8:8559999	CLDN23	0.51	6.91	0.35	2.45e-11	Obesity-related traits;
LUSC	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg16989719	chr2:238392110	NA	-0.36	-5.9	-0.31	9.01e-9	Prostate cancer;
LUSC	cis	rs6704644	0.719	rs3768802	chr2:234373725	G/A	cg05711037	chr2:234359783	DGKD	0.68	6.41	0.33	5.01e-10	Bilirubin levels;
LUSC	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg13902645	chr11:5959945	NA	-0.57	-7.94	-0.4	3.17e-14	DNA methylation (variation);
LUSC	cis	rs1983891	0.955	rs4714479	chr6:41518807	A/G	cg20194872	chr6:41519635	FOXP4	0.34	5.97	0.31	5.96e-9	Prostate cancer;
LUSC	trans	rs656319	0.605	rs60278284	chr8:10003210	G/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.47	-0.38	7.21e-13	Myopia (pathological);
LUSC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-9.38	-0.46	1.02e-18	Type 2 diabetes;
LUSC	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg11161011	chr14:65562177	MAX	-0.81	-12.4	-0.56	2.58e-29	Obesity-related traits;
LUSC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg13206674	chr6:150067644	NUP43	0.57	8.93	0.44	2.85e-17	Lung cancer;
LUSC	cis	rs7614311	0.636	rs73130576	chr3:63890875	T/C	cg22134162	chr3:63841271	THOC7	-0.48	-6.13	-0.32	2.43e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg01689657	chr7:91764605	CYP51A1	-0.32	-5.88	-0.31	9.85e-9	Breast cancer;
LUSC	cis	rs6987853	0.563	rs2923406	chr8:42448873	G/T	cg09913449	chr8:42400586	C8orf40	0.43	7.11	0.36	7.1e-12	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg13319975	chr6:146136371	FBXO30	-0.53	-8.1	-0.41	1.06e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg03806693	chr22:41940476	POLR3H	1.03	14.29	0.62	1.71e-36	Cannabis dependence symptom count;
LUSC	trans	rs28541881	0.536	rs7247747	chr19:34787144	G/C	cg00351152	chr3:12837017	CAND2	-0.66	-5.99	-0.31	5.49e-9	Colorectal cancer;
LUSC	cis	rs9359856	0.518	rs72929359	chr6:90260111	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.6	-6.23	-0.32	1.42e-9	Bipolar disorder;
LUSC	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg08975724	chr8:8085496	FLJ10661	0.53	8.0	0.4	2.05e-14	Neuroticism;
LUSC	cis	rs68170813	0.617	rs76923959	chr7:107182915	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.45	-5.65	-0.3	3.52e-8	Coronary artery disease;
LUSC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24838063	chr12:130822603	PIWIL1	0.7	10.93	0.51	5.55e-24	Menopause (age at onset);
LUSC	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg01073479	chr16:3509474	NAT15	-0.4	-5.76	-0.3	1.9e-8	Tuberculosis;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg01335785	chr19:7505029	ARHGEF18	-0.47	-7.33	-0.37	1.72e-12	N-glycan levels;
LUSC	cis	rs6847149	0.759	rs13117220	chr4:110811575	A/G	cg07850274	chr4:110748770	RRH	0.52	7.29	0.37	2.31e-12	Exercise treadmill test traits;
LUSC	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-10.27	-0.49	1.11e-21	Morning vs. evening chronotype;
LUSC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg19046167	chr17:80928561	B3GNTL1	0.45	6.48	0.33	3.2e-10	Glycated hemoglobin levels;
LUSC	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg24881330	chr22:46731750	TRMU	0.68	8.04	0.4	1.61e-14	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs3772130	0.924	rs55643643	chr3:121440197	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.64	9.06	0.44	1.15e-17	Cognitive performance;
LUSC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg04756594	chr16:24857601	SLC5A11	0.35	5.77	0.3	1.81e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg10596483	chr8:143751796	JRK	0.52	7.52	0.38	5.15e-13	Schizophrenia;
LUSC	cis	rs61931739	0.612	rs1906137	chr12:33939676	T/A	cg06521331	chr12:34319734	NA	-0.41	-6.71	-0.34	8.31e-11	Morning vs. evening chronotype;
LUSC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg11965913	chr1:205819406	PM20D1	0.9	17.65	0.69	9.91e-50	Menarche (age at onset);
LUSC	cis	rs62400317	0.762	rs6908606	chr6:44998888	A/G	cg20913747	chr6:44695427	NA	-0.45	-7.12	-0.36	6.8e-12	Total body bone mineral density;
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.93	-0.4	3.38e-14	Lymphocyte counts;
LUSC	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	6.93	0.35	2.2e-11	Total body bone mineral density;
LUSC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg01879757	chr17:41196368	BRCA1	-0.46	-6.92	-0.35	2.26e-11	Menopause (age at onset);
LUSC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.41	-6.27	-0.32	1.14e-9	Tonsillectomy;
LUSC	cis	rs7674212	0.570	rs2711899	chr4:104062414	T/C	cg16532752	chr4:104119610	CENPE	-0.5	-7.17	-0.37	4.8e-12	Type 2 diabetes;
LUSC	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg18478394	chr8:109455254	TTC35	0.42	6.57	0.34	1.93e-10	Dupuytren's disease;
LUSC	cis	rs911119	0.955	rs2067488	chr20:23594331	T/G	cg16589663	chr20:23618590	CST3	0.56	6.77	0.35	5.8200000000000003e-11	Chronic kidney disease;
LUSC	cis	rs17401966	0.540	rs6682868	chr1:10454773	C/T	cg19773385	chr1:10388646	KIF1B	0.39	6.84	0.35	3.73e-11	Hepatocellular carcinoma;
LUSC	cis	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg05299278	chr17:33885742	SLFN14	-0.31	-6.38	-0.33	5.88e-10	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg17376030	chr22:41985996	PMM1	0.46	5.87	0.31	1.07e-8	Vitiligo;
LUSC	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg11502198	chr6:26597334	ABT1	0.71	12.06	0.55	4.63e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.52	-0.34	2.57e-10	Neuroticism;
LUSC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg20887711	chr4:1340912	KIAA1530	0.45	6.75	0.35	6.74e-11	Obesity-related traits;
LUSC	cis	rs2369473	1	rs2369473	chr1:160210727	C/A	cg07195126	chr1:160370843	VANGL2	0.49	7.58	0.38	3.36e-13	Squamous cell lung carcinoma;
LUSC	cis	rs9815354	0.951	rs6793520	chr3:41865289	C/G	cg03022575	chr3:42003672	ULK4	0.59	6.55	0.34	2.2e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4665630	0.614	rs6739646	chr2:23946840	A/C	cg08063864	chr2:24346004	PFN4;LOC375190	-0.81	-7.25	-0.37	2.87e-12	Hypertension;
LUSC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.74	0.51	2.65e-23	Bladder cancer;
LUSC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg04315214	chr1:2043799	PRKCZ	-0.38	-7.51	-0.38	5.41e-13	Height;
LUSC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg20744362	chr22:50050164	C22orf34	0.4	8.37	0.42	1.64e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07677032	chr17:61819896	STRADA	0.54	8.94	0.44	2.71e-17	Prudent dietary pattern;
LUSC	cis	rs1322512	0.917	rs1727047	chr6:152942610	T/A	cg27316956	chr6:152958899	SYNE1	-0.35	-5.77	-0.3	1.77e-8	Tonometry;
LUSC	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02176678	chr2:219576539	TTLL4	0.64	11.85	0.54	2.83e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs17286411	0.750	rs4788561	chr16:71878255	G/A	cg03805757	chr16:71968109	PKD1L3	0.41	6.76	0.35	6.12e-11	Blood protein levels;
LUSC	cis	rs360798	0.532	rs189671	chr2:62959308	T/A	cg17519650	chr2:63277830	OTX1	-0.51	-7.17	-0.37	4.85e-12	Coronary artery disease;
LUSC	cis	rs8044995	0.563	rs7190134	chr16:68381516	A/G	cg05110241	chr16:68378359	PRMT7	0.83	9.32	0.45	1.66e-18	Schizophrenia;
LUSC	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg26384229	chr12:38710491	ALG10B	0.59	8.84	0.44	5.5e-17	Heart rate;
LUSC	cis	rs7247513	1.000	rs12459123	chr19:12689741	T/C	cg01871581	chr19:12707946	ZNF490	-0.57	-8.68	-0.43	1.73e-16	Bipolar disorder;
LUSC	cis	rs9650657	0.737	rs4504595	chr8:10655505	A/G	cg27411982	chr8:10470053	RP1L1	-0.36	-5.88	-0.31	1.01e-8	Neuroticism;
LUSC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg14552801	chr7:65878734	NA	0.38	6.02	0.31	4.53e-9	Aortic root size;
LUSC	cis	rs909002	0.800	rs2176807	chr1:32092735	T/G	cg01639898	chr1:32083012	HCRTR1	0.31	7.46	0.38	7.66e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg03585969	chr10:35415529	CREM	0.61	8.94	0.44	2.75e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg03563238	chr19:33554763	RHPN2	-0.41	-6.63	-0.34	1.35e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg26876637	chr1:152193138	HRNR	-0.41	-5.66	-0.3	3.3e-8	Atopic dermatitis;
LUSC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.37	-6.08	-0.32	3.3e-9	Systemic lupus erythematosus;
LUSC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.24	0.41	3.95e-15	Melanoma;
LUSC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.14e-35	Breast cancer;
LUSC	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg20701182	chr2:24300061	SF3B14	0.55	5.85	0.3	1.2e-8	Lymphocyte counts;
LUSC	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.89	14.89	0.63	8.25e-39	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3764563	1.000	rs11673070	chr19:15746095	A/G	cg20725493	chr19:15740067	CYP4F8	-0.64	-6.54	-0.34	2.35e-10	Inflammatory biomarkers;
LUSC	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg05855489	chr10:104503620	C10orf26	0.42	5.74	0.3	2.09e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg13385521	chr17:29058706	SUZ12P	0.58	5.98	0.31	5.68e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg05527609	chr1:210001259	C1orf107	0.68	9.89	0.48	2.18e-20	Orofacial clefts;
LUSC	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg18681998	chr4:17616180	MED28	0.84	15.29	0.64	2.27e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg19862616	chr7:65841803	NCRNA00174	0.83	9.74	0.47	6.94e-20	Eotaxin levels;
LUSC	cis	rs67981189	0.593	rs221926	chr14:71579135	A/C	cg15816911	chr14:71606274	NA	-0.34	-5.94	-0.31	7.1e-9	Schizophrenia;
LUSC	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg13073564	chr4:8508604	NA	-0.43	-7.95	-0.4	2.93e-14	Response to antineoplastic agents;
LUSC	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg02023728	chr11:77925099	USP35	0.42	6.34	0.33	7.44e-10	Testicular germ cell tumor;
LUSC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg01657329	chr11:68192670	LRP5	-0.45	-7.17	-0.37	4.75e-12	Total body bone mineral density;
LUSC	cis	rs4363385	0.747	rs2879488	chr1:152975241	G/A	cg25856811	chr1:152973957	SPRR3	-0.34	-5.65	-0.3	3.43e-8	Inflammatory skin disease;
LUSC	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg07936489	chr17:37558343	FBXL20	-0.67	-9.4	-0.46	9.18e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs7178375	0.607	rs71474639	chr15:31213257	A/G	cg01738805	chr15:31195741	MTMR15	0.87	7.88	0.4	4.64e-14	Hypertriglyceridemia;
LUSC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs2296342	0.522	rs1536036	chr6:33632014	A/G	cg14003231	chr6:33640908	ITPR3	0.36	7.22	0.37	3.56e-12	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	12.08	0.55	4.15e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg12292205	chr6:26970375	C6orf41	-0.64	-7.58	-0.38	3.48e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs9865818	0.702	rs6778720	chr3:188118877	G/A	cg23651889	chr3:188115336	LPP	-0.39	-5.97	-0.31	6.18e-9	Allergic sensitization;
LUSC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.66	-11.04	-0.52	2.35e-24	Diastolic blood pressure;
LUSC	trans	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.74	-0.35	7.03e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg10756647	chr7:56101905	PSPH	0.85	8.14	0.41	7.78e-15	Diabetic kidney disease;
LUSC	trans	rs17301259	0.602	rs1858847	chr7:88336663	T/C	cg21771463	chr3:44626400	ZNF660	-0.37	-6.0	-0.31	5.14e-9	Heschl's gyrus morphology;
LUSC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03264133	chr6:25882463	NA	-0.5	-9.15	-0.45	5.97e-18	Blood metabolite levels;
LUSC	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg27432699	chr2:27873401	GPN1	0.81	14.96	0.63	4.41e-39	Oral cavity cancer;
LUSC	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg13256891	chr4:100009986	ADH5	0.43	5.97	0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg04362960	chr10:104952993	NT5C2	0.61	9.77	0.47	5.38e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Bladder cancer;
LUSC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs56283067	0.847	rs12204270	chr6:44697502	A/T	cg18551225	chr6:44695536	NA	-0.48	-8.1	-0.41	1.06e-14	Total body bone mineral density;
LUSC	cis	rs7809950	0.953	rs1468336	chr7:107208250	T/C	cg23024343	chr7:107201750	COG5	0.55	8.54	0.42	4.66e-16	Coronary artery disease;
LUSC	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.74	-12.96	-0.58	2.21e-31	Longevity;
LUSC	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg26102564	chr10:131424627	MGMT	-0.43	-6.89	-0.35	2.81e-11	Response to temozolomide;
LUSC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg06134567	chr22:46658398	PKDREJ	-0.46	-5.65	-0.3	3.48e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg25970082	chr1:119683285	WARS2	-0.5	-6.21	-0.32	1.56e-9	Neuroticism;
LUSC	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg18232548	chr7:50535776	DDC	-0.59	-9.08	-0.45	9.41e-18	Systemic sclerosis;
LUSC	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg10523679	chr1:76189770	ACADM	-0.45	-6.63	-0.34	1.36e-10	Daytime sleep phenotypes;
LUSC	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.91	0.4	3.75e-14	Colorectal cancer;
LUSC	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg24375607	chr4:120327624	NA	0.73	10.63	0.5	6.28e-23	Corneal astigmatism;
LUSC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.62	-0.34	1.45e-10	Life satisfaction;
LUSC	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg23625390	chr15:77176239	SCAPER	0.61	9.5	0.46	4.29e-19	Blood metabolite levels;
LUSC	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-6.98	-0.36	1.55e-11	Blood metabolite levels;
LUSC	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg15103426	chr22:29168792	CCDC117	0.48	5.94	0.31	7.07e-9	Lymphocyte counts;
LUSC	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.44	0.5	2.82e-22	Colorectal cancer;
LUSC	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg01616529	chr11:638424	DRD4	-0.35	-6.02	-0.31	4.64e-9	Systemic lupus erythematosus;
LUSC	cis	rs477692	0.692	rs12265758	chr10:131445144	A/G	cg05714579	chr10:131428358	MGMT	-0.65	-10.47	-0.5	2.29e-22	Response to temozolomide;
LUSC	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg22782873	chr19:19639568	YJEFN3	-0.48	-6.1	-0.32	2.86e-9	Bipolar disorder;
LUSC	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg05985134	chr18:33552581	C18orf21	0.51	7.01	0.36	1.33e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.77	0.3	1.8e-8	Lung cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14945867	chr14:54908007	CNIH	-0.44	-6.47	-0.33	3.51e-10	Electrocardiographic conduction measures;
LUSC	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg03563238	chr19:33554763	RHPN2	-0.37	-6.47	-0.33	3.54e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg05805236	chr11:65401703	PCNXL3	-0.56	-8.86	-0.44	4.89e-17	Acne (severe);
LUSC	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg05555928	chr11:63887634	MACROD1	-0.5	-6.1	-0.32	2.93e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg14036092	chr11:66035641	RAB1B	0.43	6.07	0.32	3.47e-9	Gout;
LUSC	cis	rs11112613	0.550	rs73186004	chr12:106043512	A/C	cg03607813	chr12:105948248	NA	0.57	7.36	0.37	1.4e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg24375607	chr4:120327624	NA	0.69	10.26	0.49	1.17e-21	Corneal astigmatism;
LUSC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg25258033	chr6:167368657	RNASET2	0.48	7.93	0.4	3.43e-14	Crohn's disease;
LUSC	trans	rs877282	0.838	rs11253374	chr10:774961	C/T	cg13042288	chr15:90349979	ANPEP	-0.48	-6.83	-0.35	3.94e-11	Uric acid levels;
LUSC	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg00049323	chr5:472564	LOC25845	-0.43	-6.48	-0.33	3.34e-10	Cystic fibrosis severity;
LUSC	cis	rs6906287	0.647	rs6925641	chr6:118821894	C/T	cg21191810	chr6:118973309	C6orf204	0.34	6.09	0.32	3.06e-9	Electrocardiographic conduction measures;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11490987	chr7:149535717	ZNF862	-0.48	-6.26	-0.32	1.18e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18502334	chr7:4681577	NA	-0.42	-6.78	-0.35	5.34e-11	Electrocardiographic conduction measures;
LUSC	cis	rs7106204	0.620	rs35008727	chr11:24258035	A/T	ch.11.24196551F	chr11:24239977	NA	0.73	6.22	0.32	1.49e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00166722	chr3:10149974	C3orf24	0.61	8.26	0.41	3.47e-15	Alzheimer's disease;
LUSC	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	7.33	0.37	1.8e-12	Height;
LUSC	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.91	15.42	0.64	7e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-1.04	-19.98	-0.74	5.38e-59	Height;
LUSC	trans	rs75804782	0.641	rs72987309	chr2:239348025	A/G	cg01134436	chr17:81009848	B3GNTL1	0.63	6.09	0.32	3.04e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs738321	0.757	rs9622732	chr22:38524149	G/C	cg25457927	chr22:38595422	NA	-0.38	-7.09	-0.36	7.98e-12	Breast cancer;
LUSC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.63	0.5	6.47e-23	Menopause (age at onset);
LUSC	cis	rs7945705	0.875	rs10769955	chr11:8784647	G/C	cg09997546	chr11:8931473	C11orf17;ST5	0.34	6.76	0.35	6.18e-11	Hemoglobin concentration;
LUSC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10207060	0.500	rs56346503	chr2:240719409	T/C	cg20333904	chr2:240724165	NA	-0.35	-6.11	-0.32	2.84e-9	Obesity-related traits;
LUSC	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18932078	chr1:2524107	MMEL1	-0.32	-7.0	-0.36	1.42e-11	Ulcerative colitis;
LUSC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg14416269	chr4:6271139	WFS1	0.54	11.41	0.53	1.08e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg10596483	chr8:143751796	JRK	0.6	9.13	0.45	6.74e-18	Schizophrenia;
LUSC	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.64	14.39	0.62	7.53e-37	Hemoglobin concentration;
LUSC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg13939156	chr17:80058883	NA	0.34	6.69	0.34	9.61e-11	Life satisfaction;
LUSC	cis	rs68170813	0.652	rs12533694	chr7:107102817	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-8.37	-0.42	1.59e-15	Coronary artery disease;
LUSC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.53	-9.59	-0.46	2.06e-19	Longevity;Endometriosis;
LUSC	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.4	-7.7	-0.39	1.51e-13	Axial length;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09717979	chr4:103790325	UBE2D3;CISD2	0.45	6.76	0.35	6.1e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg13047869	chr3:10149882	C3orf24	0.63	8.73	0.43	1.21e-16	Alzheimer's disease;
LUSC	cis	rs7394190	0.748	rs3740293	chr10:75406141	A/C	cg07699608	chr10:75541558	CHCHD1	0.46	5.8	0.3	1.5e-8	Incident atrial fibrillation;
LUSC	cis	rs4280164	0.943	rs2516564	chr14:24778643	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.62	-7.37	-0.37	1.33e-12	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.58	9.0	0.44	1.77e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg12292205	chr6:26970375	C6orf41	0.62	10.0	0.48	9.16e-21	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.37	0.46	1.1e-18	Monocyte percentage of white cells;
LUSC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg23711669	chr6:146136114	FBXO30	0.87	15.73	0.65	4.02e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg16447950	chr5:562315	NA	-0.57	-6.87	-0.35	3.21e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg02466173	chr16:30829666	NA	0.68	15.93	0.66	6.81e-43	Dementia with Lewy bodies;
LUSC	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg11502198	chr6:26597334	ABT1	0.6	9.37	0.46	1.11e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg04691961	chr3:161091175	C3orf57	-0.33	-5.7	-0.3	2.65e-8	Morning vs. evening chronotype;
LUSC	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg11266682	chr4:10021025	SLC2A9	0.44	8.17	0.41	6.58e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.88	15.05	0.64	1.94e-39	Bladder cancer;
LUSC	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg08975724	chr8:8085496	FLJ10661	0.49	7.05	0.36	1.04e-11	Monocyte count;
LUSC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	0.88	15.18	0.64	5.99e-40	Cognitive function;
LUSC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg13047869	chr3:10149882	C3orf24	0.56	7.86	0.4	5.18e-14	Alzheimer's disease;
LUSC	cis	rs6545883	0.929	rs7606167	chr2:61742654	C/G	cg15711740	chr2:61764176	XPO1	-0.5	-7.93	-0.4	3.3e-14	Tuberculosis;
LUSC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg14895029	chr7:2775587	GNA12	-0.44	-6.65	-0.34	1.19e-10	Height;
LUSC	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg27539214	chr16:67997921	SLC12A4	-0.39	-5.97	-0.31	5.99e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21293242	chr8:11204541	TDH	0.34	6.51	0.34	2.71e-10	Retinal vascular caliber;
LUSC	cis	rs7640424	0.652	rs12152307	chr3:107861766	T/C	cg09227934	chr3:107805635	CD47	-0.41	-6.41	-0.33	4.95e-10	Body mass index;
LUSC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg21782813	chr7:2030301	MAD1L1	0.48	7.81	0.39	7.37e-14	Schizophrenia;
LUSC	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21659725	chr3:3221576	CRBN	-0.59	-9.76	-0.47	5.59e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs4964805	1.000	rs11111791	chr12:104193271	C/G	cg02344784	chr12:104178138	NT5DC3	0.43	6.71	0.34	8.11e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg01973587	chr1:228161476	NA	-0.4	-6.98	-0.36	1.64e-11	Diastolic blood pressure;
LUSC	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.37	-0.91	1.58e-130	Myeloid white cell count;
LUSC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg05206690	chr13:30881675	KATNAL1	0.36	6.11	0.32	2.7e-9	Breast cancer;
LUSC	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg04865166	chr7:105162814	PUS7	0.51	5.71	0.3	2.49e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	14.34	0.62	1.11e-36	Total body bone mineral density;
LUSC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.17	0.45	4.8e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg20283391	chr11:68216788	NA	-0.61	-8.46	-0.42	8.4e-16	Total body bone mineral density;
LUSC	cis	rs10740039	0.804	rs7902456	chr10:62403695	A/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.92	-0.35	2.38e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-10.78	-0.51	1.93e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg05044414	chr3:183734942	ABCC5	0.2	6.8	0.35	4.95e-11	Anterior chamber depth;
LUSC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.75e-14	Melanoma;
LUSC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-9.91	-0.48	1.85e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs701145	0.938	rs355749	chr3:153972500	T/C	cg17054900	chr3:154042577	DHX36	0.83	8.41	0.42	1.21e-15	Coronary artery disease;
LUSC	cis	rs977987	0.778	rs12930452	chr16:75462055	A/G	cg03315344	chr16:75512273	CHST6	0.5	9.56	0.46	2.75e-19	Dupuytren's disease;
LUSC	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg08601574	chr20:25228251	PYGB	0.44	6.69	0.34	9.59e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg06636551	chr8:101224915	SPAG1	-0.43	-7.99	-0.4	2.14e-14	Atrioventricular conduction;
LUSC	trans	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg27411982	chr8:10470053	RP1L1	0.4	6.36	0.33	6.76e-10	Parkinson's disease;
LUSC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	0.92	13.9	0.61	5.47e-35	Breast cancer;
LUSC	cis	rs2307022	0.586	rs11075672	chr16:68384039	A/G	cg02226672	chr16:68398533	SMPD3	0.3	5.78	0.3	1.73e-8	Body mass index;
LUSC	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg22437258	chr11:111473054	SIK2	-0.43	-5.66	-0.3	3.21e-8	Primary sclerosing cholangitis;
LUSC	cis	rs1568889	0.667	rs7123947	chr11:28399908	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.47	6.27	0.32	1.1e-9	Bipolar disorder;
LUSC	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg17595323	chr11:93583763	C11orf90	-0.31	-5.66	-0.3	3.3e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	6.7	0.34	8.94e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	11.09	0.52	1.47e-24	Prudent dietary pattern;
LUSC	cis	rs9322817	0.691	rs6922441	chr6:105216405	T/C	cg02098413	chr6:105308735	HACE1	-0.28	-5.76	-0.3	1.9e-8	Thyroid stimulating hormone;
LUSC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	0.93	18.64	0.71	1.19e-53	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1775715	0.678	rs7096139	chr10:32217404	A/C	cg18675610	chr10:32216311	ARHGAP12	0.28	6.17	0.32	1.97e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.33	-0.37	1.78e-12	Retinal vascular caliber;
LUSC	cis	rs17001868	0.568	rs9611314	chr22:40735798	C/G	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs4692589	0.802	rs2877501	chr4:170955277	G/T	cg19918862	chr4:170955249	NA	0.32	6.24	0.32	1.33e-9	Anxiety disorder;
LUSC	cis	rs10207060	0.500	rs62183161	chr2:240699856	C/T	cg20333904	chr2:240724165	NA	-0.38	-6.33	-0.33	7.69e-10	Obesity-related traits;
LUSC	cis	rs3849570	0.925	rs6765917	chr3:81891116	C/T	cg07356753	chr3:81810745	GBE1	-0.67	-10.95	-0.51	4.77e-24	Waist circumference;Body mass index;
LUSC	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg18904891	chr8:8559673	CLDN23	0.59	8.1	0.41	1.03e-14	Obesity-related traits;
LUSC	trans	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg10756647	chr7:56101905	PSPH	0.84	8.31	0.41	2.46e-15	Diabetic kidney disease;
LUSC	trans	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg12856521	chr11:46389249	DGKZ	-0.4	-6.38	-0.33	5.78e-10	Leprosy;
LUSC	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.66	-0.43	2.04e-16	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs656319	0.513	rs17746227	chr8:9981654	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.43	-0.33	4.44e-10	Myopia (pathological);
LUSC	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs6142102	0.602	rs2268086	chr20:32648738	C/T	cg24642439	chr20:33292090	TP53INP2	-0.39	-5.66	-0.3	3.24e-8	Skin pigmentation;
LUSC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg16325326	chr1:53192061	ZYG11B	0.9	17.08	0.68	1.86e-47	Monocyte count;
LUSC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs7590255	0.876	rs4629139	chr2:37985487	A/G	cg23497611	chr2:37985316	NA	-0.41	-6.26	-0.32	1.18e-9	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs6429082	0.634	rs3856245	chr1:235571428	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.5	-6.82	-0.35	4.3e-11	Adiposity;
LUSC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg26924012	chr15:45694286	SPATA5L1	1.13	20.84	0.75	2.15e-62	Homoarginine levels;
LUSC	cis	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg02972257	chr16:68554789	NA	-0.5	-6.23	-0.32	1.4e-9	Ulcerative colitis;
LUSC	cis	rs12210905	0.841	rs72839470	chr6:27309304	T/A	cg11502198	chr6:26597334	ABT1	-0.83	-5.72	-0.3	2.39e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs9395066	0.545	rs3799977	chr6:44837356	G/T	cg25276700	chr6:44698697	NA	-0.3	-6.12	-0.32	2.58e-9	Height;
LUSC	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-14.01	-0.61	2.13e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.62	-0.43	2.71e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23194354	chr7:3340459	SDK1	-0.46	-6.06	-0.31	3.77e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.68	12.94	0.58	2.53e-31	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs617219	0.819	rs72764990	chr5:78536190	C/G	cg24856658	chr5:78533917	JMY	-0.29	-5.79	-0.3	1.65e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg18357645	chr12:58087776	OS9	-0.5	-6.67	-0.34	1.03e-10	Multiple sclerosis;
LUSC	cis	rs6736093	0.799	rs13025651	chr2:112777853	A/G	cg12686935	chr2:112915763	FBLN7	-0.4	-6.29	-0.33	1.01e-9	Coronary artery disease;
LUSC	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.17	-0.32	1.98e-9	Triglycerides;
LUSC	cis	rs7945718	0.967	rs11022491	chr11:12777620	A/G	cg25843174	chr11:12811716	TEAD1	-0.3	-6.87	-0.35	3.2e-11	Educational attainment (years of education);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13319488	chr13:44361064	ENOX1	-0.55	-6.52	-0.34	2.55e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.43	0.56	1.97e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	9.42	0.46	7.44e-19	Bipolar disorder and schizophrenia;
LUSC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.78	-12.29	-0.56	6.65e-29	Height;
LUSC	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg11245181	chr6:149772854	ZC3H12D	0.29	6.3	0.33	9.28e-10	Dupuytren's disease;
LUSC	cis	rs858239	0.601	rs4599714	chr7:23168801	C/T	cg23682824	chr7:23144976	KLHL7	0.41	5.94	0.31	7.13e-9	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg09876464	chr15:85330779	ZNF592	0.36	6.69	0.34	9.21e-11	P wave terminal force;
LUSC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg00343986	chr7:65444356	GUSB	0.43	6.65	0.34	1.21e-10	Aortic root size;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03024714	chr1:29557626	MECR	-0.47	-6.11	-0.32	2.71e-9	Hepatitis;
LUSC	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.28	-0.41	3.06e-15	Body mass index;
LUSC	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg00945038	chr17:61921165	SMARCD2	0.37	5.64	0.3	3.58e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg20991723	chr1:152506922	NA	0.52	9.7	0.47	8.97e-20	Hair morphology;
LUSC	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg23093090	chr10:104574429	C10orf26	-0.5	-5.91	-0.31	8.52e-9	Arsenic metabolism;
LUSC	cis	rs2637266	0.627	rs1992396	chr10:78482228	T/C	cg18941641	chr10:78392320	NA	0.33	6.02	0.31	4.51e-9	Pulmonary function;
LUSC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg18512352	chr11:47633146	NA	-0.46	-9.19	-0.45	4.42e-18	Subjective well-being;
LUSC	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg13114125	chr14:105738426	BRF1	-0.86	-14.21	-0.61	3.63e-36	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06637938	chr14:75390232	RPS6KL1	0.85	15.8	0.65	2.12e-42	Caffeine consumption;
LUSC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg13560548	chr3:10150139	C3orf24	0.48	6.6	0.34	1.6e-10	Alzheimer's disease;
LUSC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg00343986	chr7:65444356	GUSB	-0.42	-6.44	-0.33	4.24e-10	Aortic root size;
LUSC	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg02023728	chr11:77925099	USP35	0.52	7.2	0.37	4.11e-12	Testicular germ cell tumor;
LUSC	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg03929089	chr4:120376271	NA	-0.54	-6.71	-0.34	8.48e-11	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs1941687	1.000	rs1941687	chr18:31334667	A/C	cg27147174	chr7:100797783	AP1S1	-0.44	-6.53	-0.34	2.49e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs4363385	0.747	rs4568784	chr1:152972694	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.88	-0.4	4.72e-14	Inflammatory skin disease;
LUSC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg03526776	chr6:41159608	TREML2	0.33	6.25	0.32	1.26e-9	Alzheimer's disease (late onset);
LUSC	cis	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.69	-0.34	9.21e-11	Morning vs. evening chronotype;
LUSC	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg23262351	chr6:79576851	IRAK1BP1	-0.39	-5.92	-0.31	7.88e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.88	-0.4	4.78e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	13.19	0.59	2.82e-32	Blood protein levels;
LUSC	cis	rs35771425	0.626	rs6677230	chr1:211652902	A/C	cg10512769	chr1:211675356	NA	-0.27	-6.07	-0.32	3.5e-9	Educational attainment (years of education);
LUSC	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.19	-0.49	2e-21	Eye color traits;
LUSC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg27535305	chr1:53392650	SCP2	0.33	5.97	0.31	6e-9	Monocyte count;
LUSC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg03806693	chr22:41940476	POLR3H	-1.03	-13.9	-0.61	5.73e-35	Vitiligo;
LUSC	cis	rs2970818	0.831	rs2907499	chr12:4616901	G/T	cg11146114	chr12:4671731	NA	0.58	6.12	0.32	2.61e-9	Phosphorus levels;
LUSC	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.34	-0.42	1.91e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs793571	0.614	rs347117	chr15:59000957	C/T	cg05156742	chr15:59063176	FAM63B	0.52	7.63	0.39	2.44e-13	Schizophrenia;
LUSC	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg15848620	chr12:58087721	OS9	-0.53	-7.69	-0.39	1.68e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg17948913	chr5:572064	NA	0.38	6.27	0.32	1.09e-9	Obesity-related traits;
LUSC	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg16006841	chr5:176797999	RGS14	0.68	8.72	0.43	1.35e-16	Urate levels in lean individuals;
LUSC	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg05340658	chr4:99064831	C4orf37	0.6	9.76	0.47	5.95e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.8	-0.35	4.9e-11	Lung cancer;
LUSC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg27411982	chr8:10470053	RP1L1	0.4	6.24	0.32	1.29e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19096424	chr1:120255104	PHGDH	0.45	6.11	0.32	2.76e-9	Blood metabolite levels;
LUSC	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.15	-0.36	5.36e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.6	0.38	2.98e-13	Bipolar disorder;
LUSC	trans	rs1922233	0.943	rs1922228	chr4:92380200	A/G	cg24250684	chr1:219729030	NA	-0.32	-5.99	-0.31	5.54e-9	Gut microbiome composition (summer and winter);
LUSC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.99	-16.66	-0.67	9.09e-46	Systemic lupus erythematosus;
LUSC	trans	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg27517281	chr16:2148693	PKD1	-0.31	-6.18	-0.32	1.9e-9	Triglycerides;
LUSC	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg27068330	chr11:65405492	SIPA1	-0.66	-9.42	-0.46	7.5e-19	Non-alcoholic fatty liver disease histology (lobular);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14825729	chr4:147866863	TTC29	-0.52	-7.11	-0.36	6.94e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg20991723	chr1:152506922	NA	0.5	9.28	0.45	2.18e-18	Hair morphology;
LUSC	cis	rs6005807	0.719	rs2881496	chr22:28921265	C/G	cg12565055	chr22:29076175	TTC28	-0.54	-5.79	-0.3	1.6e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	trans	rs1422110	0.681	rs35625401	chr5:85465408	G/A	cg01787110	chr1:109008453	NBPF6	0.54	8.87	0.44	4.37e-17	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs10992471	0.603	rs11794346	chr9:95247288	C/T	cg14631576	chr9:95140430	CENPP	-0.33	-6.05	-0.31	3.83e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg26441486	chr22:50317300	CRELD2	-0.54	-8.25	-0.41	3.75e-15	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.79	-0.43	8.19e-17	Bipolar disorder;
LUSC	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg23029597	chr12:123009494	RSRC2	-0.7	-9.69	-0.47	9.71e-20	Body mass index;
LUSC	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-10.38	-0.49	4.53e-22	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg12365402	chr11:9010492	NRIP3	0.37	6.35	0.33	6.85e-10	Hemoglobin concentration;
LUSC	cis	rs1847202	0.859	rs4550778	chr3:72949198	G/A	cg25664220	chr3:72788482	NA	-0.41	-7.36	-0.37	1.44e-12	Motion sickness;
LUSC	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.48	-0.5	2.04e-22	Coffee consumption (cups per day);
LUSC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	9.14	0.45	6.38e-18	Mood instability;
LUSC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg26335602	chr6:28129616	ZNF389	0.46	6.34	0.33	7.57e-10	Parkinson's disease;
LUSC	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg17366294	chr4:99064904	C4orf37	0.56	8.2	0.41	5.13e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg20701182	chr2:24300061	SF3B14	0.74	7.28	0.37	2.48e-12	Lymphocyte counts;
LUSC	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg05855489	chr10:104503620	C10orf26	-0.68	-10.06	-0.48	5.7e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1696756	0.638	rs1285274	chr17:77829907	G/A	cg00646381	chr17:77835854	NA	0.59	9.34	0.46	1.36e-18	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUSC	cis	rs8113142	0.651	rs8104685	chr19:29058834	A/G	cg04546413	chr19:29218101	NA	0.46	6.02	0.31	4.7e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg16743903	chr16:89593216	SPG7	-0.39	-6.18	-0.32	1.83e-9	Multiple myeloma (IgH translocation);
LUSC	trans	rs7552393	0.636	rs12135529	chr1:84293113	C/T	cg23537141	chr10:80875585	ZMIZ1	-0.36	-6.02	-0.31	4.64e-9	Select biomarker traits;
LUSC	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg02807482	chr3:125708958	NA	-0.43	-5.65	-0.3	3.41e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.56	-10.84	-0.51	1.18e-23	Asthma (sex interaction);
LUSC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs4499344	0.805	rs116855540	chr19:33083830	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.59	-7.75	-0.39	1.13e-13	Mean platelet volume;
LUSC	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg12062639	chr20:23401060	NAPB	0.98	8.38	0.42	1.5e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs708547	0.836	rs1612191	chr4:57724320	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.57	-7.14	-0.36	5.92e-12	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7705502	1.000	rs17696147	chr5:173373143	T/C	cg18693985	chr5:173351052	CPEB4	-0.37	-5.83	-0.3	1.3e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs7760535	0.826	rs3851229	chr6:111854660	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.38	-7.1	-0.36	7.54e-12	Metabolic traits;
LUSC	cis	rs9341808	0.667	rs3805919	chr6:80906809	C/G	cg08355045	chr6:80787529	NA	0.46	7.96	0.4	2.75e-14	Sitting height ratio;
LUSC	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg04733989	chr22:42467013	NAGA	0.39	6.07	0.32	3.39e-9	Cognitive function;
LUSC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg00024416	chr22:24240387	NA	-0.47	-7.59	-0.38	3.27e-13	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg06636001	chr8:8085503	FLJ10661	0.58	8.39	0.42	1.4e-15	Retinal vascular caliber;
LUSC	cis	rs7727544	0.547	rs10076758	chr5:131524299	A/G	cg14196790	chr5:131705035	SLC22A5	0.46	7.64	0.39	2.29e-13	Blood metabolite levels;
LUSC	trans	rs61931739	0.629	rs708146	chr12:33731808	C/G	cg26384229	chr12:38710491	ALG10B	0.43	6.18	0.32	1.9e-9	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10699881	chr4:6271512	WFS1	-0.42	-6.41	-0.33	4.85e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg12386194	chr3:101231763	SENP7	0.54	7.08	0.36	8.81e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7582720	0.943	rs72934546	chr2:203980033	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.7	0.43	1.56e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs9693857	0.501	rs67985496	chr8:9263128	T/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.06	-0.31	3.63e-9	Systolic blood pressure;
LUSC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg08888203	chr3:10149979	C3orf24	0.58	7.61	0.38	2.91e-13	Alzheimer's disease;
LUSC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg07701084	chr6:150067640	NUP43	0.55	8.41	0.42	1.21e-15	Lung cancer;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg22090150	chr17:4098227	ANKFY1	-0.37	-5.94	-0.31	7.03e-9	N-glycan levels;
LUSC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	7.17	0.37	4.8e-12	Platelet count;
LUSC	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.67	10.13	0.48	3.23e-21	Morning vs. evening chronotype;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20061884	chr7:108210449	THAP5;DNAJB9	-0.4	-6.09	-0.32	3.07e-9	Electrocardiographic conduction measures;
LUSC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.46	-8.23	-0.41	4.21e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg02475777	chr4:1388615	CRIPAK	0.45	6.65	0.34	1.2e-10	Obesity-related traits;
LUSC	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg15556689	chr8:8085844	FLJ10661	0.58	9.06	0.44	1.08e-17	Retinal vascular caliber;
LUSC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.23	0.32	1.43e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.93	0.35	2.22e-11	IgG glycosylation;
LUSC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.13	0.45	6.5e-18	Motion sickness;
LUSC	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.47	-0.38	7.08e-13	Morning vs. evening chronotype;
LUSC	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-10.93	-0.51	5.48e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.7	12.7	0.57	1.95e-30	Prudent dietary pattern;
LUSC	cis	rs7804356	0.953	rs12534921	chr7:26877210	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.12	-0.32	2.58e-9	Type 1 diabetes;
LUSC	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg22089800	chr15:90895588	ZNF774	-0.64	-9.65	-0.47	1.3e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.03e-14	Corneal astigmatism;
LUSC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.45	7.41	0.38	1.07e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg22508957	chr16:3507546	NAT15	-0.4	-5.84	-0.3	1.22e-8	Body mass index (adult);
LUSC	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg05855489	chr10:104503620	C10orf26	-0.49	-7.42	-0.38	9.5e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2806561	0.808	rs1413974	chr1:23347125	C/T	cg19743168	chr1:23544995	NA	-0.44	-9.11	-0.45	7.89e-18	Height;
LUSC	cis	rs6594499	0.500	rs12514810	chr5:110455357	T/A	cg04022379	chr5:110408740	TSLP	0.6	9.15	0.45	5.73e-18	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-9.02	-0.44	1.55e-17	Gut microbiome composition (summer);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg00661222	chr13:52343378	DHRS12	-0.37	-6.04	-0.31	4.06e-9	N-glycan levels;
LUSC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	9.43	0.46	7.19e-19	Bipolar disorder;
LUSC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08859206	chr1:53392774	SCP2	0.5	8.57	0.42	4e-16	Monocyte count;
LUSC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-12.68	-0.57	2.34e-30	Platelet count;
LUSC	trans	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg11887960	chr12:57824829	NA	0.46	6.47	0.33	3.41e-10	Obesity-related traits;
LUSC	trans	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	5.96	0.31	6.55e-9	Neuroticism;
LUSC	cis	rs7523273	0.586	rs2796264	chr1:207919968	A/G	cg22525895	chr1:207977042	MIR29B2	0.4	6.62	0.34	1.42e-10	Schizophrenia;
LUSC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg10556349	chr10:835070	NA	0.54	6.11	0.32	2.81e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs10392	0.543	rs62204117	chr20:37565335	T/C	cg27552599	chr20:37590471	DHX35	0.43	7.11	0.36	7e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	5.78	0.3	1.72e-8	Schizophrenia;
LUSC	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg03929089	chr4:120376271	NA	0.66	6.16	0.32	2.03e-9	Axial length;
LUSC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg03188948	chr7:1209495	NA	0.66	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7336332	0.598	rs1885989	chr13:28010117	G/A	cg22138327	chr13:27999177	GTF3A	0.8	9.68	0.47	1.1e-19	Weight;
LUSC	trans	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg14227996	chr4:17616232	MED28	-0.54	-6.01	-0.31	4.92e-9	Opioid sensitivity;
LUSC	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.78	-0.3	1.75e-8	Tonsillectomy;
LUSC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg22800045	chr5:56110881	MAP3K1	-0.42	-5.74	-0.3	2.17e-8	Coronary artery disease;
LUSC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg06096015	chr1:231504339	EGLN1	-0.55	-9.81	-0.47	3.99e-20	Hemoglobin concentration;
LUSC	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-7.82	-0.39	6.9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg13319975	chr6:146136371	FBXO30	0.46	7.09	0.36	7.87e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg12935359	chr14:103987150	CKB	-0.56	-8.48	-0.42	7.62e-16	Body mass index;
LUSC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg19468946	chr17:37922297	IKZF3	-0.39	-6.33	-0.33	7.85e-10	Self-reported allergy;
LUSC	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg16989719	chr2:238392110	NA	-0.41	-7.25	-0.37	3e-12	Prostate cancer;
LUSC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	0.61	9.8	0.47	4.17e-20	Breast cancer;
LUSC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg05347473	chr6:146136440	FBXO30	0.46	7.77	0.39	9.95e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs36093844	1.000	rs11234452	chr11:85576801	C/T	cg16165120	chr11:85566439	CCDC83	-0.35	-5.8	-0.3	1.54e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.59	0.5	8.87e-23	Colorectal cancer;
LUSC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03934478	chr11:495069	RNH1	0.89	10.11	0.48	3.79e-21	Body mass index;
LUSC	cis	rs34375054	0.672	rs10400509	chr12:125592173	T/C	cg06287003	chr12:125626642	AACS	-0.39	-6.85	-0.35	3.55e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.73e-23	Bladder cancer;
LUSC	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg23625390	chr15:77176239	SCAPER	0.46	7.04	0.36	1.09e-11	Blood metabolite levels;
LUSC	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.68	-12.14	-0.55	2.53e-28	White blood cell count (basophil);
LUSC	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg03859395	chr2:55845619	SMEK2	0.83	15.2	0.64	5.18e-40	Metabolic syndrome;
LUSC	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg18811423	chr2:55921094	PNPT1	0.83	14.37	0.62	8.87e-37	Metabolic syndrome;
LUSC	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg09754948	chr16:28834200	ATXN2L	0.41	5.84	0.3	1.24e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg04414720	chr1:150670196	GOLPH3L	0.56	9.1	0.45	8.47e-18	Tonsillectomy;
LUSC	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-7.04	-0.36	1.07e-11	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs11613704	1	rs11613704	chr12:980925	C/A	cg27417659	chr7:98567827	TRRAP	-0.5	-6.08	-0.32	3.21e-9	Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11764359	chr7:65958608	NA	0.62	9.34	0.46	1.4e-18	Aortic root size;
LUSC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg09455208	chr3:40491958	NA	0.6	10.67	0.5	4.72e-23	Renal cell carcinoma;
LUSC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg11645453	chr3:52864694	ITIH4	0.38	8.65	0.43	2.25e-16	Bipolar disorder;
LUSC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.57	-7.02	-0.36	1.27e-11	Lung function (FEV1/FVC);
LUSC	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.2	-0.32	1.69e-9	Systolic blood pressure;
LUSC	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg03804128	chr16:635623	NA	0.31	6.16	0.32	2.1e-9	Height;
LUSC	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg25173405	chr17:45401733	C17orf57	-0.4	-6.47	-0.33	3.57e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-14.87	-0.63	9.93e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg11244672	chr19:19639970	YJEFN3	-0.52	-6.49	-0.33	3.05e-10	Bipolar disorder;
LUSC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.87	0.35	3.14e-11	Total body bone mineral density;
LUSC	cis	rs2857891	0.695	rs2857895	chr11:6982992	C/G	cg04053776	chr11:6947353	ZNF215	-0.4	-6.1	-0.32	2.95e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.2	-11.16	-0.52	8.34e-25	Alzheimer's disease (late onset);
LUSC	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg05729581	chr11:3078854	CARS	0.41	6.08	0.32	3.36e-9	Calcium levels;
LUSC	trans	rs1910358	0.554	rs10057796	chr5:23759746	C/T	cg18225582	chr14:65171304	PLEKHG3	0.41	6.13	0.32	2.5e-9	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg21775007	chr8:11205619	TDH	-0.5	-7.05	-0.36	1.01e-11	Triglycerides;
LUSC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.48	0.53	6.2e-26	Prudent dietary pattern;
LUSC	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg24375607	chr4:120327624	NA	-0.7	-11.03	-0.52	2.45e-24	Corneal astigmatism;
LUSC	cis	rs9467711	0.720	rs1417998	chr6:26162019	T/A	cg16898833	chr6:26189333	HIST1H4D	0.71	6.88	0.35	3.05e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs35000415	0.938	rs12531711	chr7:128617466	A/G	cg19972273	chr7:128594194	NA	0.64	6.68	0.34	9.76e-11	Systemic lupus erythematosus;
LUSC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg11871910	chr12:69753446	YEATS4	-0.91	-17.32	-0.69	2.16e-48	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.87e-20	Coronary artery disease;
LUSC	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.7	-10.7	-0.51	3.54e-23	Alcohol dependence;
LUSC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg05425664	chr17:57184151	TRIM37	0.54	8.01	0.4	1.91e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg17410650	chr12:54324560	NA	-0.57	-10.35	-0.49	5.7e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	cis	rs17739794	0.517	rs6982473	chr8:773986	G/T	cg07178994	chr8:816998	NA	-0.39	-5.78	-0.3	1.74e-8	Clozapine-induced cytotoxicity;
LUSC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg05132306	chr1:1846340	CALML6	0.24	5.95	0.31	6.74e-9	Body mass index;
LUSC	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg16989719	chr2:238392110	NA	-0.44	-7.45	-0.38	7.93e-13	Prostate cancer;
LUSC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg08859206	chr1:53392774	SCP2	0.47	7.88	0.4	4.71e-14	Monocyte count;
LUSC	cis	rs6977940	0.558	rs117222922	chr7:2891608	G/A	cg19731401	chr7:2775893	GNA12	0.69	7.54	0.38	4.62e-13	White matter integrity;
LUSC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg23029597	chr12:123009494	RSRC2	-0.64	-8.27	-0.41	3.19e-15	Body mass index;
LUSC	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg05925327	chr15:68127851	NA	-0.47	-6.88	-0.35	3e-11	Restless legs syndrome;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21200380	chr17:5342446	C1QBP	-0.44	-5.98	-0.31	5.83e-9	Hepatitis;
LUSC	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg24634471	chr8:143751801	JRK	0.51	7.27	0.37	2.6e-12	Schizophrenia;
LUSC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.44	6.62	0.34	1.47e-10	Systemic lupus erythematosus;
LUSC	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg15704280	chr7:45808275	SEPT13	0.67	7.37	0.37	1.35e-12	Axial length;
LUSC	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-5.97	-0.31	6.08e-9	Ulcerative colitis;
LUSC	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg20701182	chr2:24300061	SF3B14	0.9	11.58	0.54	2.61e-26	Lymphocyte counts;
LUSC	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg16989719	chr2:238392110	NA	-0.35	-5.84	-0.3	1.22e-8	Prostate cancer;
LUSC	cis	rs1505368	0.505	rs1394781	chr2:213248822	C/T	cg16329650	chr2:213403929	ERBB4	-0.49	-7.97	-0.4	2.61e-14	Symmetrical dimethylarginine levels;
LUSC	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg19773385	chr1:10388646	KIF1B	-0.53	-8.3	-0.41	2.57e-15	Hepatocellular carcinoma;
LUSC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg25174290	chr11:3078921	CARS	0.57	8.76	0.43	1.03e-16	Longevity;
LUSC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.65	0.3	3.51e-8	Self-reported allergy;
LUSC	cis	rs6084875	0.840	rs743252	chr20:4720667	C/T	cg07258627	chr20:4721683	PRNT	-0.34	-6.2	-0.32	1.69e-9	Systemic lupus erythematosus;
LUSC	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg11901034	chr3:128598214	ACAD9	-0.41	-6.46	-0.33	3.62e-10	IgG glycosylation;
LUSC	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.3	5.74	0.3	2.18e-8	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.78	-0.35	5.44e-11	Menopause (age at onset);
LUSC	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg07828024	chr6:149772892	ZC3H12D	-0.34	-7.38	-0.37	1.23e-12	Dupuytren's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22435081	chr17:41323035	NBR1	0.45	6.0	0.31	5.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.19	-0.41	5.51e-15	Axial length;
LUSC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.73e-23	Bladder cancer;
LUSC	trans	rs1325195	0.879	rs10913695	chr1:179083469	T/G	cg11624085	chr17:8464688	MYH10	-0.45	-7.36	-0.37	1.49e-12	IgE grass sensitization;
LUSC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg23985595	chr17:80112537	CCDC57	0.31	5.88	0.31	9.8e-9	Life satisfaction;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14737296	chr12:133212394	POLE	-0.48	-7.56	-0.38	3.82e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg05472934	chr7:22766657	IL6	0.53	8.28	0.41	2.91e-15	Lung cancer;
LUSC	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.54	-10.77	-0.51	2.06e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.96	-16.54	-0.67	2.55e-45	Body mass index;
LUSC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg05425664	chr17:57184151	TRIM37	-0.55	-8.01	-0.4	1.94e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg06784218	chr1:46089804	CCDC17	0.34	5.69	0.3	2.77e-8	Platelet count;
LUSC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.86	0.35	3.37e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg24060327	chr5:131705240	SLC22A5	-0.53	-8.78	-0.43	8.48e-17	Acylcarnitine levels;
LUSC	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.56	8.71	0.43	1.42e-16	Menopause (age at onset);
LUSC	cis	rs9302690	0.557	rs223869	chr16:57494992	C/A	cg27017172	chr16:57497170	POLR2C	0.67	5.99	0.31	5.41e-9	Blood protein levels;
LUSC	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg26893861	chr17:41843967	DUSP3	0.88	13.8	0.6	1.38e-34	Triglycerides;
LUSC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-8.4	-0.42	1.29e-15	Alzheimer's disease;
LUSC	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg21487550	chr3:127056955	NA	-0.47	-6.53	-0.34	2.41e-10	Interleukin-10 levels;Interleukin-13 levels;
LUSC	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg04827223	chr11:72435913	ARAP1	-0.65	-8.26	-0.41	3.37e-15	Type 2 diabetes;
LUSC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.47	6.9	0.35	2.56e-11	Schizophrenia;
LUSC	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg04850211	chr1:228464232	OBSCN	-0.37	-6.24	-0.32	1.35e-9	Diastolic blood pressure;
LUSC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.11	-0.48	3.98e-21	Hemoglobin concentration;
LUSC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	7.62	0.39	2.57e-13	Calcium levels;
LUSC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.78	0.47	4.89e-20	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg07507251	chr3:52567010	NT5DC2	0.32	6.25	0.32	1.28e-9	Bipolar disorder;
LUSC	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg03732007	chr1:2071316	PRKCZ	0.47	7.61	0.38	2.8e-13	Height;
LUSC	cis	rs12973672	1.000	rs1052033	chr19:35770471	C/T	cg12095397	chr19:35769544	USF2	0.44	6.91	0.35	2.42e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs394563	0.601	rs376269	chr6:149795154	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.38	-7.85	-0.39	5.65e-14	Dupuytren's disease;
LUSC	cis	rs1775715	1.000	rs1251363	chr10:32328526	G/C	cg26784012	chr10:32216390	ARHGAP12	-0.39	-6.19	-0.32	1.74e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23628684	chr21:30446052	CCT8	0.44	6.17	0.32	1.96e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg06808227	chr14:105710500	BRF1	-0.72	-11.64	-0.54	1.66e-26	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6736093	0.862	rs79798002	chr2:112733978	G/A	cg12686935	chr2:112915763	FBLN7	-0.37	-5.96	-0.31	6.32e-9	Coronary artery disease;
LUSC	cis	rs2658782	0.738	rs2605628	chr11:93261560	C/A	cg15737290	chr11:93063684	CCDC67	0.62	7.6	0.38	3.02e-13	Pulmonary function decline;
LUSC	trans	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg26043149	chr18:55253948	FECH	-0.45	-6.89	-0.35	2.86e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg24060327	chr5:131705240	SLC22A5	-0.36	-5.98	-0.31	5.89e-9	Blood metabolite levels;
LUSC	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.66	10.0	0.48	9.39e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.39	-0.37	1.2e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6142102	0.961	rs4911393	chr20:32570926	A/G	cg08999081	chr20:33150536	PIGU	0.34	5.9	0.31	9.15e-9	Skin pigmentation;
LUSC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg00800038	chr16:89945340	TCF25	-0.75	-6.58	-0.34	1.83e-10	Skin colour saturation;
LUSC	cis	rs981844	1.000	rs2606329	chr4:154654643	A/C	cg14289246	chr4:154710475	SFRP2	0.49	6.11	0.32	2.74e-9	Response to statins (LDL cholesterol change);
LUSC	trans	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg24644049	chr4:85504048	CDS1	0.88	7.56	0.38	4e-13	Skin colour saturation;
LUSC	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.12	-18.79	-0.72	3.08e-54	Primary sclerosing cholangitis;
LUSC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.73	-0.51	2.85e-23	Alzheimer's disease (late onset);
LUSC	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg27661571	chr11:113659931	NA	-0.71	-8.0	-0.4	2.07e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs4776059	0.798	rs4776063	chr15:52904046	C/A	cg22715398	chr15:52968154	KIAA1370	-0.6	-7.79	-0.39	8.29e-14	Schizophrenia;
LUSC	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg21427119	chr20:30132790	HM13	-0.39	-5.71	-0.3	2.45e-8	Mean corpuscular hemoglobin;
LUSC	trans	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg14791747	chr16:20752902	THUMPD1	0.73	9.57	0.46	2.51e-19	Cognitive test performance;
LUSC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	9.09	0.45	8.9e-18	Prudent dietary pattern;
LUSC	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg00310523	chr12:86230176	RASSF9	0.44	8.25	0.41	3.7e-15	Major depressive disorder;
LUSC	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	6.95	0.36	1.88e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg24399712	chr22:39784796	NA	-0.56	-8.82	-0.43	6.33e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg12463550	chr7:65579703	CRCP	0.63	5.7	0.3	2.7e-8	Diabetic kidney disease;
LUSC	trans	rs7556950	0.572	rs61554827	chr2:41932102	T/C	cg13792581	chr20:43590115	TOMM34	0.77	6.26	0.32	1.17e-9	Major depression and alcohol dependence;
LUSC	cis	rs4494114	0.967	rs1886748	chr1:39333775	C/A	cg25970120	chr1:39325951	RRAGC	-0.42	-6.41	-0.33	4.92e-10	Blood protein levels;
LUSC	trans	rs10411161	0.702	rs8113584	chr19:52383874	A/G	cg22319618	chr22:45562946	NUP50	-0.49	-5.94	-0.31	6.97e-9	Breast cancer;
LUSC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.78	-0.3	1.67e-8	Alzheimer's disease (late onset);
LUSC	cis	rs4786125	0.665	rs1565634	chr16:6919370	T/C	cg03623568	chr16:6915990	A2BP1	-0.5	-8.39	-0.42	1.38e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs10886558	0.517	rs9732120	chr10:121800656	A/T	cg02041677	chr10:121771263	NA	0.37	6.93	0.35	2.2e-11	Shingles;
LUSC	cis	rs7712401	0.601	rs246306	chr5:122279218	G/C	cg19077854	chr5:122220652	SNX24	0.41	9.15	0.45	5.72e-18	Mean platelet volume;
LUSC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg02038168	chr22:39784481	NA	-0.47	-7.53	-0.38	4.64e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg09323728	chr8:95962352	TP53INP1	-0.3	-5.69	-0.3	2.78e-8	Type 2 diabetes;
LUSC	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg23958373	chr8:599963	NA	-0.89	-9.02	-0.44	1.52e-17	IgG glycosylation;
LUSC	cis	rs1044826	1.000	rs973691	chr3:139197858	G/C	cg00490450	chr3:139108681	COPB2	0.52	6.76	0.35	6.18e-11	Obesity-related traits;
LUSC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.84	-13.65	-0.6	5.08e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.58	-8.53	-0.42	5.17e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg03676636	chr4:99064102	C4orf37	0.36	7.89	0.4	4.25e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.34e-17	Motion sickness;
LUSC	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg12560992	chr17:57184187	TRIM37	0.6	9.58	0.46	2.23e-19	Testicular germ cell tumor;
LUSC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.48	-0.67	4.45e-45	Monocyte count;
LUSC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.87	0.68	1.25e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg21775007	chr8:11205619	TDH	-0.65	-10.34	-0.49	6.55e-22	Retinal vascular caliber;
LUSC	cis	rs3740540	0.507	rs942014	chr10:126290070	C/T	cg04949429	chr10:126290192	LHPP	0.35	7.46	0.38	7.61e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.72	0.39	1.33e-13	Mean platelet volume;
LUSC	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	14.83	0.63	1.39e-38	Lymphocyte percentage of white cells;
LUSC	cis	rs11112613	0.609	rs4991814	chr12:106046709	G/A	cg03607813	chr12:105948248	NA	0.62	7.84	0.39	6.02e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg00290607	chr11:67383545	NA	-0.38	-6.42	-0.33	4.74e-10	Mean corpuscular volume;
LUSC	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg10547527	chr2:198650123	BOLL	-0.5	-5.92	-0.31	7.84e-9	Ulcerative colitis;
LUSC	cis	rs2692947	0.644	rs772178	chr2:96963684	C/T	cg23100626	chr2:96804247	ASTL	-0.29	-6.87	-0.35	3.09e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.88	-0.35	3.05e-11	Response to antipsychotic treatment;
LUSC	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.96e-9	Prostate cancer;
LUSC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg15921436	chr17:44337874	NA	0.83	11.86	0.54	2.54e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.31	-5.85	-0.3	1.19e-8	Lymphocyte counts;
LUSC	cis	rs654351	0.572	rs813274	chr6:10387731	C/T	cg17959970	chr6:10383164	NA	-0.36	-6.69	-0.34	9.31e-11	Squamous cell lung carcinoma;
LUSC	cis	rs2425143	1.000	rs60646509	chr20:34303409	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.33	-0.33	8.1e-10	Blood protein levels;
LUSC	cis	rs460214	0.564	rs464519	chr21:40024182	A/G	cg12884169	chr21:40033163	ERG	-0.35	-5.73	-0.3	2.25e-8	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.14	0.41	8.16e-15	Axial length;
LUSC	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg03474202	chr17:45855739	NA	-0.3	-6.99	-0.36	1.46e-11	IgG glycosylation;
LUSC	cis	rs34526934	0.608	rs13017511	chr2:177035395	A/G	cg26754761	chr2:177040938	NA	-0.4	-7.72	-0.39	1.39e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs72827839	0.516	rs72833461	chr17:45938105	T/G	cg23391107	chr17:45924227	SP6	0.42	7.42	0.38	9.86e-13	Ease of getting up in the morning;
LUSC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.71	11.85	0.54	2.87e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg01475377	chr6:109611718	NA	-0.37	-6.46	-0.33	3.61e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg16006841	chr5:176797999	RGS14	0.62	9.8	0.47	4.25e-20	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg19046167	chr17:80928561	B3GNTL1	-0.45	-6.49	-0.33	3.03e-10	Breast cancer;
LUSC	cis	rs6960043	0.905	rs7786873	chr7:15060410	A/G	cg19272540	chr7:15055459	NA	-0.31	-7.32	-0.37	1.85e-12	Type 2 diabetes;
LUSC	trans	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg06606381	chr12:133084897	FBRSL1	-0.67	-7.52	-0.38	5.13e-13	Depression;
LUSC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg18477163	chr1:228402036	OBSCN	-0.56	-10.27	-0.49	1.13e-21	Diastolic blood pressure;
LUSC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg09034736	chr1:150693464	HORMAD1	-0.46	-6.34	-0.33	7.24e-10	Melanoma;
LUSC	cis	rs354225	0.544	rs10208219	chr2:54806047	G/A	cg26097391	chr2:54893211	SPTBN1	0.46	6.95	0.36	1.88e-11	Schizophrenia;
LUSC	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg27205649	chr11:78285834	NARS2	-0.49	-5.79	-0.3	1.6e-8	Alzheimer's disease (survival time);
LUSC	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	22.93	0.78	1.45e-70	Colorectal cancer;
LUSC	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg15704280	chr7:45808275	SEPT13	0.75	8.5	0.42	6.55e-16	Axial length;
LUSC	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	7.13	0.36	6.15e-12	Ovarian reserve;
LUSC	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.26	-0.37	2.65e-12	Bipolar disorder;
LUSC	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg19116668	chr7:99932089	PMS2L1	0.34	5.99	0.31	5.31e-9	Coronary artery disease;
LUSC	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg24558204	chr6:135376177	HBS1L	0.57	8.61	0.43	2.87e-16	Red blood cell count;
LUSC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg25767906	chr1:53392781	SCP2	-0.45	-7.9	-0.4	4e-14	Monocyte count;
LUSC	cis	rs10108704	0.917	rs72682697	chr8:110348649	T/C	cg20147595	chr8:110349212	ENY2	-0.45	-5.67	-0.3	3.14e-8	Multiple system atrophy (pathologically confirmed);
LUSC	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.62	0.34	1.39e-10	IgG glycosylation;
LUSC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg12463550	chr7:65579703	CRCP	-0.43	-6.16	-0.32	2.11e-9	Corneal structure;
LUSC	cis	rs4343996	0.626	rs4722723	chr7:3398320	C/T	cg21248987	chr7:3385318	SDK1	-0.37	-6.21	-0.32	1.61e-9	Motion sickness;
LUSC	cis	rs977987	0.806	rs11648176	chr16:75456423	C/G	cg03315344	chr16:75512273	CHST6	0.5	9.36	0.46	1.2e-18	Dupuytren's disease;
LUSC	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.17	-0.32	1.94e-9	Bipolar disorder;
LUSC	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg21433313	chr16:3507492	NAT15	0.41	6.35	0.33	6.97e-10	Body mass index (adult);
LUSC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg16393715	chr7:1948819	MAD1L1	0.4	6.92	0.35	2.35e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg23281280	chr6:28129359	ZNF389	0.45	5.67	0.3	3.04e-8	Depression;
LUSC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg12463550	chr7:65579703	CRCP	0.47	6.96	0.36	1.86e-11	Aortic root size;
LUSC	cis	rs9517320	0.935	rs1886089	chr13:99124356	C/T	cg20487152	chr13:99095054	FARP1	0.35	6.5	0.33	3.01e-10	Longevity;
LUSC	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg21427119	chr20:30132790	HM13	-0.45	-6.52	-0.34	2.66e-10	Mean corpuscular hemoglobin;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00345230	chr4:151936469	LRBA	0.42	6.16	0.32	2.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.34	0.56	4.41e-29	Cognitive test performance;
LUSC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg19622623	chr12:86230825	RASSF9	-0.45	-6.18	-0.32	1.87e-9	Major depressive disorder;
LUSC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg24675658	chr1:53192096	ZYG11B	-0.65	-10.18	-0.49	2.16e-21	Monocyte count;
LUSC	trans	rs11681884	0.786	rs34466405	chr2:113808054	A/T	cg19632953	chr13:113635898	MCF2L	0.7	6.06	0.31	3.63e-9	Stroke;
LUSC	cis	rs1864400	0.696	rs2742239	chr10:43621712	A/G	cg02780029	chr10:43622663	RET	-0.33	-5.67	-0.3	3.01e-8	Hirschsprung disease;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg12569071	chr8:22102812	POLR3D;MIR320A	0.51	6.24	0.32	1.34e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10865541	0.869	rs13020433	chr2:3417577	G/A	cg15807143	chr2:3452624	TTC15	0.33	5.84	0.3	1.21e-8	Obesity-related traits;
LUSC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg13175981	chr1:150552382	MCL1	0.53	7.4	0.38	1.09e-12	Tonsillectomy;
LUSC	cis	rs7572644	0.679	rs12986980	chr2:28030437	A/G	cg27432699	chr2:27873401	GPN1	0.55	7.3	0.37	2.19e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-11.89	-0.55	2.04e-27	Platelet count;
LUSC	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.7	10.71	0.51	3.35e-23	Smoking initiation;
LUSC	cis	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.83	-0.39	6.43e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg06618935	chr21:46677482	NA	-0.41	-8.0	-0.4	2.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg24631222	chr15:78858424	CHRNA5	0.84	11.33	0.53	2.16e-25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg17764715	chr19:33622953	WDR88	0.6	8.29	0.41	2.72e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg07952391	chr2:88470173	THNSL2	0.75	6.49	0.33	3.06e-10	Plasma clusterin levels;
LUSC	cis	rs12220238	1.000	rs10824098	chr10:75943579	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.3	0.37	2.06e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs2637266	1.000	rs2579746	chr10:78327674	C/T	cg18941641	chr10:78392320	NA	0.37	6.79	0.35	5.01e-11	Pulmonary function;
LUSC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.48	0.38	6.75e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00631329	chr6:26305371	NA	-0.47	-9.21	-0.45	3.71e-18	Educational attainment;
LUSC	cis	rs977987	0.843	rs4146810	chr16:75415831	A/G	cg03315344	chr16:75512273	CHST6	0.53	10.44	0.5	2.81e-22	Dupuytren's disease;
LUSC	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs7712401	0.601	rs30038	chr5:122277362	A/C	cg19077854	chr5:122220652	SNX24	0.41	9.09	0.45	8.76e-18	Mean platelet volume;
LUSC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.59	10.82	0.51	1.39e-23	Bone mineral density;
LUSC	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg20476274	chr7:133979776	SLC35B4	0.88	16.77	0.68	3.06e-46	Mean platelet volume;
LUSC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.55	-0.53	3.41e-26	Alzheimer's disease;
LUSC	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	11.58	0.54	2.61e-26	Menopause (age at onset);
LUSC	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg07169764	chr2:136633963	MCM6	0.76	10.77	0.51	2.09e-23	Mosquito bite size;
LUSC	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.45	-0.46	6.1e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg12751644	chr20:60527061	NA	-0.34	-6.0	-0.31	5.03e-9	Body mass index;
LUSC	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.12	-0.36	6.84e-12	Response to antipsychotic treatment;
LUSC	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg01620082	chr3:125678407	NA	-0.77	-6.9	-0.35	2.57e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg22907277	chr7:1156413	C7orf50	0.71	7.6	0.38	2.98e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11700980	0.551	rs2832034	chr21:30114927	T/C	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg23950597	chr19:37808831	NA	-0.62	-7.31	-0.37	2e-12	Coronary artery calcification;
LUSC	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg12386194	chr3:101231763	SENP7	0.53	7.4	0.38	1.08e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2458413	0.669	rs1812214	chr8:105344070	A/G	cg04554929	chr8:105342491	NA	-0.36	-6.4	-0.33	5.22e-10	Paget's disease;
LUSC	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg11245181	chr6:149772854	ZC3H12D	0.3	6.58	0.34	1.82e-10	Dupuytren's disease;
LUSC	cis	rs17102423	0.826	rs10873181	chr14:65604459	A/C	cg11161011	chr14:65562177	MAX	-0.69	-10.54	-0.5	1.26e-22	Obesity-related traits;
LUSC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.45	7.36	0.37	1.47e-12	Menarche (age at onset);
LUSC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06221963	chr1:154839813	KCNN3	0.59	13.45	0.59	2.87e-33	Prostate cancer;
LUSC	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.92e-20	Coronary artery disease;
LUSC	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg07936489	chr17:37558343	FBXL20	0.78	9.96	0.48	1.27e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg02175503	chr12:58329896	NA	-0.41	-5.79	-0.3	1.6e-8	Multiple sclerosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24681695	chr2:170550946	C2orf77;PHOSPHO2;KLHL23	-0.42	-6.26	-0.32	1.17e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs68170813	0.559	rs74906766	chr7:106885236	T/A	cg02696742	chr7:106810147	HBP1	-0.63	-9.48	-0.46	5.01e-19	Coronary artery disease;
LUSC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.55	-0.42	4.46e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	0.85	10.47	0.5	2.22e-22	Cognitive function;
LUSC	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg23649088	chr2:200775458	C2orf69	0.5	7.55	0.38	4.27e-13	Osteoporosis;
LUSC	cis	rs6076065	0.683	rs2424528	chr20:23361613	C/T	cg11657817	chr20:23433608	CST11	0.42	7.99	0.4	2.19e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs4285028	0.580	rs2293611	chr3:121643163	G/C	cg11130432	chr3:121712080	ILDR1	-0.5	-8.33	-0.41	2.08e-15	Multiple sclerosis;
LUSC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.36e-8	Lung cancer;
LUSC	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg05340658	chr4:99064831	C4orf37	0.59	8.94	0.44	2.79e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21643547	chr1:205240462	TMCC2	-0.53	-10.15	-0.49	2.88e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg11859384	chr17:80120422	CCDC57	-0.36	-5.67	-0.3	3.04e-8	Life satisfaction;
LUSC	cis	rs59104589	0.550	rs62193172	chr2:242277715	G/C	cg14842376	chr2:242211374	HDLBP	0.57	6.46	0.33	3.65e-10	Fibrinogen levels;
LUSC	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg03342759	chr3:160939853	NMD3	-0.49	-8.18	-0.41	5.82e-15	Morning vs. evening chronotype;
LUSC	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg24503407	chr1:205819492	PM20D1	0.44	6.07	0.32	3.42e-9	Parkinson's disease;
LUSC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.71	0.47	8.46e-20	Bipolar disorder;
LUSC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg06636001	chr8:8085503	FLJ10661	0.62	9.67	0.47	1.16e-19	Joint mobility (Beighton score);
LUSC	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg21100191	chr22:23484243	RTDR1	0.92	15.74	0.65	3.94e-42	Bone mineral density;
LUSC	cis	rs4478858	0.735	rs7523509	chr1:31788329	A/G	cg00250761	chr1:31883323	NA	-0.36	-8.92	-0.44	3.03e-17	Alcohol dependence;
LUSC	trans	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg12856521	chr11:46389249	DGKZ	-0.38	-6.08	-0.32	3.23e-9	Leprosy;
LUSC	cis	rs9300255	0.782	rs12809602	chr12:123768916	T/G	cg13010344	chr12:123464640	ARL6IP4	0.55	6.75	0.35	6.75e-11	Neutrophil percentage of white cells;
LUSC	cis	rs79387448	0.808	rs77518775	chr2:103237642	T/C	cg09003973	chr2:102972529	NA	0.69	6.86	0.35	3.37e-11	Gut microbiota (bacterial taxa);
LUSC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.97	0.48	1.19e-20	Bipolar disorder;
LUSC	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.9	-10.62	-0.5	6.96e-23	Lung cancer in ever smokers;
LUSC	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg18681998	chr4:17616180	MED28	-0.86	-15.42	-0.64	6.85e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.07	16.54	0.67	2.67e-45	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg24375607	chr4:120327624	NA	0.72	11.39	0.53	1.28e-25	Corneal astigmatism;
LUSC	cis	rs9309473	1.000	rs6711033	chr2:73746643	T/C	cg20560298	chr2:73613845	ALMS1	-0.42	-6.04	-0.31	4.18e-9	Metabolite levels;
LUSC	cis	rs62400317	0.826	rs4400216	chr6:45237955	T/G	cg20913747	chr6:44695427	NA	-0.47	-7.65	-0.39	2.2e-13	Total body bone mineral density;
LUSC	cis	rs2279817	0.820	rs924686	chr1:18027726	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.43	6.02	0.31	4.54e-9	Neuroticism;
LUSC	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	7.64	0.39	2.32e-13	Height;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14959291	chr3:96532006	EPHA6	-0.43	-6.84	-0.35	3.78e-11	Triglycerides;
LUSC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg26897989	chr16:1907736	C16orf73	-0.42	-6.63	-0.34	1.37e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.89	15.83	0.65	1.63e-42	Metabolic syndrome;
LUSC	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg08484992	chr16:88977278	CBFA2T3	0.35	6.13	0.32	2.46e-9	Social autistic-like traits;
LUSC	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.63	-0.47	1.54e-19	Coronary artery disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03191565	chr19:47987374	KPTN	-0.43	-6.22	-0.32	1.5e-9	Electrocardiographic conduction measures;
LUSC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg06636001	chr8:8085503	FLJ10661	0.51	7.9	0.4	4.11e-14	Joint mobility (Beighton score);
LUSC	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs6546886	0.957	rs4853005	chr2:74258049	G/C	cg14702570	chr2:74259524	NA	-0.31	-5.91	-0.31	8.36e-9	Dialysis-related mortality;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09151521	chr3:137834591	DZIP1L	0.4	6.04	0.31	4.22e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	11.93	0.55	1.4e-27	Exhaled nitric oxide output;
LUSC	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg14346243	chr4:90757452	SNCA	-0.42	-6.06	-0.31	3.59e-9	Neuroticism;
LUSC	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg11502198	chr6:26597334	ABT1	0.6	9.37	0.46	1.12e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs11997175	1.000	rs10453046	chr8:33773179	T/C	ch.8.33884649F	chr8:33765107	NA	0.53	8.5	0.42	6.26e-16	Body mass index;
LUSC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06850241	chr22:41845214	NA	0.33	6.0	0.31	5.1e-9	Vitiligo;
LUSC	cis	rs1256061	0.603	rs1256038	chr14:64740739	T/C	cg23250157	chr14:64679961	SYNE2	0.32	5.7	0.3	2.68e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs7527798	0.592	rs12025522	chr1:207854355	A/C	cg09232269	chr1:207846808	CR1L	0.28	6.08	0.32	3.33e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.46	6.83	0.35	4.02e-11	Schizophrenia;
LUSC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg20135002	chr11:47629003	NA	-0.52	-8.0	-0.4	2.05e-14	Subjective well-being;
LUSC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12826209	chr6:26865740	GUSBL1	0.76	9.18	0.45	4.6e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12667521	chr19:29218732	NA	0.62	9.4	0.46	8.75e-19	Methadone dose in opioid dependence;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09964670	chr19:5720572	TMEM146;LONP1	-0.44	-6.04	-0.31	4.22e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg02780029	chr10:43622663	RET	-0.35	-6.68	-0.34	9.99e-11	Hirschsprung disease;
LUSC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-7.02	-0.36	1.22e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg09904177	chr6:26538194	HMGN4	-0.73	-13.7	-0.6	3.28e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs9840812	0.861	rs1153871	chr3:135954599	T/C	cg15507776	chr3:136538369	TMEM22	0.42	5.93	0.31	7.63e-9	Fibrinogen levels;
LUSC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.42	-0.33	4.7e-10	Personality dimensions;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07449447	chr14:55228808	SAMD4A	-0.38	-6.86	-0.35	3.31e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs258324	0.790	rs258318	chr16:89732050	T/C	cg04287289	chr16:89883240	FANCA	-0.68	-6.1	-0.32	2.91e-9	Height;
LUSC	cis	rs17604090	1.000	rs10272065	chr7:29694236	A/T	cg19413766	chr7:29689036	LOC646762	-0.62	-7.44	-0.38	8.54e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg02018176	chr4:1364513	KIAA1530	0.45	6.4	0.33	5.18e-10	Recombination rate (females);
LUSC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg14558114	chr2:88469736	THNSL2	0.78	7.07	0.36	9.21e-12	Plasma clusterin levels;
LUSC	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg24375607	chr4:120327624	NA	0.72	11.4	0.53	1.23e-25	Corneal astigmatism;
LUSC	cis	rs4285028	0.948	rs2877560	chr3:121699238	C/A	cg11130432	chr3:121712080	ILDR1	-0.65	-9.82	-0.47	3.69e-20	Multiple sclerosis;
LUSC	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg08213375	chr14:104286397	PPP1R13B	0.38	6.14	0.32	2.35e-9	Reticulocyte count;
LUSC	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg16482183	chr6:26056742	HIST1H1C	0.63	9.05	0.44	1.24e-17	Iron status biomarkers;
LUSC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.03	0.55	6.29e-28	Motion sickness;
LUSC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg17264618	chr3:40429014	ENTPD3	0.29	6.27	0.32	1.14e-9	Renal cell carcinoma;
LUSC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.16	0.36	5.3e-12	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9815354	0.680	rs57525756	chr3:41843591	A/C	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg24375607	chr4:120327624	NA	-0.45	-6.96	-0.36	1.86e-11	Diastolic blood pressure;
LUSC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs4919087	0.926	rs7072078	chr10:99026509	G/A	cg25902810	chr10:99078978	FRAT1	0.44	6.3	0.33	9.18e-10	Monocyte count;
LUSC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg05802129	chr4:122689817	NA	-0.37	-6.54	-0.34	2.29e-10	Type 2 diabetes;
LUSC	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg12927641	chr6:109611667	NA	-0.41	-7.22	-0.37	3.52e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.93	0.48	1.54e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10045504	0.502	rs72746032	chr5:38743982	T/C	cg15396434	chr5:38725168	NA	-0.51	-5.73	-0.3	2.29e-8	Night sleep phenotypes;
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22338127	chr1:209979572	IRF6	0.63	11.26	0.52	3.75e-25	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06112835	chr11:68658793	MRPL21	0.52	8.08	0.4	1.21e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.92	0.4	3.59e-14	Colorectal cancer;
LUSC	cis	rs1595825	0.786	rs74484541	chr2:198894223	T/C	cg10547527	chr2:198650123	BOLL	-0.52	-6.25	-0.32	1.23e-9	Ulcerative colitis;
LUSC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	trans	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	6.49	0.33	3.12e-10	Neuroticism;
LUSC	trans	rs11671005	0.504	rs3794964	chr19:59070916	T/C	cg22037779	chr5:139682734	PFDN1	-0.57	-7.4	-0.38	1.15e-12	Mean platelet volume;
LUSC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg09021430	chr5:549028	NA	0.39	7.11	0.36	7.29e-12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05535760	chr7:792225	HEATR2	0.81	9.48	0.46	4.93e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg18681998	chr4:17616180	MED28	0.84	15.62	0.65	1.13e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg05925327	chr15:68127851	NA	-0.38	-5.99	-0.31	5.48e-9	Restless legs syndrome;
LUSC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg07395648	chr5:131743802	NA	-0.39	-5.86	-0.31	1.11e-8	Breast cancer;
LUSC	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg09904177	chr6:26538194	HMGN4	-0.64	-6.29	-0.33	9.82e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-9.32	-0.45	1.6e-18	Coffee consumption (cups per day);
LUSC	cis	rs1595825	1.000	rs61605589	chr2:198876532	T/C	cg00982548	chr2:198649783	BOLL	-0.51	-6.31	-0.33	8.95e-10	Ulcerative colitis;
LUSC	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg26597838	chr10:835615	NA	0.57	7.41	0.38	1.02e-12	Eosinophil percentage of granulocytes;
LUSC	trans	rs17685	0.515	rs111240556	chr7:75600863	T/C	cg19862616	chr7:65841803	NCRNA00174	0.46	6.14	0.32	2.35e-9	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1524927	1.000	rs1524927	chr7:96371732	C/T	cg03808172	chr7:96339361	SHFM1	-0.41	-6.41	-0.33	5.01e-10	Total body bone mineral density;
LUSC	trans	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.54	0.53	3.8e-26	Mean corpuscular volume;
LUSC	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg04218760	chr10:45406644	TMEM72	-0.28	-6.76	-0.35	6.15e-11	Mean corpuscular volume;
LUSC	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.47	-7.02	-0.36	1.26e-11	Height;
LUSC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg03806693	chr22:41940476	POLR3H	1.0	14.26	0.62	2.35e-36	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg13628971	chr7:2884303	GNA12	0.5	6.92	0.35	2.25e-11	Height;
LUSC	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg21775007	chr8:11205619	TDH	0.78	12.47	0.56	1.4e-29	Retinal vascular caliber;
LUSC	cis	rs6960043	0.936	rs62448618	chr7:15052211	T/A	cg19272540	chr7:15055459	NA	-0.29	-6.94	-0.35	2.05e-11	Type 2 diabetes;
LUSC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg07741184	chr6:167504864	NA	0.39	7.01	0.36	1.29e-11	Crohn's disease;
LUSC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.48	-6.61	-0.34	1.56e-10	Renal function-related traits (BUN);
LUSC	cis	rs10740039	0.810	rs7098097	chr10:62364991	G/A	cg18175470	chr10:62150864	ANK3	-0.47	-7.08	-0.36	8.72e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs72634258	0.786	rs9434993	chr1:8179744	G/C	cg00042356	chr1:8021962	PARK7	0.54	6.55	0.34	2.23e-10	Inflammatory bowel disease;
LUSC	cis	rs11039100	0.607	rs11038939	chr11:5777395	G/A	cg05234568	chr11:5960015	NA	-0.42	-5.68	-0.3	2.97e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg08085267	chr17:45401833	C17orf57	0.6	9.83	0.47	3.5e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs35771425	0.600	rs6667063	chr1:211660746	G/A	cg10512769	chr1:211675356	NA	-0.27	-6.19	-0.32	1.76e-9	Educational attainment (years of education);
LUSC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg00945038	chr17:61921165	SMARCD2	0.4	6.03	0.31	4.3e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg08975724	chr8:8085496	FLJ10661	0.46	6.65	0.34	1.22e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-0.95	-18.42	-0.71	8.69e-53	Headache;
LUSC	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg12384639	chr17:618140	VPS53	0.36	5.65	0.3	3.51e-8	Prostate cancer;
LUSC	cis	rs7927771	0.524	rs7114813	chr11:47801101	A/G	cg20307385	chr11:47447363	PSMC3	0.44	6.43	0.33	4.36e-10	Subjective well-being;
LUSC	cis	rs9811920	0.809	rs793476	chr3:99541747	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-6.01	-0.31	4.84e-9	Axial length;
LUSC	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-0.53	-8.18	-0.41	6.04e-15	Breast cancer;
LUSC	cis	rs6494488	0.500	rs72742957	chr15:64905227	A/C	cg08069370	chr15:64387884	SNX1	-0.65	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	cis	rs73198271	0.681	rs11987924	chr8:8649972	T/C	cg01851573	chr8:8652454	MFHAS1	0.53	8.49	0.42	7.11e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg24375607	chr4:120327624	NA	0.75	10.86	0.51	9.79e-24	Corneal astigmatism;
LUSC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	9.69	0.47	9.58e-20	Cognitive test performance;
LUSC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg23711669	chr6:146136114	FBXO30	-0.92	-17.44	-0.69	7.11e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1775715	0.737	rs2808028	chr10:32101189	G/A	cg04359828	chr10:32216031	ARHGAP12	0.39	6.75	0.35	6.68e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs13390641	0.614	rs67403844	chr2:104079582	G/A	cg03260781	chr1:16346299	HSPB7	-0.46	-6.09	-0.32	3.14e-9	Blood pressure;Blood pressure (anthropometric measures interaction);
LUSC	cis	rs3733418	0.929	rs13120990	chr4:165905118	A/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-5.93	-0.31	7.54e-9	Obesity-related traits;
LUSC	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.67	0.5	4.65e-23	Lung cancer in ever smokers;
LUSC	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg08888203	chr3:10149979	C3orf24	0.59	8.21	0.41	5.04e-15	Alzheimer's disease;
LUSC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08704250	chr15:31115839	NA	0.46	7.01	0.36	1.32e-11	Huntington's disease progression;
LUSC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg19774624	chr17:42201019	HDAC5	-0.77	-11.73	-0.54	7.6e-27	Total body bone mineral density;
LUSC	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.68	10.65	0.5	5.51e-23	Total cholesterol levels;
LUSC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.52	8.08	0.4	1.22e-14	Schizophrenia;
LUSC	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.59	-9.46	-0.46	5.85e-19	Body mass index;
LUSC	cis	rs12200782	1.000	rs3800304	chr6:26598798	G/A	cg11502198	chr6:26597334	ABT1	-0.76	-5.8	-0.3	1.51e-8	Small cell lung carcinoma;
LUSC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12311346	chr5:56204834	C5orf35	-0.83	-12.91	-0.58	3.15e-31	Initial pursuit acceleration;
LUSC	cis	rs73206853	0.841	rs73191834	chr12:110963841	T/G	cg12870014	chr12:110450643	ANKRD13A	0.67	6.47	0.33	3.57e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg21051086	chr3:73046214	PPP4R2	-0.47	-7.21	-0.37	3.82e-12	Pancreatic cancer;
LUSC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg23719950	chr11:63933701	MACROD1	-0.6	-7.86	-0.4	5.33e-14	Mean platelet volume;
LUSC	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg07150166	chr2:30669952	LCLAT1	0.55	6.53	0.34	2.44e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg11861562	chr11:117069780	TAGLN	0.45	8.08	0.4	1.2e-14	Blood protein levels;
LUSC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11764359	chr7:65958608	NA	0.78	13.01	0.58	1.41e-31	Aortic root size;
LUSC	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-10.18	-0.49	2.21e-21	Migraine;Coronary artery disease;
LUSC	cis	rs7804356	1.000	rs13438513	chr7:26860633	C/G	cg03456212	chr7:26904342	SKAP2	0.55	6.37	0.33	6.39e-10	Type 1 diabetes;
LUSC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.8	12.63	0.57	3.53e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg02966332	chr20:62369605	LIME1	0.38	5.99	0.31	5.42e-9	Prostate cancer;
LUSC	trans	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg25214090	chr10:38739885	LOC399744	0.43	6.58	0.34	1.77e-10	Corneal astigmatism;
LUSC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg17366294	chr4:99064904	C4orf37	0.55	9.67	0.47	1.18e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg01652190	chr22:50026171	C22orf34	-0.31	-6.39	-0.33	5.51e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg22029157	chr1:209979665	IRF6	0.73	8.59	0.43	3.46e-16	Coronary artery disease;
LUSC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg21951975	chr1:209979733	IRF6	0.61	7.89	0.4	4.43e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.5	8.77	0.43	8.96e-17	Bone mineral density;
LUSC	cis	rs6138458	0.828	rs6132785	chr20:24993414	T/C	cg06937882	chr20:24974362	C20orf3	-0.33	-5.95	-0.31	6.75e-9	Blood protein levels;
LUSC	cis	rs10779751	0.770	rs6674994	chr1:11239515	T/C	cg08854313	chr1:11322531	MTOR	0.87	13.93	0.61	4.14e-35	Body mass index;
LUSC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg16339924	chr4:17578868	LAP3	0.55	8.23	0.41	4.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7011049	1.000	rs10958336	chr8:53841318	G/A	cg26025543	chr8:53854495	NA	0.53	6.4	0.33	5.18e-10	Systolic blood pressure;
LUSC	cis	rs9311676	0.609	rs11719450	chr3:58456811	A/G	cg13750441	chr3:58318267	PXK	-0.35	-6.64	-0.34	1.25e-10	Systemic lupus erythematosus;
LUSC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs10186029	0.582	rs1441165	chr2:214009831	A/G	cg08319019	chr2:214017104	IKZF2	0.49	6.7	0.34	9.06e-11	Systemic sclerosis;
LUSC	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg24631222	chr15:78858424	CHRNA5	-0.69	-9.76	-0.47	5.78e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg15145296	chr3:125709740	NA	-0.55	-6.57	-0.34	1.89e-10	Blood pressure (smoking interaction);
LUSC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg10729496	chr3:10149963	C3orf24	0.55	7.21	0.37	3.79e-12	Alzheimer's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03646922	chr17:4167316	ANKFY1	0.4	6.28	0.32	1.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg13010199	chr12:38710504	ALG10B	-0.44	-6.67	-0.34	1.06e-10	Morning vs. evening chronotype;
LUSC	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.67	-8.36	-0.42	1.68e-15	Post bronchodilator FEV1;
LUSC	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg09998033	chr7:158218633	PTPRN2	-0.61	-9.8	-0.47	4.15e-20	Obesity-related traits;
LUSC	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg04362960	chr10:104952993	NT5C2	0.6	9.58	0.46	2.38e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg18758796	chr5:131593413	PDLIM4	0.42	6.79	0.35	5.01e-11	Acylcarnitine levels;
LUSC	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg00898013	chr13:113819073	PROZ	-0.54	-7.93	-0.4	3.32e-14	Platelet distribution width;
LUSC	cis	rs6960043	0.714	rs4719430	chr7:15047280	C/G	cg19272540	chr7:15055459	NA	-0.34	-8.76	-0.43	9.64e-17	Type 2 diabetes;
LUSC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06481639	chr22:41940642	POLR3H	-0.53	-5.96	-0.31	6.38e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-0.86	-15.33	-0.64	1.51e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg10756647	chr7:56101905	PSPH	0.89	8.94	0.44	2.61e-17	Diabetic kidney disease;
LUSC	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg11117266	chr17:43971461	MAPT;LOC100128977	-0.39	-5.8	-0.3	1.58e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs3771570	0.901	rs869943	chr2:242431585	C/G	cg21155796	chr2:242212141	HDLBP	0.61	6.84	0.35	3.83e-11	Prostate cancer;
LUSC	cis	rs977987	0.806	rs11642572	chr16:75452782	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.37e-11	Dupuytren's disease;
LUSC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg20406979	chr6:167373233	NA	0.25	5.81	0.3	1.49e-8	Crohn's disease;
LUSC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.54	-0.46	3.1400000000000002e-19	Bipolar disorder and schizophrenia;
LUSC	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg18876405	chr7:65276391	NA	-0.68	-11.68	-0.54	1.18e-26	Aortic root size;
LUSC	cis	rs12900413	0.603	rs2351494	chr15:90299541	C/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.9	-0.31	8.76e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs9311676	0.594	rs55954186	chr3:58436476	G/A	cg26110898	chr3:58419937	PDHB	0.41	6.68	0.34	1.01e-10	Systemic lupus erythematosus;
LUSC	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	1.41	17.72	0.7	5.44e-50	Atopic dermatitis;
LUSC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg05585544	chr11:47624801	NA	-0.41	-7.24	-0.37	3.01e-12	Subjective well-being;
LUSC	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg05855489	chr10:104503620	C10orf26	0.52	7.93	0.4	3.25e-14	Arsenic metabolism;
LUSC	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg13010199	chr12:38710504	ALG10B	0.68	10.71	0.51	3.28e-23	Bladder cancer;
LUSC	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg19920283	chr7:105172520	RINT1	0.58	6.22	0.32	1.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg21545522	chr1:205238299	TMCC2	0.49	9.28	0.45	2.13e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6867913	0.561	rs9324864	chr5:141469000	A/G	cg08523384	chr5:141488047	NDFIP1	0.43	6.97	0.36	1.74e-11	Asthma;
LUSC	cis	rs3750965	0.959	rs3376	chr11:68856680	G/A	cg06818126	chr11:68850279	TPCN2	-0.44	-6.42	-0.33	4.7e-10	Hair color;
LUSC	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.36e-13	Type 2 diabetes;
LUSC	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg12382846	chr20:60892121	LAMA5	0.32	6.22	0.32	1.47e-9	Pelvic organ prolapse;
LUSC	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	0.89	16.7	0.67	5.82e-46	Heart rate;
LUSC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.65	0.39	2.18e-13	Prudent dietary pattern;
LUSC	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg12698349	chr2:225449008	CUL3	0.84	13.79	0.6	1.5e-34	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg01879757	chr17:41196368	BRCA1	-0.5	-7.85	-0.39	5.88e-14	Menopause (age at onset);
LUSC	cis	rs56804039	1.000	rs6986470	chr8:8381430	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.29	-0.33	1.02e-9	Cervical cancer;
LUSC	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg22705602	chr4:152727874	NA	-0.3	-6.11	-0.32	2.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg02269571	chr22:50332266	NA	-0.59	-9.11	-0.45	7.8e-18	Schizophrenia;
LUSC	cis	rs11608355	0.846	rs60945232	chr12:109854401	A/G	cg05360138	chr12:110035743	NA	0.61	8.19	0.41	5.79e-15	Neuroticism;
LUSC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg00990874	chr7:1149470	C7orf50	-0.61	-8.03	-0.4	1.66e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg21100191	chr22:23484243	RTDR1	-0.66	-9.75	-0.47	6.1e-20	Bone mineral density;
LUSC	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.7	0.75	7.91e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7766436	0.885	rs1418311	chr6:22594964	T/G	cg13666174	chr6:22585274	NA	-0.41	-5.66	-0.3	3.18e-8	Coronary artery disease;
LUSC	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg11608241	chr8:8085544	FLJ10661	0.44	6.2	0.32	1.64e-9	Neuroticism;
LUSC	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg12940439	chr1:67600707	NA	0.36	6.11	0.32	2.76e-9	Psoriasis;
LUSC	cis	rs9815354	0.904	rs73081347	chr3:41903582	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.67	0.43	1.88e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4771122	0.728	rs1475221	chr13:28037566	C/T	cg22138327	chr13:27999177	GTF3A	-0.67	-8.77	-0.43	9.11e-17	Body mass index;
LUSC	cis	rs2019216	0.521	rs9807074	chr17:21930856	T/C	cg22648282	chr17:21454238	C17orf51	-0.53	-8.01	-0.4	1.96e-14	Pelvic organ prolapse;
LUSC	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg03342759	chr3:160939853	NMD3	-0.41	-5.98	-0.31	5.71e-9	Morning vs. evening chronotype;
LUSC	cis	rs1595825	0.838	rs58576043	chr2:198524149	C/T	cg19156104	chr2:198669113	PLCL1	-0.45	-5.69	-0.3	2.74e-8	Ulcerative colitis;
LUSC	cis	rs4478037	0.822	rs4320035	chr3:33113697	C/G	cg19404215	chr3:33155277	CRTAP	-0.93	-9.54	-0.46	2.99e-19	Major depressive disorder;
LUSC	cis	rs2075165	0.901	rs1804999	chr1:156219450	A/G	cg20302342	chr1:156215951	PAQR6	0.32	6.18	0.32	1.85e-9	Tonsillectomy;
LUSC	trans	rs61931739	0.635	rs10743837	chr12:33982162	A/G	cg13010199	chr12:38710504	ALG10B	0.4	5.97	0.31	5.96e-9	Morning vs. evening chronotype;
LUSC	cis	rs155346	1.000	rs265153	chr5:139380832	C/A	cg01090482	chr5:139365336	NRG2	-0.4	-6.62	-0.34	1.43e-10	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg18825076	chr15:78729989	IREB2	-0.51	-8.06	-0.4	1.4e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs7577851	0.595	rs67662551	chr2:69650445	T/A	cg10773587	chr2:69614142	GFPT1	0.52	5.77	0.3	1.84e-8	Parkinson's disease (age of onset);
LUSC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	cis	rs6845621	0.727	rs12331530	chr4:18905938	T/C	cg12196642	chr4:18937545	NA	-0.33	-6.18	-0.32	1.85e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs17401966	0.540	rs11121566	chr1:10472848	C/G	cg19773385	chr1:10388646	KIF1B	-0.42	-7.28	-0.37	2.4e-12	Hepatocellular carcinoma;
LUSC	cis	rs721399	0.553	rs13282367	chr8:18244986	T/G	cg18736775	chr8:18248649	NAT2	-0.56	-6.57	-0.34	1.99e-10	Blood metabolite levels;
LUSC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg13770153	chr20:60521292	NA	-0.59	-8.16	-0.41	6.74e-15	Body mass index;
LUSC	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg17410650	chr12:54324560	NA	-0.58	-9.94	-0.48	1.51e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs11039100	1.000	rs1470873	chr11:5827395	A/C	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg21918786	chr6:109611834	NA	-0.36	-6.05	-0.31	3.89e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs9311676	0.656	rs6800514	chr3:58358717	C/T	cg26110898	chr3:58419937	PDHB	0.45	7.2	0.37	4.08e-12	Systemic lupus erythematosus;
LUSC	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.37	6.17	0.32	2.03e-9	Neutrophil percentage of white cells;
LUSC	cis	rs295137	0.798	rs1900706	chr2:201214071	A/C	cg23649088	chr2:200775458	C2orf69	0.38	5.79	0.3	1.63e-8	Asthma (bronchodilator response);
LUSC	cis	rs11229555	0.645	rs7926682	chr11:58189495	A/G	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6076065	0.723	rs16985308	chr20:23359780	A/T	cg11657817	chr20:23433608	CST11	0.42	7.99	0.4	2.19e-14	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs12043259	1.000	rs6688709	chr1:204830071	C/T	cg23865240	chr7:27134109	HOXA1	0.5	6.09	0.32	3.07e-9	Addiction;
LUSC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.04	-0.36	1.07e-11	Bipolar disorder;
LUSC	cis	rs7189233	0.955	rs72801853	chr16:53516824	A/G	cg04059762	chr16:53544020	NA	-0.32	-5.64	-0.3	3.57e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg10664184	chr19:17420304	DDA1	0.46	5.7	0.3	2.6e-8	Systemic lupus erythematosus;
LUSC	cis	rs11971779	0.616	rs6949963	chr7:139054325	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1535500	0.905	rs2146262	chr6:39283793	C/T	cg03252829	chr6:39282164	KCNK17	-0.33	-5.84	-0.3	1.21e-8	Type 2 diabetes;
LUSC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.85	0.3	1.2e-8	Tonsillectomy;
LUSC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg04756594	chr16:24857601	SLC5A11	-0.49	-7.21	-0.37	3.79e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs354225	0.554	rs10166844	chr2:54798272	T/C	cg01766943	chr2:54829624	SPTBN1	0.49	7.82	0.39	7.15e-14	Schizophrenia;
LUSC	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg20016023	chr10:99160130	RRP12	-0.31	-7.75	-0.39	1.12e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.86	0.39	5.5e-14	Bipolar disorder;
LUSC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	7.14	0.36	5.77e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs259282	0.813	rs259250	chr19:33149216	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.71	10.54	0.5	1.35e-22	Schizophrenia;
LUSC	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg18512352	chr11:47633146	NA	0.28	5.85	0.3	1.16e-8	Subjective well-being;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04856841	chr1:156308275	CCT3;C1orf182	-0.4	-6.01	-0.31	4.73e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-6.04	-0.31	4.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg02972257	chr16:68554789	NA	-0.49	-6.35	-0.33	7.09e-10	Ulcerative colitis;
LUSC	cis	rs2273669	0.667	rs76430494	chr6:109350128	C/A	cg05315195	chr6:109294784	ARMC2	-0.52	-5.64	-0.3	3.53e-8	Prostate cancer;
LUSC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18099408	chr3:52552593	STAB1	-0.43	-7.53	-0.38	4.71e-13	Electroencephalogram traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00230899	chr16:89766723	SPATA2L	-0.42	-6.2	-0.32	1.64e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.73	-10.41	-0.5	3.53e-22	Gut microbiome composition (summer);
LUSC	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.75	12.7	0.57	2.03e-30	Retinal vascular caliber;
LUSC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg04727924	chr7:799746	HEATR2	-0.55	-6.57	-0.34	1.98e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.5	-8.53	-0.42	5.22e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6674970	0.966	rs10788800	chr1:151104950	G/A	cg03258749	chr1:151040405	MLLT11	-0.43	-6.55	-0.34	2.18e-10	Childhood ear infection;
LUSC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-12.2	-0.56	1.43e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	trans	rs2392780	0.536	rs622556	chr8:128333197	C/T	cg10897648	chr18:56338258	MALT1	0.41	6.31	0.33	8.66e-10	Breast cancer (early onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16636271	chr6:139694487	CITED2	-0.56	-6.57	-0.34	1.98e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10186029	0.680	rs1530238	chr2:213957928	G/C	cg08319019	chr2:214017104	IKZF2	0.55	7.98	0.4	2.43e-14	Systemic sclerosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07224438	chr2:97426485	CNNM4	0.49	6.73	0.35	7.29e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg11941060	chr3:133502564	NA	-0.47	-6.79	-0.35	5.27e-11	Iron status biomarkers;
LUSC	cis	rs6969780	1.000	rs6973182	chr7:27172321	C/T	cg26364809	chr7:27145159	NA	-0.58	-5.97	-0.31	5.98e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg00012203	chr2:219082015	ARPC2	-0.76	-13.09	-0.58	6.86e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.54	-0.38	4.37e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg06636551	chr8:101224915	SPAG1	0.46	8.47	0.42	7.81e-16	Atrioventricular conduction;
LUSC	cis	rs2354432	0.607	rs59606861	chr1:146761478	G/A	cg25205988	chr1:146714368	CHD1L	-0.99	-9.14	-0.45	6.32e-18	Mitochondrial DNA levels;
LUSC	cis	rs12900413	0.603	rs7177841	chr15:90302117	C/A	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.56e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.11	-0.48	3.92e-21	Monocyte count;
LUSC	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg23950597	chr19:37808831	NA	-0.64	-7.61	-0.38	2.77e-13	Coronary artery calcification;
LUSC	cis	rs9653442	0.545	rs4490209	chr2:100766711	C/G	cg07810366	chr2:100720526	AFF3	-0.44	-7.54	-0.38	4.45e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4654899	0.758	rs7521711	chr1:21400218	A/G	cg01072550	chr1:21505969	NA	-0.51	-7.77	-0.39	9.76e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg19622623	chr12:86230825	RASSF9	-0.44	-6.21	-0.32	1.62e-9	Major depressive disorder;
LUSC	cis	rs983392	0.679	rs611418	chr11:60011013	C/T	cg24026212	chr11:59952134	MS4A6A	0.36	6.21	0.32	1.55e-9	Alzheimer's disease (late onset);
LUSC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg19318889	chr4:1322082	MAEA	-0.43	-7.25	-0.37	2.96e-12	Obesity-related traits;
LUSC	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-7.02	-0.36	1.24e-11	Subjective well-being;
LUSC	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg22676075	chr6:135203613	NA	-0.64	-9.85	-0.47	2.84e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.84	13.87	0.6	7.24e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs5985	0.583	rs7758057	chr6:6307578	C/G	cg22185065	chr6:6318785	F13A1	-0.32	-6.53	-0.34	2.41e-10	End-stage coagulation;
LUSC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg23172400	chr8:95962367	TP53INP1	-0.43	-8.96	-0.44	2.27e-17	Type 2 diabetes;
LUSC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg09655341	chr17:79618100	PDE6G	-0.27	-6.28	-0.33	1.03e-9	Eye color traits;
LUSC	cis	rs6076065	0.723	rs2252824	chr20:23354748	C/T	cg11657817	chr20:23433608	CST11	0.41	7.33	0.37	1.73e-12	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.72	7.61	0.38	2.9e-13	Initial pursuit acceleration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23365699	chr2:197504454	CCDC150	0.44	6.17	0.32	1.97e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-6.14	-0.32	2.29e-9	Height;
LUSC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	18.1	0.7	1.66e-51	Chronic sinus infection;
LUSC	cis	rs1506636	0.708	rs7788702	chr7:123237421	C/T	cg03229431	chr7:123269106	ASB15	0.62	9.38	0.46	1.02e-18	Plateletcrit;Platelet count;
LUSC	cis	rs7178572	1.000	rs952471	chr15:77776498	C/G	cg22256960	chr15:77711686	NA	-0.55	-9.2	-0.45	4.07e-18	Type 2 diabetes;
LUSC	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg27411982	chr8:10470053	RP1L1	0.39	6.03	0.31	4.29e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7759001	0.857	rs6923108	chr6:27362109	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.3e-11	Uric acid levels;
LUSC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11645453	chr3:52864694	ITIH4	0.31	7.19	0.37	4.16e-12	Bipolar disorder;
LUSC	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg20487152	chr13:99095054	FARP1	-0.43	-7.2	-0.37	4.05e-12	Longevity;
LUSC	cis	rs7572644	0.766	rs4578809	chr2:28082494	G/A	cg27432699	chr2:27873401	GPN1	0.51	6.47	0.33	3.46e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg26597838	chr10:835615	NA	0.64	8.08	0.4	1.21e-14	Eosinophil percentage of granulocytes;
LUSC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.3	-0.41	2.54e-15	Platelet count;
LUSC	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.04	-0.31	4.1e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs17385675	1.000	rs16838482	chr2:202814422	C/G	cg01096478	chr12:50898751	DIP2B	-0.76	-6.02	-0.31	4.5e-9	Response to antipsychotic treatment;
LUSC	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg14186256	chr22:23484241	RTDR1	0.95	17.83	0.7	1.95e-50	Bone mineral density;
LUSC	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06544989	chr22:39130855	UNC84B	0.33	5.81	0.3	1.49e-8	Menopause (age at onset);
LUSC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-0.87	-12.65	-0.57	3.07e-30	Vitiligo;
LUSC	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg22705602	chr4:152727874	NA	-0.32	-6.54	-0.34	2.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg11584989	chr19:19387371	SF4	0.6	7.08	0.36	8.81e-12	Bipolar disorder;
LUSC	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg04362960	chr10:104952993	NT5C2	0.91	11.51	0.53	4.9e-26	Arsenic metabolism;
LUSC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.34	-6.73	-0.35	7.36e-11	Total body bone mineral density;
LUSC	cis	rs500891	0.525	rs2324416	chr6:84074210	A/G	cg08257003	chr6:84140564	ME1	0.35	8.63	0.43	2.58e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs9303280	0.870	rs1011082	chr17:38068514	T/C	cg19468946	chr17:37922297	IKZF3	0.39	6.24	0.32	1.3e-9	Self-reported allergy;
LUSC	cis	rs6960043	0.818	rs10258074	chr7:15064216	A/T	cg19272540	chr7:15055459	NA	-0.32	-7.79	-0.39	8.77e-14	Type 2 diabetes;
LUSC	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg18002602	chr11:66138449	SLC29A2	0.46	8.27	0.41	3.17e-15	Educational attainment (years of education);
LUSC	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg10909506	chr17:38081995	ORMDL3	0.34	6.07	0.32	3.55e-9	Self-reported allergy;
LUSC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	0.92	15.52	0.65	2.79e-41	Menopause (age at onset);
LUSC	cis	rs6901250	0.632	rs1853080	chr6:117196157	T/C	cg12892004	chr6:117198278	RFX6	-0.4	-7.76	-0.39	1.05e-13	C-reactive protein levels;
LUSC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg06740227	chr12:86229804	RASSF9	-0.36	-5.7	-0.3	2.61e-8	Major depressive disorder;
LUSC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg16060761	chr17:80687452	NA	-0.52	-8.23	-0.41	4.16e-15	Glycated hemoglobin levels;
LUSC	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.76	-12.25	-0.56	9.47e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9473147	0.543	rs1004173	chr6:47445017	C/T	cg02130027	chr6:47444894	CD2AP	0.35	5.66	0.3	3.33e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg17168535	chr8:21777572	XPO7	0.65	9.67	0.47	1.16e-19	Mean corpuscular volume;
LUSC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.8	14.58	0.62	1.32e-37	Cognitive function;
LUSC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.78	9.42	0.46	7.77e-19	Body mass index;
LUSC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg23711669	chr6:146136114	FBXO30	0.76	13.58	0.6	9.51e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg22815214	chr1:201083145	CACNA1S	0.58	10.25	0.49	1.25e-21	Permanent tooth development;
LUSC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg18225595	chr11:63971243	STIP1	0.53	9.03	0.44	1.38e-17	Platelet count;
LUSC	trans	rs1422110	0.513	rs1363264	chr5:85450380	G/C	cg01787110	chr1:109008453	NBPF6	0.43	8.01	0.4	1.98e-14	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs4629180	0.586	rs7583526	chr2:102124665	G/A	cg04415270	chr2:102091202	RFX8	-0.44	-7.51	-0.38	5.38e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg08477640	chr19:41863820	B9D2	0.48	7.24	0.37	3.2e-12	Migraine;Coronary artery disease;
LUSC	cis	rs12900413	0.687	rs13343250	chr15:90311410	T/C	cg24249390	chr15:90295951	MESP1	-0.37	-5.91	-0.31	8.6e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg18681998	chr4:17616180	MED28	0.85	15.67	0.65	6.85e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs62400317	0.859	rs72870950	chr6:45154779	A/G	cg18551225	chr6:44695536	NA	-0.42	-6.87	-0.35	3.24e-11	Total body bone mineral density;
LUSC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg16060761	chr17:80687452	NA	0.44	7.05	0.36	1.03e-11	Breast cancer;
LUSC	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.83	14.55	0.62	1.78e-37	Metabolic syndrome;
LUSC	cis	rs7851660	0.809	rs1561961	chr9:100667599	C/T	cg13688889	chr9:100608707	NA	-0.54	-8.47	-0.42	7.71e-16	Strep throat;
LUSC	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.72	-7.8	-0.39	8.18e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs12681287	0.547	rs7465511	chr8:87521481	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.27	-0.37	2.64e-12	Caudate activity during reward;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18737971	chr15:43941642	CATSPER2	0.43	6.48	0.33	3.31e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs243505	0.861	rs243525	chr7:148418140	G/A	cg09806900	chr7:148480153	CUL1	-0.47	-6.69	-0.34	9.69e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs28830936	0.966	rs62002090	chr15:42092326	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.96	-0.31	6.55e-9	Diastolic blood pressure;
LUSC	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.61	-0.43	2.92e-16	Rheumatoid arthritis;
LUSC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	1e-64	Prudent dietary pattern;
LUSC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.23	0.37	3.42e-12	Bipolar disorder;
LUSC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg27284194	chr4:1044797	NA	-0.35	-5.83	-0.3	1.29e-8	Longevity;
LUSC	trans	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg02030672	chr11:45687055	CHST1	0.44	7.05	0.36	1.03e-11	Obesity-related traits;
LUSC	cis	rs2455601	0.638	rs2742485	chr11:8986787	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-6.23	-0.32	1.44e-9	Schizophrenia;
LUSC	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	14.91	0.63	6.66e-39	Lymphocyte percentage of white cells;
LUSC	cis	rs61990749	0.597	rs176955	chr14:78181220	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	6.46	0.33	3.77e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs10484885	0.887	rs17764308	chr6:90602268	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.79	-8.48	-0.42	7.58e-16	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11764359	chr7:65958608	NA	0.81	13.62	0.6	6.4e-34	Aortic root size;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10130314	chr10:71993273	PPA1	-0.52	-6.32	-0.33	8.56e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs62400317	0.859	rs10948211	chr6:45156767	G/A	cg18551225	chr6:44695536	NA	-0.44	-7.18	-0.37	4.62e-12	Total body bone mineral density;
LUSC	cis	rs2625529	0.526	rs8031386	chr15:72508799	C/A	cg16672083	chr15:72433130	SENP8	-0.48	-7.55	-0.38	4.23e-13	Red blood cell count;
LUSC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg16479474	chr6:28041457	NA	0.34	5.89	0.31	9.45e-9	Parkinson's disease;
LUSC	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg03676636	chr4:99064102	C4orf37	0.36	7.77	0.39	9.65e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg09021430	chr5:549028	NA	0.43	7.59	0.38	3.16e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs17604090	0.818	rs28390296	chr7:29687091	C/T	cg19413766	chr7:29689036	LOC646762	-0.58	-6.93	-0.35	2.12e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13012494	chr21:47604986	C21orf56	-0.47	-7.05	-0.36	1.03e-11	Testicular germ cell tumor;
LUSC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.63	-11.27	-0.52	3.58e-25	Extrinsic epigenetic age acceleration;
LUSC	trans	rs28735056	0.508	rs67651675	chr18:77673562	A/G	cg05926928	chr17:57297772	GDPD1	-0.58	-8.47	-0.42	7.7e-16	Schizophrenia;
LUSC	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg13385521	chr17:29058706	SUZ12P	0.69	6.79	0.35	5.27e-11	Body mass index;
LUSC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg04871131	chr7:94954202	PON1	-0.38	-6.03	-0.31	4.43e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6960043	0.782	rs1558317	chr7:15065564	T/A	cg19272540	chr7:15055459	NA	-0.28	-6.84	-0.35	3.8e-11	Type 2 diabetes;
LUSC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.83	15.25	0.64	3.13e-40	Dental caries;
LUSC	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06002616	chr8:101225028	SPAG1	0.41	6.45	0.33	3.95e-10	Atrioventricular conduction;
LUSC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg09796270	chr17:17721594	SREBF1	-0.4	-6.98	-0.36	1.56e-11	Total body bone mineral density;
LUSC	cis	rs500891	0.525	rs2023241	chr6:84051460	G/A	cg08257003	chr6:84140564	ME1	0.33	7.98	0.4	2.44e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg10792982	chr14:105748885	BRF1	0.52	9.22	0.45	3.53e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg23093090	chr10:104574429	C10orf26	-0.46	-8.24	-0.41	3.87e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs2067615	0.579	rs3782709	chr12:107205753	A/G	cg15890332	chr12:107067104	RFX4	0.33	5.94	0.31	7.24e-9	Heart rate;
LUSC	cis	rs4629710	0.545	rs11755717	chr6:131547028	A/T	cg12606694	chr6:131520996	AKAP7	-0.51	-7.62	-0.38	2.68e-13	Multiple myeloma (IgH translocation);
LUSC	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	19.01	0.72	3.91e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs8141797	0.901	rs6004051	chr22:24462072	A/C	cg00411358	chr22:24577142	SUSD2	0.62	6.08	0.32	3.31e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg13010199	chr12:38710504	ALG10B	0.55	8.27	0.41	3.16e-15	Morning vs. evening chronotype;
LUSC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.66	10.5	0.5	1.73e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7209700	0.574	rs3851806	chr17:45350919	G/C	cg18085866	chr17:45331354	ITGB3	-0.54	-5.82	-0.3	1.36e-8	IgG glycosylation;
LUSC	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.97	0.36	1.69e-11	Menarche (age at onset);
LUSC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg12463550	chr7:65579703	CRCP	-0.56	-8.3	-0.41	2.67e-15	Aortic root size;
LUSC	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg12884169	chr21:40033163	ERG	0.61	12.36	0.56	3.74e-29	Coronary artery disease;
LUSC	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg21573476	chr21:45109991	RRP1B	-0.46	-7.26	-0.37	2.77e-12	Mean corpuscular volume;
LUSC	cis	rs6469656	0.892	rs7013617	chr8:117746231	G/A	cg24004040	chr8:117650383	NA	-0.43	-6.23	-0.32	1.4e-9	Colorectal cancer;
LUSC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg00933542	chr6:150070202	PCMT1	0.32	6.63	0.34	1.34e-10	Lung cancer;
LUSC	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18131467	chr2:239335373	ASB1	1.04	25.38	0.81	6.46e-80	Multiple system atrophy;
LUSC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg09165964	chr15:75287851	SCAMP5	0.51	7.5	0.38	5.66e-13	Breast cancer;
LUSC	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.79	-0.3	1.67e-8	Bipolar disorder;
LUSC	cis	rs977987	0.843	rs59465235	chr16:75483810	C/G	cg04384234	chr16:75411784	CFDP1	-0.44	-7.35	-0.37	1.49e-12	Dupuytren's disease;
LUSC	trans	rs1493916	0.748	rs1941684	chr18:31304421	C/G	cg27147174	chr7:100797783	AP1S1	-0.57	-9.07	-0.44	1.01e-17	Life satisfaction;
LUSC	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg00864171	chr11:67383662	NA	0.35	6.14	0.32	2.31e-9	Mean corpuscular volume;
LUSC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs6500395	0.962	rs9923371	chr16:48628015	C/T	cg04672837	chr16:48644449	N4BP1	0.49	7.31	0.37	1.95e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg01973587	chr1:228161476	NA	0.45	8.11	0.41	9.98e-15	Diastolic blood pressure;
LUSC	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg07157834	chr1:205819609	PM20D1	-0.44	-5.87	-0.31	1.03e-8	Menarche (age at onset);
LUSC	cis	rs2729354	0.903	rs2729371	chr11:57321322	A/G	cg24343310	chr11:57249947	NA	0.33	5.97	0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.19e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.12	-0.36	6.69e-12	Triglycerides;
LUSC	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	0.93	17.56	0.69	2.32e-49	Headache;
LUSC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.75	10.34	0.49	6.37e-22	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg18964960	chr10:1102726	WDR37	0.62	6.02	0.31	4.72e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.45	-6.75	-0.35	6.68e-11	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg02403541	chr12:121454288	C12orf43	-0.72	-11.01	-0.52	2.86e-24	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-9.57	-0.46	2.55e-19	Morning vs. evening chronotype;
LUSC	cis	rs71636778	0.543	rs12749822	chr1:27221963	T/C	cg12203394	chr1:27248618	NUDC	0.54	5.71	0.3	2.52e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg05340658	chr4:99064831	C4orf37	0.61	9.62	0.47	1.72e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-6.83	-0.35	4.03e-11	Coronary artery disease;
LUSC	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg08999081	chr20:33150536	PIGU	0.38	6.93	0.35	2.15e-11	Height;
LUSC	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg24375607	chr4:120327624	NA	0.71	10.61	0.5	7.32e-23	Corneal astigmatism;
LUSC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05165339	chr4:1420672	NA	-0.31	-6.96	-0.36	1.84e-11	Longevity;
LUSC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs13089785	0.965	rs67028142	chr3:123635213	A/G	cg02558132	chr3:123411198	MYLK	0.35	5.95	0.31	6.61e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg16346588	chr10:242978	ZMYND11	0.43	6.19	0.32	1.76e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg05082376	chr22:42548792	NA	0.44	6.6	0.34	1.57e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-1.07	-24.0	-0.8	1.07e-74	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.26	-0.32	1.16e-9	Joint mobility (Beighton score);
LUSC	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-7.96	-0.4	2.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11650494	0.710	rs11651666	chr17:47474571	C/T	cg08112188	chr17:47440006	ZNF652	1.07	8.88	0.44	4.3e-17	Prostate cancer;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg27582017	chr1:1057683	NA	0.38	6.19	0.32	1.73e-9	Asthma;
LUSC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.71	9.71	0.47	8.7e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg27147174	chr7:100797783	AP1S1	-0.65	-10.41	-0.49	3.75e-22	Life satisfaction;
LUSC	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg05855489	chr10:104503620	C10orf26	0.59	9.54	0.46	3.05e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg09033563	chr22:24373618	LOC391322	-0.69	-10.61	-0.5	7.48e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs2790216	0.526	rs1199093	chr10:59896794	C/G	cg05008406	chr3:118959563	B4GALT4	-0.38	-6.04	-0.31	4.05e-9	Inflammatory bowel disease;
LUSC	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.91	-0.35	2.51e-11	Mood instability;
LUSC	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg23625390	chr15:77176239	SCAPER	0.47	7.06	0.36	9.67e-12	Blood metabolite levels;
LUSC	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-16.64	-0.67	1.03e-45	Exhaled nitric oxide output;
LUSC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg00310523	chr12:86230176	RASSF9	0.52	9.86	0.47	2.61e-20	Major depressive disorder;
LUSC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06022373	chr22:39101656	GTPBP1	0.78	12.14	0.55	2.33e-28	Menopause (age at onset);
LUSC	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg26384229	chr12:38710491	ALG10B	0.55	9.03	0.44	1.41e-17	Morning vs. evening chronotype;
LUSC	cis	rs7914558	0.646	rs7909286	chr10:104658992	A/G	cg05855489	chr10:104503620	C10orf26	0.42	5.76	0.3	1.92e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.73	0.51	2.9e-23	Bladder cancer;
LUSC	trans	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.1	-0.32	2.94e-9	Joint mobility (Beighton score);
LUSC	trans	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg10756647	chr7:56101905	PSPH	0.87	8.84	0.44	5.54e-17	Diabetic kidney disease;
LUSC	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg12292205	chr6:26970375	C6orf41	-0.63	-7.57	-0.38	3.72e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg09491104	chr22:46646882	C22orf40	-0.59	-8.51	-0.42	6.12e-16	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.04	15.66	0.65	8.17e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11030122	0.632	rs714380	chr11:4059653	A/T	cg08557956	chr11:4115526	RRM1	-0.5	-6.37	-0.33	6.13e-10	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg13010199	chr12:38710504	ALG10B	0.69	10.56	0.5	1.13e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg14552801	chr7:65878734	NA	0.38	5.76	0.3	1.96e-8	Aortic root size;
LUSC	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg25566285	chr7:158114605	PTPRN2	0.33	6.16	0.32	2.14e-9	Calcium levels;
LUSC	cis	rs11039100	0.599	rs34123108	chr11:5834724	A/G	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2274273	0.686	rs2296489	chr14:55624977	T/C	cg04306507	chr14:55594613	LGALS3	0.48	9.62	0.47	1.68e-19	Protein biomarker;
LUSC	cis	rs2742234	0.590	rs2075912	chr10:43622217	T/C	cg02780029	chr10:43622663	RET	-0.33	-5.67	-0.3	3.01e-8	Hirschsprung disease;
LUSC	cis	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.19	-0.32	1.76e-9	Ulcerative colitis;
LUSC	cis	rs1185460	0.967	rs11217137	chr11:118931030	A/G	cg01677386	chr11:118938358	VPS11	-0.51	-7.03	-0.36	1.18e-11	Coronary artery disease;
LUSC	cis	rs7677751	0.806	rs4864858	chr4:55089953	T/A	cg17187183	chr4:55093834	PDGFRA	0.38	5.83	0.3	1.3e-8	Corneal astigmatism;
LUSC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06221963	chr1:154839813	KCNN3	-0.61	-13.83	-0.6	1.03e-34	Prostate cancer;
LUSC	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg18758796	chr5:131593413	PDLIM4	0.4	7.06	0.36	9.75e-12	Blood metabolite levels;
LUSC	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg00191853	chr8:101177733	SPAG1	-0.37	-6.15	-0.32	2.2e-9	Atrioventricular conduction;
LUSC	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	8.78	0.43	8.59e-17	Response to antipsychotic treatment;
LUSC	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.83	-11.37	-0.53	1.48e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg03340356	chr1:67600835	NA	0.43	6.78	0.35	5.46e-11	Psoriasis;
LUSC	cis	rs1983891	0.955	rs7753653	chr6:41548430	C/T	cg20194872	chr6:41519635	FOXP4	-0.34	-6.15	-0.32	2.18e-9	Prostate cancer;
LUSC	cis	rs9612	0.718	rs346532	chr19:44248878	A/G	cg08581076	chr19:44259116	C19orf61	0.51	6.38	0.33	5.94e-10	Exhaled nitric oxide output;
LUSC	cis	rs1009647	0.645	rs117502961	chr14:55599914	T/G	cg04306507	chr14:55594613	LGALS3	0.45	6.26	0.32	1.21e-9	Testicular germ cell tumor;
LUSC	cis	rs7246967	0.673	rs7247191	chr19:22899585	C/T	cg23217946	chr19:22817039	ZNF492	0.41	5.68	0.3	2.93e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs11608355	0.515	rs56244055	chr12:109936211	G/A	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	trans	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg11887960	chr12:57824829	NA	0.48	6.67	0.34	1.04e-10	Obesity-related traits;
LUSC	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.54	8.76	0.43	1.01e-16	Breast cancer;
LUSC	cis	rs1190596	0.525	rs7153005	chr14:102698599	G/T	cg18135206	chr14:102964638	TECPR2	-0.47	-6.02	-0.31	4.48e-9	Behavioural disinhibition (generation interaction);
LUSC	cis	rs4073416	0.535	rs7150448	chr14:65871502	C/T	cg03016385	chr14:66212404	NA	-0.38	-5.8	-0.3	1.5e-8	N-glycan levels;
LUSC	cis	rs6594499	0.872	rs13178997	chr5:110444249	G/T	cg04022379	chr5:110408740	TSLP	0.45	6.78	0.35	5.56e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7945718	0.805	rs11022510	chr11:12833262	G/A	cg25843174	chr11:12811716	TEAD1	0.31	7.24	0.37	3.17e-12	Educational attainment (years of education);
LUSC	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg17052675	chr2:3827356	NA	-0.63	-10.1	-0.48	4.21e-21	Type 2 diabetes;
LUSC	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.67	-0.34	1.06e-10	Mood instability;
LUSC	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg07701084	chr6:150067640	NUP43	0.47	7.03	0.36	1.15e-11	Testicular germ cell tumor;
LUSC	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg05283184	chr6:79620031	NA	0.43	7.95	0.4	2.87e-14	Left atrial antero-posterior diameter;
LUSC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg07701084	chr6:150067640	NUP43	0.58	9.11	0.45	7.91e-18	Lung cancer;
LUSC	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.19	-0.37	4.4e-12	Neuroticism;
LUSC	cis	rs96067	0.805	rs6425966	chr1:36611287	C/T	cg24686825	chr1:36642396	MAP7D1	0.68	9.56	0.46	2.59e-19	Corneal structure;
LUSC	cis	rs354225	0.544	rs11902987	chr2:54805587	C/T	cg26097391	chr2:54893211	SPTBN1	0.46	6.99	0.36	1.55e-11	Schizophrenia;
LUSC	cis	rs7106204	0.514	rs2083753	chr11:24255896	A/G	ch.11.24196551F	chr11:24239977	NA	0.91	10.22	0.49	1.7e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.71	0.43	1.43e-16	Menopause (age at onset);
LUSC	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	9.38	0.46	1.06e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18728699	chr15:90931313	IQGAP1	0.47	6.27	0.32	1.11e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	9.19	0.45	4.34e-18	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg12463550	chr7:65579703	CRCP	0.5	6.99	0.36	1.46e-11	Aortic root size;
LUSC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.3	0.45	1.95e-18	Bipolar disorder;
LUSC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24110177	chr3:50126178	RBM5	0.57	9.24	0.45	3e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6693567	0.516	rs7554686	chr1:150265619	A/T	cg15654264	chr1:150340011	RPRD2	-0.45	-7.25	-0.37	2.9e-12	Migraine;
LUSC	cis	rs483180	0.531	rs539708	chr1:120208503	G/T	cg19096424	chr1:120255104	PHGDH	-0.47	-6.62	-0.34	1.41e-10	Macular telangiectasia type 2;
LUSC	cis	rs71403859	0.730	rs17356316	chr16:71746921	C/T	cg08717414	chr16:71523259	ZNF19	-0.66	-7.29	-0.37	2.2e-12	Post bronchodilator FEV1;
LUSC	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg20019720	chr6:154832845	CNKSR3	0.64	8.73	0.43	1.22e-16	Lipoprotein (a) levels;
LUSC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg26380479	chr7:97908229	NA	-0.27	-6.06	-0.31	3.66e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg21100191	chr22:23484243	RTDR1	0.91	15.5	0.65	3.21e-41	Bone mineral density;
LUSC	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.9	-0.35	2.69e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg09796270	chr17:17721594	SREBF1	0.42	7.51	0.38	5.43e-13	Total body bone mineral density;
LUSC	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg13902645	chr11:5959945	NA	-0.57	-8.07	-0.4	1.3e-14	DNA methylation (variation);
LUSC	cis	rs6681460	1.000	rs7521111	chr1:67121634	T/C	cg02459107	chr1:67143332	SGIP1	0.48	8.99	0.44	1.94e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg05863683	chr7:1912471	MAD1L1	-0.3	-5.8	-0.3	1.52e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs977987	0.806	rs6564252	chr16:75388940	C/T	cg04384234	chr16:75411784	CFDP1	-0.39	-6.22	-0.32	1.46e-9	Dupuytren's disease;
LUSC	trans	rs10885582	0.839	rs11196794	chr10:116349314	A/G	cg01002288	chr1:43166549	YBX1	-0.36	-6.07	-0.32	3.5e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-6.19	-0.32	1.78e-9	Crohn's disease;
LUSC	cis	rs977987	0.815	rs11646677	chr16:75408981	T/C	cg03315344	chr16:75512273	CHST6	0.53	10.42	0.5	3.39e-22	Dupuytren's disease;
LUSC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg24733560	chr20:60626293	TAF4	0.43	7.82	0.39	6.95e-14	Body mass index;
LUSC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg22834771	chr12:69754056	YEATS4	-0.43	-5.89	-0.31	9.32e-9	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs617219	0.671	rs2607144	chr5:78556798	G/T	cg24856658	chr5:78533917	JMY	-0.29	-5.91	-0.31	8.46e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs4363385	0.818	rs436621	chr1:153005492	A/G	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.45e-8	Inflammatory skin disease;
LUSC	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg26102564	chr10:131424627	MGMT	0.4	6.1	0.32	2.94e-9	Response to temozolomide;
LUSC	cis	rs6961069	0.745	rs3212160	chr7:80273308	A/C	cg04458919	chr7:80252533	CD36	0.34	6.15	0.32	2.26e-9	Platelet count;
LUSC	cis	rs1594829	0.500	rs2046223	chr8:26210178	C/T	cg13160058	chr8:26243215	BNIP3L	0.32	5.74	0.3	2.08e-8	Height;
LUSC	cis	rs1882538	0.596	rs10281827	chr7:133081810	A/G	cg10665199	chr7:133106180	EXOC4	0.58	8.04	0.4	1.53e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg18512352	chr11:47633146	NA	0.46	9.21	0.45	3.61e-18	Subjective well-being;
LUSC	cis	rs10992471	0.603	rs7873397	chr9:95205928	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.72	-0.39	1.34e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg06238570	chr21:40685208	BRWD1	0.48	7.24	0.37	3.06e-12	Cognitive function;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg00358695	chr19:42463363	RABAC1	0.39	5.97	0.31	6.21e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg07173049	chr1:7289937	CAMTA1	0.31	6.4	0.33	5.27e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg17385448	chr1:15911702	AGMAT	0.36	5.86	0.31	1.12e-8	Systolic blood pressure;
LUSC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg00838250	chr3:186287958	TBCCD1;DNAJB11	-0.34	-6.15	-0.32	2.22e-9	Breast cancer;
LUSC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.91	-0.4	3.82e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10193935	0.792	rs6735571	chr2:42491951	C/T	cg27598129	chr2:42591480	NA	-0.58	-7.98	-0.4	2.35e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg00701064	chr4:6280414	WFS1	0.57	13.7	0.6	3.15e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs10090774	0.687	rs11774679	chr8:141917656	A/T	cg16477744	chr7:157367142	PTPRN2;MIR153-2	0.28	5.99	0.31	5.42e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg15412446	chr2:106886593	NA	-0.5	-6.22	-0.32	1.47e-9	Facial morphology (factor 23);
LUSC	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.34	0.46	1.39e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg03676636	chr4:99064102	C4orf37	0.33	7.29	0.37	2.3e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg22732515	chr19:44031385	ETHE1	0.62	10.29	0.49	9.12e-22	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg25251562	chr2:3704773	ALLC	-0.36	-6.26	-0.32	1.17e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg18335740	chr13:41363409	SLC25A15	0.75	13.62	0.6	6.9e-34	Lewy body disease;
LUSC	cis	rs11785693	0.862	rs10503292	chr8:4992275	A/G	cg26367366	chr8:4980734	NA	0.6	7.05	0.36	1.02e-11	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs2932538	0.961	rs6537747	chr1:113179597	C/T	cg22162597	chr1:113214053	CAPZA1	-0.52	-7.51	-0.38	5.52e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg13390004	chr1:15929781	NA	0.42	7.04	0.36	1.07e-11	Systolic blood pressure;
LUSC	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.5	8.1	0.41	1.05e-14	IgG glycosylation;
LUSC	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg05373962	chr22:49881684	NA	-0.39	-8.55	-0.42	4.37e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.53	-0.34	2.44e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.42	6.65	0.34	1.2e-10	Response to antipsychotic treatment;
LUSC	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg13114125	chr14:105738426	BRF1	-0.89	-14.18	-0.61	4.61e-36	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs859767	0.741	rs1516991	chr2:135370052	G/A	cg12500956	chr2:135428796	TMEM163	-0.28	-6.42	-0.33	4.7e-10	Neuroticism;
LUSC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg02269571	chr22:50332266	NA	-0.57	-8.59	-0.43	3.41e-16	Schizophrenia;
LUSC	cis	rs9677476	0.779	rs12612219	chr2:232107363	G/T	cg07929768	chr2:232055508	NA	0.36	6.18	0.32	1.83e-9	Food antigen IgG levels;
LUSC	cis	rs12681287	0.547	rs9942792	chr8:87509046	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg09650180	chr20:62225654	GMEB2	-0.66	-9.69	-0.47	1.03e-19	Glioblastoma;
LUSC	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg08079166	chr15:68083412	MAP2K5	0.4	8.28	0.41	3.04e-15	Restless legs syndrome;
LUSC	cis	rs17092148	1.000	rs62211617	chr20:33400355	C/G	cg16810054	chr20:33298113	TP53INP2	0.45	6.77	0.35	5.85e-11	Neuroticism;
LUSC	cis	rs3849570	0.643	rs6797240	chr3:81971856	T/C	cg07356753	chr3:81810745	GBE1	-0.49	-7.22	-0.37	3.44e-12	Waist circumference;Body mass index;
LUSC	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg22705602	chr4:152727874	NA	-0.37	-7.97	-0.4	2.61e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg00310523	chr12:86230176	RASSF9	0.43	7.66	0.39	2.07e-13	Major depressive disorder;
LUSC	cis	rs1113500	0.897	rs11185263	chr1:108639804	C/G	cg11967332	chr1:108735228	SLC25A24	0.38	5.71	0.3	2.45e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs7572644	0.699	rs6731650	chr2:28261163	C/A	cg27432699	chr2:27873401	GPN1	-0.52	-7.07	-0.36	9.22e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.88	-15.45	-0.65	5.46e-41	Cognitive function;
LUSC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.75	-0.51	2.45e-23	Chronic sinus infection;
LUSC	trans	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.45	-0.33	3.95e-10	Bladder cancer;
LUSC	trans	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg13565492	chr6:43139072	SRF	-0.63	-6.57	-0.34	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	8.33	0.41	2.06e-15	Lung cancer in ever smokers;
LUSC	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.76	-15.2	-0.64	5.12e-40	Gut microbiota (bacterial taxa);
LUSC	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg21132104	chr15:45694354	SPATA5L1	0.55	7.54	0.38	4.48e-13	Homoarginine levels;
LUSC	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg05340658	chr4:99064831	C4orf37	0.46	7.28	0.37	2.39e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg24562669	chr7:97807699	LMTK2	0.34	6.01	0.31	4.73e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3857536	0.813	rs1891599	chr6:66941699	A/G	cg07460842	chr6:66804631	NA	-0.46	-6.35	-0.33	6.98e-10	Blood trace element (Cu levels);
LUSC	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	11.92	0.55	1.56e-27	Height;
LUSC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs9653442	1.000	rs9653442	chr2:100825367	A/G	cg22139774	chr2:100720529	AFF3	0.42	7.54	0.38	4.52e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.52	-6.89	-0.35	2.76e-11	Homoarginine levels;
LUSC	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	1.05	19.12	0.72	1.42e-55	Menopause (age at onset);
LUSC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00684032	chr4:1343700	KIAA1530	0.34	6.13	0.32	2.5e-9	Obesity-related traits;
LUSC	cis	rs751728	0.648	rs6922275	chr6:33749739	G/A	cg25922239	chr6:33757077	LEMD2	0.42	6.28	0.33	1.05e-9	Crohn's disease;
LUSC	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg08601574	chr20:25228251	PYGB	-0.4	-5.99	-0.31	5.42e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg02221750	chr19:17393354	ANKLE1	-0.92	-14.18	-0.61	4.48e-36	Systemic lupus erythematosus;
LUSC	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg12483005	chr1:23474871	LUZP1	0.41	6.09	0.32	3.12e-9	Height;
LUSC	cis	rs17824933	0.848	rs11230559	chr11:60769534	T/C	cg16817237	chr11:60793675	NA	0.4	6.34	0.33	7.24e-10	Multiple sclerosis;
LUSC	cis	rs73206853	0.841	rs73206845	chr12:110660556	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	6.45	0.33	3.99e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.5	-7.09	-0.36	8.28e-12	Iron status biomarkers;
LUSC	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08645402	chr16:4508243	NA	0.51	8.64	0.43	2.29e-16	Schizophrenia;
LUSC	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg04733989	chr22:42467013	NAGA	0.62	9.64	0.47	1.5e-19	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg04450456	chr4:17643702	FAM184B	-0.35	-6.0	-0.31	5.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg15744005	chr10:104629667	AS3MT	-0.29	-6.27	-0.32	1.13e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg05283184	chr6:79620031	NA	-0.57	-11.83	-0.54	3.38e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg02269571	chr22:50332266	NA	-0.45	-6.96	-0.36	1.78e-11	Schizophrenia;
LUSC	cis	rs11648785	0.735	rs868372	chr16:90097995	C/G	cg16611967	chr16:90144006	NA	0.44	5.84	0.3	1.23e-8	Tanning;
LUSC	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg21573476	chr21:45109991	RRP1B	-0.38	-5.92	-0.31	7.85e-9	Mean corpuscular volume;
LUSC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07677032	chr17:61819896	STRADA	0.54	8.95	0.44	2.52e-17	Prudent dietary pattern;
LUSC	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg05340658	chr4:99064831	C4orf37	-0.45	-7.14	-0.36	5.83e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg27494647	chr7:150038898	RARRES2	0.53	8.12	0.41	9.22e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg03060546	chr3:49711283	APEH	-0.62	-7.37	-0.37	1.37e-12	Menarche (age at onset);
LUSC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	0.92	13.73	0.6	2.61e-34	Breast cancer;
LUSC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-0.88	-17.59	-0.69	1.82e-49	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1728785	0.892	rs4783648	chr16:68558334	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.56	-6.74	-0.35	7.16e-11	Ulcerative colitis;
LUSC	cis	rs2625529	0.824	rs16956328	chr15:72143855	A/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.5	-0.38	5.83e-13	Red blood cell count;
LUSC	cis	rs12286929	0.617	rs11607928	chr11:115102224	A/G	cg04055981	chr11:115044050	NA	0.35	6.21	0.32	1.6e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg05340658	chr4:99064831	C4orf37	-0.5	-7.64	-0.39	2.32e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	7.59	0.38	3.22e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.53	0.38	4.92e-13	Longevity;
LUSC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg08088566	chr11:430123	ANO9	0.64	7.47	0.38	7.09e-13	Body mass index;
LUSC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.77	0.39	9.79e-14	Prudent dietary pattern;
LUSC	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg03676636	chr4:99064102	C4orf37	0.37	7.95	0.4	2.83e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg20476274	chr7:133979776	SLC35B4	0.79	13.49	0.59	2.12e-33	Mean platelet volume;
LUSC	cis	rs9311676	0.656	rs3191903	chr3:58382846	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.45	0.33	3.95e-10	Systemic lupus erythematosus;
LUSC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg23711669	chr6:146136114	FBXO30	0.87	16.39	0.67	1.03e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05165339	chr4:1420672	NA	-0.3	-6.58	-0.34	1.78e-10	Longevity;
LUSC	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	0.69	11.04	0.52	2.29e-24	Blood metabolite ratios;
LUSC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg20887711	chr4:1340912	KIAA1530	0.4	5.79	0.3	1.62e-8	Obesity-related traits;
LUSC	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg05868516	chr6:26286170	HIST1H4H	0.37	6.09	0.32	3.03e-9	Educational attainment;
LUSC	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg17366294	chr4:99064904	C4orf37	0.55	8.77	0.43	9.47e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs62400317	0.859	rs6919998	chr6:45159289	C/T	cg18551225	chr6:44695536	NA	-0.44	-7.2	-0.37	4.1e-12	Total body bone mineral density;
LUSC	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg06239285	chr11:62104954	ASRGL1	-0.98	-10.97	-0.51	4.05e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	0.63	13.54	0.6	1.31e-33	Prudent dietary pattern;
LUSC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg13319975	chr6:146136371	FBXO30	-0.53	-7.93	-0.4	3.44e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg02569458	chr12:86230093	RASSF9	0.38	6.07	0.32	3.39e-9	Major depressive disorder;
LUSC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg09034736	chr1:150693464	HORMAD1	0.45	6.43	0.33	4.36e-10	Melanoma;
LUSC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-13.67	-0.6	4.29e-34	Chronic sinus infection;
LUSC	trans	rs2679649	1.000	rs2679644	chr6:122352782	C/T	cg00167820	chr8:131663355	NA	0.54	6.35	0.33	6.96e-10	Subcutaneous adipose tissue;
LUSC	cis	rs4363385	0.776	rs1415957	chr1:152948909	A/G	cg07796016	chr1:152779584	LCE1C	-0.46	-6.55	-0.34	2.23e-10	Inflammatory skin disease;
LUSC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg00074818	chr8:8560427	CLDN23	0.59	10.04	0.48	6.92e-21	Obesity-related traits;
LUSC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg09365446	chr1:150670422	GOLPH3L	0.48	6.99	0.36	1.47e-11	Melanoma;
LUSC	trans	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.47	0.38	6.96e-13	Ulcerative colitis;
LUSC	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg13390004	chr1:15929781	NA	0.42	7.03	0.36	1.18e-11	Systolic blood pressure;
LUSC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.55	0.42	4.56e-16	Motion sickness;
LUSC	cis	rs3087591	1.000	rs7216033	chr17:29574642	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.55	-8.04	-0.4	1.56e-14	Hip circumference;
LUSC	cis	rs113835537	0.529	rs2276406	chr11:66283257	C/T	cg24851651	chr11:66362959	CCS	0.53	7.93	0.4	3.42e-14	Airway imaging phenotypes;
LUSC	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg05855489	chr10:104503620	C10orf26	-0.71	-10.41	-0.49	3.63e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg23711669	chr6:146136114	FBXO30	0.81	14.02	0.61	1.86e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	trans	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.38	-0.33	5.95e-10	Bladder cancer;
LUSC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg03396347	chr1:1875803	NA	0.39	7.73	0.39	1.27e-13	Body mass index;
LUSC	cis	rs981844	0.816	rs56109239	chr4:154726500	A/G	cg14289246	chr4:154710475	SFRP2	0.48	6.18	0.32	1.89e-9	Response to statins (LDL cholesterol change);
LUSC	trans	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.69	-0.34	9.51e-11	Endometrial cancer;
LUSC	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	8.86e-24	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg11062466	chr8:58055876	NA	0.66	8.52	0.42	5.58e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg22117172	chr7:91764530	CYP51A1	-0.33	-5.85	-0.3	1.19e-8	Breast cancer;
LUSC	trans	rs149866169	1	rs149866169	chr6:27441723	T/A	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.03	-0.4	1.72e-14	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg05340658	chr4:99064831	C4orf37	0.61	9.55	0.46	2.78e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg21854759	chr1:92012499	NA	-0.55	-9.23	-0.45	3.2e-18	Breast cancer;
LUSC	cis	rs1413885	0.516	rs6588137	chr1:65837282	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	7.45	0.38	8.26e-13	Anticoagulant levels;
LUSC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg08742575	chr21:47604166	C21orf56	0.38	5.65	0.3	3.36e-8	Testicular germ cell tumor;
LUSC	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.93	-18.48	-0.71	5.1e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs7809950	1.000	rs10243340	chr7:107090955	A/G	cg23024343	chr7:107201750	COG5	-0.54	-8.64	-0.43	2.43e-16	Coronary artery disease;
LUSC	cis	rs5771069	0.933	rs137848	chr22:50440296	A/G	cg27068297	chr22:50451975	IL17REL	0.27	5.69	0.3	2.79e-8	Ulcerative colitis;
LUSC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg08742575	chr21:47604166	C21orf56	0.42	6.4	0.33	5.16e-10	Testicular germ cell tumor;
LUSC	trans	rs11039798	0.764	rs11040208	chr11:49012509	A/G	cg15704280	chr7:45808275	SEPT13	0.86	7.15	0.36	5.51e-12	Axial length;
LUSC	cis	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg04837898	chr3:45731254	SACM1L	0.46	6.85	0.35	3.62e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg18479299	chr3:125709523	NA	-0.49	-5.67	-0.3	3.06e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	8.95	0.44	2.42e-17	Menopause (age at onset);
LUSC	cis	rs6977660	0.652	rs10254427	chr7:19816240	C/T	cg05791153	chr7:19748676	TWISTNB	0.62	6.86	0.35	3.45e-11	Thyroid stimulating hormone;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04250904	chr19:12623422	ZNF709	0.51	6.06	0.31	3.74e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg23630131	chr7:65973040	NA	-0.21	-5.93	-0.31	7.77e-9	Aortic root size;
LUSC	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg14004847	chr7:1930337	MAD1L1	-0.55	-8.36	-0.42	1.76e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg09455208	chr3:40491958	NA	-0.51	-9.43	-0.46	7.29e-19	Renal cell carcinoma;
LUSC	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-6.98	-0.36	1.59e-11	Height;
LUSC	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg02187348	chr16:89574699	SPG7	0.52	8.13	0.41	8.4e-15	Multiple myeloma (IgH translocation);
LUSC	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg15556689	chr8:8085844	FLJ10661	0.59	9.07	0.44	1.07e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.41	7.35	0.37	1.55e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	10.94	0.51	5.08e-24	Lung cancer in ever smokers;
LUSC	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg20026190	chr17:76395443	PGS1	0.47	8.04	0.4	1.56e-14	HDL cholesterol levels;
LUSC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg26566898	chr11:117069891	TAGLN	0.48	8.4	0.42	1.33e-15	Blood protein levels;
LUSC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg13683864	chr3:40499215	RPL14	-1.01	-17.38	-0.69	1.23e-48	Renal cell carcinoma;
LUSC	cis	rs7651039	0.619	rs7640807	chr3:15685137	A/G	cg16303742	chr3:15540471	COLQ	0.44	8.35	0.42	1.85e-15	Coronary heart disease;
LUSC	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	1.25	19.76	0.73	4.26e-58	Corneal structure;
LUSC	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg00564555	chr16:1970112	NA	0.38	6.43	0.33	4.34e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.65	10.29	0.49	9.28e-22	Endometrial cancer;
LUSC	cis	rs79387448	0.638	rs7600961	chr2:103035455	G/A	cg09003973	chr2:102972529	NA	0.97	10.11	0.48	3.74e-21	Gut microbiota (bacterial taxa);
LUSC	cis	rs9612	0.718	rs346522	chr19:44262545	C/T	cg08581076	chr19:44259116	C19orf61	-0.51	-6.59	-0.34	1.69e-10	Exhaled nitric oxide output;
LUSC	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.54	-0.34	2.34e-10	Schizophrenia;
LUSC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg10978503	chr1:24200527	CNR2	0.53	13.15	0.58	4.1e-32	Immature fraction of reticulocytes;
LUSC	trans	rs1491818	0.697	rs973862	chr11:29256133	A/G	cg21356630	chr6:167753807	TTLL2	0.36	6.03	0.31	4.36e-9	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg09904177	chr6:26538194	HMGN4	0.76	14.41	0.62	5.82e-37	Intelligence (multi-trait analysis);
LUSC	cis	rs870825	0.616	rs4386643	chr4:185624281	A/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.83	-14.2	-0.61	4e-36	Menarche (age at onset);
LUSC	cis	rs17818399	0.574	rs6544907	chr2:46868319	T/C	cg21493583	chr2:46842958	PIGF;CRIPT	0.33	6.02	0.31	4.56e-9	Height;
LUSC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	0.97	13.03	0.58	1.12e-31	Eosinophil percentage of granulocytes;
LUSC	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg20503657	chr10:835505	NA	0.79	9.87	0.48	2.49e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg13010199	chr12:38710504	ALG10B	0.65	10.01	0.48	8.31e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg04586622	chr2:25135609	ADCY3	0.42	8.79	0.43	7.87e-17	Body mass index;
LUSC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-6.27	-0.32	1.11e-9	Menopause (age at onset);
LUSC	cis	rs611744	0.810	rs619227	chr8:109215100	C/A	cg18478394	chr8:109455254	TTC35	0.4	5.89	0.31	9.48e-9	Dupuytren's disease;
LUSC	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.9	12.15	0.55	2.14e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs9311676	0.609	rs55797456	chr3:58378206	C/T	cg13750441	chr3:58318267	PXK	0.36	6.98	0.36	1.64e-11	Systemic lupus erythematosus;
LUSC	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.23	0.49	1.56e-21	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	6.96	0.36	1.83e-11	Neuroticism;
LUSC	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03713592	chr11:72463424	ARAP1	-0.69	-8.16	-0.41	6.89e-15	Type 2 diabetes;
LUSC	cis	rs3784262	0.867	rs8036453	chr15:58371635	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-5.96	-0.31	6.57e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg08392591	chr16:89556376	ANKRD11	0.47	7.09	0.36	8.17e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.43	0.5	3.23e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.5	8.86	0.44	4.88e-17	HDL cholesterol;
LUSC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg17420585	chr12:42539391	GXYLT1	-0.33	-6.28	-0.32	1.07e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs12200782	1.000	rs12207181	chr6:26431285	C/T	cg11837749	chr1:55047332	ACOT11	0.58	6.23	0.32	1.41e-9	Small cell lung carcinoma;
LUSC	cis	rs9815354	0.638	rs73071259	chr3:42001847	G/A	cg03022575	chr3:42003672	ULK4	0.84	8.8	0.43	7.21e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg14784868	chr12:69753453	YEATS4	0.63	9.4	0.46	8.65e-19	Blood protein levels;
LUSC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg19077165	chr18:44547161	KATNAL2	-0.37	-5.68	-0.3	2.94e-8	Personality dimensions;
LUSC	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.54	-7.63	-0.39	2.52e-13	Renal function-related traits (BUN);
LUSC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg16423285	chr20:60520624	NA	0.87	11.89	0.55	1.93e-27	Obesity-related traits;
LUSC	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.96	0.4	2.78e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1375194	0.606	rs17657783	chr2:33814590	A/G	cg04131969	chr2:33951647	MYADML	-0.63	-8.84	-0.44	5.4e-17	Response to antidepressants in depression;
LUSC	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg05925327	chr15:68127851	NA	-0.49	-7.43	-0.38	9.21e-13	Restless legs syndrome;
LUSC	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.94	-18.67	-0.71	8.71e-54	Ulcerative colitis;
LUSC	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg27432699	chr2:27873401	GPN1	0.8	15.03	0.64	2.42e-39	Oral cavity cancer;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.67	10.36	0.49	5.33e-22	Lymphocyte counts;
LUSC	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg07701084	chr6:150067640	NUP43	0.45	6.72	0.35	7.84e-11	Testicular germ cell tumor;
LUSC	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	10.98	0.51	3.76e-24	Lung cancer in ever smokers;
LUSC	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	10.72	0.51	3.12e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg02018176	chr4:1364513	KIAA1530	-0.56	-9.75	-0.47	6.05e-20	Obesity-related traits;
LUSC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.15e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs34779708	0.801	rs12246600	chr10:35538121	A/C	cg03585969	chr10:35415529	CREM	0.55	7.67	0.39	1.92e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg19156104	chr2:198669113	PLCL1	-0.48	-5.83	-0.3	1.29e-8	Ulcerative colitis;
LUSC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	28.67	0.84	4.56e-92	Chronic sinus infection;
LUSC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg10523860	chr14:103875565	MARK3	0.39	6.21	0.32	1.55e-9	Body mass index;
LUSC	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	8.04	0.4	1.54e-14	Mood instability;
LUSC	cis	rs62400317	0.859	rs4267941	chr6:45241302	A/C	cg20913747	chr6:44695427	NA	-0.47	-7.65	-0.39	2.2e-13	Total body bone mineral density;
LUSC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.11e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9309473	0.718	rs10175529	chr2:73606093	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-8.14	-0.41	7.85e-15	Metabolite levels;
LUSC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.27	0.59	1.45e-32	Chronic sinus infection;
LUSC	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg00376283	chr12:123451042	ABCB9	0.76	8.36	0.42	1.66e-15	Neutrophil percentage of white cells;
LUSC	trans	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	6.69	0.34	9.19e-11	Retinal vascular caliber;
LUSC	cis	rs2963155	0.518	rs10515522	chr5:142758394	A/G	cg17617527	chr5:142782415	NR3C1	0.72	8.55	0.42	4.59e-16	Breast cancer;
LUSC	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	12.95	0.58	2.32e-31	Bipolar disorder;
LUSC	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg05283184	chr6:79620031	NA	-0.46	-8.75	-0.43	1.05e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg09904177	chr6:26538194	HMGN4	0.42	6.14	0.32	2.41e-9	Schizophrenia;
LUSC	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg25664220	chr3:72788482	NA	-0.72	-12.38	-0.56	3.03e-29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	1.12	19.01	0.72	3.91e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Depression;
LUSC	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.18	-0.45	4.78e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7241530	0.662	rs9946782	chr18:75888634	C/T	cg14642773	chr18:75888474	NA	0.36	5.91	0.31	8.59e-9	Educational attainment (years of education);
LUSC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-6.24	-0.32	1.35e-9	Crohn's disease;
LUSC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	0.92	15.42	0.64	7.18e-41	Breast cancer;
LUSC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg27170947	chr2:26402098	FAM59B	0.68	10.27	0.49	1.11e-21	Gut microbiome composition (summer);
LUSC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg05665937	chr4:1216051	CTBP1	-0.37	-5.79	-0.3	1.65e-8	Obesity-related traits;
LUSC	cis	rs611744	0.839	rs638238	chr8:109169152	A/G	cg18478394	chr8:109455254	TTC35	0.41	6.19	0.32	1.75e-9	Dupuytren's disease;
LUSC	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.5	7.2	0.37	3.9e-12	Coronary heart disease;
LUSC	trans	rs2562456	0.754	rs58338799	chr19:21521811	G/T	cg00806126	chr19:22604979	ZNF98	-0.43	-6.23	-0.32	1.38e-9	Pain;
LUSC	cis	rs17102423	0.559	rs11624169	chr14:65481710	C/G	cg11161011	chr14:65562177	MAX	-0.72	-9.82	-0.47	3.79e-20	Obesity-related traits;
LUSC	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg04545296	chr12:48745243	ZNF641	0.35	6.39	0.33	5.48e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg27494647	chr7:150038898	RARRES2	0.58	8.54	0.42	4.74e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg04733989	chr22:42467013	NAGA	0.5	7.72	0.39	1.35e-13	Schizophrenia;
LUSC	cis	rs12145833	0.538	rs61833885	chr1:243397188	C/A	cg02356786	chr1:243265016	LOC731275	0.69	6.31	0.33	9.05e-10	Obesity (early onset extreme);
LUSC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg19773385	chr1:10388646	KIF1B	0.54	8.48	0.42	7.41e-16	Hepatocellular carcinoma;
LUSC	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg27124370	chr19:33622961	WDR88	0.55	7.86	0.39	5.46e-14	Bone properties (heel);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19496744	chr17:80231639	CSNK1D	-0.56	-6.67	-0.34	1.04e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-9.26	-0.45	2.58e-18	Gut microbiome composition (summer);
LUSC	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg02023728	chr11:77925099	USP35	0.45	6.68	0.34	9.85e-11	Testicular germ cell tumor;
LUSC	cis	rs10788264	0.504	rs4751887	chr10:124029758	G/A	cg09507567	chr10:124027408	NA	0.55	9.67	0.47	1.18e-19	Total body bone mineral density;
LUSC	cis	rs9811920	0.931	rs7629487	chr3:99860401	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.39	5.75	0.3	2.02e-8	Axial length;
LUSC	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg02023728	chr11:77925099	USP35	0.46	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	trans	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg09781936	chr22:19749961	TBX1	-0.34	-6.01	-0.31	4.74e-9	Inflammatory bowel disease;
LUSC	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg21433313	chr16:3507492	NAT15	0.41	5.71	0.3	2.53e-8	Body mass index (adult);
LUSC	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg26395211	chr5:140044315	WDR55	-0.4	-6.15	-0.32	2.25e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg07810366	chr2:100720526	AFF3	-0.5	-8.71	-0.43	1.44e-16	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs3820928	0.874	rs10202239	chr2:227901819	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.89	-0.4	4.48e-14	Pulmonary function;
LUSC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg07507251	chr3:52567010	NT5DC2	0.32	6.29	0.33	9.79e-10	Bipolar disorder;
LUSC	trans	rs9944715	1.000	rs9951624	chr18:43840829	A/G	cg01718231	chr17:29326311	RNF135	-0.55	-7.59	-0.38	3.17e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs12413816	0.963	rs10796116	chr10:13762786	C/T	cg16485048	chr10:13749193	FRMD4A	-0.48	-8.41	-0.42	1.21e-15	Red cell distribution width;
LUSC	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg20701182	chr2:24300061	SF3B14	0.73	7.31	0.37	2.04e-12	Lymphocyte counts;
LUSC	cis	rs11166629	0.637	rs7816909	chr8:135551597	G/T	cg27224718	chr8:135614730	ZFAT	-0.51	-7.46	-0.38	7.55e-13	Smoking quantity;
LUSC	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg27284194	chr4:1044797	NA	0.6	8.76	0.43	9.9900000000000006e-17	Recombination rate (females);
LUSC	cis	rs2637266	1.000	rs12260492	chr10:78365242	C/A	cg18941641	chr10:78392320	NA	0.39	7.11	0.36	7.28e-12	Pulmonary function;
LUSC	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg09904177	chr6:26538194	HMGN4	0.75	14.21	0.61	3.52e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg09455208	chr3:40491958	NA	0.52	9.8	0.47	4.21e-20	Renal cell carcinoma;
LUSC	cis	rs9653442	0.593	rs2309811	chr2:100862359	A/G	cg07810366	chr2:100720526	AFF3	-0.4	-6.55	-0.34	2.17e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1983891	0.955	rs6917270	chr6:41548755	A/G	cg20194872	chr6:41519635	FOXP4	0.35	6.25	0.32	1.27e-9	Prostate cancer;
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.48	-8.13	-0.41	8.56e-15	Lymphocyte counts;
LUSC	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.31	-0.41	2.43e-15	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs56399783	0.901	rs73047387	chr7:2774125	G/A	cg14895029	chr7:2775587	GNA12	0.53	5.77	0.3	1.81e-8	Childhood ear infection;
LUSC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg02896835	chr1:92012615	NA	-0.59	-9.97	-0.48	1.13e-20	Breast cancer;
LUSC	trans	rs979233	0.502	rs687238	chr5:42084883	G/T	cg07010552	chr17:7358735	CHRNB1	0.41	5.96	0.31	6.43e-9	Systemic lupus erythematosus;
LUSC	cis	rs8005677	0.611	rs11624528	chr14:23459156	A/G	cg00579484	chr14:23475993	C14orf93	0.43	6.27	0.32	1.1e-9	Cognitive ability (multi-trait analysis);
LUSC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg04369109	chr6:150039330	LATS1	-0.6	-8.85	-0.44	5.18e-17	Lung cancer;
LUSC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg23711669	chr6:146136114	FBXO30	0.88	16.35	0.67	1.5e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1832871	0.965	rs262827	chr6:158683646	A/T	cg07165851	chr6:158734300	TULP4	0.38	6.43	0.33	4.36e-10	Height;
LUSC	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg01689657	chr7:91764605	CYP51A1	-0.32	-5.88	-0.31	9.85e-9	Breast cancer;
LUSC	cis	rs76935404	0.811	rs28417358	chr19:41428105	G/A	cg04176888	chr19:41596066	CYP2A13	0.38	5.98	0.31	5.73e-9	nicotine metabolite ratio in current smokers;
LUSC	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg13256891	chr4:100009986	ADH5	-0.42	-5.69	-0.3	2.74e-8	Alcohol dependence;
LUSC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11764359	chr7:65958608	NA	0.56	7.36	0.37	1.48e-12	Aortic root size;
LUSC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-18.15	-0.7	1.08e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.3e-11	Uric acid levels;
LUSC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.79	0.6	1.44e-34	Platelet count;
LUSC	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	13.13	0.58	4.96e-32	Cognitive test performance;
LUSC	trans	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg10756647	chr7:56101905	PSPH	0.85	8.22	0.41	4.44e-15	Diabetic kidney disease;
LUSC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg09626299	chr10:82213104	TSPAN14	-0.2	-5.92	-0.31	8.16e-9	Post bronchodilator FEV1;
LUSC	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg01097406	chr16:89675127	NA	0.34	6.61	0.34	1.51e-10	Vitiligo;
LUSC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.47	-8.41	-0.42	1.17e-15	Longevity;Endometriosis;
LUSC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg24675658	chr1:53192096	ZYG11B	-0.55	-8.83	-0.44	5.91e-17	Monocyte count;
LUSC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg01657329	chr11:68192670	LRP5	-0.44	-6.59	-0.34	1.67e-10	Total body bone mineral density;
LUSC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg02018176	chr4:1364513	KIAA1530	0.5	8.54	0.42	4.76e-16	Obesity-related traits;
LUSC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.12	-0.61	8.03e-36	Eye color traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12830327	chr11:85339628	TMEM126B;DLG2	0.43	6.58	0.34	1.87e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg23750338	chr8:142222470	SLC45A4	0.58	11.26	0.52	3.68e-25	Immature fraction of reticulocytes;
LUSC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg17554472	chr22:41940697	POLR3H	-0.47	-5.73	-0.3	2.29e-8	Vitiligo;
LUSC	cis	rs17102423	0.964	rs868814	chr14:65584508	C/T	cg11161011	chr14:65562177	MAX	-0.64	-10.11	-0.48	3.77e-21	Obesity-related traits;
LUSC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg02428538	chr16:24856791	SLC5A11	0.5	5.81	0.3	1.48e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg18758796	chr5:131593413	PDLIM4	-0.43	-6.89	-0.35	2.72e-11	Blood metabolite levels;
LUSC	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-6.21	-0.32	1.55e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.18	0.77	1.27e-67	Prudent dietary pattern;
LUSC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.09	-0.32	3.02e-9	Initial pursuit acceleration;
LUSC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08280861	chr8:58055591	NA	0.56	5.85	0.3	1.16e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs10754283	0.967	rs4658307	chr1:90117586	G/T	cg21401794	chr1:90099060	LRRC8C	0.62	8.81	0.43	7.07e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg02972257	chr16:68554789	NA	-0.49	-6.31	-0.33	8.74e-10	Ulcerative colitis;
LUSC	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg23649088	chr2:200775458	C2orf69	0.47	7.06	0.36	9.77e-12	Asthma (bronchodilator response);
LUSC	cis	rs16937	0.662	rs10900472	chr1:205181526	A/G	cg21643547	chr1:205240462	TMCC2	-0.35	-6.35	-0.33	7.22e-10	Schizophrenia;
LUSC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg10755058	chr3:40428713	ENTPD3	0.33	5.67	0.3	3.16e-8	Renal cell carcinoma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18756060	chr2:27294719	LOC100128731	-0.46	-6.64	-0.34	1.3e-10	Electrocardiographic conduction measures;
LUSC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg22963979	chr7:1858916	MAD1L1	-0.47	-6.87	-0.35	3.23e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs17125944	0.615	rs7145392	chr14:53321016	G/A	cg00686598	chr14:53173677	PSMC6	-0.62	-5.67	-0.3	3.02e-8	Alzheimer's disease (late onset);
LUSC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg06937882	chr20:24974362	C20orf3	-0.44	-7.67	-0.39	1.89e-13	Blood protein levels;
LUSC	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg22089800	chr15:90895588	ZNF774	-0.66	-10.25	-0.49	1.24e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.38	-0.33	5.98e-10	Bipolar disorder;
LUSC	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg16032841	chr13:111522222	C13orf29	-0.52	-6.22	-0.32	1.49e-9	Sitting height ratio;
LUSC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.74	-11.25	-0.52	4.21e-25	Menarche (age at onset);
LUSC	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg24879335	chr3:133465180	TF	0.45	7.74	0.39	1.21e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-6.7	-0.34	8.73e-11	Schizophrenia;
LUSC	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	11.31	0.53	2.46e-25	Coffee consumption (cups per day);
LUSC	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg22676075	chr6:135203613	NA	-0.45	-7.0	-0.36	1.38e-11	Red blood cell count;
LUSC	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.18	-0.45	4.78e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.49	-11.79	-0.54	4.81e-27	Urate levels in overweight individuals;
LUSC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.5	6.24	0.32	1.33e-9	Renal function-related traits (BUN);
LUSC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg06808227	chr14:105710500	BRF1	-0.64	-9.35	-0.46	1.33e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00166722	chr3:10149974	C3orf24	-0.62	-7.4	-0.38	1.11e-12	Alzheimer's disease;
LUSC	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.74	-10.9	-0.51	7.23e-24	Glomerular filtration rate;
LUSC	cis	rs1953600	0.645	rs2573351	chr10:81931441	A/G	cg00277334	chr10:82204260	NA	-0.49	-7.69	-0.39	1.68e-13	Sarcoidosis;
LUSC	cis	rs7246967	0.551	rs34563787	chr19:22837736	A/T	cg23217946	chr19:22817039	ZNF492	0.47	5.89	0.31	9.48e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs55665837	1.000	rs11023229	chr11:14461001	G/C	cg05501817	chr11:14380813	RRAS2	-0.41	-6.51	-0.34	2.72e-10	Vitamin D levels;
LUSC	trans	rs72674100	1.000	rs10005721	chr4:97983681	G/T	cg16405019	chr1:18959625	PAX7	-0.57	-6.19	-0.32	1.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10203711	1.000	rs907100	chr2:239563579	G/C	cg14580085	chr2:239553406	NA	0.41	6.88	0.35	2.9100000000000002e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs701145	0.617	rs355775	chr3:154036129	A/G	cg17054900	chr3:154042577	DHX36	0.46	5.98	0.31	5.67e-9	Coronary artery disease;
LUSC	cis	rs4363385	0.626	rs12062847	chr1:153062994	A/G	cg07796016	chr1:152779584	LCE1C	-0.39	-5.83	-0.3	1.27e-8	Inflammatory skin disease;
LUSC	cis	rs9341808	0.644	rs59371711	chr6:80942027	G/T	cg08355045	chr6:80787529	NA	-0.42	-7.13	-0.36	6.17e-12	Sitting height ratio;
LUSC	cis	rs7089973	0.966	rs749649	chr10:116641999	G/A	cg23260525	chr10:116636907	FAM160B1	0.37	7.13	0.36	6.35e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs3099143	1.000	rs1913001	chr15:77179408	A/C	cg21673338	chr15:77095150	SCAPER	0.78	7.34	0.37	1.64e-12	Recalcitrant atopic dermatitis;
LUSC	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg03605463	chr16:89740564	NA	0.56	8.97	0.44	2.21e-17	Hemoglobin concentration;
LUSC	cis	rs1355223	0.506	rs7130774	chr11:34869267	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.67	-0.34	1.05e-10	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.36	6.06	0.31	3.76e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18854424	chr1:2615690	NA	-0.49	-9.81	-0.47	3.96e-20	Ulcerative colitis;
LUSC	cis	rs9837602	1.000	rs1688766	chr3:99647850	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.37	5.89	0.31	9.38e-9	Breast cancer;
LUSC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	12.05	0.55	5.41e-28	Chronic sinus infection;
LUSC	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg14829155	chr15:31115871	NA	0.47	6.77	0.35	5.71e-11	Huntington's disease progression;
LUSC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg25019033	chr10:957182	NA	-0.55	-6.33	-0.33	8e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.78	0.51	1.95e-23	Hypertriglyceridemia;
LUSC	cis	rs7827545	0.545	rs57219802	chr8:135554231	C/T	cg17885191	chr8:135476712	NA	0.65	8.03	0.4	1.65e-14	Hypertension (SNP x SNP interaction);
LUSC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.5	5.96	0.31	6.46e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg08079166	chr15:68083412	MAP2K5	0.41	8.68	0.43	1.78e-16	Restless legs syndrome;
LUSC	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg07169764	chr2:136633963	MCM6	0.56	7.43	0.38	9.28e-13	Mosquito bite size;
LUSC	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg03465714	chr1:152285911	FLG	-0.4	-5.75	-0.3	2.05e-8	Atopic dermatitis;
LUSC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.27	0.37	2.61e-12	Mean platelet volume;
LUSC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.49	9.52	0.46	3.58e-19	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg13010199	chr12:38710504	ALG10B	0.57	9.05	0.44	1.22e-17	Morning vs. evening chronotype;
LUSC	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg13852791	chr20:30311386	BCL2L1	0.94	14.61	0.62	1.01e-37	Mean corpuscular hemoglobin;
LUSC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg13319975	chr6:146136371	FBXO30	-0.66	-9.92	-0.48	1.64e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg15445000	chr17:37608096	MED1	0.39	6.71	0.34	8.2e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.79	-12.54	-0.57	8.06e-30	Dilated cardiomyopathy;
LUSC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg20406979	chr6:167373233	NA	-0.26	-6.22	-0.32	1.5e-9	Crohn's disease;
LUSC	cis	rs7937682	0.562	rs955744	chr11:111374334	C/T	cg09085632	chr11:111637200	PPP2R1B	0.53	7.19	0.37	4.2e-12	Primary sclerosing cholangitis;
LUSC	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg03929089	chr4:120376271	NA	0.74	6.95	0.36	1.87e-11	Axial length;
LUSC	cis	rs9463078	0.605	rs9472407	chr6:44908800	T/C	cg25276700	chr6:44698697	NA	0.29	6.06	0.31	3.59e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg04058563	chr4:185651563	MLF1IP	0.44	7.55	0.38	4.13e-13	Kawasaki disease;
LUSC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs55883249	0.957	rs17362839	chr2:9754439	T/C	cg23886495	chr2:9695866	ADAM17	0.48	5.75	0.3	2.07e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs7575217	0.767	rs13400798	chr2:101750350	C/T	cg23907051	chr2:101730305	TBC1D8	-0.28	-7.38	-0.37	1.24e-12	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg26335602	chr6:28129616	ZNF389	0.43	5.77	0.3	1.82e-8	Depression;
LUSC	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg02023728	chr11:77925099	USP35	0.43	6.58	0.34	1.77e-10	Testicular germ cell tumor;
LUSC	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg21775007	chr8:11205619	TDH	-0.46	-6.94	-0.36	2.03e-11	Mood instability;
LUSC	cis	rs11031096	0.641	rs232054	chr11:4123427	C/G	cg18678763	chr11:4115507	RRM1	0.38	5.73	0.3	2.29e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs4925114	0.532	rs11655029	chr17:17649172	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-7.24	-0.37	3.05e-12	Body mass index;
LUSC	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	6.29	0.33	9.72e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg20608306	chr11:116969690	SIK3	0.4	6.68	0.34	9.91e-11	Blood protein levels;
LUSC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.8	12.57	0.57	6.1e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs981844	0.712	rs10014763	chr4:154739140	C/T	cg14289246	chr4:154710475	SFRP2	0.44	5.94	0.31	7.3e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs10779751	1.000	rs7525957	chr1:11318236	C/T	cg08854313	chr1:11322531	MTOR	0.89	15.01	0.63	2.78e-39	Body mass index;
LUSC	cis	rs9534288	0.664	rs1926446	chr13:46629995	A/C	cg15192986	chr13:46630673	CPB2	0.72	11.49	0.53	5.82e-26	Blood protein levels;
LUSC	cis	rs1499972	0.887	rs73168397	chr3:117657197	C/T	cg07612923	chr3:117604196	NA	0.63	5.71	0.3	2.49e-8	Schizophrenia;
LUSC	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg09582351	chr12:29534625	ERGIC2	-0.34	-6.91	-0.35	2.44e-11	QT interval;
LUSC	cis	rs6977660	0.714	rs12530537	chr7:19822641	A/G	cg05791153	chr7:19748676	TWISTNB	-0.63	-6.85	-0.35	3.67e-11	Thyroid stimulating hormone;
LUSC	cis	rs1322512	0.917	rs2758781	chr6:153008828	C/T	cg27316956	chr6:152958899	SYNE1	0.35	6.06	0.31	3.59e-9	Tonometry;
LUSC	cis	rs3741798	1.000	rs61922049	chr12:12497395	C/T	cg08615371	chr12:12503544	MANSC1	1.08	11.07	0.52	1.79e-24	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18854424	chr1:2615690	NA	-0.5	-10.01	-0.48	8.72e-21	Ulcerative colitis;
LUSC	cis	rs62158211	1.000	rs1807282	chr2:114110036	A/T	cg17784749	chr2:114082611	LOC440839	0.51	6.06	0.31	3.71e-9	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LUSC	cis	rs2348418	0.864	rs7977850	chr12:28715648	C/T	cg13890972	chr12:28721907	NA	-0.34	-5.81	-0.3	1.49e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg22535103	chr8:58192502	C8orf71	-0.73	-7.44	-0.38	8.49e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs2736345	0.502	rs12680762	chr8:11332026	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.22	-0.37	3.58e-12	Sjögren's syndrome;Systemic lupus erythematosus;
LUSC	trans	rs3903072	0.528	rs12800497	chr11:65579762	C/T	cg17712092	chr4:129076599	LARP1B	0.55	7.09	0.36	7.88e-12	Breast cancer;
LUSC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.27	-0.37	2.59e-12	Bipolar disorder;
LUSC	cis	rs1957429	0.614	rs75819890	chr14:65370321	T/G	cg23373153	chr14:65346875	NA	-1.01	-8.51	-0.42	6.09e-16	Pediatric areal bone mineral density (radius);
LUSC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg07424592	chr7:64974309	NA	0.63	5.69	0.3	2.81e-8	Diabetic kidney disease;
LUSC	cis	rs11585357	0.793	rs11587669	chr1:17616259	C/T	cg08277548	chr1:17600880	PADI3	-0.63	-6.51	-0.34	2.7e-10	Hair shape;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14974841	chr3:51975970	PARP3;RRP9	-0.41	-6.01	-0.31	4.81e-9	Electrocardiographic conduction measures;
LUSC	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg16576597	chr16:28551801	NUPR1	-0.32	-6.31	-0.33	9.02e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg04310649	chr10:35416472	CREM	-0.41	-6.32	-0.33	8.54e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg13057898	chr1:3703894	LRRC47	0.51	8.88	0.44	4.14e-17	Red cell distribution width;
LUSC	cis	rs909002	0.800	rs3753613	chr1:32082000	C/T	cg01639898	chr1:32083012	HCRTR1	-0.32	-7.72	-0.39	1.34e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs74181299	0.927	rs2723064	chr2:65279805	T/C	cg05010058	chr2:65284262	CEP68	0.31	6.21	0.32	1.54e-9	Pulse pressure;
LUSC	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.98	-0.36	1.63e-11	Neuroticism;
LUSC	cis	rs7613051	0.947	rs13093698	chr3:33063050	A/G	cg19000631	chr3:33138515	GLB1;TMPPE	0.49	5.84	0.3	1.24e-8	Atopic dermatitis;
LUSC	cis	rs9653442	0.564	rs56054309	chr2:100794940	T/C	cg07810366	chr2:100720526	AFF3	-0.42	-7.18	-0.37	4.46e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	ch.11.42038R	chr11:967971	AP2A2	0.47	7.07	0.36	8.92e-12	Alzheimer's disease (late onset);
LUSC	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.01	0.4	1.89e-14	Corneal astigmatism;
LUSC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg07741184	chr6:167504864	NA	0.38	6.8	0.35	4.7e-11	Crohn's disease;
LUSC	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07080220	chr10:102295463	HIF1AN	-0.62	-8.25	-0.41	3.73e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12618769	0.597	rs3754891	chr2:99088018	T/C	cg10123293	chr2:99228465	UNC50	0.43	7.06	0.36	9.74e-12	Bipolar disorder;
LUSC	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg21033440	chr11:65409861	SIPA1	-0.51	-7.47	-0.38	6.93e-13	Blood pressure (age interaction);
LUSC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg18850127	chr7:39170497	POU6F2	0.63	10.19	0.49	2.09e-21	IgG glycosylation;
LUSC	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.38	-0.37	1.23e-12	Psoriasis;
LUSC	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg26597838	chr10:835615	NA	0.52	6.07	0.32	3.42e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs977987	0.806	rs4888383	chr16:75386349	C/T	cg04384234	chr16:75411784	CFDP1	-0.39	-6.25	-0.32	1.22e-9	Dupuytren's disease;
LUSC	cis	rs3736594	0.879	rs77154381	chr2:27982119	A/G	cg27432699	chr2:27873401	GPN1	0.65	9.21	0.45	3.79e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg02038168	chr22:39784481	NA	-0.49	-7.88	-0.4	4.79e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.41	6.23	0.32	1.41e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.46	0.38	7.78e-13	Motion sickness;
LUSC	cis	rs4654899	1.000	rs10799685	chr1:21465930	A/C	cg01072550	chr1:21505969	NA	0.53	8.19	0.41	5.55e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06850241	chr22:41845214	NA	0.34	6.3	0.33	9.5e-10	Vitiligo;
LUSC	cis	rs10779751	1.000	rs6670821	chr1:11308762	T/C	cg08854313	chr1:11322531	MTOR	0.87	14.95	0.63	4.62e-39	Body mass index;
LUSC	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg03465714	chr1:152285911	FLG	-0.36	-6.41	-0.33	4.84e-10	Inflammatory skin disease;
LUSC	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.29	-0.41	2.82e-15	Mean platelet volume;
LUSC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	20.42	0.75	1.03e-60	Prudent dietary pattern;
LUSC	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg02574844	chr11:5959923	NA	-0.43	-5.96	-0.31	6.58e-9	DNA methylation (variation);
LUSC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg14895029	chr7:2775587	GNA12	-0.42	-6.44	-0.33	4.22e-10	Height;
LUSC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-7.66	-0.39	2.01e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg06074448	chr4:187884817	NA	0.4	6.78	0.35	5.38e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg22800045	chr5:56110881	MAP3K1	0.77	9.59	0.46	2.16e-19	Initial pursuit acceleration;
LUSC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg21251018	chr6:28226885	NKAPL	0.33	6.38	0.33	5.84e-10	Pubertal anthropometrics;
LUSC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg27121462	chr16:89883253	FANCA	-0.54	-8.59	-0.43	3.34e-16	Vitiligo;
LUSC	cis	rs6740322	0.895	rs28456986	chr2:43553321	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-7.49	-0.38	6.29e-13	Coronary artery disease;
LUSC	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.44	6.57	0.34	1.89e-10	Axial length;
LUSC	cis	rs4363385	0.818	rs4452994	chr1:152986871	G/A	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.16	-0.36	5.23e-12	Inflammatory skin disease;
LUSC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg18512352	chr11:47633146	NA	-0.46	-9.25	-0.45	2.82e-18	Subjective well-being;
LUSC	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg03806693	chr22:41940476	POLR3H	0.93	13.54	0.6	1.3e-33	Vitiligo;
LUSC	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg10760299	chr15:45669010	GATM	0.4	5.68	0.3	2.99e-8	Homoarginine levels;
LUSC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg23711669	chr6:146136114	FBXO30	0.76	13.58	0.6	9.51e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg21724239	chr8:58056113	NA	0.69	7.54	0.38	4.44e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9807989	0.839	rs3755276	chr2:102978459	C/T	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.5e-9	Asthma;
LUSC	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg02493740	chr2:85810744	VAMP5	-0.53	-9.2	-0.45	3.97e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10489202	1.000	rs718885	chr1:167954659	A/G	cg24449463	chr1:168025552	DCAF6	-0.58	-7.37	-0.37	1.32e-12	Schizophrenia;
LUSC	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	0.87	14.27	0.62	2.11e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs28735056	0.508	rs67651675	chr18:77673562	A/G	cg20368463	chr18:77673604	PQLC1	-1.0	-19.3	-0.73	2.84e-56	Schizophrenia;
LUSC	cis	rs2219968	0.962	rs6999835	chr8:78948855	T/C	cg00738934	chr8:78996279	NA	0.37	6.62	0.34	1.47e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6426558	0.559	rs2813947	chr1:227459413	G/T	cg10327440	chr1:227177885	CDC42BPA	0.55	7.41	0.38	1.02e-12	Neutrophil percentage of white cells;
LUSC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04871131	chr7:94954202	PON1	-0.38	-6.75	-0.35	6.73e-11	Paraoxonase activity;
LUSC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg12927641	chr6:109611667	NA	-0.43	-7.6	-0.38	2.93e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11645453	chr3:52864694	ITIH4	0.38	8.65	0.43	2.25e-16	Bipolar disorder;
LUSC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.3	-0.33	9.44e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg10255544	chr17:80519551	FOXK2	0.41	6.73	0.35	7.32e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.9	0.31	8.8e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg10756647	chr7:56101905	PSPH	0.87	8.46	0.42	8.27e-16	Diabetic kidney disease;
LUSC	cis	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.29	-0.41	2.72e-15	Coronary artery disease;
LUSC	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	0.88	13.86	0.6	7.72e-35	Blood protein levels;
LUSC	cis	rs4363385	0.747	rs2075739	chr1:152975495	G/A	cg25856811	chr1:152973957	SPRR3	-0.34	-5.65	-0.3	3.43e-8	Inflammatory skin disease;
LUSC	cis	rs17030434	1.000	rs12646758	chr4:154731625	A/G	cg14289246	chr4:154710475	SFRP2	-0.52	-6.96	-0.36	1.82e-11	Electrocardiographic conduction measures;
LUSC	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.28	0.32	1.08e-9	Corneal astigmatism;
LUSC	cis	rs710216	0.957	rs841570	chr1:43435571	C/G	cg03128534	chr1:43423976	SLC2A1	0.45	5.74	0.3	2.1e-8	Red cell distribution width;
LUSC	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg00012203	chr2:219082015	ARPC2	-0.77	-12.98	-0.58	1.74e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs6494488	0.500	rs112226132	chr15:64911475	A/G	cg08069370	chr15:64387884	SNX1	-0.65	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	cis	rs12776158	0.901	rs56979471	chr10:71216760	G/A	cg12610070	chr10:71211762	TSPAN15	-0.46	-6.05	-0.31	3.9e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9039	0.959	rs12148920	chr16:9183900	C/G	cg08831531	chr16:9218945	NA	0.66	10.28	0.49	9.93e-22	Menopause (age at onset);
LUSC	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21545522	chr1:205238299	TMCC2	-0.47	-8.97	-0.44	2.16e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg18357645	chr12:58087776	OS9	0.58	8.75	0.43	1.05e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.81	0.35	4.44e-11	Rheumatoid arthritis;
LUSC	trans	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs6901250	0.523	rs592669	chr6:117090944	T/C	cg12892004	chr6:117198278	RFX6	0.37	6.63	0.34	1.34e-10	C-reactive protein levels;
LUSC	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg25457927	chr22:38595422	NA	-0.34	-6.81	-0.35	4.62e-11	Cutaneous nevi;
LUSC	cis	rs7147624	0.882	rs1956008	chr14:66085429	G/T	cg03016385	chr14:66212404	NA	-0.82	-9.13	-0.45	6.78e-18	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3847687	0.901	rs12370258	chr12:131527301	G/T	cg25772418	chr12:131519998	GPR133	-0.27	-5.82	-0.3	1.4e-8	Longevity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11332484	chr1:20208967	OTUD3	-0.44	-6.53	-0.34	2.5e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.63	-10.04	-0.48	6.71e-21	Longevity;Endometriosis;
LUSC	cis	rs41271473	1.000	rs17352654	chr1:228878193	T/C	cg10167378	chr1:228756711	NA	0.54	6.59	0.34	1.72e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs9473147	0.516	rs9381564	chr6:47443806	A/G	cg20196966	chr6:47445060	CD2AP	0.42	5.78	0.3	1.74e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg04117972	chr1:227635322	NA	0.74	7.79	0.39	8.75e-14	Major depressive disorder;
LUSC	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	6.52	0.34	2.61e-10	Schizophrenia;
LUSC	cis	rs3789045	0.560	rs4626956	chr1:204407298	T/C	cg17419461	chr1:204415978	PIK3C2B	-0.51	-5.9	-0.31	9.07e-9	Educational attainment (college completion);
LUSC	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg12552261	chr5:112820674	MCC	-0.42	-6.77	-0.35	5.78e-11	Type 2 diabetes;
LUSC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-0.91	-16.63	-0.67	1.17e-45	Cognitive function;
LUSC	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg05043794	chr9:111880884	C9orf5	-0.4	-8.75	-0.43	1.09e-16	Menarche (age at onset);
LUSC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg20887711	chr4:1340912	KIAA1530	0.42	6.18	0.32	1.87e-9	Obesity-related traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20696912	chr3:183146011	MCF2L2	-0.4	-6.04	-0.31	4.05e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs11264799	0.765	rs12125713	chr1:157636657	A/G	cg18268488	chr1:157545234	FCRL4	0.33	5.8	0.3	1.53e-8	IgA nephropathy;
LUSC	trans	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg21775007	chr8:11205619	TDH	-0.45	-6.43	-0.33	4.31e-10	Mood instability;
LUSC	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.93	0.31	7.45e-9	Lung cancer;
LUSC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.76	-10.36	-0.49	5.26e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs56283067	0.887	rs12215095	chr6:44756910	T/C	cg18551225	chr6:44695536	NA	-0.46	-7.41	-0.38	1.01e-12	Total body bone mineral density;
LUSC	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg00277334	chr10:82204260	NA	-0.49	-6.77	-0.35	5.73e-11	Post bronchodilator FEV1;
LUSC	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg09835421	chr16:68378352	PRMT7	-0.54	-6.12	-0.32	2.56e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg06784218	chr1:46089804	CCDC17	0.31	5.69	0.3	2.81e-8	Platelet count;
LUSC	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg03647239	chr10:116582469	FAM160B1	0.44	7.14	0.36	5.78e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9311676	0.656	rs4681679	chr3:58332068	A/G	cg26110898	chr3:58419937	PDHB	-0.43	-6.96	-0.36	1.85e-11	Systemic lupus erythematosus;
LUSC	cis	rs6977660	0.714	rs6945533	chr7:19813913	G/C	cg07541023	chr7:19748670	TWISTNB	0.66	7.21	0.37	3.71e-12	Thyroid stimulating hormone;
LUSC	cis	rs3824867	0.920	rs3740684	chr11:47468820	C/T	cg20307385	chr11:47447363	PSMC3	0.64	9.48	0.46	4.83e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs3740713	0.748	rs35292478	chr11:18429991	A/C	cg07915343	chr11:18477680	LDHAL6A	-0.49	-6.11	-0.32	2.84e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs3740713	0.592	rs73434674	chr11:18411497	C/A	cg07915343	chr11:18477680	LDHAL6A	-0.46	-5.84	-0.3	1.26e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs6987853	0.787	rs2923402	chr8:42445400	G/A	cg09913449	chr8:42400586	C8orf40	0.5	8.6	0.43	3.23e-16	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04565464	chr8:145669602	NFKBIL2	0.37	5.99	0.31	5.49e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6076065	0.748	rs6048779	chr20:23374709	C/G	cg11657817	chr20:23433608	CST11	0.53	11.03	0.52	2.42e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.47	-0.38	7.17e-13	Morning vs. evening chronotype;
LUSC	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg02709834	chr1:75198841	CRYZ;TYW3	0.38	5.82	0.3	1.36e-8	Resistin levels;
LUSC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg07507251	chr3:52567010	NT5DC2	0.31	5.98	0.31	5.7e-9	Bipolar disorder;
LUSC	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg03465714	chr1:152285911	FLG	-0.41	-5.86	-0.31	1.09e-8	Atopic dermatitis;
LUSC	cis	rs713477	1.000	rs10782426	chr14:55890702	G/A	cg13175173	chr14:55914753	NA	-0.29	-5.94	-0.31	7.17e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.93	15.97	0.66	4.9e-43	Morning vs. evening chronotype;
LUSC	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg05973401	chr12:123451056	ABCB9	0.51	6.24	0.32	1.33e-9	Neutrophil percentage of white cells;
LUSC	cis	rs911119	1.000	rs6515375	chr20:23610841	G/A	cg16589663	chr20:23618590	CST3	0.6	7.01	0.36	1.36e-11	Chronic kidney disease;
LUSC	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg13334819	chr7:99746414	C7orf59	0.5	6.79	0.35	5.04e-11	Coronary artery disease;
LUSC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.42e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3790645	1.000	rs369385	chr1:26893229	C/T	cg17456097	chr1:26900765	RPS6KA1	0.42	6.03	0.31	4.23e-9	Glucose homeostasis traits;
LUSC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg26380479	chr7:97908229	NA	-0.27	-5.83	-0.3	1.31e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg15691649	chr6:25882328	NA	-0.38	-6.14	-0.32	2.36e-9	Blood metabolite levels;
LUSC	cis	rs68170813	0.527	rs78133594	chr7:107025260	T/C	cg02696742	chr7:106810147	HBP1	-0.61	-8.98	-0.44	2.05e-17	Coronary artery disease;
LUSC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg17294928	chr15:75287854	SCAMP5	-0.83	-11.23	-0.52	4.94e-25	Blood trace element (Zn levels);
LUSC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg02915803	chr1:1606292	LOC728661;CDK11B	0.37	5.7	0.3	2.59e-8	Body mass index;
LUSC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg13256891	chr4:100009986	ADH5	-0.46	-6.44	-0.33	4.23e-10	Alcohol dependence;
LUSC	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg24375607	chr4:120327624	NA	0.75	11.05	0.52	2.18e-24	Corneal astigmatism;
LUSC	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg09307838	chr4:120376055	NA	0.75	10.72	0.51	3.04e-23	Corneal astigmatism;
LUSC	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.93	-0.4	3.42e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.66	14.47	0.62	3.51e-37	Hemoglobin concentration;
LUSC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21016266	chr12:122356598	WDR66	0.58	8.74	0.43	1.17e-16	Mean corpuscular volume;
LUSC	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15664640	chr17:80829946	TBCD	-0.75	-13.68	-0.6	3.81e-34	Breast cancer;
LUSC	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg23711669	chr6:146136114	FBXO30	0.88	16.22	0.66	4.78e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11650494	0.908	rs74830554	chr17:47431950	G/A	cg08112188	chr17:47440006	ZNF652	1.27	10.65	0.5	5.39e-23	Prostate cancer;
LUSC	trans	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg06606381	chr12:133084897	FBRSL1	0.6	6.03	0.31	4.39e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.38	0.33	5.94e-10	Personality dimensions;
LUSC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg05163923	chr11:71159392	DHCR7	0.75	11.19	0.52	6.57e-25	Vitamin D levels;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24341944	chr3:157827791	RSRC1	0.36	6.02	0.31	4.53e-9	Triglycerides;
LUSC	cis	rs9473147	0.516	rs9395286	chr6:47575332	T/C	cg20196966	chr6:47445060	CD2AP	0.43	6.07	0.32	3.55e-9	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27252137	chr12:124155579	TCTN2	0.5	6.78	0.35	5.32e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	0.8	9.85	0.47	2.9e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg26924012	chr15:45694286	SPATA5L1	0.8	12.45	0.56	1.8e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg05855489	chr10:104503620	C10orf26	-0.71	-10.34	-0.49	6.51e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.11e-11	Crohn's disease;
LUSC	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg17143192	chr8:8559678	CLDN23	0.6	8.07	0.4	1.26e-14	Obesity-related traits;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg17749735	chr1:155051360	EFNA3	0.36	6.07	0.32	3.52e-9	Schizophrenia (age at onset);
LUSC	cis	rs6063312	0.935	rs6066827	chr20:47341005	T/C	cg18078177	chr20:47281410	PREX1	0.61	7.34	0.37	1.67e-12	Tonometry;
LUSC	cis	rs6545883	0.602	rs11125871	chr2:61470126	C/T	cg15711740	chr2:61764176	XPO1	0.4	6.15	0.32	2.21e-9	Tuberculosis;
LUSC	cis	rs12042938	0.902	rs1094658	chr1:231773397	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.43	6.28	0.33	1.05e-9	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg06627628	chr2:24431161	ITSN2	-0.58	-8.19	-0.41	5.69e-15	Asthma;
LUSC	cis	rs2667011	0.570	rs4664305	chr2:160859235	A/G	cg06573604	chr2:160760825	LY75	0.48	6.67	0.34	1.03e-10	Bilirubin levels;
LUSC	cis	rs11031096	0.702	rs11030980	chr11:4130543	C/G	cg18678763	chr11:4115507	RRM1	0.38	5.72	0.3	2.39e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg02487499	chr1:33937968	ZSCAN20	0.48	6.14	0.32	2.32e-9	Neuroticism;
LUSC	cis	rs72781680	0.716	rs78332127	chr2:24150163	C/G	cg08917208	chr2:24149416	ATAD2B	0.6	6.85	0.35	3.66e-11	Lymphocyte counts;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25858983	chr17:42295711	UBTF	-0.36	-6.18	-0.32	1.83e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-6.11	-0.32	2.77e-9	Major depressive disorder;
LUSC	cis	rs2658782	0.654	rs2605617	chr11:93243333	T/C	cg15737290	chr11:93063684	CCDC67	0.64	8.11	0.41	9.62e-15	Pulmonary function decline;
LUSC	cis	rs73198271	0.855	rs57301822	chr8:8608642	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.63	-0.34	1.37e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg23173402	chr1:227635558	NA	0.56	6.28	0.32	1.07e-9	Major depressive disorder;
LUSC	cis	rs539096	0.692	rs6669157	chr1:44216876	T/C	cg15962314	chr1:44399869	ARTN	0.24	5.73	0.3	2.28e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg15117754	chr3:10150083	C3orf24	0.44	5.71	0.3	2.53e-8	Alzheimer's disease;
LUSC	cis	rs9341808	0.718	rs9448898	chr6:80845341	T/A	cg08355045	chr6:80787529	NA	0.57	10.03	0.48	6.94e-21	Sitting height ratio;
LUSC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10862848	chr6:42927986	GNMT	-0.28	-6.56	-0.34	2.01e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg09517075	chr8:22133004	PIWIL2	0.41	8.18	0.41	6.01e-15	Hypertriglyceridemia;
LUSC	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg15556689	chr8:8085844	FLJ10661	0.56	8.54	0.42	4.93e-16	Retinal vascular caliber;
LUSC	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg02574844	chr11:5959923	NA	-0.42	-6.06	-0.31	3.6e-9	DNA methylation (variation);
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg23034840	chr1:205782522	SLC41A1	0.59	8.28	0.41	2.93e-15	Menarche (age at onset);
LUSC	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.71	-0.54	9.26e-27	Coffee consumption (cups per day);
LUSC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.72	14.49	0.62	2.98e-37	Breast cancer;
LUSC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg10018233	chr7:150070692	REPIN1	0.46	9.38	0.46	1.06e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2282300	0.739	rs34951229	chr11:30265166	C/G	cg25418670	chr11:30344373	C11orf46	-0.65	-9.34	-0.45	1.43e-18	Morning vs. evening chronotype;
LUSC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg23719950	chr11:63933701	MACROD1	-0.38	-6.08	-0.32	3.31e-9	Platelet count;
LUSC	cis	rs10465746	0.657	rs67045520	chr1:84414998	G/T	cg10977910	chr1:84465055	TTLL7	0.43	6.24	0.32	1.32e-9	Obesity-related traits;
LUSC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.43	-6.84	-0.35	3.78e-11	Mean platelet volume;
LUSC	cis	rs8038465	0.967	rs61012032	chr15:73973978	C/T	cg15420318	chr15:73925796	NPTN	0.43	7.01	0.36	1.36e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg11984989	chr7:158649758	WDR60	1.1	13.96	0.61	3.25e-35	Height;
LUSC	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg17410650	chr12:54324560	NA	-0.58	-9.95	-0.48	1.3e-20	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs644799	0.511	rs11021302	chr11:95485768	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	7.46	0.38	7.77e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.11	-0.36	7.21e-12	Urate levels;
LUSC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.43	6.88	0.35	3.03e-11	Menopause (age at onset);
LUSC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.47	0.38	7.16e-13	Motion sickness;
LUSC	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.77	-0.43	9.17e-17	Response to antipsychotic treatment;
LUSC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg20476274	chr7:133979776	SLC35B4	0.8	13.24	0.59	1.79e-32	Mean platelet volume;
LUSC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-8.61	-0.43	2.94e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg27490568	chr2:178487706	NA	-0.42	-5.78	-0.3	1.73e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7197653	0.667	rs16957831	chr16:68378341	C/T	cg09835421	chr16:68378352	PRMT7	-0.76	-8.49	-0.42	7.06e-16	Magnesium levels;
LUSC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg22868518	chr11:507468	RNH1	-0.6	-6.04	-0.31	4.07e-9	Body mass index;
LUSC	cis	rs35094601	0.731	rs10180719	chr2:139214202	C/T	cg10095539	chr2:139258744	SPOPL	0.25	5.86	0.31	1.13e-8	Schizophrenia;
LUSC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg24531977	chr5:56204891	C5orf35	-0.72	-10.33	-0.49	6.8e-22	Coronary artery disease;
LUSC	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg17127132	chr2:85788382	GGCX	0.44	7.0	0.36	1.43e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.69	0.34	9.21e-11	IgG glycosylation;
LUSC	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.17	-0.32	1.92e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg02800362	chr5:177631904	HNRNPAB	0.88	13.12	0.58	5.45e-32	Obesity-related traits;
LUSC	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.39	-0.46	9.7e-19	Bone mineral density;
LUSC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg16405210	chr4:1374714	KIAA1530	-0.56	-8.26	-0.41	3.53e-15	Obesity-related traits;
LUSC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.44	-10.04	-0.48	6.63e-21	Schizophrenia;
LUSC	trans	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg15704280	chr7:45808275	SEPT13	-0.53	-6.12	-0.32	2.57e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-11.55	-0.53	3.45e-26	Migraine;Coronary artery disease;
LUSC	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg00898013	chr13:113819073	PROZ	-0.64	-8.93	-0.44	2.89e-17	Platelet distribution width;
LUSC	cis	rs524023	1.000	rs559946	chr11:64358605	T/C	cg19131476	chr11:64387923	NRXN2	0.37	9.84	0.47	3.17e-20	Urate levels in obese individuals;
LUSC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg06640241	chr16:89574553	SPG7	0.84	14.95	0.63	4.7e-39	Multiple myeloma (IgH translocation);
LUSC	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.36e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg07212818	chr11:638076	DRD4	-0.38	-6.49	-0.33	3.07e-10	Systemic lupus erythematosus;
LUSC	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg23241863	chr10:102295624	HIF1AN	0.49	5.98	0.31	5.84e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1775715	0.677	rs2808105	chr10:32110907	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.75	0.35	6.68e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg22166914	chr1:53195759	ZYG11B	0.68	11.41	0.53	1.08e-25	Monocyte count;
LUSC	cis	rs4713675	0.505	rs753890	chr6:33652880	G/A	cg14003231	chr6:33640908	ITPR3	0.33	6.16	0.32	2.04e-9	Plateletcrit;
LUSC	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-1.1	-16.62	-0.67	1.3e-45	Exhaled nitric oxide output;
LUSC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.26	-0.32	1.2e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg24069376	chr3:38537580	EXOG	0.41	7.95	0.4	2.89e-14	Electrocardiographic conduction measures;
LUSC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg04155289	chr7:94953770	PON1	-0.36	-5.9	-0.31	9.16e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	0.9	17.07	0.68	2.11e-47	Menarche (age at onset);
LUSC	cis	rs72960926	1.000	rs72969218	chr6:75042124	T/G	cg03266952	chr6:74778945	NA	-0.76	-6.4	-0.33	5.11e-10	Metabolite levels (MHPG);
LUSC	cis	rs593982	0.920	rs72939198	chr11:65438079	G/A	cg08755490	chr11:65554678	OVOL1	-1.56	-11.97	-0.55	1.06e-27	Atopic dermatitis;
LUSC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.26	0.32	1.19e-9	Mean platelet volume;
LUSC	cis	rs61990749	0.597	rs176952	chr14:78180736	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.59	6.45	0.33	3.85e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs2953174	0.786	rs8662	chr2:241517770	G/A	cg07929629	chr2:241523174	NA	0.53	8.06	0.4	1.34e-14	Bipolar disorder;
LUSC	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	7.82	0.39	6.89e-14	Retinal vascular caliber;
LUSC	cis	rs11997175	0.574	rs4389890	chr8:33658018	C/T	ch.8.33884649F	chr8:33765107	NA	0.55	9.44	0.46	6.83e-19	Body mass index;
LUSC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg22823121	chr1:150693482	HORMAD1	0.5	7.44	0.38	8.47e-13	Melanoma;
LUSC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	0.96	18.5	0.71	4.06e-53	Heart rate;
LUSC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.55e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.68	-0.57	2.41e-30	Chronic sinus infection;
LUSC	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg26875233	chr11:93583750	C11orf90	-0.31	-6.07	-0.32	3.45e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18099408	chr3:52552593	STAB1	-0.43	-6.97	-0.36	1.7e-11	Bipolar disorder;
LUSC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg01283332	chr5:1856932	NA	-0.34	-6.46	-0.33	3.73e-10	Cardiovascular disease risk factors;
LUSC	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.42	6.51	0.34	2.78e-10	Dupuytren's disease;
LUSC	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.42	-0.42	1.09e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg24879335	chr3:133465180	TF	0.45	7.83	0.39	6.33e-14	Iron status biomarkers (transferrin levels);
LUSC	cis	rs4285028	0.580	rs1523519	chr3:121631841	C/T	cg11130432	chr3:121712080	ILDR1	-0.49	-8.15	-0.41	7.15e-15	Multiple sclerosis;
LUSC	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg01420254	chr6:26195488	NA	0.48	5.94	0.31	7.2e-9	Gout;Renal underexcretion gout;
LUSC	cis	rs7289126	0.966	rs5995554	chr22:38630272	T/C	cg25457927	chr22:38595422	NA	-0.29	-5.65	-0.3	3.53e-8	Mammographic density (dense area);Percent mammographic density;
LUSC	trans	rs724744	0.804	rs1205940	chr6:22357113	G/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.05	-0.31	3.89e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg10633931	chr6:34164263	NA	0.73	6.02	0.31	4.72e-9	Cognitive performance;
LUSC	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg00540400	chr15:79124168	NA	0.46	7.91	0.4	3.85e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-0.82	-11.43	-0.53	9.09e-26	Response to hepatitis C treatment;
LUSC	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg18827107	chr12:86230957	RASSF9	0.44	6.77	0.35	5.96e-11	Major depressive disorder;
LUSC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg13722127	chr7:150037890	RARRES2	0.38	5.79	0.3	1.63e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg05985134	chr18:33552581	C18orf21	0.5	6.73	0.35	7.6e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.32	-0.33	8.49e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg27411982	chr8:10470053	RP1L1	0.44	6.62	0.34	1.47e-10	Retinal vascular caliber;
LUSC	cis	rs2742417	1.000	rs2742373	chr3:45784046	C/G	cg04837898	chr3:45731254	SACM1L	-0.38	-6.33	-0.33	7.75e-10	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs55665837	1.000	rs12276938	chr11:14463488	C/G	cg05501817	chr11:14380813	RRAS2	-0.4	-6.31	-0.33	8.87e-10	Vitamin D levels;
LUSC	trans	rs2055729	0.736	rs11249965	chr8:9740863	C/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.43	-0.33	4.49e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs10465746	0.780	rs10874423	chr1:84374071	C/T	cg10977910	chr1:84465055	TTLL7	0.44	6.23	0.32	1.42e-9	Obesity-related traits;
LUSC	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg09323728	chr8:95962352	TP53INP1	-0.3	-5.69	-0.3	2.78e-8	Type 2 diabetes;
LUSC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg06028605	chr16:24865363	SLC5A11	-0.51	-8.98	-0.44	1.98e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.31	-0.33	8.68e-10	Total body bone mineral density;
LUSC	cis	rs738321	0.756	rs12169611	chr22:38513735	T/C	cg25457927	chr22:38595422	NA	-0.32	-6.11	-0.32	2.8e-9	Breast cancer;
LUSC	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg23093090	chr10:104574429	C10orf26	-0.46	-8.34	-0.42	2.01e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.04	0.48	6.68e-21	Birth weight;
LUSC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.09	0.61	1.02e-35	Platelet count;
LUSC	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.72	11.06	0.52	1.99e-24	Alcohol dependence;
LUSC	trans	rs4714291	0.963	rs2475496	chr6:39963850	A/G	cg02267698	chr19:7991119	CTXN1	0.5	7.04	0.36	1.13e-11	Strep throat;
LUSC	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-16.0	-0.66	3.67e-43	Exhaled nitric oxide output;
LUSC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg04851639	chr8:1020857	NA	-0.39	-7.84	-0.39	5.93e-14	Schizophrenia;
LUSC	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.4	0.38	1.11e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg21132104	chr15:45694354	SPATA5L1	0.57	7.96	0.4	2.63e-14	Homoarginine levels;
LUSC	cis	rs2625529	0.652	rs8027164	chr15:72407733	A/T	cg16672083	chr15:72433130	SENP8	0.49	8.14	0.41	7.93e-15	Red blood cell count;
LUSC	cis	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg17218026	chr1:154582156	ADAR	-0.5	-8.53	-0.42	5.25e-16	Blood protein levels;
LUSC	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	8.74	0.43	1.14e-16	Systolic blood pressure;
LUSC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg14019146	chr3:50243930	SLC38A3	0.32	7.09	0.36	7.92e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs62400317	0.859	rs17209678	chr6:45163601	C/T	cg18551225	chr6:44695536	NA	-0.45	-7.22	-0.37	3.47e-12	Total body bone mineral density;
LUSC	cis	rs2307022	0.586	rs1562479	chr16:68387373	C/T	cg02226672	chr16:68398533	SMPD3	0.3	5.82	0.3	1.42e-8	Body mass index;
LUSC	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg13010199	chr12:38710504	ALG10B	0.69	10.88	0.51	8.56e-24	Morning vs. evening chronotype;
LUSC	cis	rs7582720	1.000	rs72926769	chr2:203798318	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg26924012	chr15:45694286	SPATA5L1	1.12	19.49	0.73	4.86e-57	Homoarginine levels;
LUSC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21963583	chr11:68658836	MRPL21	0.55	8.45	0.42	9.37e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg00343986	chr7:65444356	GUSB	0.48	7.16	0.36	5.26e-12	Calcium levels;
LUSC	trans	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg25214090	chr10:38739885	LOC399744	0.43	6.53	0.34	2.51e-10	Corneal astigmatism;
LUSC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg25019033	chr10:957182	NA	-0.53	-6.1	-0.32	2.91e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.77	0.35	5.8200000000000003e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	9.43	0.46	7.4e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2236918	0.687	rs2797600	chr1:242029331	C/T	cg17736920	chr1:242011382	EXO1	0.42	6.61	0.34	1.52e-10	Menopause (age at onset);
LUSC	trans	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg18335740	chr13:41363409	SLC25A15	0.79	14.99	0.63	3.41e-39	Lewy body disease;
LUSC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg13683864	chr3:40499215	RPL14	-1.13	-21.95	-0.77	9.5e-67	Renal cell carcinoma;
LUSC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg22823121	chr1:150693482	HORMAD1	0.58	9.09	0.45	8.66e-18	Tonsillectomy;
LUSC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.89	0.44	3.86e-17	Schizophrenia;
LUSC	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg12963246	chr6:28129442	ZNF389	0.54	7.61	0.38	2.73e-13	Depression;
LUSC	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg26354017	chr1:205819088	PM20D1	-0.42	-5.76	-0.3	1.9e-8	Parkinson's disease;
LUSC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13126279	chr21:47581558	C21orf56	-0.56	-8.67	-0.43	1.86e-16	Testicular germ cell tumor;
LUSC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg05084668	chr3:125655381	ALG1L	-0.49	-6.99	-0.36	1.49e-11	Blood pressure (smoking interaction);
LUSC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg17279839	chr7:150038598	RARRES2	0.48	7.6	0.38	3.05e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs75804782	0.641	rs3769123	chr2:239349328	C/G	cg18131467	chr2:239335373	ASB1	-0.73	-6.63	-0.34	1.37e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.6	-5.73	-0.3	2.28e-8	Major depressive disorder;
LUSC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg05082376	chr22:42548792	NA	0.43	6.47	0.33	3.4e-10	Schizophrenia;
LUSC	trans	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg10756647	chr7:56101905	PSPH	-0.87	-8.68	-0.43	1.81e-16	Diabetic kidney disease;
LUSC	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg06191203	chr2:152266755	RIF1	-0.52	-7.13	-0.36	6.27e-12	Lung cancer;
LUSC	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg11845111	chr2:191398756	TMEM194B	-0.89	-11.07	-0.52	1.83e-24	Diastolic blood pressure;
LUSC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs926938	0.765	rs2268701	chr1:115233046	C/T	cg12756093	chr1:115239321	AMPD1	-0.56	-8.86	-0.44	4.81e-17	Autism;
LUSC	cis	rs926392	0.572	rs6129159	chr20:37675011	A/T	cg16355469	chr20:37678765	NA	0.54	7.47	0.38	7.3e-13	Dialysis-related mortality;
LUSC	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17507749	chr15:85114479	UBE2QP1	0.58	7.38	0.37	1.3e-12	Schizophrenia;
LUSC	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.71	-8.37	-0.42	1.59e-15	Refractive error;
LUSC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	15.92	0.66	7.26e-43	Platelet count;
LUSC	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg10578777	chr12:7781093	NA	0.57	6.31	0.33	8.68e-10	HDL cholesterol levels;
LUSC	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg11861562	chr11:117069780	TAGLN	0.35	6.71	0.34	8.11e-11	Blood protein levels;
LUSC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg06697600	chr4:7070879	GRPEL1	-0.39	-6.55	-0.34	2.24e-10	Monocyte percentage of white cells;
LUSC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.4	0.53	1.16e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs3857536	0.813	rs6931701	chr6:66940905	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs7106204	0.514	rs7107321	chr11:24259879	T/C	ch.11.24196551F	chr11:24239977	NA	0.83	8.6	0.43	3.21e-16	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.46	0.53	7.16e-26	Eye color traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04732910	chr12:69201696	MDM2	-0.46	-6.93	-0.35	2.23e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg08345082	chr10:99160200	RRP12	-0.41	-7.95	-0.4	2.99e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	6.87	0.35	3.09e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4356932	0.967	rs7659236	chr4:76953611	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg26408565	chr15:76604113	ETFA	-0.52	-8.41	-0.42	1.19e-15	Blood metabolite levels;
LUSC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg02475777	chr4:1388615	CRIPAK	0.43	6.36	0.33	6.48e-10	Obesity-related traits;
LUSC	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg09904177	chr6:26538194	HMGN4	0.73	13.27	0.59	1.45e-32	Intelligence (multi-trait analysis);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg18807929	chr2:217558075	IGFBP5	0.4	6.13	0.32	2.42e-9	N-glycan levels;
LUSC	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg09184832	chr6:79620586	NA	-0.44	-7.09	-0.36	8.12e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01341218	chr17:43662625	NA	0.76	11.13	0.52	1.07e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg02030672	chr11:45687055	CHST1	0.49	7.81	0.39	7.6e-14	Obesity-related traits;
LUSC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12681287	0.547	rs7459877	chr8:87505660	G/A	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg14689365	chr7:158441557	NCAPG2	0.51	7.4	0.38	1.13e-12	Height;
LUSC	cis	rs10761482	0.954	rs10761475	chr10:62061257	T/C	cg18175470	chr10:62150864	ANK3	-0.48	-6.56	-0.34	2.1e-10	Schizophrenia;
LUSC	trans	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg05839875	chr5:39203190	FYB	-0.32	-6.03	-0.31	4.39e-9	Prostate cancer;
LUSC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03517284	chr6:25882590	NA	-0.52	-9.72	-0.47	7.59e-20	Blood metabolite levels;
LUSC	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg05110241	chr16:68378359	PRMT7	-0.56	-6.32	-0.33	8.54e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg20887711	chr4:1340912	KIAA1530	0.43	6.67	0.34	1.07e-10	Obesity-related traits;
LUSC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.02	-0.4	1.76e-14	Bipolar disorder and schizophrenia;
LUSC	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.58	-0.42	3.61e-16	Neuroticism;
LUSC	cis	rs698813	0.572	rs12712914	chr2:44478649	C/G	cg00619915	chr2:44497795	NA	-0.53	-7.6	-0.38	2.97e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12791010	chr2:190305806	WDR75	0.46	6.68	0.34	9.87e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12618769	0.597	rs3769730	chr2:99101453	T/C	cg10123293	chr2:99228465	UNC50	0.47	7.67	0.39	1.89e-13	Bipolar disorder;
LUSC	cis	rs4478858	0.735	rs1566964	chr1:31792794	C/A	cg00250761	chr1:31883323	NA	-0.35	-8.75	-0.43	1.09e-16	Alcohol dependence;
LUSC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.39	0.56	2.97e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg00432049	chr6:150390894	ULBP3	-0.27	-5.74	-0.3	2.11e-8	Alopecia areata;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23979971	chr5:138677953	PAIP2	-0.53	-6.8	-0.35	4.7e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs2835872	0.759	rs2835895	chr21:39066353	C/T	cg20424643	chr21:39039972	KCNJ6	0.42	6.46	0.33	3.74e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg16230307	chr14:35515116	FAM177A1	0.57	7.36	0.37	1.43e-12	Psoriasis;
LUSC	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg06951627	chr6:26196580	NA	0.53	5.72	0.3	2.39e-8	Gout;Renal underexcretion gout;
LUSC	trans	rs6601327	0.670	rs10092751	chr8:9426325	T/C	cg15556689	chr8:8085844	FLJ10661	0.44	6.22	0.32	1.47e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg05738196	chr6:26577821	NA	-0.76	-14.67	-0.63	5.88e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg08999081	chr20:33150536	PIGU	-0.37	-6.83	-0.35	3.97e-11	Height;
LUSC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg25258033	chr6:167368657	RNASET2	0.47	7.83	0.39	6.33e-14	Crohn's disease;
LUSC	cis	rs10992471	0.603	rs10761160	chr9:95208701	A/T	cg14631576	chr9:95140430	CENPP	-0.35	-6.47	-0.33	3.54e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg23497857	chr14:24685372	MDP1	-0.45	-7.05	-0.36	1.05e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg19622623	chr12:86230825	RASSF9	-0.43	-6.11	-0.32	2.77e-9	Major depressive disorder;
LUSC	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg13390004	chr1:15929781	NA	0.4	6.71	0.34	8.4e-11	Systolic blood pressure;
LUSC	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	0.58	9.31	0.45	1.69e-18	Breast cancer;
LUSC	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.34	5.71	0.3	2.54e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05165339	chr4:1420672	NA	0.29	6.5	0.33	2.98e-10	Longevity;
LUSC	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg19812747	chr11:111475976	SIK2	-0.5	-7.05	-0.36	1.05e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00166722	chr3:10149974	C3orf24	0.55	7.51	0.38	5.38e-13	Alzheimer's disease;
LUSC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg02475777	chr4:1388615	CRIPAK	0.43	6.41	0.33	4.95e-10	Obesity-related traits;
LUSC	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg10518543	chr12:38710700	ALG10B	-0.4	-5.64	-0.3	3.53e-8	Morning vs. evening chronotype;
LUSC	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg03859395	chr2:55845619	SMEK2	0.85	15.89	0.66	9.53e-43	Metabolic syndrome;
LUSC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg21984481	chr17:79567631	NPLOC4	-0.54	-9.9	-0.48	1.96e-20	Eye color traits;
LUSC	cis	rs11676348	0.935	rs13007992	chr2:218964051	G/T	cg00012203	chr2:219082015	ARPC2	-0.54	-8.52	-0.42	5.65e-16	Ulcerative colitis;
LUSC	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.79	-0.35	5.2e-11	Response to antipsychotic treatment;
LUSC	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.83	-0.39	6.71e-14	Body mass index;
LUSC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg21972741	chr5:435613	AHRR	0.36	6.86	0.35	3.25e-11	Cystic fibrosis severity;
LUSC	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg10909506	chr17:38081995	ORMDL3	0.33	5.87	0.31	1.02e-8	Self-reported allergy;
LUSC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg23625390	chr15:77176239	SCAPER	0.51	7.83	0.39	6.53e-14	Blood metabolite levels;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14813579	chr19:2328694	SPPL2B;LSM7	0.35	6.31	0.33	8.84e-10	Asthma;
LUSC	cis	rs926392	0.965	rs6129166	chr20:37688825	T/C	cg27552599	chr20:37590471	DHX35	0.33	5.69	0.3	2.85e-8	Dialysis-related mortality;
LUSC	cis	rs4665630	0.522	rs2551350	chr2:23913985	T/C	cg08063864	chr2:24346004	PFN4;LOC375190	-0.88	-7.67	-0.39	1.92e-13	Hypertension;
LUSC	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-9.45	-0.46	6.27e-19	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg13010199	chr12:38710504	ALG10B	0.62	9.02	0.44	1.49e-17	Morning vs. evening chronotype;
LUSC	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg08999081	chr20:33150536	PIGU	-0.42	-7.7	-0.39	1.53e-13	Glomerular filtration rate (creatinine);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11728497	chr12:12871887	CDKN1B	-0.43	-6.06	-0.31	3.74e-9	Hepatitis;
LUSC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg11812906	chr14:75593930	NEK9	0.65	11.14	0.52	1.03e-24	Height;
LUSC	cis	rs6840360	0.653	rs13136369	chr4:152731283	T/G	cg22705602	chr4:152727874	NA	0.28	5.92	0.31	7.79e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.43	-6.19	-0.32	1.75e-9	Longevity;Endometriosis;
LUSC	trans	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg07211511	chr3:129823064	LOC729375	-0.75	-9.75	-0.47	6.42e-20	Blood pressure (smoking interaction);
LUSC	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	16.09	0.66	1.53e-43	Platelet count;
LUSC	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg17644776	chr2:200775616	C2orf69	0.38	6.07	0.32	3.5e-9	Osteoporosis;
LUSC	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.67	10.69	0.5	3.99e-23	Body mass index (adult);
LUSC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.86	-0.35	3.34e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9646944	0.501	rs2075186	chr2:103057251	G/T	cg20060108	chr2:102954350	IL1RL1	0.47	6.56	0.34	2.08e-10	Blood protein levels;
LUSC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.42	0.42	1.16e-15	Prudent dietary pattern;
LUSC	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.83	-0.39	6.48e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.47	0.38	6.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg18681998	chr4:17616180	MED28	-0.79	-14.52	-0.62	2.28e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg19233923	chr11:63753598	OTUB1	0.36	6.33	0.33	7.75e-10	Triglycerides;
LUSC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg26566898	chr11:117069891	TAGLN	0.47	8.45	0.42	9.18e-16	Blood protein levels;
LUSC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.95	-0.31	6.92e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.48	-6.83	-0.35	4.12e-11	Monocyte count;
LUSC	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg10978503	chr1:24200527	CNR2	0.53	13.1	0.58	6.34e-32	Immature fraction of reticulocytes;
LUSC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg11062466	chr8:58055876	NA	0.75	9.12	0.45	7.24e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs6728642	0.572	rs2872686	chr2:97601024	A/G	cg26665480	chr2:98280029	ACTR1B	-0.76	-7.62	-0.38	2.67e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.5	7.19	0.37	4.32e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg03983476	chr2:10830698	NOL10	-0.37	-5.69	-0.3	2.71e-8	Prostate cancer;
LUSC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg04455712	chr21:45112962	RRP1B	0.45	8.53	0.42	5.06e-16	Mean corpuscular volume;
LUSC	cis	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-6.76	-0.35	5.99e-11	Morning vs. evening chronotype;
LUSC	cis	rs1014246	0.541	rs887195	chr10:118507976	G/A	cg14919929	chr10:118506882	NA	-0.49	-7.97	-0.4	2.55e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs3857536	0.813	rs7757118	chr6:66946661	T/C	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	trans	rs747782	0.527	rs2279822	chr11:48146114	C/T	cg15704280	chr7:45808275	SEPT13	0.71	6.42	0.33	4.6e-10	Intraocular pressure;
LUSC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.9	0.31	9.03e-9	Menopause (age at onset);
LUSC	cis	rs4380275	1.000	rs73143802	chr2:773826	T/C	cg21665850	chr2:731073	NA	0.42	6.75	0.35	6.49e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.62	9.95	0.48	1.38e-20	Blood metabolite ratios;
LUSC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.04	0.61	1.63e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1335645	0.570	rs61804624	chr1:111653917	A/G	cg00321911	chr1:111669324	DRAM2	-0.68	-6.9	-0.35	2.64e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg21226059	chr5:178986404	RUFY1	-0.64	-11.24	-0.52	4.46e-25	Lung cancer;
LUSC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11644478	chr21:40555479	PSMG1	-0.59	-9.3	-0.45	1.91e-18	Menarche (age at onset);
LUSC	cis	rs6005807	0.719	rs6005809	chr22:28942227	C/T	cg12565055	chr22:29076175	TTC28	-0.54	-5.69	-0.3	2.81e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	0.87	7.92	0.4	3.64e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg21724239	chr8:58056113	NA	0.58	7.15	0.36	5.42e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6940638	0.956	rs12199218	chr6:27025281	T/C	cg09904177	chr6:26538194	HMGN4	-0.48	-5.86	-0.31	1.13e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg22963979	chr7:1858916	MAD1L1	0.46	6.11	0.32	2.7e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	13.19	0.59	2.77e-32	Lung cancer in ever smokers;
LUSC	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg01849466	chr14:104193079	ZFYVE21	0.54	8.25	0.41	3.62e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12541635	0.677	rs6999580	chr8:107018254	C/T	cg10147462	chr8:107024639	NA	0.67	14.04	0.61	1.56e-35	Age of smoking initiation;
LUSC	cis	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg06521331	chr12:34319734	NA	-0.42	-6.46	-0.33	3.61e-10	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-10.24	-0.49	1.4e-21	Monocyte count;
LUSC	cis	rs600231	0.623	rs3015966	chr11:65217589	T/C	cg17120908	chr11:65337727	SSSCA1	-0.53	-9.16	-0.45	5.48e-18	Bone mineral density;
LUSC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg21960279	chr19:17905606	B3GNT3	0.38	5.99	0.31	5.49e-9	Tumor biomarkers;
LUSC	cis	rs7659604	0.540	rs4075065	chr4:122683906	A/G	cg20573242	chr4:122745356	CCNA2	-0.38	-5.79	-0.3	1.64e-8	Type 2 diabetes;
LUSC	cis	rs2067615	0.579	rs10861665	chr12:107193836	T/C	cg15890332	chr12:107067104	RFX4	0.34	6.18	0.32	1.91e-9	Heart rate;
LUSC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.69	-11.93	-0.55	1.44e-27	Dental caries;
LUSC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-1.13	-24.89	-0.81	4.3e-78	Height;
LUSC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19346786	chr7:2764209	NA	-0.39	-6.54	-0.34	2.37e-10	Height;
LUSC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg20503657	chr10:835505	NA	0.73	8.71	0.43	1.41e-16	Eosinophil percentage of granulocytes;
LUSC	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg18132916	chr6:79620363	NA	-0.38	-5.77	-0.3	1.8e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.81	-13.49	-0.59	2.12e-33	Aortic root size;
LUSC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg03354898	chr7:1950403	MAD1L1	-0.31	-5.89	-0.31	9.34e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs55910451	0.549	rs72772355	chr10:5813473	C/T	cg11519256	chr10:5708881	ASB13	-0.51	-6.29	-0.33	1.01e-9	Breast cancer;
LUSC	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg10978503	chr1:24200527	CNR2	0.54	13.24	0.59	1.85e-32	Immature fraction of reticulocytes;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09154213	chr1:25756855	TMEM57	-0.38	-5.97	-0.31	5.98e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg02503808	chr4:7069936	GRPEL1	0.98	14.21	0.61	3.67e-36	Monocyte percentage of white cells;
LUSC	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.82	0.43	6.43e-17	Coffee consumption (cups per day);
LUSC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg26441486	chr22:50317300	CRELD2	0.49	7.46	0.38	7.33e-13	Schizophrenia;
LUSC	cis	rs372883	0.901	rs8133749	chr21:30615935	C/T	cg24692254	chr21:30365293	RNF160	-0.41	-5.72	-0.3	2.31e-8	Pancreatic cancer;
LUSC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg23711669	chr6:146136114	FBXO30	-0.9	-16.98	-0.68	4.7e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2235649	0.798	rs9932875	chr16:1848012	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-6.02	-0.31	4.48e-9	Blood metabolite levels;
LUSC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg18190219	chr22:46762943	CELSR1	-0.48	-5.94	-0.31	7.32e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	6.07	0.31	3.56e-9	Menopause (age at onset);
LUSC	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg05925327	chr15:68127851	NA	-0.32	-5.75	-0.3	2.05e-8	Restless legs syndrome;
LUSC	cis	rs11690935	0.632	rs12998411	chr2:172530707	G/C	cg13550731	chr2:172543902	DYNC1I2	0.59	9.42	0.46	7.79e-19	Schizophrenia;
LUSC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg17554472	chr22:41940697	POLR3H	-0.47	-5.73	-0.3	2.26e-8	Vitiligo;
LUSC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg27165867	chr14:105738592	BRF1	-0.53	-7.81	-0.39	7.53e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg23985595	chr17:80112537	CCDC57	0.31	5.97	0.31	6.13e-9	Life satisfaction;
LUSC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg09455208	chr3:40491958	NA	0.59	10.38	0.49	4.46e-22	Renal cell carcinoma;
LUSC	cis	rs1982963	0.627	rs61971552	chr14:52481524	G/T	cg10843707	chr14:52510701	NID2	0.42	5.9	0.31	8.96e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27574256	chr1:52607756	ZFYVE9	-0.4	-6.07	-0.32	3.53e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.49	-6.9	-0.35	2.63e-11	Mean platelet volume;
LUSC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg06671706	chr8:8559999	CLDN23	0.48	6.58	0.34	1.82e-10	Obesity-related traits;
LUSC	cis	rs59698941	0.882	rs66537260	chr5:132309237	C/T	cg02081065	chr5:132209139	LEAP2	-0.61	-5.87	-0.31	1.03e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg05110241	chr16:68378359	PRMT7	-0.57	-6.59	-0.34	1.73e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.33	0.49	6.71e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.28	0.59	1.28e-32	Cognitive test performance;
LUSC	cis	rs2070433	0.752	rs11700468	chr21:47776391	C/T	cg12379764	chr21:47803548	PCNT	0.75	9.31	0.45	1.8e-18	Lymphocyte counts;
LUSC	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.67	-0.5	4.42e-23	Glomerular filtration rate;
LUSC	cis	rs4812048	0.649	rs6070705	chr20:57625231	A/C	cg14073986	chr20:57617431	SLMO2	0.88	9.5	0.46	4.16e-19	Mean platelet volume;
LUSC	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03605463	chr16:89740564	NA	0.45	7.17	0.37	4.97e-12	Vitiligo;
LUSC	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.58	-8.35	-0.42	1.84e-15	Hip circumference;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11905131	chr22:24372483	LOC391322	-0.6	-10.29	-0.49	9.14e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.61	12.65	0.57	3.12e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg00330888	chr2:46524148	EPAS1	0.37	6.41	0.33	5.07e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs113835537	0.529	rs3741360	chr11:66300348	A/G	cg24851651	chr11:66362959	CCS	0.55	7.97	0.4	2.62e-14	Airway imaging phenotypes;
LUSC	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg15448220	chr1:150897856	SETDB1	0.43	6.23	0.32	1.43e-9	Melanoma;
LUSC	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg15704280	chr7:45808275	SEPT13	-0.46	-6.29	-0.33	1e-9	HDL cholesterol;
LUSC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	0.6	9.36	0.46	1.17e-18	Breast cancer;
LUSC	cis	rs12900413	0.687	rs28475471	chr15:90311749	C/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.85	-0.3	1.17e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs4919087	1.000	rs10786333	chr10:99090390	A/G	cg25902810	chr10:99078978	FRAT1	-0.46	-6.66	-0.34	1.15e-10	Monocyte count;
LUSC	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-6.61	-0.34	1.48e-10	Mean platelet volume;
LUSC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.63	7.68	0.39	1.79e-13	Lung function (FEV1/FVC);
LUSC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06022373	chr22:39101656	GTPBP1	0.71	11.56	0.53	3.23e-26	Menopause (age at onset);
LUSC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg08888203	chr3:10149979	C3orf24	0.6	8.26	0.41	3.39e-15	Alzheimer's disease;
LUSC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00339695	chr16:24857497	SLC5A11	-0.41	-7.19	-0.37	4.38e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg23625390	chr15:77176239	SCAPER	-0.62	-9.14	-0.45	6.04e-18	Blood metabolite levels;
LUSC	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg04546413	chr19:29218101	NA	0.57	7.4	0.38	1.12e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	trans	rs11700980	0.551	rs2832031	chr21:30114680	T/C	cg14791747	chr16:20752902	THUMPD1	0.55	5.99	0.31	5.36e-9	QRS complex (12-leadsum);
LUSC	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg17366294	chr4:99064904	C4orf37	-0.58	-10.36	-0.49	5.23e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6138458	0.828	rs6138466	chr20:24997137	A/G	cg26195577	chr20:24973756	C20orf3	0.81	12.42	0.56	2.2e-29	Blood protein levels;
LUSC	cis	rs7605827	0.866	rs35237017	chr2:15615704	T/C	cg19274914	chr2:15703543	NA	0.45	8.55	0.42	4.36e-16	Educational attainment (years of education);
LUSC	cis	rs6987853	0.787	rs2974358	chr8:42434403	T/C	cg09913449	chr8:42400586	C8orf40	0.5	8.52	0.42	5.4e-16	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg22823121	chr1:150693482	HORMAD1	0.49	7.18	0.37	4.44e-12	Melanoma;
LUSC	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg14844989	chr11:31128820	NA	-0.37	-5.79	-0.3	1.67e-8	Red blood cell count;
LUSC	cis	rs3733418	0.929	rs17623445	chr4:165894658	C/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.43	-5.87	-0.31	1.04e-8	Obesity-related traits;
LUSC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg20203395	chr5:56204925	C5orf35	-0.75	-10.3	-0.49	8.8e-22	Initial pursuit acceleration;
LUSC	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg02569458	chr12:86230093	RASSF9	0.54	8.82	0.43	6.7e-17	Major depressive disorder;
LUSC	trans	rs1325195	0.920	rs2816213	chr1:179183766	T/C	cg11624085	chr17:8464688	MYH10	0.41	6.62	0.34	1.41e-10	IgE grass sensitization;
LUSC	trans	rs2262909	0.962	rs411020	chr19:22231102	G/A	cg05197062	chr11:11642011	GALNTL4	-0.56	-7.81	-0.39	7.34e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1971762	0.523	rs3852562	chr12:54085750	T/C	cg23533419	chr12:54090519	NA	-0.37	-6.1	-0.32	2.94e-9	Height;
LUSC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06022373	chr22:39101656	GTPBP1	0.79	12.3	0.56	6.14e-29	Menopause (age at onset);
LUSC	trans	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	-0.44	-6.16	-0.32	2.1e-9	Corneal astigmatism;
LUSC	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.41	-0.42	1.21e-15	Neuroticism;
LUSC	cis	rs12519773	0.967	rs1496331	chr5:92445784	G/T	cg18783429	chr5:92414398	NA	0.27	5.94	0.31	7.35e-9	Migraine;
LUSC	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg19875535	chr5:140030758	IK	-0.45	-7.28	-0.37	2.4e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg06521331	chr12:34319734	NA	-0.37	-6.34	-0.33	7.53e-10	Morning vs. evening chronotype;
LUSC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg11663144	chr21:46675770	NA	-0.41	-7.12	-0.36	6.7e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.32	6.25	0.32	1.22e-9	Obesity-related traits;
LUSC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg09034736	chr1:150693464	HORMAD1	0.48	7.01	0.36	1.33e-11	Melanoma;
LUSC	cis	rs16854884	0.657	rs920159	chr3:143753194	A/T	cg06585982	chr3:143692056	C3orf58	0.5	7.91	0.4	3.89e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg05855489	chr10:104503620	C10orf26	0.61	8.01	0.4	1.97e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg24296786	chr1:45957014	TESK2	0.46	6.63	0.34	1.38e-10	High light scatter reticulocyte count;
LUSC	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19346786	chr7:2764209	NA	-0.45	-7.63	-0.39	2.49e-13	Height;
LUSC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-5.75	-0.3	1.99e-8	Total body bone mineral density;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.85	-15.28	-0.64	2.53e-40	Menarche (age at onset);
LUSC	cis	rs10761482	0.861	rs2061490	chr10:62103662	A/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs7071206	0.853	rs114936111	chr10:79430143	G/A	cg07817648	chr10:79422355	NA	-0.45	-6.3	-0.33	9.53e-10	Bone mineral density;
LUSC	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.58	9.89	0.48	2.08e-20	Bone mineral density;
LUSC	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.2e-13	Corneal astigmatism;
LUSC	cis	rs75804782	0.641	rs56000747	chr2:239318541	T/G	cg18131467	chr2:239335373	ASB1	-0.74	-6.59	-0.34	1.67e-10	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.07	0.44	1.02e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.91	0.61	5.12e-35	Cognitive test performance;
LUSC	cis	rs6840360	0.870	rs7680604	chr4:152469917	C/T	cg22705602	chr4:152727874	NA	-0.3	-6.27	-0.32	1.12e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.59	-0.34	1.76e-10	Triglycerides;
LUSC	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg26597838	chr10:835615	NA	-0.48	-6.53	-0.34	2.45e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs500891	0.547	rs34533621	chr6:84069099	C/T	cg08257003	chr6:84140564	ME1	0.32	7.34	0.37	1.61e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs72634258	0.786	rs9434991	chr1:8178708	G/C	cg26816564	chr1:7831052	VAMP3	0.47	6.17	0.32	1.99e-9	Inflammatory bowel disease;
LUSC	cis	rs834811	0.505	rs7789711	chr7:135938979	C/T	cg01726295	chr7:135938950	NA	-0.41	-7.43	-0.38	9.16e-13	Post-traumatic stress disorder;
LUSC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.61e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18876405	chr7:65276391	NA	-0.55	-8.93	-0.44	2.85e-17	Aortic root size;
LUSC	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg22875332	chr1:76189707	ACADM	-0.42	-6.25	-0.32	1.26e-9	Daytime sleep phenotypes;
LUSC	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-8.03	-0.4	1.69e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7168353	0.519	rs11074140	chr15:93635244	C/G	cg02918577	chr15:93633145	RGMA	-0.33	-6.22	-0.32	1.52e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs59698941	0.943	rs12520928	chr5:132305891	C/A	cg02081065	chr5:132209139	LEAP2	-0.59	-5.89	-0.31	9.68e-9	Apolipoprotein A-IV levels;
LUSC	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg16928487	chr17:17741425	SREBF1	-0.43	-8.43	-0.42	1.03e-15	Total body bone mineral density;
LUSC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.81	-14.28	-0.62	1.92e-36	Sudden cardiac arrest;
LUSC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg02454025	chr1:11042201	C1orf127	0.93	17.26	0.69	3.66e-48	Ewing sarcoma;
LUSC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.48e-24	Aortic root size;
LUSC	trans	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg01620082	chr3:125678407	NA	-0.54	-6.38	-0.33	5.89e-10	Depression;
LUSC	cis	rs1113500	0.933	rs11185260	chr1:108635079	A/T	cg11967332	chr1:108735228	SLC25A24	-0.42	-6.35	-0.33	6.98e-10	Growth-regulated protein alpha levels;
LUSC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.86	-14.17	-0.61	5.27e-36	Coronary artery disease;
LUSC	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3750965	0.959	rs11228490	chr11:68860872	C/G	cg06818126	chr11:68850279	TPCN2	0.44	6.57	0.34	1.92e-10	Hair color;
LUSC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-14.38	-0.62	7.95e-37	Vitiligo;
LUSC	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg01557791	chr16:72042693	DHODH	-0.54	-7.61	-0.38	2.87e-13	Fibrinogen levels;
LUSC	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.77	-0.39	9.67e-14	Glomerular filtration rate;
LUSC	cis	rs7605827	0.930	rs13019216	chr2:15659539	A/G	cg19274914	chr2:15703543	NA	0.46	8.83	0.43	6.22e-17	Educational attainment (years of education);
LUSC	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg00495681	chr13:53174319	NA	0.41	5.97	0.31	6.04e-9	Lewy body disease;
LUSC	cis	rs7212590	0.655	rs16943969	chr17:58031153	A/G	cg10252138	chr17:58120427	NA	-0.8	-7.53	-0.38	4.68e-13	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	0.8	9.91	0.48	1.86e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20738406	chr15:90233884	WDR93;PEX11A	-0.48	-6.16	-0.32	2.08e-9	Hepatitis;
LUSC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg06784218	chr1:46089804	CCDC17	0.3	5.95	0.31	6.92e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg05729581	chr11:3078854	CARS	0.4	5.77	0.3	1.82e-8	Calcium levels;
LUSC	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.66e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.69	11.08	0.52	1.61e-24	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg22535103	chr8:58192502	C8orf71	-0.61	-7.13	-0.36	6.28e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg05855489	chr10:104503620	C10orf26	0.53	8.09	0.4	1.13e-14	Arsenic metabolism;
LUSC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg26116260	chr4:7069785	GRPEL1	0.92	11.82	0.54	3.53e-27	Monocyte percentage of white cells;
LUSC	cis	rs9359856	0.564	rs17735590	chr6:90330268	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.82	-7.91	-0.4	3.71e-14	Bipolar disorder;
LUSC	cis	rs757081	0.667	rs12420958	chr11:17100432	G/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-6.04	-0.31	4e-9	Systolic blood pressure;
LUSC	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg17168535	chr8:21777572	XPO7	-0.78	-14.39	-0.62	7.36e-37	Mean corpuscular volume;
LUSC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.69e-9	Aortic root size;
LUSC	cis	rs1107366	0.722	rs750714	chr3:125904688	G/A	cg08481491	chr3:125900108	ALDH1L1	-0.29	-5.73	-0.3	2.3e-8	Metabolite levels;
LUSC	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.33	-0.33	7.81e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.21	-0.37	3.87e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs1775715	0.707	rs1541261	chr10:32179523	G/A	cg26784012	chr10:32216390	ARHGAP12	0.47	7.91	0.4	3.92e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6693567	0.565	rs1260408	chr1:150307270	T/G	cg15654264	chr1:150340011	RPRD2	0.46	7.36	0.37	1.46e-12	Migraine;
LUSC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg00049323	chr5:472564	LOC25845	-0.41	-6.44	-0.33	4.11e-10	Cystic fibrosis severity;
LUSC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg04944784	chr2:26401820	FAM59B	-0.75	-10.33	-0.49	7.09e-22	Gut microbiome composition (summer);
LUSC	cis	rs4409675	0.576	rs7535816	chr1:28234054	A/G	cg23691781	chr1:28212827	C1orf38	0.33	7.8	0.39	7.87e-14	Corneal astigmatism;
LUSC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg22563815	chr15:78856949	CHRNA5	-0.27	-6.4	-0.33	5.2400000000000005e-10	Sudden cardiac arrest;
LUSC	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg13073564	chr4:8508604	NA	-0.45	-8.31	-0.41	2.46e-15	Response to antineoplastic agents;
LUSC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.02	-15.13	-0.64	9.69e-40	Gut microbiome composition (summer);
LUSC	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg23950597	chr19:37808831	NA	-0.63	-7.58	-0.38	3.49e-13	Coronary artery calcification;
LUSC	cis	rs1355223	1.000	rs35365094	chr11:34767790	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-5.84	-0.3	1.23e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	15.26	0.64	2.99e-40	Platelet count;
LUSC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.27	-0.32	1.1e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg08000102	chr2:233561755	GIGYF2	0.82	14.1	0.61	9.27e-36	Schizophrenia;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg18538332	chr22:24372958	LOC391322	-0.49	-8.74	-0.43	1.12e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg16007573	chr7:152373310	XRCC2	0.47	6.06	0.31	3.67e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.96	0.36	1.78e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	1.05	19.12	0.72	1.42e-55	Menopause (age at onset);
LUSC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.77	-12.44	-0.56	1.82e-29	Colorectal cancer;
LUSC	cis	rs11209185	0.509	rs9326077	chr1:68452192	A/G	cg22082780	chr1:68452167	NA	0.46	8.39	0.42	1.42e-15	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg00101154	chr16:420108	MRPL28	-0.45	-6.76	-0.35	6.11e-11	Bone mineral density (spine);Bone mineral density;
LUSC	trans	rs1941687	0.797	rs12967889	chr18:31399371	G/A	cg27147174	chr7:100797783	AP1S1	-0.47	-6.87	-0.35	3.06e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs2932538	0.922	rs12739994	chr1:113131159	T/C	cg22162597	chr1:113214053	CAPZA1	0.71	9.93	0.48	1.55e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs57920188	0.584	rs12080516	chr1:4089613	C/T	cg20703997	chr1:4087676	NA	0.53	8.12	0.41	9.14e-15	Interleukin-17 levels;
LUSC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	8.35	0.42	1.82e-15	Mean platelet volume;
LUSC	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	0.58	9.15	0.45	5.95e-18	Breast cancer;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14021555	chr22:43485536	TTLL1	0.41	6.1	0.32	2.99e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg00033643	chr7:134001901	SLC35B4	0.45	6.91	0.35	2.52e-11	Mean platelet volume;
LUSC	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.5	-7.3	-0.37	2.15e-12	Neutrophil percentage of white cells;
LUSC	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg13010199	chr12:38710504	ALG10B	0.55	8.38	0.42	1.44e-15	Morning vs. evening chronotype;
LUSC	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.36	-0.33	6.46e-10	Total body bone mineral density;
LUSC	cis	rs2594714	1.000	rs12162265	chr19:13955161	G/A	cg18576835	chr19:13944261	NA	-0.42	-5.99	-0.31	5.47e-9	Breast cancer;
LUSC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.79	-0.35	5.09e-11	Schizophrenia;
LUSC	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg23752985	chr2:85803571	VAMP8	-0.33	-7.02	-0.36	1.23e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18876405	chr7:65276391	NA	-0.56	-8.82	-0.43	6.67e-17	Aortic root size;
LUSC	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	7.92	0.4	3.64e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg09509183	chr1:209979624	IRF6	0.54	6.26	0.32	1.21e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.2e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs3935685	0.934	rs11072664	chr15:77999859	C/G	cg25212270	chr15:78015279	NA	0.29	6.38	0.33	5.98e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4474465	1.000	rs57042969	chr11:78160120	C/T	cg27205649	chr11:78285834	NARS2	-0.5	-5.94	-0.31	7.16e-9	Alzheimer's disease (survival time);
LUSC	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg13642260	chr9:130955380	CIZ1	0.47	7.61	0.38	2.82e-13	Attention deficit hyperactivity disorder;
LUSC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs722599	0.683	rs8022046	chr14:75278302	G/A	cg06637938	chr14:75390232	RPS6KL1	0.4	5.67	0.3	3.02e-8	IgG glycosylation;
LUSC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.54	-0.38	4.51e-13	Aortic root size;
LUSC	cis	rs4319547	0.688	rs10744287	chr12:123077485	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.45	-6.19	-0.32	1.74e-9	Body mass index;
LUSC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg27432699	chr2:27873401	GPN1	-0.57	-8.48	-0.42	7.28e-16	Total body bone mineral density;
LUSC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg25019033	chr10:957182	NA	-0.49	-6.15	-0.32	2.16e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.47	-7.19	-0.37	4.34e-12	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.01e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg22676075	chr6:135203613	NA	0.59	9.41	0.46	8.46e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg05187965	chr10:45406764	TMEM72	-0.36	-8.4	-0.42	1.33e-15	Mean corpuscular volume;
LUSC	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg05283184	chr6:79620031	NA	-0.56	-11.88	-0.54	2.27e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg19052272	chr2:3704530	ALLC	-0.46	-7.61	-0.38	2.76e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg13010199	chr12:38710504	ALG10B	0.64	9.99	0.48	9.72e-21	Bladder cancer;
LUSC	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.75	0.39	1.13e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg15448220	chr1:150897856	SETDB1	0.4	5.83	0.3	1.29e-8	Melanoma;
LUSC	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg17507749	chr15:85114479	UBE2QP1	0.48	6.37	0.33	6.12e-10	Schizophrenia;
LUSC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg10792982	chr14:105748885	BRF1	0.48	8.75	0.43	1.09e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg00431813	chr7:1051703	C7orf50	-0.47	-8.13	-0.41	8.72e-15	Longevity;Endometriosis;
LUSC	cis	rs6429082	0.967	rs834143	chr1:235626406	C/T	cg26050004	chr1:235667680	B3GALNT2	0.42	6.07	0.32	3.49e-9	Adiposity;
LUSC	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg12317470	chr15:67143691	NA	-0.63	-6.06	-0.31	3.6e-9	Lung cancer (smoking interaction);
LUSC	cis	rs6460942	0.908	rs112049544	chr7:12242551	A/G	cg06484146	chr7:12443880	VWDE	-0.59	-5.87	-0.31	1.02e-8	Coronary artery disease;
LUSC	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	0.79	10.08	0.48	5.01e-21	Coronary artery disease;
LUSC	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg25801113	chr15:45476975	SHF	0.34	7.04	0.36	1.13e-11	Uric acid levels;
LUSC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.98	13.75	0.6	2.2e-34	Smoking behavior;
LUSC	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.54	0.42	4.94e-16	Lung cancer in ever smokers;
LUSC	trans	rs2392780	0.785	rs13256275	chr8:128356226	G/A	cg10897648	chr18:56338258	MALT1	-0.38	-5.96	-0.31	6.46e-9	Breast cancer (early onset);
LUSC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg00784671	chr22:46762841	CELSR1	-0.49	-6.67	-0.34	1.04e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs432925	0.529	rs2885415	chr16:395396	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.38	-6.09	-0.32	3.03e-9	Morning vs. evening chronotype;
LUSC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg16060761	chr17:80687452	NA	0.46	7.33	0.37	1.76e-12	Breast cancer;
LUSC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.83	15.3	0.64	2.09e-40	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.66	0.57	2.79e-30	Prudent dietary pattern;
LUSC	cis	rs57590327	0.555	rs13099615	chr3:81729101	T/A	cg07356753	chr3:81810745	GBE1	-0.68	-10.51	-0.5	1.68e-22	Extraversion;
LUSC	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg21095983	chr6:86352623	SYNCRIP	0.54	8.57	0.42	4.02e-16	Smooth-surface caries;
LUSC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.21	0.32	1.54e-9	Personality dimensions;
LUSC	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg04896959	chr15:78267971	NA	-0.42	-6.72	-0.34	8.09e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.79	-13.37	-0.59	5.98e-33	Schizophrenia;
LUSC	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg22906224	chr7:99728672	NA	-0.46	-6.49	-0.33	3.17e-10	Coronary artery disease;
LUSC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg16308533	chr17:40838983	CNTNAP1	0.51	8.97	0.44	2.21e-17	Colorectal or endometrial cancer;
LUSC	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg02018176	chr4:1364513	KIAA1530	0.45	6.34	0.33	7.29e-10	Recombination rate (females);
LUSC	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04978709	chr7:75101039	POM121C	-0.39	-5.73	-0.3	2.3e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg05283184	chr6:79620031	NA	-0.55	-11.29	-0.53	2.85e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg07701084	chr6:150067640	NUP43	0.53	7.85	0.39	5.88e-14	Lung cancer;
LUSC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg06877462	chr1:205807181	PM20D1	0.45	8.0	0.4	2.11e-14	Menarche (age at onset);
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg25703541	chr22:24373054	LOC391322	0.87	14.28	0.62	1.88e-36	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg12615879	chr12:58013172	SLC26A10	0.36	8.25	0.41	3.72e-15	Multiple sclerosis;
LUSC	cis	rs1832871	0.672	rs62437361	chr6:158728759	C/T	cg07165851	chr6:158734300	TULP4	0.45	6.63	0.34	1.36e-10	Height;
LUSC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.63	-8.13	-0.41	8.49e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg26677194	chr12:130822605	PIWIL1	0.59	8.77	0.43	9.52e-17	Menopause (age at onset);
LUSC	cis	rs835154	0.845	rs835156	chr5:14875813	C/A	cg14843632	chr5:14870594	ANKH	0.36	6.54	0.34	2.28e-10	Blood metabolite levels;
LUSC	cis	rs2274273	0.661	rs8019978	chr14:55557284	A/G	cg04306507	chr14:55594613	LGALS3	-0.51	-11.26	-0.52	3.75e-25	Protein biomarker;
LUSC	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg10326726	chr10:51549505	MSMB	-0.36	-6.18	-0.32	1.86e-9	Prostate-specific antigen levels;
LUSC	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg20219074	chr11:18656078	SPTY2D1	0.76	11.3	0.53	2.83e-25	Breast cancer;
LUSC	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg23601095	chr6:26197514	HIST1H3D	0.72	7.7	0.39	1.51e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg05805236	chr11:65401703	PCNXL3	0.4	6.87	0.35	3.1e-11	Acne (severe);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.41	-6.18	-0.32	1.84e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg22601191	chr20:60968625	CABLES2	-0.53	-7.55	-0.38	4.16e-13	Colorectal cancer;
LUSC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.63	9.8	0.47	4.22e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs1459104	0.866	rs28873990	chr11:54812748	G/A	cg03929089	chr4:120376271	NA	0.72	6.26	0.32	1.17e-9	Body mass index;
LUSC	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg16545954	chr1:2118288	C1orf86	0.38	7.41	0.38	1.06e-12	Height;
LUSC	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg01503450	chr10:980765	NA	-0.38	-5.7	-0.3	2.68e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg27494647	chr7:150038898	RARRES2	0.46	6.99	0.36	1.52e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3820068	0.577	rs9728986	chr1:16040603	G/A	cg24675056	chr1:15929824	NA	0.4	6.58	0.34	1.87e-10	Systolic blood pressure;
LUSC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg26441486	chr22:50317300	CRELD2	-0.54	-8.2	-0.41	5.07e-15	Schizophrenia;
LUSC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg25767906	chr1:53392781	SCP2	0.49	8.74	0.43	1.13e-16	Monocyte count;
LUSC	cis	rs9921338	0.961	rs8060767	chr16:11370598	C/G	cg00044050	chr16:11439710	C16orf75	-0.51	-6.81	-0.35	4.64e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg00484396	chr16:3507460	NAT15	0.69	12.08	0.55	3.93e-28	Tuberculosis;
LUSC	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg05855489	chr10:104503620	C10orf26	-0.68	-9.98	-0.48	1.09e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs11690935	0.632	rs62184165	chr2:172558328	A/G	cg13550731	chr2:172543902	DYNC1I2	0.6	9.54	0.46	3.05e-19	Schizophrenia;
LUSC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.46	-0.53	7.24e-26	Schizophrenia;
LUSC	cis	rs9399401	0.849	rs962554	chr6:142734204	T/C	cg03128060	chr6:142623767	GPR126	0.34	6.1	0.32	2.95e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs10208940	0.920	rs7423646	chr2:68758180	A/G	cg12452813	chr2:68675892	NA	0.56	5.81	0.3	1.45e-8	Urate levels in lean individuals;
LUSC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg00945038	chr17:61921165	SMARCD2	0.35	5.9	0.31	8.8e-9	Prudent dietary pattern;
LUSC	cis	rs2274273	0.529	rs7149965	chr14:55508191	G/A	cg04306507	chr14:55594613	LGALS3	0.44	8.95	0.44	2.53e-17	Protein biomarker;
LUSC	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg21782813	chr7:2030301	MAD1L1	0.38	6.19	0.32	1.78e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs10843647	1.000	rs1968879	chr12:30322860	T/A	cg12718339	chr12:29936407	TMTC1	-0.35	-5.77	-0.3	1.85e-8	Glucose homeostasis traits;
LUSC	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg25214090	chr10:38739885	LOC399744	0.54	8.06	0.4	1.36e-14	Corneal astigmatism;
LUSC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02034447	chr16:89574710	SPG7	0.45	6.73	0.35	7.36e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg21775007	chr8:11205619	TDH	0.55	7.91	0.4	3.87e-14	Neuroticism;
LUSC	cis	rs10887741	0.690	rs7908056	chr10:89444650	G/A	cg24243914	chr10:89418206	PAPSS2	0.33	6.37	0.33	6.17e-10	Exercise (leisure time);
LUSC	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.67	-9.09	-0.45	8.91e-18	Large artery stroke;
LUSC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg14668632	chr7:2872130	GNA12	-0.41	-6.02	-0.31	4.65e-9	Height;
LUSC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg20203395	chr5:56204925	C5orf35	-0.58	-8.34	-0.42	1.93e-15	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg17366294	chr4:99064904	C4orf37	0.59	10.39	0.49	4.12e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3755132	0.929	rs41264163	chr2:15763788	C/T	cg12888861	chr2:15731646	DDX1	0.51	7.2	0.37	3.99e-12	Wilms tumor;
LUSC	cis	rs4280164	0.551	rs3212243	chr14:24810370	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.55	-6.86	-0.35	3.38e-11	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg10978503	chr1:24200527	CNR2	-0.44	-9.28	-0.45	2.14e-18	Immature fraction of reticulocytes;
LUSC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	trans	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg17830980	chr10:43048298	ZNF37B	-0.5	-6.26	-0.32	1.15e-9	Obesity (extreme);
LUSC	trans	rs11088226	1.000	rs11701091	chr21:33920244	T/A	cg09050820	chr6:167586206	TCP10L2	0.55	7.17	0.37	4.88e-12	Gastritis;
LUSC	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-1.0	-13.81	-0.6	1.2e-34	Blood pressure (smoking interaction);
LUSC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.7	-10.13	-0.48	3.24e-21	Systemic lupus erythematosus;
LUSC	cis	rs28647808	0.881	rs28622217	chr9:136267323	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-10.3	-0.49	8.86e-22	Body mass index;
LUSC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg16393715	chr7:1948819	MAD1L1	0.36	6.22	0.32	1.48e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg06917634	chr15:78832804	PSMA4	-0.57	-7.1	-0.36	7.66e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg09307838	chr4:120376055	NA	0.52	7.87	0.4	4.95e-14	Diastolic blood pressure;
LUSC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg13683864	chr3:40499215	RPL14	-0.95	-16.3	-0.67	2.4e-44	Renal cell carcinoma;
LUSC	cis	rs7607369	0.536	rs13033409	chr2:219666509	T/G	cg02176678	chr2:219576539	TTLL4	-0.51	-8.94	-0.44	2.63e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg03433033	chr1:76189801	ACADM	-0.4	-5.89	-0.31	9.31e-9	Daytime sleep phenotypes;
LUSC	cis	rs7827545	1.000	rs7827545	chr8:135566567	C/T	cg17885191	chr8:135476712	NA	0.57	8.73	0.43	1.24e-16	Hypertension (SNP x SNP interaction);
LUSC	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.58	0.5	9.49e-23	Colorectal cancer;
LUSC	cis	rs9463078	0.608	rs608941	chr6:44888740	C/T	cg25276700	chr6:44698697	NA	-0.28	-5.78	-0.3	1.76e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.82	-15.25	-0.64	3.22e-40	Birth weight;
LUSC	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg08854313	chr1:11322531	MTOR	0.81	12.26	0.56	8.54e-29	Body mass index;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23564928	chr14:32030597	NUBPL	-0.4	-6.31	-0.33	8.89e-10	Electrocardiographic conduction measures;
LUSC	cis	rs1692580	0.870	rs263533	chr1:2163568	C/T	cg21194808	chr1:2205498	SKI	0.36	5.71	0.3	2.44e-8	Coronary artery disease;
LUSC	cis	rs34421088	0.506	rs2572426	chr8:11147123	C/T	cg21775007	chr8:11205619	TDH	0.51	7.46	0.38	7.58e-13	Neuroticism;
LUSC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg05347473	chr6:146136440	FBXO30	0.45	7.68	0.39	1.73e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg14582100	chr15:45693742	SPATA5L1	0.49	8.36	0.42	1.69e-15	Homoarginine levels;
LUSC	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg00944433	chr1:107599041	PRMT6	0.39	7.11	0.36	7.09e-12	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg05373962	chr22:49881684	NA	-0.4	-8.46	-0.42	8.69e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg04733989	chr22:42467013	NAGA	0.39	6.54	0.34	2.33e-10	Cognitive function;
LUSC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg18110333	chr6:292329	DUSP22	-0.53	-7.93	-0.4	3.38e-14	Menopause (age at onset);
LUSC	cis	rs72960926	0.744	rs16884519	chr6:74967946	C/T	cg03266952	chr6:74778945	NA	0.65	6.3	0.33	9.54e-10	Metabolite levels (MHPG);
LUSC	cis	rs7589342	0.862	rs12613864	chr2:106515869	G/A	cg16077055	chr2:106428750	NCK2	0.35	6.5	0.34	2.96e-10	Addiction;
LUSC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg15145296	chr3:125709740	NA	-0.57	-6.97	-0.36	1.66e-11	Blood pressure (smoking interaction);
LUSC	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.5	-7.68	-0.39	1.74e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6028335	0.674	rs974561	chr20:37591184	G/C	cg27552599	chr20:37590471	DHX35	0.45	5.67	0.3	3.15e-8	Alcohol and nicotine co-dependence;
LUSC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg03146154	chr1:46216737	IPP	-0.5	-7.26	-0.37	2.69e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.59	-0.34	1.75e-10	Triglycerides;
LUSC	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg20933634	chr6:27740509	NA	0.43	5.93	0.31	7.46e-9	Parkinson's disease;
LUSC	trans	rs57046232	0.552	rs6133307	chr20:6333298	C/T	cg17788362	chr6:86352627	SYNCRIP	0.42	5.96	0.31	6.34e-9	Colorectal cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26824705	chr1:20834772	MUL1	0.43	6.46	0.33	3.7e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg06671706	chr8:8559999	CLDN23	0.51	6.55	0.34	2.12e-10	Obesity-related traits;
LUSC	cis	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg07460842	chr6:66804631	NA	-0.48	-6.72	-0.35	7.74e-11	Blood trace element (Cu levels);
LUSC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.27	0.52	3.55e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg16479474	chr6:28041457	NA	0.32	5.72	0.3	2.31e-8	Parkinson's disease;
LUSC	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.91	0.35	2.51e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg14036092	chr11:66035641	RAB1B	0.42	5.93	0.31	7.38e-9	Gout;
LUSC	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg18132916	chr6:79620363	NA	-0.39	-5.91	-0.31	8.33e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg08999081	chr20:33150536	PIGU	0.46	8.35	0.42	1.84e-15	Coronary artery disease;
LUSC	cis	rs3007729	0.509	rs6665151	chr1:18800247	A/G	cg04846421	chr1:18800208	NA	-0.41	-7.14	-0.36	5.69e-12	Diabetic retinopathy;
LUSC	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.54	0.5	1.27e-22	Colorectal cancer;
LUSC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg27532560	chr4:187881888	NA	-0.41	-6.72	-0.35	7.9e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.11	-0.48	3.92e-21	Monocyte count;
LUSC	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg04989706	chr14:50066350	PPIL5	-0.46	-6.21	-0.32	1.57e-9	Carotid intima media thickness;
LUSC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.64	0.6	5.79e-34	Cognitive test performance;
LUSC	cis	rs4594175	0.926	rs12101170	chr14:51611902	T/C	cg23942311	chr14:51606299	NA	0.3	5.79	0.3	1.6e-8	Cancer;
LUSC	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg02423579	chr7:2872169	GNA12	-0.41	-6.13	-0.32	2.43e-9	Height;
LUSC	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg04455712	chr21:45112962	RRP1B	0.48	9.18	0.45	4.67e-18	Mean corpuscular volume;
LUSC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg15445000	chr17:37608096	MED1	-0.39	-6.63	-0.34	1.35e-10	Glomerular filtration rate (creatinine);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17504096	chr1:205649242	SLC45A3	-0.5	-6.25	-0.32	1.24e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs11694459	0.661	rs731399	chr2:46457657	A/C	cg01370541	chr4:41882812	NA	0.68	6.34	0.33	7.33e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg16586182	chr3:47516702	SCAP	-0.51	-7.84	-0.39	6.3e-14	Colorectal cancer;
LUSC	cis	rs7246967	0.673	rs12974988	chr19:22925965	G/T	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.04e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs17253792	0.822	rs75288952	chr14:56034010	C/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.04	-0.36	1.1e-11	Putamen volume;
LUSC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	13.67	0.6	4.2e-34	Monocyte percentage of white cells;
LUSC	cis	rs10871290	1.000	rs11149710	chr16:74472546	G/T	cg01733217	chr16:74700730	RFWD3	-0.54	-7.84	-0.39	6e-14	Breast cancer;
LUSC	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg22705602	chr4:152727874	NA	0.38	7.85	0.39	5.54e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.818	rs406350	chr1:153007492	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg27661571	chr11:113659931	NA	-0.62	-7.41	-0.38	1.05e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg19875535	chr5:140030758	IK	0.37	5.66	0.3	3.3e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	0.9	13.42	0.59	3.99e-33	Menopause (age at onset);
LUSC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.9	12.03	0.55	6.16e-28	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.15	-0.32	2.25e-9	Bipolar disorder;
LUSC	trans	rs9944715	1.000	rs3744858	chr18:43845269	C/T	cg01718231	chr17:29326311	RNF135	-0.5	-6.95	-0.36	1.97e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg12754571	chr1:247694271	LOC148824;OR2C3	0.37	5.65	0.3	3.45e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs11605924	0.901	rs7112505	chr11:45840939	A/T	ch.11.939596F	chr11:45881766	CRY2	-0.5	-7.44	-0.38	8.7e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.06	-0.36	9.62e-12	Bipolar disorder;
LUSC	cis	rs4363385	0.693	rs7556517	chr1:152925755	G/T	cg00922841	chr1:152955080	SPRR1A	0.42	7.03	0.36	1.18e-11	Inflammatory skin disease;
LUSC	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg09654669	chr8:57350985	NA	-0.57	-7.83	-0.39	6.46e-14	Obesity-related traits;
LUSC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.67	-7.91	-0.4	3.69e-14	Lung function (FEV1/FVC);
LUSC	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	6.84	0.35	3.68e-11	Height;
LUSC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg16339924	chr4:17578868	LAP3	0.62	9.56	0.46	2.68e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg12288994	chr5:1860383	NA	0.31	6.91	0.35	2.43e-11	Cardiovascular disease risk factors;
LUSC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg20608306	chr11:116969690	SIK3	0.34	6.35	0.33	6.84e-10	Blood protein levels;
LUSC	cis	rs12586317	0.531	rs60049741	chr14:35719842	G/A	cg07166546	chr14:35805898	NA	-0.28	-6.51	-0.34	2.7e-10	Psoriasis;
LUSC	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg06885757	chr1:42089581	HIVEP3	0.46	9.38	0.46	1.07e-18	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg24531977	chr5:56204891	C5orf35	-0.71	-10.56	-0.5	1.11e-22	Coronary artery disease;
LUSC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg18230493	chr5:56204884	C5orf35	-0.86	-13.06	-0.58	8.73e-32	Initial pursuit acceleration;
LUSC	cis	rs9309473	0.528	rs7573275	chr2:73552542	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-7.66	-0.39	2.01e-13	Metabolite levels;
LUSC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg09021430	chr5:549028	NA	-0.54	-7.41	-0.38	1.05e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg10596483	chr8:143751796	JRK	-0.52	-7.39	-0.37	1.19e-12	Schizophrenia;
LUSC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg27094323	chr7:1216898	NA	0.4	6.99	0.36	1.51e-11	Longevity;Endometriosis;
LUSC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.46	-7.51	-0.38	5.47e-13	Vitiligo;
LUSC	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	12.02	0.55	6.84e-28	Nonalcoholic fatty liver disease;
LUSC	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg04455712	chr21:45112962	RRP1B	0.42	7.82	0.39	6.79e-14	Mean corpuscular volume;
LUSC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg18305652	chr10:134549665	INPP5A	-0.42	-6.42	-0.33	4.69e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs3931020	0.688	rs452242	chr1:75225625	G/T	cg00121533	chr1:75199117	CRYZ;TYW3	-0.47	-5.86	-0.31	1.11e-8	Resistin levels;
LUSC	cis	rs7615316	1.000	rs1357529	chr3:142351097	T/G	cg16271453	chr3:142027066	XRN1	-0.34	-5.82	-0.3	1.36e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg26384229	chr12:38710491	ALG10B	0.58	9.3	0.45	1.91e-18	Morning vs. evening chronotype;
LUSC	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg13683864	chr3:40499215	RPL14	0.79	13.04	0.58	1.07e-31	Renal cell carcinoma;
LUSC	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	0.58	9.24	0.45	2.88e-18	Breast cancer;
LUSC	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg13755796	chr4:20253514	NA	-0.42	-6.51	-0.34	2.74e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg13390004	chr1:15929781	NA	0.4	6.68	0.34	1e-10	Systolic blood pressure;
LUSC	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.83	12.22	0.56	1.26e-28	Cognitive ability;
LUSC	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg05887092	chr17:76393375	PGS1	0.51	8.66	0.43	2.12e-16	HDL cholesterol levels;
LUSC	trans	rs62238980	0.614	rs4821027	chr22:32442074	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs12122100	1.000	rs12122100	chr1:146508934	C/T	cg03526459	chr1:146549940	NA	-0.41	-6.74	-0.35	7.12e-11	HIV-1 control;
LUSC	cis	rs2580764	0.565	rs2919129	chr2:55216545	G/T	cg09592903	chr2:55203963	RTN4	0.49	10.18	0.49	2.16e-21	Mean platelet volume;
LUSC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg09491104	chr22:46646882	C22orf40	-0.64	-7.22	-0.37	3.64e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs735860	0.674	rs209485	chr6:53174448	C/T	cg10236188	chr6:53219634	NA	-0.39	-6.23	-0.32	1.43e-9	Glaucoma;
LUSC	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg25208724	chr1:156163844	SLC25A44	1.02	20.47	0.75	6.66e-61	Testicular germ cell tumor;
LUSC	cis	rs1775715	0.870	rs10827003	chr10:32266216	A/G	cg18675610	chr10:32216311	ARHGAP12	0.27	5.74	0.3	2.07e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	7.18	0.37	4.43e-12	Retinal vascular caliber;
LUSC	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.05	0.48	6.03e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs67981189	0.679	rs221901	chr14:71602226	C/T	cg15816911	chr14:71606274	NA	-0.35	-6.33	-0.33	7.7e-10	Schizophrenia;
LUSC	cis	rs8099014	0.861	rs17669	chr18:56118493	C/T	cg12907477	chr18:56117327	MIR122	0.45	7.01	0.36	1.29e-11	Platelet count;
LUSC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22442454	chr1:209979470	IRF6	0.44	5.99	0.31	5.49e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg21643547	chr1:205240462	TMCC2	-0.53	-10.02	-0.48	7.99e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7523273	0.606	rs859706	chr1:207962270	G/A	cg22525895	chr1:207977042	MIR29B2	-0.41	-6.66	-0.34	1.15e-10	Schizophrenia;
LUSC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg06671706	chr8:8559999	CLDN23	0.48	6.52	0.34	2.59e-10	Obesity-related traits;
LUSC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg00933542	chr6:150070202	PCMT1	0.3	6.0	0.31	5.27e-9	Lung cancer;
LUSC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg01206211	chr2:36825736	FEZ2	0.52	10.89	0.51	7.67e-24	Height;
LUSC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg23985595	chr17:80112537	CCDC57	0.3	5.74	0.3	2.14e-8	Life satisfaction;
LUSC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.17	-0.45	4.93e-18	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg27661571	chr11:113659931	NA	-0.6	-7.25	-0.37	2.83e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs6736093	0.932	rs7595212	chr2:112662767	A/G	cg12686935	chr2:112915763	FBLN7	-0.39	-5.99	-0.31	5.37e-9	Coronary artery disease;
LUSC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg04287289	chr16:89883240	FANCA	-0.48	-7.15	-0.36	5.47e-12	Vitiligo;
LUSC	cis	rs4867766	0.871	rs2242419	chr5:173959332	C/T	cg20434911	chr5:173954559	NA	0.51	7.09	0.36	8.18e-12	Stroke;
LUSC	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.4	6.21	0.32	1.56e-9	Neutrophil percentage of white cells;
LUSC	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.24	-0.37	3.07e-12	Bipolar disorder;
LUSC	cis	rs13089785	1.000	rs34159794	chr3:123645893	A/G	cg02558132	chr3:123411198	MYLK	0.34	5.85	0.3	1.19e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.59	-0.5	8.37e-23	Gut microbiome composition (summer);
LUSC	cis	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg17469321	chr7:55412551	NA	0.66	10.63	0.5	6.09e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg16362232	chr11:430036	ANO9	0.57	7.49	0.38	6.26e-13	Body mass index;
LUSC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg14582100	chr15:45693742	SPATA5L1	0.6	10.95	0.51	4.7e-24	Homoarginine levels;
LUSC	cis	rs7523050	0.643	rs12741194	chr1:109400390	T/C	cg08274380	chr1:109419600	GPSM2	1.1	10.69	0.51	3.76e-23	Fat distribution (HIV);
LUSC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg09455208	chr3:40491958	NA	0.57	10.34	0.49	6.5600000000000005e-22	Renal cell carcinoma;
LUSC	cis	rs11971779	0.616	rs2883772	chr7:139072756	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg04155289	chr7:94953770	PON1	-0.36	-5.96	-0.31	6.54e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg19773385	chr1:10388646	KIF1B	-0.5	-8.63	-0.43	2.62e-16	Hepatocellular carcinoma;
LUSC	cis	rs34779708	0.733	rs7914560	chr10:35548099	G/A	cg03585969	chr10:35415529	CREM	0.53	7.38	0.37	1.3e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06112835	chr11:68658793	MRPL21	0.51	7.88	0.4	4.58e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22987389	chr8:22428557	SORBS3	0.5	6.76	0.35	5.99e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-13.93	-0.61	4.39e-35	Exhaled nitric oxide output;
LUSC	cis	rs17407555	0.738	rs55731306	chr4:10067885	G/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-6.27	-0.32	1.15e-9	Schizophrenia (age at onset);
LUSC	trans	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg03886242	chr7:26192032	NFE2L3	-0.39	-6.38	-0.33	5.9e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg06494592	chr3:125709126	NA	-0.5	-5.75	-0.3	2.04e-8	Blood pressure (smoking interaction);
LUSC	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg09365446	chr1:150670422	GOLPH3L	0.48	7.21	0.37	3.71e-12	Melanoma;
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.61	-10.45	-0.5	2.71e-22	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	ch.11.42038R	chr11:967971	AP2A2	0.54	8.19	0.41	5.56e-15	Alzheimer's disease (late onset);
LUSC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-8.68	-0.43	1.83e-16	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2274273	0.624	rs10129505	chr14:55776375	C/T	cg04306507	chr14:55594613	LGALS3	0.49	10.11	0.48	3.86e-21	Protein biomarker;
LUSC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	trans	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	10.54	0.5	1.29e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.84	0.44	5.54e-17	Diabetic kidney disease;
LUSC	trans	rs17683430	0.718	rs117277832	chr22:32369667	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.45	-0.38	8.3e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7178572	0.568	rs12914345	chr15:77670401	A/C	cg22256960	chr15:77711686	NA	-0.49	-7.82	-0.39	6.91e-14	Type 2 diabetes;
LUSC	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg03585969	chr10:35415529	CREM	0.62	8.97	0.44	2.2e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg00033643	chr7:134001901	SLC35B4	0.45	6.83	0.35	3.97e-11	Mean platelet volume;
LUSC	cis	rs6977660	0.714	rs6945297	chr7:19814029	A/C	cg05791153	chr7:19748676	TWISTNB	0.7	7.47	0.38	7.27e-13	Thyroid stimulating hormone;
LUSC	cis	rs7202877	0.519	rs4887811	chr16:75307251	C/T	cg04384234	chr16:75411784	CFDP1	-0.65	-9.36	-0.46	1.18e-18	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7945718	0.905	rs10831908	chr11:12812419	G/A	cg25843174	chr11:12811716	TEAD1	0.33	7.25	0.37	2.99e-12	Educational attainment (years of education);
LUSC	cis	rs13315871	0.790	rs13071148	chr3:58310838	A/C	cg12435725	chr3:58293450	RPP14	-0.76	-7.39	-0.37	1.23e-12	Cholesterol, total;
LUSC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg04450456	chr4:17643702	FAM184B	-0.41	-6.02	-0.31	4.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg05373962	chr22:49881684	NA	-0.41	-8.72	-0.43	1.37e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2742234	0.579	rs2503881	chr10:43686026	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.03	-0.36	1.17e-11	Hirschsprung disease;
LUSC	cis	rs4363385	0.818	rs529077	chr1:153012149	T/C	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.65	0.47	1.33e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7809950	1.000	rs2178497	chr7:107278901	T/C	cg23024343	chr7:107201750	COG5	0.54	8.23	0.41	4.16e-15	Coronary artery disease;
LUSC	trans	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.96	-0.31	6.49e-9	Dementia with Lewy bodies;
LUSC	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg24631222	chr15:78858424	CHRNA5	-0.42	-5.78	-0.3	1.74e-8	Coronary artery disease or large artery stroke;
LUSC	cis	rs35883536	0.588	rs114540631	chr1:101101249	A/G	cg06223162	chr1:101003688	GPR88	0.34	6.21	0.32	1.55e-9	Monocyte count;
LUSC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03264133	chr6:25882463	NA	-0.43	-6.61	-0.34	1.52e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg16362232	chr11:430036	ANO9	0.61	7.97	0.4	2.51e-14	Body mass index;
LUSC	cis	rs7809950	1.000	rs12668402	chr7:107173020	G/A	cg23024343	chr7:107201750	COG5	-0.56	-8.81	-0.43	7.12e-17	Coronary artery disease;
LUSC	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg13535736	chr9:111863775	C9orf5	-0.38	-5.95	-0.31	6.63e-9	Menarche (age at onset);
LUSC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	0.8	10.65	0.5	5.38e-23	Menopause (age at onset);
LUSC	cis	rs7584330	0.628	rs7591065	chr2:238390739	G/T	cg14458575	chr2:238380390	NA	0.47	6.0	0.31	5.11e-9	Prostate cancer;
LUSC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03264133	chr6:25882463	NA	0.37	6.46	0.33	3.61e-10	Blood metabolite levels;
LUSC	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg00540400	chr15:79124168	NA	-0.48	-8.43	-0.42	1.04e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	6.02	0.31	4.67e-9	Height;
LUSC	cis	rs354225	0.544	rs7556752	chr2:54810044	G/C	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg26597838	chr10:835615	NA	0.81	11.35	0.53	1.73e-25	Eosinophil percentage of granulocytes;
LUSC	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg20016023	chr10:99160130	RRP12	-0.35	-8.3	-0.41	2.63e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs57590327	0.555	rs13088603	chr3:81791167	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-10.65	-0.5	5.4e-23	Extraversion;
LUSC	trans	rs67133203	0.904	rs7975147	chr12:51425549	A/G	cg17484237	chr5:156536107	HAVCR2	0.44	5.97	0.31	6.2e-9	Urinary tract infection frequency;
LUSC	cis	rs4474465	0.920	rs10899527	chr11:78207394	A/G	cg27205649	chr11:78285834	NARS2	0.51	5.91	0.31	8.55e-9	Alzheimer's disease (survival time);
LUSC	cis	rs4845570	0.764	rs12141652	chr1:151716711	A/T	cg07092448	chr1:151763213	TDRKH	-1.05	-10.9	-0.51	6.96e-24	Coronary artery disease;
LUSC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg04944784	chr2:26401820	FAM59B	0.74	10.32	0.49	7.14e-22	Gut microbiome composition (summer);
LUSC	cis	rs617219	0.819	rs2591387	chr5:78558425	C/T	cg24856658	chr5:78533917	JMY	-0.3	-5.82	-0.3	1.37e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg05738196	chr6:26577821	NA	-0.59	-7.08	-0.36	8.49e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg22823121	chr1:150693482	HORMAD1	0.6	9.34	0.46	1.35e-18	Tonsillectomy;
LUSC	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.83	-0.44	6.04e-17	Total cholesterol levels;
LUSC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg07703079	chr11:430292	ANO9	0.72	7.38	0.37	1.23e-12	Body mass index;
LUSC	cis	rs1483890	0.723	rs6783070	chr3:69411596	A/C	cg22125112	chr3:69402811	FRMD4B	-0.39	-5.9	-0.31	8.82e-9	Resting heart rate;
LUSC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.37	-0.33	6.29e-10	Lung cancer;
LUSC	cis	rs4947962	0.564	rs11764130	chr7:55078791	A/G	cg23757825	chr7:55092271	EGFR	0.69	8.77	0.43	9.39e-17	Subjective response to lithium treatment;
LUSC	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg11502198	chr6:26597334	ABT1	0.64	10.07	0.48	5.31e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs12493885	0.654	rs61793488	chr3:153730551	T/C	cg17054900	chr3:154042577	DHX36	-0.7	-7.28	-0.37	2.4e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg07393940	chr7:158741817	NA	-0.37	-6.7	-0.34	8.85e-11	Life satisfaction;
LUSC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg06238570	chr21:40685208	BRWD1	-0.63	-11.0	-0.52	3.14e-24	Cognitive function;
LUSC	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.7	-6.44	-0.33	4.06e-10	Lung cancer in ever smokers;
LUSC	cis	rs6599077	1.000	rs11920120	chr3:40094795	T/C	cg13683864	chr3:40499215	RPL14	-0.6	-7.66	-0.39	2.06e-13	Sleep-related phenotypes;
LUSC	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.96	18.97	0.72	5.76e-55	Colorectal cancer;
LUSC	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg20283391	chr11:68216788	NA	0.5	6.78	0.35	5.4e-11	Bone mineral density (spine);
LUSC	cis	rs3772130	1.000	rs13083794	chr3:121464928	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.64	9.28	0.45	2.14e-18	Cognitive performance;
LUSC	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg16339924	chr4:17578868	LAP3	0.49	7.46	0.38	7.73e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01516881	chr6:292596	DUSP22	-0.7	-11.29	-0.53	3.07e-25	Menopause (age at onset);
LUSC	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg26597838	chr10:835615	NA	0.79	9.3	0.45	1.88e-18	Eosinophil percentage of granulocytes;
LUSC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg05585544	chr11:47624801	NA	-0.36	-6.6	-0.34	1.64e-10	Subjective well-being;
LUSC	cis	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg20159608	chr7:32802032	NA	-0.7	-9.12	-0.45	7.4e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg10523679	chr1:76189770	ACADM	-0.5	-7.31	-0.37	2.02e-12	Daytime sleep phenotypes;
LUSC	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02176678	chr2:219576539	TTLL4	0.64	11.77	0.54	5.36e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9807989	0.839	rs6543123	chr2:102977196	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	5.74	0.3	2.08e-8	Asthma;
LUSC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-10.39	-0.49	4.1e-22	Gut microbiome composition (summer);
LUSC	cis	rs974417	0.508	rs17743380	chr6:97312271	C/T	cg10979063	chr6:97285822	GPR63	0.45	7.3	0.37	2.06e-12	Body mass index;
LUSC	cis	rs7178572	0.633	rs12900004	chr15:77844904	A/G	cg22256960	chr15:77711686	NA	-0.5	-7.68	-0.39	1.79e-13	Type 2 diabetes;
LUSC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.28	0.59	1.28e-32	Cognitive test performance;
LUSC	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.89	0.58	3.95e-31	Bipolar disorder;
LUSC	cis	rs4704187	0.687	rs9293643	chr5:74365053	C/T	cg03227963	chr5:74354835	NA	-0.3	-6.5	-0.34	2.95e-10	Response to amphetamines;
LUSC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg05347473	chr6:146136440	FBXO30	0.56	9.76	0.47	5.93e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg27631724	chr1:11040367	C1orf127	0.54	9.56	0.46	2.75e-19	Ewing sarcoma;
LUSC	cis	rs2481665	0.806	rs55725347	chr1:62538252	G/A	cg18591186	chr1:62594603	INADL	-0.43	-6.42	-0.33	4.73e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6693567	0.565	rs12736375	chr1:150411912	T/C	cg15654264	chr1:150340011	RPRD2	0.44	7.11	0.36	7.28e-12	Migraine;
LUSC	cis	rs7200543	1.000	rs3803575	chr16:15138447	T/C	cg03427771	chr16:15082598	PDXDC1	-0.41	-5.82	-0.3	1.42e-8	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg16786304	chr2:206950888	INO80D	-0.52	-6.85	-0.35	3.57e-11	Hepatitis;
LUSC	cis	rs2629540	0.765	rs11245387	chr10:126537825	C/T	cg08799069	chr10:126477246	METTL10	-0.52	-7.78	-0.39	9.23e-14	Cocaine dependence;
LUSC	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg08219700	chr8:58056026	NA	0.65	7.53	0.38	4.69e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.12	-0.36	6.5e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg06064525	chr11:970664	AP2A2	-0.47	-10.5	-0.5	1.81e-22	Alzheimer's disease (late onset);
LUSC	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg23625390	chr15:77176239	SCAPER	-0.46	-7.02	-0.36	1.22e-11	Blood metabolite levels;
LUSC	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg22676075	chr6:135203613	NA	0.46	7.13	0.36	6.1e-12	Red blood cell count;
LUSC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.53	0.57	8.34e-30	Motion sickness;
LUSC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg23625390	chr15:77176239	SCAPER	0.59	9.22	0.45	3.51e-18	Blood metabolite levels;
LUSC	cis	rs4903604	0.581	rs12879719	chr14:78035253	C/A	cg18872420	chr14:78023429	SPTLC2	0.38	5.87	0.31	1.05e-8	Gut microbiome composition (winter);
LUSC	cis	rs9400467	0.528	rs7752361	chr6:111780705	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.46	-0.33	3.79e-10	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	1.1	17.27	0.69	3.24e-48	Exhaled nitric oxide output;
LUSC	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	0.9	14.64	0.63	7.94e-38	Schizophrenia;
LUSC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg04315214	chr1:2043799	PRKCZ	0.48	10.08	0.48	4.95e-21	Height;
LUSC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.64	0.43	2.33e-16	Migraine;Coronary artery disease;
LUSC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg10172584	chr19:19639581	YJEFN3	0.49	5.8	0.3	1.5e-8	Bipolar disorder;
LUSC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg14784868	chr12:69753453	YEATS4	0.64	9.5	0.46	4.18e-19	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01330670	chr2:101767621	TBC1D8	-0.44	-6.49	-0.33	3.01e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg13256891	chr4:100009986	ADH5	0.52	7.03	0.36	1.2e-11	Smoking initiation;
LUSC	cis	rs710216	0.957	rs710215	chr1:43429105	T/C	cg22176566	chr1:43424700	SLC2A1	0.48	5.98	0.31	5.71e-9	Red cell distribution width;
LUSC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21862992	chr11:68658383	NA	0.49	7.91	0.4	3.92e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg12924262	chr12:102091054	CHPT1	0.43	6.07	0.32	3.47e-9	Blood protein levels;
LUSC	cis	rs16910800	0.953	rs7126961	chr11:23204237	C/T	cg20040320	chr11:23191996	NA	-0.44	-6.46	-0.33	3.8e-10	Cancer;
LUSC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05025164	chr4:1340916	KIAA1530	0.63	9.75	0.47	6.5e-20	Longevity;
LUSC	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.49	6.33	0.33	7.99e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg18721089	chr20:30220636	NA	-0.39	-6.15	-0.32	2.2e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs12541635	0.966	rs4734128	chr8:107026913	G/A	cg10147462	chr8:107024639	NA	0.55	10.01	0.48	8.31e-21	Age of smoking initiation;
LUSC	cis	rs721399	0.553	rs13262341	chr8:18243097	A/G	cg18736775	chr8:18248649	NAT2	-0.57	-6.75	-0.35	6.68e-11	Blood metabolite levels;
LUSC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg13683864	chr3:40499215	RPL14	-1.13	-21.03	-0.75	3.87e-63	Renal cell carcinoma;
LUSC	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg21141812	chr3:48556323	PFKFB4	-0.32	-6.63	-0.34	1.33e-10	Prion diseases;
LUSC	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg22906224	chr7:99728672	NA	-0.5	-6.96	-0.36	1.78e-11	Coronary artery disease;
LUSC	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg25237894	chr2:233734115	C2orf82	-0.36	-6.68	-0.34	1.01e-10	Coronary artery disease;
LUSC	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg20135002	chr11:47629003	NA	-0.49	-7.56	-0.38	4.02e-13	Subjective well-being;
LUSC	cis	rs3803170	0.513	rs10849944	chr12:111825389	C/T	cg10833066	chr12:111807467	FAM109A	-0.4	-7.51	-0.38	5.54e-13	Mean corpuscular hemoglobin;
LUSC	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22455342	chr2:225449267	CUL3	-0.43	-6.2	-0.32	1.71e-9	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg25767906	chr1:53392781	SCP2	-0.5	-9.11	-0.45	7.51e-18	Monocyte count;
LUSC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.64	0.6	5.58e-34	Cognitive test performance;
LUSC	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg24375607	chr4:120327624	NA	-0.73	-10.83	-0.51	1.25e-23	Corneal astigmatism;
LUSC	cis	rs17739794	0.517	rs4439155	chr8:781047	C/T	cg01971667	chr8:817044	NA	-0.4	-6.53	-0.34	2.48e-10	Clozapine-induced cytotoxicity;
LUSC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-6.36	-0.33	6.74e-10	Longevity;Endometriosis;
LUSC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg16586182	chr3:47516702	SCAP	0.52	7.4	0.38	1.13e-12	Birth weight;
LUSC	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg27661571	chr11:113659931	NA	-0.54	-6.49	-0.33	3.02e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg21194808	chr1:2205498	SKI	-0.46	-7.8	-0.39	7.93e-14	Coronary artery disease;
LUSC	trans	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg21775007	chr8:11205619	TDH	0.44	6.32	0.33	8.36e-10	Mood instability;
LUSC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	5.98	0.31	5.72e-9	Breast cancer;
LUSC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg12463550	chr7:65579703	CRCP	0.51	7.38	0.37	1.26e-12	Aortic root size;
LUSC	cis	rs4690686	0.500	rs11723131	chr4:177268602	G/A	cg17059388	chr4:177262070	NA	0.46	8.6	0.43	3.22e-16	Essential tremor;
LUSC	cis	rs8038465	1.000	rs8041181	chr15:73982336	C/T	cg15420318	chr15:73925796	NPTN	0.39	6.15	0.32	2.17e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg06096015	chr1:231504339	EGLN1	0.56	9.92	0.48	1.75e-20	Hemoglobin concentration;
LUSC	cis	rs7760535	0.794	rs3851225	chr6:111825132	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.9	-0.35	2.59e-11	Metabolic traits;
LUSC	trans	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg13565492	chr6:43139072	SRF	-0.57	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg11812906	chr14:75593930	NEK9	0.64	10.69	0.51	3.74e-23	Height;
LUSC	cis	rs11264213	0.901	rs581459	chr1:36375110	C/T	cg27506609	chr1:36549197	TEKT2	0.49	6.87	0.35	3.06e-11	Schizophrenia;
LUSC	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg24675056	chr1:15929824	NA	0.46	8.03	0.4	1.73e-14	Systolic blood pressure;
LUSC	cis	rs2279817	0.735	rs34571066	chr1:18002777	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.2	-0.32	1.71e-9	Neuroticism;
LUSC	cis	rs12249377	0.519	rs11599902	chr10:92598823	A/G	cg14313238	chr10:92632228	RPP30	0.43	6.15	0.32	2.25e-9	White matter microstructure (global fractional anisotropy);
LUSC	cis	rs9309473	1.000	rs13398956	chr2:73720258	C/A	cg20560298	chr2:73613845	ALMS1	-0.45	-6.38	-0.33	5.81e-10	Metabolite levels;
LUSC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.86	-0.35	3.27e-11	Lung cancer;
LUSC	cis	rs75804782	0.521	rs56087929	chr2:239455564	G/A	cg18131467	chr2:239335373	ASB1	-0.63	-5.87	-0.31	1.03e-8	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg25036284	chr2:26402008	FAM59B	-0.7	-9.87	-0.48	2.52e-20	Gut microbiome composition (summer);
LUSC	cis	rs3736594	0.879	rs4666011	chr2:27980912	G/C	cg27432699	chr2:27873401	GPN1	0.64	8.82	0.43	6.5e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg06060754	chr5:176797920	RGS14	-0.6	-8.78	-0.43	8.75e-17	Urate levels in lean individuals;
LUSC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.7	-0.51	3.47e-23	Aortic root size;
LUSC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg12365402	chr11:9010492	NRIP3	0.47	8.62	0.43	2.64e-16	Hemoglobin concentration;
LUSC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg06618935	chr21:46677482	NA	-0.39	-7.84	-0.39	6.23e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12801636	0.512	rs12420618	chr11:65412974	C/G	cg24147428	chr11:65409760	SIPA1	-0.51	-5.89	-0.31	9.41e-9	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg08048268	chr3:133502702	NA	-0.4	-7.25	-0.37	2.99e-12	Iron status biomarkers;
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.3	-5.69	-0.3	2.85e-8	Lymphocyte counts;
LUSC	cis	rs7582180	0.874	rs13031270	chr2:100896311	G/T	cg08017756	chr2:100939284	LONRF2	-0.36	-6.01	-0.31	4.77e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg13042288	chr15:90349979	ANPEP	-0.49	-7.08	-0.36	8.42e-12	Uric acid levels;
LUSC	cis	rs17253792	0.749	rs17747301	chr14:56125030	C/G	cg01858014	chr14:56050164	KTN1	-0.8	-6.58	-0.34	1.79e-10	Putamen volume;
LUSC	cis	rs6961069	0.777	rs2366855	chr7:80253455	A/T	cg04458919	chr7:80252533	CD36	-0.35	-6.27	-0.32	1.1e-9	Platelet count;
LUSC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Parkinson's disease;
LUSC	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg18200150	chr17:30822561	MYO1D	-0.3	-5.82	-0.3	1.4e-8	Schizophrenia;
LUSC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg14664628	chr15:75095509	CSK	-0.57	-8.94	-0.44	2.68e-17	Breast cancer;
LUSC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg06740227	chr12:86229804	RASSF9	-0.46	-7.46	-0.38	7.4e-13	Major depressive disorder;
LUSC	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.87	-10.92	-0.51	6.28e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg09626299	chr10:82213104	TSPAN14	-0.2	-6.01	-0.31	4.78e-9	Post bronchodilator FEV1;
LUSC	cis	rs3820068	0.608	rs7514858	chr1:16035246	G/A	cg24675056	chr1:15929824	NA	0.41	6.84	0.35	3.9e-11	Systolic blood pressure;
LUSC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.71e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs3087591	0.960	rs2905797	chr17:29537458	G/C	cg24425628	chr17:29625626	OMG;NF1	0.6	8.86	0.44	4.68e-17	Hip circumference;
LUSC	cis	rs6736093	0.966	rs34527376	chr2:112755699	C/T	cg12686935	chr2:112915763	FBLN7	-0.37	-6.06	-0.31	3.65e-9	Coronary artery disease;
LUSC	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.21	-0.32	1.57e-9	Resting heart rate;
LUSC	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.37	-0.56	3.42e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg25237894	chr2:233734115	C2orf82	0.35	6.59	0.34	1.69e-10	Coronary artery disease;
LUSC	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg20607287	chr7:12443886	VWDE	-0.59	-6.14	-0.32	2.35e-9	Coronary artery disease;
LUSC	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg00745463	chr17:30367425	LRRC37B	0.63	7.58	0.38	3.37e-13	Hip circumference adjusted for BMI;
LUSC	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg12856521	chr11:46389249	DGKZ	0.41	6.38	0.33	6.02e-10	Leprosy;
LUSC	trans	rs4734806	0.579	rs72677049	chr8:105871357	T/C	cg19267248	chr12:98849532	NA	0.39	6.06	0.31	3.72e-9	Periodontitis (DPAL);
LUSC	cis	rs977987	0.581	rs8056141	chr16:75497162	A/T	cg03315344	chr16:75512273	CHST6	0.51	9.38	0.46	1.04e-18	Dupuytren's disease;
LUSC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg13126279	chr21:47581558	C21orf56	0.41	5.86	0.31	1.08e-8	Testicular germ cell tumor;
LUSC	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14240646	chr10:27532245	ACBD5	-0.88	-8.77	-0.43	9.31e-17	Breast cancer;
LUSC	cis	rs4622329	0.636	rs10860812	chr12:102288370	A/G	cg23541617	chr12:102225335	GNPTAB	-0.27	-6.02	-0.31	4.52e-9	Systemic lupus erythematosus;
LUSC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.49	-8.51	-0.42	6.01e-16	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	7.81	0.39	7.51e-14	Motion sickness;
LUSC	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg08085267	chr17:45401833	C17orf57	0.61	10.3	0.49	8.8e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25072359	chr17:41440525	NA	0.65	9.19	0.45	4.21e-18	Menopause (age at onset);
LUSC	cis	rs2274273	0.624	rs7152390	chr14:55811701	C/T	cg04306507	chr14:55594613	LGALS3	0.48	9.46	0.46	5.53e-19	Protein biomarker;
LUSC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.3	0.56	6.25e-29	Prudent dietary pattern;
LUSC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg25036284	chr2:26402008	FAM59B	-0.68	-9.56	-0.46	2.62e-19	Gut microbiome composition (summer);
LUSC	cis	rs6121246	0.529	rs41310803	chr20:30452709	A/G	cg13852791	chr20:30311386	BCL2L1	0.6	6.22	0.32	1.45e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs2455601	1.000	rs56336128	chr11:8908299	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.5	-7.68	-0.39	1.81e-13	Schizophrenia;
LUSC	cis	rs2667011	0.697	rs2667002	chr2:160856492	C/T	cg06573604	chr2:160760825	LY75	-0.5	-6.31	-0.33	8.89e-10	Bilirubin levels;
LUSC	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg07148914	chr20:33460835	GGT7	0.54	8.4	0.42	1.33e-15	Height;
LUSC	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg06623918	chr6:96969491	KIAA0776	-0.83	-9.99	-0.48	9.96e-21	Migraine;Coronary artery disease;
LUSC	cis	rs977987	0.806	rs11860284	chr16:75412907	A/G	cg04384234	chr16:75411784	CFDP1	-0.44	-7.26	-0.37	2.79e-12	Dupuytren's disease;
LUSC	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg16950941	chr11:66035639	RAB1B	0.53	7.8	0.39	7.78e-14	Gout;
LUSC	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg13813247	chr22:41461852	NA	-0.36	-6.45	-0.33	3.82e-10	Neuroticism;
LUSC	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg19468946	chr17:37922297	IKZF3	-0.43	-6.79	-0.35	5.22e-11	Self-reported allergy;
LUSC	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	6.35	0.33	6.88e-10	Rheumatoid arthritis;
LUSC	cis	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.88	0.31	9.74e-9	Menopause (age at onset);
LUSC	cis	rs9921338	0.961	rs72773833	chr16:11413274	G/A	cg00044050	chr16:11439710	C16orf75	-0.49	-6.69	-0.34	9.14e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	trans	rs984440	0.621	rs12550578	chr8:139078255	A/G	cg03334052	chr1:168888044	NA	-0.41	-6.51	-0.34	2.79e-10	Obesity-related traits;
LUSC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.52	-7.96	-0.4	2.66e-14	Parkinson's disease;
LUSC	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg05535760	chr7:792225	HEATR2	0.78	9.06	0.44	1.09e-17	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24110177	chr3:50126178	RBM5	-0.55	-9.03	-0.44	1.35e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg06134567	chr22:46658398	PKDREJ	-0.53	-5.93	-0.31	7.54e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6977660	0.714	rs34451907	chr7:19824538	A/G	cg05791153	chr7:19748676	TWISTNB	0.68	7.08	0.36	8.71e-12	Thyroid stimulating hormone;
LUSC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg12639453	chr1:2035780	PRKCZ	0.3	6.24	0.32	1.36e-9	Height;
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.66	10.01	0.48	8.59e-21	Lymphocyte counts;
LUSC	cis	rs2446066	0.872	rs111939932	chr12:53843771	C/T	cg20730629	chr12:53886622	MAP3K12	-0.43	-5.79	-0.3	1.63e-8	Red blood cell count;
LUSC	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.33	5.93	0.31	7.6e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg03929089	chr4:120376271	NA	0.83	11.27	0.52	3.58e-25	Coronary artery disease;
LUSC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg05347473	chr6:146136440	FBXO30	0.44	7.53	0.38	4.89e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg04155289	chr7:94953770	PON1	-0.34	-5.83	-0.3	1.33e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.3	0.53	2.83e-25	Prudent dietary pattern;
LUSC	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg00225070	chr15:80189496	MTHFS	0.62	9.63	0.47	1.61e-19	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9921338	0.923	rs72771877	chr16:11368616	T/A	cg00044050	chr16:11439710	C16orf75	-0.5	-6.75	-0.35	6.68e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs9311676	0.632	rs57700771	chr3:58360327	G/A	cg26110898	chr3:58419937	PDHB	0.41	6.64	0.34	1.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs7095944	0.614	rs7099316	chr10:126469005	G/A	cg08799069	chr10:126477246	METTL10	-0.43	-6.74	-0.35	7.17e-11	Asthma;
LUSC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg22903657	chr4:1355424	KIAA1530	-0.4	-7.04	-0.36	1.11e-11	Longevity;
LUSC	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.49	7.59	0.38	3.1400000000000003e-13	Breast cancer;
LUSC	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg00791764	chr4:53727839	RASL11B	0.56	7.73	0.39	1.31e-13	Optic nerve measurement (cup area);
LUSC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.88	-15.38	-0.64	9.98e-41	Cognitive function;
LUSC	cis	rs738322	0.511	rs2267371	chr22:38577119	T/G	cg17652424	chr22:38574118	PLA2G6	-0.3	-6.1	-0.32	3e-9	Cutaneous nevi;
LUSC	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.7	-0.6	3.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg23978390	chr7:1156363	C7orf50	0.42	5.9	0.31	8.96e-9	Longevity;Endometriosis;
LUSC	cis	rs10761482	0.769	rs990685	chr10:62098149	C/T	cg18175470	chr10:62150864	ANK3	-0.5	-7.06	-0.36	9.52e-12	Schizophrenia;
LUSC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg05802129	chr4:122689817	NA	-0.37	-6.62	-0.34	1.44e-10	Type 2 diabetes;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23247000	chr7:138794512	ZC3HAV1	0.36	6.06	0.31	3.6e-9	Triglycerides;
LUSC	cis	rs11608355	1.000	rs2075439	chr12:109859374	A/G	cg05360138	chr12:110035743	NA	0.46	6.34	0.33	7.51e-10	Neuroticism;
LUSC	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	5.7	0.3	2.69e-8	Schizophrenia;
LUSC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg26513180	chr16:89883248	FANCA	0.79	6.36	0.33	6.64e-10	Skin colour saturation;
LUSC	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg18964960	chr10:1102726	WDR37	0.7	6.34	0.33	7.58e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7589342	0.839	rs6747023	chr2:106431856	A/G	cg14210321	chr2:106509881	NCK2	-0.53	-7.92	-0.4	3.47e-14	Addiction;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11236850	chr4:8443022	ACOX3	-0.42	-6.07	-0.32	3.39e-9	Hepatitis;
LUSC	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	1.01	14.04	0.61	1.57e-35	Uric acid levels;
LUSC	cis	rs4423214	0.515	rs4944042	chr11:71118788	C/A	cg05163923	chr11:71159392	DHCR7	0.5	7.26	0.37	2.67e-12	Vitamin D levels;
LUSC	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.53	10.0	0.48	9.14e-21	Bone mineral density;
LUSC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.72	12.3	0.56	6.22e-29	Motion sickness;
LUSC	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	0.87	13.94	0.61	3.78e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	trans	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg09904177	chr6:26538194	HMGN4	0.43	6.45	0.33	3.91e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4654899	0.828	rs6668591	chr1:21066557	A/G	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.36	9.47e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.58	-6.22	-0.32	1.49e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15664640	chr17:80829946	TBCD	-0.74	-12.62	-0.57	4.15e-30	Breast cancer;
LUSC	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21028142	chr17:79581711	NPLOC4	-0.33	-7.64	-0.39	2.3e-13	Eye color traits;
LUSC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.6	-0.34	1.59e-10	Life satisfaction;
LUSC	trans	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.89	-0.4	4.29e-14	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22346581	chr8:107282483	OXR1	-0.4	-6.0	-0.31	5.15e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg03351412	chr1:154909251	PMVK	0.55	8.7	0.43	1.52e-16	Prostate cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20000099	chr19:33864973	CEBPG	-0.43	-6.54	-0.34	2.33e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.9	0.51	6.98e-24	Hypertriglyceridemia;
LUSC	cis	rs829883	0.738	rs249846	chr12:98868739	T/C	cg25150519	chr12:98850993	NA	0.79	13.64	0.6	5.53e-34	Colorectal adenoma (advanced);
LUSC	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg24130564	chr14:104152367	KLC1	-0.7	-11.34	-0.53	1.9e-25	Intelligence (multi-trait analysis);
LUSC	trans	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg01620082	chr3:125678407	NA	-0.75	-6.29	-0.33	9.67e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4776059	1.000	rs10851521	chr15:52942111	G/A	cg22715398	chr15:52968154	KIAA1370	-0.64	-9.13	-0.45	6.58e-18	Schizophrenia;
LUSC	cis	rs3093024	0.935	rs10946216	chr6:167538897	T/C	cg07741184	chr6:167504864	NA	-0.48	-8.4	-0.42	1.32e-15	Rheumatoid arthritis;
LUSC	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.91	15.42	0.64	7e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs911119	1.000	rs6114209	chr20:23622266	G/C	cg16589663	chr20:23618590	CST3	0.62	7.63	0.39	2.56e-13	Chronic kidney disease;
LUSC	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg08601574	chr20:25228251	PYGB	-0.44	-6.79	-0.35	5.29e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7809950	1.000	rs2894475	chr7:107262558	A/T	cg23024343	chr7:107201750	COG5	-0.49	-7.85	-0.39	5.76e-14	Coronary artery disease;
LUSC	trans	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg26384229	chr12:38710491	ALG10B	0.56	8.61	0.43	3.03e-16	Morning vs. evening chronotype;
LUSC	cis	rs1957429	0.614	rs73279833	chr14:65352523	A/G	cg23373153	chr14:65346875	NA	-0.99	-8.98	-0.44	1.97e-17	Pediatric areal bone mineral density (radius);
LUSC	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg13755796	chr4:20253514	NA	-0.41	-6.29	-0.33	1.01e-9	Life satisfaction;
LUSC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg18681998	chr4:17616180	MED28	0.88	16.23	0.66	4.6e-44	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.14	-0.32	2.31e-9	Menopause (age at onset);
LUSC	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.75	-12.48	-0.56	1.29e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg03806693	chr22:41940476	POLR3H	-0.59	-8.61	-0.43	2.85e-16	Neuroticism;
LUSC	trans	rs13390641	0.614	rs10496374	chr2:104079777	C/T	cg03260781	chr1:16346299	HSPB7	0.47	6.36	0.33	6.58e-10	Blood pressure;Blood pressure (anthropometric measures interaction);
LUSC	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg02176678	chr2:219576539	TTLL4	0.59	10.82	0.51	1.36e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg20487152	chr13:99095054	FARP1	-0.41	-6.83	-0.35	4.14e-11	Neuroticism;
LUSC	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-10.45	-0.5	2.62e-22	Bladder cancer;
LUSC	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-9.64	-0.47	1.46e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.77	0.35	5.68e-11	Tonsillectomy;
LUSC	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg06885757	chr1:42089581	HIVEP3	-0.45	-8.56	-0.42	4.1e-16	Airway imaging phenotypes;
LUSC	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg24154853	chr7:158122151	PTPRN2	0.45	8.8	0.43	7.55e-17	Calcium levels;
LUSC	cis	rs4363385	0.776	rs2879490	chr1:152947163	A/G	cg07796016	chr1:152779584	LCE1C	-0.47	-6.65	-0.34	1.23e-10	Inflammatory skin disease;
LUSC	cis	rs921665	0.748	rs1869421	chr2:3202068	G/T	cg16434511	chr2:3151078	NA	-0.58	-5.93	-0.31	7.76e-9	World class endurance athleticism;
LUSC	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg15423357	chr2:25149977	NA	-0.37	-7.34	-0.37	1.66e-12	Body mass index in non-asthmatics;
LUSC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.35	0.42	1.88e-15	Hemoglobin concentration;
LUSC	trans	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.04	21.33	0.76	2.7e-64	Cognitive function;
LUSC	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg03676636	chr4:99064102	C4orf37	0.35	7.61	0.38	2.85e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg14227996	chr4:17616232	MED28	0.8	8.1	0.41	1.06e-14	Opioid sensitivity;
LUSC	cis	rs7267979	0.549	rs6138537	chr20:25184466	A/G	cg08601574	chr20:25228251	PYGB	0.5	7.81	0.39	7.27e-14	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.2	-0.37	3.96e-12	Neuroticism;
LUSC	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-7.12	-0.36	6.86e-12	Bipolar disorder;
LUSC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg27124370	chr19:33622961	WDR88	0.58	7.63	0.39	2.56e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.45	-0.33	3.84e-10	Total body bone mineral density;
LUSC	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01341218	chr17:43662625	NA	-0.73	-10.61	-0.5	7.68e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.48	8.17	0.41	6.27e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17467752	chr17:38218738	THRA	0.77	12.45	0.56	1.7e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.42	0.42	1.09e-15	Prudent dietary pattern;
LUSC	cis	rs4363385	0.747	rs6587716	chr1:152966705	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.61	-0.38	2.77e-13	Inflammatory skin disease;
LUSC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.19	-0.52	6.61e-25	Alzheimer's disease;
LUSC	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.19	-0.41	5.51e-15	Axial length;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18755653	chr4:108910870	HADH	-0.44	-6.49	-0.33	3.19e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg26043149	chr18:55253948	FECH	0.47	7.12	0.36	6.68e-12	Bone mineral density;
LUSC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05535760	chr7:792225	HEATR2	0.78	9.17	0.45	5.01e-18	Cerebrospinal P-tau181p levels;
LUSC	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg25809561	chr17:30822961	MYO1D	-0.38	-6.4	-0.33	5.31e-10	Schizophrenia;
LUSC	trans	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg07211511	chr3:129823064	LOC729375	-0.75	-9.81	-0.47	4.1e-20	Blood pressure (smoking interaction);
LUSC	cis	rs7071206	0.898	rs28706743	chr10:79394329	T/G	cg07817648	chr10:79422355	NA	-0.59	-7.51	-0.38	5.33e-13	Bone mineral density;
LUSC	cis	rs3126085	0.935	rs4634913	chr1:152249932	T/C	cg26876637	chr1:152193138	HRNR	0.46	6.38	0.33	6.03e-10	Atopic dermatitis;
LUSC	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.53	-7.18	-0.37	4.47e-12	Renal function-related traits (BUN);
LUSC	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg21665744	chr7:39171113	POU6F2	0.45	7.34	0.37	1.64e-12	IgG glycosylation;
LUSC	cis	rs13006833	0.668	rs2136566	chr2:191141283	C/T	cg21644426	chr2:191273491	MFSD6	0.47	6.58	0.34	1.86e-10	Urinary metabolites;
LUSC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg12639453	chr1:2035780	PRKCZ	0.29	6.29	0.33	9.71e-10	Height;
LUSC	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg03929089	chr4:120376271	NA	0.69	7.76	0.39	1.06e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg07148914	chr20:33460835	GGT7	-0.42	-6.25	-0.32	1.26e-9	Coronary artery disease;
LUSC	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg23241863	chr10:102295624	HIF1AN	0.46	5.73	0.3	2.22e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2835872	0.869	rs73203821	chr21:39046744	C/T	cg20424643	chr21:39039972	KCNJ6	0.51	7.58	0.38	3.38e-13	Electroencephalographic traits in alcoholism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24830314	chr6:83775579	UBE2CBP	-0.51	-6.04	-0.31	4.18e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg26384229	chr12:38710491	ALG10B	0.72	11.71	0.54	9.17e-27	Morning vs. evening chronotype;
LUSC	cis	rs6426558	0.537	rs488104	chr1:227300277	G/A	cg10327440	chr1:227177885	CDC42BPA	0.54	7.39	0.37	1.18e-12	Neutrophil percentage of white cells;
LUSC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06544989	chr22:39130855	UNC84B	-0.39	-7.08	-0.36	8.37e-12	Menopause (age at onset);
LUSC	cis	rs7202877	0.656	rs8048677	chr16:75392028	C/G	cg03315344	chr16:75512273	CHST6	0.44	6.47	0.33	3.59e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.53	-8.68	-0.43	1.76e-16	Longevity;Endometriosis;
LUSC	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.57	-0.46	2.51e-19	Extrinsic epigenetic age acceleration;
LUSC	trans	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.7	12.83	0.57	6.7e-31	Mean corpuscular volume;
LUSC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg07217954	chr7:1067459	C7orf50	0.52	5.67	0.3	3.02e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg03609598	chr5:56110824	MAP3K1	-0.41	-6.09	-0.32	3.02e-9	Initial pursuit acceleration;
LUSC	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg04851639	chr8:1020857	NA	0.31	6.14	0.32	2.37e-9	Schizophrenia;
LUSC	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-8.26	-0.41	3.35e-15	Total cholesterol levels;
LUSC	cis	rs7707921	0.881	rs2407153	chr5:81555328	T/G	cg15871215	chr5:81402204	ATG10	0.43	6.14	0.32	2.29e-9	Breast cancer;
LUSC	cis	rs897080	0.515	rs1067366	chr2:44655094	T/C	cg00619915	chr2:44497795	NA	-0.41	-6.14	-0.32	2.36e-9	Height;
LUSC	cis	rs11030122	0.632	rs10835556	chr11:4083013	A/G	cg08557956	chr11:4115526	RRM1	-0.46	-6.0	-0.31	5.25e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-6.02	-0.31	4.47e-9	Huntington's disease progression;
LUSC	cis	rs6977660	1.000	rs2892940	chr7:19794750	G/A	cg07541023	chr7:19748670	TWISTNB	0.59	6.72	0.35	7.84e-11	Thyroid stimulating hormone;
LUSC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	14.72	0.63	3.88e-38	Platelet count;
LUSC	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg05855489	chr10:104503620	C10orf26	0.52	8.08	0.4	1.19e-14	Arsenic metabolism;
LUSC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg26441486	chr22:50317300	CRELD2	0.49	7.28	0.37	2.45e-12	Schizophrenia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17658546	chr4:90032747	TIGD2	-0.49	-6.59	-0.34	1.75e-10	Hepatitis;
LUSC	trans	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07923666	chr12:49932857	KCNH3	-0.52	-6.48	-0.33	3.31e-10	Resting heart rate;
LUSC	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg15423357	chr2:25149977	NA	0.43	8.71	0.43	1.4e-16	Body mass index;
LUSC	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14829155	chr15:31115871	NA	-0.57	-7.96	-0.4	2.7e-14	Huntington's disease progression;
LUSC	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.59	0.38	3.32e-13	Bipolar disorder;
LUSC	cis	rs6545883	0.894	rs2167566	chr2:61519408	G/T	cg15711740	chr2:61764176	XPO1	-0.44	-6.99	-0.36	1.49e-11	Tuberculosis;
LUSC	cis	rs68170813	0.559	rs4515482	chr7:107072681	A/C	cg02696742	chr7:106810147	HBP1	-0.61	-8.96	-0.44	2.35e-17	Coronary artery disease;
LUSC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg12560992	chr17:57184187	TRIM37	0.83	15.01	0.63	2.71e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg10018233	chr7:150070692	REPIN1	0.45	9.1	0.45	8.14e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10802521	chr3:52805072	NEK4	-0.54	-8.7	-0.43	1.54e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05901451	chr6:126070800	HEY2	-0.92	-17.95	-0.7	6.65e-51	Brugada syndrome;
LUSC	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg04455712	chr21:45112962	RRP1B	0.46	8.8	0.43	7.66e-17	Mean corpuscular volume;
LUSC	cis	rs3818285	0.504	rs1973972	chr10:111651133	A/T	cg00817464	chr10:111662876	XPNPEP1	0.6	8.63	0.43	2.53e-16	Superior crus of antihelix expression;
LUSC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg04871131	chr7:94954202	PON1	-0.39	-6.14	-0.32	2.41e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.89	14.82	0.63	1.52e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	cis	rs2130392	0.962	rs13132498	chr4:185611454	T/C	cg04058563	chr4:185651563	MLF1IP	-0.44	-7.18	-0.37	4.62e-12	Kawasaki disease;
LUSC	cis	rs2236918	1.000	rs1635509	chr1:242028027	C/T	cg17736920	chr1:242011382	EXO1	0.43	6.85	0.35	3.62e-11	Menopause (age at onset);
LUSC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.63	-9.26	-0.45	2.61e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.69	-0.43	1.65e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs12760731	0.720	rs10913540	chr1:178340060	T/C	cg00404053	chr1:178313656	RASAL2	0.62	6.45	0.33	3.85e-10	Obesity-related traits;
LUSC	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg02380750	chr20:61661411	NA	0.33	5.77	0.3	1.81e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs909002	0.789	rs2139539	chr1:32117779	C/T	cg01639898	chr1:32083012	HCRTR1	0.3	7.59	0.38	3.25e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg14196790	chr5:131705035	SLC22A5	0.43	7.17	0.37	4.76e-12	Blood metabolite levels;
LUSC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	12.81	0.57	7.9e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11168618	0.875	rs11168606	chr12:48892689	G/T	cg24011408	chr12:48396354	COL2A1	0.39	6.25	0.32	1.22e-9	Adiponectin levels;
LUSC	cis	rs727505	0.954	rs59673207	chr7:124596982	G/C	cg23710748	chr7:124431027	NA	-0.38	-6.6	-0.34	1.58e-10	Lewy body disease;
LUSC	cis	rs10754283	0.934	rs10754284	chr1:90113702	A/C	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.73	-0.39	1.31e-13	Lymphocyte counts;
LUSC	cis	rs11051970	0.879	rs950080	chr12:32588503	G/A	cg24626660	chr12:32551988	NA	0.33	5.66	0.3	3.2e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg25457927	chr22:38595422	NA	-0.42	-8.93	-0.44	2.89e-17	Cutaneous nevi;
LUSC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-6.99	-0.36	1.51e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs12493885	0.585	rs701264	chr3:153628080	A/G	cg17054900	chr3:154042577	DHX36	-0.59	-6.07	-0.32	3.51e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg06532163	chr17:45867833	NA	0.34	6.23	0.32	1.41e-9	IgG glycosylation;
LUSC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg17264618	chr3:40429014	ENTPD3	0.36	7.47	0.38	6.9e-13	Renal cell carcinoma;
LUSC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	0.84	14.13	0.61	7.18e-36	Cognitive function;
LUSC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12311346	chr5:56204834	C5orf35	0.83	13.38	0.59	5.6e-33	Initial pursuit acceleration;
LUSC	cis	rs77216612	0.840	rs11055030	chr12:12878349	G/C	cg04607235	chr12:12878440	APOLD1	-0.95	-15.62	-0.65	1.15e-41	Lymphocyte counts;
LUSC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.66	-11.27	-0.53	3.39e-25	Personality dimensions;
LUSC	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.46	-0.46	5.87e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.4	0.38	1.15e-12	Schizophrenia;
LUSC	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg22875332	chr1:76189707	ACADM	-0.41	-5.81	-0.3	1.43e-8	Daytime sleep phenotypes;
LUSC	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg13010199	chr12:38710504	ALG10B	0.7	10.91	0.51	6.68e-24	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg07424592	chr7:64974309	NA	0.71	6.19	0.32	1.72e-9	Diabetic kidney disease;
LUSC	cis	rs6967385	0.934	rs2098364	chr7:12368783	C/A	cg06484146	chr7:12443880	VWDE	0.42	6.15	0.32	2.26e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg00898013	chr13:113819073	PROZ	-0.55	-7.91	-0.4	3.91e-14	Platelet distribution width;
LUSC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.03	21.12	0.76	1.7e-63	Cognitive function;
LUSC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg02153584	chr22:29168773	CCDC117	0.62	9.67	0.47	1.13e-19	Lymphocyte counts;
LUSC	cis	rs7072216	0.881	rs2147896	chr10:100148176	A/G	cg26618903	chr10:100175079	PYROXD2	-0.3	-5.78	-0.3	1.74e-8	Metabolite levels;
LUSC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg07414643	chr4:187882934	NA	0.56	10.64	0.5	5.99e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6845621	0.717	rs1518002	chr4:18843657	G/A	cg12196642	chr4:18937545	NA	-0.32	-5.8	-0.3	1.53e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg13852791	chr20:30311386	BCL2L1	0.93	14.15	0.61	6.1e-36	Mean corpuscular hemoglobin;
LUSC	cis	rs10979	0.597	rs9496685	chr6:143908690	G/A	cg25407410	chr6:143891975	LOC285740	-0.65	-8.17	-0.41	6.6e-15	Hypospadias;
LUSC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg17691542	chr6:26056736	HIST1H1C	0.53	8.09	0.4	1.1e-14	Height;
LUSC	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg24675056	chr1:15929824	NA	0.42	6.82	0.35	4.36e-11	Systolic blood pressure;
LUSC	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg02380750	chr20:61661411	NA	0.34	5.89	0.31	9.22e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7605827	0.930	rs12692261	chr2:15511967	T/G	cg19274914	chr2:15703543	NA	0.46	8.95	0.44	2.45e-17	Educational attainment (years of education);
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.34	-7.27	-0.37	2.63e-12	Longevity;Endometriosis;
LUSC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg15145296	chr3:125709740	NA	-0.58	-6.56	-0.34	2.03e-10	Blood pressure (smoking interaction);
LUSC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg03060546	chr3:49711283	APEH	0.65	7.31	0.37	1.97e-12	Menarche (age at onset);
LUSC	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg22089800	chr15:90895588	ZNF774	0.56	8.06	0.4	1.36e-14	Rheumatoid arthritis;
LUSC	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.37	-5.83	-0.3	1.33e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUSC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.45	-6.99	-0.36	1.51e-11	Blood metabolite levels;
LUSC	cis	rs8092503	1.000	rs1819886	chr18:52493622	A/G	cg12377874	chr18:52495404	RAB27B	0.34	6.14	0.32	2.38e-9	Childhood body mass index;
LUSC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg17971929	chr21:40555470	PSMG1	-0.52	-7.52	-0.38	5.25e-13	Menarche (age at onset);
LUSC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg03213289	chr20:61660250	NA	0.67	13.96	0.61	3.26e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05665937	chr4:1216051	CTBP1	0.36	5.69	0.3	2.8e-8	Obesity-related traits;
LUSC	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.52	-0.5	1.49e-22	Eye color traits;
LUSC	cis	rs6987853	0.966	rs2923428	chr8:42388301	T/C	cg09913449	chr8:42400586	C8orf40	0.49	8.29	0.41	2.78e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg06521331	chr12:34319734	NA	-0.39	-5.83	-0.3	1.33e-8	Resting heart rate;
LUSC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06544989	chr22:39130855	UNC84B	0.34	5.8	0.3	1.54e-8	Menopause (age at onset);
LUSC	cis	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg27411982	chr8:10470053	RP1L1	0.38	5.81	0.3	1.48e-8	Systolic blood pressure;
LUSC	trans	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	12.34	0.56	4.42e-29	Exhaled nitric oxide output;
LUSC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.68	11.69	0.54	1.03e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg14500267	chr11:67383377	NA	0.35	6.66	0.34	1.14e-10	Mean corpuscular volume;
LUSC	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg05043794	chr9:111880884	C9orf5	-0.36	-7.45	-0.38	7.86e-13	Menarche (age at onset);
LUSC	cis	rs9815354	0.951	rs12492599	chr3:42005734	C/A	cg03022575	chr3:42003672	ULK4	-0.51	-5.79	-0.3	1.64e-8	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg16434002	chr17:42200994	HDAC5	-0.45	-6.32	-0.33	8.15e-10	Total body bone mineral density;
LUSC	cis	rs9475752	1.000	rs1460561	chr6:56797574	G/T	cg26366048	chr6:56820386	BEND6;DST	0.53	5.72	0.3	2.36e-8	Menarche (age at onset);
LUSC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg25319279	chr11:5960081	NA	0.43	6.65	0.34	1.17e-10	DNA methylation (variation);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25417551	chr17:35767582	TADA2A;ACACA	0.41	6.01	0.31	4.94e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	10.52	0.5	1.53e-22	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg03651054	chr13:50194643	NA	0.36	6.23	0.32	1.38e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg18350739	chr11:68623251	NA	-0.37	-6.66	-0.34	1.14e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.59	0.62	1.2e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2625529	0.824	rs2306488	chr15:72292115	A/G	cg16672083	chr15:72433130	SENP8	-0.52	-7.49	-0.38	6.03e-13	Red blood cell count;
LUSC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg22800045	chr5:56110881	MAP3K1	0.67	9.15	0.45	5.56e-18	Initial pursuit acceleration;
LUSC	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10986311	0.802	rs7049097	chr9:127110457	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.47	7.54	0.38	4.57e-13	Vitiligo;
LUSC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	trans	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg25214090	chr10:38739885	LOC399744	0.38	6.15	0.32	2.25e-9	Diastolic blood pressure;
LUSC	cis	rs4792901	0.802	rs28636996	chr17:41572786	T/C	cg22562494	chr17:41607896	ETV4	-0.33	-6.18	-0.32	1.9e-9	Dupuytren's disease;
LUSC	cis	rs67072384	1.000	rs72964181	chr11:72440124	C/G	cg04827223	chr11:72435913	ARAP1	-0.83	-7.37	-0.37	1.38e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	trans	rs747782	0.527	rs3741410	chr11:48168664	A/C	cg15704280	chr7:45808275	SEPT13	0.58	5.96	0.31	6.43e-9	Intraocular pressure;
LUSC	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.52	5.89	0.31	9.29e-9	Red blood cell traits;
LUSC	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg09877947	chr5:131593287	PDLIM4	0.49	7.93	0.4	3.22e-14	Blood metabolite levels;
LUSC	cis	rs7605827	0.930	rs10208972	chr2:15676686	G/A	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.77e-16	Educational attainment (years of education);
LUSC	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-6.15	-0.32	2.23e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg05110241	chr16:68378359	PRMT7	-0.5	-6.26	-0.32	1.17e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.18	0.37	4.46e-12	Mean platelet volume;
LUSC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg03526776	chr6:41159608	TREML2	0.33	6.44	0.33	4.24e-10	Alzheimer's disease (late onset);
LUSC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07677032	chr17:61819896	STRADA	0.54	9.03	0.44	1.36e-17	Prudent dietary pattern;
LUSC	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg22139774	chr2:100720529	AFF3	0.52	9.51	0.46	4.01e-19	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26314531	chr2:26401878	FAM59B	-0.68	-9.1	-0.45	8.35e-18	Gut microbiome composition (summer);
LUSC	trans	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg26811252	chr16:29126840	RRN3P2	0.57	9.15	0.45	5.58e-18	Menopause (age at onset);
LUSC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg23262073	chr20:60523788	NA	-0.44	-6.23	-0.32	1.4e-9	Body mass index;
LUSC	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg06484146	chr7:12443880	VWDE	-0.69	-7.28	-0.37	2.41e-12	Coronary artery disease;
LUSC	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-0.86	-16.62	-0.67	1.25e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg26850624	chr5:429559	AHRR	-0.41	-8.0	-0.4	2.1e-14	Cystic fibrosis severity;
LUSC	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg26384229	chr12:38710491	ALG10B	0.63	10.16	0.49	2.59e-21	Morning vs. evening chronotype;
LUSC	cis	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg17469321	chr7:55412551	NA	0.65	10.41	0.5	3.51e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg06521331	chr12:34319734	NA	0.41	6.67	0.34	1.07e-10	Morning vs. evening chronotype;
LUSC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.15	-0.49	2.88e-21	Obesity-related traits;
LUSC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg01579765	chr21:45077557	HSF2BP	0.56	12.06	0.55	4.64e-28	Mean corpuscular volume;
LUSC	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg15501526	chr10:2543763	NA	0.67	12.24	0.56	1.08e-28	Age-related hearing impairment;
LUSC	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.5	-12.29	-0.56	6.71e-29	Urate levels in overweight individuals;
LUSC	cis	rs9837602	0.882	rs6807176	chr3:99760864	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.17	-0.32	1.99e-9	Breast cancer;
LUSC	cis	rs17407555	0.606	rs3775945	chr4:10011996	A/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-6.21	-0.32	1.53e-9	Schizophrenia (age at onset);
LUSC	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg22482690	chr17:47019901	SNF8	0.38	7.01	0.36	1.35e-11	Type 2 diabetes;
LUSC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg12463550	chr7:65579703	CRCP	0.45	6.73	0.35	7.31e-11	Aortic root size;
LUSC	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg19875535	chr5:140030758	IK	0.46	7.43	0.38	8.98e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg07148914	chr20:33460835	GGT7	-0.47	-7.2	-0.37	3.98e-12	Height;
LUSC	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg05347473	chr6:146136440	FBXO30	0.47	7.77	0.39	9.89e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg20243544	chr17:37824526	PNMT	0.5	6.95	0.36	1.96e-11	Asthma;
LUSC	cis	rs6545883	0.783	rs12713442	chr2:61848078	G/A	cg15711740	chr2:61764176	XPO1	-0.38	-6.07	-0.32	3.5e-9	Tuberculosis;
LUSC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg23093090	chr10:104574429	C10orf26	-0.38	-7.21	-0.37	3.77e-12	Reticulocyte count;
LUSC	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg03676636	chr4:99064102	C4orf37	-0.3	-6.35	-0.33	7.12e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6545883	0.894	rs778158	chr2:61555421	A/G	cg15711740	chr2:61764176	XPO1	0.43	6.65	0.34	1.22e-10	Tuberculosis;
LUSC	cis	rs9296092	0.560	rs7765393	chr6:33525598	A/T	cg13560919	chr6:33536144	NA	-0.84	-16.34	-0.67	1.67e-44	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7527798	0.592	rs6702222	chr1:207825627	C/T	cg09232269	chr1:207846808	CR1L	-0.3	-6.39	-0.33	5.46e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg20026190	chr17:76395443	PGS1	0.45	8.17	0.41	6.52e-15	HDL cholesterol levels;
LUSC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg26924012	chr15:45694286	SPATA5L1	1.11	20.39	0.74	1.27e-60	Homoarginine levels;
LUSC	trans	rs481331	0.741	rs683538	chr10:43148854	A/G	cg10296513	chr8:37963428	ASH2L	0.56	6.1	0.32	2.97e-9	Systemic juvenile idiopathic arthritis;
LUSC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03934478	chr11:495069	RNH1	0.84	10.03	0.48	7.31e-21	Body mass index;
LUSC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.57	-8.23	-0.41	4.36e-15	Obesity-related traits;
LUSC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg25039879	chr17:56429692	SUPT4H1	0.5	7.04	0.36	1.07e-11	Cognitive test performance;
LUSC	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg16386425	chr10:429943	DIP2C	0.41	5.98	0.31	5.74e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg16482183	chr6:26056742	HIST1H1C	0.63	8.9	0.44	3.71e-17	Iron status biomarkers;
LUSC	cis	rs1981331	1.000	rs1981331	chr21:47995443	A/C	cg17243659	chr21:48055224	PRMT2	0.86	6.24	0.32	1.31e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
LUSC	cis	rs3820068	0.608	rs10927840	chr1:16045250	A/G	cg24675056	chr1:15929824	NA	0.42	6.8	0.35	4.81e-11	Systolic blood pressure;
LUSC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.39	-0.46	9.87e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg09323728	chr8:95962352	TP53INP1	0.37	7.08	0.36	8.39e-12	Type 2 diabetes;
LUSC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg19302996	chr17:73780495	UNK	0.47	6.9	0.35	2.6e-11	White matter hyperintensity burden;
LUSC	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg13010199	chr12:38710504	ALG10B	0.7	10.86	0.51	9.83e-24	Morning vs. evening chronotype;
LUSC	cis	rs3106136	0.967	rs61514245	chr4:95165053	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.08	-0.32	3.26e-9	Capecitabine sensitivity;
LUSC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-0.99	-14.32	-0.62	1.34e-36	Vitiligo;
LUSC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.89	0.55	2.01e-27	Prudent dietary pattern;
LUSC	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg04058563	chr4:185651563	MLF1IP	-0.79	-11.92	-0.55	1.5e-27	Blood protein levels;
LUSC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-6.11	-0.32	2.79e-9	Menopause (age at onset);
LUSC	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg25457927	chr22:38595422	NA	-0.41	-8.04	-0.4	1.62e-14	Cutaneous nevi;
LUSC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00149659	chr3:10157352	C3orf10	0.88	12.31	0.56	5.78e-29	Alzheimer's disease;
LUSC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-0.92	-17.71	-0.7	5.74e-50	Heart rate;
LUSC	cis	rs4285028	0.747	rs1574133	chr3:121468794	G/C	cg11130432	chr3:121712080	ILDR1	-0.52	-7.64	-0.39	2.36e-13	Multiple sclerosis;
LUSC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.85	-0.3	1.17e-8	Neutrophil percentage of white cells;
LUSC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs1775715	0.870	rs3847414	chr10:32219176	A/G	cg03015672	chr10:32216066	ARHGAP12	0.31	5.68	0.3	2.98e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg22868518	chr11:507468	RNH1	-0.63	-5.87	-0.31	1.08e-8	Body mass index;
LUSC	cis	rs1891275	0.515	rs6583784	chr10:93491576	A/G	cg07889827	chr10:93443413	NA	0.39	8.97	0.44	2.1e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs308403	0.509	rs309379	chr4:123671456	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.97	18.46	0.71	6.18e-53	Blood protein levels;
LUSC	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg00857998	chr1:205179979	DSTYK	0.62	9.69	0.47	9.86e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs870825	0.655	rs35397385	chr4:185639095	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.55	0.6	1.23e-33	Blood protein levels;
LUSC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg11608241	chr8:8085544	FLJ10661	-0.39	-5.8	-0.3	1.52e-8	Mood instability;
LUSC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg07424592	chr7:64974309	NA	-0.64	-5.72	-0.3	2.34e-8	Diabetic kidney disease;
LUSC	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg08601574	chr20:25228251	PYGB	0.43	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg26876637	chr1:152193138	HRNR	0.45	6.44	0.33	4.15e-10	Atopic dermatitis;
LUSC	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg10765909	chr12:53715428	AAAS	-0.42	-5.98	-0.31	5.77e-9	Platelet distribution width;
LUSC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.49	6.8	0.35	4.84e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07677032	chr17:61819896	STRADA	0.55	8.97	0.44	2.18e-17	Prudent dietary pattern;
LUSC	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.75	0.43	1.1e-16	Axial length;
LUSC	cis	rs965469	1.000	rs6051807	chr20:3350485	A/G	cg25506879	chr20:3388711	C20orf194	-0.53	-5.68	-0.3	2.89e-8	IFN-related cytopenia;
LUSC	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg21775007	chr8:11205619	TDH	-0.47	-6.8	-0.35	4.72e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs6686643	0.868	rs9333471	chr1:165619712	A/G	cg16553119	chr1:165599451	MGST3	-0.42	-6.76	-0.35	6.06e-11	Total ventricular volume;
LUSC	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg22153463	chr1:85462885	MCOLN2	-0.68	-8.57	-0.42	3.94e-16	Serum sulfate level;
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.84	15.09	0.64	1.35e-39	Menarche (age at onset);
LUSC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg12560992	chr17:57184187	TRIM37	-0.9	-17.71	-0.7	5.7e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs360798	0.512	rs4461246	chr2:63027671	C/T	cg17519650	chr2:63277830	OTX1	-0.52	-7.25	-0.37	2.89e-12	Coronary artery disease;
LUSC	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg10172584	chr19:19639581	YJEFN3	0.48	5.69	0.3	2.73e-8	Bipolar disorder;
LUSC	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg13334819	chr7:99746414	C7orf59	0.49	6.5	0.34	2.96e-10	Coronary artery disease;
LUSC	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23158103	chr7:148848205	ZNF398	-0.44	-7.18	-0.37	4.59e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg12826209	chr6:26865740	GUSBL1	0.68	7.67	0.39	1.85e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs10887741	1.000	rs12412482	chr10:89443799	C/T	cg24243914	chr10:89418206	PAPSS2	0.32	5.9	0.31	8.84e-9	Exercise (leisure time);
LUSC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	6.07	0.32	3.43e-9	Parkinson's disease;
LUSC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg12560992	chr17:57184187	TRIM37	0.86	15.57	0.65	1.69e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg25233709	chr10:116636983	FAM160B1	0.36	6.41	0.33	4.99e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2286885	0.965	rs741024	chr9:129251821	A/G	cg15282417	chr9:129245246	FAM125B	-0.36	-6.12	-0.32	2.62e-9	Intraocular pressure;
LUSC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.71	-0.43	1.46e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg08017756	chr2:100939284	LONRF2	-0.44	-8.27	-0.41	3.33e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg06609049	chr19:2785107	THOP1	0.71	11.22	0.52	5.42e-25	Total cholesterol levels;
LUSC	cis	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg07460842	chr6:66804631	NA	0.66	7.94	0.4	3.02e-14	Type 2 diabetes;
LUSC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.84	-0.35	3.67e-11	Total body bone mineral density;
LUSC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.91	-0.44	3.3e-17	Bipolar disorder;
LUSC	cis	rs7804356	1.000	rs3801840	chr7:26832986	A/G	cg03456212	chr7:26904342	SKAP2	-0.55	-6.5	-0.33	2.98e-10	Type 1 diabetes;
LUSC	cis	rs7043114	0.563	rs987554	chr9:95298738	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.37	-6.55	-0.34	2.14e-10	Height;
LUSC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	12.31	0.56	5.85e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	0.52	7.41	0.38	1.07e-12	Breast cancer;
LUSC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg22166914	chr1:53195759	ZYG11B	0.57	9.31	0.45	1.81e-18	Monocyte count;
LUSC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00389176	chr19:41859014	TGFB1	-0.41	-5.97	-0.31	6.11e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg23625390	chr15:77176239	SCAPER	0.47	6.96	0.36	1.8e-11	Blood metabolite levels;
LUSC	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg03894339	chr8:19674705	INTS10	-0.49	-6.97	-0.36	1.67e-11	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg15556689	chr8:8085844	FLJ10661	0.54	7.85	0.39	5.76e-14	Retinal vascular caliber;
LUSC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg15649852	chr7:65879115	NA	-0.41	-5.78	-0.3	1.74e-8	Aortic root size;
LUSC	cis	rs61990749	0.597	rs176980	chr14:78198449	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.57	-6.49	-0.33	3.03e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg06212747	chr3:49208901	KLHDC8B	0.44	6.03	0.31	4.44e-9	Parkinson's disease;
LUSC	cis	rs7659604	0.502	rs13128434	chr4:122672461	A/C	cg19748678	chr4:122722346	EXOSC9	-0.41	-6.07	-0.32	3.45e-9	Type 2 diabetes;
LUSC	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg02696742	chr7:106810147	HBP1	-0.62	-9.51	-0.46	3.83e-19	Coronary artery disease;
LUSC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03517284	chr6:25882590	NA	-0.51	-9.63	-0.47	1.56e-19	Blood metabolite levels;
LUSC	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg00599273	chr12:58146742	CDK4	0.31	5.81	0.3	1.48e-8	Multiple sclerosis;
LUSC	cis	rs6750047	0.625	rs59363818	chr2:38261973	A/C	cg07380506	chr2:38303506	CYP1B1	-0.44	-6.09	-0.32	3.08e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs7524258	0.868	rs6693725	chr1:7307810	G/T	cg07173049	chr1:7289937	CAMTA1	0.36	7.46	0.38	7.69e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg02018176	chr4:1364513	KIAA1530	0.48	8.15	0.41	7.43e-15	Longevity;
LUSC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg22903471	chr2:27725779	GCKR	-0.41	-6.83	-0.35	4.11e-11	Total body bone mineral density;
LUSC	cis	rs17125944	0.615	rs17125798	chr14:53319905	G/A	cg00686598	chr14:53173677	PSMC6	0.83	7.19	0.37	4.35e-12	Alzheimer's disease (late onset);
LUSC	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.99	0.31	5.41e-9	Morning vs. evening chronotype;
LUSC	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg13852791	chr20:30311386	BCL2L1	0.84	10.27	0.49	1.12e-21	Mean corpuscular hemoglobin;
LUSC	trans	rs236907	0.812	rs35249022	chr1:171760767	A/G	cg13482142	chr2:234261155	NA	0.48	6.05	0.31	3.8e-9	Mean platelet volume;
LUSC	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.62	-8.96	-0.44	2.29e-17	Superior crus of antihelix expression;
LUSC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.59	10.66	0.5	4.78e-23	Bone mineral density;
LUSC	cis	rs662064	1.000	rs662064	chr1:10557251	T/C	cg20482658	chr1:10539492	PEX14	-0.31	-6.46	-0.33	3.75e-10	Asthma;
LUSC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg04317338	chr11:64019027	PLCB3	0.56	6.64	0.34	1.29e-10	Mean platelet volume;
LUSC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.36	-6.18	-0.32	1.88e-9	Breast cancer;
LUSC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.64	-0.47	1.47e-19	Gut microbiome composition (summer);
LUSC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg12463550	chr7:65579703	CRCP	0.44	6.53	0.34	2.4e-10	Aortic root size;
LUSC	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-7.72	-0.39	1.4e-13	Morning vs. evening chronotype;
LUSC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg24101359	chr6:42928495	GNMT	0.37	6.07	0.32	3.5e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg12560992	chr17:57184187	TRIM37	-0.77	-11.86	-0.54	2.51e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg01416388	chr22:39784598	NA	-0.45	-7.03	-0.36	1.15e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.77	12.98	0.58	1.72e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg02018176	chr4:1364513	KIAA1530	-0.46	-6.15	-0.32	2.22e-9	Recombination rate (females);
LUSC	cis	rs11971779	0.680	rs6954547	chr7:139054734	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1712517	0.904	rs10883863	chr10:105161879	G/A	cg05636881	chr10:105038444	INA	-0.41	-6.86	-0.35	3.3e-11	Migraine;
LUSC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-10.01	-0.48	8.25e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.52	0.65	2.71e-41	Bladder cancer;
LUSC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg18402987	chr7:1209562	NA	0.68	7.4	0.38	1.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg04586622	chr2:25135609	ADCY3	0.43	8.99	0.44	1.89e-17	Body mass index;
LUSC	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg05738196	chr6:26577821	NA	0.79	15.24	0.64	3.59e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg25838465	chr1:92012736	NA	-0.66	-12.07	-0.55	4.57e-28	Breast cancer;
LUSC	cis	rs4478858	0.735	rs6679365	chr1:31787866	A/C	cg00250761	chr1:31883323	NA	0.33	8.33	0.41	2.18e-15	Alcohol dependence;
LUSC	trans	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.62	-6.93	-0.35	2.2e-11	Menarche (age at onset);
LUSC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.54e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg24562669	chr7:97807699	LMTK2	-0.4	-6.56	-0.34	2.02e-10	Breast cancer;
LUSC	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20135002	chr11:47629003	NA	0.49	7.79	0.39	8.39e-14	Subjective well-being;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20713102	chr15:85144157	ZSCAN2	0.45	6.31	0.33	8.8e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg15423357	chr2:25149977	NA	0.35	6.43	0.33	4.46e-10	Body mass index;
LUSC	trans	rs8085804	0.504	rs16976532	chr18:40240283	T/C	cg04486886	chr5:56784195	NA	-0.33	-6.48	-0.33	3.3e-10	Cognitive performance;
LUSC	cis	rs78663649	0.908	rs113779505	chr19:16527982	G/A	cg05286348	chr19:16641544	CHERP	-0.61	-5.93	-0.31	7.38e-9	White blood cell count;
LUSC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06634786	chr22:41940651	POLR3H	0.49	5.76	0.3	1.88e-8	Vitiligo;
LUSC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg15557168	chr22:42548783	NA	-0.46	-7.35	-0.37	1.51e-12	Schizophrenia;
LUSC	cis	rs4363385	0.782	rs1933381	chr1:153003255	C/G	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.53	-0.38	4.82e-13	Inflammatory skin disease;
LUSC	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg27661571	chr11:113659931	NA	-0.59	-7.18	-0.37	4.61e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs2455601	0.638	rs2568092	chr11:8987438	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.38	6.65	0.34	1.16e-10	Schizophrenia;
LUSC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-17.32	-0.69	2.06e-48	Primary sclerosing cholangitis;
LUSC	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg19682013	chr15:45996608	NA	0.38	5.8	0.3	1.53e-8	Waist circumference;Weight;
LUSC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.26	0.45	2.6e-18	Prudent dietary pattern;
LUSC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.02	0.36	1.28e-11	Gut microbiome composition (summer);
LUSC	cis	rs3126085	1.000	rs4845756	chr1:152254919	T/A	cg26876637	chr1:152193138	HRNR	0.46	6.38	0.33	6.03e-10	Atopic dermatitis;
LUSC	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg05283184	chr6:79620031	NA	-0.45	-8.45	-0.42	9.37e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.56	-8.44	-0.42	9.86e-16	Longevity;Endometriosis;
LUSC	trans	rs7939886	0.920	rs11534518	chr11:55808146	C/T	cg15704280	chr7:45808275	SEPT13	0.8	6.88	0.35	3.04e-11	Myopia (pathological);
LUSC	cis	rs61935443	0.614	rs11107792	chr12:95317126	G/C	cg21533806	chr12:95267307	NA	0.49	5.69	0.3	2.72e-8	Schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07156296	chr4:108911347	HADH	0.36	6.03	0.31	4.24e-9	Triglycerides;
LUSC	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg10434728	chr15:90938212	IQGAP1	0.33	6.2	0.32	1.63e-9	Rheumatoid arthritis;
LUSC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg06238570	chr21:40685208	BRWD1	-0.6	-10.14	-0.49	3e-21	Cognitive function;
LUSC	cis	rs1443512	0.947	rs4759309	chr12:54342786	G/A	cg17410650	chr12:54324560	NA	-0.43	-6.95	-0.36	1.87e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.46	5.87	0.31	1.07e-8	Huntington's disease progression;
LUSC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg18904891	chr8:8559673	CLDN23	0.61	8.47	0.42	7.74e-16	Obesity-related traits;
LUSC	cis	rs6681460	0.934	rs4655631	chr1:67054907	C/G	cg02459107	chr1:67143332	SGIP1	0.48	8.96	0.44	2.32e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg00999904	chr2:3704751	ALLC	-0.44	-6.76	-0.35	6.12e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg27170947	chr2:26402098	FAM59B	0.66	9.86	0.47	2.78e-20	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg14552801	chr7:65878734	NA	0.46	6.65	0.34	1.22e-10	Aortic root size;
LUSC	cis	rs4776059	0.798	rs13329393	chr15:52920505	A/T	cg24008177	chr15:52972085	KIAA1370	-0.34	-6.26	-0.32	1.2e-9	Schizophrenia;
LUSC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-6.91	-0.35	2.48e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2667011	0.756	rs2715920	chr2:160837815	T/C	cg06573604	chr2:160760825	LY75	-0.49	-6.31	-0.33	8.87e-10	Bilirubin levels;
LUSC	cis	rs6426558	0.537	rs4351610	chr1:227325245	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.55	-7.4	-0.38	1.11e-12	Neutrophil percentage of white cells;
LUSC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg24250549	chr1:154909240	PMVK	0.65	10.87	0.51	9.05e-24	Prostate cancer;
LUSC	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.35	0.42	1.83e-15	Lung cancer;
LUSC	trans	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.81	-0.39	7.71e-14	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg16989719	chr2:238392110	NA	-0.49	-6.21	-0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.08	16.47	0.67	4.75e-45	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg21775007	chr8:11205619	TDH	-0.52	-7.45	-0.38	7.96e-13	Neuroticism;
LUSC	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08048268	chr3:133502702	NA	-0.44	-8.51	-0.42	6.17e-16	Iron status biomarkers;
LUSC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg02487422	chr3:49467188	NICN1	0.45	7.08	0.36	8.74e-12	Resting heart rate;
LUSC	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.44	6.26	0.32	1.17e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs4780401	0.728	rs6498239	chr16:11780774	T/C	cg01061890	chr16:11836724	TXNDC11	-0.43	-6.08	-0.32	3.27e-9	Rheumatoid arthritis;
LUSC	trans	rs2392780	0.536	rs444318	chr8:128333513	A/G	cg10195415	chr17:73887371	TRIM65	0.4	6.49	0.33	3.15e-10	Breast cancer (early onset);
LUSC	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg02696742	chr7:106810147	HBP1	-0.62	-9.45	-0.46	5.95e-19	Coronary artery disease;
LUSC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.86	16.61	0.67	1.4e-45	Mean platelet volume;
LUSC	cis	rs9644630	0.932	rs4921653	chr8:19359853	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.37	7.04	0.36	1.1e-11	Oropharynx cancer;
LUSC	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg01871581	chr19:12707946	ZNF490	-0.6	-9.62	-0.47	1.73e-19	Bipolar disorder;
LUSC	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg16339924	chr4:17578868	LAP3	-0.46	-6.77	-0.35	5.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg05299278	chr17:33885742	SLFN14	-0.31	-6.4	-0.33	5.36e-10	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg20406979	chr6:167373233	NA	-0.26	-6.18	-0.32	1.83e-9	Crohn's disease;
LUSC	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg14582100	chr15:45693742	SPATA5L1	0.46	8.67	0.43	1.87e-16	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs7523273	0.606	rs10449303	chr1:207961058	A/G	cg22525895	chr1:207977042	MIR29B2	-0.4	-6.31	-0.33	8.89e-10	Schizophrenia;
LUSC	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg08017634	chr8:144659831	NAPRT1	0.69	6.16	0.32	2.1e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs1904096	0.506	rs8336	chr4:95211610	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.67	-0.43	1.84e-16	Type 2 diabetes;
LUSC	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg11845111	chr2:191398756	TMEM194B	-0.84	-11.15	-0.52	9.03e-25	Diastolic blood pressure;
LUSC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	trans	rs2414059	0.518	rs56398519	chr15:50773432	A/G	cg06848185	chr17:75368902	SEPT9	0.37	6.05	0.31	3.87e-9	QT interval;
LUSC	cis	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg10665199	chr7:133106180	EXOC4	0.58	8.16	0.41	6.67e-15	Intelligence;Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg13206674	chr6:150067644	NUP43	0.61	9.71	0.47	8.23e-20	Lung cancer;
LUSC	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	0.8	9.85	0.47	2.9e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg21132104	chr15:45694354	SPATA5L1	0.49	6.5	0.34	2.92e-10	Homoarginine levels;
LUSC	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg23260525	chr10:116636907	FAM160B1	0.4	8.18	0.41	6.16e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg03563238	chr19:33554763	RHPN2	-0.4	-6.23	-0.32	1.43e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.72	-0.35	7.86e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4588572	0.644	rs11742212	chr5:77779033	G/A	cg11547950	chr5:77652471	NA	-0.44	-6.23	-0.32	1.4e-9	Triglycerides;
LUSC	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg05283184	chr6:79620031	NA	-0.57	-11.68	-0.54	1.16e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs7216064	1.000	rs3935969	chr17:65881959	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-9.37	-0.46	1.13e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg04554929	chr8:105342491	NA	-0.4	-7.28	-0.37	2.35e-12	Paget's disease;
LUSC	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg19789473	chr17:27170043	C17orf63	-0.3	-5.69	-0.3	2.75e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg11789530	chr4:8429930	ACOX3	-0.42	-6.1	-0.32	2.95e-9	Response to antineoplastic agents;
LUSC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	0.99	13.86	0.6	8.07e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg13010199	chr12:38710504	ALG10B	0.66	10.17	0.49	2.5e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.65	-9.66	-0.47	1.3e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-7.59	-0.38	3.13e-13	Neuroticism;
LUSC	cis	rs9487051	0.738	rs449850	chr6:109525045	A/G	cg00509249	chr6:109615579	CCDC162	-0.33	-5.74	-0.3	2.09e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg16325326	chr1:53192061	ZYG11B	0.86	15.02	0.63	2.62e-39	Monocyte count;
LUSC	cis	rs6596100	0.538	rs67652061	chr5:132280347	T/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Breast cancer;
LUSC	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-7.96	-0.4	2.77e-14	Bone mineral density;
LUSC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2281845	0.929	rs7549337	chr1:201097609	T/G	cg22815214	chr1:201083145	CACNA1S	0.57	9.36	0.46	1.18e-18	Permanent tooth development;
LUSC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs17286411	0.787	rs1834036	chr16:71972060	G/A	cg03805757	chr16:71968109	PKD1L3	0.42	6.94	0.36	2.03e-11	Blood protein levels;
LUSC	cis	rs27434	0.583	rs193482	chr5:96157846	A/G	cg16492584	chr5:96139282	ERAP1	-0.56	-7.53	-0.38	4.91e-13	Ankylosing spondylitis;
LUSC	cis	rs17407555	0.738	rs56402960	chr4:10086473	T/A	cg00071950	chr4:10020882	SLC2A9	-0.52	-6.28	-0.33	1.03e-9	Schizophrenia (age at onset);
LUSC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00149659	chr3:10157352	C3orf10	1.0	14.13	0.61	7.39e-36	Alzheimer's disease;
LUSC	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg10518543	chr12:38710700	ALG10B	0.41	5.79	0.3	1.66e-8	Morning vs. evening chronotype;
LUSC	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.38	0.49	4.76e-22	Schizophrenia;
LUSC	cis	rs6692729	0.966	rs7547071	chr1:227014390	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.48	-6.89	-0.35	2.82e-11	Electrodermal activity;
LUSC	cis	rs9549260	0.755	rs9549236	chr13:41147158	C/T	cg21288729	chr13:41239152	FOXO1	-0.53	-7.86	-0.4	5.27e-14	Red blood cell count;
LUSC	cis	rs1971762	0.563	rs4759284	chr12:54079491	G/A	cg23533419	chr12:54090519	NA	-0.37	-6.01	-0.31	4.79e-9	Height;
LUSC	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg16339924	chr4:17578868	LAP3	0.65	9.84	0.47	3.21e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-9.42	-0.46	7.57e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs1470506	0.507	rs62171962	chr2:77224930	C/T	cg01707656	chr12:12503030	MANSC1	0.45	5.94	0.31	7.05e-9	IgG glycosylation;
LUSC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-9.92	-0.48	1.68e-20	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1395	0.778	rs72810794	chr2:27401260	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.49	7.26	0.37	2.77e-12	Blood metabolite levels;
LUSC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg21918786	chr6:109611834	NA	-0.42	-7.28	-0.37	2.36e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs12599106	0.629	rs1391904	chr16:34548934	C/T	cg21548813	chr6:291882	DUSP22	-0.51	-7.67	-0.39	1.87e-13	Menopause (age at onset);
LUSC	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg03929089	chr4:120376271	NA	0.82	11.14	0.52	9.93e-25	Coronary artery disease;
LUSC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25072359	chr17:41440525	NA	0.68	9.69	0.47	9.97e-20	Menopause (age at onset);
LUSC	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.83	0.35	4.1e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2692947	0.832	rs2579519	chr2:96675166	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.61	0.34	1.54e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg04586622	chr2:25135609	ADCY3	0.43	9.0	0.44	1.7e-17	Body mass index;
LUSC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.96	0.77	8.44e-67	Prudent dietary pattern;
LUSC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg03233332	chr7:66118400	NA	-0.4	-5.92	-0.31	8.15e-9	Aortic root size;
LUSC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg01657329	chr11:68192670	LRP5	-0.44	-6.59	-0.34	1.73e-10	Total body bone mineral density;
LUSC	trans	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg06606381	chr12:133084897	FBRSL1	-0.7	-6.25	-0.32	1.26e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-7.43	-0.38	9.08e-13	Retinal vascular caliber;
LUSC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg07395648	chr5:131743802	NA	0.38	6.01	0.31	4.87e-9	Asthma (sex interaction);
LUSC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.54	-0.42	4.74e-16	Personality dimensions;
LUSC	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg13010199	chr12:38710504	ALG10B	0.45	6.38	0.33	5.87e-10	Morning vs. evening chronotype;
LUSC	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg16049864	chr8:95962084	TP53INP1	-0.62	-11.56	-0.53	3.2e-26	Type 2 diabetes;
LUSC	cis	rs10979	0.965	rs9390109	chr6:143892806	T/C	cg25407410	chr6:143891975	LOC285740	-0.73	-11.95	-0.55	1.25e-27	Hypospadias;
LUSC	cis	rs9837602	0.935	rs9810235	chr3:99736538	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.09	-0.32	3.14e-9	Breast cancer;
LUSC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	15.59	0.65	1.47e-41	Platelet count;
LUSC	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17467752	chr17:38218738	THRA	-0.69	-11.22	-0.52	5.09e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg16797656	chr11:68205561	LRP5	0.49	9.01	0.44	1.67e-17	Total body bone mineral density;
LUSC	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg02023728	chr11:77925099	USP35	0.4	6.16	0.32	2.14e-9	Testicular germ cell tumor;
LUSC	trans	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg16660971	chr17:78860029	RPTOR	0.37	6.01	0.31	4.78e-9	Major depressive disorder;
LUSC	cis	rs12900413	0.603	rs2882677	chr15:90299514	C/T	cg24249390	chr15:90295951	MESP1	-0.35	-5.77	-0.3	1.83e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.31	-0.49	7.92e-22	Hemoglobin concentration;
LUSC	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg00277334	chr10:82204260	NA	-0.51	-7.43	-0.38	9.29e-13	Post bronchodilator FEV1;
LUSC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	8.81	0.43	6.79e-17	Mean platelet volume;
LUSC	cis	rs7178572	0.568	rs11072643	chr15:77415508	T/A	cg22256960	chr15:77711686	NA	0.49	7.57	0.38	3.75e-13	Type 2 diabetes;
LUSC	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg08755490	chr11:65554678	OVOL1	0.42	6.02	0.31	4.69e-9	Acne (severe);
LUSC	trans	rs34421088	0.532	rs2736385	chr8:11148613	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	7.17	0.37	4.8e-12	Neuroticism;
LUSC	cis	rs603446	0.967	rs108533	chr11:116601711	A/T	cg08985259	chr11:116699649	APOC3	0.24	5.69	0.3	2.72e-8	Triglycerides;
LUSC	cis	rs9837602	1.000	rs6790877	chr3:99779658	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.86	-0.31	1.09e-8	Breast cancer;
LUSC	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg06287003	chr12:125626642	AACS	0.38	5.92	0.31	7.84e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.69	-12.42	-0.56	2.15e-29	Aortic root size;
LUSC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18932078	chr1:2524107	MMEL1	0.3	6.49	0.33	3.19e-10	Ulcerative colitis;
LUSC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg02475777	chr4:1388615	CRIPAK	0.45	6.73	0.35	7.61e-11	Obesity-related traits;
LUSC	cis	rs11676348	0.712	rs12694426	chr2:218942351	T/G	cg00012203	chr2:219082015	ARPC2	-0.46	-7.02	-0.36	1.22e-11	Ulcerative colitis;
LUSC	cis	rs13315871	0.858	rs78946071	chr3:58318523	G/T	cg20936604	chr3:58311152	NA	-0.77	-7.1	-0.36	7.59e-12	Cholesterol, total;
LUSC	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.41	-0.33	5e-10	Cutaneous nevi;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05989775	chr11:2906934	CDKN1C	-0.48	-6.39	-0.33	5.65e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1403694	0.515	rs1648699	chr3:186449890	G/C	cg12454167	chr3:186435060	KNG1	0.28	7.6	0.38	2.98e-13	Blood protein levels;
LUSC	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg16482183	chr6:26056742	HIST1H1C	0.6	8.77	0.43	9.05e-17	Iron status biomarkers;
LUSC	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.94	-0.44	2.67e-17	Response to antipsychotic treatment;
LUSC	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.43	-0.33	4.49e-10	Bladder cancer;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg18357908	chr19:41107082	LTBP4	0.36	6.05	0.31	3.86e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg17469321	chr7:55412551	NA	0.66	10.63	0.5	6.09e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07283595	chr17:5372003	DHX33	0.44	6.71	0.34	8.15e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs970548	0.697	rs11239534	chr10:45968590	A/T	cg14222797	chr10:16859974	RSU1	0.6	5.97	0.31	6.16e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg12560992	chr17:57184187	TRIM37	0.83	15.26	0.64	2.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.27	-0.41	3.24e-15	Cystic fibrosis severity;
LUSC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.14	-0.8	3.2e-75	Height;
LUSC	trans	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg04450456	chr4:17643702	FAM184B	0.41	6.96	0.36	1.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg15790184	chr11:494944	RNH1	0.53	5.77	0.3	1.85e-8	Body mass index;
LUSC	cis	rs12760731	0.720	rs10913545	chr1:178360201	G/A	cg00404053	chr1:178313656	RASAL2	0.6	6.32	0.33	8.53e-10	Obesity-related traits;
LUSC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg03146154	chr1:46216737	IPP	0.52	7.67	0.39	1.9e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	6.97	0.36	1.69e-11	Neuroticism;
LUSC	cis	rs909002	0.849	rs6425777	chr1:32105447	G/C	cg01639898	chr1:32083012	HCRTR1	0.25	5.74	0.3	2.08e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg04166393	chr7:2884313	GNA12	0.44	5.69	0.3	2.71e-8	Height;
LUSC	cis	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg27411982	chr8:10470053	RP1L1	-0.46	-6.8	-0.35	4.87e-11	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.66	11.28	0.53	3.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.38	5.85	0.3	1.16e-8	Longevity;Endometriosis;
LUSC	cis	rs829883	0.659	rs11109517	chr12:98921574	A/C	cg25150519	chr12:98850993	NA	0.63	8.59	0.43	3.43e-16	Colorectal adenoma (advanced);
LUSC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.79	0.39	8.37e-14	Parkinson's disease;
LUSC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02018176	chr4:1364513	KIAA1530	0.72	13.64	0.6	5.72e-34	Longevity;
LUSC	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg03929089	chr4:120376271	NA	-0.58	-7.53	-0.38	4.82e-13	Height;
LUSC	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg11802864	chr11:65308245	LTBP3	0.84	5.81	0.3	1.45e-8	Height;
LUSC	cis	rs921665	0.831	rs2242084	chr2:3196040	A/G	cg16434511	chr2:3151078	NA	-0.63	-6.83	-0.35	3.92e-11	World class endurance athleticism;
LUSC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08704250	chr15:31115839	NA	-0.59	-9.2	-0.45	3.95e-18	Huntington's disease progression;
LUSC	cis	rs2273669	0.667	rs111523655	chr6:109301664	G/A	cg05315195	chr6:109294784	ARMC2	-0.55	-6.18	-0.32	1.86e-9	Prostate cancer;
LUSC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.47	-8.44	-0.42	9.48e-16	Longevity;Endometriosis;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10189605	chr6:58287430	GUSBL2	-0.36	-6.13	-0.32	2.49e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2969070	0.639	rs886629	chr7:2528060	A/C	cg03277898	chr7:2518824	NA	-0.29	-6.19	-0.32	1.8e-9	Diastolic blood pressure;
LUSC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg14552801	chr7:65878734	NA	-0.38	-5.86	-0.31	1.13e-8	Aortic root size;
LUSC	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-7.09	-0.36	7.83e-12	HDL cholesterol;
LUSC	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg03721641	chr22:50451245	IL17REL	0.28	5.88	0.31	9.87e-9	Ulcerative colitis;
LUSC	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.75	-11.79	-0.54	4.82e-27	Itch intensity from mosquito bite;
LUSC	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg13010199	chr12:38710504	ALG10B	0.53	8.16	0.41	6.69e-15	Morning vs. evening chronotype;
LUSC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg01657329	chr11:68192670	LRP5	-0.44	-6.6	-0.34	1.64e-10	Total body bone mineral density;
LUSC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg08470875	chr2:26401718	FAM59B	0.65	8.56	0.42	4.16e-16	Gut microbiome composition (summer);
LUSC	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.91	-0.4	3.89e-14	Glomerular filtration rate;
LUSC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.85	0.39	5.56e-14	Colorectal cancer;
LUSC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.48	7.66	0.39	2.06e-13	Schizophrenia;
LUSC	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg03627880	chr6:151815985	C6orf97	-0.57	-6.12	-0.32	2.63e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs6076065	0.630	rs2424558	chr20:23429344	A/G	cg11657817	chr20:23433608	CST11	0.52	10.91	0.51	6.34e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg23992470	chr4:843637	GAK	0.6	6.41	0.33	5.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3857536	0.813	rs2040594	chr6:66943966	A/G	cg07460842	chr6:66804631	NA	-0.46	-6.41	-0.33	4.93e-10	Blood trace element (Cu levels);
LUSC	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07080220	chr10:102295463	HIF1AN	0.64	9.31	0.45	1.73e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg00191853	chr8:101177733	SPAG1	-0.41	-6.57	-0.34	1.92e-10	Atrioventricular conduction;
LUSC	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg02023728	chr11:77925099	USP35	0.47	6.53	0.34	2.39e-10	Testicular germ cell tumor;
LUSC	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.3e-21	Lymphocyte counts;
LUSC	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg13010199	chr12:38710504	ALG10B	0.66	10.22	0.49	1.61e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9323205	0.765	rs2999390	chr14:51654944	C/G	cg23942311	chr14:51606299	NA	-0.31	-6.44	-0.33	4.12e-10	Cancer;
LUSC	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00684032	chr4:1343700	KIAA1530	0.37	6.51	0.34	2.82e-10	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00149659	chr3:10157352	C3orf10	0.99	14.48	0.62	3.24e-37	Alzheimer's disease;
LUSC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.48	7.19	0.37	4.32e-12	Schizophrenia;
LUSC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg27189623	chr16:705930	WDR90	0.35	5.68	0.3	2.86e-8	Height;
LUSC	cis	rs981844	0.775	rs62324020	chr4:154763851	G/A	cg14289246	chr4:154710475	SFRP2	0.5	6.67	0.34	1.09e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg10556349	chr10:835070	NA	0.58	6.49	0.33	3.12e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs13385	0.724	rs60714373	chr5:139651321	T/C	cg26211634	chr5:139558579	C5orf32	0.44	6.21	0.32	1.53e-9	Atrial fibrillation;
LUSC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3741151	0.773	rs11820577	chr11:73261424	C/G	cg17517138	chr11:73019481	ARHGEF17	0.92	7.8	0.39	8.22e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg06454157	chr6:167490870	NA	-0.25	-6.02	-0.31	4.66e-9	Crohn's disease;
LUSC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg13256891	chr4:100009986	ADH5	0.52	8.48	0.42	7.24e-16	Alcohol dependence;
LUSC	cis	rs924607	0.583	rs12516251	chr5:608939	C/T	cg07001201	chr5:642380	CEP72	0.35	5.78	0.3	1.67e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg23711669	chr6:146136114	FBXO30	0.84	15.31	0.64	1.92e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs73198271	0.562	rs55961293	chr8:8675478	T/C	cg01851573	chr8:8652454	MFHAS1	0.65	8.45	0.42	8.99e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs9944715	0.906	rs8095729	chr18:43741982	T/C	cg01718231	chr17:29326311	RNF135	0.45	6.31	0.33	9.11e-10	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.12	0.58	5.41e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14594481	chr12:6863015	MLF2	-0.4	-6.12	-0.32	2.62e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.68	10.56	0.5	1.1e-22	Height;
LUSC	cis	rs7572644	0.699	rs4390729	chr2:28162861	T/C	cg27432699	chr2:27873401	GPN1	-0.51	-6.83	-0.35	4.08e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.43	-0.33	4.53e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg05147244	chr20:61493195	TCFL5	0.94	7.43	0.38	9.04e-13	Obesity-related traits;
LUSC	trans	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-8.29	-0.41	2.72e-15	Ulcerative colitis;
LUSC	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg08345082	chr10:99160200	RRP12	-0.35	-7.02	-0.36	1.25e-11	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	ch.11.42038R	chr11:967971	AP2A2	0.42	6.15	0.32	2.2e-9	Alzheimer's disease (late onset);
LUSC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.32	0.33	8.28e-10	Bipolar disorder;
LUSC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg26408565	chr15:76604113	ETFA	-0.51	-8.14	-0.41	7.82e-15	Blood metabolite levels;
LUSC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg16240275	chr20:61666158	NCRNA00029	0.42	9.23	0.45	3.14e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg17075019	chr10:79541650	NA	-0.76	-12.11	-0.55	3.16e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs710865	0.519	rs3748759	chr1:19487656	C/T	cg13387374	chr1:19411106	UBR4	-0.53	-8.31	-0.41	2.39e-15	Brain structure;
LUSC	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg13010199	chr12:38710504	ALG10B	0.62	9.65	0.47	1.3e-19	Bladder cancer;
LUSC	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg00484396	chr16:3507460	NAT15	0.38	6.01	0.31	4.8e-9	Body mass index (adult);
LUSC	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg25457927	chr22:38595422	NA	0.52	11.56	0.53	3.14e-26	Cutaneous nevi;
LUSC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg21573476	chr21:45109991	RRP1B	-0.36	-5.7	-0.3	2.66e-8	Mean corpuscular volume;
LUSC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11645453	chr3:52864694	ITIH4	0.33	7.6	0.38	3.08e-13	Bipolar disorder;
LUSC	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg26816564	chr1:7831052	VAMP3	0.96	13.23	0.59	1.99e-32	Inflammatory bowel disease;
LUSC	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.21	-0.32	1.59e-9	Type 2 diabetes;
LUSC	cis	rs9920506	0.536	rs11636605	chr15:78928878	A/G	cg04896959	chr15:78267971	NA	0.38	6.7	0.34	8.66e-11	Post bronchodilator FEV1;
LUSC	cis	rs3916	0.911	rs7313271	chr12:121152667	C/T	cg27246729	chr12:121163418	ACADS	0.5	7.25	0.37	2.99e-12	Urinary metabolites (H-NMR features);
LUSC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06634786	chr22:41940651	POLR3H	0.53	6.16	0.32	2.08e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg23719950	chr11:63933701	MACROD1	-0.37	-5.67	-0.3	3.03e-8	Platelet count;
LUSC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18854424	chr1:2615690	NA	-0.49	-9.94	-0.48	1.48e-20	Ulcerative colitis;
LUSC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-0.8	-15.6	-0.65	1.37e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4363385	0.668	rs6587717	chr1:152984443	G/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.61	-0.38	2.89e-13	Inflammatory skin disease;
LUSC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-6.9	-0.35	2.59e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg12002119	chr2:101014098	CHST10	0.37	6.19	0.32	1.78e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7605827	0.866	rs9710962	chr2:15533884	C/A	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs12467847	1.000	rs4387792	chr2:113691288	T/C	cg12858261	chr2:113808755	IL1F8	-0.38	-5.72	-0.3	2.32e-8	Response to amphetamines;
LUSC	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg03585969	chr10:35415529	CREM	0.6	8.97	0.44	2.11e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7903847	0.642	rs12258560	chr10:99137048	T/C	cg20016023	chr10:99160130	RRP12	-0.34	-8.41	-0.42	1.22e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.67	10.74	0.51	2.52e-23	Menarche (age at onset);
LUSC	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	1.08	14.22	0.61	3.19e-36	Nonalcoholic fatty liver disease;
LUSC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03517284	chr6:25882590	NA	-0.51	-9.52	-0.46	3.59e-19	Blood metabolite levels;
LUSC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08677398	chr8:58056175	NA	0.45	6.43	0.33	4.38e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg06212747	chr3:49208901	KLHDC8B	0.43	5.82	0.3	1.39e-8	Parkinson's disease;
LUSC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg06028605	chr16:24865363	SLC5A11	0.49	8.57	0.42	3.76e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.56	-0.34	2e-10	Recombination measurement;
LUSC	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg23093090	chr10:104574429	C10orf26	0.43	7.72	0.39	1.37e-13	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg08477640	chr19:41863820	B9D2	0.53	7.68	0.39	1.75e-13	Colorectal cancer;
LUSC	cis	rs55871839	0.708	rs4738731	chr8:59809840	C/G	cg07426533	chr8:59803705	TOX	-0.36	-5.92	-0.31	7.88e-9	Pneumonia;
LUSC	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.41	5.83	0.3	1.31e-8	Bipolar disorder;
LUSC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18404041	chr3:52824283	ITIH1	-0.6	-11.57	-0.53	3.03e-26	Bipolar disorder;
LUSC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg25174290	chr11:3078921	CARS	0.59	9.57	0.46	2.48e-19	Longevity;
LUSC	cis	rs137603	0.562	rs470080	chr22:39712368	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.45	-6.99	-0.36	1.51e-11	Primary biliary cholangitis;
LUSC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg13206674	chr6:150067644	NUP43	0.58	8.91	0.44	3.38e-17	Lung cancer;
LUSC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.33	-0.33	7.78e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.88	17.27	0.69	3.45e-48	Menarche (age at onset);
LUSC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-6.9	-0.35	2.64e-11	Tonsillectomy;
LUSC	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg15704280	chr7:45808275	SEPT13	0.73	8.22	0.41	4.64e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg13319975	chr6:146136371	FBXO30	0.5	7.46	0.38	7.55e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9902453	0.967	rs1042173	chr17:28525011	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.97	0.44	2.21e-17	Coffee consumption (cups per day);
LUSC	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	11.58	0.54	2.64e-26	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg06212747	chr3:49208901	KLHDC8B	0.5	6.38	0.33	5.87e-10	Parkinson's disease;
LUSC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg02772935	chr3:125709198	NA	-0.47	-5.71	-0.3	2.45e-8	Blood pressure (smoking interaction);
LUSC	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg09184832	chr6:79620586	NA	-0.37	-5.83	-0.3	1.34e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08280861	chr8:58055591	NA	0.52	6.83	0.35	3.92e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg15445000	chr17:37608096	MED1	-0.42	-7.05	-0.36	1.02e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11644478	chr21:40555479	PSMG1	-0.59	-9.3	-0.45	1.88e-18	Menarche (age at onset);
LUSC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.35	-6.14	-0.32	2.38e-9	Longevity;Endometriosis;
LUSC	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg27284194	chr4:1044797	NA	0.59	8.91	0.44	3.33e-17	Recombination rate (females);
LUSC	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg09904177	chr6:26538194	HMGN4	-0.49	-7.68	-0.39	1.8e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	0.9	16.11	0.66	1.35e-43	Cognitive function;
LUSC	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg24556660	chr7:106842632	COG5;HBP1	0.42	5.89	0.31	9.67e-9	Coronary artery disease;
LUSC	cis	rs1160297	0.609	rs6715847	chr2:53097378	T/G	cg07782112	chr2:53107842	NA	0.4	6.58	0.34	1.84e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg06191203	chr2:152266755	RIF1	-0.42	-5.84	-0.3	1.27e-8	Lung cancer;
LUSC	cis	rs6942756	1.000	rs11763056	chr7:128960871	C/A	cg02491457	chr7:128862824	NA	-0.47	-6.31	-0.33	9.1e-10	White matter hyperintensity burden;
LUSC	cis	rs9517320	1.000	rs9584857	chr13:99128572	T/C	cg20487152	chr13:99095054	FARP1	0.35	6.41	0.33	4.96e-10	Longevity;
LUSC	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg10811474	chr19:8428787	ANGPTL4	-0.39	-5.97	-0.31	6.07e-9	HDL cholesterol;
LUSC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg05896524	chr21:47604654	C21orf56	-0.57	-8.9	-0.44	3.65e-17	Testicular germ cell tumor;
LUSC	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg14505434	chr11:89522851	NA	0.39	6.07	0.31	3.56e-9	White blood cell types;
LUSC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg15103426	chr22:29168792	CCDC117	0.57	7.88	0.4	4.68e-14	Lymphocyte counts;
LUSC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg27284194	chr4:1044797	NA	0.35	5.83	0.3	1.32e-8	Obesity-related traits;
LUSC	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg25457927	chr22:38595422	NA	-0.34	-6.8	-0.35	4.76e-11	Cutaneous nevi;
LUSC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.58	-9.51	-0.46	4.03e-19	Aortic root size;
LUSC	trans	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.71e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg05110241	chr16:68378359	PRMT7	-0.59	-7.28	-0.37	2.48e-12	Schizophrenia;
LUSC	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg13939156	chr17:80058883	NA	0.36	7.27	0.37	2.55e-12	Life satisfaction;
LUSC	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	8.96	0.44	2.36e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg04673462	chr1:38461896	NA	0.56	10.48	0.5	2.08e-22	Coronary artery disease;
LUSC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg00701064	chr4:6280414	WFS1	0.58	14.15	0.61	6.19e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg25214090	chr10:38739885	LOC399744	0.49	7.53	0.38	4.82e-13	Corneal astigmatism;
LUSC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg13319975	chr6:146136371	FBXO30	0.49	7.33	0.37	1.73e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2734839	0.537	rs11214603	chr11:113279922	G/A	cg14159747	chr11:113255604	NA	0.27	7.1	0.36	7.73e-12	Information processing speed;
LUSC	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg04586622	chr2:25135609	ADCY3	0.4	8.37	0.42	1.6e-15	Body mass index;
LUSC	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg03188948	chr7:1209495	NA	0.66	6.93	0.35	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.63	-9.2	-0.45	4.07e-18	Blood trace element (Cu levels);
LUSC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.06	-16.96	-0.68	5.39e-47	Primary sclerosing cholangitis;
LUSC	cis	rs1881396	0.945	rs1881395	chr2:27838549	G/A	cg27432699	chr2:27873401	GPN1	0.65	8.8	0.43	7.39e-17	Nonalcoholic fatty liver disease;
LUSC	cis	rs11229555	0.874	rs10896794	chr11:58339124	T/C	cg15696309	chr11:58395628	NA	-0.7	-9.06	-0.44	1.12e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg08917208	chr2:24149416	ATAD2B	0.99	10.48	0.5	2.04e-22	Lymphocyte counts;
LUSC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg22834771	chr12:69754056	YEATS4	-0.5	-7.45	-0.38	8.08e-13	Blood protein levels;
LUSC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.63	9.96	0.48	1.28e-20	Parkinson's disease;
LUSC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg09035930	chr12:129282057	SLC15A4	0.73	15.47	0.65	4.48e-41	Systemic lupus erythematosus;
LUSC	cis	rs11153730	0.503	rs4946336	chr6:118632335	A/C	cg21191810	chr6:118973309	C6orf204	0.34	5.77	0.3	1.78e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUSC	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg00129232	chr17:37814104	STARD3	-0.48	-7.22	-0.37	3.56e-12	Asthma;
LUSC	cis	rs6596100	0.538	rs67519234	chr5:132199359	C/A	cg02081065	chr5:132209139	LEAP2	-0.62	-5.9	-0.31	9.1e-9	Breast cancer;
LUSC	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg02269571	chr22:50332266	NA	0.58	7.48	0.38	6.75e-13	Schizophrenia;
LUSC	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg16928487	chr17:17741425	SREBF1	0.45	8.85	0.44	5.16e-17	Total body bone mineral density;
LUSC	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg13852791	chr20:30311386	BCL2L1	0.77	8.73	0.43	1.25e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg16624210	chr5:671434	TPPP	0.5	6.38	0.33	6.07e-10	Obesity-related traits;
LUSC	cis	rs2629751	0.512	rs2723868	chr12:104422317	C/T	cg14987745	chr12:104360022	TDG	-0.69	-8.49	-0.42	6.79e-16	Hepatitis C induced liver fibrosis;
LUSC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg26566898	chr11:117069891	TAGLN	0.38	7.38	0.37	1.24e-12	Blood protein levels;
LUSC	cis	rs7707921	0.767	rs862245	chr5:81585737	A/C	cg15871215	chr5:81402204	ATG10	-0.46	-7.28	-0.37	2.37e-12	Breast cancer;
LUSC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg03146154	chr1:46216737	IPP	0.56	8.41	0.42	1.24e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs56283067	0.773	rs56115627	chr6:44683049	G/A	cg18551225	chr6:44695536	NA	-0.48	-8.36	-0.42	1.71e-15	Total body bone mineral density;
LUSC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.81	14.65	0.63	7.13e-38	Blood protein levels;
LUSC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-9.92	-0.48	1.69e-20	Schizophrenia;
LUSC	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg21573476	chr21:45109991	RRP1B	-0.36	-5.78	-0.3	1.72e-8	Mean corpuscular volume;
LUSC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.89	0.44	3.79e-17	Motion sickness;
LUSC	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg11584989	chr19:19387371	SF4	-0.5	-5.89	-0.31	9.61e-9	Bipolar disorder;
LUSC	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg17469321	chr7:55412551	NA	0.65	10.58	0.5	9.39e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs17507216	1.000	rs17158413	chr15:83235408	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.45	-6.13	-0.32	2.49e-9	Excessive daytime sleepiness;
LUSC	cis	rs1775715	0.737	rs12256714	chr10:32216262	A/G	cg03015672	chr10:32216066	ARHGAP12	-0.32	-5.66	-0.3	3.23e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.99	-18.68	-0.71	7.96e-54	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg06238570	chr21:40685208	BRWD1	-0.48	-7.43	-0.38	9.18e-13	Cognitive function;
LUSC	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.45	-0.5	2.56e-22	Eye color traits;
LUSC	cis	rs2219968	0.743	rs34849429	chr8:78909689	G/T	cg00738934	chr8:78996279	NA	-0.4	-7.2	-0.37	3.89e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg01652190	chr22:50026171	C22orf34	-0.29	-6.06	-0.31	3.77e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4776970	0.632	rs8030996	chr15:68031406	C/G	cg08079166	chr15:68083412	MAP2K5	-0.38	-7.8	-0.39	7.74e-14	Waist circumference;Body mass index;
LUSC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg05776053	chr2:74358815	NA	0.49	7.71	0.39	1.43e-13	Gestational age at birth (maternal effect);
LUSC	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg03060546	chr3:49711283	APEH	0.56	8.06	0.4	1.36e-14	Resting heart rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14589014	chr11:2952043	PHLDA2	0.42	6.2	0.32	1.65e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7849782	0.664	rs4742820	chr9:104394585	G/A	cg22914338	chr19:14376960	NA	0.25	6.13	0.32	2.42e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg20991723	chr1:152506922	NA	0.52	9.8	0.47	4.32e-20	Hair morphology;
LUSC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg02569458	chr12:86230093	RASSF9	0.59	10.15	0.49	2.81e-21	Major depressive disorder;
LUSC	cis	rs6700896	0.931	rs10789193	chr1:66129646	A/T	cg04111102	chr1:66153794	NA	0.33	7.26	0.37	2.81e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-5.91	-0.31	8.35e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg25258033	chr6:167368657	RNASET2	-0.47	-7.87	-0.4	5.12e-14	Crohn's disease;
LUSC	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg08079166	chr15:68083412	MAP2K5	0.47	7.68	0.39	1.78e-13	Restless legs syndrome;
LUSC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	4.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs727505	0.954	rs59670428	chr7:124520966	C/A	cg23710748	chr7:124431027	NA	-0.4	-7.18	-0.37	4.56e-12	Lewy body disease;
LUSC	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.81	-0.39	7.72e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7178572	0.568	rs11632966	chr15:77621805	A/C	cg22256960	chr15:77711686	NA	-0.5	-8.04	-0.4	1.57e-14	Type 2 diabetes;
LUSC	cis	rs7149337	0.836	rs4901087	chr14:51668499	T/C	cg23942311	chr14:51606299	NA	0.46	10.06	0.48	5.75e-21	Cancer;
LUSC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg13453750	chr1:205783389	SLC41A1	0.27	5.65	0.3	3.39e-8	Monocyte percentage of white cells;
LUSC	cis	rs34638657	0.872	rs6420437	chr16:82187181	T/C	cg09439754	chr16:82129088	HSD17B2	-0.41	-6.54	-0.34	2.37e-10	Lung adenocarcinoma;
LUSC	cis	rs11677416	1.000	rs4848300	chr2:113527906	T/C	cg27083787	chr2:113543245	IL1A	0.45	7.09	0.36	7.87e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs965604	1.000	rs1062980	chr15:78792527	T/C	cg18825076	chr15:78729989	IREB2	0.45	7.1	0.36	7.64e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.03	-0.44	1.45e-17	Total cholesterol levels;
LUSC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg17264618	chr3:40429014	ENTPD3	0.33	6.95	0.36	1.91e-11	Renal cell carcinoma;
LUSC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg05347473	chr6:146136440	FBXO30	0.51	8.66	0.43	2e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.23	14.01	0.61	2.04e-35	Diabetic kidney disease;
LUSC	cis	rs4290604	0.665	rs4316893	chr2:238089767	T/C	cg23555395	chr2:238036564	NA	-0.46	-6.23	-0.32	1.4e-9	Asthma;
LUSC	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg00852783	chr1:26633632	UBXN11	0.6	8.87	0.44	4.35e-17	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg03522245	chr20:25566470	NINL	0.35	5.7	0.3	2.66e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg13010199	chr12:38710504	ALG10B	-0.65	-11.12	-0.52	1.18e-24	Heart rate;
LUSC	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg24675056	chr1:15929824	NA	0.44	7.52	0.38	5.13e-13	Systolic blood pressure;
LUSC	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg09092052	chr15:45571596	NA	0.45	6.27	0.32	1.12e-9	Glomerular filtration rate;
LUSC	trans	rs890100	0.643	rs12619332	chr2:56659016	T/A	cg01657744	chr10:88471748	LDB3	0.43	5.95	0.31	6.75e-9	Gut microbiome composition (summer);
LUSC	trans	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.47	6.99	0.36	1.53e-11	Endometrial cancer;
LUSC	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg27539214	chr16:67997921	SLC12A4	-0.62	-7.43	-0.38	9.22e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg11941060	chr3:133502564	NA	-0.47	-6.79	-0.35	5.27e-11	Iron status biomarkers;
LUSC	cis	rs6429082	0.764	rs291377	chr1:235695186	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.57	-7.82	-0.39	7.03e-14	Adiposity;
LUSC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg08200582	chr11:442649	ANO9	-0.55	-6.15	-0.32	2.16e-9	Body mass index;
LUSC	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg11812906	chr14:75593930	NEK9	0.66	11.49	0.53	5.68e-26	Height;
LUSC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.35	7.79	0.39	8.81e-14	Hemoglobin concentration;
LUSC	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg17749961	chr2:30669863	LCLAT1	0.67	8.37	0.42	1.62e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg08859206	chr1:53392774	SCP2	0.52	9.03	0.44	1.39e-17	Monocyte count;
LUSC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg27284194	chr4:1044797	NA	0.34	5.72	0.3	2.33e-8	Obesity-related traits;
LUSC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg17623882	chr6:41773611	USP49	-0.61	-10.36	-0.49	5.25e-22	Menarche (age at onset);
LUSC	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg12924262	chr12:102091054	CHPT1	0.43	6.12	0.32	2.57e-9	Blood protein levels;
LUSC	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9807841	0.592	rs10407349	chr19:10758453	G/A	cg09936142	chr19:10668400	KRI1	-0.43	-6.95	-0.36	1.88e-11	Inflammatory skin disease;
LUSC	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg05855489	chr10:104503620	C10orf26	0.53	7.73	0.39	1.25e-13	Arsenic metabolism;
LUSC	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.43	6.09	0.32	3.12e-9	Lung cancer;
LUSC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg00815214	chr21:47717953	NA	-0.4	-6.04	-0.31	4.12e-9	Testicular germ cell tumor;
LUSC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	0.86	11.62	0.54	2e-26	Eosinophil percentage of granulocytes;
LUSC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.5	0.5	1.81e-22	Ileal carcinoids;
LUSC	cis	rs12956009	0.583	rs16951972	chr18:44898600	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.14	0.32	2.36e-9	Educational attainment (years of education);
LUSC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg17971929	chr21:40555470	PSMG1	-0.65	-10.61	-0.5	7.42e-23	Cognitive function;
LUSC	cis	rs12541635	1.000	rs1896919	chr8:107090357	C/G	cg10147462	chr8:107024639	NA	-0.48	-8.76	-0.43	1.03e-16	Age of smoking initiation;
LUSC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.24	0.52	4.63e-25	Prudent dietary pattern;
LUSC	cis	rs4776059	1.000	rs8026800	chr15:52933548	C/G	cg22715398	chr15:52968154	KIAA1370	-0.7	-10.18	-0.49	2.23e-21	Schizophrenia;
LUSC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-6.07	-0.32	3.38e-9	Tonsillectomy;
LUSC	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04267008	chr7:1944627	MAD1L1	-0.48	-7.19	-0.37	4.27e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg04546413	chr19:29218101	NA	0.72	11.5	0.53	5.38e-26	Methadone dose in opioid dependence;
LUSC	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg25233709	chr10:116636983	FAM160B1	0.44	7.84	0.39	6.17e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg23978390	chr7:1156363	C7orf50	0.44	5.96	0.31	6.41e-9	Longevity;Endometriosis;
LUSC	cis	rs4561483	0.831	rs33621	chr16:12008513	G/A	cg08843971	chr16:11963173	GSPT1	-0.46	-6.81	-0.35	4.51e-11	Testicular germ cell tumor;
LUSC	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg05973401	chr12:123451056	ABCB9	0.56	8.17	0.41	6.27e-15	Platelet count;
LUSC	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.6	0.6	7.86e-34	Morning vs. evening chronotype;
LUSC	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg23093090	chr10:104574429	C10orf26	-0.4	-5.66	-0.3	3.31e-8	Arsenic metabolism;
LUSC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.73	12.38	0.56	3.18e-29	Menarche (age at onset);
LUSC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg04756594	chr16:24857601	SLC5A11	-0.5	-7.44	-0.38	8.85e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3931020	0.688	rs452242	chr1:75225625	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.62	-8.14	-0.41	8.11e-15	Resistin levels;
LUSC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg17948913	chr5:572064	NA	0.33	5.81	0.3	1.43e-8	Obesity-related traits;
LUSC	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg05844789	chr1:228464394	OBSCN	0.3	5.7	0.3	2.57e-8	Diastolic blood pressure;
LUSC	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg00750074	chr16:89608354	SPG7	-0.56	-9.89	-0.48	2.15e-20	Multiple myeloma (IgH translocation);
LUSC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs77741769	0.571	rs869781	chr12:121340246	T/C	cg02419362	chr12:121203948	SPPL3	0.46	8.64	0.43	2.3e-16	Mean corpuscular volume;
LUSC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.08	-0.32	3.35e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7677751	0.806	rs61320297	chr4:55088175	G/A	cg17187183	chr4:55093834	PDGFRA	0.38	5.83	0.3	1.3e-8	Corneal astigmatism;
LUSC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.53	0.34	2.51e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg09307838	chr4:120376055	NA	0.64	9.67	0.47	1.19e-19	Educational attainment;
LUSC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	12.59	0.57	4.98e-30	Cognitive test performance;
LUSC	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg01176363	chr20:62369445	LIME1	0.47	7.32	0.37	1.92e-12	Prostate cancer;
LUSC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.88	12.77	0.57	1.09e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.83	-0.39	6.55e-14	Body mass index;
LUSC	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg19554555	chr3:13937349	NA	-0.38	-5.71	-0.3	2.47e-8	Ovarian reserve;
LUSC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg00033643	chr7:134001901	SLC35B4	0.47	7.35	0.37	1.53e-12	Mean platelet volume;
LUSC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg02475777	chr4:1388615	CRIPAK	0.45	6.68	0.34	1.02e-10	Obesity-related traits;
LUSC	trans	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg26043149	chr18:55253948	FECH	-0.45	-6.91	-0.35	2.43e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg06784218	chr1:46089804	CCDC17	0.48	9.45	0.46	6.3e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg09835421	chr16:68378352	PRMT7	-0.53	-5.9	-0.31	9e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg06494592	chr3:125709126	NA	-0.5	-5.77	-0.3	1.86e-8	Blood pressure (smoking interaction);
LUSC	cis	rs4363385	0.510	rs10888528	chr1:153050516	A/G	cg25856811	chr1:152973957	SPRR3	0.36	5.97	0.31	5.91e-9	Inflammatory skin disease;
LUSC	cis	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg17469321	chr7:55412551	NA	0.65	10.58	0.5	9.39e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg22875332	chr1:76189707	ACADM	-0.68	-9.28	-0.45	2.24e-18	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg10483660	chr13:112241077	NA	0.37	6.4	0.33	5.12e-10	Menarche (age at onset);
LUSC	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg08975724	chr8:8085496	FLJ10661	0.47	6.89	0.35	2.75e-11	Retinal vascular caliber;
LUSC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs7107174	1.000	rs2511158	chr11:77973980	C/T	cg02023728	chr11:77925099	USP35	0.51	7.11	0.36	7.03e-12	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-7.94	-0.4	3.08e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg15839431	chr19:19639596	YJEFN3	-0.66	-7.28	-0.37	2.39e-12	Bipolar disorder;
LUSC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg24578937	chr1:2090814	PRKCZ	-0.41	-8.99	-0.44	1.82e-17	Height;
LUSC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg25767906	chr1:53392781	SCP2	-0.4	-6.69	-0.34	9.53e-11	Monocyte count;
LUSC	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg01629716	chr15:45996671	NA	0.4	5.96	0.31	6.25e-9	Waist circumference;Weight;
LUSC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-7.58	-0.38	3.43e-13	Menarche (age at onset);
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg11686214	chr19:59084984	MZF1;LOC100131691	-0.51	-6.02	-0.31	4.66e-9	Height;
LUSC	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg00290607	chr11:67383545	NA	-0.32	-5.86	-0.31	1.09e-8	Mean corpuscular volume;
LUSC	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.5	7.2	0.37	3.9e-12	Coronary heart disease;
LUSC	cis	rs601339	1.000	rs11059384	chr12:123170301	C/A	cg11919336	chr12:123188078	GPR109A	0.42	6.22	0.32	1.45e-9	Adiponectin levels;
LUSC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg05347473	chr6:146136440	FBXO30	0.51	8.77	0.43	9.4e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg01420254	chr6:26195488	NA	0.68	7.52	0.38	5.21e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.75	10.74	0.51	2.53e-23	Gut microbiome composition (summer);
LUSC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12016809	chr21:47604291	C21orf56	0.47	7.03	0.36	1.18e-11	Testicular germ cell tumor;
LUSC	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg11645453	chr3:52864694	ITIH4	0.58	14.03	0.61	1.85e-35	Schizophrenia;
LUSC	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg01620082	chr3:125678407	NA	-0.6	-6.71	-0.34	8.4e-11	Depression;
LUSC	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg07828340	chr4:882639	GAK	1.08	11.43	0.53	9.63e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-8.59	-0.43	3.4e-16	Systemic lupus erythematosus;
LUSC	cis	rs3087591	0.960	rs2269855	chr17:29482878	G/A	cg24425628	chr17:29625626	OMG;NF1	0.56	8.3	0.41	2.68e-15	Hip circumference;
LUSC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.68	-11.28	-0.53	3.1e-25	Systemic lupus erythematosus;
LUSC	cis	rs9462027	0.606	rs1201874	chr6:34549810	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.03	-0.31	4.43e-9	Systemic lupus erythematosus;
LUSC	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg13010199	chr12:38710504	ALG10B	0.66	9.97	0.48	1.11e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.31	0.49	8.3e-22	Bladder cancer;
LUSC	cis	rs427394	1.000	rs274672	chr5:6744176	G/A	cg10857441	chr5:6722123	POLS	-0.41	-7.7	-0.39	1.6e-13	Menopause (age at onset);
LUSC	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.45	0.33	3.86e-10	IgG glycosylation;
LUSC	cis	rs244293	1.000	rs244289	chr17:53231788	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-5.83	-0.3	1.34e-8	Menarche (age at onset);
LUSC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg06808227	chr14:105710500	BRF1	-0.65	-9.82	-0.47	3.77e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg01181863	chr3:195395398	SDHAP2	-0.61	-8.25	-0.41	3.62e-15	Pancreatic cancer;
LUSC	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg03929089	chr4:120376271	NA	0.69	6.43	0.33	4.38e-10	Axial length;
LUSC	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg18200150	chr17:30822561	MYO1D	0.52	10.59	0.5	8.41e-23	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	12.62	0.57	3.88e-30	Motion sickness;
LUSC	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg22676075	chr6:135203613	NA	-0.65	-10.27	-0.49	1.13e-21	Red blood cell count;
LUSC	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg01283332	chr5:1856932	NA	-0.32	-5.99	-0.31	5.55e-9	Cardiovascular disease risk factors;
LUSC	cis	rs4363385	0.818	rs57311099	chr1:153005597	A/C	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.43e-12	Inflammatory skin disease;
LUSC	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.72	0.39	1.38e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.39e-22	Alzheimer's disease (late onset);
LUSC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-0.82	-14.19	-0.61	4.12e-36	Longevity;
LUSC	cis	rs7759001	0.857	rs6934748	chr6:27354781	T/G	cg18711553	chr6:27366782	ZNF391	0.39	5.76	0.3	1.96e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	0.64	13.37	0.59	5.97e-33	Prudent dietary pattern;
LUSC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg11062466	chr8:58055876	NA	0.51	6.7	0.34	8.73e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs11605275	1.000	rs78091560	chr11:20032279	G/A	cg14835545	chr11:20032148	NAV2	-0.86	-6.53	-0.34	2.43e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs477692	0.569	rs871028	chr10:131293478	C/T	cg05714579	chr10:131428358	MGMT	-0.42	-6.31	-0.33	9.03e-10	Response to temozolomide;
LUSC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg00033643	chr7:134001901	SLC35B4	0.42	6.14	0.32	2.37e-9	Mean platelet volume;
LUSC	cis	rs6967385	0.934	rs7812164	chr7:12368389	A/T	cg06484146	chr7:12443880	VWDE	0.4	5.84	0.3	1.21e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7709377	0.620	rs10051302	chr5:115488698	G/C	cg23108291	chr5:115420582	COMMD10	0.41	5.79	0.3	1.62e-8	Metabolite levels  (X-11787);
LUSC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22307029	chr19:49891270	CCDC155	0.58	8.32	0.41	2.32e-15	Multiple sclerosis;
LUSC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.65	-0.3	3.41e-8	Monocyte count;
LUSC	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.55	-7.88	-0.4	4.53e-14	Reticulocyte count;
LUSC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg12560992	chr17:57184187	TRIM37	-0.71	-12.61	-0.57	4.42e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.84	-0.35	3.67e-11	Total body bone mineral density;
LUSC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg09365446	chr1:150670422	GOLPH3L	0.54	8.33	0.41	2.13e-15	Tonsillectomy;
LUSC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	12.88	0.58	4.32e-31	Platelet count;
LUSC	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.97	-0.31	6.07e-9	Resting heart rate;
LUSC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-7.96	-0.4	2.78e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2905347	0.656	rs2051723	chr7:22665843	C/G	cg23521230	chr7:22704884	NA	0.42	5.71	0.3	2.53e-8	Major depression and alcohol dependence;
LUSC	cis	rs10754283	0.967	rs10801761	chr1:90115269	C/T	cg21401794	chr1:90099060	LRRC8C	0.63	9.17	0.45	4.84e-18	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05901451	chr6:126070800	HEY2	0.57	8.51	0.42	5.97e-16	Endometrial cancer;
LUSC	trans	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg03522245	chr20:25566470	NINL	0.35	5.75	0.3	2.02e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11141652	chr22:24348549	GSTTP1	0.41	6.28	0.32	1.08e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.45	-6.1	-0.32	2.91e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg05163923	chr11:71159392	DHCR7	0.74	11.04	0.52	2.38e-24	Vitamin D levels;
LUSC	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg10857441	chr5:6722123	POLS	-0.47	-9.21	-0.45	3.6e-18	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg17366294	chr4:99064904	C4orf37	0.62	11.11	0.52	1.29e-24	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26726542	chr13:20702031	NA	-0.47	-5.95	-0.31	6.95e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs273573	0.922	rs35194615	chr11:30813303	C/T	cg14844989	chr11:31128820	NA	-0.36	-5.72	-0.3	2.35e-8	Total body bone mineral density;
LUSC	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.68	10.33	0.49	6.9e-22	Corneal astigmatism;
LUSC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg13531842	chr10:38383804	ZNF37A	-0.43	-6.5	-0.34	2.95e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.64	0.39	2.31e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9309473	0.607	rs4641966	chr2:73590806	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-8.06	-0.4	1.39e-14	Metabolite levels;
LUSC	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg17470449	chr10:769945	NA	0.53	7.31	0.37	1.98e-12	Uric acid levels;
LUSC	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg27124370	chr19:33622961	WDR88	0.57	7.42	0.38	1.01e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.67	-10.97	-0.51	4e-24	Longevity;Endometriosis;
LUSC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg26924012	chr15:45694286	SPATA5L1	1.13	20.89	0.75	1.35e-62	Homoarginine levels;
LUSC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg16624210	chr5:671434	TPPP	0.49	6.11	0.32	2.72e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.96	-0.44	2.41e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg23262073	chr20:60523788	NA	-0.44	-6.52	-0.34	2.6e-10	Body mass index;
LUSC	trans	rs79057730	0.599	rs9458	chr7:825494	A/G	cg26647312	chr5:1645268	NA	-0.6	-5.98	-0.31	5.6e-9	Initial pursuit acceleration;
LUSC	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.44	6.47	0.33	3.51e-10	Neuroticism;
LUSC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg02269571	chr22:50332266	NA	0.59	8.79	0.43	8.05e-17	Schizophrenia;
LUSC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg13319975	chr6:146136371	FBXO30	-0.68	-10.57	-0.5	1.05e-22	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs953492	0.672	rs1766030	chr1:243314577	C/T	cg04438194	chr4:119512985	NA	-0.41	-6.19	-0.32	1.8e-9	Diastolic blood pressure;
LUSC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-0.82	-12.42	-0.56	2.25e-29	Gut microbiome composition (summer);
LUSC	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg16482183	chr6:26056742	HIST1H1C	0.65	9.03	0.44	1.43e-17	Iron status biomarkers;
LUSC	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg19628046	chr18:33552617	C18orf21	0.52	6.12	0.32	2.59e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg17541715	chr7:1216824	NA	-0.36	-5.69	-0.3	2.83e-8	Longevity;Endometriosis;
LUSC	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg02569458	chr12:86230093	RASSF9	0.49	8.22	0.41	4.69e-15	Major depressive disorder;
LUSC	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.51	-7.94	-0.4	3.01e-14	Colorectal cancer;
LUSC	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg19116668	chr7:99932089	PMS2L1	0.33	5.7	0.3	2.64e-8	Coronary artery disease;
LUSC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-1.17	-16.86	-0.68	1.46e-46	Breast cancer;
LUSC	cis	rs10504073	0.669	rs818560	chr8:50035417	C/T	cg00325661	chr8:49890786	NA	0.6	9.75	0.47	6.18e-20	Blood metabolite ratios;
LUSC	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg03676636	chr4:99064102	C4orf37	0.3	5.99	0.31	5.55e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg24060327	chr5:131705240	SLC22A5	-0.37	-6.08	-0.32	3.29e-9	Blood metabolite levels;
LUSC	cis	rs12681287	0.640	rs2953516	chr8:87332545	C/T	cg27223183	chr8:87520930	FAM82B	-0.51	-6.62	-0.34	1.43e-10	Caudate activity during reward;
LUSC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg17330251	chr7:94953956	PON1	-0.38	-6.02	-0.31	4.69e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg03886242	chr7:26192032	NFE2L3	0.37	6.25	0.32	1.22e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg24812749	chr6:127587940	RNF146	0.49	7.19	0.37	4.33e-12	Breast cancer;
LUSC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10802521	chr3:52805072	NEK4	-0.57	-9.39	-0.46	9.84e-19	Electroencephalogram traits;
LUSC	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-6.97	-0.36	1.73e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs4144743	1.000	rs72823474	chr17:45321776	G/C	cg18085866	chr17:45331354	ITGB3	-0.75	-8.07	-0.4	1.24e-14	Body mass index;
LUSC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg09796270	chr17:17721594	SREBF1	0.39	6.74	0.35	7.12e-11	Total body bone mineral density;
LUSC	trans	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.68	-11.72	-0.54	8.38e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2303282	0.664	rs2432540	chr16:56419628	A/G	cg00500540	chr16:56394104	NA	0.4	6.76	0.35	6.21e-11	Breast cancer;
LUSC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg21435336	chr19:17392852	ANKLE1	-0.44	-6.12	-0.32	2.69e-9	Systemic lupus erythematosus;
LUSC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.95	-0.51	4.58e-24	Aortic root size;
LUSC	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg08219700	chr8:58056026	NA	0.44	5.82	0.3	1.35e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04767207	chr11:60929031	VPS37C	0.49	6.86	0.35	3.44e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs290268	0.669	rs10993693	chr9:93557698	C/T	cg02608019	chr9:93564028	SYK	0.52	8.6	0.43	3.13e-16	Platelet count;
LUSC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.64	-0.6	5.38e-34	Chronic sinus infection;
LUSC	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg00784671	chr22:46762841	CELSR1	-0.47	-5.97	-0.31	6.02e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg23711669	chr6:146136114	FBXO30	0.85	15.62	0.65	1.15e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.3	-6.04	-0.31	4.15e-9	Longevity;Endometriosis;
LUSC	cis	rs10504073	0.525	rs10081464	chr8:50058707	A/G	cg00325661	chr8:49890786	NA	0.47	7.0	0.36	1.43e-11	Blood metabolite ratios;
LUSC	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	6.28	0.33	1.04e-9	Multiple sclerosis;
LUSC	cis	rs7903847	0.642	rs12415424	chr10:99117897	C/A	cg20016023	chr10:99160130	RRP12	-0.3	-6.3	-0.33	9.27e-10	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.67	11.85	0.54	2.92e-27	Aortic root size;
LUSC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-0.9	-17.6	-0.69	1.54e-49	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg22920501	chr2:26401640	FAM59B	-0.75	-10.64	-0.5	5.79e-23	Gut microbiome composition (summer);
LUSC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	7.81	0.39	7.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2625529	0.556	rs8038007	chr15:72568043	C/G	cg16672083	chr15:72433130	SENP8	0.46	7.48	0.38	6.55e-13	Red blood cell count;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg27267900	chr19:1924559	SCAMP4	-0.69	-6.1	-0.32	3.02e-9	Body mass index;
LUSC	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg23172400	chr8:95962367	TP53INP1	-0.32	-5.93	-0.31	7.76e-9	Type 2 diabetes;
LUSC	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg04036182	chr15:45458818	NA	-0.37	-6.01	-0.31	4.99e-9	Glomerular filtration rate;
LUSC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.46	-7.93	-0.4	3.32e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg06808227	chr14:105710500	BRF1	-0.67	-10.31	-0.49	8.31e-22	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg17509989	chr5:176798049	RGS14	-0.68	-9.67	-0.47	1.16e-19	Urate levels in lean individuals;
LUSC	cis	rs41271473	0.898	rs12028277	chr1:228829657	A/G	cg16512390	chr1:228756714	NA	0.57	7.03	0.36	1.19e-11	Chronic lymphocytic leukemia;
LUSC	trans	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg18335740	chr13:41363409	SLC25A15	0.59	9.16	0.45	5.36e-18	Lewy body disease;
LUSC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	0.94	17.87	0.7	1.34e-50	Heart rate;
LUSC	cis	rs4654899	0.865	rs72975078	chr1:21476196	A/G	cg02927042	chr1:21476669	EIF4G3	-0.36	-5.76	-0.3	1.88e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs662735	0.515	rs2022130	chr11:30819811	T/C	cg14844989	chr11:31128820	NA	-0.37	-5.86	-0.31	1.11e-8	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08736216	chr1:53307985	ZYG11A	0.3	6.19	0.32	1.78e-9	Monocyte count;
LUSC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	0.93	15.52	0.65	2.8e-41	Menopause (age at onset);
LUSC	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg22676075	chr6:135203613	NA	-0.58	-9.28	-0.45	2.22e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.74	12.09	0.55	3.59e-28	Lymphocyte percentage of white cells;
LUSC	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg22782873	chr19:19639568	YJEFN3	-0.46	-6.12	-0.32	2.63e-9	Bipolar disorder;
LUSC	cis	rs10743315	0.557	rs74478800	chr12:19367517	A/T	cg02471346	chr12:19282374	PLEKHA5	0.78	6.28	0.33	1.03e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs10788264	0.544	rs911786	chr10:124017583	C/G	cg09507567	chr10:124027408	NA	0.54	9.4	0.46	9.12e-19	Total body bone mineral density;
LUSC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.86	0.47	2.69e-20	Personality dimensions;
LUSC	cis	rs2346177	0.874	rs4953372	chr2:46651624	C/G	cg02822958	chr2:46747628	ATP6V1E2	-0.34	-5.94	-0.31	7.01e-9	HDL cholesterol;
LUSC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg26408565	chr15:76604113	ETFA	-0.47	-7.42	-0.38	9.75e-13	Blood metabolite levels;
LUSC	cis	rs939574	1.000	rs3817424	chr2:220096903	A/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.07	8.71	0.43	1.42e-16	Platelet distribution width;
LUSC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg11645453	chr3:52864694	ITIH4	0.35	8.37	0.42	1.63e-15	Bipolar disorder;
LUSC	cis	rs73198271	0.855	rs57301822	chr8:8608642	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.98	-0.31	5.63e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg03188948	chr7:1209495	NA	0.67	7.1	0.36	7.38e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.46e-23	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg06008330	chr7:65541103	ASL	0.4	6.19	0.32	1.77e-9	Aortic root size;
LUSC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg20406979	chr6:167373233	NA	0.25	5.69	0.3	2.76e-8	Crohn's disease;
LUSC	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg11189052	chr15:85197271	WDR73	0.5	6.39	0.33	5.74e-10	Schizophrenia;
LUSC	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg12935359	chr14:103987150	CKB	0.64	8.39	0.42	1.34e-15	Bone mineral density;
LUSC	cis	rs3770081	1.000	rs17584578	chr2:86307624	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	1.03	7.43	0.38	9.06e-13	Facial emotion recognition (sad faces);
LUSC	cis	rs3849570	0.925	rs2873054	chr3:81888255	A/C	cg07356753	chr3:81810745	GBE1	-0.68	-10.95	-0.51	4.75e-24	Waist circumference;Body mass index;
LUSC	cis	rs752010	0.574	rs10890161	chr1:42121623	T/C	cg06885757	chr1:42089581	HIVEP3	0.44	9.33	0.45	1.49e-18	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.3	-6.4	-0.33	5.38e-10	Dupuytren's disease;
LUSC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	0.6	9.45	0.46	5.98e-19	Breast cancer;
LUSC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.58	0.34	1.86e-10	Lung cancer;
LUSC	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg23229984	chr5:148520753	ABLIM3	0.38	5.93	0.31	7.63e-9	Breast cancer;
LUSC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.14	-0.8	3.2e-75	Height;
LUSC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21028142	chr17:79581711	NPLOC4	0.35	8.24	0.41	4.03e-15	Eye color traits;
LUSC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03576123	chr11:487126	PTDSS2	-0.95	-10.54	-0.5	1.27e-22	Body mass index;
LUSC	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg22681709	chr2:178499509	PDE11A	-0.4	-6.18	-0.32	1.91e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.9	0.35	2.57e-11	Endometrial cancer;
LUSC	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	7.42	0.38	9.86e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg07507251	chr3:52567010	NT5DC2	0.34	6.55	0.34	2.21e-10	Bipolar disorder;
LUSC	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg25214090	chr10:38739885	LOC399744	0.5	7.39	0.37	1.19e-12	Corneal astigmatism;
LUSC	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg11244672	chr19:19639970	YJEFN3	-0.55	-6.84	-0.35	3.86e-11	Bipolar disorder;
LUSC	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg27572855	chr1:25598939	RHD	0.43	7.69	0.39	1.69e-13	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs977987	0.806	rs11862684	chr16:75461746	T/G	cg03315344	chr16:75512273	CHST6	0.51	9.57	0.46	2.55e-19	Dupuytren's disease;
LUSC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.88	-0.4	4.57e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg16145915	chr7:1198662	ZFAND2A	0.43	7.77	0.39	9.61e-14	Longevity;Endometriosis;
LUSC	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	7.34	0.37	1.66e-12	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg22166914	chr1:53195759	ZYG11B	-0.48	-7.5	-0.38	5.93e-13	Monocyte count;
LUSC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg14346243	chr4:90757452	SNCA	-0.43	-6.21	-0.32	1.61e-9	Neuroticism;
LUSC	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg17366294	chr4:99064904	C4orf37	0.53	9.12	0.45	7.31e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg23262073	chr20:60523788	NA	-0.46	-6.76	-0.35	6.33e-11	Body mass index;
LUSC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22509189	chr2:225307070	NA	-0.47	-6.13	-0.32	2.55e-9	IgE levels in asthmatics (D.p. specific);
LUSC	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.09	0.4	1.12e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs472402	0.623	rs8192135	chr5:6636757	T/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.51	-7.69	-0.39	1.66e-13	Response to amphetamines;
LUSC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.52	0.34	2.54e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg20135002	chr11:47629003	NA	-0.52	-8.21	-0.41	5e-15	Subjective well-being;
LUSC	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg01483505	chr11:975446	AP2A2	0.44	6.12	0.32	2.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg22029157	chr1:209979665	IRF6	0.76	9.84	0.47	3.17e-20	Cleft lip with or without cleft palate;
LUSC	cis	rs1577917	0.958	rs7382798	chr6:86559834	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg00129232	chr17:37814104	STARD3	-0.5	-7.4	-0.38	1.11e-12	Asthma;
LUSC	trans	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg02030672	chr11:45687055	CHST1	-0.41	-6.31	-0.33	8.65e-10	Obesity-related traits;
LUSC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg06027949	chr8:82754900	SNX16	-0.45	-6.42	-0.33	4.7e-10	Diastolic blood pressure;
LUSC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg11608241	chr8:8085544	FLJ10661	0.38	5.72	0.3	2.31e-8	Mood instability;
LUSC	cis	rs6580649	0.941	rs57054831	chr12:48486892	C/T	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.61	11.79	0.54	4.5e-27	Pulse pressure;
LUSC	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg14675211	chr2:100938903	LONRF2	0.37	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg19748678	chr4:122722346	EXOSC9	0.51	7.8	0.39	7.9e-14	Type 2 diabetes;
LUSC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.54	-0.38	4.39e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg01652190	chr22:50026171	C22orf34	-0.28	-5.72	-0.3	2.36e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.65	-0.3	3.5e-8	Coronary artery disease;
LUSC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.06	-0.55	4.59e-28	Type 2 diabetes;
LUSC	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.49	-5.7	-0.3	2.69e-8	Schizophrenia;
LUSC	cis	rs17401966	0.522	rs17396973	chr1:10334924	C/T	cg17425144	chr1:10567563	PEX14	-0.32	-5.83	-0.3	1.34e-8	Hepatocellular carcinoma;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03738868	chr7:100281714	GIGYF1	-0.81	-6.61	-0.34	1.51e-10	Cognitive performance;
LUSC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg12963246	chr6:28129442	ZNF389	0.52	7.2	0.37	3.93e-12	Parkinson's disease;
LUSC	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.7	11.02	0.52	2.77e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg12091567	chr17:66097778	LOC651250	-0.74	-9.25	-0.45	2.79e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	8.18	0.41	5.91e-15	Height;
LUSC	trans	rs4252134	0.959	rs4252090	chr6:161133544	A/T	cg15416064	chr12:49209402	NA	-0.43	-6.04	-0.31	4.18e-9	Giant cell arteritis;
LUSC	cis	rs56804039	1.000	rs7017341	chr8:8381664	C/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.24	-0.32	1.32e-9	Cervical cancer;
LUSC	cis	rs11051970	0.704	rs7312698	chr12:32554695	G/T	cg02745156	chr12:32552066	NA	0.37	6.8	0.35	4.69e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7241530	0.636	rs4798996	chr18:75889558	G/A	cg14642773	chr18:75888474	NA	0.36	5.93	0.31	7.46e-9	Educational attainment (years of education);
LUSC	cis	rs540254	0.619	rs4656270	chr1:160779412	A/G	cg20255094	chr1:160771763	LY9	0.55	6.64	0.34	1.24e-10	Blood protein levels;
LUSC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg12751644	chr20:60527061	NA	-0.33	-6.22	-0.32	1.46e-9	Body mass index;
LUSC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg13206674	chr6:150067644	NUP43	0.64	10.48	0.5	2.17e-22	Lung cancer;
LUSC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg01802117	chr1:53393560	SCP2	0.46	7.51	0.38	5.33e-13	Monocyte count;
LUSC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg04352962	chr1:209979756	IRF6	0.52	7.09	0.36	7.81e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18404041	chr3:52824283	ITIH1	-0.57	-11.03	-0.52	2.41e-24	Bipolar disorder;
LUSC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg14019146	chr3:50243930	SLC38A3	0.32	7.07	0.36	9.29e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg05896524	chr21:47604654	C21orf56	0.5	7.74	0.39	1.17e-13	Testicular germ cell tumor;
LUSC	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg10840412	chr1:235813424	GNG4	-0.66	-9.08	-0.44	9.63e-18	Bipolar disorder;
LUSC	cis	rs4919087	0.715	rs8181326	chr10:98998195	G/A	cg25902810	chr10:99078978	FRAT1	0.39	5.68	0.3	2.99e-8	Monocyte count;
LUSC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	1.1	26.73	0.83	5.84e-85	Testicular germ cell tumor;
LUSC	cis	rs2742417	1.000	rs2673034	chr3:45755138	A/G	cg04837898	chr3:45731254	SACM1L	-0.34	-5.73	-0.3	2.26e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg04586622	chr2:25135609	ADCY3	-0.36	-7.57	-0.38	3.6e-13	Body mass index in non-asthmatics;
LUSC	cis	rs72960926	0.744	rs72950546	chr6:74907293	A/T	cg03266952	chr6:74778945	NA	-0.78	-6.3	-0.33	9.2e-10	Metabolite levels (MHPG);
LUSC	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.11	0.52	1.28e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.69	0.39	1.65e-13	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.54	0.46	3.22e-19	Prudent dietary pattern;
LUSC	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg25643088	chr3:52874325	TMEM110	0.39	5.82	0.3	1.4e-8	Schizophrenia;
LUSC	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-7.97	-0.4	2.58e-14	Total cholesterol levels;
LUSC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg09365446	chr1:150670422	GOLPH3L	0.49	7.33	0.37	1.8e-12	Melanoma;
LUSC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg01802117	chr1:53393560	SCP2	-0.37	-6.02	-0.31	4.52e-9	Monocyte count;
LUSC	cis	rs11018904	0.817	rs11606060	chr11:89928597	T/C	cg26834418	chr11:89957033	CHORDC1	-0.51	-6.02	-0.31	4.67e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg11812906	chr14:75593930	NEK9	0.66	11.34	0.53	2.04e-25	Height;
LUSC	cis	rs7712401	0.584	rs39820	chr5:122299921	G/A	cg19077854	chr5:122220652	SNX24	0.43	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg09462578	chr12:12878428	APOLD1	-0.68	-7.89	-0.4	4.41e-14	Systemic lupus erythematosus;
LUSC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26769984	chr7:1090371	C7orf50	0.72	10.19	0.49	2.05e-21	Bronchopulmonary dysplasia;
LUSC	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	8.74	0.43	1.11e-16	Bipolar disorder;
LUSC	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg08601574	chr20:25228251	PYGB	0.47	7.29	0.37	2.28e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10992471	0.603	rs12336415	chr9:95195458	G/T	cg14631576	chr9:95140430	CENPP	-0.35	-6.48	-0.33	3.26e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg20608306	chr11:116969690	SIK3	0.37	6.92	0.35	2.28e-11	Blood protein levels;
LUSC	cis	rs59104589	0.517	rs3821281	chr2:242385340	A/G	cg14842376	chr2:242211374	HDLBP	0.53	6.19	0.32	1.81e-9	Fibrinogen levels;
LUSC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	8.55	0.42	4.56e-16	Motion sickness;
LUSC	cis	rs12891047	0.804	rs11626769	chr14:68291467	G/A	cg20999565	chr14:68265668	ZFYVE26	0.38	5.8	0.3	1.54e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg05973401	chr12:123451056	ABCB9	0.54	6.71	0.34	8.23e-11	Neutrophil percentage of white cells;
LUSC	cis	rs3772130	0.583	rs34051021	chr3:121433005	C/A	cg20356878	chr3:121714668	ILDR1	0.51	8.14	0.41	7.72e-15	Cognitive performance;
LUSC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	7.16	0.36	5.11e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.78	0.6	1.67e-34	Chronic sinus infection;
LUSC	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	1.18	14.04	0.61	1.62e-35	Arsenic metabolism;
LUSC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.87	16.62	0.67	1.21e-45	Gestational age at birth (maternal effect);
LUSC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-11.03	-0.52	2.39e-24	Menarche (age at onset);
LUSC	cis	rs6982240	0.514	rs10481391	chr8:142277149	A/G	cg00131261	chr8:142287264	NA	-0.38	-6.25	-0.32	1.28e-9	Tonsillectomy;
LUSC	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	1.0	20.02	0.74	3.92e-59	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs4494114	1.000	rs4607833	chr1:39354272	G/C	cg25970120	chr1:39325951	RRAGC	-0.4	-6.19	-0.32	1.8e-9	Blood protein levels;
LUSC	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg11965913	chr1:205819406	PM20D1	-0.48	-6.67	-0.34	1.08e-10	Menarche (age at onset);
LUSC	cis	rs722599	0.683	rs2302834	chr14:75279395	T/A	cg08847533	chr14:75593920	NEK9	0.45	6.4	0.33	5.18e-10	IgG glycosylation;
LUSC	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg03929089	chr4:120376271	NA	-0.52	-6.05	-0.31	3.94e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs834811	0.796	rs2349456	chr7:135901545	G/T	cg01726295	chr7:135938950	NA	-0.39	-7.03	-0.36	1.19e-11	Post-traumatic stress disorder;
LUSC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg21972741	chr5:435613	AHRR	0.36	6.8	0.35	4.8e-11	Cystic fibrosis severity;
LUSC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08280861	chr8:58055591	NA	0.52	6.8	0.35	4.9e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg27411982	chr8:10470053	RP1L1	-0.36	-5.81	-0.3	1.46e-8	Retinal vascular caliber;
LUSC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.77	-0.43	8.98e-17	Obesity-related traits;
LUSC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg03538708	chr1:25844672	NA	-0.37	-6.22	-0.32	1.47e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg05425664	chr17:57184151	TRIM37	-0.56	-8.29	-0.41	2.84e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg11218175	chr11:495084	RNH1	-0.5	-5.66	-0.3	3.22e-8	Body mass index;
LUSC	cis	rs714027	1.000	rs5763767	chr22:30493882	G/A	cg11564601	chr22:30592435	NA	-0.37	-6.95	-0.36	1.91e-11	Lymphocyte counts;
LUSC	cis	rs1957429	0.520	rs2181127	chr14:65336455	C/T	cg23373153	chr14:65346875	NA	-0.87	-7.56	-0.38	4.04e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.42	5.79	0.3	1.62e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg24596788	chr1:163392923	NA	0.36	6.35	0.33	7.21e-10	Motion sickness;
LUSC	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg00191853	chr8:101177733	SPAG1	-0.41	-6.53	-0.34	2.46e-10	Atrioventricular conduction;
LUSC	cis	rs9326248	0.861	rs7120449	chr11:117042899	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.46	5.66	0.3	3.2e-8	Blood protein levels;
LUSC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg11189052	chr15:85197271	WDR73	-0.53	-7.51	-0.38	5.32e-13	P wave terminal force;
LUSC	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00321850	chr1:175162397	KIAA0040	0.46	7.98	0.4	2.36e-14	Alcohol dependence;
LUSC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg15649852	chr7:65879115	NA	-0.41	-5.75	-0.3	2.02e-8	Aortic root size;
LUSC	cis	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg06521331	chr12:34319734	NA	-0.37	-6.16	-0.32	2.06e-9	Morning vs. evening chronotype;
LUSC	trans	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg03886242	chr7:26192032	NFE2L3	0.37	6.01	0.31	4.9e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg22782873	chr19:19639568	YJEFN3	0.52	6.43	0.33	4.48e-10	Bipolar disorder;
LUSC	cis	rs11051970	0.879	rs10844201	chr12:32575029	A/G	cg02745156	chr12:32552066	NA	0.43	7.24	0.37	3.02e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6845621	0.835	rs11736810	chr4:18937568	C/T	cg12196642	chr4:18937545	NA	-0.36	-6.71	-0.34	8.42e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs3740393	0.562	rs11191389	chr10:104523018	C/T	cg05855489	chr10:104503620	C10orf26	0.56	5.84	0.3	1.24e-8	Microalbuminuria;
LUSC	cis	rs78579285	0.584	rs34908386	chr16:88800913	C/T	cg01900006	chr16:88814613	FAM38A	0.6	6.75	0.35	6.42e-11	Joint mobility (Beighton score);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg11021200	chr13:21750354	SKA3;MRP63	0.45	6.44	0.33	4.06e-10	Triglycerides;
LUSC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg07741184	chr6:167504864	NA	0.35	6.23	0.32	1.41e-9	Crohn's disease;
LUSC	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg19700328	chr14:106028568	NA	-0.41	-6.89	-0.35	2.83e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg11344533	chr11:111475393	SIK2	-0.49	-6.87	-0.35	3.18e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg23711669	chr6:146136114	FBXO30	-0.72	-10.32	-0.49	7.28e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg15147215	chr3:52552868	STAB1	0.31	6.08	0.32	3.33e-9	Bipolar disorder;
LUSC	cis	rs67366981	1.000	rs2287379	chr14:77705411	A/C	cg22824376	chr14:77648248	TMEM63C	0.67	6.3	0.33	9.16e-10	Obsessive-compulsive symptoms;
LUSC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs921665	0.584	rs5019161	chr2:3174761	A/G	cg02624386	chr2:3182749	NA	0.6	6.73	0.35	7.43e-11	World class endurance athleticism;
LUSC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.8	-13.41	-0.59	4.21e-33	Aortic root size;
LUSC	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	0.56	9.01	0.44	1.58e-17	Breast cancer;
LUSC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg00677455	chr12:58241039	CTDSP2	0.59	8.48	0.42	7.35e-16	Multiple sclerosis;
LUSC	cis	rs4363385	0.747	rs1577963	chr1:152961882	T/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.64	-0.39	2.25e-13	Inflammatory skin disease;
LUSC	cis	rs244293	0.965	rs244301	chr17:53239140	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-5.93	-0.31	7.63e-9	Menarche (age at onset);
LUSC	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.4	5.75	0.3	2.04e-8	Lung cancer;
LUSC	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg06484146	chr7:12443880	VWDE	-0.57	-6.07	-0.31	3.57e-9	Coronary artery disease;
LUSC	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg07148914	chr20:33460835	GGT7	-0.55	-8.43	-0.42	1.06e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg22823121	chr1:150693482	HORMAD1	0.51	7.44	0.38	8.56e-13	Melanoma;
LUSC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg12257692	chr3:49977190	RBM6	0.25	6.96	0.36	1.76e-11	Body mass index;
LUSC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg23281280	chr6:28129359	ZNF389	0.49	6.24	0.32	1.34e-9	Parkinson's disease;
LUSC	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg26384229	chr12:38710491	ALG10B	0.5	7.2	0.37	3.91e-12	Morning vs. evening chronotype;
LUSC	cis	rs7215564	0.818	rs4890054	chr17:78587195	C/T	cg23238734	chr17:78661607	RPTOR	0.49	5.97	0.31	6.07e-9	Myopia (pathological);
LUSC	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-9.48	-0.46	4.98e-19	Bipolar disorder;
LUSC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.59	-14.58	-0.62	1.37e-37	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg20573242	chr4:122745356	CCNA2	0.45	6.89	0.35	2.72e-11	Type 2 diabetes;
LUSC	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg13010199	chr12:38710504	ALG10B	0.64	9.85	0.47	2.98e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12618769	0.947	rs72825708	chr2:99239269	C/T	cg10123293	chr2:99228465	UNC50	0.42	5.82	0.3	1.35e-8	Bipolar disorder;
LUSC	cis	rs8051149	0.652	rs9926829	chr16:87883089	A/G	cg01412419	chr16:87856264	NA	-0.39	-5.96	-0.31	6.48e-9	Blood metabolite levels;
LUSC	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06022373	chr22:39101656	GTPBP1	0.75	12.34	0.56	4.27e-29	Menopause (age at onset);
LUSC	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.84	-13.79	-0.6	1.43e-34	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	6.75	0.35	6.74e-11	Personality dimensions;
LUSC	cis	rs7615316	0.751	rs6800695	chr3:142044904	G/A	cg16271453	chr3:142027066	XRN1	-0.41	-7.17	-0.37	4.74e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7727544	0.582	rs10052046	chr5:131544466	G/T	cg14196790	chr5:131705035	SLC22A5	0.42	6.95	0.36	1.88e-11	Blood metabolite levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06140764	chr6:30539234	ABCF1	-0.46	-6.97	-0.36	1.71e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg24250549	chr1:154909240	PMVK	0.65	10.87	0.51	9.05e-24	Prostate cancer;
LUSC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20887711	chr4:1340912	KIAA1530	0.55	8.62	0.43	2.79e-16	Longevity;
LUSC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.71	-12.36	-0.56	3.78e-29	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg04691961	chr3:161091175	C3orf57	-0.35	-5.97	-0.31	5.96e-9	Morning vs. evening chronotype;
LUSC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg14019146	chr3:50243930	SLC38A3	0.39	8.57	0.42	3.81e-16	Menarche (age at onset);
LUSC	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg22681709	chr2:178499509	PDE11A	-0.39	-5.99	-0.31	5.42e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg19743168	chr1:23544995	NA	0.41	8.04	0.4	1.62e-14	Height;
LUSC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg18402987	chr7:1209562	NA	0.73	7.85	0.39	5.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16804848	chr11:64052165	GPR137;BAD	0.41	6.12	0.32	2.66e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg24881330	chr22:46731750	TRMU	0.69	8.33	0.41	2.12e-15	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4363385	0.818	rs368912	chr1:153016204	C/G	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.89	-0.4	4.44e-14	Inflammatory skin disease;
LUSC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg13628971	chr7:2884303	GNA12	0.5	7.22	0.37	3.47e-12	Height;
LUSC	cis	rs2853333	1.000	rs2853333	chr19:35747663	C/T	cg12287945	chr19:35758300	LSR	-0.37	-5.87	-0.31	1.05e-8	Red blood cell count;
LUSC	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.74	0.47	6.69e-20	Arsenic metabolism;
LUSC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.86	0.31	1.13e-8	Tonsillectomy;
LUSC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg09323728	chr8:95962352	TP53INP1	-0.4	-8.62	-0.43	2.78e-16	Type 2 diabetes;
LUSC	cis	rs6484504	0.576	rs208090	chr11:31190992	T/C	cg14844989	chr11:31128820	NA	-0.37	-5.83	-0.3	1.27e-8	Red blood cell count;
LUSC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg12751644	chr20:60527061	NA	-0.36	-6.46	-0.33	3.73e-10	Body mass index;
LUSC	cis	rs11997175	0.713	rs4733454	chr8:33651253	C/A	ch.8.33884649F	chr8:33765107	NA	0.47	7.5	0.38	5.7e-13	Body mass index;
LUSC	cis	rs17604090	0.793	rs17150667	chr7:29689338	G/T	cg19413766	chr7:29689036	LOC646762	-0.55	-6.82	-0.35	4.31e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg05729581	chr11:3078854	CARS	0.39	5.75	0.3	1.97e-8	Calcium levels;
LUSC	cis	rs4363385	0.791	rs4041401	chr1:152985629	A/G	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.16	-0.36	5.23e-12	Inflammatory skin disease;
LUSC	cis	rs6977660	0.714	rs28371050	chr7:19816882	C/T	cg05791153	chr7:19748676	TWISTNB	0.68	7.22	0.37	3.49e-12	Thyroid stimulating hormone;
LUSC	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	9.14	0.45	6.28e-18	Menarche (age at onset);
LUSC	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.12	-0.52	1.2e-24	Coffee consumption (cups per day);
LUSC	trans	rs208520	0.837	rs208509	chr6:66941706	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-13.62	-0.6	6.51e-34	Exhaled nitric oxide output;
LUSC	cis	rs9309473	0.950	rs11126412	chr2:73887634	A/T	cg20560298	chr2:73613845	ALMS1	-0.46	-6.57	-0.34	1.88e-10	Metabolite levels;
LUSC	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg00504896	chr12:9437009	LOC642846	-0.48	-7.63	-0.39	2.41e-13	Breast size;
LUSC	cis	rs13385	0.769	rs2337131	chr5:139571288	G/A	cg26211634	chr5:139558579	C5orf32	0.44	6.57	0.34	1.96e-10	Atrial fibrillation;
LUSC	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg21427119	chr20:30132790	HM13	-0.39	-6.06	-0.31	3.76e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg19230755	chr7:65878503	NA	-0.42	-5.95	-0.31	6.95e-9	Aortic root size;
LUSC	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg15133208	chr4:90757351	SNCA	-0.57	-8.74	-0.43	1.12e-16	Neuroticism;
LUSC	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg12140854	chr5:148520817	ABLIM3	-0.35	-5.79	-0.3	1.66e-8	Breast cancer;
LUSC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg16339924	chr4:17578868	LAP3	0.64	10.14	0.49	3.14e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg04398451	chr17:18023971	MYO15A	-0.44	-6.93	-0.35	2.19e-11	Total body bone mineral density;
LUSC	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21293242	chr8:11204541	TDH	-0.33	-6.42	-0.33	4.76e-10	Retinal vascular caliber;
LUSC	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg09021430	chr5:549028	NA	-0.55	-7.28	-0.37	2.47e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9660992	0.967	rs1172135	chr1:205247160	G/C	cg00857998	chr1:205179979	DSTYK	0.52	7.78	0.39	9.27e-14	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.36	-0.37	1.42e-12	Schizophrenia;
LUSC	cis	rs2652834	0.851	rs4774475	chr15:63407357	T/C	cg05507819	chr15:63340323	TPM1	0.45	5.71	0.3	2.53e-8	HDL cholesterol;
LUSC	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.11	-0.61	8.49e-36	Exhaled nitric oxide output;
LUSC	cis	rs911119	0.954	rs116786204	chr20:23599918	T/G	cg16589663	chr20:23618590	CST3	0.57	6.82	0.35	4.18e-11	Chronic kidney disease;
LUSC	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg24313572	chr1:56050060	NA	-0.31	-6.63	-0.34	1.35e-10	Morning vs. evening chronotype;
LUSC	cis	rs56399783	0.901	rs73049362	chr7:2826822	G/A	cg19731401	chr7:2775893	GNA12	0.69	9.48	0.46	4.97e-19	Childhood ear infection;
LUSC	cis	rs2637266	1.000	rs7900616	chr10:78367075	C/T	cg18941641	chr10:78392320	NA	0.39	7.11	0.36	7.28e-12	Pulmonary function;
LUSC	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg26395211	chr5:140044315	WDR55	-0.38	-5.74	-0.3	2.14e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg14004847	chr7:1930337	MAD1L1	0.6	9.45	0.46	6.12e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg09021430	chr5:549028	NA	-0.42	-7.49	-0.38	6.29e-13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs4443100	0.670	rs9608071	chr22:23408118	G/T	cg14186256	chr22:23484241	RTDR1	0.47	6.03	0.31	4.27e-9	Serum parathyroid hormone levels;
LUSC	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg03676636	chr4:99064102	C4orf37	-0.37	-8.19	-0.41	5.56e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.03	-0.31	4.29e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12210905	0.844	rs7773336	chr6:26993555	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.99	-0.31	5.28e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg19156104	chr2:198669113	PLCL1	-0.46	-5.65	-0.3	3.47e-8	Ulcerative colitis;
LUSC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg08470875	chr2:26401718	FAM59B	0.74	9.25	0.45	2.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg04352962	chr1:209979756	IRF6	0.52	6.08	0.32	3.28e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg11266682	chr4:10021025	SLC2A9	0.51	9.43	0.46	7.16e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1009647	0.645	rs17672298	chr14:55700284	T/C	cg04306507	chr14:55594613	LGALS3	0.45	6.1	0.32	2.99e-9	Testicular germ cell tumor;
LUSC	cis	rs981844	0.712	rs6535956	chr4:154746001	G/A	cg14289246	chr4:154710475	SFRP2	-0.44	-6.12	-0.32	2.6e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.5	0.53	5.33e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.97	-0.36	1.74e-11	Lung cancer;
LUSC	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	1.1	17.27	0.69	3.24e-48	Exhaled nitric oxide output;
LUSC	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg13010199	chr12:38710504	ALG10B	0.71	10.91	0.51	6.53e-24	Bladder cancer;
LUSC	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg13010199	chr12:38710504	ALG10B	0.42	6.08	0.32	3.25e-9	Morning vs. evening chronotype;
LUSC	cis	rs9886651	0.935	rs4733759	chr8:128804840	C/T	cg07795030	chr8:128802207	NA	-0.34	-6.05	-0.31	3.97e-9	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LUSC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg06074448	chr4:187884817	NA	-0.43	-7.22	-0.37	3.62e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26314531	chr2:26401878	FAM59B	-0.68	-9.23	-0.45	3.18e-18	Gut microbiome composition (summer);
LUSC	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.57	0.34	1.95e-10	Intraocular pressure;
LUSC	cis	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg06521331	chr12:34319734	NA	-0.47	-7.61	-0.38	2.87e-13	Morning vs. evening chronotype;
LUSC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg07424592	chr7:64974309	NA	-0.64	-5.79	-0.3	1.61e-8	Diabetic kidney disease;
LUSC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	0.97	13.47	0.59	2.55e-33	Eosinophil percentage of granulocytes;
LUSC	trans	rs1486139	1.000	rs2126443	chr7:46286354	G/A	cg17534202	chr9:96721102	NA	-0.37	-6.62	-0.34	1.45e-10	Select biomarker traits;
LUSC	trans	rs6600671	1.000	rs12145080	chr1:121185531	C/T	cg08727972	chr1:148025634	NBPF14	-0.45	-6.28	-0.32	1.08e-9	Hip geometry;
LUSC	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.31	0.33	9.08e-10	Myopia (pathological);
LUSC	cis	rs965604	1.000	rs12910910	chr15:78767850	C/T	cg18825076	chr15:78729989	IREB2	-0.42	-6.83	-0.35	3.99e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg09085632	chr11:111637200	PPP2R1B	0.96	13.81	0.6	1.28e-34	Primary sclerosing cholangitis;
LUSC	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg05347473	chr6:146136440	FBXO30	0.41	6.63	0.34	1.38e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.2	-0.41	5.4e-15	Longevity;
LUSC	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-0.53	-8.24	-0.41	4.03e-15	Breast cancer;
LUSC	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-10.33	-0.49	6.89e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.62	8.82	0.43	6.25e-17	Diastolic blood pressure;
LUSC	cis	rs4319547	0.955	rs6489159	chr12:123112806	G/A	cg23029597	chr12:123009494	RSRC2	-0.73	-9.26	-0.45	2.61e-18	Body mass index;
LUSC	cis	rs1185460	0.547	rs34150933	chr11:118911039	C/T	cg01677386	chr11:118938358	VPS11	0.46	6.66	0.34	1.12e-10	Coronary artery disease;
LUSC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg01475377	chr6:109611718	NA	-0.45	-8.11	-0.41	9.58e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs62229266	0.626	rs2835268	chr21:37449136	C/G	cg12218747	chr21:37451666	NA	-0.43	-6.59	-0.34	1.71e-10	Mitral valve prolapse;
LUSC	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-7.61	-0.38	2.74e-13	Schizophrenia;
LUSC	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg03929089	chr4:120376271	NA	0.68	7.58	0.38	3.49e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2115536	0.730	rs4238512	chr15:80183898	A/C	cg02196730	chr15:80188777	MTHFS	-0.38	-5.75	-0.3	2.05e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg06060754	chr5:176797920	RGS14	-0.59	-9.32	-0.45	1.61e-18	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs6577655	0.517	rs6998749	chr8:135584316	A/G	cg17885191	chr8:135476712	NA	-0.6	-7.79	-0.39	8.73e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg00321850	chr1:175162397	KIAA0040	-0.45	-7.76	-0.39	1.05e-13	Alcohol dependence;
LUSC	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg05973401	chr12:123451056	ABCB9	0.55	6.8	0.35	4.9e-11	Neutrophil percentage of white cells;
LUSC	cis	rs1322512	0.713	rs1631241	chr6:152939860	T/C	cg27316956	chr6:152958899	SYNE1	-0.35	-5.8	-0.3	1.58e-8	Tonometry;
LUSC	cis	rs2548003	0.541	rs1160444	chr5:28763652	G/A	cg22863700	chr5:28928346	NA	0.45	6.31	0.33	8.68e-10	Hip geometry;
LUSC	trans	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg03886242	chr7:26192032	NFE2L3	-0.42	-6.69	-0.34	9.24e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2742417	0.967	rs2742439	chr3:45744248	G/A	cg09608765	chr3:45636137	LIMD1	-0.38	-7.5	-0.38	5.91e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg00225070	chr15:80189496	MTHFS	0.63	9.49	0.46	4.54e-19	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg06636001	chr8:8085503	FLJ10661	0.6	9.36	0.46	1.19e-18	Mood instability;
LUSC	cis	rs73206853	0.841	rs17187412	chr12:110766767	C/T	cg12870014	chr12:110450643	ANKRD13A	-0.69	-6.32	-0.33	8.47e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg05925327	chr15:68127851	NA	-0.4	-6.4	-0.33	5.35e-10	Restless legs syndrome;
LUSC	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg03929089	chr4:120376271	NA	0.68	6.39	0.33	5.54e-10	Intraocular pressure;
LUSC	cis	rs7131987	0.650	rs10843382	chr12:29451721	G/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.55	-0.34	2.21e-10	QT interval;
LUSC	trans	rs2262909	0.962	rs73021832	chr19:22316144	G/C	cg05197062	chr11:11642011	GALNTL4	0.55	7.76	0.39	1.03e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs72799341	1.000	rs35675346	chr16:30936081	G/A	cg02466173	chr16:30829666	NA	-0.5	-7.7	-0.39	1.55e-13	Diastolic blood pressure;
LUSC	cis	rs977987	0.624	rs59867374	chr16:75432682	G/A	cg03315344	chr16:75512273	CHST6	0.48	8.93	0.44	2.98e-17	Dupuytren's disease;
LUSC	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg04990556	chr1:26633338	UBXN11	0.88	11.59	0.54	2.55e-26	Obesity-related traits;
LUSC	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	8.96	0.44	2.34e-17	Iron status biomarkers;
LUSC	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg04362960	chr10:104952993	NT5C2	0.61	9.77	0.47	5.38e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.71	-0.34	8.49e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg07701084	chr6:150067640	NUP43	0.53	7.82	0.39	7.22e-14	Lung cancer;
LUSC	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.94	0.48	1.47e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs892085	0.681	rs10417071	chr19:10872431	G/T	cg17710535	chr19:10819994	QTRT1	0.34	5.66	0.3	3.21e-8	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg01990225	chr2:97406019	LMAN2L	-1.08	-7.25	-0.37	3.01e-12	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.63	-0.34	1.37e-10	Response to antipsychotic treatment;
LUSC	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.06	0.74	2.65e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.44	-0.42	9.51e-16	Cystic fibrosis severity;
LUSC	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg07148914	chr20:33460835	GGT7	-0.55	-8.46	-0.42	8.69e-16	Glomerular filtration rate (creatinine);
LUSC	cis	rs477692	0.569	rs871028	chr10:131293478	C/T	cg26102564	chr10:131424627	MGMT	-0.35	-5.68	-0.3	2.9e-8	Response to temozolomide;
LUSC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg11812906	chr14:75593930	NEK9	-0.62	-10.45	-0.5	2.6e-22	Height;
LUSC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg10207240	chr12:122356781	WDR66	0.48	6.81	0.35	4.6e-11	Mean corpuscular volume;
LUSC	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg15839431	chr19:19639596	YJEFN3	-0.6	-6.87	-0.35	3.14e-11	Bipolar disorder;
LUSC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg20203395	chr5:56204925	C5orf35	-0.78	-10.4	-0.49	4.07e-22	Initial pursuit acceleration;
LUSC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg12863693	chr15:85201151	NMB	-0.26	-5.92	-0.31	7.9e-9	P wave terminal force;
LUSC	cis	rs714027	0.546	rs5997549	chr22:30265344	C/T	cg11564601	chr22:30592435	NA	0.33	5.83	0.3	1.33e-8	Lymphocyte counts;
LUSC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.92	0.31	8e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.55	-9.99	-0.48	1e-20	Bipolar disorder;
LUSC	cis	rs11785693	0.865	rs7815144	chr8:4970788	G/T	cg26367366	chr8:4980734	NA	-0.74	-9.21	-0.45	3.74e-18	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs7582720	1.000	rs114395475	chr2:203769112	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.66	0.43	2.06e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg01879757	chr17:41196368	BRCA1	-0.47	-7.07	-0.36	8.95e-12	Menopause (age at onset);
LUSC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg12615879	chr12:58013172	SLC26A10	-0.28	-5.83	-0.3	1.32e-8	Multiple sclerosis;
LUSC	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-9.33	-0.45	1.55e-18	Morning vs. evening chronotype;
LUSC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg02569458	chr12:86230093	RASSF9	0.58	9.93	0.48	1.56e-20	Major depressive disorder;
LUSC	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.8e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	8.18	0.41	5.91e-15	Height;
LUSC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg18404041	chr3:52824283	ITIH1	0.4	6.78	0.35	5.59e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg13628971	chr7:2884303	GNA12	0.37	5.71	0.3	2.53e-8	Height;
LUSC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg08270630	chr22:50330655	NA	0.41	6.05	0.31	3.86e-9	Schizophrenia;
LUSC	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg22676075	chr6:135203613	NA	0.59	9.48	0.46	5e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg13939156	chr17:80058883	NA	-0.34	-6.76	-0.35	6.08e-11	Life satisfaction;
LUSC	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg20701182	chr2:24300061	SF3B14	0.89	11.69	0.54	1.08e-26	Lymphocyte counts;
LUSC	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg11871910	chr12:69753446	YEATS4	0.44	5.78	0.3	1.74e-8	Response to diuretic therapy;
LUSC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg24920358	chr1:40204285	PPIE	0.6	10.8	0.51	1.64e-23	Blood protein levels;
LUSC	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg23795048	chr12:9217529	LOC144571	0.34	6.01	0.31	4.82e-9	Sjögren's syndrome;
LUSC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.58	-10.26	-0.49	1.17e-21	Extrinsic epigenetic age acceleration;
LUSC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg24675658	chr1:53192096	ZYG11B	0.72	11.91	0.55	1.75e-27	Monocyte count;
LUSC	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg21775007	chr8:11205619	TDH	-0.73	-11.66	-0.54	1.43e-26	Retinal vascular caliber;
LUSC	cis	rs9837602	1.000	rs9833980	chr3:99767096	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.89	-0.31	9.61e-9	Breast cancer;
LUSC	trans	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg19694781	chr19:47549865	TMEM160	-0.4	-6.25	-0.32	1.24e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs2109514	1.000	rs3919515	chr7:116151784	C/G	cg12739419	chr7:116140593	CAV2	0.31	6.99	0.36	1.53e-11	Prevalent atrial fibrillation;
LUSC	cis	rs6494488	0.500	rs7173216	chr15:65023156	C/T	cg08069370	chr15:64387884	SNX1	-0.58	-5.66	-0.3	3.23e-8	Coronary artery disease;
LUSC	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.66	-8.65	-0.43	2.2e-16	Body mass index;
LUSC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg15557168	chr22:42548783	NA	0.46	7.01	0.36	1.35e-11	Schizophrenia;
LUSC	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg12564285	chr5:131593104	PDLIM4	0.32	5.68	0.3	3.01e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg10018233	chr7:150070692	REPIN1	0.34	5.97	0.31	6.05e-9	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg04995722	chr7:26192034	NFE2L3	0.37	6.15	0.32	2.24e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2692947	0.800	rs2692936	chr2:96745729	G/A	cg23100626	chr2:96804247	ASTL	0.3	7.05	0.36	1.02e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-10.94	-0.51	5.25e-24	Response to antipsychotic treatment;
LUSC	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg01579765	chr21:45077557	HSF2BP	-0.47	-9.81	-0.47	3.94e-20	Mean corpuscular volume;
LUSC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg19812747	chr11:111475976	SIK2	-0.55	-8.2	-0.41	5.19e-15	Primary sclerosing cholangitis;
LUSC	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg23422044	chr7:1970798	MAD1L1	-0.6	-6.27	-0.32	1.13e-9	Bipolar disorder;
LUSC	cis	rs2294693	0.634	rs4714425	chr6:41012916	A/G	cg14769373	chr6:40998127	UNC5CL	0.42	5.96	0.31	6.55e-9	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs11625487	1.000	rs11625487	chr14:77961609	G/C	cg21822146	chr14:77961897	ISM2	-0.33	-5.78	-0.3	1.72e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg05855489	chr10:104503620	C10orf26	0.53	7.73	0.39	1.25e-13	Arsenic metabolism;
LUSC	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.83	-0.35	4.12e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs12410462	0.581	rs7541809	chr1:227547299	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.67	-6.41	-0.33	4.99e-10	Major depressive disorder;
LUSC	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg26217441	chr16:89643414	CPNE7	-0.52	-5.66	-0.3	3.33e-8	Plateletcrit;
LUSC	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg22508957	chr16:3507546	NAT15	0.48	6.46	0.33	3.69e-10	Body mass index (adult);
LUSC	cis	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg09307838	chr4:120376055	NA	-0.49	-7.48	-0.38	6.79e-13	Diastolic blood pressure;
LUSC	cis	rs72949976	0.934	rs1441172	chr2:214037703	C/T	cg08319019	chr2:214017104	IKZF2	-0.58	-8.92	-0.44	3.09e-17	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg08000102	chr2:233561755	GIGYF2	-0.75	-11.24	-0.52	4.38e-25	Schizophrenia;
LUSC	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg12365402	chr11:9010492	NRIP3	-0.36	-5.87	-0.31	1.05e-8	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.64	0.6	5.37e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg03395511	chr6:291903	DUSP22	-0.48	-7.28	-0.37	2.42e-12	Menopause (age at onset);
LUSC	cis	rs10203711	0.966	rs907105	chr2:239565052	A/G	cg14580085	chr2:239553406	NA	0.42	7.15	0.36	5.57e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7605827	0.897	rs7590198	chr2:15536314	C/T	cg19274914	chr2:15703543	NA	0.46	9.03	0.44	1.45e-17	Educational attainment (years of education);
LUSC	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg06636001	chr8:8085503	FLJ10661	0.53	7.9	0.4	3.97e-14	Retinal vascular caliber;
LUSC	trans	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.89	0.48	2.13e-20	Mean corpuscular volume;
LUSC	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.0	-0.31	5.16e-9	Retinal vascular caliber;
LUSC	cis	rs6961069	0.585	rs10247260	chr7:80255763	A/T	cg04458919	chr7:80252533	CD36	-0.4	-7.1	-0.36	7.4e-12	Platelet count;
LUSC	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg21141812	chr3:48556323	PFKFB4	0.33	5.73	0.3	2.2e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg03579872	chr1:53393473	SCP2	-0.4	-5.87	-0.31	1.07e-8	Monocyte count;
LUSC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	9.14	0.45	6.39e-18	Mean platelet volume;
LUSC	trans	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg22153745	chr1:153894579	GATAD2B	-0.5	-6.89	-0.35	2.84e-11	Total cholesterol levels;
LUSC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.68	11.53	0.53	4.19e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg10911889	chr6:126070802	HEY2	-0.38	-5.91	-0.31	8.41e-9	Brugada syndrome;
LUSC	cis	rs7107174	0.901	rs1055250	chr11:77925708	C/G	cg02023728	chr11:77925099	USP35	0.5	7.17	0.37	4.75e-12	Testicular germ cell tumor;
LUSC	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg16898833	chr6:26189333	HIST1H4D	0.64	6.14	0.32	2.39e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11955175	1.000	rs77394428	chr5:40743517	A/G	cg04002187	chr5:40835754	RPL37	0.69	5.79	0.3	1.66e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1005224	0.963	rs11626062	chr14:76136329	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.63	-8.64	-0.43	2.42e-16	Large artery stroke;
LUSC	cis	rs2797160	0.547	rs9401837	chr6:125956853	T/C	cg05901451	chr6:126070800	HEY2	-0.42	-5.91	-0.31	8.39e-9	Endometrial cancer;
LUSC	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg24375607	chr4:120327624	NA	0.69	10.92	0.51	6.06e-24	Corneal astigmatism;
LUSC	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg06454157	chr6:167490870	NA	-0.27	-6.13	-0.32	2.48e-9	Crohn's disease;
LUSC	cis	rs3771570	0.901	rs35256094	chr2:242439938	A/C	cg21155796	chr2:242212141	HDLBP	0.62	6.8	0.35	4.74e-11	Prostate cancer;
LUSC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg24562669	chr7:97807699	LMTK2	-0.35	-6.23	-0.32	1.38e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg02175503	chr12:58329896	NA	0.62	10.21	0.49	1.81e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs17604090	0.938	rs850029	chr7:29678087	A/G	cg19413766	chr7:29689036	LOC646762	-0.55	-6.42	-0.33	4.71e-10	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg00277334	chr10:82204260	NA	-0.58	-8.73	-0.43	1.25e-16	Post bronchodilator FEV1;
LUSC	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg11584989	chr19:19387371	SF4	0.58	6.85	0.35	3.58e-11	Bipolar disorder;
LUSC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.79	-0.54	4.53e-27	Chronic sinus infection;
LUSC	cis	rs62400317	0.859	rs11967630	chr6:45128524	G/C	cg20913747	chr6:44695427	NA	-0.46	-7.49	-0.38	6.22e-13	Total body bone mineral density;
LUSC	cis	rs7804356	0.953	rs3823928	chr7:26893317	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.13	-0.32	2.54e-9	Type 1 diabetes;
LUSC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg16624210	chr5:671434	TPPP	0.47	5.92	0.31	8.21e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs847851	0.630	rs9462021	chr6:34758640	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.02	-0.31	4.55e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg25281562	chr12:121454272	C12orf43	-0.43	-5.76	-0.3	1.9e-8	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs4842666	0.915	rs11105354	chr12:90026523	A/G	cg00757033	chr12:89920650	WDR51B	0.48	6.39	0.33	5.49e-10	Blood pressure;
LUSC	cis	rs9341808	0.556	rs1535075	chr6:81034806	A/G	cg08355045	chr6:80787529	NA	0.51	8.85	0.44	5.25e-17	Sitting height ratio;
LUSC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg17971929	chr21:40555470	PSMG1	-0.5	-7.35	-0.37	1.57e-12	Menarche (age at onset);
LUSC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	27.87	0.84	3.57e-89	Chronic sinus infection;
LUSC	cis	rs8099014	0.814	rs7227488	chr18:56113233	A/G	cg12907477	chr18:56117327	MIR122	0.45	7.04	0.36	1.12e-11	Platelet count;
LUSC	cis	rs17095355	1.000	rs12263484	chr10:111697255	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.61	-7.83	-0.39	6.72e-14	Biliary atresia;
LUSC	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg21064579	chr19:49206444	FUT2	0.46	8.66	0.43	2.07e-16	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
LUSC	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-10.59	-0.5	8.96e-23	Body mass index (adult);
LUSC	cis	rs3812762	1.000	rs3812762	chr11:8751640	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.36	-6.03	-0.31	4.31e-9	Hypospadias;
LUSC	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	10.95	0.51	4.95e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs4363385	0.588	rs11205180	chr1:153022070	A/G	cg00922841	chr1:152955080	SPRR1A	-0.37	-6.3	-0.33	9.57e-10	Inflammatory skin disease;
LUSC	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg15147215	chr3:52552868	STAB1	0.31	6.14	0.32	2.4e-9	Electroencephalogram traits;
LUSC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg03233332	chr7:66118400	NA	-0.39	-5.73	-0.3	2.23e-8	Aortic root size;
LUSC	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg02903104	chr8:1507517	DLGAP2	0.4	7.56	0.38	3.99e-13	Lung cancer;
LUSC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg18357645	chr12:58087776	OS9	0.55	8.23	0.41	4.17e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1524927	0.966	rs55837946	chr7:96330682	C/T	cg03808172	chr7:96339361	SHFM1	0.43	6.63	0.34	1.34e-10	Total body bone mineral density;
LUSC	cis	rs4654899	0.758	rs6698462	chr1:21341293	G/C	cg01072550	chr1:21505969	NA	-0.53	-8.16	-0.41	7.06e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg02423579	chr7:2872169	GNA12	-0.45	-6.76	-0.35	6.23e-11	Height;
LUSC	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg09582351	chr12:29534625	ERGIC2	-0.34	-6.91	-0.35	2.44e-11	QT interval;
LUSC	cis	rs68170813	0.523	rs79619227	chr7:107025335	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.3	-0.45	1.88e-18	Coronary artery disease;
LUSC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg16339924	chr4:17578868	LAP3	0.65	10.05	0.48	6.41e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg16423285	chr20:60520624	NA	-0.47	-5.75	-0.3	2.06e-8	Body mass index;
LUSC	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.9	-0.31	8.7e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg01073479	chr16:3509474	NAT15	-0.39	-5.97	-0.31	5.96e-9	Tuberculosis;
LUSC	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg13114125	chr14:105738426	BRF1	-0.91	-15.83	-0.65	1.68e-42	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg13010199	chr12:38710504	ALG10B	0.57	8.51	0.42	6.15e-16	Morning vs. evening chronotype;
LUSC	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg16339924	chr4:17578868	LAP3	-0.51	-7.52	-0.38	4.97e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs701145	0.585	rs959376	chr3:153866707	A/T	cg17054900	chr3:154042577	DHX36	0.63	6.18	0.32	1.9e-9	Coronary artery disease;
LUSC	cis	rs7804356	1.000	rs10486485	chr7:26900356	C/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.1	-0.32	2.9e-9	Type 1 diabetes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21039410	chr2:26568409	SELI;GPR113	-0.52	-6.94	-0.36	2.06e-11	Hepatitis;
LUSC	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg03678062	chr6:149772716	ZC3H12D	-0.37	-7.49	-0.38	6.32e-13	Dupuytren's disease;
LUSC	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.91	-0.31	8.58e-9	Reticulocyte count;
LUSC	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg24069376	chr3:38537580	EXOG	0.42	8.17	0.41	6.5e-15	Electrocardiographic conduction measures;
LUSC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.63	0.5	6.32e-23	Schizophrenia;
LUSC	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.56	0.6	1.12e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.71	-9.96	-0.48	1.21e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs7945718	0.839	rs11022511	chr11:12834638	A/T	cg25843174	chr11:12811716	TEAD1	0.3	6.77	0.35	5.83e-11	Educational attainment (years of education);
LUSC	cis	rs1476679	1.000	rs1476679	chr7:100004446	C/T	cg19116668	chr7:99932089	PMS2L1	0.45	8.08	0.4	1.17e-14	Alzheimer's disease (late onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18009825	chr17:62503196	CCDC45;DDX5	-0.45	-6.64	-0.34	1.25e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	2.01e-12	Bone mineral density;
LUSC	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-7.47	-0.38	7.17e-13	Chronic sinus infection;
LUSC	cis	rs9837602	1.000	rs1038294	chr3:99503728	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-5.73	-0.3	2.26e-8	Breast cancer;
LUSC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg08125733	chr17:73851984	WBP2	-0.45	-6.42	-0.33	4.56e-10	White matter hyperintensity burden;
LUSC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg05623727	chr3:50126028	RBM5	0.31	5.73	0.3	2.2e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.89	-17.54	-0.69	2.85e-49	Diastolic blood pressure;
LUSC	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg07395648	chr5:131743802	NA	-0.48	-7.67	-0.39	1.86e-13	Breast cancer;Mosquito bite size;
LUSC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	12.01	0.55	7.54e-28	Cognitive test performance;
LUSC	cis	rs3741151	0.881	rs7951174	chr11:73093135	G/C	cg17517138	chr11:73019481	ARHGEF17	0.99	8.39	0.42	1.4e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7084921	0.578	rs12783521	chr10:101871748	C/A	cg02250046	chr10:101825185	CPN1	-0.35	-6.24	-0.32	1.34e-9	Bone mineral density;
LUSC	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg05754148	chr16:3507555	NAT15	0.79	9.49	0.46	4.51e-19	Tuberculosis;
LUSC	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg03806693	chr22:41940476	POLR3H	-0.59	-8.58	-0.43	3.58e-16	Neuroticism;
LUSC	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg23093090	chr10:104574429	C10orf26	-0.42	-7.31	-0.37	1.99e-12	Immature fraction of reticulocytes;Schizophrenia;
LUSC	trans	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.64	10.17	0.49	2.35e-21	Endometrial cancer;
LUSC	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg02696742	chr7:106810147	HBP1	-0.63	-9.4	-0.46	8.74e-19	Coronary artery disease;
LUSC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21028142	chr17:79581711	NPLOC4	0.33	7.99	0.4	2.22e-14	Eye color traits;
LUSC	cis	rs2625529	0.689	rs12050794	chr15:72169466	G/A	cg16672083	chr15:72433130	SENP8	0.47	7.64	0.39	2.31e-13	Red blood cell count;
LUSC	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg26195577	chr20:24973756	C20orf3	1.12	18.09	0.7	1.76e-51	Blood protein levels;
LUSC	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg17252645	chr8:143867129	LY6D	-0.37	-6.46	-0.33	3.61e-10	Urinary tract infection frequency;
LUSC	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg12560992	chr17:57184187	TRIM37	0.62	9.89	0.48	2.14e-20	Testicular germ cell tumor;
LUSC	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.52	-9.37	-0.46	1.08e-18	Menopause (age at onset);
LUSC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-10.41	-0.5	3.6e-22	Bipolar disorder;
LUSC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg13944838	chr5:179740914	GFPT2	-0.67	-10.74	-0.51	2.58e-23	Height;
LUSC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg06238570	chr21:40685208	BRWD1	-0.56	-8.73	-0.43	1.25e-16	Menarche (age at onset);
LUSC	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	6.79	0.35	5.27e-11	Lung cancer;
LUSC	cis	rs8040855	0.627	rs12905036	chr15:85637788	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-5.71	-0.3	2.52e-8	Bulimia nervosa;
LUSC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	11.98	0.55	9.51e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.34	-0.42	1.91e-15	Lung cancer;
LUSC	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg21699342	chr2:239360505	ASB1	0.56	10.33	0.49	6.86e-22	Multiple system atrophy;
LUSC	cis	rs34638657	0.872	rs7202258	chr16:82195013	T/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.12	-0.32	2.68e-9	Lung adenocarcinoma;
LUSC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18404041	chr3:52824283	ITIH1	-0.53	-10.21	-0.49	1.76e-21	Electroencephalogram traits;
LUSC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.53	-5.74	-0.3	2.09e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs3768617	0.811	rs4366285	chr1:183013672	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.59	0.43	3.46e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg23093090	chr10:104574429	C10orf26	0.35	6.32	0.33	8.25e-10	Arsenic metabolism;
LUSC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg22903657	chr4:1355424	KIAA1530	-0.37	-6.3	-0.33	9.34e-10	Obesity-related traits;
LUSC	cis	rs7771547	0.519	rs6457912	chr6:36373794	C/A	cg07856975	chr6:36356162	ETV7	0.44	6.43	0.33	4.32e-10	Platelet distribution width;
LUSC	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg07169764	chr2:136633963	MCM6	1.06	14.11	0.61	8.61e-36	Corneal structure;
LUSC	cis	rs9369695	0.881	rs9349409	chr6:47463126	G/T	cg20196966	chr6:47445060	CD2AP	0.42	5.81	0.3	1.49e-8	Reticulocyte count;
LUSC	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg16339924	chr4:17578868	LAP3	0.51	7.6	0.38	3.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs67696533	0.600	rs3746615	chr20:31123592	A/T	cg13636640	chr20:31349939	DNMT3B	0.46	6.13	0.32	2.51e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs2346177	0.875	rs2881327	chr2:46641955	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-8.99	-0.44	1.85e-17	HDL cholesterol;
LUSC	cis	rs4776059	0.798	rs11855616	chr15:52874833	C/T	cg24008177	chr15:52972085	KIAA1370	-0.33	-5.66	-0.3	3.22e-8	Schizophrenia;
LUSC	cis	rs7560272	0.723	rs1320374	chr2:73828310	T/C	cg20560298	chr2:73613845	ALMS1	0.51	7.84	0.39	6.19e-14	Schizophrenia;
LUSC	cis	rs711244	0.748	rs10193295	chr2:37169049	C/T	cg14987922	chr2:37194071	STRN	0.43	6.39	0.33	5.45e-10	Mean platelet volume;
LUSC	cis	rs12136530	0.774	rs4912096	chr1:19775113	T/C	cg01832549	chr1:19774989	CAPZB	-0.32	-6.05	-0.31	3.97e-9	Lead levels in blood;
LUSC	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg20891283	chr12:69753455	YEATS4	-0.45	-6.08	-0.32	3.3e-9	Response to diuretic therapy;
LUSC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18099408	chr3:52552593	STAB1	0.41	7.05	0.36	1.03e-11	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24586432	chr2:238969253	SCLY	-0.44	-6.45	-0.33	3.81e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01704862	chr7:150780657	TMUB1	-0.4	-5.99	-0.31	5.45e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9811920	0.683	rs1718235	chr3:99583484	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.35	-6.91	-0.35	2.4e-11	Axial length;
LUSC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg22800045	chr5:56110881	MAP3K1	0.68	8.13	0.41	8.74e-15	Initial pursuit acceleration;
LUSC	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	7.69	0.39	1.67e-13	Lung cancer in ever smokers;
LUSC	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg26587870	chr6:27730563	NA	-0.61	-5.79	-0.3	1.62e-8	Breast cancer;
LUSC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06022373	chr22:39101656	GTPBP1	-0.83	-14.16	-0.61	5.55e-36	Menopause (age at onset);
LUSC	cis	rs9837602	1.000	rs6806178	chr3:99780393	A/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	5.67	0.3	3.16e-8	Breast cancer;
LUSC	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg22532475	chr10:104410764	TRIM8	-0.26	-6.07	-0.32	3.42e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg22139774	chr2:100720529	AFF3	-0.45	-7.75	-0.39	1.15e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7809950	0.678	rs7777950	chr7:107004672	T/C	cg23024343	chr7:107201750	COG5	-0.66	-9.88	-0.48	2.37e-20	Coronary artery disease;
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.5	-8.33	-0.41	2.1e-15	Lymphocyte counts;
LUSC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.8	0.35	4.77e-11	Lung cancer;
LUSC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg24642844	chr7:1081250	C7orf50	-0.8	-10.56	-0.5	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg14092988	chr3:52407081	DNAH1	0.32	6.25	0.32	1.27e-9	Bipolar disorder;
LUSC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg16434002	chr17:42200994	HDAC5	0.47	6.52	0.34	2.56e-10	Total body bone mineral density;
LUSC	cis	rs56399783	0.614	rs11765492	chr7:2771642	G/A	cg19731401	chr7:2775893	GNA12	0.73	8.86	0.44	4.67e-17	Childhood ear infection;
LUSC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs12791968	0.527	rs4755924	chr11:45013328	A/G	cg11846598	chr11:44996168	LOC221122	-0.59	-7.12	-0.36	6.77e-12	Inhibitory control;
LUSC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.67	-0.34	1.04e-10	Lung cancer;
LUSC	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg06096015	chr1:231504339	EGLN1	0.57	9.97	0.48	1.16e-20	Hemoglobin concentration;
LUSC	trans	rs8030485	0.545	rs939662	chr15:79428249	A/T	cg16586880	chr8:140854244	TRAPPC9	-0.37	-6.07	-0.32	3.56e-9	Left ventricle wall thickness;
LUSC	cis	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05901451	chr6:126070800	HEY2	-0.58	-8.59	-0.43	3.43e-16	Endometrial cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14933266	chr17:29422051	NF1	0.45	5.99	0.31	5.38e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9942416	0.503	rs253393	chr5:74929647	G/A	cg06933384	chr5:74808293	COL4A3BP;POLK	-0.41	-5.8	-0.3	1.55e-8	Age-related disease endophenotypes;
LUSC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.88	-0.31	9.73e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg17971929	chr21:40555470	PSMG1	-0.47	-6.93	-0.35	2.15e-11	Menarche (age at onset);
LUSC	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg11102782	chr19:18549136	ISYNA1	-0.32	-6.05	-0.31	3.93e-9	Breast cancer;
LUSC	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	6.22	0.32	1.48e-9	Multiple sclerosis;
LUSC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24110177	chr3:50126178	RBM5	0.55	9.1	0.45	8.06e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.43	5.82	0.3	1.37e-8	Total body bone mineral density;
LUSC	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg03342759	chr3:160939853	NMD3	-0.57	-9.81	-0.47	4.11e-20	Morning vs. evening chronotype;
LUSC	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg22491629	chr6:157744540	C6orf35	-0.89	-10.93	-0.51	5.63e-24	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs1044826	0.957	rs12494556	chr3:139223719	T/C	cg00490450	chr3:139108681	COPB2	0.51	6.8	0.35	4.8e-11	Obesity-related traits;
LUSC	cis	rs7193541	0.662	rs8063458	chr16:74469121	G/T	cg01733217	chr16:74700730	RFWD3	-0.75	-11.76	-0.54	6.08e-27	Multiple myeloma;
LUSC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg13683864	chr3:40499215	RPL14	-1.14	-20.68	-0.75	9.18e-62	Renal cell carcinoma;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.85	15.62	0.65	1.11e-41	Menarche (age at onset);
LUSC	trans	rs7765175	0.598	rs1388219	chr6:113620699	C/T	cg14711201	chr5:36152436	SKP2;LMBRD2	-0.35	-5.95	-0.31	6.61e-9	Coronary artery calcification;
LUSC	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.88	15.09	0.64	1.36e-39	Morning vs. evening chronotype;
LUSC	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-1.11	-15.3	-0.64	1.99e-40	Hip circumference adjusted for BMI;
LUSC	trans	rs2055729	0.677	rs10104353	chr8:9740358	G/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.37	-0.33	6.24e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.48	-0.5	2.16e-22	Eye color traits;
LUSC	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.52	-0.42	5.75e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7923609	0.967	rs10761762	chr10:65184717	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.01e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.3e-11	Uric acid levels;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg12527909	chr1:109241986	PRPF38B	-0.37	-6.24	-0.32	1.34e-9	N-glycan levels;
LUSC	cis	rs9359856	0.529	rs72919922	chr6:90492997	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.24	-0.41	3.84e-15	Bipolar disorder;
LUSC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg14664628	chr15:75095509	CSK	-0.41	-5.84	-0.3	1.27e-8	Caffeine consumption;
LUSC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	13.62	0.6	6.6e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9341808	0.600	rs2505930	chr6:80837058	A/G	cg08355045	chr6:80787529	NA	0.48	8.23	0.41	4.2e-15	Sitting height ratio;
LUSC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg01125463	chr6:42946178	PEX6	-0.35	-5.65	-0.3	3.35e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.09	-0.32	3.05e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg09034736	chr1:150693464	HORMAD1	0.43	5.93	0.31	7.46e-9	Melanoma;
LUSC	cis	rs77741769	0.571	rs12831094	chr12:121292704	T/C	cg02419362	chr12:121203948	SPPL3	0.46	8.49	0.42	6.64e-16	Mean corpuscular volume;
LUSC	trans	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg04995722	chr7:26192034	NFE2L3	-0.39	-6.22	-0.32	1.5e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs897080	0.515	rs1145519	chr2:44708709	C/A	cg00619915	chr2:44497795	NA	-0.42	-6.06	-0.31	3.6e-9	Height;
LUSC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg05805236	chr11:65401703	PCNXL3	-0.38	-5.81	-0.3	1.48e-8	Breast cancer;
LUSC	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg18721089	chr20:30220636	NA	-0.35	-5.94	-0.31	7.09e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg00012203	chr2:219082015	ARPC2	-0.7	-11.58	-0.54	2.78e-26	Colorectal cancer;
LUSC	cis	rs6594499	0.872	rs6865932	chr5:110436852	G/C	cg04022379	chr5:110408740	TSLP	0.45	6.82	0.35	4.17e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.31	-0.33	8.95e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg00310523	chr12:86230176	RASSF9	0.45	8.34	0.42	2.01e-15	Major depressive disorder;
LUSC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.99	0.4	2.22e-14	Bipolar disorder;
LUSC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.73	-11.33	-0.53	2.15e-25	Menarche (age at onset);
LUSC	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg02016764	chr4:38805732	TLR1	-0.54	-5.92	-0.31	7.93e-9	Breast cancer;
LUSC	cis	rs2262909	0.962	rs17459246	chr19:22278121	T/C	cg11619707	chr19:22235551	ZNF257	0.39	5.79	0.3	1.63e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	0.97	19.5	0.73	4.43e-57	Menarche (age at onset);
LUSC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg06618935	chr21:46677482	NA	-0.4	-7.99	-0.4	2.2e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.66	-0.39	2.07e-13	Myopia;Myopia (pathological);
LUSC	cis	rs1775715	0.737	rs1541260	chr10:32105570	C/T	cg03015672	chr10:32216066	ARHGAP12	0.33	5.84	0.3	1.22e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6542838	0.646	rs2008648	chr2:99408323	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.75	-0.35	6.74e-11	Fear of minor pain;
LUSC	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-15.97	-0.66	4.77e-43	Heart rate;
LUSC	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.49	0.33	3.18e-10	Corneal astigmatism;
LUSC	cis	rs59104589	0.617	rs6672	chr2:242293021	A/G	cg14842376	chr2:242211374	HDLBP	0.54	6.16	0.32	2.05e-9	Fibrinogen levels;
LUSC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.78	0.6	1.67e-34	Chronic sinus infection;
LUSC	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg08213375	chr14:104286397	PPP1R13B	0.53	10.16	0.49	2.57e-21	Schizophrenia;
LUSC	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg06363034	chr20:62225388	GMEB2	-0.45	-7.71	-0.39	1.47e-13	Glioblastoma;
LUSC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.52	-8.25	-0.41	3.72e-15	Facial morphology (factor 21, depth of nasal alae);
LUSC	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg13755796	chr4:20253514	NA	-0.43	-6.67	-0.34	1.07e-10	Life satisfaction;
LUSC	cis	rs9807989	0.507	rs1833174	chr2:103034843	T/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.72e-12	Asthma;
LUSC	cis	rs4443100	0.670	rs8139280	chr22:23405957	G/A	cg14186256	chr22:23484241	RTDR1	0.54	6.83	0.35	4.03e-11	Serum parathyroid hormone levels;
LUSC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.39	0.53	1.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg09904177	chr6:26538194	HMGN4	-0.39	-5.71	-0.3	2.52e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.56	0.42	4.23e-16	Neutrophil percentage of white cells;
LUSC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.39	-5.66	-0.3	3.21e-8	Tonsillectomy;
LUSC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-1.06	-15.42	-0.64	6.98e-41	Vitiligo;
LUSC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-9.95	-0.48	1.34e-20	Bipolar disorder and schizophrenia;
LUSC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.78	0.43	8.88e-17	Motion sickness;
LUSC	cis	rs6500395	1.000	rs1115758	chr16:48599609	T/C	cg04672837	chr16:48644449	N4BP1	0.43	6.47	0.33	3.44e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08736216	chr1:53307985	ZYG11A	-0.3	-6.17	-0.32	1.96e-9	Monocyte count;
LUSC	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg00792783	chr2:198669748	PLCL1	0.43	5.87	0.31	1.04e-8	Dermatomyositis;
LUSC	trans	rs6693295	0.625	rs6680215	chr1:246347153	G/A	cg13514129	chr1:39547527	MACF1	0.46	6.02	0.31	4.58e-9	Migraine - clinic-based;Migraine with aura;
LUSC	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg21153622	chr11:89784906	NA	-0.39	-5.96	-0.31	6.45e-9	HDL cholesterol;
LUSC	cis	rs16854884	0.690	rs35885310	chr3:143771333	A/G	cg06585982	chr3:143692056	C3orf58	0.5	7.73	0.39	1.25e-13	Economic and political preferences (feminism/equality);
LUSC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg23625390	chr15:77176239	SCAPER	0.5	7.75	0.39	1.11e-13	Blood metabolite levels;
LUSC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg20283391	chr11:68216788	NA	-0.61	-8.46	-0.42	8.4e-16	Total body bone mineral density;
LUSC	cis	rs1018836	0.774	rs35159732	chr8:91633094	A/G	cg16814680	chr8:91681699	NA	-0.75	-11.49	-0.53	5.55e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11676348	0.772	rs11687200	chr2:218944615	A/G	cg18102446	chr2:218934044	RUFY4	0.36	5.88	0.31	9.97e-9	Ulcerative colitis;
LUSC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg17143192	chr8:8559678	CLDN23	0.66	9.23	0.45	3.25e-18	Obesity-related traits;
LUSC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg14668632	chr7:2872130	GNA12	-0.46	-6.45	-0.33	3.83e-10	Height;
LUSC	cis	rs4746818	1.000	rs4746817	chr10:70882515	T/C	cg11621586	chr10:70884670	VPS26A	1.15	11.17	0.52	8.19e-25	Left atrial antero-posterior diameter;
LUSC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.41	-6.33	-0.33	7.82e-10	Longevity;Endometriosis;
LUSC	cis	rs2637266	0.655	rs2588335	chr10:78510229	C/G	cg18941641	chr10:78392320	NA	0.39	7.03	0.36	1.16e-11	Pulmonary function;
LUSC	cis	rs6733011	0.582	rs6757099	chr2:99415235	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-6.99	-0.36	1.53e-11	Bipolar disorder;
LUSC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26314531	chr2:26401878	FAM59B	0.72	10.03	0.48	7.17e-21	Gut microbiome composition (summer);
LUSC	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg03929089	chr4:120376271	NA	0.61	6.58	0.34	1.83e-10	Axial length;
LUSC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.81	0.51	1.53e-23	Monocyte percentage of white cells;
LUSC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.57	8.68	0.43	1.83e-16	Longevity;
LUSC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02475777	chr4:1388615	CRIPAK	0.62	9.17	0.45	4.98e-18	Longevity;
LUSC	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg05340658	chr4:99064831	C4orf37	0.6	9.0	0.44	1.76e-17	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg07607462	chr15:43398173	UBR1	0.34	5.97	0.31	6.01e-9	Tuberculosis;
LUSC	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg16405210	chr4:1374714	KIAA1530	0.46	5.66	0.3	3.25e-8	Recombination rate (females);
LUSC	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	0.98	18.93	0.72	8.55e-55	Bone mineral density;
LUSC	trans	rs17112190	1.000	rs7090880	chr10:98559018	C/A	cg05472874	chr22:44258179	SULT4A1	0.71	6.17	0.32	2.02e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-10.27	-0.49	1.11e-21	Morning vs. evening chronotype;
LUSC	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.71	-10.62	-0.5	6.77e-23	Glomerular filtration rate;
LUSC	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg13683864	chr3:40499215	RPL14	0.91	15.11	0.64	1.1e-39	Renal cell carcinoma;
LUSC	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.57	0.5	9.91e-23	Colorectal cancer;
LUSC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg27170947	chr2:26402098	FAM59B	-0.69	-10.66	-0.5	4.93e-23	Gut microbiome composition (summer);
LUSC	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg04374321	chr14:90722782	PSMC1	0.76	12.12	0.55	2.88e-28	Mortality in heart failure;
LUSC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg07212818	chr11:638076	DRD4	-0.38	-6.49	-0.33	3.07e-10	Systemic lupus erythematosus;
LUSC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg01879757	chr17:41196368	BRCA1	-0.47	-7.09	-0.36	8.11e-12	Menopause (age at onset);
LUSC	cis	rs62458065	0.640	rs10241303	chr7:32534203	T/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.55	-5.89	-0.31	9.58e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9341808	0.718	rs1324123	chr6:80932894	G/A	cg08355045	chr6:80787529	NA	0.58	10.04	0.48	6.79e-21	Sitting height ratio;
LUSC	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.15	-0.32	2.23e-9	Morning vs. evening chronotype;
LUSC	trans	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg13010199	chr12:38710504	ALG10B	0.48	7.56	0.38	3.82e-13	Morning vs. evening chronotype;
LUSC	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg13390004	chr1:15929781	NA	0.41	6.85	0.35	3.63e-11	Systolic blood pressure;
LUSC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg06096015	chr1:231504339	EGLN1	0.48	8.33	0.41	2.13e-15	Hemoglobin concentration;
LUSC	cis	rs2625529	0.526	rs7179942	chr15:72563074	C/G	cg16672083	chr15:72433130	SENP8	0.47	7.8	0.39	7.96e-14	Red blood cell count;
LUSC	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs13401104	0.796	rs1073463	chr2:237118096	G/A	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg10167378	chr1:228756711	NA	0.73	9.33	0.45	1.48e-18	Chronic lymphocytic leukemia;
LUSC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg25258033	chr6:167368657	RNASET2	0.47	7.84	0.39	6.15e-14	Crohn's disease;
LUSC	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg19784903	chr17:45786737	TBKBP1	-0.43	-6.26	-0.32	1.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00166722	chr3:10149974	C3orf24	0.6	8.06	0.4	1.33e-14	Alzheimer's disease;
LUSC	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg04369109	chr6:150039330	LATS1	-0.57	-8.44	-0.42	1e-15	Lung cancer;
LUSC	cis	rs4363385	0.747	rs4240868	chr1:152981599	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.43e-13	Inflammatory skin disease;
LUSC	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg08645402	chr16:4508243	NA	0.54	9.09	0.45	8.92e-18	Schizophrenia;
LUSC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.3	-0.41	2.69e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.85	-15.75	-0.65	3.56e-42	Dental caries;
LUSC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	9.29	0.45	2.07e-18	Total body bone mineral density;
LUSC	trans	rs800082	0.516	rs1726545	chr3:144244807	T/A	cg24215973	chr2:240111563	HDAC4	0.46	7.02	0.36	1.28e-11	Smoking behavior;
LUSC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11645453	chr3:52864694	ITIH4	0.38	8.48	0.42	7.14e-16	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs654950	0.806	rs10749832	chr1:42041806	C/T	cg06885757	chr1:42089581	HIVEP3	0.43	8.53	0.42	5.23e-16	Airway imaging phenotypes;
LUSC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg04352962	chr1:209979756	IRF6	0.53	6.22	0.32	1.45e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17467752	chr17:38218738	THRA	-0.71	-11.36	-0.53	1.64e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.37e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03576123	chr11:487126	PTDSS2	-0.95	-10.56	-0.5	1.11e-22	Body mass index;
LUSC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-0.99	-17.82	-0.7	2.23e-50	Height;
LUSC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.57	-8.05	-0.4	1.44e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg01802117	chr1:53393560	SCP2	0.4	6.53	0.34	2.43e-10	Monocyte count;
LUSC	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.76	12.44	0.56	1.91e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg12940439	chr1:67600707	NA	0.39	6.2	0.32	1.7e-9	Psoriasis;
LUSC	cis	rs78579285	0.507	rs1061247	chr16:88781791	A/C	cg01900006	chr16:88814613	FAM38A	0.51	5.66	0.3	3.33e-8	Joint mobility (Beighton score);
LUSC	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg15445000	chr17:37608096	MED1	0.41	6.89	0.35	2.81e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.48	0.65	4.06e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg11473876	chr11:109292803	C11orf87	0.35	5.97	0.31	5.95e-9	Schizophrenia;
LUSC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg06212747	chr3:49208901	KLHDC8B	0.44	5.98	0.31	5.68e-9	Parkinson's disease;
LUSC	cis	rs796825	0.530	rs4676676	chr3:119987645	C/T	cg21790991	chr3:120137480	FSTL1	-0.34	-6.1	-0.32	2.93e-9	HIV-1 susceptibility;
LUSC	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.55	0.62	1.76e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.3e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs4499344	0.633	rs259262	chr19:33153951	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	11.42	0.53	1.02e-25	Mean platelet volume;
LUSC	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg23711669	chr6:146136114	FBXO30	0.87	16.12	0.66	1.19e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg25258033	chr6:167368657	RNASET2	0.38	5.82	0.3	1.38e-8	Primary biliary cholangitis;
LUSC	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg03676636	chr4:99064102	C4orf37	0.38	8.0	0.4	2.1e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	10.89	0.51	7.85e-24	Hip circumference adjusted for BMI;
LUSC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23158103	chr7:148848205	ZNF398	-0.42	-6.6	-0.34	1.57e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg07424592	chr7:64974309	NA	0.69	6.19	0.32	1.81e-9	Diabetic kidney disease;
LUSC	cis	rs6977660	1.000	rs7812001	chr7:19803323	A/G	cg07541023	chr7:19748670	TWISTNB	-0.57	-6.6	-0.34	1.61e-10	Thyroid stimulating hormone;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19455335	chr8:22457658	C8orf58	0.42	6.26	0.32	1.18e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg22482690	chr17:47019901	SNF8	0.4	7.47	0.38	6.92e-13	Type 2 diabetes;
LUSC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.77	13.29	0.59	1.21e-32	Cognitive function;
LUSC	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg00579200	chr11:133705235	NA	-0.39	-5.97	-0.31	6.21e-9	Childhood ear infection;
LUSC	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg17420585	chr12:42539391	GXYLT1	-0.57	-13.18	-0.58	3.23e-32	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg21361702	chr7:150065534	REPIN1	0.5	6.79	0.35	5.18e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3741798	1.000	rs61922047	chr12:12496471	C/A	cg08615371	chr12:12503544	MANSC1	1.08	11.07	0.52	1.79e-24	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	20.89	0.75	1.43e-62	Prudent dietary pattern;
LUSC	trans	rs9393777	0.920	rs34071253	chr6:27391802	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.93	-0.44	2.85e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.73	0.3	2.25e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.46	-6.88	-0.35	2.87e-11	Melanoma;
LUSC	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03611598	chr17:48586076	MYCBPAP	-0.49	-6.19	-0.32	1.81e-9	Visceral fat;
LUSC	cis	rs1712517	0.835	rs2506961	chr10:105007926	G/T	cg05636881	chr10:105038444	INA	-0.42	-6.91	-0.35	2.4e-11	Migraine;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11858416	chr22:29279592	ZNRF3	-0.42	-6.33	-0.33	7.9e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2055729	0.885	rs13268133	chr8:9731470	C/T	cg27411982	chr8:10470053	RP1L1	0.41	5.93	0.31	7.41e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.67	11.56	0.53	3.25e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9462027	0.527	rs6939600	chr6:34822176	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.09e-8	Systemic lupus erythematosus;
LUSC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	7.41	0.38	1.02e-12	Electroencephalogram traits;
LUSC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg12310025	chr6:25882481	NA	-0.37	-6.3	-0.33	9.33e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11645453	chr3:52864694	ITIH4	0.34	7.89	0.4	4.4e-14	Electroencephalogram traits;
LUSC	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg26769984	chr7:1090371	C7orf50	0.58	7.3	0.37	2.18e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg05855489	chr10:104503620	C10orf26	0.6	9.66	0.47	1.28e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11625487	0.915	rs11845826	chr14:77966145	C/A	cg16049707	chr14:77965284	ISM2	0.6	8.58	0.43	3.58e-16	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	trans	rs67133203	0.904	rs12831269	chr12:51398441	C/T	cg17484237	chr5:156536107	HAVCR2	0.44	5.99	0.31	5.35e-9	Urinary tract infection frequency;
LUSC	cis	rs1983891	1.000	rs9296365	chr6:41535379	A/G	cg15051332	chr6:41514432	FOXP4	0.39	5.69	0.3	2.84e-8	Prostate cancer;
LUSC	cis	rs13223928	0.621	rs10228451	chr7:3150859	C/G	cg19214707	chr7:3157722	NA	0.42	8.46	0.42	8.26e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs12900413	0.603	rs2351493	chr15:90299536	A/G	cg24249390	chr15:90295951	MESP1	-0.37	-5.9	-0.31	8.76e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg27284194	chr4:1044797	NA	0.57	8.42	0.42	1.12e-15	Recombination rate (females);
LUSC	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg00792783	chr2:198669748	PLCL1	-0.43	-5.95	-0.31	6.91e-9	Dermatomyositis;
LUSC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg04287289	chr16:89883240	FANCA	0.77	6.21	0.32	1.57e-9	Skin colour saturation;
LUSC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg12432903	chr7:1882776	MAD1L1	-0.37	-5.8	-0.3	1.56e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs4654899	1.000	rs4654902	chr1:21435056	T/G	cg01072550	chr1:21505969	NA	-0.53	-8.07	-0.4	1.27e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs240764	0.687	rs239248	chr6:101088315	T/A	cg09795085	chr6:101329169	ASCC3	0.42	6.12	0.32	2.68e-9	Neuroticism;
LUSC	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.82	10.66	0.5	4.87e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs34734847	0.750	rs3915	chr12:121176679	C/T	cg27246729	chr12:121163418	ACADS	0.4	6.25	0.32	1.25e-9	Mean corpuscular volume;
LUSC	cis	rs8027181	0.839	rs4777532	chr15:73041767	A/G	cg25632853	chr15:73088954	NA	0.31	6.4	0.33	5.34e-10	Triglyceride levels;
LUSC	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg04733989	chr22:42467013	NAGA	-0.41	-6.76	-0.35	6.04e-11	Cognitive function;
LUSC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13126279	chr21:47581558	C21orf56	-0.52	-7.84	-0.39	5.9e-14	Testicular germ cell tumor;
LUSC	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.5	9.25	0.45	2.82e-18	HDL cholesterol;
LUSC	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg13535736	chr9:111863775	C9orf5	-0.4	-6.5	-0.34	2.93e-10	Menarche (age at onset);
LUSC	cis	rs12760731	0.565	rs12030488	chr1:178094751	A/C	cg00404053	chr1:178313656	RASAL2	-0.66	-6.86	-0.35	3.29e-11	Obesity-related traits;
LUSC	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg05110241	chr16:68378359	PRMT7	-0.53	-6.56	-0.34	2.04e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9400467	0.509	rs463854	chr6:111673207	C/G	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg02269571	chr22:50332266	NA	0.59	8.74	0.43	1.17e-16	Schizophrenia;
LUSC	cis	rs11997175	0.587	rs72612118	chr8:33695225	T/C	ch.8.33884649F	chr8:33765107	NA	0.45	6.65	0.34	1.2e-10	Body mass index;
LUSC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg14552801	chr7:65878734	NA	0.38	5.84	0.3	1.27e-8	Aortic root size;
LUSC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.74	0.3	2.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg08213375	chr14:104286397	PPP1R13B	0.34	5.77	0.3	1.78e-8	Reticulocyte count;
LUSC	cis	rs72949976	0.707	rs62186571	chr2:214038673	C/G	cg08319019	chr2:214017104	IKZF2	-0.54	-7.28	-0.37	2.39e-12	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg08493051	chr2:3487164	NA	-0.56	-8.8	-0.43	7.33e-17	Neurofibrillary tangles;
LUSC	trans	rs17266958	1.000	rs62576986	chr9:83294455	T/C	cg01905489	chr1:26616534	UBXN11	-0.51	-5.95	-0.31	6.9e-9	Preschool internalizing problems;
LUSC	cis	rs9560113	1.000	rs11069895	chr13:112178824	C/T	cg14154082	chr13:112174009	NA	0.37	7.62	0.38	2.72e-13	Menarche (age at onset);
LUSC	cis	rs9815354	0.812	rs73828254	chr3:41810180	T/A	cg03022575	chr3:42003672	ULK4	0.83	8.32	0.41	2.2e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg00857998	chr1:205179979	DSTYK	0.65	10.16	0.49	2.63e-21	Red blood cell count;
LUSC	cis	rs4494114	1.000	rs4491033	chr1:39352083	A/C	cg25970120	chr1:39325951	RRAGC	-0.38	-6.0	-0.31	5.06e-9	Blood protein levels;
LUSC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06221963	chr1:154839813	KCNN3	0.59	12.92	0.58	2.92e-31	Prostate cancer;
LUSC	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg05925327	chr15:68127851	NA	-0.32	-5.75	-0.3	2.02e-8	Restless legs syndrome;
LUSC	trans	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg27411982	chr8:10470053	RP1L1	0.38	6.1	0.32	2.94e-9	Mood instability;
LUSC	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg02696742	chr7:106810147	HBP1	-0.64	-9.7	-0.47	8.88e-20	Coronary artery disease;
LUSC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg14895029	chr7:2775587	GNA12	-0.38	-5.81	-0.3	1.44e-8	Height;
LUSC	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg04546413	chr19:29218101	NA	0.52	7.38	0.37	1.24e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg09165964	chr15:75287851	SCAMP5	0.46	6.94	0.35	2.09e-11	Breast cancer;
LUSC	cis	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg06521331	chr12:34319734	NA	-0.48	-7.71	-0.39	1.43e-13	Morning vs. evening chronotype;
LUSC	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg06096015	chr1:231504339	EGLN1	0.56	9.95	0.48	1.33e-20	Hemoglobin concentration;
LUSC	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg13010199	chr12:38710504	ALG10B	-0.6	-9.33	-0.45	1.56e-18	Morning vs. evening chronotype;
LUSC	cis	rs7615316	0.528	rs7636909	chr3:142260562	A/G	cg16271453	chr3:142027066	XRN1	-0.5	-8.82	-0.43	6.64e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg12863693	chr15:85201151	NMB	0.35	6.89	0.35	2.73e-11	Schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18497098	chr6:83775582	UBE2CBP	0.73	6.17	0.32	2.02e-9	Cognitive performance;
LUSC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-7.51	-0.38	5.35e-13	Aortic root size;
LUSC	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.34	6.14	0.32	2.28e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs654950	0.841	rs2810549	chr1:41991761	C/T	cg06885757	chr1:42089581	HIVEP3	-0.37	-7.28	-0.37	2.38e-12	Airway imaging phenotypes;
LUSC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06481639	chr22:41940642	POLR3H	0.49	5.81	0.3	1.48e-8	Vitiligo;
LUSC	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg14019146	chr3:50243930	SLC38A3	0.36	8.26	0.41	3.53e-15	Body mass index;
LUSC	cis	rs7188861	0.768	rs62023624	chr16:11399603	C/A	cg00044050	chr16:11439710	C16orf75	0.51	5.83	0.3	1.32e-8	HDL cholesterol;
LUSC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.72	9.08	0.44	9.6e-18	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.55	-0.34	2.12e-10	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.71	0.39	1.48e-13	Corneal astigmatism;
LUSC	cis	rs7178572	0.568	rs7176302	chr15:77671216	C/G	cg22256960	chr15:77711686	NA	-0.51	-8.09	-0.4	1.11e-14	Type 2 diabetes;
LUSC	cis	rs17102423	0.689	rs7158239	chr14:65520616	G/A	cg11161011	chr14:65562177	MAX	-0.58	-8.87	-0.44	4.37e-17	Obesity-related traits;
LUSC	cis	rs2932538	0.922	rs12138335	chr1:113122760	T/C	cg22162597	chr1:113214053	CAPZA1	0.7	10.06	0.48	5.71e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.75	14.64	0.63	7.48e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3099143	1.000	rs2629034	chr15:77042240	G/A	cg21673338	chr15:77095150	SCAPER	-0.82	-8.07	-0.4	1.26e-14	Recalcitrant atopic dermatitis;
LUSC	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.57	-9.18	-0.45	4.64e-18	Body mass index;
LUSC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.37	0.37	1.35e-12	Bipolar disorder;
LUSC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-14.2	-0.61	4e-36	Chronic sinus infection;
LUSC	cis	rs2834256	0.517	rs7280365	chr21:34952583	G/C	cg14850771	chr21:34775459	IFNGR2	0.39	5.68	0.3	2.86e-8	Red cell distribution width;
LUSC	cis	rs2354432	0.556	rs1932979	chr1:146708912	A/G	cg25205988	chr1:146714368	CHD1L	-1.01	-8.99	-0.44	1.91e-17	Mitochondrial DNA levels;
LUSC	cis	rs977987	0.843	rs7499872	chr16:75426529	G/A	cg04384234	chr16:75411784	CFDP1	-0.45	-7.41	-0.38	1.04e-12	Dupuytren's disease;
LUSC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg17376030	chr22:41985996	PMM1	0.46	5.85	0.3	1.2e-8	Vitiligo;
LUSC	cis	rs7809950	1.000	rs986994	chr7:107104115	G/T	cg23024343	chr7:107201750	COG5	-0.54	-8.76	-0.43	9.95e-17	Coronary artery disease;
LUSC	cis	rs4629710	0.617	rs28360555	chr6:131538952	C/A	cg12700074	chr6:131571435	AKAP7	-0.37	-6.15	-0.32	2.17e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs2299587	0.519	rs3850746	chr8:17787536	C/T	cg01800426	chr8:17659068	MTUS1	0.46	6.3	0.33	9.15e-10	Economic and political preferences;
LUSC	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg15556689	chr8:8085844	FLJ10661	0.56	8.47	0.42	7.64e-16	Neuroticism;
LUSC	cis	rs2637266	0.967	rs4553314	chr10:78358244	C/T	cg18941641	chr10:78392320	NA	0.39	7.22	0.37	3.53e-12	Pulmonary function;
LUSC	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg11941060	chr3:133502564	NA	-0.42	-6.12	-0.32	2.68e-9	Iron status biomarkers;
LUSC	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg21856205	chr7:94953877	PON1	-0.36	-5.69	-0.3	2.72e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7937682	0.601	rs2187388	chr11:111387116	C/T	cg09085632	chr11:111637200	PPP2R1B	0.51	6.7	0.34	9e-11	Primary sclerosing cholangitis;
LUSC	cis	rs3931020	0.688	rs277374	chr1:75200486	G/A	cg21535942	chr1:75199100	CRYZ;TYW3	-0.47	-5.93	-0.31	7.37e-9	Resistin levels;
LUSC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	5.99	0.31	5.53e-9	Breast cancer;
LUSC	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	0.65	9.21	0.45	3.62e-18	Methadone dose in opioid dependence;
LUSC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg23281280	chr6:28129359	ZNF389	0.43	5.72	0.3	2.38e-8	Parkinson's disease;
LUSC	cis	rs7089973	0.523	rs11197017	chr10:116737738	C/A	cg23260525	chr10:116636907	FAM160B1	0.29	5.68	0.3	2.97e-8	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg08470875	chr2:26401718	FAM59B	-0.69	-9.28	-0.45	2.21e-18	Gut microbiome composition (summer);
LUSC	trans	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg07393940	chr7:158741817	NA	-0.37	-6.65	-0.34	1.22e-10	Life satisfaction;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg16980360	chr17:29298148	RNF135	-0.49	-6.18	-0.32	1.9e-9	Neuroticism;
LUSC	cis	rs10992471	0.580	rs7847534	chr9:95282653	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.9	-0.35	2.68e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs892085	0.681	rs7246673	chr19:10876841	T/G	cg17710535	chr19:10819994	QTRT1	0.34	5.66	0.3	3.21e-8	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08219700	chr8:58056026	NA	0.65	7.64	0.39	2.29e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg07507251	chr3:52567010	NT5DC2	0.36	7.19	0.37	4.16e-12	Electroencephalogram traits;
LUSC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg15147215	chr3:52552868	STAB1	0.29	5.7	0.3	2.69e-8	Electroencephalogram traits;
LUSC	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-22.83	-0.78	3.76e-70	Ulcerative colitis;
LUSC	cis	rs12519773	0.846	rs1496332	chr5:92439320	A/G	cg18783429	chr5:92414398	NA	0.29	6.4	0.33	5.16e-10	Migraine;
LUSC	cis	rs752010	0.695	rs10890156	chr1:42108090	T/C	cg06885757	chr1:42089581	HIVEP3	0.44	8.53	0.42	5.25e-16	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs6546886	0.957	rs11885172	chr2:74257094	T/C	cg14702570	chr2:74259524	NA	-0.3	-5.78	-0.3	1.7e-8	Dialysis-related mortality;
LUSC	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg09537434	chr19:41945824	ATP5SL	-0.64	-9.24	-0.45	2.99e-18	Migraine;Coronary artery disease;
LUSC	cis	rs9905704	0.633	rs2531727	chr17:56502264	C/T	cg19466818	chr17:56409534	MIR142	-0.32	-6.08	-0.32	3.26e-9	Testicular germ cell tumor;
LUSC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10802521	chr3:52805072	NEK4	-0.52	-8.0	-0.4	2e-14	Bipolar disorder;
LUSC	cis	rs354225	0.544	rs12713268	chr2:54808845	C/G	cg26097391	chr2:54893211	SPTBN1	-0.4	-6.19	-0.32	1.73e-9	Schizophrenia;
LUSC	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg17052675	chr2:3827356	NA	-0.63	-10.1	-0.48	4.21e-21	Type 2 diabetes;
LUSC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09241243	chr14:64970743	ZBTB25;ZBTB1	0.73	5.69	0.3	2.73e-8	Cognitive performance;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg07066635	chr12:110434276	GIT2	0.47	5.98	0.31	5.68e-9	Neuroticism;
LUSC	cis	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg26958806	chr6:27640298	NA	0.74	6.04	0.31	4.02e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs67539049	1.000	rs67526040	chr8:11302996	G/A	cg26241650	chr22:40417538	FAM83F	0.43	5.95	0.31	6.83e-9	Itch intensity from mosquito bite;
LUSC	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg00484396	chr16:3507460	NAT15	0.86	11.42	0.53	9.83e-26	Tuberculosis;
LUSC	cis	rs6977940	0.818	rs35450876	chr7:2894852	A/G	cg19731401	chr7:2775893	GNA12	0.65	7.31	0.37	2.04e-12	White matter integrity;
LUSC	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.52	0.42	5.39e-16	Menopause (age at onset);
LUSC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg17691542	chr6:26056736	HIST1H1C	0.49	7.22	0.37	3.46e-12	Height;
LUSC	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg09184832	chr6:79620586	NA	0.42	6.63	0.34	1.35e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg22920501	chr2:26401640	FAM59B	-0.81	-12.05	-0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs10740039	0.883	rs2119912	chr10:62399512	C/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg16624210	chr5:671434	TPPP	0.49	6.1	0.32	2.89e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg02018176	chr4:1364513	KIAA1530	0.53	9.01	0.44	1.61e-17	Obesity-related traits;
LUSC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg12560992	chr17:57184187	TRIM37	0.85	15.53	0.65	2.58e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.75	-0.73	4.73e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.77	11.34	0.53	1.91e-25	Corneal astigmatism;
LUSC	cis	rs12541635	0.934	rs4734893	chr8:106990275	T/G	cg10147462	chr8:107024639	NA	0.56	10.1	0.48	4.04e-21	Age of smoking initiation;
LUSC	cis	rs2798269	1.000	rs2761911	chr13:22131801	T/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.13	-0.32	2.42e-9	PR segment;
LUSC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg03388025	chr16:89894329	SPIRE2	0.34	7.07	0.36	9.13e-12	Vitiligo;
LUSC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg04287289	chr16:89883240	FANCA	0.78	6.24	0.32	1.3e-9	Skin colour saturation;
LUSC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-8.74	-0.43	1.16e-16	Hemoglobin concentration;
LUSC	cis	rs6674970	1.000	rs6656450	chr1:151089602	A/T	cg03258749	chr1:151040405	MLLT11	-0.43	-6.45	-0.33	3.86e-10	Childhood ear infection;
LUSC	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7428496	0.528	rs13092234	chr3:142273836	G/C	cg16271453	chr3:142027066	XRN1	-0.49	-8.48	-0.42	7.25e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg11946769	chr3:48343235	NME6	0.82	13.51	0.59	1.7e-33	Coronary artery disease;
LUSC	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.11	-0.41	9.52e-15	Body mass index;
LUSC	cis	rs12760731	0.565	rs35926996	chr1:178075351	A/G	cg00404053	chr1:178313656	RASAL2	0.67	6.7	0.34	8.81e-11	Obesity-related traits;
LUSC	cis	rs16854884	1.000	rs7649614	chr3:143789028	G/A	cg06585982	chr3:143692056	C3orf58	0.46	6.35	0.33	7.15e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.44	0.5	2.94e-22	Colorectal cancer;
LUSC	trans	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg26043149	chr18:55253948	FECH	-0.47	-7.29	-0.37	2.19e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10207060	0.500	rs28540721	chr2:240714045	C/T	cg20333904	chr2:240724165	NA	-0.35	-6.07	-0.32	3.43e-9	Obesity-related traits;
LUSC	cis	rs12289510	1.000	rs12289510	chr11:124947051	C/T	cg03868193	chr11:124958746	SLC37A2	0.56	8.98	0.44	1.97e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg05110241	chr16:68378359	PRMT7	-0.69	-7.3	-0.37	2.09e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg02569458	chr12:86230093	RASSF9	0.58	9.89	0.48	2.1e-20	Major depressive disorder;
LUSC	cis	rs2445762	0.518	rs6493496	chr15:51628119	A/T	cg00184732	chr15:51633821	GLDN	0.3	6.02	0.31	4.64e-9	Hormone measurements;
LUSC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.82	14.29	0.62	1.77e-36	Blood protein levels;
LUSC	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg08508325	chr11:3079039	CARS	0.38	8.4	0.42	1.33e-15	Calcium levels;
LUSC	cis	rs62458065	1.000	rs6462364	chr7:32464776	C/T	cg20159608	chr7:32802032	NA	-0.57	-7.01	-0.36	1.34e-11	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9420	0.528	rs10896632	chr11:57390302	G/A	cg23127183	chr11:57508653	C11orf31	-0.48	-6.68	-0.34	9.81e-11	Schizophrenia;
LUSC	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.64	-5.78	-0.3	1.73e-8	Major depressive disorder;
LUSC	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg05805236	chr11:65401703	PCNXL3	0.39	6.63	0.34	1.33e-10	Acne (severe);
LUSC	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg01528321	chr10:82214614	TSPAN14	1.08	11.99	0.55	8.7e-28	Post bronchodilator FEV1;
LUSC	cis	rs859767	0.774	rs6758396	chr2:135416857	T/C	cg12500956	chr2:135428796	TMEM163	-0.27	-6.13	-0.32	2.46e-9	Neuroticism;
LUSC	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg12927641	chr6:109611667	NA	0.37	6.23	0.32	1.37e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs185694	0.779	rs653221	chr13:30894567	G/C	cg07600127	chr13:30881527	KATNAL1	-0.51	-5.97	-0.31	6.21e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
LUSC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg05425664	chr17:57184151	TRIM37	-0.52	-7.83	-0.39	6.45e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.92	-0.35	2.31e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-9.85	-0.47	2.84e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6495367	1.000	rs3851677	chr15:79380869	C/T	cg17916960	chr15:79447300	NA	0.35	6.67	0.34	1.04e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-6.02	-0.31	4.48e-9	Personality dimensions;
LUSC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg15704280	chr7:45808275	SEPT13	0.93	13.36	0.59	6.38e-33	Coronary artery disease;
LUSC	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-11.7	-0.54	9.99e-27	Morning vs. evening chronotype;
LUSC	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg12884169	chr21:40033163	ERG	0.56	11.08	0.52	1.62e-24	Coronary artery disease;
LUSC	cis	rs7814319	0.966	rs2319603	chr8:97270991	G/A	cg20787634	chr8:97240163	UQCRB	-0.35	-6.12	-0.32	2.62e-9	Lung function (FVC);
LUSC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.19	21.79	0.77	3.98e-66	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs1376359	0.537	rs537755	chr1:103260776	G/C	cg17154563	chr19:40477487	PSMC4	0.48	6.06	0.31	3.61e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg01528321	chr10:82214614	TSPAN14	-1.06	-17.15	-0.68	9.98e-48	Post bronchodilator FEV1;
LUSC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	8.33	0.41	2.16e-15	Total body bone mineral density;
LUSC	cis	rs11229555	0.645	rs11229443	chr11:58197188	G/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg04865166	chr7:105162814	PUS7	0.51	5.84	0.3	1.25e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.68	0.34	1e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2274273	0.935	rs8004787	chr14:55607366	C/T	cg04306507	chr14:55594613	LGALS3	0.58	13.35	0.59	6.92e-33	Protein biomarker;
LUSC	cis	rs2658782	0.789	rs3019206	chr11:93111073	A/G	cg15737290	chr11:93063684	CCDC67	0.64	7.91	0.4	3.87e-14	Pulmonary function decline;
LUSC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	10.54	0.5	1.27e-22	Cognitive test performance;
LUSC	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg18721089	chr20:30220636	NA	-0.34	-5.93	-0.31	7.53e-9	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg09359103	chr1:154839909	KCNN3	-0.58	-11.8	-0.54	4.43e-27	Prostate cancer;
LUSC	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.17	-24.06	-0.8	6.35e-75	Exhaled nitric oxide output;
LUSC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg12463550	chr7:65579703	CRCP	-0.55	-8.12	-0.41	9.02e-15	Aortic root size;
LUSC	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg06002616	chr8:101225028	SPAG1	-0.41	-6.82	-0.35	4.37e-11	Atrioventricular conduction;
LUSC	cis	rs35123781	1.000	rs585101	chr5:139058454	T/C	cg10513866	chr5:139070639	NA	0.47	9.14	0.45	6.25e-18	Schizophrenia;
LUSC	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22980127	chr19:33182716	NUDT19	0.95	12.94	0.58	2.44e-31	Red blood cell traits;
LUSC	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg25811766	chr13:21894605	NA	-0.69	-8.16	-0.41	6.96e-15	White matter hyperintensity burden;
LUSC	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg06002616	chr8:101225028	SPAG1	0.46	7.56	0.38	4.05e-13	Atrioventricular conduction;
LUSC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.81	0.39	7.4e-14	Prudent dietary pattern;
LUSC	cis	rs7511006	0.798	rs11703673	chr22:50652427	A/G	cg08875078	chr22:50639485	SELO	-0.43	-5.83	-0.3	1.3e-8	Obesity-related traits;
LUSC	cis	rs2348418	0.831	rs7977525	chr12:28715517	A/G	cg13890972	chr12:28721907	NA	-0.34	-5.81	-0.3	1.49e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs6062509	1.000	rs6011066	chr20:62364180	G/A	cg21849932	chr20:62369462	LIME1	-0.41	-5.95	-0.31	6.8e-9	Prostate cancer;
LUSC	cis	rs7106204	0.609	rs12788920	chr11:24284514	C/T	ch.11.24196551F	chr11:24239977	NA	0.72	6.04	0.31	4.08e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs4363385	0.747	rs4568784	chr1:152972694	G/A	cg25856811	chr1:152973957	SPRR3	-0.34	-5.67	-0.3	3.09e-8	Inflammatory skin disease;
LUSC	trans	rs12651329	1.000	rs12651329	chr4:36079594	A/G	cg08740729	chr20:35491708	C20orf117	-0.4	-6.0	-0.31	5.23e-9	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs8099014	0.601	rs4503880	chr18:56084054	A/G	cg12907477	chr18:56117327	MIR122	0.41	5.81	0.3	1.46e-8	Platelet count;
LUSC	cis	rs2303282	0.690	rs2440473	chr16:56433534	A/G	cg00500540	chr16:56394104	NA	-0.43	-7.32	-0.37	1.88e-12	Breast cancer;
LUSC	cis	rs6460942	0.915	rs2216050	chr7:12304073	T/C	cg06484146	chr7:12443880	VWDE	-0.52	-6.29	-0.33	9.98e-10	Coronary artery disease;
LUSC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.87	-17.82	-0.7	2.23e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg26566898	chr11:117069891	TAGLN	0.42	7.22	0.37	3.64e-12	Blood protein levels;
LUSC	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg11473876	chr11:109292803	C11orf87	0.41	6.47	0.33	3.54e-10	Schizophrenia;
LUSC	cis	rs2540226	0.655	rs2160199	chr2:39930191	A/G	cg23576258	chr2:39999331	THUMPD2	0.35	5.9	0.31	8.74e-9	Personality dimensions;
LUSC	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg23795048	chr12:9217529	LOC144571	0.34	5.86	0.31	1.1e-8	Sjögren's syndrome;
LUSC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg04166393	chr7:2884313	GNA12	0.41	5.82	0.3	1.36e-8	Height;
LUSC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-7.81	-0.39	7.54e-14	Lymphocyte counts;
LUSC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.73	0.35	7.31e-11	Aortic root size;
LUSC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7180079	0.620	rs11071803	chr15:64965815	G/T	cg08069370	chr15:64387884	SNX1	-0.5	-5.74	-0.3	2.16e-8	Monocyte count;
LUSC	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg24558204	chr6:135376177	HBS1L	-0.59	-8.67	-0.43	1.9e-16	Red blood cell count;
LUSC	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg22569836	chr15:43028916	CDAN1	0.36	6.04	0.31	4.02e-9	Educational attainment (years of education);
LUSC	cis	rs7674212	0.507	rs223331	chr4:103793565	T/A	cg16532752	chr4:104119610	CENPE	-0.42	-5.72	-0.3	2.41e-8	Type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03480210	chr2:39103037	DHX57;MORN2	-0.43	-6.42	-0.33	4.61e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg04944784	chr2:26401820	FAM59B	0.68	10.16	0.49	2.67e-21	Gut microbiome composition (summer);
LUSC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.12	-0.32	2.62e-9	Total body bone mineral density;
LUSC	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg16070123	chr10:51489643	NA	-0.58	-9.66	-0.47	1.24e-19	Prostate-specific antigen levels;
LUSC	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.65	8.63	0.43	2.52e-16	Menarche (age at onset);
LUSC	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg27432699	chr2:27873401	GPN1	-0.51	-7.63	-0.39	2.43e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs2562456	0.755	rs2914646	chr19:21637161	A/C	cg00806126	chr19:22604979	ZNF98	0.4	6.14	0.32	2.4e-9	Pain;
LUSC	cis	rs7560272	0.538	rs3980695	chr2:73939552	A/G	cg20560298	chr2:73613845	ALMS1	0.41	6.19	0.32	1.71e-9	Schizophrenia;
LUSC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg00166722	chr3:10149974	C3orf24	0.42	6.21	0.32	1.56e-9	Alzheimer's disease;
LUSC	cis	rs9549260	0.564	rs9577110	chr13:41271878	T/G	cg21288729	chr13:41239152	FOXO1	0.54	8.3	0.41	2.7e-15	Red blood cell count;
LUSC	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	6.79	0.35	5.13e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7202877	0.706	rs4887813	chr16:75312494	A/G	cg03315344	chr16:75512273	CHST6	0.43	6.18	0.32	1.87e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.81	-0.3	1.44e-8	Alzheimer's disease (late onset);
LUSC	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg11019008	chr10:131425282	MGMT	0.44	6.65	0.34	1.21e-10	Response to temozolomide;
LUSC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg11812906	chr14:75593930	NEK9	-0.64	-10.04	-0.48	6.67e-21	Height;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21580350	chr7:148680565	NA	-0.49	-6.34	-0.33	7.42e-10	Hepatitis;
LUSC	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	1.06	24.09	0.8	4.92e-75	Platelet distribution width;
LUSC	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg23176889	chr5:176863531	GRK6	0.66	13.72	0.6	2.73e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-10.93	-0.51	5.71e-24	Mean corpuscular volume;
LUSC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg09904177	chr6:26538194	HMGN4	0.76	14.14	0.61	6.79e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	15.89	0.66	9.4e-43	Platelet count;
LUSC	cis	rs12999616	0.817	rs35530168	chr2:98328477	C/G	cg26665480	chr2:98280029	ACTR1B	0.53	6.05	0.31	3.91e-9	Colorectal cancer;
LUSC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg00800038	chr16:89945340	TCF25	-0.76	-6.58	-0.34	1.78e-10	Skin colour saturation;
LUSC	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg09367891	chr1:107599246	PRMT6	0.47	7.35	0.37	1.55e-12	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg09021430	chr5:549028	NA	-0.56	-7.67	-0.39	1.85e-13	Obesity-related traits;
LUSC	cis	rs11971779	0.680	rs10274480	chr7:139052428	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.23	0.32	1.4e-9	Diisocyanate-induced asthma;
LUSC	cis	rs77741769	0.926	rs4767941	chr12:121359586	G/A	cg02403541	chr12:121454288	C12orf43	0.51	7.48	0.38	6.41e-13	Mean corpuscular volume;
LUSC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.57	10.37	0.49	5.01e-22	Bone mineral density;
LUSC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg04317338	chr11:64019027	PLCB3	0.66	7.51	0.38	5.28e-13	Mean platelet volume;
LUSC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.93	-0.51	5.8e-24	Alzheimer's disease (late onset);
LUSC	cis	rs240764	0.578	rs12215909	chr6:101227598	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.2	-0.32	1.62e-9	Neuroticism;
LUSC	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg09021430	chr5:549028	NA	-0.6	-9.41	-0.46	8.29e-19	Obesity-related traits;
LUSC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.82	12.4	0.56	2.57e-29	Cognitive test performance;
LUSC	cis	rs4132509	0.793	rs7522883	chr1:243803022	C/T	cg21452805	chr1:244014465	NA	0.62	5.94	0.31	7.28e-9	RR interval (heart rate);
LUSC	cis	rs3087591	0.959	rs2051505	chr17:29699859	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.56	-8.02	-0.4	1.81e-14	Hip circumference;
LUSC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.68	-11.86	-0.54	2.52e-27	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.07	-17.76	-0.7	3.74e-50	Primary sclerosing cholangitis;
LUSC	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.5	-7.43	-0.38	9.2e-13	Menarche (age at onset);
LUSC	trans	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg10756647	chr7:56101905	PSPH	0.84	8.39	0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.96e-9	Prostate cancer;
LUSC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.79	14.71	0.63	4.27e-38	Dental caries;
LUSC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-6.65	-0.34	1.22e-10	Blood pressure (smoking interaction);
LUSC	cis	rs6500395	1.000	rs7191028	chr16:48626023	T/C	cg04672837	chr16:48644449	N4BP1	0.49	7.31	0.37	1.95e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1775715	0.677	rs2799034	chr10:32175896	A/G	cg03015672	chr10:32216066	ARHGAP12	0.34	6.12	0.32	2.62e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1028488	0.543	rs9460113	chr6:170627651	G/A	cg20370364	chr6:170703943	FAM120B	-0.47	-7.05	-0.36	1.02e-11	Interferon alpha levels in systemic lupus erythematosus;
LUSC	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	0.95	15.11	0.64	1.16e-39	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg14343924	chr8:8086146	FLJ10661	0.4	5.86	0.31	1.13e-8	Mood instability;
LUSC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg20203395	chr5:56204925	C5orf35	-0.54	-7.86	-0.39	5.45e-14	Coronary artery disease;
LUSC	trans	rs3857536	0.785	rs6455089	chr6:66944733	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg17470449	chr10:769945	NA	0.53	7.12	0.36	6.81e-12	Uric acid levels;
LUSC	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg02344993	chr17:57696989	CLTC	0.48	7.11	0.36	7.3e-12	Hemoglobin concentration;
LUSC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg02772935	chr3:125709198	NA	-0.47	-6.12	-0.32	2.66e-9	Blood pressure (smoking interaction);
LUSC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07677032	chr17:61819896	STRADA	0.54	9.09	0.45	9.15e-18	Prudent dietary pattern;
LUSC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-0.77	-11.41	-0.53	1.12e-25	Gut microbiome composition (summer);
LUSC	trans	rs629535	0.814	rs62513378	chr8:70095788	G/C	cg21567404	chr3:27674614	NA	-0.98	-16.02	-0.66	3.01e-43	Dupuytren's disease;
LUSC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	7.17	0.37	4.89e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg04369109	chr6:150039330	LATS1	-0.55	-8.1	-0.41	1.07e-14	Lung cancer;
LUSC	cis	rs7605827	0.930	rs4668926	chr2:15704944	C/T	cg19274914	chr2:15703543	NA	0.46	8.77	0.43	9.41e-17	Educational attainment (years of education);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20656751	chr4:2061512	NAT8L	0.64	9.93	0.48	1.58e-20	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs10805346	0.501	rs4604059	chr4:10115065	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.66	-0.34	1.12e-10	Urate levels in overweight individuals;Urate levels in obese individuals;
LUSC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.47	7.77	0.39	1e-13	Vitiligo;
LUSC	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg09537434	chr19:41945824	ATP5SL	0.94	16.03	0.66	2.77e-43	Height;
LUSC	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21659725	chr3:3221576	CRBN	-0.62	-10.14	-0.49	3.01e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg13175981	chr1:150552382	MCL1	0.53	7.4	0.38	1.09e-12	Tonsillectomy;
LUSC	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg24011408	chr12:48396354	COL2A1	0.4	5.82	0.3	1.38e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg03732007	chr1:2071316	PRKCZ	0.45	7.2	0.37	3.97e-12	Height;
LUSC	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg24579218	chr15:68104479	NA	-0.36	-6.45	-0.33	4.01e-10	Restless legs syndrome;
LUSC	cis	rs12190007	0.573	rs13202383	chr6:169826544	A/G	ch.6.169577133F	chr6:169835210	NA	-0.39	-5.88	-0.31	9.87e-9	Obesity-related traits;
LUSC	cis	rs698813	0.604	rs768007	chr2:44487486	G/A	cg00619915	chr2:44497795	NA	-0.53	-7.53	-0.38	4.67e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg02269571	chr22:50332266	NA	-0.69	-9.93	-0.48	1.61e-20	Schizophrenia;
LUSC	cis	rs6500395	0.962	rs9921741	chr16:48589896	G/A	cg04672837	chr16:48644449	N4BP1	0.43	6.17	0.32	1.94e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06850241	chr22:41845214	NA	-0.31	-5.68	-0.3	2.98e-8	Vitiligo;
LUSC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	0.96	9.4	0.46	8.76e-19	Plasma clusterin levels;
LUSC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg17173187	chr15:85201210	NMB	0.37	6.42	0.33	4.7e-10	Schizophrenia;
LUSC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.71	-9.51	-0.46	3.8e-19	Blood trace element (Zn levels);
LUSC	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg00852783	chr1:26633632	UBXN11	0.61	9.44	0.46	6.37e-19	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg24375607	chr4:120327624	NA	0.76	11.59	0.54	2.52e-26	Corneal astigmatism;
LUSC	cis	rs6912958	0.677	rs111990232	chr6:88022240	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.54	7.59	0.38	3.16e-13	Monocyte percentage of white cells;
LUSC	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg13010199	chr12:38710504	ALG10B	-0.46	-6.83	-0.35	4.05e-11	Heart rate;
LUSC	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg20701182	chr2:24300061	SF3B14	0.9	11.62	0.54	1.84e-26	Lymphocyte counts;
LUSC	trans	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg26811252	chr16:29126840	RRN3P2	0.49	8.39	0.42	1.35e-15	Menopause (age at onset);
LUSC	cis	rs6457821	1.000	rs73415612	chr6:35437650	A/G	cg06087101	chr6:35551932	FKBP5	0.63	5.79	0.3	1.63e-8	Height;
LUSC	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg11502198	chr6:26597334	ABT1	0.59	9.37	0.46	1.15e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg24812749	chr6:127587940	RNF146	0.64	9.52	0.46	3.74e-19	Breast cancer;
LUSC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.77	-10.39	-0.49	4.35e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.98	19.14	0.72	1.17e-55	Diastolic blood pressure;
LUSC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08219700	chr8:58056026	NA	0.65	8.54	0.42	4.74e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg14584255	chr6:163149320	PACRG;PARK2	-0.33	-6.3	-0.33	9.63e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6939532	0.597	rs2273558	chr6:26466035	A/C	cg09904177	chr6:26538194	HMGN4	-0.5	-7.22	-0.37	3.54e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg26441486	chr22:50317300	CRELD2	0.44	6.71	0.34	8.46e-11	Schizophrenia;
LUSC	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.86	14.7	0.63	4.43e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2976388	0.647	rs2585174	chr8:143782044	A/G	cg17252645	chr8:143867129	LY6D	0.38	6.49	0.33	3.03e-10	Urinary tract infection frequency;
LUSC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg14552801	chr7:65878734	NA	0.38	5.91	0.31	8.41e-9	Aortic root size;
LUSC	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg02569458	chr12:86230093	RASSF9	0.49	8.22	0.41	4.69e-15	Major depressive disorder;
LUSC	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg20129853	chr10:51489980	NA	0.37	8.07	0.4	1.27e-14	Prostate-specific antigen levels;
LUSC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg20849893	chr7:64541193	NA	-0.67	-5.78	-0.3	1.71e-8	Diabetic kidney disease;
LUSC	cis	rs240764	0.717	rs13208757	chr6:101175014	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-5.75	-0.3	2.02e-8	Neuroticism;
LUSC	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-5.85	-0.3	1.16e-8	IgG glycosylation;
LUSC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.8	-0.51	1.61e-23	Alzheimer's disease (late onset);
LUSC	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg07701084	chr6:150067640	NUP43	0.53	7.99	0.4	2.25e-14	Lung cancer;
LUSC	cis	rs1775715	0.737	rs55859032	chr10:32213239	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.66	0.34	1.16e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg00071950	chr4:10020882	SLC2A9	0.51	8.56	0.42	4.33e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg20090143	chr19:45452003	APOC2	0.34	5.79	0.3	1.6e-8	Blood protein levels;
LUSC	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg08917208	chr2:24149416	ATAD2B	0.87	9.73	0.47	7.07e-20	Lymphocyte counts;
LUSC	cis	rs7937682	0.564	rs7115263	chr11:111379054	C/A	cg09085632	chr11:111637200	PPP2R1B	0.5	6.45	0.33	3.86e-10	Primary sclerosing cholangitis;
LUSC	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg03732007	chr1:2071316	PRKCZ	0.58	10.38	0.49	4.73e-22	Height;
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.54	6.96	0.36	1.86e-11	Renal function-related traits (BUN);
LUSC	cis	rs500891	0.505	rs1145910	chr6:84003056	G/A	cg08257003	chr6:84140564	ME1	0.32	7.75	0.39	1.08e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg27426351	chr10:43362370	NA	0.42	5.82	0.3	1.4e-8	Blood protein levels;
LUSC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg23281280	chr6:28129359	ZNF389	0.49	6.24	0.32	1.34e-9	Parkinson's disease;
LUSC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-19.14	-0.72	1.16e-55	Height;
LUSC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg03354898	chr7:1950403	MAD1L1	-0.32	-6.34	-0.33	7.65e-10	Schizophrenia;
LUSC	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg13072238	chr3:49761600	GMPPB	-0.69	-8.19	-0.41	5.44e-15	Menarche (age at onset);
LUSC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg03289416	chr15:75166202	SCAMP2	0.45	7.01	0.36	1.34e-11	Breast cancer;
LUSC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg24101359	chr6:42928495	GNMT	-0.39	-6.45	-0.33	3.98e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.27	-0.41	3.15e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.39e-8	Aortic root size;
LUSC	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg17173187	chr15:85201210	NMB	0.36	7.08	0.36	8.5e-12	Schizophrenia;
LUSC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg25767906	chr1:53392781	SCP2	0.48	8.69	0.43	1.67e-16	Monocyte count;
LUSC	cis	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.37e-9	Ulcerative colitis;
LUSC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg14773178	chr5:1868261	NA	0.31	5.72	0.3	2.38e-8	Cardiovascular disease risk factors;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10236687	chr16:10626884	EMP2	0.41	6.02	0.31	4.56e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg23711669	chr6:146136114	FBXO30	0.92	18.15	0.7	1.08e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg14343924	chr8:8086146	FLJ10661	0.42	6.08	0.32	3.23e-9	Mood instability;
LUSC	cis	rs6674970	1.000	rs61819219	chr1:151084375	C/G	cg11822372	chr1:151115635	SEMA6C	0.54	8.31	0.41	2.51e-15	Childhood ear infection;
LUSC	cis	rs865483	0.895	rs2680718	chr17:35816451	T/C	cg06716730	chr17:35851459	DUSP14	0.27	6.04	0.31	4.13e-9	Monocyte count;
LUSC	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg08048268	chr3:133502702	NA	-0.41	-7.41	-0.38	1.07e-12	Iron status biomarkers;
LUSC	cis	rs4474465	0.920	rs7944485	chr11:78225261	T/C	cg27205649	chr11:78285834	NARS2	0.51	5.78	0.3	1.67e-8	Alzheimer's disease (survival time);
LUSC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg25258033	chr6:167368657	RNASET2	0.38	5.86	0.31	1.11e-8	Primary biliary cholangitis;
LUSC	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg05714579	chr10:131428358	MGMT	-0.77	-12.41	-0.56	2.36e-29	Response to temozolomide;
LUSC	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg16482183	chr6:26056742	HIST1H1C	0.63	8.97	0.44	2.11e-17	Iron status biomarkers;
LUSC	cis	rs7188861	0.638	rs35342456	chr16:11401503	A/C	cg00044050	chr16:11439710	C16orf75	0.61	6.49	0.33	3.06e-10	HDL cholesterol;
LUSC	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg03929089	chr4:120376271	NA	0.64	5.98	0.31	5.65e-9	Intraocular pressure;
LUSC	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg19508488	chr2:152266495	RIF1	-0.53	-7.74	-0.39	1.23e-13	Lung cancer;
LUSC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg13560548	chr3:10150139	C3orf24	0.54	7.75	0.39	1.09e-13	Alzheimer's disease;
LUSC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg24578937	chr1:2090814	PRKCZ	-0.42	-9.06	-0.44	1.09e-17	Height;
LUSC	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.16	-18.16	-0.7	9.79e-52	Primary sclerosing cholangitis;
LUSC	cis	rs72772090	0.539	rs11741100	chr5:96113245	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.69	-7.09	-0.36	7.99e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg24375607	chr4:120327624	NA	0.76	11.3	0.53	2.72e-25	Corneal astigmatism;
LUSC	cis	rs250677	0.522	rs12523526	chr5:148349107	A/C	cg18129178	chr5:148520854	ABLIM3	0.53	7.16	0.36	5.28e-12	Breast cancer;
LUSC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-7.57	-0.38	3.79e-13	Personality dimensions;
LUSC	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg23711669	chr6:146136114	FBXO30	0.82	14.39	0.62	7.07e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6969780	1.000	rs6976129	chr7:27177746	C/T	cg26364809	chr7:27145159	NA	-0.6	-6.04	-0.31	4.05e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs2219968	0.828	rs12543027	chr8:78887060	T/A	cg00738934	chr8:78996279	NA	-0.39	-6.95	-0.36	1.93e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg12744634	chr1:26560303	CCDC21	0.39	5.84	0.3	1.25e-8	Obesity-related traits;
LUSC	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg24375607	chr4:120327624	NA	0.79	11.56	0.53	3.26e-26	Corneal astigmatism;
LUSC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.77	0.35	5.78e-11	Tonsillectomy;
LUSC	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.46	-7.37	-0.37	1.4e-12	IgG glycosylation;
LUSC	cis	rs243505	0.762	rs734004	chr7:148505460	C/G	cg09806900	chr7:148480153	CUL1	0.57	8.52	0.42	5.55e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2273669	0.667	rs12154092	chr6:109313303	C/T	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs12986413	0.935	rs36065733	chr19:2163771	T/G	cg09261902	chr19:2140048	AP3D1	0.33	6.18	0.32	1.89e-9	Height;
LUSC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	8.62	0.43	2.7e-16	Colorectal cancer;
LUSC	trans	rs6450176	0.587	rs10471884	chr5:53344135	T/C	cg12559925	chr2:235863365	SH3BP4	0.36	5.94	0.31	7.06e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LUSC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg22709100	chr7:91322751	NA	0.41	6.0	0.31	5.02e-9	Breast cancer;
LUSC	cis	rs6740322	0.895	rs6710656	chr2:43566941	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-7.31	-0.37	1.96e-12	Coronary artery disease;
LUSC	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg20933634	chr6:27740509	NA	0.42	6.12	0.32	2.63e-9	Parkinson's disease;
LUSC	trans	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.81e-10	Life satisfaction;
LUSC	cis	rs4363385	0.747	rs6684188	chr1:152974285	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.78	-0.39	9.11e-14	Inflammatory skin disease;
LUSC	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg05738196	chr6:26577821	NA	-0.8	-15.45	-0.65	5.25e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14893161	chr1:205819251	PM20D1	0.85	15.4	0.64	8.18e-41	Menarche (age at onset);
LUSC	cis	rs9648716	0.515	rs62485391	chr7:140666718	C/T	cg23214464	chr7:140373596	ADCK2	0.72	6.05	0.31	3.88e-9	Type 2 diabetes;
LUSC	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg24375607	chr4:120327624	NA	0.69	10.99	0.52	3.39e-24	Corneal astigmatism;
LUSC	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.06	0.36	9.49e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6012953	1.000	rs6020559	chr20:49118631	A/G	cg13958625	chr20:49123093	NA	0.31	6.57	0.34	1.88e-10	Vitiligo;
LUSC	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg05347473	chr6:146136440	FBXO30	-0.5	-8.48	-0.42	7.57e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg00031303	chr3:195681400	NA	0.69	9.92	0.48	1.72e-20	Pancreatic cancer;
LUSC	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg26395211	chr5:140044315	WDR55	-0.38	-5.85	-0.3	1.15e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.39	-6.05	-0.31	3.89e-9	Platelet count;
LUSC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg09323728	chr8:95962352	TP53INP1	-0.41	-8.55	-0.42	4.44e-16	Type 2 diabetes;
LUSC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.56	-9.23	-0.45	3.27e-18	Breast cancer;
LUSC	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg03563238	chr19:33554763	RHPN2	-0.41	-6.45	-0.33	3.91e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg12810548	chr4:53579237	SNORA26;KIAA0114	-0.5	-6.31	-0.33	8.92e-10	Height;
LUSC	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.85	0.51	1.05e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg04871131	chr7:94954202	PON1	-0.38	-6.07	-0.32	3.44e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs68170813	0.652	rs74374590	chr7:107172470	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.45	-5.65	-0.3	3.52e-8	Coronary artery disease;
LUSC	cis	rs3956705	0.762	rs13437980	chr7:32997749	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.47	6.7	0.34	8.79e-11	Red cell distribution width;
LUSC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg00933542	chr6:150070202	PCMT1	0.33	6.82	0.35	4.37e-11	Lung cancer;
LUSC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.76	12.14	0.55	2.44e-28	Coronary artery disease;
LUSC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg24562669	chr7:97807699	LMTK2	0.35	6.22	0.32	1.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg13010199	chr12:38710504	ALG10B	0.54	8.29	0.41	2.88e-15	Morning vs. evening chronotype;
LUSC	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg23173402	chr1:227635558	NA	0.69	7.51	0.38	5.36e-13	Major depressive disorder;
LUSC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg06238570	chr21:40685208	BRWD1	-0.58	-9.12	-0.45	7.27e-18	Menarche (age at onset);
LUSC	cis	rs3741151	0.892	rs7105705	chr11:73012319	T/G	cg17517138	chr11:73019481	ARHGEF17	0.92	8.39	0.42	1.44e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.38	6.6	0.34	1.62e-10	Obesity-related traits;
LUSC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.73	0.57	1.51e-30	Prudent dietary pattern;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg02597269	chr16:77225049	MON1B	0.42	6.51	0.34	2.81e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.79	0.57	9.24e-31	Prudent dietary pattern;
LUSC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	0.64	13.71	0.6	2.91e-34	Prudent dietary pattern;
LUSC	cis	rs710216	0.917	rs900834	chr1:43412343	A/G	cg22176566	chr1:43424700	SLC2A1	-0.48	-6.08	-0.32	3.34e-9	Red cell distribution width;
LUSC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg03146154	chr1:46216737	IPP	-0.58	-8.47	-0.42	7.7e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12220238	1.000	rs7076721	chr10:75996682	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.08	0.36	8.3e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg18110333	chr6:292329	DUSP22	-0.5	-7.15	-0.36	5.62e-12	Menopause (age at onset);
LUSC	trans	rs6030	0.957	rs4656687	chr1:169505158	T/C	cg25052156	chr10:123355454	FGFR2	0.32	5.94	0.31	6.99e-9	Uric acid levels;
LUSC	trans	rs1347297	0.526	rs890579	chr2:179263287	C/T	cg14011486	chr1:26737247	LIN28	0.38	6.05	0.31	3.79e-9	Alzheimer disease and age of onset;
LUSC	cis	rs6977940	0.730	rs56296737	chr7:2889250	C/T	cg19731401	chr7:2775893	GNA12	0.7	7.58	0.38	3.54e-13	White matter integrity;
LUSC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08677398	chr8:58056175	NA	0.52	7.02	0.36	1.23e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs977987	0.806	rs8054769	chr16:75401113	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.33	0.45	1.48e-18	Dupuytren's disease;
LUSC	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.42	0.38	9.9e-13	Blood metabolite levels;
LUSC	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg16989719	chr2:238392110	NA	-0.48	-6.07	-0.32	3.56e-9	Prostate cancer;
LUSC	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg22676075	chr6:135203613	NA	0.48	7.48	0.38	6.5e-13	Red blood cell count;
LUSC	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg01448562	chr3:133502909	NA	-0.65	-10.47	-0.5	2.34e-22	Iron status biomarkers;
LUSC	cis	rs2294693	0.687	rs4714424	chr6:41012506	T/C	cg14769373	chr6:40998127	UNC5CL	-0.44	-6.15	-0.32	2.19e-9	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg02951883	chr7:2050386	MAD1L1	-0.52	-9.08	-0.44	9.9e-18	Schizophrenia;
LUSC	cis	rs55883249	1.000	rs55883249	chr2:9741535	C/A	cg23886495	chr2:9695866	ADAM17	0.49	5.7	0.3	2.67e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	0.99	19.44	0.73	7.79e-57	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg11871910	chr12:69753446	YEATS4	0.48	6.41	0.33	4.93e-10	Response to diuretic therapy;
LUSC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg23630131	chr7:65973040	NA	-0.21	-6.0	-0.31	5.21e-9	Aortic root size;
LUSC	cis	rs10979	0.571	rs6909701	chr6:143922918	C/G	cg25407410	chr6:143891975	LOC285740	-0.57	-6.87	-0.35	3.17e-11	Hypospadias;
LUSC	cis	rs7246967	0.611	rs73030508	chr19:22826032	T/C	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs4700695	0.719	rs27080	chr5:65442271	A/G	cg21114390	chr5:65439923	SFRS12	-0.63	-9.02	-0.44	1.47e-17	Facial morphology (factor 19);
LUSC	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg04369109	chr6:150039330	LATS1	-0.4	-5.78	-0.3	1.67e-8	Testicular germ cell tumor;
LUSC	cis	rs2190422	0.651	rs1004245	chr7:103088409	A/C	cg04218035	chr7:103086829	SLC26A5	0.31	6.08	0.32	3.21e-9	Morning vs. evening chronotype;
LUSC	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg02493740	chr2:85810744	VAMP5	-0.31	-5.68	-0.3	2.94e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs17767294	0.708	rs6908688	chr6:27886051	A/G	cg08851530	chr6:28072375	NA	1.06	6.92	0.35	2.26e-11	Parkinson's disease;
LUSC	cis	rs13385	0.769	rs4913073	chr5:139612854	A/G	cg26211634	chr5:139558579	C5orf32	0.46	7.05	0.36	1.04e-11	Atrial fibrillation;
LUSC	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg20503657	chr10:835505	NA	0.78	9.73	0.47	7.08e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs17014483	1.000	rs17014483	chr4:89667591	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.65	5.85	0.3	1.18e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.76	0.35	5.99e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg15395560	chr15:45543142	SLC28A2	0.33	5.71	0.3	2.54e-8	Uric acid levels;
LUSC	cis	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg05084668	chr3:125655381	ALG1L	-0.75	-11.27	-0.53	3.36e-25	Blood pressure (smoking interaction);
LUSC	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg04117972	chr1:227635322	NA	0.81	8.43	0.42	1.08e-15	Major depressive disorder;
LUSC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.03	-0.44	1.39e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.25	-0.32	1.23e-9	Response to antipsychotic treatment;
LUSC	cis	rs3741151	1.000	rs7129663	chr11:73045129	C/T	cg17517138	chr11:73019481	ARHGEF17	1.14	9.67	0.47	1.15e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg22907277	chr7:1156413	C7orf50	0.71	8.13	0.41	8.21e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg13114125	chr14:105738426	BRF1	-0.9	-15.72	-0.65	4.49e-42	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9648716	0.515	rs62485453	chr7:140681937	G/A	cg23214464	chr7:140373596	ADCK2	0.7	5.92	0.31	7.86e-9	Type 2 diabetes;
LUSC	cis	rs4423214	0.592	rs10898234	chr11:71236684	A/G	cg05163923	chr11:71159392	DHCR7	-0.65	-6.57	-0.34	1.95e-10	Vitamin D levels;
LUSC	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-7.12	-0.36	6.8e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6977660	0.714	rs4721827	chr7:19825655	A/G	cg07541023	chr7:19748670	TWISTNB	0.6	6.3	0.33	9.45e-10	Thyroid stimulating hormone;
LUSC	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.95	-0.55	1.25e-27	Mean corpuscular volume;
LUSC	cis	rs7605827	0.930	rs7587257	chr2:15513256	A/G	cg19274914	chr2:15703543	NA	0.45	8.78	0.43	8.83e-17	Educational attainment (years of education);
LUSC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00166722	chr3:10149974	C3orf24	0.62	8.47	0.42	8.07e-16	Alzheimer's disease;
LUSC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.07	20.54	0.75	3.36e-61	Cognitive ability;
LUSC	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg10434728	chr15:90938212	IQGAP1	0.43	8.72	0.43	1.3e-16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg02269571	chr22:50332266	NA	-0.57	-8.69	-0.43	1.68e-16	Schizophrenia;
LUSC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg27494647	chr7:150038898	RARRES2	0.52	7.89	0.4	4.43e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9341808	0.700	rs12215236	chr6:80975058	A/T	cg08355045	chr6:80787529	NA	0.56	9.76	0.47	5.61e-20	Sitting height ratio;
LUSC	cis	rs62400317	0.762	rs17423748	chr6:44943982	T/C	cg18551225	chr6:44695536	NA	-0.45	-7.27	-0.37	2.53e-12	Total body bone mineral density;
LUSC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-10.2	-0.49	1.9e-21	Chronic sinus infection;
LUSC	cis	rs9487051	0.738	rs449850	chr6:109525045	A/G	cg01475377	chr6:109611718	NA	-0.35	-5.9	-0.31	9.15e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs12791968	0.527	rs12285862	chr11:45014326	T/G	cg11846598	chr11:44996168	LOC221122	-0.58	-6.86	-0.35	3.35e-11	Inhibitory control;
LUSC	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg21521518	chr4:53727714	RASL11B	0.46	6.1	0.32	2.99e-9	Optic nerve measurement (cup area);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21131493	chr3:12923969	NA	0.42	6.15	0.32	2.18e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6545883	0.783	rs7579651	chr2:61800279	C/G	cg15711740	chr2:61764176	XPO1	-0.47	-7.54	-0.38	4.35e-13	Tuberculosis;
LUSC	cis	rs2063714	0.658	rs12196864	chr6:157212862	C/T	cg23222435	chr6:157204239	ARID1B	-0.56	-9.02	-0.44	1.56e-17	Sitting height ratio;
LUSC	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.38	-0.33	5.75e-10	Retinal vascular caliber;
LUSC	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg20701182	chr2:24300061	SF3B14	0.55	5.83	0.3	1.32e-8	Lymphocyte counts;
LUSC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg20203395	chr5:56204925	C5orf35	-0.78	-10.4	-0.49	4.07e-22	Initial pursuit acceleration;
LUSC	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02176678	chr2:219576539	TTLL4	-0.75	-14.57	-0.62	1.41e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs17767294	0.708	rs72848755	chr6:27878553	T/C	cg08851530	chr6:28072375	NA	1.31	8.29	0.41	2.8e-15	Parkinson's disease;
LUSC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg11247378	chr22:39784982	NA	0.63	12.48	0.56	1.37e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.28	-0.32	1.06e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.72e-12	Type 2 diabetes;
LUSC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg11235426	chr6:292522	DUSP22	-0.46	-6.9	-0.35	2.64e-11	Menopause (age at onset);
LUSC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg11843238	chr5:131593191	PDLIM4	0.42	7.04	0.36	1.09e-11	Breast cancer;
LUSC	cis	rs2227564	0.700	rs12413039	chr10:75524759	C/G	cg23231163	chr10:75533350	FUT11	0.49	6.85	0.35	3.64e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18932078	chr1:2524107	MMEL1	-0.32	-7.13	-0.36	6.29e-12	Ulcerative colitis;
LUSC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.51	-8.73	-0.43	1.28e-16	Prudent dietary pattern;
LUSC	cis	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg17187183	chr4:55093834	PDGFRA	0.39	5.87	0.31	1.06e-8	Corneal astigmatism;
LUSC	cis	rs713477	0.967	rs6573028	chr14:55913397	C/T	cg13175173	chr14:55914753	NA	-0.3	-6.41	-0.33	4.98e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg05585544	chr11:47624801	NA	0.41	7.02	0.36	1.24e-11	Subjective well-being;
LUSC	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-9.42	-0.46	7.94e-19	Platelet distribution width;
LUSC	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg05585544	chr11:47624801	NA	0.4	7.02	0.36	1.27e-11	Subjective well-being;
LUSC	trans	rs9409565	0.717	rs61470662	chr9:97189472	T/C	cg05679027	chr9:99775184	HIATL2	-0.49	-7.07	-0.36	9.26e-12	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs12900413	0.687	rs11629590	chr15:90304644	A/G	cg24249390	chr15:90295951	MESP1	0.38	6.04	0.31	4.19e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs9467773	0.595	rs2237236	chr6:26451553	A/G	cg09904177	chr6:26538194	HMGN4	-0.59	-8.96	-0.44	2.27e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg08847533	chr14:75593920	NEK9	-0.49	-7.16	-0.36	5.32e-12	Caffeine consumption;
LUSC	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg24881330	chr22:46731750	TRMU	0.91	7.03	0.36	1.15e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.6	9.73	0.47	7.17e-20	Aortic root size;
LUSC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg21918786	chr6:109611834	NA	-0.38	-6.46	-0.33	3.69e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg02696742	chr7:106810147	HBP1	-0.62	-9.36	-0.46	1.19e-18	Coronary artery disease;
LUSC	cis	rs7528684	0.546	rs11264794	chr1:157647789	A/C	cg18268488	chr1:157545234	FCRL4	-0.29	-5.68	-0.3	2.87e-8	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
LUSC	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg11693508	chr17:37793320	STARD3	0.7	7.89	0.4	4.28e-14	Bipolar disorder;
LUSC	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg00579484	chr14:23475993	C14orf93	0.39	5.77	0.3	1.85e-8	Cognitive ability (multi-trait analysis);
LUSC	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg13298116	chr11:62369859	EML3;MTA2	-0.52	-7.82	-0.39	6.92e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs2237234	0.542	rs7755997	chr6:26483048	G/A	cg05738196	chr6:26577821	NA	0.55	8.59	0.43	3.46e-16	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4343996	0.558	rs11981092	chr7:3412100	C/T	cg21248987	chr7:3385318	SDK1	0.35	5.9	0.31	8.73e-9	Motion sickness;
LUSC	cis	rs1847202	1.000	rs7634188	chr3:72941289	A/G	cg25664220	chr3:72788482	NA	0.34	6.35	0.33	6.98e-10	Motion sickness;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18625286	chr20:44717989	NCOA5	-0.44	-6.44	-0.33	4.14e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg04450456	chr4:17643702	FAM184B	-0.36	-6.01	-0.31	4.78e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs72960926	0.744	rs55867620	chr6:75038763	G/A	cg03266952	chr6:74778945	NA	-0.81	-6.81	-0.35	4.63e-11	Metabolite levels (MHPG);
LUSC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18099408	chr3:52552593	STAB1	-0.4	-7.14	-0.36	5.82e-12	Bipolar disorder;
LUSC	cis	rs9463078	0.547	rs4449629	chr6:44717808	T/C	cg25276700	chr6:44698697	NA	0.31	6.35	0.33	7.05e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs72627509	0.951	rs6554401	chr4:57825336	C/G	cg26694713	chr4:57773883	REST	0.48	5.72	0.3	2.32e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1152591	0.811	rs1255986	chr14:64655161	A/G	cg21174375	chr14:64681225	SYNE2	-0.31	-5.69	-0.3	2.75e-8	Atrial fibrillation;
LUSC	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg26924012	chr15:45694286	SPATA5L1	1.12	20.32	0.74	2.51e-60	Homoarginine levels;
LUSC	cis	rs617219	0.819	rs1870058	chr5:78593158	C/T	cg24856658	chr5:78533917	JMY	-0.3	-5.84	-0.3	1.22e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25792367	chr7:127291747	SND1	-0.48	-7.3	-0.37	2.06e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.6	0.57	4.81e-30	Motion sickness;
LUSC	cis	rs6840360	0.642	rs7682837	chr4:152427686	C/T	cg20465933	chr4:152376761	FAM160A1	0.33	5.85	0.31	1.15e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg27432699	chr2:27873401	GPN1	-0.55	-8.17	-0.41	6.52e-15	Total body bone mineral density;
LUSC	cis	rs7582720	1.000	rs72934763	chr2:203758396	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.3	-0.49	8.79e-22	Electroencephalogram traits;
LUSC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.57	-9.59	-0.46	2.06e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs6496044	0.963	rs11853972	chr15:86062440	A/G	cg13263323	chr15:86062960	AKAP13	-0.37	-5.79	-0.3	1.58e-8	Interstitial lung disease;
LUSC	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.73	-12.85	-0.58	5.45e-31	White blood cell count (basophil);
LUSC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg09365446	chr1:150670422	GOLPH3L	0.47	6.94	0.36	2.04e-11	Melanoma;
LUSC	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.66	-10.92	-0.51	6.22e-24	Type 2 diabetes;
LUSC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-7.49	-0.38	6.2e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	0.89	17.83	0.7	1.93e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.26	-0.37	2.67e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2108225	1.000	rs2108225	chr7:107453103	G/A	cg18560240	chr7:107437656	SLC26A3	-0.38	-5.84	-0.3	1.22e-8	Ulcerative colitis;
LUSC	cis	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg06360820	chr2:242988706	NA	-0.65	-8.23	-0.41	4.34e-15	Obesity-related traits;
LUSC	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg03733263	chr8:22462867	KIAA1967	0.87	14.82	0.63	1.47e-38	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg22535103	chr8:58192502	C8orf71	-0.75	-9.55	-0.46	2.95e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg04995722	chr7:26192034	NFE2L3	-0.39	-6.38	-0.33	6.03e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs71403859	0.502	rs36122765	chr16:71504183	G/C	cg08717414	chr16:71523259	ZNF19	-0.75	-8.71	-0.43	1.46e-16	Post bronchodilator FEV1;
LUSC	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg04374321	chr14:90722782	PSMC1	-0.69	-10.69	-0.5	3.86e-23	Mortality in heart failure;
LUSC	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg19183879	chr15:85880815	NA	-0.28	-6.65	-0.34	1.17e-10	Central corneal thickness;Corneal structure;
LUSC	cis	rs1784581	0.588	rs9346893	chr6:162417511	C/G	cg17173639	chr6:162384350	PARK2	0.56	9.89	0.48	2.07e-20	Itch intensity from mosquito bite;
LUSC	trans	rs7737355	0.947	rs6879005	chr5:130615445	C/T	cg07715041	chr7:99302981	CYP3A7	-0.39	-6.14	-0.32	2.3e-9	Life satisfaction;
LUSC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg20887711	chr4:1340912	KIAA1530	0.43	6.37	0.33	6.12e-10	Obesity-related traits;
LUSC	trans	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg13010199	chr12:38710504	ALG10B	0.4	6.33	0.33	7.75e-10	Morning vs. evening chronotype;
LUSC	trans	rs8002861	0.664	rs4942247	chr13:44405107	A/G	cg12856521	chr11:46389249	DGKZ	0.43	6.33	0.33	7.82e-10	Leprosy;
LUSC	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.62	-0.43	2.78e-16	Total cholesterol levels;
LUSC	cis	rs4481887	0.800	rs28680862	chr1:248515419	T/C	cg26353448	chr1:248524236	OR2T4	-0.32	-6.01	-0.31	4.91e-9	Common traits (Other);
LUSC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg14552801	chr7:65878734	NA	0.38	5.84	0.3	1.25e-8	Aortic root size;
LUSC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.12e-18	Menopause (age at onset);
LUSC	trans	rs7567288	0.636	rs4440017	chr2:134465710	T/C	cg12381416	chr3:14359266	NA	0.53	5.99	0.31	5.3e-9	Height;
LUSC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg18758796	chr5:131593413	PDLIM4	0.34	5.78	0.3	1.75e-8	Lung function (FEV1/FVC);
LUSC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg07507251	chr3:52567010	NT5DC2	0.33	6.39	0.33	5.47e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4919694	0.611	rs76695159	chr10:105070837	C/T	cg04362960	chr10:104952993	NT5C2	1.04	10.76	0.51	2.18e-23	Arsenic metabolism;
LUSC	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.59	-8.55	-0.42	4.56e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7640424	0.819	rs162070	chr3:107835448	G/A	cg09227934	chr3:107805635	CD47	0.43	6.68	0.34	1.01e-10	Body mass index;
LUSC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg26513180	chr16:89883248	FANCA	-0.84	-14.39	-0.62	7.55e-37	Vitiligo;
LUSC	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs17095355	1.000	rs921351	chr10:111704715	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.79	-0.39	8.71e-14	Biliary atresia;
LUSC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	8.96	0.44	2.3e-17	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9650315	0.866	rs7815925	chr8:57200382	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.28	0.37	2.42e-12	Height;
LUSC	cis	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg21775007	chr8:11205619	TDH	-0.5	-7.53	-0.38	4.88e-13	Systolic blood pressure;
LUSC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-8.35	-0.42	1.82e-15	Chronic sinus infection;
LUSC	cis	rs970548	0.688	rs2082109	chr10:45931102	T/C	cg15590007	chr10:45870220	ALOX5	0.55	6.29	0.33	1.01e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs3764563	1.000	rs1022413	chr19:15741984	G/A	cg20725493	chr19:15740067	CYP4F8	-0.64	-6.62	-0.34	1.44e-10	Inflammatory biomarkers;
LUSC	cis	rs4776059	0.798	rs4390542	chr15:52937960	T/C	cg24008177	chr15:52972085	KIAA1370	0.36	6.53	0.34	2.42e-10	Schizophrenia;
LUSC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	7.34	0.37	1.67e-12	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7084921	0.552	rs12780023	chr10:101874829	C/T	cg02250046	chr10:101825185	CPN1	-0.31	-5.85	-0.3	1.16e-8	Bone mineral density;
LUSC	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.45	-0.38	8.08e-13	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-15.15	-0.64	8.22e-40	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg27094323	chr7:1216898	NA	-0.34	-5.8	-0.3	1.5e-8	Longevity;Endometriosis;
LUSC	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg05621596	chr22:47072043	GRAMD4	-0.54	-8.59	-0.43	3.48e-16	Urate levels in obese individuals;
LUSC	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg06636001	chr8:8085503	FLJ10661	0.58	8.98	0.44	1.96e-17	Joint mobility (Beighton score);
LUSC	cis	rs7503807	0.905	rs62068345	chr17:78608040	C/T	cg09596252	chr17:78655493	RPTOR	0.45	7.68	0.39	1.78e-13	Obesity;
LUSC	trans	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Educational attainment;
LUSC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.06e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3916	0.911	rs3999408	chr12:121167387	C/T	cg27246729	chr12:121163418	ACADS	0.49	7.14	0.36	5.75e-12	Urinary metabolites (H-NMR features);
LUSC	cis	rs2573652	0.963	rs2573649	chr15:100514040	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.41	-7.63	-0.39	2.49e-13	Height;
LUSC	cis	rs35000415	0.938	rs35188261	chr7:128683539	G/A	cg19972273	chr7:128594194	NA	0.67	6.75	0.35	6.46e-11	Systemic lupus erythematosus;
LUSC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg05347473	chr6:146136440	FBXO30	-0.51	-8.74	-0.43	1.19e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3820928	0.874	rs4675137	chr2:227883910	G/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.8	-0.39	7.97e-14	Pulmonary function;
LUSC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg13395646	chr4:1353034	KIAA1530	-0.6	-9.47	-0.46	5.4e-19	Obesity-related traits;
LUSC	cis	rs7000551	0.675	rs2469758	chr8:22363032	C/T	cg12081754	chr8:22256438	SLC39A14	0.41	6.23	0.32	1.39e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-16.89	-0.68	1.11e-46	Monocyte count;
LUSC	cis	rs2224391	0.590	rs2773312	chr6:5251798	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.48	-6.65	-0.34	1.22e-10	Height;
LUSC	cis	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg06521331	chr12:34319734	NA	-0.47	-7.59	-0.38	3.21e-13	Morning vs. evening chronotype;
LUSC	trans	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg21659725	chr3:3221576	CRBN	-0.69	-8.35	-0.42	1.83e-15	Menarche (age at onset);
LUSC	cis	rs710216	0.917	rs1681859	chr1:43411829	G/A	cg03128534	chr1:43423976	SLC2A1	0.48	6.07	0.32	3.45e-9	Red cell distribution width;
LUSC	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.89	-0.44	3.97e-17	Coffee consumption (cups per day);
LUSC	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	7.84	0.39	6.02e-14	Coffee consumption (cups per day);
LUSC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-5.87	-0.31	1.04e-8	Lung cancer;
LUSC	cis	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg05299278	chr17:33885742	SLFN14	0.3	6.23	0.32	1.38e-9	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg14552801	chr7:65878734	NA	0.44	6.27	0.32	1.12e-9	Aortic root size;
LUSC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00166722	chr3:10149974	C3orf24	0.61	8.61	0.43	2.97e-16	Alzheimer's disease;
LUSC	cis	rs9581857	0.579	rs75326986	chr13:27997758	C/T	cg22138327	chr13:27999177	GTF3A	0.82	9.34	0.46	1.37e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg03060546	chr3:49711283	APEH	0.65	6.99	0.36	1.46e-11	Menarche (age at onset);
LUSC	cis	rs56399783	0.901	rs73049362	chr7:2826822	G/A	cg14895029	chr7:2775587	GNA12	0.51	6.25	0.32	1.22e-9	Childhood ear infection;
LUSC	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg25797454	chr6:150327115	RAET1K	0.34	7.8	0.39	8.08e-14	Alopecia areata;
LUSC	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.07	0.4	1.27e-14	Breast cancer;
LUSC	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	0.72	12.88	0.58	4.37e-31	Gut microbiome composition (winter);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02959429	chr17:27916858	GIT1	-0.42	-6.09	-0.32	3.04e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.68	0.47	1.09e-19	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.74	-0.51	2.58e-23	Alzheimer's disease (late onset);
LUSC	cis	rs12681288	0.676	rs6559208	chr8:1018833	A/G	cg15309053	chr8:964076	NA	0.39	7.88	0.4	4.68e-14	Schizophrenia;
LUSC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg14095795	chr11:129122128	NA	-0.31	-5.98	-0.31	5.81e-9	Breast cancer;
LUSC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg06494592	chr3:125709126	NA	-0.53	-6.08	-0.32	3.31e-9	Blood pressure (smoking interaction);
LUSC	cis	rs77633900	0.614	rs2459363	chr15:76874952	T/C	cg21673338	chr15:77095150	SCAPER	-0.71	-6.94	-0.36	2.05e-11	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg13902645	chr11:5959945	NA	-0.63	-8.73	-0.43	1.2e-16	DNA methylation (variation);
LUSC	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.85	13.98	0.61	2.76e-35	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg16447950	chr5:562315	NA	-0.59	-7.08	-0.36	8.54e-12	Lung disease severity in cystic fibrosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26335527	chr1:155100185	EFNA1	-0.4	-6.05	-0.31	3.89e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg20608306	chr11:116969690	SIK3	0.36	6.72	0.35	7.92e-11	Blood protein levels;
LUSC	trans	rs9944715	0.906	rs7241829	chr18:43737111	G/C	cg01718231	chr17:29326311	RNF135	0.47	6.49	0.33	3.06e-10	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25525087	chr17:17743565	NA	-0.4	-6.34	-0.33	7.47e-10	Electrocardiographic conduction measures;
LUSC	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg09826364	chr7:158789723	NA	-0.4	-6.2	-0.32	1.69e-9	Facial morphology (factor 20);
LUSC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg09699651	chr6:150184138	LRP11	0.38	5.75	0.3	2.06e-8	Lung cancer;
LUSC	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg13206674	chr6:150067644	NUP43	0.43	6.44	0.33	4.2e-10	Testicular germ cell tumor;
LUSC	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg25124228	chr12:125621409	AACS	-0.48	-7.87	-0.4	4.96e-14	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs877282	1.000	rs11253370	chr10:773712	G/A	cg17470449	chr10:769945	NA	0.49	6.88	0.35	2.93e-11	Uric acid levels;
LUSC	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg08601574	chr20:25228251	PYGB	0.41	6.1	0.32	3e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs79149102	0.579	rs7172065	chr15:75321910	C/T	cg17294928	chr15:75287854	SCAMP5	-0.77	-6.46	-0.33	3.62e-10	Lung cancer;
LUSC	cis	rs113835537	0.935	rs57043177	chr11:66423147	A/G	cg24851651	chr11:66362959	CCS	0.53	6.54	0.34	2.38e-10	Airway imaging phenotypes;
LUSC	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg13902645	chr11:5959945	NA	-0.52	-7.72	-0.39	1.34e-13	DNA methylation (variation);
LUSC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg20573242	chr4:122745356	CCNA2	0.65	9.5	0.46	4.14e-19	Type 2 diabetes;
LUSC	cis	rs12815613	0.621	rs11065360	chr12:121386532	A/G	cg02403541	chr12:121454288	C12orf43	-0.44	-6.19	-0.32	1.73e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs72960926	1.000	rs72950596	chr6:74921364	C/T	cg03266952	chr6:74778945	NA	-0.78	-6.04	-0.31	4.11e-9	Metabolite levels (MHPG);
LUSC	cis	rs4499344	0.960	rs17833075	chr19:33075134	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.59	-7.74	-0.39	1.15e-13	Mean platelet volume;
LUSC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03264133	chr6:25882463	NA	-0.51	-9.43	-0.46	7.02e-19	Blood metabolite levels;
LUSC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	0.64	13.45	0.59	3.06e-33	Prudent dietary pattern;
LUSC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	trans	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg21659725	chr3:3221576	CRBN	-0.49	-7.42	-0.38	9.7e-13	Menarche (age at onset);
LUSC	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg19683494	chr5:74908142	NA	0.56	7.65	0.39	2.21e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.8	0.35	4.77e-11	Tonsillectomy;
LUSC	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg07741184	chr6:167504864	NA	-0.33	-5.8	-0.3	1.57e-8	Primary biliary cholangitis;
LUSC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.63	-10.78	-0.51	1.91e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11608355	0.515	rs61941591	chr12:109919965	A/C	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs41271473	0.607	rs6692032	chr1:228853984	G/C	cg10167378	chr1:228756711	NA	0.48	6.72	0.35	7.79e-11	Chronic lymphocytic leukemia;
LUSC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg09165964	chr15:75287851	SCAMP5	-1.01	-15.09	-0.64	1.37e-39	Blood trace element (Zn levels);
LUSC	cis	rs617219	0.889	rs12519500	chr5:78436905	C/A	cg24856658	chr5:78533917	JMY	-0.31	-5.7	-0.3	2.69e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.4	-0.38	1.08e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg25214090	chr10:38739885	LOC399744	0.43	6.53	0.34	2.42e-10	Corneal astigmatism;
LUSC	cis	rs7674212	0.556	rs13151569	chr4:103942790	A/G	cg16532752	chr4:104119610	CENPE	-0.43	-5.87	-0.31	1.04e-8	Type 2 diabetes;
LUSC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.51	-0.34	2.83e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg19628046	chr18:33552617	C18orf21	0.51	6.17	0.32	1.97e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg09455208	chr3:40491958	NA	0.52	9.33	0.45	1.48e-18	Renal cell carcinoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20807030	chr8:67525572	MYBL1	-0.43	-6.23	-0.32	1.37e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg01657329	chr11:68192670	LRP5	0.47	6.21	0.32	1.53e-9	Bone mineral density (spine);
LUSC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.8	14.57	0.62	1.48e-37	Longevity;
LUSC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg12564285	chr5:131593104	PDLIM4	-0.48	-8.27	-0.41	3.22e-15	Blood metabolite levels;
LUSC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	0.93	17.45	0.69	6.12e-49	Heart rate;
LUSC	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg05110241	chr16:68378359	PRMT7	-0.6	-6.65	-0.34	1.19e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg26924012	chr15:45694286	SPATA5L1	1.13	20.81	0.75	2.85e-62	Homoarginine levels;
LUSC	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg15557168	chr22:42548783	NA	0.35	5.87	0.31	1.03e-8	Cognitive function;
LUSC	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg24069376	chr3:38537580	EXOG	0.36	6.35	0.33	6.89e-10	Electrocardiographic conduction measures;
LUSC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-10.86	-0.51	9.54e-24	Schizophrenia;
LUSC	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.61	-8.99	-0.44	1.84e-17	Dilated cardiomyopathy;
LUSC	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg01294253	chr9:136912663	BRD3	0.34	5.76	0.3	1.9e-8	Platelet distribution width;
LUSC	cis	rs9398803	0.965	rs9491624	chr6:126679106	A/T	cg19875578	chr6:126661172	C6orf173	0.41	6.1	0.32	2.95e-9	Male-pattern baldness;
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.28	-5.69	-0.3	2.78e-8	Longevity;Endometriosis;
LUSC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.03	-0.36	1.15e-11	Total body bone mineral density;
LUSC	cis	rs2067615	0.599	rs12369214	chr12:107198611	G/A	cg19260189	chr12:106995001	RFX4	0.22	5.68	0.3	2.89e-8	Heart rate;
LUSC	cis	rs9894429	0.527	rs7405469	chr17:79566596	G/C	cg21984481	chr17:79567631	NPLOC4	0.36	5.7	0.3	2.64e-8	Eye color traits;
LUSC	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg25206134	chr2:45395956	NA	0.62	7.23	0.37	3.24e-12	Bipolar disorder;
LUSC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg12560992	chr17:57184187	TRIM37	0.5	7.58	0.38	3.48e-13	Cognitive test performance;
LUSC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg18230493	chr5:56204884	C5orf35	-0.8	-12.34	-0.56	4.25e-29	Initial pursuit acceleration;
LUSC	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	1.1	16.8	0.68	2.48e-46	Primary sclerosing cholangitis;
LUSC	cis	rs9420	0.961	rs11604333	chr11:57467035	C/G	cg02958346	chr11:57425731	CLP1	-0.44	-6.45	-0.33	4.02e-10	Schizophrenia;
LUSC	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg06191203	chr2:152266755	RIF1	-0.56	-7.07	-0.36	9.05e-12	Lung cancer;
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg12432903	chr7:1882776	MAD1L1	-0.41	-6.69	-0.34	9.34e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6977660	1.000	rs5017193	chr7:19820103	G/A	cg07541023	chr7:19748670	TWISTNB	0.5	5.69	0.3	2.79e-8	Thyroid stimulating hormone;
LUSC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg04176532	chr22:50317003	CRELD2	-0.39	-5.66	-0.3	3.3e-8	Schizophrenia;
LUSC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg19318889	chr4:1322082	MAEA	0.43	7.0	0.36	1.39e-11	Obesity-related traits;
LUSC	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg19875535	chr5:140030758	IK	-0.49	-7.99	-0.4	2.19e-14	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9921338	0.961	rs9936328	chr16:11438221	T/A	cg00044050	chr16:11439710	C16orf75	-0.51	-6.87	-0.35	3.19e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs2559856	1.000	rs2695296	chr12:102085487	T/C	cg12924262	chr12:102091054	CHPT1	0.43	5.99	0.31	5.47e-9	Blood protein levels;
LUSC	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg14830002	chr1:247616686	OR2B11	0.49	7.05	0.36	1.05e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3772130	0.962	rs6791046	chr3:121394707	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.67	9.75	0.47	6.41e-20	Cognitive performance;
LUSC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg06096015	chr1:231504339	EGLN1	0.56	10.03	0.48	7.06e-21	Hemoglobin concentration;
LUSC	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.99	-0.31	5.52e-9	Retinal vascular caliber;
LUSC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.79	0.63	2.05e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	11.44	0.53	8.24e-26	Coronary artery disease;
LUSC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg00316803	chr15:76480434	C15orf27	-0.4	-6.96	-0.36	1.83e-11	Blood metabolite levels;
LUSC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	9.04	0.44	1.27e-17	Prudent dietary pattern;
LUSC	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.35	-0.33	7.16e-10	Arsenic metabolism;
LUSC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.0	-0.36	1.44e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	13.04	0.58	1.06e-31	Hip circumference adjusted for BMI;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24739457	chr1:205821442	NA	0.42	7.46	0.38	7.38e-13	Menarche (age at onset);
LUSC	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg18806716	chr10:30721971	MAP3K8	0.73	11.61	0.54	2.07e-26	Inflammatory bowel disease;
LUSC	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.37	1.18e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg21775007	chr8:11205619	TDH	0.44	6.14	0.32	2.29e-9	Neuroticism;
LUSC	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg16230307	chr14:35515116	FAM177A1	0.78	9.88	0.48	2.39e-20	Psoriasis;
LUSC	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg17470723	chr8:74884337	TCEB1	0.52	7.92	0.4	3.66e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.68	0.43	1.76e-16	Prudent dietary pattern;
LUSC	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.95	-0.4	2.91e-14	Chronic sinus infection;
LUSC	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg09238746	chr17:78121135	EIF4A3	-0.64	-10.05	-0.48	6.22e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg21280719	chr6:42927975	GNMT	-0.31	-7.84	-0.39	6.14e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs10221833	0.602	rs355885	chr2:165633939	G/A	cg26993132	chr16:89239499	CDH15	0.31	5.97	0.31	6.09e-9	Response to statin therapy;
LUSC	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.79	11.8	0.54	4.37e-27	Corneal astigmatism;
LUSC	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.2	-0.37	3.99e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4595586	0.679	rs11169992	chr12:39317207	C/T	cg26384229	chr12:38710491	ALG10B	0.44	6.1	0.32	2.87e-9	Morning vs. evening chronotype;
LUSC	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg00277334	chr10:82204260	NA	-0.53	-7.33	-0.37	1.73e-12	Post bronchodilator FEV1;
LUSC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg20302342	chr1:156215951	PAQR6	0.32	6.09	0.32	3.11e-9	Tonsillectomy;
LUSC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg05347473	chr6:146136440	FBXO30	0.44	7.57	0.38	3.75e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-6.39	-0.33	5.61e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11567041	chr10:12391824	CAMK1D	0.43	6.26	0.32	1.18e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.62	-7.89	-0.4	4.43e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg17173187	chr15:85201210	NMB	0.4	8.0	0.4	2.09e-14	Schizophrenia;
LUSC	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg02696742	chr7:106810147	HBP1	-0.63	-9.25	-0.45	2.77e-18	Coronary artery disease;
LUSC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg22907277	chr7:1156413	C7orf50	0.65	7.3	0.37	2.17e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg10483660	chr13:112241077	NA	-0.31	-5.68	-0.3	2.99e-8	Hepatitis;
LUSC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg07741184	chr6:167504864	NA	0.39	6.88	0.35	2.9e-11	Primary biliary cholangitis;
LUSC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg20573242	chr4:122745356	CCNA2	0.43	6.65	0.34	1.19e-10	Type 2 diabetes;
LUSC	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.93	-0.35	2.18e-11	Response to antipsychotic treatment;
LUSC	cis	rs1865721	0.958	rs57073257	chr18:73172316	A/G	cg26385618	chr18:73139727	C18orf62	-0.47	-7.85	-0.39	5.88e-14	Intelligence;
LUSC	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg00677455	chr12:58241039	CTDSP2	0.69	10.46	0.5	2.41e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-14.75	-0.63	2.96e-38	Gut microbiome composition (summer);
LUSC	cis	rs9905704	0.918	rs444393	chr17:56709222	A/G	cg12560992	chr17:57184187	TRIM37	0.55	7.78	0.39	9.1e-14	Testicular germ cell tumor;
LUSC	trans	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg26384229	chr12:38710491	ALG10B	0.55	8.76	0.43	1e-16	Morning vs. evening chronotype;
LUSC	cis	rs250677	0.522	rs6872701	chr5:148359086	C/G	cg18129178	chr5:148520854	ABLIM3	0.52	7.36	0.37	1.41e-12	Breast cancer;
LUSC	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-7.35	-0.37	1.5e-12	Axial length;
LUSC	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg02574844	chr11:5959923	NA	-0.45	-6.36	-0.33	6.66e-10	DNA methylation (variation);
LUSC	cis	rs3829109	0.564	rs11145910	chr9:139300494	A/G	cg14169450	chr9:139327907	INPP5E	0.42	6.22	0.32	1.46e-9	Peak insulin response;Acute insulin response;
LUSC	cis	rs5753037	0.774	rs140118	chr22:30135806	G/A	cg11564601	chr22:30592435	NA	0.34	6.06	0.31	3.61e-9	Type 1 diabetes;
LUSC	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg27432699	chr2:27873401	GPN1	-0.89	-17.87	-0.7	1.36e-50	Oral cavity cancer;
LUSC	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06544989	chr22:39130855	UNC84B	0.34	5.71	0.3	2.53e-8	Menopause (age at onset);
LUSC	cis	rs3857536	0.813	rs7768944	chr6:66951088	C/T	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.14e-35	Breast cancer;
LUSC	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg19418458	chr7:158789849	NA	-0.63	-10.4	-0.49	3.97e-22	Facial morphology (factor 20);
LUSC	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.65	-5.84	-0.3	1.21e-8	Major depressive disorder;
LUSC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg10556349	chr10:835070	NA	0.55	6.01	0.31	4.98e-9	Eosinophil percentage of granulocytes;
LUSC	trans	rs4650994	0.525	rs10913567	chr1:178511941	A/C	cg05059571	chr16:84539110	KIAA1609	-0.45	-8.57	-0.42	3.89e-16	HDL cholesterol levels;HDL cholesterol;
LUSC	trans	rs12510870	0.554	rs4591567	chr4:74208645	G/A	cg01940055	chr4:146018582	ANAPC10;ABCE1	0.39	6.39	0.33	5.46e-10	Iris color (b* coordinate);
LUSC	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg18209359	chr17:80159595	CCDC57	0.37	5.93	0.31	7.71e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6541297	0.645	rs2296065	chr1:230301776	G/A	cg05784532	chr1:230284198	GALNT2	0.57	6.73	0.35	7.55e-11	Coronary artery disease;
LUSC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg06784218	chr1:46089804	CCDC17	0.5	9.66	0.47	1.24e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	1.25	19.74	0.73	4.9e-58	Corneal structure;
LUSC	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg24642844	chr7:1081250	C7orf50	-0.69	-6.56	-0.34	2.02e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	0.95	17.57	0.69	2.05e-49	Headache;
LUSC	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg23260525	chr10:116636907	FAM160B1	0.4	8.18	0.41	5.96e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.56	-8.5	-0.42	6.33e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.8	0.35	4.94e-11	Corneal astigmatism;
LUSC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg23172400	chr8:95962367	TP53INP1	-0.41	-8.19	-0.41	5.55e-15	Type 2 diabetes;
LUSC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.53	-0.57	8.8e-30	Chronic sinus infection;
LUSC	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg14092571	chr14:90743983	NA	-0.89	-18.73	-0.72	5.11e-54	Gut microbiota (bacterial taxa);
LUSC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg03388025	chr16:89894329	SPIRE2	0.31	6.5	0.34	2.89e-10	Vitiligo;
LUSC	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg20608306	chr11:116969690	SIK3	0.37	6.91	0.35	2.5e-11	Blood protein levels;
LUSC	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.41	5.97	0.31	5.96e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg01657329	chr11:68192670	LRP5	-0.4	-5.77	-0.3	1.85e-8	Total body bone mineral density;
LUSC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg02951883	chr7:2050386	MAD1L1	0.62	12.22	0.56	1.18e-28	Bipolar disorder and schizophrenia;
LUSC	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg12927641	chr6:109611667	NA	-0.36	-6.12	-0.32	2.56e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg04450456	chr4:17643702	FAM184B	0.35	5.87	0.31	1.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1507153	0.549	rs699182	chr6:79327328	T/G	cg05283184	chr6:79620031	NA	0.39	7.08	0.36	8.31e-12	Sjögren's syndrome;
LUSC	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg13010199	chr12:38710504	ALG10B	-0.62	-9.61	-0.47	1.87e-19	Morning vs. evening chronotype;
LUSC	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg15848620	chr12:58087721	OS9	-0.55	-7.87	-0.4	4.88e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg04990556	chr1:26633338	UBXN11	0.86	11.39	0.53	1.3e-25	Obesity-related traits;
LUSC	cis	rs2304069	0.614	rs216140	chr5:149443298	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.39	5.71	0.3	2.56e-8	HIV-1 control;
LUSC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg21770322	chr7:97807741	LMTK2	0.39	6.76	0.35	6.01e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4692589	0.581	rs12646523	chr4:170944698	C/T	cg19918862	chr4:170955249	NA	0.38	6.99	0.36	1.54e-11	Anxiety disorder;
LUSC	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.53	-7.21	-0.37	3.73e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Parkinson's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01182386	chr15:75182373	MPI	-0.51	-6.73	-0.35	7.48e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs977987	0.778	rs1109341	chr16:75445605	G/A	cg04384234	chr16:75411784	CFDP1	-0.41	-6.53	-0.34	2.45e-10	Dupuytren's disease;
LUSC	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg08213375	chr14:104286397	PPP1R13B	0.38	6.31	0.33	9.06e-10	Reticulocyte count;
LUSC	cis	rs8016982	0.662	rs2288498	chr14:81660710	T/C	cg01989461	chr14:81687754	GTF2A1	0.5	6.71	0.34	8.52e-11	Schizophrenia;
LUSC	cis	rs7119	0.717	rs62007350	chr15:77804590	G/A	cg27398640	chr15:77910606	LINGO1	-0.29	-6.18	-0.32	1.89e-9	Type 2 diabetes;
LUSC	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg13010199	chr12:38710504	ALG10B	0.68	10.46	0.5	2.4e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg18352616	chr4:3374830	RGS12	0.31	6.15	0.32	2.19e-9	Serum sulfate level;
LUSC	trans	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.44	-0.33	4.28e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs961253	0.501	rs6054183	chr20:6354161	T/C	cg17788362	chr6:86352627	SYNCRIP	0.43	6.13	0.32	2.5e-9	Colorectal cancer;
LUSC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg08859206	chr1:53392774	SCP2	0.46	7.75	0.39	1.13e-13	Monocyte count;
LUSC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg23711669	chr6:146136114	FBXO30	0.86	16.18	0.66	6.9e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	0.95	19.5	0.73	4.4e-57	Cognitive function;
LUSC	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg03264133	chr6:25882463	NA	-0.34	-5.68	-0.3	2.9e-8	Height;
LUSC	cis	rs6565189	0.865	rs4500746	chr16:30504344	T/C	cg17640201	chr16:30407289	ZNF48	0.44	5.74	0.3	2.15e-8	Tonsillectomy;
LUSC	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg07150166	chr2:30669952	LCLAT1	0.53	6.17	0.32	1.93e-9	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg19875535	chr5:140030758	IK	-0.49	-7.93	-0.4	3.37e-14	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg06238570	chr21:40685208	BRWD1	-0.54	-8.54	-0.42	4.65e-16	Menarche (age at onset);
LUSC	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg26384229	chr12:38710491	ALG10B	0.6	9.14	0.45	6.29e-18	Morning vs. evening chronotype;
LUSC	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg05973401	chr12:123451056	ABCB9	0.52	6.43	0.33	4.36e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7681440	0.669	rs7693616	chr4:90792230	G/T	cg20003494	chr4:90757398	SNCA	0.37	6.23	0.32	1.43e-9	Dementia with Lewy bodies;
LUSC	cis	rs2354432	0.607	rs6685775	chr1:146744294	A/G	cg25205988	chr1:146714368	CHD1L	-1.0	-9.35	-0.46	1.26e-18	Mitochondrial DNA levels;
LUSC	cis	rs75920871	0.588	rs4620758	chr11:116945718	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-6.72	-0.35	7.68e-11	Subjective well-being;
LUSC	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-0.88	-12.89	-0.58	4.05e-31	Asthma;
LUSC	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.85	11.22	0.52	5.05e-25	Mean corpuscular hemoglobin;
LUSC	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.47	-0.38	7.08e-13	Morning vs. evening chronotype;
LUSC	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	0.85	13.38	0.59	5.28e-33	Blood protein levels;
LUSC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg06671706	chr8:8559999	CLDN23	0.5	6.74	0.35	7.09e-11	Obesity-related traits;
LUSC	cis	rs977987	0.931	rs11641430	chr16:75495276	T/C	cg04384234	chr16:75411784	CFDP1	-0.48	-7.83	-0.39	6.46e-14	Dupuytren's disease;
LUSC	cis	rs554111	0.656	rs4654893	chr1:21305596	G/C	cg01072550	chr1:21505969	NA	0.4	6.19	0.32	1.75e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg03036452	chr22:46663545	TTC38	0.59	5.88	0.31	1e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6722750	0.818	rs13411753	chr2:64394417	A/G	cg22352474	chr2:64371530	PELI1	0.64	10.13	0.48	3.31e-21	Neuroticism;
LUSC	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-9.59	-0.46	2.08e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs4595586	0.644	rs10437944	chr12:39308786	A/C	cg26384229	chr12:38710491	ALG10B	0.46	6.25	0.32	1.24e-9	Morning vs. evening chronotype;
LUSC	cis	rs1160297	0.575	rs6725912	chr2:53097030	A/G	cg07782112	chr2:53107842	NA	0.43	7.0	0.36	1.42e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg24503407	chr1:205819492	PM20D1	0.57	9.41	0.46	8.41e-19	Menarche (age at onset);
LUSC	cis	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg18131467	chr2:239335373	ASB1	-0.72	-6.54	-0.34	2.25e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg23172400	chr8:95962367	TP53INP1	-0.39	-8.19	-0.41	5.47e-15	Type 2 diabetes;
LUSC	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg24110177	chr3:50126178	RBM5	0.4	6.45	0.33	3.85e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.74	-13.8	-0.6	1.41e-34	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg13047869	chr3:10149882	C3orf24	0.65	9.51	0.46	3.98e-19	Alzheimer's disease;
LUSC	cis	rs977987	0.836	rs7200053	chr16:75474618	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.16	-0.36	5.2e-12	Dupuytren's disease;
LUSC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg24675658	chr1:53192096	ZYG11B	-0.53	-8.33	-0.41	2.18e-15	Monocyte count;
LUSC	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg04990556	chr1:26633338	UBXN11	-0.46	-6.1	-0.32	2.91e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs78572108	0.844	rs12475650	chr2:42268956	A/G	cg00607755	chr2:42274082	PKDCC	0.35	5.98	0.31	5.72e-9	Total body bone mineral density;
LUSC	cis	rs10740039	0.883	rs1470237	chr10:62413139	C/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.81	-0.35	4.43e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-9.61	-0.47	1.85e-19	Gut microbiome composition (summer);
LUSC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg04369109	chr6:150039330	LATS1	-0.54	-8.13	-0.41	8.67e-15	Lung cancer;
LUSC	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-1.14	-18.17	-0.71	8.4e-52	Exhaled nitric oxide output;
LUSC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg04141948	chr7:1023156	CYP2W1	0.26	5.67	0.3	3.06e-8	Longevity;Endometriosis;
LUSC	cis	rs1775715	0.707	rs1541262	chr10:32179771	A/G	cg04359828	chr10:32216031	ARHGAP12	0.39	6.65	0.34	1.17e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg02187348	chr16:89574699	SPG7	0.56	9.02	0.44	1.47e-17	Multiple myeloma (IgH translocation);
LUSC	cis	rs11971779	0.688	rs1862880	chr7:139020100	T/C	cg07862535	chr7:139043722	LUC7L2	0.61	7.31	0.37	1.99e-12	Diisocyanate-induced asthma;
LUSC	cis	rs6543140	0.964	rs2160200	chr2:103033963	G/T	cg09003973	chr2:102972529	NA	0.57	7.44	0.38	8.7e-13	Blood protein levels;
LUSC	cis	rs9644630	0.932	rs6991941	chr8:19352377	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.37	6.96	0.36	1.84e-11	Oropharynx cancer;
LUSC	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg22906224	chr7:99728672	NA	0.47	6.54	0.34	2.36e-10	Coronary artery disease;
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	0.96	20.06	0.74	2.79e-59	Menarche (age at onset);
LUSC	cis	rs9473147	0.543	rs4715019	chr6:47447041	T/A	cg20196966	chr6:47445060	CD2AP	0.42	5.92	0.31	7.99e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg19773385	chr1:10388646	KIF1B	-0.54	-8.42	-0.42	1.11e-15	Hepatocellular carcinoma;
LUSC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg13560548	chr3:10150139	C3orf24	-0.45	-6.73	-0.35	7.19e-11	Alzheimer's disease;
LUSC	cis	rs12210905	0.925	rs7753123	chr6:26991540	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.99	-0.31	5.28e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg24531977	chr5:56204891	C5orf35	-0.66	-9.33	-0.45	1.56e-18	Coronary artery disease;
LUSC	cis	rs7527798	0.545	rs6696228	chr1:207846830	G/A	cg09232269	chr1:207846808	CR1L	-0.29	-6.26	-0.32	1.16e-9	Erythrocyte sedimentation rate;
LUSC	trans	rs57046232	0.552	rs1887412	chr20:6340856	A/G	cg17788362	chr6:86352627	SYNCRIP	0.43	6.09	0.32	3.05e-9	Colorectal cancer;
LUSC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	ch.11.42038R	chr11:967971	AP2A2	0.55	8.32	0.41	2.3e-15	Alzheimer's disease (late onset);
LUSC	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg04989706	chr14:50066350	PPIL5	-0.43	-5.65	-0.3	3.44e-8	Carotid intima media thickness;
LUSC	trans	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg27275811	chr11:74457193	NA	-0.64	-6.18	-0.32	1.87e-9	Type 2 diabetes nephropathy;
LUSC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg26304593	chr6:42947056	PEX6	0.47	7.09	0.36	8.23e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg19610905	chr11:61596333	FADS2	-0.55	-8.28	-0.41	2.97e-15	Trans fatty acid levels;
LUSC	cis	rs6740322	0.748	rs1549723	chr2:43460514	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-7.12	-0.36	6.73e-12	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg05855489	chr10:104503620	C10orf26	0.48	7.28	0.37	2.41e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg27411982	chr8:10470053	RP1L1	0.48	7.64	0.39	2.27e-13	Neuroticism;
LUSC	cis	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg06521331	chr12:34319734	NA	-0.35	-5.7	-0.3	2.61e-8	Morning vs. evening chronotype;
LUSC	cis	rs1030877	1.000	rs2241797	chr2:105885961	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.78	14.96	0.63	4.33e-39	Obesity-related traits;
LUSC	cis	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-8.28	-0.41	2.98e-15	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg08807101	chr21:30365312	RNF160	-0.66	-10.05	-0.48	6.34e-21	Pancreatic cancer;
LUSC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15506890	chr2:3487001	NA	-0.54	-8.85	-0.44	5.13e-17	Neurofibrillary tangles;
LUSC	cis	rs3857536	0.813	rs7769683	chr6:66946256	G/A	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	trans	rs17039065	1.000	rs719786	chr4:109396732	G/A	cg07444054	chr2:108107501	NA	0.43	6.3	0.33	9.24e-10	Gut microbiome composition (summer);
LUSC	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg10857441	chr5:6722123	POLS	-0.44	-7.97	-0.4	2.61e-14	Menopause (age at onset);
LUSC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg06074448	chr4:187884817	NA	-0.41	-6.87	-0.35	3.24e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9788721	0.836	rs17483548	chr15:78730313	G/A	cg18825076	chr15:78729989	IREB2	-0.62	-9.99	-0.48	9.8e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg10434728	chr15:90938212	IQGAP1	-0.46	-9.48	-0.46	4.96e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs9311676	0.656	rs11130632	chr3:58369324	C/T	cg13750441	chr3:58318267	PXK	0.34	6.66	0.34	1.16e-10	Systemic lupus erythematosus;
LUSC	cis	rs9811920	0.809	rs793464	chr3:99626028	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.44	6.6	0.34	1.63e-10	Axial length;
LUSC	cis	rs554111	0.593	rs7540023	chr1:21310092	T/C	cg01072550	chr1:21505969	NA	0.41	6.31	0.33	8.82e-10	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	trans	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg25214090	chr10:38739885	LOC399744	0.42	6.07	0.32	3.41e-9	Corneal astigmatism;
LUSC	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.1	23.97	0.8	1.43e-74	Schizophrenia;
LUSC	cis	rs4948102	0.551	rs4275190	chr7:56104388	C/T	cg17215666	chr7:56131930	SUMF2	0.47	6.32	0.33	8.27e-10	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg06627628	chr2:24431161	ITSN2	-0.61	-7.32	-0.37	1.88e-12	Lymphocyte counts;
LUSC	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg19875535	chr5:140030758	IK	0.5	8.23	0.41	4.2e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6736093	0.966	rs1122970	chr2:112716697	A/C	cg12686935	chr2:112915763	FBLN7	-0.36	-5.75	-0.3	1.97e-8	Coronary artery disease;
LUSC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg19774624	chr17:42201019	HDAC5	0.49	7.19	0.37	4.25e-12	Total body bone mineral density;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg12794691	chr3:111805077	C3orf52	0.45	6.32	0.33	8.42e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg09796270	chr17:17721594	SREBF1	-0.45	-7.96	-0.4	2.72e-14	Total body bone mineral density;
LUSC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.95	-20.09	-0.74	2e-59	Post bronchodilator FEV1;
LUSC	cis	rs11690935	0.610	rs59844139	chr2:172731983	C/A	cg13550731	chr2:172543902	DYNC1I2	0.55	8.37	0.42	1.57e-15	Schizophrenia;
LUSC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg05347473	chr6:146136440	FBXO30	-0.58	-10.38	-0.49	4.52e-22	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10070969	chr6:27861007	HIST1H2AM;HIST1H2BO	-0.43	-6.41	-0.33	4.93e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23158103	chr7:148848205	ZNF398	-0.44	-6.64	-0.34	1.26e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg18200150	chr17:30822561	MYO1D	0.44	8.9	0.44	3.59e-17	Schizophrenia;
LUSC	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg02574844	chr11:5959923	NA	-0.4	-6.17	-0.32	1.94e-9	DNA methylation (variation);
LUSC	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg04865166	chr7:105162814	PUS7	0.53	5.65	0.3	3.42e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs950881	1.000	rs950881	chr2:102932512	G/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.36	0.33	6.7e-10	Allergy;
LUSC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.4	0.33	5.39e-10	Alzheimer's disease (late onset);
LUSC	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg26587870	chr6:27730563	NA	-0.61	-5.79	-0.3	1.62e-8	Breast cancer;
LUSC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	0.91	12.25	0.56	9.31e-29	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg02551604	chr5:131831745	NA	0.44	7.07	0.36	9.27e-12	Asthma (sex interaction);
LUSC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.78	-12.7	-0.57	2.07e-30	Pancreatic cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02458384	chr16:2021763	TBL3	-0.53	-6.7	-0.34	9.07e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4474465	1.000	rs2063726	chr11:78183533	T/C	cg27205649	chr11:78285834	NARS2	-0.48	-5.71	-0.3	2.51e-8	Alzheimer's disease (survival time);
LUSC	cis	rs4363385	0.667	rs2050674	chr1:152913356	C/G	cg07796016	chr1:152779584	LCE1C	0.44	6.67	0.34	1.06e-10	Inflammatory skin disease;
LUSC	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg18825076	chr15:78729989	IREB2	-0.51	-8.02	-0.4	1.75e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs3741151	0.892	rs11821094	chr11:73061905	C/G	cg17517138	chr11:73019481	ARHGEF17	0.85	8.03	0.4	1.63e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs10186029	0.676	rs4673721	chr2:213941643	T/G	cg08319019	chr2:214017104	IKZF2	0.55	8.08	0.4	1.23e-14	Systemic sclerosis;
LUSC	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.99	0.55	8.74e-28	Ileal carcinoids;
LUSC	cis	rs11608355	1.000	rs11066591	chr12:109880523	G/A	cg05360138	chr12:110035743	NA	0.45	6.22	0.32	1.49e-9	Neuroticism;
LUSC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.75	-15.37	-0.64	1.06e-40	Breast cancer;
LUSC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	1.12	21.67	0.76	1.25e-65	Total cholesterol levels;
LUSC	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.46	-5.75	-0.3	2.02e-8	Schizophrenia;
LUSC	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.69	12.9	0.58	3.71e-31	Metabolite levels;
LUSC	cis	rs4450131	1.000	rs4450131	chr10:126383363	C/T	cg20435097	chr10:126320824	FAM53B	0.21	5.75	0.3	2.06e-8	White blood cell count (basophil);
LUSC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.49	-7.4	-0.38	1.12e-12	Colorectal cancer;
LUSC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.76	11.67	0.54	1.28e-26	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs5758511	0.773	rs11913631	chr22:42347371	G/T	cg12850546	chr22:42539477	CYP2D7P1	-0.47	-5.89	-0.31	9.29e-9	Birth weight;
LUSC	cis	rs981844	1.000	rs2606341	chr4:154658702	T/C	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg02493740	chr2:85810744	VAMP5	-0.36	-6.49	-0.33	3.19e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs12704876	0.509	rs10257162	chr7:96343642	T/C	cg03808172	chr7:96339361	SHFM1	0.54	8.19	0.41	5.76e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18854424	chr1:2615690	NA	-0.49	-9.78	-0.47	5.1e-20	Ulcerative colitis;
LUSC	cis	rs11039100	0.607	rs968989	chr11:5783420	T/C	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg00024416	chr22:24240387	NA	-0.33	-5.77	-0.3	1.8e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.46	0.38	7.36e-13	Bipolar disorder;
LUSC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg24642844	chr7:1081250	C7orf50	-0.79	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg06606381	chr12:133084897	FBRSL1	-0.45	-5.95	-0.31	6.74e-9	Depression;
LUSC	cis	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg17325771	chr7:75508891	RHBDD2	-0.42	-5.9	-0.31	8.88e-9	Eotaxin levels;
LUSC	cis	rs12220238	1.000	rs11000901	chr10:75919971	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.92	0.35	2.36e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg27494647	chr7:150038898	RARRES2	0.56	8.05	0.4	1.44e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.41	-6.21	-0.32	1.59e-9	Myopia;
LUSC	cis	rs2377585	0.653	rs6487333	chr12:8848929	A/T	cg03761649	chr12:8850719	RIMKLB	-0.46	-6.58	-0.34	1.8e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs11209002	1.000	rs11209002	chr1:67590461	C/T	cg02640540	chr1:67518911	SLC35D1	-0.61	-6.63	-0.34	1.39e-10	Crohn's disease;
LUSC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.39	-0.42	1.43e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs9837602	1.000	rs13323143	chr3:99811553	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.13	0.32	2.46e-9	Breast cancer;
LUSC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24531977	chr5:56204891	C5orf35	0.85	13.41	0.59	4.35e-33	Initial pursuit acceleration;
LUSC	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg06532163	chr17:45867833	NA	0.37	6.88	0.35	3.04e-11	IgG glycosylation;
LUSC	cis	rs7465272	0.515	rs34087536	chr8:143720876	G/A	cg10596483	chr8:143751796	JRK	0.5	6.9	0.35	2.65e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg20129853	chr10:51489980	NA	0.32	6.6	0.34	1.62e-10	Prostate-specific antigen levels;
LUSC	cis	rs56283067	0.847	rs2128543	chr6:44685552	G/A	cg18551225	chr6:44695536	NA	-0.49	-8.6	-0.43	3.25e-16	Total body bone mineral density;
LUSC	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.24	-0.37	3.09e-12	Bipolar disorder;
LUSC	cis	rs12997796	0.556	rs35129240	chr2:86929217	G/A	cg25203885	chr2:87302643	LOC285074	-0.81	-8.39	-0.42	1.42e-15	Schizophrenia;
LUSC	cis	rs10193935	1.000	rs13399869	chr2:42386041	C/G	cg27598129	chr2:42591480	NA	-0.59	-8.1	-0.41	1.01e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg21775007	chr8:11205619	TDH	-0.47	-6.84	-0.35	3.71e-11	Neuroticism;
LUSC	cis	rs3916	0.794	rs10431386	chr12:121128926	A/G	cg27246729	chr12:121163418	ACADS	-0.42	-6.21	-0.32	1.55e-9	Urinary metabolites (H-NMR features);
LUSC	cis	rs1451375	0.698	rs11489734	chr7:50635730	A/T	cg18232548	chr7:50535776	DDC	0.5	7.67	0.39	1.94e-13	Malaria;
LUSC	cis	rs9283706	0.593	rs10077634	chr5:66303346	G/A	cg11590213	chr5:66331682	MAST4	0.39	5.79	0.3	1.64e-8	Coronary artery disease;
LUSC	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg16414030	chr3:133502952	NA	-0.41	-6.47	-0.33	3.45e-10	Iron status biomarkers;
LUSC	cis	rs4363385	0.747	rs1015995	chr1:152976114	G/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.76	-0.39	1.05e-13	Inflammatory skin disease;
LUSC	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	8.62	0.43	2.69e-16	Schizophrenia;
LUSC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11890956	chr21:40555474	PSMG1	1.03	19.22	0.72	5.92e-56	Cognitive function;
LUSC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg16405210	chr4:1374714	KIAA1530	0.51	7.74	0.39	1.23e-13	Obesity-related traits;
LUSC	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg03678062	chr6:149772716	ZC3H12D	0.31	6.1	0.32	2.93e-9	Dupuytren's disease;
LUSC	trans	rs7737355	0.812	rs6868007	chr5:130824810	T/C	cg19409254	chr13:36431974	MIR548F5;DCLK1	-0.36	-5.97	-0.31	5.99e-9	Life satisfaction;
LUSC	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg25797454	chr6:150327115	RAET1K	0.32	7.36	0.37	1.46e-12	Alopecia areata;
LUSC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.72	17.19	0.69	6.66e-48	Prostate cancer;
LUSC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27286337	chr10:134555280	INPP5A	0.92	11.96	0.55	1.07e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs78545713	0.649	rs11751062	chr6:26216165	C/T	cg23601095	chr6:26197514	HIST1H3D	0.66	5.79	0.3	1.64e-8	Iron status biomarkers (total iron binding capacity);
LUSC	trans	rs2018683	0.707	rs917219	chr7:28975343	A/G	cg19402173	chr7:128379420	CALU	-0.47	-7.16	-0.36	5.15e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg03289416	chr15:75166202	SCAMP2	0.45	6.76	0.35	6.11e-11	Breast cancer;
LUSC	trans	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg26043149	chr18:55253948	FECH	0.5	7.44	0.38	8.47e-13	Bone mineral density;
LUSC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg11335335	chr11:637885	DRD4	-0.33	-6.11	-0.32	2.82e-9	Systemic lupus erythematosus;
LUSC	cis	rs2137920	1.000	rs2244967	chr10:50224766	A/G	cg27141751	chr10:50231850	C10orf72	-0.38	-5.89	-0.31	9.32e-9	Migraine with aura;
LUSC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg06028605	chr16:24865363	SLC5A11	-0.5	-8.95	-0.44	2.53e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg00277334	chr10:82204260	NA	-0.51	-7.41	-0.38	1.05e-12	Post bronchodilator FEV1;
LUSC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.34	0.37	1.62e-12	Motion sickness;
LUSC	cis	rs983392	0.679	rs10736701	chr11:60031476	C/T	cg20284999	chr11:59952153	MS4A6A	0.38	6.38	0.33	5.85e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.93	-0.4	3.36e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs977987	0.843	rs12928036	chr16:75483132	G/A	cg03315344	chr16:75512273	CHST6	0.53	10.39	0.49	4.28e-22	Dupuytren's disease;
LUSC	cis	rs7178572	0.568	rs3743479	chr15:77406396	A/G	cg22256960	chr15:77711686	NA	0.5	7.94	0.4	3.15e-14	Type 2 diabetes;
LUSC	cis	rs7188861	0.681	rs12935137	chr16:11422015	T/C	cg00044050	chr16:11439710	C16orf75	0.58	6.03	0.31	4.46e-9	HDL cholesterol;
LUSC	cis	rs2522056	1.000	rs2706339	chr5:131800105	G/T	cg24060327	chr5:131705240	SLC22A5	0.46	6.17	0.32	1.96e-9	Lymphocyte counts;Fibrinogen;
LUSC	trans	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	cis	rs6499755	0.896	rs8058278	chr16:55344508	G/A	cg02859129	chr16:55357253	IRX6	0.36	6.15	0.32	2.27e-9	Hypospadias;
LUSC	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg23093090	chr10:104574429	C10orf26	-0.34	-6.25	-0.32	1.25e-9	Arsenic metabolism;
LUSC	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg07936489	chr17:37558343	FBXL20	0.71	9.91	0.48	1.88e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs11229555	0.645	rs11229450	chr11:58201629	G/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg27489772	chr12:121021490	NA	-0.54	-6.75	-0.35	6.5e-11	Type 1 diabetes nephropathy;
LUSC	cis	rs981844	0.961	rs17299034	chr4:154671396	A/G	cg14289246	chr4:154710475	SFRP2	0.51	6.57	0.34	1.98e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg05110241	chr16:68378359	PRMT7	-0.77	-8.61	-0.43	2.89e-16	Schizophrenia;
LUSC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.83	-0.3	1.28e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7246967	0.673	rs57736314	chr19:22880272	T/G	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-6.68	-0.34	9.79e-11	Monocyte percentage of white cells;
LUSC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.63	6.06	0.31	3.58e-9	Cerebrospinal P-tau181p levels;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg00510787	chr6:151772946	C6orf211;RMND1	0.35	6.37	0.33	6.35e-10	Triglycerides;
LUSC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.52	-7.09	-0.36	7.9e-12	Longevity;Endometriosis;
LUSC	cis	rs4631830	0.863	rs4935162	chr10:51525699	C/G	cg10326726	chr10:51549505	MSMB	-0.33	-5.7	-0.3	2.68e-8	Prostate-specific antigen levels;
LUSC	cis	rs7605827	0.930	rs4668448	chr2:15521740	T/C	cg19274914	chr2:15703543	NA	0.45	8.78	0.43	8.82e-17	Educational attainment (years of education);
LUSC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg12963246	chr6:28129442	ZNF389	-0.44	-6.47	-0.33	3.55e-10	Depression;
LUSC	cis	rs12530845	0.945	rs7799891	chr7:135322853	T/C	cg23117316	chr7:135346802	PL-5283	-0.57	-9.77	-0.47	5.48e-20	Red blood cell traits;
LUSC	cis	rs9921338	0.961	rs4781055	chr16:11369428	C/T	cg00044050	chr16:11439710	C16orf75	-0.51	-6.83	-0.35	4.15e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs3931020	0.688	rs277374	chr1:75200486	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	-0.63	-8.42	-0.42	1.1e-15	Resistin levels;
LUSC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.48	-7.97	-0.4	2.6e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.66	14.54	0.62	1.9e-37	Hemoglobin concentration;
LUSC	cis	rs1595825	0.636	rs111540926	chr2:198885578	G/A	cg10547527	chr2:198650123	BOLL	-0.52	-6.3	-0.33	9.56e-10	Ulcerative colitis;
LUSC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.89	-0.4	4.34e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4792901	0.759	rs9915640	chr17:41603882	T/C	cg22562494	chr17:41607896	ETV4	-0.31	-5.95	-0.31	6.72e-9	Dupuytren's disease;
LUSC	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg04944784	chr2:26401820	FAM59B	-0.58	-7.97	-0.4	2.62e-14	Gut microbiome composition (summer);
LUSC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg23711669	chr6:146136114	FBXO30	0.91	17.88	0.7	1.27e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg22709100	chr7:91322751	NA	-0.39	-5.72	-0.3	2.37e-8	Breast cancer;
LUSC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.91	-0.35	2.41e-11	Lung cancer;
LUSC	cis	rs6669072	0.527	rs34401202	chr1:91269160	A/G	cg08895590	chr1:91227319	NA	-0.27	-5.82	-0.3	1.41e-8	Cognitive function;
LUSC	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg17366294	chr4:99064904	C4orf37	0.54	9.41	0.46	8.59e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs67696533	0.636	rs6141741	chr20:31106567	C/T	cg13636640	chr20:31349939	DNMT3B	0.48	6.59	0.34	1.67e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg20243544	chr17:37824526	PNMT	0.52	7.41	0.38	1.06e-12	Asthma;
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.61	-11.76	-0.54	5.96e-27	Longevity;Endometriosis;
LUSC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.22	-13.19	-0.59	2.98e-32	Diabetic kidney disease;
LUSC	cis	rs2267137	0.903	rs2072051	chr22:29755888	C/T	cg07256473	chr22:29710276	RASL10A	-0.37	-7.14	-0.36	6.02e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg00857998	chr1:205179979	DSTYK	0.64	9.84	0.47	3.12e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg04871131	chr7:94954202	PON1	-0.38	-6.07	-0.31	3.57e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg03790207	chr6:42947109	PEX6	-0.44	-6.75	-0.35	6.73e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-1.11	-24.8	-0.81	9.96e-78	Height;
LUSC	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.0	-15.94	-0.66	5.94e-43	Lymphocyte percentage of white cells;
LUSC	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.85	14.55	0.62	1.78e-37	Bladder cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05379947	chr6:35436047	RPL10A	-0.39	-6.03	-0.31	4.4e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg19249749	chr1:223853145	CAPN8	-0.51	-6.31	-0.33	8.65e-10	Gut microbiome composition (summer);
LUSC	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg01689657	chr7:91764605	CYP51A1	-0.32	-5.77	-0.3	1.79e-8	Breast cancer;
LUSC	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.15	0.32	2.27e-9	Corneal astigmatism;
LUSC	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.9	0.61	5.49e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg25214090	chr10:38739885	LOC399744	-0.5	-7.32	-0.37	1.83e-12	Corneal astigmatism;
LUSC	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg18240062	chr17:79603768	NPLOC4	0.78	15.06	0.64	1.71e-39	Eye color traits;
LUSC	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg11984989	chr7:158649758	WDR60	1.0	17.99	0.7	4.43e-51	Height;
LUSC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg22532475	chr10:104410764	TRIM8	0.34	6.69	0.34	9.52e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs3733418	0.929	rs13149062	chr4:165905360	T/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-5.93	-0.31	7.64e-9	Obesity-related traits;
LUSC	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg06223162	chr1:101003688	GPR88	-0.47	-8.96	-0.44	2.29e-17	Monocyte count;
LUSC	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg23601095	chr6:26197514	HIST1H3D	0.71	7.35	0.37	1.57e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg01879757	chr17:41196368	BRCA1	-0.45	-6.85	-0.35	3.63e-11	Menopause (age at onset);
LUSC	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg21643547	chr1:205240462	TMCC2	-0.42	-7.65	-0.39	2.17e-13	Red blood cell count;
LUSC	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg22903471	chr2:27725779	GCKR	-0.38	-6.36	-0.33	6.65e-10	Total body bone mineral density;
LUSC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.16	-0.32	2.06e-9	Total body bone mineral density;
LUSC	cis	rs9463078	0.845	rs1023090	chr6:45012381	T/C	cg25276700	chr6:44698697	NA	-0.28	-5.67	-0.3	3.13e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg27497285	chr9:95432195	IPPK	0.5	6.32	0.33	8.47e-10	Cognitive function;Information processing speed;
LUSC	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg23711669	chr6:146136114	FBXO30	-0.75	-11.85	-0.54	2.83e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.59e-11	Morning vs. evening chronotype;
LUSC	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-13.69	-0.6	3.72e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg05283184	chr6:79620031	NA	-0.58	-11.98	-0.55	9.46e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs6574644	1.000	rs4903980	chr14:81778263	T/C	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs6087990	0.965	rs2424903	chr20:31349315	C/T	cg13636640	chr20:31349939	DNMT3B	1.03	23.1	0.78	3.15e-71	Ulcerative colitis;
LUSC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.48	-7.09	-0.36	7.91e-12	Vitiligo;
LUSC	cis	rs7119038	0.818	rs11217032	chr11:118669605	T/A	cg19308663	chr11:118741387	NA	0.35	6.29	0.33	1.01e-9	Sjögren's syndrome;
LUSC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.15	0.41	7.58e-15	Lung cancer;
LUSC	cis	rs9837602	1.000	rs35844878	chr3:99796626	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-5.96	-0.31	6.33e-9	Breast cancer;
LUSC	cis	rs9314323	1.000	rs9314323	chr8:26243136	A/G	cg13160058	chr8:26243215	BNIP3L	-0.44	-7.89	-0.4	4.26e-14	Red cell distribution width;
LUSC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg26769984	chr7:1090371	C7orf50	0.58	7.24	0.37	3.1e-12	Bronchopulmonary dysplasia;
LUSC	trans	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	14.41	0.62	6.07e-37	Exhaled nitric oxide levels;
LUSC	cis	rs12493885	0.769	rs11710560	chr3:153777276	A/G	cg17054900	chr3:154042577	DHX36	-0.72	-7.06	-0.36	9.58e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2698530	0.607	rs1019686	chr2:64462122	A/G	cg22352474	chr2:64371530	PELI1	-0.45	-5.83	-0.3	1.32e-8	Iron status biomarkers;
LUSC	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.74	-14.38	-0.62	8.23e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7809950	0.768	rs2701678	chr7:107283711	A/G	cg23024343	chr7:107201750	COG5	0.56	8.22	0.41	4.55e-15	Coronary artery disease;
LUSC	cis	rs1858037	0.867	rs6727013	chr2:65558375	C/A	cg08085232	chr2:65598271	SPRED2	-0.41	-6.17	-0.32	2.01e-9	Rheumatoid arthritis;
LUSC	cis	rs35150201	0.529	rs7806221	chr7:135318779	T/C	cg23117316	chr7:135346802	PL-5283	-0.39	-7.23	-0.37	3.42e-12	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25315855	chr11:6440704	APBB1	0.43	5.97	0.31	6.01e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg01475377	chr6:109611718	NA	-0.45	-8.21	-0.41	4.87e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.71	-0.3	2.46e-8	Life satisfaction;
LUSC	cis	rs239198	0.602	rs17672397	chr6:101288160	C/T	cg09795085	chr6:101329169	ASCC3	0.43	6.11	0.32	2.78e-9	Menarche (age at onset);
LUSC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.69	-0.57	2.24e-30	Platelet count;
LUSC	cis	rs11018904	0.861	rs61903723	chr11:89968246	C/T	cg26138821	chr11:89956704	CHORDC1	-0.6	-7.19	-0.37	4.17e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg14440974	chr22:39074834	NA	-0.36	-5.96	-0.31	6.56e-9	Menopause (age at onset);
LUSC	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.33	0.59	8.18e-33	Blood protein levels;
LUSC	cis	rs240764	0.717	rs239215	chr6:101147426	A/G	cg09795085	chr6:101329169	ASCC3	0.41	5.91	0.31	8.26e-9	Neuroticism;
LUSC	cis	rs6076065	0.748	rs2253834	chr20:23387816	C/T	cg11657817	chr20:23433608	CST11	-0.52	-10.52	-0.5	1.53e-22	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15320075	chr8:145703422	NA	-0.65	-10.94	-0.51	5.04e-24	Age at first birth;
LUSC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg04455712	chr21:45112962	RRP1B	0.42	7.91	0.4	3.79e-14	Mean corpuscular volume;
LUSC	trans	rs140364877	1	rs140364877	chr7:1885178	C/T	cg24247370	chr13:99142703	STK24	-0.33	-5.98	-0.31	5.85e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11229555	0.645	rs11229457	chr11:58207203	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7131987	0.903	rs2216853	chr12:29413248	C/G	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.25	-0.32	1.28e-9	QT interval;
LUSC	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg05347473	chr6:146136440	FBXO30	0.4	6.78	0.35	5.5e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg06238570	chr21:40685208	BRWD1	-0.53	-8.21	-0.41	4.79e-15	Menarche (age at onset);
LUSC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05025164	chr4:1340916	KIAA1530	0.53	8.41	0.42	1.21e-15	Longevity;
LUSC	cis	rs72627509	0.767	rs6853156	chr4:57774843	C/T	cg26694713	chr4:57773883	REST	0.52	6.42	0.33	4.64e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg25182066	chr10:30743637	MAP3K8	-0.45	-6.36	-0.33	6.48e-10	Inflammatory bowel disease;
LUSC	cis	rs243505	0.660	rs3807450	chr7:148522269	C/A	cg09806900	chr7:148480153	CUL1	0.49	6.61	0.34	1.53e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2710642	0.888	rs13418889	chr2:63079775	T/C	cg17519650	chr2:63277830	OTX1	0.48	6.61	0.34	1.56e-10	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg24375607	chr4:120327624	NA	-0.7	-11.24	-0.52	4.41e-25	Corneal astigmatism;
LUSC	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg10117171	chr1:25599238	RHD	0.4	6.08	0.32	3.29e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs2235544	0.541	rs928442	chr1:54473488	C/G	cg25741118	chr1:54482237	LDLRAD1	-0.28	-6.11	-0.32	2.83e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.43	-7.64	-0.39	2.35e-13	Menopause (age at onset);
LUSC	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg17385448	chr1:15911702	AGMAT	0.36	6.18	0.32	1.82e-9	Systolic blood pressure;
LUSC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00149659	chr3:10157352	C3orf10	0.95	12.63	0.57	3.62e-30	Alzheimer's disease;
LUSC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg27165867	chr14:105738592	BRF1	-0.54	-7.81	-0.39	7.62e-14	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs11696501	0.694	rs6094184	chr20:44256575	G/A	cg03272292	chr12:48577362	C12orf68	0.49	6.01	0.31	4.83e-9	Brain structure;
LUSC	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg27446573	chr6:127587934	RNF146	0.46	7.14	0.36	5.74e-12	Breast cancer;
LUSC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg17294928	chr15:75287854	SCAMP5	0.41	5.88	0.31	1e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs5167	0.583	rs7252480	chr19:45458925	C/T	cg25746394	chr19:45450501	APOC2	0.32	5.95	0.31	6.75e-9	Blood protein levels;
LUSC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-6.23	-0.32	1.42e-9	Electroencephalogram traits;
LUSC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	7.44	0.38	8.69e-13	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	0.6	9.41	0.46	8.58e-19	Breast cancer;
LUSC	trans	rs75804782	0.641	rs11902599	chr2:239348400	C/T	cg01134436	chr17:81009848	B3GNTL1	0.66	6.4	0.33	5.41e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg25767906	chr1:53392781	SCP2	-0.34	-5.79	-0.3	1.67e-8	Monocyte count;
LUSC	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2425143	1.000	rs11699793	chr20:34271574	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.17	-0.32	1.96e-9	Blood protein levels;
LUSC	cis	rs12618769	0.597	rs3754886	chr2:99107677	A/G	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.62	0.47	1.63e-19	Bipolar disorder;
LUSC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg27535305	chr1:53392650	SCP2	0.36	6.73	0.35	7.3e-11	Monocyte count;
LUSC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10802521	chr3:52805072	NEK4	-0.54	-8.71	-0.43	1.43e-16	Electroencephalogram traits;
LUSC	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg15896084	chr13:114927664	NA	0.37	6.58	0.34	1.86e-10	Schizophrenia;
LUSC	cis	rs9815354	0.812	rs10510729	chr3:41831998	G/A	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9359856	0.510	rs2768936	chr6:90441851	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.92	-10.78	-0.51	1.92e-23	Bipolar disorder;
LUSC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg07424592	chr7:64974309	NA	0.63	5.69	0.3	2.81e-8	Diabetic kidney disease;
LUSC	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg02466173	chr16:30829666	NA	0.52	8.36	0.42	1.67e-15	Dementia with Lewy bodies;
LUSC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg02896835	chr1:92012615	NA	-0.65	-11.73	-0.54	7.95e-27	Breast cancer;
LUSC	cis	rs57590327	0.503	rs7618973	chr3:81619588	C/T	cg07356753	chr3:81810745	GBE1	0.44	6.12	0.32	2.66e-9	Extraversion;
LUSC	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-7.52	-0.38	5.14e-13	Parkinson's disease;
LUSC	cis	rs8179	0.620	rs73232029	chr7:92287283	G/C	cg15732164	chr7:92237376	CDK6	-0.41	-5.73	-0.3	2.26e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg03395511	chr6:291903	DUSP22	-0.69	-11.5	-0.53	5.32e-26	Menopause (age at onset);
LUSC	cis	rs6977660	0.652	rs10249291	chr7:19844448	C/G	cg05791153	chr7:19748676	TWISTNB	0.79	7.36	0.37	1.44e-12	Thyroid stimulating hormone;
LUSC	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-5.87	-0.31	1.05e-8	Major depressive disorder;
LUSC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	0.94	15.65	0.65	8.63e-42	Parkinson's disease;
LUSC	cis	rs36051895	0.589	rs17492549	chr9:5202830	A/C	cg02405213	chr9:5042618	JAK2	-0.55	-8.33	-0.41	2.18e-15	Pediatric autoimmune diseases;
LUSC	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg12473912	chr3:136751656	NA	0.39	6.81	0.35	4.51e-11	Neuroticism;
LUSC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg03388025	chr16:89894329	SPIRE2	0.35	7.42	0.38	1e-12	Vitiligo;
LUSC	cis	rs5771069	0.933	rs137848	chr22:50440296	A/G	cg27467552	chr22:50353597	PIM3	-0.39	-6.64	-0.34	1.27e-10	Ulcerative colitis;
LUSC	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg05985134	chr18:33552581	C18orf21	0.51	6.92	0.35	2.35e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs2599510	0.811	rs2710625	chr2:32822957	G/A	cg02381751	chr2:32503542	YIPF4	0.39	5.71	0.3	2.48e-8	Interleukin-18 levels;
LUSC	cis	rs939574	0.790	rs79225383	chr2:220093972	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	6.07	0.32	3.4e-9	Platelet distribution width;
LUSC	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg00376283	chr12:123451042	ABCB9	0.67	8.42	0.42	1.1e-15	Neutrophil percentage of white cells;
LUSC	cis	rs10162002	1.000	rs10162002	chr13:24042510	G/A	cg00158254	chr13:24040743	NA	0.54	6.08	0.32	3.31e-9	Hypothyroidism;
LUSC	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg09307838	chr4:120376055	NA	0.69	10.01	0.48	8.32e-21	Corneal astigmatism;
LUSC	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.69	-0.43	1.6e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4474465	1.000	rs11237495	chr11:78155090	A/G	cg27205649	chr11:78285834	NARS2	-0.5	-5.94	-0.31	7.09e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg20003494	chr4:90757398	SNCA	-0.33	-5.71	-0.3	2.5e-8	Dementia with Lewy bodies;
LUSC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg16558253	chr16:72132732	DHX38	0.41	6.15	0.32	2.26e-9	Fibrinogen levels;
LUSC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.72	0.43	1.34e-16	Prudent dietary pattern;
LUSC	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg03732007	chr1:2071316	PRKCZ	0.56	9.99	0.48	1.01e-20	Height;
LUSC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.42	5.71	0.3	2.49e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17807624	0.780	rs11250152	chr8:11454200	A/C	cg21175976	chr8:11421337	BLK	-0.35	-5.85	-0.3	1.17e-8	Systemic lupus erythematosus;
LUSC	trans	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.23	-0.41	4.21e-15	Retinal vascular caliber;
LUSC	cis	rs3755132	0.778	rs73915402	chr2:15732238	G/C	cg12888861	chr2:15731646	DDX1	0.5	7.15	0.36	5.48e-12	Wilms tumor;
LUSC	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.74	-7.15	-0.36	5.52e-12	Lung cancer in ever smokers;
LUSC	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg19743168	chr1:23544995	NA	0.46	9.11	0.45	8.03e-18	Height;
LUSC	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.88	-0.31	9.9e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg26751094	chr13:95954534	ABCC4	-0.44	-7.98	-0.4	2.43e-14	Blood metabolite levels;
LUSC	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg06547715	chr2:218990976	CXCR2	0.33	6.41	0.33	5.05e-10	Ulcerative colitis;
LUSC	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.53	-0.38	4.89e-13	Height;
LUSC	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg15445000	chr17:37608096	MED1	0.41	6.95	0.36	1.92e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg03676636	chr4:99064102	C4orf37	0.32	6.12	0.32	2.62e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4566357	1.000	rs7567796	chr2:227922109	T/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.67	-0.3	3.07e-8	Coronary artery disease;
LUSC	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg02569458	chr12:86230093	RASSF9	0.37	6.03	0.31	4.36e-9	Major depressive disorder;
LUSC	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg18357645	chr12:58087776	OS9	-0.52	-8.17	-0.41	6.36e-15	Multiple sclerosis;
LUSC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg02153584	chr22:29168773	CCDC117	0.59	8.84	0.44	5.63e-17	Lymphocyte counts;
LUSC	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.49	-0.42	6.64e-16	Morning vs. evening chronotype;
LUSC	cis	rs7192380	1.000	rs11075726	chr16:69584523	A/G	cg26679644	chr16:69762563	NA	0.34	6.03	0.31	4.25e-9	Sjögren's syndrome;
LUSC	trans	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg06606381	chr12:133084897	FBRSL1	-0.66	-7.14	-0.36	5.96e-12	Depression;
LUSC	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg21132104	chr15:45694354	SPATA5L1	0.42	6.13	0.32	2.45e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25072359	chr17:41440525	NA	0.65	9.41	0.46	8.16e-19	Menopause (age at onset);
LUSC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15664640	chr17:80829946	TBCD	0.49	8.75	0.43	1.08e-16	Breast cancer;
LUSC	cis	rs2559856	1.000	rs2695292	chr12:102087290	G/A	cg12924262	chr12:102091054	CHPT1	0.43	6.04	0.31	4e-9	Blood protein levels;
LUSC	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg03465714	chr1:152285911	FLG	0.39	5.65	0.3	3.44e-8	Atopic dermatitis;
LUSC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.82	0.35	4.17e-11	Platelet count;
LUSC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.46	-8.85	-0.44	5.16e-17	Monocyte percentage of white cells;
LUSC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg25019033	chr10:957182	NA	-0.51	-6.35	-0.33	6.88e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg00310523	chr12:86230176	RASSF9	0.49	9.39	0.46	9.64e-19	Major depressive disorder;
LUSC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.63	8.41	0.42	1.21e-15	High light scatter reticulocyte count;
LUSC	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.49	9.93	0.48	1.59e-20	Anterior chamber depth;
LUSC	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.06	0.36	9.63e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21659725	chr3:3221576	CRBN	-0.58	-8.19	-0.41	5.8e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg01657329	chr11:68192670	LRP5	-0.43	-6.45	-0.33	3.99e-10	Total body bone mineral density;
LUSC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	0.93	12.97	0.58	1.99e-31	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4629710	0.592	rs13205441	chr6:131575069	G/A	cg12606694	chr6:131520996	AKAP7	0.62	9.42	0.46	7.5e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	0.67	14.25	0.61	2.47e-36	Prudent dietary pattern;
LUSC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.31	-0.37	1.97e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.95	-0.31	6.66e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7705502	0.926	rs112299234	chr5:173339531	T/C	cg18693985	chr5:173351052	CPEB4	-0.37	-5.97	-0.31	5.91e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.23	-39.49	-0.91	6.94e-128	Myeloid white cell count;
LUSC	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.39	-0.42	1.41e-15	Schizophrenia;
LUSC	cis	rs6542838	0.641	rs4499468	chr2:99475204	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.42	-5.66	-0.3	3.32e-8	Fear of minor pain;
LUSC	cis	rs8048589	0.604	rs11646584	chr16:12207975	G/A	cg02910054	chr16:12241554	SNX29	0.47	6.08	0.32	3.2e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs2219968	0.828	rs4077569	chr8:78918381	C/A	cg00738934	chr8:78996279	NA	-0.4	-7.18	-0.37	4.67e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1775715	0.870	rs7095322	chr10:32248491	C/T	cg03015672	chr10:32216066	ARHGAP12	-0.32	-5.66	-0.3	3.33e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg18301423	chr5:131593218	PDLIM4	0.38	6.2	0.32	1.66e-9	Blood metabolite levels;
LUSC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.92	-0.35	2.31e-11	Alzheimer's disease (late onset);
LUSC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.35	0.56	3.93e-29	Prudent dietary pattern;
LUSC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.55	8.6	0.43	3.08e-16	Depressive symptoms;
LUSC	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg25233709	chr10:116636983	FAM160B1	0.44	7.9	0.4	3.98e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.61	-7.34	-0.37	1.63e-12	Coronary artery calcification;
LUSC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs4664304	0.658	rs2667015	chr2:160868586	T/C	cg03641300	chr2:160917029	PLA2R1	-0.36	-6.04	-0.31	4.03e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg06494592	chr3:125709126	NA	-0.5	-5.75	-0.3	2.04e-8	Blood pressure (smoking interaction);
LUSC	cis	rs1564271	0.528	rs1980756	chr10:26979371	G/C	cg13837822	chr10:26931731	LOC731789	0.45	9.55	0.46	2.98e-19	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LUSC	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg06484146	chr7:12443880	VWDE	-0.69	-7.2	-0.37	4.01e-12	Coronary artery disease;
LUSC	cis	rs11018904	0.906	rs7925507	chr11:89940146	T/C	cg26138821	chr11:89956704	CHORDC1	-0.58	-6.7	-0.34	8.78e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg12935359	chr14:103987150	CKB	0.63	10.49	0.5	1.97e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg09877947	chr5:131593287	PDLIM4	0.44	6.86	0.35	3.33e-11	Blood metabolite levels;
LUSC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	0.95	16.07	0.66	1.92e-43	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg03676636	chr4:99064102	C4orf37	0.36	7.91	0.4	3.77e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg05519781	chr21:40033154	ERG	0.78	13.57	0.6	1.01e-33	Coronary artery disease;
LUSC	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.6	-0.34	1.66e-10	Neuroticism;
LUSC	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg14895029	chr7:2775587	GNA12	-0.41	-6.23	-0.32	1.4e-9	Height;
LUSC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg05941027	chr17:61774174	LIMD2	0.22	5.75	0.3	1.98e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs75804782	0.641	rs6715311	chr2:239363321	A/G	cg18131467	chr2:239335373	ASB1	-0.68	-6.21	-0.32	1.58e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg12292205	chr6:26970375	C6orf41	-0.62	-7.65	-0.39	2.15e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg08859206	chr1:53392774	SCP2	-0.42	-6.71	-0.34	8.12e-11	Monocyte count;
LUSC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg09365446	chr1:150670422	GOLPH3L	0.55	8.45	0.42	9.42e-16	Tonsillectomy;
LUSC	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg01097406	chr16:89675127	NA	0.49	10.15	0.49	2.77e-21	Vitiligo;
LUSC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg22907277	chr7:1156413	C7orf50	0.53	5.88	0.31	9.94e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg22437258	chr11:111473054	SIK2	0.5	6.79	0.35	4.99e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg14019146	chr3:50243930	SLC38A3	0.36	8.37	0.42	1.6e-15	Body mass index;
LUSC	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg23649088	chr2:200775458	C2orf69	0.53	7.25	0.37	2.9e-12	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.72	12.86	0.58	4.88e-31	Prudent dietary pattern;
LUSC	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-0.95	-18.47	-0.71	5.31e-53	Brugada syndrome;
LUSC	cis	rs10740039	0.729	rs6479728	chr10:62490801	A/G	cg18175470	chr10:62150864	ANK3	0.38	5.94	0.31	7.06e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg25182066	chr10:30743637	MAP3K8	-0.44	-6.64	-0.34	1.24e-10	Inflammatory bowel disease;
LUSC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.58	9.84	0.47	3.02e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg16070123	chr10:51489643	NA	-0.53	-8.58	-0.42	3.67e-16	Prostate-specific antigen levels;
LUSC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.9	0.31	8.8e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-1.12	-24.92	-0.81	3.6e-78	Height;
LUSC	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg09835421	chr16:68378352	PRMT7	-0.56	-6.31	-0.33	8.67e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2637266	0.745	rs2579732	chr10:78442778	T/C	cg18941641	chr10:78392320	NA	0.32	5.82	0.3	1.36e-8	Pulmonary function;
LUSC	cis	rs10207060	0.500	rs28540721	chr2:240714045	C/T	cg07506560	chr2:240697449	NA	0.43	6.8	0.35	4.88e-11	Obesity-related traits;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.4	-5.99	-0.31	5.44e-9	Hepatitis;
LUSC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-10.91	-0.51	6.48e-24	Gut microbiome composition (summer);
LUSC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg11494091	chr17:61959527	GH2	0.39	6.77	0.35	5.68e-11	Height;
LUSC	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.71e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs977987	0.843	rs11641801	chr16:75455448	A/C	cg04384234	chr16:75411784	CFDP1	-0.43	-6.97	-0.36	1.65e-11	Dupuytren's disease;
LUSC	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg15744005	chr10:104629667	AS3MT	-0.38	-7.87	-0.4	4.99e-14	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.62	-7.89	-0.4	4.46e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08859206	chr1:53392774	SCP2	0.51	8.67	0.43	1.91e-16	Monocyte count;
LUSC	cis	rs10875746	0.903	rs11168386	chr12:48467977	C/T	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg09184832	chr6:79620586	NA	0.42	6.75	0.35	6.5500000000000006e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.54	0.38	4.59e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg11244813	chr1:145039882	PDE4DIP	0.38	6.04	0.31	4.08e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.9	-0.44	3.52e-17	Uric acid levels;
LUSC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13770153	chr20:60521292	NA	-0.6	-8.19	-0.41	5.59e-15	Body mass index;
LUSC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg13319975	chr6:146136371	FBXO30	0.71	11.22	0.52	5.19e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1808579	0.904	rs1652344	chr18:21128857	T/C	cg14672496	chr18:21087552	C18orf8	0.37	6.59	0.34	1.76e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	0.91	17.76	0.7	3.8e-50	Metabolite levels;
LUSC	cis	rs11229555	0.645	rs12269745	chr11:58176875	G/A	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.03	0.44	1.44e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg25456477	chr12:86230367	RASSF9	0.44	7.83	0.39	6.31e-14	Major depressive disorder;
LUSC	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg17507749	chr15:85114479	UBE2QP1	0.63	7.88	0.4	4.62e-14	Schizophrenia;
LUSC	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg12011299	chr4:100065546	ADH4	0.64	10.08	0.48	5.01e-21	Alcohol dependence;
LUSC	cis	rs11039100	1.000	rs12798822	chr11:5826711	T/C	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg04362960	chr10:104952993	NT5C2	-0.61	-9.8	-0.47	4.17e-20	Arsenic metabolism;
LUSC	cis	rs9633740	0.685	rs4934284	chr10:82277297	C/G	cg01528321	chr10:82214614	TSPAN14	-0.76	-5.96	-0.31	6.47e-9	Post bronchodilator FEV1;
LUSC	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.58	0.6	9.51e-34	Morning vs. evening chronotype;
LUSC	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg20734569	chr3:48348370	SPINK8	-0.46	-7.81	-0.39	7.43e-14	Coronary artery disease;
LUSC	cis	rs12681287	0.547	rs4961197	chr8:87512436	T/C	cg00550725	chr8:87521180	FAM82B	0.43	5.68	0.3	2.98e-8	Caudate activity during reward;
LUSC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg05872129	chr22:39784769	NA	-0.61	-11.21	-0.52	5.78e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs240764	0.658	rs11155635	chr6:101199367	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-6.27	-0.32	1.11e-9	Neuroticism;
LUSC	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg21775007	chr8:11205619	TDH	-0.54	-7.79	-0.39	8.58e-14	Neuroticism;
LUSC	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg05147244	chr20:61493195	TCFL5	0.88	7.12	0.36	6.74e-12	Obesity-related traits;
LUSC	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg21095983	chr6:86352623	SYNCRIP	0.51	7.89	0.4	4.31e-14	Smooth-surface caries;
LUSC	trans	rs6600671	0.934	rs7528274	chr1:121286901	A/T	cg00646200	chr1:148855367	NA	0.5	7.99	0.4	2.25e-14	Hip geometry;
LUSC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg22920501	chr2:26401640	FAM59B	0.83	12.02	0.55	6.49e-28	Gut microbiome composition (summer);
LUSC	trans	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg02113368	chr10:135107346	TUBGCP2	-0.34	-6.0	-0.31	5.12e-9	Dementia with Lewy bodies;
LUSC	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.67	11.87	0.54	2.37e-27	Itch intensity from mosquito bite;
LUSC	cis	rs11051970	0.636	rs10844198	chr12:32563479	G/T	cg24626660	chr12:32551988	NA	0.31	5.66	0.3	3.25e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7246967	0.673	rs34671960	chr19:22948693	G/A	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.05e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.73	-12.34	-0.56	4.61e-29	White blood cell count (basophil);
LUSC	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	0.8	11.33	0.53	2.14e-25	Response to hepatitis C treatment;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.9	17.75	0.7	3.98e-50	Menarche (age at onset);
LUSC	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18342900	chr16:46865048	C16orf87	0.42	6.23	0.32	1.4e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg21211680	chr2:198530	NA	-0.67	-7.89	-0.4	4.5e-14	Blood protein levels;
LUSC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg24642844	chr7:1081250	C7orf50	-0.79	-10.52	-0.5	1.56e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7577696	0.524	rs805831	chr2:32484228	C/G	cg02381751	chr2:32503542	YIPF4	0.51	6.88	0.35	2.95e-11	Inflammatory biomarkers;
LUSC	trans	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Bladder cancer;
LUSC	cis	rs56399783	0.901	rs73051469	chr7:2877811	A/G	cg14895029	chr7:2775587	GNA12	0.52	6.3	0.33	9.29e-10	Childhood ear infection;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03990565	chr11:64885225	ZNHIT2	-0.42	-6.25	-0.32	1.26e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg00277334	chr10:82204260	NA	-0.52	-7.74	-0.39	1.21e-13	Post bronchodilator FEV1;
LUSC	cis	rs9549260	0.753	rs10507486	chr13:41186501	A/G	cg21288729	chr13:41239152	FOXO1	-0.54	-6.27	-0.32	1.09e-9	Red blood cell count;
LUSC	trans	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg18187862	chr3:45730750	SACM1L	-0.53	-6.43	-0.33	4.3e-10	Primary sclerosing cholangitis;
LUSC	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg00745463	chr17:30367425	LRRC37B	0.58	7.3	0.37	2.1e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg03972071	chr18:72917163	ZADH2	0.47	5.76	0.3	1.93e-8	Vascular endothelial growth factor levels;
LUSC	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg11693508	chr17:37793320	STARD3	0.5	6.29	0.33	1e-9	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26917132	chr16:87425759	FBXO31;MAP1LC3B	0.53	7.32	0.37	1.9e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.73	0.54	7.78e-27	Prudent dietary pattern;
LUSC	cis	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05901451	chr6:126070800	HEY2	0.57	8.59	0.43	3.32e-16	Endometrial cancer;
LUSC	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg24692254	chr21:30365293	RNF160	-0.58	-7.22	-0.37	3.57e-12	Cognitive test performance;
LUSC	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg06637938	chr14:75390232	RPS6KL1	0.52	8.2	0.41	5.08e-15	Height;
LUSC	cis	rs6484504	0.532	rs2616799	chr11:31319044	T/C	cg14844989	chr11:31128820	NA	0.39	5.93	0.31	7.53e-9	Red blood cell count;
LUSC	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg19812747	chr11:111475976	SIK2	-0.49	-7.0	-0.36	1.4e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.62	-8.23	-0.41	4.18e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18301423	chr5:131593218	PDLIM4	-0.47	-7.41	-0.38	1.02e-12	Acylcarnitine levels;
LUSC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg16339924	chr4:17578868	LAP3	0.61	9.17	0.45	5.09e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg01884057	chr2:25150051	NA	0.49	11.57	0.54	2.8e-26	Body mass index;
LUSC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg11502198	chr6:26597334	ABT1	-0.61	-9.62	-0.47	1.64e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs72960926	0.744	rs11753898	chr6:74861057	C/T	cg03266952	chr6:74778945	NA	-0.85	-7.25	-0.37	2.94e-12	Metabolite levels (MHPG);
LUSC	cis	rs7804356	0.953	rs10256250	chr7:26895080	A/T	cg03456212	chr7:26904342	SKAP2	-0.52	-6.04	-0.31	4.16e-9	Type 1 diabetes;
LUSC	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	7.86	0.4	5.26e-14	Iron status biomarkers;
LUSC	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg14092571	chr14:90743983	NA	-0.36	-5.82	-0.3	1.36e-8	Mortality in heart failure;
LUSC	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg11161011	chr14:65562177	MAX	-0.71	-10.76	-0.51	2.24e-23	Obesity-related traits;
LUSC	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.9	0.35	2.67e-11	Height;
LUSC	cis	rs1030268	0.577	rs13244007	chr7:133260825	A/G	cg10665199	chr7:133106180	EXOC4	0.63	7.12	0.36	6.59e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.09	0.55	3.63e-28	Prudent dietary pattern;
LUSC	cis	rs9463078	0.547	rs9472360	chr6:44747410	T/C	cg25276700	chr6:44698697	NA	0.3	6.33	0.33	7.67e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs11645898	0.935	rs72787077	chr16:72156674	C/T	cg14768367	chr16:72042858	DHODH	-0.64	-7.22	-0.37	3.49e-12	Blood protein levels;
LUSC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.56	-8.36	-0.42	1.77e-15	Gut microbiome composition (summer);
LUSC	cis	rs8099014	1.000	rs8099014	chr18:56109859	C/A	cg12907477	chr18:56117327	MIR122	0.45	7.21	0.37	3.77e-12	Platelet count;
LUSC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.98	0.31	5.73e-9	Menopause (age at onset);
LUSC	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg22532475	chr10:104410764	TRIM8	-0.32	-7.09	-0.36	8.12e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-5.73	-0.3	2.23e-8	Response to antipsychotic treatment;
LUSC	cis	rs2540226	0.935	rs6722610	chr2:39985742	C/T	cg23576258	chr2:39999331	THUMPD2	0.35	5.87	0.31	1.03e-8	Personality dimensions;
LUSC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.92	0.4	3.59e-14	Colorectal cancer;
LUSC	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg24375607	chr4:120327624	NA	0.78	11.42	0.53	1.03e-25	Corneal astigmatism;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg18538332	chr22:24372958	LOC391322	-0.47	-8.31	-0.41	2.41e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4919687	0.550	rs12783444	chr10:104480659	G/A	cg05855489	chr10:104503620	C10orf26	0.71	11.5	0.53	5.26e-26	Colorectal cancer;
LUSC	trans	rs2288327	0.557	rs7577862	chr2:179352857	G/A	cg14011486	chr1:26737247	LIN28	0.78	9.73	0.47	7.51e-20	Atrial fibrillation;
LUSC	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg08048268	chr3:133502702	NA	-0.37	-6.6	-0.34	1.6e-10	Iron status biomarkers;
LUSC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-1.07	-15.83	-0.65	1.64e-42	Initial pursuit acceleration;
LUSC	cis	rs7084921	0.547	rs12780035	chr10:101874844	C/T	cg11888571	chr10:102027403	CWF19L1	-0.45	-6.11	-0.32	2.85e-9	Bone mineral density;
LUSC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.82	-0.3	1.37e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.2	0.32	1.7e-9	Corneal astigmatism;
LUSC	cis	rs6967385	0.867	rs62451462	chr7:12359234	A/G	cg06484146	chr7:12443880	VWDE	0.39	5.76	0.3	1.87e-8	Response to taxane treatment (placlitaxel);
LUSC	trans	rs800082	1.000	rs7613909	chr3:144308606	A/G	cg24215973	chr2:240111563	HDAC4	0.42	6.38	0.33	5.79e-10	Smoking behavior;
LUSC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.81	13.5	0.59	1.91e-33	Aortic root size;
LUSC	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.7e-16	Menopause (age at onset);
LUSC	trans	rs6852435	1.000	rs34400328	chr4:175298214	T/A	cg23753247	chr11:8615842	STK33	-0.54	-6.14	-0.32	2.36e-9	Response to acetaminophen (hepatotoxicity);
LUSC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.84	-0.35	3.89e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs3087591	1.000	rs2107360	chr17:29697901	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.59	-8.43	-0.42	1.08e-15	Hip circumference;
LUSC	cis	rs6785206	0.772	rs6439134	chr3:128323504	C/T	cg16766828	chr3:128327626	NA	-0.71	-7.68	-0.39	1.76e-13	Lymphocyte percentage of white cells;
LUSC	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.61	-0.43	2.97e-16	Total cholesterol levels;
LUSC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Parkinson's disease;
LUSC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg05855489	chr10:104503620	C10orf26	-0.7	-10.14	-0.49	3.15e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs72674100	1.000	rs7695114	chr4:97968711	C/T	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs12474201	0.928	rs12998762	chr2:46938393	A/C	cg06386533	chr2:46925753	SOCS5	0.76	11.34	0.53	1.89e-25	Height;
LUSC	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg08601574	chr20:25228251	PYGB	0.49	7.55	0.38	4.23e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6906287	0.647	rs6569013	chr6:118681328	G/T	cg21191810	chr6:118973309	C6orf204	-0.38	-6.63	-0.34	1.32e-10	Electrocardiographic conduction measures;
LUSC	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg05564266	chr6:118973597	C6orf204	0.24	5.67	0.3	3.06e-8	Electrocardiographic conduction measures;
LUSC	cis	rs1160297	0.609	rs2356680	chr2:53095313	T/C	cg07782112	chr2:53107842	NA	0.45	7.22	0.37	3.65e-12	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg04310649	chr10:35416472	CREM	-0.41	-6.36	-0.33	6.52e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.89	15.73	0.65	4.11e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs1014246	0.813	rs1014245	chr10:118466129	G/A	cg14919929	chr10:118506882	NA	0.44	6.82	0.35	4.28e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs10992471	0.603	rs12342019	chr9:95192508	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-7.95	-0.4	2.84e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.42	-8.07	-0.4	1.25e-14	Schizophrenia;
LUSC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg12365402	chr11:9010492	NRIP3	0.41	7.52	0.38	5.13e-13	Hemoglobin concentration;
LUSC	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	0.97	10.96	0.51	4.58e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg03929089	chr4:120376271	NA	0.8	10.15	0.49	2.92e-21	Coronary artery disease;
LUSC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	0.93	16.12	0.66	1.16e-43	Menopause (age at onset);
LUSC	cis	rs12956009	0.518	rs1347343	chr18:44818996	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.77	0.35	5.8200000000000003e-11	Educational attainment (years of education);
LUSC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg23280166	chr11:118938394	VPS11	0.48	7.62	0.39	2.57e-13	Coronary artery disease;
LUSC	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg11019008	chr10:131425282	MGMT	0.39	5.84	0.3	1.26e-8	Response to temozolomide;
LUSC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg25036284	chr2:26402008	FAM59B	-0.72	-9.87	-0.48	2.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg23992470	chr4:843637	GAK	0.58	6.05	0.31	3.98e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg04990556	chr1:26633338	UBXN11	-0.48	-6.18	-0.32	1.87e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg00310523	chr12:86230176	RASSF9	0.49	9.32	0.45	1.62e-18	Major depressive disorder;
LUSC	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.11	0.64	1.12e-39	Lymphocyte percentage of white cells;
LUSC	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	8.16	0.41	6.7e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg13010344	chr12:123464640	ARL6IP4	-0.5	-8.05	-0.4	1.42e-14	Platelet count;
LUSC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg19812747	chr11:111475976	SIK2	0.53	7.68	0.39	1.77e-13	Primary sclerosing cholangitis;
LUSC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.22	0.52	5.46e-25	Menopause (age at onset);
LUSC	cis	rs714027	1.000	rs2412970	chr22:30486826	C/T	cg11564601	chr22:30592435	NA	0.38	6.98	0.36	1.58e-11	Lymphocyte counts;
LUSC	trans	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg26384229	chr12:38710491	ALG10B	0.57	9.04	0.44	1.32e-17	Morning vs. evening chronotype;
LUSC	cis	rs977987	0.835	rs8057535	chr16:75347941	C/T	cg04384234	chr16:75411784	CFDP1	-0.41	-6.71	-0.34	8.56e-11	Dupuytren's disease;
LUSC	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.8	-9.43	-0.46	7e-19	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
LUSC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.59	9.56	0.46	2.58e-19	Bronchopulmonary dysplasia;
LUSC	cis	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg07460842	chr6:66804631	NA	0.47	5.8	0.3	1.53e-8	Metabolite levels;
LUSC	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg22782873	chr19:19639568	YJEFN3	-0.53	-6.29	-0.33	9.98e-10	Bipolar disorder;
LUSC	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.58	7.95	0.4	2.87e-14	Iron status biomarkers;
LUSC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg05110241	chr16:68378359	PRMT7	-0.78	-8.78	-0.43	8.66e-17	Schizophrenia;
LUSC	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg11861562	chr11:117069780	TAGLN	0.34	6.59	0.34	1.76e-10	Blood protein levels;
LUSC	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg04990556	chr1:26633338	UBXN11	-0.48	-6.15	-0.32	2.24e-9	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg26384229	chr12:38710491	ALG10B	0.93	15.94	0.66	5.93e-43	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs62400317	0.859	rs11966878	chr6:45328265	C/T	cg20913747	chr6:44695427	NA	0.48	7.69	0.39	1.69e-13	Total body bone mineral density;
LUSC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg18306943	chr3:40428807	ENTPD3	0.38	5.86	0.31	1.13e-8	Renal cell carcinoma;
LUSC	cis	rs6580649	0.941	rs7959755	chr12:48446318	T/A	cg24011408	chr12:48396354	COL2A1	-0.46	-6.13	-0.32	2.43e-9	Lung cancer;
LUSC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg04155289	chr7:94953770	PON1	-0.34	-5.76	-0.3	1.9e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.63	9.59	0.46	2.07e-19	Corneal astigmatism;
LUSC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.82	0.43	6.37e-17	Lung cancer;
LUSC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.57	-8.64	-0.43	2.28e-16	Menarche (age at onset);
LUSC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg24250549	chr1:154909240	PMVK	-0.45	-6.85	-0.35	3.49e-11	Prostate cancer;
LUSC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg21770322	chr7:97807741	LMTK2	0.41	7.08	0.36	8.48e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4862307	0.836	rs11132220	chr4:184997247	A/T	cg06737308	chr4:185021514	ENPP6	-0.5	-7.73	-0.39	1.31e-13	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUSC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg02772935	chr3:125709198	NA	-0.48	-5.78	-0.3	1.7e-8	Blood pressure (smoking interaction);
LUSC	trans	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg15556689	chr8:8085844	FLJ10661	0.47	7.26	0.37	2.66e-12	Retinal vascular caliber;
LUSC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.03	20.21	0.74	6.86e-60	Cognitive function;
LUSC	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg04733989	chr22:42467013	NAGA	0.42	7.08	0.36	8.62e-12	Cognitive function;
LUSC	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg00191853	chr8:101177733	SPAG1	0.39	6.16	0.32	2.14e-9	Atrioventricular conduction;
LUSC	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg03732007	chr1:2071316	PRKCZ	0.48	7.85	0.39	5.6e-14	Height;
LUSC	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg04218760	chr10:45406644	TMEM72	-0.3	-7.09	-0.36	7.8e-12	Mean corpuscular volume;
LUSC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg18230493	chr5:56204884	C5orf35	-0.95	-13.95	-0.61	3.51e-35	Initial pursuit acceleration;
LUSC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08677398	chr8:58056175	NA	0.58	6.91	0.35	2.52e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.56	-0.34	2.06e-10	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg21724239	chr8:58056113	NA	0.78	9.03	0.44	1.43e-17	Developmental language disorder (linguistic errors);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00128877	chr1:47070178	MKNK1	0.46	7.13	0.36	6.15e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.57	9.05	0.44	1.19e-17	Longevity;Endometriosis;
LUSC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg24733560	chr20:60626293	TAF4	0.37	6.09	0.32	3.12e-9	Body mass index;
LUSC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.51	6.15	0.32	2.17e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg27068330	chr11:65405492	SIPA1	0.74	10.78	0.51	1.89e-23	Acne (severe);
LUSC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg02038168	chr22:39784481	NA	-0.5	-8.18	-0.41	5.88e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg10130564	chr11:117069849	TAGLN	0.37	6.26	0.32	1.16e-9	Blood protein levels;
LUSC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15664640	chr17:80829946	TBCD	0.47	8.44	0.42	9.53e-16	Breast cancer;
LUSC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg13319975	chr6:146136371	FBXO30	0.69	10.63	0.5	6.28e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00149659	chr3:10157352	C3orf10	0.92	12.88	0.58	4.25e-31	Alzheimer's disease;
LUSC	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg09654669	chr8:57350985	NA	-0.61	-8.51	-0.42	6.03e-16	Obesity-related traits;
LUSC	cis	rs524023	1.000	rs9734313	chr11:64358311	C/T	cg19131476	chr11:64387923	NRXN2	-0.37	-10.05	-0.48	5.96e-21	Urate levels in obese individuals;
LUSC	cis	rs997295	0.713	rs9302245	chr15:68021137	C/T	cg08079166	chr15:68083412	MAP2K5	-0.34	-6.67	-0.34	1.07e-10	Motion sickness;
LUSC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg23649088	chr2:200775458	C2orf69	0.54	7.35	0.37	1.58e-12	Schizophrenia;
LUSC	cis	rs2932538	0.922	rs36029940	chr1:113106444	T/G	cg22162597	chr1:113214053	CAPZA1	0.7	9.96	0.48	1.21e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg13047869	chr3:10149882	C3orf24	-0.41	-6.36	-0.33	6.45e-10	Alzheimer's disease;
LUSC	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg27661571	chr11:113659931	NA	-0.69	-7.82	-0.39	6.91e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs977987	0.872	rs1542864	chr16:75471378	G/A	cg04384234	chr16:75411784	CFDP1	-0.45	-7.44	-0.38	8.61e-13	Dupuytren's disease;
LUSC	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.81e-22	Eye color traits;
LUSC	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg07080220	chr10:102295463	HIF1AN	-0.56	-7.61	-0.38	2.74e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg02466173	chr16:30829666	NA	-0.6	-11.22	-0.52	5.43e-25	Multiple myeloma;
LUSC	cis	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg21775007	chr8:11205619	TDH	0.42	5.72	0.3	2.38e-8	Neuroticism;
LUSC	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg06609049	chr19:2785107	THOP1	0.65	10.31	0.49	8.33e-22	Total cholesterol levels;
LUSC	cis	rs791888	0.688	rs1980649	chr10:89422375	T/C	cg13926569	chr10:89418898	PAPSS2	0.36	7.1	0.36	7.63e-12	Magnesium levels;
LUSC	cis	rs12760731	0.565	rs71628268	chr1:178151908	T/C	cg00404053	chr1:178313656	RASAL2	0.75	7.4	0.38	1.12e-12	Obesity-related traits;
LUSC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg04414720	chr1:150670196	GOLPH3L	0.56	9.1	0.45	8.47e-18	Urate levels;
LUSC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	6.66	0.34	1.1e-10	Schizophrenia;
LUSC	cis	rs9633740	0.773	rs1870148	chr10:82271341	G/A	cg01528321	chr10:82214614	TSPAN14	1.07	11.78	0.54	4.98e-27	Post bronchodilator FEV1;
LUSC	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg01528321	chr10:82214614	TSPAN14	0.82	12.33	0.56	4.69e-29	Post bronchodilator FEV1;
LUSC	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.3	5.81	0.3	1.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.61	-10.22	-0.49	1.57e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg13575925	chr12:9217583	LOC144571	0.34	6.27	0.32	1.14e-9	Sjögren's syndrome;
LUSC	trans	rs7838490	0.780	rs28783381	chr8:89705802	T/G	cg24558378	chr1:183589673	NA	0.34	6.26	0.32	1.22e-9	Body mass index and cholesterol (psychopharmacological treatment);
LUSC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg20406979	chr6:167373233	NA	0.25	5.81	0.3	1.49e-8	Crohn's disease;
LUSC	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.31	-0.37	1.98e-12	Mood instability;
LUSC	trans	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-9.89	-0.48	2.09e-20	Brugada syndrome;
LUSC	cis	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.47	-0.33	3.46e-10	Morning vs. evening chronotype;
LUSC	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg26924012	chr15:45694286	SPATA5L1	0.79	12.5	0.56	1.13e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.67e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg08773314	chr2:239334832	ASB1	-0.43	-9.38	-0.46	1.06e-18	Multiple system atrophy;
LUSC	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg24881330	chr22:46731750	TRMU	0.83	7.5	0.38	5.79e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg09640425	chr7:158790006	NA	0.53	8.45	0.42	9.06e-16	Facial morphology (factor 20);
LUSC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg14784868	chr12:69753453	YEATS4	0.64	9.48	0.46	4.97e-19	Blood protein levels;
LUSC	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg23173402	chr1:227635558	NA	0.65	6.54	0.34	2.35e-10	Major depressive disorder;
LUSC	trans	rs853679	0.567	rs2232427	chr6:28359709	T/G	cg01620082	chr3:125678407	NA	-0.44	-6.38	-0.33	6.04e-10	Depression;
LUSC	cis	rs7586879	0.789	rs7560156	chr2:25124794	T/C	cg01884057	chr2:25150051	NA	0.42	8.8	0.43	7.49e-17	Body mass index;
LUSC	cis	rs28493229	0.748	rs10426415	chr19:41183590	A/G	cg21869046	chr19:41225005	ITPKC	0.54	7.03	0.36	1.21e-11	Kawasaki disease;
LUSC	cis	rs3126085	0.935	rs3126048	chr1:152260165	T/C	cg26876637	chr1:152193138	HRNR	-0.46	-6.37	-0.33	6.23e-10	Atopic dermatitis;
LUSC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg05347473	chr6:146136440	FBXO30	0.4	6.55	0.34	2.17e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs34779708	0.733	rs12249814	chr10:35542757	T/C	cg03585969	chr10:35415529	CREM	0.55	7.69	0.39	1.71e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	6.07	0.32	3.53e-9	Schizophrenia;
LUSC	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg09976142	chr9:130955436	CIZ1	0.45	7.7	0.39	1.59e-13	Attention deficit hyperactivity disorder;
LUSC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.23	0.41	4.12e-15	Melanoma;
LUSC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.52	8.61	0.43	2.88e-16	Immature fraction of reticulocytes;
LUSC	cis	rs56399783	0.901	rs73049305	chr7:2778755	C/T	cg19731401	chr7:2775893	GNA12	0.72	8.67	0.43	1.95e-16	Childhood ear infection;
LUSC	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg17168535	chr8:21777572	XPO7	0.82	14.97	0.63	3.82e-39	Mean corpuscular volume;
LUSC	cis	rs6060717	0.536	rs17431878	chr20:34502107	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.69	-0.3	2.76e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs6463523	0.933	rs79984239	chr7:766220	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.0	21.64	0.76	1.6e-65	Subjective well-being;
LUSC	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.42	0.38	9.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg16070123	chr10:51489643	NA	-0.56	-9.31	-0.45	1.72e-18	Prostate-specific antigen levels;
LUSC	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg21775007	chr8:11205619	TDH	0.42	5.87	0.31	1.03e-8	Myopia (pathological);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08036850	chr12:121124877	MLEC	0.44	6.42	0.33	4.73e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.17	-0.32	2.03e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6669072	0.546	rs1025962	chr1:91264088	A/G	cg08895590	chr1:91227319	NA	-0.27	-5.8	-0.3	1.54e-8	Cognitive function;
LUSC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg03188948	chr7:1209495	NA	0.66	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg06521331	chr12:34319734	NA	-0.4	-6.93	-0.35	2.23e-11	Morning vs. evening chronotype;
LUSC	cis	rs4654899	0.865	rs12410467	chr1:21356055	G/A	cg01072550	chr1:21505969	NA	-0.54	-7.91	-0.4	3.75e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-11.01	-0.52	2.85e-24	Bipolar disorder;
LUSC	cis	rs806215	0.723	rs1090682	chr7:127245159	T/C	cg25922125	chr7:127225783	GCC1	0.57	7.17	0.37	4.78e-12	Type 2 diabetes;
LUSC	cis	rs7707921	1.000	rs17245188	chr5:81469082	A/C	cg15871215	chr5:81402204	ATG10	0.43	6.47	0.33	3.57e-10	Breast cancer;
LUSC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg15839431	chr19:19639596	YJEFN3	-0.51	-6.06	-0.31	3.66e-9	Tonsillectomy;
LUSC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	1.05	19.36	0.73	1.62e-56	Parkinson's disease;
LUSC	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-6.09	-0.32	3.18e-9	Bipolar disorder;
LUSC	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg08975724	chr8:8085496	FLJ10661	0.48	7.06	0.36	9.6e-12	Retinal vascular caliber;
LUSC	cis	rs6693567	0.545	rs9436009	chr1:150459426	T/A	cg15654264	chr1:150340011	RPRD2	0.43	6.9	0.35	2.56e-11	Migraine;
LUSC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg03676636	chr4:99064102	C4orf37	0.35	7.54	0.38	4.59e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	1.14	12.86	0.58	5.13e-31	Diabetic kidney disease;
LUSC	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg21293242	chr8:11204541	TDH	0.34	6.57	0.34	1.89e-10	Retinal vascular caliber;
LUSC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg03806693	chr22:41940476	POLR3H	-0.99	-14.25	-0.61	2.49e-36	Vitiligo;
LUSC	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	0.57	8.69	0.43	1.62e-16	Breast cancer;
LUSC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	0.92	15.38	0.64	1.02e-40	Breast cancer;
LUSC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg26030610	chr1:113933950	MAGI3	0.41	6.43	0.33	4.41e-10	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg02974815	chr3:52091604	DUSP7	0.39	6.02	0.31	4.7e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-9.42	-0.46	7.58e-19	Gut microbiome composition (summer);
LUSC	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg19875535	chr5:140030758	IK	0.47	7.66	0.39	2.01e-13	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs13233308	0.836	rs6966166	chr7:87455155	C/T	cg22633988	chr4:77610603	SHROOM3	-0.43	-6.32	-0.33	8.47e-10	Schizophrenia;
LUSC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg04850211	chr1:228464232	OBSCN	0.32	5.68	0.3	2.92e-8	Diastolic blood pressure;
LUSC	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg05182265	chr7:156933206	UBE3C	0.58	9.44	0.46	6.38e-19	Body mass index;
LUSC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg01802117	chr1:53393560	SCP2	-0.37	-6.06	-0.31	3.75e-9	Monocyte count;
LUSC	cis	rs2230307	0.536	rs506044	chr1:100611931	A/G	cg24955406	chr1:100503596	HIAT1	-0.64	-6.87	-0.35	3.07e-11	Carotid intima media thickness;
LUSC	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.02	-0.4	1.78e-14	Body mass index;
LUSC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.1	-0.58	6.15e-32	Platelet count;
LUSC	cis	rs710216	1.000	rs710216	chr1:43428757	A/G	cg22176566	chr1:43424700	SLC2A1	0.46	5.83	0.3	1.33e-8	Red cell distribution width;
LUSC	cis	rs9479482	0.967	rs1543547	chr6:150346532	T/C	cg25797454	chr6:150327115	RAET1K	0.33	7.43	0.38	8.97e-13	Alopecia areata;
LUSC	cis	rs721399	0.553	rs10109286	chr8:18243603	A/G	cg18736775	chr8:18248649	NAT2	-0.62	-7.84	-0.39	6.07e-14	Blood metabolite levels;
LUSC	cis	rs2742417	1.000	rs2742420	chr3:45732237	A/G	cg09608765	chr3:45636137	LIMD1	-0.37	-7.21	-0.37	3.68e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7903847	0.642	rs2297667	chr10:99145492	A/T	cg20016023	chr10:99160130	RRP12	-0.32	-7.7	-0.39	1.54e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1152591	0.505	rs1152601	chr14:64667337	T/C	cg21174375	chr14:64681225	SYNE2	0.32	5.82	0.3	1.39e-8	Atrial fibrillation;
LUSC	cis	rs4622329	0.636	rs7976056	chr12:102313506	A/G	cg23541617	chr12:102225335	GNPTAB	0.27	5.9	0.31	8.91e-9	Systemic lupus erythematosus;
LUSC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.4e-22	Alzheimer's disease (late onset);
LUSC	cis	rs2996428	0.561	rs16824192	chr1:3748605	G/A	cg23277830	chr1:3704460	LRRC47	0.32	5.99	0.31	5.44e-9	Red cell distribution width;
LUSC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.1	-0.41	1.07e-14	Lung cancer;
LUSC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	ch.11.42038R	chr11:967971	AP2A2	0.53	7.83	0.39	6.49e-14	Alzheimer's disease (late onset);
LUSC	cis	rs4499344	0.589	rs259218	chr19:33138125	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	13.06	0.58	9.07e-32	Mean platelet volume;
LUSC	cis	rs7104764	0.507	rs7121085	chr11:258523	A/G	cg00562011	chr11:252351	PSMD13	-0.51	-6.62	-0.34	1.42e-10	Menarche (age at onset);
LUSC	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg12011299	chr4:100065546	ADH4	-0.42	-6.82	-0.35	4.17e-11	Alcohol dependence;
LUSC	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg05855489	chr10:104503620	C10orf26	0.58	7.7	0.39	1.51e-13	Arsenic metabolism;
LUSC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg00343986	chr7:65444356	GUSB	-0.47	-7.01	-0.36	1.3e-11	Calcium levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07552157	chr3:142720316	SR140	-0.51	-6.88	-0.35	3.01e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9549260	0.755	rs2721044	chr13:41162225	C/T	cg21288729	chr13:41239152	FOXO1	0.61	9.48	0.46	4.84e-19	Red blood cell count;
LUSC	cis	rs11997175	0.692	rs6995075	chr8:33673816	G/A	ch.8.33884649F	chr8:33765107	NA	0.37	5.71	0.3	2.52e-8	Body mass index;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg16504335	chr14:81902346	NA	0.76	6.25	0.32	1.24e-9	Cognitive performance;
LUSC	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.82	0.47	3.57e-20	Resting heart rate;
LUSC	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.48	7.88	0.4	4.78e-14	Alcohol dependence;
LUSC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg03806693	chr22:41940476	POLR3H	-1.01	-13.75	-0.6	2.04e-34	Vitiligo;
LUSC	cis	rs7084921	0.608	rs12773948	chr10:101865115	T/A	cg11888571	chr10:102027403	CWF19L1	-0.45	-6.29	-0.33	1.02e-9	Bone mineral density;
LUSC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg05347473	chr6:146136440	FBXO30	-0.67	-11.39	-0.53	1.34e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3740713	1.000	rs16935432	chr11:18470487	G/A	cg15463284	chr11:18477534	LDHAL6A	-0.5	-5.73	-0.3	2.21e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg09365446	chr1:150670422	GOLPH3L	0.5	7.73	0.39	1.3e-13	Tonsillectomy;
LUSC	cis	rs12545109	0.671	rs35500854	chr8:57424303	G/A	cg09654669	chr8:57350985	NA	-0.51	-6.62	-0.34	1.43e-10	Obesity-related traits;
LUSC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.33	-0.37	1.76e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg15485101	chr11:133734466	NA	0.42	7.58	0.38	3.54e-13	Childhood ear infection;
LUSC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg06521331	chr12:34319734	NA	-0.35	-5.7	-0.3	2.61e-8	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg13319975	chr6:146136371	FBXO30	-0.52	-7.66	-0.39	1.97e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs59698941	0.943	rs67843388	chr5:132288007	C/T	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg17757837	chr7:157058334	UBE3C	0.82	13.05	0.58	9.46e-32	Body mass index;
LUSC	trans	rs7726558	0.543	rs76058893	chr5:118844238	C/G	cg14402224	chr7:50570049	DDC	-0.47	-6.14	-0.32	2.31e-9	QT interval (sulfonylurea treatment interaction);
LUSC	cis	rs12912251	1.000	rs12912251	chr15:38986368	G/T	cg01338139	chr15:38987640	C15orf53	-0.49	-6.72	-0.35	7.68e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs4919694	1.000	rs76892505	chr10:104719290	G/A	cg04362960	chr10:104952993	NT5C2	1.18	13.25	0.59	1.78e-32	Arsenic metabolism;
LUSC	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg10911889	chr6:126070802	HEY2	0.39	5.75	0.3	2.03e-8	High light scatter reticulocyte count;
LUSC	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg14092571	chr14:90743983	NA	-0.38	-6.44	-0.33	4.25e-10	Mortality in heart failure;
LUSC	cis	rs12984174	1.000	rs403439	chr19:18142075	A/G	cg21649277	chr19:18117794	ARRDC2	-0.62	-6.7	-0.34	8.79e-11	Pulmonary function in asthmatics;
LUSC	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	cis	rs1018836	0.631	rs9987133	chr8:91470730	T/C	cg16814680	chr8:91681699	NA	-0.56	-8.27	-0.41	3.28e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.94	0.55	1.29e-27	Exhaled nitric oxide output;
LUSC	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg20891283	chr12:69753455	YEATS4	0.46	6.31	0.33	9.07e-10	Response to diuretic therapy;
LUSC	cis	rs1983891	1.000	rs2104506	chr6:41533579	C/A	cg15051332	chr6:41514432	FOXP4	0.4	5.85	0.3	1.16e-8	Prostate cancer;
LUSC	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.0	-0.4	2.14e-14	Glomerular filtration rate;
LUSC	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg20933634	chr6:27740509	NA	0.42	6.02	0.31	4.64e-9	Parkinson's disease;
LUSC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	0.95	12.93	0.58	2.72e-31	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg23262073	chr20:60523788	NA	-0.38	-5.83	-0.3	1.34e-8	Body mass index;
LUSC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04871131	chr7:94954202	PON1	-0.47	-8.85	-0.44	5.31e-17	Paraoxonase activity;
LUSC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.74	-0.3	2.1e-8	Alzheimer's disease (late onset);
LUSC	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg01097406	chr16:89675127	NA	-0.36	-6.88	-0.35	2.99e-11	Hemoglobin concentration;
LUSC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg17252645	chr8:143867129	LY6D	-0.56	-10.58	-0.5	9.6e-23	Urinary tract infection frequency;
LUSC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08219700	chr8:58056026	NA	0.65	8.72	0.43	1.36e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg15571903	chr15:79123663	NA	-0.33	-6.13	-0.32	2.47e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26314531	chr2:26401878	FAM59B	0.72	10.16	0.49	2.55e-21	Gut microbiome composition (summer);
LUSC	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	6.33	0.33	7.79e-10	Menarche (age at onset);
LUSC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11645453	chr3:52864694	ITIH4	0.32	7.48	0.38	6.77e-13	Bipolar disorder;
LUSC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg24250549	chr1:154909240	PMVK	0.57	9.03	0.44	1.37e-17	Prostate cancer;
LUSC	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg13042288	chr15:90349979	ANPEP	-0.5	-6.94	-0.36	2.01e-11	Uric acid levels;
LUSC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.41	0.46	8.32e-19	Monocyte percentage of white cells;
LUSC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12379764	chr21:47803548	PCNT	-0.42	-5.88	-0.31	9.69e-9	Testicular germ cell tumor;
LUSC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg04518342	chr5:131593106	PDLIM4	-0.43	-7.28	-0.37	2.38e-12	Breast cancer;
LUSC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg03146154	chr1:46216737	IPP	0.51	7.42	0.38	9.87e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7914558	0.621	rs12219346	chr10:104657300	T/C	cg05855489	chr10:104503620	C10orf26	0.43	5.77	0.3	1.84e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.07	-0.36	8.87e-12	Schizophrenia;
LUSC	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	6.18	0.32	1.84e-9	Rheumatoid arthritis;
LUSC	cis	rs3784262	1.000	rs10851630	chr15:58242148	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.06	-0.31	3.72e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs7582720	1.000	rs4510208	chr2:203734866	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	8.31	0.41	2.46e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7605827	0.930	rs6705287	chr2:15529368	A/C	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg08213375	chr14:104286397	PPP1R13B	0.54	10.89	0.51	7.59e-24	Schizophrenia;
LUSC	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.39	7.63	0.39	2.4e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg16031515	chr1:205743344	RAB7L1	-0.3	-6.36	-0.33	6.52e-10	Menarche (age at onset);
LUSC	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.35	-0.33	7.06e-10	Systolic blood pressure;
LUSC	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg24692254	chr21:30365293	RNF160	-0.54	-6.96	-0.36	1.79e-11	Cognitive test performance;
LUSC	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg05340658	chr4:99064831	C4orf37	-0.46	-7.26	-0.37	2.68e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9840812	0.725	rs3821445	chr3:136002809	T/C	cg15507776	chr3:136538369	TMEM22	-0.45	-5.87	-0.31	1.06e-8	Fibrinogen levels;
LUSC	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg13206674	chr6:150067644	NUP43	0.59	9.24	0.45	2.87e-18	Lung cancer;
LUSC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18876405	chr7:65276391	NA	-0.56	-8.81	-0.43	7.03e-17	Aortic root size;
LUSC	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg01283332	chr5:1856932	NA	-0.34	-6.38	-0.33	6.02e-10	Cardiovascular disease risk factors;
LUSC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg00857998	chr1:205179979	DSTYK	0.58	8.82	0.43	6.39e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.14	0.36	5.96e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg02980000	chr4:1222292	CTBP1	0.73	7.34	0.37	1.59e-12	Systolic blood pressure;
LUSC	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg23711669	chr6:146136114	FBXO30	0.72	12.58	0.57	5.87e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg16647868	chr5:131706066	SLC22A5	0.39	5.94	0.31	7.3e-9	Breast cancer;
LUSC	cis	rs6430585	0.584	rs4954276	chr2:136402117	A/G	cg07169764	chr2:136633963	MCM6	0.53	7.08	0.36	8.77e-12	Corneal structure;
LUSC	cis	rs4664304	0.802	rs3749114	chr2:160832996	A/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.24	-0.32	1.34e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg09835421	chr16:68378352	PRMT7	-0.76	-8.23	-0.41	4.35e-15	Schizophrenia;
LUSC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg18301423	chr5:131593218	PDLIM4	0.38	6.2	0.32	1.66e-9	Blood metabolite levels;
LUSC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg15691649	chr6:25882328	NA	-0.39	-5.78	-0.3	1.75e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg08079166	chr15:68083412	MAP2K5	0.36	6.23	0.32	1.39e-9	Obesity;
LUSC	cis	rs8014204	0.816	rs4903262	chr14:75340818	A/G	cg06637938	chr14:75390232	RPS6KL1	0.53	8.37	0.42	1.55e-15	Caffeine consumption;
LUSC	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4811340	0.600	rs6068251	chr20:51180110	G/A	cg15736553	chr3:11610338	VGLL4	-0.33	-5.95	-0.31	6.7e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg16576597	chr16:28551801	NUPR1	0.29	5.75	0.3	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.65	-11.23	-0.52	4.66e-25	Itch intensity from mosquito bite;
LUSC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.46	0.53	7.26e-26	Menopause (age at onset);
LUSC	cis	rs7577696	0.597	rs212751	chr2:32418808	T/A	cg02381751	chr2:32503542	YIPF4	0.53	7.1	0.36	7.62e-12	Inflammatory biomarkers;
LUSC	cis	rs12681287	0.547	rs60982560	chr8:87515046	C/T	cg00550725	chr8:87521180	FAM82B	0.44	5.75	0.3	2.07e-8	Caudate activity during reward;
LUSC	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg10547527	chr2:198650123	BOLL	-0.49	-5.89	-0.31	9.29e-9	Ulcerative colitis;
LUSC	cis	rs5758511	0.773	rs62241023	chr22:42385429	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.56	-6.74	-0.35	7.04e-11	Birth weight;
LUSC	cis	rs672059	1.000	rs551569	chr1:183158293	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.54	7.98	0.4	2.42e-14	Hypertriglyceridemia;
LUSC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg12963246	chr6:28129442	ZNF389	0.41	5.69	0.3	2.75e-8	Parkinson's disease;
LUSC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	7.78	0.39	9.16e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg06671706	chr8:8559999	CLDN23	0.5	6.69	0.34	9.65e-11	Obesity-related traits;
LUSC	cis	rs911119	0.913	rs2405392	chr20:23569186	C/T	cg16589663	chr20:23618590	CST3	0.63	7.33	0.37	1.74e-12	Chronic kidney disease;
LUSC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.5	-8.85	-0.44	5.02e-17	Osteoporosis;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20550224	chr17:47929286	NA	0.74	6.37	0.33	6.3e-10	Cognitive performance;
LUSC	trans	rs11700980	0.551	rs77334403	chr21:30109398	A/G	cg14791747	chr16:20752902	THUMPD1	0.55	5.98	0.31	5.75e-9	QRS complex (12-leadsum);
LUSC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg15445000	chr17:37608096	MED1	0.4	6.86	0.35	3.35e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg07150166	chr2:30669952	LCLAT1	0.64	7.23	0.37	3.21e-12	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.09	14.9	0.63	7.52e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs868036	1.000	rs8037262	chr15:68108572	C/T	cg08079166	chr15:68083412	MAP2K5	0.4	8.28	0.41	3.04e-15	Restless legs syndrome;
LUSC	cis	rs57590327	0.503	rs1461611	chr3:81512061	C/A	cg07356753	chr3:81810745	GBE1	0.46	6.1	0.32	3.01e-9	Extraversion;
LUSC	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg24675056	chr1:15929824	NA	0.48	7.96	0.4	2.79e-14	Systolic blood pressure;
LUSC	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg16928487	chr17:17741425	SREBF1	-0.51	-9.63	-0.47	1.55e-19	Total body bone mineral density;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03584783	chr1:173836803	GAS5;SNORD76;SNORD75;SNORD77;ZBTB37	-0.51	-6.48	-0.33	3.33e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4478858	0.684	rs1546375	chr1:31765968	C/T	cg00250761	chr1:31883323	NA	-0.35	-8.37	-0.42	1.61e-15	Alcohol dependence;
LUSC	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.79	11.38	0.53	1.46e-25	Corneal astigmatism;
LUSC	cis	rs62400317	0.859	rs62436760	chr6:45112604	T/C	cg18551225	chr6:44695536	NA	-0.41	-6.84	-0.35	3.88e-11	Total body bone mineral density;
LUSC	cis	rs977987	0.800	rs12935787	chr16:75332335	C/T	cg04384234	chr16:75411784	CFDP1	-0.37	-5.94	-0.31	7.31e-9	Dupuytren's disease;
LUSC	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg03351412	chr1:154909251	PMVK	0.51	7.84	0.39	5.99e-14	Prostate cancer;
LUSC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg21918786	chr6:109611834	NA	-0.38	-6.45	-0.33	3.9e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs926938	0.527	rs360681	chr1:115496741	C/G	cg12756093	chr1:115239321	AMPD1	0.46	6.92	0.35	2.35e-11	Autism;
LUSC	cis	rs6556937	0.627	rs7705824	chr5:96005617	A/C	cg07690455	chr5:95997198	CAST	0.49	6.78	0.35	5.52e-11	Blood protein levels;
LUSC	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg09904177	chr6:26538194	HMGN4	-0.74	-6.95	-0.36	1.9e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg25174290	chr11:3078921	CARS	-0.41	-6.22	-0.32	1.49e-9	Calcium levels;
LUSC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg14552801	chr7:65878734	NA	-0.38	-5.96	-0.31	6.31e-9	Aortic root size;
LUSC	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg17168535	chr8:21777572	XPO7	0.85	15.85	0.66	1.34e-42	Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg10701640	chr17:43249399	NA	0.46	10.02	0.48	7.96e-21	Height;
LUSC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg15423357	chr2:25149977	NA	0.37	7.35	0.37	1.49e-12	Body mass index in non-asthmatics;
LUSC	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg15083037	chr5:83017644	HAPLN1	-0.6	-8.01	-0.4	1.94e-14	Prostate cancer;
LUSC	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg03859395	chr2:55845619	SMEK2	0.81	14.81	0.63	1.66e-38	Metabolic syndrome;
LUSC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg15103426	chr22:29168792	CCDC117	0.6	8.37	0.42	1.65e-15	Lymphocyte counts;
LUSC	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	12.21	0.56	1.35e-28	Height;
LUSC	cis	rs17828380	0.920	rs35902265	chr15:63600524	C/T	cg05507819	chr15:63340323	TPM1	-0.75	-6.13	-0.32	2.5e-9	Social communication problems;
LUSC	cis	rs10504229	0.516	rs4060631	chr8:57990757	G/A	cg22535103	chr8:58192502	C8orf71	-0.49	-6.43	-0.33	4.5e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs72674100	1.000	rs72880546	chr4:97973701	T/C	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10089	0.953	rs758179	chr5:127354424	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	11.32	0.53	2.27e-25	Ileal carcinoids;
LUSC	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg08079166	chr15:68083412	MAP2K5	-0.42	-8.68	-0.43	1.8e-16	Restless legs syndrome;
LUSC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg24642439	chr20:33292090	TP53INP2	0.47	7.1	0.36	7.61e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs10463316	0.894	rs11167542	chr5:150760282	A/G	cg03212797	chr5:150827313	SLC36A1	0.49	7.39	0.38	1.16e-12	Metabolite levels (Pyroglutamine);
LUSC	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg05347473	chr6:146136440	FBXO30	0.5	8.56	0.42	4.31e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1018697	1.000	rs4919678	chr10:104554363	C/G	cg04362960	chr10:104952993	NT5C2	0.47	6.46	0.33	3.65e-10	Colorectal adenoma (advanced);
LUSC	cis	rs1385374	0.858	rs12305142	chr12:129277490	C/T	cg09035930	chr12:129282057	SLC15A4	-0.61	-6.52	-0.34	2.53e-10	Systemic lupus erythematosus;
LUSC	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22980127	chr19:33182716	NUDT19	0.89	11.63	0.54	1.81e-26	Red blood cell traits;
LUSC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.74	0.35	6.99e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19717773	chr7:2847554	GNA12	-0.38	-6.04	-0.31	4.12e-9	Height;
LUSC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg09436375	chr6:42928200	GNMT	-0.3	-6.87	-0.35	3.09e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25427524	chr10:38739819	LOC399744	0.73	13.19	0.59	2.77e-32	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7799006	0.606	rs12535174	chr7:2310974	C/T	cg02951883	chr7:2050386	MAD1L1	-0.35	-5.76	-0.3	1.95e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7189233	0.531	rs1072911	chr16:53499725	T/C	cg09728985	chr16:53543985	NA	-0.33	-6.21	-0.32	1.58e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg13042288	chr15:90349979	ANPEP	-0.47	-6.49	-0.33	3.1e-10	Uric acid levels;
LUSC	cis	rs116988415	0.786	rs118028978	chr14:65302112	C/T	cg00114569	chr14:65239327	SPTB	0.54	5.76	0.3	1.9e-8	Daytime sleep phenotypes;
LUSC	cis	rs6489785	0.710	rs3213566	chr12:121222578	T/C	cg02403541	chr12:121454288	C12orf43	0.39	5.75	0.3	2.03e-8	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.64	8.55	0.42	4.47e-16	Gut microbiome composition (summer);
LUSC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.13	0.55	2.61e-28	Motion sickness;
LUSC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	9.58	0.46	2.35e-19	Personality dimensions;
LUSC	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg04990556	chr1:26633338	UBXN11	-0.44	-5.88	-0.31	9.82e-9	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.2	0.32	1.7e-9	Corneal astigmatism;
LUSC	trans	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.53e-10	Corneal astigmatism;
LUSC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.81	-0.43	7.12e-17	Bipolar disorder;
LUSC	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg21573476	chr21:45109991	RRP1B	-0.44	-7.04	-0.36	1.1e-11	Mean corpuscular volume;
LUSC	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	0.77	12.59	0.57	5.21e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs11676348	0.712	rs11687434	chr2:218945143	A/G	cg00012203	chr2:219082015	ARPC2	-0.5	-7.77	-0.39	9.46e-14	Ulcerative colitis;
LUSC	cis	rs713477	0.935	rs4901567	chr14:55912698	C/T	cg13175173	chr14:55914753	NA	-0.3	-6.37	-0.33	6.32e-10	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs6574644	0.916	rs6574640	chr14:81771810	T/G	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg05347473	chr6:146136440	FBXO30	-0.59	-9.32	-0.45	1.58e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg24881330	chr22:46731750	TRMU	0.85	7.29	0.37	2.25e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1322512	0.917	rs1918331	chr6:152944123	T/G	cg27316956	chr6:152958899	SYNE1	-0.36	-5.89	-0.31	9.32e-9	Tonometry;
LUSC	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg13575925	chr12:9217583	LOC144571	0.35	6.48	0.33	3.2e-10	Sjögren's syndrome;
LUSC	cis	rs911119	0.955	rs8115423	chr20:23605253	T/C	cg16589663	chr20:23618590	CST3	0.57	6.82	0.35	4.37e-11	Chronic kidney disease;
LUSC	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg03806693	chr22:41940476	POLR3H	-0.78	-11.21	-0.52	5.55e-25	Vitiligo;
LUSC	cis	rs6087990	1.000	rs1007123	chr20:31345840	G/A	cg13636640	chr20:31349939	DNMT3B	1.04	22.97	0.78	1.05e-70	Ulcerative colitis;
LUSC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg01557791	chr16:72042693	DHODH	-0.51	-7.33	-0.37	1.74e-12	Fibrinogen levels;
LUSC	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.38	-5.65	-0.3	3.53e-8	Calcium levels;
LUSC	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg01879757	chr17:41196368	BRCA1	-0.46	-6.97	-0.36	1.72e-11	Menopause (age at onset);
LUSC	cis	rs6426558	0.537	rs7512409	chr1:227484038	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.55	-7.68	-0.39	1.73e-13	Neutrophil percentage of white cells;
LUSC	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-14.55	-0.62	1.72e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06022373	chr22:39101656	GTPBP1	-0.68	-10.47	-0.5	2.22e-22	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20932348	chr4:26862197	STIM2	0.46	6.45	0.33	3.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12618769	0.597	rs3769725	chr2:99105967	A/G	cg10123293	chr2:99228465	UNC50	0.45	7.48	0.38	6.81e-13	Bipolar disorder;
LUSC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.56	11.17	0.52	7.79e-25	Asthma (sex interaction);
LUSC	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg08875078	chr22:50639485	SELO	0.44	6.09	0.32	3.13e-9	Obesity-related traits;
LUSC	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg17127132	chr2:85788382	GGCX	0.42	6.02	0.31	4.48e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.02	-0.36	1.24e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs870825	0.616	rs10022834	chr4:185649431	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.71	-0.43	1.44e-16	Uric acid levels;
LUSC	cis	rs1864400	0.605	rs12360493	chr10:43718613	A/G	cg15436174	chr10:43711423	RASGEF1A	0.39	6.5	0.34	2.9e-10	Hirschsprung disease;
LUSC	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg21053147	chr12:120880522	NA	-0.48	-5.83	-0.3	1.33e-8	Type 1 diabetes nephropathy;
LUSC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg22709100	chr7:91322751	NA	0.4	5.85	0.3	1.16e-8	Breast cancer;
LUSC	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg02344993	chr17:57696989	CLTC	0.48	7.11	0.36	7.3e-12	Hemoglobin concentration;
LUSC	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg05340658	chr4:99064831	C4orf37	0.6	10.04	0.48	6.58e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg08999081	chr20:33150536	PIGU	0.44	8.24	0.41	3.86e-15	Coronary artery disease;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg05451912	chr6:26285795	HIST1H4H	0.48	6.0	0.31	5.19e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg06454157	chr6:167490870	NA	-0.28	-6.71	-0.34	8.57e-11	Primary biliary cholangitis;
LUSC	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg13010199	chr12:38710504	ALG10B	0.7	10.93	0.51	5.81e-24	Bladder cancer;
LUSC	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.84	0.44	5.5e-17	Heart rate;
LUSC	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg22709100	chr7:91322751	NA	-0.4	-5.84	-0.3	1.21e-8	Breast cancer;
LUSC	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	0.96	17.77	0.7	3.33e-50	Bone mineral density;
LUSC	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg14186256	chr22:23484241	RTDR1	0.93	16.57	0.67	1.93e-45	Bone mineral density;
LUSC	cis	rs9535307	0.929	rs1407441	chr13:50290990	T/C	cg04663916	chr13:50265991	EBPL	0.49	5.71	0.3	2.44e-8	Obesity-related traits;
LUSC	trans	rs961253	0.522	rs2148813	chr20:6352470	T/C	cg21095983	chr6:86352623	SYNCRIP	0.46	6.97	0.36	1.67e-11	Colorectal cancer;
LUSC	cis	rs73206853	0.841	rs78843188	chr12:110827923	G/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	0.66	10.02	0.48	7.77e-21	Platelet distribution width;
LUSC	cis	rs8048589	0.615	rs12599107	chr16:12238602	G/A	cg02910054	chr16:12241554	SNX29	0.51	6.35	0.33	7.18e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg08027265	chr7:2291960	NA	-0.39	-6.43	-0.33	4.52e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg15782153	chr7:917662	C7orf20	0.45	6.79	0.35	5.25e-11	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs1185460	0.967	rs11217133	chr11:118928249	G/A	cg01677386	chr11:118938358	VPS11	-0.51	-6.94	-0.35	2.06e-11	Coronary artery disease;
LUSC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg16405210	chr4:1374714	KIAA1530	0.71	10.97	0.51	4.08e-24	Obesity-related traits;
LUSC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.45	-7.12	-0.36	6.52e-12	Alzheimer's disease (late onset);
LUSC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg19318889	chr4:1322082	MAEA	0.79	14.07	0.61	1.21e-35	Longevity;
LUSC	cis	rs3741151	0.773	rs17244616	chr11:73293112	C/T	cg17517138	chr11:73019481	ARHGEF17	0.93	8.04	0.4	1.55e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs62055045	0.528	rs62056191	chr16:71533831	C/T	cg23742233	chr15:96890880	NA	-0.47	-6.21	-0.32	1.53e-9	Schizophrenia;
LUSC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg18681998	chr4:17616180	MED28	0.81	13.83	0.6	1e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs890448	0.796	rs7698946	chr4:102358076	C/T	cg05120309	chr14:100485494	NA	-0.37	-6.04	-0.31	4.22e-9	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.67	11.44	0.53	8.92e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.71	0.34	8.43e-11	Schizophrenia;
LUSC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg08859206	chr1:53392774	SCP2	0.47	7.84	0.39	5.91e-14	Monocyte count;
LUSC	cis	rs716316	1.000	rs716316	chr20:14908741	C/T	cg04470754	chr20:14904432	MACROD2	0.49	8.38	0.42	1.52e-15	Advanced glycation end-product levels;
LUSC	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs732765	0.644	rs2268613	chr14:75408500	G/A	cg06637938	chr14:75390232	RPS6KL1	0.58	6.92	0.35	2.33e-11	Non-small cell lung cancer;
LUSC	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg11584989	chr19:19387371	SF4	0.62	7.39	0.38	1.16e-12	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11207300	chr12:95867190	METAP2	0.48	6.96	0.36	1.78e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg13575925	chr12:9217583	LOC144571	0.34	6.31	0.33	8.69e-10	Sjögren's syndrome;
LUSC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg17372223	chr3:52568218	NT5DC2	0.39	6.34	0.33	7.54e-10	Electroencephalogram traits;
LUSC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.0	-0.36	1.37e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2425143	1.000	rs45595739	chr20:34320759	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.18	-0.32	1.83e-9	Blood protein levels;
LUSC	cis	rs7851660	0.809	rs10512255	chr9:100652582	C/T	cg13688889	chr9:100608707	NA	-0.54	-7.72	-0.39	1.37e-13	Strep throat;
LUSC	trans	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	2.01e-12	Bone mineral density;
LUSC	cis	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg06521852	chr22:38141419	TRIOBP	0.39	5.9	0.31	9.05e-9	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs75920871	0.528	rs7935913	chr11:116944348	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.51	6.62	0.34	1.44e-10	Subjective well-being;
LUSC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg03929089	chr4:120376271	NA	-0.91	-15.0	-0.63	3.18e-39	Height;
LUSC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg05347473	chr6:146136440	FBXO30	-0.6	-10.6	-0.5	7.93e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg24733560	chr20:60626293	TAF4	0.41	6.65	0.34	1.17e-10	Body mass index;
LUSC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.56e-23	Alzheimer's disease (late onset);
LUSC	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.63	6.97	0.36	1.72e-11	Crohn's disease;
LUSC	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg03806693	chr22:41940476	POLR3H	1.01	14.37	0.62	8.38e-37	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg27094323	chr7:1216898	NA	0.37	6.56	0.34	2.07e-10	Longevity;Endometriosis;
LUSC	cis	rs752010	0.619	rs10736421	chr1:42106230	G/A	cg06885757	chr1:42089581	HIVEP3	0.59	11.96	0.55	1.1e-27	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg06238570	chr21:40685208	BRWD1	0.53	8.03	0.4	1.66e-14	Cognitive function;
LUSC	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg25214090	chr10:38739885	LOC399744	0.55	7.8	0.39	8.24e-14	Corneal astigmatism;
LUSC	cis	rs4363385	0.934	rs4240865	chr1:152954839	G/T	cg00922841	chr1:152955080	SPRR1A	0.45	7.57	0.38	3.6e-13	Inflammatory skin disease;
LUSC	cis	rs977987	0.778	rs4888412	chr16:75443196	A/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.61	-0.34	1.52e-10	Dupuytren's disease;
LUSC	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.07	-0.4	1.31e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1113500	0.698	rs1781078	chr1:108591642	G/A	cg06207961	chr1:108661230	NA	-0.3	-5.65	-0.3	3.49e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg26384229	chr12:38710491	ALG10B	-0.6	-9.14	-0.45	6.34e-18	Morning vs. evening chronotype;
LUSC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-0.79	-13.61	-0.6	7.46e-34	Cognitive function;
LUSC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg18230493	chr5:56204884	C5orf35	-0.71	-10.95	-0.51	4.86e-24	Coronary artery disease;
LUSC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg06008330	chr7:65541103	ASL	0.4	6.24	0.32	1.34e-9	Aortic root size;
LUSC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.23	-0.41	4.36e-15	Obesity-related traits;
LUSC	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-38.77	-0.9	1.09e-125	Myeloid white cell count;
LUSC	cis	rs77633900	0.772	rs387321	chr15:76743565	A/G	cg21673338	chr15:77095150	SCAPER	-0.7	-6.08	-0.32	3.24e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg04310649	chr10:35416472	CREM	-0.43	-6.55	-0.34	2.18e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg07701084	chr6:150067640	NUP43	0.56	8.51	0.42	6.04e-16	Lung cancer;
LUSC	cis	rs10189230	0.967	rs13002861	chr2:222352859	T/G	cg14652038	chr2:222343519	EPHA4	0.32	5.73	0.3	2.2e-8	Urate levels in lean individuals;
LUSC	trans	rs895636	0.898	rs10205310	chr2:45188646	A/G	cg14014731	chr9:19378679	RPS6	0.51	6.26	0.32	1.15e-9	Metabolite levels;Fasting plasma glucose;
LUSC	cis	rs16917546	0.935	rs12766391	chr10:64441204	C/T	cg03961010	chr10:64397487	ZNF365	-0.4	-6.28	-0.33	1.03e-9	Basal cell carcinoma;
LUSC	cis	rs7542375	0.524	rs2807869	chr1:221094068	A/G	cg16008148	chr1:221062819	NA	0.43	8.29	0.41	2.89e-15	Obesity-related traits;
LUSC	cis	rs17102423	0.755	rs11625045	chr14:65549089	C/T	cg11161011	chr14:65562177	MAX	-0.8	-12.27	-0.56	8.2e-29	Obesity-related traits;
LUSC	cis	rs6580649	0.941	rs6580651	chr12:48429933	A/T	cg24011408	chr12:48396354	COL2A1	-0.46	-6.17	-0.32	1.95e-9	Lung cancer;
LUSC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg02475777	chr4:1388615	CRIPAK	-0.42	-6.18	-0.32	1.87e-9	Obesity-related traits;
LUSC	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg09754948	chr16:28834200	ATXN2L	0.42	6.02	0.31	4.62e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.89	0.48	2.14e-20	Bipolar disorder;
LUSC	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg13206674	chr6:150067644	NUP43	0.43	6.55	0.34	2.17e-10	Testicular germ cell tumor;
LUSC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg02018176	chr4:1364513	KIAA1530	0.52	9.13	0.45	6.57e-18	Obesity-related traits;
LUSC	cis	rs12900413	0.603	rs12909833	chr15:90301518	G/A	cg24249390	chr15:90295951	MESP1	-0.38	-5.93	-0.31	7.77e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.32	0.53	2.22e-25	Menopause (age at onset);
LUSC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-18.91	-0.72	9.91e-55	Height;
LUSC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	14.29	0.62	1.7e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg12310025	chr6:25882481	NA	0.42	6.89	0.35	2.76e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.47	-6.84	-0.35	3.77e-11	Menarche (age at onset);
LUSC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg03579872	chr1:53393473	SCP2	0.39	5.65	0.3	3.38e-8	Monocyte count;
LUSC	cis	rs41271473	1.000	rs17352654	chr1:228878193	T/C	cg16512390	chr1:228756714	NA	0.5	6.04	0.31	4.05e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	9.93	0.48	1.51e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg05872129	chr22:39784769	NA	-0.58	-10.76	-0.51	2.14e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg16342193	chr10:102329863	NA	-0.39	-6.85	-0.35	3.56e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg06917634	chr15:78832804	PSMA4	-0.49	-6.51	-0.34	2.79e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.55	7.74	0.39	1.22e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg21918786	chr6:109611834	NA	-0.44	-7.65	-0.39	2.22e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg08888203	chr3:10149979	C3orf24	0.57	8.06	0.4	1.33e-14	Alzheimer's disease;
LUSC	cis	rs6977660	0.619	rs10950752	chr7:19781531	A/G	cg07541023	chr7:19748670	TWISTNB	0.61	6.5	0.34	2.89e-10	Thyroid stimulating hormone;
LUSC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.06	0.4	1.36e-14	Prudent dietary pattern;
LUSC	cis	rs9359856	0.510	rs3736984	chr6:90408589	C/T	cg13799429	chr6:90582589	CASP8AP2	0.96	11.58	0.54	2.69e-26	Bipolar disorder;
LUSC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg26513180	chr16:89883248	FANCA	0.79	6.37	0.33	6.26e-10	Skin colour saturation;
LUSC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg11062466	chr8:58055876	NA	0.72	8.93	0.44	2.94e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11645453	chr3:52864694	ITIH4	0.35	8.17	0.41	6.58e-15	Bipolar disorder;
LUSC	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg09754948	chr16:28834200	ATXN2L	0.41	5.86	0.31	1.13e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.84e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.81	0.43	7.02e-17	Prudent dietary pattern;
LUSC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg05313129	chr8:58192883	C8orf71	-0.5	-6.51	-0.34	2.8e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg18827107	chr12:86230957	RASSF9	-0.49	-7.29	-0.37	2.22e-12	Major depressive disorder;
LUSC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25427524	chr10:38739819	LOC399744	0.45	7.4	0.38	1.13e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.35e-30	Motion sickness;
LUSC	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7582720	0.943	rs72926799	chr2:203828192	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg19318889	chr4:1322082	MAEA	0.81	14.74	0.63	3.17e-38	Longevity;
LUSC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg15839431	chr19:19639596	YJEFN3	0.44	6.11	0.32	2.85e-9	Tonsillectomy;
LUSC	cis	rs259282	0.574	rs12610727	chr19:33116138	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.68	10.01	0.48	8.73e-21	Schizophrenia;
LUSC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg12615879	chr12:58013172	SLC26A10	-0.27	-5.77	-0.3	1.78e-8	Multiple sclerosis;
LUSC	cis	rs501916	0.604	rs616871	chr15:48058259	T/A	cg16110827	chr15:48056943	SEMA6D	-0.38	-5.9	-0.31	8.75e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	trans	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg02030672	chr11:45687055	CHST1	0.49	7.79	0.39	8.31e-14	Obesity-related traits;
LUSC	cis	rs7246967	0.673	rs34676724	chr19:22918473	A/C	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.04e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs13089785	0.898	rs13062100	chr3:123674337	A/G	cg02558132	chr3:123411198	MYLK	0.34	5.66	0.3	3.33e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg14196790	chr5:131705035	SLC22A5	0.48	8.2	0.41	5.4e-15	Blood metabolite levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15711037	chr19:50379834	AKT1S1;TBC1D17	-0.4	-6.07	-0.32	3.38e-9	Electrocardiographic conduction measures;
LUSC	trans	rs4942242	0.640	rs17538959	chr13:44229911	T/G	cg19169023	chr15:41853346	TYRO3	-0.61	-9.01	-0.44	1.56e-17	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs8077577	0.945	rs8065026	chr17:18046290	A/G	cg16794390	chr17:18148240	FLII	0.39	5.84	0.3	1.21e-8	Obesity-related traits;
LUSC	trans	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg07393940	chr7:158741817	NA	0.37	6.78	0.35	5.58e-11	Life satisfaction;
LUSC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg06713675	chr4:122721982	EXOSC9	-0.72	-12.31	-0.56	5.85e-29	Type 2 diabetes;
LUSC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg21951975	chr1:209979733	IRF6	0.61	7.89	0.4	4.43e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24110177	chr3:50126178	RBM5	-0.64	-11.47	-0.53	6.53e-26	Body mass index;
LUSC	cis	rs7582720	1.000	rs72934512	chr2:203926271	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.65	0.43	2.2e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6484504	0.532	rs12788257	chr11:31255045	T/C	cg06552810	chr11:31128660	NA	-0.42	-7.4	-0.38	1.09e-12	Red blood cell count;
LUSC	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-6.51	-0.34	2.82e-10	Colorectal cancer;
LUSC	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	10.32	0.49	7.33e-22	Mean corpuscular hemoglobin;
LUSC	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg00376283	chr12:123451042	ABCB9	0.69	9.71	0.47	8.35e-20	Neutrophil percentage of white cells;
LUSC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg14343924	chr8:8086146	FLJ10661	0.42	6.08	0.32	3.23e-9	Mood instability;
LUSC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg19230755	chr7:65878503	NA	-0.42	-5.93	-0.31	7.43e-9	Aortic root size;
LUSC	cis	rs3087591	0.683	rs2854306	chr17:29648146	G/A	cg24425628	chr17:29625626	OMG;NF1	0.46	6.88	0.35	2.93e-11	Hip circumference;
LUSC	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg07926092	chr13:79233506	RNF219	0.49	5.84	0.3	1.24e-8	Large artery stroke;
LUSC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg05082376	chr22:42548792	NA	-0.39	-6.53	-0.34	2.43e-10	Cognitive function;
LUSC	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.39	0.46	9.91e-19	Coffee consumption (cups per day);
LUSC	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-6.07	-0.32	3.56e-9	Fear of minor pain;
LUSC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg16680214	chr1:154839983	KCNN3	-0.55	-10.52	-0.5	1.49e-22	Prostate cancer;
LUSC	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg26727032	chr16:67993705	SLC12A4	-0.4	-5.98	-0.31	5.79e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	-0.31	-5.77	-0.3	1.84e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.86	0.35	3.34e-11	Endometrial cancer;
LUSC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg06784218	chr1:46089804	CCDC17	0.47	9.26	0.45	2.6e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg25110126	chr1:46999211	NA	0.77	11.11	0.52	1.28e-24	Monobrow;
LUSC	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-9.41	-0.46	8.58e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.6	9.11	0.45	7.58e-18	Endometrial cancer;
LUSC	cis	rs72781680	0.652	rs12618900	chr2:23910775	C/T	cg20701182	chr2:24300061	SF3B14	0.8	7.59	0.38	3.2e-13	Lymphocyte counts;
LUSC	cis	rs9905704	0.633	rs72841019	chr17:56496346	G/A	cg19466818	chr17:56409534	MIR142	-0.35	-6.39	-0.33	5.58e-10	Testicular germ cell tumor;
LUSC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg23630131	chr7:65973040	NA	-0.21	-5.82	-0.3	1.38e-8	Aortic root size;
LUSC	cis	rs7246657	0.653	rs4805208	chr19:37674259	G/A	cg23950597	chr19:37808831	NA	-0.56	-5.66	-0.3	3.23e-8	Coronary artery calcification;
LUSC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.55	0.34	2.2e-10	Menopause (age at onset);
LUSC	cis	rs7572644	0.699	rs7577437	chr2:28168415	A/G	cg27432699	chr2:27873401	GPN1	-0.51	-6.95	-0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg24069376	chr3:38537580	EXOG	0.35	6.29	0.33	9.81e-10	Electrocardiographic conduction measures;
LUSC	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.61	7.99	0.4	2.19e-14	Schizophrenia;
LUSC	trans	rs2074977	0.530	rs10401784	chr19:3445721	A/C	cg08382705	chr11:45687319	CHST1	-0.47	-7.21	-0.37	3.79e-12	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06957321	chr12:50236806	BCDIN3D	-0.4	-6.01	-0.31	4.82e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7561273	0.586	rs4149372	chr2:24305512	T/G	cg06627628	chr2:24431161	ITSN2	-0.51	-6.66	-0.34	1.12e-10	Quantitative traits;
LUSC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.49	-6.95	-0.36	1.95e-11	Mean platelet volume;
LUSC	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg20307385	chr11:47447363	PSMC3	0.45	6.6	0.34	1.6e-10	Subjective well-being;
LUSC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg22535103	chr8:58192502	C8orf71	-0.66	-7.44	-0.38	8.86e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	10.41	0.49	3.71e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg23791538	chr6:167370224	RNASET2	0.42	6.79	0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg11189052	chr15:85197271	WDR73	0.47	5.8	0.3	1.56e-8	Schizophrenia;
LUSC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07343612	chr16:622815	PIGQ	-0.73	-12.49	-0.56	1.22e-29	Height;
LUSC	cis	rs12760731	0.623	rs12023044	chr1:178407772	G/A	cg00404053	chr1:178313656	RASAL2	0.48	5.76	0.3	1.91e-8	Obesity-related traits;
LUSC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	7.16	0.36	5.32e-12	Platelet count;
LUSC	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg15485101	chr11:133734466	NA	-0.34	-5.83	-0.3	1.28e-8	Childhood ear infection;
LUSC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg22143856	chr6:28129313	ZNF389	0.41	5.68	0.3	2.98e-8	Parkinson's disease;
LUSC	cis	rs11625487	0.915	rs11845826	chr14:77966145	C/A	cg20045696	chr14:77926864	AHSA1	0.43	5.79	0.3	1.61e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LUSC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	0.99	14.12	0.61	8.22e-36	Eosinophil percentage of granulocytes;
LUSC	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg23241863	chr10:102295624	HIF1AN	-0.48	-6.08	-0.32	3.26e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg04586622	chr2:25135609	ADCY3	0.44	9.24	0.45	2.86e-18	Body mass index;
LUSC	cis	rs8067354	0.831	rs2333617	chr17:57896220	T/A	cg02344993	chr17:57696989	CLTC	-0.37	-5.65	-0.3	3.42e-8	Hemoglobin concentration;
LUSC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.44	7.16	0.36	5.02e-12	Vitiligo;
LUSC	cis	rs3771570	1.000	rs4675811	chr2:242402062	A/T	cg21155796	chr2:242212141	HDLBP	0.5	6.02	0.31	4.49e-9	Prostate cancer;
LUSC	cis	rs11051970	0.636	rs2733705	chr12:32561564	T/C	cg24626660	chr12:32551988	NA	0.31	5.66	0.3	3.25e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.58	9.09	0.45	8.86e-18	Schizophrenia;
LUSC	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg22705602	chr4:152727874	NA	-0.31	-6.09	-0.32	3.14e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6736093	0.830	rs11680463	chr2:112775611	T/A	cg12686935	chr2:112915763	FBLN7	-0.39	-6.24	-0.32	1.31e-9	Coronary artery disease;
LUSC	cis	rs16854884	0.632	rs35716467	chr3:143684993	C/A	cg06585982	chr3:143692056	C3orf58	0.49	7.62	0.38	2.6e-13	Economic and political preferences (feminism/equality);
LUSC	cis	rs7523273	0.526	rs3849274	chr1:208021557	T/A	cg22525895	chr1:207977042	MIR29B2	-0.37	-5.86	-0.31	1.12e-8	Schizophrenia;
LUSC	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.49	-6.8	-0.35	4.7e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.88	18.31	0.71	2.39e-52	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24715260	chr17:80056221	FASN	-0.5	-5.95	-0.31	6.62e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.21	0.52	5.93e-25	Prudent dietary pattern;
LUSC	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg25301532	chr20:43378953	KCNK15	-0.35	-6.48	-0.33	3.3e-10	Obesity-related traits;
LUSC	trans	rs1256061	0.845	rs6573549	chr14:64721649	T/C	cg07874507	chr10:24503148	KIAA1217	0.34	5.96	0.31	6.37e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	6.58	0.34	1.82e-10	Resting heart rate;
LUSC	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	1.06	14.42	0.62	5.65e-37	Exhaled nitric oxide levels;
LUSC	cis	rs9653442	0.511	rs6739695	chr2:100859622	A/G	cg07810366	chr2:100720526	AFF3	-0.38	-6.19	-0.32	1.8e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05535760	chr7:792225	HEATR2	0.81	9.46	0.46	5.76e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg15744005	chr10:104629667	AS3MT	-0.4	-8.21	-0.41	4.9e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg25482853	chr8:67687455	SGK3	1.18	16.74	0.68	4.07e-46	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-0.89	-18.07	-0.7	2.11e-51	Dental caries;
LUSC	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg26816564	chr1:7831052	VAMP3	0.46	6.27	0.32	1.1e-9	Inflammatory bowel disease;
LUSC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	1.04	25.8	0.82	1.72e-81	Multiple system atrophy;
LUSC	trans	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg25214090	chr10:38739885	LOC399744	0.42	6.49	0.33	3.02e-10	Corneal astigmatism;
LUSC	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.27	-0.32	1.11e-9	Bipolar disorder;
LUSC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg25767906	chr1:53392781	SCP2	0.45	7.9	0.4	4.06e-14	Monocyte count;
LUSC	trans	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg18187862	chr3:45730750	SACM1L	-0.5	-6.17	-0.32	1.95e-9	Primary sclerosing cholangitis;
LUSC	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.8	-11.75	-0.54	6.33e-27	Blood pressure (smoking interaction);
LUSC	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg11062466	chr8:58055876	NA	0.7	8.73	0.43	1.26e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs4845570	0.850	rs11204892	chr1:151768048	A/G	cg07092448	chr1:151763213	TDRKH	1.26	16.6	0.67	1.47e-45	Coronary artery disease;
LUSC	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-10.84	-0.51	1.12e-23	Response to antipsychotic treatment;
LUSC	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg18827107	chr12:86230957	RASSF9	-0.45	-6.77	-0.35	5.7e-11	Major depressive disorder;
LUSC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.57	0.38	3.72e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.99	0.31	5.41e-9	Rheumatoid arthritis;
LUSC	cis	rs6969780	1.000	rs929249	chr7:27167537	T/C	cg26364809	chr7:27145159	NA	-0.59	-5.89	-0.31	9.42e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs12618769	0.625	rs61180742	chr2:99148078	A/G	cg10123293	chr2:99228465	UNC50	0.47	7.76	0.39	1.04e-13	Bipolar disorder;
LUSC	cis	rs6489882	0.867	rs1859335	chr12:113367325	C/T	cg20102336	chr12:113376681	OAS3	-0.42	-5.96	-0.31	6.39e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24549020	chr5:56110836	MAP3K1	-0.48	-5.66	-0.3	3.23e-8	Initial pursuit acceleration;
LUSC	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.54	-8.63	-0.43	2.55e-16	Coronary artery disease;
LUSC	cis	rs907612	0.638	rs907613	chr11:1874292	G/A	cg26158194	chr11:1874320	LSP1	0.37	6.76	0.35	6.02e-11	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg08668359	chr10:1443807	ADARB2	0.41	6.2	0.32	1.66e-9	Radiation response;
LUSC	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg01346077	chr3:125931526	NA	0.31	5.79	0.3	1.62e-8	Metabolite levels;
LUSC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.26	-0.41	3.57e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg10756647	chr7:56101905	PSPH	-0.87	-8.66	-0.43	2.02e-16	Diabetic kidney disease;
LUSC	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg00191853	chr8:101177733	SPAG1	-0.36	-5.82	-0.3	1.38e-8	Atrioventricular conduction;
LUSC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.44	8.53	0.42	5.14e-16	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg03808149	chr6:10747832	TMEM14B	0.39	6.37	0.33	6.37e-10	Asthma;
LUSC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.36	-0.33	6.46e-10	Total body bone mineral density;
LUSC	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg01629716	chr15:45996671	NA	0.4	6.06	0.31	3.68e-9	Waist circumference;Weight;
LUSC	cis	rs6489785	0.643	rs2015462	chr12:121238204	G/C	cg02419362	chr12:121203948	SPPL3	0.41	7.3	0.37	2.15e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs17095355	1.000	rs17126890	chr10:111699169	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.6	-0.38	2.95e-13	Biliary atresia;
LUSC	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg21775007	chr8:11205619	TDH	0.79	13.48	0.59	2.26e-33	Retinal vascular caliber;
LUSC	cis	rs10875746	0.904	rs11168422	chr12:48519505	T/G	cg13454099	chr12:49076203	C12orf41	-0.5	-5.87	-0.31	1.07e-8	Longevity (90 years and older);
LUSC	cis	rs4776059	0.550	rs73396766	chr15:52911516	C/T	cg25063058	chr15:52860530	ARPP19	-0.54	-5.87	-0.31	1.04e-8	Schizophrenia;
LUSC	cis	rs11229555	0.645	rs11229436	chr11:58186009	G/A	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg16576597	chr16:28551801	NUPR1	0.34	6.73	0.35	7.35e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.69	9.0	0.44	1.78e-17	Huntington's disease progression;
LUSC	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg04545296	chr12:48745243	ZNF641	0.34	6.15	0.32	2.27e-9	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs7712401	0.623	rs30032	chr5:122238387	G/T	cg19077854	chr5:122220652	SNX24	0.39	8.23	0.41	4.14e-15	Mean platelet volume;
LUSC	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg15309053	chr8:964076	NA	0.43	8.82	0.43	6.26e-17	Schizophrenia;
LUSC	cis	rs7106204	0.748	rs6484032	chr11:24237153	C/A	ch.11.24196551F	chr11:24239977	NA	1.16	14.62	0.62	8.9e-38	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg03146154	chr1:46216737	IPP	-0.5	-7.19	-0.37	4.3e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2742234	0.590	rs2293020	chr10:43692887	A/G	cg15436174	chr10:43711423	RASGEF1A	0.43	7.0	0.36	1.38e-11	Hirschsprung disease;
LUSC	cis	rs2012796	1.000	rs10450939	chr14:81825202	A/T	cg02996355	chr14:81879375	NA	0.5	7.25	0.37	2.83e-12	Night sleep phenotypes;
LUSC	cis	rs6076065	0.692	rs6083092	chr20:23348836	T/C	cg11657817	chr20:23433608	CST11	0.43	8.01	0.4	1.88e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.82	0.35	4.23e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs17095355	1.000	rs11194920	chr10:111695412	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.57	-6.96	-0.36	1.81e-11	Biliary atresia;
LUSC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08677398	chr8:58056175	NA	0.61	6.98	0.36	1.59e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs17815608	1.000	rs17815571	chr12:77398434	C/T	cg18631743	chr22:20104954	RANBP1;TRMT2A	-0.59	-6.93	-0.35	2.17e-11	Type 2 diabetes;
LUSC	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg05941027	chr17:61774174	LIMD2	0.23	5.93	0.31	7.7e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.03	-0.36	1.18e-11	Neuroticism;
LUSC	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg16359550	chr11:109292809	C11orf87	0.35	5.97	0.31	5.9e-9	Schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24340807	chr12:57853743	GLI1	0.44	6.78	0.35	5.54e-11	Triglycerides;
LUSC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.78	-0.3	1.68e-8	Platelet count;
LUSC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.86	0.31	1.09e-8	Menopause (age at onset);
LUSC	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg02175503	chr12:58329896	NA	0.48	6.9	0.35	2.68e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs16854884	0.584	rs59768870	chr3:143738366	G/A	cg06585982	chr3:143692056	C3orf58	0.51	8.06	0.4	1.33e-14	Economic and political preferences (feminism/equality);
LUSC	trans	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg09050820	chr6:167586206	TCP10L2	0.74	9.55	0.46	2.82e-19	Gastritis;
LUSC	cis	rs2932538	0.922	rs3790611	chr1:113067792	A/G	cg22162597	chr1:113214053	CAPZA1	0.72	10.19	0.49	2.02e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.54	0.38	4.47e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg06064525	chr11:970664	AP2A2	-0.34	-6.88	-0.35	2.98e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7712401	0.601	rs246271	chr5:122212822	A/G	cg19077854	chr5:122220652	SNX24	0.41	9.2	0.45	3.93e-18	Mean platelet volume;
LUSC	cis	rs11608355	0.515	rs11610558	chr12:109925865	C/T	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.59e-9	Menopause (age at onset);
LUSC	trans	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg21659725	chr3:3221576	CRBN	-0.49	-7.42	-0.38	9.7e-13	Menarche (age at onset);
LUSC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9315204	0.645	rs602133	chr13:33697449	C/T	cg06602200	chr11:46412424	NA	0.32	6.05	0.31	3.78e-9	Intracranial aneurysm;
LUSC	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg25457927	chr22:38595422	NA	-0.42	-8.87	-0.44	4.61e-17	Cutaneous nevi;
LUSC	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.14	-0.45	6.29e-18	Morning vs. evening chronotype;
LUSC	trans	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg26384229	chr12:38710491	ALG10B	-0.52	-7.86	-0.4	5.34e-14	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg05347473	chr6:146136440	FBXO30	0.5	8.45	0.42	9.26e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg12560992	chr17:57184187	TRIM37	0.84	15.29	0.64	2.31e-40	Intelligence (multi-trait analysis);
LUSC	trans	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.69	-0.34	9.7e-11	Retinal vascular caliber;
LUSC	cis	rs1256061	0.654	rs1256031	chr14:64746179	C/T	cg23250157	chr14:64679961	SYNE2	0.32	6.03	0.31	4.38e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg08975724	chr8:8085496	FLJ10661	0.43	6.2	0.32	1.7e-9	Myopia (pathological);
LUSC	cis	rs9815354	1.000	rs73071329	chr3:41810539	G/A	cg03022575	chr3:42003672	ULK4	0.55	6.17	0.32	2e-9	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs12681287	0.752	rs10111095	chr8:87250984	T/C	cg27223183	chr8:87520930	FAM82B	-0.45	-5.69	-0.3	2.72e-8	Caudate activity during reward;
LUSC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.56	0.62	1.57e-37	Platelet count;
LUSC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18854424	chr1:2615690	NA	-0.51	-10.44	-0.5	2.96e-22	Multiple sclerosis;
LUSC	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg09184832	chr6:79620586	NA	-0.44	-7.18	-0.37	4.63e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg09365446	chr1:150670422	GOLPH3L	0.55	8.44	0.42	9.59e-16	Tonsillectomy;
LUSC	trans	rs4729127	1.000	rs8180727	chr7:94011085	A/G	cg14660007	chr13:78271894	SLAIN1	-0.5	-6.23	-0.32	1.4e-9	Intelligence;
LUSC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	10.74	0.51	2.64e-23	Homoarginine levels;
LUSC	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg22709100	chr7:91322751	NA	-0.4	-5.83	-0.3	1.3e-8	Breast cancer;
LUSC	trans	rs1547374	1.000	rs1547374	chr21:43778895	C/T	cg09521743	chr10:75415752	SYNPO2L	0.4	6.46	0.33	3.65e-10	Pancreatic cancer;
LUSC	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg00074818	chr8:8560427	CLDN23	0.59	9.56	0.46	2.63e-19	Obesity-related traits;
LUSC	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-1.02	-20.42	-0.75	1.04e-60	Dilated cardiomyopathy;
LUSC	cis	rs4889855	0.614	rs7221663	chr17:78484166	T/C	cg16591659	chr17:78472290	NA	-0.48	-7.83	-0.39	6.57e-14	Fractional excretion of uric acid;
LUSC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg02551604	chr5:131831745	NA	-0.41	-6.47	-0.33	3.5e-10	Asthma (sex interaction);
LUSC	cis	rs9311676	0.656	rs11718352	chr3:58401480	G/A	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg25233709	chr10:116636983	FAM160B1	0.38	6.63	0.34	1.38e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs1325195	0.537	rs2793805	chr1:179195777	A/G	cg11624085	chr17:8464688	MYH10	0.43	6.38	0.33	5.94e-10	IgE grass sensitization;
LUSC	cis	rs4737010	0.501	rs1579274	chr8:41658923	T/G	cg08923054	chr8:41654455	ANK1	0.35	6.19	0.32	1.75e-9	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg13395646	chr4:1353034	KIAA1530	-0.62	-10.04	-0.48	6.69e-21	Obesity-related traits;
LUSC	cis	rs308403	0.568	rs13138520	chr4:123675483	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.79	9.88	0.48	2.3e-20	Blood protein levels;
LUSC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg23711669	chr6:146136114	FBXO30	0.91	17.21	0.69	5.62e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4845570	1.000	rs6659705	chr1:151769750	T/C	cg07092448	chr1:151763213	TDRKH	-1.27	-15.07	-0.64	1.68e-39	Coronary artery disease;
LUSC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	7.03	0.36	1.18e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9644630	0.696	rs13261824	chr8:19313912	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.49	8.25	0.41	3.62e-15	Oropharynx cancer;
LUSC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.5	6.79	0.35	5.16e-11	Cognitive ability;
LUSC	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg15664640	chr17:80829946	TBCD	-0.45	-8.02	-0.4	1.76e-14	Breast cancer;
LUSC	cis	rs2692947	0.860	rs2579520	chr2:96660300	C/T	cg22654517	chr2:96458247	NA	-0.32	-6.58	-0.34	1.77e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs12760731	0.623	rs6688546	chr1:178332511	A/G	cg00404053	chr1:178313656	RASAL2	0.47	5.75	0.3	2.03e-8	Obesity-related traits;
LUSC	cis	rs9815354	1.000	rs56121764	chr3:41883975	T/C	cg03022575	chr3:42003672	ULK4	0.64	7.02	0.36	1.21e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.29	-0.33	9.79e-10	Total body bone mineral density;
LUSC	cis	rs10761482	0.813	rs12776510	chr10:62167928	C/T	cg18175470	chr10:62150864	ANK3	-0.57	-8.46	-0.42	8.62e-16	Schizophrenia;
LUSC	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg03972071	chr18:72917163	ZADH2	0.5	5.82	0.3	1.39e-8	Vascular endothelial growth factor levels;
LUSC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-7.54	-0.38	4.33e-13	Blood metabolite levels;
LUSC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg23711669	chr6:146136114	FBXO30	0.9	17.33	0.69	1.89e-48	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21545467	chr11:124543651	SIAE;SPA17	0.41	6.07	0.32	3.54e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg11752832	chr7:134001865	SLC35B4	0.55	8.64	0.43	2.45e-16	Mean platelet volume;
LUSC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.7	11.69	0.54	1.07e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg06064525	chr11:970664	AP2A2	-0.29	-5.83	-0.3	1.33e-8	Alzheimer's disease (late onset);
LUSC	cis	rs73206853	0.764	rs55913108	chr12:110816507	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	11.86	0.54	2.59e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.14	16.34	0.67	1.69e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs1923243	0.546	rs11210226	chr1:73854284	A/G	cg18358762	chr2:73298974	SFXN5	-0.41	-6.15	-0.32	2.2e-9	Migraine;
LUSC	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg15423357	chr2:25149977	NA	0.33	6.42	0.33	4.67e-10	Body mass index;
LUSC	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg25922239	chr6:33757077	LEMD2	0.53	7.91	0.4	3.84e-14	Crohn's disease;
LUSC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-5.75	-0.3	2e-8	Monocyte count;
LUSC	cis	rs227833	0.826	rs4714813	chr6:44709890	C/A	cg20913747	chr6:44695427	NA	0.4	6.26	0.32	1.15e-9	Monobrow;
LUSC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.27	-0.32	1.1e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs117352156	0.943	rs10826542	chr10:29220419	C/A	cg06394621	chr10:29236369	NA	-0.45	-5.91	-0.31	8.29e-9	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg02569458	chr12:86230093	RASSF9	-0.49	-8.25	-0.41	3.64e-15	Major depressive disorder;
LUSC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg03526776	chr6:41159608	TREML2	0.32	6.07	0.32	3.44e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6429082	0.667	rs10802800	chr1:235706283	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.46	-5.94	-0.31	7.32e-9	Adiposity;
LUSC	cis	rs10170846	0.731	rs10180632	chr2:223526384	G/A	cg25565276	chr2:223520875	FARSB	0.64	9.7	0.47	9.46e-20	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-0.86	-13.81	-0.6	1.23e-34	Breast cancer;
LUSC	cis	rs6940638	1.000	rs6940638	chr6:27046250	A/G	cg05738196	chr6:26577821	NA	-0.5	-5.79	-0.3	1.66e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	8.7	0.43	1.54e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg01097406	chr16:89675127	NA	-0.34	-6.7	-0.34	8.66e-11	Vitiligo;
LUSC	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg23711669	chr6:146136114	FBXO30	0.77	12.55	0.57	7.37e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg04362960	chr10:104952993	NT5C2	0.59	9.4	0.46	9.13e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs921665	0.831	rs4402798	chr2:3190969	G/A	cg02624386	chr2:3182749	NA	0.51	5.81	0.3	1.46e-8	World class endurance athleticism;
LUSC	cis	rs7520050	0.897	rs4440807	chr1:46470878	T/C	cg06784218	chr1:46089804	CCDC17	-0.29	-5.69	-0.3	2.78e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg03354898	chr7:1950403	MAD1L1	-0.45	-9.32	-0.45	1.63e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.95	-0.31	6.7e-9	Neutrophil percentage of white cells;
LUSC	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg27432699	chr2:27873401	GPN1	-0.58	-8.68	-0.43	1.72e-16	Total body bone mineral density;
LUSC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg11645453	chr3:52864694	ITIH4	0.34	7.84	0.39	6.19e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg05527609	chr1:210001259	C1orf107	-0.4	-5.95	-0.31	6.73e-9	Monobrow;
LUSC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.68	-9.58	-0.46	2.3e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg10729496	chr3:10149963	C3orf24	0.58	7.69	0.39	1.61e-13	Alzheimer's disease;
LUSC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg23711669	chr6:146136114	FBXO30	0.76	13.53	0.6	1.43e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.99	-0.36	1.54e-11	Lung cancer;
LUSC	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg19554555	chr3:13937349	NA	-0.42	-6.13	-0.32	2.53e-9	Ovarian reserve;
LUSC	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg13813247	chr22:41461852	NA	-0.37	-6.75	-0.35	6.38e-11	Neuroticism;
LUSC	cis	rs11030122	0.673	rs4910590	chr11:4018619	C/T	cg18678763	chr11:4115507	RRM1	-0.47	-6.19	-0.32	1.79e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg22875332	chr1:76189707	ACADM	-0.42	-6.24	-0.32	1.35e-9	Daytime sleep phenotypes;
LUSC	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg04827223	chr11:72435913	ARAP1	-0.66	-8.5	-0.42	6.6e-16	Type 2 diabetes;
LUSC	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	7.29	0.37	2.22e-12	Iron status biomarkers;
LUSC	cis	rs3087591	0.960	rs9303642	chr17:29578360	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.57	-8.54	-0.42	4.83e-16	Hip circumference;
LUSC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.73	-14.1	-0.61	9.54e-36	Type 2 diabetes;
LUSC	cis	rs35146811	0.700	rs866500	chr7:99840461	A/G	cg22906224	chr7:99728672	NA	-0.47	-6.04	-0.31	4.2e-9	Coronary artery disease;
LUSC	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg19629631	chr7:2060116	MAD1L1	-0.34	-5.68	-0.3	2.89e-8	Neuroticism;
LUSC	cis	rs73206853	0.841	rs57299791	chr12:110954021	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	7.83e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.21	0.59	2.34e-32	Total body bone mineral density;
LUSC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg09877947	chr5:131593287	PDLIM4	-0.41	-6.78	-0.35	5.36e-11	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08409451	chr16:2273123	E4F1	0.41	6.61	0.34	1.56e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg08470875	chr2:26401718	FAM59B	-0.66	-9.05	-0.44	1.19e-17	Gut microbiome composition (summer);
LUSC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs7119038	0.818	rs10892287	chr11:118642999	C/T	cg19308663	chr11:118741387	NA	-0.33	-5.89	-0.31	9.24e-9	Sjögren's syndrome;
LUSC	cis	rs9309473	0.500	rs2421582	chr2:73898420	A/G	cg20560298	chr2:73613845	ALMS1	0.48	7.17	0.37	4.99e-12	Metabolite levels;
LUSC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg17264618	chr3:40429014	ENTPD3	0.36	7.52	0.38	5.26e-13	Renal cell carcinoma;
LUSC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.77	-0.35	5.93e-11	Menopause (age at onset);
LUSC	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg23750338	chr8:142222470	SLC45A4	0.47	9.04	0.44	1.34e-17	Immature fraction of reticulocytes;
LUSC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg13047869	chr3:10149882	C3orf24	0.59	7.75	0.39	1.13e-13	Alzheimer's disease;
LUSC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg02380750	chr20:61661411	NA	0.34	5.86	0.31	1.11e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg09650180	chr20:62225654	GMEB2	-0.68	-9.77	-0.47	5.51e-20	Glioblastoma;
LUSC	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg21427119	chr20:30132790	HM13	-0.37	-5.98	-0.31	5.71e-9	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg13206674	chr6:150067644	NUP43	0.49	7.38	0.37	1.3e-12	Lung cancer;
LUSC	cis	rs11690935	0.589	rs62182403	chr2:172747182	G/A	cg13550731	chr2:172543902	DYNC1I2	0.5	7.42	0.38	9.91e-13	Schizophrenia;
LUSC	cis	rs752010	0.574	rs10890157	chr1:42117689	C/G	cg06885757	chr1:42089581	HIVEP3	0.44	9.05	0.44	1.25e-17	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.79	11.9	0.55	1.79e-27	Cognitive ability;
LUSC	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.72	9.03	0.44	1.38e-17	Type 2 diabetes;
LUSC	cis	rs6901250	0.744	rs636872	chr6:117087944	C/T	cg12892004	chr6:117198278	RFX6	0.41	7.36	0.37	1.45e-12	C-reactive protein levels;
LUSC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08736216	chr1:53307985	ZYG11A	-0.27	-5.7	-0.3	2.68e-8	Monocyte count;
LUSC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.15	-0.36	5.34e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-0.91	-17.45	-0.69	6.14e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg24768116	chr2:27665128	KRTCAP3	-0.29	-5.68	-0.3	2.92e-8	Total body bone mineral density;
LUSC	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	trans	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg26043149	chr18:55253948	FECH	0.51	7.52	0.38	5.09e-13	Bone mineral density;
LUSC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg02951883	chr7:2050386	MAD1L1	-0.47	-8.02	-0.4	1.8e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs4888262	0.508	rs4462623	chr16:74692426	C/T	cg01733217	chr16:74700730	RFWD3	0.79	13.19	0.59	2.83e-32	Testicular germ cell tumor;
LUSC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg03233332	chr7:66118400	NA	0.42	6.1	0.32	2.91e-9	Aortic root size;
LUSC	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg17366294	chr4:99064904	C4orf37	0.54	9.28	0.45	2.14e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg04155289	chr7:94953770	PON1	-0.34	-5.77	-0.3	1.76e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg19468946	chr17:37922297	IKZF3	-0.44	-6.91	-0.35	2.54e-11	Self-reported allergy;
LUSC	cis	rs2172802	0.660	rs10001410	chr4:62474229	C/A	cg04118610	chr4:62707027	LPHN3	0.44	5.84	0.3	1.23e-8	Partial epilepsies;
LUSC	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg05472934	chr7:22766657	IL6	0.38	6.05	0.31	3.94e-9	Lung cancer;
LUSC	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg03060546	chr3:49711283	APEH	-0.63	-7.27	-0.37	2.56e-12	Menarche (age at onset);
LUSC	cis	rs4664304	0.742	rs67017730	chr2:160732793	T/G	cg03641300	chr2:160917029	PLA2R1	-0.35	-5.67	-0.3	3.06e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2658782	0.756	rs2658777	chr11:93148423	C/T	cg15737290	chr11:93063684	CCDC67	0.64	7.99	0.4	2.17e-14	Pulmonary function decline;
LUSC	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg18854424	chr1:2615690	NA	0.47	9.69	0.47	1.01e-19	Ulcerative colitis;
LUSC	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg13393036	chr8:95962371	TP53INP1	-0.4	-8.43	-0.42	1.07e-15	Hemoglobin concentration;
LUSC	cis	rs950881	0.562	rs11692335	chr2:103077893	C/T	cg20060108	chr2:102954350	IL1RL1	0.45	6.18	0.32	1.91e-9	Allergy;
LUSC	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg19812747	chr11:111475976	SIK2	-0.49	-6.99	-0.36	1.52e-11	Primary sclerosing cholangitis;
LUSC	trans	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.59e-15	Diabetic kidney disease;
LUSC	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg03282975	chr18:77638264	KCNG2	-0.32	-5.65	-0.3	3.44e-8	Schizophrenia;
LUSC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg22800045	chr5:56110881	MAP3K1	0.78	9.7	0.47	9.52e-20	Initial pursuit acceleration;
LUSC	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.61	-0.34	1.55e-10	Platelet count;
LUSC	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg01884057	chr2:25150051	NA	0.48	11.43	0.53	9.16e-26	Body mass index;
LUSC	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-39.71	-0.91	1.49e-128	Myeloid white cell count;
LUSC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-0.88	-12.74	-0.57	1.45e-30	Vitiligo;
LUSC	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg08645402	chr16:4508243	NA	0.53	8.69	0.43	1.6e-16	Schizophrenia;
LUSC	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.72	-0.3	2.38e-8	Alzheimer's disease (survival time);
LUSC	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg04362960	chr10:104952993	NT5C2	0.59	9.33	0.45	1.51e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg01884057	chr2:25150051	NA	0.49	11.58	0.54	2.59e-26	Body mass index in non-asthmatics;
LUSC	cis	rs76935404	0.811	rs11083589	chr19:41428416	A/T	cg04176888	chr19:41596066	CYP2A13	0.38	6.06	0.31	3.59e-9	nicotine metabolite ratio in current smokers;
LUSC	trans	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.37	0.33	6.42e-10	Corneal astigmatism;
LUSC	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg09307838	chr4:120376055	NA	0.68	9.74	0.47	6.64e-20	Corneal astigmatism;
LUSC	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.76	-0.35	6.24e-11	Heart rate;
LUSC	cis	rs3755132	0.778	rs4668953	chr2:15785856	T/C	cg12888861	chr2:15731646	DDX1	0.53	7.54	0.38	4.42e-13	Wilms tumor;
LUSC	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg06026331	chr20:60912101	LAMA5	-0.46	-6.21	-0.32	1.6e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg24550644	chr17:30846204	MYO1D	-0.44	-7.06	-0.36	9.51e-12	Schizophrenia;
LUSC	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21545522	chr1:205238299	TMCC2	-0.5	-9.37	-0.46	1.15e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg02475777	chr4:1388615	CRIPAK	-0.43	-6.3	-0.33	9.62e-10	Obesity-related traits;
LUSC	cis	rs7799006	0.929	rs71525363	chr7:2268792	G/A	cg08027265	chr7:2291960	NA	-0.46	-7.75	-0.39	1.12e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg09455208	chr3:40491958	NA	0.58	10.2	0.49	1.96e-21	Renal cell carcinoma;
LUSC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.76	0.35	6.2e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg10645314	chr2:3704589	ALLC	-0.49	-7.33	-0.37	1.72e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg20891283	chr12:69753455	YEATS4	0.45	5.97	0.31	6.19e-9	Response to diuretic therapy;
LUSC	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg18681998	chr4:17616180	MED28	-0.79	-13.36	-0.59	6.56e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-8.88	-0.44	4.03e-17	Retinal vascular caliber;
LUSC	cis	rs11641365	0.517	rs73262667	chr16:88779753	C/T	cg00034003	chr16:88779146	CTU2	0.75	8.22	0.41	4.65e-15	Autism spectrum disorder-related traits;
LUSC	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg22089800	chr15:90895588	ZNF774	-0.65	-10.12	-0.48	3.58e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg18129178	chr5:148520854	ABLIM3	-0.73	-10.54	-0.5	1.27e-22	Breast cancer;
LUSC	cis	rs3820928	0.904	rs4414671	chr2:227816200	T/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.03	-0.4	1.67e-14	Pulmonary function;
LUSC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs17373728	0.739	rs7835101	chr8:76169185	T/C	cg07016329	chr8:76221503	NA	-0.49	-6.98	-0.36	1.57e-11	Diabetic kidney disease;
LUSC	cis	rs9323205	0.861	rs55763867	chr14:51608567	G/A	cg23942311	chr14:51606299	NA	-0.5	-10.18	-0.49	2.19e-21	Cancer;
LUSC	cis	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg06521331	chr12:34319734	NA	-0.46	-7.33	-0.37	1.73e-12	Morning vs. evening chronotype;
LUSC	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.19	-0.32	1.78e-9	Triglycerides;
LUSC	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg14458575	chr2:238380390	NA	0.59	6.82	0.35	4.29e-11	Prostate cancer;
LUSC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg04733989	chr22:42467013	NAGA	0.61	9.41	0.46	8.37e-19	Schizophrenia;
LUSC	cis	rs13064411	0.696	rs11921931	chr3:113015091	G/A	cg18753928	chr3:113234510	CCDC52	-0.41	-5.87	-0.31	1.06e-8	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs62229266	0.804	rs62230822	chr21:37429945	T/C	cg12218747	chr21:37451666	NA	-0.38	-5.68	-0.3	2.97e-8	Mitral valve prolapse;
LUSC	trans	rs11743006	0.626	rs13361324	chr5:136507512	G/C	cg07379741	chr17:7311030	NLGN2	0.41	6.28	0.32	1.05e-9	Mathematical ability;
LUSC	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg16329197	chr12:53359506	NA	-0.54	-8.0	-0.4	2e-14	Prostate cancer;
LUSC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.91	-0.31	8.51e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-8.04	-0.4	1.62e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs12651329	1.000	rs12651329	chr4:36079594	A/G	cg12553538	chr17:8191987	RANGRF;SLC25A35	-0.36	-6.19	-0.32	1.76e-9	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg09034736	chr1:150693464	HORMAD1	0.47	6.76	0.35	6.03e-11	Melanoma;
LUSC	trans	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.06	-0.31	3.67e-9	Depression;
LUSC	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg08601574	chr20:25228251	PYGB	-0.44	-6.8	-0.35	4.83e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg09796270	chr17:17721594	SREBF1	0.43	7.43	0.38	9.19e-13	Total body bone mineral density;
LUSC	cis	rs8014204	0.816	rs4903262	chr14:75340818	A/G	cg08847533	chr14:75593920	NEK9	0.39	5.67	0.3	3.12e-8	Caffeine consumption;
LUSC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.64	10.63	0.5	6.24e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg16359550	chr11:109292809	C11orf87	0.32	5.65	0.3	3.38e-8	Schizophrenia;
LUSC	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.56e-22	Colorectal cancer;
LUSC	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg07828024	chr6:149772892	ZC3H12D	-0.33	-7.36	-0.37	1.4e-12	Dupuytren's disease;
LUSC	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg02176678	chr2:219576539	TTLL4	-0.71	-11.87	-0.54	2.41e-27	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-10.73	-0.51	2.83e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg26116260	chr4:7069785	GRPEL1	-1.14	-14.53	-0.62	2.07e-37	Monocyte percentage of white cells;
LUSC	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg23093090	chr10:104574429	C10orf26	-0.37	-6.74	-0.35	6.98e-11	Arsenic metabolism;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg09775780	chr17:18585893	ZNF286B	-0.5	-6.81	-0.35	4.63e-11	Hepatitis;
LUSC	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.1	0.32	2.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg13072238	chr3:49761600	GMPPB	0.66	8.7	0.43	1.53e-16	Menarche (age at onset);
LUSC	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.9	-0.4	3.99e-14	Blood metabolite levels;
LUSC	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg12935359	chr14:103987150	CKB	-0.55	-8.44	-0.42	9.86e-16	Body mass index;
LUSC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.65	0.39	2.2e-13	Prudent dietary pattern;
LUSC	cis	rs847577	0.609	rs705308	chr7:97695363	C/A	cg21770322	chr7:97807741	LMTK2	-0.55	-9.9	-0.48	1.97e-20	Breast cancer;
LUSC	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-0.95	-18.47	-0.71	5.31e-53	Brugada syndrome;
LUSC	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21775007	chr8:11205619	TDH	0.73	11.84	0.54	3.02e-27	Retinal vascular caliber;
LUSC	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.35	0.49	6.03e-22	Lung cancer in ever smokers;
LUSC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg27532560	chr4:187881888	NA	-0.37	-6.01	-0.31	4.85e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2455601	0.744	rs7938995	chr11:8975675	T/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.46	-8.06	-0.4	1.38e-14	Schizophrenia;
LUSC	cis	rs897080	0.515	rs1067319	chr2:44633458	A/G	cg00619915	chr2:44497795	NA	-0.41	-5.8	-0.3	1.54e-8	Height;
LUSC	cis	rs12476592	0.602	rs10865339	chr2:63811884	G/T	cg10828910	chr2:63850056	LOC388955	0.48	5.69	0.3	2.77e-8	Childhood ear infection;
LUSC	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg21045802	chr8:109455806	TTC35	0.49	7.69	0.39	1.62e-13	Dupuytren's disease;
LUSC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg18230493	chr5:56204884	C5orf35	-0.88	-13.23	-0.59	2.03e-32	Initial pursuit acceleration;
LUSC	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg22676075	chr6:135203613	NA	0.48	7.51	0.38	5.47e-13	Red blood cell count;
LUSC	cis	rs12210905	0.925	rs10946896	chr6:26988576	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs600231	0.577	rs12269965	chr11:65232087	C/T	cg17120908	chr11:65337727	SSSCA1	-0.62	-9.01	-0.44	1.61e-17	Bone mineral density;
LUSC	cis	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg14019146	chr3:50243930	SLC38A3	-0.44	-9.97	-0.48	1.14e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg03213289	chr20:61660250	NA	0.68	14.14	0.61	6.77e-36	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg13010199	chr12:38710504	ALG10B	0.55	8.37	0.42	1.63e-15	Morning vs. evening chronotype;
LUSC	cis	rs34891900	0.507	rs1008378	chr22:18207251	T/C	cg08824373	chr22:18117835	NA	-0.39	-5.88	-0.31	9.82e-9	Sum neutrophil eosinophil counts;
LUSC	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	14.3	0.62	1.57e-36	Platelet count;
LUSC	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg05373962	chr22:49881684	NA	-0.4	-8.28	-0.41	3.1e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7246967	0.673	rs2194112	chr19:22926189	A/C	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.04e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg15848620	chr12:58087721	OS9	-0.53	-7.47	-0.38	6.89e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-7.1	-0.36	7.52e-12	Neuroticism;
LUSC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg00033643	chr7:134001901	SLC35B4	0.42	6.17	0.32	2e-9	Mean platelet volume;
LUSC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-1.02	-17.12	-0.68	1.27e-47	Body mass index;
LUSC	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.63	-8.12	-0.41	9.37e-15	Body mass index;
LUSC	cis	rs2742234	0.911	rs3004214	chr10:43631698	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.46	-7.75	-0.39	1.08e-13	Hirschsprung disease;
LUSC	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-0.85	-14.16	-0.61	5.78e-36	Headache;
LUSC	trans	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg08975724	chr8:8085496	FLJ10661	0.43	6.09	0.32	3.06e-9	Retinal vascular caliber;
LUSC	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	11.65	0.54	1.45e-26	Blood protein levels;
LUSC	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg02038168	chr22:39784481	NA	-0.48	-7.72	-0.39	1.35e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.8e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg04733989	chr22:42467013	NAGA	0.41	6.5	0.34	2.89e-10	Cognitive function;
LUSC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.74	-0.3	2.14e-8	Monocyte count;
LUSC	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21293242	chr8:11204541	TDH	0.32	5.96	0.31	6.38e-9	Retinal vascular caliber;
LUSC	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg21433313	chr16:3507492	NAT15	0.41	5.84	0.3	1.22e-8	Body mass index (adult);
LUSC	trans	rs975730	0.801	rs6998301	chr8:129435018	A/G	cg06138505	chr3:127317209	MCM2	0.36	6.17	0.32	1.93e-9	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg11693508	chr17:37793320	STARD3	0.6	7.17	0.37	4.77e-12	Bipolar disorder;
LUSC	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg08330031	chr10:104623503	C10orf32	0.31	5.64	0.3	3.54e-8	Arsenic metabolism;
LUSC	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg14835575	chr10:16859367	RSU1	0.78	9.82	0.47	3.58e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg13010199	chr12:38710504	ALG10B	0.58	9.27	0.45	2.32e-18	Morning vs. evening chronotype;
LUSC	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg10840412	chr1:235813424	GNG4	0.57	7.34	0.37	1.61e-12	Bipolar disorder;
LUSC	cis	rs34375054	0.573	rs12581367	chr12:125654641	T/C	cg25124228	chr12:125621409	AACS	-0.53	-6.97	-0.36	1.7e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	12.96	0.58	2.12e-31	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2019216	0.500	rs4325621	chr17:21926257	T/G	cg22648282	chr17:21454238	C17orf51	-0.53	-7.87	-0.4	5.11e-14	Pelvic organ prolapse;
LUSC	cis	rs1864400	0.690	rs7098237	chr10:43740513	T/A	cg15436174	chr10:43711423	RASGEF1A	0.43	6.94	0.36	2.02e-11	Hirschsprung disease;
LUSC	cis	rs977987	0.843	rs2059256	chr16:75395835	G/T	cg04384234	chr16:75411784	CFDP1	-0.45	-7.53	-0.38	4.67e-13	Dupuytren's disease;
LUSC	cis	rs7707921	1.000	rs891159	chr5:81491087	A/G	cg15871215	chr5:81402204	ATG10	-0.45	-6.7	-0.34	8.63e-11	Breast cancer;
LUSC	cis	rs11264799	0.539	rs11264775	chr1:157578884	A/G	cg18268488	chr1:157545234	FCRL4	0.37	6.94	0.36	2.03e-11	IgA nephropathy;
LUSC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg13395646	chr4:1353034	KIAA1530	-0.62	-9.81	-0.47	3.86e-20	Obesity-related traits;
LUSC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.56	-0.38	3.9e-13	Bipolar disorder;
LUSC	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.43	-0.46	7.21e-19	Extrinsic epigenetic age acceleration;
LUSC	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.85	-0.39	5.83e-14	Morning vs. evening chronotype;
LUSC	cis	rs7759001	0.817	rs6913122	chr6:27355292	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	1.97e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg20476274	chr7:133979776	SLC35B4	0.85	16.26	0.66	3.22e-44	Mean platelet volume;
LUSC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg04414720	chr1:150670196	GOLPH3L	-0.41	-6.27	-0.32	1.14e-9	Tonsillectomy;
LUSC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg09877947	chr5:131593287	PDLIM4	0.42	6.91	0.35	2.42e-11	Blood metabolite levels;
LUSC	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg05294307	chr14:35346193	BAZ1A	-0.63	-7.66	-0.39	2.06e-13	Psoriasis;
LUSC	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg06637938	chr14:75390232	RPS6KL1	0.65	11.0	0.52	3.23e-24	Caffeine consumption;
LUSC	trans	rs7581030	0.517	rs6731420	chr2:71533300	T/C	cg06465196	chr4:154387603	KIAA0922	0.42	6.05	0.31	3.81e-9	Testicular germ cell tumor;
LUSC	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg04117972	chr1:227635322	NA	0.58	7.01	0.36	1.36e-11	Major depressive disorder;
LUSC	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.77e-22	Eye color traits;
LUSC	cis	rs9650315	0.586	rs67705717	chr8:57208798	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.8	0.39	7.83e-14	Height;
LUSC	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.71	-12.51	-0.56	1.04e-29	White blood cell count (basophil);
LUSC	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg13010344	chr12:123464640	ARL6IP4	0.42	5.68	0.3	3e-8	Neutrophil percentage of white cells;
LUSC	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg24375607	chr4:120327624	NA	0.77	11.46	0.53	7.45e-26	Corneal astigmatism;
LUSC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg05025164	chr4:1340916	KIAA1530	-0.49	-7.52	-0.38	5.06e-13	Obesity-related traits;
LUSC	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg25930673	chr12:123319894	HIP1R	-0.72	-7.12	-0.36	6.69e-12	Schizophrenia;
LUSC	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.44	6.47	0.33	3.58e-10	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg03188948	chr7:1209495	NA	0.66	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg26875233	chr11:93583750	C11orf90	-0.31	-6.04	-0.31	4.07e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs4077468	1.000	rs9662221	chr1:205915745	G/T	cg11965913	chr1:205819406	PM20D1	-0.43	-6.41	-0.33	4.91e-10	Cystic fibrosis-related diabetes;
LUSC	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg17691542	chr6:26056736	HIST1H1C	0.49	6.95	0.36	1.88e-11	Iron status biomarkers;
LUSC	cis	rs4499344	0.664	rs4286210	chr19:33101221	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26314531	chr2:26401878	FAM59B	-0.7	-9.84	-0.47	3.09e-20	Gut microbiome composition (summer);
LUSC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg05347473	chr6:146136440	FBXO30	0.54	9.33	0.45	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg08472276	chr7:1133186	C7orf50;GPER	0.36	6.12	0.32	2.58e-9	Longevity;Endometriosis;
LUSC	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	0.81	15.07	0.64	1.65e-39	Gut microbiome composition (winter);
LUSC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg23283495	chr1:209979779	IRF6	0.64	7.9	0.4	4.12e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	6.74	0.35	6.91e-11	Menarche (age at onset);
LUSC	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg14289826	chr9:140003911	NA	0.37	7.71	0.39	1.46e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	7.65	0.39	2.17e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg18187862	chr3:45730750	SACM1L	0.53	7.05	0.36	1.06e-11	Primary sclerosing cholangitis;
LUSC	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-5.99	-0.31	5.41e-9	Body mass index;
LUSC	trans	rs1941687	0.527	rs12608181	chr18:31339351	T/G	cg27147174	chr7:100797783	AP1S1	-0.54	-8.53	-0.42	5.32e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg09365446	chr1:150670422	GOLPH3L	0.51	7.93	0.4	3.36e-14	Tonsillectomy;
LUSC	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg22535103	chr8:58192502	C8orf71	-0.68	-7.55	-0.38	4.11e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg15212455	chr7:39170539	POU6F2	0.65	11.02	0.52	2.71e-24	IgG glycosylation;
LUSC	cis	rs9487051	0.768	rs399561	chr6:109524979	G/A	cg01475377	chr6:109611718	NA	-0.35	-5.9	-0.31	9.15e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs1962073	0.528	rs9329223	chr8:10331754	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-5.78	-0.3	1.69e-8	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LUSC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.84	-0.3	1.23e-8	Total body bone mineral density;
LUSC	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg15309053	chr8:964076	NA	0.31	6.18	0.32	1.82e-9	Schizophrenia;
LUSC	cis	rs1451375	1.000	rs6949897	chr7:50621920	C/T	cg18232548	chr7:50535776	DDC	0.51	7.83	0.39	6.32e-14	Malaria;
LUSC	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.27e-17	Morning vs. evening chronotype;
LUSC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg12292205	chr6:26970375	C6orf41	0.51	8.56	0.42	4.13e-16	Schizophrenia;
LUSC	trans	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg12856521	chr11:46389249	DGKZ	0.41	6.52	0.34	2.54e-10	Leprosy;
LUSC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg23711669	chr6:146136114	FBXO30	0.7	10.72	0.51	3.12e-23	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg13565492	chr6:43139072	SRF	-0.72	-10.87	-0.51	8.9e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10871290	0.650	rs3760055	chr16:74490529	G/A	cg01733217	chr16:74700730	RFWD3	0.7	10.52	0.5	1.58e-22	Breast cancer;
LUSC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	11.22	0.52	5.28e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.59	0.34	1.68e-10	Corneal astigmatism;
LUSC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21028142	chr17:79581711	NPLOC4	0.32	7.79	0.39	8.41e-14	Eye color traits;
LUSC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.69	11.37	0.53	1.55e-25	Longevity;
LUSC	cis	rs4776059	0.798	rs4390542	chr15:52937960	T/C	cg22715398	chr15:52968154	KIAA1370	-0.58	-7.27	-0.37	2.52e-12	Schizophrenia;
LUSC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg05347473	chr6:146136440	FBXO30	0.4	6.78	0.35	5.5e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg17507749	chr15:85114479	UBE2QP1	0.56	6.39	0.33	5.58e-10	Schizophrenia;
LUSC	cis	rs9650315	0.733	rs13260778	chr8:57204375	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.33	0.37	1.73e-12	Height;
LUSC	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.7	13.39	0.59	4.88e-33	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.32	-0.37	1.85e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg22535103	chr8:58192502	C8orf71	-0.58	-6.88	-0.35	2.89e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10802521	chr3:52805072	NEK4	-0.56	-8.85	-0.44	5.15e-17	Bipolar disorder;
LUSC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.66	11.35	0.53	1.82e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg27102117	chr16:15229624	NA	0.56	9.24	0.45	2.99e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.24e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9837602	1.000	rs28714363	chr3:99752068	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.18	0.32	1.82e-9	Breast cancer;
LUSC	trans	rs1941687	0.563	rs7238931	chr18:31334993	G/A	cg13755796	chr4:20253514	NA	-0.39	-6.01	-0.31	4.87e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg20701182	chr2:24300061	SF3B14	0.58	6.19	0.32	1.72e-9	Lymphocyte counts;
LUSC	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg12011299	chr4:100065546	ADH4	-0.72	-10.42	-0.5	3.38e-22	Alcohol dependence;
LUSC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10177180	chr13:96329362	DNAJC3	-0.46	-6.29	-0.33	1e-9	Hepatitis;
LUSC	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg17366294	chr4:99064904	C4orf37	0.59	10.48	0.5	2.01e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg12257692	chr3:49977190	RBM6	-0.24	-6.6	-0.34	1.6e-10	Body mass index;
LUSC	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg10130564	chr11:117069849	TAGLN	0.35	5.98	0.31	5.65e-9	Blood protein levels;
LUSC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg13560548	chr3:10150139	C3orf24	0.53	7.43	0.38	9.1e-13	Alzheimer's disease;
LUSC	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg18753928	chr3:113234510	CCDC52	-0.49	-7.49	-0.38	6.23e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs9837602	1.000	rs923471	chr3:99757853	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.37	0.33	6.38e-10	Breast cancer;
LUSC	cis	rs7771547	0.573	rs7744363	chr6:36424665	A/C	cg07856975	chr6:36356162	ETV7	-0.36	-6.32	-0.33	8.61e-10	Platelet distribution width;
LUSC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18854424	chr1:2615690	NA	0.5	10.1	0.48	4.29e-21	Multiple sclerosis;
LUSC	cis	rs9534288	0.699	rs9567621	chr13:46665814	A/G	cg15192986	chr13:46630673	CPB2	-0.67	-9.89	-0.48	2.05e-20	Blood protein levels;
LUSC	cis	rs12620999	0.941	rs4408676	chr2:238085280	C/T	cg23555395	chr2:238036564	NA	-0.47	-8.19	-0.41	5.77e-15	Systemic lupus erythematosus;
LUSC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.79	-0.3	1.64e-8	Platelet count;
LUSC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	7.89	0.4	4.4e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.13	0.36	6.16e-12	IgG glycosylation;
LUSC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg20887711	chr4:1340912	KIAA1530	-0.48	-7.25	-0.37	2.88e-12	Obesity-related traits;
LUSC	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg05347473	chr6:146136440	FBXO30	0.51	8.55	0.42	4.43e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10761482	0.861	rs10761487	chr10:62104309	C/T	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg24531977	chr5:56204891	C5orf35	0.67	9.31	0.45	1.73e-18	Coronary artery disease;
LUSC	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg02569458	chr12:86230093	RASSF9	0.42	6.81	0.35	4.67e-11	Major depressive disorder;
LUSC	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg03585969	chr10:35415529	CREM	-0.59	-8.76	-0.43	9.74e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg20821713	chr7:1055600	C7orf50	-0.57	-7.53	-0.38	4.85e-13	Bronchopulmonary dysplasia;
LUSC	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-1.13	-17.72	-0.7	5.26e-50	Exhaled nitric oxide output;
LUSC	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	7.16	0.36	5.06e-12	Cognitive test performance;
LUSC	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.7	-12.34	-0.56	4.49e-29	Prostate cancer;
LUSC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.11	-0.41	9.41e-15	Lung cancer;
LUSC	trans	rs9841829	0.807	rs9309980	chr3:85505874	A/G	cg20344388	chr21:46829943	COL18A1	-0.29	-6.0	-0.31	5.17e-9	Alcohol consumption;
LUSC	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.67	0.65	7.43e-42	Bladder cancer;
LUSC	cis	rs1007190	0.764	rs8082522	chr17:42876340	G/C	cg15406952	chr17:42872593	NA	-0.59	-6.13	-0.32	2.45e-9	DNA methylation (variation);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23926253	chr19:19303735	LOC729991-MEF2B;LOC729991;RFXANK	-0.43	-6.39	-0.33	5.51e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21284370	chr13:42621865	DGKH	0.5	7.7	0.39	1.52e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg26384229	chr12:38710491	ALG10B	0.72	11.22	0.52	5.39e-25	Morning vs. evening chronotype;
LUSC	cis	rs1572072	0.762	rs56917105	chr13:24132142	A/T	cg24350296	chr13:24144486	TNFRSF19	-0.31	-5.88	-0.31	9.76e-9	Nasopharyngeal carcinoma;
LUSC	cis	rs6845621	0.727	rs4697195	chr4:18900688	C/T	cg12196642	chr4:18937545	NA	-0.33	-6.24	-0.32	1.32e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.69	0.34	9.68e-11	Lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25307593	chr12:40499811	SLC2A13	-0.46	-7.06	-0.36	9.62e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg19318889	chr4:1322082	MAEA	-0.71	-12.08	-0.55	4.11e-28	Obesity-related traits;
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg12432903	chr7:1882776	MAD1L1	-0.4	-6.4	-0.33	5.21e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg25482853	chr8:67687455	SGK3	1.2	17.05	0.68	2.38e-47	Lung disease severity in cystic fibrosis;
LUSC	trans	rs10511400	0.618	rs7637828	chr3:119907510	A/G	cg02809009	chr19:50354510	PTOV1	-0.74	-6.32	-0.33	8.57e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg04374321	chr14:90722782	PSMC1	0.76	12.0	0.55	7.68e-28	Mortality in heart failure;
LUSC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg17366294	chr4:99064904	C4orf37	0.6	10.61	0.5	7.52e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.44	0.53	8.42e-26	Menopause (age at onset);
LUSC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs907683	0.584	rs2854903	chr2:220288979	C/T	cg15015639	chr2:220282977	DES	-0.31	-7.16	-0.36	5.22e-12	Resting heart rate;
LUSC	cis	rs10207060	0.500	rs28640956	chr2:240714001	G/C	cg07506560	chr2:240697449	NA	0.44	6.9	0.35	2.67e-11	Obesity-related traits;
LUSC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg06008330	chr7:65541103	ASL	-0.4	-6.37	-0.33	6.38e-10	Aortic root size;
LUSC	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg15557168	chr22:42548783	NA	-0.4	-6.78	-0.35	5.32e-11	Cognitive function;
LUSC	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg23241863	chr10:102295624	HIF1AN	0.48	5.98	0.31	5.7e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7799006	0.755	rs2256545	chr7:2291943	G/A	cg12823233	chr7:2316876	SNX8	-0.47	-8.07	-0.4	1.27e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.58	10.63	0.5	6.51e-23	Bone mineral density;
LUSC	cis	rs12208915	0.708	rs9361481	chr6:79726750	T/A	cg05283184	chr6:79620031	NA	0.48	7.42	0.38	9.76e-13	Left atrial antero-posterior diameter;
LUSC	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg23173402	chr1:227635558	NA	0.61	7.44	0.38	8.82e-13	Major depressive disorder;
LUSC	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg16586182	chr3:47516702	SCAP	-0.5	-7.85	-0.39	5.69e-14	Colorectal cancer;
LUSC	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg00531865	chr16:30841666	NA	-0.34	-6.11	-0.32	2.81e-9	Dementia with Lewy bodies;
LUSC	cis	rs1775715	0.737	rs2799000	chr10:32124894	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	6.75	0.35	6.68e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4792901	0.759	rs9907813	chr17:41602858	T/G	cg22562494	chr17:41607896	ETV4	-0.32	-6.1	-0.32	2.92e-9	Dupuytren's disease;
LUSC	cis	rs7524258	0.868	rs1304711	chr1:7270320	G/T	cg07173049	chr1:7289937	CAMTA1	-0.32	-6.69	-0.34	9.16e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12368653	0.641	rs11172300	chr12:58076515	C/T	cg15848620	chr12:58087721	OS9	-0.4	-5.68	-0.3	2.95e-8	Multiple sclerosis;
LUSC	cis	rs1941023	0.584	rs2233253	chr11:60157166	C/T	cg08716584	chr11:60157161	MS4A7	-0.65	-12.23	-0.56	1.11e-28	Congenital heart disease (maternal effect);
LUSC	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg21918786	chr6:109611834	NA	-0.36	-6.05	-0.31	3.93e-9	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
LUSC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg00684032	chr4:1343700	KIAA1530	-0.34	-6.11	-0.32	2.83e-9	Obesity-related traits;
LUSC	cis	rs61612642	0.590	rs6931028	chr6:42193064	A/T	cg10382835	chr6:42185730	MRPS10	0.65	6.44	0.33	4.12e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg13073564	chr4:8508604	NA	-0.41	-8.16	-0.41	6.75e-15	Response to antineoplastic agents;
LUSC	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg25797454	chr6:150327115	RAET1K	-0.37	-8.59	-0.43	3.48e-16	Alopecia areata;
LUSC	cis	rs4903604	0.581	rs4899658	chr14:78035392	A/T	cg18872420	chr14:78023429	SPTLC2	-0.37	-5.71	-0.3	2.49e-8	Gut microbiome composition (winter);
LUSC	cis	rs9549260	0.564	rs9549270	chr13:41284193	G/T	cg21288729	chr13:41239152	FOXO1	0.55	8.45	0.42	9.22e-16	Red blood cell count;
LUSC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg11062466	chr8:58055876	NA	0.58	7.3	0.37	2.12e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg08999081	chr20:33150536	PIGU	0.37	6.78	0.35	5.42e-11	Height;
LUSC	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.63	-10.62	-0.5	6.66e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg26102564	chr10:131424627	MGMT	0.39	6.16	0.32	2.05e-9	Response to temozolomide;
LUSC	cis	rs34734847	0.787	rs1814851	chr12:121128633	C/G	cg21892295	chr12:121157589	UNC119B	-0.36	-6.3	-0.33	9.23e-10	Mean corpuscular volume;
LUSC	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg05855489	chr10:104503620	C10orf26	-0.49	-7.5	-0.38	5.96e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg23711669	chr6:146136114	FBXO30	0.75	13.26	0.59	1.61e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.8	13.27	0.59	1.43e-32	Aortic root size;
LUSC	cis	rs9341808	0.718	rs12203867	chr6:80820833	G/T	cg08355045	chr6:80787529	NA	0.56	9.85	0.47	2.85e-20	Sitting height ratio;
LUSC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.63	0.5	6.32e-23	Schizophrenia;
LUSC	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg13010199	chr12:38710504	ALG10B	0.66	10.17	0.49	2.5e-21	Bladder cancer;
LUSC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-16.5	-0.67	3.6e-45	Cognitive function;
LUSC	cis	rs9653442	0.510	rs13415583	chr2:100764087	T/G	cg07810366	chr2:100720526	AFF3	-0.45	-7.76	-0.39	1.05e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.81	0.3	1.44e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.93	-18.42	-0.71	9.11e-53	Brugada syndrome;
LUSC	cis	rs9398803	0.830	rs1490387	chr6:126834083	C/A	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	1.97e-9	Male-pattern baldness;
LUSC	cis	rs7678296	0.649	rs73128366	chr4:37241908	T/C	cg06805348	chr4:37245195	KIAA1239	0.58	5.93	0.31	7.47e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg02951883	chr7:2050386	MAD1L1	-0.45	-7.66	-0.39	2.07e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.99	-0.48	1.01e-20	Hemoglobin concentration;
LUSC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg06671706	chr8:8559999	CLDN23	0.47	6.46	0.33	3.77e-10	Obesity-related traits;
LUSC	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg20283391	chr11:68216788	NA	-0.6	-8.37	-0.42	1.6e-15	Total body bone mineral density;
LUSC	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg23598886	chr18:12777645	NA	0.65	6.47	0.33	3.49e-10	Inflammatory skin disease;
LUSC	cis	rs240764	0.658	rs11155618	chr6:101181811	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-6.32	-0.33	8.54e-10	Neuroticism;
LUSC	cis	rs13315871	1.000	rs11708590	chr3:58336635	A/G	cg12435725	chr3:58293450	RPP14	0.68	7.38	0.37	1.26e-12	Cholesterol, total;
LUSC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg03213289	chr20:61660250	NA	0.67	13.65	0.6	5.25e-34	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs54211	1.000	rs137611	chr22:39697855	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.59	5.82	0.3	1.39e-8	Sudden cardiac arrest;
LUSC	cis	rs4285028	0.699	rs4676758	chr3:121583415	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.79	10.79	0.51	1.74e-23	Multiple sclerosis;
LUSC	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg12856521	chr11:46389249	DGKZ	0.45	6.59	0.34	1.74e-10	Leprosy;
LUSC	cis	rs9653442	0.522	rs4851274	chr2:100870862	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-6.21	-0.32	1.56e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7188861	0.768	rs412861	chr16:11382756	T/G	cg00044050	chr16:11439710	C16orf75	0.57	6.25	0.32	1.24e-9	HDL cholesterol;
LUSC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.25	0.32	1.25e-9	Menopause (age at onset);
LUSC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg06238570	chr21:40685208	BRWD1	-0.63	-10.59	-0.5	8.77e-23	Cognitive function;
LUSC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.84	13.3	0.59	1.14e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg13072238	chr3:49761600	GMPPB	-0.7	-8.84	-0.44	5.75e-17	Menarche (age at onset);
LUSC	cis	rs9549260	0.739	rs7330614	chr13:41199421	G/A	cg21288729	chr13:41239152	FOXO1	0.6	9.21	0.45	3.75e-18	Red blood cell count;
LUSC	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.71	-0.39	1.44e-13	Bladder cancer;
LUSC	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg24881330	chr22:46731750	TRMU	0.89	6.82	0.35	4.27e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9283706	0.655	rs4016246	chr5:66310192	A/G	cg11590213	chr5:66331682	MAST4	0.45	6.93	0.35	2.21e-11	Coronary artery disease;
LUSC	cis	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg21775007	chr8:11205619	TDH	0.44	5.96	0.31	6.52e-9	Monocyte count;
LUSC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg07936489	chr17:37558343	FBXL20	0.71	9.88	0.48	2.23e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.55	-0.38	4.18e-13	Glomerular filtration rate (creatinine);
LUSC	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34734847	0.703	rs7978125	chr12:121167039	A/G	cg27246729	chr12:121163418	ACADS	0.41	6.5	0.34	2.86e-10	Mean corpuscular volume;
LUSC	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg20307385	chr11:47447363	PSMC3	0.43	6.08	0.32	3.24e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg25237894	chr2:233734115	C2orf82	0.34	6.39	0.33	5.47e-10	Coronary artery disease;
LUSC	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.39	0.46	9.49e-19	Resting heart rate;
LUSC	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	0.69	7.11	0.36	7.26e-12	Prostate cancer;
LUSC	cis	rs6500395	1.000	rs1362636	chr16:48712779	T/C	cg04672837	chr16:48644449	N4BP1	-0.47	-7.06	-0.36	9.68e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9462027	0.628	rs2814957	chr6:34702689	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.31	-5.65	-0.3	3.46e-8	Systemic lupus erythematosus;
LUSC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg08508325	chr11:3079039	CARS	-0.55	-13.94	-0.61	4.05e-35	Longevity;
LUSC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg05868516	chr6:26286170	HIST1H4H	0.36	5.77	0.3	1.79e-8	Educational attainment;
LUSC	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-8.78	-0.43	8.73e-17	Response to antipsychotic treatment;
LUSC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg06064525	chr11:970664	AP2A2	-0.49	-10.84	-0.51	1.15e-23	Alzheimer's disease (late onset);
LUSC	cis	rs7712401	0.645	rs154497	chr5:122221420	T/C	cg19077854	chr5:122220652	SNX24	0.4	9.02	0.44	1.46e-17	Mean platelet volume;
LUSC	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.51	0.38	5.48e-13	Iron status biomarkers;
LUSC	trans	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg19694781	chr19:47549865	TMEM160	-0.39	-6.06	-0.31	3.61e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15506890	chr2:3487001	NA	-0.58	-9.58	-0.46	2.23e-19	Neurofibrillary tangles;
LUSC	cis	rs12541635	0.934	rs7008840	chr8:107016404	T/C	cg10147462	chr8:107024639	NA	0.55	9.6	0.47	1.96e-19	Age of smoking initiation;
LUSC	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.6	11.27	0.52	3.59e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg09365446	chr1:150670422	GOLPH3L	0.49	7.26	0.37	2.73e-12	Melanoma;
LUSC	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.8	0.39	8.05e-14	Coffee consumption (cups per day);
LUSC	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-6.56	-0.34	2.08e-10	Monocyte percentage of white cells;
LUSC	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg15556689	chr8:8085844	FLJ10661	0.59	8.57	0.42	3.88e-16	Neuroticism;
LUSC	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.25	0.52	4.11e-25	Eye color traits;
LUSC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.27	0.45	2.29e-18	Prudent dietary pattern;
LUSC	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg08000102	chr2:233561755	GIGYF2	0.72	11.92	0.55	1.5e-27	Coronary artery disease;
LUSC	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg17691542	chr6:26056736	HIST1H1C	-0.5	-6.73	-0.35	7.49e-11	Iron status biomarkers;
LUSC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg12863693	chr15:85201151	NMB	0.34	6.76	0.35	6.19e-11	Schizophrenia;
LUSC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.63	9.72	0.47	7.61e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.59	0.38	3.26e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg21775007	chr8:11205619	TDH	-0.43	-5.98	-0.31	5.87e-9	Neuroticism;
LUSC	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg18002602	chr11:66138449	SLC29A2	0.45	7.98	0.4	2.43e-14	Educational attainment (years of education);
LUSC	cis	rs1808579	0.935	rs1623060	chr18:21143183	C/T	cg14672496	chr18:21087552	C18orf8	0.38	6.75	0.35	6.4e-11	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.51	-0.34	2.82e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9807989	0.507	rs10203558	chr2:103027640	T/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.69e-12	Asthma;
LUSC	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg09307838	chr4:120376055	NA	0.73	10.42	0.5	3.49e-22	Corneal astigmatism;
LUSC	cis	rs4253772	0.872	rs78864133	chr22:46638486	C/T	cg18190219	chr22:46762943	CELSR1	-0.47	-5.66	-0.3	3.23e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg00376283	chr12:123451042	ABCB9	-0.69	-7.76	-0.39	1.05e-13	Neutrophil percentage of white cells;
LUSC	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg20701182	chr2:24300061	SF3B14	0.53	5.87	0.31	1.05e-8	Lymphocyte counts;
LUSC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg25206134	chr2:45395956	NA	0.63	7.26	0.37	2.74e-12	Bipolar disorder;
LUSC	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg04539111	chr16:67997858	SLC12A4	0.49	6.12	0.32	2.59e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.53	-8.27	-0.41	3.21e-15	Longevity;Endometriosis;
LUSC	cis	rs4805834	0.719	rs55977451	chr19:33298122	A/G	cg00891608	chr19:33463040	C19orf40;CCDC123	-0.58	-5.67	-0.3	3.14e-8	Creatinine levels;
LUSC	trans	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.27	-0.32	1.11e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg11941060	chr3:133502564	NA	0.51	7.87	0.4	4.92e-14	Iron status biomarkers;
LUSC	trans	rs8000245	0.643	rs9530284	chr13:74718939	C/G	cg00896254	chr7:45149652	TBRG4	-0.49	-6.22	-0.32	1.49e-9	Optic nerve measurement (rim area);
LUSC	cis	rs1775715	0.737	rs2808072	chr10:32205504	A/T	cg26784012	chr10:32216390	ARHGAP12	0.45	7.49	0.38	6.37e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg17691542	chr6:26056736	HIST1H1C	0.54	8.12	0.41	9.26e-15	Height;
LUSC	cis	rs17253792	0.822	rs80321745	chr14:56162947	T/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.82	-0.35	4.29e-11	Putamen volume;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg10339542	chr17:10600919	C17orf48;SCO1	0.37	6.06	0.31	3.59e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg05347473	chr6:146136440	FBXO30	0.46	7.96	0.4	2.72e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg12935359	chr14:103987150	CKB	-0.39	-5.66	-0.3	3.21e-8	Body mass index;
LUSC	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.9	0.61	5.49e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs56346965	0.967	rs2293765	chr2:191520845	C/A	cg11845111	chr2:191398756	TMEM194B	0.41	5.88	0.31	9.8e-9	Bone mineral density (Ward's triangle area);
LUSC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.72	0.43	1.29e-16	Menopause (age at onset);
LUSC	trans	rs1171606	0.731	rs1171645	chr10:61452592	A/T	cg14119616	chr11:17099403	RPS13	-0.41	-6.0	-0.31	5.23e-9	Acylcarnitine levels;
LUSC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg07414643	chr4:187882934	NA	-0.53	-9.82	-0.47	3.67e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7180079	0.686	rs11071801	chr15:64883884	C/T	cg08069370	chr15:64387884	SNX1	0.54	5.76	0.3	1.93e-8	Monocyte count;
LUSC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg21854759	chr1:92012499	NA	-0.53	-8.99	-0.44	1.82e-17	Breast cancer;
LUSC	cis	rs977987	0.806	rs766521	chr16:75424154	A/G	cg04384234	chr16:75411784	CFDP1	0.43	7.07	0.36	8.88e-12	Dupuytren's disease;
LUSC	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg27411982	chr8:10470053	RP1L1	-0.4	-6.25	-0.32	1.24e-9	Neuroticism;
LUSC	cis	rs2573652	0.723	rs4577068	chr15:100515959	T/A	cg09918751	chr15:100517450	ADAMTS17	-0.52	-9.66	-0.47	1.28e-19	Height;
LUSC	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.97	21.48	0.76	6.55e-65	Longevity;
LUSC	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg20026190	chr17:76395443	PGS1	0.45	8.07	0.4	1.29e-14	HDL cholesterol levels;
LUSC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	1.0	18.59	0.71	1.79e-53	Cognitive function;
LUSC	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg09365446	chr1:150670422	GOLPH3L	0.47	7.01	0.36	1.33e-11	Melanoma;
LUSC	cis	rs829880	0.858	rs733180	chr12:98842588	C/T	cg25150519	chr12:98850993	NA	0.69	10.87	0.51	9.24e-24	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg11693508	chr17:37793320	STARD3	-0.65	-7.91	-0.4	3.87e-14	Bipolar disorder;
LUSC	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg09307838	chr4:120376055	NA	0.65	9.8	0.47	4.22e-20	Corneal astigmatism;
LUSC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg09034736	chr1:150693464	HORMAD1	0.45	6.48	0.33	3.36e-10	Melanoma;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg04633298	chr17:71229235	FAM104A;C17orf80	0.51	6.18	0.32	1.89e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg05855489	chr10:104503620	C10orf26	0.59	9.39	0.46	9.82e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6484504	0.532	rs12222329	chr11:31274340	T/C	cg14844989	chr11:31128820	NA	-0.39	-6.0	-0.31	5.2e-9	Red blood cell count;
LUSC	cis	rs2303282	0.716	rs2550308	chr16:56416228	C/G	cg00500540	chr16:56394104	NA	-0.44	-7.57	-0.38	3.6e-13	Breast cancer;
LUSC	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg00898013	chr13:113819073	PROZ	-0.57	-8.04	-0.4	1.55e-14	Platelet distribution width;
LUSC	cis	rs1882538	0.503	rs1345938	chr7:133137867	C/T	cg10665199	chr7:133106180	EXOC4	-0.59	-8.07	-0.4	1.3e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.51	0.75	4.37e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg09165964	chr15:75287851	SCAMP5	-1.06	-16.07	-0.66	1.91e-43	Blood trace element (Zn levels);
LUSC	cis	rs7582720	1.000	rs72936870	chr2:203789679	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-6.99	-0.36	1.51e-11	Blood metabolite levels;
LUSC	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg05163923	chr11:71159392	DHCR7	0.74	11.12	0.52	1.22e-24	Vitamin D levels;
LUSC	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs10992471	0.603	rs12342019	chr9:95192508	C/T	cg14631576	chr9:95140430	CENPP	-0.35	-6.48	-0.33	3.26e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs34779708	0.966	rs11010135	chr10:35518063	A/G	cg03585969	chr10:35415529	CREM	0.61	8.69	0.43	1.64e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs273218	0.573	rs16882051	chr5:53342979	T/C	cg12559925	chr2:235863365	SH3BP4	0.45	5.95	0.31	6.79e-9	Migraine;
LUSC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.89	0.31	9.52e-9	Menopause (age at onset);
LUSC	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.75	9.66	0.47	1.28e-19	Gastritis;
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg01238044	chr22:24384105	GSTT1	0.69	11.09	0.52	1.54e-24	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	8.16	0.41	6.97e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg06784218	chr1:46089804	CCDC17	0.32	5.76	0.3	1.92e-8	Platelet count;
LUSC	cis	rs7598759	0.548	rs1584462	chr2:232369798	A/G	cg19187155	chr2:232395269	NMUR1	0.92	16.08	0.66	1.8e-43	Noise-induced hearing loss;
LUSC	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg05855489	chr10:104503620	C10orf26	0.93	18.71	0.72	6.16e-54	Waist circumference;Hip circumference;
LUSC	cis	rs1107366	0.618	rs1447657	chr3:125929471	A/G	cg01346077	chr3:125931526	NA	0.51	9.96	0.48	1.2e-20	Metabolite levels;
LUSC	cis	rs2731664	0.792	rs652242	chr5:176873010	C/G	cg23176889	chr5:176863531	GRK6	-0.69	-14.3	-0.62	1.63e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-8.16	-0.41	6.99e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.66	-9.67	-0.47	1.15e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg05343316	chr1:45956843	TESK2	-0.59	-8.37	-0.42	1.59e-15	Platelet count;
LUSC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.53	-0.38	4.63e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.2e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.64	-0.34	1.24e-10	Response to antipsychotic treatment;
LUSC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs4974559	0.739	rs28411197	chr4:1279781	C/T	cg02980000	chr4:1222292	CTBP1	1.02	9.29	0.45	2.09e-18	Systolic blood pressure;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19969113	chr12:118810441	TAOK3	-0.45	-6.0	-0.31	5.14e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg05340658	chr4:99064831	C4orf37	0.58	9.52	0.46	3.6e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg26408565	chr15:76604113	ETFA	0.53	8.77	0.43	9.05e-17	Blood metabolite levels;
LUSC	cis	rs62400317	0.762	rs10484626	chr6:44882271	A/G	cg20913747	chr6:44695427	NA	-0.47	-7.43	-0.38	9.43e-13	Total body bone mineral density;
LUSC	cis	rs3740713	1.000	rs73440634	chr11:18473546	T/A	cg23797887	chr11:18477753	LDHAL6A	-0.54	-6.53	-0.34	2.45e-10	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs4786125	0.519	rs1388805	chr16:6929947	C/T	cg03623568	chr16:6915990	A2BP1	-0.48	-7.79	-0.39	8.49e-14	Heart rate variability traits (SDNN);
LUSC	cis	rs9644630	0.504	rs62496181	chr8:19318989	A/T	cg06562184	chr8:19319451	CSGALNACT1	0.48	8.06	0.4	1.33e-14	Oropharynx cancer;
LUSC	cis	rs4965006	0.915	rs7969545	chr12:132419157	C/T	cg00588090	chr12:132412438	PUS1	-0.46	-8.03	-0.4	1.7e-14	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs877282	0.853	rs10904544	chr10:756966	A/G	cg17470449	chr10:769945	NA	0.5	6.73	0.35	7.34e-11	Uric acid levels;
LUSC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg08213375	chr14:104286397	PPP1R13B	0.44	7.55	0.38	4.2e-13	Reticulocyte count;
LUSC	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg23649088	chr2:200775458	C2orf69	0.59	7.35	0.37	1.56e-12	Schizophrenia;
LUSC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg04369109	chr6:150039330	LATS1	-0.6	-8.71	-0.43	1.44e-16	Lung cancer;
LUSC	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg01283332	chr5:1856932	NA	-0.34	-6.46	-0.33	3.77e-10	Cardiovascular disease risk factors;
LUSC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg08999081	chr20:33150536	PIGU	0.46	8.24	0.41	3.95e-15	Coronary artery disease;
LUSC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg05973401	chr12:123451056	ABCB9	0.53	7.68	0.39	1.73e-13	Platelet count;
LUSC	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg17143192	chr8:8559678	CLDN23	0.64	8.71	0.43	1.41e-16	Obesity-related traits;
LUSC	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg00784671	chr22:46762841	CELSR1	-0.53	-6.26	-0.32	1.21e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.83	0.35	3.98e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg07741184	chr6:167504864	NA	0.43	7.49	0.38	6.4e-13	Primary biliary cholangitis;
LUSC	cis	rs78472555	0.507	rs2061007	chr15:100269680	C/G	cg23669855	chr15:100272142	LYSMD4	0.36	5.74	0.3	2.08e-8	Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	8.16	0.41	6.96e-15	Total body bone mineral density;
LUSC	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg00750074	chr16:89608354	SPG7	-0.45	-7.89	-0.4	4.49e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs2425143	1.000	rs11699690	chr20:34271774	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.37	-0.33	6.32e-10	Blood protein levels;
LUSC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg18190219	chr22:46762943	CELSR1	-0.49	-6.08	-0.32	3.25e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs501916	0.634	rs10851459	chr15:48061510	C/A	cg16110827	chr15:48056943	SEMA6D	-0.4	-6.19	-0.32	1.73e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.65	-8.64	-0.43	2.29e-16	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg18721089	chr20:30220636	NA	-0.35	-5.94	-0.31	7.09e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg24675056	chr1:15929824	NA	0.4	6.95	0.36	1.96e-11	Systolic blood pressure;
LUSC	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg23229984	chr5:148520753	ABLIM3	0.37	5.97	0.31	6.15e-9	Breast cancer;
LUSC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.16	15.5	0.65	3.26e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg10792982	chr14:105748885	BRF1	0.48	8.55	0.42	4.51e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg13206674	chr6:150067644	NUP43	0.43	6.44	0.33	4.2e-10	Testicular germ cell tumor;
LUSC	cis	rs6845621	0.727	rs7676193	chr4:18889088	C/T	cg12196642	chr4:18937545	NA	-0.38	-6.74	-0.35	6.91e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg18196295	chr10:418757	DIP2C	0.38	5.89	0.31	9.49e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs1355223	0.752	rs17359064	chr11:34673884	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.98	-0.31	5.76e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs909002	0.800	rs7549590	chr1:32109849	G/A	cg13919466	chr1:32135498	COL16A1	-0.31	-5.83	-0.3	1.3e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg14582100	chr15:45693742	SPATA5L1	0.43	7.61	0.38	2.88e-13	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg00310523	chr12:86230176	RASSF9	0.45	8.0	0.4	2.02e-14	Major depressive disorder;
LUSC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg22089800	chr15:90895588	ZNF774	-0.65	-9.81	-0.47	3.93e-20	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg24686825	chr1:36642396	MAP7D1	-0.75	-13.25	-0.59	1.71e-32	Schizophrenia;
LUSC	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.52	10.42	0.5	3.46e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01538021	chr17:38296400	CASC3	-0.39	-6.03	-0.31	4.39e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00377757	chr17:76921538	TIMP2	-0.52	-6.7	-0.34	8.81e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7605827	0.930	rs7575290	chr2:15597322	C/T	cg19274914	chr2:15703543	NA	0.46	8.8	0.43	7.47e-17	Educational attainment (years of education);
LUSC	cis	rs12760731	0.623	rs12045201	chr1:178399218	A/G	cg00404053	chr1:178313656	RASAL2	0.49	5.94	0.31	7.13e-9	Obesity-related traits;
LUSC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	0.97	13.52	0.59	1.62e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg27494647	chr7:150038898	RARRES2	0.45	7.08	0.36	8.32e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg13852791	chr20:30311386	BCL2L1	0.86	12.49	0.56	1.18e-29	Mean corpuscular hemoglobin;
LUSC	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg02753203	chr1:228287806	NA	1.0	19.88	0.74	1.44e-58	Diastolic blood pressure;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18923964	chr14:35451807	SRP54	-0.42	-6.15	-0.32	2.26e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg01416388	chr22:39784598	NA	-0.44	-7.18	-0.37	4.61e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg18850127	chr7:39170497	POU6F2	0.62	9.39	0.46	9.69e-19	IgG glycosylation;
LUSC	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg26384229	chr12:38710491	ALG10B	0.55	7.71	0.39	1.48e-13	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg21972741	chr5:435613	AHRR	0.36	6.8	0.35	4.8e-11	Cystic fibrosis severity;
LUSC	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22307029	chr19:49891270	CCDC155	0.61	7.78	0.39	9.21e-14	Multiple sclerosis;
LUSC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-0.93	-15.59	-0.65	1.53e-41	Body mass index;
LUSC	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21659725	chr3:3221576	CRBN	0.61	8.48	0.42	7.14e-16	Resting heart rate;
LUSC	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg15934090	chr1:100435551	SLC35A3	0.48	8.34	0.42	1.92e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg22491629	chr6:157744540	C6orf35	-0.9	-10.83	-0.51	1.29e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg00677455	chr12:58241039	CTDSP2	0.59	8.48	0.42	7.33e-16	Multiple sclerosis;
LUSC	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg21385522	chr1:16154831	NA	-0.54	-8.48	-0.42	7.6e-16	Systolic blood pressure;
LUSC	cis	rs3862435	1.000	rs7496379	chr15:91074531	T/C	cg22089800	chr15:90895588	ZNF774	-0.59	-5.66	-0.3	3.19e-8	Response to exercise (triglyceride level interaction);
LUSC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-7.74	-0.39	1.17e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.06	15.04	0.64	2.08e-39	Uric acid levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22734315	chr16:81069742	ATMIN	-0.57	-6.85	-0.35	3.57e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg05347473	chr6:146136440	FBXO30	-0.48	-8.14	-0.41	8e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg07061783	chr6:25882402	NA	0.43	6.06	0.31	3.6e-9	Blood metabolite levels;
LUSC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.52	8.52	0.42	5.56e-16	Parkinson's disease;
LUSC	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-8.41	-0.42	1.22e-15	Chronic sinus infection;
LUSC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	12.53	0.57	9.03e-30	Cognitive test performance;
LUSC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg12292205	chr6:26970375	C6orf41	-0.54	-9.22	-0.45	3.48e-18	Schizophrenia;
LUSC	cis	rs6681460	0.674	rs2121051	chr1:67017177	G/A	cg02459107	chr1:67143332	SGIP1	0.37	6.12	0.32	2.67e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs7608623	0.773	rs3795942	chr2:23919375	C/T	cg08917208	chr2:24149416	ATAD2B	-0.42	-5.74	-0.3	2.12e-8	Obesity-related traits;
LUSC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.72	8.89	0.44	3.76e-17	Gut microbiome composition (summer);
LUSC	cis	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05901451	chr6:126070800	HEY2	0.58	8.94	0.44	2.75e-17	Endometrial cancer;
LUSC	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.63	-9.97	-0.48	1.11e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg06363034	chr20:62225388	GMEB2	-0.47	-7.88	-0.4	4.78e-14	Glioblastoma;
LUSC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg23711669	chr6:146136114	FBXO30	0.74	11.89	0.55	1.96e-27	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg25152348	chr22:50946712	NCAPH2;LMF2	0.37	6.24	0.32	1.35e-9	Calcium levels;
LUSC	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg12288994	chr5:1860383	NA	0.32	7.06	0.36	9.85e-12	Cardiovascular disease risk factors;
LUSC	cis	rs4363385	0.747	rs4845508	chr1:152968421	G/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.9	-0.4	3.97e-14	Inflammatory skin disease;
LUSC	cis	rs7677751	0.848	rs7673625	chr4:55088586	C/T	cg17187183	chr4:55093834	PDGFRA	0.38	5.83	0.3	1.3e-8	Corneal astigmatism;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01777103	chr8:145550585	DGAT1	0.66	6.25	0.32	1.23e-9	Cognitive performance;
LUSC	cis	rs4356932	0.905	rs6532086	chr4:76937278	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.82	0.3	1.34e-8	Blood protein levels;
LUSC	cis	rs6494488	0.500	rs72742909	chr15:64841440	A/G	cg08069370	chr15:64387884	SNX1	-0.64	-5.65	-0.3	3.48e-8	Coronary artery disease;
LUSC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg06028605	chr16:24865363	SLC5A11	-0.57	-8.33	-0.41	2.16e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg15704280	chr7:45808275	SEPT13	0.99	14.44	0.62	4.72e-37	Coronary artery disease;
LUSC	cis	rs4692589	0.581	rs6817357	chr4:170962516	A/G	cg19918862	chr4:170955249	NA	0.36	6.59	0.34	1.73e-10	Anxiety disorder;
LUSC	cis	rs4851251	1.000	rs4851251	chr2:100753490	C/T	cg22139774	chr2:100720529	AFF3	0.47	7.02	0.36	1.26e-11	Educational attainment (years of education);
LUSC	trans	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04565464	chr8:145669602	NFKBIL2	0.39	6.37	0.33	6.11e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1185460	0.565	rs657685	chr11:118912982	G/C	cg01677386	chr11:118938358	VPS11	0.44	6.34	0.33	7.52e-10	Coronary artery disease;
LUSC	cis	rs12200782	1.000	rs72845509	chr6:26639865	T/C	cg11502198	chr6:26597334	ABT1	-0.76	-5.8	-0.3	1.53e-8	Small cell lung carcinoma;
LUSC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-1.01	-16.53	-0.67	2.89e-45	Body mass index;
LUSC	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	0.89	12.15	0.55	2.2e-28	Corneal structure;
LUSC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg00012203	chr2:219082015	ARPC2	-0.7	-11.59	-0.54	2.53e-26	Colorectal cancer;
LUSC	cis	rs2997447	0.846	rs3008417	chr1:26403470	G/A	cg19633962	chr1:26362018	EXTL1	-0.5	-5.88	-0.31	9.7e-9	QRS complex (12-leadsum);
LUSC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg24154853	chr7:158122151	PTPRN2	-0.42	-8.24	-0.41	3.89e-15	Calcium levels;
LUSC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.71	10.08	0.48	4.93e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg05347473	chr6:146136440	FBXO30	0.57	9.79	0.47	4.77e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.71	-8.73	-0.43	1.28e-16	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg06521331	chr12:34319734	NA	0.4	6.42	0.33	4.74e-10	Bladder cancer;
LUSC	cis	rs472402	0.580	rs11738248	chr5:6657494	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.44	-6.45	-0.33	4.03e-10	Response to amphetamines;
LUSC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.3e-10	Alzheimer's disease (late onset);
LUSC	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg04450456	chr4:17643702	FAM184B	-0.36	-5.78	-0.3	1.73e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.78	0.43	8.33e-17	Menopause (age at onset);
LUSC	cis	rs9513627	0.915	rs73556177	chr13:100121840	G/A	cg25919922	chr13:100150906	NA	-0.8	-6.96	-0.36	1.83e-11	Obesity-related traits;
LUSC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg11752832	chr7:134001865	SLC35B4	0.6	9.43	0.46	7.36e-19	Mean platelet volume;
LUSC	cis	rs2281558	0.876	rs2274890	chr20:25301022	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.63	9.49	0.46	4.45e-19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs701145	0.585	rs1727919	chr3:153788757	G/A	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg16928487	chr17:17741425	SREBF1	-0.44	-8.6	-0.43	3.22e-16	Total body bone mineral density;
LUSC	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg17385448	chr1:15911702	AGMAT	0.35	6.08	0.32	3.25e-9	Systolic blood pressure;
LUSC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg04450456	chr4:17643702	FAM184B	0.35	5.8	0.3	1.56e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21862992	chr11:68658383	NA	0.52	8.06	0.4	1.39e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg17252645	chr8:143867129	LY6D	0.38	6.58	0.34	1.8e-10	Urinary tract infection frequency;
LUSC	cis	rs2637266	0.905	rs2579772	chr10:78406555	A/G	cg18941641	chr10:78392320	NA	0.41	7.37	0.37	1.34e-12	Pulmonary function;
LUSC	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.44	-8.03	-0.4	1.63e-14	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg22482690	chr17:47019901	SNF8	0.38	7.01	0.36	1.35e-11	Type 2 diabetes;
LUSC	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg13010199	chr12:38710504	ALG10B	0.58	9.23	0.45	3.24e-18	Morning vs. evening chronotype;
LUSC	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg13813247	chr22:41461852	NA	-0.36	-6.41	-0.33	4.96e-10	Neuroticism;
LUSC	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg11244672	chr19:19639970	YJEFN3	-0.54	-7.01	-0.36	1.36e-11	Bipolar disorder;
LUSC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.3	-0.49	8.89e-22	Hemoglobin concentration;
LUSC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg25019033	chr10:957182	NA	-0.52	-5.79	-0.3	1.62e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg11062466	chr8:58055876	NA	0.48	5.96	0.31	6.37e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg01475377	chr6:109611718	NA	0.46	8.35	0.42	1.83e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg05347473	chr6:146136440	FBXO30	0.56	9.49	0.46	4.63e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-7.98	-0.4	2.36e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-10.28	-0.49	9.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs554111	0.574	rs4060971	chr1:21506930	C/T	cg01072550	chr1:21505969	NA	-0.39	-5.88	-0.31	9.87e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05901451	chr6:126070800	HEY2	-0.96	-18.52	-0.71	3.38e-53	Brugada syndrome;
LUSC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg16584290	chr5:462447	EXOC3	-0.34	-5.81	-0.3	1.46e-8	Cystic fibrosis severity;
LUSC	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.59	-0.34	1.75e-10	Myopia (pathological);
LUSC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	11.14	0.52	1.03e-24	Platelet count;
LUSC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.78	9.42	0.46	7.77e-19	Body mass index;
LUSC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.41	-5.9	-0.31	8.89e-9	Platelet count;
LUSC	trans	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg04995722	chr7:26192034	NFE2L3	-0.42	-6.45	-0.33	3.83e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg13010199	chr12:38710504	ALG10B	0.44	6.92	0.35	2.3e-11	Morning vs. evening chronotype;
LUSC	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.74	14.4	0.62	6.68e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1506636	0.927	rs6959270	chr7:123310628	G/A	cg03229431	chr7:123269106	ASB15	-0.65	-10.68	-0.5	4.12e-23	Plateletcrit;Platelet count;
LUSC	cis	rs7524258	0.934	rs6689453	chr1:7288384	C/T	cg07173049	chr1:7289937	CAMTA1	0.34	7.03	0.36	1.19e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7192750	0.583	rs8046916	chr16:72047751	C/G	cg14768367	chr16:72042858	DHODH	-0.7	-5.78	-0.3	1.68e-8	LDL cholesterol levels;Total cholesterol levels;
LUSC	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	7.98	0.4	2.44e-14	Neuroticism;
LUSC	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg00277334	chr10:82204260	NA	-0.48	-6.6	-0.34	1.62e-10	Post bronchodilator FEV1;
LUSC	cis	rs62408225	0.888	rs58453446	chr6:90948093	G/C	cg06866423	chr6:90926672	BACH2	0.4	5.68	0.3	2.92e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg01028140	chr2:1542097	TPO	-0.6	-7.99	-0.4	2.16e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg05347473	chr6:146136440	FBXO30	0.65	11.19	0.52	6.52e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg12463550	chr7:65579703	CRCP	0.53	7.66	0.39	2.06e-13	Aortic root size;
LUSC	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg09835421	chr16:68378352	PRMT7	-0.54	-6.09	-0.32	3.03e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg00800038	chr16:89945340	TCF25	-0.75	-6.52	-0.34	2.56e-10	Skin colour saturation;
LUSC	cis	rs3736594	1.000	rs3736594	chr2:27995781	A/C	cg27432699	chr2:27873401	GPN1	-0.61	-8.9	-0.44	3.65e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.49	-0.42	6.65e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg12311346	chr5:56204834	C5orf35	-0.63	-9.14	-0.45	6.27e-18	Coronary artery disease;
LUSC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	cis	rs10089	0.552	rs17607942	chr5:127555435	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	8.71	0.43	1.47e-16	Ileal carcinoids;
LUSC	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg21782813	chr7:2030301	MAD1L1	0.57	10.33	0.49	7.03e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg15556689	chr8:8085844	FLJ10661	0.46	5.79	0.3	1.61e-8	Obesity-related traits;
LUSC	cis	rs1712517	0.836	rs7093039	chr10:105149547	A/G	cg05636881	chr10:105038444	INA	0.41	6.81	0.35	4.43e-11	Migraine;
LUSC	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg10909506	chr17:38081995	ORMDL3	0.33	5.98	0.31	5.81e-9	Self-reported allergy;
LUSC	cis	rs3741151	0.892	rs7930454	chr11:73085034	T/C	cg17517138	chr11:73019481	ARHGEF17	0.83	7.55	0.38	4.15e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	0.79	11.55	0.53	3.54e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs58235267	0.656	rs12713469	chr2:63059927	C/T	cg17519650	chr2:63277830	OTX1	-0.7	-9.67	-0.47	1.15e-19	Prostate-specific antigen levels (conditioned on lead SNPs);
LUSC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg07061783	chr6:25882402	NA	-0.5	-6.68	-0.34	1.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7681423	0.951	rs13130318	chr4:155538470	T/G	cg20735720	chr4:155535218	FGG	-0.52	-7.53	-0.38	4.87e-13	Fibrinogen;
LUSC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08219700	chr8:58056026	NA	0.66	8.37	0.42	1.58e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.73	-11.15	-0.52	9.02e-25	Menarche (age at onset);
LUSC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.59	11.2	0.52	6.09e-25	Longevity;Endometriosis;
LUSC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg16606324	chr3:10149918	C3orf24	0.68	9.9	0.48	2.05e-20	Alzheimer's disease;
LUSC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.62	-10.01	-0.48	8.56e-21	Personality dimensions;
LUSC	trans	rs61931739	0.817	rs866515	chr12:34215479	A/G	cg13010199	chr12:38710504	ALG10B	0.4	6.28	0.32	1.06e-9	Morning vs. evening chronotype;
LUSC	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	7.83	0.39	6.4e-14	Coronary artery disease;
LUSC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg06713675	chr4:122721982	EXOSC9	0.46	8.24	0.41	4.1e-15	Type 2 diabetes;
LUSC	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg03522245	chr20:25566470	NINL	0.35	5.66	0.3	3.26e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7173743	0.967	rs28694044	chr15:79134718	A/T	cg00540400	chr15:79124168	NA	-0.33	-5.67	-0.3	3.08e-8	Coronary artery disease;
LUSC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg17294928	chr15:75287854	SCAMP5	0.41	5.85	0.3	1.2e-8	Breast cancer;
LUSC	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.88	0.31	9.93e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg02569458	chr12:86230093	RASSF9	0.46	7.63	0.39	2.54e-13	Major depressive disorder;
LUSC	cis	rs2677744	0.719	rs1266492	chr15:91456102	T/C	cg23684204	chr15:91497937	RCCD1	0.43	6.18	0.32	1.83e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.3	-5.71	-0.3	2.53e-8	Schizophrenia;
LUSC	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg04176472	chr15:90893244	GABARAPL3	0.34	6.2	0.32	1.7e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs4499344	0.921	rs12982788	chr19:33085501	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.6	-7.75	-0.39	1.13e-13	Mean platelet volume;
LUSC	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg23649088	chr2:200775458	C2orf69	0.49	6.77	0.35	5.85e-11	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	6.54	0.34	2.27e-10	Mean platelet volume;
LUSC	trans	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg13565492	chr6:43139072	SRF	-0.56	-6.01	-0.31	4.81e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg03859395	chr2:55845619	SMEK2	0.88	16.56	0.67	2.26e-45	Metabolic syndrome;
LUSC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg13393036	chr8:95962371	TP53INP1	-0.44	-9.17	-0.45	5.12e-18	Type 2 diabetes;
LUSC	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg04990556	chr1:26633338	UBXN11	0.88	11.59	0.54	2.55e-26	Obesity-related traits;
LUSC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg02569458	chr12:86230093	RASSF9	0.59	10.15	0.49	2.81e-21	Major depressive disorder;
LUSC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg12963246	chr6:28129442	ZNF389	-0.57	-7.96	-0.4	2.74e-14	Parkinson's disease;
LUSC	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg08917208	chr2:24149416	ATAD2B	0.87	9.73	0.47	7.07e-20	Lymphocyte counts;
LUSC	cis	rs897984	0.568	rs8050107	chr16:30893451	C/T	cg02466173	chr16:30829666	NA	0.52	8.42	0.42	1.14e-15	Dementia with Lewy bodies;
LUSC	cis	rs6500395	1.000	rs9936454	chr16:48617782	T/G	cg04672837	chr16:48644449	N4BP1	0.49	7.4	0.38	1.15e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs72960926	0.744	rs72959653	chr6:75012112	C/T	cg03266952	chr6:74778945	NA	-0.78	-6.76	-0.35	6.21e-11	Metabolite levels (MHPG);
LUSC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg14092988	chr3:52407081	DNAH1	0.31	6.14	0.32	2.33e-9	Bipolar disorder;
LUSC	cis	rs11997175	1.000	rs6468203	chr8:33749572	T/A	ch.8.33884649F	chr8:33765107	NA	0.52	8.32	0.41	2.29e-15	Body mass index;
LUSC	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	11.91	0.55	1.75e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	0.64	13.56	0.6	1.12e-33	Prudent dietary pattern;
LUSC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22968622	chr17:43663579	NA	0.79	12.27	0.56	7.76e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg19773385	chr1:10388646	KIF1B	-0.49	-8.61	-0.43	2.84e-16	Hepatocellular carcinoma;
LUSC	trans	rs62238980	0.614	rs41430344	chr22:32381973	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.52	-5.94	-0.31	7e-9	Childhood ear infection;
LUSC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg17264618	chr3:40429014	ENTPD3	0.36	7.38	0.37	1.26e-12	Renal cell carcinoma;
LUSC	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.88	12.64	0.57	3.48e-30	Coronary artery disease;
LUSC	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg02903104	chr8:1507517	DLGAP2	0.35	6.9	0.35	2.6e-11	Lung cancer;
LUSC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg26338869	chr17:61819248	STRADA	0.42	6.18	0.32	1.88e-9	Prudent dietary pattern;
LUSC	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg07148914	chr20:33460835	GGT7	0.44	6.57	0.34	1.92e-10	Height;
LUSC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg27170947	chr2:26402098	FAM59B	-0.64	-9.34	-0.45	1.43e-18	Gut microbiome composition (summer);
LUSC	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg04539111	chr16:67997858	SLC12A4	-0.45	-6.06	-0.31	3.75e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10743315	0.778	rs965861	chr12:19360719	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.49	-6.24	-0.32	1.3e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.47	-0.42	7.8e-16	Response to antipsychotic treatment;
LUSC	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg08085267	chr17:45401833	C17orf57	-0.59	-10.14	-0.49	2.99e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3764563	1.000	rs4808326	chr19:15726147	A/G	cg20725493	chr19:15740067	CYP4F8	-0.66	-7.03	-0.36	1.17e-11	Inflammatory biomarkers;
LUSC	cis	rs1941023	0.503	rs12798266	chr11:60118851	G/A	cg08716584	chr11:60157161	MS4A7	-0.59	-10.86	-0.51	9.87e-24	Congenital heart disease (maternal effect);
LUSC	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg11189052	chr15:85197271	WDR73	-0.41	-5.91	-0.31	8.47e-9	P wave terminal force;
LUSC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.54	-0.38	4.33e-13	Blood metabolite levels;
LUSC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg05084668	chr3:125655381	ALG1L	-0.5	-7.04	-0.36	1.11e-11	Blood pressure (smoking interaction);
LUSC	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg20991723	chr1:152506922	NA	0.5	9.18	0.45	4.77e-18	Hair morphology;
LUSC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg08470875	chr2:26401718	FAM59B	-0.66	-8.63	-0.43	2.55e-16	Gut microbiome composition (summer);
LUSC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-0.82	-12.42	-0.56	2.25e-29	Gut microbiome composition (summer);
LUSC	cis	rs12220238	1.000	rs11000900	chr10:75918440	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.57	6.78	0.35	5.33e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs7605827	0.897	rs4668922	chr2:15675130	C/T	cg19274914	chr2:15703543	NA	0.46	8.86	0.44	4.79e-17	Educational attainment (years of education);
LUSC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	1.18	10.79	0.51	1.76e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg14205524	chr15:42787946	SNAP23	0.39	5.94	0.31	7.02e-9	Triglycerides;
LUSC	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.09	-0.32	3.17e-9	Testicular germ cell tumor;
LUSC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-6.95	-0.36	1.92e-11	Bipolar disorder;
LUSC	cis	rs10489202	0.865	rs744168	chr1:168094079	G/T	cg24449463	chr1:168025552	DCAF6	-0.57	-6.9	-0.35	2.66e-11	Schizophrenia;
LUSC	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg09323728	chr8:95962352	TP53INP1	-0.3	-5.7	-0.3	2.69e-8	Type 2 diabetes;
LUSC	cis	rs12900413	0.687	rs28435184	chr15:90306732	T/C	cg24249390	chr15:90295951	MESP1	-0.37	-5.92	-0.31	7.96e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg02344993	chr17:57696989	CLTC	0.48	7.11	0.36	7.3e-12	Hemoglobin concentration;
LUSC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg16524733	chr11:117070046	TAGLN	0.43	7.34	0.37	1.67e-12	Blood protein levels;
LUSC	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.6	9.39	0.46	9.59e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7582720	1.000	rs72934749	chr2:203746816	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg25456477	chr12:86230367	RASSF9	0.38	6.45	0.33	4.03e-10	Major depressive disorder;
LUSC	cis	rs4851254	0.626	rs71413861	chr2:100673501	A/G	cg07810366	chr2:100720526	AFF3	-0.47	-6.19	-0.32	1.81e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs965469	1.000	rs8123289	chr20:3253831	T/C	cg25506879	chr20:3388711	C20orf194	-0.56	-6.29	-0.33	9.9e-10	IFN-related cytopenia;
LUSC	cis	rs926938	0.527	rs360665	chr1:115478503	A/T	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.49	-0.33	3.08e-10	Autism;
LUSC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg14552801	chr7:65878734	NA	0.38	5.84	0.3	1.24e-8	Aortic root size;
LUSC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg26304593	chr6:42947056	PEX6	-0.53	-8.31	-0.41	2.44e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg15448220	chr1:150897856	SETDB1	0.41	6.02	0.31	4.48e-9	Melanoma;
LUSC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg03146154	chr1:46216737	IPP	0.55	7.81	0.39	7.55e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg08847533	chr14:75593920	NEK9	0.85	15.55	0.65	2.07e-41	Height;
LUSC	cis	rs9362426	0.708	rs4707367	chr6:88101188	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-6.47	-0.33	3.55e-10	Depressive episodes in bipolar disorder;
LUSC	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-16.09	-0.66	1.58e-43	Height;
LUSC	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg20607287	chr7:12443886	VWDE	-0.66	-6.5	-0.33	2.99e-10	Coronary artery disease;
LUSC	cis	rs3755132	0.929	rs3770466	chr2:15758293	T/C	cg12888861	chr2:15731646	DDX1	0.52	7.46	0.38	7.57e-13	Wilms tumor;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg16303686	chr3:132136102	DNAJC13	0.77	6.18	0.32	1.89e-9	Cognitive performance;
LUSC	cis	rs3760982	0.813	rs8104447	chr19:44293278	T/C	cg11993925	chr19:44307056	LYPD5	-0.31	-6.86	-0.35	3.39e-11	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	trans	rs7939886	0.920	rs11227507	chr11:55972274	G/A	cg15704280	chr7:45808275	SEPT13	0.91	6.86	0.35	3.36e-11	Myopia (pathological);
LUSC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	cis	rs9303542	0.625	rs17703660	chr17:46567134	T/C	cg09704116	chr17:46666958	LOC404266	-0.38	-6.43	-0.33	4.51e-10	Ovarian cancer;Epithelial ovarian cancer;
LUSC	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg06636001	chr8:8085503	FLJ10661	0.5	7.52	0.38	5.04e-13	Neuroticism;
LUSC	cis	rs75804782	0.581	rs3191996	chr2:239344412	A/G	cg18131467	chr2:239335373	ASB1	0.7	6.49	0.33	3.19e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	0.9	16.92	0.68	8.31e-47	Coronary artery disease;
LUSC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.84	-0.39	5.96e-14	Schizophrenia;
LUSC	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg14092571	chr14:90743983	NA	-0.35	-5.77	-0.3	1.84e-8	Mortality in heart failure;
LUSC	trans	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg07393940	chr7:158741817	NA	0.36	6.47	0.33	3.44e-10	Life satisfaction;
LUSC	cis	rs9513627	0.915	rs73556173	chr13:100121766	C/T	cg25919922	chr13:100150906	NA	-0.8	-6.96	-0.36	1.83e-11	Obesity-related traits;
LUSC	cis	rs3740540	0.507	rs897292	chr10:126290035	A/G	cg04949429	chr10:126290192	LHPP	0.36	7.71	0.39	1.44e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9581857	0.519	rs9581880	chr13:28105850	C/A	cg22138327	chr13:27999177	GTF3A	0.66	7.22	0.37	3.44e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg26380479	chr7:97908229	NA	-0.28	-6.13	-0.32	2.54e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg01097406	chr16:89675127	NA	-0.34	-6.82	-0.35	4.39e-11	Vitiligo;
LUSC	cis	rs9905704	0.918	rs304271	chr17:56802458	C/T	cg12560992	chr17:57184187	TRIM37	0.54	7.75	0.39	1.15e-13	Testicular germ cell tumor;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10475689	chr16:12142335	RUNDC2A	0.49	6.45	0.33	3.99e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg26043149	chr18:55253948	FECH	0.47	7.16	0.36	5.06e-12	Bone mineral density;
LUSC	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	6.38	0.33	5.99e-10	Schizophrenia;
LUSC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg12963246	chr6:28129442	ZNF389	0.48	6.68	0.34	9.77e-11	Depression;
LUSC	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg01620082	chr3:125678407	NA	0.76	7.1	0.36	7.41e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs17092148	1.000	rs6060043	chr20:33364584	C/T	cg16810054	chr20:33298113	TP53INP2	-0.43	-6.81	-0.35	4.68e-11	Neuroticism;
LUSC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg17948913	chr5:572064	NA	0.33	5.66	0.3	3.27e-8	Ulcerative colitis;
LUSC	cis	rs11229555	0.645	rs4506677	chr11:58213852	T/C	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-11.94	-0.55	1.27e-27	Total body bone mineral density;
LUSC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	1.07	17.34	0.69	1.71e-48	Testicular germ cell tumor;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04571355	chr1:201489142	RPS10P7	-0.39	-6.92	-0.35	2.26e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs981844	0.775	rs1020704	chr4:154736494	C/T	cg14289246	chr4:154710475	SFRP2	0.48	6.53	0.34	2.38e-10	Response to statins (LDL cholesterol change);
LUSC	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.11	15.31	0.64	1.94e-40	Uric acid levels;
LUSC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	11.02	0.52	2.77e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	5.75	0.3	1.97e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg19682013	chr15:45996608	NA	0.4	6.05	0.31	3.79e-9	Waist circumference;Weight;
LUSC	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg17517138	chr11:73019481	ARHGEF17	1.11	9.05	0.44	1.23e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs2742234	0.541	rs7098236	chr10:43740508	T/C	cg15436174	chr10:43711423	RASGEF1A	0.43	6.94	0.36	2.02e-11	Hirschsprung disease;
LUSC	cis	rs12620999	0.941	rs1986830	chr2:237978320	C/T	cg23555395	chr2:238036564	NA	0.44	7.7	0.39	1.59e-13	Systemic lupus erythematosus;
LUSC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg08888203	chr3:10149979	C3orf24	0.67	9.34	0.46	1.37e-18	Alzheimer's disease;
LUSC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.29	-5.69	-0.3	2.74e-8	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg07211511	chr3:129823064	LOC729375	-0.8	-10.65	-0.5	5.31e-23	Blood pressure (smoking interaction);
LUSC	cis	rs7809950	0.678	rs7803151	chr7:106934246	G/A	cg23024343	chr7:107201750	COG5	-0.66	-9.99	-0.48	9.74e-21	Coronary artery disease;
LUSC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg27535305	chr1:53392650	SCP2	-0.4	-7.7	-0.39	1.52e-13	Monocyte count;
LUSC	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.49	-0.33	3.17e-10	Schizophrenia;
LUSC	cis	rs8099014	0.954	rs28497563	chr18:56134147	C/A	cg12907477	chr18:56117327	MIR122	0.43	6.55	0.34	2.21e-10	Platelet count;
LUSC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg19318889	chr4:1322082	MAEA	0.49	8.05	0.4	1.5e-14	Obesity-related traits;
LUSC	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg19700328	chr14:106028568	NA	-0.41	-6.94	-0.36	1.99e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg02997394	chr19:33096574	ANKRD27	0.82	9.28	0.45	2.14e-18	Eosinophilic esophagitis;
LUSC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg26408565	chr15:76604113	ETFA	-0.53	-8.38	-0.42	1.45e-15	Blood metabolite levels;
LUSC	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg20283391	chr11:68216788	NA	-0.6	-8.4	-0.42	1.25e-15	Total body bone mineral density;
LUSC	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg13334819	chr7:99746414	C7orf59	0.5	6.79	0.35	5.04e-11	Coronary artery disease;
LUSC	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg01528321	chr10:82214614	TSPAN14	1.03	16.02	0.66	3.03e-43	Post bronchodilator FEV1;
LUSC	cis	rs1775715	0.870	rs1775737	chr10:32256871	T/C	cg18675610	chr10:32216311	ARHGAP12	0.28	5.93	0.31	7.38e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs1941687	0.831	rs35740221	chr18:31387714	T/G	cg27147174	chr7:100797783	AP1S1	-0.46	-6.78	-0.35	5.62e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs6087990	0.806	rs4911258	chr20:31369479	G/A	cg13636640	chr20:31349939	DNMT3B	0.89	17.61	0.69	1.43e-49	Ulcerative colitis;
LUSC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg20573242	chr4:122745356	CCNA2	0.64	9.38	0.46	1.04e-18	Type 2 diabetes;
LUSC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.43	0.46	6.92e-19	Mean platelet volume;
LUSC	cis	rs965469	0.947	rs6051692	chr20:3244098	T/C	cg25506879	chr20:3388711	C20orf194	-0.56	-6.38	-0.33	5.98e-10	IFN-related cytopenia;
LUSC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-1.0	-18.23	-0.71	4.89e-52	Height;
LUSC	cis	rs2425143	0.730	rs6058354	chr20:34491110	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.67	-0.3	3.14e-8	Blood protein levels;
LUSC	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg12863693	chr15:85201151	NMB	0.36	7.06	0.36	9.44e-12	Schizophrenia;
LUSC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.53	-0.34	2.47e-10	Melanoma;
LUSC	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg04546413	chr19:29218101	NA	0.58	7.23	0.37	3.31e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs6457821	1.000	rs114672225	chr6:35440288	G/A	cg06087101	chr6:35551932	FKBP5	0.63	5.77	0.3	1.8e-8	Height;
LUSC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg06713675	chr4:122721982	EXOSC9	-0.45	-7.97	-0.4	2.59e-14	Type 2 diabetes;
LUSC	cis	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg02972257	chr16:68554789	NA	-0.49	-6.3	-0.33	9.24e-10	Ulcerative colitis;
LUSC	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg04733989	chr22:42467013	NAGA	0.42	7.08	0.36	8.61e-12	Cognitive function;
LUSC	cis	rs9427116	0.840	rs9427113	chr1:154626477	A/G	cg17218026	chr1:154582156	ADAR	0.51	8.76	0.43	9.71e-17	Blood protein levels;
LUSC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg00857998	chr1:205179979	DSTYK	0.57	8.89	0.44	3.91e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22024783	chr19:45393916	TOMM40	0.49	7.23	0.37	3.27e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11608355	1.000	rs10850135	chr12:109866528	C/A	cg19025524	chr12:109796872	NA	-0.39	-6.0	-0.31	5.04e-9	Neuroticism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17330695	chr2:216973988	XRCC5	-0.44	-6.56	-0.34	2.03e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg18512352	chr11:47633146	NA	-0.48	-9.65	-0.47	1.38e-19	Subjective well-being;
LUSC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.59	0.5	8.66e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2067615	0.524	rs7959062	chr12:107107334	G/T	cg19260189	chr12:106995001	RFX4	0.23	5.92	0.31	7.83e-9	Heart rate;
LUSC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg24130564	chr14:104152367	KLC1	-0.42	-5.94	-0.31	7.02e-9	Bone mineral density;
LUSC	cis	rs2562456	0.833	rs2968078	chr19:21641744	A/G	cg00806126	chr19:22604979	ZNF98	0.37	5.84	0.3	1.24e-8	Pain;
LUSC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg17173187	chr15:85201210	NMB	0.37	6.52	0.34	2.64e-10	Schizophrenia;
LUSC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg13939156	chr17:80058883	NA	-0.32	-6.37	-0.33	6.34e-10	Life satisfaction;
LUSC	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg25039879	chr17:56429692	SUPT4H1	0.5	7.83	0.39	6.47e-14	Primary tooth development (time to first tooth eruption);
LUSC	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg09796270	chr17:17721594	SREBF1	0.43	7.57	0.38	3.78e-13	Total body bone mineral density;
LUSC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg08888203	chr3:10149979	C3orf24	0.65	8.79	0.43	8.22e-17	Alzheimer's disease;
LUSC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03517284	chr6:25882590	NA	0.43	7.76	0.39	1.07e-13	Blood metabolite levels;
LUSC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	0.99	19.95	0.74	7.12e-59	Menopause (age at onset);
LUSC	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.3e-11	Uric acid levels;
LUSC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg01579765	chr21:45077557	HSF2BP	-0.51	-10.94	-0.51	5.22e-24	Mean corpuscular volume;
LUSC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	14.38	0.62	7.93e-37	Platelet count;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22870994	chr11:71340352	NA	-0.41	-5.99	-0.31	5.51e-9	Neuroticism;
LUSC	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-8.92	-0.44	3.09e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg16342193	chr10:102329863	NA	-0.35	-6.3	-0.33	9.17e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.88	13.44	0.59	3.2e-33	Menarche (age at onset);
LUSC	cis	rs1832871	0.711	rs9459918	chr6:158703604	A/C	cg07165851	chr6:158734300	TULP4	0.5	7.72	0.39	1.36e-13	Height;
LUSC	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs977987	0.806	rs4888416	chr16:75449176	C/G	cg03315344	chr16:75512273	CHST6	0.48	8.94	0.44	2.68e-17	Dupuytren's disease;
LUSC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.74	-10.89	-0.51	7.56e-24	Corneal astigmatism;
LUSC	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg03929089	chr4:120376271	NA	0.72	6.86	0.35	3.37e-11	Axial length;
LUSC	cis	rs977987	0.806	rs4888386	chr16:75389740	A/G	cg04384234	chr16:75411784	CFDP1	-0.4	-6.46	-0.33	3.68e-10	Dupuytren's disease;
LUSC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.63	8.39	0.42	1.42e-15	High light scatter reticulocyte count;
LUSC	cis	rs9346649	0.630	rs6913441	chr6:168491271	C/T	cg02770688	chr6:168491649	NA	0.5	9.54	0.46	3e-19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	trans	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg13010199	chr12:38710504	ALG10B	0.44	7.08	0.36	8.41e-12	Morning vs. evening chronotype;
LUSC	cis	rs4494114	0.936	rs9439092	chr1:39375157	T/G	cg25970120	chr1:39325951	RRAGC	-0.4	-6.22	-0.32	1.47e-9	Blood protein levels;
LUSC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg04756594	chr16:24857601	SLC5A11	0.49	7.19	0.37	4.4e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg16524733	chr11:117070046	TAGLN	0.44	7.53	0.38	4.89e-13	Blood protein levels;
LUSC	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.72e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg20283391	chr11:68216788	NA	-0.53	-7.94	-0.4	3.19e-14	Total body bone mineral density;
LUSC	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.62	-0.43	2.78e-16	Total cholesterol levels;
LUSC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg12463550	chr7:65579703	CRCP	0.43	6.06	0.31	3.74e-9	Calcium levels;
LUSC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg08270630	chr22:50330655	NA	0.4	5.9	0.31	8.78e-9	Schizophrenia;
LUSC	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg02004499	chr7:4244250	SDK1	0.48	7.73	0.39	1.25e-13	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LUSC	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.0	0.52	3.23e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg17420585	chr12:42539391	GXYLT1	-0.3	-5.71	-0.3	2.54e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.09	0.4	1.12e-14	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg20243544	chr17:37824526	PNMT	0.41	6.37	0.33	6.21e-10	Self-reported allergy;
LUSC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg12463550	chr7:65579703	CRCP	-0.49	-7.22	-0.37	3.63e-12	Aortic root size;
LUSC	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.27	-0.41	3.3e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg05887092	chr17:76393375	PGS1	0.67	13.24	0.59	1.92e-32	HDL cholesterol;
LUSC	cis	rs9815354	0.597	rs80066790	chr3:42000843	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.43	0.42	1.06e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg20849893	chr7:64541193	NA	-0.65	-5.68	-0.3	2.99e-8	Diabetic kidney disease;
LUSC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00149659	chr3:10157352	C3orf10	0.92	12.88	0.58	4.25e-31	Alzheimer's disease;
LUSC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg06671706	chr8:8559999	CLDN23	0.51	6.65	0.34	1.18e-10	Obesity-related traits;
LUSC	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg12935359	chr14:103987150	CKB	0.68	10.99	0.52	3.53e-24	Intelligence (multi-trait analysis);
LUSC	trans	rs12637928	0.580	rs7638452	chr3:110180719	A/G	cg17371621	chr15:61264283	RORA	0.38	6.38	0.33	5.74e-10	Neuroticism;
LUSC	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg13010199	chr12:38710504	ALG10B	0.67	10.31	0.49	8.3e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.45	0.67	5.97e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg07810366	chr2:100720526	AFF3	-0.52	-9.08	-0.45	9.54e-18	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg11494091	chr17:61959527	GH2	0.38	6.24	0.32	1.31e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg05343316	chr1:45956843	TESK2	0.64	8.86	0.44	4.88e-17	Platelet count;
LUSC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg12442385	chr7:1034912	NA	-0.36	-6.09	-0.32	3.02e-9	Longevity;Endometriosis;
LUSC	cis	rs13253111	0.624	rs28372101	chr8:28099384	G/T	cg26534493	chr8:28060551	NA	0.37	6.82	0.35	4.35e-11	Childhood body mass index;
LUSC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.62	9.37	0.46	1.11e-18	Menarche (age at onset);
LUSC	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg20587970	chr11:113659929	NA	-1.06	-13.08	-0.58	7.3e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg01689657	chr7:91764605	CYP51A1	0.34	6.19	0.32	1.79e-9	Breast cancer;
LUSC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.35	5.95	0.31	6.93e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg05623727	chr3:50126028	RBM5	-0.35	-6.66	-0.34	1.1e-10	Body mass index;
LUSC	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07080220	chr10:102295463	HIF1AN	0.67	8.9	0.44	3.54e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg12963246	chr6:28129442	ZNF389	-0.44	-6.34	-0.33	7.6e-10	Depression;
LUSC	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22433210	chr17:43662623	NA	-0.74	-10.73	-0.51	2.92e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg27295185	chr5:154320610	MRPL22	0.43	6.77	0.35	5.87e-11	Schizophrenia;
LUSC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.06	-0.58	8.6e-32	Alzheimer's disease;
LUSC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.74	11.02	0.52	2.64e-24	Multiple sclerosis;
LUSC	cis	rs4901869	0.966	rs431343	chr14:59345530	C/T	cg02291164	chr14:59296302	NA	0.53	9.57	0.46	2.5e-19	Panic disorder;
LUSC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.17	0.58	3.33e-32	Chronic sinus infection;
LUSC	cis	rs7524258	0.835	rs75096060	chr1:7270248	G/C	cg07173049	chr1:7289937	CAMTA1	0.33	6.72	0.35	7.64e-11	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs11648785	0.661	rs870856	chr16:90089463	C/G	cg16611967	chr16:90144006	NA	0.46	6.26	0.32	1.15e-9	Tanning;
LUSC	cis	rs57502260	0.834	rs3736228	chr11:68201295	A/G	cg20283391	chr11:68216788	NA	0.61	5.86	0.31	1.08e-8	Total body bone mineral density (age 45-60);
LUSC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-5.94	-0.31	7.16e-9	Vitiligo;
LUSC	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg01579765	chr21:45077557	HSF2BP	-0.5	-10.59	-0.5	8.88e-23	Mean corpuscular volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08340572	chr15:76196139	FBXO22	0.42	6.17	0.32	2.01e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	7.12	0.36	6.78e-12	Lung cancer in ever smokers;
LUSC	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg09307838	chr4:120376055	NA	0.7	9.91	0.48	1.9e-20	Corneal astigmatism;
LUSC	cis	rs1865721	1.000	rs72977888	chr18:73195250	C/T	cg26385618	chr18:73139727	C18orf62	-0.48	-7.97	-0.4	2.56e-14	Intelligence;
LUSC	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg05855489	chr10:104503620	C10orf26	-0.7	-10.37	-0.49	4.99e-22	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	5.95	0.31	6.6e-9	Cystic fibrosis severity;
LUSC	cis	rs3768617	0.903	rs10911251	chr1:183081194	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.4	0.42	1.26e-15	Fuchs's corneal dystrophy;
LUSC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg20821713	chr7:1055600	C7orf50	-0.45	-5.87	-0.31	1.05e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.25	-0.32	1.26e-9	Personality dimensions;
LUSC	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg09904177	chr6:26538194	HMGN4	0.66	11.63	0.54	1.81e-26	Intelligence (multi-trait analysis);
LUSC	trans	rs11700980	0.551	rs2832029	chr21:30114574	G/A	cg14791747	chr16:20752902	THUMPD1	0.56	6.1	0.32	2.98e-9	QRS complex (12-leadsum);
LUSC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg14895029	chr7:2775587	GNA12	-0.42	-6.37	-0.33	6.31e-10	Height;
LUSC	cis	rs79911532	0.515	rs117982500	chr7:75758907	C/A	cg03592824	chr7:75666768	STYXL1	0.67	6.37	0.33	6.32e-10	Mononucleosis;
LUSC	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg24069376	chr3:38537580	EXOG	0.42	8.05	0.4	1.51e-14	Electrocardiographic conduction measures;
LUSC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-14.67	-0.63	5.92e-38	Vitiligo;
LUSC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-6.27	-0.32	1.12e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs354225	0.544	rs12713265	chr2:54805409	C/T	cg26097391	chr2:54893211	SPTBN1	0.45	6.89	0.35	2.83e-11	Schizophrenia;
LUSC	cis	rs13067593	1.000	rs35687668	chr3:188573711	T/G	cg17809494	chr3:188572244	LPP	0.42	5.7	0.3	2.57e-8	Immune reponse to smallpox (secreted IFN-alpha);
LUSC	cis	rs9487051	0.735	rs1761608	chr6:109517706	G/A	cg01475377	chr6:109611718	NA	-0.36	-6.12	-0.32	2.66e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg27489772	chr12:121021490	NA	0.58	7.71	0.39	1.44e-13	Type 1 diabetes nephropathy;
LUSC	cis	rs1957429	0.808	rs11628910	chr14:65332392	A/G	cg23373153	chr14:65346875	NA	0.95	10.83	0.51	1.25e-23	Pediatric areal bone mineral density (radius);
LUSC	trans	rs11696501	0.739	rs6073784	chr20:44201931	T/A	cg03272292	chr12:48577362	C12orf68	0.51	5.98	0.31	5.86e-9	Brain structure;
LUSC	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg13010199	chr12:38710504	ALG10B	0.58	9.13	0.45	6.73e-18	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg24829409	chr8:58192753	C8orf71	-0.63	-6.58	-0.34	1.79e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12997796	1.000	rs12997796	chr2:86974318	A/G	cg25203885	chr2:87302643	LOC285074	-0.61	-6.84	-0.35	3.87e-11	Schizophrenia;
LUSC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg08088566	chr11:430123	ANO9	0.61	7.04	0.36	1.07e-11	Body mass index;
LUSC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	7.88	0.4	4.72e-14	Menarche (age at onset);
LUSC	cis	rs6977660	1.000	rs10279525	chr7:19822305	C/T	cg07541023	chr7:19748670	TWISTNB	0.51	5.74	0.3	2.08e-8	Thyroid stimulating hormone;
LUSC	cis	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg27411982	chr8:10470053	RP1L1	-0.47	-7.02	-0.36	1.24e-11	Neuroticism;
LUSC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06112835	chr11:68658793	MRPL21	0.5	7.9	0.4	4.19e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg27494647	chr7:150038898	RARRES2	0.44	6.77	0.35	5.88e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	15.29	0.64	2.22e-40	Lung cancer in ever smokers;
LUSC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg15557168	chr22:42548783	NA	0.46	7.12	0.36	6.7e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg05110241	chr16:68378359	PRMT7	-0.54	-6.34	-0.33	7.48e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg10756647	chr7:56101905	PSPH	0.85	8.25	0.41	3.59e-15	Diabetic kidney disease;
LUSC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg14343924	chr8:8086146	FLJ10661	-0.44	-6.18	-0.32	1.86e-9	Mood instability;
LUSC	cis	rs9296092	0.538	rs112113649	chr6:33524529	A/G	cg13560919	chr6:33536144	NA	-0.84	-16.11	-0.66	1.37e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs11030122	0.673	rs10835596	chr11:4099666	C/T	cg18678763	chr11:4115507	RRM1	-0.48	-6.37	-0.33	6.3e-10	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs9860340	0.687	rs6806250	chr3:87651951	T/G	cg03644585	chr7:884825	UNC84A	0.44	6.12	0.32	2.65e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg18132916	chr6:79620363	NA	-0.38	-5.81	-0.3	1.44e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-9.29	-0.45	2.04e-18	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	11.55	0.53	3.45e-26	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.85	-0.47	2.85e-20	Platelet count;
LUSC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg17971929	chr21:40555470	PSMG1	0.52	7.98	0.4	2.33e-14	Cognitive function;
LUSC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg03146154	chr1:46216737	IPP	0.56	8.34	0.42	2.02e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg10326726	chr10:51549505	MSMB	0.35	6.08	0.32	3.37e-9	Prostate-specific antigen levels;
LUSC	cis	rs4842666	0.831	rs11105337	chr12:89993507	A/T	cg00757033	chr12:89920650	WDR51B	0.45	6.26	0.32	1.21e-9	Blood pressure;
LUSC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	6.87	0.35	3.08e-11	Multiple sclerosis;
LUSC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.48	-8.81	-0.43	7.08e-17	Urinary metabolites;
LUSC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg17366294	chr4:99064904	C4orf37	0.56	10.0	0.48	8.92e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-14.91	-0.63	7.11e-39	Height;
LUSC	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg23093090	chr10:104574429	C10orf26	-0.36	-6.61	-0.34	1.54e-10	Arsenic metabolism;
LUSC	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg19875535	chr5:140030758	IK	0.49	8.14	0.41	7.85e-15	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs12692738	0.526	rs355864	chr2:165630414	A/T	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4308124	0.708	rs56693625	chr2:111965155	G/A	cg04571233	chr2:111982156	NA	-0.51	-6.6	-0.34	1.62e-10	Vitiligo;
LUSC	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg21827317	chr3:136751795	NA	0.38	6.83	0.35	4.01e-11	Neuroticism;
LUSC	trans	rs7939886	0.920	rs11231901	chr11:55811529	A/G	cg15704280	chr7:45808275	SEPT13	0.84	6.97	0.36	1.68e-11	Myopia (pathological);
LUSC	cis	rs722599	0.562	rs2193597	chr14:75234329	G/A	cg08847533	chr14:75593920	NEK9	0.41	5.86	0.31	1.11e-8	IgG glycosylation;
LUSC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg25258033	chr6:167368657	RNASET2	0.42	6.69	0.34	9.53e-11	Crohn's disease;
LUSC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg18479299	chr3:125709523	NA	-0.49	-5.98	-0.31	5.67e-9	Blood pressure (smoking interaction);
LUSC	cis	rs7903847	0.620	rs61863815	chr10:99124389	A/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.22	-0.37	3.46e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs983392	0.667	rs662196	chr11:59942757	C/T	cg20284999	chr11:59952153	MS4A6A	0.35	6.08	0.32	3.34e-9	Alzheimer's disease (late onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04026000	chr5:79628372	NA	0.51	6.33	0.33	8.08e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg21770322	chr7:97807741	LMTK2	0.41	7.25	0.37	2.92e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.67	10.6	0.5	8.09e-23	Alcohol dependence;
LUSC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.48	-8.04	-0.4	1.57e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg23791538	chr6:167370224	RNASET2	-0.38	-5.94	-0.31	7.05e-9	Crohn's disease;
LUSC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg19592336	chr6:28129416	ZNF389	0.48	6.3	0.33	9.46e-10	Depression;
LUSC	cis	rs9283706	0.548	rs10044452	chr5:66302605	C/T	cg11590213	chr5:66331682	MAST4	0.43	6.53	0.34	2.4e-10	Coronary artery disease;
LUSC	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg25319279	chr11:5960081	NA	-0.45	-6.29	-0.33	1.01e-9	DNA methylation (variation);
LUSC	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.6	-0.34	1.66e-10	Retinal vascular caliber;
LUSC	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	8.15	0.41	7.6e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4343996	0.902	rs4349886	chr7:3370038	C/T	cg21248987	chr7:3385318	SDK1	-0.37	-6.32	-0.33	8.33e-10	Motion sickness;
LUSC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.11	14.28	0.62	1.9e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg10253484	chr15:75165896	SCAMP2	0.39	5.64	0.3	3.56e-8	Caffeine consumption;
LUSC	cis	rs10979	0.631	rs12530338	chr6:143872563	C/T	cg25407410	chr6:143891975	LOC285740	-0.52	-7.64	-0.39	2.27e-13	Hypospadias;
LUSC	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg09307838	chr4:120376055	NA	0.63	9.5	0.46	4.35e-19	Corneal astigmatism;
LUSC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg07507251	chr3:52567010	NT5DC2	0.32	6.25	0.32	1.28e-9	Bipolar disorder;
LUSC	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg23029597	chr12:123009494	RSRC2	-0.74	-9.13	-0.45	6.67e-18	Body mass index;
LUSC	trans	rs9860340	0.730	rs7617101	chr3:87633556	C/T	cg03644585	chr7:884825	UNC84A	0.42	6.09	0.32	3.17e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg16342193	chr10:102329863	NA	-0.34	-5.94	-0.31	7.31e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26036478	chr4:124319962	SPRY1	-0.45	-6.8	-0.35	4.93e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	0.94	13.9	0.61	5.76e-35	Vitiligo;
LUSC	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg06640241	chr16:89574553	SPG7	0.67	10.72	0.51	3.06e-23	Multiple myeloma (IgH translocation);
LUSC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg13119609	chr19:45449297	APOC2	-0.51	-10.1	-0.48	4.1e-21	Blood protein levels;
LUSC	trans	rs12692738	0.526	rs392050	chr2:165630793	G/A	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg14004847	chr7:1930337	MAD1L1	-0.49	-7.53	-0.38	4.65e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg21251018	chr6:28226885	NKAPL	0.31	5.91	0.31	8.57e-9	Pubertal anthropometrics;
LUSC	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-1.15	-18.51	-0.71	3.92e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg13010199	chr12:38710504	ALG10B	0.65	10.12	0.48	3.51e-21	Bladder cancer;
LUSC	cis	rs10489202	0.644	rs11584210	chr1:167846853	A/G	cg24449463	chr1:168025552	DCAF6	-0.54	-6.37	-0.33	6.3e-10	Schizophrenia;
LUSC	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.42	0.53	9.82e-26	Eye color traits;
LUSC	cis	rs68170813	0.559	rs6967745	chr7:106850548	G/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.27e-20	Coronary artery disease;
LUSC	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg21466736	chr12:48725269	NA	-0.3	-5.7	-0.3	2.7e-8	Glycated hemoglobin levels;
LUSC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg23205692	chr1:25664452	TMEM50A	0.4	5.85	0.31	1.15e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg18904891	chr8:8559673	CLDN23	0.6	8.13	0.41	8.6e-15	Obesity-related traits;
LUSC	cis	rs2219968	1.000	rs1481511	chr8:78955014	A/G	cg00738934	chr8:78996279	NA	0.34	6.17	0.32	1.94e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg06026331	chr20:60912101	LAMA5	0.61	7.32	0.37	1.81e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs7043114	0.525	rs2025388	chr9:95128740	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.82	-0.35	4.34e-11	Height;
LUSC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg24209194	chr3:40518798	ZNF619	0.46	6.33	0.33	8.01e-10	Renal cell carcinoma;
LUSC	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg05855489	chr10:104503620	C10orf26	0.66	10.09	0.48	4.62e-21	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs11608355	0.515	rs6606727	chr12:109941450	T/A	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg27124370	chr19:33622961	WDR88	0.54	7.16	0.36	5.12e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-0.81	-9.89	-0.48	2.2e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs9837602	1.000	rs13064704	chr3:99767541	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	6.15	0.32	2.19e-9	Breast cancer;
LUSC	cis	rs6012953	0.817	rs16995294	chr20:49181345	T/A	cg13958625	chr20:49123093	NA	-0.26	-5.76	-0.3	1.91e-8	Vitiligo;
LUSC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.59	-11.49	-0.53	5.83e-26	Prostate cancer;
LUSC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.79e-23	Schizophrenia;
LUSC	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-0.53	-8.15	-0.41	7.34e-15	Breast cancer;
LUSC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.66	-0.57	2.91e-30	Chronic sinus infection;
LUSC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.28	0.53	3.21e-25	Prudent dietary pattern;
LUSC	cis	rs9807989	1.000	rs9807989	chr2:102971200	T/C	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.67e-9	Asthma;
LUSC	cis	rs4853525	0.923	rs2204859	chr2:191736873	C/A	cg11845111	chr2:191398756	TMEM194B	-0.42	-6.17	-0.32	1.93e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg17366294	chr4:99064904	C4orf37	0.55	8.99	0.44	1.94e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-0.69	-10.77	-0.51	2.11e-23	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	13.05	0.58	9.94e-32	Platelet count;
LUSC	trans	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg14791747	chr16:20752902	THUMPD1	-0.4	-6.02	-0.31	4.49e-9	Dental caries;
LUSC	cis	rs3125734	0.572	rs3864794	chr10:64041956	A/C	cg09941381	chr10:64027924	RTKN2	-0.39	-7.12	-0.36	6.82e-12	Rheumatoid arthritis;
LUSC	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.86	-13.88	-0.6	6.6e-35	Schizophrenia;
LUSC	cis	rs7804356	1.000	rs7785798	chr7:26861943	A/G	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.05e-9	Type 1 diabetes;
LUSC	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.6	-9.5	-0.46	4.24e-19	Breast size;
LUSC	cis	rs1692580	0.840	rs696094	chr1:2169215	G/A	cg03732007	chr1:2071316	PRKCZ	0.4	6.49	0.33	3.07e-10	Coronary artery disease;
LUSC	cis	rs62027291	0.654	rs56402836	chr15:77081967	A/C	cg26408565	chr15:76604113	ETFA	0.78	7.02	0.36	1.25e-11	Plateletcrit;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01100864	chr12:122750645	VPS33A	0.46	6.12	0.32	2.58e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg11941060	chr3:133502564	NA	0.53	8.03	0.4	1.63e-14	Iron status biomarkers;
LUSC	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg08277548	chr1:17600880	PADI3	-0.64	-6.64	-0.34	1.27e-10	Hair shape;
LUSC	trans	rs62458065	0.850	rs62458098	chr7:32471129	G/A	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.08	-0.32	3.33e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg01251360	chr16:68772225	CDH1	-0.25	-5.92	-0.31	7.88e-9	Colorectal cancer;
LUSC	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg21770322	chr7:97807741	LMTK2	0.57	10.37	0.49	5.03e-22	Breast cancer;
LUSC	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02176678	chr2:219576539	TTLL4	0.66	12.75	0.57	1.36e-30	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg22800045	chr5:56110881	MAP3K1	0.67	9.13	0.45	6.52e-18	Initial pursuit acceleration;
LUSC	cis	rs4356932	1.000	rs10014837	chr4:76941818	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.82	0.3	1.4e-8	Blood protein levels;
LUSC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.75	12.89	0.58	3.77e-31	Motion sickness;
LUSC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.0	-0.48	9.09e-21	Hemoglobin concentration;
LUSC	cis	rs8064299	0.565	rs12453550	chr17:72786086	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.93	19.1	0.72	1.69e-55	Monocyte count;
LUSC	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-1.14	-18.19	-0.71	7.14e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.6	-0.43	3.22e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	11.54	0.53	3.72e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg07701084	chr6:150067640	NUP43	0.53	7.86	0.39	5.52e-14	Lung cancer;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11905131	chr22:24372483	LOC391322	-0.6	-10.09	-0.48	4.65e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11971779	0.938	rs28477480	chr7:139036058	C/T	cg07862535	chr7:139043722	LUC7L2	-0.65	-7.51	-0.38	5.38e-13	Diisocyanate-induced asthma;
LUSC	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg20848291	chr7:100343083	ZAN	-0.68	-9.4	-0.46	9.08e-19	Other erythrocyte phenotypes;
LUSC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg11632617	chr15:75315747	PPCDC	-0.52	-6.76	-0.35	6.09e-11	Blood trace element (Zn levels);
LUSC	cis	rs7799006	1.000	rs7810970	chr7:2276385	A/G	cg02951883	chr7:2050386	MAD1L1	-0.34	-5.81	-0.3	1.49e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.73	-12.84	-0.57	5.97e-31	White blood cell count (basophil);
LUSC	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.54	8.38	0.42	1.48e-15	Depressive symptoms;
LUSC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.26	0.77	6.18e-68	Prudent dietary pattern;
LUSC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.95	0.31	6.59e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25134909	chr11:47587211	PTPMT1	0.48	6.59	0.34	1.72e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2324229	0.828	rs1180208	chr6:83954322	A/T	cg08257003	chr6:84140564	ME1	0.28	6.75	0.35	6.49e-11	Platelet-derived growth factor BB levels;
LUSC	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.83	-0.39	6.41e-14	Retinal vascular caliber;
LUSC	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg24562669	chr7:97807699	LMTK2	0.38	6.44	0.33	4.19e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	5.67	0.3	3.15e-8	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.95e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16148416	chr1:33116824	RBBP4;ZBTB8OS	-0.4	-6.07	-0.32	3.43e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2970818	0.831	rs12366731	chr12:4636095	A/G	cg11146114	chr12:4671731	NA	-0.6	-5.91	-0.31	8.39e-9	Phosphorus levels;
LUSC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11645453	chr3:52864694	ITIH4	0.34	7.77	0.39	9.51e-14	Bipolar disorder;
LUSC	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.72	9.71	0.47	8.26e-20	Systemic sclerosis;
LUSC	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg17644776	chr2:200775616	C2orf69	0.36	5.75	0.3	2.04e-8	Osteoporosis;
LUSC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg26516362	chr5:178986906	RUFY1	0.47	8.15	0.41	7.4e-15	Lung cancer;
LUSC	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg08601574	chr20:25228251	PYGB	0.49	7.52	0.38	5.16e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8038465	0.615	rs6495075	chr15:73981005	A/G	cg15420318	chr15:73925796	NPTN	0.57	9.59	0.46	2.1e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg00310523	chr12:86230176	RASSF9	0.52	9.81	0.47	3.84e-20	Major depressive disorder;
LUSC	cis	rs1062746	1.000	rs1062746	chr16:87364650	A/G	cg02258303	chr16:87377426	FBXO31	-0.54	-9.11	-0.45	7.91e-18	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	trans	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg07393940	chr7:158741817	NA	-0.51	-8.09	-0.4	1.12e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg27411982	chr8:10470053	RP1L1	0.42	6.33	0.33	7.72e-10	Monocyte count;
LUSC	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg21890820	chr11:65308645	LTBP3	0.49	7.16	0.36	5.14e-12	Bone mineral density;
LUSC	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	7.3	0.37	2.09e-12	Schizophrenia;
LUSC	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19748678	chr4:122722346	EXOSC9	-0.48	-7.0	-0.36	1.42e-11	Type 2 diabetes;
LUSC	cis	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg07460842	chr6:66804631	NA	0.88	8.93	0.44	2.87e-17	Exhaled nitric oxide output;
LUSC	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.66	-10.09	-0.48	4.59e-21	Brugada syndrome;
LUSC	trans	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg07393940	chr7:158741817	NA	0.37	6.78	0.35	5.58e-11	Life satisfaction;
LUSC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-12.61	-0.57	4.44e-30	Chronic sinus infection;
LUSC	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg00277334	chr10:82204260	NA	-0.43	-6.15	-0.32	2.24e-9	Post bronchodilator FEV1;
LUSC	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg25566285	chr7:158114605	PTPRN2	0.31	5.87	0.31	1.05e-8	Calcium levels;
LUSC	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg25237894	chr2:233734115	C2orf82	0.35	6.51	0.34	2.71e-10	Coronary artery disease;
LUSC	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg15744005	chr10:104629667	AS3MT	-0.27	-5.75	-0.3	2.06e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg26408565	chr15:76604113	ETFA	-0.52	-8.39	-0.42	1.38e-15	Blood metabolite levels;
LUSC	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14240646	chr10:27532245	ACBD5	-0.69	-7.97	-0.4	2.58e-14	Breast cancer;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg10659624	chr3:9885815	RPUSD3	0.44	6.12	0.32	2.69e-9	Mosquito bite size;
LUSC	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.74	-13.12	-0.58	5.27e-32	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9649465	0.561	rs600420	chr7:123408050	G/A	cg03229431	chr7:123269106	ASB15	0.48	7.7	0.39	1.56e-13	Migraine;
LUSC	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.61	9.6	0.47	1.93e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg12564285	chr5:131593104	PDLIM4	0.34	6.27	0.32	1.09e-9	Blood metabolite levels;
LUSC	cis	rs12618769	0.652	rs72823796	chr2:99227812	C/T	cg10123293	chr2:99228465	UNC50	0.45	7.09	0.36	8.29e-12	Bipolar disorder;
LUSC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg04362960	chr10:104952993	NT5C2	0.52	6.47	0.33	3.44e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-0.9	-16.77	-0.68	3.14e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6681460	1.000	rs1536115	chr1:67121001	A/T	cg02459107	chr1:67143332	SGIP1	0.47	9.0	0.44	1.75e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	7.96	0.4	2.69e-14	Cognitive test performance;
LUSC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg05802129	chr4:122689817	NA	-0.5	-8.47	-0.42	7.92e-16	Type 2 diabetes;
LUSC	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg00857998	chr1:205179979	DSTYK	0.64	10.09	0.48	4.63e-21	Red blood cell count;
LUSC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-9.47	-0.46	5.41e-19	Chronic sinus infection;
LUSC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg06145435	chr7:1022769	CYP2W1	0.27	5.83	0.3	1.3e-8	Longevity;Endometriosis;
LUSC	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	12.49	0.56	1.24e-29	Electrocardiographic conduction measures;
LUSC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg11366901	chr6:160182831	ACAT2	0.93	13.06	0.58	8.98e-32	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg13010199	chr12:38710504	ALG10B	0.54	8.45	0.42	9.36e-16	Morning vs. evening chronotype;
LUSC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg12463550	chr7:65579703	CRCP	-0.56	-8.43	-0.42	1.02e-15	Aortic root size;
LUSC	trans	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg26043149	chr18:55253948	FECH	-0.46	-7.05	-0.36	1.02e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs3815700	0.925	rs395136	chr19:33106742	A/G	cg02997394	chr19:33096574	ANKRD27	0.56	6.57	0.34	1.9e-10	Eosinophilic esophagitis;
LUSC	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.14	-0.45	6.2e-18	Monocyte percentage of white cells;
LUSC	cis	rs16867321	0.950	rs9677293	chr2:181499459	C/G	cg23363182	chr2:181467187	NA	-0.44	-5.74	-0.3	2.16e-8	Obesity;
LUSC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.94	0.48	1.4e-20	Bipolar disorder;
LUSC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	6.81	0.35	4.45e-11	Renal function-related traits (BUN);
LUSC	cis	rs6599077	1.000	rs6763643	chr3:40097991	A/G	cg13683864	chr3:40499215	RPL14	-0.6	-6.55	-0.34	2.24e-10	Sleep-related phenotypes;
LUSC	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21643547	chr1:205240462	TMCC2	-0.5	-9.3	-0.45	1.95e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs300703	0.872	rs12233077	chr2:120949	T/A	cg21211680	chr2:198530	NA	-0.77	-7.44	-0.38	8.86e-13	Blood protein levels;
LUSC	cis	rs9311676	0.632	rs62259780	chr3:58428078	T/G	cg13750441	chr3:58318267	PXK	0.35	6.77	0.35	5.67e-11	Systemic lupus erythematosus;
LUSC	cis	rs921665	0.749	rs7563563	chr2:3201417	A/G	cg16434511	chr2:3151078	NA	0.57	5.84	0.3	1.23e-8	World class endurance athleticism;
LUSC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-13.2	-0.59	2.59e-32	Alzheimer's disease;
LUSC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg21970626	chr13:21893289	NA	-0.52	-9.64	-0.47	1.5e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs977987	0.843	rs11649638	chr16:75488285	G/A	cg04384234	chr16:75411784	CFDP1	-0.45	-7.43	-0.38	9.37e-13	Dupuytren's disease;
LUSC	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg10426581	chr7:100472382	SRRT	0.85	12.37	0.56	3.31e-29	Resting heart rate;
LUSC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.53	-0.34	2.42e-10	Monocyte count;
LUSC	cis	rs9815354	0.638	rs76276404	chr3:41931770	A/G	cg03022575	chr3:42003672	ULK4	0.82	8.55	0.42	4.49e-16	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg07663200	chr17:42030104	NA	-0.37	-6.17	-0.32	1.99e-9	Post bronchodilator FEV1;
LUSC	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.61	8.93	0.44	2.98e-17	Total cholesterol levels;
LUSC	cis	rs16854884	0.609	rs2885197	chr3:143636616	A/T	cg06585982	chr3:143692056	C3orf58	-0.4	-6.38	-0.33	6.02e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs9309473	1.000	rs13421462	chr2:73719875	A/C	cg20560298	chr2:73613845	ALMS1	-0.46	-6.54	-0.34	2.31e-10	Metabolite levels;
LUSC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg14552801	chr7:65878734	NA	-0.45	-6.51	-0.34	2.83e-10	Aortic root size;
LUSC	cis	rs13089785	0.791	rs16834826	chr3:123584488	C/T	cg19611163	chr3:123411211	MYLK	-0.34	-5.89	-0.31	9.67e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg08000102	chr2:233561755	GIGYF2	-0.72	-10.24	-0.49	1.43e-21	Schizophrenia;
LUSC	cis	rs17092148	1.000	rs6060017	chr20:33313042	G/T	cg16810054	chr20:33298113	TP53INP2	-0.38	-5.97	-0.31	6.19e-9	Neuroticism;
LUSC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg20821713	chr7:1055600	C7orf50	-0.53	-6.81	-0.35	4.66e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs34375054	0.672	rs10400509	chr12:125592173	T/C	cg00522288	chr12:125625016	AACS	-0.31	-5.9	-0.31	8.95e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg26924012	chr15:45694286	SPATA5L1	1.14	20.79	0.75	3.36e-62	Homoarginine levels;
LUSC	cis	rs4363385	0.574	rs4845505	chr1:152960943	T/A	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.47	-0.33	3.44e-10	Inflammatory skin disease;
LUSC	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg16558253	chr16:72132732	DHX38	-0.37	-5.76	-0.3	1.86e-8	Fibrinogen levels;
LUSC	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg11189052	chr15:85197271	WDR73	-0.45	-6.44	-0.33	4.19e-10	P wave terminal force;
LUSC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg02380750	chr20:61661411	NA	0.34	5.9	0.31	8.82e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs858239	0.539	rs28716381	chr7:23189015	G/A	cg23682824	chr7:23144976	KLHL7	0.4	5.71	0.3	2.52e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs4629180	0.586	rs290773	chr2:102125930	G/A	cg01388757	chr2:102091195	RFX8	0.37	6.43	0.33	4.35e-10	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.36	-0.37	1.47e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	10.74	0.51	2.64e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.81	14.14	0.61	6.96e-36	Adiposity;
LUSC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg01416388	chr22:39784598	NA	-0.43	-7.21	-0.37	3.82e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg13683864	chr3:40499215	RPL14	-1.12	-20.02	-0.74	3.68e-59	Renal cell carcinoma;
LUSC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg01238044	chr22:24384105	GSTT1	-0.63	-10.11	-0.48	3.85e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2835872	0.965	rs2835855	chr21:39015754	T/A	cg20424643	chr21:39039972	KCNJ6	0.43	6.5	0.34	2.94e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg15654264	chr1:150340011	RPRD2	0.62	10.32	0.49	7.51e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg11764359	chr7:65958608	NA	-0.69	-10.46	-0.5	2.43e-22	Aortic root size;
LUSC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg01973587	chr1:228161476	NA	0.43	7.81	0.39	7.46e-14	Diastolic blood pressure;
LUSC	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg27411982	chr8:10470053	RP1L1	-0.52	-7.89	-0.4	4.32e-14	Neuroticism;
LUSC	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.06	0.55	4.74e-28	Cognitive test performance;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg27462969	chr1:67896192	SERBP1	0.41	6.35	0.33	6.92e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg05738196	chr6:26577821	NA	0.82	15.84	0.66	1.48e-42	Intelligence (multi-trait analysis);
LUSC	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.54	-0.42	4.78e-16	Morning vs. evening chronotype;
LUSC	cis	rs6545883	0.811	rs778753	chr2:61780200	T/A	cg15711740	chr2:61764176	XPO1	-0.44	-6.94	-0.36	2e-11	Tuberculosis;
LUSC	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.4	8.34	0.41	2.03e-15	Hemoglobin concentration;
LUSC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.37	-6.27	-0.32	1.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg24397884	chr7:158709396	WDR60	0.8	8.96	0.44	2.34e-17	Height;
LUSC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg01528321	chr10:82214614	TSPAN14	0.62	8.98	0.44	2.09e-17	Post bronchodilator FEV1;
LUSC	trans	rs11696501	0.688	rs6124726	chr20:44307866	T/A	cg03272292	chr12:48577362	C12orf68	0.5	5.98	0.31	5.74e-9	Brain structure;
LUSC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg23711669	chr6:146136114	FBXO30	0.7	12.0	0.55	7.79e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21293242	chr8:11204541	TDH	0.31	5.93	0.31	7.54e-9	Retinal vascular caliber;
LUSC	cis	rs4285028	0.747	rs7153	chr3:121383297	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-12.76	-0.57	1.17e-30	Multiple sclerosis;
LUSC	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg21573476	chr21:45109991	RRP1B	-0.38	-6.22	-0.32	1.47e-9	Mean corpuscular volume;
LUSC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	12.66	0.57	2.74e-30	Cognitive test performance;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27489481	chr12:53399999	EIF4B	-0.42	-6.19	-0.32	1.74e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6500395	1.000	rs3848321	chr16:48620780	A/T	cg04672837	chr16:48644449	N4BP1	0.5	7.49	0.38	6.16e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.45	6.21	0.32	1.61e-9	Osteoporosis;
LUSC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg18904891	chr8:8559673	CLDN23	0.56	7.69	0.39	1.68e-13	Obesity-related traits;
LUSC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.46	7.44	0.38	8.85e-13	Alzheimer's disease (late onset);
LUSC	trans	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg25214090	chr10:38739885	LOC399744	0.55	8.1	0.41	1.04e-14	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26492318	chr16:68344786	PRMT7;SLC7A6OS	-0.41	-6.34	-0.33	7.55e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3126085	1.000	rs3120662	chr1:152302865	G/T	cg26876637	chr1:152193138	HRNR	-0.46	-5.81	-0.3	1.47e-8	Atopic dermatitis;
LUSC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg01652190	chr22:50026171	C22orf34	0.34	7.17	0.37	4.81e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg15556689	chr8:8085844	FLJ10661	0.58	8.74	0.43	1.19e-16	Neuroticism;
LUSC	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-10.05	-0.48	6e-21	Morning vs. evening chronotype;
LUSC	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg13010199	chr12:38710504	ALG10B	0.64	10.02	0.48	7.68e-21	Bladder cancer;
LUSC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.59	7.93	0.4	3.43e-14	High light scatter reticulocyte count;
LUSC	trans	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.57	9.24	0.45	2.99e-18	Brugada syndrome;
LUSC	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg15103426	chr22:29168792	CCDC117	0.58	7.88	0.4	4.78e-14	Lymphocyte counts;
LUSC	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.2	-0.32	1.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7212590	0.655	rs56198517	chr17:57976582	G/T	cg10252138	chr17:58120427	NA	-0.78	-7.19	-0.37	4.2e-12	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6722750	0.783	rs4671550	chr2:64389314	T/A	cg22352474	chr2:64371530	PELI1	0.64	10.08	0.48	4.86e-21	Neuroticism;
LUSC	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg14440974	chr22:39074834	NA	-0.35	-5.8	-0.3	1.56e-8	Menopause (age at onset);
LUSC	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg23029597	chr12:123009494	RSRC2	-0.62	-8.08	-0.4	1.17e-14	Body mass index;
LUSC	cis	rs72960926	0.744	rs72964214	chr6:74864851	T/C	cg03266952	chr6:74778945	NA	-0.85	-7.25	-0.37	2.94e-12	Metabolite levels (MHPG);
LUSC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs11645898	0.765	rs112439757	chr16:72168337	C/T	cg14768367	chr16:72042858	DHODH	-0.52	-5.79	-0.3	1.61e-8	Blood protein levels;
LUSC	cis	rs7177699	0.557	rs7176187	chr15:79121373	A/G	cg00540400	chr15:79124168	NA	0.45	7.78	0.39	8.97e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24378470	chr17:9478950	WDR16;STX8	0.37	6.34	0.33	7.57e-10	Triglycerides;
LUSC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.8	8.21	0.41	5.03e-15	Initial pursuit acceleration;
LUSC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg21724239	chr8:58056113	NA	0.62	7.02	0.36	1.21e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg19920283	chr7:105172520	RINT1	0.6	6.38	0.33	5.9e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs11637445	0.640	rs4508380	chr15:68109049	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	7.21	0.37	3.84e-12	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs3087591	0.960	rs1124918	chr17:29492423	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.51	-7.36	-0.37	1.48e-12	Hip circumference;
LUSC	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17261708	chr5:176794207	RGS14	0.34	5.95	0.31	6.9e-9	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg09367891	chr1:107599246	PRMT6	0.5	7.07	0.36	9.12e-12	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs8010715	0.636	rs3825584	chr14:24587639	C/T	cg23112188	chr14:24563095	PCK2	-0.33	-6.09	-0.32	3.17e-9	IgG glycosylation;
LUSC	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg12863693	chr15:85201151	NMB	0.35	7.1	0.36	7.35e-12	Schizophrenia;
LUSC	cis	rs11650494	0.908	rs11656535	chr17:47425588	C/T	cg08112188	chr17:47440006	ZNF652	1.19	9.8	0.47	4.43e-20	Prostate cancer;
LUSC	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg08847533	chr14:75593920	NEK9	0.85	15.72	0.65	4.5e-42	Height;
LUSC	cis	rs7560272	0.538	rs2012574	chr2:73928366	G/C	cg20560298	chr2:73613845	ALMS1	0.38	5.77	0.3	1.86e-8	Schizophrenia;
LUSC	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.68	-9.08	-0.44	9.73e-18	Lymphocyte counts;Red cell distribution width;
LUSC	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg05340658	chr4:99064831	C4orf37	0.65	10.77	0.51	2.08e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg01579765	chr21:45077557	HSF2BP	-0.5	-10.31	-0.49	7.72e-22	Mean corpuscular volume;
LUSC	cis	rs9687065	1.000	rs75777806	chr5:148403428	T/G	cg23229984	chr5:148520753	ABLIM3	-0.38	-5.66	-0.3	3.24e-8	Diastolic blood pressure;
LUSC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg06641503	chr3:48959341	ARIH2	-0.38	-5.87	-0.31	1.06e-8	Parkinson's disease;
LUSC	trans	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg03732007	chr1:2071316	PRKCZ	0.54	9.8	0.47	4.25e-20	Height;
LUSC	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-0.99	-17.23	-0.69	4.58e-48	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg05855489	chr10:104503620	C10orf26	-0.68	-10.21	-0.49	1.74e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.01	0.48	8.37e-21	Bladder cancer;
LUSC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-11.64	-0.54	1.6e-26	Systemic lupus erythematosus;
LUSC	trans	rs10411161	0.702	rs10402630	chr19:52384570	G/A	cg22319618	chr22:45562946	NUP50	-0.49	-5.94	-0.31	6.97e-9	Breast cancer;
LUSC	cis	rs672059	0.967	rs514183	chr1:183163174	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.11	0.41	9.58e-15	Hypertriglyceridemia;
LUSC	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg08508325	chr11:3079039	CARS	0.37	8.24	0.41	3.91e-15	Calcium levels;
LUSC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	29.03	0.85	2.44e-93	Chronic sinus infection;
LUSC	cis	rs11958404	0.932	rs61478293	chr5:157426299	G/A	cg05962755	chr5:157440814	NA	0.5	6.04	0.31	4.18e-9	IgG glycosylation;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg17541922	chr11:86511813	PRSS23	-0.43	-6.11	-0.32	2.85e-9	Cognitive function;Information processing speed;
LUSC	cis	rs1847202	0.826	rs1979884	chr3:72948515	T/C	cg25664220	chr3:72788482	NA	-0.41	-7.35	-0.37	1.49e-12	Motion sickness;
LUSC	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg20203395	chr5:56204925	C5orf35	-0.48	-7.2	-0.37	4.06e-12	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs4789693	0.518	rs6502108	chr17:80374899	A/C	cg04308225	chr17:80449738	NA	-0.37	-6.32	-0.33	8.22e-10	Glucocorticoid-induced osteonecrosis;
LUSC	cis	rs10419226	0.555	rs3764627	chr19:18747696	C/T	cg22001208	chr19:18782374	NA	-0.35	-5.78	-0.3	1.72e-8	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05025164	chr4:1340916	KIAA1530	0.65	9.83	0.47	3.46e-20	Longevity;
LUSC	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	8.19	0.41	5.5e-15	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7107174	0.688	rs2063725	chr11:78133452	T/G	cg02023728	chr11:77925099	USP35	0.41	6.29	0.33	9.67e-10	Testicular germ cell tumor;
LUSC	trans	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.48	0.33	3.33e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12575480	0.637	rs56204981	chr11:2094852	T/C	cg15541987	chr11:2077307	NA	-0.44	-6.59	-0.34	1.76e-10	Pursuit maintenance gain;
LUSC	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg21433313	chr16:3507492	NAT15	-0.4	-5.67	-0.3	3.07e-8	Body mass index (adult);
LUSC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs12681287	0.604	rs7017716	chr8:87429001	A/C	cg27223183	chr8:87520930	FAM82B	-0.54	-7.46	-0.38	7.36e-13	Caudate activity during reward;
LUSC	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg25237894	chr2:233734115	C2orf82	0.36	6.76	0.35	6.32e-11	Coronary artery disease;
LUSC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	9.71	0.47	8.57e-20	Height;
LUSC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.6	-0.38	3.03e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-9.85	-0.47	2.84e-20	Mood instability;
LUSC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg16989086	chr20:62203971	PRIC285	0.46	6.4	0.33	5.3e-10	Glioblastoma;
LUSC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg22868518	chr11:507468	RNH1	-0.57	-5.68	-0.3	2.93e-8	Body mass index;
LUSC	trans	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg21775007	chr8:11205619	TDH	-0.44	-6.29	-0.33	9.91e-10	Joint mobility (Beighton score);
LUSC	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg03929089	chr4:120376271	NA	-0.58	-7.09	-0.36	7.98e-12	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs1973993	0.967	rs2181375	chr1:96940119	A/G	cg10631902	chr5:14652156	NA	0.53	8.82	0.43	6.25e-17	Weight;
LUSC	cis	rs6942756	0.806	rs2718096	chr7:128951000	A/G	cg02491457	chr7:128862824	NA	0.48	7.17	0.37	4.82e-12	White matter hyperintensity burden;
LUSC	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg11764359	chr7:65958608	NA	-0.59	-8.85	-0.44	5.05e-17	Aortic root size;
LUSC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg15997130	chr1:24165203	NA	0.53	8.68	0.43	1.71e-16	Immature fraction of reticulocytes;
LUSC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg04111992	chr7:158790115	NA	0.38	5.92	0.31	7.92e-9	Facial morphology (factor 20);
LUSC	cis	rs9309473	0.632	rs11885217	chr2:73553208	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-7.74	-0.39	1.18e-13	Metabolite levels;
LUSC	trans	rs4942242	1.000	rs4942242	chr13:44217064	A/G	cg19169023	chr15:41853346	TYRO3	0.47	8.09	0.4	1.09e-14	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11169552	0.510	rs10876061	chr12:50968685	G/A	cg12884762	chr12:50931848	DIP2B	-0.32	-5.67	-0.3	3.11e-8	Colorectal cancer;
LUSC	cis	rs748404	0.697	rs1814323	chr15:43563237	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-8.6	-0.43	3.05e-16	Lung cancer;
LUSC	cis	rs11023332	0.617	rs1451678	chr11:14781621	A/G	cg05501817	chr11:14380813	RRAS2	-0.37	-5.71	-0.3	2.48e-8	Adiponectin levels;Vitamin D levels;
LUSC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg20203395	chr5:56204925	C5orf35	-0.63	-9.41	-0.46	8.16e-19	Coronary artery disease;
LUSC	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg05527609	chr1:210001259	C1orf107	0.94	12.38	0.56	3.09e-29	Orofacial clefts;
LUSC	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.52	8.14	0.41	8.04e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg08330031	chr10:104623503	C10orf32	0.32	5.69	0.3	2.76e-8	Arsenic metabolism;
LUSC	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg25457927	chr22:38595422	NA	-0.44	-9.11	-0.45	7.93e-18	Cutaneous nevi;
LUSC	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg05082376	chr22:42548792	NA	-0.39	-6.53	-0.34	2.5e-10	Cognitive function;
LUSC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.51	-8.49	-0.42	7.05e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs11051970	0.545	rs2728681	chr12:32582977	T/C	cg02745156	chr12:32552066	NA	0.36	6.51	0.34	2.71e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05195612	chr2:175869986	CHN1	-0.47	-6.16	-0.32	2.13e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.69	-0.43	1.68e-16	Metabolite levels;
LUSC	cis	rs9283706	0.641	rs1990894	chr5:66331685	C/T	cg11590213	chr5:66331682	MAST4	0.45	7.47	0.38	6.91e-13	Coronary artery disease;
LUSC	cis	rs4601821	1.000	rs4601821	chr11:113250346	A/G	cg14159747	chr11:113255604	NA	0.26	6.12	0.32	2.69e-9	Alcoholic chronic pancreatitis;
LUSC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg16479474	chr6:28041457	NA	0.32	5.65	0.3	3.45e-8	Parkinson's disease;
LUSC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.41	-0.46	8.54e-19	Platelet count;
LUSC	trans	rs9929218	1.000	rs13339591	chr16:68809273	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.72	-0.54	8.62e-27	Colorectal cancer;
LUSC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg21782813	chr7:2030301	MAD1L1	0.58	10.34	0.49	6.26e-22	Bipolar disorder and schizophrenia;
LUSC	trans	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg11887960	chr12:57824829	NA	0.47	6.54	0.34	2.29e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	1.08	25.08	0.81	8.45e-79	Testicular germ cell tumor;
LUSC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg16262614	chr3:133464971	TF	-0.44	-7.88	-0.4	4.55e-14	Iron status biomarkers (transferrin levels);
LUSC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-6.73	-0.35	7.23e-11	Mean platelet volume;
LUSC	cis	rs6426558	0.537	rs6685823	chr1:227270835	A/G	cg10327440	chr1:227177885	CDC42BPA	0.55	7.51	0.38	5.46e-13	Neutrophil percentage of white cells;
LUSC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.88	12.76	0.57	1.19e-30	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.97	-0.61	2.98e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg21951975	chr1:209979733	IRF6	0.57	8.52	0.42	5.74e-16	Cleft lip with or without cleft palate;
LUSC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.18	-0.32	1.87e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg10483660	chr13:112241077	NA	-0.32	-5.9	-0.31	9.07e-9	Hepatitis;
LUSC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg27165867	chr14:105738592	BRF1	-0.57	-8.61	-0.43	2.87e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2357013	0.725	rs1858211	chr2:53165520	G/C	cg07782112	chr2:53107842	NA	-0.39	-6.16	-0.32	2.04e-9	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg18721089	chr20:30220636	NA	-0.34	-5.89	-0.31	9.62e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg05855489	chr10:104503620	C10orf26	0.49	7.36	0.37	1.48e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs2629751	0.512	rs2583271	chr12:104440855	C/T	cg14987745	chr12:104360022	TDG	-0.71	-8.36	-0.42	1.73e-15	Hepatitis C induced liver fibrosis;
LUSC	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-8.81	-0.43	6.93e-17	Hepatocellular carcinoma;
LUSC	cis	rs4561483	0.801	rs33643	chr16:11986149	A/G	cg08843971	chr16:11963173	GSPT1	-0.46	-6.89	-0.35	2.75e-11	Testicular germ cell tumor;
LUSC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg19468946	chr17:37922297	IKZF3	0.47	7.45	0.38	8.3e-13	Self-reported allergy;
LUSC	cis	rs12995491	0.933	rs12995212	chr2:88527184	C/T	cg18302933	chr2:88491318	NA	-0.35	-6.5	-0.34	2.85e-10	Response to metformin (IC50);
LUSC	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.69	-10.77	-0.51	2.01e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-0.72	-12.42	-0.56	2.14e-29	Gut microbiome composition (winter);
LUSC	cis	rs10761482	0.861	rs2893830	chr10:62099945	C/T	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	10.32	0.49	7.36e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg16339924	chr4:17578868	LAP3	-0.47	-6.88	-0.35	3.01e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.48	5.9	0.31	9.16e-9	Renal function-related traits (BUN);
LUSC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg00033643	chr7:134001901	SLC35B4	0.46	7.2	0.37	4.12e-12	Mean platelet volume;
LUSC	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg18478394	chr8:109455254	TTC35	0.44	6.88	0.35	3.02e-11	Dupuytren's disease;
LUSC	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg09165964	chr15:75287851	SCAMP5	-0.46	-6.67	-0.34	1.06e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs12220238	1.000	rs10824099	chr10:75943625	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.85	0.35	3.57e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.63	-9.61	-0.47	1.88e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg20573242	chr4:122745356	CCNA2	0.44	6.78	0.35	5.48e-11	Type 2 diabetes;
LUSC	cis	rs308403	0.509	rs6811183	chr4:123671551	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.94	17.03	0.68	3.01e-47	Blood protein levels;
LUSC	cis	rs870825	0.616	rs6810600	chr4:185616814	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.5	0.59	1.86e-33	Blood protein levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03909902	chr12:108154529	PRDM4	0.37	5.97	0.31	6.08e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs367615	0.552	rs2963022	chr5:108727185	A/G	cg17395555	chr5:108820864	NA	-0.46	-8.0	-0.4	2.07e-14	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs4654899	1.000	rs7522722	chr1:21481840	G/A	cg01072550	chr1:21505969	NA	-0.55	-8.5	-0.42	6.28e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	0.85	13.0	0.58	1.46e-31	Obesity-related traits;
LUSC	cis	rs9420	0.528	rs11229075	chr11:57391023	A/C	cg23127183	chr11:57508653	C11orf31	-0.48	-6.69	-0.34	9.42e-11	Schizophrenia;
LUSC	cis	rs240764	0.658	rs13196803	chr6:101188052	A/T	cg09795085	chr6:101329169	ASCC3	-0.45	-6.56	-0.34	2.03e-10	Neuroticism;
LUSC	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg25214090	chr10:38739885	LOC399744	0.54	8.06	0.4	1.36e-14	Corneal astigmatism;
LUSC	cis	rs9399401	0.677	rs6925979	chr6:142651052	G/A	cg03128060	chr6:142623767	GPR126	0.58	9.37	0.46	1.12e-18	Chronic obstructive pulmonary disease;
LUSC	trans	rs72674100	1.000	rs2865757	chr4:97992597	C/T	cg16405019	chr1:18959625	PAX7	-0.61	-6.41	-0.33	5.09e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg08017634	chr8:144659831	NAPRT1	0.68	5.94	0.31	7.24e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg06454157	chr6:167490870	NA	-0.3	-6.89	-0.35	2.83e-11	Crohn's disease;
LUSC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg14092988	chr3:52407081	DNAH1	0.43	8.13	0.41	8.27e-15	Bipolar disorder;
LUSC	cis	rs2274273	0.682	rs7141975	chr14:55542216	G/C	cg04306507	chr14:55594613	LGALS3	0.49	10.14	0.49	3.09e-21	Protein biomarker;
LUSC	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg02175503	chr12:58329896	NA	0.49	7.18	0.37	4.51e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg12463550	chr7:65579703	CRCP	0.54	8.13	0.41	8.63e-15	Aortic root size;
LUSC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg13206674	chr6:150067644	NUP43	0.61	9.85	0.47	2.82e-20	Lung cancer;
LUSC	trans	rs10432489	0.708	rs3922471	chr2:181771937	T/C	cg04744134	chr19:8408128	KANK3	0.83	6.27	0.32	1.13e-9	QT interval;
LUSC	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.7	11.72	0.54	8.25e-27	Colorectal cancer;
LUSC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.61	12.65	0.57	3.12e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.17	-0.41	6.24e-15	Chronic sinus infection;
LUSC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.79	14.93	0.63	5.62e-39	Dental caries;
LUSC	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg20848291	chr7:100343083	ZAN	-0.65	-8.69	-0.43	1.6e-16	Other erythrocyte phenotypes;
LUSC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg24562669	chr7:97807699	LMTK2	0.36	6.31	0.33	8.71e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg00757033	chr12:89920650	WDR51B	0.59	10.15	0.49	2.74e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg05673287	chr15:77411982	SGK269	-0.44	-6.97	-0.36	1.7e-11	Type 2 diabetes;
LUSC	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg23283495	chr1:209979779	IRF6	0.72	9.14	0.45	6.03e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg17462356	chr17:80056334	FASN	-0.45	-6.18	-0.32	1.86e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs11229555	0.645	rs12801475	chr11:58189034	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg24558204	chr6:135376177	HBS1L	-0.6	-8.7	-0.43	1.53e-16	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.81	0.54	3.94e-27	Prudent dietary pattern;
LUSC	cis	rs829883	0.659	rs11109522	chr12:98930964	C/T	cg25150519	chr12:98850993	NA	-0.63	-8.71	-0.43	1.47e-16	Colorectal adenoma (advanced);
LUSC	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	0.91	17.84	0.7	1.74e-50	Metabolite levels;
LUSC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg13319975	chr6:146136371	FBXO30	0.52	7.75	0.39	1.12e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg04727924	chr7:799746	HEATR2	-0.57	-5.91	-0.31	8.66e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs10848704	0.525	rs4765709	chr12:2883637	C/T	cg19995117	chr12:2880862	NA	0.47	8.55	0.42	4.5e-16	Quantitative traits;
LUSC	cis	rs6500395	1.000	rs1486411	chr16:48587083	T/C	cg04672837	chr16:48644449	N4BP1	0.43	6.36	0.33	6.48e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05608588	chr7:98476815	TRRAP	-0.5	-6.1	-0.32	2.9e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg07959070	chr22:50026188	C22orf34	-0.36	-7.39	-0.37	1.18e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg12165864	chr7:66369176	NA	-0.54	-7.36	-0.37	1.48e-12	Corneal structure;
LUSC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	11.29	0.53	2.88e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg26441486	chr22:50317300	CRELD2	-0.55	-8.31	-0.41	2.4e-15	Schizophrenia;
LUSC	trans	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.41	-0.33	4.96e-10	Blood trace element (Cu levels);
LUSC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg12564285	chr5:131593104	PDLIM4	0.35	6.42	0.33	4.59e-10	Blood metabolite levels;
LUSC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg18904891	chr8:8559673	CLDN23	-0.42	-6.32	-0.33	8.28e-10	Mood instability;
LUSC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.24	-0.37	3.21e-12	Blood metabolite levels;
LUSC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	14.07	0.61	1.24e-35	Platelet count;
LUSC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.71	-11.04	-0.52	2.31e-24	Aortic root size;
LUSC	cis	rs11971779	0.878	rs4732378	chr7:139120395	C/T	cg07862535	chr7:139043722	LUC7L2	0.73	8.29	0.41	2.73e-15	Diisocyanate-induced asthma;
LUSC	cis	rs7011049	1.000	rs72640849	chr8:53836430	A/T	cg26025543	chr8:53854495	NA	0.5	6.01	0.31	4.83e-9	Systolic blood pressure;
LUSC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.2	-0.37	4.1e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg25214090	chr10:38739885	LOC399744	-0.4	-6.42	-0.33	4.56e-10	Corneal astigmatism;
LUSC	cis	rs1018697	1.000	rs6584525	chr10:104551981	G/A	cg04362960	chr10:104952993	NT5C2	0.47	6.48	0.33	3.29e-10	Colorectal adenoma (advanced);
LUSC	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-8.22	-0.41	4.63e-15	Schizophrenia;
LUSC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.72	9.46	0.46	5.66e-19	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.27	-0.32	1.1e-9	Dupuytren's disease;
LUSC	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg18478394	chr8:109455254	TTC35	0.41	6.33	0.33	7.89e-10	Dupuytren's disease;
LUSC	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.88	0.31	9.8e-9	Schizophrenia;
LUSC	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.9	-0.4	4.02e-14	Glomerular filtration rate;
LUSC	cis	rs714027	1.000	rs5997579	chr22:30537526	A/G	cg11564601	chr22:30592435	NA	-0.38	-7.17	-0.37	4.9e-12	Lymphocyte counts;
LUSC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.88	0.4	4.75e-14	Major depressive disorder;
LUSC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg02079420	chr8:82753780	SNX16	0.39	6.87	0.35	3.14e-11	Diastolic blood pressure;
LUSC	cis	rs977987	0.966	rs6564261	chr16:75492242	C/T	cg04384234	chr16:75411784	CFDP1	-0.46	-7.7	-0.39	1.6e-13	Dupuytren's disease;
LUSC	cis	rs7681440	0.606	rs2619342	chr4:90744170	A/T	cg06632027	chr4:90757378	SNCA	-0.36	-5.7	-0.3	2.57e-8	Dementia with Lewy bodies;
LUSC	cis	rs2901656	0.691	rs10798005	chr1:172382965	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	-0.37	-7.48	-0.38	6.5e-13	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg02896835	chr1:92012615	NA	-0.68	-12.38	-0.56	3.13e-29	Breast cancer;
LUSC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-10.91	-0.51	6.48e-24	Gut microbiome composition (summer);
LUSC	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg05855489	chr10:104503620	C10orf26	0.65	9.66	0.47	1.21e-19	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6142102	0.923	rs3787230	chr20:32640272	A/G	cg08999081	chr20:33150536	PIGU	0.34	5.83	0.3	1.3e-8	Skin pigmentation;
LUSC	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.07	16.68	0.67	7.3e-46	Exhaled nitric oxide output;
LUSC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg11344533	chr11:111475393	SIK2	-0.5	-6.95	-0.36	1.88e-11	Primary sclerosing cholangitis;
LUSC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.73	-13.09	-0.58	7.06e-32	Personality dimensions;
LUSC	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.47	6.55	0.34	2.2e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4654899	0.727	rs11805169	chr1:21156862	A/T	cg01072550	chr1:21505969	NA	0.49	7.48	0.38	6.8e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	0.93	17.58	0.69	1.94e-49	Headache;
LUSC	cis	rs7818688	0.697	rs11778553	chr8:95978260	C/T	cg16049864	chr8:95962084	TP53INP1	0.47	5.71	0.3	2.53e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LUSC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg05425664	chr17:57184151	TRIM37	0.54	8.01	0.4	1.87e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13257044	chr4:1714050	SLBP	-0.42	-6.29	-0.33	9.83e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg15445000	chr17:37608096	MED1	-0.4	-6.79	-0.35	5.16e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-1.16	-15.97	-0.66	4.56e-43	Hip circumference adjusted for BMI;
LUSC	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg08000102	chr2:233561755	GIGYF2	-0.61	-10.24	-0.49	1.38e-21	Coronary artery disease;
LUSC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg09904177	chr6:26538194	HMGN4	0.72	12.71	0.57	1.82e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs12618769	0.597	rs4851131	chr2:99036802	A/C	cg10123293	chr2:99228465	UNC50	0.46	7.69	0.39	1.66e-13	Bipolar disorder;
LUSC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.13	0.55	2.54e-28	Cognitive test performance;
LUSC	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg03342759	chr3:160939853	NMD3	-0.44	-6.84	-0.35	3.83e-11	Morning vs. evening chronotype;
LUSC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.92	15.71	0.65	5.07e-42	Height;
LUSC	cis	rs17604090	0.877	rs68169519	chr7:29685158	A/G	cg19413766	chr7:29689036	LOC646762	-0.58	-6.82	-0.35	4.19e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs977987	0.806	rs4888389	chr16:75395228	T/C	cg04384234	chr16:75411784	CFDP1	-0.42	-6.95	-0.36	1.94e-11	Dupuytren's disease;
LUSC	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.4	-6.01	-0.31	4.76e-9	QT interval;
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	0.85	15.08	0.64	1.49e-39	Menarche (age at onset);
LUSC	cis	rs3862435	0.706	rs2301828	chr15:90992654	G/T	cg22089800	chr15:90895588	ZNF774	0.57	5.97	0.31	5.95e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg26384229	chr12:38710491	ALG10B	0.54	7.54	0.38	4.39e-13	Morning vs. evening chronotype;
LUSC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19717773	chr7:2847554	GNA12	-0.34	-5.85	-0.31	1.15e-8	Height;
LUSC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg04369109	chr6:150039330	LATS1	-0.54	-8.03	-0.4	1.7e-14	Lung cancer;
LUSC	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg11993925	chr19:44307056	LYPD5	0.35	7.65	0.39	2.11e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	7.02	0.36	1.24e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.23	14.01	0.61	2.04e-35	Diabetic kidney disease;
LUSC	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs73036520	0.560	rs346750	chr19:45737218	G/T	cg01416317	chr19:45737208	EXOC3L2	-0.47	-8.44	-0.42	9.82e-16	Monocyte percentage of white cells;
LUSC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg05347473	chr6:146136440	FBXO30	0.52	8.98	0.44	2.02e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg22532475	chr10:104410764	TRIM8	0.24	5.76	0.3	1.93e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg02696742	chr7:106810147	HBP1	-0.63	-9.54	-0.46	3.16e-19	Coronary artery disease;
LUSC	cis	rs113835537	0.529	rs17147644	chr11:66256660	C/T	cg24851651	chr11:66362959	CCS	0.54	8.03	0.4	1.71e-14	Airway imaging phenotypes;
LUSC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg18404041	chr3:52824283	ITIH1	-0.36	-6.19	-0.32	1.79e-9	Electroencephalogram traits;
LUSC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.16	-0.32	2.04e-9	Alzheimer's disease (late onset);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg06787431	chr3:185827293	ETV5	0.47	8.05	0.4	1.48e-14	Triglycerides;
LUSC	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg13072238	chr3:49761600	GMPPB	-0.65	-8.27	-0.41	3.11e-15	Menarche (age at onset);
LUSC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg13319975	chr6:146136371	FBXO30	0.48	7.28	0.37	2.35e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs939658	0.728	rs8031638	chr15:79422726	C/T	cg17916960	chr15:79447300	NA	-0.5	-9.52	-0.46	3.7e-19	Refractive error;
LUSC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.66	6.38	0.33	5.83e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.65	-10.18	-0.49	2.18e-21	Menarche (age at onset);
LUSC	cis	rs934734	0.563	rs11684155	chr2:65581300	C/T	cg08085232	chr2:65598271	SPRED2	-0.43	-6.71	-0.34	8.27e-11	Rheumatoid arthritis;
LUSC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg10729496	chr3:10149963	C3orf24	0.54	7.24	0.37	3.16e-12	Alzheimer's disease;
LUSC	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg24006582	chr15:45444508	DUOX1	-0.6	-8.75	-0.43	1.11e-16	Uric acid levels;
LUSC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg02153584	chr22:29168773	CCDC117	-0.58	-8.6	-0.43	3.11e-16	Lymphocyte counts;
LUSC	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg19116668	chr7:99932089	PMS2L1	0.35	6.12	0.32	2.68e-9	Coronary artery disease;
LUSC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11764359	chr7:65958608	NA	-0.62	-9.38	-0.46	1.03e-18	Aortic root size;
LUSC	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	1.01	20.85	0.75	1.94e-62	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg11189052	chr15:85197271	WDR73	0.5	6.39	0.33	5.56e-10	Schizophrenia;
LUSC	trans	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Parkinson's disease;
LUSC	trans	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg02030672	chr11:45687055	CHST1	0.47	7.35	0.37	1.52e-12	Obesity-related traits;
LUSC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25816013	chr10:124913724	BUB3	-0.48	-7.14	-0.36	5.76e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg10326726	chr10:51549505	MSMB	-0.36	-6.19	-0.32	1.8e-9	Prostate-specific antigen levels;
LUSC	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg22532475	chr10:104410764	TRIM8	-0.25	-6.01	-0.31	4.97e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	trans	rs7507204	0.767	rs12982509	chr19:3412057	C/T	cg08382705	chr11:45687319	CHST1	0.53	7.27	0.37	2.54e-12	Height;
LUSC	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg03599575	chr15:90893182	GABARAPL3	0.34	5.89	0.31	9.29e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.54	-0.42	4.74e-16	Personality dimensions;
LUSC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.2	0.37	3.98e-12	Bipolar disorder;
LUSC	cis	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg20368463	chr18:77673604	PQLC1	-0.54	-7.75	-0.39	1.15e-13	Schizophrenia;
LUSC	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.26	0.37	2.68e-12	Blood metabolite levels;
LUSC	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg26384229	chr12:38710491	ALG10B	0.49	6.99	0.36	1.51e-11	Morning vs. evening chronotype;
LUSC	cis	rs4132509	1.000	rs10927051	chr1:243805936	G/C	cg21452805	chr1:244014465	NA	0.5	5.94	0.31	6.99e-9	RR interval (heart rate);
LUSC	trans	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg14791747	chr16:20752902	THUMPD1	0.73	9.55	0.46	2.84e-19	Cognitive test performance;
LUSC	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.41	-0.49	3.71e-22	Eye color traits;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00762468	chr16:103568	POLR3K;SNRNP25	-0.48	-6.31	-0.33	8.65e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.16	0.36	5.14e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg02187348	chr16:89574699	SPG7	0.47	7.0	0.36	1.39e-11	Multiple myeloma (IgH translocation);
LUSC	trans	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg07393940	chr7:158741817	NA	-0.37	-6.76	-0.35	6.27e-11	Life satisfaction;
LUSC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	8.33	0.41	2.14e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2932538	0.922	rs6681371	chr1:113101168	A/C	cg22162597	chr1:113214053	CAPZA1	0.6	8.3	0.41	2.64e-15	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	0.64	13.4	0.59	4.72e-33	Prudent dietary pattern;
LUSC	cis	rs1953600	0.870	rs2788296	chr10:81937889	G/A	cg00277334	chr10:82204260	NA	0.45	7.12	0.36	6.85e-12	Sarcoidosis;
LUSC	cis	rs17001868	0.614	rs61467436	chr22:40736713	T/C	cg07138101	chr22:40742427	ADSL	0.63	7.6	0.38	3.04e-13	Mammographic density (dense area);
LUSC	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg09092052	chr15:45571596	NA	0.45	6.31	0.33	8.87e-10	Glomerular filtration rate;
LUSC	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg19610905	chr11:61596333	FADS2	-0.43	-5.88	-0.31	9.69e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg24558204	chr6:135376177	HBS1L	0.58	9.03	0.44	1.38e-17	Red blood cell count;
LUSC	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg19773385	chr1:10388646	KIF1B	-0.5	-8.71	-0.43	1.4e-16	Hepatocellular carcinoma;
LUSC	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg09835421	chr16:68378352	PRMT7	-0.48	-5.95	-0.31	6.7e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.8	-0.43	7.35e-17	Obesity-related traits;
LUSC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg25767906	chr1:53392781	SCP2	0.48	8.69	0.43	1.67e-16	Monocyte count;
LUSC	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg08000102	chr2:233561755	GIGYF2	0.76	11.82	0.54	3.75e-27	Coronary artery disease;
LUSC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	8.62	0.43	2.75e-16	Chronic sinus infection;
LUSC	cis	rs6700896	0.500	rs11208690	chr1:66092349	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	6.17	0.32	2.02e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg25566285	chr7:158114605	PTPRN2	0.32	5.89	0.31	9.5e-9	Calcium levels;
LUSC	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg27494647	chr7:150038898	RARRES2	0.51	7.42	0.38	9.68e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg05738196	chr6:26577821	NA	-0.54	-8.48	-0.42	7.42e-16	Schizophrenia;
LUSC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg06877462	chr1:205807181	PM20D1	0.39	7.35	0.37	1.56e-12	Menarche (age at onset);
LUSC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.46	6.74	0.35	6.79e-11	Systemic lupus erythematosus;
LUSC	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-6.64	-0.34	1.28e-10	Blood metabolite levels;
LUSC	cis	rs4722404	0.739	rs10951044	chr7:3141147	C/T	cg19214707	chr7:3157722	NA	-0.37	-6.88	-0.35	3.01e-11	Atopic dermatitis;
LUSC	cis	rs9362426	1.000	rs9450662	chr6:88088593	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	6.16	0.32	2.06e-9	Depressive episodes in bipolar disorder;
LUSC	cis	rs9372253	0.843	rs28721292	chr6:110719631	T/C	cg01119278	chr6:110721349	DDO	-0.49	-8.85	-0.44	5.04e-17	Platelet distribution width;
LUSC	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg17691542	chr6:26056736	HIST1H1C	0.41	6.06	0.31	3.71e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.97	0.58	1.89e-31	Prudent dietary pattern;
LUSC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25072359	chr17:41440525	NA	0.65	9.37	0.46	1.09e-18	Menopause (age at onset);
LUSC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.42	0.42	1.16e-15	Tonsillectomy;
LUSC	cis	rs7605827	0.897	rs6431713	chr2:15691382	C/T	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.32e-17	Educational attainment (years of education);
LUSC	cis	rs290268	0.585	rs290992	chr9:93561309	C/T	cg02608019	chr9:93564028	SYK	-0.37	-6.15	-0.32	2.26e-9	Platelet count;
LUSC	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7202877	0.561	rs2865532	chr16:75350975	A/G	cg04384234	chr16:75411784	CFDP1	-0.61	-8.27	-0.41	3.15e-15	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs80130819	0.515	rs1793956	chr12:48392914	C/G	cg24011408	chr12:48396354	COL2A1	0.59	7.8	0.39	7.82e-14	Prostate cancer;
LUSC	trans	rs225245	0.817	rs225299	chr17:33922742	T/C	cg19694781	chr19:47549865	TMEM160	-0.42	-6.59	-0.34	1.69e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg07148914	chr20:33460835	GGT7	0.54	8.23	0.41	4.3e-15	Height;
LUSC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.52	9.64	0.47	1.43e-19	Eosinophil percentage of white cells;
LUSC	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg00071950	chr4:10020882	SLC2A9	0.52	8.69	0.43	1.68e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7945718	0.839	rs11022512	chr11:12835952	G/A	cg25843174	chr11:12811716	TEAD1	0.3	6.9	0.35	2.61e-11	Educational attainment (years of education);
LUSC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	0.63	11.01	0.52	2.81e-24	Blood metabolite levels;
LUSC	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.59e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg05425664	chr17:57184151	TRIM37	-0.53	-7.99	-0.4	2.25e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg03060546	chr3:49711283	APEH	0.47	6.29	0.33	1.02e-9	Menarche (age at onset);
LUSC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg08132940	chr7:1081526	C7orf50	-0.47	-6.13	-0.32	2.46e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs72700829	0.531	rs12070288	chr1:151009984	C/G	cg11822372	chr1:151115635	SEMA6C	-0.76	-6.94	-0.35	2.06e-11	Schizophrenia;
LUSC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.98	-16.4	-0.67	9.19e-45	Coronary artery disease;
LUSC	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg13575925	chr12:9217583	LOC144571	0.34	6.07	0.32	3.51e-9	Sjögren's syndrome;
LUSC	cis	rs672059	0.967	rs657901	chr1:183163411	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.1	0.41	1.04e-14	Hypertriglyceridemia;
LUSC	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21545522	chr1:205238299	TMCC2	0.51	9.69	0.47	9.59e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs698813	0.604	rs1596009	chr2:44492102	G/T	cg00619915	chr2:44497795	NA	-0.53	-7.51	-0.38	5.62e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	trans	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.54	0.53	3.8e-26	Mean corpuscular volume;
LUSC	cis	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg06521331	chr12:34319734	NA	0.4	6.62	0.34	1.44e-10	Morning vs. evening chronotype;
LUSC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs36093844	0.590	rs10898402	chr11:85498447	C/G	cg25872744	chr11:85566296	CCDC83	-0.43	-6.67	-0.34	1.04e-10	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-6.72	-0.34	8.07e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.64	8.28	0.41	3.09e-15	Gut microbiome composition (summer);
LUSC	trans	rs72674100	1.000	rs72880559	chr4:97975513	A/G	cg16405019	chr1:18959625	PAX7	-0.64	-6.78	-0.35	5.33e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10779751	0.770	rs12041740	chr1:11236524	G/A	cg08854313	chr1:11322531	MTOR	0.87	14.05	0.61	1.55e-35	Body mass index;
LUSC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg09436375	chr6:42928200	GNMT	-0.3	-6.8	-0.35	4.73e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.55	-0.38	4.27e-13	Morning vs. evening chronotype;
LUSC	cis	rs11158026	0.603	rs68065548	chr14:55446553	C/T	cg04306507	chr14:55594613	LGALS3	0.4	7.37	0.37	1.39e-12	Parkinson's disease;
LUSC	cis	rs7589342	0.839	rs12995333	chr2:106436366	A/C	cg14210321	chr2:106509881	NCK2	0.54	8.09	0.4	1.11e-14	Addiction;
LUSC	cis	rs12122100	0.913	rs61838896	chr1:146513139	A/G	cg03526459	chr1:146549940	NA	-0.42	-6.75	-0.35	6.47e-11	HIV-1 control;
LUSC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg24562669	chr7:97807699	LMTK2	-0.35	-6.27	-0.32	1.14e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7188861	0.681	rs12162021	chr16:11403013	G/A	cg00044050	chr16:11439710	C16orf75	0.59	6.1	0.32	2.99e-9	HDL cholesterol;
LUSC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.75	0.39	1.08e-13	Bipolar disorder;
LUSC	cis	rs970548	0.688	rs2082110	chr10:45931070	A/G	cg15590007	chr10:45870220	ALOX5	0.55	6.34	0.33	7.67e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.46	-0.38	7.42e-13	Schizophrenia;
LUSC	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg00806126	chr19:22604979	ZNF98	0.37	5.71	0.3	2.5e-8	Pain;
LUSC	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg05855489	chr10:104503620	C10orf26	0.6	9.68	0.47	1.1e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg16405210	chr4:1374714	KIAA1530	-0.53	-8.02	-0.4	1.78e-14	Obesity-related traits;
LUSC	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg20307385	chr11:47447363	PSMC3	0.83	11.89	0.55	2.07e-27	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-9.39	-0.46	9.29e-19	Neuroticism;
LUSC	cis	rs1018836	0.595	rs2223010	chr8:91480068	A/G	cg16814680	chr8:91681699	NA	-0.65	-9.69	-0.47	9.64e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg05043794	chr9:111880884	C9orf5	-0.36	-7.61	-0.38	2.86e-13	Menarche (age at onset);
LUSC	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg12310025	chr6:25882481	NA	0.34	5.79	0.3	1.61e-8	Blood metabolite levels;
LUSC	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.38	0.37	1.26e-12	Iron status biomarkers;
LUSC	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	0.96	11.21	0.52	5.67e-25	Nonalcoholic fatty liver disease;
LUSC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg27121462	chr16:89883253	FANCA	-0.5	-7.49	-0.38	6.09e-13	Vitiligo;
LUSC	cis	rs500891	0.533	rs9361995	chr6:84126776	C/T	cg08257003	chr6:84140564	ME1	0.35	8.66	0.43	2.02e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs96067	0.805	rs12033824	chr1:36600307	C/T	cg24686825	chr1:36642396	MAP7D1	-0.42	-5.91	-0.31	8.42e-9	Corneal structure;
LUSC	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19717773	chr7:2847554	GNA12	-0.45	-7.82	-0.39	6.88e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs9341835	0.772	rs4710254	chr6:64137609	C/T	cg03326410	chr6:64151739	NA	-0.38	-6.26	-0.32	1.15e-9	Schizophrenia;
LUSC	cis	rs9612	0.948	rs12609587	chr19:44268654	T/C	cg08581076	chr19:44259116	C19orf61	0.48	5.92	0.31	8.17e-9	Exhaled nitric oxide output;
LUSC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg16797656	chr11:68205561	LRP5	0.37	6.17	0.32	2.03e-9	Total body bone mineral density;
LUSC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08280861	chr8:58055591	NA	0.56	6.05	0.31	3.96e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs8114671	0.935	rs35193912	chr20:33785050	C/T	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.93	-0.31	7.41e-9	Height;
LUSC	cis	rs6693567	0.565	rs1776275	chr1:150269437	G/T	cg15654264	chr1:150340011	RPRD2	-0.47	-7.69	-0.39	1.65e-13	Migraine;
LUSC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	0.94	18.71	0.72	5.98e-54	Cognitive function;
LUSC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg05343316	chr1:45956843	TESK2	-0.6	-8.39	-0.42	1.36e-15	Platelet count;
LUSC	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17173187	chr15:85201210	NMB	0.45	8.52	0.42	5.75e-16	Schizophrenia;
LUSC	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg09835421	chr16:68378352	PRMT7	-0.45	-5.71	-0.3	2.45e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg09469691	chr10:81107165	PPIF	0.67	10.91	0.51	6.35e-24	Height;
LUSC	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg25456477	chr12:86230367	RASSF9	0.41	7.24	0.37	3.2e-12	Major depressive disorder;
LUSC	cis	rs6084875	0.840	rs6052822	chr20:4726510	T/G	cg26097573	chr20:4721490	PRNT	-0.31	-5.74	-0.3	2.16e-8	Systemic lupus erythematosus;
LUSC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18404041	chr3:52824283	ITIH1	-0.58	-11.18	-0.52	7.29e-25	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21487267	chr8:41386754	GINS4	-0.43	-6.6	-0.34	1.59e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6977660	0.714	rs6976972	chr7:19818315	C/A	cg05791153	chr7:19748676	TWISTNB	0.66	7.0	0.36	1.38e-11	Thyroid stimulating hormone;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11830880	chr17:34136324	TAF15	0.45	6.1	0.32	2.87e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs62400317	0.859	rs10948219	chr6:45229307	A/T	cg18551225	chr6:44695536	NA	-0.44	-7.28	-0.37	2.46e-12	Total body bone mineral density;
LUSC	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg10426581	chr7:100472382	SRRT	0.86	12.37	0.56	3.44e-29	Resting heart rate;
LUSC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg16434002	chr17:42200994	HDAC5	0.43	5.84	0.3	1.26e-8	Total body bone mineral density;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13710969	chr17:79393463	BAHCC1	-0.29	-6.66	-0.34	1.11e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.86	15.14	0.64	8.29e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg04218760	chr10:45406644	TMEM72	0.33	7.88	0.4	4.77e-14	Mean corpuscular volume;
LUSC	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.28	-0.37	2.48e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg08847533	chr14:75593920	NEK9	0.8	13.43	0.59	3.65e-33	Height;
LUSC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg15556689	chr8:8085844	FLJ10661	0.7	11.61	0.54	2.14e-26	Mood instability;
LUSC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23158103	chr7:148848205	ZNF398	-0.42	-6.65	-0.34	1.18e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-11.94	-0.55	1.27e-27	Total body bone mineral density;
LUSC	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg22029157	chr1:209979665	IRF6	-0.62	-9.92	-0.48	1.63e-20	Monobrow;
LUSC	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg23435118	chr5:141488016	NDFIP1	-0.53	-7.38	-0.37	1.3e-12	Crohn's disease;
LUSC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg13206674	chr6:150067644	NUP43	0.58	9.35	0.46	1.35e-18	Lung cancer;
LUSC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg06238570	chr21:40685208	BRWD1	0.47	7.24	0.37	3.13e-12	Cognitive function;
LUSC	cis	rs7607369	0.536	rs4646535	chr2:219664663	C/T	cg02176678	chr2:219576539	TTLL4	-0.54	-9.34	-0.46	1.37e-18	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.75	-0.3	2.01e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9473147	0.516	rs2151975	chr6:47515663	T/C	cg02130027	chr6:47444894	CD2AP	0.36	5.74	0.3	2.09e-8	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg21775007	chr8:11205619	TDH	0.45	6.45	0.33	3.87e-10	Mood instability;
LUSC	cis	rs2692947	0.696	rs2576437	chr2:96800417	T/C	cg22654517	chr2:96458247	NA	0.36	7.26	0.37	2.69e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg05754148	chr16:3507555	NAT15	-0.54	-8.28	-0.41	3.06e-15	Tuberculosis;
LUSC	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.62	10.34	0.49	6.46e-22	Blood metabolite ratios;
LUSC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.95	0.31	6.62e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4812048	0.649	rs3761258	chr20:57618596	C/G	cg14073986	chr20:57617431	SLMO2	-0.87	-9.34	-0.46	1.4e-18	Mean platelet volume;
LUSC	cis	rs7561273	0.586	rs11900665	chr2:24298198	T/C	cg06627628	chr2:24431161	ITSN2	-0.51	-6.83	-0.35	4.03e-11	Quantitative traits;
LUSC	cis	rs713477	0.524	rs7149317	chr14:55902542	G/A	cg13175173	chr14:55914753	NA	-0.31	-6.03	-0.31	4.43e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.73	10.84	0.51	1.15e-23	Type 2 diabetes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07580707	chr3:14220061	XPC;LSM3	-0.48	-6.55	-0.34	2.2e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.4	0.33	5.39e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.97	-0.31	6.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg03929089	chr4:120376271	NA	0.72	6.77	0.35	5.71e-11	Axial length;
LUSC	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg08213375	chr14:104286397	PPP1R13B	0.53	10.41	0.5	3.56e-22	Schizophrenia;
LUSC	cis	rs926392	0.932	rs4812360	chr20:37689259	A/G	cg27552599	chr20:37590471	DHX35	0.33	5.8	0.3	1.51e-8	Dialysis-related mortality;
LUSC	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	0.85	8.28	0.41	3e-15	Skin colour saturation;
LUSC	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.22	-0.32	1.46e-9	Neuroticism;
LUSC	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs7589342	0.628	rs35622044	chr2:106404095	G/A	cg14210321	chr2:106509881	NCK2	-0.45	-5.81	-0.3	1.49e-8	Addiction;
LUSC	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg16482183	chr6:26056742	HIST1H1C	0.63	8.91	0.44	3.44e-17	Iron status biomarkers;
LUSC	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.44	-8.17	-0.41	6.26e-15	Monocyte percentage of white cells;
LUSC	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg19773385	chr1:10388646	KIF1B	-0.5	-8.66	-0.43	2e-16	Hepatocellular carcinoma;
LUSC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg06600287	chr1:53387719	ECHDC2	-0.31	-6.35	-0.33	7.19e-10	Monocyte count;
LUSC	cis	rs12210905	0.925	rs7753284	chr6:26991615	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.95	-0.31	6.94e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs3733418	0.799	rs13110766	chr4:165956628	C/T	cg11630554	chr4:165878136	TRIM61;C4orf39	-0.5	-6.49	-0.33	3.1e-10	Obesity-related traits;
LUSC	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-11.93	-0.55	1.44e-27	Hemoglobin concentration;
LUSC	cis	rs7215564	0.908	rs35151535	chr17:78661695	C/T	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	ch.11.42038R	chr11:967971	AP2A2	0.4	6.01	0.31	4.95e-9	Alzheimer's disease (late onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07023527	chr16:72699106	NA	0.81	6.57	0.34	1.9e-10	Cognitive performance;
LUSC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-0.81	-16.05	-0.66	2.25e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg07148914	chr20:33460835	GGT7	0.54	8.28	0.41	3.01e-15	Height;
LUSC	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.67	-0.43	1.88e-16	Body mass index;
LUSC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.43	-0.56	2.07e-29	Chronic sinus infection;
LUSC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg09034736	chr1:150693464	HORMAD1	0.44	6.32	0.33	8.16e-10	Melanoma;
LUSC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg13319975	chr6:146136371	FBXO30	-0.51	-7.81	-0.39	7.54e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6076065	0.723	rs6083099	chr20:23358233	A/G	cg11657817	chr20:23433608	CST11	-0.42	-7.85	-0.39	5.65e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs7851660	0.805	rs10759981	chr9:100635780	A/G	cg13688889	chr9:100608707	NA	-0.55	-8.73	-0.43	1.24e-16	Strep throat;
LUSC	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	8.04	0.4	1.6e-14	Axial length;
LUSC	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.66	0.34	1.16e-10	Corneal astigmatism;
LUSC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg19812747	chr11:111475976	SIK2	-0.55	-8.2	-0.41	5.19e-15	Primary sclerosing cholangitis;
LUSC	trans	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg17675199	chr6:35436792	RPL10A	-0.43	-6.32	-0.33	8.21e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.71	-9.26	-0.45	2.63e-18	Refractive error;
LUSC	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg23601095	chr6:26197514	HIST1H3D	0.7	7.53	0.38	4.89e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.77	10.81	0.51	1.49e-23	Corneal astigmatism;
LUSC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	13.52	0.59	1.6e-33	Total body bone mineral density;
LUSC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.77	14.21	0.61	3.61e-36	Longevity;
LUSC	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg05738196	chr6:26577821	NA	0.52	6.12	0.32	2.56e-9	Small cell lung carcinoma;
LUSC	cis	rs10492096	1.000	rs12427239	chr12:6590626	C/T	cg13857086	chr12:6580257	VAMP1	0.58	6.78	0.35	5.5e-11	Hip geometry;
LUSC	cis	rs7119038	0.774	rs11217020	chr11:118639353	G/A	cg19308663	chr11:118741387	NA	0.36	6.17	0.32	1.96e-9	Sjögren's syndrome;
LUSC	cis	rs500891	0.553	rs12194267	chr6:84146177	G/A	cg08257003	chr6:84140564	ME1	0.35	7.74	0.39	1.18e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg26727032	chr16:67993705	SLC12A4	-0.45	-5.89	-0.31	9.42e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg24324837	chr19:49891574	CCDC155	0.5	6.4	0.33	5.23e-10	Multiple sclerosis;
LUSC	cis	rs6674970	0.932	rs12569193	chr1:151115186	C/T	cg03258749	chr1:151040405	MLLT11	-0.42	-6.37	-0.33	6.13e-10	Childhood ear infection;
LUSC	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg04450456	chr4:17643702	FAM184B	0.39	6.55	0.34	2.21e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7614311	0.681	rs73117083	chr3:63948455	G/C	cg22134162	chr3:63841271	THOC7	-0.48	-5.89	-0.31	9.6e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg26408565	chr15:76604113	ETFA	-0.47	-7.5	-0.38	5.79e-13	Blood metabolite levels;
LUSC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg17724175	chr1:150552817	MCL1	0.38	6.72	0.35	7.87e-11	Urate levels;
LUSC	cis	rs61931739	0.963	rs12310956	chr12:33970682	A/G	cg06521331	chr12:34319734	NA	0.38	6.08	0.32	3.2e-9	Morning vs. evening chronotype;
LUSC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-8.77	-0.43	9.05e-17	Bipolar disorder;
LUSC	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.47	-9.95	-0.48	1.38e-20	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs73001065	0.636	rs10415849	chr19:19505087	C/T	cg03709012	chr19:19516395	GATAD2A	0.94	8.87	0.44	4.66e-17	LDL cholesterol;
LUSC	trans	rs62238980	0.614	rs10483162	chr22:32394890	G/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg15819921	chr19:927150	ARID3A	-0.45	-6.72	-0.35	7.88e-11	Life satisfaction;
LUSC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg19774624	chr17:42201019	HDAC5	-0.45	-6.47	-0.33	3.57e-10	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg24634471	chr8:143751801	JRK	0.58	8.87	0.44	4.56e-17	Schizophrenia;
LUSC	cis	rs68170813	0.559	rs76145119	chr7:107052368	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.32	-0.45	1.62e-18	Coronary artery disease;
LUSC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg13770153	chr20:60521292	NA	-0.46	-6.57	-0.34	1.99e-10	Body mass index;
LUSC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.28	-0.32	1.07e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11997175	0.600	rs6468188	chr8:33639478	T/C	ch.8.33884649F	chr8:33765107	NA	0.48	7.72	0.39	1.34e-13	Body mass index;
LUSC	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg10523860	chr14:103875565	MARK3	-0.39	-6.06	-0.31	3.71e-9	Body mass index;
LUSC	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.79	-0.43	8.32e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg20503657	chr10:835505	NA	0.73	8.85	0.44	5.35e-17	Eosinophil percentage of granulocytes;
LUSC	cis	rs2200578	0.786	rs62154639	chr2:99646954	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.64	7.35	0.37	1.53e-12	IgG glycosylation;
LUSC	cis	rs4776059	0.798	rs10851520	chr15:52912978	C/G	cg25063058	chr15:52860530	ARPP19	-0.45	-5.72	-0.3	2.37e-8	Schizophrenia;
LUSC	cis	rs11168618	0.846	rs7974213	chr12:48881492	C/T	cg24011408	chr12:48396354	COL2A1	-0.4	-6.5	-0.34	2.89e-10	Adiponectin levels;
LUSC	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg08017756	chr2:100939284	LONRF2	0.41	7.66	0.39	2.07e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07923666	chr12:49932857	KCNH3	-0.48	-6.22	-0.32	1.48e-9	Resting heart rate;
LUSC	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg18190219	chr22:46762943	CELSR1	-0.52	-5.96	-0.31	6.55e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg25039879	chr17:56429692	SUPT4H1	0.41	5.85	0.3	1.17e-8	Cognitive test performance;
LUSC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.6	0.38	2.92e-13	Parkinson's disease;
LUSC	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg22117172	chr7:91764530	CYP51A1	0.32	5.74	0.3	2.15e-8	Breast cancer;
LUSC	trans	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg04995722	chr7:26192034	NFE2L3	-0.39	-6.32	-0.33	8.15e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6736093	0.966	rs2271701	chr2:112731173	C/G	cg12686935	chr2:112915763	FBLN7	-0.36	-5.9	-0.31	9.09e-9	Coronary artery disease;
LUSC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg12365402	chr11:9010492	NRIP3	-0.47	-8.98	-0.44	2.03e-17	Hemoglobin concentration;
LUSC	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg05738196	chr6:26577821	NA	-0.47	-7.31	-0.37	2e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg23306229	chr2:178417860	TTC30B	-0.53	-5.7	-0.3	2.61e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg17052675	chr2:3827356	NA	-0.64	-10.2	-0.49	1.87e-21	Type 2 diabetes;
LUSC	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.81	-0.3	1.49e-8	Type 2 diabetes;
LUSC	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.86	-0.31	1.09e-8	Height;
LUSC	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg09509183	chr1:209979624	IRF6	-0.48	-7.52	-0.38	4.94e-13	Monobrow;
LUSC	cis	rs9942416	0.660	rs34905687	chr5:74997736	A/G	cg19683494	chr5:74908142	NA	0.45	6.9	0.35	2.58e-11	Age-related disease endophenotypes;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg16041806	chr1:173991823	NA	0.4	6.54	0.34	2.29e-10	Triglycerides;
LUSC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.76	-0.47	5.77e-20	Chronic sinus infection;
LUSC	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg17366294	chr4:99064904	C4orf37	0.62	11.15	0.52	9.52e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg16584290	chr5:462447	EXOC3	-0.34	-5.8	-0.3	1.57e-8	Cystic fibrosis severity;
LUSC	cis	rs7241530	0.662	rs6506756	chr18:75905196	C/G	cg14642773	chr18:75888474	NA	0.39	6.02	0.31	4.59e-9	Educational attainment (years of education);
LUSC	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg11812906	chr14:75593930	NEK9	0.66	11.36	0.53	1.59e-25	Height;
LUSC	cis	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg07460842	chr6:66804631	NA	-0.48	-6.72	-0.35	7.74e-11	Blood trace element (Cu levels);
LUSC	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg02775129	chr4:119771670	NA	-0.74	-5.91	-0.31	8.36e-9	Cannabis dependence symptom count;
LUSC	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg12317470	chr15:67143691	NA	-0.61	-7.06	-0.36	9.86e-12	Lung cancer (smoking interaction);
LUSC	cis	rs10484885	0.588	rs9344947	chr6:90304789	A/G	cg13799429	chr6:90582589	CASP8AP2	0.68	7.26	0.37	2.72e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg27219399	chr15:67835830	MAP2K5	0.34	5.66	0.3	3.33e-8	Restless legs syndrome;
LUSC	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg12935359	chr14:103987150	CKB	-0.57	-8.6	-0.43	3.09e-16	Body mass index;
LUSC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg24642844	chr7:1081250	C7orf50	-0.79	-10.46	-0.5	2.44e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg24733560	chr20:60626293	TAF4	0.41	6.56	0.34	2.04e-10	Body mass index;
LUSC	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.69	-0.39	1.7e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg07211511	chr3:129823064	LOC729375	-1.0	-13.81	-0.6	1.2e-34	Blood pressure (smoking interaction);
LUSC	cis	rs6500395	1.000	rs9937610	chr16:48671274	C/G	cg04672837	chr16:48644449	N4BP1	0.46	6.73	0.35	7.32e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg12935359	chr14:103987150	CKB	-0.62	-10.18	-0.49	2.24e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.34	-0.49	6.57e-22	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.09	0.52	1.52e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7851660	0.844	rs10984103	chr9:100639275	G/T	cg13688889	chr9:100608707	NA	0.54	8.4	0.42	1.27e-15	Strep throat;
LUSC	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17830980	chr10:43048298	ZNF37B	0.57	9.25	0.45	2.76e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.51	0.38	5.48e-13	Iron status biomarkers;
LUSC	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg09307838	chr4:120376055	NA	0.66	9.29	0.45	2.07e-18	Corneal astigmatism;
LUSC	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.67	11.45	0.53	7.92e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11997175	0.756	rs4739435	chr8:33818818	A/G	ch.8.33884649F	chr8:33765107	NA	0.53	8.16	0.41	6.69e-15	Body mass index;
LUSC	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg00677455	chr12:58241039	CTDSP2	0.69	10.45	0.5	2.74e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	13.25	0.59	1.64e-32	Post bronchodilator FEV1;
LUSC	cis	rs2067615	0.579	rs10861663	chr12:107183589	G/A	cg15890332	chr12:107067104	RFX4	0.34	6.06	0.31	3.76e-9	Heart rate;
LUSC	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg24375607	chr4:120327624	NA	0.77	12.34	0.56	4.45e-29	Corneal astigmatism;
LUSC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.57	-9.01	-0.44	1.61e-17	Menopause (age at onset);
LUSC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg16606324	chr3:10149918	C3orf24	-0.42	-6.79	-0.35	5e-11	Alzheimer's disease;
LUSC	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg11965913	chr1:205819406	PM20D1	0.45	6.41	0.33	5e-10	Parkinson's disease;
LUSC	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg13010199	chr12:38710504	ALG10B	0.56	8.55	0.42	4.54e-16	Morning vs. evening chronotype;
LUSC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg06212747	chr3:49208901	KLHDC8B	0.45	5.85	0.31	1.14e-8	Parkinson's disease;
LUSC	cis	rs3740713	1.000	rs2643872	chr11:18450444	A/T	cg07915343	chr11:18477680	LDHAL6A	-0.54	-6.79	-0.35	5.16e-11	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs73206853	0.764	rs61227741	chr12:110598319	G/T	cg12870014	chr12:110450643	ANKRD13A	0.62	6.3	0.33	9.4e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6500395	1.000	rs6500395	chr16:48621402	T/C	cg04672837	chr16:48644449	N4BP1	0.49	7.28	0.37	2.46e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11971779	0.648	rs9656512	chr7:139054046	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg05855489	chr10:104503620	C10orf26	-0.5	-7.45	-0.38	8.21e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg11766577	chr21:47581405	C21orf56	-0.46	-6.84	-0.35	3.84e-11	Testicular germ cell tumor;
LUSC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg07828024	chr6:149772892	ZC3H12D	-0.34	-7.43	-0.38	8.88e-13	Dupuytren's disease;
LUSC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg21849932	chr20:62369462	LIME1	-0.41	-6.02	-0.31	4.7e-9	Prostate cancer;
LUSC	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg19784903	chr17:45786737	TBKBP1	-0.42	-6.15	-0.32	2.24e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2882667	0.690	rs9942422	chr5:138272536	A/G	cg04439458	chr5:138467593	SIL1	-0.41	-7.46	-0.38	7.63e-13	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg19920283	chr7:105172520	RINT1	0.61	6.76	0.35	6.2e-11	Bipolar disorder (body mass index interaction);
LUSC	trans	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg07393940	chr7:158741817	NA	-0.38	-6.83	-0.35	4.02e-11	Life satisfaction;
LUSC	cis	rs7119	0.637	rs12913005	chr15:77856571	T/A	cg27398640	chr15:77910606	LINGO1	-0.36	-7.84	-0.39	6.18e-14	Type 2 diabetes;
LUSC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-17.18	-0.68	7.55e-48	Body mass index;
LUSC	trans	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg14343924	chr8:8086146	FLJ10661	-0.45	-6.23	-0.32	1.43e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg09307838	chr4:120376055	NA	0.7	10.0	0.48	9.4499999999999992e-21	Corneal astigmatism;
LUSC	trans	rs3824451	1.000	rs10985817	chr9:101071090	T/C	cg02729030	chr7:110879415	IMMP2L	0.44	6.03	0.31	4.41e-9	Schizophrenia;
LUSC	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg09479241	chr17:27052676	TLCD1	-0.4	-5.69	-0.3	2.85e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg15704280	chr7:45808275	SEPT13	-0.46	-6.35	-0.33	6.87e-10	HDL cholesterol;
LUSC	trans	rs629535	0.508	rs56207225	chr8:70146628	C/A	cg21567404	chr3:27674614	NA	-0.93	-13.53	-0.6	1.45e-33	Dupuytren's disease;
LUSC	cis	rs2835872	0.965	rs2835853	chr21:39014892	C/A	cg20424643	chr21:39039972	KCNJ6	0.43	6.47	0.33	3.47e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg16743903	chr16:89593216	SPG7	-0.38	-6.07	-0.32	3.42e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg05234568	chr11:5960015	NA	-0.65	-9.41	-0.46	8.45e-19	DNA methylation (variation);
LUSC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg16325326	chr1:53192061	ZYG11B	0.97	18.46	0.71	6.26e-53	Monocyte count;
LUSC	cis	rs10934753	0.632	rs2001273	chr3:125926110	C/T	cg01346077	chr3:125931526	NA	0.48	8.88	0.44	4.28e-17	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs10979	1.000	rs9386032	chr6:143887492	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-12.01	-0.55	7.28e-28	Hypospadias;
LUSC	cis	rs78572108	0.858	rs72613884	chr2:42264869	A/G	cg00607755	chr2:42274082	PKDCC	0.37	6.56	0.34	2.03e-10	Total body bone mineral density;
LUSC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24110177	chr3:50126178	RBM5	-0.55	-8.98	-0.44	2.05e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.97	-0.68	5.26e-47	Coronary artery disease;
LUSC	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg23029597	chr12:123009494	RSRC2	-0.72	-9.25	-0.45	2.74e-18	Body mass index;
LUSC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg13866156	chr1:1669148	SLC35E2	-0.49	-8.0	-0.4	2.08e-14	Body mass index;
LUSC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg11502198	chr6:26597334	ABT1	0.64	10.07	0.48	5.3e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg24531977	chr5:56204891	C5orf35	-0.71	-10.4	-0.49	3.84e-22	Coronary artery disease;
LUSC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.67	-11.0	-0.52	3.08e-24	Urinary electrolytes (magnesium/calcium ratio);
LUSC	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg10596483	chr8:143751796	JRK	0.62	9.5	0.46	4.11e-19	Schizophrenia;
LUSC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13732083	chr21:47605072	C21orf56	0.46	6.94	0.35	2.07e-11	Testicular germ cell tumor;
LUSC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg23711669	chr6:146136114	FBXO30	-0.75	-12.1	-0.55	3.52e-28	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg00631329	chr6:26305371	NA	0.33	5.78	0.3	1.68e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg27661571	chr11:113659931	NA	-0.71	-8.16	-0.41	6.87e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg00255919	chr5:131827918	IRF1	0.4	7.31	0.37	2.02e-12	Asthma (sex interaction);
LUSC	cis	rs7572644	0.723	rs12473400	chr2:28024024	G/T	cg27432699	chr2:27873401	GPN1	0.55	7.23	0.37	3.31e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs3106136	0.967	rs282448	chr4:95141411	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.12	-0.32	2.68e-9	Capecitabine sensitivity;
LUSC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08280861	chr8:58055591	NA	0.54	5.89	0.31	9.55e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.51	-0.34	2.73e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	9.64	0.47	1.44e-19	Multiple sclerosis;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg15137760	chr8:21988747	HR	0.8	6.84	0.35	3.68e-11	Cognitive performance;
LUSC	trans	rs7044246	0.924	rs9411424	chr9:134864382	C/T	cg17477578	chr8:129552914	NA	0.32	5.97	0.31	6.13e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06463759	chr7:128502823	ATP6V1F	0.5	8.15	0.41	7.49e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	1.11	18.8	0.72	2.7e-54	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23158103	chr7:148848205	ZNF398	-0.5	-8.17	-0.41	6.41e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs12122100	0.651	rs12728300	chr1:146542184	T/C	cg03526459	chr1:146549940	NA	-0.42	-6.76	-0.35	6.19e-11	HIV-1 control;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.67	10.06	0.48	5.62e-21	Lymphocyte counts;
LUSC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg21724239	chr8:58056113	NA	0.56	6.92	0.35	2.35e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg05865280	chr17:75406074	SEPT9	0.45	9.47	0.46	5.42e-19	Airflow obstruction;
LUSC	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg07828024	chr6:149772892	ZC3H12D	0.33	7.13	0.36	6.14e-12	Dupuytren's disease;
LUSC	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9399401	0.925	rs2039987	chr6:142655490	A/C	cg03128060	chr6:142623767	GPR126	0.33	5.87	0.31	1.03e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	1.04	19.22	0.72	5.83e-56	Menopause (age at onset);
LUSC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.6	-11.83	-0.54	3.22e-27	Asthma (sex interaction);
LUSC	cis	rs9462027	0.628	rs9368832	chr6:34679587	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.33	5.79	0.3	1.65e-8	Systemic lupus erythematosus;
LUSC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	14.51	0.62	2.45e-37	Platelet count;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg24436578	chr11:2398521	CD81	0.35	5.98	0.31	5.78e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg11584989	chr19:19387371	SF4	0.57	6.82	0.35	4.18e-11	Bipolar disorder;
LUSC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg24881330	chr22:46731750	TRMU	0.88	8.84	0.44	5.44e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs61990749	0.597	rs717683	chr14:78255453	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	6.45	0.33	3.84e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.36	5.86	0.31	1.14e-8	Menopause (age at onset);
LUSC	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg07936489	chr17:37558343	FBXL20	0.76	9.28	0.45	2.14e-18	Glomerular filtration rate (creatinine);
LUSC	trans	rs12637928	0.580	rs13081130	chr3:110210864	G/C	cg17371621	chr15:61264283	RORA	0.36	6.08	0.32	3.29e-9	Neuroticism;
LUSC	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg15691649	chr6:25882328	NA	0.5	7.5	0.38	5.92e-13	Blood metabolite levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09667226	chr13:73632762	KLF5	0.44	6.53	0.34	2.46e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4704187	0.687	rs6872475	chr5:74419793	G/A	cg03227963	chr5:74354835	NA	0.32	6.81	0.35	4.62e-11	Response to amphetamines;
LUSC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg00033643	chr7:134001901	SLC35B4	0.46	7.24	0.37	3.13e-12	Mean platelet volume;
LUSC	cis	rs7582720	0.943	rs72926800	chr2:203829225	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg23625390	chr15:77176239	SCAPER	0.67	10.48	0.5	2.02e-22	Blood metabolite levels;
LUSC	cis	rs7127900	0.614	rs72853920	chr11:2206429	T/C	cg25635251	chr11:2234043	NA	-0.6	-8.13	-0.41	8.32e-15	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
LUSC	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg20016023	chr10:99160130	RRP12	-0.37	-8.68	-0.43	1.83e-16	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg07332563	chr6:291687	DUSP22	-0.5	-7.62	-0.38	2.67e-13	Menopause (age at onset);
LUSC	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg02415014	chr8:143852576	LYNX1	0.35	8.32	0.41	2.21e-15	Urinary tract infection frequency;
LUSC	cis	rs6723226	0.650	rs6729952	chr2:32764922	T/C	cg02381751	chr2:32503542	YIPF4	0.49	7.36	0.37	1.49e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	6.87	0.35	3.08e-11	Multiple sclerosis;
LUSC	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-7.09	-0.36	8.2e-12	Homocysteine levels;
LUSC	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.61	11.15	0.52	9.41e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg03146154	chr1:46216737	IPP	-0.55	-8.08	-0.4	1.22e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs17253792	0.822	rs77555779	chr14:56078430	A/G	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg06637938	chr14:75390232	RPS6KL1	0.53	8.61	0.43	2.95e-16	Height;
LUSC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg03146154	chr1:46216737	IPP	0.5	7.51	0.38	5.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2652834	0.851	rs2652796	chr15:63408042	T/A	cg05507819	chr15:63340323	TPM1	0.46	5.94	0.31	7.3e-9	HDL cholesterol;
LUSC	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.98	-0.36	1.58e-11	Response to antipsychotic treatment;
LUSC	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg17385448	chr1:15911702	AGMAT	0.38	6.42	0.33	4.64e-10	Systolic blood pressure;
LUSC	trans	rs1973993	0.967	rs11165643	chr1:96924097	C/T	cg10631902	chr5:14652156	NA	0.53	8.86	0.44	4.82e-17	Weight;
LUSC	trans	rs2288327	0.841	rs16866418	chr2:179490954	C/T	cg14011486	chr1:26737247	LIN28	0.46	5.95	0.31	6.61e-9	Atrial fibrillation;
LUSC	cis	rs7705502	1.000	rs72812842	chr5:173374760	C/T	cg18693985	chr5:173351052	CPEB4	-0.37	-5.86	-0.31	1.11e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	trans	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs1979679	0.572	rs6487692	chr12:28726042	C/T	cg13890972	chr12:28721907	NA	-0.43	-6.12	-0.32	2.56e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs73206853	0.698	rs73194015	chr12:111116651	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	6.52	0.34	2.65e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg18478394	chr8:109455254	TTC35	0.41	6.32	0.33	8.55e-10	Dupuytren's disease;
LUSC	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-8.87	-0.44	4.48e-17	Systolic blood pressure;
LUSC	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs12122100	0.837	rs6681167	chr1:146506862	C/T	cg03526459	chr1:146549940	NA	0.36	5.87	0.31	1.06e-8	HIV-1 control;
LUSC	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg00310523	chr12:86230176	RASSF9	0.35	6.23	0.32	1.44e-9	Major depressive disorder;
LUSC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.5	-7.97	-0.4	2.61e-14	Vitiligo;
LUSC	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs7705502	1.000	rs72812816	chr5:173356638	G/A	cg18693985	chr5:173351052	CPEB4	-0.37	-5.82	-0.3	1.35e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.09	-0.48	4.66e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg25214090	chr10:38739885	LOC399744	0.53	7.75	0.39	1.12e-13	Corneal astigmatism;
LUSC	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg07195577	chr17:27052828	TLCD1	0.44	5.67	0.3	3.15e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg13628971	chr7:2884303	GNA12	0.49	6.79	0.35	5.12e-11	Height;
LUSC	cis	rs4595586	0.655	rs7953715	chr12:39325539	T/C	cg26384229	chr12:38710491	ALG10B	0.44	5.97	0.31	6.12e-9	Morning vs. evening chronotype;
LUSC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-5.78	-0.3	1.71e-8	Neuroticism;
LUSC	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg18825076	chr15:78729989	IREB2	0.46	6.23	0.32	1.39e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.36	-0.62	9.67e-37	Schizophrenia;
LUSC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg12560992	chr17:57184187	TRIM37	0.9	17.84	0.7	1.78e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-6.75	-0.35	6.46e-11	Heart rate;
LUSC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06850241	chr22:41845214	NA	-0.31	-5.7	-0.3	2.7e-8	Vitiligo;
LUSC	cis	rs2115536	0.606	rs8024713	chr15:80206958	C/G	cg00225070	chr15:80189496	MTHFS	0.62	9.98	0.48	1.04e-20	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg11062466	chr8:58055876	NA	0.58	8.24	0.41	3.94e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.58	-0.34	1.79e-10	QT interval;
LUSC	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg18681998	chr4:17616180	MED28	0.77	13.74	0.6	2.29e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg05738196	chr6:26577821	NA	0.82	15.82	0.65	1.9e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18301423	chr5:131593218	PDLIM4	0.47	7.42	0.38	9.66e-13	Acylcarnitine levels;
LUSC	trans	rs2262909	0.962	rs439574	chr19:22232024	A/C	cg05197062	chr11:11642011	GALNTL4	-0.49	-6.9	-0.35	2.54e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs500891	0.533	rs13204045	chr6:84152329	C/T	cg08257003	chr6:84140564	ME1	0.37	9.01	0.44	1.57e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs78545713	0.649	rs11754368	chr6:26221173	G/A	cg23601095	chr6:26197514	HIST1H3D	0.66	5.79	0.3	1.64e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs13082711	0.595	rs6783818	chr3:27361988	C/G	cg02860705	chr3:27208620	NA	0.8	12.69	0.57	2.23e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.96	-0.31	6.31e-9	Aortic root size;
LUSC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg20573242	chr4:122745356	CCNA2	0.67	10.52	0.5	1.49e-22	Type 2 diabetes;
LUSC	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg05855489	chr10:104503620	C10orf26	0.6	9.61	0.47	1.88e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Smoking initiation;
LUSC	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.29	-5.76	-0.3	1.95e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11132352	chr1:161719642	DUSP12	-0.41	-6.11	-0.32	2.84e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.46	-8.96	-0.44	2.28e-17	Monocyte percentage of white cells;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00850756	chr6:41909180	CCND3	0.38	6.39	0.33	5.53e-10	Asthma;
LUSC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg16423285	chr20:60520624	NA	-0.64	-8.15	-0.41	7.59e-15	Body mass index;
LUSC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg25036284	chr2:26402008	FAM59B	-0.68	-9.38	-0.46	1.06e-18	Gut microbiome composition (summer);
LUSC	cis	rs11779988	0.545	rs375203	chr8:17769054	T/A	cg01800426	chr8:17659068	MTUS1	-0.44	-5.77	-0.3	1.79e-8	Breast cancer;
LUSC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg23649088	chr2:200775458	C2orf69	0.59	7.28	0.37	2.36e-12	Schizophrenia;
LUSC	cis	rs3087591	0.708	rs2854320	chr17:29694063	C/A	cg24425628	chr17:29625626	OMG;NF1	0.49	7.25	0.37	2.9e-12	Hip circumference;
LUSC	cis	rs75804782	0.641	rs72983861	chr2:239326126	G/A	cg18131467	chr2:239335373	ASB1	-0.74	-6.52	-0.34	2.57e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg13114125	chr14:105738426	BRF1	-0.92	-15.78	-0.65	2.58e-42	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs12980942	0.935	rs11880564	chr19:41831196	C/A	cg25627403	chr19:41769009	HNRNPUL1	0.58	6.12	0.32	2.65e-9	Coronary artery disease;
LUSC	trans	rs13390641	0.614	rs56169538	chr2:104086506	C/T	cg03260781	chr1:16346299	HSPB7	-0.46	-6.09	-0.32	3.14e-9	Blood pressure;Blood pressure (anthropometric measures interaction);
LUSC	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.73	10.36	0.49	5.62e-22	Corneal astigmatism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10387458	chr1:93645817	TMED5;CCDC18	-0.5	-6.32	-0.33	8.56e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg09021430	chr5:549028	NA	-0.56	-7.58	-0.38	3.52e-13	Obesity-related traits;
LUSC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06634786	chr22:41940651	POLR3H	-0.47	-6.0	-0.31	5.16e-9	Vitiligo;
LUSC	cis	rs41271473	0.950	rs72751907	chr1:228867648	C/T	cg10167378	chr1:228756711	NA	0.58	6.96	0.36	1.77e-11	Chronic lymphocytic leukemia;
LUSC	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg18721089	chr20:30220636	NA	-0.41	-6.57	-0.34	1.93e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg10729496	chr3:10149963	C3orf24	0.57	7.66	0.39	2.08e-13	Alzheimer's disease;
LUSC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg14895029	chr7:2775587	GNA12	-0.37	-5.68	-0.3	2.94e-8	Height;
LUSC	cis	rs2573652	1.000	rs2581346	chr15:100514178	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.42	-7.71	-0.39	1.45e-13	Height;
LUSC	cis	rs11676348	0.751	rs6715591	chr2:219019871	T/C	cg00012203	chr2:219082015	ARPC2	-0.56	-8.87	-0.44	4.35e-17	Ulcerative colitis;
LUSC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg17515076	chr17:73810948	UNK	-0.39	-6.57	-0.34	1.92e-10	White matter hyperintensity burden;
LUSC	cis	rs6001027	0.540	rs1005529	chr22:38541266	T/C	cg25457927	chr22:38595422	NA	-0.36	-7.17	-0.37	4.86e-12	Melanoma;
LUSC	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg01657329	chr11:68192670	LRP5	0.48	6.32	0.33	8.42e-10	Bone mineral density (spine);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01801750	chr12:72148484	RAB21	-0.4	-5.97	-0.31	6.19e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2179367	0.537	rs12192159	chr6:149767105	C/A	cg07828024	chr6:149772892	ZC3H12D	-0.35	-5.84	-0.3	1.21e-8	Dupuytren's disease;
LUSC	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-0.48	-7.42	-0.38	9.81e-13	Breast cancer;
LUSC	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg20701182	chr2:24300061	SF3B14	0.57	6.19	0.32	1.73e-9	Lymphocyte counts;
LUSC	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.04	-21.09	-0.76	2.22e-63	Ulcerative colitis;
LUSC	cis	rs6901250	0.807	rs1606366	chr6:117132438	C/G	cg12892004	chr6:117198278	RFX6	0.43	8.12	0.41	8.98e-15	C-reactive protein levels;
LUSC	cis	rs57502260	0.704	rs2186937	chr11:68256847	G/A	cg20283391	chr11:68216788	NA	-0.63	-5.77	-0.3	1.83e-8	Total body bone mineral density (age 45-60);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14331148	chr19:47551893	TMEM160	-0.35	-6.12	-0.32	2.62e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23871527	chr20:2854169	PTPRA	-0.42	-6.08	-0.32	3.37e-9	Electrocardiographic conduction measures;
LUSC	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-1.14	-18.49	-0.71	4.69e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg24558204	chr6:135376177	HBS1L	-0.59	-9.23	-0.45	3.1e-18	Red blood cell count;
LUSC	cis	rs7615316	0.779	rs6802631	chr3:142080583	G/T	cg16271453	chr3:142027066	XRN1	-0.4	-6.99	-0.36	1.51e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6545883	0.894	rs6545867	chr2:61651027	C/T	cg15711740	chr2:61764176	XPO1	0.43	6.55	0.34	2.13e-10	Tuberculosis;
LUSC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.53	-0.34	2.5e-10	Life satisfaction;
LUSC	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.83	-15.53	-0.65	2.62e-41	Heart rate;
LUSC	cis	rs6445797	0.632	rs6802051	chr3:56670924	G/A	cg13792233	chr3:56591045	CCDC66	0.41	5.72	0.3	2.33e-8	Gastritis;
LUSC	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04362095	chr11:63592001	C11orf84	-0.58	-8.9	-0.44	3.59e-17	Pulse pressure;
LUSC	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg14664628	chr15:75095509	CSK	0.46	6.32	0.33	8.14e-10	Systemic lupus erythematosus;
LUSC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg13206674	chr6:150067644	NUP43	0.56	8.67	0.43	1.95e-16	Lung cancer;
LUSC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg25204440	chr1:209979598	IRF6	-0.5	-6.74	-0.35	6.9e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs3740713	0.669	rs34740438	chr11:18415330	C/A	cg23797887	chr11:18477753	LDHAL6A	-0.47	-5.67	-0.3	3.1e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.5	-8.14	-0.41	7.91e-15	Platelet count;
LUSC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg16743903	chr16:89593216	SPG7	-0.39	-6.17	-0.32	1.93e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg02023728	chr11:77925099	USP35	0.44	6.72	0.35	7.74e-11	Testicular germ cell tumor;
LUSC	cis	rs56283067	0.887	rs12215971	chr6:44784566	A/G	cg18551225	chr6:44695536	NA	-0.46	-7.11	-0.36	7.16e-12	Total body bone mineral density;
LUSC	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg07382826	chr16:28625726	SULT1A1	0.28	5.81	0.3	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg08027265	chr7:2291960	NA	-0.4	-6.64	-0.34	1.25e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg18352616	chr4:3374830	RGS12	-0.33	-6.78	-0.35	5.57e-11	Serum sulfate level;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.66	9.93	0.48	1.52e-20	Lymphocyte counts;
LUSC	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg09092052	chr15:45571596	NA	0.46	6.51	0.34	2.84e-10	Glomerular filtration rate;
LUSC	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-6.92	-0.35	2.31e-11	Coronary artery disease;
LUSC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg19774624	chr17:42201019	HDAC5	0.72	10.53	0.5	1.36e-22	Total body bone mineral density;
LUSC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.68	0.5	4.13e-23	Monocyte percentage of white cells;
LUSC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-13.1	-0.58	6.15e-32	Platelet count;
LUSC	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg14634687	chr17:47094252	IGF2BP1	0.3	6.4	0.33	5.21e-10	Intelligence (multi-trait analysis);Body fat percentage;
LUSC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg07741184	chr6:167504864	NA	0.48	8.3	0.41	2.61e-15	Crohn's disease;
LUSC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg19230755	chr7:65878503	NA	0.43	6.04	0.31	4.17e-9	Aortic root size;
LUSC	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg08601574	chr20:25228251	PYGB	0.42	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg03522245	chr20:25566470	NINL	-0.36	-5.8	-0.3	1.56e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2625529	0.529	rs7183055	chr15:72377048	C/T	cg16672083	chr15:72433130	SENP8	0.49	8.12	0.41	9.35e-15	Red blood cell count;
LUSC	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.75	0.35	6.4e-11	Corneal astigmatism;
LUSC	cis	rs7781370	0.921	rs4729260	chr7:96117918	G/C	cg00604640	chr7:96133485	NA	-0.34	-5.76	-0.3	1.9e-8	Bone mineral density (hip);
LUSC	cis	rs3824488	0.765	rs10512247	chr9:98296403	C/T	cg22073802	chr9:98269255	PTCH1	-0.46	-5.73	-0.3	2.29e-8	Neuroticism;
LUSC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7572644	0.640	rs13027427	chr2:28021043	G/T	cg27432699	chr2:27873401	GPN1	0.59	7.55	0.38	4.15e-13	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.38	-0.42	1.44e-15	Response to antipsychotic treatment;
LUSC	cis	rs11608355	0.545	rs9943724	chr12:109902903	G/A	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg03676636	chr4:99064102	C4orf37	0.38	8.03	0.4	1.74e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg23649088	chr2:200775458	C2orf69	-0.4	-6.23	-0.32	1.38e-9	QT interval;
LUSC	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.41	5.99	0.31	5.3e-9	Lung cancer;
LUSC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19346786	chr7:2764209	NA	-0.49	-8.11	-0.41	9.78e-15	Height;
LUSC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs6500395	1.000	rs9925406	chr16:48671436	C/A	cg04672837	chr16:48644449	N4BP1	0.46	6.92	0.35	2.37e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02018176	chr4:1364513	KIAA1530	-0.66	-11.53	-0.53	4.16e-26	Obesity-related traits;
LUSC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	8.31	0.41	2.36e-15	Menarche (age at onset);
LUSC	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg20608306	chr11:116969690	SIK3	0.37	6.97	0.36	1.73e-11	Blood protein levels;
LUSC	cis	rs7131987	0.650	rs11050187	chr12:29472876	T/C	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.68	-0.34	9.9e-11	QT interval;
LUSC	cis	rs2798269	0.966	rs2093804	chr13:22138384	T/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.04	-0.31	4.15e-9	PR segment;
LUSC	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg18681998	chr4:17616180	MED28	0.84	14.53	0.62	2.14e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg18105134	chr13:113819100	PROZ	-0.71	-10.19	-0.49	2.1e-21	Platelet distribution width;
LUSC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	12.03	0.55	6.07e-28	Chronic sinus infection;
LUSC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg11766577	chr21:47581405	C21orf56	-0.53	-8.21	-0.41	4.88e-15	Testicular germ cell tumor;
LUSC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg24101359	chr6:42928495	GNMT	0.36	5.93	0.31	7.37e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2798269	1.000	rs12429479	chr13:22145941	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.39	-5.94	-0.31	7.18e-9	PR segment;
LUSC	trans	rs1941687	0.702	rs8090097	chr18:31413448	A/C	cg27147174	chr7:100797783	AP1S1	-0.45	-6.82	-0.35	4.31e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs62400317	0.859	rs12201005	chr6:45136922	A/T	cg20913747	chr6:44695427	NA	-0.46	-7.49	-0.38	6.22e-13	Total body bone mineral density;
LUSC	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg18240062	chr17:79603768	NPLOC4	-0.79	-15.28	-0.64	2.35e-40	Eye color traits;
LUSC	trans	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg13565492	chr6:43139072	SRF	-0.63	-6.57	-0.34	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg15704280	chr7:45808275	SEPT13	0.63	6.66	0.34	1.16e-10	Axial length;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03468541	chr14:89029199	ZC3H14	0.55	9.43	0.46	7.18e-19	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs501916	0.634	rs1561483	chr15:48069488	A/C	cg16110827	chr15:48056943	SEMA6D	-0.37	-5.67	-0.3	3.14e-8	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg23034840	chr1:205782522	SLC41A1	-0.58	-8.23	-0.41	4.27e-15	Menarche (age at onset);
LUSC	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg19628046	chr18:33552617	C18orf21	0.51	6.27	0.32	1.12e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg10978503	chr1:24200527	CNR2	0.49	11.46	0.53	6.97e-26	Immature fraction of reticulocytes;
LUSC	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.26	0.45	2.61e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs28785552	0.589	rs11669056	chr19:53244443	G/A	cg22067481	chr19:53234126	ZNF611	-0.48	-6.33	-0.33	8.07e-10	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg07703079	chr11:430292	ANO9	0.6	6.31	0.33	8.81e-10	Body mass index;
LUSC	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg00310523	chr12:86230176	RASSF9	-0.42	-7.95	-0.4	2.83e-14	Major depressive disorder;
LUSC	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg19773385	chr1:10388646	KIF1B	-0.52	-8.84	-0.44	5.63e-17	Hepatocellular carcinoma;
LUSC	cis	rs59698941	0.765	rs12163971	chr5:132226669	C/A	cg02081065	chr5:132209139	LEAP2	-0.65	-6.75	-0.35	6.45e-11	Apolipoprotein A-IV levels;
LUSC	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg16797656	chr11:68205561	LRP5	0.47	8.48	0.42	7.56e-16	Total body bone mineral density;
LUSC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.34	-5.65	-0.3	3.4e-8	Longevity;Endometriosis;
LUSC	cis	rs113835537	0.597	rs7939759	chr11:66337964	C/T	cg24851651	chr11:66362959	CCS	0.58	9.04	0.44	1.28e-17	Airway imaging phenotypes;
LUSC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg17366294	chr4:99064904	C4orf37	0.59	10.54	0.5	1.24e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg08000102	chr2:233561755	GIGYF2	0.7	11.73	0.54	7.36e-27	Coronary artery disease;
LUSC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg26380479	chr7:97908229	NA	-0.26	-5.86	-0.31	1.13e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg24596788	chr1:163392923	NA	-0.44	-7.39	-0.38	1.15e-12	Motion sickness;
LUSC	cis	rs2637266	0.538	rs2130800	chr10:78274818	C/T	cg18941641	chr10:78392320	NA	-0.34	-6.36	-0.33	6.6e-10	Pulmonary function;
LUSC	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.64	-8.15	-0.41	7.63e-15	Body mass index;
LUSC	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.63	6.79	0.35	5e-11	Schizophrenia;
LUSC	cis	rs4474465	0.646	rs10793335	chr11:78279005	C/G	cg27205649	chr11:78285834	NARS2	0.56	6.82	0.35	4.31e-11	Alzheimer's disease (survival time);
LUSC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg16339924	chr4:17578868	LAP3	0.66	10.34	0.49	6.42e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg07274523	chr3:49395745	GPX1	0.67	10.52	0.5	1.5e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs6722750	0.905	rs10170666	chr2:64379672	G/A	cg22352474	chr2:64371530	PELI1	0.73	11.59	0.54	2.54e-26	Neuroticism;
LUSC	trans	rs2262909	0.962	rs55728714	chr19:22262899	A/G	cg17074339	chr11:11642133	GALNTL4	0.48	7.3	0.37	2.13e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3087591	0.708	rs2285894	chr17:29654876	T/A	cg24425628	chr17:29625626	OMG;NF1	0.46	6.86	0.35	3.37e-11	Hip circumference;
LUSC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12756686	chr19:29218302	NA	0.68	9.28	0.45	2.12e-18	Methadone dose in opioid dependence;
LUSC	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-0.99	-19.0	-0.72	4.38e-55	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg10253484	chr15:75165896	SCAMP2	-0.58	-7.83	-0.39	6.5e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs72674100	1.000	rs7671134	chr4:97990088	A/G	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs4596713	0.538	rs10125494	chr9:71770861	C/G	cg25283916	chr1:242222868	NA	-0.31	-6.3	-0.33	9.33e-10	Headache;
LUSC	cis	rs28830936	1.000	rs17678138	chr15:42043067	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.03	-0.31	4.33e-9	Diastolic blood pressure;
LUSC	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg07828024	chr6:149772892	ZC3H12D	0.33	7.15	0.36	5.37e-12	Dupuytren's disease;
LUSC	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg22782873	chr19:19639568	YJEFN3	-0.47	-5.83	-0.3	1.34e-8	Bipolar disorder;
LUSC	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg09034736	chr1:150693464	HORMAD1	0.45	6.48	0.33	3.36e-10	Tonsillectomy;
LUSC	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg00579484	chr14:23475993	C14orf93	0.39	5.77	0.3	1.85e-8	Cognitive ability (multi-trait analysis);
LUSC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg13047869	chr3:10149882	C3orf24	0.62	8.87	0.44	4.43e-17	Alzheimer's disease;
LUSC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.82	13.25	0.59	1.67e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4363385	0.693	rs76987906	chr1:152964530	A/G	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.34	-0.37	1.62e-12	Inflammatory skin disease;
LUSC	trans	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg24675658	chr1:53192096	ZYG11B	-0.62	-9.53	-0.46	3.4e-19	Monocyte count;
LUSC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg07777115	chr5:623756	CEP72	-0.45	-5.77	-0.3	1.79e-8	Obesity-related traits;
LUSC	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.87	-12.82	-0.57	7e-31	Asthma;
LUSC	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.84	-15.93	-0.66	6.45e-43	Heart rate;
LUSC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg15448220	chr1:150897856	SETDB1	0.44	6.36	0.33	6.63e-10	Melanoma;
LUSC	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg01028140	chr2:1542097	TPO	-0.4	-6.17	-0.32	1.95e-9	IgG glycosylation;
LUSC	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg03676636	chr4:99064102	C4orf37	0.36	7.99	0.4	2.18e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-10.37	-0.49	5.05e-22	Body mass index (adult);
LUSC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg10556349	chr10:835070	NA	0.57	6.4	0.33	5.2e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.64	-10.7	-0.51	3.46e-23	Lung cancer;
LUSC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.71	12.2	0.56	1.4e-28	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg24596788	chr1:163392923	NA	0.43	7.23	0.37	3.29e-12	Motion sickness;
LUSC	cis	rs12541635	0.707	rs2099150	chr8:107109408	A/T	cg10147462	chr8:107024639	NA	-0.41	-7.14	-0.36	5.97e-12	Age of smoking initiation;
LUSC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.83	-0.54	3.32e-27	Chronic sinus infection;
LUSC	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg03585969	chr10:35415529	CREM	0.64	9.48	0.46	5.01e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3847687	1.000	rs78233646	chr12:131520170	G/T	cg25772418	chr12:131519998	GPR133	-0.28	-6.09	-0.32	3.04e-9	Longevity;
LUSC	cis	rs983392	0.805	rs7926344	chr11:59962166	G/A	cg24026212	chr11:59952134	MS4A6A	-0.37	-6.27	-0.32	1.1e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.72	-16.65	-0.67	9.91e-46	Prostate cancer;
LUSC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	0.93	18.35	0.71	1.61e-52	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9473147	0.543	rs9349407	chr6:47453378	C/G	cg02130027	chr6:47444894	CD2AP	0.36	5.69	0.3	2.78e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.66	-10.94	-0.51	5.26e-24	Longevity;Endometriosis;
LUSC	cis	rs6580649	0.941	rs17122611	chr12:48458149	C/T	cg24011408	chr12:48396354	COL2A1	-0.45	-6.07	-0.32	3.47e-9	Lung cancer;
LUSC	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg18478394	chr8:109455254	TTC35	0.41	6.28	0.32	1.06e-9	Dupuytren's disease;
LUSC	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg12140854	chr5:148520817	ABLIM3	0.35	5.74	0.3	2.16e-8	Breast cancer;
LUSC	trans	rs12637928	0.560	rs4682579	chr3:110153261	G/T	cg17371621	chr15:61264283	RORA	0.36	6.13	0.32	2.51e-9	Neuroticism;
LUSC	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	7.28	0.37	2.47e-12	Retinal vascular caliber;
LUSC	cis	rs662064	0.925	rs669701	chr1:10544725	A/G	cg20482658	chr1:10539492	PEX14	-0.3	-6.33	-0.33	8.09e-10	Asthma;
LUSC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-6.89	-0.35	2.72e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs259282	0.524	rs4805006	chr19:33124136	G/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.79	12.73	0.57	1.6e-30	Schizophrenia;
LUSC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-9.77	-0.47	5.39e-20	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11764359	chr7:65958608	NA	-0.69	-11.09	-0.52	1.5e-24	Aortic root size;
LUSC	cis	rs240764	0.782	rs239235	chr6:101100528	A/G	cg09795085	chr6:101329169	ASCC3	0.42	6.09	0.32	3.09e-9	Neuroticism;
LUSC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg14019146	chr3:50243930	SLC38A3	-0.36	-8.03	-0.4	1.74e-14	Body mass index;
LUSC	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg13390004	chr1:15929781	NA	0.41	6.74	0.35	7.15e-11	Systolic blood pressure;
LUSC	cis	rs3741151	0.686	rs12288753	chr11:73136261	A/T	cg17517138	chr11:73019481	ARHGEF17	0.81	7.52	0.38	5.05e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg16624210	chr5:671434	TPPP	0.5	6.47	0.33	3.58e-10	Obesity-related traits;
LUSC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg11645453	chr3:52864694	ITIH4	0.35	8.21	0.41	4.87e-15	Bipolar disorder;
LUSC	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg13813247	chr22:41461852	NA	0.37	6.81	0.35	4.57e-11	Neuroticism;
LUSC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg01879757	chr17:41196368	BRCA1	-0.49	-7.72	-0.39	1.37e-13	Menopause (age at onset);
LUSC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18595196	chr3:52726726	GNL3;SNORD69	-0.29	-5.73	-0.3	2.2e-8	Bipolar disorder;
LUSC	cis	rs7202877	0.572	rs8051611	chr16:75388933	C/T	cg03315344	chr16:75512273	CHST6	0.45	6.63	0.34	1.32e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	trans	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-6.87	-0.35	3.22e-11	Menarche (age at onset);
LUSC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg03790207	chr6:42947109	PEX6	-0.45	-6.74	-0.35	6.84e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg11845111	chr2:191398756	TMEM194B	-0.88	-11.24	-0.52	4.35e-25	Diastolic blood pressure;
LUSC	cis	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg06521331	chr12:34319734	NA	-0.38	-6.38	-0.33	6.01e-10	Morning vs. evening chronotype;
LUSC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.44	-7.33	-0.37	1.77e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1005224	0.520	rs6574249	chr14:76087152	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.48	-5.92	-0.31	7.89e-9	Large artery stroke;
LUSC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg14582100	chr15:45693742	SPATA5L1	0.58	10.56	0.5	1.11e-22	Homoarginine levels;
LUSC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	9.61	0.47	1.78e-19	Height;
LUSC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg05564831	chr3:52568323	NT5DC2	0.33	5.78	0.3	1.68e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs708547	0.697	rs67479587	chr4:57878884	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	7.64	0.39	2.31e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs62400317	0.762	rs62436369	chr6:44867539	C/G	cg20913747	chr6:44695427	NA	-0.48	-7.44	-0.38	8.79e-13	Total body bone mineral density;
LUSC	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg17252645	chr8:143867129	LY6D	0.38	6.62	0.34	1.45e-10	Urinary tract infection frequency;
LUSC	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg19052272	chr2:3704530	ALLC	-0.36	-6.82	-0.35	4.28e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg22333733	chr11:31391482	DNAJC24;DCDC1	0.48	6.85	0.35	3.63e-11	Calcium levels;
LUSC	cis	rs9905704	0.681	rs8081247	chr17:56557837	G/A	cg19466818	chr17:56409534	MIR142	0.35	6.3	0.33	9.47e-10	Testicular germ cell tumor;
LUSC	cis	rs72634258	0.554	rs4908705	chr1:7926401	C/T	cg00042356	chr1:8021962	PARK7	0.65	8.04	0.4	1.62e-14	Inflammatory bowel disease;
LUSC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg17462356	chr17:80056334	FASN	0.46	6.23	0.32	1.41e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.74	-11.17	-0.52	7.82e-25	Menarche (age at onset);
LUSC	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.01	-0.31	4.98e-9	Triglycerides;
LUSC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg23034840	chr1:205782522	SLC41A1	0.62	8.81	0.43	6.94e-17	Menarche (age at onset);
LUSC	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	0.59	9.35	0.46	1.26e-18	Breast cancer;
LUSC	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg08000102	chr2:233561755	GIGYF2	0.7	11.67	0.54	1.21e-26	Coronary artery disease;
LUSC	cis	rs6681460	1.000	rs6670378	chr1:67126585	C/T	cg02459107	chr1:67143332	SGIP1	0.48	9.02	0.44	1.49e-17	Presence of antiphospholipid antibodies;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17144760	chr11:27384507	CCDC34	0.51	7.41	0.38	1.01e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg08132940	chr7:1081526	C7orf50	-0.52	-6.27	-0.32	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-8.11	-0.41	9.97e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11229555	0.645	rs10466659	chr11:58190112	A/G	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg22029157	chr1:209979665	IRF6	-0.54	-6.37	-0.33	6.17e-10	Coronary artery disease;
LUSC	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg09904177	chr6:26538194	HMGN4	-0.63	-6.27	-0.32	1.1e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg14791747	chr16:20752902	THUMPD1	-0.7	-7.31	-0.37	2e-12	Cognitive test performance;
LUSC	cis	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg09307838	chr4:120376055	NA	-0.46	-7.02	-0.36	1.27e-11	Diastolic blood pressure;
LUSC	trans	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	9.19	0.45	4.34e-18	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs722599	0.639	rs12882676	chr14:75272433	A/G	cg06637938	chr14:75390232	RPS6KL1	0.4	5.67	0.3	3.17e-8	IgG glycosylation;
LUSC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	1.05	19.18	0.72	8.03e-56	Parkinson's disease;
LUSC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg08508325	chr11:3079039	CARS	0.5	13.05	0.58	9.38e-32	Longevity;
LUSC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg24060327	chr5:131705240	SLC22A5	-0.52	-8.62	-0.43	2.72e-16	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02674562	chr19:17837854	MAP1S	0.45	6.13	0.32	2.52e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4566357	0.787	rs12475134	chr2:227880511	C/T	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.1	-0.36	7.77e-12	Coronary artery disease;
LUSC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg19077165	chr18:44547161	KATNAL2	0.44	6.54	0.34	2.25e-10	Personality dimensions;
LUSC	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg05729581	chr11:3078854	CARS	0.4	5.92	0.31	7.83e-9	Calcium levels;
LUSC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.46	-0.38	7.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6464929	0.956	rs10272564	chr7:148705490	G/A	cg23583168	chr7:148888333	NA	0.47	5.99	0.31	5.41e-9	Pediatric bone mineral content (hip);
LUSC	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg15704280	chr7:45808275	SEPT13	0.73	8.26	0.41	3.44e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg14440974	chr22:39074834	NA	-0.35	-5.84	-0.3	1.23e-8	Menopause (age at onset);
LUSC	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg27432699	chr2:27873401	GPN1	-0.59	-8.88	-0.44	4.11e-17	Total body bone mineral density;
LUSC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg23985595	chr17:80112537	CCDC57	-0.3	-5.81	-0.3	1.45e-8	Life satisfaction;
LUSC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.49	-9.69	-0.47	9.78e-20	Monocyte percentage of white cells;
LUSC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.9	16.94	0.68	6.93e-47	Menarche (age at onset);
LUSC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.23	0.49	1.46e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg26116260	chr4:7069785	GRPEL1	1.15	18.04	0.7	2.86e-51	Monocyte percentage of white cells;
LUSC	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg05163923	chr11:71159392	DHCR7	-0.69	-10.51	-0.5	1.61e-22	Vitamin D levels;
LUSC	trans	rs4773505	0.839	rs2882189	chr13:90380864	A/T	cg07142010	chr1:21901166	ALPL	-0.3	-6.0	-0.31	5.2e-9	Loneliness (multivariate analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10181911	chr2:210867059	RPE	0.43	5.98	0.31	5.82e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg26380479	chr7:97908229	NA	-0.27	-6.06	-0.31	3.67e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg18681998	chr4:17616180	MED28	0.83	15.08	0.64	1.46e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2235649	0.703	rs2076428	chr16:1817768	T/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.49	6.33	0.33	7.7e-10	Blood metabolite levels;
LUSC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-0.99	-17.72	-0.7	5.35e-50	Coronary artery disease;
LUSC	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg24375607	chr4:120327624	NA	0.79	11.87	0.54	2.34e-27	Corneal astigmatism;
LUSC	cis	rs2820315	0.867	rs2819349	chr1:201885026	C/T	cg10061532	chr1:201886748	LMOD1	0.28	6.41	0.33	5.09e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	9.4	0.46	8.73e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg06562184	chr8:19319451	CSGALNACT1	-0.5	-8.37	-0.42	1.57e-15	Oropharynx cancer;
LUSC	trans	rs12651329	1.000	rs12651329	chr4:36079594	A/G	cg21087160	chr19:2269166	OAZ1	-0.37	-6.01	-0.31	4.75e-9	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg04756594	chr16:24857601	SLC5A11	-0.37	-6.19	-0.32	1.81e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.61	9.47	0.46	5.23e-19	Response to antineoplastic agents;
LUSC	cis	rs10465746	0.746	rs12749350	chr1:84456948	T/A	cg10977910	chr1:84465055	TTLL7	0.43	6.28	0.32	1.08e-9	Obesity-related traits;
LUSC	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg05738196	chr6:26577821	NA	0.81	15.89	0.66	9.79e-43	Intelligence (multi-trait analysis);
LUSC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.05	-24.22	-0.8	1.54e-75	IgG glycosylation;
LUSC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg21724239	chr8:58056113	NA	0.59	6.76	0.35	6.05e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs11030122	0.702	rs17279635	chr11:3973083	A/C	cg08557956	chr11:4115526	RRM1	0.47	6.04	0.31	4e-9	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg10756647	chr7:56101905	PSPH	-0.84	-8.42	-0.42	1.14e-15	Diabetic kidney disease;
LUSC	cis	rs713477	1.000	rs28478984	chr14:55911326	C/A	cg13175173	chr14:55914753	NA	-0.32	-6.74	-0.35	7.01e-11	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.54	0.53	3.8e-26	Mean corpuscular volume;
LUSC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg25258033	chr6:167368657	RNASET2	-0.45	-7.42	-0.38	9.84e-13	Crohn's disease;
LUSC	cis	rs35995292	1.000	rs10266891	chr7:38914805	A/G	cg19327137	chr7:38886074	VPS41	0.34	5.71	0.3	2.47e-8	Subjective well-being (multi-trait analysis);
LUSC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg19592336	chr6:28129416	ZNF389	0.46	6.14	0.32	2.37e-9	Depression;
LUSC	cis	rs8016982	1.000	rs12147118	chr14:81652975	A/C	cg01989461	chr14:81687754	GTF2A1	-0.6	-9.16	-0.45	5.47e-18	Schizophrenia;
LUSC	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg17757837	chr7:157058334	UBE3C	-0.82	-13.31	-0.59	1.01e-32	Body mass index;
LUSC	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg08017756	chr2:100939284	LONRF2	-0.45	-8.44	-0.42	9.64e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-10.52	-0.5	1.46e-22	Gut microbiome composition (summer);
LUSC	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-7.14	-0.36	5.83e-12	HDL cholesterol;
LUSC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.26e-12	Aortic root size;
LUSC	trans	rs9886428	1.000	rs2059671	chr8:14116229	C/G	cg19037007	chr20:741798	C20orf54	-0.39	-6.11	-0.32	2.77e-9	IgG glycosylation;
LUSC	cis	rs4851254	0.618	rs7596359	chr2:100665274	T/G	cg07810366	chr2:100720526	AFF3	-0.45	-5.95	-0.31	6.68e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg17168535	chr8:21777572	XPO7	0.86	15.77	0.65	3.01e-42	Mean corpuscular volume;
LUSC	cis	rs12594515	1.000	rs57299255	chr15:45996532	C/A	cg19682013	chr15:45996608	NA	0.39	5.79	0.3	1.67e-8	Waist circumference;Weight;
LUSC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg05347473	chr6:146136440	FBXO30	0.43	7.47	0.38	6.89e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs377070	0.816	rs309404	chr4:123617741	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.4	-5.98	-0.31	5.86e-9	Mosquito bite size;
LUSC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23158103	chr7:148848205	ZNF398	-0.5	-8.21	-0.41	5.03e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs981844	0.922	rs75543972	chr4:154664792	G/C	cg14289246	chr4:154710475	SFRP2	0.46	5.72	0.3	2.41e-8	Response to statins (LDL cholesterol change);
LUSC	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.24	0.32	1.32e-9	Corneal astigmatism;
LUSC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg08470875	chr2:26401718	FAM59B	-0.65	-8.92	-0.44	3.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs7605827	0.897	rs7590963	chr2:15527888	T/C	cg19274914	chr2:15703543	NA	0.45	8.78	0.43	8.59e-17	Educational attainment (years of education);
LUSC	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg25173405	chr17:45401733	C17orf57	0.37	5.89	0.31	9.67e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-6.77	-0.35	5.91e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6977660	0.660	rs28663574	chr7:19816905	G/A	cg05791153	chr7:19748676	TWISTNB	0.68	7.22	0.37	3.49e-12	Thyroid stimulating hormone;
LUSC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg15445000	chr17:37608096	MED1	0.4	6.95	0.36	1.93e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg05855489	chr10:104503620	C10orf26	0.47	7.24	0.37	3.07e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg14092571	chr14:90743983	NA	0.37	5.93	0.31	7.72e-9	Mortality in heart failure;
LUSC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg11843238	chr5:131593191	PDLIM4	0.39	6.56	0.34	2.05e-10	Breast cancer;
LUSC	cis	rs9487051	0.735	rs1260596	chr6:109519847	T/C	cg01475377	chr6:109611718	NA	-0.36	-6.11	-0.32	2.7e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg17691542	chr6:26056736	HIST1H1C	0.53	7.38	0.37	1.26e-12	Iron status biomarkers;
LUSC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg12927641	chr6:109611667	NA	-0.43	-7.58	-0.38	3.46e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg12292205	chr6:26970375	C6orf41	-0.63	-7.57	-0.38	3.72e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg06454157	chr6:167490870	NA	-0.24	-5.94	-0.31	7.24e-9	Crohn's disease;
LUSC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg18512352	chr11:47633146	NA	0.48	9.71	0.47	8.44e-20	Subjective well-being;
LUSC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg23985595	chr17:80112537	CCDC57	-0.3	-5.75	-0.3	2.05e-8	Life satisfaction;
LUSC	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-7.02	-0.36	1.25e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg04414720	chr1:150670196	GOLPH3L	0.53	8.47	0.42	7.75e-16	Tonsillectomy;
LUSC	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg01884057	chr2:25150051	NA	0.44	10.16	0.49	2.67e-21	Body mass index;
LUSC	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg22029157	chr1:209979665	IRF6	0.81	10.42	0.5	3.33e-22	Cleft lip with or without cleft palate;
LUSC	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg09754948	chr16:28834200	ATXN2L	0.42	6.11	0.32	2.78e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg12826209	chr6:26865740	GUSBL1	0.74	6.4	0.33	5.23e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.79	13.95	0.61	3.62e-35	Monocyte count;
LUSC	cis	rs6977940	0.818	rs73033488	chr7:2908343	A/G	cg19731401	chr7:2775893	GNA12	0.55	6.4	0.33	5.17e-10	White matter integrity;
LUSC	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg18825076	chr15:78729989	IREB2	-0.45	-6.29	-0.33	9.84e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg04586622	chr2:25135609	ADCY3	0.43	9.07	0.44	1.01e-17	Body mass index;
LUSC	cis	rs12541635	0.934	rs62527361	chr8:107021574	T/A	cg10147462	chr8:107024639	NA	0.55	9.8	0.47	4.39e-20	Age of smoking initiation;
LUSC	cis	rs9790314	0.690	rs1903423	chr3:160842252	A/G	cg03342759	chr3:160939853	NMD3	-0.42	-6.85	-0.35	3.55e-11	Morning vs. evening chronotype;
LUSC	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg06740227	chr12:86229804	RASSF9	0.38	6.06	0.31	3.64e-9	Major depressive disorder;
LUSC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.6	-0.38	3.11e-13	Longevity;Endometriosis;
LUSC	cis	rs2406342	0.511	rs472676	chr18:74607924	C/T	cg16472389	chr18:74514291	NA	0.46	6.84	0.35	3.78e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LUSC	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg23029597	chr12:123009494	RSRC2	-0.75	-9.47	-0.46	5.19e-19	Body mass index;
LUSC	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.7	10.6	0.5	8.3e-23	Corneal astigmatism;
LUSC	cis	rs9925964	0.967	rs4889620	chr16:31131174	G/A	cg02466173	chr16:30829666	NA	0.34	6.16	0.32	2.05e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4443100	0.916	rs8139695	chr22:23373902	A/T	cg21100191	chr22:23484243	RTDR1	-0.51	-6.19	-0.32	1.73e-9	Serum parathyroid hormone levels;
LUSC	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	0.6	9.65	0.47	1.34e-19	Breast cancer;
LUSC	trans	rs72674100	1.000	rs4308366	chr4:97972932	G/C	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg00677455	chr12:58241039	CTDSP2	-0.58	-7.87	-0.4	4.92e-14	Multiple sclerosis;
LUSC	trans	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.6	0.38	3.08e-13	Ulcerative colitis;
LUSC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg09034736	chr1:150693464	HORMAD1	0.49	7.11	0.36	7.05e-12	Melanoma;
LUSC	cis	rs6460942	0.908	rs78374554	chr7:12242285	G/A	cg06484146	chr7:12443880	VWDE	-0.59	-5.73	-0.3	2.25e-8	Coronary artery disease;
LUSC	trans	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg27411982	chr8:10470053	RP1L1	0.41	6.49	0.33	3.11e-10	Mood instability;
LUSC	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-17.62	-0.69	1.39e-49	Exhaled nitric oxide output;
LUSC	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg22705602	chr4:152727874	NA	-0.39	-8.31	-0.41	2.49e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg22834771	chr12:69754056	YEATS4	-0.54	-8.08	-0.4	1.23e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg03585969	chr10:35415529	CREM	0.64	9.55	0.46	2.91e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.86	-0.31	1.14e-8	Vitiligo;
LUSC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.85	0.3	1.18e-8	Breast cancer;
LUSC	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg13514129	chr1:39547527	MACF1	-0.71	-11.89	-0.55	1.99e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs4478858	0.735	rs12563669	chr1:31858067	A/G	cg00250761	chr1:31883323	NA	-0.31	-7.17	-0.37	4.9e-12	Alcohol dependence;
LUSC	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg20307385	chr11:47447363	PSMC3	0.44	6.46	0.33	3.71e-10	Subjective well-being;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06936779	chr1:151171405	PIP5K1A	-0.5	-6.44	-0.33	4.08e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1395	0.778	rs62128743	chr2:27390169	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.49	7.2	0.37	4.12e-12	Blood metabolite levels;
LUSC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.46	6.19	0.32	1.81e-9	Renal function-related traits (BUN);
LUSC	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg23649088	chr2:200775458	C2orf69	0.55	7.68	0.39	1.74e-13	Schizophrenia;
LUSC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg16383222	chr8:145688536	CYHR1	0.33	5.75	0.3	2.06e-8	Age at first birth;
LUSC	cis	rs7945718	0.934	rs11022478	chr11:12741104	T/C	cg25843174	chr11:12811716	TEAD1	0.31	6.89	0.35	2.79e-11	Educational attainment (years of education);
LUSC	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg00042356	chr1:8021962	PARK7	0.77	9.26	0.45	2.61e-18	Inflammatory bowel disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15504408	chr10:120101904	C10orf84	0.41	5.95	0.31	6.6e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg11244672	chr19:19639970	YJEFN3	-0.61	-7.59	-0.38	3.3e-13	Bipolar disorder;
LUSC	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg07936489	chr17:37558343	FBXL20	0.72	9.94	0.48	1.47e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg20573242	chr4:122745356	CCNA2	0.65	9.5	0.46	4.14e-19	Type 2 diabetes;
LUSC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg11663144	chr21:46675770	NA	-0.4	-6.85	-0.35	3.59e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg25838465	chr1:92012736	NA	-0.56	-10.12	-0.48	3.62e-21	Breast cancer;
LUSC	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	6.39	0.33	5.53e-10	Rheumatoid arthritis;
LUSC	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg15073853	chr19:18549131	ISYNA1	-0.31	-5.76	-0.3	1.96e-8	Breast cancer;
LUSC	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.75	0.35	6.47e-11	Tonsillectomy;
LUSC	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg06606381	chr12:133084897	FBRSL1	-0.92	-8.75	-0.43	1.06e-16	Depression;
LUSC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14442939	chr10:27389572	ANKRD26	0.85	9.88	0.48	2.24e-20	Breast cancer;
LUSC	cis	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg23942311	chr14:51606299	NA	0.47	10.33	0.49	6.89e-22	Cancer;
LUSC	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg23173402	chr1:227635558	NA	0.58	7.0	0.36	1.45e-11	Major depressive disorder;
LUSC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg25036284	chr2:26402008	FAM59B	0.72	9.54	0.46	3.19e-19	Gut microbiome composition (summer);
LUSC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg25258033	chr6:167368657	RNASET2	0.45	6.9	0.35	2.57e-11	Crohn's disease;
LUSC	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg03806693	chr22:41940476	POLR3H	-0.91	-12.72	-0.57	1.7e-30	Vitiligo;
LUSC	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg20283391	chr11:68216788	NA	-0.61	-8.55	-0.42	4.43e-16	Total body bone mineral density;
LUSC	cis	rs9900062	1.000	rs11871616	chr17:62737602	C/T	cg02598441	chr17:62777298	LOC146880	-0.7	-8.65	-0.43	2.17e-16	QT interval;
LUSC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	0.73	13.09	0.58	7.01e-32	Methadone dose in opioid dependence;
LUSC	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg25922239	chr6:33757077	LEMD2	0.42	6.23	0.32	1.43e-9	Crohn's disease;
LUSC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg05084668	chr3:125655381	ALG1L	-0.51	-7.19	-0.37	4.35e-12	Blood pressure (smoking interaction);
LUSC	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg23649088	chr2:200775458	C2orf69	0.53	7.36	0.37	1.46e-12	Schizophrenia;
LUSC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-9.83	-0.47	3.34e-20	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg12856521	chr11:46389249	DGKZ	0.44	6.9	0.35	2.62e-11	Leprosy;
LUSC	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg13206674	chr6:150067644	NUP43	0.55	8.04	0.4	1.57e-14	Lung cancer;
LUSC	trans	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg14791747	chr16:20752902	THUMPD1	-0.45	-6.55	-0.34	2.15e-10	Pancreatic cancer;
LUSC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg10130564	chr11:117069849	TAGLN	0.37	6.31	0.33	8.86e-10	Blood protein levels;
LUSC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg25019033	chr10:957182	NA	-0.54	-6.87	-0.35	3.15e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg17340268	chr14:105411764	AHNAK2	-0.39	-6.3	-0.33	9.59e-10	Rheumatoid arthritis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18247054	chr6:167369941	RNASET2	-0.41	-6.07	-0.32	3.42e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00149659	chr3:10157352	C3orf10	0.89	12.15	0.55	2.18e-28	Alzheimer's disease;
LUSC	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg00405596	chr8:11794950	NA	0.36	5.98	0.31	5.72e-9	Myopia (pathological);
LUSC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg18827107	chr12:86230957	RASSF9	-0.47	-7.06	-0.36	9.99e-12	Major depressive disorder;
LUSC	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg18825076	chr15:78729989	IREB2	0.48	6.37	0.33	6.17e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg01475377	chr6:109611718	NA	-0.42	-7.38	-0.37	1.27e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs7336332	0.628	rs9581854	chr13:28017782	C/T	cg22138327	chr13:27999177	GTF3A	0.77	9.83	0.47	3.36e-20	Weight;
LUSC	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg11502198	chr6:26597334	ABT1	0.73	12.23	0.56	1.17e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25072359	chr17:41440525	NA	0.6	9.0	0.44	1.76e-17	Menopause (age at onset);
LUSC	cis	rs793571	0.521	rs12594872	chr15:58912749	T/C	cg05156742	chr15:59063176	FAM63B	0.46	6.96	0.36	1.86e-11	Schizophrenia;
LUSC	cis	rs34115320	1	rs34115320	chr7:148783936	CT/C	cg23583168	chr7:148888333	NA	-0.8	-13.54	-0.6	1.3e-33	Sum basophil neutrophil counts;Neutrophil count;
LUSC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	ch.11.42038R	chr11:967971	AP2A2	0.54	8.2	0.41	5.14e-15	Alzheimer's disease (late onset);
LUSC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg03146154	chr1:46216737	IPP	0.51	7.27	0.37	2.61e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.07	0.4	1.27e-14	Axial length;
LUSC	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg07856975	chr6:36356162	ETV7	0.34	6.21	0.32	1.61e-9	Platelet distribution width;
LUSC	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg02574844	chr11:5959923	NA	-0.44	-6.02	-0.31	4.71e-9	DNA methylation (variation);
LUSC	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.55	0.5	1.21e-22	Hypertriglyceridemia;
LUSC	cis	rs3087591	1.000	rs2854332	chr17:29712378	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.65	-9.45	-0.46	6.23e-19	Hip circumference;
LUSC	trans	rs10432489	0.708	rs6730421	chr2:181755815	A/G	cg09897338	chr1:211849090	NEK2	-0.77	-5.97	-0.31	6.21e-9	QT interval;
LUSC	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg24634471	chr8:143751801	JRK	0.53	7.36	0.37	1.46e-12	Schizophrenia;
LUSC	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg25456477	chr12:86230367	RASSF9	0.33	5.78	0.3	1.68e-8	Major depressive disorder;
LUSC	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.71	10.73	0.51	2.88e-23	Corneal astigmatism;
LUSC	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg27284194	chr4:1044797	NA	-0.35	-5.68	-0.3	2.93e-8	Obesity-related traits;
LUSC	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg12935359	chr14:103987150	CKB	-0.5	-7.75	-0.39	1.1e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6543140	0.927	rs917999	chr2:103067869	G/A	cg09003973	chr2:102972529	NA	0.51	6.61	0.34	1.53e-10	Blood protein levels;
LUSC	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg19875535	chr5:140030758	IK	0.46	7.38	0.37	1.31e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-6.37	-0.33	6.44e-10	Reticulocyte count;
LUSC	cis	rs2742234	0.955	rs2503865	chr10:43659536	C/T	cg02780029	chr10:43622663	RET	-0.35	-6.69	-0.34	9.32e-11	Hirschsprung disease;
LUSC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg03146154	chr1:46216737	IPP	0.52	7.79	0.39	8.3e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg20935933	chr6:143382018	AIG1	0.5	7.32	0.37	1.92e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.33	-0.37	1.74e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.0	-0.36	1.41e-11	Blood metabolite levels;
LUSC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg18827107	chr12:86230957	RASSF9	-0.48	-6.96	-0.36	1.84e-11	Major depressive disorder;
LUSC	cis	rs6714788	0.503	rs2309748	chr2:100681449	A/T	cg22139774	chr2:100720529	AFF3	-0.39	-6.21	-0.32	1.61e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg04155289	chr7:94953770	PON1	-0.34	-5.75	-0.3	2.01e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs9463078	0.683	rs1342640	chr6:44743516	T/C	cg25276700	chr6:44698697	NA	0.32	6.29	0.33	9.73e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18876405	chr7:65276391	NA	-0.55	-8.76	-0.43	9.78e-17	Aortic root size;
LUSC	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg06092702	chr1:163392909	NA	-0.47	-7.82	-0.39	7.14e-14	Motion sickness;
LUSC	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg11244672	chr19:19639970	YJEFN3	-0.6	-7.18	-0.37	4.52e-12	Bipolar disorder;
LUSC	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg07828340	chr4:882639	GAK	1.0	10.76	0.51	2.16e-23	Intelligence (multi-trait analysis);
LUSC	trans	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.63	0.54	1.7e-26	Mean corpuscular volume;
LUSC	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.12	-0.32	2.64e-9	Bipolar disorder;
LUSC	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg26441486	chr22:50317300	CRELD2	-0.53	-8.01	-0.4	1.93e-14	Schizophrenia;
LUSC	cis	rs662064	0.755	rs6667629	chr1:10524467	T/C	cg20482658	chr1:10539492	PEX14	0.31	5.73	0.3	2.26e-8	Asthma;
LUSC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg20607798	chr8:58055168	NA	0.52	5.72	0.3	2.41e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg17366294	chr4:99064904	C4orf37	0.57	9.9	0.48	2.03e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	0.79	13.88	0.6	6.93e-35	Cognitive function;
LUSC	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg18132916	chr6:79620363	NA	-0.39	-6.02	-0.31	4.68e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9650657	0.683	rs7005905	chr8:10585144	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.48	0.33	3.22e-10	Neuroticism;
LUSC	cis	rs2074977	0.550	rs11085020	chr19:3446107	C/T	cg08380311	chr19:3435252	NFIC	-0.65	-10.64	-0.5	5.79e-23	Height;
LUSC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg27532560	chr4:187881888	NA	-0.39	-6.41	-0.33	5.1e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.89	0.31	9.57e-9	Menopause (age at onset);
LUSC	cis	rs9648716	0.515	rs1009772	chr7:140428000	A/G	cg23214464	chr7:140373596	ADCK2	0.74	6.15	0.32	2.18e-9	Type 2 diabetes;
LUSC	cis	rs11039100	0.607	rs2047462	chr11:5783948	C/A	cg05234568	chr11:5960015	NA	-0.43	-5.65	-0.3	3.38e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg24130564	chr14:104152367	KLC1	0.46	6.85	0.35	3.51e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10843647	1.000	rs7300499	chr12:30323196	G/T	cg12718339	chr12:29936407	TMTC1	-0.35	-5.77	-0.3	1.77e-8	Glucose homeostasis traits;
LUSC	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg18180107	chr4:99064573	C4orf37	0.42	5.77	0.3	1.77e-8	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg25809561	chr17:30822961	MYO1D	-0.44	-7.39	-0.37	1.22e-12	Schizophrenia;
LUSC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.45	6.13	0.32	2.53e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4588572	0.537	rs7719228	chr5:77730576	G/A	cg11547950	chr5:77652471	NA	-0.48	-7.19	-0.37	4.18e-12	Triglycerides;
LUSC	cis	rs9905704	0.836	rs170024	chr17:56831887	T/C	cg12560992	chr17:57184187	TRIM37	0.58	8.32	0.41	2.29e-15	Testicular germ cell tumor;
LUSC	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg01629716	chr15:45996671	NA	0.4	5.96	0.31	6.25e-9	Waist circumference;Weight;
LUSC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg10792982	chr14:105748885	BRF1	0.48	8.68	0.43	1.75e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2562456	0.833	rs8106025	chr19:21634724	A/C	cg00806126	chr19:22604979	ZNF98	0.38	5.92	0.31	8.02e-9	Pain;
LUSC	cis	rs6688613	0.685	rs10800276	chr1:166858941	A/G	cg07049167	chr1:166818506	POGK	-0.42	-6.31	-0.33	8.92e-10	Refractive astigmatism;
LUSC	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg14440974	chr22:39074834	NA	-0.36	-5.91	-0.31	8.35e-9	Menopause (age at onset);
LUSC	cis	rs11039100	0.850	rs11039117	chr11:5832464	G/A	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg23173402	chr1:227635558	NA	0.69	7.6	0.38	2.96e-13	Major depressive disorder;
LUSC	cis	rs2274273	1.000	rs1047556	chr14:55600282	A/T	cg04306507	chr14:55594613	LGALS3	0.53	11.37	0.53	1.48e-25	Protein biomarker;
LUSC	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.47	-10.44	-0.5	2.96e-22	Airflow obstruction;
LUSC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg06145435	chr7:1022769	CYP2W1	0.29	6.38	0.33	5.99e-10	Longevity;Endometriosis;
LUSC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.38	-0.33	5.89e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6906287	0.573	rs12198461	chr6:118880640	T/G	cg21191810	chr6:118973309	C6orf204	0.33	6.05	0.31	3.83e-9	Electrocardiographic conduction measures;
LUSC	cis	rs35995292	0.963	rs2893567	chr7:38902934	A/G	cg19327137	chr7:38886074	VPS41	0.34	5.79	0.3	1.66e-8	Subjective well-being (multi-trait analysis);
LUSC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg15147215	chr3:52552868	STAB1	-0.32	-6.33	-0.33	7.76e-10	Electroencephalogram traits;
LUSC	cis	rs617219	0.746	rs7724909	chr5:78559632	T/C	cg24856658	chr5:78533917	JMY	-0.31	-6.04	-0.31	4.22e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.13e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9925964	0.900	rs9934438	chr16:31104878	G/A	cg02466173	chr16:30829666	NA	0.35	6.32	0.33	8.39e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4604732	0.588	rs4925551	chr1:247631724	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.45	6.87	0.35	3.13e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs422421	1.000	rs434434	chr5:176516953	A/G	cg00618323	chr5:176515533	FGFR4	0.36	5.97	0.31	6.03e-9	Height;
LUSC	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg13010199	chr12:38710504	ALG10B	0.55	8.48	0.42	7.46e-16	Morning vs. evening chronotype;
LUSC	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg06552810	chr11:31128660	NA	-0.4	-7.09	-0.36	8.26e-12	Red blood cell count;
LUSC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg01125463	chr6:42946178	PEX6	-0.36	-6.02	-0.31	4.59e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	9.22	0.45	3.51e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg26677194	chr12:130822605	PIWIL1	0.59	8.79	0.43	7.91e-17	Menopause (age at onset);
LUSC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg17507749	chr15:85114479	UBE2QP1	0.68	8.55	0.42	4.36e-16	Schizophrenia;
LUSC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.01	0.31	4.93e-9	Personality dimensions;
LUSC	cis	rs9463078	0.845	rs6458419	chr6:45085038	T/C	cg25276700	chr6:44698697	NA	-0.28	-5.67	-0.3	3.04e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.43	-0.56	1.99e-29	Chronic sinus infection;
LUSC	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg12386194	chr3:101231763	SENP7	0.63	8.59	0.43	3.44e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12618769	1.000	rs72825727	chr2:99252750	G/C	cg10123293	chr2:99228465	UNC50	0.43	5.93	0.31	7.49e-9	Bipolar disorder;
LUSC	cis	rs2236918	1.000	rs2526704	chr1:242015820	A/G	cg17736920	chr1:242011382	EXO1	0.44	6.82	0.35	4.24e-11	Menopause (age at onset);
LUSC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg19592336	chr6:28129416	ZNF389	0.48	6.24	0.32	1.29e-9	Depression;
LUSC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg25767906	chr1:53392781	SCP2	-0.62	-12.18	-0.55	1.78e-28	Monocyte count;
LUSC	cis	rs9549260	0.564	rs4943808	chr13:41293950	C/T	cg21288729	chr13:41239152	FOXO1	0.53	7.92	0.4	3.48e-14	Red blood cell count;
LUSC	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg01448562	chr3:133502909	NA	-0.54	-7.94	-0.4	3.16e-14	Iron status biomarkers;
LUSC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg21141812	chr3:48556323	PFKFB4	0.37	6.22	0.32	1.46e-9	Menarche (age at onset);
LUSC	cis	rs72829446	0.530	rs4796422	chr17:7380004	T/C	cg02795151	chr17:7402630	POLR2A	0.61	7.4	0.38	1.13e-12	Androgen levels;
LUSC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg16524733	chr11:117070046	TAGLN	-0.44	-7.71	-0.39	1.44e-13	Blood protein levels;
LUSC	cis	rs9309473	0.950	rs2947860	chr2:73855386	A/G	cg20560298	chr2:73613845	ALMS1	-0.41	-5.87	-0.31	1.06e-8	Metabolite levels;
LUSC	cis	rs11031096	0.655	rs10835736	chr11:4212013	G/A	cg18678763	chr11:4115507	RRM1	-0.41	-5.72	-0.3	2.32e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg02807482	chr3:125708958	NA	0.48	5.85	0.31	1.15e-8	Blood pressure (smoking interaction);
LUSC	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg00898013	chr13:113819073	PROZ	-0.56	-8.09	-0.4	1.12e-14	Platelet distribution width;
LUSC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24549020	chr5:56110836	MAP3K1	0.49	6.2	0.32	1.64e-9	Initial pursuit acceleration;
LUSC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg15445000	chr17:37608096	MED1	0.4	6.76	0.35	6.29e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21984481	chr17:79567631	NPLOC4	-0.69	-14.08	-0.61	1.09e-35	Eye color traits;
LUSC	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg02175503	chr12:58329896	NA	0.48	6.84	0.35	3.74e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.14	0.41	7.79e-15	Coffee consumption (cups per day);
LUSC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-0.93	-15.59	-0.65	1.53e-41	Body mass index;
LUSC	cis	rs6496667	0.683	rs1869180	chr15:90895467	T/C	cg03599575	chr15:90893182	GABARAPL3	0.35	5.71	0.3	2.46e-8	Rheumatoid arthritis;
LUSC	cis	rs12618769	0.656	rs3820943	chr2:99123177	G/C	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs17253792	0.822	rs17253730	chr14:56157911	A/G	cg01858014	chr14:56050164	KTN1	-0.83	-6.93	-0.35	2.24e-11	Putamen volume;
LUSC	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg09307838	chr4:120376055	NA	0.53	7.92	0.4	3.64e-14	Diastolic blood pressure;
LUSC	trans	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg26043149	chr18:55253948	FECH	-0.45	-6.99	-0.36	1.49e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.26	14.54	0.62	1.94e-37	Gout;
LUSC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg22535103	chr8:58192502	C8orf71	-0.78	-8.33	-0.41	2.18e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg11859384	chr17:80120422	CCDC57	-0.36	-5.65	-0.3	3.35e-8	Life satisfaction;
LUSC	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.9	-0.35	2.69e-11	Response to antipsychotic treatment;
LUSC	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg18132916	chr6:79620363	NA	-0.4	-6.08	-0.32	3.29e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9807989	0.811	rs4485584	chr2:102970750	T/C	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.67e-9	Asthma;
LUSC	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg15848620	chr12:58087721	OS9	-0.54	-7.71	-0.39	1.47e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg18301423	chr5:131593218	PDLIM4	0.43	6.73	0.35	7.46e-11	Blood metabolite levels;
LUSC	cis	rs4704187	0.506	rs3935470	chr5:74352180	A/G	cg03227963	chr5:74354835	NA	0.31	6.99	0.36	1.5e-11	Response to amphetamines;
LUSC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg24733560	chr20:60626293	TAF4	0.41	6.77	0.35	5.69e-11	Body mass index;
LUSC	cis	rs36093844	0.706	rs1445503	chr11:85585011	G/A	cg25872744	chr11:85566296	CCDC83	-0.46	-6.0	-0.31	5.07e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg11663144	chr21:46675770	NA	-0.41	-7.23	-0.37	3.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4343996	0.543	rs2140114	chr7:3407568	C/T	cg21248987	chr7:3385318	SDK1	0.36	6.02	0.31	4.64e-9	Motion sickness;
LUSC	cis	rs7589342	0.839	rs6747023	chr2:106431856	A/G	cg16077055	chr2:106428750	NCK2	0.38	7.2	0.37	4.02e-12	Addiction;
LUSC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg05347473	chr6:146136440	FBXO30	0.54	9.03	0.44	1.44e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11764359	chr7:65958608	NA	-0.58	-8.91	-0.44	3.26e-17	Aortic root size;
LUSC	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.65	-0.3	3.5e-8	Coronary artery disease;
LUSC	cis	rs1775715	0.835	rs12266771	chr10:32231380	G/A	cg04359828	chr10:32216031	ARHGAP12	0.38	6.44	0.33	4.26e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.78	0.35	5.49e-11	Rheumatoid arthritis;
LUSC	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	10.79	0.51	1.7e-23	Coffee consumption (cups per day);
LUSC	cis	rs9925964	0.967	rs1549293	chr16:31141993	C/T	cg02466173	chr16:30829666	NA	0.33	6.06	0.31	3.7e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs193541	0.626	rs6862779	chr5:122087282	C/T	cg19077854	chr5:122220652	SNX24	0.28	6.21	0.32	1.59e-9	Glucose homeostasis traits;
LUSC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg12463550	chr7:65579703	CRCP	-0.46	-6.82	-0.35	4.21e-11	Aortic root size;
LUSC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg09035930	chr12:129282057	SLC15A4	0.67	13.48	0.59	2.31e-33	Systemic lupus erythematosus;
LUSC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg26924012	chr15:45694286	SPATA5L1	1.13	20.89	0.75	1.35e-62	Homoarginine levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23396286	chr10:99258505	UBTD1;MMS19	0.45	6.67	0.34	1.06e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg21226059	chr5:178986404	RUFY1	0.7	13.44	0.59	3.24e-33	Lung cancer;
LUSC	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg09307838	chr4:120376055	NA	0.73	10.22	0.49	1.58e-21	Corneal astigmatism;
LUSC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg17366294	chr4:99064904	C4orf37	0.59	10.64	0.5	5.96e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg11645453	chr3:52864694	ITIH4	0.35	8.13	0.41	8.64e-15	Bipolar disorder;
LUSC	cis	rs7119167	0.901	rs10047442	chr11:73186864	A/T	cg17517138	chr11:73019481	ARHGEF17	0.49	5.81	0.3	1.47e-8	Blood protein levels;
LUSC	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg22906224	chr7:99728672	NA	0.47	6.58	0.34	1.86e-10	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg01879757	chr17:41196368	BRCA1	-0.42	-6.54	-0.34	2.36e-10	Menopause (age at onset);
LUSC	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.43	6.65	0.34	1.18e-10	Dupuytren's disease;
LUSC	cis	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg05299278	chr17:33885742	SLFN14	0.28	6.14	0.32	2.41e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg00779328	chr1:33745989	ZNF362	-0.4	-6.04	-0.31	4.17e-9	N-glycan levels;
LUSC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg12011299	chr4:100065546	ADH4	-0.72	-10.42	-0.5	3.31e-22	Alcohol dependence;
LUSC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.46	0.5	2.43e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg22907277	chr7:1156413	C7orf50	0.6	9.37	0.46	1.14e-18	Longevity;Endometriosis;
LUSC	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg15704280	chr7:45808275	SEPT13	0.73	8.41	0.42	1.21e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.24	0.37	3.09e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg00540400	chr15:79124168	NA	0.46	8.1	0.41	1.06e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg21100191	chr22:23484243	RTDR1	0.91	15.12	0.64	9.94e-40	Bone mineral density;
LUSC	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.71	-0.3	2.47e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg00484396	chr16:3507460	NAT15	-0.48	-7.95	-0.4	2.98e-14	Body mass index (adult);
LUSC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg26304593	chr6:42947056	PEX6	0.52	8.23	0.41	4.24e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs12760731	0.720	rs10913560	chr1:178452629	A/G	cg00404053	chr1:178313656	RASAL2	0.68	7.5	0.38	5.94e-13	Obesity-related traits;
LUSC	cis	rs1044826	0.692	rs184155	chr3:139229772	G/A	cg15131784	chr3:139108705	COPB2	-0.4	-6.42	-0.33	4.62e-10	Obesity-related traits;
LUSC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg04369109	chr6:150039330	LATS1	-0.57	-8.47	-0.42	8.03e-16	Lung cancer;
LUSC	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg27124370	chr19:33622961	WDR88	0.57	7.37	0.37	1.37e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.8	0.39	8.05e-14	Coffee consumption (cups per day);
LUSC	cis	rs7180079	1.000	rs77627789	chr15:64444276	G/C	cg02848875	chr15:64387786	SNX1	-0.5	-6.4	-0.33	5.26e-10	Monocyte count;
LUSC	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg19812747	chr11:111475976	SIK2	-0.5	-7.04	-0.36	1.1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg04352962	chr1:209979756	IRF6	0.52	6.96	0.36	1.86e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg03146154	chr1:46216737	IPP	-0.58	-8.42	-0.42	1.11e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1413885	0.516	rs9326063	chr1:65835911	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.49	7.09	0.36	7.85e-12	Anticoagulant levels;
LUSC	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.92	-0.35	2.38e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg13047869	chr3:10149882	C3orf24	0.43	6.39	0.33	5.61e-10	Alzheimer's disease;
LUSC	cis	rs865483	0.929	rs8064314	chr17:35858392	A/G	cg06716730	chr17:35851459	DUSP14	0.28	6.38	0.33	5.92e-10	Monocyte count;
LUSC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.83	15.27	0.64	2.72e-40	Total body bone mineral density;
LUSC	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.91	16.67	0.67	8.11e-46	Bone mineral density;
LUSC	cis	rs2239815	0.515	rs9625591	chr22:29232564	A/G	cg02153584	chr22:29168773	CCDC117	0.52	6.0	0.31	5.14e-9	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	cis	rs240764	0.645	rs240111	chr6:101059499	C/A	cg09795085	chr6:101329169	ASCC3	0.4	5.81	0.3	1.48e-8	Neuroticism;
LUSC	cis	rs1712517	0.740	rs4917387	chr10:105108455	T/C	cg05636881	chr10:105038444	INA	0.4	6.74	0.35	7.11e-11	Migraine;
LUSC	cis	rs7202877	0.572	rs4888371	chr16:75308781	G/A	cg03315344	chr16:75512273	CHST6	0.43	6.43	0.33	4.44e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9653442	0.564	rs4851261	chr2:100786717	A/G	cg07810366	chr2:100720526	AFF3	-0.44	-7.49	-0.38	6.12e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg14552801	chr7:65878734	NA	-0.45	-6.35	-0.33	6.96e-10	Aortic root size;
LUSC	cis	rs870825	0.929	rs72689266	chr4:185591053	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	11.29	0.53	2.87e-25	Blood protein levels;
LUSC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.65e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-7.15	-0.36	5.61e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-0.76	-12.33	-0.56	4.73e-29	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg17515076	chr17:73810948	UNK	-0.39	-6.47	-0.33	3.54e-10	White matter hyperintensity burden;
LUSC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.79	-0.39	8.52e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs17092148	0.945	rs6087622	chr20:33310471	A/G	cg16810054	chr20:33298113	TP53INP2	-0.39	-6.21	-0.32	1.53e-9	Neuroticism;
LUSC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4666002	0.789	rs13023094	chr2:27910706	G/T	cg27432699	chr2:27873401	GPN1	-0.51	-6.98	-0.36	1.56e-11	Phospholipid levels (plasma);
LUSC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg03289416	chr15:75166202	SCAMP2	0.45	7.11	0.36	7.17e-12	Breast cancer;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05828906	chr6:126278519	HINT3	-0.44	-6.03	-0.31	4.37e-9	Hepatitis;
LUSC	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	13.19	0.59	2.77e-32	Lung cancer in ever smokers;
LUSC	cis	rs3087591	0.960	rs2905880	chr17:29546175	A/G	cg24425628	chr17:29625626	OMG;NF1	0.56	8.24	0.41	3.92e-15	Hip circumference;
LUSC	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg05110241	chr16:68378359	PRMT7	-0.57	-6.57	-0.34	1.89e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21016266	chr12:122356598	WDR66	0.58	8.43	0.42	1.04e-15	Mean corpuscular volume;
LUSC	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	6.17	0.32	1.96e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2070433	0.851	rs1029231	chr21:47931653	A/G	cg12379764	chr21:47803548	PCNT	0.7	9.23	0.45	3.29e-18	Lymphocyte counts;
LUSC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21862992	chr11:68658383	NA	0.51	8.19	0.41	5.71e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg19875535	chr5:140030758	IK	-0.5	-8.23	-0.41	4.37e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs60154123	0.614	rs628423	chr1:210460137	C/T	cg22029157	chr1:209979665	IRF6	0.52	5.93	0.31	7.46e-9	Coronary artery disease;
LUSC	cis	rs11166629	1.000	rs4909331	chr8:135644540	T/C	cg21672855	chr8:135614777	ZFAT	0.36	5.84	0.3	1.26e-8	Smoking quantity;
LUSC	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg05585544	chr11:47624801	NA	0.41	6.61	0.34	1.54e-10	Subjective well-being;
LUSC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg13047869	chr3:10149882	C3orf24	0.66	9.61	0.47	1.79e-19	Alzheimer's disease;
LUSC	cis	rs6546886	0.957	rs28450901	chr2:74252382	C/G	cg14702570	chr2:74259524	NA	-0.31	-5.86	-0.31	1.09e-8	Dialysis-related mortality;
LUSC	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	5.68	0.3	2.97e-8	Menopause (age at onset);
LUSC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg06238570	chr21:40685208	BRWD1	0.49	7.43	0.38	9.13e-13	Cognitive function;
LUSC	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.17	0.45	4.93e-18	Red blood cell count;
LUSC	cis	rs13089785	1.000	rs13092912	chr3:123604942	C/T	cg01860459	chr3:123419554	MYLK	0.34	5.7	0.3	2.64e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9814567	0.778	rs4955546	chr3:134334738	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.77	-0.57	1.1e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg18187862	chr3:45730750	SACM1L	-0.52	-6.72	-0.35	7.81e-11	Primary sclerosing cholangitis;
LUSC	trans	rs62238980	0.614	rs78247456	chr22:32442531	G/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg07169764	chr2:136633963	MCM6	1.2	18.29	0.71	3.01e-52	Corneal structure;
LUSC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.92	0.7	8.72e-51	Chronic sinus infection;
LUSC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg03351412	chr1:154909251	PMVK	0.54	8.6	0.43	3.1e-16	Prostate cancer;
LUSC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg02569458	chr12:86230093	RASSF9	-0.48	-7.95	-0.4	2.92e-14	Major depressive disorder;
LUSC	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg09582351	chr12:29534625	ERGIC2	-0.32	-6.69	-0.34	9.32e-11	QT interval;
LUSC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.67	14.66	0.63	6.6e-38	Hemoglobin concentration;
LUSC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg22800045	chr5:56110881	MAP3K1	0.72	8.9	0.44	3.68e-17	Initial pursuit acceleration;
LUSC	trans	rs1997103	1.000	rs7779040	chr7:55412947	T/C	cg20935933	chr6:143382018	AIG1	0.51	7.38	0.37	1.26e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9398803	0.865	rs9388494	chr6:126776094	G/T	cg19875578	chr6:126661172	C6orf173	0.42	6.18	0.32	1.9e-9	Male-pattern baldness;
LUSC	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg07382826	chr16:28625726	SULT1A1	0.28	5.97	0.31	6.13e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2282300	0.739	rs35229181	chr11:30241698	A/G	cg25418670	chr11:30344373	C11orf46	-0.66	-9.53	-0.46	3.4e-19	Morning vs. evening chronotype;
LUSC	cis	rs9677476	0.863	rs5018532	chr2:232077075	A/G	cg07929768	chr2:232055508	NA	0.35	6.78	0.35	5.51e-11	Food antigen IgG levels;
LUSC	cis	rs57502260	0.790	rs7129320	chr11:68388220	G/A	cg20283391	chr11:68216788	NA	-0.6	-5.81	-0.3	1.46e-8	Total body bone mineral density (age 45-60);
LUSC	cis	rs1003719	0.688	rs2000413	chr21:38539718	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-9.99	-0.48	1.02e-20	Eye color traits;
LUSC	cis	rs9463078	0.605	rs13215618	chr6:44936568	A/G	cg25276700	chr6:44698697	NA	0.29	6.06	0.31	3.65e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs4629180	0.544	rs7595274	chr2:102140086	T/C	cg04415270	chr2:102091202	RFX8	-0.43	-7.36	-0.37	1.47e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	1.24	19.67	0.73	9.29e-58	Corneal structure;
LUSC	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.36e-8	Lung cancer;
LUSC	cis	rs6545883	0.894	rs2694643	chr2:61604383	A/G	cg15711740	chr2:61764176	XPO1	-0.41	-6.08	-0.32	3.36e-9	Tuberculosis;
LUSC	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg11812906	chr14:75593930	NEK9	0.66	11.27	0.52	3.54e-25	Height;
LUSC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg00945038	chr17:61921165	SMARCD2	0.54	9.41	0.46	8.24e-19	Prudent dietary pattern;
LUSC	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg00376283	chr12:123451042	ABCB9	0.65	8.31	0.41	2.45e-15	Neutrophil percentage of white cells;
LUSC	cis	rs6681460	0.649	rs1415974	chr1:67005503	C/T	cg02459107	chr1:67143332	SGIP1	-0.36	-6.07	-0.32	3.43e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg22532475	chr10:104410764	TRIM8	-0.32	-7.11	-0.36	7.04e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg25797454	chr6:150327115	RAET1K	0.37	8.56	0.42	4.17e-16	Alopecia areata;
LUSC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.25	-0.32	1.22e-9	Initial pursuit acceleration;
LUSC	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.63	6.79	0.35	5e-11	Schizophrenia;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg01503640	chr19:18963027	UPF1	-0.4	-6.3	-0.33	9.49e-10	N-glycan levels;
LUSC	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg08213375	chr14:104286397	PPP1R13B	0.44	7.58	0.38	3.4e-13	Reticulocyte count;
LUSC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6722750	0.716	rs2028149	chr2:64415259	A/G	cg22352474	chr2:64371530	PELI1	-0.52	-7.69	-0.39	1.7e-13	Neuroticism;
LUSC	cis	rs13385	0.769	rs34675890	chr5:139622272	T/C	cg26211634	chr5:139558579	C5orf32	0.47	7.2	0.37	3.92e-12	Atrial fibrillation;
LUSC	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg06640241	chr16:89574553	SPG7	0.73	11.87	0.54	2.44e-27	Multiple myeloma (IgH translocation);
LUSC	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.43	0.53	9.68e-26	Eye color traits;
LUSC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00149659	chr3:10157352	C3orf10	0.9	12.57	0.57	6.42e-30	Alzheimer's disease;
LUSC	trans	rs7181230	0.885	rs2412478	chr15:40361172	C/T	cg22705835	chr10:65332833	REEP3	-0.39	-6.5	-0.34	2.95e-10	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg17971929	chr21:40555470	PSMG1	-0.61	-10.07	-0.48	5.14e-21	Cognitive function;
LUSC	cis	rs377070	0.844	rs309415	chr4:123621228	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.42	6.34	0.33	7.57e-10	Mosquito bite size;
LUSC	cis	rs877282	0.898	rs11253350	chr10:765968	G/A	cg17470449	chr10:769945	NA	0.53	7.09	0.36	8.21e-12	Uric acid levels;
LUSC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg00012203	chr2:219082015	ARPC2	-0.7	-11.59	-0.54	2.53e-26	Colorectal cancer;
LUSC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg01097406	chr16:89675127	NA	0.35	6.99	0.36	1.51e-11	Vitiligo;
LUSC	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.7	0.34	8.73e-11	Tonsillectomy;
LUSC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	16.76	0.68	3.58e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9653442	0.564	rs11687586	chr2:100789346	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-7.04	-0.36	1.09e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.49	0.46	4.39e-19	Bipolar disorder;
LUSC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg03351412	chr1:154909251	PMVK	0.49	7.54	0.38	4.55e-13	Prostate cancer;
LUSC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg11062466	chr8:58055876	NA	0.67	7.98	0.4	2.36e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg13565492	chr6:43139072	SRF	-0.73	-10.9	-0.51	7.13e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12618769	0.597	rs17031905	chr2:99070902	A/G	cg10123293	chr2:99228465	UNC50	0.41	6.96	0.36	1.8e-11	Bipolar disorder;
LUSC	trans	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs2282802	0.711	rs1864970	chr5:139633042	T/C	cg26211634	chr5:139558579	C5orf32	0.44	8.13	0.41	8.41e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs17253792	0.822	rs75995456	chr14:56073194	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-6.95	-0.36	1.95e-11	Putamen volume;
LUSC	cis	rs983392	0.709	rs7932740	chr11:59976111	G/A	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.19	-0.32	1.74e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg17691542	chr6:26056736	HIST1H1C	0.39	5.8	0.3	1.57e-8	Schizophrenia;
LUSC	cis	rs2479724	1.000	rs2254479	chr6:41831143	G/A	cg17623882	chr6:41773611	USP49	-0.63	-10.41	-0.5	3.52e-22	Menarche (age at onset);
LUSC	cis	rs7580658	0.724	rs6712551	chr2:127998485	G/A	cg09760422	chr2:128146352	NA	-0.3	-6.79	-0.35	5.27e-11	Protein C levels;
LUSC	trans	rs9860340	0.730	rs1509780	chr3:87642396	G/A	cg03644585	chr7:884825	UNC84A	0.42	6.0	0.31	5.03e-9	Electroencephalographic traits in alcoholism;
LUSC	trans	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	7.05	0.36	1.01e-11	Endometrial cancer;
LUSC	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg00579200	chr11:133705235	NA	-0.39	-5.67	-0.3	3.12e-8	Childhood ear infection;
LUSC	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg13390004	chr1:15929781	NA	0.42	6.95	0.36	1.92e-11	Systolic blood pressure;
LUSC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.43	0.42	1.02e-15	Tonsillectomy;
LUSC	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg15103426	chr22:29168792	CCDC117	0.5	6.47	0.33	3.44e-10	Lymphocyte counts;
LUSC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-7.44	-0.38	8.49e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg12432903	chr7:1882776	MAD1L1	-0.51	-8.77	-0.43	9.05e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs12819124	0.502	rs10875718	chr12:48411102	G/T	cg21466736	chr12:48725269	NA	-0.33	-6.08	-0.32	3.33e-9	Glycated hemoglobin levels;
LUSC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.53	9.47	0.46	5.31e-19	Osteoporosis;
LUSC	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.56	0.5	1.15e-22	Colorectal cancer;
LUSC	cis	rs1595825	0.891	rs1851779	chr2:198647108	C/T	cg10547527	chr2:198650123	BOLL	-0.51	-5.97	-0.31	5.92e-9	Ulcerative colitis;
LUSC	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg00012203	chr2:219082015	ARPC2	0.59	9.45	0.46	5.98e-19	Ulcerative colitis;
LUSC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg12751644	chr20:60527061	NA	-0.33	-5.86	-0.31	1.1e-8	Body mass index;
LUSC	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.05	0.31	3.84e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02968854	chr7:30518406	NOD1	-0.4	-5.96	-0.31	6.54e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg27490568	chr2:178487706	NA	0.48	6.31	0.33	8.92e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2652834	0.718	rs2729832	chr15:63396401	A/G	cg05507819	chr15:63340323	TPM1	0.54	6.93	0.35	2.19e-11	HDL cholesterol;
LUSC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg08088566	chr11:430123	ANO9	0.62	7.21	0.37	3.77e-12	Body mass index;
LUSC	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.4	-5.66	-0.3	3.18e-8	Bipolar disorder;
LUSC	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg26850624	chr5:429559	AHRR	-0.42	-8.32	-0.41	2.32e-15	Cystic fibrosis severity;
LUSC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.8	0.63	1.84e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.23	0.52	4.66e-25	Menopause (age at onset);
LUSC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.58	8.24	0.41	4.06e-15	Alzheimer's disease;
LUSC	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.71	-0.3	2.45e-8	Type 2 diabetes;
LUSC	cis	rs17095355	1.000	rs72828232	chr10:111725298	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.66	-7.68	-0.39	1.75e-13	Biliary atresia;
LUSC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg00945038	chr17:61921165	SMARCD2	0.54	9.52	0.46	3.65e-19	Prudent dietary pattern;
LUSC	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg06784218	chr1:46089804	CCDC17	-0.3	-5.83	-0.3	1.31e-8	Red blood cell count;Reticulocyte count;
LUSC	trans	rs11935423	0.778	rs11937107	chr4:100503761	C/T	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.05	-0.31	3.97e-9	Gut microbiome composition (summer);
LUSC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg11247378	chr22:39784982	NA	-0.64	-11.42	-0.53	9.95e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg03465714	chr1:152285911	FLG	0.42	5.88	0.31	1.02e-8	Atopic dermatitis;
LUSC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.5	-0.34	2.94e-10	Alzheimer's disease (late onset);
LUSC	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg04374321	chr14:90722782	PSMC1	0.73	11.55	0.53	3.52e-26	Mortality in heart failure;
LUSC	cis	rs3936840	0.565	rs8011721	chr14:102986388	C/G	cg18135206	chr14:102964638	TECPR2	-0.47	-6.29	-0.33	9.7e-10	Plateletcrit;
LUSC	cis	rs2274273	0.686	rs68083077	chr14:55574428	G/A	cg04306507	chr14:55594613	LGALS3	0.48	9.61	0.47	1.87e-19	Protein biomarker;
LUSC	trans	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg07455318	chr14:91772383	CCDC88C	0.38	6.05	0.31	3.89e-9	Asthma (sex interaction);
LUSC	cis	rs5167	0.566	rs35080293	chr19:45496624	T/G	cg25746394	chr19:45450501	APOC2	0.32	6.07	0.32	3.55e-9	Blood protein levels;
LUSC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg22907277	chr7:1156413	C7orf50	0.55	5.96	0.31	6.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg23711669	chr6:146136114	FBXO30	-0.82	-14.5	-0.62	2.82e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg23711669	chr6:146136114	FBXO30	0.87	16.19	0.66	6.55e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.17	-0.32	2.02e-9	Platelet count;
LUSC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg17724175	chr1:150552817	MCL1	0.37	6.7	0.34	8.92e-11	Tonsillectomy;
LUSC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06481639	chr22:41940642	POLR3H	0.49	5.75	0.3	2.06e-8	Vitiligo;
LUSC	cis	rs7582720	1.000	rs72926782	chr2:203811628	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9296092	0.538	rs9461887	chr6:33526827	C/T	cg13560919	chr6:33536144	NA	-0.85	-16.28	-0.67	2.73e-44	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.13e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg23544223	chr18:12777786	NA	0.58	6.15	0.32	2.24e-9	Inflammatory skin disease;
LUSC	cis	rs9788721	0.835	rs17487223	chr15:78923987	A/G	cg18825076	chr15:78729989	IREB2	0.46	7.19	0.37	4.26e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg00857998	chr1:205179979	DSTYK	0.67	10.59	0.5	8.52e-23	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1113500	0.524	rs12145813	chr1:108569904	C/T	cg11967332	chr1:108735228	SLC25A24	0.41	5.72	0.3	2.31e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs977987	0.806	rs1895490	chr16:75392806	G/A	cg04384234	chr16:75411784	CFDP1	-0.42	-6.87	-0.35	3.1e-11	Dupuytren's disease;
LUSC	cis	rs7809950	0.817	rs34325395	chr7:107113808	C/G	cg23024343	chr7:107201750	COG5	-0.69	-10.28	-0.49	1.05e-21	Coronary artery disease;
LUSC	cis	rs4654899	0.772	rs7548269	chr1:21089472	T/C	cg01072550	chr1:21505969	NA	-0.47	-6.97	-0.36	1.67e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg16606324	chr3:10149918	C3orf24	0.44	7.01	0.36	1.36e-11	Alzheimer's disease;
LUSC	trans	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.38	-0.33	5.98e-10	Retinal vascular caliber;
LUSC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.35	-6.3	-0.33	9.6e-10	Longevity;Endometriosis;
LUSC	cis	rs13720	0.722	rs163800	chr20:57578508	C/T	cg23907860	chr20:57583709	CTSZ	0.47	6.23	0.32	1.37e-9	Platelet distribution width;
LUSC	cis	rs7215564	0.908	rs2873059	chr17:78663874	T/C	cg23238734	chr17:78661607	RPTOR	0.48	6.12	0.32	2.63e-9	Myopia (pathological);
LUSC	cis	rs76878669	0.917	rs10444359	chr11:66102807	G/A	cg18002602	chr11:66138449	SLC29A2	-0.38	-5.91	-0.31	8.64e-9	Educational attainment (years of education);
LUSC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg14895029	chr7:2775587	GNA12	-0.39	-5.99	-0.31	5.43e-9	Height;
LUSC	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	0.83	11.69	0.54	1.03e-26	Response to hepatitis C treatment;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg15539395	chr19:59086703	MGC2752	0.47	6.42	0.33	4.78e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05665937	chr4:1216051	CTBP1	-0.37	-5.89	-0.31	9.51e-9	Obesity-related traits;
LUSC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15541040	chr2:3486749	NA	-0.58	-8.86	-0.44	4.81e-17	Neurofibrillary tangles;
LUSC	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.58	-9.58	-0.46	2.29e-19	Body mass index;
LUSC	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg03188948	chr7:1209495	NA	0.66	6.92	0.35	2.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2227930	0.506	rs13061409	chr3:142025340	G/A	cg16271453	chr3:142027066	XRN1	-0.55	-9.89	-0.48	2.13e-20	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08859206	chr1:53392774	SCP2	0.5	8.51	0.42	6.03e-16	Monocyte count;
LUSC	cis	rs11158026	0.757	rs10150110	chr14:55462010	G/T	cg04306507	chr14:55594613	LGALS3	0.36	7.02	0.36	1.23e-11	Parkinson's disease;
LUSC	cis	rs7560272	0.538	rs4852976	chr2:73936322	T/C	cg20560298	chr2:73613845	ALMS1	0.38	5.86	0.31	1.1e-8	Schizophrenia;
LUSC	cis	rs3935685	0.934	rs61331678	chr15:77995949	G/C	cg25212270	chr15:78015279	NA	0.28	6.17	0.32	1.95e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg06363034	chr20:62225388	GMEB2	-0.45	-7.62	-0.38	2.63e-13	Glioblastoma;
LUSC	trans	rs72674100	0.867	rs28673828	chr4:97991632	T/C	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg21782813	chr7:2030301	MAD1L1	0.48	8.33	0.41	2.05e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08219700	chr8:58056026	NA	0.65	7.59	0.38	3.13e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs10875746	0.951	rs4760690	chr12:48563653	G/A	cg13454099	chr12:49076203	C12orf41	-0.5	-5.84	-0.3	1.25e-8	Longevity (90 years and older);
LUSC	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.42	6.11	0.32	2.85e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs2882667	0.690	rs160405	chr5:138084076	A/G	cg04439458	chr5:138467593	SIL1	-0.4	-7.29	-0.37	2.21e-12	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs977987	0.806	rs4993969	chr16:75411521	A/T	cg03315344	chr16:75512273	CHST6	0.48	9.54	0.46	3.1e-19	Dupuytren's disease;
LUSC	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg23711669	chr6:146136114	FBXO30	0.83	14.52	0.62	2.22e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7084402	1.000	rs1863665	chr10:60266640	T/C	cg07615347	chr10:60278583	BICC1	-0.35	-5.76	-0.3	1.95e-8	Refractive error;
LUSC	cis	rs1863824	0.502	rs11202058	chr10:88282611	G/A	cg07322936	chr10:88137208	NA	-0.58	-7.98	-0.4	2.29e-14	Schizophrenia;
LUSC	cis	rs7973719	0.833	rs7970916	chr12:7357746	T/C	cg07052231	chr12:7363540	PEX5	0.54	9.42	0.46	7.85e-19	IgG glycosylation;
LUSC	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg04362960	chr10:104952993	NT5C2	0.62	9.74	0.47	6.69e-20	Arsenic metabolism;
LUSC	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.45	0.33	4.01e-10	Corneal astigmatism;
LUSC	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.68	-10.35	-0.49	5.84e-22	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg10909506	chr17:38081995	ORMDL3	0.35	6.16	0.32	2.11e-9	Self-reported allergy;
LUSC	cis	rs11677416	1.000	rs2856841	chr2:113537339	A/G	cg27083787	chr2:113543245	IL1A	0.48	7.39	0.37	1.21e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg02454025	chr1:11042201	C1orf127	1.03	18.67	0.71	8.68e-54	Ewing sarcoma;
LUSC	cis	rs72772090	0.539	rs10515248	chr5:96112005	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-7.27	-0.37	2.59e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg02772935	chr3:125709198	NA	-0.47	-5.71	-0.3	2.44e-8	Blood pressure (smoking interaction);
LUSC	cis	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg27411982	chr8:10470053	RP1L1	-0.45	-6.56	-0.34	2.05e-10	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11158959	chr15:65102290	NA	-0.41	-6.1	-0.32	2.9e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg04176532	chr22:50317003	CRELD2	-0.4	-5.76	-0.3	1.92e-8	Schizophrenia;
LUSC	trans	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg01620082	chr3:125678407	NA	-0.69	-6.59	-0.34	1.68e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg15485101	chr11:133734466	NA	0.36	6.26	0.32	1.16e-9	Childhood ear infection;
LUSC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg19318889	chr4:1322082	MAEA	-0.47	-7.73	-0.39	1.27e-13	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	0.94	8.24	0.41	3.94e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg11845111	chr2:191398756	TMEM194B	0.86	11.42	0.53	1.01e-25	Diastolic blood pressure;
LUSC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg13397359	chr6:42928475	GNMT	0.58	9.85	0.47	2.9e-20	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.84	13.62	0.6	6.77e-34	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg09526685	chr4:187126073	CYP4V2	-0.67	-6.71	-0.34	8.49e-11	Blood protein levels;
LUSC	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg26162295	chr17:38119207	GSDMA	0.25	5.78	0.3	1.76e-8	Myeloid white cell count;
LUSC	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg17173187	chr15:85201210	NMB	0.47	8.9	0.44	3.57e-17	Schizophrenia;
LUSC	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.2	-0.37	3.92e-12	Schizophrenia;
LUSC	cis	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg13609457	chr4:120235615	NA	0.37	5.66	0.3	3.22e-8	Corneal astigmatism;
LUSC	cis	rs4474465	0.688	rs7937225	chr11:78278126	T/A	cg27205649	chr11:78285834	NARS2	0.59	7.28	0.37	2.38e-12	Alzheimer's disease (survival time);
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.58	-9.37	-0.46	1.14e-18	Lymphocyte counts;
LUSC	cis	rs1506636	0.886	rs6466878	chr7:123272278	T/C	cg03229431	chr7:123269106	ASB15	-0.7	-11.62	-0.54	2e-26	Plateletcrit;Platelet count;
LUSC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg03929089	chr4:120376271	NA	-0.95	-16.52	-0.67	3.18e-45	Height;
LUSC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg21854759	chr1:92012499	NA	-0.53	-8.87	-0.44	4.35e-17	Breast cancer;
LUSC	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg08847533	chr14:75593920	NEK9	-0.54	-8.04	-0.4	1.56e-14	Neuroticism;
LUSC	cis	rs934734	0.789	rs2661798	chr2:65635688	A/T	cg08085232	chr2:65598271	SPRED2	0.36	5.66	0.3	3.34e-8	Rheumatoid arthritis;
LUSC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.1	14.01	0.61	2.21e-35	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11792861	0.546	rs7873569	chr9:111796753	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.46	7.56	0.38	3.96e-13	Menarche (age at onset);
LUSC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg05564831	chr3:52568323	NT5DC2	0.36	6.66	0.34	1.12e-10	Electroencephalogram traits;
LUSC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.71	10.8	0.51	1.58e-23	Smoking initiation;
LUSC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-10.9	-0.51	6.89e-24	Hemoglobin concentration;
LUSC	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg21782813	chr7:2030301	MAD1L1	0.35	5.75	0.3	1.98e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg03709012	chr19:19516395	GATAD2A	0.77	11.94	0.55	1.37e-27	Tonsillectomy;
LUSC	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.73	11.99	0.55	8.57e-28	Corneal astigmatism;
LUSC	cis	rs7605827	0.930	rs6748451	chr2:15521088	A/G	cg19274914	chr2:15703543	NA	0.45	8.78	0.43	8.82e-17	Educational attainment (years of education);
LUSC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg04450456	chr4:17643702	FAM184B	0.36	6.0	0.31	5.09e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21381360	chr12:92538746	BTG1	0.69	6.06	0.31	3.7e-9	Cognitive performance;
LUSC	cis	rs8113142	0.614	rs16961775	chr19:29196997	C/A	cg04546413	chr19:29218101	NA	0.44	5.93	0.31	7.76e-9	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs243505	0.559	rs2072407	chr7:148508833	A/G	cg09806900	chr7:148480153	CUL1	0.64	9.74	0.47	6.86e-20	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.79	0.35	5.03e-11	Menarche (age at onset);
LUSC	trans	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	12.12	0.55	2.85e-28	Exhaled nitric oxide output;
LUSC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg14993813	chr1:46806288	NSUN4	0.5	7.06	0.36	9.66e-12	Menopause (age at onset);
LUSC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg14004847	chr7:1930337	MAD1L1	-0.56	-8.38	-0.42	1.54e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg27494647	chr7:150038898	RARRES2	0.54	7.8	0.39	8.01e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03517284	chr6:25882590	NA	-0.52	-9.66	-0.47	1.25e-19	Blood metabolite levels;
LUSC	cis	rs3768617	0.811	rs11590958	chr1:183023636	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.64	0.43	2.41e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg01802117	chr1:53393560	SCP2	0.39	6.46	0.33	3.72e-10	Monocyte count;
LUSC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs11264799	0.603	rs12755544	chr1:157553017	C/T	cg18268488	chr1:157545234	FCRL4	0.35	6.42	0.33	4.66e-10	IgA nephropathy;
LUSC	cis	rs12505328	0.966	rs10023094	chr4:174356664	C/T	cg12145043	chr4:174357286	NA	-0.35	-6.25	-0.32	1.22e-9	Chin dimples;
LUSC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg22166914	chr1:53195759	ZYG11B	0.57	9.28	0.45	2.22e-18	Monocyte count;
LUSC	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg06781209	chr11:61594997	FADS2	0.37	5.78	0.3	1.69e-8	Neutrophil count;Sum basophil neutrophil counts;
LUSC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg24920358	chr1:40204285	PPIE	0.6	10.83	0.51	1.29e-23	Blood protein levels;
LUSC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg18402987	chr7:1209562	NA	0.71	7.71	0.39	1.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.3	0.53	2.79e-25	Prudent dietary pattern;
LUSC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg25456477	chr12:86230367	RASSF9	0.35	6.25	0.32	1.24e-9	Major depressive disorder;
LUSC	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12908607	chr1:44402522	ARTN	-0.48	-7.21	-0.37	3.85e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg22823121	chr1:150693482	HORMAD1	-0.53	-8.14	-0.41	7.93e-15	Tonsillectomy;
LUSC	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg05110241	chr16:68378359	PRMT7	-0.51	-6.42	-0.33	4.73e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.77	-0.39	1.01e-13	Neuroticism;
LUSC	cis	rs7833787	1.000	rs7002237	chr8:18704514	A/G	cg17701159	chr8:18705777	PSD3	0.37	6.21	0.32	1.54e-9	Obesity-related traits;
LUSC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20887711	chr4:1340912	KIAA1530	0.53	8.32	0.41	2.22e-15	Longevity;
LUSC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.45	-0.33	3.84e-10	Life satisfaction;
LUSC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.5	7.58	0.38	3.5e-13	Lymphocyte counts;
LUSC	cis	rs7582720	1.000	rs72926771	chr2:203801226	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-8.45	-0.42	8.97e-16	Menopause (age at onset);
LUSC	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg12924262	chr12:102091054	CHPT1	-0.44	-5.65	-0.3	3.52e-8	Blood protein levels;
LUSC	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.77	10.78	0.51	1.93e-23	Corneal astigmatism;
LUSC	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg23093090	chr10:104574429	C10orf26	-0.36	-6.6	-0.34	1.6e-10	Arsenic metabolism;
LUSC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg17366294	chr4:99064904	C4orf37	0.56	9.82	0.47	3.53e-20	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02467765	chr4:78978708	FRAS1	0.42	6.39	0.33	5.7e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg18099408	chr3:52552593	STAB1	-0.35	-6.08	-0.32	3.37e-9	Electroencephalogram traits;
LUSC	cis	rs11264799	0.520	rs861998	chr1:157543878	G/A	cg18268488	chr1:157545234	FCRL4	0.39	7.45	0.38	7.95e-13	IgA nephropathy;
LUSC	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg24642439	chr20:33292090	TP53INP2	-0.48	-7.39	-0.37	1.2e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs3741798	1.000	rs61922045	chr12:12494394	A/C	cg08615371	chr12:12503544	MANSC1	1.08	11.06	0.52	1.87e-24	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.41	-5.88	-0.31	9.77e-9	Alzheimer's disease (late onset);
LUSC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	0.46	7.3	0.37	2.09e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.9	15.03	0.64	2.37e-39	Bladder cancer;
LUSC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg19318889	chr4:1322082	MAEA	0.5	7.61	0.38	2.91e-13	Obesity-related traits;
LUSC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05025164	chr4:1340916	KIAA1530	-0.51	-7.84	-0.39	6.3e-14	Obesity-related traits;
LUSC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06634786	chr22:41940651	POLR3H	0.51	6.11	0.32	2.82e-9	Vitiligo;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13326172	chr17:34122745	MMP28	0.73	6.45	0.33	3.84e-10	Cognitive performance;
LUSC	cis	rs11718455	0.629	rs4082418	chr3:43908243	C/T	cg08738300	chr3:44038990	NA	-0.61	-9.33	-0.45	1.46e-18	Coronary artery disease;
LUSC	cis	rs3820068	0.608	rs12091326	chr1:16048005	A/G	cg24675056	chr1:15929824	NA	0.41	6.72	0.35	7.82e-11	Systolic blood pressure;
LUSC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg16339924	chr4:17578868	LAP3	0.64	10.13	0.48	3.35e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg24739457	chr1:205821442	NA	0.33	5.66	0.3	3.19e-8	Menarche (age at onset);
LUSC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg24881330	chr22:46731750	TRMU	0.88	8.82	0.43	6.33e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg08270630	chr22:50330655	NA	0.4	5.98	0.31	5.84e-9	Schizophrenia;
LUSC	trans	rs1547374	0.737	rs178741	chr21:43779408	G/A	cg09521743	chr10:75415752	SYNPO2L	0.5	8.96	0.44	2.42e-17	Pancreatic cancer;
LUSC	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-7.57	-0.38	3.77e-13	Atrioventricular conduction;
LUSC	cis	rs2769264	0.593	rs4971040	chr1:151366494	A/C	cg18801370	chr1:151430492	POGZ	0.66	7.76	0.39	1.02e-13	Blood trace element (Cu levels);
LUSC	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-0.92	-17.47	-0.69	5.16e-49	Headache;
LUSC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg06238570	chr21:40685208	BRWD1	-0.62	-10.34	-0.49	6.4e-22	Cognitive function;
LUSC	cis	rs9463078	0.764	rs9367208	chr6:44830180	G/A	cg25276700	chr6:44698697	NA	-0.28	-5.72	-0.3	2.34e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs4280164	1.000	rs4280164	chr14:24771285	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.57	-6.73	-0.35	7.49e-11	Parent of origin effect on language impairment (paternal);
LUSC	trans	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg23241863	chr10:102295624	HIF1AN	0.49	5.98	0.31	5.84e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.87	-0.31	1.03e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11247915	0.583	rs66569416	chr1:26659737	C/G	cg15628303	chr1:26608928	UBXN11	0.47	7.67	0.39	1.85e-13	Obesity-related traits;
LUSC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.44	-0.33	4.08e-10	Alzheimer's disease (late onset);
LUSC	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg26659404	chr1:25747437	RHCE	-0.28	-5.75	-0.3	2.01e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23158103	chr7:148848205	ZNF398	-0.49	-8.02	-0.4	1.76e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg18478394	chr8:109455254	TTC35	0.42	6.54	0.34	2.35e-10	Dupuytren's disease;
LUSC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg08888203	chr3:10149979	C3orf24	-0.66	-9.74	-0.47	6.63e-20	Alzheimer's disease;
LUSC	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg22906224	chr7:99728672	NA	0.42	5.68	0.3	2.88e-8	Coronary artery disease;
LUSC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg09359103	chr1:154839909	KCNN3	-0.43	-8.17	-0.41	6.59e-15	Schizophrenia;
LUSC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg00031303	chr3:195681400	NA	0.67	9.55	0.46	2.79e-19	Pancreatic cancer;
LUSC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-12.53	-0.57	8.55e-30	Electrocardiographic conduction measures;
LUSC	cis	rs6690583	0.623	rs1371141	chr1:85455372	C/A	cg11262906	chr1:85462892	MCOLN2	0.67	6.53	0.34	2.51e-10	Serum sulfate level;
LUSC	trans	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.54	0.53	3.8e-26	Mean corpuscular volume;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg23088430	chr8:144679052	EEF1D;TIGD5	0.36	6.13	0.32	2.49e-9	Triglycerides;
LUSC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.71	-0.43	1.38e-16	Bipolar disorder;
LUSC	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg09307838	chr4:120376055	NA	0.64	9.55	0.46	2.93e-19	Corneal astigmatism;
LUSC	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.47	7.42	0.38	1e-12	Resistin levels;
LUSC	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.07	15.31	0.64	1.78e-40	Uric acid levels;
LUSC	cis	rs9311676	0.656	rs56028017	chr3:58372508	C/T	cg13750441	chr3:58318267	PXK	0.35	6.7	0.34	9.04e-11	Systemic lupus erythematosus;
LUSC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg22834771	chr12:69754056	YEATS4	-0.5	-7.45	-0.38	8.09e-13	Blood protein levels;
LUSC	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg24596788	chr1:163392923	NA	-0.45	-7.66	-0.39	2e-13	Motion sickness;
LUSC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg08270630	chr22:50330655	NA	-0.42	-6.17	-0.32	1.94e-9	Schizophrenia;
LUSC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg12564285	chr5:131593104	PDLIM4	-0.48	-8.3	-0.41	2.69e-15	Breast cancer;
LUSC	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg10018233	chr7:150070692	REPIN1	0.36	6.35	0.33	7.02e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg16989719	chr2:238392110	NA	-0.39	-6.7	-0.34	9.08e-11	Prostate cancer;
LUSC	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg13057898	chr1:3703894	LRRC47	0.49	8.44	0.42	9.58e-16	Red cell distribution width;
LUSC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg25838465	chr1:92012736	NA	-0.73	-14.78	-0.63	2.21e-38	Breast cancer;
LUSC	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.74	-0.35	6.77e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.95	0.7	6.41e-51	Chronic sinus infection;
LUSC	cis	rs2273669	0.667	rs76094073	chr6:109288036	C/G	cg05315195	chr6:109294784	ARMC2	-0.59	-6.44	-0.33	4.18e-10	Prostate cancer;
LUSC	cis	rs10743315	0.557	rs17271690	chr12:19450236	A/G	cg02471346	chr12:19282374	PLEKHA5	0.82	6.15	0.32	2.23e-9	Gut microbiota (bacterial taxa);
LUSC	trans	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg25214090	chr10:38739885	LOC399744	0.43	6.56	0.34	2.08e-10	Corneal astigmatism;
LUSC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.19e-30	Aortic root size;
LUSC	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg14835575	chr10:16859367	RSU1	0.72	8.84	0.44	5.52e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg17764715	chr19:33622953	WDR88	0.6	8.33	0.41	2.08e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs17162190	0.698	rs4659444	chr1:26825116	C/T	cg17456097	chr1:26900765	RPS6KA1	0.39	5.75	0.3	1.98e-8	Mean corpuscular volume;
LUSC	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg05283184	chr6:79620031	NA	-0.57	-11.99	-0.55	8.43e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.82	15.09	0.64	1.37e-39	Heart rate;
LUSC	cis	rs9648716	0.515	rs2079827	chr7:140682675	C/T	cg23214464	chr7:140373596	ADCK2	0.7	5.92	0.31	7.78e-9	Type 2 diabetes;
LUSC	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg24450063	chr1:156163899	SLC25A44	1.15	23.5	0.79	8.98e-73	Testicular germ cell tumor;
LUSC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg11645453	chr3:52864694	ITIH4	0.28	6.43	0.33	4.34e-10	Electroencephalogram traits;
LUSC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-8.0	-0.4	2.09e-14	Prudent dietary pattern;
LUSC	cis	rs1790761	0.967	rs1638588	chr11:67199706	C/A	cg24690094	chr11:67383802	NA	-0.32	-5.84	-0.3	1.21e-8	Mean corpuscular volume;
LUSC	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.04	21.28	0.76	3.93e-64	Cognitive function;
LUSC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg08917208	chr2:24149416	ATAD2B	0.53	5.88	0.31	1e-8	Lymphocyte counts;
LUSC	cis	rs897984	0.770	rs12930657	chr16:30931968	C/T	cg02466173	chr16:30829666	NA	0.56	11.19	0.52	6.77e-25	Dementia with Lewy bodies;
LUSC	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.12	-0.32	2.63e-9	Neutrophil percentage of white cells;
LUSC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg25019033	chr10:957182	NA	-0.55	-6.33	-0.33	8e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs4663866	0.901	rs3739067	chr2:239184203	G/A	cg16914508	chr2:239161102	PER2	0.65	6.86	0.35	3.26e-11	Irritable bowel syndrome;
LUSC	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00791764	chr4:53727839	RASL11B	0.58	7.98	0.4	2.42e-14	Optic nerve measurement (cup area);
LUSC	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg24558204	chr6:135376177	HBS1L	0.58	8.94	0.44	2.75e-17	Red blood cell count;
LUSC	cis	rs72634258	0.699	rs2493214	chr1:7994420	A/G	cg00042356	chr1:8021962	PARK7	0.58	7.59	0.38	3.29e-13	Inflammatory bowel disease;
LUSC	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.61	-0.43	2.98e-16	Lung cancer;
LUSC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg18225595	chr11:63971243	STIP1	0.54	9.16	0.45	5.45e-18	Platelet count;
LUSC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	trans	rs1015291	0.806	rs2638431	chr12:19986746	A/G	cg01501474	chr7:55323552	NA	0.47	6.32	0.33	8.39e-10	Diastolic blood pressure;
LUSC	trans	rs9929218	0.953	rs17772411	chr16:68810923	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-11.47	-0.53	6.87e-26	Colorectal cancer;
LUSC	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg11901034	chr3:128598214	ACAD9	-0.41	-6.47	-0.33	3.54e-10	IgG glycosylation;
LUSC	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.15	-0.36	5.52e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg11498726	chr8:26250323	BNIP3L	-0.43	-6.18	-0.32	1.9e-9	Red cell distribution width;
LUSC	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg12473912	chr3:136751656	NA	0.39	6.81	0.35	4.51e-11	Neuroticism;
LUSC	trans	rs6030	1.000	rs1557572	chr1:169508576	A/C	cg16792071	chr10:134842795	NA	0.28	6.06	0.31	3.58e-9	Uric acid levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09861171	chr8:95731968	DPY19L4	0.41	6.26	0.32	1.17e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg00945038	chr17:61921165	SMARCD2	0.39	5.67	0.3	3.08e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs8114671	0.967	rs1577924	chr20:33784288	C/G	cg24642439	chr20:33292090	TP53INP2	-0.39	-5.67	-0.3	3.01e-8	Height;
LUSC	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.69	-0.43	1.66e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.89	15.25	0.64	3.11e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg26513180	chr16:89883248	FANCA	0.9	17.4	0.69	1.04e-48	Vitiligo;
LUSC	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	0.89	15.55	0.65	2.09e-41	Metabolic syndrome;
LUSC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg12751644	chr20:60527061	NA	-0.33	-5.99	-0.31	5.41e-9	Body mass index;
LUSC	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg03684893	chr10:554711	DIP2C	-0.39	-7.22	-0.37	3.59e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs9473147	0.516	rs7754971	chr6:47590476	C/T	cg20196966	chr6:47445060	CD2AP	0.43	6.08	0.32	3.24e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg09359103	chr1:154839909	KCNN3	-0.7	-15.52	-0.65	2.9e-41	Prostate cancer;
LUSC	cis	rs6494488	0.500	rs72744751	chr15:65064657	C/T	cg08069370	chr15:64387884	SNX1	-0.65	-5.91	-0.31	8.23e-9	Coronary artery disease;
LUSC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00166722	chr3:10149974	C3orf24	0.63	8.91	0.44	3.26e-17	Alzheimer's disease;
LUSC	cis	rs6429082	0.807	rs4659857	chr1:235581411	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.55	-7.81	-0.39	7.26e-14	Adiposity;
LUSC	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg08085267	chr17:45401833	C17orf57	0.54	8.82	0.43	6.58e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg03526776	chr6:41159608	TREML2	0.32	6.12	0.32	2.62e-9	Alzheimer's disease (late onset);
LUSC	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg19418458	chr7:158789849	NA	0.55	7.16	0.36	5.1e-12	Facial morphology (factor 20);
LUSC	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	12.09	0.55	3.72e-28	Ileal carcinoids;
LUSC	cis	rs834811	0.829	rs10252049	chr7:135903178	G/A	cg01726295	chr7:135938950	NA	-0.39	-6.82	-0.35	4.37e-11	Post-traumatic stress disorder;
LUSC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg24562669	chr7:97807699	LMTK2	0.35	6.12	0.32	2.64e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1595825	0.891	rs59938443	chr2:198497105	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.67	-0.34	1.04e-10	Ulcerative colitis;
LUSC	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-9.95	-0.48	1.37e-20	Hemoglobin concentration;
LUSC	cis	rs2932538	0.883	rs7549547	chr1:113086717	A/T	cg22162597	chr1:113214053	CAPZA1	0.69	10.04	0.48	6.82e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg12641515	chr19:46296257	DMWD	0.48	7.22	0.37	3.63e-12	Coronary artery disease;
LUSC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.62	10.88	0.51	8.36e-24	Type 2 diabetes;
LUSC	cis	rs7106204	0.764	rs79427715	chr11:24247046	G/A	ch.11.24196551F	chr11:24239977	NA	0.92	7.85	0.39	5.82e-14	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs73206853	0.619	rs112148402	chr12:111171493	T/C	cg12870014	chr12:110450643	ANKRD13A	0.69	7.34	0.37	1.62e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg23505145	chr19:12996616	KLF1	0.64	10.7	0.51	3.62e-23	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg00999904	chr2:3704751	ALLC	-0.43	-6.67	-0.34	1.06e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.75	-9.0	-0.44	1.8e-17	Refractive error;
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.84	14.54	0.62	1.97e-37	Menarche (age at onset);
LUSC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg01973587	chr1:228161476	NA	-0.41	-7.39	-0.37	1.17e-12	Diastolic blood pressure;
LUSC	cis	rs7011049	0.673	rs17256515	chr8:53827232	C/T	cg26025543	chr8:53854495	NA	0.46	6.22	0.32	1.48e-9	Systolic blood pressure;
LUSC	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg00105475	chr2:10696890	NA	0.38	6.27	0.32	1.11e-9	Prostate cancer;
LUSC	cis	rs6845621	0.901	rs6834863	chr4:18919159	C/A	cg12196642	chr4:18937545	NA	-0.34	-6.37	-0.33	6.12e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.3	0.53	2.77e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	6.3	0.33	9.27e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs193541	0.626	rs6878780	chr5:122093740	T/C	cg19077854	chr5:122220652	SNX24	0.28	6.26	0.32	1.22e-9	Glucose homeostasis traits;
LUSC	cis	rs6009527	1.000	rs2318941	chr22:49573400	G/A	cg12746016	chr22:49560550	NA	0.35	6.0	0.31	5.19e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
LUSC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.43	-6.2	-0.32	1.63e-9	Platelet count;
LUSC	cis	rs2361710	0.611	rs3816257	chr17:78074446	G/T	cg24585782	chr17:78113791	EIF4A3	0.46	7.26	0.37	2.68e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11764359	chr7:65958608	NA	-0.58	-8.99	-0.44	1.87e-17	Aortic root size;
LUSC	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.52	6.52	0.34	2.6200000000000003e-10	Renal function-related traits (BUN);
LUSC	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg27661571	chr11:113659931	NA	-0.59	-7.18	-0.37	4.61e-12	Hip circumference adjusted for BMI;
LUSC	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.72e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg15133208	chr4:90757351	SNCA	-0.53	-8.16	-0.41	6.98e-15	Neuroticism;
LUSC	cis	rs7527798	0.592	rs12563520	chr1:207844062	C/T	cg09232269	chr1:207846808	CR1L	-0.28	-6.0	-0.31	5.05e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg18758796	chr5:131593413	PDLIM4	0.36	6.19	0.32	1.81e-9	Blood metabolite levels;
LUSC	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg04374321	chr14:90722782	PSMC1	0.71	11.26	0.52	3.82e-25	Mortality in heart failure;
LUSC	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22980127	chr19:33182716	NUDT19	0.91	12.49	0.56	1.25e-29	Red blood cell traits;
LUSC	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg00012203	chr2:219082015	ARPC2	-0.57	-9.03	-0.44	1.37e-17	Ulcerative colitis;
LUSC	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg13393036	chr8:95962371	TP53INP1	0.3	6.16	0.32	2.12e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4776059	1.000	rs4776066	chr15:52930499	T/C	cg22715398	chr15:52968154	KIAA1370	-0.65	-9.41	-0.46	8.6e-19	Schizophrenia;
LUSC	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg09904177	chr6:26538194	HMGN4	0.77	14.98	0.63	3.78e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg12573674	chr2:1569213	NA	-0.63	-8.69	-0.43	1.66e-16	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg03563238	chr19:33554763	RHPN2	-0.41	-6.56	-0.34	2.09e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	0.9	13.19	0.59	2.94e-32	Uric acid levels;
LUSC	cis	rs2413583	0.536	rs17304621	chr22:39690791	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.65	6.24	0.32	1.36e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12986413	0.874	rs4806832	chr19:2184652	C/T	cg09261902	chr19:2140048	AP3D1	0.31	5.68	0.3	2.92e-8	Height;
LUSC	cis	rs7589342	0.536	rs55830542	chr2:106387206	C/T	cg09152813	chr2:106391379	NCK2	-0.38	-6.24	-0.32	1.31e-9	Addiction;
LUSC	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg12552261	chr5:112820674	MCC	-0.43	-6.95	-0.36	1.98e-11	Type 2 diabetes;
LUSC	cis	rs7336332	0.598	rs77055070	chr13:28010516	C/G	cg22138327	chr13:27999177	GTF3A	0.8	10.02	0.48	7.6e-21	Weight;
LUSC	cis	rs6834538	0.597	rs4833414	chr4:113469913	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.36	5.82	0.3	1.37e-8	Free thyroxine concentration;
LUSC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	13.71	0.6	2.89e-34	Cognitive test performance;
LUSC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	15.29	0.64	2.21e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs62400317	0.859	rs10456122	chr6:45163057	C/G	cg18551225	chr6:44695536	NA	-0.44	-7.2	-0.37	4.1e-12	Total body bone mineral density;
LUSC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02034447	chr16:89574710	SPG7	0.4	5.87	0.31	1.05e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	7.03	0.36	1.17e-11	Parkinson's disease;
LUSC	cis	rs6723226	0.503	rs4952262	chr2:32597234	G/A	cg02381751	chr2:32503542	YIPF4	-0.51	-7.56	-0.38	3.91e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs11112613	0.775	rs12305225	chr12:105963266	G/C	cg03607813	chr12:105948248	NA	0.74	10.47	0.5	2.35e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs7903847	0.642	rs10882908	chr10:99134970	T/C	cg20016023	chr10:99160130	RRP12	-0.34	-8.41	-0.42	1.2e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4919687	0.550	rs12780827	chr10:104467954	T/C	cg04362960	chr10:104952993	NT5C2	0.46	6.55	0.34	2.12e-10	Colorectal cancer;
LUSC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg24642844	chr7:1081250	C7orf50	-0.46	-7.39	-0.37	1.21e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.66	0.3	3.26e-8	Menopause (age at onset);
LUSC	cis	rs11153730	0.503	rs283042	chr6:118631282	G/A	cg21191810	chr6:118973309	C6orf204	0.34	5.77	0.3	1.78e-8	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
LUSC	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg11244672	chr19:19639970	YJEFN3	-0.54	-6.56	-0.34	1.99e-10	Bipolar disorder;
LUSC	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg09092052	chr15:45571596	NA	0.44	6.29	0.33	1e-9	Glomerular filtration rate;
LUSC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg13531842	chr10:38383804	ZNF37A	-0.45	-6.95	-0.36	1.91e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.81	0.43	6.77e-17	Axial length;
LUSC	trans	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg26043149	chr18:55253948	FECH	-0.45	-6.93	-0.35	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg24675658	chr1:53192096	ZYG11B	-0.56	-8.86	-0.44	4.82e-17	Monocyte count;
LUSC	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.51	-9.47	-0.46	5.36e-19	Height;
LUSC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	1.07	13.24	0.59	1.9e-32	Sexual dysfunction (female);
LUSC	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	6.45	0.33	3.83e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs6545883	0.894	rs2593633	chr2:61571513	T/C	cg15711740	chr2:61764176	XPO1	0.42	6.5	0.34	2.87e-10	Tuberculosis;
LUSC	cis	rs7224314	1.000	rs6504503	chr17:65386690	A/T	cg01507342	chr17:65387096	PITPNC1	-0.42	-7.54	-0.38	4.58e-13	Diisocyanate-induced asthma;
LUSC	cis	rs6494488	0.500	rs72742913	chr15:64846710	G/A	cg08069370	chr15:64387884	SNX1	-0.64	-5.73	-0.3	2.26e-8	Coronary artery disease;
LUSC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06634786	chr22:41940651	POLR3H	0.51	6.1	0.32	2.91e-9	Vitiligo;
LUSC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg07660663	chr8:117886887	RAD21	0.47	6.12	0.32	2.67e-9	Thyroid stimulating hormone;
LUSC	trans	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.35	0.49	5.71e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	10.1	0.48	4.1e-21	Bipolar disorder;
LUSC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg05313129	chr8:58192883	C8orf71	-0.5	-6.9	-0.35	2.65e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2274273	0.870	rs8018110	chr14:55641714	C/T	cg04306507	chr14:55594613	LGALS3	0.58	13.58	0.6	9.41e-34	Protein biomarker;
LUSC	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.53	-7.42	-0.38	9.89e-13	Gut microbiome composition (winter);
LUSC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg24250549	chr1:154909240	PMVK	0.64	10.35	0.49	5.96e-22	Prostate cancer;
LUSC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.19	-0.37	4.4e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.51e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.6	-0.34	1.61e-10	Neuroticism;
LUSC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18876405	chr7:65276391	NA	-0.53	-8.4	-0.42	1.28e-15	Aortic root size;
LUSC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08280861	chr8:58055591	NA	0.53	5.81	0.3	1.5e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06022373	chr22:39101656	GTPBP1	-0.65	-10.0	-0.48	8.97e-21	Menopause (age at onset);
LUSC	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg23950597	chr19:37808831	NA	-0.62	-7.38	-0.37	1.27e-12	Coronary artery calcification;
LUSC	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg00071950	chr4:10020882	SLC2A9	0.48	7.79	0.39	8.76e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25072359	chr17:41440525	NA	0.68	9.5	0.46	4.34e-19	Menopause (age at onset);
LUSC	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg23280166	chr11:118938394	VPS11	0.47	7.24	0.37	3.07e-12	Coronary artery disease;
LUSC	trans	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.63	-0.34	1.36e-10	Life satisfaction;
LUSC	cis	rs10170310	1.000	rs10803568	chr2:139290914	T/C	cg03782584	chr2:139258740	SPOPL	0.33	5.74	0.3	2.17e-8	Response to antipsychotic treatment;
LUSC	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.52	10.44	0.5	2.89e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.61	-0.38	2.81e-13	Height;
LUSC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11764359	chr7:65958608	NA	0.68	10.94	0.51	4.97e-24	Aortic root size;
LUSC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.63	13.71	0.6	3.01e-34	Hemoglobin concentration;
LUSC	cis	rs4363385	0.818	rs2070964	chr1:153004213	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.66	-0.3	3.33e-8	Inflammatory skin disease;
LUSC	cis	rs1322512	0.917	rs2258926	chr6:152973974	C/T	cg27316956	chr6:152958899	SYNE1	-0.37	-6.3	-0.33	9.2e-10	Tonometry;
LUSC	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg05855489	chr10:104503620	C10orf26	0.46	7.08	0.36	8.39e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg23422044	chr7:1970798	MAD1L1	-0.59	-6.63	-0.34	1.32e-10	Neuroticism;
LUSC	cis	rs7572644	0.713	rs4666025	chr2:28073894	C/T	cg27432699	chr2:27873401	GPN1	0.52	6.62	0.34	1.45e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg26102564	chr10:131424627	MGMT	0.4	6.07	0.32	3.41e-9	Response to temozolomide;
LUSC	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg00864171	chr11:67383662	NA	0.34	6.06	0.31	3.7e-9	Mean corpuscular volume;
LUSC	cis	rs3087591	0.922	rs757383	chr17:29596045	C/G	cg24425628	chr17:29625626	OMG;NF1	0.56	8.14	0.41	8.05e-15	Hip circumference;
LUSC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11764359	chr7:65958608	NA	0.63	9.45	0.46	6.07e-19	Calcium levels;
LUSC	cis	rs9296092	0.500	rs35150558	chr6:33519612	T/A	cg13560919	chr6:33536144	NA	-0.82	-15.74	-0.65	3.89e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08645402	chr16:4508243	NA	0.53	8.8	0.43	7.36e-17	Schizophrenia;
LUSC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg24675658	chr1:53192096	ZYG11B	-0.67	-11.08	-0.52	1.7e-24	Monocyte count;
LUSC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18301423	chr5:131593218	PDLIM4	0.47	7.48	0.38	6.75e-13	Acylcarnitine levels;
LUSC	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	9.05	0.44	1.25e-17	Total body bone mineral density;
LUSC	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg19610905	chr11:61596333	FADS2	-0.54	-7.68	-0.39	1.82e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14995716	chr1:32687918	C1orf91;EIF3I	-0.43	-6.03	-0.31	4.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg04310649	chr10:35416472	CREM	-0.43	-6.7	-0.34	9.05e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4919687	0.550	rs4264100	chr10:104454113	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-5.89	-0.31	9.25e-9	Colorectal cancer;
LUSC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg05535760	chr7:792225	HEATR2	0.79	9.68	0.47	1.06e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15664640	chr17:80829946	TBCD	0.49	8.68	0.43	1.73e-16	Breast cancer;
LUSC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.58	-9.51	-0.46	4.03e-19	Aortic root size;
LUSC	cis	rs7923609	0.811	rs3847325	chr10:65331511	G/C	cg01631684	chr10:65280961	REEP3	0.4	5.92	0.31	7.83e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg22563815	chr15:78856949	CHRNA5	0.25	5.98	0.31	5.68e-9	Sudden cardiac arrest;
LUSC	cis	rs9311676	0.632	rs62258094	chr3:58371770	T/G	cg13750441	chr3:58318267	PXK	0.35	6.7	0.34	9.04e-11	Systemic lupus erythematosus;
LUSC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.05e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7582720	1.000	rs72934764	chr2:203758521	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs28647808	0.881	rs28622217	chr9:136267323	A/G	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg04546413	chr19:29218101	NA	0.56	7.2	0.37	4.1e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	trans	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg07211511	chr3:129823064	LOC729375	-0.81	-10.59	-0.5	8.36e-23	Blood pressure (smoking interaction);
LUSC	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg13334819	chr7:99746414	C7orf59	-0.42	-5.7	-0.3	2.64e-8	Coronary artery disease;
LUSC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.88	14.24	0.61	2.76e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.26	-0.49	1.22e-21	Alzheimer's disease;
LUSC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg00376283	chr12:123451042	ABCB9	-0.79	-12.12	-0.55	2.85e-28	Platelet count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06792154	chr17:29157990	ATAD5	0.42	6.12	0.32	2.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7106204	0.514	rs7117803	chr11:24253214	A/T	ch.11.24196551F	chr11:24239977	NA	0.92	10.2	0.49	1.98e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs427941	0.669	rs417013	chr7:101820155	G/A	cg06246474	chr7:101738831	CUX1	0.35	5.69	0.3	2.83e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.25	-0.45	2.79e-18	Acne (severe);
LUSC	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.52e-8	Breast cancer;
LUSC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg13319975	chr6:146136371	FBXO30	0.51	7.73	0.39	1.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg21724239	chr8:58056113	NA	-0.56	-6.92	-0.35	2.3e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.63	9.73	0.47	7.25e-20	Lymphocyte counts;
LUSC	cis	rs870825	0.929	rs72689273	chr4:185592750	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	11.77	0.54	5.29e-27	Blood protein levels;
LUSC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.48	-9.22	-0.45	3.42e-18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg05347473	chr6:146136440	FBXO30	-0.59	-10.32	-0.49	7.39e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg05863683	chr7:1912471	MAD1L1	0.3	5.69	0.3	2.74e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg24375607	chr4:120327624	NA	0.74	11.06	0.52	1.94e-24	Corneal astigmatism;
LUSC	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg24579218	chr15:68104479	NA	-0.34	-5.74	-0.3	2.17e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21201659	chr10:121652288	SEC23IP	-0.43	-6.14	-0.32	2.33e-9	Electrocardiographic conduction measures;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13854399	chr2:203736430	ICA1L	-0.42	-6.3	-0.33	9.16e-10	Electrocardiographic conduction measures;
LUSC	trans	rs13112683	0.638	rs2667364	chr4:140782082	C/T	cg23590389	chr7:157102769	NA	-0.31	-5.98	-0.31	5.58e-9	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LUSC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.57	-11.99	-0.55	8.37e-28	Prudent dietary pattern;
LUSC	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	8.14	0.41	8.06e-15	Response to antipsychotic treatment;
LUSC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg08219700	chr8:58056026	NA	0.5	6.39	0.33	5.55e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs77633900	0.772	rs157778	chr15:76759444	G/C	cg21673338	chr15:77095150	SCAPER	-0.72	-6.25	-0.32	1.23e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg22681709	chr2:178499509	PDE11A	-0.49	-7.61	-0.38	2.82e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.81	12.85	0.58	5.63e-31	Breast cancer;
LUSC	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg10434728	chr15:90938212	IQGAP1	0.31	5.81	0.3	1.45e-8	Rheumatoid arthritis;
LUSC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg04414720	chr1:150670196	GOLPH3L	0.49	7.74	0.39	1.17e-13	Melanoma;
LUSC	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg01858014	chr14:56050164	KTN1	-0.81	-6.82	-0.35	4.32e-11	Putamen volume;
LUSC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02187348	chr16:89574699	SPG7	0.6	9.86	0.47	2.67e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.35	0.56	4.21e-29	Motion sickness;
LUSC	cis	rs3936840	0.539	rs11850701	chr14:102983857	G/A	cg18135206	chr14:102964638	TECPR2	0.51	6.39	0.33	5.6e-10	Plateletcrit;
LUSC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.78	11.33	0.53	2.21e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.63	-8.96	-0.44	2.28e-17	Other erythrocyte phenotypes;
LUSC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	trans	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg24644049	chr4:85504048	CDS1	0.88	7.53	0.38	4.81e-13	Skin colour saturation;
LUSC	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg26677194	chr12:130822605	PIWIL1	0.59	8.77	0.43	9.52e-17	Menopause (age at onset);
LUSC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.86	14.12	0.61	7.7e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11051970	0.918	rs325417	chr12:32574217	A/G	cg24626660	chr12:32551988	NA	0.36	6.14	0.32	2.37e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01341218	chr17:43662625	NA	-0.73	-10.68	-0.5	4.35e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg06951627	chr6:26196580	NA	0.53	5.72	0.3	2.39e-8	Gout;Renal underexcretion gout;
LUSC	trans	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	trans	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.98	0.51	3.7e-24	Mean corpuscular volume;
LUSC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.83	-13.97	-0.61	2.97e-35	Height;
LUSC	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg03522245	chr20:25566470	NINL	-0.36	-5.79	-0.3	1.64e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg03388025	chr16:89894329	SPIRE2	0.34	6.94	0.35	2.1e-11	Vitiligo;
LUSC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg10523679	chr1:76189770	ACADM	0.85	11.3	0.53	2.74e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs35146811	0.589	rs1727142	chr7:99816179	T/C	cg22906224	chr7:99728672	NA	-0.46	-6.18	-0.32	1.83e-9	Coronary artery disease;
LUSC	cis	rs6489882	0.867	rs7305035	chr12:113365803	T/C	cg20102336	chr12:113376681	OAS3	-0.4	-5.7	-0.3	2.59e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg02569458	chr12:86230093	RASSF9	0.58	9.84	0.47	3.05e-20	Major depressive disorder;
LUSC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs79149102	0.649	rs1531163	chr15:75113083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.84	-5.9	-0.31	8.85e-9	Lung cancer;
LUSC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg00701064	chr4:6280414	WFS1	-0.54	-13.77	-0.6	1.79e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg24634471	chr8:143751801	JRK	0.6	8.99	0.44	1.83e-17	Schizophrenia;
LUSC	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg04756594	chr16:24857601	SLC5A11	0.46	6.62	0.34	1.47e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg15556689	chr8:8085844	FLJ10661	0.69	11.68	0.54	1.17e-26	Mood instability;
LUSC	cis	rs4589502	0.800	rs4776855	chr15:67202075	T/C	cg09911534	chr15:67153556	NA	0.5	6.43	0.33	4.51e-10	Lung cancer (smoking interaction);
LUSC	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg08886695	chr4:3369023	RGS12	-0.37	-5.73	-0.3	2.2e-8	Serum sulfate level;
LUSC	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.21	0.49	1.83e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7246657	0.551	rs12972146	chr19:37626095	G/T	cg23950597	chr19:37808831	NA	-0.53	-5.79	-0.3	1.59e-8	Coronary artery calcification;
LUSC	cis	rs7572644	0.603	rs4666013	chr2:28019106	C/T	cg27432699	chr2:27873401	GPN1	0.55	7.26	0.37	2.74e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs877282	0.685	rs56234340	chr10:781339	A/G	cg17470449	chr10:769945	NA	0.44	6.24	0.32	1.32e-9	Uric acid levels;
LUSC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.67	-16.18	-0.66	6.96e-44	Prostate cancer;
LUSC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.56	-9.51	-0.46	3.77e-19	Neurofibrillary tangles;
LUSC	cis	rs4072705	0.904	rs721863	chr9:127536267	A/T	cg13476313	chr9:127244764	NR5A1	0.3	5.97	0.31	6.1e-9	Menarche (age at onset);
LUSC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.45	-5.93	-0.31	7.38e-9	Menarche (age at onset);
LUSC	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08109568	chr15:31115862	NA	-0.66	-9.07	-0.44	1.01e-17	Huntington's disease progression;
LUSC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.19	-0.52	6.61e-25	Alzheimer's disease;
LUSC	cis	rs6500395	1.000	rs7206647	chr16:48709220	G/C	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg13010199	chr12:38710504	ALG10B	0.66	9.86	0.47	2.65e-20	Bladder cancer;
LUSC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg13047869	chr3:10149882	C3orf24	0.6	8.23	0.41	4.26e-15	Alzheimer's disease;
LUSC	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg06219351	chr7:158114137	PTPRN2	0.5	9.02	0.44	1.51e-17	Calcium levels;
LUSC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.66	0.43	1.98e-16	Lung cancer;
LUSC	cis	rs1971762	0.563	rs4759285	chr12:54079513	G/T	cg23533419	chr12:54090519	NA	-0.35	-5.82	-0.3	1.41e-8	Height;
LUSC	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg22705602	chr4:152727874	NA	-0.39	-8.61	-0.43	3.03e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg11645453	chr3:52864694	ITIH4	0.35	8.14	0.41	7.76e-15	Bipolar disorder;
LUSC	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg20991723	chr1:152506922	NA	0.5	9.18	0.45	4.77e-18	Hair morphology;
LUSC	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg20790798	chr5:1857306	NA	-0.49	-8.5	-0.42	6.19e-16	Cardiovascular disease risk factors;
LUSC	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg12365402	chr11:9010492	NRIP3	-0.4	-6.92	-0.35	2.29e-11	Hematocrit;
LUSC	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg23029597	chr12:123009494	RSRC2	-0.64	-8.41	-0.42	1.21e-15	Body mass index;
LUSC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22509189	chr2:225307070	NA	-0.49	-6.37	-0.33	6.13e-10	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs9359856	0.564	rs17292425	chr6:90372128	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.89	-8.73	-0.43	1.25e-16	Bipolar disorder;
LUSC	cis	rs225245	0.817	rs225299	chr17:33922742	T/C	cg05299278	chr17:33885742	SLFN14	0.31	6.85	0.35	3.64e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs11971779	0.938	rs11981688	chr7:139088895	A/G	cg07862535	chr7:139043722	LUC7L2	0.73	8.41	0.42	1.23e-15	Diisocyanate-induced asthma;
LUSC	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg11812906	chr14:75593930	NEK9	-0.65	-10.19	-0.49	2.08e-21	Height;
LUSC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.15	0.49	2.78e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3820928	0.874	rs4675134	chr2:227843489	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.83	-0.39	6.69e-14	Pulmonary function;
LUSC	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.21	-0.32	1.56e-9	Retinal vascular caliber;
LUSC	trans	rs12043259	1.000	rs4370813	chr1:204852893	A/G	cg23865240	chr7:27134109	HOXA1	0.56	6.06	0.31	3.6e-9	Addiction;
LUSC	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	8.09	0.4	1.13e-14	Iron status biomarkers;
LUSC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	0.79	13.99	0.61	2.56e-35	Cognitive function;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg06877462	chr1:205807181	PM20D1	0.47	8.48	0.42	7.53e-16	Menarche (age at onset);
LUSC	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg01982873	chr5:490308	SLC9A3	-0.35	-6.29	-0.33	1.02e-9	Cystic fibrosis severity;
LUSC	cis	rs12541635	0.677	rs10086055	chr8:107024129	C/T	cg10147462	chr8:107024639	NA	0.67	14.1	0.61	9.64e-36	Age of smoking initiation;
LUSC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.57	8.68	0.43	1.72e-16	Lymphocyte counts;
LUSC	cis	rs7582720	1.000	rs6738618	chr2:203749439	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg20587970	chr11:113659929	NA	-1.11	-13.57	-0.6	1.02e-33	Hip circumference adjusted for BMI;
LUSC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg20406979	chr6:167373233	NA	-0.26	-5.95	-0.31	6.67e-9	Crohn's disease;
LUSC	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.85	-0.3	1.18e-8	Testicular germ cell tumor;
LUSC	cis	rs2652834	0.851	rs2729823	chr15:63420660	A/G	cg05507819	chr15:63340323	TPM1	0.47	6.06	0.31	3.77e-9	HDL cholesterol;
LUSC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg20203395	chr5:56204925	C5orf35	-0.76	-10.1	-0.48	4.17e-21	Initial pursuit acceleration;
LUSC	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg08470875	chr2:26401718	FAM59B	-0.53	-6.81	-0.35	4.5e-11	Gut microbiome composition (summer);
LUSC	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.35e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9815354	0.680	rs73073285	chr3:42027566	T/G	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg06145435	chr7:1022769	CYP2W1	0.29	6.37	0.33	6.14e-10	Longevity;Endometriosis;
LUSC	cis	rs6424115	1.000	rs4649115	chr1:24155731	A/G	cg10978503	chr1:24200527	CNR2	-0.51	-12.0	-0.55	7.98e-28	Immature fraction of reticulocytes;
LUSC	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-0.55	-8.63	-0.43	2.47e-16	Breast cancer;
LUSC	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.78	-0.43	8.95e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	0.7	11.12	0.52	1.19e-24	Blood metabolite ratios;
LUSC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-10.15	-0.49	2.92e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	8.8	0.43	7.62e-17	Myopia (pathological);
LUSC	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg24006582	chr15:45444508	DUOX1	-0.62	-9.07	-0.44	1.03e-17	Uric acid levels;
LUSC	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg23093090	chr10:104574429	C10orf26	0.34	6.51	0.34	2.71e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs4252134	0.959	rs4252093	chr6:161133685	A/G	cg15416064	chr12:49209402	NA	-0.43	-6.02	-0.31	4.47e-9	Giant cell arteritis;
LUSC	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg24851651	chr11:66362959	CCS	-0.36	-5.74	-0.3	2.17e-8	Educational attainment (years of education);
LUSC	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg13072238	chr3:49761600	GMPPB	0.68	8.57	0.42	4.02e-16	Menarche (age at onset);
LUSC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18252515	chr7:66147081	NA	-0.56	-7.71	-0.39	1.44e-13	Corneal structure;
LUSC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.77	-0.35	5.74e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg13047869	chr3:10149882	C3orf24	0.56	8.01	0.4	1.93e-14	Alzheimer's disease;
LUSC	cis	rs2190422	0.651	rs2965086	chr7:103084913	C/T	cg04218035	chr7:103086829	SLC26A5	0.31	6.08	0.32	3.21e-9	Morning vs. evening chronotype;
LUSC	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	11.06	0.52	2.02e-24	Lung cancer in ever smokers;
LUSC	cis	rs7605827	0.930	rs11694485	chr2:15676154	C/T	cg19274914	chr2:15703543	NA	0.45	8.67	0.43	1.88e-16	Educational attainment (years of education);
LUSC	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-0.9	-15.71	-0.65	4.81e-42	Height;
LUSC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg07701084	chr6:150067640	NUP43	0.55	8.45	0.42	9.18e-16	Lung cancer;
LUSC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg03433033	chr1:76189801	ACADM	0.72	9.47	0.46	5.43e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg03433033	chr1:76189801	ACADM	-0.48	-7.33	-0.37	1.8e-12	Daytime sleep phenotypes;
LUSC	trans	rs2288327	0.591	rs2255167	chr2:179558282	T/A	cg14011486	chr1:26737247	LIN28	0.52	6.61	0.34	1.51e-10	Atrial fibrillation;
LUSC	cis	rs3092073	1.000	rs3092073	chr20:44595649	G/A	cg27529037	chr20:44575021	PCIF1	-0.35	-6.06	-0.31	3.69e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs6030	1.000	rs1557572	chr1:169508576	A/C	cg25052156	chr10:123355454	FGFR2	0.32	5.95	0.31	6.8e-9	Uric acid levels;
LUSC	trans	rs6498114	0.541	rs72770017	chr16:10973612	G/A	cg03103192	chr4:52917271	SPATA18	0.33	6.0	0.31	5.02e-9	Nasopharyngeal carcinoma;
LUSC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.48	-0.42	7.39e-16	Obesity-related traits;
LUSC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg04455712	chr21:45112962	RRP1B	0.45	8.46	0.42	8.63e-16	Mean corpuscular volume;
LUSC	cis	rs7523273	0.606	rs2796271	chr1:207941927	A/G	cg22525895	chr1:207977042	MIR29B2	0.42	6.72	0.35	7.81e-11	Schizophrenia;
LUSC	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg01528321	chr10:82214614	TSPAN14	1.09	12.1	0.55	3.36e-28	Post bronchodilator FEV1;
LUSC	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg13010199	chr12:38710504	ALG10B	0.56	8.42	0.42	1.12e-15	Morning vs. evening chronotype;
LUSC	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14240646	chr10:27532245	ACBD5	-0.66	-7.91	-0.4	3.77e-14	Breast cancer;
LUSC	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg04362960	chr10:104952993	NT5C2	0.62	9.77	0.47	5.41e-20	Arsenic metabolism;
LUSC	cis	rs2070997	0.667	rs12156431	chr9:133719540	A/G	cg11464064	chr9:133710261	ABL1	0.48	5.68	0.3	2.97e-8	Response to amphetamines;
LUSC	cis	rs6500395	0.962	rs2101372	chr16:48627306	G/A	cg04672837	chr16:48644449	N4BP1	0.49	7.06	0.36	9.81e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg25036284	chr2:26402008	FAM59B	-0.68	-9.58	-0.46	2.22e-19	Gut microbiome composition (summer);
LUSC	cis	rs6690583	0.623	rs6679539	chr1:85479457	G/T	cg11262906	chr1:85462892	MCOLN2	-0.66	-6.66	-0.34	1.14e-10	Serum sulfate level;
LUSC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs727505	1.000	rs66922607	chr7:124512555	T/A	cg23710748	chr7:124431027	NA	-0.42	-7.42	-0.38	1e-12	Lewy body disease;
LUSC	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.6	9.74	0.47	6.75e-20	Body mass index;
LUSC	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.72	-10.6	-0.5	8.24e-23	Glomerular filtration rate;
LUSC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg26566898	chr11:117069891	TAGLN	0.47	8.3	0.41	2.56e-15	Blood protein levels;
LUSC	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.3	-5.74	-0.3	2.07e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg25036284	chr2:26402008	FAM59B	-0.71	-10.01	-0.48	8.54e-21	Gut microbiome composition (summer);
LUSC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg13047869	chr3:10149882	C3orf24	0.64	8.61	0.43	2.98e-16	Alzheimer's disease;
LUSC	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg20203395	chr5:56204925	C5orf35	0.41	6.14	0.32	2.36e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg07217954	chr7:1067459	C7orf50	0.53	5.77	0.3	1.83e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg00701064	chr4:6280414	WFS1	0.62	15.62	0.65	1.16e-41	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-8.49	-0.42	6.96e-16	Bladder cancer;
LUSC	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-6.92	-0.35	2.37e-11	Bladder cancer;
LUSC	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg10426581	chr7:100472382	SRRT	0.86	12.48	0.56	1.36e-29	Resting heart rate;
LUSC	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.64	9.97	0.48	1.16e-20	Schizophrenia;
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg06877462	chr1:205807181	PM20D1	0.49	8.82	0.43	6.26e-17	Menarche (age at onset);
LUSC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06112835	chr11:68658793	MRPL21	0.52	7.83	0.39	6.4e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10761482	0.813	rs2061487	chr10:62102842	T/C	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.67	0.5	4.62e-23	Colorectal cancer;
LUSC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25072359	chr17:41440525	NA	0.65	9.21	0.45	3.66e-18	Menopause (age at onset);
LUSC	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.62	9.88	0.48	2.23e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs12545109	0.765	rs1960727	chr8:57411368	G/A	cg09654669	chr8:57350985	NA	-0.52	-6.66	-0.34	1.11e-10	Obesity-related traits;
LUSC	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg08847533	chr14:75593920	NEK9	-0.81	-14.58	-0.62	1.31e-37	Height;
LUSC	cis	rs9311676	0.632	rs67904096	chr3:58365508	T/A	cg26110898	chr3:58419937	PDHB	0.44	7.22	0.37	3.62e-12	Systemic lupus erythematosus;
LUSC	cis	rs950881	0.932	rs3771180	chr2:102953617	G/T	cg20060108	chr2:102954350	IL1RL1	0.45	5.9	0.31	8.86e-9	Allergy;
LUSC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.61	-0.43	2.88e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg12751644	chr20:60527061	NA	0.41	6.98	0.36	1.6e-11	Obesity-related traits;
LUSC	cis	rs12421382	0.636	rs34802147	chr11:109380008	C/T	cg27471124	chr11:109292789	C11orf87	0.36	6.49	0.33	3.17e-10	Schizophrenia;
LUSC	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.55e-13	Putamen volume;
LUSC	cis	rs2398893	0.774	rs3909256	chr9:96889505	C/T	cg14459158	chr9:96720562	NA	-0.34	-6.05	-0.31	3.87e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg25457927	chr22:38595422	NA	-0.44	-9.11	-0.45	7.93e-18	Cutaneous nevi;
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.55	-8.29	-0.41	2.85e-15	Lymphocyte counts;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03158666	chr17:7199744	NA	0.46	6.03	0.31	4.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs73198271	0.562	rs76702427	chr8:8660141	G/T	cg01851573	chr8:8652454	MFHAS1	0.65	8.7	0.43	1.49e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg25048357	chr11:118955763	HMBS	0.48	5.99	0.31	5.39e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.51	7.23	0.37	3.38e-12	Gut microbiome composition (summer);
LUSC	cis	rs9650315	0.866	rs4601281	chr8:57182353	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	6.34	0.33	7.34e-10	Height;
LUSC	trans	rs1459104	0.714	rs1851614	chr11:54836269	C/T	cg15704280	chr7:45808275	SEPT13	0.77	6.69	0.34	9.32e-11	Body mass index;
LUSC	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg22800045	chr5:56110881	MAP3K1	0.44	6.26	0.32	1.18e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs9311676	0.656	rs9881869	chr3:58333255	G/A	cg13750441	chr3:58318267	PXK	-0.31	-5.88	-0.31	1.01e-8	Systemic lupus erythematosus;
LUSC	cis	rs62400317	0.859	rs2038765	chr6:45076494	A/G	cg18551225	chr6:44695536	NA	-0.41	-6.81	-0.35	4.56e-11	Total body bone mineral density;
LUSC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg21918786	chr6:109611834	NA	-0.42	-7.31	-0.37	1.99e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.17	-0.37	4.88e-12	Alzheimer's disease (late onset);
LUSC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.35	0.59	7.08e-33	Cognitive test performance;
LUSC	trans	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg07393940	chr7:158741817	NA	-0.36	-6.46	-0.33	3.76e-10	Life satisfaction;
LUSC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.39	0.53	1.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg03342759	chr3:160939853	NMD3	-0.57	-9.81	-0.47	4.11e-20	Morning vs. evening chronotype;
LUSC	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.89	-0.4	4.48e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg05472934	chr7:22766657	IL6	0.41	6.39	0.33	5.49e-10	Lung cancer;
LUSC	cis	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg06521331	chr12:34319734	NA	-0.49	-8.11	-0.41	9.94e-15	Morning vs. evening chronotype;
LUSC	trans	rs1994089	0.781	rs7215469	chr17:33510235	G/A	cg25602930	chr2:9533887	ASAP2	0.43	6.42	0.33	4.81e-10	Macrophage inflammatory protein 1b levels;
LUSC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg24642844	chr7:1081250	C7orf50	-0.51	-7.95	-0.4	2.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.68	0.39	1.78e-13	Obesity-related traits;
LUSC	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg08854313	chr1:11322531	MTOR	0.8	12.45	0.56	1.6800000000000001e-29	Body mass index;
LUSC	cis	rs12474201	0.894	rs4952842	chr2:46925730	C/A	cg06386533	chr2:46925753	SOCS5	0.79	12.1	0.55	3.33e-28	Height;
LUSC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg17178900	chr1:205818956	PM20D1	0.42	5.79	0.3	1.66e-8	Menarche (age at onset);
LUSC	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.36e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-7.77	-0.39	9.77e-14	Menarche (age at onset);
LUSC	cis	rs3750965	0.920	rs4930644	chr11:68819097	C/T	cg06818126	chr11:68850279	TPCN2	-0.45	-6.3	-0.33	9.46e-10	Hair color;
LUSC	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.2	22.43	0.78	1.32e-68	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2625529	0.775	rs35673773	chr15:72399886	C/A	cg16672083	chr15:72433130	SENP8	-0.52	-7.64	-0.39	2.26e-13	Red blood cell count;
LUSC	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg03605463	chr16:89740564	NA	0.38	6.01	0.31	4.83e-9	Vitiligo;
LUSC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg08975724	chr8:8085496	FLJ10661	0.53	8.17	0.41	6.57e-15	Mood instability;
LUSC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.09	0.55	3.85e-28	Prudent dietary pattern;
LUSC	cis	rs10208940	0.920	rs6714976	chr2:68764873	G/T	cg12452813	chr2:68675892	NA	0.58	5.96	0.31	6.45e-9	Urate levels in lean individuals;
LUSC	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.05	0.44	1.19e-17	Eosinophil percentage of white cells;
LUSC	cis	rs2413583	0.591	rs116136126	chr22:39729557	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.63	5.76	0.3	1.96e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.47	6.32	0.33	8.35e-10	Multiple sclerosis;
LUSC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg00033643	chr7:134001901	SLC35B4	0.43	6.6	0.34	1.59e-10	Mean platelet volume;
LUSC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg21782813	chr7:2030301	MAD1L1	0.54	9.4	0.46	9.01e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	16.06	0.66	2.05e-43	Platelet count;
LUSC	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg13042288	chr15:90349979	ANPEP	-0.47	-6.45	-0.33	3.95e-10	Uric acid levels;
LUSC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.03	0.31	4.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	14.32	0.62	1.33e-36	Tonsillectomy;
LUSC	cis	rs501916	0.833	rs10519143	chr15:48055567	T/G	cg16110827	chr15:48056943	SEMA6D	-0.47	-7.33	-0.37	1.74e-12	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.98	-0.31	5.8e-9	Retinal vascular caliber;
LUSC	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.55	-0.53	3.36e-26	Mean corpuscular volume;
LUSC	cis	rs6690583	0.573	rs61768854	chr1:85460021	T/C	cg11262906	chr1:85462892	MCOLN2	0.69	6.27	0.32	1.13e-9	Serum sulfate level;
LUSC	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg03342759	chr3:160939853	NMD3	-0.5	-8.39	-0.42	1.43e-15	Morning vs. evening chronotype;
LUSC	cis	rs4845570	0.834	rs1196467	chr1:151710038	T/C	cg07092448	chr1:151763213	TDRKH	1.05	11.46	0.53	7.17e-26	Coronary artery disease;
LUSC	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg08213375	chr14:104286397	PPP1R13B	0.53	10.54	0.5	1.28e-22	Schizophrenia;
LUSC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03517284	chr6:25882590	NA	-0.46	-8.83	-0.44	5.81e-17	Blood metabolite levels;
LUSC	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.85	-0.44	5.09e-17	Response to antipsychotic treatment;
LUSC	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	13.13	0.58	4.83e-32	Menopause (age at onset);
LUSC	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg15819921	chr19:927150	ARID3A	-0.42	-6.15	-0.32	2.2e-9	Life satisfaction;
LUSC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.3	-0.33	9.44e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07080220	chr10:102295463	HIF1AN	0.64	8.46	0.42	8.25e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.46	-7.85	-0.39	5.67e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg20302533	chr7:39170763	POU6F2	-0.42	-6.09	-0.32	3.12e-9	IgG glycosylation;
LUSC	cis	rs73200209	0.744	rs11616043	chr12:116559922	T/C	cg01776926	chr12:116560359	MED13L	-0.49	-6.01	-0.31	4.82e-9	Total body bone mineral density;
LUSC	trans	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg01620082	chr3:125678407	NA	0.5	5.95	0.31	6.59e-9	Depression;
LUSC	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg01689657	chr7:91764605	CYP51A1	0.31	5.79	0.3	1.63e-8	Breast cancer;
LUSC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-7.07	-0.36	9.2e-12	Alzheimer's disease (late onset);
LUSC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.45	0.33	3.86e-10	Menopause (age at onset);
LUSC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg23815491	chr16:72088622	HP	0.34	5.97	0.31	6.12e-9	Fibrinogen levels;
LUSC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg21770322	chr7:97807741	LMTK2	0.4	6.84	0.35	3.82e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs11650494	0.908	rs73340392	chr17:47358308	G/A	cg08112188	chr17:47440006	ZNF652	1.19	10.13	0.48	3.41e-21	Prostate cancer;
LUSC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs931127	0.719	rs2127507	chr11:65454430	A/G	cg05805236	chr11:65401703	PCNXL3	-0.42	-7.3	-0.37	2.13e-12	Systemic lupus erythematosus;
LUSC	cis	rs11756438	0.572	rs902779	chr6:119000593	A/C	cg21191810	chr6:118973309	C6orf204	0.33	5.73	0.3	2.21e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg02475777	chr4:1388615	CRIPAK	0.43	6.36	0.33	6.48e-10	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08677398	chr8:58056175	NA	0.54	6.65	0.34	1.23e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10465746	0.935	rs12410617	chr1:84379461	G/C	cg10977910	chr1:84465055	TTLL7	0.43	6.18	0.32	1.88e-9	Obesity-related traits;
LUSC	cis	rs10392	0.543	rs4812336	chr20:37547374	G/A	cg27552599	chr20:37590471	DHX35	0.44	6.94	0.36	2.03e-11	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LUSC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-9.22	-0.45	3.35e-18	Bipolar disorder;
LUSC	trans	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg25214090	chr10:38739885	LOC399744	0.5	7.64	0.39	2.31e-13	Corneal astigmatism;
LUSC	cis	rs981844	0.961	rs56288418	chr4:154668228	C/A	cg14289246	chr4:154710475	SFRP2	0.48	6.1	0.32	2.87e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs4423214	0.879	rs1790330	chr11:71147825	C/T	cg05163923	chr11:71159392	DHCR7	-0.7	-9.2	-0.45	4.07e-18	Vitamin D levels;
LUSC	cis	rs73206853	0.563	rs7960749	chr12:111164369	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.52	0.38	5.1e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2348418	0.864	rs1343859	chr12:28712470	A/G	cg13890972	chr12:28721907	NA	-0.34	-5.82	-0.3	1.39e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs9462027	0.585	rs1201873	chr6:34550657	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.06	-0.31	3.73e-9	Systemic lupus erythematosus;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10541313	chr22:46663664	TTC38	-0.4	-6.06	-0.31	3.59e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1832871	0.711	rs9459769	chr6:158666493	T/C	cg07165851	chr6:158734300	TULP4	0.5	7.61	0.38	2.81e-13	Height;
LUSC	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-5.77	-0.3	1.85e-8	Neutrophil percentage of white cells;
LUSC	trans	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg26043149	chr18:55253948	FECH	-0.46	-7.07	-0.36	9.1e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4474465	1.000	rs7124043	chr11:78205644	G/T	cg27205649	chr11:78285834	NARS2	0.51	5.91	0.31	8.55e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg17366294	chr4:99064904	C4orf37	0.52	8.55	0.42	4.5e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg09367891	chr1:107599246	PRMT6	-0.49	-7.81	-0.39	7.31e-14	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg11130432	chr3:121712080	ILDR1	-0.63	-9.61	-0.47	1.89e-19	Multiple sclerosis;
LUSC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg13206674	chr6:150067644	NUP43	0.6	9.58	0.46	2.27e-19	Lung cancer;
LUSC	cis	rs2742234	0.541	rs11528481	chr10:43737767	C/A	cg02780029	chr10:43622663	RET	0.35	5.79	0.3	1.6e-8	Hirschsprung disease;
LUSC	trans	rs72674100	1.000	rs4308366	chr4:97972932	G/C	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs56283067	0.887	rs12215971	chr6:44784566	A/G	cg20913747	chr6:44695427	NA	-0.43	-6.46	-0.33	3.6e-10	Total body bone mineral density;
LUSC	cis	rs1190552	0.637	rs7150548	chr14:102959962	T/C	cg18135206	chr14:102964638	TECPR2	0.53	5.81	0.3	1.42e-8	Blood protein levels;
LUSC	cis	rs722599	0.715	rs2080086	chr14:75338408	G/A	cg08847533	chr14:75593920	NEK9	-0.46	-6.54	-0.34	2.34e-10	IgG glycosylation;
LUSC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg11645453	chr3:52864694	ITIH4	0.37	8.61	0.43	2.99e-16	Bipolar disorder;
LUSC	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-7.52	-0.38	4.96e-13	Response to antipsychotic treatment;
LUSC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg21017887	chr14:105400489	NA	0.7	13.31	0.59	9.7e-33	Rheumatoid arthritis;
LUSC	cis	rs4280164	0.830	rs2144494	chr14:24773387	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.57	-6.81	-0.35	4.43e-11	Parent of origin effect on language impairment (paternal);
LUSC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-1.03	-20.21	-0.74	7.12e-60	Height;
LUSC	cis	rs3135063	0.504	rs3129315	chr4:3290600	C/T	cg08817983	chr4:3391423	RGS12	-0.51	-6.92	-0.35	2.27e-11	Blood protein levels;
LUSC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg22166914	chr1:53195759	ZYG11B	0.56	9.03	0.44	1.44e-17	Monocyte count;
LUSC	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg19318889	chr4:1322082	MAEA	0.48	7.83	0.39	6.69e-14	Obesity-related traits;
LUSC	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg00376283	chr12:123451042	ABCB9	0.7	7.93	0.4	3.22e-14	Neutrophil percentage of white cells;
LUSC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.48	-6.15	-0.32	2.21e-9	Mean platelet volume;
LUSC	cis	rs3099143	0.908	rs3102716	chr15:77051003	T/G	cg21673338	chr15:77095150	SCAPER	-0.84	-8.24	-0.41	4.05e-15	Recalcitrant atopic dermatitis;
LUSC	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg25214090	chr10:38739885	LOC399744	0.54	7.98	0.4	2.36e-14	Corneal astigmatism;
LUSC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg02475777	chr4:1388615	CRIPAK	0.37	5.65	0.3	3.46e-8	Obesity-related traits;
LUSC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.18	0.37	4.51e-12	Cystic fibrosis severity;
LUSC	cis	rs2742234	0.590	rs2257767	chr10:43657811	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.06	-0.36	9.53e-12	Hirschsprung disease;
LUSC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.24	0.45	3.06e-18	Motion sickness;
LUSC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-11.1	-0.52	1.45e-24	Alzheimer's disease;
LUSC	cis	rs7804356	1.000	rs3801823	chr7:26861031	T/C	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.05e-9	Type 1 diabetes;
LUSC	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg09165964	chr15:75287851	SCAMP5	-0.92	-8.15	-0.41	7.37e-15	Lung cancer;
LUSC	cis	rs2742417	1.000	rs2673033	chr3:45756350	C/G	cg09608765	chr3:45636137	LIMD1	-0.36	-7.17	-0.37	4.9e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg26441486	chr22:50317300	CRELD2	0.49	7.28	0.37	2.45e-12	Schizophrenia;
LUSC	cis	rs9513627	1.000	rs9585075	chr13:100128634	G/A	cg25919922	chr13:100150906	NA	-0.75	-6.44	-0.33	4.11e-10	Obesity-related traits;
LUSC	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.72	-0.39	1.37e-13	Joint mobility (Beighton score);
LUSC	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-5.65	-0.3	3.48e-8	IgG glycosylation;
LUSC	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.68	-11.8	-0.54	4.21e-27	Electrocardiographic conduction measures;
LUSC	cis	rs12410462	0.581	rs7541809	chr1:227547299	G/A	cg23173402	chr1:227635558	NA	0.56	6.34	0.33	7.53e-10	Major depressive disorder;
LUSC	cis	rs2625529	0.824	rs11072339	chr15:72247190	C/T	cg16672083	chr15:72433130	SENP8	-0.52	-7.51	-0.38	5.28e-13	Red blood cell count;
LUSC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg25124228	chr12:125621409	AACS	-0.48	-7.14	-0.36	6e-12	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg23711669	chr6:146136114	FBXO30	-0.91	-17.81	-0.7	2.33e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1322512	1.000	rs2758776	chr6:153006317	C/T	cg27316956	chr6:152958899	SYNE1	0.34	5.98	0.31	5.72e-9	Tonometry;
LUSC	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg02403541	chr12:121454288	C12orf43	0.56	8.66	0.43	2e-16	Subjective well-being;Cardiovascular disease risk factors;
LUSC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.36	0.53	1.61e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.42	-6.87	-0.35	3.2e-11	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.17	0.32	1.99e-9	Corneal astigmatism;
LUSC	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.59	10.28	0.49	9.88e-22	Birth weight;
LUSC	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08439880	chr3:133502540	NA	-0.4	-7.16	-0.36	5.05e-12	Iron status biomarkers;
LUSC	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.59	-9.45	-0.46	6.32e-19	Body mass index;
LUSC	cis	rs62400317	0.859	rs62436779	chr6:45124911	G/A	cg20913747	chr6:44695427	NA	-0.47	-7.55	-0.38	4.27e-13	Total body bone mineral density;
LUSC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg21724239	chr8:58056113	NA	0.78	8.17	0.41	6.56e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.48	-7.16	-0.36	5.07e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14769373	chr6:40998127	UNC5CL	-0.58	-8.06	-0.4	1.39e-14	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg16325326	chr1:53192061	ZYG11B	-0.82	-14.27	-0.62	2.19e-36	Monocyte count;
LUSC	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-6.5	-0.34	2.95e-10	Monocyte percentage of white cells;
LUSC	cis	rs73206853	0.563	rs7960761	chr12:111164415	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.35	0.37	1.52e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs62103177	0.564	rs3930043	chr18:77723832	G/A	cg14227996	chr4:17616232	MED28	0.64	6.84	0.35	3.71e-11	Opioid sensitivity;
LUSC	cis	rs2262909	0.745	rs1989120	chr19:22205528	T/C	cg11619707	chr19:22235551	ZNF257	-0.38	-5.79	-0.3	1.66e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs62400317	0.859	rs12191751	chr6:45282111	G/T	cg20913747	chr6:44695427	NA	-0.46	-7.44	-0.38	8.87e-13	Total body bone mineral density;
LUSC	cis	rs295140	0.605	rs1436164	chr2:201158411	C/T	cg04283868	chr2:201171347	SPATS2L	0.4	5.8	0.3	1.55e-8	QT interval;
LUSC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg02569458	chr12:86230093	RASSF9	0.6	10.0	0.48	8.96e-21	Major depressive disorder;
LUSC	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg03342759	chr3:160939853	NMD3	-0.5	-8.5	-0.42	6.49e-16	Morning vs. evening chronotype;
LUSC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.52	0.57	9.28e-30	Motion sickness;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18470468	chr7:98985742	ARPC1B	-0.8	-6.9	-0.35	2.58e-11	Cognitive performance;
LUSC	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg25214090	chr10:38739885	LOC399744	0.54	8.0	0.4	2.12e-14	Corneal astigmatism;
LUSC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg17294928	chr15:75287854	SCAMP5	0.43	6.19	0.32	1.72e-9	Breast cancer;
LUSC	cis	rs62408225	0.963	rs55885254	chr6:90976234	T/C	cg06866423	chr6:90926672	BACH2	0.42	5.96	0.31	6.26e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg05043794	chr9:111880884	C9orf5	-0.38	-7.97	-0.4	2.47e-14	Menarche (age at onset);
LUSC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg04733989	chr22:42467013	NAGA	-0.62	-9.65	-0.47	1.39e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-0.51	-7.89	-0.4	4.24e-14	Breast cancer;
LUSC	cis	rs926938	0.765	rs12407408	chr1:115234275	A/G	cg12756093	chr1:115239321	AMPD1	0.48	7.08	0.36	8.4e-12	Autism;
LUSC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg05347473	chr6:146136440	FBXO30	0.53	8.95	0.44	2.54e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs908922	0.887	rs4596895	chr1:152528075	T/G	cg20991723	chr1:152506922	NA	0.51	8.8	0.43	7.56e-17	Hair morphology;
LUSC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg00166722	chr3:10149974	C3orf24	-0.39	-5.98	-0.31	5.7e-9	Alzheimer's disease;
LUSC	cis	rs721399	0.512	rs4560828	chr8:18276294	A/T	cg18736775	chr8:18248649	NAT2	-0.56	-6.58	-0.34	1.82e-10	Blood metabolite levels;
LUSC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg27284194	chr4:1044797	NA	0.35	5.69	0.3	2.73e-8	Longevity;
LUSC	cis	rs7523050	0.643	rs7551313	chr1:109399881	G/A	cg08274380	chr1:109419600	GPSM2	1.1	10.69	0.51	3.76e-23	Fat distribution (HIV);
LUSC	cis	rs4253772	0.550	rs9615347	chr22:46728153	A/G	cg00784671	chr22:46762841	CELSR1	-0.5	-5.92	-0.31	7.92e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	6.7	0.34	8.74e-11	Ovarian reserve;
LUSC	cis	rs870825	0.860	rs60523653	chr4:185604676	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	10.26	0.49	1.17e-21	Blood protein levels;
LUSC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg27170947	chr2:26402098	FAM59B	-0.7	-10.76	-0.51	2.21e-23	Gut microbiome composition (summer);
LUSC	trans	rs194045	0.511	rs1611991	chr16:29151593	C/T	cg17334114	chr3:133646504	NA	0.54	6.46	0.33	3.61e-10	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg22482690	chr17:47019901	SNF8	0.39	7.34	0.37	1.6e-12	Type 2 diabetes;
LUSC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg27535305	chr1:53392650	SCP2	-0.4	-7.5	-0.38	5.74e-13	Monocyte count;
LUSC	cis	rs11229555	0.598	rs12289876	chr11:58185250	C/T	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg24324837	chr19:49891574	CCDC155	0.55	7.71	0.39	1.5e-13	Multiple sclerosis;
LUSC	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-7.85	-0.39	5.79e-14	Morning vs. evening chronotype;
LUSC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg16606324	chr3:10149918	C3orf24	0.44	6.77	0.35	5.91e-11	Alzheimer's disease;
LUSC	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13893634	chr17:48229117	PPP1R9B	-0.51	-7.78	-0.39	8.93e-14	Temporomandibular joint disorder;
LUSC	cis	rs4077515	0.967	rs11794847	chr9:139271747	G/A	cg14019695	chr9:139328340	INPP5E	0.44	8.12	0.41	8.86e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg13699009	chr12:122356056	WDR66	0.5	7.77	0.39	1e-13	Mean corpuscular volume;
LUSC	cis	rs12318506	0.826	rs11180434	chr12:75662128	T/C	cg04728562	chr12:75699417	CAPS2	-0.77	-5.93	-0.31	7.49e-9	Coronary artery calcification;
LUSC	cis	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg16346588	chr10:242978	ZMYND11	-0.46	-6.02	-0.31	4.53e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.29	0.33	1e-9	Height;
LUSC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.09	16.92	0.68	7.95e-47	Gut microbiome composition (summer);
LUSC	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.55	0.62	1.76e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg05855489	chr10:104503620	C10orf26	-0.63	-8.18	-0.41	6.14e-15	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.68	12.15	0.55	2.13e-28	Aortic root size;
LUSC	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-0.94	-16.34	-0.67	1.61e-44	Height;
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg22907277	chr7:1156413	C7orf50	0.64	10.18	0.49	2.28e-21	Longevity;Endometriosis;
LUSC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.05	-0.36	1.02e-11	Colorectal cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20789464	chr11:85565977	CCDC83	0.43	6.26	0.32	1.17e-9	Triglycerides;
LUSC	trans	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.37	-5.71	-0.3	2.53e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LUSC	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg23791538	chr6:167370224	RNASET2	0.51	8.52	0.42	5.74e-16	Graves' disease;
LUSC	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg17757837	chr7:157058334	UBE3C	-0.92	-15.6	-0.65	1.37e-41	Body mass index;
LUSC	cis	rs4792901	0.918	rs12103666	chr17:41636310	G/A	cg22562494	chr17:41607896	ETV4	-0.28	-5.65	-0.3	3.44e-8	Dupuytren's disease;
LUSC	cis	rs2652834	0.851	rs2729778	chr15:63407332	T/G	cg05507819	chr15:63340323	TPM1	0.47	6.0	0.31	5.26e-9	HDL cholesterol;
LUSC	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.37	5.85	0.3	1.17e-8	Lymphocyte counts;
LUSC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg16524733	chr11:117070046	TAGLN	0.32	6.0	0.31	5.05e-9	Blood protein levels;
LUSC	cis	rs240764	0.610	rs41288423	chr6:101166095	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-6.09	-0.32	3.03e-9	Neuroticism;
LUSC	trans	rs1256061	0.874	rs12435857	chr14:64723525	G/A	cg07874507	chr10:24503148	KIAA1217	0.34	6.0	0.31	5.24e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs12249377	0.519	rs4520504	chr10:92602373	T/C	cg14313238	chr10:92632228	RPP30	0.43	5.96	0.31	6.36e-9	White matter microstructure (global fractional anisotropy);
LUSC	trans	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.47	-0.38	6.98e-13	Menarche (age at onset);
LUSC	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg03975922	chr5:140080575	ZMAT2	0.32	5.68	0.3	2.88e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2281845	0.560	rs12079819	chr1:201085420	G/A	cg06714761	chr1:201096289	NA	0.37	6.88	0.35	3e-11	Permanent tooth development;
LUSC	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg05738196	chr6:26577821	NA	0.78	14.99	0.63	3.4e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.67	-8.84	-0.44	5.49e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7264396	0.887	rs6060431	chr20:34059337	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.52	-0.34	2.58e-10	Total cholesterol levels;
LUSC	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.66	-8.16	-0.41	6.69e-15	Iron status biomarkers;
LUSC	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg22529645	chr1:3704559	LRRC47	0.36	6.41	0.33	4.99e-10	Red cell distribution width;
LUSC	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg13256891	chr4:100009986	ADH5	0.49	6.79	0.35	5.04e-11	Smoking initiation;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg26668828	chr6:292823	DUSP22	-0.72	-12.17	-0.55	1.83e-28	Menopause (age at onset);
LUSC	trans	rs6011368	0.840	rs6062361	chr20:62904542	C/T	cg13869341	chr1:15865	WASH5P	-0.43	-6.77	-0.35	5.72e-11	Clozapine-induced cytotoxicity;
LUSC	cis	rs77633900	0.614	rs2629021	chr15:76974083	C/T	cg21673338	chr15:77095150	SCAPER	-0.8	-8.15	-0.41	7.48e-15	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg25287198	chr4:183728479	NA	0.56	7.88	0.4	4.73e-14	Pediatric autoimmune diseases;
LUSC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.83	12.68	0.57	2.41e-30	IgG glycosylation;
LUSC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg27535305	chr1:53392650	SCP2	0.36	6.78	0.35	5.33e-11	Monocyte count;
LUSC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg00677455	chr12:58241039	CTDSP2	0.5	7.49	0.38	6.04e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg02423579	chr7:2872169	GNA12	-0.47	-6.53	-0.34	2.46e-10	Height;
LUSC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.7	0.51	3.69e-23	Hip circumference adjusted for BMI;
LUSC	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg20090143	chr19:45452003	APOC2	0.35	5.94	0.31	7.21e-9	Blood protein levels;
LUSC	cis	rs1451375	0.572	rs12666409	chr7:50634976	A/T	cg18232548	chr7:50535776	DDC	-0.48	-6.4	-0.33	5.39e-10	Malaria;
LUSC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg22467129	chr15:76604101	ETFA	-0.51	-8.26	-0.41	3.38e-15	Blood metabolite levels;
LUSC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18876405	chr7:65276391	NA	0.55	8.56	0.42	4.15e-16	Aortic root size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19587038	chr1:46598331	PIK3R3	0.47	6.72	0.35	7.73e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.53	-7.22	-0.37	3.6e-12	Renal function-related traits (BUN);
LUSC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	15.41	0.64	7.23e-41	Platelet count;
LUSC	cis	rs3820928	1.000	rs7561378	chr2:227772248	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.84	-0.39	5.96e-14	Pulmonary function;
LUSC	cis	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05901451	chr6:126070800	HEY2	-0.58	-8.59	-0.43	3.43e-16	Endometrial cancer;
LUSC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.43	-6.59	-0.34	1.74e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg21775007	chr8:11205619	TDH	0.46	6.67	0.34	1.09e-10	Neuroticism;
LUSC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg24375607	chr4:120327624	NA	0.78	11.49	0.53	5.51e-26	Corneal astigmatism;
LUSC	cis	rs807669	0.527	rs11089259	chr22:19190143	C/T	cg02655711	chr22:19163373	SLC25A1	0.69	12.61	0.57	4.43e-30	Metabolite levels;
LUSC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg04369109	chr6:150039330	LATS1	-0.52	-7.43	-0.38	8.98e-13	Lung cancer;
LUSC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg04733989	chr22:42467013	NAGA	0.62	9.75	0.47	6.31e-20	Schizophrenia;
LUSC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.55	0.57	7.07e-30	Motion sickness;
LUSC	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-14.55	-0.62	1.71e-37	Electrocardiographic conduction measures;
LUSC	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg13010199	chr12:38710504	ALG10B	0.53	7.34	0.37	1.65e-12	Resting heart rate;
LUSC	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg03684893	chr10:554711	DIP2C	-0.45	-8.52	-0.42	5.64e-16	Psychosis in Alzheimer's disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07477187	chr1:155243300	CLK2	0.7	6.09	0.32	3.08e-9	Cognitive performance;
LUSC	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg17330251	chr7:94953956	PON1	-0.38	-6.12	-0.32	2.62e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg01528321	chr10:82214614	TSPAN14	0.62	9.08	0.45	9.41e-18	Post bronchodilator FEV1;
LUSC	cis	rs4474465	0.688	rs7927494	chr11:78280578	G/A	cg27205649	chr11:78285834	NARS2	0.55	6.77	0.35	5.66e-11	Alzheimer's disease (survival time);
LUSC	cis	rs2816316	1.000	rs1323298	chr1:192519865	T/C	cg02586212	chr1:192544902	RGS1	0.32	5.87	0.31	1.04e-8	Celiac disease;
LUSC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg02527881	chr3:46936655	PTH1R	0.41	7.25	0.37	2.93e-12	Colorectal cancer;
LUSC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.46	-7.77	-0.39	9.61e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg23992470	chr4:843637	GAK	0.61	6.56	0.34	2.1e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs12210905	0.688	rs12191373	chr6:27484330	C/T	cg08851530	chr6:28072375	NA	0.9	6.03	0.31	4.25e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg17691542	chr6:26056736	HIST1H1C	1.03	13.2	0.59	2.7e-32	Iron status biomarkers;
LUSC	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.68	9.38	0.46	1e-18	Other erythrocyte phenotypes;
LUSC	cis	rs4851254	0.961	rs6713524	chr2:100747357	A/G	cg07810366	chr2:100720526	AFF3	-0.37	-5.7	-0.3	2.6e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg10523679	chr1:76189770	ACADM	-0.43	-6.06	-0.31	3.66e-9	Daytime sleep phenotypes;
LUSC	cis	rs7178572	0.568	rs1565757	chr15:77657682	C/T	cg22256960	chr15:77711686	NA	-0.49	-7.9	-0.4	4.02e-14	Type 2 diabetes;
LUSC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.32	0.53	2.29e-25	Menopause (age at onset);
LUSC	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg15556689	chr8:8085844	FLJ10661	-0.63	-9.49	-0.46	4.37e-19	Neuroticism;
LUSC	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg21775007	chr8:11205619	TDH	-0.68	-10.04	-0.48	6.64e-21	Neuroticism;
LUSC	trans	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.35	0.33	7.22e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.51	-9.17	-0.45	5.1e-18	Primary biliary cholangitis;
LUSC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.95	15.19	0.64	5.71e-40	Coronary artery disease;
LUSC	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg11235426	chr6:292522	DUSP22	-0.42	-6.05	-0.31	3.97e-9	Menopause (age at onset);
LUSC	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.04	0.36	1.11e-11	Multiple sclerosis;
LUSC	cis	rs1451375	0.669	rs10274172	chr7:50637575	G/A	cg18232548	chr7:50535776	DDC	-0.5	-7.6	-0.38	3.11e-13	Malaria;
LUSC	trans	rs12902680	0.632	rs12440590	chr15:46585511	G/A	cg04321580	chr8:143696133	ARC	-0.4	-6.04	-0.31	4.18e-9	Neuroticism;
LUSC	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg06484146	chr7:12443880	VWDE	-0.68	-7.06	-0.36	9.43e-12	Coronary artery disease;
LUSC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	trans	rs9380880	0.826	rs9380882	chr6:39547428	A/T	cg19893670	chr10:60097505	UBE2D1	0.65	5.96	0.31	6.24e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg24397884	chr7:158709396	WDR60	0.6	9.28	0.45	2.2e-18	Height;
LUSC	cis	rs9807989	0.507	rs10200952	chr2:103027651	A/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.69e-12	Asthma;
LUSC	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg08645402	chr16:4508243	NA	0.48	7.18	0.37	4.53e-12	Schizophrenia;
LUSC	cis	rs16976116	0.901	rs28591259	chr15:55498940	T/A	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs13196614	0.756	rs9485317	chr6:149018295	G/A	cg01343097	chr1:248284971	OR2M1P	0.41	6.04	0.31	4e-9	Migraine;
LUSC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg14552801	chr7:65878734	NA	0.37	5.66	0.3	3.2e-8	Aortic root size;
LUSC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg01416388	chr22:39784598	NA	-0.44	-7.24	-0.37	3.17e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-0.85	-15.52	-0.65	2.7e-41	Height;
LUSC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.31	-7.85	-0.39	5.85e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2658782	0.724	rs2248020	chr11:93259965	A/C	cg15737290	chr11:93063684	CCDC67	0.56	7.17	0.37	4.77e-12	Pulmonary function decline;
LUSC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg22166914	chr1:53195759	ZYG11B	0.5	8.25	0.41	3.81e-15	Monocyte count;
LUSC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.56	0.65	1.98e-41	Platelet count;
LUSC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg22800045	chr5:56110881	MAP3K1	0.77	9.63	0.47	1.5700000000000001e-19	Initial pursuit acceleration;
LUSC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg20203395	chr5:56204925	C5orf35	-0.78	-10.4	-0.49	4.07e-22	Initial pursuit acceleration;
LUSC	cis	rs11608355	0.545	rs35590455	chr12:109893514	A/G	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.1e-26	Neuroticism;
LUSC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg02807482	chr3:125708958	NA	-0.54	-6.69	-0.34	9.15e-11	Blood pressure (smoking interaction);
LUSC	cis	rs12618769	0.597	rs17446058	chr2:99164160	A/G	cg10123293	chr2:99228465	UNC50	0.46	7.35	0.37	1.49e-12	Bipolar disorder;
LUSC	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg01528321	chr10:82214614	TSPAN14	1.01	15.61	0.65	1.22e-41	Post bronchodilator FEV1;
LUSC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg05347473	chr6:146136440	FBXO30	0.56	9.71	0.47	8.3e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22980127	chr19:33182716	NUDT19	0.95	12.94	0.58	2.44e-31	Red blood cell traits;
LUSC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg27427491	chr17:78079615	GAA	0.38	6.62	0.34	1.45e-10	Yeast infection;
LUSC	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg14993813	chr1:46806288	NSUN4	-0.5	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg08601574	chr20:25228251	PYGB	-0.44	-6.8	-0.35	4.71e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24160036	chr20:55966451	RBM38	-0.43	-6.21	-0.32	1.55e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg23791538	chr6:167370224	RNASET2	-0.37	-5.72	-0.3	2.38e-8	Crohn's disease;
LUSC	cis	rs9815354	0.812	rs73081361	chr3:41912535	G/A	cg03022575	chr3:42003672	ULK4	0.83	8.67	0.43	1.88e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg06454157	chr6:167490870	NA	-0.28	-6.71	-0.34	8.57e-11	Primary biliary cholangitis;
LUSC	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg13390004	chr1:15929781	NA	0.43	7.31	0.37	1.94e-12	Systolic blood pressure;
LUSC	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.23	-0.69	4.77e-48	Exhaled nitric oxide output;
LUSC	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg19789473	chr17:27170043	C17orf63	-0.3	-5.69	-0.3	2.75e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg00129232	chr17:37814104	STARD3	-0.49	-7.32	-0.37	1.91e-12	Asthma;
LUSC	trans	rs1325195	0.881	rs10913690	chr1:179067071	G/T	cg11624085	chr17:8464688	MYH10	-0.41	-6.63	-0.34	1.34e-10	IgE grass sensitization;
LUSC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.46	-7.86	-0.4	5.19e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1712517	0.873	rs1891292	chr10:105001510	A/G	cg05636881	chr10:105038444	INA	-0.39	-6.46	-0.33	3.61e-10	Migraine;
LUSC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg03146154	chr1:46216737	IPP	0.54	8.12	0.41	8.97e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs9409565	0.762	rs60964095	chr9:97175774	G/T	cg05679027	chr9:99775184	HIATL2	-0.48	-6.81	-0.35	4.59e-11	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg16928487	chr17:17741425	SREBF1	-0.43	-8.62	-0.43	2.81e-16	Total body bone mineral density;
LUSC	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg03585969	chr10:35415529	CREM	0.64	9.5	0.46	4.29e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg09904177	chr6:26538194	HMGN4	-0.8	-5.92	-0.31	7.81e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-1.01	-24.69	-0.8	2.52e-77	Urate levels in lean individuals;
LUSC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.72	10.21	0.49	1.79e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.92	0.35	2.25e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg09835421	chr16:68378352	PRMT7	-0.61	-6.38	-0.33	5.77e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg18404041	chr3:52824283	ITIH1	-0.36	-6.15	-0.32	2.21e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg22709100	chr7:91322751	NA	0.39	5.79	0.3	1.67e-8	Breast cancer;
LUSC	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg15412446	chr2:106886593	NA	-0.47	-6.74	-0.35	6.88e-11	Facial morphology (factor 23);
LUSC	cis	rs381815	1.000	rs448671	chr11:16900103	T/G	cg05701403	chr11:16947551	PLEKHA7	0.38	5.77	0.3	1.78e-8	Diastolic blood pressure;Systolic blood pressure;Blood pressure;
LUSC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.41	-5.65	-0.3	3.39e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg17633681	chr16:88106987	BANP	0.5	9.19	0.45	4.32e-18	Menopause (age at onset);
LUSC	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg27539214	chr16:67997921	SLC12A4	-0.53	-6.42	-0.33	4.58e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg03676636	chr4:99064102	C4orf37	0.3	5.96	0.31	6.35e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg02153584	chr22:29168773	CCDC117	0.59	8.99	0.44	1.84e-17	Lymphocyte counts;
LUSC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg09021430	chr5:549028	NA	-0.56	-7.67	-0.39	1.85e-13	Obesity-related traits;
LUSC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg07414643	chr4:187882934	NA	0.56	10.64	0.5	5.99e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg18105134	chr13:113819100	PROZ	-0.74	-10.34	-0.49	6.21e-22	Platelet distribution width;
LUSC	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.54	-0.42	4.96e-16	Retinal vascular caliber;
LUSC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg13939156	chr17:80058883	NA	-0.32	-6.38	-0.33	5.99e-10	Life satisfaction;
LUSC	cis	rs10761482	0.500	rs2211220	chr10:62271491	A/G	cg18175470	chr10:62150864	ANK3	-0.42	-5.97	-0.31	6.14e-9	Schizophrenia;
LUSC	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg11766577	chr21:47581405	C21orf56	-0.54	-8.08	-0.4	1.19e-14	Testicular germ cell tumor;
LUSC	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg06627628	chr2:24431161	ITSN2	0.62	9.22	0.45	3.54e-18	Asthma;
LUSC	cis	rs11039100	0.850	rs11039121	chr11:5833161	T/C	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg25039879	chr17:56429692	SUPT4H1	0.68	9.08	0.45	9.54e-18	Cognitive test performance;
LUSC	trans	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg12856521	chr11:46389249	DGKZ	0.4	6.37	0.33	6.37e-10	Leprosy;
LUSC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10802521	chr3:52805072	NEK4	-0.56	-8.98	-0.44	2e-17	Bipolar disorder;
LUSC	cis	rs12421382	0.778	rs11213128	chr11:109489575	G/A	cg16359550	chr11:109292809	C11orf87	0.37	6.1	0.32	2.89e-9	Schizophrenia;
LUSC	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg21293242	chr8:11204541	TDH	0.31	5.82	0.3	1.35e-8	Retinal vascular caliber;
LUSC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg06521331	chr12:34319734	NA	-0.45	-7.21	-0.37	3.74e-12	Morning vs. evening chronotype;
LUSC	trans	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs134594	1.000	rs134602	chr22:29473884	A/G	cg03665785	chr22:29458676	C22orf31	0.28	5.75	0.3	2.04e-8	Birth weight;
LUSC	cis	rs4654899	0.680	rs4233274	chr1:21121678	C/T	cg01072550	chr1:21505969	NA	-0.49	-7.17	-0.37	4.81e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg09436375	chr6:42928200	GNMT	-0.31	-7.09	-0.36	8.29e-12	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg05347473	chr6:146136440	FBXO30	-0.48	-7.93	-0.4	3.23e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg18200150	chr17:30822561	MYO1D	0.31	5.9	0.31	8.71e-9	Schizophrenia;
LUSC	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg21643547	chr1:205240462	TMCC2	-0.4	-7.3	-0.37	2.13e-12	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.49	-7.36	-0.37	1.48e-12	Blood protein levels;
LUSC	cis	rs793571	0.544	rs12912699	chr15:58917021	T/C	cg05156742	chr15:59063176	FAM63B	0.54	8.32	0.41	2.25e-15	Schizophrenia;
LUSC	cis	rs10886558	0.502	rs4752376	chr10:121830185	C/G	cg02041677	chr10:121771263	NA	0.31	5.68	0.3	2.98e-8	Shingles;
LUSC	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg08219700	chr8:58056026	NA	0.67	6.27	0.32	1.12e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs16854884	0.837	rs13062793	chr3:143808387	A/G	cg06585982	chr3:143692056	C3orf58	0.43	6.27	0.32	1.14e-9	Economic and political preferences (feminism/equality);
LUSC	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg05855489	chr10:104503620	C10orf26	-0.49	-7.47	-0.38	7.25e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24110177	chr3:50126178	RBM5	0.65	11.57	0.53	2.85e-26	Body mass index;
LUSC	cis	rs10492096	0.947	rs61918022	chr12:6614521	C/T	cg13857086	chr12:6580257	VAMP1	0.6	7.07	0.36	9.06e-12	Hip geometry;
LUSC	cis	rs3784262	1.000	rs4646638	chr15:58248783	C/T	cg12031962	chr15:58353849	ALDH1A2	0.31	5.8	0.3	1.51e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs7827545	0.960	rs1372661	chr8:135566859	A/G	cg17885191	chr8:135476712	NA	0.57	8.55	0.42	4.4e-16	Hypertension (SNP x SNP interaction);
LUSC	cis	rs7586879	0.765	rs10171663	chr2:25086431	T/C	cg04586622	chr2:25135609	ADCY3	0.3	5.66	0.3	3.32e-8	Body mass index;
LUSC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg04315214	chr1:2043799	PRKCZ	-0.39	-7.74	-0.39	1.18e-13	Height;
LUSC	cis	rs9039	1.000	rs1128001	chr16:9207003	T/C	cg08831531	chr16:9218945	NA	-0.66	-10.43	-0.5	3.11e-22	Menopause (age at onset);
LUSC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	0.88	12.16	0.55	2.07e-28	Vitiligo;
LUSC	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg22709100	chr7:91322751	NA	-0.38	-5.72	-0.3	2.37e-8	Breast cancer;
LUSC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg00376283	chr12:123451042	ABCB9	0.7	9.83	0.47	3.33e-20	Neutrophil percentage of white cells;
LUSC	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.32	-0.37	1.9e-12	Putamen volume;
LUSC	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg24375607	chr4:120327624	NA	-0.69	-10.81	-0.51	1.47e-23	Corneal astigmatism;
LUSC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.59	-8.5	-0.42	6.31e-16	Blood protein levels;
LUSC	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.15	0.55	2.14e-28	Height;
LUSC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg27165867	chr14:105738592	BRF1	-0.51	-7.41	-0.38	1.04e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.18	0.61	4.59e-36	Platelet count;
LUSC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs193541	0.507	rs56346354	chr5:122076344	G/A	cg19077854	chr5:122220652	SNX24	0.28	6.02	0.31	4.53e-9	Glucose homeostasis traits;
LUSC	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg05110241	chr16:68378359	PRMT7	-0.77	-8.71	-0.43	1.4e-16	Schizophrenia;
LUSC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg04546413	chr19:29218101	NA	0.62	8.12	0.41	8.94e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg16325326	chr1:53192061	ZYG11B	-0.88	-16.23	-0.66	4.3e-44	Monocyte count;
LUSC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg26659404	chr1:25747437	RHCE	-0.3	-6.4	-0.33	5.37e-10	Erythrocyte sedimentation rate;
LUSC	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg07211511	chr3:129823064	LOC729375	-1.01	-12.65	-0.57	3.12e-30	Blood pressure (smoking interaction);
LUSC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg15147215	chr3:52552868	STAB1	-0.3	-5.96	-0.31	6.55e-9	Bipolar disorder;
LUSC	cis	rs1577917	0.958	rs4707229	chr6:86546237	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.83	-0.35	4.14e-11	Response to antipsychotic treatment;
LUSC	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	8.66	0.43	2.1e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-9.31	-0.45	1.71e-18	Coffee consumption (cups per day);
LUSC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.78	-0.43	8.4e-17	Bipolar disorder;
LUSC	trans	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg05926928	chr17:57297772	GDPD1	-0.47	-6.58	-0.34	1.83e-10	Schizophrenia;
LUSC	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.72	-0.3	2.4e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06022373	chr22:39101656	GTPBP1	0.77	12.0	0.55	7.71e-28	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21378393	chr17:2239733	TSR1;SGSM2	-0.41	-5.99	-0.31	5.4e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-8.22	-0.41	4.62e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.7	-10.63	-0.5	6.55e-23	Aortic root size;
LUSC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg04518342	chr5:131593106	PDLIM4	0.45	8.44	0.42	9.6e-16	Breast cancer;
LUSC	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg19767477	chr5:127420684	SLC12A2	-0.43	-5.79	-0.3	1.64e-8	Ileal carcinoids;
LUSC	cis	rs10100465	1.000	rs16890041	chr8:118665691	T/C	cg09430518	chr8:118662568	NA	-0.3	-5.68	-0.3	2.91e-8	Leprosy;
LUSC	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg13010199	chr12:38710504	ALG10B	-0.63	-9.81	-0.47	4.06e-20	Bladder cancer;
LUSC	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg04486885	chr5:176823424	SLC34A1	0.39	6.09	0.32	3.08e-9	Urinary electrolytes (magnesium/calcium ratio);
LUSC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg24296786	chr1:45957014	TESK2	0.5	7.56	0.38	3.93e-13	High light scatter reticulocyte count;
LUSC	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg22709100	chr7:91322751	NA	0.47	6.87	0.35	3.1e-11	Breast cancer;
LUSC	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg05527609	chr1:210001259	C1orf107	0.67	9.63	0.47	1.5700000000000001e-19	Orofacial clefts;
LUSC	trans	rs800082	0.799	rs9870285	chr3:144236432	C/A	cg24215973	chr2:240111563	HDAC4	0.41	6.03	0.31	4.33e-9	Smoking behavior;
LUSC	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg03563238	chr19:33554763	RHPN2	-0.41	-6.57	-0.34	1.92e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.54	8.13	0.41	8.56e-15	Axial length;
LUSC	cis	rs2692947	0.832	rs2579519	chr2:96675166	T/C	cg22654517	chr2:96458247	NA	0.35	6.99	0.36	1.47e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs16854884	0.586	rs13081286	chr3:143723757	A/T	cg01302019	chr3:143689584	C3orf58	-0.34	-5.68	-0.3	2.96e-8	Economic and political preferences (feminism/equality);
LUSC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08677398	chr8:58056175	NA	0.53	6.36	0.33	6.53e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg05110241	chr16:68378359	PRMT7	-0.47	-6.07	-0.32	3.45e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg26043149	chr18:55253948	FECH	-0.45	-6.89	-0.35	2.86e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.2	-0.37	3.93e-12	Retinal vascular caliber;
LUSC	trans	rs62103177	0.713	rs3744886	chr18:77659561	G/T	cg14227996	chr4:17616232	MED28	0.81	7.12	0.36	6.76e-12	Opioid sensitivity;
LUSC	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg27068330	chr11:65405492	SIPA1	0.65	9.7	0.47	9.4e-20	Acne (severe);
LUSC	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	7.12	0.36	6.54e-12	Ovarian reserve;
LUSC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.91e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg13319975	chr6:146136371	FBXO30	0.49	7.43	0.38	9.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg24209194	chr3:40518798	ZNF619	0.47	6.35	0.33	7.15e-10	Renal cell carcinoma;
LUSC	cis	rs877282	0.842	rs12357963	chr10:757562	C/T	cg17470449	chr10:769945	NA	0.52	6.97	0.36	1.72e-11	Uric acid levels;
LUSC	cis	rs10754283	0.967	rs7519971	chr1:90108743	G/A	cg21401794	chr1:90099060	LRRC8C	0.64	9.62	0.47	1.65e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	12.23	0.56	1.11e-28	Menopause (age at onset);
LUSC	cis	rs1385374	0.858	rs10773578	chr12:129290026	G/C	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.78	-0.35	5.5e-11	Systemic lupus erythematosus;
LUSC	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg15448220	chr1:150897856	SETDB1	-0.41	-6.14	-0.32	2.38e-9	Melanoma;
LUSC	cis	rs28829049	0.597	rs71645438	chr1:19502349	G/A	cg13387374	chr1:19411106	UBR4	0.44	6.23	0.32	1.39e-9	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg23711669	chr6:146136114	FBXO30	-0.81	-14.85	-0.63	1.16e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg22709100	chr7:91322751	NA	0.39	5.82	0.3	1.38e-8	Breast cancer;
LUSC	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg23093090	chr10:104574429	C10orf26	-0.37	-6.87	-0.35	3.08e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3820928	0.904	rs59135978	chr2:227857763	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.31	-0.37	1.99e-12	Pulmonary function;
LUSC	cis	rs6967385	0.560	rs10434998	chr7:12348375	C/T	cg10578991	chr7:12443926	VWDE	0.4	6.02	0.31	4.66e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7106204	0.748	rs28656439	chr11:24207653	G/C	ch.11.24196551F	chr11:24239977	NA	1.1	13.51	0.59	1.75e-33	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.88	0.66	1.09e-42	Platelet count;
LUSC	cis	rs12493885	0.725	rs11717851	chr3:153741735	G/A	cg17054900	chr3:154042577	DHX36	-0.61	-6.63	-0.34	1.32e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14240646	chr10:27532245	ACBD5	-0.48	-6.04	-0.31	4.14e-9	Breast cancer;
LUSC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg26116260	chr4:7069785	GRPEL1	1.15	17.83	0.7	2.02e-50	Monocyte percentage of white cells;
LUSC	cis	rs6696846	0.515	rs12136320	chr1:205110946	T/C	cg00857998	chr1:205179979	DSTYK	0.47	6.68	0.34	9.82e-11	Red blood cell count;
LUSC	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg20503657	chr10:835505	NA	0.82	11.66	0.54	1.36e-26	Eosinophil percentage of granulocytes;
LUSC	cis	rs1044826	0.692	rs176987	chr3:139233001	G/A	cg00490450	chr3:139108681	COPB2	-0.46	-7.05	-0.36	1.05e-11	Obesity-related traits;
LUSC	cis	rs4901869	0.966	rs425764	chr14:59334997	A/G	cg02291164	chr14:59296302	NA	0.48	8.83	0.44	5.82e-17	Panic disorder;
LUSC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg20821713	chr7:1055600	C7orf50	-0.57	-7.41	-0.38	1.01e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg19628046	chr18:33552617	C18orf21	0.52	6.26	0.32	1.15e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg02800362	chr5:177631904	HNRNPAB	0.84	12.5	0.56	1.17e-29	Obesity-related traits;
LUSC	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00321850	chr1:175162397	KIAA0040	-0.45	-7.7	-0.39	1.53e-13	Alcohol dependence;
LUSC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg09021430	chr5:549028	NA	-0.54	-7.06	-0.36	9.57e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg04374321	chr14:90722782	PSMC1	0.75	12.04	0.55	5.52e-28	Mortality in heart failure;
LUSC	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg13073564	chr4:8508604	NA	0.46	8.62	0.43	2.79e-16	Response to antineoplastic agents;
LUSC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg06238570	chr21:40685208	BRWD1	0.54	8.03	0.4	1.64e-14	Cognitive function;
LUSC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg01579765	chr21:45077557	HSF2BP	0.55	11.77	0.54	5.58e-27	Mean corpuscular volume;
LUSC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.44	-6.21	-0.32	1.57e-9	Platelet count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23201549	chr2:43454852	ZFP36L2;LOC100129726	-0.43	-6.49	-0.33	3.14e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg12165864	chr7:66369176	NA	-0.53	-7.14	-0.36	5.77e-12	Corneal structure;
LUSC	cis	rs6574644	1.000	rs6574642	chr14:81774316	A/G	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.11	-28.57	-0.84	1.04e-91	Myeloid white cell count;
LUSC	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg17467752	chr17:38218738	THRA	0.5	7.39	0.37	1.17e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.65	8.4	0.42	1.32e-15	Schizophrenia;
LUSC	cis	rs3790645	0.831	rs873151	chr1:26880989	T/C	cg17456097	chr1:26900765	RPS6KA1	0.43	6.22	0.32	1.47e-9	Glucose homeostasis traits;
LUSC	trans	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg11887960	chr12:57824829	NA	0.48	6.47	0.33	3.46e-10	Obesity-related traits;
LUSC	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg17757837	chr7:157058334	UBE3C	-0.76	-11.55	-0.53	3.57e-26	Body mass index;
LUSC	trans	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg05926928	chr17:57297772	GDPD1	1.11	13.96	0.61	3.39e-35	Opioid sensitivity;
LUSC	cis	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg26850624	chr5:429559	AHRR	0.32	6.15	0.32	2.24e-9	Cystic fibrosis severity;
LUSC	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	9.66	0.47	1.22e-19	Lymphocyte counts;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg20690916	chr5:140700301	TAF7	0.76	6.8	0.35	4.89e-11	Cognitive performance;
LUSC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg01973587	chr1:228161476	NA	0.45	8.21	0.41	5.03e-15	Diastolic blood pressure;
LUSC	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg12091567	chr17:66097778	LOC651250	-0.74	-9.32	-0.45	1.62e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.49	0.38	6.14e-13	Parkinson's disease;
LUSC	trans	rs11700980	0.551	rs34161405	chr21:30113840	T/C	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.78e-9	QRS complex (12-leadsum);
LUSC	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg18478394	chr8:109455254	TTC35	0.45	6.53	0.34	2.45e-10	Dupuytren's disease;
LUSC	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.8	-0.35	4.91e-11	Menarche (age at onset);
LUSC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-1.25	-13.99	-0.61	2.56e-35	Diabetic kidney disease;
LUSC	cis	rs6142102	0.961	rs8119937	chr20:32645551	C/T	cg08999081	chr20:33150536	PIGU	0.34	5.9	0.31	8.81e-9	Skin pigmentation;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00837290	chr16:89350068	ANKRD11	0.4	6.14	0.32	2.31e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg22089800	chr15:90895588	ZNF774	0.65	10.19	0.49	2.09e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs2235649	0.798	rs9932875	chr16:1848012	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.1	-0.32	2.93e-9	Blood metabolite levels;
LUSC	cis	rs3771570	0.901	rs6757876	chr2:242245570	T/C	cg21155796	chr2:242212141	HDLBP	0.56	6.77	0.35	5.72e-11	Prostate cancer;
LUSC	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-6.98	-0.36	1.63e-11	Colorectal cancer;
LUSC	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.2	-0.41	5.22e-15	Retinal vascular caliber;
LUSC	cis	rs72772090	0.539	rs56120748	chr5:96110622	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.75	-7.64	-0.39	2.26e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4919044	1.000	rs17108042	chr10:94770488	A/C	cg00519463	chr10:94352821	KIF11	0.65	5.64	0.3	3.57e-8	Coronary artery disease;
LUSC	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg18190219	chr22:46762943	CELSR1	-0.59	-6.2	-0.32	1.65e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	9.01	0.44	1.6e-17	Prudent dietary pattern;
LUSC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg00310523	chr12:86230176	RASSF9	0.52	9.84	0.47	3.1e-20	Major depressive disorder;
LUSC	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-16.23	-0.66	4.58e-44	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs240764	0.658	rs7747014	chr6:101201898	T/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.35	-0.33	6.85e-10	Neuroticism;
LUSC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg12963246	chr6:28129442	ZNF389	0.45	6.07	0.32	3.44e-9	Parkinson's disease;
LUSC	cis	rs3754214	0.823	rs494041	chr1:150270026	T/C	cg15654264	chr1:150340011	RPRD2	-0.45	-7.4	-0.38	1.09e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg12963246	chr6:28129442	ZNF389	0.51	7.06	0.36	9.81e-12	Depression;
LUSC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.42	-6.41	-0.33	4.96e-10	Menarche (age at onset);
LUSC	cis	rs73200209	0.744	rs58471589	chr12:116573035	A/C	cg01776926	chr12:116560359	MED13L	-0.51	-6.13	-0.32	2.45e-9	Total body bone mineral density;
LUSC	cis	rs7106204	0.534	rs76397001	chr11:24254188	A/C	ch.11.24196551F	chr11:24239977	NA	0.72	6.09	0.32	3.05e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg06784218	chr1:46089804	CCDC17	0.31	5.69	0.3	2.74e-8	Platelet count;
LUSC	cis	rs6939532	0.517	rs733528	chr6:26374903	A/G	cg09904177	chr6:26538194	HMGN4	-0.45	-6.39	-0.33	5.46e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11214589	0.719	rs10891535	chr11:113201280	C/G	cg14159747	chr11:113255604	NA	0.26	6.54	0.34	2.34e-10	Neuroticism;
LUSC	cis	rs9905704	0.552	rs8071623	chr17:56621286	G/T	cg19466818	chr17:56409534	MIR142	0.35	6.54	0.34	2.31e-10	Testicular germ cell tumor;
LUSC	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg05373962	chr22:49881684	NA	-0.41	-8.76	-0.43	1.01e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs56161922	0.908	rs55952744	chr1:207860158	C/G	cg11752769	chr1:207818423	CR1L	-0.7	-5.91	-0.31	8.43e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04232541	chr6:144384895	PLAGL1	0.37	6.51	0.34	2.81e-10	Triglycerides;
LUSC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg23283495	chr1:209979779	IRF6	0.73	9.34	0.46	1.37e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg08330031	chr10:104623503	C10orf32	0.33	6.02	0.31	4.7e-9	Arsenic metabolism;
LUSC	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.07	0.36	8.86e-12	Body mass index;
LUSC	trans	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-6.0	-0.31	5.19e-9	Mood instability;
LUSC	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg22491629	chr6:157744540	C6orf35	-0.87	-10.55	-0.5	1.22e-22	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs13082711	0.911	rs2371065	chr3:27494589	A/C	cg02860705	chr3:27208620	NA	0.49	7.94	0.4	3.03e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.71	0.34	8.3e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7224314	1.000	rs8075952	chr17:65381358	C/T	cg01507342	chr17:65387096	PITPNC1	-0.44	-7.87	-0.4	4.95e-14	Diisocyanate-induced asthma;
LUSC	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.29	-6.35	-0.33	7.12e-10	Dupuytren's disease;
LUSC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.39	0.56	2.97e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg04352962	chr1:209979756	IRF6	0.51	6.12	0.32	2.69e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-10.87	-0.51	9.13e-24	Heart rate;
LUSC	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-8.89	-0.44	3.93e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.07	0.44	1.06e-17	Motion sickness;
LUSC	trans	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.68	-0.34	9.77e-11	Depression;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg13758310	chr4:1834493	LETM1	0.51	7.25	0.37	2.92e-12	Cognitive function;Information processing speed;
LUSC	cis	rs7119	0.717	rs12911854	chr15:77817288	T/C	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs6012953	0.654	rs6067471	chr20:49127282	A/C	cg13958625	chr20:49123093	NA	0.27	5.75	0.3	2.02e-8	Vitiligo;
LUSC	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg26513180	chr16:89883248	FANCA	0.61	9.08	0.44	9.64e-18	Vitiligo;
LUSC	cis	rs897080	0.552	rs1067384	chr2:44644554	G/A	cg00619915	chr2:44497795	NA	-0.41	-5.84	-0.3	1.27e-8	Height;
LUSC	cis	rs7590368	0.779	rs3856465	chr2:10916670	C/T	cg15705551	chr2:10952987	PDIA6	0.48	6.38	0.33	6.06e-10	Educational attainment (years of education);
LUSC	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg07169764	chr2:136633963	MCM6	-0.61	-7.99	-0.4	2.24e-14	Mosquito bite size;
LUSC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg09455208	chr3:40491958	NA	0.57	9.87	0.48	2.41e-20	Renal cell carcinoma;
LUSC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg09034736	chr1:150693464	HORMAD1	-0.4	-5.73	-0.3	2.29e-8	Tonsillectomy;
LUSC	cis	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg24375607	chr4:120327624	NA	0.52	8.16	0.41	7.07e-15	Diastolic blood pressure;
LUSC	trans	rs3942852	1.000	rs3942852	chr11:48115089	C/T	cg03929089	chr4:120376271	NA	-0.54	-6.18	-0.32	1.89e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	7.47	0.38	6.86e-13	Menarche (age at onset);
LUSC	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg23029597	chr12:123009494	RSRC2	-0.74	-9.38	-0.46	1.03e-18	Body mass index;
LUSC	cis	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg06521331	chr12:34319734	NA	-0.49	-8.13	-0.41	8.54e-15	Morning vs. evening chronotype;
LUSC	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg05555928	chr11:63887634	MACROD1	-0.49	-6.18	-0.32	1.87e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2289328	0.823	rs35565646	chr15:40660515	G/A	cg13931752	chr15:40660718	DISP2	0.46	6.46	0.33	3.64e-10	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs2860975	1.000	rs11492718	chr10:96787377	A/T	cg09036531	chr10:96991505	NA	-0.41	-5.75	-0.3	2.06e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg02569458	chr12:86230093	RASSF9	0.44	6.96	0.36	1.77e-11	Major depressive disorder;
LUSC	cis	rs3760982	1.000	rs4803658	chr19:44290013	T/A	cg11993925	chr19:44307056	LYPD5	0.28	6.26	0.32	1.18e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.86	-0.35	3.41e-11	Lung cancer;
LUSC	cis	rs2285947	1.000	rs10229224	chr7:21583921	G/A	cg04471919	chr7:21584483	DNAH11	0.34	7.73	0.39	1.29e-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	trans	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg07211511	chr3:129823064	LOC729375	-0.78	-9.97	-0.48	1.18e-20	Blood pressure (smoking interaction);
LUSC	cis	rs10875746	0.903	rs17122666	chr12:48502574	C/T	cg13454099	chr12:49076203	C12orf41	-0.52	-6.02	-0.31	4.69e-9	Longevity (90 years and older);
LUSC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg04518342	chr5:131593106	PDLIM4	0.34	6.18	0.32	1.92e-9	Blood metabolite levels;
LUSC	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.33e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2625529	0.730	rs3759900	chr15:72451827	A/C	cg16672083	chr15:72433130	SENP8	0.47	7.59	0.38	3.27e-13	Red blood cell count;
LUSC	cis	rs9650657	0.683	rs7836366	chr8:10585683	A/G	cg14992524	chr8:10586135	SOX7	-0.35	-6.24	-0.32	1.32e-9	Neuroticism;
LUSC	cis	rs7216064	0.953	rs4791300	chr17:65930772	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-9.56	-0.46	2.67e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7927771	0.524	rs2170815	chr11:47875910	T/C	cg20307385	chr11:47447363	PSMC3	0.46	6.76	0.35	6.07e-11	Subjective well-being;
LUSC	cis	rs727505	1.000	rs3925331	chr7:124446137	C/G	cg23710748	chr7:124431027	NA	-0.41	-7.32	-0.37	1.89e-12	Lewy body disease;
LUSC	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	8.73	0.43	1.2e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg12257692	chr3:49977190	RBM6	-0.26	-7.2	-0.37	3.93e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.94	-0.31	7.28e-9	IgG glycosylation;
LUSC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	1.09	19.01	0.72	3.83e-55	Parkinson's disease;
LUSC	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg19743168	chr1:23544995	NA	0.41	7.96	0.4	2.75e-14	Height;
LUSC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.45	6.68	0.34	9.94e-11	Systemic lupus erythematosus;
LUSC	cis	rs68170813	0.559	rs58663672	chr7:106949444	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.66	-0.47	1.27e-19	Coronary artery disease;
LUSC	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg19628046	chr18:33552617	C18orf21	-0.56	-6.79	-0.35	5.03e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg00990874	chr7:1149470	C7orf50	-0.5	-6.02	-0.31	4.72e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	8.34	0.42	2.01e-15	Response to antipsychotic treatment;
LUSC	cis	rs4363385	0.818	rs419721	chr1:153006902	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.65	-0.3	3.44e-8	Inflammatory skin disease;
LUSC	cis	rs2573652	1.000	rs2727199	chr15:100514417	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.46	-8.59	-0.43	3.38e-16	Height;
LUSC	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.81	-13.55	-0.6	1.28e-33	Bladder cancer;
LUSC	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg27411982	chr8:10470053	RP1L1	-0.46	-6.82	-0.35	4.23e-11	Morning vs. evening chronotype;
LUSC	cis	rs1957429	0.901	rs17102320	chr14:65384693	T/C	cg23373153	chr14:65346875	NA	-1.04	-11.35	-0.53	1.85e-25	Pediatric areal bone mineral density (radius);
LUSC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.75e-10	Crohn's disease;
LUSC	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	1.1	17.21	0.69	5.97e-48	Exhaled nitric oxide output;
LUSC	cis	rs9905704	1.000	rs9905704	chr17:56632543	G/T	cg12560992	chr17:57184187	TRIM37	-0.55	-7.79	-0.39	8.29e-14	Testicular germ cell tumor;
LUSC	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.99	-19.0	-0.72	4.38e-55	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg27411982	chr8:10470053	RP1L1	-0.36	-5.8	-0.3	1.56e-8	Retinal vascular caliber;
LUSC	cis	rs77633900	0.772	rs283799	chr15:76752834	A/C	cg21673338	chr15:77095150	SCAPER	-0.72	-6.24	-0.32	1.33e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs34421088	0.532	rs3808515	chr8:11156041	C/T	cg21775007	chr8:11205619	TDH	0.47	6.87	0.35	3.08e-11	Neuroticism;
LUSC	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.86	-0.35	3.32e-11	Monocyte percentage of white cells;
LUSC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.81	14.39	0.62	6.93e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg24209194	chr3:40518798	ZNF619	0.49	6.42	0.33	4.63e-10	Renal cell carcinoma;
LUSC	cis	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg21775007	chr8:11205619	TDH	-0.42	-5.71	-0.3	2.47e-8	Monocyte count;
LUSC	cis	rs9650315	0.659	rs60698069	chr8:57206322	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.33	0.37	1.73e-12	Height;
LUSC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.82	0.39	7.1e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.27	-0.52	3.59e-25	Mean corpuscular volume;
LUSC	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg14582100	chr15:45693742	SPATA5L1	0.45	8.4	0.42	1.25e-15	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.7	0.43	1.53e-16	Prudent dietary pattern;
LUSC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg07061783	chr6:25882402	NA	0.42	5.99	0.31	5.49e-9	Blood metabolite levels;
LUSC	cis	rs1775715	0.737	rs2808090	chr10:32143208	A/C	cg26784012	chr10:32216390	ARHGAP12	0.46	7.76	0.39	1.06e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg05197062	chr11:11642011	GALNTL4	0.42	6.77	0.35	5.76e-11	Telomere length;
LUSC	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg17127132	chr2:85788382	GGCX	0.41	5.93	0.31	7.66e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22590775	chr19:49891494	CCDC155	0.55	8.02	0.4	1.81e-14	Multiple sclerosis;
LUSC	cis	rs9398803	0.865	rs9388496	chr6:126785062	A/G	cg19875578	chr6:126661172	C6orf173	0.42	6.25	0.32	1.22e-9	Male-pattern baldness;
LUSC	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.88	0.31	1.02e-8	Lung cancer;
LUSC	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg05043794	chr9:111880884	C9orf5	-0.38	-7.96	-0.4	2.74e-14	Menarche (age at onset);
LUSC	cis	rs10904908	1.000	rs10795465	chr10:17260525	C/T	cg01003015	chr10:17271136	VIM	-0.41	-5.86	-0.31	1.09e-8	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg26061582	chr7:22766209	IL6	0.5	7.23	0.37	3.28e-12	Lung cancer;
LUSC	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg15432903	chr11:17409602	KCNJ11	-0.47	-7.74	-0.39	1.16e-13	Type 2 diabetes;
LUSC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg25036284	chr2:26402008	FAM59B	-0.67	-9.58	-0.46	2.32e-19	Gut microbiome composition (summer);
LUSC	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.31e-11	Response to antipsychotic treatment;
LUSC	cis	rs7851660	0.901	rs7873389	chr9:100609230	C/T	cg13688889	chr9:100608707	NA	-0.62	-10.67	-0.5	4.61e-23	Strep throat;
LUSC	cis	rs13253111	1.000	rs17411738	chr8:28060572	T/G	cg26534493	chr8:28060551	NA	0.46	8.86	0.44	4.92e-17	Childhood body mass index;
LUSC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.65	-11.08	-0.52	1.69e-24	Diastolic blood pressure;
LUSC	trans	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg04310649	chr10:35416472	CREM	-0.41	-6.34	-0.33	7.54e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg18301423	chr5:131593218	PDLIM4	0.37	6.1	0.32	2.94e-9	Blood metabolite levels;
LUSC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg22800045	chr5:56110881	MAP3K1	0.58	7.64	0.39	2.32e-13	Type 2 diabetes;
LUSC	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg08917208	chr2:24149416	ATAD2B	0.96	10.07	0.48	5.08e-21	Lymphocyte counts;
LUSC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg27170947	chr2:26402098	FAM59B	-0.69	-10.53	-0.5	1.42e-22	Gut microbiome composition (summer);
LUSC	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.17	-0.32	1.92e-9	Retinal vascular caliber;
LUSC	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg07080220	chr10:102295463	HIF1AN	0.69	8.93	0.44	2.86e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1322512	1.000	rs2758816	chr6:152968338	A/T	cg27316956	chr6:152958899	SYNE1	-0.33	-5.84	-0.3	1.27e-8	Tonometry;
LUSC	trans	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg24247370	chr13:99142703	STK24	-0.34	-6.17	-0.32	1.96e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg26695010	chr11:65641043	EFEMP2	-0.47	-7.08	-0.36	8.68e-12	Eosinophil percentage of white cells;
LUSC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg01528321	chr10:82214614	TSPAN14	0.62	8.98	0.44	2.09e-17	Post bronchodilator FEV1;
LUSC	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg02569458	chr12:86230093	RASSF9	0.39	6.37	0.33	6.12e-10	Major depressive disorder;
LUSC	trans	rs208520	1.000	rs208529	chr6:66957549	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-12.26	-0.56	8.59e-29	Exhaled nitric oxide output;
LUSC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.26	0.49	1.17e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs61990749	0.597	rs3783980	chr14:78219807	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	6.58	0.34	1.78e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs2677744	0.719	rs877285	chr15:91452204	A/G	cg23684204	chr15:91497937	RCCD1	0.39	5.64	0.3	3.53e-8	Attention deficit hyperactivity disorder;
LUSC	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.82	14.19	0.61	4.35e-36	Metabolic syndrome;
LUSC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg07701084	chr6:150067640	NUP43	0.53	7.99	0.4	2.25e-14	Lung cancer;
LUSC	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.75	-12.22	-0.56	1.22e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs61931739	0.570	rs7315655	chr12:33912869	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.67	-0.34	1.04e-10	Morning vs. evening chronotype;
LUSC	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.12	0.41	8.96e-15	Corneal astigmatism;
LUSC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	9.19	0.45	4.4e-18	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg25251562	chr2:3704773	ALLC	-0.39	-6.87	-0.35	3.13e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.26e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs7657257	1.000	rs12640554	chr4:15730107	C/T	cg17675199	chr6:35436792	RPL10A	-0.88	-6.15	-0.32	2.26e-9	Blood protein levels;
LUSC	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg27068330	chr11:65405492	SIPA1	-0.8	-11.33	-0.53	2.13e-25	Acne (severe);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg06665941	chr21:34602869	IFNAR2	0.44	6.72	0.35	7.72e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg14416269	chr4:6271139	WFS1	0.54	11.47	0.53	6.76e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2425143	1.000	rs11907811	chr20:34428078	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.92	-0.31	7.86e-9	Blood protein levels;
LUSC	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg06740227	chr12:86229804	RASSF9	0.39	6.33	0.33	7.71e-10	Major depressive disorder;
LUSC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-11.1	-0.52	1.4e-24	Bipolar disorder;
LUSC	cis	rs10193935	0.901	rs13413617	chr2:42537546	A/G	cg27598129	chr2:42591480	NA	-0.57	-7.96	-0.4	2.65e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg07148914	chr20:33460835	GGT7	-0.52	-7.93	-0.4	3.28e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs75804782	0.521	rs56387296	chr2:239426298	A/G	cg18131467	chr2:239335373	ASB1	-0.67	-5.97	-0.31	6.17e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07256732	chr16:621771	PIGQ	-0.36	-6.44	-0.33	4.11e-10	Height;
LUSC	cis	rs10986311	0.862	rs912353	chr9:127119356	A/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.36	5.69	0.3	2.83e-8	Vitiligo;
LUSC	cis	rs13089785	1.000	rs13089785	chr3:123653909	A/C	cg02012769	chr3:123398346	MYLK	0.34	6.23	0.32	1.42e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg16482183	chr6:26056742	HIST1H1C	0.65	9.06	0.44	1.15e-17	Iron status biomarkers;
LUSC	cis	rs2282300	0.739	rs1933343	chr11:30310992	T/C	cg25418670	chr11:30344373	C11orf46	0.64	9.15	0.45	5.83e-18	Morning vs. evening chronotype;
LUSC	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.2	-0.37	4.1e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg08017634	chr8:144659831	NAPRT1	0.7	6.19	0.32	1.79e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14289826	chr9:140003911	NA	-0.38	-7.89	-0.4	4.5e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg11247378	chr22:39784982	NA	-0.64	-12.52	-0.57	9.19e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg04398451	chr17:18023971	MYO15A	-0.37	-5.82	-0.3	1.37e-8	Total body bone mineral density;
LUSC	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg05855489	chr10:104503620	C10orf26	0.51	7.94	0.4	3.02e-14	Arsenic metabolism;
LUSC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg01238044	chr22:24384105	GSTT1	-0.53	-7.64	-0.39	2.25e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs34421088	0.586	rs2272594	chr8:11142625	T/C	cg15556689	chr8:8085844	FLJ10661	0.47	6.79	0.35	5.08e-11	Neuroticism;
LUSC	cis	rs2200578	0.786	rs57656020	chr2:99799378	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.62	7.29	0.37	2.3e-12	IgG glycosylation;
LUSC	cis	rs7605827	0.930	rs7605077	chr2:15546240	C/A	cg19274914	chr2:15703543	NA	0.46	8.81	0.43	6.89e-17	Educational attainment (years of education);
LUSC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-11.81	-0.54	3.99e-27	Systemic lupus erythematosus;
LUSC	cis	rs7241530	0.662	rs9951456	chr18:75888704	A/G	cg14642773	chr18:75888474	NA	0.36	5.91	0.31	8.59e-9	Educational attainment (years of education);
LUSC	trans	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04565464	chr8:145669602	NFKBIL2	0.37	5.99	0.31	5.49e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs12464559	0.522	rs7424335	chr2:152593741	C/T	cg01189475	chr2:152685088	ARL5A	0.67	7.53	0.38	4.8e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02018176	chr4:1364513	KIAA1530	-0.66	-11.56	-0.53	3.28e-26	Obesity-related traits;
LUSC	trans	rs7893279	0.822	rs6415974	chr10:18715259	T/C	cg01840055	chr3:141338555	NA	0.5	5.99	0.31	5.41e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06481639	chr22:41940642	POLR3H	-0.47	-5.75	-0.3	2.07e-8	Vitiligo;
LUSC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.78	12.84	0.57	5.97e-31	Developmental language disorder (linguistic errors);
LUSC	cis	rs2282300	0.739	rs7925340	chr11:30280408	A/C	cg25418670	chr11:30344373	C11orf46	0.64	9.04	0.44	1.28e-17	Morning vs. evening chronotype;
LUSC	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg23173402	chr1:227635558	NA	0.75	7.92	0.4	3.64e-14	Major depressive disorder;
LUSC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08280861	chr8:58055591	NA	0.54	6.3	0.33	9.15e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.44e-17	Iron status biomarkers;
LUSC	trans	rs1941687	0.509	rs2282632	chr18:31320229	A/G	cg27147174	chr7:100797783	AP1S1	-0.51	-8.07	-0.4	1.27e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg20019365	chr2:219134978	PNKD;AAMP	0.5	7.87	0.4	4.94e-14	Colorectal cancer;
LUSC	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg16342193	chr10:102329863	NA	-0.37	-6.66	-0.34	1.15e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg27068330	chr11:65405492	SIPA1	-0.76	-10.92	-0.51	5.9e-24	Acne (severe);
LUSC	trans	rs11088226	0.681	rs74779447	chr21:33929013	G/A	cg09050820	chr6:167586206	TCP10L2	0.73	9.59	0.46	2.1e-19	Gastritis;
LUSC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg04369109	chr6:150039330	LATS1	-0.53	-7.9	-0.4	3.96e-14	Lung cancer;
LUSC	cis	rs6489882	0.703	rs10850096	chr12:113360786	T/C	cg20102336	chr12:113376681	OAS3	-0.4	-5.71	-0.3	2.46e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg17971929	chr21:40555470	PSMG1	-0.62	-10.25	-0.49	1.34e-21	Cognitive function;
LUSC	cis	rs2294693	0.947	rs6924722	chr6:41002195	C/T	cg14769373	chr6:40998127	UNC5CL	0.53	7.93	0.4	3.26e-14	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg22676075	chr6:135203613	NA	0.59	9.37	0.46	1.1e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs10788264	0.544	rs9630083	chr10:124017423	C/T	cg09507567	chr10:124027408	NA	0.54	9.47	0.46	5.26e-19	Total body bone mineral density;
LUSC	cis	rs965469	0.603	rs6051849	chr20:3404860	C/G	cg25506879	chr20:3388711	C20orf194	-0.46	-6.2	-0.32	1.66e-9	IFN-related cytopenia;
LUSC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.71	-12.58	-0.57	5.85e-30	Lung cancer;
LUSC	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg19318889	chr4:1322082	MAEA	0.8	14.34	0.62	1.13e-36	Longevity;
LUSC	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg24375607	chr4:120327624	NA	0.76	11.72	0.54	8.59e-27	Corneal astigmatism;
LUSC	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	0.81	11.42	0.53	1.05e-25	Response to hepatitis C treatment;
LUSC	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg12573674	chr2:1569213	NA	-0.55	-6.03	-0.31	4.38e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg03585969	chr10:35415529	CREM	0.6	8.81	0.43	6.71e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg27170947	chr2:26402098	FAM59B	-0.65	-9.58	-0.46	2.34e-19	Gut microbiome composition (summer);
LUSC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.52	6.86	0.35	3.39e-11	Blood protein levels;
LUSC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg08132940	chr7:1081526	C7orf50	-0.52	-6.27	-0.32	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs977987	0.645	rs34904236	chr16:75498253	G/T	cg03315344	chr16:75512273	CHST6	0.56	10.85	0.51	1.1e-23	Dupuytren's disease;
LUSC	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-14.1	-0.61	9.27e-36	Height;
LUSC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-9.41	-0.46	8.39e-19	Gut microbiome composition (summer);
LUSC	trans	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg25214090	chr10:38739885	LOC399744	0.45	6.6	0.34	1.61e-10	Corneal astigmatism;
LUSC	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.64	-0.43	2.38e-16	Total cholesterol levels;
LUSC	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg13042288	chr15:90349979	ANPEP	-0.48	-6.77	-0.35	5.86e-11	Uric acid levels;
LUSC	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	9.4	0.46	8.83e-19	Response to antipsychotic treatment;
LUSC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg04369109	chr6:150039330	LATS1	-0.55	-7.51	-0.38	5.46e-13	Lung cancer;
LUSC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg24829409	chr8:58192753	C8orf71	-0.6	-7.35	-0.37	1.59e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.15	-0.49	2.88e-21	Obesity-related traits;
LUSC	trans	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg27411982	chr8:10470053	RP1L1	0.39	6.37	0.33	6.37e-10	Mood instability;
LUSC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.99	0.36	1.54e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12697442	chr11:101981167	YAP1	0.39	6.18	0.32	1.91e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg23719950	chr11:63933701	MACROD1	-0.38	-6.11	-0.32	2.8e-9	Platelet count;
LUSC	cis	rs7131987	0.801	rs6487804	chr12:29454934	G/A	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.89	-0.35	2.71e-11	QT interval;
LUSC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	9.37	0.46	1.13e-18	Motion sickness;
LUSC	cis	rs6504340	0.793	rs12946855	chr17:46608030	G/A	cg09704116	chr17:46666958	LOC404266	-0.37	-6.79	-0.35	5.27e-11	Primary tooth development (number of teeth);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02634421	chr16:3767934	TRAP1	-0.45	-6.32	-0.33	8.33e-10	Hepatitis;
LUSC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-16.33	-0.67	1.77e-44	Blood trace element (Zn levels);
LUSC	cis	rs12220238	1.000	rs11000916	chr10:75953909	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.3	0.37	2.12e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg12463550	chr7:65579703	CRCP	-0.53	-7.72	-0.39	1.4e-13	Aortic root size;
LUSC	trans	rs4662863	0.529	rs17049005	chr2:129766414	C/T	cg05506011	chr3:118864587	C3orf30;IGSF11	0.36	6.09	0.32	3.1e-9	Gut microbiome composition (winter);
LUSC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg17333051	chr19:2783644	SGTA	0.49	7.31	0.37	2.01e-12	Total cholesterol levels;
LUSC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg05941027	chr17:61774174	LIMD2	0.22	5.84	0.3	1.26e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg04545296	chr12:48745243	ZNF641	0.37	6.82	0.35	4.23e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.63	-8.24	-0.41	4.04e-15	Body mass index;
LUSC	cis	rs11677416	0.885	rs4849119	chr2:113523463	G/C	cg27083787	chr2:113543245	IL1A	0.46	7.0	0.36	1.44e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg25208724	chr1:156163844	SLC25A44	1.04	20.69	0.75	8.55e-62	Intracerebral hemorrhage;White matter hyperintensity burden;
LUSC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.66	11.04	0.52	2.33e-24	Tuberculosis;
LUSC	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-10.54	-0.5	1.29e-22	Monocyte percentage of white cells;
LUSC	cis	rs6546550	0.901	rs6546556	chr2:70139001	A/G	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg18904891	chr8:8559673	CLDN23	0.6	8.24	0.41	3.84e-15	Obesity-related traits;
LUSC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg16647868	chr5:131706066	SLC22A5	-0.41	-6.39	-0.33	5.65e-10	Breast cancer;
LUSC	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg14092571	chr14:90743983	NA	0.36	5.77	0.3	1.78e-8	Mortality in heart failure;
LUSC	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.38	6.27	0.32	1.14e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06481639	chr22:41940642	POLR3H	-0.53	-5.96	-0.31	6.38e-9	Vitiligo;
LUSC	cis	rs6542838	0.646	rs2008648	chr2:99408323	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-6.04	-0.31	4.08e-9	Fear of minor pain;
LUSC	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg27205649	chr11:78285834	NARS2	0.53	6.41	0.33	5.05e-10	Alzheimer's disease (survival time);
LUSC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	12.1	0.55	3.39e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2274273	1.000	rs7493394	chr14:55617755	A/T	cg04306507	chr14:55594613	LGALS3	0.54	11.95	0.55	1.23e-27	Protein biomarker;
LUSC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg06454157	chr6:167490870	NA	-0.28	-6.87	-0.35	3.1e-11	Primary biliary cholangitis;
LUSC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.49	7.35	0.37	1.51e-12	Eosinophil percentage of white cells;
LUSC	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg13647721	chr17:30228624	UTP6	-0.69	-7.5	-0.38	5.71e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg22705602	chr4:152727874	NA	-0.35	-7.63	-0.39	2.41e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg16989719	chr2:238392110	NA	-0.41	-5.77	-0.3	1.85e-8	Prostate cancer;
LUSC	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06544989	chr22:39130855	UNC84B	0.32	5.81	0.3	1.48e-8	Menopause (age at onset);
LUSC	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg13902645	chr11:5959945	NA	-0.64	-8.7	-0.43	1.55e-16	DNA methylation (variation);
LUSC	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg06271696	chr7:157225062	NA	-0.41	-8.01	-0.4	1.91e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg08999081	chr20:33150536	PIGU	0.44	8.04	0.4	1.6e-14	Coronary artery disease;
LUSC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg25344623	chr2:136566232	LCT	0.38	5.73	0.3	2.27e-8	Mosquito bite size;
LUSC	cis	rs7582720	1.000	rs72936326	chr2:204054141	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.29	0.41	2.71e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6977660	1.000	rs12666159	chr7:19804199	T/C	cg07541023	chr7:19748670	TWISTNB	0.54	6.18	0.32	1.83e-9	Thyroid stimulating hormone;
LUSC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg20608306	chr11:116969690	SIK3	0.36	6.74	0.35	7.05e-11	Blood protein levels;
LUSC	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.45	-0.42	9.15e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg18306943	chr3:40428807	ENTPD3	0.38	5.73	0.3	2.23e-8	Renal cell carcinoma;
LUSC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	7.65	0.39	2.12e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg03453431	chr7:157225567	NA	0.57	9.12	0.45	7.31e-18	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18099408	chr3:52552593	STAB1	-0.4	-7.02	-0.36	1.23e-11	Bipolar disorder;
LUSC	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg00791764	chr4:53727839	RASL11B	0.58	7.35	0.37	1.54e-12	Optic nerve measurement (cup area);
LUSC	cis	rs6723226	0.764	rs176403	chr2:32637864	C/A	cg02381751	chr2:32503542	YIPF4	-0.62	-9.36	-0.46	1.18e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2742417	0.967	rs9877499	chr3:45734404	G/A	cg09608765	chr3:45636137	LIMD1	-0.37	-7.23	-0.37	3.35e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg06784218	chr1:46089804	CCDC17	0.57	11.63	0.54	1.79e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2742417	0.967	rs1534875	chr3:45741043	T/G	cg09608765	chr3:45636137	LIMD1	-0.37	-7.43	-0.38	8.99e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08677398	chr8:58056175	NA	0.54	6.63	0.34	1.35e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg04944784	chr2:26401820	FAM59B	-0.75	-11.04	-0.52	2.23e-24	Gut microbiome composition (summer);
LUSC	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg09307838	chr4:120376055	NA	0.69	10.21	0.49	1.77e-21	Corneal astigmatism;
LUSC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.61	0.5	7.35e-23	Monocyte percentage of white cells;
LUSC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg07741184	chr6:167504864	NA	0.49	8.61	0.43	3.03e-16	Crohn's disease;
LUSC	cis	rs17604090	0.550	rs111649163	chr7:29689176	C/T	cg19413766	chr7:29689036	LOC646762	-0.63	-7.69	-0.39	1.62e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg19812747	chr11:111475976	SIK2	-0.55	-7.91	-0.4	3.85e-14	Primary sclerosing cholangitis;
LUSC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg06784218	chr1:46089804	CCDC17	-0.46	-8.86	-0.44	4.7e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2742234	0.578	rs2742241	chr10:43625223	G/A	cg02780029	chr10:43622663	RET	-0.35	-5.97	-0.31	5.99e-9	Hirschsprung disease;
LUSC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.73	12.98	0.58	1.75e-31	Prudent dietary pattern;
LUSC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg13939156	chr17:80058883	NA	-0.33	-6.56	-0.34	2.02e-10	Life satisfaction;
LUSC	cis	rs12704876	0.509	rs1608741	chr7:96354206	G/A	cg03808172	chr7:96339361	SHFM1	0.52	8.04	0.4	1.52e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.6	11.64	0.54	1.6e-26	Pulse pressure;
LUSC	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.84	-0.35	3.76e-11	Mood instability;
LUSC	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs7804356	1.000	rs3801803	chr7:26901740	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.1	-0.32	2.9e-9	Type 1 diabetes;
LUSC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg11632617	chr15:75315747	PPCDC	-0.5	-6.58	-0.34	1.86e-10	Blood trace element (Zn levels);
LUSC	cis	rs55728055	0.661	rs73162106	chr22:32034875	A/G	cg01338084	chr22:32026380	PISD	0.82	6.18	0.32	1.83e-9	Age-related hearing impairment;
LUSC	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg13010199	chr12:38710504	ALG10B	0.69	10.63	0.5	6.13e-23	Bladder cancer;
LUSC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg11062466	chr8:58055876	NA	0.5	6.45	0.33	3.85e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg16325326	chr1:53192061	ZYG11B	-0.9	-16.97	-0.68	4.92e-47	Monocyte count;
LUSC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg05729581	chr11:3078854	CARS	0.41	6.03	0.31	4.4e-9	Longevity;
LUSC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	8.06	0.4	1.37e-14	Prudent dietary pattern;
LUSC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg09877947	chr5:131593287	PDLIM4	-0.46	-7.64	-0.39	2.37e-13	Breast cancer;
LUSC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg06108461	chr20:60628389	TAF4	-0.97	-16.59	-0.67	1.62e-45	Body mass index;
LUSC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.95	-12.54	-0.57	8.28e-30	Platelet count;
LUSC	cis	rs2274273	0.648	rs58553156	chr14:55582694	T/A	cg04306507	chr14:55594613	LGALS3	0.48	9.74	0.47	6.8e-20	Protein biomarker;
LUSC	cis	rs7246967	0.604	rs58536761	chr19:22880331	G/C	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.97	0.48	1.11e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35000415	0.938	rs35234849	chr7:128648953	T/C	cg19972273	chr7:128594194	NA	0.68	6.79	0.35	5.04e-11	Systemic lupus erythematosus;
LUSC	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg13010199	chr12:38710504	ALG10B	0.4	5.79	0.3	1.58e-8	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11461694	chr4:103266404	SLC39A8	0.4	6.05	0.31	3.88e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg14993813	chr1:46806288	NSUN4	-0.53	-7.41	-0.38	1.06e-12	Menopause (age at onset);
LUSC	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.25	0.52	4.11e-25	Eye color traits;
LUSC	cis	rs62458065	0.640	rs79619897	chr7:32514819	C/T	cg20159608	chr7:32802032	NA	-0.74	-9.31	-0.45	1.7e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	12.46	0.56	1.61e-29	Height;
LUSC	cis	rs79387448	0.745	rs9677607	chr2:103149520	A/T	cg09003973	chr2:102972529	NA	0.87	8.58	0.42	3.72e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs590121	0.876	rs585821	chr11:75282882	C/T	cg26104986	chr11:75275303	SERPINH1	-0.28	-5.87	-0.31	1.05e-8	Coronary artery disease;
LUSC	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs4363385	0.818	rs409986	chr1:153014741	A/C	cg25856811	chr1:152973957	SPRR3	0.34	5.82	0.3	1.37e-8	Inflammatory skin disease;
LUSC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg15017067	chr4:17643749	FAM184B	0.34	5.66	0.3	3.27e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg16797656	chr11:68205561	LRP5	0.38	6.2	0.32	1.62e-9	Total body bone mineral density;
LUSC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg09877947	chr5:131593287	PDLIM4	0.38	6.13	0.32	2.47e-9	Blood metabolite levels;
LUSC	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg23260525	chr10:116636907	FAM160B1	0.42	8.27	0.41	3.12e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.45	-0.33	3.84e-10	Total body bone mineral density;
LUSC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg25566285	chr7:158114605	PTPRN2	-0.33	-6.21	-0.32	1.55e-9	Calcium levels;
LUSC	cis	rs6714710	0.603	rs6757357	chr2:98491750	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.56	0.42	4.18e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05025164	chr4:1340916	KIAA1530	0.65	9.98	0.48	1.08e-20	Longevity;
LUSC	cis	rs8114671	0.647	rs6060268	chr20:33734293	T/C	cg24642439	chr20:33292090	TP53INP2	0.4	5.74	0.3	2.08e-8	Height;
LUSC	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg16989719	chr2:238392110	NA	-0.38	-6.69	-0.34	9.7e-11	Prostate cancer;
LUSC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	10.78	0.51	1.84e-23	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.3	-0.33	9.49e-10	Rheumatoid arthritis;
LUSC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg22535103	chr8:58192502	C8orf71	-0.69	-7.61	-0.38	2.77e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.17	-0.52	7.89e-25	Mean corpuscular volume;
LUSC	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	6.04	0.31	4e-9	Fibroblast growth factor basic levels;
LUSC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.57	0.34	1.9e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2219968	0.717	rs4739188	chr8:78912778	G/T	cg00738934	chr8:78996279	NA	-0.38	-7.02	-0.36	1.26e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg02018176	chr4:1364513	KIAA1530	0.43	5.93	0.31	7.5e-9	Recombination rate (females);
LUSC	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg25427524	chr10:38739819	LOC399744	0.43	5.69	0.3	2.75e-8	Obesity (extreme);
LUSC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07677032	chr17:61819896	STRADA	0.55	9.2	0.45	4.08e-18	Prudent dietary pattern;
LUSC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg01879757	chr17:41196368	BRCA1	-0.47	-7.58	-0.38	3.45e-13	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22755008	chr11:1715418	HCCA2	-0.42	-6.3	-0.33	9.13e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	12.33	0.56	4.85e-29	Chronic sinus infection;
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01171360	chr6:293285	DUSP22	-0.68	-10.94	-0.51	5.25e-24	Menopause (age at onset);
LUSC	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.71	-0.43	1.39e-16	Monocyte percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15709784	chr12:64845926	TBK1	-0.44	-6.79	-0.35	5.12e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg02569458	chr12:86230093	RASSF9	-0.37	-5.89	-0.31	9.65e-9	Major depressive disorder;
LUSC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.1	0.52	1.39e-24	Alzheimer's disease;
LUSC	cis	rs9807989	0.839	rs10192157	chr2:102968356	C/T	cg09003973	chr2:102972529	NA	0.44	6.01	0.31	4.83e-9	Asthma;
LUSC	trans	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg26043149	chr18:55253948	FECH	-0.45	-6.86	-0.35	3.42e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg17971929	chr21:40555470	PSMG1	-0.51	-7.57	-0.38	3.69e-13	Menarche (age at onset);
LUSC	cis	rs16958440	0.581	rs11873880	chr18:44692465	T/C	cg17192377	chr18:44677553	HDHD2	0.52	6.12	0.32	2.6e-9	Sitting height ratio;
LUSC	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.86	-11.36	-0.53	1.64e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.73	-0.43	1.21e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs853679	0.567	rs1005126	chr6:28367623	C/G	cg01620082	chr3:125678407	NA	-0.44	-6.53	-0.34	2.47e-10	Depression;
LUSC	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg03684893	chr10:554711	DIP2C	0.38	6.94	0.36	2.03e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg08508325	chr11:3079039	CARS	0.36	8.22	0.41	4.48e-15	Calcium levels;
LUSC	cis	rs4786125	0.920	rs7194057	chr16:6895960	T/C	cg03623568	chr16:6915990	A2BP1	-0.46	-7.63	-0.39	2.44e-13	Heart rate variability traits (SDNN);
LUSC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	6.16	0.32	2.04e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11060661	chr22:24314208	DDT;DDTL	0.48	7.87	0.4	4.96e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1973993	0.745	rs56119386	chr1:96962215	C/T	cg10631902	chr5:14652156	NA	-0.41	-6.03	-0.31	4.46e-9	Weight;
LUSC	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs1113500	0.787	rs12047429	chr1:108633239	C/T	cg06207961	chr1:108661230	NA	0.3	5.71	0.3	2.5e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.88e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg13683864	chr3:40499215	RPL14	-0.89	-13.23	-0.59	2.07e-32	Renal cell carcinoma;
LUSC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg12257692	chr3:49977190	RBM6	0.24	6.61	0.34	1.49e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.2	-0.37	4.1e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.54	0.34	2.24e-10	Corneal astigmatism;
LUSC	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.92	0.35	2.34e-11	IgG glycosylation;
LUSC	cis	rs6424115	1.000	rs12121387	chr1:24166536	T/G	cg10978503	chr1:24200527	CNR2	-0.5	-11.76	-0.54	5.88e-27	Immature fraction of reticulocytes;
LUSC	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg00579200	chr11:133705235	NA	-0.41	-6.19	-0.32	1.74e-9	Childhood ear infection;
LUSC	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-1.15	-18.35	-0.71	1.67e-52	Exhaled nitric oxide output;
LUSC	cis	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg02972257	chr16:68554789	NA	0.42	5.73	0.3	2.3e-8	Colorectal cancer;
LUSC	cis	rs4356932	1.000	rs4356932	chr4:76955194	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.81	0.3	1.45e-8	Blood protein levels;
LUSC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg22166914	chr1:53195759	ZYG11B	-0.48	-7.62	-0.39	2.57e-13	Monocyte count;
LUSC	cis	rs4654899	0.865	rs61779065	chr1:21356474	A/T	cg01072550	chr1:21505969	NA	-0.54	-7.93	-0.4	3.4e-14	Superior frontal gyrus grey matter volume;
LUSC	trans	rs853679	1.000	rs853679	chr6:28296863	C/A	cg01620082	chr3:125678407	NA	-0.57	-6.5	-0.34	2.91e-10	Depression;
LUSC	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg01528321	chr10:82214614	TSPAN14	0.86	13.02	0.58	1.23e-31	Post bronchodilator FEV1;
LUSC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.72	13.83	0.6	1.03e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg03948781	chr1:205179583	DSTYK	0.33	6.32	0.33	8.23e-10	Red blood cell count;
LUSC	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg00376283	chr12:123451042	ABCB9	0.64	8.07	0.4	1.24e-14	Neutrophil percentage of white cells;
LUSC	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg13256891	chr4:100009986	ADH5	0.48	7.11	0.36	7.05e-12	Alcohol dependence;
LUSC	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg26195577	chr20:24973756	C20orf3	1.12	18.21	0.71	6.24e-52	Blood protein levels;
LUSC	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.52	10.24	0.49	1.44e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs3857536	0.611	rs7748258	chr6:66932840	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.44e-9	Blood trace element (Cu levels);
LUSC	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	9.08	0.45	9.34e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg27535305	chr1:53392650	SCP2	0.36	6.73	0.35	7.3e-11	Monocyte count;
LUSC	cis	rs9815354	1.000	rs17063649	chr3:41863406	C/T	cg03022575	chr3:42003672	ULK4	0.58	6.54	0.34	2.3e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg01238044	chr22:24384105	GSTT1	0.58	9.52	0.46	3.65e-19	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11018904	0.906	rs55685917	chr11:89964365	T/C	cg26834418	chr11:89957033	CHORDC1	-0.5	-6.34	-0.33	7.54e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg20935933	chr6:143382018	AIG1	0.5	7.32	0.37	1.92e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg13683864	chr3:40499215	RPL14	-0.91	-15.79	-0.65	2.46e-42	Renal cell carcinoma;
LUSC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg02951883	chr7:2050386	MAD1L1	-0.35	-6.09	-0.32	3.08e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg18825076	chr15:78729989	IREB2	-0.63	-10.25	-0.49	1.32e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg04800585	chr6:26043546	HIST1H2BB	0.39	5.83	0.3	1.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.1	0.32	2.97e-9	Mean platelet volume;
LUSC	trans	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg03886242	chr7:26192032	NFE2L3	0.38	6.16	0.32	2.1e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1163251	0.869	rs487884	chr1:120217330	C/T	cg19096424	chr1:120255104	PHGDH	0.48	6.53	0.34	2.39e-10	Blood metabolite levels;
LUSC	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg06627628	chr2:24431161	ITSN2	0.55	7.75	0.39	1.13e-13	Asthma;
LUSC	cis	rs983392	0.679	rs10736701	chr11:60031476	C/T	cg02771260	chr11:59836817	MS4A3	0.37	6.11	0.32	2.83e-9	Alzheimer's disease (late onset);
LUSC	trans	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.2	-0.37	4e-12	Rheumatoid arthritis;
LUSC	cis	rs7605827	0.897	rs13017859	chr2:15537641	T/C	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.59	0.5	8.56e-23	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04428535	chr19:50432391	NUP62;IL4I1;ATF5	-0.46	-6.3	-0.33	9.66e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg12365402	chr11:9010492	NRIP3	0.37	6.76	0.35	5.99e-11	Hemoglobin concentration;
LUSC	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg09699651	chr6:150184138	LRP11	0.44	6.98	0.36	1.64e-11	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	8.48	0.42	7.32e-16	Motion sickness;
LUSC	cis	rs1979679	0.608	rs1581073	chr12:28724039	A/G	cg13890972	chr12:28721907	NA	-0.42	-6.07	-0.32	3.45e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.7	-11.82	-0.54	3.53e-27	Prudent dietary pattern;
LUSC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-11.67	-0.54	1.23e-26	Bipolar disorder;
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg25243455	chr2:114033360	PAX8;LOC440839	-0.34	-7.67	-0.39	1.88e-13	Lymphocyte counts;
LUSC	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg23093090	chr10:104574429	C10orf26	-0.37	-7.06	-0.36	9.42e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg20476274	chr7:133979776	SLC35B4	0.87	17.01	0.68	3.4e-47	Mean platelet volume;
LUSC	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg22676075	chr6:135203613	NA	0.47	7.4	0.38	1.13e-12	Red blood cell count;
LUSC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg24642844	chr7:1081250	C7orf50	-0.45	-7.25	-0.37	2.97e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg08330031	chr10:104623503	C10orf32	0.31	5.65	0.3	3.36e-8	Arsenic metabolism;
LUSC	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg15556689	chr8:8085844	FLJ10661	0.56	8.47	0.42	7.64e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs1692580	0.840	rs696094	chr1:2169215	G/A	cg24578937	chr1:2090814	PRKCZ	0.37	7.65	0.39	2.21e-13	Coronary artery disease;
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.56	-8.72	-0.43	1.33e-16	Lymphocyte counts;
LUSC	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg11262906	chr1:85462892	MCOLN2	-0.72	-8.8	-0.43	7.73e-17	Serum sulfate level;
LUSC	cis	rs10465746	0.905	rs11163875	chr1:84429605	T/G	cg10977910	chr1:84465055	TTLL7	0.43	6.29	0.33	1.01e-9	Obesity-related traits;
LUSC	cis	rs3916	1.000	rs3916	chr12:121177272	G/C	cg02419362	chr12:121203948	SPPL3	0.36	5.76	0.3	1.87e-8	Urinary metabolites (H-NMR features);
LUSC	cis	rs61142792	0.590	rs747861	chr5:177037397	C/G	cg03428951	chr5:177434336	FAM153C	0.66	5.68	0.3	2.88e-8	Alzheimer disease and age of onset;
LUSC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg02772935	chr3:125709198	NA	-0.48	-5.82	-0.3	1.36e-8	Blood pressure (smoking interaction);
LUSC	cis	rs17401966	0.522	rs10864450	chr1:10333959	G/T	cg19773385	chr1:10388646	KIF1B	-0.35	-6.17	-0.32	2.01e-9	Hepatocellular carcinoma;
LUSC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.72	12.04	0.55	5.79e-28	Motion sickness;
LUSC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19717773	chr7:2847554	GNA12	0.37	6.06	0.31	3.62e-9	Height;
LUSC	cis	rs4654899	0.865	rs10916910	chr1:21283192	G/T	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.44	-0.33	4.17e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg07274523	chr3:49395745	GPX1	0.68	10.47	0.5	2.21e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	trans	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-12.26	-0.56	8.92e-29	Colorectal cancer;
LUSC	cis	rs2860975	0.936	rs7904000	chr10:96767858	A/T	cg09036531	chr10:96991505	NA	-0.4	-5.66	-0.3	3.31e-8	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg09655341	chr17:79618100	PDE6G	-0.3	-7.07	-0.36	9.28e-12	Eye color traits;
LUSC	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg22508957	chr16:3507546	NAT15	0.44	6.26	0.32	1.16e-9	Body mass index (adult);
LUSC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-10.15	-0.49	2.83e-21	Alzheimer's disease;
LUSC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.85	0.3	1.2e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12618769	0.572	rs4851141	chr2:99112966	A/C	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	trans	rs7980799	0.649	rs10772088	chr12:33663849	A/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.22	-0.41	4.44e-15	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg03233332	chr7:66118400	NA	-0.43	-6.15	-0.32	2.22e-9	Aortic root size;
LUSC	cis	rs10779751	1.000	rs2300092	chr1:11266464	T/C	cg08854313	chr1:11322531	MTOR	0.92	16.42	0.67	7.99e-45	Body mass index;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg26309655	chr1:150459725	TARS2	0.49	6.07	0.32	3.54e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11051970	0.877	rs2728671	chr12:32589715	T/A	cg02745156	chr12:32552066	NA	0.43	7.29	0.37	2.29e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg07080220	chr10:102295463	HIF1AN	0.68	8.7	0.43	1.54e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7428496	0.528	rs11923612	chr3:142290490	T/C	cg16271453	chr3:142027066	XRN1	-0.49	-8.44	-0.42	9.99e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	9.4	0.46	8.73e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg01657329	chr11:68192670	LRP5	-0.45	-7.18	-0.37	4.58e-12	Total body bone mineral density;
LUSC	cis	rs4409675	0.576	rs11247706	chr1:28213983	G/C	cg23691781	chr1:28212827	C1orf38	0.32	7.68	0.39	1.8e-13	Corneal astigmatism;
LUSC	cis	rs2274273	0.870	rs8023197	chr14:55767395	G/T	cg04306507	chr14:55594613	LGALS3	0.56	13.11	0.58	5.6199999999999995e-32	Protein biomarker;
LUSC	cis	rs4629180	0.586	rs10206804	chr2:102132431	C/T	cg01388757	chr2:102091195	RFX8	0.37	6.4	0.33	5.12e-10	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg03676636	chr4:99064102	C4orf37	0.3	5.96	0.31	6.52e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9469578	0.792	rs73743331	chr6:33714036	G/T	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg23625390	chr15:77176239	SCAPER	-0.62	-8.91	-0.44	3.33e-17	Blood metabolite levels;
LUSC	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg18512352	chr11:47633146	NA	0.28	5.76	0.3	1.89e-8	Subjective well-being;
LUSC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg11766577	chr21:47581405	C21orf56	-0.46	-6.85	-0.35	3.5e-11	Testicular germ cell tumor;
LUSC	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg23992470	chr4:843637	GAK	0.69	7.0	0.36	1.42e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg04058563	chr4:185651563	MLF1IP	0.41	6.63	0.34	1.36e-10	Kawasaki disease;
LUSC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg22907277	chr7:1156413	C7orf50	0.39	5.82	0.3	1.39e-8	Longevity;Endometriosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05264411	chr1:171455311	BAT2L2	0.48	6.64	0.34	1.27e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg00310523	chr12:86230176	RASSF9	0.38	6.91	0.35	2.45e-11	Major depressive disorder;
LUSC	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg20203395	chr5:56204925	C5orf35	-0.46	-6.88	-0.35	3.03e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs6750047	0.638	rs336031	chr2:38265130	C/A	cg07380506	chr2:38303506	CYP1B1	-0.43	-5.84	-0.3	1.23e-8	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs2455601	0.507	rs7948452	chr11:8877704	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-8.3	-0.41	2.67e-15	Schizophrenia;
LUSC	cis	rs2932538	0.922	rs112363416	chr1:113107543	T/C	cg22162597	chr1:113214053	CAPZA1	0.71	10.07	0.48	5.38e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg05896524	chr21:47604654	C21orf56	0.42	6.2	0.32	1.69e-9	Testicular germ cell tumor;
LUSC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg19318889	chr4:1322082	MAEA	0.46	7.48	0.38	6.61e-13	Obesity-related traits;
LUSC	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg01620082	chr3:125678407	NA	-0.77	-7.12	-0.36	6.8e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6674970	0.933	rs12134957	chr1:151045419	A/G	cg03258749	chr1:151040405	MLLT11	-0.44	-6.7	-0.34	8.69e-11	Childhood ear infection;
LUSC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg24130564	chr14:104152367	KLC1	-0.42	-6.03	-0.31	4.31e-9	Body mass index;
LUSC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-7.07	-0.36	9.27e-12	Lung cancer;
LUSC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg03354898	chr7:1950403	MAD1L1	-0.42	-8.43	-0.42	1.05e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Body mass index;
LUSC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25072359	chr17:41440525	NA	0.65	9.34	0.46	1.37e-18	Menopause (age at onset);
LUSC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.86	0.39	5.51e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.52	-6.09	-0.32	3.13e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg08470875	chr2:26401718	FAM59B	-0.65	-8.59	-0.43	3.38e-16	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08219700	chr8:58056026	NA	0.66	8.37	0.42	1.58e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.08	0.52	1.71e-24	Colorectal cancer;
LUSC	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-20.39	-0.74	1.35e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg16558253	chr16:72132732	DHX38	-0.38	-6.07	-0.32	3.45e-9	Fibrinogen levels;
LUSC	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21659725	chr3:3221576	CRBN	-0.59	-8.27	-0.41	3.21e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	9.4	0.46	8.76e-19	Mean platelet volume;
LUSC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.88	0.58	4.26e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg07217954	chr7:1067459	C7orf50	0.54	5.7	0.3	2.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg04995722	chr7:26192034	NFE2L3	-0.4	-6.36	-0.33	6.8e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg22676075	chr6:135203613	NA	0.49	7.66	0.39	2.02e-13	Red blood cell count;
LUSC	trans	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg13010199	chr12:38710504	ALG10B	0.41	6.26	0.32	1.17e-9	Morning vs. evening chronotype;
LUSC	cis	rs77741769	0.529	rs1467283	chr12:121210220	G/C	cg02419362	chr12:121203948	SPPL3	0.46	8.46	0.42	8.71e-16	Mean corpuscular volume;
LUSC	cis	rs10504229	0.516	rs1866994	chr8:57990092	A/C	cg21724239	chr8:58056113	NA	0.43	5.66	0.3	3.18e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg18512352	chr11:47633146	NA	0.48	9.94	0.48	1.45e-20	Subjective well-being;
LUSC	cis	rs11690935	0.632	rs1607254	chr2:172626552	A/G	cg13550731	chr2:172543902	DYNC1I2	0.57	8.96	0.44	2.37e-17	Schizophrenia;
LUSC	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08045932	chr20:61659980	NA	0.57	9.68	0.47	1.09e-19	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1957429	0.808	rs1957436	chr14:65348207	T/G	cg23373153	chr14:65346875	NA	1.07	12.89	0.58	3.85e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05901451	chr6:126070800	HEY2	0.57	8.57	0.42	3.96e-16	Endometrial cancer;
LUSC	cis	rs308447	0.516	rs13142203	chr4:123679002	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.84	11.13	0.52	1.08e-24	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs7560272	0.538	rs7370393	chr2:73925636	A/C	cg20560298	chr2:73613845	ALMS1	0.4	6.1	0.32	2.92e-9	Schizophrenia;
LUSC	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg05110241	chr16:68378359	PRMT7	-0.55	-6.45	-0.33	4.01e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg18479299	chr3:125709523	NA	-0.49	-6.0	-0.31	5.05e-9	Blood pressure (smoking interaction);
LUSC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg06784218	chr1:46089804	CCDC17	0.48	9.2	0.45	3.91e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.67	-0.34	1.06e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-0.99	-14.45	-0.62	4.26e-37	Initial pursuit acceleration;
LUSC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg26513180	chr16:89883248	FANCA	0.74	11.33	0.53	2.06e-25	Vitiligo;
LUSC	cis	rs35771425	0.518	rs1055565	chr1:211605697	G/A	cg25617285	chr1:211431773	RCOR3	-0.36	-5.72	-0.3	2.42e-8	Educational attainment (years of education);
LUSC	cis	rs1904096	0.506	rs28701470	chr4:95167088	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.08	-0.4	1.18e-14	Type 2 diabetes;
LUSC	cis	rs677665	0.918	rs11590326	chr1:9339205	A/G	cg25755851	chr1:9335794	NA	-0.61	-10.1	-0.48	4.15e-21	Eosinophil percentage of white cells;
LUSC	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg09877947	chr5:131593287	PDLIM4	-0.38	-6.15	-0.32	2.27e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs78366141	0.649	rs76401410	chr4:89694624	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	1.02	7.32	0.37	1.85e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg16797656	chr11:68205561	LRP5	0.36	6.04	0.31	4.2e-9	Total body bone mineral density;
LUSC	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg08079166	chr15:68083412	MAP2K5	0.4	7.13	0.36	6.39e-12	Restless legs syndrome;
LUSC	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg26924012	chr15:45694286	SPATA5L1	0.76	11.7	0.54	9.97e-27	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	0.93	15.63	0.65	1.01e-41	Menopause (age at onset);
LUSC	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg27539214	chr16:67997921	SLC12A4	-0.58	-7.71	-0.39	1.42e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	9.4	0.46	9.01e-19	Height;
LUSC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg01256987	chr12:42539512	GXYLT1	0.36	6.69	0.34	9.16e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg13010199	chr12:38710504	ALG10B	-0.44	-6.55	-0.34	2.23e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg24558204	chr6:135376177	HBS1L	0.61	9.55	0.46	2.86e-19	Red blood cell count;
LUSC	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.57	-0.42	3.84e-16	Neuroticism;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg17243540	chr1:12018611	PLOD1	-0.73	-6.51	-0.34	2.73e-10	Body mass index;
LUSC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg02380750	chr20:61661411	NA	0.34	5.97	0.31	6.11e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.49	16.86	0.68	1.38e-46	Opioid sensitivity;
LUSC	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg20933634	chr6:27740509	NA	-0.42	-6.01	-0.31	4.94e-9	Parkinson's disease;
LUSC	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.16e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.53	-8.04	-0.4	1.62e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg00024416	chr22:24240387	NA	-0.33	-5.67	-0.3	3.09e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs16857609	0.600	rs10932715	chr2:218259783	A/G	cg15335768	chr2:218268053	DIRC3	-0.32	-5.95	-0.31	6.85e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
LUSC	cis	rs2742234	0.541	rs1317214	chr10:43733531	C/G	cg15436174	chr10:43711423	RASGEF1A	0.43	7.05	0.36	1.03e-11	Hirschsprung disease;
LUSC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.9	0.48	2.03e-20	Bipolar disorder;
LUSC	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14240646	chr10:27532245	ACBD5	-0.65	-7.75	-0.39	1.15e-13	Breast cancer;
LUSC	cis	rs6733011	0.578	rs12712039	chr2:99497980	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.04	-0.31	4.14e-9	Bipolar disorder;
LUSC	cis	rs9807989	0.839	rs11695627	chr2:102970105	A/G	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.67e-9	Asthma;
LUSC	cis	rs9914988	1.000	rs6803	chr17:27187789	C/T	cg09479241	chr17:27052676	TLCD1	-0.43	-5.73	-0.3	2.23e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs10432489	0.541	rs6724902	chr2:181739323	A/T	cg04744134	chr19:8408128	KANK3	-0.77	-6.18	-0.32	1.87e-9	QT interval;
LUSC	cis	rs10761482	0.861	rs2393625	chr10:62119206	A/G	cg18175470	chr10:62150864	ANK3	0.5	7.16	0.36	5.17e-12	Schizophrenia;
LUSC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg04398451	chr17:18023971	MYO15A	0.5	8.03	0.4	1.73e-14	Strep throat;
LUSC	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-1.14	-17.96	-0.7	6.12e-51	Exhaled nitric oxide output;
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10150615	chr22:24372951	LOC391322	0.4	6.39	0.33	5.51e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs17433780	0.666	rs2624	chr1:89518623	C/T	cg09516651	chr1:89888402	LOC400759	-0.59	-11.0	-0.52	3.19e-24	Carotid intima media thickness;
LUSC	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	7.29	0.37	2.32e-12	Neuroticism;
LUSC	cis	rs7119038	0.818	rs7942535	chr11:118681464	C/T	cg19308663	chr11:118741387	NA	-0.32	-5.72	-0.3	2.32e-8	Sjögren's syndrome;
LUSC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.83	-0.3	1.29e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg19418458	chr7:158789849	NA	0.52	6.68	0.34	1e-10	Facial morphology (factor 20);
LUSC	cis	rs981844	1.000	rs72731670	chr4:154662471	C/T	cg14289246	chr4:154710475	SFRP2	0.5	6.44	0.33	4.05e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.95	0.51	4.66e-24	Hypertriglyceridemia;
LUSC	trans	rs6104690	1.000	rs6078006	chr20:10986451	T/A	cg07172334	chr21:31655261	KRTAP24-1	-0.34	-6.08	-0.32	3.23e-9	Bladder cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11659435	chr20:30310674	BCL2L1	-0.41	-6.39	-0.33	5.49e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg26380479	chr7:97908229	NA	-0.27	-6.04	-0.31	4.07e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg15242686	chr22:24348715	GSTTP1	-0.55	-9.11	-0.45	7.83e-18	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7267979	0.586	rs6037057	chr20:25182089	T/C	cg08601574	chr20:25228251	PYGB	0.43	6.62	0.34	1.47e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15557168	chr22:42548783	NA	0.38	6.32	0.33	8.44e-10	Cognitive function;
LUSC	cis	rs4343996	0.558	rs10454314	chr7:3411725	A/G	cg21248987	chr7:3385318	SDK1	0.37	6.23	0.32	1.38e-9	Motion sickness;
LUSC	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg18190219	chr22:46762943	CELSR1	-0.55	-6.28	-0.33	1.05e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs711245	0.702	rs1110127	chr2:36768456	G/C	cg09467607	chr2:36825704	FEZ2	0.5	10.1	0.48	4.02e-21	Height;
LUSC	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg26384229	chr12:38710491	ALG10B	0.72	11.22	0.52	5.39e-25	Morning vs. evening chronotype;
LUSC	cis	rs9837602	1.000	rs6802422	chr3:99778655	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-6.12	-0.32	2.58e-9	Breast cancer;
LUSC	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg17143192	chr8:8559678	CLDN23	0.63	9.07	0.44	1.02e-17	Obesity-related traits;
LUSC	cis	rs4776059	1.000	rs34431049	chr15:52940538	G/C	cg22715398	chr15:52968154	KIAA1370	-0.64	-9.13	-0.45	6.58e-18	Schizophrenia;
LUSC	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg04518342	chr5:131593106	PDLIM4	-0.36	-6.56	-0.34	2.01e-10	Blood metabolite levels;
LUSC	cis	rs9487051	0.743	rs388526	chr6:109543425	C/G	cg00509249	chr6:109615579	CCDC162	-0.34	-5.81	-0.3	1.42e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg00431813	chr7:1051703	C7orf50	-0.48	-8.04	-0.4	1.62e-14	Longevity;Endometriosis;
LUSC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg07701084	chr6:150067640	NUP43	0.5	7.43	0.38	8.98e-13	Lung cancer;
LUSC	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg09650180	chr20:62225654	GMEB2	-0.67	-9.66	-0.47	1.23e-19	Glioblastoma;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00087298	chr7:33149137	RP9	0.41	5.98	0.31	5.59e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-6.98	-0.36	1.61e-11	Breast cancer;
LUSC	trans	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17712092	chr4:129076599	LARP1B	0.73	10.83	0.51	1.25e-23	Eosinophil percentage of white cells;
LUSC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg04518342	chr5:131593106	PDLIM4	0.5	8.89	0.44	3.87e-17	Acylcarnitine levels;
LUSC	trans	rs1864729	1.000	rs2053480	chr8:98278951	A/T	cg08679828	chr8:102218111	ZNF706	0.81	7.38	0.37	1.28e-12	Estradiol plasma levels (breast cancer);
LUSC	cis	rs17604090	0.646	rs75322793	chr7:29683176	G/A	cg19413766	chr7:29689036	LOC646762	-0.61	-6.95	-0.36	1.97e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs3812762	0.871	rs11603335	chr11:8809844	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.37	6.13	0.32	2.43e-9	Hypospadias;
LUSC	cis	rs12681287	0.752	rs10104242	chr8:87247714	G/C	cg27223183	chr8:87520930	FAM82B	-0.46	-5.75	-0.3	2.06e-8	Caudate activity during reward;
LUSC	cis	rs698813	0.674	rs6725676	chr2:44497828	T/A	cg00619915	chr2:44497795	NA	-0.51	-7.16	-0.36	5.33e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg01802117	chr1:53393560	SCP2	0.47	7.57	0.38	3.62e-13	Monocyte count;
LUSC	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.69	-0.43	1.65e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg17366294	chr4:99064904	C4orf37	0.61	10.9	0.51	7.28e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs701145	0.938	rs355778	chr3:154030349	C/T	cg17054900	chr3:154042577	DHX36	0.84	8.81	0.43	7.07e-17	Coronary artery disease;
LUSC	cis	rs9612	1.000	rs28446957	chr19:44246600	T/A	cg08581076	chr19:44259116	C19orf61	0.54	6.57	0.34	1.88e-10	Exhaled nitric oxide output;
LUSC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.76	0.39	1.05e-13	Parkinson's disease;
LUSC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs12541635	0.902	rs13277300	chr8:107062819	C/T	cg10147462	chr8:107024639	NA	-0.55	-10.03	-0.48	7.49e-21	Age of smoking initiation;
LUSC	trans	rs539514	0.690	rs504273	chr13:76310850	C/T	cg05302441	chr11:125157402	PKNOX2	0.26	6.02	0.31	4.7e-9	Type 1 diabetes;
LUSC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg27266027	chr21:40555129	PSMG1	-0.4	-5.82	-0.3	1.41e-8	Cognitive function;
LUSC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg13560548	chr3:10150139	C3orf24	0.47	6.65	0.34	1.18e-10	Alzheimer's disease;
LUSC	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg22878388	chr2:105853796	NA	-0.33	-6.03	-0.31	4.3e-9	Type 2 diabetes;
LUSC	cis	rs6087990	1.000	rs2424900	chr20:31344342	G/C	cg13636640	chr20:31349939	DNMT3B	1.04	23.38	0.79	2.63e-72	Ulcerative colitis;
LUSC	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg08601574	chr20:25228251	PYGB	0.43	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2688608	0.933	rs2688614	chr10:75652876	G/A	cg23231163	chr10:75533350	FUT11	-0.39	-6.26	-0.32	1.2e-9	Inflammatory bowel disease;
LUSC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	13.03	0.58	1.12e-31	Cognitive test performance;
LUSC	cis	rs96067	0.740	rs10752586	chr1:36614713	C/G	cg24686825	chr1:36642396	MAP7D1	-0.69	-9.25	-0.45	2.78e-18	Corneal structure;
LUSC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12379764	chr21:47803548	PCNT	0.47	6.56	0.34	2.08e-10	Testicular germ cell tumor;
LUSC	cis	rs7119038	0.818	rs10892293	chr11:118665575	A/T	cg19308663	chr11:118741387	NA	0.35	6.1	0.32	2.94e-9	Sjögren's syndrome;
LUSC	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-8.84	-0.44	5.69e-17	Response to antipsychotic treatment;
LUSC	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg17420585	chr12:42539391	GXYLT1	-0.55	-12.26	-0.56	8.85e-29	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2652834	0.851	rs2652824	chr15:63420001	C/T	cg05507819	chr15:63340323	TPM1	0.47	6.02	0.31	4.65e-9	HDL cholesterol;
LUSC	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg19468946	chr17:37922297	IKZF3	-0.38	-6.07	-0.32	3.47e-9	Self-reported allergy;
LUSC	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24838063	chr12:130822603	PIWIL1	0.69	10.73	0.51	2.84e-23	Menopause (age at onset);
LUSC	cis	rs12042938	0.600	rs1094655	chr1:231774362	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	6.13	0.32	2.43e-9	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06544989	chr22:39130855	UNC84B	0.36	6.43	0.33	4.5e-10	Menopause (age at onset);
LUSC	cis	rs7169223	0.653	rs3971703	chr15:79092481	G/C	cg21242079	chr15:79101063	ADAMTS7	0.41	6.25	0.32	1.27e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15945262	chr7:1881887	MAD1L1	0.48	6.12	0.32	2.55e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4132509	0.948	rs1458023	chr1:243886673	A/G	cg21452805	chr1:244014465	NA	0.52	6.28	0.32	1.07e-9	RR interval (heart rate);
LUSC	cis	rs9392556	0.829	rs617790	chr6:4115758	C/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.35	-6.14	-0.32	2.31e-9	Blood metabolite levels;
LUSC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.17	-0.37	4.86e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2324229	0.861	rs1180183	chr6:83972041	C/T	cg08257003	chr6:84140564	ME1	0.29	6.61	0.34	1.57e-10	Platelet-derived growth factor BB levels;
LUSC	cis	rs925550	0.932	rs6811007	chr4:123585362	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.64	6.25	0.32	1.26e-9	Primary biliary cholangitis;
LUSC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.28	-0.32	1.06e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3087591	0.639	rs1048317	chr17:29704002	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	7.37	0.37	1.31e-12	Hip circumference;
LUSC	cis	rs1783925	1.000	rs610236	chr11:125297925	T/A	cg03464685	chr11:125439445	EI24	-0.47	-6.29	-0.33	9.69e-10	Formal thought disorder in schizophrenia;
LUSC	cis	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.79	-0.3	1.66e-8	Eotaxin levels;
LUSC	cis	rs600231	0.690	rs1152619	chr11:65255589	C/A	cg17120908	chr11:65337727	SSSCA1	-0.65	-10.71	-0.51	3.39e-23	Bone mineral density;
LUSC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.6	-7.7	-0.39	1.58e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg06521331	chr12:34319734	NA	-0.48	-7.86	-0.39	5.48e-14	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg05738196	chr6:26577821	NA	-0.51	-8.14	-0.41	8.1e-15	Schizophrenia;
LUSC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-1.09	-20.95	-0.75	8e-63	Height;
LUSC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg12310025	chr6:25882481	NA	-0.52	-9.44	-0.46	6.43e-19	Blood metabolite levels;
LUSC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg26373071	chr5:1325741	CLPTM1L	0.38	7.14	0.36	5.92e-12	Lung cancer;
LUSC	cis	rs6599077	0.950	rs6773620	chr3:40100738	T/G	cg13683864	chr3:40499215	RPL14	-0.59	-7.4	-0.38	1.11e-12	Sleep-related phenotypes;
LUSC	cis	rs28735056	0.660	rs12454454	chr18:77674634	C/T	cg05491587	chr18:77659695	KCNG2	0.37	5.8	0.3	1.56e-8	Schizophrenia;
LUSC	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg13010199	chr12:38710504	ALG10B	0.49	7.49	0.38	6.08e-13	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs7395662	0.864	rs10839201	chr11:48989417	A/G	cg15704280	chr7:45808275	SEPT13	0.44	6.12	0.32	2.7e-9	HDL cholesterol;
LUSC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.57	-8.23	-0.41	4.36e-15	Obesity-related traits;
LUSC	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg11789530	chr4:8429930	ACOX3	0.62	9.53	0.46	3.26e-19	Response to antineoplastic agents;
LUSC	cis	rs4356932	1.000	rs6532121	chr4:76962606	A/T	cg00809888	chr4:76862425	NAAA	-0.38	-6.36	-0.33	6.53e-10	Blood protein levels;
LUSC	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.47	8.34	0.42	1.94e-15	HDL cholesterol;
LUSC	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg22823121	chr1:150693482	HORMAD1	0.47	7.0	0.36	1.44e-11	Melanoma;
LUSC	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg25214090	chr10:38739885	LOC399744	0.56	8.19	0.41	5.49e-15	Corneal astigmatism;
LUSC	trans	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg07393940	chr7:158741817	NA	-0.51	-8.09	-0.4	1.12e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4363385	0.510	rs11588463	chr1:152901984	T/C	cg25856811	chr1:152973957	SPRR3	-0.39	-6.35	-0.33	7.09e-10	Inflammatory skin disease;
LUSC	cis	rs4285028	0.699	rs1574115	chr3:121469225	T/C	cg11130432	chr3:121712080	ILDR1	-0.61	-8.71	-0.43	1.48e-16	Multiple sclerosis;
LUSC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg00049323	chr5:472564	LOC25845	-0.44	-6.8	-0.35	4.79e-11	Cystic fibrosis severity;
LUSC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-9.51	-0.46	4.02e-19	Chronic sinus infection;
LUSC	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg17279839	chr7:150038598	RARRES2	0.43	6.9	0.35	2.58e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg01879757	chr17:41196368	BRCA1	-0.47	-7.26	-0.37	2.74e-12	Menopause (age at onset);
LUSC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg23630131	chr7:65973040	NA	-0.2	-5.67	-0.3	3.15e-8	Aortic root size;
LUSC	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg09654669	chr8:57350985	NA	-0.56	-7.78	-0.39	9.24e-14	Obesity-related traits;
LUSC	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	11.06	0.52	2e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg23625390	chr15:77176239	SCAPER	0.45	6.9	0.35	2.55e-11	Blood metabolite levels;
LUSC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg08219700	chr8:58056026	NA	0.51	6.35	0.33	7.03e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.8	10.9	0.51	7.21e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs62238980	0.614	rs117959136	chr22:32373225	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg22705602	chr4:152727874	NA	-0.31	-6.17	-0.32	1.98e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg02023728	chr11:77925099	USP35	0.43	6.58	0.34	1.77e-10	Testicular germ cell tumor;
LUSC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Depression;
LUSC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-19.9	-0.74	1.14e-58	Coronary artery disease;
LUSC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.47	-7.22	-0.37	3.52e-12	Urate levels;
LUSC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg13206674	chr6:150067644	NUP43	0.64	10.55	0.5	1.15e-22	Lung cancer;
LUSC	cis	rs12220238	1.000	rs10824083	chr10:75911342	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.27	0.37	2.65e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg11502198	chr6:26597334	ABT1	0.62	9.85	0.47	2.95e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs6500395	1.000	rs1909765	chr16:48597358	A/G	cg04672837	chr16:48644449	N4BP1	0.43	6.41	0.33	4.9e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg27068330	chr11:65405492	SIPA1	0.64	9.61	0.47	1.85e-19	Acne (severe);
LUSC	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg13010199	chr12:38710504	ALG10B	-0.6	-9.33	-0.45	1.56e-18	Morning vs. evening chronotype;
LUSC	cis	rs4664308	0.658	rs12987602	chr2:160960788	G/T	cg03641300	chr2:160917029	PLA2R1	-0.62	-10.19	-0.49	2.01e-21	Idiopathic membranous nephropathy;
LUSC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.67	-0.3	3.15e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	9.14	0.45	6.2e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-7.29	-0.37	2.23e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06212747	chr3:49208901	KLHDC8B	0.63	8.85	0.44	5.22e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	trans	rs459571	0.920	rs460154	chr9:136909309	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-12.47	-0.56	1.41e-29	Platelet distribution width;
LUSC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg21361702	chr7:150065534	REPIN1	0.43	6.11	0.32	2.74e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3740713	1.000	rs12289603	chr11:18471370	T/C	cg07915343	chr11:18477680	LDHAL6A	-0.56	-7.14	-0.36	5.8e-12	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg04117972	chr1:227635322	NA	-0.59	-6.77	-0.35	5.71e-11	Major depressive disorder;
LUSC	cis	rs929596	0.793	rs2741045	chr2:234580140	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-6.82	-0.35	4.22e-11	Total bilirubin levels in HIV-1 infection;
LUSC	trans	rs7939886	0.920	rs58405266	chr11:55863225	G/A	cg15704280	chr7:45808275	SEPT13	0.79	6.65	0.34	1.22e-10	Myopia (pathological);
LUSC	cis	rs9303280	0.617	rs8079416	chr17:38092713	T/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.35	-5.66	-0.3	3.22e-8	Self-reported allergy;
LUSC	cis	rs35883536	0.626	rs10493933	chr1:101111282	A/G	cg06223162	chr1:101003688	GPR88	-0.43	-7.51	-0.38	5.39e-13	Monocyte count;
LUSC	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg27068330	chr11:65405492	SIPA1	-0.76	-10.78	-0.51	1.92e-23	Acne (severe);
LUSC	cis	rs67696533	0.871	rs159058	chr20:31108108	A/C	cg13636640	chr20:31349939	DNMT3B	0.42	6.09	0.32	3.04e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg25319279	chr11:5960081	NA	-0.46	-6.47	-0.33	3.48e-10	DNA methylation (variation);
LUSC	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-6.05	-0.31	3.92e-9	Fear of minor pain;
LUSC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.71	-12.33	-0.56	4.93e-29	Aortic root size;
LUSC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.11	0.48	3.78e-21	Bipolar disorder;
LUSC	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg16524733	chr11:117070046	TAGLN	0.33	6.14	0.32	2.4e-9	Blood protein levels;
LUSC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.65	13.79	0.6	1.52e-34	Monocyte percentage of white cells;
LUSC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg11861562	chr11:117069780	TAGLN	0.44	7.91	0.4	3.75e-14	Blood protein levels;
LUSC	cis	rs28829049	0.536	rs12405382	chr1:19548981	C/T	cg13387374	chr1:19411106	UBR4	0.43	5.7	0.3	2.64e-8	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11158026	0.603	rs34988865	chr14:55474849	T/C	cg04306507	chr14:55594613	LGALS3	0.39	7.2	0.37	4.06e-12	Parkinson's disease;
LUSC	cis	rs2249625	0.545	rs2463743	chr6:72874741	C/T	cg18830697	chr6:72922368	RIMS1	-0.36	-7.2	-0.37	4.04e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg08270630	chr22:50330655	NA	-0.53	-6.74	-0.35	7.12e-11	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24715260	chr17:80056221	FASN	-0.44	-6.69	-0.34	9.21e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs754466	1.000	rs12220311	chr10:79681507	C/T	cg17075019	chr10:79541650	NA	-0.64	-8.4	-0.42	1.32e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26818010	chr10:134567672	INPP5A	-0.86	-11.07	-0.52	1.83e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg15556689	chr8:8085844	FLJ10661	0.56	8.47	0.42	7.67e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs925255	0.743	rs4426489	chr2:28639641	C/G	cg01273330	chr2:28605224	NA	-0.43	-6.89	-0.35	2.84e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11764359	chr7:65958608	NA	0.66	10.4	0.49	3.85e-22	Aortic root size;
LUSC	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg04455712	chr21:45112962	RRP1B	0.48	8.94	0.44	2.77e-17	Mean corpuscular volume;
LUSC	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg15654264	chr1:150340011	RPRD2	0.64	10.58	0.5	9.37e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg03146154	chr1:46216737	IPP	0.56	8.34	0.42	2.02e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21984481	chr17:79567631	NPLOC4	-0.56	-10.74	-0.51	2.6e-23	Eye color traits;
LUSC	cis	rs9653442	0.527	rs10185059	chr2:100790172	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-7.14	-0.36	5.74e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	0.56	9.04	0.44	1.3e-17	Breast cancer;
LUSC	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg12927641	chr6:109611667	NA	-0.34	-5.8	-0.3	1.53e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg10255544	chr17:80519551	FOXK2	-0.39	-6.35	-0.33	7.02e-10	Reticulocyte fraction of red cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07199032	chr16:23607617	NDUFAB1	-0.41	-6.04	-0.31	4.11e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg19920283	chr7:105172520	RINT1	0.62	6.94	0.36	2.04e-11	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6545883	0.929	rs2593627	chr2:61618574	T/C	cg15711740	chr2:61764176	XPO1	0.42	6.49	0.33	3.17e-10	Tuberculosis;
LUSC	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-1.11	-16.94	-0.68	6.59e-47	Exhaled nitric oxide output;
LUSC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg26855724	chr1:75198818	TYW3;CRYZ	0.46	7.16	0.36	5.2e-12	Resistin levels;
LUSC	cis	rs6460942	0.731	rs7799372	chr7:12233784	T/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.09	-0.32	3.08e-9	Coronary artery disease;
LUSC	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Smoking initiation;
LUSC	cis	rs6499755	0.932	rs714507	chr16:55339777	C/T	cg02859129	chr16:55357253	IRX6	0.33	5.68	0.3	2.97e-8	Hypospadias;
LUSC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg00631329	chr6:26305371	NA	0.33	5.76	0.3	1.88e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs1973993	0.507	rs2759670	chr1:97002864	A/G	cg10631902	chr5:14652156	NA	0.47	7.53	0.38	4.85e-13	Weight;
LUSC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg00080972	chr5:178986291	RUFY1	0.66	12.68	0.57	2.39e-30	Lung cancer;
LUSC	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.37	-6.45	-0.33	3.85e-10	Breast cancer;
LUSC	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg07701084	chr6:150067640	NUP43	0.46	6.93	0.35	2.23e-11	Testicular germ cell tumor;
LUSC	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg05855489	chr10:104503620	C10orf26	-0.52	-8.04	-0.4	1.52e-14	Arsenic metabolism;
LUSC	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg00677455	chr12:58241039	CTDSP2	0.62	8.93	0.44	2.89e-17	Multiple sclerosis;
LUSC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg22496339	chr2:162101262	NA	0.74	11.98	0.55	9.48e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg17366294	chr4:99064904	C4orf37	0.55	9.67	0.47	1.18e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.74	0.35	7.17e-11	Lung cancer;
LUSC	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg13246856	chr1:44399776	ARTN	0.35	7.39	0.37	1.18e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs7712401	0.580	rs35902490	chr5:122323398	G/T	cg19077854	chr5:122220652	SNX24	-0.43	-9.48	-0.46	4.83e-19	Mean platelet volume;
LUSC	cis	rs3850699	0.683	rs67481356	chr10:104317811	C/A	cg05855489	chr10:104503620	C10orf26	0.64	8.99	0.44	1.87e-17	Prostate cancer;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg00431813	chr7:1051703	C7orf50	-0.47	-7.82	-0.39	7.03e-14	Longevity;Endometriosis;
LUSC	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg13319975	chr6:146136371	FBXO30	0.5	7.52	0.38	5.2e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.88	15.01	0.63	2.73e-39	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg05738196	chr6:26577821	NA	0.52	8.3	0.41	2.53e-15	Schizophrenia;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01171360	chr6:293285	DUSP22	0.72	12.04	0.55	5.76e-28	Menopause (age at onset);
LUSC	cis	rs354225	0.544	rs10205410	chr2:54799599	G/T	cg01766943	chr2:54829624	SPTBN1	0.45	6.99	0.36	1.51e-11	Schizophrenia;
LUSC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg14019146	chr3:50243930	SLC38A3	0.36	8.26	0.41	3.53e-15	Body mass index;
LUSC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg01802117	chr1:53393560	SCP2	0.38	6.2	0.32	1.67e-9	Monocyte count;
LUSC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg22437258	chr11:111473054	SIK2	0.52	7.08	0.36	8.73e-12	Primary sclerosing cholangitis;
LUSC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg05425664	chr17:57184151	TRIM37	0.56	8.34	0.42	1.94e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07573057	chr8:82754234	SNX16	-0.45	-6.02	-0.31	4.66e-9	Hepatitis;
LUSC	cis	rs9905704	0.681	rs4277402	chr17:56581651	C/G	cg19466818	chr17:56409534	MIR142	0.37	6.97	0.36	1.74e-11	Testicular germ cell tumor;
LUSC	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.0	-0.44	1.72e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg06008330	chr7:65541103	ASL	0.39	6.13	0.32	2.42e-9	Aortic root size;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg25660386	chr3:13009126	IQSEC1	0.42	5.98	0.31	5.75e-9	Mosquito bite size;
LUSC	cis	rs977987	0.836	rs4888376	chr16:75322573	T/C	cg04384234	chr16:75411784	CFDP1	-0.38	-5.97	-0.31	5.94e-9	Dupuytren's disease;
LUSC	cis	rs10740039	1.000	rs10761543	chr10:62415391	C/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.92	-0.35	2.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9469578	0.579	rs73743309	chr6:33683548	A/G	cg18708504	chr6:33715942	IP6K3	0.67	6.33	0.33	8e-10	Phosphorus levels;
LUSC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg22655196	chr4:3374909	RGS12	0.31	5.85	0.31	1.14e-8	Serum sulfate level;
LUSC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg06238570	chr21:40685208	BRWD1	-0.59	-9.21	-0.45	3.78e-18	Menarche (age at onset);
LUSC	cis	rs1784581	0.588	rs9295178	chr6:162419226	T/A	cg17173639	chr6:162384350	PARK2	0.57	9.98	0.48	1.09e-20	Itch intensity from mosquito bite;
LUSC	cis	rs11997175	0.646	rs4593495	chr8:33692649	C/T	ch.8.33884649F	chr8:33765107	NA	0.45	6.62	0.34	1.41e-10	Body mass index;
LUSC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg05861140	chr6:150128134	PCMT1	-0.4	-6.31	-0.33	8.8e-10	Lung cancer;
LUSC	cis	rs4363385	0.747	rs1415960	chr1:152973571	G/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.67	-0.3	3.09e-8	Inflammatory skin disease;
LUSC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg24829409	chr8:58192753	C8orf71	-0.52	-6.15	-0.32	2.24e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg12310025	chr6:25882481	NA	0.42	7.02	0.36	1.27e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6700896	0.966	rs4655557	chr1:66080787	T/C	cg04111102	chr1:66153794	NA	0.3	6.61	0.34	1.5e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg18721089	chr20:30220636	NA	-0.35	-6.05	-0.31	3.82e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs12701220	0.597	rs10253153	chr7:1001974	G/A	cg04102894	chr7:1000210	NA	-0.28	-6.44	-0.33	4.07e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg05340658	chr4:99064831	C4orf37	0.64	10.42	0.5	3.48e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg00933542	chr6:150070202	PCMT1	-0.32	-6.54	-0.34	2.25e-10	Lung cancer;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14047339	chr6:45345544	RUNX2;SUPT3H	-0.38	-6.41	-0.33	4.86e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.1	-0.36	7.36e-12	Bipolar disorder;
LUSC	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.74	0.35	6.9e-11	Schizophrenia;
LUSC	cis	rs6693567	0.565	rs1260407	chr1:150306125	T/C	cg15654264	chr1:150340011	RPRD2	0.44	7.02	0.36	1.22e-11	Migraine;
LUSC	trans	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg20587970	chr11:113659929	NA	0.82	9.9	0.48	2.02e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.69	-0.47	1e-19	Bipolar disorder;
LUSC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg13685155	chr2:88473871	THNSL2	0.36	5.7	0.3	2.6e-8	Response to metformin (IC50);
LUSC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg15649852	chr7:65879115	NA	-0.41	-5.76	-0.3	1.96e-8	Aortic root size;
LUSC	cis	rs1005224	0.963	rs11626062	chr14:76136329	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-5.88	-0.31	1.01e-8	Large artery stroke;
LUSC	trans	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.44	-6.5	-0.34	2.9e-10	Endometrial cancer;
LUSC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg11062466	chr8:58055876	NA	0.72	8.93	0.44	2.94e-17	Developmental language disorder (linguistic errors);
LUSC	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg03929089	chr4:120376271	NA	-0.44	-6.11	-0.32	2.71e-9	Height;
LUSC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg13390004	chr1:15929781	NA	0.42	7.04	0.36	1.07e-11	Systolic blood pressure;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg22476893	chr17:7210162	EIF5A	0.39	5.98	0.31	5.82e-9	Triglycerides;
LUSC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.47	7.33	0.37	1.77e-12	Alzheimer's disease (late onset);
LUSC	cis	rs4842666	0.915	rs11105368	chr12:90074441	G/C	cg00757033	chr12:89920650	WDR51B	0.49	7.05	0.36	1.02e-11	Blood pressure;
LUSC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	8.73	0.43	1.22e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6674970	0.966	rs4512652	chr1:151115690	G/C	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.46	-6.18	-0.32	1.89e-9	Childhood ear infection;
LUSC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg16423285	chr20:60520624	NA	-0.44	-5.67	-0.3	3.14e-8	Body mass index;
LUSC	cis	rs7216064	1.000	rs62084238	chr17:65856573	T/A	cg12091567	chr17:66097778	LOC651250	-0.74	-9.27	-0.45	2.4e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.84	-0.3	1.21e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg03585969	chr10:35415529	CREM	0.59	8.79	0.43	8.14e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6977660	1.000	rs714239	chr7:19803944	C/T	cg05791153	chr7:19748676	TWISTNB	0.55	6.16	0.32	2.05e-9	Thyroid stimulating hormone;
LUSC	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg10547527	chr2:198650123	BOLL	-0.49	-5.71	-0.3	2.49e-8	Ulcerative colitis;
LUSC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg20607798	chr8:58055168	NA	0.52	5.66	0.3	3.33e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs3862435	0.764	rs7181764	chr15:91050771	G/A	cg22089800	chr15:90895588	ZNF774	-0.56	-6.02	-0.31	4.67e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg17515076	chr17:73810948	UNK	-0.39	-6.55	-0.34	2.14e-10	White matter hyperintensity burden;
LUSC	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.88	14.98	0.63	3.51e-39	Body mass index (adult);
LUSC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg05802129	chr4:122689817	NA	-0.52	-8.75	-0.43	1.04e-16	Type 2 diabetes;
LUSC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-10.3	-0.49	8.65e-22	Gut microbiome composition (summer);
LUSC	cis	rs728616	0.558	rs12767261	chr10:82162323	G/A	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.8	-0.3	1.57e-8	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-10.3	-0.49	8.75e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06634786	chr22:41940651	POLR3H	0.52	6.16	0.32	2.11e-9	Vitiligo;
LUSC	cis	rs7575217	0.622	rs12466496	chr2:101768115	T/C	cg23907051	chr2:101730305	TBC1D8	-0.3	-7.85	-0.39	5.65e-14	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	8.08	0.4	1.17e-14	Coffee consumption (cups per day);
LUSC	cis	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg26958806	chr6:27640298	NA	0.74	5.93	0.31	7.37e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs3857536	0.813	rs6455091	chr6:66949127	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg26513180	chr16:89883248	FANCA	0.91	17.79	0.7	2.82e-50	Vitiligo;
LUSC	trans	rs61931739	0.635	rs1352208	chr12:33932543	T/C	cg26384229	chr12:38710491	ALG10B	0.51	7.63	0.39	2.51e-13	Morning vs. evening chronotype;
LUSC	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.69	13.07	0.58	7.94e-32	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg05855489	chr10:104503620	C10orf26	0.59	9.42	0.46	7.63e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs16976116	0.901	rs1061824	chr15:55495963	T/C	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg09359103	chr1:154839909	KCNN3	-0.69	-15.84	-0.65	1.53e-42	Prostate cancer;
LUSC	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.84	14.45	0.62	4.06e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7121446	0.520	rs7943463	chr11:121850960	T/C	cg13820391	chr11:121835505	NA	0.37	6.15	0.32	2.21e-9	Cardiovascular risk factors (age interaction);
LUSC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg22166914	chr1:53195759	ZYG11B	0.6	9.82	0.47	3.58e-20	Monocyte count;
LUSC	cis	rs4664308	0.967	rs56293836	chr2:160910958	T/C	cg03641300	chr2:160917029	PLA2R1	-0.67	-11.33	-0.53	2.16e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.4	-6.41	-0.33	4.92e-10	Systemic lupus erythematosus;
LUSC	cis	rs870825	0.655	rs28451943	chr4:185645572	C/T	cg04058563	chr4:185651563	MLF1IP	0.82	12.63	0.57	3.7e-30	Blood protein levels;
LUSC	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.52	0.42	5.66e-16	Lung cancer in ever smokers;
LUSC	cis	rs9420	0.961	rs12146541	chr11:57508678	G/C	cg23127183	chr11:57508653	C11orf31	-0.58	-8.94	-0.44	2.65e-17	Schizophrenia;
LUSC	cis	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg07460842	chr6:66804631	NA	0.47	5.78	0.3	1.71e-8	Metabolite levels;
LUSC	cis	rs6163	0.540	rs11191385	chr10:104513049	G/T	cg04362960	chr10:104952993	NT5C2	0.51	7.17	0.37	4.83e-12	Waist circumference;Hip circumference;
LUSC	cis	rs2637266	1.000	rs12413656	chr10:78379666	A/C	cg18941641	chr10:78392320	NA	0.41	7.43	0.38	9.3e-13	Pulmonary function;
LUSC	cis	rs6669072	0.703	rs3843306	chr1:91288130	A/T	cg08895590	chr1:91227319	NA	0.34	7.56	0.38	4.05e-13	Cognitive function;
LUSC	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg06219351	chr7:158114137	PTPRN2	-0.51	-9.28	-0.45	2.14e-18	Calcium levels;
LUSC	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg27411982	chr8:10470053	RP1L1	0.42	6.05	0.31	3.89e-9	Neuroticism;
LUSC	cis	rs2898681	0.567	rs77657787	chr4:53729981	G/A	cg00791764	chr4:53727839	RASL11B	0.57	7.24	0.37	3.1e-12	Optic nerve measurement (cup area);
LUSC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.42	-7.63	-0.39	2.54e-13	Longevity;Endometriosis;
LUSC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs981844	0.775	rs1037656	chr4:154750786	A/G	cg14289246	chr4:154710475	SFRP2	-0.49	-6.73	-0.35	7.37e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs6546550	0.901	rs7573442	chr2:70154037	G/A	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.31	-0.37	2.02e-12	Prevalent atrial fibrillation;
LUSC	cis	rs2067615	0.579	rs9651957	chr12:107170128	A/G	cg15890332	chr12:107067104	RFX4	0.33	6.06	0.31	3.76e-9	Heart rate;
LUSC	cis	rs4862307	0.623	rs11730046	chr4:184988245	C/G	cg06737308	chr4:185021514	ENPP6	0.48	7.06	0.36	9.93e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
LUSC	cis	rs977987	0.778	rs2865528	chr16:75455942	T/C	cg03315344	chr16:75512273	CHST6	0.54	10.31	0.49	7.88e-22	Dupuytren's disease;
LUSC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.34	0.33	7.36e-10	Menopause (age at onset);
LUSC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00149659	chr3:10157352	C3orf10	0.91	11.8	0.54	4.3e-27	Alzheimer's disease;
LUSC	cis	rs3916	0.910	rs7306541	chr12:121130046	A/G	cg27246729	chr12:121163418	ACADS	0.48	6.98	0.36	1.58e-11	Urinary metabolites (H-NMR features);
LUSC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg19774624	chr17:42201019	HDAC5	0.7	10.35	0.49	5.79e-22	Total body bone mineral density;
LUSC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg24733560	chr20:60626293	TAF4	-0.39	-6.15	-0.32	2.16e-9	Body mass index;
LUSC	cis	rs35995292	0.517	rs6948026	chr7:38920854	A/G	cg19327137	chr7:38886074	VPS41	0.55	10.26	0.49	1.21e-21	Subjective well-being (multi-trait analysis);
LUSC	trans	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg05926928	chr17:57297772	GDPD1	-0.48	-6.66	-0.34	1.11e-10	Schizophrenia;
LUSC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg03929089	chr4:120376271	NA	-0.93	-16.14	-0.66	9.76e-44	Height;
LUSC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg17971929	chr21:40555470	PSMG1	-0.49	-7.12	-0.36	6.67e-12	Menarche (age at onset);
LUSC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg15445000	chr17:37608096	MED1	0.41	6.84	0.35	3.85e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs12137294	0.866	rs1172140	chr1:205213024	G/A	cg21643547	chr1:205240462	TMCC2	-0.35	-6.33	-0.33	7.82e-10	Red cell distribution width;
LUSC	trans	rs62103177	0.564	rs3930042	chr18:77723843	G/A	cg05926928	chr17:57297772	GDPD1	1.0	11.17	0.52	7.71e-25	Opioid sensitivity;
LUSC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.93	0.31	7.63e-9	Menopause (age at onset);
LUSC	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg11244672	chr19:19639970	YJEFN3	-0.57	-6.94	-0.36	2.02e-11	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15558129	chr1:219347279	LYPLAL1	0.42	6.0	0.31	5.18e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg23933602	chr10:16859644	RSU1	0.63	8.32	0.41	2.33e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs611744	0.810	rs672161	chr8:109164182	G/A	cg18478394	chr8:109455254	TTC35	0.42	6.32	0.33	8.15e-10	Dupuytren's disease;
LUSC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg01973587	chr1:228161476	NA	0.47	8.51	0.42	6.05e-16	Diastolic blood pressure;
LUSC	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.34	-7.38	-0.37	1.26e-12	Dupuytren's disease;
LUSC	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.77	12.76	0.57	1.2e-30	Metabolic syndrome;
LUSC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg19230755	chr7:65878503	NA	0.44	6.19	0.32	1.74e-9	Aortic root size;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26143820	chr14:100071437	CCDC85C	-0.4	-6.35	-0.33	7.12e-10	Electrocardiographic conduction measures;
LUSC	cis	rs35123781	1.000	rs599946	chr5:139057461	A/G	cg10513866	chr5:139070639	NA	0.46	8.9	0.44	3.62e-17	Schizophrenia;
LUSC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg24642844	chr7:1081250	C7orf50	-0.7	-9.66	-0.47	1.25e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.38	5.73	0.3	2.24e-8	Schizophrenia;
LUSC	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg01629716	chr15:45996671	NA	0.4	6.06	0.31	3.68e-9	Waist circumference;Weight;
LUSC	cis	rs11690935	0.527	rs7586556	chr2:172901887	G/C	cg13550731	chr2:172543902	DYNC1I2	0.52	8.08	0.4	1.22e-14	Schizophrenia;
LUSC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg20203395	chr5:56204925	C5orf35	-0.6	-8.44	-0.42	1.01e-15	Coronary artery disease;
LUSC	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.1	15.13	0.64	9.03e-40	Uric acid levels;
LUSC	cis	rs6714710	0.603	rs11691494	chr2:98419726	T/A	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.44	0.53	8.49e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg03647239	chr10:116582469	FAM160B1	0.43	6.97	0.36	1.66e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs2307022	0.530	rs3826166	chr16:68388781	C/G	cg02226672	chr16:68398533	SMPD3	0.3	5.68	0.3	2.93e-8	Body mass index;
LUSC	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg06718696	chr17:78121285	EIF4A3	0.45	6.4	0.33	5.31e-10	Yeast infection;
LUSC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08219700	chr8:58056026	NA	0.64	7.88	0.4	4.52e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs62432291	0.681	rs431205	chr6:159662499	A/G	cg14500486	chr6:159655392	FNDC1	-0.54	-6.07	-0.32	3.39e-9	Joint mobility (Beighton score);
LUSC	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-8.0	-0.4	2.03e-14	Glomerular filtration rate;
LUSC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg13206674	chr6:150067644	NUP43	0.6	9.7	0.47	9.47e-20	Lung cancer;
LUSC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.87	0.54	2.36e-27	Prudent dietary pattern;
LUSC	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.48	-0.33	3.28e-10	Blood metabolite levels;
LUSC	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.42	-8.24	-0.41	3.85e-15	Late-onset Alzheimer's disease;
LUSC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	10.35	0.49	5.83e-22	Electrocardiographic conduction measures;
LUSC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg03146154	chr1:46216737	IPP	-0.5	-7.26	-0.37	2.69e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs475616	1.000	rs503598	chr10:30496125	A/G	cg02841571	chr6:169977833	WDR27	-0.43	-6.22	-0.32	1.52e-9	Monocyte count;
LUSC	cis	rs10789491	0.565	rs2897107	chr1:47206178	A/T	cg15501359	chr1:47185051	KIAA0494	0.78	10.13	0.48	3.24e-21	Response to hepatitis C treatment;
LUSC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00149659	chr3:10157352	C3orf10	1.0	14.77	0.63	2.33e-38	Alzheimer's disease;
LUSC	cis	rs7615316	0.836	rs6768093	chr3:142298200	A/T	cg16271453	chr3:142027066	XRN1	-0.36	-6.03	-0.31	4.46e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg23093090	chr10:104574429	C10orf26	-0.38	-7.03	-0.36	1.14e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg07507251	chr3:52567010	NT5DC2	0.33	6.51	0.34	2.78e-10	Bipolar disorder;
LUSC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg06238570	chr21:40685208	BRWD1	0.46	7.05	0.36	1.02e-11	Cognitive function;
LUSC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg06212747	chr3:49208901	KLHDC8B	0.44	5.98	0.31	5.79e-9	Parkinson's disease;
LUSC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.5	-8.56	-0.42	4.13e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-9.16	-0.45	5.33e-18	Gut microbiome composition (summer);
LUSC	cis	rs10911251	0.546	rs10911267	chr1:183115323	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.59	0.5	8.72e-23	Colorectal cancer;
LUSC	cis	rs1113500	1.000	rs1777483	chr1:108609408	A/C	cg06207961	chr1:108661230	NA	-0.39	-7.01	-0.36	1.29e-11	Growth-regulated protein alpha levels;
LUSC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.08	-0.36	8.53e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg11244672	chr19:19639970	YJEFN3	-0.53	-6.54	-0.34	2.26e-10	Bipolar disorder;
LUSC	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.55e-13	Putamen volume;
LUSC	cis	rs136211	0.577	rs9607339	chr22:36768932	G/T	cg21778268	chr22:36877729	TXN2	-0.42	-6.01	-0.31	4.98e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.44	7.77	0.39	9.69e-14	Obesity-related traits;
LUSC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg22437258	chr11:111473054	SIK2	0.46	6.15	0.32	2.21e-9	Primary sclerosing cholangitis;
LUSC	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg05738196	chr6:26577821	NA	0.83	16.11	0.66	1.29e-43	Intelligence (multi-trait analysis);
LUSC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.47	7.3	0.37	2.13e-12	Colorectal cancer;
LUSC	cis	rs7605827	0.930	rs6749063	chr2:15565278	T/G	cg19274914	chr2:15703543	NA	0.47	8.97	0.44	2.17e-17	Educational attainment (years of education);
LUSC	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg23625390	chr15:77176239	SCAPER	0.45	6.9	0.35	2.55e-11	Blood metabolite levels;
LUSC	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg22777020	chr22:31556080	RNF185	-0.47	-5.94	-0.31	7.04e-9	Colorectal cancer;
LUSC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg08079166	chr15:68083412	MAP2K5	0.42	7.47	0.38	6.94e-13	Restless legs syndrome;
LUSC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19346786	chr7:2764209	NA	0.5	8.73	0.43	1.22e-16	Height;
LUSC	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg05855489	chr10:104503620	C10orf26	-0.53	-8.09	-0.4	1.13e-14	Arsenic metabolism;
LUSC	cis	rs28647808	0.786	rs28649804	chr9:136257709	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg03806693	chr22:41940476	POLR3H	-0.56	-7.76	-0.39	1.03e-13	Neuroticism;
LUSC	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.08	0.52	1.71e-24	Hypertriglyceridemia;
LUSC	cis	rs834603	0.575	rs2665775	chr7:47465387	C/T	cg09696706	chr7:47479511	TNS3	0.32	5.7	0.3	2.6e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs2227564	0.729	rs2633303	chr10:75645882	G/T	cg23231163	chr10:75533350	FUT11	-0.44	-6.11	-0.32	2.85e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	20.81	0.75	2.85e-62	Height;
LUSC	trans	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg22153745	chr1:153894579	GATAD2B	-0.57	-8.89	-0.44	3.8e-17	Total cholesterol levels;
LUSC	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg27490568	chr2:178487706	NA	0.4	5.8	0.3	1.55e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6574644	1.000	rs8010545	chr14:81778787	G/C	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs7580658	0.963	rs4233584	chr2:128060163	C/T	cg09760422	chr2:128146352	NA	-0.33	-7.27	-0.37	2.51e-12	Protein C levels;
LUSC	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg04369109	chr6:150039330	LATS1	-0.56	-8.28	-0.41	2.98e-15	Lung cancer;
LUSC	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg02023728	chr11:77925099	USP35	0.45	6.85	0.35	3.49e-11	Testicular germ cell tumor;
LUSC	cis	rs3931020	0.688	rs277374	chr1:75200486	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	-0.47	-6.02	-0.31	4.66e-9	Resistin levels;
LUSC	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.5	-0.46	4.07e-19	Schizophrenia;
LUSC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06481639	chr22:41940642	POLR3H	0.52	5.86	0.31	1.1e-8	Vitiligo;
LUSC	cis	rs73200209	0.704	rs56258518	chr12:116596371	G/A	cg01776926	chr12:116560359	MED13L	-0.51	-6.13	-0.32	2.45e-9	Total body bone mineral density;
LUSC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg05347473	chr6:146136440	FBXO30	-0.67	-11.71	-0.54	9.19e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs727505	0.954	rs58618031	chr7:124583896	T/C	cg23710748	chr7:124431027	NA	-0.38	-6.73	-0.35	7.42e-11	Lewy body disease;
LUSC	cis	rs11608355	0.545	rs11066737	chr12:109904792	A/G	cg05360138	chr12:110035743	NA	-0.9	-11.66	-0.54	1.37e-26	Neuroticism;
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.68	-14.45	-0.62	4.37e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg13628971	chr7:2884303	GNA12	0.37	5.71	0.3	2.49e-8	Height;
LUSC	cis	rs7180079	0.925	rs62024254	chr15:64461098	T/C	cg08069370	chr15:64387884	SNX1	-0.54	-5.65	-0.3	3.37e-8	Monocyte count;
LUSC	cis	rs9815354	0.812	rs73071358	chr3:41830487	G/A	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg01879757	chr17:41196368	BRCA1	-0.39	-5.96	-0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg21775007	chr8:11205619	TDH	0.82	13.51	0.59	1.71e-33	Retinal vascular caliber;
LUSC	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.6	13.58	0.6	9.62e-34	Height;
LUSC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-6.72	-0.35	7.77e-11	Eosinophil percentage of white cells;
LUSC	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg22878388	chr2:105853796	NA	-0.33	-6.02	-0.31	4.68e-9	Type 2 diabetes;
LUSC	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg14809332	chr8:144654887	C8orf73	0.54	6.51	0.34	2.78e-10	Attention deficit hyperactivity disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13028789	chr6:34856920	ANKS1A;TAF11	-0.39	-6.1	-0.32	2.88e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg04727924	chr7:799746	HEATR2	0.57	6.04	0.31	4.18e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs6494488	0.500	rs72744763	chr15:65076652	C/T	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	cis	rs9309473	1.000	rs1114380	chr2:73804708	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-6.46	-0.33	3.6e-10	Metabolite levels;
LUSC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.22	0.32	1.45e-9	Menopause (age at onset);
LUSC	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg10547527	chr2:198650123	BOLL	-0.51	-5.94	-0.31	7.2e-9	Ulcerative colitis;
LUSC	trans	rs61931739	0.649	rs708139	chr12:33733265	C/A	cg26384229	chr12:38710491	ALG10B	0.43	6.18	0.32	1.9e-9	Morning vs. evening chronotype;
LUSC	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg11062466	chr8:58055876	NA	0.5	5.86	0.31	1.11e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg15423357	chr2:25149977	NA	0.44	8.98	0.44	1.96e-17	Body mass index;
LUSC	cis	rs9463078	0.585	rs7754378	chr6:44863106	A/G	cg25276700	chr6:44698697	NA	0.28	5.83	0.3	1.28e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg22753607	chr9:37120306	ZCCHC7	0.43	6.08	0.32	3.36e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	6.46	0.33	3.62e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg05941027	chr17:61774174	LIMD2	0.22	5.83	0.3	1.29e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-5.99	-0.31	5.52e-9	Neuroticism;
LUSC	trans	rs76540505	1.000	rs3758722	chr11:45243543	A/T	cg03253268	chr21:44592883	CRYAA	0.6	6.01	0.31	4.92e-9	Mononucleosis;
LUSC	trans	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg13010199	chr12:38710504	ALG10B	-0.46	-7.29	-0.37	2.23e-12	Morning vs. evening chronotype;
LUSC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg06064525	chr11:970664	AP2A2	-0.35	-6.87	-0.35	3.12e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg23752985	chr2:85803571	VAMP8	0.33	7.06	0.36	9.48e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.98	-0.31	5.74e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg11764359	chr7:65958608	NA	-0.54	-7.02	-0.36	1.23e-11	Aortic root size;
LUSC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.94	-15.4	-0.64	8.59e-41	Body mass index;
LUSC	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21659725	chr3:3221576	CRBN	0.63	10.53	0.5	1.38e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs10208940	0.764	rs6546420	chr2:68799454	G/A	cg12452813	chr2:68675892	NA	0.57	5.92	0.31	7.99e-9	Urate levels in lean individuals;
LUSC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.4	-0.33	5.22e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg12002119	chr2:101014098	CHST10	-0.37	-6.17	-0.32	1.95e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg17971929	chr21:40555470	PSMG1	-0.53	-7.93	-0.4	3.22e-14	Menarche (age at onset);
LUSC	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg01579765	chr21:45077557	HSF2BP	0.49	10.11	0.48	3.8e-21	Mean corpuscular volume;
LUSC	cis	rs2629540	0.889	rs7476729	chr10:126428174	C/G	cg08799069	chr10:126477246	METTL10	-0.68	-9.81	-0.47	4.03e-20	Cocaine dependence;
LUSC	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.69	-10.35	-0.49	6.07e-22	Schizophrenia;
LUSC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03352830	chr11:487213	PTDSS2	0.72	8.65	0.43	2.24e-16	Body mass index;
LUSC	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg00012203	chr2:219082015	ARPC2	0.81	14.27	0.62	2.11e-36	Colorectal cancer;
LUSC	cis	rs2658782	0.666	rs2925361	chr11:93098823	G/A	cg15737290	chr11:93063684	CCDC67	0.63	7.54	0.38	4.52e-13	Pulmonary function decline;
LUSC	cis	rs8027181	0.839	rs8024986	chr15:73024868	A/G	cg25632853	chr15:73088954	NA	-0.31	-6.35	-0.33	6.89e-10	Triglyceride levels;
LUSC	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg03676636	chr4:99064102	C4orf37	0.35	7.41	0.38	1.03e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs883565	0.502	rs11129810	chr3:38946064	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.38	5.75	0.3	2.02e-8	Handedness;
LUSC	trans	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	7.6	0.38	3.08e-13	Ulcerative colitis;
LUSC	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.55	0.34	2.17e-10	Corneal astigmatism;
LUSC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-10.27	-0.49	1.06e-21	Gut microbiome composition (summer);
LUSC	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg01448562	chr3:133502909	NA	0.44	6.77	0.35	5.67e-11	Iron status biomarkers (transferrin levels);
LUSC	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg14664628	chr15:75095509	CSK	0.42	6.07	0.32	3.49e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	trans	rs11650494	0.516	rs13341862	chr17:47494203	A/G	cg00927294	chr7:122526408	CADPS2	-0.67	-5.95	-0.31	6.88e-9	Prostate cancer;
LUSC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03576123	chr11:487126	PTDSS2	-0.95	-10.54	-0.5	1.29e-22	Body mass index;
LUSC	trans	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg26384229	chr12:38710491	ALG10B	0.55	8.74	0.43	1.16e-16	Morning vs. evening chronotype;
LUSC	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg19875535	chr5:140030758	IK	-0.47	-7.59	-0.38	3.12e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg04865166	chr7:105162814	PUS7	0.51	5.67	0.3	3.06e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg08684580	chr7:98029266	BAIAP2L1	-0.41	-7.43	-0.38	9.13e-13	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg07393940	chr7:158741817	NA	0.36	6.42	0.33	4.57e-10	Life satisfaction;
LUSC	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg13256891	chr4:100009986	ADH5	0.51	6.94	0.35	2.07e-11	Smoking initiation;
LUSC	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg06671706	chr8:8559999	CLDN23	0.5	6.49	0.33	3.18e-10	Obesity-related traits;
LUSC	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg05731713	chr7:157510257	PTPRN2	0.43	7.78	0.39	9.28e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg24838063	chr12:130822603	PIWIL1	-0.63	-9.86	-0.47	2.66e-20	Menopause (age at onset);
LUSC	cis	rs7577851	0.625	rs12620315	chr2:69529531	C/T	cg10773587	chr2:69614142	GFPT1	0.55	6.29	0.33	9.69e-10	Parkinson's disease (age of onset);
LUSC	cis	rs11809207	1.000	rs34587428	chr1:26522392	C/T	cg00300879	chr1:26503847	CNKSR1	0.31	5.87	0.31	1.05e-8	Height;
LUSC	cis	rs9309473	1.000	rs56154726	chr2:73721767	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-6.38	-0.33	5.81e-10	Metabolite levels;
LUSC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-1.05	-15.91	-0.66	7.99e-43	Initial pursuit acceleration;
LUSC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg03146154	chr1:46216737	IPP	-0.49	-6.79	-0.35	5.01e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg25801113	chr15:45476975	SHF	0.33	6.78	0.35	5.39e-11	Uric acid levels;
LUSC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	7.41	0.38	1.02e-12	Personality dimensions;
LUSC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.53	10.17	0.49	2.45e-21	Coronary artery disease;
LUSC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg07507251	chr3:52567010	NT5DC2	0.32	6.25	0.32	1.28e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4654899	0.865	rs72973154	chr1:21459125	G/T	cg01072550	chr1:21505969	NA	-0.53	-7.93	-0.4	3.23e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg25456477	chr12:86230367	RASSF9	-0.34	-6.13	-0.32	2.42e-9	Major depressive disorder;
LUSC	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg24375607	chr4:120327624	NA	-0.69	-10.9	-0.51	6.88e-24	Corneal astigmatism;
LUSC	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg18827107	chr12:86230957	RASSF9	-0.5	-7.48	-0.38	6.66e-13	Major depressive disorder;
LUSC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	11.0	0.52	3.11e-24	Bone mineral density;
LUSC	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.56	-0.34	2.02e-10	Daytime sleep phenotypes;
LUSC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg13206674	chr6:150067644	NUP43	0.56	8.62	0.43	2.72e-16	Lung cancer;
LUSC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08219700	chr8:58056026	NA	0.64	8.51	0.42	5.97e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6543140	0.964	rs1523206	chr2:103070175	A/T	cg09003973	chr2:102972529	NA	0.54	6.87	0.35	3.08e-11	Blood protein levels;
LUSC	trans	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.53e-10	Corneal astigmatism;
LUSC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg07741184	chr6:167504864	NA	0.39	6.95	0.36	1.96e-11	Primary biliary cholangitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09911399	chr19:49999601	RPS11;SNORD35B	-0.45	-6.67	-0.34	1.09e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.9	-18.4	-0.71	1.05e-52	Intelligence (multi-trait analysis);
LUSC	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg22782873	chr19:19639568	YJEFN3	-0.48	-5.71	-0.3	2.43e-8	Bipolar disorder;
LUSC	cis	rs9341808	0.644	rs62408577	chr6:80942024	T/A	cg08355045	chr6:80787529	NA	-0.42	-7.13	-0.36	6.17e-12	Sitting height ratio;
LUSC	cis	rs9660992	1.000	rs9660992	chr1:205249450	A/G	cg21643547	chr1:205240462	TMCC2	-0.47	-9.08	-0.44	9.58e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6546550	0.901	rs6750488	chr2:70146125	C/T	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.26	-0.37	2.67e-12	Prevalent atrial fibrillation;
LUSC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg13206674	chr6:150067644	NUP43	0.6	9.66	0.47	1.21e-19	Lung cancer;
LUSC	cis	rs6542838	0.698	rs6732017	chr2:99434381	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-6.16	-0.32	2.08e-9	Fear of minor pain;
LUSC	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg25309564	chr22:51001381	C22orf41	0.44	6.21	0.32	1.54e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg20243544	chr17:37824526	PNMT	0.51	7.39	0.38	1.15e-12	Asthma;
LUSC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg07424592	chr7:64974309	NA	-0.64	-5.79	-0.3	1.61e-8	Diabetic kidney disease;
LUSC	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg03585969	chr10:35415529	CREM	0.61	9.01	0.44	1.64e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08677398	chr8:58056175	NA	0.52	6.32	0.33	8.27e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs76662990	0.570	rs10070279	chr5:73898568	A/G	cg01264639	chr5:73839484	NA	0.55	5.78	0.3	1.72e-8	Residual cognition;
LUSC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-1.07	-15.83	-0.65	1.64e-42	Initial pursuit acceleration;
LUSC	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg17173187	chr15:85201210	NMB	0.5	9.42	0.46	7.89e-19	Schizophrenia;
LUSC	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg05973401	chr12:123451056	ABCB9	0.63	9.19	0.45	4.44e-18	Platelet count;
LUSC	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.89	-0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	trans	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.56	-9.11	-0.45	7.53e-18	Mean corpuscular volume;
LUSC	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg08508325	chr11:3079039	CARS	0.47	11.16	0.52	8.37e-25	Longevity;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg25061763	chr12:62860430	MON2	0.4	6.07	0.32	3.56e-9	Mosquito bite size;
LUSC	cis	rs6546550	0.901	rs6729760	chr2:70161032	C/T	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.19e-12	Prevalent atrial fibrillation;
LUSC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg04234412	chr22:24373322	LOC391322	-0.92	-16.14	-0.66	9.72e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg06784218	chr1:46089804	CCDC17	0.47	9.11	0.45	7.84e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6499755	0.901	rs4784522	chr16:55348749	C/T	cg02859129	chr16:55357253	IRX6	0.37	6.27	0.32	1.08e-9	Hypospadias;
LUSC	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg13010199	chr12:38710504	ALG10B	0.47	7.3	0.37	2.17e-12	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.68	0.65	6.55e-42	Morning vs. evening chronotype;
LUSC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg00509249	chr6:109615579	CCDC162	-0.32	-5.75	-0.3	2e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs2742417	1.000	rs1609554	chr3:45735192	A/G	cg09608765	chr3:45636137	LIMD1	-0.38	-7.38	-0.37	1.24e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.88	-0.31	9.9e-9	Testicular germ cell tumor;
LUSC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.6	9.71	0.47	8.76e-20	Aortic root size;
LUSC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12311346	chr5:56204834	C5orf35	0.83	13.27	0.59	1.46e-32	Initial pursuit acceleration;
LUSC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg06134567	chr22:46658398	PKDREJ	-0.53	-6.0	-0.31	5.15e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg06484146	chr7:12443880	VWDE	-0.69	-7.28	-0.37	2.41e-12	Coronary artery disease;
LUSC	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.27	-0.41	3.23e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg15595755	chr5:1867978	NA	0.35	5.76	0.3	1.91e-8	Cardiovascular disease risk factors;
LUSC	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg05872129	chr22:39784769	NA	-0.63	-11.86	-0.54	2.61e-27	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg16482183	chr6:26056742	HIST1H1C	0.57	8.24	0.41	4.04e-15	Height;
LUSC	cis	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg06521331	chr12:34319734	NA	0.38	6.41	0.33	4.83e-10	Morning vs. evening chronotype;
LUSC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg24585782	chr17:78113791	EIF4A3	-0.54	-8.12	-0.41	9.39e-15	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.68	-0.57	2.41e-30	Chronic sinus infection;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg27368511	chr5:159826822	C5orf54	0.46	6.77	0.35	5.71e-11	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	11.09	0.52	1.53e-24	Mean corpuscular hemoglobin;
LUSC	cis	rs6982240	1.000	rs6982240	chr8:142257378	A/T	cg27411547	chr8:142287226	NA	-0.35	-6.14	-0.32	2.33e-9	Tonsillectomy;
LUSC	cis	rs9394159	0.583	rs4713650	chr6:33616828	C/T	cg14003231	chr6:33640908	ITPR3	-0.44	-8.83	-0.44	5.87e-17	Graves' disease;
LUSC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18876405	chr7:65276391	NA	0.55	8.79	0.43	8.1e-17	Aortic root size;
LUSC	cis	rs55882075	0.936	rs34646062	chr5:179186318	A/G	cg14593053	chr5:179126677	CANX	-0.4	-6.65	-0.34	1.17e-10	Monocyte percentage of white cells;
LUSC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg04166393	chr7:2884313	GNA12	0.48	6.18	0.32	1.9e-9	Height;
LUSC	cis	rs1982963	0.572	rs61971551	chr14:52479975	C/G	cg10843707	chr14:52510701	NID2	0.42	5.87	0.31	1.04e-8	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg07274523	chr3:49395745	GPX1	0.35	5.65	0.3	3.47e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.81	11.76	0.54	6.2e-27	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.66	-0.57	2.83e-30	Platelet count;
LUSC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24110177	chr3:50126178	RBM5	0.54	8.88	0.44	4.34e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs11229555	1.000	rs8373	chr11:58378424	A/G	cg15696309	chr11:58395628	NA	-0.7	-9.26	-0.45	2.49e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-1.12	-25.06	-0.81	9.82e-79	Height;
LUSC	cis	rs8067354	0.830	rs2453913	chr17:57860150	G/T	cg02344993	chr17:57696989	CLTC	0.37	5.69	0.3	2.78e-8	Hemoglobin concentration;
LUSC	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg18110333	chr6:292329	DUSP22	-0.52	-7.68	-0.39	1.76e-13	Menopause (age at onset);
LUSC	cis	rs7705502	1.000	rs72812852	chr5:173379347	G/T	cg18693985	chr5:173351052	CPEB4	-0.4	-6.17	-0.32	2.01e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg23260525	chr10:116636907	FAM160B1	0.47	9.82	0.47	3.75e-20	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	0.7	6.97	0.36	1.74e-11	Prostate cancer;
LUSC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	7.79	0.39	8.3e-14	Parkinson's disease;
LUSC	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg00990874	chr7:1149470	C7orf50	-0.57	-7.02	-0.36	1.21e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg13628971	chr7:2884303	GNA12	0.46	6.58	0.34	1.8e-10	Height;
LUSC	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.74	-14.22	-0.61	3.41e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.58	9.4	0.46	9.19e-19	Aortic root size;
LUSC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg12143784	chr7:64541923	NA	0.41	6.46	0.33	3.61e-10	Calcium levels;
LUSC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12379764	chr21:47803548	PCNT	-0.42	-5.96	-0.31	6.38e-9	Testicular germ cell tumor;
LUSC	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg14835575	chr10:16859367	RSU1	0.66	8.75	0.43	1.09e-16	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg08557956	chr11:4115526	RRM1	-0.42	-5.72	-0.3	2.34e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg04362960	chr10:104952993	NT5C2	0.63	9.99	0.48	9.53e-21	Arsenic metabolism;
LUSC	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg18240062	chr17:79603768	NPLOC4	0.63	11.22	0.52	5.37e-25	Eye color traits;
LUSC	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg13072238	chr3:49761600	GMPPB	-0.71	-9.47	-0.46	5.11e-19	Menarche (age at onset);
LUSC	cis	rs7172677	0.732	rs1867147	chr15:75363357	C/T	cg14664628	chr15:75095509	CSK	0.49	6.15	0.32	2.22e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs911119	0.908	rs6048949	chr20:23603199	C/T	cg16589663	chr20:23618590	CST3	0.57	6.82	0.35	4.18e-11	Chronic kidney disease;
LUSC	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg21548813	chr6:291882	DUSP22	-0.48	-6.95	-0.36	1.91e-11	Menopause (age at onset);
LUSC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg03146154	chr1:46216737	IPP	-0.57	-8.23	-0.41	4.16e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg01884057	chr2:25150051	NA	0.47	11.13	0.52	1.11e-24	Body mass index in non-asthmatics;
LUSC	cis	rs3126085	0.867	rs11204948	chr1:152218473	A/G	cg03465714	chr1:152285911	FLG	-0.42	-5.71	-0.3	2.47e-8	Atopic dermatitis;
LUSC	cis	rs9549260	0.534	rs4943809	chr13:41297404	T/A	cg21288729	chr13:41239152	FOXO1	0.58	6.65	0.34	1.18e-10	Red blood cell count;
LUSC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08859206	chr1:53392774	SCP2	0.56	9.82	0.47	3.69e-20	Monocyte count;
LUSC	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.77	-0.43	9.44e-17	Axial length;
LUSC	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg25019033	chr10:957182	NA	-0.52	-7.06	-0.36	9.93e-12	Eosinophil percentage of granulocytes;
LUSC	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg26384229	chr12:38710491	ALG10B	0.74	11.71	0.54	8.93e-27	Morning vs. evening chronotype;
LUSC	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg17652424	chr22:38574118	PLA2G6	0.3	6.56	0.34	2.06e-10	Cutaneous nevi;
LUSC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00149659	chr3:10157352	C3orf10	0.92	12.88	0.58	4.25e-31	Alzheimer's disease;
LUSC	trans	rs59551326	0.688	rs2829660	chr21:26622137	A/G	cg19883748	chr14:71905595	NA	-0.43	-6.18	-0.32	1.83e-9	Alcohol dependence;
LUSC	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg23093090	chr10:104574429	C10orf26	-0.36	-6.66	-0.34	1.11e-10	Arsenic metabolism;
LUSC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg23711669	chr6:146136114	FBXO30	-0.91	-17.88	-0.7	1.27e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs912330	0.825	rs7317938	chr13:99234361	C/T	cg07423050	chr13:99094983	FARP1	-0.39	-7.36	-0.37	1.46e-12	Alzheimer's disease;
LUSC	cis	rs1788820	0.917	rs1788760	chr18:21137442	A/G	cg14672496	chr18:21087552	C18orf8	0.43	6.94	0.35	2.06e-11	Body mass index;
LUSC	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-7.48	-0.38	6.82e-13	Fear of minor pain;
LUSC	cis	rs17490626	0.568	rs12413529	chr10:71211644	G/T	cg12610070	chr10:71211762	TSPAN15	-0.49	-9.43	-0.46	7e-19	Thrombosis;
LUSC	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg06092702	chr1:163392909	NA	-0.43	-7.22	-0.37	3.47e-12	Motion sickness;
LUSC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg02580895	chr19:2754563	NA	0.47	7.09	0.36	8.05e-12	Total cholesterol levels;
LUSC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.39	0.53	1.32e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.4	6.04	0.31	4.15e-9	Height;
LUSC	cis	rs2346177	0.777	rs7587138	chr2:46657089	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.54	8.38	0.42	1.46e-15	HDL cholesterol;
LUSC	cis	rs12410462	0.581	rs112572966	chr1:227553905	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.58	-5.65	-0.3	3.51e-8	Major depressive disorder;
LUSC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.85	-13.95	-0.61	3.48e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg22437258	chr11:111473054	SIK2	0.51	7.08	0.36	8.78e-12	Primary sclerosing cholangitis;
LUSC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg13114125	chr14:105738426	BRF1	-0.93	-16.06	-0.66	2.05e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7178572	0.568	rs12905951	chr15:77649431	G/A	cg22256960	chr15:77711686	NA	-0.51	-8.12	-0.41	9.12e-15	Type 2 diabetes;
LUSC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.01	-0.31	4.79e-9	Total body bone mineral density;
LUSC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.75	13.25	0.59	1.76e-32	Aortic root size;
LUSC	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg13902645	chr11:5959945	NA	0.61	8.65	0.43	2.25e-16	DNA methylation (variation);
LUSC	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.76	-12.7	-0.57	2.04e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.51	-6.54	-0.34	2.27e-10	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Height;Educational attainment;Head circumference (infant);
LUSC	trans	rs12517041	1.000	rs10520890	chr5:23290143	C/T	cg09395612	chr16:86018936	NA	0.4	6.13	0.32	2.49e-9	Calcium levels;
LUSC	cis	rs7598759	0.679	rs6740843	chr2:232332139	A/C	cg19187155	chr2:232395269	NMUR1	0.49	7.28	0.37	2.37e-12	Noise-induced hearing loss;
LUSC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.86	-14.05	-0.61	1.45e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg20307385	chr11:47447363	PSMC3	-0.45	-6.69	-0.34	9.64e-11	Subjective well-being;
LUSC	cis	rs4363385	0.818	rs3820141	chr1:153004778	C/T	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.46e-8	Inflammatory skin disease;
LUSC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.92	0.31	7.86e-9	Menopause (age at onset);
LUSC	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.48	-0.33	3.38e-10	Blood metabolite levels;
LUSC	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.88	14.28	0.62	1.99e-36	Coronary artery disease;
LUSC	cis	rs7241530	0.595	rs12957925	chr18:75900192	G/A	cg14642773	chr18:75888474	NA	0.38	5.72	0.3	2.43e-8	Educational attainment (years of education);
LUSC	cis	rs7582720	1.000	rs77230711	chr2:203805552	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg18404041	chr3:52824283	ITIH1	-0.58	-9.62	-0.47	1.75e-19	Schizophrenia;
LUSC	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.33	-0.33	7.84e-10	Response to antipsychotic treatment;
LUSC	trans	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.46	0.5	2.41e-22	Mean corpuscular volume;
LUSC	cis	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg26958806	chr6:27640298	NA	0.74	6.04	0.31	4.02e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg16797656	chr11:68205561	LRP5	0.47	8.43	0.42	1.07e-15	Total body bone mineral density;
LUSC	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg17757837	chr7:157058334	UBE3C	-0.82	-13.3	-0.59	1.14e-32	Body mass index;
LUSC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg07701084	chr6:150067640	NUP43	0.57	8.96	0.44	2.36e-17	Lung cancer;
LUSC	cis	rs4478037	1.000	rs4074418	chr3:33161165	G/T	cg19404215	chr3:33155277	CRTAP	0.96	9.76	0.47	5.72e-20	Major depressive disorder;
LUSC	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg05855489	chr10:104503620	C10orf26	0.92	18.24	0.71	4.68e-52	Waist circumference;Hip circumference;
LUSC	cis	rs73200209	0.744	rs61354255	chr12:116444609	A/T	cg01776926	chr12:116560359	MED13L	-0.51	-5.9	-0.31	8.97e-9	Total body bone mineral density;
LUSC	cis	rs238295	0.805	rs6053527	chr20:5582457	G/T	cg15842884	chr20:5591925	RP5-1022P6.2	-0.44	-5.98	-0.31	5.89e-9	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs16866061	1.000	rs72974263	chr2:225447371	C/T	cg12698349	chr2:225449008	CUL3	0.85	13.9	0.61	5.46e-35	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg04518342	chr5:131593106	PDLIM4	0.45	8.24	0.41	3.96e-15	Breast cancer;
LUSC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.86	-0.35	3.42e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.49	-5.67	-0.3	3.13e-8	Schizophrenia;
LUSC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg12463550	chr7:65579703	CRCP	0.5	7.18	0.37	4.47e-12	Aortic root size;
LUSC	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	5.71	0.3	2.56e-8	Schizophrenia;
LUSC	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg11344533	chr11:111475393	SIK2	0.44	5.77	0.3	1.8e-8	Primary sclerosing cholangitis;
LUSC	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg05360949	chr19:41903737	BCKDHA;EXOSC5	0.42	5.74	0.3	2.13e-8	Height;
LUSC	trans	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	5.95	0.31	6.6e-9	Cystic fibrosis severity;
LUSC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg16447950	chr5:562315	NA	-0.54	-6.69	-0.34	9.21e-11	Obesity-related traits;
LUSC	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg27499820	chr13:21296301	IL17D	-0.3	-5.72	-0.3	2.34e-8	Dental caries;
LUSC	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg06207120	chr15:45996521	NA	0.4	6.23	0.32	1.38e-9	Waist circumference;Weight;
LUSC	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.9	0.66	8.5e-43	Bladder cancer;
LUSC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg01557791	chr16:72042693	DHODH	-0.51	-7.33	-0.37	1.74e-12	Fibrinogen levels;
LUSC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg09455208	chr3:40491958	NA	-0.55	-9.93	-0.48	1.51e-20	Renal cell carcinoma;
LUSC	cis	rs2274273	0.905	rs2075601	chr14:55609234	C/T	cg04306507	chr14:55594613	LGALS3	0.58	13.35	0.59	6.92e-33	Protein biomarker;
LUSC	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22980127	chr19:33182716	NUDT19	0.9	13.02	0.58	1.21e-31	Red blood cell traits;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07786668	chr16:73092391	ZFHX3	0.38	6.8	0.35	4.9e-11	Triglycerides;
LUSC	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg03806693	chr22:41940476	POLR3H	-0.78	-11.2	-0.52	6.07e-25	Vitiligo;
LUSC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.49	0.46	4.39e-19	Bipolar disorder;
LUSC	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg07679836	chr6:33548423	BAK1	0.51	8.12	0.41	9.22e-15	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
LUSC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-7.34	-0.37	1.59e-12	Menarche (age at onset);
LUSC	cis	rs9677476	1.000	rs6704770	chr2:232109816	T/G	cg07929768	chr2:232055508	NA	0.32	6.06	0.31	3.67e-9	Food antigen IgG levels;
LUSC	cis	rs12618769	0.793	rs6741558	chr2:99258487	G/T	cg10123293	chr2:99228465	UNC50	0.43	5.99	0.31	5.36e-9	Bipolar disorder;
LUSC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg08392591	chr16:89556376	ANKRD11	0.38	5.78	0.3	1.68e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs10979	0.964	rs35205240	chr6:143898676	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-11.79	-0.54	4.66e-27	Hypospadias;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06851336	chr10:104678166	CNNM2	-0.41	-5.99	-0.31	5.45e-9	Electrocardiographic conduction measures;
LUSC	cis	rs870825	0.932	rs13136635	chr4:185574807	C/T	cg04058563	chr4:185651563	MLF1IP	-0.83	-11.2	-0.52	6.41e-25	Blood protein levels;
LUSC	cis	rs16854884	0.770	rs1530477	chr3:143819506	A/G	cg06585982	chr3:143692056	C3orf58	-0.45	-6.73	-0.35	7.58e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-9.28	-0.45	2.25e-18	Gut microbiome composition (summer);
LUSC	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg25344623	chr2:136566232	LCT	0.37	5.68	0.3	2.96e-8	Mosquito bite size;
LUSC	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.84	-0.44	5.62e-17	Metabolite levels;
LUSC	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.46	6.3	0.33	9.18e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08439880	chr3:133502540	NA	0.36	6.35	0.33	7.13e-10	Iron status biomarkers;
LUSC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg18306943	chr3:40428807	ENTPD3	0.38	5.95	0.31	6.88e-9	Renal cell carcinoma;
LUSC	cis	rs983392	0.868	rs11605427	chr11:59928672	G/C	cg24026212	chr11:59952134	MS4A6A	-0.35	-5.83	-0.3	1.33e-8	Alzheimer's disease (late onset);
LUSC	trans	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg01620082	chr3:125678407	NA	0.51	6.07	0.32	3.41e-9	Depression;
LUSC	cis	rs10886558	0.674	rs10788015	chr10:121781396	C/T	cg02041677	chr10:121771263	NA	-0.35	-6.48	-0.33	3.21e-10	Shingles;
LUSC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg16325326	chr1:53192061	ZYG11B	0.88	16.16	0.66	7.99e-44	Monocyte count;
LUSC	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg10130564	chr11:117069849	TAGLN	0.33	6.28	0.33	1.03e-9	Blood protein levels;
LUSC	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-9.05	-0.44	1.23e-17	Response to antipsychotic treatment;
LUSC	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06634786	chr22:41940651	POLR3H	-0.53	-6.19	-0.32	1.81e-9	Vitiligo;
LUSC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg01065977	chr19:18549689	ISYNA1	-0.23	-5.74	-0.3	2.18e-8	Breast cancer;
LUSC	cis	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg23231163	chr10:75533350	FUT11	-0.41	-6.54	-0.34	2.27e-10	Inflammatory bowel disease;
LUSC	cis	rs981844	0.712	rs1456397	chr4:154744554	C/G	cg14289246	chr4:154710475	SFRP2	0.45	6.23	0.32	1.44e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs2224391	0.628	rs2753230	chr6:5248538	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	0.47	6.48	0.33	3.34e-10	Height;
LUSC	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg00310523	chr12:86230176	RASSF9	-0.44	-8.11	-0.41	9.88e-15	Major depressive disorder;
LUSC	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.5	7.91	0.4	3.78e-14	Depressive symptoms;
LUSC	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg09904177	chr6:26538194	HMGN4	0.72	13.1	0.58	6.25e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg05347473	chr6:146136440	FBXO30	0.55	9.26	0.45	2.5e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg19682013	chr15:45996608	NA	0.38	5.88	0.31	1.02e-8	Waist circumference;Weight;
LUSC	cis	rs12348691	0.503	rs7848950	chr9:100612774	T/C	cg13688889	chr9:100608707	NA	-0.81	-12.63	-0.57	3.79e-30	Alopecia areata;
LUSC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg13607699	chr17:42295918	UBTF	-0.48	-7.24	-0.37	3.15e-12	Total body bone mineral density;
LUSC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg14019146	chr3:50243930	SLC38A3	-0.32	-6.96	-0.36	1.82e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg23649088	chr2:200775458	C2orf69	-0.57	-7.85	-0.39	5.7e-14	Schizophrenia;
LUSC	cis	rs778371	0.659	rs2289911	chr2:233704252	A/G	cg08000102	chr2:233561755	GIGYF2	-0.78	-12.26	-0.56	8.89e-29	Schizophrenia;
LUSC	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg13073564	chr4:8508604	NA	0.48	8.96	0.44	2.37e-17	Response to antineoplastic agents;
LUSC	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg22467129	chr15:76604101	ETFA	0.43	6.89	0.35	2.8e-11	Blood metabolite levels;
LUSC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg03929089	chr4:120376271	NA	-0.94	-16.47	-0.67	5.04e-45	Height;
LUSC	cis	rs11264213	0.901	rs72661625	chr1:36401003	T/C	cg27506609	chr1:36549197	TEKT2	0.7	8.04	0.4	1.62e-14	Schizophrenia;
LUSC	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg11812906	chr14:75593930	NEK9	0.66	11.36	0.53	1.7e-25	Height;
LUSC	cis	rs41271473	0.950	rs72751907	chr1:228867648	C/T	cg16512390	chr1:228756714	NA	0.53	6.22	0.32	1.5e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg13010199	chr12:38710504	ALG10B	0.47	7.39	0.37	1.17e-12	Morning vs. evening chronotype;
LUSC	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	8.07	0.4	1.27e-14	Personality dimensions;
LUSC	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg14458575	chr2:238380390	NA	0.85	14.52	0.62	2.26e-37	Prostate cancer;
LUSC	cis	rs2835872	0.758	rs1787394	chr21:39036176	C/A	cg20424643	chr21:39039972	KCNJ6	-0.44	-7.42	-0.38	9.81e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-6.16	-0.32	2.11e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg17294928	chr15:75287854	SCAMP5	-0.72	-6.65	-0.34	1.2e-10	Lung cancer;
LUSC	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg18827107	chr12:86230957	RASSF9	-0.48	-7.13	-0.36	6.22e-12	Major depressive disorder;
LUSC	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.1	24.6	0.8	5.88e-77	Schizophrenia;
LUSC	cis	rs11229555	0.645	rs7929868	chr11:58209418	C/T	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg25024717	chr12:54324583	NA	-0.38	-6.32	-0.33	8.32e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs6967385	0.900	rs10278941	chr7:12364646	G/C	cg06484146	chr7:12443880	VWDE	0.42	6.21	0.32	1.56e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs12410462	0.581	rs77430808	chr1:227540880	C/T	cg23173402	chr1:227635558	NA	0.55	6.46	0.33	3.76e-10	Major depressive disorder;
LUSC	cis	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.89	0.35	2.78e-11	Educational attainment;
LUSC	cis	rs9653442	0.527	rs4851258	chr2:100780830	T/C	cg22139774	chr2:100720529	AFF3	-0.41	-7.12	-0.36	6.51e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg15557168	chr22:42548783	NA	0.47	7.33	0.37	1.76e-12	Schizophrenia;
LUSC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg13531842	chr10:38383804	ZNF37A	-0.45	-6.91	-0.35	2.53e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1113500	0.897	rs55980437	chr1:108639498	G/A	cg06207961	chr1:108661230	NA	0.41	7.61	0.38	2.76e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-15.73	-0.65	4.07e-42	Heart rate;
LUSC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg20203395	chr5:56204925	C5orf35	0.57	8.13	0.41	8.57e-15	Initial pursuit acceleration;
LUSC	cis	rs997295	0.675	rs12912974	chr15:67974379	G/C	cg08079166	chr15:68083412	MAP2K5	-0.33	-6.56	-0.34	2.11e-10	Motion sickness;
LUSC	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg25214090	chr10:38739885	LOC399744	0.54	7.9	0.4	4.18e-14	Corneal astigmatism;
LUSC	cis	rs1595825	0.891	rs7595819	chr2:198543156	A/C	cg00982548	chr2:198649783	BOLL	0.57	7.09	0.36	8.19e-12	Ulcerative colitis;
LUSC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg06484146	chr7:12443880	VWDE	-0.7	-7.51	-0.38	5.55e-13	Coronary artery disease;
LUSC	cis	rs4132509	0.744	rs12124113	chr1:243904366	A/G	cg21452805	chr1:244014465	NA	0.59	6.63	0.34	1.36e-10	RR interval (heart rate);
LUSC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg08088566	chr11:430123	ANO9	0.67	7.4	0.38	1.08e-12	Body mass index;
LUSC	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg11019008	chr10:131425282	MGMT	0.42	6.31	0.33	8.97e-10	Response to temozolomide;
LUSC	trans	rs7567288	0.636	rs12998999	chr2:134466938	T/G	cg12381416	chr3:14359266	NA	0.53	5.99	0.31	5.3e-9	Height;
LUSC	cis	rs4713118	0.824	rs9468229	chr6:27750086	G/A	cg20933634	chr6:27740509	NA	0.42	5.92	0.31	8.17e-9	Parkinson's disease;
LUSC	cis	rs4144027	0.791	rs11160770	chr14:104362291	A/C	cg12183467	chr14:104352244	NA	0.29	5.78	0.3	1.73e-8	Blood metabolite levels;
LUSC	cis	rs600231	0.571	rs10896000	chr11:65218018	A/G	cg21890820	chr11:65308645	LTBP3	0.48	6.99	0.36	1.51e-11	Bone mineral density;
LUSC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.82	-14.89	-0.63	8.52e-39	Cognitive function;
LUSC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.48	-0.33	3.34e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg17366294	chr4:99064904	C4orf37	0.61	10.83	0.51	1.3e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322817	0.691	rs2400071	chr6:105344075	C/T	cg02098413	chr6:105308735	HACE1	0.28	5.96	0.31	6.43e-9	Thyroid stimulating hormone;
LUSC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.39	-0.37	1.2e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11785400	0.890	rs13279182	chr8:143720544	A/G	cg10596483	chr8:143751796	JRK	0.59	8.83	0.44	6.04e-17	Schizophrenia;
LUSC	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg21605333	chr4:119757512	SEC24D	-1.34	-10.81	-0.51	1.49e-23	Cannabis dependence symptom count;
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg03461704	chr1:205818484	PM20D1	0.39	6.42	0.33	4.66e-10	Menarche (age at onset);
LUSC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.67	-11.49	-0.53	5.46e-26	IgG glycosylation;
LUSC	trans	rs4942242	0.663	rs7319346	chr13:44218201	T/C	cg19169023	chr15:41853346	TYRO3	-0.57	-8.73	-0.43	1.23e-16	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs2562456	0.754	rs11673320	chr19:21507603	G/A	cg00806126	chr19:22604979	ZNF98	-0.42	-5.99	-0.31	5.56e-9	Pain;
LUSC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	7.41	0.38	1.05e-12	Colorectal cancer;
LUSC	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg06462663	chr19:18546047	ISYNA1	0.47	7.81	0.39	7.61e-14	Breast cancer;
LUSC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg07424592	chr7:64974309	NA	-0.64	-5.79	-0.3	1.61e-8	Diabetic kidney disease;
LUSC	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.27	0.59	1.47e-32	Blood protein levels;
LUSC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.81	12.65	0.57	3.15e-30	Menopause (age at onset);
LUSC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	7.17	0.37	4.86e-12	Platelet count;
LUSC	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.76	-0.51	2.3e-23	Glomerular filtration rate;
LUSC	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg27539214	chr16:67997921	SLC12A4	-0.45	-5.78	-0.3	1.75e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08380311	chr19:3435252	NFIC	0.85	16.17	0.66	7.78e-44	Height;
LUSC	trans	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg17830980	chr10:43048298	ZNF37B	-0.44	-7.05	-0.36	1.06e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1832871	0.711	rs9457248	chr6:158681204	C/T	cg07165851	chr6:158734300	TULP4	0.51	7.87	0.4	4.91e-14	Height;
LUSC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg13175981	chr1:150552382	MCL1	0.44	5.9	0.31	8.83e-9	Urate levels;
LUSC	trans	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08382705	chr11:45687319	CHST1	-0.48	-7.68	-0.39	1.79e-13	Height;
LUSC	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.63	-0.34	1.34e-10	Bladder cancer;
LUSC	cis	rs7180079	1.000	rs6494475	chr15:64634884	C/A	cg02848875	chr15:64387786	SNX1	0.4	5.76	0.3	1.92e-8	Monocyte count;
LUSC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.93	14.84	0.63	1.3e-38	Parkinson's disease;
LUSC	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21775007	chr8:11205619	TDH	0.73	11.84	0.54	3.02e-27	Retinal vascular caliber;
LUSC	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg17218026	chr1:154582156	ADAR	0.58	10.31	0.49	7.74e-22	Blood protein levels;
LUSC	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg07701084	chr6:150067640	NUP43	0.49	7.32	0.37	1.85e-12	Lung cancer;
LUSC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.82	-13.82	-0.6	1.12e-34	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg23711669	chr6:146136114	FBXO30	0.89	16.85	0.68	1.48e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-0.94	-17.65	-0.69	1.06e-49	Headache;
LUSC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg18305652	chr10:134549665	INPP5A	0.46	6.85	0.35	3.6e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	trans	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg25214090	chr10:38739885	LOC399744	0.43	6.41	0.33	5.04e-10	Corneal astigmatism;
LUSC	cis	rs7674212	0.865	rs13149311	chr4:103977700	C/T	cg16532752	chr4:104119610	CENPE	-0.41	-5.77	-0.3	1.85e-8	Type 2 diabetes;
LUSC	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg05784532	chr1:230284198	GALNT2	0.5	7.45	0.38	7.91e-13	Coronary artery disease;
LUSC	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.77	11.37	0.53	1.54e-25	Corneal astigmatism;
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg16031515	chr1:205743344	RAB7L1	-0.27	-5.92	-0.31	8.15e-9	Menarche (age at onset);
LUSC	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.98	-0.31	5.72e-9	IgG glycosylation;
LUSC	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.77	-0.43	9.18e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg18827107	chr12:86230957	RASSF9	0.46	6.96	0.36	1.86e-11	Major depressive disorder;
LUSC	cis	rs8044995	0.501	rs73613999	chr16:68390099	C/A	cg09835421	chr16:68378352	PRMT7	-0.77	-8.56	-0.42	4.3e-16	Schizophrenia;
LUSC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.77	0.39	9.46e-14	Parkinson's disease;
LUSC	trans	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg22800045	chr5:56110881	MAP3K1	0.74	9.54	0.46	3.05e-19	Initial pursuit acceleration;
LUSC	cis	rs921665	0.831	rs4337500	chr2:3190786	T/C	cg02624386	chr2:3182749	NA	0.59	6.58	0.34	1.8e-10	World class endurance athleticism;
LUSC	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg04450456	chr4:17643702	FAM184B	0.4	6.71	0.34	8.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg01420254	chr6:26195488	NA	0.72	7.45	0.38	8.01e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg20891283	chr12:69753455	YEATS4	0.43	5.8	0.3	1.57e-8	Response to diuretic therapy;
LUSC	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg00376283	chr12:123451042	ABCB9	0.68	7.74	0.39	1.19e-13	Neutrophil percentage of white cells;
LUSC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08859206	chr1:53392774	SCP2	-0.54	-9.35	-0.46	1.34e-18	Monocyte count;
LUSC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.08	-0.48	4.83e-21	Obesity-related traits;
LUSC	trans	rs1409005	1.000	rs76429909	chr13:79161195	G/T	cg04653021	chr3:122514541	DIRC2	0.47	6.0	0.31	5.25e-9	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg19743168	chr1:23544995	NA	0.39	7.27	0.37	2.51e-12	Height;
LUSC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg01579765	chr21:45077557	HSF2BP	-0.49	-10.42	-0.5	3.44e-22	Mean corpuscular volume;
LUSC	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg09184832	chr6:79620586	NA	-0.43	-6.96	-0.36	1.76e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg00376283	chr12:123451042	ABCB9	0.69	9.84	0.47	3.25e-20	Height;Educational attainment;Head circumference (infant);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17783671	chr19:59070436	UBE2M;LOC100131691	-0.54	-6.59	-0.34	1.72e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs977987	0.806	rs4888390	chr16:75400320	G/A	cg03315344	chr16:75512273	CHST6	0.49	9.33	0.45	1.48e-18	Dupuytren's disease;
LUSC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg06238570	chr21:40685208	BRWD1	0.6	9.97	0.48	1.11e-20	Cognitive function;
LUSC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.78	0.3	1.7e-8	Menopause (age at onset);
LUSC	cis	rs2617583	0.509	rs10630	chr5:1462720	G/A	cg13982541	chr5:1466431	LPCAT1	0.41	5.74	0.3	2.12e-8	Breast cancer;
LUSC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.56	0.5	1.1e-22	Schizophrenia;
LUSC	cis	rs977987	0.835	rs3851734	chr16:75371920	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.4	0.46	8.79e-19	Dupuytren's disease;
LUSC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.79	14.5	0.62	2.8e-37	Blood protein levels;
LUSC	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg23711669	chr6:146136114	FBXO30	0.88	16.26	0.66	3.3e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg11057378	chr10:81107060	PPIF	0.38	6.29	0.33	9.67e-10	Height;
LUSC	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	0.58	8.83	0.44	6.01e-17	Breast cancer;
LUSC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.53	-6.82	-0.35	4.33e-11	Multiple sclerosis;
LUSC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg15605315	chr1:45957053	TESK2	0.49	8.12	0.41	9.19e-15	High light scatter reticulocyte count;
LUSC	cis	rs28655083	0.956	rs7184198	chr16:77069490	T/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-6.43	-0.33	4.39e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg11189052	chr15:85197271	WDR73	0.48	5.93	0.31	7.56e-9	Schizophrenia;
LUSC	cis	rs36093844	0.904	rs7113656	chr11:85594739	T/C	cg25872744	chr11:85566296	CCDC83	-0.42	-6.89	-0.35	2.71e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg18538332	chr22:24372958	LOC391322	0.47	8.13	0.41	8.28e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-8.3	-0.41	2.62e-15	Longevity;Endometriosis;
LUSC	cis	rs9394438	0.628	rs804843	chr6:37545923	A/G	cg00985040	chr6:37553208	NA	-0.39	-9.11	-0.45	7.79e-18	IgG glycosylation;
LUSC	trans	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg18187862	chr3:45730750	SACM1L	0.55	7.0	0.36	1.43e-11	Primary sclerosing cholangitis;
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.92	18.09	0.7	1.75e-51	Menarche (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04943085	chr2:73340257	RAB11FIP5	-0.4	-5.95	-0.31	6.77e-9	Electrocardiographic conduction measures;
LUSC	cis	rs16854884	1.000	rs16854886	chr3:143781492	A/G	cg06585982	chr3:143692056	C3orf58	0.46	6.43	0.33	4.37e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	11.51	0.53	4.64e-26	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	8.21	0.41	5.03e-15	Colorectal cancer;
LUSC	cis	rs12824058	0.737	rs873663	chr12:130816316	C/T	cg24838063	chr12:130822603	PIWIL1	0.7	10.36	0.49	5.41e-22	Menopause (age at onset);
LUSC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.54	8.34	0.42	1.98e-15	Colorectal cancer;
LUSC	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg14696996	chr19:15285081	NOTCH3	1.02	9.38	0.46	1.03e-18	Pulse pressure;
LUSC	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg08085267	chr17:45401833	C17orf57	0.54	8.8	0.43	7.36e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6469656	1.000	rs10505286	chr8:117727804	A/T	cg24004040	chr8:117650383	NA	0.44	6.46	0.33	3.81e-10	Colorectal cancer;
LUSC	trans	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg26384229	chr12:38710491	ALG10B	0.65	10.29	0.49	9.41e-22	Morning vs. evening chronotype;
LUSC	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg24881330	chr22:46731750	TRMU	0.83	7.52	0.38	5e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7589342	0.501	rs13429800	chr2:106441002	C/T	cg14210321	chr2:106509881	NCK2	-0.41	-6.13	-0.32	2.54e-9	Addiction;
LUSC	cis	rs10193935	0.901	rs62142596	chr2:42529339	C/T	cg27598129	chr2:42591480	NA	-0.6	-8.34	-0.42	1.94e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12760731	0.720	rs12022731	chr1:178416358	A/G	cg00404053	chr1:178313656	RASAL2	0.59	6.22	0.32	1.46e-9	Obesity-related traits;
LUSC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	0.99	13.71	0.6	3.01e-34	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06850241	chr22:41845214	NA	0.34	6.3	0.33	9.5e-10	Vitiligo;
LUSC	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg05373962	chr22:49881684	NA	-0.39	-8.25	-0.41	3.62e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4654899	0.865	rs957163	chr1:21416181	G/T	cg02927042	chr1:21476669	EIF4G3	-0.4	-6.3	-0.33	9.29e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg13126279	chr21:47581558	C21orf56	-0.43	-6.37	-0.33	6.09e-10	Testicular germ cell tumor;
LUSC	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.97	-0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.94	-0.36	1.99e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.36e-12	Motion sickness;
LUSC	trans	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg06521331	chr12:34319734	NA	-0.4	-6.21	-0.32	1.59e-9	Bladder cancer;
LUSC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg12365402	chr11:9010492	NRIP3	-0.52	-10.14	-0.49	3.05e-21	Hemoglobin concentration;
LUSC	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg04374321	chr14:90722782	PSMC1	-0.43	-6.51	-0.34	2.72e-10	Mortality in heart failure;
LUSC	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg21827317	chr3:136751795	NA	0.39	6.9	0.35	2.67e-11	Neuroticism;
LUSC	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg17168535	chr8:21777572	XPO7	0.67	10.28	0.49	1.06e-21	Mean corpuscular volume;
LUSC	cis	rs7180079	0.544	rs11071804	chr15:64975763	C/G	cg08069370	chr15:64387884	SNX1	0.53	5.83	0.3	1.29e-8	Monocyte count;
LUSC	cis	rs3126085	0.935	rs11204943	chr1:152203906	A/C	cg26876637	chr1:152193138	HRNR	0.45	6.29	0.33	9.81e-10	Atopic dermatitis;
LUSC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.57	-9.3	-0.45	1.88e-18	Neurofibrillary tangles;
LUSC	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg23544223	chr18:12777786	NA	0.59	6.25	0.32	1.26e-9	Inflammatory skin disease;
LUSC	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg06636001	chr8:8085503	FLJ10661	0.54	7.87	0.4	5.15e-14	Retinal vascular caliber;
LUSC	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.81	13.26	0.59	1.57e-32	Testicular germ cell tumor;
LUSC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg13683864	chr3:40499215	RPL14	-1.12	-21.74	-0.77	6.43e-66	Renal cell carcinoma;
LUSC	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.81	14.14	0.61	6.81e-36	Adiposity;
LUSC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.12	-0.32	2.59e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9650657	0.648	rs7833945	chr8:10700266	T/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.39	-0.33	5.55e-10	Neuroticism;
LUSC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.58	10.64	0.5	5.72e-23	Homoarginine levels;
LUSC	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	0.88	13.29	0.59	1.19e-32	Blood protein levels;
LUSC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg27170947	chr2:26402098	FAM59B	-0.64	-9.43	-0.46	7.05e-19	Gut microbiome composition (summer);
LUSC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.82	14.09	0.61	1.02e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg23625390	chr15:77176239	SCAPER	0.46	7.11	0.36	6.92e-12	Blood metabolite levels;
LUSC	cis	rs7584330	0.737	rs6758246	chr2:238359891	G/C	cg14458575	chr2:238380390	NA	0.69	12.18	0.55	1.66e-28	Prostate cancer;
LUSC	cis	rs2798269	0.528	rs9509802	chr13:22148698	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.42	-6.81	-0.35	4.49e-11	PR segment;
LUSC	trans	rs1325195	0.734	rs2791943	chr1:179107430	T/C	cg11624085	chr17:8464688	MYH10	0.42	6.85	0.35	3.5e-11	IgE grass sensitization;
LUSC	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-6.81	-0.35	4.42e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg13939156	chr17:80058883	NA	-0.34	-6.75	-0.35	6.61e-11	Life satisfaction;
LUSC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.67	0.43	1.91e-16	Prudent dietary pattern;
LUSC	cis	rs9648716	0.515	rs809005	chr7:140721242	C/A	cg23214464	chr7:140373596	ADCK2	-0.72	-6.24	-0.32	1.34e-9	Type 2 diabetes;
LUSC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.46	-0.42	8.72e-16	Obesity-related traits;
LUSC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg07061783	chr6:25882402	NA	-0.4	-5.85	-0.3	1.17e-8	Blood metabolite levels;
LUSC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.06	0.31	3.75e-9	Personality dimensions;
LUSC	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg03806693	chr22:41940476	POLR3H	0.88	12.58	0.57	5.59e-30	Vitiligo;
LUSC	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg17507749	chr15:85114479	UBE2QP1	0.56	6.91	0.35	2.41e-11	Schizophrenia;
LUSC	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg26384229	chr12:38710491	ALG10B	0.5	7.24	0.37	3.07e-12	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg22907277	chr7:1156413	C7orf50	0.5	5.75	0.3	2.01e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg00684032	chr4:1343700	KIAA1530	0.33	5.81	0.3	1.49e-8	Obesity-related traits;
LUSC	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.47	7.51	0.38	5.34e-13	Resistin levels;
LUSC	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.73	11.94	0.55	1.32e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08048268	chr3:133502702	NA	-0.46	-9.0	-0.44	1.74e-17	Iron status biomarkers;
LUSC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg03233332	chr7:66118400	NA	-0.43	-6.26	-0.32	1.19e-9	Aortic root size;
LUSC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15369054	chr17:80825471	TBCD	-0.41	-6.64	-0.34	1.27e-10	Breast cancer;
LUSC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00339695	chr16:24857497	SLC5A11	-0.62	-9.67	-0.47	1.2e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg24634471	chr8:143751801	JRK	0.6	8.98	0.44	1.95e-17	Schizophrenia;
LUSC	trans	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg25214090	chr10:38739885	LOC399744	0.41	6.26	0.32	1.18e-9	Corneal astigmatism;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10659575	chr11:102188233	BIRC3	0.41	6.32	0.33	8.38e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs75804782	0.521	rs55973123	chr2:239416264	G/A	cg18131467	chr2:239335373	ASB1	-0.62	-5.95	-0.31	6.81e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg03894339	chr8:19674705	INTS10	-0.51	-7.08	-0.36	8.75e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg19539972	chr4:7069911	GRPEL1	0.71	8.87	0.44	4.66e-17	Monocyte percentage of white cells;
LUSC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg00677455	chr12:58241039	CTDSP2	0.62	8.7	0.43	1.52e-16	Multiple sclerosis;
LUSC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-0.8	-15.54	-0.65	2.27e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg04398451	chr17:18023971	MYO15A	-0.57	-9.66	-0.47	1.29e-19	Total body bone mineral density;
LUSC	cis	rs472402	0.540	rs3776431	chr5:6618756	T/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.51	-7.41	-0.38	1.01e-12	Response to amphetamines;
LUSC	cis	rs7605827	0.866	rs9710889	chr2:15533779	G/A	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg12365402	chr11:9010492	NRIP3	0.43	7.91	0.4	3.84e-14	Hemoglobin concentration;
LUSC	cis	rs6484504	0.576	rs208071	chr11:31144996	C/T	cg14844989	chr11:31128820	NA	-0.39	-6.09	-0.32	3.1e-9	Red blood cell count;
LUSC	cis	rs240764	0.817	rs12216304	chr6:101174161	A/G	cg09795085	chr6:101329169	ASCC3	-0.41	-5.91	-0.31	8.31e-9	Neuroticism;
LUSC	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs6546550	0.743	rs6731941	chr2:70018496	A/G	cg02498382	chr2:70120550	SNRNP27	-0.26	-6.23	-0.32	1.41e-9	Prevalent atrial fibrillation;
LUSC	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg20848291	chr7:100343083	ZAN	-0.68	-9.44	-0.46	6.61e-19	Other erythrocyte phenotypes;
LUSC	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg26195577	chr20:24973756	C20orf3	1.11	18.4	0.71	1.06e-52	Blood protein levels;
LUSC	trans	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.63	0.39	2.44e-13	Ulcerative colitis;
LUSC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-11.68	-0.54	1.17e-26	Chronic sinus infection;
LUSC	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg20503657	chr10:835505	NA	-0.49	-6.86	-0.35	3.31e-11	Response to angiotensin II receptor blocker therapy;
LUSC	trans	rs57046232	0.552	rs6054184	chr20:6354592	A/G	cg17788362	chr6:86352627	SYNCRIP	0.43	6.07	0.32	3.44e-9	Colorectal cancer;
LUSC	cis	rs1160297	0.585	rs12614959	chr2:53090302	T/C	cg07782112	chr2:53107842	NA	0.4	6.44	0.33	4.27e-10	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs2700987	0.716	rs1986568	chr7:37386824	G/C	cg26076750	chr5:98105150	RGMB	-0.37	-6.64	-0.34	1.28e-10	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg13256891	chr4:100009986	ADH5	0.41	5.91	0.31	8.51e-9	Alcohol dependence;
LUSC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.36	-0.33	6.67e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08677398	chr8:58056175	NA	0.52	7.2	0.37	4.08e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.36	-0.33	6.65e-10	Breast cancer;
LUSC	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.72	-13.66	-0.6	4.63e-34	Ulcerative colitis;
LUSC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg12463550	chr7:65579703	CRCP	0.42	6.04	0.31	4.03e-9	Aortic root size;
LUSC	trans	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.35	-0.46	1.33e-18	Depression;
LUSC	cis	rs72627509	0.638	rs7658601	chr4:57781347	C/T	cg26694713	chr4:57773883	REST	0.52	6.36	0.33	6.5e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.8	13.09	0.58	7.15e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg06008330	chr7:65541103	ASL	-0.4	-6.16	-0.32	2.14e-9	Aortic root size;
LUSC	cis	rs654950	0.775	rs28972757	chr1:41993013	T/C	cg06885757	chr1:42089581	HIVEP3	-0.37	-7.28	-0.37	2.44e-12	Airway imaging phenotypes;
LUSC	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.76	-14.42	-0.62	5.41e-37	Ulcerative colitis;
LUSC	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg08975724	chr8:8085496	FLJ10661	0.48	7.07	0.36	9.25e-12	Retinal vascular caliber;
LUSC	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.42	-0.62	5.29e-37	Schizophrenia;
LUSC	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg11266682	chr4:10021025	SLC2A9	0.46	7.81	0.39	7.37e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7814319	0.899	rs1878638	chr8:97258719	C/T	cg20787634	chr8:97240163	UQCRB	-0.34	-5.94	-0.31	7.3e-9	Lung function (FVC);
LUSC	cis	rs757081	0.608	rs214938	chr11:17188516	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-5.98	-0.31	5.7e-9	Systolic blood pressure;
LUSC	trans	rs1864729	0.818	rs2583510	chr8:98294452	A/G	cg08679828	chr8:102218111	ZNF706	-0.72	-6.16	-0.32	2.1e-9	Estradiol plasma levels (breast cancer);
LUSC	cis	rs6967385	0.934	rs2098364	chr7:12368783	C/A	cg20607287	chr7:12443886	VWDE	0.4	5.84	0.3	1.25e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg20607287	chr7:12443886	VWDE	-0.61	-6.34	-0.33	7.27e-10	Coronary artery disease;
LUSC	cis	rs7584330	0.554	rs9646716	chr2:238443784	C/T	cg16989719	chr2:238392110	NA	-0.41	-5.97	-0.31	6.05e-9	Prostate cancer;
LUSC	cis	rs4901869	0.966	rs4901868	chr14:59333792	C/T	cg02291164	chr14:59296302	NA	-0.56	-10.65	-0.5	5.44e-23	Panic disorder;
LUSC	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg03433033	chr1:76189801	ACADM	-0.46	-6.66	-0.34	1.11e-10	Daytime sleep phenotypes;
LUSC	cis	rs12928939	0.911	rs7202840	chr16:71824714	C/T	cg03805757	chr16:71968109	PKD1L3	-0.46	-6.65	-0.34	1.23e-10	Post bronchodilator FEV1;
LUSC	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg07884673	chr3:53033167	SFMBT1	-0.77	-7.81	-0.39	7.4e-14	Immune reponse to smallpox (secreted IL-2);
LUSC	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg13010199	chr12:38710504	ALG10B	0.68	10.59	0.5	8.41e-23	Bladder cancer;
LUSC	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07080220	chr10:102295463	HIF1AN	0.67	8.92	0.44	3.14e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21775007	chr8:11205619	TDH	0.71	11.36	0.53	1.72e-25	Retinal vascular caliber;
LUSC	trans	rs12692738	0.526	rs355861	chr2:165629963	A/G	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs2018683	0.834	rs733485	chr7:29026685	C/A	cg19402173	chr7:128379420	CALU	-0.56	-9.16	-0.45	5.4e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs8077577	0.895	rs1563371	chr17:18111793	C/T	cg16794390	chr17:18148240	FLII	0.41	5.75	0.3	2.01e-8	Obesity-related traits;
LUSC	cis	rs6546537	1.000	rs6712370	chr2:69855094	C/G	cg10773587	chr2:69614142	GFPT1	0.51	7.53	0.38	4.87e-13	Serum thyroid-stimulating hormone levels;
LUSC	trans	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.82	12.07	0.55	4.44e-28	Corneal astigmatism;
LUSC	cis	rs4132509	1.000	rs12403316	chr1:243956903	C/T	cg21452805	chr1:244014465	NA	0.5	5.82	0.3	1.41e-8	RR interval (heart rate);
LUSC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg25767906	chr1:53392781	SCP2	-0.5	-9.21	-0.45	3.66e-18	Monocyte count;
LUSC	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg09092052	chr15:45571596	NA	0.47	6.53	0.34	2.42e-10	Glomerular filtration rate;
LUSC	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg08601574	chr20:25228251	PYGB	-0.42	-6.49	-0.33	3.1e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.59	0.46	2.1e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg26384229	chr12:38710491	ALG10B	-0.53	-7.8	-0.39	7.98e-14	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg23711669	chr6:146136114	FBXO30	0.86	15.54	0.65	2.22e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7267979	0.702	rs449801	chr20:25491847	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	15.43	0.65	6.07e-41	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2481665	0.772	rs6668600	chr1:62536683	C/G	cg18591186	chr1:62594603	INADL	0.49	7.9	0.4	4.12e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg11764359	chr7:65958608	NA	0.54	7.05	0.36	1.04e-11	Aortic root size;
LUSC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.47	-0.5	2.33e-22	Bipolar disorder;
LUSC	cis	rs2200578	0.841	rs111592987	chr2:99601250	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.63	7.56	0.38	3.97e-13	IgG glycosylation;
LUSC	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg07810366	chr2:100720526	AFF3	-0.43	-7.19	-0.37	4.29e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs250677	0.522	rs919731	chr5:148352150	T/C	cg18129178	chr5:148520854	ABLIM3	0.54	7.6	0.38	2.97e-13	Breast cancer;
LUSC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg19773385	chr1:10388646	KIF1B	-0.57	-9.79	-0.47	4.78e-20	Hepatocellular carcinoma;
LUSC	cis	rs3916	0.911	rs12829722	chr12:121155622	C/T	cg27246729	chr12:121163418	ACADS	0.48	6.86	0.35	3.45e-11	Urinary metabolites (H-NMR features);
LUSC	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg05340658	chr4:99064831	C4orf37	-0.69	-11.88	-0.55	2.15e-27	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.42	0.46	7.53e-19	Bipolar disorder;
LUSC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg04166393	chr7:2884313	GNA12	0.43	5.75	0.3	2.06e-8	Height;
LUSC	cis	rs1440410	0.835	rs7684481	chr4:144054405	C/G	cg01719995	chr4:144104893	USP38	0.32	5.84	0.3	1.22e-8	Ischemic stroke;
LUSC	cis	rs7212590	0.618	rs59767604	chr17:58041339	C/G	cg10252138	chr17:58120427	NA	-0.79	-7.51	-0.38	5.45e-13	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-7.18	-0.37	4.57e-12	Renal function-related traits (BUN);
LUSC	cis	rs68170813	0.523	rs79607134	chr7:107033619	A/T	cg02696742	chr7:106810147	HBP1	-0.61	-8.98	-0.44	1.96e-17	Coronary artery disease;
LUSC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg16797656	chr11:68205561	LRP5	-0.34	-5.69	-0.3	2.78e-8	Total body bone mineral density;
LUSC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg21918786	chr6:109611834	NA	-0.41	-7.21	-0.37	3.87e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.04	-0.44	1.25e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7953508	0.711	rs3825198	chr12:93977465	T/A	cg18151635	chr12:93972918	NA	-0.56	-7.96	-0.4	2.79e-14	Pubertal anthropometrics;
LUSC	cis	rs12681287	0.547	rs6985066	chr8:87526439	A/C	cg00550725	chr8:87521180	FAM82B	0.43	5.66	0.3	3.21e-8	Caudate activity during reward;
LUSC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07362569	chr17:61921086	SMARCD2	0.36	7.35	0.37	1.51e-12	Prudent dietary pattern;
LUSC	cis	rs7923609	0.967	rs3956912	chr10:65205881	C/T	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.03e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg24675658	chr1:53192096	ZYG11B	0.58	9.02	0.44	1.54e-17	Monocyte count;
LUSC	cis	rs4285028	0.747	rs9852845	chr3:121390618	A/C	cg11130432	chr3:121712080	ILDR1	-0.56	-8.13	-0.41	8.7e-15	Multiple sclerosis;
LUSC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg16606324	chr3:10149918	C3orf24	0.62	9.45	0.46	6.19e-19	Alzheimer's disease;
LUSC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg19046167	chr17:80928561	B3GNTL1	0.48	6.93	0.35	2.2e-11	Glycated hemoglobin levels;
LUSC	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg04310649	chr10:35416472	CREM	-0.4	-6.04	-0.31	4.2e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11997175	0.646	rs4609158	chr8:33693420	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	7.0	0.36	1.44e-11	Body mass index;
LUSC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg06263672	chr7:65235340	NA	0.42	6.07	0.32	3.53e-9	Calcium levels;
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg24739457	chr1:205821442	NA	0.35	6.0	0.31	5.22e-9	Menarche (age at onset);
LUSC	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17830980	chr10:43048298	ZNF37B	0.57	9.25	0.45	2.8e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	6.06	0.31	3.6e-9	Breast cancer;
LUSC	cis	rs10089	0.552	rs1351141	chr5:127550055	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.66	-8.46	-0.42	8.39e-16	Ileal carcinoids;
LUSC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg05527609	chr1:210001259	C1orf107	-0.4	-5.92	-0.31	8.19e-9	Monobrow;
LUSC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.6	-7.34	-0.37	1.67e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	6.38	0.33	6.05e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg26043149	chr18:55253948	FECH	0.46	7.19	0.37	4.36e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg23262073	chr20:60523788	NA	-0.43	-6.02	-0.31	4.47e-9	Body mass index;
LUSC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg22166914	chr1:53195759	ZYG11B	-0.49	-7.65	-0.39	2.23e-13	Monocyte count;
LUSC	cis	rs6545883	0.831	rs2592356	chr2:61810428	G/C	cg15711740	chr2:61764176	XPO1	-0.46	-7.37	-0.37	1.34e-12	Tuberculosis;
LUSC	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg22980127	chr19:33182716	NUDT19	0.97	15.01	0.63	2.66e-39	Red blood cell traits;
LUSC	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg24006582	chr15:45444508	DUOX1	0.69	10.0	0.48	9.11e-21	Uric acid levels;
LUSC	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg10909506	chr17:38081995	ORMDL3	0.34	6.08	0.32	3.34e-9	Self-reported allergy;
LUSC	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.65	9.82	0.47	3.77e-20	Alcohol dependence;
LUSC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg12463550	chr7:65579703	CRCP	0.62	5.67	0.3	3.04e-8	Diabetic kidney disease;
LUSC	cis	rs6484504	0.576	rs441975	chr11:31233351	C/T	cg14844989	chr11:31128820	NA	-0.37	-5.74	-0.3	2.1e-8	Red blood cell count;
LUSC	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg12179176	chr11:130786555	SNX19	0.63	9.47	0.46	5.34e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs977987	0.806	rs56343285	chr16:75409797	A/G	cg04384234	chr16:75411784	CFDP1	-0.42	-6.85	-0.35	3.49e-11	Dupuytren's disease;
LUSC	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg12884169	chr21:40033163	ERG	0.61	12.26	0.56	8.41e-29	Coronary artery disease;
LUSC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg04546413	chr19:29218101	NA	-0.59	-7.77	-0.39	9.56e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.97	-0.61	2.98e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6500395	0.962	rs13331902	chr16:48644989	A/G	cg04672837	chr16:48644449	N4BP1	0.47	6.66	0.34	1.16e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4285028	0.580	rs1523519	chr3:121631841	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.51	-7.2	-0.37	3.92e-12	Multiple sclerosis;
LUSC	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg25206134	chr2:45395956	NA	0.54	6.44	0.33	4.06e-10	Bipolar disorder;
LUSC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg03146154	chr1:46216737	IPP	0.55	8.21	0.41	5.01e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg04218760	chr10:45406644	TMEM72	-0.31	-7.53	-0.38	4.69e-13	Mean corpuscular volume;
LUSC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg08470875	chr2:26401718	FAM59B	-0.64	-8.58	-0.42	3.75e-16	Gut microbiome composition (summer);
LUSC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg06096015	chr1:231504339	EGLN1	0.56	9.93	0.48	1.56e-20	Hemoglobin concentration;
LUSC	trans	rs4811340	0.561	rs6063828	chr20:51173568	G/T	cg15736553	chr3:11610338	VGLL4	-0.34	-6.06	-0.31	3.74e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.39	-0.37	1.17e-12	Electroencephalogram traits;
LUSC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.65	8.79	0.43	8.03e-17	High light scatter reticulocyte count;
LUSC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.7	-12.65	-0.57	3.22e-30	Aortic root size;
LUSC	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg04176472	chr15:90893244	GABARAPL3	0.35	6.27	0.32	1.1e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg18721089	chr20:30220636	NA	-0.35	-6.0	-0.31	5.1e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.58	-6.91	-0.35	2.47e-11	Birth weight;
LUSC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.23	0.52	4.91e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg04374321	chr14:90722782	PSMC1	0.7	10.69	0.5	3.9699999999999997e-23	Mortality in heart failure;
LUSC	cis	rs7944735	0.578	rs7949985	chr11:48062449	C/T	cg20307385	chr11:47447363	PSMC3	-0.64	-5.83	-0.3	1.31e-8	Intraocular pressure;
LUSC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.27	0.37	2.52e-12	Bipolar disorder;
LUSC	trans	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04565464	chr8:145669602	NFKBIL2	0.38	6.18	0.32	1.87e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs1268789	0.545	rs2054721	chr4:79351249	C/A	cg06112894	chr8:141469983	TRAPPC9	0.22	5.96	0.31	6.33e-9	Hair shape;Hair morphology;
LUSC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.59	-9.59	-0.46	2.12e-19	Personality dimensions;
LUSC	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.39	-0.37	1.18e-12	Joint mobility (Beighton score);
LUSC	cis	rs6604026	0.524	rs532834	chr1:93468062	A/T	cg17283838	chr1:93427260	FAM69A	0.4	5.83	0.3	1.32e-8	Multiple sclerosis;
LUSC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg23630131	chr7:65973040	NA	0.21	5.79	0.3	1.62e-8	Aortic root size;
LUSC	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg08219700	chr8:58056026	NA	0.47	6.27	0.32	1.1e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	4.73e-15	Homoarginine levels;
LUSC	trans	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg07393940	chr7:158741817	NA	-0.37	-6.62	-0.34	1.46e-10	Life satisfaction;
LUSC	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg05373962	chr22:49881684	NA	-0.41	-9.84	-0.47	3.06e-20	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg08975724	chr8:8085496	FLJ10661	0.46	6.46	0.33	3.8e-10	Retinal vascular caliber;
LUSC	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg15556689	chr8:8085844	FLJ10661	0.53	7.38	0.37	1.23e-12	Neuroticism;
LUSC	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg24642439	chr20:33292090	TP53INP2	-0.5	-7.51	-0.38	5.6e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.02	0.4	1.82e-14	Lung cancer;
LUSC	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg08017756	chr2:100939284	LONRF2	-0.47	-8.7	-0.43	1.49e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02187348	chr16:89574699	SPG7	0.64	10.63	0.5	6.51e-23	Multiple myeloma (IgH translocation);
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg26668828	chr6:292823	DUSP22	-0.73	-12.02	-0.55	6.87e-28	Menopause (age at onset);
LUSC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg23711669	chr6:146136114	FBXO30	0.9	17.22	0.69	5.08e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1775715	0.677	rs2808105	chr10:32110907	C/T	cg18675610	chr10:32216311	ARHGAP12	0.29	6.34	0.33	7.56e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06634786	chr22:41940651	POLR3H	0.49	5.78	0.3	1.74e-8	Vitiligo;
LUSC	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg05501817	chr11:14380813	RRAS2	0.43	6.14	0.32	2.38e-9	Mitochondrial DNA levels;
LUSC	trans	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04565464	chr8:145669602	NFKBIL2	0.38	6.12	0.32	2.55e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.75	-11.49	-0.53	5.82e-26	Menarche (age at onset);
LUSC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg10792982	chr14:105748885	BRF1	0.49	9.03	0.44	1.41e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-8.13	-0.41	8.66e-15	Response to antipsychotic treatment;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08940097	chr17:74094040	EXOC7	0.44	6.0	0.31	5.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg20503657	chr10:835505	NA	-0.49	-6.8	-0.35	4.7e-11	Response to angiotensin II receptor blocker therapy;
LUSC	trans	rs17039065	0.920	rs12508024	chr4:109413413	A/G	cg07444054	chr2:108107501	NA	-0.42	-5.99	-0.31	5.5e-9	Gut microbiome composition (summer);
LUSC	cis	rs8133932	0.654	rs382303	chr21:47349284	G/A	cg14185626	chr21:47401492	COL6A1	-0.45	-5.8	-0.3	1.54e-8	Schizophrenia;
LUSC	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg22875332	chr1:76189707	ACADM	-0.4	-5.9	-0.31	8.76e-9	Daytime sleep phenotypes;
LUSC	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg26528668	chr16:1614120	IFT140	0.45	7.53	0.38	4.86e-13	Coronary artery disease;
LUSC	cis	rs10886558	0.674	rs78755284	chr10:121802984	T/C	cg02041677	chr10:121771263	NA	-0.34	-6.27	-0.32	1.13e-9	Shingles;
LUSC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.86e-9	Major depressive disorder;
LUSC	cis	rs7084921	0.579	rs2862951	chr10:101844948	A/C	cg11888571	chr10:102027403	CWF19L1	-0.44	-6.08	-0.32	3.21e-9	Bone mineral density;
LUSC	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg05110241	chr16:68378359	PRMT7	-0.58	-6.72	-0.35	7.89e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg12863693	chr15:85201151	NMB	0.43	8.86	0.44	4.77e-17	Schizophrenia;
LUSC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.68	11.04	0.52	2.23e-24	Heart rate;
LUSC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg16434002	chr17:42200994	HDAC5	0.44	5.81	0.3	1.48e-8	Total body bone mineral density;
LUSC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.84	15.28	0.64	2.38e-40	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg26043149	chr18:55253948	FECH	-0.44	-6.8	-0.35	4.9e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg20399509	chr21:47717575	C21orf57	-0.38	-5.73	-0.3	2.29e-8	Testicular germ cell tumor;
LUSC	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-7.97	-0.4	2.53e-14	Body mass index;
LUSC	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg24642439	chr20:33292090	TP53INP2	-0.5	-7.5	-0.38	5.92e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg15105969	chr2:36825350	FEZ2	0.45	6.21	0.32	1.57e-9	Height;
LUSC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg12463550	chr7:65579703	CRCP	-0.52	-7.55	-0.38	4.17e-13	Aortic root size;
LUSC	cis	rs997295	0.713	rs3784695	chr15:68002602	A/G	cg08079166	chr15:68083412	MAP2K5	-0.33	-6.68	-0.34	9.93e-11	Motion sickness;
LUSC	cis	rs7589728	1.000	rs6722069	chr2:88533151	C/T	cg04511125	chr2:88470314	THNSL2	0.65	6.0	0.31	5.24e-9	Plasma clusterin levels;
LUSC	cis	rs17401966	0.597	rs56221672	chr1:10247313	A/G	cg19773385	chr1:10388646	KIF1B	-0.41	-7.01	-0.36	1.34e-11	Hepatocellular carcinoma;
LUSC	cis	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg07460842	chr6:66804631	NA	0.94	11.32	0.53	2.27e-25	Exhaled nitric oxide output;
LUSC	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.28	-0.41	2.9e-15	Retinal vascular caliber;
LUSC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg14440974	chr22:39074834	NA	-0.4	-6.54	-0.34	2.25e-10	Menopause (age at onset);
LUSC	trans	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg14227996	chr4:17616232	MED28	-0.55	-6.39	-0.33	5.69e-10	Opioid sensitivity;
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.68	-10.28	-0.49	1.03e-21	Lymphocyte counts;
LUSC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.69	11.65	0.54	1.5e-26	Heart rate;
LUSC	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg08079166	chr15:68083412	MAP2K5	0.41	7.43	0.38	9.02e-13	Restless legs syndrome;
LUSC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.84	14.89	0.63	7.84e-39	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.24	0.74	5.15e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.4	0.53	1.16e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg21433313	chr16:3507492	NAT15	-0.68	-11.34	-0.53	2.03e-25	Tuberculosis;
LUSC	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg11189052	chr15:85197271	WDR73	0.48	5.92	0.31	7.86e-9	Schizophrenia;
LUSC	cis	rs12458462	0.859	rs34242155	chr18:77425192	G/A	cg20476159	chr18:77451067	CTDP1	-0.33	-5.86	-0.31	1.09e-8	Monocyte count;
LUSC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg13047869	chr3:10149882	C3orf24	0.56	7.73	0.39	1.24e-13	Alzheimer's disease;
LUSC	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg07701084	chr6:150067640	NUP43	0.46	6.71	0.34	8.46e-11	Lung cancer;
LUSC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg15445000	chr17:37608096	MED1	-0.4	-6.81	-0.35	4.56e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg16339924	chr4:17578868	LAP3	0.5	7.35	0.37	1.54e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg09408571	chr1:101003634	GPR88	-0.29	-5.71	-0.3	2.51e-8	Monocyte count;
LUSC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.08	-0.48	4.83e-21	Obesity-related traits;
LUSC	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.89	-0.35	2.78e-11	Response to antipsychotic treatment;
LUSC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	trans	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	12.24	0.56	1.06e-28	Mean corpuscular volume;
LUSC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg13395646	chr4:1353034	KIAA1530	-0.54	-8.19	-0.41	5.49e-15	Obesity-related traits;
LUSC	cis	rs7119	0.717	rs11630916	chr15:77821331	G/A	cg27398640	chr15:77910606	LINGO1	-0.31	-6.51	-0.34	2.69e-10	Type 2 diabetes;
LUSC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-11.77	-0.54	5.53e-27	Mood instability;
LUSC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg10729496	chr3:10149963	C3orf24	0.52	6.88	0.35	2.9100000000000002e-11	Alzheimer's disease;
LUSC	cis	rs68170813	0.559	rs76307631	chr7:107058018	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.21	-0.45	3.73e-18	Coronary artery disease;
LUSC	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.09	-0.32	3.13e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg02176678	chr2:219576539	TTLL4	0.6	10.84	0.51	1.18e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.75	-0.63	2.9e-38	Schizophrenia;
LUSC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	1.24	16.51	0.67	3.35e-45	Eosinophil percentage of granulocytes;
LUSC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.62	-0.38	2.7e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1775715	0.870	rs1251407	chr10:32238325	A/G	cg03015672	chr10:32216066	ARHGAP12	0.33	5.86	0.31	1.09e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7495132	0.563	rs4404048	chr15:91196423	T/C	cg05609160	chr15:91208370	NA	-0.4	-5.65	-0.3	3.48e-8	Inflammatory bowel disease;Ulcerative colitis;
LUSC	trans	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.33	-0.33	8.07e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18019004	chr20:3209307	SLC4A11	0.52	7.6	0.38	2.97e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4942242	1.000	rs7335094	chr13:44223936	T/C	cg19169023	chr15:41853346	TYRO3	-0.45	-7.27	-0.37	2.63e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	0.79	10.08	0.48	5.01e-21	Coronary artery disease;
LUSC	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg12863693	chr15:85201151	NMB	0.36	7.22	0.37	3.54e-12	Schizophrenia;
LUSC	cis	rs6987853	0.749	rs13250124	chr8:42404737	G/A	cg09913449	chr8:42400586	C8orf40	0.53	9.22	0.45	3.48e-18	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg25214090	chr10:38739885	LOC399744	0.56	8.2	0.41	5.25e-15	Corneal astigmatism;
LUSC	cis	rs35094601	0.731	rs4954928	chr2:139212763	G/T	cg10095539	chr2:139258744	SPOPL	0.25	5.86	0.31	1.13e-8	Schizophrenia;
LUSC	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg05887092	chr17:76393375	PGS1	0.51	9.01	0.44	1.61e-17	HDL cholesterol levels;
LUSC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg03790207	chr6:42947109	PEX6	-0.44	-6.59	-0.34	1.67e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7113850	0.541	rs56732861	chr11:24234333	C/G	ch.11.24196551F	chr11:24239977	NA	1.0	9.14	0.45	6e-18	Bone fracture in osteoporosis;
LUSC	trans	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	7.84	0.39	6.24e-14	Ulcerative colitis;
LUSC	trans	rs7944735	0.545	rs4752805	chr11:48018355	A/G	cg15704280	chr7:45808275	SEPT13	0.57	6.66	0.34	1.14e-10	Intraocular pressure;
LUSC	cis	rs12210905	0.925	rs10456349	chr6:26975459	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs71403859	0.502	rs8053720	chr16:71456142	C/G	cg08717414	chr16:71523259	ZNF19	-0.63	-7.41	-0.38	1.02e-12	Post bronchodilator FEV1;
LUSC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg18827107	chr12:86230957	RASSF9	-0.48	-7.16	-0.36	5.24e-12	Major depressive disorder;
LUSC	cis	rs929596	0.561	rs6431625	chr2:234637912	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-8.9	-0.44	3.64e-17	Total bilirubin levels in HIV-1 infection;
LUSC	trans	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg06521331	chr12:34319734	NA	-0.39	-6.12	-0.32	2.68e-9	Bladder cancer;
LUSC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.75	-0.51	2.37e-23	Alzheimer's disease (late onset);
LUSC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg03526776	chr6:41159608	TREML2	0.34	6.53	0.34	2.51e-10	Alzheimer's disease (late onset);
LUSC	cis	rs612683	0.536	rs1335753	chr1:101027157	G/T	cg06223162	chr1:101003688	GPR88	0.53	9.93	0.48	1.59e-20	Breast cancer;
LUSC	cis	rs9287719	0.556	rs10168351	chr2:10736810	T/C	cg00105475	chr2:10696890	NA	0.34	5.75	0.3	1.98e-8	Prostate cancer;
LUSC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg14440974	chr22:39074834	NA	-0.36	-6.0	-0.31	5.18e-9	Menopause (age at onset);
LUSC	cis	rs7605827	0.860	rs13425097	chr2:15528920	C/G	cg19274914	chr2:15703543	NA	0.46	8.94	0.44	2.79e-17	Educational attainment (years of education);
LUSC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.08	-0.36	8.41e-12	Menopause (age at onset);
LUSC	cis	rs10216189	0.967	rs4724700	chr7:5526789	A/G	cg11800390	chr7:5515995	FBXL18	0.33	7.32	0.37	1.85e-12	Relative hand skill in reading disability;
LUSC	cis	rs77741769	0.571	rs11611087	chr12:121267126	C/T	cg02419362	chr12:121203948	SPPL3	0.45	8.36	0.42	1.66e-15	Mean corpuscular volume;
LUSC	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg12091567	chr17:66097778	LOC651250	-0.71	-9.45	-0.46	6.25e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg23711669	chr6:146136114	FBXO30	0.85	15.8	0.65	2.19e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-12.46	-0.56	1.61e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg18357645	chr12:58087776	OS9	0.52	7.86	0.4	5.41e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs62458065	0.850	rs7808992	chr7:32470677	C/T	cg20159608	chr7:32802032	NA	-0.68	-8.09	-0.4	1.1e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs12618769	0.597	rs3769743	chr2:99063653	C/T	cg10123293	chr2:99228465	UNC50	0.45	7.64	0.39	2.31e-13	Bipolar disorder;
LUSC	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.72	0.35	7.9e-11	Educational attainment;
LUSC	cis	rs10761482	0.544	rs1938544	chr10:62284659	C/G	cg18175470	chr10:62150864	ANK3	-0.51	-7.4	-0.38	1.12e-12	Schizophrenia;
LUSC	cis	rs500891	0.525	rs13192260	chr6:84110729	T/C	cg08257003	chr6:84140564	ME1	0.33	7.36	0.37	1.4e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07169764	chr2:136633963	MCM6	0.98	13.72	0.6	2.83e-34	Corneal structure;
LUSC	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.79	-11.9	-0.55	1.87e-27	Blood pressure (smoking interaction);
LUSC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg11645453	chr3:52864694	ITIH4	0.35	8.1	0.41	1.07e-14	Bipolar disorder;
LUSC	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.02	-0.36	1.24e-11	Schizophrenia;
LUSC	cis	rs13089785	1.000	rs2332682	chr3:123654633	C/T	cg01860459	chr3:123419554	MYLK	0.35	6.14	0.32	2.33e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg00990874	chr7:1149470	C7orf50	-0.61	-8.15	-0.41	7.3e-15	Bronchopulmonary dysplasia;
LUSC	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg09163369	chr1:210001066	C1orf107	0.58	6.87	0.35	3.15e-11	Orofacial clefts;
LUSC	trans	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg10756647	chr7:56101905	PSPH	0.85	8.47	0.42	7.94e-16	Gout;
LUSC	cis	rs9323205	0.954	rs7150336	chr14:51584596	A/T	cg23942311	chr14:51606299	NA	-0.43	-8.32	-0.41	2.22e-15	Cancer;
LUSC	cis	rs72634258	0.732	rs6577464	chr1:8171302	T/C	cg00042356	chr1:8021962	PARK7	-0.55	-6.56	-0.34	1.99e-10	Inflammatory bowel disease;
LUSC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	13.36	0.59	6.54e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg18225595	chr11:63971243	STIP1	0.52	6.54	0.34	2.38e-10	Mean platelet volume;
LUSC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg18758796	chr5:131593413	PDLIM4	-0.37	-6.19	-0.32	1.74e-9	Breast cancer;
LUSC	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.88	-0.4	4.64e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.89	-0.4	4.44e-14	Obesity-related traits;
LUSC	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.92	15.81	0.65	1.92e-42	Bladder cancer;
LUSC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.18	0.88	4.53e-111	Chronic sinus infection;
LUSC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18876405	chr7:65276391	NA	0.55	8.65	0.43	2.22e-16	Aortic root size;
LUSC	cis	rs11039100	0.850	rs34286221	chr11:5834852	G/T	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1062746	0.528	rs11646030	chr16:87339278	T/C	cg02258303	chr16:87377426	FBXO31	-0.53	-8.07	-0.4	1.24e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.95	12.04	0.55	5.59e-28	Exhaled nitric oxide output;
LUSC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7523273	0.606	rs2796268	chr1:207925192	G/A	cg22525895	chr1:207977042	MIR29B2	0.4	6.36	0.33	6.81e-10	Schizophrenia;
LUSC	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg22681709	chr2:178499509	PDE11A	-0.46	-8.44	-0.42	9.71e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10979	0.557	rs9390116	chr6:143907577	A/G	cg25407410	chr6:143891975	LOC285740	-0.65	-8.19	-0.41	5.6e-15	Hypospadias;
LUSC	cis	rs7428	0.539	rs4247303	chr2:85554080	G/A	cg24342717	chr2:85555507	TGOLN2	-0.71	-11.01	-0.52	3.01e-24	Ear protrusion;
LUSC	trans	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg25214090	chr10:38739885	LOC399744	0.42	6.49	0.33	3.18e-10	Corneal astigmatism;
LUSC	cis	rs7075426	0.753	rs11202040	chr10:88208199	C/T	cg07322936	chr10:88137208	NA	-0.46	-6.72	-0.35	7.88e-11	Migraine without aura;
LUSC	cis	rs1982963	1.000	rs10139288	chr14:52506486	T/C	cg10843707	chr14:52510701	NID2	-0.4	-6.45	-0.33	3.99e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg02018176	chr4:1364513	KIAA1530	-0.57	-9.89	-0.48	2.17e-20	Obesity-related traits;
LUSC	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg12940439	chr1:67600707	NA	0.37	6.02	0.31	4.51e-9	Psoriasis;
LUSC	cis	rs13082711	0.911	rs34878935	chr3:27466123	A/C	cg02860705	chr3:27208620	NA	0.52	8.71	0.43	1.44e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.66	-0.73	1.02e-57	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg08975724	chr8:8085496	FLJ10661	0.48	6.91	0.35	2.49e-11	Myopia (pathological);
LUSC	trans	rs2262909	0.962	rs411020	chr19:22231102	G/A	cg17074339	chr11:11642133	GALNTL4	-0.46	-7.07	-0.36	9.1e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg06521331	chr12:34319734	NA	-0.44	-7.18	-0.37	4.6e-12	Morning vs. evening chronotype;
LUSC	trans	rs3857536	0.813	rs6455090	chr6:66948909	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.05	-0.31	3.84e-9	Blood trace element (Cu levels);
LUSC	cis	rs11039100	0.850	rs35990969	chr11:5834242	G/A	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.59	-0.34	1.73e-10	High light scatter reticulocyte count;
LUSC	cis	rs2242663	0.705	rs551708	chr11:66486143	T/C	cg24851651	chr11:66362959	CCS	-0.37	-5.92	-0.31	7.81e-9	Bipolar disorder;
LUSC	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg24851651	chr11:66362959	CCS	-0.38	-6.19	-0.32	1.77e-9	Educational attainment (years of education);
LUSC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08859206	chr1:53392774	SCP2	-0.55	-9.61	-0.47	1.81e-19	Monocyte count;
LUSC	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.78	-0.35	5.36e-11	Monocyte percentage of white cells;
LUSC	cis	rs12519773	0.597	rs17360518	chr5:92457899	A/C	cg18783429	chr5:92414398	NA	0.35	7.39	0.37	1.22e-12	Migraine;
LUSC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.36	-0.42	1.66e-15	Obesity-related traits;
LUSC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg13206674	chr6:150067644	NUP43	0.6	9.63	0.47	1.59e-19	Lung cancer;
LUSC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg08392591	chr16:89556376	ANKRD11	0.43	6.43	0.33	4.34e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.33	0.53	2.12e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg25456477	chr12:86230367	RASSF9	-0.32	-5.69	-0.3	2.83e-8	Major depressive disorder;
LUSC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7106204	0.688	rs7131103	chr11:24219299	A/G	ch.11.24196551F	chr11:24239977	NA	0.95	9.06	0.44	1.12e-17	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	1.02	19.7	0.73	7.26e-58	Menopause (age at onset);
LUSC	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg03929089	chr4:120376271	NA	0.61	6.58	0.34	1.78e-10	Axial length;
LUSC	cis	rs6546550	0.901	rs6754896	chr2:70138170	T/C	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg01802117	chr1:53393560	SCP2	0.38	6.41	0.33	5.01e-10	Monocyte count;
LUSC	trans	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.61	-0.34	1.55e-10	Life satisfaction;
LUSC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-9.43	-0.46	7.05e-19	Gut microbiome composition (summer);
LUSC	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg18681998	chr4:17616180	MED28	-0.88	-15.48	-0.65	3.97e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-6.95	-0.36	1.92e-11	Bipolar disorder;
LUSC	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg24375607	chr4:120327624	NA	0.8	11.97	0.55	1.04e-27	Corneal astigmatism;
LUSC	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg00857998	chr1:205179979	DSTYK	0.59	8.86	0.44	4.91e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg20887711	chr4:1340912	KIAA1530	0.47	7.29	0.37	2.27e-12	Obesity-related traits;
LUSC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.73	-9.98	-0.48	1.02e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg15485101	chr11:133734466	NA	-0.37	-6.57	-0.34	1.99e-10	Childhood ear infection;
LUSC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg20821713	chr7:1055600	C7orf50	-0.5	-6.62	-0.34	1.46e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.28	0.45	2.26e-18	Red blood cell count;
LUSC	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.41	-6.47	-0.33	3.55e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg00999904	chr2:3704751	ALLC	0.44	7.75	0.39	1.13e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs3849570	0.961	rs13340130	chr3:81790970	A/T	cg07356753	chr3:81810745	GBE1	-0.69	-11.29	-0.53	2.99e-25	Waist circumference;Body mass index;
LUSC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg00747290	chr2:42721154	KCNG3	-0.62	-6.83	-0.35	4.14e-11	Schizophrenia;
LUSC	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	0.94	17.82	0.7	2.22e-50	Bone mineral density;
LUSC	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg08270630	chr22:50330655	NA	-0.39	-5.82	-0.3	1.41e-8	Schizophrenia;
LUSC	cis	rs16937	0.618	rs6659069	chr1:205182031	A/G	cg21643547	chr1:205240462	TMCC2	-0.35	-6.16	-0.32	2.15e-9	Schizophrenia;
LUSC	cis	rs9815354	0.904	rs73073368	chr3:41843391	A/G	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7759001	0.817	rs6456779	chr6:27370473	T/C	cg18711553	chr6:27366782	ZNF391	0.39	5.73	0.3	2.25e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg04733989	chr22:42467013	NAGA	0.39	6.54	0.34	2.32e-10	Cognitive function;
LUSC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg09323728	chr8:95962352	TP53INP1	-0.37	-7.34	-0.37	1.63e-12	Type 2 diabetes;
LUSC	trans	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	6.27	0.32	1.14e-9	Retinal vascular caliber;
LUSC	cis	rs9322817	0.691	rs2400072	chr6:105344116	C/T	cg02098413	chr6:105308735	HACE1	0.28	5.96	0.31	6.43e-9	Thyroid stimulating hormone;
LUSC	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08645402	chr16:4508243	NA	0.48	7.98	0.4	2.44e-14	Schizophrenia;
LUSC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg02772935	chr3:125709198	NA	-0.5	-5.99	-0.31	5.3300000000000004e-09	Blood pressure (smoking interaction);
LUSC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18404041	chr3:52824283	ITIH1	-0.6	-11.62	-0.54	1.93e-26	Bipolar disorder;
LUSC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg09165964	chr15:75287851	SCAMP5	0.5	7.22	0.37	3.46e-12	Breast cancer;
LUSC	trans	rs800082	0.867	rs2717393	chr3:144280290	T/C	cg24215973	chr2:240111563	HDAC4	0.47	6.98	0.36	1.59e-11	Smoking behavior;
LUSC	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg22676075	chr6:135203613	NA	0.48	7.42	0.38	9.61e-13	Red blood cell count;
LUSC	cis	rs977987	0.835	rs3863445	chr16:75371744	C/G	cg03315344	chr16:75512273	CHST6	0.53	10.0	0.48	9.13e-21	Dupuytren's disease;
LUSC	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg05855489	chr10:104503620	C10orf26	0.61	9.82	0.47	3.67e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg00049323	chr5:472564	LOC25845	0.49	7.77	0.39	9.73e-14	Cystic fibrosis severity;
LUSC	cis	rs2625529	0.823	rs11072332	chr15:72108307	G/T	cg16672083	chr15:72433130	SENP8	-0.5	-7.19	-0.37	4.26e-12	Red blood cell count;
LUSC	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg18352616	chr4:3374830	RGS12	0.3	5.92	0.31	8.03e-9	Serum sulfate level;
LUSC	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-1.13	-17.68	-0.7	7.6600000000000005e-50	Exhaled nitric oxide output;
LUSC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg16339924	chr4:17578868	LAP3	0.59	9.12	0.45	7.13e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs28647808	0.881	rs7029256	chr9:136263655	T/C	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs9394152	0.845	rs9380367	chr6:33474975	G/A	cg13560919	chr6:33536144	NA	0.6	10.77	0.51	2.06e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.41	5.98	0.31	5.59e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs2425143	1.000	rs1056196	chr20:34327159	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.18	-0.32	1.83e-9	Blood protein levels;
LUSC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg02931644	chr1:25747376	RHCE	0.37	6.86	0.35	3.32e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.69	-10.09	-0.48	4.37e-21	Systemic lupus erythematosus;
LUSC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.8	10.73	0.51	2.82e-23	Alzheimer's disease;
LUSC	cis	rs72627509	0.904	rs58408429	chr4:57769824	T/C	cg26694713	chr4:57773883	REST	0.52	6.42	0.33	4.78e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	8.35	0.42	1.88e-15	Neuroticism;
LUSC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.61	-0.6	7.34e-34	Chronic sinus infection;
LUSC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg16606324	chr3:10149918	C3orf24	-0.43	-6.83	-0.35	3.93e-11	Alzheimer's disease;
LUSC	cis	rs2731664	0.792	rs335432	chr5:176866258	G/A	cg23176889	chr5:176863531	GRK6	-0.69	-14.35	-0.62	1.06e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs6504340	0.793	rs56128659	chr17:46621828	T/A	cg09704116	chr17:46666958	LOC404266	-0.38	-6.41	-0.33	4.87e-10	Primary tooth development (number of teeth);
LUSC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg05393297	chr12:53359155	NA	-0.56	-8.58	-0.43	3.53e-16	Prostate cancer;
LUSC	cis	rs2798269	0.902	rs10492455	chr13:22102976	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-5.86	-0.31	1.08e-8	PR segment;
LUSC	cis	rs4664308	0.837	rs56172865	chr2:160967333	C/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-10.76	-0.51	2.18e-23	Idiopathic membranous nephropathy;
LUSC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg00745463	chr17:30367425	LRRC37B	-0.81	-9.51	-0.46	3.78e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg08213375	chr14:104286397	PPP1R13B	0.49	9.29	0.45	1.97e-18	Schizophrenia;
LUSC	cis	rs1443512	0.812	rs1992563	chr12:54330441	G/T	cg25024717	chr12:54324583	NA	-0.4	-6.9	-0.35	2.69e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg03213289	chr20:61660250	NA	0.66	12.81	0.57	7.61e-31	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg25767906	chr1:53392781	SCP2	0.4	6.92	0.35	2.37e-11	Monocyte count;
LUSC	trans	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg26384229	chr12:38710491	ALG10B	0.57	8.87	0.44	4.41e-17	Morning vs. evening chronotype;
LUSC	cis	rs7605827	0.897	rs11674618	chr2:15593035	T/C	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.26e-17	Educational attainment (years of education);
LUSC	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	0.96	14.62	0.62	9.17e-38	Triglycerides;
LUSC	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg25457927	chr22:38595422	NA	-0.34	-6.81	-0.35	4.62e-11	Cutaneous nevi;
LUSC	cis	rs72634258	0.679	rs7523227	chr1:8180097	G/A	cg00042356	chr1:8021962	PARK7	0.54	6.59	0.34	1.72e-10	Inflammatory bowel disease;
LUSC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg21573476	chr21:45109991	RRP1B	-0.37	-5.92	-0.31	7.93e-9	Mean corpuscular volume;
LUSC	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	9.23	0.45	3.08e-18	Lung cancer in ever smokers;
LUSC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg07703079	chr11:430292	ANO9	0.6	6.56	0.34	2.03e-10	Body mass index;
LUSC	cis	rs9303542	0.625	rs62065846	chr17:46592858	G/A	cg09704116	chr17:46666958	LOC404266	-0.36	-6.73	-0.35	7.56e-11	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	5.97	0.31	6.22e-9	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg23241863	chr10:102295624	HIF1AN	0.48	5.91	0.31	8.26e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg20607798	chr8:58055168	NA	0.49	5.84	0.3	1.24e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg06552810	chr11:31128660	NA	-0.42	-7.34	-0.37	1.61e-12	Red blood cell count;
LUSC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	11.03	0.52	2.57e-24	Cognitive test performance;
LUSC	trans	rs10432169	1	rs10432169	chr18:31347098	C/G	cg27147174	chr7:100797783	AP1S1	-0.46	-6.68	-0.34	1.01e-10	Subjective well-being;
LUSC	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg13010199	chr12:38710504	ALG10B	0.54	8.05	0.4	1.48e-14	Morning vs. evening chronotype;
LUSC	cis	rs4343996	0.902	rs4521670	chr7:3383603	C/T	cg21248987	chr7:3385318	SDK1	0.41	7.03	0.36	1.15e-11	Motion sickness;
LUSC	trans	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	7.69	0.39	1.67e-13	Ulcerative colitis;
LUSC	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.33e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg00431813	chr7:1051703	C7orf50	-0.47	-7.85	-0.39	5.58e-14	Longevity;Endometriosis;
LUSC	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.31	-0.45	1.82e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg06609049	chr19:2785107	THOP1	0.7	11.07	0.52	1.78e-24	Total cholesterol levels;
LUSC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg24562669	chr7:97807699	LMTK2	0.35	6.16	0.32	2.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg05347473	chr6:146136440	FBXO30	0.51	8.42	0.42	1.13e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.12	0.32	2.57e-9	Systolic blood pressure;
LUSC	cis	rs1045714	0.895	rs73043180	chr7:2645972	C/T	cg24848437	chr7:2645542	IQCE	0.61	6.74	0.35	6.84e-11	Urate levels in lean individuals;
LUSC	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.68	11.35	0.53	1.79e-25	Alcohol dependence;
LUSC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06481639	chr22:41940642	POLR3H	-0.53	-5.98	-0.31	5.59e-9	Vitiligo;
LUSC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.61	0.38	2.82e-13	Menarche (age at onset);
LUSC	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg09479241	chr17:27052676	TLCD1	0.44	6.23	0.32	1.39e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1215050	0.874	rs17545594	chr4:98652689	A/G	cg05340658	chr4:99064831	C4orf37	-0.42	-6.49	-0.33	3.09e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.9	0.35	2.56e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg04727924	chr7:799746	HEATR2	-0.57	-5.91	-0.31	8.66e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.79	13.66	0.6	4.69e-34	Blood protein levels;
LUSC	cis	rs16854884	0.657	rs35067746	chr3:143747147	T/A	cg06585982	chr3:143692056	C3orf58	0.5	7.93	0.4	3.36e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.31	-0.37	1.96e-12	Mood instability;
LUSC	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.8	15.01	0.63	2.67e-39	Longevity;
LUSC	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg13010199	chr12:38710504	ALG10B	0.53	7.92	0.4	3.45e-14	Morning vs. evening chronotype;
LUSC	cis	rs75804782	0.580	rs72987332	chr2:239362529	G/T	cg18131467	chr2:239335373	ASB1	-0.74	-6.67	-0.34	1.06e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg06521852	chr22:38141419	TRIOBP	0.42	6.29	0.33	1.01e-9	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg13010199	chr12:38710504	ALG10B	0.66	10.05	0.48	6.31e-21	Bladder cancer;
LUSC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.96	-0.4	2.65e-14	Type 2 diabetes;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg21702128	chr5:142784721	NR3C1	0.48	6.4	0.33	5.37e-10	Cognitive function;Information processing speed;
LUSC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	1.05	19.12	0.72	1.42e-55	Menopause (age at onset);
LUSC	cis	rs354225	0.544	rs11892443	chr2:54805776	A/G	cg26097391	chr2:54893211	SPTBN1	0.46	6.95	0.36	1.88e-11	Schizophrenia;
LUSC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg13206674	chr6:150067644	NUP43	0.61	9.78	0.47	4.8e-20	Lung cancer;
LUSC	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg17420585	chr12:42539391	GXYLT1	-0.39	-7.65	-0.39	2.19e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs3824867	0.920	rs10742805	chr11:47454701	A/G	cg20307385	chr11:47447363	PSMC3	0.65	9.74	0.47	6.75e-20	Mean corpuscular hemoglobin;
LUSC	cis	rs4851254	0.618	rs4851243	chr2:100639482	G/A	cg07810366	chr2:100720526	AFF3	-0.47	-6.04	-0.31	4e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg09307838	chr4:120376055	NA	0.71	10.32	0.49	7.35e-22	Corneal astigmatism;
LUSC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.62	-10.43	-0.5	3.2e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg24846343	chr22:24311635	DDTL	0.56	11.32	0.53	2.27e-25	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg00012203	chr2:219082015	ARPC2	-0.56	-8.89	-0.44	3.81e-17	Ulcerative colitis;
LUSC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.71	12.8	0.57	8.38e-31	Prudent dietary pattern;
LUSC	cis	rs4953318	0.694	rs3768747	chr2:46352058	G/T	cg12428440	chr2:46370979	PRKCE	-0.42	-7.69	-0.39	1.67e-13	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg18512352	chr11:47633146	NA	0.47	9.59	0.46	2.21e-19	Subjective well-being;
LUSC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg17376030	chr22:41985996	PMM1	-0.46	-5.73	-0.3	2.3e-8	Vitiligo;
LUSC	trans	rs62055045	0.656	rs112777805	chr16:71425165	G/C	cg15281710	chr15:96890452	NA	-0.43	-5.95	-0.31	6.93e-9	Schizophrenia;
LUSC	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.54	0.5	1.34e-22	Hypertriglyceridemia;
LUSC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg06238570	chr21:40685208	BRWD1	0.48	7.54	0.38	4.41e-13	Cognitive function;
LUSC	cis	rs10992471	0.603	rs6479422	chr9:95190694	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-7.95	-0.4	2.9e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs656319	0.559	rs60384372	chr8:9974584	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.8	-0.35	4.9e-11	Myopia (pathological);
LUSC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg03161606	chr19:29218774	NA	0.6	8.75	0.43	1.08e-16	Methadone dose in opioid dependence;
LUSC	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14829155	chr15:31115871	NA	-0.56	-7.83	-0.39	6.49e-14	Huntington's disease progression;
LUSC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg25767906	chr1:53392781	SCP2	-0.55	-10.73	-0.51	2.88e-23	Monocyte count;
LUSC	cis	rs12200782	1.000	rs4292511	chr6:26622290	G/T	cg11502198	chr6:26597334	ABT1	-0.76	-5.8	-0.3	1.53e-8	Small cell lung carcinoma;
LUSC	cis	rs2455601	0.638	rs2742478	chr11:8996099	G/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-6.7	-0.34	9.05e-11	Schizophrenia;
LUSC	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg22705602	chr4:152727874	NA	-0.32	-6.37	-0.33	6.11e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-6.27	-0.32	1.14e-9	Neuroticism;
LUSC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg20476274	chr7:133979776	SLC35B4	0.84	15.3	0.64	1.96e-40	Mean platelet volume;
LUSC	cis	rs17092148	1.000	rs6058117	chr20:33366905	A/G	cg16810054	chr20:33298113	TP53INP2	-0.43	-6.81	-0.35	4.68e-11	Neuroticism;
LUSC	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg06627628	chr2:24431161	ITSN2	0.84	12.5	0.56	1.12e-29	Asthma;
LUSC	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg10512202	chr3:45649293	LIMD1	0.34	5.85	0.3	1.18e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg05623727	chr3:50126028	RBM5	-0.33	-6.17	-0.32	2.02e-9	Body mass index;
LUSC	cis	rs4746818	0.793	rs2805913	chr10:70858062	A/G	cg11621586	chr10:70884670	VPS26A	0.87	10.87	0.51	9.1e-24	Left atrial antero-posterior diameter;
LUSC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg22800045	chr5:56110881	MAP3K1	-0.65	-9.04	-0.44	1.27e-17	Initial pursuit acceleration;
LUSC	cis	rs6545883	0.929	rs1186710	chr2:61688727	T/A	cg15711740	chr2:61764176	XPO1	-0.44	-6.66	-0.34	1.11e-10	Tuberculosis;
LUSC	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg22681709	chr2:178499509	PDE11A	-0.48	-8.86	-0.44	4.69e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9487051	0.768	rs386696	chr6:109520166	G/A	cg00509249	chr6:109615579	CCDC162	-0.34	-5.88	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs62400317	0.826	rs11970496	chr6:45125833	A/G	cg18551225	chr6:44695536	NA	-0.42	-6.89	-0.35	2.76e-11	Total body bone mineral density;
LUSC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg08888203	chr3:10149979	C3orf24	0.61	8.36	0.42	1.68e-15	Alzheimer's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03425468	chr1:155164676	MIR92B	-0.48	-6.37	-0.33	6.28e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2224391	0.628	rs2773313	chr6:5252213	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.48	-6.73	-0.35	7.62e-11	Height;
LUSC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.31	0.33	8.63e-10	Personality dimensions;
LUSC	cis	rs7577696	0.814	rs479333	chr2:32489158	C/G	cg02381751	chr2:32503542	YIPF4	-0.39	-5.84	-0.3	1.21e-8	Inflammatory biomarkers;
LUSC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg06008330	chr7:65541103	ASL	-0.4	-6.22	-0.32	1.49e-9	Aortic root size;
LUSC	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Smoking initiation;
LUSC	cis	rs2273669	0.504	rs79374607	chr6:109398257	C/T	cg05315195	chr6:109294784	ARMC2	-0.56	-5.91	-0.31	8.4e-9	Prostate cancer;
LUSC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.42	5.88	0.31	9.8e-9	Height;
LUSC	cis	rs672059	1.000	rs625917	chr1:183157991	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.55	7.98	0.4	2.31e-14	Hypertriglyceridemia;
LUSC	cis	rs738322	0.600	rs4821751	chr22:38564457	T/C	cg25457927	chr22:38595422	NA	-0.38	-7.51	-0.38	5.39e-13	Cutaneous nevi;
LUSC	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg22815214	chr1:201083145	CACNA1S	0.54	9.39	0.46	9.49e-19	Permanent tooth development;
LUSC	trans	rs2894969	0.664	rs11252703	chr10:4795125	A/T	cg27081603	chr5:175788876	KIAA1191	0.4	6.31	0.33	9.02e-10	Major depressive disorder;
LUSC	cis	rs61990749	0.597	rs1477262	chr14:78226653	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.62	6.58	0.34	1.78e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02176678	chr2:219576539	TTLL4	-0.72	-13.35	-0.59	7.3e-33	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg14019146	chr3:50243930	SLC38A3	0.36	8.23	0.41	4.28e-15	Body mass index;
LUSC	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg00191853	chr8:101177733	SPAG1	-0.39	-6.47	-0.33	3.49e-10	Atrioventricular conduction;
LUSC	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-10.3	-0.49	8.79e-22	Monocyte percentage of white cells;
LUSC	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.02	0.31	4.7e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs36093844	0.948	rs56271770	chr11:85548400	C/T	cg25872744	chr11:85566296	CCDC83	-0.46	-6.68	-0.34	9.92e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	trans	rs561341	0.689	rs578635	chr17:30289897	A/C	cg20587970	chr11:113659929	NA	-0.62	-8.34	-0.42	2.01e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg22535103	chr8:58192502	C8orf71	-0.67	-7.57	-0.38	3.68e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-9.05	-0.44	1.17e-17	Metabolite levels;
LUSC	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.13	20.88	0.75	1.5e-62	Exhaled nitric oxide output;
LUSC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12311346	chr5:56204834	C5orf35	0.84	13.41	0.59	4.26e-33	Initial pursuit acceleration;
LUSC	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg16797656	chr11:68205561	LRP5	0.38	6.2	0.32	1.62e-9	Total body bone mineral density;
LUSC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg11645453	chr3:52864694	ITIH4	0.34	7.68	0.39	1.76e-13	Bipolar disorder;
LUSC	cis	rs55665837	1.000	rs7945167	chr11:14451820	T/G	cg19336497	chr11:14380999	RRAS2	-0.37	-7.47	-0.38	7.25e-13	Vitamin D levels;
LUSC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.56	8.67	0.43	1.91e-16	Menopause (age at onset);
LUSC	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	0.58	8.93	0.44	2.97e-17	Breast cancer;
LUSC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.92	-0.48	1.7e-20	Hemoglobin concentration;
LUSC	cis	rs11677416	1.000	rs6542092	chr2:113528322	C/G	cg27083787	chr2:113543245	IL1A	0.44	6.97	0.36	1.65e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg22924838	chr2:200715629	NA	0.49	5.99	0.31	5.31e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2274273	0.967	rs2094102	chr14:55591098	T/C	cg04306507	chr14:55594613	LGALS3	0.55	12.71	0.57	1.79e-30	Protein biomarker;
LUSC	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg06363034	chr20:62225388	GMEB2	-0.45	-7.71	-0.39	1.47e-13	Glioblastoma;
LUSC	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.56	-9.25	-0.45	2.75e-18	Breast cancer;
LUSC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg14552801	chr7:65878734	NA	0.38	5.88	0.31	9.94e-9	Aortic root size;
LUSC	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg21427119	chr20:30132790	HM13	-0.42	-6.12	-0.32	2.69e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg00376283	chr12:123451042	ABCB9	0.71	10.93	0.51	5.64e-24	Platelet count;
LUSC	cis	rs1904096	0.506	rs4558832	chr4:95148042	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.37	-0.42	1.57e-15	Type 2 diabetes;
LUSC	cis	rs10465746	0.780	rs7550413	chr1:84423891	T/A	cg10977910	chr1:84465055	TTLL7	0.45	6.51	0.34	2.77e-10	Obesity-related traits;
LUSC	trans	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-7.43	-0.38	8.88e-13	Morning vs. evening chronotype;
LUSC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg10360139	chr7:1886902	MAD1L1	-0.46	-7.21	-0.37	3.66e-12	Bipolar disorder and schizophrenia;
LUSC	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg27411982	chr8:10470053	RP1L1	0.41	6.29	0.33	1.02e-9	Neuroticism;
LUSC	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg22782873	chr19:19639568	YJEFN3	0.49	6.17	0.32	2e-9	Bipolar disorder;
LUSC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-10.19	-0.49	2.08e-21	Bipolar disorder;
LUSC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg21782813	chr7:2030301	MAD1L1	0.35	5.79	0.3	1.61e-8	Schizophrenia;
LUSC	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg15147215	chr3:52552868	STAB1	-0.3	-5.98	-0.31	5.71e-9	Electroencephalogram traits;
LUSC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg05043794	chr9:111880884	C9orf5	-0.33	-7.04	-0.36	1.13e-11	Menarche (age at onset);
LUSC	cis	rs2298450	1.000	rs2298450	chr21:37623447	C/T	cg02919814	chr21:37666008	DOPEY2	-0.43	-6.33	-0.33	8.11e-10	Schizophrenia;
LUSC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg18306943	chr3:40428807	ENTPD3	0.37	5.67	0.3	3.12e-8	Renal cell carcinoma;
LUSC	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg10518572	chr11:65560635	OVOL1	-0.25	-5.75	-0.3	1.97e-8	Acne (severe);
LUSC	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg01028140	chr2:1542097	TPO	-0.37	-6.08	-0.32	3.19e-9	IgG glycosylation;
LUSC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-0.91	-17.2	-0.69	6.01e-48	Heart rate;
LUSC	cis	rs9487051	0.735	rs1146246	chr6:109519741	C/T	cg01475377	chr6:109611718	NA	-0.36	-6.11	-0.32	2.7e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-10.44	-0.5	2.9e-22	Alzheimer's disease (late onset);
LUSC	cis	rs9815354	0.680	rs115754309	chr3:42017246	A/G	cg03022575	chr3:42003672	ULK4	0.76	7.6	0.38	3e-13	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	7.08	0.36	8.62e-12	Neuroticism;
LUSC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg05665937	chr4:1216051	CTBP1	0.38	5.98	0.31	5.89e-9	Obesity-related traits;
LUSC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg09455208	chr3:40491958	NA	-0.52	-9.7	-0.47	9.02e-20	Renal cell carcinoma;
LUSC	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05901451	chr6:126070800	HEY2	0.78	12.65	0.57	2.99e-30	Endometrial cancer;
LUSC	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.62	9.98	0.48	1.1e-20	Blood metabolite ratios;
LUSC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.8	-13.99	-0.61	2.63e-35	Cognitive function;
LUSC	trans	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg10840412	chr1:235813424	GNG4	0.51	6.12	0.32	2.63e-9	Neuroticism;
LUSC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg25019033	chr10:957182	NA	-0.52	-5.94	-0.31	7.24e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.6	-8.7	-0.43	1.59e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08048268	chr3:133502702	NA	0.47	8.96	0.44	2.35e-17	Iron status biomarkers;
LUSC	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg26924012	chr15:45694286	SPATA5L1	0.77	11.96	0.55	1.09e-27	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg24579218	chr15:68104479	NA	-0.38	-6.74	-0.35	7.08e-11	Restless legs syndrome;
LUSC	cis	rs9420	0.961	rs11601320	chr11:57642617	T/C	cg23127183	chr11:57508653	C11orf31	-0.54	-7.84	-0.39	6e-14	Schizophrenia;
LUSC	cis	rs977987	0.843	rs10431974	chr16:75435461	A/G	cg03315344	chr16:75512273	CHST6	0.48	8.91	0.44	3.31e-17	Dupuytren's disease;
LUSC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg09699651	chr6:150184138	LRP11	0.37	5.78	0.3	1.7e-8	Lung cancer;
LUSC	trans	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg19676328	chr12:49525230	TUBA1B	-0.54	-7.74	-0.39	1.19e-13	Total cholesterol levels;
LUSC	cis	rs2797160	0.547	rs9401836	chr6:125956736	T/C	cg05901451	chr6:126070800	HEY2	-0.42	-5.91	-0.31	8.39e-9	Endometrial cancer;
LUSC	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg02023728	chr11:77925099	USP35	0.48	7.08	0.36	8.8e-12	Testicular germ cell tumor;
LUSC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.23	-14.17	-0.61	5.08e-36	Gout;
LUSC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg12963246	chr6:28129442	ZNF389	0.5	6.45	0.33	4.02e-10	Parkinson's disease;
LUSC	cis	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg24459738	chr19:57751996	ZNF805	-0.52	-7.69	-0.39	1.66e-13	Hyperactive-impulsive symptoms;
LUSC	trans	rs6601327	0.670	rs7004937	chr8:9420961	T/A	cg15556689	chr8:8085844	FLJ10661	0.45	6.39	0.33	5.51e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	6.98	0.36	1.6e-11	Bipolar disorder;
LUSC	trans	rs12439619	0.846	rs7496227	chr15:82567582	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.5	-6.66	-0.34	1.1e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg19676328	chr12:49525230	TUBA1B	-0.5	-7.92	-0.4	3.59e-14	Total cholesterol levels;
LUSC	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg14582100	chr15:45693742	SPATA5L1	0.57	10.11	0.48	3.85e-21	Homoarginine levels;
LUSC	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg00944433	chr1:107599041	PRMT6	-0.35	-6.27	-0.32	1.1e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg12826209	chr6:26865740	GUSBL1	0.77	7.67	0.39	1.92e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg06784218	chr1:46089804	CCDC17	0.48	9.43	0.46	7e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.89	0.35	2.81e-11	Tonsillectomy;
LUSC	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.74	-11.69	-0.54	1.07e-26	Schizophrenia;
LUSC	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg27411982	chr8:10470053	RP1L1	-0.37	-5.91	-0.31	8.24e-9	Retinal vascular caliber;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17713864	chr17:48784765	ANKRD40	-0.46	-6.18	-0.32	1.87e-9	Hepatitis;
LUSC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.33	-0.49	7.12e-22	Platelet count;
LUSC	cis	rs8077889	0.703	rs231534	chr17:41945564	C/T	cg26893861	chr17:41843967	DUSP3	-0.81	-10.59	-0.5	8.59e-23	Triglycerides;
LUSC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg12935359	chr14:103987150	CKB	-0.52	-8.07	-0.4	1.24e-14	Body mass index;
LUSC	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg09904177	chr6:26538194	HMGN4	0.68	12.18	0.55	1.72e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg13072238	chr3:49761600	GMPPB	0.39	6.42	0.33	4.61e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.67	0.6	4.46e-34	Cognitive test performance;
LUSC	cis	rs10740039	0.768	rs10994432	chr10:62383589	A/T	cg18175470	chr10:62150864	ANK3	-0.45	-6.65	-0.34	1.22e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.78e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	6.88	0.35	2.95e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs354225	0.544	rs12713265	chr2:54805409	C/T	cg01766943	chr2:54829624	SPTBN1	0.46	7.43	0.38	8.96e-13	Schizophrenia;
LUSC	cis	rs4423214	0.650	rs2186777	chr11:71219803	C/A	cg05163923	chr11:71159392	DHCR7	0.61	8.05	0.4	1.46e-14	Vitamin D levels;
LUSC	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg02574844	chr11:5959923	NA	-0.45	-6.36	-0.33	6.66e-10	DNA methylation (variation);
LUSC	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg17385448	chr1:15911702	AGMAT	0.35	5.97	0.31	6.18e-9	Systolic blood pressure;
LUSC	cis	rs2835872	0.758	rs1709820	chr21:39035971	A/C	cg20424643	chr21:39039972	KCNJ6	-0.44	-7.35	-0.37	1.57e-12	Electroencephalographic traits in alcoholism;
LUSC	cis	rs2729354	0.953	rs1846567	chr11:57357593	T/C	cg24343310	chr11:57249947	NA	0.36	6.53	0.34	2.48e-10	Blood protein levels;
LUSC	cis	rs4474465	1.000	rs10899506	chr11:78168705	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.66	-0.3	3.32e-8	Alzheimer's disease (survival time);
LUSC	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg18825076	chr15:78729989	IREB2	-0.5	-7.85	-0.39	5.8e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.64	10.11	0.48	3.85e-21	Alcohol dependence;
LUSC	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.24	-11.41	-0.53	1.14e-25	Reticulocyte fraction of red cells;Reticulocyte count;
LUSC	cis	rs2559856	1.000	rs10778139	chr12:102083202	C/T	cg12924262	chr12:102091054	CHPT1	-0.42	-5.86	-0.31	1.12e-8	Blood protein levels;
LUSC	cis	rs62400317	0.859	rs55779653	chr6:45265960	C/T	cg18551225	chr6:44695536	NA	-0.42	-7.08	-0.36	8.7e-12	Total body bone mineral density;
LUSC	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg18578876	chr12:123200353	GPR109B	-0.87	-7.06	-0.36	9.48e-12	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LUSC	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg03806693	chr22:41940476	POLR3H	-0.96	-13.04	-0.58	1.08e-31	Vitiligo;
LUSC	cis	rs238295	0.805	rs6053499	chr20:5542546	C/T	cg15842884	chr20:5591925	RP5-1022P6.2	-0.41	-5.77	-0.3	1.84e-8	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs4690686	0.500	rs7667671	chr4:177275599	T/C	cg17059388	chr4:177262070	NA	0.47	8.66	0.43	2.06e-16	Essential tremor;
LUSC	cis	rs4474465	0.688	rs10793336	chr11:78281867	A/G	cg27205649	chr11:78285834	NARS2	0.56	6.74	0.35	7.04e-11	Alzheimer's disease (survival time);
LUSC	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg13010199	chr12:38710504	ALG10B	0.67	10.19	0.49	2.03e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7215564	0.908	rs4889884	chr17:78664465	A/G	cg23238734	chr17:78661607	RPTOR	0.48	6.12	0.32	2.63e-9	Myopia (pathological);
LUSC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg14458575	chr2:238380390	NA	0.74	12.98	0.58	1.84e-31	Prostate cancer;
LUSC	cis	rs7246657	0.551	rs11084873	chr19:37583910	A/G	cg23950597	chr19:37808831	NA	-0.55	-6.05	-0.31	3.86e-9	Coronary artery calcification;
LUSC	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg01620082	chr3:125678407	NA	-0.7	-7.25	-0.37	2.89e-12	Depression;
LUSC	cis	rs7000551	0.751	rs1116085	chr8:22394920	A/G	cg12081754	chr8:22256438	SLC39A14	0.43	6.4	0.33	5.15e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.88	-0.31	9.83e-9	Resting heart rate;
LUSC	trans	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg03886242	chr7:26192032	NFE2L3	-0.41	-6.25	-0.32	1.28e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs75920871	0.588	rs7119185	chr11:116886096	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-6.7	-0.34	8.86e-11	Subjective well-being;
LUSC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.84	12.9	0.58	3.62e-31	Smoking behavior;
LUSC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg10253484	chr15:75165896	SCAMP2	-0.49	-7.46	-0.38	7.72e-13	Breast cancer;
LUSC	cis	rs926938	0.527	rs360583	chr1:115462743	C/T	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.44	-0.33	4.23e-10	Autism;
LUSC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg22437258	chr11:111473054	SIK2	0.48	6.51	0.34	2.69e-10	Primary sclerosing cholangitis;
LUSC	cis	rs11630290	0.640	rs1811744	chr15:64167428	T/C	cg12036633	chr15:63758958	NA	0.5	6.1	0.32	2.89e-9	Iris characteristics;
LUSC	cis	rs8077577	0.945	rs997315	chr17:18085286	A/G	cg16794390	chr17:18148240	FLII	0.44	6.19	0.32	1.72e-9	Obesity-related traits;
LUSC	cis	rs11997175	0.646	rs6468197	chr8:33734894	G/T	ch.8.33884649F	chr8:33765107	NA	0.53	8.04	0.4	1.59e-14	Body mass index;
LUSC	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-0.81	-12.68	-0.57	2.35e-30	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg10909506	chr17:38081995	ORMDL3	0.32	5.68	0.3	2.88e-8	Self-reported allergy;
LUSC	cis	rs1865721	1.000	rs11659761	chr18:73186974	A/G	cg26385618	chr18:73139727	C18orf62	-0.43	-6.94	-0.35	2.07e-11	Intelligence;
LUSC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg16447950	chr5:562315	NA	-0.43	-6.4	-0.33	5.4e-10	Obesity-related traits;
LUSC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg06096015	chr1:231504339	EGLN1	0.58	10.39	0.49	4.2e-22	Hemoglobin concentration;
LUSC	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg15448220	chr1:150897856	SETDB1	0.4	5.85	0.3	1.18e-8	Melanoma;
LUSC	cis	rs11168618	0.743	rs12815151	chr12:48874836	A/C	cg24011408	chr12:48396354	COL2A1	0.38	6.06	0.31	3.62e-9	Adiponectin levels;
LUSC	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg13010199	chr12:38710504	ALG10B	0.64	10.0	0.48	9.35e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg25036284	chr2:26402008	FAM59B	-0.68	-9.64	-0.47	1.49e-19	Gut microbiome composition (summer);
LUSC	cis	rs977987	0.806	rs35787595	chr16:75466847	G/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.4e-11	Dupuytren's disease;
LUSC	cis	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg02972257	chr16:68554789	NA	-0.51	-6.26	-0.32	1.21e-9	Ulcerative colitis;
LUSC	cis	rs9929218	0.911	rs4783686	chr16:68834156	C/G	cg02972257	chr16:68554789	NA	0.42	5.74	0.3	2.09e-8	Colorectal cancer;
LUSC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg07507251	chr3:52567010	NT5DC2	0.36	6.91	0.35	2.39e-11	Bipolar disorder;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg01855118	chr6:157007725	NA	0.45	6.66	0.34	1.15e-10	Triglycerides;
LUSC	cis	rs2652834	0.528	rs12908992	chr15:63428427	A/G	cg05507819	chr15:63340323	TPM1	-0.82	-6.28	-0.33	1.03e-9	HDL cholesterol;
LUSC	cis	rs922692	0.744	rs4886592	chr15:79082547	T/C	cg00540400	chr15:79124168	NA	-0.41	-7.08	-0.36	8.5e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg04414720	chr1:150670196	GOLPH3L	0.52	8.31	0.41	2.42e-15	Melanoma;
LUSC	cis	rs4737010	0.501	rs12548116	chr8:41645074	A/G	cg17182837	chr8:41585554	ANK1	-0.38	-6.69	-0.34	9.23e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg01528321	chr10:82214614	TSPAN14	0.64	9.49	0.46	4.45e-19	Post bronchodilator FEV1;
LUSC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07677032	chr17:61819896	STRADA	0.54	9.15	0.45	5.76e-18	Prudent dietary pattern;
LUSC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg19747945	chr6:42946146	PEX6	-0.34	-5.67	-0.3	3.11e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-8.8	-0.43	7.6e-17	Bipolar disorder;
LUSC	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg08601574	chr20:25228251	PYGB	0.44	6.76	0.35	6.18e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.2	0.41	5.24e-15	Homoarginine levels;
LUSC	cis	rs981844	1.000	rs62325092	chr4:154668674	T/C	cg14289246	chr4:154710475	SFRP2	0.48	6.03	0.31	4.34e-9	Response to statins (LDL cholesterol change);
LUSC	trans	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg04492929	chr16:2155436	PKD1	-0.31	-6.03	-0.31	4.36e-9	Triglycerides;
LUSC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	8.87	0.44	4.51e-17	Prudent dietary pattern;
LUSC	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-5.76	-0.3	1.88e-8	Ulcerative colitis;
LUSC	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg10820045	chr2:198174542	NA	-0.33	-6.02	-0.31	4.49e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg20276088	chr3:133502917	NA	0.37	5.69	0.3	2.78e-8	Iron status biomarkers;
LUSC	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg19812747	chr11:111475976	SIK2	0.55	7.85	0.39	5.81e-14	Primary sclerosing cholangitis;
LUSC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08677398	chr8:58056175	NA	0.53	7.08	0.36	8.75e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg08470875	chr2:26401718	FAM59B	0.75	9.99	0.48	1e-20	Gut microbiome composition (summer);
LUSC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26314531	chr2:26401878	FAM59B	-0.68	-9.11	-0.45	7.87e-18	Gut microbiome composition (summer);
LUSC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg09034736	chr1:150693464	HORMAD1	-0.48	-7.09	-0.36	8.03e-12	Tonsillectomy;
LUSC	cis	rs806215	1.000	rs806214	chr7:127237003	C/T	cg25922125	chr7:127225783	GCC1	-0.59	-7.15	-0.36	5.49e-12	Type 2 diabetes;
LUSC	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg00745463	chr17:30367425	LRRC37B	-0.71	-8.74	-0.43	1.14e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19346786	chr7:2764209	NA	0.39	6.74	0.35	6.9e-11	Height;
LUSC	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg23752985	chr2:85803571	VAMP8	-0.31	-6.57	-0.34	1.91e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7523273	0.526	rs1204706	chr1:208021060	G/T	cg22525895	chr1:207977042	MIR29B2	-0.39	-6.28	-0.32	1.06e-9	Schizophrenia;
LUSC	trans	rs7939886	0.920	rs7112964	chr11:55866408	T/C	cg15704280	chr7:45808275	SEPT13	0.79	6.65	0.34	1.23e-10	Myopia (pathological);
LUSC	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	10.36	0.49	5.24e-22	Response to antipsychotic treatment;
LUSC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg15448220	chr1:150897856	SETDB1	0.44	6.49	0.33	3.08e-10	Melanoma;
LUSC	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.52	-0.34	2.67e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6495367	1.000	rs755362	chr15:79376601	C/T	cg17916960	chr15:79447300	NA	-0.35	-6.59	-0.34	1.67e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21643547	chr1:205240462	TMCC2	-0.5	-9.54	-0.46	3e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg21017887	chr14:105400489	NA	0.66	12.75	0.57	1.34e-30	Rheumatoid arthritis;
LUSC	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg13852791	chr20:30311386	BCL2L1	0.91	11.5	0.53	5.28e-26	Mean corpuscular hemoglobin;
LUSC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.5	-7.98	-0.4	2.37e-14	Longevity;Endometriosis;
LUSC	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg22563815	chr15:78856949	CHRNA5	0.26	6.23	0.32	1.37e-9	Sudden cardiac arrest;
LUSC	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg08680598	chr22:49984980	NA	-0.33	-6.23	-0.32	1.4e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg13010199	chr12:38710504	ALG10B	-0.62	-10.36	-0.49	5.5e-22	Heart rate;
LUSC	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.36	5.68	0.3	2.94e-8	Ulcerative colitis;
LUSC	cis	rs6580649	0.941	rs726354	chr12:48500334	G/A	cg24011408	chr12:48396354	COL2A1	-0.45	-6.1	-0.32	2.9e-9	Lung cancer;
LUSC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	1.0	24.24	0.8	1.32e-75	Multiple system atrophy;
LUSC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12667521	chr19:29218732	NA	0.62	8.99	0.44	1.87e-17	Methadone dose in opioid dependence;
LUSC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.95	-0.31	6.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg18225595	chr11:63971243	STIP1	-0.47	-7.62	-0.38	2.71e-13	Platelet count;
LUSC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05165339	chr4:1420672	NA	-0.3	-6.94	-0.35	2.09e-11	Longevity;
LUSC	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg17173187	chr15:85201210	NMB	0.37	6.37	0.33	6.23e-10	Schizophrenia;
LUSC	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg12483005	chr1:23474871	LUZP1	0.42	6.62	0.34	1.4e-10	Height;
LUSC	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg00376283	chr12:123451042	ABCB9	0.65	8.22	0.41	4.63e-15	Neutrophil percentage of white cells;
LUSC	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg00376283	chr12:123451042	ABCB9	0.67	8.36	0.42	1.68e-15	Neutrophil percentage of white cells;
LUSC	cis	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.89	-0.31	9.61e-9	Ulcerative colitis;
LUSC	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.31	5.84	0.3	1.24e-8	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg22709100	chr7:91322751	NA	0.4	5.85	0.3	1.17e-8	Breast cancer;
LUSC	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.59	-0.34	1.73e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg13047869	chr3:10149882	C3orf24	0.61	8.67	0.43	1.93e-16	Alzheimer's disease;
LUSC	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg02454025	chr1:11042201	C1orf127	1.03	18.59	0.71	1.77e-53	Ewing sarcoma;
LUSC	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.63	-10.59	-0.5	8.65e-23	Post bronchodilator FEV1;
LUSC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg25456477	chr12:86230367	RASSF9	-0.32	-5.65	-0.3	3.46e-8	Major depressive disorder;
LUSC	cis	rs62400317	0.859	rs12199256	chr6:45303493	T/G	cg18551225	chr6:44695536	NA	-0.45	-7.44	-0.38	8.38e-13	Total body bone mineral density;
LUSC	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.53	-0.5	1.46e-22	Coffee consumption (cups per day);
LUSC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.71	-0.34	8.54e-11	Lung cancer;
LUSC	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg24531977	chr5:56204891	C5orf35	-0.57	-8.2	-0.41	5.16e-15	Coronary artery disease;
LUSC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg17211192	chr8:82754475	SNX16	0.81	11.11	0.52	1.32e-24	Diastolic blood pressure;
LUSC	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.9	14.83	0.63	1.4e-38	Testicular germ cell tumor;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17105151	chr1:32666292	CCDC28B	0.42	6.19	0.32	1.77e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1395	0.778	rs1978881	chr2:27400850	C/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.49	7.26	0.37	2.77e-12	Blood metabolite levels;
LUSC	cis	rs2249625	0.545	rs2496488	chr6:72875985	A/T	cg18830697	chr6:72922368	RIMS1	-0.36	-7.26	-0.37	2.69e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.43	-5.75	-0.3	2.05e-8	Coronary artery disease;
LUSC	cis	rs8099014	0.861	rs8097365	chr18:56131080	G/A	cg12907477	chr18:56117327	MIR122	0.46	7.02	0.36	1.28e-11	Platelet count;
LUSC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.43	-6.28	-0.33	1.03e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg02023728	chr11:77925099	USP35	0.44	6.52	0.34	2.64e-10	Testicular germ cell tumor;
LUSC	cis	rs7561273	0.586	rs4149372	chr2:24305512	T/G	cg20701182	chr2:24300061	SF3B14	0.51	6.58	0.34	1.78e-10	Quantitative traits;
LUSC	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg05340658	chr4:99064831	C4orf37	0.63	10.64	0.5	5.75e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	13.84	0.6	9.47e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-1.15	-18.32	-0.71	2.27e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg17467752	chr17:38218738	THRA	0.5	7.39	0.37	1.17e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg21238619	chr17:78079768	GAA	0.46	8.68	0.43	1.81e-16	Yeast infection;
LUSC	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.54	-6.99	-0.36	1.52e-11	Schizophrenia;
LUSC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.72	9.62	0.47	1.67e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.7	10.51	0.5	1.6400000000000001e-22	Dilated cardiomyopathy;
LUSC	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.62	-7.12	-0.36	6.86e-12	Iron status biomarkers;
LUSC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg04013166	chr16:89971882	TCF25	0.62	7.24	0.37	3.1e-12	Skin colour saturation;
LUSC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg10968187	chr4:17616003	MED28	-0.38	-5.69	-0.3	2.71e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg18721089	chr20:30220636	NA	-0.41	-6.49	-0.33	3.1e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg17691542	chr6:26056736	HIST1H1C	0.67	9.98	0.48	1.03e-20	Height;
LUSC	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.84	13.62	0.6	6.77e-34	Bladder cancer;
LUSC	cis	rs4704187	0.687	rs9293642	chr5:74365026	C/T	cg03227963	chr5:74354835	NA	0.32	6.99	0.36	1.49e-11	Response to amphetamines;
LUSC	cis	rs7760535	0.763	rs10457240	chr6:111848874	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.4	-7.63	-0.39	2.49e-13	Metabolic traits;
LUSC	cis	rs2019216	0.542	rs7405615	chr17:21935430	C/G	cg22648282	chr17:21454238	C17orf51	-0.53	-7.71	-0.39	1.46e-13	Pelvic organ prolapse;
LUSC	cis	rs9815354	1.000	rs1564716	chr3:41862613	A/G	cg03022575	chr3:42003672	ULK4	0.59	6.57	0.34	1.93e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14442939	chr10:27389572	ANKRD26	0.84	9.84	0.47	3.2e-20	Breast cancer;
LUSC	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg24851651	chr11:66362959	CCS	-0.4	-6.52	-0.34	2.63e-10	Educational attainment (years of education);
LUSC	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg12863693	chr15:85201151	NMB	0.34	6.15	0.32	2.27e-9	Schizophrenia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg17843125	chr1:100598159	SASS6;CCDC76	-0.41	-5.96	-0.31	6.58e-9	Hepatitis;
LUSC	trans	rs953492	0.672	rs10926964	chr1:243359347	G/A	cg04438194	chr4:119512985	NA	-0.41	-6.05	-0.31	3.86e-9	Diastolic blood pressure;
LUSC	cis	rs7147624	0.938	rs10467734	chr14:65913947	C/T	cg03016385	chr14:66212404	NA	-0.85	-9.62	-0.47	1.74e-19	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs4596713	0.568	rs7034179	chr9:71746838	C/T	cg25283916	chr1:242222868	NA	-0.3	-6.17	-0.32	2e-9	Headache;
LUSC	cis	rs17253792	0.822	rs8018142	chr14:56173288	C/T	cg01858014	chr14:56050164	KTN1	-0.74	-6.32	-0.33	8.44e-10	Putamen volume;
LUSC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg18404041	chr3:52824283	ITIH1	-0.43	-7.39	-0.37	1.21e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.68	0.39	1.75e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg09399716	chr2:46890238	NA	-0.42	-8.95	-0.44	2.52e-17	Height;
LUSC	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	18.81	0.72	2.36e-54	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg13628971	chr7:2884303	GNA12	0.46	6.66	0.34	1.14e-10	Height;
LUSC	cis	rs2230307	0.536	rs490669	chr1:100484430	C/T	cg24955406	chr1:100503596	HIAT1	0.57	6.14	0.32	2.35e-9	Carotid intima media thickness;
LUSC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.35	0.59	7.08e-33	Cognitive test performance;
LUSC	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg05729581	chr11:3078854	CARS	0.4	5.92	0.31	7.83e-9	Calcium levels;
LUSC	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg05555928	chr11:63887634	MACROD1	-0.49	-6.05	-0.31	3.95e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06320606	chr5:60139941	ELOVL7	-0.51	-6.66	-0.34	1.16e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.03	0.58	1.11e-31	Chronic sinus infection;
LUSC	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg15744005	chr10:104629667	AS3MT	-0.33	-6.79	-0.35	5.08e-11	Arsenic metabolism;
LUSC	trans	rs12651329	1.000	rs12651329	chr4:36079594	A/G	cg25296646	chr22:38349726	POLR2F;C22orf23	-0.39	-6.25	-0.32	1.29e-9	Amyotrophic lateral sclerosis (age of onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08134618	chr7:8008133	GLCCI1	-0.47	-7.06	-0.36	9.81e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.62	-0.39	2.57e-13	Pulmonary function;
LUSC	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg04287289	chr16:89883240	FANCA	0.47	6.85	0.35	3.5e-11	Hemoglobin concentration;
LUSC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg06784218	chr1:46089804	CCDC17	0.47	9.26	0.45	2.6e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19717773	chr7:2847554	GNA12	-0.34	-5.68	-0.3	2.95e-8	Height;
LUSC	cis	rs72960926	0.744	rs115559526	chr6:75027796	T/G	cg03266952	chr6:74778945	NA	-0.87	-6.36	-0.33	6.5e-10	Metabolite levels (MHPG);
LUSC	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg23093090	chr10:104574429	C10orf26	-0.46	-5.74	-0.3	2.12e-8	Arsenic metabolism;
LUSC	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.31	-6.31	-0.33	8.62e-10	Total body bone mineral density;
LUSC	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg20243544	chr17:37824526	PNMT	0.5	7.21	0.37	3.83e-12	Asthma;
LUSC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.68	0.7	7.58e-50	Chronic sinus infection;
LUSC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg19912559	chr1:40204330	PPIE	0.53	8.18	0.41	6.17e-15	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12044295	chr8:56686133	TMEM68;TGS1	-0.41	-6.41	-0.33	4.84e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.54	7.47	0.38	7.14e-13	Breast cancer;
LUSC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg20821713	chr7:1055600	C7orf50	-0.48	-6.59	-0.34	1.74e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06481639	chr22:41940642	POLR3H	-0.48	-5.99	-0.31	5.38e-9	Vitiligo;
LUSC	cis	rs4812048	0.649	rs6100319	chr20:57626568	A/C	cg14073986	chr20:57617431	SLMO2	0.88	9.5	0.46	4.16e-19	Mean platelet volume;
LUSC	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.56	-9.23	-0.45	3.27e-18	Breast cancer;
LUSC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.59	-11.34	-0.53	2.02e-25	Pulse pressure;
LUSC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	5e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11168618	0.904	rs10875829	chr12:48927197	A/C	cg24011408	chr12:48396354	COL2A1	0.39	6.34	0.33	7.56e-10	Adiponectin levels;
LUSC	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg10840412	chr1:235813424	GNG4	0.68	9.13	0.45	6.54e-18	Bipolar disorder;
LUSC	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg19318889	chr4:1322082	MAEA	0.43	5.66	0.3	3.22e-8	Recombination rate (females);
LUSC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg17971929	chr21:40555470	PSMG1	0.65	10.44	0.5	2.87e-22	Cognitive function;
LUSC	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	trans	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	9.79	0.47	4.65e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg10755058	chr3:40428713	ENTPD3	0.36	5.83	0.3	1.29e-8	Renal cell carcinoma;
LUSC	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	6.74	0.35	6.82e-11	Schizophrenia;
LUSC	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.41	0.53	1.08e-25	Eye color traits;
LUSC	cis	rs668210	0.793	rs590531	chr11:65773939	C/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.59	-7.62	-0.38	2.73e-13	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.93	0.31	7.55e-9	Rheumatoid arthritis;
LUSC	cis	rs6714710	0.603	rs11123974	chr2:98605982	A/G	cg26665480	chr2:98280029	ACTR1B	0.56	8.08	0.4	1.18e-14	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs9865818	0.702	rs6790260	chr3:188117079	C/G	cg23651889	chr3:188115336	LPP	0.39	5.92	0.31	8.07e-9	Allergic sensitization;
LUSC	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg21770322	chr7:97807741	LMTK2	0.4	7.05	0.36	1.06e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.52	-0.38	5.06e-13	Height;
LUSC	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg20503657	chr10:835505	NA	0.78	9.77	0.47	5.42e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg11941060	chr3:133502564	NA	-0.53	-8.03	-0.4	1.67e-14	Iron status biomarkers;
LUSC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03352830	chr11:487213	PTDSS2	0.68	8.61	0.43	2.91e-16	Body mass index;
LUSC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg05347473	chr6:146136440	FBXO30	0.5	8.45	0.42	8.88e-16	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00959118	chr1:169455055	SLC19A2	-0.4	-6.04	-0.31	4.1e-9	Hepatitis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg14173624	chr17:72199366	RPL38	0.43	6.43	0.33	4.42e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs62238980	0.614	rs80035296	chr22:32387536	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5.04e-9	Childhood ear infection;
LUSC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.85	0.31	1.15e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1865721	0.839	rs59718187	chr18:73144032	C/T	cg26385618	chr18:73139727	C18orf62	-0.53	-9.69	-0.47	9.64e-20	Intelligence;
LUSC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg16928487	chr17:17741425	SREBF1	0.38	7.29	0.37	2.3e-12	Total body bone mineral density;
LUSC	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg22906224	chr7:99728672	NA	-0.47	-6.58	-0.34	1.84e-10	Coronary artery disease;
LUSC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg25767906	chr1:53392781	SCP2	0.52	9.56	0.46	2.72e-19	Monocyte count;
LUSC	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg24558204	chr6:135376177	HBS1L	0.58	9.0	0.44	1.69e-17	Red blood cell count;
LUSC	cis	rs17621444	0.522	rs10886574	chr10:121792801	C/T	cg02041677	chr10:121771263	NA	-0.34	-6.32	-0.33	8.17e-10	IgG glycosylation;
LUSC	cis	rs7614311	0.731	rs56126667	chr3:63866286	A/G	cg22134162	chr3:63841271	THOC7	-0.49	-6.07	-0.32	3.43e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg01256987	chr12:42539512	GXYLT1	-0.46	-8.71	-0.43	1.47e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.01	-0.31	4.85e-9	Depression;
LUSC	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-1.04	-12.57	-0.57	6.35e-30	Schizophrenia;
LUSC	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	10.16	0.49	2.57e-21	Response to antipsychotic treatment;
LUSC	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg03676636	chr4:99064102	C4orf37	0.36	7.77	0.39	9.65e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-8.2	-0.41	5.37e-15	Body mass index;
LUSC	trans	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg19862616	chr7:65841803	NCRNA00174	0.85	9.66	0.47	1.22e-19	Eotaxin levels;
LUSC	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg09904177	chr6:26538194	HMGN4	0.66	11.81	0.54	3.86e-27	Intelligence (multi-trait analysis);
LUSC	trans	rs1325195	0.920	rs2816209	chr1:179171494	A/G	cg11624085	chr17:8464688	MYH10	0.44	6.91	0.35	2.49e-11	IgE grass sensitization;
LUSC	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	0.93	12.58	0.57	5.56e-30	Primary sclerosing cholangitis;
LUSC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg13607699	chr17:42295918	UBTF	-0.73	-12.67	-0.57	2.61e-30	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg08000102	chr2:233561755	GIGYF2	0.8	13.3	0.59	1.09e-32	Schizophrenia;
LUSC	cis	rs2835872	0.965	rs17814920	chr21:39015897	C/T	cg20424643	chr21:39039972	KCNJ6	0.41	6.17	0.32	1.97e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.83	-0.3	1.32e-8	Coronary artery disease;
LUSC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	16.33	0.67	1.77e-44	Platelet count;
LUSC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg23630131	chr7:65973040	NA	0.21	5.94	0.31	7.16e-9	Aortic root size;
LUSC	cis	rs60015123	0.850	rs57438850	chr12:7100540	C/T	cg26269324	chr12:6977084	TPI1	0.78	6.01	0.31	4.91e-9	Red cell distribution width;
LUSC	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.14	0.32	2.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.71	-0.6	2.98e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs68092024	0.704	rs704575	chr3:99486075	A/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.36	-7.02	-0.36	1.28e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs599083	0.793	rs471966	chr11:68173861	C/T	cg16797656	chr11:68205561	LRP5	-0.38	-6.31	-0.33	8.85e-10	Bone mineral density (spine);
LUSC	trans	rs11039798	0.541	rs11040166	chr11:48965449	T/C	cg03929089	chr4:120376271	NA	0.73	6.31	0.33	8.91e-10	Axial length;
LUSC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg11645453	chr3:52864694	ITIH4	0.35	8.16	0.41	6.82e-15	Bipolar disorder;
LUSC	cis	rs3106136	1.000	rs2664871	chr4:95146281	A/G	cg11021082	chr4:95130006	SMARCAD1	0.34	6.11	0.32	2.76e-9	Capecitabine sensitivity;
LUSC	cis	rs6599077	1.000	rs2068978	chr3:40095238	T/C	cg13683864	chr3:40499215	RPL14	-0.6	-7.66	-0.39	2.06e-13	Sleep-related phenotypes;
LUSC	cis	rs2200578	1.000	rs60025964	chr2:99880577	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.57	6.55	0.34	2.16e-10	IgG glycosylation;
LUSC	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.87	14.25	0.61	2.49e-36	Bladder cancer;
LUSC	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.31	-0.37	2.01e-12	Bipolar disorder;
LUSC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.58	-0.38	3.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	10.43	0.5	3.17e-22	Hemoglobin concentration;
LUSC	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg14675211	chr2:100938903	LONRF2	0.37	5.73	0.3	2.29e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg26395211	chr5:140044315	WDR55	0.45	6.99	0.36	1.5e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.68	-0.34	1.03e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9403521	0.947	rs7741424	chr6:143981662	G/A	cg18240653	chr6:144019428	PHACTR2	-0.52	-6.16	-0.32	2.13e-9	Obesity-related traits;
LUSC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1451375	0.698	rs12669770	chr7:50656334	G/A	cg18232548	chr7:50535776	DDC	0.51	7.55	0.38	4.29e-13	Malaria;
LUSC	cis	rs3862260	0.967	rs3862261	chr1:120160822	G/A	cg11530693	chr1:120165357	ZNF697	0.51	7.92	0.4	3.49e-14	Systemic lupus erythematosus;
LUSC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-5.84	-0.3	1.21e-8	Tonsillectomy;
LUSC	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.06e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	11.03	0.52	2.45e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg21951975	chr1:209979733	IRF6	-0.48	-8.18	-0.41	5.98e-15	Orofacial clefts;
LUSC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.63e-17	Motion sickness;
LUSC	cis	rs9640161	0.830	rs11972067	chr7:150071605	G/A	cg17279839	chr7:150038598	RARRES2	0.35	5.76	0.3	1.92e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg12463550	chr7:65579703	CRCP	-0.42	-6.2	-0.32	1.64e-9	Aortic root size;
LUSC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.51e-14	Prudent dietary pattern;
LUSC	cis	rs2073300	1.000	rs6137976	chr20:23463241	C/T	cg12062639	chr20:23401060	NAPB	0.73	5.67	0.3	3.06e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07080220	chr10:102295463	HIF1AN	0.63	8.36	0.42	1.71e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg18825076	chr15:78729989	IREB2	-0.43	-5.91	-0.31	8.37e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7193541	0.965	rs8050262	chr16:74661159	T/C	cg01733217	chr16:74700730	RFWD3	0.86	14.94	0.63	5.22e-39	Multiple myeloma;
LUSC	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21659725	chr3:3221576	CRBN	-0.52	-8.38	-0.42	1.5e-15	Body mass index;
LUSC	cis	rs113835537	0.866	rs59320108	chr11:66365996	A/T	cg24851651	chr11:66362959	CCS	0.52	6.43	0.33	4.44e-10	Airway imaging phenotypes;
LUSC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-7.1	-0.36	7.45e-12	Alzheimer's disease (late onset);
LUSC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.3	-0.41	2.56e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs478607	0.831	rs3825074	chr11:64415767	G/A	cg19131476	chr11:64387923	NRXN2	0.34	6.06	0.31	3.76e-9	Urate levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07709635	chr12:3000034	TULP3	0.43	5.99	0.31	5.56e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	11.05	0.52	2.16e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.66	8.48	0.42	7.25e-16	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg12935359	chr14:103987150	CKB	-0.53	-8.12	-0.41	9.04e-15	Body mass index;
LUSC	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg00129232	chr17:37814104	STARD3	-0.41	-5.96	-0.31	6.38e-9	Asthma;
LUSC	cis	rs1775715	0.705	rs2778651	chr10:32106575	C/T	cg18675610	chr10:32216311	ARHGAP12	0.31	6.58	0.34	1.8e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg11189052	chr15:85197271	WDR73	0.5	6.39	0.33	5.56e-10	Schizophrenia;
LUSC	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg19628046	chr18:33552617	C18orf21	0.5	6.11	0.32	2.83e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	trans	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg07817883	chr1:32538562	TMEM39B	1.02	10.16	0.49	2.69e-21	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg12863693	chr15:85201151	NMB	0.34	6.79	0.35	5.13e-11	Schizophrenia;
LUSC	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg25922239	chr6:33757077	LEMD2	0.45	6.72	0.34	8e-11	Crohn's disease;
LUSC	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.76	-12.12	-0.55	2.93e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg06671706	chr8:8559999	CLDN23	0.5	6.83	0.35	3.98e-11	Obesity-related traits;
LUSC	cis	rs317689	0.959	rs317688	chr12:69726850	T/C	cg14784868	chr12:69753453	YEATS4	0.56	7.18	0.37	4.6e-12	Response to diuretic therapy;
LUSC	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg16743903	chr16:89593216	SPG7	-0.39	-6.13	-0.32	2.54e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg25036284	chr2:26402008	FAM59B	0.77	10.97	0.51	3.94e-24	Gut microbiome composition (summer);
LUSC	trans	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg25482853	chr8:67687455	SGK3	1.04	15.58	0.65	1.6e-41	Obesity-related traits;
LUSC	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg08079166	chr15:68083412	MAP2K5	0.35	6.07	0.32	3.42e-9	Obesity;
LUSC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06544989	chr22:39130855	UNC84B	0.37	6.45	0.33	3.82e-10	Menopause (age at onset);
LUSC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg19678392	chr7:94953810	PON1	-0.36	-5.65	-0.3	3.47e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg02380750	chr20:61661411	NA	0.34	5.92	0.31	7.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg09877947	chr5:131593287	PDLIM4	0.41	6.77	0.35	5.68e-11	Blood metabolite levels;
LUSC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1775715	0.870	rs1251400	chr10:32235145	A/G	cg03015672	chr10:32216066	ARHGAP12	0.33	6.02	0.31	4.72e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7809950	0.678	rs2237665	chr7:106906998	T/C	cg23024343	chr7:107201750	COG5	-0.66	-10.06	-0.48	5.78e-21	Coronary artery disease;
LUSC	cis	rs4423214	0.610	rs12789253	chr11:71125765	G/A	cg05163923	chr11:71159392	DHCR7	0.55	8.12	0.41	9.22e-15	Vitamin D levels;
LUSC	cis	rs4619890	0.528	rs62289335	chr4:7877655	G/C	cg24250820	chr4:7887609	AFAP1	0.36	6.15	0.32	2.17e-9	Glaucoma (primary open-angle);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg16790682	chr12:57984821	PIP4K2C	0.46	6.29	0.33	1e-9	Mosquito bite size;
LUSC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg07701084	chr6:150067640	NUP43	0.54	8.13	0.41	8.7e-15	Lung cancer;
LUSC	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	6.3	0.33	9.42e-10	Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24034412	chr19:49122294	RPL18;SPHK2	-0.49	-6.52	-0.34	2.67e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg08999081	chr20:33150536	PIGU	-0.4	-7.58	-0.38	3.53e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs3772130	0.962	rs9848027	chr3:121551227	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.19	0.49	1.99e-21	Cognitive performance;
LUSC	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg20016023	chr10:99160130	RRP12	-0.33	-8.07	-0.4	1.26e-14	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00106499	chr7:44163141	POLD2	-0.41	-5.95	-0.31	6.95e-9	Electrocardiographic conduction measures;
LUSC	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg27411982	chr8:10470053	RP1L1	0.4	6.1	0.32	2.91e-9	Myopia (pathological);
LUSC	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.7	12.26	0.56	8.46e-29	White blood cell count;
LUSC	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg18825076	chr15:78729989	IREB2	-0.45	-6.1	-0.32	2.87e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg18230493	chr5:56204884	C5orf35	-0.73	-11.77	-0.54	5.25e-27	Coronary artery disease;
LUSC	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg15083037	chr5:83017644	HAPLN1	-0.61	-7.93	-0.4	3.22e-14	Prostate cancer;
LUSC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg15352829	chr14:105391018	PLD4	-0.4	-8.41	-0.42	1.18e-15	Rheumatoid arthritis;
LUSC	cis	rs699	0.556	rs2478517	chr1:230867887	A/G	cg07502417	chr1:230849801	AGT	0.27	6.46	0.33	3.72e-10	Coronary artery disease;
LUSC	trans	rs3960554	0.867	rs11489553	chr7:75843062	G/A	cg19862616	chr7:65841803	NCRNA00174	0.89	9.56	0.46	2.71e-19	Eotaxin levels;
LUSC	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg02958346	chr11:57425731	CLP1	-0.41	-5.98	-0.31	5.73e-9	Schizophrenia;
LUSC	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	8.73	0.43	1.25e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs66716358	0.744	rs10838253	chr11:44317477	C/T	cg16977035	chr11:44330474	ALX4	0.35	5.76	0.3	1.87e-8	Monobrow;
LUSC	trans	rs3857536	0.741	rs9363556	chr6:66934399	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.78	13.25	0.59	1.72e-32	Metabolic syndrome;
LUSC	cis	rs11997175	0.646	rs10954936	chr8:33686165	C/T	ch.8.33884649F	chr8:33765107	NA	0.48	7.11	0.36	7.29e-12	Body mass index;
LUSC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg10596483	chr8:143751796	JRK	0.61	9.41	0.46	8.19e-19	Schizophrenia;
LUSC	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.76	-0.51	2.15e-23	Glomerular filtration rate;
LUSC	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg05347473	chr6:146136440	FBXO30	0.41	6.84	0.35	3.78e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg06718696	chr17:78121285	EIF4A3	0.44	6.26	0.32	1.16e-9	Yeast infection;
LUSC	cis	rs7119	0.634	rs2667782	chr15:77862296	A/C	cg27398640	chr15:77910606	LINGO1	0.36	7.96	0.4	2.63e-14	Type 2 diabetes;
LUSC	cis	rs57024841	0.562	rs2071006	chr9:139839904	G/T	cg00693599	chr9:139836323	FBXW5	-0.57	-10.15	-0.49	2.75e-21	Beta-trace protein levels;
LUSC	trans	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.45	6.87	0.35	3.12e-11	Endometrial cancer;
LUSC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.72	-13.53	-0.6	1.46e-33	Extrinsic epigenetic age acceleration;
LUSC	cis	rs34734847	0.750	rs3829290	chr12:121126438	T/C	cg27246729	chr12:121163418	ACADS	0.41	6.54	0.34	2.35e-10	Mean corpuscular volume;
LUSC	cis	rs6546550	0.901	rs1979214	chr2:70137498	G/C	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.29	-0.37	2.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs10986311	0.802	rs3780201	chr9:127104775	C/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.43	-6.92	-0.35	2.37e-11	Vitiligo;
LUSC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg13047869	chr3:10149882	C3orf24	-0.43	-6.03	-0.31	4.23e-9	Alzheimer's disease;
LUSC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg01802117	chr1:53393560	SCP2	-0.37	-6.06	-0.31	3.74e-9	Monocyte count;
LUSC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-0.99	-17.82	-0.7	2.23e-50	Height;
LUSC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg02503808	chr4:7069936	GRPEL1	-1.05	-12.07	-0.55	4.51e-28	Monocyte percentage of white cells;
LUSC	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg24375607	chr4:120327624	NA	-0.63	-10.05	-0.48	6.3e-21	Corneal astigmatism;
LUSC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg17376030	chr22:41985996	PMM1	-0.48	-6.02	-0.31	4.57e-9	Vitiligo;
LUSC	cis	rs9369695	0.883	rs9381581	chr6:47580695	G/A	cg02130027	chr6:47444894	CD2AP	0.36	5.76	0.3	1.86e-8	Reticulocyte count;
LUSC	cis	rs921665	0.680	rs4411731	chr2:3189324	C/A	cg02624386	chr2:3182749	NA	0.59	6.59	0.34	1.68e-10	World class endurance athleticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02125727	chr4:47916636	NFXL1	0.44	6.13	0.32	2.45e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg10130564	chr11:117069849	TAGLN	0.39	6.66	0.34	1.16e-10	Blood protein levels;
LUSC	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg09998033	chr7:158218633	PTPRN2	0.44	6.98	0.36	1.56e-11	Obesity-related traits;
LUSC	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-8.0	-0.4	2.02e-14	Height;
LUSC	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg04155231	chr12:9217510	LOC144571	0.3	5.66	0.3	3.26e-8	Sjögren's syndrome;
LUSC	trans	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg25214090	chr10:38739885	LOC399744	0.43	6.58	0.34	1.77e-10	Corneal astigmatism;
LUSC	trans	rs7243066	0.529	rs1391471	chr18:11297066	A/G	cg23062198	chr2:14774063	FAM84A	-0.45	-6.14	-0.32	2.4e-9	Dental caries;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16313264	chr11:57103491	SSRP1	0.46	6.06	0.31	3.59e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs35771425	0.626	rs11119744	chr1:211644575	C/T	cg10512769	chr1:211675356	NA	-0.26	-5.75	-0.3	2.05e-8	Educational attainment (years of education);
LUSC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg18681998	chr4:17616180	MED28	0.84	15.62	0.65	1.13e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7953508	0.506	rs2053196	chr12:93962959	T/C	cg18151635	chr12:93972918	NA	-0.62	-8.96	-0.44	2.35e-17	Pubertal anthropometrics;
LUSC	cis	rs4474465	1.000	rs10899518	chr11:78180508	A/C	cg27205649	chr11:78285834	NARS2	-0.48	-5.71	-0.3	2.51e-8	Alzheimer's disease (survival time);
LUSC	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg23422044	chr7:1970798	MAD1L1	-0.59	-6.66	-0.34	1.11e-10	Bipolar disorder;
LUSC	trans	rs12439619	0.693	rs4778989	chr15:82569304	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.45	-6.13	-0.32	2.44e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	0.97	15.32	0.64	1.75e-40	Dupuytren's disease;
LUSC	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg27426351	chr10:43362370	NA	-0.43	-6.0	-0.31	5.26e-9	Blood protein levels;
LUSC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19346786	chr7:2764209	NA	-0.41	-7.22	-0.37	3.64e-12	Height;
LUSC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg12963246	chr6:28129442	ZNF389	0.4	6.25	0.32	1.27e-9	Parkinson's disease;
LUSC	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg04756594	chr16:24857601	SLC5A11	0.46	6.45	0.33	4.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	13.19	0.59	2.92e-32	Alzheimer's disease;
LUSC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.21	16.82	0.68	1.93e-46	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4811340	0.561	rs4811367	chr20:51183224	G/A	cg15736553	chr3:11610338	VGLL4	-0.33	-5.97	-0.31	5.9e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs3768617	0.811	rs6674729	chr1:183059143	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	8.73	0.43	1.26e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs9473147	0.543	rs9473122	chr6:47474962	C/T	cg12968598	chr6:47444699	CD2AP	0.53	7.97	0.4	2.49e-14	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-7.4	-0.38	1.15e-12	Menarche (age at onset);
LUSC	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg27284194	chr4:1044797	NA	0.58	8.7	0.43	1.57e-16	Recombination rate (females);
LUSC	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg18478394	chr8:109455254	TTC35	0.41	6.32	0.33	8.55e-10	Dupuytren's disease;
LUSC	cis	rs7582720	0.943	rs72934762	chr2:203756677	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg01879757	chr17:41196368	BRCA1	-0.47	-7.2	-0.37	3.93e-12	Menopause (age at onset);
LUSC	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	1.01	15.33	0.64	1.5e-40	Corneal structure;
LUSC	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs10779751	0.770	rs11581010	chr1:11212458	A/G	cg08854313	chr1:11322531	MTOR	-0.82	-12.15	-0.55	2.19e-28	Body mass index;
LUSC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg18225595	chr11:63971243	STIP1	0.43	6.95	0.36	1.98e-11	Platelet count;
LUSC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07167872	chr1:205819463	PM20D1	0.53	8.88	0.44	4.04e-17	Menarche (age at onset);
LUSC	cis	rs2274273	0.837	rs8011329	chr14:55677255	G/A	cg04306507	chr14:55594613	LGALS3	0.56	13.1	0.58	6.45e-32	Protein biomarker;
LUSC	cis	rs7605827	0.930	rs13007310	chr2:15710058	A/G	cg19274914	chr2:15703543	NA	-0.45	-8.93	-0.44	2.81e-17	Educational attainment (years of education);
LUSC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg02569458	chr12:86230093	RASSF9	-0.58	-9.89	-0.48	2.15e-20	Major depressive disorder;
LUSC	cis	rs4629710	0.592	rs10484763	chr6:131549060	T/C	cg12606694	chr6:131520996	AKAP7	0.61	9.21	0.45	3.72e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg06197492	chr11:2016605	H19	0.37	6.0	0.31	5.27e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06164185	chr17:26662378	TNFAIP1;IFT20	-0.42	-6.12	-0.32	2.61e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.17	-0.32	1.95e-9	Neutrophil percentage of white cells;
LUSC	cis	rs10266483	1.000	rs1960321	chr7:63731284	T/C	cg24201672	chr7:64023550	ZNF680	-0.43	-5.97	-0.31	6.02e-9	Response to statin therapy;
LUSC	cis	rs6693567	0.565	rs698914	chr1:150298750	A/G	cg15654264	chr1:150340011	RPRD2	0.45	7.33	0.37	1.8e-12	Migraine;
LUSC	cis	rs1451375	1.000	rs1451374	chr7:50622653	G/A	cg18232548	chr7:50535776	DDC	0.51	7.83	0.39	6.32e-14	Malaria;
LUSC	cis	rs1018836	0.851	rs10808620	chr8:91622940	T/C	cg16814680	chr8:91681699	NA	-0.79	-13.27	-0.59	1.48e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-7.73	-0.39	1.25e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg08017756	chr2:100939284	LONRF2	-0.45	-8.41	-0.42	1.24e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-1.11	-12.91	-0.58	3.35e-31	Diabetic retinopathy;
LUSC	cis	rs4356932	1.000	rs7377856	chr4:76964096	T/C	cg00809888	chr4:76862425	NAAA	0.36	6.0	0.31	5.07e-9	Blood protein levels;
LUSC	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-1.24	-18.99	-0.72	4.75e-55	Blood pressure (smoking interaction);
LUSC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs7827290	0.863	rs7014099	chr8:142305766	C/T	cg22052514	chr8:142401722	NA	0.37	5.68	0.3	2.92e-8	Bipolar disorder;
LUSC	cis	rs2692947	0.770	rs62153678	chr2:96558346	C/T	cg22654517	chr2:96458247	NA	0.37	6.92	0.35	2.38e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg16743903	chr16:89593216	SPG7	-0.38	-5.82	-0.3	1.42e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.3	-0.41	2.56e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.81	0.54	3.97e-27	Cognitive ability;
LUSC	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	1.08	16.95	0.68	6.24e-47	Exhaled nitric oxide output;
LUSC	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.4	0.59	4.64e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-1.1	-22.92	-0.78	1.56e-70	Height;
LUSC	cis	rs2708977	1.000	rs13029764	chr2:97328874	C/T	cg01950434	chr2:97203154	ARID5A	-0.57	-8.93	-0.44	2.95e-17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-0.65	-11.44	-0.53	8.81e-26	Blood metabolite levels;
LUSC	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08439880	chr3:133502540	NA	-0.31	-5.65	-0.3	3.36e-8	Iron status biomarkers;
LUSC	cis	rs483180	0.512	rs612430	chr1:120216025	A/G	cg19096424	chr1:120255104	PHGDH	0.5	6.78	0.35	5.43e-11	Macular telangiectasia type 2;
LUSC	cis	rs9815354	0.627	rs80120812	chr3:42021760	C/T	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11676348	0.772	rs7422358	chr2:218952778	C/T	cg00012203	chr2:219082015	ARPC2	-0.5	-7.78	-0.39	8.99e-14	Ulcerative colitis;
LUSC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21862992	chr11:68658383	NA	0.5	7.95	0.4	2.82e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7605827	0.930	rs2380657	chr2:15678482	T/C	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.27e-17	Educational attainment (years of education);
LUSC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs9815354	0.680	rs73071354	chr3:41829186	C/A	cg03022575	chr3:42003672	ULK4	0.85	8.62	0.43	2.78e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg05754148	chr16:3507555	NAT15	0.81	9.85	0.47	2.96e-20	Tuberculosis;
LUSC	cis	rs1113500	0.933	rs10881500	chr1:108638895	C/T	cg11967332	chr1:108735228	SLC25A24	0.39	5.93	0.31	7.44e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs4704187	0.687	rs2335136	chr5:74407994	T/C	cg03227963	chr5:74354835	NA	0.32	6.87	0.35	3.09e-11	Response to amphetamines;
LUSC	cis	rs554111	0.656	rs10916891	chr1:21199974	A/C	cg01072550	chr1:21505969	NA	0.4	6.21	0.32	1.56e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	trans	rs12439619	0.810	rs28876157	chr15:82509049	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.47	-6.37	-0.33	6.24e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg13010199	chr12:38710504	ALG10B	0.48	7.28	0.37	2.47e-12	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.65	-10.04	-0.48	6.66e-21	Menarche (age at onset);
LUSC	cis	rs4499344	0.531	rs863905	chr19:33146403	T/C	cg22980127	chr19:33182716	NUDT19	-0.43	-6.39	-0.33	5.7e-10	Mean platelet volume;
LUSC	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	8.46	0.42	8.25e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.89	14.3	0.62	1.64e-36	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs500891	0.818	rs983140	chr6:84103896	T/A	cg08257003	chr6:84140564	ME1	0.33	6.72	0.35	7.85e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.4	-0.59	4.55e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-6.55	-0.34	2.2e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg06219351	chr7:158114137	PTPRN2	-0.54	-8.37	-0.42	1.65e-15	Response to amphetamines;
LUSC	cis	rs78545713	0.649	rs41266811	chr6:26216656	T/C	cg23601095	chr6:26197514	HIST1H3D	0.66	5.79	0.3	1.64e-8	Iron status biomarkers (total iron binding capacity);
LUSC	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	0.81	11.38	0.53	1.37e-25	Coronary artery disease;
LUSC	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg06484146	chr7:12443880	VWDE	-0.69	-7.35	-0.37	1.53e-12	Coronary artery disease;
LUSC	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg13852791	chr20:30311386	BCL2L1	0.9	13.34	0.59	7.48e-33	Mean corpuscular hemoglobin;
LUSC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg21535247	chr6:8435926	SLC35B3	0.56	8.55	0.42	4.56e-16	Motion sickness;
LUSC	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg03522245	chr20:25566470	NINL	-0.35	-5.72	-0.3	2.36e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.41	0.53	1.1e-25	Eye color traits;
LUSC	cis	rs17661538	0.504	rs11598236	chr10:18451884	C/T	cg03634479	chr10:18430412	CACNB2	-0.63	-6.05	-0.31	3.92e-9	Response to antipsychotic treatment;
LUSC	cis	rs4947962	0.590	rs6969537	chr7:55082418	C/T	cg23757825	chr7:55092271	EGFR	-0.67	-8.76	-0.43	1.01e-16	Subjective response to lithium treatment;
LUSC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg12564285	chr5:131593104	PDLIM4	0.44	7.92	0.4	3.48e-14	Breast cancer;
LUSC	cis	rs9796	0.870	rs2306083	chr15:41347658	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.41	-7.18	-0.37	4.46e-12	Menopause (age at onset);
LUSC	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	7.85	0.39	5.78e-14	Axial length;
LUSC	cis	rs12541635	1.000	rs12541635	chr8:107090000	C/T	cg10147462	chr8:107024639	NA	-0.48	-8.76	-0.43	1.03e-16	Age of smoking initiation;
LUSC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.59	-9.63	-0.47	1.56e-19	Aortic root size;
LUSC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08219700	chr8:58056026	NA	0.69	7.91	0.4	3.7e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.6	9.24	0.45	2.99e-18	Blood protein levels;
LUSC	trans	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg13010199	chr12:38710504	ALG10B	-0.4	-5.97	-0.31	6.16e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg08962590	chr3:180631158	FXR1	0.35	6.09	0.32	3.03e-9	Tuberculosis;
LUSC	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.68	-9.38	-0.46	1.04e-18	Large artery stroke;
LUSC	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg17173187	chr15:85201210	NMB	0.5	9.31	0.45	1.77e-18	Schizophrenia;
LUSC	trans	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg23029597	chr12:123009494	RSRC2	-0.73	-9.73	-0.47	7.55e-20	Body mass index;
LUSC	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg27572855	chr1:25598939	RHD	0.43	7.5	0.38	5.96e-13	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg04662567	chr6:169592167	NA	0.41	6.18	0.32	1.82e-9	Pulse pressure;
LUSC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.48	7.28	0.37	2.34e-12	Testicular germ cell tumor;
LUSC	cis	rs11690935	0.550	rs62183784	chr2:172866696	A/G	cg13550731	chr2:172543902	DYNC1I2	0.53	7.96	0.4	2.7e-14	Schizophrenia;
LUSC	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg19196401	chr6:110721138	DDO	-0.45	-8.49	-0.42	7.05e-16	Platelet distribution width;
LUSC	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	1.09	16.97	0.68	5.21e-47	Corneal structure;
LUSC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg00800038	chr16:89945340	TCF25	-0.63	-6.68	-0.34	1.02e-10	Skin colour saturation;
LUSC	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg14456004	chr13:21872349	NA	-1.14	-15.66	-0.65	7.98e-42	White matter hyperintensity burden;
LUSC	cis	rs7523050	0.643	rs12752417	chr1:109400639	A/C	cg08274380	chr1:109419600	GPSM2	-1.16	-10.07	-0.48	5.09e-21	Fat distribution (HIV);
LUSC	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.53	0.46	3.28e-19	Resting heart rate;
LUSC	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg00310523	chr12:86230176	RASSF9	-0.35	-6.2	-0.32	1.68e-9	Major depressive disorder;
LUSC	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.63	10.04	0.48	6.9299999999999992e-21	Morning vs. evening chronotype;
LUSC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.4	6.18	0.32	1.89e-9	Menopause (age at onset);
LUSC	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg22782873	chr19:19639568	YJEFN3	-0.5	-6.24	-0.32	1.3e-9	Bipolar disorder;
LUSC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg12292205	chr6:26970375	C6orf41	0.68	11.53	0.53	4.12e-26	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg22800045	chr5:56110881	MAP3K1	-0.62	-8.56	-0.42	4.14e-16	Initial pursuit acceleration;
LUSC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg11502198	chr6:26597334	ABT1	0.67	10.6	0.5	8.06e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg01028140	chr2:1542097	TPO	-0.6	-8.21	-0.41	5.04e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg21567404	chr3:27674614	NA	-0.97	-15.56	-0.65	1.92e-41	Dupuytren's disease;
LUSC	cis	rs9473147	0.543	rs9367279	chr6:47448336	A/G	cg02130027	chr6:47444894	CD2AP	0.35	5.67	0.3	3.01e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	17.35	0.69	1.59e-48	Chronic sinus infection;
LUSC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.99	0.4	2.24e-14	Prudent dietary pattern;
LUSC	cis	rs9905704	0.718	rs4793953	chr17:56613104	C/G	cg19466818	chr17:56409534	MIR142	0.34	6.45	0.33	3.98e-10	Testicular germ cell tumor;
LUSC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.4	6.15	0.32	2.2e-9	Platelet count;
LUSC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4474465	0.833	rs10793317	chr11:78212011	G/A	cg27205649	chr11:78285834	NARS2	0.51	5.86	0.31	1.13e-8	Alzheimer's disease (survival time);
LUSC	cis	rs2932538	0.922	rs7535636	chr1:113101799	C/T	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.87	-0.48	2.54e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg12310025	chr6:25882481	NA	-0.5	-9.09	-0.45	9.27e-18	Blood metabolite levels;
LUSC	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg09184832	chr6:79620586	NA	-0.43	-6.88	-0.35	3.06e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4285028	0.699	rs1344279	chr3:121615679	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.8	-10.63	-0.5	6.5e-23	Multiple sclerosis;
LUSC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-7.05	-0.36	1.01e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg03585969	chr10:35415529	CREM	0.61	9.2	0.45	4.12e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-11.95	-0.55	1.18e-27	Colorectal cancer;
LUSC	cis	rs7605827	0.930	rs6760888	chr2:15537863	T/C	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.71	9.22	0.45	3.37e-18	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs11958404	0.860	rs72816577	chr5:157431806	A/G	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg01448562	chr3:133502909	NA	-0.66	-10.77	-0.51	2.06e-23	Iron status biomarkers;
LUSC	trans	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg07393940	chr7:158741817	NA	-0.37	-6.49	-0.33	3.18e-10	Life satisfaction;
LUSC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.48	0.38	6.57e-13	Motion sickness;
LUSC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg09796270	chr17:17721594	SREBF1	0.4	6.78	0.35	5.58e-11	Total body bone mineral density;
LUSC	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	0.88	13.37	0.59	6.01e-33	Triglycerides;
LUSC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-7.61	-0.38	2.77e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg03585969	chr10:35415529	CREM	0.59	8.83	0.44	6.06e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg26441486	chr22:50317300	CRELD2	-0.54	-8.21	-0.41	4.86e-15	Schizophrenia;
LUSC	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg24375607	chr4:120327624	NA	0.74	11.2	0.52	6.18e-25	Corneal astigmatism;
LUSC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg01097406	chr16:89675127	NA	-0.34	-6.81	-0.35	4.55e-11	Vitiligo;
LUSC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg18904891	chr8:8559673	CLDN23	0.62	8.59	0.43	3.27e-16	Obesity-related traits;
LUSC	trans	rs12210905	0.925	rs12190201	chr6:27001458	A/C	cg11837749	chr1:55047332	ACOT11	0.58	6.2	0.32	1.62e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg24375607	chr4:120327624	NA	0.79	11.49	0.53	5.43e-26	Corneal astigmatism;
LUSC	cis	rs4363385	0.510	rs11590369	chr1:152903603	G/C	cg25856811	chr1:152973957	SPRR3	-0.39	-6.36	-0.33	6.76e-10	Inflammatory skin disease;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg04210991	chr1:226374609	ACBD3	0.45	6.1	0.32	2.9e-9	Mosquito bite size;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg27069263	chr2:55278118	RTN4	0.38	6.2	0.32	1.71e-9	Tuberculosis;
LUSC	cis	rs6736093	0.796	rs13001162	chr2:112805997	C/T	cg12686935	chr2:112915763	FBLN7	-0.4	-6.35	-0.33	7.12e-10	Coronary artery disease;
LUSC	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg25072359	chr17:41440525	NA	0.66	8.18	0.41	5.99e-15	Menopause (age at onset);
LUSC	cis	rs6967385	0.583	rs1116972	chr7:12348307	A/C	cg06484146	chr7:12443880	VWDE	0.41	6.21	0.32	1.53e-9	Response to taxane treatment (placlitaxel);
LUSC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg05872129	chr22:39784769	NA	-0.6	-10.25	-0.49	1.3e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2692947	0.683	rs1813381	chr2:96422939	C/T	cg22654517	chr2:96458247	NA	-0.33	-6.0	-0.31	5.19e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg14584255	chr6:163149320	PACRG;PARK2	-0.4	-7.93	-0.4	3.41e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg13010199	chr12:38710504	ALG10B	-0.43	-6.47	-0.33	3.41e-10	Bladder cancer;
LUSC	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.73	-6.23	-0.32	1.41e-9	Major depressive disorder;
LUSC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.63	0.34	1.34e-10	Tonsillectomy;
LUSC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02176678	chr2:219576539	TTLL4	0.63	11.43	0.53	8.94e-26	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg02508848	chr16:68573721	ZFP90	-0.43	-5.82	-0.3	1.42e-8	Ulcerative colitis;
LUSC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg22166914	chr1:53195759	ZYG11B	0.61	10.07	0.48	5.44e-21	Monocyte count;
LUSC	cis	rs3743104	0.510	rs16973303	chr15:33020928	A/C	cg07179000	chr15:33023586	GREM1	-0.35	-6.77	-0.35	5.64e-11	Hypospadias;
LUSC	cis	rs859767	0.501	rs10193171	chr2:135403199	C/T	cg12500956	chr2:135428796	TMEM163	0.28	6.51	0.34	2.72e-10	Neuroticism;
LUSC	cis	rs11958404	0.932	rs7711898	chr5:157430688	A/G	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg04546413	chr19:29218101	NA	0.58	7.22	0.37	3.57e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg20129853	chr10:51489980	NA	-0.34	-7.04	-0.36	1.07e-11	Prostate-specific antigen levels;
LUSC	cis	rs10484885	0.553	rs72911820	chr6:90281934	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.55	-5.67	-0.3	3.03e-8	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg05714579	chr10:131428358	MGMT	0.53	7.68	0.39	1.76e-13	Response to temozolomide;
LUSC	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg13256891	chr4:100009986	ADH5	-0.43	-6.0	-0.31	5.06e-9	Alcohol dependence;
LUSC	cis	rs2710642	0.962	rs4671051	chr2:63032696	A/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.19	-0.32	1.75e-9	LDL cholesterol levels;LDL cholesterol;
LUSC	trans	rs4714291	0.832	rs6936016	chr6:40097013	A/G	cg02267698	chr19:7991119	CTXN1	-0.55	-8.25	-0.41	3.8e-15	Strep throat;
LUSC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg25019033	chr10:957182	NA	-0.53	-6.1	-0.32	2.91e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg13263323	chr15:86062960	AKAP13	-0.36	-5.89	-0.31	9.33e-9	Coronary artery disease;
LUSC	trans	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	8.49	0.42	7.01e-16	Type 2 diabetes;
LUSC	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.75	14.64	0.63	7.48e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg12863693	chr15:85201151	NMB	0.36	7.06	0.36	9.44e-12	Schizophrenia;
LUSC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.7	-12.19	-0.56	1.54e-28	Aortic root size;
LUSC	cis	rs4423214	0.559	rs11234042	chr11:71239086	C/A	cg05163923	chr11:71159392	DHCR7	-0.69	-7.02	-0.36	1.26e-11	Vitamin D levels;
LUSC	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg04607235	chr12:12878440	APOLD1	-0.94	-15.44	-0.65	5.89e-41	Lymphocyte counts;
LUSC	cis	rs977987	0.843	rs10514396	chr16:75422903	T/C	cg04384234	chr16:75411784	CFDP1	-0.46	-7.65	-0.39	2.21e-13	Dupuytren's disease;
LUSC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-8.43	-0.42	1.02e-15	Aortic root size;
LUSC	cis	rs6977660	0.943	rs10249996	chr7:19844935	G/A	cg07541023	chr7:19748670	TWISTNB	0.53	6.07	0.32	3.48e-9	Thyroid stimulating hormone;
LUSC	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.69	10.35	0.49	5.71e-22	Corneal astigmatism;
LUSC	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg22535103	chr8:58192502	C8orf71	-0.56	-6.65	-0.34	1.18e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg19773385	chr1:10388646	KIF1B	-0.54	-8.42	-0.42	1.11e-15	Hepatocellular carcinoma;
LUSC	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24838063	chr12:130822603	PIWIL1	0.69	10.79	0.51	1.69e-23	Menopause (age at onset);
LUSC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.16	16.54	0.67	2.7e-45	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-6.08	-0.32	3.22e-9	Fear of minor pain;
LUSC	cis	rs2274273	0.870	rs10147434	chr14:55674847	C/T	cg04306507	chr14:55594613	LGALS3	0.58	13.44	0.59	3.15e-33	Protein biomarker;
LUSC	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg02569458	chr12:86230093	RASSF9	-0.42	-6.75	-0.35	6.7e-11	Major depressive disorder;
LUSC	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11645453	chr3:52864694	ITIH4	-0.56	-13.3	-0.59	1.14e-32	Schizophrenia;
LUSC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.48	8.17	0.41	6.27e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1461503	0.966	rs10790545	chr11:122838350	G/C	cg27398637	chr11:122830231	C11orf63	-0.4	-6.34	-0.33	7.32e-10	Menarche (age at onset);
LUSC	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg00579200	chr11:133705235	NA	-0.39	-5.68	-0.3	2.93e-8	Childhood ear infection;
LUSC	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.98	-0.48	1.1e-20	Migraine;Coronary artery disease;
LUSC	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	8.9	0.44	3.71e-17	Iron status biomarkers;
LUSC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	8.09e-16	Aortic root size;
LUSC	cis	rs6840360	1.000	rs10049991	chr4:152664163	A/T	cg22705602	chr4:152727874	NA	-0.27	-5.66	-0.3	3.26e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs757278	0.591	rs10266116	chr7:117304459	T/C	cg10524701	chr7:117356490	CTTNBP2	0.4	5.76	0.3	1.9e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs1223397	0.938	rs34505804	chr6:13292514	G/A	cg13974761	chr1:152670598	LCE2A	0.38	6.11	0.32	2.79e-9	Blood pressure;
LUSC	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg23791538	chr6:167370224	RNASET2	0.54	9.07	0.44	1.01e-17	Crohn's disease;
LUSC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.04	21.28	0.76	3.93e-64	Cognitive function;
LUSC	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg05973401	chr12:123451056	ABCB9	0.52	6.49	0.33	3.19e-10	Neutrophil percentage of white cells;
LUSC	trans	rs1493916	0.805	rs1452648	chr18:31411003	G/T	cg27147174	chr7:100797783	AP1S1	-0.55	-8.73	-0.43	1.21e-16	Life satisfaction;
LUSC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08704250	chr15:31115839	NA	-0.48	-7.16	-0.36	5.21e-12	Huntington's disease progression;
LUSC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg06713675	chr4:122721982	EXOSC9	-0.44	-7.77	-0.39	9.93e-14	Type 2 diabetes;
LUSC	cis	rs427941	0.595	rs6465851	chr7:101827463	A/C	cg06246474	chr7:101738831	CUX1	0.35	5.74	0.3	2.18e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	trans	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17712092	chr4:129076599	LARP1B	0.8	11.88	0.55	2.11e-27	Eosinophil percentage of white cells;
LUSC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg21724239	chr8:58056113	NA	-0.75	-8.3	-0.41	2.62e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg05347473	chr6:146136440	FBXO30	-0.57	-9.85	-0.47	2.97e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9436747	0.605	rs11587159	chr1:65987205	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.43	-5.88	-0.31	1.02e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs7107174	1.000	rs10899452	chr11:77995143	A/C	cg02023728	chr11:77925099	USP35	0.48	6.61	0.34	1.52e-10	Testicular germ cell tumor;
LUSC	cis	rs1712517	0.838	rs1891293	chr10:105001797	C/T	cg05636881	chr10:105038444	INA	-0.43	-7.17	-0.37	4.98e-12	Migraine;
LUSC	cis	rs7089973	0.523	rs61869297	chr10:116779005	G/C	cg23260525	chr10:116636907	FAM160B1	0.32	6.24	0.32	1.35e-9	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	trans	rs62238980	0.614	rs4821006	chr22:32370060	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs12681287	0.640	rs12544463	chr8:87481114	A/G	cg27223183	chr8:87520930	FAM82B	-0.53	-7.13	-0.36	6.24e-12	Caudate activity during reward;
LUSC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg03563238	chr19:33554763	RHPN2	0.35	5.65	0.3	3.48e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2742417	1.000	rs2742436	chr3:45741397	T/C	cg09608765	chr3:45636137	LIMD1	-0.37	-7.42	-0.38	9.67e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg13390004	chr1:15929781	NA	0.42	7.0	0.36	1.43e-11	Systolic blood pressure;
LUSC	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg00857998	chr1:205179979	DSTYK	0.66	10.59	0.5	8.42e-23	Red blood cell count;
LUSC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg06238570	chr21:40685208	BRWD1	-0.58	-9.0	-0.44	1.78e-17	Menarche (age at onset);
LUSC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	1.03	17.61	0.69	1.42e-49	Coronary artery disease;
LUSC	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.08	-0.32	3.19e-9	Systemic lupus erythematosus;
LUSC	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.69	10.49	0.5	1.93e-22	Corneal astigmatism;
LUSC	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.75	-13.65	-0.6	5.14e-34	Brugada syndrome;
LUSC	cis	rs2840044	1.000	rs225262	chr17:33959697	A/G	cg05299278	chr17:33885742	SLFN14	0.3	6.14	0.32	2.29e-9	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.23e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg12463550	chr7:65579703	CRCP	0.45	6.74	0.35	6.98e-11	Aortic root size;
LUSC	cis	rs4588572	0.643	rs1560195	chr5:77701913	A/G	cg11547950	chr5:77652471	NA	0.51	7.37	0.37	1.33e-12	Triglycerides;
LUSC	cis	rs6060717	0.536	rs6060670	chr20:34481143	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.67	-0.3	3.14e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-0.93	-15.59	-0.65	1.53e-41	Body mass index;
LUSC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg13319975	chr6:146136371	FBXO30	-0.71	-10.79	-0.51	1.81e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg24011408	chr12:48396354	COL2A1	0.39	5.8	0.3	1.54e-8	Glycated hemoglobin levels;
LUSC	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg18232548	chr7:50535776	DDC	-0.56	-7.46	-0.38	7.72e-13	Malaria;
LUSC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03352830	chr11:487213	PTDSS2	0.75	8.72	0.43	1.37e-16	Body mass index;
LUSC	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg23505145	chr19:12996616	KLF1	0.65	11.09	0.52	1.57e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg00522288	chr12:125625016	AACS	-0.33	-6.2	-0.32	1.62e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg25319279	chr11:5960081	NA	-0.41	-5.78	-0.3	1.68e-8	DNA methylation (variation);
LUSC	cis	rs80282103	0.618	rs1079390	chr10:1161653	C/A	cg18964960	chr10:1102726	WDR37	0.7	5.84	0.3	1.22e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs2179367	0.600	rs111564088	chr6:149765782	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.34	-5.69	-0.3	2.72e-8	Dupuytren's disease;
LUSC	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs10193935	0.901	rs9789740	chr2:42486799	A/G	cg27598129	chr2:42591480	NA	-0.61	-8.3	-0.41	2.67e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg02176678	chr2:219576539	TTLL4	-0.57	-10.03	-0.48	7.16e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs28647808	0.881	rs28494844	chr9:136266188	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg15242686	chr22:24348715	GSTTP1	0.47	7.4	0.38	1.13e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg03233332	chr7:66118400	NA	-0.41	-6.03	-0.31	4.28e-9	Aortic root size;
LUSC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg13770153	chr20:60521292	NA	-0.64	-8.92	-0.44	3.17e-17	Body mass index;
LUSC	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg24642439	chr20:33292090	TP53INP2	0.43	6.16	0.32	2.07e-9	Height;
LUSC	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	19.01	0.72	3.91e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs4729127	1.000	rs12665908	chr7:94010770	T/C	cg14660007	chr13:78271894	SLAIN1	0.5	6.45	0.33	3.88e-10	Intelligence;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26005303	chr7:5821307	RNF216	-0.41	-6.0	-0.31	5.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg14092571	chr14:90743983	NA	-0.36	-5.86	-0.31	1.11e-8	Mortality in heart failure;
LUSC	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg06636001	chr8:8085503	FLJ10661	0.6	9.35	0.46	1.28e-18	Mood instability;
LUSC	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg15556689	chr8:8085844	FLJ10661	0.67	11.08	0.52	1.7e-24	Systolic blood pressure;
LUSC	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.62	-0.34	1.45e-10	Schizophrenia;
LUSC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.21	0.52	5.58e-25	Alzheimer's disease;
LUSC	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg11812906	chr14:75593930	NEK9	-0.42	-6.34	-0.33	7.66e-10	Neuroticism;
LUSC	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	7.56	0.38	3.93e-13	Multiple sclerosis;
LUSC	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg22437258	chr11:111473054	SIK2	0.54	7.68	0.39	1.75e-13	Primary sclerosing cholangitis;
LUSC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00149659	chr3:10157352	C3orf10	1.0	14.77	0.63	2.33e-38	Alzheimer's disease;
LUSC	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg04362960	chr10:104952993	NT5C2	0.6	9.48	0.46	4.82e-19	Arsenic metabolism;
LUSC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.17	-14.8	-0.63	1.76e-38	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs12210905	0.688	rs12212389	chr6:27326397	T/C	cg02699829	chr19:13216355	TRMT1	-0.56	-6.23	-0.32	1.39e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.6	0.54	2.33e-26	Prudent dietary pattern;
LUSC	trans	rs11700980	0.551	rs11701765	chr21:30115651	C/T	cg14791747	chr16:20752902	THUMPD1	-0.58	-6.28	-0.32	1.05e-9	QRS complex (12-leadsum);
LUSC	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.45	-0.33	3.88e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12681287	0.752	rs12677470	chr8:87260559	G/A	cg27223183	chr8:87520930	FAM82B	-0.45	-5.72	-0.3	2.33e-8	Caudate activity during reward;
LUSC	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg20026190	chr17:76395443	PGS1	0.46	8.2	0.41	5.16e-15	HDL cholesterol levels;
LUSC	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg09462578	chr12:12878428	APOLD1	-0.62	-7.29	-0.37	2.31e-12	Systemic lupus erythematosus;
LUSC	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg13852791	chr20:30311386	BCL2L1	0.72	8.29	0.41	2.73e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg08859206	chr1:53392774	SCP2	0.47	7.88	0.4	4.71e-14	Monocyte count;
LUSC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg16386425	chr10:429943	DIP2C	0.44	7.21	0.37	3.82e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.55	-9.14	-0.45	6.18e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs3784262	0.512	rs4646571	chr15:58343137	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.36	-6.58	-0.34	1.86e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	8.03	0.4	1.68e-14	Iron status biomarkers;
LUSC	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	6.85	0.35	3.59e-11	Multiple sclerosis;
LUSC	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg20608306	chr11:116969690	SIK3	0.36	6.69	0.34	9.29e-11	Blood protein levels;
LUSC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg00339695	chr16:24857497	SLC5A11	0.39	6.98	0.36	1.62e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg14092988	chr3:52407081	DNAH1	0.32	6.34	0.33	7.4e-10	Bipolar disorder;
LUSC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.5	-8.59	-0.43	3.48e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7903847	0.656	rs11189208	chr10:99169172	C/G	cg20016023	chr10:99160130	RRP12	-0.25	-5.78	-0.3	1.69e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg01802117	chr1:53393560	SCP2	0.37	6.0	0.31	5.15e-9	Monocyte count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16878075	chr8:145050837	PLEC1	-0.4	-6.19	-0.32	1.8e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.67	-10.77	-0.51	2.04e-23	Height;
LUSC	cis	rs727505	1.000	rs56321835	chr7:124529622	T/C	cg23710748	chr7:124431027	NA	-0.42	-7.42	-0.38	1e-12	Lewy body disease;
LUSC	cis	rs1322512	0.917	rs2800629	chr6:153007917	A/C	cg27316956	chr6:152958899	SYNE1	0.36	6.12	0.32	2.57e-9	Tonometry;
LUSC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.69	0.83	1.71e-88	Chronic sinus infection;
LUSC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg21724239	chr8:58056113	NA	0.56	6.63	0.34	1.35e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.25	-0.45	2.68e-18	Joint mobility (Beighton score);
LUSC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg13319975	chr6:146136371	FBXO30	-0.53	-8.1	-0.41	1.05e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7589342	0.566	rs11895542	chr2:106390429	G/A	cg14210321	chr2:106509881	NCK2	-0.41	-5.94	-0.31	7.29e-9	Addiction;
LUSC	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	0.8	15.0	0.63	3.01e-39	Gut microbiome composition (winter);
LUSC	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg18240062	chr17:79603768	NPLOC4	0.79	15.24	0.64	3.35e-40	Eye color traits;
LUSC	cis	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg18252515	chr7:66147081	NA	-0.38	-5.77	-0.3	1.82e-8	Corneal structure;
LUSC	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg05926928	chr17:57297772	GDPD1	-0.96	-10.73	-0.51	2.9e-23	Opioid sensitivity;
LUSC	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg05347473	chr6:146136440	FBXO30	0.47	7.75	0.39	1.1e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg07701084	chr6:150067640	NUP43	0.54	8.12	0.41	9.26e-15	Lung cancer;
LUSC	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03264133	chr6:25882463	NA	-0.38	-6.71	-0.34	8.45e-11	Height;
LUSC	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg07148914	chr20:33460835	GGT7	0.48	7.17	0.37	4.83e-12	Height;
LUSC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.81	-13.1	-0.58	6.17e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg11050988	chr7:1952600	MAD1L1	-0.32	-6.04	-0.31	4.14e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1983891	0.955	rs6917029	chr6:41548540	C/G	cg20194872	chr6:41519635	FOXP4	0.35	6.23	0.32	1.38e-9	Prostate cancer;
LUSC	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg09165964	chr15:75287851	SCAMP5	-0.76	-6.87	-0.35	3.24e-11	Lung cancer;
LUSC	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.44	-0.42	9.55e-16	Response to antipsychotic treatment;
LUSC	cis	rs295140	0.668	rs3769482	chr2:201173100	C/G	cg04283868	chr2:201171347	SPATS2L	0.43	6.18	0.32	1.82e-9	QT interval;
LUSC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-8.31	-0.41	2.44e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg24247370	chr13:99142703	STK24	-0.33	-6.01	-0.31	4.74e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg13010199	chr12:38710504	ALG10B	0.7	10.85	0.51	1.1e-23	Bladder cancer;
LUSC	cis	rs3770081	1.000	rs17618001	chr2:86289303	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.84	-0.35	3.84e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg13628971	chr7:2884303	GNA12	0.44	6.01	0.31	4.77e-9	Height;
LUSC	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.15	-0.36	5.46e-12	Coronary artery disease;
LUSC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg06815965	chr1:205818668	PM20D1	0.38	5.84	0.3	1.22e-8	Menarche (age at onset);
LUSC	cis	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg27411982	chr8:10470053	RP1L1	0.47	7.7	0.39	1.6e-13	Neuroticism;
LUSC	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg19773385	chr1:10388646	KIF1B	-0.49	-8.64	-0.43	2.45e-16	Hepatocellular carcinoma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07600211	chr1:145516081	GNRHR2;PEX11B	-0.51	-6.52	-0.34	2.55e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg05802129	chr4:122689817	NA	-0.52	-8.81	-0.43	6.92e-17	Type 2 diabetes;
LUSC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg08859206	chr1:53392774	SCP2	0.47	7.84	0.39	6.27e-14	Monocyte count;
LUSC	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg05340658	chr4:99064831	C4orf37	0.69	11.63	0.54	1.69e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	14.63	0.62	8.8e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg18722847	chr3:44754129	ZNF502	-0.36	-5.71	-0.3	2.45e-8	Depressive symptoms;
LUSC	cis	rs17286411	0.750	rs4788579	chr16:71951845	A/C	cg03805757	chr16:71968109	PKD1L3	0.39	6.51	0.34	2.7e-10	Blood protein levels;
LUSC	cis	rs2012796	0.957	rs7151434	chr14:81819468	A/G	cg02996355	chr14:81879375	NA	0.46	6.67	0.34	1.08e-10	Night sleep phenotypes;
LUSC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18932078	chr1:2524107	MMEL1	-0.31	-6.9	-0.35	2.61e-11	Ulcerative colitis;
LUSC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.09	-0.45	8.83e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.76	13.76	0.6	1.96e-34	Colorectal cancer;
LUSC	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.62	-0.43	2.71e-16	Mood instability;
LUSC	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg09699651	chr6:150184138	LRP11	0.45	7.15	0.36	5.64e-12	Testicular germ cell tumor;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg15620207	chr1:150207153	ANP32E	-0.42	-6.14	-0.32	2.33e-9	Triglycerides;
LUSC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24531977	chr5:56204891	C5orf35	-0.89	-13.8	-0.6	1.31e-34	Initial pursuit acceleration;
LUSC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.34	0.59	7.79e-33	Cognitive test performance;
LUSC	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.26	-0.32	1.17e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg13535736	chr9:111863775	C9orf5	-0.43	-6.81	-0.35	4.43e-11	Menarche (age at onset);
LUSC	cis	rs2991971	1.000	rs2991970	chr1:46011005	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.44	-0.33	4.09e-10	High light scatter reticulocyte count;
LUSC	trans	rs3942852	0.869	rs4752806	chr11:48118199	G/C	cg15704280	chr7:45808275	SEPT13	-0.54	-6.26	-0.32	1.21e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg23324259	chr8:82754387	SNX16	-0.43	-5.77	-0.3	1.85e-8	Diastolic blood pressure;
LUSC	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg09904177	chr6:26538194	HMGN4	-0.73	-6.49	-0.33	3.11e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1018697	1.000	rs4919677	chr10:104554304	G/A	cg04362960	chr10:104952993	NT5C2	0.47	6.46	0.33	3.65e-10	Colorectal adenoma (advanced);
LUSC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.6	-11.78	-0.54	5.08e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.47	-6.9	-0.35	2.65e-11	Alzheimer's disease (late onset);
LUSC	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg00684032	chr4:1343700	KIAA1530	-0.35	-6.23	-0.32	1.44e-9	Obesity-related traits;
LUSC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg11764359	chr7:65958608	NA	-0.51	-6.6	-0.34	1.57e-10	Aortic root size;
LUSC	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg04989706	chr14:50066350	PPIL5	-0.46	-5.83	-0.3	1.31e-8	Carotid intima media thickness;
LUSC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg08742575	chr21:47604166	C21orf56	-0.46	-7.16	-0.36	5.09e-12	Testicular germ cell tumor;
LUSC	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg18132916	chr6:79620363	NA	-0.39	-5.99	-0.31	5.41e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.31	-6.17	-0.32	2.03e-9	Menopause (age at onset);
LUSC	cis	rs4443100	0.670	rs13054331	chr22:23407063	G/A	cg14186256	chr22:23484241	RTDR1	0.54	6.98	0.36	1.64e-11	Serum parathyroid hormone levels;
LUSC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg13319975	chr6:146136371	FBXO30	0.49	7.37	0.37	1.35e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2979489	0.624	rs62505275	chr8:30437639	C/T	cg26383811	chr8:30366931	RBPMS	-0.43	-6.75	-0.35	6.4e-11	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg15704280	chr7:45808275	SEPT13	0.81	7.73	0.39	1.27e-13	Axial length;
LUSC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg09509183	chr1:209979624	IRF6	0.5	6.09	0.32	3.17e-9	Cleft lip with or without cleft palate;
LUSC	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.11	0.32	2.82e-9	Corneal astigmatism;
LUSC	trans	rs7493138	0.967	rs4384536	chr14:28997083	C/A	cg10573181	chr4:170533618	NEK1	0.41	6.03	0.31	4.25e-9	Longevity;
LUSC	cis	rs8092503	1.000	rs12956208	chr18:52473167	C/T	cg12377874	chr18:52495404	RAB27B	0.33	6.08	0.32	3.32e-9	Childhood body mass index;
LUSC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg13883939	chr12:118541731	VSIG10	0.38	5.96	0.31	6.51e-9	Calcium levels;
LUSC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.57	-0.5	1.04e-22	Alzheimer's disease;
LUSC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg15145296	chr3:125709740	NA	-0.58	-6.41	-0.33	4.9e-10	Blood pressure (smoking interaction);
LUSC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.48	-6.87	-0.35	3.21e-11	Mean platelet volume;
LUSC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg05347473	chr6:146136440	FBXO30	0.59	10.32	0.49	7.62e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21028142	chr17:79581711	NPLOC4	0.32	7.65	0.39	2.12e-13	Eye color traits;
LUSC	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21643547	chr1:205240462	TMCC2	-0.51	-9.43	-0.46	7.06e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.36	5.68	0.3	2.92e-8	Response to antipsychotic treatment;
LUSC	cis	rs4654899	0.965	rs61781115	chr1:21322860	C/T	cg01072550	chr1:21505969	NA	-0.55	-8.45	-0.42	9.03e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2625529	0.557	rs7496582	chr15:72147831	T/G	cg16672083	chr15:72433130	SENP8	-0.5	-8.22	-0.41	4.64e-15	Red blood cell count;
LUSC	cis	rs6445967	0.530	rs12490706	chr3:58408247	C/T	cg23715586	chr3:58305044	RPP14	-0.39	-6.31	-0.33	8.8e-10	Platelet count;
LUSC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	29.03	0.85	2.44e-93	Chronic sinus infection;
LUSC	cis	rs2235649	0.828	rs9938694	chr16:1849872	T/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-6.11	-0.32	2.71e-9	Blood metabolite levels;
LUSC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg25039879	chr17:56429692	SUPT4H1	0.67	8.85	0.44	5.03e-17	Cognitive test performance;
LUSC	cis	rs2303282	0.664	rs4783938	chr16:56407023	G/A	cg00500540	chr16:56394104	NA	-0.4	-6.96	-0.36	1.78e-11	Breast cancer;
LUSC	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.81e-22	Eye color traits;
LUSC	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg24011408	chr12:48396354	COL2A1	-0.53	-8.72	-0.43	1.33e-16	Plateletcrit;
LUSC	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.53	10.54	0.5	1.31e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.68	11.59	0.54	2.5e-26	Aortic root size;
LUSC	cis	rs2742417	1.000	rs2742385	chr3:45756270	G/A	cg09608765	chr3:45636137	LIMD1	-0.38	-7.53	-0.38	4.87e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs17039065	1.000	rs75264077	chr4:109393185	T/G	cg07444054	chr2:108107501	NA	0.43	6.3	0.33	9.65e-10	Gut microbiome composition (summer);
LUSC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.35	5.75	0.3	2e-8	Menopause (age at onset);
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18000306	chr6:288505	NA	0.34	6.47	0.33	3.52e-10	Menopause (age at onset);
LUSC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg00990874	chr7:1149470	C7orf50	-0.49	-6.53	-0.34	2.46e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg23262073	chr20:60523788	NA	-0.43	-6.42	-0.33	4.79e-10	Body mass index;
LUSC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg10018233	chr7:150070692	REPIN1	0.39	6.74	0.35	6.82e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3772130	0.962	rs9856641	chr3:121566859	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	9.98	0.48	1.09e-20	Cognitive performance;
LUSC	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg16624210	chr5:671434	TPPP	0.47	5.92	0.31	8.21e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9818941	0.826	rs2712321	chr3:157644344	C/T	cg08654915	chr3:157813417	NA	0.27	6.32	0.33	8.51e-10	Height;
LUSC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg01416388	chr22:39784598	NA	-0.44	-7.34	-0.37	1.67e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg05347473	chr6:146136440	FBXO30	0.65	11.01	0.52	3.01e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3087591	0.881	rs2905804	chr17:29519995	T/C	cg24425628	chr17:29625626	OMG;NF1	0.6	8.55	0.42	4.36e-16	Hip circumference;
LUSC	cis	rs41307935	0.722	rs12724052	chr1:27234682	G/A	cg12203394	chr1:27248618	NUDC	0.54	5.71	0.3	2.52e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg01206211	chr2:36825736	FEZ2	0.56	13.11	0.58	5.71e-32	Height;
LUSC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg17173187	chr15:85201210	NMB	0.37	6.56	0.34	2.08e-10	Schizophrenia;
LUSC	trans	rs61931739	0.612	rs2004961	chr12:33994599	A/G	cg26384229	chr12:38710491	ALG10B	0.49	7.51	0.38	5.61e-13	Morning vs. evening chronotype;
LUSC	cis	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg27102117	chr16:15229624	NA	0.38	5.66	0.3	3.27e-8	Triglycerides;
LUSC	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg27219399	chr15:67835830	MAP2K5	0.35	5.7	0.3	2.63e-8	Obesity;
LUSC	cis	rs360798	0.532	rs12994674	chr2:62996645	G/A	cg17519650	chr2:63277830	OTX1	-0.46	-6.21	-0.32	1.55e-9	Coronary artery disease;
LUSC	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg07157834	chr1:205819609	PM20D1	-0.43	-6.4	-0.33	5.32e-10	Menarche (age at onset);
LUSC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg22823121	chr1:150693482	HORMAD1	0.57	8.85	0.44	5.33e-17	Tonsillectomy;
LUSC	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg09367891	chr1:107599246	PRMT6	0.51	7.86	0.4	5.26e-14	Facial morphology (factor 21, depth of nasal alae);
LUSC	trans	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg26043149	chr18:55253948	FECH	-0.53	-7.63	-0.39	2.54e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.57	8.76	0.43	9.71e-17	Menopause (age at onset);
LUSC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.39	-6.05	-0.31	3.89e-9	Platelet count;
LUSC	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg02023728	chr11:77925099	USP35	0.42	6.2	0.32	1.63e-9	Testicular germ cell tumor;
LUSC	trans	rs72674100	1.000	rs72882317	chr4:97991290	C/G	cg16405019	chr1:18959625	PAX7	-0.63	-6.65	-0.34	1.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg15556689	chr8:8085844	FLJ10661	0.62	8.98	0.44	2.09e-17	Neuroticism;
LUSC	cis	rs7119	0.700	rs2867311	chr15:77902191	A/C	cg27398640	chr15:77910606	LINGO1	0.38	8.85	0.44	5.14e-17	Type 2 diabetes;
LUSC	trans	rs28647808	1.000	rs28591209	chr9:136259668	T/C	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs9399401	0.626	rs13198644	chr6:142783233	A/G	cg03128060	chr6:142623767	GPR126	0.58	9.61	0.47	1.76e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-6.89	-0.35	2.77e-11	Alzheimer's disease (late onset);
LUSC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07677032	chr17:61819896	STRADA	0.52	8.72	0.43	1.29e-16	Prudent dietary pattern;
LUSC	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg23649088	chr2:200775458	C2orf69	-0.54	-6.53	-0.34	2.39e-10	Schizophrenia;
LUSC	cis	rs9831754	0.906	rs9840031	chr3:78396140	C/T	cg06138941	chr3:78371609	NA	0.66	9.23	0.45	3.25e-18	Calcium levels;
LUSC	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg08779649	chr13:50194554	NA	0.4	6.89	0.35	2.85e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs12681287	0.608	rs2953511	chr8:87340870	G/A	cg27223183	chr8:87520930	FAM82B	-0.54	-7.08	-0.36	8.62e-12	Caudate activity during reward;
LUSC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg25767906	chr1:53392781	SCP2	0.45	8.02	0.4	1.84e-14	Monocyte count;
LUSC	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg12179176	chr11:130786555	SNX19	0.77	13.25	0.59	1.74e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.82	-0.35	4.17e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg17757837	chr7:157058334	UBE3C	0.83	13.33	0.59	8.46e-33	Body mass index;
LUSC	cis	rs7605827	0.893	rs2098463	chr2:15512175	C/G	cg19274914	chr2:15703543	NA	0.46	8.94	0.44	2.66e-17	Educational attainment (years of education);
LUSC	cis	rs11649653	0.502	rs62057232	chr16:30820866	T/C	cg02466173	chr16:30829666	NA	0.48	9.4	0.46	8.97e-19	Triglycerides;
LUSC	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg15309053	chr8:964076	NA	0.32	6.27	0.32	1.13e-9	Schizophrenia;
LUSC	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	0.98	12.85	0.58	5.65e-31	Uric acid levels;
LUSC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg18225595	chr11:63971243	STIP1	0.47	5.68	0.3	3.01e-8	Mean platelet volume;
LUSC	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.58	9.96	0.48	1.27e-20	Bone mineral density;
LUSC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg16325326	chr1:53192061	ZYG11B	0.71	11.6	0.54	2.19e-26	Monocyte count;
LUSC	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg11161011	chr14:65562177	MAX	0.71	11.12	0.52	1.21e-24	Obesity-related traits;
LUSC	cis	rs13253111	0.766	rs56232071	chr8:28063230	A/T	cg26534493	chr8:28060551	NA	0.45	8.67	0.43	1.92e-16	Childhood body mass index;
LUSC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg05896524	chr21:47604654	C21orf56	0.5	7.18	0.37	4.54e-12	Testicular germ cell tumor;
LUSC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg17173187	chr15:85201210	NMB	0.37	6.54	0.34	2.26e-10	Schizophrenia;
LUSC	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg10978503	chr1:24200527	CNR2	0.49	11.17	0.52	7.73e-25	Immature fraction of reticulocytes;
LUSC	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg13390004	chr1:15929781	NA	0.4	6.74	0.35	7.14e-11	Systolic blood pressure;
LUSC	cis	rs4356932	0.967	rs4859586	chr4:76943235	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.78	0.3	1.72e-8	Blood protein levels;
LUSC	cis	rs12493885	0.818	rs10935970	chr3:153770237	C/G	cg17054900	chr3:154042577	DHX36	-0.54	-5.8	-0.3	1.58e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.81	13.27	0.59	1.49e-32	Blood protein levels;
LUSC	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg26924012	chr15:45694286	SPATA5L1	0.78	12.41	0.56	2.5e-29	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs6977660	0.714	rs10270204	chr7:19819544	C/T	cg05791153	chr7:19748676	TWISTNB	0.65	6.87	0.35	3.09e-11	Thyroid stimulating hormone;
LUSC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg08949735	chr16:89699720	DPEP1	-0.24	-5.88	-0.31	9.91e-9	Vitiligo;
LUSC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg17724175	chr1:150552817	MCL1	0.37	6.79	0.35	5.02e-11	Tonsillectomy;
LUSC	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	6.0	0.31	5.06e-9	Breast cancer;
LUSC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00339695	chr16:24857497	SLC5A11	0.6	9.48	0.46	5e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-8.14	-0.41	8e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg25019033	chr10:957182	NA	-0.55	-6.33	-0.33	8e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs9653442	0.527	rs10176782	chr2:100782827	C/A	cg07810366	chr2:100720526	AFF3	-0.44	-7.49	-0.38	6.12e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg07080220	chr10:102295463	HIF1AN	0.61	8.14	0.41	8.11e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs983392	0.709	rs1820428	chr11:59986333	A/T	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.1	-0.32	2.9e-9	Alzheimer's disease (late onset);
LUSC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.49	6.12	0.32	2.68e-9	Renal function-related traits (BUN);
LUSC	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg01579765	chr21:45077557	HSF2BP	-0.48	-10.13	-0.48	3.21e-21	Mean corpuscular volume;
LUSC	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06002616	chr8:101225028	SPAG1	-0.45	-7.39	-0.38	1.17e-12	Atrioventricular conduction;
LUSC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23158103	chr7:148848205	ZNF398	-0.46	-7.49	-0.38	6.07e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg05472934	chr7:22766657	IL6	0.5	7.84	0.39	6.13e-14	Lung cancer;
LUSC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg24578937	chr1:2090814	PRKCZ	-0.43	-9.56	-0.46	2.76e-19	Height;
LUSC	cis	rs7809950	0.817	rs2237678	chr7:107203265	T/G	cg23024343	chr7:107201750	COG5	-0.71	-10.29	-0.49	9.59e-22	Coronary artery disease;
LUSC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	13.13	0.58	5.03e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.21	-13.64	-0.6	5.65e-34	Diabetic kidney disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09311052	chr1:154531418	UBE2Q1	0.46	6.92	0.35	2.36e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg15445000	chr17:37608096	MED1	0.4	6.75	0.35	6.65e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.75	-12.43	-0.56	2.08e-29	Hemoglobin concentration;Hematocrit;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07889337	chr17:38257022	NR1D1	-0.6	-7.69	-0.39	1.65e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg16928487	chr17:17741425	SREBF1	0.46	9.0	0.44	1.72e-17	Total body bone mineral density;
LUSC	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg12317470	chr15:67143691	NA	0.6	5.89	0.31	9.43e-9	Lung cancer (smoking interaction);
LUSC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.44e-12	Motion sickness;
LUSC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg12927641	chr6:109611667	NA	-0.43	-7.62	-0.38	2.71e-13	Reticulocyte fraction of red cells;
LUSC	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.6	-0.34	1.57e-10	Neuroticism;
LUSC	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg27284194	chr4:1044797	NA	0.59	8.96	0.44	2.37e-17	Recombination rate (females);
LUSC	cis	rs4702	0.611	rs11539637	chr15:91428290	C/T	cg05469396	chr15:91419421	FURIN	0.46	8.21	0.41	5.05e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs6961069	0.585	rs13228738	chr7:80250811	C/T	cg04458919	chr7:80252533	CD36	-0.37	-6.55	-0.34	2.12e-10	Platelet count;
LUSC	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg05313129	chr8:58192883	C8orf71	-0.49	-5.69	-0.3	2.74e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07988820	chr12:82153109	PPFIA2	-0.42	-5.78	-0.3	1.68e-8	Resting heart rate;
LUSC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg25039879	chr17:56429692	SUPT4H1	0.5	7.04	0.36	1.07e-11	Cognitive test performance;
LUSC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-10.35	-0.49	5.88e-22	Alzheimer's disease;
LUSC	cis	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg06521331	chr12:34319734	NA	-0.46	-7.59	-0.38	3.28e-13	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.98	-0.4	2.39e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg27284194	chr4:1044797	NA	-0.35	-5.71	-0.3	2.52e-8	Obesity-related traits;
LUSC	cis	rs4356932	1.000	rs6532114	chr4:76957974	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.63e-8	Blood protein levels;
LUSC	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	7.73	0.39	1.29e-13	Iron status biomarkers;
LUSC	cis	rs1044826	1.000	rs12695700	chr3:139212098	C/G	cg00490450	chr3:139108681	COPB2	0.51	6.8	0.35	4.8e-11	Obesity-related traits;
LUSC	cis	rs8092503	1.000	rs62091462	chr18:52488698	T/C	cg12377874	chr18:52495404	RAB27B	0.35	6.25	0.32	1.27e-9	Childhood body mass index;
LUSC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg17143192	chr8:8559678	CLDN23	0.65	9.49	0.46	4.57e-19	Obesity-related traits;
LUSC	cis	rs4450131	0.522	rs3781451	chr10:126355477	G/A	cg20435097	chr10:126320824	FAM53B	0.23	5.87	0.31	1.06e-8	White blood cell count (basophil);
LUSC	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.84	0.35	3.9e-11	IgG glycosylation;
LUSC	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.54	-0.38	4.58e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg03676636	chr4:99064102	C4orf37	-0.35	-7.69	-0.39	1.65e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.51	-7.43	-0.38	9.43e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg04362960	chr10:104952993	NT5C2	1.13	12.36	0.56	3.72e-29	Arsenic metabolism;
LUSC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.62	8.31	0.41	2.42e-15	High light scatter reticulocyte count;
LUSC	cis	rs11671005	0.735	rs12977592	chr19:58961056	C/G	cg26874164	chr19:58962979	ZNF324B	-0.45	-5.84	-0.3	1.23e-8	Mean platelet volume;
LUSC	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.86	13.87	0.6	7.36e-35	Coronary artery disease;
LUSC	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg04374321	chr14:90722782	PSMC1	0.72	11.28	0.53	3.3e-25	Mortality in heart failure;
LUSC	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.04	0.44	1.29e-17	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg07716408	chr11:68623521	NA	-0.33	-6.44	-0.33	4.23e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.38	-7.46	-0.38	7.71e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg16558253	chr16:72132732	DHX38	-0.38	-5.97	-0.31	6.17e-9	Fibrinogen levels;
LUSC	trans	rs13011075	0.919	rs6709464	chr2:68622220	C/T	cg14221825	chr19:46271408	SIX5	0.42	6.03	0.31	4.32e-9	Mean corpuscular volume;
LUSC	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg25237894	chr2:233734115	C2orf82	0.34	6.36	0.33	6.67e-10	Coronary artery disease;
LUSC	cis	rs4654899	0.865	rs6673455	chr1:21361048	T/C	cg01072550	chr1:21505969	NA	-0.51	-7.45	-0.38	7.9e-13	Superior frontal gyrus grey matter volume;
LUSC	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg06606381	chr12:133084897	FBRSL1	-1.03	-9.54	-0.46	3.07e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg15017067	chr4:17643749	FAM184B	0.33	5.66	0.3	3.3e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg12081754	chr8:22256438	SLC39A14	0.8	13.08	0.58	7.67e-32	Verbal declarative memory;
LUSC	cis	rs5744897	0.655	rs35131280	chr12:133275974	A/G	cg26621607	chr12:133180238	NA	0.46	5.68	0.3	2.93e-8	Urate levels in overweight individuals;
LUSC	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg23205692	chr1:25664452	TMEM50A	-0.38	-5.69	-0.3	2.85e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs1681630	0.545	rs12790666	chr11:47983477	G/A	cg18512352	chr11:47633146	NA	-0.3	-6.05	-0.31	3.8e-9	Height;
LUSC	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg24675056	chr1:15929824	NA	0.45	7.76	0.39	1.03e-13	Systolic blood pressure;
LUSC	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg19610905	chr11:61596333	FADS2	-0.51	-7.74	-0.39	1.21e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LUSC	cis	rs7215564	0.908	rs7503757	chr17:78685599	A/G	cg23238734	chr17:78661607	RPTOR	0.55	6.71	0.34	8.4e-11	Myopia (pathological);
LUSC	cis	rs500891	0.868	rs62419326	chr6:84145041	C/T	cg08257003	chr6:84140564	ME1	0.35	7.27	0.37	2.56e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg26769984	chr7:1090371	C7orf50	0.58	8.06	0.4	1.34e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg19318889	chr4:1322082	MAEA	0.48	7.69	0.39	1.68e-13	Obesity-related traits;
LUSC	trans	rs804280	1.000	rs804281	chr8:11611865	A/G	cg08975724	chr8:8085496	FLJ10661	0.52	7.23	0.37	3.28e-12	Myopia (pathological);
LUSC	cis	rs4629180	0.586	rs1995826	chr2:102129420	A/G	cg04415270	chr2:102091202	RFX8	0.42	7.19	0.37	4.34e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.25	-27.41	-0.83	1.81e-87	Exhaled nitric oxide output;
LUSC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg07701084	chr6:150067640	NUP43	0.55	8.35	0.42	1.9e-15	Lung cancer;
LUSC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg06640241	chr16:89574553	SPG7	0.92	17.22	0.69	5.16e-48	Multiple myeloma (IgH translocation);
LUSC	trans	rs6982636	1.000	rs17321515	chr8:126486409	C/T	cg13325919	chr3:181432053	SOX2;SOX2OT	0.34	6.68	0.34	1.01e-10	Lipid metabolism phenotypes;
LUSC	cis	rs9549260	0.755	rs59308928	chr13:41245079	C/T	cg21288729	chr13:41239152	FOXO1	0.63	9.8	0.47	4.43e-20	Red blood cell count;
LUSC	cis	rs7202877	0.706	rs4888393	chr16:75413673	C/T	cg03315344	chr16:75512273	CHST6	0.43	6.42	0.33	4.69e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-17.36	-0.69	1.44e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.43	0.53	9.29e-26	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg03676636	chr4:99064102	C4orf37	0.32	7.05	0.36	1.06e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06850241	chr22:41845214	NA	-0.32	-6.01	-0.31	4.96e-9	Vitiligo;
LUSC	cis	rs9297145	0.585	rs17147666	chr7:98781457	A/C	cg05967295	chr7:98741636	SMURF1	-0.66	-10.33	-0.49	6.79e-22	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs68092024	0.704	rs792832	chr3:99474862	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	6.39	0.33	5.43e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs2273669	0.667	rs77936298	chr6:109350616	A/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs12760731	0.641	rs10047148	chr1:178250266	T/C	cg00404053	chr1:178313656	RASAL2	0.63	6.63	0.34	1.37e-10	Obesity-related traits;
LUSC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg13939156	chr17:80058883	NA	0.34	6.69	0.34	9.5e-11	Life satisfaction;
LUSC	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg13813247	chr22:41461852	NA	-0.36	-6.55	-0.34	2.19e-10	Neuroticism;
LUSC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg13114125	chr14:105738426	BRF1	-0.91	-15.96	-0.66	5.33e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	0.94	18.94	0.72	7.18e-55	Cognitive function;
LUSC	cis	rs7202877	0.561	rs4888369	chr16:75307277	T/C	cg04384234	chr16:75411784	CFDP1	-0.66	-8.92	-0.44	3.07e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg09034736	chr1:150693464	HORMAD1	0.47	6.8	0.35	4.71e-11	Melanoma;
LUSC	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg27284194	chr4:1044797	NA	0.59	8.86	0.44	4.9e-17	Recombination rate (females);
LUSC	trans	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg07393940	chr7:158741817	NA	-0.53	-8.42	-0.42	1.09e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	9.98	0.48	1.09e-20	Mean corpuscular volume;
LUSC	cis	rs9420	0.890	rs547891	chr11:57499065	C/T	cg02958346	chr11:57425731	CLP1	0.42	6.12	0.32	2.64e-9	Schizophrenia;
LUSC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.44	-7.5	-0.38	6e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg26727032	chr16:67993705	SLC12A4	-0.45	-5.94	-0.31	7.32e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18872604	chr11:64002754	VEGFB	0.41	6.21	0.32	1.58e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg07810366	chr2:100720526	AFF3	-0.45	-7.61	-0.38	2.86e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg02038168	chr22:39784481	NA	-0.51	-8.08	-0.4	1.22e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13921387	chr1:109655348	C1orf194;KIAA1324	0.46	6.36	0.33	6.61e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs13315871	0.929	rs13101057	chr3:58291467	A/G	cg20936604	chr3:58311152	NA	-0.71	-6.33	-0.33	7.74e-10	Cholesterol, total;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27053636	chr16:58163123	C16orf80	0.43	6.09	0.32	3.12e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg14227996	chr4:17616232	MED28	-0.54	-6.06	-0.31	3.69e-9	Opioid sensitivity;
LUSC	cis	rs804280	0.662	rs11784764	chr8:11610874	C/T	cg00262122	chr8:11665843	FDFT1	-0.51	-6.5	-0.34	2.89e-10	Myopia (pathological);
LUSC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg00033643	chr7:134001901	SLC35B4	0.47	7.42	0.38	9.63e-13	Mean platelet volume;
LUSC	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.39	-0.33	5.59e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg14668632	chr7:2872130	GNA12	-0.43	-6.81	-0.35	4.42e-11	Height;
LUSC	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-10.98	-0.51	3.86e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg05805236	chr11:65401703	PCNXL3	-0.65	-10.61	-0.5	7.57e-23	Acne (severe);
LUSC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.44	-7.39	-0.37	1.18e-12	Electroencephalogram traits;
LUSC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg02551604	chr5:131831745	NA	-0.42	-6.62	-0.34	1.39e-10	Asthma (sex interaction);
LUSC	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg00945038	chr17:61921165	SMARCD2	0.4	6.09	0.32	3.17e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9807989	0.765	rs9807962	chr2:102971664	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.88	0.31	9.76e-9	Asthma;
LUSC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg03146154	chr1:46216737	IPP	0.56	8.34	0.42	2.02e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg11062466	chr8:58055876	NA	0.49	6.3	0.33	9.37e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg19812747	chr11:111475976	SIK2	-0.55	-8.08	-0.4	1.16e-14	Primary sclerosing cholangitis;
LUSC	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-0.87	-12.7	-0.57	2.07e-30	Asthma;
LUSC	cis	rs981844	0.712	rs1012029	chr4:154749233	C/T	cg14289246	chr4:154710475	SFRP2	-0.46	-6.32	-0.33	8.22e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05776053	chr2:74358815	NA	0.45	7.26	0.37	2.76e-12	Gestational age at birth (maternal effect);
LUSC	cis	rs12617721	0.756	rs3754889	chr2:99088633	T/G	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg09640425	chr7:158790006	NA	-0.51	-8.1	-0.41	1.05e-14	Facial morphology (factor 20);
LUSC	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg17173187	chr15:85201210	NMB	0.47	8.97	0.44	2.21e-17	Schizophrenia;
LUSC	cis	rs73206853	0.841	rs74503171	chr12:111061652	A/G	cg12870014	chr12:110450643	ANKRD13A	0.69	7.17	0.37	4.73e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs61869271	0.871	rs6585310	chr10:116732726	G/A	cg23260525	chr10:116636907	FAM160B1	0.31	5.99	0.31	5.47e-9	Tonsillectomy;
LUSC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.52	7.27	0.37	2.56e-12	Gut microbiome composition (summer);
LUSC	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.22	-0.32	1.48e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	1.02	19.7	0.73	7.26e-58	Menopause (age at onset);
LUSC	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg05283184	chr6:79620031	NA	-0.58	-12.26	-0.56	9.1e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg23791538	chr6:167370224	RNASET2	-0.41	-6.49	-0.33	3.17e-10	Crohn's disease;
LUSC	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.42	-0.69	8.72e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8027181	0.839	rs11072385	chr15:73020839	A/G	cg25632853	chr15:73088954	NA	0.32	6.63	0.34	1.36e-10	Triglyceride levels;
LUSC	trans	rs4650994	0.544	rs10798613	chr1:178500022	C/T	cg05059571	chr16:84539110	KIAA1609	-0.48	-9.16	-0.45	5.48e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.54	-8.64	-0.43	2.43e-16	Personality dimensions;
LUSC	trans	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg07211511	chr3:129823064	LOC729375	-0.78	-10.06	-0.48	5.66e-21	Blood pressure (smoking interaction);
LUSC	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg03585969	chr10:35415529	CREM	0.66	9.47	0.46	5.19e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg14227996	chr4:17616232	MED28	0.85	7.96	0.4	2.66e-14	Opioid sensitivity;
LUSC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg26408565	chr15:76604113	ETFA	-0.47	-7.44	-0.38	8.35e-13	Blood metabolite levels;
LUSC	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg18209359	chr17:80159595	CCDC57	-0.36	-5.82	-0.3	1.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg00982548	chr2:198649783	BOLL	-0.56	-7.01	-0.36	1.33e-11	Ulcerative colitis;
LUSC	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.75	0.51	2.35e-23	Fuchs's corneal dystrophy;
LUSC	trans	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg14004847	chr7:1930337	MAD1L1	-0.5	-7.58	-0.38	3.54e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	7.75	0.39	1.14e-13	Coronary artery disease;
LUSC	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg10172584	chr19:19639581	YJEFN3	0.48	5.69	0.3	2.73e-8	Bipolar disorder;
LUSC	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.35	-19.01	-0.72	3.8e-55	Hip circumference adjusted for BMI;
LUSC	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg00982548	chr2:198649783	BOLL	-0.58	-7.29	-0.37	2.32e-12	Ulcerative colitis;
LUSC	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg09165964	chr15:75287851	SCAMP5	-1.15	-18.88	-0.72	1.33e-54	Blood trace element (Zn levels);
LUSC	cis	rs829883	0.664	rs865509	chr12:98854444	T/A	cg25150519	chr12:98850993	NA	0.83	14.13	0.61	7.1e-36	Colorectal adenoma (advanced);
LUSC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg13560548	chr3:10150139	C3orf24	0.52	7.18	0.37	4.45e-12	Alzheimer's disease;
LUSC	cis	rs9653442	0.545	rs12987209	chr2:100761148	C/T	cg07810366	chr2:100720526	AFF3	-0.45	-7.75	-0.39	1.13e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	0.59	9.24	0.45	2.93e-18	Breast cancer;
LUSC	cis	rs6500395	0.962	rs9924483	chr16:48646258	C/T	cg04672837	chr16:48644449	N4BP1	0.47	6.66	0.34	1.16e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs5753618	0.509	rs2413033	chr22:31574213	A/G	cg22777020	chr22:31556080	RNF185	-0.46	-5.8	-0.3	1.54e-8	Colorectal cancer;
LUSC	cis	rs231513	0.681	rs8079623	chr17:42027330	C/G	cg26893861	chr17:41843967	DUSP3	-0.54	-5.68	-0.3	2.93e-8	Cognitive function;
LUSC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg05283184	chr6:79620031	NA	-0.57	-12.0	-0.55	8.16e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg03060546	chr3:49711283	APEH	-0.63	-7.46	-0.38	7.34e-13	Menarche (age at onset);
LUSC	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg01528321	chr10:82214614	TSPAN14	0.84	12.92	0.58	2.91e-31	Post bronchodilator FEV1;
LUSC	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.69	-0.39	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg13010199	chr12:38710504	ALG10B	-0.63	-9.78	-0.47	5e-20	Morning vs. evening chronotype;
LUSC	cis	rs6700896	0.500	rs12043772	chr1:66135034	T/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.93	0.31	7.6e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg17948913	chr5:572064	NA	0.37	5.73	0.3	2.21e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9420	0.961	rs80304923	chr11:57522823	C/G	cg02958346	chr11:57425731	CLP1	-0.44	-6.44	-0.33	4.22e-10	Schizophrenia;
LUSC	cis	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg09307838	chr4:120376055	NA	-0.48	-7.33	-0.37	1.77e-12	Diastolic blood pressure;
LUSC	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg06636001	chr8:8085503	FLJ10661	0.47	6.95	0.36	1.93e-11	Neuroticism;
LUSC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg08683831	chr4:1404607	NA	0.35	5.94	0.31	7.14e-9	Obesity-related traits;
LUSC	cis	rs2414059	0.518	rs8026653	chr15:50736620	G/C	cg08437265	chr15:50716283	USP8	-0.41	-6.0	-0.31	5.14e-9	QT interval;
LUSC	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg05234568	chr11:5960015	NA	-0.6	-8.67	-0.43	1.97e-16	DNA methylation (variation);
LUSC	cis	rs977987	0.778	rs11149825	chr16:75434878	C/T	cg03315344	chr16:75512273	CHST6	0.48	9.03	0.44	1.41e-17	Dupuytren's disease;
LUSC	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg16586182	chr3:47516702	SCAP	0.52	7.41	0.38	1.03e-12	Birth weight;
LUSC	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21984481	chr17:79567631	NPLOC4	0.75	15.75	0.65	3.55e-42	Eye color traits;
LUSC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg27170947	chr2:26402098	FAM59B	-0.71	-10.67	-0.5	4.58e-23	Gut microbiome composition (summer);
LUSC	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg06623918	chr6:96969491	KIAA0776	0.73	8.64	0.43	2.33e-16	Migraine;Coronary artery disease;
LUSC	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21293242	chr8:11204541	TDH	-0.35	-6.78	-0.35	5.61e-11	Retinal vascular caliber;
LUSC	cis	rs9463078	0.527	rs2040032	chr6:44743009	C/T	cg25276700	chr6:44698697	NA	0.3	6.33	0.33	7.67e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg09904177	chr6:26538194	HMGN4	-0.74	-6.53	-0.34	2.5e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg12863693	chr15:85201151	NMB	-0.27	-6.16	-0.32	2.06e-9	P wave terminal force;
LUSC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22307029	chr19:49891270	CCDC155	-0.62	-7.91	-0.4	3.84e-14	Multiple sclerosis;
LUSC	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-8.19	-0.41	5.45e-15	Vitamin D levels;
LUSC	cis	rs2953174	0.938	rs2953167	chr2:241539366	T/C	cg07929629	chr2:241523174	NA	0.47	6.11	0.32	2.82e-9	Bipolar disorder;
LUSC	cis	rs4654899	0.965	rs6692081	chr1:21296363	T/C	cg01072550	chr1:21505969	NA	-0.55	-8.41	-0.42	1.23e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg17718321	chr1:152188247	HRNR	-0.38	-6.81	-0.35	4.58e-11	Inflammatory skin disease;
LUSC	cis	rs11608355	0.545	rs4766603	chr12:109892106	T/C	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.1e-26	Neuroticism;
LUSC	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	7.84	0.39	6.24e-14	Coffee consumption (cups per day);
LUSC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.79	0.35	5.19e-11	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg15704280	chr7:45808275	SEPT13	-0.63	-7.68	-0.39	1.83e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs981844	0.775	rs17299519	chr4:154762123	C/T	cg14289246	chr4:154710475	SFRP2	0.5	6.67	0.34	1.09e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg26597838	chr10:835615	NA	-0.48	-6.43	-0.33	4.3e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg02807482	chr3:125708958	NA	-0.49	-6.08	-0.32	3.22e-9	Blood pressure (smoking interaction);
LUSC	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-0.93	-10.31	-0.49	7.79e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.16e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	0.9	17.03	0.68	2.9e-47	Cognitive function;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14450231	chr5:172199425	DUSP1	0.44	6.53	0.34	2.44e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9494145	0.667	rs1331309	chr6:135406178	T/G	cg24558204	chr6:135376177	HBS1L	0.48	5.93	0.31	7.51e-9	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs829880	0.558	rs249820	chr12:98897473	A/G	cg25150519	chr12:98850993	NA	0.44	5.65	0.3	3.52e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg15445000	chr17:37608096	MED1	0.4	6.8	0.35	4.85e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9818941	0.793	rs9874758	chr3:157735625	A/G	cg08654915	chr3:157813417	NA	-0.33	-7.6	-0.38	3.03e-13	Height;
LUSC	cis	rs3849570	0.643	rs1851928	chr3:81975395	C/T	cg07356753	chr3:81810745	GBE1	-0.49	-7.28	-0.37	2.44e-12	Waist circumference;Body mass index;
LUSC	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg03676636	chr4:99064102	C4orf37	-0.26	-5.65	-0.3	3.41e-8	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg20203395	chr5:56204925	C5orf35	-0.79	-10.38	-0.49	4.48e-22	Initial pursuit acceleration;
LUSC	cis	rs30380	0.632	rs30186	chr5:96124447	G/C	cg16492584	chr5:96139282	ERAP1	-0.52	-7.05	-0.36	1e-11	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs77741769	0.571	rs4766979	chr12:121281748	G/A	cg02419362	chr12:121203948	SPPL3	0.46	8.51	0.42	5.89e-16	Mean corpuscular volume;
LUSC	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg11189052	chr15:85197271	WDR73	0.53	6.74	0.35	6.78e-11	Schizophrenia;
LUSC	cis	rs981844	1.000	rs2606325	chr4:154652681	C/T	cg14289246	chr4:154710475	SFRP2	0.54	6.77	0.35	5.92e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg06074448	chr4:187884817	NA	-0.46	-7.66	-0.39	2.08e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10170310	0.872	rs62161711	chr2:139259222	A/G	cg10095539	chr2:139258744	SPOPL	0.33	5.92	0.31	8.04e-9	Response to antipsychotic treatment;
LUSC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-9.64	-0.47	1.42e-19	Schizophrenia;
LUSC	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg27284194	chr4:1044797	NA	0.58	8.7	0.43	1.57e-16	Recombination rate (females);
LUSC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg24829409	chr8:58192753	C8orf71	-0.54	-5.92	-0.31	8.21e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg12257692	chr3:49977190	RBM6	-0.26	-7.17	-0.37	4.7e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg21775007	chr8:11205619	TDH	-0.5	-7.19	-0.37	4.41e-12	Neuroticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11236850	chr4:8443022	ACOX3	0.46	6.78	0.35	5.44e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg00750074	chr16:89608354	SPG7	-0.45	-7.83	-0.39	6.45e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs7122539	0.768	rs7931485	chr11:66578635	G/A	cg24851651	chr11:66362959	CCS	0.46	7.53	0.38	4.9e-13	HIV-1 susceptibility;
LUSC	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.55	-8.07	-0.4	1.29e-14	Colorectal cancer;
LUSC	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-14.1	-0.61	9.35e-36	Exhaled nitric oxide output;
LUSC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs9905704	0.846	rs304262	chr17:56814456	A/G	cg12560992	chr17:57184187	TRIM37	0.58	8.21	0.41	5.05e-15	Testicular germ cell tumor;
LUSC	trans	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg13902645	chr11:5959945	NA	-0.55	-8.45	-0.42	9.18e-16	DNA methylation (variation);
LUSC	cis	rs793571	0.502	rs395601	chr15:59063196	G/C	cg05156742	chr15:59063176	FAM63B	0.57	9.01	0.44	1.66e-17	Schizophrenia;
LUSC	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg11211951	chr8:145729740	GPT	-0.57	-11.22	-0.52	5.23e-25	Age at first birth;
LUSC	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg16342193	chr10:102329863	NA	-0.37	-6.45	-0.33	3.86e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs877282	0.898	rs11253353	chr10:766862	C/A	cg22713356	chr15:30763199	NA	1.15	14.94	0.63	5.3e-39	Uric acid levels;
LUSC	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg04362960	chr10:104952993	NT5C2	0.61	9.64	0.47	1.4e-19	Arsenic metabolism;
LUSC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg27124370	chr19:33622961	WDR88	0.58	8.07	0.4	1.24e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs9653442	0.564	rs11902705	chr2:100795207	A/G	cg22139774	chr2:100720529	AFF3	0.38	6.61	0.34	1.55e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg04518342	chr5:131593106	PDLIM4	0.51	8.96	0.44	2.31e-17	Acylcarnitine levels;
LUSC	cis	rs6138458	0.847	rs56312312	chr20:24959386	C/A	cg06937882	chr20:24974362	C20orf3	-0.46	-7.78	-0.39	9.13e-14	Blood protein levels;
LUSC	cis	rs806215	0.951	rs327516	chr7:127255795	C/G	cg25922125	chr7:127225783	GCC1	0.53	6.58	0.34	1.87e-10	Type 2 diabetes;
LUSC	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg21918786	chr6:109611834	NA	-0.36	-6.01	-0.31	4.73e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7119038	0.865	rs7951740	chr11:118740418	G/C	cg19308663	chr11:118741387	NA	-0.35	-5.99	-0.31	5.49e-9	Sjögren's syndrome;
LUSC	trans	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg15556689	chr8:8085844	FLJ10661	0.45	6.69	0.34	9.39e-11	Retinal vascular caliber;
LUSC	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg18825076	chr15:78729989	IREB2	0.47	6.49	0.33	3.14e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	trans	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.1	-0.32	2.97e-9	Neuroticism;
LUSC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.17	0.45	4.94e-18	Monocyte percentage of white cells;
LUSC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.74	0.43	1.16e-16	Prudent dietary pattern;
LUSC	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg11019008	chr10:131425282	MGMT	0.42	6.4	0.33	5.3e-10	Response to temozolomide;
LUSC	cis	rs7681440	0.583	rs2619339	chr4:90777468	G/C	cg06632027	chr4:90757378	SNCA	-0.37	-5.75	-0.3	1.99e-8	Dementia with Lewy bodies;
LUSC	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.74	-11.28	-0.53	3.34e-25	Heart rate;
LUSC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg12560992	chr17:57184187	TRIM37	-0.79	-14.97	-0.63	4.14e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs7587476	0.601	rs1129804	chr2:215674323	C/G	cg04004882	chr2:215674386	BARD1	-0.52	-7.27	-0.37	2.54e-12	Neuroblastoma;
LUSC	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg13813247	chr22:41461852	NA	-0.36	-6.59	-0.34	1.72e-10	Neuroticism;
LUSC	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg05738196	chr6:26577821	NA	-0.48	-6.8	-0.35	4.9e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg26380479	chr7:97908229	NA	-0.28	-6.13	-0.32	2.54e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.76	11.48	0.53	6.24e-26	Itch intensity from mosquito bite;
LUSC	cis	rs11971779	0.680	rs10271297	chr7:139052310	A/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.04	0.36	1.12e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.74	-13.22	-0.59	2.21e-32	Cognitive function;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg03745386	chr12:29534188	ERGIC2	0.36	6.02	0.31	4.48e-9	Triglycerides;
LUSC	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg13010199	chr12:38710504	ALG10B	0.71	10.9	0.51	7.24e-24	Bladder cancer;
LUSC	cis	rs2219968	1.000	rs13262830	chr8:78957669	C/T	cg00738934	chr8:78996279	NA	0.37	6.89	0.35	2.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg16606324	chr3:10149918	C3orf24	0.62	9.08	0.44	9.81e-18	Alzheimer's disease;
LUSC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	9.51	0.46	3.94e-19	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg16339924	chr4:17578868	LAP3	0.55	8.25	0.41	3.69e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7582720	1.000	rs6435169	chr2:203753016	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	10.85	0.51	1.11e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs7584330	0.554	rs729389	chr2:238425118	G/A	cg16989719	chr2:238392110	NA	-0.43	-6.13	-0.32	2.41e-9	Prostate cancer;
LUSC	cis	rs243505	0.737	rs243538	chr7:148404379	G/A	cg09806900	chr7:148480153	CUL1	-0.52	-6.67	-0.34	1.06e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs2262909	0.925	rs73019900	chr19:22286680	G/A	cg05197062	chr11:11642011	GALNTL4	0.54	7.5	0.38	5.64e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.69	-10.77	-0.51	2.04e-23	Aortic root size;
LUSC	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg22029157	chr1:209979665	IRF6	0.51	8.12	0.41	9e-15	Monobrow;
LUSC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.57	-6.95	-0.36	1.91e-11	Birth weight;
LUSC	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.69	11.82	0.54	3.47e-27	Myeloid white cell count;
LUSC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	11.95	0.55	1.25e-27	Personality dimensions;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13914598	chr12:123460194	OGFOD2;ABCB9	0.44	6.79	0.35	5.01e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.95	0.31	6.7e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.8	15.13	0.64	9.03e-40	Dental caries;
LUSC	cis	rs10911363	0.592	rs2702205	chr1:183457198	A/G	cg09173681	chr1:183549694	NCF2	0.66	12.24	0.56	1.08e-28	Systemic lupus erythematosus;
LUSC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg17143192	chr8:8559678	CLDN23	0.63	9.27	0.45	2.34e-18	Obesity-related traits;
LUSC	trans	rs1486139	1.000	rs990525	chr7:46296689	C/T	cg17534202	chr9:96721102	NA	0.34	6.14	0.32	2.36e-9	Select biomarker traits;
LUSC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.37	-0.37	1.34e-12	Electroencephalogram traits;
LUSC	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg21132104	chr15:45694354	SPATA5L1	0.41	6.04	0.31	4.09e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	8.18	0.41	5.91e-15	Height;
LUSC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.06	0.66	2.06e-43	Platelet count;
LUSC	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg03806693	chr22:41940476	POLR3H	-0.85	-12.2	-0.56	1.5e-28	Vitiligo;
LUSC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg06212747	chr3:49208901	KLHDC8B	0.44	6.02	0.31	4.7e-9	Parkinson's disease;
LUSC	cis	rs2573652	0.722	rs12908133	chr15:100544405	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.3	-5.66	-0.3	3.26e-8	Height;
LUSC	cis	rs9682041	0.627	rs11924474	chr3:170091333	T/G	cg11886554	chr3:170076028	SKIL	0.69	9.41	0.46	8.26e-19	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg22963979	chr7:1858916	MAD1L1	-0.63	-10.07	-0.48	5.44e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-6.01	-0.31	4.97e-9	Retinal vascular caliber;
LUSC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-10.92	-0.51	6.2e-24	Chronic sinus infection;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg14963534	chr19:17420130	DDA1	0.66	6.02	0.31	4.66e-9	Cognitive performance;
LUSC	cis	rs2227564	0.700	rs2675677	chr10:75648249	C/A	cg23231163	chr10:75533350	FUT11	-0.42	-5.94	-0.31	7.35e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs2490361	1.000	rs10925334	chr1:237326051	A/T	cg15653282	chr18:11689218	GNAL	0.39	6.02	0.31	4.6e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	-0.52	-7.19	-0.37	4.27e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg26338869	chr17:61819248	STRADA	0.42	6.01	0.31	4.85e-9	Prudent dietary pattern;
LUSC	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.19	-0.45	4.31e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.21	0.66	5.1e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg20276088	chr3:133502917	NA	-0.38	-5.68	-0.3	2.98e-8	Iron status biomarkers;
LUSC	cis	rs8032315	0.965	rs4932373	chr15:91429287	A/C	cg05469396	chr15:91419421	FURIN	-0.42	-6.53	-0.34	2.52e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.83	-14.7	-0.63	4.53e-38	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	0.74	14.56	0.62	1.6e-37	Gestational age at birth (maternal effect);
LUSC	cis	rs16854884	1.000	rs58251824	chr3:143786258	T/C	cg06585982	chr3:143692056	C3orf58	0.47	6.56	0.34	2e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg15557168	chr22:42548783	NA	-0.42	-6.57	-0.34	1.94e-10	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	0.81	12.93	0.58	2.74e-31	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs12618769	0.652	rs7585747	chr2:99219071	T/C	cg10123293	chr2:99228465	UNC50	0.47	7.6	0.38	2.98e-13	Bipolar disorder;
LUSC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	7.12	0.36	6.77e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg07507251	chr3:52567010	NT5DC2	0.34	6.72	0.35	7.67e-11	Bipolar disorder;
LUSC	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.57	-0.38	3.69e-13	Educational attainment;
LUSC	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg01579765	chr21:45077557	HSF2BP	-0.47	-9.7	-0.47	8.9e-20	Mean corpuscular volume;
LUSC	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg17764715	chr19:33622953	WDR88	0.58	7.88	0.4	4.53e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg23711669	chr6:146136114	FBXO30	0.9	17.08	0.68	1.94e-47	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22098556	chr9:138798463	CAMSAP1	-0.43	-6.64	-0.34	1.3e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg08875078	chr22:50639485	SELO	0.45	6.28	0.32	1.07e-9	Obesity-related traits;
LUSC	cis	rs66731853	0.771	rs541244	chr1:20889380	G/A	cg04087271	chr1:20915334	CDA	-0.51	-8.89	-0.44	3.89e-17	Mean corpuscular volume;
LUSC	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.44	-0.33	4.26e-10	Arsenic metabolism;
LUSC	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg03929089	chr4:120376271	NA	-0.45	-6.26	-0.32	1.18e-9	Height;
LUSC	cis	rs4499344	0.524	rs259242	chr19:33144248	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.91	13.4	0.59	4.59e-33	Mean platelet volume;
LUSC	trans	rs7178375	1.000	rs1474381	chr15:31214991	T/C	cg04373760	chr16:53404718	NA	0.64	8.88	0.44	4.28e-17	Hypertriglyceridemia;
LUSC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08219700	chr8:58056026	NA	0.65	7.55	0.38	4.23e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.75	-7.51	-0.38	5.59e-13	Diabetic retinopathy;
LUSC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg24154853	chr7:158122151	PTPRN2	-0.42	-8.26	-0.41	3.33e-15	Calcium levels;
LUSC	cis	rs2637266	0.935	rs12414653	chr10:78394071	C/G	cg18941641	chr10:78392320	NA	0.42	7.59	0.38	3.29e-13	Pulmonary function;
LUSC	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.49	-0.42	6.8e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	0.58	9.15	0.45	5.95e-18	Breast cancer;
LUSC	cis	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg17469321	chr7:55412551	NA	0.66	10.62	0.5	6.87e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg08219700	chr8:58056026	NA	0.51	6.35	0.33	7.03e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.77	0.3	1.8e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg02454025	chr1:11042201	C1orf127	1.03	18.59	0.71	1.77e-53	Ewing sarcoma;
LUSC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg03388025	chr16:89894329	SPIRE2	-0.32	-6.7	-0.34	8.66e-11	Vitiligo;
LUSC	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.55e-13	Putamen volume;
LUSC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.57	-8.38	-0.42	1.51e-15	Obesity-related traits;
LUSC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg23262073	chr20:60523788	NA	-0.43	-6.2	-0.32	1.69e-9	Body mass index;
LUSC	trans	rs2935183	1	rs2935183	chr17:45607572	T/G	cg03886242	chr7:26192032	NFE2L3	0.37	6.01	0.31	4.8e-9	Multiple sclerosis or amyotrophic lateral sclerosis;
LUSC	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg05163923	chr11:71159392	DHCR7	-0.76	-9.95	-0.48	1.32e-20	Vitamin D levels;
LUSC	cis	rs8099014	0.954	rs4294895	chr18:56126867	T/C	cg12907477	chr18:56117327	MIR122	0.43	6.69	0.34	9.48e-11	Platelet count;
LUSC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg11632617	chr15:75315747	PPCDC	-0.5	-6.58	-0.34	1.86e-10	Blood trace element (Zn levels);
LUSC	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17916960	chr15:79447300	NA	-0.53	-10.55	-0.5	1.24e-22	Refractive error;
LUSC	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg22532475	chr10:104410764	TRIM8	-0.32	-7.18	-0.37	4.55e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7246967	0.673	rs35061555	chr19:22963766	T/C	cg23217946	chr19:22817039	ZNF492	0.43	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg23289794	chr7:2394357	EIF3B	-0.76	-9.99	-0.48	9.5e-21	Multiple sclerosis;
LUSC	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.43	6.62	0.34	1.41e-10	Dupuytren's disease;
LUSC	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.7	-11.46	-0.53	7.05e-26	Height;
LUSC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg03146154	chr1:46216737	IPP	0.53	7.75	0.39	1.09e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg01879757	chr17:41196368	BRCA1	-0.46	-6.92	-0.35	2.26e-11	Menopause (age at onset);
LUSC	cis	rs939574	0.929	rs10190834	chr2:220070301	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.95	-8.17	-0.41	6.53e-15	Platelet distribution width;
LUSC	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.69	-0.39	1.68e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg20790798	chr5:1857306	NA	-0.38	-5.71	-0.3	2.46e-8	Cardiovascular disease risk factors;
LUSC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg19592336	chr6:28129416	ZNF389	-0.44	-5.97	-0.31	6.02e-9	Depression;
LUSC	cis	rs1358748	0.522	rs7531589	chr1:67555366	A/G	cg02640540	chr1:67518911	SLC35D1	0.67	6.57	0.34	1.98e-10	Tuberculosis;
LUSC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg25072359	chr17:41440525	NA	0.6	8.66	0.43	2.05e-16	Menopause (age at onset);
LUSC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-1.02	-15.49	-0.65	3.7e-41	Initial pursuit acceleration;
LUSC	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg04725166	chr1:7887271	PER3	-0.42	-5.79	-0.3	1.66e-8	Crohn's disease;
LUSC	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg05729581	chr11:3078854	CARS	-0.38	-5.78	-0.3	1.71e-8	Longevity;
LUSC	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg07148914	chr20:33460835	GGT7	0.54	8.4	0.42	1.33e-15	Height;
LUSC	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg11019008	chr10:131425282	MGMT	-0.4	-6.2	-0.32	1.68e-9	Response to temozolomide;
LUSC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.23	14.23	0.61	2.91e-36	Diabetic kidney disease;
LUSC	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg11244672	chr19:19639970	YJEFN3	-0.54	-6.59	-0.34	1.76e-10	Bipolar disorder;
LUSC	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg24375607	chr4:120327624	NA	0.77	12.51	0.56	1.08e-29	Corneal astigmatism;
LUSC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26818010	chr10:134567672	INPP5A	-0.88	-11.35	-0.53	1.85e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg22834771	chr12:69754056	YEATS4	-0.44	-5.75	-0.3	1.97e-8	Response to diuretic therapy;
LUSC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15541040	chr2:3486749	NA	0.5	7.76	0.39	1.04e-13	Neurofibrillary tangles;
LUSC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg09796270	chr17:17721594	SREBF1	-0.4	-6.98	-0.36	1.56e-11	Total body bone mineral density;
LUSC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-5.95	-0.31	6.85e-9	Vitiligo;
LUSC	cis	rs7258465	1.000	rs271624	chr19:18627953	A/G	cg06462663	chr19:18546047	ISYNA1	0.45	7.32	0.37	1.88e-12	Breast cancer;
LUSC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg05347473	chr6:146136440	FBXO30	-0.6	-10.6	-0.5	7.93e-23	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-1.13	-18.15	-0.7	1.04e-51	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs17155006	0.655	rs94604	chr7:107733856	C/T	cg05962710	chr7:107745446	LAMB4	-0.32	-5.69	-0.3	2.82e-8	Pneumococcal bacteremia;
LUSC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg12963246	chr6:28129442	ZNF389	-0.44	-6.12	-0.32	2.55e-9	Depression;
LUSC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.48	-0.42	7.37e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs4654899	0.758	rs6688147	chr1:21335894	A/G	cg01072550	chr1:21505969	NA	-0.53	-8.16	-0.41	7.06e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg03599575	chr15:90893182	GABARAPL3	0.34	5.86	0.31	1.13e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg07677032	chr17:61819896	STRADA	0.53	9.02	0.44	1.56e-17	Prudent dietary pattern;
LUSC	cis	rs12210905	0.688	rs12193557	chr6:27435944	T/C	cg08851530	chr6:28072375	NA	0.95	5.82	0.3	1.37e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs2303282	0.716	rs2920704	chr16:56441862	A/G	cg00500540	chr16:56394104	NA	-0.43	-7.32	-0.37	1.88e-12	Breast cancer;
LUSC	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg19774624	chr17:42201019	HDAC5	-0.65	-9.08	-0.45	9.46e-18	Total body bone mineral density;
LUSC	cis	rs7188861	0.768	rs243315	chr16:11385011	C/T	cg00044050	chr16:11439710	C16orf75	0.56	6.1	0.32	2.97e-9	HDL cholesterol;
LUSC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.62	9.24	0.45	2.87e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg02527881	chr3:46936655	PTH1R	-0.43	-7.67	-0.39	1.85e-13	Colorectal cancer;
LUSC	cis	rs78366141	0.536	rs80239864	chr4:89698183	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.88	6.47	0.33	3.55e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs926938	0.541	rs360623	chr1:115407268	G/C	cg01522456	chr1:115632236	TSPAN2	-0.39	-5.79	-0.3	1.59e-8	Autism;
LUSC	cis	rs72777070	0.895	rs12615784	chr2:9789403	A/G	cg14973360	chr2:9800511	NA	-0.5	-6.69	-0.34	9.24e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17467752	chr17:38218738	THRA	-0.49	-6.87	-0.35	3.12e-11	White blood cell count;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16229772	chr11:535615	HRAS	-0.42	-6.45	-0.33	4.04e-10	Electrocardiographic conduction measures;
LUSC	cis	rs2708977	0.901	rs2579505	chr2:97167962	T/C	cg01950434	chr2:97203154	ARID5A	-0.54	-8.04	-0.4	1.62e-14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.79	-0.57	9.28e-31	Platelet count;
LUSC	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg05043794	chr9:111880884	C9orf5	-0.34	-7.23	-0.37	3.33e-12	Menarche (age at onset);
LUSC	cis	rs10782582	0.609	rs5745469	chr1:76347394	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-6.22	-0.32	1.46e-9	Daytime sleep phenotypes;
LUSC	cis	rs7582720	1.000	rs72934537	chr2:203969504	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.7	0.43	1.56e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2413583	0.591	rs114556035	chr22:39734647	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.64	5.82	0.3	1.39e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg00431813	chr7:1051703	C7orf50	-0.45	-7.25	-0.37	2.92e-12	Longevity;Endometriosis;
LUSC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12292205	chr6:26970375	C6orf41	-0.6	-7.36	-0.37	1.47e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg03563238	chr19:33554763	RHPN2	-0.37	-6.25	-0.32	1.25e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.48e-28	Motion sickness;
LUSC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg17366294	chr4:99064904	C4orf37	0.56	10.01	0.48	8.36e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg25643088	chr3:52874325	TMEM110	0.39	6.0	0.31	5.11e-9	Schizophrenia;
LUSC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg04414720	chr1:150670196	GOLPH3L	0.55	8.52	0.42	5.5e-16	Melanoma;
LUSC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07362569	chr17:61921086	SMARCD2	-0.38	-7.91	-0.4	3.84e-14	Prudent dietary pattern;
LUSC	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.89	16.06	0.66	2.02e-43	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs240764	0.781	rs12212736	chr6:101151410	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-6.15	-0.32	2.16e-9	Neuroticism;
LUSC	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	5.99	0.31	5.55e-9	Schizophrenia;
LUSC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg06784218	chr1:46089804	CCDC17	0.53	10.55	0.5	1.22e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	1.04	20.73	0.75	5.84e-62	Cognitive function;
LUSC	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg15744005	chr10:104629667	AS3MT	-0.34	-6.93	-0.35	2.22e-11	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs2997447	0.655	rs1317709	chr1:26384690	A/C	cg19633962	chr1:26362018	EXTL1	-0.55	-6.79	-0.35	5.03e-11	QRS complex (12-leadsum);
LUSC	cis	rs7851660	0.809	rs7037324	chr9:100658318	A/G	cg13688889	chr9:100608707	NA	-0.54	-8.46	-0.42	8.24e-16	Strep throat;
LUSC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg22875332	chr1:76189707	ACADM	0.76	10.15	0.49	2.87e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg19920283	chr7:105172520	RINT1	0.58	6.22	0.32	1.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2932538	0.845	rs6682678	chr1:113206920	A/G	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.58	-0.46	2.23e-19	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg14552801	chr7:65878734	NA	-0.37	-5.65	-0.3	3.53e-8	Aortic root size;
LUSC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg03354898	chr7:1950403	MAD1L1	0.31	6.18	0.32	1.89e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.08	0.52	1.64e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg13256891	chr4:100009986	ADH5	0.52	7.09	0.36	8.03e-12	Smoking initiation;
LUSC	cis	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg07460842	chr6:66804631	NA	-0.48	-6.72	-0.35	7.74e-11	Blood trace element (Cu levels);
LUSC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-0.81	-16.0	-0.66	3.69e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg21770322	chr7:97807741	LMTK2	-0.47	-8.38	-0.42	1.53e-15	Breast cancer;
LUSC	cis	rs4443100	0.670	rs8139280	chr22:23405957	G/A	cg21100191	chr22:23484243	RTDR1	0.56	6.91	0.35	2.43e-11	Serum parathyroid hormone levels;
LUSC	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg08601574	chr20:25228251	PYGB	-0.45	-6.89	-0.35	2.73e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg26528668	chr16:1614120	IFT140	0.47	8.13	0.41	8.24e-15	Coronary artery disease;
LUSC	cis	rs9326248	0.861	rs1871757	chr11:117030581	A/T	cg26566898	chr11:117069891	TAGLN	0.38	6.2	0.32	1.63e-9	Blood protein levels;
LUSC	cis	rs72634258	0.796	rs6703955	chr1:8165975	C/G	cg00042356	chr1:8021962	PARK7	-0.63	-7.87	-0.4	4.85e-14	Inflammatory bowel disease;
LUSC	cis	rs6484504	0.532	rs2761589	chr11:31311429	C/G	cg26647111	chr11:31128758	NA	0.43	6.11	0.32	2.77e-9	Red blood cell count;
LUSC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8102732	1.000	rs8102732	chr19:1023867	C/G	cg13770691	chr19:1021866	C19orf6	0.46	6.87	0.35	3.08e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg07423050	chr13:99094983	FARP1	-0.53	-9.76	-0.47	5.79e-20	Neuroticism;
LUSC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.06	15.48	0.65	4.08e-41	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg23262073	chr20:60523788	NA	-0.43	-6.42	-0.33	4.79e-10	Body mass index;
LUSC	trans	rs11165623	0.564	rs7541109	chr1:96995960	C/A	cg10631902	chr5:14652156	NA	-0.41	-6.06	-0.31	3.69e-9	Hip circumference;Waist circumference;
LUSC	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg15962314	chr1:44399869	ARTN	-0.24	-5.78	-0.3	1.7e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.65	-0.47	1.39e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg11993925	chr19:44307056	LYPD5	0.45	9.48	0.46	5.02e-19	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	8.98	0.44	2.08e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.23e-19	Chronic sinus infection;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08722104	chr11:47448306	PSMC3	0.42	6.26	0.32	1.18e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-9.16	-0.45	5.18e-18	Neuroticism;
LUSC	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg13010199	chr12:38710504	ALG10B	0.57	9.03	0.44	1.35e-17	Morning vs. evening chronotype;
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg00431813	chr7:1051703	C7orf50	-0.44	-7.02	-0.36	1.21e-11	Longevity;Endometriosis;
LUSC	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg05738196	chr6:26577821	NA	0.82	15.81	0.65	1.93e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs2273669	0.667	rs11153147	chr6:109304058	A/G	cg05315195	chr6:109294784	ARMC2	-0.55	-6.19	-0.32	1.76e-9	Prostate cancer;
LUSC	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg08219700	chr8:58056026	NA	0.57	6.78	0.35	5.49e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg18721089	chr20:30220636	NA	-0.41	-6.49	-0.33	3.1e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs4704187	0.574	rs4704184	chr5:74471677	A/G	cg03227963	chr5:74354835	NA	0.3	6.59	0.34	1.68e-10	Response to amphetamines;
LUSC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg18512352	chr11:47633146	NA	0.48	9.94	0.48	1.45e-20	Subjective well-being;
LUSC	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg24006582	chr15:45444508	DUOX1	0.67	9.7	0.47	9.32e-20	Uric acid levels;
LUSC	cis	rs6901250	0.589	rs684023	chr6:117092308	T/C	cg12892004	chr6:117198278	RFX6	0.37	6.62	0.34	1.48e-10	C-reactive protein levels;
LUSC	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-6.64	-0.34	1.26e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg11752832	chr7:134001865	SLC35B4	0.55	8.51	0.42	5.91e-16	Mean platelet volume;
LUSC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg00750074	chr16:89608354	SPG7	-0.46	-7.47	-0.38	7.17e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs2219968	0.962	rs9643734	chr8:78950552	C/T	cg00738934	chr8:78996279	NA	0.37	6.65	0.34	1.21e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11958404	0.932	rs6895484	chr5:157429159	T/C	cg05962755	chr5:157440814	NA	0.54	6.35	0.33	7.18e-10	IgG glycosylation;
LUSC	cis	rs6741892	0.793	rs34391548	chr2:38906486	G/A	cg23643435	chr2:38893251	GALM	-0.75	-5.93	-0.31	7.55e-9	5-HTT brain serotonin transporter levels;
LUSC	cis	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg20368463	chr18:77673604	PQLC1	0.68	10.63	0.5	6.46e-23	Schizophrenia;
LUSC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg22920501	chr2:26401640	FAM59B	0.68	9.9	0.48	1.98e-20	Gut microbiome composition (summer);
LUSC	cis	rs9463078	0.683	rs911524	chr6:44747204	G/A	cg25276700	chr6:44698697	NA	0.32	6.29	0.33	9.73e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.23	-0.32	1.38e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1904096	0.506	rs2632412	chr4:95149319	A/C	cg11021082	chr4:95130006	SMARCAD1	0.39	7.02	0.36	1.26e-11	Type 2 diabetes;
LUSC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.8	-9.81	-0.47	3.97e-20	Refractive error;
LUSC	trans	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg13565492	chr6:43139072	SRF	-0.57	-6.0	-0.31	5.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg24881330	chr22:46731750	TRMU	0.9	10.18	0.49	2.17e-21	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21659725	chr3:3221576	CRBN	-0.59	-8.86	-0.44	4.84e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.57	-8.9	-0.44	3.53e-17	Height;
LUSC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-7.48	-0.38	6.67e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg22800045	chr5:56110881	MAP3K1	0.78	9.71	0.47	8.45e-20	Initial pursuit acceleration;
LUSC	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg02023728	chr11:77925099	USP35	0.46	6.65	0.34	1.23e-10	Testicular germ cell tumor;
LUSC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg16680214	chr1:154839983	KCNN3	-0.51	-9.63	-0.47	1.55e-19	Prostate cancer;
LUSC	cis	rs10979	1.000	rs12203151	chr6:143884856	C/T	cg25407410	chr6:143891975	LOC285740	-0.74	-11.83	-0.54	3.36e-27	Hypospadias;
LUSC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.33	-0.45	1.56e-18	Platelet count;
LUSC	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg03465714	chr1:152285911	FLG	-0.42	-5.88	-0.31	9.75e-9	Atopic dermatitis;
LUSC	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg24813613	chr7:1882135	MAD1L1	-0.44	-7.33	-0.37	1.76e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs62400317	0.859	rs10456542	chr6:45107579	G/A	cg20913747	chr6:44695427	NA	-0.47	-7.57	-0.38	3.61e-13	Total body bone mineral density;
LUSC	cis	rs6669072	1.000	rs10922923	chr1:91248029	A/T	cg08895590	chr1:91227319	NA	-0.36	-8.14	-0.41	7.85e-15	Cognitive function;
LUSC	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg09165964	chr15:75287851	SCAMP5	-0.93	-8.84	-0.44	5.7e-17	Lung cancer;
LUSC	cis	rs4780401	0.527	rs4780402	chr16:11839809	C/T	cg01061890	chr16:11836724	TXNDC11	-0.51	-7.41	-0.38	1.05e-12	Rheumatoid arthritis;
LUSC	cis	rs9420	0.961	rs7117205	chr11:57641883	A/G	cg02958346	chr11:57425731	CLP1	-0.46	-6.52	-0.34	2.57e-10	Schizophrenia;
LUSC	trans	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg11887960	chr12:57824829	NA	0.54	6.7	0.34	8.71e-11	Obesity-related traits;
LUSC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.77	0.35	5.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs601339	0.838	rs2454702	chr12:123209159	C/T	cg11919336	chr12:123188078	GPR109A	0.41	6.34	0.33	7.28e-10	Adiponectin levels;
LUSC	cis	rs394563	0.602	rs409111	chr6:149766860	A/G	cg11245181	chr6:149772854	ZC3H12D	-0.3	-6.57	-0.34	1.96e-10	Dupuytren's disease;
LUSC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.38	0.37	1.23e-12	Motion sickness;
LUSC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg24531977	chr5:56204891	C5orf35	-0.66	-9.73	-0.47	7.11e-20	Coronary artery disease;
LUSC	cis	rs7818345	0.967	rs11787230	chr8:19280982	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.36	0.37	1.44e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.65	-0.5	5.31e-23	Schizophrenia;
LUSC	cis	rs62400317	0.762	rs12193264	chr6:44930793	T/C	cg18551225	chr6:44695536	NA	-0.45	-7.23	-0.37	3.38e-12	Total body bone mineral density;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg21280719	chr6:42927975	GNMT	-0.34	-8.61	-0.43	2.86e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs73019876	0.869	rs1849006	chr19:22142764	A/C	cg16204205	chr18:19753432	GATA6	0.32	6.14	0.32	2.3e-9	Testicular germ cell tumor;
LUSC	trans	rs7581030	0.517	rs4314015	chr2:71528309	G/T	cg06465196	chr4:154387603	KIAA0922	0.42	6.04	0.31	4.18e-9	Testicular germ cell tumor;
LUSC	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg24881330	chr22:46731750	TRMU	0.82	7.29	0.37	2.32e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg05347473	chr6:146136440	FBXO30	0.49	8.04	0.4	1.6e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg26384229	chr12:38710491	ALG10B	-0.56	-8.35	-0.42	1.8e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1506636	1.000	rs1506636	chr7:123317140	C/T	cg03229431	chr7:123269106	ASB15	0.64	10.51	0.5	1.59e-22	Plateletcrit;Platelet count;
LUSC	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.98	-0.44	1.99e-17	Response to antipsychotic treatment;
LUSC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg00750074	chr16:89608354	SPG7	-0.46	-7.47	-0.38	7.02e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs3925075	1.000	rs9673404	chr16:31347592	A/T	cg02846316	chr16:31340340	ITGAM	0.36	6.66	0.34	1.11e-10	IgA nephropathy;
LUSC	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg25801113	chr15:45476975	SHF	0.34	7.07	0.36	9.18e-12	Uric acid levels;
LUSC	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg17366294	chr4:99064904	C4orf37	0.54	8.83	0.43	6.14e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2414856	0.510	rs112523289	chr15:64905835	C/T	cg08069370	chr15:64387884	SNX1	-0.65	-5.75	-0.3	2.03e-8	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg21064579	chr19:49206444	FUT2	0.44	8.42	0.42	1.14e-15	Dietary macronutrient intake;
LUSC	cis	rs10426930	0.690	rs710956	chr19:5054510	T/C	cg15820610	chr19:5044198	KDM4B	-0.41	-6.25	-0.32	1.26e-9	Monocyte percentage of white cells;
LUSC	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg23093090	chr10:104574429	C10orf26	-0.38	-7.09	-0.36	8.04e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg14092988	chr3:52407081	DNAH1	0.31	6.12	0.32	2.56e-9	Bipolar disorder;
LUSC	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg24069376	chr3:38537580	EXOG	-0.46	-9.54	-0.46	3.08e-19	Electrocardiographic conduction measures;
LUSC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg23625390	chr15:77176239	SCAPER	0.51	7.83	0.39	6.5e-14	Blood metabolite levels;
LUSC	cis	rs1113500	0.509	rs17020915	chr1:108647006	G/T	cg06207961	chr1:108661230	NA	0.35	5.65	0.3	3.5e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs4629180	0.701	rs10202801	chr2:102106670	T/C	cg01388757	chr2:102091195	RFX8	-0.36	-6.26	-0.32	1.19e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg23093090	chr10:104574429	C10orf26	-0.37	-7.04	-0.36	1.12e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7940866	0.678	rs61909201	chr11:130839547	C/T	cg12179176	chr11:130786555	SNX19	0.56	8.13	0.41	8.25e-15	Schizophrenia;
LUSC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.78	13.98	0.61	2.84e-35	Dental caries;
LUSC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-7.48	-0.38	6.84e-13	Lung function (FEV1/FVC);
LUSC	cis	rs17401966	0.540	rs11121566	chr1:10472848	C/G	cg17425144	chr1:10567563	PEX14	-0.32	-5.66	-0.3	3.31e-8	Hepatocellular carcinoma;
LUSC	cis	rs2414856	0.510	rs72757002	chr15:64615024	C/A	cg08069370	chr15:64387884	SNX1	-0.73	-6.43	-0.33	4.3e-10	Pulse pressure;Systolic blood pressure;
LUSC	trans	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg13565492	chr6:43139072	SRF	-0.61	-6.4	-0.33	5.21e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-0.85	-14.83	-0.63	1.36e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg03342759	chr3:160939853	NMD3	-0.44	-7.37	-0.37	1.34e-12	Morning vs. evening chronotype;
LUSC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs4499344	0.556	rs259227	chr19:33134791	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	13.74	0.6	2.35e-34	Mean platelet volume;
LUSC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg15147215	chr3:52552868	STAB1	-0.34	-6.8	-0.35	4.95e-11	Electroencephalogram traits;
LUSC	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.1	-0.41	1.01e-14	Retinal vascular caliber;
LUSC	cis	rs6940638	0.956	rs72838268	chr6:27021173	A/G	cg09904177	chr6:26538194	HMGN4	-0.49	-5.7	-0.3	2.64e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg00432049	chr6:150390894	ULBP3	-0.27	-5.76	-0.3	1.93e-8	Alopecia areata;
LUSC	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg24296786	chr1:45957014	TESK2	0.41	5.84	0.3	1.24e-8	Red blood cell count;Reticulocyte count;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25626869	chr8:93978374	C8orf83	0.48	7.01	0.36	1.34e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.62	0.5	6.6e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs748404	0.650	rs556851	chr15:43571219	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.43	5.99	0.31	5.34e-9	Lung cancer;
LUSC	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg17075019	chr10:79541650	NA	-0.76	-12.24	-0.56	1.03e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.12	0.52	1.15e-24	Menopause (age at onset);
LUSC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg25039879	chr17:56429692	SUPT4H1	0.69	9.14	0.45	6.35e-18	Cognitive test performance;
LUSC	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg13798780	chr7:105162888	PUS7	0.56	6.16	0.32	2.11e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.08	-0.36	8.55e-12	Menopause (age at onset);
LUSC	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg08916839	chr5:415575	AHRR	0.75	7.09	0.36	7.88e-12	Fat distribution (HIV);
LUSC	cis	rs7580658	0.963	rs2090574	chr2:128131391	C/A	cg09760422	chr2:128146352	NA	-0.33	-7.25	-0.37	2.91e-12	Protein C levels;
LUSC	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg05501817	chr11:14380813	RRAS2	-0.57	-9.51	-0.46	4e-19	Sense of smell;
LUSC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.66	-11.86	-0.54	2.59e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg12564285	chr5:131593104	PDLIM4	0.37	6.85	0.35	3.53e-11	Blood metabolite levels;
LUSC	cis	rs4737010	0.530	rs4026	chr8:41645710	C/T	cg17182837	chr8:41585554	ANK1	-0.35	-6.34	-0.33	7.44e-10	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	trans	rs7944735	0.517	rs11039520	chr11:48130794	A/G	cg15704280	chr7:45808275	SEPT13	0.69	6.34	0.33	7.4e-10	Intraocular pressure;
LUSC	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.42	6.45	0.33	3.98e-10	Height;
LUSC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg00745463	chr17:30367425	LRRC37B	-0.64	-7.81	-0.39	7.55e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg05855489	chr10:104503620	C10orf26	0.59	9.63	0.47	1.63e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11644478	chr21:40555479	PSMG1	-0.63	-9.59	-0.46	2.12e-19	Menarche (age at onset);
LUSC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.69	11.55	0.53	3.31e-26	Heart rate;
LUSC	cis	rs6750795	0.641	rs10933375	chr2:232367296	A/T	cg19187155	chr2:232395269	NMUR1	-0.63	-8.52	-0.42	5.39e-16	Height;
LUSC	cis	rs240764	0.853	rs11155498	chr6:101019551	G/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.19	-0.32	1.8e-9	Neuroticism;
LUSC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg22467129	chr15:76604101	ETFA	-0.48	-7.7	-0.39	1.54e-13	Blood metabolite levels;
LUSC	cis	rs7503807	0.967	rs12949279	chr17:78558411	T/C	cg09596252	chr17:78655493	RPTOR	0.39	6.31	0.33	8.81e-10	Obesity;
LUSC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg26695010	chr11:65641043	EFEMP2	0.46	6.68	0.34	1.02e-10	Eosinophil percentage of white cells;
LUSC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.73	-0.43	1.25e-16	Monocyte count;
LUSC	cis	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg06521331	chr12:34319734	NA	-0.45	-7.38	-0.37	1.29e-12	Morning vs. evening chronotype;
LUSC	trans	rs724744	0.710	rs1205942	chr6:22357011	T/C	cg13807341	chr11:118445984	ARCN1	-0.36	-6.07	-0.32	3.43e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs28647808	0.786	rs4962136	chr9:136256794	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg21435336	chr19:17392852	ANKLE1	-0.43	-5.87	-0.31	1.07e-8	Systemic lupus erythematosus;
LUSC	cis	rs75804782	0.641	rs72983834	chr2:239319895	G/A	cg18131467	chr2:239335373	ASB1	-0.74	-6.64	-0.34	1.28e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs2637266	0.846	rs2637261	chr10:78320593	A/G	cg18941641	chr10:78392320	NA	-0.43	-7.99	-0.4	2.17e-14	Pulmonary function;
LUSC	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs66716358	0.710	rs12793949	chr11:44317265	C/T	cg16977035	chr11:44330474	ALX4	0.34	5.65	0.3	3.36e-8	Monobrow;
LUSC	cis	rs11677416	1.000	rs7570215	chr2:113527660	G/T	cg27083787	chr2:113543245	IL1A	0.44	6.97	0.36	1.65e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs10740039	0.804	rs1837950	chr10:62444965	C/T	cg18175470	chr10:62150864	ANK3	0.46	7.25	0.37	2.86e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg18230493	chr5:56204884	C5orf35	-0.93	-13.72	-0.6	2.66e-34	Initial pursuit acceleration;
LUSC	cis	rs7178572	0.524	rs12904088	chr15:77399397	C/G	cg22256960	chr15:77711686	NA	-0.49	-7.66	-0.39	1.99e-13	Type 2 diabetes;
LUSC	cis	rs12999616	0.817	rs7425883	chr2:98331521	C/G	cg26665480	chr2:98280029	ACTR1B	-0.52	-6.01	-0.31	4.82e-9	Colorectal cancer;
LUSC	cis	rs2267137	0.835	rs2267133	chr22:29765382	A/T	cg07256473	chr22:29710276	RASL10A	0.35	6.77	0.35	5.84e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03934478	chr11:495069	RNH1	0.89	10.25	0.49	1.3e-21	Body mass index;
LUSC	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg22676075	chr6:135203613	NA	0.59	9.32	0.45	1.67e-18	High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg03473377	chr10:33568029	NRP1	0.37	6.21	0.32	1.57e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.56	-0.46	2.62e-19	Extrinsic epigenetic age acceleration;
LUSC	trans	rs12761450	0.500	rs10740011	chr10:61890937	G/T	cg04781339	chr21:44781686	NA	0.29	6.2	0.32	1.67e-9	Plasma amyloid beta peptide concentrations (ABx-42);
LUSC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg25258033	chr6:167368657	RNASET2	0.43	6.53	0.34	2.49e-10	Crohn's disease;
LUSC	cis	rs7264396	1.000	rs224436	chr20:34154124	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.19	-0.37	4.16e-12	Total cholesterol levels;
LUSC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg15790184	chr11:494944	RNH1	0.4	6.2	0.32	1.65e-9	Systemic lupus erythematosus;
LUSC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg22508957	chr16:3507546	NAT15	0.93	10.43	0.5	3.22e-22	Tuberculosis;
LUSC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	7.79	0.39	8.66e-14	Mean platelet volume;
LUSC	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg26395211	chr5:140044315	WDR55	-0.38	-5.82	-0.3	1.4e-8	Schizophrenia;
LUSC	cis	rs8099014	1.000	rs7226817	chr18:56128289	T/A	cg12907477	chr18:56117327	MIR122	0.44	6.99	0.36	1.52e-11	Platelet count;
LUSC	cis	rs7503807	0.967	rs8064502	chr17:78562434	C/A	cg09596252	chr17:78655493	RPTOR	0.39	6.43	0.33	4.36e-10	Obesity;
LUSC	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg16342193	chr10:102329863	NA	0.34	6.26	0.32	1.21e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.58	-0.34	1.81e-10	Initial pursuit acceleration in psychotic disorders;
LUSC	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg26384229	chr12:38710491	ALG10B	0.55	8.85	0.44	5.14e-17	Morning vs. evening chronotype;
LUSC	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	9.72	0.47	7.7e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs7202877	0.706	rs247434	chr16:75445304	G/A	cg04384234	chr16:75411784	CFDP1	0.65	8.43	0.42	1.04e-15	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs2562784	0.638	rs2585045	chr15:84306314	G/A	cg17507749	chr15:85114479	UBE2QP1	0.58	5.65	0.3	3.53e-8	Height;
LUSC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg09034736	chr1:150693464	HORMAD1	0.47	6.49	0.33	3.03e-10	Melanoma;
LUSC	cis	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg17325771	chr7:75508891	RHBDD2	-0.42	-5.92	-0.31	7.78e-9	Eotaxin levels;
LUSC	cis	rs2346177	0.844	rs34791442	chr2:46655169	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.38	6.59	0.34	1.73e-10	HDL cholesterol;
LUSC	cis	rs11696739	0.761	rs2254458	chr20:1551485	C/T	cg02198625	chr20:1600641	SIRPB1	-0.26	-5.78	-0.3	1.76e-8	Mean platelet volume;
LUSC	cis	rs965604	1.000	rs1964678	chr15:78754000	A/G	cg18825076	chr15:78729989	IREB2	-0.42	-6.78	-0.35	5.38e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.98	-0.44	2.01e-17	Electroencephalogram traits;
LUSC	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-1.13	-17.71	-0.7	5.82e-50	Exhaled nitric oxide output;
LUSC	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg11608241	chr8:8085544	FLJ10661	-0.5	-7.11	-0.36	7.23e-12	Neuroticism;
LUSC	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	8.95	0.44	2.54e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22590775	chr19:49891494	CCDC155	0.57	8.23	0.41	4.15e-15	Multiple sclerosis;
LUSC	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-0.79	-11.85	-0.54	2.84e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg04733989	chr22:42467013	NAGA	0.53	8.22	0.41	4.56e-15	Schizophrenia;
LUSC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08736216	chr1:53307985	ZYG11A	0.3	6.2	0.32	1.64e-9	Monocyte count;
LUSC	cis	rs9921338	0.923	rs4563054	chr16:11447546	T/G	cg00044050	chr16:11439710	C16orf75	-0.52	-6.85	-0.35	3.55e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.21	-0.49	1.83e-21	Eye color traits;
LUSC	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg25206134	chr2:45395956	NA	0.59	6.71	0.34	8.32e-11	Bipolar disorder;
LUSC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg16325326	chr1:53192061	ZYG11B	0.74	12.76	0.57	1.23e-30	Monocyte count;
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.57	-8.7	-0.43	1.58e-16	Lymphocyte counts;
LUSC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg16325326	chr1:53192061	ZYG11B	-0.83	-14.56	-0.62	1.63e-37	Monocyte count;
LUSC	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg08270630	chr22:50330655	NA	-0.63	-7.3	-0.37	2.06e-12	Acne (severe);
LUSC	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.14	-0.41	7.93e-15	Triglycerides;
LUSC	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.46	6.31	0.33	9.11e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg05738196	chr6:26577821	NA	0.82	15.85	0.66	1.46e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	10.88	0.51	8.55e-24	Ileal carcinoids;
LUSC	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	5.9	0.31	8.95e-9	Schizophrenia;
LUSC	cis	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg02508848	chr16:68573721	ZFP90	-0.42	-5.68	-0.3	2.96e-8	Ulcerative colitis;
LUSC	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg20476274	chr7:133979776	SLC35B4	-0.77	-12.45	-0.56	1.67e-29	Mean platelet volume;
LUSC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg21361702	chr7:150065534	REPIN1	-0.48	-6.66	-0.34	1.14e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg09021430	chr5:549028	NA	-0.53	-6.97	-0.36	1.7e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1044826	0.913	rs9849039	chr3:139147106	A/G	cg00490450	chr3:139108681	COPB2	0.55	7.32	0.37	1.82e-12	Obesity-related traits;
LUSC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg14789911	chr21:47582049	C21orf56	-0.41	-6.52	-0.34	2.55e-10	Testicular germ cell tumor;
LUSC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg02023728	chr11:77925099	USP35	0.43	6.6	0.34	1.63e-10	Testicular germ cell tumor;
LUSC	cis	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg27411982	chr8:10470053	RP1L1	0.4	6.09	0.32	3.02e-9	Systemic lupus erythematosus;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26919459	chr4:79472874	ANXA3	0.44	6.83	0.35	3.91e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg11189052	chr15:85197271	WDR73	-0.45	-6.48	-0.33	3.33e-10	P wave terminal force;
LUSC	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg26441486	chr22:50317300	CRELD2	0.49	7.25	0.37	2.87e-12	Schizophrenia;
LUSC	cis	rs2282032	1.000	rs114316342	chr14:90736477	C/T	cg14092571	chr14:90743983	NA	0.55	6.88	0.35	2.96e-11	Longevity;
LUSC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.7	10.69	0.5	3.82e-23	Aortic root size;
LUSC	trans	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.53e-10	Corneal astigmatism;
LUSC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.86	-0.4	5.18e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	9.5	0.46	4.12e-19	Eotaxin levels;
LUSC	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg08557956	chr11:4115526	RRM1	0.47	5.83	0.3	1.3e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg00254258	chr1:3105189	PRDM16	-0.31	-6.0	-0.31	5.15e-9	Migraine;
LUSC	cis	rs4654899	0.802	rs76122612	chr1:21243059	C/T	cg01072550	chr1:21505969	NA	-0.47	-6.84	-0.35	3.87e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs12815613	0.961	rs1134464	chr12:121406574	C/A	cg02403541	chr12:121454288	C12orf43	-0.46	-5.84	-0.3	1.21e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg22166914	chr1:53195759	ZYG11B	-0.71	-12.23	-0.56	1.11e-28	Monocyte count;
LUSC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.78	14.84	0.63	1.27e-38	Longevity;
LUSC	cis	rs308447	0.576	rs10005301	chr4:123715055	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.91	-15.03	-0.64	2.36e-39	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12292205	chr6:26970375	C6orf41	-0.58	-7.35	-0.37	1.49e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg11812906	chr14:75593930	NEK9	-0.67	-11.46	-0.53	7.28e-26	Height;
LUSC	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg03359095	chr20:61002866	C20orf151	-0.29	-5.77	-0.3	1.78e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.79	11.75	0.54	6.73e-27	Corneal astigmatism;
LUSC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg24642844	chr7:1081250	C7orf50	-0.46	-7.52	-0.38	5.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg12011299	chr4:100065546	ADH4	-0.72	-10.43	-0.5	3.12e-22	Alcohol dependence;
LUSC	cis	rs4363385	0.509	rs11576882	chr1:152918785	T/G	cg25856811	chr1:152973957	SPRR3	-0.38	-6.16	-0.32	2.12e-9	Inflammatory skin disease;
LUSC	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg15556689	chr8:8085844	FLJ10661	0.68	11.09	0.52	1.57e-24	Neuroticism;
LUSC	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.24	-0.45	3.03e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs1524927	0.966	rs1524928	chr7:96356794	C/T	cg03808172	chr7:96339361	SHFM1	0.43	6.53	0.34	2.48e-10	Total body bone mineral density;
LUSC	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg04058563	chr4:185651563	MLF1IP	-0.79	-11.92	-0.55	1.5e-27	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16638648	chr17:38083781	ORMDL3	-0.4	-6.05	-0.31	3.97e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.27	-0.41	3.15e-15	Neuroticism;
LUSC	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg27494647	chr7:150038898	RARRES2	0.46	7.02	0.36	1.28e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02034447	chr16:89574710	SPG7	0.4	5.96	0.31	6.41e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg01689657	chr7:91764605	CYP51A1	0.31	5.65	0.3	3.48e-8	Breast cancer;
LUSC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg03354898	chr7:1950403	MAD1L1	-0.37	-7.13	-0.36	6.14e-12	Bipolar disorder and schizophrenia;
LUSC	trans	rs12200782	0.674	rs12207224	chr6:26519280	A/T	cg18180407	chr1:55047736	ACOT11	0.48	5.97	0.31	6.12e-9	Small cell lung carcinoma;
LUSC	cis	rs1595825	0.891	rs58111212	chr2:198889896	T/C	cg10547527	chr2:198650123	BOLL	-0.52	-6.3	-0.33	9.56e-10	Ulcerative colitis;
LUSC	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg08601574	chr20:25228251	PYGB	0.48	7.55	0.38	4.24e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.63	9.8	0.47	4.4e-20	Blood protein levels;
LUSC	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.72	-0.35	7.84e-11	Response to antipsychotic treatment;
LUSC	cis	rs1009647	0.645	rs73271727	chr14:55600430	G/T	cg04306507	chr14:55594613	LGALS3	0.45	6.18	0.32	1.83e-9	Testicular germ cell tumor;
LUSC	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	7.95	0.4	2.94e-14	Melanoma;
LUSC	cis	rs6540559	0.611	rs11810817	chr1:210011747	C/G	cg21951975	chr1:209979733	IRF6	0.55	7.02	0.36	1.22e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg11879182	chr18:77439856	CTDP1	0.72	11.98	0.55	8.99e-28	Monocyte count;
LUSC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg04450456	chr4:17643702	FAM184B	-0.39	-6.44	-0.33	4.08e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg05340658	chr4:99064831	C4orf37	0.57	9.45	0.46	6.02e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg24342717	chr2:85555507	TGOLN2	-0.74	-12.3	-0.56	6.28e-29	Ear protrusion;
LUSC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg25036284	chr2:26402008	FAM59B	-0.69	-9.57	-0.46	2.39e-19	Gut microbiome composition (summer);
LUSC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg26354017	chr1:205819088	PM20D1	0.48	6.98	0.36	1.63e-11	Prostate-specific antigen levels;
LUSC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-7.72	-0.39	1.4e-13	Aortic root size;
LUSC	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg07636037	chr3:49044803	WDR6	0.78	10.25	0.49	1.25e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	8.33	0.41	2.18e-15	Lung cancer;
LUSC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg10518572	chr11:65560635	OVOL1	-0.26	-6.03	-0.31	4.24e-9	Acne (severe);
LUSC	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg12935359	chr14:103987150	CKB	-0.59	-8.75	-0.43	1.1e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg14664628	chr15:75095509	CSK	-0.91	-14.12	-0.61	7.8e-36	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg21724239	chr8:58056113	NA	0.79	9.53	0.46	3.43e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs12571093	0.803	rs2241969	chr10:70031010	C/T	cg04882175	chr6:131122610	NA	-0.54	-6.2	-0.32	1.65e-9	Optic nerve measurement (disc area);
LUSC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.21	0.37	3.87e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs58235267	0.591	rs2162014	chr2:63345507	C/A	cg17519650	chr2:63277830	OTX1	0.62	9.11	0.45	7.65e-18	Prostate-specific antigen levels (conditioned on lead SNPs);
LUSC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.64	-0.6	5.38e-34	Chronic sinus infection;
LUSC	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.65	-0.39	2.15e-13	Neuroticism;
LUSC	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg25173405	chr17:45401733	C17orf57	0.38	6.13	0.32	2.52e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg09904177	chr6:26538194	HMGN4	-0.74	-6.83	-0.35	4.11e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg25025879	chr12:53359317	NA	-0.47	-7.6	-0.38	2.98e-13	Prostate cancer;
LUSC	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21659725	chr3:3221576	CRBN	0.6	8.62	0.43	2.79e-16	Resting heart rate;
LUSC	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg21132104	chr15:45694354	SPATA5L1	0.42	6.13	0.32	2.45e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.16	0.45	5.44e-18	Coffee consumption (cups per day);
LUSC	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg11102782	chr19:18549136	ISYNA1	-0.32	-5.97	-0.31	6.12e-9	Breast cancer;
LUSC	cis	rs977987	0.806	rs4638613	chr16:75425553	C/T	cg04384234	chr16:75411784	CFDP1	-0.43	-7.05	-0.36	1.04e-11	Dupuytren's disease;
LUSC	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg07930552	chr6:133119739	C6orf192	0.85	10.68	0.5	4.3e-23	Type 2 diabetes nephropathy;
LUSC	cis	rs9400467	0.528	rs445349	chr6:111662102	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.37	6.97	0.36	1.71e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg23625390	chr15:77176239	SCAPER	-0.64	-9.88	-0.48	2.35e-20	Blood metabolite levels;
LUSC	cis	rs2859741	0.546	rs3845491	chr1:37497521	C/T	cg09363841	chr1:37513479	NA	-0.38	-7.16	-0.36	5.31e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg26384229	chr12:38710491	ALG10B	0.73	11.56	0.53	3.22e-26	Morning vs. evening chronotype;
LUSC	cis	rs6500395	1.000	rs34844432	chr16:48682418	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.8	0.35	4.69e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.54	0.46	3.22e-19	Prudent dietary pattern;
LUSC	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.81	-15.13	-0.64	9.06e-40	Heart rate;
LUSC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg02018176	chr4:1364513	KIAA1530	0.56	10.58	0.5	9.19e-23	Longevity;
LUSC	cis	rs7809950	0.817	rs4727679	chr7:107085018	T/C	cg23024343	chr7:107201750	COG5	-0.7	-10.35	-0.49	5.7e-22	Coronary artery disease;
LUSC	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.56	-8.65	-0.43	2.15e-16	Menarche (age at onset);
LUSC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.55	-8.98	-0.44	2.02e-17	Intelligence (multi-trait analysis);
LUSC	trans	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	7.72	0.39	1.35e-13	Neuroticism;
LUSC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg12386194	chr3:101231763	SENP7	0.63	8.74	0.43	1.13e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.37	-5.78	-0.3	1.69e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs983392	0.679	rs655231	chr11:60013857	A/G	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.22	-0.32	1.5e-9	Alzheimer's disease (late onset);
LUSC	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-8.09	-0.4	1.09e-14	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09654908	chr15:62989952	TLN2	-0.69	-6.16	-0.32	2.15e-9	Cognitive performance;
LUSC	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	6.87	0.35	3.07e-11	Lung cancer in ever smokers;
LUSC	cis	rs2637266	0.935	rs2252652	chr10:78405022	C/T	cg18941641	chr10:78392320	NA	0.38	6.81	0.35	4.41e-11	Pulmonary function;
LUSC	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.89	-0.31	9.19e-9	Birth weight;
LUSC	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-6.07	-0.32	3.51e-9	Fear of minor pain;
LUSC	cis	rs6741892	0.536	rs11688977	chr2:38896631	C/T	cg23643435	chr2:38893251	GALM	-0.66	-6.79	-0.35	5.29e-11	5-HTT brain serotonin transporter levels;
LUSC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.05	-0.4	1.49e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21984481	chr17:79567631	NPLOC4	-0.54	-10.41	-0.5	3.57e-22	Eye color traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08753222	chr11:71934705	INPPL1	-0.41	-6.17	-0.32	2.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg06636551	chr8:101224915	SPAG1	-0.38	-7.06	-0.36	1e-11	Atrioventricular conduction;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18500192	chr3:19189930	KCNH8	-0.49	-6.71	-0.34	8.27e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg22089800	chr15:90895588	ZNF774	0.62	9.66	0.47	1.26e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-9.44	-0.46	6.64e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.7	-8.5	-0.42	6.26e-16	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs2688608	0.869	rs2633308	chr10:75653904	A/T	cg23231163	chr10:75533350	FUT11	-0.36	-5.92	-0.31	8.03e-9	Inflammatory bowel disease;
LUSC	cis	rs7539542	0.556	rs6692075	chr1:202881302	C/T	cg19681188	chr1:202830198	LOC148709	0.39	5.8	0.3	1.54e-8	Mean platelet volume;
LUSC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg02534363	chr3:47050950	NBEAL2	0.35	5.71	0.3	2.49e-8	Colorectal cancer;
LUSC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18932078	chr1:2524107	MMEL1	0.31	6.92	0.35	2.35e-11	Ulcerative colitis;
LUSC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	9.05	0.44	1.21e-17	Prudent dietary pattern;
LUSC	cis	rs1975991	0.597	rs715790	chr3:187985004	A/G	cg17585528	chr3:187988060	LPP	0.36	5.68	0.3	2.94e-8	White matter integrity (bipolar disorder risk interaction);
LUSC	cis	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg09904177	chr6:26538194	HMGN4	-0.8	-6.07	-0.32	3.46e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg24838063	chr12:130822603	PIWIL1	0.69	10.74	0.51	2.6e-23	Menopause (age at onset);
LUSC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg00701064	chr4:6280414	WFS1	0.59	14.34	0.62	1.17e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg06623918	chr6:96969491	KIAA0776	-0.84	-10.5	-0.5	1.72e-22	Migraine;Coronary artery disease;
LUSC	trans	rs1422110	0.616	rs6452688	chr5:85445038	C/T	cg01787110	chr1:109008453	NBPF6	0.55	9.3	0.45	1.91e-18	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs9326248	0.813	rs474488	chr11:117068977	A/G	cg26566898	chr11:117069891	TAGLN	0.38	5.9	0.31	9.11e-9	Blood protein levels;
LUSC	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.41	-5.94	-0.31	7.29e-9	Bipolar disorder;
LUSC	cis	rs7523050	0.643	rs34114412	chr1:109402866	C/T	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18089134	chr4:130014711	C4orf33;SCLT1	-0.44	-6.32	-0.33	8.4e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg06219351	chr7:158114137	PTPRN2	0.5	9.02	0.44	1.46e-17	Calcium levels;
LUSC	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg20821713	chr7:1055600	C7orf50	-0.49	-5.9	-0.31	8.74e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg18681998	chr4:17616180	MED28	0.78	13.81	0.6	1.26e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg18187862	chr3:45730750	SACM1L	0.55	7.02	0.36	1.27e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	11.61	0.54	2.12e-26	Alzheimer's disease;
LUSC	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg19875535	chr5:140030758	IK	0.48	7.8	0.39	8.07e-14	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19863752	chr5:175970067	NA	-0.48	-6.22	-0.32	1.46e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg00809820	chr17:80708513	TBCD;FN3K	-0.37	-6.49	-0.33	3.1e-10	Glycated hemoglobin levels;
LUSC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg03732007	chr1:2071316	PRKCZ	-0.54	-9.99	-0.48	9.71e-21	Height;
LUSC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg16262614	chr3:133464971	TF	0.43	7.38	0.37	1.24e-12	Iron status biomarkers (transferrin levels);
LUSC	cis	rs354225	0.544	rs4455200	chr2:54801591	T/A	cg26097391	chr2:54893211	SPTBN1	0.46	6.93	0.35	2.21e-11	Schizophrenia;
LUSC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.53	0.5	1.45e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs12210905	0.925	rs10456349	chr6:26975459	G/A	cg11837749	chr1:55047332	ACOT11	0.57	6.09	0.32	3.07e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg01171360	chr6:293285	DUSP22	-0.5	-7.54	-0.38	4.58e-13	Menopause (age at onset);
LUSC	cis	rs72960926	0.744	rs3897895	chr6:74917550	C/T	cg03266952	chr6:74778945	NA	-0.85	-7.11	-0.36	7.08e-12	Metabolite levels (MHPG);
LUSC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15506890	chr2:3487001	NA	0.47	7.65	0.39	2.19e-13	Neurofibrillary tangles;
LUSC	cis	rs10992471	0.528	rs4744133	chr9:95226702	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.34	-6.01	-0.31	4.94e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs683250	1.000	rs558104	chr11:83276244	C/A	cg26617787	chr11:123396133	GRAMD1B	-0.32	-6.09	-0.32	3.14e-9	Subcortical brain region volumes;
LUSC	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg22709100	chr7:91322751	NA	-0.38	-5.72	-0.3	2.37e-8	Breast cancer;
LUSC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg06238570	chr21:40685208	BRWD1	-0.57	-8.82	-0.43	6.66e-17	Menarche (age at onset);
LUSC	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg20487152	chr13:99095054	FARP1	-0.43	-7.54	-0.38	4.61e-13	Longevity;
LUSC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.92	-0.44	3.14e-17	Bipolar disorder;
LUSC	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg05234568	chr11:5960015	NA	-0.59	-8.45	-0.42	9.26e-16	DNA methylation (variation);
LUSC	cis	rs13720	0.556	rs151335	chr20:57579950	A/G	cg23907860	chr20:57583709	CTSZ	-0.57	-7.98	-0.4	2.3e-14	Platelet distribution width;
LUSC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg16372103	chr5:203701	NA	0.44	5.81	0.3	1.43e-8	Breast cancer;
LUSC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.15	16.21	0.66	5.28e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4786125	0.804	rs6500850	chr16:6896389	A/T	cg03623568	chr16:6915990	A2BP1	-0.39	-6.76	-0.35	6.23e-11	Heart rate variability traits (SDNN);
LUSC	cis	rs8044868	0.586	rs7200854	chr16:72083318	G/A	cg16579770	chr16:72058938	DHODH	0.34	5.77	0.3	1.86e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg08847533	chr14:75593920	NEK9	-0.48	-6.91	-0.35	2.41e-11	IgG glycosylation;
LUSC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg18758796	chr5:131593413	PDLIM4	-0.41	-7.04	-0.36	1.07e-11	Breast cancer;
LUSC	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.68	13.5	0.59	1.91e-33	Birth weight;
LUSC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.51	7.83	0.39	6.42e-14	Prudent dietary pattern;
LUSC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.98	-0.4	2.34e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg05472934	chr7:22766657	IL6	0.5	7.69	0.39	1.71e-13	Lung cancer;
LUSC	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg24375607	chr4:120327624	NA	0.77	12.48	0.56	1.28e-29	Corneal astigmatism;
LUSC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg22907277	chr7:1156413	C7orf50	0.68	7.3	0.37	2.12e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg06026331	chr20:60912101	LAMA5	-0.45	-6.02	-0.31	4.69e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.56	-8.52	-0.42	5.69e-16	Longevity;Endometriosis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08761102	chr2:38303844	CYP1B1	0.47	6.92	0.35	2.38e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs16976116	0.901	rs1050931	chr15:55497691	G/A	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4654899	0.897	rs710311	chr1:21062001	T/C	cg01072550	chr1:21505969	NA	-0.43	-6.43	-0.33	4.35e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg13560548	chr3:10150139	C3orf24	0.49	6.89	0.35	2.82e-11	Alzheimer's disease;
LUSC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.97	0.31	5.94e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.76	-13.57	-0.6	1.01e-33	Cognitive function;
LUSC	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg19116668	chr7:99932089	PMS2L1	-0.33	-5.67	-0.3	3.17e-8	Coronary artery disease;
LUSC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg26380479	chr7:97908229	NA	0.26	5.86	0.31	1.1e-8	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12559031	chr17:48046365	DLX4	0.45	7.16	0.36	5.02e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2692947	0.794	rs2692949	chr2:96673525	G/A	cg22654517	chr2:96458247	NA	0.3	5.85	0.3	1.16e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	0.67	14.17	0.61	5.09e-36	Prudent dietary pattern;
LUSC	cis	rs11997175	0.583	rs12680811	chr8:33778426	A/C	ch.8.33884649F	chr8:33765107	NA	0.5	7.63	0.39	2.41e-13	Body mass index;
LUSC	cis	rs1784581	0.674	rs1784592	chr6:162387365	T/A	cg17173639	chr6:162384350	PARK2	-0.66	-11.91	-0.55	1.63e-27	Itch intensity from mosquito bite;
LUSC	cis	rs10186029	0.509	rs7592621	chr2:213941177	C/T	cg08319019	chr2:214017104	IKZF2	-0.43	-6.21	-0.32	1.61e-9	Systemic sclerosis;
LUSC	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.66	-0.47	1.23e-19	Multiple sclerosis;
LUSC	cis	rs977987	0.806	rs2161684	chr16:75479153	T/C	cg04384234	chr16:75411784	CFDP1	-0.42	-6.96	-0.36	1.8e-11	Dupuytren's disease;
LUSC	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg01802117	chr1:53393560	SCP2	0.4	6.63	0.34	1.38e-10	Monocyte count;
LUSC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.21	-13.94	-0.61	4.07e-35	Diabetic kidney disease;
LUSC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06221963	chr1:154839813	KCNN3	-0.59	-13.47	-0.59	2.55e-33	Prostate cancer;
LUSC	cis	rs868036	0.958	rs11635424	chr15:68037578	C/T	cg05925327	chr15:68127851	NA	-0.33	-5.91	-0.31	8.29e-9	Restless legs syndrome;
LUSC	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg06917634	chr15:78832804	PSMA4	0.49	5.83	0.3	1.33e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg13319975	chr6:146136371	FBXO30	0.51	7.63	0.39	2.49e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs27434	0.821	rs28337	chr5:96125314	A/T	cg16492584	chr5:96139282	ERAP1	-0.52	-7.05	-0.36	1e-11	Ankylosing spondylitis;
LUSC	cis	rs9815354	0.812	rs73069203	chr3:41938767	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.64	0.43	2.32e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.71	11.86	0.54	2.64e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs7608623	0.773	rs3795944	chr2:23920545	A/G	cg08917208	chr2:24149416	ATAD2B	-0.42	-5.74	-0.3	2.12e-8	Obesity-related traits;
LUSC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg09365446	chr1:150670422	GOLPH3L	0.47	6.91	0.35	2.47e-11	Melanoma;
LUSC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg08200582	chr11:442649	ANO9	-0.57	-6.39	-0.33	5.63e-10	Body mass index;
LUSC	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	11.84	0.54	3.17e-27	Blood protein levels;
LUSC	cis	rs2279817	1.000	rs2279817	chr1:18021858	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.48	-6.58	-0.34	1.87e-10	Neuroticism;
LUSC	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg27661571	chr11:113659931	NA	-0.59	-7.05	-0.36	1.06e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg20701182	chr2:24300061	SF3B14	0.58	6.16	0.32	2.05e-9	Lymphocyte counts;
LUSC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg02487422	chr3:49467188	NICN1	0.44	7.04	0.36	1.12e-11	Resting heart rate;
LUSC	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg10356904	chr22:49881777	NA	-0.29	-6.45	-0.33	3.9e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18876405	chr7:65276391	NA	0.54	8.33	0.41	2.06e-15	Aortic root size;
LUSC	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg03929089	chr4:120376271	NA	-0.59	-6.27	-0.32	1.13e-9	Axial length;
LUSC	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg11130432	chr3:121712080	ILDR1	-0.63	-9.57	-0.46	2.41e-19	Multiple sclerosis;
LUSC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.67	-11.18	-0.52	7.15e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg03579872	chr1:53393473	SCP2	-0.39	-5.71	-0.3	2.46e-8	Monocyte count;
LUSC	cis	rs17533156	0.612	rs62078287	chr17:75128493	C/T	cg11416367	chr17:75137675	SEC14L1	0.5	5.96	0.31	6.5e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4786125	0.879	rs11645781	chr16:6896128	C/T	cg03623568	chr16:6915990	A2BP1	0.39	6.56	0.34	2.06e-10	Heart rate variability traits (SDNN);
LUSC	cis	rs5167	0.534	rs56803710	chr19:45481884	C/T	cg25746394	chr19:45450501	APOC2	0.32	6.07	0.32	3.55e-9	Blood protein levels;
LUSC	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg14346243	chr4:90757452	SNCA	-0.44	-6.28	-0.32	1.08e-9	Neuroticism;
LUSC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07256732	chr16:621771	PIGQ	-0.36	-6.54	-0.34	2.33e-10	Height;
LUSC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg02153584	chr22:29168773	CCDC117	0.55	7.94	0.4	3.01e-14	Lymphocyte counts;
LUSC	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	9.06	0.44	1.13e-17	Schizophrenia;
LUSC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.59	-8.74	-0.43	1.13e-16	Mean platelet volume;
LUSC	trans	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.66	-11.66	-0.54	1.43e-26	Mean corpuscular volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23162396	chr3:195808345	TFRC	-0.46	-5.96	-0.31	6.27e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg07424592	chr7:64974309	NA	0.69	6.18	0.32	1.88e-9	Diabetic kidney disease;
LUSC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.86	0.6	8.34e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg00343986	chr7:65444356	GUSB	-0.46	-6.88	-0.35	2.94e-11	Corneal structure;
LUSC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg06238570	chr21:40685208	BRWD1	-0.58	-9.02	-0.44	1.46e-17	Menarche (age at onset);
LUSC	cis	rs11039100	1.000	rs61875915	chr11:5828568	A/G	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.15	0.52	9.13e-25	Hypertriglyceridemia;
LUSC	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg10978503	chr1:24200527	CNR2	-0.49	-11.59	-0.54	2.39e-26	Immature fraction of reticulocytes;
LUSC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg25039879	chr17:56429692	SUPT4H1	0.68	9.11	0.45	7.7e-18	Cognitive test performance;
LUSC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6736093	0.966	rs6743523	chr2:112693875	G/A	cg12686935	chr2:112915763	FBLN7	-0.36	-5.84	-0.3	1.25e-8	Coronary artery disease;
LUSC	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg20243544	chr17:37824526	PNMT	0.57	8.19	0.41	5.64e-15	Asthma;
LUSC	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.1e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg00509249	chr6:109615579	CCDC162	0.32	5.74	0.3	2.15e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19096424	chr1:120255104	PHGDH	0.44	5.98	0.31	5.65e-9	Blood metabolite levels;
LUSC	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.37	-6.7	-0.34	8.82e-11	Hematocrit;
LUSC	trans	rs9503598	0.636	rs7745968	chr6:3467745	G/T	cg05722439	chr19:14072965	RFX1	-0.3	-5.95	-0.31	6.8e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.72	0.43	1.34e-16	Prudent dietary pattern;
LUSC	cis	rs929596	0.785	rs17864701	chr2:234652717	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.71	-12.24	-0.56	1.05e-28	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.61	0.54	2.04e-26	Ileal carcinoids;
LUSC	trans	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg03886242	chr7:26192032	NFE2L3	0.37	6.23	0.32	1.41e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6967385	0.560	rs10248602	chr7:12347113	G/C	cg10578991	chr7:12443926	VWDE	0.39	5.73	0.3	2.26e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs77741769	0.529	rs525425	chr12:121195625	A/G	cg02419362	chr12:121203948	SPPL3	0.46	8.38	0.42	1.47e-15	Mean corpuscular volume;
LUSC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg21433313	chr16:3507492	NAT15	0.65	10.59	0.5	8.68e-23	Tuberculosis;
LUSC	cis	rs4919087	0.620	rs793518	chr10:98986970	C/T	cg25902810	chr10:99078978	FRAT1	-0.44	-6.14	-0.32	2.4e-9	Monocyte count;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10247162	chr16:15068775	PDXDC1	-0.47	-6.14	-0.32	2.35e-9	Hepatitis;
LUSC	cis	rs977987	0.806	rs1549306	chr16:75415341	A/G	cg03315344	chr16:75512273	CHST6	0.48	9.23	0.45	3.15e-18	Dupuytren's disease;
LUSC	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-8.93	-0.44	2.99e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24877558	chr1:42801138	FOXJ3	-0.49	-6.14	-0.32	2.4e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2932538	0.922	rs61818800	chr1:113148571	A/G	cg22162597	chr1:113214053	CAPZA1	0.65	8.97	0.44	2.25e-17	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg06618935	chr21:46677482	NA	-0.43	-8.2	-0.41	5.38e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg08079166	chr15:68083412	MAP2K5	0.4	8.28	0.41	3.04e-15	Restless legs syndrome;
LUSC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.38	7.72	0.39	1.36e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.29	-0.37	2.28e-12	Morning vs. evening chronotype;
LUSC	cis	rs965469	0.779	rs6051693	chr20:3244449	T/G	cg25506879	chr20:3388711	C20orf194	-0.49	-5.68	-0.3	2.88e-8	IFN-related cytopenia;
LUSC	trans	rs61931739	0.635	rs10772123	chr12:33975557	C/T	cg13010199	chr12:38710504	ALG10B	0.4	6.05	0.31	3.86e-9	Morning vs. evening chronotype;
LUSC	cis	rs1784581	0.855	rs1893101	chr6:162384371	G/C	cg17173639	chr6:162384350	PARK2	-0.84	-15.86	-0.66	1.23e-42	Itch intensity from mosquito bite;
LUSC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg00074818	chr8:8560427	CLDN23	0.58	9.91	0.48	1.88e-20	Obesity-related traits;
LUSC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.51	-8.83	-0.44	5.94e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.31	-0.49	7.77e-22	Eye color traits;
LUSC	cis	rs117623576	0.941	rs72784857	chr10:32441029	C/T	cg03047570	chr10:32398778	NA	-0.57	-5.7	-0.3	2.57e-8	Anti-saccade response;
LUSC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg00945038	chr17:61921165	SMARCD2	0.51	8.67	0.43	1.94e-16	Prudent dietary pattern;
LUSC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg20203395	chr5:56204925	C5orf35	-0.82	-11.32	-0.53	2.28e-25	Initial pursuit acceleration;
LUSC	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg05855489	chr10:104503620	C10orf26	-0.68	-10.21	-0.49	1.74e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg08601574	chr20:25228251	PYGB	-0.44	-6.78	-0.35	5.38e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs617219	0.853	rs1664552	chr5:78438492	A/C	cg24856658	chr5:78533917	JMY	-0.31	-5.74	-0.3	2.14e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.43	6.6	0.34	1.58e-10	Dupuytren's disease;
LUSC	cis	rs137603	0.644	rs137636	chr22:39722477	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.52	-8.34	-0.42	1.99e-15	Primary biliary cholangitis;
LUSC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg15790184	chr11:494944	RNH1	0.52	5.98	0.31	5.62e-9	Body mass index;
LUSC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg07741184	chr6:167504864	NA	0.43	7.65	0.39	2.19e-13	Crohn's disease;
LUSC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg11901034	chr3:128598214	ACAD9	-0.42	-6.66	-0.34	1.16e-10	IgG glycosylation;
LUSC	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg08601574	chr20:25228251	PYGB	0.55	8.83	0.43	6.23e-17	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-7.25	-0.37	2.87e-12	Body mass index;
LUSC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg06640241	chr16:89574553	SPG7	0.72	9.88	0.48	2.25e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs11690935	0.549	rs62183819	chr2:172904520	G/T	cg13550731	chr2:172543902	DYNC1I2	0.53	8.14	0.41	7.95e-15	Schizophrenia;
LUSC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.07	16.44	0.67	6.79e-45	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg11887960	chr12:57824829	NA	0.56	6.84	0.35	3.75e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg21951975	chr1:209979733	IRF6	0.4	6.67	0.34	1.08e-10	Monobrow;
LUSC	cis	rs2668423	0.501	rs502121	chr19:1387299	T/C	cg02639931	chr19:1387894	NDUFS7	-0.67	-13.21	-0.59	2.49e-32	Nonalcoholic fatty liver disease;
LUSC	cis	rs4132509	1.000	rs12116882	chr1:243959106	G/A	cg21452805	chr1:244014465	NA	0.52	5.97	0.31	6.07e-9	RR interval (heart rate);
LUSC	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg04267008	chr7:1944627	MAD1L1	-0.45	-6.46	-0.33	3.61e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6426558	0.537	rs6699828	chr1:227274591	T/C	cg10327440	chr1:227177885	CDC42BPA	0.55	7.46	0.38	7.53e-13	Neutrophil percentage of white cells;
LUSC	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg27284194	chr4:1044797	NA	0.58	8.93	0.44	2.81e-17	Recombination rate (females);
LUSC	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg26566898	chr11:117069891	TAGLN	0.35	6.56	0.34	2.05e-10	Blood protein levels;
LUSC	cis	rs34891900	0.507	rs1008378	chr22:18207251	T/C	cg19898043	chr22:18121309	BCL2L13	0.43	6.6	0.34	1.58e-10	Sum neutrophil eosinophil counts;
LUSC	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-15.48	-0.65	3.84e-41	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs524023	1.000	rs537246	chr11:64360630	G/A	cg07220939	chr11:64358617	SLC22A12	0.23	6.08	0.32	3.35e-9	Urate levels in obese individuals;
LUSC	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.34	0.41	2.03e-15	Coffee consumption (cups per day);
LUSC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg19592336	chr6:28129416	ZNF389	0.45	5.81	0.3	1.46e-8	Depression;
LUSC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg07701084	chr6:150067640	NUP43	-0.57	-8.98	-0.44	1.97e-17	Lung cancer;
LUSC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	trans	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.17	-0.41	6.33e-15	Neuroticism;
LUSC	cis	rs8040855	0.756	rs2342118	chr15:85693016	C/T	cg04831495	chr15:85060580	GOLGA6L5	0.42	6.45	0.33	3.95e-10	Bulimia nervosa;
LUSC	cis	rs367943	0.712	rs9326887	chr5:112728581	T/A	cg12552261	chr5:112820674	MCC	0.36	5.84	0.3	1.21e-8	Type 2 diabetes;
LUSC	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg16701003	chr16:89028210	CBFA2T3	0.34	5.91	0.31	8.53e-9	Social autistic-like traits;
LUSC	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg19508488	chr2:152266495	RIF1	0.44	6.33	0.33	8.07e-10	Lung cancer;
LUSC	cis	rs3106136	0.967	rs2664892	chr4:95154186	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.34	-5.93	-0.31	7.72e-9	Capecitabine sensitivity;
LUSC	cis	rs9646944	0.501	rs10166330	chr2:103050390	C/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.55	0.34	2.23e-10	Blood protein levels;
LUSC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg05043794	chr9:111880884	C9orf5	-0.33	-6.97	-0.36	1.72e-11	Menarche (age at onset);
LUSC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg27432699	chr2:27873401	GPN1	-0.56	-8.41	-0.42	1.23e-15	Total body bone mineral density;
LUSC	cis	rs9807989	0.839	rs4988957	chr2:102968075	C/T	cg09003973	chr2:102972529	NA	-0.44	-5.98	-0.31	5.86e-9	Asthma;
LUSC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg22920501	chr2:26401640	FAM59B	-0.8	-11.76	-0.54	6.2e-27	Gut microbiome composition (summer);
LUSC	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.93	-0.35	2.13e-11	Response to antipsychotic treatment;
LUSC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg27411982	chr8:10470053	RP1L1	0.48	7.21	0.37	3.68e-12	Neuroticism;
LUSC	trans	rs4729127	1.000	rs7793690	chr7:94013594	A/T	cg20086523	chr13:52378287	DHRS12	0.56	6.35	0.33	6.97e-10	Intelligence;
LUSC	trans	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg06606381	chr12:133084897	FBRSL1	0.56	6.57	0.34	1.98e-10	Depression;
LUSC	cis	rs28595532	0.702	rs72670250	chr4:119337134	T/C	cg21605333	chr4:119757512	SEC24D	1.02	8.31	0.41	2.47e-15	Cannabis dependence symptom count;
LUSC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	1.22	16.05	0.66	2.2e-43	Eosinophil percentage of granulocytes;
LUSC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg27535305	chr1:53392650	SCP2	-0.39	-7.36	-0.37	1.43e-12	Monocyte count;
LUSC	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg02807482	chr3:125708958	NA	-0.53	-7.07	-0.36	9.31e-12	Blood pressure (smoking interaction);
LUSC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg03351412	chr1:154909251	PMVK	-0.43	-6.55	-0.34	2.19e-10	Prostate cancer;
LUSC	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.77	16.18	0.66	7.08e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9905704	0.589	rs2680696	chr17:56473013	C/T	cg19466818	chr17:56409534	MIR142	0.31	5.86	0.31	1.09e-8	Testicular germ cell tumor;
LUSC	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg05855489	chr10:104503620	C10orf26	0.52	8.02	0.4	1.81e-14	Arsenic metabolism;
LUSC	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	7.08	0.36	8.75e-12	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.47	0.53	6.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6961069	0.671	rs10261849	chr7:80224467	A/C	cg04458919	chr7:80252533	CD36	-0.41	-7.25	-0.37	2.89e-12	Platelet count;
LUSC	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11645453	chr3:52864694	ITIH4	-0.5	-11.33	-0.53	2.17e-25	Schizophrenia;
LUSC	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg01657329	chr11:68192670	LRP5	0.48	6.32	0.33	8.42e-10	Bone mineral density (spine);
LUSC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.63	9.23	0.45	3.08e-18	Testicular germ cell tumor;
LUSC	cis	rs478607	1.000	rs551890	chr11:64477999	C/T	cg19131476	chr11:64387923	NRXN2	-0.32	-5.82	-0.3	1.38e-8	Urate levels;
LUSC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg23630131	chr7:65973040	NA	0.21	5.94	0.31	7.16e-9	Aortic root size;
LUSC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.71	13.9	0.61	5.76e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9462027	0.628	rs2395598	chr6:34640686	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.35	-6.21	-0.32	1.53e-9	Systemic lupus erythematosus;
LUSC	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg09835421	chr16:68378352	PRMT7	-0.54	-5.94	-0.31	7.01e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.29	6.26	0.32	1.16e-9	Electroencephalogram traits;
LUSC	cis	rs7560272	0.669	rs7598660	chr2:73740425	C/T	cg20560298	chr2:73613845	ALMS1	-0.39	-6.0	-0.31	5.27e-9	Schizophrenia;
LUSC	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg21880101	chr17:80066754	CCDC57	-0.31	-5.93	-0.31	7.5e-9	Life satisfaction;
LUSC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg03289416	chr15:75166202	SCAMP2	0.38	5.66	0.3	3.28e-8	Caffeine consumption;
LUSC	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	1.1	17.27	0.69	3.24e-48	Exhaled nitric oxide output;
LUSC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.14	-22.53	-0.78	5.51e-69	Exhaled nitric oxide output;
LUSC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg01973587	chr1:228161476	NA	-0.41	-7.15	-0.36	5.48e-12	Diastolic blood pressure;
LUSC	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg23625390	chr15:77176239	SCAPER	-0.63	-9.23	-0.45	3.2e-18	Blood metabolite levels;
LUSC	cis	rs11229555	0.645	rs12283414	chr11:58176920	C/T	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-8.1	-0.41	1.03e-14	Chronic sinus infection;
LUSC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	9.8e-65	Prudent dietary pattern;
LUSC	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg05738196	chr6:26577821	NA	0.54	8.58	0.42	3.72e-16	Schizophrenia;
LUSC	cis	rs3087591	0.810	rs2269856	chr17:29482701	C/T	cg24425628	chr17:29625626	OMG;NF1	0.59	8.37	0.42	1.61e-15	Hip circumference;
LUSC	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.07	-0.44	1.05e-17	Monocyte percentage of white cells;
LUSC	trans	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg06453172	chr10:134556979	INPP5A	-0.48	-5.95	-0.31	6.62e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg18721089	chr20:30220636	NA	-0.41	-6.49	-0.33	3.1e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1506636	0.962	rs17623873	chr7:123417100	C/A	cg03229431	chr7:123269106	ASB15	0.63	10.1	0.48	4.34e-21	Plateletcrit;Platelet count;
LUSC	cis	rs748404	0.723	rs560134	chr15:43555699	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.41	5.88	0.31	1e-8	Lung cancer;
LUSC	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.31	22.15	0.77	1.62e-67	Type 1 diabetes nephropathy;
LUSC	cis	rs6977660	0.714	rs4719585	chr7:19823727	C/G	cg07541023	chr7:19748670	TWISTNB	0.6	6.3	0.33	9.45e-10	Thyroid stimulating hormone;
LUSC	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg19875535	chr5:140030758	IK	0.5	8.28	0.41	3.06e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.83	14.27	0.62	2.19e-36	Metabolic syndrome;
LUSC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	13.55	0.6	1.19e-33	Menopause (age at onset);
LUSC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg18827107	chr12:86230957	RASSF9	-0.43	-6.37	-0.33	6.35e-10	Major depressive disorder;
LUSC	cis	rs9361491	0.604	rs1158575	chr6:79459206	A/G	cg05283184	chr6:79620031	NA	-0.32	-5.86	-0.31	1.13e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg27600084	chr12:12264075	NA	0.46	7.08	0.36	8.78e-12	Breast size;
LUSC	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	8.8	0.43	7.22e-17	Myopia (pathological);
LUSC	cis	rs4499344	0.577	rs259289	chr19:33164927	G/C	cg22980127	chr19:33182716	NUDT19	-0.42	-6.3	-0.33	9.55e-10	Mean platelet volume;
LUSC	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg05973401	chr12:123451056	ABCB9	0.53	6.59	0.34	1.73e-10	Neutrophil percentage of white cells;
LUSC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg09796270	chr17:17721594	SREBF1	-0.4	-7.05	-0.36	1.06e-11	Total body bone mineral density;
LUSC	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg17691542	chr6:26056736	HIST1H1C	0.49	7.02	0.36	1.28e-11	Iron status biomarkers;
LUSC	cis	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.68	-0.39	1.78e-13	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.67	11.21	0.52	5.92e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg25922239	chr6:33757077	LEMD2	0.53	7.82	0.39	7.07e-14	Crohn's disease;
LUSC	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg08079166	chr15:68083412	MAP2K5	-0.4	-8.01	-0.4	1.9e-14	Restless legs syndrome;
LUSC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	12.92	0.58	2.98e-31	Platelet count;
LUSC	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg01884057	chr2:25150051	NA	0.42	9.1	0.45	8.06e-18	Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02331583	chr17:40021711	KLHL11	0.48	6.49	0.33	3.08e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs963731	0.649	rs2278913	chr2:39199880	A/G	cg04010122	chr2:39346883	SOS1	-0.77	-5.67	-0.3	3.1e-8	Corticobasal degeneration;
LUSC	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg05043794	chr9:111880884	C9orf5	-0.37	-7.81	-0.39	7.29e-14	Menarche (age at onset);
LUSC	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg12863693	chr15:85201151	NMB	0.36	7.06	0.36	9.44e-12	Schizophrenia;
LUSC	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-9.41	-0.46	8.44e-19	Morning vs. evening chronotype;
LUSC	cis	rs6750047	0.605	rs2121260	chr2:38268763	T/G	cg07380506	chr2:38303506	CYP1B1	0.44	6.0	0.31	5.02e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg09035930	chr12:129282057	SLC15A4	0.75	15.94	0.66	6.21e-43	Systemic lupus erythematosus;
LUSC	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	10.1	0.48	4.15e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.45	6.97	0.36	1.66e-11	Schizophrenia;
LUSC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.25	-14.44	-0.62	4.77e-37	Gout;
LUSC	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg12935359	chr14:103987150	CKB	0.65	10.46	0.5	2.5e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs10740039	0.804	rs10821824	chr10:62450207	G/T	cg18175470	chr10:62150864	ANK3	-0.44	-6.67	-0.34	1.08e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs16867321	1.000	rs10185265	chr2:181438860	G/C	cg23363182	chr2:181467187	NA	-0.44	-5.91	-0.31	8.26e-9	Obesity;
LUSC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg23791538	chr6:167370224	RNASET2	0.41	6.55	0.34	2.21e-10	Lung cancer;
LUSC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.78	0.35	5.31e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg20587970	chr11:113659929	NA	-0.7	-9.18	-0.45	4.53e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs1858037	0.806	rs12612780	chr2:65583101	A/G	cg08085232	chr2:65598271	SPRED2	-0.38	-5.73	-0.3	2.18e-8	Rheumatoid arthritis;
LUSC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg01802117	chr1:53393560	SCP2	0.38	6.23	0.32	1.42e-9	Monocyte count;
LUSC	cis	rs58785573	0.504	rs9522	chr4:38666972	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.55	8.39	0.42	1.41e-15	Lymphocyte percentage of white cells;
LUSC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg00033643	chr7:134001901	SLC35B4	0.42	6.29	0.33	1.01e-9	Mean platelet volume;
LUSC	cis	rs8027181	0.958	rs4776614	chr15:73082468	C/G	cg25632853	chr15:73088954	NA	0.34	6.59	0.34	1.75e-10	Triglyceride levels;
LUSC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.31	-0.37	2.04e-12	Body mass index;
LUSC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg10792982	chr14:105748885	BRF1	0.49	8.62	0.43	2.7e-16	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs1512268	0.672	rs6557705	chr8:23496546	A/G	cg08659539	chr15:41098188	ZFYVE19;DNAJC17	-0.38	-5.99	-0.31	5.46e-9	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4776059	1.000	rs2414166	chr15:52901977	C/T	cg22715398	chr15:52968154	KIAA1370	-0.67	-9.86	-0.47	2.61e-20	Schizophrenia;
LUSC	cis	rs4494114	1.000	rs2147914	chr1:39352271	G/T	cg25970120	chr1:39325951	RRAGC	-0.39	-5.99	-0.31	5.39e-9	Blood protein levels;
LUSC	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg23093090	chr10:104574429	C10orf26	-0.45	-5.65	-0.3	3.37e-8	Arsenic metabolism;
LUSC	trans	rs9467603	0.800	rs4236040	chr6:25761209	T/C	cg06606381	chr12:133084897	FBRSL1	0.6	6.21	0.32	1.53e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg01677386	chr11:118938358	VPS11	-0.44	-6.12	-0.32	2.65e-9	Coronary artery disease;
LUSC	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.68	0.34	9.97e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg17376030	chr22:41985996	PMM1	-0.47	-6.05	-0.31	3.85e-9	Vitiligo;
LUSC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23158103	chr7:148848205	ZNF398	-0.45	-7.06	-0.36	9.42e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18932078	chr1:2524107	MMEL1	-0.33	-7.23	-0.37	3.33e-12	Ulcerative colitis;
LUSC	cis	rs4285028	0.747	rs9838301	chr3:121375144	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-12.87	-0.58	4.62e-31	Multiple sclerosis;
LUSC	trans	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg20587970	chr11:113659929	NA	-0.64	-8.94	-0.44	2.68e-17	Hip circumference adjusted for BMI;
LUSC	trans	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg07211511	chr3:129823064	LOC729375	-0.75	-9.67	-0.47	1.2e-19	Blood pressure (smoking interaction);
LUSC	cis	rs34779708	0.733	rs16935948	chr10:35549748	C/G	cg03585969	chr10:35415529	CREM	0.49	6.75	0.35	6.45e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.2	0.49	1.98e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg00204512	chr16:28754710	NA	0.34	6.14	0.32	2.4e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg13073564	chr4:8508604	NA	0.48	8.96	0.44	2.37e-17	Response to antineoplastic agents;
LUSC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	14.02	0.61	1.88e-35	Alzheimer's disease;
LUSC	trans	rs62387962	0.764	rs3846685	chr5:157292978	T/A	cg09066361	chr7:126890254	GRM8	0.49	6.42	0.33	4.71e-10	Platelet distribution width;
LUSC	cis	rs7267979	0.586	rs1007708	chr20:25190959	C/T	cg08601574	chr20:25228251	PYGB	0.45	6.84	0.35	3.81e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg15445000	chr17:37608096	MED1	-0.37	-6.46	-0.33	3.73e-10	Glomerular filtration rate (creatinine);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03027774	chr7:100304043	POP7	-0.48	-6.16	-0.32	2.04e-9	Hepatitis;
LUSC	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg21238619	chr17:78079768	GAA	-0.3	-5.97	-0.31	6.09e-9	Yeast infection;
LUSC	cis	rs273573	0.961	rs163854	chr11:30964632	G/T	cg14844989	chr11:31128820	NA	0.38	6.03	0.31	4.37e-9	Total body bone mineral density;
LUSC	cis	rs4363385	0.818	rs441229	chr1:153015059	A/C	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.89	-0.4	4.44e-14	Inflammatory skin disease;
LUSC	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17467752	chr17:38218738	THRA	0.53	7.9	0.4	3.96e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	6.41	0.33	5.06e-10	Platelet count;
LUSC	trans	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg05059571	chr16:84539110	KIAA1609	-0.48	-9.14	-0.45	6.21e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20887711	chr4:1340912	KIAA1530	0.55	8.73	0.43	1.28e-16	Longevity;
LUSC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg22166914	chr1:53195759	ZYG11B	0.58	9.68	0.47	1.04e-19	Monocyte count;
LUSC	trans	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg26043149	chr18:55253948	FECH	-0.44	-6.86	-0.35	3.45e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg04851639	chr8:1020857	NA	-0.37	-7.48	-0.38	6.58e-13	Schizophrenia;
LUSC	cis	rs3931020	0.688	rs968358	chr1:75193989	G/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.46	5.77	0.3	1.8e-8	Resistin levels;
LUSC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg10729496	chr3:10149963	C3orf24	0.56	7.62	0.38	2.65e-13	Alzheimer's disease;
LUSC	cis	rs7267979	0.714	rs6115107	chr20:25237390	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.66	12.25	0.56	9.41e-29	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg25036284	chr2:26402008	FAM59B	-0.68	-9.45	-0.46	6.03e-19	Gut microbiome composition (summer);
LUSC	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-5.99	-0.31	5.41e-9	Body mass index;
LUSC	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.88	-0.44	4.13e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg15790184	chr11:494944	RNH1	0.5	7.16	0.36	5.23e-12	Systemic lupus erythematosus;
LUSC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.96	0.36	1.85e-11	Platelet count;
LUSC	cis	rs925255	0.817	rs12624279	chr2:28634790	G/A	cg01273330	chr2:28605224	NA	0.44	7.14	0.36	5.76e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg26384229	chr12:38710491	ALG10B	0.72	11.31	0.53	2.59e-25	Morning vs. evening chronotype;
LUSC	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg13575925	chr12:9217583	LOC144571	0.33	6.07	0.32	3.55e-9	Sjögren's syndrome;
LUSC	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg27426351	chr10:43362370	NA	-0.42	-5.87	-0.31	1.08e-8	Blood protein levels;
LUSC	cis	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.19	-0.32	1.76e-9	Ulcerative colitis;
LUSC	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg11645453	chr3:52864694	ITIH4	0.47	10.67	0.5	4.58e-23	Schizophrenia;
LUSC	cis	rs6690583	0.623	rs12042845	chr1:85429801	A/G	cg22153463	chr1:85462885	MCOLN2	0.64	6.3	0.33	9.63e-10	Serum sulfate level;
LUSC	cis	rs7589342	0.839	rs11895235	chr2:106432355	C/G	cg14210321	chr2:106509881	NCK2	-0.53	-7.92	-0.4	3.47e-14	Addiction;
LUSC	trans	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg26811252	chr16:29126840	RRN3P2	0.57	8.95	0.44	2.47e-17	Menopause (age at onset);
LUSC	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg12002119	chr2:101014098	CHST10	0.36	6.02	0.31	4.56e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg24011408	chr12:48396354	COL2A1	-0.39	-5.72	-0.3	2.34e-8	Glycated hemoglobin levels;
LUSC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg03684893	chr10:554711	DIP2C	-0.37	-6.68	-0.34	9.82e-11	Psychosis in Alzheimer's disease;
LUSC	trans	rs116175374	0.793	rs6728152	chr2:31431651	A/G	cg15543616	chr12:5019024	KCNA1	-0.73	-6.09	-0.32	3.13e-9	Endometriosis;
LUSC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-7.42	-0.38	9.7e-13	Aortic root size;
LUSC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-17.56	-0.69	2.3e-49	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11878476	chr22:39898238	SMCR7L	-0.4	-6.08	-0.32	3.21e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg24692254	chr21:30365293	RNF160	-0.54	-7.86	-0.4	5.38e-14	Dental caries;
LUSC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.2	0.45	4.02e-18	Motion sickness;
LUSC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.53	8.48	0.42	7.63e-16	Height;
LUSC	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg22508957	chr16:3507546	NAT15	0.43	6.68	0.34	1.02e-10	Body mass index (adult);
LUSC	cis	rs965604	1.000	rs965604	chr15:78789223	G/A	cg18825076	chr15:78729989	IREB2	-0.43	-6.82	-0.35	4.31e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2969070	0.674	rs2906146	chr7:2524939	A/G	cg03277898	chr7:2518824	NA	-0.3	-6.3	-0.33	9.6e-10	Diastolic blood pressure;
LUSC	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.49	-9.05	-0.44	1.18e-17	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-1.14	-17.89	-0.7	1.12e-50	Exhaled nitric oxide output;
LUSC	cis	rs4718428	1.000	rs868961	chr7:66437208	G/T	cg18252515	chr7:66147081	NA	-0.45	-6.83	-0.35	3.98e-11	Corneal structure;
LUSC	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg09877947	chr5:131593287	PDLIM4	-0.36	-5.76	-0.3	1.87e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs3803170	0.513	rs4766574	chr12:111832372	C/T	cg10833066	chr12:111807467	FAM109A	0.39	7.29	0.37	2.19e-12	Mean corpuscular hemoglobin;
LUSC	trans	rs800082	0.698	rs800074	chr3:144347638	A/G	cg24215973	chr2:240111563	HDAC4	-0.7	-10.35	-0.49	6.06e-22	Smoking behavior;
LUSC	cis	rs907683	0.545	rs3755054	chr2:220280974	C/T	cg15015639	chr2:220282977	DES	0.31	7.43	0.38	9e-13	Resting heart rate;
LUSC	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg19875535	chr5:140030758	IK	0.47	7.56	0.38	4.05e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	0.99	14.03	0.61	1.78e-35	Vitiligo;
LUSC	cis	rs6961069	0.527	rs3211820	chr7:80278465	A/C	cg04458919	chr7:80252533	CD36	0.39	6.82	0.35	4.16e-11	Platelet count;
LUSC	cis	rs4796285	1.000	rs4796285	chr17:35181996	A/G	cg10754668	chr17:35168702	NA	-0.26	-6.13	-0.32	2.45e-9	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg26513180	chr16:89883248	FANCA	0.61	5.79	0.3	1.61e-8	Skin colour saturation;
LUSC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	8.62	0.43	2.81e-16	Colorectal cancer;
LUSC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg04800585	chr6:26043546	HIST1H2BB	0.44	6.29	0.33	9.96e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.73	-12.82	-0.57	7.16e-31	Dental caries;
LUSC	cis	rs4363385	0.626	rs6664183	chr1:153064002	A/G	cg00922841	chr1:152955080	SPRR1A	-0.33	-5.81	-0.3	1.44e-8	Inflammatory skin disease;
LUSC	cis	rs58804349	0.581	rs12221397	chr10:43239833	A/G	cg08461752	chr10:43522343	NA	0.53	5.83	0.3	1.34e-8	Pediatric bone mineral content (radius);
LUSC	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg05025164	chr4:1340916	KIAA1530	0.43	6.42	0.33	4.66e-10	Obesity-related traits;
LUSC	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg04539111	chr16:67997858	SLC12A4	-0.42	-5.88	-0.31	1.02e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.91	-0.4	3.79e-14	Joint mobility (Beighton score);
LUSC	cis	rs6484504	0.576	rs11031324	chr11:31250299	T/C	cg06552810	chr11:31128660	NA	-0.4	-7.12	-0.36	6.5e-12	Red blood cell count;
LUSC	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg17366294	chr4:99064904	C4orf37	0.53	8.34	0.42	1.98e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs870825	0.616	rs28442259	chr4:185646962	T/G	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs1358748	0.522	rs4655675	chr1:67576075	C/T	cg02640540	chr1:67518911	SLC35D1	0.64	6.17	0.32	2.03e-9	Tuberculosis;
LUSC	cis	rs1775715	0.651	rs2808033	chr10:32194127	A/T	cg26784012	chr10:32216390	ARHGAP12	0.47	7.91	0.4	3.91e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs72960926	0.744	rs3898077	chr6:74959122	G/A	cg03266952	chr6:74778945	NA	-0.85	-7.14	-0.36	5.86e-12	Metabolite levels (MHPG);
LUSC	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg23283495	chr1:209979779	IRF6	0.45	7.14	0.36	5.85e-12	Monobrow;
LUSC	cis	rs2637266	1.000	rs7098790	chr10:78361077	T/A	cg18941641	chr10:78392320	NA	0.4	7.45	0.38	7.84e-13	Pulmonary function;
LUSC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.62	-7.79	-0.39	8.39e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.51	-8.02	-0.4	1.77e-14	Height;
LUSC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.88	13.2	0.59	2.7e-32	Platelet count;
LUSC	cis	rs829883	0.659	rs11109524	chr12:98939172	G/A	cg25150519	chr12:98850993	NA	-0.63	-8.71	-0.43	1.47e-16	Colorectal adenoma (advanced);
LUSC	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg20848291	chr7:100343083	ZAN	-0.53	-6.6	-0.34	1.61e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs3916	0.794	rs10431384	chr12:121127347	C/T	cg27246729	chr12:121163418	ACADS	-0.47	-7.2	-0.37	3.95e-12	Urinary metabolites (H-NMR features);
LUSC	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	0.99	12.43	0.56	2.08e-29	Vitiligo;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24517925	chr1:155715448	MSTO2P	-0.45	-6.07	-0.32	3.57e-9	Hepatitis;
LUSC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg15117754	chr3:10150083	C3orf24	0.45	5.72	0.3	2.4e-8	Alzheimer's disease;
LUSC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg13319975	chr6:146136371	FBXO30	-0.66	-9.86	-0.47	2.74e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6736093	0.966	rs13013340	chr2:112694988	C/A	cg12686935	chr2:112915763	FBLN7	-0.37	-5.9	-0.31	8.73e-9	Coronary artery disease;
LUSC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg22903657	chr4:1355424	KIAA1530	-0.48	-8.13	-0.41	8.52e-15	Obesity-related traits;
LUSC	cis	rs9309473	0.687	rs6748040	chr2:73609928	A/G	cg20560298	chr2:73613845	ALMS1	0.55	8.24	0.41	3.93e-15	Metabolite levels;
LUSC	cis	rs262150	0.566	rs262159	chr7:158772172	C/T	cg19418458	chr7:158789849	NA	0.41	5.67	0.3	3.02e-8	Facial morphology (factor 20);
LUSC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.14e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg26566898	chr11:117069891	TAGLN	0.37	7.22	0.37	3.49e-12	Blood protein levels;
LUSC	cis	rs1891275	0.515	rs7911755	chr10:93489817	G/A	cg07889827	chr10:93443413	NA	-0.41	-9.4	-0.46	8.94e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-7.04	-0.36	1.13e-11	Blood metabolite levels;
LUSC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.69	-10.82	-0.51	1.38e-23	Monocyte percentage of white cells;
LUSC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	0.83	14.07	0.61	1.24e-35	Tonsillectomy;
LUSC	cis	rs73198271	0.515	rs78922347	chr8:8627916	G/C	cg01851573	chr8:8652454	MFHAS1	0.63	7.36	0.37	1.45e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg27661571	chr11:113659931	NA	-0.7	-8.16	-0.41	6.68e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg19743168	chr1:23544995	NA	0.46	9.21	0.45	3.75e-18	Height;
LUSC	cis	rs11677416	1.000	rs1800587	chr2:113542960	C/T	cg27083787	chr2:113543245	IL1A	0.45	7.17	0.37	4.92e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs10843647	0.967	rs973485	chr12:30326144	T/A	cg12718339	chr12:29936407	TMTC1	-0.35	-5.84	-0.3	1.27e-8	Glucose homeostasis traits;
LUSC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg08088566	chr11:430123	ANO9	0.64	7.2	0.37	4.01e-12	Body mass index;
LUSC	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.6	11.27	0.52	3.59e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg09904177	chr6:26538194	HMGN4	0.63	10.57	0.5	1.02e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.35	-0.37	1.5e-12	Morning vs. evening chronotype;
LUSC	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.97	0.31	6.23e-9	Schizophrenia;
LUSC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	14.26	0.62	2.26e-36	Tonsillectomy;
LUSC	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg06637938	chr14:75390232	RPS6KL1	0.54	8.69	0.43	1.63e-16	Height;
LUSC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	19.95	0.74	7.16e-59	Height;
LUSC	cis	rs7178572	0.633	rs4886876	chr15:77838491	C/T	cg22256960	chr15:77711686	NA	-0.46	-6.85	-0.35	3.6e-11	Type 2 diabetes;
LUSC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.39	-7.35	-0.37	1.5e-12	Longevity;Endometriosis;
LUSC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg05552183	chr6:42928497	GNMT	0.49	8.17	0.41	6.42e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-6.92	-0.35	2.31e-11	Arsenic metabolism;
LUSC	cis	rs11168618	0.967	rs1895996	chr12:48955571	A/C	cg24011408	chr12:48396354	COL2A1	0.41	6.35	0.33	6.89e-10	Adiponectin levels;
LUSC	cis	rs11644601	1	rs11644601	chr16:15172118	T/C	cg27102117	chr16:15229624	NA	0.37	5.66	0.3	3.33e-8	Metabolite levels (lipid measures);
LUSC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg09904177	chr6:26538194	HMGN4	-0.52	-5.8	-0.3	1.51e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.73	-14.14	-0.61	6.67e-36	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	10.83	0.51	1.25e-23	Homoarginine levels;
LUSC	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg24642844	chr7:1081250	C7orf50	-0.71	-9.69	-0.47	1.01e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg21672276	chr3:44754072	ZNF502	-0.37	-5.8	-0.3	1.56e-8	Depressive symptoms;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15864354	chr12:120966977	COQ5	-0.41	-6.13	-0.32	2.41e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.54	-8.64	-0.43	2.42e-16	Schizophrenia;
LUSC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg08470875	chr2:26401718	FAM59B	0.75	10.02	0.48	7.77e-21	Mean corpuscular hemoglobin;
LUSC	cis	rs131777	0.545	rs140514	chr22:51018579	A/G	cg00083937	chr22:51039805	MAPK8IP2	0.52	9.02	0.44	1.48e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg13010199	chr12:38710504	ALG10B	0.65	10.24	0.49	1.34e-21	Bladder cancer;
LUSC	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.27	0.32	1.13e-9	Corneal astigmatism;
LUSC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg23034840	chr1:205782522	SLC41A1	0.55	7.51	0.38	5.52e-13	Menarche (age at onset);
LUSC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.7	-12.66	-0.57	2.88e-30	Aortic root size;
LUSC	cis	rs6504340	0.739	rs66459980	chr17:46672716	C/T	cg09704116	chr17:46666958	LOC404266	-0.4	-6.2	-0.32	1.71e-9	Primary tooth development (number of teeth);
LUSC	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg04234412	chr22:24373322	LOC391322	-0.92	-16.31	-0.67	2.03e-44	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg26850624	chr5:429559	AHRR	-0.41	-8.0	-0.4	2.1e-14	Cystic fibrosis severity;
LUSC	cis	rs17401966	0.558	rs4846218	chr1:10452040	G/T	cg17425144	chr1:10567563	PEX14	-0.33	-6.04	-0.31	4.2e-9	Hepatocellular carcinoma;
LUSC	cis	rs9341808	0.538	rs667097	chr6:80978943	G/A	cg08355045	chr6:80787529	NA	-0.4	-6.84	-0.35	3.71e-11	Sitting height ratio;
LUSC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg15790184	chr11:494944	RNH1	0.58	6.33	0.33	7.7e-10	Body mass index;
LUSC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24110177	chr3:50126178	RBM5	0.63	11.14	0.52	1.05e-24	Body mass index;
LUSC	cis	rs6539267	0.847	rs12831519	chr12:106682917	A/G	cg00173435	chr12:106696525	TCP11L2	0.58	7.7	0.39	1.6e-13	Tourette syndrome;
LUSC	trans	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg26384229	chr12:38710491	ALG10B	-0.58	-9.4	-0.46	9.08e-19	Morning vs. evening chronotype;
LUSC	trans	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg25482853	chr8:67687455	SGK3	1.14	16.0	0.66	3.65e-43	Lung disease severity in cystic fibrosis;
LUSC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg02423579	chr7:2872169	GNA12	-0.44	-6.42	-0.33	4.76e-10	Height;
LUSC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7607980	1.000	rs7607980	chr2:165551201	A/G	cg21604450	chr1:66998563	SGIP1	0.52	6.23	0.32	1.41e-9	Fasting blood insulin (BMI interaction);Fasting blood insulin;Type 2 diabetes;
LUSC	cis	rs804280	1.000	rs804281	chr8:11611865	A/G	cg12395012	chr8:11607386	GATA4	-0.33	-5.77	-0.3	1.83e-8	Myopia (pathological);
LUSC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.41	6.29	0.33	9.85e-10	Colorectal cancer;
LUSC	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.56e-8	Breast cancer;
LUSC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg10755058	chr3:40428713	ENTPD3	0.38	6.27	0.32	1.12e-9	Renal cell carcinoma;
LUSC	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg13699009	chr12:122356056	WDR66	0.48	7.22	0.37	3.64e-12	Mean corpuscular volume;
LUSC	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg14895029	chr7:2775587	GNA12	-0.37	-6.05	-0.31	3.87e-9	Height;
LUSC	cis	rs367943	0.712	rs6594707	chr5:112700503	C/T	cg12552261	chr5:112820674	MCC	0.39	6.47	0.33	3.44e-10	Type 2 diabetes;
LUSC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11645453	chr3:52864694	ITIH4	0.33	7.67	0.39	1.87e-13	Bipolar disorder;
LUSC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg13770153	chr20:60521292	NA	-0.67	-9.58	-0.46	2.31e-19	Body mass index;
LUSC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg05347473	chr6:146136440	FBXO30	0.53	8.77	0.43	9.28e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.7	12.21	0.56	1.32e-28	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	7.08	0.36	8.59e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.76	8.88	0.44	4.19e-17	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg03146154	chr1:46216737	IPP	0.5	7.41	0.38	1.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg14789911	chr21:47582049	C21orf56	0.41	6.42	0.33	4.79e-10	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-9.6	-0.47	1.96e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22571926	chr5:56112222	MAP3K1	0.41	6.08	0.32	3.25e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.61	10.16	0.49	2.63e-21	Bone mineral density;
LUSC	cis	rs500891	0.533	rs10943934	chr6:84181508	C/G	cg08257003	chr6:84140564	ME1	0.33	8.1	0.41	1.05e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg14675211	chr2:100938903	LONRF2	0.36	5.68	0.3	2.94e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7582720	1.000	rs72926779	chr2:203805929	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7149337	0.836	rs35345236	chr14:51671817	T/C	cg23942311	chr14:51606299	NA	0.48	10.53	0.5	1.39e-22	Cancer;
LUSC	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg18681998	chr4:17616180	MED28	0.77	13.59	0.6	8.66e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	10.72	0.51	3.12e-23	Cognitive test performance;
LUSC	trans	rs877282	0.898	rs11253356	chr10:768604	G/A	cg13042288	chr15:90349979	ANPEP	-0.42	-6.12	-0.32	2.66e-9	Uric acid levels;
LUSC	cis	rs727505	1.000	rs28702851	chr7:124442991	G/A	cg23710748	chr7:124431027	NA	-0.43	-7.66	-0.39	2.02e-13	Lewy body disease;
LUSC	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg16359550	chr11:109292809	C11orf87	0.35	6.05	0.31	3.96e-9	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg03146154	chr1:46216737	IPP	-0.51	-7.68	-0.39	1.81e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg12435725	chr3:58293450	RPP14	-0.71	-7.18	-0.37	4.5e-12	Cholesterol, total;
LUSC	cis	rs936229	0.906	rs9210	chr15:75128501	T/C	cg14664628	chr15:75095509	CSK	-0.94	-14.78	-0.63	2.11e-38	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg11062466	chr8:58055876	NA	-0.73	-9.43	-0.46	6.93e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.62	-6.63	-0.34	1.33e-10	Birth weight;
LUSC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg17294928	chr15:75287854	SCAMP5	0.41	5.99	0.31	5.56e-9	Breast cancer;
LUSC	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg18357645	chr12:58087776	OS9	0.52	7.72	0.39	1.32e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg27411982	chr8:10470053	RP1L1	0.44	6.58	0.34	1.85e-10	Neuroticism;
LUSC	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg01652190	chr22:50026171	C22orf34	-0.3	-6.32	-0.33	8.5e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6700896	0.897	rs11208696	chr1:66121781	T/G	cg04111102	chr1:66153794	NA	0.33	7.26	0.37	2.81e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs7939886	0.920	rs7934132	chr11:55942463	T/A	cg03929089	chr4:120376271	NA	0.8	6.07	0.32	3.54e-9	Myopia (pathological);
LUSC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.76	-9.32	-0.45	1.64e-18	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03934478	chr11:495069	RNH1	0.84	9.62	0.47	1.75e-19	Body mass index;
LUSC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg00343986	chr7:65444356	GUSB	-0.42	-6.44	-0.33	4.24e-10	Aortic root size;
LUSC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	trans	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.77	0.35	5.73e-11	Monocyte count;
LUSC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.46	6.68	0.34	1.02e-10	Eosinophil percentage of white cells;
LUSC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-7.72	-0.39	1.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg01097406	chr16:89675127	NA	0.3	5.95	0.31	6.82e-9	Hemoglobin concentration;
LUSC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.74	11.86	0.54	2.6e-27	N-glycan levels;
LUSC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg22800045	chr5:56110881	MAP3K1	0.75	9.72	0.47	7.76e-20	Initial pursuit acceleration;
LUSC	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg10547527	chr2:198650123	BOLL	-0.51	-5.97	-0.31	6.08e-9	Ulcerative colitis;
LUSC	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.74	-0.6	2.34e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10875746	0.903	rs58952582	chr12:48458448	T/G	cg13454099	chr12:49076203	C12orf41	-0.5	-5.73	-0.3	2.22e-8	Longevity (90 years and older);
LUSC	cis	rs6960043	0.738	rs10950548	chr7:15057728	G/A	cg19272540	chr7:15055459	NA	0.35	8.5	0.42	6.52e-16	Type 2 diabetes;
LUSC	cis	rs62400317	0.859	rs12201899	chr6:45298204	C/A	cg20913747	chr6:44695427	NA	-0.48	-7.77	-0.39	9.74e-14	Total body bone mineral density;
LUSC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg00033643	chr7:134001901	SLC35B4	0.43	6.56	0.34	2.09e-10	Mean platelet volume;
LUSC	cis	rs7923609	0.967	rs6479896	chr10:65126832	T/C	cg01631684	chr10:65280961	REEP3	-0.39	-6.08	-0.32	3.24e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-10.09	-0.48	4.57e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg25456477	chr12:86230367	RASSF9	0.44	7.88	0.4	4.75e-14	Major depressive disorder;
LUSC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.61	10.45	0.5	2.59e-22	Lung cancer;
LUSC	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg24375607	chr4:120327624	NA	0.77	11.0	0.52	3.29e-24	Corneal astigmatism;
LUSC	cis	rs9473147	0.516	rs9357546	chr6:47549495	C/T	cg20196966	chr6:47445060	CD2AP	0.41	5.74	0.3	2.1e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs2235649	0.833	rs9925460	chr16:1849943	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.42	-5.82	-0.3	1.39e-8	Blood metabolite levels;
LUSC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg13395646	chr4:1353034	KIAA1530	-0.66	-11.22	-0.52	5.13e-25	Longevity;
LUSC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg12463550	chr7:65579703	CRCP	-0.55	-8.26	-0.41	3.47e-15	Aortic root size;
LUSC	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21659725	chr3:3221576	CRBN	-0.62	-9.09	-0.45	9.04e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg07169764	chr2:136633963	MCM6	1.06	15.68	0.65	6.59e-42	Corneal structure;
LUSC	cis	rs6066835	1.000	rs3817991	chr20:47296365	G/C	cg18078177	chr20:47281410	PREX1	0.77	5.94	0.31	7.31e-9	Multiple myeloma;
LUSC	cis	rs12220238	0.730	rs4746177	chr10:75913033	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	7.21	0.37	3.81e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs11018904	0.906	rs35286339	chr11:89965679	A/G	cg26834418	chr11:89957033	CHORDC1	-0.5	-6.34	-0.33	7.54e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg04455712	chr21:45112962	RRP1B	0.44	8.34	0.42	1.98e-15	Mean corpuscular volume;
LUSC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg05347473	chr6:146136440	FBXO30	-0.66	-11.7	-0.54	9.51e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg06740227	chr12:86229804	RASSF9	0.41	6.3	0.33	9.5e-10	Major depressive disorder;
LUSC	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg24375607	chr4:120327624	NA	0.77	11.46	0.53	7.47e-26	Corneal astigmatism;
LUSC	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.89	11.91	0.55	1.75e-27	Mean corpuscular hemoglobin;
LUSC	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.03	-0.4	1.68e-14	Morning vs. evening chronotype;
LUSC	cis	rs4700695	0.841	rs251608	chr5:65247893	C/T	cg21114390	chr5:65439923	SFRS12	0.5	5.93	0.31	7.61e-9	Facial morphology (factor 19);
LUSC	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg04586622	chr2:25135609	ADCY3	0.42	8.98	0.44	1.97e-17	Body mass index in non-asthmatics;
LUSC	cis	rs1559088	0.744	rs12462426	chr19:33536683	A/C	cg17764715	chr19:33622953	WDR88	0.48	6.36	0.33	6.56e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9815354	1.000	rs9846634	chr3:41894049	G/A	cg03022575	chr3:42003672	ULK4	0.63	6.84	0.35	3.85e-11	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg18440188	chr14:50999316	MAP4K5;ATL1	0.39	5.97	0.31	6.05e-9	Mosquito bite size;
LUSC	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-0.95	-10.53	-0.5	1.45e-22	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg16989086	chr20:62203971	PRIC285	0.52	7.21	0.37	3.8e-12	Atopic dermatitis;
LUSC	trans	rs72674100	1.000	rs10002900	chr4:97974161	T/A	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.14	0.32	2.34e-9	Rheumatoid arthritis;
LUSC	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg23625390	chr15:77176239	SCAPER	0.48	7.12	0.36	6.86e-12	Blood metabolite levels;
LUSC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg19622623	chr12:86230825	RASSF9	-0.43	-6.16	-0.32	2.05e-9	Major depressive disorder;
LUSC	cis	rs4731207	1.000	rs4731207	chr7:124396645	G/A	cg14311320	chr7:124405732	GPR37	0.31	6.02	0.31	4.49e-9	Cutaneous malignant melanoma;
LUSC	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.25	0.37	2.93e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg12927641	chr6:109611667	NA	-0.35	-5.85	-0.3	1.19e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg03585969	chr10:35415529	CREM	-0.65	-9.59	-0.46	2.12e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	8.95	0.44	2.54e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-8.2	-0.41	5.32e-15	Schizophrenia;
LUSC	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg26384229	chr12:38710491	ALG10B	0.57	8.51	0.42	6.11e-16	Heart rate;
LUSC	cis	rs12545109	0.800	rs1595940	chr8:57398309	T/C	cg09654669	chr8:57350985	NA	-0.52	-6.89	-0.35	2.85e-11	Obesity-related traits;
LUSC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.63	11.73	0.54	7.41e-27	Bipolar disorder;
LUSC	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.24	-0.32	1.34e-9	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg03146154	chr1:46216737	IPP	-0.56	-8.22	-0.41	4.54e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg08999081	chr20:33150536	PIGU	0.37	6.82	0.35	4.34e-11	Height;
LUSC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.05	-0.31	3.93e-9	Platelet count;
LUSC	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.21	-0.41	4.85e-15	Response to antipsychotic treatment;
LUSC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg06521331	chr12:34319734	NA	0.37	6.29	0.33	1e-9	Morning vs. evening chronotype;
LUSC	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg11189052	chr15:85197271	WDR73	0.48	5.86	0.31	1.14e-8	Schizophrenia;
LUSC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg12257692	chr3:49977190	RBM6	-0.24	-6.57	-0.34	1.97e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs73416724	1.000	rs111408004	chr6:43326139	T/A	cg26312998	chr6:43337775	ZNF318	0.57	6.66	0.34	1.16e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg07701084	chr6:150067640	NUP43	0.46	6.89	0.35	2.73e-11	Testicular germ cell tumor;
LUSC	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.27	-0.32	1.14e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg25922239	chr6:33757077	LEMD2	-0.41	-6.27	-0.32	1.11e-9	Crohn's disease;
LUSC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.66	9.0	0.44	1.71e-17	High light scatter reticulocyte count;
LUSC	cis	rs4629180	0.586	rs10172555	chr2:102126837	C/T	cg04415270	chr2:102091202	RFX8	-0.44	-7.74	-0.39	1.16e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08704250	chr15:31115839	NA	-0.55	-8.05	-0.4	1.43e-14	Huntington's disease progression;
LUSC	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg24011408	chr12:48396354	COL2A1	0.39	5.79	0.3	1.59e-8	Glycated hemoglobin levels;
LUSC	cis	rs1007190	0.881	rs9909048	chr17:42973517	G/C	cg15406952	chr17:42872593	NA	0.56	5.76	0.3	1.88e-8	DNA methylation (variation);
LUSC	cis	rs4851254	0.961	rs13028981	chr2:100795783	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.72	-0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs11039798	0.764	rs11039771	chr11:48513273	C/T	cg15704280	chr7:45808275	SEPT13	0.71	6.65	0.34	1.21e-10	Axial length;
LUSC	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg02176678	chr2:219576539	TTLL4	0.61	11.01	0.52	2.96e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13012494	chr21:47604986	C21orf56	0.53	8.1	0.41	1.05e-14	Testicular germ cell tumor;
LUSC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg25174290	chr11:3078921	CARS	0.61	9.89	0.48	2.17e-20	Longevity;
LUSC	cis	rs12900413	0.564	rs8035800	chr15:90314790	T/C	cg24249390	chr15:90295951	MESP1	-0.37	-5.75	-0.3	2.05e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs9549260	0.664	rs9532575	chr13:41225361	G/C	cg21288729	chr13:41239152	FOXO1	0.65	10.04	0.48	6.48e-21	Red blood cell count;
LUSC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg00049323	chr5:472564	LOC25845	0.48	7.62	0.38	2.73e-13	Cystic fibrosis severity;
LUSC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg13395646	chr4:1353034	KIAA1530	0.6	9.19	0.45	4.14e-18	Obesity-related traits;
LUSC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	0.95	19.4	0.73	1.07e-56	Cognitive function;
LUSC	cis	rs2282032	0.550	rs58363992	chr14:90766361	T/C	cg14092571	chr14:90743983	NA	0.47	7.89	0.4	4.38e-14	Longevity;
LUSC	cis	rs10733682	0.715	rs3814119	chr9:129462901	A/G	cg00232160	chr9:129468157	NA	0.36	6.38	0.33	5.97e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6088813	0.961	rs6060369	chr20:33907161	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.37	-5.8	-0.3	1.51e-8	Height;
LUSC	cis	rs2692947	0.644	rs1168968	chr2:96825363	C/T	cg22654517	chr2:96458247	NA	0.33	6.03	0.31	4.38e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9359856	0.510	rs74437492	chr6:90338728	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.92	-10.86	-0.51	9.93e-24	Bipolar disorder;
LUSC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg00701064	chr4:6280414	WFS1	0.53	13.22	0.59	2.16e-32	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg17470449	chr10:769945	NA	0.51	7.01	0.36	1.33e-11	Uric acid levels;
LUSC	cis	rs7818345	0.967	rs11786847	chr8:19277200	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.38	7.31	0.37	1.95e-12	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs1185460	0.904	rs1003081	chr11:118913993	A/G	cg01677386	chr11:118938358	VPS11	0.45	6.29	0.33	9.67e-10	Coronary artery disease;
LUSC	cis	rs796825	0.530	rs4146300	chr3:120000196	A/G	cg21790991	chr3:120137480	FSTL1	-0.38	-6.88	-0.35	2.92e-11	HIV-1 susceptibility;
LUSC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg11766577	chr21:47581405	C21orf56	-0.43	-6.41	-0.33	4.9e-10	Testicular germ cell tumor;
LUSC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg05855489	chr10:104503620	C10orf26	-0.45	-6.82	-0.35	4.2e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs1524927	0.966	rs2140742	chr7:96364115	G/A	cg03808172	chr7:96339361	SHFM1	0.43	6.52	0.34	2.63e-10	Total body bone mineral density;
LUSC	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg04733989	chr22:42467013	NAGA	0.62	9.67	0.47	1.12e-19	Schizophrenia;
LUSC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-8.57	-0.42	3.77e-16	Personality dimensions;
LUSC	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.65	5.67	0.3	3.04e-8	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.15	-15.97	-0.66	4.67e-43	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.82	-0.43	6.68e-17	Response to antipsychotic treatment;
LUSC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06481639	chr22:41940642	POLR3H	0.5	5.72	0.3	2.42e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg07169764	chr2:136633963	MCM6	1.18	17.58	0.69	2e-49	Corneal structure;
LUSC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg18200150	chr17:30822561	MYO1D	0.49	9.4	0.46	8.83e-19	Schizophrenia;
LUSC	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-9.84	-0.47	3.22e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg01579765	chr21:45077557	HSF2BP	0.53	11.1	0.52	1.37e-24	Mean corpuscular volume;
LUSC	trans	rs4788815	1.000	rs4788815	chr16:71634811	A/T	cg19812283	chr5:173021074	NA	-0.35	-6.2	-0.32	1.68e-9	Metabolite levels;
LUSC	cis	rs11024102	0.830	rs11024110	chr11:17028390	T/A	cg15378786	chr11:17036137	PLEKHA7	0.44	5.93	0.31	7.44e-9	Glaucoma (primary angle closure);
LUSC	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.62	-0.57	4.01e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg07424592	chr7:64974309	NA	0.69	5.99	0.31	5.45e-9	Diabetic kidney disease;
LUSC	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.34	-5.76	-0.3	1.94e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg03585969	chr10:35415529	CREM	0.6	8.79	0.43	8.31e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7903847	0.642	rs7074511	chr10:99140177	G/A	cg20016023	chr10:99160130	RRP12	-0.33	-8.18	-0.41	6.15e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2629540	0.781	rs11245362	chr10:126458649	T/C	cg08799069	chr10:126477246	METTL10	-0.68	-10.11	-0.48	3.87e-21	Cocaine dependence;
LUSC	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg13902645	chr11:5959945	NA	-0.57	-8.11	-0.41	1.01e-14	DNA methylation (variation);
LUSC	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg17168535	chr8:21777572	XPO7	0.65	10.0	0.48	8.94e-21	Mean corpuscular volume;
LUSC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg13206674	chr6:150067644	NUP43	0.57	9.07	0.44	1.06e-17	Lung cancer;
LUSC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg16339924	chr4:17578868	LAP3	0.55	8.38	0.42	1.46e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	0.85	14.66	0.63	6.35e-38	Tonsillectomy;
LUSC	trans	rs2687481	0.718	rs1419500	chr7:125932208	A/G	cg07319014	chr16:89777268	C16orf7	-0.47	-6.55	-0.34	2.16e-10	Hearing function;
LUSC	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg02493740	chr2:85810744	VAMP5	0.52	9.16	0.45	5.48e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.29	-5.71	-0.3	2.51e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	14.26	0.62	2.24e-36	Platelet count;
LUSC	trans	rs17086172	0.630	rs1432075	chr18:70273078	C/T	cg02919422	chr8:55370544	SOX17	-0.61	-6.29	-0.33	1.02e-9	Airflow obstruction;
LUSC	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg11861562	chr11:117069780	TAGLN	0.35	6.74	0.35	6.81e-11	Blood protein levels;
LUSC	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	11.57	0.53	2.96e-26	Tonsillectomy;
LUSC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg06640241	chr16:89574553	SPG7	0.86	15.69	0.65	6.11e-42	Multiple myeloma (IgH translocation);
LUSC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.61	-9.06	-0.44	1.12e-17	Alzheimer's disease;
LUSC	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.74	-0.35	6.81e-11	Neuroticism;
LUSC	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.82	14.19	0.61	4.4e-36	Metabolic syndrome;
LUSC	cis	rs11997175	0.583	rs12680755	chr8:33815282	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	6.49	0.33	3.06e-10	Body mass index;
LUSC	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg11584989	chr19:19387371	SF4	0.5	6.07	0.32	3.47e-9	Bipolar disorder;
LUSC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg27165867	chr14:105738592	BRF1	-0.51	-7.54	-0.38	4.43e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs698813	0.604	rs11676798	chr2:44479982	G/C	cg00619915	chr2:44497795	NA	-0.51	-7.31	-0.37	1.98e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs9788721	0.836	rs72738732	chr15:78752188	C/G	cg18825076	chr15:78729989	IREB2	-0.64	-10.39	-0.49	4.35e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg02825653	chr17:7383046	ZBTB4	0.42	6.27	0.32	1.12e-9	N-glycan levels;
LUSC	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.46	-0.42	8.72e-16	Response to antipsychotic treatment;
LUSC	cis	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg13636640	chr20:31349939	DNMT3B	-0.81	-15.5	-0.65	3.37e-41	Inflammatory bowel disease;
LUSC	cis	rs7246967	0.611	rs7246424	chr19:22882185	A/G	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.81	-0.35	4.54e-11	Morning vs. evening chronotype;
LUSC	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg11189052	chr15:85197271	WDR73	0.49	5.98	0.31	5.78e-9	Schizophrenia;
LUSC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg03351412	chr1:154909251	PMVK	0.47	7.24	0.37	3.19e-12	Prostate cancer;
LUSC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.65	10.94	0.51	5.38e-24	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg06627628	chr2:24431161	ITSN2	-0.58	-8.4	-0.42	1.28e-15	Asthma;
LUSC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	11.58	0.54	2.69e-26	Menarche (age at onset);
LUSC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg25258033	chr6:167368657	RNASET2	0.36	5.66	0.3	3.2e-8	Primary biliary cholangitis;
LUSC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg03146154	chr1:46216737	IPP	0.5	7.51	0.38	5.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.61	-10.38	-0.49	4.57e-22	Schizophrenia;
LUSC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg10729496	chr3:10149963	C3orf24	0.54	7.36	0.37	1.4e-12	Alzheimer's disease;
LUSC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg23625390	chr15:77176239	SCAPER	-0.66	-10.01	-0.48	8.54e-21	Blood metabolite levels;
LUSC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6674176	0.542	rs803679	chr1:44349405	G/A	cg15962314	chr1:44399869	ARTN	0.27	6.1	0.32	2.89e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.47	0.38	7.29e-13	Motion sickness;
LUSC	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg13736514	chr6:26305472	NA	-0.46	-9.26	-0.45	2.64e-18	Educational attainment;
LUSC	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg16235748	chr6:149772707	ZC3H12D	0.28	5.69	0.3	2.72e-8	Dupuytren's disease;
LUSC	cis	rs79387448	0.810	rs75218113	chr2:103239356	C/G	cg09003973	chr2:102972529	NA	0.85	8.02	0.4	1.81e-14	Gut microbiota (bacterial taxa);
LUSC	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.16	0.32	2.14e-9	Corneal astigmatism;
LUSC	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg03036452	chr22:46663545	TTC38	0.59	5.88	0.31	1e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg00101154	chr16:420108	MRPL28	-0.39	-5.75	-0.3	2.01e-8	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.52	10.43	0.5	3.13e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-7.33	-0.37	1.74e-12	Fibrinogen levels;
LUSC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg20887711	chr4:1340912	KIAA1530	-0.65	-9.97	-0.48	1.11e-20	Obesity-related traits;
LUSC	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg19812747	chr11:111475976	SIK2	-0.5	-7.04	-0.36	1.1e-11	Primary sclerosing cholangitis;
LUSC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg23102388	chr7:1867652	MAD1L1	-0.3	-5.71	-0.3	2.44e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.61	0.57	4.22e-30	Prudent dietary pattern;
LUSC	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg01420254	chr6:26195488	NA	0.72	7.62	0.38	2.59e-13	Gout;Renal underexcretion gout;
LUSC	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg17470723	chr8:74884337	TCEB1	0.51	7.91	0.4	3.71e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	8.1	0.41	1.03e-14	Coronary artery disease;
LUSC	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg14092571	chr14:90743983	NA	-0.37	-6.11	-0.32	2.84e-9	Mortality in heart failure;
LUSC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.13	15.62	0.65	1.16e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg00546932	chr16:1947055	NA	0.37	5.7	0.3	2.62e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs4596713	0.965	rs7855905	chr9:71700035	C/G	cg07090356	chr18:23668764	SS18	-0.29	-6.41	-0.33	5.04e-10	Headache;
LUSC	cis	rs2236918	1.000	rs1627006	chr1:242038004	C/T	cg17736920	chr1:242011382	EXO1	0.43	6.74	0.35	6.87e-11	Menopause (age at onset);
LUSC	cis	rs1775715	0.737	rs2799017	chr10:32203460	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	7.03	0.36	1.2e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4730250	0.707	rs10953537	chr7:107027905	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.43	-5.65	-0.3	3.51e-8	Osteoarthritis;
LUSC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.07	-0.36	9.37e-12	Longevity;Endometriosis;
LUSC	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg11062466	chr8:58055876	NA	0.66	8.52	0.42	5.58e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg00343986	chr7:65444356	GUSB	0.48	7.13	0.36	6.36e-12	Calcium levels;
LUSC	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg13072238	chr3:49761600	GMPPB	0.43	7.19	0.37	4.33e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2387326	0.671	rs11016104	chr10:129946512	G/A	cg16087940	chr10:129947807	NA	-0.4	-6.0	-0.31	5.04e-9	Select biomarker traits;
LUSC	cis	rs9534288	0.659	rs2146882	chr13:46668111	A/G	cg15192986	chr13:46630673	CPB2	-0.72	-10.5	-0.5	1.77e-22	Blood protein levels;
LUSC	trans	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg06606381	chr12:133084897	FBRSL1	-0.87	-7.03	-0.36	1.17e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs10486158	0.739	rs7796385	chr7:7409119	G/A	cg01895333	chr3:109035405	DPPA2	-0.36	-5.95	-0.31	6.6e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00713605	chr2:232063387	ARMC9	-0.41	-5.96	-0.31	6.41e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.15	0.36	5.57e-12	Bipolar disorder;
LUSC	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg27446573	chr6:127587934	RNF146	0.46	7.15	0.36	5.36e-12	Breast cancer;
LUSC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg13560548	chr3:10150139	C3orf24	0.49	6.89	0.35	2.83e-11	Alzheimer's disease;
LUSC	trans	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	11.22	0.52	5.13e-25	Exhaled nitric oxide output;
LUSC	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg03859395	chr2:55845619	SMEK2	0.87	16.2	0.66	5.62e-44	Metabolic syndrome;
LUSC	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg09699651	chr6:150184138	LRP11	0.47	7.36	0.37	1.43e-12	Testicular germ cell tumor;
LUSC	cis	rs6700896	0.500	rs112247468	chr1:66115008	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	6.36	0.33	6.62e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg22815214	chr1:201083145	CACNA1S	-0.61	-10.71	-0.51	3.26e-23	Permanent tooth development;
LUSC	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg25801113	chr15:45476975	SHF	0.35	7.04	0.36	1.07e-11	Uric acid levels;
LUSC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg06221963	chr1:154839813	KCNN3	-0.49	-10.21	-0.49	1.74e-21	Prostate cancer;
LUSC	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg03585969	chr10:35415529	CREM	0.61	8.85	0.44	5.02e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs71435601	0.628	rs312944	chr2:21325188	A/T	cg20757404	chr19:378427	NA	0.37	6.02	0.31	4.62e-9	Cholesterol, total;
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg08472276	chr7:1133186	C7orf50;GPER	-0.42	-6.97	-0.36	1.72e-11	Longevity;Endometriosis;
LUSC	cis	rs4842666	0.831	rs11105378	chr12:90090741	C/T	cg00757033	chr12:89920650	WDR51B	0.44	6.13	0.32	2.41e-9	Blood pressure;
LUSC	trans	rs9886428	1.000	rs35969875	chr8:14119221	A/G	cg11959399	chr20:741723	C20orf54	-0.4	-6.28	-0.32	1.05e-9	IgG glycosylation;
LUSC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg09021430	chr5:549028	NA	-0.56	-7.57	-0.38	3.56e-13	Obesity-related traits;
LUSC	trans	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12541635	0.801	rs9642802	chr8:107101364	A/T	cg10147462	chr8:107024639	NA	-0.44	-7.74	-0.39	1.23e-13	Age of smoking initiation;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg18112904	chr7:102312315	POLR2J2	0.73	6.16	0.32	2.14e-9	Body mass index;
LUSC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg20573242	chr4:122745356	CCNA2	0.43	6.63	0.34	1.35e-10	Type 2 diabetes;
LUSC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg03351412	chr1:154909251	PMVK	0.41	6.09	0.32	3.15e-9	Prostate cancer;
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg16614638	chr11:34073070	CAPRIN1	0.41	6.03	0.31	4.4e-9	Eotaxin levels;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg26609550	chr19:14017309	C19orf57;CC2D1A	-0.43	-6.31	-0.33	8.89e-10	Hepatitis;
LUSC	cis	rs17253792	0.822	rs10145687	chr14:56124384	T/C	cg01858014	chr14:56050164	KTN1	-0.69	-6.06	-0.31	3.61e-9	Putamen volume;
LUSC	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg25922239	chr6:33757077	LEMD2	0.42	6.23	0.32	1.43e-9	Crohn's disease;
LUSC	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg13852791	chr20:30311386	BCL2L1	0.95	14.85	0.63	1.15e-38	Mean corpuscular hemoglobin;
LUSC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.68	9.99	0.48	1.02e-20	Methadone dose in opioid dependence;
LUSC	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.08	13.25	0.59	1.64e-32	Sexual dysfunction (female);
LUSC	cis	rs9323205	0.773	rs4334206	chr14:51702414	G/C	cg23942311	chr14:51606299	NA	-0.45	-8.81	-0.43	6.82e-17	Cancer;
LUSC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg00409905	chr10:38381863	ZNF37A	-0.35	-6.07	-0.32	3.56e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs57502260	0.704	rs55975204	chr11:68249124	C/T	cg20283391	chr11:68216788	NA	-0.64	-5.86	-0.31	1.14e-8	Total body bone mineral density (age 45-60);
LUSC	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg10523679	chr1:76189770	ACADM	-0.48	-6.96	-0.36	1.81e-11	Daytime sleep phenotypes;
LUSC	cis	rs10979	1.000	rs12212011	chr6:143894694	C/A	cg25407410	chr6:143891975	LOC285740	-0.74	-12.25	-0.56	9.15e-29	Hypospadias;
LUSC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	1.0	20.45	0.75	7.78e-61	Menopause (age at onset);
LUSC	cis	rs9815354	0.812	rs55916959	chr3:41849130	G/A	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.52e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg23034840	chr1:205782522	SLC41A1	0.62	7.41	0.38	1.02e-12	Prostate-specific antigen levels;
LUSC	trans	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg18187862	chr3:45730750	SACM1L	0.55	7.01	0.36	1.35e-11	Primary sclerosing cholangitis;
LUSC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg12963246	chr6:28129442	ZNF389	0.49	6.73	0.35	7.47e-11	Depression;
LUSC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	11.33	0.53	2.05e-25	Menopause (age at onset);
LUSC	cis	rs1712517	0.873	rs1163086	chr10:105039579	A/G	cg05636881	chr10:105038444	INA	0.4	6.61	0.34	1.52e-10	Migraine;
LUSC	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg04310649	chr10:35416472	CREM	-0.44	-6.58	-0.34	1.85e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg27432699	chr2:27873401	GPN1	-0.87	-17.29	-0.69	2.78e-48	Oral cavity cancer;
LUSC	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg16624210	chr5:671434	TPPP	0.47	5.92	0.31	8.21e-9	Lung disease severity in cystic fibrosis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg25328477	chr19:33571995	GPATCH1	-0.46	-6.08	-0.32	3.2e-9	Hepatitis;
LUSC	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-11.75	-0.54	6.58e-27	Alcohol dependence;
LUSC	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.69	10.49	0.5	1.93e-22	Corneal astigmatism;
LUSC	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	0.65	9.43	0.46	7.26e-19	Platelet distribution width;
LUSC	cis	rs4851254	0.920	rs13011874	chr2:100752497	C/T	cg07810366	chr2:100720526	AFF3	-0.38	-5.86	-0.31	1.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg23719950	chr11:63933701	MACROD1	-0.38	-5.78	-0.3	1.7e-8	Platelet count;
LUSC	cis	rs1127311	1.000	rs9427094	chr1:154557685	C/T	cg17218026	chr1:154582156	ADAR	0.57	9.84	0.47	3.21e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg16262614	chr3:133464971	TF	0.43	7.49	0.38	6.05e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg06627628	chr2:24431161	ITSN2	0.61	9.09	0.45	9.2e-18	Asthma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21697007	chr12:57623759	SHMT2	-0.42	-6.16	-0.32	2.11e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.42	5.86	0.31	1.13e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs240764	0.853	rs1875401	chr6:101023588	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-6.06	-0.31	3.78e-9	Neuroticism;
LUSC	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs3771570	0.818	rs73008126	chr2:242443157	A/C	cg21155796	chr2:242212141	HDLBP	0.63	6.93	0.35	2.19e-11	Prostate cancer;
LUSC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.7	-12.17	-0.55	1.91e-28	Obesity-related traits;
LUSC	cis	rs2239815	0.515	rs5762829	chr22:29228130	A/G	cg02153584	chr22:29168773	CCDC117	0.57	6.74	0.35	7.14e-11	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	trans	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.14	0.45	6.09e-18	Mean corpuscular volume;
LUSC	cis	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg06521331	chr12:34319734	NA	-0.41	-6.8	-0.35	4.96e-11	Morning vs. evening chronotype;
LUSC	cis	rs11051970	0.918	rs6488050	chr12:32532499	A/T	cg24626660	chr12:32551988	NA	0.37	5.89	0.31	9.5e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.12	-18.21	-0.71	5.94e-52	Primary sclerosing cholangitis;
LUSC	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg20243544	chr17:37824526	PNMT	0.39	5.82	0.3	1.36e-8	Self-reported allergy;
LUSC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18876405	chr7:65276391	NA	-0.55	-8.76	-0.43	9.78e-17	Aortic root size;
LUSC	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.97	12.68	0.57	2.31e-30	Exhaled nitric oxide output;
LUSC	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.61	9.25	0.45	2.71e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9900062	0.546	rs2428352	chr17:62694738	C/T	cg02598441	chr17:62777298	LOC146880	0.55	7.17	0.37	4.94e-12	QT interval;
LUSC	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.41	-0.42	1.25e-15	Body mass index;
LUSC	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.36	-0.46	1.2e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	12.06	0.55	4.66e-28	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg13939156	chr17:80058883	NA	0.34	6.76	0.35	6.06e-11	Life satisfaction;
LUSC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.77	-0.35	5.69e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg08219700	chr8:58056026	NA	0.43	5.68	0.3	2.99e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg09365446	chr1:150670422	GOLPH3L	0.51	7.5	0.38	5.68e-13	Melanoma;
LUSC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.85	-0.35	3.66e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs672059	1.000	rs483783	chr1:183162152	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.53	8.0	0.4	2.08e-14	Hypertriglyceridemia;
LUSC	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg15556689	chr8:8085844	FLJ10661	0.46	7.26	0.37	2.74e-12	Retinal vascular caliber;
LUSC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-5.88	-0.31	9.94e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg13736514	chr6:26305472	NA	-0.45	-8.75	-0.43	1.08e-16	Educational attainment;
LUSC	cis	rs6876348	0.598	rs1898550	chr5:128285661	C/T	cg25555059	chr5:128301488	SLC27A6	-0.33	-6.03	-0.31	4.4e-9	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg25214090	chr10:38739885	LOC399744	0.47	6.93	0.35	2.18e-11	Corneal astigmatism;
LUSC	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg06360820	chr2:242988706	NA	-1.06	-10.67	-0.5	4.72e-23	Obesity-related traits;
LUSC	cis	rs2637266	1.000	rs10824431	chr10:78356622	C/A	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg26958806	chr6:27640298	NA	0.65	5.67	0.3	3.11e-8	Depression;
LUSC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg03146154	chr1:46216737	IPP	-0.48	-7.26	-0.37	2.74e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg11189052	chr15:85197271	WDR73	0.47	5.87	0.31	1.05e-8	Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05168378	chr7:100425517	EPHB4	-0.51	-6.15	-0.32	2.23e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg25000938	chr5:43484273	C5orf28	-0.37	-6.26	-0.32	1.15e-9	Triglycerides;
LUSC	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.93	0.31	7.45e-9	Lung cancer;
LUSC	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg12463550	chr7:65579703	CRCP	0.53	7.87	0.4	4.83e-14	Aortic root size;
LUSC	cis	rs6084875	0.840	rs6052822	chr20:4726510	T/G	cg07258627	chr20:4721683	PRNT	-0.34	-6.16	-0.32	2.05e-9	Systemic lupus erythematosus;
LUSC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.72	-13.42	-0.59	3.74e-33	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg02807482	chr3:125708958	NA	-0.54	-6.69	-0.34	9.15e-11	Blood pressure (smoking interaction);
LUSC	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg17252645	chr8:143867129	LY6D	0.37	6.58	0.34	1.82e-10	Urinary tract infection frequency;
LUSC	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg22777020	chr22:31556080	RNF185	-0.46	-5.92	-0.31	8.18e-9	Colorectal cancer;
LUSC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	7.38	0.37	1.28e-12	Personality dimensions;
LUSC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg13560548	chr3:10150139	C3orf24	0.52	7.42	0.38	9.94e-13	Alzheimer's disease;
LUSC	cis	rs1044826	0.642	rs6799312	chr3:139211932	C/T	cg00490450	chr3:139108681	COPB2	0.46	6.96	0.36	1.82e-11	Obesity-related traits;
LUSC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14893161	chr1:205819251	PM20D1	0.79	14.01	0.61	2.16e-35	Menarche (age at onset);
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg15242686	chr22:24348715	GSTTP1	0.39	5.83	0.3	1.33e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg09491104	chr22:46646882	C22orf40	-0.61	-7.01	-0.36	1.35e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg04865166	chr7:105162814	PUS7	0.51	5.84	0.3	1.25e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg08917208	chr2:24149416	ATAD2B	0.56	6.27	0.32	1.14e-9	Lymphocyte counts;
LUSC	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg13010199	chr12:38710504	ALG10B	0.56	8.51	0.42	5.98e-16	Morning vs. evening chronotype;
LUSC	cis	rs7727544	0.526	rs4705908	chr5:131347520	G/A	cg14196790	chr5:131705035	SLC22A5	0.45	7.38	0.37	1.3e-12	Blood metabolite levels;
LUSC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg18681998	chr4:17616180	MED28	0.83	14.97	0.63	3.9e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.61	-0.38	2.92e-13	Bipolar disorder;
LUSC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	0.86	14.59	0.62	1.24e-37	Tonsillectomy;
LUSC	cis	rs1957429	0.803	rs10873177	chr14:65318228	G/C	cg23373153	chr14:65346875	NA	0.91	10.2	0.49	1.84e-21	Pediatric areal bone mineral density (radius);
LUSC	trans	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.57	9.22	0.45	3.49e-18	Brugada syndrome;
LUSC	cis	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg06239285	chr11:62104954	ASRGL1	-0.94	-10.17	-0.49	2.5e-21	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.64	-9.63	-0.47	1.5700000000000001e-19	Glaucoma (primary open-angle);
LUSC	cis	rs7129556	0.520	rs6592730	chr11:77274203	T/C	cg12586386	chr11:77299805	AQP11	0.23	5.71	0.3	2.49e-8	Weight loss (gastric bypass surgery);
LUSC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.85	0.3	1.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9815354	0.680	rs73073242	chr3:42015335	G/A	cg03022575	chr3:42003672	ULK4	0.76	7.6	0.38	3e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg12463550	chr7:65579703	CRCP	-0.46	-6.82	-0.35	4.21e-11	Aortic root size;
LUSC	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg17623882	chr6:41773611	USP49	0.63	10.34	0.49	6.28e-22	Menarche (age at onset);
LUSC	trans	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg18187862	chr3:45730750	SACM1L	-0.51	-6.21	-0.32	1.57e-9	Primary sclerosing cholangitis;
LUSC	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.89	-10.29	-0.49	9.09e-22	Lung cancer in ever smokers;
LUSC	cis	rs2273669	0.667	rs11153155	chr6:109359963	G/A	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg21775007	chr8:11205619	TDH	0.71	11.27	0.52	3.47e-25	Retinal vascular caliber;
LUSC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg04374321	chr14:90722782	PSMC1	0.57	8.46	0.42	8.63e-16	Mortality in heart failure;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg27201871	chr17:79212816	C17orf56;C17orf89	0.4	6.09	0.32	3.03e-9	Triglycerides;
LUSC	trans	rs724744	0.772	rs1772079	chr6:22354105	A/T	cg13807341	chr11:118445984	ARCN1	0.37	6.37	0.33	6.25e-10	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg16473166	chr22:50639996	SELO	0.58	7.86	0.4	5.38e-14	Obesity-related traits;
LUSC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg21141812	chr3:48556323	PFKFB4	0.36	6.19	0.32	1.76e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs727505	0.721	rs67277928	chr7:124776704	G/T	cg23710748	chr7:124431027	NA	-0.39	-6.99	-0.36	1.5e-11	Lewy body disease;
LUSC	trans	rs6819013	0.765	rs2035442	chr4:16893170	A/G	cg11493509	chr11:5991173	OR56A5	0.41	6.11	0.32	2.8e-9	QT interval;
LUSC	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.16	-0.36	5.08e-12	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg03605463	chr16:89740564	NA	-0.61	-9.97	-0.48	1.14e-20	Vitiligo;
LUSC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg24250549	chr1:154909240	PMVK	0.64	10.43	0.5	3.19e-22	Prostate cancer;
LUSC	cis	rs7189233	0.550	rs9927982	chr16:53474108	C/T	cg09728985	chr16:53543985	NA	-0.31	-5.69	-0.3	2.78e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	16.95	0.68	6.24e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg03948781	chr1:205179583	DSTYK	-0.33	-6.48	-0.33	3.33e-10	Red blood cell count;
LUSC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg13683864	chr3:40499215	RPL14	-1.02	-17.47	-0.69	5.06e-49	Renal cell carcinoma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16558908	chr1:33896237	NA	-0.45	-6.38	-0.33	5.83e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	trans	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg03886242	chr7:26192032	NFE2L3	-0.4	-6.21	-0.32	1.55e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg21782813	chr7:2030301	MAD1L1	0.35	5.83	0.3	1.27e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs977987	0.806	rs4888389	chr16:75395228	T/C	cg03315344	chr16:75512273	CHST6	0.48	9.2	0.45	4.05e-18	Dupuytren's disease;
LUSC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.18	0.37	4.7e-12	Bipolar disorder;
LUSC	cis	rs2734839	0.964	rs12363125	chr11:113285916	C/T	cg14159747	chr11:113255604	NA	0.26	6.58	0.34	1.84e-10	Information processing speed;
LUSC	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg05585544	chr11:47624801	NA	-0.4	-6.87	-0.35	3.1e-11	Subjective well-being;
LUSC	cis	rs7674212	0.570	rs2251634	chr4:104082349	C/T	cg16532752	chr4:104119610	CENPE	-0.5	-7.4	-0.38	1.11e-12	Type 2 diabetes;
LUSC	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.41	6.8	0.35	4.81e-11	Cystic fibrosis severity;
LUSC	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg19792802	chr11:65647270	CTSW	0.47	6.47	0.33	3.47e-10	Crohn's disease;
LUSC	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-0.81	-11.07	-0.52	1.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg05855489	chr10:104503620	C10orf26	0.53	8.11	0.41	9.87e-15	Arsenic metabolism;
LUSC	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.48	-6.52	-0.34	2.59e-10	Neutrophil percentage of white cells;
LUSC	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-9.64	-0.47	1.4e-19	Body mass index;
LUSC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg13319975	chr6:146136371	FBXO30	0.48	7.37	0.37	1.31e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2425143	0.730	rs7263640	chr20:34314725	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.27	-0.32	1.14e-9	Blood protein levels;
LUSC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg05025164	chr4:1340916	KIAA1530	0.42	6.68	0.34	1e-10	Longevity;
LUSC	cis	rs1775715	0.870	rs3847415	chr10:32219456	G/T	cg03015672	chr10:32216066	ARHGAP12	0.32	5.81	0.3	1.49e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg21251018	chr6:28226885	NKAPL	0.31	5.99	0.31	5.55e-9	Cardiac Troponin-T levels;
LUSC	cis	rs116139393	0.540	rs13224907	chr7:6773892	C/T	cg09896999	chr7:6746977	ZNF12	-0.51	-7.19	-0.37	4.33e-12	Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg17143192	chr8:8559678	CLDN23	0.62	9.06	0.44	1.12e-17	Obesity-related traits;
LUSC	cis	rs3820928	0.874	rs10188770	chr2:227877037	G/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.93	-0.4	3.36e-14	Pulmonary function;
LUSC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	18.25	0.71	4.18e-52	Chronic sinus infection;
LUSC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.1	-0.41	1.07e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06481639	chr22:41940642	POLR3H	0.47	5.77	0.3	1.82e-8	Vitiligo;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg18033235	chr19:16989681	SIN3B	0.43	6.07	0.32	3.48e-9	Calcium levels;
LUSC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg06618935	chr21:46677482	NA	-0.4	-8.05	-0.4	1.48e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg06784218	chr1:46089804	CCDC17	0.49	9.41	0.46	8.49e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg07936489	chr17:37558343	FBXL20	0.73	10.18	0.49	2.22e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg05360949	chr19:41903737	BCKDHA;EXOSC5	0.42	5.75	0.3	1.98e-8	Height;
LUSC	cis	rs4363385	0.782	rs4845336	chr1:153003853	C/T	cg00922841	chr1:152955080	SPRR1A	-0.4	-6.94	-0.35	2.1e-11	Inflammatory skin disease;
LUSC	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg12560992	chr17:57184187	TRIM37	0.85	15.34	0.64	1.47e-40	Intelligence (multi-trait analysis);
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg19725989	chr11:67007604	KDM2A	0.4	6.22	0.32	1.51e-9	Mosquito bite size;
LUSC	cis	rs75804782	0.641	rs3769125	chr2:239349562	A/G	cg18131467	chr2:239335373	ASB1	-0.73	-6.63	-0.34	1.37e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.93	-0.4	3.36e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3106136	0.903	rs35361491	chr4:95202492	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.18	-0.32	1.91e-9	Capecitabine sensitivity;
LUSC	cis	rs4654899	0.931	rs4654730	chr1:21229286	A/T	cg01072550	chr1:21505969	NA	-0.54	-8.08	-0.4	1.16e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.39	-0.56	2.83e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1044826	0.642	rs1080371	chr3:139210894	C/T	cg00490450	chr3:139108681	COPB2	0.46	6.96	0.36	1.82e-11	Obesity-related traits;
LUSC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg11965913	chr1:205819406	PM20D1	0.46	6.42	0.33	4.66e-10	Parkinson's disease;
LUSC	trans	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg10756647	chr7:56101905	PSPH	0.89	8.88	0.44	4.11e-17	Diabetic kidney disease;
LUSC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs3768617	0.868	rs2296299	chr1:183104013	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.67	0.43	1.94e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs2997447	0.846	rs3008418	chr1:26403098	G/A	cg19633962	chr1:26362018	EXTL1	-0.48	-5.76	-0.3	1.89e-8	QRS complex (12-leadsum);
LUSC	cis	rs3820928	0.904	rs10933161	chr2:227764872	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.75	-0.39	1.1e-13	Pulmonary function;
LUSC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg22535103	chr8:58192502	C8orf71	-0.75	-7.83	-0.39	6.49e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg09184832	chr6:79620586	NA	-0.45	-7.43	-0.38	9.27e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21171335	chr12:122356390	WDR66	0.59	8.95	0.44	2.51e-17	Mean corpuscular volume;
LUSC	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg22709100	chr7:91322751	NA	0.4	5.75	0.3	2.03e-8	Breast cancer;
LUSC	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg04398451	chr17:18023971	MYO15A	-0.48	-7.72	-0.39	1.34e-13	Total body bone mineral density;
LUSC	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	12.44	0.56	1.93e-29	Ileal carcinoids;
LUSC	cis	rs2742234	0.590	rs1254962	chr10:43696992	G/A	cg02780029	chr10:43622663	RET	0.34	5.68	0.3	2.87e-8	Hirschsprung disease;
LUSC	cis	rs6500395	0.963	rs4785528	chr16:48687908	A/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs67072384	1.000	rs7122017	chr11:72448558	C/G	cg04827223	chr11:72435913	ARAP1	-0.79	-7.25	-0.37	2.93e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg26597838	chr10:835615	NA	0.9	12.26	0.56	8.57e-29	Eosinophil percentage of granulocytes;
LUSC	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-1.02	-12.68	-0.57	2.4e-30	Blood pressure (smoking interaction);
LUSC	trans	rs334147	1.000	rs334140	chr2:128235148	A/G	cg06224766	chr8:120499470	NA	-0.61	-6.04	-0.31	4.11e-9	Educational attainment;
LUSC	cis	rs12711979	1.000	rs6542655	chr2:3872434	T/C	cg17052675	chr2:3827356	NA	-0.44	-7.87	-0.4	5.15e-14	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg02016764	chr4:38805732	TLR1	-0.54	-5.92	-0.31	7.93e-9	Breast cancer;
LUSC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.25	-0.32	1.26e-9	Retinal vascular caliber;
LUSC	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg25427524	chr10:38739819	LOC399744	0.45	5.83	0.3	1.34e-8	Obesity (extreme);
LUSC	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg27165867	chr14:105738592	BRF1	0.51	7.56	0.38	3.87e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26314531	chr2:26401878	FAM59B	-0.7	-9.75	-0.47	6.29e-20	Gut microbiome composition (summer);
LUSC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26314531	chr2:26401878	FAM59B	0.68	8.9	0.44	3.71e-17	Gut microbiome composition (summer);
LUSC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06544989	chr22:39130855	UNC84B	0.33	5.79	0.3	1.59e-8	Menopause (age at onset);
LUSC	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.43e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.44	-0.33	4.14e-10	Total body bone mineral density;
LUSC	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-8.93	-0.44	2.92e-17	Coffee consumption (cups per day);
LUSC	trans	rs11696501	0.694	rs6073827	chr20:44265556	T/C	cg03272292	chr12:48577362	C12orf68	0.49	5.98	0.31	5.75e-9	Brain structure;
LUSC	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg09034736	chr1:150693464	HORMAD1	0.45	6.5	0.34	2.91e-10	Melanoma;
LUSC	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg10547527	chr2:198650123	BOLL	-0.49	-5.68	-0.3	3e-8	Ulcerative colitis;
LUSC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-6.95	-0.36	1.88e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg12463550	chr7:65579703	CRCP	0.52	7.59	0.38	3.16e-13	Aortic root size;
LUSC	trans	rs7737355	1.000	rs12719444	chr5:130607378	C/T	cg07715041	chr7:99302981	CYP3A7	-0.38	-6.03	-0.31	4.27e-9	Life satisfaction;
LUSC	trans	rs629535	0.590	rs62513427	chr8:70138891	A/T	cg21567404	chr3:27674614	NA	-0.94	-13.31	-0.59	1.01e-32	Dupuytren's disease;
LUSC	trans	rs1493916	0.905	rs10460051	chr18:31413679	C/T	cg15819921	chr19:927150	ARID3A	-0.44	-6.53	-0.34	2.41e-10	Life satisfaction;
LUSC	trans	rs10097669	0.679	rs2725067	chr8:4438113	T/C	cg16451306	chr5:71475356	MAP1B	0.3	6.4	0.33	5.15e-10	Trans fatty acid levels;
LUSC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	5.65	0.3	3.5e-8	Breast cancer;
LUSC	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg05555928	chr11:63887634	MACROD1	-0.49	-6.05	-0.31	3.95e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs4474465	0.790	rs7932315	chr11:78214878	G/A	cg27205649	chr11:78285834	NARS2	0.51	5.92	0.31	7.81e-9	Alzheimer's disease (survival time);
LUSC	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg10909506	chr17:38081995	ORMDL3	-0.34	-6.28	-0.33	1.03e-9	Self-reported allergy;
LUSC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg27266060	chr8:22091797	NA	-0.37	-6.85	-0.35	3.65e-11	Hypertriglyceridemia;
LUSC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	8.55	0.42	4.63e-16	Menarche (age at onset);
LUSC	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg04310649	chr10:35416472	CREM	-0.42	-6.45	-0.33	4.02e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.87	12.45	0.56	1.77e-29	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.58	0.34	1.86e-10	Lung cancer;
LUSC	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	8.41	0.42	1.19e-15	Lung cancer in ever smokers;
LUSC	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-1.16	-18.75	-0.72	4.22e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.78	-12.8	-0.57	8.35e-31	Aortic root size;
LUSC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg00074818	chr8:8560427	CLDN23	0.58	9.91	0.48	1.88e-20	Obesity-related traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08111106	chr17:4901164	INCA1;KIF1C	-0.43	-6.18	-0.32	1.82e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4629180	1.000	rs59246268	chr2:102089021	G/A	cg01388757	chr2:102091195	RFX8	-0.45	-7.1	-0.36	7.61e-12	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg04315214	chr1:2043799	PRKCZ	0.48	10.09	0.48	4.68e-21	Height;
LUSC	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg16359550	chr11:109292809	C11orf87	-0.32	-5.69	-0.3	2.79e-8	Schizophrenia;
LUSC	cis	rs2236918	1.000	rs2995544	chr1:242020495	C/T	cg17736920	chr1:242011382	EXO1	0.47	7.41	0.38	1.03e-12	Menopause (age at onset);
LUSC	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg12826209	chr6:26865740	GUSBL1	0.68	6.04	0.31	4.03e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg18382599	chr1:43124310	PPIH	0.48	6.01	0.31	4.79e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.28e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg10729496	chr3:10149963	C3orf24	-0.47	-6.12	-0.32	2.66e-9	Alzheimer's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07285953	chr17:27572551	CRYBA1	-0.42	-6.87	-0.35	3.17e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12410462	0.579	rs77529417	chr1:227547895	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.67	-6.41	-0.33	4.99e-10	Major depressive disorder;
LUSC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg11752832	chr7:134001865	SLC35B4	0.52	7.82	0.39	6.78e-14	Mean platelet volume;
LUSC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.83	13.25	0.59	1.78e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.3	-5.66	-0.3	3.27e-8	Lymphocyte counts;
LUSC	cis	rs34638657	0.732	rs11645372	chr16:82202136	C/T	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.45	-0.33	3.97e-10	Lung adenocarcinoma;
LUSC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	1.19	16.28	0.67	2.87e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg23840854	chr1:161414152	NA	-0.92	-11.22	-0.52	5.42e-25	Rheumatoid arthritis;
LUSC	cis	rs9039	1.000	rs11862745	chr16:9218887	C/T	cg08831531	chr16:9218945	NA	0.66	10.57	0.5	1e-22	Menopause (age at onset);
LUSC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-9.1	-0.45	8.23e-18	Bipolar disorder;
LUSC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg11871910	chr12:69753446	YEATS4	0.67	10.16	0.49	2.61e-21	Blood protein levels;
LUSC	cis	rs7771547	0.642	rs1003250	chr6:36437412	A/G	cg07856975	chr6:36356162	ETV7	-0.35	-6.34	-0.33	7.26e-10	Platelet distribution width;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24015817	chr6:96025855	MANEA	0.44	6.19	0.32	1.74e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.49e-9	Depression;
LUSC	cis	rs699	0.583	rs2493150	chr1:230868427	C/T	cg07502417	chr1:230849801	AGT	0.25	5.92	0.31	7.9e-9	Coronary artery disease;
LUSC	cis	rs28595532	0.800	rs111626798	chr4:119352517	C/T	cg02775129	chr4:119771670	NA	-0.8	-6.59	-0.34	1.7e-10	Cannabis dependence symptom count;
LUSC	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.81	-15.17	-0.64	6.88e-40	Prudent dietary pattern;
LUSC	cis	rs2708377	0.929	rs2708334	chr12:11269668	G/A	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	8.25	0.41	3.76e-15	Response to antipsychotic treatment;
LUSC	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg25174290	chr11:3078921	CARS	-0.5	-7.5	-0.38	5.81e-13	Longevity;
LUSC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg00310523	chr12:86230176	RASSF9	0.51	9.68	0.47	1.07e-19	Major depressive disorder;
LUSC	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-9.46	-0.46	5.63e-19	Chronic sinus infection;
LUSC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	18.98	0.72	5.41e-55	Chronic sinus infection;
LUSC	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg06641503	chr3:48959341	ARIH2	-0.39	-5.88	-0.31	9.73e-9	Parkinson's disease;
LUSC	trans	rs12439619	0.739	rs4778988	chr15:82540337	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.52	-8.06	-0.4	1.38e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.35	-5.67	-0.3	3.09e-8	Total body bone mineral density;
LUSC	cis	rs6967414	0.605	rs7786706	chr7:6747267	C/T	cg09896999	chr7:6746977	ZNF12	-0.6	-7.58	-0.38	3.37e-13	Hematocrit;Hemoglobin concentration;
LUSC	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg27432699	chr2:27873401	GPN1	0.8	15.0	0.63	3.16e-39	Oral cavity cancer;
LUSC	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-6.39	-0.33	5.48e-10	Monocyte percentage of white cells;
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg22907277	chr7:1156413	C7orf50	0.49	7.31	0.37	2.04e-12	Longevity;Endometriosis;
LUSC	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12292205	chr6:26970375	C6orf41	-0.58	-7.39	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg04733989	chr22:42467013	NAGA	0.39	6.55	0.34	2.22e-10	Cognitive function;
LUSC	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg15605315	chr1:45957053	TESK2	-0.44	-6.81	-0.35	4.52e-11	High light scatter reticulocyte count;
LUSC	cis	rs1882538	0.551	rs6974618	chr7:133084031	C/A	cg10665199	chr7:133106180	EXOC4	0.57	8.22	0.41	4.6e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs8060686	0.516	rs8048364	chr16:68253324	T/G	cg05110241	chr16:68378359	PRMT7	-0.46	-5.95	-0.31	6.6e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	0.96	13.3	0.59	1.14e-32	Primary sclerosing cholangitis;
LUSC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg23262073	chr20:60523788	NA	-0.42	-5.84	-0.3	1.21e-8	Body mass index;
LUSC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg10130564	chr11:117069849	TAGLN	0.31	5.99	0.31	5.49e-9	Blood protein levels;
LUSC	cis	rs7428496	0.528	rs3923464	chr3:142225388	G/A	cg16271453	chr3:142027066	XRN1	-0.51	-8.95	-0.44	2.6e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-11.47	-0.53	6.48e-26	Chronic sinus infection;
LUSC	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg07150166	chr2:30669952	LCLAT1	0.58	6.52	0.34	2.63e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.87	-0.35	3.2e-11	Lung cancer;
LUSC	cis	rs524023	0.957	rs528211	chr11:64351721	C/T	cg19131476	chr11:64387923	NRXN2	0.37	9.89	0.48	2.11e-20	Urate levels in obese individuals;
LUSC	cis	rs4363385	0.720	rs1984197	chr1:152962915	C/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.65	-0.39	2.21e-13	Inflammatory skin disease;
LUSC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg10523679	chr1:76189770	ACADM	0.86	11.41	0.53	1.11e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2708377	0.929	rs7487324	chr12:11299218	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.6	-5.72	-0.3	2.32e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	6.8	0.35	4.89e-11	Renal cell carcinoma;
LUSC	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-8.1	-0.41	1.03e-14	Morning vs. evening chronotype;
LUSC	cis	rs2274459	0.841	rs2281918	chr6:33663055	G/A	cg06253072	chr6:33679850	C6orf125	0.48	5.76	0.3	1.94e-8	Obesity (extreme);
LUSC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg11752832	chr7:134001865	SLC35B4	0.59	9.29	0.45	2.08e-18	Mean platelet volume;
LUSC	cis	rs6681460	0.565	rs6689755	chr1:67113050	G/A	cg02459107	chr1:67143332	SGIP1	0.43	7.96	0.4	2.65e-14	Presence of antiphospholipid antibodies;
LUSC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.7	-10.83	-0.51	1.31e-23	Aortic root size;
LUSC	cis	rs919433	0.679	rs6757669	chr2:198530355	C/T	cg00792783	chr2:198669748	PLCL1	0.42	5.66	0.3	3.23e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg15083158	chr17:2615176	KIAA0664	0.64	6.04	0.31	4.06e-9	Body mass index;
LUSC	cis	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg06521331	chr12:34319734	NA	-0.35	-5.68	-0.3	2.98e-8	Morning vs. evening chronotype;
LUSC	cis	rs10875746	0.551	rs1471998	chr12:48712002	C/T	cg13454099	chr12:49076203	C12orf41	-0.5	-5.78	-0.3	1.69e-8	Longevity (90 years and older);
LUSC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg25566285	chr7:158114605	PTPRN2	-0.33	-6.22	-0.32	1.5e-9	Calcium levels;
LUSC	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg03522245	chr20:25566470	NINL	-0.35	-5.71	-0.3	2.53e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.83	-14.2	-0.61	4e-36	Menarche (age at onset);
LUSC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.31e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2991971	1.000	rs2991970	chr1:46011005	C/T	cg24296786	chr1:45957014	TESK2	0.47	6.8	0.35	4.8e-11	High light scatter reticulocyte count;
LUSC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg06238570	chr21:40685208	BRWD1	0.51	7.73	0.39	1.26e-13	Cognitive function;
LUSC	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.62	0.43	2.64e-16	Menarche (age at onset);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21318521	chr6:107349259	C6orf203	-0.47	-6.2	-0.32	1.66e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7246967	0.611	rs3951784	chr19:22851926	G/A	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs6542838	0.641	rs4553869	chr2:99505940	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-5.97	-0.31	5.98e-9	Fear of minor pain;
LUSC	cis	rs1881396	0.947	rs77350364	chr2:27866139	A/G	cg27432699	chr2:27873401	GPN1	0.64	8.61	0.43	3.03e-16	Nonalcoholic fatty liver disease;
LUSC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg13319975	chr6:146136371	FBXO30	0.46	6.97	0.36	1.7e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg21775007	chr8:11205619	TDH	-0.48	-7.1	-0.36	7.46e-12	Systolic blood pressure;
LUSC	cis	rs7215564	0.908	rs4969246	chr17:78740579	G/A	cg23238734	chr17:78661607	RPTOR	-0.45	-5.73	-0.3	2.24e-8	Myopia (pathological);
LUSC	cis	rs7572644	0.723	rs3935148	chr2:28020966	T/A	cg27432699	chr2:27873401	GPN1	0.58	7.5	0.38	5.86e-13	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg13628971	chr7:2884303	GNA12	-0.49	-7.24	-0.37	3.15e-12	Height;
LUSC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.17	-0.32	1.95e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg03146154	chr1:46216737	IPP	0.51	7.59	0.38	3.1400000000000003e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.27	0.52	3.49e-25	Menopause (age at onset);
LUSC	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg03585969	chr10:35415529	CREM	0.59	8.73	0.43	1.28e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2742417	0.603	rs2673055	chr3:45772772	G/A	cg04837898	chr3:45731254	SACM1L	-0.45	-7.25	-0.37	2.97e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01161889	chr6:27145367	NA	-0.45	-6.01	-0.31	4.77e-9	Hepatitis;
LUSC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg23625390	chr15:77176239	SCAPER	0.49	7.44	0.38	8.57e-13	Blood metabolite levels;
LUSC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg03128534	chr1:43423976	SLC2A1	0.64	11.01	0.52	2.96e-24	Red cell distribution width;
LUSC	trans	rs11681884	0.892	rs56948778	chr2:113853893	C/T	cg09636715	chr7:27217057	HOXA10	0.73	6.12	0.32	2.61e-9	Stroke;
LUSC	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-1.09	-15.67	-0.65	7.19e-42	Corneal structure;
LUSC	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-25.83	-0.82	1.29e-81	Exhaled nitric oxide output;
LUSC	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg14690467	chr7:148917905	ZNF282	-0.25	-5.7	-0.3	2.59e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg07212818	chr11:638076	DRD4	-0.38	-6.51	-0.34	2.79e-10	Systemic lupus erythematosus;
LUSC	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.07	14.17	0.61	5.24e-36	Uric acid levels;
LUSC	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg18099408	chr3:52552593	STAB1	-0.35	-5.97	-0.31	6.05e-9	Electroencephalogram traits;
LUSC	cis	rs1107366	0.695	rs10934754	chr3:125906237	T/C	cg08481491	chr3:125900108	ALDH1L1	-0.28	-5.69	-0.3	2.85e-8	Metabolite levels;
LUSC	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.21	-0.41	5.02e-15	Retinal vascular caliber;
LUSC	trans	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.22	0.41	4.57e-15	Ulcerative colitis;
LUSC	cis	rs1371867	0.810	rs3020182	chr8:101233008	T/C	cg06636551	chr8:101224915	SPAG1	0.47	8.73	0.43	1.25e-16	Atrioventricular conduction;
LUSC	cis	rs4954585	0.683	rs4072434	chr2:137014023	C/G	cg05194412	chr2:137003533	NA	0.41	7.57	0.38	3.79e-13	Colorectal cancer;
LUSC	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Body mass index;
LUSC	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06634786	chr22:41940651	POLR3H	-0.59	-6.85	-0.35	3.65e-11	Vitiligo;
LUSC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	7.14	0.36	6e-12	Renal cell carcinoma;
LUSC	trans	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg03886242	chr7:26192032	NFE2L3	-0.42	-6.67	-0.34	1.03e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6433857	0.505	rs12471899	chr2:181369856	C/T	cg23363182	chr2:181467187	NA	-0.44	-7.08	-0.36	8.68e-12	Body mass index;
LUSC	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.85	14.85	0.63	1.22e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg26384229	chr12:38710491	ALG10B	0.55	9.02	0.44	1.48e-17	Morning vs. evening chronotype;
LUSC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.63	-0.39	2.46e-13	Blood metabolite levels;
LUSC	cis	rs7043114	0.525	rs10820964	chr9:95041636	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.46	-0.33	3.63e-10	Height;
LUSC	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg01884057	chr2:25150051	NA	0.38	8.71	0.43	1.42e-16	Body mass index in non-asthmatics;
LUSC	cis	rs244293	0.965	rs244298	chr17:53241387	C/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.39	-5.66	-0.3	3.26e-8	Menarche (age at onset);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24423897	chr19:4723980	DPP9	0.38	6.03	0.31	4.46e-9	Triglycerides;
LUSC	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg17757837	chr7:157058334	UBE3C	0.82	13.01	0.58	1.35e-31	Body mass index;
LUSC	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg24154853	chr7:158122151	PTPRN2	0.45	8.75	0.43	1.06e-16	Calcium levels;
LUSC	cis	rs2522056	1.000	rs2706393	chr5:131796067	G/A	cg24060327	chr5:131705240	SLC22A5	0.45	5.96	0.31	6.39e-9	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg14440974	chr22:39074834	NA	-0.39	-6.34	-0.33	7.58e-10	Menopause (age at onset);
LUSC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg27432699	chr2:27873401	GPN1	-0.55	-8.24	-0.41	3.99e-15	Total body bone mineral density;
LUSC	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.5	7.2	0.37	3.9e-12	Coronary heart disease;
LUSC	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.32	0.33	8.34e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg11693508	chr17:37793320	STARD3	-0.52	-6.54	-0.34	2.36e-10	Bipolar disorder;
LUSC	cis	rs7681440	0.626	rs1372510	chr4:90817259	G/A	cg20003494	chr4:90757398	SNCA	-0.35	-5.87	-0.31	1.07e-8	Dementia with Lewy bodies;
LUSC	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg04545296	chr12:48745243	ZNF641	0.37	6.79	0.35	5.1e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs4622329	0.615	rs7305951	chr12:102294501	C/T	cg23541617	chr12:102225335	GNPTAB	0.25	5.97	0.31	6.17e-9	Systemic lupus erythematosus;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15253204	chr10:123687610	ATE1	-0.41	-6.15	-0.32	2.25e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2692947	0.637	rs72492201	chr2:96630201	G/A	cg23100626	chr2:96804247	ASTL	0.26	6.26	0.32	1.2e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07677032	chr17:61819896	STRADA	0.52	8.79	0.43	8.03e-17	Prudent dietary pattern;
LUSC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg05347473	chr6:146136440	FBXO30	0.58	10.26	0.49	1.21e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs35883536	0.647	rs17402665	chr1:101046940	C/T	cg06223162	chr1:101003688	GPR88	-0.47	-8.81	-0.43	6.81e-17	Monocyte count;
LUSC	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg24375607	chr4:120327624	NA	0.71	10.4	0.49	3.84e-22	Corneal astigmatism;
LUSC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06481639	chr22:41940642	POLR3H	-0.53	-5.96	-0.31	6.38e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.46	-0.33	3.72e-10	Type 2 diabetes;
LUSC	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.37	-0.42	1.62e-15	Morning vs. evening chronotype;
LUSC	cis	rs17095355	0.901	rs12569425	chr10:111758177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.35	-0.37	1.53e-12	Biliary atresia;
LUSC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg03146154	chr1:46216737	IPP	0.52	7.65	0.39	2.1e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00860370	chr1:104068121	RNPC3	0.47	6.34	0.33	7.37e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1950626	0.750	rs34228453	chr14:101440321	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.77	0.39	9.82e-14	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs9653442	0.593	rs4851273	chr2:100848321	A/G	cg07810366	chr2:100720526	AFF3	-0.41	-6.66	-0.34	1.12e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs11264799	0.520	rs849819	chr1:157541674	A/C	cg18268488	chr1:157545234	FCRL4	0.39	7.69	0.39	1.7e-13	IgA nephropathy;
LUSC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.74	-13.35	-0.59	7.01e-33	Aortic root size;
LUSC	cis	rs7131987	0.845	rs7299861	chr12:29409667	G/A	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.25	-0.32	1.28e-9	QT interval;
LUSC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg00933542	chr6:150070202	PCMT1	0.31	6.45	0.33	3.83e-10	Lung cancer;
LUSC	cis	rs7949030	0.929	rs11231173	chr11:62418921	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.52	8.6	0.43	3.04e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs8099014	0.906	rs4940693	chr18:56101171	T/G	cg12907477	chr18:56117327	MIR122	0.46	6.78	0.35	5.45e-11	Platelet count;
LUSC	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg07636037	chr3:49044803	WDR6	0.55	5.69	0.3	2.82e-8	Menarche (age at onset);
LUSC	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg15848620	chr12:58087721	OS9	-0.55	-7.93	-0.4	3.34e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg18230493	chr5:56204884	C5orf35	-0.55	-8.75	-0.43	1.06e-16	Coronary artery disease;
LUSC	cis	rs983392	0.805	rs2123314	chr11:59966295	C/T	cg24026212	chr11:59952134	MS4A6A	0.38	6.78	0.35	5.5e-11	Alzheimer's disease (late onset);
LUSC	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg01579765	chr21:45077557	HSF2BP	-0.57	-11.91	-0.55	1.66e-27	Mean corpuscular volume;
LUSC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg23791538	chr6:167370224	RNASET2	-0.36	-5.67	-0.3	3.05e-8	Crohn's disease;
LUSC	cis	rs10979	1.000	rs9376756	chr6:143886125	C/T	cg25407410	chr6:143891975	LOC285740	-0.63	-10.35	-0.49	5.69e-22	Hypospadias;
LUSC	trans	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg10756647	chr7:56101905	PSPH	0.89	9.05	0.44	1.19e-17	Diabetic kidney disease;
LUSC	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg26897989	chr16:1907736	C16orf73	-0.45	-7.02	-0.36	1.28e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-6.64	-0.34	1.26e-10	Response to antipsychotic treatment;
LUSC	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.48	8.14	0.41	8.07e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg14195823	chr19:39926698	RPS16	-0.41	-5.98	-0.31	5.63e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs4729127	1.000	rs79645457	chr7:93989950	T/G	cg20086523	chr13:52378287	DHRS12	0.58	6.16	0.32	2.04e-9	Intelligence;
LUSC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08677398	chr8:58056175	NA	0.61	6.96	0.36	1.83e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg07156844	chr16:88729753	MGC23284;MVD	0.37	6.28	0.32	1.03e-9	Asthma;
LUSC	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg16928487	chr17:17741425	SREBF1	0.45	8.88	0.44	4.18e-17	Strep throat;
LUSC	trans	rs8026898	0.501	rs1426072	chr15:69979459	C/G	cg13594869	chr14:86088946	FLRT2	-0.37	-5.98	-0.31	5.81e-9	Rheumatoid arthritis;
LUSC	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg24331049	chr13:111365604	ING1	0.6	8.28	0.41	2.9e-15	Coronary artery disease;
LUSC	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg05519781	chr21:40033154	ERG	0.75	12.54	0.57	8.19e-30	Coronary artery disease;
LUSC	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg17052675	chr2:3827356	NA	-0.63	-9.66	-0.47	1.29e-19	Type 2 diabetes;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg24291203	chr8:100025000	VPS13B	0.54	6.81	0.35	4.5e-11	Cognitive function;Information processing speed;
LUSC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.65	9.87	0.48	2.53e-20	Height;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20604927	chr2:153575133	ARL6IP6;PRPF40A	-0.42	-6.21	-0.32	1.61e-9	Electrocardiographic conduction measures;
LUSC	cis	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg20368463	chr18:77673604	PQLC1	0.68	6.9	0.35	2.6e-11	Opioid sensitivity;
LUSC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05165339	chr4:1420672	NA	-0.3	-6.94	-0.35	2.09e-11	Longevity;
LUSC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	8.78	0.43	8.45e-17	Mean platelet volume;
LUSC	trans	rs1325195	0.881	rs10913697	chr1:179088744	G/A	cg11624085	chr17:8464688	MYH10	-0.44	-7.38	-0.37	1.25e-12	IgE grass sensitization;
LUSC	cis	rs4144743	0.759	rs16941731	chr17:45317022	C/T	cg18085866	chr17:45331354	ITGB3	0.75	7.39	0.37	1.23e-12	Body mass index;
LUSC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-7.63	-0.39	2.53e-13	Platelet count;
LUSC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg17143192	chr8:8559678	CLDN23	-0.65	-9.47	-0.46	5.16e-19	Obesity-related traits;
LUSC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	11.09	0.52	1.52e-24	Alzheimer's disease;
LUSC	cis	rs4588572	0.606	rs6859161	chr5:77742776	A/G	cg11547950	chr5:77652471	NA	-0.46	-6.74	-0.35	7.08e-11	Triglycerides;
LUSC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg16447950	chr5:562315	NA	-0.55	-7.1	-0.36	7.47e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg05347473	chr6:146136440	FBXO30	0.41	6.63	0.34	1.38e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg20135002	chr11:47629003	NA	-0.5	-7.78	-0.39	8.99e-14	Subjective well-being;
LUSC	cis	rs2637266	0.807	rs2256413	chr10:78315334	C/T	cg18941641	chr10:78392320	NA	-0.34	-5.86	-0.31	1.13e-8	Pulmonary function;
LUSC	cis	rs6489882	0.902	rs1981557	chr12:113372866	G/C	cg20102336	chr12:113376681	OAS3	-0.42	-6.03	-0.31	4.29e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs12620999	1.000	rs11689249	chr2:238083542	T/A	cg23555395	chr2:238036564	NA	-0.47	-8.21	-0.41	4.92e-15	Systemic lupus erythematosus;
LUSC	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg01851573	chr8:8652454	MFHAS1	-0.54	-8.85	-0.44	5.22e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg06238570	chr21:40685208	BRWD1	0.48	7.37	0.37	1.34e-12	Cognitive function;
LUSC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg26924012	chr15:45694286	SPATA5L1	1.12	19.82	0.74	2.37e-58	Homoarginine levels;
LUSC	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg12292205	chr6:26970375	C6orf41	0.38	5.94	0.31	7.33e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg23985595	chr17:80112537	CCDC57	0.3	5.81	0.3	1.43e-8	Life satisfaction;
LUSC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg14196790	chr5:131705035	SLC22A5	0.44	6.93	0.35	2.13e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg20503657	chr10:835505	NA	0.78	9.73	0.47	7.08e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	1.04	20.11	0.74	1.65e-59	Menopause (age at onset);
LUSC	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg02023728	chr11:77925099	USP35	0.53	7.39	0.38	1.16e-12	Testicular germ cell tumor;
LUSC	cis	rs9888739	1.000	rs12928810	chr16:31311715	G/A	cg15817542	chr16:31343056	ITGAM	-0.5	-6.1	-0.32	2.98e-9	Systemic lupus erythematosus;
LUSC	cis	rs56346965	0.506	rs2159818	chr2:191532789	A/G	cg11845111	chr2:191398756	TMEM194B	-0.43	-5.98	-0.31	5.83e-9	Bone mineral density (Ward's triangle area);
LUSC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg04455712	chr21:45112962	RRP1B	0.45	8.39	0.42	1.4e-15	Mean corpuscular volume;
LUSC	trans	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg25214090	chr10:38739885	LOC399744	0.42	6.45	0.33	4.03e-10	Corneal astigmatism;
LUSC	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.24	-0.32	1.34e-9	Type 2 diabetes;
LUSC	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.16e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg17469321	chr7:55412551	NA	0.66	10.63	0.5	6.09e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg04362960	chr10:104952993	NT5C2	0.62	8.71	0.43	1.39e-16	Arsenic metabolism;
LUSC	cis	rs73206853	0.841	rs28772589	chr12:110845040	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	7.09	0.36	8.16e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.31	0.53	2.56e-25	Menopause (age at onset);
LUSC	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-8.08	-0.4	1.22e-14	Retinal vascular caliber;
LUSC	cis	rs722599	0.683	rs8014695	chr14:75301617	C/G	cg08847533	chr14:75593920	NEK9	0.44	6.21	0.32	1.58e-9	IgG glycosylation;
LUSC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg04450456	chr4:17643702	FAM184B	0.37	6.12	0.32	2.66e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg01884057	chr2:25150051	NA	0.46	10.77	0.51	2.08e-23	Body mass index;
LUSC	cis	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg02972257	chr16:68554789	NA	0.42	5.69	0.3	2.72e-8	Colorectal cancer;
LUSC	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg25237894	chr2:233734115	C2orf82	-0.36	-6.77	-0.35	5.79e-11	Coronary artery disease;
LUSC	cis	rs3743266	0.507	rs56261931	chr15:60731618	C/T	cg21667061	chr15:60772094	NARG2	0.52	7.25	0.37	2.86e-12	Menarche (age at onset);
LUSC	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg09307838	chr4:120376055	NA	0.71	10.07	0.48	5.18e-21	Corneal astigmatism;
LUSC	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg09835421	chr16:68378352	PRMT7	-0.59	-6.31	-0.33	8.82e-10	Schizophrenia;
LUSC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg00343986	chr7:65444356	GUSB	-0.43	-6.63	-0.34	1.32e-10	Aortic root size;
LUSC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-6.43	-0.33	4.47e-10	Menopause (age at onset);
LUSC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg16325326	chr1:53192061	ZYG11B	0.89	16.36	0.67	1.39e-44	Monocyte count;
LUSC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg17541715	chr7:1216824	NA	-0.42	-6.64	-0.34	1.3e-10	Longevity;Endometriosis;
LUSC	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg03929089	chr4:120376271	NA	0.59	6.44	0.33	4.04e-10	Axial length;
LUSC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.7	-13.57	-0.6	1.06e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg01733217	chr16:74700730	RFWD3	0.74	12.38	0.56	3.13e-29	Testicular germ cell tumor;
LUSC	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg00857998	chr1:205179979	DSTYK	0.62	9.51	0.46	3.81e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg20587970	chr11:113659929	NA	-1.27	-17.35	-0.69	1.62e-48	Hip circumference adjusted for BMI;
LUSC	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg09201001	chr11:18656081	SPTY2D1	0.91	14.69	0.63	4.87e-38	Breast cancer;
LUSC	cis	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.38	-0.42	1.51e-15	Morning vs. evening chronotype;
LUSC	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg25344623	chr2:136566232	LCT	0.37	5.69	0.3	2.84e-8	Mosquito bite size;
LUSC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg15147215	chr3:52552868	STAB1	-0.32	-6.3	-0.33	9.6e-10	Bipolar disorder;
LUSC	cis	rs9815354	0.812	rs73077360	chr3:41850054	C/T	cg03022575	chr3:42003672	ULK4	0.86	8.66	0.43	2.07e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg25664220	chr3:72788482	NA	-0.67	-10.69	-0.51	3.8e-23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.79	-0.3	1.62e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg20295408	chr7:1910781	MAD1L1	-0.49	-7.17	-0.37	4.96e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg00191853	chr8:101177733	SPAG1	-0.39	-6.21	-0.32	1.6e-9	Atrioventricular conduction;
LUSC	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg03676636	chr4:99064102	C4orf37	-0.29	-5.66	-0.3	3.22e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg08859206	chr1:53392774	SCP2	0.55	9.48	0.46	5.03e-19	Monocyte count;
LUSC	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04004882	chr2:215674386	BARD1	0.48	6.38	0.33	5.77e-10	Neuroblastoma;
LUSC	trans	rs17039065	1.000	rs78569046	chr4:109393475	A/G	cg07444054	chr2:108107501	NA	0.43	6.3	0.33	9.24e-10	Gut microbiome composition (summer);
LUSC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg25036284	chr2:26402008	FAM59B	0.71	10.01	0.48	8.34e-21	Gut microbiome composition (summer);
LUSC	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.12	-0.32	2.69e-9	Resting heart rate;
LUSC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17604090	0.775	rs73090343	chr7:29688768	T/C	cg19413766	chr7:29689036	LOC646762	-0.64	-8.0	-0.4	2.01e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg24829409	chr8:58192753	C8orf71	-0.55	-6.21	-0.32	1.61e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg20887711	chr4:1340912	KIAA1530	0.41	6.18	0.32	1.91e-9	Longevity;
LUSC	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg23601095	chr6:26197514	HIST1H3D	0.74	7.88	0.4	4.59e-14	Gout;Renal underexcretion gout;
LUSC	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg23229984	chr5:148520753	ABLIM3	0.37	6.05	0.31	3.85e-9	Breast cancer;
LUSC	cis	rs9311676	0.609	rs6770113	chr3:58379297	C/A	cg26110898	chr3:58419937	PDHB	0.42	6.83	0.35	4.07e-11	Systemic lupus erythematosus;
LUSC	cis	rs2708977	0.637	rs676007	chr2:97075052	G/A	cg01950434	chr2:97203154	ARID5A	-0.45	-6.24	-0.32	1.36e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs77633900	0.772	rs157775	chr15:76755641	A/G	cg21673338	chr15:77095150	SCAPER	-0.7	-6.07	-0.32	3.53e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-11.84	-0.54	3.05e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg05896524	chr21:47604654	C21orf56	0.41	6.0	0.31	5.04e-9	Testicular germ cell tumor;
LUSC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg17986701	chr20:44574422	PCIF1	0.38	6.72	0.34	7.98e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs11997175	0.603	rs4739382	chr8:33807012	C/T	ch.8.33884649F	chr8:33765107	NA	0.43	6.52	0.34	2.55e-10	Body mass index;
LUSC	cis	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg09904177	chr6:26538194	HMGN4	-0.8	-6.05	-0.31	3.85e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg11766577	chr21:47581405	C21orf56	-0.46	-6.96	-0.36	1.83e-11	Testicular germ cell tumor;
LUSC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg22834771	chr12:69754056	YEATS4	-0.49	-7.4	-0.38	1.14e-12	Blood protein levels;
LUSC	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21545522	chr1:205238299	TMCC2	0.46	8.7	0.43	1.5e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-6.62	-0.34	1.46e-10	Monocyte count;
LUSC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg27266027	chr21:40555129	PSMG1	-0.41	-6.05	-0.31	3.8e-9	Cognitive function;
LUSC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg25767906	chr1:53392781	SCP2	0.53	9.76	0.47	5.79e-20	Monocyte count;
LUSC	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg10729496	chr3:10149963	C3orf24	0.52	6.93	0.35	2.21e-11	Alzheimer's disease;
LUSC	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg05855489	chr10:104503620	C10orf26	-0.49	-7.38	-0.37	1.28e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.19	0.64	5.67e-40	Bladder cancer;
LUSC	cis	rs73206853	0.563	rs73194032	chr12:111162182	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.52	0.38	5.1e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.13	-0.45	6.62e-18	Monocyte percentage of white cells;
LUSC	cis	rs12799172	0.710	rs11041007	chr11:6786001	A/C	cg01145442	chr11:6790970	OR2AG2	0.34	5.64	0.3	3.55e-8	Periodontal disease-related phenotypes;
LUSC	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg23093090	chr10:104574429	C10orf26	-0.38	-7.2	-0.37	4.09e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	8.36	0.42	1.75e-15	Alzheimer's disease;
LUSC	cis	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg02972257	chr16:68554789	NA	-0.5	-6.18	-0.32	1.91e-9	Ulcerative colitis;
LUSC	cis	rs12210905	0.925	rs12193820	chr6:27113811	A/G	cg11502198	chr6:26597334	ABT1	-0.79	-5.71	-0.3	2.45e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg17385448	chr1:15911702	AGMAT	-0.34	-5.73	-0.3	2.27e-8	Systolic blood pressure;
LUSC	cis	rs2708377	0.929	rs2600340	chr12:11261589	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs9549260	0.564	rs4941989	chr13:41299687	T/C	cg21288729	chr13:41239152	FOXO1	0.53	7.88	0.4	4.59e-14	Red blood cell count;
LUSC	cis	rs6977660	0.607	rs12113916	chr7:19781424	G/T	cg07541023	chr7:19748670	TWISTNB	0.68	6.79	0.35	5.11e-11	Thyroid stimulating hormone;
LUSC	cis	rs3771570	0.901	rs56129392	chr2:242242439	C/T	cg21155796	chr2:242212141	HDLBP	0.67	7.52	0.38	5.23e-13	Prostate cancer;
LUSC	cis	rs7833787	0.965	rs6586777	chr8:18702471	A/C	cg17701159	chr8:18705777	PSD3	0.39	6.38	0.33	5.93e-10	Obesity-related traits;
LUSC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg00343986	chr7:65444356	GUSB	-0.43	-6.55	-0.34	2.17e-10	Aortic root size;
LUSC	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-7.17	-0.37	4.91e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg03676636	chr4:99064102	C4orf37	-0.34	-7.47	-0.38	7.08e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06873352	chr17:61820015	STRADA	0.57	8.78	0.43	8.9e-17	Height;
LUSC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2742234	0.868	rs2505512	chr10:43633596	G/A	cg02780029	chr10:43622663	RET	-0.34	-6.24	-0.32	1.35e-9	Hirschsprung disease;
LUSC	cis	rs11166629	1.000	rs3739423	chr8:135614705	A/G	cg27224718	chr8:135614730	ZFAT	0.67	10.8	0.51	1.61e-23	Smoking quantity;
LUSC	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	1.47	13.15	0.58	4.26e-32	Atopic dermatitis;
LUSC	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.94	-0.31	7.25e-9	Resting heart rate;
LUSC	cis	rs4285028	0.580	rs12496036	chr3:121640362	G/A	cg11130432	chr3:121712080	ILDR1	-0.5	-8.33	-0.41	2.08e-15	Multiple sclerosis;
LUSC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg13685833	chr1:53393034	SCP2	-0.39	-5.86	-0.31	1.11e-8	Monocyte count;
LUSC	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg02466173	chr16:30829666	NA	0.56	11.11	0.52	1.3e-24	Dementia with Lewy bodies;
LUSC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg13722127	chr7:150037890	RARRES2	0.39	5.85	0.31	1.14e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg18512352	chr11:47633146	NA	-0.48	-9.65	-0.47	1.38e-19	Subjective well-being;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12355862	chr5:148205911	ADRB2	0.39	6.03	0.31	4.31e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-7.23	-0.37	3.33e-12	Joint mobility (Beighton score);
LUSC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg22868518	chr11:507468	RNH1	-0.65	-6.15	-0.32	2.27e-9	Body mass index;
LUSC	cis	rs983392	0.719	rs610932	chr11:59939307	T/G	cg24026212	chr11:59952134	MS4A6A	0.33	5.95	0.31	6.89e-9	Alzheimer's disease (late onset);
LUSC	cis	rs71403859	0.554	rs12373065	chr16:71870032	T/A	cg08717414	chr16:71523259	ZNF19	-0.58	-5.88	-0.31	9.84e-9	Post bronchodilator FEV1;
LUSC	cis	rs4776059	0.798	rs2414167	chr15:52907428	A/G	cg25063058	chr15:52860530	ARPP19	-0.44	-5.71	-0.3	2.57e-8	Schizophrenia;
LUSC	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg25173405	chr17:45401733	C17orf57	0.37	5.85	0.3	1.17e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs11608355	1.000	rs930356	chr12:109852372	T/C	cg05360138	chr12:110035743	NA	0.46	6.31	0.33	8.72e-10	Neuroticism;
LUSC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg15147215	chr3:52552868	STAB1	0.31	6.53	0.34	2.52e-10	Electroencephalogram traits;
LUSC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg10729496	chr3:10149963	C3orf24	0.54	7.17	0.37	4.98e-12	Alzheimer's disease;
LUSC	cis	rs68170813	0.559	rs3823959	chr7:107009379	T/G	cg02696742	chr7:106810147	HBP1	-0.64	-9.56	-0.46	2.74e-19	Coronary artery disease;
LUSC	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02034447	chr16:89574710	SPG7	0.42	6.33	0.33	7.77e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18099408	chr3:52552593	STAB1	-0.43	-7.53	-0.38	4.71e-13	Bipolar disorder;
LUSC	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg26850624	chr5:429559	AHRR	-0.42	-7.91	-0.4	3.74e-14	Cystic fibrosis severity;
LUSC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.47	7.44	0.38	8.84e-13	Uric acid clearance;
LUSC	trans	rs4729127	1.000	rs60238694	chr7:94008118	C/T	cg20086523	chr13:52378287	DHRS12	0.54	6.31	0.33	9.11e-10	Intelligence;
LUSC	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.81	0.51	1.48e-23	Bladder cancer;
LUSC	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg17623882	chr6:41773611	USP49	-0.62	-10.36	-0.49	5.22e-22	Menarche (age at onset);
LUSC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg15352829	chr14:105391018	PLD4	-0.42	-8.89	-0.44	3.84e-17	Rheumatoid arthritis;
LUSC	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08704250	chr15:31115839	NA	-0.45	-6.97	-0.36	1.68e-11	Huntington's disease progression;
LUSC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg06784218	chr1:46089804	CCDC17	0.56	11.13	0.52	1.11e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2303282	0.933	rs9929724	chr16:56535613	A/C	cg00500540	chr16:56394104	NA	-0.45	-7.26	-0.37	2.66e-12	Breast cancer;
LUSC	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg13755796	chr4:20253514	NA	-0.43	-6.59	-0.34	1.69e-10	Life satisfaction;
LUSC	cis	rs2233152	0.572	rs10403040	chr19:41296046	A/T	cg21869046	chr19:41225005	ITPKC	-0.48	-7.16	-0.36	5.12e-12	Kawasaki disease;
LUSC	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg24397884	chr7:158709396	WDR60	0.78	8.95	0.44	2.56e-17	Height;
LUSC	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg10840412	chr1:235813424	GNG4	-0.55	-7.14	-0.36	5.78e-12	Bipolar disorder;
LUSC	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg05714579	chr10:131428358	MGMT	-0.47	-7.22	-0.37	3.62e-12	Response to temozolomide;
LUSC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg09034736	chr1:150693464	HORMAD1	0.45	6.43	0.33	4.36e-10	Melanoma;
LUSC	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg22906224	chr7:99728672	NA	0.53	7.82	0.39	7.08e-14	Coronary artery disease;
LUSC	trans	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg21775007	chr8:11205619	TDH	0.45	6.47	0.33	3.59e-10	Joint mobility (Beighton score);
LUSC	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg24154853	chr7:158122151	PTPRN2	0.45	8.87	0.44	4.48e-17	Calcium levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06839777	chr6:122720676	HSF2	-0.44	-6.63	-0.34	1.39e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg01528321	chr10:82214614	TSPAN14	0.83	12.43	0.56	2.11e-29	Post bronchodilator FEV1;
LUSC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg02018176	chr4:1364513	KIAA1530	0.56	10.41	0.49	3.64e-22	Longevity;
LUSC	cis	rs554111	0.679	rs906254	chr1:21324760	G/A	cg01072550	chr1:21505969	NA	0.4	6.07	0.31	3.57e-9	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs2692947	0.673	rs2229169	chr2:96780716	T/G	cg23100626	chr2:96804247	ASTL	-0.3	-7.15	-0.36	5.67e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24802771	chr4:331610	ZNF141	-0.42	-6.05	-0.31	3.89e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg09184832	chr6:79620586	NA	-0.45	-7.43	-0.38	9.27e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg07701084	chr6:150067640	NUP43	0.56	8.46	0.42	8.31e-16	Lung cancer;
LUSC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg13918804	chr1:2043761	PRKCZ	0.27	5.76	0.3	1.86e-8	Height;
LUSC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.29	-0.33	9.8e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg05863683	chr7:1912471	MAD1L1	0.31	6.12	0.32	2.68e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6545883	0.860	rs4671399	chr2:61458518	C/T	cg15711740	chr2:61764176	XPO1	0.43	6.8	0.35	4.87e-11	Tuberculosis;
LUSC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg13319975	chr6:146136371	FBXO30	0.5	7.6	0.38	3.04e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs16917546	0.935	rs10995271	chr10:64438486	G/C	cg03961010	chr10:64397487	ZNF365	-0.39	-6.12	-0.32	2.65e-9	Basal cell carcinoma;
LUSC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg23791538	chr6:167370224	RNASET2	-0.36	-5.69	-0.3	2.76e-8	Crohn's disease;
LUSC	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg24558204	chr6:135376177	HBS1L	0.68	10.81	0.51	1.43e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02858162	chr2:122512910	TSN	0.46	6.19	0.32	1.72e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg24296786	chr1:45957014	TESK2	0.47	6.86	0.35	3.33e-11	High light scatter reticulocyte count;
LUSC	cis	rs11030122	0.673	rs4910590	chr11:4018619	C/T	cg08557956	chr11:4115526	RRM1	-0.46	-5.89	-0.31	9.45e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	trans	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg10756647	chr7:56101905	PSPH	0.89	8.63	0.43	2.6e-16	Diabetic kidney disease;
LUSC	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg19875535	chr5:140030758	IK	-0.55	-9.1	-0.45	8.22e-18	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg05110241	chr16:68378359	PRMT7	-0.57	-6.5	-0.33	3.01e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2230307	0.536	rs496798	chr1:100507990	G/A	cg24955406	chr1:100503596	HIAT1	0.57	6.15	0.32	2.23e-9	Carotid intima media thickness;
LUSC	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg13798780	chr7:105162888	PUS7	0.57	6.16	0.32	2.05e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg20887711	chr4:1340912	KIAA1530	-0.49	-7.36	-0.37	1.4e-12	Obesity-related traits;
LUSC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg23093090	chr10:104574429	C10orf26	-0.38	-7.2	-0.37	4e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs2282300	0.739	rs1631451	chr11:30349133	G/C	cg25418670	chr11:30344373	C11orf46	-0.64	-9.27	-0.45	2.28e-18	Morning vs. evening chronotype;
LUSC	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	12.62	0.57	3.89e-30	Lung cancer in ever smokers;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06210887	chr1:156471006	MEF2D	0.55	7.61	0.38	2.83e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1172822	0.665	rs897796	chr19:55831589	A/G	cg04391588	chr19:55832610	TMEM150B	0.29	5.79	0.3	1.65e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs6500395	0.928	rs4785532	chr16:48695500	G/A	cg04672837	chr16:48644449	N4BP1	-0.46	-6.84	-0.35	3.75e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg12463550	chr7:65579703	CRCP	0.57	8.47	0.42	7.7e-16	Aortic root size;
LUSC	cis	rs11997175	0.625	rs7825931	chr8:33583627	A/C	ch.8.33884649F	chr8:33765107	NA	-0.4	-6.35	-0.33	7.03e-10	Body mass index;
LUSC	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.89	-0.31	9.19e-9	Birth weight;
LUSC	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg04733989	chr22:42467013	NAGA	0.4	6.45	0.33	3.96e-10	Cognitive function;
LUSC	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg14196790	chr5:131705035	SLC22A5	-0.42	-6.93	-0.35	2.14e-11	Breast cancer;Mosquito bite size;
LUSC	trans	rs4664304	0.629	rs57751799	chr2:160854180	A/T	cg05371993	chr16:1458494	UNKL	0.41	6.01	0.31	4.74e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg27068330	chr11:65405492	SIPA1	-0.76	-10.88	-0.51	8.57e-24	Acne (severe);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04208734	chr7:73270063	NA	-0.53	-6.29	-0.33	1e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-7.49	-0.38	6.11e-13	Bladder cancer;
LUSC	cis	rs870825	0.550	rs57301026	chr4:185646505	C/G	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg21827317	chr3:136751795	NA	0.38	6.89	0.35	2.73e-11	Neuroticism;
LUSC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	7.0	0.36	1.39e-11	Bipolar disorder;
LUSC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg08999081	chr20:33150536	PIGU	0.44	8.08	0.4	1.19e-14	Coronary artery disease;
LUSC	cis	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs3820928	1.000	rs10193316	chr2:227777650	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-8.07	-0.4	1.32e-14	Pulmonary function;
LUSC	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg05729581	chr11:3078854	CARS	0.41	6.14	0.32	2.35e-9	Calcium levels;
LUSC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg24531977	chr5:56204891	C5orf35	-0.62	-9.2	-0.45	3.87e-18	Coronary artery disease;
LUSC	cis	rs68170813	0.559	rs74898466	chr7:107053998	C/A	cg02696742	chr7:106810147	HBP1	-0.61	-8.98	-0.44	1.96e-17	Coronary artery disease;
LUSC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.28	0.56	7.31e-29	Prudent dietary pattern;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24767315	chr2:241525811	CAPN10	-0.45	-6.73	-0.35	7.18e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg22709100	chr7:91322751	NA	0.39	5.74	0.3	2.13e-8	Breast cancer;
LUSC	cis	rs4478858	0.735	rs3806255	chr1:31791578	A/G	cg00250761	chr1:31883323	NA	-0.35	-8.75	-0.43	1.09e-16	Alcohol dependence;
LUSC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg04756594	chr16:24857601	SLC5A11	0.35	5.77	0.3	1.81e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6977660	1.000	rs6974669	chr7:19793296	T/A	cg07541023	chr7:19748670	TWISTNB	0.59	6.74	0.35	6.88e-11	Thyroid stimulating hormone;
LUSC	trans	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg06207120	chr15:45996521	NA	0.39	5.99	0.31	5.51e-9	Waist circumference;Weight;
LUSC	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.45	5.73	0.3	2.19e-8	Renal function-related traits (BUN);
LUSC	cis	rs17767294	0.803	rs59701161	chr6:27646117	T/C	cg08851530	chr6:28072375	NA	0.92	6.13	0.32	2.54e-9	Parkinson's disease;
LUSC	cis	rs1124376	1.000	rs1124376	chr3:20108546	A/G	cg05072819	chr3:20081367	KAT2B	-0.61	-6.63	-0.34	1.34e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.56e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg16482183	chr6:26056742	HIST1H1C	0.63	8.97	0.44	2.11e-17	Iron status biomarkers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18159230	chr1:169076004	ATP1B1	-0.48	-6.2	-0.32	1.64e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg05729581	chr11:3078854	CARS	-0.58	-9.0	-0.44	1.78e-17	Longevity;
LUSC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg07424592	chr7:64974309	NA	0.63	5.69	0.3	2.81e-8	Diabetic kidney disease;
LUSC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.21	-0.49	1.79e-21	Platelet count;
LUSC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	-0.46	-6.86	-0.35	3.25e-11	Menarche (age at onset);
LUSC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg04398451	chr17:18023971	MYO15A	0.57	9.53	0.46	3.41e-19	Total body bone mineral density;
LUSC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg11247378	chr22:39784982	NA	-0.65	-13.23	-0.59	2.05e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg27535305	chr1:53392650	SCP2	-0.37	-6.89	-0.35	2.86e-11	Monocyte count;
LUSC	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg12091567	chr17:66097778	LOC651250	-0.76	-9.59	-0.46	2.18e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7762018	0.607	rs77972667	chr6:170130456	G/C	cg19338460	chr6:170058176	WDR27	-0.99	-8.07	-0.4	1.27e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	trans	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.35	-0.46	1.33e-18	Brugada syndrome;
LUSC	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.53	10.66	0.5	4.78e-23	Coronary artery disease;
LUSC	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg04586622	chr2:25135609	ADCY3	0.39	7.94	0.4	3.1e-14	Body mass index in non-asthmatics;
LUSC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg04176472	chr15:90893244	GABARAPL3	0.33	5.98	0.31	5.61e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg16584290	chr5:462447	EXOC3	-0.37	-6.43	-0.33	4.39e-10	Cystic fibrosis severity;
LUSC	cis	rs6599077	0.616	rs9834531	chr3:40173809	A/T	cg13683864	chr3:40499215	RPL14	0.45	6.05	0.31	3.8e-9	Sleep-related phenotypes;
LUSC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.57	-10.02	-0.48	7.74e-21	Extrinsic epigenetic age acceleration;
LUSC	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg05754148	chr16:3507555	NAT15	0.53	8.09	0.4	1.08e-14	Tuberculosis;
LUSC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12667521	chr19:29218732	NA	0.62	9.36	0.46	1.19e-18	Methadone dose in opioid dependence;
LUSC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg13114125	chr14:105738426	BRF1	0.92	16.14	0.66	9.84e-44	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03004097	chr2:239197782	PER2	-0.35	-6.17	-0.32	1.99e-9	Electrocardiographic conduction measures;
LUSC	trans	rs72674100	1.000	rs77899474	chr4:97952494	C/A	cg16405019	chr1:18959625	PAX7	-0.62	-6.45	-0.33	3.85e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg06219351	chr7:158114137	PTPRN2	-0.52	-9.51	-0.46	3.88e-19	Calcium levels;
LUSC	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg09365446	chr1:150670422	GOLPH3L	-0.41	-5.94	-0.31	7.12e-9	Tonsillectomy;
LUSC	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg23950597	chr19:37808831	NA	-0.6	-5.96	-0.31	6.46e-9	Coronary artery calcification;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02335971	chr8:121457381	MTBP;MRPL13	-0.48	-6.13	-0.32	2.45e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg01097406	chr16:89675127	NA	0.3	5.69	0.3	2.72e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg13939156	chr17:80058883	NA	0.34	6.61	0.34	1.52e-10	Life satisfaction;
LUSC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg00701064	chr4:6280414	WFS1	0.6	15.3	0.64	1.99e-40	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.84	-13.98	-0.61	2.77e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9318086	0.904	rs9580769	chr13:24439724	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.4	-6.08	-0.32	3.25e-9	Myopia (pathological);
LUSC	cis	rs11637783	1	rs11637783	chr15:79139000	T/C	cg00540400	chr15:79124168	NA	-0.33	-5.69	-0.3	2.85e-8	Coronary artery disease;
LUSC	cis	rs11871801	0.517	rs646123	chr17:40720632	G/A	cg16308533	chr17:40838983	CNTNAP1	0.41	6.07	0.32	3.49e-9	Crohn's disease;
LUSC	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg22437258	chr11:111473054	SIK2	0.48	6.35	0.33	6.88e-10	Primary sclerosing cholangitis;
LUSC	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg01420254	chr6:26195488	NA	0.64	7.28	0.37	2.35e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.8	-14.96	-0.63	4.46e-39	Dental caries;
LUSC	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg21775007	chr8:11205619	TDH	-0.52	-7.33	-0.37	1.76e-12	Neuroticism;
LUSC	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-8.19	-0.41	5.7e-15	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.95	-16.12	-0.66	1.23e-43	Coronary artery disease;
LUSC	cis	rs4378355	1	rs4378355	chr11:34783417	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.41	5.86	0.31	1.09e-8	Prostate-specific antigen levels;
LUSC	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg13114125	chr14:105738426	BRF1	-0.92	-14.78	-0.63	2.28e-38	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.17	-0.32	1.92e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs68170813	0.522	rs12535814	chr7:107038432	A/T	cg02696742	chr7:106810147	HBP1	-0.61	-8.88	-0.44	4.17e-17	Coronary artery disease;
LUSC	cis	rs554111	0.656	rs3121071	chr1:21128420	C/T	cg01072550	chr1:21505969	NA	0.38	5.72	0.3	2.4e-8	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	trans	rs6601327	0.641	rs11782886	chr8:9587891	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.4	-0.33	5.21e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg09491104	chr22:46646882	C22orf40	-0.64	-7.39	-0.37	1.22e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10761482	0.861	rs7096250	chr10:62106319	C/A	cg18175470	chr10:62150864	ANK3	-0.54	-7.78	-0.39	9.31e-14	Schizophrenia;
LUSC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23158103	chr7:148848205	ZNF398	-0.5	-8.15	-0.41	7.35e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2637266	0.783	rs860167	chr10:78532936	A/G	cg18941641	chr10:78392320	NA	0.35	6.38	0.33	5.84e-10	Pulmonary function;
LUSC	cis	rs6906287	0.669	rs6913012	chr6:118973137	G/A	cg21191810	chr6:118973309	C6orf204	0.34	6.32	0.33	8.48e-10	Electrocardiographic conduction measures;
LUSC	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07080220	chr10:102295463	HIF1AN	0.62	8.5	0.42	6.24e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12476592	0.602	rs262472	chr2:63833616	G/A	cg10828910	chr2:63850056	LOC388955	0.5	5.81	0.3	1.49e-8	Childhood ear infection;
LUSC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.96	0.4	2.64e-14	Prudent dietary pattern;
LUSC	cis	rs67366981	1.000	rs67130018	chr14:77703280	C/T	cg22824376	chr14:77648248	TMEM63C	0.69	6.44	0.33	4.23e-10	Obsessive-compulsive symptoms;
LUSC	cis	rs79911532	0.515	rs111356249	chr7:75716527	A/G	cg03592824	chr7:75666768	STYXL1	0.67	6.39	0.33	5.42e-10	Mononucleosis;
LUSC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg03929089	chr4:120376271	NA	-0.59	-6.27	-0.32	1.13e-9	Axial length;
LUSC	cis	rs6969780	0.778	rs11564055	chr7:27145350	A/G	cg26364809	chr7:27145159	NA	-0.59	-5.98	-0.31	5.69e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs73071352	0.588	rs55744136	chr3:41812293	A/C	cg03022575	chr3:42003672	ULK4	0.85	8.67	0.43	1.87e-16	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
LUSC	cis	rs6500395	1.000	rs11859909	chr16:48668441	T/C	cg04672837	chr16:48644449	N4BP1	0.46	6.91	0.35	2.41e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs5758511	0.573	rs2267438	chr22:42237565	C/T	cg03131358	chr22:42195972	CCDC134	-0.33	-5.75	-0.3	2.01e-8	Birth weight;
LUSC	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg21775007	chr8:11205619	TDH	0.45	6.49	0.33	3.03e-10	Mood instability;
LUSC	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.49	-9.98	-0.48	1.1e-20	Mean corpuscular volume;
LUSC	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg01191920	chr7:158217561	PTPRN2	0.48	9.47	0.46	5.21e-19	Obesity-related traits;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg01298356	chr11:64889837	FAU;MRPL49	0.46	7.18	0.37	4.69e-12	Schizophrenia;
LUSC	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg14458575	chr2:238380390	NA	0.69	11.77	0.54	5.54e-27	Prostate cancer;
LUSC	cis	rs2273669	0.667	rs11755471	chr6:109342169	T/C	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	8.89e-9	Prostate cancer;
LUSC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg20607798	chr8:58055168	NA	0.53	5.78	0.3	1.73e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg11843238	chr5:131593191	PDLIM4	-0.4	-6.55	-0.34	2.16e-10	Breast cancer;
LUSC	cis	rs2249625	0.564	rs2463734	chr6:72882558	C/T	cg18830697	chr6:72922368	RIMS1	-0.37	-7.38	-0.37	1.25e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	trans	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg01620082	chr3:125678407	NA	-0.82	-7.32	-0.37	1.84e-12	Depression;
LUSC	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.47	-0.42	7.8e-16	Response to antipsychotic treatment;
LUSC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg18230493	chr5:56204884	C5orf35	0.58	9.16	0.45	5.22e-18	Coronary artery disease;
LUSC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.64	-0.39	2.27e-13	Personality dimensions;
LUSC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg06387496	chr7:2775674	GNA12	-0.37	-5.71	-0.3	2.51e-8	Height;
LUSC	cis	rs72634258	0.679	rs7523227	chr1:8180097	G/A	cg26816564	chr1:7831052	VAMP3	0.47	6.17	0.32	1.92e-9	Inflammatory bowel disease;
LUSC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg13319975	chr6:146136371	FBXO30	0.5	7.46	0.38	7.55e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13385	0.769	rs28450136	chr5:139598090	A/G	cg26211634	chr5:139558579	C5orf32	0.45	6.81	0.35	4.63e-11	Atrial fibrillation;
LUSC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.64	0.57	3.49e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg27535305	chr1:53392650	SCP2	0.39	7.3	0.37	2.07e-12	Monocyte count;
LUSC	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg15839431	chr19:19639596	YJEFN3	0.64	7.27	0.37	2.55e-12	Bipolar disorder;
LUSC	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-1.15	-18.25	-0.71	4.26e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg02972257	chr16:68554789	NA	-0.47	-6.14	-0.32	2.33e-9	Ulcerative colitis;
LUSC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	1.02	17.86	0.7	1.43e-50	Parkinson's disease;
LUSC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-8.51	-0.42	5.93e-16	Chronic sinus infection;
LUSC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg13319975	chr6:146136371	FBXO30	-0.51	-7.74	-0.39	1.17e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg18854424	chr1:2615690	NA	0.51	10.44	0.5	2.83e-22	Ulcerative colitis;
LUSC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg21770322	chr7:97807741	LMTK2	0.4	6.98	0.36	1.55e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9902453	0.578	rs8073217	chr17:28164263	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	10.7	0.51	3.55e-23	Coffee consumption (cups per day);
LUSC	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg05234568	chr11:5960015	NA	-0.54	-8.11	-0.41	9.72e-15	DNA methylation (variation);
LUSC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg25767906	chr1:53392781	SCP2	0.4	6.78	0.35	5.52e-11	Monocyte count;
LUSC	cis	rs7264396	0.887	rs6120951	chr20:34045191	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.71	-0.34	8.33e-11	Total cholesterol levels;
LUSC	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	11.08	0.52	1.62e-24	Electrocardiographic conduction measures;
LUSC	cis	rs10484885	0.618	rs292241	chr6:90603505	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-11.31	-0.53	2.41e-25	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.98	0.44	2e-17	Lung cancer in ever smokers;
LUSC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg12463550	chr7:65579703	CRCP	-0.46	-6.82	-0.35	4.21e-11	Aortic root size;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg01609171	chr16:127997	MPG	0.66	5.99	0.31	5.49e-9	Cognitive performance;
LUSC	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.92	12.13	0.55	2.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03352830	chr11:487213	PTDSS2	0.66	8.3	0.41	2.59e-15	Body mass index;
LUSC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.03	20.65	0.75	1.23e-61	Cognitive function;
LUSC	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg03395511	chr6:291903	DUSP22	-0.47	-7.1	-0.36	7.35e-12	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.51	-8.74	-0.43	1.16e-16	Prudent dietary pattern;
LUSC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg02403541	chr12:121454288	C12orf43	0.71	11.16	0.52	8.71e-25	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg26893861	chr17:41843967	DUSP3	0.88	13.8	0.6	1.38e-34	Triglycerides;
LUSC	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg23625390	chr15:77176239	SCAPER	-0.66	-9.97	-0.48	1.16e-20	Blood metabolite levels;
LUSC	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.63	-0.47	1.55e-19	Multiple sclerosis;
LUSC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	8.24	0.41	4.08e-15	Height;
LUSC	cis	rs977987	0.741	rs10514393	chr16:75344476	C/T	cg03315344	chr16:75512273	CHST6	0.52	9.99	0.48	9.79e-21	Dupuytren's disease;
LUSC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg01879757	chr17:41196368	BRCA1	-0.54	-8.7	-0.43	1.55e-16	Menopause (age at onset);
LUSC	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg05234568	chr11:5960015	NA	-0.6	-8.66	-0.43	2.01e-16	DNA methylation (variation);
LUSC	cis	rs9811920	0.660	rs11719468	chr3:99671848	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.35	-6.58	-0.34	1.84e-10	Axial length;
LUSC	cis	rs16976116	0.901	rs2899582	chr15:55491734	T/C	cg11288833	chr15:55489084	RSL24D1	0.49	5.87	0.31	1.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	11.26	0.52	3.93e-25	Menarche (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19565306	chr22:51222011	RPL23AP82;RABL2B	-0.43	-6.62	-0.34	1.4e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7799006	0.606	rs2286207	chr7:2303109	G/A	cg08027265	chr7:2291960	NA	-0.59	-10.54	-0.5	1.3e-22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.48	-0.33	3.25e-10	Total body bone mineral density;
LUSC	cis	rs7760949	0.889	rs9475816	chr6:13935425	T/C	cg27413430	chr6:13925136	RNF182	0.62	9.09	0.45	9.03e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg06808227	chr14:105710500	BRF1	-0.67	-10.02	-0.48	7.94e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg03146154	chr1:46216737	IPP	0.56	8.35	0.42	1.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs28647808	0.881	rs7042326	chr9:136266636	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg15704280	chr7:45808275	SEPT13	0.78	7.51	0.38	5.55e-13	Axial length;
LUSC	cis	rs60154123	0.505	rs76101197	chr1:210044089	T/C	cg21951975	chr1:209979733	IRF6	0.55	6.68	0.34	9.75e-11	Coronary artery disease;
LUSC	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg22089800	chr15:90895588	ZNF774	-0.63	-10.05	-0.48	6.26e-21	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7833986	1.000	rs34037954	chr8:57096841	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	9.2	0.45	3.84e-18	Height;
LUSC	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg17127132	chr2:85788382	GGCX	0.46	7.28	0.37	2.43e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10484885	0.763	rs56401039	chr6:90522486	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.85	-7.95	-0.4	2.9e-14	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg04369109	chr6:150039330	LATS1	-0.57	-8.47	-0.42	8.03e-16	Lung cancer;
LUSC	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg18904891	chr8:8559673	CLDN23	0.6	7.87	0.4	4.93e-14	Obesity-related traits;
LUSC	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg19554555	chr3:13937349	NA	-0.38	-5.75	-0.3	2e-8	Ovarian reserve;
LUSC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg09436375	chr6:42928200	GNMT	-0.29	-6.82	-0.35	4.33e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs35883536	0.545	rs56674564	chr1:101097718	T/C	cg06223162	chr1:101003688	GPR88	0.34	6.22	0.32	1.51e-9	Monocyte count;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03839934	chr5:95997987	CAST	0.72	5.99	0.31	5.54e-9	Cognitive performance;
LUSC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg11764359	chr7:65958608	NA	0.53	7.03	0.36	1.14e-11	Aortic root size;
LUSC	cis	rs701145	0.585	rs9839821	chr3:153796323	G/A	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg13010199	chr12:38710504	ALG10B	0.67	10.59	0.5	8.6e-23	Morning vs. evening chronotype;
LUSC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.82	-13.78	-0.6	1.69e-34	Aortic root size;
LUSC	cis	rs9283706	0.608	rs1991492	chr5:66328309	A/G	cg11590213	chr5:66331682	MAST4	0.47	7.13	0.36	6.3e-12	Coronary artery disease;
LUSC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg13798912	chr7:905769	UNC84A	-0.59	-5.95	-0.31	6.63e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7582720	1.000	rs72932784	chr2:203698470	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.73	0.43	1.22e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7192380	1.000	rs7191292	chr16:69669427	G/A	cg26679644	chr16:69762563	NA	0.34	6.08	0.32	3.25e-9	Sjögren's syndrome;
LUSC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg08888203	chr3:10149979	C3orf24	0.65	9.23	0.45	3.31e-18	Alzheimer's disease;
LUSC	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg15704280	chr7:45808275	SEPT13	0.82	7.82	0.39	6.96e-14	Axial length;
LUSC	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg13334819	chr7:99746414	C7orf59	-0.49	-6.65	-0.34	1.23e-10	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg20607798	chr8:58055168	NA	0.53	5.78	0.3	1.73e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg07169764	chr2:136633963	MCM6	-1.15	-18.77	-0.72	3.45e-54	Corneal structure;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07560662	chr1:117113232	CD58	0.45	6.86	0.35	3.39e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-0.85	-13.08	-0.58	7.26e-32	Blood protein levels;
LUSC	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	0.58	9.08	0.44	9.76e-18	Breast cancer;
LUSC	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg18827107	chr12:86230957	RASSF9	-0.4	-5.94	-0.31	7.34e-9	Major depressive disorder;
LUSC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg04518342	chr5:131593106	PDLIM4	-0.45	-7.66	-0.39	2.05e-13	Blood metabolite levels;
LUSC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg01616529	chr11:638424	DRD4	-0.36	-6.08	-0.32	3.2e-9	Systemic lupus erythematosus;
LUSC	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg03929089	chr4:120376271	NA	0.6	7.71	0.39	1.49e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.08	15.3	0.64	2.06e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.46	-0.33	3.66e-10	Arsenic metabolism;
LUSC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg04871131	chr7:94954202	PON1	-0.38	-6.08	-0.32	3.2e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1983891	0.954	rs1886816	chr6:41544494	A/G	cg15051332	chr6:41514432	FOXP4	0.41	5.91	0.31	8.43e-9	Prostate cancer;
LUSC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg18402987	chr7:1209562	NA	0.7	7.64	0.39	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.44	6.38	0.33	5.9e-10	Schizophrenia;
LUSC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18404041	chr3:52824283	ITIH1	-0.62	-12.01	-0.55	7.56e-28	Bipolar disorder;
LUSC	cis	rs6494488	0.500	rs72744715	chr15:65016145	G/C	cg08069370	chr15:64387884	SNX1	-0.66	-5.78	-0.3	1.71e-8	Coronary artery disease;
LUSC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg11859384	chr17:80120422	CCDC57	-0.36	-5.71	-0.3	2.55e-8	Life satisfaction;
LUSC	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg09021430	chr5:549028	NA	-0.54	-7.07	-0.36	8.97e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg01528321	chr10:82214614	TSPAN14	0.87	13.17	0.58	3.37e-32	Post bronchodilator FEV1;
LUSC	cis	rs2857891	0.909	rs56261447	chr11:6939382	A/C	cg14883916	chr11:6947541	ZNF215	0.46	5.96	0.31	6.39e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.4	-0.33	5.26e-10	Ulcerative colitis;
LUSC	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.84	-14.63	-0.63	8.14e-38	Ulcerative colitis;
LUSC	cis	rs965513	1.000	rs7030241	chr9:100550375	T/A	cg13688889	chr9:100608707	NA	-0.54	-8.05	-0.4	1.51e-14	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg19767477	chr5:127420684	SLC12A2	-0.42	-5.65	-0.3	3.46e-8	Ileal carcinoids;
LUSC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-0.88	-18.62	-0.71	1.43e-53	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12618769	0.597	rs4850875	chr2:99069815	A/G	cg10123293	chr2:99228465	UNC50	0.46	7.65	0.39	2.13e-13	Bipolar disorder;
LUSC	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg08499158	chr17:42289980	UBTF	0.54	8.9	0.44	3.67e-17	Total body bone mineral density;
LUSC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg26958806	chr6:27640298	NA	0.68	5.75	0.3	2.02e-8	Depression;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg12975862	chr15:48937319	FBN1	0.4	6.0	0.31	5.1e-9	Schizophrenia;
LUSC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.53	-7.24	-0.37	3.11e-12	Mean platelet volume;
LUSC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg18681998	chr4:17616180	MED28	0.85	16.06	0.66	2.03e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.67	-8.78	-0.43	8.68e-17	Schizophrenia;
LUSC	cis	rs12220238	1.000	rs11000888	chr10:75901929	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.6	7.11	0.36	7.28e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs7000551	0.751	rs1482337	chr8:22395509	A/G	cg12081754	chr8:22256438	SLC39A14	-0.47	-7.21	-0.37	3.88e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-0.92	-16.56	-0.67	2.2e-45	Cognitive function;
LUSC	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg12560992	chr17:57184187	TRIM37	0.59	9.51	0.46	4e-19	Testicular germ cell tumor;
LUSC	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.73	-0.39	1.3e-13	Total cholesterol levels;
LUSC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg04287289	chr16:89883240	FANCA	0.78	13.7	0.6	3.27e-34	Vitiligo;
LUSC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg02376097	chr19:46275166	DMPK	0.4	6.93	0.35	2.15e-11	Coronary artery disease;
LUSC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg18850127	chr7:39170497	POU6F2	-0.64	-10.01	-0.48	8.5e-21	IgG glycosylation;
LUSC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.17	0.58	3.43e-32	Chronic sinus infection;
LUSC	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg02569458	chr12:86230093	RASSF9	0.57	9.68	0.47	1.05e-19	Major depressive disorder;
LUSC	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.77	-0.35	5.85e-11	Retinal vascular caliber;
LUSC	cis	rs4478858	0.735	rs7556340	chr1:31788453	A/T	cg00250761	chr1:31883323	NA	-0.34	-8.57	-0.42	3.81e-16	Alcohol dependence;
LUSC	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs66716358	0.773	rs7118653	chr11:44327797	T/C	cg16977035	chr11:44330474	ALX4	0.35	5.79	0.3	1.61e-8	Monobrow;
LUSC	cis	rs10740039	0.516	rs7072678	chr10:62344769	C/T	cg18175470	chr10:62150864	ANK3	0.47	7.08	0.36	8.67e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg08859206	chr1:53392774	SCP2	0.49	8.26	0.41	3.56e-15	Monocyte count;
LUSC	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg06740227	chr12:86229804	RASSF9	0.39	6.09	0.32	3.05e-9	Major depressive disorder;
LUSC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg15848620	chr12:58087721	OS9	-0.54	-7.73	-0.39	1.25e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs12220238	0.818	rs115350439	chr10:75899365	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.14	0.36	5.91e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg23093090	chr10:104574429	C10orf26	0.36	6.78	0.35	5.36e-11	Arsenic metabolism;
LUSC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg08219700	chr8:58056026	NA	0.5	6.18	0.32	1.84e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.53	-8.38	-0.42	1.47e-15	Schizophrenia;
LUSC	cis	rs4400599	0.618	rs1194599	chr1:154236452	C/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.9	-0.31	8.93e-9	Platelet distribution width;
LUSC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg12560992	chr17:57184187	TRIM37	0.86	15.56	0.65	1.86e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.79	11.58	0.54	2.77e-26	Corneal astigmatism;
LUSC	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-6.72	-0.35	7.83e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs727505	0.721	rs67817822	chr7:124769572	A/G	cg23710748	chr7:124431027	NA	-0.39	-7.01	-0.36	1.29e-11	Lewy body disease;
LUSC	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.52	-7.18	-0.37	4.68e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.4	-0.38	1.1e-12	Breast cancer;
LUSC	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg07148914	chr20:33460835	GGT7	0.46	6.81	0.35	4.63e-11	Height;
LUSC	cis	rs2625529	0.590	rs12442886	chr15:72473611	T/C	cg16672083	chr15:72433130	SENP8	0.46	7.19	0.37	4.29e-12	Red blood cell count;
LUSC	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg12432903	chr7:1882776	MAD1L1	0.52	6.32	0.33	8.26e-10	Bipolar disorder;
LUSC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg18404041	chr3:52824283	ITIH1	-0.36	-6.13	-0.32	2.54e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.81	0.39	7.58e-14	Prudent dietary pattern;
LUSC	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg24110177	chr3:50126178	RBM5	0.42	6.74	0.35	6.9e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7605827	0.930	rs6704723	chr2:15599895	A/G	cg19274914	chr2:15703543	NA	0.46	8.8	0.43	7.47e-17	Educational attainment (years of education);
LUSC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg19812747	chr11:111475976	SIK2	-0.54	-7.76	-0.39	1.05e-13	Primary sclerosing cholangitis;
LUSC	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg00012203	chr2:219082015	ARPC2	0.81	13.69	0.6	3.57e-34	Colorectal cancer;
LUSC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg14343924	chr8:8086146	FLJ10661	0.43	6.09	0.32	3.12e-9	Mood instability;
LUSC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg13154104	chr2:10443632	HPCAL1	-0.43	-6.08	-0.32	3.23e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg05373962	chr22:49881684	NA	-0.44	-10.77	-0.51	2.12e-23	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs710216	0.917	rs710223	chr1:43411038	C/G	cg22176566	chr1:43424700	SLC2A1	0.5	6.28	0.32	1.07e-9	Red cell distribution width;
LUSC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.79	0.7	2.73e-50	Chronic sinus infection;
LUSC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23158103	chr7:148848205	ZNF398	-0.49	-8.01	-0.4	1.98e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.0	-0.31	5.14e-9	Retinal vascular caliber;
LUSC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg08798685	chr6:27730294	NA	-0.69	-6.12	-0.32	2.55e-9	Depression;
LUSC	cis	rs7927771	0.524	rs10769299	chr11:47865160	G/T	cg20307385	chr11:47447363	PSMC3	0.46	6.8	0.35	4.78e-11	Subjective well-being;
LUSC	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg01191920	chr7:158217561	PTPRN2	-0.59	-12.07	-0.55	4.37e-28	Obesity-related traits;
LUSC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-6.27	-0.32	1.1e-9	Blood protein levels;
LUSC	cis	rs7605827	0.930	rs13029846	chr2:15674686	T/C	cg19274914	chr2:15703543	NA	0.45	8.55	0.42	4.49e-16	Educational attainment (years of education);
LUSC	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-7.94	-0.4	3.11e-14	Bladder cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13472656	chr22:25960710	ADRBK2	0.43	6.43	0.33	4.42e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg04310649	chr10:35416472	CREM	-0.39	-6.06	-0.31	3.76e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.8	-0.81	9.79e-78	Height;
LUSC	cis	rs11229555	1.000	rs11229543	chr11:58370698	G/A	cg15696309	chr11:58395628	NA	-0.69	-9.27	-0.45	2.43e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg16325326	chr1:53192061	ZYG11B	0.92	18.5	0.71	4.18e-53	Monocyte count;
LUSC	cis	rs6681460	0.966	rs10789215	chr1:67151185	C/T	cg02459107	chr1:67143332	SGIP1	-0.48	-8.89	-0.44	3.87e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg05373962	chr22:49881684	NA	-0.41	-8.81	-0.43	6.75e-17	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17410650	chr12:54324560	NA	-0.58	-10.66	-0.5	4.93e-23	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.93	0.31	7.55e-9	Rheumatoid arthritis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08093216	chr19:12944890	RTBDN	-0.4	-5.98	-0.31	5.88e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9517320	0.967	rs2274056	chr13:99134839	G/C	cg07423050	chr13:99094983	FARP1	0.35	6.64	0.34	1.25e-10	Longevity;
LUSC	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg04586622	chr2:25135609	ADCY3	0.28	5.69	0.3	2.8e-8	Body mass index in non-asthmatics;
LUSC	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg19812747	chr11:111475976	SIK2	-0.44	-6.08	-0.32	3.29e-9	Primary sclerosing cholangitis;
LUSC	trans	rs12439619	0.846	rs62011975	chr15:82451554	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.46	-6.11	-0.32	2.81e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg10255544	chr17:80519551	FOXK2	0.38	6.25	0.32	1.23e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19346786	chr7:2764209	NA	-0.4	-7.01	-0.36	1.34e-11	Height;
LUSC	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg03585969	chr10:35415529	CREM	0.58	8.48	0.42	7.17e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9323205	0.954	rs9672122	chr14:51582391	A/G	cg23942311	chr14:51606299	NA	-0.42	-8.06	-0.4	1.41e-14	Cancer;
LUSC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-9.26	-0.45	2.58e-18	Gut microbiome composition (summer);
LUSC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.4	-6.0	-0.31	5.27e-9	Menarche (age at onset);
LUSC	cis	rs6723226	0.521	rs1991626	chr2:32602450	G/A	cg02381751	chr2:32503542	YIPF4	-0.51	-7.57	-0.38	3.57e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg26876637	chr1:152193138	HRNR	-0.43	-6.19	-0.32	1.75e-9	Atopic dermatitis;
LUSC	trans	rs3857536	0.776	rs9294687	chr6:66942919	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs925255	0.810	rs1396733	chr2:28642747	A/C	cg01273330	chr2:28605224	NA	0.42	6.84	0.35	3.68e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg09033563	chr22:24373618	LOC391322	0.48	6.87	0.35	3.09e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9925964	0.967	rs2032915	chr16:31117413	C/T	cg02466173	chr16:30829666	NA	0.34	6.28	0.33	1.04e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1775715	0.737	rs2808078	chr10:32172552	C/T	cg04359828	chr10:32216031	ARHGAP12	0.4	6.9	0.35	2.69e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-8.52	-0.42	5.39e-16	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26949087	chr2:26467503	HADHB;HADHA	0.48	6.89	0.35	2.71e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	1.01	10.69	0.51	3.78e-23	Skin colour saturation;
LUSC	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.54	-10.65	-0.5	5.47e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg05714579	chr10:131428358	MGMT	0.5	7.46	0.38	7.74e-13	Response to temozolomide;
LUSC	cis	rs55665837	1.000	rs10832254	chr11:14434698	A/G	cg05501817	chr11:14380813	RRAS2	-0.41	-6.73	-0.35	7.47e-11	Vitamin D levels;
LUSC	cis	rs3741151	0.687	rs724111	chr11:73238645	G/A	cg17517138	chr11:73019481	ARHGEF17	0.96	8.06	0.4	1.35e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg07936489	chr17:37558343	FBXL20	-0.43	-5.89	-0.31	9.32e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs10186029	0.582	rs10497995	chr2:213995346	G/A	cg08319019	chr2:214017104	IKZF2	0.49	7.55	0.38	4.22e-13	Systemic sclerosis;
LUSC	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg22431228	chr1:16359049	CLCNKA	0.34	6.41	0.33	5.1e-10	Dilated cardiomyopathy;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02399652	chr3:169684620	LOC100128164;SEC62	0.47	6.58	0.34	1.81e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs10463316	0.779	rs1810084	chr5:150777048	A/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-7.01	-0.36	1.29e-11	Metabolite levels (Pyroglutamine);
LUSC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg26755928	chr19:10363173	MRPL4	0.45	6.69	0.34	9.18e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.48	-0.38	6.65e-13	Retinal vascular caliber;
LUSC	trans	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.97	-0.4	2.47e-14	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs4363385	0.600	rs10888532	chr1:153063407	C/A	cg07796016	chr1:152779584	LCE1C	-0.38	-5.78	-0.3	1.73e-8	Inflammatory skin disease;
LUSC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.49	-8.34	-0.42	1.93e-15	Homoarginine levels;
LUSC	trans	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-9.6	-0.47	1.91e-19	Morning vs. evening chronotype;
LUSC	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg26924012	chr15:45694286	SPATA5L1	1.13	20.62	0.75	1.62e-61	Homoarginine levels;
LUSC	cis	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg06521331	chr12:34319734	NA	-0.47	-7.63	-0.39	2.42e-13	Morning vs. evening chronotype;
LUSC	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06636551	chr8:101224915	SPAG1	0.39	7.15	0.36	5.67e-12	Atrioventricular conduction;
LUSC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg12463550	chr7:65579703	CRCP	-0.42	-5.95	-0.31	6.71e-9	Aortic root size;
LUSC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.17	0.37	4.88e-12	Mean platelet volume;
LUSC	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	0.93	16.11	0.66	1.32e-43	Menopause (age at onset);
LUSC	trans	rs8060598	0.866	rs3135499	chr16:50766127	G/T	cg25618513	chr4:153456716	FBXW7	-0.35	-6.02	-0.31	4.64e-9	Leprosy;
LUSC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg10609677	chr17:41278573	BRCA1;NBR2	0.35	5.68	0.3	2.99e-8	Menopause (age at onset);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg00763096	chr15:63893530	FBXL22	0.41	6.01	0.31	4.81e-9	N-glycan levels;
LUSC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-8.07	-0.4	1.26e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.86	13.94	0.61	3.91e-35	Coronary artery disease;
LUSC	cis	rs9549260	0.620	rs12583418	chr13:41195411	G/A	cg21288729	chr13:41239152	FOXO1	0.6	9.16	0.45	5.25e-18	Red blood cell count;
LUSC	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2.04e-10	Reticulocyte fraction of red cells;
LUSC	trans	rs12571093	0.773	rs4142047	chr10:70021255	A/C	cg04882175	chr6:131122610	NA	-0.54	-6.21	-0.32	1.59e-9	Optic nerve measurement (disc area);
LUSC	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg23306229	chr2:178417860	TTC30B	0.55	5.7	0.3	2.62e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.6	8.25	0.41	3.6e-15	Body mass index (adult);
LUSC	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.1	0.52	1.46e-24	Fuchs's corneal dystrophy;
LUSC	trans	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg07211511	chr3:129823064	LOC729375	-0.53	-6.08	-0.32	3.25e-9	Blood pressure (smoking interaction);
LUSC	cis	rs4842666	0.915	rs11105364	chr12:90069276	T/G	cg00757033	chr12:89920650	WDR51B	0.49	7.08	0.36	8.61e-12	Blood pressure;
LUSC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.96	0.31	6.27e-9	Menopause (age at onset);
LUSC	cis	rs16976116	0.803	rs7168737	chr15:55501344	T/C	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08704250	chr15:31115839	NA	0.52	7.99	0.4	2.24e-14	Huntington's disease progression;
LUSC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg09367891	chr1:107599246	PRMT6	-0.56	-8.82	-0.43	6.58e-17	Facial morphology (factor 21, depth of nasal alae);
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg20770540	chr3:123304003	PTPLB	0.66	6.18	0.32	1.82e-9	Body mass index;
LUSC	cis	rs4253772	1.000	rs4253772	chr22:46627603	C/T	cg18190219	chr22:46762943	CELSR1	-0.52	-6.02	-0.31	4.71e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6489882	0.867	rs4988618	chr12:113363178	G/A	cg20102336	chr12:113376681	OAS3	-0.42	-5.93	-0.31	7.36e-9	Chronic lymphocytic leukemia;
LUSC	trans	rs62238980	0.614	rs79110727	chr22:32377455	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs1568889	0.877	rs12786351	chr11:28271122	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.6	6.94	0.35	2.06e-11	Bipolar disorder;
LUSC	cis	rs243505	0.898	rs243542	chr7:148403194	G/A	cg09806900	chr7:148480153	CUL1	-0.47	-6.76	-0.35	6.01e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg03342759	chr3:160939853	NMD3	-0.55	-8.11	-0.41	9.81e-15	Parkinson's disease;
LUSC	cis	rs2835872	0.760	rs2835893	chr21:39060893	G/A	cg20424643	chr21:39039972	KCNJ6	0.47	7.15	0.36	5.37e-12	Electroencephalographic traits in alcoholism;
LUSC	cis	rs12530845	1.000	rs6975251	chr7:135328689	C/G	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg11632617	chr15:75315747	PPCDC	-0.5	-6.58	-0.34	1.86e-10	Blood trace element (Zn levels);
LUSC	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg15744005	chr10:104629667	AS3MT	-0.32	-6.18	-0.32	1.82e-9	Arsenic metabolism;
LUSC	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg24060327	chr5:131705240	SLC22A5	0.5	6.91	0.35	2.49e-11	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg24881330	chr22:46731750	TRMU	0.82	7.39	0.37	1.21e-12	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22253313	chr4:2011099	WHSC2	-0.48	-5.97	-0.31	6.04e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg23791538	chr6:167370224	RNASET2	0.4	6.46	0.33	3.81e-10	Crohn's disease;
LUSC	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	8.65	0.43	2.17e-16	Lung cancer in ever smokers;
LUSC	cis	rs9462027	0.561	rs2235568	chr6:34570094	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-6.15	-0.32	2.19e-9	Systemic lupus erythematosus;
LUSC	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.49	0.75	5.16e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.74	11.46	0.53	6.99e-26	Hypertriglyceridemia;
LUSC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg22563815	chr15:78856949	CHRNA5	0.27	6.37	0.33	6.43e-10	Sudden cardiac arrest;
LUSC	cis	rs9837602	0.938	rs1017968	chr3:99787011	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.17	0.32	1.97e-9	Breast cancer;
LUSC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13770153	chr20:60521292	NA	-0.64	-8.6	-0.43	3.17e-16	Body mass index;
LUSC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.45	-6.85	-0.35	3.48e-11	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg17075019	chr10:79541650	NA	-0.75	-12.05	-0.55	4.99e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	0.93	13.22	0.59	2.25e-32	Primary sclerosing cholangitis;
LUSC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.11	-0.48	3.92e-21	Monocyte count;
LUSC	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg13390004	chr1:15929781	NA	0.41	6.74	0.35	7.15e-11	Systolic blood pressure;
LUSC	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg14530993	chr4:882597	GAK	0.8	7.72	0.39	1.4e-13	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00860370	chr1:104068121	RNPC3	-0.43	-6.06	-0.31	3.74e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg23791538	chr6:167370224	RNASET2	-0.41	-6.65	-0.34	1.21e-10	Crohn's disease;
LUSC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	8.28	0.41	2.95e-15	Neuroticism;
LUSC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	15.59	0.65	1.47e-41	Platelet count;
LUSC	cis	rs793571	0.543	rs11854073	chr15:58972995	G/A	cg05156742	chr15:59063176	FAM63B	0.52	7.61	0.38	2.82e-13	Schizophrenia;
LUSC	cis	rs1215050	0.904	rs890469	chr4:98923293	T/C	cg05340658	chr4:99064831	C4orf37	-0.43	-6.53	-0.34	2.48e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg16339924	chr4:17578868	LAP3	0.57	8.63	0.43	2.51e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.89	0.31	9.5e-9	Lung cancer;
LUSC	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg05738196	chr6:26577821	NA	0.81	15.89	0.66	9.79e-43	Intelligence (multi-trait analysis);
LUSC	cis	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg21775007	chr8:11205619	TDH	-0.48	-7.11	-0.36	7.19e-12	Neuroticism;
LUSC	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.11	-0.41	9.76e-15	Retinal vascular caliber;
LUSC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg14019146	chr3:50243930	SLC38A3	0.36	8.27	0.41	3.28e-15	Body mass index;
LUSC	cis	rs9309473	0.687	rs6710659	chr2:73607510	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-8.34	-0.42	1.96e-15	Metabolite levels;
LUSC	cis	rs73206853	0.841	rs56209636	chr12:110841998	T/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4974559	0.947	rs6847321	chr4:1347374	C/T	cg02980000	chr4:1222292	CTBP1	0.72	7.55	0.38	4.26e-13	Systolic blood pressure;
LUSC	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg02958346	chr11:57425731	CLP1	-0.43	-6.27	-0.32	1.13e-9	Schizophrenia;
LUSC	cis	rs9308433	0.529	rs9430133	chr1:214496313	C/T	cg06198575	chr1:214491504	SMYD2	0.45	7.06	0.36	9.75e-12	IgG glycosylation;
LUSC	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	trans	rs11700980	0.551	rs2832011	chr21:30110690	T/C	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.31e-9	QRS complex (12-leadsum);
LUSC	cis	rs11608355	0.597	rs2304548	chr12:109795166	T/G	cg19025524	chr12:109796872	NA	-0.48	-9.16	-0.45	5.49e-18	Neuroticism;
LUSC	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg03929089	chr4:120376271	NA	0.79	10.87	0.51	8.96e-24	Coronary artery disease;
LUSC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg11645453	chr3:52864694	ITIH4	0.29	6.71	0.34	8.27e-11	Electroencephalogram traits;
LUSC	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg06951627	chr6:26196580	NA	0.53	5.72	0.3	2.39e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg02016764	chr4:38805732	TLR1	-0.54	-5.92	-0.31	7.93e-9	Breast cancer;
LUSC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg03146154	chr1:46216737	IPP	0.56	8.37	0.42	1.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg12473912	chr3:136751656	NA	0.38	6.78	0.35	5.53e-11	Neuroticism;
LUSC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg05347473	chr6:146136440	FBXO30	0.57	10.06	0.48	5.51e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg25319279	chr11:5960081	NA	-0.4	-5.92	-0.31	7.97e-9	DNA methylation (variation);
LUSC	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg03806693	chr22:41940476	POLR3H	-0.57	-7.94	-0.4	3.2e-14	Neuroticism;
LUSC	cis	rs28647808	0.881	rs28494844	chr9:136266188	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg20503657	chr10:835505	NA	0.78	9.42	0.46	7.61e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs1775715	0.870	rs1755072	chr10:32266642	A/G	cg26784012	chr10:32216390	ARHGAP12	-0.43	-6.97	-0.36	1.7e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg02466173	chr16:30829666	NA	0.56	11.38	0.53	1.4e-25	Dementia with Lewy bodies;
LUSC	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-9.69	-0.47	1e-19	Hemoglobin concentration;
LUSC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg24631222	chr15:78858424	CHRNA5	-0.66	-8.7	-0.43	1.52e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg17366294	chr4:99064904	C4orf37	0.53	9.03	0.44	1.35e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6426558	0.537	rs2718193	chr1:227404672	C/G	cg10327440	chr1:227177885	CDC42BPA	0.54	7.35	0.37	1.55e-12	Neutrophil percentage of white cells;
LUSC	cis	rs2599510	0.729	rs1135484	chr2:32749060	G/A	cg02381751	chr2:32503542	YIPF4	0.4	5.82	0.3	1.38e-8	Interleukin-18 levels;
LUSC	cis	rs6987853	0.563	rs10958723	chr8:42448188	T/C	cg09913449	chr8:42400586	C8orf40	0.4	6.65	0.34	1.23e-10	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1524927	1.000	rs11765843	chr7:96341168	T/A	cg03808172	chr7:96339361	SHFM1	0.43	6.66	0.34	1.12e-10	Total body bone mineral density;
LUSC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg06027949	chr8:82754900	SNX16	-0.43	-5.81	-0.3	1.48e-8	Diastolic blood pressure;
LUSC	cis	rs17685	0.740	rs4732514	chr7:75613998	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.44	6.79	0.35	5.03e-11	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs968451	1.000	rs11704615	chr22:39696834	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	9.0	0.44	1.8e-17	Primary biliary cholangitis;
LUSC	cis	rs9677476	0.779	rs72983683	chr2:232100970	G/T	cg07929768	chr2:232055508	NA	0.38	6.43	0.33	4.39e-10	Food antigen IgG levels;
LUSC	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg05855489	chr10:104503620	C10orf26	0.59	9.45	0.46	6.11e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg14416269	chr4:6271139	WFS1	0.44	8.21	0.41	5.02e-15	Cisplatin-induced ototoxicity;
LUSC	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19717773	chr7:2847554	GNA12	-0.33	-5.81	-0.3	1.46e-8	Height;
LUSC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.18	0.52	7.44e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg22532475	chr10:104410764	TRIM8	-0.3	-6.9	-0.35	2.62e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg24562669	chr7:97807699	LMTK2	0.35	6.08	0.32	3.26e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg25882455	chr22:38599073	MAFF	-0.49	-5.96	-0.31	6.23e-9	Neuroticism;
LUSC	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg22532475	chr10:104410764	TRIM8	-0.32	-7.14	-0.36	5.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg03579872	chr1:53393473	SCP2	0.4	6.1	0.32	3e-9	Monocyte count;
LUSC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.53	-0.62	2.15e-37	Schizophrenia;
LUSC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08219700	chr8:58056026	NA	0.69	7.91	0.4	3.7e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6596100	0.500	rs67904956	chr5:132274044	A/G	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Breast cancer;
LUSC	cis	rs7809950	0.953	rs2520267	chr7:107187497	T/C	cg23024343	chr7:107201750	COG5	-0.55	-8.73	-0.43	1.25e-16	Coronary artery disease;
LUSC	trans	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.51	0.53	4.62e-26	Mean corpuscular volume;
LUSC	cis	rs8044995	0.501	rs55793998	chr16:68378985	G/T	cg05110241	chr16:68378359	PRMT7	-0.77	-9.01	-0.44	1.6e-17	Schizophrenia;
LUSC	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg11502198	chr6:26597334	ABT1	0.59	9.08	0.44	9.97e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg04850211	chr1:228464232	OBSCN	-0.33	-5.94	-0.31	7.25e-9	Diastolic blood pressure;
LUSC	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12016809	chr21:47604291	C21orf56	0.45	6.91	0.35	2.46e-11	Testicular germ cell tumor;
LUSC	cis	rs3087591	1.000	rs2051507	chr17:29700101	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.56	-8.09	-0.4	1.14e-14	Hip circumference;
LUSC	cis	rs3736594	1.000	rs3792252	chr2:27995931	A/G	cg27432699	chr2:27873401	GPN1	0.58	7.96	0.4	2.69e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg25456477	chr12:86230367	RASSF9	0.34	5.69	0.3	2.78e-8	Major depressive disorder;
LUSC	cis	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg02508848	chr16:68573721	ZFP90	-0.42	-5.75	-0.3	2.07e-8	Ulcerative colitis;
LUSC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg27535305	chr1:53392650	SCP2	0.36	6.71	0.34	8.29e-11	Monocyte count;
LUSC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg00255919	chr5:131827918	IRF1	0.43	8.28	0.41	3.11e-15	Asthma (sex interaction);
LUSC	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg24375607	chr4:120327624	NA	0.73	10.88	0.51	8.47e-24	Corneal astigmatism;
LUSC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.72	-12.8	-0.57	8.5e-31	Dental caries;
LUSC	cis	rs8062405	0.698	rs10499	chr16:28915527	G/A	cg05966235	chr16:28915196	ATP2A1	-0.36	-6.07	-0.32	3.53e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg05347473	chr6:146136440	FBXO30	-0.35	-5.67	-0.3	3.05e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.42	-7.76	-0.39	1.05e-13	Monocyte percentage of white cells;
LUSC	cis	rs6542838	0.641	rs6704682	chr2:99499602	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.39	-0.33	5.63e-10	Fear of minor pain;
LUSC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg12963246	chr6:28129442	ZNF389	0.37	5.7	0.3	2.57e-8	Cardiac Troponin-T levels;
LUSC	cis	rs9309473	0.528	rs6546820	chr2:73553397	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-7.01	-0.36	1.35e-11	Metabolite levels;
LUSC	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg19774624	chr17:42201019	HDAC5	0.48	7.2	0.37	4.14e-12	Total body bone mineral density;
LUSC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.74	0.84	1.09e-88	Chronic sinus infection;
LUSC	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg21772509	chr8:41503840	NKX6-3	0.58	9.38	0.46	1.07e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg01851573	chr8:8652454	MFHAS1	-0.52	-8.52	-0.42	5.73e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06634786	chr22:41940651	POLR3H	0.53	6.19	0.32	1.81e-9	Vitiligo;
LUSC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg24562669	chr7:97807699	LMTK2	0.36	6.23	0.32	1.37e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11676348	0.774	rs57545959	chr2:219047718	A/G	cg18102446	chr2:218934044	RUFY4	-0.35	-5.81	-0.3	1.47e-8	Ulcerative colitis;
LUSC	cis	rs2274273	0.840	rs943590	chr14:55738596	T/C	cg04306507	chr14:55594613	LGALS3	0.57	13.25	0.59	1.68e-32	Protein biomarker;
LUSC	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	0.93	12.62	0.57	3.86e-30	Primary sclerosing cholangitis;
LUSC	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg11984989	chr7:158649758	WDR60	1.06	21.05	0.76	3.25e-63	Height;
LUSC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.77	-13.73	-0.6	2.61e-34	Height;
LUSC	cis	rs4964805	0.626	rs11111771	chr12:104179271	A/G	cg02344784	chr12:104178138	NT5DC3	-0.42	-6.73	-0.35	7.5e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg15744005	chr10:104629667	AS3MT	-0.28	-6.11	-0.32	2.76e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg20701182	chr2:24300061	SF3B14	0.57	6.01	0.31	4.88e-9	Lymphocyte counts;
LUSC	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg21427119	chr20:30132790	HM13	-0.44	-6.18	-0.32	1.83e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg12257692	chr3:49977190	RBM6	0.24	6.65	0.34	1.19e-10	Body mass index;
LUSC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.56	10.98	0.52	3.71e-24	Asthma (sex interaction);
LUSC	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg26384229	chr12:38710491	ALG10B	0.74	11.93	0.55	1.42e-27	Morning vs. evening chronotype;
LUSC	cis	rs6977940	0.512	rs6461600	chr7:2816537	C/T	cg19731401	chr7:2775893	GNA12	0.62	8.48	0.42	7.54e-16	White matter integrity;
LUSC	cis	rs7605827	0.930	rs12692263	chr2:15539206	G/A	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs12049330	0.689	rs10494041	chr1:110031990	C/G	cg05049280	chr1:110155535	GNAT2	0.4	5.94	0.31	7.14e-9	Major depressive disorder;
LUSC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	15.72	0.65	4.67e-42	Platelet count;
LUSC	cis	rs2859741	0.565	rs12031540	chr1:37513757	C/T	cg09363841	chr1:37513479	NA	-0.36	-6.89	-0.35	2.82e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg24399712	chr22:39784796	NA	-0.63	-10.72	-0.51	3.08e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-9.1	-0.45	8.44e-18	Gut microbiome composition (summer);
LUSC	cis	rs4789693	0.938	rs8078595	chr17:80426988	G/T	cg04308225	chr17:80449738	NA	0.47	7.72	0.39	1.36e-13	Glucocorticoid-induced osteonecrosis;
LUSC	trans	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg18844304	chr19:55851052	SUV420H2	-0.39	-6.18	-0.32	1.88e-9	Cognitive function;
LUSC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg08219700	chr8:58056026	NA	0.49	6.11	0.32	2.75e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.71	-11.08	-0.52	1.62e-24	Body mass index;
LUSC	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg19640130	chr10:64028056	RTKN2	0.42	7.38	0.37	1.28e-12	Rheumatoid arthritis;
LUSC	cis	rs7597155	0.967	rs6749078	chr2:69986037	C/G	cg02498382	chr2:70120550	SNRNP27	-0.24	-5.77	-0.3	1.81e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg14552801	chr7:65878734	NA	-0.46	-6.54	-0.34	2.28e-10	Aortic root size;
LUSC	cis	rs6596100	0.538	rs72799458	chr5:132188063	C/T	cg02081065	chr5:132209139	LEAP2	-0.63	-6.05	-0.31	3.88e-9	Breast cancer;
LUSC	cis	rs3096299	0.702	rs2086825	chr16:89471542	C/T	cg02187348	chr16:89574699	SPG7	0.37	5.74	0.3	2.16e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg21724239	chr8:58056113	NA	0.81	9.61	0.47	1.86e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg05501817	chr11:14380813	RRAS2	-0.46	-7.26	-0.37	2.69e-12	Vitamin D levels;
LUSC	cis	rs7799006	0.606	rs2286207	chr7:2303109	G/A	cg12823233	chr7:2316876	SNX8	-0.43	-7.32	-0.37	1.89e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.59	7.67	0.39	1.86e-13	Response to diuretic therapy;
LUSC	cis	rs7267979	0.780	rs2500413	chr20:25241155	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	12.25	0.56	9.31e-29	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6541297	0.941	rs6693579	chr1:230282707	T/C	cg05784532	chr1:230284198	GALNT2	0.61	7.62	0.38	2.69e-13	Coronary artery disease;
LUSC	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.84	-0.39	6.14e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg02228329	chr11:64053129	BAD;GPR137	-0.4	-6.16	-0.32	2.12e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7575217	0.921	rs1192785	chr2:101783573	C/T	cg23907051	chr2:101730305	TBC1D8	-0.27	-6.56	-0.34	2.06e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs2281558	0.917	rs3787080	chr20:25232604	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.55	8.18	0.41	6.04e-15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg11871910	chr12:69753446	YEATS4	0.81	14.38	0.62	8.22e-37	Blood protein levels;
LUSC	cis	rs2625529	0.775	rs4777489	chr15:72430434	C/T	cg16672083	chr15:72433130	SENP8	0.52	7.78	0.39	9.17e-14	Red blood cell count;
LUSC	cis	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.77	-0.3	1.77e-8	Resting heart rate;
LUSC	trans	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg13010199	chr12:38710504	ALG10B	-0.4	-6.04	-0.31	4.04e-9	Morning vs. evening chronotype;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02361781	chr15:52043731	TMOD2;LYSMD2	-0.41	-6.14	-0.32	2.29e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg18654377	chr3:49208889	KLHDC8B	0.44	5.86	0.31	1.09e-8	Menarche (age at onset);
LUSC	cis	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.54	0.42	4.71e-16	Endometrial cancer;
LUSC	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg27661571	chr11:113659931	NA	-0.59	-7.18	-0.37	4.61e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs1577917	0.883	rs2166664	chr6:86596622	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-6.36	-0.33	6.51e-10	Response to antipsychotic treatment;
LUSC	cis	rs7215564	0.908	rs2316059	chr17:78663732	C/T	cg09596252	chr17:78655493	RPTOR	0.53	5.85	0.31	1.15e-8	Myopia (pathological);
LUSC	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.87	15.11	0.64	1.15e-39	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg17509989	chr5:176798049	RGS14	-0.68	-9.35	-0.46	1.26e-18	Urate levels in lean individuals;
LUSC	trans	rs60843830	1.000	rs9213	chr2:218386	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	10.49	0.5	1.98e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	16.09	0.66	1.53e-43	Platelet count;
LUSC	trans	rs9467603	0.925	rs1954598	chr6:25776060	T/C	cg06606381	chr12:133084897	FBRSL1	0.59	5.95	0.31	6.9e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg21880101	chr17:80066754	CCDC57	-0.31	-5.89	-0.31	9.22e-9	Life satisfaction;
LUSC	trans	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.37	-0.33	6.35e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg09876464	chr15:85330779	ZNF592	0.36	6.65	0.34	1.17e-10	P wave terminal force;
LUSC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg03161606	chr19:29218774	NA	0.65	10.27	0.49	1.12e-21	Methadone dose in opioid dependence;
LUSC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs12824058	0.707	rs2398509	chr12:130816464	T/C	cg24838063	chr12:130822603	PIWIL1	0.7	10.3	0.49	8.96e-22	Menopause (age at onset);
LUSC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.75	0.43	1.09e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.75	10.36	0.49	5.28e-22	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9677476	0.821	rs6708809	chr2:232112730	A/C	cg07929768	chr2:232055508	NA	0.34	6.28	0.32	1.06e-9	Food antigen IgG levels;
LUSC	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg23982607	chr1:1823379	GNB1	0.53	9.57	0.46	2.57e-19	Body mass index;
LUSC	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg21770322	chr7:97807741	LMTK2	-0.36	-6.15	-0.32	2.18e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.52	10.41	0.49	3.65e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-7.22	-0.37	3.54e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg18721089	chr20:30220636	NA	-0.34	-5.82	-0.3	1.35e-8	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg24459738	chr19:57751996	ZNF805	0.51	7.62	0.38	2.71e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs354225	0.544	rs10169975	chr2:54808159	C/T	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg23093090	chr10:104574429	C10orf26	-0.38	-7.03	-0.36	1.17e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	6.38	0.33	5.9e-10	Height;
LUSC	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00852613	chr13:50159829	RCBTB1	-0.48	-6.46	-0.33	3.72e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.56	7.6	0.38	3.06e-13	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs11048434	0.761	rs12827055	chr12:9130861	G/T	cg13575925	chr12:9217583	LOC144571	0.34	6.18	0.32	1.92e-9	Sjögren's syndrome;
LUSC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00166722	chr3:10149974	C3orf24	0.6	8.41	0.42	1.19e-15	Alzheimer's disease;
LUSC	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-9.46	-0.46	5.75e-19	Monocyte percentage of white cells;
LUSC	trans	rs2262909	0.962	rs11669110	chr19:22296485	A/G	cg05197062	chr11:11642011	GALNTL4	0.55	7.68	0.39	1.83e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg01256987	chr12:42539512	GXYLT1	0.35	6.4	0.33	5.35e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg09455208	chr3:40491958	NA	0.52	9.16	0.45	5.22e-18	Renal cell carcinoma;
LUSC	cis	rs10465746	0.935	rs35946036	chr1:84438991	A/G	cg10977910	chr1:84465055	TTLL7	0.42	6.23	0.32	1.42e-9	Obesity-related traits;
LUSC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg11764359	chr7:65958608	NA	-0.55	-7.26	-0.37	2.79e-12	Aortic root size;
LUSC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg00074818	chr8:8560427	CLDN23	0.57	9.71	0.47	8.22e-20	Obesity-related traits;
LUSC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.03e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg11941060	chr3:133502564	NA	-0.46	-6.66	-0.34	1.12e-10	Iron status biomarkers;
LUSC	cis	rs7084402	1.000	rs12257983	chr10:60266555	A/C	cg07615347	chr10:60278583	BICC1	-0.35	-5.76	-0.3	1.95e-8	Refractive error;
LUSC	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.61	9.46	0.46	5.83e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19717773	chr7:2847554	GNA12	-0.37	-6.62	-0.34	1.43e-10	Height;
LUSC	cis	rs1982963	0.627	rs61971554	chr14:52491583	A/G	cg10843707	chr14:52510701	NID2	0.46	6.23	0.32	1.4e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg11344533	chr11:111475393	SIK2	-0.46	-6.35	-0.33	7.19e-10	Primary sclerosing cholangitis;
LUSC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	13.63	0.6	6.14e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21545522	chr1:205238299	TMCC2	0.45	8.43	0.42	1.08e-15	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg03433033	chr1:76189801	ACADM	-0.46	-7.0	-0.36	1.37e-11	Daytime sleep phenotypes;
LUSC	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.51	7.77	0.39	9.91e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-8.09	-0.4	1.14e-14	Bipolar disorder;
LUSC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	0.63	11.04	0.52	2.3e-24	Blood metabolite levels;
LUSC	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg14196790	chr5:131705035	SLC22A5	0.45	7.73	0.39	1.27e-13	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs2540226	0.935	rs3732122	chr2:39988703	T/C	cg23576258	chr2:39999331	THUMPD2	0.35	5.81	0.3	1.47e-8	Personality dimensions;
LUSC	cis	rs9314323	0.767	rs6557915	chr8:26209062	C/A	cg13160058	chr8:26243215	BNIP3L	-0.4	-6.98	-0.36	1.63e-11	Red cell distribution width;
LUSC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg16339924	chr4:17578868	LAP3	0.64	9.6	0.47	1.92e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	1.08	17.88	0.7	1.23e-50	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg13072238	chr3:49761600	GMPPB	0.68	8.73	0.43	1.23e-16	Menarche (age at onset);
LUSC	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17691542	chr6:26056736	HIST1H1C	1.0	12.67	0.57	2.59e-30	Iron status biomarkers;
LUSC	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.97	0.4	2.55e-14	Corneal astigmatism;
LUSC	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg02023728	chr11:77925099	USP35	0.51	7.08	0.36	8.52e-12	Testicular germ cell tumor;
LUSC	cis	rs11997175	0.646	rs66856932	chr8:33700782	A/G	ch.8.33884649F	chr8:33765107	NA	0.45	6.65	0.34	1.2e-10	Body mass index;
LUSC	cis	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.43	-0.33	4.47e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg14458575	chr2:238380390	NA	0.49	8.63	0.43	2.48e-16	Prostate cancer;
LUSC	cis	rs4917300	0.605	rs7820768	chr8:143110823	C/T	cg25363559	chr8:143086065	NA	-0.29	-6.51	-0.34	2.76e-10	Amyotrophic lateral sclerosis;
LUSC	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg11502198	chr6:26597334	ABT1	0.63	9.98	0.48	1.07e-20	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg27584171	chr15:49338887	SECISBP2L	0.8	6.22	0.32	1.46e-9	Cognitive performance;
LUSC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg09035930	chr12:129282057	SLC15A4	0.73	15.62	0.65	1.14e-41	Systemic lupus erythematosus;
LUSC	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-8.04	-0.4	1.55e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg21017887	chr14:105400489	NA	-0.71	-13.59	-0.6	8.35e-34	Rheumatoid arthritis;
LUSC	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.47	8.42	0.42	1.14e-15	HDL cholesterol;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	0.98	21.18	0.76	9.77e-64	Menarche (age at onset);
LUSC	cis	rs17373728	0.526	rs10957753	chr8:76133428	T/C	cg07016329	chr8:76221503	NA	0.43	6.07	0.31	3.57e-9	Diabetic kidney disease;
LUSC	cis	rs193541	0.626	rs6884058	chr5:122087298	T/C	cg19077854	chr5:122220652	SNX24	0.28	6.21	0.32	1.59e-9	Glucose homeostasis traits;
LUSC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25072359	chr17:41440525	NA	0.66	9.42	0.46	7.64e-19	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21143892	chr7:132937713	EXOC4	-0.45	-6.49	-0.33	3.06e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.72	-9.64	-0.47	1.43e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg24375607	chr4:120327624	NA	0.72	11.49	0.53	5.61e-26	Corneal astigmatism;
LUSC	cis	rs4363385	0.818	rs3181787	chr1:153004809	T/C	cg25856811	chr1:152973957	SPRR3	-0.35	-5.81	-0.3	1.47e-8	Inflammatory skin disease;
LUSC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	7.82	0.39	7.02e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg22800045	chr5:56110881	MAP3K1	-0.63	-8.81	-0.43	7.02e-17	Initial pursuit acceleration;
LUSC	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-13.69	-0.6	3.44e-34	Coronary artery disease;
LUSC	cis	rs870825	0.615	rs2696038	chr4:185610903	C/T	cg04058563	chr4:185651563	MLF1IP	-0.79	-12.05	-0.55	4.98e-28	Blood protein levels;
LUSC	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-0.6	-6.26	-0.32	1.17e-9	Hair shape;
LUSC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg17366294	chr4:99064904	C4orf37	0.58	10.21	0.49	1.83e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg11130432	chr3:121712080	ILDR1	-0.63	-9.61	-0.47	1.89e-19	Multiple sclerosis;
LUSC	cis	rs4363385	0.643	rs12734348	chr1:152924650	A/G	cg00922841	chr1:152955080	SPRR1A	-0.39	-6.56	-0.34	1.99e-10	Inflammatory skin disease;
LUSC	cis	rs62432291	0.614	rs370434	chr6:159654551	C/G	cg14500486	chr6:159655392	FNDC1	-0.52	-5.84	-0.3	1.22e-8	Joint mobility (Beighton score);
LUSC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg15704280	chr7:45808275	SEPT13	-0.53	-7.51	-0.38	5.47e-13	HDL cholesterol;
LUSC	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg08847533	chr14:75593920	NEK9	0.85	15.88	0.66	1.08e-42	Height;
LUSC	cis	rs4888262	0.545	rs7195499	chr16:74693973	C/G	cg01733217	chr16:74700730	RFWD3	0.8	13.24	0.59	1.94e-32	Testicular germ cell tumor;
LUSC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	2.02e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.3	0.69	2.6e-48	Chronic sinus infection;
LUSC	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg21153622	chr11:89784906	NA	-0.47	-7.25	-0.37	3.01e-12	Height;
LUSC	cis	rs13006833	0.668	rs2136569	chr2:191167414	C/T	cg21644426	chr2:191273491	MFSD6	-0.45	-6.49	-0.33	3.05e-10	Urinary metabolites;
LUSC	cis	rs7923609	0.934	rs10761763	chr10:65188318	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.01e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg13852791	chr20:30311386	BCL2L1	0.72	8.29	0.41	2.73e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg08219700	chr8:58056026	NA	0.46	6.12	0.32	2.59e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4474465	0.920	rs9804428	chr11:78158948	G/A	cg27205649	chr11:78285834	NARS2	-0.49	-5.85	-0.3	1.18e-8	Alzheimer's disease (survival time);
LUSC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg17264618	chr3:40429014	ENTPD3	0.3	6.29	0.33	9.8e-10	Renal cell carcinoma;
LUSC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg10729496	chr3:10149963	C3orf24	0.58	7.75	0.39	1.13e-13	Alzheimer's disease;
LUSC	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg24375607	chr4:120327624	NA	0.79	12.05	0.55	5.19e-28	Corneal astigmatism;
LUSC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg20384732	chr3:195601375	TNK2	0.37	5.96	0.31	6.51e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg08470875	chr2:26401718	FAM59B	-0.7	-9.1	-0.45	8.49e-18	Gut microbiome composition (summer);
LUSC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg00933542	chr6:150070202	PCMT1	-0.33	-6.74	-0.35	6.92e-11	Lung cancer;
LUSC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg07701084	chr6:150067640	NUP43	0.55	8.57	0.42	3.99e-16	Lung cancer;
LUSC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg05805236	chr11:65401703	PCNXL3	-0.38	-5.75	-0.3	2.05e-8	Breast cancer;
LUSC	trans	rs1325195	0.920	rs2171959	chr1:179087934	T/C	cg11624085	chr17:8464688	MYH10	-0.44	-7.38	-0.37	1.25e-12	IgE grass sensitization;
LUSC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg05973401	chr12:123451056	ABCB9	0.54	6.64	0.34	1.24e-10	Neutrophil percentage of white cells;
LUSC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg18230493	chr5:56204884	C5orf35	-0.65	-9.6	-0.47	1.94e-19	Type 2 diabetes;
LUSC	cis	rs4400599	0.600	rs12095767	chr1:154188028	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.93	-0.31	7.48e-9	Platelet distribution width;
LUSC	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg14154082	chr13:112174009	NA	0.38	7.84	0.39	6.29e-14	Menarche (age at onset);
LUSC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.22	0.45	3.32e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2688608	0.901	rs2633312	chr10:75631755	T/A	cg23231163	chr10:75533350	FUT11	-0.41	-6.43	-0.33	4.45e-10	Inflammatory bowel disease;
LUSC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg06627628	chr2:24431161	ITSN2	0.61	7.38	0.37	1.3e-12	Lymphocyte counts;
LUSC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg02569458	chr12:86230093	RASSF9	0.58	9.78	0.47	4.91e-20	Major depressive disorder;
LUSC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.57	0.6	1.05e-33	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg01191920	chr7:158217561	PTPRN2	-0.51	-10.6	-0.5	8.05e-23	Obesity-related traits;
LUSC	cis	rs12956009	0.518	rs3889651	chr18:44865012	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	6.62	0.34	1.41e-10	Educational attainment (years of education);
LUSC	cis	rs4947962	0.555	rs2538079	chr7:54986656	A/G	cg23757825	chr7:55092271	EGFR	0.63	7.67	0.39	1.95e-13	Subjective response to lithium treatment;
LUSC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.64	-0.73	1.22e-57	Height;
LUSC	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg16989719	chr2:238392110	NA	-0.38	-6.23	-0.32	1.42e-9	Prostate cancer;
LUSC	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg26408565	chr15:76604113	ETFA	-0.49	-7.86	-0.4	5.27e-14	Blood metabolite levels;
LUSC	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg23625390	chr15:77176239	SCAPER	0.46	7.04	0.36	1.09e-11	Blood metabolite levels;
LUSC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg23711669	chr6:146136114	FBXO30	0.71	11.86	0.54	2.48e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3947	0.950	rs1293331	chr8:11698436	C/T	cg00262122	chr8:11665843	FDFT1	-0.5	-5.82	-0.3	1.4e-8	Blood protein levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22585957	chr12:8234808	NECAP1	-0.41	-6.47	-0.33	3.47e-10	Electrocardiographic conduction measures;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21939482	chr7:6388130	C7orf70	0.45	6.2	0.32	1.71e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg12307764	chr15:40861449	RPUSD2	0.36	6.35	0.33	7.2e-10	Tuberculosis;
LUSC	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg00129232	chr17:37814104	STARD3	-0.54	-7.99	-0.4	2.22e-14	Asthma;
LUSC	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg14583973	chr4:3374767	RGS12	0.37	7.84	0.39	5.95e-14	Serum sulfate level;
LUSC	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg04989706	chr14:50066350	PPIL5	-0.44	-5.77	-0.3	1.85e-8	Carotid intima media thickness;
LUSC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg18827107	chr12:86230957	RASSF9	0.49	7.32	0.37	1.87e-12	Major depressive disorder;
LUSC	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-13.69	-0.6	3.72e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-8.06	-0.4	1.35e-14	Total cholesterol levels;
LUSC	cis	rs59104589	0.570	rs3771569	chr2:242382606	A/T	cg14842376	chr2:242211374	HDLBP	0.5	5.77	0.3	1.79e-8	Fibrinogen levels;
LUSC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-1.12	-25.08	-0.81	8.21e-79	Height;
LUSC	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg25214090	chr10:38739885	LOC399744	0.53	7.68	0.39	1.73e-13	Corneal astigmatism;
LUSC	cis	rs6961069	0.550	rs34493313	chr7:80246150	T/C	cg04458919	chr7:80252533	CD36	-0.39	-6.9	-0.35	2.58e-11	Platelet count;
LUSC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.78	-12.94	-0.58	2.43e-31	Aortic root size;
LUSC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg01483505	chr11:975446	AP2A2	0.41	5.66	0.3	3.29e-8	Alzheimer's disease (late onset);
LUSC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05165339	chr4:1420672	NA	0.28	6.47	0.33	3.53e-10	Obesity-related traits;
LUSC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg06740227	chr12:86229804	RASSF9	0.45	7.24	0.37	3.17e-12	Major depressive disorder;
LUSC	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg27427491	chr17:78079615	GAA	-0.32	-5.98	-0.31	5.69e-9	Yeast infection;
LUSC	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-16.94	-0.68	6.8e-47	Exhaled nitric oxide output;
LUSC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg07701084	chr6:150067640	NUP43	0.58	9.02	0.44	1.46e-17	Lung cancer;
LUSC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg22681709	chr2:178499509	PDE11A	-0.52	-9.65	-0.47	1.35e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7188861	0.681	rs66718203	chr16:11428643	C/G	cg00044050	chr16:11439710	C16orf75	0.59	5.92	0.31	8.11e-9	HDL cholesterol;
LUSC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg18230493	chr5:56204884	C5orf35	0.77	12.51	0.56	1.06e-29	Initial pursuit acceleration;
LUSC	cis	rs1808579	0.904	rs12457261	chr18:21146085	C/T	cg14672496	chr18:21087552	C18orf8	0.35	6.19	0.32	1.74e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg27411982	chr8:10470053	RP1L1	0.41	6.37	0.33	6.17e-10	Mood instability;
LUSC	cis	rs3126085	0.935	rs1496049	chr1:152161949	C/T	cg26876637	chr1:152193138	HRNR	-0.43	-5.81	-0.3	1.48e-8	Atopic dermatitis;
LUSC	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.89e-12	Blood metabolite levels;
LUSC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.44	-5.98	-0.31	5.62e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.05	12.84	0.57	6.06e-31	Sexual dysfunction (female);
LUSC	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg16482183	chr6:26056742	HIST1H1C	0.65	9.37	0.46	1.15e-18	Height;
LUSC	trans	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg26043149	chr18:55253948	FECH	-0.54	-8.06	-0.4	1.41e-14	Bone mineral density;
LUSC	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg08213375	chr14:104286397	PPP1R13B	0.44	7.54	0.38	4.61e-13	Reticulocyte count;
LUSC	cis	rs9925964	0.933	rs56314408	chr16:31117389	T/C	cg02466173	chr16:30829666	NA	-0.32	-5.95	-0.31	6.78e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg05425664	chr17:57184151	TRIM37	-0.54	-8.13	-0.41	8.36e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.44	-6.66	-0.34	1.15e-10	Platelet distribution width;
LUSC	cis	rs2879627	0.504	rs6480585	chr10:53673192	A/C	cg06976598	chr10:53639124	PRKG1	-0.43	-5.79	-0.3	1.63e-8	Coronary artery disease;
LUSC	trans	rs7916697	0.593	rs3740587	chr10:70020802	G/A	cg04882175	chr6:131122610	NA	0.46	6.08	0.32	3.21e-9	Optic disc area;
LUSC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg27165867	chr14:105738592	BRF1	0.52	7.72	0.39	1.33e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg06784218	chr1:46089804	CCDC17	-0.48	-9.38	-0.46	1.02e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg14019146	chr3:50243930	SLC38A3	0.35	7.79	0.39	8.56e-14	Body mass index;
LUSC	cis	rs12413816	0.963	rs12359348	chr10:13765950	C/T	cg16485048	chr10:13749193	FRMD4A	-0.46	-7.67	-0.39	1.86e-13	Red cell distribution width;
LUSC	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.83	-0.35	4.14e-11	Response to antipsychotic treatment;
LUSC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.69	0.3	2.75e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1172822	0.698	rs10425848	chr19:55834448	C/G	cg04391588	chr19:55832610	TMEM150B	0.3	5.91	0.31	8.49e-9	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs4919687	0.550	rs12761195	chr10:104465374	T/C	cg04362960	chr10:104952993	NT5C2	0.47	6.84	0.35	3.68e-11	Colorectal cancer;
LUSC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.99	0.55	8.84e-28	Personality dimensions;
LUSC	cis	rs983392	0.679	rs72920867	chr11:60005424	T/C	cg02771260	chr11:59836817	MS4A3	-0.36	-5.75	-0.3	1.98e-8	Alzheimer's disease (late onset);
LUSC	cis	rs727505	1.000	rs12111865	chr7:124498035	G/A	cg23710748	chr7:124431027	NA	-0.4	-7.18	-0.37	4.56e-12	Lewy body disease;
LUSC	cis	rs2637266	1.000	rs1907298	chr10:78329928	A/T	cg18941641	chr10:78392320	NA	0.38	6.86	0.35	3.37e-11	Pulmonary function;
LUSC	trans	rs17607347	0.542	rs16971114	chr16:72667858	T/C	cg12945194	chr11:64703312	GPHA2	0.37	5.99	0.31	5.53e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs8018967	1.000	rs8018967	chr14:73976934	A/G	cg19682024	chr14:74008259	HEATR4;ACOT1	-0.43	-6.01	-0.31	4.81e-9	Blood metabolite ratios;
LUSC	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.94	0.31	7.21e-9	Schizophrenia;
LUSC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg27398817	chr8:82754497	SNX16	0.44	5.95	0.31	6.79e-9	Diastolic blood pressure;
LUSC	cis	rs7119	0.717	rs12916515	chr15:77818518	G/T	cg27398640	chr15:77910606	LINGO1	-0.32	-6.92	-0.35	2.29e-11	Type 2 diabetes;
LUSC	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg02574844	chr11:5959923	NA	-0.46	-6.45	-0.33	4.02e-10	DNA methylation (variation);
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08258788	chr8:109455865	TTC35	0.52	6.92	0.35	2.26e-11	Neuroticism;
LUSC	cis	rs1322512	1.000	rs2758784	chr6:153010489	A/G	cg27316956	chr6:152958899	SYNE1	0.35	6.06	0.31	3.59e-9	Tonometry;
LUSC	cis	rs7580658	0.963	rs12463451	chr2:128053883	C/T	cg09760422	chr2:128146352	NA	-0.33	-7.27	-0.37	2.51e-12	Protein C levels;
LUSC	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg08773314	chr2:239334832	ASB1	0.43	9.34	0.46	1.42e-18	Multiple system atrophy;
LUSC	trans	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg18187862	chr3:45730750	SACM1L	-0.53	-6.69	-0.34	9.31e-11	Primary sclerosing cholangitis;
LUSC	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-8.91	-0.44	3.32e-17	Hip circumference adjusted for BMI;
LUSC	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg03929089	chr4:120376271	NA	0.66	7.36	0.37	1.42e-12	Axial length;
LUSC	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21545522	chr1:205238299	TMCC2	0.51	9.57	0.46	2.54e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg12963246	chr6:28129442	ZNF389	-0.44	-6.35	-0.33	6.87e-10	Depression;
LUSC	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg11812906	chr14:75593930	NEK9	-0.62	-10.08	-0.48	5.03e-21	Height;
LUSC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	7.83	0.39	6.49e-14	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg18825119	chr6:163149453	PACRG;PARK2	-0.38	-6.73	-0.35	7.56e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13385	0.769	rs7705090	chr5:139618146	C/G	cg26211634	chr5:139558579	C5orf32	0.46	6.74	0.35	7.11e-11	Atrial fibrillation;
LUSC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.1	16.96	0.68	5.39e-47	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs11209002	0.956	rs10749772	chr1:67586231	A/G	cg02640540	chr1:67518911	SLC35D1	0.67	7.34	0.37	1.69e-12	Crohn's disease;
LUSC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.97	-16.77	-0.68	3.3e-46	Cognitive ability;
LUSC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg07716408	chr11:68623521	NA	-0.32	-6.09	-0.32	3.16e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg01579765	chr21:45077557	HSF2BP	-0.49	-10.31	-0.49	7.85e-22	Mean corpuscular volume;
LUSC	cis	rs16910800	0.689	rs56101126	chr11:23188861	T/A	cg20040320	chr11:23191996	NA	-0.59	-7.63	-0.39	2.4e-13	Cancer;
LUSC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg26338869	chr17:61819248	STRADA	0.41	5.8	0.3	1.52e-8	Prudent dietary pattern;
LUSC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.52	0.34	2.54e-10	Schizophrenia;
LUSC	cis	rs12210905	0.610	rs12204953	chr6:27396737	G/A	cg08851530	chr6:28072375	NA	0.93	5.77	0.3	1.77e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs28647808	1.000	rs28591209	chr9:136259668	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11644478	chr21:40555479	PSMG1	-0.62	-9.62	-0.47	1.74e-19	Menarche (age at onset);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22963414	chr14:73493969	ZFYVE1	-0.5	-6.6	-0.34	1.65e-10	Hepatitis;
LUSC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs796825	0.512	rs34964758	chr3:119942440	A/C	cg21790991	chr3:120137480	FSTL1	-0.33	-5.83	-0.3	1.32e-8	HIV-1 susceptibility;
LUSC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg05623727	chr3:50126028	RBM5	0.37	6.89	0.35	2.86e-11	Body mass index;
LUSC	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.5e-8	Breast cancer;
LUSC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg04352962	chr1:209979756	IRF6	0.55	6.46	0.33	3.73e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg10326726	chr10:51549505	MSMB	0.34	5.94	0.31	7.09e-9	Prostate-specific antigen levels;
LUSC	cis	rs28719689	0.541	rs28376074	chr8:1274394	A/T	cg22761795	chr8:1265118	NA	0.56	6.48	0.33	3.27e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg22963979	chr7:1858916	MAD1L1	-0.58	-8.9	-0.44	3.65e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.36	0.42	1.68e-15	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg05347473	chr6:146136440	FBXO30	-0.59	-10.26	-0.49	1.22e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg11189052	chr15:85197271	WDR73	0.5	6.33	0.33	7.89e-10	Schizophrenia;
LUSC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg27170947	chr2:26402098	FAM59B	-0.7	-10.84	-0.51	1.17e-23	Gut microbiome composition (summer);
LUSC	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg12826209	chr6:26865740	GUSBL1	0.68	7.67	0.39	1.85e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.34	-5.76	-0.3	1.95e-8	Axial length;
LUSC	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg25214090	chr10:38739885	LOC399744	0.57	8.37	0.42	1.56e-15	Corneal astigmatism;
LUSC	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg06026331	chr20:60912101	LAMA5	0.6	7.28	0.37	2.37e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9549260	0.848	rs966968	chr13:41248037	C/T	cg21288729	chr13:41239152	FOXO1	-0.6	-9.11	-0.45	7.62e-18	Red blood cell count;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00573086	chr4:2010926	WHSC2	0.38	6.03	0.31	4.25e-9	Asthma;
LUSC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.61	8.0	0.4	2.1e-14	Response to diuretic therapy;
LUSC	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.9	-0.4	4.07e-14	Glomerular filtration rate;
LUSC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.99	-17.59	-0.69	1.74e-49	Coronary artery disease;
LUSC	cis	rs6460942	0.908	rs75704904	chr7:12233583	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.09	-0.32	3.08e-9	Coronary artery disease;
LUSC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg17279839	chr7:150038598	RARRES2	0.43	6.65	0.34	1.22e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg08000102	chr2:233561755	GIGYF2	-0.5	-7.66	-0.39	2.03e-13	Coronary artery disease;
LUSC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg09796270	chr17:17721594	SREBF1	-0.4	-7.16	-0.36	5.2e-12	Total body bone mineral density;
LUSC	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.38	-5.65	-0.3	3.41e-8	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg01181863	chr3:195395398	SDHAP2	-0.53	-5.81	-0.3	1.48e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7923609	1.000	rs4379723	chr10:64963449	T/C	cg01631684	chr10:65280961	REEP3	-0.4	-6.26	-0.32	1.19e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21293242	chr8:11204541	TDH	-0.3	-5.84	-0.3	1.25e-8	Retinal vascular caliber;
LUSC	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.95	-0.31	6.69e-9	Reticulocyte count;
LUSC	cis	rs7124681	0.584	rs1471712	chr11:47912150	G/A	cg20307385	chr11:47447363	PSMC3	-0.52	-7.93	-0.4	3.3e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.94	0.44	2.61e-17	Prudent dietary pattern;
LUSC	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2230307	0.536	rs11166407	chr1:100637708	C/T	cg24955406	chr1:100503596	HIAT1	0.57	6.23	0.32	1.4e-9	Carotid intima media thickness;
LUSC	cis	rs6840360	1.000	rs2007218	chr4:152643972	A/G	cg22705602	chr4:152727874	NA	0.28	5.97	0.31	6.11e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg20734569	chr3:48348370	SPINK8	-0.46	-8.09	-0.4	1.11e-14	Coronary artery disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00320862	chr3:170588302	RPL22L1	-0.48	-5.95	-0.31	6.6e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4776059	0.959	rs12898644	chr15:52905233	A/G	cg25063058	chr15:52860530	ARPP19	0.41	5.69	0.3	2.78e-8	Schizophrenia;
LUSC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg07636037	chr3:49044803	WDR6	-0.44	-6.49	-0.33	3.15e-10	Resting heart rate;
LUSC	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg15711740	chr2:61764176	XPO1	-0.5	-7.92	-0.4	3.58e-14	Tuberculosis;
LUSC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	0.95	18.51	0.71	3.91e-53	Cognitive function;
LUSC	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg15934090	chr1:100435551	SLC35A3	0.48	8.32	0.41	2.2e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg03684893	chr10:554711	DIP2C	-0.38	-7.08	-0.36	8.42e-12	Psychosis in Alzheimer's disease;
LUSC	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-1.09	-24.93	-0.81	3.14e-78	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-7.97	-0.4	2.6e-14	Homoarginine levels;
LUSC	trans	rs853679	0.546	rs200949	chr6:27835435	A/G	cg01620082	chr3:125678407	NA	-0.62	-6.53	-0.34	2.45e-10	Depression;
LUSC	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg15704280	chr7:45808275	SEPT13	-0.92	-14.23	-0.61	3.04e-36	Coronary artery disease;
LUSC	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	13.91	0.61	5.27e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs10411161	0.702	rs7250138	chr19:52385232	G/C	cg22319618	chr22:45562946	NUP50	-0.49	-5.94	-0.31	6.97e-9	Breast cancer;
LUSC	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.86	-0.31	1.13e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg07701084	chr6:150067640	NUP43	0.5	7.48	0.38	6.61e-13	Lung cancer;
LUSC	cis	rs7727544	0.582	rs3792894	chr5:131547271	C/T	cg14196790	chr5:131705035	SLC22A5	0.4	6.85	0.35	3.54e-11	Blood metabolite levels;
LUSC	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg26384229	chr12:38710491	ALG10B	0.49	7.02	0.36	1.28e-11	Morning vs. evening chronotype;
LUSC	cis	rs62400317	0.826	rs10807321	chr6:45330974	T/C	cg18551225	chr6:44695536	NA	-0.44	-7.32	-0.37	1.92e-12	Total body bone mineral density;
LUSC	cis	rs9311676	0.632	rs56033718	chr3:58446398	A/G	cg26110898	chr3:58419937	PDHB	0.41	6.83	0.35	4.11e-11	Systemic lupus erythematosus;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22712797	chr1:65720580	NA	0.44	6.13	0.32	2.5e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg01528321	chr10:82214614	TSPAN14	0.63	9.13	0.45	6.88e-18	Post bronchodilator FEV1;
LUSC	cis	rs2219968	0.701	rs1994035	chr8:79003651	C/T	cg00738934	chr8:78996279	NA	-0.4	-7.25	-0.37	2.84e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg04362960	chr10:104952993	NT5C2	-0.46	-5.92	-0.31	7.92e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.28	6.12	0.32	2.61e-9	Electroencephalogram traits;
LUSC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg04414720	chr1:150670196	GOLPH3L	0.57	9.13	0.45	6.81e-18	Tonsillectomy;
LUSC	cis	rs716595	1.000	rs12412423	chr10:112002170	C/G	cg13996003	chr10:112034540	MXI1	-0.71	-5.8	-0.3	1.55e-8	Normalized brain volume;
LUSC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.2	13.62	0.6	6.4e-34	Diabetic kidney disease;
LUSC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.18	0.41	6.01e-15	Parkinson's disease;
LUSC	cis	rs7589342	0.899	rs879900	chr2:106494347	A/G	cg14210321	chr2:106509881	NCK2	-0.57	-8.69	-0.43	1.66e-16	Addiction;
LUSC	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg12940439	chr1:67600707	NA	0.39	6.42	0.33	4.68e-10	Psoriasis;
LUSC	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg03342759	chr3:160939853	NMD3	-0.5	-8.44	-0.42	9.97e-16	Morning vs. evening chronotype;
LUSC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.23	0.45	3.24e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg21782813	chr7:2030301	MAD1L1	0.36	5.97	0.31	5.91e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2882667	0.537	rs7704790	chr5:138410096	A/C	cg04439458	chr5:138467593	SIL1	-0.33	-6.73	-0.35	7.56e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg05855489	chr10:104503620	C10orf26	-0.67	-9.93	-0.48	1.56e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg05738196	chr6:26577821	NA	0.79	14.93	0.63	5.72e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs652260	0.819	rs55656533	chr19:7902976	G/C	cg26014689	chr19:7917955	EVI5L	-0.49	-8.57	-0.42	3.87e-16	Menarche (age at onset);
LUSC	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg21045802	chr8:109455806	TTC35	0.42	6.65	0.34	1.17e-10	Dupuytren's disease;
LUSC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg00745463	chr17:30367425	LRRC37B	-0.81	-9.49	-0.46	4.37e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.15	0.32	2.18e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs12136530	0.774	rs12092284	chr1:19778323	C/T	cg01832549	chr1:19774989	CAPZB	-0.32	-5.72	-0.3	2.34e-8	Lead levels in blood;
LUSC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg12463550	chr7:65579703	CRCP	0.41	5.93	0.31	7.77e-9	Aortic root size;
LUSC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-11.84	-0.54	3.05e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05901451	chr6:126070800	HEY2	0.57	8.54	0.42	4.71e-16	Endometrial cancer;
LUSC	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg05973401	chr12:123451056	ABCB9	0.53	6.52	0.34	2.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs2455601	1.000	rs7104661	chr11:8902501	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.5	-7.66	-0.39	2e-13	Schizophrenia;
LUSC	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg09904177	chr6:26538194	HMGN4	0.75	14.37	0.62	8.69e-37	Intelligence (multi-trait analysis);
LUSC	cis	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg26958806	chr6:27640298	NA	0.77	6.55	0.34	2.23e-10	Urinary tract infection frequency;
LUSC	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg27284194	chr4:1044797	NA	0.6	8.95	0.44	2.51e-17	Recombination rate (females);
LUSC	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg19052272	chr2:3704530	ALLC	0.47	8.34	0.42	2.01e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs12541635	1.000	rs11992752	chr8:107083122	G/A	cg10147462	chr8:107024639	NA	-0.47	-8.61	-0.43	2.85e-16	Age of smoking initiation;
LUSC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg21724239	chr8:58056113	NA	0.56	6.9	0.35	2.7e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg27535305	chr1:53392650	SCP2	-0.48	-9.58	-0.46	2.21e-19	Monocyte count;
LUSC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.23	0.52	4.91e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4729127	1.000	rs7799378	chr7:94007546	C/G	cg08292968	chr12:111020671	PPTC7	-0.56	-5.98	-0.31	5.84e-9	Intelligence;
LUSC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg03563238	chr19:33554763	RHPN2	-0.37	-6.23	-0.32	1.37e-9	Bone properties (heel);
LUSC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg19077165	chr18:44547161	KATNAL2	-0.43	-6.23	-0.32	1.43e-9	Personality dimensions;
LUSC	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg13010199	chr12:38710504	ALG10B	0.52	7.88	0.4	4.63e-14	Morning vs. evening chronotype;
LUSC	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg05507819	chr15:63340323	TPM1	0.64	8.98	0.44	1.95e-17	Platelet count;
LUSC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.25	-0.32	1.22e-9	Sudden cardiac arrest;
LUSC	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg12483005	chr1:23474871	LUZP1	0.42	6.63	0.34	1.36e-10	Height;
LUSC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7605827	0.930	rs11676730	chr2:15563573	C/T	cg19274914	chr2:15703543	NA	0.46	8.62	0.43	2.76e-16	Educational attainment (years of education);
LUSC	trans	rs12637928	0.580	rs55688192	chr3:110183424	A/T	cg17371621	chr15:61264283	RORA	0.36	6.0	0.31	5.1e-9	Neuroticism;
LUSC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.87	16.68	0.67	7.3e-46	Mean platelet volume;
LUSC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.62	0.54	2e-26	Prudent dietary pattern;
LUSC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25072359	chr17:41440525	NA	0.68	9.5	0.46	4.34e-19	Menopause (age at onset);
LUSC	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg22782873	chr19:19639568	YJEFN3	-0.48	-5.79	-0.3	1.64e-8	Bipolar disorder;
LUSC	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.16	-0.32	2.07e-9	Total body bone mineral density;
LUSC	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg24375607	chr4:120327624	NA	0.74	11.15	0.52	9.57e-25	Corneal astigmatism;
LUSC	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg13010199	chr12:38710504	ALG10B	-0.53	-8.1	-0.41	1.03e-14	Morning vs. evening chronotype;
LUSC	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg07936489	chr17:37558343	FBXL20	-0.72	-9.75	-0.47	6.34e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00714198	chr3:12705702	RAF1	-0.43	-6.18	-0.32	1.84e-9	Electrocardiographic conduction measures;
LUSC	cis	rs56283067	0.847	rs12215181	chr6:44736076	C/T	cg18551225	chr6:44695536	NA	-0.49	-8.41	-0.42	1.17e-15	Total body bone mineral density;
LUSC	trans	rs12614435	0.512	rs2472751	chr2:179539903	C/A	cg14011486	chr1:26737247	LIN28	0.5	6.47	0.33	3.57e-10	Atrial fibrillation;
LUSC	cis	rs8141797	0.710	rs9612563	chr22:24597540	A/C	cg00411358	chr22:24577142	SUSD2	-0.6	-5.79	-0.3	1.65e-8	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg19875535	chr5:140030758	IK	0.46	7.32	0.37	1.91e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	0.83	14.07	0.61	1.24e-35	Tonsillectomy;
LUSC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg27535305	chr1:53392650	SCP2	0.39	7.38	0.37	1.25e-12	Monocyte count;
LUSC	cis	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05901451	chr6:126070800	HEY2	0.58	8.86	0.44	4.86e-17	Endometrial cancer;
LUSC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg12927641	chr6:109611667	NA	-0.41	-7.07	-0.36	9.3e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg03909863	chr11:638404	DRD4	-0.4	-5.91	-0.31	8.46e-9	Systemic lupus erythematosus;
LUSC	cis	rs7712401	0.601	rs40818	chr5:122295073	T/C	cg19077854	chr5:122220652	SNX24	0.43	9.81	0.47	3.89e-20	Mean platelet volume;
LUSC	cis	rs1358748	0.522	rs4655516	chr1:67579882	A/C	cg02640540	chr1:67518911	SLC35D1	0.63	6.1	0.32	2.9e-9	Tuberculosis;
LUSC	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.39	-0.42	1.35e-15	Coffee consumption (cups per day);
LUSC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-10.56	-0.5	1.08e-22	Alzheimer's disease (late onset);
LUSC	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.97	0.51	3.99e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.7	-12.77	-0.57	1.14e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg23711669	chr6:146136114	FBXO30	0.88	16.13	0.66	1.12e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg26384229	chr12:38710491	ALG10B	0.65	10.52	0.5	1.55e-22	Morning vs. evening chronotype;
LUSC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg26354017	chr1:205819088	PM20D1	0.53	8.6	0.43	3.06e-16	Menarche (age at onset);
LUSC	cis	rs7000551	0.715	rs2461478	chr8:22378236	A/G	cg12081754	chr8:22256438	SLC39A14	0.47	7.02	0.36	1.23e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7799006	0.929	rs6461233	chr7:2261468	G/A	cg02951883	chr7:2050386	MAD1L1	-0.36	-6.03	-0.31	4.34e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9815354	1.000	rs9847975	chr3:41786904	A/G	cg03022575	chr3:42003672	ULK4	0.65	6.92	0.35	2.3e-11	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg13265914	chr8:21999630	REEP4	0.48	6.16	0.32	2.09e-9	Cognitive function;Information processing speed;
LUSC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.21e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg27094323	chr7:1216898	NA	-0.37	-6.53	-0.34	2.51e-10	Longevity;Endometriosis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21780294	chr1:43637871	EBNA1BP2;WDR65	-0.41	-6.07	-0.32	3.52e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg00431813	chr7:1051703	C7orf50	-0.43	-6.77	-0.35	5.84e-11	Longevity;Endometriosis;
LUSC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg02896835	chr1:92012615	NA	-0.65	-11.63	-0.54	1.79e-26	Breast cancer;
LUSC	cis	rs6693567	0.545	rs11205375	chr1:150412474	C/T	cg15654264	chr1:150340011	RPRD2	0.44	7.11	0.36	7.28e-12	Migraine;
LUSC	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	1.08	15.88	0.66	1.05e-42	Primary sclerosing cholangitis;
LUSC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg09455208	chr3:40491958	NA	0.51	9.26	0.45	2.49e-18	Renal cell carcinoma;
LUSC	trans	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg06606381	chr12:133084897	FBRSL1	-0.91	-7.77	-0.39	9.91e-14	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs17155006	0.746	rs419031	chr7:107750157	G/A	cg05962710	chr7:107745446	LAMB4	-0.36	-6.36	-0.33	6.54e-10	Pneumococcal bacteremia;
LUSC	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg14631576	chr9:95140430	CENPP	-0.31	-5.68	-0.3	3.01e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg22508957	chr16:3507546	NAT15	0.86	10.92	0.51	5.95e-24	Tuberculosis;
LUSC	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	7.5	0.38	5.97e-13	Schizophrenia;
LUSC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	0.83	15.24	0.64	3.35e-40	Height;
LUSC	cis	rs13418410	0.539	rs11677468	chr2:33839053	T/C	cg04131969	chr2:33951647	MYADML	-0.71	-10.5	-0.5	1.8e-22	Non-response to antidepressants and depression;
LUSC	cis	rs727505	1.000	rs68091803	chr7:124526331	C/T	cg23710748	chr7:124431027	NA	-0.42	-7.42	-0.38	1e-12	Lewy body disease;
LUSC	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg05283184	chr6:79620031	NA	-0.57	-11.77	-0.54	5.39e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg11344533	chr11:111475393	SIK2	-0.49	-6.89	-0.35	2.86e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1692580	0.870	rs263533	chr1:2163568	C/T	cg24578937	chr1:2090814	PRKCZ	0.38	7.98	0.4	2.44e-14	Coronary artery disease;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07870486	chr7:56019566	MRPS17	-0.44	-6.43	-0.33	4.41e-10	Electrocardiographic conduction measures;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21194911	chr19:44716733	ZNF227	0.42	5.99	0.31	5.39e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-0.81	-16.0	-0.66	3.69e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9921338	0.887	rs13330151	chr16:11402399	C/T	cg00044050	chr16:11439710	C16orf75	-0.52	-6.72	-0.35	7.87e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg21138405	chr5:131827807	IRF1	-0.33	-5.79	-0.3	1.61e-8	Breast cancer;Mosquito bite size;
LUSC	trans	rs7944735	0.567	rs7946766	chr11:48004369	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.01	0.31	4.94e-9	Intraocular pressure;
LUSC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.64	9.84	0.47	3.11e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	0.7	11.08	0.52	1.68e-24	Blood metabolite ratios;
LUSC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7923609	0.703	rs7100413	chr10:65330208	T/C	cg01631684	chr10:65280961	REEP3	0.4	5.97	0.31	6.15e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg02800362	chr5:177631904	HNRNPAB	0.88	13.12	0.58	5.45e-32	Obesity-related traits;
LUSC	cis	rs12286929	0.610	rs11606838	chr11:115042859	C/A	cg04055981	chr11:115044050	NA	0.41	7.46	0.38	7.46e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg24399712	chr22:39784796	NA	-0.56	-8.96	-0.44	2.32e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg11494091	chr17:61959527	GH2	0.39	6.67	0.34	1.07e-10	Height;
LUSC	cis	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg05084668	chr3:125655381	ALG1L	-0.74	-11.37	-0.53	1.55e-25	Blood pressure (smoking interaction);
LUSC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg12365402	chr11:9010492	NRIP3	-0.48	-8.9	-0.44	3.55e-17	Hemoglobin concentration;
LUSC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg12963246	chr6:28129442	ZNF389	0.43	6.15	0.32	2.26e-9	Depression;
LUSC	cis	rs4965006	1.000	rs4965006	chr12:132419533	A/G	cg00588090	chr12:132412438	PUS1	-0.44	-7.61	-0.38	2.84e-13	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs34421088	0.506	rs2572428	chr8:11146672	T/A	cg06636001	chr8:8085503	FLJ10661	0.49	7.41	0.38	1.07e-12	Neuroticism;
LUSC	cis	rs977987	0.806	rs7202596	chr16:75491072	G/T	cg04384234	chr16:75411784	CFDP1	-0.43	-6.99	-0.36	1.49e-11	Dupuytren's disease;
LUSC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg08975724	chr8:8085496	FLJ10661	0.6	9.0	0.44	1.8e-17	Neuroticism;
LUSC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg05717871	chr11:638507	DRD4	-0.37	-6.15	-0.32	2.18e-9	Systemic lupus erythematosus;
LUSC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	0.79	15.58	0.65	1.68e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg03146154	chr1:46216737	IPP	0.51	7.66	0.39	2.08e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.89	15.22	0.64	4.2e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.03	0.44	1.35e-17	Lung cancer in ever smokers;
LUSC	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.7	10.54	0.5	1.25e-22	Corneal astigmatism;
LUSC	cis	rs354225	0.544	rs28581481	chr2:54812372	T/G	cg26097391	chr2:54893211	SPTBN1	0.42	6.44	0.33	4.18e-10	Schizophrenia;
LUSC	cis	rs9309473	0.950	rs10178678	chr2:73762236	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-6.51	-0.34	2.83e-10	Metabolite levels;
LUSC	cis	rs7590368	0.683	rs72779459	chr2:10960650	T/C	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-0.76	-12.13	-0.55	2.63e-28	Height;
LUSC	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg20026190	chr17:76395443	PGS1	0.46	8.2	0.41	5.16e-15	HDL cholesterol levels;
LUSC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg11871910	chr12:69753446	YEATS4	0.85	14.8	0.63	1.9e-38	Blood protein levels;
LUSC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06634786	chr22:41940651	POLR3H	-0.6	-6.93	-0.35	2.13e-11	Vitiligo;
LUSC	cis	rs1375194	0.582	rs13388224	chr2:33802902	T/C	cg04131969	chr2:33951647	MYADML	-0.64	-8.85	-0.44	5.04e-17	Response to antidepressants in depression;
LUSC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg06784218	chr1:46089804	CCDC17	0.56	11.62	0.54	1.92e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs926938	0.527	rs360666	chr1:115481290	C/T	cg01522456	chr1:115632236	TSPAN2	-0.4	-6.33	-0.33	8.08e-10	Autism;
LUSC	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg25456477	chr12:86230367	RASSF9	-0.33	-5.72	-0.3	2.41e-8	Major depressive disorder;
LUSC	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg19680485	chr15:31195859	MTMR15	-0.46	-6.14	-0.32	2.37e-9	Huntington's disease progression;
LUSC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.49	-8.72	-0.43	1.3e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg06096015	chr1:231504339	EGLN1	0.57	10.18	0.49	2.31e-21	Hemoglobin concentration;
LUSC	cis	rs11229555	0.645	rs17474373	chr11:58191243	G/A	cg15696309	chr11:58395628	NA	-0.67	-8.13	-0.41	8.64e-15	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs727505	1.000	rs727505	chr7:124462081	C/T	cg23710748	chr7:124431027	NA	-0.41	-7.52	-0.38	4.95e-13	Lewy body disease;
LUSC	trans	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg26384229	chr12:38710491	ALG10B	0.56	8.61	0.43	3.03e-16	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.93	-0.44	2.88e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.05	-0.36	1.06e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg18681998	chr4:17616180	MED28	0.81	14.59	0.62	1.22e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-1.04	-20.32	-0.74	2.46e-60	Height;
LUSC	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg14227996	chr4:17616232	MED28	0.77	7.69	0.39	1.68e-13	Opioid sensitivity;
LUSC	cis	rs6736093	0.966	rs34705448	chr2:112730089	C/T	cg12686935	chr2:112915763	FBLN7	-0.37	-5.96	-0.31	6.32e-9	Coronary artery disease;
LUSC	cis	rs290268	0.669	rs10448310	chr9:93556174	A/G	cg02608019	chr9:93564028	SYK	0.5	8.01	0.4	1.93e-14	Platelet count;
LUSC	cis	rs4285028	0.747	rs6791882	chr3:121373058	T/C	cg11130432	chr3:121712080	ILDR1	-0.57	-8.17	-0.41	6.35e-15	Multiple sclerosis;
LUSC	trans	rs9951602	0.651	rs2959408	chr18:76681702	T/C	cg02800362	chr5:177631904	HNRNPAB	-0.6	-6.87	-0.35	3.24e-11	Obesity-related traits;
LUSC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06850241	chr22:41845214	NA	0.3	5.75	0.3	2.05e-8	Vitiligo;
LUSC	cis	rs950173	1.000	rs6716901	chr2:172673453	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.65	-6.5	-0.34	2.92e-10	Hippocampal volume;
LUSC	cis	rs7560272	0.723	rs2421548	chr2:73641240	A/G	cg20560298	chr2:73613845	ALMS1	0.46	7.19	0.37	4.3e-12	Schizophrenia;
LUSC	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-10.49	-0.5	1.96e-22	Chronic sinus infection;
LUSC	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg16928487	chr17:17741425	SREBF1	-0.43	-8.42	-0.42	1.09e-15	Total body bone mineral density;
LUSC	trans	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.68	-8.56	-0.42	4.31e-16	Type 2 diabetes;
LUSC	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg19682013	chr15:45996608	NA	0.39	5.84	0.3	1.24e-8	Waist circumference;Weight;
LUSC	cis	rs4474465	0.679	rs10899537	chr11:78222424	C/G	cg27205649	chr11:78285834	NARS2	0.49	5.69	0.3	2.74e-8	Alzheimer's disease (survival time);
LUSC	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg18681998	chr4:17616180	MED28	0.8	13.75	0.6	2.1e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg14530993	chr4:882597	GAK	0.67	7.39	0.37	1.21e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg12386194	chr3:101231763	SENP7	0.52	7.12	0.36	6.48e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4343996	0.935	rs4722673	chr7:3357183	C/G	cg21248987	chr7:3385318	SDK1	-0.36	-6.16	-0.32	2.04e-9	Motion sickness;
LUSC	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg00944433	chr1:107599041	PRMT6	-0.33	-6.04	-0.31	4e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg17031739	chr1:67600172	NA	0.39	5.99	0.31	5.48e-9	Psoriasis;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26734912	chr5:128430241	ISOC1	0.46	6.08	0.32	3.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.87	12.67	0.57	2.67e-30	Initial pursuit acceleration;
LUSC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg04455712	chr21:45112962	RRP1B	0.45	8.48	0.42	7.21e-16	Mean corpuscular volume;
LUSC	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg03060546	chr3:49711283	APEH	0.63	7.53	0.38	4.92e-13	Menarche (age at onset);
LUSC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.04	20.95	0.75	8.37e-63	Cognitive function;
LUSC	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg22535103	chr8:58192502	C8orf71	-0.66	-7.38	-0.37	1.29e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg07701084	chr6:150067640	NUP43	0.5	7.44	0.38	8.36e-13	Lung cancer;
LUSC	cis	rs2324229	0.861	rs1180201	chr6:83957742	C/G	cg08257003	chr6:84140564	ME1	-0.25	-5.98	-0.31	5.72e-9	Platelet-derived growth factor BB levels;
LUSC	cis	rs9467160	0.651	rs9393558	chr6:24454196	G/T	cg20631270	chr6:24437470	GPLD1	0.38	5.99	0.31	5.39e-9	Liver enzyme levels;
LUSC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs28655083	0.879	rs1502444	chr16:77059172	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.42	-6.41	-0.33	5.06e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg20203395	chr5:56204925	C5orf35	-0.46	-6.81	-0.35	4.53e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7215564	0.908	rs34950888	chr17:78661779	T/G	cg23238734	chr17:78661607	RPTOR	0.47	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	trans	rs1941687	0.672	rs1026257	chr18:31418131	C/T	cg27147174	chr7:100797783	AP1S1	0.45	6.81	0.35	4.53e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs11997175	0.646	rs6984073	chr8:33700070	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	6.65	0.34	1.2e-10	Body mass index;
LUSC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg06096015	chr1:231504339	EGLN1	0.54	9.31	0.45	1.7e-18	Hemoglobin concentration;
LUSC	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg22903471	chr2:27725779	GCKR	-0.39	-6.53	-0.34	2.46e-10	Total body bone mineral density;
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg17541715	chr7:1216824	NA	-0.38	-6.05	-0.31	3.97e-9	Longevity;Endometriosis;
LUSC	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.48	-0.33	3.21e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7953508	0.750	rs11107119	chr12:93983132	T/A	cg18151635	chr12:93972918	NA	-0.56	-7.81	-0.39	7.49e-14	Pubertal anthropometrics;
LUSC	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22496380	chr5:211416	CCDC127	-0.87	-8.93	-0.44	2.83e-17	Breast cancer;
LUSC	cis	rs9653442	0.545	rs11681227	chr2:100754997	A/G	cg07810366	chr2:100720526	AFF3	-0.45	-7.65	-0.39	2.11e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.79	0.3	1.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2286885	0.965	rs4837092	chr9:129250251	T/C	cg15282417	chr9:129245246	FAM125B	0.38	6.3	0.33	9.57e-10	Intraocular pressure;
LUSC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg05844789	chr1:228464394	OBSCN	-0.3	-5.71	-0.3	2.54e-8	Diastolic blood pressure;
LUSC	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	9.04	0.44	1.25e-17	Neuroticism;
LUSC	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.37	0.33	6.32e-10	IgG glycosylation;
LUSC	cis	rs2290159	0.800	rs59821954	chr3:12687613	T/C	cg23032965	chr3:12705835	RAF1	0.73	9.09	0.45	8.9e-18	Cholesterol, total;
LUSC	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg03676636	chr4:99064102	C4orf37	0.36	8.1	0.41	1.07e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg25838465	chr1:92012736	NA	-0.45	-6.28	-0.33	1.04e-9	Eosinophil percentage of white cells;
LUSC	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg13073564	chr4:8508604	NA	-0.45	-8.29	-0.41	2.84e-15	Response to antineoplastic agents;
LUSC	cis	rs1044826	0.957	rs9882014	chr3:139176535	C/T	cg00490450	chr3:139108681	COPB2	0.5	6.61	0.34	1.5e-10	Obesity-related traits;
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.32	-0.41	2.27e-15	Lymphocyte counts;
LUSC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg19046167	chr17:80928561	B3GNTL1	0.39	6.31	0.33	8.72e-10	Breast cancer;
LUSC	cis	rs4665630	0.522	rs889866	chr2:23885168	A/G	cg08063864	chr2:24346004	PFN4;LOC375190	-0.73	-6.7	-0.34	8.74e-11	Hypertension;
LUSC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	trans	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17712092	chr4:129076599	LARP1B	-0.83	-12.42	-0.56	2.28e-29	Eosinophil percentage of white cells;
LUSC	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg23649088	chr2:200775458	C2orf69	0.49	6.71	0.34	8.6e-11	Schizophrenia;
LUSC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg17143192	chr8:8559678	CLDN23	0.64	9.54	0.46	3.03e-19	Obesity-related traits;
LUSC	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg14689365	chr7:158441557	NCAPG2	0.52	7.53	0.38	4.76e-13	Height;
LUSC	cis	rs12594515	1.000	rs11855509	chr15:45995474	C/T	cg01629716	chr15:45996671	NA	0.39	5.87	0.31	1.08e-8	Waist circumference;Weight;
LUSC	cis	rs7760949	0.963	rs1571565	chr6:13907185	A/G	cg27413430	chr6:13925136	RNF182	0.5	7.46	0.38	7.54e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg08270630	chr22:50330655	NA	-0.42	-6.43	-0.33	4.43e-10	Schizophrenia;
LUSC	cis	rs7809950	0.911	rs7778250	chr7:107224565	C/A	cg23024343	chr7:107201750	COG5	0.58	8.98	0.44	2.01e-17	Coronary artery disease;
LUSC	cis	rs4356932	1.000	rs9884374	chr4:76946718	A/T	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23797839	chr10:60094994	UBE2D1	0.39	6.66	0.34	1.13e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6484504	0.576	rs208091	chr11:31190099	G/C	cg14844989	chr11:31128820	NA	-0.37	-5.83	-0.3	1.27e-8	Red blood cell count;
LUSC	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg08213375	chr14:104286397	PPP1R13B	0.44	7.88	0.4	4.56e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.57	-11.77	-0.54	5.28e-27	Sense of smell;
LUSC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.06e-9	Testicular germ cell tumor;
LUSC	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.69	12.27	0.56	8.27e-29	White blood cell count (basophil);White blood cell count;
LUSC	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg15468180	chr1:107600409	PRMT6	-0.38	-6.12	-0.32	2.64e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg11344533	chr11:111475393	SIK2	-0.46	-6.35	-0.33	6.87e-10	Primary sclerosing cholangitis;
LUSC	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg24130564	chr14:104152367	KLC1	-0.41	-5.91	-0.31	8.4e-9	Body mass index;
LUSC	cis	rs2230307	0.572	rs11805428	chr1:100641716	T/C	cg24955406	chr1:100503596	HIAT1	-0.56	-5.75	-0.3	2.03e-8	Carotid intima media thickness;
LUSC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.41	6.27	0.32	1.09e-9	Platelet count;
LUSC	cis	rs12753569	0.934	rs10430051	chr1:76491628	T/G	cg00791851	chr1:76518896	NA	-0.31	-5.9	-0.31	8.69e-9	Personality dimensions;
LUSC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg02018176	chr4:1364513	KIAA1530	0.45	7.37	0.37	1.39e-12	Obesity-related traits;
LUSC	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg14458575	chr2:238380390	NA	0.68	12.06	0.55	4.8e-28	Prostate cancer;
LUSC	cis	rs939658	0.805	rs59104559	chr15:79438784	A/G	cg17916960	chr15:79447300	NA	-0.52	-10.38	-0.49	4.68e-22	Refractive error;
LUSC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg02423579	chr7:2872169	GNA12	-0.47	-6.69	-0.34	9.18e-11	Height;
LUSC	cis	rs7584330	0.554	rs10208231	chr2:238433225	C/T	cg16989719	chr2:238392110	NA	-0.39	-5.69	-0.3	2.79e-8	Prostate cancer;
LUSC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23158103	chr7:148848205	ZNF398	-0.47	-7.78	-0.39	9.38e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg16325326	chr1:53192061	ZYG11B	-1.01	-20.61	-0.75	1.71e-61	Monocyte count;
LUSC	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg26850624	chr5:429559	AHRR	-0.42	-7.91	-0.4	3.74e-14	Cystic fibrosis severity;
LUSC	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg20734569	chr3:48348370	SPINK8	-0.47	-8.17	-0.41	6.44e-15	Coronary artery disease;
LUSC	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg04362960	chr10:104952993	NT5C2	0.9	11.69	0.54	1.06e-26	Arsenic metabolism;
LUSC	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs9372498	0.505	rs4416700	chr6:118975461	G/C	cg18833306	chr6:118973337	C6orf204	-0.45	-5.79	-0.3	1.64e-8	Diastolic blood pressure;
LUSC	cis	rs2067615	0.542	rs4964184	chr12:107070425	A/T	cg15890332	chr12:107067104	RFX4	0.35	6.37	0.33	6.22e-10	Heart rate;
LUSC	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg06002616	chr8:101225028	SPAG1	-0.41	-6.92	-0.35	2.34e-11	Atrioventricular conduction;
LUSC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.82	0.57	7.03e-31	Chronic sinus infection;
LUSC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg22166914	chr1:53195759	ZYG11B	-0.57	-9.24	-0.45	3.07e-18	Monocyte count;
LUSC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.45	-7.62	-0.38	2.58e-13	Lymphocyte counts;
LUSC	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15320075	chr8:145703422	NA	-0.43	-7.02	-0.36	1.25e-11	Age at first birth;
LUSC	cis	rs4704187	0.687	rs6889429	chr5:74482183	C/T	cg03227963	chr5:74354835	NA	0.3	6.54	0.34	2.32e-10	Response to amphetamines;
LUSC	cis	rs751728	0.643	rs12173787	chr6:33735471	G/C	cg25922239	chr6:33757077	LEMD2	0.41	5.94	0.31	7.23e-9	Crohn's disease;
LUSC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg05163923	chr11:71159392	DHCR7	0.74	10.94	0.51	5.36e-24	Vitamin D levels;
LUSC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.72	12.05	0.55	5.22e-28	Motion sickness;
LUSC	cis	rs9420	0.528	rs11229077	chr11:57399072	A/G	cg23127183	chr11:57508653	C11orf31	0.46	6.45	0.33	4e-10	Schizophrenia;
LUSC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13126279	chr21:47581558	C21orf56	-0.43	-6.34	-0.33	7.6e-10	Testicular germ cell tumor;
LUSC	cis	rs11245387	0.633	rs2086945	chr10:126543993	C/T	cg08799069	chr10:126477246	METTL10	0.46	6.8	0.35	4.81e-11	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LUSC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg25767906	chr1:53392781	SCP2	0.52	9.44	0.46	6.73e-19	Monocyte count;
LUSC	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg24110177	chr3:50126178	RBM5	0.42	6.7	0.34	8.64e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07080220	chr10:102295463	HIF1AN	0.62	8.53	0.42	5.22e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg02426739	chr12:132285352	NA	0.35	5.83	0.3	1.3e-8	Migraine;
LUSC	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	12.46	0.56	1.61e-29	Height;
LUSC	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-10.26	-0.49	1.19e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg11645453	chr3:52864694	ITIH4	-0.33	-7.37	-0.37	1.32e-12	Body mass index;
LUSC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.27e-31	Prudent dietary pattern;
LUSC	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.89	14.89	0.63	8.25e-39	Bladder cancer;
LUSC	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg22349387	chr12:9600060	DDX12	-0.43	-6.99	-0.36	1.49e-11	Breast size;
LUSC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.49	-8.2	-0.41	5.38e-15	Total body bone mineral density;
LUSC	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg15083037	chr5:83017644	HAPLN1	-0.59	-7.74	-0.39	1.21e-13	Prostate cancer;
LUSC	cis	rs7017697	0.507	rs3816246	chr8:19682545	A/G	cg03894339	chr8:19674705	INTS10	-0.55	-7.24	-0.37	3.11e-12	Breast cancer;
LUSC	cis	rs7583236	0.500	rs6728352	chr2:70343432	G/A	cg19638749	chr2:70312615	NA	0.57	5.77	0.3	1.79e-8	Obesity-related traits;
LUSC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg17264618	chr3:40429014	ENTPD3	0.34	7.24	0.37	3.19e-12	Renal cell carcinoma;
LUSC	cis	rs56077333	1	rs56077333	chr15:78899003	C/A	cg06917634	chr15:78832804	PSMA4	-0.44	-5.9	-0.31	8.72e-9	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs8027181	0.839	rs7167076	chr15:73028873	G/A	cg25632853	chr15:73088954	NA	-0.3	-6.03	-0.31	4.39e-9	Triglyceride levels;
LUSC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	0.91	12.34	0.56	4.35e-29	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.62	-0.5	7.05e-23	Aortic root size;
LUSC	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg02023728	chr11:77925099	USP35	0.5	7.22	0.37	3.42e-12	Testicular germ cell tumor;
LUSC	cis	rs13221852	0.722	rs2177167	chr7:3423727	G/A	cg21248987	chr7:3385318	SDK1	0.37	6.3	0.33	9.65e-10	Acute graft versus host disease in bone marrow transplantation (donor effect);
LUSC	cis	rs7246967	0.604	rs58653025	chr19:22941617	T/C	cg23217946	chr19:22817039	ZNF492	0.43	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs9399401	0.710	rs12190271	chr6:142681409	A/G	cg03128060	chr6:142623767	GPR126	-0.57	-9.56	-0.46	2.75e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs9905704	0.718	rs193391	chr17:56672944	T/C	cg12560992	chr17:57184187	TRIM37	0.51	5.91	0.31	8.67e-9	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg21724239	chr8:58056113	NA	-0.79	-9.68	-0.47	1.09e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg08088566	chr11:430123	ANO9	0.67	7.4	0.38	1.08e-12	Body mass index;
LUSC	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg18232548	chr7:50535776	DDC	-0.59	-9.08	-0.45	9.41e-18	Systemic sclerosis;
LUSC	cis	rs6754311	0.593	rs313523	chr2:136432103	G/A	cg07169764	chr2:136633963	MCM6	0.55	7.29	0.37	2.32e-12	Mosquito bite size;
LUSC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg16447950	chr5:562315	NA	-0.57	-6.95	-0.36	1.97e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	13.14	0.58	4.65e-32	Total body bone mineral density;
LUSC	cis	rs6028335	0.674	rs8120715	chr20:37598781	G/A	cg27552599	chr20:37590471	DHX35	0.46	5.85	0.3	1.19e-8	Alcohol and nicotine co-dependence;
LUSC	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.41	-6.5	-0.33	2.99e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg03709012	chr19:19516395	GATAD2A	0.74	11.28	0.53	3.17e-25	Tonsillectomy;
LUSC	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg17173187	chr15:85201210	NMB	0.37	6.64	0.34	1.26e-10	Schizophrenia;
LUSC	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg18478394	chr8:109455254	TTC35	0.44	6.81	0.35	4.63e-11	Dupuytren's disease;
LUSC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg00012203	chr2:219082015	ARPC2	-0.7	-11.59	-0.54	2.53e-26	Colorectal cancer;
LUSC	cis	rs6741892	0.536	rs6761563	chr2:38891406	A/T	cg08308459	chr2:38893161	GALM	-0.58	-5.95	-0.31	6.84e-9	5-HTT brain serotonin transporter levels;
LUSC	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg14196790	chr5:131705035	SLC22A5	0.42	6.82	0.35	4.29e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg13319975	chr6:146136371	FBXO30	0.49	7.41	0.38	1.06e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.36	-0.49	5.47e-22	Eye color traits;
LUSC	cis	rs7180079	0.620	rs2046356	chr15:64706259	G/A	cg08069370	chr15:64387884	SNX1	0.51	5.64	0.3	3.55e-8	Monocyte count;
LUSC	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg10792982	chr14:105748885	BRF1	0.51	8.74	0.43	1.12e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	1.21	16.68	0.67	7.04e-46	Eosinophil percentage of granulocytes;
LUSC	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.43	-0.33	4.49e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg17054900	chr3:154042577	DHX36	0.44	5.77	0.3	1.82e-8	Coronary artery disease;
LUSC	cis	rs713477	0.524	rs2341538	chr14:55895174	C/G	cg13175173	chr14:55914753	NA	0.31	5.94	0.31	7.35e-9	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs12543725	0.799	rs13252660	chr8:142239381	C/T	cg23750338	chr8:142222470	SLC45A4	-0.42	-7.68	-0.39	1.78e-13	Birth weight;
LUSC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg00310523	chr12:86230176	RASSF9	0.52	9.83	0.47	3.37e-20	Major depressive disorder;
LUSC	cis	rs7103411	0.637	rs6416056	chr11:27646745	A/G	cg18117895	chr11:27722066	BDNF	0.46	5.97	0.31	6.09e-9	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06112835	chr11:68658793	MRPL21	0.52	8.0	0.4	2.08e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11764359	chr7:65958608	NA	-0.78	-12.75	-0.57	1.29e-30	Aortic root size;
LUSC	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg06636001	chr8:8085503	FLJ10661	0.55	8.77	0.43	9.05e-17	Retinal vascular caliber;
LUSC	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg18753928	chr3:113234510	CCDC52	-0.54	-8.23	-0.41	4.16e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02470736	chr12:50505862	C12orf62	-0.41	-6.01	-0.31	4.86e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg14558262	chr17:40713999	COASY	0.54	8.71	0.43	1.47e-16	Colorectal or endometrial cancer;
LUSC	cis	rs701145	0.938	rs1086106	chr3:154084032	C/T	cg17054900	chr3:154042577	DHX36	0.81	7.86	0.4	5.38e-14	Coronary artery disease;
LUSC	cis	rs9322817	0.617	rs9404574	chr6:105162372	T/C	cg02098413	chr6:105308735	HACE1	-0.27	-5.68	-0.3	2.97e-8	Thyroid stimulating hormone;
LUSC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.91	16.29	0.67	2.67e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg16339924	chr4:17578868	LAP3	0.55	8.61	0.43	3.02e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7605827	0.930	rs6749663	chr2:15529705	T/G	cg19274914	chr2:15703543	NA	0.46	9.07	0.44	1.07e-17	Educational attainment (years of education);
LUSC	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg18230493	chr5:56204884	C5orf35	-0.58	-9.01	-0.44	1.6e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg13073564	chr4:8508604	NA	-0.46	-8.6	-0.43	3.15e-16	Response to antineoplastic agents;
LUSC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-12.87	-0.58	4.6e-31	Platelet count;
LUSC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.64	0.6	5.58e-34	Cognitive test performance;
LUSC	cis	rs7523273	0.627	rs2724389	chr1:207933648	T/C	cg22525895	chr1:207977042	MIR29B2	0.41	6.66	0.34	1.16e-10	Schizophrenia;
LUSC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-17.36	-0.69	1.44e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs367615	0.552	rs2963025	chr5:108733256	A/C	cg17395555	chr5:108820864	NA	-0.46	-7.98	-0.4	2.41e-14	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	8.18	0.41	5.91e-15	Height;
LUSC	cis	rs4478858	0.735	rs4949382	chr1:31776731	A/G	cg00250761	chr1:31883323	NA	-0.35	-8.55	-0.42	4.58e-16	Alcohol dependence;
LUSC	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.31	-18.22	-0.71	5.26e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs968451	0.865	rs5757609	chr22:39707845	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	9.04	0.44	1.28e-17	Primary biliary cholangitis;
LUSC	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg17168535	chr8:21777572	XPO7	0.85	15.63	0.65	1.04e-41	Mean corpuscular volume;
LUSC	cis	rs16867335	1.000	rs16867335	chr2:181458934	C/T	cg23363182	chr2:181467187	NA	-0.47	-5.94	-0.31	7.31e-9	Survival in rectal cancer;
LUSC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg05552183	chr6:42928497	GNMT	0.51	8.3	0.41	2.61e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.16	0.32	2.04e-9	Menopause (age at onset);
LUSC	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg21775007	chr8:11205619	TDH	-0.46	-6.77	-0.35	5.79e-11	Neuroticism;
LUSC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg17724175	chr1:150552817	MCL1	0.36	6.51	0.34	2.7e-10	Tonsillectomy;
LUSC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.66	0.3	3.26e-8	Menopause (age at onset);
LUSC	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg21535247	chr6:8435926	SLC35B3	-0.42	-6.11	-0.32	2.82e-9	Motion sickness;
LUSC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03264133	chr6:25882463	NA	-0.42	-7.25	-0.37	2.97e-12	Blood metabolite levels;
LUSC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.26	0.45	2.57e-18	Prudent dietary pattern;
LUSC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg16797656	chr11:68205561	LRP5	0.35	5.9	0.31	9.14e-9	Total body bone mineral density;
LUSC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg20744362	chr22:50050164	C22orf34	0.39	8.1	0.41	1.04e-14	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs1027479	0.842	rs1391197	chr8:109723927	C/T	cg14904725	chr13:113777045	F10	-0.25	-6.16	-0.32	2.15e-9	Facial morphology (factor 6, height of vermillion lower lip);
LUSC	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.69	-0.47	9.86e-20	Multiple sclerosis;
LUSC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.5	7.66	0.39	2.05e-13	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.45	0.67	6.11e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10779751	0.632	rs2748876	chr1:11134157	T/G	cg08854313	chr1:11322531	MTOR	0.84	12.47	0.56	1.44e-29	Body mass index;
LUSC	cis	rs7615316	0.872	rs9879995	chr3:142307799	A/C	cg16271453	chr3:142027066	XRN1	-0.35	-5.91	-0.31	8.62e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs8081395	0.801	rs2777895	chr17:57879610	A/G	cg18434674	chr17:58106139	NA	-0.27	-5.92	-0.31	8.01e-9	White blood cell count;
LUSC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg18512352	chr11:47633146	NA	-0.46	-9.04	-0.44	1.35e-17	Subjective well-being;
LUSC	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg04352962	chr1:209979756	IRF6	0.58	6.27	0.32	1.14e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg16414030	chr3:133502952	NA	-0.52	-8.44	-0.42	9.8e-16	Iron status biomarkers;
LUSC	trans	rs6011368	0.642	rs6062362	chr20:62911229	A/G	cg13869341	chr1:15865	WASH5P	0.41	6.41	0.33	5e-10	Clozapine-induced cytotoxicity;
LUSC	cis	rs13385	0.769	rs4913078	chr5:139626680	A/T	cg26211634	chr5:139558579	C5orf32	0.46	6.95	0.36	1.88e-11	Atrial fibrillation;
LUSC	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.25	-0.52	4.05e-25	Mean corpuscular volume;
LUSC	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg16339924	chr4:17578868	LAP3	0.52	7.58	0.38	3.34e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.75	-0.35	6.41e-11	Response to antipsychotic treatment;
LUSC	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg05347473	chr6:146136440	FBXO30	0.52	8.68	0.43	1.82e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2742234	0.541	rs10899782	chr10:43736361	A/T	cg02780029	chr10:43622663	RET	0.34	5.65	0.3	3.36e-8	Hirschsprung disease;
LUSC	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg23505145	chr19:12996616	KLF1	-0.64	-10.59	-0.5	8.64e-23	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-8.5	-0.42	6.35e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18404041	chr3:52824283	ITIH1	-0.53	-10.2	-0.49	1.97e-21	Electroencephalogram traits;
LUSC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg25036284	chr2:26402008	FAM59B	-0.7	-9.85	-0.47	3.01e-20	Gut microbiome composition (summer);
LUSC	cis	rs6747952	0.866	rs4663854	chr2:239083167	C/T	cg17459225	chr2:239074497	NA	-0.34	-5.88	-0.31	1.01e-8	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1775715	0.707	rs2799024	chr10:32166922	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	7.03	0.36	1.19e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7264396	0.623	rs6119609	chr20:34039394	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.83	-0.35	3.92e-11	Total cholesterol levels;
LUSC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg02187348	chr16:89574699	SPG7	0.5	7.72	0.39	1.38e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs11997175	0.766	rs6995220	chr8:33708919	C/A	ch.8.33884649F	chr8:33765107	NA	0.37	5.8	0.3	1.5e-8	Body mass index;
LUSC	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg03859395	chr2:55845619	SMEK2	0.87	16.25	0.66	3.53e-44	Metabolic syndrome;
LUSC	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg11887960	chr12:57824829	NA	0.54	6.8	0.35	4.89e-11	Obesity-related traits;
LUSC	cis	rs7809950	1.000	rs28714607	chr7:107106253	T/C	cg23024343	chr7:107201750	COG5	-0.55	-8.74	-0.43	1.16e-16	Coronary artery disease;
LUSC	cis	rs372883	0.901	rs407463	chr21:30722440	G/A	cg08807101	chr21:30365312	RNF160	-0.42	-6.13	-0.32	2.52e-9	Pancreatic cancer;
LUSC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg14019146	chr3:50243930	SLC38A3	0.32	6.91	0.35	2.49e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4930561	0.765	rs1894204	chr11:67929671	C/T	cg16338278	chr11:67432957	ALDH3B2	0.36	5.93	0.31	7.59e-9	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg17279839	chr7:150038598	RARRES2	0.43	6.95	0.36	1.93e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg07806771	chr7:64541737	NA	0.42	6.03	0.31	4.3e-9	Calcium levels;
LUSC	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg15445000	chr17:37608096	MED1	0.41	6.82	0.35	4.34e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg25482853	chr8:67687455	SGK3	1.19	19.12	0.72	1.43e-55	Lung disease severity in cystic fibrosis;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg11965514	chr8:124253535	C8orf76	0.66	6.01	0.31	4.74e-9	Cognitive performance;
LUSC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.28	0.37	2.47e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg05026186	chr5:148520876	ABLIM3	-0.39	-5.78	-0.3	1.69e-8	Breast cancer;
LUSC	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.52	0.5	1.56e-22	Colorectal cancer;
LUSC	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg23173402	chr1:227635558	NA	0.76	7.59	0.38	3.12e-13	Major depressive disorder;
LUSC	cis	rs12220238	0.908	rs4746179	chr10:75940169	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.3	0.37	2.06e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs7215564	0.908	rs35884143	chr17:78656043	A/G	cg23238734	chr17:78661607	RPTOR	0.48	6.13	0.32	2.5e-9	Myopia (pathological);
LUSC	cis	rs6120849	0.754	rs6120790	chr20:33599090	A/T	cg24642439	chr20:33292090	TP53INP2	0.62	6.82	0.35	4.29e-11	Protein C levels;
LUSC	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg20026190	chr17:76395443	PGS1	0.46	8.06	0.4	1.37e-14	HDL cholesterol levels;
LUSC	cis	rs4478858	0.746	rs7544003	chr1:31689088	C/T	cg00250761	chr1:31883323	NA	0.36	9.36	0.46	1.19e-18	Alcohol dependence;
LUSC	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg16346588	chr10:242978	ZMYND11	-0.45	-6.15	-0.32	2.15e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06634786	chr22:41940651	POLR3H	0.49	5.76	0.3	1.91e-8	Vitiligo;
LUSC	cis	rs679087	0.606	rs302344	chr12:29940953	A/G	cg14258853	chr12:29935411	TMTC1	0.69	8.61	0.43	2.86e-16	Schizophrenia;
LUSC	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.2	-35.46	-0.89	2.9e-115	Myeloid white cell count;
LUSC	cis	rs12681287	0.752	rs34279109	chr8:87247944	G/A	cg27223183	chr8:87520930	FAM82B	-0.46	-5.78	-0.3	1.69e-8	Caudate activity during reward;
LUSC	trans	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg20587970	chr11:113659929	NA	0.64	8.83	0.44	6.1e-17	Hip circumference adjusted for BMI;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20947082	chr1:233749643	KCNK1	-0.43	-6.0	-0.31	5.06e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.26	-27.65	-0.83	2.31e-88	Exhaled nitric oxide output;
LUSC	trans	rs17133449	0.718	rs7923564	chr10:4753292	G/A	cg17844448	chr7:27782764	TAX1BP1	-0.38	-6.2	-0.32	1.68e-9	Major depressive disorder;
LUSC	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08704250	chr15:31115839	NA	-0.48	-7.13	-0.36	6.35e-12	Huntington's disease progression;
LUSC	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg16342193	chr10:102329863	NA	-0.39	-6.88	-0.35	2.96e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg06627628	chr2:24431161	ITSN2	-0.6	-7.16	-0.36	5.19e-12	Lymphocyte counts;
LUSC	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg13402656	chr8:1511478	DLGAP2	-0.62	-10.39	-0.49	4.12e-22	Lung cancer;
LUSC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06850241	chr22:41845214	NA	0.34	6.33	0.33	7.95e-10	Vitiligo;
LUSC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg08888203	chr3:10149979	C3orf24	0.62	8.65	0.43	2.17e-16	Alzheimer's disease;
LUSC	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.21	-0.45	3.77e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg22676075	chr6:135203613	NA	0.55	8.72	0.43	1.37e-16	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg07212818	chr11:638076	DRD4	-0.38	-6.49	-0.33	3.07e-10	Systemic lupus erythematosus;
LUSC	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg22089800	chr15:90895588	ZNF774	0.63	9.42	0.46	7.7e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-7.13	-0.36	6.3e-12	Blood metabolite levels;
LUSC	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg24558204	chr6:135376177	HBS1L	0.58	9.0	0.44	1.69e-17	Red blood cell count;
LUSC	cis	rs9463078	0.625	rs500773	chr6:44888464	C/T	cg25276700	chr6:44698697	NA	-0.28	-5.86	-0.31	1.09e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	trans	rs12210905	1.000	rs72843644	chr6:27211601	A/C	cg11837749	chr1:55047332	ACOT11	0.58	5.98	0.31	5.64e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg01420254	chr6:26195488	NA	0.71	7.47	0.38	7.03e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10819733	chr22:24237672	NA	-0.41	-6.14	-0.32	2.33e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg22535103	chr8:58192502	C8orf71	-0.75	-9.55	-0.46	2.95e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg03522245	chr20:25566470	NINL	0.36	5.74	0.3	2.14e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg04727924	chr7:799746	HEATR2	-0.56	-6.78	-0.35	5.48e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg22705602	chr4:152727874	NA	-0.33	-6.7	-0.34	9.13e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2398893	1.000	rs12004383	chr9:96826239	G/T	cg14459158	chr9:96720562	NA	0.34	6.49	0.33	3.15e-10	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4409675	0.549	rs72872888	chr1:28239809	G/A	cg23691781	chr1:28212827	C1orf38	0.33	7.96	0.4	2.79e-14	Corneal astigmatism;
LUSC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.9	-13.98	-0.61	2.72e-35	Initial pursuit acceleration;
LUSC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg24060327	chr5:131705240	SLC22A5	-0.34	-5.71	-0.3	2.52e-8	Blood metabolite levels;
LUSC	cis	rs2742417	0.603	rs9826208	chr3:45773991	C/T	cg10512202	chr3:45649293	LIMD1	0.36	5.94	0.31	7.3e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg02175503	chr12:58329896	NA	0.45	6.56	0.34	2.02e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.83	10.66	0.5	4.87e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs17086172	0.841	rs76610733	chr18:70268315	C/G	cg02919422	chr8:55370544	SOX17	-0.74	-6.62	-0.34	1.41e-10	Airflow obstruction;
LUSC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-8.18	-0.41	5.97e-15	Systemic lupus erythematosus;
LUSC	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg20991723	chr1:152506922	NA	0.51	9.74	0.47	6.76e-20	Hair morphology;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26789489	chr1:16941426	NBPF1	0.43	6.45	0.33	3.94e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg15335139	chr3:50242325	SLC38A3	0.26	5.77	0.3	1.83e-8	Body mass index;
LUSC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.18	0.52	7.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.53	-0.5	1.46e-22	Coffee consumption (cups per day);
LUSC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg20406979	chr6:167373233	NA	0.24	5.71	0.3	2.55e-8	Crohn's disease;
LUSC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg05360949	chr19:41903737	BCKDHA;EXOSC5	-0.43	-6.0	-0.31	5.27e-9	Height;
LUSC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.44	-8.17	-0.41	6.26e-15	Monocyte percentage of white cells;
LUSC	trans	rs11696501	0.739	rs6104250	chr20:44251479	C/T	cg03272292	chr12:48577362	C12orf68	0.49	5.99	0.31	5.29e-9	Brain structure;
LUSC	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg08847533	chr14:75593920	NEK9	0.52	7.62	0.38	2.72e-13	Caffeine consumption;
LUSC	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-0.52	-7.99	-0.4	2.17e-14	Breast cancer;
LUSC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg24675658	chr1:53192096	ZYG11B	0.59	9.39	0.46	9.87e-19	Monocyte count;
LUSC	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg13010199	chr12:38710504	ALG10B	-0.65	-10.21	-0.49	1.77e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18876405	chr7:65276391	NA	-0.55	-8.59	-0.43	3.48e-16	Aortic root size;
LUSC	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.29	-0.41	2.86e-15	Mean platelet volume;
LUSC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg21535247	chr6:8435926	SLC35B3	-0.59	-9.12	-0.45	7.09e-18	Motion sickness;
LUSC	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg19792802	chr11:65647270	CTSW	-0.41	-6.25	-0.32	1.25e-9	Crohn's disease;
LUSC	cis	rs3772130	0.885	rs9816844	chr3:121496324	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.23	0.49	1.48e-21	Cognitive performance;
LUSC	cis	rs11997175	0.713	rs6997661	chr8:33638554	A/G	ch.8.33884649F	chr8:33765107	NA	-0.47	-7.62	-0.38	2.6e-13	Body mass index;
LUSC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-19.18	-0.72	8.14e-56	Height;
LUSC	cis	rs10911251	0.528	rs10911265	chr1:183115071	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.51	0.5	1.67e-22	Colorectal cancer;
LUSC	cis	rs9815354	0.597	rs73075211	chr3:42033424	G/T	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6906287	0.647	rs12192682	chr6:118863594	A/G	cg21191810	chr6:118973309	C6orf204	0.33	5.95	0.31	6.92e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.68	-0.47	1.04e-19	Coronary artery disease;
LUSC	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg26384229	chr12:38710491	ALG10B	0.71	11.0	0.52	3.26e-24	Morning vs. evening chronotype;
LUSC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.62	-8.05	-0.4	1.49e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg14416269	chr4:6271139	WFS1	0.54	11.38	0.53	1.35e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.43	0.53	8.95e-26	Prudent dietary pattern;
LUSC	trans	rs9393777	0.777	rs56114371	chr6:27274834	C/T	cg01620082	chr3:125678407	NA	-0.74	-6.46	-0.33	3.63e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	6.48	0.33	3.36e-10	Obesity-related traits;
LUSC	cis	rs2273669	0.667	rs28504359	chr6:109330417	C/T	cg05315195	chr6:109294784	ARMC2	-0.53	-5.89	-0.31	9.28e-9	Prostate cancer;
LUSC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg26335602	chr6:28129616	ZNF389	0.45	6.01	0.31	4.83e-9	Depression;
LUSC	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg17462356	chr17:80056334	FASN	0.46	6.16	0.32	2.11e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10848704	0.956	rs10848703	chr12:2882250	C/T	cg19995117	chr12:2880862	NA	0.55	10.58	0.5	9.53e-23	Quantitative traits;
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg16393715	chr7:1948819	MAD1L1	0.36	6.2	0.32	1.66e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs977987	0.581	rs8056141	chr16:75497162	A/T	cg04384234	chr16:75411784	CFDP1	-0.49	-7.93	-0.4	3.27e-14	Dupuytren's disease;
LUSC	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg04733989	chr22:42467013	NAGA	0.39	6.55	0.34	2.22e-10	Cognitive function;
LUSC	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg09904177	chr6:26538194	HMGN4	-0.51	-5.71	-0.3	2.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9309473	0.500	rs4286298	chr2:73882108	T/A	cg20560298	chr2:73613845	ALMS1	0.47	7.18	0.37	4.5e-12	Metabolite levels;
LUSC	cis	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05901451	chr6:126070800	HEY2	0.56	8.52	0.42	5.63e-16	Endometrial cancer;
LUSC	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg02753203	chr1:228287806	NA	0.72	12.56	0.57	6.61e-30	Diastolic blood pressure;
LUSC	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg15468180	chr1:107600409	PRMT6	0.38	6.02	0.31	4.53e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-12.87	-0.58	4.6e-31	Platelet count;
LUSC	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg13390004	chr1:15929781	NA	0.41	6.76	0.35	6.35e-11	Systolic blood pressure;
LUSC	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg12826209	chr6:26865740	GUSBL1	0.64	7.35	0.37	1.55e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10761482	0.531	rs10740029	chr10:62238902	G/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.38	-0.33	5.9e-10	Schizophrenia;
LUSC	cis	rs3849570	1.000	rs78242412	chr3:81747219	A/G	cg07356753	chr3:81810745	GBE1	-0.69	-10.93	-0.51	5.51e-24	Waist circumference;Body mass index;
LUSC	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg00310523	chr12:86230176	RASSF9	0.39	6.98	0.36	1.58e-11	Major depressive disorder;
LUSC	cis	rs2652834	1.000	rs8032104	chr15:63400584	A/G	cg05507819	chr15:63340323	TPM1	0.67	8.15	0.41	7.6e-15	HDL cholesterol;
LUSC	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg23260525	chr10:116636907	FAM160B1	0.4	8.18	0.41	5.96e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs8014204	0.816	rs28426374	chr14:75346740	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.55	-8.79	-0.43	8.26e-17	Caffeine consumption;
LUSC	cis	rs56283067	0.847	rs60328783	chr6:44693099	C/G	cg18551225	chr6:44695536	NA	-0.49	-8.27	-0.41	3.22e-15	Total body bone mineral density;
LUSC	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.09	15.4	0.64	8.48e-41	Uric acid levels;
LUSC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg21770322	chr7:97807741	LMTK2	-0.46	-8.12	-0.41	8.94e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.9	16.85	0.68	1.6e-46	Menarche (age at onset);
LUSC	cis	rs2798269	0.966	rs1200039	chr13:22110476	A/C	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.07	-0.32	3.52e-9	PR segment;
LUSC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-1.23	-13.78	-0.6	1.62e-34	Diabetic kidney disease;
LUSC	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg03433033	chr1:76189801	ACADM	-0.46	-6.45	-0.33	3.86e-10	Daytime sleep phenotypes;
LUSC	cis	rs17155006	0.655	rs448742	chr7:107733993	C/T	cg05962710	chr7:107745446	LAMB4	0.32	5.73	0.3	2.27e-8	Pneumococcal bacteremia;
LUSC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg24634471	chr8:143751801	JRK	0.59	9.01	0.44	1.66e-17	Schizophrenia;
LUSC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg13647721	chr17:30228624	UTP6	0.57	5.65	0.3	3.43e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.73	12.13	0.55	2.69e-28	Alcohol dependence;
LUSC	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.68	-9.2	-0.45	4.01e-18	Large artery stroke;
LUSC	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg15848620	chr12:58087721	OS9	-0.53	-7.63	-0.39	2.45e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg07578070	chr6:150326732	RAET1K	0.36	5.67	0.3	3.1e-8	Alopecia areata;
LUSC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.73	-11.42	-0.53	9.81e-26	Menarche (age at onset);
LUSC	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg07701084	chr6:150067640	NUP43	0.53	7.8	0.39	7.88e-14	Lung cancer;
LUSC	cis	rs2731664	0.792	rs385981	chr5:176886539	C/T	cg23176889	chr5:176863531	GRK6	-0.68	-13.95	-0.61	3.62e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg11344533	chr11:111475393	SIK2	0.45	6.09	0.32	3.14e-9	Primary sclerosing cholangitis;
LUSC	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg05501817	chr11:14380813	RRAS2	-0.57	-8.9	-0.44	3.72e-17	Sense of smell;
LUSC	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg15412446	chr2:106886593	NA	-0.56	-6.33	-0.33	7.68e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LUSC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.07	-0.4	1.26e-14	Platelet count;
LUSC	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg12751644	chr20:60527061	NA	-0.33	-5.9	-0.31	8.75e-9	Body mass index;
LUSC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.61e-8	Life satisfaction;
LUSC	cis	rs713477	1.000	rs7149622	chr14:55909402	T/C	cg13175173	chr14:55914753	NA	-0.32	-6.74	-0.35	7.01e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs2230307	0.536	rs473759	chr1:100557282	C/G	cg24955406	chr1:100503596	HIAT1	0.59	6.41	0.33	4.9e-10	Carotid intima media thickness;
LUSC	cis	rs1044826	0.956	rs2233811	chr3:139195860	C/G	cg00490450	chr3:139108681	COPB2	0.52	6.76	0.35	6.18e-11	Obesity-related traits;
LUSC	cis	rs2219968	0.961	rs1121551	chr8:78958512	A/G	cg00738934	chr8:78996279	NA	0.34	6.11	0.32	2.76e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg13047869	chr3:10149882	C3orf24	0.63	8.73	0.43	1.21e-16	Alzheimer's disease;
LUSC	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg00105475	chr2:10696890	NA	0.38	6.28	0.32	1.06e-9	Prostate cancer;
LUSC	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg26102564	chr10:131424627	MGMT	0.43	6.78	0.35	5.54e-11	Response to temozolomide;
LUSC	cis	rs983392	0.679	rs764859	chr11:59978255	C/G	cg20284999	chr11:59952153	MS4A6A	-0.36	-6.02	-0.31	4.68e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9341808	0.538	rs688867	chr6:80939228	A/G	cg08355045	chr6:80787529	NA	0.4	6.89	0.35	2.82e-11	Sitting height ratio;
LUSC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg11764359	chr7:65958608	NA	-0.55	-7.3	-0.37	2.13e-12	Aortic root size;
LUSC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.63	0.39	2.44e-13	Prudent dietary pattern;
LUSC	cis	rs7598759	0.675	rs6727530	chr2:232332058	T/C	cg19187155	chr2:232395269	NMUR1	0.49	7.2	0.37	3.96e-12	Noise-induced hearing loss;
LUSC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg01874867	chr7:94954059	PON1	0.41	7.89	0.4	4.49e-14	Paraoxonase activity;
LUSC	cis	rs2742417	1.000	rs2742423	chr3:45733430	A/G	cg09608765	chr3:45636137	LIMD1	-0.34	-6.84	-0.35	3.8e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs8014204	0.816	rs10083386	chr14:75347585	C/A	cg08847533	chr14:75593920	NEK9	-0.41	-6.04	-0.31	4.04e-9	Caffeine consumption;
LUSC	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg23029597	chr12:123009494	RSRC2	-0.71	-9.23	-0.45	3.14e-18	Body mass index;
LUSC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg11663144	chr21:46675770	NA	-0.43	-7.39	-0.37	1.22e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8077889	0.703	rs72836567	chr17:41945776	G/A	cg26893861	chr17:41843967	DUSP3	0.9	11.24	0.52	4.53e-25	Triglycerides;
LUSC	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00908189	chr16:619842	PIGQ	0.67	10.32	0.49	7.66e-22	Height;
LUSC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg10792982	chr14:105748885	BRF1	0.48	8.35	0.42	1.83e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.92	-0.31	8e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg19812747	chr11:111475976	SIK2	-0.51	-7.21	-0.37	3.81e-12	Primary sclerosing cholangitis;
LUSC	trans	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	6.04	0.31	4.19e-9	Cystic fibrosis severity;
LUSC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg19592336	chr6:28129416	ZNF389	0.46	5.93	0.31	7.48e-9	Depression;
LUSC	trans	rs10990032	1.000	rs1364820	chr9:105143745	A/G	cg09125300	chr8:22447068	PDLIM2	0.65	5.96	0.31	6.48e-9	Response to fenofibrate (triglyceride levels);
LUSC	cis	rs12493885	0.818	rs61791541	chr3:153758155	G/T	cg17054900	chr3:154042577	DHX36	-0.61	-6.46	-0.33	3.78e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg12463550	chr7:65579703	CRCP	-0.41	-5.91	-0.31	8.35e-9	Aortic root size;
LUSC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22029157	chr1:209979665	IRF6	0.74	10.99	0.52	3.49e-24	Cleft lip with or without cleft palate;
LUSC	cis	rs7804356	0.953	rs73067476	chr7:26857240	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.14	-0.32	2.4e-9	Type 1 diabetes;
LUSC	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.46	-7.33	-0.37	1.71e-12	Height;
LUSC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs7123876	0.587	rs11604034	chr11:72364147	G/C	cg04827223	chr11:72435913	ARAP1	-0.63	-7.38	-0.37	1.25e-12	Body mass index;
LUSC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg12564285	chr5:131593104	PDLIM4	0.46	8.86	0.44	4.87e-17	Blood metabolite levels;
LUSC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg10729496	chr3:10149963	C3orf24	0.59	7.89	0.4	4.31e-14	Alzheimer's disease;
LUSC	cis	rs12681287	0.547	rs66808088	chr8:87521212	C/T	cg00550725	chr8:87521180	FAM82B	0.44	5.77	0.3	1.83e-8	Caudate activity during reward;
LUSC	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg24634471	chr8:143751801	JRK	0.52	7.27	0.37	2.62e-12	Schizophrenia;
LUSC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg04414720	chr1:150670196	GOLPH3L	0.54	8.53	0.42	5.19e-16	Melanoma;
LUSC	cis	rs1881396	0.947	rs4666010	chr2:27878686	T/C	cg27432699	chr2:27873401	GPN1	0.64	8.61	0.43	3.03e-16	Nonalcoholic fatty liver disease;
LUSC	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg19318889	chr4:1322082	MAEA	0.48	7.83	0.39	6.69e-14	Obesity-related traits;
LUSC	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg20243544	chr17:37824526	PNMT	0.39	5.96	0.31	6.59e-9	Self-reported allergy;
LUSC	cis	rs8040855	0.690	rs8041189	chr15:85686327	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.38	5.65	0.3	3.5e-8	Bulimia nervosa;
LUSC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg15145296	chr3:125709740	NA	-0.56	-6.29	-0.33	9.71e-10	Blood pressure (smoking interaction);
LUSC	trans	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg24643429	chr1:3562429	WDR8	0.33	6.04	0.31	4.2e-9	Monocyte count;
LUSC	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg02269571	chr22:50332266	NA	-0.56	-8.29	-0.41	2.72e-15	Schizophrenia;
LUSC	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg06627628	chr2:24431161	ITSN2	0.52	7.36	0.37	1.47e-12	Asthma;
LUSC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg20295408	chr7:1910781	MAD1L1	-0.41	-5.78	-0.3	1.71e-8	Bipolar disorder and schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05900430	chr19:48825159	NA	-0.4	-5.95	-0.31	6.62e-9	Electrocardiographic conduction measures;
LUSC	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.63	-9.88	-0.48	2.23e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-0.74	-12.03	-0.55	6.04e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg03929089	chr4:120376271	NA	0.6	7.84	0.39	6.26e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.08	0.36	8.48e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.41	-0.33	5e-10	Cutaneous nevi;
LUSC	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg10596483	chr8:143751796	JRK	0.52	7.52	0.38	5.15e-13	Schizophrenia;
LUSC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg11871910	chr12:69753446	YEATS4	0.91	16.98	0.68	4.65e-47	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9309473	0.660	rs56131703	chr2:73847260	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-6.19	-0.32	1.72e-9	Metabolite levels;
LUSC	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg00484396	chr16:3507460	NAT15	-0.43	-7.03	-0.36	1.18e-11	Body mass index (adult);
LUSC	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06636551	chr8:101224915	SPAG1	-0.45	-8.11	-0.41	9.95e-15	Atrioventricular conduction;
LUSC	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg18132916	chr6:79620363	NA	-0.39	-6.02	-0.31	4.64e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10779751	1.000	rs12730522	chr1:11284091	G/A	cg08854313	chr1:11322531	MTOR	0.93	15.93	0.66	6.78e-43	Body mass index;
LUSC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03264133	chr6:25882463	NA	-0.44	-7.74	-0.39	1.16e-13	Blood metabolite levels;
LUSC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg06028605	chr16:24865363	SLC5A11	0.49	8.49	0.42	6.67e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg17252645	chr8:143867129	LY6D	-0.36	-6.31	-0.33	9.04e-10	Urinary tract infection frequency;
LUSC	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-9.7	-0.47	9.52e-20	Morning vs. evening chronotype;
LUSC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.59	9.72	0.47	8.16e-20	Aortic root size;
LUSC	cis	rs6681460	0.966	rs7524851	chr1:67093018	T/C	cg02459107	chr1:67143332	SGIP1	0.46	8.54	0.42	4.73e-16	Presence of antiphospholipid antibodies;
LUSC	trans	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg06606381	chr12:133084897	FBRSL1	-0.62	-6.53	-0.34	2.38e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7560272	0.538	rs4852972	chr2:73916672	C/T	cg20560298	chr2:73613845	ALMS1	0.38	5.81	0.3	1.5e-8	Schizophrenia;
LUSC	trans	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	10.36	0.49	5.43e-22	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg23625390	chr15:77176239	SCAPER	0.52	7.99	0.4	2.17e-14	Blood metabolite levels;
LUSC	cis	rs68170813	0.559	rs3815148	chr7:106938420	G/T	cg02696742	chr7:106810147	HBP1	0.61	9.64	0.47	1.45e-19	Coronary artery disease;
LUSC	cis	rs11640436	0.565	rs12926676	chr16:77309505	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.37	5.76	0.3	1.94e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7805747	1.000	rs10480299	chr7:151405818	A/G	cg17611936	chr7:151411526	PRKAG2	0.46	6.29	0.33	9.69e-10	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LUSC	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.68	-10.84	-0.51	1.14e-23	Corneal astigmatism;
LUSC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.54	-0.46	3.1400000000000002e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs13401104	0.796	rs1466207	chr2:237121350	C/T	cg19324714	chr2:237145437	ASB18	0.44	5.66	0.3	3.34e-8	Educational attainment;
LUSC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg24060327	chr5:131705240	SLC22A5	0.66	11.0	0.52	3.24e-24	Breast cancer;
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.85	15.26	0.64	2.83e-40	Menarche (age at onset);
LUSC	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg00484396	chr16:3507460	NAT15	-0.46	-6.75	-0.35	6.7e-11	Body mass index (adult);
LUSC	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00631329	chr6:26305371	NA	-0.46	-9.18	-0.45	4.58e-18	Educational attainment;
LUSC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg22868518	chr11:507468	RNH1	-0.63	-5.87	-0.31	1.08e-8	Body mass index;
LUSC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.75	12.92	0.58	2.98e-31	Longevity;
LUSC	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg26677194	chr12:130822605	PIWIL1	0.59	8.51	0.42	6.12e-16	Menopause (age at onset);
LUSC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-9.34	-0.46	1.39e-18	Longevity;
LUSC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg12143784	chr7:64541923	NA	0.36	5.65	0.3	3.5e-8	Calcium levels;
LUSC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg00255919	chr5:131827918	IRF1	0.43	8.25	0.41	3.62e-15	Asthma (sex interaction);
LUSC	trans	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg27411982	chr8:10470053	RP1L1	0.4	6.13	0.32	2.49e-9	Neuroticism;
LUSC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg04450456	chr4:17643702	FAM184B	0.39	6.62	0.34	1.48e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	6.16	0.32	2.14e-9	Tonsillectomy;
LUSC	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	7.75	0.39	1.14e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg07148914	chr20:33460835	GGT7	-0.49	-7.27	-0.37	2.57e-12	Height;
LUSC	cis	rs2742234	0.541	rs11238483	chr10:43728780	A/G	cg02780029	chr10:43622663	RET	0.34	5.7	0.3	2.58e-8	Hirschsprung disease;
LUSC	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg06547715	chr2:218990976	CXCR2	0.33	6.47	0.33	3.57e-10	Ulcerative colitis;
LUSC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg06027949	chr8:82754900	SNX16	-0.43	-5.81	-0.3	1.48e-8	Diastolic blood pressure;
LUSC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg00701064	chr4:6280414	WFS1	0.59	14.24	0.61	2.82e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.89	-0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg03522245	chr20:25566470	NINL	-0.35	-5.78	-0.3	1.68e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg08847533	chr14:75593920	NEK9	0.86	16.21	0.66	5.13e-44	Height;
LUSC	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg12002119	chr2:101014098	CHST10	0.35	5.81	0.3	1.5e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg21573476	chr21:45109991	RRP1B	0.37	5.89	0.31	9.5e-9	Mean corpuscular volume;
LUSC	cis	rs4666002	0.750	rs13021208	chr2:27901728	C/T	cg27432699	chr2:27873401	GPN1	0.54	7.12	0.36	6.59e-12	Phospholipid levels (plasma);
LUSC	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg23711669	chr6:146136114	FBXO30	-0.82	-14.68	-0.63	5.24e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg02269571	chr22:50332266	NA	-0.6	-8.97	-0.44	2.2e-17	Schizophrenia;
LUSC	cis	rs6500395	1.000	rs9924078	chr16:48557918	A/C	cg04672837	chr16:48644449	N4BP1	-0.43	-6.24	-0.32	1.29e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg08873628	chr1:175162347	KIAA0040	0.39	5.67	0.3	3.14e-8	Alcohol dependence;
LUSC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg11871910	chr12:69753446	YEATS4	0.82	14.42	0.62	5.7e-37	Blood protein levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27001607	chr7:76178636	LOC100133091	-0.46	-6.73	-0.35	7.57e-11	Electrocardiographic conduction measures;
LUSC	cis	rs2282802	0.711	rs3777095	chr5:139660916	G/A	cg26211634	chr5:139558579	C5orf32	0.45	8.51	0.42	6.02e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.76e-14	Melanoma;
LUSC	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg13699009	chr12:122356056	WDR66	0.5	7.75	0.39	1.09e-13	Mean corpuscular volume;
LUSC	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg23435118	chr5:141488016	NDFIP1	-0.56	-7.79	-0.39	8.56e-14	Crohn's disease;
LUSC	cis	rs12618769	0.597	rs11888595	chr2:99084708	T/G	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg11822372	chr1:151115635	SEMA6C	0.53	8.22	0.41	4.66e-15	Childhood ear infection;
LUSC	cis	rs10986311	0.604	rs10818962	chr9:127182293	C/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.39	-6.02	-0.31	4.52e-9	Vitiligo;
LUSC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg23711669	chr6:146136114	FBXO30	0.76	13.47	0.59	2.45e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7607369	0.536	rs11892469	chr2:219669488	A/T	cg02176678	chr2:219576539	TTLL4	-0.52	-9.15	-0.45	5.72e-18	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-0.9	-16.95	-0.68	6.18e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.45	-6.89	-0.35	2.84e-11	Height;
LUSC	cis	rs4363385	0.818	rs11205174	chr1:153001230	C/T	cg00922841	chr1:152955080	SPRR1A	0.44	7.72	0.39	1.4e-13	Inflammatory skin disease;
LUSC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg02569458	chr12:86230093	RASSF9	0.61	10.31	0.49	8.24e-22	Major depressive disorder;
LUSC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg17366294	chr4:99064904	C4orf37	0.57	9.96	0.48	1.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg04362960	chr10:104952993	NT5C2	0.6	9.46	0.46	5.67e-19	Arsenic metabolism;
LUSC	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08109568	chr15:31115862	NA	-0.58	-8.17	-0.41	6.4e-15	Huntington's disease progression;
LUSC	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.95	-0.4	2.94e-14	Joint mobility (Beighton score);
LUSC	cis	rs1784581	0.722	rs1619122	chr6:162400198	G/T	cg17173639	chr6:162384350	PARK2	-0.66	-11.68	-0.54	1.14e-26	Itch intensity from mosquito bite;
LUSC	cis	rs7640424	0.835	rs1561029	chr3:107822245	A/C	cg09227934	chr3:107805635	CD47	0.39	6.31	0.33	8.92e-10	Body mass index;
LUSC	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg04450456	chr4:17643702	FAM184B	-0.41	-6.66	-0.34	1.14e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.32	-5.83	-0.3	1.34e-8	IgG glycosylation;
LUSC	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg15423357	chr2:25149977	NA	0.45	9.08	0.44	9.75e-18	Body mass index;
LUSC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06505273	chr16:24850292	NA	0.4	5.8	0.3	1.51e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg03609598	chr5:56110824	MAP3K1	-0.41	-5.74	-0.3	2.14e-8	Initial pursuit acceleration;
LUSC	cis	rs11031096	0.711	rs10767882	chr11:4205841	G/A	cg18678763	chr11:4115507	RRM1	-0.41	-5.77	-0.3	1.86e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs28647808	0.881	rs41316982	chr9:136259117	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.21	-0.49	1.74e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs965604	0.965	rs13180	chr15:78789488	C/T	cg18825076	chr15:78729989	IREB2	-0.44	-6.97	-0.36	1.65e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg17173187	chr15:85201210	NMB	-0.33	-6.81	-0.35	4.42e-11	P wave terminal force;
LUSC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.46	-7.81	-0.39	7.29e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg21545522	chr1:205238299	TMCC2	0.46	8.69	0.43	1.66e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg06640241	chr16:89574553	SPG7	-0.75	-12.56	-0.57	6.56e-30	Multiple myeloma (IgH translocation);
LUSC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg06784218	chr1:46089804	CCDC17	0.48	9.3	0.45	1.93e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg07211511	chr3:129823064	LOC729375	-0.74	-9.59	-0.46	2.12e-19	Blood pressure (smoking interaction);
LUSC	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Smoking initiation;
LUSC	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg08017756	chr2:100939284	LONRF2	-0.44	-8.21	-0.41	4.95e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg12165864	chr7:66369176	NA	-0.54	-7.22	-0.37	3.62e-12	Corneal structure;
LUSC	cis	rs10203711	0.966	rs4998694	chr2:239564713	C/T	cg14580085	chr2:239553406	NA	0.41	6.96	0.36	1.76e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.86	0.51	9.81e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs4494114	1.000	rs9439084	chr1:39345017	A/C	cg25970120	chr1:39325951	RRAGC	-0.41	-6.47	-0.33	3.56e-10	Blood protein levels;
LUSC	cis	rs8179	0.700	rs42043	chr7:92247333	A/G	cg15732164	chr7:92237376	CDK6	-0.45	-6.23	-0.32	1.36e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs4409675	0.576	rs6679432	chr1:28227665	T/C	cg23691781	chr1:28212827	C1orf38	0.32	7.65	0.39	2.21e-13	Corneal astigmatism;
LUSC	trans	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg26043149	chr18:55253948	FECH	-0.51	-7.6	-0.38	2.96e-13	Bone mineral density;
LUSC	cis	rs10992471	0.603	rs1535755	chr9:95202031	G/T	cg14631576	chr9:95140430	CENPP	-0.36	-6.5	-0.34	2.94e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	6.19	0.32	1.79e-9	Breast cancer;
LUSC	cis	rs244293	1.000	rs183618	chr17:53235974	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.42	5.98	0.31	5.84e-9	Menarche (age at onset);
LUSC	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg26441486	chr22:50317300	CRELD2	0.52	7.95	0.4	2.85e-14	Schizophrenia;
LUSC	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg23505145	chr19:12996616	KLF1	0.65	11.05	0.52	2.17e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11997175	0.549	rs4349945	chr8:33654323	T/C	ch.8.33884649F	chr8:33765107	NA	0.52	8.45	0.42	8.95e-16	Body mass index;
LUSC	cis	rs9640161	0.783	rs2021871	chr7:150071156	T/C	cg21361702	chr7:150065534	REPIN1	0.59	9.18	0.45	4.49e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg24813613	chr7:1882135	MAD1L1	-0.48	-8.16	-0.41	6.72e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg05887092	chr17:76393375	PGS1	0.55	9.81	0.47	4.04e-20	HDL cholesterol levels;
LUSC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.07	-0.4	1.31e-14	Bipolar disorder and schizophrenia;
LUSC	trans	rs5756813	0.754	rs4821706	chr22:38154690	A/G	cg19894588	chr14:64061835	NA	-0.58	-7.48	-0.38	6.74e-13	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg02475777	chr4:1388615	CRIPAK	0.45	6.86	0.35	3.37e-11	Obesity-related traits;
LUSC	cis	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg06521331	chr12:34319734	NA	-0.52	-8.62	-0.43	2.69e-16	Morning vs. evening chronotype;
LUSC	cis	rs4692589	0.581	rs62344678	chr4:170961308	G/A	cg19918862	chr4:170955249	NA	0.35	6.45	0.33	3.87e-10	Anxiety disorder;
LUSC	cis	rs73198271	0.530	rs113160067	chr8:8654521	A/C	cg01851573	chr8:8652454	MFHAS1	0.61	8.32	0.41	2.24e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.8	0.6	1.3600000000000001e-34	Chronic sinus infection;
LUSC	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg19748678	chr4:122722346	EXOSC9	0.49	6.7	0.34	8.97e-11	Type 2 diabetes;
LUSC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7246967	0.611	rs12983761	chr19:22840597	C/A	cg23217946	chr19:22817039	ZNF492	0.45	6.04	0.31	4.09e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg15031826	chr1:208136952	NA	0.41	6.12	0.32	2.59e-9	N-glycan levels;
LUSC	trans	rs1040	0.646	rs6605528	chr6:169608807	A/C	cg08069338	chr6:160207898	SNORA29;TCP1	0.36	6.03	0.31	4.37e-9	Joint mobility (Beighton score);
LUSC	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.46	-0.42	8.29e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg05347473	chr6:146136440	FBXO30	0.56	9.54	0.46	3.02e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg08392591	chr16:89556376	ANKRD11	0.47	7.09	0.36	8.07e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.91	-0.35	2.39e-11	Monocyte percentage of white cells;
LUSC	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg09509183	chr1:209979624	IRF6	-0.42	-5.68	-0.3	2.99e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs73206853	0.620	rs17682644	chr12:111156008	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	6.77	0.35	5.7e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs13314892	1.000	rs13314892	chr3:69795052	A/G	cg16641818	chr10:45869619	ALOX5	0.42	5.97	0.31	6.23e-9	QRS complex (12-leadsum);
LUSC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.44	-6.9	-0.35	2.56e-11	Bipolar disorder;
LUSC	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.81	0.35	4.44e-11	Rheumatoid arthritis;
LUSC	trans	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg21775007	chr8:11205619	TDH	-0.41	-6.22	-0.32	1.52e-9	Mood instability;
LUSC	cis	rs737008	0.922	rs11074957	chr16:11378151	G/A	cg00044050	chr16:11439710	C16orf75	-0.52	-8.03	-0.4	1.64e-14	Obesity-related traits;
LUSC	trans	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg21051086	chr3:73046214	PPP4R2	0.53	8.07	0.4	1.26e-14	Pancreatic cancer;
LUSC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.08	-0.32	3.23e-9	Life satisfaction;
LUSC	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg16898833	chr6:26189333	HIST1H4D	0.63	5.96	0.31	6.36e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10905065	0.965	rs10795520	chr10:5764160	G/A	cg11519256	chr10:5708881	ASB13	0.4	5.83	0.3	1.34e-8	Menopause (age at onset);
LUSC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg16362232	chr11:430036	ANO9	0.61	7.96	0.4	2.63e-14	Body mass index;
LUSC	trans	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.41	-6.14	-0.32	2.3e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg23711669	chr6:146136114	FBXO30	0.75	13.26	0.59	1.61e-32	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.65	0.6	5.26e-34	Alzheimer's disease;
LUSC	trans	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg10756647	chr7:56101905	PSPH	-0.87	-8.68	-0.43	1.74e-16	Diabetic kidney disease;
LUSC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg06784218	chr1:46089804	CCDC17	0.47	9.27	0.45	2.3e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg07148914	chr20:33460835	GGT7	-0.45	-6.67	-0.34	1.07e-10	Height;
LUSC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	8.75	0.43	1.06e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg08999081	chr20:33150536	PIGU	0.43	7.9	0.4	4.06e-14	Coronary artery disease;
LUSC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.74	0.35	6.99e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg15147215	chr3:52552868	STAB1	-0.32	-6.34	-0.33	7.29e-10	Electroencephalogram traits;
LUSC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs13315871	0.790	rs28502788	chr3:58296208	A/T	cg20936604	chr3:58311152	NA	-0.67	-6.59	-0.34	1.69e-10	Cholesterol, total;
LUSC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg03289416	chr15:75166202	SCAMP2	0.44	6.68	0.34	9.94e-11	Breast cancer;
LUSC	cis	rs2227564	0.620	rs11000765	chr10:75512452	G/C	cg23231163	chr10:75533350	FUT11	-0.45	-6.52	-0.34	2.63e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs983392	0.631	rs7107627	chr11:60041296	T/A	cg02771260	chr11:59836817	MS4A3	0.36	5.89	0.31	9.17e-9	Alzheimer's disease (late onset);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02999463	chr8:37707322	BRF2	-0.41	-6.19	-0.32	1.73e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs4631830	0.863	rs4935162	chr10:51525699	C/G	cg20129853	chr10:51489980	NA	-0.34	-7.04	-0.36	1.11e-11	Prostate-specific antigen levels;
LUSC	cis	rs80130819	0.688	rs7313023	chr12:48584179	T/C	cg24011408	chr12:48396354	COL2A1	0.44	5.67	0.3	3.1e-8	Prostate cancer;
LUSC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	0.92	13.16	0.58	3.76e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg01802117	chr1:53393560	SCP2	0.41	6.88	0.35	2.89e-11	Monocyte count;
LUSC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.93	0.31	7.68e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11650494	0.908	rs111834333	chr17:47411814	C/T	cg08112188	chr17:47440006	ZNF652	1.16	9.74	0.47	6.89e-20	Prostate cancer;
LUSC	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.32	0.45	1.64e-18	Lung cancer in ever smokers;
LUSC	trans	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg03886242	chr7:26192032	NFE2L3	0.37	6.27	0.32	1.12e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6681460	0.649	rs1338184	chr1:67005072	C/T	cg02459107	chr1:67143332	SGIP1	-0.36	-6.15	-0.32	2.17e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.52	8.78	0.43	8.41e-17	Blood metabolite levels;
LUSC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6541297	0.941	rs6693579	chr1:230282707	T/C	cg20703242	chr1:230279135	GALNT2	0.57	7.17	0.37	4.92e-12	Coronary artery disease;
LUSC	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg22508957	chr16:3507546	NAT15	-0.41	-6.52	-0.34	2.67e-10	Body mass index (adult);
LUSC	cis	rs12472274	0.646	rs10929269	chr2:239097423	A/G	cg17459225	chr2:239074497	NA	0.54	7.41	0.38	1.06e-12	Phospholipid levels (plasma);
LUSC	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.32	-6.54	-0.34	2.32e-10	Dupuytren's disease;
LUSC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6500395	0.926	rs1120275	chr16:48598737	T/G	cg04672837	chr16:48644449	N4BP1	0.43	6.17	0.32	1.94e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg26513180	chr16:89883248	FANCA	0.9	17.39	0.69	1.12e-48	Vitiligo;
LUSC	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg24687543	chr11:63912206	MACROD1	0.47	5.82	0.3	1.4e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	13.65	0.6	4.99e-34	Platelet count;
LUSC	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg20283391	chr11:68216788	NA	-0.61	-8.53	-0.42	5.12e-16	Total body bone mineral density;
LUSC	cis	rs9303542	0.559	rs2229302	chr17:46620402	G/A	cg09704116	chr17:46666958	LOC404266	-0.39	-6.58	-0.34	1.85e-10	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg18132916	chr6:79620363	NA	-0.38	-5.84	-0.3	1.23e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg15485101	chr11:133734466	NA	0.4	7.2	0.37	4.13e-12	Childhood ear infection;
LUSC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs6543140	0.601	rs6543135	chr2:103062406	C/T	cg09003973	chr2:102972529	NA	0.71	8.31	0.41	2.51e-15	Blood protein levels;
LUSC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.58	10.74	0.51	2.64e-23	Homoarginine levels;
LUSC	cis	rs6120849	0.707	rs3746448	chr20:33572979	C/T	cg24642439	chr20:33292090	TP53INP2	0.58	5.94	0.31	7.17e-9	Protein C levels;
LUSC	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.46	-0.33	3.73e-10	High light scatter reticulocyte count;
LUSC	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07636037	chr3:49044803	WDR6	-0.69	-9.17	-0.45	4.8e-18	Menarche (age at onset);
LUSC	trans	rs7137301	0.895	rs10842526	chr12:25447753	A/G	cg04849298	chr8:142309389	NA	-0.38	-6.0	-0.31	5.12e-9	Dysmenorrheic pain;
LUSC	cis	rs6484504	0.576	rs11031320	chr11:31242545	C/T	cg14844989	chr11:31128820	NA	-0.37	-5.74	-0.3	2.1e-8	Red blood cell count;
LUSC	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg15997130	chr1:24165203	NA	0.57	9.21	0.45	3.7e-18	Immature fraction of reticulocytes;
LUSC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg13683864	chr3:40499215	RPL14	-1.16	-21.22	-0.76	7.21e-64	Renal cell carcinoma;
LUSC	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg17507749	chr15:85114479	UBE2QP1	0.59	7.51	0.38	5.32e-13	Schizophrenia;
LUSC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg13560548	chr3:10150139	C3orf24	0.55	7.37	0.37	1.33e-12	Alzheimer's disease;
LUSC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg22800045	chr5:56110881	MAP3K1	0.67	9.13	0.45	6.52e-18	Initial pursuit acceleration;
LUSC	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg24851651	chr11:66362959	CCS	-0.37	-5.84	-0.3	1.26e-8	Educational attainment (years of education);
LUSC	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg00564555	chr16:1970112	NA	0.37	6.26	0.32	1.2e-9	Insulin-like growth factors;
LUSC	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.97	-0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg22482690	chr17:47019901	SNF8	0.4	7.64	0.39	2.33e-13	Type 2 diabetes;
LUSC	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg09307838	chr4:120376055	NA	-0.6	-8.85	-0.44	5.24e-17	Corneal astigmatism;
LUSC	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.57	7.66	0.39	2.06e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs500891	1.000	rs62419351	chr6:84192228	C/G	cg08257003	chr6:84140564	ME1	0.34	7.06	0.36	9.77e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg22563815	chr15:78856949	CHRNA5	-0.25	-6.03	-0.31	4.45e-9	Sudden cardiac arrest;
LUSC	cis	rs62408225	1.000	rs969577	chr6:90982387	T/C	cg06866423	chr6:90926672	BACH2	0.42	5.98	0.31	5.77e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1163251	0.902	rs839605	chr1:120217524	C/A	cg19096424	chr1:120255104	PHGDH	0.48	6.53	0.34	2.39e-10	Blood metabolite levels;
LUSC	trans	rs72674100	1.000	rs4075858	chr4:97991815	A/G	cg00855990	chr1:18959354	PAX7	0.59	5.95	0.31	6.74e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7818345	0.967	rs6990357	chr8:19276681	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	7.47	0.38	6.9e-13	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg08773314	chr2:239334832	ASB1	0.37	6.91	0.35	2.51e-11	Multiple system atrophy;
LUSC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.83	-0.3	1.33e-8	Platelet count;
LUSC	cis	rs10740039	0.804	rs4948424	chr10:62441570	C/T	cg18175470	chr10:62150864	ANK3	-0.45	-6.7	-0.34	8.84e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2970818	0.831	rs11063207	chr12:4603698	A/G	cg11146114	chr12:4671731	NA	-0.56	-5.92	-0.31	7.87e-9	Phosphorus levels;
LUSC	cis	rs977987	0.778	rs11149825	chr16:75434878	C/T	cg04384234	chr16:75411784	CFDP1	-0.42	-6.85	-0.35	3.56e-11	Dupuytren's disease;
LUSC	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.25	0.32	1.27e-9	Total body bone mineral density;
LUSC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg11766577	chr21:47581405	C21orf56	-0.42	-6.21	-0.32	1.53e-9	Testicular germ cell tumor;
LUSC	cis	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.3	-0.41	2.67e-15	Coronary artery disease;
LUSC	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg12442385	chr7:1034912	NA	-0.34	-5.81	-0.3	1.42e-8	Longevity;Endometriosis;
LUSC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.71	-0.34	8.39e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.87	-11.03	-0.52	2.41e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.05	-0.31	3.81e-9	Breast cancer;
LUSC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.6	0.57	4.77e-30	Motion sickness;
LUSC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg14500267	chr11:67383377	NA	0.44	8.94	0.44	2.79e-17	Mean corpuscular volume;
LUSC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg25456477	chr12:86230367	RASSF9	0.44	7.88	0.4	4.75e-14	Major depressive disorder;
LUSC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg14019146	chr3:50243930	SLC38A3	0.36	8.42	0.42	1.12e-15	Body mass index;
LUSC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-11.68	-0.54	1.15e-26	Colorectal cancer;
LUSC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	6.32	0.33	8.51e-10	Parkinson's disease;
LUSC	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	7.25	0.37	2.93e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs6546550	0.867	rs1551374	chr2:70079633	C/T	cg02498382	chr2:70120550	SNRNP27	-0.31	-7.46	-0.38	7.68e-13	Prevalent atrial fibrillation;
LUSC	cis	rs2224391	0.628	rs2753240	chr6:5254124	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.51	-6.87	-0.35	3.12e-11	Height;
LUSC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-10.8	-0.51	1.62e-23	Bipolar disorder;
LUSC	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg15423357	chr2:25149977	NA	0.41	8.15	0.41	7.16e-15	Body mass index;
LUSC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg06454157	chr6:167490870	NA	-0.26	-6.29	-0.33	9.76e-10	Crohn's disease;
LUSC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.29	0.33	9.99e-10	Menopause (age at onset);
LUSC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg22907277	chr7:1156413	C7orf50	0.72	10.44	0.5	2.92e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-6.14	-0.32	2.32e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.48	-6.95	-0.36	1.95e-11	Menarche (age at onset);
LUSC	cis	rs977987	0.788	rs7184525	chr16:75437186	A/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.58	-0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg24829409	chr8:58192753	C8orf71	-0.58	-7.43	-0.38	9.09e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs877282	0.842	rs12357963	chr10:757562	C/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.51	-0.34	2.71e-10	Uric acid levels;
LUSC	cis	rs1499972	0.941	rs62263121	chr3:117630348	T/C	cg07612923	chr3:117604196	NA	0.64	5.76	0.3	1.95e-8	Schizophrenia;
LUSC	cis	rs7605827	0.866	rs4668917	chr2:15661815	G/C	cg19274914	chr2:15703543	NA	0.47	9.19	0.45	4.24e-18	Educational attainment (years of education);
LUSC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-8.28	-0.41	2.93e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18876405	chr7:65276391	NA	0.55	8.81	0.43	6.74e-17	Aortic root size;
LUSC	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg07382826	chr16:28625726	SULT1A1	0.27	5.82	0.3	1.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg14965968	chr3:44803235	KIF15;KIAA1143	0.5	6.11	0.32	2.72e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10573403	chr14:36003118	INSM2	0.5	6.88	0.35	3.05e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.77	0.35	5.97e-11	Tonsillectomy;
LUSC	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.7	12.84	0.57	6.14e-31	Platelet distribution width;
LUSC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.61	0.34	1.5e-10	Menopause (age at onset);
LUSC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-9.95	-0.48	1.36e-20	Chronic sinus infection;
LUSC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg16797656	chr11:68205561	LRP5	0.36	6.05	0.31	3.86e-9	Total body bone mineral density;
LUSC	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.52	-6.92	-0.35	2.25e-11	Alzheimer's disease (late onset);
LUSC	cis	rs10489202	1.000	rs34192847	chr1:168064317	A/T	cg24449463	chr1:168025552	DCAF6	-0.58	-7.09	-0.36	7.9e-12	Schizophrenia;
LUSC	cis	rs41271473	0.898	rs72750015	chr1:228811318	A/G	cg10167378	chr1:228756711	NA	0.58	7.14	0.36	5.77e-12	Chronic lymphocytic leukemia;
LUSC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.89	0.55	2.01e-27	Prudent dietary pattern;
LUSC	cis	rs9341835	0.740	rs4710255	chr6:64156268	A/C	cg03326410	chr6:64151739	NA	-0.37	-5.98	-0.31	5.76e-9	Schizophrenia;
LUSC	cis	rs11785693	0.862	rs62491189	chr8:4991309	T/C	cg26367366	chr8:4980734	NA	0.8	9.4	0.46	8.78e-19	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg14458575	chr2:238380390	NA	0.71	8.53	0.42	5.04e-16	Prostate cancer;
LUSC	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg16558253	chr16:72132732	DHX38	-0.37	-5.76	-0.3	1.86e-8	Fibrinogen levels;
LUSC	cis	rs12286929	0.610	rs12807135	chr11:115053508	G/C	cg04055981	chr11:115044050	NA	0.43	7.83	0.39	6.53e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg11663144	chr21:46675770	NA	0.39	6.21	0.32	1.61e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11637445	0.627	rs4776988	chr15:68124151	C/T	cg08079166	chr15:68083412	MAP2K5	0.32	6.55	0.34	2.2e-10	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs427941	0.632	rs201500	chr7:101757806	G/C	cg06246474	chr7:101738831	CUX1	0.39	6.36	0.33	6.54e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.09	-0.4	1.11e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg02807482	chr3:125708958	NA	-0.52	-6.51	-0.34	2.69e-10	Blood pressure (smoking interaction);
LUSC	cis	rs6977940	0.818	rs73033479	chr7:2905499	G/A	cg19731401	chr7:2775893	GNA12	0.67	7.7	0.39	1.56e-13	White matter integrity;
LUSC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg23205692	chr1:25664452	TMEM50A	0.44	6.72	0.34	8.08e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg04362960	chr10:104952993	NT5C2	0.52	7.59	0.38	3.17e-13	Immature fraction of reticulocytes;Schizophrenia;
LUSC	trans	rs17807624	0.780	rs13277929	chr8:11453030	G/A	cg06636001	chr8:8085503	FLJ10661	0.44	6.18	0.32	1.92e-9	Systemic lupus erythematosus;
LUSC	cis	rs4843185	0.516	rs374029	chr16:85725953	G/A	cg26571870	chr16:85723150	GINS2	-0.34	-6.31	-0.33	8.93e-10	Platelet distribution width;
LUSC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs68170813	0.559	rs10953534	chr7:106913718	A/G	cg02696742	chr7:106810147	HBP1	0.61	9.11	0.45	7.93e-18	Coronary artery disease;
LUSC	cis	rs2073300	1.000	rs6114139	chr20:23458390	T/G	cg09953122	chr20:23471693	CST8	-0.69	-6.84	-0.35	3.84e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg20887711	chr4:1340912	KIAA1530	-0.47	-7.24	-0.37	3.1e-12	Obesity-related traits;
LUSC	cis	rs4654899	1.000	rs7525438	chr1:21458217	G/A	cg01072550	chr1:21505969	NA	-0.55	-8.41	-0.42	1.18e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg01879757	chr17:41196368	BRCA1	0.4	5.99	0.31	5.32e-9	Menopause (age at onset);
LUSC	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.67	9.52	0.46	3.67e-19	Methadone dose in opioid dependence;
LUSC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg25039879	chr17:56429692	SUPT4H1	0.41	5.91	0.31	8.31e-9	Cognitive test performance;
LUSC	cis	rs2797160	0.515	rs4897149	chr6:125980018	G/T	cg05901451	chr6:126070800	HEY2	0.41	5.94	0.31	7.1e-9	Endometrial cancer;
LUSC	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-0.84	-15.5	-0.65	3.28e-41	Height;
LUSC	cis	rs10761482	0.701	rs7087958	chr10:62121891	G/A	cg18175470	chr10:62150864	ANK3	-0.41	-6.16	-0.32	2.15e-9	Schizophrenia;
LUSC	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg18357645	chr12:58087776	OS9	0.49	7.34	0.37	1.65e-12	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg27572855	chr1:25598939	RHD	0.44	7.82	0.39	6.94e-14	Erythrocyte sedimentation rate;
LUSC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg16606324	chr3:10149918	C3orf24	0.62	8.42	0.42	1.16e-15	Alzheimer's disease;
LUSC	cis	rs400736	0.562	rs7551900	chr1:8178526	A/C	cg25007680	chr1:8021821	PARK7	-0.43	-6.16	-0.32	2.08e-9	Response to antidepressants and depression;
LUSC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg23711669	chr6:146136114	FBXO30	0.86	15.54	0.65	2.22e-41	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20404643	chr11:1492543	HCCA2	-0.39	-6.25	-0.32	1.28e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg21100191	chr22:23484243	RTDR1	0.86	14.42	0.62	5.5e-37	Bone mineral density;
LUSC	cis	rs7614311	0.681	rs73130565	chr3:63887135	T/C	cg22134162	chr3:63841271	THOC7	-0.48	-6.13	-0.32	2.43e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg26395211	chr5:140044315	WDR55	0.45	6.99	0.36	1.5e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg21573476	chr21:45109991	RRP1B	-0.41	-6.66	-0.34	1.11e-10	Mean corpuscular volume;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06569271	chr3:186501246	EIF4A2;SNORD2	-0.4	-6.18	-0.32	1.9e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.61	9.28	0.45	2.28e-18	Schizophrenia;
LUSC	cis	rs926938	0.584	rs1299780	chr1:115366014	G/A	cg12756093	chr1:115239321	AMPD1	0.53	8.05	0.4	1.44e-14	Autism;
LUSC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg16362232	chr11:430036	ANO9	0.62	7.81	0.39	7.41e-14	Body mass index;
LUSC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg20203395	chr5:56204925	C5orf35	0.55	8.02	0.4	1.86e-14	Initial pursuit acceleration;
LUSC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg07424592	chr7:64974309	NA	0.7	6.2	0.32	1.67e-9	Diabetic kidney disease;
LUSC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.02	0.31	4.59e-9	Menopause (age at onset);
LUSC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg00376283	chr12:123451042	ABCB9	0.71	10.93	0.51	5.64e-24	Platelet count;
LUSC	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg22431228	chr1:16359049	CLCNKA	-0.47	-10.12	-0.48	3.57e-21	Dilated cardiomyopathy;
LUSC	cis	rs4792901	0.918	rs76798487	chr17:41633391	A/G	cg22562494	chr17:41607896	ETV4	-0.29	-5.73	-0.3	2.3e-8	Dupuytren's disease;
LUSC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg23625390	chr15:77176239	SCAPER	-0.5	-7.79	-0.39	8.74e-14	Blood metabolite levels;
LUSC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg03146154	chr1:46216737	IPP	0.54	8.25	0.41	3.79e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg24829409	chr8:58192753	C8orf71	-0.54	-6.15	-0.32	2.18e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg19875535	chr5:140030758	IK	0.52	8.57	0.42	3.89e-16	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs11030122	0.673	rs11030639	chr11:4039056	A/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.65	-0.3	3.52e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.78	0.35	5.5e-11	Platelet count;
LUSC	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg26441486	chr22:50317300	CRELD2	0.45	6.8	0.35	4.81e-11	Schizophrenia;
LUSC	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg06808227	chr14:105710500	BRF1	-0.64	-9.22	-0.45	3.34e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9815354	0.680	rs79211428	chr3:41921810	C/T	cg03022575	chr3:42003672	ULK4	0.71	7.52	0.38	5.17e-13	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.89	0.31	9.52e-9	Menopause (age at onset);
LUSC	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg10018233	chr7:150070692	REPIN1	0.37	6.48	0.33	3.37e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs250677	0.522	rs1432801	chr5:148390979	T/C	cg18129178	chr5:148520854	ABLIM3	-0.54	-7.72	-0.39	1.34e-13	Breast cancer;
LUSC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03934478	chr11:495069	RNH1	0.79	9.53	0.46	3.34e-19	Body mass index;
LUSC	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg09904177	chr6:26538194	HMGN4	0.66	11.71	0.54	9.14e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	1.03	21.0	0.75	5.38e-63	Cognitive function;
LUSC	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg17757837	chr7:157058334	UBE3C	-0.93	-15.85	-0.66	1.45e-42	Body mass index;
LUSC	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.55	8.47	0.42	8.12e-16	Colorectal cancer;
LUSC	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg12884169	chr21:40033163	ERG	0.61	12.48	0.56	1.35e-29	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg10609677	chr17:41278573	BRCA1;NBR2	0.36	5.86	0.31	1.09e-8	Menopause (age at onset);
LUSC	cis	rs9807841	0.592	rs11085743	chr19:10759442	G/A	cg09936142	chr19:10668400	KRI1	-0.41	-6.71	-0.34	8.59e-11	Inflammatory skin disease;
LUSC	cis	rs7589342	0.509	rs10177819	chr2:106386640	G/A	cg09152813	chr2:106391379	NCK2	-0.37	-6.14	-0.32	2.32e-9	Addiction;
LUSC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg10792982	chr14:105748885	BRF1	0.47	8.3	0.41	2.56e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg16586182	chr3:47516702	SCAP	-0.45	-6.36	-0.33	6.68e-10	Birth weight;
LUSC	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg20887711	chr4:1340912	KIAA1530	0.41	6.16	0.32	2.15e-9	Obesity-related traits;
LUSC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.2	-0.37	3.9e-12	Bipolar disorder;
LUSC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.56	-8.7	-0.43	1.55e-16	Tonsillectomy;
LUSC	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg22676075	chr6:135203613	NA	0.48	7.51	0.38	5.47e-13	Red blood cell count;
LUSC	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.84	-0.44	5.46e-17	Response to antipsychotic treatment;
LUSC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg16325326	chr1:53192061	ZYG11B	-1.0	-20.85	-0.75	1.94e-62	Monocyte count;
LUSC	cis	rs17253792	0.915	rs75862063	chr14:56177769	G/T	cg01858014	chr14:56050164	KTN1	-0.85	-6.86	-0.35	3.35e-11	Putamen volume;
LUSC	cis	rs4947962	0.618	rs59119563	chr7:55090048	T/C	cg23757825	chr7:55092271	EGFR	-0.65	-8.39	-0.42	1.42e-15	Subjective response to lithium treatment;
LUSC	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg00105475	chr2:10696890	NA	0.37	6.12	0.32	2.55e-9	Prostate cancer;
LUSC	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg11102782	chr19:18549136	ISYNA1	-0.32	-5.97	-0.31	6.12e-9	Breast cancer;
LUSC	cis	rs6750047	0.771	rs1056837	chr2:38298150	A/G	cg07380506	chr2:38303506	CYP1B1	0.44	6.09	0.32	3.12e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs56399783	0.901	rs73051415	chr7:2850643	C/T	cg19731401	chr7:2775893	GNA12	0.71	9.73	0.47	7.3e-20	Childhood ear infection;
LUSC	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.61	10.08	0.48	5.02e-21	Bone mineral density;
LUSC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg15147215	chr3:52552868	STAB1	-0.31	-6.13	-0.32	2.47e-9	Bipolar disorder;
LUSC	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg08847533	chr14:75593920	NEK9	-0.82	-13.49	-0.59	2.04e-33	Height;
LUSC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.82	0.78	4.1e-70	Prudent dietary pattern;
LUSC	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg01528321	chr10:82214614	TSPAN14	1.03	15.99	0.66	3.98e-43	Post bronchodilator FEV1;
LUSC	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23598886	chr18:12777645	NA	0.65	6.58	0.34	1.83e-10	Inflammatory skin disease;
LUSC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg12935359	chr14:103987150	CKB	-0.52	-8.07	-0.4	1.26e-14	Body mass index;
LUSC	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg07211511	chr3:129823064	LOC729375	0.96	13.42	0.59	3.86e-33	Blood pressure (smoking interaction);
LUSC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg22868518	chr11:507468	RNH1	-0.63	-6.2	-0.32	1.69e-9	Body mass index;
LUSC	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg02423579	chr7:2872169	GNA12	-0.39	-5.81	-0.3	1.43e-8	Height;
LUSC	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	8.25	0.41	3.68e-15	Lung cancer in ever smokers;
LUSC	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-5.9	-0.31	8.85e-9	Neutrophil percentage of white cells;
LUSC	cis	rs524023	0.914	rs2360872	chr11:64353405	T/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.15	-0.49	2.86e-21	Urate levels in obese individuals;
LUSC	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg02766259	chr12:125626809	AACS	-0.3	-5.75	-0.3	2.04e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg12559939	chr2:27858050	GPN1	0.41	6.48	0.33	3.32e-10	Oral cavity cancer;
LUSC	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.18	-0.49	2.18e-21	Eye color traits;
LUSC	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.49	-7.58	-0.38	3.37e-13	Schizophrenia;
LUSC	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg19743168	chr1:23544995	NA	-0.46	-10.03	-0.48	7.03e-21	Height;
LUSC	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.67	11.39	0.53	1.28e-25	White blood cell count (basophil);
LUSC	cis	rs6545883	0.929	rs2264100	chr2:61670829	G/A	cg15711740	chr2:61764176	XPO1	-0.46	-7.11	-0.36	7.17e-12	Tuberculosis;
LUSC	cis	rs701145	0.585	rs1727920	chr3:153788588	C/T	cg17054900	chr3:154042577	DHX36	0.72	7.26	0.37	2.82e-12	Coronary artery disease;
LUSC	trans	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.08	-0.44	9.93e-18	Depression;
LUSC	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-8.01	-0.4	1.95e-14	Body mass index;
LUSC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg04315214	chr1:2043799	PRKCZ	0.5	10.5	0.5	1.78e-22	Height;
LUSC	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg17764715	chr19:33622953	WDR88	0.62	8.47	0.42	8.16e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg00321850	chr1:175162397	KIAA0040	0.46	7.98	0.4	2.36e-14	Alcohol dependence;
LUSC	cis	rs1113500	0.933	rs3893034	chr1:108632178	G/A	cg06207961	chr1:108661230	NA	0.4	7.45	0.38	8.2e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs6445797	0.632	rs9985253	chr3:56629250	G/C	cg13792233	chr3:56591045	CCDC66	0.39	5.64	0.3	3.55e-8	Gastritis;
LUSC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg22907277	chr7:1156413	C7orf50	0.67	7.95	0.4	2.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	0.98	13.65	0.6	5.18e-34	Uric acid levels;
LUSC	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-15.35	-0.64	1.33e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.84	0.47	3.07e-20	Lung cancer;
LUSC	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg24690094	chr11:67383802	NA	-0.45	-8.09	-0.4	1.11e-14	Mean corpuscular volume;
LUSC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg26380479	chr7:97908229	NA	-0.27	-5.9	-0.31	8.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6087990	0.735	rs2065576	chr20:31389009	C/T	cg13636640	chr20:31349939	DNMT3B	0.92	18.94	0.72	7.43e-55	Ulcerative colitis;
LUSC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg12463550	chr7:65579703	CRCP	-0.49	-7.03	-0.36	1.19e-11	Aortic root size;
LUSC	cis	rs4588572	0.644	rs10942856	chr5:77746199	A/G	cg11547950	chr5:77652471	NA	0.49	7.23	0.37	3.4e-12	Triglycerides;
LUSC	cis	rs2548003	0.518	rs1157974	chr5:28765229	C/T	cg22863700	chr5:28928346	NA	-0.44	-6.28	-0.32	1.07e-9	Hip geometry;
LUSC	cis	rs2652822	0.935	rs12148069	chr15:63443792	A/T	cg02713581	chr15:63449717	RPS27L	0.43	6.74	0.35	7.07e-11	Metabolic traits;
LUSC	cis	rs4363385	0.693	rs821755	chr1:153036245	G/C	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.2	-0.37	4.13e-12	Inflammatory skin disease;
LUSC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg05347473	chr6:146136440	FBXO30	-0.49	-8.29	-0.41	2.72e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg05373962	chr22:49881684	NA	-0.4	-8.38	-0.42	1.49e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg21280719	chr6:42927975	GNMT	-0.31	-7.84	-0.39	6.14e-14	Plasma homocysteine levels (post-methionine load test);
LUSC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	0.98	13.49	0.59	2.03e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg07080220	chr10:102295463	HIF1AN	0.58	7.59	0.38	3.1400000000000003e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg15147215	chr3:52552868	STAB1	-0.3	-5.84	-0.3	1.22e-8	Electroencephalogram traits;
LUSC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg13010199	chr12:38710504	ALG10B	-0.66	-10.08	-0.48	5.02e-21	Bladder cancer;
LUSC	cis	rs965469	0.895	rs6051841	chr20:3392871	A/G	cg25506879	chr20:3388711	C20orf194	-0.54	-5.79	-0.3	1.66e-8	IFN-related cytopenia;
LUSC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg12437481	chr16:420112	MRPL28	-0.42	-7.45	-0.38	8.17e-13	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	16.48	0.67	4.67e-45	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	8.92	0.44	3.22e-17	Monocyte percentage of white cells;
LUSC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg12311346	chr5:56204834	C5orf35	-0.67	-10.1	-0.48	4.07e-21	Coronary artery disease;
LUSC	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.43e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg14440974	chr22:39074834	NA	-0.36	-6.1	-0.32	2.87e-9	Menopause (age at onset);
LUSC	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg08755490	chr11:65554678	OVOL1	0.41	5.87	0.31	1.05e-8	Acne (severe);
LUSC	cis	rs3764563	1.000	rs2031062	chr19:15717573	T/C	cg20725493	chr19:15740067	CYP4F8	-0.67	-6.58	-0.34	1.85e-10	Inflammatory biomarkers;
LUSC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg03213289	chr20:61660250	NA	0.67	13.95	0.61	3.76e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18876405	chr7:65276391	NA	-0.58	-9.44	-0.46	6.45e-19	Aortic root size;
LUSC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-6.94	-0.35	2.11e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Depression;
LUSC	cis	rs921665	0.748	rs1869421	chr2:3202068	G/T	cg02624386	chr2:3182749	NA	0.62	6.61	0.34	1.55e-10	World class endurance athleticism;
LUSC	trans	rs7170930	0.618	rs55865344	chr15:66541771	T/C	cg06396762	chr16:3202609	NA	-0.72	-5.98	-0.31	5.75e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs1595825	0.891	rs58111212	chr2:198889896	T/C	cg00982548	chr2:198649783	BOLL	-0.54	-6.93	-0.35	2.2e-11	Ulcerative colitis;
LUSC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg27165867	chr14:105738592	BRF1	-0.56	-8.48	-0.42	7.47e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08109568	chr15:31115862	NA	0.74	11.08	0.52	1.63e-24	Huntington's disease progression;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12766407	chr15:56657635	TEX9	-0.42	-6.05	-0.31	3.91e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	6.34	0.33	7.5e-10	Tonsillectomy;
LUSC	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg06784218	chr1:46089804	CCDC17	0.37	6.26	0.32	1.15e-9	Platelet count;
LUSC	trans	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg07393940	chr7:158741817	NA	-0.51	-8.09	-0.4	1.12e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10754283	0.967	rs6698273	chr1:90106791	T/A	cg21401794	chr1:90099060	LRRC8C	0.65	9.69	0.47	9.88e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.44e-17	Iron status biomarkers;
LUSC	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg06092702	chr1:163392909	NA	-0.39	-6.55	-0.34	2.21e-10	Motion sickness;
LUSC	cis	rs12220238	1.000	rs11000887	chr10:75897542	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.6	7.11	0.36	7.3e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.51	0.34	2.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3750965	0.959	rs4930264	chr11:68852181	C/T	cg06818126	chr11:68850279	TPCN2	-0.45	-6.53	-0.34	2.4e-10	Hair color;
LUSC	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg08999081	chr20:33150536	PIGU	-0.41	-7.56	-0.38	3.88e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.82	-14.64	-0.63	7.79e-38	Cognitive function;
LUSC	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg11861562	chr11:117069780	TAGLN	0.44	7.86	0.4	5.19e-14	Blood protein levels;
LUSC	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg14458575	chr2:238380390	NA	0.66	8.32	0.41	2.25e-15	Prostate cancer;
LUSC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg23719950	chr11:63933701	MACROD1	-0.62	-8.07	-0.4	1.26e-14	Mean platelet volume;
LUSC	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	cg06064525	chr11:970664	AP2A2	-0.3	-5.92	-0.31	7.81e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg18681998	chr4:17616180	MED28	0.86	15.91	0.66	8.29e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7527798	0.592	rs12144801	chr1:207857773	A/G	cg09232269	chr1:207846808	CR1L	-0.31	-6.71	-0.34	8.55e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg24675658	chr1:53192096	ZYG11B	0.72	12.06	0.55	4.64e-28	Monocyte count;
LUSC	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.09	-0.4	1.11e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg18681998	chr4:17616180	MED28	0.86	16.03	0.66	2.84e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4919087	0.962	rs10786324	chr10:99054387	A/G	cg25902810	chr10:99078978	FRAT1	0.47	6.66	0.34	1.14e-10	Monocyte count;
LUSC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11764359	chr7:65958608	NA	-0.69	-11.11	-0.52	1.26e-24	Aortic root size;
LUSC	trans	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg25214090	chr10:38739885	LOC399744	0.46	6.71	0.34	8.23e-11	Corneal astigmatism;
LUSC	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg02574844	chr11:5959923	NA	-0.45	-6.36	-0.33	6.66e-10	DNA methylation (variation);
LUSC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg16434002	chr17:42200994	HDAC5	-0.44	-6.0	-0.31	5.26e-9	Total body bone mineral density;
LUSC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg04727924	chr7:799746	HEATR2	-0.53	-6.37	-0.33	6.27e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs806215	1.000	rs806219	chr7:127240094	A/C	cg25922125	chr7:127225783	GCC1	0.58	7.38	0.37	1.26e-12	Type 2 diabetes;
LUSC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg15383120	chr6:291909	DUSP22	-0.47	-7.36	-0.37	1.44e-12	Menopause (age at onset);
LUSC	cis	rs17155006	0.691	rs409815	chr7:107745443	A/G	cg05962710	chr7:107745446	LAMB4	0.35	6.18	0.32	1.87e-9	Pneumococcal bacteremia;
LUSC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs11264213	0.901	rs72661616	chr1:36370512	G/A	cg27506609	chr1:36549197	TEKT2	0.68	7.88	0.4	4.58e-14	Schizophrenia;
LUSC	cis	rs4730250	0.707	rs257377	chr7:106801088	G/T	cg02696742	chr7:106810147	HBP1	-0.64	-8.94	-0.44	2.63e-17	Osteoarthritis;
LUSC	cis	rs11971779	0.616	rs6965143	chr7:139026608	C/G	cg23387468	chr7:139079360	LUC7L2	0.4	6.01	0.31	4.77e-9	Diisocyanate-induced asthma;
LUSC	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg12927641	chr6:109611667	NA	-0.36	-6.12	-0.32	2.66e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg17264618	chr3:40429014	ENTPD3	0.29	6.39	0.33	5.56e-10	Renal cell carcinoma;
LUSC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.5	5.94	0.31	7.13e-9	Renal function-related traits (BUN);
LUSC	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg08854313	chr1:11322531	MTOR	0.8	12.45	0.56	1.6800000000000001e-29	Body mass index;
LUSC	cis	rs2976388	0.967	rs2976397	chr8:143764613	G/T	cg17252645	chr8:143867129	LY6D	-0.38	-6.48	-0.33	3.3e-10	Urinary tract infection frequency;
LUSC	cis	rs7267979	0.932	rs13040655	chr20:25582197	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.56	0.69	2.29e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6977660	0.943	rs6959678	chr7:19821759	C/A	cg05791153	chr7:19748676	TWISTNB	0.53	5.83	0.3	1.29e-8	Thyroid stimulating hormone;
LUSC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-9.99	-0.48	9.85e-21	Bipolar disorder and schizophrenia;
LUSC	trans	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.57	-9.37	-0.46	1.15e-18	Mean corpuscular volume;
LUSC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-10.82	-0.51	1.39e-23	Monocyte percentage of white cells;
LUSC	cis	rs6845621	0.745	rs1400939	chr4:18856479	C/T	cg12196642	chr4:18937545	NA	-0.31	-5.78	-0.3	1.72e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	0.65	13.69	0.6	3.62e-34	Prudent dietary pattern;
LUSC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.73	0.39	1.26e-13	Parkinson's disease;
LUSC	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg25173405	chr17:45401733	C17orf57	0.36	5.72	0.3	2.36e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs2262909	0.962	rs12610034	chr19:22314528	G/A	cg05197062	chr11:11642011	GALNTL4	0.54	7.62	0.38	2.7e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.73	-0.7	4.71e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg05768032	chr16:30646687	NA	0.41	6.17	0.32	2.03e-9	Multiple myeloma;
LUSC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.49	0.46	4.39e-19	Bipolar disorder;
LUSC	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	7.12	0.36	6.53e-12	Colorectal cancer;
LUSC	cis	rs540254	0.578	rs4656933	chr1:160782561	T/A	cg20255094	chr1:160771763	LY9	0.56	6.69	0.34	9.55e-11	Blood protein levels;
LUSC	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg05110241	chr16:68378359	PRMT7	-0.53	-6.16	-0.32	2.11e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21659725	chr3:3221576	CRBN	-0.53	-8.46	-0.42	8.33e-16	Body mass index;
LUSC	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-9.55	-0.46	2.9e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7178572	0.889	rs7170877	chr15:77832019	C/G	cg22256960	chr15:77711686	NA	-0.5	-8.27	-0.41	3.13e-15	Type 2 diabetes;
LUSC	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.86	-0.44	4.97e-17	Neuroticism;
LUSC	cis	rs1595825	0.891	rs7583917	chr2:198576950	A/G	cg00982548	chr2:198649783	BOLL	-0.53	-6.69	-0.34	9.32e-11	Ulcerative colitis;
LUSC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg26380479	chr7:97908229	NA	-0.28	-6.08	-0.32	3.21e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg04545296	chr12:48745243	ZNF641	0.3	5.75	0.3	2.02e-8	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs3750082	0.582	rs6462436	chr7:32970900	T/C	cg08946731	chr7:32981826	RP9P	0.41	6.5	0.34	2.95e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg17366294	chr4:99064904	C4orf37	0.54	9.6	0.47	1.91e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4499344	0.576	rs259280	chr19:33161452	C/T	cg22980127	chr19:33182716	NUDT19	-0.45	-6.66	-0.34	1.1e-10	Mean platelet volume;
LUSC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg22800045	chr5:56110881	MAP3K1	-0.53	-7.31	-0.37	2.03e-12	Type 2 diabetes;
LUSC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg20203395	chr5:56204925	C5orf35	-0.7	-9.33	-0.45	1.56e-18	Initial pursuit acceleration;
LUSC	cis	rs16976116	0.901	rs28864456	chr15:55503092	T/C	cg11288833	chr15:55489084	RSL24D1	0.51	6.16	0.32	2.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	6.07	0.32	3.53e-9	Schizophrenia;
LUSC	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.87	-0.7	1.34e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03591801	chr19:36119784	RBM42	-0.42	-6.11	-0.32	2.74e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10147044	chr15:75230572	COX5A	-0.48	-6.6	-0.34	1.61e-10	Hepatitis;
LUSC	cis	rs76662990	0.764	rs76733847	chr5:73888150	G/A	cg01264639	chr5:73839484	NA	0.54	5.71	0.3	2.43e-8	Residual cognition;
LUSC	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg02018176	chr4:1364513	KIAA1530	0.46	6.5	0.33	3e-10	Recombination rate (females);
LUSC	trans	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg13565492	chr6:43139072	SRF	-0.57	-6.23	-0.32	1.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg13834567	chr19:42817981	TMEM145	-0.52	-6.79	-0.35	5.28e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg14092571	chr14:90743983	NA	-0.88	-18.24	-0.71	4.54e-52	Gut microbiota (bacterial taxa);
LUSC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg00383909	chr3:49044727	WDR6	0.42	5.64	0.3	3.58e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg19875535	chr5:140030758	IK	-0.47	-7.7	-0.39	1.55e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21724239	chr8:58056113	NA	0.85	9.05	0.44	1.18e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg12463550	chr7:65579703	CRCP	0.5	6.98	0.36	1.65e-11	Aortic root size;
LUSC	trans	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg00343986	chr7:65444356	GUSB	-0.48	-7.29	-0.37	2.19e-12	Aortic root size;
LUSC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg22800045	chr5:56110881	MAP3K1	0.75	9.77	0.47	5.46e-20	Initial pursuit acceleration;
LUSC	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg11244672	chr19:19639970	YJEFN3	-0.6	-7.33	-0.37	1.69e-12	Bipolar disorder;
LUSC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg24562669	chr7:97807699	LMTK2	0.35	6.12	0.32	2.58e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg16339924	chr4:17578868	LAP3	-0.49	-7.55	-0.38	4.21e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2425143	1.000	rs73905926	chr20:34251982	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.57	-0.34	1.88e-10	Blood protein levels;
LUSC	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg12863693	chr15:85201151	NMB	0.41	8.27	0.41	3.15e-15	Schizophrenia;
LUSC	cis	rs1568889	0.938	rs12795971	chr11:28355104	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	8.74	0.43	1.17e-16	Bipolar disorder;
LUSC	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.26	-0.32	1.17e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	18.98	0.72	5.41e-55	Chronic sinus infection;
LUSC	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.57	-0.34	1.94e-10	Neuroticism;
LUSC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg13770153	chr20:60521292	NA	-0.46	-6.61	-0.34	1.57e-10	Body mass index;
LUSC	cis	rs1113500	0.933	rs10881497	chr1:108634515	A/G	cg06207961	chr1:108661230	NA	-0.4	-7.44	-0.38	8.48e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs16910800	1.000	rs2468655	chr11:23197060	G/A	cg20040320	chr11:23191996	NA	0.44	6.55	0.34	2.15e-10	Cancer;
LUSC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08280861	chr8:58055591	NA	0.57	8.32	0.41	2.28e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg06521331	chr12:34319734	NA	-0.47	-7.55	-0.38	4.09e-13	Morning vs. evening chronotype;
LUSC	cis	rs9549260	0.755	rs7990923	chr13:41215972	A/G	cg21288729	chr13:41239152	FOXO1	0.64	9.9	0.48	2.01e-20	Red blood cell count;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg16886045	chr19:1269073	CIRBP;C19orf23	0.7	6.14	0.32	2.31e-9	Body mass index;
LUSC	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs3106136	0.546	rs2632417	chr4:95137542	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.46	-0.42	8.25e-16	Capecitabine sensitivity;
LUSC	cis	rs6961069	0.708	rs7807445	chr7:80217974	A/G	cg04458919	chr7:80252533	CD36	-0.4	-7.12	-0.36	6.65e-12	Platelet count;
LUSC	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.35	-0.42	1.84e-15	Retinal vascular caliber;
LUSC	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg13010199	chr12:38710504	ALG10B	0.69	10.65	0.5	5.27e-23	Bladder cancer;
LUSC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs13401104	0.796	rs12472312	chr2:237113030	G/A	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.35e-8	Educational attainment;
LUSC	cis	rs6500395	1.000	rs1872654	chr16:48671050	C/T	cg04672837	chr16:48644449	N4BP1	0.46	6.91	0.35	2.41e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21862992	chr11:68658383	NA	0.48	7.71	0.39	1.45e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg08000102	chr2:233561755	GIGYF2	-0.47	-6.96	-0.36	1.79e-11	Coronary artery disease;
LUSC	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.85	-0.3	1.2e-8	Total body bone mineral density;
LUSC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg23262073	chr20:60523788	NA	0.38	6.0	0.31	5.14e-9	Body mass index;
LUSC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	18.97	0.72	5.61e-55	Prudent dietary pattern;
LUSC	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.71	-10.9	-0.51	7.13e-24	Alcohol dependence;
LUSC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-10.17	-0.49	2.42e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg20821713	chr7:1055600	C7orf50	-0.49	-6.4	-0.33	5.12e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg00750074	chr16:89608354	SPG7	-0.46	-7.84	-0.39	6.19e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	8.37	0.42	1.64e-15	Colorectal cancer;
LUSC	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg25039879	chr17:56429692	SUPT4H1	0.72	9.69	0.47	1e-19	Cognitive test performance;
LUSC	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg03015672	chr10:32216066	ARHGAP12	0.33	5.94	0.31	7.06e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg09904177	chr6:26538194	HMGN4	-0.78	-6.2	-0.32	1.68e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg04455712	chr21:45112962	RRP1B	0.46	8.78	0.43	8.8e-17	Mean corpuscular volume;
LUSC	cis	rs2387326	0.672	rs12254264	chr10:129945519	C/T	cg16087940	chr10:129947807	NA	-0.4	-6.12	-0.32	2.59e-9	Select biomarker traits;
LUSC	trans	rs11039798	0.858	rs11039730	chr11:48440495	A/G	cg15704280	chr7:45808275	SEPT13	0.72	6.05	0.31	3.95e-9	Axial length;
LUSC	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg06606381	chr12:133084897	FBRSL1	-1.01	-9.06	-0.44	1.14e-17	Depression;
LUSC	cis	rs10193935	0.901	rs13384404	chr2:42601147	G/T	cg27598129	chr2:42591480	NA	-0.65	-8.74	-0.43	1.19e-16	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg07605469	chr12:113573757	RASAL1	0.39	6.01	0.31	4.95e-9	Schizophrenia;
LUSC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	1.05	19.12	0.72	1.42e-55	Menopause (age at onset);
LUSC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg05973401	chr12:123451056	ABCB9	0.62	8.84	0.44	5.58e-17	Platelet count;
LUSC	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg06219351	chr7:158114137	PTPRN2	-0.54	-8.36	-0.42	1.71e-15	Response to amphetamines;
LUSC	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg00334542	chr7:100209784	MOSPD3	-0.48	-5.68	-0.3	2.87e-8	Other erythrocyte phenotypes;
LUSC	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg06637938	chr14:75390232	RPS6KL1	0.65	11.0	0.52	3.23e-24	Caffeine consumption;
LUSC	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg26384229	chr12:38710491	ALG10B	0.52	7.79	0.39	8.58e-14	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	8.45	0.42	9.09e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg12432903	chr7:1882776	MAD1L1	-0.4	-6.67	-0.34	1.08e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-6.57	-0.34	1.96e-10	Monocyte count;
LUSC	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg03015672	chr10:32216066	ARHGAP12	0.34	6.06	0.31	3.73e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg24675658	chr1:53192096	ZYG11B	-0.71	-12.14	-0.55	2.41e-28	Monocyte count;
LUSC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg02269571	chr22:50332266	NA	-0.62	-9.15	-0.45	5.66e-18	Schizophrenia;
LUSC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg04450456	chr4:17643702	FAM184B	0.39	6.6	0.34	1.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7923609	0.756	rs6479908	chr10:65333648	C/G	cg01631684	chr10:65280961	REEP3	0.38	5.75	0.3	2.04e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21782813	chr7:2030301	MAD1L1	-0.47	-8.04	-0.4	1.61e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg22676075	chr6:135203613	NA	0.46	7.21	0.37	3.84e-12	Red blood cell count;
LUSC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12311346	chr5:56204834	C5orf35	-0.84	-9.44	-0.46	6.7e-19	Type 2 diabetes;
LUSC	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg13877915	chr19:58951672	ZNF132	0.48	7.55	0.38	4.16e-13	Uric acid clearance;
LUSC	trans	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg26043149	chr18:55253948	FECH	-0.54	-8.17	-0.41	6.46e-15	Bone mineral density;
LUSC	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg06263672	chr7:65235340	NA	0.42	6.08	0.32	3.37e-9	Calcium levels;
LUSC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.76	-13.43	-0.59	3.45e-33	Dental caries;
LUSC	cis	rs9392556	0.829	rs693953	chr6:4120565	A/T	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.36	-6.16	-0.32	2.06e-9	Blood metabolite levels;
LUSC	cis	rs4700695	0.668	rs253214	chr5:65499401	A/G	cg21114390	chr5:65439923	SFRS12	-0.47	-6.86	-0.35	3.31e-11	Facial morphology (factor 19);
LUSC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02018176	chr4:1364513	KIAA1530	-0.67	-11.97	-0.55	1.01e-27	Obesity-related traits;
LUSC	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg17252645	chr8:143867129	LY6D	0.38	6.72	0.34	8.03e-11	Urinary tract infection frequency;
LUSC	cis	rs113835537	0.529	rs17065	chr11:66277035	G/A	cg24851651	chr11:66362959	CCS	0.52	7.58	0.38	3.34e-13	Airway imaging phenotypes;
LUSC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg06238570	chr21:40685208	BRWD1	-0.63	-10.46	-0.5	2.5e-22	Cognitive function;
LUSC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg23985595	chr17:80112537	CCDC57	-0.31	-5.86	-0.31	1.12e-8	Life satisfaction;
LUSC	cis	rs12220238	1.000	rs11000909	chr10:75944828	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.59	6.89	0.35	2.71e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	trans	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-8.42	-0.42	1.16e-15	Obesity-related traits;
LUSC	cis	rs9309711	0.961	rs11678655	chr2:3476234	T/G	cg10845886	chr2:3471009	TTC15	-0.63	-8.24	-0.41	4.09e-15	Neurofibrillary tangles;
LUSC	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-8.13	-0.41	8.66e-15	Response to antipsychotic treatment;
LUSC	trans	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.44	6.58	0.34	1.85e-10	Endometrial cancer;
LUSC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg07414643	chr4:187882934	NA	0.55	10.33	0.49	7e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg20744362	chr22:50050164	C22orf34	0.38	7.45	0.38	7.96e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.18	0.58	3.23e-32	Alzheimer's disease;
LUSC	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg18190219	chr22:46762943	CELSR1	-0.55	-6.28	-0.33	1.05e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs12477438	0.520	rs12467504	chr2:99543208	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-5.84	-0.3	1.24e-8	Chronic sinus infection;
LUSC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg07507251	chr3:52567010	NT5DC2	0.36	6.99	0.36	1.49e-11	Bipolar disorder;
LUSC	cis	rs3820928	0.874	rs55743026	chr2:227802813	G/A	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.75	-0.39	1.14e-13	Pulmonary function;
LUSC	cis	rs55675132	0.664	rs1575071	chr1:115567833	G/A	cg01522456	chr1:115632236	TSPAN2	-0.46	-5.74	-0.3	2.12e-8	Schizophrenia;
LUSC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.56	-10.99	-0.52	3.44e-24	Prostate cancer;
LUSC	cis	rs6542838	0.641	rs12467189	chr2:99495820	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.08	-0.32	3.32e-9	Fear of minor pain;
LUSC	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.47	7.67	0.39	1.9e-13	Alcohol dependence;
LUSC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.16	-0.32	2.04e-9	Personality dimensions;
LUSC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg03354898	chr7:1950403	MAD1L1	0.35	6.81	0.35	4.59e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.11	14.54	0.62	1.83e-37	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg00509249	chr6:109615579	CCDC162	-0.34	-6.12	-0.32	2.6e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg11645453	chr3:52864694	ITIH4	-0.37	-8.66	-0.43	2.02e-16	Bipolar disorder;
LUSC	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg22681709	chr2:178499509	PDE11A	-0.55	-11.03	-0.52	2.5300000000000002e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg05255149	chr17:80675120	FN3KRP	0.43	6.25	0.32	1.24e-9	Asthma;
LUSC	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg08798685	chr6:27730294	NA	-0.6	-5.89	-0.31	9.28e-9	Depression;
LUSC	cis	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg07460842	chr6:66804631	NA	-0.59	-8.32	-0.41	2.21e-15	Initial pursuit acceleration in psychotic disorders;
LUSC	trans	rs459571	0.959	rs456205	chr9:136911146	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.74	-12.41	-0.56	2.35e-29	Platelet distribution width;
LUSC	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg25801113	chr15:45476975	SHF	0.34	7.04	0.36	1.13e-11	Uric acid levels;
LUSC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg11859384	chr17:80120422	CCDC57	0.36	5.69	0.3	2.71e-8	Life satisfaction;
LUSC	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg03522245	chr20:25566470	NINL	0.36	5.81	0.3	1.46e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg05855489	chr10:104503620	C10orf26	0.62	7.84	0.39	5.91e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs748404	0.697	rs504417	chr15:43554226	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	8.35	0.42	1.82e-15	Lung cancer;
LUSC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg04511125	chr2:88470314	THNSL2	-0.43	-6.54	-0.34	2.37e-10	Response to metformin (IC50);
LUSC	cis	rs500891	0.693	rs1144196	chr6:83977714	C/A	cg08257003	chr6:84140564	ME1	0.33	7.41	0.38	1.07e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	7.67	0.39	1.86e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg05084668	chr3:125655381	ALG1L	-0.77	-11.86	-0.54	2.63e-27	Blood pressure (smoking interaction);
LUSC	trans	rs6600671	0.967	rs12069545	chr1:121172203	A/G	cg00646200	chr1:148855367	NA	0.45	7.18	0.37	4.44e-12	Hip geometry;
LUSC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.74	11.3	0.53	2.7e-25	Tonsillectomy;
LUSC	cis	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05901451	chr6:126070800	HEY2	-0.57	-8.79	-0.43	7.91e-17	Endometrial cancer;
LUSC	cis	rs9395066	0.545	rs4711807	chr6:44911652	G/A	cg25276700	chr6:44698697	NA	0.3	6.04	0.31	4.11e-9	Height;
LUSC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs4771122	0.740	rs1006353	chr13:28047269	A/G	cg22138327	chr13:27999177	GTF3A	-0.67	-10.45	-0.5	2.67e-22	Body mass index;
LUSC	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-11.28	-0.53	3.32e-25	Migraine;Coronary artery disease;
LUSC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg09904177	chr6:26538194	HMGN4	0.76	14.14	0.61	6.79e-36	Intelligence (multi-trait analysis);
LUSC	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.44	-0.33	4.05e-10	Uric acid levels;
LUSC	cis	rs9359856	0.529	rs1328017	chr6:90297603	T/C	cg13799429	chr6:90582589	CASP8AP2	0.77	7.43	0.38	9.35e-13	Bipolar disorder;
LUSC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	8.61	0.43	2.99e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg01616529	chr11:638424	DRD4	-0.35	-5.8	-0.3	1.5e-8	Systemic lupus erythematosus;
LUSC	cis	rs185694	1.000	rs613291	chr13:30894404	T/C	cg07600127	chr13:30881527	KATNAL1	-0.54	-5.9	-0.31	8.77e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
LUSC	cis	rs9547692	1.000	rs493248	chr13:37473386	C/T	cg01034396	chr13:37494802	SMAD9	0.3	5.74	0.3	2.13e-8	Coronary artery disease;
LUSC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg21361702	chr7:150065534	REPIN1	0.52	6.76	0.35	6.24e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	22.01	0.77	5.62e-67	Prudent dietary pattern;
LUSC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg13114125	chr14:105738426	BRF1	-0.91	-14.92	-0.63	6.02e-39	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.44e-17	Iron status biomarkers;
LUSC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18876405	chr7:65276391	NA	-0.55	-8.66	-0.43	2.09e-16	Aortic root size;
LUSC	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg11871910	chr12:69753446	YEATS4	0.45	5.79	0.3	1.64e-8	Response to diuretic therapy;
LUSC	trans	rs72674100	1.000	rs28496290	chr4:97969761	G/T	cg16405019	chr1:18959625	PAX7	-0.59	-6.38	-0.33	5.78e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs73198271	0.562	rs2048420	chr8:8667603	G/A	cg01851573	chr8:8652454	MFHAS1	0.65	8.46	0.42	8.7e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg06238570	chr21:40685208	BRWD1	0.52	7.96	0.4	2.73e-14	Cognitive function;
LUSC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg24562669	chr7:97807699	LMTK2	0.35	6.08	0.32	3.26e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	0.93	17.12	0.68	1.26e-47	Headache;
LUSC	cis	rs10492096	0.947	rs11559082	chr12:6602367	C/T	cg13857086	chr12:6580257	VAMP1	0.61	7.25	0.37	2.89e-12	Hip geometry;
LUSC	trans	rs61931739	0.649	rs708144	chr12:33731158	T/C	cg26384229	chr12:38710491	ALG10B	0.42	6.07	0.32	3.55e-9	Morning vs. evening chronotype;
LUSC	cis	rs116095464	1.000	rs56095714	chr5:311256	C/T	cg22857025	chr5:266934	NA	-1.13	-8.37	-0.42	1.62e-15	Breast cancer;
LUSC	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg24375607	chr4:120327624	NA	0.76	12.21	0.56	1.33e-28	Corneal astigmatism;
LUSC	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg12940439	chr1:67600707	NA	0.37	6.04	0.31	4.13e-9	Psoriasis;
LUSC	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg13206674	chr6:150067644	NUP43	0.62	9.87	0.48	2.41e-20	Lung cancer;
LUSC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg13206674	chr6:150067644	NUP43	0.57	9.09	0.45	9.1e-18	Lung cancer;
LUSC	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-9.75	-0.47	6.19e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.83	14.33	0.62	1.2e-36	Metabolic syndrome;
LUSC	cis	rs2932538	0.922	rs12125361	chr1:113144779	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	10.01	0.48	8.67e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg01475377	chr6:109611718	NA	-0.41	-7.26	-0.37	2.7e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs77741769	0.571	rs989987	chr12:121274062	C/T	cg02419362	chr12:121203948	SPPL3	0.46	8.57	0.42	3.78e-16	Mean corpuscular volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20617676	chr7:123389167	WASL	-0.47	-6.38	-0.33	5.9e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4499344	0.526	rs17832981	chr19:33034461	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	9.96	0.48	1.21e-20	Mean platelet volume;
LUSC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg22903471	chr2:27725779	GCKR	-0.41	-6.89	-0.35	2.71e-11	Total body bone mineral density;
LUSC	cis	rs4629180	0.586	rs1509494	chr2:102134862	G/T	cg04415270	chr2:102091202	RFX8	-0.45	-7.78	-0.39	8.93e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs2274273	0.837	rs6573017	chr14:55802243	G/A	cg04306507	chr14:55594613	LGALS3	0.56	12.81	0.57	8.09e-31	Protein biomarker;
LUSC	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg02176678	chr2:219576539	TTLL4	-0.61	-11.13	-0.52	1.14e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg25258033	chr6:167368657	RNASET2	0.47	7.42	0.38	9.92e-13	Crohn's disease;
LUSC	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18932078	chr1:2524107	MMEL1	-0.29	-6.44	-0.33	4.15e-10	Ulcerative colitis;
LUSC	cis	rs10875746	0.903	rs12301339	chr12:48475233	T/C	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03576123	chr11:487126	PTDSS2	-1.02	-10.84	-0.51	1.14e-23	Body mass index;
LUSC	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg06026331	chr20:60912101	LAMA5	0.62	7.34	0.37	1.64e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs28647808	0.881	rs71483207	chr9:136258698	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg22907277	chr7:1156413	C7orf50	0.46	7.34	0.37	1.69e-12	Longevity;Endometriosis;
LUSC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.92	-0.31	8.02e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.51	-0.38	5.36e-13	Neuroticism;
LUSC	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg08601574	chr20:25228251	PYGB	-0.43	-6.59	-0.34	1.71e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg05347473	chr6:146136440	FBXO30	-0.65	-11.14	-0.52	1.05e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg16346588	chr10:242978	ZMYND11	0.46	6.48	0.33	3.27e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg05802129	chr4:122689817	NA	-0.45	-7.58	-0.38	3.37e-13	Type 2 diabetes;
LUSC	cis	rs7615316	1.000	rs6440099	chr3:142356226	C/T	cg16271453	chr3:142027066	XRN1	-0.34	-5.74	-0.3	2.09e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs909002	0.925	rs10798882	chr1:32108547	C/G	cg01639898	chr1:32083012	HCRTR1	-0.25	-5.81	-0.3	1.47e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20227886	chr18:48405353	ME2	-0.48	-6.3	-0.33	9.49e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3126085	0.935	rs4845734	chr1:152167473	T/C	cg26876637	chr1:152193138	HRNR	0.45	6.36	0.33	6.5e-10	Atopic dermatitis;
LUSC	cis	rs8141797	0.792	rs3752497	chr22:24581207	C/T	cg00411358	chr22:24577142	SUSD2	-0.56	-6.0	-0.31	5.03e-9	Amyotrophic lateral sclerosis;Coronary artery disease;
LUSC	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg00277334	chr10:82204260	NA	-0.54	-8.75	-0.43	1.05e-16	Post bronchodilator FEV1;
LUSC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.5	-10.92	-0.51	6.08e-24	Type 2 diabetes;
LUSC	cis	rs911119	1.000	rs2016161	chr20:23621174	G/T	cg16589663	chr20:23618590	CST3	-0.52	-6.3	-0.33	9.18e-10	Chronic kidney disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05351267	chr16:1877388	HAGH;FAHD1	-0.43	-6.42	-0.33	4.58e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg26587870	chr6:27730563	NA	-0.65	-6.04	-0.31	4.2e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg19508488	chr2:152266495	RIF1	-0.39	-5.76	-0.3	1.95e-8	Lung cancer;
LUSC	cis	rs2637266	0.783	rs7898786	chr10:78481338	T/C	cg18941641	chr10:78392320	NA	0.36	6.49	0.33	3.06e-10	Pulmonary function;
LUSC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg14004847	chr7:1930337	MAD1L1	-0.54	-8.15	-0.41	7.48e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs12681287	0.752	rs2917557	chr8:87314071	C/T	cg27223183	chr8:87520930	FAM82B	-0.47	-5.78	-0.3	1.75e-8	Caudate activity during reward;
LUSC	cis	rs9646944	0.501	rs10176820	chr2:103054420	T/C	cg20060108	chr2:102954350	IL1RL1	0.46	6.39	0.33	5.51e-10	Blood protein levels;
LUSC	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg13813247	chr22:41461852	NA	-0.39	-7.03	-0.36	1.17e-11	Neuroticism;
LUSC	trans	rs6600671	1.000	rs11249351	chr1:121171942	G/A	cg00646200	chr1:148855367	NA	0.45	7.18	0.37	4.44e-12	Hip geometry;
LUSC	cis	rs516243	0.703	rs169538	chr1:10737045	T/C	cg02903756	chr1:10750680	CASZ1	-0.47	-8.47	-0.42	7.96e-16	Migraine - clinic-based;
LUSC	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg04896959	chr15:78267971	NA	-0.49	-10.27	-0.49	1.14e-21	Coronary artery disease or large artery stroke;
LUSC	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.75	-0.47	6.45e-20	Hemoglobin concentration;
LUSC	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg12257692	chr3:49977190	RBM6	0.2	5.65	0.3	3.36e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg24209194	chr3:40518798	ZNF619	-0.41	-5.85	-0.3	1.19e-8	Renal cell carcinoma;
LUSC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg23985595	chr17:80112537	CCDC57	0.31	5.88	0.31	9.8e-9	Life satisfaction;
LUSC	cis	rs870825	0.860	rs61165411	chr4:185604461	G/A	cg04058563	chr4:185651563	MLF1IP	0.81	10.67	0.5	4.48e-23	Blood protein levels;
LUSC	cis	rs1506636	1.000	rs2429619	chr7:123425599	C/G	cg03229431	chr7:123269106	ASB15	0.65	10.59	0.5	8.63e-23	Plateletcrit;Platelet count;
LUSC	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg15704280	chr7:45808275	SEPT13	-0.43	-5.98	-0.31	5.62e-9	Height;
LUSC	cis	rs55675132	0.833	rs7542335	chr1:115639374	G/A	cg01522456	chr1:115632236	TSPAN2	-0.45	-5.86	-0.31	1.09e-8	Schizophrenia;
LUSC	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	8.18	0.41	6.06e-15	Iron status biomarkers;
LUSC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.89	-18.1	-0.7	1.6e-51	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs757081	0.533	rs7949405	chr11:17085192	A/C	cg15084286	chr11:17036142	PLEKHA7	0.46	5.92	0.31	8.07e-9	Systolic blood pressure;
LUSC	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-6.15	-0.32	2.22e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg11494091	chr17:61959527	GH2	0.37	6.21	0.32	1.54e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg26384229	chr12:38710491	ALG10B	0.59	8.84	0.44	5.5e-17	Heart rate;
LUSC	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg08079166	chr15:68083412	MAP2K5	0.49	8.01	0.4	1.89e-14	Restless legs syndrome;
LUSC	cis	rs7843479	0.965	rs13278159	chr8:21799737	C/A	cg17168535	chr8:21777572	XPO7	0.68	10.63	0.5	6.09e-23	Mean corpuscular volume;
LUSC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg02187348	chr16:89574699	SPG7	-0.45	-6.73	-0.35	7.55e-11	Multiple myeloma (IgH translocation);
LUSC	trans	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg20935933	chr6:143382018	AIG1	0.5	7.18	0.37	4.55e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.76	-0.43	9.89e-17	Obesity-related traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25319031	chr3:119813310	GSK3B	-0.4	-5.97	-0.31	6.03e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg00343986	chr7:65444356	GUSB	-0.44	-6.76	-0.35	6.29e-11	Aortic root size;
LUSC	cis	rs13202913	0.652	rs9371528	chr6:151832668	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.52	5.7	0.3	2.69e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg26408565	chr15:76604113	ETFA	-0.47	-7.42	-0.38	9.75e-13	Blood metabolite levels;
LUSC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08045932	chr20:61659980	NA	0.59	10.4	0.49	3.85e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	8.86	0.44	4.9e-17	Alzheimer's disease;
LUSC	cis	rs9815354	0.812	rs17218264	chr3:41975847	C/T	cg03022575	chr3:42003672	ULK4	-0.81	-9.01	-0.44	1.66e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9640161	0.830	rs1051823	chr7:150070814	G/A	cg27494647	chr7:150038898	RARRES2	0.36	5.82	0.3	1.35e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg17385448	chr1:15911702	AGMAT	0.37	6.4	0.33	5.16e-10	Systolic blood pressure;
LUSC	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg00857998	chr1:205179979	DSTYK	0.67	10.55	0.5	1.19e-22	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.59	7.73	0.39	1.27e-13	Ulcerative colitis;
LUSC	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg09165964	chr15:75287851	SCAMP5	-0.72	-6.56	-0.34	2.05e-10	Lung cancer;
LUSC	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg09307838	chr4:120376055	NA	-0.72	-10.38	-0.49	4.55e-22	Corneal astigmatism;
LUSC	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg05805236	chr11:65401703	PCNXL3	0.61	10.09	0.48	4.67e-21	Acne (severe);
LUSC	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg04374321	chr14:90722782	PSMC1	0.7	10.93	0.51	5.62e-24	Mortality in heart failure;
LUSC	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg04691961	chr3:161091175	C3orf57	-0.36	-6.12	-0.32	2.6e-9	Morning vs. evening chronotype;
LUSC	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.36	6.48	0.33	3.34e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08616760	chr5:178157801	ZNF354A	0.43	6.71	0.34	8.12e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg01802117	chr1:53393560	SCP2	0.38	6.2	0.32	1.67e-9	Monocyte count;
LUSC	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg00898013	chr13:113819073	PROZ	-0.56	-8.06	-0.4	1.36e-14	Platelet distribution width;
LUSC	cis	rs600231	0.623	rs3015966	chr11:65217589	T/C	cg21890820	chr11:65308645	LTBP3	0.48	7.03	0.36	1.2e-11	Bone mineral density;
LUSC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.74	0.3	2.08e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg02389323	chr16:88786976	FAM38A	1.11	11.41	0.53	1.14e-25	Plateletcrit;
LUSC	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg24375607	chr4:120327624	NA	-0.69	-10.9	-0.51	6.88e-24	Corneal astigmatism;
LUSC	cis	rs2303282	0.865	rs370151	chr16:56561494	G/T	cg00500540	chr16:56394104	NA	-0.43	-7.03	-0.36	1.21e-11	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00771490	chr12:65008851	RASSF3	-0.48	-7.17	-0.37	4.97e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.81	-14.68	-0.63	5.44e-38	Age at first birth;
LUSC	cis	rs7804356	1.000	rs7785711	chr7:26861640	G/A	cg03456212	chr7:26904342	SKAP2	-0.52	-6.08	-0.32	3.24e-9	Type 1 diabetes;
LUSC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07677032	chr17:61819896	STRADA	0.51	8.63	0.43	2.53e-16	Prudent dietary pattern;
LUSC	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.9	-15.18	-0.64	6.12e-40	Schizophrenia;
LUSC	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg20790798	chr5:1857306	NA	-0.46	-7.99	-0.4	2.25e-14	Cardiovascular disease risk factors;
LUSC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg12257692	chr3:49977190	RBM6	0.23	6.35	0.33	7.21e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg05347473	chr6:146136440	FBXO30	0.5	8.36	0.42	1.77e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11764359	chr7:65958608	NA	0.66	10.23	0.49	1.5e-21	Aortic root size;
LUSC	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg05342945	chr12:48394962	COL2A1	-0.45	-6.04	-0.31	4.21e-9	Lung cancer;
LUSC	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg00898013	chr13:113819073	PROZ	-0.56	-8.07	-0.4	1.29e-14	Platelet distribution width;
LUSC	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14442939	chr10:27389572	ANKRD26	0.51	5.97	0.31	6.07e-9	Breast cancer;
LUSC	cis	rs7577696	0.962	rs12617289	chr2:32341399	A/G	cg02381751	chr2:32503542	YIPF4	-0.4	-5.71	-0.3	2.5e-8	Inflammatory biomarkers;
LUSC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg21963583	chr11:68658836	MRPL21	0.56	8.4	0.42	1.26e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs62458065	0.850	rs10273165	chr7:32460840	G/A	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.25	-0.32	1.28e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs2985334	1.000	rs2993715	chr1:29356050	C/G	cg05928980	chr1:29567425	PTPRU	0.33	5.69	0.3	2.84e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg16447950	chr5:562315	NA	-0.56	-6.88	-0.35	2.88e-11	Obesity-related traits;
LUSC	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg19336497	chr11:14380999	RRAS2	-0.39	-7.33	-0.37	1.72e-12	Mitochondrial DNA levels;
LUSC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.68	0.34	1.01e-10	Neutrophil percentage of white cells;
LUSC	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg13010199	chr12:38710504	ALG10B	0.61	10.27	0.49	1.14e-21	Heart rate;
LUSC	cis	rs10904908	1.000	rs10904908	chr10:17260290	A/G	cg01003015	chr10:17271136	VIM	-0.42	-6.06	-0.31	3.73e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg02023728	chr11:77925099	USP35	0.44	6.64	0.34	1.3e-10	Testicular germ cell tumor;
LUSC	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.6	-0.43	3.09e-16	Body mass index;
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.31	-6.21	-0.32	1.57e-9	Longevity;Endometriosis;
LUSC	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	11.39	0.53	1.25e-25	Coronary artery disease;
LUSC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.9	0.44	3.49e-17	Prudent dietary pattern;
LUSC	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg12940439	chr1:67600707	NA	0.37	5.98	0.31	5.76e-9	Psoriasis;
LUSC	cis	rs67366981	1.000	rs55923743	chr14:77711454	G/A	cg22824376	chr14:77648248	TMEM63C	0.65	6.19	0.32	1.75e-9	Obsessive-compulsive symptoms;
LUSC	cis	rs4629180	0.586	rs1509497	chr2:102138184	C/T	cg01388757	chr2:102091195	RFX8	-0.36	-6.26	-0.32	1.19e-9	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06544989	chr22:39130855	UNC84B	0.33	5.75	0.3	1.99e-8	Menopause (age at onset);
LUSC	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-8.94	-0.44	2.61e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-10.72	-0.51	3.16e-23	Joint mobility (Beighton score);
LUSC	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg23172400	chr8:95962367	TP53INP1	0.35	6.7	0.34	8.71e-11	Type 2 diabetes;
LUSC	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg24558204	chr6:135376177	HBS1L	0.57	8.81	0.43	6.87e-17	Red blood cell count;
LUSC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-1.17	-16.85	-0.68	1.53e-46	Breast cancer;
LUSC	cis	rs10789491	0.951	rs35050319	chr1:47103886	C/A	cg15501359	chr1:47185051	KIAA0494	-0.81	-11.09	-0.52	1.47e-24	Response to hepatitis C treatment;
LUSC	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg03929089	chr4:120376271	NA	-0.58	-7.49	-0.38	6.14e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg05855489	chr10:104503620	C10orf26	0.53	8.01	0.4	1.98e-14	Arsenic metabolism;
LUSC	cis	rs9650657	0.812	rs11250073	chr8:10632236	G/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.43	-0.33	4.37e-10	Neuroticism;
LUSC	cis	rs113835537	0.597	rs2075792	chr11:66334556	G/A	cg24851651	chr11:66362959	CCS	0.57	8.83	0.43	6.06e-17	Airway imaging phenotypes;
LUSC	cis	rs617219	0.819	rs2607145	chr5:78552400	A/G	cg24856658	chr5:78533917	JMY	-0.3	-5.88	-0.31	9.86e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-0.91	-17.45	-0.69	6.14e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.75	13.45	0.59	3.03e-33	Dental caries;
LUSC	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg22532475	chr10:104410764	TRIM8	-0.26	-6.07	-0.32	3.47e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg05966235	chr16:28915196	ATP2A1	0.34	5.96	0.31	6.41e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	7.16	0.36	5.23e-12	Height;
LUSC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.58	9.57	0.46	2.55e-19	Aortic root size;
LUSC	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg21775007	chr8:11205619	TDH	-0.53	-7.99	-0.4	2.22e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs11610422	1.000	rs12824814	chr12:31414473	G/T	cg14306366	chr12:31406441	NA	-0.51	-6.25	-0.32	1.25e-9	Coronary artery disease;
LUSC	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	7.46	0.38	7.66e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg14092988	chr3:52407081	DNAH1	0.33	6.32	0.33	8.52e-10	Bipolar disorder;
LUSC	cis	rs524023	0.958	rs3825016	chr11:64359286	C/T	cg19131476	chr11:64387923	NRXN2	-0.37	-10.05	-0.48	5.96e-21	Urate levels in obese individuals;
LUSC	cis	rs926938	0.527	rs360678	chr1:115493902	T/A	cg01522456	chr1:115632236	TSPAN2	-0.42	-6.5	-0.34	2.95e-10	Autism;
LUSC	cis	rs9677476	0.821	rs6731682	chr2:232106245	G/C	cg07929768	chr2:232055508	NA	0.33	6.26	0.32	1.2e-9	Food antigen IgG levels;
LUSC	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.42	6.56	0.34	2.04e-10	Dupuytren's disease;
LUSC	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.51e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07581978	chr13:80917058	NA	-0.5	-6.01	-0.31	4.77e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg27129171	chr3:47204927	SETD2	0.57	8.14	0.41	8.17e-15	Birth weight;
LUSC	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg00376283	chr12:123451042	ABCB9	0.69	10.66	0.5	4.96e-23	Platelet count;
LUSC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg25036284	chr2:26402008	FAM59B	-0.68	-9.64	-0.47	1.49e-19	Gut microbiome composition (summer);
LUSC	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg21211680	chr2:198530	NA	-0.64	-7.22	-0.37	3.57e-12	Blood protein levels;
LUSC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg08219700	chr8:58056026	NA	0.47	5.95	0.31	6.7e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10141207	0.531	rs1547213	chr14:32678646	C/A	cg23627301	chr14:32673368	NA	0.52	8.6	0.43	3.11e-16	Asthma;
LUSC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.12	-0.36	6.71e-12	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	0.94	15.86	0.66	1.24e-42	Menopause (age at onset);
LUSC	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg08645402	chr16:4508243	NA	0.53	9.0	0.44	1.71e-17	Schizophrenia;
LUSC	cis	rs7119	0.717	rs12917175	chr15:77818193	A/G	cg27398640	chr15:77910606	LINGO1	-0.3	-6.4	-0.33	5.19e-10	Type 2 diabetes;
LUSC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg01879757	chr17:41196368	BRCA1	-0.48	-7.64	-0.39	2.37e-13	Menopause (age at onset);
LUSC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16405210	chr4:1374714	KIAA1530	-0.58	-9.02	-0.44	1.47e-17	Longevity;
LUSC	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19717773	chr7:2847554	GNA12	-0.34	-5.69	-0.3	2.81e-8	Height;
LUSC	cis	rs377070	0.816	rs309406	chr4:123618707	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.4	5.89	0.31	9.33e-9	Mosquito bite size;
LUSC	cis	rs7112925	0.738	rs12803688	chr11:66833265	G/A	cg24851651	chr11:66362959	CCS	-0.36	-6.06	-0.31	3.65e-9	Height;
LUSC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-12.84	-0.57	5.96e-31	Platelet count;
LUSC	cis	rs11039100	0.850	rs12796660	chr11:5843681	T/C	cg13902645	chr11:5959945	NA	-0.54	-6.01	-0.31	4.72e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2303282	0.716	rs2241956	chr16:56400847	T/C	cg00500540	chr16:56394104	NA	-0.44	-7.55	-0.38	4.1e-13	Breast cancer;
LUSC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg05084668	chr3:125655381	ALG1L	-0.5	-7.04	-0.36	1.1e-11	Blood pressure (smoking interaction);
LUSC	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg22467129	chr15:76604101	ETFA	0.43	6.91	0.35	2.42e-11	Blood metabolite levels;
LUSC	cis	rs7084921	0.578	rs12776318	chr10:101868677	T/G	cg11888571	chr10:102027403	CWF19L1	-0.45	-6.12	-0.32	2.56e-9	Bone mineral density;
LUSC	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.99	0.31	5.5e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg18479299	chr3:125709523	NA	-0.51	-5.82	-0.3	1.35e-8	Blood pressure (smoking interaction);
LUSC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10986311	0.822	rs10818946	chr9:127116102	A/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.42	-7.0	-0.36	1.4e-11	Vitiligo;
LUSC	cis	rs73206853	0.764	rs60339427	chr12:110824471	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.68	-0.57	2.41e-30	Chronic sinus infection;
LUSC	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	1.01	11.41	0.53	1.14e-25	Type 2 diabetes;
LUSC	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg02782426	chr3:40428986	ENTPD3	0.38	6.65	0.34	1.2e-10	Renal cell carcinoma;
LUSC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg17376030	chr22:41985996	PMM1	0.46	5.89	0.31	9.37e-9	Vitiligo;
LUSC	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg04850211	chr1:228464232	OBSCN	0.32	5.76	0.3	1.94e-8	Diastolic blood pressure;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18276145	chr4:72052432	SLC4A4	0.82	7.76	0.39	1.04e-13	Cognitive performance;
LUSC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg25036284	chr2:26402008	FAM59B	0.67	9.1	0.45	8.39e-18	Gut microbiome composition (summer);
LUSC	trans	rs2055729	0.645	rs12544019	chr8:9742578	T/C	cg15556689	chr8:8085844	FLJ10661	0.5	6.34	0.33	7.32e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs559555	0.512	rs655548	chr2:31836658	A/C	cg02381751	chr2:32503542	YIPF4	0.41	5.7	0.3	2.57e-8	Blood metabolite ratios;Blood metabolite levels;
LUSC	trans	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.99	-0.31	5.47e-9	Dementia with Lewy bodies;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14159672	chr1:205819179	PM20D1	0.85	15.09	0.64	1.33e-39	Menarche (age at onset);
LUSC	cis	rs4663866	1.000	rs71426510	chr2:239178909	T/G	cg16914508	chr2:239161102	PER2	0.68	7.15	0.36	5.4e-12	Irritable bowel syndrome;
LUSC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-11.43	-0.53	9.53e-26	Total body bone mineral density;
LUSC	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg11993925	chr19:44307056	LYPD5	0.35	7.63	0.39	2.43e-13	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg27494647	chr7:150038898	RARRES2	0.45	6.98	0.36	1.64e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.3	-0.41	2.63e-15	Obesity-related traits;
LUSC	cis	rs12900413	0.687	rs8034777	chr15:90313057	C/T	cg24249390	chr15:90295951	MESP1	0.36	5.7	0.3	2.58e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg25767906	chr1:53392781	SCP2	-0.65	-12.85	-0.58	5.69e-31	Monocyte count;
LUSC	trans	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg01620082	chr3:125678407	NA	-0.6	-6.8	-0.35	4.77e-11	Depression;
LUSC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.56	9.55	0.46	2.89e-19	Lymphocyte counts;
LUSC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg07507251	chr3:52567010	NT5DC2	0.33	6.46	0.33	3.61e-10	Bipolar disorder;
LUSC	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg03342759	chr3:160939853	NMD3	-0.49	-8.16	-0.41	6.68e-15	Morning vs. evening chronotype;
LUSC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.48	7.07	0.36	9.38e-12	Platelet count;
LUSC	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg02023728	chr11:77925099	USP35	0.47	6.76	0.35	6.17e-11	Testicular germ cell tumor;
LUSC	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg03684893	chr10:554711	DIP2C	0.35	6.42	0.33	4.71e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg24562669	chr7:97807699	LMTK2	0.35	6.08	0.32	3.26e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg11812906	chr14:75593930	NEK9	0.67	11.75	0.54	6.22e-27	Height;
LUSC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg22709100	chr7:91322751	NA	0.39	5.74	0.3	2.13e-8	Breast cancer;
LUSC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg18306943	chr3:40428807	ENTPD3	0.4	6.22	0.32	1.48e-9	Renal cell carcinoma;
LUSC	cis	rs12137294	0.866	rs1078362	chr1:205209530	A/G	cg00857998	chr1:205179979	DSTYK	0.39	5.73	0.3	2.25e-8	Red cell distribution width;
LUSC	cis	rs10489525	0.599	rs7516121	chr1:115604317	A/G	cg01522456	chr1:115632236	TSPAN2	0.5	7.33	0.37	1.8e-12	Autism;
LUSC	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-7.04	-0.36	1.12e-11	Schizophrenia;
LUSC	cis	rs60154123	0.614	rs4844988	chr1:210459888	C/T	cg22029157	chr1:209979665	IRF6	0.52	5.93	0.31	7.46e-9	Coronary artery disease;
LUSC	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg05347473	chr6:146136440	FBXO30	0.55	9.35	0.46	1.34e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg26924012	chr15:45694286	SPATA5L1	1.14	19.82	0.74	2.49e-58	Homoarginine levels;
LUSC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg17178900	chr1:205818956	PM20D1	-0.73	-13.31	-0.59	1.04e-32	Monocyte percentage of white cells;
LUSC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg02807482	chr3:125708958	NA	-0.49	-6.1	-0.32	3.01e-9	Blood pressure (smoking interaction);
LUSC	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg12863693	chr15:85201151	NMB	0.36	7.05	0.36	1.05e-11	Schizophrenia;
LUSC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg13319975	chr6:146136371	FBXO30	-0.38	-5.8	-0.3	1.58e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg25344623	chr2:136566232	LCT	-0.37	-5.73	-0.3	2.28e-8	Mosquito bite size;
LUSC	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg14809332	chr8:144654887	C8orf73	0.5	6.27	0.32	1.12e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.54	-8.46	-0.42	8.5e-16	Personality dimensions;
LUSC	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg04369109	chr6:150039330	LATS1	-0.57	-8.45	-0.42	9.43e-16	Lung cancer;
LUSC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg16325326	chr1:53192061	ZYG11B	-0.88	-16.3	-0.67	2.36e-44	Monocyte count;
LUSC	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.46	-0.33	3.73e-10	High light scatter reticulocyte count;
LUSC	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg11965913	chr1:205819406	PM20D1	-0.49	-6.73	-0.35	7.57e-11	Menarche (age at onset);
LUSC	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg23625390	chr15:77176239	SCAPER	-0.55	-8.51	-0.42	5.79e-16	Blood metabolite levels;
LUSC	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg23093090	chr10:104574429	C10orf26	-0.38	-7.15	-0.36	5.68e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg00864183	chr17:48045973	DLX4	0.39	6.0	0.31	5.14e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg08345082	chr10:99160200	RRP12	-0.35	-7.17	-0.37	4.75e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7615316	0.779	rs9826786	chr3:142146261	A/C	cg16271453	chr3:142027066	XRN1	-0.42	-7.22	-0.37	3.51e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	13.44	0.59	3.1e-33	Electrocardiographic conduction measures;
LUSC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg01448562	chr3:133502909	NA	0.6	10.19	0.49	2.13e-21	Iron status biomarkers;
LUSC	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg18827107	chr12:86230957	RASSF9	-0.4	-6.01	-0.31	4.84e-9	Major depressive disorder;
LUSC	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg00132208	chr4:10120780	NA	0.35	5.71	0.3	2.49e-8	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg09997546	chr11:8931473	C11orf17;ST5	0.34	7.11	0.36	7.07e-12	Hemoglobin concentration;
LUSC	trans	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.19	-0.32	1.73e-9	Mood instability;
LUSC	cis	rs9341835	0.772	rs9294206	chr6:64141201	A/G	cg03326410	chr6:64151739	NA	-0.37	-6.04	-0.31	4.06e-9	Schizophrenia;
LUSC	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2.04e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.66	-8.67	-0.43	1.88e-16	Schizophrenia;
LUSC	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	1.1	17.27	0.69	3.24e-48	Exhaled nitric oxide output;
LUSC	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-11.7	-0.54	9.7e-27	Eye color traits;
LUSC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs2262909	0.962	rs11673195	chr19:22313814	T/C	cg05197062	chr11:11642011	GALNTL4	0.55	7.75	0.39	1.1e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.82	12.4	0.56	2.57e-29	Cognitive test performance;
LUSC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg13047869	chr3:10149882	C3orf24	0.43	6.53	0.34	2.46e-10	Alzheimer's disease;
LUSC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg03060546	chr3:49711283	APEH	0.7	11.52	0.53	4.57e-26	Resting heart rate;
LUSC	cis	rs9420	0.528	rs7117896	chr11:57388551	G/A	cg23127183	chr11:57508653	C11orf31	-0.47	-6.55	-0.34	2.18e-10	Schizophrenia;
LUSC	cis	rs61897795	0.657	rs174590	chr11:61616977	G/C	cg06781209	chr11:61594997	FADS2	-0.39	-5.97	-0.31	6.09e-9	Neutrophil count;Sum basophil neutrophil counts;
LUSC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.7	-9.84	-0.47	3.09e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg17143192	chr8:8559678	CLDN23	-0.4	-6.12	-0.32	2.57e-9	Mood instability;
LUSC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.45	7.44	0.38	8.7e-13	Pulse pressure;
LUSC	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg21963583	chr11:68658836	MRPL21	-0.41	-6.78	-0.35	5.57e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.42	-6.84	-0.35	3.86e-11	Longevity;Endometriosis;
LUSC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg26408565	chr15:76604113	ETFA	-0.53	-8.4	-0.42	1.32e-15	Blood metabolite levels;
LUSC	cis	rs12681287	0.640	rs7816275	chr8:87373404	A/G	cg00550725	chr8:87521180	FAM82B	-0.43	-5.7	-0.3	2.65e-8	Caudate activity during reward;
LUSC	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg26441486	chr22:50317300	CRELD2	0.46	6.53	0.34	2.41e-10	Schizophrenia;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg04790936	chr22:38035753	SH3BP1	0.46	6.23	0.32	1.36e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9494145	0.838	rs9494142	chr6:135431640	T/C	cg22676075	chr6:135203613	NA	0.58	7.68	0.39	1.84e-13	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
LUSC	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-9.68	-0.47	1.07e-19	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.71	0.34	8.52e-11	Lung cancer;
LUSC	cis	rs9467773	0.595	rs6907924	chr6:26438817	T/G	cg09904177	chr6:26538194	HMGN4	-0.56	-8.68	-0.43	1.81e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg21782813	chr7:2030301	MAD1L1	0.55	9.52	0.46	3.5e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg06784218	chr1:46089804	CCDC17	-0.36	-6.7	-0.34	8.85e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg08017756	chr2:100939284	LONRF2	-0.47	-8.7	-0.43	1.49e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25072359	chr17:41440525	NA	0.66	9.34	0.45	1.43e-18	Menopause (age at onset);
LUSC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.79	-11.74	-0.54	7.06e-27	Vitiligo;
LUSC	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg24642439	chr20:33292090	TP53INP2	0.41	5.97	0.31	5.95e-9	Height;
LUSC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	7.89	0.4	4.47e-14	Bipolar disorder;
LUSC	cis	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg02508848	chr16:68573721	ZFP90	-0.43	-5.89	-0.31	9.61e-9	Ulcerative colitis;
LUSC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg20849893	chr7:64541193	NA	0.45	6.45	0.33	3.92e-10	Calcium levels;
LUSC	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.4	6.48	0.33	3.39e-10	IgG glycosylation;
LUSC	cis	rs6723226	0.842	rs2754522	chr2:32801257	C/G	cg02381751	chr2:32503542	YIPF4	0.58	8.7	0.43	1.5e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22225685	chr22:38203998	GCAT	-0.47	-6.2	-0.32	1.66e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg16342193	chr10:102329863	NA	-0.33	-6.11	-0.32	2.83e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18876405	chr7:65276391	NA	0.56	8.84	0.44	5.78e-17	Aortic root size;
LUSC	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg01884057	chr2:25150051	NA	-0.38	-8.57	-0.42	4.02e-16	Body mass index in non-asthmatics;
LUSC	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg14893161	chr1:205819251	PM20D1	-0.48	-6.47	-0.33	3.54e-10	Menarche (age at onset);
LUSC	cis	rs952623	0.649	rs13242896	chr7:39070062	A/G	cg15212455	chr7:39170539	POU6F2	0.37	6.06	0.31	3.61e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg11965913	chr1:205819406	PM20D1	0.81	16.54	0.67	2.58e-45	Monocyte percentage of white cells;
LUSC	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.7	10.91	0.51	6.34e-24	Breast cancer;
LUSC	cis	rs721399	0.539	rs2898476	chr8:18266924	G/A	cg18736775	chr8:18248649	NAT2	-0.57	-6.47	-0.33	3.42e-10	Blood metabolite levels;
LUSC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg05347473	chr6:146136440	FBXO30	-0.56	-9.71	-0.47	8.3e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.53	8.43	0.42	1.07e-15	Longevity;Endometriosis;
LUSC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.99	0.36	1.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg02466173	chr16:30829666	NA	-0.53	-10.24	-0.49	1.43e-21	Dementia with Lewy bodies;
LUSC	cis	rs7267979	0.753	rs400357	chr20:25479058	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.77	16.03	0.66	2.63e-43	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	6.17	0.32	1.95e-9	Triglycerides;
LUSC	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-9.29	-0.45	2.08e-18	Lung cancer in ever smokers;
LUSC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg06808227	chr14:105710500	BRF1	-0.66	-10.19	-0.49	2.02e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9905704	0.633	rs2680712	chr17:56509865	C/T	cg19466818	chr17:56409534	MIR142	-0.3	-5.99	-0.31	5.5e-9	Testicular germ cell tumor;
LUSC	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg24558204	chr6:135376177	HBS1L	0.59	9.12	0.45	7.4e-18	Red blood cell count;
LUSC	trans	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg10756647	chr7:56101905	PSPH	0.86	8.4	0.42	1.27e-15	Diabetic kidney disease;
LUSC	cis	rs28785552	1.000	rs28785552	chr19:53234161	G/A	cg22067481	chr19:53234126	ZNF611	-0.48	-6.46	-0.33	3.78e-10	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg02018176	chr4:1364513	KIAA1530	0.55	9.67	0.47	1.13e-19	Longevity;
LUSC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	7.75	0.39	1.09e-13	Mean platelet volume;
LUSC	cis	rs11214589	0.651	rs17600713	chr11:113259947	C/T	cg14159747	chr11:113255604	NA	0.3	7.79	0.39	8.61e-14	Neuroticism;
LUSC	cis	rs2262909	0.962	rs411020	chr19:22231102	G/A	cg11619707	chr19:22235551	ZNF257	-0.38	-5.7	-0.3	2.7e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg08738300	chr3:44038990	NA	-0.7	-10.39	-0.49	4.18e-22	Coronary artery disease;
LUSC	cis	rs6540559	0.546	rs735694	chr1:210034029	T/C	cg04352962	chr1:209979756	IRF6	0.52	5.79	0.3	1.65e-8	Cleft lip with or without cleft palate;
LUSC	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.5	6.68	0.34	9.76e-11	Corneal astigmatism;
LUSC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11645453	chr3:52864694	ITIH4	0.34	8.08	0.4	1.21e-14	Electroencephalogram traits;
LUSC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.06e-12	Motion sickness;
LUSC	cis	rs7074356	0.569	rs17102596	chr10:82035173	T/C	cg27171509	chr10:82033454	MAT1A	-0.31	-5.67	-0.3	3.08e-8	Borderline personality disorder;
LUSC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg12257692	chr3:49977190	RBM6	0.24	6.69	0.34	9.19e-11	Body mass index;
LUSC	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg00898013	chr13:113819073	PROZ	0.55	7.65	0.39	2.24e-13	Platelet distribution width;
LUSC	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg09479241	chr17:27052676	TLCD1	0.43	5.96	0.31	6.29e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg00599273	chr12:58146742	CDK4	0.31	5.8	0.3	1.51e-8	Multiple sclerosis;
LUSC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.25	0.59	1.67e-32	Chronic sinus infection;
LUSC	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg21573476	chr21:45109991	RRP1B	-0.38	-6.14	-0.32	2.32e-9	Mean corpuscular volume;
LUSC	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg09998033	chr7:158218633	PTPRN2	0.57	9.29	0.45	1.98e-18	Obesity-related traits;
LUSC	cis	rs61931739	0.635	rs1825746	chr12:33939984	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.74	-0.35	7.17e-11	Morning vs. evening chronotype;
LUSC	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg19812747	chr11:111475976	SIK2	-0.52	-7.34	-0.37	1.67e-12	Primary sclerosing cholangitis;
LUSC	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg05714579	chr10:131428358	MGMT	0.52	7.95	0.4	2.84e-14	Response to temozolomide;
LUSC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21963583	chr11:68658836	MRPL21	0.56	8.33	0.41	2.15e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs3862260	0.905	rs3850870	chr1:120161037	C/T	cg11530693	chr1:120165357	ZNF697	0.51	7.92	0.4	3.49e-14	Systemic lupus erythematosus;
LUSC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	8.88	0.44	4.31e-17	Alzheimer's disease;
LUSC	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg22906224	chr7:99728672	NA	-0.47	-6.56	-0.34	2.03e-10	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.59	0.34	1.76e-10	Lung cancer;
LUSC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	9.59	0.46	2.2e-19	Mean platelet volume;
LUSC	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-8.3	-0.41	2.68e-15	Coffee consumption (cups per day);
LUSC	trans	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg04995722	chr7:26192034	NFE2L3	-0.36	-5.95	-0.31	6.69e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6484504	0.576	rs9971609	chr11:31434104	C/T	cg06552810	chr11:31128660	NA	0.35	6.11	0.32	2.74e-9	Red blood cell count;
LUSC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06481639	chr22:41940642	POLR3H	-0.5	-5.69	-0.3	2.78e-8	Vitiligo;
LUSC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11764359	chr7:65958608	NA	0.62	9.22	0.45	3.56e-18	Calcium levels;
LUSC	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg02574844	chr11:5959923	NA	-0.48	-6.76	-0.35	6.32e-11	DNA methylation (variation);
LUSC	trans	rs4729127	1.000	rs57515158	chr7:94007842	T/G	cg14660007	chr13:78271894	SLAIN1	0.49	6.25	0.32	1.27e-9	Intelligence;
LUSC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.03	-0.31	4.28e-9	Platelet count;
LUSC	cis	rs11657217	1.000	rs11657217	chr17:77709339	C/G	cg06901238	chr17:77706717	ENPP7	0.57	11.09	0.52	1.48e-24	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LUSC	cis	rs2579519	0.547	rs2463560	chr2:96595589	T/C	cg22654517	chr2:96458247	NA	0.34	6.82	0.35	4.29e-11	Diastolic blood pressure;
LUSC	cis	rs7193541	0.550	rs28607667	chr16:74476015	C/T	cg01733217	chr16:74700730	RFWD3	-0.67	-10.2	-0.49	1.92e-21	Multiple myeloma;
LUSC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.61	-11.79	-0.54	4.45e-27	Pulse pressure;
LUSC	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg14668632	chr7:2872130	GNA12	-0.47	-6.82	-0.35	4.29e-11	Height;
LUSC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg16680214	chr1:154839983	KCNN3	0.51	9.45	0.46	6.06e-19	Prostate cancer;
LUSC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg05623727	chr3:50126028	RBM5	-0.33	-6.18	-0.32	1.86e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.89	0.55	1.95e-27	Prudent dietary pattern;
LUSC	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg24397884	chr7:158709396	WDR60	0.8	8.96	0.44	2.31e-17	Height;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19393281	chr3:50606861	HEMK1	-0.41	-6.14	-0.32	2.31e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg09877947	chr5:131593287	PDLIM4	-0.42	-6.85	-0.35	3.57e-11	Breast cancer;
LUSC	cis	rs3820928	0.874	rs10166736	chr2:227900419	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.97	-0.4	2.58e-14	Pulmonary function;
LUSC	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg23711669	chr6:146136114	FBXO30	0.82	14.37	0.62	8.27e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg06640241	chr16:89574553	SPG7	0.6	9.13	0.45	6.69e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs7119	0.651	rs12902898	chr15:77849191	A/G	cg27398640	chr15:77910606	LINGO1	-0.3	-5.94	-0.31	7.14e-9	Type 2 diabetes;
LUSC	cis	rs7202877	0.706	rs8046184	chr16:75411725	T/C	cg03315344	chr16:75512273	CHST6	0.44	6.48	0.33	3.35e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg17724175	chr1:150552817	MCL1	0.35	6.52	0.34	2.59e-10	Tonsillectomy;
LUSC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg27266027	chr21:40555129	PSMG1	-0.4	-5.88	-0.31	9.82e-9	Cognitive function;
LUSC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.71	-11.04	-0.52	2.31e-24	Aortic root size;
LUSC	cis	rs13401104	0.796	rs1530955	chr2:237111003	C/T	cg19324714	chr2:237145437	ASB18	0.44	5.97	0.31	6.01e-9	Educational attainment;
LUSC	trans	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg13010199	chr12:38710504	ALG10B	-0.41	-6.07	-0.32	3.52e-9	Morning vs. evening chronotype;
LUSC	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg18721089	chr20:30220636	NA	-0.36	-5.64	-0.3	3.54e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	7.01	0.36	1.32e-11	Ovarian reserve;
LUSC	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg06627628	chr2:24431161	ITSN2	0.54	7.47	0.38	7.13e-13	Asthma;
LUSC	trans	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg10756647	chr7:56101905	PSPH	0.81	8.09	0.4	1.15e-14	Diabetic kidney disease;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg20410673	chr18:43684340	HAUS1;ATP5A1	0.45	6.03	0.31	4.42e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs17001868	0.568	rs2294350	chr22:40784278	C/T	cg07138101	chr22:40742427	ADSL	0.62	7.28	0.37	2.41e-12	Mammographic density (dense area);
LUSC	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg08999081	chr20:33150536	PIGU	0.42	7.28	0.37	2.47e-12	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9653442	0.545	rs1821826	chr2:100764711	C/T	cg22139774	chr2:100720529	AFF3	-0.42	-7.25	-0.37	2.9e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs721399	0.568	rs35942058	chr8:18274398	G/A	cg18736775	chr8:18248649	NAT2	-0.56	-7.0	-0.36	1.43e-11	Blood metabolite levels;
LUSC	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.68	8.41	0.42	1.25e-15	Type 2 diabetes;
LUSC	trans	rs17266958	1.000	rs62576987	chr9:83295961	C/T	cg01905489	chr1:26616534	UBXN11	-0.58	-6.38	-0.33	6.04e-10	Preschool internalizing problems;
LUSC	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.89	-0.35	2.79e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.63	-0.34	1.33e-10	Alzheimer's disease (late onset);
LUSC	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg04989706	chr14:50066350	PPIL5	-0.47	-6.1	-0.32	2.92e-9	Carotid intima media thickness;
LUSC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	10.84	0.51	1.16e-23	Lung cancer in ever smokers;
LUSC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	8.69	0.43	1.64e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg00405596	chr8:11794950	NA	0.35	5.94	0.31	7.12e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg25767906	chr1:53392781	SCP2	0.48	8.63	0.43	2.55e-16	Monocyte count;
LUSC	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg26528668	chr16:1614120	IFT140	0.47	8.13	0.41	8.24e-15	Coronary artery disease;
LUSC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg15445000	chr17:37608096	MED1	-0.39	-6.69	-0.34	9.56e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs6681460	0.932	rs665319	chr1:67175488	A/G	cg02459107	chr1:67143332	SGIP1	0.47	8.79	0.43	8.09e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs56283067	0.578	rs1321079	chr6:45358403	T/A	cg20913747	chr6:44695427	NA	-0.43	-6.31	-0.33	8.84e-10	Total body bone mineral density;
LUSC	trans	rs61931739	0.591	rs1608907	chr12:33945435	A/G	cg13010199	chr12:38710504	ALG10B	0.41	6.19	0.32	1.72e-9	Morning vs. evening chronotype;
LUSC	cis	rs897080	0.552	rs1067323	chr2:44630018	T/G	cg00619915	chr2:44497795	NA	-0.41	-5.8	-0.3	1.54e-8	Height;
LUSC	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg24634471	chr8:143751801	JRK	0.5	7.08	0.36	8.65e-12	Schizophrenia;
LUSC	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	6.39	0.33	5.53e-10	Rheumatoid arthritis;
LUSC	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.43	5.76	0.3	1.9e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs240768	1.000	rs240777	chr6:101003215	G/A	cg12253828	chr6:101329408	ASCC3	0.84	5.74	0.3	2.11e-8	Economic and political preferences (immigration/crime);
LUSC	cis	rs75920871	0.660	rs12271161	chr11:116979911	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-6.06	-0.31	3.76e-9	Subjective well-being;
LUSC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.13	0.36	6.34e-12	Bipolar disorder;
LUSC	cis	rs243505	0.867	rs243526	chr7:148417073	C/T	cg09806900	chr7:148480153	CUL1	-0.48	-6.82	-0.35	4.34e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13732083	chr21:47605072	C21orf56	0.45	6.73	0.35	7.22e-11	Testicular germ cell tumor;
LUSC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg09021430	chr5:549028	NA	-0.57	-7.76	-0.39	1.05e-13	Obesity-related traits;
LUSC	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg24692254	chr21:30365293	RNF160	-0.68	-10.49	-0.5	1.87e-22	Pancreatic cancer;
LUSC	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg00383909	chr3:49044727	WDR6	0.81	7.55	0.38	4.26e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs79481398	0.584	rs11856034	chr15:57778324	A/G	cg19997606	chr15:57842346	CGNL1	-0.42	-5.78	-0.3	1.71e-8	Facial morphology (factor 19);
LUSC	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.1	-0.32	2.96e-9	Neutrophil percentage of white cells;
LUSC	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg12615879	chr12:58013172	SLC26A10	0.42	9.91	0.48	1.87e-20	Multiple sclerosis;
LUSC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg24634471	chr8:143751801	JRK	-0.51	-7.26	-0.37	2.82e-12	Schizophrenia;
LUSC	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg02475777	chr4:1388615	CRIPAK	-0.42	-6.16	-0.32	2.05e-9	Obesity-related traits;
LUSC	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-1.01	-14.32	-0.62	1.29e-36	Exhaled nitric oxide output;
LUSC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg03146154	chr1:46216737	IPP	0.53	7.68	0.39	1.75e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg00933542	chr6:150070202	PCMT1	0.33	6.73	0.35	7.34e-11	Lung cancer;
LUSC	cis	rs4285028	0.747	rs77790376	chr3:121492211	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-12.35	-0.56	4.18e-29	Multiple sclerosis;
LUSC	trans	rs4729127	0.908	rs10464486	chr7:93983851	A/G	cg20086523	chr13:52378287	DHRS12	0.57	6.12	0.32	2.64e-9	Intelligence;
LUSC	cis	rs12956009	0.559	rs12607072	chr18:44839888	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.23	0.32	1.4e-9	Educational attainment (years of education);
LUSC	cis	rs9653442	0.527	rs2118280	chr2:100746395	G/A	cg22139774	chr2:100720529	AFF3	-0.41	-6.93	-0.35	2.13e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.66	-15.34	-0.64	1.36e-40	Neuroticism;
LUSC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	9.03	0.44	1.42e-17	Prudent dietary pattern;
LUSC	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg18854424	chr1:2615690	NA	0.48	9.53	0.46	3.32e-19	Ulcerative colitis;
LUSC	trans	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.16	0.32	2.03e-9	Corneal astigmatism;
LUSC	cis	rs6692729	0.769	rs12758915	chr1:227058344	A/G	cg10327440	chr1:227177885	CDC42BPA	0.49	7.02	0.36	1.24e-11	Electrodermal activity;
LUSC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg23711669	chr6:146136114	FBXO30	0.9	17.11	0.68	1.48e-47	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11039798	0.544	rs113253936	chr11:48160609	C/T	cg15704280	chr7:45808275	SEPT13	0.79	6.1	0.32	3.02e-9	Axial length;
LUSC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.06e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg07423050	chr13:99094983	FARP1	-0.54	-9.79	-0.47	4.71e-20	Longevity;
LUSC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25072359	chr17:41440525	NA	0.65	9.27	0.45	2.3e-18	Menopause (age at onset);
LUSC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-1.03	-22.81	-0.78	4.31e-70	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11112613	0.818	rs73184093	chr12:106010066	G/C	cg03607813	chr12:105948248	NA	0.73	8.43	0.42	1.07e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs17095355	0.901	rs6584964	chr10:111759160	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.6	-7.35	-0.37	1.53e-12	Biliary atresia;
LUSC	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg24631222	chr15:78858424	CHRNA5	0.83	11.41	0.53	1.09e-25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25203256	chr7:66205334	RABGEF1	-0.42	-6.11	-0.32	2.78e-9	Electrocardiographic conduction measures;
LUSC	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg18196295	chr10:418757	DIP2C	-0.38	-6.16	-0.32	2.1e-9	Psychosis in Alzheimer's disease;
LUSC	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg03929089	chr4:120376271	NA	-0.6	-7.19	-0.37	4.38e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Schizophrenia;
LUSC	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-1.15	-18.23	-0.71	5.05e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg02023728	chr11:77925099	USP35	-0.45	-6.84	-0.35	3.84e-11	Testicular germ cell tumor;
LUSC	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg15819921	chr19:927150	ARID3A	-0.44	-6.42	-0.33	4.77e-10	Life satisfaction;
LUSC	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg01966878	chr4:90757139	SNCA	-0.35	-6.12	-0.32	2.56e-9	Dementia with Lewy bodies;
LUSC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs71403859	0.502	rs71403849	chr16:71484365	T/C	cg08717414	chr16:71523259	ZNF19	-0.71	-8.44	-0.42	9.45e-16	Post bronchodilator FEV1;
LUSC	cis	rs1595825	0.838	rs16826872	chr2:198898055	T/C	cg10547527	chr2:198650123	BOLL	-0.53	-6.28	-0.33	1.04e-9	Ulcerative colitis;
LUSC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg07507251	chr3:52567010	NT5DC2	0.33	6.37	0.33	6.25e-10	Bipolar disorder;
LUSC	cis	rs9369695	0.842	rs2396825	chr6:47568696	A/G	cg12968598	chr6:47444699	CD2AP	0.52	8.04	0.4	1.6e-14	Reticulocyte count;
LUSC	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg02466173	chr16:30829666	NA	-0.59	-11.12	-0.52	1.19e-24	Multiple myeloma;
LUSC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg13319975	chr6:146136371	FBXO30	0.5	7.44	0.38	8.58e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927771	0.524	rs7932703	chr11:47769936	A/C	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.18e-10	Subjective well-being;
LUSC	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg25817165	chr18:72167213	CNDP2	-0.71	-9.17	-0.45	4.93e-18	Refractive error;
LUSC	cis	rs7202877	0.610	rs10871307	chr16:75335114	G/T	cg03315344	chr16:75512273	CHST6	0.45	6.21	0.32	1.56e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9905704	0.846	rs372648	chr17:56736785	A/C	cg12560992	chr17:57184187	TRIM37	0.58	8.36	0.42	1.75e-15	Testicular germ cell tumor;
LUSC	trans	rs3857536	0.813	rs9360190	chr6:66942302	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.13	-0.32	2.43e-9	Blood trace element (Cu levels);
LUSC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.53	-0.38	4.93e-13	Personality dimensions;
LUSC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.75	-0.35	6.52e-11	Lung cancer;
LUSC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg23630131	chr7:65973040	NA	0.2	5.66	0.3	3.25e-8	Aortic root size;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18404039	chr20:3184938	DDRGK1	-0.4	-5.99	-0.31	5.45e-9	Hepatitis;
LUSC	cis	rs7091068	0.518	rs1409337	chr10:95439822	T/C	cg20715218	chr10:95462985	C10orf4	0.51	6.46	0.33	3.63e-10	Urinary tract infection frequency;
LUSC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg21132104	chr15:45694354	SPATA5L1	0.57	8.13	0.41	8.21e-15	Homoarginine levels;
LUSC	cis	rs6733011	0.600	rs1568213	chr2:99432063	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.61	-0.34	1.51e-10	Bipolar disorder;
LUSC	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.9	-16.49	-0.67	4.05e-45	Bone mineral density;
LUSC	cis	rs12900413	0.879	rs2165072	chr15:90302629	A/G	cg24249390	chr15:90295951	MESP1	-0.48	-6.92	-0.35	2.25e-11	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg05025164	chr4:1340916	KIAA1530	0.46	7.07	0.36	9.08e-12	Obesity-related traits;
LUSC	cis	rs977987	0.778	rs11858992	chr16:75411445	A/C	cg03315344	chr16:75512273	CHST6	0.49	9.32	0.45	1.6e-18	Dupuytren's disease;
LUSC	cis	rs6066835	1.000	rs4455220	chr20:47335017	A/G	cg18078177	chr20:47281410	PREX1	0.7	5.91	0.31	8.34e-9	Multiple myeloma;
LUSC	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg16414030	chr3:133502952	NA	-0.43	-6.76	-0.35	6.29e-11	Iron status biomarkers;
LUSC	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg03788504	chr6:150331562	NA	-0.26	-5.78	-0.3	1.76e-8	Alopecia areata;
LUSC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg02493740	chr2:85810744	VAMP5	-0.52	-9.05	-0.44	1.22e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4654899	0.897	rs7545133	chr1:21206143	T/G	cg01072550	chr1:21505969	NA	0.49	7.41	0.38	1.07e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.19	-0.41	5.51e-15	Axial length;
LUSC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.59	-10.63	-0.5	6.12e-23	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4654899	0.606	rs13376428	chr1:21120027	T/C	cg01072550	chr1:21505969	NA	-0.5	-7.32	-0.37	1.88e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg21770322	chr7:97807741	LMTK2	0.41	7.08	0.36	8.48e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.89	12.55	0.57	7.02e-30	Ileal carcinoids;
LUSC	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-1.01	-14.32	-0.62	1.29e-36	Exhaled nitric oxide output;
LUSC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg03806693	chr22:41940476	POLR3H	0.99	13.85	0.6	9.09e-35	Vitiligo;
LUSC	cis	rs7202877	0.656	rs247427	chr16:75439132	T/C	cg03315344	chr16:75512273	CHST6	-0.46	-6.3	-0.33	9.56e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg14092571	chr14:90743983	NA	0.37	6.07	0.32	3.39e-9	Mortality in heart failure;
LUSC	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg13010199	chr12:38710504	ALG10B	0.64	9.79	0.47	4.45e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10992471	0.651	rs10124058	chr9:95522882	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-6.87	-0.35	3.2e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs4942242	0.663	rs7985489	chr13:44206148	T/C	cg19169023	chr15:41853346	TYRO3	0.58	8.97	0.44	2.11e-17	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17916960	chr15:79447300	NA	-0.53	-10.55	-0.5	1.24e-22	Refractive error;
LUSC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg06740227	chr12:86229804	RASSF9	0.44	6.96	0.36	1.77e-11	Major depressive disorder;
LUSC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg21132104	chr15:45694354	SPATA5L1	0.46	6.2	0.32	1.65e-9	Homoarginine levels;
LUSC	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg11062466	chr8:58055876	NA	0.52	7.11	0.36	7.07e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg21238619	chr17:78079768	GAA	0.34	6.72	0.35	7.76e-11	Yeast infection;
LUSC	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.87	14.93	0.63	5.9e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg15744005	chr10:104629667	AS3MT	-0.32	-6.32	-0.33	8.44e-10	Arsenic metabolism;
LUSC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg09904177	chr6:26538194	HMGN4	-0.5	-5.86	-0.31	1.08e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.37	5.67	0.3	3.05e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2273669	0.667	rs11153150	chr6:109316652	C/G	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg19318889	chr4:1322082	MAEA	0.43	5.73	0.3	2.28e-8	Recombination rate (females);
LUSC	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg06627628	chr2:24431161	ITSN2	-0.87	-12.29	-0.56	7.01e-29	Asthma;
LUSC	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg02153584	chr22:29168773	CCDC117	0.43	6.42	0.33	4.57e-10	Red cell distribution width;
LUSC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-0.81	-13.47	-0.59	2.44e-33	Menopause (age at onset);
LUSC	trans	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.51	-0.34	2.69e-10	Bladder cancer;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg09192942	chr16:75682004	KARS;TERF2IP	0.47	5.97	0.31	6.01e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1595825	0.891	rs1440086	chr2:198906354	A/G	cg00982548	chr2:198649783	BOLL	-0.55	-6.98	-0.36	1.57e-11	Ulcerative colitis;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06446895	chr17:79829189	ARHGDIA	-0.45	-7.54	-0.38	4.45e-13	Electrocardiographic conduction measures;
LUSC	cis	rs10744422	0.800	rs7138436	chr12:123223920	G/T	cg25930673	chr12:123319894	HIP1R	-0.62	-6.34	-0.33	7.48e-10	Schizophrenia;
LUSC	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg04025307	chr7:1156635	C7orf50	0.4	6.52	0.34	2.54e-10	Longevity;Endometriosis;
LUSC	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg18904891	chr8:8559673	CLDN23	0.6	7.87	0.4	4.93e-14	Obesity-related traits;
LUSC	cis	rs6942756	0.712	rs6467241	chr7:128997838	A/G	cg02491457	chr7:128862824	NA	-0.5	-7.3	-0.37	2.06e-12	White matter hyperintensity burden;
LUSC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg00933542	chr6:150070202	PCMT1	0.33	6.85	0.35	3.51e-11	Lung cancer;
LUSC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg06784218	chr1:46089804	CCDC17	-0.58	-11.51	-0.53	4.82e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg13798912	chr7:905769	UNC84A	-0.57	-5.88	-0.31	9.85e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg05855489	chr10:104503620	C10orf26	0.6	9.67	0.47	1.11e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19717773	chr7:2847554	GNA12	-0.35	-5.97	-0.31	5.99e-9	Height;
LUSC	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg27539214	chr16:67997921	SLC12A4	-0.48	-6.15	-0.32	2.18e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs1864585	0.520	rs56109041	chr8:10657154	G/C	cg26278703	chr11:58910052	FAM111A	0.53	6.0	0.31	5.2e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUSC	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg11812906	chr14:75593930	NEK9	-0.64	-11.04	-0.52	2.28e-24	Height;
LUSC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg11062466	chr8:58055876	NA	0.46	6.21	0.32	1.6e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.38	0.37	1.26e-12	Bipolar disorder;
LUSC	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.9	0.51	7.3e-24	Morning vs. evening chronotype;
LUSC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	13.28	0.59	1.28e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg16325326	chr1:53192061	ZYG11B	0.86	15.76	0.65	3.28e-42	Monocyte count;
LUSC	cis	rs61990749	0.544	rs2544566	chr14:78181738	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.59	6.45	0.33	3.85e-10	Fibroblast growth factor basic levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13043177	chr5:169010744	CCDC99	0.76	6.09	0.32	3.05e-9	Cognitive performance;
LUSC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg00074818	chr8:8560427	CLDN23	0.58	9.91	0.48	1.88e-20	Obesity-related traits;
LUSC	cis	rs12594515	1.000	rs11854554	chr15:45994546	C/G	cg06207120	chr15:45996521	NA	0.39	5.86	0.31	1.11e-8	Waist circumference;Weight;
LUSC	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg26395211	chr5:140044315	WDR55	0.37	5.66	0.3	3.21e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.66	8.37	0.42	1.63e-15	Lung function (FEV1/FVC);
LUSC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg10792982	chr14:105748885	BRF1	0.46	8.17	0.41	6.54e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg08027265	chr7:2291960	NA	-0.4	-6.52	-0.34	2.54e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs30380	0.632	rs27640	chr5:96127905	T/C	cg16492584	chr5:96139282	ERAP1	-0.53	-7.23	-0.37	3.22e-12	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg23289794	chr7:2394357	EIF3B	-0.78	-10.28	-0.49	1.05e-21	Multiple sclerosis;
LUSC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg10862848	chr6:42927986	GNMT	-0.29	-6.81	-0.35	4.44e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.81	0.43	6.77e-17	Axial length;
LUSC	cis	rs16910800	1.000	rs1384473	chr11:23194943	T/C	cg20040320	chr11:23191996	NA	0.44	6.52	0.34	2.64e-10	Cancer;
LUSC	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg08799069	chr10:126477246	METTL10	0.6	8.23	0.41	4.3e-15	Cocaine dependence;
LUSC	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg17054900	chr3:154042577	DHX36	0.44	5.68	0.3	2.86e-8	Coronary artery disease;
LUSC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg03354898	chr7:1950403	MAD1L1	-0.44	-8.79	-0.43	7.93e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg27165867	chr14:105738592	BRF1	-0.51	-7.42	-0.38	9.52e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg05887092	chr17:76393375	PGS1	0.52	9.37	0.46	1.13e-18	HDL cholesterol levels;
LUSC	cis	rs7264396	0.887	rs2236161	chr20:34101631	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.61	-0.34	1.49e-10	Total cholesterol levels;
LUSC	cis	rs77741769	0.529	rs10849791	chr12:121235280	T/C	cg02419362	chr12:121203948	SPPL3	0.46	8.42	0.42	1.14e-15	Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.05	-0.31	3.99e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7119167	0.686	rs7342205	chr11:73044351	A/G	cg17517138	chr11:73019481	ARHGEF17	0.49	5.68	0.3	2.88e-8	Blood protein levels;
LUSC	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg09796270	chr17:17721594	SREBF1	0.42	7.52	0.38	5.22e-13	Total body bone mineral density;
LUSC	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg19116668	chr7:99932089	PMS2L1	-0.33	-5.67	-0.3	3.17e-8	Coronary artery disease;
LUSC	trans	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg07393940	chr7:158741817	NA	-0.36	-6.32	-0.33	8.31e-10	Life satisfaction;
LUSC	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.32e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2857891	0.659	rs2262676	chr11:6996609	T/G	cg14883916	chr11:6947541	ZNF215	0.44	5.83	0.3	1.34e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.75	13.45	0.59	2.92e-33	Dental caries;
LUSC	cis	rs7615316	0.872	rs6414350	chr3:142316660	C/G	cg16271453	chr3:142027066	XRN1	-0.36	-6.03	-0.31	4.41e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg02574844	chr11:5959923	NA	-0.4	-6.03	-0.31	4.45e-9	DNA methylation (variation);
LUSC	cis	rs12210905	1.000	rs3999221	chr6:26959322	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-6.03	-0.31	4.45e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs7572644	0.665	rs4233716	chr2:28034384	C/T	cg27432699	chr2:27873401	GPN1	0.61	7.86	0.4	5.21e-14	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00631329	chr6:26305371	NA	-0.48	-9.41	-0.46	8.53e-19	Educational attainment;
LUSC	cis	rs2302729	0.625	rs1592573	chr12:2831556	A/T	cg19945202	chr12:2788847	CACNA1C	-0.37	-5.66	-0.3	3.28e-8	Sleep quality;
LUSC	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.71	-12.52	-0.57	9.7e-30	White blood cell count (basophil);
LUSC	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.5	-0.46	4.07e-19	Schizophrenia;
LUSC	cis	rs2976388	0.967	rs2585183	chr8:143766059	C/G	cg17252645	chr8:143867129	LY6D	-0.38	-6.44	-0.33	4.14e-10	Urinary tract infection frequency;
LUSC	cis	rs17540621	1.000	rs79390512	chr2:47199046	A/G	cg23978866	chr2:47230407	TTC7A	-0.92	-6.91	-0.35	2.44e-11	Response to statin therapy;
LUSC	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg21285383	chr16:89894308	SPIRE2	0.31	6.58	0.34	1.79e-10	Vitiligo;
LUSC	cis	rs977987	0.778	rs34222958	chr16:75398252	C/T	cg03315344	chr16:75512273	CHST6	0.48	9.19	0.45	4.25e-18	Dupuytren's disease;
LUSC	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg06028605	chr16:24865363	SLC5A11	0.37	6.0	0.31	5.1e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.82	-15.1	-0.64	1.19e-39	Dental caries;
LUSC	cis	rs4144743	0.941	rs10438782	chr17:45323892	G/A	cg18085866	chr17:45331354	ITGB3	-0.7	-7.62	-0.38	2.61e-13	Body mass index;
LUSC	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg05340658	chr4:99064831	C4orf37	0.57	8.81	0.43	7.13e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg15571903	chr15:79123663	NA	0.32	5.9	0.31	9.02e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg12940439	chr1:67600707	NA	0.35	6.12	0.32	2.56e-9	Psoriasis;
LUSC	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.39	-0.49	4.21e-22	Eye color traits;
LUSC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg04398451	chr17:18023971	MYO15A	0.43	6.86	0.35	3.37e-11	Total body bone mineral density;
LUSC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24531977	chr5:56204891	C5orf35	0.74	12.03	0.55	6.27e-28	Initial pursuit acceleration;
LUSC	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg08999081	chr20:33150536	PIGU	-0.41	-7.68	-0.39	1.79e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg19318889	chr4:1322082	MAEA	0.43	5.7	0.3	2.66e-8	Recombination rate (females);
LUSC	cis	rs7523273	0.606	rs12401619	chr1:207976276	G/C	cg22525895	chr1:207977042	MIR29B2	-0.38	-6.05	-0.31	3.98e-9	Schizophrenia;
LUSC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.87	-15.51	-0.65	3.18e-41	Cognitive function;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18839017	chr6:53660548	LRRC1	0.39	6.02	0.31	4.49e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11971779	0.680	rs4728465	chr7:139069061	G/A	cg07862535	chr7:139043722	LUC7L2	0.59	7.37	0.37	1.32e-12	Diisocyanate-induced asthma;
LUSC	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07988820	chr12:82153109	PPFIA2	-0.46	-6.47	-0.33	3.55e-10	Resting heart rate;
LUSC	trans	rs1347297	0.526	rs6757186	chr2:179259719	G/C	cg14011486	chr1:26737247	LIN28	0.42	6.68	0.34	9.76e-11	Alzheimer disease and age of onset;
LUSC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.53	-0.5	1.46e-22	Coffee consumption (cups per day);
LUSC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg24399712	chr22:39784796	NA	-0.65	-12.13	-0.55	2.6e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18357526	chr6:26021779	HIST1H4A	0.45	7.15	0.36	5.47e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs9303542	0.527	rs62066689	chr17:46609092	T/C	cg09704116	chr17:46666958	LOC404266	-0.37	-6.52	-0.34	2.56e-10	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs4363385	0.747	rs1415962	chr1:152958731	T/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.69	-0.39	1.63e-13	Inflammatory skin disease;
LUSC	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg24503407	chr1:205819492	PM20D1	-0.48	-6.38	-0.33	6.01e-10	Menarche (age at onset);
LUSC	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg02269571	chr22:50332266	NA	-0.67	-9.73	-0.47	7.13e-20	Schizophrenia;
LUSC	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-1.13	-17.85	-0.7	1.6e-50	Exhaled nitric oxide output;
LUSC	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg03060546	chr3:49711283	APEH	0.59	8.21	0.41	4.93e-15	Resting heart rate;
LUSC	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg03948781	chr1:205179583	DSTYK	0.33	6.31	0.33	8.67e-10	Red blood cell count;
LUSC	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg09184832	chr6:79620586	NA	-0.45	-7.29	-0.37	2.27e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg23173402	chr1:227635558	NA	0.56	6.28	0.32	1.07e-9	Major depressive disorder;
LUSC	cis	rs2227564	0.649	rs2948689	chr10:75657860	A/G	cg23231163	chr10:75533350	FUT11	-0.43	-6.05	-0.31	3.95e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg06064525	chr11:970664	AP2A2	-0.36	-7.17	-0.37	4.88e-12	Alzheimer's disease (late onset);
LUSC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg20406979	chr6:167373233	NA	0.26	6.11	0.32	2.77e-9	Crohn's disease;
LUSC	trans	rs4729127	1.000	rs17166229	chr7:94017673	A/G	cg20086523	chr13:52378287	DHRS12	0.59	6.58	0.34	1.78e-10	Intelligence;
LUSC	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.63	11.37	0.53	1.5e-25	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.87	-15.41	-0.64	7.3400000000000005e-41	Cognitive function;
LUSC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-6.27	-0.32	1.11e-9	Menopause (age at onset);
LUSC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg16928487	chr17:17741425	SREBF1	-0.36	-6.75	-0.35	6.65e-11	Total body bone mineral density;
LUSC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.73	-0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	0.92	19.26	0.73	3.84e-56	Ulcerative colitis;
LUSC	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg02807482	chr3:125708958	NA	-0.48	-5.65	-0.3	3.4e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg11843238	chr5:131593191	PDLIM4	0.39	6.62	0.34	1.46e-10	Breast cancer;
LUSC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg19592336	chr6:28129416	ZNF389	0.5	6.51	0.34	2.74e-10	Depression;
LUSC	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	1.06	14.5	0.62	2.72e-37	Exhaled nitric oxide levels;
LUSC	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	7.01	0.36	1.29e-11	Neuroticism;
LUSC	cis	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.69	-8.91	-0.44	3.39e-17	Lymphocyte counts;Red cell distribution width;
LUSC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06634786	chr22:41940651	POLR3H	0.51	6.11	0.32	2.82e-9	Vitiligo;
LUSC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg16606324	chr3:10149918	C3orf24	0.43	6.63	0.34	1.37e-10	Alzheimer's disease;
LUSC	cis	rs1847202	1.000	rs11918615	chr3:72942407	T/C	cg25664220	chr3:72788482	NA	-0.35	-6.43	-0.33	4.54e-10	Motion sickness;
LUSC	trans	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.14	-0.32	2.38e-9	Bladder cancer;
LUSC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg17173187	chr15:85201210	NMB	0.37	6.52	0.34	2.57e-10	Schizophrenia;
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.71	-0.39	1.46e-13	Lymphocyte counts;
LUSC	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.35	-6.82	-0.35	4.29e-11	Total body bone mineral density;
LUSC	cis	rs9309473	1.000	rs7598419	chr2:73798223	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-7.24	-0.37	3.19e-12	Metabolite levels;
LUSC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg15848620	chr12:58087721	OS9	-0.55	-7.92	-0.4	3.5e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg04727924	chr7:799746	HEATR2	-0.56	-6.77	-0.35	5.88e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.82	14.8	0.63	1.83e-38	Cognitive function;
LUSC	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg18232548	chr7:50535776	DDC	0.51	6.89	0.35	2.77e-11	Malaria;
LUSC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg08888203	chr3:10149979	C3orf24	0.64	9.15	0.45	5.82e-18	Alzheimer's disease;
LUSC	trans	rs6445525	0.875	rs7636595	chr3:65992843	A/T	cg04367164	chr11:76902992	MYO7A	0.31	6.39	0.33	5.6e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg02428538	chr16:24856791	SLC5A11	-0.58	-6.35	-0.33	6.9e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg05709478	chr1:6581295	PLEKHG5	-0.51	-6.13	-0.32	2.55e-9	Body mass index;
LUSC	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg01256987	chr12:42539512	GXYLT1	0.34	6.21	0.32	1.57e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06505273	chr16:24850292	NA	0.41	5.75	0.3	2e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2050392	1.000	rs2265186	chr10:30691743	C/T	cg18806716	chr10:30721971	MAP3K8	0.45	7.22	0.37	3.55e-12	Inflammatory bowel disease;
LUSC	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg24631222	chr15:78858424	CHRNA5	0.82	11.29	0.53	2.9e-25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg13010199	chr12:38710504	ALG10B	0.56	8.42	0.42	1.12e-15	Morning vs. evening chronotype;
LUSC	cis	rs7267979	0.816	rs6076358	chr20:25519403	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.77	-15.89	-0.66	9.82e-43	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg12463550	chr7:65579703	CRCP	0.56	8.46	0.42	8.66e-16	Aortic root size;
LUSC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.43	-6.3	-0.33	9.45e-10	Height;
LUSC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.64	6.49	0.33	3.14e-10	Initial pursuit acceleration;
LUSC	cis	rs1941023	0.503	rs7944025	chr11:60142538	C/A	cg08716584	chr11:60157161	MS4A7	-0.65	-12.39	-0.56	2.92e-29	Congenital heart disease (maternal effect);
LUSC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.92	-13.07	-0.58	8.12e-32	Blood trace element (Zn levels);
LUSC	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	0.73	7.62	0.38	2.65e-13	Yeast infection;
LUSC	cis	rs7949030	0.964	rs2957122	chr11:62392100	G/C	cg22862634	chr11:62369728	EML3;MTA2	-0.5	-8.14	-0.41	8.12e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11645453	chr3:52864694	ITIH4	0.48	11.09	0.52	1.51e-24	Schizophrenia;
LUSC	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg12927641	chr6:109611667	NA	-0.34	-5.8	-0.3	1.53e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg21132104	chr15:45694354	SPATA5L1	0.42	6.13	0.32	2.49e-9	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10380709	chr20:61558067	DIDO1	-0.45	-5.99	-0.31	5.36e-9	Hepatitis;
LUSC	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21659725	chr3:3221576	CRBN	0.64	10.62	0.5	6.82e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.65	-0.39	2.18e-13	Personality dimensions;
LUSC	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3930017	1.000	rs7783809	chr7:76719551	G/A	cg15770687	chr7:76625569	PMS2L11	0.43	6.09	0.32	3.08e-9	Body mass index;
LUSC	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg09455208	chr3:40491958	NA	0.48	7.9	0.4	4e-14	Renal cell carcinoma;
LUSC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.51	0.38	5.61e-13	Prudent dietary pattern;
LUSC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.83	-14.41	-0.62	6.07e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs10754283	0.967	rs1317864	chr1:90105448	A/G	cg21401794	chr1:90099060	LRRC8C	0.65	9.8	0.47	4.22e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17261708	chr5:176794207	RGS14	-0.36	-6.33	-0.33	7.83e-10	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg11764359	chr7:65958608	NA	0.62	9.38	0.46	1e-18	Aortic root size;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg06444730	chr1:84544284	PRKACB	-0.42	-6.3	-0.33	9.25e-10	Triglycerides;
LUSC	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg04518342	chr5:131593106	PDLIM4	0.33	6.04	0.31	4.1e-9	Blood metabolite levels;
LUSC	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg09184832	chr6:79620586	NA	-0.45	-7.35	-0.37	1.57e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.59	0.78	3.14e-69	Prudent dietary pattern;
LUSC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg07424592	chr7:64974309	NA	-0.64	-5.79	-0.3	1.61e-8	Diabetic kidney disease;
LUSC	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs427941	0.655	rs201472	chr7:101744428	C/T	cg06246474	chr7:101738831	CUX1	0.39	6.38	0.33	5.9e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg05340658	chr4:99064831	C4orf37	0.57	9.51	0.46	3.93e-19	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg20587970	chr11:113659929	NA	-1.28	-17.42	-0.69	8.23e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs240764	0.578	rs9498252	chr6:101194481	A/G	cg09795085	chr6:101329169	ASCC3	0.43	6.13	0.32	2.49e-9	Neuroticism;
LUSC	cis	rs2274273	0.868	rs9919926	chr14:55813890	G/C	cg04306507	chr14:55594613	LGALS3	0.53	11.49	0.53	5.65e-26	Protein biomarker;
LUSC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg23649088	chr2:200775458	C2orf69	0.56	7.51	0.38	5.51e-13	Schizophrenia;
LUSC	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg04865166	chr7:105162814	PUS7	0.52	5.71	0.3	2.5e-8	Bipolar disorder (body mass index interaction);
LUSC	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-9.65	-0.47	1.39e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg12091567	chr17:66097778	LOC651250	0.88	14.09	0.61	9.98e-36	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21659725	chr3:3221576	CRBN	-0.58	-8.22	-0.41	4.41e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg15117754	chr3:10150083	C3orf24	0.46	6.14	0.32	2.3e-9	Alzheimer's disease;
LUSC	cis	rs7113850	0.541	rs4367945	chr11:24215605	A/C	ch.11.24196551F	chr11:24239977	NA	1.01	8.37	0.42	1.59e-15	Bone fracture in osteoporosis;
LUSC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.55	-5.9	-0.31	8.81e-9	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs11583043	0.708	rs1335745	chr1:101546439	T/A	cg11406453	chr1:101602562	NA	-0.4	-6.75	-0.35	6.61e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg11502198	chr6:26597334	ABT1	0.53	7.9	0.4	4.21e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs75920871	0.588	rs6589587	chr11:116875338	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-6.7	-0.34	8.86e-11	Subjective well-being;
LUSC	cis	rs11229555	0.645	rs11229429	chr11:58180872	G/A	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg15556689	chr8:8085844	FLJ10661	0.45	7.07	0.36	9.21e-12	Retinal vascular caliber;
LUSC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26769984	chr7:1090371	C7orf50	0.61	8.49	0.42	6.93e-16	Bronchopulmonary dysplasia;
LUSC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.69	-12.38	-0.56	3.09e-29	Aortic root size;
LUSC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.47	-0.33	3.39e-10	Schizophrenia;
LUSC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg24060327	chr5:131705240	SLC22A5	-0.53	-8.8	-0.43	7.57e-17	Breast cancer;
LUSC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19717773	chr7:2847554	GNA12	-0.38	-5.96	-0.31	6.56e-9	Height;
LUSC	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg08085267	chr17:45401833	C17orf57	0.6	10.0	0.48	9.4e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg03859395	chr2:55845619	SMEK2	-0.84	-15.31	-0.64	1.83e-40	Metabolic syndrome;
LUSC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-6.82	-0.35	4.27e-11	Menopause (age at onset);
LUSC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.91	0.61	5.12e-35	Cognitive test performance;
LUSC	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.96	-0.36	1.83e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg10857441	chr5:6722123	POLS	-0.44	-8.67	-0.43	1.88e-16	Menopause (age at onset);
LUSC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg18230493	chr5:56204884	C5orf35	-0.93	-13.72	-0.6	2.66e-34	Initial pursuit acceleration;
LUSC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.8	-15.66	-0.65	7.56e-42	Dental caries;
LUSC	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-0.75	-11.17	-0.52	8.07e-25	Refractive error;
LUSC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg02167203	chr6:41068553	NFYA;LOC221442	-0.4	-5.8	-0.3	1.53e-8	Alzheimer's disease (late onset);
LUSC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg06145435	chr7:1022769	CYP2W1	0.34	5.78	0.3	1.74e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs61612642	0.537	rs6915565	chr6:42192582	G/A	cg10382835	chr6:42185730	MRPS10	0.65	6.44	0.33	4.12e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.79	12.23	0.56	1.17e-28	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	0.549	rs11698185	chr20:25181998	T/C	cg08601574	chr20:25228251	PYGB	0.44	6.73	0.35	7.59e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.41	0.53	1.1e-25	Eye color traits;
LUSC	cis	rs9287719	0.774	rs4997811	chr2:10755538	T/C	cg00105475	chr2:10696890	NA	0.36	5.81	0.3	1.42e-8	Prostate cancer;
LUSC	cis	rs954108	0.809	rs1592060	chr13:29368944	T/C	cg11788234	chr13:29393811	NA	-0.38	-6.68	-0.34	1.01e-10	Obesity-related traits;
LUSC	cis	rs151234	0.800	rs231972	chr16:28538336	A/C	cg01378222	chr16:28622494	SULT1A1	-0.61	-7.86	-0.4	5.37e-14	Platelet distribution width;
LUSC	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00132208	chr4:10120780	NA	0.35	5.82	0.3	1.38e-8	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.7	-7.45	-0.38	8.27e-13	Menarche (age at onset);
LUSC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg04398451	chr17:18023971	MYO15A	0.57	9.53	0.46	3.41e-19	Total body bone mineral density;
LUSC	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.45	9.5	0.46	4.27e-19	Airflow obstruction;
LUSC	cis	rs377070	0.934	rs309407	chr4:123619335	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.49	7.14	0.36	5.8e-12	Mosquito bite size;
LUSC	trans	rs11700980	0.551	rs2832024	chr21:30113692	C/A	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06850241	chr22:41845214	NA	-0.31	-5.89	-0.31	9.41e-9	Vitiligo;
LUSC	cis	rs60154123	0.505	rs1319435	chr1:210047618	C/T	cg21951975	chr1:209979733	IRF6	-0.55	-6.86	-0.35	3.42e-11	Coronary artery disease;
LUSC	cis	rs2236918	0.932	rs2488471	chr1:242019831	T/C	cg17736920	chr1:242011382	EXO1	0.46	7.25	0.37	2.92e-12	Menopause (age at onset);
LUSC	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg25482853	chr8:67687455	SGK3	1.12	16.14	0.66	1.01e-43	Obesity-related traits;
LUSC	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg08601574	chr20:25228251	PYGB	-0.43	-6.57	-0.34	1.93e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg04450456	chr4:17643702	FAM184B	0.39	6.67	0.34	1.09e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.64	10.2	0.49	1.97e-21	Blood protein levels;
LUSC	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg09904177	chr6:26538194	HMGN4	-0.51	-8.05	-0.4	1.47e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg06064525	chr11:970664	AP2A2	0.48	10.53	0.5	1.42e-22	Alzheimer's disease (late onset);
LUSC	trans	rs214467	0.579	rs214470	chr7:110865216	A/G	cg04404789	chr16:46722505	ORC6L;VPS35	0.35	6.03	0.31	4.35e-9	Schizophrenia;
LUSC	cis	rs713477	0.967	rs34652660	chr14:55919480	C/A	cg04306507	chr14:55594613	LGALS3	-0.33	-6.42	-0.33	4.73e-10	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg13010199	chr12:38710504	ALG10B	-0.55	-8.56	-0.42	4.24e-16	Morning vs. evening chronotype;
LUSC	trans	rs2262909	0.924	rs11085509	chr19:22204573	T/C	cg05197062	chr11:11642011	GALNTL4	-0.51	-7.08	-0.36	8.34e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11702148	0.552	rs6517178	chr21:34888621	C/T	cg14850771	chr21:34775459	IFNGR2	-0.4	-5.86	-0.31	1.1e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs6669072	1.000	rs10922924	chr1:91252863	A/G	cg08895590	chr1:91227319	NA	0.34	7.7	0.39	1.5700000000000001e-13	Cognitive function;
LUSC	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.79	-13.03	-0.58	1.17e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.08	-0.32	3.23e-9	Systolic blood pressure;
LUSC	cis	rs4629710	0.592	rs9492868	chr6:131542238	A/C	cg12700074	chr6:131571435	AKAP7	-0.36	-6.1	-0.32	2.88e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg00316803	chr15:76480434	C15orf27	-0.4	-6.78	-0.35	5.32e-11	Blood metabolite levels;
LUSC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg11645453	chr3:52864694	ITIH4	0.34	7.7	0.39	1.59e-13	Bipolar disorder;
LUSC	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.85	12.12	0.55	2.82e-28	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.67	-10.54	-0.5	1.26e-22	Schizophrenia;
LUSC	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-6.58	-0.34	1.82e-10	Fear of minor pain;
LUSC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.85	11.37	0.53	1.49e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	11.0	0.52	3.11e-24	Bone mineral density;
LUSC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.58	-8.65	-0.43	2.27e-16	Colorectal cancer;
LUSC	cis	rs983392	0.836	rs12453	chr11:59945745	T/C	cg24026212	chr11:59952134	MS4A6A	-0.37	-6.35	-0.33	7.09e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.39	0.59	5.16e-33	Platelet count;
LUSC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21028142	chr17:79581711	NPLOC4	0.32	7.79	0.39	8.41e-14	Eye color traits;
LUSC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg02770061	chr7:158046166	PTPRN2	0.33	5.72	0.3	2.31e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg03609598	chr5:56110824	MAP3K1	-0.44	-6.14	-0.32	2.31e-9	Initial pursuit acceleration;
LUSC	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg09034736	chr1:150693464	HORMAD1	0.46	6.77	0.35	5.7e-11	Tonsillectomy;
LUSC	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07741184	chr6:167504864	NA	0.37	6.48	0.33	3.33e-10	Primary biliary cholangitis;
LUSC	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg25036284	chr2:26402008	FAM59B	0.77	11.11	0.52	1.29e-24	Gut microbiome composition (summer);
LUSC	cis	rs9309473	0.500	rs2421668	chr2:73885096	G/A	cg20560298	chr2:73613845	ALMS1	0.47	7.23	0.37	3.33e-12	Metabolite levels;
LUSC	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.78	-9.97	-0.48	1.17e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg20821713	chr7:1055600	C7orf50	-0.39	-5.95	-0.31	6.59e-9	Longevity;Endometriosis;
LUSC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg12564285	chr5:131593104	PDLIM4	0.45	8.05	0.4	1.43e-14	Breast cancer;
LUSC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.64e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg00376283	chr12:123451042	ABCB9	0.67	8.42	0.42	1.1e-15	Neutrophil percentage of white cells;
LUSC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg25036284	chr2:26402008	FAM59B	0.67	8.92	0.44	3.14e-17	Gut microbiome composition (summer);
LUSC	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-8.97	-0.44	2.15e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	7.75	0.39	1.14e-13	Neuroticism;
LUSC	cis	rs6062509	0.895	rs55946717	chr20:62363869	G/A	cg21849932	chr20:62369462	LIME1	-0.4	-5.91	-0.31	8.37e-9	Prostate cancer;
LUSC	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.44	-6.07	-0.32	3.52e-9	Colorectal cancer;
LUSC	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg22782873	chr19:19639568	YJEFN3	0.53	6.51	0.34	2.82e-10	Bipolar disorder;
LUSC	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg02353165	chr6:42928485	GNMT	0.48	6.61	0.34	1.57e-10	Blood protein levels;
LUSC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg27094323	chr7:1216898	NA	-0.32	-5.65	-0.3	3.36e-8	Longevity;Endometriosis;
LUSC	trans	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg25214090	chr10:38739885	LOC399744	0.51	7.25	0.37	2.97e-12	Corneal astigmatism;
LUSC	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.15	10.47	0.5	2.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.35	5.85	0.3	1.19e-8	Menopause (age at onset);
LUSC	cis	rs7945705	0.846	rs905290	chr11:8753729	A/G	cg12365402	chr11:9010492	NRIP3	0.44	7.6	0.38	3.08e-13	Hemoglobin concentration;
LUSC	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.39	-0.33	5.73e-10	Retinal vascular caliber;
LUSC	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg24130564	chr14:104152367	KLC1	-0.67	-10.64	-0.5	6.05e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs72949976	0.934	rs13406406	chr2:214034826	C/T	cg08319019	chr2:214017104	IKZF2	-0.62	-9.61	-0.47	1.85e-19	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs4654899	1.000	rs12126133	chr1:21456537	T/C	cg01072550	chr1:21505969	NA	-0.55	-8.4	-0.42	1.32e-15	Superior frontal gyrus grey matter volume;
LUSC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg03395511	chr6:291903	DUSP22	-0.5	-7.57	-0.38	3.6e-13	Menopause (age at onset);
LUSC	cis	rs9473147	0.543	rs9349417	chr6:47580657	A/G	cg02130027	chr6:47444894	CD2AP	0.36	5.76	0.3	1.86e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7953508	0.506	rs3869308	chr12:93959918	A/G	cg18151635	chr12:93972918	NA	-0.6	-8.67	-0.43	1.94e-16	Pubertal anthropometrics;
LUSC	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24838063	chr12:130822603	PIWIL1	0.7	10.79	0.51	1.7e-23	Menopause (age at onset);
LUSC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg00701064	chr4:6280414	WFS1	0.6	15.05	0.64	1.98e-39	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.8e-12	Body mass index;
LUSC	cis	rs10189230	1.000	rs10189230	chr2:222357961	T/A	cg14652038	chr2:222343519	EPHA4	0.33	5.77	0.3	1.83e-8	Urate levels in lean individuals;
LUSC	cis	rs9811920	0.695	rs793497	chr3:99505610	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.38	-7.29	-0.37	2.27e-12	Axial length;
LUSC	cis	rs7180079	0.541	rs72756953	chr15:64537101	C/A	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Monocyte count;
LUSC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg10018233	chr7:150070692	REPIN1	0.33	6.11	0.32	2.72e-9	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg13565492	chr6:43139072	SRF	-0.62	-6.56	-0.34	2.09e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg21782813	chr7:2030301	MAD1L1	0.52	8.65	0.43	2.13e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg23625390	chr15:77176239	SCAPER	0.47	7.22	0.37	3.55e-12	Blood metabolite levels;
LUSC	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg17640201	chr16:30407289	ZNF48	-0.86	-14.17	-0.61	4.92e-36	Tonsillectomy;
LUSC	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg10547527	chr2:198650123	BOLL	-0.5	-5.93	-0.31	7.77e-9	Ulcerative colitis;
LUSC	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg27411982	chr8:10470053	RP1L1	-0.47	-7.33	-0.37	1.79e-12	Neuroticism;
LUSC	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-0.82	-9.8	-0.47	4.36e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs1451375	0.785	rs6593010	chr7:50629888	A/G	cg18232548	chr7:50535776	DDC	0.53	8.21	0.41	5.02e-15	Malaria;
LUSC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.72e-12	Blood metabolite levels;
LUSC	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.95	18.1	0.7	1.71e-51	Body mass index (adult);
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg14178294	chr17:43109690	DCAKD	-0.37	-5.97	-0.31	6.09e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg24675658	chr1:53192096	ZYG11B	-0.55	-8.51	-0.42	6.02e-16	Monocyte count;
LUSC	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.5	-8.12	-0.41	9.24e-15	Platelet count;
LUSC	trans	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg18187862	chr3:45730750	SACM1L	0.55	7.05	0.36	1.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7075426	0.905	rs10887612	chr10:88213946	T/C	cg07322936	chr10:88137208	NA	0.55	8.24	0.41	3.87e-15	Migraine without aura;
LUSC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.69	10.82	0.51	1.38e-23	Aortic root size;
LUSC	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg13072238	chr3:49761600	GMPPB	0.67	8.62	0.43	2.76e-16	Menarche (age at onset);
LUSC	cis	rs9323205	0.911	rs60034431	chr14:51622437	C/A	cg23942311	chr14:51606299	NA	-0.49	-10.16	-0.49	2.56e-21	Cancer;
LUSC	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.57	-8.9	-0.44	3.53e-17	Height;
LUSC	trans	rs2587949	0.593	rs1817576	chr3:4205925	T/C	cg15139668	chr4:4577005	NA	-0.41	-6.15	-0.32	2.21e-9	Periodontitis (DPAL);
LUSC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg22903657	chr4:1355424	KIAA1530	-0.37	-6.04	-0.31	4.01e-9	Longevity;
LUSC	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg12002119	chr2:101014098	CHST10	-0.35	-5.78	-0.3	1.76e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg14583973	chr4:3374767	RGS12	-0.34	-7.57	-0.38	3.74e-13	Serum sulfate level;
LUSC	cis	rs4343996	0.521	rs10277545	chr7:3424362	C/T	cg21248987	chr7:3385318	SDK1	0.38	6.41	0.33	4.97e-10	Motion sickness;
LUSC	trans	rs9409565	0.826	rs2769813	chr9:97151194	C/T	cg05679027	chr9:99775184	HIATL2	0.46	6.6	0.34	1.6e-10	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs62400317	0.762	rs12215263	chr6:44831364	C/A	cg18551225	chr6:44695536	NA	-0.47	-7.55	-0.38	4.13e-13	Total body bone mineral density;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24102266	chr1:33219584	KIAA1522	-0.42	-6.13	-0.32	2.43e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg21775007	chr8:11205619	TDH	-0.5	-7.6	-0.38	3.07e-13	Retinal vascular caliber;
LUSC	cis	rs9398803	1.000	rs9398803	chr6:126683594	A/G	cg19875578	chr6:126661172	C6orf173	0.42	6.08	0.32	3.25e-9	Male-pattern baldness;
LUSC	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg15103426	chr22:29168792	CCDC117	0.51	6.81	0.35	4.42e-11	Lymphocyte counts;
LUSC	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg16950941	chr11:66035639	RAB1B	0.5	7.28	0.37	2.42e-12	Gout;
LUSC	cis	rs2219968	1.000	rs2128017	chr8:78964682	T/G	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24838063	chr12:130822603	PIWIL1	0.69	10.79	0.51	1.69e-23	Menopause (age at onset);
LUSC	cis	rs1461503	0.966	rs10790546	chr11:122838426	C/A	cg27398637	chr11:122830231	C11orf63	-0.4	-6.37	-0.33	6.12e-10	Menarche (age at onset);
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.5	8.51	0.42	5.92e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg00792783	chr2:198669748	PLCL1	0.43	5.87	0.31	1.04e-8	Dermatomyositis;
LUSC	cis	rs6545883	0.899	rs12473030	chr2:61720497	T/A	cg15711740	chr2:61764176	XPO1	-0.5	-7.77	-0.39	9.55e-14	Tuberculosis;
LUSC	trans	rs75804782	0.641	rs72985387	chr2:239336589	G/A	cg01134436	chr17:81009848	B3GNTL1	0.63	6.13	0.32	2.54e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs6961069	0.645	rs10261980	chr7:80224566	A/T	cg04458919	chr7:80252533	CD36	-0.41	-7.25	-0.37	2.89e-12	Platelet count;
LUSC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08219700	chr8:58056026	NA	0.63	8.05	0.4	1.45e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs4363385	0.765	rs1094409	chr1:153021040	T/A	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.54	-0.38	4.53e-13	Inflammatory skin disease;
LUSC	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg11645453	chr3:52864694	ITIH4	0.59	14.12	0.61	8.31e-36	Schizophrenia;
LUSC	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.6	-7.66	-0.39	2.01e-13	Menarche (age at onset);
LUSC	cis	rs3126085	0.935	rs2152862	chr1:152259742	T/C	cg26876637	chr1:152193138	HRNR	-0.45	-6.07	-0.32	3.45e-9	Atopic dermatitis;
LUSC	cis	rs4478858	0.684	rs10798838	chr1:31719450	G/A	cg00250761	chr1:31883323	NA	-0.33	-8.03	-0.4	1.71e-14	Alcohol dependence;
LUSC	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07636037	chr3:49044803	WDR6	0.69	8.87	0.44	4.38e-17	Menarche (age at onset);
LUSC	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg16049864	chr8:95962084	TP53INP1	0.64	10.88	0.51	8.45e-24	Type 2 diabetes;
LUSC	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.06	11.28	0.53	3.2e-25	Lung cancer in ever smokers;
LUSC	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg11019008	chr10:131425282	MGMT	0.43	6.48	0.33	3.21e-10	Response to temozolomide;
LUSC	cis	rs2607426	0.681	rs2545777	chr19:41287809	C/T	cg05508168	chr19:41255947	C19orf54;SNRPA	0.97	7.37	0.37	1.34e-12	Blood protein levels;
LUSC	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg20744362	chr22:50050164	C22orf34	0.39	7.32	0.37	1.81e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg09462578	chr12:12878428	APOLD1	0.6	9.77	0.47	5.34e-20	Birth weight;
LUSC	cis	rs4728302	0.534	rs6976069	chr7:133152898	T/C	cg10665199	chr7:133106180	EXOC4	0.54	7.7	0.39	1.58e-13	Intelligence;Intelligence (multi-trait analysis);
LUSC	cis	rs752010	0.695	rs12123834	chr1:42105727	T/C	cg06885757	chr1:42089581	HIVEP3	0.44	8.57	0.42	3.9e-16	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg25643088	chr3:52874325	TMEM110	0.4	6.17	0.32	2.01e-9	Schizophrenia;
LUSC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg16928487	chr17:17741425	SREBF1	-0.43	-7.97	-0.4	2.52e-14	Total body bone mineral density;
LUSC	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg20848291	chr7:100343083	ZAN	-0.67	-9.29	-0.45	1.97e-18	Other erythrocyte phenotypes;
LUSC	cis	rs4851254	0.660	rs114552491	chr2:100709533	C/T	cg22139774	chr2:100720529	AFF3	-0.43	-5.75	-0.3	1.99e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-5.65	-0.3	3.48e-8	IgG glycosylation;
LUSC	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg08807101	chr21:30365312	RNF160	0.69	11.24	0.52	4.35e-25	Pancreatic cancer;
LUSC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.29	0.33	9.72e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1943345	0.536	rs12269817	chr11:82858667	T/C	cg07047830	chr11:82868014	PCF11	0.71	11.83	0.54	3.38e-27	Obesity-related traits;
LUSC	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg00806126	chr19:22604979	ZNF98	0.37	5.75	0.3	2e-8	Pain;
LUSC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg11766577	chr21:47581405	C21orf56	-0.42	-6.12	-0.32	2.6e-9	Testicular germ cell tumor;
LUSC	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg18132916	chr6:79620363	NA	-0.39	-6.02	-0.31	4.69e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs8179	0.645	rs11767704	chr7:92256375	C/T	cg15732164	chr7:92237376	CDK6	-0.41	-5.8	-0.3	1.5e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg13010199	chr12:38710504	ALG10B	0.61	9.55	0.46	2.98e-19	Bladder cancer;
LUSC	cis	rs524023	0.914	rs4930556	chr11:64377726	G/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.44	-0.5	2.88e-22	Urate levels in obese individuals;
LUSC	cis	rs500891	0.645	rs1143795	chr6:83995167	G/C	cg08257003	chr6:84140564	ME1	0.33	7.15	0.36	5.67e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs921665	0.749	rs7563563	chr2:3201417	A/G	cg02624386	chr2:3182749	NA	-0.57	-6.03	-0.31	4.27e-9	World class endurance athleticism;
LUSC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.43	0.53	8.95e-26	Prudent dietary pattern;
LUSC	cis	rs4474465	0.790	rs4544031	chr11:78265403	G/C	cg27205649	chr11:78285834	NARS2	0.52	6.12	0.32	2.64e-9	Alzheimer's disease (survival time);
LUSC	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg07080220	chr10:102295463	HIF1AN	0.59	7.64	0.39	2.24e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-7.09	-0.36	8.24e-12	Asthma;
LUSC	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg14530993	chr4:882597	GAK	0.73	7.39	0.37	1.17e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.54	-9.89	-0.48	2.15e-20	Longevity;Endometriosis;
LUSC	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.18	0.32	1.87e-9	Obesity-related traits;
LUSC	cis	rs7572644	0.699	rs13416434	chr2:28162274	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-6.94	-0.35	2.06e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7615316	1.000	rs2030613	chr3:142343391	G/A	cg16271453	chr3:142027066	XRN1	-0.35	-6.06	-0.31	3.69e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2274273	1.000	rs57970196	chr14:55600405	C/T	cg04306507	chr14:55594613	LGALS3	0.54	11.49	0.53	5.85e-26	Protein biomarker;
LUSC	trans	rs3857536	0.719	rs9363555	chr6:66930332	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.23	-0.32	1.4e-9	Blood trace element (Cu levels);
LUSC	cis	rs4443100	0.917	rs5996460	chr22:23393090	G/A	cg14186256	chr22:23484241	RTDR1	0.5	6.24	0.32	1.3e-9	Serum parathyroid hormone levels;
LUSC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.59	-9.5	-0.46	4.13e-19	Prudent dietary pattern;
LUSC	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg26061582	chr7:22766209	IL6	0.45	6.61	0.34	1.55e-10	Lung cancer;
LUSC	cis	rs12928939	0.954	rs34998650	chr16:71829329	T/C	cg03805757	chr16:71968109	PKD1L3	-0.46	-6.65	-0.34	1.23e-10	Post bronchodilator FEV1;
LUSC	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg20587970	chr11:113659929	NA	-1.29	-16.75	-0.68	3.69e-46	Hip circumference adjusted for BMI;
LUSC	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-7.16	-0.36	5.26e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.76	12.14	0.55	2.44e-28	Coronary artery disease;
LUSC	cis	rs11971779	0.818	rs12056045	chr7:139025430	C/G	cg07862535	chr7:139043722	LUC7L2	0.72	8.03	0.4	1.7e-14	Diisocyanate-induced asthma;
LUSC	cis	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg09904177	chr6:26538194	HMGN4	-0.76	-5.96	-0.31	6.44e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7681423	0.951	rs6050	chr4:155507590	C/T	cg20735720	chr4:155535218	FGG	0.48	7.44	0.38	8.67e-13	Fibrinogen;
LUSC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg01657329	chr11:68192670	LRP5	0.44	6.47	0.33	3.58e-10	Total body bone mineral density;
LUSC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs4363385	0.642	rs58124215	chr1:152916375	C/T	cg08895932	chr1:152778580	LCE1C	-0.33	-5.87	-0.31	1.03e-8	Inflammatory skin disease;
LUSC	cis	rs6961069	0.585	rs62461693	chr7:80248259	T/C	cg04458919	chr7:80252533	CD36	-0.4	-7.01	-0.36	1.3e-11	Platelet count;
LUSC	cis	rs4363385	0.588	rs6660878	chr1:153027068	A/G	cg00922841	chr1:152955080	SPRR1A	-0.37	-6.24	-0.32	1.31e-9	Inflammatory skin disease;
LUSC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01570182	chr17:44337453	NA	0.71	10.7	0.51	3.74e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04459753	chr16:28858035	TUFM	0.43	6.22	0.32	1.48e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg25214090	chr10:38739885	LOC399744	0.5	7.27	0.37	2.52e-12	Corneal astigmatism;
LUSC	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.55	0.62	1.76e-37	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10875746	0.903	rs10875740	chr12:48489117	C/T	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	trans	rs9291879	0.551	rs7721781	chr5:66532920	C/T	cg04621676	chr1:9599380	SLC25A33	-0.45	-6.06	-0.31	3.66e-9	Gut microbiota (bacterial taxa);
LUSC	trans	rs961253	0.556	rs6076983	chr20:6331376	C/T	cg17788362	chr6:86352627	SYNCRIP	0.41	5.98	0.31	5.82e-9	Colorectal cancer;
LUSC	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.61	8.34	0.41	2.03e-15	Adiposity;
LUSC	cis	rs9467711	0.516	rs629444	chr6:25885814	A/G	cg08501292	chr6:25962987	TRIM38	-0.62	-6.3	-0.33	9.55e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs62400317	0.859	rs62436760	chr6:45112604	T/C	cg20913747	chr6:44695427	NA	-0.46	-7.38	-0.37	1.25e-12	Total body bone mineral density;
LUSC	trans	rs72674100	1.000	rs10016960	chr4:97989075	T/A	cg09670535	chr1:18959427	PAX7	-0.62	-6.34	-0.33	7.58e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs56283067	0.887	rs9463043	chr6:44771114	T/C	cg18551225	chr6:44695536	NA	-0.45	-7.21	-0.37	3.73e-12	Total body bone mineral density;
LUSC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.54	8.7	0.43	1.51e-16	Calcium levels;
LUSC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg00945038	chr17:61921165	SMARCD2	0.54	9.61	0.47	1.85e-19	Prudent dietary pattern;
LUSC	cis	rs753778	0.962	rs2043422	chr8:142236337	C/T	cg18755752	chr8:142205143	DENND3	-0.47	-6.52	-0.34	2.6e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	trans	rs1973993	0.745	rs6593602	chr1:96951281	G/A	cg10631902	chr5:14652156	NA	-0.45	-6.66	-0.34	1.15e-10	Weight;
LUSC	trans	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.53e-10	Corneal astigmatism;
LUSC	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg09307838	chr4:120376055	NA	0.69	10.01	0.48	8.32e-21	Corneal astigmatism;
LUSC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg19622623	chr12:86230825	RASSF9	-0.44	-6.22	-0.32	1.46e-9	Major depressive disorder;
LUSC	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg20703242	chr1:230279135	GALNT2	0.56	8.61	0.43	2.97e-16	Coronary artery disease;
LUSC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.86	15.73	0.65	4.27e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg12140854	chr5:148520817	ABLIM3	-0.39	-6.07	-0.32	3.43e-9	Breast cancer;
LUSC	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.47	-7.84	-0.39	6.01e-14	Eosinophil percentage of granulocytes;
LUSC	cis	rs3099143	1.000	rs4243043	chr15:77178540	A/G	cg21673338	chr15:77095150	SCAPER	0.8	7.8	0.39	8.1e-14	Recalcitrant atopic dermatitis;
LUSC	cis	rs7705502	1.000	rs72810989	chr5:173326714	A/G	cg18693985	chr5:173351052	CPEB4	-0.37	-5.85	-0.3	1.19e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg04492858	chr10:133558786	NA	0.42	6.98	0.36	1.57e-11	Survival in rectal cancer;
LUSC	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg23950597	chr19:37808831	NA	-0.65	-7.91	-0.4	3.9e-14	Coronary artery calcification;
LUSC	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg00166722	chr3:10149974	C3orf24	0.4	6.07	0.32	3.47e-9	Alzheimer's disease;
LUSC	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.94	-18.67	-0.71	8.71e-54	Ulcerative colitis;
LUSC	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg18232548	chr7:50535776	DDC	-0.39	-5.68	-0.3	2.88e-8	Body mass index;
LUSC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.44	6.62	0.34	1.46e-10	Menarche (age at onset);
LUSC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.03	0.31	4.43e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-7.03	-0.36	1.19e-11	Electroencephalogram traits;
LUSC	cis	rs4746818	0.643	rs2855020	chr10:70856510	C/T	cg11621586	chr10:70884670	VPS26A	0.94	9.19	0.45	4.42e-18	Left atrial antero-posterior diameter;
LUSC	trans	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg25206134	chr2:45395956	NA	0.56	6.83	0.35	3.96e-11	Bipolar disorder;
LUSC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.94	-19.27	-0.73	3.78e-56	Post bronchodilator FEV1;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01500567	chr6:44355777	CDC5L	0.53	7.15	0.36	5.54e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	11.01	0.52	2.98e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg17366294	chr4:99064904	C4orf37	0.57	9.99	0.48	9.57e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.56	9.48	0.46	4.93e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6840360	1.000	rs751014	chr4:152601902	G/A	cg22705602	chr4:152727874	NA	-0.27	-5.7	-0.3	2.6e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.42	6.26	0.32	1.2e-9	Platelet count;
LUSC	cis	rs7523050	0.908	rs12036331	chr1:109398707	A/T	cg08274380	chr1:109419600	GPSM2	0.81	8.86	0.44	4.81e-17	Fat distribution (HIV);
LUSC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg21724239	chr8:58056113	NA	0.55	6.37	0.33	6.1e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg27284194	chr4:1044797	NA	0.59	8.97	0.44	2.1e-17	Recombination rate (females);
LUSC	cis	rs259282	0.602	rs194589	chr19:33144621	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.91	13.4	0.59	4.59e-33	Schizophrenia;
LUSC	trans	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-8.04	-0.4	1.57e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg13393036	chr8:95962371	TP53INP1	0.43	8.68	0.43	1.84e-16	Type 2 diabetes;
LUSC	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg09455208	chr3:40491958	NA	0.43	7.96	0.4	2.77e-14	Renal cell carcinoma;
LUSC	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg13010199	chr12:38710504	ALG10B	-0.62	-9.56	-0.46	2.74e-19	Bladder cancer;
LUSC	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg24642844	chr7:1081250	C7orf50	-0.71	-6.7	-0.34	9.1e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4072705	0.967	rs4838208	chr9:127528035	C/A	cg13476313	chr9:127244764	NR5A1	0.3	5.67	0.3	3.13e-8	Menarche (age at onset);
LUSC	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg11608241	chr8:8085544	FLJ10661	0.46	6.53	0.34	2.41e-10	Neuroticism;
LUSC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg03806693	chr22:41940476	POLR3H	0.99	14.24	0.61	2.63e-36	Vitiligo;
LUSC	cis	rs10779751	1.000	rs4845854	chr1:11261929	T/C	cg08854313	chr1:11322531	MTOR	0.89	15.89	0.66	9.61e-43	Body mass index;
LUSC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	0.82	12.14	0.55	2.42e-28	Gut microbiome composition (summer);
LUSC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg23985595	chr17:80112537	CCDC57	-0.31	-6.06	-0.31	3.68e-9	Life satisfaction;
LUSC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.38	0.33	5.95e-10	Menopause (age at onset);
LUSC	cis	rs9815354	0.767	rs61283393	chr3:41854135	T/G	cg03022575	chr3:42003672	ULK4	0.84	8.86	0.44	4.79e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg18681998	chr4:17616180	MED28	0.77	13.44	0.59	3.14e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3824867	0.920	rs4282946	chr11:47456202	G/A	cg20307385	chr11:47447363	PSMC3	0.66	9.74	0.47	6.62e-20	Mean corpuscular hemoglobin;
LUSC	cis	rs77633900	0.614	rs2469242	chr15:76876710	A/G	cg21673338	chr15:77095150	SCAPER	-0.69	-6.88	-0.35	2.95e-11	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg16342193	chr10:102329863	NA	-0.38	-6.76	-0.35	6.18e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg03351412	chr1:154909251	PMVK	-0.46	-7.06	-0.36	9.75e-12	Prostate cancer;
LUSC	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-7.04	-0.36	1.1e-11	Fear of minor pain;
LUSC	cis	rs4253772	0.530	rs9615989	chr22:46803774	A/T	cg00784671	chr22:46762841	CELSR1	-0.55	-5.78	-0.3	1.72e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg05714579	chr10:131428358	MGMT	-0.77	-11.89	-0.55	2.08e-27	Response to temozolomide;
LUSC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg06618935	chr21:46677482	NA	-0.38	-7.72	-0.39	1.38e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-7.04	-0.36	1.08e-11	Retinal vascular caliber;
LUSC	cis	rs1185460	0.967	rs1168568	chr11:118949799	G/A	cg23280166	chr11:118938394	VPS11	0.47	7.27	0.37	2.55e-12	Coronary artery disease;
LUSC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg08847533	chr14:75593920	NEK9	0.86	16.11	0.66	1.35e-43	Height;
LUSC	cis	rs3007168	1.000	rs2999356	chr14:51606543	A/G	cg23942311	chr14:51606299	NA	0.36	5.99	0.31	5.57e-9	Cancer;
LUSC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.44	0.33	4.25e-10	Menopause (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25632300	chr5:174905618	SFXN1	-0.36	-6.5	-0.34	2.86e-10	Electrocardiographic conduction measures;
LUSC	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg04539111	chr16:67997858	SLC12A4	-0.42	-5.86	-0.31	1.09e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg03684893	chr10:554711	DIP2C	-0.34	-6.1	-0.32	2.93e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg09904177	chr6:26538194	HMGN4	-0.47	-6.77	-0.35	5.64e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7903847	0.642	rs10786344	chr10:99165975	T/C	cg08345082	chr10:99160200	RRP12	-0.35	-7.22	-0.37	3.46e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg17173187	chr15:85201210	NMB	0.51	9.44	0.46	6.57e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs422249	0.593	rs174613	chr11:61628492	G/A	cg06860612	chr11:61641270	FADS3	0.28	5.85	0.31	1.14e-8	Trans fatty acid levels;
LUSC	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg24690094	chr11:67383802	NA	-0.45	-8.33	-0.41	2.14e-15	Mean corpuscular volume;
LUSC	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.4	-5.67	-0.3	3.1e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7799006	0.964	rs3757440	chr7:2272936	A/G	cg02951883	chr7:2050386	MAD1L1	-0.33	-5.76	-0.3	1.86e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg18721089	chr20:30220636	NA	-0.37	-5.85	-0.3	1.19e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg06784218	chr1:46089804	CCDC17	-0.49	-9.89	-0.48	2.18e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg18402987	chr7:1209562	NA	0.66	6.96	0.36	1.84e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-6.69	-0.34	9.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg06740227	chr12:86229804	RASSF9	0.36	5.75	0.3	2.04e-8	Major depressive disorder;
LUSC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg13902645	chr11:5959945	NA	-0.55	-8.69	-0.43	1.64e-16	DNA methylation (variation);
LUSC	cis	rs11958404	0.932	rs72816549	chr5:157417957	G/A	cg05962755	chr5:157440814	NA	0.51	6.21	0.32	1.58e-9	IgG glycosylation;
LUSC	cis	rs977987	0.806	rs12933281	chr16:75483064	T/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.91	-0.35	2.5e-11	Dupuytren's disease;
LUSC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg08027265	chr7:2291960	NA	-0.36	-5.73	-0.3	2.24e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg16342193	chr10:102329863	NA	-0.34	-5.94	-0.31	7.31e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12122100	0.862	rs6689542	chr1:146506881	G/C	cg03526459	chr1:146549940	NA	-0.41	-6.69	-0.34	9.32e-11	HIV-1 control;
LUSC	cis	rs2219968	1.000	rs13276123	chr8:78975338	G/A	cg00738934	chr8:78996279	NA	0.35	6.23	0.32	1.37e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg11766577	chr21:47581405	C21orf56	-0.48	-7.32	-0.37	1.86e-12	Testicular germ cell tumor;
LUSC	trans	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.38	-0.33	5.88e-10	Neuroticism;
LUSC	trans	rs8030485	0.571	rs7182891	chr15:79438697	G/A	cg16586880	chr8:140854244	TRAPPC9	-0.39	-6.36	-0.33	6.68e-10	Left ventricle wall thickness;
LUSC	trans	rs89107	0.688	rs422833	chr6:118608971	T/C	cg11574620	chr4:80246899	NAA11	-0.36	-5.95	-0.31	6.73e-9	Cardiac structure and function;
LUSC	cis	rs9658691	0.607	rs3740281	chr10:90772150	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.61	-6.17	-0.32	1.95e-9	Mosquito bite size;
LUSC	cis	rs10761482	0.638	rs10761507	chr10:62243232	G/T	cg18175470	chr10:62150864	ANK3	0.5	7.0	0.36	1.4e-11	Schizophrenia;
LUSC	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.36	5.71	0.3	2.55e-8	Lymphocyte counts;
LUSC	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg00071950	chr4:10020882	SLC2A9	0.59	9.55	0.46	2.93e-19	Bone mineral density;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg14872580	chr5:162886528	HMMR;NUDCD2	0.4	6.07	0.32	3.42e-9	Schizophrenia;
LUSC	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg00792783	chr2:198669748	PLCL1	0.43	5.87	0.31	1.07e-8	Dermatomyositis;
LUSC	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg21775007	chr8:11205619	TDH	0.78	13.16	0.58	3.74e-32	Retinal vascular caliber;
LUSC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg12310025	chr6:25882481	NA	-0.46	-8.61	-0.43	2.96e-16	Blood metabolite levels;
LUSC	cis	rs9650315	0.866	rs34495936	chr8:57196273	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	6.63	0.34	1.35e-10	Height;
LUSC	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.47	-0.42	7.8e-16	Response to antipsychotic treatment;
LUSC	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.65	0.34	1.17e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs711244	0.532	rs12104444	chr2:37253433	T/C	cg14987922	chr2:37194071	STRN	0.53	7.68	0.39	1.75e-13	Mean platelet volume;
LUSC	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg11062466	chr8:58055876	NA	0.49	6.52	0.34	2.59e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1775715	0.966	rs1251386	chr10:32319114	C/T	cg26784012	chr10:32216390	ARHGAP12	-0.38	-6.23	-0.32	1.39e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg16339924	chr4:17578868	LAP3	0.51	7.6	0.38	2.99e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg10756647	chr7:56101905	PSPH	-0.84	-8.46	-0.42	8.28e-16	Diabetic kidney disease;
LUSC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg05025164	chr4:1340916	KIAA1530	0.45	7.04	0.36	1.13e-11	Longevity;
LUSC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg07701084	chr6:150067640	NUP43	0.55	8.29	0.41	2.84e-15	Lung cancer;
LUSC	cis	rs7590720	1.000	rs934154	chr2:216901933	C/T	cg12620499	chr2:216877984	MREG	0.93	14.09	0.61	1.09e-35	Alcohol dependence;
LUSC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg08219700	chr8:58056026	NA	0.53	6.57	0.34	1.89e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.08	-0.32	3.24e-9	Monocyte count;
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg20093808	chr2:9563643	ITGB1BP1;CPSF3	0.51	6.54	0.34	2.26e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg12002119	chr2:101014098	CHST10	0.37	6.26	0.32	1.17e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs72674100	1.000	rs78448853	chr4:97966420	G/A	cg09670535	chr1:18959427	PAX7	-0.64	-6.12	-0.32	2.68e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.49	7.02	0.36	1.26e-11	Coronary heart disease;
LUSC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg17376030	chr22:41985996	PMM1	0.49	6.04	0.31	4.13e-9	Vitiligo;
LUSC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg11663144	chr21:46675770	NA	-0.42	-7.21	-0.37	3.67e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9462027	0.628	rs7742652	chr6:34667075	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.35	6.3	0.33	9.15e-10	Systemic lupus erythematosus;
LUSC	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg02176678	chr2:219576539	TTLL4	0.6	10.68	0.5	4.11e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9925964	0.933	rs9939417	chr16:31053467	C/T	cg02466173	chr16:30829666	NA	0.37	6.63	0.34	1.34e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.72	-11.24	-0.52	4.47e-25	Menarche (age at onset);
LUSC	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.83	-15.32	-0.64	1.67e-40	Longevity;
LUSC	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.11	-18.21	-0.71	5.74e-52	Primary sclerosing cholangitis;
LUSC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.6	-7.45	-0.38	7.81e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg08213375	chr14:104286397	PPP1R13B	0.45	8.76	0.43	9.72e-17	Schizophrenia;
LUSC	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	1.08	15.88	0.66	1.05e-42	Primary sclerosing cholangitis;
LUSC	cis	rs9356171	0.572	rs2322175	chr6:164328086	G/C	cg25752492	chr6:164341247	NA	-0.38	-6.44	-0.33	4.08e-10	Diisocyanate-induced asthma;
LUSC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg21782813	chr7:2030301	MAD1L1	0.54	9.25	0.45	2.71e-18	Bipolar disorder and schizophrenia;
LUSC	trans	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.25	0.32	1.26e-9	Corneal astigmatism;
LUSC	cis	rs68170813	0.641	rs4730248	chr7:107125939	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.38	-0.46	1.07e-18	Coronary artery disease;
LUSC	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-10.14	-0.48	3.18e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg00701064	chr4:6280414	WFS1	0.57	13.35	0.59	7.38e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg09323728	chr8:95962352	TP53INP1	-0.39	-7.79	-0.39	8.62e-14	Type 2 diabetes;
LUSC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.65	-8.99	-0.44	1.89e-17	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.73	0.39	1.27e-13	Gut microbiome composition (summer);
LUSC	cis	rs9920506	0.518	rs11072774	chr15:78952697	C/T	cg24631222	chr15:78858424	CHRNA5	0.55	6.54	0.34	2.36e-10	Post bronchodilator FEV1;
LUSC	cis	rs7940866	0.845	rs10894294	chr11:130830748	G/T	cg12179176	chr11:130786555	SNX19	0.62	9.57	0.46	2.52e-19	Schizophrenia;
LUSC	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.4	-7.17	-0.37	4.83e-12	Crohn's disease;
LUSC	cis	rs721399	0.513	rs35354956	chr8:18241319	T/C	cg18736775	chr8:18248649	NAT2	-0.58	-6.86	-0.35	3.36e-11	Blood metabolite levels;
LUSC	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.98	-18.49	-0.71	4.61e-53	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1832871	0.672	rs9457344	chr6:158742043	C/T	cg07165851	chr6:158734300	TULP4	0.46	6.89	0.35	2.81e-11	Height;
LUSC	cis	rs6977660	0.660	rs10239332	chr7:19824465	A/G	cg05791153	chr7:19748676	TWISTNB	0.67	6.98	0.36	1.55e-11	Thyroid stimulating hormone;
LUSC	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg14893161	chr1:205819251	PM20D1	-0.47	-6.44	-0.33	4.23e-10	Menarche (age at onset);
LUSC	cis	rs2273669	0.667	rs7766248	chr6:109347262	C/T	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs185694	0.779	rs628483	chr13:30895462	C/T	cg07600127	chr13:30881527	KATNAL1	-0.52	-6.22	-0.32	1.53e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
LUSC	cis	rs240764	0.755	rs12206564	chr6:100987009	A/G	cg09795085	chr6:101329169	ASCC3	-0.41	-5.99	-0.31	5.47e-9	Neuroticism;
LUSC	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.8	10.55	0.5	1.24e-22	Schizophrenia;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg14258366	chr7:41982794	NA	0.79	6.4	0.33	5.35e-10	Cognitive performance;
LUSC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15664640	chr17:80829946	TBCD	-0.48	-8.55	-0.42	4.57e-16	Breast cancer;
LUSC	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg00825309	chr19:58991885	ZNF446	-0.5	-7.23	-0.37	3.27e-12	Uric acid clearance;
LUSC	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg15654264	chr1:150340011	RPRD2	0.65	10.86	0.51	9.95e-24	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg00083206	chr6:110721305	DDO	-0.45	-8.17	-0.41	6.26e-15	Platelet distribution width;
LUSC	cis	rs1505368	0.781	rs4673664	chr2:213277649	T/C	cg16329650	chr2:213403929	ERBB4	0.54	8.78	0.43	8.92e-17	Symmetrical dimethylarginine levels;
LUSC	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg02549819	chr16:58548995	SETD6	0.96	9.01	0.44	1.62e-17	Schizophrenia;
LUSC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg21782813	chr7:2030301	MAD1L1	-0.52	-9.25	-0.45	2.68e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-1.04	-20.49	-0.75	5.24e-61	Cognitive ability;
LUSC	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg00945038	chr17:61921165	SMARCD2	-0.43	-7.27	-0.37	2.63e-12	Prudent dietary pattern;
LUSC	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg03647239	chr10:116582469	FAM160B1	0.48	7.67	0.39	1.96e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg22963979	chr7:1858916	MAD1L1	-0.48	-7.2	-0.37	3.89e-12	Bipolar disorder and schizophrenia;
LUSC	trans	rs9886428	1.000	rs34786320	chr8:14115490	G/C	cg11959399	chr20:741723	C20orf54	-0.4	-6.45	-0.33	3.98e-10	IgG glycosylation;
LUSC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg05082376	chr22:42548792	NA	0.42	6.39	0.33	5.56e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.93	-0.35	2.15e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs28829049	0.597	rs2296107	chr1:19476649	C/G	cg13387374	chr1:19411106	UBR4	0.41	5.86	0.31	1.09e-8	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg25767906	chr1:53392781	SCP2	-0.51	-9.15	-0.45	5.83e-18	Monocyte count;
LUSC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg03526776	chr6:41159608	TREML2	0.32	6.12	0.32	2.68e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg04013166	chr16:89971882	TCF25	0.64	7.68	0.39	1.76e-13	Skin colour saturation;
LUSC	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg05347473	chr6:146136440	FBXO30	0.51	8.55	0.42	4.64e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.46	-6.37	-0.33	6.41e-10	Neutrophil percentage of white cells;
LUSC	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	12.26	0.56	8.55e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg00255919	chr5:131827918	IRF1	-0.44	-8.3	-0.41	2.66e-15	Asthma (sex interaction);
LUSC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-11.8	-0.54	4.37e-27	Monocyte count;
LUSC	cis	rs500891	1.000	rs13203062	chr6:84180038	A/G	cg08257003	chr6:84140564	ME1	-0.34	-7.1	-0.36	7.33e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg04058563	chr4:185651563	MLF1IP	-0.84	-12.9	-0.58	3.69e-31	Blood protein levels;
LUSC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg20135002	chr11:47629003	NA	-0.53	-8.13	-0.41	8.36e-15	Subjective well-being;
LUSC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16680214	chr1:154839983	KCNN3	-0.52	-9.48	-0.46	4.88e-19	Prostate cancer;
LUSC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-0.91	-19.08	-0.72	2.06e-55	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg03806693	chr22:41940476	POLR3H	0.86	12.59	0.57	5.03e-30	Vitiligo;
LUSC	cis	rs10761482	0.813	rs4948409	chr10:62115820	C/T	cg18175470	chr10:62150864	ANK3	-0.48	-6.92	-0.35	2.37e-11	Schizophrenia;
LUSC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg14440974	chr22:39074834	NA	-0.38	-6.37	-0.33	6.2e-10	Menopause (age at onset);
LUSC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg05552183	chr6:42928497	GNMT	0.47	7.81	0.39	7.71e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg25554036	chr4:6271136	WFS1	0.6	12.22	0.56	1.26e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg14993813	chr1:46806288	NSUN4	-0.52	-7.31	-0.37	2.03e-12	Menopause (age at onset);
LUSC	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05535760	chr7:792225	HEATR2	-0.92	-9.63	-0.47	1.61e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18402987	chr7:1209562	NA	0.43	5.83	0.3	1.34e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-6.69	-0.34	9.46e-11	Monocyte percentage of white cells;
LUSC	trans	rs61931739	0.635	rs1601627	chr12:33962420	G/A	cg13010199	chr12:38710504	ALG10B	0.4	6.03	0.31	4.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs9677476	0.955	rs9973370	chr2:232095587	A/G	cg07929768	chr2:232055508	NA	0.31	6.1	0.32	2.93e-9	Food antigen IgG levels;
LUSC	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg23241863	chr10:102295624	HIF1AN	0.49	5.98	0.31	5.84e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg15445000	chr17:37608096	MED1	-0.39	-6.71	-0.34	8.43e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs2742234	0.504	rs10899780	chr10:43725796	T/C	cg15436174	chr10:43711423	RASGEF1A	0.44	7.08	0.36	8.82e-12	Hirschsprung disease;
LUSC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg20476274	chr7:133979776	SLC35B4	0.87	17.01	0.68	3.4e-47	Mean platelet volume;
LUSC	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg09184832	chr6:79620586	NA	-0.44	-7.24	-0.37	3.16e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-0.89	-15.75	-0.65	3.35e-42	Height;
LUSC	trans	rs1325195	0.506	rs2636265	chr1:179199076	A/G	cg11624085	chr17:8464688	MYH10	0.41	6.69	0.34	9.35e-11	IgE grass sensitization;
LUSC	cis	rs4664304	0.966	rs3792198	chr2:160760338	G/A	cg03641300	chr2:160917029	PLA2R1	-0.42	-6.79	-0.35	5.22e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6714710	0.580	rs17489915	chr2:98420431	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs7605827	0.930	rs4668444	chr2:15515642	C/T	cg19274914	chr2:15703543	NA	0.47	9.07	0.44	1.03e-17	Educational attainment (years of education);
LUSC	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg22496339	chr2:162101262	NA	-0.59	-7.93	-0.4	3.29e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
LUSC	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg03859395	chr2:55845619	SMEK2	0.85	15.18	0.64	5.99e-40	Metabolic syndrome;
LUSC	cis	rs4077468	1.000	rs9662221	chr1:205915745	G/T	cg07167872	chr1:205819463	PM20D1	-0.45	-6.58	-0.34	1.83e-10	Cystic fibrosis-related diabetes;
LUSC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg13319975	chr6:146136371	FBXO30	0.48	7.31	0.37	1.99e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11039100	1.000	rs12361754	chr11:5828027	T/C	cg05234568	chr11:5960015	NA	-0.51	-5.73	-0.3	2.27e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg26958806	chr6:27640298	NA	0.83	6.57	0.34	1.94e-10	Depression;
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.67	-10.21	-0.49	1.79e-21	Lymphocyte counts;
LUSC	trans	rs62458065	0.640	rs10241303	chr7:32534203	T/G	cg00845942	chr12:64062724	DPY19L2	-0.61	-7.62	-0.38	2.69e-13	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	8.41	0.42	1.2e-15	Response to bleomycin (chromatid breaks);
LUSC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg18350739	chr11:68623251	NA	-0.37	-6.36	-0.33	6.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.63	-14.62	-0.62	9.33e-38	Prostate cancer;
LUSC	cis	rs73206853	0.563	rs73194026	chr12:111140219	G/T	cg12870014	chr12:110450643	ANKRD13A	0.67	7.36	0.37	1.45e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-0.94	-16.08	-0.66	1.74e-43	Height;
LUSC	trans	rs11603151	0.622	rs7106125	chr11:134505804	G/C	cg16473511	chr2:192015759	STAT4	0.48	5.96	0.31	6.33e-9	Schizophrenia;
LUSC	cis	rs9612	0.718	rs346531	chr19:44239927	T/C	cg08581076	chr19:44259116	C19orf61	0.48	5.77	0.3	1.77e-8	Exhaled nitric oxide output;
LUSC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19717773	chr7:2847554	GNA12	-0.39	-6.08	-0.32	3.2e-9	Height;
LUSC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg03213289	chr20:61660250	NA	0.67	13.96	0.61	3.26e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg08501292	chr6:25962987	TRIM38	0.65	5.92	0.31	7.84e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg03929089	chr4:120376271	NA	0.8	10.15	0.49	2.78e-21	Coronary artery disease;
LUSC	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg17385448	chr1:15911702	AGMAT	0.36	6.18	0.32	1.82e-9	Systolic blood pressure;
LUSC	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg14458575	chr2:238380390	NA	0.46	7.98	0.4	2.44e-14	Prostate cancer;
LUSC	cis	rs2387326	0.717	rs12261194	chr10:129944464	T/C	cg16087940	chr10:129947807	NA	-0.39	-6.0	-0.31	5e-9	Select biomarker traits;
LUSC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg23172400	chr8:95962367	TP53INP1	-0.39	-8.02	-0.4	1.78e-14	Type 2 diabetes;
LUSC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.59	7.88	0.4	4.54e-14	Lung function (FEV1/FVC);
LUSC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg22823121	chr1:150693482	HORMAD1	-0.52	-7.34	-0.37	1.59e-12	Urate levels;
LUSC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-5.8	-0.3	1.56e-8	Vitiligo;
LUSC	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.4	0.38	1.1e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs10203711	1.000	rs4331454	chr2:239594474	G/A	cg14580085	chr2:239553406	NA	0.42	7.07	0.36	9.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg04176532	chr22:50317003	CRELD2	-0.4	-5.73	-0.3	2.28e-8	Schizophrenia;
LUSC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg16928487	chr17:17741425	SREBF1	0.37	7.13	0.36	6.28e-12	Total body bone mineral density;
LUSC	cis	rs10992471	0.528	rs10429459	chr9:95258119	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.37	6.34	0.33	7.49e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4253772	1.000	rs11705483	chr22:46630544	C/A	cg18190219	chr22:46762943	CELSR1	-0.52	-6.06	-0.31	3.61e-9	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs7567288	0.636	rs11896655	chr2:134458912	G/A	cg12381416	chr3:14359266	NA	0.57	6.29	0.33	1.01e-9	Height;
LUSC	cis	rs7804356	1.000	rs7805766	chr7:26865610	C/G	cg03456212	chr7:26904342	SKAP2	-0.56	-6.44	-0.33	4.23e-10	Type 1 diabetes;
LUSC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg14552801	chr7:65878734	NA	-0.45	-6.45	-0.33	3.83e-10	Aortic root size;
LUSC	cis	rs981844	0.603	rs13132437	chr4:154748006	T/G	cg14289246	chr4:154710475	SFRP2	-0.46	-6.32	-0.33	8.33e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg05347473	chr6:146136440	FBXO30	0.6	9.81	0.47	4.01e-20	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg25801113	chr15:45476975	SHF	0.34	7.0	0.36	1.37e-11	Uric acid levels;
LUSC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg18225595	chr11:63971243	STIP1	0.43	7.08	0.36	8.34e-12	Platelet count;
LUSC	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg14583973	chr4:3374767	RGS12	0.38	8.1	0.41	1.02e-14	Serum sulfate level;
LUSC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg26850624	chr5:429559	AHRR	-0.41	-8.14	-0.41	8.12e-15	Cystic fibrosis severity;
LUSC	cis	rs5758511	0.573	rs2284082	chr22:42240797	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-7.39	-0.37	1.19e-12	Birth weight;
LUSC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21963583	chr11:68658836	MRPL21	0.54	8.12	0.41	9.27e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg06740227	chr12:86229804	RASSF9	0.39	6.09	0.32	3.05e-9	Major depressive disorder;
LUSC	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg17691542	chr6:26056736	HIST1H1C	0.67	9.98	0.48	1.03e-20	Height;
LUSC	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg00540400	chr15:79124168	NA	0.46	8.1	0.41	1.06e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs796825	0.530	rs55762220	chr3:119956606	T/C	cg21790991	chr3:120137480	FSTL1	-0.34	-6.0	-0.31	5.02e-9	HIV-1 susceptibility;
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10150615	chr22:24372951	LOC391322	-0.37	-6.26	-0.32	1.2e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg15848620	chr12:58087721	OS9	-0.57	-8.08	-0.4	1.16e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	0.88	17.02	0.68	3.35e-47	Brugada syndrome;
LUSC	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg24110177	chr3:50126178	RBM5	-0.39	-5.94	-0.31	7.04e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6690583	0.524	rs12029690	chr1:85452867	C/G	cg22153463	chr1:85462885	MCOLN2	0.62	6.0	0.31	5.12e-9	Serum sulfate level;
LUSC	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg20607287	chr7:12443886	VWDE	-0.59	-6.14	-0.32	2.35e-9	Coronary artery disease;
LUSC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg05623727	chr3:50126028	RBM5	0.33	6.05	0.31	3.94e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg13531842	chr10:38383804	ZNF37A	-0.43	-6.71	-0.34	8.54e-11	Extrinsic epigenetic age acceleration;
LUSC	trans	rs2262909	0.962	rs409835	chr19:22230671	T/C	cg05197062	chr11:11642011	GALNTL4	-0.56	-7.81	-0.39	7.34e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.71	-0.3	2.45e-8	Depression;
LUSC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg04450456	chr4:17643702	FAM184B	0.36	6.15	0.32	2.2e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7131987	1.000	rs7131987	chr12:29406488	G/T	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.23	-0.32	1.38e-9	QT interval;
LUSC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg07701084	chr6:150067640	NUP43	0.57	8.85	0.44	5.05e-17	Lung cancer;
LUSC	cis	rs60154123	0.505	rs115881613	chr1:210040369	C/T	cg22029157	chr1:209979665	IRF6	0.74	8.76	0.43	9.93e-17	Coronary artery disease;
LUSC	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg02574844	chr11:5959923	NA	0.54	8.54	0.42	4.91e-16	DNA methylation (variation);
LUSC	cis	rs11677416	1.000	rs17561	chr2:113537223	C/A	cg27083787	chr2:113543245	IL1A	0.48	7.41	0.38	1.05e-12	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg04586622	chr2:25135609	ADCY3	0.42	8.98	0.44	1.97e-17	Body mass index;
LUSC	cis	rs78572108	0.858	rs4952569	chr2:42263169	A/G	cg00607755	chr2:42274082	PKDCC	0.36	6.49	0.33	3.05e-10	Total body bone mineral density;
LUSC	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg22508957	chr16:3507546	NAT15	0.4	6.25	0.32	1.23e-9	Body mass index (adult);
LUSC	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg21699342	chr2:239360505	ASB1	0.53	9.92	0.48	1.75e-20	Multiple system atrophy;
LUSC	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg05082376	chr22:42548792	NA	-0.39	-6.54	-0.34	2.34e-10	Cognitive function;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05725090	chr13:113242514	TUBGCP3	-0.45	-6.67	-0.34	1.03e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg01966878	chr4:90757139	SNCA	-0.36	-6.21	-0.32	1.59e-9	Dementia with Lewy bodies;
LUSC	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg24675056	chr1:15929824	NA	0.43	7.56	0.38	3.85e-13	Systolic blood pressure;
LUSC	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg22535103	chr8:58192502	C8orf71	-0.75	-9.55	-0.46	2.95e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg02574844	chr11:5959923	NA	-0.42	-6.63	-0.34	1.33e-10	DNA methylation (variation);
LUSC	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg17507749	chr15:85114479	UBE2QP1	0.46	6.11	0.32	2.79e-9	Schizophrenia;
LUSC	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg09904177	chr6:26538194	HMGN4	0.75	14.05	0.61	1.54e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs2425143	0.908	rs6060625	chr20:34414318	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-5.99	-0.31	5.43e-9	Blood protein levels;
LUSC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg06740227	chr12:86229804	RASSF9	-0.37	-5.87	-0.31	1.05e-8	Major depressive disorder;
LUSC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.42	-0.33	4.59e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-8.53	-0.42	5.23e-16	Hemoglobin concentration;
LUSC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.88	-0.31	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg11645453	chr3:52864694	ITIH4	0.32	7.26	0.37	2.76e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg02018176	chr4:1364513	KIAA1530	0.46	7.97	0.4	2.47e-14	Obesity-related traits;
LUSC	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21659725	chr3:3221576	CRBN	0.61	9.98	0.48	1.08e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg13206674	chr6:150067644	NUP43	0.59	9.24	0.45	2.87e-18	Lung cancer;
LUSC	trans	rs2262909	0.925	rs56073035	chr19:22276298	C/G	cg17074339	chr11:11642133	GALNTL4	0.44	6.76	0.35	6.13e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg22166914	chr1:53195759	ZYG11B	0.5	7.88	0.4	4.68e-14	Monocyte count;
LUSC	cis	rs62400317	0.762	rs12208605	chr6:44963735	A/C	cg20913747	chr6:44695427	NA	0.47	7.15	0.36	5.42e-12	Total body bone mineral density;
LUSC	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg04989706	chr14:50066350	PPIL5	-0.46	-5.88	-0.31	9.79e-9	Carotid intima media thickness;
LUSC	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.32	-5.75	-0.3	2.05e-8	Bone mineral density (hip);Bone mineral density;
LUSC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg12463550	chr7:65579703	CRCP	0.57	8.47	0.42	7.7e-16	Aortic root size;
LUSC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	0.93	18.29	0.71	2.88e-52	Cognitive function;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18128437	chr3:167453397	PDCD10;SERPINI1	0.46	6.73	0.35	7.32e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9487051	0.768	rs463503	chr6:109525757	T/C	cg00509249	chr6:109615579	CCDC162	-0.33	-5.74	-0.3	2.15e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg23281280	chr6:28129359	ZNF389	0.49	6.47	0.33	3.51e-10	Parkinson's disease;
LUSC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg20607798	chr8:58055168	NA	0.55	6.09	0.32	3.07e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg17168535	chr8:21777572	XPO7	0.82	14.58	0.62	1.36e-37	Mean corpuscular volume;
LUSC	cis	rs7578035	0.500	rs17021941	chr2:99384299	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.45	-6.14	-0.32	2.31e-9	Bipolar disorder;
LUSC	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg23950597	chr19:37808831	NA	-0.62	-7.21	-0.37	3.67e-12	Coronary artery calcification;
LUSC	cis	rs62027291	0.950	rs11637631	chr15:77283977	G/T	cg26408565	chr15:76604113	ETFA	0.45	5.87	0.31	1.03e-8	Plateletcrit;
LUSC	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.41	8.47	0.42	8.14e-16	Hemoglobin concentration;
LUSC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08219700	chr8:58056026	NA	0.69	8.07	0.4	1.27e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-5.87	-0.31	1.06e-8	Testicular germ cell tumor;
LUSC	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg21385522	chr1:16154831	NA	0.52	7.81	0.39	7.48e-14	Systolic blood pressure;
LUSC	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg05855489	chr10:104503620	C10orf26	0.52	8.03	0.4	1.67e-14	Arsenic metabolism;
LUSC	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg24642844	chr7:1081250	C7orf50	-0.79	-10.39	-0.49	4.39e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.46	-0.33	3.65e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs79387448	0.745	rs723292	chr2:103166804	A/G	cg09003973	chr2:102972529	NA	0.87	8.7	0.43	1.59e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19346786	chr7:2764209	NA	-0.44	-7.58	-0.38	3.44e-13	Height;
LUSC	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg26395211	chr5:140044315	WDR55	-0.38	-5.84	-0.3	1.27e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-0.63	-11.18	-0.52	7e-25	White blood cell count;
LUSC	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	0.63	13.21	0.59	2.37e-32	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-9.49	-0.46	4.49e-19	Gut microbiome composition (summer);
LUSC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24739457	chr1:205821442	NA	0.41	7.05	0.36	1.04e-11	Menarche (age at onset);
LUSC	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg21175976	chr8:11421337	BLK	0.35	5.69	0.3	2.75e-8	Neuroticism;
LUSC	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	12.25	0.56	9.92e-29	Electrocardiographic conduction measures;
LUSC	cis	rs6120849	0.707	rs6088703	chr20:33676049	T/A	cg24642439	chr20:33292090	TP53INP2	0.57	6.34	0.33	7.31e-10	Protein C levels;
LUSC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg27494647	chr7:150038898	RARRES2	0.51	7.92	0.4	3.67e-14	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs330048	0.545	rs11781008	chr8:9153239	G/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.39	0.33	5.55e-10	Systemic lupus erythematosus;
LUSC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg02951883	chr7:2050386	MAD1L1	-0.39	-6.49	-0.33	3.19e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7172677	1.000	rs11072525	chr15:75419110	G/A	cg14664628	chr15:75095509	CSK	-0.44	-5.77	-0.3	1.82e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	trans	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg13565492	chr6:43139072	SRF	-0.41	-5.95	-0.31	6.8e-9	Longevity;Endometriosis;
LUSC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-11.04	-0.52	2.2e-24	Bipolar disorder and schizophrenia;
LUSC	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	7.08	0.36	8.37e-12	Response to antipsychotic treatment;
LUSC	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.54	-10.65	-0.5	5.42e-23	Glomerular filtration rate (creatinine);
LUSC	trans	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	8.38	0.42	1.46e-15	Ulcerative colitis;
LUSC	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.63	-5.92	-0.31	8.15e-9	Major depressive disorder;
LUSC	cis	rs2294693	0.945	rs68031000	chr6:41008841	G/T	cg14769373	chr6:40998127	UNC5CL	-0.54	-7.22	-0.37	3.59e-12	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg25237894	chr2:233734115	C2orf82	0.34	6.33	0.33	7.67e-10	Coronary artery disease;
LUSC	trans	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.48	-6.9	-0.35	2.67e-11	Monocyte count;
LUSC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg07741184	chr6:167504864	NA	-0.39	-6.9	-0.35	2.69e-11	Primary biliary cholangitis;
LUSC	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg00677455	chr12:58241039	CTDSP2	0.49	7.28	0.37	2.45e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-1.23	-13.29	-0.59	1.17e-32	Diabetic kidney disease;
LUSC	cis	rs73200209	0.744	rs11612443	chr12:116518839	A/G	cg01776926	chr12:116560359	MED13L	-0.49	-6.03	-0.31	4.4e-9	Total body bone mineral density;
LUSC	cis	rs911119	0.913	rs13043610	chr20:23586941	G/A	cg16589663	chr20:23618590	CST3	0.63	7.49	0.38	6.4e-13	Chronic kidney disease;
LUSC	cis	rs75804782	0.641	rs112066551	chr2:239362486	G/A	cg18131467	chr2:239335373	ASB1	-0.74	-6.67	-0.34	1.06e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg02569458	chr12:86230093	RASSF9	-0.45	-7.26	-0.37	2.69e-12	Major depressive disorder;
LUSC	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg03647239	chr10:116582469	FAM160B1	0.44	7.15	0.36	5.58e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg24642439	chr20:33292090	TP53INP2	0.45	6.5	0.34	2.84e-10	Height;
LUSC	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg09408571	chr1:101003634	GPR88	0.29	5.84	0.3	1.25e-8	Monocyte count;
LUSC	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	14.57	0.62	1.41e-37	Post bronchodilator FEV1;
LUSC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg12412775	chr1:25698385	RHCE	-0.29	-5.87	-0.31	1.05e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg12935359	chr14:103987150	CKB	0.66	10.58	0.5	9.03e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.77	0.47	5.18e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg23649088	chr2:200775458	C2orf69	0.52	8.15	0.41	7.55e-15	Osteoporosis;
LUSC	cis	rs7923609	1.000	rs7070296	chr10:65070438	T/A	cg01631684	chr10:65280961	REEP3	-0.43	-6.62	-0.34	1.39e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7582720	0.806	rs72926770	chr2:203798585	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7246967	0.673	rs59621958	chr19:22940659	C/T	cg23217946	chr19:22817039	ZNF492	0.43	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.74	15.57	0.65	1.72e-41	Systemic lupus erythematosus;
LUSC	cis	rs1783925	0.881	rs643446	chr11:125306472	T/C	cg03464685	chr11:125439445	EI24	-0.46	-6.15	-0.32	2.22e-9	Formal thought disorder in schizophrenia;
LUSC	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.03	0.52	2.41e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	0.93	13.0	0.58	1.46e-31	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs13082711	0.555	rs73038733	chr3:27263537	C/G	cg02860705	chr3:27208620	NA	0.66	11.57	0.53	2.87e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg24631222	chr15:78858424	CHRNA5	0.65	8.65	0.43	2.2e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.4	0.53	1.16e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-6.51	-0.34	2.76e-10	Daytime sleep phenotypes;
LUSC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.13	0.48	3.37e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg11871910	chr12:69753446	YEATS4	0.69	10.65	0.5	5.18e-23	Blood protein levels;
LUSC	cis	rs7188861	0.768	rs1690500	chr16:11389986	C/T	cg00044050	chr16:11439710	C16orf75	0.57	6.35	0.33	7.17e-10	HDL cholesterol;
LUSC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg03146154	chr1:46216737	IPP	0.55	8.25	0.41	3.82e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9807989	0.801	rs4851566	chr2:102972799	G/C	cg03938978	chr2:103052716	IL18RAP	0.32	5.91	0.31	8.29e-9	Asthma;
LUSC	cis	rs12195417	0.758	rs13197684	chr6:84132963	A/C	cg08257003	chr6:84140564	ME1	0.37	9.11	0.45	7.7e-18	Schizophrenia;
LUSC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg13560548	chr3:10150139	C3orf24	0.46	6.4	0.33	5.28e-10	Alzheimer's disease;
LUSC	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.75	-10.86	-0.51	9.72e-24	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2108225	1.000	rs6466191	chr7:107453511	A/T	cg18560240	chr7:107437656	SLC26A3	-0.38	-5.8	-0.3	1.51e-8	Ulcerative colitis;
LUSC	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg24011408	chr12:48396354	COL2A1	-0.39	-5.69	-0.3	2.82e-8	Glycated hemoglobin levels;
LUSC	cis	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg06521331	chr12:34319734	NA	-0.48	-7.67	-0.39	1.84e-13	Morning vs. evening chronotype;
LUSC	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg24130564	chr14:104152367	KLC1	0.45	6.42	0.33	4.8e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.52	0.57	9.28e-30	Motion sickness;
LUSC	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.7	10.65	0.5	5.42e-23	Corneal astigmatism;
LUSC	cis	rs500891	0.553	rs4706999	chr6:84168264	A/C	cg08257003	chr6:84140564	ME1	0.36	8.74	0.43	1.17e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs7605827	0.930	rs6725454	chr2:15692879	C/A	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.82e-16	Educational attainment (years of education);
LUSC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs56399783	0.808	rs73049331	chr7:2799911	C/T	cg19731401	chr7:2775893	GNA12	0.69	9.08	0.44	9.72e-18	Childhood ear infection;
LUSC	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg03929089	chr4:120376271	NA	-0.45	-6.26	-0.32	1.18e-9	Height;
LUSC	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg06484146	chr7:12443880	VWDE	-0.6	-6.94	-0.36	2.04e-11	Coronary artery disease;
LUSC	cis	rs7833787	0.965	rs7833694	chr8:18700346	T/C	cg17701159	chr8:18705777	PSD3	-0.37	-6.01	-0.31	4.89e-9	Obesity-related traits;
LUSC	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg11235426	chr6:292522	DUSP22	-0.45	-6.7	-0.34	9.08e-11	Menopause (age at onset);
LUSC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	0.79	13.89	0.61	6.06e-35	Cognitive function;
LUSC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg00945038	chr17:61921165	SMARCD2	0.51	8.71	0.43	1.46e-16	Prudent dietary pattern;
LUSC	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	6.06	0.31	3.59e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg23942311	chr14:51606299	NA	0.49	11.44	0.53	8.76e-26	Cancer;
LUSC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs6599077	0.950	rs6782134	chr3:40100692	G/T	cg13683864	chr3:40499215	RPL14	-0.59	-7.4	-0.38	1.11e-12	Sleep-related phenotypes;
LUSC	cis	rs9921338	0.923	rs7186455	chr16:11427748	A/G	cg00044050	chr16:11439710	C16orf75	-0.49	-6.57	-0.34	1.93e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs6076065	0.683	rs2424557	chr20:23422159	C/G	cg11657817	chr20:23433608	CST11	-0.38	-6.65	-0.34	1.2e-10	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	15.11	0.64	1.18e-39	Lung cancer in ever smokers;
LUSC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-9.2	-0.45	3.99e-18	Gut microbiome composition (summer);
LUSC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg27266027	chr21:40555129	PSMG1	0.41	6.07	0.32	3.4e-9	Cognitive function;
LUSC	cis	rs6504340	0.739	rs4793938	chr17:46665229	T/G	cg09704116	chr17:46666958	LOC404266	-0.37	-5.73	-0.3	2.22e-8	Primary tooth development (number of teeth);
LUSC	cis	rs10740039	0.516	rs2068044	chr10:62320437	A/C	cg18175470	chr10:62150864	ANK3	-0.47	-6.97	-0.36	1.65e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg08355456	chr11:67383691	NA	0.38	7.17	0.37	4.86e-12	Mean corpuscular volume;
LUSC	trans	rs4111	0.592	rs9845373	chr3:56108410	C/G	cg26379258	chr6:111888446	TRAF3IP2	-0.42	-6.56	-0.34	2.08e-10	Sense of smell;
LUSC	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg21427119	chr20:30132790	HM13	-0.43	-6.1	-0.32	3.01e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg05347473	chr6:146136440	FBXO30	0.5	8.36	0.42	1.77e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg00074818	chr8:8560427	CLDN23	0.59	9.92	0.48	1.71e-20	Obesity-related traits;
LUSC	cis	rs55675132	0.620	rs1750391	chr1:115642847	A/G	cg01522456	chr1:115632236	TSPAN2	0.46	6.34	0.33	7.43e-10	Schizophrenia;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg09763514	chr7:2298050	SNX8	-0.48	-6.4	-0.33	5.22e-10	Neuroticism;
LUSC	cis	rs9341808	0.718	rs9448893	chr6:80837239	A/G	cg08355045	chr6:80787529	NA	0.57	10.02	0.48	7.75e-21	Sitting height ratio;
LUSC	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg04374321	chr14:90722782	PSMC1	0.75	12.08	0.55	4e-28	Mortality in heart failure;
LUSC	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.28	-0.37	2.48e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs12545109	0.879	rs1513317	chr8:57372966	C/G	cg09654669	chr8:57350985	NA	-0.57	-7.46	-0.38	7.7e-13	Obesity-related traits;
LUSC	cis	rs35883536	0.611	rs61070860	chr1:101097628	G/A	cg06223162	chr1:101003688	GPR88	0.36	6.32	0.33	8.51e-10	Monocyte count;
LUSC	cis	rs1551570	0.766	rs55752217	chr19:10218434	C/T	cg16327482	chr19:10226339	EIF3G	0.39	7.2	0.37	4.11e-12	Narcolepsy;
LUSC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.7	0.47	9.47e-20	Eosinophil percentage of white cells;
LUSC	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.92e-20	Coronary artery disease;
LUSC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10802521	chr3:52805072	NEK4	-0.48	-7.62	-0.38	2.69e-13	Electroencephalogram traits;
LUSC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg02527881	chr3:46936655	PTH1R	0.39	6.89	0.35	2.8e-11	Colorectal cancer;
LUSC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	7.15	0.36	5.68e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.16	0.49	2.56e-21	Bladder cancer;
LUSC	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.6	-11.81	-0.54	3.82e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	1.15	16.52	0.67	3.25e-45	Corneal structure;
LUSC	cis	rs4588572	0.643	rs6874309	chr5:77774498	A/T	cg11547950	chr5:77652471	NA	0.55	7.95	0.4	2.99e-14	Triglycerides;
LUSC	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg02023728	chr11:77925099	USP35	0.47	6.74	0.35	6.97e-11	Testicular germ cell tumor;
LUSC	cis	rs13315871	0.929	rs13101057	chr3:58291467	A/G	cg12435725	chr3:58293450	RPP14	-0.77	-7.45	-0.38	8.27e-13	Cholesterol, total;
LUSC	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg10518572	chr11:65560635	OVOL1	-0.26	-6.03	-0.31	4.29e-9	Acne (severe);
LUSC	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.63	-0.34	1.37e-10	Breast cancer;
LUSC	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.67	-0.39	1.94e-13	Height;
LUSC	cis	rs4663866	0.908	rs35093813	chr2:239153765	T/A	cg16914508	chr2:239161102	PER2	0.67	7.06	0.36	9.86e-12	Irritable bowel syndrome;
LUSC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg12463550	chr7:65579703	CRCP	0.46	6.85	0.35	3.66e-11	Aortic root size;
LUSC	cis	rs2580764	0.503	rs2972097	chr2:55267545	T/C	cg09592903	chr2:55203963	RTN4	0.48	9.58	0.46	2.34e-19	Mean platelet volume;
LUSC	cis	rs9921338	0.961	rs4780357	chr16:11370971	G/A	cg00044050	chr16:11439710	C16orf75	-0.49	-6.66	-0.34	1.11e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg11887960	chr12:57824829	NA	0.53	6.66	0.34	1.13e-10	Obesity-related traits;
LUSC	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21545522	chr1:205238299	TMCC2	0.51	9.63	0.47	1.51e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-9.35	-0.46	1.34e-18	Morning vs. evening chronotype;
LUSC	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg16342193	chr10:102329863	NA	-0.34	-6.27	-0.32	1.09e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.28	-0.32	1.07e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.94	0.7	7.29e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg01652190	chr22:50026171	C22orf34	-0.32	-6.62	-0.34	1.39e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg27426351	chr10:43362370	NA	-0.43	-6.0	-0.31	5.26e-9	Blood protein levels;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg03697856	chr19:2096672	C19orf36;MOBKL2A	0.68	6.22	0.32	1.46e-9	Body mass index;
LUSC	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg14061069	chr19:46274453	DMPK	-0.53	-9.16	-0.45	5.23e-18	Coronary artery disease;
LUSC	trans	rs11700980	0.551	rs2832019	chr21:30112207	A/G	cg14791747	chr16:20752902	THUMPD1	0.57	6.24	0.32	1.3e-9	QRS complex (12-leadsum);
LUSC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg27535305	chr1:53392650	SCP2	-0.49	-9.55	-0.46	2.99e-19	Monocyte count;
LUSC	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg00898013	chr13:113819073	PROZ	-0.56	-7.91	-0.4	3.93e-14	Platelet distribution width;
LUSC	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	8.93	0.44	2.81e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs11997175	0.655	rs72630923	chr8:33662404	C/A	ch.8.33884649F	chr8:33765107	NA	0.39	5.95	0.31	6.83e-9	Body mass index;
LUSC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg27432699	chr2:27873401	GPN1	-0.55	-8.31	-0.41	2.46e-15	Total body bone mineral density;
LUSC	cis	rs887829	0.570	rs6736743	chr2:234595950	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.38	-6.12	-0.32	2.56e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg04374321	chr14:90722782	PSMC1	0.76	12.04	0.55	5.82e-28	Mortality in heart failure;
LUSC	cis	rs4285028	0.747	rs77570895	chr3:121384565	C/T	cg11130432	chr3:121712080	ILDR1	-0.61	-8.76	-0.43	1.02e-16	Multiple sclerosis;
LUSC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg01657329	chr11:68192670	LRP5	0.47	7.65	0.39	2.14e-13	Total body bone mineral density;
LUSC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg12463550	chr7:65579703	CRCP	0.41	5.93	0.31	7.38e-9	Calcium levels;
LUSC	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg04827223	chr11:72435913	ARAP1	-0.88	-15.22	-0.64	4.31e-40	Body mass index;
LUSC	trans	rs75804782	0.641	rs72983861	chr2:239326126	G/A	cg01134436	chr17:81009848	B3GNTL1	0.67	6.38	0.33	5.87e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg22709100	chr7:91322751	NA	-0.39	-5.68	-0.3	2.88e-8	Breast cancer;
LUSC	cis	rs887829	0.569	rs6431628	chr2:234647478	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.29	-0.37	2.3e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg13047869	chr3:10149882	C3orf24	0.65	9.2	0.45	3.94e-18	Alzheimer's disease;
LUSC	cis	rs939658	1.000	rs4778935	chr15:79453282	T/C	cg17916960	chr15:79447300	NA	0.47	9.46	0.46	5.87e-19	Refractive error;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08843001	chr8:30891486	WRN;PURG	0.44	6.5	0.34	2.88e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07677032	chr17:61819896	STRADA	0.54	9.06	0.44	1.15e-17	Prudent dietary pattern;
LUSC	cis	rs9653442	0.527	rs13003982	chr2:100759078	T/C	cg22139774	chr2:100720529	AFF3	-0.42	-7.14	-0.36	5.8e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg03806693	chr22:41940476	POLR3H	-0.9	-12.72	-0.57	1.64e-30	Vitiligo;
LUSC	cis	rs4499344	0.664	rs259284	chr19:33163262	T/C	cg22980127	chr19:33182716	NUDT19	-0.43	-6.42	-0.33	4.72e-10	Mean platelet volume;
LUSC	cis	rs62481355	0.680	rs9640842	chr7:127071463	C/T	cg25922125	chr7:127225783	GCC1	-0.44	-6.22	-0.32	1.5e-9	Type 2 diabetes;
LUSC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg12927641	chr6:109611667	NA	-0.43	-7.47	-0.38	7.04e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs6494488	0.500	rs55960029	chr15:65047080	G/A	cg08069370	chr15:64387884	SNX1	-0.65	-5.91	-0.31	8.23e-9	Coronary artery disease;
LUSC	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg01420254	chr6:26195488	NA	0.69	7.45	0.38	7.81e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs11229555	0.598	rs12276438	chr11:58185419	G/A	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg01596870	chr19:55963115	NA	-0.55	-7.61	-0.38	2.91e-13	Obesity-related traits;
LUSC	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg27661571	chr11:113659931	NA	-0.69	-7.94	-0.4	3.16e-14	Hip circumference adjusted for BMI;
LUSC	trans	rs12439619	0.846	rs62012056	chr15:82539619	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.48	-6.36	-0.33	6.52e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9886651	0.935	rs4524749	chr8:128805447	G/A	cg07795030	chr8:128802207	NA	-0.34	-6.03	-0.31	4.45e-9	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LUSC	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg08847533	chr14:75593920	NEK9	-0.49	-7.01	-0.36	1.35e-11	Caffeine consumption;
LUSC	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg14696996	chr19:15285081	NOTCH3	0.96	9.25	0.45	2.69e-18	Pulse pressure;
LUSC	cis	rs4654899	0.897	rs1021077	chr1:21106016	A/G	cg01072550	chr1:21505969	NA	-0.49	-7.26	-0.37	2.7e-12	Superior frontal gyrus grey matter volume;
LUSC	trans	rs7944735	0.767	rs1017875	chr11:47999218	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.82	0.35	4.23e-11	Intraocular pressure;
LUSC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg13395646	chr4:1353034	KIAA1530	-0.6	-9.54	-0.46	3e-19	Obesity-related traits;
LUSC	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg23093090	chr10:104574429	C10orf26	-0.45	-8.08	-0.4	1.19e-14	Arsenic metabolism;
LUSC	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.28	-0.32	1.06e-9	Platelet count;
LUSC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg15790184	chr11:494944	RNH1	0.6	6.24	0.32	1.29e-9	Body mass index;
LUSC	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.83	0.3	1.32e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	7.28	0.37	2.4e-12	Cognitive ability;
LUSC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg13397359	chr6:42928475	GNMT	0.58	9.76	0.47	5.81e-20	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-10.96	-0.51	4.56e-24	Coffee consumption (cups per day);
LUSC	cis	rs7605827	0.930	rs3805106	chr2:15535863	C/G	cg19274914	chr2:15703543	NA	0.43	8.85	0.44	5.34e-17	Educational attainment (years of education);
LUSC	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg08917208	chr2:24149416	ATAD2B	0.96	10.07	0.48	5.08e-21	Lymphocyte counts;
LUSC	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg00757033	chr12:89920650	WDR51B	-0.56	-10.02	-0.48	7.54e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-1.05	-14.49	-0.62	2.84e-37	Vitiligo;
LUSC	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21643547	chr1:205240462	TMCC2	-0.5	-9.27	-0.45	2.28e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs17401966	0.540	rs58014725	chr1:10474457	T/A	cg19773385	chr1:10388646	KIF1B	-0.41	-7.1	-0.36	7.74e-12	Hepatocellular carcinoma;
LUSC	trans	rs4714291	0.832	rs1404002	chr6:40064600	C/T	cg02267698	chr19:7991119	CTXN1	-0.58	-8.63	-0.43	2.53e-16	Strep throat;
LUSC	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.47	6.35	0.33	7.02e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.39	0.53	1.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg04944784	chr2:26401820	FAM59B	-0.75	-11.21	-0.52	5.76e-25	Gut microbiome composition (summer);
LUSC	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	8.89	0.44	3.84e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.15	0.55	2.14e-28	Height;
LUSC	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.34	0.49	6.24e-22	Schizophrenia;
LUSC	cis	rs9807841	0.544	rs10407692	chr19:10770783	A/G	cg17710535	chr19:10819994	QTRT1	0.41	6.89	0.35	2.75e-11	Inflammatory skin disease;
LUSC	cis	rs4776059	0.761	rs61731670	chr15:52901283	T/C	cg24008177	chr15:52972085	KIAA1370	-0.35	-6.13	-0.32	2.46e-9	Schizophrenia;
LUSC	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg03732007	chr1:2071316	PRKCZ	-0.48	-7.76	-0.39	1.08e-13	Height;
LUSC	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-8.74	-0.43	1.16e-16	Coffee consumption (cups per day);
LUSC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.51	9.86	0.47	2.77e-20	Monocyte percentage of white cells;
LUSC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.81	-0.3	1.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7246967	0.673	rs73020703	chr19:22844339	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs243505	0.767	rs243530	chr7:148412618	T/C	cg09806900	chr7:148480153	CUL1	-0.5	-6.48	-0.33	3.22e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.33	-6.78	-0.35	5.63e-11	Hemoglobin concentration;
LUSC	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg23298862	chr7:158159286	PTPRN2	0.32	5.66	0.3	3.32e-8	Response to amphetamines;
LUSC	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg00631329	chr6:26305371	NA	-0.46	-9.11	-0.45	7.58e-18	Educational attainment;
LUSC	trans	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg07393940	chr7:158741817	NA	0.38	6.88	0.35	2.92e-11	Life satisfaction;
LUSC	cis	rs9811920	0.838	rs12488245	chr3:99835254	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.42	6.11	0.32	2.77e-9	Axial length;
LUSC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg04287289	chr16:89883240	FANCA	0.78	6.25	0.32	1.25e-9	Skin colour saturation;
LUSC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg18681998	chr4:17616180	MED28	0.9	17.84	0.7	1.85e-50	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg10011746	chr16:89865162	FANCA	0.39	6.2	0.32	1.71e-9	Vitiligo;
LUSC	cis	rs7553864	0.636	rs7543740	chr1:87609026	C/T	cg17420885	chr1:87600446	LOC339524	-0.5	-6.85	-0.35	3.63e-11	Smoking behavior;
LUSC	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg18827107	chr12:86230957	RASSF9	-0.41	-5.96	-0.31	6.57e-9	Major depressive disorder;
LUSC	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg15571903	chr15:79123663	NA	0.32	5.9	0.31	9.02e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs1568889	0.941	rs35357280	chr11:28322745	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.6	7.05	0.36	1.02e-11	Bipolar disorder;
LUSC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.68	9.61	0.47	1.82e-19	Testicular germ cell tumor;
LUSC	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.43	6.57	0.34	1.92e-10	Dupuytren's disease;
LUSC	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg17376030	chr22:41985996	PMM1	-0.43	-5.81	-0.3	1.45e-8	Vitiligo;
LUSC	cis	rs6815814	0.861	rs11936050	chr4:38789524	C/T	cg06935464	chr4:38784597	TLR10	0.45	5.74	0.3	2.1e-8	Breast cancer;
LUSC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	6.55	0.34	2.23e-10	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg00593900	chr19:10206746	ANGPTL6	-0.34	-5.69	-0.3	2.82e-8	Narcolepsy;
LUSC	trans	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg01620082	chr3:125678407	NA	-0.8	-7.13	-0.36	6.4e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs12220238	1.000	rs10824110	chr10:75968098	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.3	0.37	2.12e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg24579218	chr15:68104479	NA	0.39	6.76	0.35	6.06e-11	Restless legs syndrome;
LUSC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08704250	chr15:31115839	NA	0.59	9.41	0.46	8.34e-19	Huntington's disease progression;
LUSC	cis	rs722599	0.961	rs2359239	chr14:75326771	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.48	-7.54	-0.38	4.36e-13	IgG glycosylation;
LUSC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.8	0.6	1.34e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg22709100	chr7:91322751	NA	0.39	5.7	0.3	2.6e-8	Breast cancer;
LUSC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.05	-0.36	1.04e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.5	0.5	1.73e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.41	6.18	0.32	1.84e-9	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs2637266	1.000	rs7477433	chr10:78358116	C/T	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	8.87	0.44	4.48e-17	Neuroticism;
LUSC	trans	rs2392780	0.536	rs590574	chr8:128335715	A/G	cg10195415	chr17:73887371	TRIM65	0.42	6.65	0.34	1.23e-10	Breast cancer (early onset);
LUSC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg14541582	chr5:601475	NA	-0.37	-5.8	-0.3	1.56e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18876405	chr7:65276391	NA	0.55	8.82	0.43	6.59e-17	Aortic root size;
LUSC	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg05738196	chr6:26577821	NA	-0.46	-6.47	-0.33	3.49e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06636551	chr8:101224915	SPAG1	-0.44	-8.03	-0.4	1.63e-14	Atrioventricular conduction;
LUSC	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-5.78	-0.3	1.72e-8	Testicular germ cell tumor;
LUSC	cis	rs1322512	0.523	rs1727058	chr6:152930711	G/A	cg27316956	chr6:152958899	SYNE1	-0.38	-6.18	-0.32	1.82e-9	Tonometry;
LUSC	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg17385448	chr1:15911702	AGMAT	0.37	6.25	0.32	1.26e-9	Systolic blood pressure;
LUSC	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg08017756	chr2:100939284	LONRF2	0.41	7.22	0.37	3.42e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg06713675	chr4:122721982	EXOSC9	-0.47	-7.31	-0.37	2.02e-12	Type 2 diabetes;
LUSC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg12963246	chr6:28129442	ZNF389	0.4	6.38	0.33	5.91e-10	Parkinson's disease;
LUSC	cis	rs11031096	0.727	rs7940013	chr11:4138304	C/T	cg18678763	chr11:4115507	RRM1	-0.51	-7.58	-0.38	3.34e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2274273	0.870	rs8013713	chr14:55841252	A/G	cg04306507	chr14:55594613	LGALS3	-0.53	-11.73	-0.54	7.72e-27	Protein biomarker;
LUSC	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-7.06	-0.36	9.9e-12	Breast cancer;
LUSC	cis	rs7119	0.667	rs907392	chr15:77903393	T/C	cg27398640	chr15:77910606	LINGO1	0.38	8.86	0.44	4.7e-17	Type 2 diabetes;
LUSC	cis	rs9311676	0.681	rs4681846	chr3:58332543	T/C	cg13750441	chr3:58318267	PXK	-0.31	-5.88	-0.31	1.01e-8	Systemic lupus erythematosus;
LUSC	cis	rs9398803	0.865	rs9375441	chr6:126778600	G/A	cg19875578	chr6:126661172	C6orf173	0.42	6.18	0.32	1.9e-9	Male-pattern baldness;
LUSC	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.5	-0.38	5.71e-13	Retinal vascular caliber;
LUSC	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg16434002	chr17:42200994	HDAC5	-0.44	-6.11	-0.32	2.73e-9	Total body bone mineral density;
LUSC	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg23587288	chr2:27483067	SLC30A3	-0.29	-5.7	-0.3	2.61e-8	Blood metabolite levels;
LUSC	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg11901034	chr3:128598214	ACAD9	-0.39	-6.1	-0.32	2.91e-9	IgG glycosylation;
LUSC	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg09953122	chr20:23471693	CST8	-0.66	-5.73	-0.3	2.2e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-10.52	-0.5	1.55e-22	Alcohol dependence;
LUSC	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13126279	chr21:47581558	C21orf56	-0.55	-8.47	-0.42	8.16e-16	Testicular germ cell tumor;
LUSC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg04850211	chr1:228464232	OBSCN	-0.33	-6.17	-0.32	2.03e-9	Diastolic blood pressure;
LUSC	trans	rs800082	0.698	rs800077	chr3:144349940	A/G	cg24215973	chr2:240111563	HDAC4	-0.73	-10.84	-0.51	1.15e-23	Smoking behavior;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19429466	chr4:87515395	PTPN13	-0.52	-6.65	-0.34	1.19e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs921665	0.584	rs5019161	chr2:3174761	A/G	cg16434511	chr2:3151078	NA	-0.62	-6.65	-0.34	1.18e-10	World class endurance athleticism;
LUSC	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg09835421	chr16:68378352	PRMT7	-0.54	-6.09	-0.32	3.03e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7000551	0.606	rs3802199	chr8:22267385	A/G	cg12081754	chr8:22256438	SLC39A14	0.94	14.61	0.62	9.9e-38	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	trans	rs6256	0.929	rs56272325	chr11:13508857	C/G	cg07728579	chr15:83475013	FSD2	-0.41	-6.0	-0.31	5.1e-9	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
LUSC	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg04310649	chr10:35416472	CREM	-0.43	-6.59	-0.34	1.73e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg10547527	chr2:198650123	BOLL	-0.5	-5.71	-0.3	2.49e-8	Ulcerative colitis;
LUSC	cis	rs7520050	0.966	rs11810993	chr1:46478793	A/G	cg06784218	chr1:46089804	CCDC17	-0.29	-5.69	-0.3	2.83e-8	Red blood cell count;Reticulocyte count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25876186	chr17:77979405	TBC1D16	0.41	6.13	0.32	2.47e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg26043149	chr18:55253948	FECH	0.42	6.19	0.32	1.74e-9	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4953318	0.619	rs13406901	chr2:46363066	T/G	cg12428440	chr2:46370979	PRKCE	0.46	7.74	0.39	1.19e-13	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.93	-0.48	1.53e-20	Hemoglobin concentration;
LUSC	cis	rs7561273	0.586	rs116650625	chr2:24353212	C/G	cg20701182	chr2:24300061	SF3B14	0.46	5.87	0.31	1.05e-8	Quantitative traits;
LUSC	cis	rs56283067	0.887	rs12197593	chr6:44740895	C/T	cg18551225	chr6:44695536	NA	-0.48	-8.46	-0.42	8.24e-16	Total body bone mineral density;
LUSC	cis	rs7771547	0.508	rs3798471	chr6:36499571	C/T	cg07856975	chr6:36356162	ETV7	0.39	6.58	0.34	1.83e-10	Platelet distribution width;
LUSC	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg05527609	chr1:210001259	C1orf107	0.71	10.12	0.48	3.62e-21	Orofacial clefts;
LUSC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg27535305	chr1:53392650	SCP2	0.36	6.73	0.35	7.3e-11	Monocyte count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26603524	chr1:145713802	CD160	-0.41	-6.05	-0.31	3.82e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs62400317	0.859	rs1324536	chr6:45116261	C/T	cg20913747	chr6:44695427	NA	0.41	6.5	0.33	2.99e-10	Total body bone mineral density;
LUSC	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg05347473	chr6:146136440	FBXO30	0.4	6.78	0.35	5.5e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11764359	chr7:65958608	NA	0.68	10.96	0.51	4.39e-24	Aortic root size;
LUSC	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg13010199	chr12:38710504	ALG10B	0.57	8.61	0.43	2.89e-16	Morning vs. evening chronotype;
LUSC	cis	rs3087591	0.708	rs7406783	chr17:29689980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.47	6.98	0.36	1.57e-11	Hip circumference;
LUSC	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.42	5.74	0.3	2.11e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg22681709	chr2:178499509	PDE11A	-0.43	-6.2	-0.32	1.71e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	10.01	0.48	8.46e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs231513	0.906	rs75508812	chr17:42003397	G/A	cg26893861	chr17:41843967	DUSP3	0.55	5.75	0.3	1.99e-8	Cognitive function;
LUSC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.52	-0.42	5.6e-16	Bipolar disorder;
LUSC	cis	rs4919087	0.620	rs793515	chr10:98988469	A/C	cg25902810	chr10:99078978	FRAT1	-0.46	-6.47	-0.33	3.47e-10	Monocyte count;
LUSC	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.59	-9.29	-0.45	2.05e-18	HDL cholesterol;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg17355835	chr15:40886331	CASC5	0.38	6.18	0.32	1.86e-9	Triglycerides;
LUSC	cis	rs727505	1.000	rs67939974	chr7:124554364	C/T	cg23710748	chr7:124431027	NA	-0.42	-7.42	-0.38	9.76e-13	Lewy body disease;
LUSC	cis	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg06521331	chr12:34319734	NA	-0.47	-7.79	-0.39	8.67e-14	Morning vs. evening chronotype;
LUSC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18904891	chr8:8559673	CLDN23	0.62	8.92	0.44	3.11e-17	Obesity-related traits;
LUSC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg07952391	chr2:88470173	THNSL2	0.77	6.84	0.35	3.74e-11	Plasma clusterin levels;
LUSC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg04450456	chr4:17643702	FAM184B	-0.39	-6.6	-0.34	1.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.7	10.54	0.5	1.25e-22	Corneal astigmatism;
LUSC	cis	rs981844	0.857	rs41320045	chr4:154720615	A/T	cg14289246	chr4:154710475	SFRP2	-0.45	-5.74	-0.3	2.12e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6500395	0.775	rs11640119	chr16:48662840	C/T	cg04672837	chr16:48644449	N4BP1	0.46	6.89	0.35	2.71e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg22709100	chr7:91322751	NA	0.4	5.81	0.3	1.48e-8	Breast cancer;
LUSC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg22920501	chr2:26401640	FAM59B	0.76	10.13	0.48	3.25e-21	Gut microbiome composition (summer);
LUSC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.53	-8.94	-0.44	2.7e-17	Bipolar disorder;
LUSC	cis	rs35883536	0.647	rs12046413	chr1:101047430	T/C	cg06223162	chr1:101003688	GPR88	-0.47	-8.81	-0.43	6.81e-17	Monocyte count;
LUSC	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.65	-13.71	-0.6	2.98e-34	Monocyte percentage of white cells;
LUSC	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-8.2	-0.41	5.32e-15	Schizophrenia;
LUSC	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg13042288	chr15:90349979	ANPEP	-0.47	-6.4	-0.33	5.37e-10	Uric acid levels;
LUSC	cis	rs2290159	0.800	rs5746214	chr3:12644753	A/G	cg23032965	chr3:12705835	RAF1	0.74	8.96	0.44	2.42e-17	Cholesterol, total;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11238505	chr8:145691776	CYHR1;KIFC2	0.44	6.27	0.32	1.11e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg18451016	chr1:38461880	NA	0.58	10.36	0.49	5.32e-22	Coronary artery disease;
LUSC	cis	rs7177699	0.581	rs7165081	chr15:79123396	C/G	cg00540400	chr15:79124168	NA	0.43	7.51	0.38	5.44e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.38	0.49	4.76e-22	Schizophrenia;
LUSC	cis	rs10193935	0.901	rs13384885	chr2:42536646	G/C	cg27598129	chr2:42591480	NA	-0.6	-8.17	-0.41	6.36e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg14552801	chr7:65878734	NA	-0.43	-5.95	-0.31	6.61e-9	Aortic root size;
LUSC	cis	rs1775715	0.870	rs1755072	chr10:32266642	A/G	cg18675610	chr10:32216311	ARHGAP12	-0.29	-6.06	-0.31	3.64e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-0.51	-7.87	-0.4	5.07e-14	Breast cancer;
LUSC	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.51	7.33	0.37	1.78e-12	Coronary heart disease;
LUSC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg22823121	chr1:150693482	HORMAD1	0.59	9.14	0.45	6.13e-18	Tonsillectomy;
LUSC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21862992	chr11:68658383	NA	0.51	7.94	0.4	3.03e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.91	15.54	0.65	2.38e-41	Bladder cancer;
LUSC	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg19743168	chr1:23544995	NA	-0.41	-7.94	-0.4	3.01e-14	Height;
LUSC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg04518342	chr5:131593106	PDLIM4	-0.45	-7.7	-0.39	1.56e-13	Breast cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17728987	chr19:36485959	SDHAF1	-0.42	-6.1	-0.32	2.98e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2230307	0.536	rs7518943	chr1:100463422	G/T	cg24955406	chr1:100503596	HIAT1	0.62	6.75	0.35	6.53e-11	Carotid intima media thickness;
LUSC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-10.94	-0.51	5.17e-24	Menarche (age at onset);
LUSC	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg02466173	chr16:30829666	NA	-0.58	-10.78	-0.51	1.9e-23	Multiple myeloma;
LUSC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg22535103	chr8:58192502	C8orf71	-0.65	-7.35	-0.37	1.55e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg14552801	chr7:65878734	NA	-0.44	-6.22	-0.32	1.51e-9	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03330254	chr5:108745575	PJA2	-0.4	-6.09	-0.32	3.04e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg09050820	chr6:167586206	TCP10L2	0.73	9.47	0.46	5.31e-19	Gastritis;
LUSC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	18.98	0.72	5.41e-55	Chronic sinus infection;
LUSC	cis	rs9469578	1.000	rs73743323	chr6:33705355	C/T	cg18708504	chr6:33715942	IP6K3	0.73	9.03	0.44	1.38e-17	Phosphorus levels;
LUSC	cis	rs16976116	0.951	rs13733	chr15:55489104	A/G	cg11288833	chr15:55489084	RSL24D1	0.54	6.56	0.34	2.04e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.56	11.17	0.52	7.79e-25	Asthma (sex interaction);
LUSC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.92	0.31	7.86e-9	Menopause (age at onset);
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg24846343	chr22:24311635	DDTL	0.77	17.41	0.69	9.54e-49	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg18681998	chr4:17616180	MED28	-0.86	-15.18	-0.64	5.77e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs454953	0.533	rs211436	chr6:133612992	A/G	cg15729404	chr6:133561614	EYA4	-0.4	-5.83	-0.3	1.33e-8	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg00933542	chr6:150070202	PCMT1	0.32	6.61	0.34	1.55e-10	Lung cancer;
LUSC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg07741184	chr6:167504864	NA	0.42	7.5	0.38	5.69e-13	Crohn's disease;
LUSC	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	0.8	9.91	0.48	1.86e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.45	0.38	8.3e-13	Bipolar disorder;
LUSC	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg08079166	chr15:68083412	MAP2K5	0.4	8.42	0.42	1.13e-15	Restless legs syndrome;
LUSC	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.87	14.22	0.61	3.36e-36	Bladder cancer;
LUSC	cis	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg17469321	chr7:55412551	NA	0.65	10.53	0.5	1.45e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs4776059	0.761	rs61731670	chr15:52901283	T/C	cg25063058	chr15:52860530	ARPP19	-0.48	-5.97	-0.31	5.95e-9	Schizophrenia;
LUSC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg25319279	chr11:5960081	NA	-0.39	-6.22	-0.32	1.5e-9	DNA methylation (variation);
LUSC	cis	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.36	-0.33	6.67e-10	Morning vs. evening chronotype;
LUSC	cis	rs8032315	1.000	rs2071410	chr15:91420940	C/G	cg04510874	chr15:91427884	FES	0.32	6.24	0.32	1.32e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs981844	0.683	rs1563462	chr4:154755051	G/A	cg14289246	chr4:154710475	SFRP2	-0.47	-6.54	-0.34	2.25e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.34	6.61	0.34	1.55e-10	Hemoglobin concentration;
LUSC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg05347473	chr6:146136440	FBXO30	0.42	7.22	0.37	3.47e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06544989	chr22:39130855	UNC84B	0.37	6.41	0.33	4.91e-10	Menopause (age at onset);
LUSC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg09509183	chr1:209979624	IRF6	-0.5	-5.94	-0.31	7.25e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs34638657	0.872	rs2967349	chr16:82194405	G/C	cg09439754	chr16:82129088	HSD17B2	-0.4	-6.23	-0.32	1.37e-9	Lung adenocarcinoma;
LUSC	trans	rs10432489	0.708	rs11687566	chr2:181744418	T/C	cg00055848	chr2:62422984	B3GNT2	-0.93	-6.12	-0.32	2.67e-9	QT interval;
LUSC	trans	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.14	0.32	2.37e-9	Corneal astigmatism;
LUSC	cis	rs12318506	0.826	rs11180431	chr12:75661200	G/A	cg04728562	chr12:75699417	CAPS2	-0.77	-5.93	-0.31	7.49e-9	Coronary artery calcification;
LUSC	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg14844989	chr11:31128820	NA	0.37	5.79	0.3	1.59e-8	Red blood cell count;
LUSC	cis	rs2011503	0.597	rs8103992	chr19:19665643	A/C	cg11244672	chr19:19639970	YJEFN3	0.46	6.12	0.32	2.69e-9	Bipolar disorder;
LUSC	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.97	0.36	1.73e-11	Menarche (age at onset);
LUSC	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.66	10.01	0.48	8.54e-21	Breast cancer;
LUSC	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg03585969	chr10:35415529	CREM	0.6	8.85	0.44	5.36e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10979	1.000	rs9376761	chr6:143887165	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-12.01	-0.55	7.28e-28	Hypospadias;
LUSC	cis	rs12989701	0.825	rs4663096	chr2:127861766	T/A	cg08168897	chr2:127865431	BIN1	0.59	7.84	0.39	6.11e-14	Alzheimer's disease (late onset);
LUSC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	1.0	18.46	0.71	6.32e-53	Cognitive function;
LUSC	cis	rs228769	0.562	rs228779	chr17:42091213	A/G	cg19774624	chr17:42201019	HDAC5	0.63	6.99	0.36	1.48e-11	Bone mineral density (hip);Bone mineral density (spine);
LUSC	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	7.95	0.4	2.9e-14	Coronary artery disease;
LUSC	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg10409131	chr4:25915609	C4orf52	-0.57	-7.57	-0.38	3.56e-13	Obesity-related traits;
LUSC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-10.3	-0.49	8.6e-22	Hemoglobin concentration;
LUSC	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg26597838	chr10:835615	NA	-0.48	-6.53	-0.34	2.45e-10	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.4	7.71	0.39	1.46e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26314531	chr2:26401878	FAM59B	-0.66	-9.13	-0.45	6.46e-18	Gut microbiome composition (summer);
LUSC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg26335602	chr6:28129616	ZNF389	0.42	5.74	0.3	2.08e-8	Parkinson's disease;
LUSC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.31	5.8	0.3	1.52e-8	Obesity-related traits;
LUSC	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg14061069	chr19:46274453	DMPK	-0.54	-9.29	-0.45	2.09e-18	Coronary artery disease;
LUSC	cis	rs62400317	0.826	rs17209769	chr6:45321205	C/A	cg20913747	chr6:44695427	NA	-0.47	-7.73	-0.39	1.24e-13	Total body bone mineral density;
LUSC	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg05519781	chr21:40033154	ERG	0.77	13.32	0.59	9.59e-33	Coronary artery disease;
LUSC	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.56	13.64	0.6	5.57e-34	Schizophrenia;
LUSC	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg27572855	chr1:25598939	RHD	0.41	7.15	0.36	5.55e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs4474465	0.562	rs10793318	chr11:78215898	A/C	cg27205649	chr11:78285834	NARS2	0.52	6.0	0.31	5.01e-9	Alzheimer's disease (survival time);
LUSC	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg21100191	chr22:23484243	RTDR1	0.92	16.29	0.67	2.57e-44	Bone mineral density;
LUSC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg01657329	chr11:68192670	LRP5	-0.41	-5.88	-0.31	1.02e-8	Total body bone mineral density;
LUSC	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg13256891	chr4:100009986	ADH5	-0.42	-5.69	-0.3	2.74e-8	Alcohol dependence;
LUSC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg05623727	chr3:50126028	RBM5	-0.35	-6.41	-0.33	5.1e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg20607798	chr8:58055168	NA	0.53	5.83	0.3	1.29e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg09184832	chr6:79620586	NA	-0.42	-6.52	-0.34	2.58e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.47	0.38	7.16e-13	Motion sickness;
LUSC	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.55	-8.42	-0.42	1.12e-15	Lymphocyte counts;
LUSC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg12560992	chr17:57184187	TRIM37	0.83	15.26	0.64	2.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.77	-0.43	9.62e-17	Total cholesterol levels;
LUSC	cis	rs4776059	1.000	rs4776058	chr15:52880263	A/G	cg25063058	chr15:52860530	ARPP19	0.47	6.53	0.34	2.48e-10	Schizophrenia;
LUSC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg11645453	chr3:52864694	ITIH4	-0.33	-7.93	-0.4	3.35e-14	Electroencephalogram traits;
LUSC	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg03585969	chr10:35415529	CREM	0.59	8.81	0.43	7.18e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.21	-0.37	3.87e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg12963246	chr6:28129442	ZNF389	0.53	7.41	0.38	1.04e-12	Parkinson's disease;
LUSC	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg01119278	chr6:110721349	DDO	-0.49	-8.76	-0.43	9.88e-17	Platelet distribution width;
LUSC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06221963	chr1:154839813	KCNN3	-0.65	-15.52	-0.65	2.78e-41	Prostate cancer;
LUSC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.9	12.21	0.56	1.35e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg03474202	chr17:45855739	NA	0.29	7.18	0.37	4.62e-12	IgG glycosylation;
LUSC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.63	9.0	0.44	1.79e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9549260	0.604	rs56302456	chr13:41295887	G/T	cg21288729	chr13:41239152	FOXO1	0.57	6.35	0.33	6.84e-10	Red blood cell count;
LUSC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23158103	chr7:148848205	ZNF398	-0.5	-8.06	-0.4	1.38e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg18240062	chr17:79603768	NPLOC4	0.6	10.25	0.49	1.32e-21	Eye color traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16779626	chr15:41709933	RTF1	0.41	6.04	0.31	4.07e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11828289	0.660	rs12099049	chr11:23219311	A/G	cg20040320	chr11:23191996	NA	-0.61	-6.33	-0.33	7.8e-10	Cancer;
LUSC	cis	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg20368463	chr18:77673604	PQLC1	-0.62	-6.64	-0.34	1.29e-10	Opioid sensitivity;
LUSC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg16928487	chr17:17741425	SREBF1	0.34	6.42	0.33	4.77e-10	Total body bone mineral density;
LUSC	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00934597	chr7:893267	UNC84A	-0.48	-7.1	-0.36	7.78e-12	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs4363385	0.747	rs2339493	chr1:152975277	G/A	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.76	-0.39	1.05e-13	Inflammatory skin disease;
LUSC	cis	rs13315871	0.929	rs9857333	chr3:58293551	G/C	cg20936604	chr3:58311152	NA	-0.67	-6.59	-0.34	1.69e-10	Cholesterol, total;
LUSC	cis	rs7215564	0.908	rs35584560	chr17:78668256	G/A	cg09596252	chr17:78655493	RPTOR	0.52	5.67	0.3	3.1e-8	Myopia (pathological);
LUSC	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg11502198	chr6:26597334	ABT1	0.53	7.81	0.39	7.66e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg03929089	chr4:120376271	NA	-0.95	-16.55	-0.67	2.37e-45	Height;
LUSC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.76	-13.6	-0.6	7.84e-34	Dental caries;
LUSC	cis	rs7590368	0.715	rs12471725	chr2:10958119	C/T	cg15705551	chr2:10952987	PDIA6	0.61	6.1	0.32	3e-9	Educational attainment (years of education);
LUSC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg24250549	chr1:154909240	PMVK	0.59	9.53	0.46	3.24e-19	Prostate cancer;
LUSC	cis	rs977987	0.806	rs4888391	chr16:75400746	C/T	cg03315344	chr16:75512273	CHST6	0.49	9.33	0.45	1.48e-18	Dupuytren's disease;
LUSC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1005224	0.927	rs1981899	chr14:76175594	G/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.59	-8.1	-0.41	1.07e-14	Large artery stroke;
LUSC	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg09953122	chr20:23471693	CST8	-0.67	-5.72	-0.3	2.37e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1018836	0.608	rs12679836	chr8:91465287	A/G	cg16814680	chr8:91681699	NA	-0.53	-7.75	-0.39	1.11e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.51	-6.49	-0.33	3.1e-10	Multiple sclerosis;
LUSC	cis	rs752010	0.644	rs7541348	chr1:42113215	T/G	cg06885757	chr1:42089581	HIVEP3	0.49	9.75	0.47	6.37e-20	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs2219968	1.000	rs13266678	chr8:78958272	T/C	cg00738934	chr8:78996279	NA	0.37	6.76	0.35	6.13e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2297440	0.527	rs4809318	chr20:62264760	G/A	cg06363034	chr20:62225388	GMEB2	-0.46	-7.73	-0.39	1.24e-13	Glioma;Non-glioblastoma glioma;Glioblastoma;
LUSC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg16797656	chr11:68205561	LRP5	0.39	7.14	0.36	5.87e-12	Total body bone mineral density;
LUSC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg09640425	chr7:158790006	NA	-0.44	-6.97	-0.36	1.69e-11	Facial morphology (factor 20);
LUSC	cis	rs11039100	1.000	rs4319539	chr11:5828846	T/A	cg13902645	chr11:5959945	NA	-0.52	-5.83	-0.3	1.34e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg12463550	chr7:65579703	CRCP	0.45	6.76	0.35	6.2e-11	Aortic root size;
LUSC	cis	rs7759001	0.857	rs10080558	chr6:27362898	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg06808227	chr14:105710500	BRF1	-0.63	-9.62	-0.47	1.67e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg25930673	chr12:123319894	HIP1R	0.63	6.23	0.32	1.41e-9	Schizophrenia;
LUSC	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg24531977	chr5:56204891	C5orf35	-0.59	-8.9	-0.44	3.73e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs62400317	0.762	rs529125	chr6:44797088	C/T	cg18551225	chr6:44695536	NA	0.44	7.15	0.36	5.48e-12	Total body bone mineral density;
LUSC	trans	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg17712092	chr4:129076599	LARP1B	-0.71	-10.28	-0.49	1.02e-21	Eosinophil percentage of white cells;
LUSC	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.4	-0.38	1.1e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg11766577	chr21:47581405	C21orf56	-0.43	-6.44	-0.33	4.23e-10	Testicular germ cell tumor;
LUSC	cis	rs7000551	0.646	rs2979302	chr8:22359156	G/A	cg12081754	chr8:22256438	SLC39A14	0.47	7.1	0.36	7.72e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.3	0.41	2.67e-15	Prudent dietary pattern;
LUSC	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg01884057	chr2:25150051	NA	0.5	11.91	0.55	1.66e-27	Body mass index in non-asthmatics;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08149078	chr3:128369362	RPN1	-0.41	-6.09	-0.32	3.06e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.9	16.53	0.67	2.86e-45	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	0.94	18.94	0.72	7.18e-55	Cognitive function;
LUSC	cis	rs4285028	0.898	rs73855476	chr3:121633412	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.76	-10.16	-0.49	2.68e-21	Multiple sclerosis;
LUSC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg11062466	chr8:58055876	NA	0.66	8.67	0.43	1.93e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs57590327	0.503	rs9852235	chr3:81508355	A/G	cg07356753	chr3:81810745	GBE1	0.46	6.17	0.32	1.96e-9	Extraversion;
LUSC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.57	-0.34	1.94e-10	Schizophrenia;
LUSC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg16262614	chr3:133464971	TF	0.44	7.65	0.39	2.13e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs7582720	1.000	rs72934545	chr2:203975958	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.61	0.43	2.86e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs11676348	0.772	rs6738953	chr2:218950036	C/A	cg06547715	chr2:218990976	CXCR2	0.31	6.01	0.31	4.97e-9	Ulcerative colitis;
LUSC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg10207240	chr12:122356781	WDR66	-0.42	-5.96	-0.31	6.38e-9	Mean corpuscular volume;
LUSC	cis	rs9487051	0.803	rs410449	chr6:109539853	C/T	cg00509249	chr6:109615579	CCDC162	-0.34	-5.82	-0.3	1.38e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs8036030	0.691	rs11852760	chr15:74718699	A/G	cg14664628	chr15:75095509	CSK	-0.49	-7.3	-0.37	2.18e-12	Airflow obstruction;
LUSC	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg09796270	chr17:17721594	SREBF1	0.44	7.89	0.4	4.42e-14	Total body bone mineral density;
LUSC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg12463550	chr7:65579703	CRCP	-0.47	-6.96	-0.36	1.84e-11	Aortic root size;
LUSC	trans	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg18187862	chr3:45730750	SACM1L	0.54	7.09	0.36	8.05e-12	Primary sclerosing cholangitis;
LUSC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg22800045	chr5:56110881	MAP3K1	0.68	8.06	0.4	1.36e-14	Initial pursuit acceleration;
LUSC	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg21293242	chr8:11204541	TDH	0.31	5.87	0.31	1.04e-8	Retinal vascular caliber;
LUSC	cis	rs7123876	0.587	rs11602616	chr11:72364077	T/C	cg04827223	chr11:72435913	ARAP1	-0.61	-7.18	-0.37	4.59e-12	Body mass index;
LUSC	cis	rs965513	1.000	rs7850258	chr9:100549013	C/T	cg13688889	chr9:100608707	NA	0.56	8.61	0.43	2.95e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.38	0.42	1.47e-15	Coffee consumption (cups per day);
LUSC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg09655341	chr17:79618100	PDE6G	-0.27	-6.26	-0.32	1.16e-9	Eye color traits;
LUSC	trans	rs2055729	0.885	rs13268133	chr8:9731470	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.58	0.34	1.82e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg14581129	chr12:53358946	NA	-0.69	-9.31	-0.45	1.72e-18	Cancer (pleiotropy);
LUSC	cis	rs35995292	0.963	rs10239557	chr7:38950137	C/T	cg19327137	chr7:38886074	VPS41	0.37	6.05	0.31	3.81e-9	Subjective well-being (multi-trait analysis);
LUSC	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.6	9.51	0.46	3.96e-19	Morning vs. evening chronotype;
LUSC	cis	rs4253772	0.872	rs79700435	chr22:46638211	G/A	cg18190219	chr22:46762943	CELSR1	-0.48	-5.73	-0.3	2.3e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.95	-0.4	2.95e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.32	0.45	1.6e-18	Coffee consumption (cups per day);
LUSC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs6901250	0.655	rs1398404	chr6:117126345	A/C	cg12892004	chr6:117198278	RFX6	0.4	7.59	0.38	3.22e-13	C-reactive protein levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00412273	chr17:38296476	CASC3	0.43	6.07	0.32	3.56e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2219968	0.962	rs9643732	chr8:78946230	G/A	cg00738934	chr8:78996279	NA	0.37	6.63	0.34	1.3100000000000001e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4409675	0.576	rs10751725	chr1:28216191	A/C	cg23691781	chr1:28212827	C1orf38	-0.32	-7.55	-0.38	4.07e-13	Corneal astigmatism;
LUSC	cis	rs9359856	0.529	rs56352205	chr6:90439272	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.43	-0.42	1.02e-15	Bipolar disorder;
LUSC	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-6.17	-0.32	1.93e-9	Fear of minor pain;
LUSC	trans	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.47	7.33	0.37	1.71e-12	Endometrial cancer;
LUSC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg17507749	chr15:85114479	UBE2QP1	0.68	8.55	0.42	4.36e-16	Schizophrenia;
LUSC	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg07169764	chr2:136633963	MCM6	1.1	14.73	0.63	3.42e-38	Corneal structure;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11381792	chr21:45432451	TRAPPC10	0.51	8.77	0.43	9.18e-17	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg17143192	chr8:8559678	CLDN23	0.63	8.89	0.44	3.88e-17	Obesity-related traits;
LUSC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.93	-19.24	-0.73	4.86e-56	Post bronchodilator FEV1;
LUSC	cis	rs1256061	0.646	rs1256056	chr14:64712626	A/G	cg23250157	chr14:64679961	SYNE2	0.33	6.06	0.31	3.6e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.79	-13.16	-0.58	3.71e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1506636	1.000	rs12333705	chr7:123356062	C/T	cg03229431	chr7:123269106	ASB15	-0.64	-10.57	-0.5	1.05e-22	Plateletcrit;Platelet count;
LUSC	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg03676636	chr4:99064102	C4orf37	0.27	5.78	0.3	1.68e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.99	-19.2	-0.72	6.63e-56	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18402987	chr7:1209562	NA	0.44	5.93	0.31	7.75e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg20003494	chr4:90757398	SNCA	-0.34	-5.71	-0.3	2.51e-8	Dementia with Lewy bodies;
LUSC	trans	rs11039798	0.841	rs12221667	chr11:48548549	G/T	cg15704280	chr7:45808275	SEPT13	0.75	6.44	0.33	4.2e-10	Axial length;
LUSC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg11812906	chr14:75593930	NEK9	-0.67	-11.61	-0.54	2.11e-26	Height;
LUSC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg21665744	chr7:39171113	POU6F2	0.47	7.46	0.38	7.58e-13	IgG glycosylation;
LUSC	cis	rs73198271	0.515	rs113056462	chr8:8638568	T/C	cg01851573	chr8:8652454	MFHAS1	0.56	6.24	0.32	1.32e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.47	7.67	0.39	1.9e-13	Alcohol dependence;
LUSC	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg01849466	chr14:104193079	ZFYVE21	0.57	9.01	0.44	1.64e-17	Schizophrenia;
LUSC	cis	rs611744	0.870	rs613261	chr8:109165949	A/G	cg18478394	chr8:109455254	TTC35	0.42	6.32	0.33	8.15e-10	Dupuytren's disease;
LUSC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.77e-34	Aortic root size;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05653691	chr1:16175060	FLJ37453;SPEN	0.79	6.36	0.33	6.51e-10	Cognitive performance;
LUSC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg06713675	chr4:122721982	EXOSC9	-0.72	-12.31	-0.56	5.85e-29	Type 2 diabetes;
LUSC	cis	rs6484504	0.652	rs494464	chr11:31386150	C/T	cg06552810	chr11:31128660	NA	0.39	6.77	0.35	5.87e-11	Red blood cell count;
LUSC	trans	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg21567404	chr3:27674614	NA	0.98	15.62	0.65	1.15e-41	Dupuytren's disease;
LUSC	cis	rs1044826	0.597	rs1017468	chr3:139145778	A/G	cg15131784	chr3:139108705	COPB2	0.42	6.95	0.36	1.89e-11	Obesity-related traits;
LUSC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.46	0.46	5.88e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg13010199	chr12:38710504	ALG10B	0.57	8.61	0.43	2.89e-16	Morning vs. evening chronotype;
LUSC	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg03474202	chr17:45855739	NA	-0.29	-6.71	-0.34	8.44e-11	IgG glycosylation;
LUSC	cis	rs1950626	0.623	rs35947256	chr14:101460366	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.34	5.87	0.31	1.07e-8	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	6.39	0.33	5.53e-10	Rheumatoid arthritis;
LUSC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08677398	chr8:58056175	NA	-0.54	-7.32	-0.37	1.91e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg05714579	chr10:131428358	MGMT	-0.44	-6.35	-0.33	7.02e-10	Response to temozolomide;
LUSC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.4	0.49	3.98e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg13535736	chr9:111863775	C9orf5	-0.39	-6.2	-0.32	1.66e-9	Menarche (age at onset);
LUSC	trans	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg25206134	chr2:45395956	NA	-0.5	-6.19	-0.32	1.76e-9	Bipolar disorder;
LUSC	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg13390004	chr1:15929781	NA	0.41	6.98	0.36	1.62e-11	Systolic blood pressure;
LUSC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg06028605	chr16:24865363	SLC5A11	-0.47	-8.51	-0.42	5.9e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg05472934	chr7:22766657	IL6	0.51	7.93	0.4	3.31e-14	Lung cancer;
LUSC	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.45	-6.03	-0.31	4.45e-9	Reticulocyte count;
LUSC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg21724239	chr8:58056113	NA	0.51	6.25	0.32	1.23e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg02475777	chr4:1388615	CRIPAK	0.41	6.35	0.33	7.22e-10	Longevity;
LUSC	cis	rs6543140	0.964	rs11903551	chr2:103084181	C/G	cg09003973	chr2:102972529	NA	0.53	6.75	0.35	6.5500000000000006e-11	Blood protein levels;
LUSC	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg22709100	chr7:91322751	NA	-0.39	-5.8	-0.3	1.52e-8	Breast cancer;
LUSC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg22709100	chr7:91322751	NA	0.39	5.8	0.3	1.5e-8	Breast cancer;
LUSC	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg18302933	chr2:88491318	NA	-0.39	-7.56	-0.38	3.86e-13	Response to metformin (IC50);
LUSC	cis	rs4631830	0.932	rs4581397	chr10:51532367	A/G	cg16070123	chr10:51489643	NA	-0.49	-7.67	-0.39	1.86e-13	Prostate-specific antigen levels;
LUSC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg18681998	chr4:17616180	MED28	0.83	14.72	0.63	3.85e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4285028	0.747	rs77790376	chr3:121492211	C/T	cg11130432	chr3:121712080	ILDR1	-0.63	-9.27	-0.45	2.45e-18	Multiple sclerosis;
LUSC	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg00105475	chr2:10696890	NA	0.37	6.23	0.32	1.43e-9	Prostate cancer;
LUSC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg08873628	chr1:175162347	KIAA0040	0.39	5.68	0.3	2.99e-8	Diastolic blood pressure;
LUSC	cis	rs4604732	0.603	rs10802512	chr1:247633730	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.34	5.65	0.3	3.49e-8	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg06713675	chr4:122721982	EXOSC9	-0.69	-12.08	-0.55	3.95e-28	Type 2 diabetes;
LUSC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.8	10.01	0.48	8.37e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11828289	0.660	rs74388652	chr11:23188048	A/G	cg20040320	chr11:23191996	NA	-0.58	-6.1	-0.32	2.95e-9	Cancer;
LUSC	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg27539214	chr16:67997921	SLC12A4	0.44	5.8	0.3	1.56e-8	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	6.12	0.32	2.68e-9	Neuroticism;
LUSC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg05861140	chr6:150128134	PCMT1	-0.38	-6.04	-0.31	4.07e-9	Lung cancer;
LUSC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg23791538	chr6:167370224	RNASET2	-0.43	-6.95	-0.36	1.93e-11	Crohn's disease;
LUSC	cis	rs231513	1.000	rs231513	chr17:41965200	C/G	cg26893861	chr17:41843967	DUSP3	-0.55	-6.29	-0.33	9.82e-10	Cognitive function;
LUSC	cis	rs7940866	1.000	rs7940866	chr11:130817579	A/T	cg12179176	chr11:130786555	SNX19	-0.62	-9.15	-0.45	5.82e-18	Schizophrenia;
LUSC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.08	0.4	1.19e-14	Parkinson's disease;
LUSC	cis	rs2835872	0.726	rs12482570	chr21:39077777	A/G	cg20424643	chr21:39039972	KCNJ6	0.41	6.27	0.32	1.14e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	7.86	0.4	5.4e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4478037	1.000	rs58995409	chr3:33161404	T/C	cg19404215	chr3:33155277	CRTAP	0.96	9.76	0.47	5.72e-20	Major depressive disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25528940	chr16:57127044	CPNE2	0.49	6.59	0.34	1.67e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg25258033	chr6:167368657	RNASET2	-0.49	-8.1	-0.41	1.04e-14	Crohn's disease;
LUSC	cis	rs11997175	0.624	rs4733175	chr8:33679744	T/A	ch.8.33884649F	chr8:33765107	NA	0.47	7.08	0.36	8.69e-12	Body mass index;
LUSC	cis	rs4654899	0.931	rs3767241	chr1:21166144	C/T	cg01072550	chr1:21505969	NA	0.47	7.15	0.36	5.5e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9311676	0.632	rs1126735	chr3:58413408	A/G	cg13750441	chr3:58318267	PXK	0.36	6.87	0.35	3.18e-11	Systemic lupus erythematosus;
LUSC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.29	0.37	2.31e-12	Motion sickness;
LUSC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg15534755	chr11:117069859	TAGLN	0.34	6.09	0.32	3.16e-9	Blood protein levels;
LUSC	trans	rs2275620	0.513	rs2860976	chr10:96789846	C/A	cg08498836	chr3:149292366	WWTR1	0.36	6.16	0.32	2.12e-9	Gout;
LUSC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg03676636	chr4:99064102	C4orf37	0.35	7.54	0.38	4.59e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.5	-7.56	-0.38	3.9e-13	Bipolar disorder and schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16857015	chr3:49142290	QARS	0.44	5.97	0.31	6.13e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg08277548	chr1:17600880	PADI3	-0.61	-6.38	-0.33	5.92e-10	Hair shape;
LUSC	cis	rs34734847	0.842	rs556001	chr12:121152967	A/G	cg21892295	chr12:121157589	UNC119B	-0.49	-8.96	-0.44	2.27e-17	Mean corpuscular volume;
LUSC	cis	rs28647808	0.786	rs4962136	chr9:136256794	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg11584989	chr19:19387371	SF4	-0.61	-7.14	-0.36	5.86e-12	Bipolar disorder;
LUSC	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg05855489	chr10:104503620	C10orf26	0.53	8.12	0.41	9.19e-15	Arsenic metabolism;
LUSC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg00857998	chr1:205179979	DSTYK	0.57	8.52	0.42	5.73e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg18230493	chr5:56204884	C5orf35	-0.61	-9.65	-0.47	1.32e-19	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24739457	chr1:205821442	NA	-0.35	-6.0	-0.31	5.27e-9	Menarche (age at onset);
LUSC	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg27494647	chr7:150038898	RARRES2	0.5	7.35	0.37	1.56e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs12295403	0.964	rs34364314	chr11:18691674	G/A	cg09887367	chr11:18690185	NA	-0.37	-7.74	-0.39	1.18e-13	Ovarian reserve;
LUSC	cis	rs6723226	0.699	rs376914	chr2:32508393	G/C	cg02381751	chr2:32503542	YIPF4	0.6	8.91	0.44	3.41e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14240646	chr10:27532245	ACBD5	-0.69	-8.04	-0.4	1.55e-14	Breast cancer;
LUSC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg04398451	chr17:18023971	MYO15A	-0.53	-8.55	-0.42	4.4e-16	Total body bone mineral density;
LUSC	cis	rs8258	0.501	rs474490	chr11:117287794	T/G	cg15227623	chr11:117232454	CEP164	0.52	6.81	0.35	4.59e-11	Pulse pressure;
LUSC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-10.91	-0.51	6.51e-24	Chronic sinus infection;
LUSC	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg25457927	chr22:38595422	NA	-0.41	-8.46	-0.42	8.33e-16	Cutaneous nevi;
LUSC	cis	rs1178968	0.818	rs4717084	chr7:72764541	C/T	cg25889504	chr7:72793014	NA	0.59	7.75	0.39	1.11e-13	Triglyceride levels;
LUSC	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg26441486	chr22:50317300	CRELD2	0.5	7.85	0.39	5.61e-14	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg11645453	chr3:52864694	ITIH4	0.35	8.0	0.4	2.1e-14	Bipolar disorder;
LUSC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg15556689	chr8:8085844	FLJ10661	-0.68	-11.49	-0.53	5.68e-26	Mood instability;
LUSC	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg05738196	chr6:26577821	NA	-0.69	-11.33	-0.53	2.16e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs17767294	0.612	rs9461424	chr6:27919401	G/A	cg08851530	chr6:28072375	NA	0.84	6.48	0.33	3.21e-10	Parkinson's disease;
LUSC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.96	0.51	4.51e-24	Menopause (age at onset);
LUSC	trans	rs2392780	0.536	rs437980	chr8:128335246	A/C	cg10195415	chr17:73887371	TRIM65	0.41	6.49	0.33	3.12e-10	Breast cancer (early onset);
LUSC	cis	rs3824867	0.770	rs11820680	chr11:47452744	C/T	cg20307385	chr11:47447363	PSMC3	-0.65	-9.65	-0.47	1.35e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs2637266	0.626	rs1660914	chr10:78525319	T/A	cg18941641	chr10:78392320	NA	0.38	7.02	0.36	1.23e-11	Pulmonary function;
LUSC	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg23188684	chr11:67383651	NA	0.35	6.19	0.32	1.76e-9	Mean corpuscular volume;
LUSC	cis	rs1595825	0.891	rs73058864	chr2:198889587	C/T	cg00982548	chr2:198649783	BOLL	-0.54	-6.93	-0.35	2.2e-11	Ulcerative colitis;
LUSC	cis	rs6545883	0.718	rs3771260	chr2:61762384	G/T	cg15711740	chr2:61764176	XPO1	-0.49	-7.77	-0.39	9.91e-14	Tuberculosis;
LUSC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-1.03	-20.21	-0.74	7.12e-60	Height;
LUSC	cis	rs3820928	0.839	rs12151848	chr2:227859326	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.31	-0.37	1.99e-12	Pulmonary function;
LUSC	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg03258749	chr1:151040405	MLLT11	0.5	7.44	0.38	8.36e-13	Childhood ear infection;
LUSC	cis	rs10979	0.562	rs9399446	chr6:143874639	G/C	cg25407410	chr6:143891975	LOC285740	-0.53	-7.49	-0.38	6.01e-13	Hypospadias;
LUSC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.56	-0.6	1.12e-33	Chronic sinus infection;
LUSC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg05425664	chr17:57184151	TRIM37	0.53	7.79	0.39	8.64e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg03733263	chr8:22462867	KIAA1967	0.77	12.46	0.56	1.65e-29	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs3820928	0.904	rs6735069	chr2:227893660	A/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.51	-0.38	5.58e-13	Pulmonary function;
LUSC	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.21	-0.37	3.87e-12	Bipolar disorder;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11668638	chr6:42952412	PPP2R5D	0.47	6.79	0.35	5.12e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9595066	0.712	rs4391951	chr13:44755071	C/T	cg04068111	chr13:44716778	NA	0.47	6.08	0.32	3.26e-9	Schizophrenia;
LUSC	cis	rs611744	0.905	rs610891	chr8:109161003	C/T	cg18478394	chr8:109455254	TTC35	-0.39	-5.82	-0.3	1.41e-8	Dupuytren's disease;
LUSC	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.84	-0.3	1.23e-8	IgG glycosylation;
LUSC	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg05925327	chr15:68127851	NA	-0.4	-6.4	-0.33	5.35e-10	Restless legs syndrome;
LUSC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg13175981	chr1:150552382	MCL1	0.47	6.77	0.35	5.66e-11	Tonsillectomy;
LUSC	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg00522288	chr12:125625016	AACS	-0.31	-5.89	-0.31	9.19e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg19418458	chr7:158789849	NA	-0.53	-8.65	-0.43	2.19e-16	Facial morphology (factor 20);
LUSC	cis	rs1483890	0.642	rs1843050	chr3:69403918	C/T	cg22125112	chr3:69402811	FRMD4B	-0.41	-6.03	-0.31	4.35e-9	Resting heart rate;
LUSC	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg04310649	chr10:35416472	CREM	-0.41	-6.44	-0.33	4.26e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs1325195	0.920	rs1856968	chr1:179100045	C/T	cg11624085	chr17:8464688	MYH10	0.44	7.3	0.37	2.12e-12	IgE grass sensitization;
LUSC	cis	rs12367572	0.965	rs1506678	chr12:45249492	A/G	cg04608330	chr12:45269318	NELL2	-0.57	-9.32	-0.45	1.57e-18	Gut microbiome composition (summer);
LUSC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.69	0.54	1.04e-26	Prudent dietary pattern;
LUSC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg13395646	chr4:1353034	KIAA1530	-0.62	-9.81	-0.47	3.86e-20	Obesity-related traits;
LUSC	trans	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg19694781	chr19:47549865	TMEM160	-0.4	-6.31	-0.33	8.84e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs7605827	0.866	rs6752546	chr2:15630729	T/C	cg19274914	chr2:15703543	NA	0.46	8.87	0.44	4.51e-17	Educational attainment (years of education);
LUSC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg11247378	chr22:39784982	NA	-0.64	-11.55	-0.53	3.31e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg26338869	chr17:61819248	STRADA	0.42	6.17	0.32	1.99e-9	Prudent dietary pattern;
LUSC	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg12386194	chr3:101231763	SENP7	0.64	8.95	0.44	2.44e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18404041	chr3:52824283	ITIH1	-0.58	-11.03	-0.52	2.51e-24	Bipolar disorder;
LUSC	cis	rs2067615	0.524	rs10778499	chr12:107068387	C/T	cg15890332	chr12:107067104	RFX4	0.35	6.19	0.32	1.72e-9	Heart rate;
LUSC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg11645453	chr3:52864694	ITIH4	0.35	8.2	0.41	5.27e-15	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.08	0.55	4.01e-28	Prudent dietary pattern;
LUSC	cis	rs870825	0.616	rs28463742	chr4:185611005	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	12.92	0.58	3.12e-31	Blood protein levels;
LUSC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg26924012	chr15:45694286	SPATA5L1	1.13	20.89	0.75	1.35e-62	Homoarginine levels;
LUSC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.47	-6.97	-0.36	1.71e-11	Alzheimer's disease (late onset);
LUSC	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	6.68	0.34	9.91e-11	Lung cancer in ever smokers;
LUSC	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg08847533	chr14:75593920	NEK9	-0.81	-14.48	-0.62	3.16e-37	Height;
LUSC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.7	12.66	0.57	2.96e-30	Prudent dietary pattern;
LUSC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.71	12.66	0.57	2.84e-30	Prudent dietary pattern;
LUSC	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg22676075	chr6:135203613	NA	0.59	9.49	0.46	4.37e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	6.58	0.34	1.82e-10	Rheumatoid arthritis;
LUSC	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.41	5.72	0.3	2.38e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs9296092	0.517	rs113111213	chr6:33520790	A/G	cg13560919	chr6:33536144	NA	-0.82	-15.74	-0.65	3.89e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg00074818	chr8:8560427	CLDN23	0.58	9.9	0.48	1.91e-20	Obesity-related traits;
LUSC	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg22437258	chr11:111473054	SIK2	-0.5	-6.82	-0.35	4.24e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.4	0.38	1.13e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23158103	chr7:148848205	ZNF398	-0.48	-7.87	-0.4	5.09e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs360798	0.512	rs11893131	chr2:63079528	C/A	cg17519650	chr2:63277830	OTX1	0.48	6.75	0.35	6.56e-11	Coronary artery disease;
LUSC	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg19875535	chr5:140030758	IK	0.46	7.32	0.37	1.91e-12	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	7.13	0.36	6.41e-12	Neuroticism;
LUSC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.03	-0.36	1.2e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg27170947	chr2:26402098	FAM59B	-0.66	-9.6	-0.46	2e-19	Gut microbiome composition (summer);
LUSC	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg05519781	chr21:40033154	ERG	-0.73	-12.23	-0.56	1.11e-28	Coronary artery disease;
LUSC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg26924012	chr15:45694286	SPATA5L1	1.14	20.94	0.75	9e-63	Homoarginine levels;
LUSC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg24060327	chr5:131705240	SLC22A5	-0.38	-6.27	-0.32	1.09e-9	Lung function (FEV1/FVC);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19213194	chr7:101632618	CUX1	0.41	6.31	0.33	9.07e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs590121	0.876	rs649257	chr11:75279846	C/T	cg26104986	chr11:75275303	SERPINH1	-0.3	-6.17	-0.32	2e-9	Coronary artery disease;
LUSC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg08888203	chr3:10149979	C3orf24	0.62	8.51	0.42	5.77e-16	Alzheimer's disease;
LUSC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg20307385	chr11:47447363	PSMC3	-0.47	-6.09	-0.32	3.14e-9	Subjective well-being;
LUSC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg13206674	chr6:150067644	NUP43	0.6	9.65	0.47	1.37e-19	Lung cancer;
LUSC	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.26	-0.45	2.55e-18	Coronary artery disease;
LUSC	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg01528321	chr10:82214614	TSPAN14	0.63	9.4	0.46	8.76e-19	Post bronchodilator FEV1;
LUSC	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg02696742	chr7:106810147	HBP1	-0.62	-9.55	-0.46	2.87e-19	Coronary artery disease;
LUSC	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg25930673	chr12:123319894	HIP1R	-0.64	-6.29	-0.33	9.88e-10	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.16	0.32	2.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.82	-0.43	6.68e-17	Response to antipsychotic treatment;
LUSC	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12477438	0.520	rs12467504	chr2:99543208	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-6.32	-0.33	8.52e-10	Chronic sinus infection;
LUSC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg22535103	chr8:58192502	C8orf71	0.58	7.13	0.36	6.09e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg12179176	chr11:130786555	SNX19	0.63	9.44	0.46	6.54e-19	Schizophrenia;
LUSC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg09455208	chr3:40491958	NA	-0.56	-10.44	-0.5	2.92e-22	Renal cell carcinoma;
LUSC	cis	rs7804356	1.000	rs3801837	chr7:26851361	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg24011408	chr12:48396354	COL2A1	-0.43	-6.15	-0.32	2.17e-9	Glycated hemoglobin levels;
LUSC	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg10128416	chr1:75198403	TYW3;CRYZ	0.58	8.33	0.41	2.08e-15	Resistin levels;
LUSC	cis	rs36093844	0.800	rs11826218	chr11:85568522	T/G	cg25872744	chr11:85566296	CCDC83	-0.45	-5.85	-0.3	1.16e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg05527609	chr1:210001259	C1orf107	0.67	9.63	0.47	1.5700000000000001e-19	Orofacial clefts;
LUSC	cis	rs71403859	0.803	rs10500562	chr16:71627731	A/C	cg08717414	chr16:71523259	ZNF19	-0.75	-8.3	-0.41	2.56e-15	Post bronchodilator FEV1;
LUSC	cis	rs427941	0.703	rs1637257	chr7:101740606	T/G	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg12705353	chr12:122356852	WDR66	0.39	5.65	0.3	3.36e-8	Mean corpuscular volume;
LUSC	cis	rs4242434	0.819	rs7826059	chr8:22512068	T/C	cg03733263	chr8:22462867	KIAA1967	-0.81	-13.05	-0.58	9.62e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.63	6.65	0.34	1.23e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs4474465	0.850	rs4945294	chr11:78256864	G/A	cg27205649	chr11:78285834	NARS2	0.52	6.2	0.32	1.7e-9	Alzheimer's disease (survival time);
LUSC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	1.21	16.65	0.67	9.2e-46	Eosinophil percentage of granulocytes;
LUSC	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg24375607	chr4:120327624	NA	0.64	9.47	0.46	5.14e-19	Educational attainment;
LUSC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg05347473	chr6:146136440	FBXO30	-0.58	-10.0	-0.48	9.4e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02788857	chr8:22132959	PIWIL2	0.39	7.39	0.37	1.18e-12	Hypertriglyceridemia;
LUSC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg06008330	chr7:65541103	ASL	0.37	5.66	0.3	3.26e-8	Aortic root size;
LUSC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg10792982	chr14:105748885	BRF1	0.51	8.77	0.43	9.54e-17	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.14	-0.32	2.4e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs35000415	0.745	rs117944677	chr7:128698185	A/T	cg19972273	chr7:128594194	NA	0.63	5.72	0.3	2.34e-8	Systemic lupus erythematosus;
LUSC	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	8.18	0.41	6.18e-15	Colorectal cancer;
LUSC	cis	rs62400317	0.859	rs56283067	chr6:45100330	T/C	cg20913747	chr6:44695427	NA	-0.47	-7.4	-0.38	1.15e-12	Total body bone mineral density;
LUSC	cis	rs56399783	0.614	rs116929101	chr7:2760325	G/A	cg14895029	chr7:2775587	GNA12	0.52	5.65	0.3	3.38e-8	Childhood ear infection;
LUSC	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.54	7.79	0.39	8.47e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg25344623	chr2:136566232	LCT	0.37	5.7	0.3	2.64e-8	Mosquito bite size;
LUSC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg02018176	chr4:1364513	KIAA1530	0.51	8.74	0.43	1.14e-16	Obesity-related traits;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg25795197	chr3:88107754	CGGBP1	0.47	6.7	0.34	8.71e-11	Triglycerides;
LUSC	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg24562669	chr7:97807699	LMTK2	0.48	8.56	0.42	4.17e-16	Breast cancer;
LUSC	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.81	-15.51	-0.65	3.12e-41	Inflammatory bowel disease;
LUSC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.66	-0.54	1.34e-26	Mean corpuscular volume;
LUSC	cis	rs9815354	0.812	rs73071307	chr3:41798699	T/C	cg03022575	chr3:42003672	ULK4	0.85	8.73	0.43	1.23e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs3125734	0.582	rs7904465	chr10:64002393	G/A	cg09941381	chr10:64027924	RTKN2	-0.39	-7.34	-0.37	1.68e-12	Rheumatoid arthritis;
LUSC	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg25922239	chr6:33757077	LEMD2	0.54	8.13	0.41	8.25e-15	Crohn's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09290614	chr3:38691371	SCN5A	0.58	8.3	0.41	2.69e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.95	0.44	2.52e-17	Prudent dietary pattern;
LUSC	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg00825309	chr19:58991885	ZNF446	-0.49	-7.1	-0.36	7.49e-12	Uric acid clearance;
LUSC	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	7.39	0.37	1.19e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.12	0.45	7.13e-18	Coffee consumption (cups per day);
LUSC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-10.92	-0.51	5.97e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9322817	0.715	rs6918700	chr6:105244526	A/T	cg02098413	chr6:105308735	HACE1	-0.28	-5.77	-0.3	1.85e-8	Thyroid stimulating hormone;
LUSC	cis	rs7241530	0.662	rs7237276	chr18:75907694	C/T	cg14642773	chr18:75888474	NA	0.38	5.66	0.3	3.2e-8	Educational attainment (years of education);
LUSC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.11	0.32	2.79e-9	Schizophrenia;
LUSC	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	-0.51	-7.32	-0.37	1.92e-12	Resistin levels;
LUSC	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg15445000	chr17:37608096	MED1	-0.38	-6.57	-0.34	1.96e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs654950	0.875	rs633297	chr1:41985453	A/C	cg06885757	chr1:42089581	HIVEP3	0.35	6.95	0.36	1.97e-11	Airway imaging phenotypes;
LUSC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg03146154	chr1:46216737	IPP	0.56	8.35	0.42	1.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg04374321	chr14:90722782	PSMC1	0.7	11.18	0.52	7.29e-25	Mortality in heart failure;
LUSC	cis	rs7572644	0.699	rs10171517	chr2:28090059	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-6.72	-0.35	7.73e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg03188948	chr7:1209495	NA	0.61	6.38	0.33	5.97e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg19468946	chr17:37922297	IKZF3	-0.43	-6.78	-0.35	5.33e-11	Self-reported allergy;
LUSC	cis	rs601339	1.000	rs645491	chr12:123181661	T/C	cg11919336	chr12:123188078	GPR109A	0.44	6.58	0.34	1.87e-10	Adiponectin levels;
LUSC	cis	rs12900413	0.959	rs12902793	chr15:90304402	G/A	cg24249390	chr15:90295951	MESP1	-0.46	-6.67	-0.34	1.04e-10	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg19875535	chr5:140030758	IK	0.47	7.64	0.39	2.37e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg10523679	chr1:76189770	ACADM	-0.48	-6.96	-0.36	1.85e-11	Daytime sleep phenotypes;
LUSC	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg14668632	chr7:2872130	GNA12	-0.46	-7.07	-0.36	9.1e-12	Height;
LUSC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18876405	chr7:65276391	NA	0.55	8.79	0.43	8.1e-17	Aortic root size;
LUSC	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg10253484	chr15:75165896	SCAMP2	-0.53	-7.16	-0.36	5.12e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-7.27	-0.37	2.61e-12	Colorectal cancer;
LUSC	cis	rs7809950	0.731	rs2712196	chr7:107128797	G/T	cg23024343	chr7:107201750	COG5	-0.68	-10.18	-0.49	2.17e-21	Coronary artery disease;
LUSC	cis	rs12530845	0.623	rs73721664	chr7:135343575	A/C	cg23117316	chr7:135346802	PL-5283	-0.66	-9.89	-0.48	2.17e-20	Red blood cell traits;
LUSC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18876405	chr7:65276391	NA	-0.58	-9.35	-0.46	1.32e-18	Aortic root size;
LUSC	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg14403583	chr14:105418241	AHNAK2	-0.58	-9.75	-0.47	6.06e-20	Rheumatoid arthritis;
LUSC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg15017067	chr4:17643749	FAM184B	0.35	6.0	0.31	5.16e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18876405	chr7:65276391	NA	0.54	8.47	0.42	8.18e-16	Aortic root size;
LUSC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.6	-10.15	-0.49	2.8e-21	Intelligence (multi-trait analysis);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03043709	chr7:2046920	MAD1L1	-0.73	-6.45	-0.33	3.92e-10	Cognitive performance;
LUSC	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg11235426	chr6:292522	DUSP22	-0.47	-6.97	-0.36	1.67e-11	Menopause (age at onset);
LUSC	cis	rs62408225	0.890	rs2134814	chr6:90987512	C/G	cg06866423	chr6:90926672	BACH2	0.41	5.88	0.31	9.97e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs62458065	0.513	rs10245103	chr7:32534829	T/G	cg20159608	chr7:32802032	NA	-0.7	-9.04	-0.44	1.3e-17	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg27494647	chr7:150038898	RARRES2	0.44	6.74	0.35	6.99e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.74	-14.43	-0.62	5.11e-37	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg11244672	chr19:19639970	YJEFN3	0.57	7.25	0.37	2.99e-12	Bipolar disorder;
LUSC	cis	rs1982963	0.950	rs61973203	chr14:52510567	A/G	cg10843707	chr14:52510701	NID2	0.42	7.27	0.37	2.59e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs62432291	0.681	rs445957	chr6:159662064	C/T	cg14500486	chr6:159655392	FNDC1	-0.54	-6.11	-0.32	2.73e-9	Joint mobility (Beighton score);
LUSC	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg23625390	chr15:77176239	SCAPER	-0.66	-10.4	-0.49	3.84e-22	Blood metabolite levels;
LUSC	cis	rs6733011	0.600	rs1356424	chr2:99425838	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.41	-5.79	-0.3	1.6e-8	Bipolar disorder;
LUSC	cis	rs6942756	1.000	rs6971917	chr7:128976919	G/A	cg02491457	chr7:128862824	NA	-0.48	-6.38	-0.33	5.8e-10	White matter hyperintensity burden;
LUSC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25072359	chr17:41440525	NA	0.65	9.22	0.45	3.32e-18	Menopause (age at onset);
LUSC	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14083397	chr20:388473	RBCK1	-0.48	-6.17	-0.32	2e-9	Hepatitis;
LUSC	cis	rs6540559	0.673	rs1073150	chr1:210017083	G/A	cg21951975	chr1:209979733	IRF6	0.54	6.78	0.35	5.33e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs240764	0.658	rs11155666	chr6:101234841	G/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.09	-0.32	3.1e-9	Neuroticism;
LUSC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg22166914	chr1:53195759	ZYG11B	0.48	7.69	0.39	1.66e-13	Monocyte count;
LUSC	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.5	-6.44	-0.33	4.09e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg04369109	chr6:150039330	LATS1	-0.55	-8.11	-0.41	9.41e-15	Lung cancer;
LUSC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	0.96	17.39	0.69	1.06e-48	Cognitive function;
LUSC	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20135002	chr11:47629003	NA	-0.5	-7.76	-0.39	1.05e-13	Subjective well-being;
LUSC	cis	rs7178572	0.568	rs12900433	chr15:77495028	T/C	cg22256960	chr15:77711686	NA	-0.5	-8.05	-0.4	1.5e-14	Type 2 diabetes;
LUSC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.9	0.44	3.61e-17	Lung cancer;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg11028586	chr17:33307483	LIG3	0.4	6.35	0.33	7.1e-10	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.64	-0.34	1.3e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.82	12.4	0.56	2.57e-29	Cognitive test performance;
LUSC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg14668632	chr7:2872130	GNA12	-0.43	-5.97	-0.31	5.93e-9	Height;
LUSC	cis	rs2742234	0.955	rs1800861	chr10:43613843	G/T	cg02780029	chr10:43622663	RET	-0.33	-6.12	-0.32	2.61e-9	Hirschsprung disease;
LUSC	cis	rs6580649	0.883	rs879242	chr12:48503301	T/C	cg24011408	chr12:48396354	COL2A1	-0.45	-6.1	-0.32	2.9e-9	Lung cancer;
LUSC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.0	-0.48	9.09e-21	Hemoglobin concentration;
LUSC	cis	rs4400599	0.618	rs1194582	chr1:154215973	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.9	-0.31	8.97e-9	Platelet distribution width;
LUSC	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg00677455	chr12:58241039	CTDSP2	0.72	11.27	0.53	3.35e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21028142	chr17:79581711	NPLOC4	0.34	8.17	0.41	6.66e-15	Eye color traits;
LUSC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.7	-10.85	-0.51	1.03e-23	Aortic root size;
LUSC	cis	rs7940866	0.738	rs10791114	chr11:130889850	G/A	cg12179176	chr11:130786555	SNX19	0.63	9.78	0.47	4.87e-20	Schizophrenia;
LUSC	trans	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.89	-0.44	3.86e-17	Obesity-related traits;
LUSC	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg06096015	chr1:231504339	EGLN1	0.54	9.4	0.46	8.91e-19	Hemoglobin concentration;
LUSC	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.04	0.4	1.62e-14	Lung cancer in ever smokers;
LUSC	cis	rs4478037	1.000	rs59622575	chr3:33162249	A/C	cg19404215	chr3:33155277	CRTAP	0.96	10.11	0.48	4.01e-21	Major depressive disorder;
LUSC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg02569458	chr12:86230093	RASSF9	0.58	9.78	0.47	4.91e-20	Major depressive disorder;
LUSC	cis	rs7202877	0.706	rs11149812	chr16:75323645	T/C	cg04384234	chr16:75411784	CFDP1	-0.62	-8.63	-0.43	2.53e-16	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-9.57	-0.46	2.44e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg04369109	chr6:150039330	LATS1	-0.57	-8.41	-0.42	1.2e-15	Lung cancer;
LUSC	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.42	6.62	0.34	1.47e-10	Height;
LUSC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08048268	chr3:133502702	NA	0.38	7.61	0.38	2.85e-13	Iron status biomarkers;
LUSC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg21770322	chr7:97807741	LMTK2	0.41	7.29	0.37	2.32e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4073221	0.520	rs13072195	chr3:18199498	C/T	cg07694806	chr3:18168406	NA	-0.67	-6.48	-0.33	3.2e-10	Parkinson's disease;
LUSC	trans	rs9847048	0.715	rs78854293	chr3:116367255	C/T	cg11621464	chr19:41120268	LTBP4	-0.62	-6.02	-0.31	4.5e-9	Gut microbiome composition (summer);
LUSC	cis	rs6062509	0.965	rs6062506	chr20:62352389	T/G	cg01176363	chr20:62369445	LIME1	-0.46	-6.98	-0.36	1.63e-11	Prostate cancer;
LUSC	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg21211680	chr2:198530	NA	0.68	7.04	0.36	1.11e-11	Blood protein levels;
LUSC	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.16	-0.32	2.11e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs62400317	0.859	rs10948205	chr6:45124585	T/C	cg18551225	chr6:44695536	NA	-0.42	-6.82	-0.35	4.23e-11	Total body bone mineral density;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06987936	chr6:74406097	CD109	-0.49	-6.17	-0.32	1.97e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg00540400	chr15:79124168	NA	-0.47	-8.24	-0.41	3.92e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg26380479	chr7:97908229	NA	-0.27	-5.89	-0.31	9.67e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg23711669	chr6:146136114	FBXO30	0.92	18.0	0.7	3.97e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg22852734	chr6:133119734	C6orf192	1.08	12.84	0.57	6.03e-31	Type 2 diabetes nephropathy;
LUSC	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg15423357	chr2:25149977	NA	0.36	7.01	0.36	1.34e-11	Body mass index in non-asthmatics;
LUSC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.93	0.66	6.49e-43	Platelet count;
LUSC	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg08085267	chr17:45401833	C17orf57	-0.46	-6.63	-0.34	1.35e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg22681709	chr2:178499509	PDE11A	-0.57	-11.54	-0.53	3.62e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg09997546	chr11:8931473	C11orf17;ST5	0.35	7.33	0.37	1.75e-12	Hemoglobin concentration;
LUSC	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg17652424	chr22:38574118	PLA2G6	-0.3	-6.43	-0.33	4.3e-10	Cutaneous nevi;
LUSC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.85	-0.31	1.15e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.7	10.83	0.51	1.22e-23	Aortic root size;
LUSC	cis	rs7851660	0.772	rs6478471	chr9:100664382	A/G	cg13688889	chr9:100608707	NA	-0.54	-8.39	-0.42	1.4e-15	Strep throat;
LUSC	cis	rs10761482	0.861	rs7084803	chr10:62107101	T/C	cg18175470	chr10:62150864	ANK3	-0.51	-7.24	-0.37	3.06e-12	Schizophrenia;
LUSC	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.85	-8.82	-0.43	6.69e-17	Lung cancer in ever smokers;
LUSC	trans	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-6.62	-0.34	1.46e-10	Monocyte count;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14514174	chr9:99181512	ZNF367	-0.39	-6.53	-0.34	2.43e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.73	12.45	0.56	1.77e-29	Monocyte count;
LUSC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg17173187	chr15:85201210	NMB	0.38	6.93	0.35	2.21e-11	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.07	-0.32	3.41e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg24450063	chr1:156163899	SLC25A44	1.04	8.47	0.42	7.73e-16	Paclitaxel disposition in epithelial ovarian cancer;
LUSC	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg08017634	chr8:144659831	NAPRT1	0.7	6.15	0.32	2.16e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg04369109	chr6:150039330	LATS1	-0.52	-7.5	-0.38	5.95e-13	Lung cancer;
LUSC	trans	rs13011075	0.878	rs6714719	chr2:68593773	G/C	cg14221825	chr19:46271408	SIX5	0.43	6.03	0.31	4.38e-9	Mean corpuscular volume;
LUSC	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg13010199	chr12:38710504	ALG10B	0.58	9.2	0.45	3.89e-18	Morning vs. evening chronotype;
LUSC	cis	rs4253772	0.938	rs78336060	chr22:46641597	C/T	cg09491104	chr22:46646882	C22orf40	-0.63	-6.52	-0.34	2.57e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg13206674	chr6:150067644	NUP43	0.59	9.6	0.47	1.94e-19	Lung cancer;
LUSC	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg23029597	chr12:123009494	RSRC2	-0.74	-9.33	-0.45	1.54e-18	Body mass index;
LUSC	cis	rs17255340	0.520	rs1170513	chr6:84008588	C/T	cg08257003	chr6:84140564	ME1	0.32	7.82	0.39	7.22e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs4363385	0.719	rs2066005	chr1:152923113	G/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.16	-0.36	5.12e-12	Inflammatory skin disease;
LUSC	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg27661571	chr11:113659931	NA	-0.59	-7.18	-0.37	4.61e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs4654899	0.802	rs115818417	chr1:21200411	C/T	cg01072550	chr1:21505969	NA	-0.51	-7.59	-0.38	3.29e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg22907277	chr7:1156413	C7orf50	0.49	7.52	0.38	5.21e-13	Longevity;Endometriosis;
LUSC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.75	-0.35	6.39e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg04398603	chr3:9439238	SETD5;LOC440944	0.37	6.07	0.32	3.45e-9	Asthma;
LUSC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg09904177	chr6:26538194	HMGN4	-0.53	-6.18	-0.32	1.91e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-7.13	-0.36	6.12e-12	Menarche (age at onset);
LUSC	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.96	19.31	0.73	2.48e-56	Brugada syndrome;
LUSC	cis	rs970548	0.688	rs2082109	chr10:45931102	T/C	cg23750895	chr10:46321377	AGAP4	-0.55	-5.71	-0.3	2.51e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg06784218	chr1:46089804	CCDC17	-0.47	-9.11	-0.45	7.73e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4356932	0.691	rs4859581	chr4:76906974	A/G	cg00809888	chr4:76862425	NAAA	0.37	6.12	0.32	2.61e-9	Blood protein levels;
LUSC	cis	rs887829	0.694	rs869283	chr2:234626287	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.31	-0.37	1.99e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	trans	rs7939886	0.920	rs12221615	chr11:55999950	G/C	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg15117754	chr3:10150083	C3orf24	0.44	5.65	0.3	3.46e-8	Alzheimer's disease;
LUSC	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg09479241	chr17:27052676	TLCD1	0.43	5.96	0.31	6.29e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.87	0.31	1.08e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg19773385	chr1:10388646	KIF1B	-0.57	-9.48	-0.46	5.08e-19	Hepatocellular carcinoma;
LUSC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg09035930	chr12:129282057	SLC15A4	0.66	13.35	0.59	7.04e-33	Systemic lupus erythematosus;
LUSC	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg25214090	chr10:38739885	LOC399744	0.53	7.72	0.39	1.33e-13	Corneal astigmatism;
LUSC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg17178900	chr1:205818956	PM20D1	0.51	8.09	0.4	1.14e-14	Menarche (age at onset);
LUSC	cis	rs2742234	0.590	rs2115817	chr10:43686552	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.03	-0.36	1.17e-11	Hirschsprung disease;
LUSC	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.73	10.36	0.49	5.62e-22	Corneal astigmatism;
LUSC	cis	rs4356932	1.000	rs7683657	chr4:76962643	T/C	cg00809888	chr4:76862425	NAAA	0.36	6.13	0.32	2.5e-9	Blood protein levels;
LUSC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg24250549	chr1:154909240	PMVK	0.56	8.97	0.44	2.24e-17	Prostate cancer;
LUSC	cis	rs1775715	0.707	rs2799019	chr10:32142850	C/T	cg03015672	chr10:32216066	ARHGAP12	0.34	6.21	0.32	1.55e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6669072	0.527	rs10801831	chr1:91272391	T/A	cg08895590	chr1:91227319	NA	-0.27	-5.81	-0.3	1.48e-8	Cognitive function;
LUSC	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg04733989	chr22:42467013	NAGA	0.4	6.46	0.33	3.68e-10	Cognitive function;
LUSC	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-11.2	-0.52	6.22e-25	Hemoglobin concentration;
LUSC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.26	34.26	0.88	2.47e-111	Chronic sinus infection;
LUSC	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg12473912	chr3:136751656	NA	0.39	6.81	0.35	4.6e-11	Neuroticism;
LUSC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg12963246	chr6:28129442	ZNF389	0.49	7.14	0.36	5.76e-12	Parkinson's disease;
LUSC	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg05342945	chr12:48394962	COL2A1	-0.45	-6.01	-0.31	4.94e-9	Lung cancer;
LUSC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11764359	chr7:65958608	NA	0.55	7.18	0.37	4.51e-12	Aortic root size;
LUSC	trans	rs1998174	0.509	rs6425454	chr1:171817435	A/C	cg13482142	chr2:234261155	NA	0.42	6.05	0.31	3.82e-9	Platelet distribution width;
LUSC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg05585544	chr11:47624801	NA	-0.42	-7.31	-0.37	2.04e-12	Subjective well-being;
LUSC	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg09365446	chr1:150670422	GOLPH3L	0.47	7.05	0.36	1.02e-11	Melanoma;
LUSC	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg23029597	chr12:123009494	RSRC2	-0.71	-9.74	-0.47	6.68e-20	Body mass index;
LUSC	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg18132916	chr6:79620363	NA	-0.38	-5.81	-0.3	1.44e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6977660	0.943	rs12668201	chr7:19831610	A/C	cg05791153	chr7:19748676	TWISTNB	-0.56	-6.34	-0.33	7.39e-10	Thyroid stimulating hormone;
LUSC	cis	rs7572644	0.699	rs7595986	chr2:28085311	G/A	cg27432699	chr2:27873401	GPN1	-0.51	-6.97	-0.36	1.75e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.41	-7.36	-0.37	1.44e-12	Glomerular filtration rate;
LUSC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg16393715	chr7:1948819	MAD1L1	0.37	6.22	0.32	1.52e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9420	0.961	rs11229148	chr11:57621460	A/T	cg02958346	chr11:57425731	CLP1	-0.43	-6.26	-0.32	1.2e-9	Schizophrenia;
LUSC	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.93	15.96	0.66	5.05e-43	Bladder cancer;
LUSC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25072359	chr17:41440525	NA	0.66	9.49	0.46	4.49e-19	Menopause (age at onset);
LUSC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.39	0.53	1.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.54	8.33	0.41	2.13e-15	Colorectal cancer;
LUSC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-6.77	-0.35	5.81e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg06238570	chr21:40685208	BRWD1	0.47	7.16	0.36	5.2e-12	Cognitive function;
LUSC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg06064525	chr11:970664	AP2A2	-0.47	-10.06	-0.48	5.8e-21	Alzheimer's disease (late onset);
LUSC	cis	rs73206853	0.764	rs55823622	chr12:110781628	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	6.43	0.33	4.37e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03517284	chr6:25882590	NA	-0.53	-8.83	-0.44	5.86e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs10203711	0.933	rs4994752	chr2:239567309	C/A	cg14580085	chr2:239553406	NA	0.42	7.1	0.36	7.48e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg23229984	chr5:148520753	ABLIM3	0.37	6.01	0.31	4.76e-9	Breast cancer;
LUSC	cis	rs9309473	0.513	rs62149782	chr2:73819028	G/C	cg20560298	chr2:73613845	ALMS1	-0.5	-6.02	-0.31	4.62e-9	Metabolite levels;
LUSC	cis	rs469568	0.869	rs340124	chr5:178686590	C/T	cg08999896	chr5:178685787	ADAMTS2	-0.3	-6.5	-0.34	2.88e-10	Stroke (pediatric);
LUSC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.9	0.35	2.58e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7107174	0.892	rs2512529	chr11:77977351	C/T	cg02023728	chr11:77925099	USP35	0.48	6.73	0.35	7.36e-11	Testicular germ cell tumor;
LUSC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg26924012	chr15:45694286	SPATA5L1	1.12	20.31	0.74	2.75e-60	Homoarginine levels;
LUSC	cis	rs6714710	0.603	rs6738389	chr2:98386731	A/G	cg26665480	chr2:98280029	ACTR1B	0.6	8.81	0.43	7.07e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg13010199	chr12:38710504	ALG10B	-0.48	-6.62	-0.34	1.39e-10	Resting heart rate;
LUSC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg11812906	chr14:75593930	NEK9	0.66	11.36	0.53	1.59e-25	Height;
LUSC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg23711669	chr6:146136114	FBXO30	0.75	13.38	0.59	5.42e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg11965913	chr1:205819406	PM20D1	0.89	17.42	0.69	8e-49	Menarche (age at onset);
LUSC	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.55	10.14	0.49	3.06e-21	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg20701182	chr2:24300061	SF3B14	0.9	11.63	0.54	1.77e-26	Lymphocyte counts;
LUSC	cis	rs12760731	0.720	rs10913544	chr1:178350980	C/T	cg00404053	chr1:178313656	RASAL2	0.58	6.06	0.31	3.76e-9	Obesity-related traits;
LUSC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg23625390	chr15:77176239	SCAPER	0.48	7.48	0.38	6.53e-13	Blood metabolite levels;
LUSC	cis	rs4664308	0.618	rs4665138	chr2:160890427	C/T	cg03641300	chr2:160917029	PLA2R1	-0.49	-8.0	-0.4	2.07e-14	Idiopathic membranous nephropathy;
LUSC	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg00277334	chr10:82204260	NA	-0.54	-7.55	-0.38	4.07e-13	Post bronchodilator FEV1;
LUSC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	6.07	0.32	3.46e-9	Platelet count;
LUSC	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.72	-12.47	-0.56	1.4e-29	White blood cell count (basophil);
LUSC	cis	rs4253772	0.938	rs41378347	chr22:46636976	G/A	cg09491104	chr22:46646882	C22orf40	-0.59	-6.54	-0.34	2.27e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs3812762	0.783	rs34524863	chr11:8777408	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.36	-5.91	-0.31	8.33e-9	Hypospadias;
LUSC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.07	-0.36	8.94e-12	Colorectal cancer;
LUSC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg15212455	chr7:39170539	POU6F2	0.68	11.5	0.53	5.06e-26	IgG glycosylation;
LUSC	trans	rs6461503	0.644	rs916789	chr7:20572530	A/C	cg16873684	chr2:201828587	ORC2L	0.36	6.22	0.32	1.48e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.49	0.5	1.86e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.41	6.56	0.34	2.01e-10	Bone mineral density (hip);Bone mineral density;
LUSC	cis	rs1784581	0.588	rs9885762	chr6:162411954	G/A	cg17173639	chr6:162384350	PARK2	0.57	9.87	0.48	2.4e-20	Itch intensity from mosquito bite;
LUSC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.38	-0.33	5.84e-10	Vitiligo;
LUSC	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg07817648	chr10:79422355	NA	-0.58	-7.45	-0.38	7.99e-13	Bone mineral density;
LUSC	cis	rs6504340	0.739	rs1529334	chr17:46671792	C/T	cg09704116	chr17:46666958	LOC404266	0.35	6.34	0.33	7.4e-10	Primary tooth development (number of teeth);
LUSC	cis	rs9646944	0.501	rs11465736	chr2:103067930	C/T	cg20060108	chr2:102954350	IL1RL1	0.47	6.31	0.33	8.85e-10	Blood protein levels;
LUSC	cis	rs472402	0.580	rs10060745	chr5:6658003	T/C	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.46	-6.68	-0.34	1.02e-10	Response to amphetamines;
LUSC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	0.64	13.37	0.59	5.97e-33	Prudent dietary pattern;
LUSC	cis	rs7011049	1.000	rs11993171	chr8:53832898	C/A	cg26025543	chr8:53854495	NA	0.51	6.28	0.32	1.05e-9	Systolic blood pressure;
LUSC	cis	rs11605275	0.581	rs11606785	chr11:20030430	A/C	cg14835545	chr11:20032148	NAV2	-0.77	-6.55	-0.34	2.17e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg08048268	chr3:133502702	NA	0.34	6.63	0.34	1.39e-10	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.53	0.57	8.85e-30	Motion sickness;
LUSC	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg02023728	chr11:77925099	USP35	0.51	7.12	0.36	6.74e-12	Testicular germ cell tumor;
LUSC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg09904177	chr6:26538194	HMGN4	0.43	6.41	0.33	4.82e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7582720	0.887	rs72934589	chr2:204017937	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.83	8.78	0.43	8.34e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11764359	chr7:65958608	NA	0.68	10.88	0.51	8.15e-24	Aortic root size;
LUSC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	11.46	0.53	7.15e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg18402987	chr7:1209562	NA	0.68	7.27	0.37	2.49e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.95	-0.44	2.52e-17	Obesity-related traits;
LUSC	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg18753928	chr3:113234510	CCDC52	-0.54	-8.23	-0.41	4.16e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg13010199	chr12:38710504	ALG10B	0.42	6.14	0.32	2.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg06877462	chr1:205807181	PM20D1	-0.32	-5.9	-0.31	8.73e-9	Monocyte percentage of white cells;
LUSC	trans	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.58	-9.57	-0.46	2.48e-19	Mean corpuscular volume;
LUSC	cis	rs9467773	0.595	rs3799379	chr6:26404694	C/T	cg09904177	chr6:26538194	HMGN4	-0.54	-8.05	-0.4	1.5e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg04287289	chr16:89883240	FANCA	0.56	8.68	0.43	1.8e-16	Vitiligo;
LUSC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.8	-14.35	-0.62	1e-36	Dental caries;
LUSC	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	0.96	8.01	0.4	1.94e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-16.8	-0.68	2.51e-46	Exhaled nitric oxide output;
LUSC	cis	rs1298908	0.639	rs2993763	chr10:82033594	G/A	cg01528321	chr10:82214614	TSPAN14	0.58	8.49	0.42	6.9e-16	Diabetic kidney disease;
LUSC	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg23649088	chr2:200775458	C2orf69	0.5	6.83	0.35	4.15e-11	Schizophrenia;
LUSC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-8.54	-0.42	4.81e-16	Hemoglobin concentration;
LUSC	cis	rs6752107	0.503	rs2304776	chr2:234227693	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	7.06	0.36	9.44e-12	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg19920283	chr7:105172520	RINT1	0.6	6.35	0.33	7.01e-10	Bipolar disorder (body mass index interaction);
LUSC	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.45	9.52	0.46	3.71e-19	Airflow obstruction;
LUSC	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.8	0.51	1.65e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg19812747	chr11:111475976	SIK2	-0.52	-7.29	-0.37	2.23e-12	Primary sclerosing cholangitis;
LUSC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.69	11.84	0.54	3e-27	Colorectal cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg05731183	chr15:68132796	NA	0.55	8.31	0.41	2.49e-15	Triglycerides;
LUSC	trans	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Bladder cancer;
LUSC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg08773314	chr2:239334832	ASB1	0.38	6.92	0.35	2.28e-11	Multiple system atrophy;
LUSC	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg23422044	chr7:1970798	MAD1L1	-0.64	-7.26	-0.37	2.8e-12	Bipolar disorder;
LUSC	cis	rs12545109	0.800	rs1440747	chr8:57417924	G/T	cg09654669	chr8:57350985	NA	0.5	6.53	0.34	2.44e-10	Obesity-related traits;
LUSC	cis	rs11997175	0.524	rs12164218	chr8:33669658	G/C	ch.8.33884649F	chr8:33765107	NA	0.46	6.41	0.33	5.1e-10	Body mass index;
LUSC	cis	rs6500395	1.000	rs1224	chr16:48572817	G/A	cg04672837	chr16:48644449	N4BP1	0.45	6.7	0.34	8.93e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg07541023	chr7:19748670	TWISTNB	0.6	6.47	0.33	3.57e-10	Thyroid stimulating hormone;
LUSC	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg05294307	chr14:35346193	BAZ1A	-0.61	-7.34	-0.37	1.65e-12	Psoriasis;
LUSC	cis	rs9341808	0.718	rs12208016	chr6:80823563	G/A	cg08355045	chr6:80787529	NA	0.56	9.85	0.47	2.85e-20	Sitting height ratio;
LUSC	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.8	-14.69	-0.63	4.94e-38	Obesity-related traits;
LUSC	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg11473876	chr11:109292803	C11orf87	0.41	6.73	0.35	7.35e-11	Schizophrenia;
LUSC	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg12560992	chr17:57184187	TRIM37	0.62	10.38	0.49	4.48e-22	Testicular germ cell tumor;
LUSC	cis	rs9311676	0.656	rs6800514	chr3:58358717	C/T	cg13750441	chr3:58318267	PXK	0.36	6.72	0.35	7.74e-11	Systemic lupus erythematosus;
LUSC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.08	-0.48	4.83e-21	Obesity-related traits;
LUSC	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.68	11.57	0.53	2.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg06219351	chr7:158114137	PTPRN2	-0.54	-9.85	-0.47	2.89e-20	Calcium levels;
LUSC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg02038168	chr22:39784481	NA	0.47	7.4	0.38	1.1e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg04450456	chr4:17643702	FAM184B	0.35	5.81	0.3	1.47e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs71403859	0.614	rs12935422	chr16:71664225	T/A	cg08717414	chr16:71523259	ZNF19	-0.71	-8.01	-0.4	1.93e-14	Post bronchodilator FEV1;
LUSC	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg15704280	chr7:45808275	SEPT13	0.98	15.85	0.66	1.38e-42	Height;
LUSC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.68	-0.39	1.83e-13	Breast cancer;
LUSC	trans	rs2679649	1.000	rs2679647	chr6:122351503	C/T	cg00167820	chr8:131663355	NA	0.54	6.35	0.33	6.96e-10	Subcutaneous adipose tissue;
LUSC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg21770322	chr7:97807741	LMTK2	-0.41	-7.22	-0.37	3.52e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-1.03	-22.81	-0.78	4.31e-70	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg14440974	chr22:39074834	NA	-0.37	-6.14	-0.32	2.34e-9	Menopause (age at onset);
LUSC	cis	rs67696533	0.600	rs6119879	chr20:31105389	C/T	cg13636640	chr20:31349939	DNMT3B	0.47	6.38	0.33	5.83e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17467752	chr17:38218738	THRA	-0.56	-8.09	-0.4	1.13e-14	Myeloid white cell count;
LUSC	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg02569458	chr12:86230093	RASSF9	0.47	7.46	0.38	7.39e-13	Major depressive disorder;
LUSC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.17	-0.61	5e-36	Eye color traits;
LUSC	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.66	8.33	0.41	2.16e-15	Body mass index;
LUSC	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg02023728	chr11:77925099	USP35	0.42	6.2	0.32	1.63e-9	Testicular germ cell tumor;
LUSC	cis	rs7582720	1.000	rs6725887	chr2:203745885	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.81	-8.68	-0.43	1.82e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs3125734	0.633	rs4561099	chr10:64041163	T/C	cg09941381	chr10:64027924	RTKN2	-0.38	-6.92	-0.35	2.28e-11	Rheumatoid arthritis;
LUSC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.48	-6.44	-0.33	4.09e-10	Tonsillectomy;
LUSC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg23788917	chr6:8435910	SLC35B3	-0.49	-7.29	-0.37	2.29e-12	Motion sickness;
LUSC	cis	rs416603	0.967	rs11644184	chr16:11365104	G/A	cg00044050	chr16:11439710	C16orf75	-0.68	-12.22	-0.56	1.26e-28	Type 1 diabetes;
LUSC	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.68	0.39	1.83e-13	Neuroticism;
LUSC	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.54	-0.34	2.36e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-0.96	-16.33	-0.67	1.85e-44	Dilated cardiomyopathy;
LUSC	cis	rs2012796	0.956	rs7146802	chr14:81820515	A/G	cg02996355	chr14:81879375	NA	0.51	7.34	0.37	1.65e-12	Night sleep phenotypes;
LUSC	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg00857998	chr1:205179979	DSTYK	0.63	9.79	0.47	4.45e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	1.05	20.2	0.74	7.77e-60	Menopause (age at onset);
LUSC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05535760	chr7:792225	HEATR2	0.81	9.44	0.46	6.54e-19	Cerebrospinal P-tau181p levels;
LUSC	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.49	8.01	0.4	1.97e-14	Alcohol dependence;
LUSC	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg01448562	chr3:133502909	NA	-0.66	-10.81	-0.51	1.47e-23	Iron status biomarkers;
LUSC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.58	-10.65	-0.5	5.27e-23	Homoarginine levels;
LUSC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.41	6.27	0.32	1.09e-9	Platelet count;
LUSC	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg03806693	chr22:41940476	POLR3H	0.85	12.22	0.56	1.25e-28	Vitiligo;
LUSC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg21433313	chr16:3507492	NAT15	0.4	5.65	0.3	3.49e-8	Body mass index (adult);
LUSC	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg04362960	chr10:104952993	NT5C2	0.58	8.32	0.41	2.29e-15	Arsenic metabolism;
LUSC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg25019033	chr10:957182	NA	-0.5	-5.7	-0.3	2.64e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	trans	rs7916697	0.626	rs3858144	chr10:70011354	A/G	cg04882175	chr6:131122610	NA	-0.51	-6.79	-0.35	5.26e-11	Optic disc area;
LUSC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg00701064	chr4:6280414	WFS1	0.58	14.61	0.62	9.98e-38	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs13040088	0.872	rs13039291	chr20:61572760	C/T	cg23096297	chr20:61557774	DIDO1	0.81	10.59	0.5	8.83e-23	Menopause (age at onset);
LUSC	cis	rs11169552	0.510	rs55877451	chr12:50987378	G/A	cg12884762	chr12:50931848	DIP2B	-0.31	-5.64	-0.3	3.58e-8	Colorectal cancer;
LUSC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.12e-12	Motion sickness;
LUSC	cis	rs7432375	0.610	rs56695781	chr3:136510601	G/T	cg12473912	chr3:136751656	NA	0.32	5.68	0.3	2.96e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11158026	0.603	rs66769866	chr14:55446153	C/T	cg04306507	chr14:55594613	LGALS3	0.4	7.45	0.38	7.84e-13	Parkinson's disease;
LUSC	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg13206674	chr6:150067644	NUP43	0.45	6.79	0.35	5.02e-11	Testicular germ cell tumor;
LUSC	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg13010199	chr12:38710504	ALG10B	0.53	7.92	0.4	3.45e-14	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.24	0.37	3.16e-12	Bipolar disorder;
LUSC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg08917208	chr2:24149416	ATAD2B	0.53	5.87	0.31	1.03e-8	Lymphocyte counts;
LUSC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.38	-5.75	-0.3	2e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.22	0.64	4.18e-40	Bladder cancer;
LUSC	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	6.34	0.33	7.47e-10	Rheumatoid arthritis;
LUSC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg21535247	chr6:8435926	SLC35B3	0.57	9.0	0.44	1.69e-17	Motion sickness;
LUSC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.58	0.34	1.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg13442820	chr19:1672531	NA	0.68	6.42	0.33	4.81e-10	Body mass index;
LUSC	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg19743168	chr1:23544995	NA	0.4	8.06	0.4	1.34e-14	Height;
LUSC	trans	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg26043149	chr18:55253948	FECH	-0.44	-6.8	-0.35	4.77e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg11752832	chr7:134001865	SLC35B4	0.56	8.77	0.43	9.42e-17	Mean platelet volume;
LUSC	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.72	0.35	8.08e-11	Corneal astigmatism;
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg22907277	chr7:1156413	C7orf50	0.52	7.73	0.39	1.28e-13	Longevity;Endometriosis;
LUSC	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.51	-0.46	3.89e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4343996	0.870	rs6974075	chr7:3392071	A/G	cg21248987	chr7:3385318	SDK1	-0.42	-7.15	-0.36	5.37e-12	Motion sickness;
LUSC	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg22906224	chr7:99728672	NA	-0.5	-6.89	-0.35	2.8e-11	Coronary artery disease;
LUSC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg08470875	chr2:26401718	FAM59B	-0.66	-8.86	-0.44	4.75e-17	Gut microbiome composition (summer);
LUSC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg22920501	chr2:26401640	FAM59B	-0.78	-11.28	-0.53	3.15e-25	Gut microbiome composition (summer);
LUSC	cis	rs2455601	0.882	rs11042115	chr11:8926679	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.83	-0.35	4.1e-11	Schizophrenia;
LUSC	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg13010199	chr12:38710504	ALG10B	-0.51	-7.67	-0.39	1.87e-13	Morning vs. evening chronotype;
LUSC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.78	7.71	0.39	1.47e-13	Initial pursuit acceleration;
LUSC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg01973587	chr1:228161476	NA	-0.41	-7.4	-0.38	1.15e-12	Diastolic blood pressure;
LUSC	cis	rs1538970	0.810	rs12067642	chr1:45927517	G/T	cg05343316	chr1:45956843	TESK2	0.68	9.45	0.46	6.16e-19	Platelet count;
LUSC	cis	rs7189233	0.550	rs17193176	chr16:53518228	T/C	cg09728985	chr16:53543985	NA	-0.31	-5.9	-0.31	9.01e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.34	6.05	0.31	3.79e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg09479241	chr17:27052676	TLCD1	-0.42	-5.7	-0.3	2.61e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg03240473	chr21:43526662	UMODL1;C21orf128	0.44	7.16	0.36	5.15e-12	IgG glycosylation;
LUSC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.53	0.57	8.85e-30	Motion sickness;
LUSC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11644478	chr21:40555479	PSMG1	-0.59	-9.3	-0.45	1.91e-18	Menarche (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24695950	chr2:162364264	NA	0.43	6.32	0.33	8.58e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg13010199	chr12:38710504	ALG10B	0.48	7.56	0.38	3.82e-13	Morning vs. evening chronotype;
LUSC	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg00049323	chr5:472564	LOC25845	-0.42	-6.4	-0.33	5.37e-10	Cystic fibrosis severity;
LUSC	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg03806693	chr22:41940476	POLR3H	-0.55	-7.51	-0.38	5.5e-13	Neuroticism;
LUSC	trans	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg27411982	chr8:10470053	RP1L1	0.39	6.23	0.32	1.38e-9	Systolic blood pressure;
LUSC	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg10909506	chr17:38081995	ORMDL3	0.33	5.7	0.3	2.68e-8	Lymphocyte counts;
LUSC	cis	rs2354432	0.607	rs11587707	chr1:146707186	T/C	cg25205988	chr1:146714368	CHD1L	-1.02	-8.96	-0.44	2.35e-17	Mitochondrial DNA levels;
LUSC	cis	rs7193541	0.826	rs56143602	chr16:74694692	T/C	cg01733217	chr16:74700730	RFWD3	0.86	15.02	0.63	2.51e-39	Multiple myeloma;
LUSC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg23711669	chr6:146136114	FBXO30	-0.91	-17.44	-0.69	6.92e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-9.95	-0.48	1.31e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg01528321	chr10:82214614	TSPAN14	0.86	13.08	0.58	7.25e-32	Post bronchodilator FEV1;
LUSC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.78	-0.43	8.41e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.47	7.04	0.36	1.08e-11	Height;
LUSC	cis	rs11630290	0.736	rs28621516	chr15:64156314	G/A	cg12036633	chr15:63758958	NA	-0.64	-6.98	-0.36	1.61e-11	Iris characteristics;
LUSC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg14664628	chr15:75095509	CSK	0.55	8.41	0.42	1.18e-15	Breast cancer;
LUSC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.17	-0.49	2.5e-21	Hemoglobin concentration;
LUSC	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg27661460	chr16:88844969	FAM38A	0.48	7.16	0.36	5.13e-12	Glycated hemoglobin levels;
LUSC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.85	-0.35	3.62e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2820315	0.867	rs2820322	chr1:201880300	T/C	cg10061532	chr1:201886748	LMOD1	0.28	6.45	0.33	3.87e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13398864	chr3:122920640	SEC22A	0.44	6.74	0.35	6.79e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	11.5	0.53	5.02e-26	Personality dimensions;
LUSC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.81	-0.51	1.5e-23	Alzheimer's disease (late onset);
LUSC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg19622623	chr12:86230825	RASSF9	-0.42	-5.97	-0.31	5.98e-9	Major depressive disorder;
LUSC	cis	rs12618769	1.000	rs72825718	chr2:99247152	C/T	cg10123293	chr2:99228465	UNC50	0.41	5.7	0.3	2.57e-8	Bipolar disorder;
LUSC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.85	-0.39	5.62e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg20283391	chr11:68216788	NA	-0.5	-6.97	-0.36	1.71e-11	Total body bone mineral density;
LUSC	trans	rs724744	0.742	rs714591	chr6:22360046	T/A	cg13807341	chr11:118445984	ARCN1	-0.35	-5.97	-0.31	6.14e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg06713675	chr4:122721982	EXOSC9	-0.47	-8.26	-0.41	3.38e-15	Type 2 diabetes;
LUSC	cis	rs6539267	0.516	rs17218455	chr12:106716441	C/T	cg00173435	chr12:106696525	TCP11L2	0.6	7.24	0.37	3.17e-12	Tourette syndrome;
LUSC	cis	rs4478858	0.775	rs12139418	chr1:31706352	T/C	cg00250761	chr1:31883323	NA	-0.36	-9.35	-0.46	1.34e-18	Alcohol dependence;
LUSC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	0.95	16.09	0.66	1.58e-43	Cognitive function;
LUSC	cis	rs642803	0.551	rs1308020	chr11:65497558	G/A	cg02870584	chr11:65547924	DKFZp761E198	0.44	6.02	0.31	4.54e-9	Urate levels;
LUSC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg05623727	chr3:50126028	RBM5	0.32	5.96	0.31	6.24e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg24733560	chr20:60626293	TAF4	0.43	7.85	0.39	5.81e-14	Body mass index;
LUSC	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg19773385	chr1:10388646	KIF1B	-0.58	-9.72	-0.47	7.96e-20	Hepatocellular carcinoma;
LUSC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.05	-0.36	1.02e-11	Colorectal cancer;
LUSC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg12564285	chr5:131593104	PDLIM4	0.5	8.9	0.44	3.6e-17	Acylcarnitine levels;
LUSC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg08888203	chr3:10149979	C3orf24	0.62	8.51	0.42	5.77e-16	Alzheimer's disease;
LUSC	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.14	-0.32	2.34e-9	Triglycerides;
LUSC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg01097406	chr16:89675127	NA	-0.35	-6.85	-0.35	3.57e-11	Vitiligo;
LUSC	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-0.89	-12.36	-0.56	3.65e-29	Dilated cardiomyopathy;
LUSC	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg17507749	chr15:85114479	UBE2QP1	0.69	8.87	0.44	4.5e-17	Schizophrenia;
LUSC	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-8.29	-0.41	2.77e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs9630182	0.561	rs11022781	chr11:13402409	C/T	cg00234616	chr2:74740572	TLX2	-0.31	-6.27	-0.32	1.11e-9	Bone mineral density;
LUSC	cis	rs920590	0.573	rs12547934	chr8:19680736	T/C	cg03894339	chr8:19674705	INTS10	-0.45	-6.37	-0.33	6.26e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg21951975	chr1:209979733	IRF6	0.37	6.03	0.31	4.26e-9	Monobrow;
LUSC	cis	rs3755132	1.000	rs3770460	chr2:15729268	C/T	cg12888861	chr2:15731646	DDX1	-0.52	-7.52	-0.38	4.97e-13	Wilms tumor;
LUSC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg17971929	chr21:40555470	PSMG1	-0.62	-10.27	-0.49	1.06e-21	Cognitive function;
LUSC	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg01557791	chr16:72042693	DHODH	-0.46	-6.08	-0.32	3.2e-9	Blood protein levels;
LUSC	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-9.68	-0.47	1.09e-19	Total cholesterol levels;
LUSC	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg25251562	chr2:3704773	ALLC	0.39	6.93	0.35	2.12e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg17145862	chr1:211918768	LPGAT1	0.23	6.07	0.32	3.44e-9	Leprosy;
LUSC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg09365446	chr1:150670422	GOLPH3L	0.48	7.12	0.36	6.67e-12	Melanoma;
LUSC	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.73	12.01	0.55	7.58e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	8.13	0.41	8.4e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg03790207	chr6:42947109	PEX6	0.45	7.03	0.36	1.18e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg20203395	chr5:56204925	C5orf35	-0.45	-6.59	-0.34	1.69e-10	Coronary artery disease;
LUSC	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-9.76	-0.47	6.01e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg15848620	chr12:58087721	OS9	0.48	6.59	0.34	1.75e-10	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9462027	0.727	rs3798352	chr6:34734809	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.9	-0.31	8.69e-9	Systemic lupus erythematosus;
LUSC	cis	rs4654899	0.865	rs6700459	chr1:21279396	T/C	cg01072550	chr1:21505969	NA	-0.49	-7.28	-0.37	2.44e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg05896524	chr21:47604654	C21orf56	0.42	6.25	0.32	1.25e-9	Testicular germ cell tumor;
LUSC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg20295408	chr7:1910781	MAD1L1	0.51	7.48	0.38	6.79e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg12639453	chr1:2035780	PRKCZ	-0.3	-6.3	-0.33	9.13e-10	Height;
LUSC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg18675610	chr10:32216311	ARHGAP12	0.3	6.51	0.34	2.74e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4629710	0.592	rs11154622	chr6:131547578	C/T	cg12700074	chr6:131571435	AKAP7	-0.36	-6.05	-0.31	3.92e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.58	8.75	0.43	1.07e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg05043794	chr9:111880884	C9orf5	-0.34	-7.23	-0.37	3.33e-12	Menarche (age at onset);
LUSC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.27	-0.32	1.11e-9	Total body bone mineral density;
LUSC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-16.92	-0.68	7.95e-47	Gut microbiome composition (summer);
LUSC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.54	-9.72	-0.47	7.77e-20	Bipolar disorder;
LUSC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg14983838	chr19:29218262	NA	0.58	6.8	0.35	4.82e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9311676	0.609	rs55646457	chr3:58415263	T/A	cg26110898	chr3:58419937	PDHB	0.4	6.41	0.33	5.09e-10	Systemic lupus erythematosus;
LUSC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg18681998	chr4:17616180	MED28	0.85	16.13	0.66	1.06e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16680214	chr1:154839983	KCNN3	0.57	10.51	0.5	1.6e-22	Prostate cancer;
LUSC	trans	rs1998174	0.509	rs2206543	chr1:171835493	A/G	cg13482142	chr2:234261155	NA	-0.43	-6.32	-0.33	8.47e-10	Platelet distribution width;
LUSC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg05347473	chr6:146136440	FBXO30	-0.43	-7.41	-0.38	1.02e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11642862	1.000	rs11641321	chr16:30880319	G/A	cg02466173	chr16:30829666	NA	-0.69	-6.93	-0.35	2.24e-11	Tonsillectomy;
LUSC	trans	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg25214090	chr10:38739885	LOC399744	0.41	6.43	0.33	4.42e-10	Corneal astigmatism;
LUSC	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg25301532	chr20:43378953	KCNK15	0.36	6.28	0.33	1.03e-9	Obesity-related traits;
LUSC	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg12927641	chr6:109611667	NA	-0.36	-6.12	-0.32	2.69e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg05340658	chr4:99064831	C4orf37	0.59	8.75	0.43	1.04e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg22563815	chr15:78856949	CHRNA5	0.26	6.26	0.32	1.19e-9	Sudden cardiac arrest;
LUSC	cis	rs3768617	0.782	rs10911211	chr1:183022299	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.5	0.42	6.29e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06634786	chr22:41940651	POLR3H	-0.51	-5.99	-0.31	5.45e-9	Vitiligo;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg19165652	chr17:54671146	NOG	-0.49	-6.63	-0.34	1.38e-10	Neuroticism;
LUSC	cis	rs28647808	0.881	rs41316984	chr9:136259231	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.4	-0.42	1.26e-15	Neuroticism;
LUSC	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg15445000	chr17:37608096	MED1	0.38	6.63	0.34	1.34e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs1882538	0.503	rs13240997	chr7:133135373	C/A	cg10665199	chr7:133106180	EXOC4	0.61	8.18	0.41	5.83e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg06640241	chr16:89574553	SPG7	-0.4	-5.88	-0.31	1.02e-8	Hemoglobin concentration;
LUSC	cis	rs7428496	0.510	rs13075259	chr3:142170600	C/A	cg16271453	chr3:142027066	XRN1	-0.55	-9.42	-0.46	7.47e-19	Mean corpuscular hemoglobin;
LUSC	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg11584989	chr19:19387371	SF4	0.62	7.39	0.38	1.16e-12	Bipolar disorder;
LUSC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	5.8	0.3	1.54e-8	Menarche (age at onset);
LUSC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg13385521	chr17:29058706	SUZ12P	0.65	6.26	0.32	1.18e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.77	-0.35	5.91e-11	Response to antipsychotic treatment;
LUSC	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg22906224	chr7:99728672	NA	-0.47	-6.56	-0.34	2.03e-10	Coronary artery disease;
LUSC	cis	rs259282	0.519	rs259276	chr19:33160953	C/G	cg22980127	chr19:33182716	NUDT19	-0.49	-6.3	-0.33	9.65e-10	Schizophrenia;
LUSC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg26373071	chr5:1325741	CLPTM1L	0.41	7.72	0.39	1.41e-13	Lung cancer;
LUSC	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.94	-0.74	8.36e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg22963979	chr7:1858916	MAD1L1	-0.73	-12.52	-0.57	9.78e-30	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.75	-11.65	-0.54	1.48e-26	Menarche (age at onset);
LUSC	cis	rs16867321	0.901	rs768116	chr2:181511012	A/G	cg23363182	chr2:181467187	NA	-0.45	-5.91	-0.31	8.53e-9	Obesity;
LUSC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.49	-0.33	3.17e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg22834771	chr12:69754056	YEATS4	-0.41	-5.82	-0.3	1.36e-8	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02986546	chr7:87505538	SLC25A40;DBF4	-0.44	-6.39	-0.33	5.64e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7903847	0.642	rs10786344	chr10:99165975	T/C	cg20016023	chr10:99160130	RRP12	-0.3	-7.44	-0.38	8.68e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs67072384	1.000	rs12294368	chr11:72451239	G/A	cg04827223	chr11:72435913	ARAP1	-0.78	-6.71	-0.34	8.47e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg17554472	chr22:41940697	POLR3H	0.47	5.8	0.3	1.53e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg18681998	chr4:17616180	MED28	0.87	15.74	0.65	3.84e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg07169764	chr2:136633963	MCM6	0.54	7.62	0.38	2.66e-13	Mosquito bite size;
LUSC	cis	rs9420	1.000	rs9420	chr11:57510294	A/G	cg23127183	chr11:57508653	C11orf31	0.54	8.15	0.41	7.56e-15	Schizophrenia;
LUSC	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg23649088	chr2:200775458	C2orf69	0.53	7.23	0.37	3.26e-12	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	0.57	9.09	0.45	8.73e-18	Breast cancer;
LUSC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.11	15.45	0.65	5.04e-41	Lung cancer in ever smokers;
LUSC	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg06002616	chr8:101225028	SPAG1	0.39	6.57	0.34	1.97e-10	Atrioventricular conduction;
LUSC	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07080220	chr10:102295463	HIF1AN	0.68	9.2	0.45	3.94e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.76	-13.45	-0.59	2.85e-33	Dental caries;
LUSC	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg18721089	chr20:30220636	NA	-0.35	-6.01	-0.31	4.91e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.52	-7.83	-0.39	6.5e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg04362960	chr10:104952993	NT5C2	0.61	9.0	0.44	1.69e-17	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-9.54	-0.46	3.05e-19	Bipolar disorder;
LUSC	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg04827223	chr11:72435913	ARAP1	-0.71	-9.08	-0.45	9.39e-18	Type 2 diabetes;
LUSC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.55	11.34	0.53	1.97e-25	Coronary artery disease;
LUSC	cis	rs7592578	0.603	rs12476782	chr2:191472880	G/A	cg11845111	chr2:191398756	TMEM194B	-0.74	-9.88	-0.48	2.37e-20	Diastolic blood pressure;
LUSC	trans	rs1532331	0.933	rs6451675	chr5:43110855	C/G	cg02477305	chr13:23993013	SACS	0.36	6.32	0.33	8.13e-10	Menarche (age at onset);
LUSC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs1775715	0.737	rs2808028	chr10:32101189	G/A	cg18675610	chr10:32216311	ARHGAP12	0.29	6.34	0.33	7.56e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg16606324	chr3:10149918	C3orf24	-0.46	-6.62	-0.34	1.42e-10	Alzheimer's disease;
LUSC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg01416388	chr22:39784598	NA	-0.46	-7.84	-0.39	6.3e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg01620082	chr3:125678407	NA	-0.82	-7.24	-0.37	3.06e-12	Depression;
LUSC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.48	9.42	0.46	7.63e-19	Monocyte percentage of white cells;
LUSC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg14004847	chr7:1930337	MAD1L1	-0.56	-8.75	-0.43	1.09e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs9921222	0.786	rs3848365	chr16:374617	C/T	cg02086790	chr16:375327	AXIN1	-0.38	-6.48	-0.33	3.26e-10	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs216026	0.638	rs12312322	chr12:2771806	A/G	cg19945202	chr12:2788847	CACNA1C	-0.37	-5.72	-0.3	2.36e-8	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03352830	chr11:487213	PTDSS2	0.68	8.61	0.43	2.91e-16	Body mass index;
LUSC	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg18721089	chr20:30220636	NA	-0.37	-6.33	-0.33	7.87e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.49	9.55	0.46	2.87e-19	Eosinophil percentage of white cells;
LUSC	cis	rs698833	0.501	rs12473699	chr2:44507673	G/A	cg04920474	chr2:44395004	PPM1B	0.56	9.34	0.46	1.39e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg08738300	chr3:44038990	NA	-0.72	-9.45	-0.46	6.08e-19	Coronary artery disease;
LUSC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-9.47	-0.46	5.21e-19	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19346786	chr7:2764209	NA	-0.43	-7.25	-0.37	2.85e-12	Height;
LUSC	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg04450456	chr4:17643702	FAM184B	0.38	6.52	0.34	2.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs116161686	0.521	rs701941	chr1:210439529	G/A	cg22029157	chr1:209979665	IRF6	0.54	6.14	0.32	2.35e-9	Coronary artery disease;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25135922	chr1:226497286	LIN9	0.71	6.08	0.32	3.31e-9	Cognitive performance;
LUSC	cis	rs7523273	0.925	rs2745977	chr1:208017360	C/A	cg22525895	chr1:207977042	MIR29B2	-0.4	-6.07	-0.32	3.51e-9	Schizophrenia;
LUSC	cis	rs67072384	1.000	rs72966113	chr11:72450970	C/T	cg04827223	chr11:72435913	ARAP1	-0.78	-6.71	-0.34	8.47e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg05163923	chr11:71159392	DHCR7	-0.75	-9.79	-0.47	4.63e-20	Vitamin D levels;
LUSC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.89	-0.35	2.73e-11	Schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24185116	chr15:52044314	LYSMD2;TMOD2	-0.41	-6.8	-0.35	4.7e-11	Electrocardiographic conduction measures;
LUSC	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.76	-0.35	6.29e-11	Monocyte percentage of white cells;
LUSC	cis	rs11158026	0.757	rs7157085	chr14:55444746	G/A	cg04306507	chr14:55594613	LGALS3	0.38	7.47	0.38	6.85e-13	Parkinson's disease;
LUSC	cis	rs36093844	0.848	rs55836023	chr11:85566157	A/G	cg25872744	chr11:85566296	CCDC83	-0.51	-7.01	-0.36	1.32e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs2227564	0.620	rs3812637	chr10:75568846	C/T	cg23231163	chr10:75533350	FUT11	-0.44	-6.38	-0.33	5.94e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg20891558	chr2:74357851	NA	0.85	15.73	0.65	4.07e-42	Gestational age at birth (maternal effect);
LUSC	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg06363034	chr20:62225388	GMEB2	-0.44	-7.2	-0.37	4.01e-12	Glioblastoma;
LUSC	cis	rs2562456	0.793	rs2562420	chr19:21631305	T/A	cg00806126	chr19:22604979	ZNF98	0.37	5.85	0.3	1.19e-8	Pain;
LUSC	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.61	-0.34	1.52e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg10621924	chr7:39171070	POU6F2	0.48	7.62	0.38	2.68e-13	IgG glycosylation;
LUSC	cis	rs7247513	0.964	rs8105902	chr19:12718351	G/A	cg01871581	chr19:12707946	ZNF490	-0.54	-8.33	-0.41	2.16e-15	Bipolar disorder;
LUSC	trans	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg06606381	chr12:133084897	FBRSL1	-0.75	-6.68	-0.34	1.03e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4234798	0.500	rs34694340	chr4:7221424	A/C	cg18431297	chr4:7219810	SORCS2	0.34	6.41	0.33	4.9e-10	Insulin-like growth factors;
LUSC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg17330251	chr7:94953956	PON1	-0.37	-5.99	-0.31	5.57e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2710642	0.962	rs2058567	chr2:63091426	T/C	cg17519650	chr2:63277830	OTX1	0.47	6.41	0.33	4.83e-10	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg25208724	chr1:156163844	SLC25A44	1.05	21.75	0.77	6.06e-66	Testicular germ cell tumor;
LUSC	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg27446573	chr6:127587934	RNF146	-0.6	-9.05	-0.44	1.18e-17	Breast cancer;
LUSC	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg12940439	chr1:67600707	NA	0.36	6.26	0.32	1.16e-9	Psoriasis;
LUSC	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.51	8.03	0.4	1.64e-14	Response to antipsychotic treatment;
LUSC	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg11887960	chr12:57824829	NA	0.55	7.24	0.37	3.18e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.74	12.06	0.55	4.93e-28	Coronary artery disease;
LUSC	trans	rs4942242	1.000	rs7331003	chr13:44230253	C/T	cg19169023	chr15:41853346	TYRO3	-0.5	-8.14	-0.41	8.16e-15	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg06784218	chr1:46089804	CCDC17	-0.53	-9.91	-0.48	1.8899999999999998e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9905704	0.671	rs2531736	chr17:56552204	A/G	cg19466818	chr17:56409534	MIR142	0.36	6.61	0.34	1.53e-10	Testicular germ cell tumor;
LUSC	cis	rs727505	0.721	rs11534064	chr7:124767997	G/T	cg23710748	chr7:124431027	NA	0.38	6.93	0.35	2.15e-11	Lewy body disease;
LUSC	cis	rs1335645	0.570	rs2165145	chr1:111625213	C/T	cg00321911	chr1:111669324	DRAM2	-0.58	-6.23	-0.32	1.38e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7939886	0.920	rs11231821	chr11:55777052	C/G	cg15704280	chr7:45808275	SEPT13	0.85	7.39	0.37	1.21e-12	Myopia (pathological);
LUSC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06634786	chr22:41940651	POLR3H	0.49	5.73	0.3	2.21e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	0.78	13.94	0.61	4.02e-35	Cognitive function;
LUSC	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2274273	0.712	rs17832311	chr14:55534466	A/G	cg04306507	chr14:55594613	LGALS3	0.5	10.74	0.51	2.52e-23	Protein biomarker;
LUSC	cis	rs6977660	0.714	rs13225018	chr7:19816567	C/T	cg07541023	chr7:19748670	TWISTNB	0.63	6.74	0.35	7.05e-11	Thyroid stimulating hormone;
LUSC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg13072238	chr3:49761600	GMPPB	-0.36	-5.75	-0.3	2.02e-8	Body mass index;
LUSC	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg01966878	chr4:90757139	SNCA	-0.4	-5.67	-0.3	3.07e-8	Neuroticism;
LUSC	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg04362960	chr10:104952993	NT5C2	0.62	9.73	0.47	7.36e-20	Arsenic metabolism;
LUSC	cis	rs7760949	0.888	rs6939712	chr6:13897246	T/C	cg27413430	chr6:13925136	RNF182	0.5	7.43	0.38	9.34e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg12751644	chr20:60527061	NA	-0.35	-6.44	-0.33	4.23e-10	Body mass index;
LUSC	cis	rs9534288	0.830	rs2404963	chr13:46632836	C/T	cg15192986	chr13:46630673	CPB2	-0.8	-12.69	-0.57	2.14e-30	Blood protein levels;
LUSC	trans	rs6600671	0.899	rs6674392	chr1:121260662	C/G	cg00646200	chr1:148855367	NA	0.49	7.82	0.39	6.85e-14	Hip geometry;
LUSC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg07701084	chr6:150067640	NUP43	0.57	8.76	0.43	9.76e-17	Lung cancer;
LUSC	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.63	9.59	0.46	2.07e-19	Corneal astigmatism;
LUSC	cis	rs6500395	1.000	rs7188741	chr16:48607966	T/C	cg04672837	chr16:48644449	N4BP1	0.46	6.89	0.35	2.76e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg05501817	chr11:14380813	RRAS2	-0.56	-8.87	-0.44	4.61e-17	Sense of smell;
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg04576048	chr1:205797593	PM20D1	0.34	6.21	0.32	1.59e-9	Menarche (age at onset);
LUSC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs17828380	0.925	rs12901035	chr15:63541446	A/C	cg05507819	chr15:63340323	TPM1	-0.69	-5.87	-0.31	1.05e-8	Social communication problems;
LUSC	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg14689365	chr7:158441557	NCAPG2	-0.45	-6.13	-0.32	2.46e-9	Height;
LUSC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.46	7.2	0.37	4.13e-12	Response to antipsychotic treatment;
LUSC	cis	rs3741151	0.686	rs7941359	chr11:73158119	A/G	cg17517138	chr11:73019481	ARHGEF17	0.81	7.25	0.37	2.87e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg26752003	chr8:145688521	CYHR1	0.55	9.26	0.45	2.52e-18	Age at first birth;
LUSC	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg15445000	chr17:37608096	MED1	-0.39	-6.8	-0.35	4.94e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg02951883	chr7:2050386	MAD1L1	-0.46	-8.08	-0.4	1.2e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05901451	chr6:126070800	HEY2	0.58	8.59	0.43	3.43e-16	Endometrial cancer;
LUSC	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg22709100	chr7:91322751	NA	0.4	5.85	0.3	1.17e-8	Breast cancer;
LUSC	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg17252645	chr8:143867129	LY6D	0.37	6.05	0.31	3.87e-9	Urinary tract infection frequency;
LUSC	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.39	0.46	9.91e-19	Coffee consumption (cups per day);
LUSC	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-0.95	-18.47	-0.71	5.31e-53	Brugada syndrome;
LUSC	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg13072238	chr3:49761600	GMPPB	0.43	7.15	0.36	5.45e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10865397	0.506	rs13414160	chr2:73383261	C/A	cg24220031	chr2:73402428	NA	-0.27	-6.28	-0.33	1.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg25036284	chr2:26402008	FAM59B	-0.7	-9.68	-0.47	1.04e-19	Gut microbiome composition (summer);
LUSC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.71	10.69	0.5	3.95e-23	Aortic root size;
LUSC	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg17173187	chr15:85201210	NMB	0.36	6.59	0.34	1.72e-10	Schizophrenia;
LUSC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg09359103	chr1:154839909	KCNN3	-0.7	-16.24	-0.66	4.09e-44	Prostate cancer;
LUSC	cis	rs68170813	0.652	rs116894096	chr7:107178477	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-8.63	-0.43	2.46e-16	Coronary artery disease;
LUSC	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg13575925	chr12:9217583	LOC144571	0.33	6.09	0.32	3.06e-9	Sjögren's syndrome;
LUSC	cis	rs11971779	0.793	rs11772447	chr7:139033589	T/G	cg07862535	chr7:139043722	LUC7L2	0.59	7.11	0.36	6.97e-12	Diisocyanate-induced asthma;
LUSC	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg23625390	chr15:77176239	SCAPER	-0.63	-9.23	-0.45	3.1e-18	Blood metabolite levels;
LUSC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00166722	chr3:10149974	C3orf24	0.61	8.28	0.41	2.95e-15	Alzheimer's disease;
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg25243455	chr2:114033360	PAX8;LOC440839	-0.34	-7.62	-0.38	2.69e-13	Lymphocyte counts;
LUSC	cis	rs11809207	0.723	rs57653638	chr1:26524401	A/G	cg00147160	chr1:26503991	CNKSR1	0.42	6.86	0.35	3.26e-11	Height;
LUSC	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg15704280	chr7:45808275	SEPT13	0.63	7.17	0.37	5e-12	Axial length;
LUSC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.88	0.48	2.29e-20	Personality dimensions;
LUSC	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.33	5.75	0.3	1.97e-8	Total body bone mineral density;
LUSC	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg03465714	chr1:152285911	FLG	0.41	5.81	0.3	1.43e-8	Atopic dermatitis;
LUSC	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.08	0.4	1.2e-14	Triglycerides;
LUSC	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.7	-11.88	-0.54	2.26e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10484885	0.824	rs72919976	chr6:90526686	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-7.94	-0.4	3.01e-14	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs240764	0.817	rs11155596	chr6:101152631	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-6.04	-0.31	4.09e-9	Neuroticism;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg00024416	chr22:24240387	NA	-0.31	-5.71	-0.3	2.53e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg10755058	chr3:40428713	ENTPD3	0.35	5.89	0.31	9.27e-9	Renal cell carcinoma;
LUSC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2073300	1.000	rs6036423	chr20:23459810	A/C	cg09953122	chr20:23471693	CST8	-0.69	-6.84	-0.35	3.84e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg02038168	chr22:39784481	NA	-0.46	-6.89	-0.35	2.77e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9583531	0.891	rs61969076	chr13:111391568	C/T	cg24331049	chr13:111365604	ING1	-0.63	-6.75	-0.35	6.53e-11	Coronary artery disease;
LUSC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg10596483	chr8:143751796	JRK	0.61	9.41	0.46	8.19e-19	Schizophrenia;
LUSC	trans	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg26811252	chr16:29126840	RRN3P2	0.64	10.32	0.49	7.6e-22	Menopause (age at onset);
LUSC	cis	rs73001065	0.901	rs73004933	chr19:19675696	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	6.92	0.35	2.27e-11	LDL cholesterol;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg23682940	chr15:101419483	ALDH1A3	-0.54	-6.46	-0.33	3.7e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg25838465	chr1:92012736	NA	-0.74	-15.16	-0.64	7.24e-40	Breast cancer;
LUSC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg03289416	chr15:75166202	SCAMP2	0.45	6.87	0.35	3.13e-11	Breast cancer;
LUSC	cis	rs1160297	0.576	rs12990843	chr2:53108688	A/G	cg07782112	chr2:53107842	NA	0.43	7.26	0.37	2.66e-12	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs11828289	0.660	rs28825707	chr11:23224075	G/A	cg20040320	chr11:23191996	NA	-0.61	-6.3	-0.33	9.26e-10	Cancer;
LUSC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg00129232	chr17:37814104	STARD3	-0.5	-7.4	-0.38	1.09e-12	Asthma;
LUSC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg06784218	chr1:46089804	CCDC17	0.55	11.51	0.53	4.8e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-7.14	-0.36	5.91e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7523050	0.908	rs12404382	chr1:109397129	G/A	cg08274380	chr1:109419600	GPSM2	0.87	9.52	0.46	3.5e-19	Fat distribution (HIV);
LUSC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg06008330	chr7:65541103	ASL	-0.4	-6.37	-0.33	6.37e-10	Aortic root size;
LUSC	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-7.07	-0.36	9.36e-12	Response to antipsychotic treatment;
LUSC	cis	rs3087591	0.879	rs59015798	chr17:29580882	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.63	-9.05	-0.44	1.2e-17	Hip circumference;
LUSC	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	13.07	0.58	8.1e-32	Bipolar disorder;
LUSC	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg23093090	chr10:104574429	C10orf26	-0.36	-6.68	-0.34	1e-10	Arsenic metabolism;
LUSC	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg24296786	chr1:45957014	TESK2	0.48	7.01	0.36	1.29e-11	High light scatter reticulocyte count;
LUSC	cis	rs10492096	0.783	rs11064220	chr12:6592574	C/T	cg13857086	chr12:6580257	VAMP1	0.58	6.76	0.35	6.09e-11	Hip geometry;
LUSC	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs9487051	0.735	rs459956	chr6:109524760	A/G	cg01475377	chr6:109611718	NA	-0.35	-5.89	-0.31	9.36e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	trans	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg26043149	chr18:55253948	FECH	0.48	6.97	0.36	1.69e-11	Bone mineral density;
LUSC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg04546413	chr19:29218101	NA	0.72	11.5	0.53	5.38e-26	Methadone dose in opioid dependence;
LUSC	trans	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg26043149	chr18:55253948	FECH	0.51	7.66	0.39	2.01e-13	Bone mineral density;
LUSC	cis	rs17255340	0.520	rs1170498	chr6:83987602	T/C	cg08257003	chr6:84140564	ME1	0.33	8.18	0.41	6.19e-15	Platelet-derived growth factor BB levels;
LUSC	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg08975724	chr8:8085496	FLJ10661	0.47	6.66	0.34	1.16e-10	Neuroticism;
LUSC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg09034736	chr1:150693464	HORMAD1	0.49	7.17	0.37	4.82e-12	Tonsillectomy;
LUSC	cis	rs9925964	0.967	rs12716981	chr16:31118024	C/A	cg03418659	chr16:31128414	MYST1	0.4	6.36	0.33	6.62e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg26528668	chr16:1614120	IFT140	0.48	8.21	0.41	4.79e-15	Coronary artery disease;
LUSC	cis	rs3740713	1.000	rs35593189	chr11:18468378	C/T	cg23797887	chr11:18477753	LDHAL6A	-0.59	-7.14	-0.36	5.93e-12	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.16	-14.73	-0.63	3.53e-38	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg02997394	chr19:33096574	ANKRD27	0.79	8.95	0.44	2.44e-17	Eosinophilic esophagitis;
LUSC	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg24579218	chr15:68104479	NA	-0.37	-6.25	-0.32	1.26e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs7572644	0.699	rs12465000	chr2:28199424	G/A	cg27432699	chr2:27873401	GPN1	-0.51	-6.9	-0.35	2.65e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs2667011	0.512	rs3792161	chr2:160809223	C/T	cg06573604	chr2:160760825	LY75	0.45	6.28	0.32	1.07e-9	Bilirubin levels;
LUSC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.8	0.3	1.5e-8	Menopause (age at onset);
LUSC	cis	rs7582180	0.903	rs2309821	chr2:100900304	A/G	cg08017756	chr2:100939284	LONRF2	-0.36	-6.11	-0.32	2.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2235649	0.833	rs55684627	chr16:1848817	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.03	-0.31	4.44e-9	Blood metabolite levels;
LUSC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-13.21	-0.59	2.33e-32	Chronic sinus infection;
LUSC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg23711669	chr6:146136114	FBXO30	0.75	13.38	0.59	5.42e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-0.57	-8.08	-0.4	1.18e-14	IgG glycosylation;
LUSC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-11.15	-0.52	9.49e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.76	10.26	0.49	1.19e-21	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg09824328	chr1:43425412	SLC2A1	-0.45	-5.67	-0.3	3.06e-8	Monocyte count;
LUSC	cis	rs6545883	0.929	rs6705235	chr2:61713580	G/C	cg15711740	chr2:61764176	XPO1	-0.45	-6.84	-0.35	3.85e-11	Tuberculosis;
LUSC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg04733989	chr22:42467013	NAGA	0.55	8.57	0.42	3.78e-16	Schizophrenia;
LUSC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg02475777	chr4:1388615	CRIPAK	0.38	5.65	0.3	3.37e-8	Obesity-related traits;
LUSC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.52	0.59	1.57e-33	Platelet count;
LUSC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21963583	chr11:68658836	MRPL21	0.56	8.33	0.41	2.15e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs72772090	0.539	rs10515249	chr5:96125259	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.65	-6.96	-0.36	1.82e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.26	-0.32	1.17e-9	Neuroticism;
LUSC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.67	10.77	0.51	2.06e-23	Osteoporosis;
LUSC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg16647868	chr5:131706066	SLC22A5	-0.38	-5.73	-0.3	2.29e-8	Blood metabolite levels;
LUSC	cis	rs12620999	0.555	rs10199274	chr2:238111864	G/C	cg23555395	chr2:238036564	NA	-0.31	-5.8	-0.3	1.53e-8	Systemic lupus erythematosus;
LUSC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg18512352	chr11:47633146	NA	-0.46	-9.19	-0.45	4.42e-18	Subjective well-being;
LUSC	cis	rs939574	0.790	rs2385397	chr2:220087796	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.8	-5.93	-0.31	7.69e-9	Platelet distribution width;
LUSC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg26408565	chr15:76604113	ETFA	-0.5	-8.04	-0.4	1.61e-14	Blood metabolite levels;
LUSC	cis	rs3857536	0.776	rs7765531	chr6:66932886	G/A	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.56e-10	Blood trace element (Cu levels);
LUSC	cis	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg06521331	chr12:34319734	NA	-0.47	-7.52	-0.38	5.03e-13	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg20243544	chr17:37824526	PNMT	0.52	7.53	0.38	4.88e-13	Asthma;
LUSC	cis	rs34779708	0.733	rs12243593	chr10:35549045	C/T	cg03585969	chr10:35415529	CREM	0.53	7.38	0.37	1.3e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg18099408	chr3:52552593	STAB1	0.35	6.0	0.31	5.23e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4423214	0.592	rs10898211	chr11:71210677	T/C	cg05163923	chr11:71159392	DHCR7	-0.68	-7.16	-0.36	5.29e-12	Vitamin D levels;
LUSC	cis	rs2274273	1.000	rs15870	chr14:55619311	A/G	cg04306507	chr14:55594613	LGALS3	0.54	11.95	0.55	1.23e-27	Protein biomarker;
LUSC	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.1	26.19	0.82	5.97e-83	Colorectal cancer;
LUSC	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg13206674	chr6:150067644	NUP43	0.49	7.02	0.36	1.21e-11	Lung cancer;
LUSC	cis	rs11166629	1.000	rs11166629	chr8:135636964	C/T	cg27224718	chr8:135614730	ZFAT	0.66	11.2	0.52	5.95e-25	Smoking quantity;
LUSC	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.76	-0.43	9.87e-17	Response to antipsychotic treatment;
LUSC	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg08392591	chr16:89556376	ANKRD11	0.39	5.82	0.3	1.36e-8	Multiple myeloma (IgH translocation);
LUSC	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg13010199	chr12:38710504	ALG10B	0.57	8.51	0.42	6.15e-16	Morning vs. evening chronotype;
LUSC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.49	0.33	3.07e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9888739	1.000	rs9940397	chr16:31303201	T/C	cg15817542	chr16:31343056	ITGAM	-0.51	-6.06	-0.31	3.69e-9	Systemic lupus erythematosus;
LUSC	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg09469691	chr10:81107165	PPIF	0.69	10.46	0.5	2.42e-22	Height;
LUSC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	8.86e-24	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg20503657	chr10:835505	NA	-0.67	-10.62	-0.5	6.87e-23	Eosinophil percentage of granulocytes;
LUSC	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.47	6.31	0.33	8.91e-10	Lung disease severity in cystic fibrosis;
LUSC	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg27068330	chr11:65405492	SIPA1	-0.75	-10.5	-0.5	1.75e-22	Acne (severe);
LUSC	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg15839431	chr19:19639596	YJEFN3	-0.64	-7.21	-0.37	3.65e-12	Bipolar disorder;
LUSC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg19318889	chr4:1322082	MAEA	0.49	8.11	0.41	9.51e-15	Longevity;
LUSC	cis	rs13253111	0.624	rs4732844	chr8:28104473	A/G	cg26534493	chr8:28060551	NA	-0.39	-7.07	-0.36	9.26e-12	Childhood body mass index;
LUSC	cis	rs11166629	1.000	rs2873014	chr8:135645860	C/T	cg27224718	chr8:135614730	ZFAT	-0.63	-10.23	-0.49	1.52e-21	Smoking quantity;
LUSC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg06238570	chr21:40685208	BRWD1	-0.56	-8.74	-0.43	1.16e-16	Menarche (age at onset);
LUSC	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg08798685	chr6:27730294	NA	-0.64	-6.01	-0.31	4.93e-9	Breast cancer;
LUSC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	8.35	0.42	1.88e-15	Menopause (age at onset);
LUSC	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg03585969	chr10:35415529	CREM	0.6	8.67	0.43	1.86e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06022373	chr22:39101656	GTPBP1	0.78	12.08	0.55	3.89e-28	Menopause (age at onset);
LUSC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.18	29.35	0.85	1.67e-94	Testicular germ cell tumor;
LUSC	cis	rs2692947	0.702	rs4907291	chr2:96654605	T/G	cg22654517	chr2:96458247	NA	0.33	6.75	0.35	6.52e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg09835421	chr16:68378352	PRMT7	-0.51	-6.24	-0.32	1.33e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.39	-0.38	1.15e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.38	0.37	1.23e-12	Motion sickness;
LUSC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16405210	chr4:1374714	KIAA1530	-0.58	-9.51	-0.46	3.76e-19	Longevity;
LUSC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.77	-11.02	-0.52	2.8e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6977660	0.619	rs2158379	chr7:19783977	A/G	cg05791153	chr7:19748676	TWISTNB	0.67	6.98	0.36	1.63e-11	Thyroid stimulating hormone;
LUSC	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg08213375	chr14:104286397	PPP1R13B	0.51	10.05	0.48	6.22e-21	Schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03115081	chr17:74722049	C17orf95;JMJD6	0.48	7.0	0.36	1.4e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg12935359	chr14:103987150	CKB	-0.5	-7.75	-0.39	1.1e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg08273200	chr1:39338480	MYCBP	-0.44	-6.11	-0.32	2.75e-9	Hepatitis;
LUSC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.49	0.38	6.07e-13	Motion sickness;
LUSC	cis	rs2692947	0.550	rs4613327	chr2:96583823	G/A	cg23100626	chr2:96804247	ASTL	0.32	7.43	0.38	9.38e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg21132104	chr15:45694354	SPATA5L1	0.56	7.77	0.39	1.01e-13	Homoarginine levels;
LUSC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.53	9.36	0.46	1.16e-18	Bone mineral density;
LUSC	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg21427119	chr20:30132790	HM13	-0.42	-6.33	-0.33	7.85e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs870825	0.860	rs72703521	chr4:185603080	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	10.26	0.49	1.17e-21	Blood protein levels;
LUSC	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.55	9.5	0.46	4.33e-19	IgG glycosylation;
LUSC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg13628971	chr7:2884303	GNA12	-0.49	-7.13	-0.36	6.05e-12	Height;
LUSC	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.74	8.67	0.43	1.88e-16	Schizophrenia;
LUSC	cis	rs11030122	0.673	rs4910869	chr11:4006438	C/T	cg08557956	chr11:4115526	RRM1	-0.45	-5.74	-0.3	2.18e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg03354898	chr7:1950403	MAD1L1	-0.47	-9.64	-0.47	1.46e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg00074818	chr8:8560427	CLDN23	0.58	9.87	0.48	2.57e-20	Obesity-related traits;
LUSC	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg13206674	chr6:150067644	NUP43	0.58	8.9	0.44	3.55e-17	Lung cancer;
LUSC	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg15309053	chr8:964076	NA	0.36	7.24	0.37	3.19e-12	Schizophrenia;
LUSC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg04450456	chr4:17643702	FAM184B	0.39	6.5	0.34	2.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2742417	0.587	rs2742375	chr3:45784602	G/A	cg10512202	chr3:45649293	LIMD1	0.37	6.11	0.32	2.76e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs240764	0.681	rs12209887	chr6:101156806	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-6.08	-0.32	3.3e-9	Neuroticism;
LUSC	cis	rs354225	0.544	rs3796018	chr2:54807281	C/T	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg04455712	chr21:45112962	RRP1B	0.47	9.01	0.44	1.6e-17	Mean corpuscular volume;
LUSC	cis	rs6005807	0.719	rs9625521	chr22:29039953	T/G	cg12565055	chr22:29076175	TTC28	0.54	5.86	0.31	1.12e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg07424592	chr7:64974309	NA	0.66	5.83	0.3	1.32e-8	Diabetic kidney disease;
LUSC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg06212747	chr3:49208901	KLHDC8B	0.44	6.1	0.32	2.92e-9	Parkinson's disease;
LUSC	cis	rs11645898	0.748	rs72787056	chr16:72099694	C/T	cg14768367	chr16:72042858	DHODH	-0.69	-7.5	-0.38	5.95e-13	Blood protein levels;
LUSC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg11752832	chr7:134001865	SLC35B4	0.54	8.17	0.41	6.31e-15	Mean platelet volume;
LUSC	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg24578937	chr1:2090814	PRKCZ	-0.3	-6.31	-0.33	8.66e-10	Coronary artery disease;
LUSC	cis	rs7786877	0.582	rs2075674	chr7:100225031	G/A	cg16850897	chr7:100343110	ZAN	-0.5	-6.12	-0.32	2.55e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg05855489	chr10:104503620	C10orf26	0.66	10.21	0.49	1.8e-21	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg21361702	chr7:150065534	REPIN1	0.49	6.78	0.35	5.31e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg09491104	chr22:46646882	C22orf40	-0.67	-7.08	-0.36	8.7e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20887711	chr4:1340912	KIAA1530	0.56	8.85	0.44	5.14e-17	Longevity;
LUSC	cis	rs7043114	0.525	rs7047089	chr9:95117980	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.61	-0.34	1.51e-10	Height;
LUSC	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg17507749	chr15:85114479	UBE2QP1	0.57	7.32	0.37	1.88e-12	Schizophrenia;
LUSC	cis	rs9400467	0.509	rs11153287	chr6:111704537	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.34	-6.19	-0.32	1.75e-9	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg22907277	chr7:1156413	C7orf50	0.7	10.3	0.49	8.95e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00172270	chr12:50101356	FMNL3	-0.42	-6.3	-0.33	9.53e-10	Electrocardiographic conduction measures;
LUSC	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.59	6.44	0.33	4.27e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg26879891	chr1:152191343	HRNR	-0.38	-6.77	-0.35	5.93e-11	Inflammatory skin disease;
LUSC	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.11	-0.32	2.73e-9	Mood instability;
LUSC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg20203395	chr5:56204925	C5orf35	-0.75	-10.33	-0.49	6.65e-22	Initial pursuit acceleration;
LUSC	cis	rs17095355	1.000	rs731793	chr10:111716667	C/G	cg00817464	chr10:111662876	XPNPEP1	0.58	7.31	0.37	2.03e-12	Biliary atresia;
LUSC	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-8.17	-0.41	6.4e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg02403541	chr12:121454288	C12orf43	-0.71	-10.82	-0.51	1.4e-23	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	0.92	15.38	0.64	1.02e-40	Breast cancer;
LUSC	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	0.78	11.99	0.55	8.75e-28	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03090513	chr2:208394450	CREB1	-0.46	-7.0	-0.36	1.4e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs981844	0.712	rs4469056	chr4:154745796	A/T	cg14289246	chr4:154710475	SFRP2	0.46	6.25	0.32	1.24e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00339695	chr16:24857497	SLC5A11	-0.62	-9.69	-0.47	1e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg07636037	chr3:49044803	WDR6	0.9	12.07	0.55	4.33e-28	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg26958806	chr6:27640298	NA	0.75	6.01	0.31	4.76e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg18190219	chr22:46762943	CELSR1	-0.54	-6.02	-0.31	4.61e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	1.28	21.0	0.75	5.36e-63	Type 1 diabetes nephropathy;
LUSC	trans	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	12.09	0.55	3.62e-28	Mean corpuscular volume;
LUSC	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg03585969	chr10:35415529	CREM	0.62	8.97	0.44	2.2e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg08345082	chr10:99160200	RRP12	-0.36	-7.3	-0.37	2.19e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs60154123	0.730	rs11119455	chr1:210457762	C/T	cg22029157	chr1:209979665	IRF6	0.52	5.88	0.31	9.74e-9	Coronary artery disease;
LUSC	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.06	-0.36	9.46e-12	Coronary artery disease;
LUSC	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.84	0.44	5.53e-17	Schizophrenia;
LUSC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.47	0.38	6.96e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6484504	0.600	rs366758	chr11:31222499	A/C	cg26647111	chr11:31128758	NA	-0.42	-6.03	-0.31	4.44e-9	Red blood cell count;
LUSC	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg00277334	chr10:82204260	NA	-0.37	-5.74	-0.3	2.08e-8	Post bronchodilator FEV1;
LUSC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg00033643	chr7:134001901	SLC35B4	0.46	7.19	0.37	4.19e-12	Mean platelet volume;
LUSC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg11494091	chr17:61959527	GH2	0.39	6.75	0.35	6.74e-11	Height;
LUSC	cis	rs11605924	0.819	rs12805422	chr11:45839889	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.51	-7.54	-0.38	4.42e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.42	6.06	0.31	3.77e-9	Systemic lupus erythematosus;
LUSC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg16647868	chr5:131706066	SLC22A5	0.4	6.31	0.33	9.09e-10	Breast cancer;
LUSC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08219700	chr8:58056026	NA	0.64	7.88	0.4	4.52e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs4363385	0.720	rs1338179	chr1:152981548	T/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.58	-0.38	3.48e-13	Inflammatory skin disease;
LUSC	cis	rs2299587	0.650	rs12548412	chr8:17796970	G/T	cg01800426	chr8:17659068	MTUS1	-0.49	-6.53	-0.34	2.44e-10	Economic and political preferences;
LUSC	cis	rs62400317	0.821	rs34455867	chr6:45172071	T/C	cg20913747	chr6:44695427	NA	-0.47	-7.58	-0.38	3.5e-13	Total body bone mineral density;
LUSC	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg27219399	chr15:67835830	MAP2K5	0.35	5.7	0.3	2.63e-8	Obesity;
LUSC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00149659	chr3:10157352	C3orf10	0.95	12.55	0.57	7.6e-30	Alzheimer's disease;
LUSC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg13395646	chr4:1353034	KIAA1530	0.5	7.26	0.37	2.77e-12	Obesity-related traits;
LUSC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.5	7.81	0.39	7.71e-14	Colorectal cancer;
LUSC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg22166914	chr1:53195759	ZYG11B	-0.7	-12.09	-0.55	3.61e-28	Monocyte count;
LUSC	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23158103	chr7:148848205	ZNF398	-0.5	-8.4	-0.42	1.33e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18932078	chr1:2524107	MMEL1	-0.3	-6.41	-0.33	4.96e-10	Ulcerative colitis;
LUSC	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg16447950	chr5:562315	NA	-0.48	-6.62	-0.34	1.47e-10	Obesity-related traits;
LUSC	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg04362960	chr10:104952993	NT5C2	0.61	9.53	0.46	3.35e-19	Arsenic metabolism;
LUSC	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg24848339	chr3:12840334	CAND2	0.35	7.9	0.4	4.04e-14	QRS complex (12-leadsum);
LUSC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21171335	chr12:122356390	WDR66	0.64	9.77	0.47	5.35e-20	Mean corpuscular volume;
LUSC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.56e-13	Motion sickness;
LUSC	cis	rs10779751	0.734	rs2261217	chr1:11127764	C/A	cg08854313	chr1:11322531	MTOR	0.81	12.1	0.55	3.52e-28	Body mass index;
LUSC	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg20302533	chr7:39170763	POU6F2	0.5	7.88	0.4	4.72e-14	IgG glycosylation;
LUSC	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.78	11.81	0.54	3.97e-27	Cognitive ability;
LUSC	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg13010199	chr12:38710504	ALG10B	0.69	10.64	0.5	6.03e-23	Bladder cancer;
LUSC	cis	rs34779708	0.897	rs7900480	chr10:35338699	A/G	cg04310649	chr10:35416472	CREM	0.43	6.87	0.35	3.11e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20264566	chr11:10316295	SBF2	-0.42	-6.14	-0.32	2.33e-9	Hepatitis;
LUSC	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-1.15	-17.63	-0.69	1.21e-49	Exhaled nitric oxide output;
LUSC	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg22709100	chr7:91322751	NA	0.39	5.8	0.3	1.56e-8	Breast cancer;
LUSC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg11752832	chr7:134001865	SLC35B4	0.59	9.29	0.45	2.08e-18	Mean platelet volume;
LUSC	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg18850127	chr7:39170497	POU6F2	0.4	6.0	0.31	5.21e-9	IgG glycosylation;
LUSC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg05163923	chr11:71159392	DHCR7	-0.77	-10.02	-0.48	7.56e-21	Vitamin D levels;
LUSC	cis	rs11969893	0.649	rs1321204	chr6:101468591	A/G	cg12253828	chr6:101329408	ASCC3	0.89	7.28	0.37	2.48e-12	Economic and political preferences (immigration/crime);
LUSC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg00383909	chr3:49044727	WDR6	0.84	7.81	0.39	7.28e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg22732515	chr19:44031385	ETHE1	0.63	10.24	0.49	1.42e-21	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs2262909	0.925	rs56073035	chr19:22276298	C/G	cg11619707	chr19:22235551	ZNF257	0.39	5.79	0.3	1.63e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13732083	chr21:47605072	C21orf56	-0.45	-6.6	-0.34	1.62e-10	Testicular germ cell tumor;
LUSC	trans	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg26384229	chr12:38710491	ALG10B	0.55	9.03	0.44	1.36e-17	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg22535103	chr8:58192502	C8orf71	0.61	6.95	0.36	1.95e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg26534856	chr2:44223049	LRPPRC	0.39	6.16	0.32	2.07e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs7584330	0.554	rs10176035	chr2:238433449	T/C	cg16989719	chr2:238392110	NA	-0.39	-5.69	-0.3	2.79e-8	Prostate cancer;
LUSC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg08470875	chr2:26401718	FAM59B	-0.67	-8.99	-0.44	1.82e-17	Gut microbiome composition (summer);
LUSC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg06808227	chr14:105710500	BRF1	-0.65	-9.61	-0.47	1.89e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg13395646	chr4:1353034	KIAA1530	-0.51	-7.34	-0.37	1.59e-12	Obesity-related traits;
LUSC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	trans	rs6600671	1.000	rs1591882	chr1:121183313	G/A	cg00646200	chr1:148855367	NA	0.44	7.0	0.36	1.37e-11	Hip geometry;
LUSC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.17	-0.41	6.64e-15	Chronic sinus infection;
LUSC	cis	rs9359856	0.564	rs1179902	chr6:90321545	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-8.0	-0.4	2.09e-14	Bipolar disorder;
LUSC	cis	rs73195822	0.667	rs7967386	chr12:111239162	G/A	cg12870014	chr12:110450643	ANKRD13A	0.71	6.82	0.35	4.17e-11	Itch intensity from mosquito bite;
LUSC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg06238570	chr21:40685208	BRWD1	0.49	7.37	0.37	1.37e-12	Cognitive function;
LUSC	cis	rs240764	0.817	rs6905221	chr6:101151537	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-6.17	-0.32	2.01e-9	Neuroticism;
LUSC	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	6.53	0.34	2.4e-10	Schizophrenia;
LUSC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.65	-10.98	-0.52	3.73e-24	Diastolic blood pressure;
LUSC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-0.93	-17.89	-0.7	1.08e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg13010199	chr12:38710504	ALG10B	-0.44	-6.56	-0.34	1.99e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1957429	0.520	rs230715	chr14:65320549	G/C	cg23373153	chr14:65346875	NA	-0.81	-7.45	-0.38	8.14e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs41271473	0.898	rs72750015	chr1:228811318	A/G	cg16512390	chr1:228756714	NA	0.52	6.27	0.32	1.1e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.05	-0.52	2.07e-24	Mean corpuscular volume;
LUSC	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-7.59	-0.38	3.16e-13	Parkinson's disease;
LUSC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.77	-13.67	-0.6	4.45e-34	Cognitive function;
LUSC	cis	rs10504229	0.516	rs58244172	chr8:57987805	G/A	cg22535103	chr8:58192502	C8orf71	-0.48	-6.46	-0.33	3.76e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg06713675	chr4:122721982	EXOSC9	-0.43	-7.75	-0.39	1.09e-13	Type 2 diabetes;
LUSC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg24531977	chr5:56204891	C5orf35	-0.7	-10.28	-0.49	1.01e-21	Coronary artery disease;
LUSC	trans	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.85	-0.39	5.56e-14	Retinal vascular caliber;
LUSC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg07507251	chr3:52567010	NT5DC2	0.36	6.26	0.32	1.2e-9	Bipolar disorder;
LUSC	cis	rs10740039	0.810	rs1006956	chr10:62367976	A/G	cg18175470	chr10:62150864	ANK3	0.43	6.5	0.33	3e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg27494647	chr7:150038898	RARRES2	0.52	7.82	0.39	7.1e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg18477163	chr1:228402036	OBSCN	0.53	9.23	0.45	3.15e-18	Diastolic blood pressure;
LUSC	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg15945262	chr7:1881887	MAD1L1	-0.45	-6.51	-0.34	2.84e-10	Thyroid stimulating hormone;
LUSC	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.35	6.71	0.34	8.48e-11	Coronary artery disease;
LUSC	trans	rs6126344	0.957	rs6021437	chr20:50407162	T/C	cg03643032	chr16:85954903	IRF8	0.3	5.97	0.31	6.16e-9	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs7043114	0.525	rs7863406	chr9:95053381	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.44	-0.33	4.16e-10	Height;
LUSC	cis	rs1413885	0.549	rs9436726	chr1:65853196	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.46	6.76	0.35	6.34e-11	Anticoagulant levels;
LUSC	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg04450456	chr4:17643702	FAM184B	0.43	7.21	0.37	3.8e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2688419	0.545	rs1849478	chr3:23067010	C/G	cg00327796	chr3:23032191	NA	-0.42	-7.36	-0.37	1.45e-12	Type 2 diabetes;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24110916	chr15:65282490	SPG21	0.36	6.18	0.32	1.84e-9	Triglycerides;
LUSC	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg17764715	chr19:33622953	WDR88	0.59	7.95	0.4	2.96e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg00277334	chr10:82204260	NA	-0.57	-8.67	-0.43	1.9e-16	Post bronchodilator FEV1;
LUSC	cis	rs68170813	0.559	rs6965001	chr7:106933196	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.82	-0.47	3.55e-20	Coronary artery disease;
LUSC	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.84	13.8	0.6	1.32e-34	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2692947	0.702	rs6717101	chr2:96505552	C/T	cg23100626	chr2:96804247	ASTL	0.26	6.5	0.34	2.93e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	1.27	11.48	0.53	5.96e-26	Cognitive function;
LUSC	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg25664220	chr3:72788482	NA	-0.69	-11.58	-0.54	2.57e-26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg11752832	chr7:134001865	SLC35B4	0.6	9.38	0.46	1.04e-18	Mean platelet volume;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26317613	chr5:79784006	FAM151B	-0.41	-6.47	-0.33	3.46e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg08975724	chr8:8085496	FLJ10661	0.43	6.13	0.32	2.53e-9	Retinal vascular caliber;
LUSC	trans	rs6601327	0.678	rs10106040	chr8:9612413	C/G	cg15556689	chr8:8085844	FLJ10661	0.47	6.51	0.34	2.71e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg10596483	chr8:143751796	JRK	0.52	7.52	0.38	4.98e-13	Schizophrenia;
LUSC	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.61	9.29	0.45	1.99e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg18209359	chr17:80159595	CCDC57	0.37	5.75	0.3	2.05e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06788803	chr1:45805948	MUTYH;TOE1	0.45	6.19	0.32	1.76e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6977660	1.000	rs2107403	chr7:19819025	G/C	cg05791153	chr7:19748676	TWISTNB	0.54	5.94	0.31	7.08e-9	Thyroid stimulating hormone;
LUSC	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg18681998	chr4:17616180	MED28	0.84	15.62	0.65	1.11e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.63	-6.71	-0.34	8.37e-11	Vitiligo;
LUSC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.59	-0.38	3.27e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9653442	0.900	rs10194635	chr2:100834217	T/A	cg22139774	chr2:100720529	AFF3	-0.46	-8.09	-0.4	1.15e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	8.7	0.43	1.56e-16	Total body bone mineral density;
LUSC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg03538708	chr1:25844672	NA	-0.37	-6.01	-0.31	4.92e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg12963246	chr6:28129442	ZNF389	0.55	7.63	0.39	2.55e-13	Parkinson's disease;
LUSC	cis	rs9311676	0.656	rs11915190	chr3:58409700	G/A	cg26110898	chr3:58419937	PDHB	0.4	6.57	0.34	1.89e-10	Systemic lupus erythematosus;
LUSC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	1.04	19.77	0.73	3.88e-58	Menopause (age at onset);
LUSC	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg01557791	chr16:72042693	DHODH	-0.43	-6.38	-0.33	6.06e-10	Fibrinogen levels;
LUSC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg24296786	chr1:45957014	TESK2	0.53	8.13	0.41	8.72e-15	High light scatter reticulocyte count;
LUSC	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg01884057	chr2:25150051	NA	0.42	9.13	0.45	6.57e-18	Body mass index;
LUSC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.17	-0.32	1.99e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs977987	0.735	rs11149831	chr16:75451461	G/A	cg04384234	chr16:75411784	CFDP1	-0.48	-7.42	-0.38	9.78e-13	Dupuytren's disease;
LUSC	trans	rs4729127	1.000	rs75903658	chr7:94006668	A/C	cg08120389	chr17:19881268	AKAP10	0.56	5.96	0.31	6.37e-9	Intelligence;
LUSC	cis	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg17469321	chr7:55412551	NA	0.66	10.58	0.5	9.49e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7608623	0.773	rs3795943	chr2:23919630	C/G	cg08917208	chr2:24149416	ATAD2B	-0.42	-5.74	-0.3	2.12e-8	Obesity-related traits;
LUSC	cis	rs7903847	0.642	rs7084654	chr10:99135262	G/A	cg20016023	chr10:99160130	RRP12	-0.34	-8.41	-0.42	1.2e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs877282	0.853	rs7079450	chr10:755932	T/A	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.55	8.31	0.41	2.44e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg09367891	chr1:107599246	PRMT6	0.51	7.92	0.4	3.58e-14	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12016809	chr21:47604291	C21orf56	0.43	6.41	0.33	5e-10	Testicular germ cell tumor;
LUSC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg16447950	chr5:562315	NA	-0.55	-7.66	-0.39	2.08e-13	Ulcerative colitis;
LUSC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.85	0.54	2.71e-27	Prudent dietary pattern;
LUSC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	0.84	13.93	0.61	4.28e-35	Tonsillectomy;
LUSC	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg16647868	chr5:131706066	SLC22A5	0.34	5.71	0.3	2.51e-8	Blood metabolite levels;
LUSC	cis	rs4285028	0.747	rs7647351	chr3:121422109	T/C	cg11130432	chr3:121712080	ILDR1	-0.53	-7.84	-0.39	6.07e-14	Multiple sclerosis;
LUSC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg03213289	chr20:61660250	NA	0.66	13.54	0.6	1.31e-33	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.34	0.37	1.61e-12	Motion sickness;
LUSC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg17968037	chr7:100024898	ZCWPW1	0.39	5.96	0.31	6.49e-9	Platelet count;
LUSC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11645453	chr3:52864694	ITIH4	0.34	8.09	0.4	1.13e-14	Bipolar disorder;
LUSC	cis	rs13006833	0.739	rs6434387	chr2:191205969	C/T	cg21644426	chr2:191273491	MFSD6	0.46	6.48	0.33	3.29e-10	Urinary metabolites;
LUSC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.53	0.42	5.04e-16	Prudent dietary pattern;
LUSC	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg05082376	chr22:42548792	NA	-0.36	-6.01	-0.31	4.9e-9	Cognitive function;
LUSC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg03563238	chr19:33554763	RHPN2	-0.34	-5.9	-0.31	8.78e-9	Colorectal cancer;
LUSC	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg05738196	chr6:26577821	NA	-0.53	-8.15	-0.41	7.36e-15	Schizophrenia;
LUSC	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12756686	chr19:29218302	NA	-0.57	-6.77	-0.35	5.8e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.75	0.6	2.12e-34	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg00898013	chr13:113819073	PROZ	0.54	8.33	0.41	2.1e-15	Platelet distribution width;
LUSC	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg03354898	chr7:1950403	MAD1L1	-0.29	-5.71	-0.3	2.43e-8	Schizophrenia;
LUSC	cis	rs13089785	1.000	rs17310144	chr3:123665902	A/C	cg02558132	chr3:123411198	MYLK	0.33	5.69	0.3	2.82e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg04691961	chr3:161091175	C3orf57	-0.36	-6.12	-0.32	2.6e-9	Morning vs. evening chronotype;
LUSC	cis	rs7011049	1.000	rs74457055	chr8:53842669	T/G	cg26025543	chr8:53854495	NA	0.52	6.3	0.33	9.5e-10	Systolic blood pressure;
LUSC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg04727924	chr7:799746	HEATR2	-0.55	-6.68	-0.34	1e-10	Cerebrospinal P-tau181p levels;
LUSC	trans	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-6.8	-0.35	4.82e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg24596788	chr1:163392923	NA	-0.38	-6.48	-0.33	3.3e-10	Motion sickness;
LUSC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	7.92	0.4	3.52e-14	Bipolar disorder;
LUSC	cis	rs3790645	1.000	rs364977	chr1:26893836	G/A	cg17456097	chr1:26900765	RPS6KA1	0.45	6.6	0.34	1.57e-10	Glucose homeostasis traits;
LUSC	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg01503450	chr10:980765	NA	-0.39	-5.72	-0.3	2.34e-8	Eosinophil percentage of granulocytes;
LUSC	trans	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.65	-9.53	-0.46	3.45e-19	Obesity-related traits;
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg23034840	chr1:205782522	SLC41A1	0.57	7.91	0.4	3.91e-14	Menarche (age at onset);
LUSC	cis	rs931127	0.719	rs7949980	chr11:65445950	T/C	cg05805236	chr11:65401703	PCNXL3	-0.42	-7.42	-0.38	9.55e-13	Systemic lupus erythematosus;
LUSC	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.7	13.48	0.59	2.24e-33	Age-related hearing impairment;
LUSC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.12	0.41	9.02e-15	Prudent dietary pattern;
LUSC	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg21573476	chr21:45109991	RRP1B	-0.41	-6.55	-0.34	2.22e-10	Mean corpuscular volume;
LUSC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24110177	chr3:50126178	RBM5	0.56	9.3	0.45	1.83e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg24558204	chr6:135376177	HBS1L	0.58	8.6	0.43	3.19e-16	Red blood cell count;
LUSC	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg04374321	chr14:90722782	PSMC1	0.7	10.93	0.51	5.62e-24	Mortality in heart failure;
LUSC	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg13256891	chr4:100009986	ADH5	-0.46	-6.12	-0.32	2.58e-9	Alcohol dependence;
LUSC	cis	rs7759001	0.857	rs10807020	chr6:27356902	A/G	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	1.97e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.09e-12	Motion sickness;
LUSC	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg23625390	chr15:77176239	SCAPER	-0.65	-10.05	-0.48	5.95e-21	Blood metabolite levels;
LUSC	cis	rs62432291	0.681	rs435521	chr6:159662638	C/T	cg14500486	chr6:159655392	FNDC1	0.53	5.99	0.31	5.3e-9	Joint mobility (Beighton score);
LUSC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg15448220	chr1:150897856	SETDB1	0.38	5.69	0.3	2.84e-8	Tonsillectomy;
LUSC	cis	rs12980942	0.810	rs8105901	chr19:41792092	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.65	6.9	0.35	2.57e-11	Coronary artery disease;
LUSC	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.8	0.35	4.84e-11	IgG glycosylation;
LUSC	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg18681998	chr4:17616180	MED28	0.78	13.81	0.6	1.26e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg26695010	chr11:65641043	EFEMP2	-0.48	-7.23	-0.37	3.32e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	10.78	0.51	1.84e-23	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.43	6.55	0.34	2.22e-10	Alzheimer's disease (late onset);
LUSC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg21699342	chr2:239360505	ASB1	0.43	6.66	0.34	1.14e-10	Multiple system atrophy;
LUSC	cis	rs10992471	0.580	rs7030920	chr9:95122952	A/G	cg14631576	chr9:95140430	CENPP	-0.39	-6.71	-0.34	8.11e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.68	-0.7	7.46e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	9.07	0.44	1.07e-17	Response to antipsychotic treatment;
LUSC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4499344	0.531	rs259247	chr19:33147657	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.71	10.56	0.5	1.13e-22	Mean platelet volume;
LUSC	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg20129853	chr10:51489980	NA	-0.38	-7.3	-0.37	2.18e-12	Prostate-specific antigen levels;
LUSC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.72	-9.65	-0.47	1.32e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.51	-6.54	-0.34	2.27e-10	Response to bleomycin (chromatid breaks);
LUSC	cis	rs909341	0.909	rs2236510	chr20:62368804	C/T	cg09650180	chr20:62225654	GMEB2	-0.46	-5.94	-0.31	7.16e-9	Atopic dermatitis;
LUSC	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg25730555	chr22:47059586	GRAMD4	0.45	7.13	0.36	6.1e-12	Urate levels in obese individuals;
LUSC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg21435336	chr19:17392852	ANKLE1	-0.45	-6.27	-0.32	1.09e-9	Systemic lupus erythematosus;
LUSC	cis	rs2273669	0.667	rs6916819	chr6:109371129	A/G	cg05315195	chr6:109294784	ARMC2	-0.51	-5.74	-0.3	2.15e-8	Prostate cancer;
LUSC	trans	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.52	8.12	0.41	8.79e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.64	10.06	0.48	5.76e-21	Parkinson's disease;
LUSC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg16797656	chr11:68205561	LRP5	-0.37	-6.19	-0.32	1.79e-9	Total body bone mineral density;
LUSC	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.17	-0.41	6.41e-15	Myopia (pathological);
LUSC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.6	-10.93	-0.51	5.53e-24	Extrinsic epigenetic age acceleration;
LUSC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg23649088	chr2:200775458	C2orf69	0.55	7.42	0.38	9.66e-13	Schizophrenia;
LUSC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.7	0.47	9.26e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg08132940	chr7:1081526	C7orf50	-0.52	-6.22	-0.32	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.32	0.67	1.95e-44	Platelet count;
LUSC	trans	rs3942852	0.955	rs1503190	chr11:48117873	A/G	cg03929089	chr4:120376271	NA	-0.54	-6.2	-0.32	1.7e-9	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg20935933	chr6:143382018	AIG1	0.5	7.32	0.37	1.92e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg22535103	chr8:58192502	C8orf71	-0.65	-7.32	-0.37	1.89e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg12463550	chr7:65579703	CRCP	-0.47	-7.1	-0.36	7.74e-12	Aortic root size;
LUSC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg24060327	chr5:131705240	SLC22A5	-0.54	-7.7	-0.39	1.59e-13	Breast cancer;
LUSC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.42	6.56	0.34	2.09e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg05187965	chr10:45406764	TMEM72	-0.36	-8.42	-0.42	1.11e-15	Mean corpuscular volume;
LUSC	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.46	7.53	0.38	4.92e-13	Schizophrenia;
LUSC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.62e-9	Alzheimer's disease (late onset);
LUSC	cis	rs983392	0.679	rs603648	chr11:60012673	A/T	cg20284999	chr11:59952153	MS4A6A	0.38	6.44	0.33	4.23e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg23933602	chr10:16859644	RSU1	0.55	6.68	0.34	9.84e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg18753928	chr3:113234510	CCDC52	-0.5	-7.74	-0.39	1.2e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg21545522	chr1:205238299	TMCC2	0.47	8.69	0.43	1.68e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24738475	chr1:89149492	PKN2	0.4	6.14	0.32	2.39e-9	Triglycerides;
LUSC	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg13755796	chr4:20253514	NA	-0.41	-6.43	-0.33	4.54e-10	Life satisfaction;
LUSC	cis	rs7580658	0.929	rs4150496	chr2:128029503	C/T	cg09760422	chr2:128146352	NA	-0.3	-6.79	-0.35	5.16e-11	Protein C levels;
LUSC	cis	rs926938	0.618	rs360624	chr1:115409476	A/C	cg12756093	chr1:115239321	AMPD1	0.47	7.22	0.37	3.48e-12	Autism;
LUSC	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg13813247	chr22:41461852	NA	-0.37	-6.59	-0.34	1.67e-10	Neuroticism;
LUSC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.17	16.0	0.66	3.46e-43	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-7.68	-0.39	1.75e-13	Morning vs. evening chronotype;
LUSC	cis	rs3770081	1.000	rs59947468	chr2:86289436	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.94	-6.99	-0.36	1.51e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-12.11	-0.55	3.2e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	22.54	0.78	4.72e-69	Prudent dietary pattern;
LUSC	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg13514129	chr1:39547527	MACF1	0.71	11.76	0.54	5.97e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs113835537	0.597	rs3825065	chr11:66311011	A/G	cg24851651	chr11:66362959	CCS	0.53	7.94	0.4	3.14e-14	Airway imaging phenotypes;
LUSC	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg02569458	chr12:86230093	RASSF9	-0.49	-8.25	-0.41	3.64e-15	Major depressive disorder;
LUSC	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg12002119	chr2:101014098	CHST10	0.35	5.78	0.3	1.72e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg15445000	chr17:37608096	MED1	-0.37	-6.64	-0.34	1.29e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs10761482	0.601	rs7922622	chr10:62207523	C/T	cg18175470	chr10:62150864	ANK3	0.47	6.51	0.34	2.7e-10	Schizophrenia;
LUSC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg19230755	chr7:65878503	NA	0.42	5.84	0.3	1.25e-8	Aortic root size;
LUSC	cis	rs16976116	0.901	rs28535372	chr15:55500602	T/C	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06634786	chr22:41940651	POLR3H	-0.55	-6.33	-0.33	7.74e-10	Vitiligo;
LUSC	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg25182066	chr10:30743637	MAP3K8	0.4	6.36	0.33	6.82e-10	Inflammatory bowel disease;
LUSC	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	8.45	0.42	9.13e-16	Menarche (age at onset);
LUSC	trans	rs34421088	0.506	rs2117616	chr8:11145911	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.43	-0.33	4.36e-10	Neuroticism;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg20701977	chr5:180644504	NA	0.72	5.97	0.31	6.12e-9	Body mass index;
LUSC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	0.79	13.3	0.59	1.14e-32	Gestational age at birth (maternal effect);
LUSC	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.22	-0.37	3.45e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6782228	0.565	rs67445542	chr3:128330526	T/C	cg16766828	chr3:128327626	NA	-0.32	-5.83	-0.3	1.28e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	0.96	16.31	0.67	2.17e-44	Menopause (age at onset);
LUSC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg21573476	chr21:45109991	RRP1B	-0.41	-6.66	-0.34	1.11e-10	Mean corpuscular volume;
LUSC	trans	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg01620082	chr3:125678407	NA	-0.82	-7.72	-0.39	1.35e-13	Depression;
LUSC	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-7.68	-0.39	1.82e-13	Schizophrenia;
LUSC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-1.05	-15.07	-0.64	1.63e-39	Type 2 diabetes;
LUSC	cis	rs4474465	0.790	rs4944206	chr11:78263127	T/C	cg27205649	chr11:78285834	NARS2	0.52	6.18	0.32	1.82e-9	Alzheimer's disease (survival time);
LUSC	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg27411982	chr8:10470053	RP1L1	-0.46	-7.42	-0.38	1e-12	Neuroticism;
LUSC	cis	rs2637266	1.000	rs11001830	chr10:78346396	G/A	cg18941641	chr10:78392320	NA	0.38	7.07	0.36	8.85e-12	Pulmonary function;
LUSC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.39	0.56	3.01e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg18512352	chr11:47633146	NA	-0.48	-9.51	-0.46	3.84e-19	Subjective well-being;
LUSC	cis	rs10426930	0.700	rs7246791	chr19:5013776	T/C	cg25246084	chr19:4971487	KDM4B	-0.33	-6.11	-0.32	2.8e-9	Monocyte percentage of white cells;
LUSC	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05025164	chr4:1340916	KIAA1530	-0.51	-7.84	-0.39	6.19e-14	Obesity-related traits;
LUSC	cis	rs5167	0.777	rs56784978	chr19:45499388	T/C	cg20090143	chr19:45452003	APOC2	0.36	5.91	0.31	8.24e-9	Blood protein levels;
LUSC	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.69	-11.17	-0.52	7.74e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs912330	0.529	rs4772100	chr13:99196573	G/T	cg07423050	chr13:99094983	FARP1	-0.35	-6.82	-0.35	4.41e-11	Alzheimer's disease;
LUSC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.95	0.7	6.41e-51	Chronic sinus infection;
LUSC	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.18	0.32	1.85e-9	Corneal astigmatism;
LUSC	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg21890820	chr11:65308645	LTBP3	0.48	7.23	0.37	3.37e-12	Bone mineral density;
LUSC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg25036284	chr2:26402008	FAM59B	0.75	10.93	0.51	5.79e-24	Gut microbiome composition (summer);
LUSC	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	8.63	0.43	2.47e-16	Menopause (age at onset);
LUSC	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg19774624	chr17:42201019	HDAC5	0.51	7.28	0.37	2.43e-12	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs3862435	0.572	rs2601186	chr15:90926921	A/G	cg22089800	chr15:90895588	ZNF774	0.57	6.22	0.32	1.48e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs12545109	0.800	rs1837620	chr8:57399473	C/A	cg09654669	chr8:57350985	NA	-0.52	-7.06	-0.36	9.64e-12	Obesity-related traits;
LUSC	cis	rs8044995	0.563	rs56220628	chr16:68384837	G/A	cg09835421	chr16:68378352	PRMT7	-0.75	-8.6	-0.43	3.08e-16	Schizophrenia;
LUSC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.72	-0.3	2.37e-8	Tonsillectomy;
LUSC	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg04450456	chr4:17643702	FAM184B	0.35	5.74	0.3	2.15e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg16325326	chr1:53192061	ZYG11B	0.99	20.34	0.74	2.02e-60	Monocyte count;
LUSC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg18827107	chr12:86230957	RASSF9	-0.48	-7.07	-0.36	8.87e-12	Major depressive disorder;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg16657816	chr16:30905695	BCL7C	0.37	5.98	0.31	5.72e-9	Metabolite levels (Pyroglutamine);
LUSC	trans	rs6076960	0.598	rs3905168	chr20:6226752	C/T	cg21095983	chr6:86352623	SYNCRIP	0.5	7.72	0.39	1.35e-13	Smooth-surface caries;
LUSC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.71	12.23	0.56	1.13e-28	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	7.33	0.37	1.79e-12	Electroencephalogram traits;
LUSC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.61e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	7.83	0.39	6.66e-14	Colorectal cancer;
LUSC	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs77741769	0.700	rs7969196	chr12:121377656	A/C	cg02403541	chr12:121454288	C12orf43	-0.49	-7.29	-0.37	2.21e-12	Mean corpuscular volume;
LUSC	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg07701084	chr6:150067640	NUP43	0.52	7.83	0.39	6.48e-14	Lung cancer;
LUSC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg20203395	chr5:56204925	C5orf35	-0.76	-10.18	-0.49	2.15e-21	Initial pursuit acceleration;
LUSC	cis	rs2274273	0.870	rs28716725	chr14:55816610	T/C	cg04306507	chr14:55594613	LGALS3	0.56	12.92	0.58	2.99e-31	Protein biomarker;
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg15242686	chr22:24348715	GSTTP1	0.49	7.83	0.39	6.34e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2625529	0.730	rs6494975	chr15:72177825	T/A	cg16672083	chr15:72433130	SENP8	0.47	7.56	0.38	3.94e-13	Red blood cell count;
LUSC	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg02807482	chr3:125708958	NA	-0.48	-5.71	-0.3	2.54e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg03877680	chr5:178157825	ZNF354A	-0.78	-10.93	-0.51	5.78e-24	Neutrophil percentage of white cells;
LUSC	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg00012203	chr2:219082015	ARPC2	-0.77	-13.86	-0.6	7.77e-35	Colorectal cancer;
LUSC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg05347473	chr6:146136440	FBXO30	-0.66	-11.72	-0.54	8.35e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10904908	0.763	rs359284	chr10:17326756	T/C	cg01003015	chr10:17271136	VIM	0.42	5.99	0.31	5.28e-9	Total cholesterol levels;Cholesterol, total;
LUSC	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg05791153	chr7:19748676	TWISTNB	-0.79	-8.45	-0.42	8.85e-16	Thyroid stimulating hormone;
LUSC	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg22437258	chr11:111473054	SIK2	-0.48	-6.24	-0.32	1.33e-9	Primary sclerosing cholangitis;
LUSC	cis	rs11676348	0.774	rs57545959	chr2:219047718	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.38	5.89	0.31	9.67e-9	Ulcerative colitis;
LUSC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg21724239	chr8:58056113	NA	0.78	8.05	0.4	1.42e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg26384229	chr12:38710491	ALG10B	0.55	8.63	0.43	2.55e-16	Morning vs. evening chronotype;
LUSC	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg03465714	chr1:152285911	FLG	0.42	5.83	0.3	1.32e-8	Atopic dermatitis;
LUSC	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg15654264	chr1:150340011	RPRD2	0.64	10.58	0.5	9.37e-23	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.84	0.35	3.72e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.72	-12.56	-0.57	6.93e-30	White blood cell count (basophil);
LUSC	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	0.97	15.48	0.65	3.82e-41	Dupuytren's disease;
LUSC	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-10.13	-0.48	3.23e-21	HDL cholesterol;
LUSC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg07424592	chr7:64974309	NA	0.7	6.07	0.32	3.39e-9	Diabetic kidney disease;
LUSC	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.46	-6.3	-0.33	9.29e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.42	-6.4	-0.33	5.4e-10	Tonsillectomy;
LUSC	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg07929629	chr2:241523174	NA	0.58	10.8	0.51	1.67e-23	Bipolar disorder;
LUSC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	15.26	0.64	2.89e-40	Platelet count;
LUSC	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg03948781	chr1:205179583	DSTYK	0.3	5.65	0.3	3.5e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.32	0.37	1.83e-12	Motion sickness;
LUSC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.83	-0.3	1.31e-8	Platelet count;
LUSC	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg15704280	chr7:45808275	SEPT13	-0.56	-6.95	-0.36	1.97e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.64	10.12	0.48	3.54e-21	Inhibitory control;
LUSC	cis	rs2191566	1.000	rs2191566	chr19:44511389	A/C	cg03039196	chr19:44506973	ZNF230	-0.39	-6.49	-0.33	3.11e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg17211192	chr8:82754475	SNX16	-0.76	-10.03	-0.48	7.41e-21	Diastolic blood pressure;
LUSC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	29.03	0.85	2.44e-93	Chronic sinus infection;
LUSC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06481639	chr22:41940642	POLR3H	0.46	5.69	0.3	2.75e-8	Vitiligo;
LUSC	cis	rs185694	1.000	rs185694	chr13:30885223	C/T	cg07600127	chr13:30881527	KATNAL1	0.59	6.45	0.33	3.95e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
LUSC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg05834625	chr6:170176447	C6orf70	0.5	7.01	0.36	1.31e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg01416388	chr22:39784598	NA	-0.45	-7.64	-0.39	2.39e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg23649088	chr2:200775458	C2orf69	-0.52	-7.06	-0.36	9.41e-12	Schizophrenia;
LUSC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.0	-0.4	2.12e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	6.65	0.34	1.19e-10	Joint mobility (Beighton score);
LUSC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.27	0.56	7.85e-29	Motion sickness;
LUSC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.66	10.06	0.48	5.71e-21	Monocyte percentage of white cells;
LUSC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26314531	chr2:26401878	FAM59B	0.69	9.14	0.45	6.33e-18	Gut microbiome composition (summer);
LUSC	trans	rs71435601	0.628	rs36047821	chr2:21418719	C/A	cg20757404	chr19:378427	NA	-0.41	-6.33	-0.33	8.06e-10	Cholesterol, total;
LUSC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-1.12	-17.02	-0.68	3.33e-47	Breast cancer;
LUSC	cis	rs1045714	0.895	rs73043182	chr7:2646005	C/T	cg24848437	chr7:2645542	IQCE	0.61	6.74	0.35	6.84e-11	Urate levels in lean individuals;
LUSC	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg25019033	chr10:957182	NA	-0.53	-7.1	-0.36	7.77e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs17102423	0.788	rs11158575	chr14:65581665	T/C	cg11161011	chr14:65562177	MAX	-0.73	-11.08	-0.52	1.66e-24	Obesity-related traits;
LUSC	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.66	8.19	0.41	5.69e-15	Type 2 diabetes;
LUSC	trans	rs656319	0.513	rs1484641	chr8:9986524	A/C	cg15556689	chr8:8085844	FLJ10661	0.48	6.72	0.35	7.95e-11	Myopia (pathological);
LUSC	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg04369109	chr6:150039330	LATS1	-0.52	-7.5	-0.38	5.95e-13	Lung cancer;
LUSC	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.42	-5.68	-0.3	2.86e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg24813613	chr7:1882135	MAD1L1	-0.44	-7.31	-0.37	1.99e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.6	-0.43	3.16e-16	Total cholesterol levels;
LUSC	cis	rs7122539	0.734	rs4930391	chr11:66645254	A/G	cg24851651	chr11:66362959	CCS	-0.55	-9.86	-0.47	2.63e-20	HIV-1 susceptibility;
LUSC	trans	rs12200782	1.000	rs41267923	chr6:26452947	C/T	cg11837749	chr1:55047332	ACOT11	0.59	6.11	0.32	2.75e-9	Small cell lung carcinoma;
LUSC	trans	rs10432489	0.708	rs10178270	chr2:181773395	G/C	cg04744134	chr19:8408128	KANK3	0.83	6.27	0.32	1.13e-9	QT interval;
LUSC	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg24579218	chr15:68104479	NA	-0.35	-5.84	-0.3	1.21e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg07870213	chr5:140052090	DND1	0.79	11.7	0.54	1.01e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs10489202	0.686	rs11590282	chr1:167848231	C/T	cg24449463	chr1:168025552	DCAF6	-0.58	-6.6	-0.34	1.63e-10	Schizophrenia;
LUSC	cis	rs12618769	0.597	rs3769729	chr2:99102810	T/C	cg10123293	chr2:99228465	UNC50	0.45	7.48	0.38	6.81e-13	Bipolar disorder;
LUSC	cis	rs7712401	0.601	rs1990890	chr5:122182970	C/T	cg19077854	chr5:122220652	SNX24	0.41	9.22	0.45	3.52e-18	Mean platelet volume;
LUSC	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg21775007	chr8:11205619	TDH	-0.5	-6.79	-0.35	4.99e-11	Morning vs. evening chronotype;
LUSC	cis	rs1832871	0.655	rs6920121	chr6:158678504	C/T	cg07165851	chr6:158734300	TULP4	-0.51	-7.95	-0.4	2.92e-14	Height;
LUSC	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg04586622	chr2:25135609	ADCY3	0.4	8.21	0.41	5.03e-15	Body mass index in non-asthmatics;
LUSC	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg23719950	chr11:63933701	MACROD1	-0.63	-8.1	-0.41	1.03e-14	Mean platelet volume;
LUSC	cis	rs1185460	1.000	rs1185460	chr11:118943433	C/T	cg01677386	chr11:118938358	VPS11	0.45	6.3	0.33	9.26e-10	Coronary artery disease;
LUSC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.52	-0.34	2.63e-10	Menarche (age at onset);
LUSC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.06	-0.31	3.66e-9	Alzheimer's disease (late onset);
LUSC	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg14703610	chr5:56206110	C5orf35	0.39	5.66	0.3	3.2e-8	Coronary artery disease;
LUSC	cis	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.39	-0.33	5.57e-10	Morning vs. evening chronotype;
LUSC	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg22907277	chr7:1156413	C7orf50	0.7	7.5	0.38	5.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.61	8.56	0.42	4.2e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9650657	0.769	rs2116094	chr8:10598822	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.15	-0.32	2.17e-9	Neuroticism;
LUSC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.59	-10.31	-0.49	8.33e-22	Extrinsic epigenetic age acceleration;
LUSC	trans	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17712092	chr4:129076599	LARP1B	0.87	13.8	0.6	1.34e-34	Eosinophil percentage of white cells;
LUSC	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg15934090	chr1:100435551	SLC35A3	0.47	8.08	0.4	1.21e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.65	-10.09	-0.48	4.65e-21	Menarche (age at onset);
LUSC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg16325326	chr1:53192061	ZYG11B	0.94	17.85	0.7	1.62e-50	Monocyte count;
LUSC	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg08000102	chr2:233561755	GIGYF2	0.71	11.71	0.54	9.21e-27	Coronary artery disease;
LUSC	cis	rs9434723	0.841	rs12083129	chr1:9311323	G/A	cg04199779	chr1:9294473	H6PD	0.53	5.69	0.3	2.84e-8	Height;
LUSC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg23711669	chr6:146136114	FBXO30	0.86	16.15	0.66	8.98e-44	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.66	-9.0	-0.44	1.77e-17	Obesity-related traits;
LUSC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-16.13	-0.66	1.07e-43	Gut microbiome composition (summer);
LUSC	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg11502198	chr6:26597334	ABT1	0.72	12.19	0.56	1.53e-28	Intelligence (multi-trait analysis);
LUSC	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-1.14	-18.19	-0.71	7.14e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg01448562	chr3:133502909	NA	0.55	9.1	0.45	8.32e-18	Alcohol consumption (transferrin glycosylation);
LUSC	trans	rs7939886	0.920	rs17150096	chr11:55902996	C/T	cg03929089	chr4:120376271	NA	0.77	6.09	0.32	3.03e-9	Myopia (pathological);
LUSC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18876405	chr7:65276391	NA	-0.55	-8.79	-0.43	8.32e-17	Aortic root size;
LUSC	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg00191853	chr8:101177733	SPAG1	-0.4	-6.55	-0.34	2.2e-10	Atrioventricular conduction;
LUSC	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg06627628	chr2:24431161	ITSN2	-0.74	-10.05	-0.48	6.28e-21	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.82	-14.09	-0.61	1.03e-35	Bladder cancer;
LUSC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.99	-0.44	1.85e-17	Electroencephalogram traits;
LUSC	cis	rs72634258	0.786	rs7523335	chr1:8180210	G/A	cg26816564	chr1:7831052	VAMP3	0.47	6.17	0.32	1.92e-9	Inflammatory bowel disease;
LUSC	trans	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg18187862	chr3:45730750	SACM1L	-0.51	-6.27	-0.32	1.1e-9	Primary sclerosing cholangitis;
LUSC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg17724175	chr1:150552817	MCL1	0.36	6.6	0.34	1.58e-10	Tonsillectomy;
LUSC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08219700	chr8:58056026	NA	0.68	7.92	0.4	3.63e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1971762	0.583	rs2365345	chr12:54086820	C/T	cg23533419	chr12:54090519	NA	-0.37	-6.1	-0.32	2.95e-9	Height;
LUSC	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	10.63	0.5	6.06e-23	Coffee consumption (cups per day);
LUSC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg00509249	chr6:109615579	CCDC162	-0.33	-5.91	-0.31	8.64e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs1949829	0.826	rs73341549	chr7:51541468	C/T	cg20941110	chr15:83953819	BNC1	0.56	6.05	0.31	3.8e-9	Wegener's granulomatosis;
LUSC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg22920501	chr2:26401640	FAM59B	0.74	10.08	0.48	4.8e-21	Gut microbiome composition (summer);
LUSC	trans	rs2790216	0.526	rs1199093	chr10:59896794	C/G	cg21551132	chr17:53046152	COX11;STXBP4	-0.39	-6.27	-0.32	1.14e-9	Inflammatory bowel disease;
LUSC	cis	rs13401104	0.796	rs12468256	chr2:237111995	T/C	cg19324714	chr2:237145437	ASB18	0.43	5.71	0.3	2.46e-8	Educational attainment;
LUSC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.46	-7.39	-0.38	1.15e-12	Alzheimer's disease (late onset);
LUSC	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg04865166	chr7:105162814	PUS7	0.51	5.71	0.3	2.49e-8	Bipolar disorder (body mass index interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg26708280	chr2:190649305	PMS1;ORMDL1	0.46	6.75	0.35	6.63e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15369054	chr17:80825471	TBCD	0.7	12.21	0.56	1.28e-28	Breast cancer;
LUSC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-8.35	-0.42	1.89e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11030122	0.661	rs963998	chr11:4062803	A/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.68	-0.3	2.92e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.76	-0.3	1.92e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.34	-0.42	2.03e-15	Response to antipsychotic treatment;
LUSC	cis	rs55665837	0.539	rs10766196	chr11:14913131	A/G	cg05501817	chr11:14380813	RRAS2	-0.39	-5.68	-0.3	2.87e-8	Vitamin D levels;
LUSC	cis	rs2742234	0.541	rs7096500	chr10:43712095	C/T	cg02780029	chr10:43622663	RET	0.35	5.82	0.3	1.41e-8	Hirschsprung disease;
LUSC	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg20991723	chr1:152506922	NA	0.51	9.6	0.47	1.93e-19	Hair morphology;
LUSC	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg19875535	chr5:140030758	IK	0.5	8.24	0.41	3.98e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.21	0.32	1.54e-9	Menopause (age at onset);
LUSC	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg22089800	chr15:90895588	ZNF774	-0.64	-9.49	-0.46	4.41e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs4363385	0.818	rs407103	chr1:153007106	C/T	cg00922841	chr1:152955080	SPRR1A	0.41	7.08	0.36	8.35e-12	Inflammatory skin disease;
LUSC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.01e-14	Corneal astigmatism;
LUSC	trans	rs1941687	0.505	rs1389534	chr18:31311161	C/G	cg27147174	chr7:100797783	AP1S1	0.51	7.78	0.39	9.1e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs4642101	0.680	rs7626609	chr3:12806080	A/G	cg24848339	chr3:12840334	CAND2	-0.34	-6.99	-0.36	1.47e-11	QRS complex (12-leadsum);
LUSC	cis	rs7084921	0.608	rs12780510	chr10:101865881	T/C	cg02250046	chr10:101825185	CPN1	-0.34	-6.28	-0.33	1.03e-9	Bone mineral density;
LUSC	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.84	14.49	0.62	3.04e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg18350739	chr11:68623251	NA	-0.36	-6.26	-0.32	1.15e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg16281248	chr11:64014554	PPP1R14B	0.38	6.28	0.32	1.08e-9	Triglycerides;
LUSC	cis	rs12760731	0.668	rs12073428	chr1:178427933	G/A	cg00404053	chr1:178313656	RASAL2	0.48	5.74	0.3	2.17e-8	Obesity-related traits;
LUSC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg02951883	chr7:2050386	MAD1L1	-0.44	-7.75	-0.39	1.15e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.51	-0.34	2.78e-10	Mood instability;
LUSC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.8	13.3	0.59	1.11e-32	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	7.91	0.4	3.76e-14	Homoarginine levels;
LUSC	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg10621924	chr7:39171070	POU6F2	-0.48	-7.29	-0.37	2.26e-12	IgG glycosylation;
LUSC	trans	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg07211511	chr3:129823064	LOC729375	-1.05	-12.96	-0.58	2.17e-31	Blood pressure (smoking interaction);
LUSC	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg15309053	chr8:964076	NA	0.34	6.93	0.35	2.11e-11	Schizophrenia;
LUSC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg14552801	chr7:65878734	NA	-0.45	-6.47	-0.33	3.59e-10	Aortic root size;
LUSC	cis	rs12681287	0.511	rs7839601	chr8:87503839	G/C	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.0	0.4	2.07e-14	Parkinson's disease;
LUSC	cis	rs9534288	0.957	rs2404731	chr13:46618384	T/C	cg15192986	chr13:46630673	CPB2	-0.73	-11.34	-0.53	2.02e-25	Blood protein levels;
LUSC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg16325326	chr1:53192061	ZYG11B	-1.0	-20.25	-0.74	4.79e-60	Monocyte count;
LUSC	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	13.87	0.6	7.44e-35	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-6.96	-0.36	1.82e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs977987	0.843	rs11149824	chr16:75431830	C/G	cg03315344	chr16:75512273	CHST6	0.48	9.12	0.45	6.97e-18	Dupuytren's disease;
LUSC	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg05985134	chr18:33552581	C18orf21	0.5	6.75	0.35	6.38e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7590368	0.715	rs72779470	chr2:10964057	C/T	cg15705551	chr2:10952987	PDIA6	0.57	6.25	0.32	1.28e-9	Educational attainment (years of education);
LUSC	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-8.0	-0.4	2.02e-14	Height;
LUSC	cis	rs6740322	0.895	rs9309097	chr2:43554397	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-7.49	-0.38	6.19e-13	Coronary artery disease;
LUSC	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg27284194	chr4:1044797	NA	0.59	8.57	0.42	3.95e-16	Recombination rate (females);
LUSC	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg02176678	chr2:219576539	TTLL4	-0.64	-12.27	-0.56	7.73e-29	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22496380	chr5:211416	CCDC127	-0.74	-8.57	-0.42	3.87e-16	Breast cancer;
LUSC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg00784671	chr22:46762841	CELSR1	-0.48	-6.65	-0.34	1.18e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.43	-5.83	-0.3	1.29e-8	Osteoarthritis;
LUSC	trans	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg06521331	chr12:34319734	NA	0.41	6.48	0.33	3.2e-10	Morning vs. evening chronotype;
LUSC	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.43	0.42	1.04e-15	Coffee consumption (cups per day);
LUSC	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.2	0.32	1.62e-9	Total body bone mineral density;
LUSC	cis	rs6692729	0.933	rs2793461	chr1:227062129	C/A	cg10327440	chr1:227177885	CDC42BPA	0.51	7.32	0.37	1.9e-12	Electrodermal activity;
LUSC	cis	rs10979	1.000	rs9496681	chr6:143896964	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs427941	0.632	rs201490	chr7:101751910	C/T	cg06246474	chr7:101738831	CUX1	0.39	6.33	0.33	7.96e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7605827	0.930	rs2003592	chr2:15552153	C/T	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.08e-17	Educational attainment (years of education);
LUSC	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg13798780	chr7:105162888	PUS7	0.58	6.1	0.32	2.86e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4474465	1.000	rs2063728	chr11:78185636	G/C	cg27205649	chr11:78285834	NARS2	-0.49	-5.76	-0.3	1.9e-8	Alzheimer's disease (survival time);
LUSC	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg04362960	chr10:104952993	NT5C2	0.6	9.71	0.47	8.52e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7640424	0.620	rs34910554	chr3:107816733	C/T	cg09227934	chr3:107805635	CD47	-0.54	-7.83	-0.39	6.71e-14	Body mass index;
LUSC	cis	rs6961069	0.585	rs28645928	chr7:80258497	T/C	cg04458919	chr7:80252533	CD36	-0.41	-7.25	-0.37	2.88e-12	Platelet count;
LUSC	cis	rs921968	0.565	rs692049	chr2:219622778	G/A	cg02176678	chr2:219576539	TTLL4	-0.56	-9.87	-0.48	2.42e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10193935	0.901	rs10490552	chr2:42559947	C/T	cg27598129	chr2:42591480	NA	0.6	8.57	0.42	3.77e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg01849466	chr14:104193079	ZFYVE21	0.56	9.07	0.44	1.04e-17	Schizophrenia;
LUSC	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg04450456	chr4:17643702	FAM184B	0.37	6.36	0.33	6.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg08917208	chr2:24149416	ATAD2B	0.56	6.36	0.33	6.82e-10	Lymphocyte counts;
LUSC	cis	rs10072221	0.836	rs3886042	chr5:75704199	G/A	cg03132911	chr5:75698732	IQGAP2	0.38	6.42	0.33	4.65e-10	Mean platelet volume;
LUSC	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg13628971	chr7:2884303	GNA12	0.46	6.74	0.35	6.95e-11	Height;
LUSC	cis	rs497273	0.552	rs11065361	chr12:121386709	T/A	cg02403541	chr12:121454288	C12orf43	-0.47	-5.73	-0.3	2.26e-8	Systemic lupus erythematosus;
LUSC	cis	rs7953508	0.506	rs768775	chr12:93968197	T/C	cg18151635	chr12:93972918	NA	-0.62	-8.89	-0.44	3.85e-17	Pubertal anthropometrics;
LUSC	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.9	-10.62	-0.5	6.69e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs4077468	1.000	rs11801695	chr1:205916175	A/C	cg11965913	chr1:205819406	PM20D1	0.43	6.52	0.34	2.59e-10	Cystic fibrosis-related diabetes;
LUSC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.54	-0.38	4.53e-13	Aortic root size;
LUSC	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg00080972	chr5:178986291	RUFY1	0.57	10.07	0.48	5.47e-21	Lung cancer;
LUSC	trans	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg20887711	chr4:1340912	KIAA1530	0.46	7.11	0.36	7.11e-12	Obesity-related traits;
LUSC	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.38	-5.71	-0.3	2.52e-8	IgG glycosylation;
LUSC	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg25427524	chr10:38739819	LOC399744	0.4	6.75	0.35	6.39e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg12935359	chr14:103987150	CKB	-0.47	-7.02	-0.36	1.26e-11	Body mass index;
LUSC	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.56	-9.25	-0.45	2.75e-18	Breast cancer;
LUSC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg04315214	chr1:2043799	PRKCZ	0.46	9.6	0.47	1.96e-19	Height;
LUSC	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg10255544	chr17:80519551	FOXK2	-0.38	-6.26	-0.32	1.17e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-9.73	-0.47	7.36e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs6500395	1.000	rs9936004	chr16:48566088	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.54	0.34	2.25e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg23950597	chr19:37808831	NA	-0.64	-7.47	-0.38	6.98e-13	Coronary artery calcification;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08348959	chr3:10290087	TATDN2	-0.42	-6.36	-0.33	6.59e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.52	8.61	0.43	2.88e-16	Immature fraction of reticulocytes;
LUSC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.2	-0.41	5.37e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-17.28	-0.69	2.91e-48	Body mass index;
LUSC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13770153	chr20:60521292	NA	-0.63	-8.38	-0.42	1.45e-15	Body mass index;
LUSC	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg18230493	chr5:56204884	C5orf35	-0.58	-9.08	-0.44	9.62e-18	Coronary artery disease;
LUSC	cis	rs6669919	0.516	rs11577717	chr1:211668920	C/T	cg10512769	chr1:211675356	NA	-0.3	-7.07	-0.36	9.07e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	14.07	0.61	1.24e-35	Platelet count;
LUSC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-1.03	-20.21	-0.74	7.12e-60	Height;
LUSC	trans	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg13565492	chr6:43139072	SRF	-0.73	-10.95	-0.51	4.92e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg26380479	chr7:97908229	NA	-0.27	-6.08	-0.32	3.21e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14158573	chr20:17549682	DSTN	0.37	6.51	0.34	2.72e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg00318621	chr2:106887213	NA	-0.36	-6.54	-0.34	2.37e-10	Facial morphology (factor 23);
LUSC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg00080972	chr5:178986291	RUFY1	0.56	10.12	0.48	3.51e-21	Lung cancer;
LUSC	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.83	-0.39	6.55e-14	Body mass index;
LUSC	cis	rs11209002	0.911	rs10889656	chr1:67594559	A/G	cg02640540	chr1:67518911	SLC35D1	-0.58	-6.46	-0.33	3.68e-10	Crohn's disease;
LUSC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg15110403	chr19:17392923	ANKLE1	-0.59	-8.2	-0.41	5.07e-15	Systemic lupus erythematosus;
LUSC	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.49	7.07	0.36	9.14e-12	Bipolar disorder;
LUSC	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg09835421	chr16:68378352	PRMT7	-0.51	-6.28	-0.32	1.06e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9837602	1.000	rs7620228	chr3:99790332	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.24	0.32	1.31e-9	Breast cancer;
LUSC	cis	rs7572644	0.699	rs1395324	chr2:28276643	C/G	cg27432699	chr2:27873401	GPN1	-0.53	-7.13	-0.36	6.43e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg17911788	chr17:44343683	NA	0.31	5.89	0.31	9.19e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.41	6.04	0.31	4.01e-9	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-6.14	-0.32	2.38e-9	IgG glycosylation;
LUSC	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.85	-0.3	1.16e-8	Personality dimensions;
LUSC	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg14895029	chr7:2775587	GNA12	-0.43	-6.8	-0.35	4.89e-11	Height;
LUSC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.32	0.56	5.46e-29	Prudent dietary pattern;
LUSC	cis	rs2191566	0.540	rs436739	chr19:44495553	A/G	cg18700516	chr19:44507157	ZNF230	0.41	5.68	0.3	2.96e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.04	-0.36	1.1e-11	Electroencephalogram traits;
LUSC	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.45	-6.92	-0.35	2.35e-11	Tonsillectomy;
LUSC	cis	rs12973672	0.812	rs113185571	chr19:35758929	C/T	cg12095397	chr19:35769544	USF2	0.42	6.36	0.33	6.76e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-0.53	-8.09	-0.4	1.12e-14	Breast cancer;
LUSC	cis	rs897984	0.520	rs4889534	chr16:30865440	T/C	cg02466173	chr16:30829666	NA	0.55	9.26	0.45	2.55e-18	Dementia with Lewy bodies;
LUSC	cis	rs4588572	0.570	rs2115433	chr5:77700363	C/T	cg11547950	chr5:77652471	NA	-0.41	-6.32	-0.33	8.6e-10	Triglycerides;
LUSC	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg03676636	chr4:99064102	C4orf37	0.28	5.95	0.31	6.87e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.07	-0.44	1.01e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6060717	0.553	rs2590958	chr20:34616590	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-6.35	-0.33	7.18e-10	Hip circumference adjusted for BMI;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25739518	chr22:18560665	PEX26	-0.45	-6.79	-0.35	4.99e-11	Electrocardiographic conduction measures;
LUSC	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg03806693	chr22:41940476	POLR3H	-0.53	-7.87	-0.4	5.02e-14	Neuroticism;
LUSC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg11663144	chr21:46675770	NA	-0.41	-7.19	-0.37	4.16e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9398235	0.673	rs73526955	chr6:110699042	C/T	cg19196401	chr6:110721138	DDO	0.41	6.37	0.33	6.42e-10	Systemic lupus erythematosus;
LUSC	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg01256987	chr12:42539512	GXYLT1	-0.4	-7.38	-0.37	1.3e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg19709878	chr17:47440040	ZNF652	0.38	5.97	0.31	6.11e-9	Triglycerides;
LUSC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-12.35	-0.56	3.98e-29	Platelet count;
LUSC	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg06287003	chr12:125626642	AACS	-0.39	-6.69	-0.34	9.36e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg05343316	chr1:45956843	TESK2	0.61	8.47	0.42	7.91e-16	Platelet count;
LUSC	cis	rs662064	0.963	rs10864460	chr1:10563671	C/G	cg20482658	chr1:10539492	PEX14	-0.29	-6.54	-0.34	2.31e-10	Asthma;
LUSC	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg18105134	chr13:113819100	PROZ	0.62	9.37	0.46	1.12e-18	Platelet distribution width;
LUSC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg12463550	chr7:65579703	CRCP	-0.54	-8.14	-0.41	7.78e-15	Aortic root size;
LUSC	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.92	12.13	0.55	2.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg24675056	chr1:15929824	NA	0.46	8.03	0.4	1.73e-14	Systolic blood pressure;
LUSC	cis	rs7315438	0.600	rs34843923	chr12:115879150	C/T	cg24172291	chr12:115889509	NA	-0.33	-5.77	-0.3	1.8e-8	Colorectal cancer;
LUSC	cis	rs7572644	0.713	rs13026758	chr2:28041273	A/G	cg27432699	chr2:27873401	GPN1	0.57	7.28	0.37	2.47e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg24675658	chr1:53192096	ZYG11B	-0.64	-10.09	-0.48	4.52e-21	Monocyte count;
LUSC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg24813613	chr7:1882135	MAD1L1	-0.47	-8.11	-0.41	1e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg00334542	chr7:100209784	MOSPD3	-0.67	-7.84	-0.39	6.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg03522245	chr20:25566470	NINL	0.36	5.77	0.3	1.83e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.24	-0.32	1.29e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg02018176	chr4:1364513	KIAA1530	0.47	6.49	0.33	3.19e-10	Recombination rate (females);
LUSC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.9	0.44	3.51e-17	Motion sickness;
LUSC	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg14458575	chr2:238380390	NA	0.65	11.15	0.52	9.15e-25	Prostate cancer;
LUSC	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.19	0.64	5.67e-40	Bladder cancer;
LUSC	cis	rs35000415	0.938	rs13236009	chr7:128663173	T/G	cg19972273	chr7:128594194	NA	0.68	6.9	0.35	2.56e-11	Systemic lupus erythematosus;
LUSC	cis	rs3850699	0.666	rs7905481	chr10:104476292	T/C	cg05855489	chr10:104503620	C10orf26	0.72	11.49	0.53	5.61e-26	Prostate cancer;
LUSC	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg24130564	chr14:104152367	KLC1	0.44	6.22	0.32	1.45e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.67	-11.26	-0.52	3.88e-25	Systemic lupus erythematosus;
LUSC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.48	-6.71	-0.34	8.31e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.3	0.53	2.75e-25	Menopause (age at onset);
LUSC	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg25124228	chr12:125621409	AACS	-0.58	-9.59	-0.46	2.15e-19	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-0.83	-12.1	-0.55	3.35e-28	Migraine;Coronary artery disease;
LUSC	cis	rs9462027	0.651	rs13220394	chr6:34810172	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.75	-0.3	1.97e-8	Systemic lupus erythematosus;
LUSC	cis	rs2944755	0.919	rs2944754	chr8:141574350	A/G	cg08444833	chr8:141574162	EIF2C2	0.47	6.05	0.31	3.79e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs2573652	0.722	rs11858932	chr15:100542763	G/A	cg00587665	chr15:100533223	ADAMTS17	-0.38	-6.73	-0.35	7.25e-11	Height;
LUSC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.76	7.4	0.38	1.12e-12	Cerebrospinal P-tau181p levels;
LUSC	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg21132104	chr15:45694354	SPATA5L1	0.41	6.03	0.31	4.32e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg22823121	chr1:150693482	HORMAD1	-0.48	-6.65	-0.34	1.17e-10	Urate levels;
LUSC	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg04369109	chr6:150039330	LATS1	-0.59	-8.61	-0.43	2.98e-16	Lung cancer;
LUSC	cis	rs2282300	0.637	rs2065418	chr11:30422068	A/C	cg25418670	chr11:30344373	C11orf46	-0.37	-5.96	-0.31	6.45e-9	Morning vs. evening chronotype;
LUSC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg23791538	chr6:167370224	RNASET2	0.41	6.7	0.34	8.84e-11	Crohn's disease;
LUSC	cis	rs1568889	0.838	rs12273631	chr11:28042135	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.89	0.58	3.99e-31	Bipolar disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21075237	chr3:57132156	IL17RD	0.46	6.71	0.34	8.56e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs16937	0.711	rs10900462	chr1:205153312	A/G	cg00857998	chr1:205179979	DSTYK	-0.46	-6.51	-0.34	2.81e-10	Schizophrenia;
LUSC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg11752832	chr7:134001865	SLC35B4	0.52	7.99	0.4	2.24e-14	Mean platelet volume;
LUSC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg00074818	chr8:8560427	CLDN23	0.57	9.63	0.47	1.54e-19	Obesity-related traits;
LUSC	cis	rs4901869	0.966	rs12893803	chr14:59329655	T/C	cg02291164	chr14:59296302	NA	0.56	10.53	0.5	1.45e-22	Panic disorder;
LUSC	cis	rs870825	0.616	rs2090589	chr4:185647731	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	trans	rs8040855	0.965	rs6496766	chr15:85702375	C/A	cg00988175	chr11:59481031	OR10V1	-0.29	-6.21	-0.32	1.53e-9	Bulimia nervosa;
LUSC	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.72	-0.6	2.84e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6120849	0.754	rs6120812	chr20:33629427	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.58	0.34	1.8e-10	Protein C levels;
LUSC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-9.24	-0.45	3.06e-18	Obesity-related traits;
LUSC	cis	rs7582720	1.000	rs72936856	chr2:203775712	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.38	0.42	1.49e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs926938	0.521	rs360649	chr1:115439668	G/C	cg12756093	chr1:115239321	AMPD1	0.44	6.49	0.33	3.14e-10	Autism;
LUSC	cis	rs981844	1.000	rs116588966	chr4:154664794	T/C	cg14289246	chr4:154710475	SFRP2	0.46	5.72	0.3	2.41e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs9987353	0.519	rs11779181	chr8:9063027	A/G	cg15556689	chr8:8085844	FLJ10661	0.41	5.76	0.3	1.93e-8	Recombination measurement;
LUSC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.08	13.45	0.59	2.87e-33	Sexual dysfunction (female);
LUSC	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg22508957	chr16:3507546	NAT15	0.64	10.58	0.5	9.09e-23	Tuberculosis;
LUSC	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg25482853	chr8:67687455	SGK3	1.19	19.12	0.72	1.43e-55	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1865721	0.771	rs727893	chr18:73136931	G/A	cg26385618	chr18:73139727	C18orf62	-0.54	-9.86	-0.47	2.71e-20	Intelligence;
LUSC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	7.46	0.38	7.54e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg26893861	chr17:41843967	DUSP3	0.88	13.8	0.6	1.38e-34	Triglycerides;
LUSC	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg13010199	chr12:38710504	ALG10B	0.58	9.26	0.45	2.59e-18	Morning vs. evening chronotype;
LUSC	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg21045802	chr8:109455806	TTC35	0.46	7.12	0.36	6.47e-12	Dupuytren's disease;
LUSC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg17279839	chr7:150038598	RARRES2	0.4	6.22	0.32	1.46e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	8.59	0.43	3.47e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg20744362	chr22:50050164	C22orf34	0.4	7.64	0.39	2.26e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg08085267	chr17:45401833	C17orf57	-0.56	-9.09	-0.45	9.14e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg16230307	chr14:35515116	FAM177A1	0.77	8.84	0.44	5.41e-17	Psoriasis;
LUSC	cis	rs955333	0.685	rs884924	chr6:154894207	A/G	cg20019720	chr6:154832845	CNKSR3	0.44	6.31	0.33	8.88e-10	Diabetic kidney disease;
LUSC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.49	0.56	1.26e-29	Motion sickness;
LUSC	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg17470723	chr8:74884337	TCEB1	0.52	8.03	0.4	1.72e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.37	-5.76	-0.3	1.88e-8	Lung cancer;
LUSC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.4	-5.94	-0.31	7.35e-9	Tonsillectomy;
LUSC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg27432699	chr2:27873401	GPN1	-0.56	-8.36	-0.42	1.69e-15	Total body bone mineral density;
LUSC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg16447950	chr5:562315	NA	-0.57	-6.87	-0.35	3.21e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg18753928	chr3:113234510	CCDC52	-0.49	-7.61	-0.38	2.76e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs752010	0.619	rs7539238	chr1:42113572	A/C	cg06885757	chr1:42089581	HIVEP3	0.57	11.69	0.54	1.08e-26	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs9560113	0.960	rs9560102	chr13:112173825	G/A	cg14154082	chr13:112174009	NA	0.38	7.95	0.4	2.97e-14	Menarche (age at onset);
LUSC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg01181863	chr3:195395398	SDHAP2	-0.59	-8.04	-0.4	1.53e-14	Pancreatic cancer;
LUSC	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg08917208	chr2:24149416	ATAD2B	0.89	10.1	0.48	4.26e-21	Lymphocyte counts;
LUSC	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg05555928	chr11:63887634	MACROD1	-0.46	-6.16	-0.32	2.12e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs7188861	0.681	rs55752638	chr16:11409493	T/A	cg00044050	chr16:11439710	C16orf75	0.58	5.86	0.31	1.1e-8	HDL cholesterol;
LUSC	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg04607235	chr12:12878440	APOLD1	0.52	5.93	0.31	7.67e-9	Systemic lupus erythematosus;
LUSC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg18230493	chr5:56204884	C5orf35	-0.88	-13.27	-0.59	1.42e-32	Initial pursuit acceleration;
LUSC	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.52	9.64	0.47	1.47e-19	Bone mineral density;
LUSC	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg26597838	chr10:835615	NA	0.79	9.74	0.47	6.95e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg19784903	chr17:45786737	TBKBP1	-0.38	-5.84	-0.3	1.23e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs2018683	0.707	rs917215	chr7:28971367	C/T	cg19402173	chr7:128379420	CALU	-0.46	-7.07	-0.36	9.25e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg13453750	chr1:205783389	SLC41A1	-0.33	-6.48	-0.33	3.23e-10	Menarche (age at onset);
LUSC	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg03929089	chr4:120376271	NA	0.69	7.76	0.39	1.04e-13	Axial length;
LUSC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg02423579	chr7:2872169	GNA12	0.49	7.29	0.37	2.2e-12	Height;
LUSC	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg21293242	chr8:11204541	TDH	0.31	5.66	0.3	3.34e-8	Retinal vascular caliber;
LUSC	cis	rs4654899	0.664	rs10799665	chr1:21152640	C/T	cg01072550	chr1:21505969	NA	-0.43	-6.44	-0.33	4.15e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg02153584	chr22:29168773	CCDC117	-0.59	-9.04	-0.44	1.27e-17	Lymphocyte counts;
LUSC	cis	rs1595825	0.891	rs7580003	chr2:198517893	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.63	-0.34	1.32e-10	Ulcerative colitis;
LUSC	cis	rs9473147	0.543	rs4711880	chr6:47480676	A/G	cg12968598	chr6:47444699	CD2AP	0.53	8.07	0.4	1.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg13319975	chr6:146136371	FBXO30	0.5	7.84	0.39	6.2e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg03609598	chr5:56110824	MAP3K1	-0.35	-5.64	-0.3	3.57e-8	Initial pursuit acceleration;
LUSC	cis	rs67981189	0.593	rs10140225	chr14:71491121	T/C	cg15816911	chr14:71606274	NA	0.33	5.86	0.31	1.1e-8	Schizophrenia;
LUSC	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.74	0.35	6.99e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg21724239	chr8:58056113	NA	0.57	6.6	0.34	1.61e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg13395646	chr4:1353034	KIAA1530	0.58	8.88	0.44	4.28e-17	Obesity-related traits;
LUSC	trans	rs11949289	0.933	rs2195357	chr5:28349030	G/A	cg18220921	chr1:242687527	PLD5	0.35	5.96	0.31	6.57e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.82	-0.3	1.41e-8	IgG glycosylation;
LUSC	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg02493740	chr2:85810744	VAMP5	-0.5	-8.59	-0.43	3.45e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg23601095	chr6:26197514	HIST1H3D	0.73	7.46	0.38	7.42e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg27284194	chr4:1044797	NA	0.58	8.68	0.43	1.74e-16	Recombination rate (females);
LUSC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg08219700	chr8:58056026	NA	0.47	5.94	0.31	7.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7584330	0.554	rs3751109	chr2:238427194	T/C	cg16989719	chr2:238392110	NA	-0.43	-6.24	-0.32	1.34e-9	Prostate cancer;
LUSC	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg08684580	chr7:98029266	BAIAP2L1	0.39	5.96	0.31	6.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg18753928	chr3:113234510	CCDC52	-0.54	-8.36	-0.42	1.7e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.85	-0.35	3.57e-11	Monocyte percentage of white cells;
LUSC	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.93	-0.44	2.98e-17	Uric acid levels;
LUSC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.71	10.58	0.5	9.28e-23	Type 2 diabetes;
LUSC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.71	-10.97	-0.51	4.14e-24	Menarche (age at onset);
LUSC	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05901451	chr6:126070800	HEY2	0.77	12.54	0.57	8.32e-30	Endometrial cancer;
LUSC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg08798685	chr6:27730294	NA	0.66	6.06	0.31	3.6e-9	Depression;
LUSC	trans	rs743446	0.518	rs2836554	chr21:39973669	C/G	cg01504248	chr4:77345848	NA	-0.26	-5.95	-0.31	6.67e-9	Neonatal lupus;
LUSC	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.55	7.39	0.37	1.22e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.85	0.47	2.83e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2445762	0.659	rs12441170	chr15:51653898	G/A	cg07517944	chr15:51633816	GLDN	0.39	6.39	0.33	5.66e-10	Hormone measurements;
LUSC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	11.85	0.54	2.72e-27	Menopause (age at onset);
LUSC	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg03676636	chr4:99064102	C4orf37	0.28	5.9	0.31	8.72e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.57	-8.89	-0.44	4.03e-17	Menopause (age at onset);
LUSC	cis	rs6977940	0.818	rs55752034	chr7:2895416	T/C	cg19731401	chr7:2775893	GNA12	0.65	7.3	0.37	2.09e-12	White matter integrity;
LUSC	cis	rs6969780	0.915	rs11983200	chr7:27186596	A/G	cg26364809	chr7:27145159	NA	-0.6	-6.05	-0.31	3.79e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg04896959	chr15:78267971	NA	0.43	8.57	0.42	3.88e-16	Coronary artery disease or large artery stroke;
LUSC	cis	rs240764	0.687	rs1336245	chr6:101197640	A/T	cg09795085	chr6:101329169	ASCC3	-0.43	-6.27	-0.32	1.11e-9	Neuroticism;
LUSC	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.22e-15	Neuroticism;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14159672	chr1:205819179	PM20D1	-0.82	-14.76	-0.63	2.62e-38	Menarche (age at onset);
LUSC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg05738196	chr6:26577821	NA	0.53	8.32	0.41	2.23e-15	Schizophrenia;
LUSC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg02807482	chr3:125708958	NA	-0.54	-6.65	-0.34	1.16e-10	Blood pressure (smoking interaction);
LUSC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	10.3	0.49	8.64e-22	Alzheimer's disease;
LUSC	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg13010199	chr12:38710504	ALG10B	0.61	9.21	0.45	3.8e-18	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12541635	0.677	rs6469032	chr8:107057509	A/T	cg10147462	chr8:107024639	NA	0.66	13.82	0.6	1.17e-34	Age of smoking initiation;
LUSC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07677032	chr17:61819896	STRADA	0.52	8.79	0.43	8.03e-17	Prudent dietary pattern;
LUSC	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg25214090	chr10:38739885	LOC399744	-0.5	-7.76	-0.39	1.03e-13	Corneal astigmatism;
LUSC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-7.13	-0.36	6.22e-12	Joint mobility (Beighton score);
LUSC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg22963979	chr7:1858916	MAD1L1	-0.62	-9.88	-0.48	2.24e-20	Bipolar disorder and schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07435294	chr11:65554356	OVOL1	-0.48	-6.07	-0.32	3.5e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg05132306	chr1:1846340	CALML6	-0.33	-8.47	-0.42	8.1e-16	Body mass index;
LUSC	cis	rs686320	1.000	rs667196	chr11:65247092	A/T	cg21890820	chr11:65308645	LTBP3	0.75	7.48	0.38	6.58e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg17623882	chr6:41773611	USP49	-0.63	-10.61	-0.5	7.44e-23	Menarche (age at onset);
LUSC	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg11812906	chr14:75593930	NEK9	0.66	11.4	0.53	1.2e-25	Height;
LUSC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg07716408	chr11:68623521	NA	-0.33	-6.15	-0.32	2.24e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs8040855	0.860	rs7172266	chr15:85716213	C/T	cg04831495	chr15:85060580	GOLGA6L5	0.4	5.82	0.3	1.42e-8	Bulimia nervosa;
LUSC	cis	rs6681460	0.966	rs1325261	chr1:67110516	G/A	cg02459107	chr1:67143332	SGIP1	0.47	8.57	0.42	3.81e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.59	10.67	0.5	4.55e-23	Bone mineral density;
LUSC	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg15423357	chr2:25149977	NA	0.45	8.94	0.44	2.63e-17	Body mass index;
LUSC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	13.48	0.59	2.26e-33	Alzheimer's disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23068124	chr14:58711505	PSMA3	0.46	6.54	0.34	2.3e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg03929089	chr4:120376271	NA	-0.44	-6.19	-0.32	1.72e-9	HDL cholesterol;
LUSC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg06238570	chr21:40685208	BRWD1	0.55	8.52	0.42	5.69e-16	Menarche (age at onset);
LUSC	cis	rs965469	1.000	rs6139088	chr20:3329063	G/A	cg25506879	chr20:3388711	C20orf194	-0.51	-5.65	-0.3	3.48e-8	IFN-related cytopenia;
LUSC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg00945038	chr17:61921165	SMARCD2	0.53	9.28	0.45	2.15e-18	Prudent dietary pattern;
LUSC	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg11812906	chr14:75593930	NEK9	0.54	8.89	0.44	3.88e-17	Coronary artery disease;
LUSC	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg10253484	chr15:75165896	SCAMP2	-0.48	-6.5	-0.34	2.87e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg04369109	chr6:150039330	LATS1	-0.56	-8.37	-0.42	1.55e-15	Lung cancer;
LUSC	cis	rs7147624	1.000	rs10083363	chr14:66200768	G/A	cg03016385	chr14:66212404	NA	-0.78	-8.28	-0.41	2.9e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg26668828	chr6:292823	DUSP22	-0.52	-7.95	-0.4	2.99e-14	Menopause (age at onset);
LUSC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg08200582	chr11:442649	ANO9	-0.52	-6.1	-0.32	3.02e-9	Body mass index;
LUSC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06544989	chr22:39130855	UNC84B	0.33	5.65	0.3	3.51e-8	Menopause (age at onset);
LUSC	cis	rs2963155	0.518	rs55817235	chr5:142765733	C/T	cg17617527	chr5:142782415	NR3C1	0.72	8.29	0.41	2.88e-15	Breast cancer;
LUSC	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg00792783	chr2:198669748	PLCL1	0.43	5.68	0.3	2.9e-8	Intracranial aneurysm;
LUSC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg03709012	chr19:19516395	GATAD2A	0.75	11.61	0.54	2.13e-26	Tonsillectomy;
LUSC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	12.96	0.58	2.16e-31	Platelet count;
LUSC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.72	-13.42	-0.59	3.74e-33	Extrinsic epigenetic age acceleration;
LUSC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg12463550	chr7:65579703	CRCP	-0.41	-5.92	-0.31	7.78e-9	Aortic root size;
LUSC	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	1.11	18.62	0.71	1.39e-53	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg02972257	chr16:68554789	NA	-0.48	-6.07	-0.32	3.39e-9	Ulcerative colitis;
LUSC	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08280861	chr8:58055591	NA	0.53	5.81	0.3	1.46e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11310629	chr13:45991975	SLC25A30	0.41	6.21	0.32	1.57e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs617219	0.890	rs10060869	chr5:78489979	A/G	cg24856658	chr5:78533917	JMY	-0.3	-5.86	-0.31	1.13e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.36	0.33	6.58e-10	Personality dimensions;
LUSC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg04727924	chr7:799746	HEATR2	-0.57	-5.95	-0.31	6.85e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg01097406	chr16:89675127	NA	0.32	6.27	0.32	1.14e-9	Vitiligo;
LUSC	cis	rs67539049	1.000	rs56138616	chr8:11287550	A/G	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.42	-5.97	-0.31	6.18e-9	Itch intensity from mosquito bite;
LUSC	cis	rs2286885	0.965	rs10760440	chr9:129250831	C/T	cg15282417	chr9:129245246	FAM125B	0.4	6.61	0.34	1.54e-10	Intraocular pressure;
LUSC	cis	rs2348418	0.966	rs11049699	chr12:28688420	C/T	cg13890972	chr12:28721907	NA	-0.34	-5.74	-0.3	2.1e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg00064840	chr7:4784485	FOXK1	0.3	5.68	0.3	2.88e-8	Mosquito bite size;
LUSC	trans	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg26043149	chr18:55253948	FECH	-0.44	-6.7	-0.34	9.06e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg23422044	chr7:1970798	MAD1L1	-0.54	-6.02	-0.31	4.71e-9	Bipolar disorder;
LUSC	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg03733263	chr8:22462867	KIAA1967	0.89	15.58	0.65	1.59e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.36	0.46	1.21e-18	Coffee consumption (cups per day);
LUSC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg14416269	chr4:6271139	WFS1	0.54	11.38	0.53	1.35e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg09092052	chr15:45571596	NA	0.46	6.29	0.33	9.68e-10	Glomerular filtration rate;
LUSC	cis	rs62400317	0.793	rs6924185	chr6:45017228	C/A	cg18551225	chr6:44695536	NA	-0.42	-6.97	-0.36	1.69e-11	Total body bone mineral density;
LUSC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg09877947	chr5:131593287	PDLIM4	0.45	7.37	0.37	1.4e-12	Breast cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07521723	chr16:27280150	NSMCE1	0.71	6.05	0.31	3.8e-9	Cognitive performance;
LUSC	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg22431228	chr1:16359049	CLCNKA	0.45	8.69	0.43	1.6e-16	Dilated cardiomyopathy;
LUSC	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg24531977	chr5:56204891	C5orf35	-0.52	-7.68	-0.39	1.82e-13	Coronary artery disease;
LUSC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-1.03	-20.22	-0.74	6e-60	Height;
LUSC	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg10604040	chr11:65559109	OVOL1	0.31	5.72	0.3	2.34e-8	Acne (severe);
LUSC	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg13902645	chr11:5959945	NA	0.54	7.18	0.37	4.46e-12	DNA methylation (variation);
LUSC	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.4	-6.19	-0.32	1.77e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-9.61	-0.47	1.87e-19	Brugada syndrome;
LUSC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg13206674	chr6:150067644	NUP43	0.6	9.53	0.46	3.38e-19	Lung cancer;
LUSC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg01879757	chr17:41196368	BRCA1	-0.39	-5.96	-0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg25237894	chr2:233734115	C2orf82	0.35	6.48	0.33	3.36e-10	Coronary artery disease;
LUSC	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg24375607	chr4:120327624	NA	0.76	11.14	0.52	1e-24	Corneal astigmatism;
LUSC	cis	rs9463078	0.665	rs9472339	chr6:44711791	A/G	cg25276700	chr6:44698697	NA	0.31	6.35	0.33	7.05e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.59	9.4	0.46	9.08e-19	Pulse pressure;
LUSC	cis	rs6546886	0.957	rs4853003	chr2:74248871	A/G	cg14702570	chr2:74259524	NA	-0.31	-5.89	-0.31	9.27e-9	Dialysis-related mortality;
LUSC	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg15798862	chr7:76129360	DTX2	-0.51	-8.54	-0.42	4.77e-16	Multiple sclerosis;
LUSC	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg21724239	chr8:58056113	NA	0.55	6.75	0.35	6.63e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.12	-19.49	-0.73	4.76e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg24642439	chr20:33292090	TP53INP2	0.62	9.43	0.46	7.1e-19	Coronary artery disease;
LUSC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg20887711	chr4:1340912	KIAA1530	0.46	7.04	0.36	1.07e-11	Obesity-related traits;
LUSC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.8	-0.35	4.9e-11	Monocyte percentage of white cells;
LUSC	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg24296786	chr1:45957014	TESK2	-0.49	-7.24	-0.37	3.2e-12	High light scatter reticulocyte count;
LUSC	cis	rs4594175	0.926	rs4131365	chr14:51622444	C/T	cg23942311	chr14:51606299	NA	0.31	5.86	0.31	1.11e-8	Cancer;
LUSC	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg05855489	chr10:104503620	C10orf26	0.51	7.75	0.39	1.1e-13	Arsenic metabolism;
LUSC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg13206674	chr6:150067644	NUP43	0.58	9.09	0.45	8.72e-18	Lung cancer;
LUSC	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg12573674	chr2:1569213	NA	-0.56	-7.97	-0.4	2.61e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.11	-17.83	-0.7	1.92e-50	Primary sclerosing cholangitis;
LUSC	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg25204440	chr1:209979598	IRF6	0.53	7.08	0.36	8.6e-12	Cleft lip with or without cleft palate;
LUSC	cis	rs2625529	0.824	rs12917428	chr15:72221998	T/C	cg16672083	chr15:72433130	SENP8	-0.52	-7.51	-0.38	5.28e-13	Red blood cell count;
LUSC	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	6.54	0.34	2.33e-10	Lung cancer in ever smokers;
LUSC	cis	rs708547	0.792	rs7667084	chr4:57727435	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.57	-7.18	-0.37	4.67e-12	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg13010344	chr12:123464640	ARL6IP4	0.48	7.43	0.38	8.97e-13	Platelet count;
LUSC	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.3	-0.45	1.86e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg04317338	chr11:64019027	PLCB3	0.65	7.32	0.37	1.87e-12	Mean platelet volume;
LUSC	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg13206674	chr6:150067644	NUP43	-0.53	-8.14	-0.41	8.09e-15	Lung cancer;
LUSC	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg13010199	chr12:38710504	ALG10B	0.47	7.01	0.36	1.33e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-1.18	-13.0	-0.58	1.52e-31	Diabetic kidney disease;
LUSC	cis	rs4499344	0.622	rs7259049	chr19:33056594	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.71	-8.75	-0.43	1.04e-16	Mean platelet volume;
LUSC	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.79	0.47	4.45e-20	Migraine;Coronary artery disease;
LUSC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg23978390	chr7:1156363	C7orf50	0.46	6.44	0.33	4.17e-10	Longevity;Endometriosis;
LUSC	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg03676636	chr4:99064102	C4orf37	0.27	5.84	0.3	1.24e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7615316	0.902	rs7610557	chr3:142312371	A/G	cg16271453	chr3:142027066	XRN1	-0.36	-6.12	-0.32	2.61e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs193541	0.632	rs246279	chr5:122241263	C/G	cg19077854	chr5:122220652	SNX24	-0.43	-5.93	-0.31	7.5e-9	Glucose homeostasis traits;
LUSC	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg26587870	chr6:27730563	NA	-0.65	-5.66	-0.3	3.21e-8	Depression;
LUSC	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.46	-0.38	7.53e-13	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs12200782	0.872	rs59438701	chr6:26412527	C/T	cg18180407	chr1:55047736	ACOT11	0.44	6.01	0.31	4.8e-9	Small cell lung carcinoma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16794633	chr3:143690145	C3orf58	-0.4	-6.53	-0.34	2.47e-10	Electrocardiographic conduction measures;
LUSC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10802521	chr3:52805072	NEK4	-0.48	-7.49	-0.38	6.15e-13	Electroencephalogram traits;
LUSC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg03146154	chr1:46216737	IPP	0.49	7.33	0.37	1.73e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9283706	0.513	rs7707409	chr5:66351889	A/G	cg11590213	chr5:66331682	MAST4	0.5	7.44	0.38	8.61e-13	Coronary artery disease;
LUSC	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg22535103	chr8:58192502	C8orf71	-0.59	-6.81	-0.35	4.65e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg24562669	chr7:97807699	LMTK2	0.35	6.2	0.32	1.65e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13089785	1.000	rs13092912	chr3:123604942	C/T	cg02558132	chr3:123411198	MYLK	0.36	6.25	0.32	1.26e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1113500	0.702	rs11185262	chr1:108639742	C/T	cg11967332	chr1:108735228	SLC25A24	0.4	5.93	0.31	7.61e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs7246967	0.673	rs11881740	chr19:22843844	T/C	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs4851254	0.618	rs7572939	chr2:100654914	A/G	cg07810366	chr2:100720526	AFF3	-0.46	-5.98	-0.31	5.87e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-9.02	-0.44	1.49e-17	Mood instability;
LUSC	cis	rs9362426	1.000	rs1203156	chr6:88079694	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	5.76	0.3	1.94e-8	Depressive episodes in bipolar disorder;
LUSC	cis	rs13126513	0.519	rs12641768	chr4:100558594	C/A	cg05468953	chr4:100565104	NA	0.35	6.59	0.34	1.76e-10	Metabolite levels (MHPG);
LUSC	cis	rs9420	0.961	rs11605731	chr11:57524089	C/G	cg02958346	chr11:57425731	CLP1	-0.44	-6.44	-0.33	4.22e-10	Schizophrenia;
LUSC	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg14196790	chr5:131705035	SLC22A5	0.52	8.91	0.44	3.46e-17	Blood metabolite levels;
LUSC	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.6	-8.24	-0.41	4e-15	Body mass index (adult);
LUSC	cis	rs79387448	0.745	rs59126438	chr2:103165142	T/G	cg09003973	chr2:102972529	NA	0.88	8.56	0.42	4.18e-16	Gut microbiota (bacterial taxa);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg13188385	chr3:9291334	SRGAP3	0.45	6.41	0.33	5.09e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs72781680	0.678	rs11125293	chr2:24102423	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	6.91	0.35	2.4e-11	Lymphocyte counts;
LUSC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-5.96	-0.31	6.29e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg22834771	chr12:69754056	YEATS4	-0.45	-6.48	-0.33	3.22e-10	Blood protein levels;
LUSC	cis	rs981844	0.885	rs72731673	chr4:154667446	A/G	cg14289246	chr4:154710475	SFRP2	0.48	6.03	0.31	4.26e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs3101457	0.515	rs4658628	chr1:244516090	T/C	cg09033006	chr1:244517177	C1orf100	-0.44	-6.3	-0.33	9.61e-10	Smoking behavior;
LUSC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	16.58	0.67	1.84e-45	Platelet count;
LUSC	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg00945038	chr17:61921165	SMARCD2	0.38	5.68	0.3	2.96e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg05729581	chr11:3078854	CARS	-0.55	-8.57	-0.42	3.97e-16	Longevity;
LUSC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg19592336	chr6:28129416	ZNF389	0.45	6.0	0.31	5.12e-9	Depression;
LUSC	cis	rs9463078	0.625	rs12190513	chr6:44920679	A/T	cg25276700	chr6:44698697	NA	0.28	5.85	0.3	1.17e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg18190219	chr22:46762943	CELSR1	-0.61	-6.02	-0.31	4.52e-9	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs877282	0.583	rs10904566	chr10:821662	C/G	cg13042288	chr15:90349979	ANPEP	-0.43	-6.31	-0.33	9.06e-10	Uric acid levels;
LUSC	trans	rs2288327	0.557	rs7588593	chr2:179352450	T/C	cg14011486	chr1:26737247	LIN28	0.78	9.73	0.47	7.51e-20	Atrial fibrillation;
LUSC	cis	rs75804782	0.521	rs56373856	chr2:239437926	C/T	cg18131467	chr2:239335373	ASB1	-0.67	-6.01	-0.31	4.73e-9	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg25482853	chr8:67687455	SGK3	1.09	15.86	0.66	1.27e-42	Obesity-related traits;
LUSC	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg24375607	chr4:120327624	NA	0.79	11.89	0.55	2.04e-27	Corneal astigmatism;
LUSC	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg01256987	chr12:42539512	GXYLT1	0.35	6.27	0.32	1.11e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs554111	0.656	rs10753514	chr1:21492531	T/C	cg01072550	chr1:21505969	NA	0.39	5.87	0.31	1.05e-8	Facial morphology (factor 17, height of vermillion upper lip);
LUSC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg16606324	chr3:10149918	C3orf24	0.58	8.23	0.41	4.27e-15	Alzheimer's disease;
LUSC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06873352	chr17:61820015	STRADA	-0.54	-8.62	-0.43	2.75e-16	Height;
LUSC	cis	rs12900413	0.523	rs11636525	chr15:90300478	A/G	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.56e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.49	-6.79	-0.35	5e-11	Tonsillectomy;
LUSC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg22903471	chr2:27725779	GCKR	-0.41	-6.98	-0.36	1.64e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs7589342	0.929	rs6719896	chr2:106428404	C/G	cg16077055	chr2:106428750	NCK2	-0.37	-7.13	-0.36	6.27e-12	Addiction;
LUSC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg25828334	chr19:18545568	ISYNA1	0.34	5.97	0.31	6.04e-9	Breast cancer;
LUSC	cis	rs2067615	0.579	rs10746066	chr12:107129108	G/A	cg15890332	chr12:107067104	RFX4	0.34	6.19	0.32	1.77e-9	Heart rate;
LUSC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07362569	chr17:61921086	SMARCD2	0.38	7.87	0.4	4.99e-14	Prudent dietary pattern;
LUSC	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg18404041	chr3:52824283	ITIH1	0.45	7.8	0.39	8.03e-14	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg23173402	chr1:227635558	NA	-0.6	-7.21	-0.37	3.66e-12	Major depressive disorder;
LUSC	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs2414856	0.510	rs72756994	chr15:64606417	C/G	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.64	9.79	0.47	4.71e-20	Coronary artery disease;
LUSC	cis	rs11112613	0.609	rs2374534	chr12:106047897	A/T	cg03607813	chr12:105948248	NA	0.62	7.68	0.39	1.81e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs4285028	0.699	rs1920298	chr3:121597888	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.79	-10.77	-0.51	2.03e-23	Multiple sclerosis;
LUSC	cis	rs7202877	0.706	rs247443	chr16:75465073	G/C	cg04384234	chr16:75411784	CFDP1	0.7	9.68	0.47	1.08e-19	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg09699651	chr6:150184138	LRP11	0.45	6.99	0.36	1.46e-11	Testicular germ cell tumor;
LUSC	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.24	-0.52	4.38e-25	Coffee consumption (cups per day);
LUSC	cis	rs17253792	0.822	rs17685053	chr14:56125771	T/A	cg01858014	chr14:56050164	KTN1	-0.69	-6.06	-0.31	3.61e-9	Putamen volume;
LUSC	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-8.6	-0.43	3.16e-16	Total cholesterol levels;
LUSC	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	1.09	17.44	0.69	6.94e-49	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg08807101	chr21:30365312	RNF160	-0.63	-10.18	-0.49	2.26e-21	Pancreatic cancer;
LUSC	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg06713675	chr4:122721982	EXOSC9	0.36	6.08	0.32	3.37e-9	Type 2 diabetes;
LUSC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg08499158	chr17:42289980	UBTF	-0.53	-8.52	-0.42	5.5e-16	Total body bone mineral density;
LUSC	cis	rs727505	0.954	rs1525613	chr7:124658636	A/G	cg23710748	chr7:124431027	NA	-0.38	-6.58	-0.34	1.79e-10	Lewy body disease;
LUSC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg19592336	chr6:28129416	ZNF389	0.54	7.05	0.36	1.02e-11	Parkinson's disease;
LUSC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.19	-0.37	4.39e-12	Bipolar disorder;
LUSC	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg01073479	chr16:3509474	NAT15	-0.45	-5.91	-0.31	8.41e-9	Tuberculosis;
LUSC	cis	rs7614311	0.731	rs3774719	chr3:63950338	C/A	cg22134162	chr3:63841271	THOC7	-0.49	-5.95	-0.31	6.73e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg13206674	chr6:150067644	NUP43	0.58	9.09	0.45	8.72e-18	Lung cancer;
LUSC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.08	-0.32	3.23e-9	Platelet count;
LUSC	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg08999081	chr20:33150536	PIGU	0.36	6.68	0.34	1.03e-10	Height;
LUSC	cis	rs977987	0.806	rs4888411	chr16:75443183	T/A	cg04384234	chr16:75411784	CFDP1	-0.41	-6.61	-0.34	1.52e-10	Dupuytren's disease;
LUSC	cis	rs4285028	0.747	rs9820511	chr3:121361345	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-12.72	-0.57	1.76e-30	Multiple sclerosis;
LUSC	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg27068330	chr11:65405492	SIPA1	0.64	9.66	0.47	1.28e-19	Acne (severe);
LUSC	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14442939	chr10:27389572	ANKRD26	-0.88	-9.9	-0.48	1.97e-20	Breast cancer;
LUSC	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.54	10.78	0.51	1.93e-23	Coronary artery disease;
LUSC	cis	rs2625529	0.617	rs2128112	chr15:72186286	A/T	cg16672083	chr15:72433130	SENP8	0.48	7.93	0.4	3.28e-14	Red blood cell count;
LUSC	cis	rs7123876	0.587	rs184654	chr11:72364405	C/G	cg03713592	chr11:72463424	ARAP1	0.63	7.3	0.37	2.07e-12	Body mass index;
LUSC	cis	rs8032315	1.000	rs8032315	chr15:91418297	A/T	cg04510874	chr15:91427884	FES	0.29	5.89	0.31	9.46e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg08859206	chr1:53392774	SCP2	-0.43	-6.95	-0.36	1.98e-11	Monocyte count;
LUSC	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.25	0.52	4.11e-25	Eye color traits;
LUSC	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.49	-0.42	6.96e-16	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs2262909	0.962	rs73019889	chr19:22277826	C/G	cg05197062	chr11:11642011	GALNTL4	0.54	7.58	0.38	3.39e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06022373	chr22:39101656	GTPBP1	0.67	10.56	0.5	1.13e-22	Menopause (age at onset);
LUSC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03934478	chr11:495069	RNH1	0.82	9.84	0.47	3.08e-20	Body mass index;
LUSC	cis	rs7000551	0.700	rs2469761	chr8:22367274	A/G	cg12081754	chr8:22256438	SLC39A14	0.39	6.06	0.31	3.65e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs3764021	0.870	rs10466829	chr12:9876091	G/A	cg20894963	chr12:9885564	CLECL1	0.35	7.11	0.36	7.09e-12	Type 1 diabetes;
LUSC	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg08916839	chr5:415575	AHRR	0.75	7.14	0.36	6.01e-12	Fat distribution (HIV);
LUSC	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg12927641	chr6:109611667	NA	-0.34	-5.77	-0.3	1.76e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	0.94	13.39	0.59	4.94e-33	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.7	-0.43	1.59e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg13145458	chr22:31556086	RNF185	0.44	5.72	0.3	2.37e-8	Paclitaxel-induced neuropathy;
LUSC	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg14343924	chr8:8086146	FLJ10661	-0.45	-6.32	-0.33	8.16e-10	Acne (severe);
LUSC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg05623727	chr3:50126028	RBM5	0.35	6.56	0.34	2e-10	Body mass index;
LUSC	cis	rs1595825	0.786	rs74652956	chr2:198754247	C/T	cg10547527	chr2:198650123	BOLL	-0.49	-5.71	-0.3	2.51e-8	Ulcerative colitis;
LUSC	cis	rs34375054	0.672	rs58416336	chr12:125606428	G/T	cg25124228	chr12:125621409	AACS	-0.48	-7.75	-0.39	1.15e-13	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg02534363	chr3:47050950	NBEAL2	-0.34	-5.65	-0.3	3.42e-8	Colorectal cancer;
LUSC	cis	rs12681287	0.609	rs13281414	chr8:87495254	A/C	cg27223183	chr8:87520930	FAM82B	-0.55	-7.24	-0.37	3.19e-12	Caudate activity during reward;
LUSC	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg23887609	chr12:130822674	PIWIL1	-0.43	-6.5	-0.34	2.85e-10	Menopause (age at onset);
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg22963979	chr7:1858916	MAD1L1	-0.64	-10.24	-0.49	1.4e-21	Bipolar disorder and schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03448938	chr2:209130777	PIKFYVE	-0.41	-5.99	-0.31	5.41e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg10523860	chr14:103875565	MARK3	-0.38	-6.26	-0.32	1.15e-9	Body mass index;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05998816	chr21:47859926	PCNT	0.44	6.36	0.33	6.56e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg18351406	chr4:77819688	ANKRD56	0.59	8.48	0.42	7.37e-16	Emphysema distribution in smoking;
LUSC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg18681998	chr4:17616180	MED28	0.85	15.94	0.66	6.13e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs34734847	0.787	rs695948	chr12:121149596	A/G	cg27246729	chr12:121163418	ACADS	0.42	6.62	0.34	1.4e-10	Mean corpuscular volume;
LUSC	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg10360139	chr7:1886902	MAD1L1	-0.43	-6.61	-0.34	1.54e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg21535247	chr6:8435926	SLC35B3	0.57	8.9	0.44	3.51e-17	Motion sickness;
LUSC	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg13010199	chr12:38710504	ALG10B	0.53	8.03	0.4	1.64e-14	Morning vs. evening chronotype;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg11267619	chr7:29604021	PRR15	-0.5	-6.23	-0.32	1.43e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg19257562	chr1:2043853	PRKCZ	0.3	5.98	0.31	5.61e-9	Height;
LUSC	cis	rs2625529	0.938	rs2625530	chr15:72126034	G/A	cg16672083	chr15:72433130	SENP8	-0.5	-7.11	-0.36	7.31e-12	Red blood cell count;
LUSC	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.59	-9.56	-0.46	2.61e-19	Body mass index;
LUSC	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg07424592	chr7:64974309	NA	-0.63	-5.68	-0.3	2.9e-8	Diabetic kidney disease;
LUSC	cis	rs231513	0.822	rs231520	chr17:41956983	T/C	cg26893861	chr17:41843967	DUSP3	-0.5	-5.94	-0.31	7.03e-9	Cognitive function;
LUSC	trans	rs2268344	0.630	rs2142309	chr10:124263692	T/C	cg11199862	chr13:46108984	COG3	-0.68	-6.06	-0.31	3.75e-9	Coronary artery disease;
LUSC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.98	-0.52	3.66e-24	Alzheimer's disease;
LUSC	cis	rs17095355	1.000	rs9630102	chr10:111738662	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.57	-7.36	-0.37	1.43e-12	Biliary atresia;
LUSC	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-8.79	-0.43	8.06e-17	Response to antipsychotic treatment;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg01238044	chr22:24384105	GSTT1	-0.55	-8.01	-0.4	2e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.87	-0.31	1.08e-8	Aortic root size;
LUSC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg22907277	chr7:1156413	C7orf50	0.67	7.43	0.38	8.98e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs469568	0.543	rs4700789	chr5:178669361	A/G	cg08999896	chr5:178685787	ADAMTS2	0.39	7.67	0.39	1.86e-13	Stroke (pediatric);
LUSC	cis	rs6076065	0.723	rs2424536	chr20:23381601	C/T	cg11657817	chr20:23433608	CST11	0.43	8.24	0.41	4.07e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs6500395	1.000	rs9933187	chr16:48556573	A/C	cg04672837	chr16:48644449	N4BP1	-0.45	-6.53	-0.34	2.45e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6967385	0.519	rs7795828	chr7:12347689	C/T	cg20607287	chr7:12443886	VWDE	0.53	7.87	0.4	5.08e-14	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg20283391	chr11:68216788	NA	-0.61	-8.56	-0.42	4.24e-16	Total body bone mineral density;
LUSC	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg02176678	chr2:219576539	TTLL4	-0.58	-10.3	-0.49	8.75e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg14895029	chr7:2775587	GNA12	-0.44	-6.85	-0.35	3.65e-11	Height;
LUSC	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg05340658	chr4:99064831	C4orf37	0.66	10.97	0.51	4.2e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11958404	0.932	rs72816584	chr5:157433190	G/A	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg07703079	chr11:430292	ANO9	0.6	6.52	0.34	2.66e-10	Body mass index;
LUSC	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg18478394	chr8:109455254	TTC35	0.44	6.8	0.35	4.76e-11	Dupuytren's disease;
LUSC	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg17173187	chr15:85201210	NMB	0.47	8.99	0.44	1.84e-17	Schizophrenia;
LUSC	cis	rs7572644	0.640	rs4666014	chr2:28019175	A/G	cg27432699	chr2:27873401	GPN1	-0.56	-7.08	-0.36	8.62e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	8.23	0.41	4.2e-15	Height;
LUSC	cis	rs9503598	0.636	rs6596976	chr6:3466022	C/T	cg00476032	chr6:3446245	SLC22A23	0.32	6.43	0.33	4.53e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16726667	chr16:68002228	SLC12A4	-0.39	-5.95	-0.31	6.74e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg07194495	chr7:148958859	ZNF783	0.42	6.18	0.32	1.85e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.33	-0.33	8.06e-10	Response to antipsychotic treatment;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg25703541	chr22:24373054	LOC391322	-0.9	-14.54	-0.62	1.92e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg27661571	chr11:113659931	NA	-0.6	-7.18	-0.37	4.49e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs13315871	0.929	rs1045115	chr3:58305199	C/T	cg12435725	chr3:58293450	RPP14	-0.62	-6.78	-0.35	5.45e-11	Cholesterol, total;
LUSC	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg03676636	chr4:99064102	C4orf37	0.33	7.19	0.37	4.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9653442	0.527	rs11690905	chr2:100761473	C/T	cg07810366	chr2:100720526	AFF3	0.44	7.67	0.39	1.95e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	trans	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg07923666	chr12:49932857	KCNH3	-0.49	-6.09	-0.32	3.03e-9	Resting heart rate;
LUSC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.72	10.06	0.48	5.9e-21	Glomerular filtration rate (creatinine);
LUSC	trans	rs76248362	0.748	rs943061	chr13:24431968	C/T	cg00599770	chr7:27196825	HOXA7	-0.64	-7.42	-0.38	9.91e-13	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.91	-0.31	8.46e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	10.72	0.51	3.16e-23	Ileal carcinoids;
LUSC	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.77	11.23	0.52	4.66e-25	Corneal astigmatism;
LUSC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg11843238	chr5:131593191	PDLIM4	0.34	5.84	0.3	1.23e-8	Breast cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg22331096	chr8:128749328	MYC	-0.48	-6.25	-0.32	1.23e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7605827	0.897	rs7425203	chr2:15697410	A/G	cg19274914	chr2:15703543	NA	0.47	9.04	0.44	1.32e-17	Educational attainment (years of education);
LUSC	cis	rs6138458	0.626	rs6050259	chr20:25011423	A/G	cg26195577	chr20:24973756	C20orf3	0.71	10.65	0.5	5.5e-23	Blood protein levels;
LUSC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg04632378	chr13:21900426	NA	0.32	5.99	0.31	5.45e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg25039879	chr17:56429692	SUPT4H1	0.67	8.85	0.44	5.03e-17	Cognitive test performance;
LUSC	cis	rs2677744	0.626	rs3743452	chr15:91497515	C/T	cg01368872	chr15:91498139	RCCD1	-0.43	-5.69	-0.3	2.76e-8	Attention deficit hyperactivity disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23966157	chr14:74486355	C14orf45;ENTPD5	-0.42	-6.08	-0.32	3.36e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.73	9.09	0.45	9.29e-18	Type 2 diabetes;
LUSC	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg27432699	chr2:27873401	GPN1	-0.58	-8.68	-0.43	1.72e-16	Total body bone mineral density;
LUSC	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg17691542	chr6:26056736	HIST1H1C	0.47	7.0	0.36	1.44e-11	Height;
LUSC	trans	rs975739	0.868	rs5351	chr13:78475313	C/T	cg00971891	chr3:88199395	C3orf38	-0.35	-5.98	-0.31	5.7e-9	Hair color;
LUSC	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg07274523	chr3:49395745	GPX1	0.36	5.76	0.3	1.93e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	0.78	11.89	0.55	1.96e-27	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25072359	chr17:41440525	NA	0.66	9.4	0.46	8.95e-19	Menopause (age at onset);
LUSC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.26	-0.32	1.17e-9	Life satisfaction;
LUSC	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg08923669	chr16:420230	MRPL28	-0.43	-7.32	-0.37	1.91e-12	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg12483005	chr1:23474871	LUZP1	0.43	6.69	0.34	9.54e-11	Height;
LUSC	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg05643964	chr20:62369504	LIME1	0.39	5.95	0.31	6.65e-9	Prostate cancer;
LUSC	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08677398	chr8:58056175	NA	0.54	6.63	0.34	1.35e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg25258033	chr6:167368657	RNASET2	0.45	7.15	0.36	5.55e-12	Crohn's disease;
LUSC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs4595586	0.566	rs7135104	chr12:39411086	C/T	cg26384229	chr12:38710491	ALG10B	0.46	6.53	0.34	2.39e-10	Morning vs. evening chronotype;
LUSC	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg16950941	chr11:66035639	RAB1B	0.49	7.13	0.36	6.41e-12	Gout;
LUSC	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg24060327	chr5:131705240	SLC22A5	-0.39	-6.48	-0.33	3.38e-10	Blood metabolite levels;
LUSC	cis	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg17469321	chr7:55412551	NA	0.65	10.58	0.5	9.39e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-11.67	-0.54	1.29e-26	Coffee consumption (cups per day);
LUSC	cis	rs96067	0.711	rs795047	chr1:36637708	C/T	cg24686825	chr1:36642396	MAP7D1	0.52	7.97	0.4	2.48e-14	Corneal structure;
LUSC	cis	rs1595825	0.891	rs73058864	chr2:198889587	C/T	cg10547527	chr2:198650123	BOLL	-0.52	-6.3	-0.33	9.56e-10	Ulcerative colitis;
LUSC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg12963246	chr6:28129442	ZNF389	0.58	8.07	0.4	1.24e-14	Parkinson's disease;
LUSC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.62	-0.34	1.39e-10	High light scatter reticulocyte count;
LUSC	cis	rs1044826	0.913	rs9825064	chr3:139049804	C/T	cg00490450	chr3:139108681	COPB2	0.55	7.29	0.37	2.32e-12	Obesity-related traits;
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg23131131	chr22:24373011	LOC391322	-0.42	-6.12	-0.32	2.6e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg01528321	chr10:82214614	TSPAN14	1.13	18.28	0.71	3.23e-52	Post bronchodilator FEV1;
LUSC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.79	11.91	0.55	1.74e-27	Vitiligo;
LUSC	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg12863693	chr15:85201151	NMB	0.41	8.58	0.42	3.65e-16	Schizophrenia;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg26397265	chr12:25348258	LYRM5;CASC1	0.38	6.14	0.32	2.35e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-6.87	-0.35	3.2e-11	Homocysteine levels;
LUSC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-18.93	-0.72	8.57e-55	Height;
LUSC	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg00677455	chr12:58241039	CTDSP2	-0.47	-7.03	-0.36	1.14e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.72	10.85	0.51	1.06e-23	Body mass index;
LUSC	cis	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg06521331	chr12:34319734	NA	-0.37	-6.05	-0.31	3.81e-9	Morning vs. evening chronotype;
LUSC	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg18683606	chr7:100471612	SRRT	0.46	6.12	0.32	2.56e-9	Resting heart rate;
LUSC	trans	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg26384229	chr12:38710491	ALG10B	-0.51	-7.76	-0.39	1.07e-13	Morning vs. evening chronotype;
LUSC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.44	-6.39	-0.33	5.48e-10	Insulin-like growth factors;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07080756	chr10:104192239	CUEDC2	-0.46	-6.74	-0.35	6.91e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9905704	0.718	rs72826360	chr17:56664395	T/G	cg12560992	chr17:57184187	TRIM37	0.51	5.96	0.31	6.45e-9	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg23788917	chr6:8435910	SLC35B3	0.51	7.69	0.39	1.63e-13	Motion sickness;
LUSC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.54	-8.04	-0.4	1.53e-14	Gut microbiome composition (summer);
LUSC	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.38	5.65	0.3	3.51e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15369054	chr17:80825471	TBCD	-0.66	-10.81	-0.51	1.44e-23	Breast cancer;
LUSC	cis	rs240764	0.658	rs9386257	chr6:101252069	A/T	cg09795085	chr6:101329169	ASCC3	0.45	6.5	0.34	2.9e-10	Neuroticism;
LUSC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg21724239	chr8:58056113	NA	0.56	6.69	0.34	9.55e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303542	0.625	rs11868098	chr17:46570869	C/G	cg09704116	chr17:46666958	LOC404266	0.32	5.9	0.31	8.99e-9	Ovarian cancer;Epithelial ovarian cancer;
LUSC	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg17470723	chr8:74884337	TCEB1	0.53	8.26	0.41	3.42e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg04414720	chr1:150670196	GOLPH3L	0.49	7.88	0.4	4.66e-14	Melanoma;
LUSC	cis	rs6960043	1.000	rs62448644	chr7:15053485	C/T	cg19272540	chr7:15055459	NA	-0.3	-7.22	-0.37	3.56e-12	Type 2 diabetes;
LUSC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.8	-0.51	1.57e-23	Aortic root size;
LUSC	cis	rs4654899	0.802	rs17449966	chr1:21203996	A/G	cg02927042	chr1:21476669	EIF4G3	-0.38	-5.99	-0.31	5.4e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27297192	chr10:134578999	INPP5A	0.37	6.03	0.31	4.24e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.37	-5.94	-0.31	7.36e-9	Vitiligo;
LUSC	cis	rs6722750	0.651	rs12987393	chr2:64421514	C/T	cg22352474	chr2:64371530	PELI1	0.53	7.95	0.4	2.95e-14	Neuroticism;
LUSC	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.2	-0.37	4.06e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg08493051	chr2:3487164	NA	-0.57	-8.84	-0.44	5.51e-17	Neurofibrillary tangles;
LUSC	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-6.76	-0.35	6.22e-11	Colorectal cancer;
LUSC	trans	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.93	-0.4	3.24e-14	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg26395211	chr5:140044315	WDR55	-0.38	-6.04	-0.31	4.21e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4356932	1.000	rs4241578	chr4:76944491	T/C	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs55871839	0.708	rs4738730	chr8:59808935	A/T	cg07426533	chr8:59803705	TOX	-0.37	-6.01	-0.31	4.92e-9	Pneumonia;
LUSC	cis	rs259282	0.524	rs3760941	chr19:33130866	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.81	12.19	0.55	1.56e-28	Schizophrenia;
LUSC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg15103426	chr22:29168792	CCDC117	0.59	8.3	0.41	2.69e-15	Lymphocyte counts;
LUSC	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg05855489	chr10:104503620	C10orf26	0.6	9.61	0.47	1.88e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg20684491	chr1:25596433	NA	0.4	6.34	0.33	7.43e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg15595755	chr5:1867978	NA	0.46	8.13	0.41	8.32e-15	Cardiovascular disease risk factors;
LUSC	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg21573476	chr21:45109991	RRP1B	-0.38	-6.08	-0.32	3.2e-9	Mean corpuscular volume;
LUSC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg02423579	chr7:2872169	GNA12	-0.47	-7.06	-0.36	9.81e-12	Height;
LUSC	trans	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg10756647	chr7:56101905	PSPH	0.83	8.37	0.42	1.66e-15	Diabetic kidney disease;
LUSC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.53	17.07	0.68	1.97e-47	Opioid sensitivity;
LUSC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.45	0.33	3.85e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12292205	chr6:26970375	C6orf41	-0.58	-7.39	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.44	-7.53	-0.38	4.89e-13	Longevity;Endometriosis;
LUSC	trans	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg15556689	chr8:8085844	FLJ10661	0.42	6.26	0.32	1.17e-9	Retinal vascular caliber;
LUSC	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-6.59	-0.34	1.69e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7216064	1.000	rs12452511	chr17:65832576	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-8.81	-0.43	7.2e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-9.54	-0.46	3e-19	Total cholesterol levels;
LUSC	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg04374321	chr14:90722782	PSMC1	0.73	11.56	0.53	3.11e-26	Mortality in heart failure;
LUSC	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs501916	0.833	rs11629796	chr15:48045248	A/G	cg16110827	chr15:48056943	SEMA6D	-0.42	-6.54	-0.34	2.32e-10	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs7973719	0.966	rs7310539	chr12:7329996	C/G	cg07052231	chr12:7363540	PEX5	0.53	9.06	0.44	1.1e-17	IgG glycosylation;
LUSC	cis	rs9341808	0.905	rs3805903	chr6:80975829	T/C	cg08355045	chr6:80787529	NA	0.51	9.06	0.44	1.13e-17	Sitting height ratio;
LUSC	cis	rs2637266	0.745	rs241	chr10:78444456	G/T	cg18941641	chr10:78392320	NA	0.32	5.8	0.3	1.58e-8	Pulmonary function;
LUSC	cis	rs4474465	1.000	rs10793313	chr11:78169310	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.66	-0.3	3.32e-8	Alzheimer's disease (survival time);
LUSC	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg09479241	chr17:27052676	TLCD1	0.44	5.9	0.31	8.93e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9311676	0.632	rs62259779	chr3:58425692	C/G	cg13750441	chr3:58318267	PXK	0.35	6.73	0.35	7.53e-11	Systemic lupus erythematosus;
LUSC	cis	rs6977660	0.660	rs10253753	chr7:19823032	A/G	cg05791153	chr7:19748676	TWISTNB	0.64	6.74	0.35	6.97e-11	Thyroid stimulating hormone;
LUSC	cis	rs4474465	0.850	rs7111004	chr11:78269961	G/A	cg27205649	chr11:78285834	NARS2	0.52	6.19	0.32	1.8e-9	Alzheimer's disease (survival time);
LUSC	trans	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg07211511	chr3:129823064	LOC729375	-1.05	-12.96	-0.58	2.17e-31	Blood pressure (smoking interaction);
LUSC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.21	-0.37	3.84e-12	Major depressive disorder;
LUSC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	14.51	0.62	2.55e-37	Platelet count;
LUSC	cis	rs240764	0.658	rs9498390	chr6:101241438	T/A	cg09795085	chr6:101329169	ASCC3	-0.45	-6.46	-0.33	3.75e-10	Neuroticism;
LUSC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg23711669	chr6:146136114	FBXO30	-0.91	-17.26	-0.69	3.56e-48	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05095774	chr18:52495848	RAB27B	0.42	6.32	0.33	8.23e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2324229	0.828	rs1180228	chr6:83950566	G/A	cg08257003	chr6:84140564	ME1	0.28	6.78	0.35	5.51e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-6.1	-0.32	2.9e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg19640130	chr10:64028056	RTKN2	-0.4	-7.15	-0.36	5.41e-12	Rheumatoid arthritis;
LUSC	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.49	7.02	0.36	1.26e-11	Coronary heart disease;
LUSC	cis	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg17469321	chr7:55412551	NA	0.65	10.58	0.5	9.39e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7590368	0.715	rs7571007	chr2:10961297	C/T	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	cis	rs10865541	0.902	rs12474836	chr2:3418874	A/G	cg15807143	chr2:3452624	TTC15	0.32	5.67	0.3	3.09e-8	Obesity-related traits;
LUSC	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg20608306	chr11:116969690	SIK3	0.36	6.83	0.35	4.09e-11	Blood protein levels;
LUSC	cis	rs9361491	0.657	rs9361426	chr6:79457550	G/T	cg05283184	chr6:79620031	NA	-0.32	-5.81	-0.3	1.43e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2230307	0.536	rs6577152	chr1:100434610	A/G	cg24955406	chr1:100503596	HIAT1	0.56	6.04	0.31	4.01e-9	Carotid intima media thickness;
LUSC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05890377	chr2:74357713	NA	0.72	13.81	0.6	1.25e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs68092024	0.731	rs793480	chr3:99488364	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-6.14	-0.32	2.31e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs3087591	0.887	rs12150521	chr17:29595108	C/T	cg24425628	chr17:29625626	OMG;NF1	0.58	8.31	0.41	2.41e-15	Hip circumference;
LUSC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.66	10.98	0.52	3.72e-24	Cognitive function;
LUSC	cis	rs4363385	0.588	rs12079087	chr1:153023888	T/C	cg00922841	chr1:152955080	SPRR1A	-0.36	-5.95	-0.31	6.82e-9	Inflammatory skin disease;
LUSC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg02018176	chr4:1364513	KIAA1530	0.39	6.69	0.34	9.25e-11	Obesity-related traits;
LUSC	cis	rs11971779	0.680	rs7783619	chr7:139061437	G/A	cg07862535	chr7:139043722	LUC7L2	0.55	6.87	0.35	3.08e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg03522245	chr20:25566470	NINL	0.35	5.7	0.3	2.57e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg27661571	chr11:113659931	NA	-0.64	-5.99	-0.31	5.43e-9	Height;
LUSC	cis	rs73198271	0.515	rs77703937	chr8:8629129	G/A	cg01851573	chr8:8652454	MFHAS1	0.61	7.01	0.36	1.34e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs926938	0.520	rs2007231	chr1:115266306	C/T	cg12756093	chr1:115239321	AMPD1	-0.56	-8.12	-0.41	9.04e-15	Autism;
LUSC	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg23933602	chr10:16859644	RSU1	0.5	6.01	0.31	4.84e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg21724239	chr8:58056113	NA	0.59	7.09	0.36	8.15e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18538332	chr22:24372958	LOC391322	-0.37	-6.69	-0.34	9.68e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg13119609	chr19:45449297	APOC2	0.47	9.7	0.47	9.53e-20	Blood protein levels;
LUSC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.09	16.34	0.67	1.65e-44	Gut microbiome composition (summer);
LUSC	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.51	-6.03	-0.31	4.3e-9	Body mass index;
LUSC	cis	rs1595825	0.891	rs75946628	chr2:198546239	C/T	cg00982548	chr2:198649783	BOLL	-0.54	-6.86	-0.35	3.4e-11	Ulcerative colitis;
LUSC	cis	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg14019146	chr3:50243930	SLC38A3	0.45	10.72	0.51	3.06e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	0.99	13.4	0.59	4.76e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.47	-8.94	-0.44	2.66e-17	Breast cancer;
LUSC	cis	rs9420	0.961	rs11229131	chr11:57562525	G/A	cg23127183	chr11:57508653	C11orf31	-0.57	-8.81	-0.43	6.86e-17	Schizophrenia;
LUSC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	8.62	0.43	2.77e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg01849466	chr14:104193079	ZFYVE21	0.6	9.93	0.48	1.52e-20	Schizophrenia;
LUSC	cis	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.91	-0.35	2.41e-11	Morning vs. evening chronotype;
LUSC	trans	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg17675199	chr6:35436792	RPL10A	-0.41	-5.98	-0.31	5.73e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg05714579	chr10:131428358	MGMT	0.53	8.03	0.4	1.74e-14	Response to temozolomide;
LUSC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg26380479	chr7:97908229	NA	-0.26	-5.81	-0.3	1.43e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1127311	1.000	rs10908419	chr1:154567699	G/A	cg17218026	chr1:154582156	ADAR	0.57	10.15	0.49	2.89e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	0.5	7.71	0.39	1.46e-13	Breast cancer;
LUSC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg24289452	chr6:170231220	NA	-0.39	-6.7	-0.34	8.96e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg04414720	chr1:150670196	GOLPH3L	0.5	7.67	0.39	1.86e-13	Melanoma;
LUSC	cis	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg21775007	chr8:11205619	TDH	-0.49	-6.99	-0.36	1.53e-11	Triglycerides;
LUSC	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.45	-0.38	8.18e-13	Morning vs. evening chronotype;
LUSC	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg04362960	chr10:104952993	NT5C2	0.57	8.31	0.41	2.36e-15	Arsenic metabolism;
LUSC	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg03585969	chr10:35415529	CREM	0.61	8.99	0.44	1.93e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg06547715	chr2:218990976	CXCR2	0.33	6.38	0.33	5.81e-10	Ulcerative colitis;
LUSC	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-7.05	-0.36	1.01e-11	Height;
LUSC	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg27068330	chr11:65405492	SIPA1	-0.73	-10.14	-0.49	3.13e-21	Acne (severe);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03062665	chr14:90863127	CALM1	-0.4	-6.01	-0.31	4.91e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.89	12.61	0.57	4.5e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs983392	0.679	rs7121656	chr11:60024008	C/T	cg02771260	chr11:59836817	MS4A3	0.38	6.21	0.32	1.53e-9	Alzheimer's disease (late onset);
LUSC	cis	rs72772090	0.539	rs11135480	chr5:96110582	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.74	-7.49	-0.38	6.25e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg20307385	chr11:47447363	PSMC3	-0.44	-6.61	-0.34	1.51e-10	Subjective well-being;
LUSC	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg00376283	chr12:123451042	ABCB9	0.71	7.93	0.4	3.43e-14	Neutrophil percentage of white cells;
LUSC	trans	rs12439619	0.508	rs8042665	chr15:82481349	A/T	cg04831495	chr15:85060580	GOLGA6L5	-0.49	-7.87	-0.4	4.93e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	0.66	14.13	0.61	7.05e-36	Prudent dietary pattern;
LUSC	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg12564285	chr5:131593104	PDLIM4	0.38	7.04	0.36	1.13e-11	Blood metabolite levels;
LUSC	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	9.27	0.45	2.43e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg03538708	chr1:25844672	NA	-0.37	-6.08	-0.32	3.22e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg06271696	chr7:157225062	NA	-0.37	-6.81	-0.35	4.58e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs2191566	0.761	rs446016	chr19:44501518	A/G	cg18700516	chr19:44507157	ZNF230	-0.45	-5.96	-0.31	6.47e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-5.99	-0.31	5.29e-9	Joint mobility (Beighton score);
LUSC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.78	0.57	9.99e-31	Prudent dietary pattern;
LUSC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21211367	chr2:162094118	NA	0.44	7.13	0.36	6.31e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs4964805	0.865	rs4964780	chr12:104206859	A/G	cg02344784	chr12:104178138	NT5DC3	0.44	6.83	0.35	4.09e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.8	13.42	0.59	3.9e-33	Menarche (age at onset);
LUSC	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg23649088	chr2:200775458	C2orf69	-0.5	-6.77	-0.35	5.92e-11	Schizophrenia;
LUSC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg16325326	chr1:53192061	ZYG11B	0.86	15.95	0.66	5.42e-43	Monocyte count;
LUSC	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.65	-0.3	3.45e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.53e-10	Corneal astigmatism;
LUSC	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg04851639	chr8:1020857	NA	-0.35	-6.97	-0.36	1.67e-11	Schizophrenia;
LUSC	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-0.93	-17.45	-0.69	6.07e-49	Headache;
LUSC	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg18005901	chr6:33739558	LEMD2	-0.39	-5.74	-0.3	2.07e-8	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23589045	chr1:51983759	EPS15	-0.41	-6.09	-0.32	3.12e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg23791538	chr6:167370224	RNASET2	0.41	6.52	0.34	2.59e-10	Crohn's disease;
LUSC	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg05805236	chr11:65401703	PCNXL3	-0.65	-10.61	-0.5	7.57e-23	Acne (severe);
LUSC	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg20243544	chr17:37824526	PNMT	-0.46	-6.55	-0.34	2.18e-10	Asthma;
LUSC	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-7.09	-0.36	8.23e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg04374321	chr14:90722782	PSMC1	-0.67	-10.27	-0.49	1.08e-21	Mortality in heart failure;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23849483	chr19:15224544	SYDE1	-0.39	-5.95	-0.31	6.64e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs4654899	0.680	rs10916885	chr1:21188703	A/T	cg01072550	chr1:21505969	NA	0.48	7.39	0.37	1.21e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.3	-0.37	2.06e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.72	-9.63	-0.47	1.61e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.27	0.45	2.3e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.8	-0.3	1.51e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg27124370	chr19:33622961	WDR88	-0.59	-8.01	-0.4	1.95e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	14.06	0.61	1.38e-35	Platelet count;
LUSC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.15	0.36	5.64e-12	Mean platelet volume;
LUSC	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg06002616	chr8:101225028	SPAG1	-0.41	-6.82	-0.35	4.37e-11	Atrioventricular conduction;
LUSC	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.35	-5.79	-0.3	1.6e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.36	1.02e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6429082	0.689	rs10925965	chr1:235708443	C/A	cg26050004	chr1:235667680	B3GALNT2	-0.47	-6.25	-0.32	1.29e-9	Adiposity;
LUSC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-17.16	-0.68	8.97e-48	Primary sclerosing cholangitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg27425452	chr6:163148853	PARK2;PACRG	-0.42	-6.18	-0.32	1.82e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.63	9.73	0.47	7.29e-20	Response to antineoplastic agents;
LUSC	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg21775007	chr8:11205619	TDH	0.46	6.4	0.33	5.19e-10	Neuroticism;
LUSC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs3127573	1.000	rs3119309	chr6:160685072	A/G	cg25150520	chr1:3142530	PRDM16	-0.42	-5.96	-0.31	6.25e-9	Creatinine levels;
LUSC	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.53	-0.38	4.91e-13	Retinal vascular caliber;
LUSC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg22117172	chr7:91764530	CYP51A1	0.32	5.84	0.3	1.21e-8	Breast cancer;
LUSC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	9.37	0.46	1.09e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	1.13	13.19	0.59	2.98e-32	Diabetic kidney disease;
LUSC	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg22508957	chr16:3507546	NAT15	0.44	6.41	0.33	5.08e-10	Body mass index (adult);
LUSC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg19318889	chr4:1322082	MAEA	0.48	7.92	0.4	3.46e-14	Obesity-related traits;
LUSC	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg01966878	chr4:90757139	SNCA	-0.35	-6.12	-0.32	2.56e-9	Dementia with Lewy bodies;
LUSC	cis	rs4478858	0.735	rs10914361	chr1:31817542	T/G	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg04166393	chr7:2884313	GNA12	0.44	6.06	0.31	3.7e-9	Height;
LUSC	cis	rs7771547	0.607	rs632943	chr6:36469121	A/G	cg07856975	chr6:36356162	ETV7	0.38	6.65	0.34	1.2e-10	Platelet distribution width;
LUSC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.8	-0.43	7.35e-17	Obesity-related traits;
LUSC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.66	0.63	6.18e-38	Platelet count;
LUSC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg02551604	chr5:131831745	NA	-0.42	-6.62	-0.34	1.39e-10	Asthma (sex interaction);
LUSC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.2	-0.37	3.9e-12	Bipolar disorder;
LUSC	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg20243544	chr17:37824526	PNMT	0.39	5.85	0.3	1.19e-8	Self-reported allergy;
LUSC	trans	rs12310956	0.510	rs4931759	chr12:33871969	T/C	cg13010199	chr12:38710504	ALG10B	0.43	6.67	0.34	1.07e-10	Morning vs. evening chronotype;
LUSC	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg06627628	chr2:24431161	ITSN2	0.63	9.41	0.46	8.56e-19	Asthma;
LUSC	trans	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg20587970	chr11:113659929	NA	-1.18	-12.16	-0.55	1.97e-28	Height;
LUSC	cis	rs4704187	0.687	rs6879894	chr5:74498164	C/A	cg03227963	chr5:74354835	NA	0.3	6.64	0.34	1.24e-10	Response to amphetamines;
LUSC	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.52	-5.77	-0.3	1.81e-8	Fibroblast growth factor basic levels;
LUSC	cis	rs6681460	0.546	rs12117649	chr1:67168606	G/A	cg02459107	chr1:67143332	SGIP1	0.34	5.98	0.31	5.75e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg06671706	chr8:8559999	CLDN23	0.5	6.49	0.33	3.11e-10	Obesity-related traits;
LUSC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg14582100	chr15:45693742	SPATA5L1	0.5	8.26	0.41	3.35e-15	Homoarginine levels;
LUSC	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22455342	chr2:225449267	CUL3	-0.46	-6.35	-0.33	7.17e-10	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs3736594	0.649	rs867282	chr2:27951658	A/G	cg27432699	chr2:27873401	GPN1	-0.62	-9.13	-0.45	6.81e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs35995292	1.000	rs56098802	chr7:38913730	T/C	cg19327137	chr7:38886074	VPS41	0.34	5.67	0.3	3.1e-8	Subjective well-being (multi-trait analysis);
LUSC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg06454157	chr6:167490870	NA	-0.24	-6.04	-0.31	4.19e-9	Crohn's disease;
LUSC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.58	8.94	0.44	2.63e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs12618769	0.597	rs1961651	chr2:99049674	G/C	cg10123293	chr2:99228465	UNC50	0.47	7.94	0.4	3.19e-14	Bipolar disorder;
LUSC	cis	rs12575480	0.637	rs73398080	chr11:2094599	G/A	cg15541987	chr11:2077307	NA	-0.45	-6.82	-0.35	4.22e-11	Pursuit maintenance gain;
LUSC	cis	rs4851254	0.660	rs35869550	chr2:100684578	T/A	cg07810366	chr2:100720526	AFF3	-0.47	-6.19	-0.32	1.81e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4478858	0.735	rs34960310	chr1:31816197	A/G	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs7129556	0.520	rs4945185	chr11:77318142	G/A	cg12586386	chr11:77299805	AQP11	0.22	5.64	0.3	3.56e-8	Weight loss (gastric bypass surgery);
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.05	-0.31	3.82e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg04374321	chr14:90722782	PSMC1	-0.44	-6.63	-0.34	1.34e-10	Mortality in heart failure;
LUSC	cis	rs9905704	0.633	rs2632511	chr17:56490989	G/A	cg12560992	chr17:57184187	TRIM37	0.49	5.8	0.3	1.51e-8	Testicular germ cell tumor;
LUSC	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg24459738	chr19:57751996	ZNF805	-0.51	-7.54	-0.38	4.6e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg17385448	chr1:15911702	AGMAT	0.37	5.86	0.31	1.08e-8	Systolic blood pressure;
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg23034840	chr1:205782522	SLC41A1	0.67	9.98	0.48	1.04e-20	Menarche (age at onset);
LUSC	cis	rs829883	0.664	rs829864	chr12:98850195	C/T	cg25150519	chr12:98850993	NA	0.83	14.13	0.61	7.1e-36	Colorectal adenoma (advanced);
LUSC	cis	rs10779751	0.734	rs1034528	chr1:11249132	G/C	cg08854313	chr1:11322531	MTOR	-0.86	-13.56	-0.6	1.08e-33	Body mass index;
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg12419862	chr22:24373484	LOC391322	-0.95	-18.21	-0.71	6.25e-52	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10170310	1.000	rs6720716	chr2:139268802	A/G	cg03782584	chr2:139258740	SPOPL	0.33	5.86	0.31	1.12e-8	Response to antipsychotic treatment;
LUSC	cis	rs35123781	1.000	rs673632	chr5:139057237	G/T	cg10513866	chr5:139070639	NA	0.46	8.88	0.44	4.25e-17	Schizophrenia;
LUSC	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg16386425	chr10:429943	DIP2C	0.39	5.78	0.3	1.69e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg00579200	chr11:133705235	NA	-0.39	-5.7	-0.3	2.58e-8	Childhood ear infection;
LUSC	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg19554555	chr3:13937349	NA	-0.38	-5.72	-0.3	2.32e-8	Ovarian reserve;
LUSC	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.12	0.41	9.02e-15	Homoarginine levels;
LUSC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.39	0.37	1.21e-12	Schizophrenia;
LUSC	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg20356878	chr3:121714668	ILDR1	-0.45	-5.81	-0.3	1.49e-8	Multiple sclerosis;
LUSC	cis	rs6977660	0.714	rs17141945	chr7:19805056	T/A	cg05791153	chr7:19748676	TWISTNB	0.69	7.43	0.38	9.12e-13	Thyroid stimulating hormone;
LUSC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.66	-0.6	4.86e-34	Chronic sinus infection;
LUSC	cis	rs7399018	0.739	rs7953955	chr12:51608467	A/G	cg10377582	chr12:51612794	POU6F1	-0.34	-5.82	-0.3	1.41e-8	Cisplatin-induced ototoxicity;
LUSC	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg19773385	chr1:10388646	KIF1B	-0.54	-9.03	-0.44	1.35e-17	Hepatocellular carcinoma;
LUSC	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg13010199	chr12:38710504	ALG10B	0.47	7.33	0.37	1.75e-12	Morning vs. evening chronotype;
LUSC	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-6.23	-0.32	1.41e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg04058563	chr4:185651563	MLF1IP	0.89	11.84	0.54	3.17e-27	Blood protein levels;
LUSC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg14092988	chr3:52407081	DNAH1	0.31	6.12	0.32	2.56e-9	Bipolar disorder;
LUSC	cis	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg06521331	chr12:34319734	NA	-0.48	-7.67	-0.39	1.84e-13	Morning vs. evening chronotype;
LUSC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg09021430	chr5:549028	NA	-0.54	-7.18	-0.37	4.43e-12	Obesity-related traits;
LUSC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg09034736	chr1:150693464	HORMAD1	-0.43	-6.36	-0.33	6.47e-10	Tonsillectomy;
LUSC	cis	rs965513	1.000	rs4743130	chr9:100546040	C/T	cg13688889	chr9:100608707	NA	-0.55	-8.14	-0.41	7.97e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.11e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-10.71	-0.51	3.45e-23	Alzheimer's disease (late onset);
LUSC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.96	-13.31	-0.59	9.89e-33	Alzheimer's disease;
LUSC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.05	-0.36	1.03e-11	Longevity;Endometriosis;
LUSC	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg18755752	chr8:142205143	DENND3	-0.67	-12.05	-0.55	5.24e-28	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg26384229	chr12:38710491	ALG10B	0.73	11.89	0.55	2.05e-27	Morning vs. evening chronotype;
LUSC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-14.21	-0.61	3.52e-36	Hemoglobin concentration;
LUSC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg02423579	chr7:2872169	GNA12	-0.48	-6.64	-0.34	1.29e-10	Height;
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg08472276	chr7:1133186	C7orf50;GPER	-0.37	-6.05	-0.31	3.95e-9	Longevity;Endometriosis;
LUSC	cis	rs1950626	0.569	rs4143956	chr14:101434356	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.4	7.47	0.38	7.07e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	0.93	15.72	0.65	4.37e-42	Menopause (age at onset);
LUSC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	8.48	0.42	7.38e-16	Colorectal cancer;
LUSC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg13114125	chr14:105738426	BRF1	-0.87	-14.7	-0.63	4.53e-38	Platelet count;
LUSC	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	8.15	0.41	7.28e-15	Total body bone mineral density;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg15218456	chr17:25289681	NA	0.44	6.11	0.32	2.74e-9	Calcium levels;
LUSC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg10018233	chr7:150070692	REPIN1	0.38	6.54	0.34	2.32e-10	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs11696501	0.688	rs6073850	chr20:44301084	C/T	cg03272292	chr12:48577362	C12orf68	0.53	6.34	0.33	7.41e-10	Brain structure;
LUSC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg25258033	chr6:167368657	RNASET2	0.47	7.82	0.39	7.18e-14	Crohn's disease;
LUSC	cis	rs10992471	0.603	rs13301537	chr9:95229047	A/G	cg14631576	chr9:95140430	CENPP	-0.34	-6.17	-0.32	1.97e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18404041	chr3:52824283	ITIH1	0.43	8.23	0.41	4.3e-15	Electroencephalogram traits;
LUSC	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg08085267	chr17:45401833	C17orf57	-0.47	-6.62	-0.34	1.47e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg23303369	chr20:44641161	MMP9	0.38	6.58	0.34	1.83e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg21724239	chr8:58056113	NA	0.74	6.34	0.33	7.32e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs290268	0.838	rs1333635	chr9:93566406	A/G	cg02608019	chr9:93564028	SYK	0.54	9.43	0.46	7.11e-19	Platelet count;
LUSC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06028605	chr16:24865363	SLC5A11	0.61	9.46	0.46	5.74e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs643955	0.609	rs13259465	chr8:9982953	C/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.67	-0.34	1.06e-10	Systemic lupus erythematosus;
LUSC	cis	rs12980942	0.872	rs3752705	chr19:41798111	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.63	6.84	0.35	3.89e-11	Coronary artery disease;
LUSC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-1.01	-15.03	-0.64	2.33e-39	Initial pursuit acceleration;
LUSC	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-7.96	-0.4	2.77e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg12639453	chr1:2035780	PRKCZ	-0.32	-7.08	-0.36	8.63e-12	Height;
LUSC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.47	-6.54	-0.34	2.34e-10	Gut microbiome composition (summer);
LUSC	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg18827107	chr12:86230957	RASSF9	-0.5	-7.46	-0.38	7.71e-13	Major depressive disorder;
LUSC	cis	rs806215	0.951	rs327510	chr7:127257894	G/A	cg25922125	chr7:127225783	GCC1	0.49	6.36	0.33	6.61e-10	Type 2 diabetes;
LUSC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.62	0.5	6.6e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.88	10.45	0.5	2.57e-22	Body mass index;
LUSC	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg08847533	chr14:75593920	NEK9	0.85	15.75	0.65	3.43e-42	Height;
LUSC	cis	rs2562456	0.720	rs6511250	chr19:21656046	C/T	cg00806126	chr19:22604979	ZNF98	0.4	6.26	0.32	1.18e-9	Pain;
LUSC	cis	rs17095355	1.000	rs12570820	chr10:111732507	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.54	-0.38	4.55e-13	Biliary atresia;
LUSC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.33	0.56	4.75e-29	Prudent dietary pattern;
LUSC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.57	-9.35	-0.46	1.26e-18	Aortic root size;
LUSC	cis	rs7605827	0.930	rs6735633	chr2:15706096	G/A	cg19274914	chr2:15703543	NA	0.46	8.94	0.44	2.77e-17	Educational attainment (years of education);
LUSC	cis	rs7659604	0.540	rs11934307	chr4:122677514	G/A	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.91	-0.31	8.47e-9	Type 2 diabetes;
LUSC	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.48	-7.21	-0.37	3.74e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.45	6.11	0.32	2.76e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	trans	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg26384229	chr12:38710491	ALG10B	0.51	7.68	0.39	1.82e-13	Morning vs. evening chronotype;
LUSC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	0.65	11.4	0.53	1.23e-25	Blood metabolite levels;
LUSC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.78	10.89	0.51	7.61e-24	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg18721089	chr20:30220636	NA	-0.38	-6.32	-0.33	8.15e-10	Mean corpuscular hemoglobin;
LUSC	trans	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.88e-10	Life satisfaction;
LUSC	cis	rs6489882	0.703	rs10850092	chr12:113359703	C/G	cg20102336	chr12:113376681	OAS3	-0.41	-5.79	-0.3	1.59e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg17366294	chr4:99064904	C4orf37	0.55	9.8	0.47	4.17e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg09184832	chr6:79620586	NA	0.43	6.9	0.35	2.58e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg08219700	chr8:58056026	NA	0.67	6.31	0.33	8.71e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25193484	chr1:43282654	ERMAP;CCDC23	0.81	6.63	0.34	1.35e-10	Cognitive performance;
LUSC	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg12311346	chr5:56204834	C5orf35	-0.55	-8.26	-0.41	3.34e-15	Coronary artery disease;
LUSC	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg18512352	chr11:47633146	NA	-0.46	-9.21	-0.45	3.67e-18	Subjective well-being;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08206623	chr11:2907334	CDKN1C	0.38	6.42	0.33	4.73e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7640424	0.649	rs13091474	chr3:107877134	A/T	cg09227934	chr3:107805635	CD47	-0.36	-5.71	-0.3	2.51e-8	Body mass index;
LUSC	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg05373962	chr22:49881684	NA	-0.41	-8.79	-0.43	8.29e-17	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10802521	chr3:52805072	NEK4	-0.55	-8.67	-0.43	1.92e-16	Bipolar disorder;
LUSC	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg09165964	chr15:75287851	SCAMP5	-0.47	-6.79	-0.35	5.1e-11	Systemic lupus erythematosus;
LUSC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-7.39	-0.37	1.23e-12	Mood instability;
LUSC	trans	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg04995722	chr7:26192034	NFE2L3	-0.4	-6.36	-0.33	6.8e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2464469	0.654	rs4646570	chr15:58343146	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-5.85	-0.31	1.15e-8	Barrett's esophagus  or Esophageal adenocarcinoma;
LUSC	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg21361702	chr7:150065534	REPIN1	0.57	8.07	0.4	1.25e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg09365446	chr1:150670422	GOLPH3L	0.47	7.01	0.36	1.33e-11	Melanoma;
LUSC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08109568	chr15:31115862	NA	0.74	11.09	0.52	1.47e-24	Huntington's disease progression;
LUSC	cis	rs4478858	0.735	rs6425737	chr1:31790288	T/C	cg00250761	chr1:31883323	NA	-0.35	-8.72	-0.43	1.35e-16	Alcohol dependence;
LUSC	cis	rs12190007	0.573	rs3006218	chr6:169868769	G/A	cg15038512	chr6:170123185	PHF10	-0.4	-6.55	-0.34	2.17e-10	Obesity-related traits;
LUSC	cis	rs4343996	0.558	rs11761186	chr7:3412450	A/G	cg21248987	chr7:3385318	SDK1	0.37	6.23	0.32	1.38e-9	Motion sickness;
LUSC	cis	rs7577696	0.597	rs212689	chr2:32437338	G/A	cg02381751	chr2:32503542	YIPF4	0.53	6.84	0.35	3.76e-11	Inflammatory biomarkers;
LUSC	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg03585969	chr10:35415529	CREM	0.6	8.95	0.44	2.53e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg09904177	chr6:26538194	HMGN4	-0.74	-6.95	-0.36	1.9e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg22029157	chr1:209979665	IRF6	0.8	10.25	0.49	1.27e-21	Cleft lip with or without cleft palate;
LUSC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-1.02	-19.67	-0.73	9.47e-58	Height;
LUSC	cis	rs7017697	1.000	rs7017697	chr8:19685909	G/T	cg03894339	chr8:19674705	INTS10	-0.48	-6.84	-0.35	3.7e-11	Breast cancer;
LUSC	cis	rs193541	0.564	rs407230	chr5:122345727	G/A	cg19077854	chr5:122220652	SNX24	-0.4	-8.29	-0.41	2.76e-15	Glucose homeostasis traits;
LUSC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.9	-15.73	-0.65	4e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg26043149	chr18:55253948	FECH	-0.44	-6.69	-0.34	9.38e-11	Bone mineral density;
LUSC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00149659	chr3:10157352	C3orf10	1.01	14.42	0.62	5.3e-37	Alzheimer's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26539232	chr19:924834	ARID3A	0.42	6.3	0.33	9.14e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg13775593	chr10:823151	NA	0.32	6.4	0.33	5.22e-10	Uric acid levels;
LUSC	cis	rs155346	1.000	rs265149	chr5:139401891	G/A	cg01090482	chr5:139365336	NRG2	-0.36	-5.74	-0.3	2.07e-8	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg19920283	chr7:105172520	RINT1	0.58	6.22	0.32	1.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg19592336	chr6:28129416	ZNF389	0.46	6.01	0.31	4.81e-9	Depression;
LUSC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg22920501	chr2:26401640	FAM59B	-0.79	-11.8	-0.54	4.09e-27	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	7.77e-16	Aortic root size;
LUSC	cis	rs6987853	0.787	rs2974335	chr8:42417272	C/T	cg09913449	chr8:42400586	C8orf40	0.53	9.19	0.45	4.2e-18	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2573652	0.722	rs11630930	chr15:100544145	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.3	-5.76	-0.3	1.86e-8	Height;
LUSC	cis	rs7113850	0.541	rs11819948	chr11:24231257	A/C	ch.11.24196551F	chr11:24239977	NA	1.0	9.14	0.45	6e-18	Bone fracture in osteoporosis;
LUSC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg19592336	chr6:28129416	ZNF389	0.46	5.93	0.31	7.48e-9	Parkinson's disease;
LUSC	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg09526685	chr4:187126073	CYP4V2	0.64	6.32	0.33	8.41e-10	Blood protein levels;
LUSC	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.53	7.39	0.37	1.17e-12	Total body bone mineral density;
LUSC	trans	rs2236293	0.755	rs10758325	chr9:35804149	A/G	cg11239633	chr3:37903682	CTDSPL	0.35	6.35	0.33	6.92e-10	Blood protein levels;
LUSC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg04352962	chr1:209979756	IRF6	0.55	6.46	0.33	3.73e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg22029157	chr1:209979665	IRF6	0.51	8.12	0.41	9e-15	Monobrow;
LUSC	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.37	5.84	0.3	1.23e-8	Response to antipsychotic treatment;
LUSC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.46e-35	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25942691	chr19:36705733	ZNF565;ZNF146	0.45	6.08	0.32	3.36e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs16854884	1.000	rs13067695	chr3:143781054	C/T	cg06585982	chr3:143692056	C3orf58	0.47	6.61	0.34	1.51e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs12493885	0.697	rs11710478	chr3:153777037	A/C	cg17054900	chr3:154042577	DHX36	-0.72	-7.06	-0.36	9.58e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14452650	chr2:42396274	EML4	0.41	6.72	0.35	7.72e-11	Asthma;
LUSC	cis	rs4718428	0.705	rs4718430	chr7:66432024	G/T	cg18252515	chr7:66147081	NA	-0.47	-5.96	-0.31	6.55e-9	Corneal structure;
LUSC	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg26597838	chr10:835615	NA	0.79	9.74	0.47	6.95e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg01966878	chr4:90757139	SNCA	-0.34	-5.93	-0.31	7.6e-9	Dementia with Lewy bodies;
LUSC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg00750074	chr16:89608354	SPG7	-0.58	-10.55	-0.5	1.21e-22	Multiple myeloma (IgH translocation);
LUSC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg06784218	chr1:46089804	CCDC17	-0.47	-8.88	-0.44	4.2e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg06547715	chr2:218990976	CXCR2	-0.33	-6.29	-0.33	9.87e-10	Ulcerative colitis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03901462	chr11:62572874	NXF1	-0.49	-6.21	-0.32	1.56e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08859206	chr1:53392774	SCP2	0.56	9.89	0.48	2.1e-20	Monocyte count;
LUSC	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.46	7.07	0.36	9.04e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.4e-10	Corneal astigmatism;
LUSC	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg00484396	chr16:3507460	NAT15	-0.45	-7.0	-0.36	1.43e-11	Body mass index (adult);
LUSC	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg05283184	chr6:79620031	NA	-0.57	-12.15	-0.55	2.25e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18932078	chr1:2524107	MMEL1	-0.33	-7.15	-0.36	5.47e-12	Ulcerative colitis;
LUSC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.67	-10.43	-0.5	3.04e-22	Menarche (age at onset);
LUSC	cis	rs28595532	0.748	rs17594978	chr4:119336398	T/C	cg02775129	chr4:119771670	NA	-0.76	-6.32	-0.33	8.37e-10	Cannabis dependence symptom count;
LUSC	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg03340356	chr1:67600835	NA	0.42	6.69	0.34	9.68e-11	Psoriasis;
LUSC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13732083	chr21:47605072	C21orf56	0.43	6.35	0.33	6.83e-10	Testicular germ cell tumor;
LUSC	cis	rs10210302	0.502	rs880116	chr2:234246264	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.45	6.45	0.33	4.04e-10	Crohn's disease;
LUSC	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg25214090	chr10:38739885	LOC399744	0.55	8.04	0.4	1.62e-14	Corneal astigmatism;
LUSC	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-5.79	-0.3	1.64e-8	Testicular germ cell tumor;
LUSC	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg05163923	chr11:71159392	DHCR7	0.7	10.46	0.5	2.44e-22	Vitamin D levels;
LUSC	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08045932	chr20:61659980	NA	0.55	9.23	0.45	3.17e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3768617	0.811	rs12043805	chr1:183008150	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	8.54	0.42	4.75e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs17030434	0.954	rs11724154	chr4:154753108	G/T	cg14289246	chr4:154710475	SFRP2	-0.52	-6.83	-0.35	4.15e-11	Electrocardiographic conduction measures;
LUSC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.53	8.41	0.42	1.24e-15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4594175	0.926	rs11624975	chr14:51628347	T/C	cg23942311	chr14:51606299	NA	0.31	5.83	0.3	1.33e-8	Cancer;
LUSC	cis	rs6942756	0.840	rs963465	chr7:128875612	C/G	cg02491457	chr7:128862824	NA	0.52	7.86	0.4	5.21e-14	White matter hyperintensity burden;
LUSC	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg27068330	chr11:65405492	SIPA1	0.66	9.46	0.46	5.75e-19	Acne (severe);
LUSC	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg13798780	chr7:105162888	PUS7	0.56	6.15	0.32	2.23e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.54	-9.0	-0.44	1.71e-17	Lymphocyte counts;
LUSC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg09455208	chr3:40491958	NA	0.59	10.13	0.48	3.39e-21	Renal cell carcinoma;
LUSC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg02807482	chr3:125708958	NA	-0.52	-6.51	-0.34	2.69e-10	Blood pressure (smoking interaction);
LUSC	cis	rs6681460	0.934	rs4655628	chr1:67052609	T/C	cg02459107	chr1:67143332	SGIP1	0.46	8.51	0.42	5.83e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs6546537	1.000	rs17036866	chr2:69857711	T/C	cg10773587	chr2:69614142	GFPT1	-0.54	-8.1	-0.41	1.07e-14	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg13609457	chr4:120235615	NA	0.42	5.66	0.3	3.31e-8	Corneal astigmatism;
LUSC	trans	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg07923666	chr12:49932857	KCNH3	-0.49	-6.12	-0.32	2.55e-9	Resting heart rate;
LUSC	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.5	-12.09	-0.55	3.55e-28	Urate levels in overweight individuals;
LUSC	cis	rs7560272	0.538	rs35767294	chr2:73922834	A/G	cg20560298	chr2:73613845	ALMS1	0.38	5.87	0.31	1.06e-8	Schizophrenia;
LUSC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.66	6.3	0.33	9.47e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs1832871	0.672	rs9457363	chr6:158777515	C/T	cg07165851	chr6:158734300	TULP4	0.46	7.16	0.36	5.04e-12	Height;
LUSC	cis	rs921665	0.749	rs2368682	chr2:3197387	C/T	cg16434511	chr2:3151078	NA	-0.61	-6.64	-0.34	1.29e-10	World class endurance athleticism;
LUSC	cis	rs11997175	0.646	rs2006792	chr8:33694423	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	6.65	0.34	1.2e-10	Body mass index;
LUSC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg16339924	chr4:17578868	LAP3	0.61	9.31	0.45	1.8e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-5.84	-0.3	1.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg20135002	chr11:47629003	NA	-0.52	-8.17	-0.41	6.65e-15	Subjective well-being;
LUSC	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08564027	chr20:61660810	NA	0.91	17.17	0.68	8.22e-48	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.63	10.36	0.49	5.57e-22	Response to diuretic therapy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25088355	chr8:144691901	PYCRL	-0.44	-6.61	-0.34	1.49e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08039791	chr14:21945223	RAB2B;TOX4	-0.41	-6.12	-0.32	2.59e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7577696	0.785	rs11689817	chr2:32364241	T/A	cg02381751	chr2:32503542	YIPF4	-0.44	-6.22	-0.32	1.53e-9	Inflammatory biomarkers;
LUSC	trans	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg20935933	chr6:143382018	AIG1	0.5	7.33	0.37	1.71e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg21963583	chr11:68658836	MRPL21	0.56	8.68	0.43	1.81e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.7	11.0	0.52	3.29e-24	Aortic root size;
LUSC	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.63	0.5	6.32e-23	Schizophrenia;
LUSC	cis	rs4494114	1.000	rs12127091	chr1:39339449	C/T	cg25970120	chr1:39325951	RRAGC	-0.4	-6.27	-0.32	1.14e-9	Blood protein levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07870003	chr12:107381075	MTERFD3	0.52	7.21	0.37	3.84e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg17644776	chr2:200775616	C2orf69	0.37	5.78	0.3	1.75e-8	Osteoporosis;
LUSC	cis	rs6076065	0.723	rs2424537	chr20:23382026	T/C	cg11657817	chr20:23433608	CST11	0.42	7.93	0.4	3.31e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.72	-0.35	7.84e-11	Response to antipsychotic treatment;
LUSC	cis	rs6969780	1.000	rs6461985	chr7:27150634	T/C	cg26364809	chr7:27145159	NA	-0.59	-5.91	-0.31	8.35e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	0.8	14.27	0.62	2.18e-36	Cognitive function;
LUSC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.29	0.37	2.29e-12	Platelet count;
LUSC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg06637938	chr14:75390232	RPS6KL1	0.53	8.52	0.42	5.51e-16	Height;
LUSC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg16434002	chr17:42200994	HDAC5	-0.45	-6.41	-0.33	5.09e-10	Total body bone mineral density;
LUSC	cis	rs7215564	0.818	rs34754307	chr17:78652758	C/G	cg09596252	chr17:78655493	RPTOR	0.56	6.05	0.31	3.85e-9	Myopia (pathological);
LUSC	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg25817165	chr18:72167213	CNDP2	-0.75	-11.17	-0.52	8.07e-25	Refractive error;
LUSC	cis	rs243505	0.762	rs1019218	chr7:148488964	C/T	cg09806900	chr7:148480153	CUL1	0.58	8.51	0.42	5.84e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg13042288	chr15:90349979	ANPEP	-0.47	-6.41	-0.33	4.97e-10	Uric acid levels;
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg22963979	chr7:1858916	MAD1L1	-0.61	-9.72	-0.47	7.72e-20	Bipolar disorder and schizophrenia;
LUSC	cis	rs2637266	0.538	rs2637246	chr10:78272913	G/A	cg18941641	chr10:78392320	NA	0.33	6.03	0.31	4.32e-9	Pulmonary function;
LUSC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.16	-0.32	2.04e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.59	0.43	3.35e-16	Coffee consumption (cups per day);
LUSC	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg14092571	chr14:90743983	NA	-0.35	-5.83	-0.3	1.29e-8	Mortality in heart failure;
LUSC	cis	rs240764	0.554	rs6570970	chr6:101233082	C/A	cg09795085	chr6:101329169	ASCC3	0.44	6.27	0.32	1.13e-9	Neuroticism;
LUSC	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg05855489	chr10:104503620	C10orf26	0.59	9.6	0.46	1.99e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs12483240	0.793	rs10154112	chr21:26819664	C/T	cg08463788	chr1:197888068	LHX9	-0.66	-6.06	-0.31	3.76e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg18825076	chr15:78729989	IREB2	0.44	6.13	0.32	2.46e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg01765077	chr12:122356316	WDR66	0.5	6.85	0.35	3.63e-11	Mean corpuscular volume;
LUSC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg27398817	chr8:82754497	SNX16	-0.47	-6.21	-0.32	1.58e-9	Diastolic blood pressure;
LUSC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-8.02	-0.4	1.84e-14	Obesity-related traits;
LUSC	trans	rs75804782	0.581	rs3191996	chr2:239344412	A/G	cg01134436	chr17:81009848	B3GNTL1	-0.64	-6.43	-0.33	4.4e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg23625390	chr15:77176239	SCAPER	-0.64	-9.69	-0.47	9.62e-20	Blood metabolite levels;
LUSC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.21	-0.37	3.85e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg23711669	chr6:146136114	FBXO30	0.75	13.38	0.59	5.46e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg20487152	chr13:99095054	FARP1	-0.41	-6.83	-0.35	4.06e-11	Neuroticism;
LUSC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg04998671	chr14:104000505	TRMT61A	0.36	5.66	0.3	3.33e-8	Body mass index;
LUSC	cis	rs2354432	0.556	rs4295925	chr1:146857335	T/C	cg25205988	chr1:146714368	CHD1L	0.88	7.92	0.4	3.6e-14	Mitochondrial DNA levels;
LUSC	cis	rs240764	0.817	rs239239	chr6:101094554	A/G	cg09795085	chr6:101329169	ASCC3	0.42	6.09	0.32	3.09e-9	Neuroticism;
LUSC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.45	-0.46	6.1e-19	Type 2 diabetes;
LUSC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08677398	chr8:58056175	NA	0.51	6.33	0.33	7.97e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7605827	0.930	rs7596435	chr2:15605091	T/C	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.37e-17	Educational attainment (years of education);
LUSC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg16049864	chr8:95962084	TP53INP1	-0.62	-11.6	-0.54	2.3e-26	Type 2 diabetes;
LUSC	cis	rs2108225	0.872	rs4618632	chr7:107440952	T/G	cg18560240	chr7:107437656	SLC26A3	-0.44	-6.5	-0.34	2.91e-10	Ulcerative colitis;
LUSC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00166722	chr3:10149974	C3orf24	0.59	7.65	0.39	2.17e-13	Alzheimer's disease;
LUSC	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-8.78	-0.43	8.85e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs10979	0.679	rs2275345	chr6:143872960	G/A	cg25407410	chr6:143891975	LOC285740	-0.62	-8.69	-0.43	1.65e-16	Hypospadias;
LUSC	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg00376283	chr12:123451042	ABCB9	0.65	8.3	0.41	2.63e-15	Neutrophil percentage of white cells;
LUSC	cis	rs983392	0.836	rs72918674	chr11:59944580	C/T	cg02771260	chr11:59836817	MS4A3	-0.37	-5.87	-0.31	1.06e-8	Alzheimer's disease (late onset);
LUSC	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg23992470	chr4:843637	GAK	0.56	6.53	0.34	2.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs612683	0.826	rs7556246	chr1:100828914	A/G	cg06223162	chr1:101003688	GPR88	0.39	7.12	0.36	6.67e-12	Breast cancer;
LUSC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg16362232	chr11:430036	ANO9	0.63	7.92	0.4	3.5e-14	Body mass index;
LUSC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg20406979	chr6:167373233	NA	-0.26	-6.07	-0.32	3.4e-9	Crohn's disease;
LUSC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg12463550	chr7:65579703	CRCP	-0.48	-7.19	-0.37	4.32e-12	Aortic root size;
LUSC	cis	rs4654899	0.931	rs10799669	chr1:21172501	T/C	cg01072550	chr1:21505969	NA	0.49	7.34	0.37	1.65e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg10167378	chr1:228756711	NA	0.76	10.11	0.48	3.94e-21	Chronic lymphocytic leukemia;
LUSC	cis	rs7605827	0.897	rs4459705	chr2:15526584	C/T	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs11166629	1.000	rs2315838	chr8:135645968	C/T	cg27224718	chr8:135614730	ZFAT	0.63	10.52	0.5	1.48e-22	Smoking quantity;
LUSC	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg18132916	chr6:79620363	NA	-0.38	-5.77	-0.3	1.8e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs151349	1.000	rs151344	chr20:57585301	A/G	cg23907860	chr20:57583709	CTSZ	-0.48	-7.9	-0.4	3.95e-14	Platelet distribution width;
LUSC	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg17330251	chr7:94953956	PON1	-0.38	-6.17	-0.32	1.92e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs11958404	0.932	rs10045597	chr5:157451963	T/C	cg05962755	chr5:157440814	NA	0.47	5.93	0.31	7.43e-9	IgG glycosylation;
LUSC	cis	rs7614311	0.681	rs2241822	chr3:63965304	A/G	cg22134162	chr3:63841271	THOC7	-0.5	-6.07	-0.32	3.5e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs9434723	0.920	rs2239560	chr1:9304731	C/T	cg04199779	chr1:9294473	H6PD	0.54	6.3	0.33	9.48e-10	Height;
LUSC	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg27661571	chr11:113659931	NA	-0.67	-7.74	-0.39	1.16e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.35	0.59	7.08e-33	Cognitive test performance;
LUSC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg13560548	chr3:10150139	C3orf24	0.52	7.14	0.36	5.82e-12	Alzheimer's disease;
LUSC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg23093090	chr10:104574429	C10orf26	-0.37	-6.94	-0.36	2.02e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs12980942	0.872	rs12974420	chr19:41798660	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.63	6.79	0.35	5.05e-11	Coronary artery disease;
LUSC	cis	rs4243830	1.000	rs41278016	chr1:6584045	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.93	9.08	0.44	9.68e-18	Body mass index;
LUSC	cis	rs2413583	0.591	rs17305131	chr22:39718564	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	6.41	0.33	4.86e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	9.44	0.46	6.42e-19	Prudent dietary pattern;
LUSC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06634786	chr22:41940651	POLR3H	-0.54	-6.22	-0.32	1.49e-9	Vitiligo;
LUSC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21582582	chr3:182698605	DCUN1D1	0.46	8.2	0.41	5.18e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg05868516	chr6:26286170	HIST1H4H	0.37	6.14	0.32	2.29e-9	Educational attainment;
LUSC	cis	rs4363385	0.510	rs7531076	chr1:153039167	G/T	cg00922841	chr1:152955080	SPRR1A	-0.37	-6.19	-0.32	1.72e-9	Inflammatory skin disease;
LUSC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.77	0.57	1.06e-30	Motion sickness;
LUSC	cis	rs4481887	0.676	rs7524978	chr1:248527319	A/T	cg26353448	chr1:248524236	OR2T4	-0.32	-6.12	-0.32	2.63e-9	Common traits (Other);
LUSC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg17971929	chr21:40555470	PSMG1	0.73	11.94	0.55	1.28e-27	Cognitive function;
LUSC	cis	rs5753037	0.809	rs140150	chr22:30185719	C/G	cg11564601	chr22:30592435	NA	0.33	5.84	0.3	1.23e-8	Type 1 diabetes;
LUSC	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg18478394	chr8:109455254	TTC35	-0.42	-6.5	-0.34	2.87e-10	Dupuytren's disease;
LUSC	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-1.21	-14.54	-0.62	1.92e-37	Breast cancer;
LUSC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.73	0.63	3.45e-38	Platelet count;
LUSC	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.3	21.62	0.76	1.91e-65	Type 1 diabetes nephropathy;
LUSC	cis	rs12042938	0.600	rs1094656	chr1:231773675	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.4	5.95	0.31	6.92e-9	Neuranatomic and neurocognitive phenotypes;
LUSC	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02187348	chr16:89574699	SPG7	0.61	9.92	0.48	1.75e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg22823121	chr1:150693482	HORMAD1	0.49	7.28	0.37	2.48e-12	Melanoma;
LUSC	trans	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg15556689	chr8:8085844	FLJ10661	0.48	6.83	0.35	4.05e-11	Monocyte count;
LUSC	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg20701182	chr2:24300061	SF3B14	0.52	6.74	0.35	6.86e-11	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg01448562	chr3:133502909	NA	-0.52	-7.75	-0.39	1.13e-13	Iron status biomarkers;
LUSC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg08999081	chr20:33150536	PIGU	0.43	7.33	0.37	1.77e-12	Coronary artery disease;
LUSC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg06486467	chr15:102282101	NA	-0.38	-5.95	-0.31	6.88e-9	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg01733217	chr16:74700730	RFWD3	0.81	13.44	0.59	3.34e-33	Testicular germ cell tumor;
LUSC	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.7	0.34	8.72e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs73195822	0.667	rs117806977	chr12:111235324	C/T	cg12870014	chr12:110450643	ANKRD13A	0.7	6.57	0.34	1.96e-10	Itch intensity from mosquito bite;
LUSC	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg17470449	chr10:769945	NA	0.53	7.13	0.36	6.24e-12	Uric acid levels;
LUSC	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg12863693	chr15:85201151	NMB	-0.35	-7.24	-0.37	3.1e-12	Schizophrenia;
LUSC	cis	rs7659604	0.521	rs10001697	chr4:122677737	G/T	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.91	-0.31	8.47e-9	Type 2 diabetes;
LUSC	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg05234568	chr11:5960015	NA	-0.55	-8.68	-0.43	1.83e-16	DNA methylation (variation);
LUSC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg07741184	chr6:167504864	NA	0.36	6.53	0.34	2.52e-10	Crohn's disease;
LUSC	cis	rs1355223	0.573	rs1148930	chr11:34732225	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.41	5.72	0.3	2.4e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg02782426	chr3:40428986	ENTPD3	0.34	6.72	0.34	8.08e-11	Renal cell carcinoma;
LUSC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg06784218	chr1:46089804	CCDC17	0.49	9.92	0.48	1.68e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.62	9.97	0.48	1.12e-20	Blood metabolite ratios;
LUSC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	0.87	14.79	0.63	1.95e-38	Tonsillectomy;
LUSC	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg02997394	chr19:33096574	ANKRD27	0.79	8.95	0.44	2.49e-17	Eosinophilic esophagitis;
LUSC	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg13334819	chr7:99746414	C7orf59	-0.43	-5.73	-0.3	2.26e-8	Coronary artery disease;
LUSC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg15145296	chr3:125709740	NA	-0.58	-6.56	-0.34	2.01e-10	Blood pressure (smoking interaction);
LUSC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg21724239	chr8:58056113	NA	0.79	9.5	0.46	4.34e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.67	-9.93	-0.48	1.54e-20	Systemic lupus erythematosus;
LUSC	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.47	5.69	0.3	2.75e-8	Renal function-related traits (BUN);
LUSC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-1.04	-20.46	-0.75	7.01e-61	Height;
LUSC	cis	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg24375607	chr4:120327624	NA	0.51	7.87	0.4	4.84e-14	Diastolic blood pressure;
LUSC	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02187348	chr16:89574699	SPG7	0.62	10.11	0.48	4e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	7.38	0.37	1.25e-12	Bipolar disorder;
LUSC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-1.03	-19.85	-0.74	1.79e-58	Height;
LUSC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg27266027	chr21:40555129	PSMG1	-0.39	-5.77	-0.3	1.83e-8	Cognitive function;
LUSC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg14895029	chr7:2775587	GNA12	-0.42	-6.42	-0.33	4.77e-10	Height;
LUSC	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg08213375	chr14:104286397	PPP1R13B	0.53	10.51	0.5	1.69e-22	Schizophrenia;
LUSC	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg04546413	chr19:29218101	NA	0.71	11.42	0.53	1.02e-25	Methadone dose in opioid dependence;
LUSC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg13556452	chr1:2391241	NA	-0.34	-6.2	-0.32	1.68e-9	Schizophrenia;
LUSC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg20744362	chr22:50050164	C22orf34	0.4	8.21	0.41	4.86e-15	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg08219700	chr8:58056026	NA	0.47	6.27	0.32	1.1e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg07777115	chr5:623756	CEP72	-0.48	-5.88	-0.31	1.02e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg22823121	chr1:150693482	HORMAD1	0.46	6.6	0.34	1.64e-10	Melanoma;
LUSC	cis	rs13089785	1.000	rs34246651	chr3:123664105	T/C	cg02558132	chr3:123411198	MYLK	0.34	5.7	0.3	2.7e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-6.08	-0.32	3.33e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs290268	1.000	rs290274	chr9:93546913	C/T	cg02608019	chr9:93564028	SYK	0.53	8.92	0.44	3.11e-17	Platelet count;
LUSC	trans	rs62238980	0.614	rs78354020	chr22:32394259	A/G	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs7923609	1.000	rs4595427	chr10:65012944	A/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.55	-0.34	2.14e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.88	0.4	4.78e-14	Prudent dietary pattern;
LUSC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg17294928	chr15:75287854	SCAMP5	-0.82	-10.91	-0.51	6.64e-24	Blood trace element (Zn levels);
LUSC	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg06636551	chr8:101224915	SPAG1	0.38	7.06	0.36	9.56e-12	Atrioventricular conduction;
LUSC	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg25817165	chr18:72167213	CNDP2	-0.74	-9.03	-0.44	1.42e-17	Refractive error;
LUSC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg18512352	chr11:47633146	NA	-0.46	-9.42	-0.46	7.43e-19	Subjective well-being;
LUSC	cis	rs1549118	0.595	rs17106478	chr14:78328310	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.42	5.69	0.3	2.8e-8	Resting heart rate;
LUSC	cis	rs7789940	0.904	rs73140040	chr7:75936240	C/T	cg10167463	chr7:75959203	YWHAG	-0.59	-8.6	-0.43	3.22e-16	Multiple sclerosis;
LUSC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg16325326	chr1:53192061	ZYG11B	0.96	19.94	0.74	7.76e-59	Monocyte count;
LUSC	trans	rs12692738	0.526	rs355848	chr2:165625277	T/C	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10498514	1.000	rs76202452	chr14:65027352	C/G	cg25134081	chr14:64931936	AKAP5	0.81	6.03	0.31	4.25e-9	Cognitive performance;
LUSC	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg18132916	chr6:79620363	NA	-0.39	-5.94	-0.31	7.08e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg01849466	chr14:104193079	ZFYVE21	0.57	8.93	0.44	2.83e-17	Schizophrenia;
LUSC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	8.56	0.42	4.3e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg09904177	chr6:26538194	HMGN4	0.76	14.42	0.62	5.75e-37	Intelligence (multi-trait analysis);
LUSC	trans	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg16724585	chr3:197361211	NA	-0.58	-8.18	-0.41	6.01e-15	Pancreatic cancer;
LUSC	cis	rs1395	0.922	rs13404446	chr2:27519254	C/T	cg23587288	chr2:27483067	SLC30A3	-0.3	-5.87	-0.31	1.02e-8	Blood metabolite levels;
LUSC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg07716408	chr11:68623521	NA	0.33	6.54	0.34	2.28e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05039488	chr6:79577232	IRAK1BP1	0.43	6.43	0.33	4.51e-10	Endometrial cancer;
LUSC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.34	-0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6961069	0.743	rs3211870	chr7:80287209	C/T	cg04458919	chr7:80252533	CD36	-0.33	-5.99	-0.31	5.52e-9	Platelet count;
LUSC	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg05855489	chr10:104503620	C10orf26	0.63	8.2	0.41	5.12e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg26513180	chr16:89883248	FANCA	0.9	17.56	0.69	2.29e-49	Vitiligo;
LUSC	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.33	-0.56	4.74e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1371867	0.846	rs2083499	chr8:101230534	T/A	cg00191853	chr8:101177733	SPAG1	0.41	6.64	0.34	1.27e-10	Atrioventricular conduction;
LUSC	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg01620082	chr3:125678407	NA	-0.83	-7.33	-0.37	1.76e-12	Lung cancer in ever smokers;
LUSC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.69	-11.53	-0.53	4.06e-26	Cognitive function;
LUSC	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.87	-0.35	3.22e-11	Monocyte percentage of white cells;
LUSC	cis	rs1124376	0.748	rs6771367	chr3:20160266	A/T	cg05072819	chr3:20081367	KAT2B	0.57	6.59	0.34	1.76e-10	Bipolar disorder and schizophrenia;
LUSC	trans	rs7939886	0.920	rs10501343	chr11:55759573	G/T	cg03929089	chr4:120376271	NA	0.79	6.5	0.34	2.94e-10	Myopia (pathological);
LUSC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.47	6.99	0.36	1.53e-11	Schizophrenia;
LUSC	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.86	14.05	0.61	1.47e-35	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.44	0.33	4.12e-10	Menopause (age at onset);
LUSC	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg15744005	chr10:104629667	AS3MT	-0.36	-7.41	-0.38	1.06e-12	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs6487679	1.000	rs6487679	chr12:9371332	C/T	cg00504896	chr12:9437009	LOC642846	-0.45	-5.8	-0.3	1.55e-8	Non-alcoholic fatty liver disease histology (AST);
LUSC	cis	rs9463078	0.505	rs2038556	chr6:44740568	A/G	cg25276700	chr6:44698697	NA	0.3	6.33	0.33	7.67e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00166722	chr3:10149974	C3orf24	0.62	8.71	0.43	1.38e-16	Alzheimer's disease;
LUSC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg16423285	chr20:60520624	NA	-0.47	-5.84	-0.3	1.22e-8	Body mass index;
LUSC	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg08847533	chr14:75593920	NEK9	-0.81	-14.57	-0.62	1.41e-37	Height;
LUSC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4147929	0.532	rs757232	chr19:1075979	C/T	cg26576206	chr19:1064938	ABCA7	-0.41	-5.77	-0.3	1.8e-8	Alzheimer's disease (late onset);
LUSC	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.69	10.49	0.5	1.93e-22	Corneal astigmatism;
LUSC	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.88	0.31	9.9e-9	Rheumatoid arthritis;
LUSC	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg17173187	chr15:85201210	NMB	0.48	8.9	0.44	3.51e-17	Schizophrenia;
LUSC	trans	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg25457927	chr22:38595422	NA	0.49	10.59	0.5	8.35e-23	Cutaneous nevi;
LUSC	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	8.15	0.41	7.55e-15	Myopia (pathological);
LUSC	cis	rs1003719	0.667	rs3753073	chr21:38466615	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	9.39	0.46	9.98e-19	Eye color traits;
LUSC	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg00376283	chr12:123451042	ABCB9	0.66	7.74	0.39	1.2e-13	Neutrophil percentage of white cells;
LUSC	cis	rs727505	1.000	rs68007199	chr7:124491307	T/C	cg23710748	chr7:124431027	NA	-0.42	-7.47	-0.38	6.9e-13	Lewy body disease;
LUSC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg04553112	chr3:125709451	NA	-0.49	-5.86	-0.31	1.11e-8	Blood pressure (smoking interaction);
LUSC	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	8.78	0.43	8.65e-17	Coffee consumption (cups per day);
LUSC	cis	rs2742234	0.541	rs7098236	chr10:43740508	T/C	cg07801480	chr10:43725741	RASGEF1A	-0.39	-5.88	-0.31	1.01e-8	Hirschsprung disease;
LUSC	cis	rs59698941	0.943	rs67437142	chr5:132306722	T/C	cg02081065	chr5:132209139	LEAP2	-0.61	-5.88	-0.31	9.99e-9	Apolipoprotein A-IV levels;
LUSC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs3087591	0.960	rs2952976	chr17:29486152	G/A	cg24425628	chr17:29625626	OMG;NF1	0.56	8.3	0.41	2.68e-15	Hip circumference;
LUSC	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg21775007	chr8:11205619	TDH	-0.52	-7.36	-0.37	1.43e-12	Triglycerides;
LUSC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg13010199	chr12:38710504	ALG10B	0.7	10.93	0.51	5.81e-24	Morning vs. evening chronotype;
LUSC	cis	rs9650315	0.538	rs67159733	chr8:57208791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.8	0.39	7.83e-14	Height;
LUSC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-7.25	-0.37	2.96e-12	Menopause (age at onset);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg15409468	chr5:31532111	RNASEN;C5orf22	0.38	6.32	0.33	8.27e-10	Triglycerides;
LUSC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.24	-0.41	3.84e-15	Joint mobility (Beighton score);
LUSC	cis	rs6545883	0.929	rs12612982	chr2:61747355	G/A	cg15711740	chr2:61764176	XPO1	-0.49	-7.84	-0.39	6.08e-14	Tuberculosis;
LUSC	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-0.94	-18.32	-0.71	2.25e-52	Brugada syndrome;
LUSC	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	11.31	0.53	2.56e-25	Coffee consumption (cups per day);
LUSC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.16	15.5	0.65	3.26e-41	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	6.68	0.34	9.92e-11	Monocyte percentage of white cells;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.54	-9.0	-0.44	1.71e-17	Lymphocyte counts;
LUSC	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg22491629	chr6:157744540	C6orf35	-0.9	-10.67	-0.5	4.68e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-6.76	-0.35	6.01e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.92	15.67	0.65	7e-42	Bladder cancer;
LUSC	cis	rs262150	0.851	rs2657326	chr7:158766262	C/T	cg19418458	chr7:158789849	NA	-0.5	-8.17	-0.41	6.45e-15	Facial morphology (factor 20);
LUSC	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg21545522	chr1:205238299	TMCC2	0.46	8.53	0.42	5.08e-16	Red blood cell count;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17675882	chr20:35374068	NDRG3	0.42	6.41	0.33	5.1e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg07606381	chr6:8435919	SLC35B3	0.72	12.17	0.55	1.89e-28	Motion sickness;
LUSC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12379764	chr21:47803548	PCNT	-0.42	-5.91	-0.31	8.56e-9	Testicular germ cell tumor;
LUSC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg12257692	chr3:49977190	RBM6	0.24	6.52	0.34	2.6e-10	Body mass index;
LUSC	cis	rs72781680	0.583	rs6731333	chr2:24113354	C/T	cg08917208	chr2:24149416	ATAD2B	0.58	6.6	0.34	1.62e-10	Lymphocyte counts;
LUSC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg25767906	chr1:53392781	SCP2	-0.5	-9.09	-0.45	8.88e-18	Monocyte count;
LUSC	cis	rs3862435	0.764	rs2107435	chr15:90994633	T/C	cg22089800	chr15:90895588	ZNF774	0.57	6.02	0.31	4.62e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg15595755	chr5:1867978	NA	0.4	6.31	0.33	8.93e-10	Cardiovascular disease risk factors;
LUSC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg07741184	chr6:167504864	NA	0.43	7.49	0.38	6.4e-13	Primary biliary cholangitis;
LUSC	trans	rs2074977	0.550	rs11085020	chr19:3446107	C/T	cg08382705	chr11:45687319	CHST1	0.49	7.82	0.39	7.15e-14	Height;
LUSC	cis	rs71403859	0.803	rs8063455	chr16:71599977	G/A	cg08717414	chr16:71523259	ZNF19	-0.75	-8.16	-0.41	7.1e-15	Post bronchodilator FEV1;
LUSC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.99	0.36	1.47e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02396040	chr6:88117726	C6orf165	-0.48	-7.55	-0.38	4.23e-13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2692947	0.644	rs1168976	chr2:96813480	G/A	cg23100626	chr2:96804247	ASTL	0.3	7.17	0.37	4.93e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg26513180	chr16:89883248	FANCA	-0.55	-8.11	-0.41	9.65e-15	Vitiligo;
LUSC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg11062466	chr8:58055876	NA	0.49	6.38	0.33	6.03e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg08847533	chr14:75593920	NEK9	-0.83	-15.07	-0.64	1.67e-39	Height;
LUSC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.11	-0.32	2.82e-9	Total body bone mineral density;
LUSC	trans	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg08975724	chr8:8085496	FLJ10661	0.41	5.95	0.31	6.75e-9	Retinal vascular caliber;
LUSC	cis	rs6484504	0.532	rs11031332	chr11:31278962	T/C	cg14844989	chr11:31128820	NA	-0.39	-6.0	-0.31	5.2e-9	Red blood cell count;
LUSC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.98	0.31	5.84e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1127311	0.846	rs61811388	chr1:154581231	G/C	cg17218026	chr1:154582156	ADAR	0.55	9.75	0.47	6.47e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7215564	0.908	rs34914062	chr17:78655909	C/T	cg09596252	chr17:78655493	RPTOR	0.59	6.14	0.32	2.33e-9	Myopia (pathological);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg01663295	chr11:65837194	PACS1	0.49	6.74	0.35	6.76e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.75	-0.35	6.58e-11	Neuroticism;
LUSC	cis	rs965469	1.000	rs6139103	chr20:3361140	T/C	cg25506879	chr20:3388711	C20orf194	-0.53	-5.71	-0.3	2.55e-8	IFN-related cytopenia;
LUSC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.84	-13.66	-0.6	4.64e-34	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7580658	0.864	rs4150454	chr2:128038544	T/C	cg09760422	chr2:128146352	NA	-0.28	-5.89	-0.31	9.64e-9	Protein C levels;
LUSC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.54	-8.02	-0.4	1.76e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg02569458	chr12:86230093	RASSF9	0.51	8.53	0.42	5.01e-16	Major depressive disorder;
LUSC	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.85	-12.85	-0.58	5.65e-31	Body mass index;
LUSC	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg08601574	chr20:25228251	PYGB	-0.43	-6.61	-0.34	1.53e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs17604090	0.529	rs2392128	chr7:29711139	A/G	cg19413766	chr7:29689036	LOC646762	0.53	7.18	0.37	4.63e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs738322	0.577	rs4820320	chr22:38572977	G/A	cg17652424	chr22:38574118	PLA2G6	-0.32	-6.59	-0.34	1.68e-10	Cutaneous nevi;
LUSC	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg06623918	chr6:96969491	KIAA0776	-0.77	-9.6	-0.47	1.98e-19	Migraine;Coronary artery disease;
LUSC	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg17467752	chr17:38218738	THRA	0.42	5.68	0.3	2.88e-8	Asthma;
LUSC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-8.47	-0.42	7.9e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg24631222	chr15:78858424	CHRNA5	-0.69	-9.46	-0.46	5.59e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg13047869	chr3:10149882	C3orf24	0.56	7.73	0.39	1.24e-13	Alzheimer's disease;
LUSC	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg05738196	chr6:26577821	NA	-0.81	-16.51	-0.67	3.37e-45	Intelligence (multi-trait analysis);
LUSC	cis	rs3126085	1.000	rs2338555	chr1:152309380	G/A	cg26876637	chr1:152193138	HRNR	-0.44	-5.67	-0.3	3.13e-8	Atopic dermatitis;
LUSC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg26354017	chr1:205819088	PM20D1	-0.79	-13.84	-0.6	9.5e-35	Menarche (age at onset);
LUSC	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg11189052	chr15:85197271	WDR73	-0.4	-5.79	-0.3	1.62e-8	P wave terminal force;
LUSC	cis	rs3764021	1.000	rs7977720	chr12:9866349	C/T	cg20894963	chr12:9885564	CLECL1	0.32	6.57	0.34	1.98e-10	Type 1 diabetes;
LUSC	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg22709100	chr7:91322751	NA	0.47	6.9	0.35	2.61e-11	Breast cancer;
LUSC	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg17470723	chr8:74884337	TCEB1	0.52	8.17	0.41	6.5e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg02580895	chr19:2754563	NA	-0.46	-6.98	-0.36	1.57e-11	Total cholesterol levels;
LUSC	cis	rs4953076	0.573	rs9973609	chr2:44450435	T/C	cg04920474	chr2:44395004	PPM1B	0.62	7.91	0.4	3.76e-14	Height;
LUSC	trans	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg15371732	chr17:78194151	SLC26A11;SGSH	0.38	5.95	0.31	6.6e-9	Cystic fibrosis severity;
LUSC	cis	rs4243830	1.000	rs10158949	chr1:6583701	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.89	-8.87	-0.44	4.58e-17	Body mass index;
LUSC	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.59	-9.67	-0.47	1.2e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs433852	1.000	rs433852	chr19:49117104	C/T	cg06530960	chr19:49140787	SEC1;DBP	-0.72	-9.26	-0.45	2.53e-18	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-7.28	-0.37	2.48e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs1322512	0.917	rs2623938	chr6:153001870	A/T	cg27316956	chr6:152958899	SYNE1	0.37	6.23	0.32	1.4e-9	Tonometry;
LUSC	cis	rs6669072	0.739	rs3843305	chr1:91243376	G/A	cg08895590	chr1:91227319	NA	-0.39	-8.75	-0.43	1.09e-16	Cognitive function;
LUSC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.2	-0.32	1.68e-9	Platelet count;
LUSC	trans	rs2262909	0.962	rs425781	chr19:22229306	A/G	cg05197062	chr11:11642011	GALNTL4	-0.56	-7.81	-0.39	7.34e-14	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg18352616	chr4:3374830	RGS12	0.33	6.71	0.34	8.42e-11	Serum sulfate level;
LUSC	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg17173187	chr15:85201210	NMB	0.36	6.41	0.33	5.06e-10	Schizophrenia;
LUSC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg22166914	chr1:53195759	ZYG11B	0.7	11.91	0.55	1.73e-27	Monocyte count;
LUSC	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	6.78	0.35	5.57e-11	Retinal vascular caliber;
LUSC	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17467752	chr17:38218738	THRA	0.77	12.5	0.56	1.14e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg09184832	chr6:79620586	NA	-0.45	-7.38	-0.37	1.26e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.68	-11.99	-0.55	8.92e-28	White blood cell count (basophil);
LUSC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.53	-7.1	-0.36	7.33e-12	Renal function-related traits (BUN);
LUSC	cis	rs738322	0.772	rs9619724	chr22:38517880	T/G	cg17652424	chr22:38574118	PLA2G6	-0.28	-5.76	-0.3	1.9e-8	Cutaneous nevi;
LUSC	cis	rs7818345	0.512	rs4922029	chr8:19304533	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.37	6.72	0.35	7.95e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg22903471	chr2:27725779	GCKR	-0.41	-6.82	-0.35	4.23e-11	Total body bone mineral density;
LUSC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg12639453	chr1:2035780	PRKCZ	-0.33	-7.07	-0.36	8.95e-12	Height;
LUSC	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg22906224	chr7:99728672	NA	0.47	6.57	0.34	1.98e-10	Coronary artery disease;
LUSC	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg17470723	chr8:74884337	TCEB1	-0.46	-7.05	-0.36	1.01e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg18209359	chr17:80159595	CCDC57	-0.37	-6.28	-0.32	1.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg21573476	chr21:45109991	RRP1B	-0.42	-6.66	-0.34	1.13e-10	Mean corpuscular volume;
LUSC	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.29	0.45	1.97e-18	Menarche (age at onset);
LUSC	cis	rs1127311	0.905	rs6702449	chr1:154583210	A/C	cg17218026	chr1:154582156	ADAR	0.56	10.06	0.48	5.92e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg01851573	chr8:8652454	MFHAS1	0.53	8.57	0.42	3.77e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7804356	1.000	rs3801846	chr7:26828653	C/T	cg03456212	chr7:26904342	SKAP2	-0.52	-6.16	-0.32	2.14e-9	Type 1 diabetes;
LUSC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg26338869	chr17:61819248	STRADA	0.42	6.07	0.32	3.4e-9	Prudent dietary pattern;
LUSC	cis	rs6987853	0.966	rs2974349	chr8:42404040	A/G	cg09913449	chr8:42400586	C8orf40	-0.47	-7.85	-0.39	5.87e-14	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg18240062	chr17:79603768	NPLOC4	-0.69	-12.86	-0.58	4.98e-31	Eye color traits;
LUSC	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg13535736	chr9:111863775	C9orf5	-0.41	-6.67	-0.34	1.08e-10	Menarche (age at onset);
LUSC	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg10483660	chr13:112241077	NA	-0.31	-5.68	-0.3	3e-8	Hepatitis;
LUSC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.13	0.45	6.62e-18	Height;
LUSC	cis	rs9796	0.727	rs61203391	chr15:41352912	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.03	-0.4	1.73e-14	Menopause (age at onset);
LUSC	cis	rs3087591	0.708	rs2525568	chr17:29675878	T/G	cg24425628	chr17:29625626	OMG;NF1	0.47	7.0	0.36	1.44e-11	Hip circumference;
LUSC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.64	-11.14	-0.52	1.02e-24	Aortic root size;
LUSC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12016809	chr21:47604291	C21orf56	0.44	6.54	0.34	2.32e-10	Testicular germ cell tumor;
LUSC	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg22705602	chr4:152727874	NA	-0.33	-6.7	-0.34	9.13e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg26441486	chr22:50317300	CRELD2	0.47	6.96	0.36	1.82e-11	Schizophrenia;
LUSC	cis	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg02972257	chr16:68554789	NA	-0.48	-6.23	-0.32	1.4e-9	Ulcerative colitis;
LUSC	cis	rs4664308	1.000	rs6759924	chr2:160912747	G/A	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.93	-0.51	5.76e-24	Idiopathic membranous nephropathy;
LUSC	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg22823121	chr1:150693482	HORMAD1	0.46	6.6	0.34	1.64e-10	Melanoma;
LUSC	cis	rs12532214	0.617	rs73673328	chr7:3149140	G/C	cg19214707	chr7:3157722	NA	-0.44	-7.02	-0.36	1.21e-11	Itch intensity from mosquito bite;
LUSC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.49	-7.33	-0.37	1.71e-12	Longevity;
LUSC	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-9.65	-0.47	1.4e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.78	0.3	1.71e-8	Rheumatoid arthritis;
LUSC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg13798912	chr7:905769	UNC84A	-0.58	-5.83	-0.3	1.29e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2607426	0.681	rs2607413	chr19:41268214	C/T	cg05508168	chr19:41255947	C19orf54;SNRPA	0.85	6.72	0.35	7.9e-11	Blood protein levels;
LUSC	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg06740227	chr12:86229804	RASSF9	0.39	6.09	0.32	3.05e-9	Major depressive disorder;
LUSC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg18681998	chr4:17616180	MED28	0.88	17.17	0.68	8.26e-48	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1113500	0.836	rs1122158	chr1:108588668	G/T	cg11967332	chr1:108735228	SLC25A24	0.39	5.89	0.31	9.26e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs4363385	0.818	rs3795382	chr1:153004853	C/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.42e-12	Inflammatory skin disease;
LUSC	cis	rs2882667	0.537	rs7701338	chr5:138405994	C/T	cg04439458	chr5:138467593	SIL1	-0.34	-6.84	-0.35	3.75e-11	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg09365446	chr1:150670422	GOLPH3L	0.46	6.88	0.35	3.01e-11	Melanoma;
LUSC	cis	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg17085576	chr10:5658249	NA	-0.44	-6.8	-0.35	4.95e-11	Breast cancer;
LUSC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.85	-0.47	2.85e-20	Platelet count;
LUSC	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg02187348	chr16:89574699	SPG7	0.52	7.11	0.36	7.26e-12	Multiple myeloma (IgH translocation);
LUSC	cis	rs17255340	0.539	rs1144191	chr6:83981512	C/T	cg08257003	chr6:84140564	ME1	0.32	7.68	0.39	1.76e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg18002602	chr11:66138449	SLC29A2	0.46	8.27	0.41	3.17e-15	Educational attainment (years of education);
LUSC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.69	-0.6	3.55e-34	Chronic sinus infection;
LUSC	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg23933602	chr10:16859644	RSU1	0.51	6.19	0.32	1.74e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs7809950	0.678	rs7788271	chr7:106985873	A/G	cg23024343	chr7:107201750	COG5	-0.66	-9.9	-0.48	1.99e-20	Coronary artery disease;
LUSC	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg04455712	chr21:45112962	RRP1B	0.43	8.34	0.42	1.95e-15	Mean corpuscular volume;
LUSC	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg17691542	chr6:26056736	HIST1H1C	0.46	6.88	0.35	3.01e-11	Height;
LUSC	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg14689365	chr7:158441557	NCAPG2	-0.45	-6.13	-0.32	2.46e-9	Height;
LUSC	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg19920283	chr7:105172520	RINT1	0.58	6.22	0.32	1.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.81	10.64	0.5	5.76e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.46	-0.33	3.71e-10	Menopause (age at onset);
LUSC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg20203395	chr5:56204925	C5orf35	-0.73	-9.94	-0.48	1.45e-20	Initial pursuit acceleration;
LUSC	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg27432699	chr2:27873401	GPN1	-0.59	-8.84	-0.44	5.7e-17	Total body bone mineral density;
LUSC	cis	rs3733631	0.948	rs28438896	chr4:104625753	C/T	cg24090629	chr4:104641072	TACR3	-0.45	-5.68	-0.3	2.93e-8	Menarche (age at onset);
LUSC	cis	rs73206853	0.563	rs73194051	chr12:111204186	T/C	cg12870014	chr12:110450643	ANKRD13A	0.66	6.98	0.36	1.55e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg15485101	chr11:133734466	NA	0.43	7.61	0.38	2.87e-13	Childhood ear infection;
LUSC	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg00376283	chr12:123451042	ABCB9	0.71	10.79	0.51	1.74e-23	Platelet count;
LUSC	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg13902645	chr11:5959945	NA	-0.61	-8.48	-0.42	7.35e-16	DNA methylation (variation);
LUSC	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg27433088	chr4:174089019	GALNT7	0.39	5.64	0.3	3.55e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg14552801	chr7:65878734	NA	0.38	5.9	0.31	8.97e-9	Aortic root size;
LUSC	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg06784218	chr1:46089804	CCDC17	0.32	5.9	0.31	9.08e-9	Platelet count;
LUSC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg23711669	chr6:146136114	FBXO30	-0.92	-17.68	-0.7	7.87e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg10560079	chr2:191398806	TMEM194B	-0.71	-8.69	-0.43	1.7e-16	Diastolic blood pressure;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17597744	chr8:53627099	RB1CC1	-0.49	-6.35	-0.33	7.16e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	9.33	0.45	1.46e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg05738196	chr6:26577821	NA	0.46	6.74	0.35	7.09e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs295140	0.706	rs3769483	chr2:201173048	A/G	cg04283868	chr2:201171347	SPATS2L	0.43	6.18	0.32	1.82e-9	QT interval;
LUSC	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg16989719	chr2:238392110	NA	-0.36	-5.9	-0.31	9.01e-9	Prostate cancer;
LUSC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg18681998	chr4:17616180	MED28	0.85	15.29	0.64	2.17e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.51	0.38	5.48e-13	Iron status biomarkers;
LUSC	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg09323728	chr8:95962352	TP53INP1	-0.36	-7.42	-0.38	9.69e-13	Type 2 diabetes;
LUSC	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg27284194	chr4:1044797	NA	0.57	8.42	0.42	1.12e-15	Recombination rate (females);
LUSC	cis	rs778371	0.697	rs11893358	chr2:233636922	T/C	cg08000102	chr2:233561755	GIGYF2	0.8	13.48	0.59	2.37e-33	Schizophrenia;
LUSC	cis	rs897080	0.516	rs1067361	chr2:44661217	G/C	cg00619915	chr2:44497795	NA	-0.41	-6.02	-0.31	4.5e-9	Height;
LUSC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg22166914	chr1:53195759	ZYG11B	0.67	11.81	0.54	3.87e-27	Monocyte count;
LUSC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-10.48	-0.5	2.06e-22	Mood instability;
LUSC	cis	rs7577696	0.962	rs17767988	chr2:32286826	G/A	cg02381751	chr2:32503542	YIPF4	-0.39	-5.66	-0.3	3.3e-8	Inflammatory biomarkers;
LUSC	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg02018176	chr4:1364513	KIAA1530	0.52	8.87	0.44	4.63e-17	Obesity-related traits;
LUSC	cis	rs2898681	0.561	rs58577680	chr4:53734294	C/T	cg21521518	chr4:53727714	RASL11B	0.44	5.84	0.3	1.27e-8	Optic nerve measurement (cup area);
LUSC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.86	0.35	3.34e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs61931739	0.556	rs7954221	chr12:33825077	C/T	cg26384229	chr12:38710491	ALG10B	0.45	7.28	0.37	2.4e-12	Morning vs. evening chronotype;
LUSC	trans	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	6.12	0.32	2.62e-9	Retinal vascular caliber;
LUSC	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg06671706	chr8:8559999	CLDN23	0.49	6.61	0.34	1.48e-10	Obesity-related traits;
LUSC	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-10.53	-0.5	1.36e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg22834771	chr12:69754056	YEATS4	-0.41	-5.84	-0.3	1.25e-8	Blood protein levels;
LUSC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg05738196	chr6:26577821	NA	0.47	6.8	0.35	4.7e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9309473	1.000	rs6745368	chr2:73809974	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-6.67	-0.34	1.05e-10	Metabolite levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16785698	chr4:186456103	PDLIM3	0.44	7.09	0.36	7.96e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.73	11.98	0.55	9.08e-28	Coronary artery disease;
LUSC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg04450456	chr4:17643702	FAM184B	0.42	7.06	0.36	9.89e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg27494647	chr7:150038898	RARRES2	0.58	8.48	0.42	7.55e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg22907277	chr7:1156413	C7orf50	0.72	7.65	0.39	2.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg23711669	chr6:146136114	FBXO30	-0.77	-12.37	-0.56	3.54e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg23281280	chr6:28129359	ZNF389	0.45	5.86	0.31	1.14e-8	Parkinson's disease;
LUSC	cis	rs1595825	0.891	rs1440086	chr2:198906354	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-6.31	-0.33	8.84e-10	Ulcerative colitis;
LUSC	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg03929089	chr4:120376271	NA	-0.45	-6.18	-0.32	1.92e-9	HDL cholesterol;
LUSC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs9462027	0.606	rs6906129	chr6:34801160	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-6.03	-0.31	4.4e-9	Systemic lupus erythematosus;
LUSC	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg08213375	chr14:104286397	PPP1R13B	0.36	6.12	0.32	2.58e-9	Reticulocyte count;
LUSC	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-1.06	-15.98	-0.66	4.32e-43	Exhaled nitric oxide output;
LUSC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03576123	chr11:487126	PTDSS2	-0.95	-10.57	-0.5	9.88e-23	Body mass index;
LUSC	trans	rs2587949	0.615	rs1485269	chr3:4222976	C/T	cg15139668	chr4:4577005	NA	0.41	6.13	0.32	2.44e-9	Periodontitis (DPAL);
LUSC	cis	rs9650657	0.770	rs6601529	chr8:10670550	A/G	cg27411982	chr8:10470053	RP1L1	-0.37	-6.21	-0.32	1.59e-9	Neuroticism;
LUSC	cis	rs1044826	0.692	rs176987	chr3:139233001	G/A	cg15131784	chr3:139108705	COPB2	-0.39	-6.31	-0.33	8.61e-10	Obesity-related traits;
LUSC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg06387496	chr7:2775674	GNA12	0.37	5.9	0.31	8.73e-9	Height;
LUSC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg02891314	chr5:179741120	GFPT2	-0.65	-10.65	-0.5	5.3e-23	Height;
LUSC	cis	rs17621444	0.522	rs67595246	chr10:121812443	C/G	cg02041677	chr10:121771263	NA	-0.33	-6.34	-0.33	7.26e-10	IgG glycosylation;
LUSC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg17294928	chr15:75287854	SCAMP5	-0.93	-13.63	-0.6	6.13e-34	Blood trace element (Zn levels);
LUSC	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-10.09	-0.48	4.54e-21	HDL cholesterol;
LUSC	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg02696742	chr7:106810147	HBP1	-0.63	-9.54	-0.46	3.16e-19	Coronary artery disease;
LUSC	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg10596483	chr8:143751796	JRK	0.52	7.38	0.37	1.3e-12	Schizophrenia;
LUSC	cis	rs55871839	0.708	rs13263261	chr8:59814688	T/G	cg07426533	chr8:59803705	TOX	-0.36	-5.8	-0.3	1.57e-8	Pneumonia;
LUSC	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-0.52	-8.03	-0.4	1.64e-14	Breast cancer;
LUSC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg00800038	chr16:89945340	TCF25	-0.66	-6.82	-0.35	4.41e-11	Skin colour saturation;
LUSC	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg07936489	chr17:37558343	FBXL20	0.72	9.92	0.48	1.64e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18252515	chr7:66147081	NA	-0.42	-6.36	-0.33	6.48e-10	Corneal structure;
LUSC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.52	-8.28	-0.41	2.95e-15	Facial morphology (factor 20);
LUSC	cis	rs1160297	0.585	rs4143203	chr2:53035763	C/T	cg07782112	chr2:53107842	NA	0.42	6.54	0.34	2.34e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg18132916	chr6:79620363	NA	-0.39	-6.02	-0.31	4.69e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg20734569	chr3:48348370	SPINK8	-0.48	-8.3	-0.41	2.64e-15	Coronary artery disease;
LUSC	cis	rs2219968	0.798	rs4739185	chr8:78879189	A/G	cg00738934	chr8:78996279	NA	-0.39	-6.85	-0.35	3.54e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg20283391	chr11:68216788	NA	-0.61	-8.42	-0.42	1.15e-15	Total body bone mineral density;
LUSC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	6.3	0.33	9.14e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.71	-13.02	-0.58	1.25e-31	Alcohol dependence;
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg23034840	chr1:205782522	SLC41A1	0.59	8.38	0.42	1.52e-15	Menarche (age at onset);
LUSC	cis	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.83	-0.3	1.32e-8	Resting heart rate;
LUSC	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.85	-0.47	2.99e-20	Hemoglobin concentration;
LUSC	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.61	-8.29	-0.41	2.89e-15	Red cell distribution width;
LUSC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-6.51	-0.34	2.82e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs16910800	0.953	rs73481419	chr11:23204953	A/G	cg20040320	chr11:23191996	NA	-0.44	-6.46	-0.33	3.8e-10	Cancer;
LUSC	cis	rs9463078	0.764	rs6923519	chr6:44864152	A/G	cg25276700	chr6:44698697	NA	-0.28	-5.65	-0.3	3.51e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg23422044	chr7:1970798	MAD1L1	-0.56	-6.15	-0.32	2.18e-9	Bipolar disorder;
LUSC	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg03806693	chr22:41940476	POLR3H	-0.54	-7.5	-0.38	5.79e-13	Neuroticism;
LUSC	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg03806693	chr22:41940476	POLR3H	-0.63	-9.05	-0.44	1.18e-17	Vitiligo;
LUSC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-1.07	-15.83	-0.65	1.64e-42	Initial pursuit acceleration;
LUSC	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg08017634	chr8:144659831	NAPRT1	0.72	6.17	0.32	2.03e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs3772130	0.962	rs11721291	chr3:121563285	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	9.98	0.48	1.09e-20	Cognitive performance;
LUSC	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-0.85	-13.41	-0.59	4.32e-33	Refractive error;
LUSC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	9.14	0.45	6.02e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg12140854	chr5:148520817	ABLIM3	-0.39	-6.13	-0.32	2.51e-9	Breast cancer;
LUSC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.82	14.39	0.62	7.5e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg25566285	chr7:158114605	PTPRN2	0.31	5.85	0.3	1.2e-8	Calcium levels;
LUSC	cis	rs738322	0.511	rs2267370	chr22:38576826	G/A	cg17652424	chr22:38574118	PLA2G6	-0.3	-5.84	-0.3	1.27e-8	Cutaneous nevi;
LUSC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg00745463	chr17:30367425	LRRC37B	-0.79	-9.11	-0.45	7.81e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs11030122	0.673	rs10767767	chr11:4003678	C/T	cg08557956	chr11:4115526	RRM1	-0.45	-5.97	-0.31	5.96e-9	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs7939886	0.920	rs7112964	chr11:55866408	T/C	cg03929089	chr4:120376271	NA	0.73	6.06	0.31	3.74e-9	Myopia (pathological);
LUSC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-7.89	-0.4	4.39e-14	Longevity;Endometriosis;
LUSC	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg23262351	chr6:79576851	IRAK1BP1	-0.37	-5.7	-0.3	2.64e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	1.19	16.28	0.67	2.87e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs7523050	0.643	rs12736534	chr1:109399934	T/C	cg08274380	chr1:109419600	GPSM2	1.1	10.69	0.51	3.76e-23	Fat distribution (HIV);
LUSC	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.59	8.36	0.42	1.71e-15	Macular telangiectasia type 2;
LUSC	trans	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg24644049	chr4:85504048	CDS1	-0.69	-6.97	-0.36	1.68e-11	Skin colour saturation;
LUSC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg26335602	chr6:28129616	ZNF389	0.43	5.78	0.3	1.7e-8	Parkinson's disease;
LUSC	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg12863693	chr15:85201151	NMB	0.39	8.17	0.41	6.62e-15	Schizophrenia;
LUSC	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg23750338	chr8:142222470	SLC45A4	0.45	8.22	0.41	4.47e-15	Immature fraction of reticulocytes;
LUSC	cis	rs16854884	0.837	rs7644767	chr3:143803092	C/G	cg06585982	chr3:143692056	C3orf58	0.43	6.42	0.33	4.8e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs3087591	1.000	rs2905800	chr17:29531980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.55	8.0	0.4	2.11e-14	Hip circumference;
LUSC	cis	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg15711740	chr2:61764176	XPO1	-0.47	-7.6	-0.38	2.97e-13	Tuberculosis;
LUSC	cis	rs6460942	0.732	rs73677576	chr7:12286535	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.11	-0.32	2.71e-9	Coronary artery disease;
LUSC	cis	rs7766436	0.885	rs13199041	chr6:22577718	A/G	cg13666174	chr6:22585274	NA	-0.41	-5.73	-0.3	2.29e-8	Coronary artery disease;
LUSC	cis	rs7572644	0.699	rs10170872	chr2:28164553	C/T	cg27432699	chr2:27873401	GPN1	-0.51	-6.95	-0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.57	-9.44	-0.46	6.79e-19	Breast cancer;
LUSC	cis	rs12765878	1.000	rs11191843	chr10:105648651	G/C	cg11005552	chr10:105648138	OBFC1	0.36	5.65	0.3	3.38e-8	Coronary artery disease;
LUSC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.23	14.1	0.61	9.75e-36	Diabetic kidney disease;
LUSC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08045932	chr20:61659980	NA	0.58	10.07	0.48	5.3e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21984481	chr17:79567631	NPLOC4	-0.55	-10.24	-0.49	1.39e-21	Eye color traits;
LUSC	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-10.11	-0.48	3.72e-21	Mood instability;
LUSC	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg09479241	chr17:27052676	TLCD1	0.43	5.84	0.3	1.26e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7202877	0.656	rs9923834	chr16:75507253	T/A	cg04384234	chr16:75411784	CFDP1	-0.62	-8.48	-0.42	7.33e-16	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg17507749	chr15:85114479	UBE2QP1	0.65	8.1	0.41	1.04e-14	Schizophrenia;
LUSC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.38	8.03	0.4	1.68e-14	Hemoglobin concentration;
LUSC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg11965913	chr1:205819406	PM20D1	0.51	7.61	0.38	2.81e-13	Prostate-specific antigen levels;
LUSC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.77	-13.77	-0.6	1.84e-34	Dental caries;
LUSC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.58	0.34	1.85e-10	Personality dimensions;
LUSC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg09640425	chr7:158790006	NA	0.51	8.39	0.42	1.44e-15	Facial morphology (factor 20);
LUSC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-7.46	-0.38	7.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7106204	0.534	rs56157310	chr11:24260694	A/G	ch.11.24196551F	chr11:24239977	NA	0.73	6.22	0.32	1.49e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20135002	chr11:47629003	NA	-0.5	-7.76	-0.39	1.05e-13	Subjective well-being;
LUSC	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg23595222	chr22:46449430	C22orf26;LOC150381	0.37	5.93	0.31	7.49e-9	Dupuytren's disease;Subjective well-being;
LUSC	cis	rs7523050	0.643	rs35907086	chr1:109406625	A/G	cg08274380	chr1:109419600	GPSM2	1.12	10.7	0.51	3.48e-23	Fat distribution (HIV);
LUSC	cis	rs12760731	0.720	rs12021983	chr1:178323800	C/T	cg00404053	chr1:178313656	RASAL2	0.54	6.16	0.32	2.04e-9	Obesity-related traits;
LUSC	cis	rs868036	1.000	rs1026736	chr15:68101813	T/C	cg08079166	chr15:68083412	MAP2K5	0.4	8.28	0.41	3.04e-15	Restless legs syndrome;
LUSC	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg20811857	chr17:78079795	GAA	-0.32	-5.94	-0.31	7.01e-9	Yeast infection;
LUSC	cis	rs1712517	0.904	rs6584547	chr10:105065409	C/T	cg05636881	chr10:105038444	INA	0.38	6.22	0.32	1.48e-9	Migraine;
LUSC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg13770153	chr20:60521292	NA	-0.64	-9.0	-0.44	1.69e-17	Body mass index;
LUSC	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg26395211	chr5:140044315	WDR55	-0.38	-5.74	-0.3	2.09e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-6.89	-0.35	2.82e-11	Breast cancer;
LUSC	cis	rs7577696	0.850	rs11124276	chr2:32318428	C/G	cg02381751	chr2:32503542	YIPF4	-0.4	-5.74	-0.3	2.15e-8	Inflammatory biomarkers;
LUSC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg22907277	chr7:1156413	C7orf50	0.51	7.72	0.39	1.36e-13	Longevity;Endometriosis;
LUSC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg10018233	chr7:150070692	REPIN1	-0.38	-6.69	-0.34	9.37e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.61	-8.34	-0.42	1.95e-15	Red cell distribution width;
LUSC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg25019033	chr10:957182	NA	-0.51	-5.69	-0.3	2.84e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.45	-8.27	-0.41	3.29e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg00484396	chr16:3507460	NAT15	-0.47	-7.11	-0.36	6.9e-12	Body mass index (adult);
LUSC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03517284	chr6:25882590	NA	-0.46	-8.19	-0.41	5.6e-15	Blood metabolite levels;
LUSC	trans	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg07393940	chr7:158741817	NA	-0.37	-6.51	-0.34	2.81e-10	Life satisfaction;
LUSC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.07	-0.32	3.48e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg09904177	chr6:26538194	HMGN4	0.47	7.48	0.38	6.8e-13	Schizophrenia;
LUSC	cis	rs10419226	0.577	rs886443	chr19:18783785	A/G	cg22001208	chr19:18782374	NA	-0.38	-6.36	-0.33	6.69e-10	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26384229	chr12:38710491	ALG10B	-0.87	-14.94	-0.63	5.21e-39	Morning vs. evening chronotype;
LUSC	cis	rs4443100	0.670	rs13056137	chr22:23407261	C/A	cg21100191	chr22:23484243	RTDR1	0.56	7.0	0.36	1.37e-11	Serum parathyroid hormone levels;
LUSC	cis	rs12541635	0.801	rs12155858	chr8:107105205	G/A	cg10147462	chr8:107024639	NA	-0.45	-7.99	-0.4	2.18e-14	Age of smoking initiation;
LUSC	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21659725	chr3:3221576	CRBN	-0.54	-8.38	-0.42	1.46e-15	Body mass index;
LUSC	cis	rs11048434	0.761	rs2110190	chr12:9128289	A/C	cg13575925	chr12:9217583	LOC144571	0.34	6.12	0.32	2.63e-9	Sjögren's syndrome;
LUSC	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	1.09	15.49	0.65	3.65e-41	Uric acid levels;
LUSC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.81	-0.35	4.59e-11	Lung cancer;
LUSC	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg16482183	chr6:26056742	HIST1H1C	0.56	8.34	0.42	2.02e-15	Height;
LUSC	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg09835421	chr16:68378352	PRMT7	-0.55	-5.98	-0.31	5.84e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	9.23	0.45	3.31e-18	Lung cancer;
LUSC	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg20991723	chr1:152506922	NA	0.51	9.59	0.46	2.12e-19	Hair morphology;
LUSC	cis	rs6494488	0.500	rs112698132	chr15:64906413	C/T	cg08069370	chr15:64387884	SNX1	-0.65	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	8.31	0.41	2.41e-15	Response to antipsychotic treatment;
LUSC	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg12564285	chr5:131593104	PDLIM4	0.37	6.64	0.34	1.28e-10	Blood metabolite levels;
LUSC	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.41	-0.38	1.07e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-6.72	-0.35	7.84e-11	Colorectal cancer;
LUSC	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg13256891	chr4:100009986	ADH5	0.46	6.32	0.33	8.54e-10	Alcohol dependence;
LUSC	cis	rs1847202	0.859	rs4566476	chr3:72948995	G/C	cg25664220	chr3:72788482	NA	-0.41	-7.36	-0.37	1.44e-12	Motion sickness;
LUSC	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.52	-0.57	9.71e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg13319975	chr6:146136371	FBXO30	0.48	7.23	0.37	3.33e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.82	-0.3	1.38e-8	Monocyte count;
LUSC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg10546459	chr2:36825355	FEZ2	-0.44	-6.25	-0.32	1.26e-9	Height;
LUSC	cis	rs36093844	0.752	rs17817308	chr11:85593529	G/A	cg25872744	chr11:85566296	CCDC83	-0.46	-6.04	-0.31	4.16e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg16545954	chr1:2118288	C1orf86	0.38	7.29	0.37	2.25e-12	Height;
LUSC	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg24130564	chr14:104152367	KLC1	0.45	6.36	0.33	6.71e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg05855489	chr10:104503620	C10orf26	0.62	7.91	0.4	3.85e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg04691961	chr3:161091175	C3orf57	-0.34	-5.85	-0.3	1.18e-8	Morning vs. evening chronotype;
LUSC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg23711669	chr6:146136114	FBXO30	0.78	12.84	0.57	6.16e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg13390004	chr1:15929781	NA	0.41	6.76	0.35	6.35e-11	Systolic blood pressure;
LUSC	cis	rs601339	1.000	rs4759361	chr12:123178280	T/A	cg11919336	chr12:123188078	GPR109A	0.42	6.28	0.32	1.07e-9	Adiponectin levels;
LUSC	cis	rs243505	0.726	rs734005	chr7:148505864	G/A	cg09806900	chr7:148480153	CUL1	0.59	8.56	0.42	4.16e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg23625390	chr15:77176239	SCAPER	0.63	9.85	0.47	2.92e-20	Blood metabolite levels;
LUSC	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg02153584	chr22:29168773	CCDC117	0.55	8.07	0.4	1.31e-14	Lymphocyte counts;
LUSC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Parkinson's disease;
LUSC	cis	rs6982240	0.514	rs10089212	chr8:142265380	T/A	cg00131261	chr8:142287264	NA	-0.37	-6.11	-0.32	2.8e-9	Tonsillectomy;
LUSC	cis	rs9638182	0.666	rs2286276	chr7:72987354	C/T	cg07452164	chr7:72993570	TBL2	0.45	6.33	0.33	7.91e-10	Triglycerides;
LUSC	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg24069376	chr3:38537580	EXOG	0.36	7.0	0.36	1.43e-11	Electrocardiographic conduction measures;
LUSC	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	7.97	0.4	2.54e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg05855489	chr10:104503620	C10orf26	0.55	8.26	0.41	3.39e-15	Arsenic metabolism;
LUSC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg13867718	chr16:29973267	TMEM219	0.57	7.46	0.38	7.5e-13	Cognitive function;Information processing speed;
LUSC	cis	rs9653442	0.564	rs10185510	chr2:100790581	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-7.13	-0.36	6.27e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs2736345	0.788	rs998683	chr8:11353000	A/G	cg08224773	chr8:11311868	FAM167A	-0.32	-5.64	-0.3	3.57e-8	Sjögren's syndrome;Systemic lupus erythematosus;
LUSC	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg19156104	chr2:198669113	PLCL1	-0.47	-5.68	-0.3	2.88e-8	Ulcerative colitis;
LUSC	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg06191203	chr2:152266755	RIF1	-0.53	-7.3	-0.37	2.17e-12	Lung cancer;
LUSC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	8.13	0.41	8.33e-15	Response to antipsychotic treatment;
LUSC	cis	rs9309473	0.500	rs10865398	chr2:73741497	A/C	cg20560298	chr2:73613845	ALMS1	0.47	7.33	0.37	1.76e-12	Metabolite levels;
LUSC	cis	rs10542411	1	rs10542411	chr2:61768239	ATATAT/A	cg15711740	chr2:61764176	XPO1	-0.49	-7.56	-0.38	4.03e-13	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.55	-0.6	1.2e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7202877	0.519	rs4887811	chr16:75307251	C/T	cg03315344	chr16:75512273	CHST6	0.43	6.54	0.34	2.29e-10	Type 2 diabetes;Type 1 diabetes;
LUSC	trans	rs853679	0.546	rs200490	chr6:27796935	G/T	cg01620082	chr3:125678407	NA	-0.68	-6.86	-0.35	3.42e-11	Depression;
LUSC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	7.36	0.37	1.48e-12	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg18187862	chr3:45730750	SACM1L	0.52	6.64	0.34	1.29e-10	Primary sclerosing cholangitis;
LUSC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13126279	chr21:47581558	C21orf56	-0.42	-6.16	-0.32	2.08e-9	Testicular germ cell tumor;
LUSC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg03929089	chr4:120376271	NA	-0.93	-15.94	-0.66	6.07e-43	Height;
LUSC	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg01448562	chr3:133502909	NA	0.59	9.19	0.45	4.24e-18	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs9815354	1.000	rs73069392	chr3:41787009	C/T	cg03022575	chr3:42003672	ULK4	0.64	6.86	0.35	3.44e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg20203395	chr5:56204925	C5orf35	-0.75	-8.37	-0.42	1.58e-15	Type 2 diabetes;
LUSC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10802521	chr3:52805072	NEK4	-0.57	-8.96	-0.44	2.39e-17	Bipolar disorder;
LUSC	cis	rs78366141	0.536	rs76806573	chr4:89682729	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.93	7.35	0.37	1.53e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	6.73	0.35	7.62e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-15.8	-0.65	2.22e-42	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg13939156	chr17:80058883	NA	0.33	6.42	0.33	4.73e-10	Life satisfaction;
LUSC	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.43	6.36	0.33	6.59e-10	Schizophrenia;
LUSC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg20203395	chr5:56204925	C5orf35	-0.78	-10.56	-0.5	1.09e-22	Initial pursuit acceleration;
LUSC	cis	rs9796	0.866	rs66818965	chr15:41402279	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.46	-8.04	-0.4	1.55e-14	Menopause (age at onset);
LUSC	cis	rs3741151	1.000	rs74749711	chr11:73052839	A/T	cg17517138	chr11:73019481	ARHGEF17	0.91	8.2	0.41	5.22e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg13175981	chr1:150552382	MCL1	-0.41	-5.67	-0.3	3.17e-8	Tonsillectomy;
LUSC	trans	rs445114	0.527	rs606677	chr8:128334485	T/C	cg10897648	chr18:56338258	MALT1	-0.41	-6.23	-0.32	1.4e-9	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.48	-7.2	-0.37	3.96e-12	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	7.01	0.36	1.32e-11	Ovarian reserve;
LUSC	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg01475377	chr6:109611718	NA	-0.37	-6.55	-0.34	2.18e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.74	-14.48	-0.62	3.28e-37	Ulcerative colitis;
LUSC	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg05340658	chr4:99064831	C4orf37	-0.44	-7.0	-0.36	1.39e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg17279839	chr7:150038598	RARRES2	0.55	8.11	0.41	9.5e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2688608	0.869	rs2250140	chr10:75612881	T/C	cg23231163	chr10:75533350	FUT11	-0.39	-6.26	-0.32	1.21e-9	Inflammatory bowel disease;
LUSC	cis	rs2932538	0.922	rs12048528	chr1:113210534	A/C	cg22162597	chr1:113214053	CAPZA1	-0.68	-9.72	-0.47	8.05e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs7188861	0.681	rs1345880	chr16:11404857	G/T	cg00044050	chr16:11439710	C16orf75	0.57	5.79	0.3	1.66e-8	HDL cholesterol;
LUSC	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg04352962	chr1:209979756	IRF6	0.5	6.74	0.35	7.02e-11	Cleft lip with or without cleft palate;
LUSC	trans	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg25214090	chr10:38739885	LOC399744	0.49	7.45	0.38	8e-13	Corneal astigmatism;
LUSC	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg17178900	chr1:205818956	PM20D1	-0.4	-5.68	-0.3	2.88e-8	Menarche (age at onset);
LUSC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg11645453	chr3:52864694	ITIH4	0.34	7.91	0.4	3.72e-14	Bipolar disorder;
LUSC	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg01420254	chr6:26195488	NA	0.72	7.5	0.38	5.65e-13	Gout;Renal underexcretion gout;
LUSC	trans	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.4	-0.33	5.19e-10	Neuroticism;
LUSC	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg23505145	chr19:12996616	KLF1	0.64	10.97	0.51	4.2e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg03585969	chr10:35415529	CREM	-0.6	-8.88	-0.44	4.16e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	13.63	0.6	5.91e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg12744634	chr1:26560303	CCDC21	0.38	5.66	0.3	3.33e-8	Obesity-related traits;
LUSC	cis	rs12519773	0.501	rs10428523	chr5:92536365	G/A	cg18783429	chr5:92414398	NA	0.34	7.15	0.36	5.41e-12	Migraine;
LUSC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.64	6.16	0.32	2.07e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9815354	0.812	rs73073361	chr3:41842926	C/G	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs9944715	0.911	rs8090542	chr18:43771364	G/A	cg01718231	chr17:29326311	RNF135	-0.52	-7.44	-0.38	8.4e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg20993868	chr7:22813445	NA	0.62	11.08	0.52	1.63e-24	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	8.36	0.42	1.7e-15	Lung cancer;
LUSC	cis	rs7707921	1.000	rs6888977	chr5:81533735	C/T	cg15871215	chr5:81402204	ATG10	0.45	6.88	0.35	2.99e-11	Breast cancer;
LUSC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.16	16.28	0.67	2.76e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9296092	0.538	rs62407565	chr6:33535739	A/G	cg13560919	chr6:33536144	NA	-0.86	-16.9	-0.68	1.02e-46	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9658691	0.607	rs34891735	chr10:90779212	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.6	-6.15	-0.32	2.25e-9	Mosquito bite size;
LUSC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	0.65	11.4	0.53	1.23e-25	Blood metabolite levels;
LUSC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.47	-0.8	1.82e-76	Height;
LUSC	trans	rs370763	0.547	rs6872582	chr5:64400653	A/G	cg23238483	chr3:3886090	LRRN1	-0.38	-6.03	-0.31	4.39e-9	Inguinal hernia;
LUSC	cis	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg01251360	chr16:68772225	CDH1	-0.25	-5.81	-0.3	1.47e-8	Colorectal cancer;
LUSC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg08888203	chr3:10149979	C3orf24	0.65	8.99	0.44	1.81e-17	Alzheimer's disease;
LUSC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.66	-0.3	3.26e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.43	0.53	9.55e-26	Lung cancer in ever smokers;
LUSC	trans	rs1325195	0.920	rs2816186	chr1:179122779	T/C	cg11624085	chr17:8464688	MYH10	0.42	6.85	0.35	3.64e-11	IgE grass sensitization;
LUSC	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg06096015	chr1:231504339	EGLN1	0.56	9.88	0.48	2.27e-20	Hemoglobin concentration;
LUSC	cis	rs11955175	1.000	rs11953977	chr5:40674690	G/C	cg05478818	chr5:40835740	RPL37	0.7	5.77	0.3	1.81e-8	Bipolar disorder and schizophrenia;
LUSC	trans	rs2665103	0.687	rs11633000	chr15:82561661	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.44	-6.83	-0.35	3.96e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg06781209	chr11:61594997	FADS2	-0.43	-6.52	-0.34	2.53e-10	Neutrophil count;Sum basophil neutrophil counts;
LUSC	trans	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.39	0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg22963979	chr7:1858916	MAD1L1	-0.51	-7.65	-0.39	2.14e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs983392	0.559	rs1426249	chr11:60002261	C/A	cg24026212	chr11:59952134	MS4A6A	-0.35	-5.92	-0.31	8.06e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2742234	0.590	rs2503864	chr10:43666767	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.03	-0.36	1.17e-11	Hirschsprung disease;
LUSC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg05313129	chr8:58192883	C8orf71	-0.59	-6.35	-0.33	6.85e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820928	0.935	rs12151597	chr2:227859224	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-7.31	-0.37	1.99e-12	Pulmonary function;
LUSC	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.35	-0.37	1.51e-12	Testicular germ cell tumor;
LUSC	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.4	-6.41	-0.33	4.92e-10	Systemic lupus erythematosus;
LUSC	cis	rs12891047	0.866	rs181564	chr14:68279356	A/G	cg20999565	chr14:68265668	ZFYVE26	-0.37	-5.68	-0.3	2.95e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs400736	0.671	rs2472862	chr1:7991203	G/A	cg25007680	chr1:8021821	PARK7	-0.47	-6.88	-0.35	2.89e-11	Response to antidepressants and depression;
LUSC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9341808	0.600	rs668329	chr6:80968578	G/A	cg08355045	chr6:80787529	NA	-0.41	-6.9	-0.35	2.65e-11	Sitting height ratio;
LUSC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg08027265	chr7:2291960	NA	-0.36	-5.79	-0.3	1.58e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs79911532	0.515	rs78827697	chr7:75687725	C/G	cg03592824	chr7:75666768	STYXL1	0.69	6.81	0.35	4.46e-11	Mononucleosis;
LUSC	cis	rs10162002	1.000	rs73449251	chr13:24042272	C/T	cg00158254	chr13:24040743	NA	0.54	6.01	0.31	4.73e-9	Hypothyroidism;
LUSC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg02073558	chr3:44770973	ZNF501	-0.44	-6.93	-0.35	2.17e-11	Depressive symptoms;
LUSC	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg05887092	chr17:76393375	PGS1	0.52	9.5	0.46	4.27e-19	HDL cholesterol levels;
LUSC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.53	-0.5	1.39e-22	Alzheimer's disease (late onset);
LUSC	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg01528321	chr10:82214614	TSPAN14	0.87	13.27	0.59	1.39e-32	Post bronchodilator FEV1;
LUSC	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg04455712	chr21:45112962	RRP1B	0.48	9.0	0.44	1.76e-17	Mean corpuscular volume;
LUSC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.09	0.4	1.14e-14	Prudent dietary pattern;
LUSC	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs7572733	0.515	rs12619300	chr2:198786490	A/C	cg00792783	chr2:198669748	PLCL1	-0.44	-5.96	-0.31	6.57e-9	Dermatomyositis;
LUSC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.35	-0.37	1.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-6.44	-0.33	4.28e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.24	0.52	4.29e-25	Eye color traits;
LUSC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg09436375	chr6:42928200	GNMT	0.24	5.65	0.3	3.36e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg22166914	chr1:53195759	ZYG11B	0.5	7.97	0.4	2.55e-14	Monocyte count;
LUSC	cis	rs9815354	0.812	rs73073230	chr3:42008263	G/A	cg03022575	chr3:42003672	ULK4	0.82	8.57	0.42	3.93e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.7	-12.66	-0.57	2.88e-30	Aortic root size;
LUSC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg18230493	chr5:56204884	C5orf35	-0.61	-8.82	-0.43	6.24e-17	Type 2 diabetes;
LUSC	cis	rs2235649	0.843	rs9932890	chr16:1847868	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.43	5.97	0.31	6.08e-9	Blood metabolite levels;
LUSC	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg25456477	chr12:86230367	RASSF9	0.39	6.84	0.35	3.72e-11	Major depressive disorder;
LUSC	trans	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg03886242	chr7:26192032	NFE2L3	-0.37	-6.07	-0.32	3.55e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7615316	0.751	rs9847364	chr3:142155763	A/G	cg16271453	chr3:142027066	XRN1	-0.42	-7.33	-0.37	1.77e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg25039879	chr17:56429692	SUPT4H1	0.66	8.88	0.44	4.12e-17	Cognitive test performance;
LUSC	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.5	7.2	0.37	3.9e-12	Coronary heart disease;
LUSC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.08	0.44	9.59e-18	Motion sickness;
LUSC	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.98	-0.44	1.98e-17	Monocyte percentage of white cells;
LUSC	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg05340658	chr4:99064831	C4orf37	-0.39	-6.02	-0.31	4.58e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg23985595	chr17:80112537	CCDC57	-0.33	-6.39	-0.33	5.61e-10	Life satisfaction;
LUSC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg12463550	chr7:65579703	CRCP	-0.51	-7.47	-0.38	7.17e-13	Aortic root size;
LUSC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg16989719	chr2:238392110	NA	-0.37	-6.36	-0.33	6.66e-10	Prostate cancer;
LUSC	cis	rs931127	0.836	rs523029	chr11:65476487	T/G	cg05805236	chr11:65401703	PCNXL3	-0.41	-6.79	-0.35	5.3e-11	Systemic lupus erythematosus;
LUSC	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg12863693	chr15:85201151	NMB	0.39	7.83	0.39	6.58e-14	Schizophrenia;
LUSC	cis	rs9925964	0.933	rs4889530	chr16:31065918	T/A	cg02466173	chr16:30829666	NA	0.35	6.33	0.33	7.84e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg08601574	chr20:25228251	PYGB	-0.43	-6.59	-0.34	1.69e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.54	-14.85	-0.63	1.21e-38	Urate levels in overweight individuals;
LUSC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06505273	chr16:24850292	NA	0.41	5.7	0.3	2.58e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.71	9.63	0.47	1.55e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg03188948	chr7:1209495	NA	0.68	7.83	0.39	6.68e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs240764	0.853	rs10457809	chr6:100984400	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-5.89	-0.31	9.28e-9	Neuroticism;
LUSC	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg05110241	chr16:68378359	PRMT7	-0.53	-6.55	-0.34	2.14e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg04586622	chr2:25135609	ADCY3	0.32	6.22	0.32	1.51e-9	Body mass index;
LUSC	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.69	-0.39	1.62e-13	Glomerular filtration rate;
LUSC	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg09904177	chr6:26538194	HMGN4	-0.48	-7.56	-0.38	3.93e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-8.77	-0.43	9.38e-17	Bipolar disorder;
LUSC	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.16	-0.32	2.06e-9	Alcohol dependence;
LUSC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19717773	chr7:2847554	GNA12	-0.35	-5.67	-0.3	3.17e-8	Height;
LUSC	cis	rs4363385	0.667	rs454186	chr1:153049149	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.65	-0.3	3.48e-8	Inflammatory skin disease;
LUSC	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg18825076	chr15:78729989	IREB2	0.46	6.14	0.32	2.35e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1018697	1.000	rs7073114	chr10:104555651	C/T	cg04362960	chr10:104952993	NT5C2	0.46	6.41	0.33	5.1e-10	Colorectal adenoma (advanced);
LUSC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg20283391	chr11:68216788	NA	-0.52	-7.67	-0.39	1.9e-13	Total body bone mineral density;
LUSC	cis	rs2580764	0.598	rs6755468	chr2:55240026	A/C	cg09592903	chr2:55203963	RTN4	-0.49	-10.14	-0.49	2.97e-21	Mean platelet volume;
LUSC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.12	0.52	1.18e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg21433313	chr16:3507492	NAT15	-0.81	-8.92	-0.44	3.07e-17	Tuberculosis;
LUSC	trans	rs867371	0.502	rs28610286	chr15:82525655	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.38	-0.33	5.88e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs10489525	0.599	rs7526323	chr1:115604241	G/A	cg01522456	chr1:115632236	TSPAN2	0.51	7.6	0.38	3.08e-13	Autism;
LUSC	cis	rs4629180	1.000	rs908133	chr2:102092374	A/C	cg04415270	chr2:102091202	RFX8	-0.55	-8.88	-0.44	4.14e-17	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs1113500	0.933	rs12035689	chr1:108636756	T/C	cg11967332	chr1:108735228	SLC25A24	0.39	5.97	0.31	6.23e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs35883536	0.545	rs115017855	chr1:101101830	T/A	cg06223162	chr1:101003688	GPR88	0.36	6.32	0.33	8.21e-10	Monocyte count;
LUSC	cis	rs9420	0.961	rs10896647	chr11:57571883	C/T	cg02958346	chr11:57425731	CLP1	-0.44	-6.4	-0.33	5.12e-10	Schizophrenia;
LUSC	trans	rs1922233	0.943	rs1922229	chr4:92375659	T/C	cg24250684	chr1:219729030	NA	-0.36	-6.48	-0.33	3.29e-10	Gut microbiome composition (summer and winter);
LUSC	cis	rs4474465	0.688	rs7108439	chr11:78277708	A/T	cg27205649	chr11:78285834	NARS2	0.56	6.87	0.35	3.23e-11	Alzheimer's disease (survival time);
LUSC	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.42	-6.29	-0.33	1.01e-9	Menarche (age at onset);
LUSC	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00321850	chr1:175162397	KIAA0040	0.46	7.87	0.4	4.94e-14	Alcohol dependence;
LUSC	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	14.02	0.61	1.89e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg18827107	chr12:86230957	RASSF9	-0.45	-6.73	-0.35	7.51e-11	Major depressive disorder;
LUSC	trans	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.99	-0.36	1.49e-11	Retinal vascular caliber;
LUSC	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg27539214	chr16:67997921	SLC12A4	-0.55	-7.56	-0.38	3.86e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9309473	0.583	rs6546822	chr2:73575098	G/A	cg20560298	chr2:73613845	ALMS1	-0.51	-7.38	-0.37	1.27e-12	Metabolite levels;
LUSC	cis	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg27411982	chr8:10470053	RP1L1	0.37	5.76	0.3	1.88e-8	Neuroticism;
LUSC	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg21775007	chr8:11205619	TDH	-0.67	-10.67	-0.5	4.64e-23	Retinal vascular caliber;
LUSC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg06808227	chr14:105710500	BRF1	-0.71	-11.54	-0.53	3.73e-26	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg08601574	chr20:25228251	PYGB	0.42	6.41	0.33	4.9e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.39	6.67	0.34	1.05e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg06212747	chr3:49208901	KLHDC8B	0.43	5.81	0.3	1.43e-8	Parkinson's disease;
LUSC	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg21775007	chr8:11205619	TDH	-0.57	-8.74	-0.43	1.19e-16	Retinal vascular caliber;
LUSC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-7.42	-0.38	9.84e-13	Aortic root size;
LUSC	trans	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.03	-0.31	4.31e-9	Morning vs. evening chronotype;
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.69	-13.36	-0.59	6.41e-33	Longevity;Endometriosis;
LUSC	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21171335	chr12:122356390	WDR66	0.63	9.47	0.46	5.14e-19	Mean corpuscular volume;
LUSC	trans	rs34421088	0.576	rs2736369	chr8:11101398	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.99	-0.36	1.53e-11	Neuroticism;
LUSC	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.91	15.28	0.64	2.36e-40	Bladder cancer;
LUSC	cis	rs4845570	1.000	rs6673002	chr1:151743275	G/T	cg07092448	chr1:151763213	TDRKH	1.26	14.48	0.62	3.09e-37	Coronary artery disease;
LUSC	cis	rs16958440	0.708	rs62096462	chr18:44625179	C/G	cg17192377	chr18:44677553	HDHD2	0.43	5.67	0.3	3.06e-8	Sitting height ratio;
LUSC	cis	rs1358748	0.555	rs7528804	chr1:67593819	C/T	cg02640540	chr1:67518911	SLC35D1	0.69	6.63	0.34	1.38e-10	Tuberculosis;
LUSC	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg24881330	chr22:46731750	TRMU	0.81	6.23	0.32	1.39e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs12931792	0.712	rs4787495	chr16:30165725	C/T	cg17640201	chr16:30407289	ZNF48	-0.55	-8.64	-0.43	2.38e-16	Tonsillectomy;
LUSC	cis	rs1044826	0.957	rs4544576	chr3:139143196	G/T	cg00490450	chr3:139108681	COPB2	0.55	7.36	0.37	1.44e-12	Obesity-related traits;
LUSC	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-0.77	-12.27	-0.56	8.08e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12826209	chr6:26865740	GUSBL1	0.74	9.08	0.44	9.64e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg24375607	chr4:120327624	NA	0.75	10.65	0.5	5.47e-23	Corneal astigmatism;
LUSC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg11062466	chr8:58055876	NA	0.75	9.12	0.45	7.24e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs2637266	1.000	rs12258924	chr10:78364758	G/A	cg18941641	chr10:78392320	NA	0.39	7.11	0.36	7.28e-12	Pulmonary function;
LUSC	cis	rs75920871	0.528	rs11216241	chr11:116899249	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.42	-0.33	4.68e-10	Subjective well-being;
LUSC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.62	10.07	0.48	5.32e-21	Longevity;
LUSC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg01879757	chr17:41196368	BRCA1	-0.4	-6.12	-0.32	2.62e-9	Menopause (age at onset);
LUSC	cis	rs240764	0.817	rs240146	chr6:101078718	G/A	cg09795085	chr6:101329169	ASCC3	0.42	6.04	0.31	4.03e-9	Neuroticism;
LUSC	cis	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg05299278	chr17:33885742	SLFN14	-0.3	-6.36	-0.33	6.82e-10	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg02187348	chr16:89574699	SPG7	0.48	7.54	0.38	4.47e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs7589342	0.598	rs7602442	chr2:106402795	C/T	cg14210321	chr2:106509881	NCK2	0.41	5.86	0.31	1.13e-8	Addiction;
LUSC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	11.93	0.55	1.41e-27	Colorectal cancer;
LUSC	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.93	15.96	0.66	5.05e-43	Bladder cancer;
LUSC	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg12002119	chr2:101014098	CHST10	0.36	5.99	0.31	5.44e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg08219700	chr8:58056026	NA	0.47	5.86	0.31	1.1e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg18225595	chr11:63971243	STIP1	0.49	6.1	0.32	2.88e-9	Mean platelet volume;
LUSC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs72781680	0.716	rs2551343	chr2:24027002	C/G	cg08917208	chr2:24149416	ATAD2B	0.63	7.2	0.37	4.03e-12	Lymphocyte counts;
LUSC	trans	rs9944715	0.906	rs7241527	chr18:43736932	G/A	cg01718231	chr17:29326311	RNF135	0.45	6.15	0.32	2.24e-9	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-8.74	-0.43	1.19e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6906287	0.647	rs12214483	chr6:118780146	G/C	cg21191810	chr6:118973309	C6orf204	0.33	6.0	0.31	5.17e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1957429	0.614	rs61012404	chr14:65347649	C/T	cg23373153	chr14:65346875	NA	-1.03	-9.4	-0.46	8.72e-19	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7113850	0.541	rs4360696	chr11:24217119	C/G	ch.11.24196551F	chr11:24239977	NA	0.96	8.77	0.43	9.54e-17	Bone fracture in osteoporosis;
LUSC	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.92	0.35	2.38e-11	IgG glycosylation;
LUSC	cis	rs1113500	0.932	rs1343205	chr1:108597873	C/G	cg06207961	chr1:108661230	NA	0.4	7.45	0.38	8.24e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg06096015	chr1:231504339	EGLN1	0.58	10.37	0.49	5e-22	Hemoglobin concentration;
LUSC	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg02336364	chr1:24764700	NIPAL3	0.35	6.2	0.32	1.66e-9	Response to interferon beta in multiple sclerosis;
LUSC	trans	rs11611246	0.882	rs2286028	chr12:1015469	C/G	cg27417659	chr7:98567827	TRRAP	-0.46	-6.15	-0.32	2.16e-9	Body mass index;
LUSC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.59	-0.54	2.5e-26	Schizophrenia;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07212969	chr2:241506132	NA	-0.49	-6.54	-0.34	2.32e-10	Hepatitis;
LUSC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.31	0.53	2.45e-25	Menopause (age at onset);
LUSC	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg08085267	chr17:45401833	C17orf57	-0.46	-6.83	-0.35	4.13e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7833986	1.000	rs66553445	chr8:57096781	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.63	9.35	0.46	1.28e-18	Height;
LUSC	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg16386425	chr10:429943	DIP2C	-0.38	-6.03	-0.31	4.43e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	6.88	0.35	2.99e-11	Height;
LUSC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.8	12.36	0.56	3.63e-29	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05756109	chr10:103347662	POLL;RP11-529I10.4	0.4	6.19	0.32	1.78e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21659725	chr3:3221576	CRBN	-0.61	-10.09	-0.48	4.34e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg12823233	chr7:2316876	SNX8	-0.35	-5.85	-0.3	1.18e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg26384229	chr12:38710491	ALG10B	0.55	7.79	0.39	8.68e-14	Morning vs. evening chronotype;
LUSC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg07424592	chr7:64974309	NA	0.67	5.98	0.31	5.72e-9	Diabetic kidney disease;
LUSC	cis	rs34734847	1.000	rs10431385	chr12:121128882	T/C	cg27246729	chr12:121163418	ACADS	0.46	7.38	0.37	1.3e-12	Mean corpuscular volume;
LUSC	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg26850624	chr5:429559	AHRR	-0.37	-6.86	-0.35	3.34e-11	Cystic fibrosis severity;
LUSC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg16606324	chr3:10149918	C3orf24	0.44	6.83	0.35	4.05e-11	Alzheimer's disease;
LUSC	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	7.23	0.37	3.38e-12	Rheumatoid arthritis;
LUSC	cis	rs2224391	0.628	rs1609808	chr6:5246333	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.49	-6.61	-0.34	1.5e-10	Height;
LUSC	cis	rs7119	0.717	rs62007348	chr15:77804501	C/T	cg27398640	chr15:77910606	LINGO1	-0.29	-6.08	-0.32	3.2e-9	Type 2 diabetes;
LUSC	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.07	-22.54	-0.78	4.9e-69	Ulcerative colitis;
LUSC	trans	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.65	-11.41	-0.53	1.07e-25	Mean corpuscular volume;
LUSC	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15664640	chr17:80829946	TBCD	-0.73	-12.72	-0.57	1.69e-30	Breast cancer;
LUSC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg04450456	chr4:17643702	FAM184B	0.4	6.86	0.35	3.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2282300	0.739	rs10835648	chr11:30320506	A/G	cg25418670	chr11:30344373	C11orf46	0.61	8.73	0.43	1.26e-16	Morning vs. evening chronotype;
LUSC	cis	rs7712401	0.623	rs30044	chr5:122272080	T/C	cg19077854	chr5:122220652	SNX24	0.41	9.01	0.44	1.58e-17	Mean platelet volume;
LUSC	trans	rs3889199	0.859	rs6587848	chr1:59657488	A/C	cg24327262	chr19:46929907	NA	-0.38	-6.12	-0.32	2.69e-9	Pulse pressure;
LUSC	cis	rs7923609	0.967	rs7085018	chr10:65286667	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.46	-0.33	3.74e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs2950393	0.804	rs898611	chr12:57163316	A/G	cg14367344	chr1:146644336	PRKAB2	0.43	6.11	0.32	2.8e-9	Platelet distribution width;
LUSC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.05	-0.31	3.9e-9	Triglycerides;
LUSC	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg24296786	chr1:45957014	TESK2	0.46	6.52	0.34	2.65e-10	Red blood cell count;Reticulocyte count;
LUSC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg07362569	chr17:61921086	SMARCD2	-0.32	-6.6	-0.34	1.66e-10	Prudent dietary pattern;
LUSC	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg25801113	chr15:45476975	SHF	-0.35	-6.82	-0.35	4.34e-11	Uric acid levels;
LUSC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg06618935	chr21:46677482	NA	-0.39	-7.81	-0.39	7.65e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg11871910	chr12:69753446	YEATS4	0.65	9.94	0.48	1.49e-20	Blood protein levels;
LUSC	cis	rs12421382	0.570	rs10789736	chr11:109478039	G/C	cg27471124	chr11:109292789	C11orf87	0.38	6.53	0.34	2.4e-10	Schizophrenia;
LUSC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg05896524	chr21:47604654	C21orf56	0.52	8.05	0.4	1.51e-14	Testicular germ cell tumor;
LUSC	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs887829	0.570	rs13002774	chr2:234593706	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.21	-0.32	1.58e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs62400317	0.859	rs62400313	chr6:45256366	A/T	cg18551225	chr6:44695536	NA	-0.42	-6.99	-0.36	1.52e-11	Total body bone mineral density;
LUSC	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg01881094	chr2:180872142	CWC22	-0.82	-10.71	-0.51	3.19e-23	Schizophrenia;
LUSC	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.05	-0.91	1.39e-129	Myeloid white cell count;
LUSC	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg02016764	chr4:38805732	TLR1	-0.53	-5.74	-0.3	2.16e-8	Breast cancer;
LUSC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.83	-15.09	-0.64	1.3e-39	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.57	-9.3	-0.45	1.95e-18	Aortic root size;
LUSC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg03146154	chr1:46216737	IPP	-0.5	-7.23	-0.37	3.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg07923666	chr12:49932857	KCNH3	-0.49	-6.1	-0.32	3e-9	Resting heart rate;
LUSC	cis	rs12310956	0.510	rs7301767	chr12:33886529	A/T	cg06521331	chr12:34319734	NA	-0.37	-6.09	-0.32	3.09e-9	Morning vs. evening chronotype;
LUSC	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg07148914	chr20:33460835	GGT7	0.54	8.4	0.42	1.33e-15	Height;
LUSC	cis	rs4363385	0.510	rs7541328	chr1:152894142	C/G	cg25856811	chr1:152973957	SPRR3	-0.38	-6.21	-0.32	1.62e-9	Inflammatory skin disease;
LUSC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg07701084	chr6:150067640	NUP43	0.57	8.74	0.43	1.16e-16	Lung cancer;
LUSC	trans	rs1325195	0.803	rs10913696	chr1:179088721	A/T	cg11624085	chr17:8464688	MYH10	-0.44	-7.38	-0.37	1.25e-12	IgE grass sensitization;
LUSC	cis	rs1997103	0.871	rs9649855	chr7:55410222	T/C	cg17469321	chr7:55412551	NA	0.64	10.38	0.49	4.6e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs17490626	0.568	rs12416520	chr10:71211945	A/G	cg14388049	chr10:71211838	TSPAN15	-0.32	-5.81	-0.3	1.47e-8	Thrombosis;
LUSC	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg03676636	chr4:99064102	C4orf37	0.33	7.19	0.37	4.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg10130564	chr11:117069849	TAGLN	0.38	6.65	0.34	1.17e-10	Blood protein levels;
LUSC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg10207240	chr12:122356781	WDR66	0.47	6.77	0.35	5.69e-11	Mean corpuscular volume;
LUSC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.94	-0.31	6.99e-9	Reticulocyte count;
LUSC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg04727924	chr7:799746	HEATR2	-0.55	-6.71	-0.34	8.16e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05901451	chr6:126070800	HEY2	0.57	8.57	0.42	3.98e-16	Endometrial cancer;
LUSC	cis	rs1549118	0.669	rs11625414	chr14:78375344	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.42	-5.77	-0.3	1.82e-8	Resting heart rate;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02850933	chr1:249167489	NA	-0.42	-6.3	-0.33	9.37e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.55	-8.47	-0.42	7.87e-16	Personality dimensions;
LUSC	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-1.13	-17.99	-0.7	4.71e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	trans	rs62238980	0.614	rs75074953	chr22:32374314	C/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg20701182	chr2:24300061	SF3B14	0.73	7.39	0.37	1.2e-12	Lymphocyte counts;
LUSC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	0.87	14.7	0.63	4.34e-38	Tonsillectomy;
LUSC	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.52	7.61	0.38	2.85e-13	Night sleep phenotypes;
LUSC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg13319975	chr6:146136371	FBXO30	0.49	7.43	0.38	9.4e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	0.9	17.13	0.68	1.15e-47	Heart rate;
LUSC	cis	rs10876993	0.893	rs7979246	chr12:58092554	A/G	cg18357645	chr12:58087776	OS9	0.6	9.07	0.44	1.01e-17	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs56399783	0.901	rs73047393	chr7:2775879	C/T	cg14895029	chr7:2775587	GNA12	0.53	5.82	0.3	1.41e-8	Childhood ear infection;
LUSC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg02079420	chr8:82753780	SNX16	0.38	5.7	0.3	2.68e-8	Diastolic blood pressure;
LUSC	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg23601095	chr6:26197514	HIST1H3D	0.73	7.46	0.38	7.42e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs372883	0.869	rs2027605	chr21:30726773	A/G	cg08807101	chr21:30365312	RNF160	0.41	6.14	0.32	2.29e-9	Pancreatic cancer;
LUSC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg22800045	chr5:56110881	MAP3K1	0.79	10.07	0.48	5.15e-21	Initial pursuit acceleration;
LUSC	cis	rs6546537	0.955	rs2312215	chr2:69839825	T/A	cg10773587	chr2:69614142	GFPT1	-0.56	-8.41	-0.42	1.22e-15	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg01689657	chr7:91764605	CYP51A1	0.34	6.07	0.32	3.49e-9	Breast cancer;
LUSC	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg27068330	chr11:65405492	SIPA1	-0.75	-10.39	-0.49	4.12e-22	Acne (severe);
LUSC	cis	rs10843647	1.000	rs4930900	chr12:30325008	T/C	cg12718339	chr12:29936407	TMTC1	-0.36	-5.91	-0.31	8.65e-9	Glucose homeostasis traits;
LUSC	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg20991723	chr1:152506922	NA	0.54	10.32	0.49	7.39e-22	Hair morphology;
LUSC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg15649852	chr7:65879115	NA	0.41	5.79	0.3	1.64e-8	Aortic root size;
LUSC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.76	0.57	1.17e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7523050	0.643	rs35924015	chr1:109404626	T/C	cg08274380	chr1:109419600	GPSM2	0.93	9.49	0.46	4.66e-19	Fat distribution (HIV);
LUSC	cis	rs10193935	0.901	rs7605782	chr2:42502332	C/T	cg27598129	chr2:42591480	NA	-0.59	-7.88	-0.4	4.77e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg11843606	chr2:227700838	RHBDD1	-0.66	-10.24	-0.49	1.43e-21	Pulmonary function;
LUSC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.71	-11.04	-0.52	2.31e-24	Aortic root size;
LUSC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg00750074	chr16:89608354	SPG7	-0.57	-10.17	-0.49	2.36e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg07636037	chr3:49044803	WDR6	0.44	6.35	0.33	7.23e-10	Resting heart rate;
LUSC	cis	rs1113500	0.933	rs11185255	chr1:108633191	T/A	cg06207961	chr1:108661230	NA	0.41	7.61	0.38	2.89e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.81	-14.32	-0.62	1.36e-36	Cognitive function;
LUSC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-10.04	-0.48	6.92e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs977987	0.806	rs7185640	chr16:75394399	A/G	cg03315344	chr16:75512273	CHST6	0.48	9.26	0.45	2.6e-18	Dupuytren's disease;
LUSC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg18477163	chr1:228402036	OBSCN	-0.54	-10.17	-0.49	2.33e-21	Diastolic blood pressure;
LUSC	trans	rs13219787	0.915	rs13214703	chr6:27941387	A/G	cg01426208	chr6:29720641	NA	0.77	6.01	0.31	4.83e-9	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;
LUSC	cis	rs6714788	0.565	rs9308833	chr2:100662618	C/T	cg07810366	chr2:100720526	AFF3	-0.4	-6.35	-0.33	6.95e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg25214090	chr10:38739885	LOC399744	-0.4	-6.38	-0.33	6.06e-10	Corneal astigmatism;
LUSC	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.0	14.25	0.61	2.51e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg03342759	chr3:160939853	NMD3	-0.48	-6.69	-0.34	9.56e-11	Parkinson's disease;
LUSC	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg22875332	chr1:76189707	ACADM	0.57	8.24	0.41	4.01e-15	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg13047869	chr3:10149882	C3orf24	0.61	8.24	0.41	3.97e-15	Alzheimer's disease;
LUSC	trans	rs62458065	0.568	rs62466415	chr7:32518254	C/T	cg00845942	chr12:64062724	DPY19L2	-0.52	-6.12	-0.32	2.6e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs10197940	0.578	rs2444264	chr2:152310928	G/T	cg19508488	chr2:152266495	RIF1	-0.39	-5.71	-0.3	2.47e-8	Lung cancer;
LUSC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs548181	0.736	rs540723	chr11:125489621	A/G	cg03464685	chr11:125439445	EI24	1.17	14.17	0.61	4.96e-36	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg19539972	chr4:7069911	GRPEL1	-0.6	-6.09	-0.32	3.14e-9	Monocyte percentage of white cells;
LUSC	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17467752	chr17:38218738	THRA	0.77	12.47	0.56	1.47e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg24631222	chr15:78858424	CHRNA5	-0.64	-8.55	-0.42	4.48e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg10523860	chr14:103875565	MARK3	-0.36	-5.69	-0.3	2.79e-8	Body mass index;
LUSC	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg12365402	chr11:9010492	NRIP3	-0.39	-6.79	-0.35	5.19e-11	Hemoglobin concentration;
LUSC	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.99	0.4	2.18e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg11057378	chr10:81107060	PPIF	0.34	6.05	0.31	3.96e-9	Height;
LUSC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg24642439	chr20:33292090	TP53INP2	0.48	7.33	0.37	1.8e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs4740619	0.905	rs6474974	chr9:15794897	C/G	cg14451791	chr9:16040625	NA	0.31	5.94	0.31	7.3e-9	Body mass index;
LUSC	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.88	15.08	0.64	1.52e-39	Morning vs. evening chronotype;
LUSC	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg02493740	chr2:85810744	VAMP5	-0.32	-5.67	-0.3	3.1e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	0.95	18.98	0.72	5.3e-55	Cognitive function;
LUSC	cis	rs55910451	0.779	rs72774075	chr10:5764998	G/A	cg11519256	chr10:5708881	ASB13	-0.48	-5.85	-0.3	1.19e-8	Breast cancer;
LUSC	trans	rs7939886	0.920	rs7950386	chr11:55931513	C/T	cg15704280	chr7:45808275	SEPT13	0.88	6.69	0.34	9.39e-11	Myopia (pathological);
LUSC	cis	rs7523273	0.548	rs3109808	chr1:207948477	C/A	cg22525895	chr1:207977042	MIR29B2	0.41	6.6	0.34	1.6e-10	Schizophrenia;
LUSC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13012494	chr21:47604986	C21orf56	0.46	6.87	0.35	3.18e-11	Testicular germ cell tumor;
LUSC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26314531	chr2:26401878	FAM59B	0.69	9.49	0.46	4.66e-19	Gut microbiome composition (summer);
LUSC	cis	rs71403859	0.570	rs78972826	chr16:71454264	A/G	cg08717414	chr16:71523259	ZNF19	-0.62	-7.03	-0.36	1.14e-11	Post bronchodilator FEV1;
LUSC	cis	rs7264396	0.887	rs4911502	chr20:34063034	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-5.83	-0.3	1.28e-8	Total cholesterol levels;
LUSC	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.44	0.33	4.04e-10	Corneal astigmatism;
LUSC	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg26408565	chr15:76604113	ETFA	-0.48	-7.63	-0.39	2.4e-13	Blood metabolite levels;
LUSC	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg05084668	chr3:125655381	ALG1L	-0.52	-7.96	-0.4	2.63e-14	Blood pressure (smoking interaction);
LUSC	cis	rs753274	0.562	rs888876	chr19:14416793	T/C	cg19560656	chr19:14444267	NA	-0.35	-6.33	-0.33	7.75e-10	Tumor necrosis factor beta levels;
LUSC	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.9	-0.31	8.79e-9	Recombination measurement;
LUSC	cis	rs4474465	0.920	rs4945285	chr11:78221698	C/T	cg27205649	chr11:78285834	NARS2	0.49	5.69	0.3	2.74e-8	Alzheimer's disease (survival time);
LUSC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.14	15.8	0.65	2.11e-42	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg11663144	chr21:46675770	NA	0.41	7.15	0.36	5.37e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-0.87	-16.89	-0.68	1.09e-46	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg10483660	chr13:112241077	NA	0.31	5.77	0.3	1.8e-8	Hepatitis;
LUSC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.17	-0.37	4.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg23173402	chr1:227635558	NA	0.56	6.26	0.32	1.2e-9	Major depressive disorder;
LUSC	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.74	-0.35	6.88e-11	Lung cancer;
LUSC	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg03522245	chr20:25566470	NINL	-0.35	-5.77	-0.3	1.83e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg18105134	chr13:113819100	PROZ	0.65	9.75	0.47	6.22e-20	Platelet distribution width;
LUSC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg10360139	chr7:1886902	MAD1L1	-0.39	-5.91	-0.31	8.48e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg24642439	chr20:33292090	TP53INP2	0.5	7.5	0.38	5.77e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-8.68	-0.43	1.8e-16	Response to antipsychotic treatment;
LUSC	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.45	0.59	3.01e-33	Morning vs. evening chronotype;
LUSC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-6.29	-0.33	9.99e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg05313129	chr8:58192883	C8orf71	0.51	5.97	0.31	6.22e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	10.01	0.48	8.46e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.75	0.65	3.43e-42	Platelet count;
LUSC	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.47	-0.33	3.43e-10	Mood instability;
LUSC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg18825119	chr6:163149453	PACRG;PARK2	-0.45	-6.93	-0.35	2.21e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg06784218	chr1:46089804	CCDC17	-0.56	-11.07	-0.52	1.85e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6722750	0.716	rs1973848	chr2:64418456	T/C	cg22352474	chr2:64371530	PELI1	-0.53	-7.94	-0.4	3.04e-14	Neuroticism;
LUSC	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg17366294	chr4:99064904	C4orf37	0.53	9.09	0.45	8.73e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.53	-8.88	-0.44	4.21e-17	Neurofibrillary tangles;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25953536	chr17:26684567	POLDIP2;TMEM199	0.67	5.94	0.31	7.02e-9	Cognitive performance;
LUSC	cis	rs2004776	0.656	rs12042306	chr1:230866063	G/A	cg07502417	chr1:230849801	AGT	0.25	5.8	0.3	1.51e-8	Diastolic blood pressure;
LUSC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg27427491	chr17:78079615	GAA	-0.44	-7.49	-0.38	6.08e-13	Yeast infection;
LUSC	cis	rs859767	0.741	rs11682346	chr2:135388261	G/A	cg12500956	chr2:135428796	TMEM163	-0.28	-6.36	-0.33	6.66e-10	Neuroticism;
LUSC	cis	rs36715	1.000	rs36697	chr5:127549613	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.53	6.93	0.35	2.18e-11	Breast cancer;
LUSC	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg09307838	chr4:120376055	NA	0.64	9.71	0.47	8.2e-20	Corneal astigmatism;
LUSC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg08132940	chr7:1081526	C7orf50	-0.51	-5.93	-0.31	7.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7230711	1.000	rs60651868	chr18:48781036	C/T	cg07422195	chr1:23894874	NA	-0.6	-5.95	-0.31	6.87e-9	Immune response to anthrax vaccine;
LUSC	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg26441486	chr22:50317300	CRELD2	0.5	7.26	0.37	2.79e-12	Schizophrenia;
LUSC	trans	rs9944715	1.000	rs9959813	chr18:43841082	C/T	cg01718231	chr17:29326311	RNF135	0.54	7.43	0.38	9.28e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs11153306	0.818	rs7764009	chr6:111944596	G/T	cg22127309	chr6:111907043	TRAF3IP2	0.33	6.3	0.33	9.58e-10	Tonsillectomy;
LUSC	trans	rs2392780	0.896	rs13249993	chr8:128350515	G/A	cg10897648	chr18:56338258	MALT1	-0.4	-5.97	-0.31	6.19e-9	Breast cancer (early onset);
LUSC	cis	rs6547741	0.816	rs7560847	chr2:27882700	A/G	cg27432699	chr2:27873401	GPN1	-0.89	-17.81	-0.7	2.35e-50	Oral cavity cancer;
LUSC	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg16434002	chr17:42200994	HDAC5	0.45	6.3	0.33	9.28e-10	Total body bone mineral density;
LUSC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg05973401	chr12:123451056	ABCB9	0.54	6.68	0.34	1.01e-10	Neutrophil percentage of white cells;
LUSC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg25767906	chr1:53392781	SCP2	0.45	7.9	0.4	4.06e-14	Monocyte count;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.78	17.87	0.7	1.41e-50	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs367943	0.712	rs9326888	chr5:112731133	A/C	cg12552261	chr5:112820674	MCC	0.36	5.87	0.31	1.03e-8	Type 2 diabetes;
LUSC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.85	15.28	0.64	2.52e-40	Menarche (age at onset);
LUSC	cis	rs6723226	0.765	rs12612824	chr2:32579759	C/T	cg02381751	chr2:32503542	YIPF4	-0.62	-9.48	-0.46	4.88e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-9.69	-0.47	1.02e-19	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs17030434	0.834	rs6535958	chr4:154760834	C/G	cg14289246	chr4:154710475	SFRP2	0.42	5.73	0.3	2.26e-8	Electrocardiographic conduction measures;
LUSC	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Bladder cancer;
LUSC	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg17911788	chr17:44343683	NA	-0.3	-5.72	-0.3	2.41e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg06008330	chr7:65541103	ASL	0.4	6.2	0.32	1.64e-9	Aortic root size;
LUSC	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.58	-9.78	-0.47	4.94e-20	Bone mineral density;
LUSC	cis	rs11158026	0.757	rs56206440	chr14:55450886	T/C	cg04306507	chr14:55594613	LGALS3	0.37	7.38	0.37	1.23e-12	Parkinson's disease;
LUSC	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg21100191	chr22:23484243	RTDR1	0.7	10.23	0.49	1.46e-21	Bone mineral density;
LUSC	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg20283391	chr11:68216788	NA	-0.6	-8.37	-0.42	1.6e-15	Total body bone mineral density;
LUSC	trans	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.19	-0.37	4.19e-12	Triglycerides;
LUSC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg16479474	chr6:28041457	NA	0.32	5.72	0.3	2.31e-8	Depression;
LUSC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg01765077	chr12:122356316	WDR66	-0.53	-7.74	-0.39	1.22e-13	Mean corpuscular volume;
LUSC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg21238619	chr17:78079768	GAA	-0.29	-5.93	-0.31	7.53e-9	Yeast infection;
LUSC	cis	rs9549260	0.577	rs6563841	chr13:41239178	A/C	cg21288729	chr13:41239152	FOXO1	0.63	9.78	0.47	5.12e-20	Red blood cell count;
LUSC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	0.99	13.71	0.6	3.01e-34	Vitiligo;
LUSC	cis	rs10761482	0.813	rs4291629	chr10:62104758	C/T	cg18175470	chr10:62150864	ANK3	-0.49	-7.08	-0.36	8.6e-12	Schizophrenia;
LUSC	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg15485101	chr11:133734466	NA	0.4	7.43	0.38	8.9e-13	Childhood ear infection;
LUSC	cis	rs7587476	0.601	rs17489363	chr2:215674341	A/G	cg04004882	chr2:215674386	BARD1	-0.52	-7.27	-0.37	2.54e-12	Neuroblastoma;
LUSC	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg00757033	chr12:89920650	WDR51B	0.6	10.33	0.49	7.01e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg20476274	chr7:133979776	SLC35B4	0.87	16.9	0.68	9.98e-47	Mean platelet volume;
LUSC	cis	rs73200209	0.744	rs11612907	chr12:116495255	A/G	cg01776926	chr12:116560359	MED13L	-0.5	-5.94	-0.31	7.14e-9	Total body bone mineral density;
LUSC	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg04998671	chr14:104000505	TRMT61A	-0.42	-6.15	-0.32	2.17e-9	Reticulocyte count;
LUSC	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg24011408	chr12:48396354	COL2A1	-0.44	-7.33	-0.37	1.7e-12	Plateletcrit;
LUSC	trans	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg04995722	chr7:26192034	NFE2L3	-0.43	-6.72	-0.35	8.08e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg04851639	chr8:1020857	NA	-0.35	-6.97	-0.36	1.67e-11	Schizophrenia;
LUSC	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg06637938	chr14:75390232	RPS6KL1	0.54	8.76	0.43	9.67e-17	Height;
LUSC	trans	rs6549438	1.000	rs6798993	chr3:72161623	A/C	cg12629250	chr15:20149347	NA	-0.48	-6.17	-0.32	1.95e-9	Migraine - clinic-based;
LUSC	cis	rs6728642	0.572	rs60621865	chr2:97598001	T/C	cg26665480	chr2:98280029	ACTR1B	-0.75	-7.48	-0.38	6.53e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs7523050	0.730	rs12079547	chr1:109469314	A/C	cg08274380	chr1:109419600	GPSM2	1.03	10.3	0.49	8.35e-22	Fat distribution (HIV);
LUSC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg05347473	chr6:146136440	FBXO30	0.56	9.72	0.47	8.14e-20	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4729127	1.000	rs8180725	chr7:94010953	G/C	cg20086523	chr13:52378287	DHRS12	0.56	6.4	0.33	5.18e-10	Intelligence;
LUSC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04267008	chr7:1944627	MAD1L1	0.42	6.17	0.32	1.93e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg18323236	chr1:24743029	NIPAL3	0.39	6.7	0.34	9.02e-11	Response to interferon beta in multiple sclerosis;
LUSC	cis	rs10193935	0.901	rs2374429	chr2:42677888	A/G	cg27598129	chr2:42591480	NA	-0.54	-8.21	-0.41	4.93e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7989336	0.562	rs7323705	chr13:97029792	G/A	cg02571835	chr13:96230311	CLDN10	-0.35	-5.66	-0.3	3.23e-8	Obesity;
LUSC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg27588902	chr6:42928151	GNMT	-0.27	-5.93	-0.31	7.5e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg03806693	chr22:41940476	POLR3H	1.02	14.1	0.61	9.48e-36	Vitiligo;
LUSC	trans	rs7830939	1.000	rs7830939	chr8:9380132	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.59	-0.34	1.76e-10	Neuroticism;
LUSC	cis	rs977987	0.806	rs11860284	chr16:75412907	A/G	cg03315344	chr16:75512273	CHST6	0.49	9.33	0.45	1.46e-18	Dupuytren's disease;
LUSC	trans	rs11165623	0.792	rs12132069	chr1:96918809	A/C	cg10631902	chr5:14652156	NA	-0.53	-8.75	-0.43	1.1e-16	Hip circumference;Waist circumference;
LUSC	cis	rs7572644	0.699	rs10209126	chr2:28209283	C/T	cg27432699	chr2:27873401	GPN1	-0.51	-6.95	-0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	trans	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg13010199	chr12:38710504	ALG10B	-0.4	-6.01	-0.31	4.99e-9	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg14092988	chr3:52407081	DNAH1	0.3	5.8	0.3	1.53e-8	Bipolar disorder;
LUSC	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-6.89	-0.35	2.82e-11	Breast cancer;
LUSC	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg27284194	chr4:1044797	NA	0.51	8.44	0.42	1e-15	Recombination rate (males);
LUSC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.1e-12	Motion sickness;
LUSC	cis	rs7615316	0.779	rs2171035	chr3:142002786	C/T	cg16271453	chr3:142027066	XRN1	-0.36	-6.33	-0.33	7.77e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.71	-0.6	2.98e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9660992	0.626	rs9326600	chr1:205245268	G/A	cg21545522	chr1:205238299	TMCC2	0.41	7.74	0.39	1.17e-13	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.45	5.93	0.31	7.38e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-6.88	-0.35	2.94e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs62400317	0.762	rs3997499	chr6:44864552	G/T	cg18551225	chr6:44695536	NA	-0.46	-7.44	-0.38	8.7e-13	Total body bone mineral density;
LUSC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg16434002	chr17:42200994	HDAC5	0.44	6.0	0.31	5.23e-9	Total body bone mineral density;
LUSC	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.68	-0.6	3.86e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.69	-0.73	7.91e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg02149193	chr12:132512069	EP400	-0.34	-5.94	-0.31	7.04e-9	N-glycan levels;
LUSC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.46	-6.71	-0.34	8.44e-11	Menarche (age at onset);
LUSC	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg23711669	chr6:146136114	FBXO30	0.88	16.39	0.67	1.06e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-0.75	-11.9	-0.55	1.78e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg11395062	chr17:14139857	CDRT15	0.4	6.35	0.33	6.87e-10	Temperament;
LUSC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.08	0.4	1.19e-14	Parkinson's disease;
LUSC	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.36	-6.92	-0.35	2.38e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg11812906	chr14:75593930	NEK9	-0.41	-6.2	-0.32	1.63e-9	Neuroticism;
LUSC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.73	-12.23	-0.56	1.12e-28	Longevity;
LUSC	cis	rs9362426	1.000	rs414013	chr6:88085866	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.39	6.19	0.32	1.8e-9	Depressive episodes in bipolar disorder;
LUSC	cis	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.88	-0.31	9.71e-9	Eotaxin levels;
LUSC	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.57	-6.18	-0.32	1.87e-9	Mean platelet volume;
LUSC	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg15557168	chr22:42548783	NA	-0.43	-6.78	-0.35	5.59e-11	Schizophrenia;
LUSC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg05347473	chr6:146136440	FBXO30	0.48	8.01	0.4	1.89e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg27165867	chr14:105738592	BRF1	-0.54	-7.98	-0.4	2.45e-14	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg00945038	chr17:61921165	SMARCD2	-0.55	-9.47	-0.46	5.14e-19	Prudent dietary pattern;
LUSC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg26338869	chr17:61819248	STRADA	0.41	5.94	0.31	7.15e-9	Prudent dietary pattern;
LUSC	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg06636001	chr8:8085503	FLJ10661	0.68	11.16	0.52	8.75e-25	Parkinson's disease;
LUSC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.42	-8.88	-0.44	4.19e-17	Hemoglobin concentration;
LUSC	cis	rs9650315	0.538	rs7833143	chr8:57208850	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.63	7.71	0.39	1.47e-13	Height;
LUSC	cis	rs68170813	0.559	rs75203426	chr7:107017589	G/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.52	-0.46	3.73e-19	Coronary artery disease;
LUSC	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.74	9.16	0.45	5.4e-18	Schizophrenia;
LUSC	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.31	5.73	0.3	2.2e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg13939156	chr17:80058883	NA	-0.34	-6.66	-0.34	1.16e-10	Life satisfaction;
LUSC	cis	rs7524258	0.778	rs12028181	chr1:7315085	C/T	cg07173049	chr1:7289937	CAMTA1	-0.31	-6.37	-0.33	6.39e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.97	0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12541635	0.966	rs10955409	chr8:107022586	A/C	cg10147462	chr8:107024639	NA	0.52	9.64	0.47	1.46e-19	Age of smoking initiation;
LUSC	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.74	0.35	7.03e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg18512352	chr11:47633146	NA	-0.47	-9.56	-0.46	2.72e-19	Subjective well-being;
LUSC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg25039879	chr17:56429692	SUPT4H1	0.69	9.08	0.44	9.99e-18	Cognitive test performance;
LUSC	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg04374321	chr14:90722782	PSMC1	0.74	12.09	0.55	3.76e-28	Mortality in heart failure;
LUSC	cis	rs9326248	0.689	rs236916	chr11:117089628	G/A	cg26566898	chr11:117069891	TAGLN	-0.43	-6.2	-0.32	1.63e-9	Blood protein levels;
LUSC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.54	5.66	0.3	3.24e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs981844	0.961	rs6827685	chr4:154662227	C/T	cg14289246	chr4:154710475	SFRP2	0.46	5.8	0.3	1.54e-8	Response to statins (LDL cholesterol change);
LUSC	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg03128534	chr1:43423976	SLC2A1	-0.51	-6.63	-0.34	1.36e-10	Red cell distribution width;
LUSC	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg08270630	chr22:50330655	NA	-0.45	-6.64	-0.34	1.3e-10	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	8.63	0.43	2.49e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.47	6.56	0.34	2.09e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	trans	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg19694781	chr19:47549865	TMEM160	-0.59	-9.43	-0.46	7.14e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg10434728	chr15:90938212	IQGAP1	0.32	5.98	0.31	5.58e-9	Rheumatoid arthritis;
LUSC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03264133	chr6:25882463	NA	-0.5	-9.23	-0.45	3.21e-18	Blood metabolite levels;
LUSC	cis	rs17767294	0.522	rs78037434	chr6:27848898	A/T	cg08851530	chr6:28072375	NA	1.18	7.81	0.39	7.25e-14	Parkinson's disease;
LUSC	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg24692254	chr21:30365293	RNF160	0.71	11.53	0.53	3.91e-26	Pancreatic cancer;
LUSC	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg11887960	chr12:57824829	NA	0.55	6.69	0.34	9.64e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.96	-0.44	2.38e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg20608306	chr11:116969690	SIK3	-0.38	-6.34	-0.33	7.56e-10	Blood protein levels;
LUSC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg22963979	chr7:1858916	MAD1L1	-0.7	-11.75	-0.54	6.52e-27	Bipolar disorder and schizophrenia;
LUSC	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg04362960	chr10:104952993	NT5C2	0.62	9.65	0.47	1.35e-19	Arsenic metabolism;
LUSC	cis	rs4363385	0.550	rs6661932	chr1:152896734	T/C	cg00922841	chr1:152955080	SPRR1A	-0.39	-6.33	-0.33	7.87e-10	Inflammatory skin disease;
LUSC	cis	rs295140	0.903	rs10931898	chr2:201171191	C/G	cg04283868	chr2:201171347	SPATS2L	0.43	6.45	0.33	3.85e-10	QT interval;
LUSC	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg07148914	chr20:33460835	GGT7	0.46	6.84	0.35	3.87e-11	Height;
LUSC	cis	rs6977660	1.000	rs12672557	chr7:19804237	G/A	cg05791153	chr7:19748676	TWISTNB	0.58	6.43	0.33	4.34e-10	Thyroid stimulating hormone;
LUSC	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg14825688	chr5:132208181	LEAP2	-0.43	-6.41	-0.33	4.95e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.76	-12.96	-0.58	2.15e-31	QT interval;
LUSC	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg18753928	chr3:113234510	CCDC52	-0.44	-6.68	-0.34	9.9e-11	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs6920965	0.545	rs2326242	chr6:126174859	A/C	cg05901451	chr6:126070800	HEY2	-0.39	-5.65	-0.3	3.48e-8	High light scatter reticulocyte count;
LUSC	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg00745463	chr17:30367425	LRRC37B	0.78	8.21	0.41	4.91e-15	Hip circumference adjusted for BMI;
LUSC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	8.24	0.41	3.92e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg03060546	chr3:49711283	APEH	0.5	6.74	0.35	6.97e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs4654899	0.897	rs6679753	chr1:21066634	G/C	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.36	9.47e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs12801636	0.846	rs1078457	chr11:65380124	C/T	cg27068330	chr11:65405492	SIPA1	0.57	6.29	0.33	1.02e-9	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12292205	chr6:26970375	C6orf41	-0.56	-7.39	-0.37	1.18e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	0.6	9.43	0.46	7.09e-19	Breast cancer;
LUSC	cis	rs9311676	0.632	rs62259772	chr3:58417416	C/T	cg13750441	chr3:58318267	PXK	0.35	6.83	0.35	4.14e-11	Systemic lupus erythematosus;
LUSC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg08219700	chr8:58056026	NA	0.5	6.25	0.32	1.27e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs12493885	0.725	rs57740056	chr3:153744530	A/C	cg17054900	chr3:154042577	DHX36	-0.55	-6.02	-0.31	4.59e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6987853	0.933	rs1343875	chr8:42424749	C/T	cg09913449	chr8:42400586	C8orf40	0.48	8.02	0.4	1.77e-14	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.9	16.2	0.66	5.81e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.8	-0.35	4.9e-11	Lung cancer;
LUSC	cis	rs427941	0.632	rs201504	chr7:101759878	C/G	cg06246474	chr7:101738831	CUX1	0.38	6.34	0.33	7.32e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.45	3.08e-18	Morning vs. evening chronotype;
LUSC	cis	rs1557765	0.527	rs11024272	chr11:17395760	T/C	cg15432903	chr11:17409602	KCNJ11	0.45	7.82	0.39	6.88e-14	Body mass index;Social communication problems;
LUSC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg19318889	chr4:1322082	MAEA	0.44	7.27	0.37	2.49e-12	Obesity-related traits;
LUSC	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg09904177	chr6:26538194	HMGN4	0.72	13.02	0.58	1.28e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs11608355	0.515	rs7311488	chr12:109930905	C/G	cg05360138	chr12:110035743	NA	-0.9	-12.17	-0.55	1.95e-28	Neuroticism;
LUSC	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg03522245	chr20:25566470	NINL	-0.35	-5.72	-0.3	2.36e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg25258033	chr6:167368657	RNASET2	0.39	6.3	0.33	9.49e-10	Crohn's disease;
LUSC	cis	rs2414856	0.510	rs10400921	chr15:64661937	C/T	cg08069370	chr15:64387884	SNX1	-0.74	-6.48	-0.33	3.34e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg25036284	chr2:26402008	FAM59B	0.7	9.36	0.46	1.19e-18	Gut microbiome composition (summer);
LUSC	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.97	-0.4	2.55e-14	Schizophrenia;
LUSC	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg19812747	chr11:111475976	SIK2	0.5	6.7	0.34	8.87e-11	Primary sclerosing cholangitis;
LUSC	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.9	0.35	2.61e-11	Height;
LUSC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	0.8	14.27	0.62	2.18e-36	Cognitive function;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg22709601	chr15:67408553	SMAD3	0.46	6.2	0.32	1.64e-9	Cognitive function;Information processing speed;
LUSC	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg11584989	chr19:19387371	SF4	-0.62	-7.14	-0.36	5.8e-12	Bipolar disorder;
LUSC	cis	rs8056893	0.686	rs3826167	chr16:68397530	T/G	cg02226672	chr16:68398533	SMPD3	0.32	5.72	0.3	2.32e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08564027	chr20:61660810	NA	0.93	17.11	0.68	1.47e-47	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.68	-0.3	2.87e-8	Eotaxin levels;
LUSC	cis	rs6722750	0.506	rs12612392	chr2:64373635	G/A	cg22352474	chr2:64371530	PELI1	0.68	10.54	0.5	1.27e-22	Neuroticism;
LUSC	cis	rs17034641	0.744	rs2053797	chr2:46370892	C/T	cg12428440	chr2:46370979	PRKCE	0.51	7.67	0.39	1.9e-13	Hemoglobin;Hematocrit;
LUSC	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-5.97	-0.31	6.08e-9	Ulcerative colitis;
LUSC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.82	0.39	7.14e-14	Electroencephalogram traits;
LUSC	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg05855489	chr10:104503620	C10orf26	-0.72	-10.16	-0.49	2.64e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg20933634	chr6:27740509	NA	0.41	5.76	0.3	1.94e-8	Parkinson's disease;
LUSC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg25258033	chr6:167368657	RNASET2	0.46	7.65	0.39	2.2e-13	Crohn's disease;
LUSC	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg23711669	chr6:146136114	FBXO30	0.77	13.37	0.59	6.01e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1881396	0.947	rs10173720	chr2:27855397	A/T	cg27432699	chr2:27873401	GPN1	-0.66	-8.71	-0.43	1.48e-16	Nonalcoholic fatty liver disease;
LUSC	cis	rs7523050	0.643	rs71655970	chr1:109403895	A/G	cg08274380	chr1:109419600	GPSM2	1.1	10.67	0.5	4.47e-23	Fat distribution (HIV);
LUSC	cis	rs6987853	0.623	rs10109400	chr8:42455353	T/C	cg09913449	chr8:42400586	C8orf40	0.44	7.42	0.38	9.89e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg10523679	chr1:76189770	ACADM	-0.44	-6.44	-0.33	4.11e-10	Daytime sleep phenotypes;
LUSC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.76	13.69	0.6	3.45e-34	Prudent dietary pattern;
LUSC	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg24851651	chr11:66362959	CCS	0.39	6.14	0.32	2.37e-9	Educational attainment (years of education);
LUSC	cis	rs2274273	0.638	rs3759667	chr14:55658421	A/G	cg04306507	chr14:55594613	LGALS3	0.49	9.76	0.47	5.85e-20	Protein biomarker;
LUSC	cis	rs2274273	0.588	rs2880103	chr14:55737832	A/C	cg04306507	chr14:55594613	LGALS3	0.49	9.81	0.47	4.08e-20	Protein biomarker;
LUSC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.86	-12.63	-0.57	3.67e-30	Multiple sclerosis;
LUSC	cis	rs11209185	0.509	rs1926279	chr1:68450681	A/G	cg22082780	chr1:68452167	NA	0.42	7.19	0.37	4.2e-12	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	0.93	16.18	0.66	6.77e-44	Menopause (age at onset);
LUSC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-1.01	-17.18	-0.68	7.43e-48	Body mass index;
LUSC	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.25	-0.59	1.75e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs11608355	1.000	rs3742020	chr12:109883254	T/C	cg05360138	chr12:110035743	NA	0.45	6.25	0.32	1.23e-9	Neuroticism;
LUSC	cis	rs11971779	0.680	rs4732379	chr7:139122814	T/C	cg23387468	chr7:139079360	LUC7L2	0.38	5.73	0.3	2.19e-8	Diisocyanate-induced asthma;
LUSC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.81	-13.29	-0.59	1.2e-32	Alcohol dependence;
LUSC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg20887711	chr4:1340912	KIAA1530	0.47	7.15	0.36	5.57e-12	Obesity-related traits;
LUSC	cis	rs12618769	0.601	rs56118505	chr2:99139832	T/G	cg10123293	chr2:99228465	UNC50	0.45	7.42	0.38	9.52e-13	Bipolar disorder;
LUSC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg26335602	chr6:28129616	ZNF389	0.44	5.88	0.31	9.91e-9	Parkinson's disease;
LUSC	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.23e-8	Breast cancer;
LUSC	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.94	-0.31	7.2e-9	Birth weight;
LUSC	trans	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg04995722	chr7:26192034	NFE2L3	0.37	6.03	0.31	4.35e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg09904177	chr6:26538194	HMGN4	-0.53	-6.21	-0.32	1.57e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg25703541	chr22:24373054	LOC391322	0.83	10.23	0.49	1.52e-21	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs1832871	0.711	rs9459829	chr6:158680799	C/T	cg07165851	chr6:158734300	TULP4	0.51	7.87	0.4	4.91e-14	Height;
LUSC	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg22705602	chr4:152727874	NA	-0.34	-7.58	-0.38	3.36e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4964805	0.549	rs11111752	chr12:104156552	C/T	cg02344784	chr12:104178138	NT5DC3	0.41	6.47	0.33	3.42e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs427941	0.632	rs201527	chr7:101774451	T/C	cg06246474	chr7:101738831	CUX1	0.38	6.14	0.32	2.34e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.48	7.88	0.4	4.78e-14	Alcohol dependence;
LUSC	cis	rs2281558	0.517	rs16987966	chr20:25643414	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.53	6.39	0.33	5.49e-10	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LUSC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg12560992	chr17:57184187	TRIM37	0.86	15.46	0.65	5e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26314531	chr2:26401878	FAM59B	0.73	10.05	0.48	6.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs67696533	0.636	rs910889	chr20:31104950	T/C	cg13636640	chr20:31349939	DNMT3B	0.45	6.21	0.32	1.62e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs7582720	1.000	rs115953525	chr2:203744445	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.69	0.43	1.7e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.11	-0.32	2.77e-9	Depression;
LUSC	cis	rs7795096	0.743	rs9648730	chr7:151537785	G/A	cg17008978	chr7:151542804	PRKAG2	0.34	6.53	0.34	2.44e-10	Bipolar disorder (age of onset and psychotic symptoms);
LUSC	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg24130564	chr14:104152367	KLC1	-0.46	-6.34	-0.33	7.27e-10	Body mass index;
LUSC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg26513180	chr16:89883248	FANCA	0.91	17.74	0.7	4.55e-50	Vitiligo;
LUSC	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg24006582	chr15:45444508	DUOX1	-0.6	-8.77	-0.43	9.28e-17	Uric acid levels;
LUSC	cis	rs698813	0.763	rs786614	chr2:44590567	C/G	cg00619915	chr2:44497795	NA	-0.42	-6.01	-0.31	4.75e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-16.46	-0.67	5.61e-45	Primary sclerosing cholangitis;
LUSC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.68	10.57	0.5	1.03e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs1178968	0.688	rs2528708	chr7:72788583	C/A	cg25889504	chr7:72793014	NA	0.59	7.63	0.39	2.52e-13	Triglyceride levels;
LUSC	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg09835421	chr16:68378352	PRMT7	-0.47	-5.78	-0.3	1.69e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg05110241	chr16:68378359	PRMT7	-0.53	-6.55	-0.34	2.19e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9929218	0.954	rs7199991	chr16:68818245	T/G	cg02972257	chr16:68554789	NA	0.43	5.93	0.31	7.62e-9	Colorectal cancer;
LUSC	cis	rs2073300	1.000	rs59283536	chr20:23457575	A/T	cg09953122	chr20:23471693	CST8	-0.69	-6.86	-0.35	3.28e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg03948781	chr1:205179583	DSTYK	0.33	6.24	0.32	1.32e-9	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-20.34	-0.74	2.17e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg16584290	chr5:462447	EXOC3	-0.39	-6.94	-0.36	2.02e-11	Cystic fibrosis severity;
LUSC	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg02023728	chr11:77925099	USP35	0.44	6.67	0.34	1.05e-10	Testicular germ cell tumor;
LUSC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08677398	chr8:58056175	NA	0.53	6.91	0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.48	-0.33	3.36e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg15133208	chr4:90757351	SNCA	-0.52	-8.17	-0.41	6.42e-15	Neuroticism;
LUSC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.96	0.61	3.35e-35	Platelet count;
LUSC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg16423285	chr20:60520624	NA	-0.48	-6.01	-0.31	4.98e-9	Body mass index;
LUSC	cis	rs9865818	0.702	rs4686483	chr3:188118225	T/A	cg23651889	chr3:188115336	LPP	-0.39	-5.92	-0.31	8.09e-9	Allergic sensitization;
LUSC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg16434002	chr17:42200994	HDAC5	-0.46	-6.44	-0.33	4.27e-10	Total body bone mineral density;
LUSC	cis	rs2282300	0.739	rs1933342	chr11:30312825	C/T	cg25418670	chr11:30344373	C11orf46	0.64	9.21	0.45	3.67e-18	Morning vs. evening chronotype;
LUSC	cis	rs6500395	0.926	rs11076572	chr16:48623621	T/G	cg04672837	chr16:48644449	N4BP1	0.49	7.02	0.36	1.26e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6840360	0.967	rs1105534	chr4:152605312	C/A	cg22705602	chr4:152727874	NA	-0.28	-5.88	-0.31	9.85e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17467752	chr17:38218738	THRA	-0.49	-6.95	-0.36	1.87e-11	White blood cell count;
LUSC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg06600287	chr1:53387719	ECHDC2	-0.31	-6.54	-0.34	2.29e-10	Monocyte count;
LUSC	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.62	-10.01	-0.48	8.17e-21	Height;
LUSC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.42	-7.44	-0.38	8.53e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1551570	0.819	rs11666402	chr19:10219076	A/G	cg16327482	chr19:10226339	EIF3G	0.37	7.11	0.36	6.96e-12	Narcolepsy;
LUSC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	0.84	14.04	0.61	1.65e-35	Menopause (age at onset);
LUSC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg25039879	chr17:56429692	SUPT4H1	0.72	9.82	0.47	3.63e-20	Cognitive test performance;
LUSC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg14500267	chr11:67383377	NA	-0.43	-8.45	-0.42	8.87e-16	Mean corpuscular volume;
LUSC	cis	rs13082711	0.911	rs67104968	chr3:27510304	A/G	cg02860705	chr3:27208620	NA	0.47	7.96	0.4	2.67e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg15445000	chr17:37608096	MED1	0.4	6.92	0.35	2.26e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg12463550	chr7:65579703	CRCP	-0.47	-6.7	-0.34	8.75e-11	Aortic root size;
LUSC	cis	rs5758511	0.689	rs11913578	chr22:42347391	A/C	cg12850546	chr22:42539477	CYP2D7P1	-0.49	-6.02	-0.31	4.65e-9	Birth weight;
LUSC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg23788917	chr6:8435910	SLC35B3	0.51	7.56	0.38	4.03e-13	Motion sickness;
LUSC	cis	rs10498514	0.590	rs117242159	chr14:65045360	G/A	cg25134081	chr14:64931936	AKAP5	0.98	7.11	0.36	7.11e-12	Cognitive performance;
LUSC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg07741184	chr6:167504864	NA	0.39	6.88	0.35	2.9e-11	Crohn's disease;
LUSC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg20684491	chr1:25596433	NA	0.38	5.92	0.31	7.97e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg17173187	chr15:85201210	NMB	-0.31	-6.1	-0.32	2.91e-9	Schizophrenia;
LUSC	cis	rs4343996	0.650	rs10274594	chr7:3463561	T/G	cg21248987	chr7:3385318	SDK1	0.35	5.84	0.3	1.21e-8	Motion sickness;
LUSC	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.67	-6.65	-0.34	1.2e-10	Lung cancer in ever smokers;
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	0.94	18.91	0.72	9.99e-55	Menarche (age at onset);
LUSC	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-13.99	-0.61	2.61e-35	Morning vs. evening chronotype;
LUSC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg12463550	chr7:65579703	CRCP	0.45	6.65	0.34	1.23e-10	Aortic root size;
LUSC	cis	rs9309473	0.514	rs62149630	chr2:73581755	C/G	cg20560298	chr2:73613845	ALMS1	-0.51	-5.98	-0.31	5.79e-9	Metabolite levels;
LUSC	cis	rs7903847	0.642	rs7074511	chr10:99140177	G/A	cg08345082	chr10:99160200	RRP12	-0.37	-7.46	-0.38	7.46e-13	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg04398451	chr17:18023971	MYO15A	0.4	6.24	0.32	1.36e-9	Total body bone mineral density;
LUSC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	trans	rs9886428	1.000	rs10099853	chr8:14115675	G/C	cg19037007	chr20:741798	C20orf54	-0.39	-6.11	-0.32	2.77e-9	IgG glycosylation;
LUSC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg03188948	chr7:1209495	NA	0.66	7.02	0.36	1.28e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg22868518	chr11:507468	RNH1	-0.6	-5.94	-0.31	7.19e-9	Body mass index;
LUSC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.55	-0.34	2.2e-10	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12541635	1.000	rs1366969	chr8:107092851	A/T	cg10147462	chr8:107024639	NA	-0.47	-8.64	-0.43	2.37e-16	Age of smoking initiation;
LUSC	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg17691542	chr6:26056736	HIST1H1C	0.48	6.88	0.35	3.02e-11	Iron status biomarkers;
LUSC	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg21361702	chr7:150065534	REPIN1	0.59	8.57	0.42	3.96e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg08888203	chr3:10149979	C3orf24	0.63	9.09	0.45	8.92e-18	Alzheimer's disease;
LUSC	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg05805236	chr11:65401703	PCNXL3	0.46	6.48	0.33	3.2e-10	Glomerular filtration rate (creatinine);Chronic kidney disease;
LUSC	cis	rs500891	0.620	rs1034260	chr6:84162873	T/C	cg08257003	chr6:84140564	ME1	0.37	9.06	0.44	1.1e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg27432699	chr2:27873401	GPN1	-0.59	-8.76	-0.43	1e-16	Menopause (age at onset);
LUSC	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-7.15	-0.36	5.59e-12	Total bilirubin levels in HIV-1 infection;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg08539889	chr16:71496259	ZNF23	0.42	5.96	0.31	6.44e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg20848291	chr7:100343083	ZAN	-0.65	-8.46	-0.42	8.42e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg00277334	chr10:82204260	NA	-0.5	-7.28	-0.37	2.37e-12	Post bronchodilator FEV1;
LUSC	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg24829409	chr8:58192753	C8orf71	0.55	5.9	0.31	8.96e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00152838	chr16:24741724	TNRC6A	-0.46	-5.71	-0.3	2.55e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.85	12.67	0.57	2.64e-30	Cognitive ability;
LUSC	cis	rs4851254	0.618	rs4851243	chr2:100639482	G/A	cg22139774	chr2:100720529	AFF3	-0.45	-5.91	-0.31	8.36e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs35883536	0.588	rs17403878	chr1:101105310	C/T	cg06223162	chr1:101003688	GPR88	0.35	6.01	0.31	4.92e-9	Monocyte count;
LUSC	cis	rs2996428	0.667	rs61768932	chr1:3765671	G/C	cg17443473	chr1:3703550	LRRC47	0.34	5.89	0.31	9.5e-9	Red cell distribution width;
LUSC	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.93	15.96	0.66	5.05e-43	Bladder cancer;
LUSC	cis	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg15711740	chr2:61764176	XPO1	-0.5	-7.98	-0.4	2.31e-14	Tuberculosis;
LUSC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	8.05	0.4	1.46e-14	Lung function (FEV1/FVC);
LUSC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg09035930	chr12:129282057	SLC15A4	0.67	13.45	0.59	3.02e-33	Systemic lupus erythematosus;
LUSC	cis	rs11677416	1.000	rs1800794	chr2:113543273	G/A	cg27083787	chr2:113543245	IL1A	0.51	7.92	0.4	3.52e-14	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg22800045	chr5:56110881	MAP3K1	0.77	9.91	0.48	1.87e-20	Initial pursuit acceleration;
LUSC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg13372766	chr1:228464049	OBSCN	0.33	6.24	0.32	1.31e-9	Diastolic blood pressure;
LUSC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.61	9.72	0.47	7.83e-20	Pulse pressure;
LUSC	cis	rs4631830	0.863	rs4554834	chr10:51530146	A/C	cg16070123	chr10:51489643	NA	-0.5	-7.96	-0.4	2.78e-14	Prostate-specific antigen levels;
LUSC	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg13390004	chr1:15929781	NA	0.4	6.7	0.34	9.07e-11	Systolic blood pressure;
LUSC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.48	7.54	0.38	4.59e-13	Menarche (age at onset);
LUSC	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg06117184	chr2:113522207	CKAP2L	0.4	6.79	0.35	5.09e-11	Triglycerides;
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-8.39	-0.42	1.35e-15	Lymphocyte counts;
LUSC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs75804782	0.521	rs72993073	chr2:239412925	G/A	cg18131467	chr2:239335373	ASB1	-0.71	-6.29	-0.33	9.82e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.5	-6.77	-0.35	5.89e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4889855	0.530	rs8079792	chr17:78609394	A/G	cg16591659	chr17:78472290	NA	-0.33	-5.82	-0.3	1.37e-8	Fractional excretion of uric acid;
LUSC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg24060327	chr5:131705240	SLC22A5	-0.53	-8.22	-0.41	4.42e-15	Acylcarnitine levels;
LUSC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg18681998	chr4:17616180	MED28	0.83	15.93	0.66	6.53e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17548431	chr4:160024475	NA	-0.48	-6.44	-0.33	4.06e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg27432699	chr2:27873401	GPN1	-0.57	-8.45	-0.42	9.15e-16	Total body bone mineral density;
LUSC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	5.67	0.3	3.1e-8	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08280861	chr8:58055591	NA	0.55	6.58	0.34	1.79e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-9.17	-0.45	4.9e-18	Gut microbiome composition (summer);
LUSC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.26	0.52	3.89e-25	Menopause (age at onset);
LUSC	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg14664628	chr15:75095509	CSK	0.43	6.28	0.32	1.08e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg06454157	chr6:167490870	NA	-0.28	-6.71	-0.34	8.57e-11	Primary biliary cholangitis;
LUSC	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg02569458	chr12:86230093	RASSF9	0.49	8.22	0.41	4.69e-15	Major depressive disorder;
LUSC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg25703541	chr22:24373054	LOC391322	0.98	18.03	0.7	3.08e-51	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6977660	0.652	rs10254427	chr7:19816240	C/T	cg07541023	chr7:19748670	TWISTNB	0.58	6.49	0.33	3.14e-10	Thyroid stimulating hormone;
LUSC	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	8.89	0.44	3.81e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs62408225	1.000	rs943689	chr6:90984035	C/T	cg06866423	chr6:90926672	BACH2	0.41	5.91	0.31	8.67e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg10911889	chr6:126070802	HEY2	0.43	6.54	0.34	2.28e-10	Brugada syndrome;
LUSC	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.41	5.83	0.3	1.28e-8	Lung cancer;
LUSC	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg06917634	chr15:78832804	PSMA4	-0.52	-6.51	-0.34	2.68e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-7.13	-0.36	6.33e-12	Alzheimer's disease (late onset);
LUSC	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg05580060	chr16:74700937	RFWD3	0.41	5.76	0.3	1.95e-8	Testicular germ cell tumor;
LUSC	cis	rs6084875	0.840	rs1999665	chr20:4720988	C/T	cg26097573	chr20:4721490	PRNT	-0.31	-5.75	-0.3	2.03e-8	Systemic lupus erythematosus;
LUSC	cis	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.43	-0.42	1.09e-15	Morning vs. evening chronotype;
LUSC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.0	14.83	0.63	1.46e-38	Platelet count;
LUSC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06634786	chr22:41940651	POLR3H	0.5	6.04	0.31	4.07e-9	Vitiligo;
LUSC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08219700	chr8:58056026	NA	0.63	8.08	0.4	1.22e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg15571903	chr15:79123663	NA	-0.34	-6.27	-0.32	1.13e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg04546413	chr19:29218101	NA	0.63	7.93	0.4	3.39e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg05738196	chr6:26577821	NA	-0.58	-6.79	-0.35	5.04e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2455601	0.507	rs7948452	chr11:8877704	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-7.69	-0.39	1.68e-13	Schizophrenia;
LUSC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.04	0.55	5.42e-28	Cognitive test performance;
LUSC	cis	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg06521331	chr12:34319734	NA	-0.47	-7.63	-0.39	2.42e-13	Morning vs. evening chronotype;
LUSC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg24813613	chr7:1882135	MAD1L1	-0.39	-6.41	-0.33	4.89e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs17095355	1.000	rs12570145	chr10:111712913	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.68	-7.87	-0.4	4.85e-14	Biliary atresia;
LUSC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	0.524	rs7929725	chr11:47881740	A/G	cg20307385	chr11:47447363	PSMC3	0.46	6.76	0.35	6.07e-11	Subjective well-being;
LUSC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg14552801	chr7:65878734	NA	-0.43	-6.16	-0.32	2.05e-9	Aortic root size;
LUSC	trans	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg26043149	chr18:55253948	FECH	-0.52	-7.6	-0.38	3e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs4664308	0.870	rs2198918	chr2:161015052	C/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-10.92	-0.51	6.16e-24	Idiopathic membranous nephropathy;
LUSC	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg12432903	chr7:1882776	MAD1L1	0.45	6.12	0.32	2.66e-9	Bipolar disorder;
LUSC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.7	9.43	0.46	7.25e-19	Chronic sinus infection;
LUSC	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg22705602	chr4:152727874	NA	-0.31	-6.21	-0.32	1.53e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13024018	chr3:133380790	TOPBP1	-0.42	-6.07	-0.32	3.45e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg27170947	chr2:26402098	FAM59B	-0.63	-9.1	-0.45	8.18e-18	Gut microbiome composition (summer);
LUSC	cis	rs7107174	1.000	rs2510049	chr11:77985459	G/T	cg02023728	chr11:77925099	USP35	0.48	6.82	0.35	4.26e-11	Testicular germ cell tumor;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11327809	chr8:101965577	YWHAZ	0.43	6.27	0.32	1.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	cis	rs55910451	0.779	rs72774070	chr10:5760199	A/G	cg11519256	chr10:5708881	ASB13	-0.48	-5.85	-0.3	1.19e-8	Breast cancer;
LUSC	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg22906224	chr7:99728672	NA	0.47	6.54	0.34	2.36e-10	Coronary artery disease;
LUSC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.81	-12.91	-0.58	3.31e-31	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg25797454	chr6:150327115	RAET1K	0.35	7.93	0.4	3.32e-14	Alopecia areata;
LUSC	trans	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg01596870	chr19:55963115	NA	-0.51	-5.99	-0.31	5.34e-9	Obesity-related traits;
LUSC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg17143192	chr8:8559678	CLDN23	0.66	9.55	0.46	2.97e-19	Obesity-related traits;
LUSC	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg21724239	chr8:58056113	NA	0.62	7.07	0.36	9.3e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg17279839	chr7:150038598	RARRES2	0.55	8.13	0.41	8.65e-15	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7264396	1.000	rs224437	chr20:34154371	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-7.32	-0.37	1.88e-12	Total cholesterol levels;
LUSC	cis	rs57549656	0.799	rs72980731	chr19:2711234	G/A	cg06609049	chr19:2785107	THOP1	0.49	6.21	0.32	1.62e-9	Schizophrenia;
LUSC	cis	rs9653442	0.545	rs11900482	chr2:100758709	G/C	cg22139774	chr2:100720529	AFF3	-0.43	-7.28	-0.37	2.38e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.7	11.58	0.54	2.64e-26	Heart rate;
LUSC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg14895029	chr7:2775587	GNA12	-0.42	-6.65	-0.34	1.23e-10	Height;
LUSC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.8	0.6	1.3600000000000001e-34	Chronic sinus infection;
LUSC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.38	-5.92	-0.31	7.78e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.82	0.35	4.17e-11	Platelet count;
LUSC	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg22508957	chr16:3507546	NAT15	-0.43	-6.1	-0.32	2.92e-9	Body mass index (adult);
LUSC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg08888203	chr3:10149979	C3orf24	0.45	6.83	0.35	4.08e-11	Alzheimer's disease;
LUSC	trans	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.15	-0.32	2.16e-9	Depression;
LUSC	cis	rs1448094	0.565	rs73177163	chr12:86317533	G/T	cg18827107	chr12:86230957	RASSF9	-0.43	-5.67	-0.3	3.01e-8	Major depressive disorder;
LUSC	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg26876637	chr1:152193138	HRNR	-0.46	-6.34	-0.33	7.49e-10	Atopic dermatitis;
LUSC	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19717773	chr7:2847554	GNA12	-0.36	-6.2	-0.32	1.63e-9	Height;
LUSC	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg06671706	chr8:8559999	CLDN23	0.48	6.44	0.33	4.23e-10	Obesity-related traits;
LUSC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.08	21.02	0.75	4.3e-63	Cognitive ability;
LUSC	cis	rs2299587	0.560	rs11996792	chr8:17781012	C/G	cg01800426	chr8:17659068	MTUS1	-0.49	-6.46	-0.33	3.74e-10	Economic and political preferences;
LUSC	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg05973401	chr12:123451056	ABCB9	0.54	7.91	0.4	3.73e-14	Platelet count;
LUSC	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg21211680	chr2:198530	NA	0.72	7.52	0.38	5.05e-13	Blood protein levels;
LUSC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg11317459	chr13:21872234	NA	1.03	14.65	0.63	6.78e-38	White matter hyperintensity burden;
LUSC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg00504896	chr12:9437009	LOC642846	-0.48	-7.64	-0.39	2.28e-13	Breast size;
LUSC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg12311346	chr5:56204834	C5orf35	-0.64	-9.47	-0.46	5.12e-19	Coronary artery disease;
LUSC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-6.18	-0.32	1.82e-9	Total body bone mineral density;
LUSC	trans	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg10756647	chr7:56101905	PSPH	0.87	8.4	0.42	1.31e-15	Diabetic kidney disease;
LUSC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06481639	chr22:41940642	POLR3H	0.52	5.95	0.31	6.65e-9	Vitiligo;
LUSC	cis	rs17029056	0.527	rs1806627	chr2:42157655	C/T	cg25815440	chr2:42134162	NA	-0.33	-6.84	-0.35	3.69e-11	Breast cancer;
LUSC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg11871910	chr12:69753446	YEATS4	-0.47	-6.29	-0.33	1.01e-9	Response to diuretic therapy;
LUSC	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg22532475	chr10:104410764	TRIM8	-0.26	-6.05	-0.31	3.8e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg04455712	chr21:45112962	RRP1B	0.46	8.73	0.43	1.2e-16	Mean corpuscular volume;
LUSC	cis	rs239198	0.577	rs34716527	chr6:101284416	T/C	cg09795085	chr6:101329169	ASCC3	0.45	6.37	0.33	6.14e-10	Menarche (age at onset);
LUSC	cis	rs12220238	1.000	rs10824105	chr10:75952881	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.8	0.35	4.73e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs13315871	1.000	rs28489489	chr3:58443755	C/A	cg20936604	chr3:58311152	NA	-0.72	-6.77	-0.35	5.83e-11	Cholesterol, total;
LUSC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	ch.11.42038R	chr11:967971	AP2A2	0.53	7.83	0.39	6.49e-14	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg11062466	chr8:58055876	NA	0.66	8.57	0.42	3.86e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg14830002	chr1:247616686	OR2B11	0.49	7.05	0.36	1.05e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs62400317	0.859	rs72860105	chr6:45265201	A/T	cg18551225	chr6:44695536	NA	-0.42	-7.08	-0.36	8.7e-12	Total body bone mineral density;
LUSC	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.91	0.35	2.39e-11	Myopia (pathological);
LUSC	cis	rs7258465	0.931	rs76195	chr19:18629830	A/G	cg06462663	chr19:18546047	ISYNA1	0.42	7.26	0.37	2.65e-12	Breast cancer;
LUSC	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.82	0.43	6.39e-17	Menopause (age at onset);
LUSC	cis	rs8038465	0.623	rs6495073	chr15:73947534	A/T	cg15420318	chr15:73925796	NPTN	0.6	10.15	0.49	2.93e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.88	14.7	0.63	4.61e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21518248	chr2:162101506	NA	0.45	6.87	0.35	3.14e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs35883536	0.609	rs12747197	chr1:101036831	A/C	cg06223162	chr1:101003688	GPR88	-0.48	-9.06	-0.44	1.13e-17	Monocyte count;
LUSC	cis	rs7945705	0.818	rs10769948	chr11:8761782	C/T	cg12365402	chr11:9010492	NRIP3	-0.41	-7.22	-0.37	3.45e-12	Hemoglobin concentration;
LUSC	cis	rs4654899	0.865	rs6426674	chr1:21483906	C/T	cg02927042	chr1:21476669	EIF4G3	-0.36	-5.69	-0.3	2.82e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg11843238	chr5:131593191	PDLIM4	0.39	6.52	0.34	2.63e-10	Breast cancer;
LUSC	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs897984	0.542	rs4468641	chr16:31096876	A/C	cg02466173	chr16:30829666	NA	-0.51	-9.89	-0.48	2.09e-20	Dementia with Lewy bodies;
LUSC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.49	8.29	0.41	2.79e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs77372450	0.551	rs11739081	chr5:157087119	C/G	cg10450108	chr5:140208893	PCDHA6;PCDHA2;PCDHA1;PCDHA5;PCDHA3;PCDHA4	-0.51	-6.08	-0.32	3.3e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21724239	chr8:58056113	NA	0.86	9.61	0.47	1.83e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.49	-6.17	-0.32	1.94e-9	Schizophrenia;
LUSC	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg10356904	chr22:49881777	NA	-0.28	-5.82	-0.3	1.35e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg02873098	chr16:4524103	NMRAL1;HMOX2	-0.44	-6.47	-0.33	3.54e-10	Schizophrenia;
LUSC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.83	0.39	6.38e-14	Parkinson's disease;
LUSC	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg14689365	chr7:158441557	NCAPG2	-0.46	-6.34	-0.33	7.64e-10	Height;
LUSC	cis	rs55883249	1.000	rs76964971	chr2:9763904	C/A	cg23886495	chr2:9695866	ADAM17	0.51	6.07	0.32	3.38e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17403046	chr12:113596797	DDX54;CCDC42B	0.49	6.32	0.33	8.15e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg18225595	chr11:63971243	STIP1	-0.49	-8.14	-0.41	8.16e-15	Platelet count;
LUSC	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg18404041	chr3:52824283	ITIH1	0.44	7.82	0.39	6.94e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg24324837	chr19:49891574	CCDC155	-0.49	-6.29	-0.33	9.72e-10	Multiple sclerosis;
LUSC	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg15744005	chr10:104629667	AS3MT	-0.28	-5.9	-0.31	8.73e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.19	-0.32	1.74e-9	Alcohol dependence;
LUSC	cis	rs3820928	0.874	rs6740108	chr2:227889559	G/T	cg11843606	chr2:227700838	RHBDD1	0.51	7.42	0.38	1.01e-12	Pulmonary function;
LUSC	cis	rs113835537	0.529	rs12099041	chr11:66232773	C/T	cg24851651	chr11:66362959	CCS	0.54	8.27	0.41	3.33e-15	Airway imaging phenotypes;
LUSC	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.57	0.65	1.71e-41	Morning vs. evening chronotype;
LUSC	cis	rs965469	1.000	rs6051763	chr20:3321616	T/G	cg25506879	chr20:3388711	C20orf194	-0.51	-5.7	-0.3	2.57e-8	IFN-related cytopenia;
LUSC	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg12311346	chr5:56204834	C5orf35	-0.63	-9.66	-0.47	1.28e-19	Coronary artery disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg27629023	chr11:62648823	SLC3A2	-0.54	-6.34	-0.33	7.65e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.71	0.34	8.47e-11	Educational attainment;
LUSC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg21724239	chr8:58056113	NA	0.74	8.15	0.41	7.47e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg02153584	chr22:29168773	CCDC117	-0.55	-7.55	-0.38	4.19e-13	Lymphocyte counts;
LUSC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg18904891	chr8:8559673	CLDN23	-0.56	-8.03	-0.4	1.65e-14	Obesity-related traits;
LUSC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-15.46	-0.65	4.94e-41	Gut microbiome composition (summer);
LUSC	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.86	19.97	0.74	5.81e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs59104589	0.617	rs3771561	chr2:242353704	A/G	cg14842376	chr2:242211374	HDLBP	-0.52	-6.15	-0.32	2.23e-9	Fibrinogen levels;
LUSC	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg22709100	chr7:91322751	NA	-0.4	-5.84	-0.3	1.21e-8	Breast cancer;
LUSC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg23262073	chr20:60523788	NA	-0.44	-6.51	-0.34	2.69e-10	Body mass index;
LUSC	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg01966878	chr4:90757139	SNCA	0.44	5.94	0.31	7e-9	Neuroticism;
LUSC	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg15445000	chr17:37608096	MED1	-0.39	-6.75	-0.35	6.68e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg06521331	chr12:34319734	NA	-0.44	-7.29	-0.37	2.31e-12	Morning vs. evening chronotype;
LUSC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00166722	chr3:10149974	C3orf24	0.69	9.23	0.45	3.28e-18	Alzheimer's disease;
LUSC	cis	rs7106204	0.925	rs3924745	chr11:24223001	G/A	ch.11.24196551F	chr11:24239977	NA	1.13	14.59	0.62	1.21e-37	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7084921	0.552	rs1324693	chr10:101890617	A/G	cg02250046	chr10:101825185	CPN1	-0.33	-6.08	-0.32	3.29e-9	Bone mineral density;
LUSC	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg03585969	chr10:35415529	CREM	0.61	9.13	0.45	6.77e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg09835421	chr16:68378352	PRMT7	-0.73	-8.02	-0.4	1.85e-14	Magnesium levels;
LUSC	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg02569458	chr12:86230093	RASSF9	0.4	6.54	0.34	2.28e-10	Major depressive disorder;
LUSC	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg06917634	chr15:78832804	PSMA4	0.82	14.69	0.63	4.94e-38	Sudden cardiac arrest;
LUSC	cis	rs6460942	1.000	rs17668923	chr7:12302873	A/T	cg06484146	chr7:12443880	VWDE	-0.55	-6.12	-0.32	2.63e-9	Coronary artery disease;
LUSC	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg00277334	chr10:82204260	NA	-0.51	-7.34	-0.37	1.64e-12	Post bronchodilator FEV1;
LUSC	cis	rs4704187	0.617	rs12656177	chr5:74354422	G/A	cg03227963	chr5:74354835	NA	0.32	6.94	0.36	2.03e-11	Response to amphetamines;
LUSC	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.49	5.86	0.31	1.08e-8	Renal function-related traits (BUN);
LUSC	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.54	-10.4	-0.49	3.89e-22	Educational attainment;
LUSC	cis	rs62238980	0.614	rs4821018	chr22:32403318	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	-0.81	-5.9	-0.31	8.82e-9	Childhood ear infection;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14848284	chr2:73143293	EMX1	-0.5	-5.95	-0.31	6.72e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg04398451	chr17:18023971	MYO15A	0.39	5.96	0.31	6.28e-9	Total body bone mineral density;
LUSC	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg23625390	chr15:77176239	SCAPER	0.48	7.28	0.37	2.37e-12	Blood metabolite levels;
LUSC	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg11861562	chr11:117069780	TAGLN	-0.33	-6.3	-0.33	9.22e-10	Blood protein levels;
LUSC	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg10253484	chr15:75165896	SCAMP2	0.57	7.65	0.39	2.2e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs2820315	1.000	rs2820310	chr1:201838107	G/A	cg10061532	chr1:201886748	LMOD1	0.26	5.84	0.3	1.24e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg23625390	chr15:77176239	SCAPER	-0.62	-9.44	-0.46	6.65e-19	Blood metabolite levels;
LUSC	trans	rs2262909	0.924	rs4290587	chr19:22164646	A/G	cg17074339	chr11:11642133	GALNTL4	-0.41	-6.17	-0.32	1.96e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg18758796	chr5:131593413	PDLIM4	0.41	6.69	0.34	9.39e-11	Breast cancer;
LUSC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-16.7	-0.67	6e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs977987	0.736	rs4888392	chr16:75412262	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.32	0.45	1.6e-18	Dupuytren's disease;
LUSC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-0.93	-19.78	-0.73	3.55e-58	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg16479474	chr6:28041457	NA	0.32	5.72	0.3	2.31e-8	Parkinson's disease;
LUSC	cis	rs9663711	1	rs9663711	chr10:104547628	C/A	cg04362960	chr10:104952993	NT5C2	0.47	6.48	0.33	3.25e-10	Carotid plaque burden;
LUSC	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg26677194	chr12:130822605	PIWIL1	0.59	8.8	0.43	7.28e-17	Menopause (age at onset);
LUSC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg23788917	chr6:8435910	SLC35B3	0.51	7.49	0.38	6.32e-13	Motion sickness;
LUSC	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg18825076	chr15:78729989	IREB2	-0.43	-5.85	-0.31	1.15e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10761482	0.861	rs2061488	chr10:62103166	A/G	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-12.35	-0.56	3.96e-29	Prudent dietary pattern;
LUSC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.86e-9	Major depressive disorder;
LUSC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg25767906	chr1:53392781	SCP2	0.46	8.31	0.41	2.37e-15	Monocyte count;
LUSC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg09034736	chr1:150693464	HORMAD1	0.46	6.34	0.33	7.64e-10	Melanoma;
LUSC	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.52	8.61	0.43	2.98e-16	Immature fraction of reticulocytes;
LUSC	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.1	15.06	0.64	1.72e-39	Lung cancer in ever smokers;
LUSC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg06212747	chr3:49208901	KLHDC8B	0.53	7.03	0.36	1.17e-11	Parkinson's disease;
LUSC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg24585782	chr17:78113791	EIF4A3	-0.53	-7.88	-0.4	4.79e-14	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22857025	chr5:266934	NA	-1.2	-13.69	-0.6	3.65e-34	Breast cancer;
LUSC	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-6.12	-0.32	2.69e-9	Schizophrenia;
LUSC	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.39	-7.77	-0.39	1.01e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs9807989	0.839	rs9808453	chr2:102971306	C/A	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.67e-9	Asthma;
LUSC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13732083	chr21:47605072	C21orf56	-0.45	-6.7	-0.34	8.72e-11	Testicular germ cell tumor;
LUSC	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg08213375	chr14:104286397	PPP1R13B	0.53	10.54	0.5	1.28e-22	Schizophrenia;
LUSC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg26380479	chr7:97908229	NA	-0.27	-5.97	-0.31	6.08e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg26338869	chr17:61819248	STRADA	0.4	5.77	0.3	1.81e-8	Prudent dietary pattern;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02934834	chr6:116575324	TSPYL4	0.45	6.15	0.32	2.27e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7106204	0.590	rs7115417	chr11:24247696	A/G	ch.11.24196551F	chr11:24239977	NA	1.03	12.33	0.56	4.87e-29	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1832871	0.521	rs62437411	chr6:158823211	G/A	cg07165851	chr6:158734300	TULP4	0.38	6.1	0.32	2.9e-9	Height;
LUSC	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.53	-0.38	4.7e-13	Retinal vascular caliber;
LUSC	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg13010199	chr12:38710504	ALG10B	0.45	7.01	0.36	1.31e-11	Morning vs. evening chronotype;
LUSC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg03146154	chr1:46216737	IPP	-0.51	-7.43	-0.38	9.2e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.23	-0.37	3.3e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	trans	rs12210905	0.688	rs12213533	chr6:27346021	C/T	cg02699829	chr19:13216355	TRMT1	-0.56	-6.33	-0.33	7.7e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg19875535	chr5:140030758	IK	0.54	8.98	0.44	2.03e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg05973401	chr12:123451056	ABCB9	-0.49	-6.05	-0.31	3.86e-9	Neutrophil percentage of white cells;
LUSC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.8	-13.13	-0.58	4.83e-32	Aortic root size;
LUSC	cis	rs4343996	0.902	rs12540305	chr7:3376072	A/T	cg21248987	chr7:3385318	SDK1	-0.4	-6.92	-0.35	2.29e-11	Motion sickness;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10493356	chr22:31608270	LIMK2	-0.43	-6.44	-0.33	4.05e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16514724	chr10:97453245	TCTN3	-0.43	-6.32	-0.33	8.39e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs10207060	0.522	rs62183177	chr2:240712665	A/G	cg07506560	chr2:240697449	NA	0.41	6.49	0.33	3.19e-10	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.87	0.54	2.36e-27	Prudent dietary pattern;
LUSC	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg17757837	chr7:157058334	UBE3C	0.82	13.01	0.58	1.35e-31	Body mass index;
LUSC	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.75	14.64	0.63	7.48e-38	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs12902680	0.641	rs7183417	chr15:46586088	C/T	cg04321580	chr8:143696133	ARC	-0.4	-6.04	-0.31	4.18e-9	Neuroticism;
LUSC	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg17633681	chr16:88106987	BANP	0.52	9.83	0.47	3.32e-20	Menopause (age at onset);
LUSC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg11766577	chr21:47581405	C21orf56	-0.41	-5.99	-0.31	5.37e-9	Testicular germ cell tumor;
LUSC	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg10857441	chr5:6722123	POLS	-0.46	-8.95	-0.44	2.58e-17	Menopause (age at onset);
LUSC	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19346786	chr7:2764209	NA	-0.45	-7.54	-0.38	4.6e-13	Height;
LUSC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg00509249	chr6:109615579	CCDC162	-0.33	-6.05	-0.31	3.86e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-17.57	-0.69	2.11e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg23711669	chr6:146136114	FBXO30	0.77	13.91	0.61	5.36e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1044826	0.692	rs188420	chr3:139233865	G/A	cg15131784	chr3:139108705	COPB2	-0.39	-6.34	-0.33	7.63e-10	Obesity-related traits;
LUSC	cis	rs1018836	0.923	rs7826178	chr8:91649592	C/A	cg16814680	chr8:91681699	NA	-0.8	-13.66	-0.6	4.74e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg23711669	chr6:146136114	FBXO30	0.93	18.15	0.7	1e-51	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg13010199	chr12:38710504	ALG10B	0.66	10.24	0.49	1.42e-21	Morning vs. evening chronotype;
LUSC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg13560548	chr3:10150139	C3orf24	0.51	7.35	0.37	1.56e-12	Alzheimer's disease;
LUSC	cis	rs28647808	0.786	rs4962137	chr9:136256826	G/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	trans	rs7944735	0.517	rs11039538	chr11:48154990	A/T	cg03929089	chr4:120376271	NA	0.71	6.42	0.33	4.71e-10	Intraocular pressure;
LUSC	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg21361702	chr7:150065534	REPIN1	0.57	8.0	0.4	2.14e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg14552801	chr7:65878734	NA	0.38	6.03	0.31	4.28e-9	Aortic root size;
LUSC	cis	rs4911259	0.513	rs4287835	chr20:31457337	T/C	cg13636640	chr20:31349939	DNMT3B	-0.8	-15.48	-0.65	4.16e-41	Inflammatory bowel disease;
LUSC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.81	9.81	0.47	3.85e-20	Gut microbiome composition (summer);
LUSC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg13531842	chr10:38383804	ZNF37A	0.47	7.39	0.38	1.16e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg04369109	chr6:150039330	LATS1	-0.41	-5.77	-0.3	1.84e-8	Lung cancer;
LUSC	trans	rs6427356	1.000	rs1176555	chr1:157136541	C/G	cg04591034	chr5:178017937	COL23A1	0.39	6.48	0.33	3.27e-10	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.25	-0.32	1.23e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg17252645	chr8:143867129	LY6D	-0.37	-6.44	-0.33	4.28e-10	Urinary tract infection frequency;
LUSC	cis	rs7640424	0.716	rs35703078	chr3:107859558	A/G	cg09227934	chr3:107805635	CD47	-0.4	-6.27	-0.32	1.09e-9	Body mass index;
LUSC	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg09060608	chr5:178986726	RUFY1	0.62	10.87	0.51	9.18e-24	Lung cancer;
LUSC	trans	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg10756647	chr7:56101905	PSPH	0.75	7.6	0.38	3.06e-13	Diabetic kidney disease;
LUSC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg16647868	chr5:131706066	SLC22A5	0.4	6.08	0.32	3.24e-9	Acylcarnitine levels;
LUSC	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg04352962	chr1:209979756	IRF6	0.52	5.78	0.3	1.74e-8	Coronary artery disease;
LUSC	cis	rs559928	1.000	rs641168	chr11:64146289	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.61	-6.68	-0.34	1.02e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg16240275	chr20:61666158	NCRNA00029	0.42	8.89	0.44	3.82e-17	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg04733989	chr22:42467013	NAGA	-0.41	-6.64	-0.34	1.24e-10	Cognitive function;
LUSC	cis	rs2580764	0.566	rs2972072	chr2:55295370	G/T	cg20993754	chr2:55226987	RTN4	-0.37	-6.28	-0.32	1.07e-9	Mean platelet volume;
LUSC	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg26727032	chr16:67993705	SLC12A4	-0.42	-6.71	-0.34	8.2e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22590775	chr19:49891494	CCDC155	0.59	8.33	0.41	2.16e-15	Multiple sclerosis;
LUSC	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg24642439	chr20:33292090	TP53INP2	0.54	8.13	0.41	8.78e-15	Height;
LUSC	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-1.0	-24.12	-0.8	3.83e-75	Urate levels in lean individuals;
LUSC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg02038168	chr22:39784481	NA	-0.43	-6.39	-0.33	5.45e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.17	0.49	2.5e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg20243544	chr17:37824526	PNMT	0.39	5.85	0.3	1.19e-8	Self-reported allergy;
LUSC	cis	rs2692947	0.759	rs2949885	chr2:96662415	A/G	cg23100626	chr2:96804247	ASTL	0.26	6.18	0.32	1.86e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4776059	0.761	rs12594964	chr15:52900208	G/A	cg25063058	chr15:52860530	ARPP19	-0.47	-5.86	-0.31	1.13e-8	Schizophrenia;
LUSC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07677032	chr17:61819896	STRADA	0.53	9.0	0.44	1.69e-17	Prudent dietary pattern;
LUSC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.17	15.04	0.64	2.12e-39	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-0.98	-17.49	-0.69	4.27e-49	Height;
LUSC	trans	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg14791747	chr16:20752902	THUMPD1	0.73	9.63	0.47	1.54e-19	Cognitive test performance;
LUSC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg04267008	chr7:1944627	MAD1L1	-0.46	-6.97	-0.36	1.74e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg25767906	chr1:53392781	SCP2	-0.52	-9.58	-0.46	2.27e-19	Monocyte count;
LUSC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg06600287	chr1:53387719	ECHDC2	0.28	5.66	0.3	3.29e-8	Monocyte count;
LUSC	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	6.85	0.35	3.64e-11	Menarche (age at onset);
LUSC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.98	-0.36	1.62e-11	Lung cancer;
LUSC	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.51	-10.02	-0.48	7.54e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.5	0.62	2.79e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07677032	chr17:61819896	STRADA	0.53	8.85	0.44	5.06e-17	Prudent dietary pattern;
LUSC	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg05527609	chr1:210001259	C1orf107	0.67	9.63	0.47	1.5700000000000001e-19	Orofacial clefts;
LUSC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg06740227	chr12:86229804	RASSF9	0.4	6.19	0.32	1.77e-9	Major depressive disorder;
LUSC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg07507251	chr3:52567010	NT5DC2	0.37	7.5	0.38	5.96e-13	Electroencephalogram traits;
LUSC	cis	rs8044995	0.563	rs56899435	chr16:68395675	G/A	cg05110241	chr16:68378359	PRMT7	-0.78	-8.77	-0.43	9.38e-17	Schizophrenia;
LUSC	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg14893161	chr1:205819251	PM20D1	-0.48	-6.46	-0.33	3.63e-10	Menarche (age at onset);
LUSC	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg12927641	chr6:109611667	NA	-0.35	-6.0	-0.31	5.18e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg06223162	chr1:101003688	GPR88	-0.48	-9.13	-0.45	6.71e-18	Monocyte count;
LUSC	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg15839431	chr19:19639596	YJEFN3	-0.63	-7.15	-0.36	5.48e-12	Bipolar disorder;
LUSC	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg06606381	chr12:133084897	FBRSL1	-0.88	-7.56	-0.38	3.87e-13	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6732160	0.691	rs2007191	chr2:73421463	T/G	cg24220031	chr2:73402428	NA	-0.23	-5.76	-0.3	1.9e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg25173405	chr17:45401733	C17orf57	0.38	6.13	0.32	2.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg19773385	chr1:10388646	KIF1B	-0.58	-9.93	-0.48	1.59e-20	Hepatocellular carcinoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23227555	chr2:3523215	ADI1	-0.4	-6.38	-0.33	5.94e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.78	-15.02	-0.63	2.54e-39	Multiple sclerosis;
LUSC	cis	rs6942756	0.876	rs2303303	chr7:129019736	G/A	cg02491457	chr7:128862824	NA	-0.4	-5.84	-0.3	1.23e-8	White matter hyperintensity burden;
LUSC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	0.63	13.39	0.59	4.87e-33	Prudent dietary pattern;
LUSC	cis	rs17767294	0.612	rs9461425	chr6:27919688	G/A	cg08851530	chr6:28072375	NA	0.86	6.66	0.34	1.15e-10	Parkinson's disease;
LUSC	cis	rs3820928	0.874	rs4234062	chr2:227819050	C/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.63	-0.39	2.4e-13	Pulmonary function;
LUSC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-13.71	-0.6	3.02e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg18904891	chr8:8559673	CLDN23	0.42	6.49	0.33	3.03e-10	Mood instability;
LUSC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.59	9.6	0.47	1.9e-19	Aortic root size;
LUSC	cis	rs9715521	0.557	rs13146381	chr4:59853842	T/C	cg11281224	chr4:60001000	NA	-0.48	-6.85	-0.35	3.62e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.91	0.51	6.56e-24	Hypertriglyceridemia;
LUSC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg14668632	chr7:2872130	GNA12	-0.43	-6.05	-0.31	3.84e-9	Height;
LUSC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg06238570	chr21:40685208	BRWD1	0.53	8.3	0.41	2.54e-15	Cognitive function;
LUSC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg20476274	chr7:133979776	SLC35B4	0.87	16.7	0.67	6.08e-46	Mean platelet volume;
LUSC	trans	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.62	9.74	0.47	6.83e-20	Endometrial cancer;
LUSC	trans	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.79	0.35	5.24e-11	Corneal astigmatism;
LUSC	cis	rs10992471	1.000	rs10992471	chr9:95559505	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.33	6.06	0.31	3.72e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.77	11.79	0.54	4.52e-27	Tonsillectomy;
LUSC	cis	rs7178572	0.889	rs907388	chr15:77828668	G/A	cg22256960	chr15:77711686	NA	-0.52	-8.63	-0.43	2.45e-16	Type 2 diabetes;
LUSC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	8.38	0.42	1.45e-15	Colorectal cancer;
LUSC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs2267681	0.508	rs10277705	chr7:139519293	C/G	cg14116596	chr7:139528673	TBXAS1	0.38	6.63	0.34	1.34e-10	Cervical cancer;
LUSC	cis	rs11587682	0.760	rs1043293	chr1:150448766	G/C	cg11822372	chr1:151115635	SEMA6C	-0.43	-5.71	-0.3	2.48e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg23625390	chr15:77176239	SCAPER	-0.66	-10.18	-0.49	2.17e-21	Blood metabolite levels;
LUSC	cis	rs7598759	1.000	rs7598759	chr2:232321956	C/T	cg19187155	chr2:232395269	NMUR1	0.5	7.63	0.39	2.56e-13	Noise-induced hearing loss;
LUSC	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-20.58	-0.75	2.39e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs54211	1.000	rs137610	chr22:39697793	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.6	5.78	0.3	1.72e-8	Sudden cardiac arrest;
LUSC	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg17143192	chr8:8559678	CLDN23	0.64	9.02	0.44	1.47e-17	Obesity-related traits;
LUSC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg19678392	chr7:94953810	PON1	-0.38	-6.21	-0.32	1.61e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16333535	chr22:24093440	ZNF70	0.44	6.31	0.33	8.82e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg03983476	chr2:10830698	NOL10	-0.37	-5.67	-0.3	3.09e-8	Prostate cancer;
LUSC	cis	rs5758511	0.731	rs5751186	chr22:42349710	G/A	cg00645731	chr22:42541494	CYP2D7P1	-0.43	-7.13	-0.36	6.18e-12	Birth weight;
LUSC	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg16989719	chr2:238392110	NA	-0.37	-6.34	-0.33	7.24e-10	Prostate cancer;
LUSC	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg09904177	chr6:26538194	HMGN4	0.66	11.11	0.52	1.27e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs9469578	0.579	rs73743401	chr6:33716945	G/T	cg18708504	chr6:33715942	IP6K3	0.64	6.16	0.32	2.04e-9	Phosphorus levels;
LUSC	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg00376283	chr12:123451042	ABCB9	0.66	8.34	0.42	2e-15	Neutrophil percentage of white cells;
LUSC	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg12564285	chr5:131593104	PDLIM4	0.37	6.9	0.35	2.57e-11	Blood metabolite levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21692735	chr1:1691997	NADK	0.46	6.5	0.34	3e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs977987	0.806	rs8057203	chr16:75404974	T/C	cg04384234	chr16:75411784	CFDP1	-0.42	-6.85	-0.35	3.47e-11	Dupuytren's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15705266	chr17:33914268	AP2B1	0.43	6.06	0.31	3.7e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1506636	1.000	rs2259457	chr7:123424350	A/G	cg03229431	chr7:123269106	ASB15	0.65	10.68	0.5	4.29e-23	Plateletcrit;Platelet count;
LUSC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg13072238	chr3:49761600	GMPPB	-0.65	-7.68	-0.39	1.74e-13	Menarche (age at onset);
LUSC	trans	rs7313075	0.850	rs35512374	chr12:102653564	T/C	cg03720887	chr8:101963845	YWHAZ	0.67	6.18	0.32	1.82e-9	Height;
LUSC	cis	rs3736594	0.959	rs10201247	chr2:27974971	A/G	cg27432699	chr2:27873401	GPN1	-0.64	-9.13	-0.45	6.53e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	0.69	12.19	0.55	1.59e-28	Longevity;
LUSC	trans	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg26043149	chr18:55253948	FECH	0.5	7.5	0.38	5.88e-13	Bone mineral density;
LUSC	cis	rs3862435	1.000	rs3862435	chr15:91082532	A/G	cg22089800	chr15:90895588	ZNF774	-0.61	-5.8	-0.3	1.55e-8	Response to exercise (triglyceride level interaction);
LUSC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06634786	chr22:41940651	POLR3H	-0.55	-6.4	-0.33	5.2400000000000005e-10	Vitiligo;
LUSC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg12463550	chr7:65579703	CRCP	0.62	5.67	0.3	3.04e-8	Diabetic kidney disease;
LUSC	cis	rs8038465	0.638	rs8036954	chr15:73974282	T/C	cg15420318	chr15:73925796	NPTN	0.59	10.04	0.48	6.91e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg18827107	chr12:86230957	RASSF9	-0.47	-7.06	-0.36	9.99e-12	Major depressive disorder;
LUSC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	14.08	0.61	1.17e-35	Platelet count;
LUSC	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg09517075	chr8:22133004	PIWIL2	0.41	8.11	0.41	9.94e-15	Hypertriglyceridemia;
LUSC	cis	rs7091068	0.536	rs503758	chr10:95406935	C/A	cg20715218	chr10:95462985	C10orf4	-0.64	-8.34	-0.42	1.91e-15	Urinary tract infection frequency;
LUSC	trans	rs17266958	1.000	rs17083743	chr9:83291465	A/G	cg01905489	chr1:26616534	UBXN11	-0.59	-6.46	-0.33	3.79e-10	Preschool internalizing problems;
LUSC	cis	rs7759001	0.857	rs6936356	chr6:27358853	A/C	cg18711553	chr6:27366782	ZNF391	0.39	5.72	0.3	2.32e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg26338869	chr17:61819248	STRADA	0.41	5.77	0.3	1.84e-8	Prudent dietary pattern;
LUSC	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg08270630	chr22:50330655	NA	0.41	6.05	0.31	3.98e-9	Schizophrenia;
LUSC	cis	rs2798269	0.966	rs2798271	chr13:22136765	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.04	-0.31	4.15e-9	PR segment;
LUSC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg08888203	chr3:10149979	C3orf24	-0.62	-8.07	-0.4	1.3e-14	Alzheimer's disease;
LUSC	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.63	9.99	0.48	9.69e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg26408565	chr15:76604113	ETFA	-0.49	-7.84	-0.39	6.1e-14	Blood metabolite levels;
LUSC	trans	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg13010199	chr12:38710504	ALG10B	0.45	6.92	0.35	2.27e-11	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.54	0.5	1.24e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg18681998	chr4:17616180	MED28	-0.83	-14.73	-0.63	3.54e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg21782813	chr7:2030301	MAD1L1	0.53	9.11	0.45	7.53e-18	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.49	0.33	3.09e-10	Lung cancer;
LUSC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg25456477	chr12:86230367	RASSF9	0.33	5.73	0.3	2.21e-8	Major depressive disorder;
LUSC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24531977	chr5:56204891	C5orf35	0.86	13.9	0.61	5.79e-35	Initial pursuit acceleration;
LUSC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg24881330	chr22:46731750	TRMU	-0.89	-10.03	-0.48	6.95e-21	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-0.93	-13.27	-0.59	1.43e-32	Vitiligo;
LUSC	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg24851651	chr11:66362959	CCS	-0.36	-5.73	-0.3	2.25e-8	Educational attainment (years of education);
LUSC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.4	-7.4	-0.38	1.15e-12	Longevity;Endometriosis;
LUSC	cis	rs7605827	0.930	rs11898971	chr2:15613678	C/T	cg19274914	chr2:15703543	NA	-0.47	-9.22	-0.45	3.49e-18	Educational attainment (years of education);
LUSC	trans	rs2262909	1.000	rs765527	chr19:22129555	A/G	cg05197062	chr11:11642011	GALNTL4	0.5	6.85	0.35	3.6e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	7.97	0.4	2.46e-14	Mood instability;
LUSC	cis	rs17227506	0.529	rs13258748	chr8:13470909	A/T	cg03566418	chr8:13424080	C8orf48	-0.38	-5.72	-0.3	2.42e-8	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg05347473	chr6:146136440	FBXO30	0.53	8.86	0.44	4.86e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg13010199	chr12:38710504	ALG10B	0.67	10.36	0.49	5.56e-22	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg17507749	chr15:85114479	UBE2QP1	0.65	8.1	0.41	1.04e-14	Schizophrenia;
LUSC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08280861	chr8:58055591	NA	0.53	5.81	0.3	1.5e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg12560992	chr17:57184187	TRIM37	0.84	15.44	0.65	5.6e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg05985134	chr18:33552581	C18orf21	0.5	6.92	0.35	2.27e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.18	0.41	5.81e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg14601938	chr1:150122016	PLEKHO1	0.39	6.17	0.32	1.99e-9	Asthma;
LUSC	cis	rs10208940	0.920	rs35005506	chr2:68814238	A/T	cg12452813	chr2:68675892	NA	0.59	6.08	0.32	3.21e-9	Urate levels in lean individuals;
LUSC	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg09323728	chr8:95962352	TP53INP1	-0.3	-5.71	-0.3	2.44e-8	Type 2 diabetes;
LUSC	cis	rs10979	1.000	rs12738	chr6:143890049	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-11.94	-0.55	1.31e-27	Hypospadias;
LUSC	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06636551	chr8:101224915	SPAG1	-0.45	-8.26	-0.41	3.54e-15	Atrioventricular conduction;
LUSC	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg11812906	chr14:75593930	NEK9	0.67	11.56	0.53	3.11e-26	Height;
LUSC	trans	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-9.51	-0.46	3.84e-19	Morning vs. evening chronotype;
LUSC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg06784218	chr1:46089804	CCDC17	0.57	11.33	0.53	2.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg26354017	chr1:205819088	PM20D1	0.52	8.56	0.42	4.25e-16	Menarche (age at onset);
LUSC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.05	0.4	1.51e-14	Prudent dietary pattern;
LUSC	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg17178900	chr1:205818956	PM20D1	-0.48	-7.24	-0.37	3.02e-12	Menarche (age at onset);
LUSC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg05082376	chr22:42548792	NA	-0.45	-7.14	-0.36	5.74e-12	Schizophrenia;
LUSC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	0.93	17.88	0.7	1.24e-50	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.71	12.72	0.57	1.68e-30	Prudent dietary pattern;
LUSC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11764359	chr7:65958608	NA	0.68	11.06	0.52	2e-24	Aortic root size;
LUSC	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.34	-5.66	-0.3	3.24e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs8085804	0.611	rs11082292	chr18:40278773	A/G	cg04486886	chr5:56784195	NA	-0.31	-5.99	-0.31	5.5e-9	Cognitive performance;
LUSC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg06096015	chr1:231504339	EGLN1	0.56	9.96	0.48	1.25e-20	Hemoglobin concentration;
LUSC	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg09165964	chr15:75287851	SCAMP5	0.52	7.63	0.39	2.49e-13	Breast cancer;
LUSC	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg02423579	chr7:2872169	GNA12	-0.46	-6.4	-0.33	5.2400000000000005e-10	Height;
LUSC	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg24375607	chr4:120327624	NA	0.77	11.32	0.53	2.32e-25	Corneal astigmatism;
LUSC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.18	-0.32	1.84e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg01528321	chr10:82214614	TSPAN14	0.88	13.27	0.59	1.49e-32	Post bronchodilator FEV1;
LUSC	cis	rs11051970	0.636	rs2733704	chr12:32567858	C/T	cg24626660	chr12:32551988	NA	0.3	5.65	0.3	3.46e-8	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg05025164	chr4:1340916	KIAA1530	0.4	5.93	0.31	7.51e-9	Obesity-related traits;
LUSC	trans	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg14791747	chr16:20752902	THUMPD1	-0.45	-6.59	-0.34	1.74e-10	Pancreatic cancer;
LUSC	trans	rs1973993	0.745	rs986427	chr1:96932736	A/G	cg10631902	chr5:14652156	NA	-0.5	-7.52	-0.38	5.08e-13	Weight;
LUSC	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.61	10.19	0.49	2e-21	Breast cancer;
LUSC	cis	rs6076065	0.722	rs6048760	chr20:23345844	G/T	cg11657817	chr20:23433608	CST11	-0.54	-10.83	-0.51	1.24e-23	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08470875	chr2:26401718	FAM59B	-0.72	-9.82	-0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs1506636	1.000	rs2429616	chr7:123406034	C/T	cg03229431	chr7:123269106	ASB15	0.65	10.7	0.51	3.69e-23	Plateletcrit;Platelet count;
LUSC	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg19610905	chr11:61596333	FADS2	-0.54	-7.91	-0.4	3.92e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LUSC	cis	rs1904096	0.513	rs2632405	chr4:95152215	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.41	-0.42	1.2e-15	Type 2 diabetes;
LUSC	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg14664628	chr15:75095509	CSK	0.46	6.32	0.33	8.14e-10	Systemic lupus erythematosus;
LUSC	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg01073479	chr16:3509474	NAT15	-0.42	-5.66	-0.3	3.21e-8	Tuberculosis;
LUSC	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg05043794	chr9:111880884	C9orf5	-0.4	-8.75	-0.43	1.09e-16	Menarche (age at onset);
LUSC	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.38	0.59	5.58e-33	Morning vs. evening chronotype;
LUSC	cis	rs6714710	0.603	rs34502870	chr2:98405929	A/G	cg26665480	chr2:98280029	ACTR1B	0.58	8.58	0.42	3.69e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg05872129	chr22:39784769	NA	-0.57	-10.51	-0.5	1.6e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	cis	rs11645898	0.625	rs8047930	chr16:72106024	C/T	cg14768367	chr16:72042858	DHODH	-0.51	-6.04	-0.31	4.14e-9	Blood protein levels;
LUSC	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg25801113	chr15:45476975	SHF	-0.34	-6.7	-0.34	8.82e-11	Uric acid levels;
LUSC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg22549504	chr19:17448937	GTPBP3	0.54	6.74	0.35	6.84e-11	Systemic lupus erythematosus;
LUSC	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.98	-0.51	3.78e-24	Smoking initiation;
LUSC	trans	rs10851478	0.872	rs12591317	chr15:49945675	A/G	cg23074453	chr15:44487924	FRMD5	-0.33	-6.12	-0.32	2.61e-9	Oral cavity cancer;
LUSC	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg05340658	chr4:99064831	C4orf37	-0.45	-7.28	-0.37	2.35e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs41271473	0.948	rs72750016	chr1:228816786	G/C	cg16512390	chr1:228756714	NA	0.53	6.45	0.33	3.93e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs62400317	0.859	rs62436779	chr6:45124911	G/A	cg18551225	chr6:44695536	NA	-0.42	-6.89	-0.35	2.76e-11	Total body bone mineral density;
LUSC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg12963246	chr6:28129442	ZNF389	0.48	6.73	0.35	7.46e-11	Depression;
LUSC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00149659	chr3:10157352	C3orf10	0.91	12.29	0.56	6.74e-29	Alzheimer's disease;
LUSC	cis	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg05084668	chr3:125655381	ALG1L	-0.8	-11.75	-0.54	6.33e-27	Blood pressure (smoking interaction);
LUSC	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg20991723	chr1:152506922	NA	0.52	9.72	0.47	7.81e-20	Hair morphology;
LUSC	cis	rs9420	0.807	rs12807357	chr11:57656902	C/T	cg23127183	chr11:57508653	C11orf31	-0.53	-7.56	-0.38	3.97e-13	Schizophrenia;
LUSC	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg00310523	chr12:86230176	RASSF9	0.38	6.87	0.35	3.09e-11	Major depressive disorder;
LUSC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.48	0.38	6.59e-13	Motion sickness;
LUSC	trans	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.42	0.53	9.87e-26	Mean corpuscular volume;
LUSC	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	0.94	16.27	0.66	3.01e-44	Height;
LUSC	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg14196790	chr5:131705035	SLC22A5	0.51	8.92	0.44	3.06e-17	Blood metabolite levels;
LUSC	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs56399783	0.901	rs73033408	chr7:2879755	C/T	cg19731401	chr7:2775893	GNA12	0.76	9.51	0.46	3.95e-19	Childhood ear infection;
LUSC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-1.24	-13.82	-0.6	1.13e-34	Diabetic kidney disease;
LUSC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.09	0.36	7.93e-12	Bipolar disorder;
LUSC	cis	rs7106204	1.000	rs35876423	chr11:24214859	G/T	ch.11.24196551F	chr11:24239977	NA	0.99	9.81	0.47	4.07e-20	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs11039100	0.850	rs12796660	chr11:5843681	T/C	cg05234568	chr11:5960015	NA	-0.52	-5.92	-0.31	7.97e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg10018233	chr7:150070692	REPIN1	0.41	6.76	0.35	6.13e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs76878669	0.538	rs73489638	chr11:66127639	C/T	cg18002602	chr11:66138449	SLC29A2	-0.48	-8.44	-0.42	9.93e-16	Educational attainment (years of education);
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.52	-7.27	-0.37	2.54e-12	Longevity;Endometriosis;
LUSC	cis	rs7202877	0.611	rs7187263	chr16:75308978	C/A	cg04384234	chr16:75411784	CFDP1	-0.67	-9.3	-0.45	1.95e-18	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg03146154	chr1:46216737	IPP	0.52	7.66	0.39	2e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6076065	0.748	rs6048781	chr20:23380027	T/C	cg11657817	chr20:23433608	CST11	0.53	11.03	0.52	2.42e-24	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg06096015	chr1:231504339	EGLN1	0.53	8.95	0.44	2.47e-17	Hemoglobin concentration;
LUSC	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg03806693	chr22:41940476	POLR3H	-0.9	-12.72	-0.57	1.64e-30	Vitiligo;
LUSC	cis	rs12476592	0.602	rs262484	chr2:63878015	A/G	cg10828910	chr2:63850056	LOC388955	0.5	6.07	0.32	3.47e-9	Childhood ear infection;
LUSC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08859206	chr1:53392774	SCP2	-0.54	-9.35	-0.46	1.34e-18	Monocyte count;
LUSC	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg26597838	chr10:835615	NA	0.9	12.25	0.56	9.21e-29	Eosinophil percentage of granulocytes;
LUSC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10802521	chr3:52805072	NEK4	-0.52	-8.33	-0.41	2.05e-15	Bipolar disorder;
LUSC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg02423579	chr7:2872169	GNA12	-0.5	-7.3	-0.37	2.18e-12	Height;
LUSC	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg18825076	chr15:78729989	IREB2	-0.49	-7.64	-0.39	2.28e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs6977660	1.000	rs35784097	chr7:19818848	A/G	cg05791153	chr7:19748676	TWISTNB	0.54	5.94	0.31	7.08e-9	Thyroid stimulating hormone;
LUSC	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.83	14.47	0.62	3.58e-37	Metabolic syndrome;
LUSC	cis	rs6570726	0.516	rs10457779	chr6:145736663	C/T	cg23711669	chr6:146136114	FBXO30	0.48	7.44	0.38	8.51e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	9.16	0.45	5.39e-18	Bipolar disorder;
LUSC	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg27147174	chr7:100797783	AP1S1	-0.65	-10.57	-0.5	1.04e-22	Life satisfaction;
LUSC	cis	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg10665199	chr7:133106180	EXOC4	0.58	8.16	0.41	6.67e-15	Intelligence;Intelligence (multi-trait analysis);
LUSC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg19592336	chr6:28129416	ZNF389	0.45	6.0	0.31	5.12e-9	Depression;
LUSC	cis	rs16937	0.711	rs10900470	chr1:205168614	C/T	cg00857998	chr1:205179979	DSTYK	0.47	6.76	0.35	6.08e-11	Schizophrenia;
LUSC	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg14675211	chr2:100938903	LONRF2	0.37	5.76	0.3	1.91e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg04455712	chr21:45112962	RRP1B	-0.45	-8.35	-0.42	1.9e-15	Mean corpuscular volume;
LUSC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg01475377	chr6:109611718	NA	-0.44	-8.07	-0.4	1.29e-14	Reticulocyte fraction of red cells;
LUSC	cis	rs9650657	0.644	rs3808603	chr8:10698218	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-6.0	-0.31	5.23e-9	Neuroticism;
LUSC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg13010199	chr12:38710504	ALG10B	0.64	10.1	0.48	4.04e-21	Morning vs. evening chronotype;
LUSC	cis	rs2114646	1.000	rs2114646	chr2:170624221	C/T	cg17598339	chr2:170624727	NA	0.47	5.86	0.31	1.1e-8	Obesity-related traits;
LUSC	cis	rs1358748	0.522	rs6588239	chr1:67572361	G/A	cg02640540	chr1:67518911	SLC35D1	0.67	6.47	0.33	3.46e-10	Tuberculosis;
LUSC	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.85	0.39	5.59e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-13.33	-0.59	8.44e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs394563	0.559	rs7753269	chr6:149671360	G/A	cg07828024	chr6:149772892	ZC3H12D	0.33	7.23	0.37	3.3e-12	Dupuytren's disease;
LUSC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg11871910	chr12:69753446	YEATS4	0.67	10.29	0.49	9.66e-22	Blood protein levels;
LUSC	cis	rs9660992	1.000	rs1779410	chr1:205248759	A/G	cg21643547	chr1:205240462	TMCC2	-0.47	-9.08	-0.44	9.58e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13126279	chr21:47581558	C21orf56	-0.48	-7.06	-0.36	9.71e-12	Testicular germ cell tumor;
LUSC	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg08508325	chr11:3079039	CARS	0.36	8.1	0.41	1.02e-14	Calcium levels;
LUSC	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	12.64	0.57	3.43e-30	Total body bone mineral density;
LUSC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18099408	chr3:52552593	STAB1	-0.41	-6.99	-0.36	1.46e-11	Bipolar disorder;
LUSC	cis	rs7300001	0.538	rs7968848	chr12:110941059	T/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.5	0.38	5.91e-13	Headache;
LUSC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	0.99	13.93	0.61	4.13e-35	Eosinophil percentage of granulocytes;
LUSC	trans	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	10.2	0.49	1.96e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.93	-0.35	2.13e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7246967	0.551	rs1835994	chr19:22833045	T/C	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs11577318	0.626	rs11806568	chr1:26686837	C/A	cg00852783	chr1:26633632	UBXN11	-0.54	-7.44	-0.38	8.85e-13	Granulocyte percentage of myeloid white cells;
LUSC	trans	rs7939886	0.920	rs4489763	chr11:55944474	G/A	cg15704280	chr7:45808275	SEPT13	0.88	6.69	0.34	9.39e-11	Myopia (pathological);
LUSC	cis	rs12900413	0.687	rs6496601	chr15:90317694	C/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.76	-0.3	1.92e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg06713675	chr4:122721982	EXOSC9	-0.61	-10.65	-0.5	5.56e-23	Type 2 diabetes;
LUSC	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg05887092	chr17:76393375	PGS1	0.66	12.88	0.58	4.22e-31	HDL cholesterol levels;
LUSC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg26338869	chr17:61819248	STRADA	0.42	6.17	0.32	1.99e-9	Prudent dietary pattern;
LUSC	trans	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg11887960	chr12:57824829	NA	0.54	6.7	0.34	8.62e-11	Obesity-related traits;
LUSC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg06713675	chr4:122721982	EXOSC9	-0.61	-10.57	-0.5	1.01e-22	Type 2 diabetes;
LUSC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg01879757	chr17:41196368	BRCA1	-0.45	-6.84	-0.35	3.68e-11	Menopause (age at onset);
LUSC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	0.95	18.18	0.71	8.19e-52	Heart rate;
LUSC	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg18357645	chr12:58087776	OS9	0.44	6.9	0.35	2.64e-11	Multiple sclerosis;
LUSC	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg23260525	chr10:116636907	FAM160B1	0.4	8.18	0.41	5.96e-15	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.34	-0.37	1.64e-12	Morning vs. evening chronotype;
LUSC	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg13206674	chr6:150067644	NUP43	0.43	6.56	0.34	2.01e-10	Testicular germ cell tumor;
LUSC	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg24558204	chr6:135376177	HBS1L	0.58	9.06	0.44	1.1e-17	Red blood cell count;
LUSC	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.34	-6.22	-0.32	1.52e-9	IgG glycosylation;
LUSC	cis	rs17155006	0.746	rs435744	chr7:107748549	A/G	cg05962710	chr7:107745446	LAMB4	-0.36	-6.52	-0.34	2.57e-10	Pneumococcal bacteremia;
LUSC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-0.8	-11.08	-0.52	1.72e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg05347473	chr6:146136440	FBXO30	0.55	9.44	0.46	6.44e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg15744005	chr10:104629667	AS3MT	-0.28	-5.95	-0.31	6.77e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6141769	0.866	rs79384779	chr20:31214944	C/T	cg13636640	chr20:31349939	DNMT3B	0.52	5.66	0.3	3.3e-8	Subjective well-being;
LUSC	cis	rs35123781	1.000	rs9687282	chr5:139065988	T/G	cg10513866	chr5:139070639	NA	0.43	8.4	0.42	1.3e-15	Schizophrenia;
LUSC	trans	rs1941687	0.509	rs7230319	chr18:31321289	A/T	cg27147174	chr7:100797783	AP1S1	-0.52	-8.27	-0.41	3.24e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7833986	1.000	rs36088882	chr8:57092914	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	9.2	0.45	3.84e-18	Height;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg06861087	chr14:53019167	TXNDC16;GPR137C	0.76	5.95	0.31	6.64e-9	Cognitive performance;
LUSC	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.51	-0.46	3.89e-19	Schizophrenia;
LUSC	trans	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg11887960	chr12:57824829	NA	0.51	6.69	0.34	9.16e-11	Obesity-related traits;
LUSC	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-9.65	-0.47	1.4e-19	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs934734	0.563	rs11126034	chr2:65580221	C/T	cg08085232	chr2:65598271	SPRED2	0.42	6.74	0.35	6.98e-11	Rheumatoid arthritis;
LUSC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.85	0.6	8.46e-35	Cognitive test performance;
LUSC	cis	rs10489202	0.954	rs11586522	chr1:168091031	G/T	cg24449463	chr1:168025552	DCAF6	-0.57	-7.29	-0.37	2.32e-12	Schizophrenia;
LUSC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.83	0.35	3.98e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.9	0.35	2.64e-11	IgG glycosylation;
LUSC	cis	rs4812048	0.649	rs3761257	chr20:57618787	C/T	cg14073986	chr20:57617431	SLMO2	0.9	9.75	0.47	6.21e-20	Mean platelet volume;
LUSC	cis	rs10489202	1.000	rs17557135	chr1:167985888	A/G	cg24449463	chr1:168025552	DCAF6	-0.59	-7.39	-0.37	1.21e-12	Schizophrenia;
LUSC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.0	-0.31	5.03e-9	Platelet count;
LUSC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg16606324	chr3:10149918	C3orf24	0.59	8.17	0.41	6.61e-15	Alzheimer's disease;
LUSC	trans	rs72792513	1.000	rs55999417	chr2:22907370	G/A	cg05844895	chr16:88969569	CBFA2T3	0.53	6.19	0.32	1.77e-9	Hepatitis B;
LUSC	cis	rs870825	0.549	rs10015956	chr4:185614705	T/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.6	0.6	7.9e-34	Blood protein levels;
LUSC	cis	rs6580649	0.941	rs78649179	chr12:48508196	T/A	cg24011408	chr12:48396354	COL2A1	-0.45	-6.09	-0.32	3.05e-9	Lung cancer;
LUSC	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg20891283	chr12:69753455	YEATS4	0.45	6.15	0.32	2.19e-9	Response to diuretic therapy;
LUSC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.57	-9.49	-0.46	4.46e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg11146114	chr12:4671731	NA	-0.57	-6.06	-0.31	3.63e-9	Phosphorus levels;
LUSC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.51	0.34	2.76e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg00484396	chr16:3507460	NAT15	-0.45	-7.42	-0.38	9.52e-13	Body mass index (adult);
LUSC	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg24531977	chr5:56204891	C5orf35	-0.53	-7.8	-0.39	7.87e-14	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7173743	0.730	rs6495340	chr15:79128396	A/G	cg00540400	chr15:79124168	NA	0.35	5.99	0.31	5.29e-9	Coronary artery disease;
LUSC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-0.8	-13.29	-0.59	1.19e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.7	-0.34	9.08e-11	Monocyte percentage of white cells;
LUSC	cis	rs72634258	0.945	rs12727642	chr1:8046672	C/A	cg26816564	chr1:7831052	VAMP3	0.49	6.27	0.32	1.12e-9	Inflammatory bowel disease;
LUSC	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	7.49	0.38	6.1e-13	Retinal vascular caliber;
LUSC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg13531842	chr10:38383804	ZNF37A	-0.45	-6.97	-0.36	1.74e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.21	24.67	0.8	2.96e-77	Exhaled nitric oxide output;
LUSC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg06784218	chr1:46089804	CCDC17	0.54	10.88	0.51	8.41e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.88	17.08	0.68	1.93e-47	Body mass index (adult);
LUSC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06028605	chr16:24865363	SLC5A11	0.65	10.22	0.49	1.66e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg14552801	chr7:65878734	NA	0.42	5.88	0.31	9.95e-9	Aortic root size;
LUSC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.6	-9.63	-0.47	1.59e-19	Body mass index;
LUSC	cis	rs6714710	0.603	rs11679828	chr2:98517626	G/A	cg26665480	chr2:98280029	ACTR1B	0.61	8.9	0.44	3.72e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs12681287	0.640	rs13280468	chr8:87338452	C/T	cg00550725	chr8:87521180	FAM82B	0.43	5.67	0.3	3.15e-8	Caudate activity during reward;
LUSC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg06618935	chr21:46677482	NA	-0.39	-7.95	-0.4	2.85e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg25214090	chr10:38739885	LOC399744	0.42	6.53	0.34	2.38e-10	Corneal astigmatism;
LUSC	cis	rs6565189	0.865	rs4350585	chr16:30505513	A/G	cg17640201	chr16:30407289	ZNF48	0.47	6.21	0.32	1.62e-9	Tonsillectomy;
LUSC	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-9.9	-0.48	2.05e-20	Platelet distribution width;
LUSC	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg16797656	chr11:68205561	LRP5	0.37	6.16	0.32	2.13e-9	Total body bone mineral density;
LUSC	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg24069376	chr3:38537580	EXOG	0.41	7.99	0.4	2.28e-14	Electrocardiographic conduction measures;
LUSC	trans	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.0	0.48	9.32e-21	Mean corpuscular volume;
LUSC	cis	rs7945705	0.846	rs11042055	chr11:8756856	G/A	cg09997546	chr11:8931473	C11orf17;ST5	0.32	6.13	0.32	2.54e-9	Hemoglobin concentration;
LUSC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg18225595	chr11:63971243	STIP1	0.49	6.1	0.32	2.88e-9	Mean platelet volume;
LUSC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg00012203	chr2:219082015	ARPC2	-0.71	-11.73	-0.54	7.42e-27	Colorectal cancer;
LUSC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg05347473	chr6:146136440	FBXO30	0.45	7.69	0.39	1.72e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.8	-0.39	7.92e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs4654899	0.772	rs10916892	chr1:21201325	A/G	cg02927042	chr1:21476669	EIF4G3	-0.37	-5.92	-0.31	8.18e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.56e-10	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11641254	chr5:68665600	RAD17;TAF9	-0.42	-6.31	-0.33	8.9e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg00431813	chr7:1051703	C7orf50	-0.45	-7.4	-0.38	1.15e-12	Longevity;Endometriosis;
LUSC	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.99	0.36	1.51e-11	Lung cancer in ever smokers;
LUSC	cis	rs7809950	1.000	rs4730245	chr7:107087294	C/T	cg23024343	chr7:107201750	COG5	-0.56	-8.8	-0.43	7.42e-17	Coronary artery disease;
LUSC	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.01	-0.44	1.61e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs714027	0.967	rs4823077	chr22:30545149	A/G	cg11564601	chr22:30592435	NA	-0.37	-6.81	-0.35	4.67e-11	Lymphocyte counts;
LUSC	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg25174290	chr11:3078921	CARS	-0.41	-6.11	-0.32	2.76e-9	Calcium levels;
LUSC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg03676636	chr4:99064102	C4orf37	0.34	7.48	0.38	6.43e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9473147	0.571	rs9395285	chr6:47554177	G/A	cg12968598	chr6:47444699	CD2AP	0.52	7.98	0.4	2.3e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg26566898	chr11:117069891	TAGLN	0.45	7.93	0.4	3.38e-14	Blood protein levels;
LUSC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg04733989	chr22:42467013	NAGA	0.62	9.71	0.47	8.3e-20	Schizophrenia;
LUSC	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-6.84	-0.35	3.85e-11	Mood instability;
LUSC	cis	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg06521331	chr12:34319734	NA	-0.47	-7.61	-0.38	2.85e-13	Morning vs. evening chronotype;
LUSC	cis	rs6484504	0.516	rs1999250	chr11:31287455	C/T	cg14844989	chr11:31128820	NA	-0.39	-6.03	-0.31	4.39e-9	Red blood cell count;
LUSC	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg23625390	chr15:77176239	SCAPER	0.46	7.04	0.36	1.09e-11	Blood metabolite levels;
LUSC	cis	rs748404	0.697	rs572959	chr15:43550502	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	8.09	0.4	1.15e-14	Lung cancer;
LUSC	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-1.09	-17.42	-0.69	8.74e-49	Exhaled nitric oxide output;
LUSC	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg13319975	chr6:146136371	FBXO30	0.53	8.11	0.41	9.95e-15	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.75	-0.8	1.56e-77	Height;
LUSC	cis	rs9311676	0.656	rs6799077	chr3:58404096	C/T	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.28e-10	Systemic lupus erythematosus;
LUSC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg22549504	chr19:17448937	GTPBP3	-0.54	-7.1	-0.36	7.38e-12	Systemic lupus erythematosus;
LUSC	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	14.08	0.61	1.14e-35	Exhaled nitric oxide levels;
LUSC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg05084668	chr3:125655381	ALG1L	-0.53	-8.06	-0.4	1.42e-14	Blood pressure (smoking interaction);
LUSC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg08499158	chr17:42289980	UBTF	-0.49	-8.24	-0.41	4.03e-15	Total body bone mineral density;
LUSC	cis	rs75804782	0.641	rs72985397	chr2:239341354	A/G	cg18131467	chr2:239335373	ASB1	-0.68	-6.25	-0.32	1.29e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.0	-0.44	1.72e-17	Monocyte percentage of white cells;
LUSC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg14895029	chr7:2775587	GNA12	-0.36	-5.87	-0.31	1.08e-8	Height;
LUSC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg18806716	chr10:30721971	MAP3K8	-0.7	-11.12	-0.52	1.15e-24	Inflammatory bowel disease;
LUSC	cis	rs67072384	1.000	rs11235577	chr11:72451380	C/T	cg04827223	chr11:72435913	ARAP1	-0.76	-6.53	-0.34	2.39e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs427941	0.703	rs201448	chr7:101738860	T/C	cg06246474	chr7:101738831	CUX1	0.41	6.71	0.34	8.45e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg25643088	chr3:52874325	TMEM110	0.4	5.97	0.31	6.08e-9	Schizophrenia;
LUSC	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	10.18	0.49	2.23e-21	Homoarginine levels;
LUSC	cis	rs6700896	0.931	rs4655574	chr1:66135328	T/A	cg04111102	chr1:66153794	NA	0.33	7.22	0.37	3.53e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg24399712	chr22:39784796	NA	-0.63	-11.31	-0.53	2.43e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg01557791	chr16:72042693	DHODH	-0.48	-6.18	-0.32	1.92e-9	Blood protein levels;
LUSC	cis	rs4363385	0.747	rs1015996	chr1:152976108	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.76	-0.39	1.05e-13	Inflammatory skin disease;
LUSC	cis	rs7241530	0.662	rs6506754	chr18:75904989	A/G	cg14642773	chr18:75888474	NA	0.39	5.94	0.31	7.29e-9	Educational attainment (years of education);
LUSC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg11062466	chr8:58055876	NA	0.51	6.48	0.33	3.36e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg18452880	chr6:170151829	C6orf70;TCTE3	-0.5	-6.35	-0.33	7.2e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg17764715	chr19:33622953	WDR88	0.59	8.53	0.42	5e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg07959070	chr22:50026188	C22orf34	-0.34	-7.03	-0.36	1.13e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6681460	1.000	rs7524818	chr1:67072031	C/T	cg02459107	chr1:67143332	SGIP1	0.5	9.24	0.45	2.89e-18	Presence of antiphospholipid antibodies;
LUSC	cis	rs7903847	0.620	rs11189168	chr10:99125769	T/C	cg20016023	chr10:99160130	RRP12	-0.34	-8.16	-0.41	6.97e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.95	-16.93	-0.68	7.57e-47	Chronic sinus infection;
LUSC	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg23173402	chr1:227635558	NA	-0.46	-5.73	-0.3	2.2e-8	Major depressive disorder;
LUSC	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg07148914	chr20:33460835	GGT7	0.43	6.28	0.33	1.04e-9	Coronary artery disease;
LUSC	trans	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.62	0.34	1.39e-10	Resting heart rate;
LUSC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.59	9.24	0.45	3.06e-18	Blood protein levels;
LUSC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.28	-0.37	2.44e-12	Electroencephalogram traits;
LUSC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg21724239	chr8:58056113	NA	0.69	8.86	0.44	4.93e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs250677	0.522	rs12520924	chr5:148349149	C/T	cg18129178	chr5:148520854	ABLIM3	0.54	7.3	0.37	2.16e-12	Breast cancer;
LUSC	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg13575925	chr12:9217583	LOC144571	0.35	6.43	0.33	4.51e-10	Sjögren's syndrome;
LUSC	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.39	-0.46	9.51e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs75920871	0.588	rs7112111	chr11:116980858	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.55	-7.0	-0.36	1.43e-11	Subjective well-being;
LUSC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg04553112	chr3:125709451	NA	-0.5	-5.66	-0.3	3.27e-8	Blood pressure (smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05039583	chr15:75660780	MAN2C1	-0.42	-6.12	-0.32	2.64e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2050392	0.799	rs2907	chr10:30728250	A/G	cg18806716	chr10:30721971	MAP3K8	-0.48	-8.01	-0.4	1.93e-14	Inflammatory bowel disease;
LUSC	cis	rs9905704	0.914	rs34556895	chr17:56826953	G/T	cg12560992	chr17:57184187	TRIM37	0.56	7.89	0.4	4.39e-14	Testicular germ cell tumor;
LUSC	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12292205	chr6:26970375	C6orf41	-0.63	-8.74	-0.43	1.12e-16	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg17845761	chr1:175162550	KIAA0040	-0.31	-6.0	-0.31	5.07e-9	Alcohol dependence;
LUSC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-8.19	-0.41	5.62e-15	Longevity;
LUSC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg19592336	chr6:28129416	ZNF389	0.46	6.01	0.31	4.81e-9	Depression;
LUSC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg18681998	chr4:17616180	MED28	0.88	17.23	0.69	4.87e-48	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3931020	0.657	rs7522428	chr1:75178360	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.63	8.39	0.42	1.43e-15	Resistin levels;
LUSC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-1.09	-22.35	-0.77	2.54e-68	Height;
LUSC	trans	rs7951105	1.000	rs2220444	chr11:39247768	A/G	cg24085930	chr3:21832523	NA	0.5	6.24	0.32	1.33e-9	Free thyroxine concentration;
LUSC	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	6.33	0.33	7.99e-10	Schizophrenia;
LUSC	cis	rs1034435	0.755	rs5768680	chr22:48892919	T/C	cg05992904	chr22:48892994	FAM19A5	-0.41	-8.16	-0.41	6.85e-15	Late-onset Alzheimer's disease;
LUSC	trans	rs877282	0.583	rs11253441	chr10:828288	C/T	cg13042288	chr15:90349979	ANPEP	0.4	6.06	0.31	3.73e-9	Uric acid levels;
LUSC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-7.47	-0.38	6.88e-13	Personality dimensions;
LUSC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg17971929	chr21:40555470	PSMG1	-0.69	-11.31	-0.53	2.42e-25	Cognitive function;
LUSC	trans	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	trans	rs11088226	1.000	rs11701627	chr21:33927794	T/A	cg09050820	chr6:167586206	TCP10L2	0.54	7.19	0.37	4.38e-12	Gastritis;
LUSC	cis	rs13092825	1.000	rs7623311	chr3:113284698	A/C	cg18753928	chr3:113234510	CCDC52	-0.38	-5.65	-0.3	3.45e-8	Dental caries;
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg09033563	chr22:24373618	LOC391322	-0.69	-10.72	-0.51	2.94e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1865721	1.000	rs62089507	chr18:73179019	C/T	cg26385618	chr18:73139727	C18orf62	-0.48	-8.19	-0.41	5.65e-15	Intelligence;
LUSC	trans	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg16660971	chr17:78860029	RPTOR	0.37	6.01	0.31	4.78e-9	Major depressive disorder;
LUSC	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.39	-0.46	9.83e-19	Schizophrenia;
LUSC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg00701064	chr4:6280414	WFS1	0.59	14.2	0.61	3.93e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7712401	0.601	rs13164134	chr5:122337941	T/A	cg19077854	chr5:122220652	SNX24	-0.43	-9.22	-0.45	3.4e-18	Mean platelet volume;
LUSC	cis	rs62400317	0.859	rs58769170	chr6:45298531	C/T	cg18551225	chr6:44695536	NA	-0.45	-7.44	-0.38	8.38e-13	Total body bone mineral density;
LUSC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	0.93	18.06	0.7	2.35e-51	Cognitive function;
LUSC	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg13852791	chr20:30311386	BCL2L1	0.73	8.34	0.42	2.01e-15	Mean corpuscular hemoglobin;
LUSC	trans	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg18187862	chr3:45730750	SACM1L	-0.54	-6.6	-0.34	1.62e-10	Primary sclerosing cholangitis;
LUSC	cis	rs4700695	0.668	rs153393	chr5:65428707	A/G	cg21114390	chr5:65439923	SFRS12	-0.6	-8.22	-0.41	4.44e-15	Facial morphology (factor 19);
LUSC	trans	rs853679	0.567	rs13209596	chr6:28396190	C/A	cg01620082	chr3:125678407	NA	-0.42	-6.27	-0.32	1.13e-9	Depression;
LUSC	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02176678	chr2:219576539	TTLL4	-0.73	-14.0	-0.61	2.25e-35	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.69	10.35	0.49	5.71e-22	Corneal astigmatism;
LUSC	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg26769984	chr7:1090371	C7orf50	0.45	6.76	0.35	6.08e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg08501292	chr6:25962987	TRIM38	0.69	6.56	0.34	2.07e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg27068330	chr11:65405492	SIPA1	-0.46	-5.92	-0.31	7.94e-9	Breast cancer;
LUSC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg15147215	chr3:52552868	STAB1	-0.33	-6.51	-0.34	2.79e-10	Bipolar disorder;
LUSC	cis	rs9929218	0.954	rs9928796	chr16:68820718	A/G	cg02972257	chr16:68554789	NA	0.41	5.73	0.3	2.19e-8	Colorectal cancer;
LUSC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg16362232	chr11:430036	ANO9	0.66	8.17	0.41	6.51e-15	Body mass index;
LUSC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg01475377	chr6:109611718	NA	-0.46	-8.44	-0.42	1e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.79	-0.51	1.71e-23	Chronic sinus infection;
LUSC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg07716408	chr11:68623521	NA	-0.3	-5.66	-0.3	3.2e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs617219	0.787	rs12189006	chr5:78539672	G/T	cg24856658	chr5:78533917	JMY	-0.3	-5.86	-0.31	1.12e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	1.05	17.32	0.69	2.13e-48	Parkinson's disease;
LUSC	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg22508957	chr16:3507546	NAT15	-0.4	-6.18	-0.32	1.92e-9	Body mass index (adult);
LUSC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.59	-0.46	2.18e-19	Chronic sinus infection;
LUSC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.55	-8.29	-0.41	2.7e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs244293	0.965	rs244287	chr17:53232036	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.4	5.78	0.3	1.73e-8	Menarche (age at onset);
LUSC	cis	rs4843185	0.637	rs4143866	chr16:85716366	A/G	cg26571870	chr16:85723150	GINS2	-0.34	-5.97	-0.31	6.08e-9	Platelet distribution width;
LUSC	cis	rs11585357	0.947	rs3003441	chr1:17611869	C/T	cg08277548	chr1:17600880	PADI3	0.63	6.78	0.35	5.57e-11	Hair shape;
LUSC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg09359103	chr1:154839909	KCNN3	-0.69	-15.84	-0.65	1.53e-42	Prostate cancer;
LUSC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg08888203	chr3:10149979	C3orf24	0.59	8.28	0.41	2.93e-15	Alzheimer's disease;
LUSC	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.72	-11.51	-0.53	4.79e-26	Schizophrenia;
LUSC	cis	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg20307385	chr11:47447363	PSMC3	0.52	6.2	0.32	1.71e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	0.76	12.72	0.57	1.71e-30	Cognitive function;
LUSC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg04369109	chr6:150039330	LATS1	0.59	8.76	0.43	9.63e-17	Lung cancer;
LUSC	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg02569458	chr12:86230093	RASSF9	0.54	9.21	0.45	3.78e-18	Major depressive disorder;
LUSC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg11062466	chr8:58055876	NA	0.76	9.09	0.45	9.22e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs3820068	0.608	rs10927836	chr1:16034368	G/C	cg13390004	chr1:15929781	NA	0.42	6.82	0.35	4.38e-11	Systolic blood pressure;
LUSC	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.76e-12	Type 2 diabetes;
LUSC	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg06360820	chr2:242988706	NA	-1.01	-10.85	-0.51	1.11e-23	Obesity-related traits;
LUSC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg10596483	chr8:143751796	JRK	0.61	9.39	0.46	9.87e-19	Schizophrenia;
LUSC	trans	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg04995722	chr7:26192034	NFE2L3	-0.43	-6.64	-0.34	1.24e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.76	-12.82	-0.57	6.92e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs240764	0.717	rs1039032	chr6:101161931	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.09	-0.32	3.03e-9	Neuroticism;
LUSC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-6.86	-0.35	3.25e-11	Tonsillectomy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10314172	chr2:64681735	HSPC159	0.45	6.1	0.32	3e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg16680214	chr1:154839983	KCNN3	-0.52	-9.8	-0.47	4.2e-20	Prostate cancer;
LUSC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-9.39	-0.46	9.41e-19	Bipolar disorder and schizophrenia;
LUSC	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg21775007	chr8:11205619	TDH	-0.54	-7.7	-0.39	1.5700000000000001e-13	Triglycerides;
LUSC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg15848620	chr12:58087721	OS9	-0.54	-7.89	-0.4	4.33e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg12590608	chr7:158785262	NA	0.32	6.07	0.32	3.48e-9	Facial morphology (factor 20);
LUSC	trans	rs12043259	1.000	rs12239961	chr1:204827537	C/A	cg23865240	chr7:27134109	HOXA1	-0.53	-6.01	-0.31	4.8e-9	Addiction;
LUSC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg07424592	chr7:64974309	NA	-0.45	-6.38	-0.33	5.82e-10	Calcium levels;
LUSC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg00945038	chr17:61921165	SMARCD2	0.4	6.14	0.32	2.33e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.62	0.47	1.7e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.39	-5.68	-0.3	2.93e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg19767477	chr5:127420684	SLC12A2	-0.4	-5.74	-0.3	2.12e-8	Ileal carcinoids;
LUSC	trans	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg17567195	chr5:167378696	ODZ2	-0.38	-6.03	-0.31	4.23e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs4073582	1.000	rs801732	chr11:65935502	T/A	cg16950941	chr11:66035639	RAB1B	0.45	5.86	0.31	1.13e-8	Gout;
LUSC	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg18825076	chr15:78729989	IREB2	0.46	6.45	0.33	4.04e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg19812747	chr11:111475976	SIK2	-0.5	-7.05	-0.36	1.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.34	-7.73	-0.39	1.26e-13	Lymphocyte counts;
LUSC	cis	rs72781680	0.752	rs72796110	chr2:23905658	T/A	cg08917208	chr2:24149416	ATAD2B	0.98	9.71	0.47	8.25e-20	Lymphocyte counts;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05109266	chr11:810147	RPLP2	0.77	6.32	0.33	8.36e-10	Cognitive performance;
LUSC	trans	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg25214090	chr10:38739885	LOC399744	-0.43	-6.37	-0.33	6.28e-10	Corneal astigmatism;
LUSC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.23	0.56	1.17e-28	Prudent dietary pattern;
LUSC	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg25930673	chr12:123319894	HIP1R	-0.63	-6.23	-0.32	1.41e-9	Schizophrenia;
LUSC	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-6.51	-0.34	2.77e-10	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	0.89	13.58	0.6	9.2e-34	Pulmonary function decline;
LUSC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg22709100	chr7:91322751	NA	0.4	5.73	0.3	2.29e-8	Breast cancer;
LUSC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg13010199	chr12:38710504	ALG10B	0.57	9.09	0.45	9.21e-18	Morning vs. evening chronotype;
LUSC	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg19767477	chr5:127420684	SLC12A2	-0.43	-5.9	-0.31	8.87e-9	Ileal carcinoids;
LUSC	cis	rs7615316	0.751	rs11925693	chr3:142153453	A/G	cg16271453	chr3:142027066	XRN1	-0.43	-7.42	-0.38	9.9e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs11088226	0.846	rs2833884	chr21:33923075	A/G	cg09050820	chr6:167586206	TCP10L2	0.65	9.88	0.48	2.25e-20	Gastritis;
LUSC	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg12011299	chr4:100065546	ADH4	-0.73	-10.73	-0.51	2.92e-23	Alcohol dependence;
LUSC	cis	rs2481665	1.000	rs2481665	chr1:62594677	T/C	cg18591186	chr1:62594603	INADL	-0.55	-8.78	-0.43	8.62e-17	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg12863693	chr15:85201151	NMB	0.34	6.78	0.35	5.49e-11	Schizophrenia;
LUSC	trans	rs7980799	0.649	rs2389218	chr12:33680929	C/A	cg26384229	chr12:38710491	ALG10B	0.57	8.2	0.41	5.22e-15	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg07424592	chr7:64974309	NA	-0.63	-5.65	-0.3	3.53e-8	Diabetic kidney disease;
LUSC	cis	rs599083	0.590	rs10791984	chr11:68407835	T/G	cg16797656	chr11:68205561	LRP5	-0.4	-7.1	-0.36	7.5e-12	Bone mineral density (spine);
LUSC	cis	rs2692947	0.673	rs3111873	chr2:96781986	G/C	cg23100626	chr2:96804247	ASTL	-0.3	-7.28	-0.37	2.47e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs6484504	0.576	rs208088	chr11:31192686	T/C	cg14844989	chr11:31128820	NA	-0.37	-5.77	-0.3	1.81e-8	Red blood cell count;
LUSC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00166722	chr3:10149974	C3orf24	0.55	7.46	0.38	7.77e-13	Alzheimer's disease;
LUSC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-0.88	-16.71	-0.67	5.44e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1866706	0.896	rs4757957	chr11:12881398	C/G	cg25843174	chr11:12811716	TEAD1	-0.28	-5.93	-0.31	7.65e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2742417	1.000	rs2742389	chr3:45756683	G/C	cg04837898	chr3:45731254	SACM1L	-0.34	-5.73	-0.3	2.26e-8	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2742417	1.000	rs2673065	chr3:45771222	C/T	cg09608765	chr3:45636137	LIMD1	-0.37	-7.39	-0.37	1.17e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg13319975	chr6:146136371	FBXO30	-0.45	-6.52	-0.34	2.59e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.36	-5.82	-0.3	1.41e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.88	0.31	1.02e-8	Lung cancer;
LUSC	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-7.17	-0.37	4.79e-12	Retinal vascular caliber;
LUSC	trans	rs11700980	0.551	rs2251447	chr21:30109202	C/G	cg14791747	chr16:20752902	THUMPD1	0.56	6.1	0.32	2.88e-9	QRS complex (12-leadsum);
LUSC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg25456477	chr12:86230367	RASSF9	0.33	5.8	0.3	1.55e-8	Major depressive disorder;
LUSC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg24531977	chr5:56204891	C5orf35	-0.69	-10.01	-0.48	8.66e-21	Coronary artery disease;
LUSC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg18230493	chr5:56204884	C5orf35	0.66	10.14	0.49	3.04e-21	Coronary artery disease;
LUSC	cis	rs1107366	0.695	rs10934754	chr3:125906237	T/C	cg01346077	chr3:125931526	NA	0.34	6.44	0.33	4.06e-10	Metabolite levels;
LUSC	trans	rs1062753	0.771	rs932376	chr22:42614362	T/C	cg02551029	chr5:82767394	VCAN	-0.4	-6.18	-0.32	1.83e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs2273669	0.667	rs78550764	chr6:109312239	C/T	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg05855489	chr10:104503620	C10orf26	-0.66	-9.42	-0.46	7.63e-19	Arsenic metabolism;
LUSC	cis	rs4660306	0.672	rs534534	chr1:46024701	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.03	-0.31	4.3e-9	Homocysteine levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg21605859	chr18:48723183	MEX3C	-0.42	-6.25	-0.32	1.22e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg23093090	chr10:104574429	C10orf26	-0.36	-6.77	-0.35	5.67e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08677398	chr8:58056175	NA	0.53	6.47	0.33	3.43e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	0.94	17.59	0.69	1.81e-49	Headache;
LUSC	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.7	10.53	0.5	1.36e-22	Smoking initiation;
LUSC	cis	rs1403694	0.695	rs3774291	chr3:186433471	C/T	cg12454167	chr3:186435060	KNG1	0.34	8.42	0.42	1.15e-15	Blood protein levels;
LUSC	cis	rs78707713	0.560	rs61848397	chr10:71225584	C/A	cg12610070	chr10:71211762	TSPAN15	-0.5	-9.42	-0.46	7.88e-19	Venous thromboembolism;
LUSC	cis	rs3935685	0.967	rs62009151	chr15:77999264	C/A	cg25212270	chr15:78015279	NA	0.29	6.4	0.33	5.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7759001	0.817	rs2206250	chr6:27355842	A/C	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	1.97e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.63	-8.5	-0.42	6.54e-16	Multiple sclerosis;
LUSC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg16362232	chr11:430036	ANO9	0.64	8.16	0.41	7.08e-15	Body mass index;
LUSC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg19156104	chr2:198669113	PLCL1	-0.46	-5.66	-0.3	3.3e-8	Ulcerative colitis;
LUSC	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.49	7.07	0.36	8.98e-12	Coronary heart disease;
LUSC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg20203395	chr5:56204925	C5orf35	-0.64	-8.91	-0.44	3.34e-17	Initial pursuit acceleration;
LUSC	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-9.44	-0.46	6.59e-19	Schizophrenia;
LUSC	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg01528321	chr10:82214614	TSPAN14	0.61	9.07	0.44	1.06e-17	Post bronchodilator FEV1;
LUSC	cis	rs12760731	0.565	rs12048698	chr1:178136792	T/C	cg00404053	chr1:178313656	RASAL2	0.68	6.84	0.35	3.78e-11	Obesity-related traits;
LUSC	cis	rs2273669	0.588	rs11153151	chr6:109316754	C/G	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg02503808	chr4:7069936	GRPEL1	0.88	10.52	0.5	1.53e-22	Monocyte percentage of white cells;
LUSC	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs400736	0.602	rs6694154	chr1:8163520	G/A	cg25007680	chr1:8021821	PARK7	-0.45	-6.75	-0.35	6.58e-11	Response to antidepressants and depression;
LUSC	trans	rs1171606	0.738	rs3763747	chr10:61412335	A/G	cg14119616	chr11:17099403	RPS13	-0.41	-5.94	-0.31	6.99e-9	Acylcarnitine levels;
LUSC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg14343924	chr8:8086146	FLJ10661	-0.42	-5.79	-0.3	1.59e-8	Mood instability;
LUSC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.07	-0.4	1.31e-14	Type 2 diabetes;
LUSC	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg19610905	chr11:61596333	FADS2	-0.54	-7.88	-0.4	4.52e-14	Trans fatty acid levels;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg12232778	chr20:56324064	NA	0.49	5.95	0.31	6.7e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg23625390	chr15:77176239	SCAPER	-0.66	-9.91	-0.48	1.79e-20	Blood metabolite levels;
LUSC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg07701084	chr6:150067640	NUP43	0.56	8.43	0.42	1.07e-15	Lung cancer;
LUSC	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg01689657	chr7:91764605	CYP51A1	0.32	5.89	0.31	9.34e-9	Breast cancer;
LUSC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.45	0.53	7.58e-26	Prudent dietary pattern;
LUSC	cis	rs1355223	0.867	rs7925421	chr11:34681677	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-5.65	-0.3	3.53e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.24	-0.37	3.2e-12	Blood metabolite levels;
LUSC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.72	-12.97	-0.58	1.92e-31	Prudent dietary pattern;
LUSC	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.38	-0.42	1.48e-15	Response to antipsychotic treatment;
LUSC	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg19743168	chr1:23544995	NA	0.4	7.69	0.39	1.72e-13	Height;
LUSC	trans	rs2790216	0.526	rs1199093	chr10:59896794	C/G	cg14931586	chr11:85780345	PICALM	-0.35	-6.1	-0.32	2.86e-9	Inflammatory bowel disease;
LUSC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg12311346	chr5:56204834	C5orf35	-0.66	-10.02	-0.48	7.91e-21	Coronary artery disease;
LUSC	trans	rs6429422	0.725	rs2787232	chr1:243306475	G/C	cg25284624	chr1:224180302	NA	0.47	7.36	0.37	1.48e-12	Cognitive ability (multi-trait analysis);
LUSC	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg22777020	chr22:31556080	RNF185	-0.45	-5.79	-0.3	1.6e-8	Colorectal cancer;
LUSC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg06238570	chr21:40685208	BRWD1	-0.55	-8.53	-0.42	5.28e-16	Menarche (age at onset);
LUSC	cis	rs240764	0.658	rs11155637	chr6:101203592	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-6.46	-0.33	3.67e-10	Neuroticism;
LUSC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.3	0.33	9.2e-10	Alzheimer's disease (late onset);
LUSC	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-0.72	-12.31	-0.56	5.78e-29	Gut microbiome composition (winter);
LUSC	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.63	10.03	0.48	7.4e-21	Morning vs. evening chronotype;
LUSC	cis	rs12931792	0.682	rs12373078	chr16:30187676	T/G	cg17640201	chr16:30407289	ZNF48	0.61	9.82	0.47	3.61e-20	Tonsillectomy;
LUSC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg09365446	chr1:150670422	GOLPH3L	0.53	8.27	0.41	3.25e-15	Tonsillectomy;
LUSC	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg02023728	chr11:77925099	USP35	0.45	6.7	0.34	9.1e-11	Testicular germ cell tumor;
LUSC	cis	rs4290604	0.665	rs6761002	chr2:238038873	T/C	cg23555395	chr2:238036564	NA	-0.55	-7.2	-0.37	3.91e-12	Asthma;
LUSC	trans	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg18187862	chr3:45730750	SACM1L	-0.5	-6.18	-0.32	1.82e-9	Primary sclerosing cholangitis;
LUSC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg05941027	chr17:61774174	LIMD2	0.24	6.6	0.34	1.59e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.08	-0.32	3.31e-9	Depression;
LUSC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	0.85	11.14	0.52	1e-24	Glomerular filtration rate (creatinine);
LUSC	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg26876637	chr1:152193138	HRNR	0.46	6.57	0.34	1.89e-10	Atopic dermatitis;
LUSC	cis	rs11608355	0.545	rs11066782	chr12:109910552	C/T	cg05360138	chr12:110035743	NA	0.88	11.29	0.53	2.95e-25	Neuroticism;
LUSC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg18110333	chr6:292329	DUSP22	-0.53	-7.97	-0.4	2.57e-14	Menopause (age at onset);
LUSC	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.11	-0.36	7.29e-12	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs1062746	0.520	rs17770996	chr16:87330207	G/A	cg02258303	chr16:87377426	FBXO31	-0.52	-7.79	-0.39	8.46e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg26039829	chr8:22132926	PIWIL2	-0.43	-8.11	-0.41	1e-14	Hypertriglyceridemia;
LUSC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.18	0.37	4.5e-12	Bipolar disorder;
LUSC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18876405	chr7:65276391	NA	0.54	8.27	0.41	3.22e-15	Aortic root size;
LUSC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg02782426	chr3:40428986	ENTPD3	0.39	7.01	0.36	1.33e-11	Renal cell carcinoma;
LUSC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg10360139	chr7:1886902	MAD1L1	-0.4	-5.96	-0.31	6.3e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg21427119	chr20:30132790	HM13	-0.46	-6.65	-0.34	1.23e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg13395646	chr4:1353034	KIAA1530	-0.67	-11.62	-0.54	1.95e-26	Longevity;
LUSC	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg03929089	chr4:120376271	NA	-0.5	-6.92	-0.35	2.34e-11	HDL cholesterol;
LUSC	cis	rs4356932	1.000	rs8878	chr4:76942300	C/T	cg00809888	chr4:76862425	NAAA	-0.35	-5.73	-0.3	2.29e-8	Blood protein levels;
LUSC	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg14416269	chr4:6271139	WFS1	0.52	10.7	0.51	3.6e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg05872129	chr22:39784769	NA	-0.6	-10.98	-0.51	3.82e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.74	-0.39	1.2e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.0	-0.44	1.74e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	10.27	0.49	1.11e-21	Lymphocyte counts;
LUSC	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg23176270	chr14:23476067	C14orf93	0.37	6.02	0.31	4.68e-9	Cognitive ability (multi-trait analysis);
LUSC	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg10560079	chr2:191398806	TMEM194B	-0.75	-9.1	-0.45	8.61e-18	Diastolic blood pressure;
LUSC	trans	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18876405	chr7:65276391	NA	0.48	6.53	0.34	2.39e-10	Corneal structure;
LUSC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	11.89	0.55	2.01e-27	Prudent dietary pattern;
LUSC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg08244238	chr11:790193	CEND1	0.4	6.9	0.35	2.59e-11	Breast cancer;
LUSC	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-0.93	-17.57	-0.69	2.04e-49	Headache;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09859293	chr2:3605851	RNASEH1	-0.49	-5.99	-0.31	5.49e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.49	-0.42	7e-16	Total cholesterol levels;
LUSC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg11764359	chr7:65958608	NA	0.53	6.79	0.35	5.17e-11	Aortic root size;
LUSC	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg17691542	chr6:26056736	HIST1H1C	0.4	5.9	0.31	9.13e-9	Schizophrenia;
LUSC	cis	rs10465746	0.901	rs17475760	chr1:84398435	A/T	cg10977910	chr1:84465055	TTLL7	0.44	6.42	0.33	4.58e-10	Obesity-related traits;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02278959	chr17:18576472	ZNF286B;FOXO3B	-0.5	-6.1	-0.32	2.89e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	0.65	9.51	0.46	3.84e-19	Methadone dose in opioid dependence;
LUSC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg19622623	chr12:86230825	RASSF9	-0.44	-6.32	-0.33	8.47e-10	Major depressive disorder;
LUSC	cis	rs2274273	0.934	rs10144418	chr14:55817708	T/C	cg04306507	chr14:55594613	LGALS3	0.53	11.47	0.53	6.66e-26	Protein biomarker;
LUSC	cis	rs9807989	0.839	rs4851565	chr2:102971481	C/A	cg03938978	chr2:103052716	IL18RAP	0.32	5.88	0.31	9.76e-9	Asthma;
LUSC	cis	rs11158026	0.757	rs17128120	chr14:55474598	C/T	cg04306507	chr14:55594613	LGALS3	0.37	7.27	0.37	2.57e-12	Parkinson's disease;
LUSC	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.97	-0.36	1.7e-11	Response to antipsychotic treatment;
LUSC	trans	rs12043259	1.000	rs12239394	chr1:204825794	A/C	cg23865240	chr7:27134109	HOXA1	-0.53	-6.01	-0.31	4.8e-9	Addiction;
LUSC	cis	rs4901869	0.932	rs12878445	chr14:59339361	A/G	cg02291164	chr14:59296302	NA	0.58	11.11	0.52	1.33e-24	Panic disorder;
LUSC	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-6.15	-0.32	2.26e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.72	-0.43	1.34e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg13560548	chr3:10150139	C3orf24	0.5	6.84	0.35	3.81e-11	Alzheimer's disease;
LUSC	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg16482183	chr6:26056742	HIST1H1C	0.38	5.64	0.3	3.53e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg00757033	chr12:89920650	WDR51B	0.57	10.03	0.48	7.32e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg05855489	chr10:104503620	C10orf26	-0.52	-8.04	-0.4	1.56e-14	Arsenic metabolism;
LUSC	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.35e-16	Menopause (age at onset);
LUSC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg04733989	chr22:42467013	NAGA	-0.54	-8.57	-0.42	4.01e-16	Schizophrenia;
LUSC	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg05283184	chr6:79620031	NA	-0.57	-11.82	-0.54	3.53e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg23625390	chr15:77176239	SCAPER	0.59	9.22	0.45	3.51e-18	Blood metabolite levels;
LUSC	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	10.31	0.49	7.95e-22	Mean corpuscular hemoglobin;
LUSC	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg24579218	chr15:68104479	NA	-0.37	-6.58	-0.34	1.85e-10	Restless legs syndrome;
LUSC	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg05372495	chr19:1063624	ABCA7	-0.38	-5.93	-0.31	7.65e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.07	0.48	5.41e-21	Lung cancer in ever smokers;
LUSC	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	8.87	0.44	4.39e-17	Height;
LUSC	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg00310523	chr12:86230176	RASSF9	0.47	8.6	0.43	3.1e-16	Major depressive disorder;
LUSC	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg12935359	chr14:103987150	CKB	0.6	9.84	0.47	3.16e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs62380364	0.566	rs1705565	chr5:88048457	C/T	cg22951263	chr5:87985283	NA	-0.47	-7.72	-0.39	1.39e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7210086	0.768	rs4485409	chr17:70640381	C/T	cg04206342	chr17:70636940	NA	-0.34	-5.76	-0.3	1.92e-8	Ulcerative colitis;
LUSC	cis	rs6961069	0.773	rs1761661	chr7:80238041	A/C	cg04458919	chr7:80252533	CD36	-0.38	-6.88	-0.35	2.99e-11	Platelet count;
LUSC	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg23277830	chr1:3704460	LRRC47	0.3	5.8	0.3	1.55e-8	Red cell distribution width;
LUSC	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg24375607	chr4:120327624	NA	0.74	12.02	0.55	6.96e-28	Corneal astigmatism;
LUSC	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg10596483	chr8:143751796	JRK	0.53	7.53	0.38	4.93e-13	Schizophrenia;
LUSC	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.74	-10.42	-0.5	3.49e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg20701182	chr2:24300061	SF3B14	0.58	6.2	0.32	1.71e-9	Lymphocyte counts;
LUSC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg06008330	chr7:65541103	ASL	-0.4	-6.16	-0.32	2.05e-9	Aortic root size;
LUSC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg04455712	chr21:45112962	RRP1B	0.45	8.72	0.43	1.29e-16	Mean corpuscular volume;
LUSC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg15790184	chr11:494944	RNH1	0.55	6.2	0.32	1.67e-9	Body mass index;
LUSC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08859206	chr1:53392774	SCP2	-0.56	-9.52	-0.46	3.53e-19	Monocyte count;
LUSC	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.5	7.57	0.38	3.77e-13	Colorectal cancer;
LUSC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg04518342	chr5:131593106	PDLIM4	0.35	6.32	0.33	8.19e-10	Blood metabolite levels;
LUSC	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.78	-0.35	5.36e-11	Monocyte percentage of white cells;
LUSC	cis	rs472402	0.560	rs2288447	chr5:6626091	C/T	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.4	-5.93	-0.31	7.71e-9	Response to amphetamines;
LUSC	trans	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.57	0.5	1.01e-22	Mean corpuscular volume;
LUSC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	0.94	18.64	0.71	1.19e-53	Menarche (age at onset);
LUSC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg27284194	chr4:1044797	NA	-0.35	-5.68	-0.3	2.93e-8	Obesity-related traits;
LUSC	cis	rs73206853	0.764	rs3026425	chr12:110688168	A/G	cg12870014	chr12:110450643	ANKRD13A	0.7	7.64	0.39	2.37e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4363385	0.667	rs454245	chr1:153031979	A/C	cg25856811	chr1:152973957	SPRR3	0.34	5.67	0.3	3.14e-8	Inflammatory skin disease;
LUSC	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg11062466	chr8:58055876	NA	0.59	7.34	0.37	1.65e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs73129298	0.551	rs16995009	chr20:48602526	T/C	cg25655593	chr20:48599521	SNAI1	0.59	6.3	0.33	9.63e-10	Inflammatory skin disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg04204557	chr21:46065774	KRTAP10-11;C21orf29	0.53	6.57	0.34	1.89e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2227930	0.510	rs6809448	chr3:142353730	A/G	cg16271453	chr3:142027066	XRN1	0.47	8.28	0.41	3.01e-15	Reticulocyte count;Reticulocyte fraction of red cells;
LUSC	cis	rs9815354	0.812	rs73077365	chr3:41851559	T/C	cg03022575	chr3:42003672	ULK4	0.85	8.74	0.43	1.16e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg07148914	chr20:33460835	GGT7	0.51	8.02	0.4	1.77e-14	Glomerular filtration rate (creatinine);
LUSC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg11663144	chr21:46675770	NA	-0.38	-6.44	-0.33	4.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg26102564	chr10:131424627	MGMT	0.36	5.68	0.3	2.97e-8	Response to temozolomide;
LUSC	cis	rs1355223	0.557	rs7936076	chr11:34724672	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-6.15	-0.32	2.24e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg04450456	chr4:17643702	FAM184B	0.38	6.24	0.32	1.34e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-10.4	-0.49	3.82e-22	Morning vs. evening chronotype;
LUSC	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg07862535	chr7:139043722	LUC7L2	0.54	6.75	0.35	6.59e-11	Diisocyanate-induced asthma;
LUSC	cis	rs6982240	0.514	rs11778579	chr8:142261621	C/T	cg00131261	chr8:142287264	NA	-0.36	-6.0	-0.31	5.17e-9	Tonsillectomy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20709868	chr19:12992305	DNASE2	0.47	7.17	0.37	4.95e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-8.85	-0.44	5.25e-17	Obesity-related traits;
LUSC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg21951975	chr1:209979733	IRF6	0.57	8.45	0.42	9.06e-16	Cleft lip with or without cleft palate;
LUSC	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg27661571	chr11:113659931	NA	-0.69	-7.92	-0.4	3.66e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.87	-0.35	3.2e-11	Lung cancer;
LUSC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg11871910	chr12:69753446	YEATS4	0.91	16.98	0.68	4.65e-47	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs4252134	0.764	rs62436704	chr6:161199736	C/T	cg15416064	chr12:49209402	NA	-0.43	-5.96	-0.31	6.39e-9	Giant cell arteritis;
LUSC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.28	0.56	7.31e-29	Prudent dietary pattern;
LUSC	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg01620082	chr3:125678407	NA	-0.76	-7.37	-0.37	1.34e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00149659	chr3:10157352	C3orf10	0.89	12.11	0.55	3.04e-28	Alzheimer's disease;
LUSC	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-0.87	-15.27	-0.64	2.67e-40	Headache;
LUSC	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg20487152	chr13:99095054	FARP1	-0.46	-8.87	-0.44	4.39e-17	Neuroticism;
LUSC	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg23625390	chr15:77176239	SCAPER	-0.66	-10.12	-0.48	3.62e-21	Blood metabolite levels;
LUSC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.96	0.31	6.32e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg18196295	chr10:418757	DIP2C	-0.37	-5.86	-0.31	1.09e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg24250549	chr1:154909240	PMVK	0.64	10.36	0.49	5.26e-22	Prostate cancer;
LUSC	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg13010199	chr12:38710504	ALG10B	0.65	9.93	0.48	1.57e-20	Bladder cancer;
LUSC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7719624	0.756	rs13188659	chr5:135396468	T/A	cg12897067	chr5:135418308	NA	0.4	5.7	0.3	2.63e-8	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg06521331	chr12:34319734	NA	0.43	7.06	0.36	9.56e-12	Morning vs. evening chronotype;
LUSC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg16624210	chr5:671434	TPPP	0.5	6.47	0.33	3.58e-10	Obesity-related traits;
LUSC	cis	rs240768	1.000	rs72949504	chr6:100969648	G/C	cg12253828	chr6:101329408	ASCC3	0.93	6.4	0.33	5.13e-10	Economic and political preferences (immigration/crime);
LUSC	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg07169764	chr2:136633963	MCM6	0.58	7.67	0.39	1.87e-13	Mosquito bite size;
LUSC	cis	rs1858037	0.867	rs9789444	chr2:65569227	T/C	cg08085232	chr2:65598271	SPRED2	-0.4	-5.97	-0.31	6.2e-9	Rheumatoid arthritis;
LUSC	trans	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg13010199	chr12:38710504	ALG10B	-0.4	-5.99	-0.31	5.35e-9	Morning vs. evening chronotype;
LUSC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	8.2	0.41	5.37e-15	Cognitive test performance;
LUSC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-9.8	-0.47	4.27e-20	Gut microbiome composition (summer);
LUSC	cis	rs67696533	0.620	rs911529	chr20:31146939	A/G	cg13636640	chr20:31349939	DNMT3B	0.48	6.6	0.34	1.62e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs662064	0.852	rs2056417	chr1:10581658	G/A	cg20482658	chr1:10539492	PEX14	0.31	6.22	0.32	1.52e-9	Asthma;
LUSC	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	10.57	0.5	9.82e-23	Response to antipsychotic treatment;
LUSC	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.55	7.98	0.4	2.31e-14	Breast cancer;
LUSC	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg05738196	chr6:26577821	NA	0.77	14.7	0.63	4.65e-38	Intelligence (multi-trait analysis);
LUSC	cis	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg27411982	chr8:10470053	RP1L1	0.4	5.97	0.31	6.17e-9	Retinal vascular caliber;
LUSC	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg22532475	chr10:104410764	TRIM8	-0.25	-6.03	-0.31	4.33e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7760535	0.735	rs240974	chr6:111649316	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.77	-0.35	5.94e-11	Metabolic traits;
LUSC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-13.8	-0.6	1.42e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.7	10.4	0.49	3.93e-22	Smoking initiation;
LUSC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg20821713	chr7:1055600	C7orf50	-0.48	-6.54	-0.34	2.34e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg22532475	chr10:104410764	TRIM8	-0.32	-7.09	-0.36	8.12e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg00522288	chr12:125625016	AACS	-0.31	-5.97	-0.31	5.93e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg00310523	chr12:86230176	RASSF9	0.5	9.44	0.46	6.58e-19	Major depressive disorder;
LUSC	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg23887609	chr12:130822674	PIWIL1	0.49	7.33	0.37	1.78e-12	Menopause (age at onset);
LUSC	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg27284194	chr4:1044797	NA	0.58	7.84	0.39	6.31e-14	Recombination rate (females);
LUSC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg18681998	chr4:17616180	MED28	0.85	15.67	0.65	6.85e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.91	15.13	0.64	9.11e-40	Bladder cancer;
LUSC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg04111992	chr7:158790115	NA	-0.44	-6.99	-0.36	1.46e-11	Facial morphology (factor 20);
LUSC	trans	rs62103177	0.535	rs34299914	chr18:77949236	C/A	cg05926928	chr17:57297772	GDPD1	0.86	9.05	0.44	1.24e-17	Opioid sensitivity;
LUSC	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-12.78	-0.57	1.02e-30	Body mass index;
LUSC	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg26408565	chr15:76604113	ETFA	-0.49	-7.74	-0.39	1.19e-13	Blood metabolite levels;
LUSC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.65	-0.39	2.19e-13	Type 2 diabetes;
LUSC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg15448220	chr1:150897856	SETDB1	0.38	5.7	0.3	2.58e-8	Tonsillectomy;
LUSC	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg03522245	chr20:25566470	NINL	0.35	5.67	0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05499262	chr2:222437089	EPHA4	-0.41	-6.12	-0.32	2.65e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.62	-0.34	1.42e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.61	0.34	1.5e-10	Lung cancer;
LUSC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg08270630	chr22:50330655	NA	-0.43	-6.58	-0.34	1.79e-10	Schizophrenia;
LUSC	cis	rs6496044	0.568	rs7176291	chr15:86067398	T/C	cg13263323	chr15:86062960	AKAP13	-0.39	-6.39	-0.33	5.66e-10	Interstitial lung disease;
LUSC	cis	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg21775007	chr8:11205619	TDH	-0.56	-7.53	-0.38	4.65e-13	Neuroticism;
LUSC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	7.47	0.38	7.1e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg06917634	chr15:78832804	PSMA4	0.82	14.69	0.63	4.94e-38	Sudden cardiac arrest;
LUSC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg22963979	chr7:1858916	MAD1L1	-0.56	-8.83	-0.43	6.21e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.36	-7.06	-0.36	9.47e-12	Total body bone mineral density;
LUSC	cis	rs12956009	0.583	rs4331415	chr18:44885048	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.06	0.31	3.6e-9	Educational attainment (years of education);
LUSC	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg26597838	chr10:835615	NA	0.79	9.79	0.47	4.53e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg11266682	chr4:10021025	SLC2A9	0.5	9.25	0.45	2.66e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-1.04	-20.3	-0.74	2.97e-60	Height;
LUSC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg08219700	chr8:58056026	NA	0.51	6.08	0.32	3.25e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg09163369	chr1:210001066	C1orf107	0.58	6.87	0.35	3.15e-11	Orofacial clefts;
LUSC	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg11757124	chr7:157526947	PTPRN2	-0.42	-6.25	-0.32	1.27e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03517284	chr6:25882590	NA	-0.52	-9.87	-0.48	2.47e-20	Blood metabolite levels;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg19131103	chr20:62205648	PRIC285	0.7	6.16	0.32	2.05e-9	Cognitive performance;
LUSC	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg03585969	chr10:35415529	CREM	0.6	8.97	0.44	2.11e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.03	-0.36	1.17e-11	Colorectal cancer;
LUSC	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.04	0.48	6.66e-21	Birth weight;
LUSC	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg09307838	chr4:120376055	NA	0.69	10.21	0.49	1.76e-21	Corneal astigmatism;
LUSC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.1	0.68	1.61e-47	Gut microbiome composition (summer);
LUSC	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	7.34	0.37	1.62e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg13206674	chr6:150067644	NUP43	0.55	8.65	0.43	2.21e-16	Lung cancer;
LUSC	cis	rs977987	0.751	rs56004344	chr16:75474189	T/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.11	-0.36	6.95e-12	Dupuytren's disease;
LUSC	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg08684580	chr7:98029266	BAIAP2L1	0.35	5.7	0.3	2.61e-8	Breast cancer;
LUSC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg12463550	chr7:65579703	CRCP	0.42	6.04	0.31	4.16e-9	Aortic root size;
LUSC	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg25930673	chr12:123319894	HIP1R	-0.67	-6.83	-0.35	4.15e-11	Schizophrenia;
LUSC	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg05187965	chr10:45406764	TMEM72	-0.36	-8.59	-0.43	3.28e-16	Mean corpuscular volume;
LUSC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.27	-0.32	1.11e-9	Menopause (age at onset);
LUSC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg04369109	chr6:150039330	LATS1	-0.57	-8.5	-0.42	6.6e-16	Lung cancer;
LUSC	cis	rs12220238	1.000	rs8255	chr10:75879750	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	7.78	0.39	9.02e-14	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg00677455	chr12:58241039	CTDSP2	0.59	8.39	0.42	1.35e-15	Multiple sclerosis;
LUSC	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg03526776	chr6:41159608	TREML2	0.33	6.19	0.32	1.74e-9	Alzheimer's disease (late onset);
LUSC	cis	rs11264799	0.626	rs12726950	chr1:157575676	A/T	cg18268488	chr1:157545234	FCRL4	0.36	6.44	0.33	4.18e-10	IgA nephropathy;
LUSC	cis	rs899997	0.862	rs8032552	chr15:78971136	T/C	cg04896959	chr15:78267971	NA	-0.43	-8.5	-0.42	6.44e-16	Coronary artery disease or large artery stroke;
LUSC	cis	rs7799006	0.606	rs4721527	chr7:2306655	G/A	cg08027265	chr7:2291960	NA	-0.62	-11.02	-0.52	2.78e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg00677455	chr12:58241039	CTDSP2	0.5	7.49	0.38	6.04e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg09021430	chr5:549028	NA	-0.57	-7.7	-0.39	1.61e-13	Obesity-related traits;
LUSC	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs6066835	1.000	rs6066833	chr20:47354494	G/C	cg18078177	chr20:47281410	PREX1	0.71	6.21	0.32	1.61e-9	Multiple myeloma;
LUSC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg25036284	chr2:26402008	FAM59B	-0.67	-9.69	-0.47	1.02e-19	Gut microbiome composition (summer);
LUSC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg15155738	chr12:121454335	C12orf43	0.41	5.68	0.3	2.92e-8	N-glycan levels;
LUSC	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-8.69	-0.43	1.61e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.15	-0.41	7.43e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg21132104	chr15:45694354	SPATA5L1	0.4	5.94	0.31	7.32e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg05973401	chr12:123451056	ABCB9	0.52	6.42	0.33	4.78e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1403694	0.515	rs1648697	chr3:186449194	A/G	cg12454167	chr3:186435060	KNG1	0.28	7.6	0.38	2.98e-13	Blood protein levels;
LUSC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs10851478	0.872	rs7172906	chr15:49922775	C/G	cg23074453	chr15:44487924	FRMD5	-0.33	-6.1	-0.32	2.9e-9	Oral cavity cancer;
LUSC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg21535247	chr6:8435926	SLC35B3	0.56	8.55	0.42	4.56e-16	Motion sickness;
LUSC	cis	rs9807989	0.801	rs10173193	chr2:102975050	G/A	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.5e-9	Asthma;
LUSC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19748678	chr4:122722346	EXOSC9	0.61	9.21	0.45	3.74e-18	Type 2 diabetes;
LUSC	cis	rs16854884	0.802	rs6783329	chr3:143798454	T/G	cg06585982	chr3:143692056	C3orf58	0.47	6.98	0.36	1.63e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg03806693	chr22:41940476	POLR3H	-0.5	-6.92	-0.35	2.35e-11	Neuroticism;
LUSC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.81	-0.51	1.48e-23	Alzheimer's disease (late onset);
LUSC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg09092052	chr15:45571596	NA	0.45	6.13	0.32	2.51e-9	Glomerular filtration rate;
LUSC	cis	rs6500395	0.775	rs7198145	chr16:48666500	A/C	cg04672837	chr16:48644449	N4BP1	0.45	6.72	0.35	7.95e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg23711669	chr6:146136114	FBXO30	0.78	12.86	0.58	4.98e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17092148	1.000	rs62211612	chr20:33386156	C/T	cg16810054	chr20:33298113	TP53INP2	0.43	6.81	0.35	4.68e-11	Neuroticism;
LUSC	trans	rs1325195	0.520	rs410589	chr1:179232077	A/G	cg11624085	chr17:8464688	MYH10	0.45	6.89	0.35	2.85e-11	IgE grass sensitization;
LUSC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg17845761	chr1:175162550	KIAA0040	0.31	5.94	0.31	7.14e-9	Alcohol dependence;
LUSC	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.48	6.11	0.32	2.81e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg20744362	chr22:50050164	C22orf34	0.37	6.87	0.35	3.14e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.91	0.35	2.46e-11	Retinal vascular caliber;
LUSC	trans	rs9693857	0.553	rs10100760	chr8:9370559	C/T	cg21775007	chr8:11205619	TDH	-0.43	-6.34	-0.33	7.27e-10	Systolic blood pressure;
LUSC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg24642844	chr7:1081250	C7orf50	-0.72	-10.13	-0.48	3.32e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg11764359	chr7:65958608	NA	0.52	6.63	0.34	1.35e-10	Aortic root size;
LUSC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg23630131	chr7:65973040	NA	-0.21	-5.9	-0.31	8.71e-9	Aortic root size;
LUSC	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg00376283	chr12:123451042	ABCB9	0.76	8.36	0.42	1.66e-15	Neutrophil percentage of white cells;
LUSC	cis	rs1707322	0.638	rs1707302	chr1:46600917	A/G	cg06784218	chr1:46089804	CCDC17	-0.36	-6.66	-0.34	1.1e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-17.57	-0.69	2.11e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4363385	0.776	rs3170863	chr1:152944594	C/T	cg07796016	chr1:152779584	LCE1C	-0.45	-6.42	-0.33	4.6e-10	Inflammatory skin disease;
LUSC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg24578937	chr1:2090814	PRKCZ	-0.43	-9.4	-0.46	8.93e-19	Height;
LUSC	cis	rs9436747	0.618	rs1171266	chr1:66003824	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.43	-5.74	-0.3	2.08e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.62	-8.05	-0.4	1.49e-14	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7712401	0.755	rs1870560	chr5:122111210	G/C	cg19077854	chr5:122220652	SNX24	0.35	7.79	0.39	8.8e-14	Mean platelet volume;
LUSC	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21171335	chr12:122356390	WDR66	0.58	8.51	0.42	5.88e-16	Mean corpuscular volume;
LUSC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg19318889	chr4:1322082	MAEA	0.56	9.5	0.46	4.31e-19	Obesity-related traits;
LUSC	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg05373962	chr22:49881684	NA	-0.4	-8.66	-0.43	2.03e-16	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs939574	1.000	rs9989854	chr2:220086280	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.92	-8.42	-0.42	1.09e-15	Platelet distribution width;
LUSC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Parkinson's disease;
LUSC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.38	-0.56	3.24e-29	Rheumatoid arthritis;
LUSC	cis	rs13315871	1.000	rs13096020	chr3:58367771	G/A	cg12435725	chr3:58293450	RPP14	-0.72	-7.16	-0.36	5.13e-12	Cholesterol, total;
LUSC	cis	rs259282	0.538	rs12151311	chr19:33112707	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.74	10.76	0.51	2.24e-23	Schizophrenia;
LUSC	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg19875535	chr5:140030758	IK	-0.55	-9.07	-0.44	1.04e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs977987	0.806	rs11862582	chr16:75431295	T/C	cg04384234	chr16:75411784	CFDP1	-0.41	-6.7	-0.34	9e-11	Dupuytren's disease;
LUSC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg22638593	chr5:131593259	PDLIM4	-0.46	-6.84	-0.35	3.76e-11	Acylcarnitine levels;
LUSC	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg04036182	chr15:45458818	NA	-0.35	-5.97	-0.31	6.02e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	11.73	0.54	7.53e-27	Menarche (age at onset);
LUSC	trans	rs13011075	0.919	rs2241947	chr2:68615395	C/T	cg14221825	chr19:46271408	SIX5	0.45	6.34	0.33	7.62e-10	Mean corpuscular volume;
LUSC	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg12062639	chr20:23401060	NAPB	0.97	8.32	0.41	2.25e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.6	9.19	0.45	4.26e-18	Blood protein levels;
LUSC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg13685833	chr1:53393034	SCP2	0.43	6.38	0.33	5.91e-10	Monocyte count;
LUSC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg10503236	chr1:231470652	EXOC8	0.35	5.65	0.3	3.46e-8	Hemoglobin concentration;
LUSC	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg16482183	chr6:26056742	HIST1H1C	0.63	8.97	0.44	2.11e-17	Iron status biomarkers;
LUSC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg27124370	chr19:33622961	WDR88	-0.51	-7.06	-0.36	9.63e-12	Bone properties (heel);
LUSC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg01802117	chr1:53393560	SCP2	0.38	6.17	0.32	1.97e-9	Monocyte count;
LUSC	cis	rs2273669	0.667	rs10457187	chr6:109336051	G/A	cg05315195	chr6:109294784	ARMC2	-0.53	-5.89	-0.31	9.28e-9	Prostate cancer;
LUSC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg11062466	chr8:58055876	NA	0.47	6.28	0.32	1.07e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs909002	0.800	rs11589306	chr1:32082822	C/G	cg01639898	chr1:32083012	HCRTR1	0.32	7.69	0.39	1.65e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg07701084	chr6:150067640	NUP43	0.5	7.52	0.38	5.19e-13	Lung cancer;
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.69	10.63	0.5	6.38e-23	Lymphocyte counts;
LUSC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	0.89	17.98	0.7	4.87e-51	Metabolite levels;
LUSC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg26335602	chr6:28129616	ZNF389	0.45	5.99	0.31	5.47e-9	Depression;
LUSC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg16606324	chr3:10149918	C3orf24	0.63	8.86	0.44	4.76e-17	Alzheimer's disease;
LUSC	cis	rs9581857	0.547	rs17753121	chr13:28052613	T/C	cg22138327	chr13:27999177	GTF3A	0.77	8.21	0.41	4.96e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg26335602	chr6:28129616	ZNF389	0.44	5.83	0.3	1.31e-8	Depression;
LUSC	cis	rs2952156	1.000	rs4252627	chr17:37868715	C/T	cg20243544	chr17:37824526	PNMT	0.49	6.94	0.36	2.01e-11	Asthma;
LUSC	trans	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg26811252	chr16:29126840	RRN3P2	0.57	9.15	0.45	5.58e-18	Menopause (age at onset);
LUSC	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg17507749	chr15:85114479	UBE2QP1	0.54	6.74	0.35	7.17e-11	Schizophrenia;
LUSC	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.08	-0.36	8.81e-12	Response to antipsychotic treatment;
LUSC	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.78	11.14	0.52	1.05e-24	Corneal astigmatism;
LUSC	cis	rs7011049	1.000	rs72640857	chr8:53839067	T/A	cg26025543	chr8:53854495	NA	0.52	6.3	0.33	9.5e-10	Systolic blood pressure;
LUSC	cis	rs295140	1.000	rs12618057	chr2:201171355	T/C	cg04283868	chr2:201171347	SPATS2L	0.43	6.57	0.34	1.88e-10	QT interval;
LUSC	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg24397884	chr7:158709396	WDR60	-0.77	-12.12	-0.55	2.77e-28	Height;
LUSC	cis	rs983392	0.776	rs2278867	chr11:59943109	A/T	cg20284999	chr11:59952153	MS4A6A	-0.38	-6.28	-0.32	1.07e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6429082	0.818	rs704706	chr1:235614378	G/A	cg26050004	chr1:235667680	B3GALNT2	0.63	8.57	0.42	3.88e-16	Adiposity;
LUSC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg13393036	chr8:95962371	TP53INP1	-0.48	-10.43	-0.5	3.08e-22	Type 2 diabetes;
LUSC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.58	9.4	0.46	9.25e-19	Vitiligo;
LUSC	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg05347473	chr6:146136440	FBXO30	0.39	6.55	0.34	2.19e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg01879757	chr17:41196368	BRCA1	-0.49	-7.99	-0.4	2.21e-14	Menopause (age at onset);
LUSC	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg12826209	chr6:26865740	GUSBL1	0.68	7.57	0.38	3.63e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06636551	chr8:101224915	SPAG1	-0.45	-8.26	-0.41	3.54e-15	Atrioventricular conduction;
LUSC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg23791538	chr6:167370224	RNASET2	-0.42	-6.55	-0.34	2.15e-10	Crohn's disease;
LUSC	cis	rs12973672	1.000	rs10405246	chr19:35768949	A/G	cg12095397	chr19:35769544	USF2	0.44	6.91	0.35	2.42e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg06937882	chr20:24974362	C20orf3	-0.44	-7.66	-0.39	1.97e-13	Blood protein levels;
LUSC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg23711669	chr6:146136114	FBXO30	0.81	14.85	0.63	1.16e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.6	0.57	4.77e-30	Motion sickness;
LUSC	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-10.46	-0.5	2.51e-22	Eye color traits;
LUSC	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg16447950	chr5:562315	NA	-0.48	-6.55	-0.34	2.23e-10	Obesity-related traits;
LUSC	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg25173405	chr17:45401733	C17orf57	0.41	5.91	0.31	8.48e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg22166914	chr1:53195759	ZYG11B	-0.61	-10.16	-0.49	2.54e-21	Monocyte count;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg25103766	chr1:120838445	FAM72B	-0.46	-6.1	-0.32	2.95e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg08470875	chr2:26401718	FAM59B	0.66	8.3	0.41	2.55e-15	Gut microbiome composition (summer);
LUSC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg07701084	chr6:150067640	NUP43	0.56	8.37	0.42	1.65e-15	Lung cancer;
LUSC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg18230493	chr5:56204884	C5orf35	-0.58	-9.22	-0.45	3.55e-18	Coronary artery disease;
LUSC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg25036284	chr2:26402008	FAM59B	0.77	10.92	0.51	5.98e-24	Gut microbiome composition (summer);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22345911	chr17:80231263	CSNK1D	-0.39	-7.4	-0.38	1.1e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg13397359	chr6:42928475	GNMT	0.44	5.72	0.3	2.4e-8	Blood protein levels;
LUSC	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg01420254	chr6:26195488	NA	0.65	6.99	0.36	1.54e-11	Gout;Renal underexcretion gout;
LUSC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg07424592	chr7:64974309	NA	0.66	5.82	0.3	1.38e-8	Diabetic kidney disease;
LUSC	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg03342759	chr3:160939853	NMD3	-0.43	-6.29	-0.33	9.75e-10	Parkinson's disease;
LUSC	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg01420254	chr6:26195488	NA	0.64	6.99	0.36	1.53e-11	Gout;Renal underexcretion gout;
LUSC	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg20744362	chr22:50050164	C22orf34	0.39	7.13	0.36	6.39e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg23601095	chr6:26197514	HIST1H3D	0.69	7.46	0.38	7.54e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.85	-0.47	2.99e-20	Hemoglobin concentration;
LUSC	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg03948781	chr1:205179583	DSTYK	-0.3	-5.82	-0.3	1.4e-8	Red blood cell count;
LUSC	cis	rs7605827	0.930	rs4140713	chr2:15536128	C/T	cg19274914	chr2:15703543	NA	0.46	9.03	0.44	1.45e-17	Educational attainment (years of education);
LUSC	trans	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg06521331	chr12:34319734	NA	-0.4	-6.21	-0.32	1.54e-9	Morning vs. evening chronotype;
LUSC	cis	rs6546550	0.935	rs2872075	chr2:70068635	G/T	cg02498382	chr2:70120550	SNRNP27	-0.27	-6.38	-0.33	5.95e-10	Prevalent atrial fibrillation;
LUSC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg18681998	chr4:17616180	MED28	0.81	13.56	0.6	1.11e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	10.87	0.51	9.31e-24	Tonsillectomy;
LUSC	cis	rs3126085	1.000	rs11485508	chr1:152253167	T/G	cg26876637	chr1:152193138	HRNR	0.46	6.38	0.33	6.03e-10	Atopic dermatitis;
LUSC	cis	rs983392	0.679	rs603648	chr11:60012673	A/T	cg02771260	chr11:59836817	MS4A3	0.37	6.15	0.32	2.16e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg16576597	chr16:28551801	NUPR1	0.28	5.65	0.3	3.52e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg21775007	chr8:11205619	TDH	0.54	7.51	0.38	5.35e-13	Monocyte count;
LUSC	cis	rs57502260	0.680	rs55654976	chr11:68393541	C/T	cg20283391	chr11:68216788	NA	-0.65	-6.03	-0.31	4.36e-9	Total body bone mineral density (age 45-60);
LUSC	cis	rs12928939	0.815	rs12448022	chr16:71724369	T/C	cg08717414	chr16:71523259	ZNF19	-0.41	-5.78	-0.3	1.71e-8	Post bronchodilator FEV1;
LUSC	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.35	-5.79	-0.3	1.63e-8	Reticulocyte count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23430742	chr12:120907701	DYNLL1;SFRS9	-0.43	-6.4	-0.33	5.41e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg17075019	chr10:79541650	NA	-0.76	-12.15	-0.55	2.21e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22481344	chr6:144607497	NA	-0.39	-6.1	-0.32	2.88e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-1.05	-16.41	-0.67	8.79e-45	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg03585969	chr10:35415529	CREM	0.64	9.13	0.45	6.76e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10489202	1.000	rs17485889	chr1:168018840	G/T	cg24449463	chr1:168025552	DCAF6	-0.56	-7.04	-0.36	1.08e-11	Schizophrenia;
LUSC	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg07211511	chr3:129823064	LOC729375	-1.24	-20.13	-0.74	1.47e-59	Blood pressure (smoking interaction);
LUSC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	1.03	19.23	0.72	5.24e-56	Menopause (age at onset);
LUSC	cis	rs7202877	0.656	rs4887812	chr16:75310052	G/A	cg04384234	chr16:75411784	CFDP1	-0.65	-8.65	-0.43	2.26e-16	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-0.9	-16.03	-0.66	2.7e-43	Height;
LUSC	cis	rs10740039	0.804	rs2028563	chr10:62436897	C/T	cg18175470	chr10:62150864	ANK3	0.48	7.26	0.37	2.71e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6087990	0.966	rs1883730	chr20:31337487	T/A	cg13636640	chr20:31349939	DNMT3B	1.03	24.07	0.8	5.89e-75	Ulcerative colitis;
LUSC	cis	rs9462027	0.628	rs9296127	chr6:34719628	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.92	-0.31	7.98e-9	Systemic lupus erythematosus;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11403890	chr1:41708077	SCMH1	-0.42	-6.27	-0.32	1.11e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4308124	0.708	rs61358692	chr2:111965159	T/C	cg04571233	chr2:111982156	NA	-0.51	-6.6	-0.34	1.62e-10	Vitiligo;
LUSC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	6.61	0.34	1.52e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.51	7.96	0.4	2.65e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg20129853	chr10:51489980	NA	-0.35	-7.0	-0.36	1.41e-11	Prostate-specific antigen levels;
LUSC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	11.21	0.52	5.59e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg07148914	chr20:33460835	GGT7	-0.56	-8.54	-0.42	4.68e-16	Glomerular filtration rate (creatinine);
LUSC	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18854424	chr1:2615690	NA	-0.49	-9.82	-0.47	3.55e-20	Ulcerative colitis;
LUSC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg15445000	chr17:37608096	MED1	0.39	6.71	0.34	8.49e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg04586622	chr2:25135609	ADCY3	0.38	7.71	0.39	1.45e-13	Body mass index in non-asthmatics;
LUSC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg07395648	chr5:131743802	NA	0.38	5.8	0.3	1.52e-8	Asthma (sex interaction);
LUSC	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17467752	chr17:38218738	THRA	0.77	12.44	0.56	1.94e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg21285383	chr16:89894308	SPIRE2	0.34	7.29	0.37	2.24e-12	Vitiligo;
LUSC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	9.78	0.47	4.85e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6546537	0.840	rs34743816	chr2:69813345	A/C	cg10773587	chr2:69614142	GFPT1	-0.52	-8.12	-0.41	9.36e-15	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs4285028	0.699	rs2689290	chr3:121585146	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.75	-10.59	-0.5	8.94e-23	Multiple sclerosis;
LUSC	cis	rs7215564	0.908	rs35646299	chr17:78653506	T/G	cg23238734	chr17:78661607	RPTOR	0.49	6.28	0.32	1.08e-9	Myopia (pathological);
LUSC	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg22508957	chr16:3507546	NAT15	-0.38	-6.14	-0.32	2.41e-9	Body mass index (adult);
LUSC	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg01338084	chr22:32026380	PISD	1.0	7.04	0.36	1.08e-11	Age-related hearing impairment;
LUSC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03934478	chr11:495069	RNH1	0.91	10.47	0.5	2.32e-22	Body mass index;
LUSC	cis	rs11168618	0.626	rs11514105	chr12:48820934	G/C	cg24011408	chr12:48396354	COL2A1	0.41	6.5	0.34	2.85e-10	Adiponectin levels;
LUSC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg04369109	chr6:150039330	LATS1	-0.55	-8.11	-0.41	9.41e-15	Lung cancer;
LUSC	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg05373962	chr22:49881684	NA	-0.41	-10.1	-0.48	4.19e-21	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs925550	0.592	rs1026157	chr4:123623893	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.52	6.89	0.35	2.78e-11	Primary biliary cholangitis;
LUSC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20135002	chr11:47629003	NA	-0.48	-7.57	-0.38	3.61e-13	Subjective well-being;
LUSC	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-7.05	-0.36	1.06e-11	Blood metabolite levels;
LUSC	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg21466736	chr12:48725269	NA	-0.33	-5.74	-0.3	2.16e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs509477	0.718	rs273342	chr18:32604956	G/A	cg23791764	chr18:32556832	MAPRE2	0.4	5.79	0.3	1.65e-8	Cerebrospinal fluid AB1-42 levels;
LUSC	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg16339924	chr4:17578868	LAP3	-0.52	-7.51	-0.38	5.41e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg17971929	chr21:40555470	PSMG1	-0.5	-7.4	-0.38	1.08e-12	Menarche (age at onset);
LUSC	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.52	6.11	0.32	2.77e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg18478394	chr8:109455254	TTC35	0.41	6.33	0.33	7.89e-10	Dupuytren's disease;
LUSC	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg18825119	chr6:163149453	PACRG;PARK2	-0.36	-6.42	-0.33	4.7e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	6.28	0.32	1.08e-9	Tonsillectomy;
LUSC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg16797656	chr11:68205561	LRP5	0.36	6.1	0.32	2.96e-9	Total body bone mineral density;
LUSC	cis	rs708547	0.874	rs781551	chr4:57718406	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.58	-7.03	-0.36	1.15e-11	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg03146154	chr1:46216737	IPP	0.54	8.24	0.41	4e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7191700	1.000	rs7191700	chr16:11406803	C/T	cg00044050	chr16:11439710	C16orf75	0.59	8.78	0.43	8.9e-17	Multiple sclerosis;
LUSC	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05901451	chr6:126070800	HEY2	-0.76	-12.99	-0.58	1.61e-31	Brugada syndrome;
LUSC	cis	rs9925964	0.967	rs12716981	chr16:31118024	C/A	cg02466173	chr16:30829666	NA	0.33	6.05	0.31	3.89e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-7.7	-0.39	1.58e-13	Schizophrenia;
LUSC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-7.2	-0.37	3.89e-12	Menarche (age at onset);
LUSC	cis	rs612683	0.602	rs12565245	chr1:101019326	T/G	cg09408571	chr1:101003634	GPR88	0.31	5.88	0.31	1.01e-8	Breast cancer;
LUSC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-11.06	-0.52	1.88e-24	Chronic sinus infection;
LUSC	trans	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg07393940	chr7:158741817	NA	0.36	6.49	0.33	3.02e-10	Life satisfaction;
LUSC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg17173187	chr15:85201210	NMB	0.37	6.57	0.34	1.96e-10	Schizophrenia;
LUSC	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg06138931	chr13:21896616	NA	0.4	6.81	0.35	4.65e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	trans	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg20935933	chr6:143382018	AIG1	0.5	7.32	0.37	1.92e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.5	-6.03	-0.31	4.42e-9	Crohn's disease;
LUSC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg10792982	chr14:105748885	BRF1	0.45	8.08	0.4	1.2e-14	Platelet count;
LUSC	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg21609526	chr1:3105151	PRDM16	-0.31	-6.19	-0.32	1.73e-9	Migraine;
LUSC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg20243544	chr17:37824526	PNMT	0.52	7.4	0.38	1.12e-12	Asthma;
LUSC	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg24375607	chr4:120327624	NA	0.66	10.52	0.5	1.48e-22	Corneal astigmatism;
LUSC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.92e-10	Life satisfaction;
LUSC	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg04865166	chr7:105162814	PUS7	0.51	5.7	0.3	2.65e-8	Bipolar disorder (body mass index interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15249164	chr21:35288186	ATP5O	-0.52	-6.03	-0.31	4.26e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6076065	0.723	rs743023	chr20:23400852	T/C	cg11657817	chr20:23433608	CST11	0.42	7.45	0.38	7.98e-13	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg14500267	chr11:67383377	NA	-0.32	-5.81	-0.3	1.42e-8	Mean corpuscular volume;
LUSC	cis	rs72480748	0.509	rs3865457	chr19:41398969	C/T	cg14550611	chr19:41354682	CYP2A6	0.4	6.84	0.35	3.88e-11	Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LUSC	cis	rs7241530	0.636	rs66549018	chr18:75904099	C/A	cg14642773	chr18:75888474	NA	0.39	6.02	0.31	4.59e-9	Educational attainment (years of education);
LUSC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg20203395	chr5:56204925	C5orf35	-0.58	-8.14	-0.41	7.93e-15	Initial pursuit acceleration;
LUSC	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg04508216	chr1:11107452	MASP2	0.31	5.67	0.3	3.17e-8	Body mass index;
LUSC	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg24531977	chr5:56204891	C5orf35	-0.67	-9.76	-0.47	5.87e-20	Coronary artery disease;
LUSC	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg19682013	chr15:45996608	NA	0.38	5.88	0.31	1.02e-8	Waist circumference;Weight;
LUSC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.56	7.81	0.39	7.3e-14	Gut microbiome composition (summer);
LUSC	cis	rs2357013	0.752	rs4672085	chr2:53154899	G/A	cg07782112	chr2:53107842	NA	-0.41	-6.36	-0.33	6.66e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-8.92	-0.44	3.19e-17	Monocyte count;
LUSC	cis	rs1712517	0.771	rs11191645	chr10:105059308	G/T	cg05636881	chr10:105038444	INA	0.39	6.42	0.33	4.73e-10	Migraine;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	ch.8.1736467F	chr8:84114645	NA	0.44	6.39	0.33	5.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs73206853	0.764	rs7960705	chr12:111084540	G/A	cg12870014	chr12:110450643	ANKRD13A	0.7	7.69	0.39	1.68e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg04586622	chr2:25135609	ADCY3	0.4	8.37	0.42	1.58e-15	Body mass index in non-asthmatics;
LUSC	cis	rs662064	0.962	rs668805	chr1:10544547	A/G	cg20482658	chr1:10539492	PEX14	0.33	7.01	0.36	1.3e-11	Asthma;
LUSC	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg00745463	chr17:30367425	LRRC37B	-0.76	-8.58	-0.43	3.6e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06112835	chr11:68658793	MRPL21	0.52	7.81	0.39	7.23e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06636551	chr8:101224915	SPAG1	-0.44	-8.03	-0.4	1.63e-14	Atrioventricular conduction;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08693705	chr5:179719171	MAPK9	-0.43	-6.3	-0.33	9.23e-10	Electrocardiographic conduction measures;
LUSC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.95	0.7	6.41e-51	Chronic sinus infection;
LUSC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06221963	chr1:154839813	KCNN3	-0.65	-15.56	-0.65	1.89e-41	Prostate cancer;
LUSC	cis	rs714027	1.000	rs5763821	chr22:30549071	A/C	cg11564601	chr22:30592435	NA	-0.36	-6.61	-0.34	1.49e-10	Lymphocyte counts;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22507989	chr22:21356069	FLJ39582;THAP7	-0.38	-6.2	-0.32	1.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg05855489	chr10:104503620	C10orf26	0.53	8.01	0.4	1.98e-14	Arsenic metabolism;
LUSC	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg24634471	chr8:143751801	JRK	0.51	7.23	0.37	3.23e-12	Schizophrenia;
LUSC	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.08	-0.48	4.71e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs368755101	1	rs368755101	chr2:100762215	AG/A	cg07810366	chr2:100720526	AFF3	-0.47	-7.87	-0.4	4.93e-14	Plateletcrit;Red blood cell count;
LUSC	cis	rs7945718	0.967	rs12291695	chr11:12795662	A/G	cg25843174	chr11:12811716	TEAD1	-0.34	-6.9	-0.35	2.57e-11	Educational attainment (years of education);
LUSC	trans	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg25482853	chr8:67687455	SGK3	1.02	16.18	0.66	6.92e-44	Obesity-related traits;
LUSC	cis	rs10489202	1.000	rs66950781	chr1:168018779	C/A	cg24449463	chr1:168025552	DCAF6	-0.6	-7.54	-0.38	4.36e-13	Schizophrenia;
LUSC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.84	-16.83	-0.68	1.88e-46	Prudent dietary pattern;
LUSC	cis	rs2976388	0.625	rs2257840	chr8:143809193	C/T	cg17252645	chr8:143867129	LY6D	0.38	6.59	0.34	1.76e-10	Urinary tract infection frequency;
LUSC	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg18232548	chr7:50535776	DDC	-0.54	-7.54	-0.38	4.37e-13	Malaria;
LUSC	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg23260525	chr10:116636907	FAM160B1	0.43	9.21	0.45	3.72e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg08470875	chr2:26401718	FAM59B	0.69	8.92	0.44	3.02e-17	Gut microbiome composition (summer);
LUSC	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Educational attainment;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07540722	chr2:70056697	GMCL1	-0.4	-6.09	-0.32	3.05e-9	Electrocardiographic conduction measures;
LUSC	trans	rs72674100	1.000	rs72880598	chr4:97988599	A/G	cg09670535	chr1:18959427	PAX7	-0.56	-6.01	-0.31	4.76e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs204247	0.565	rs411094	chr6:13718264	C/A	cg07534331	chr6:13574296	SIRT5	0.42	5.72	0.3	2.37e-8	Breast cancer;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg01994308	chr8:57122990	PLAG1;CHCHD7	0.35	6.34	0.33	7.54e-10	Schizophrenia;
LUSC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00149659	chr3:10157352	C3orf10	0.92	12.88	0.58	4.25e-31	Alzheimer's disease;
LUSC	trans	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07923666	chr12:49932857	KCNH3	-0.5	-6.41	-0.33	5.08e-10	Resting heart rate;
LUSC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	1.0	19.61	0.73	1.66e-57	Menopause (age at onset);
LUSC	cis	rs2219968	1.000	rs16939594	chr8:78969920	T/A	cg00738934	chr8:78996279	NA	0.34	6.2	0.32	1.62e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg00701064	chr4:6280414	WFS1	0.58	14.33	0.62	1.25e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1538970	0.924	rs4660851	chr1:45843810	A/T	cg05343316	chr1:45956843	TESK2	0.6	8.49	0.42	7.07e-16	Platelet count;
LUSC	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg05340658	chr4:99064831	C4orf37	0.66	10.86	0.51	9.9899999999999993e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-7.11	-0.36	6.89e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg00509249	chr6:109615579	CCDC162	-0.32	-5.87	-0.31	1.03e-8	Reticulocyte fraction of red cells;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg13807970	chr2:145274441	ZEB2	0.43	6.1	0.32	2.9e-9	Mosquito bite size;
LUSC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg01238044	chr22:24384105	GSTT1	-0.73	-12.52	-0.57	9.58e-30	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.47	-0.73	5.98e-57	Height;
LUSC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg13072238	chr3:49761600	GMPPB	-0.36	-5.85	-0.3	1.16e-8	Body mass index;
LUSC	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg26597838	chr10:835615	NA	0.57	7.44	0.38	8.8e-13	Eosinophil percentage of granulocytes;
LUSC	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg01028140	chr2:1542097	TPO	-0.61	-8.06	-0.4	1.36e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-7.36	-0.37	1.46e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg18225595	chr11:63971243	STIP1	-0.48	-7.75	-0.39	1.1e-13	Platelet count;
LUSC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.52	-6.96	-0.36	1.78e-11	Renal function-related traits (BUN);
LUSC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg12560992	chr17:57184187	TRIM37	0.84	15.48	0.65	3.82e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg15445000	chr17:37608096	MED1	0.4	6.77	0.35	5.85e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg25566285	chr7:158114605	PTPRN2	0.31	5.85	0.3	1.2e-8	Calcium levels;
LUSC	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg08917208	chr2:24149416	ATAD2B	0.87	9.86	0.47	2.6e-20	Lymphocyte counts;
LUSC	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg23933602	chr10:16859644	RSU1	0.59	6.92	0.35	2.36e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg13390004	chr1:15929781	NA	0.43	7.27	0.37	2.61e-12	Systolic blood pressure;
LUSC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg03233332	chr7:66118400	NA	-0.43	-6.18	-0.32	1.85e-9	Aortic root size;
LUSC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg00800038	chr16:89945340	TCF25	-0.75	-6.64	-0.34	1.26e-10	Skin colour saturation;
LUSC	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg04733989	chr22:42467013	NAGA	-0.4	-6.52	-0.34	2.63e-10	Cognitive function;
LUSC	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg26441486	chr22:50317300	CRELD2	0.48	7.15	0.36	5.66e-12	Schizophrenia;
LUSC	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg11473876	chr11:109292803	C11orf87	0.41	6.58	0.34	1.82e-10	Schizophrenia;
LUSC	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg19743168	chr1:23544995	NA	0.43	9.3	0.45	1.9e-18	Height;
LUSC	cis	rs12928939	0.815	rs34731378	chr16:71745748	C/T	cg03805757	chr16:71968109	PKD1L3	-0.39	-5.7	-0.3	2.61e-8	Post bronchodilator FEV1;
LUSC	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg09307838	chr4:120376055	NA	0.53	7.92	0.4	3.59e-14	Diastolic blood pressure;
LUSC	trans	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.4	-0.38	1.1e-12	Breast cancer;
LUSC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.66	-9.42	-0.46	7.42e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.84	-15.61	-0.65	1.18e-41	Longevity;
LUSC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg06494592	chr3:125709126	NA	-0.51	-6.21	-0.32	1.55e-9	Blood pressure (smoking interaction);
LUSC	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg23625390	chr15:77176239	SCAPER	-0.66	-9.75	-0.47	6.09e-20	Blood metabolite levels;
LUSC	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg05925327	chr15:68127851	NA	0.33	5.88	0.31	9.84e-9	Restless legs syndrome;
LUSC	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-6.43	-0.33	4.45e-10	Fear of minor pain;
LUSC	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg16576597	chr16:28551801	NUPR1	0.34	6.88	0.35	2.97e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs939574	1.000	rs1109866	chr2:220083279	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.94	-8.06	-0.4	1.42e-14	Platelet distribution width;
LUSC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-7.24	-0.37	3.19e-12	Chronic sinus infection;
LUSC	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg12620499	chr2:216877984	MREG	0.69	11.06	0.52	1.91e-24	Alcohol dependence;
LUSC	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg18825076	chr15:78729989	IREB2	-0.5	-7.86	-0.39	5.49e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs427941	0.632	rs382228	chr7:101786064	A/C	cg06246474	chr7:101738831	CUX1	0.38	6.24	0.32	1.32e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs7180079	0.620	rs12903003	chr15:64711986	A/G	cg08069370	chr15:64387884	SNX1	0.51	5.64	0.3	3.55e-8	Monocyte count;
LUSC	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg25024717	chr12:54324583	NA	-0.39	-6.74	-0.35	6.93e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg12927641	chr6:109611667	NA	0.43	7.48	0.38	6.44e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg21827317	chr3:136751795	NA	0.38	6.86	0.35	3.34e-11	Neuroticism;
LUSC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg06096015	chr1:231504339	EGLN1	0.54	9.34	0.46	1.39e-18	Hemoglobin concentration;
LUSC	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg06718696	chr17:78121285	EIF4A3	0.45	6.38	0.33	5.87e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs10423674	0.526	rs12462498	chr19:18832950	A/G	cg14292368	chr19:18793705	CRTC1	0.44	6.94	0.35	2.08e-11	Menarche (age at onset);
LUSC	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-9.38	-0.46	1.06e-18	Neuroticism;
LUSC	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg13010199	chr12:38710504	ALG10B	0.56	8.62	0.43	2.81e-16	Morning vs. evening chronotype;
LUSC	cis	rs75920871	0.588	rs721783	chr11:116907449	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-6.59	-0.34	1.69e-10	Subjective well-being;
LUSC	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg20991723	chr1:152506922	NA	0.51	9.64	0.47	1.51e-19	Hair morphology;
LUSC	cis	rs2548003	0.541	rs1895416	chr5:28754530	A/T	cg22863700	chr5:28928346	NA	0.42	5.72	0.3	2.36e-8	Hip geometry;
LUSC	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-7.07	-0.36	8.85e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg18721089	chr20:30220636	NA	0.31	5.65	0.3	3.47e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	11.21	0.52	5.67e-25	Nonalcoholic fatty liver disease;
LUSC	cis	rs17014483	0.749	rs3017902	chr4:89638082	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.68	5.97	0.31	5.92e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.58	9.62	0.47	1.68e-19	Breast cancer;
LUSC	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.66	-10.27	-0.49	1.11e-21	Morning vs. evening chronotype;
LUSC	cis	rs17095355	1.000	rs55728195	chr10:111715599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.63	-7.93	-0.4	3.36e-14	Biliary atresia;
LUSC	trans	rs9467603	0.925	rs6456701	chr6:25774130	C/T	cg06606381	chr12:133084897	FBRSL1	0.59	5.95	0.31	6.9e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg05855489	chr10:104503620	C10orf26	0.49	7.41	0.38	1.05e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg03388025	chr16:89894329	SPIRE2	0.36	7.53	0.38	4.78e-13	Vitiligo;
LUSC	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-0.95	-20.47	-0.75	6.48e-61	Ulcerative colitis;
LUSC	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg03983476	chr2:10830698	NOL10	0.38	5.79	0.3	1.61e-8	Prostate cancer;
LUSC	cis	rs7267979	0.586	rs1007707	chr20:25190598	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.66	0.34	1.11e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg27411982	chr8:10470053	RP1L1	0.39	6.24	0.32	1.34e-9	Mood instability;
LUSC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.98	0.4	2.38e-14	Parkinson's disease;
LUSC	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg04365224	chr3:72788183	NA	-0.49	-5.94	-0.31	7.13e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg01966878	chr4:90757139	SNCA	-0.42	-5.96	-0.31	6.24e-9	Neuroticism;
LUSC	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-1.01	-14.4	-0.62	6.88e-37	Exhaled nitric oxide output;
LUSC	cis	rs1335645	0.570	rs6662965	chr1:111642226	C/A	cg00321911	chr1:111669324	DRAM2	-0.59	-6.23	-0.32	1.39e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg09904177	chr6:26538194	HMGN4	0.66	12.02	0.55	6.77e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs617219	0.819	rs7711939	chr5:78599519	T/C	cg24856658	chr5:78533917	JMY	0.3	5.93	0.31	7.68e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs5758511	0.773	rs8140869	chr22:42344297	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.46	5.77	0.3	1.79e-8	Birth weight;
LUSC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg08875078	chr22:50639485	SELO	0.44	6.19	0.32	1.77e-9	Obesity-related traits;
LUSC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg20283391	chr11:68216788	NA	-0.58	-8.16	-0.41	6.89e-15	Total body bone mineral density;
LUSC	trans	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg21775007	chr8:11205619	TDH	-0.42	-5.99	-0.31	5.4e-9	Joint mobility (Beighton score);
LUSC	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg17294928	chr15:75287854	SCAMP5	-0.92	-13.07	-0.58	8.12e-32	Blood trace element (Zn levels);
LUSC	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.36	0.46	1.21e-18	Coffee consumption (cups per day);
LUSC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg13607699	chr17:42295918	UBTF	-0.79	-15.17	-0.64	6.39e-40	Total body bone mineral density;
LUSC	cis	rs3784262	1.000	rs11855259	chr15:58249377	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.34	-6.2	-0.32	1.68e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg18230493	chr5:56204884	C5orf35	-0.58	-9.31	-0.45	1.72e-18	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg07703079	chr11:430292	ANO9	0.61	6.64	0.34	1.26e-10	Body mass index;
LUSC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06022373	chr22:39101656	GTPBP1	0.77	11.95	0.55	1.22e-27	Menopause (age at onset);
LUSC	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg02466173	chr16:30829666	NA	-0.69	-16.41	-0.67	8.62e-45	Dementia with Lewy bodies;
LUSC	cis	rs372883	0.901	rs13048365	chr21:30740394	T/C	cg08807101	chr21:30365312	RNF160	0.43	6.36	0.33	6.8e-10	Pancreatic cancer;
LUSC	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg02569458	chr12:86230093	RASSF9	0.48	7.72	0.39	1.41e-13	Major depressive disorder;
LUSC	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-11.39	-0.53	1.24e-25	Coronary artery disease;
LUSC	cis	rs4654899	0.929	rs7515845	chr1:21314455	G/A	cg01072550	chr1:21505969	NA	-0.56	-8.5	-0.42	6.28e-16	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9420	0.961	rs7936998	chr11:57639017	G/A	cg02958346	chr11:57425731	CLP1	-0.44	-6.33	-0.33	8.01e-10	Schizophrenia;
LUSC	cis	rs4919694	0.611	rs75182663	chr10:105058104	A/G	cg04362960	chr10:104952993	NT5C2	1.04	10.73	0.51	2.73e-23	Arsenic metabolism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13912035	chr5:179105622	CBY3	-0.42	-6.17	-0.32	1.96e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg09904177	chr6:26538194	HMGN4	0.47	7.48	0.38	6.76e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg05973401	chr12:123451056	ABCB9	0.52	6.6	0.34	1.64e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.94	12.97	0.58	1.9e-31	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg18512352	chr11:47633146	NA	0.45	9.05	0.44	1.22e-17	Subjective well-being;
LUSC	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg17691542	chr6:26056736	HIST1H1C	0.4	5.94	0.31	7.21e-9	Schizophrenia;
LUSC	cis	rs4964805	0.594	rs11111759	chr12:104163183	T/C	cg02344784	chr12:104178138	NT5DC3	0.36	5.86	0.31	1.09e-8	Attention deficit hyperactivity disorder;
LUSC	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg18721089	chr20:30220636	NA	-0.34	-6.01	-0.31	4.97e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg13560548	chr3:10150139	C3orf24	0.53	7.2	0.37	3.99e-12	Alzheimer's disease;
LUSC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg07701084	chr6:150067640	NUP43	0.57	8.85	0.44	5.05e-17	Lung cancer;
LUSC	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg10547527	chr2:198650123	BOLL	-0.51	-5.9	-0.31	8.72e-9	Ulcerative colitis;
LUSC	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg24558204	chr6:135376177	HBS1L	0.59	9.26	0.45	2.5e-18	Red blood cell count;
LUSC	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.81	13.64	0.6	5.83e-34	Aortic root size;
LUSC	cis	rs9517302	0.847	rs9517297	chr13:99094961	A/C	cg22223119	chr13:99095684	FARP1	-0.73	-11.53	-0.53	4.04e-26	Obesity-related traits;
LUSC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	6.58	0.34	1.8e-10	Renal function-related traits (BUN);
LUSC	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg17911788	chr17:44343683	NA	0.31	6.06	0.31	3.61e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs1185460	0.547	rs667584	chr11:118911544	C/T	cg01677386	chr11:118938358	VPS11	0.44	6.35	0.33	7.22e-10	Coronary artery disease;
LUSC	trans	rs4269383	0.774	rs9397275	chr6:156255097	A/G	cg11658975	chr6:170700107	FAM120B	0.35	5.95	0.31	6.6e-9	Pancreatic cancer;
LUSC	cis	rs4474465	0.688	rs7940720	chr11:78276674	C/T	cg27205649	chr11:78285834	NARS2	0.55	6.95	0.36	1.97e-11	Alzheimer's disease (survival time);
LUSC	cis	rs2742417	1.000	rs2673047	chr3:45743113	A/G	cg09608765	chr3:45636137	LIMD1	-0.38	-7.5	-0.38	5.91e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg22834771	chr12:69754056	YEATS4	-0.5	-7.45	-0.38	8.09e-13	Blood protein levels;
LUSC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02475777	chr4:1388615	CRIPAK	-0.59	-8.88	-0.44	4.2e-17	Obesity-related traits;
LUSC	trans	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-8.72	-0.43	1.31e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg27094323	chr7:1216898	NA	-0.43	-7.35	-0.37	1.51e-12	Longevity;Endometriosis;
LUSC	cis	rs16976116	1.000	rs16976116	chr15:55480467	T/C	cg11288833	chr15:55489084	RSL24D1	0.52	6.28	0.33	1.04e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	10.21	0.49	1.77e-21	Lymphocyte counts;
LUSC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13732083	chr21:47605072	C21orf56	0.42	6.21	0.32	1.55e-9	Testicular germ cell tumor;
LUSC	cis	rs501916	0.761	rs79925748	chr15:48046412	G/C	cg16110827	chr15:48056943	SEMA6D	-0.44	-6.74	-0.35	6.87e-11	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.71	-0.39	1.43e-13	Lymphocyte counts;
LUSC	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg21699342	chr2:239360505	ASB1	-0.54	-10.03	-0.48	6.95e-21	Multiple system atrophy;
LUSC	cis	rs16986825	0.607	rs5762852	chr22:29242473	T/C	cg02153584	chr22:29168773	CCDC117	0.53	6.04	0.31	4.15e-9	Pancreatic cancer;
LUSC	cis	rs2067615	0.579	rs10778510	chr12:107162965	A/G	cg15890332	chr12:107067104	RFX4	-0.34	-6.14	-0.32	2.41e-9	Heart rate;
LUSC	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg04455712	chr21:45112962	RRP1B	0.49	9.27	0.45	2.37e-18	Mean corpuscular volume;
LUSC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.65	-11.16	-0.52	8.28e-25	Diastolic blood pressure;
LUSC	cis	rs4924935	0.851	rs12936834	chr17:18807078	A/G	cg26306683	chr17:18585705	ZNF286B	0.54	7.35	0.37	1.57e-12	Pancreatic cancer;
LUSC	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg07937631	chr13:79184529	NA	0.36	6.08	0.32	3.3e-9	Large artery stroke;
LUSC	cis	rs6541297	1.000	rs7543050	chr1:230278291	C/G	cg20703242	chr1:230279135	GALNT2	0.5	7.58	0.38	3.37e-13	Coronary artery disease;
LUSC	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg14458575	chr2:238380390	NA	0.71	12.44	0.56	1.93e-29	Prostate cancer;
LUSC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg01657329	chr11:68192670	LRP5	-0.45	-7.24	-0.37	3.17e-12	Total body bone mineral density;
LUSC	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.44	-6.94	-0.36	1.99e-11	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg21435336	chr19:17392852	ANKLE1	-0.45	-6.19	-0.32	1.79e-9	Systemic lupus erythematosus;
LUSC	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg03433033	chr1:76189801	ACADM	-0.48	-7.18	-0.37	4.59e-12	Daytime sleep phenotypes;
LUSC	cis	rs239198	0.602	rs11755579	chr6:101322469	A/C	cg09795085	chr6:101329169	ASCC3	0.45	6.36	0.33	6.54e-10	Menarche (age at onset);
LUSC	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	9.13	0.45	6.68e-18	Response to antipsychotic treatment;
LUSC	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg05855489	chr10:104503620	C10orf26	0.52	8.06	0.4	1.35e-14	Arsenic metabolism;
LUSC	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs892085	0.681	rs873016	chr19:10894728	G/A	cg17710535	chr19:10819994	QTRT1	0.36	5.76	0.3	1.93e-8	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.38	-0.42	1.49e-15	Response to antipsychotic treatment;
LUSC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg07362569	chr17:61921086	SMARCD2	-0.31	-6.19	-0.32	1.78e-9	Prudent dietary pattern;
LUSC	trans	rs984440	0.560	rs7816346	chr8:139084529	A/G	cg03334052	chr1:168888044	NA	-0.41	-6.56	-0.34	2.04e-10	Obesity-related traits;
LUSC	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.03	0.31	4.42e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs354225	0.584	rs7591231	chr2:54829596	C/G	cg26097391	chr2:54893211	SPTBN1	0.42	6.27	0.32	1.14e-9	Schizophrenia;
LUSC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-1.03	-20.21	-0.74	7.12e-60	Height;
LUSC	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg05368731	chr17:41323189	NBR1	0.86	14.28	0.62	1.85e-36	Menopause (age at onset);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg22078572	chr18:61033618	KDSR	-0.46	-6.07	-0.32	3.45e-9	Hepatitis;
LUSC	trans	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.33	-0.33	7.72e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs6545883	0.894	rs7572603	chr2:61552145	C/G	cg15711740	chr2:61764176	XPO1	0.43	6.67	0.34	1.03e-10	Tuberculosis;
LUSC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.5	0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg16989719	chr2:238392110	NA	-0.45	-7.15	-0.36	5.66e-12	Prostate cancer;
LUSC	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg10518572	chr11:65560635	OVOL1	-0.26	-5.98	-0.31	5.73e-9	Acne (severe);
LUSC	cis	rs10887741	1.000	rs12412482	chr10:89443799	C/T	cg13926569	chr10:89418898	PAPSS2	0.31	6.23	0.32	1.43e-9	Exercise (leisure time);
LUSC	cis	rs6704644	0.651	rs11675254	chr2:234364047	C/T	cg05711037	chr2:234359783	DGKD	0.61	6.7	0.34	8.61e-11	Bilirubin levels;
LUSC	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg26898376	chr11:64110657	CCDC88B	0.36	6.84	0.35	3.81e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.79	11.59	0.54	2.5e-26	Corneal astigmatism;
LUSC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.9	-0.55	1.86e-27	Chronic sinus infection;
LUSC	cis	rs7572733	0.555	rs13395030	chr2:198750806	A/G	cg00792783	chr2:198669748	PLCL1	0.46	6.15	0.32	2.17e-9	Dermatomyositis;
LUSC	cis	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.8	-0.35	4.96e-11	Morning vs. evening chronotype;
LUSC	cis	rs17095355	1.000	rs12246851	chr10:111726340	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.54	-0.38	4.55e-13	Biliary atresia;
LUSC	cis	rs4363385	0.719	rs2066005	chr1:152923113	G/C	cg07796016	chr1:152779584	LCE1C	-0.49	-7.02	-0.36	1.25e-11	Inflammatory skin disease;
LUSC	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg17691542	chr6:26056736	HIST1H1C	0.45	6.87	0.35	3.11e-11	Height;
LUSC	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg13319975	chr6:146136371	FBXO30	0.49	7.42	0.38	9.93e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12519773	0.502	rs4613686	chr5:92498497	A/G	cg18783429	chr5:92414398	NA	0.36	7.87	0.4	4.91e-14	Migraine;
LUSC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg21724239	chr8:58056113	NA	0.57	6.58	0.34	1.87e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.17	-0.32	2.02e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7809950	0.911	rs1015411	chr7:107135612	C/T	cg23024343	chr7:107201750	COG5	-0.56	-8.96	-0.44	2.31e-17	Coronary artery disease;
LUSC	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg04310649	chr10:35416472	CREM	-0.4	-6.24	-0.32	1.35e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg01528321	chr10:82214614	TSPAN14	0.62	8.94	0.44	2.67e-17	Post bronchodilator FEV1;
LUSC	cis	rs2267137	0.903	rs715494	chr22:29782433	G/T	cg07256473	chr22:29710276	RASL10A	-0.38	-7.36	-0.37	1.4e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	trans	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg06606381	chr12:133084897	FBRSL1	-0.92	-8.28	-0.41	3e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs6076960	0.744	rs6053961	chr20:6176793	A/G	cg21095983	chr6:86352623	SYNCRIP	0.39	6.02	0.31	4.66e-9	Smooth-surface caries;
LUSC	trans	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg07817883	chr1:32538562	TMEM39B	-0.61	-7.45	-0.38	7.97e-13	Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08280861	chr8:58055591	NA	0.54	6.44	0.33	4.06e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.43	-0.38	9.37e-13	Monocyte count;
LUSC	cis	rs12760731	0.565	rs7550699	chr1:178209584	T/G	cg00404053	chr1:178313656	RASAL2	0.68	6.9	0.35	2.55e-11	Obesity-related traits;
LUSC	cis	rs6674970	0.777	rs12087892	chr1:151118500	T/C	cg11822372	chr1:151115635	SEMA6C	-0.84	-13.58	-0.6	9.82e-34	Childhood ear infection;
LUSC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.71	0.51	3.24e-23	Menopause (age at onset);
LUSC	cis	rs17253792	0.731	rs3736876	chr14:56120178	T/C	cg01858014	chr14:56050164	KTN1	-0.8	-6.58	-0.34	1.79e-10	Putamen volume;
LUSC	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg14458575	chr2:238380390	NA	0.7	8.47	0.42	7.99e-16	Prostate cancer;
LUSC	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.83	0.51	1.22e-23	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.84	11.99	0.55	8.91e-28	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06861087	chr14:53019167	TXNDC16;GPR137C	-0.41	-6.09	-0.32	3.06e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg04800585	chr6:26043546	HIST1H2BB	0.38	5.65	0.3	3.35e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20964285	chr5:65892109	MAST4	-0.42	-6.19	-0.32	1.73e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg14552801	chr7:65878734	NA	-0.46	-6.69	-0.34	9.24e-11	Aortic root size;
LUSC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg16797656	chr11:68205561	LRP5	0.35	5.94	0.31	7.22e-9	Total body bone mineral density;
LUSC	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.13	-20.97	-0.75	7.04e-63	Homoarginine levels;
LUSC	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.52	-0.34	2.52e-10	Type 2 diabetes;
LUSC	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg08916839	chr5:415575	AHRR	0.77	7.39	0.38	1.15e-12	Fat distribution (HIV);
LUSC	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.73	-12.43	-0.56	2.12e-29	White blood cell count (basophil);
LUSC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	0.36	6.15	0.32	2.16e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs72960926	0.744	rs117811116	chr6:74898143	C/A	cg03266952	chr6:74778945	NA	-0.8	-6.24	-0.32	1.3e-9	Metabolite levels (MHPG);
LUSC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	9.22	0.45	3.51e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg05863683	chr7:1912471	MAD1L1	-0.3	-5.68	-0.3	2.96e-8	Bipolar disorder and schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23051282	chr17:78940161	RPTOR	0.45	6.29	0.33	9.86e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.66	9.89	0.48	2.09e-20	Corneal astigmatism;
LUSC	cis	rs9811920	0.809	rs902159	chr3:99747445	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.37	7.09	0.36	8.18e-12	Axial length;
LUSC	cis	rs4566357	1.000	rs1317770	chr2:227911725	C/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.84	-0.3	1.23e-8	Coronary artery disease;
LUSC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg20887711	chr4:1340912	KIAA1530	0.44	6.57	0.34	1.97e-10	Obesity-related traits;
LUSC	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg24011408	chr12:48396354	COL2A1	0.58	7.76	0.39	1.06e-13	Lung cancer;
LUSC	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg10523679	chr1:76189770	ACADM	-0.46	-6.51	-0.34	2.74e-10	Daytime sleep phenotypes;
LUSC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06873352	chr17:61820015	STRADA	0.58	8.99	0.44	1.82e-17	Height;
LUSC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg12463550	chr7:65579703	CRCP	0.52	7.46	0.38	7.59e-13	Aortic root size;
LUSC	trans	rs71435601	0.657	rs10221876	chr2:21419809	A/T	cg20757404	chr19:378427	NA	-0.41	-6.32	-0.33	8.46e-10	Cholesterol, total;
LUSC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg25019033	chr10:957182	NA	-0.51	-5.68	-0.3	2.9e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg11812906	chr14:75593930	NEK9	-0.62	-10.33	-0.49	6.91e-22	Height;
LUSC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg26566898	chr11:117069891	TAGLN	0.31	5.86	0.31	1.13e-8	Blood protein levels;
LUSC	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg03684893	chr10:554711	DIP2C	-0.38	-6.96	-0.36	1.79e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg06484146	chr7:12443880	VWDE	-0.68	-7.08	-0.36	8.67e-12	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg00945038	chr17:61921165	SMARCD2	0.4	6.03	0.31	4.4e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg00857998	chr1:205179979	DSTYK	0.65	9.84	0.47	3.12e-20	Red blood cell count;
LUSC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg17211192	chr8:82754475	SNX16	-0.64	-9.11	-0.45	7.56e-18	Diastolic blood pressure;
LUSC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg06238570	chr21:40685208	BRWD1	-0.62	-10.95	-0.51	4.73e-24	Cognitive function;
LUSC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.49	-0.33	3.15e-10	Life satisfaction;
LUSC	cis	rs9650315	0.866	rs13260966	chr8:57182832	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	6.41	0.33	4.87e-10	Height;
LUSC	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.18	-0.45	4.59e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs13082711	0.911	rs57317249	chr3:27515854	A/C	cg02860705	chr3:27208620	NA	0.47	7.91	0.4	3.88e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg06740227	chr12:86229804	RASSF9	0.45	7.14	0.36	5.83e-12	Major depressive disorder;
LUSC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg02038168	chr22:39784481	NA	-0.43	-6.26	-0.32	1.21e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg21211680	chr2:198530	NA	-0.54	-6.68	-0.34	9.72e-11	Blood protein levels;
LUSC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.64	-11.62	-0.54	1.91e-26	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg17554472	chr22:41940697	POLR3H	0.48	5.9	0.31	8.76e-9	Vitiligo;
LUSC	cis	rs9818941	0.824	rs2712318	chr3:157776053	C/T	cg08654915	chr3:157813417	NA	-0.33	-7.68	-0.39	1.73e-13	Height;
LUSC	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg04310649	chr10:35416472	CREM	-0.42	-6.59	-0.34	1.74e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.59	10.79	0.51	1.81e-23	Homoarginine levels;
LUSC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	10.43	0.5	3.16e-22	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg14196790	chr5:131705035	SLC22A5	0.5	8.46	0.42	8.3e-16	Blood metabolite levels;
LUSC	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	12.74	0.57	1.47e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7707921	0.957	rs226205	chr5:81593654	C/T	cg15871215	chr5:81402204	ATG10	0.41	5.72	0.3	2.38e-8	Breast cancer;
LUSC	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.4	-6.0	-0.31	5.17e-9	Height;
LUSC	trans	rs12692738	0.526	rs355856	chr2:165628977	T/A	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4924935	0.851	rs12936834	chr17:18807078	A/G	cg26378065	chr17:18585709	ZNF286B	0.6	8.24	0.41	3.87e-15	Pancreatic cancer;
LUSC	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg01689657	chr7:91764605	CYP51A1	-0.33	-5.87	-0.31	1.06e-8	Breast cancer;
LUSC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg26373071	chr5:1325741	CLPTM1L	0.42	7.81	0.39	7.35e-14	Lung cancer;
LUSC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23158103	chr7:148848205	ZNF398	-0.43	-6.47	-0.33	3.43e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg12002119	chr2:101014098	CHST10	0.34	5.66	0.3	3.21e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg24375607	chr4:120327624	NA	0.71	10.38	0.49	4.68e-22	Corneal astigmatism;
LUSC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-6.86	-0.35	3.35e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7818345	1.000	rs7835461	chr8:19307051	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.49	0.33	3.19e-10	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg18876405	chr7:65276391	NA	0.76	13.71	0.6	3.02e-34	Aortic root size;
LUSC	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg13390004	chr1:15929781	NA	0.4	6.74	0.35	7.14e-11	Systolic blood pressure;
LUSC	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-17.52	-0.69	3.23e-49	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7809950	1.000	rs7778270	chr7:107224667	A/G	cg23024343	chr7:107201750	COG5	0.57	8.81	0.43	6.71e-17	Coronary artery disease;
LUSC	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.56	7.9	0.4	3.96e-14	Lung cancer;
LUSC	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.65	-0.39	2.13e-13	Total cholesterol levels;
LUSC	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.7	0.3	2.65e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.66	-10.16	-0.49	2.59e-21	Morning vs. evening chronotype;
LUSC	cis	rs11971779	0.680	rs11772026	chr7:139052589	T/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.82	15.09	0.64	1.36e-39	Cognitive function;
LUSC	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.41	-7.56	-0.38	3.97e-13	Social autistic-like traits;
LUSC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.25	-0.49	1.28e-21	Hemoglobin concentration;
LUSC	cis	rs2688608	0.967	rs2688609	chr10:75658181	A/G	cg23231163	chr10:75533350	FUT11	0.39	6.39	0.33	5.44e-10	Inflammatory bowel disease;
LUSC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.7	11.0	0.52	3.29e-24	Aortic root size;
LUSC	cis	rs4363385	0.510	rs6587724	chr1:153034501	T/A	cg25856811	chr1:152973957	SPRR3	-0.37	-6.13	-0.32	2.44e-9	Inflammatory skin disease;
LUSC	cis	rs911119	1.000	rs73318135	chr20:23618571	T/G	cg16589663	chr20:23618590	CST3	0.6	7.0	0.36	1.39e-11	Chronic kidney disease;
LUSC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg19774624	chr17:42201019	HDAC5	0.7	10.49	0.5	1.99e-22	Total body bone mineral density;
LUSC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg05861140	chr6:150128134	PCMT1	-0.42	-6.81	-0.35	4.67e-11	Lung cancer;
LUSC	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg15432903	chr11:17409602	KCNJ11	0.63	11.34	0.53	1.98e-25	Type 2 diabetes;
LUSC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.51	-11.18	-0.52	7.54e-25	Type 2 diabetes;
LUSC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg11632617	chr15:75315747	PPCDC	-0.52	-6.78	-0.35	5.39e-11	Blood trace element (Zn levels);
LUSC	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.01	-0.44	1.57e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	6.59	0.34	1.72e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.93	0.31	7.55e-9	Rheumatoid arthritis;
LUSC	cis	rs4889855	0.556	rs11547301	chr17:78518780	C/T	cg16591659	chr17:78472290	NA	0.32	5.66	0.3	3.29e-8	Fractional excretion of uric acid;
LUSC	cis	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg17469321	chr7:55412551	NA	0.67	10.4	0.49	3.79e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-0.95	-17.57	-0.69	2.07e-49	Cognitive function;
LUSC	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.39	6.15	0.32	2.16e-9	Cystic fibrosis severity;
LUSC	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg07148914	chr20:33460835	GGT7	0.49	7.38	0.37	1.24e-12	Height;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01854491	chr8:144815021	FAM83H	-0.22	-6.03	-0.31	4.27e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg12463550	chr7:65579703	CRCP	0.55	8.19	0.41	5.73e-15	Aortic root size;
LUSC	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg02023728	chr11:77925099	USP35	0.53	7.53	0.38	4.91e-13	Testicular germ cell tumor;
LUSC	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg03806693	chr22:41940476	POLR3H	-0.74	-10.94	-0.51	5.32e-24	Vitiligo;
LUSC	trans	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.45	6.66	0.34	1.16e-10	Endometrial cancer;
LUSC	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23158103	chr7:148848205	ZNF398	-0.47	-7.53	-0.38	4.81e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg23950597	chr19:37808831	NA	-0.62	-7.47	-0.38	6.98e-13	Coronary artery calcification;
LUSC	cis	rs2625529	0.816	rs8025504	chr15:72294757	C/T	cg16672083	chr15:72433130	SENP8	-0.52	-7.58	-0.38	3.51e-13	Red blood cell count;
LUSC	cis	rs698813	0.674	rs6544752	chr2:44499049	G/A	cg00619915	chr2:44497795	NA	-0.5	-6.83	-0.35	3.91e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs7123876	0.587	rs11600831	chr11:72360220	C/T	cg03713592	chr11:72463424	ARAP1	0.69	7.18	0.37	4.54e-12	Body mass index;
LUSC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg20887711	chr4:1340912	KIAA1530	0.49	7.75	0.39	1.1e-13	Obesity-related traits;
LUSC	cis	rs2067615	0.542	rs4433659	chr12:107082496	G/T	cg15890332	chr12:107067104	RFX4	0.35	6.27	0.32	1.08e-9	Heart rate;
LUSC	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg05343316	chr1:45956843	TESK2	0.62	8.63	0.43	2.49e-16	Platelet count;
LUSC	cis	rs977987	0.806	rs8050769	chr16:75388434	C/T	cg04384234	chr16:75411784	CFDP1	-0.39	-6.25	-0.32	1.22e-9	Dupuytren's disease;
LUSC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg17644776	chr2:200775616	C2orf69	0.52	8.94	0.44	2.74e-17	Osteoporosis;
LUSC	cis	rs3790515	0.826	rs2280471	chr1:151783736	A/G	cg07092448	chr1:151763213	TDRKH	0.7	5.97	0.31	6.13e-9	Depressive symptoms (SSRI exposure interaction);
LUSC	cis	rs3126085	0.877	rs7537633	chr1:152223333	T/G	cg26876637	chr1:152193138	HRNR	0.44	6.2	0.32	1.7e-9	Atopic dermatitis;
LUSC	cis	rs7246967	0.611	rs7250964	chr19:22822494	T/C	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg08017634	chr8:144659831	NAPRT1	0.71	6.01	0.31	4.81e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg25703541	chr22:24373054	LOC391322	-0.94	-17.19	-0.69	6.69e-48	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.18	0.32	1.83e-9	Lung cancer;
LUSC	cis	rs9436747	0.585	rs11581702	chr1:65987659	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.44	-5.9	-0.31	9.08e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg16482183	chr6:26056742	HIST1H1C	0.47	7.06	0.36	9.87e-12	Height;
LUSC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg05064044	chr6:292385	DUSP22	-0.52	-7.6	-0.38	3.09e-13	Menopause (age at onset);
LUSC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.92	-0.35	2.25e-11	Monocyte percentage of white cells;
LUSC	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg07148914	chr20:33460835	GGT7	0.48	7.26	0.37	2.72e-12	Height;
LUSC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-8.02	-0.4	1.8e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg17515076	chr17:73810948	UNK	-0.39	-6.46	-0.33	3.6e-10	White matter hyperintensity burden;
LUSC	trans	rs800082	0.698	rs800070	chr3:144346614	A/T	cg24215973	chr2:240111563	HDAC4	-0.7	-10.3	-0.49	8.74e-22	Smoking behavior;
LUSC	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg17143192	chr8:8559678	CLDN23	0.64	9.02	0.44	1.47e-17	Obesity-related traits;
LUSC	cis	rs617219	0.853	rs10078815	chr5:78522895	C/T	cg24856658	chr5:78533917	JMY	-0.3	-5.85	-0.31	1.14e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg09201001	chr11:18656081	SPTY2D1	-0.89	-14.44	-0.62	4.72e-37	Breast cancer;
LUSC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9341808	0.718	rs10943696	chr6:80901272	C/G	cg08355045	chr6:80787529	NA	0.59	10.22	0.49	1.64e-21	Sitting height ratio;
LUSC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg05973401	chr12:123451056	ABCB9	0.53	7.26	0.37	2.68e-12	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs1322512	0.874	rs2758768	chr6:152986239	C/T	cg27316956	chr6:152958899	SYNE1	0.37	6.32	0.33	8.37e-10	Tonometry;
LUSC	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg08079166	chr15:68083412	MAP2K5	0.42	7.46	0.38	7.41e-13	Restless legs syndrome;
LUSC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg22105103	chr4:187893119	NA	0.71	13.88	0.6	6.72e-35	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs72674100	1.000	rs72882340	chr4:97993584	A/C	cg16405019	chr1:18959625	PAX7	-0.61	-6.41	-0.33	5.09e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs754466	0.651	rs55738779	chr10:79652395	C/T	cg17075019	chr10:79541650	NA	-0.74	-11.86	-0.54	2.56e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg18721089	chr20:30220636	NA	-0.35	-5.88	-0.31	1.01e-8	Monocyte count;
LUSC	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg11019008	chr10:131425282	MGMT	0.4	6.2	0.32	1.68e-9	Response to temozolomide;
LUSC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-1.24	-13.61	-0.6	7.37e-34	Diabetic kidney disease;
LUSC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg16339924	chr4:17578868	LAP3	-0.55	-8.41	-0.42	1.22e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg08277548	chr1:17600880	PADI3	-0.68	-6.88	-0.35	2.88e-11	Hair shape;
LUSC	cis	rs7178572	0.568	rs12443386	chr15:77491389	C/T	cg22256960	chr15:77711686	NA	0.48	7.73	0.39	1.24e-13	Type 2 diabetes;
LUSC	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.71	-11.17	-0.52	7.69e-25	Alcohol dependence;
LUSC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg20295408	chr7:1910781	MAD1L1	-0.5	-7.18	-0.37	4.55e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg15147215	chr3:52552868	STAB1	-0.31	-6.13	-0.32	2.54e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg08601574	chr20:25228251	PYGB	0.42	6.41	0.33	4.9e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg14343924	chr8:8086146	FLJ10661	-0.4	-5.65	-0.3	3.37e-8	Mood instability;
LUSC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg10792982	chr14:105748885	BRF1	0.52	9.43	0.46	7.25e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg00431813	chr7:1051703	C7orf50	-0.43	-6.93	-0.35	2.19e-11	Longevity;Endometriosis;
LUSC	cis	rs12594515	1.000	rs57299255	chr15:45996532	C/A	cg01629716	chr15:45996671	NA	0.39	5.83	0.3	1.31e-8	Waist circumference;Weight;
LUSC	cis	rs2898681	0.561	rs7699960	chr4:53735661	C/A	cg21521518	chr4:53727714	RASL11B	0.45	5.92	0.31	7.81e-9	Optic nerve measurement (cup area);
LUSC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-7.66	-0.39	1.98e-13	Bipolar disorder;
LUSC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg00012203	chr2:219082015	ARPC2	-0.73	-12.77	-0.57	1.11e-30	Colorectal cancer;
LUSC	trans	rs72674100	1.000	rs72874654	chr4:97966415	A/G	cg09670535	chr1:18959427	PAX7	-0.64	-6.61	-0.34	1.53e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.65	9.99	0.48	9.81e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.54	11.12	0.52	1.22e-24	Height;
LUSC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.02	-0.44	1.53e-17	Gut microbiome composition (summer);
LUSC	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg22508957	chr16:3507546	NAT15	-0.41	-5.84	-0.3	1.25e-8	Body mass index (adult);
LUSC	cis	rs73198271	0.515	rs75155748	chr8:8628957	G/C	cg01851573	chr8:8652454	MFHAS1	0.61	7.01	0.36	1.34e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg17469321	chr7:55412551	NA	0.68	10.92	0.51	5.92e-24	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg00071950	chr4:10020882	SLC2A9	-0.49	-8.23	-0.41	4.17e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg24692254	chr21:30365293	RNF160	0.68	10.88	0.51	8.46e-24	Pancreatic cancer;
LUSC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg16624210	chr5:671434	TPPP	0.48	6.12	0.32	2.67e-9	Obesity-related traits;
LUSC	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg13334819	chr7:99746414	C7orf59	0.5	6.73	0.35	7.31e-11	Coronary artery disease;
LUSC	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg13072238	chr3:49761600	GMPPB	-0.69	-8.14	-0.41	8.15e-15	Menarche (age at onset);
LUSC	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg05855489	chr10:104503620	C10orf26	0.5	7.53	0.38	4.72e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.96	0.7	5.97e-51	Chronic sinus infection;
LUSC	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg11395062	chr17:14139857	CDRT15	0.48	7.22	0.37	3.52e-12	Temperament;
LUSC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.68	-11.24	-0.52	4.49e-25	Systemic lupus erythematosus;
LUSC	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-11.1	-0.52	1.43e-24	Response to antipsychotic treatment;
LUSC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg08200582	chr11:442649	ANO9	-0.57	-6.32	-0.33	8.2e-10	Body mass index;
LUSC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg16606324	chr3:10149918	C3orf24	0.64	9.58	0.46	2.37e-19	Alzheimer's disease;
LUSC	cis	rs834603	0.575	rs1534137	chr7:47482719	T/C	cg09696706	chr7:47479511	TNS3	0.35	6.42	0.33	4.81e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.34	0.64	1.46e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-6.27	-0.32	1.11e-9	Menopause (age at onset);
LUSC	trans	rs9975851	0.687	rs219695	chr21:27739335	G/T	cg13892514	chr2:241853394	NA	0.34	5.96	0.31	6.43e-9	Airflow obstruction;
LUSC	cis	rs7777754	0.734	rs4947709	chr7:50672907	A/G	cg18232548	chr7:50535776	DDC	-0.52	-7.46	-0.38	7.59e-13	Response to zileuton treatment in asthma (FEV1 change interaction);
LUSC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	trans	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.22	-0.32	1.45e-9	Monocyte count;
LUSC	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg21951975	chr1:209979733	IRF6	0.42	6.97	0.36	1.69e-11	Monobrow;
LUSC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	7.23	0.37	3.39e-12	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs4665630	0.708	rs4078753	chr2:23896727	C/T	cg08063864	chr2:24346004	PFN4;LOC375190	-0.62	-5.72	-0.3	2.31e-8	Hypertension;
LUSC	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg27490568	chr2:178487706	NA	0.4	5.84	0.3	1.22e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7582720	1.000	rs72928609	chr2:203837573	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg12564285	chr5:131593104	PDLIM4	0.39	7.47	0.38	6.96e-13	Blood metabolite levels;
LUSC	trans	rs800082	0.734	rs1527236	chr3:144246938	G/A	cg24215973	chr2:240111563	HDAC4	0.41	6.03	0.31	4.37e-9	Smoking behavior;
LUSC	cis	rs6066835	1.000	rs73136396	chr20:47337174	T/A	cg18078177	chr20:47281410	PREX1	0.75	5.78	0.3	1.68e-8	Multiple myeloma;
LUSC	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	5.65	0.3	3.39e-8	Bipolar disorder;
LUSC	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.73	12.03	0.55	5.91e-28	Alcohol dependence;
LUSC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.83	15.71	0.65	5.2e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	trans	rs74338693	0.778	rs10930189	chr2:166790998	G/A	cg07963046	chr1:155764892	GON4L	-0.47	-6.05	-0.31	3.97e-9	Schizophrenia;
LUSC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg15557168	chr22:42548783	NA	-0.44	-6.94	-0.36	2e-11	Schizophrenia;
LUSC	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg12292205	chr6:26970375	C6orf41	0.6	7.21	0.37	3.75e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2425143	1.000	rs13038622	chr20:34319343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.27	-0.32	1.14e-9	Blood protein levels;
LUSC	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.66	-12.42	-0.56	2.22e-29	Longevity;Endometriosis;
LUSC	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.15	10.47	0.5	2.35e-22	Alzheimer's disease (late onset);
LUSC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg03146154	chr1:46216737	IPP	0.56	8.37	0.42	1.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg23630131	chr7:65973040	NA	-0.21	-5.93	-0.31	7.77e-9	Aortic root size;
LUSC	cis	rs11630290	0.806	rs72752906	chr15:64093465	G/T	cg12036633	chr15:63758958	NA	-0.61	-7.08	-0.36	8.51e-12	Iris characteristics;
LUSC	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg05896524	chr21:47604654	C21orf56	0.52	7.8	0.39	8.06e-14	Testicular germ cell tumor;
LUSC	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg17691542	chr6:26056736	HIST1H1C	0.54	8.15	0.41	7.62e-15	Height;
LUSC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	0.91	16.32	0.67	1.89e-44	Cognitive function;
LUSC	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.31	-0.33	8.95e-10	Bipolar disorder;
LUSC	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg09699651	chr6:150184138	LRP11	0.45	7.15	0.36	5.64e-12	Testicular germ cell tumor;
LUSC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07362569	chr17:61921086	SMARCD2	0.36	7.32	0.37	1.92e-12	Prudent dietary pattern;
LUSC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-1.05	-15.06	-0.64	1.71e-39	Vitiligo;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25834275	chr19:3359809	NFIC	0.44	6.08	0.32	3.36e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg13531842	chr10:38383804	ZNF37A	-0.48	-7.42	-0.38	9.51e-13	Extrinsic epigenetic age acceleration;
LUSC	cis	rs56804039	1.000	rs34154295	chr8:8383477	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.76	-0.35	6.05e-11	Cervical cancer;
LUSC	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg04362960	chr10:104952993	NT5C2	0.59	9.23	0.45	3.21e-18	Arsenic metabolism;
LUSC	cis	rs80282103	0.571	rs10047269	chr10:1103058	G/A	cg08668510	chr10:1095578	IDI1	0.72	6.39	0.33	5.53e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7512552	0.839	rs1625468	chr1:150321486	G/A	cg15654264	chr1:150340011	RPRD2	0.68	11.51	0.53	4.95e-26	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg24313572	chr1:56050060	NA	-0.31	-6.58	-0.34	1.83e-10	Morning vs. evening chronotype;
LUSC	cis	rs4343996	0.967	rs1525556	chr7:3351304	G/C	cg21248987	chr7:3385318	SDK1	-0.39	-6.67	-0.34	1.09e-10	Motion sickness;
LUSC	cis	rs9920506	0.536	rs11072768	chr15:78929478	A/C	cg24631222	chr15:78858424	CHRNA5	-0.56	-7.31	-0.37	2.03e-12	Post bronchodilator FEV1;
LUSC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg14558114	chr2:88469736	THNSL2	0.79	7.1	0.36	7.72e-12	Plasma clusterin levels;
LUSC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.46	0.59	2.79e-33	Platelet count;
LUSC	cis	rs11997175	0.655	rs72630922	chr8:33662401	G/A	ch.8.33884649F	chr8:33765107	NA	0.39	5.95	0.31	6.83e-9	Body mass index;
LUSC	cis	rs2637266	0.783	rs2588334	chr10:78518504	C/T	cg18941641	chr10:78392320	NA	0.38	6.83	0.35	4.15e-11	Pulmonary function;
LUSC	cis	rs2303282	0.839	rs9937444	chr16:56543558	A/G	cg00500540	chr16:56394104	NA	-0.44	-7.25	-0.37	2.9e-12	Breast cancer;
LUSC	cis	rs977987	0.806	rs56343285	chr16:75409797	A/G	cg03315344	chr16:75512273	CHST6	0.48	9.24	0.45	3.06e-18	Dupuytren's disease;
LUSC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15556689	chr8:8085844	FLJ10661	0.89	15.99	0.66	3.85e-43	Neuroticism;
LUSC	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg22676075	chr6:135203613	NA	0.48	7.47	0.38	7.29e-13	Red blood cell count;
LUSC	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg11843238	chr5:131593191	PDLIM4	0.32	5.75	0.3	2.05e-8	Blood metabolite levels;
LUSC	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg22823121	chr1:150693482	HORMAD1	0.49	7.1	0.36	7.47e-12	Melanoma;
LUSC	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg00277334	chr10:82204260	NA	-0.5	-7.28	-0.37	2.38e-12	Post bronchodilator FEV1;
LUSC	cis	rs8014204	0.575	rs1045430	chr14:75130235	T/G	cg06637938	chr14:75390232	RPS6KL1	0.59	9.26	0.45	2.49e-18	Caffeine consumption;
LUSC	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg02753203	chr1:228287806	NA	0.9	16.76	0.68	3.56e-46	Diastolic blood pressure;
LUSC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.65	14.72	0.63	3.61e-38	Hemoglobin concentration;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg25372275	chr1:161102558	DEDD	0.39	6.18	0.32	1.82e-9	Mosquito bite size;
LUSC	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.79	-12.36	-0.56	3.58e-29	Metabolic syndrome;
LUSC	trans	rs7980799	0.682	rs1601006	chr12:33629519	C/T	cg13010199	chr12:38710504	ALG10B	-0.41	-6.22	-0.32	1.5e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07080220	chr10:102295463	HIF1AN	0.69	9.09	0.45	8.83e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg01858014	chr14:56050164	KTN1	-0.89	-7.32	-0.37	1.9e-12	Putamen volume;
LUSC	cis	rs4356932	0.691	rs6827617	chr4:76916146	G/A	cg00809888	chr4:76862425	NAAA	0.36	5.78	0.3	1.73e-8	Blood protein levels;
LUSC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg06238570	chr21:40685208	BRWD1	-0.63	-10.54	-0.5	1.29e-22	Cognitive function;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02610898	chr3:128400220	NA	0.4	6.33	0.33	7.94e-10	Triglycerides;
LUSC	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg22709100	chr7:91322751	NA	0.47	6.93	0.35	2.16e-11	Breast cancer;
LUSC	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg09034736	chr1:150693464	HORMAD1	0.41	5.72	0.3	2.38e-8	Melanoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23757506	chr17:56429622	SUPT4H1	-0.41	-6.06	-0.31	3.63e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.23e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg25039879	chr17:56429692	SUPT4H1	0.74	10.11	0.48	4e-21	Cognitive test performance;
LUSC	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.9	11.32	0.53	2.34e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	1.11	14.96	0.63	4.34e-39	Nonalcoholic fatty liver disease;
LUSC	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg10911889	chr6:126070802	HEY2	0.41	6.4	0.33	5.2e-10	Brugada syndrome;
LUSC	cis	rs9361491	0.508	rs9341739	chr6:79419076	C/G	cg05283184	chr6:79620031	NA	-0.4	-7.01	-0.36	1.29e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.01e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.25	0.52	4.23e-25	Prudent dietary pattern;
LUSC	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg24375607	chr4:120327624	NA	-0.74	-12.09	-0.55	3.65e-28	Corneal astigmatism;
LUSC	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg13042288	chr15:90349979	ANPEP	-0.49	-6.79	-0.35	5.14e-11	Uric acid levels;
LUSC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.82	13.74	0.6	2.25e-34	Aortic root size;
LUSC	trans	rs9490306	0.941	rs2389542	chr6:121783130	A/G	cg08848140	chr9:124982018	LHX6	0.34	6.08	0.32	3.36e-9	Migraine without aura;Migraine;
LUSC	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg14343924	chr8:8086146	FLJ10661	0.45	6.06	0.31	3.74e-9	Neuroticism;
LUSC	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg18825076	chr15:78729989	IREB2	0.46	6.34	0.33	7.33e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg17764715	chr19:33622953	WDR88	0.59	8.88	0.44	4.04e-17	Bone properties (heel);
LUSC	cis	rs728616	0.558	rs72817596	chr10:82151594	T/C	cg05935833	chr10:81318306	SFTPA2	-0.44	-5.8	-0.3	1.57e-8	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9837602	1.000	rs13064704	chr3:99767541	G/A	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	5.64	0.3	3.56e-8	Breast cancer;
LUSC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg22166914	chr1:53195759	ZYG11B	0.62	10.4	0.49	3.95e-22	Monocyte count;
LUSC	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg15819921	chr19:927150	ARID3A	-0.41	-6.17	-0.32	1.95e-9	Life satisfaction;
LUSC	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg13010199	chr12:38710504	ALG10B	0.56	7.7	0.39	1.59e-13	Resting heart rate;
LUSC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg09650180	chr20:62225654	GMEB2	0.66	9.86	0.47	2.7e-20	Glioblastoma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03067192	chr7:72300134	SBDSP;TYW1B	-0.42	-6.32	-0.33	8.29e-10	Electrocardiographic conduction measures;
LUSC	trans	rs2055729	0.528	rs11987861	chr8:9742206	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.62	-0.34	1.45e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	trans	rs1268789	0.545	rs1496584	chr4:79375590	G/A	cg06112894	chr8:141469983	TRAPPC9	0.23	6.0	0.31	5.11e-9	Hair shape;Hair morphology;
LUSC	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg16989719	chr2:238392110	NA	-0.4	-5.65	-0.3	3.42e-8	Prostate cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05086178	chr16:2588345	PDPK1	0.78	6.37	0.33	6.17e-10	Cognitive performance;
LUSC	trans	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg27275811	chr11:74457193	NA	-0.64	-6.22	-0.32	1.51e-9	Type 2 diabetes nephropathy;
LUSC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg01256987	chr12:42539512	GXYLT1	-0.39	-7.06	-0.36	9.87e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg24375607	chr4:120327624	NA	0.75	11.11	0.52	1.25e-24	Corneal astigmatism;
LUSC	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg01483505	chr11:975446	AP2A2	0.41	5.7	0.3	2.58e-8	Alzheimer's disease (late onset);
LUSC	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg06636551	chr8:101224915	SPAG1	-0.38	-7.13	-0.36	6.31e-12	Atrioventricular conduction;
LUSC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg08470875	chr2:26401718	FAM59B	-0.66	-8.89	-0.44	3.88e-17	Gut microbiome composition (summer);
LUSC	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg05234568	chr11:5960015	NA	-0.62	-10.44	-0.5	2.95e-22	DNA methylation (variation);
LUSC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-10.62	-0.5	6.83e-23	Alzheimer's disease;
LUSC	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg07423050	chr13:99094983	FARP1	-0.51	-9.26	-0.45	2.63e-18	Neuroticism;
LUSC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.56	-0.67	2.26e-45	Monocyte count;
LUSC	cis	rs4363385	0.782	rs310105	chr1:153022253	A/G	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.44	-0.38	8.47e-13	Inflammatory skin disease;
LUSC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg17264618	chr3:40429014	ENTPD3	0.35	7.08	0.36	8.58e-12	Renal cell carcinoma;
LUSC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	1.04	20.11	0.74	1.65e-59	Menopause (age at onset);
LUSC	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg14895029	chr7:2775587	GNA12	-0.37	-6.05	-0.31	3.78e-9	Height;
LUSC	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.27	-0.41	3.27e-15	Response to antipsychotic treatment;
LUSC	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg21827317	chr3:136751795	NA	0.39	6.93	0.35	2.24e-11	Neuroticism;
LUSC	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg02176678	chr2:219576539	TTLL4	-0.58	-10.22	-0.49	1.62e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg23791538	chr6:167370224	RNASET2	-0.43	-6.91	-0.35	2.4e-11	Crohn's disease;
LUSC	cis	rs2692947	0.637	rs1168967	chr2:96826016	A/G	cg22654517	chr2:96458247	NA	0.35	7.03	0.36	1.16e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7572644	0.640	rs9678430	chr2:28057129	G/C	cg27432699	chr2:27873401	GPN1	0.52	6.95	0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.47	-0.38	7.13e-13	Aortic root size;
LUSC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg25894440	chr7:65020034	NA	-0.37	-5.94	-0.31	7.08e-9	Calcium levels;
LUSC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg00024416	chr22:24240387	NA	-0.35	-6.17	-0.32	1.98e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9469578	0.901	rs16869459	chr6:33714908	G/A	cg18708504	chr6:33715942	IP6K3	0.72	9.18	0.45	4.73e-18	Phosphorus levels;
LUSC	cis	rs3736594	0.559	rs62141292	chr2:27784300	A/C	cg27432699	chr2:27873401	GPN1	0.66	8.77	0.43	9.35e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg26395211	chr5:140044315	WDR55	-0.37	-5.77	-0.3	1.78e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs9929218	0.539	rs1125557	chr16:68809599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.97	19.26	0.73	3.88e-56	Colorectal cancer;
LUSC	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg11984989	chr7:158649758	WDR60	-0.98	-16.39	-0.67	9.96e-45	Height;
LUSC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg00033643	chr7:134001901	SLC35B4	0.45	6.91	0.35	2.52e-11	Mean platelet volume;
LUSC	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg15819921	chr19:927150	ARID3A	-0.43	-6.41	-0.33	5.02e-10	Life satisfaction;
LUSC	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04873961	chr2:70418194	C2orf42	-0.42	-6.08	-0.32	3.28e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1178968	1.000	rs917247	chr7:72761420	C/T	cg25889504	chr7:72793014	NA	-0.52	-6.9	-0.35	2.57e-11	Triglyceride levels;
LUSC	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg09953122	chr20:23471693	CST8	-0.66	-5.72	-0.3	2.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg02775129	chr4:119771670	NA	0.73	7.06	0.36	9.55e-12	Cannabis dependence symptom count;
LUSC	cis	rs748404	0.697	rs475227	chr15:43546446	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	7.79	0.39	8.69e-14	Lung cancer;
LUSC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	8.52	0.42	5.58e-16	Menarche (age at onset);
LUSC	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg13256891	chr4:100009986	ADH5	0.51	6.96	0.36	1.79e-11	Smoking initiation;
LUSC	cis	rs2455601	0.744	rs2568085	chr11:8975748	G/T	cg09997546	chr11:8931473	C11orf17;ST5	0.38	7.12	0.36	6.83e-12	Schizophrenia;
LUSC	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg13607699	chr17:42295918	UBTF	-0.41	-6.52	-0.34	2.67e-10	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs9287719	0.649	rs10929684	chr2:10732224	C/T	cg00105475	chr2:10696890	NA	-0.34	-5.68	-0.3	2.99e-8	Prostate cancer;
LUSC	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg09184832	chr6:79620586	NA	-0.44	-7.18	-0.37	4.63e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs17095355	1.000	rs12571674	chr10:111717608	C/T	cg00817464	chr10:111662876	XPNPEP1	0.63	7.38	0.37	1.3e-12	Biliary atresia;
LUSC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10802521	chr3:52805072	NEK4	0.56	8.92	0.44	3.08e-17	Bipolar disorder;
LUSC	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg18827107	chr12:86230957	RASSF9	-0.42	-6.08	-0.32	3.35e-9	Major depressive disorder;
LUSC	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg18357645	chr12:58087776	OS9	0.54	8.11	0.41	9.5e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs6845621	0.901	rs7697704	chr4:18922478	C/G	cg12196642	chr4:18937545	NA	-0.34	-6.5	-0.33	2.97e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12756686	chr19:29218302	NA	0.58	6.53	0.34	2.47e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg02117656	chr17:79614917	TSPAN10	0.31	5.77	0.3	1.85e-8	Eye color traits;
LUSC	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg10523679	chr1:76189770	ACADM	-0.48	-6.83	-0.35	4.02e-11	Daytime sleep phenotypes;
LUSC	cis	rs975210	0.656	rs16954106	chr15:70357918	C/T	cg01666796	chr15:70364327	TLE3	-0.71	-8.25	-0.41	3.78e-15	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LUSC	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg09904177	chr6:26538194	HMGN4	0.66	11.73	0.54	7.4e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.510	rs1500937	chr1:153045483	G/C	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.31	-0.33	8.76e-10	Inflammatory skin disease;
LUSC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg14440974	chr22:39074834	NA	-0.38	-6.21	-0.32	1.55e-9	Menopause (age at onset);
LUSC	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg24558204	chr6:135376177	HBS1L	0.58	9.0	0.44	1.69e-17	Red blood cell count;
LUSC	cis	rs7582720	0.561	rs114407963	chr2:204154677	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	7.79	0.39	8.3e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg12365402	chr11:9010492	NRIP3	0.42	8.16	0.41	7e-15	Hemoglobin concentration;
LUSC	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg01448562	chr3:133502909	NA	-0.58	-8.7	-0.43	1.48e-16	Iron status biomarkers;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg03372779	chr16:2069785	NPW	0.65	5.96	0.31	6.45e-9	Cognitive performance;
LUSC	cis	rs240764	0.658	rs9404054	chr6:101256597	A/G	cg09795085	chr6:101329169	ASCC3	-0.45	-6.47	-0.33	3.57e-10	Neuroticism;
LUSC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.37	-0.37	1.34e-12	Electroencephalogram traits;
LUSC	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg17749961	chr2:30669863	LCLAT1	0.7	8.04	0.4	1.57e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg22920501	chr2:26401640	FAM59B	-0.74	-10.59	-0.5	8.59e-23	Gut microbiome composition (summer);
LUSC	cis	rs6977660	1.000	rs5017196	chr7:19819983	T/C	cg05791153	chr7:19748676	TWISTNB	0.53	5.81	0.3	1.42e-8	Thyroid stimulating hormone;
LUSC	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg26408565	chr15:76604113	ETFA	-0.42	-6.78	-0.35	5.53e-11	Blood metabolite levels;
LUSC	cis	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.51	7.86	0.4	5.35e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg09021430	chr5:549028	NA	-0.53	-7.36	-0.37	1.43e-12	Obesity-related traits;
LUSC	cis	rs11630290	0.736	rs2197259	chr15:64154156	T/C	cg12036633	chr15:63758958	NA	0.59	6.36	0.33	6.51e-10	Iris characteristics;
LUSC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg01475377	chr6:109611718	NA	-0.46	-8.44	-0.42	1e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs7119038	0.818	rs11217033	chr11:118673706	T/C	cg19308663	chr11:118741387	NA	0.36	6.47	0.33	3.49e-10	Sjögren's syndrome;
LUSC	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs28719689	0.655	rs58892423	chr8:1276014	A/C	cg22761795	chr8:1265118	NA	0.59	6.78	0.35	5.61e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg07169764	chr2:136633963	MCM6	0.53	7.38	0.37	1.25e-12	Mosquito bite size;
LUSC	cis	rs9359856	0.564	rs17506403	chr6:90499059	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.8	-7.93	-0.4	3.22e-14	Bipolar disorder;
LUSC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg24562669	chr7:97807699	LMTK2	-0.35	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.13	-0.45	6.73e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs3812762	0.917	rs11042066	chr11:8809560	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.4	6.83	0.35	3.98e-11	Hypospadias;
LUSC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.38	6.02	0.31	4.54e-9	Electroencephalogram traits;
LUSC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.05	0.36	1.01e-11	Tonsillectomy;
LUSC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg00933542	chr6:150070202	PCMT1	0.33	6.7	0.34	8.84e-11	Lung cancer;
LUSC	cis	rs727505	0.866	rs73227503	chr7:124721044	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.96	-0.36	1.79e-11	Lewy body disease;
LUSC	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-10.04	-0.48	6.87e-21	Coronary artery disease;
LUSC	cis	rs12618769	0.625	rs56232707	chr2:99032298	G/A	cg10123293	chr2:99228465	UNC50	0.47	7.9	0.4	3.99e-14	Bipolar disorder;
LUSC	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg23283495	chr1:209979779	IRF6	0.63	7.97	0.4	2.61e-14	Cleft lip with or without cleft palate;
LUSC	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg08017756	chr2:100939284	LONRF2	-0.46	-8.51	-0.42	5.85e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs12476592	0.602	rs262538	chr2:63908025	A/T	cg10828910	chr2:63850056	LOC388955	-0.5	-5.79	-0.3	1.65e-8	Childhood ear infection;
LUSC	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg26876637	chr1:152193138	HRNR	0.42	5.96	0.31	6.41e-9	Atopic dermatitis;
LUSC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg01416388	chr22:39784598	NA	0.41	6.76	0.35	6.28e-11	IgG glycosylation;
LUSC	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg02807482	chr3:125708958	NA	-0.49	-5.79	-0.3	1.66e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.85	-14.81	-0.63	1.72e-38	Cognitive function;
LUSC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg23711669	chr6:146136114	FBXO30	0.91	17.06	0.68	2.16e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.23	0.32	1.42e-9	Height;
LUSC	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg17764715	chr19:33622953	WDR88	0.59	8.14	0.41	7.89e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9534288	0.830	rs1126363	chr13:46633459	C/T	cg15192986	chr13:46630673	CPB2	-0.8	-12.69	-0.57	2.14e-30	Blood protein levels;
LUSC	cis	rs9467773	0.595	rs2237236	chr6:26451553	A/G	cg05738196	chr6:26577821	NA	-0.54	-7.77	-0.39	9.53e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs9815354	0.638	rs113712591	chr3:42050624	C/T	cg03022575	chr3:42003672	ULK4	0.78	7.85	0.39	5.64e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.67	0.43	1.91e-16	Prudent dietary pattern;
LUSC	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg13206674	chr6:150067644	NUP43	0.44	6.74	0.35	6.76e-11	Testicular germ cell tumor;
LUSC	cis	rs3733418	0.929	rs4691138	chr4:165908641	A/G	cg11630554	chr4:165878136	TRIM61;C4orf39	-0.51	-5.83	-0.3	1.34e-8	Obesity-related traits;
LUSC	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg10857441	chr5:6722123	POLS	-0.45	-8.98	-0.44	2.05e-17	Menopause (age at onset);
LUSC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.66	11.15	0.52	9.54e-25	Bone mineral density;
LUSC	cis	rs11585357	0.895	rs72646798	chr1:17614422	C/T	cg08277548	chr1:17600880	PADI3	-0.64	-6.62	-0.34	1.42e-10	Hair shape;
LUSC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.81	0.39	7.4e-14	Prudent dietary pattern;
LUSC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.43	0.38	8.9e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-12.01	-0.55	6.98e-28	Body mass index;
LUSC	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.7	10.67	0.5	4.72e-23	Corneal astigmatism;
LUSC	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg09516651	chr1:89888402	LOC400759	0.42	7.48	0.38	6.69e-13	Carotid intima media thickness;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16711083	chr3:125239198	SNX4	-0.43	-6.24	-0.32	1.31e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.65	-8.23	-0.41	4.31e-15	Body mass index;
LUSC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg06454157	chr6:167490870	NA	0.25	6.15	0.32	2.18e-9	Crohn's disease;
LUSC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.78	10.04	0.48	6.49e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg03806693	chr22:41940476	POLR3H	-0.63	-9.21	-0.45	3.59e-18	Vitiligo;
LUSC	cis	rs1403694	0.515	rs5030058	chr3:186452415	T/G	cg12454167	chr3:186435060	KNG1	0.29	7.45	0.38	7.85e-13	Blood protein levels;
LUSC	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12210905	0.925	rs7740207	chr6:27001623	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.97	-0.31	5.9e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs13242816	1.000	rs56275709	chr7:116108489	A/G	cg16553024	chr7:116138462	CAV2	-0.54	-5.92	-0.31	7.84e-9	P wave duration;
LUSC	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.61	-9.34	-0.46	1.35e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05901451	chr6:126070800	HEY2	-0.96	-18.94	-0.72	7.19e-55	Brugada syndrome;
LUSC	cis	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg21775007	chr8:11205619	TDH	-0.52	-7.4	-0.38	1.13e-12	Monocyte count;
LUSC	cis	rs6722750	1.000	rs35573827	chr2:64394433	C/G	cg22352474	chr2:64371530	PELI1	0.57	8.61	0.43	2.9e-16	Neuroticism;
LUSC	cis	rs11958404	0.932	rs76601259	chr5:157430337	C/T	cg05962755	chr5:157440814	NA	0.55	6.27	0.32	1.11e-9	IgG glycosylation;
LUSC	trans	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.35	-0.33	7.02e-10	Bladder cancer;
LUSC	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg05182265	chr7:156933206	UBE3C	0.45	6.9	0.35	2.58e-11	Body mass index;
LUSC	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg24631222	chr15:78858424	CHRNA5	-0.67	-9.13	-0.45	6.9e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2845885	1.000	rs11231698	chr11:63877163	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.81	7.11	0.36	6.94e-12	Body mass index;
LUSC	cis	rs68170813	0.641	rs4730248	chr7:107125939	A/G	cg24556660	chr7:106842632	COG5;HBP1	-0.44	-5.9	-0.31	8.81e-9	Coronary artery disease;
LUSC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg25258033	chr6:167368657	RNASET2	0.36	5.68	0.3	2.88e-8	Primary biliary cholangitis;
LUSC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	0.99	13.84	0.6	9.21e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs7202877	0.610	rs468079	chr16:75428474	G/A	cg03315344	chr16:75512273	CHST6	-0.41	-6.1	-0.32	3e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs72949976	0.864	rs13389834	chr2:214025112	G/A	cg08319019	chr2:214017104	IKZF2	-0.65	-10.19	-0.49	2.04e-21	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs2130392	0.961	rs2696035	chr4:185612953	A/G	cg04058563	chr4:185651563	MLF1IP	0.39	6.37	0.33	6.28e-10	Kawasaki disease;
LUSC	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg09835421	chr16:68378352	PRMT7	-0.67	-7.02	-0.36	1.28e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12618769	0.652	rs17033813	chr2:99196483	A/G	cg10123293	chr2:99228465	UNC50	-0.45	-7.2	-0.37	3.9e-12	Bipolar disorder;
LUSC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg06618935	chr21:46677482	NA	-0.37	-7.58	-0.38	3.42e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg06008330	chr7:65541103	ASL	0.39	6.06	0.31	3.65e-9	Aortic root size;
LUSC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	9.1	0.45	8.56e-18	Motion sickness;
LUSC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.02e-28	Motion sickness;
LUSC	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg04398451	chr17:18023971	MYO15A	0.44	6.96	0.36	1.79e-11	Total body bone mineral density;
LUSC	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg07274523	chr3:49395745	GPX1	0.68	10.46	0.5	2.38e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs2294693	0.530	rs2073016	chr6:41020922	T/C	cg14769373	chr6:40998127	UNC5CL	-0.47	-5.86	-0.31	1.08e-8	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg25019033	chr10:957182	NA	-0.52	-7.2	-0.37	3.99e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	0.49	6.1	0.32	3.02e-9	Yeast infection;
LUSC	cis	rs713477	0.967	rs2152975	chr14:55907919	C/T	cg13175173	chr14:55914753	NA	-0.32	-6.67	-0.34	1.07e-10	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-6.36	-0.33	6.46e-10	Resting heart rate;
LUSC	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg17691542	chr6:26056736	HIST1H1C	0.56	8.33	0.41	2.14e-15	Height;
LUSC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg02696742	chr7:106810147	HBP1	0.66	9.78	0.47	4.89e-20	Coronary artery disease;
LUSC	cis	rs12541635	0.677	rs11781234	chr8:107012342	G/T	cg10147462	chr8:107024639	NA	0.68	14.28	0.62	1.94e-36	Age of smoking initiation;
LUSC	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg01119278	chr6:110721349	DDO	0.43	7.73	0.39	1.27e-13	Platelet distribution width;
LUSC	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg15423357	chr2:25149977	NA	0.35	6.78	0.35	5.59e-11	Body mass index in non-asthmatics;
LUSC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-1.03	-20.07	-0.74	2.43e-59	Height;
LUSC	cis	rs2273669	0.667	rs78383792	chr6:109312498	A/G	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg12379764	chr21:47803548	PCNT	-0.41	-5.73	-0.3	2.26e-8	Testicular germ cell tumor;
LUSC	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-9.02	-0.44	1.54e-17	Total cholesterol levels;
LUSC	cis	rs1957429	0.614	rs7144637	chr14:65349709	A/G	cg23373153	chr14:65346875	NA	-1.03	-9.4	-0.46	8.72e-19	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18099408	chr3:52552593	STAB1	-0.41	-6.99	-0.36	1.46e-11	Bipolar disorder;
LUSC	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg15556689	chr8:8085844	FLJ10661	0.69	11.07	0.52	1.76e-24	Joint mobility (Beighton score);
LUSC	cis	rs9296092	0.538	rs5000098	chr6:33519231	T/G	cg13560919	chr6:33536144	NA	-0.82	-15.68	-0.65	6.59e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03934478	chr11:495069	RNH1	0.86	9.38	0.46	1.06e-18	Body mass index;
LUSC	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.46	-6.77	-0.35	5.66e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs7524258	0.868	rs4908610	chr1:7311260	C/A	cg07173049	chr1:7289937	CAMTA1	0.33	6.61	0.34	1.57e-10	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.98	-0.31	5.84e-9	Longevity;
LUSC	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	1.18	13.93	0.61	4.45e-35	Arsenic metabolism;
LUSC	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg11189052	chr15:85197271	WDR73	0.49	6.03	0.31	4.45e-9	Schizophrenia;
LUSC	cis	rs10761482	0.769	rs4442496	chr10:62101371	T/C	cg18175470	chr10:62150864	ANK3	-0.52	-7.35	-0.37	1.56e-12	Schizophrenia;
LUSC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg15557168	chr22:42548783	NA	0.46	6.98	0.36	1.62e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg16512390	chr1:228756714	NA	0.7	8.82	0.43	6.67e-17	Chronic lymphocytic leukemia;
LUSC	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg06636001	chr8:8085503	FLJ10661	0.48	6.68	0.34	1.02e-10	Neuroticism;
LUSC	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg00898013	chr13:113819073	PROZ	0.52	7.8	0.39	7.74e-14	Platelet distribution width;
LUSC	cis	rs4746818	0.711	rs4745976	chr10:70845181	A/G	cg11621586	chr10:70884670	VPS26A	0.71	7.42	0.38	1.01e-12	Left atrial antero-posterior diameter;
LUSC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-7.38	-0.37	1.3e-12	Aortic root size;
LUSC	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg05340658	chr4:99064831	C4orf37	0.57	9.54	0.46	3.03e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg12310025	chr6:25882481	NA	0.34	5.86	0.31	1.1e-8	Blood metabolite levels;
LUSC	cis	rs9378688	0.929	rs9392373	chr6:2210006	T/A	cg12303981	chr6:2244766	GMDS	-0.51	-6.34	-0.33	7.53e-10	Caudate nucleus volume;
LUSC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.49	0.42	6.97e-16	Prudent dietary pattern;
LUSC	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg05855489	chr10:104503620	C10orf26	0.59	9.51	0.46	3.79e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg04545296	chr12:48745243	ZNF641	0.33	6.22	0.32	1.5e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg18350739	chr11:68623251	NA	-0.38	-6.71	-0.34	8.13e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.71	10.7	0.51	3.64e-23	Aortic root size;
LUSC	cis	rs7605827	0.897	rs4668908	chr2:15589290	G/T	cg19274914	chr2:15703543	NA	0.45	8.5	0.42	6.41e-16	Educational attainment (years of education);
LUSC	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg01368799	chr11:117014884	PAFAH1B2	0.5	6.68	0.34	9.92e-11	Blood protein levels;
LUSC	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg23625390	chr15:77176239	SCAPER	0.52	7.98	0.4	2.38e-14	Blood metabolite levels;
LUSC	cis	rs2219968	0.798	rs57034374	chr8:78911919	T/C	cg00738934	chr8:78996279	NA	-0.41	-7.37	-0.37	1.35e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg05347473	chr6:146136440	FBXO30	0.46	7.96	0.4	2.72e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4074961	0.692	rs11264075	chr1:38083941	C/G	cg02930200	chr1:38022384	DNALI1	0.29	5.92	0.31	7.91e-9	Axial length;
LUSC	trans	rs867371	0.502	rs2047679	chr15:82531881	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.35	-0.33	7.13e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.55	-8.24	-0.41	4.07e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs9469578	0.579	rs77528762	chr6:33683068	A/T	cg18708504	chr6:33715942	IP6K3	0.67	6.33	0.33	8e-10	Phosphorus levels;
LUSC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg23283495	chr1:209979779	IRF6	0.73	9.34	0.46	1.37e-18	Cleft lip with or without cleft palate;
LUSC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03264133	chr6:25882463	NA	0.43	7.34	0.37	1.66e-12	Blood metabolite levels;
LUSC	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg27661571	chr11:113659931	NA	0.58	6.35	0.33	7.05e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs12368653	0.534	rs923828	chr12:58015494	G/A	cg12615879	chr12:58013172	SLC26A10	0.43	10.27	0.49	1.07e-21	Multiple sclerosis;
LUSC	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg27446573	chr6:127587934	RNF146	0.64	10.32	0.49	7.57e-22	Breast cancer;
LUSC	cis	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-6.03	-0.31	4.46e-9	Neuroticism;
LUSC	cis	rs4845570	0.920	rs1196456	chr1:151737349	T/A	cg07092448	chr1:151763213	TDRKH	1.25	15.93	0.66	6.67e-43	Coronary artery disease;
LUSC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg22166914	chr1:53195759	ZYG11B	-0.71	-12.23	-0.56	1.11e-28	Monocyte count;
LUSC	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg17143192	chr8:8559678	CLDN23	0.64	9.02	0.44	1.47e-17	Obesity-related traits;
LUSC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg22907277	chr7:1156413	C7orf50	0.72	7.67	0.39	1.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs59104589	0.617	rs12233133	chr2:242256812	G/C	cg14842376	chr2:242211374	HDLBP	0.58	6.49	0.33	3.17e-10	Fibrinogen levels;
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg00431813	chr7:1051703	C7orf50	-0.39	-6.03	-0.31	4.28e-9	Longevity;Endometriosis;
LUSC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.76	0.84	8.98e-89	Chronic sinus infection;
LUSC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg22834771	chr12:69754056	YEATS4	-0.56	-8.42	-0.42	1.11e-15	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs71403859	0.570	rs76231867	chr16:71449926	G/A	cg08717414	chr16:71523259	ZNF19	-0.62	-7.03	-0.36	1.14e-11	Post bronchodilator FEV1;
LUSC	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg15556689	chr8:8085844	FLJ10661	0.53	7.96	0.4	2.74e-14	Neuroticism;
LUSC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.69	11.25	0.52	4.11e-25	Longevity;
LUSC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg03579872	chr1:53393473	SCP2	-0.39	-5.97	-0.31	6.13e-9	Monocyte count;
LUSC	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg24642439	chr20:33292090	TP53INP2	0.55	8.2	0.41	5.38e-15	Height;
LUSC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	7.83	0.39	6.43e-14	Menarche (age at onset);
LUSC	cis	rs10992471	0.603	rs7873397	chr9:95205928	G/C	cg14631576	chr9:95140430	CENPP	-0.35	-6.46	-0.33	3.65e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg25703541	chr22:24373054	LOC391322	-0.92	-16.03	-0.66	2.66e-43	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7953508	0.619	rs11107114	chr12:93972927	G/A	cg18151635	chr12:93972918	NA	-0.62	-8.8	-0.43	7.38e-17	Pubertal anthropometrics;
LUSC	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg00083937	chr22:51039805	MAPK8IP2	0.5	8.34	0.42	1.99e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg02428538	chr16:24856791	SLC5A11	-0.52	-5.89	-0.31	9.52e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg24375607	chr4:120327624	NA	-0.46	-7.11	-0.36	7.19e-12	Diastolic blood pressure;
LUSC	cis	rs35883536	0.528	rs1542837	chr1:101029768	T/C	cg06223162	chr1:101003688	GPR88	0.46	8.57	0.42	3.92e-16	Monocyte count;
LUSC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg02569458	chr12:86230093	RASSF9	0.52	8.57	0.42	3.81e-16	Major depressive disorder;
LUSC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg25258033	chr6:167368657	RNASET2	0.48	7.83	0.39	6.61e-14	Crohn's disease;
LUSC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.66	-0.3	3.22e-8	Personality dimensions;
LUSC	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05962382	chr2:130345044	NA	-0.39	-6.85	-0.35	3.57e-11	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg06263672	chr7:65235340	NA	0.47	6.75	0.35	6.73e-11	Calcium levels;
LUSC	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg13010199	chr12:38710504	ALG10B	0.47	7.14	0.36	5.79e-12	Morning vs. evening chronotype;
LUSC	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.91	16.66	0.67	9.06e-46	Bone mineral density;
LUSC	cis	rs9612	1.000	rs346534	chr19:44250831	A/G	cg08581076	chr19:44259116	C19orf61	0.54	6.71	0.34	8.5e-11	Exhaled nitric oxide output;
LUSC	cis	rs10193935	0.901	rs222478	chr2:42656919	G/T	cg27598129	chr2:42591480	NA	-0.56	-7.74	-0.39	1.16e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg24375607	chr4:120327624	NA	0.76	11.15	0.52	9.61e-25	Corneal astigmatism;
LUSC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.21	-0.41	4.88e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.75	-11.65	-0.54	1.47e-26	Menarche (age at onset);
LUSC	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg22705602	chr4:152727874	NA	-0.37	-7.93	-0.4	3.32e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs67366981	1.000	rs2287383	chr14:77713036	C/G	cg22824376	chr14:77648248	TMEM63C	0.65	6.19	0.32	1.75e-9	Obsessive-compulsive symptoms;
LUSC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg26850624	chr5:429559	AHRR	-0.41	-8.0	-0.4	2.1e-14	Cystic fibrosis severity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19783675	chr5:132362235	ZCCHC10	-0.45	-6.79	-0.35	5.2e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg16482183	chr6:26056742	HIST1H1C	0.59	8.36	0.42	1.71e-15	Iron status biomarkers;
LUSC	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg11344533	chr11:111475393	SIK2	-0.45	-6.14	-0.32	2.31e-9	Primary sclerosing cholangitis;
LUSC	trans	rs8060598	0.866	rs3135499	chr16:50766127	G/T	cg25118631	chr4:120206103	USP53	-0.39	-5.96	-0.31	6.24e-9	Leprosy;
LUSC	cis	rs137603	0.623	rs470075	chr22:39686806	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.54	-8.62	-0.43	2.69e-16	Primary biliary cholangitis;
LUSC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg10253484	chr15:75165896	SCAMP2	-0.45	-6.43	-0.33	4.29e-10	Breast cancer;
LUSC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.53	0.38	4.76e-13	Parkinson's disease;
LUSC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.56	8.33	0.41	2.05e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.53	-7.75	-0.39	1.12e-13	Gut microbiome composition (summer);
LUSC	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg00071950	chr4:10020882	SLC2A9	0.55	8.93	0.44	2.81e-17	Bone mineral density;
LUSC	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg04727924	chr7:799746	HEATR2	-0.54	-6.78	-0.35	5.6e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg05519781	chr21:40033154	ERG	0.62	9.95	0.48	1.32e-20	Coronary artery disease;
LUSC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg23102388	chr7:1867652	MAD1L1	0.31	5.82	0.3	1.35e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg27432699	chr2:27873401	GPN1	-0.88	-17.51	-0.69	3.63e-49	Oral cavity cancer;
LUSC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.92	0.44	3.02e-17	Motion sickness;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12791010	chr2:190305806	WDR75	-0.41	-6.3	-0.33	9.31e-10	Electrocardiographic conduction measures;
LUSC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg03806693	chr22:41940476	POLR3H	-0.99	-14.12	-0.61	8.14e-36	Vitiligo;
LUSC	cis	rs12586317	0.531	rs60049741	chr14:35719842	G/A	cg05294307	chr14:35346193	BAZ1A	-0.39	-5.67	-0.3	3.16e-8	Psoriasis;
LUSC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg05863683	chr7:1912471	MAD1L1	0.3	5.77	0.3	1.83e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg24562669	chr7:97807699	LMTK2	0.34	5.97	0.31	6.16e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg04450456	chr4:17643702	FAM184B	0.35	5.8	0.3	1.56e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.76	-0.51	2.15e-23	Glomerular filtration rate;
LUSC	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-7.05	-0.36	1.03e-11	Total cholesterol levels;
LUSC	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg21211680	chr2:198530	NA	0.73	8.21	0.41	4.75e-15	Blood protein levels;
LUSC	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg11342453	chr6:26196699	NA	0.56	5.92	0.31	8.04e-9	Gout;Renal underexcretion gout;
LUSC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11764359	chr7:65958608	NA	-0.68	-11.03	-0.52	2.59e-24	Aortic root size;
LUSC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg05802129	chr4:122689817	NA	-0.36	-6.53	-0.34	2.41e-10	Type 2 diabetes;
LUSC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-1.23	-13.29	-0.59	1.17e-32	Diabetic kidney disease;
LUSC	cis	rs62400317	0.762	rs529125	chr6:44797088	C/T	cg20913747	chr6:44695427	NA	0.44	6.84	0.35	3.88e-11	Total body bone mineral density;
LUSC	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg27124370	chr19:33622961	WDR88	0.53	6.69	0.34	9.21e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg06521331	chr12:34319734	NA	-0.48	-7.77	-0.39	9.54e-14	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.39	0.46	9.85e-19	Prudent dietary pattern;
LUSC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.17	0.61	5.11e-36	Platelet count;
LUSC	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	7.64	0.39	2.25e-13	Iron status biomarkers;
LUSC	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.16	0.49	2.55e-21	Lymphocyte counts;
LUSC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg15147215	chr3:52552868	STAB1	-0.31	-6.13	-0.32	2.47e-9	Electroencephalogram traits;
LUSC	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg09469691	chr10:81107165	PPIF	0.7	10.86	0.51	1.01e-23	Height;
LUSC	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.26	-0.32	1.15e-9	Bipolar disorder;
LUSC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg12927641	chr6:109611667	NA	0.43	7.57	0.38	3.57e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg03975922	chr5:140080575	ZMAT2	0.31	5.66	0.3	3.25e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	14.18	0.61	4.69e-36	Monocyte count;
LUSC	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	0.9	17.9	0.7	9.82e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg07167872	chr1:205819463	PM20D1	-0.44	-5.94	-0.31	7.02e-9	Menarche (age at onset);
LUSC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.17	0.32	2e-9	Schizophrenia;
LUSC	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg12552261	chr5:112820674	MCC	-0.44	-7.02	-0.36	1.25e-11	Type 2 diabetes;
LUSC	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg17691542	chr6:26056736	HIST1H1C	0.4	5.92	0.31	8.02e-9	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-8.29	-0.41	2.86e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg11887960	chr12:57824829	NA	0.51	6.7	0.34	8.99e-11	Obesity-related traits;
LUSC	cis	rs354225	0.544	rs10182538	chr2:54808251	T/A	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg17470723	chr8:74884337	TCEB1	-0.5	-7.61	-0.38	2.88e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	8.64	0.43	2.39e-16	Alzheimer's disease;
LUSC	cis	rs2414856	0.510	rs72758912	chr15:64641491	T/C	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.78	14.39	0.62	7.48e-37	Dental caries;
LUSC	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.67	9.56	0.46	2.68e-19	Methadone dose in opioid dependence;
LUSC	trans	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg20935933	chr6:143382018	AIG1	0.5	7.24	0.37	3.1e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7216064	0.861	rs62084252	chr17:65879578	G/C	cg12091567	chr17:66097778	LOC651250	-0.72	-9.46	-0.46	5.74e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg13575925	chr12:9217583	LOC144571	0.35	6.66	0.34	1.12e-10	Sjögren's syndrome;
LUSC	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg04586622	chr2:25135609	ADCY3	0.39	8.1	0.41	1.03e-14	Body mass index in non-asthmatics;
LUSC	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg18721089	chr20:30220636	NA	-0.36	-6.19	-0.32	1.81e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.87	-14.43	-0.62	4.92e-37	Schizophrenia;
LUSC	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg11861562	chr11:117069780	TAGLN	0.35	6.81	0.35	4.49e-11	Blood protein levels;
LUSC	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg22705602	chr4:152727874	NA	-0.32	-6.54	-0.34	2.28e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-8.91	-0.44	3.32e-17	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-10.02	-0.48	7.71e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs9653442	0.564	rs7590378	chr2:100789877	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-7.04	-0.36	1.09e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9039	1.000	rs9921107	chr16:9219845	G/T	cg08831531	chr16:9218945	NA	-0.66	-10.37	-0.49	4.91e-22	Menopause (age at onset);
LUSC	cis	rs62400317	0.826	rs62400330	chr6:45321455	G/A	cg18551225	chr6:44695536	NA	-0.43	-7.25	-0.37	2.9e-12	Total body bone mineral density;
LUSC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg25036284	chr2:26402008	FAM59B	-0.71	-9.84	-0.47	3.15e-20	Gut microbiome composition (summer);
LUSC	trans	rs57046232	0.552	rs932828	chr20:6340080	G/A	cg17788362	chr6:86352627	SYNCRIP	0.42	6.03	0.31	4.36e-9	Colorectal cancer;
LUSC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg00343986	chr7:65444356	GUSB	-0.39	-5.87	-0.31	1.05e-8	Aortic root size;
LUSC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg01879757	chr17:41196368	BRCA1	-0.39	-5.96	-0.31	6.57e-9	Menopause (age at onset);
LUSC	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg00277334	chr10:82204260	NA	-0.56	-7.53	-0.38	4.92e-13	Post bronchodilator FEV1;
LUSC	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg26536354	chr8:144654954	C8orf73	0.67	7.3	0.37	2.18e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg00334542	chr7:100209784	MOSPD3	-0.67	-7.82	-0.39	6.88e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	trans	rs12210905	0.688	rs72843151	chr6:27359268	A/C	cg11837749	chr1:55047332	ACOT11	0.68	6.07	0.32	3.38e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.64	0.57	3.49e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	7.02	0.36	1.24e-11	Ovarian reserve;
LUSC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06850241	chr22:41845214	NA	0.32	5.83	0.3	1.28e-8	Vitiligo;
LUSC	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg00101154	chr16:420108	MRPL28	-0.44	-6.59	-0.34	1.74e-10	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs11686934	0.780	rs6731423	chr2:70173327	A/C	cg02498382	chr2:70120550	SNRNP27	-0.26	-6.58	-0.34	1.79e-10	High light scatter reticulocyte count;
LUSC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.67	6.48	0.33	3.25e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs977987	0.806	rs6564258	chr16:75447363	G/A	cg03315344	chr16:75512273	CHST6	0.48	8.92	0.44	3.16e-17	Dupuytren's disease;
LUSC	cis	rs16910800	0.954	rs2449440	chr11:23200335	T/G	cg20040320	chr11:23191996	NA	0.44	6.53	0.34	2.41e-10	Cancer;
LUSC	trans	rs9944715	0.954	rs4453594	chr18:43788332	G/T	cg01718231	chr17:29326311	RNF135	-0.54	-7.69	-0.39	1.65e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs1461503	0.966	rs10790547	chr11:122842110	T/A	cg27398637	chr11:122830231	C11orf63	-0.41	-6.54	-0.34	2.29e-10	Menarche (age at onset);
LUSC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08219700	chr8:58056026	NA	0.64	8.18	0.41	6.2e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg17830980	chr10:43048298	ZNF37B	-0.4	-6.35	-0.33	7.16e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg20887711	chr4:1340912	KIAA1530	-0.65	-9.97	-0.48	1.14e-20	Obesity-related traits;
LUSC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg14092988	chr3:52407081	DNAH1	0.32	6.21	0.32	1.59e-9	Bipolar disorder;
LUSC	cis	rs2708377	0.932	rs2257110	chr12:11202522	G/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs11229555	0.874	rs12800710	chr11:58314540	C/T	cg15696309	chr11:58395628	NA	-0.69	-8.94	-0.44	2.61e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs61931739	0.649	rs815045	chr12:33722057	C/G	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg26727032	chr16:67993705	SLC12A4	-0.45	-5.81	-0.3	1.43e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12541635	0.677	rs7003520	chr8:107061724	G/A	cg10147462	chr8:107024639	NA	0.66	13.87	0.6	7.11e-35	Age of smoking initiation;
LUSC	cis	rs9309473	0.528	rs10191517	chr2:73558403	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-7.79	-0.39	8.68e-14	Metabolite levels;
LUSC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg17143192	chr8:8559678	CLDN23	-0.68	-9.68	-0.47	1.1e-19	Obesity-related traits;
LUSC	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg21132104	chr15:45694354	SPATA5L1	0.56	7.77	0.39	1.01e-13	Homoarginine levels;
LUSC	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg08999081	chr20:33150536	PIGU	0.38	6.89	0.35	2.76e-11	Height;
LUSC	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.56	-9.25	-0.45	2.75e-18	Breast cancer;
LUSC	cis	rs7759001	0.817	rs10080571	chr6:27363150	G/C	cg18711553	chr6:27366782	ZNF391	0.39	5.73	0.3	2.27e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg27471124	chr11:109292789	C11orf87	0.41	7.09	0.36	8.05e-12	Schizophrenia;
LUSC	trans	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04565464	chr8:145669602	NFKBIL2	0.36	6.02	0.31	4.47e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6690583	0.623	rs898036	chr1:85521904	A/T	cg11262906	chr1:85462892	MCOLN2	0.68	6.32	0.33	8.43e-10	Serum sulfate level;
LUSC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	1.23	16.23	0.66	4.34e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg22681709	chr2:178499509	PDE11A	-0.59	-11.83	-0.54	3.26e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7215564	0.818	rs35459747	chr17:78661475	T/C	cg09596252	chr17:78655493	RPTOR	0.55	6.05	0.31	3.97e-9	Myopia (pathological);
LUSC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	16.51	0.67	3.47e-45	Gut microbiome composition (summer);
LUSC	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg09904177	chr6:26538194	HMGN4	-0.75	-6.61	-0.34	1.51e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-14.75	-0.63	2.85e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg02034447	chr16:89574710	SPG7	0.41	6.34	0.33	7.62e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.52	-8.69	-0.43	1.7e-16	Lymphocyte counts;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03315476	chr1:40915606	ZNF643	-0.43	-5.97	-0.31	6.01e-9	Hepatitis;
LUSC	cis	rs72777070	0.652	rs7608996	chr2:9795757	C/T	cg14973360	chr2:9800511	NA	0.38	5.73	0.3	2.2e-8	Platelet-derived growth factor BB levels;
LUSC	cis	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg21775007	chr8:11205619	TDH	-0.52	-7.15	-0.36	5.38e-12	Triglycerides;
LUSC	cis	rs7584330	0.554	rs76980036	chr2:238426750	G/A	cg16989719	chr2:238392110	NA	-0.43	-6.2	-0.32	1.65e-9	Prostate cancer;
LUSC	trans	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-6.87	-0.35	3.06e-11	Menarche (age at onset);
LUSC	cis	rs7520050	0.898	rs34175029	chr1:46483871	C/T	cg06784218	chr1:46089804	CCDC17	-0.29	-5.69	-0.3	2.83e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs1113500	0.933	rs11185256	chr1:108633957	C/T	cg06207961	chr1:108661230	NA	0.41	7.61	0.38	2.89e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg00898013	chr13:113819073	PROZ	-0.56	-8.49	-0.42	6.86e-16	Platelet distribution width;
LUSC	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.16	0.45	5.47e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4343996	0.754	rs2340848	chr7:3492446	G/A	cg21248987	chr7:3385318	SDK1	0.35	5.69	0.3	2.81e-8	Motion sickness;
LUSC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg05623727	chr3:50126028	RBM5	0.31	5.81	0.3	1.43e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs2262909	0.889	rs61268244	chr19:22310130	C/T	cg17074339	chr11:11642133	GALNTL4	0.44	6.69	0.34	9.25e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg22907277	chr7:1156413	C7orf50	0.73	10.41	0.5	3.58e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs62458065	0.713	rs1597560	chr7:32493886	C/G	cg00845942	chr12:64062724	DPY19L2	-0.54	-6.45	-0.33	3.83e-10	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg23711669	chr6:146136114	FBXO30	0.86	15.72	0.65	4.59e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg02800362	chr5:177631904	HNRNPAB	0.84	12.56	0.57	6.68e-30	Obesity-related traits;
LUSC	cis	rs6736093	1.000	rs4848861	chr2:112668835	A/G	cg12686935	chr2:112915763	FBLN7	0.38	5.76	0.3	1.89e-8	Coronary artery disease;
LUSC	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	11.13	0.52	1.07e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg19789473	chr17:27170043	C17orf63	0.31	6.19	0.32	1.79e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.28	-0.32	1.06e-9	Neuroticism;
LUSC	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg23262351	chr6:79576851	IRAK1BP1	-0.4	-6.14	-0.32	2.3e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9296092	0.560	rs9469500	chr6:33526196	C/T	cg13560919	chr6:33536144	NA	-0.84	-16.17	-0.66	7.8e-44	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18404041	chr3:52824283	ITIH1	0.56	10.81	0.51	1.46e-23	Bipolar disorder;
LUSC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg06636001	chr8:8085503	FLJ10661	0.59	8.89	0.44	3.97e-17	Mood instability;
LUSC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.36	-0.33	6.82e-10	Joint mobility (Beighton score);
LUSC	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.35	2.1e-11	Monocyte percentage of white cells;
LUSC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg06784218	chr1:46089804	CCDC17	0.51	9.89	0.48	2.11e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23712970	chr14:23540735	ACIN1	0.55	7.54	0.38	4.41e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.67	11.93	0.55	1.38e-27	Aortic root size;
LUSC	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06482044	chr16:31191169	FUS	-0.39	-6.05	-0.31	3.95e-9	Smoking initiation;
LUSC	trans	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.75	-0.35	6.52e-11	Lung cancer;
LUSC	trans	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07923666	chr12:49932857	KCNH3	-0.53	-6.59	-0.34	1.74e-10	Resting heart rate;
LUSC	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg22906224	chr7:99728672	NA	-0.5	-6.99	-0.36	1.49e-11	Coronary artery disease;
LUSC	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg10253484	chr15:75165896	SCAMP2	-0.52	-6.84	-0.35	3.9e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25637963	chr5:138629068	MATR3	0.37	6.21	0.32	1.53e-9	Schizophrenia;
LUSC	cis	rs45535039	0.506	rs4936467	chr11:119086629	A/T	cg16724696	chr11:118992527	HINFP	-0.53	-7.62	-0.38	2.66e-13	Plateletcrit;
LUSC	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg16482183	chr6:26056742	HIST1H1C	-0.56	-8.03	-0.4	1.73e-14	Iron status biomarkers;
LUSC	cis	rs3087591	0.887	rs1013946	chr17:29530350	A/C	cg24425628	chr17:29625626	OMG;NF1	0.58	8.72	0.43	1.34e-16	Hip circumference;
LUSC	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg05855489	chr10:104503620	C10orf26	0.5	7.48	0.38	6.64e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg27432699	chr2:27873401	GPN1	0.88	17.32	0.69	2.17e-48	Oral cavity cancer;
LUSC	cis	rs11031096	0.536	rs894459	chr11:4213590	A/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.82	-0.3	1.38e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg27205649	chr11:78285834	NARS2	-0.52	-5.69	-0.3	2.85e-8	Testicular germ cell tumor;
LUSC	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg13256891	chr4:100009986	ADH5	-0.42	-5.69	-0.3	2.74e-8	Alcohol dependence;
LUSC	cis	rs3126085	0.778	rs9887901	chr1:152248552	A/C	cg26876637	chr1:152193138	HRNR	0.45	6.03	0.31	4.34e-9	Atopic dermatitis;
LUSC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.8	14.43	0.62	4.94e-37	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13824859	chr6:109804376	ZBTB24	-0.4	-6.1	-0.32	3e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg15691649	chr6:25882328	NA	-0.51	-7.11	-0.36	6.97e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.91	15.54	0.65	2.38e-41	Bladder cancer;
LUSC	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg13042288	chr15:90349979	ANPEP	-0.48	-6.91	-0.35	2.46e-11	Uric acid levels;
LUSC	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.7	10.69	0.5	3.89e-23	Corneal astigmatism;
LUSC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg12463550	chr7:65579703	CRCP	0.41	5.89	0.31	9.19e-9	Aortic root size;
LUSC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg12639453	chr1:2035780	PRKCZ	-0.33	-7.17	-0.37	4.76e-12	Height;
LUSC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg09034736	chr1:150693464	HORMAD1	-0.5	-7.32	-0.37	1.87e-12	Tonsillectomy;
LUSC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.47	-0.56	1.43e-29	Rheumatoid arthritis;
LUSC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.74	11.17	0.52	7.89e-25	Type 2 diabetes;
LUSC	cis	rs710216	0.797	rs1770811	chr1:43400547	A/T	cg03128534	chr1:43423976	SLC2A1	0.45	5.73	0.3	2.2e-8	Red cell distribution width;
LUSC	cis	rs9341808	0.655	rs9350846	chr6:80865481	T/A	cg08355045	chr6:80787529	NA	0.56	9.59	0.46	2.07e-19	Sitting height ratio;
LUSC	cis	rs3106136	0.967	rs13132963	chr4:95219780	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.25	-0.32	1.29e-9	Capecitabine sensitivity;
LUSC	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg25703541	chr22:24373054	LOC391322	-0.89	-14.5	-0.62	2.8e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.97	0.36	1.7e-11	Bipolar disorder;
LUSC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07256732	chr16:621771	PIGQ	-0.36	-6.54	-0.34	2.24e-10	Height;
LUSC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	29.03	0.85	2.44e-93	Chronic sinus infection;
LUSC	trans	rs11123259	0.761	rs6723421	chr2:115699213	C/T	cg00844339	chr9:138873417	NA	0.3	5.99	0.31	5.35e-9	Gut microbiome composition (winter);
LUSC	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.79	-14.19	-0.61	4.31e-36	Brugada syndrome;
LUSC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-1.12	-24.19	-0.8	2.08e-75	Height;
LUSC	cis	rs3740540	0.530	rs2362505	chr10:126290739	T/G	cg04949429	chr10:126290192	LHPP	0.36	7.64	0.39	2.29e-13	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg03929089	chr4:120376271	NA	-0.53	-6.5	-0.34	3.01e-10	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg03522245	chr20:25566470	NINL	-0.35	-5.78	-0.3	1.68e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg01802117	chr1:53393560	SCP2	0.38	6.2	0.32	1.67e-9	Monocyte count;
LUSC	cis	rs1358748	0.520	rs2815342	chr1:67532313	G/A	cg02640540	chr1:67518911	SLC35D1	0.62	6.52	0.34	2.6e-10	Tuberculosis;
LUSC	cis	rs793571	0.590	rs17190727	chr15:59073790	C/A	cg05156742	chr15:59063176	FAM63B	0.55	8.44	0.42	9.9e-16	Schizophrenia;
LUSC	cis	rs1808579	0.904	rs1788783	chr18:21161134	C/T	cg14672496	chr18:21087552	C18orf8	0.35	6.16	0.32	2.08e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12379764	chr21:47803548	PCNT	-0.42	-5.95	-0.31	6.93e-9	Testicular germ cell tumor;
LUSC	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg02574844	chr11:5959923	NA	-0.45	-6.21	-0.32	1.56e-9	DNA methylation (variation);
LUSC	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg03929089	chr4:120376271	NA	0.5	7.14	0.36	5.78e-12	Coronary artery disease;
LUSC	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg07169764	chr2:136633963	MCM6	0.87	12.0	0.55	7.99e-28	Mosquito bite size;
LUSC	cis	rs3820928	0.874	rs7582251	chr2:227791703	G/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.72	-0.39	1.38e-13	Pulmonary function;
LUSC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	9.93	0.48	1.57e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-7.93	-0.4	3.33e-14	Acylcarnitine levels;
LUSC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg24675658	chr1:53192096	ZYG11B	-0.64	-10.67	-0.5	4.56e-23	Monocyte count;
LUSC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg09033563	chr22:24373618	LOC391322	-0.59	-9.05	-0.44	1.16e-17	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2742417	0.603	rs2742374	chr3:45784082	T/C	cg10512202	chr3:45649293	LIMD1	0.36	6.09	0.32	3.17e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg09365446	chr1:150670422	GOLPH3L	0.52	7.9	0.4	4.17e-14	Melanoma;
LUSC	cis	rs73198271	0.700	rs10090152	chr8:8652104	C/A	cg01851573	chr8:8652454	MFHAS1	0.51	8.18	0.41	5.98e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7575217	0.767	rs4851407	chr2:101759182	G/A	cg23907051	chr2:101730305	TBC1D8	-0.28	-7.33	-0.37	1.77e-12	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.38	-8.49	-0.42	6.67e-16	Longevity;Endometriosis;
LUSC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.67	13.0	0.58	1.45e-31	Gestational age at birth (maternal effect);
LUSC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.44	6.01	0.31	4.96e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs4588572	0.643	rs1529499	chr5:77721431	T/C	cg11547950	chr5:77652471	NA	-0.55	-7.91	-0.4	3.82e-14	Triglycerides;
LUSC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg04673462	chr1:38461896	NA	-0.54	-8.61	-0.43	2.88e-16	Coronary artery disease;
LUSC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg23711669	chr6:146136114	FBXO30	0.85	15.91	0.66	8.01e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg05623727	chr3:50126028	RBM5	-0.34	-6.37	-0.33	6.27e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	12.09	0.55	3.72e-28	Ileal carcinoids;
LUSC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.7	11.31	0.53	2.55e-25	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs7169223	0.653	rs2904228	chr15:79086099	G/A	cg21242079	chr15:79101063	ADAMTS7	-0.4	-5.74	-0.3	2.07e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9420	0.961	rs17455520	chr11:57540458	C/A	cg23127183	chr11:57508653	C11orf31	-0.57	-8.81	-0.43	6.86e-17	Schizophrenia;
LUSC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg12463550	chr7:65579703	CRCP	-0.57	-8.62	-0.43	2.65e-16	Aortic root size;
LUSC	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg05925327	chr15:68127851	NA	-0.43	-6.95	-0.36	1.91e-11	Restless legs syndrome;
LUSC	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg01677386	chr11:118938358	VPS11	-0.48	-6.82	-0.35	4.41e-11	Coronary artery disease;
LUSC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg03188948	chr7:1209495	NA	0.46	6.16	0.32	2.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg06096015	chr1:231504339	EGLN1	0.56	9.99	0.48	9.69e-21	Hemoglobin concentration;
LUSC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg02475777	chr4:1388615	CRIPAK	0.45	6.76	0.35	6.33e-11	Obesity-related traits;
LUSC	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg00191853	chr8:101177733	SPAG1	0.36	5.93	0.31	7.41e-9	Atrioventricular conduction;
LUSC	cis	rs17401966	0.540	rs1467653	chr1:10413123	A/G	cg17425144	chr1:10567563	PEX14	0.34	6.1	0.32	2.99e-9	Hepatocellular carcinoma;
LUSC	cis	rs9815354	0.638	rs75687617	chr3:42044664	C/T	cg03022575	chr3:42003672	ULK4	0.78	7.87	0.4	5.1e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12311346	chr5:56204834	C5orf35	0.84	13.98	0.61	2.88e-35	Initial pursuit acceleration;
LUSC	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg08847533	chr14:75593920	NEK9	-0.85	-15.31	-0.64	1.84e-40	Height;
LUSC	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06634786	chr22:41940651	POLR3H	-0.55	-6.46	-0.33	3.75e-10	Vitiligo;
LUSC	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg17644776	chr2:200775616	C2orf69	-0.46	-7.33	-0.37	1.75e-12	Osteoporosis;
LUSC	cis	rs11645898	0.687	rs1424241	chr16:72078907	G/A	cg14768367	chr16:72042858	DHODH	-0.56	-6.62	-0.34	1.47e-10	Blood protein levels;
LUSC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-1.13	-24.93	-0.81	3.04e-78	Height;
LUSC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg19592336	chr6:28129416	ZNF389	0.48	6.29	0.33	1.02e-9	Depression;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg19187486	chr15:74833838	ARID3B	0.39	6.14	0.32	2.3e-9	Schizophrenia;
LUSC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg23283495	chr1:209979779	IRF6	0.51	8.28	0.41	3.04e-15	Monobrow;
LUSC	cis	rs7119	0.717	rs35284122	chr15:77804568	G/T	cg27398640	chr15:77910606	LINGO1	-0.29	-6.18	-0.32	1.89e-9	Type 2 diabetes;
LUSC	cis	rs7538876	0.935	rs4920607	chr1:17760098	A/G	cg07965774	chr1:17746286	RCC2	0.35	6.54	0.34	2.29e-10	Basal cell carcinoma;
LUSC	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg02023728	chr11:77925099	USP35	-0.56	-8.03	-0.4	1.67e-14	Testicular germ cell tumor;
LUSC	cis	rs250677	0.522	rs2217638	chr5:148364355	A/G	cg18129178	chr5:148520854	ABLIM3	0.54	7.89	0.4	4.28e-14	Breast cancer;
LUSC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg05738196	chr6:26577821	NA	-0.59	-6.93	-0.35	2.12e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg15103426	chr22:29168792	CCDC117	0.46	5.93	0.31	7.38e-9	Lymphocyte counts;
LUSC	cis	rs12760731	0.565	rs2095133	chr1:178198612	C/G	cg00404053	chr1:178313656	RASAL2	0.66	6.86	0.35	3.32e-11	Obesity-related traits;
LUSC	cis	rs9378688	1.000	rs56196406	chr6:2219565	T/C	cg12303981	chr6:2244766	GMDS	-0.5	-5.98	-0.31	5.89e-9	Caudate nucleus volume;
LUSC	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg20703242	chr1:230279135	GALNT2	0.52	8.2	0.41	5.22e-15	Coronary artery disease;
LUSC	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg08601574	chr20:25228251	PYGB	0.43	6.51	0.34	2.77e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06481639	chr22:41940642	POLR3H	0.5	5.72	0.3	2.42e-8	Vitiligo;
LUSC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg03453431	chr7:157225567	NA	-0.69	-13.33	-0.59	8.46e-33	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-8.96	-0.44	2.33e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg22089800	chr15:90895588	ZNF774	0.63	9.4	0.46	9.03e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs12474201	0.832	rs4952843	chr2:46957845	A/G	cg06386533	chr2:46925753	SOCS5	0.68	9.96	0.48	1.2e-20	Height;
LUSC	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg17810781	chr1:201082982	CACNA1S	0.33	6.33	0.33	7.95e-10	Permanent tooth development;
LUSC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg02487422	chr3:49467188	NICN1	0.47	7.38	0.37	1.27e-12	Resting heart rate;
LUSC	cis	rs71636778	0.543	rs17162333	chr1:27236757	C/G	cg12203394	chr1:27248618	NUDC	0.54	5.71	0.3	2.52e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.57	-9.23	-0.45	3.22e-18	Aortic root size;
LUSC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.63	10.06	0.48	5.51e-21	Longevity;
LUSC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.65	13.93	0.61	4.22e-35	Monocyte percentage of white cells;
LUSC	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg03676636	chr4:99064102	C4orf37	0.3	5.97	0.31	6.04e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg18478394	chr8:109455254	TTC35	0.47	7.28	0.37	2.38e-12	Dupuytren's disease;
LUSC	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg00757033	chr12:89920650	WDR51B	0.6	10.35	0.49	5.9e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg06636001	chr8:8085503	FLJ10661	0.53	7.47	0.38	6.85e-13	Joint mobility (Beighton score);
LUSC	cis	rs6977660	0.714	rs6945297	chr7:19814029	A/C	cg07541023	chr7:19748670	TWISTNB	0.66	7.24	0.37	3.12e-12	Thyroid stimulating hormone;
LUSC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg04450456	chr4:17643702	FAM184B	0.4	6.75	0.35	6.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs2055729	0.528	rs11987861	chr8:9742206	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.07	-0.32	3.48e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs372883	0.967	rs2832290	chr21:30728863	C/T	cg08807101	chr21:30365312	RNF160	-0.45	-6.54	-0.34	2.29e-10	Pancreatic cancer;
LUSC	cis	rs7560272	0.538	rs12053242	chr2:73937168	G/A	cg20560298	chr2:73613845	ALMS1	0.4	6.11	0.32	2.8e-9	Schizophrenia;
LUSC	cis	rs56161922	0.908	rs78159416	chr1:207820375	C/A	cg11752769	chr1:207818423	CR1L	-0.7	-6.1	-0.32	2.87e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LUSC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.76	11.63	0.54	1.78e-26	Selective IgA deficiency;
LUSC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.84	12.01	0.55	7.01e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg08683831	chr4:1404607	NA	0.35	5.7	0.3	2.62e-8	Obesity-related traits;
LUSC	cis	rs9398803	0.865	rs2184968	chr6:126760994	A/G	cg19875578	chr6:126661172	C6orf173	0.39	5.73	0.3	2.18e-8	Male-pattern baldness;
LUSC	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg13010199	chr12:38710504	ALG10B	0.56	8.47	0.42	7.79e-16	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.57	0.65	1.71e-41	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.72e-10	Bipolar disorder;
LUSC	cis	rs4704187	0.687	rs6885887	chr5:74497842	A/C	cg03227963	chr5:74354835	NA	0.31	6.76	0.35	6.17e-11	Response to amphetamines;
LUSC	cis	rs12681287	0.640	rs4961193	chr8:87486168	C/T	cg27223183	chr8:87520930	FAM82B	0.53	7.29	0.37	2.33e-12	Caudate activity during reward;
LUSC	cis	rs2901656	0.652	rs3213563	chr1:172412995	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.39	8.13	0.41	8.32e-15	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg11102782	chr19:18549136	ISYNA1	-0.32	-6.05	-0.31	3.93e-9	Breast cancer;
LUSC	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg13010199	chr12:38710504	ALG10B	0.66	10.19	0.49	2.02e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs16910800	0.953	rs7110229	chr11:23200546	C/T	cg20040320	chr11:23191996	NA	-0.45	-6.63	-0.34	1.37e-10	Cancer;
LUSC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.54	0.38	4.59e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg03146154	chr1:46216737	IPP	0.54	8.22	0.41	4.47e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08393024	chr5:115177154	ATG12;AP3S1	0.39	6.05	0.31	3.96e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg08807101	chr21:30365312	RNF160	0.66	10.28	0.49	1.01e-21	Pancreatic cancer;
LUSC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg03732007	chr1:2071316	PRKCZ	-0.5	-8.63	-0.43	2.49e-16	Height;
LUSC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg25258033	chr6:167368657	RNASET2	0.46	7.63	0.39	2.55e-13	Crohn's disease;
LUSC	cis	rs2625529	0.730	rs7177242	chr15:72184114	A/G	cg16672083	chr15:72433130	SENP8	0.52	8.13	0.41	8.41e-15	Red blood cell count;
LUSC	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.93	0.35	2.12e-11	Lung cancer in ever smokers;
LUSC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08677398	chr8:58056175	NA	0.54	6.29	0.33	9.81e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg26162295	chr17:38119207	GSDMA	0.24	5.68	0.3	3.01e-8	Self-reported allergy;
LUSC	trans	rs2386661	0.547	rs57893347	chr10:5646191	G/A	cg11398623	chr21:37499189	NA	0.27	6.19	0.32	1.77e-9	Breast cancer;
LUSC	cis	rs1858037	0.867	rs72621551	chr2:65615221	C/T	cg08085232	chr2:65598271	SPRED2	-0.42	-6.29	-0.33	9.78e-10	Rheumatoid arthritis;
LUSC	cis	rs6681460	1.000	rs6696927	chr1:67070381	A/G	cg02459107	chr1:67143332	SGIP1	0.49	9.23	0.45	3.18e-18	Presence of antiphospholipid antibodies;
LUSC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg04518342	chr5:131593106	PDLIM4	-0.45	-7.65	-0.39	2.15e-13	Breast cancer;
LUSC	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg24642439	chr20:33292090	TP53INP2	0.5	7.43	0.38	8.94e-13	Height;
LUSC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg18230493	chr5:56204884	C5orf35	0.77	12.46	0.56	1.63e-29	Initial pursuit acceleration;
LUSC	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06873352	chr17:61820015	STRADA	0.57	8.78	0.43	8.9e-17	Height;
LUSC	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs965513	1.000	rs10983701	chr9:100537577	G/A	cg13688889	chr9:100608707	NA	-0.57	-8.61	-0.43	2.87e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.3	6.68	0.34	9.74e-11	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25462384	chr19:7985170	SNAPC2	-0.39	-6.06	-0.31	3.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg19622623	chr12:86230825	RASSF9	-0.44	-6.34	-0.33	7.26e-10	Major depressive disorder;
LUSC	cis	rs926938	0.527	rs7526844	chr1:115543759	T/C	cg12756093	chr1:115239321	AMPD1	0.48	7.19	0.37	4.23e-12	Autism;
LUSC	cis	rs1775715	0.870	rs3847414	chr10:32219176	A/G	cg04359828	chr10:32216031	ARHGAP12	0.38	6.55	0.34	2.23e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs41271473	0.948	rs17437060	chr1:228822374	C/T	cg10167378	chr1:228756711	NA	0.6	7.15	0.36	5.44e-12	Chronic lymphocytic leukemia;
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg08472276	chr7:1133186	C7orf50;GPER	-0.38	-6.21	-0.32	1.57e-9	Longevity;Endometriosis;
LUSC	cis	rs36093844	0.660	rs12274717	chr11:85577714	A/C	cg25872744	chr11:85566296	CCDC83	-0.45	-5.98	-0.31	5.7e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.61	0.38	2.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg03526776	chr6:41159608	TREML2	0.33	6.12	0.32	2.67e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg21435336	chr19:17392852	ANKLE1	-0.42	-5.77	-0.3	1.82e-8	Systemic lupus erythematosus;
LUSC	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg27494647	chr7:150038898	RARRES2	0.47	7.29	0.37	2.19e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg12463550	chr7:65579703	CRCP	0.42	6.01	0.31	4.74e-9	Aortic root size;
LUSC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg06784218	chr1:46089804	CCDC17	0.48	9.63	0.47	1.62e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg06637938	chr14:75390232	RPS6KL1	0.54	8.65	0.43	2.16e-16	Height;
LUSC	cis	rs10905065	0.931	rs11255228	chr10:5837671	T/C	cg11519256	chr10:5708881	ASB13	0.4	5.78	0.3	1.68e-8	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03609454	chr4:36245858	ARAP2	-0.44	-6.63	-0.34	1.34e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.49	8.08	0.4	1.21e-14	Alcohol dependence;
LUSC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-7.73	-0.39	1.31e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.28	-0.41	2.99e-15	Bladder cancer;
LUSC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg25204440	chr1:209979598	IRF6	0.53	6.98	0.36	1.59e-11	Cleft lip with or without cleft palate;
LUSC	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg11608241	chr8:8085544	FLJ10661	0.42	6.04	0.31	4.1e-9	Neuroticism;
LUSC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	29.03	0.85	2.35e-93	Chronic sinus infection;
LUSC	cis	rs8044995	0.563	rs2279540	chr16:68395061	T/C	cg09835421	chr16:68378352	PRMT7	-0.76	-8.47	-0.42	7.75e-16	Schizophrenia;
LUSC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.24	14.21	0.61	3.56e-36	Diabetic kidney disease;
LUSC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.75	10.28	0.49	1.02e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	1.04	19.86	0.74	1.7e-58	Menopause (age at onset);
LUSC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6464929	0.955	rs7793916	chr7:148724043	G/A	cg23583168	chr7:148888333	NA	0.46	5.87	0.31	1.07e-8	Pediatric bone mineral content (hip);
LUSC	cis	rs2078087	0.522	rs4652787	chr1:183225089	G/A	cg13843938	chr1:183241246	NMNAT2	0.4	6.52	0.34	2.65e-10	Obesity-related traits;
LUSC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg22823121	chr1:150693482	HORMAD1	0.51	7.47	0.38	7.01e-13	Melanoma;
LUSC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.9	16.03	0.66	2.76e-43	Metabolic syndrome;
LUSC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg07701084	chr6:150067640	NUP43	0.58	9.17	0.45	5.08e-18	Lung cancer;
LUSC	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg07211511	chr3:129823064	LOC729375	-1.23	-20.54	-0.75	3.35e-61	Blood pressure (smoking interaction);
LUSC	trans	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.74	-0.35	7.16e-11	Neuroticism;
LUSC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg10792982	chr14:105748885	BRF1	0.47	8.55	0.42	4.54e-16	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg24375607	chr4:120327624	NA	0.78	11.63	0.54	1.74e-26	Corneal astigmatism;
LUSC	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg04315214	chr1:2043799	PRKCZ	0.48	10.08	0.48	4.71e-21	Height;
LUSC	cis	rs1506636	0.525	rs7812023	chr7:123260228	C/T	cg03229431	chr7:123269106	ASB15	-0.61	-9.21	-0.45	3.77e-18	Plateletcrit;Platelet count;
LUSC	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg17757837	chr7:157058334	UBE3C	-0.92	-15.79	-0.65	2.34e-42	Body mass index;
LUSC	trans	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg13010199	chr12:38710504	ALG10B	0.4	5.99	0.31	5.56e-9	Morning vs. evening chronotype;
LUSC	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg01733217	chr16:74700730	RFWD3	0.74	12.32	0.56	5.29e-29	Testicular germ cell tumor;
LUSC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg03188948	chr7:1209495	NA	0.46	6.14	0.32	2.34e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg17366294	chr4:99064904	C4orf37	-0.59	-10.49	-0.5	1.94e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7202877	0.706	rs247438	chr16:75432649	C/G	cg03315344	chr16:75512273	CHST6	-0.41	-6.18	-0.32	1.84e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg17376030	chr22:41985996	PMM1	-0.46	-5.72	-0.3	2.42e-8	Vitiligo;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg09368129	chr5:140071347	HARS2;HARS	0.47	6.13	0.32	2.48e-9	Cognitive function;Information processing speed;
LUSC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg20811857	chr17:78079795	GAA	-0.46	-7.64	-0.39	2.39e-13	Yeast infection;
LUSC	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg24112000	chr20:60950667	NA	0.35	6.56	0.34	2.08e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs10463316	0.862	rs11740475	chr5:150777997	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-7.69	-0.39	1.67e-13	Metabolite levels (Pyroglutamine);
LUSC	cis	rs7707921	0.881	rs7733122	chr5:81351443	C/T	cg15871215	chr5:81402204	ATG10	-0.45	-6.48	-0.33	3.3e-10	Breast cancer;
LUSC	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg13010199	chr12:38710504	ALG10B	0.56	8.27	0.41	3.18e-15	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08470875	chr2:26401718	FAM59B	0.74	9.89	0.48	2.15e-20	Gut microbiome composition (summer);
LUSC	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg02403541	chr12:121454288	C12orf43	0.72	10.41	0.5	3.5e-22	N-glycan levels;
LUSC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg27094323	chr7:1216898	NA	-0.37	-6.74	-0.35	7.05e-11	Longevity;Endometriosis;
LUSC	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg10523679	chr1:76189770	ACADM	-0.48	-7.06	-0.36	9.79e-12	Daytime sleep phenotypes;
LUSC	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg20684491	chr1:25596433	NA	-0.37	-5.81	-0.3	1.47e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs12900413	0.687	rs12908468	chr15:90304236	T/G	cg24249390	chr15:90295951	MESP1	-0.38	-5.85	-0.3	1.17e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12506373	chr2:27440548	CAD	0.5	7.26	0.37	2.81e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg25036284	chr2:26402008	FAM59B	-0.71	-9.84	-0.47	3.19e-20	Gut microbiome composition (summer);
LUSC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	7.07	0.36	9.34e-12	Tonsillectomy;
LUSC	cis	rs716595	1.000	rs17127166	chr10:111989325	C/T	cg13996003	chr10:112034540	MXI1	-0.67	-5.88	-0.31	9.89e-9	Normalized brain volume;
LUSC	cis	rs7215564	0.730	rs34405143	chr17:78585681	G/C	cg23238734	chr17:78661607	RPTOR	0.49	5.94	0.31	7.19e-9	Myopia (pathological);
LUSC	cis	rs5771225	0.563	rs738334	chr22:50688235	T/C	cg16473166	chr22:50639996	SELO	0.61	8.07	0.4	1.33e-14	Late-onset Alzheimer's disease;
LUSC	cis	rs6084875	0.840	rs2422942	chr20:4726116	A/G	cg26097573	chr20:4721490	PRNT	-0.31	-5.74	-0.3	2.16e-8	Systemic lupus erythematosus;
LUSC	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.07	0.48	5.33e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg23625390	chr15:77176239	SCAPER	0.52	7.98	0.4	2.38e-14	Blood metabolite levels;
LUSC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.6	11.01	0.52	2.92e-24	Bone mineral density;
LUSC	cis	rs2742234	0.503	rs1254968	chr10:43691691	C/T	cg15436174	chr10:43711423	RASGEF1A	0.43	7.03	0.36	1.17e-11	Hirschsprung disease;
LUSC	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg22709100	chr7:91322751	NA	0.43	6.25	0.32	1.24e-9	Breast cancer;
LUSC	cis	rs77633900	0.614	rs279997	chr15:76949262	T/C	cg21673338	chr15:77095150	SCAPER	-0.77	-7.74	-0.39	1.2e-13	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs6681460	0.634	rs994396	chr1:67012236	G/A	cg02459107	chr1:67143332	SGIP1	0.38	6.12	0.32	2.62e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg17541715	chr7:1216824	NA	-0.4	-6.26	-0.32	1.19e-9	Longevity;Endometriosis;
LUSC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg24503407	chr1:205819492	PM20D1	0.87	16.51	0.67	3.53e-45	Menarche (age at onset);
LUSC	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg17077180	chr1:38461687	NA	-0.43	-6.18	-0.32	1.91e-9	Coronary artery disease;
LUSC	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.6	-9.63	-0.47	1.59e-19	Body mass index;
LUSC	cis	rs317689	0.959	rs317688	chr12:69726850	T/C	cg20891283	chr12:69753455	YEATS4	0.54	7.21	0.37	3.71e-12	Response to diuretic therapy;
LUSC	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.73	12.0	0.55	7.65e-28	Height;
LUSC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg24324837	chr19:49891574	CCDC155	0.53	7.29	0.37	2.33e-12	Multiple sclerosis;
LUSC	trans	rs17169634	1.000	rs73329116	chr7:34055590	T/C	cg18512313	chr14:70700886	NA	0.59	5.98	0.31	5.6e-9	Alzheimer's disease;
LUSC	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg23625390	chr15:77176239	SCAPER	-0.53	-7.34	-0.37	1.63e-12	Blood metabolite levels;
LUSC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg06521331	chr12:34319734	NA	-0.4	-6.21	-0.32	1.6e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg02017074	chr12:117425053	FBXW8	-0.69	-7.93	-0.4	3.43e-14	Subcortical brain region volumes;Hippocampal volume;
LUSC	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg15556689	chr8:8085844	FLJ10661	0.54	8.26	0.41	3.34e-15	Retinal vascular caliber;
LUSC	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg05343316	chr1:45956843	TESK2	0.65	9.04	0.44	1.28e-17	Platelet count;
LUSC	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg04310649	chr10:35416472	CREM	-0.43	-6.62	-0.34	1.45e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg13010199	chr12:38710504	ALG10B	0.46	7.07	0.36	9.3e-12	Morning vs. evening chronotype;
LUSC	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg22709100	chr7:91322751	NA	-0.39	-5.75	-0.3	1.99e-8	Breast cancer;
LUSC	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg06808227	chr14:105710500	BRF1	-0.64	-9.34	-0.46	1.37e-18	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg08601574	chr20:25228251	PYGB	0.47	7.29	0.37	2.28e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg13175981	chr1:150552382	MCL1	0.53	7.4	0.38	1.09e-12	Tonsillectomy;
LUSC	cis	rs737337	0.623	rs3810308	chr19:11333596	T/C	cg00586551	chr19:11347513	LOC55908;DOCK6	0.55	6.77	0.35	5.74e-11	HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs3857067	0.806	rs7654919	chr4:95136164	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.32	-0.33	8.37e-10	QT interval;
LUSC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg12963246	chr6:28129442	ZNF389	0.52	7.17	0.37	4.94e-12	Parkinson's disease;
LUSC	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg22535103	chr8:58192502	C8orf71	-0.57	-6.74	-0.35	6.81e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	11.59	0.54	2.57e-26	Coronary artery disease;
LUSC	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg05784532	chr1:230284198	GALNT2	0.49	7.39	0.38	1.16e-12	Coronary artery disease;
LUSC	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg02569458	chr12:86230093	RASSF9	-0.47	-7.97	-0.4	2.6e-14	Major depressive disorder;
LUSC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.42	-0.33	4.78e-10	Personality dimensions;
LUSC	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg23029597	chr12:123009494	RSRC2	-0.75	-9.63	-0.47	1.61e-19	Body mass index;
LUSC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22442454	chr1:209979470	IRF6	0.44	5.95	0.31	6.65e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	7.21	0.37	3.79e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs10791323	0.517	rs1120246	chr11:133745212	G/A	cg15485101	chr11:133734466	NA	0.35	6.27	0.32	1.1e-9	Childhood ear infection;
LUSC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	5.93	0.31	7.54e-9	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.26	-0.41	3.4e-15	Response to antipsychotic treatment;
LUSC	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.07	-0.44	1.05e-17	Bone mineral density;
LUSC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg25039879	chr17:56429692	SUPT4H1	0.69	9.14	0.45	6.35e-18	Cognitive test performance;
LUSC	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg20307385	chr11:47447363	PSMC3	0.46	6.72	0.34	8.08e-11	Subjective well-being;
LUSC	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.85	-0.3	1.15e-8	Resting heart rate;
LUSC	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg08558340	chr7:100472263	SRRT	0.51	6.37	0.33	6.41e-10	Resting heart rate;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24703941	chr19:36036726	TMEM147	0.44	6.14	0.32	2.28e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.35	-7.29	-0.37	2.3e-12	Longevity;Endometriosis;
LUSC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg01802117	chr1:53393560	SCP2	0.4	6.53	0.34	2.44e-10	Monocyte count;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02010894	chr19:16653629	CHERP	0.48	6.48	0.33	3.37e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs3744061	0.557	rs4544269	chr17:74648646	G/A	cg27546012	chr17:74684504	MXRA7	-0.38	-6.55	-0.34	2.2e-10	Retinal arteriolar caliber;
LUSC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.75	-13.15	-0.58	4.2e-32	Cognitive function;
LUSC	cis	rs7681440	0.647	rs1442136	chr4:90819026	C/T	cg20003494	chr4:90757398	SNCA	0.35	5.67	0.3	3.17e-8	Dementia with Lewy bodies;
LUSC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg21724239	chr8:58056113	NA	0.57	6.61	0.34	1.56e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	0.97	13.39	0.59	4.87e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.77	-0.43	9.17e-17	Response to antipsychotic treatment;
LUSC	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg07741184	chr6:167504864	NA	-0.35	-6.41	-0.33	5.07e-10	Crohn's disease;
LUSC	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.29	0.37	2.24e-12	Platelet count;
LUSC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.33	0.53	2.1e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg21573476	chr21:45109991	RRP1B	-0.36	-5.67	-0.3	3.13e-8	Mean corpuscular volume;
LUSC	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg05340658	chr4:99064831	C4orf37	0.44	7.02	0.36	1.28e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.54	9.44	0.46	6.53e-19	Birth weight;
LUSC	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg00049323	chr5:472564	LOC25845	-0.41	-6.16	-0.32	2.04e-9	Cystic fibrosis severity;
LUSC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg23262073	chr20:60523788	NA	-0.4	-5.93	-0.31	7.71e-9	Body mass index;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19850565	chr19:35168394	ZNF302	0.49	6.87	0.35	3.12e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1178127	0.580	rs1178168	chr7:18792822	A/G	cg02370815	chr7:18831390	HDAC9	-0.38	-5.74	-0.3	2.09e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
LUSC	cis	rs17253792	0.822	rs77420254	chr14:56069646	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-6.96	-0.36	1.81e-11	Putamen volume;
LUSC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg02807482	chr3:125708958	NA	-0.52	-6.49	-0.33	3.08e-10	Blood pressure (smoking interaction);
LUSC	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.64	14.16	0.61	5.81e-36	Hemoglobin concentration;
LUSC	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg24692254	chr21:30365293	RNF160	0.62	9.18	0.45	4.55e-18	Pancreatic cancer;
LUSC	cis	rs7582720	1.000	rs114110842	chr2:203823400	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.19	0.41	5.42e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg26043149	chr18:55253948	FECH	-0.45	-6.9	-0.35	2.59e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.5	7.17	0.37	4.93e-12	Colorectal cancer;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg12968540	chr22:41572924	EP300	0.41	6.31	0.33	8.85e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg01879757	chr17:41196368	BRCA1	-0.43	-6.0	-0.31	5.03e-9	Menopause (age at onset);
LUSC	cis	rs16867321	0.639	rs12466770	chr2:181441312	C/G	cg23363182	chr2:181467187	NA	0.57	9.2	0.45	4.03e-18	Obesity;
LUSC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.95	-0.51	4.72e-24	Schizophrenia;
LUSC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.63	10.36	0.49	5.45e-22	Mood instability;
LUSC	cis	rs4786125	0.636	rs11644404	chr16:6904030	C/A	cg03623568	chr16:6915990	A2BP1	-0.49	-7.74	-0.39	1.23e-13	Heart rate variability traits (SDNN);
LUSC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg26566898	chr11:117069891	TAGLN	0.46	8.33	0.41	2.12e-15	Blood protein levels;
LUSC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg15448220	chr1:150897856	SETDB1	0.38	5.69	0.3	2.84e-8	Tonsillectomy;
LUSC	cis	rs738321	0.757	rs6001020	chr22:38538246	C/G	cg25457927	chr22:38595422	NA	-0.31	-5.79	-0.3	1.62e-8	Breast cancer;
LUSC	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.46	-0.42	8.73e-16	Heart rate;
LUSC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	12.99	0.58	1.61e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg01616529	chr11:638424	DRD4	-0.34	-5.8	-0.3	1.58e-8	Systemic lupus erythematosus;
LUSC	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg12311346	chr5:56204834	C5orf35	-0.58	-8.5	-0.42	6.41e-16	Coronary artery disease;
LUSC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg06454157	chr6:167490870	NA	-0.28	-6.58	-0.34	1.78e-10	Primary biliary cholangitis;
LUSC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	12.61	0.57	4.24e-30	Menopause (age at onset);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25453430	chr21:37433068	SETD4	-0.42	-6.23	-0.32	1.41e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg01620082	chr3:125678407	NA	-0.83	-7.16	-0.36	5.24e-12	Depression;
LUSC	cis	rs7674212	0.531	rs4699048	chr4:103926727	A/G	cg16532752	chr4:104119610	CENPE	-0.41	-5.67	-0.3	3.14e-8	Type 2 diabetes;
LUSC	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg19717773	chr7:2847554	GNA12	-0.4	-7.3	-0.37	2.06e-12	Height;
LUSC	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg05283184	chr6:79620031	NA	-0.57	-12.2	-0.56	1.41e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs2282802	0.685	rs13170475	chr5:139671062	C/T	cg26211634	chr5:139558579	C5orf32	0.4	7.62	0.38	2.58e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs981844	1.000	rs2579917	chr4:154652648	T/G	cg14289246	chr4:154710475	SFRP2	0.54	6.77	0.35	5.92e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg09491104	chr22:46646882	C22orf40	-0.67	-7.08	-0.36	8.7e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg09179987	chr1:167433047	CD247	0.37	6.06	0.31	3.71e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	trans	rs10432489	0.708	rs12693263	chr2:181740210	A/G	cg00055848	chr2:62422984	B3GNT2	-0.91	-6.16	-0.32	2.13e-9	QT interval;
LUSC	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg04673462	chr1:38461896	NA	-0.54	-7.83	-0.39	6.51e-14	Coronary artery disease;
LUSC	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg15654264	chr1:150340011	RPRD2	0.67	11.18	0.52	7.2e-25	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg19302996	chr17:73780495	UNK	-0.49	-7.08	-0.36	8.35e-12	White matter hyperintensity burden;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17001531	chr1:16825540	NA	-0.5	-6.53	-0.34	2.5e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs57549656	0.659	rs72980733	chr19:2711316	G/C	cg06609049	chr19:2785107	THOP1	0.49	6.19	0.32	1.75e-9	Schizophrenia;
LUSC	cis	rs9677476	0.731	rs1477470	chr2:232076724	A/C	cg07929768	chr2:232055508	NA	0.37	7.03	0.36	1.15e-11	Food antigen IgG levels;
LUSC	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	trans	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.68	-0.34	1.03e-10	Endometrial cancer;
LUSC	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.26e-18	Breast cancer;
LUSC	cis	rs2742417	1.000	rs1534876	chr3:45741257	G/T	cg18779283	chr3:45636154	LIMD1	-0.34	-5.88	-0.31	9.79e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg05043794	chr9:111880884	C9orf5	0.34	7.56	0.38	4.02e-13	Menarche (age at onset);
LUSC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg22166914	chr1:53195759	ZYG11B	-0.49	-7.76	-0.39	1.04e-13	Monocyte count;
LUSC	cis	rs3087591	0.960	rs2952999	chr17:29509801	G/T	cg24425628	chr17:29625626	OMG;NF1	0.56	8.11	0.41	9.79e-15	Hip circumference;
LUSC	cis	rs9800506	0.866	rs6931945	chr6:35525751	C/T	cg03566752	chr6:35512600	NA	0.25	6.1	0.32	2.89e-9	Neutrophil percentage of granulocytes;
LUSC	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-6.77	-0.35	5.71e-11	Height;
LUSC	cis	rs4786125	0.512	rs55694271	chr16:6930378	G/A	cg03623568	chr16:6915990	A2BP1	-0.48	-7.79	-0.39	8.49e-14	Heart rate variability traits (SDNN);
LUSC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	11.11	0.52	1.34e-24	Menopause (age at onset);
LUSC	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg07926092	chr13:79233506	RNF219	-0.46	-5.76	-0.3	1.92e-8	Large artery stroke;
LUSC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg11062466	chr8:58055876	NA	0.47	5.98	0.31	5.85e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg25214090	chr10:38739885	LOC399744	0.54	8.12	0.41	9.19e-15	Corneal astigmatism;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	10.11	0.48	3.76e-21	Lymphocyte counts;
LUSC	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.83	14.27	0.62	2.16e-36	Metabolic syndrome;
LUSC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.81	-15.23	-0.64	3.85e-40	Prudent dietary pattern;
LUSC	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg24631222	chr15:78858424	CHRNA5	0.64	8.37	0.42	1.62e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg27529037	chr20:44575021	PCIF1	0.39	6.76	0.35	6.33e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg18230493	chr5:56204884	C5orf35	-0.94	-13.79	-0.6	1.43e-34	Initial pursuit acceleration;
LUSC	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.74	12.3	0.56	6e-29	Platelet distribution width;
LUSC	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg23791538	chr6:167370224	RNASET2	0.41	5.86	0.31	1.12e-8	Graves' disease;
LUSC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-10.36	-0.49	5.5e-22	Chronic sinus infection;
LUSC	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg00310523	chr12:86230176	RASSF9	0.51	9.71	0.47	8.41e-20	Major depressive disorder;
LUSC	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg13010199	chr12:38710504	ALG10B	0.54	8.45	0.42	9.43e-16	Morning vs. evening chronotype;
LUSC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg19592336	chr6:28129416	ZNF389	0.53	7.13	0.36	6.34e-12	Parkinson's disease;
LUSC	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg12560992	chr17:57184187	TRIM37	-0.43	-6.61	-0.34	1.51e-10	Primary tooth development (time to first tooth eruption);
LUSC	trans	rs9630182	0.561	rs12802900	chr11:13437923	C/A	cg00234616	chr2:74740572	TLX2	0.31	5.98	0.31	5.68e-9	Bone mineral density;
LUSC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16744531	chr19:17905626	B3GNT3	0.43	6.48	0.33	3.31e-10	Tumor biomarkers;
LUSC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg05585544	chr11:47624801	NA	-0.44	-7.66	-0.39	1.99e-13	Subjective well-being;
LUSC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg06145435	chr7:1022769	CYP2W1	0.29	6.14	0.32	2.36e-9	Longevity;Endometriosis;
LUSC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	11.0	0.52	3.16e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs55883249	1.000	rs75139639	chr2:9763905	A/T	cg23886495	chr2:9695866	ADAM17	0.51	6.12	0.32	2.59e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg05925327	chr15:68127851	NA	-0.4	-6.4	-0.33	5.35e-10	Restless legs syndrome;
LUSC	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.41	-0.33	5e-10	Cutaneous nevi;
LUSC	cis	rs727505	1.000	rs6952721	chr7:124480075	T/C	cg23710748	chr7:124431027	NA	-0.4	-7.24	-0.37	3.06e-12	Lewy body disease;
LUSC	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg19622623	chr12:86230825	RASSF9	-0.41	-5.71	-0.3	2.44e-8	Major depressive disorder;
LUSC	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg15448220	chr1:150897856	SETDB1	0.43	6.38	0.33	5.75e-10	Melanoma;
LUSC	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg13615516	chr5:77269221	NA	0.4	6.56	0.34	2.02e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10761482	0.728	rs4290174	chr10:62104583	C/G	cg18175470	chr10:62150864	ANK3	-0.49	-7.07	-0.36	9.31e-12	Schizophrenia;
LUSC	cis	rs6500395	0.962	rs1039341	chr16:48574869	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.52	0.34	2.66e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg01256987	chr12:42539512	GXYLT1	0.34	6.19	0.32	1.79e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg05861140	chr6:150128134	PCMT1	-0.44	-7.04	-0.36	1.1e-11	Lung cancer;
LUSC	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg11019008	chr10:131425282	MGMT	0.41	6.28	0.32	1.08e-9	Response to temozolomide;
LUSC	cis	rs12519773	0.501	rs4449514	chr5:92521022	T/C	cg18783429	chr5:92414398	NA	0.34	7.38	0.37	1.28e-12	Migraine;
LUSC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12379764	chr21:47803548	PCNT	-0.42	-5.89	-0.31	9.57e-9	Testicular germ cell tumor;
LUSC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.47	-0.42	8.16e-16	Bipolar disorder;
LUSC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg17330251	chr7:94953956	PON1	-0.38	-5.97	-0.31	6.02e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs6460942	0.630	rs62448731	chr7:12341174	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-6.24	-0.32	1.36e-9	Coronary artery disease;
LUSC	trans	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.95	0.36	1.88e-11	Endometrial cancer;
LUSC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg01528321	chr10:82214614	TSPAN14	0.59	8.48	0.42	7.37e-16	Post bronchodilator FEV1;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10884867	chr2:74618939	LOC100189589	-0.43	-6.4	-0.33	5.22e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.13	0.48	3.22e-21	Electroencephalogram traits;
LUSC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg00376283	chr12:123451042	ABCB9	0.67	8.42	0.42	1.1e-15	Neutrophil percentage of white cells;
LUSC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg01973587	chr1:228161476	NA	0.46	8.31	0.41	2.49e-15	Diastolic blood pressure;
LUSC	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14829155	chr15:31115871	NA	-0.57	-7.96	-0.4	2.7e-14	Huntington's disease progression;
LUSC	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.61	0.5	7.28e-23	Colorectal cancer;
LUSC	cis	rs654950	0.806	rs1535505	chr1:42026152	A/G	cg06885757	chr1:42089581	HIVEP3	0.41	7.79	0.39	8.68e-14	Airway imaging phenotypes;
LUSC	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	0.87	12.21	0.56	1.39e-28	Coronary artery disease;
LUSC	cis	rs1003719	0.667	rs13050226	chr21:38457708	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.6	9.35	0.46	1.26e-18	Eye color traits;
LUSC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg03146154	chr1:46216737	IPP	-0.51	-7.44	-0.38	8.45e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	7.7	0.39	1.56e-13	Height;
LUSC	cis	rs55665837	1.000	rs12804549	chr11:14437758	A/T	cg19336497	chr11:14380999	RRAS2	-0.36	-7.41	-0.38	1.04e-12	Vitamin D levels;
LUSC	cis	rs727505	0.607	rs67313231	chr7:124804532	T/A	cg23710748	chr7:124431027	NA	-0.36	-6.27	-0.32	1.11e-9	Lewy body disease;
LUSC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg12463550	chr7:65579703	CRCP	0.52	7.46	0.38	7.59e-13	Aortic root size;
LUSC	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg00484396	chr16:3507460	NAT15	-0.65	-10.93	-0.51	5.53e-24	Tuberculosis;
LUSC	cis	rs6845621	0.727	rs28791037	chr4:18909682	G/T	cg12196642	chr4:18937545	NA	-0.33	-6.27	-0.32	1.1e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg26695010	chr11:65641043	EFEMP2	-0.48	-7.2	-0.37	4.05e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg13852791	chr20:30311386	BCL2L1	0.94	14.73	0.63	3.46e-38	Mean corpuscular hemoglobin;
LUSC	cis	rs79387448	0.745	rs79107058	chr2:103164257	C/A	cg09003973	chr2:102972529	NA	0.88	8.56	0.42	4.18e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.88	14.67	0.63	6.03e-38	Bladder cancer;
LUSC	cis	rs9650315	0.866	rs13248165	chr8:57192842	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.54	7.02	0.36	1.21e-11	Height;
LUSC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21852757	chr3:179424616	USP13	-0.45	-7.78	-0.39	9.25e-14	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg13319975	chr6:146136371	FBXO30	0.49	7.47	0.38	7.15e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2658782	0.789	rs2259633	chr11:93141580	C/A	cg15737290	chr11:93063684	CCDC67	0.64	7.96	0.4	2.78e-14	Pulmonary function decline;
LUSC	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg05343316	chr1:45956843	TESK2	0.62	8.7	0.43	1.55e-16	Platelet count;
LUSC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	15.62	0.65	1.12e-41	Platelet count;
LUSC	cis	rs6754311	0.593	rs1446584	chr2:136419961	C/T	cg07169764	chr2:136633963	MCM6	-0.57	-7.63	-0.39	2.41e-13	Mosquito bite size;
LUSC	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	8.28	0.41	2.95e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9297145	0.565	rs941001	chr7:98735185	A/T	cg05967295	chr7:98741636	SMURF1	-0.66	-10.59	-0.5	8.87e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg13010199	chr12:38710504	ALG10B	-0.52	-7.86	-0.39	5.45e-14	Bladder cancer;
LUSC	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg20135002	chr11:47629003	NA	0.48	7.46	0.38	7.41e-13	Subjective well-being;
LUSC	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.81	12.4	0.56	2.75e-29	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg17719053	chr1:75198211	TYW3;CRYZ	0.39	6.31	0.33	8.67e-10	Resistin levels;
LUSC	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.71	-0.3	2.44e-8	Recombination rate (females);
LUSC	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg25427524	chr10:38739819	LOC399744	0.51	7.44	0.38	8.74e-13	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg08499158	chr17:42289980	UBTF	0.4	6.21	0.32	1.55e-9	Total body bone mineral density;
LUSC	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg17366294	chr4:99064904	C4orf37	0.53	9.15	0.45	5.58e-18	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs939574	1.000	rs11689596	chr2:220093423	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.95	-8.25	-0.41	3.82e-15	Platelet distribution width;
LUSC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg23625390	chr15:77176239	SCAPER	0.39	5.66	0.3	3.26e-8	Blood metabolite levels;
LUSC	cis	rs6563842	0.572	rs9549263	chr13:41264784	G/T	cg21288729	chr13:41239152	FOXO1	0.56	8.31	0.41	2.4e-15	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15572692	chr19:14016919	C19orf57;CC2D1A	-0.41	-6.07	-0.32	3.57e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg19318889	chr4:1322082	MAEA	0.54	8.97	0.44	2.1e-17	Obesity-related traits;
LUSC	cis	rs7705502	0.926	rs72812804	chr5:173340496	T/G	cg18693985	chr5:173351052	CPEB4	-0.36	-5.79	-0.3	1.63e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04004882	chr2:215674386	BARD1	0.49	6.44	0.33	4.06e-10	Neuroblastoma;
LUSC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.3	-6.01	-0.31	4.96e-9	Total body bone mineral density;
LUSC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.41	-0.33	4.94e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg05872129	chr22:39784769	NA	-0.57	-10.57	-0.5	1.02e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.81	13.6	0.6	7.98e-34	Aortic root size;
LUSC	cis	rs9807989	0.839	rs10204837	chr2:102977730	C/A	cg03938978	chr2:103052716	IL18RAP	0.31	5.74	0.3	2.08e-8	Asthma;
LUSC	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg18129178	chr5:148520854	ABLIM3	-0.69	-10.62	-0.5	6.72e-23	Breast cancer;
LUSC	cis	rs6496667	0.558	rs10459677	chr15:91042399	A/C	cg22089800	chr15:90895588	ZNF774	-0.56	-8.0	-0.4	2e-14	Rheumatoid arthritis;
LUSC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg27535305	chr1:53392650	SCP2	-0.39	-7.36	-0.37	1.43e-12	Monocyte count;
LUSC	trans	rs1559759	0.736	rs11032995	chr11:35111292	A/G	cg10143416	chr2:241907034	NA	0.45	6.23	0.32	1.38e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06544989	chr22:39130855	UNC84B	0.34	6.01	0.31	4.93e-9	Menopause (age at onset);
LUSC	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg09904177	chr6:26538194	HMGN4	0.75	14.34	0.62	1.18e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs1385374	0.698	rs2170988	chr12:129290876	A/C	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.78	-0.35	5.5e-11	Systemic lupus erythematosus;
LUSC	cis	rs4234798	0.500	rs7661077	chr4:7219889	C/T	cg18431297	chr4:7219810	SORCS2	0.32	5.99	0.31	5.46e-9	Insulin-like growth factors;
LUSC	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	7.57	0.38	3.63e-13	Multiple sclerosis;
LUSC	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg04455712	chr21:45112962	RRP1B	0.46	8.92	0.44	3.06e-17	Mean corpuscular volume;
LUSC	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg11502198	chr6:26597334	ABT1	0.6	9.22	0.45	3.34e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14288330	chr14:36003208	INSM2	0.44	6.12	0.32	2.64e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg23231163	chr10:75533350	FUT11	0.44	7.26	0.37	2.79e-12	Inflammatory bowel disease;
LUSC	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	7.3	0.37	2.17e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs7181230	1.000	rs9972424	chr15:40365851	A/G	cg22705835	chr10:65332833	REEP3	-0.43	-7.37	-0.37	1.32e-12	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs9815354	1.000	rs17062109	chr3:41810364	C/T	cg03022575	chr3:42003672	ULK4	0.52	5.86	0.31	1.12e-8	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.54	-8.62	-0.43	2.72e-16	Facial morphology (factor 20);
LUSC	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg26395211	chr5:140044315	WDR55	0.46	6.91	0.35	2.42e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg22166914	chr1:53195759	ZYG11B	0.62	10.3	0.49	8.51e-22	Monocyte count;
LUSC	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg00129232	chr17:37814104	STARD3	-0.44	-6.32	-0.33	8.34e-10	Asthma;
LUSC	cis	rs8028313	0.529	rs16951358	chr15:68153732	G/C	cg08079166	chr15:68083412	MAP2K5	0.31	5.76	0.3	1.9e-8	Obesity;
LUSC	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg23855989	chr12:50355821	AQP5	0.6	10.72	0.51	3.14e-23	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg18681998	chr4:17616180	MED28	0.79	13.6	0.6	8.08e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg06064525	chr11:970664	AP2A2	-0.48	-10.53	-0.5	1.37e-22	Alzheimer's disease (late onset);
LUSC	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-8.0	-0.4	2.11e-14	Bladder cancer;
LUSC	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg10818794	chr15:86012489	AKAP13	-0.42	-6.55	-0.34	2.13e-10	Coronary artery disease;
LUSC	cis	rs8103278	0.507	rs7246377	chr19:46292259	G/A	cg20908204	chr19:46285434	DMPK	0.43	8.46	0.42	8.69e-16	Coronary artery disease;
LUSC	cis	rs17255340	0.539	rs1144193	chr6:83979034	A/G	cg08257003	chr6:84140564	ME1	0.32	8.13	0.41	8.21e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg18200150	chr17:30822561	MYO1D	0.53	10.55	0.5	1.17e-22	Schizophrenia;
LUSC	cis	rs11191270	0.554	rs77616533	chr10:104055983	A/G	cg15320455	chr10:103880129	LDB1	0.6	6.17	0.32	1.99e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2835872	0.663	rs73220488	chr21:38987025	C/T	cg20424643	chr21:39039972	KCNJ6	0.37	5.71	0.3	2.51e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs6709815	0.841	rs12694442	chr2:219663599	T/C	cg02176678	chr2:219576539	TTLL4	-0.52	-9.12	-0.45	7.39e-18	Reticulocyte count;High light scatter reticulocyte count;
LUSC	cis	rs7582720	1.000	rs72934563	chr2:203995405	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.83	8.78	0.43	8.34e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg08847533	chr14:75593920	NEK9	0.84	15.46	0.65	4.83e-41	Height;
LUSC	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07741184	chr6:167504864	NA	0.5	9.09	0.45	9.21e-18	Rheumatoid arthritis;
LUSC	cis	rs7075426	0.716	rs11598718	chr10:88294484	G/A	cg07322936	chr10:88137208	NA	0.44	6.2	0.32	1.66e-9	Migraine without aura;
LUSC	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg18002602	chr11:66138449	SLC29A2	0.45	8.2	0.41	5.14e-15	Educational attainment (years of education);
LUSC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg02551604	chr5:131831745	NA	0.43	6.61	0.34	1.48e-10	Asthma (sex interaction);
LUSC	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg01065977	chr19:18549689	ISYNA1	-0.23	-5.94	-0.31	7.06e-9	Breast cancer;
LUSC	cis	rs6484504	0.576	rs208093	chr11:31184400	C/T	cg26647111	chr11:31128758	NA	0.42	6.14	0.32	2.4e-9	Red blood cell count;
LUSC	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.91	0.7	9.06e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg21095983	chr6:86352623	SYNCRIP	0.57	8.83	0.44	6.02e-17	Smooth-surface caries;
LUSC	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.68	-11.24	-0.52	4.52e-25	Colorectal cancer;
LUSC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-25.08	-0.81	8.21e-79	Height;
LUSC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10269783	0.651	rs2158546	chr7:49625671	C/A	cg27385590	chr7:49619841	NA	-0.31	-5.71	-0.3	2.47e-8	Body mass index;
LUSC	cis	rs2522056	1.000	rs2522047	chr5:131795882	G/T	cg24060327	chr5:131705240	SLC22A5	0.45	5.96	0.31	6.39e-9	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.92	12.96	0.58	2.11e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs748404	0.697	rs546170	chr15:43564849	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	8.47	0.42	7.96e-16	Lung cancer;
LUSC	cis	rs7582720	1.000	rs72932774	chr2:203685728	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	7.98	0.4	2.35e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs629535	0.514	rs55653755	chr8:70154383	A/C	cg21567404	chr3:27674614	NA	-0.93	-13.37	-0.59	5.88e-33	Dupuytren's disease;
LUSC	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-6.19	-0.32	1.78e-9	Self-reported allergy;
LUSC	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg25019033	chr10:957182	NA	-0.5	-6.2	-0.32	1.69e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg00012203	chr2:219082015	ARPC2	0.81	13.82	0.6	1.1e-34	Colorectal cancer;
LUSC	cis	rs11018904	0.861	rs61903723	chr11:89968246	C/T	cg26028595	chr11:89956573	CHORDC1	-0.53	-6.15	-0.32	2.22e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.54	0.38	4.44e-13	Menarche (age at onset);
LUSC	cis	rs4285028	0.747	rs11928871	chr3:121483388	G/C	cg11130432	chr3:121712080	ILDR1	-0.63	-9.29	-0.45	2.08e-18	Multiple sclerosis;
LUSC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg23711669	chr6:146136114	FBXO30	0.76	13.58	0.6	9.51e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg14552801	chr7:65878734	NA	-0.46	-6.53	-0.34	2.45e-10	Aortic root size;
LUSC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	11.26	0.52	3.72e-25	Menopause (age at onset);
LUSC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg11663144	chr21:46675770	NA	-0.41	-7.03	-0.36	1.15e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	7.57	0.38	3.58e-13	Prudent dietary pattern;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg18755547	chr17:556432	VPS53	0.46	6.25	0.32	1.26e-9	Hepatitis;
LUSC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg18306943	chr3:40428807	ENTPD3	0.39	5.75	0.3	2.03e-8	Renal cell carcinoma;
LUSC	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg13010199	chr12:38710504	ALG10B	-0.65	-10.22	-0.49	1.61e-21	Bladder cancer;
LUSC	trans	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg21775007	chr8:11205619	TDH	-0.43	-5.97	-0.31	6e-9	Neuroticism;
LUSC	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg18105134	chr13:113819100	PROZ	-0.67	-9.57	-0.46	2.49e-19	Platelet distribution width;
LUSC	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.77	0.47	5.22e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg05863683	chr7:1912471	MAD1L1	0.29	5.72	0.3	2.42e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs6599077	1.000	rs2887952	chr3:40098229	G/C	cg13683864	chr3:40499215	RPL14	-0.59	-7.4	-0.38	1.11e-12	Sleep-related phenotypes;
LUSC	cis	rs2073300	1.000	rs6048824	chr20:23457645	C/A	cg09953122	chr20:23471693	CST8	-0.69	-6.86	-0.35	3.28e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.69	10.49	0.5	1.88e-22	Corneal astigmatism;
LUSC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.1	-0.48	4.24e-21	Platelet count;
LUSC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-6.95	-0.36	1.93e-11	Blood metabolite levels;
LUSC	cis	rs1982963	1.000	rs3742536	chr14:52507429	C/T	cg10843707	chr14:52510701	NID2	0.41	7.39	0.37	1.17e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-11.86	-0.54	2.51e-27	Chronic sinus infection;
LUSC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7759001	0.857	rs2223464	chr6:27356216	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.78	0.3	1.73e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg19318889	chr4:1322082	MAEA	0.54	9.01	0.44	1.66e-17	Longevity;
LUSC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg00101154	chr16:420108	MRPL28	-0.41	-6.47	-0.33	3.53e-10	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.52	-8.02	-0.4	1.8e-14	Menarche (age at onset);
LUSC	cis	rs911119	0.955	rs6048930	chr20:23592492	T/C	cg16589663	chr20:23618590	CST3	0.57	6.79	0.35	5.12e-11	Chronic kidney disease;
LUSC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	7.51	0.38	5.51e-13	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg19592336	chr6:28129416	ZNF389	0.47	6.19	0.32	1.75e-9	Depression;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg01881136	chr16:89438758	ANKRD11	-0.4	-6.41	-0.33	5.09e-10	Asthma;
LUSC	trans	rs7939886	0.920	rs10896157	chr11:56037621	T/G	cg15704280	chr7:45808275	SEPT13	0.86	6.54	0.34	2.26e-10	Myopia (pathological);
LUSC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg02475777	chr4:1388615	CRIPAK	0.42	6.37	0.33	6.09e-10	Longevity;
LUSC	trans	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg07211511	chr3:129823064	LOC729375	-0.78	-9.97	-0.48	1.18e-20	Blood pressure (smoking interaction);
LUSC	trans	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.49	-0.33	3.01e-10	Triglycerides;
LUSC	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-1.15	-18.29	-0.71	2.9e-52	Exhaled nitric oxide output;
LUSC	cis	rs1335645	0.570	rs56740658	chr1:111647508	C/G	cg00321911	chr1:111669324	DRAM2	-0.59	-6.16	-0.32	2.13e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg17294928	chr15:75287854	SCAMP5	-0.84	-11.42	-0.53	1.01e-25	Blood trace element (Zn levels);
LUSC	cis	rs9311676	0.632	rs34086582	chr3:58419944	C/T	cg13750441	chr3:58318267	PXK	0.35	6.83	0.35	4.14e-11	Systemic lupus erythematosus;
LUSC	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	11.8	0.54	4.3e-27	Ileal carcinoids;
LUSC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg23711669	chr6:146136114	FBXO30	0.88	16.37	0.67	1.21e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6484504	0.576	rs16922084	chr11:31371109	C/T	cg06552810	chr11:31128660	NA	0.39	6.77	0.35	5.78e-11	Red blood cell count;
LUSC	cis	rs72960926	0.744	rs7755776	chr6:74967405	C/G	cg03266952	chr6:74778945	NA	0.78	6.92	0.35	2.37e-11	Metabolite levels (MHPG);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10619042	chr17:66202065	NA	-0.4	-6.07	-0.32	3.53e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.35	5.95	0.31	6.73e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03865648	chr3:173113856	NA	-0.43	-6.13	-0.32	2.52e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	0.64	13.71	0.6	2.91e-34	Prudent dietary pattern;
LUSC	trans	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg25206134	chr2:45395956	NA	0.56	6.15	0.32	2.2e-9	Neuroticism;
LUSC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-10.12	-0.48	3.46e-21	Longevity;Endometriosis;
LUSC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg02475777	chr4:1388615	CRIPAK	0.4	5.87	0.31	1.04e-8	Obesity-related traits;
LUSC	cis	rs7589342	0.628	rs35866817	chr2:106402569	T/C	cg14210321	chr2:106509881	NCK2	-0.46	-5.83	-0.3	1.3e-8	Addiction;
LUSC	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-7.51	-0.38	5.52e-13	Retinal vascular caliber;
LUSC	cis	rs11997175	0.558	rs6468207	chr8:33798095	G/A	ch.8.33884649F	chr8:33765107	NA	-0.43	-6.25	-0.32	1.26e-9	Body mass index;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18313702	chr3:183853126	EIF2B5	0.49	7.04	0.36	1.1e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1322512	0.917	rs2258722	chr6:152969710	C/T	cg27316956	chr6:152958899	SYNE1	-0.36	-6.28	-0.32	1.07e-9	Tonometry;
LUSC	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg14789911	chr21:47582049	C21orf56	-0.4	-6.27	-0.32	1.1e-9	Testicular germ cell tumor;
LUSC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.61	-0.34	1.55e-10	High light scatter reticulocyte count;
LUSC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg25258033	chr6:167368657	RNASET2	-0.46	-7.62	-0.38	2.68e-13	Crohn's disease;
LUSC	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg21775007	chr8:11205619	TDH	-0.69	-10.93	-0.51	5.48e-24	Retinal vascular caliber;
LUSC	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg16482183	chr6:26056742	HIST1H1C	0.64	9.14	0.45	6.03e-18	Iron status biomarkers;
LUSC	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg25643088	chr3:52874325	TMEM110	-0.4	-6.01	-0.31	4.85e-9	Schizophrenia;
LUSC	cis	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg17469321	chr7:55412551	NA	0.65	10.58	0.5	9.39e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg23277830	chr1:3704460	LRRC47	0.3	5.85	0.3	1.16e-8	Red cell distribution width;
LUSC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.9	0.61	5.47e-35	Breast cancer;
LUSC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.59	0.38	3.31e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg23795048	chr12:9217529	LOC144571	0.34	5.82	0.3	1.35e-8	Sjögren's syndrome;
LUSC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10802521	chr3:52805072	NEK4	-0.55	-9.19	-0.45	4.41e-18	Bipolar disorder;
LUSC	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg09359103	chr1:154839909	KCNN3	-0.69	-15.43	-0.65	6.29e-41	Prostate cancer;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg23505966	chr3:101443535	CEP97	0.39	5.95	0.31	6.59e-9	Calcium levels;
LUSC	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg26677194	chr12:130822605	PIWIL1	0.6	8.96	0.44	2.29e-17	Menopause (age at onset);
LUSC	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg19789473	chr17:27170043	C17orf63	-0.3	-5.87	-0.31	1.04e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg12751644	chr20:60527061	NA	-0.35	-6.11	-0.32	2.73e-9	Body mass index;
LUSC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg05623727	chr3:50126028	RBM5	0.32	5.97	0.31	6.04e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.49	8.48	0.42	7.15e-16	Prudent dietary pattern;
LUSC	cis	rs354225	0.544	rs13391522	chr2:54805854	T/C	cg26097391	chr2:54893211	SPTBN1	0.46	6.93	0.35	2.19e-11	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07050772	chr17:48423262	XYLT2	-0.39	-5.95	-0.31	6.62e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg11584989	chr19:19387371	SF4	0.59	6.99	0.36	1.46e-11	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	0.65	13.74	0.6	2.37e-34	Prudent dietary pattern;
LUSC	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg07959070	chr22:50026188	C22orf34	-0.33	-6.3	-0.33	9.33e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.73	-11.65	-0.54	1.52e-26	Body mass index;
LUSC	cis	rs7584330	0.554	rs74001399	chr2:238445440	G/A	cg14458575	chr2:238380390	NA	0.43	5.66	0.3	3.31e-8	Prostate cancer;
LUSC	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg14458575	chr2:238380390	NA	0.52	8.86	0.44	4.97e-17	Prostate cancer;
LUSC	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg20283391	chr11:68216788	NA	-0.61	-8.56	-0.42	4.24e-16	Total body bone mineral density;
LUSC	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.54	-10.53	-0.5	1.4e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-8.52	-0.42	5.56e-16	Obesity-related traits;
LUSC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.64	-0.6	5.38e-34	Chronic sinus infection;
LUSC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.64	10.17	0.49	2.41e-21	Hemoglobin concentration;
LUSC	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg08807101	chr21:30365312	RNF160	-0.53	-8.17	-0.41	6.45e-15	Selective IgA deficiency;
LUSC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	6.47	0.33	3.47e-10	Renal function-related traits (BUN);
LUSC	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg15556689	chr8:8085844	FLJ10661	0.56	8.54	0.42	4.93e-16	Retinal vascular caliber;
LUSC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.65	11.05	0.52	2.17e-24	Bone mineral density;
LUSC	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.43	-6.55	-0.34	2.17e-10	Rheumatoid arthritis;
LUSC	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-7.59	-0.38	3.19e-13	Systolic blood pressure;
LUSC	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg16743903	chr16:89593216	SPG7	-0.38	-5.85	-0.3	1.19e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg04545296	chr12:48745243	ZNF641	0.35	6.39	0.33	5.48e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs2230307	0.572	rs2810419	chr1:100643968	C/A	cg24955406	chr1:100503596	HIAT1	-0.59	-6.45	-0.33	3.94e-10	Carotid intima media thickness;
LUSC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	19.14	0.72	1.19e-55	Chronic sinus infection;
LUSC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.6e-29	Motion sickness;
LUSC	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg13535736	chr9:111863775	C9orf5	-0.44	-6.99	-0.36	1.47e-11	Menarche (age at onset);
LUSC	cis	rs7572644	0.509	rs13001060	chr2:28025061	T/C	cg27432699	chr2:27873401	GPN1	0.56	7.3	0.37	2.09e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	15.35	0.64	1.33e-40	Platelet count;
LUSC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.68	-0.3	2.93e-8	Tonsillectomy;
LUSC	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11764359	chr7:65958608	NA	-0.58	-8.91	-0.44	3.25e-17	Aortic root size;
LUSC	cis	rs593982	0.925	rs603509	chr11:65507605	C/T	cg08755490	chr11:65554678	OVOL1	-1.36	-17.19	-0.69	6.56e-48	Atopic dermatitis;
LUSC	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-8.09	-0.4	1.09e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg18240062	chr17:79603768	NPLOC4	0.58	9.87	0.48	2.58e-20	Eye color traits;
LUSC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg17366294	chr4:99064904	C4orf37	0.58	10.3	0.49	8.56e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg20991723	chr1:152506922	NA	0.54	10.25	0.49	1.33e-21	Hair morphology;
LUSC	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.35	-0.46	1.35e-18	Extrinsic epigenetic age acceleration;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15399604	chr12:109535328	UNG	-0.48	-7.17	-0.37	4.98e-12	Electrocardiographic conduction measures;
LUSC	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg26061582	chr7:22766209	IL6	0.49	7.02	0.36	1.25e-11	Lung cancer;
LUSC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg17971929	chr21:40555470	PSMG1	-0.5	-7.46	-0.38	7.45e-13	Menarche (age at onset);
LUSC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg20891283	chr12:69753455	YEATS4	0.63	9.56	0.46	2.7e-19	Response to diuretic therapy;
LUSC	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg05535760	chr7:792225	HEATR2	0.76	8.9	0.44	3.54e-17	Cerebrospinal P-tau181p levels;
LUSC	cis	rs483180	0.512	rs597308	chr1:120214953	G/A	cg19096424	chr1:120255104	PHGDH	0.47	6.5	0.33	2.99e-10	Macular telangiectasia type 2;
LUSC	cis	rs13401104	0.796	rs10929174	chr2:237116829	A/G	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg14227996	chr4:17616232	MED28	-0.59	-6.39	-0.33	5.67e-10	Opioid sensitivity;
LUSC	cis	rs78545713	0.649	rs114015443	chr6:26221979	A/G	cg23601095	chr6:26197514	HIST1H3D	0.67	5.68	0.3	2.87e-8	Iron status biomarkers (total iron binding capacity);
LUSC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg12257692	chr3:49977190	RBM6	-0.24	-6.42	-0.33	4.77e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.82	0.3	1.39e-8	Rheumatoid arthritis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18746451	chr11:20385301	HTATIP2	-0.39	-5.96	-0.31	6.45e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-6.69	-0.34	9.46e-11	Monocyte percentage of white cells;
LUSC	cis	rs877282	1.000	rs11253361	chr10:770387	T/C	cg17470449	chr10:769945	NA	0.52	7.33	0.37	1.74e-12	Uric acid levels;
LUSC	cis	rs62400317	0.859	rs4267941	chr6:45241302	A/C	cg18551225	chr6:44695536	NA	-0.44	-7.28	-0.37	2.46e-12	Total body bone mineral density;
LUSC	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-14.68	-0.63	5.56e-38	Total body bone mineral density;
LUSC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.85e-10	Bipolar disorder;
LUSC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg21171335	chr12:122356390	WDR66	0.54	7.77	0.39	9.57e-14	Mean corpuscular volume;
LUSC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg07777115	chr5:623756	CEP72	-0.45	-5.77	-0.3	1.79e-8	Obesity-related traits;
LUSC	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg11645453	chr3:52864694	ITIH4	0.47	10.67	0.5	4.58e-23	Schizophrenia;
LUSC	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg18196295	chr10:418757	DIP2C	0.46	7.67	0.39	1.89e-13	Psychosis in Alzheimer's disease;
LUSC	cis	rs1358748	0.555	rs2475169	chr1:67534270	A/G	cg02640540	chr1:67518911	SLC35D1	0.62	6.52	0.34	2.6e-10	Tuberculosis;
LUSC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.59	0.38	3.32e-13	Bipolar disorder;
LUSC	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg00745463	chr17:30367425	LRRC37B	-0.71	-8.74	-0.43	1.14e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	5.88	0.31	1.02e-8	Rheumatoid arthritis;
LUSC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg06740227	chr12:86229804	RASSF9	0.44	7.11	0.36	7.01e-12	Major depressive disorder;
LUSC	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	trans	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg04606887	chr12:46121035	LOC400027	0.74	5.97	0.31	5.92e-9	Cholesterol, total;
LUSC	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg24459738	chr19:57751996	ZNF805	0.5	7.33	0.37	1.72e-12	Hyperactive-impulsive symptoms;
LUSC	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg11473876	chr11:109292803	C11orf87	0.39	6.32	0.33	8.41e-10	Schizophrenia;
LUSC	cis	rs380904	0.519	rs1377663	chr8:144644787	T/A	cg13399544	chr8:144649678	C8orf73	-0.43	-6.66	-0.34	1.15e-10	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	6.29	0.33	1.01e-9	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg17420585	chr12:42539391	GXYLT1	-0.39	-7.67	-0.39	1.93e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10005894	chr3:186649165	ST6GAL1	0.39	6.17	0.32	2e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs193541	0.530	rs6595405	chr5:122084745	C/T	cg19077854	chr5:122220652	SNX24	0.36	7.17	0.37	4.74e-12	Glucose homeostasis traits;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg24846343	chr22:24311635	DDTL	0.77	17.41	0.69	9.54e-49	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	0.82	14.2	0.61	3.92e-36	Menopause (age at onset);
LUSC	cis	rs9905704	0.671	rs2531733	chr17:56548811	A/G	cg19466818	chr17:56409534	MIR142	0.37	6.69	0.34	9.44e-11	Testicular germ cell tumor;
LUSC	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg24578937	chr1:2090814	PRKCZ	0.61	13.84	0.6	9.41e-35	Height;
LUSC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.36	-0.37	1.45e-12	Bipolar disorder;
LUSC	cis	rs7527798	1.000	rs17186897	chr1:207839505	C/G	cg09232269	chr1:207846808	CR1L	-0.33	-6.28	-0.32	1.06e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.47	6.96	0.36	1.76e-11	Alzheimer's disease (late onset);
LUSC	trans	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg26384229	chr12:38710491	ALG10B	0.67	10.53	0.5	1.43e-22	Morning vs. evening chronotype;
LUSC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg04450456	chr4:17643702	FAM184B	0.35	5.8	0.3	1.56e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8077577	1.000	rs8077577	chr17:18064730	C/T	cg16794390	chr17:18148240	FLII	0.44	6.28	0.33	1.03e-9	Obesity-related traits;
LUSC	cis	rs4925114	0.568	rs11656775	chr17:17654319	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.48	-6.96	-0.36	1.79e-11	Body mass index;
LUSC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08859206	chr1:53392774	SCP2	0.5	8.51	0.42	6.03e-16	Monocyte count;
LUSC	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.4	-0.33	5.18e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg00024416	chr22:24240387	NA	-0.33	-5.71	-0.3	2.56e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.86	13.95	0.61	3.66e-35	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs7586879	0.789	rs67221599	chr2:25131948	T/C	cg01884057	chr2:25150051	NA	0.41	8.47	0.42	8.07e-16	Body mass index;
LUSC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18099408	chr3:52552593	STAB1	-0.4	-6.96	-0.36	1.81e-11	Bipolar disorder;
LUSC	cis	rs11828289	0.607	rs76811253	chr11:23222885	G/A	cg20040320	chr11:23191996	NA	-0.61	-6.3	-0.33	9.26e-10	Cancer;
LUSC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	9.36	0.46	1.18e-18	Personality dimensions;
LUSC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	8.21	0.41	4.85e-15	Homoarginine levels;
LUSC	cis	rs2455601	0.529	rs2653569	chr11:8986978	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-6.92	-0.35	2.34e-11	Schizophrenia;
LUSC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg02187348	chr16:89574699	SPG7	0.58	9.58	0.46	2.31e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg00945038	chr17:61921165	SMARCD2	0.38	5.77	0.3	1.77e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg11584989	chr19:19387371	SF4	0.67	8.0	0.4	2.06e-14	Bipolar disorder;
LUSC	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg03585969	chr10:35415529	CREM	0.59	8.75	0.43	1.07e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1044826	0.667	rs2083336	chr3:139201272	T/G	cg15131784	chr3:139108705	COPB2	0.4	6.38	0.33	5.94e-10	Obesity-related traits;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg07869135	chr8:123794843	ZHX2	0.45	6.36	0.33	6.56e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.95	13.36	0.59	6.28e-33	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg07393940	chr7:158741817	NA	-0.54	-8.75	-0.43	1.06e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg00376283	chr12:123451042	ABCB9	0.68	9.69	0.47	9.85e-20	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg27572855	chr1:25598939	RHD	0.47	8.3	0.41	2.53e-15	Erythrocyte sedimentation rate;
LUSC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg02153584	chr22:29168773	CCDC117	0.66	10.7	0.51	3.52e-23	Lymphocyte counts;
LUSC	trans	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg05926928	chr17:57297772	GDPD1	-0.47	-6.73	-0.35	7.39e-11	Schizophrenia;
LUSC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-1.19	-12.84	-0.57	5.85e-31	Diabetic kidney disease;
LUSC	cis	rs11039100	0.607	rs11038961	chr11:5780983	A/G	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9653442	0.564	rs2164711	chr2:100775422	G/T	cg22139774	chr2:100720529	AFF3	-0.42	-7.2	-0.37	3.92e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22029157	chr1:209979665	IRF6	0.72	10.69	0.5	3.82e-23	Cleft lip with or without cleft palate;
LUSC	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg02269571	chr22:50332266	NA	-0.54	-8.11	-0.41	1e-14	Schizophrenia;
LUSC	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg12863693	chr15:85201151	NMB	0.41	8.48	0.42	7.34e-16	Schizophrenia;
LUSC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03934478	chr11:495069	RNH1	0.82	9.84	0.47	3.08e-20	Body mass index;
LUSC	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg01475377	chr6:109611718	NA	-0.43	-7.78	-0.39	8.93e-14	Reticulocyte fraction of red cells;
LUSC	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.51	5.98	0.31	5.78e-9	Schizophrenia;
LUSC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.37	0.37	1.32e-12	Motion sickness;
LUSC	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg13042288	chr15:90349979	ANPEP	-0.49	-6.86	-0.35	3.39e-11	Uric acid levels;
LUSC	cis	rs225245	0.817	rs225290	chr17:33927904	C/G	cg05299278	chr17:33885742	SLFN14	0.31	6.9	0.35	2.59e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg04025307	chr7:1156635	C7orf50	0.44	6.09	0.32	3.17e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs739496	0.542	rs10219736	chr12:111788402	C/T	cg10833066	chr12:111807467	FAM109A	0.6	11.76	0.54	6.2e-27	Platelet count;
LUSC	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg17366294	chr4:99064904	C4orf37	0.61	10.91	0.51	6.76e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg08000102	chr2:233561755	GIGYF2	-0.8	-14.03	-0.61	1.85e-35	Schizophrenia;
LUSC	cis	rs273573	0.925	rs163883	chr11:30947248	A/G	cg06552810	chr11:31128660	NA	0.33	5.73	0.3	2.26e-8	Total body bone mineral density;
LUSC	cis	rs7590720	1.000	rs7559031	chr2:216902583	A/G	cg12620499	chr2:216877984	MREG	0.93	14.09	0.61	1.09e-35	Alcohol dependence;
LUSC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg14552801	chr7:65878734	NA	0.38	5.93	0.31	7.55e-9	Aortic root size;
LUSC	cis	rs1124376	1.000	rs61457790	chr3:20136186	G/A	cg05072819	chr3:20081367	KAT2B	0.66	7.43	0.38	9.24e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00166722	chr3:10149974	C3orf24	-0.6	-7.92	-0.4	3.51e-14	Alzheimer's disease;
LUSC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	0.93	18.01	0.7	3.73e-51	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg00750074	chr16:89608354	SPG7	-0.54	-9.72	-0.47	7.68e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.34	0.59	7.64e-33	Platelet count;
LUSC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	0.93	15.66	0.65	7.69e-42	Menopause (age at onset);
LUSC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg27284194	chr4:1044797	NA	0.35	5.9	0.31	8.97e-9	Longevity;
LUSC	cis	rs12618769	0.652	rs72821965	chr2:99188783	T/C	cg10123293	chr2:99228465	UNC50	0.46	7.37	0.37	1.38e-12	Bipolar disorder;
LUSC	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg18357645	chr12:58087776	OS9	0.42	6.25	0.32	1.25e-9	Multiple sclerosis;
LUSC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg27170947	chr2:26402098	FAM59B	0.73	10.81	0.51	1.45e-23	Gut microbiome composition (summer);
LUSC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg18681998	chr4:17616180	MED28	0.85	16.09	0.66	1.53e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs9886428	1.000	rs1427025	chr8:14118890	T/C	cg11959399	chr20:741723	C20orf54	-0.4	-6.28	-0.32	1.05e-9	IgG glycosylation;
LUSC	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg16359550	chr11:109292809	C11orf87	0.34	5.99	0.31	5.43e-9	Schizophrenia;
LUSC	cis	rs55665837	1.000	rs11023227	chr11:14459087	T/C	cg19336497	chr11:14380999	RRAS2	-0.37	-7.47	-0.38	6.93e-13	Vitamin D levels;
LUSC	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg06784218	chr1:46089804	CCDC17	0.33	5.99	0.31	5.45e-9	Platelet count;
LUSC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg02018176	chr4:1364513	KIAA1530	0.5	8.8	0.43	7.3e-17	Obesity-related traits;
LUSC	trans	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.67	-0.34	1.07e-10	Monocyte count;
LUSC	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg07173049	chr1:7289937	CAMTA1	-0.35	-7.24	-0.37	3.07e-12	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7681440	0.647	rs1442133	chr4:90819195	C/T	cg15133208	chr4:90757351	SNCA	-0.35	-5.97	-0.31	5.96e-9	Dementia with Lewy bodies;
LUSC	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg22800045	chr5:56110881	MAP3K1	0.4	5.66	0.3	3.29e-8	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg24375607	chr4:120327624	NA	-0.75	-11.61	-0.54	2.15e-26	Corneal astigmatism;
LUSC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs738321	0.757	rs3788536	chr22:38534209	C/T	cg25457927	chr22:38595422	NA	-0.37	-7.07	-0.36	9.26e-12	Breast cancer;
LUSC	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg07661805	chr8:143867942	LY6D	-0.25	-5.78	-0.3	1.73e-8	Urinary tract infection frequency;
LUSC	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg04369109	chr6:150039330	LATS1	-0.52	-7.46	-0.38	7.37e-13	Lung cancer;
LUSC	cis	rs4144743	1.000	rs55827077	chr17:45331083	G/C	cg18085866	chr17:45331354	ITGB3	-0.75	-7.81	-0.39	7.52e-14	Body mass index;
LUSC	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg13813247	chr22:41461852	NA	-0.37	-6.59	-0.34	1.67e-10	Neuroticism;
LUSC	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg17173187	chr15:85201210	NMB	-0.3	-5.97	-0.31	5.96e-9	P wave terminal force;
LUSC	cis	rs10465746	0.653	rs11163877	chr1:84441848	T/A	cg10977910	chr1:84465055	TTLL7	0.44	6.41	0.33	4.83e-10	Obesity-related traits;
LUSC	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg16102102	chr5:83017553	HAPLN1	-0.93	-14.07	-0.61	1.2e-35	Prostate cancer;
LUSC	cis	rs360798	0.512	rs12989754	chr2:63020970	A/G	cg17519650	chr2:63277830	OTX1	-0.52	-7.37	-0.37	1.37e-12	Coronary artery disease;
LUSC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.74	11.16	0.52	8.74e-25	Eosinophil percentage of white cells;
LUSC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.44	0.38	8.79e-13	Motion sickness;
LUSC	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg00376283	chr12:123451042	ABCB9	0.66	7.57	0.38	3.57e-13	Neutrophil percentage of white cells;
LUSC	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21659725	chr3:3221576	CRBN	-0.58	-8.15	-0.41	7.26e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg06636001	chr8:8085503	FLJ10661	0.57	8.45	0.42	8.8e-16	Neuroticism;
LUSC	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg10326726	chr10:51549505	MSMB	-0.38	-6.53	-0.34	2.51e-10	Prostate-specific antigen levels;
LUSC	cis	rs7953508	0.711	rs10492321	chr12:93980088	T/A	cg18151635	chr12:93972918	NA	-0.56	-7.74	-0.39	1.17e-13	Pubertal anthropometrics;
LUSC	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.85	14.85	0.63	1.22e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg21100191	chr22:23484243	RTDR1	0.86	14.34	0.62	1.11e-36	Bone mineral density;
LUSC	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg22800045	chr5:56110881	MAP3K1	-0.43	-5.93	-0.31	7.39e-9	Coronary artery disease;
LUSC	cis	rs7759001	0.817	rs6934985	chr6:27354943	T/G	cg18711553	chr6:27366782	ZNF391	0.39	5.74	0.3	2.1e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	11.96	0.55	1.14e-27	Personality dimensions;
LUSC	cis	rs1113500	0.614	rs6677839	chr1:108599341	G/T	cg06207961	chr1:108661230	NA	-0.36	-5.94	-0.31	7.02e-9	Growth-regulated protein alpha levels;
LUSC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-1.04	-20.22	-0.74	5.96e-60	Height;
LUSC	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.28	-5.75	-0.3	2.02e-8	Total body bone mineral density;
LUSC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg08470875	chr2:26401718	FAM59B	-0.66	-8.63	-0.43	2.55e-16	Gut microbiome composition (summer);
LUSC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg22166914	chr1:53195759	ZYG11B	-0.57	-9.26	-0.45	2.57e-18	Monocyte count;
LUSC	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-8.54	-0.42	4.84e-16	Joint mobility (Beighton score);
LUSC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03264133	chr6:25882463	NA	-0.5	-9.15	-0.45	5.74e-18	Blood metabolite levels;
LUSC	trans	rs2261181	0.803	rs2583937	chr12:66235464	C/T	cg19918230	chr2:219745647	WNT10A	0.55	6.09	0.32	3.02e-9	Type 2 diabetes;
LUSC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg20891283	chr12:69753455	YEATS4	0.57	7.63	0.39	2.42e-13	Response to diuretic therapy;
LUSC	cis	rs12476592	0.602	rs262503	chr2:63860437	G/A	cg10828910	chr2:63850056	LOC388955	0.48	5.7	0.3	2.69e-8	Childhood ear infection;
LUSC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06634786	chr22:41940651	POLR3H	0.52	6.16	0.32	2.11e-9	Vitiligo;
LUSC	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg15423357	chr2:25149977	NA	0.37	7.38	0.37	1.3e-12	Body mass index;
LUSC	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.27	-0.41	3.33e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs79911532	0.515	rs76180651	chr7:75704350	T/G	cg03592824	chr7:75666768	STYXL1	0.67	6.42	0.33	4.79e-10	Mononucleosis;
LUSC	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg08085267	chr17:45401833	C17orf57	0.45	6.62	0.34	1.44e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6500395	0.889	rs2080507	chr16:48688634	T/A	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.52	10.43	0.5	3.08e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs240764	0.584	rs11155653	chr6:101217123	G/A	cg09795085	chr6:101329169	ASCC3	-0.41	-6.04	-0.31	4.05e-9	Neuroticism;
LUSC	cis	rs9633740	1.000	rs1870138	chr10:82269611	A/G	cg01528321	chr10:82214614	TSPAN14	1.08	12.05	0.55	5.18e-28	Post bronchodilator FEV1;
LUSC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00166722	chr3:10149974	C3orf24	0.59	7.87	0.4	4.84e-14	Alzheimer's disease;
LUSC	cis	rs4786125	0.636	rs7187960	chr16:6919183	G/T	cg03623568	chr16:6915990	A2BP1	-0.5	-8.39	-0.42	1.38e-15	Heart rate variability traits (SDNN);
LUSC	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-0.59	-6.26	-0.32	1.16e-9	Hair shape;
LUSC	cis	rs12541635	0.966	rs2029881	chr8:107002226	A/G	cg10147462	chr8:107024639	NA	0.55	9.96	0.48	1.27e-20	Age of smoking initiation;
LUSC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg15691649	chr6:25882328	NA	0.51	7.52	0.38	5.19e-13	Blood metabolite levels;
LUSC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-10.49	-0.5	1.86e-22	Chronic sinus infection;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07747515	chr11:61659326	FADS3	-0.41	-6.08	-0.32	3.31e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg03585969	chr10:35415529	CREM	0.61	8.87	0.44	4.36e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.87	12.06	0.55	4.93e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-1.02	-20.5	-0.75	4.92e-61	Dilated cardiomyopathy;
LUSC	cis	rs7131987	0.834	rs11050167	chr12:29426387	C/T	cg09582351	chr12:29534625	ERGIC2	-0.33	-6.66	-0.34	1.14e-10	QT interval;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.82	-13.22	-0.59	2.27e-32	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.51	0.62	2.44e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg05283184	chr6:79620031	NA	-0.57	-12.18	-0.55	1.73e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg18404041	chr3:52824283	ITIH1	0.43	7.45	0.38	7.93e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9398803	0.678	rs1155938	chr6:126866472	C/A	cg19875578	chr6:126661172	C6orf173	0.4	5.71	0.3	2.5e-8	Male-pattern baldness;
LUSC	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg11189052	chr15:85197271	WDR73	0.53	5.99	0.31	5.36e-9	Schizophrenia;
LUSC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg04450456	chr4:17643702	FAM184B	0.36	5.97	0.31	6.17e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	0.94	13.57	0.6	1.03e-33	Eosinophil percentage of granulocytes;
LUSC	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg13575925	chr12:9217583	LOC144571	0.34	6.17	0.32	2.02e-9	Sjögren's syndrome;
LUSC	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg06808227	chr14:105710500	BRF1	-0.65	-9.96	-0.48	1.23e-20	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs1775715	1.000	rs1775715	chr10:32309005	A/G	cg26784012	chr10:32216390	ARHGAP12	-0.38	-6.15	-0.32	2.27e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg20302342	chr1:156215951	PAQR6	0.33	6.29	0.33	9.95e-10	Tonsillectomy;
LUSC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.18	0.37	4.61e-12	Mean platelet volume;
LUSC	cis	rs500891	0.574	rs12208468	chr6:84134464	C/T	cg08257003	chr6:84140564	ME1	0.35	7.74	0.39	1.18e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs8135665	0.600	rs6519097	chr22:38451465	C/T	cg13116946	chr22:38479732	SLC16A8	0.41	6.17	0.32	1.95e-9	Advanced age-related macular degeneration;Age-related macular degeneration;
LUSC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg13319975	chr6:146136371	FBXO30	0.5	7.48	0.38	6.84e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-7.71	-0.39	1.46e-13	Lymphocyte counts;
LUSC	cis	rs7681440	0.583	rs2583965	chr4:90740103	G/T	cg06632027	chr4:90757378	SNCA	-0.36	-5.69	-0.3	2.71e-8	Dementia with Lewy bodies;
LUSC	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-8.33	-0.41	2.14e-15	Body mass index;
LUSC	cis	rs1550582	0.662	rs6981748	chr8:135501309	A/C	cg17885191	chr8:135476712	NA	-0.89	-14.21	-0.61	3.58e-36	Educational attainment;
LUSC	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg09904177	chr6:26538194	HMGN4	0.49	7.77	0.39	9.71e-14	Schizophrenia;
LUSC	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.44	-0.33	4.16e-10	Total body bone mineral density;
LUSC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.85	-0.35	3.55e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg04362960	chr10:104952993	NT5C2	0.59	9.23	0.45	3.21e-18	Arsenic metabolism;
LUSC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg03929089	chr4:120376271	NA	0.71	6.79	0.35	5.04e-11	Axial length;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14728310	chr19:9879317	ZNF846	0.45	7.16	0.36	5.28e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg13010199	chr12:38710504	ALG10B	0.49	7.48	0.38	6.62e-13	Morning vs. evening chronotype;
LUSC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg10360323	chr17:41437877	NA	0.41	5.92	0.31	7.78e-9	Menopause (age at onset);
LUSC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg11645453	chr3:52864694	ITIH4	0.36	8.63	0.43	2.5e-16	Bipolar disorder;
LUSC	trans	rs1486139	1.000	rs723287	chr7:46283897	T/G	cg17534202	chr9:96721102	NA	-0.37	-6.56	-0.34	2.01e-10	Select biomarker traits;
LUSC	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg11645453	chr3:52864694	ITIH4	-0.33	-7.37	-0.37	1.32e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg13010199	chr12:38710504	ALG10B	0.58	9.27	0.45	2.37e-18	Morning vs. evening chronotype;
LUSC	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg24687543	chr11:63912206	MACROD1	0.47	5.82	0.3	1.4e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg13535736	chr9:111863775	C9orf5	-0.36	-6.0	-0.31	5.15e-9	Menarche (age at onset);
LUSC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg20406979	chr6:167373233	NA	0.25	5.94	0.31	7.16e-9	Crohn's disease;
LUSC	cis	rs4363385	0.510	rs6689066	chr1:153045154	T/C	cg00922841	chr1:152955080	SPRR1A	-0.36	-6.07	-0.32	3.4e-9	Inflammatory skin disease;
LUSC	trans	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg07393940	chr7:158741817	NA	0.38	6.79	0.35	5.07e-11	Life satisfaction;
LUSC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg02187348	chr16:89574699	SPG7	-0.47	-7.02	-0.36	1.24e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-6.89	-0.35	2.75e-11	Bipolar disorder;
LUSC	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.47	-8.73	-0.43	1.28e-16	Total body bone mineral density;
LUSC	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg17366294	chr4:99064904	C4orf37	0.54	8.44	0.42	9.91e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg16797656	chr11:68205561	LRP5	0.37	6.16	0.32	2.14e-9	Total body bone mineral density;
LUSC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.44	-0.33	4.21e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg00750074	chr16:89608354	SPG7	0.43	7.04	0.36	1.11e-11	Multiple myeloma (IgH translocation);
LUSC	cis	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg05084668	chr3:125655381	ALG1L	0.82	12.04	0.55	5.48e-28	Blood pressure (smoking interaction);
LUSC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg13390004	chr1:15929781	NA	-0.4	-6.77	-0.35	5.79e-11	Systolic blood pressure;
LUSC	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg23933602	chr10:16859644	RSU1	0.62	8.22	0.41	4.6e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.97	0.36	1.74e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg09044154	chr16:88155775	NA	-0.55	-7.35	-0.37	1.54e-12	Menopause (age at onset);
LUSC	cis	rs11622475	1.000	rs8021692	chr14:104428576	C/G	cg12183467	chr14:104352244	NA	-0.43	-7.32	-0.37	1.81e-12	Bipolar disorder;
LUSC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-7.79	-0.39	8.33e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg03806693	chr22:41940476	POLR3H	1.01	14.56	0.62	1.55e-37	Vitiligo;
LUSC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.63	12.17	0.55	1.83e-28	Pulse pressure;
LUSC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg09021430	chr5:549028	NA	-0.55	-7.45	-0.38	8.21e-13	Obesity-related traits;
LUSC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg12463550	chr7:65579703	CRCP	0.42	6.17	0.32	1.98e-9	Aortic root size;
LUSC	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg15571903	chr15:79123663	NA	-0.36	-6.58	-0.34	1.8e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg23598886	chr18:12777645	NA	0.65	6.47	0.33	3.49e-10	Inflammatory skin disease;
LUSC	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg03676636	chr4:99064102	C4orf37	0.36	8.04	0.4	1.54e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg14092988	chr3:52407081	DNAH1	0.3	5.96	0.31	6.38e-9	Bipolar disorder;
LUSC	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg03340356	chr1:67600835	NA	0.4	6.48	0.33	3.37e-10	Psoriasis;
LUSC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg02772935	chr3:125709198	NA	-0.48	-5.84	-0.3	1.23e-8	Blood pressure (smoking interaction);
LUSC	trans	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-12.78	-0.57	9.91e-31	Colorectal cancer;
LUSC	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg15704280	chr7:45808275	SEPT13	-0.83	-11.57	-0.53	2.98e-26	Coronary artery disease;
LUSC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg07061783	chr6:25882402	NA	-0.38	-5.94	-0.31	7.15e-9	Blood metabolite levels;
LUSC	trans	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg08975724	chr8:8085496	FLJ10661	0.43	6.2	0.32	1.62e-9	Retinal vascular caliber;
LUSC	cis	rs4845459	0.967	rs477392	chr1:152555176	C/G	cg08895932	chr1:152778580	LCE1C	-0.37	-6.34	-0.33	7.64e-10	Psoriasis;
LUSC	cis	rs2637266	0.756	rs846631	chr10:78536928	T/G	cg18941641	chr10:78392320	NA	0.39	7.05	0.36	1.05e-11	Pulmonary function;
LUSC	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg08079166	chr15:68083412	MAP2K5	0.38	6.46	0.33	3.8e-10	Obesity;
LUSC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.67	-13.21	-0.59	2.45e-32	Longevity;Endometriosis;
LUSC	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.79	0.3	1.6e-8	Breast cancer;
LUSC	cis	rs9308433	0.643	rs4655330	chr1:214466068	A/G	cg06198575	chr1:214491504	SMYD2	-0.44	-6.75	-0.35	6.64e-11	IgG glycosylation;
LUSC	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg11214544	chr1:2391121	NA	-0.6	-9.44	-0.46	6.82e-19	Non-obstructive azoospermia;
LUSC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.96	-0.31	6.37e-9	Platelet count;
LUSC	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg17173187	chr15:85201210	NMB	0.51	9.69	0.47	9.71e-20	Schizophrenia;
LUSC	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg03948781	chr1:205179583	DSTYK	0.31	5.78	0.3	1.67e-8	Red blood cell count;
LUSC	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg25801113	chr15:45476975	SHF	-0.36	-7.07	-0.36	8.83e-12	Uric acid levels;
LUSC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg21770322	chr7:97807741	LMTK2	0.41	7.06	0.36	9.5e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.02	0.31	4.61e-9	Neuroticism;
LUSC	cis	rs8056893	0.714	rs9931501	chr16:68402686	A/G	cg02226672	chr16:68398533	SMPD3	0.32	5.69	0.3	2.85e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	cis	rs7903847	0.620	rs10882903	chr10:99115584	A/T	cg20016023	chr10:99160130	RRP12	-0.33	-8.0	-0.4	2.03e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1950626	0.623	rs34448411	chr14:101429287	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.4	7.45	0.38	7.95e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg14983838	chr19:29218262	NA	0.48	5.92	0.31	8e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs2898681	0.567	rs77657787	chr4:53729981	G/A	cg21521518	chr4:53727714	RASL11B	0.49	6.05	0.31	3.97e-9	Optic nerve measurement (cup area);
LUSC	trans	rs867371	0.502	rs1846908	chr15:82522526	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.4	-0.33	5.18e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg19257562	chr1:2043853	PRKCZ	0.31	6.16	0.32	2.04e-9	Height;
LUSC	trans	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.66	0.34	1.14e-10	Corneal astigmatism;
LUSC	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg17252645	chr8:143867129	LY6D	0.38	6.7	0.34	8.92e-11	Urinary tract infection frequency;
LUSC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12310025	chr6:25882481	NA	-0.48	-8.31	-0.41	2.45e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg04508216	chr1:11107452	MASP2	-0.32	-5.87	-0.31	1.05e-8	Body mass index;
LUSC	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg26384229	chr12:38710491	ALG10B	0.49	6.88	0.35	2.88e-11	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg24829409	chr8:58192753	C8orf71	-0.54	-5.92	-0.31	8.21e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-8.05	-0.4	1.46e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7973719	0.769	rs61917956	chr12:7348659	T/C	cg07052231	chr12:7363540	PEX5	0.53	9.27	0.45	2.41e-18	IgG glycosylation;
LUSC	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	0.69	11.04	0.52	2.2e-24	Blood metabolite ratios;
LUSC	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg25554036	chr4:6271136	WFS1	0.51	9.11	0.45	7.56e-18	Cisplatin-induced ototoxicity;
LUSC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.16	-0.36	5.16e-12	Colorectal cancer;
LUSC	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	16.82	0.68	2.11e-46	Exhaled nitric oxide output;
LUSC	cis	rs1322512	0.917	rs2758811	chr6:152964405	G/A	cg27316956	chr6:152958899	SYNE1	-0.37	-6.39	-0.33	5.51e-10	Tonometry;
LUSC	trans	rs11696501	0.688	rs6073848	chr20:44298550	G/A	cg03272292	chr12:48577362	C12orf68	0.5	6.07	0.32	3.47e-9	Brain structure;
LUSC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.42	0.53	1.03e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg24375607	chr4:120327624	NA	-0.68	-10.75	-0.51	2.31e-23	Corneal astigmatism;
LUSC	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg07076509	chr9:96720819	NA	0.31	6.18	0.32	1.91e-9	Esophageal adenocarcinoma;
LUSC	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg22709100	chr7:91322751	NA	0.39	5.79	0.3	1.64e-8	Breast cancer;
LUSC	cis	rs727505	1.000	rs10230610	chr7:124425398	A/C	cg14311320	chr7:124405732	GPR37	-0.33	-5.77	-0.3	1.79e-8	Lewy body disease;
LUSC	cis	rs6733011	0.500	rs11123754	chr2:99433782	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-5.73	-0.3	2.27e-8	Bipolar disorder;
LUSC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	14.07	0.61	1.24e-35	Platelet count;
LUSC	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg00757033	chr12:89920650	WDR51B	0.61	10.77	0.51	2.12e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg18681998	chr4:17616180	MED28	0.76	13.24	0.59	1.83e-32	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.78e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	0.81	11.34	0.53	2e-25	Coronary artery disease;
LUSC	cis	rs9581857	0.512	rs9581874	chr13:28086956	A/G	cg22138327	chr13:27999177	GTF3A	0.69	7.16	0.36	5.12e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs16854884	0.770	rs7653331	chr3:143810909	G/A	cg06585982	chr3:143692056	C3orf58	0.45	6.7	0.34	8.88e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg20203395	chr5:56204925	C5orf35	-0.54	-7.65	-0.39	2.19e-13	Coronary artery disease;
LUSC	cis	rs7949030	1.000	rs3018561	chr11:62392229	C/A	cg13298116	chr11:62369859	EML3;MTA2	-0.51	-8.58	-0.42	3.62e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16439512	chr15:57598924	LOC283663	0.38	5.96	0.31	6.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	0.83	13.78	0.6	1.6e-34	Tonsillectomy;
LUSC	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg26102564	chr10:131424627	MGMT	0.37	5.79	0.3	1.59e-8	Response to temozolomide;
LUSC	cis	rs59698941	0.943	rs57550938	chr5:132248104	G/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs7760949	0.963	rs7761500	chr6:13917140	G/A	cg27413430	chr6:13925136	RNF182	0.55	8.1	0.41	1.04e-14	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	5.67	0.3	3.14e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18211447	chr14:102771717	RAGE	0.43	6.32	0.33	8.4e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg08773314	chr2:239334832	ASB1	0.42	9.13	0.45	6.68e-18	Multiple system atrophy;
LUSC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.63	11.26	0.52	3.76e-25	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg05368731	chr17:41323189	NBR1	0.84	14.11	0.61	8.91e-36	Menopause (age at onset);
LUSC	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg14769373	chr6:40998127	UNC5CL	-0.56	-8.18	-0.41	5.95e-15	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg02018176	chr4:1364513	KIAA1530	0.46	6.44	0.33	4.26e-10	Recombination rate (females);
LUSC	cis	rs7119	0.636	rs34020536	chr15:77819586	G/A	cg27398640	chr15:77910606	LINGO1	-0.31	-6.39	-0.33	5.48e-10	Type 2 diabetes;
LUSC	cis	rs4073416	0.502	rs4359350	chr14:65863748	T/C	cg03016385	chr14:66212404	NA	-0.37	-5.98	-0.31	5.67e-9	N-glycan levels;
LUSC	cis	rs7523273	0.606	rs1830764	chr1:207917052	G/A	cg22525895	chr1:207977042	MIR29B2	0.4	6.62	0.34	1.42e-10	Schizophrenia;
LUSC	cis	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05901451	chr6:126070800	HEY2	0.57	8.45	0.42	9.24e-16	Endometrial cancer;
LUSC	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	1.11	17.18	0.69	7.27e-48	Exhaled nitric oxide output;
LUSC	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg20295408	chr7:1910781	MAD1L1	-0.46	-6.35	-0.33	7.01e-10	Schizophrenia;
LUSC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg19592336	chr6:28129416	ZNF389	0.46	6.38	0.33	5.9e-10	Parkinson's disease;
LUSC	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.88	-0.4	4.58e-14	Neuroticism;
LUSC	cis	rs10740039	0.804	rs894383	chr10:62443117	A/G	cg18175470	chr10:62150864	ANK3	-0.43	-6.54	-0.34	2.29e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg20785333	chr3:119013442	CDGAP	-0.52	-6.41	-0.33	5.06e-10	Neuroticism;
LUSC	cis	rs1692580	0.870	rs263532	chr1:2164116	T/C	cg24578937	chr1:2090814	PRKCZ	0.39	8.2	0.41	5.23e-15	Coronary artery disease;
LUSC	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg25482853	chr8:67687455	SGK3	1.18	16.97	0.68	5.1e-47	Lung disease severity in cystic fibrosis;
LUSC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg20887711	chr4:1340912	KIAA1530	0.47	7.15	0.36	5.57e-12	Obesity-related traits;
LUSC	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	9.77	0.47	5.46e-20	Lung cancer in ever smokers;
LUSC	cis	rs9398803	0.865	rs9398808	chr6:126758791	G/T	cg19875578	chr6:126661172	C6orf173	0.41	6.09	0.32	3.18e-9	Male-pattern baldness;
LUSC	cis	rs28655083	0.828	rs7404322	chr16:77130003	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.53	8.07	0.4	1.31e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs897080	0.515	rs1085444	chr2:44624155	A/G	cg00619915	chr2:44497795	NA	-0.41	-5.82	-0.3	1.35e-8	Height;
LUSC	cis	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg21775007	chr8:11205619	TDH	-0.48	-6.8	-0.35	4.79e-11	Triglycerides;
LUSC	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg18904891	chr8:8559673	CLDN23	0.57	7.98	0.4	2.33e-14	Obesity-related traits;
LUSC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.3	0.37	2.16e-12	Platelet count;
LUSC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg07507251	chr3:52567010	NT5DC2	0.33	6.54	0.34	2.28e-10	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg11062466	chr8:58055876	NA	0.69	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7586879	0.765	rs6545758	chr2:25074874	C/T	cg04586622	chr2:25135609	ADCY3	-0.31	-5.92	-0.31	8.2e-9	Body mass index;
LUSC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.56	0.53	3.14e-26	Menopause (age at onset);
LUSC	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg27588902	chr6:42928151	GNMT	-0.29	-6.44	-0.33	4.12e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.5	11.5	0.53	5.23e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg12002119	chr2:101014098	CHST10	0.36	5.93	0.31	7.62e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg20701182	chr2:24300061	SF3B14	0.88	11.35	0.53	1.86e-25	Lymphocyte counts;
LUSC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg11062466	chr8:58055876	NA	0.71	8.71	0.43	1.45e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg04545296	chr12:48745243	ZNF641	0.37	6.79	0.35	5.1e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs4561483	0.583	rs62038798	chr16:12001569	C/T	cg08843971	chr16:11963173	GSPT1	0.42	6.32	0.33	8.53e-10	Testicular germ cell tumor;
LUSC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg08888203	chr3:10149979	C3orf24	0.59	8.21	0.41	4.83e-15	Alzheimer's disease;
LUSC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	7.23	0.37	3.39e-12	Mean platelet volume;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg08513622	chr7:1889785	MAD1L1	-0.36	-6.02	-0.31	4.52e-9	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5009270	0.512	rs6977807	chr7:112249863	C/T	cg23628563	chr7:112262597	NA	0.42	5.79	0.3	1.64e-8	Osteoarthritis (hip);
LUSC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-11.7	-0.54	1.02e-26	Gut microbiome composition (summer);
LUSC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	9.71	0.47	8.71e-20	Personality dimensions;
LUSC	cis	rs7119167	0.901	rs6592523	chr11:73109877	T/C	cg17517138	chr11:73019481	ARHGEF17	0.53	6.12	0.32	2.61e-9	Blood protein levels;
LUSC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg00033643	chr7:134001901	SLC35B4	-0.43	-6.78	-0.35	5.54e-11	Mean platelet volume;
LUSC	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg07148914	chr20:33460835	GGT7	0.47	6.95	0.36	1.92e-11	Height;
LUSC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06481639	chr22:41940642	POLR3H	-0.53	-5.96	-0.31	6.38e-9	Vitiligo;
LUSC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg24060327	chr5:131705240	SLC22A5	0.67	11.1	0.52	1.38e-24	Breast cancer;
LUSC	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg19196401	chr6:110721138	DDO	-0.44	-8.34	-0.42	1.92e-15	Platelet distribution width;
LUSC	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.83	11.15	0.52	9.49e-25	Mean corpuscular hemoglobin;
LUSC	cis	rs1775715	0.870	rs3847414	chr10:32219176	A/G	cg26784012	chr10:32216390	ARHGAP12	0.41	6.98	0.36	1.61e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7246967	0.673	rs34174596	chr19:22933519	G/A	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.04e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10276303	0.519	rs6971307	chr7:3396217	T/C	cg21248987	chr7:3385318	SDK1	-0.37	-6.2	-0.32	1.71e-9	Dupuytren's disease;
LUSC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg24829409	chr8:58192753	C8orf71	-0.54	-6.09	-0.32	3.05e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg14675211	chr2:100938903	LONRF2	0.37	5.77	0.3	1.81e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	1.05	13.29	0.59	1.24e-32	Mitochondrial DNA levels;
LUSC	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg22777020	chr22:31556080	RNF185	-0.45	-5.72	-0.3	2.32e-8	Colorectal cancer;
LUSC	cis	rs7215564	0.908	rs80183474	chr17:78655070	T/A	cg23238734	chr17:78661607	RPTOR	0.48	6.13	0.32	2.5e-9	Myopia (pathological);
LUSC	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg11019008	chr10:131425282	MGMT	0.46	6.7	0.34	8.9e-11	Response to temozolomide;
LUSC	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.28	0.53	3.34e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.32	-0.37	1.91e-12	Morning vs. evening chronotype;
LUSC	cis	rs12980942	1.000	rs8109167	chr19:41823167	G/T	cg25627403	chr19:41769009	HNRNPUL1	0.55	5.99	0.31	5.54e-9	Coronary artery disease;
LUSC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.98	0.55	9.29e-28	Chronic sinus infection;
LUSC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg00074818	chr8:8560427	CLDN23	0.58	9.87	0.48	2.46e-20	Obesity-related traits;
LUSC	cis	rs11997175	0.784	rs36083407	chr8:33812930	G/T	ch.8.33884649F	chr8:33765107	NA	0.53	8.05	0.4	1.43e-14	Body mass index;
LUSC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-9.09	-0.45	9.12e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg25566285	chr7:158114605	PTPRN2	-0.33	-6.15	-0.32	2.25e-9	Calcium levels;
LUSC	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg21427119	chr20:30132790	HM13	-0.43	-6.19	-0.32	1.77e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-6.84	-0.35	3.82e-11	Bipolar disorder;
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg05788437	chr3:197476880	FYTTD1;KIAA0226	-0.45	-6.41	-0.33	4.99e-10	Height;
LUSC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg15556689	chr8:8085844	FLJ10661	0.69	11.73	0.54	7.82e-27	Mood instability;
LUSC	trans	rs7939886	0.764	rs7113688	chr11:55946865	C/T	cg03929089	chr4:120376271	NA	0.82	6.22	0.32	1.53e-9	Myopia (pathological);
LUSC	trans	rs28647808	0.618	rs7025970	chr9:136267173	G/A	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs3733418	0.929	rs12510464	chr4:165919040	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-5.99	-0.31	5.39e-9	Obesity-related traits;
LUSC	cis	rs7091068	0.536	rs6583901	chr10:95409998	C/T	cg20715218	chr10:95462985	C10orf4	-0.62	-8.38	-0.42	1.51e-15	Urinary tract infection frequency;
LUSC	cis	rs2688419	0.537	rs528649	chr3:23051934	C/T	cg00327796	chr3:23032191	NA	0.37	6.09	0.32	3.07e-9	Type 2 diabetes;
LUSC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2273669	0.667	rs12216104	chr6:109317635	C/T	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08048268	chr3:133502702	NA	-0.46	-8.93	-0.44	3.01e-17	Iron status biomarkers;
LUSC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.9	0.35	2.64e-11	Tonsillectomy;
LUSC	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg20628663	chr10:43360327	NA	0.78	11.37	0.53	1.53e-25	Blood protein levels;
LUSC	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg15848620	chr12:58087721	OS9	-0.52	-7.56	-0.38	3.89e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-7.63	-0.39	2.45e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg13319975	chr6:146136371	FBXO30	0.5	7.45	0.38	8.21e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs727505	0.607	rs67673811	chr7:124802694	C/G	cg23710748	chr7:124431027	NA	-0.37	-6.55	-0.34	2.16e-10	Lewy body disease;
LUSC	cis	rs7715806	0.500	rs77544433	chr5:75001025	C/A	cg19683494	chr5:74908142	NA	0.54	7.4	0.38	1.1e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg04492858	chr10:133558786	NA	-0.38	-6.45	-0.33	3.9e-10	Survival in rectal cancer;
LUSC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7131987	0.834	rs1989478	chr12:29442229	C/T	cg09582351	chr12:29534625	ERGIC2	-0.34	-6.96	-0.36	1.86e-11	QT interval;
LUSC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg03676636	chr4:99064102	C4orf37	0.35	7.58	0.38	3.43e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.57	-0.46	2.51e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg21361702	chr7:150065534	REPIN1	0.59	8.6	0.43	3.13e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18876405	chr7:65276391	NA	-0.55	-8.77	-0.43	9.25e-17	Aortic root size;
LUSC	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg21775007	chr8:11205619	TDH	-0.57	-8.02	-0.4	1.74e-14	Neuroticism;
LUSC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg03396347	chr1:1875803	NA	-0.55	-12.31	-0.56	5.54e-29	Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09493401	chr6:139094915	CCDC28A	-0.52	-7.55	-0.38	4.06e-13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10186029	0.509	rs10203838	chr2:213935900	T/C	cg08319019	chr2:214017104	IKZF2	-0.41	-6.03	-0.31	4.3e-9	Systemic sclerosis;
LUSC	cis	rs16917546	1.000	rs10995255	chr10:64402433	G/A	cg03961010	chr10:64397487	ZNF365	-0.41	-6.5	-0.33	2.98e-10	Basal cell carcinoma;
LUSC	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg10253484	chr15:75165896	SCAMP2	-0.47	-6.31	-0.33	8.66e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.83	17.73	0.7	4.74e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.79	-0.47	4.53e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg00031303	chr3:195681400	NA	0.7	10.07	0.48	5.22e-21	Pancreatic cancer;
LUSC	cis	rs13401104	0.796	rs35819191	chr2:237119051	T/C	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	trans	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.55	-0.38	4.32e-13	Triglycerides;
LUSC	cis	rs1950626	0.787	rs34857222	chr14:101391354	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.41	7.24	0.37	3.17e-12	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg20734569	chr3:48348370	SPINK8	-0.46	-7.81	-0.39	7.43e-14	Coronary artery disease;
LUSC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.47	6.1	0.32	2.88e-9	Renal function-related traits (BUN);
LUSC	cis	rs1775715	0.966	rs1755067	chr10:32296195	C/T	cg18675610	chr10:32216311	ARHGAP12	-0.29	-6.13	-0.32	2.5e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.59	10.02	0.48	7.91e-21	Lymphocyte counts;
LUSC	cis	rs4073416	0.542	rs7140695	chr14:65929132	T/C	cg03016385	chr14:66212404	NA	-0.39	-5.76	-0.3	1.89e-8	N-glycan levels;
LUSC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg12432903	chr7:1882776	MAD1L1	-0.5	-8.3	-0.41	2.69e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs34421088	0.532	rs1545073	chr8:11167700	C/T	cg21775007	chr8:11205619	TDH	0.45	6.61	0.34	1.55e-10	Neuroticism;
LUSC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.44e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg20119798	chr7:94954144	PON1	-0.33	-5.78	-0.3	1.74e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2970818	0.764	rs11063181	chr12:4580657	C/A	cg11146114	chr12:4671731	NA	-0.69	-6.48	-0.33	3.34e-10	Phosphorus levels;
LUSC	cis	rs597583	0.715	rs2276340	chr11:117391966	G/A	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.45	-0.42	9.26e-16	Putamen volume;
LUSC	cis	rs7808935	0.768	rs757137	chr7:27989343	T/C	cg22168087	chr7:27702803	HIBADH	0.45	5.85	0.31	1.15e-8	Prostate cancer;
LUSC	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.27e-20	Coronary artery disease;
LUSC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-1.07	-24.87	-0.81	5.49e-78	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	6.23	0.32	1.44e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	4.91e-23	Aortic root size;
LUSC	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg24296786	chr1:45957014	TESK2	0.46	6.34	0.33	7.6e-10	Red blood cell count;Reticulocyte count;
LUSC	cis	rs6460942	0.908	rs6978857	chr7:12232665	A/G	cg06484146	chr7:12443880	VWDE	-0.56	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	cis	rs73206853	0.841	rs56306150	chr12:110716775	A/T	cg12870014	chr12:110450643	ANKRD13A	0.68	6.45	0.33	3.98e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7091068	0.518	rs9633674	chr10:95455431	C/T	cg20715218	chr10:95462985	C10orf4	0.48	6.35	0.33	6.88e-10	Urinary tract infection frequency;
LUSC	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg19468946	chr17:37922297	IKZF3	-0.38	-6.18	-0.32	1.86e-9	Self-reported allergy;
LUSC	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.61	0.65	1.27e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1775715	0.870	rs11008696	chr10:32218614	G/A	cg04359828	chr10:32216031	ARHGAP12	0.39	6.65	0.34	1.23e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03934478	chr11:495069	RNH1	0.87	9.53	0.46	3.33e-19	Body mass index;
LUSC	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg04450456	chr4:17643702	FAM184B	0.37	6.22	0.32	1.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.71	12.72	0.57	1.63e-30	Diastolic blood pressure;
LUSC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg12560992	chr17:57184187	TRIM37	0.85	15.29	0.64	2.33e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg07636037	chr3:49044803	WDR6	0.45	6.46	0.33	3.81e-10	Resting heart rate;
LUSC	cis	rs185694	0.779	rs609919	chr13:30895904	C/G	cg07600127	chr13:30881527	KATNAL1	-0.5	-5.86	-0.31	1.1e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
LUSC	trans	rs208520	0.874	rs208456	chr6:66907942	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-12.9	-0.58	3.55e-31	Exhaled nitric oxide output;
LUSC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg09092052	chr15:45571596	NA	0.45	6.43	0.33	4.35e-10	Glomerular filtration rate;
LUSC	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.11	15.37	0.64	1.1e-40	Uric acid levels;
LUSC	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23158103	chr7:148848205	ZNF398	-0.44	-7.13	-0.36	6.27e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs3126085	0.935	rs6675889	chr1:152213066	G/A	cg26876637	chr1:152193138	HRNR	0.45	6.29	0.33	9.81e-10	Atopic dermatitis;
LUSC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg05623727	chr3:50126028	RBM5	-0.35	-6.66	-0.34	1.11e-10	Body mass index;
LUSC	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg04310649	chr10:35416472	CREM	-0.41	-6.31	-0.33	8.91e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg00034003	chr16:88779146	CTU2	0.55	7.72	0.39	1.39e-13	Autism spectrum disorder-related traits;
LUSC	cis	rs16976116	0.901	rs9920220	chr15:55503982	T/C	cg11288833	chr15:55489084	RSL24D1	0.5	5.95	0.31	6.81e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-0.81	-15.8	-0.65	2.26e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg02018176	chr4:1364513	KIAA1530	0.48	8.47	0.42	8.06e-16	Obesity-related traits;
LUSC	cis	rs9816226	0.645	rs16860471	chr3:185847441	G/T	cg00760338	chr3:185826511	ETV5	-0.56	-7.09	-0.36	7.99e-12	Obesity;Body mass index;
LUSC	cis	rs10986311	0.832	rs10818952	chr9:127137803	T/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.4	-6.36	-0.33	6.48e-10	Vitiligo;
LUSC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg16506815	chr2:162101123	NA	0.42	6.28	0.32	1.07e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg08213375	chr14:104286397	PPP1R13B	0.53	10.4	0.49	4.03e-22	Schizophrenia;
LUSC	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg06713675	chr4:122721982	EXOSC9	-0.64	-11.34	-0.53	2.02e-25	Type 2 diabetes;
LUSC	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg22907277	chr7:1156413	C7orf50	0.47	7.6	0.38	2.92e-13	Longevity;Endometriosis;
LUSC	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg09165964	chr15:75287851	SCAMP5	0.52	7.78	0.39	9.07e-14	Breast cancer;
LUSC	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg13615516	chr5:77269221	NA	0.39	6.67	0.34	1.03e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg01652190	chr22:50026171	C22orf34	-0.3	-6.09	-0.32	3.18e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00020297	chr6:17600383	FAM8A1	-0.42	-6.26	-0.32	1.18e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9311676	0.632	rs12487420	chr3:58399511	A/G	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.11e-10	Systemic lupus erythematosus;
LUSC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg04166393	chr7:2884313	GNA12	0.43	5.66	0.3	3.28e-8	Height;
LUSC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg25258033	chr6:167368657	RNASET2	0.47	7.76	0.39	1.03e-13	Crohn's disease;
LUSC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg26304593	chr6:42947056	PEX6	-0.52	-8.11	-0.41	9.65e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-10.19	-0.49	2.13e-21	Hemoglobin concentration;
LUSC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-11.9	-0.55	1.77e-27	Extrinsic epigenetic age acceleration;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04368796	chr17:40171968	NKIRAS2	0.66	6.15	0.32	2.18e-9	Cognitive performance;
LUSC	trans	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg07393940	chr7:158741817	NA	-0.38	-6.83	-0.35	4.05e-11	Life satisfaction;
LUSC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	20.91	0.75	1.13e-62	Prudent dietary pattern;
LUSC	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg24006582	chr15:45444508	DUOX1	0.67	9.7	0.47	9.32e-20	Uric acid levels;
LUSC	cis	rs2282032	0.527	rs41309248	chr14:90767386	C/T	cg04374321	chr14:90722782	PSMC1	0.44	6.09	0.32	3.08e-9	Longevity;
LUSC	cis	rs11039100	0.850	rs12792672	chr11:5833938	C/T	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9303542	0.625	rs4793889	chr17:46592352	A/G	cg09704116	chr17:46666958	LOC404266	0.32	6.02	0.31	4.5e-9	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg23289794	chr7:2394357	EIF3B	-0.74	-9.73	-0.47	7.49e-20	Multiple sclerosis;
LUSC	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg13263323	chr15:86062960	AKAP13	-0.36	-5.99	-0.31	5.34e-9	Interstitial lung disease;
LUSC	cis	rs68170813	0.559	rs12538090	chr7:106974647	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.64	-0.47	1.47e-19	Coronary artery disease;
LUSC	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg13575925	chr12:9217583	LOC144571	0.35	6.66	0.34	1.12e-10	Sjögren's syndrome;
LUSC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.59	0.34	1.72e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg12826209	chr6:26865740	GUSBL1	0.68	7.53	0.38	4.76e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg18230493	chr5:56204884	C5orf35	-0.57	-8.99	-0.44	1.83e-17	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.33	0.49	6.76e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs28647808	0.618	rs7025970	chr9:136267173	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs6942756	0.955	rs2056694	chr7:128923817	C/T	cg02491457	chr7:128862824	NA	-0.49	-6.72	-0.35	7.96e-11	White matter hyperintensity burden;
LUSC	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.99	-0.44	1.89e-17	Response to antipsychotic treatment;
LUSC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs10214930	0.560	rs42089	chr7:27702940	C/T	cg22168087	chr7:27702803	HIBADH	-0.51	-7.1	-0.36	7.35e-12	Hypospadias;
LUSC	cis	rs7246967	0.673	rs1433085	chr19:22811099	T/A	cg23217946	chr19:22817039	ZNF492	0.45	6.33	0.33	7.68e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg24634471	chr8:143751801	JRK	0.51	7.21	0.37	3.71e-12	Schizophrenia;
LUSC	cis	rs8092503	1.000	rs12956220	chr18:52481750	A/T	cg12377874	chr18:52495404	RAB27B	0.32	5.65	0.3	3.4e-8	Childhood body mass index;
LUSC	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.62	-9.43	-0.46	7.08e-19	Response to antineoplastic agents;
LUSC	cis	rs17828380	1.000	rs35884071	chr15:63477314	C/A	cg05507819	chr15:63340323	TPM1	-0.75	-6.2	-0.32	1.7e-9	Social communication problems;
LUSC	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.0	0.31	5.02e-9	Corneal astigmatism;
LUSC	cis	rs6554196	0.525	rs2192159	chr4:55505529	C/G	cg18836493	chr4:55524333	KIT	-0.47	-7.85	-0.39	5.85e-14	Monocyte count;
LUSC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg13685833	chr1:53393034	SCP2	0.39	5.88	0.31	9.87e-9	Monocyte count;
LUSC	cis	rs9309473	0.950	rs17009149	chr2:73790368	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-6.52	-0.34	2.66e-10	Metabolite levels;
LUSC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.26	-0.32	1.2e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.44	6.21	0.32	1.61e-9	Multiple sclerosis;
LUSC	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg02574844	chr11:5959923	NA	-0.41	-5.8	-0.3	1.55e-8	DNA methylation (variation);
LUSC	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg07423050	chr13:99094983	FARP1	-0.55	-10.73	-0.51	2.77e-23	Longevity;
LUSC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg14552801	chr7:65878734	NA	-0.37	-5.68	-0.3	2.96e-8	Aortic root size;
LUSC	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg09904177	chr6:26538194	HMGN4	-0.54	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg13206674	chr6:150067644	NUP43	0.63	10.32	0.49	7.59e-22	Lung cancer;
LUSC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.52	-0.34	2.53e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg06453172	chr10:134556979	INPP5A	-0.44	-5.67	-0.3	3.01e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs9399401	0.667	rs11155242	chr6:142691549	A/C	cg03128060	chr6:142623767	GPR126	0.62	10.11	0.48	3.99e-21	Chronic obstructive pulmonary disease;
LUSC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.69	-0.67	6.52e-46	Coronary artery disease;
LUSC	cis	rs1385374	0.858	rs3765107	chr12:129278310	A/G	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.62	-0.34	1.42e-10	Systemic lupus erythematosus;
LUSC	cis	rs80130819	0.688	rs2468945	chr12:48652414	G/A	cg24011408	chr12:48396354	COL2A1	0.46	5.84	0.3	1.22e-8	Prostate cancer;
LUSC	cis	rs4900538	0.821	rs12586673	chr14:102827643	C/T	cg18135206	chr14:102964638	TECPR2	-0.99	-17.51	-0.69	3.63e-49	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs9886428	0.967	rs4831289	chr8:14122196	A/C	cg11959399	chr20:741723	C20orf54	-0.39	-6.04	-0.31	4.13e-9	IgG glycosylation;
LUSC	cis	rs11997175	0.511	rs4613957	chr8:33673130	C/T	ch.8.33884649F	chr8:33765107	NA	-0.43	-6.32	-0.33	8.42e-10	Body mass index;
LUSC	cis	rs2835872	0.758	rs1787401	chr21:39038893	C/T	cg20424643	chr21:39039972	KCNJ6	-0.47	-7.66	-0.39	2.02e-13	Electroencephalographic traits in alcoholism;
LUSC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg16339924	chr4:17578868	LAP3	0.63	9.88	0.48	2.3e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs55883249	1.000	rs56372340	chr2:9741536	A/G	cg23886495	chr2:9695866	ADAM17	0.5	5.85	0.3	1.15e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	8.68	0.43	1.75e-16	Coffee consumption (cups per day);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg08448040	chr3:13521693	HDAC11	0.49	6.43	0.33	4.31e-10	Cognitive function;Information processing speed;
LUSC	cis	rs2324229	0.790	rs1180235	chr6:83945614	A/G	cg08257003	chr6:84140564	ME1	0.27	6.35	0.33	7.05e-10	Platelet-derived growth factor BB levels;
LUSC	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg01858014	chr14:56050164	KTN1	0.89	7.34	0.37	1.61e-12	Putamen volume;
LUSC	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg10818794	chr15:86012489	AKAP13	-0.42	-6.55	-0.34	2.23e-10	Coronary artery disease;
LUSC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.07	-17.76	-0.7	3.74e-50	Primary sclerosing cholangitis;
LUSC	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-7.15	-0.36	5.48e-12	Homocysteine levels;
LUSC	cis	rs4919687	0.550	rs12784517	chr10:104464970	T/C	cg04362960	chr10:104952993	NT5C2	0.47	6.86	0.35	3.35e-11	Colorectal cancer;
LUSC	cis	rs4285028	0.699	rs7637495	chr3:121573850	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.79	-10.61	-0.5	7.31e-23	Multiple sclerosis;
LUSC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg06784218	chr1:46089804	CCDC17	-0.55	-11.21	-0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg22166914	chr1:53195759	ZYG11B	0.66	11.18	0.52	7.01e-25	Monocyte count;
LUSC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg07395648	chr5:131743802	NA	0.37	5.8	0.3	1.52e-8	Asthma (sex interaction);
LUSC	trans	rs61931739	0.649	rs1093031	chr12:33722730	C/T	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	trans	rs11039798	1.000	rs7942284	chr11:48520424	A/G	cg15704280	chr7:45808275	SEPT13	-0.67	-6.5	-0.34	2.85e-10	Axial length;
LUSC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.76	-9.13	-0.45	6.87e-18	Refractive error;
LUSC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.55	8.62	0.43	2.75e-16	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg15744005	chr10:104629667	AS3MT	-0.32	-5.94	-0.31	7.23e-9	Arsenic metabolism;
LUSC	cis	rs76793172	0.920	rs77799462	chr19:46342500	G/A	cg27118825	chr19:46318748	RSPH6A;SYMPK	0.46	5.83	0.3	1.32e-8	Eosinophil counts;
LUSC	cis	rs9807841	0.617	rs892087	chr19:10794793	C/T	cg09936142	chr19:10668400	KRI1	-0.42	-6.73	-0.35	7.43e-11	Inflammatory skin disease;
LUSC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	15.41	0.64	7.74e-41	Total body bone mineral density;
LUSC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg00012203	chr2:219082015	ARPC2	0.7	11.53	0.53	4.08e-26	Colorectal cancer;
LUSC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg01125463	chr6:42946178	PEX6	-0.36	-5.8	-0.3	1.55e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4629710	0.592	rs9492877	chr6:131562577	C/G	cg12700074	chr6:131571435	AKAP7	-0.35	-5.9	-0.31	8.89e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg08085267	chr17:45401833	C17orf57	-0.56	-8.48	-0.42	7.23e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg27266060	chr8:22091797	NA	0.4	7.38	0.37	1.23e-12	Hypertriglyceridemia;
LUSC	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg05340658	chr4:99064831	C4orf37	0.69	11.84	0.54	2.99e-27	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg09955084	chr16:413813	NA	0.27	5.77	0.3	1.83e-8	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs1808579	0.935	rs58609749	chr18:21108613	T/C	cg14672496	chr18:21087552	C18orf8	0.36	6.17	0.32	1.93e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs7147624	0.683	rs8017258	chr14:66231017	C/G	cg03016385	chr14:66212404	NA	0.61	6.46	0.33	3.65e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg06462663	chr19:18546047	ISYNA1	0.49	8.2	0.41	5.22e-15	Breast cancer;
LUSC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12667521	chr19:29218732	NA	0.63	9.44	0.46	6.38e-19	Methadone dose in opioid dependence;
LUSC	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs10992471	0.603	rs10761155	chr9:95153729	C/G	cg14631576	chr9:95140430	CENPP	-0.37	-6.57	-0.34	1.99e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg22437258	chr11:111473054	SIK2	0.52	7.05	0.36	1.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg03522245	chr20:25566470	NINL	-0.36	-5.76	-0.3	1.9e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg05855489	chr10:104503620	C10orf26	0.49	7.36	0.37	1.42e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1385374	0.858	rs10847698	chr12:129300222	T/C	cg09035930	chr12:129282057	SLC15A4	-0.61	-6.58	-0.34	1.82e-10	Systemic lupus erythematosus;
LUSC	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.88	14.49	0.62	2.95e-37	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.45	8.75	0.43	1.09e-16	Axial length;
LUSC	trans	rs4596713	0.508	rs7467352	chr9:71766081	G/A	cg25283916	chr1:242222868	NA	-0.31	-6.44	-0.33	4.09e-10	Headache;
LUSC	cis	rs6987853	0.933	rs2974352	chr8:42408483	C/T	cg09913449	chr8:42400586	C8orf40	0.49	8.12	0.41	9.3e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg22117172	chr7:91764530	CYP51A1	0.33	5.81	0.3	1.49e-8	Breast cancer;
LUSC	cis	rs6906287	0.647	rs3752581	chr6:118869730	G/A	cg21191810	chr6:118973309	C6orf204	0.33	6.04	0.31	4.16e-9	Electrocardiographic conduction measures;
LUSC	cis	rs10170310	1.000	rs10170310	chr2:139278922	C/T	cg03782584	chr2:139258740	SPOPL	0.31	5.91	0.31	8.34e-9	Response to antipsychotic treatment;
LUSC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg10664184	chr19:17420304	DDA1	0.47	6.19	0.32	1.75e-9	Systemic lupus erythematosus;
LUSC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	0.8	14.09	0.61	1.04e-35	Cognitive function;
LUSC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11030122	0.673	rs4910869	chr11:4006438	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.3	2.19e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs3770081	1.000	rs77621359	chr2:86330353	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.92	-0.35	2.37e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg07703079	chr11:430292	ANO9	0.63	6.64	0.34	1.3e-10	Body mass index;
LUSC	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg05373962	chr22:49881684	NA	-0.44	-10.74	-0.51	2.5e-23	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs151234	0.741	rs11647881	chr16:28606173	C/A	cg01378222	chr16:28622494	SULT1A1	-0.64	-8.14	-0.41	8.09e-15	Platelet distribution width;
LUSC	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.76	-12.82	-0.57	7.37e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1639906	0.965	rs1639908	chr7:2230644	C/G	cg18044113	chr7:2236405	MAD1L1	0.3	5.68	0.3	2.89e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg21724239	chr8:58056113	NA	0.68	8.81	0.43	6.96e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg09307838	chr4:120376055	NA	-0.75	-11.17	-0.52	8.19e-25	Corneal astigmatism;
LUSC	cis	rs9296092	0.538	rs62405942	chr6:33517346	G/A	cg13560919	chr6:33536144	NA	-0.81	-15.57	-0.65	1.72e-41	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.73	-6.86	-0.35	3.3e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs16854884	0.584	rs2164554	chr3:143755528	A/G	cg06585982	chr3:143692056	C3orf58	0.46	7.06	0.36	9.42e-12	Economic and political preferences (feminism/equality);
LUSC	cis	rs9905704	0.681	rs7225128	chr17:56636854	T/C	cg12560992	chr17:57184187	TRIM37	-0.51	-5.9	-0.31	8.83e-9	Testicular germ cell tumor;
LUSC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.16	-0.32	2.13e-9	Life satisfaction;
LUSC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg25237894	chr2:233734115	C2orf82	0.35	6.42	0.33	4.67e-10	Coronary artery disease;
LUSC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.5	-8.08	-0.4	1.21e-14	Platelet count;
LUSC	cis	rs2692947	0.794	rs2692893	chr2:96756547	C/T	cg23100626	chr2:96804247	ASTL	0.31	7.52	0.38	5.05e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.62	-0.54	1.97e-26	Migraine;Coronary artery disease;
LUSC	cis	rs9473147	0.503	rs2171086	chr6:47590104	C/T	cg20196966	chr6:47445060	CD2AP	0.44	6.13	0.32	2.46e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg22532475	chr10:104410764	TRIM8	0.32	7.12	0.36	6.45e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg07169764	chr2:136633963	MCM6	1.18	17.48	0.69	4.99e-49	Corneal structure;
LUSC	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.01	0.44	1.63e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs500891	0.525	rs1591396	chr6:84107897	T/C	cg08257003	chr6:84140564	ME1	0.34	8.29	0.41	2.85e-15	Platelet-derived growth factor BB levels;
LUSC	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22442454	chr1:209979470	IRF6	0.42	5.77	0.3	1.77e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg05754148	chr16:3507555	NAT15	0.58	8.53	0.42	5.18e-16	Tuberculosis;
LUSC	cis	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05901451	chr6:126070800	HEY2	0.59	8.99	0.44	1.86e-17	Endometrial cancer;
LUSC	cis	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg26958806	chr6:27640298	NA	0.67	5.88	0.31	1.01e-8	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg09655341	chr17:79618100	PDE6G	-0.3	-6.86	-0.35	3.27e-11	Eye color traits;
LUSC	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg16797656	chr11:68205561	LRP5	0.47	8.45	0.42	8.91e-16	Total body bone mineral density;
LUSC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg14552801	chr7:65878734	NA	-0.37	-5.82	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg25838465	chr1:92012736	NA	-0.75	-15.6	-0.65	1.34e-41	Breast cancer;
LUSC	cis	rs4474465	1.000	rs2373199	chr11:78142982	G/A	cg27205649	chr11:78285834	NARS2	-0.53	-6.18	-0.32	1.84e-9	Alzheimer's disease (survival time);
LUSC	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-1.14	-18.02	-0.7	3.5e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs3784262	0.512	rs4646572	chr15:58343021	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.37	-6.74	-0.35	6.81e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.61	-0.38	2.74e-13	Neuroticism;
LUSC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg18225595	chr11:63971243	STIP1	0.49	6.1	0.32	2.88e-9	Mean platelet volume;
LUSC	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg24631222	chr15:78858424	CHRNA5	0.83	11.44	0.53	8.32e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg20587970	chr11:113659929	NA	-0.98	-13.44	-0.59	3.25e-33	Hip circumference adjusted for BMI;
LUSC	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg26395211	chr5:140044315	WDR55	-0.37	-5.78	-0.3	1.74e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg05347473	chr6:146136440	FBXO30	-0.49	-8.27	-0.41	3.27e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.74	-0.6	2.4e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg22907277	chr7:1156413	C7orf50	0.71	7.45	0.38	8.27e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-8.59	-0.43	3.4e-16	Systemic lupus erythematosus;
LUSC	cis	rs1507153	0.775	rs9361413	chr6:79345249	A/G	cg05283184	chr6:79620031	NA	-0.43	-7.45	-0.38	7.95e-13	Sjögren's syndrome;
LUSC	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	0.69	11.04	0.52	2.33e-24	Blood metabolite ratios;
LUSC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg12463550	chr7:65579703	CRCP	-0.45	-6.65	-0.34	1.17e-10	Aortic root size;
LUSC	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg23796481	chr11:64053134	BAD;GPR137	0.61	9.92	0.48	1.68e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.57	-7.73	-0.39	1.28e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg20203395	chr5:56204925	C5orf35	0.58	8.59	0.43	3.43e-16	Initial pursuit acceleration;
LUSC	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg01528321	chr10:82214614	TSPAN14	0.95	14.47	0.62	3.61e-37	Post bronchodilator FEV1;
LUSC	cis	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05901451	chr6:126070800	HEY2	-0.58	-8.7	-0.43	1.5e-16	Endometrial cancer;
LUSC	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg25801113	chr15:45476975	SHF	0.35	7.32	0.37	1.82e-12	Uric acid levels;
LUSC	cis	rs9398803	0.865	rs2050644	chr6:126805255	A/G	cg19875578	chr6:126661172	C6orf173	0.42	6.18	0.32	1.88e-9	Male-pattern baldness;
LUSC	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg24006582	chr15:45444508	DUOX1	0.7	10.01	0.48	8.51e-21	Uric acid levels;
LUSC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21984481	chr17:79567631	NPLOC4	-0.68	-14.27	-0.62	2.02e-36	Eye color traits;
LUSC	cis	rs2637266	0.783	rs720249	chr10:78476143	T/C	cg18941641	chr10:78392320	NA	0.34	6.21	0.32	1.61e-9	Pulmonary function;
LUSC	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg05738196	chr6:26577821	NA	0.81	15.7	0.65	5.52e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg22563815	chr15:78856949	CHRNA5	-0.27	-6.4	-0.33	5.4e-10	Sudden cardiac arrest;
LUSC	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg03585969	chr10:35415529	CREM	0.64	9.5	0.46	4.23e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	1.03	12.16	0.55	2.04e-28	Schizophrenia;
LUSC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg13531842	chr10:38383804	ZNF37A	-0.45	-7.02	-0.36	1.21e-11	Extrinsic epigenetic age acceleration;
LUSC	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21659725	chr3:3221576	CRBN	0.63	10.57	0.5	1.04e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg12884169	chr21:40033163	ERG	0.59	12.03	0.55	6.13e-28	Coronary artery disease;
LUSC	cis	rs4804416	1.000	rs4804416	chr19:7223848	G/T	cg09779027	chr19:7224513	INSR	-0.3	-6.02	-0.31	4.72e-9	Thyroid hormone levels;Hypothyroidism;
LUSC	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg11984989	chr7:158649758	WDR60	-1.07	-13.12	-0.58	5.11e-32	Height;
LUSC	trans	rs800082	0.516	rs1178894	chr3:144239854	A/G	cg24215973	chr2:240111563	HDAC4	0.44	6.81	0.35	4.59e-11	Smoking behavior;
LUSC	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg24558204	chr6:135376177	HBS1L	0.67	10.36	0.49	5.35e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg24375607	chr4:120327624	NA	0.76	11.19	0.52	6.99e-25	Corneal astigmatism;
LUSC	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg24675056	chr1:15929824	NA	0.53	9.47	0.46	5.12e-19	Systolic blood pressure;
LUSC	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg01346077	chr3:125931526	NA	-0.35	-6.81	-0.35	4.46e-11	Metabolite levels;
LUSC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg12963246	chr6:28129442	ZNF389	0.56	7.89	0.4	4.28e-14	Parkinson's disease;
LUSC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg22166914	chr1:53195759	ZYG11B	-0.48	-7.74	-0.39	1.18e-13	Monocyte count;
LUSC	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.77	0.3	1.77e-8	Breast cancer;
LUSC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg06238570	chr21:40685208	BRWD1	-0.63	-10.67	-0.5	4.51e-23	Cognitive function;
LUSC	cis	rs6066835	1.000	rs6095247	chr20:47320835	T/C	cg18078177	chr20:47281410	PREX1	0.71	5.96	0.31	6.29e-9	Multiple myeloma;
LUSC	cis	rs2463822	0.669	rs72919496	chr11:62052730	T/C	cg06239285	chr11:62104954	ASRGL1	-0.72	-6.87	-0.35	3.15e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg02503808	chr4:7069936	GRPEL1	-0.98	-12.93	-0.58	2.76e-31	Monocyte percentage of white cells;
LUSC	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg03585969	chr10:35415529	CREM	0.61	8.85	0.44	5.37e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs1347297	0.526	rs10201175	chr2:179265348	C/T	cg14011486	chr1:26737247	LIN28	0.44	6.93	0.35	2.22e-11	Alzheimer disease and age of onset;
LUSC	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	cis	rs6500395	0.962	rs3743780	chr16:48647480	A/G	cg04672837	chr16:48644449	N4BP1	0.47	6.91	0.35	2.43e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg13319975	chr6:146136371	FBXO30	-0.4	-5.98	-0.31	5.63e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs977987	0.806	rs1364077	chr16:75396991	C/T	cg04384234	chr16:75411784	CFDP1	-0.42	-6.91	-0.35	2.52e-11	Dupuytren's disease;
LUSC	cis	rs7000551	0.527	rs11783730	chr8:22244897	C/T	cg12081754	chr8:22256438	SLC39A14	0.97	15.19	0.64	5.68e-40	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg08601574	chr20:25228251	PYGB	0.47	7.32	0.37	1.83e-12	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	0.86	15.24	0.64	3.37e-40	Prostate cancer;
LUSC	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg23298862	chr7:158159286	PTPRN2	0.32	5.66	0.3	3.27e-8	Response to amphetamines;
LUSC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg23590916	chr17:43697445	MGC57346	0.5	6.7	0.34	9.07e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs3106136	0.967	rs13135934	chr4:95207688	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.17	-0.32	1.99e-9	Capecitabine sensitivity;
LUSC	cis	rs2354432	0.556	rs11239964	chr1:146753902	G/C	cg25205988	chr1:146714368	CHD1L	-1.04	-9.38	-0.46	1.05e-18	Mitochondrial DNA levels;
LUSC	cis	rs6545883	0.859	rs2694644	chr2:61604856	A/T	cg15711740	chr2:61764176	XPO1	0.41	6.3	0.33	9.61e-10	Tuberculosis;
LUSC	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.64	0.39	2.25e-13	Iron status biomarkers;
LUSC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg07741184	chr6:167504864	NA	0.39	6.95	0.36	1.96e-11	Primary biliary cholangitis;
LUSC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.91e-9	Major depressive disorder;
LUSC	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg17385448	chr1:15911702	AGMAT	0.36	6.16	0.32	2.06e-9	Systolic blood pressure;
LUSC	trans	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg21659725	chr3:3221576	CRBN	-0.68	-8.22	-0.41	4.6e-15	Menarche (age at onset);
LUSC	cis	rs6693567	0.545	rs1694386	chr1:150377965	C/G	cg15654264	chr1:150340011	RPRD2	0.45	7.19	0.37	4.26e-12	Migraine;
LUSC	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.62	9.9	0.48	1.99e-20	Blood metabolite ratios;
LUSC	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg01420254	chr6:26195488	NA	0.65	7.28	0.37	2.44e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	10.21	0.49	1.74e-21	Bone mineral density;
LUSC	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg00012203	chr2:219082015	ARPC2	-0.57	-9.06	-0.44	1.11e-17	Ulcerative colitis;
LUSC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	6.31	0.33	8.86e-10	Electroencephalogram traits;
LUSC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg21280719	chr6:42927975	GNMT	-0.32	-7.81	-0.39	7.38e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg20503657	chr10:835505	NA	0.52	6.32	0.33	8.27e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs4974559	0.947	rs28678404	chr4:1374919	G/A	cg02980000	chr4:1222292	CTBP1	0.73	6.5	0.34	2.95e-10	Systolic blood pressure;
LUSC	cis	rs11077998	0.840	rs9894993	chr17:80481088	T/C	cg10255544	chr17:80519551	FOXK2	0.41	6.64	0.34	1.28e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg05775895	chr3:12838266	CAND2	0.52	9.06	0.44	1.08e-17	QRS complex (12-leadsum);
LUSC	cis	rs3770081	1.000	rs75109362	chr2:86289889	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.05	-6.84	-0.35	3.84e-11	Facial emotion recognition (sad faces);
LUSC	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg13755796	chr4:20253514	NA	-0.45	-6.99	-0.36	1.53e-11	Life satisfaction;
LUSC	cis	rs1044826	0.597	rs6803593	chr3:139193987	T/C	cg15131784	chr3:139108705	COPB2	0.4	6.38	0.33	5.77e-10	Obesity-related traits;
LUSC	cis	rs10886558	0.502	rs10788026	chr10:121827450	C/T	cg02041677	chr10:121771263	NA	-0.32	-5.9	-0.31	8.79e-9	Shingles;
LUSC	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg26876637	chr1:152193138	HRNR	-0.46	-6.78	-0.35	5.58e-11	Atopic dermatitis;
LUSC	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg23093090	chr10:104574429	C10orf26	-0.35	-6.41	-0.33	4.97e-10	Arsenic metabolism;
LUSC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25072359	chr17:41440525	NA	0.69	9.65	0.47	1.36e-19	Menopause (age at onset);
LUSC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg13560548	chr3:10150139	C3orf24	0.49	6.59	0.34	1.76e-10	Alzheimer's disease;
LUSC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg17376030	chr22:41985996	PMM1	-0.47	-5.81	-0.3	1.49e-8	Vitiligo;
LUSC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	5.72	0.3	2.42e-8	Breast cancer;
LUSC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00631329	chr6:26305371	NA	-0.49	-9.52	-0.46	3.63e-19	Educational attainment;
LUSC	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg11871910	chr12:69753446	YEATS4	0.48	6.48	0.33	3.35e-10	Response to diuretic therapy;
LUSC	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg00800038	chr16:89945340	TCF25	-0.75	-6.64	-0.34	1.26e-10	Skin colour saturation;
LUSC	cis	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg21775007	chr8:11205619	TDH	-0.5	-6.79	-0.35	5.17e-11	Morning vs. evening chronotype;
LUSC	cis	rs57590327	0.503	rs1524557	chr3:81892031	A/G	cg07356753	chr3:81810745	GBE1	-0.61	-9.62	-0.47	1.73e-19	Extraversion;
LUSC	cis	rs3916	0.911	rs34673751	chr12:121171891	G/A	cg02419362	chr12:121203948	SPPL3	0.36	5.67	0.3	3.05e-8	Urinary metabolites (H-NMR features);
LUSC	cis	rs3741151	1.000	rs79794992	chr11:73049352	A/G	cg17517138	chr11:73019481	ARHGEF17	1.12	9.16	0.45	5.39e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg15934090	chr1:100435551	SLC35A3	0.47	7.72	0.39	1.4e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg20203395	chr5:56204925	C5orf35	-0.57	-8.55	-0.42	4.43e-16	Initial pursuit acceleration;
LUSC	cis	rs11958404	0.932	rs6870115	chr5:157436960	T/C	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.78	11.23	0.52	4.76e-25	Corneal astigmatism;
LUSC	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-7.51	-0.38	5.56e-13	Retinal vascular caliber;
LUSC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg23622369	chr17:40706682	HSD17B1	-0.38	-6.21	-0.32	1.58e-9	Colorectal or endometrial cancer;
LUSC	cis	rs34421088	0.506	rs2117616	chr8:11145911	A/G	cg21775007	chr8:11205619	TDH	-0.45	-5.75	-0.3	1.98e-8	Neuroticism;
LUSC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg13114125	chr14:105738426	BRF1	-0.94	-16.25	-0.66	3.63e-44	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs13315871	1.000	rs9864325	chr3:58336846	A/C	cg12435725	chr3:58293450	RPP14	-0.7	-7.64	-0.39	2.28e-13	Cholesterol, total;
LUSC	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg08085267	chr17:45401833	C17orf57	0.55	8.89	0.44	3.85e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.92	-0.35	2.39e-11	Response to antipsychotic treatment;
LUSC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	9.57	0.46	2.52e-19	Menopause (age at onset);
LUSC	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.58	-9.14	-0.45	6.35e-18	Total body bone mineral density;
LUSC	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg13010199	chr12:38710504	ALG10B	0.68	10.74	0.51	2.68e-23	Morning vs. evening chronotype;
LUSC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.77	-0.43	9.4e-17	Bipolar disorder;
LUSC	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.87	-12.8	-0.57	8.73e-31	Asthma;
LUSC	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.56	-8.07	-0.4	1.32e-14	Other erythrocyte phenotypes;
LUSC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08736216	chr1:53307985	ZYG11A	0.3	6.19	0.32	1.78e-9	Monocyte count;
LUSC	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg11266682	chr4:10021025	SLC2A9	0.43	7.33	0.37	1.7e-12	Bone mineral density;
LUSC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg08132940	chr7:1081526	C7orf50	-0.52	-6.22	-0.32	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12681287	0.752	rs4427148	chr8:87250668	G/A	cg27223183	chr8:87520930	FAM82B	-0.45	-5.75	-0.3	2.03e-8	Caudate activity during reward;
LUSC	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-9.31	-0.45	1.74e-18	Chronic sinus infection;
LUSC	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-0.98	-21.65	-0.76	1.43e-65	Ulcerative colitis;
LUSC	cis	rs72960926	0.744	rs56405366	chr6:75035257	T/C	cg03266952	chr6:74778945	NA	-0.84	-7.05	-0.36	1.01e-11	Metabolite levels (MHPG);
LUSC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs890100	0.736	rs2033015	chr2:56702871	A/T	cg01657744	chr10:88471748	LDB3	-0.44	-6.19	-0.32	1.79e-9	Gut microbiome composition (summer);
LUSC	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.78	-0.7	2.97e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg06606381	chr12:133084897	FBRSL1	0.64	6.83	0.35	4.06e-11	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg21076271	chr14:32546633	ARHGAP5;C14orf128	0.42	6.81	0.35	4.67e-11	Triglycerides;
LUSC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.31	-0.45	1.71e-18	Platelet count;
LUSC	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.61	-0.6	7.24e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg09021430	chr5:549028	NA	-0.57	-7.7	-0.39	1.61e-13	Obesity-related traits;
LUSC	trans	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-12.86	-0.58	4.86e-31	Brugada syndrome;
LUSC	cis	rs2235642	0.525	rs8048290	chr16:1562026	T/C	cg26528668	chr16:1614120	IFT140	0.41	6.03	0.31	4.43e-9	Coronary artery disease;
LUSC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg09323728	chr8:95962352	TP53INP1	-0.43	-8.74	-0.43	1.15e-16	Type 2 diabetes;
LUSC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11764359	chr7:65958608	NA	-0.6	-8.86	-0.44	4.92e-17	Aortic root size;
LUSC	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg14019695	chr9:139328340	INPP5E	0.44	8.2	0.41	5.3e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg09034736	chr1:150693464	HORMAD1	0.45	6.48	0.33	3.36e-10	Melanoma;
LUSC	trans	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg19694781	chr19:47549865	TMEM160	-0.42	-6.65	-0.34	1.19e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg01448562	chr3:133502909	NA	-0.53	-7.84	-0.39	6.2e-14	Iron status biomarkers;
LUSC	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg00277334	chr10:82204260	NA	-0.51	-7.41	-0.38	1.05e-12	Post bronchodilator FEV1;
LUSC	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-0.89	-12.79	-0.57	9.46e-31	Blood pressure (smoking interaction);
LUSC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg05313129	chr8:58192883	C8orf71	-0.51	-6.64	-0.34	1.26e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg15744005	chr10:104629667	AS3MT	-0.28	-6.11	-0.32	2.76e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg04362960	chr10:104952993	NT5C2	1.1	12.99	0.58	1.63e-31	Arsenic metabolism;
LUSC	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	8.58	0.42	3.75e-16	Lung cancer in ever smokers;
LUSC	trans	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg19694781	chr19:47549865	TMEM160	0.59	9.56	0.46	2.64e-19	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.39	0.49	4.4e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg16558253	chr16:72132732	DHX38	-0.37	-5.76	-0.3	1.9e-8	Fibrinogen levels;
LUSC	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs11676348	0.838	rs17844697	chr2:218999255	G/A	cg06547715	chr2:218990976	CXCR2	0.31	5.85	0.31	1.14e-8	Ulcerative colitis;
LUSC	cis	rs6785206	0.803	rs2712380	chr3:128338661	A/C	cg16766828	chr3:128327626	NA	-0.7	-7.66	-0.39	2.01e-13	Lymphocyte percentage of white cells;
LUSC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg00074818	chr8:8560427	CLDN23	0.57	9.67	0.47	1.14e-19	Obesity-related traits;
LUSC	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	7.29	0.37	2.24e-12	Response to antipsychotic treatment;
LUSC	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	1.41	17.72	0.7	5.44e-50	Atopic dermatitis;
LUSC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	14.68	0.63	5.52e-38	Menopause (age at onset);
LUSC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-0.92	-12.84	-0.57	5.9e-31	Blood trace element (Zn levels);
LUSC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08859206	chr1:53392774	SCP2	-0.5	-8.55	-0.42	4.59e-16	Monocyte count;
LUSC	cis	rs10746514	1.000	rs12129814	chr1:232251730	C/A	cg09506761	chr1:232265262	NA	0.51	8.37	0.42	1.64e-15	Response to statin therapy;
LUSC	cis	rs7215564	0.818	rs4889878	chr17:78662479	G/T	cg23238734	chr17:78661607	RPTOR	0.45	5.81	0.3	1.49e-8	Myopia (pathological);
LUSC	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.51	8.07	0.4	1.3e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.62	-8.36	-0.42	1.68e-15	Lung function (FEV1/FVC);
LUSC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg02428538	chr16:24856791	SLC5A11	-0.51	-6.0	-0.31	5.09e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg03806693	chr22:41940476	POLR3H	-0.9	-12.72	-0.57	1.64e-30	Vitiligo;
LUSC	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg19629631	chr7:2060116	MAD1L1	-0.35	-5.7	-0.3	2.65e-8	Neuroticism;
LUSC	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg03676636	chr4:99064102	C4orf37	0.3	6.48	0.33	3.37e-10	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	0.93	16.11	0.66	1.32e-43	Menopause (age at onset);
LUSC	cis	rs698833	0.521	rs35627501	chr2:44506971	G/C	cg04920474	chr2:44395004	PPM1B	0.55	9.05	0.44	1.23e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs6120849	0.754	rs11167253	chr20:33614449	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	6.74	0.35	6.84e-11	Protein C levels;
LUSC	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg20503657	chr10:835505	NA	-0.51	-7.01	-0.36	1.36e-11	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs8048589	0.660	rs11075054	chr16:12216295	C/A	cg02910054	chr16:12241554	SNX29	0.46	5.97	0.31	6.22e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg20476274	chr7:133979776	SLC35B4	0.82	14.95	0.63	4.64e-39	Mean platelet volume;
LUSC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg04398451	chr17:18023971	MYO15A	-0.57	-9.5	-0.46	4.2e-19	Total body bone mineral density;
LUSC	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg12935359	chr14:103987150	CKB	-0.57	-8.56	-0.42	4.26e-16	Body mass index;
LUSC	trans	rs28647808	0.786	rs4962134	chr9:136256626	G/A	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg14581129	chr12:53358946	NA	-0.56	-7.84	-0.39	6.19e-14	Prostate cancer;
LUSC	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg15848620	chr12:58087721	OS9	-0.57	-8.13	-0.41	8.39e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg11019008	chr10:131425282	MGMT	0.4	5.99	0.31	5.55e-9	Response to temozolomide;
LUSC	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.17e-9	Resting heart rate;
LUSC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg06637938	chr14:75390232	RPS6KL1	0.49	7.43	0.38	9.37e-13	Height;
LUSC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-8.03	-0.4	1.68e-14	Aortic root size;
LUSC	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.92	0.51	6.09e-24	Colorectal cancer;
LUSC	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg03359095	chr20:61002866	C20orf151	-0.29	-5.65	-0.3	3.53e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs427941	0.703	rs201457	chr7:101741338	C/A	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.57	-10.02	-0.48	7.76e-21	Extrinsic epigenetic age acceleration;
LUSC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	trans	rs800082	0.674	rs4681328	chr3:144190767	C/G	cg24215973	chr2:240111563	HDAC4	0.41	5.97	0.31	6.07e-9	Smoking behavior;
LUSC	trans	rs564343	0.563	rs574335	chr11:65833266	C/T	cg26701943	chr11:108369231	KDELC2	0.44	6.05	0.31	3.96e-9	Obesity (early onset extreme);
LUSC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg14092988	chr3:52407081	DNAH1	0.33	6.4	0.33	5.28e-10	Bipolar disorder;
LUSC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg26752003	chr8:145688521	CYHR1	-0.6	-10.08	-0.48	5.03e-21	Age at first birth;
LUSC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-0.86	-14.86	-0.63	1.04e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	trans	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg03886242	chr7:26192032	NFE2L3	-0.42	-6.64	-0.34	1.25e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs236907	0.859	rs17650340	chr1:171757921	A/T	cg13482142	chr2:234261155	NA	0.48	5.95	0.31	6.7e-9	Mean platelet volume;
LUSC	trans	rs1459104	0.866	rs66989058	chr11:54823043	C/A	cg15704280	chr7:45808275	SEPT13	0.72	6.3	0.33	9.53e-10	Body mass index;
LUSC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg16606324	chr3:10149918	C3orf24	0.67	9.78	0.47	4.99e-20	Alzheimer's disease;
LUSC	cis	rs73206853	0.640	rs2098140	chr12:110726081	T/A	cg12870014	chr12:110450643	ANKRD13A	0.68	6.52	0.34	2.63e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg13683864	chr3:40499215	RPL14	0.98	16.68	0.67	7.24e-46	Renal cell carcinoma;
LUSC	cis	rs3849570	0.961	rs11915042	chr3:81834060	G/A	cg07356753	chr3:81810745	GBE1	-0.68	-11.09	-0.52	1.46e-24	Waist circumference;Body mass index;
LUSC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg26408565	chr15:76604113	ETFA	-0.48	-7.55	-0.38	4.07e-13	Blood metabolite levels;
LUSC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg22535103	chr8:58192502	C8orf71	-0.78	-7.98	-0.4	2.41e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg20821713	chr7:1055600	C7orf50	-0.56	-7.29	-0.37	2.2e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-9.26	-0.45	2.58e-18	Gut microbiome composition (summer);
LUSC	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.79	11.22	0.52	5.45e-25	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07545535	chr7:76256818	POMZP3;LOC100133091	-0.43	-6.48	-0.33	3.38e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg24829409	chr8:58192753	C8orf71	-0.46	-5.73	-0.3	2.2e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg01420254	chr6:26195488	NA	0.66	7.31	0.37	2.05e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg04691961	chr3:161091175	C3orf57	-0.36	-6.24	-0.32	1.35e-9	Morning vs. evening chronotype;
LUSC	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.55	0.38	4.06e-13	Iron status biomarkers;
LUSC	cis	rs7189233	0.531	rs13332406	chr16:53489705	G/A	cg09728985	chr16:53543985	NA	-0.31	-5.81	-0.3	1.46e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-14.43	-0.62	5.1e-37	Height;
LUSC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.6	8.02	0.4	1.85e-14	High light scatter reticulocyte count;
LUSC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg09455208	chr3:40491958	NA	0.59	10.38	0.49	4.46e-22	Renal cell carcinoma;
LUSC	cis	rs154659	0.961	rs164739	chr16:89667699	C/G	cg01710450	chr16:89662404	CPNE7	-0.43	-6.58	-0.34	1.79e-10	Tanning;
LUSC	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg00852783	chr1:26633632	UBXN11	0.61	9.67	0.47	1.18e-19	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.67	-10.84	-0.51	1.18e-23	Longevity;Endometriosis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17474435	chr12:50135167	TMBIM6	0.45	6.25	0.32	1.28e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg24154853	chr7:158122151	PTPRN2	-0.42	-8.24	-0.41	4.06e-15	Calcium levels;
LUSC	cis	rs6463523	0.933	rs79984239	chr7:766220	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	1.01	20.88	0.75	1.6e-62	Subjective well-being;
LUSC	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg06636001	chr8:8085503	FLJ10661	0.56	8.27	0.41	3.13e-15	Monocyte count;
LUSC	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-40.05	-0.91	1.39e-129	Myeloid white cell count;
LUSC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg25019033	chr10:957182	NA	-0.53	-7.03	-0.36	1.2e-11	Eosinophil percentage of granulocytes;
LUSC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg08508325	chr11:3079039	CARS	0.49	12.34	0.56	4.56e-29	Longevity;
LUSC	cis	rs11583043	0.708	rs874905	chr1:101539702	G/A	cg11406453	chr1:101602562	NA	-0.38	-6.38	-0.33	5.98e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg14154082	chr13:112174009	NA	0.37	7.7	0.39	1.6e-13	Menarche (age at onset);
LUSC	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg24634471	chr8:143751801	JRK	0.5	7.05	0.36	1.03e-11	Schizophrenia;
LUSC	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg26893861	chr17:41843967	DUSP3	1.1	22.46	0.78	9.56e-69	Triglycerides;
LUSC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg13393036	chr8:95962371	TP53INP1	-0.43	-9.37	-0.46	1.14e-18	Type 2 diabetes;
LUSC	cis	rs34734847	1.000	rs3021338	chr12:121162989	A/G	cg27246729	chr12:121163418	ACADS	0.47	7.5	0.38	5.91e-13	Mean corpuscular volume;
LUSC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg13531842	chr10:38383804	ZNF37A	-0.45	-6.98	-0.36	1.57e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg15556689	chr8:8085844	FLJ10661	-0.67	-10.78	-0.51	1.94e-23	Mood instability;
LUSC	cis	rs738321	0.658	rs5756916	chr22:38507047	G/A	cg25457927	chr22:38595422	NA	-0.34	-6.31	-0.33	8.63e-10	Breast cancer;
LUSC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg20818283	chr2:191399100	TMEM194B	0.44	6.78	0.35	5.56e-11	Pulse pressure;
LUSC	cis	rs1577917	0.916	rs4706252	chr6:86555180	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.69	-0.34	9.59e-11	Response to antipsychotic treatment;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10190329	chr10:126605450	NA	-0.34	-6.03	-0.31	4.37e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs16976116	0.901	rs62020097	chr15:55491007	A/T	cg11288833	chr15:55489084	RSL24D1	0.5	5.98	0.31	5.65e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg27661571	chr11:113659931	NA	-0.73	-7.95	-0.4	2.97e-14	Hip circumference adjusted for BMI;
LUSC	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs12410462	0.581	rs111356515	chr1:227537236	C/G	cg04117972	chr1:227635322	NA	0.62	6.98	0.36	1.55e-11	Major depressive disorder;
LUSC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg08493051	chr2:3487164	NA	-0.53	-8.21	-0.41	4.82e-15	Neurofibrillary tangles;
LUSC	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.8	-0.3	1.51e-8	Type 2 diabetes;
LUSC	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg13010199	chr12:38710504	ALG10B	-0.44	-6.57	-0.34	1.95e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg26924012	chr15:45694286	SPATA5L1	1.14	20.79	0.75	3.36e-62	Homoarginine levels;
LUSC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg23711669	chr6:146136114	FBXO30	0.69	10.41	0.5	3.55e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10740039	0.883	rs7068934	chr10:62396248	C/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.9	-0.35	2.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg18301423	chr5:131593218	PDLIM4	0.35	5.75	0.3	2.06e-8	Blood metabolite levels;
LUSC	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg01557791	chr16:72042693	DHODH	0.46	6.98	0.36	1.55e-11	Fibrinogen levels;
LUSC	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg02023728	chr11:77925099	USP35	0.47	6.76	0.35	6.01e-11	Testicular germ cell tumor;
LUSC	cis	rs7605827	0.866	rs9287665	chr2:15667263	A/T	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.31e-17	Educational attainment (years of education);
LUSC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg05025164	chr4:1340916	KIAA1530	0.53	8.41	0.42	1.17e-15	Longevity;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09260951	chr22:39096513	JOSD1	-0.5	-6.17	-0.32	1.95e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3087591	1.000	rs2057769	chr17:29691368	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.59	-8.31	-0.41	2.4e-15	Hip circumference;
LUSC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg23743428	chr13:21893420	NA	-0.41	-8.55	-0.42	4.59e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg05552183	chr6:42928497	GNMT	0.47	7.81	0.39	7.71e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4851254	0.961	rs11682173	chr2:100759810	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.69	-0.3	2.82e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-17.07	-0.68	2.11e-47	Exhaled nitric oxide output;
LUSC	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg06636001	chr8:8085503	FLJ10661	0.51	7.72	0.39	1.39e-13	Morning vs. evening chronotype;
LUSC	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg00945038	chr17:61921165	SMARCD2	0.39	5.65	0.3	3.42e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg00945038	chr17:61921165	SMARCD2	-0.56	-9.71	-0.47	8.42e-20	Prudent dietary pattern;
LUSC	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	7.98	0.4	2.36e-14	Coronary artery disease;
LUSC	cis	rs500891	0.525	rs1937783	chr6:84097858	G/C	cg08257003	chr6:84140564	ME1	0.35	8.51	0.42	5.77e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	6.25	0.32	1.23e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg03461704	chr1:205818484	PM20D1	-0.37	-6.16	-0.32	2.09e-9	Menarche (age at onset);
LUSC	cis	rs2806561	0.754	rs648322	chr1:23294839	C/T	cg19743168	chr1:23544995	NA	0.4	8.63	0.43	2.51e-16	Height;
LUSC	trans	rs6601327	0.602	rs7820917	chr8:9647868	C/T	cg08975724	chr8:8085496	FLJ10661	0.47	6.79	0.35	5.23e-11	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.66	0.3	3.2e-8	Menopause (age at onset);
LUSC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg01065977	chr19:18549689	ISYNA1	-0.23	-5.95	-0.31	6.72e-9	Breast cancer;
LUSC	cis	rs2798269	0.902	rs11616720	chr13:22115822	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.38	-5.75	-0.3	2.02e-8	PR segment;
LUSC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg18402987	chr7:1209562	NA	0.67	7.08	0.36	8.56e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg13206674	chr6:150067644	NUP43	0.43	6.52	0.34	2.67e-10	Testicular germ cell tumor;
LUSC	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg09904177	chr6:26538194	HMGN4	0.49	7.72	0.39	1.4e-13	Schizophrenia;
LUSC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.85	11.36	0.53	1.72e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7605827	0.930	rs3805102	chr2:15518312	G/A	cg19274914	chr2:15703543	NA	0.47	9.2	0.45	4.07e-18	Educational attainment (years of education);
LUSC	cis	rs701145	0.585	rs6789213	chr3:153792795	T/C	cg17054900	chr3:154042577	DHX36	0.72	7.3	0.37	2.17e-12	Coronary artery disease;
LUSC	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.46	7.89	0.4	4.26e-14	Breast cancer;
LUSC	cis	rs9811920	0.893	rs720688	chr3:99880569	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.33	6.16	0.32	2.05e-9	Axial length;
LUSC	cis	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg06521331	chr12:34319734	NA	-0.43	-6.69	-0.34	9.47e-11	Morning vs. evening chronotype;
LUSC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg00343986	chr7:65444356	GUSB	0.44	6.73	0.35	7.5e-11	Aortic root size;
LUSC	cis	rs9359856	0.872	rs9344948	chr6:90308226	T/G	cg13799429	chr6:90582589	CASP8AP2	0.55	6.41	0.33	5.1e-10	Bipolar disorder;
LUSC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.84	12.34	0.56	4.57e-29	Alzheimer's disease;
LUSC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg21782813	chr7:2030301	MAD1L1	0.58	10.22	0.49	1.6e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg01448562	chr3:133502909	NA	0.64	10.5	0.5	1.8e-22	Iron status biomarkers;
LUSC	cis	rs2153904	0.793	rs12564209	chr1:205720212	C/G	cg23034840	chr1:205782522	SLC41A1	-0.62	-6.51	-0.34	2.72e-10	Prostate-specific antigen levels;
LUSC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg23630131	chr7:65973040	NA	-0.2	-5.64	-0.3	3.55e-8	Aortic root size;
LUSC	cis	rs7809950	0.798	rs2701684	chr7:107299527	C/T	cg23024343	chr7:107201750	COG5	0.39	6.04	0.31	4.17e-9	Coronary artery disease;
LUSC	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg17385448	chr1:15911702	AGMAT	0.34	5.95	0.31	6.92e-9	Systolic blood pressure;
LUSC	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg08085267	chr17:45401833	C17orf57	0.53	8.6	0.43	3.14e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.85	-0.47	2.85e-20	Platelet count;
LUSC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg23630131	chr7:65973040	NA	0.2	5.72	0.3	2.4e-8	Aortic root size;
LUSC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.13	0.45	6.72e-18	Motion sickness;
LUSC	cis	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg06521331	chr12:34319734	NA	0.4	6.5	0.34	2.87e-10	Morning vs. evening chronotype;
LUSC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg13206674	chr6:150067644	NUP43	0.63	10.17	0.49	2.44e-21	Lung cancer;
LUSC	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	7.29	0.37	2.2e-12	Response to antipsychotic treatment;
LUSC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg13770153	chr20:60521292	NA	-0.62	-8.46	-0.42	8.32e-16	Body mass index;
LUSC	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.35e-33	Morning vs. evening chronotype;
LUSC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	9.05	0.44	1.21e-17	Monocyte percentage of white cells;
LUSC	trans	rs2688325	0.520	rs10107710	chr8:3761737	C/T	cg10396673	chr16:31104726	VKORC1	0.33	6.12	0.32	2.69e-9	Menarche (age at onset);
LUSC	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg20016023	chr10:99160130	RRP12	-0.33	-8.07	-0.4	1.26e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7119038	0.818	rs11217040	chr11:118680648	C/A	cg19308663	chr11:118741387	NA	0.33	5.71	0.3	2.54e-8	Sjögren's syndrome;
LUSC	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	0.78	11.48	0.53	6.09e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg17845761	chr1:175162550	KIAA0040	0.31	5.94	0.31	7.14e-9	Diastolic blood pressure;
LUSC	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-8.26	-0.41	3.4e-15	Response to antipsychotic treatment;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.44	6.83	0.35	3.93e-11	Longevity;Endometriosis;
LUSC	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg21890820	chr11:65308645	LTBP3	1.41	9.74	0.47	7e-20	Height;
LUSC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9323205	0.765	rs2999388	chr14:51654157	A/G	cg23942311	chr14:51606299	NA	0.32	6.66	0.34	1.13e-10	Cancer;
LUSC	trans	rs6601327	0.575	rs7001832	chr8:9607235	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.24	-0.32	1.36e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg02423579	chr7:2872169	GNA12	-0.41	-6.17	-0.32	2e-9	Height;
LUSC	cis	rs4654899	1.000	rs7554997	chr1:21400139	C/T	cg01072550	chr1:21505969	NA	-0.54	-8.15	-0.41	7.63e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg23034840	chr1:205782522	SLC41A1	-0.55	-7.79	-0.39	8.57e-14	Menarche (age at onset);
LUSC	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg13010199	chr12:38710504	ALG10B	0.64	9.96	0.48	1.23e-20	Bladder cancer;
LUSC	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-0.59	-9.17	-0.45	4.97e-18	Breast cancer;
LUSC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg06238570	chr21:40685208	BRWD1	-0.62	-10.65	-0.5	5.48e-23	Cognitive function;
LUSC	cis	rs9311676	0.632	rs4228	chr3:58413669	G/T	cg26110898	chr3:58419937	PDHB	0.4	6.48	0.33	3.3e-10	Systemic lupus erythematosus;
LUSC	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22980127	chr19:33182716	NUDT19	0.92	12.61	0.57	4.49e-30	Red blood cell traits;
LUSC	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.57	-6.63	-0.34	1.36e-10	Iron status biomarkers;
LUSC	cis	rs1983170	0.736	rs745731	chr1:92011467	G/T	cg25838465	chr1:92012736	NA	0.46	5.73	0.3	2.2e-8	Eosinophil percentage of white cells;
LUSC	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17467752	chr17:38218738	THRA	0.77	12.44	0.56	1.94e-29	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-17.16	-0.68	8.97e-48	Primary sclerosing cholangitis;
LUSC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg18230493	chr5:56204884	C5orf35	-0.97	-14.44	-0.62	4.51e-37	Initial pursuit acceleration;
LUSC	cis	rs4664304	0.903	rs72957578	chr2:160754133	G/C	cg23995753	chr2:160760732	LY75	-0.31	-5.75	-0.3	2.05e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05901451	chr6:126070800	HEY2	0.57	8.57	0.42	3.94e-16	Endometrial cancer;
LUSC	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg23303369	chr20:44641161	MMP9	0.35	6.11	0.32	2.77e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg16482183	chr6:26056742	HIST1H1C	0.65	9.06	0.44	1.15e-17	Iron status biomarkers;
LUSC	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg02269571	chr22:50332266	NA	0.59	8.73	0.43	1.21e-16	Schizophrenia;
LUSC	cis	rs3818285	0.885	rs10787217	chr10:111621103	A/T	cg00817464	chr10:111662876	XPNPEP1	0.57	7.52	0.38	5.04e-13	Superior crus of antihelix expression;
LUSC	trans	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg03886242	chr7:26192032	NFE2L3	-0.4	-6.48	-0.33	3.34e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7605827	0.836	rs9287662	chr2:15595994	A/G	cg19274914	chr2:15703543	NA	0.47	9.02	0.44	1.51e-17	Educational attainment (years of education);
LUSC	cis	rs11264799	0.581	rs2779158	chr1:157549170	A/T	cg18268488	chr1:157545234	FCRL4	-0.36	-6.61	-0.34	1.55e-10	IgA nephropathy;
LUSC	cis	rs67696533	0.600	rs12625036	chr20:31112689	G/A	cg13636640	chr20:31349939	DNMT3B	0.49	6.66	0.34	1.13e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-8.94	-0.44	2.66e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-13.92	-0.61	4.61e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4499344	0.730	rs28416849	chr19:33099758	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg06096015	chr1:231504339	EGLN1	0.55	9.66	0.47	1.23e-19	Hemoglobin concentration;
LUSC	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg20307385	chr11:47447363	PSMC3	-0.44	-6.61	-0.34	1.51e-10	Subjective well-being;
LUSC	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg01620082	chr3:125678407	NA	-0.74	-7.22	-0.37	3.52e-12	Depression;
LUSC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg11632617	chr15:75315747	PPCDC	-0.52	-6.72	-0.35	7.64e-11	Blood trace element (Zn levels);
LUSC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.93	15.89	0.66	9.63e-43	Bladder cancer;
LUSC	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.01	-19.84	-0.74	2.06e-58	Ulcerative colitis;
LUSC	cis	rs9811920	0.641	rs58704213	chr3:99690331	T/C	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.34	-6.46	-0.33	3.75e-10	Axial length;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19784910	chr11:101785671	KIAA1377;ANGPTL5	0.41	5.95	0.31	6.61e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg09491104	chr22:46646882	C22orf40	-0.65	-6.65	-0.34	1.22e-10	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.41	6.04	0.31	4.14e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-1.01	-17.18	-0.68	7.43e-48	Body mass index;
LUSC	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg13256891	chr4:100009986	ADH5	-0.42	-5.78	-0.3	1.71e-8	Alcohol dependence;
LUSC	cis	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg01251360	chr16:68772225	CDH1	-0.27	-6.48	-0.33	3.23e-10	Colorectal cancer;
LUSC	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.65	0.3	3.36e-8	Lung cancer;
LUSC	cis	rs9807841	0.592	rs7250071	chr19:10765819	A/G	cg17710535	chr19:10819994	QTRT1	-0.38	-6.18	-0.32	1.86e-9	Inflammatory skin disease;
LUSC	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg10857441	chr5:6722123	POLS	0.43	7.98	0.4	2.38e-14	Menopause (age at onset);
LUSC	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg00277334	chr10:82204260	NA	-0.52	-7.79	-0.39	8.72e-14	Post bronchodilator FEV1;
LUSC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	10.15	0.49	2.9e-21	Hip circumference adjusted for BMI;
LUSC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg05861140	chr6:150128134	PCMT1	-0.37	-5.93	-0.31	7.38e-9	Lung cancer;
LUSC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg14780466	chr2:20870812	GDF7	-0.39	-7.86	-0.4	5.32e-14	Abdominal aortic aneurysm;
LUSC	cis	rs4363385	0.782	rs1933381	chr1:153003255	C/G	cg25856811	chr1:152973957	SPRR3	-0.35	-5.8	-0.3	1.52e-8	Inflammatory skin disease;
LUSC	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg17031739	chr1:67600172	NA	0.46	7.08	0.36	8.8e-12	Psoriasis;
LUSC	cis	rs500891	0.570	rs13219666	chr6:83916069	A/G	cg08257003	chr6:84140564	ME1	0.25	5.69	0.3	2.75e-8	Platelet-derived growth factor BB levels;
LUSC	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.85	-0.44	5.12e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg06671706	chr8:8559999	CLDN23	0.48	6.52	0.34	2.59e-10	Obesity-related traits;
LUSC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.43	-0.73	8.64e-57	Height;
LUSC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg08888203	chr3:10149979	C3orf24	-0.53	-7.03	-0.36	1.18e-11	Alzheimer's disease;
LUSC	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.28	-0.45	2.13e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg26566898	chr11:117069891	TAGLN	0.46	8.08	0.4	1.24e-14	Blood protein levels;
LUSC	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg13010199	chr12:38710504	ALG10B	0.49	7.64	0.39	2.32e-13	Morning vs. evening chronotype;
LUSC	cis	rs1355223	1.000	rs1396883	chr11:34757447	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-5.79	-0.3	1.63e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9323205	1.000	rs9323205	chr14:51586467	A/G	cg23942311	chr14:51606299	NA	-0.43	-8.27	-0.41	3.27e-15	Cancer;
LUSC	cis	rs1775715	0.678	rs7096139	chr10:32217404	A/C	cg04359828	chr10:32216031	ARHGAP12	0.39	6.63	0.34	1.36e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg05340658	chr4:99064831	C4orf37	0.59	8.88	0.44	4.12e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg16928487	chr17:17741425	SREBF1	0.37	7.13	0.36	6.28e-12	Total body bone mineral density;
LUSC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.58	0.34	1.83e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	6.64	0.34	1.28e-10	Retinal vascular caliber;
LUSC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg08219700	chr8:58056026	NA	0.5	6.4	0.33	5.22e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg06636001	chr8:8085503	FLJ10661	0.56	7.8	0.39	8.01e-14	Neuroticism;
LUSC	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg15423357	chr2:25149977	NA	-0.42	-8.44	-0.42	1.01e-15	Body mass index;
LUSC	cis	rs9815354	0.767	rs6805140	chr3:41995791	A/G	cg03022575	chr3:42003672	ULK4	0.82	8.59	0.43	3.29e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg02972257	chr16:68554789	NA	0.52	6.73	0.35	7.2e-11	Ulcerative colitis;
LUSC	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg03684893	chr10:554711	DIP2C	-0.45	-8.55	-0.42	4.64e-16	Psychosis in Alzheimer's disease;
LUSC	cis	rs983392	0.868	rs11605427	chr11:59928672	G/C	cg20284999	chr11:59952153	MS4A6A	-0.35	-5.65	-0.3	3.46e-8	Alzheimer's disease (late onset);
LUSC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg12935359	chr14:103987150	CKB	-0.49	-7.75	-0.39	1.1e-13	Body mass index;
LUSC	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg06223162	chr1:101003688	GPR88	0.49	9.35	0.46	1.26e-18	Monocyte count;
LUSC	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg13334819	chr7:99746414	C7orf59	-0.5	-6.67	-0.34	1.05e-10	Coronary artery disease;
LUSC	cis	rs2377585	0.653	rs10770955	chr12:8842752	C/T	cg03761649	chr12:8850719	RIMKLB	0.48	6.25	0.32	1.26e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs887829	0.570	rs4261716	chr2:234593117	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.38	-6.16	-0.32	2.13e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg08558340	chr7:100472263	SRRT	0.5	6.23	0.32	1.39e-9	Resting heart rate;
LUSC	trans	rs683250	0.965	rs684857	chr11:83308002	A/G	cg26617787	chr11:123396133	GRAMD1B	0.32	6.12	0.32	2.67e-9	Subcortical brain region volumes;
LUSC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg25287198	chr4:183728479	NA	0.57	7.59	0.38	3.3e-13	Pediatric autoimmune diseases;
LUSC	cis	rs9462027	0.628	rs9689820	chr6:34752963	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.11e-8	Systemic lupus erythematosus;
LUSC	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	13.1	0.58	6.19e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs6545977	1.000	rs6545977	chr2:63301164	G/A	cg17519650	chr2:63277830	OTX1	-0.79	-12.94	-0.58	2.49e-31	Prostate cancer;
LUSC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02187348	chr16:89574699	SPG7	0.63	10.33	0.49	7.02e-22	Multiple myeloma (IgH translocation);
LUSC	trans	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg05926928	chr17:57297772	GDPD1	-0.47	-6.54	-0.34	2.33e-10	Schizophrenia;
LUSC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg02951883	chr7:2050386	MAD1L1	-0.35	-5.9	-0.31	8.75e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01171360	chr6:293285	DUSP22	-0.68	-11.24	-0.52	4.33e-25	Menopause (age at onset);
LUSC	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00908189	chr16:619842	PIGQ	0.71	11.15	0.52	9.52e-25	Height;
LUSC	cis	rs7561273	0.586	rs11900665	chr2:24298198	T/C	cg20701182	chr2:24300061	SF3B14	0.45	5.77	0.3	1.78e-8	Quantitative traits;
LUSC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg06640241	chr16:89574553	SPG7	-0.62	-9.12	-0.45	7.21e-18	Multiple myeloma (IgH translocation);
LUSC	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg00757033	chr12:89920650	WDR51B	0.59	10.28	0.49	1.03e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	12.46	0.56	1.65e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.44	-7.03	-0.36	1.18e-11	Tonsillectomy;
LUSC	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg01943577	chr7:158741284	NA	-0.39	-5.73	-0.3	2.29e-8	Height;
LUSC	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg18758796	chr5:131593413	PDLIM4	0.34	5.91	0.31	8.44e-9	Blood metabolite levels;
LUSC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg04553112	chr3:125709451	NA	-0.51	-5.75	-0.3	2.06e-8	Blood pressure (smoking interaction);
LUSC	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08280861	chr8:58055591	NA	0.54	5.89	0.31	9.6e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg19901468	chr14:105411992	AHNAK2	-0.71	-12.67	-0.57	2.53e-30	Rheumatoid arthritis;
LUSC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg06718696	chr17:78121285	EIF4A3	0.79	11.72	0.54	8.6e-27	Plateletcrit;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.48	-8.1	-0.41	1.04e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg24375607	chr4:120327624	NA	0.77	11.32	0.53	2.32e-25	Corneal astigmatism;
LUSC	cis	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg02972257	chr16:68554789	NA	0.51	6.54	0.34	2.27e-10	Ulcerative colitis;
LUSC	cis	rs6681460	0.901	rs1570815	chr1:67139667	C/T	cg02459107	chr1:67143332	SGIP1	0.49	9.13	0.45	6.62e-18	Presence of antiphospholipid antibodies;
LUSC	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg15839431	chr19:19639596	YJEFN3	-0.59	-6.31	-0.33	8.91e-10	Bipolar disorder;
LUSC	trans	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24838063	chr12:130822603	PIWIL1	0.71	10.99	0.52	3.57e-24	Menopause (age at onset);
LUSC	trans	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-9.33	-0.45	1.55e-18	Obesity-related traits;
LUSC	cis	rs8018808	0.935	rs11159262	chr14:77928735	A/G	cg20045696	chr14:77926864	AHSA1	0.34	5.76	0.3	1.95e-8	Myeloid white cell count;
LUSC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg20243544	chr17:37824526	PNMT	0.48	6.84	0.35	3.81e-11	Asthma;
LUSC	cis	rs35123781	1.000	rs601728	chr5:139057076	T/C	cg10513866	chr5:139070639	NA	0.46	8.9	0.44	3.62e-17	Schizophrenia;
LUSC	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	7.5	0.38	5.89e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg08601574	chr20:25228251	PYGB	0.45	6.9	0.35	2.69e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs231513	0.911	rs231521	chr17:41955158	A/G	cg26893861	chr17:41843967	DUSP3	-0.54	-5.96	-0.31	6.54e-9	Cognitive function;
LUSC	cis	rs1595825	0.891	rs16826873	chr2:198898222	A/C	cg10547527	chr2:198650123	BOLL	0.51	6.18	0.32	1.85e-9	Ulcerative colitis;
LUSC	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg08213375	chr14:104286397	PPP1R13B	0.54	10.89	0.51	7.59e-24	Schizophrenia;
LUSC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg18357645	chr12:58087776	OS9	0.57	8.64	0.43	2.29e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg06212747	chr3:49208901	KLHDC8B	0.45	5.87	0.31	1.06e-8	Parkinson's disease;
LUSC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21028142	chr17:79581711	NPLOC4	0.32	7.68	0.39	1.78e-13	Eye color traits;
LUSC	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.44	-8.08	-0.4	1.17e-14	Monocyte percentage of white cells;
LUSC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-8.55	-0.42	4.64e-16	Hemoglobin concentration;
LUSC	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.71	0.43	1.4e-16	Axial length;
LUSC	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg07828340	chr4:882639	GAK	0.86	9.99	0.48	9.49e-21	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.56	-0.67	2.25e-45	Monocyte count;
LUSC	cis	rs2307022	0.586	rs4783623	chr16:68390113	A/G	cg02226672	chr16:68398533	SMPD3	0.3	5.68	0.3	2.93e-8	Body mass index;
LUSC	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg08017756	chr2:100939284	LONRF2	-0.49	-9.18	-0.45	4.73e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs1461503	0.512	rs4259833	chr11:122809205	G/A	cg27398637	chr11:122830231	C11orf63	-0.39	-6.28	-0.32	1.07e-9	Menarche (age at onset);
LUSC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs362296	0.698	rs362282	chr4:3259671	G/A	cg14583973	chr4:3374767	RGS12	-0.31	-5.9	-0.31	8.95e-9	Parental longevity (mother's age at death);
LUSC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg08999081	chr20:33150536	PIGU	0.44	8.14	0.41	8e-15	Coronary artery disease;
LUSC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.4	7.37	0.37	1.32e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg07959070	chr22:50026188	C22orf34	-0.33	-6.24	-0.32	1.35e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.66	-0.34	1.16e-10	Endometrial cancer;
LUSC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.77	-0.8	1.22e-77	Height;
LUSC	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg05110241	chr16:68378359	PRMT7	-0.45	-5.94	-0.31	7.27e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg03342759	chr3:160939853	NMD3	-0.48	-8.21	-0.41	4.92e-15	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg13010199	chr12:38710504	ALG10B	0.48	7.56	0.38	3.82e-13	Morning vs. evening chronotype;
LUSC	cis	rs5167	0.566	rs60876330	chr19:45488133	C/T	cg13119609	chr19:45449297	APOC2	0.34	5.67	0.3	3.01e-8	Blood protein levels;
LUSC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg13535736	chr9:111863775	C9orf5	0.4	6.73	0.35	7.24e-11	Menarche (age at onset);
LUSC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg06028605	chr16:24865363	SLC5A11	0.51	9.08	0.44	9.73e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg11871910	chr12:69753446	YEATS4	0.68	10.44	0.5	2.95e-22	Blood protein levels;
LUSC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg21770322	chr7:97807741	LMTK2	0.42	7.23	0.37	3.25e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12493885	0.769	rs11718319	chr3:153776944	G/A	cg17054900	chr3:154042577	DHX36	-0.72	-7.06	-0.36	9.58e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs17401966	0.537	rs3748575	chr1:10342352	C/T	cg17425144	chr1:10567563	PEX14	-0.34	-6.19	-0.32	1.72e-9	Hepatocellular carcinoma;
LUSC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg05043794	chr9:111880884	C9orf5	-0.37	-7.81	-0.39	7.29e-14	Menarche (age at onset);
LUSC	cis	rs2274273	0.840	rs10136596	chr14:55836773	A/G	cg04306507	chr14:55594613	LGALS3	0.54	11.8	0.54	4.11e-27	Protein biomarker;
LUSC	cis	rs4631830	1.000	rs4631830	chr10:51543344	C/T	cg10326726	chr10:51549505	MSMB	-0.34	-5.69	-0.3	2.81e-8	Prostate-specific antigen levels;
LUSC	cis	rs877282	0.755	rs2486578	chr10:785227	C/T	cg17470449	chr10:769945	NA	-0.4	-6.04	-0.31	4.1e-9	Uric acid levels;
LUSC	cis	rs7188861	0.768	rs1646025	chr16:11379938	A/G	cg00044050	chr16:11439710	C16orf75	0.54	6.16	0.32	2.14e-9	HDL cholesterol;
LUSC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.68	-8.53	-0.42	5.08e-16	Lung function (FEV1/FVC);
LUSC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.05	0.31	3.79e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg07414643	chr4:187882934	NA	-0.56	-10.2	-0.49	1.98e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg23241863	chr10:102295624	HIF1AN	0.48	5.91	0.31	8.26e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg09699651	chr6:150184138	LRP11	-0.43	-6.88	-0.35	2.93e-11	Testicular germ cell tumor;
LUSC	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.06	0.44	1.14e-17	Monocyte percentage of white cells;
LUSC	trans	rs656319	0.580	rs13252589	chr8:10005526	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.16	-0.41	6.76e-15	Myopia (pathological);
LUSC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2742417	0.603	rs2673032	chr3:45756927	C/T	cg04837898	chr3:45731254	SACM1L	-0.43	-7.01	-0.36	1.34e-11	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg03146154	chr1:46216737	IPP	0.56	8.36	0.42	1.77e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7180079	1.000	rs7175456	chr15:64534620	C/G	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.76	-14.42	-0.62	5.41e-37	Ulcerative colitis;
LUSC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg07636037	chr3:49044803	WDR6	0.45	6.44	0.33	4.27e-10	Resting heart rate;
LUSC	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.48	10.33	0.49	7e-22	Airflow obstruction;
LUSC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	8.94	0.44	2.77e-17	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19208331	chr3:37035345	MLH1;EPM2AIP1	-0.43	-6.32	-0.33	8.23e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg09594475	chr20:60884601	LAMA5	-0.44	-5.69	-0.3	2.79e-8	Colorectal cancer;
LUSC	cis	rs16854884	0.586	rs4561830	chr3:143735572	C/T	cg06585982	chr3:143692056	C3orf58	0.54	8.66	0.43	2.12e-16	Economic and political preferences (feminism/equality);
LUSC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-0.9	-16.62	-0.67	1.27e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg16339924	chr4:17578868	LAP3	0.55	8.43	0.42	1.04e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg05998816	chr21:47859926	PCNT	0.37	5.67	0.3	3.12e-8	Lymphocyte counts;
LUSC	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.57	-7.8	-0.39	8.24e-14	Body mass index (adult);
LUSC	cis	rs3770081	0.793	rs75675321	chr2:86238994	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.09	-6.81	-0.35	4.43e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg25427524	chr10:38739819	LOC399744	-0.5	-6.3	-0.33	9.41e-10	Obesity (extreme);
LUSC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21984481	chr17:79567631	NPLOC4	-0.67	-13.81	-0.6	1.19e-34	Eye color traits;
LUSC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg07741184	chr6:167504864	NA	0.36	6.51	0.34	2.84e-10	Crohn's disease;
LUSC	cis	rs1395	0.744	rs1122227	chr2:27544285	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.46	6.7	0.34	8.69e-11	Blood metabolite levels;
LUSC	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg11473876	chr11:109292803	C11orf87	-0.42	-6.61	-0.34	1.5e-10	Schizophrenia;
LUSC	cis	rs6845621	0.745	rs2048962	chr4:18862059	T/A	cg12196642	chr4:18937545	NA	-0.31	-5.84	-0.3	1.23e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	trans	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	8.5	0.42	6.47e-16	Ulcerative colitis;
LUSC	cis	rs1979679	0.608	rs1355472	chr12:28721414	C/T	cg13890972	chr12:28721907	NA	0.39	5.67	0.3	3.17e-8	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg14530993	chr4:882597	GAK	0.72	7.41	0.38	1.07e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg21775007	chr8:11205619	TDH	-0.61	-9.26	-0.45	2.55e-18	Retinal vascular caliber;
LUSC	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg21643547	chr1:205240462	TMCC2	-0.41	-7.55	-0.38	4.08e-13	Red blood cell count;
LUSC	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg04234412	chr22:24373322	LOC391322	-0.79	-11.71	-0.54	8.94e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg00509249	chr6:109615579	CCDC162	-0.34	-6.12	-0.32	2.6e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg13683864	chr3:40499215	RPL14	0.99	17.72	0.7	5.34e-50	Renal cell carcinoma;
LUSC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-1.17	-16.86	-0.68	1.46e-46	Breast cancer;
LUSC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg22823121	chr1:150693482	HORMAD1	0.59	9.05	0.44	1.17e-17	Tonsillectomy;
LUSC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03301945	chr19:10764555	ILF3;LOC147727	-0.42	-6.33	-0.33	7.85e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg15839431	chr19:19639596	YJEFN3	-0.58	-6.27	-0.32	1.12e-9	Bipolar disorder;
LUSC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-8.62	-0.43	2.81e-16	Obesity-related traits;
LUSC	cis	rs7043114	0.525	rs7850432	chr9:95130510	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.39	-6.84	-0.35	3.71e-11	Height;
LUSC	cis	rs11030122	0.702	rs1349583	chr11:3972236	G/A	cg18678763	chr11:4115507	RRM1	-0.47	-6.15	-0.32	2.26e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4917385	1	rs4917385	chr10:105003721	T/G	cg04362960	chr10:104952993	NT5C2	0.53	7.06	0.36	9.48e-12	Systemic lupus erythematosus;
LUSC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.18	0.88	4.53e-111	Chronic sinus infection;
LUSC	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg06627628	chr2:24431161	ITSN2	0.54	7.44	0.38	8.49e-13	Asthma;
LUSC	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-0.77	-12.31	-0.56	5.8e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10761482	0.639	rs2067612	chr10:62212334	T/C	cg18175470	chr10:62150864	ANK3	-0.52	-7.25	-0.37	3e-12	Schizophrenia;
LUSC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	10.89	0.51	7.96e-24	Hip circumference adjusted for BMI;
LUSC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.93	-0.51	5.8e-24	Alzheimer's disease (late onset);
LUSC	cis	rs2274273	0.773	rs28430823	chr14:55816560	C/G	cg04306507	chr14:55594613	LGALS3	0.53	11.62	0.54	1.95e-26	Protein biomarker;
LUSC	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg22676075	chr6:135203613	NA	0.46	7.09	0.36	7.84e-12	Red blood cell count;
LUSC	cis	rs2274273	0.837	rs6573010	chr14:55721592	T/C	cg04306507	chr14:55594613	LGALS3	0.58	13.54	0.6	1.33e-33	Protein biomarker;
LUSC	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg04545296	chr12:48745243	ZNF641	0.34	6.26	0.32	1.2e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg22437258	chr11:111473054	SIK2	0.5	6.78	0.35	5.6e-11	Primary sclerosing cholangitis;
LUSC	cis	rs6725041	0.547	rs4672645	chr2:213204955	C/T	cg16329650	chr2:213403929	ERBB4	-0.41	-6.58	-0.34	1.77e-10	QT interval (ambient particulate matter interaction);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15190599	chr6:26156487	HIST1H1E	-0.36	-6.1	-0.32	2.98e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7178572	0.568	rs4886850	chr15:77404160	G/C	cg22256960	chr15:77711686	NA	-0.51	-8.1	-0.41	1.07e-14	Type 2 diabetes;
LUSC	cis	rs2219968	0.756	rs10504661	chr8:78846469	T/G	cg00738934	chr8:78996279	NA	-0.36	-6.13	-0.32	2.55e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg05973401	chr12:123451056	ABCB9	0.52	6.53	0.34	2.39e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg05343316	chr1:45956843	TESK2	0.7	9.29	0.45	2e-18	Platelet count;
LUSC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg22823121	chr1:150693482	HORMAD1	0.58	8.88	0.44	4.07e-17	Tonsillectomy;
LUSC	cis	rs7705502	0.962	rs72812861	chr5:173387509	T/C	cg18693985	chr5:173351052	CPEB4	-0.4	-6.28	-0.33	1.04e-9	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg24375607	chr4:120327624	NA	0.76	11.01	0.52	2.89e-24	Corneal astigmatism;
LUSC	cis	rs6906287	0.625	rs7453914	chr6:118692981	A/T	cg05564266	chr6:118973597	C6orf204	0.25	6.08	0.32	3.36e-9	Electrocardiographic conduction measures;
LUSC	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg22491629	chr6:157744540	C6orf35	-0.9	-10.67	-0.5	4.68e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg00376283	chr12:123451042	ABCB9	0.66	8.31	0.41	2.45e-15	Neutrophil percentage of white cells;
LUSC	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.59	-5.73	-0.3	2.3e-8	Narcolepsy;
LUSC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.61	-7.7	-0.39	1.58e-13	Birth weight;
LUSC	cis	rs4851254	0.660	rs4851244	chr2:100671449	C/T	cg22139774	chr2:100720529	AFF3	0.43	5.9	0.31	9.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg01765077	chr12:122356316	WDR66	0.54	7.76	0.39	1.07e-13	Mean corpuscular volume;
LUSC	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg09307838	chr4:120376055	NA	0.52	7.79	0.39	8.65e-14	Diastolic blood pressure;
LUSC	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.7	10.54	0.5	1.25e-22	Corneal astigmatism;
LUSC	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg02269571	chr22:50332266	NA	0.58	8.57	0.42	3.99e-16	Schizophrenia;
LUSC	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg05182265	chr7:156933206	UBE3C	0.45	6.85	0.35	3.46e-11	Body mass index;
LUSC	cis	rs2274273	0.743	rs7161656	chr14:55524530	A/G	cg04306507	chr14:55594613	LGALS3	0.49	10.72	0.51	3.06e-23	Protein biomarker;
LUSC	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg08999081	chr20:33150536	PIGU	-0.33	-5.83	-0.3	1.31e-8	Height;
LUSC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg19318889	chr4:1322082	MAEA	0.58	9.99	0.48	9.57e-21	Longevity;
LUSC	cis	rs9815354	1.000	rs12639255	chr3:41861738	T/C	cg03022575	chr3:42003672	ULK4	0.59	6.57	0.34	1.93e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg00376283	chr12:123451042	ABCB9	0.68	8.6	0.43	3.1e-16	Neutrophil percentage of white cells;
LUSC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg09021430	chr5:549028	NA	-0.55	-7.24	-0.37	3.12e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.16	-0.32	2.04e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.08	-0.36	8.5e-12	Blood metabolite levels;
LUSC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg13770153	chr20:60521292	NA	-0.61	-8.39	-0.42	1.43e-15	Body mass index;
LUSC	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg04851639	chr8:1020857	NA	-0.35	-7.03	-0.36	1.19e-11	Schizophrenia;
LUSC	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.12	-0.45	7.26e-18	Monocyte percentage of white cells;
LUSC	cis	rs2479724	0.572	rs6920885	chr6:41941169	T/C	cg17623882	chr6:41773611	USP49	-0.46	-7.71	-0.39	1.5e-13	Menarche (age at onset);
LUSC	cis	rs6537837	0.701	rs12021920	chr1:110147287	C/T	cg05049280	chr1:110155535	GNAT2	0.57	7.33	0.37	1.72e-12	Major depressive disorder;
LUSC	trans	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg06521331	chr12:34319734	NA	-0.39	-5.99	-0.31	5.58e-9	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg20993868	chr7:22813445	NA	-0.63	-11.4	-0.53	1.17e-25	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.32	0.45	1.64e-18	Lung cancer in ever smokers;
LUSC	cis	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg27411982	chr8:10470053	RP1L1	0.45	7.04	0.36	1.08e-11	Neuroticism;
LUSC	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.68	-0.43	1.81e-16	Body mass index;
LUSC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.33	-0.49	7.03e-22	Alzheimer's disease;
LUSC	cis	rs2455601	0.574	rs2568094	chr11:8992218	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-6.73	-0.35	7.35e-11	Schizophrenia;
LUSC	cis	rs3087591	0.708	rs964288	chr17:29679246	G/A	cg24425628	chr17:29625626	OMG;NF1	0.47	7.04	0.36	1.09e-11	Hip circumference;
LUSC	cis	rs2425143	1.000	rs113203744	chr20:34253656	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.56	-0.34	2.09e-10	Blood protein levels;
LUSC	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17467752	chr17:38218738	THRA	-0.55	-7.66	-0.39	1.98e-13	Myeloid white cell count;
LUSC	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg20476159	chr18:77451067	CTDP1	-0.32	-5.8	-0.3	1.58e-8	Monocyte count;
LUSC	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg01097406	chr16:89675127	NA	-0.37	-6.95	-0.36	1.95e-11	Vitiligo;
LUSC	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.34	-0.33	7.55e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg26162295	chr17:38119207	GSDMA	-0.29	-6.96	-0.36	1.85e-11	Asthma and hay fever;
LUSC	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg26924012	chr15:45694286	SPATA5L1	0.71	10.73	0.51	2.94e-23	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2273669	0.667	rs12215614	chr6:109313629	T/C	cg05315195	chr6:109294784	ARMC2	-0.53	-5.96	-0.31	6.41e-9	Prostate cancer;
LUSC	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg19743168	chr1:23544995	NA	0.41	7.91	0.4	3.79e-14	Height;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13453053	chr17:26662113	TNFAIP1;IFT20	0.66	6.18	0.32	1.9e-9	Cognitive performance;
LUSC	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg03647239	chr10:116582469	FAM160B1	0.45	7.27	0.37	2.55e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg22484793	chr3:52261325	TLR9	0.27	6.15	0.32	2.21e-9	Electroencephalogram traits;
LUSC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg17264618	chr3:40429014	ENTPD3	0.31	6.9	0.35	2.65e-11	Renal cell carcinoma;
LUSC	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg04865166	chr7:105162814	PUS7	0.52	5.92	0.31	7.79e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	8.25	0.41	3.61e-15	Bipolar disorder;
LUSC	cis	rs73198271	0.595	rs117424193	chr8:8591377	T/C	cg01851573	chr8:8652454	MFHAS1	0.46	5.77	0.3	1.83e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.71	-12.97	-0.58	1.96e-31	Ulcerative colitis;
LUSC	trans	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg13010199	chr12:38710504	ALG10B	0.48	7.56	0.38	3.82e-13	Morning vs. evening chronotype;
LUSC	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.4	-0.38	1.09e-12	Type 2 diabetes;
LUSC	cis	rs7582720	1.000	rs72932793	chr2:203701004	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.73	0.43	1.22e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs925550	0.560	rs17006053	chr4:123629661	C/A	cg10495464	chr4:123653540	BBS12;LOC729338	-0.51	-6.67	-0.34	1.08e-10	Primary biliary cholangitis;
LUSC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18876405	chr7:65276391	NA	0.56	8.91	0.44	3.3e-17	Aortic root size;
LUSC	cis	rs12618769	0.625	rs78518453	chr2:99213899	T/C	cg10123293	chr2:99228465	UNC50	0.47	7.7	0.39	1.59e-13	Bipolar disorder;
LUSC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.38	0.53	1.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4642101	0.561	rs9831765	chr3:12805934	A/T	cg24848339	chr3:12840334	CAND2	0.31	6.19	0.32	1.75e-9	QRS complex (12-leadsum);
LUSC	cis	rs3857536	0.813	rs6904511	chr6:66939102	A/C	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs7091068	0.754	rs6583903	chr10:95422174	T/C	cg20715218	chr10:95462985	C10orf4	0.58	6.61	0.34	1.56e-10	Urinary tract infection frequency;
LUSC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.87	0.4	4.87e-14	Bipolar disorder;
LUSC	cis	rs10992471	0.580	rs1535756	chr9:95202032	G/A	cg14631576	chr9:95140430	CENPP	-0.36	-6.5	-0.34	2.94e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7605827	0.930	rs13001923	chr2:15521264	A/T	cg19274914	chr2:15703543	NA	0.45	8.78	0.43	8.82e-17	Educational attainment (years of education);
LUSC	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg23241863	chr10:102295624	HIF1AN	0.47	5.65	0.3	3.41e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg16482183	chr6:26056742	HIST1H1C	0.66	9.2	0.45	4e-18	Iron status biomarkers;
LUSC	cis	rs3820928	0.904	rs2217359	chr2:227759892	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.86	-0.4	5.36e-14	Pulmonary function;
LUSC	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg13902645	chr11:5959945	NA	-0.54	-8.03	-0.4	1.73e-14	DNA methylation (variation);
LUSC	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-9.84	-0.47	3.07e-20	Morning vs. evening chronotype;
LUSC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg03929089	chr4:120376271	NA	-0.94	-14.95	-0.63	4.73e-39	Coronary artery disease;
LUSC	cis	rs6977660	0.619	rs4721823	chr7:19785888	G/C	cg05791153	chr7:19748676	TWISTNB	0.62	6.33	0.33	7.74e-10	Thyroid stimulating hormone;
LUSC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.83	0.35	3.98e-11	Platelet count;
LUSC	cis	rs12541635	1.000	rs2881037	chr8:107090901	C/T	cg10147462	chr8:107024639	NA	-0.47	-8.64	-0.43	2.37e-16	Age of smoking initiation;
LUSC	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg11244672	chr19:19639970	YJEFN3	-0.61	-7.59	-0.38	3.3e-13	Bipolar disorder;
LUSC	cis	rs116988415	0.584	rs17180252	chr14:65239316	G/A	cg25083366	chr14:65239357	SPTB	0.7	6.65	0.34	1.19e-10	Daytime sleep phenotypes;
LUSC	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg09365446	chr1:150670422	GOLPH3L	0.47	6.83	0.35	4.12e-11	Melanoma;
LUSC	trans	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	6.7	0.34	8.7e-11	Menarche (age at onset);
LUSC	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg20587970	chr11:113659929	NA	-1.07	-14.87	-0.63	1.01e-38	Hip circumference adjusted for BMI;
LUSC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	trans	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-8.0	-0.4	2.09e-14	Obesity-related traits;
LUSC	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg18132916	chr6:79620363	NA	-0.38	-5.74	-0.3	2.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10465746	0.967	rs11163874	chr1:84424437	G/C	cg10977910	chr1:84465055	TTLL7	0.43	6.29	0.33	1.01e-9	Obesity-related traits;
LUSC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.12	0.48	3.52e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg08048268	chr3:133502702	NA	-0.38	-6.92	-0.35	2.25e-11	Iron status biomarkers;
LUSC	cis	rs11748023	0.605	rs155943	chr5:139529987	A/T	cg26211634	chr5:139558579	C5orf32	0.35	6.29	0.33	9.86e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.53	-8.64	-0.43	2.32e-16	Longevity;Endometriosis;
LUSC	cis	rs858239	0.601	rs929507	chr7:23166664	G/C	cg23682824	chr7:23144976	KLHL7	0.4	5.82	0.3	1.4e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg20219074	chr11:18656078	SPTY2D1	0.75	10.99	0.52	3.5e-24	Breast cancer;
LUSC	cis	rs61990749	0.597	rs72685264	chr14:78152998	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.61	-6.49	-0.33	3.14e-10	Fibroblast growth factor basic levels;
LUSC	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg12856521	chr11:46389249	DGKZ	0.44	6.6	0.34	1.64e-10	Leprosy;
LUSC	cis	rs7539409	0.651	rs969724	chr1:84300712	T/G	cg10977910	chr1:84465055	TTLL7	0.71	7.5	0.38	5.92e-13	Alzheimer's disease;
LUSC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.59	-11.2	-0.52	6.23e-25	Longevity;Endometriosis;
LUSC	cis	rs62458065	0.850	rs62458100	chr7:32473142	C/G	cg20159608	chr7:32802032	NA	-0.66	-7.83	-0.39	6.35e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.68	10.52	0.5	1.52e-22	Alcohol dependence;
LUSC	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg24060327	chr5:131705240	SLC22A5	0.48	6.73	0.35	7.49e-11	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs68170813	0.605	rs2299428	chr7:107134384	A/G	cg24556660	chr7:106842632	COG5;HBP1	-0.44	-5.9	-0.31	8.9e-9	Coronary artery disease;
LUSC	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg24829409	chr8:58192753	C8orf71	-0.55	-6.21	-0.32	1.55e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg10255544	chr17:80519551	FOXK2	-0.39	-6.44	-0.33	4.14e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.26	0.45	2.6e-18	Prudent dietary pattern;
LUSC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.58	-9.39	-0.46	9.82e-19	Aortic root size;
LUSC	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-21.69	-0.76	1e-65	Height;
LUSC	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg22532475	chr10:104410764	TRIM8	-0.32	-7.15	-0.36	5.59e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs939658	0.935	rs34859518	chr15:79450422	A/G	cg17916960	chr15:79447300	NA	-0.52	-10.37	-0.49	5.1e-22	Refractive error;
LUSC	cis	rs4704187	0.640	rs7721018	chr5:74492978	C/T	cg03227963	chr5:74354835	NA	0.31	6.73	0.35	7.43e-11	Response to amphetamines;
LUSC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.38	-6.49	-0.33	3.09e-10	High light scatter reticulocyte count;
LUSC	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg13514129	chr1:39547527	MACF1	0.73	11.95	0.55	1.19e-27	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg03522245	chr20:25566470	NINL	-0.35	-5.69	-0.3	2.85e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19346786	chr7:2764209	NA	-0.42	-7.25	-0.37	2.94e-12	Height;
LUSC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg03289416	chr15:75166202	SCAMP2	0.45	7.04	0.36	1.13e-11	Breast cancer;
LUSC	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg11244672	chr19:19639970	YJEFN3	-0.64	-7.75	-0.39	1.11e-13	Bipolar disorder;
LUSC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg01879757	chr17:41196368	BRCA1	-0.45	-6.99	-0.36	1.54e-11	Menopause (age at onset);
LUSC	cis	rs2625529	0.641	rs2035379	chr15:72293202	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-7.44	-0.38	8.7e-13	Red blood cell count;
LUSC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.36	5.9	0.31	8.71e-9	Menopause (age at onset);
LUSC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg05552183	chr6:42928497	GNMT	0.52	8.58	0.42	3.71e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg10326726	chr10:51549505	MSMB	0.34	5.88	0.31	9.99e-9	Prostate-specific antigen levels;
LUSC	cis	rs10875746	0.551	rs1471997	chr12:48723595	G/A	cg13454099	chr12:49076203	C12orf41	-0.49	-5.74	-0.3	2.08e-8	Longevity (90 years and older);
LUSC	cis	rs981844	0.961	rs62325084	chr4:154662603	C/T	cg14289246	chr4:154710475	SFRP2	0.5	6.44	0.33	4.05e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg19468946	chr17:37922297	IKZF3	-0.41	-6.35	-0.33	6.91e-10	Self-reported allergy;
LUSC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.42	-6.39	-0.33	5.42e-10	Tonsillectomy;
LUSC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg09365446	chr1:150670422	GOLPH3L	0.53	8.05	0.4	1.46e-14	Tonsillectomy;
LUSC	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg07930552	chr6:133119739	C6orf192	0.76	10.16	0.49	2.56e-21	Type 2 diabetes nephropathy;
LUSC	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.53	0.5	1.37e-22	Colorectal cancer;
LUSC	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg13042288	chr15:90349979	ANPEP	-0.49	-7.21	-0.37	3.86e-12	Uric acid levels;
LUSC	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg01557791	chr16:72042693	DHODH	-0.47	-6.05	-0.31	3.94e-9	Blood protein levels;
LUSC	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.68	-11.04	-0.52	2.39e-24	Type 2 diabetes;
LUSC	trans	rs7939886	0.920	rs11227434	chr11:55945251	G/T	cg15704280	chr7:45808275	SEPT13	0.87	6.66	0.34	1.1e-10	Myopia (pathological);
LUSC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.26	0.45	2.6e-18	Prudent dietary pattern;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02930664	chr19:44506841	ZNF230	-0.42	-6.13	-0.32	2.45e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg03188948	chr7:1209495	NA	0.42	5.67	0.3	3.09e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg22705228	chr6:37400926	FTSJD2	0.52	6.36	0.33	6.52e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.71e-10	Life satisfaction;
LUSC	cis	rs4132509	0.948	rs12048930	chr1:243940076	C/T	cg21452805	chr1:244014465	NA	0.51	5.71	0.3	2.51e-8	RR interval (heart rate);
LUSC	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg00071950	chr4:10020882	SLC2A9	0.45	7.65	0.39	2.13e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg05043794	chr9:111880884	C9orf5	-0.33	-6.88	-0.35	2.97e-11	Menarche (age at onset);
LUSC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.69	8.88	0.44	4.05e-17	Menarche (age at onset);
LUSC	cis	rs11748023	0.605	rs155949	chr5:139523684	A/G	cg26211634	chr5:139558579	C5orf32	0.34	6.18	0.32	1.85e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.62	-0.57	4.01e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs440932	0.757	rs330943	chr8:9021026	G/A	cg06636001	chr8:8085503	FLJ10661	0.42	5.99	0.31	5.53e-9	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg18357645	chr12:58087776	OS9	0.52	7.81	0.39	7.27e-14	Celiac disease or Rheumatoid arthritis;
LUSC	trans	rs1486139	1.000	rs1486156	chr7:46289564	G/A	cg17534202	chr9:96721102	NA	-0.37	-6.64	-0.34	1.3e-10	Select biomarker traits;
LUSC	cis	rs17253792	0.822	rs111467375	chr14:56046159	T/G	cg01858014	chr14:56050164	KTN1	-0.88	-7.07	-0.36	8.91e-12	Putamen volume;
LUSC	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg25457927	chr22:38595422	NA	-0.4	-7.85	-0.39	5.85e-14	Cutaneous nevi;
LUSC	cis	rs9311676	0.632	rs56398717	chr3:58404355	G/A	cg26110898	chr3:58419937	PDHB	0.39	6.31	0.33	9.11e-10	Systemic lupus erythematosus;
LUSC	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg03522245	chr20:25566470	NINL	-0.36	-5.8	-0.3	1.56e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg15744005	chr10:104629667	AS3MT	-0.38	-7.93	-0.4	3.22e-14	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg21905437	chr5:178450457	ZNF879	-0.43	-5.88	-0.31	9.69e-9	Pubertal anthropometrics;
LUSC	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg18105134	chr13:113819100	PROZ	0.61	9.08	0.44	9.89e-18	Platelet distribution width;
LUSC	cis	rs9398803	0.830	rs4053271	chr6:126830512	T/C	cg19875578	chr6:126661172	C6orf173	0.42	6.17	0.32	1.97e-9	Male-pattern baldness;
LUSC	cis	rs416603	0.967	rs11640138	chr16:11362729	A/G	cg00044050	chr16:11439710	C16orf75	0.65	11.61	0.54	2.09e-26	Type 1 diabetes;
LUSC	cis	rs1113500	0.787	rs10881501	chr1:108641745	C/T	cg06207961	chr1:108661230	NA	0.3	5.66	0.3	3.18e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs9534288	0.830	rs3783202	chr13:46631869	G/A	cg15192986	chr13:46630673	CPB2	-0.8	-12.69	-0.57	2.14e-30	Blood protein levels;
LUSC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg12257692	chr3:49977190	RBM6	-0.23	-6.38	-0.33	5.75e-10	Body mass index;
LUSC	cis	rs7589342	0.501	rs7602971	chr2:106440675	G/A	cg14210321	chr2:106509881	NCK2	-0.41	-6.11	-0.32	2.77e-9	Addiction;
LUSC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg26958806	chr6:27640298	NA	-0.65	-5.72	-0.3	2.38e-8	Depression;
LUSC	cis	rs11608355	0.846	rs4766471	chr12:109853462	G/A	cg19025524	chr12:109796872	NA	-0.39	-5.72	-0.3	2.35e-8	Neuroticism;
LUSC	cis	rs9549260	0.755	rs7986407	chr13:41179798	A/G	cg21288729	chr13:41239152	FOXO1	0.6	8.74	0.43	1.16e-16	Red blood cell count;
LUSC	cis	rs9309473	0.687	rs6706409	chr2:73606508	G/T	cg20560298	chr2:73613845	ALMS1	0.52	7.51	0.38	5.39e-13	Metabolite levels;
LUSC	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg02153584	chr22:29168773	CCDC117	0.68	10.54	0.5	1.26e-22	Lymphocyte counts;
LUSC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg24642439	chr20:33292090	TP53INP2	0.66	9.78	0.47	4.96e-20	Coronary artery disease;
LUSC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-7.23	-0.37	3.4e-12	Alzheimer's disease (late onset);
LUSC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg19592336	chr6:28129416	ZNF389	0.51	6.58	0.34	1.8e-10	Depression;
LUSC	trans	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg16724585	chr3:197361211	NA	0.61	8.54	0.42	4.9e-16	Pancreatic cancer;
LUSC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg18479299	chr3:125709523	NA	-0.52	-5.94	-0.31	7.16e-9	Blood pressure (smoking interaction);
LUSC	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg25456477	chr12:86230367	RASSF9	0.4	6.91	0.35	2.42e-11	Major depressive disorder;
LUSC	cis	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg06360820	chr2:242988706	NA	-0.6	-7.8	-0.39	7.89e-14	Obesity-related traits;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26317405	chr11:67188521	ATPGD1	0.8	6.28	0.32	1.06e-9	Cognitive performance;
LUSC	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs259282	0.538	rs8105481	chr19:33118095	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	10.46	0.5	2.52e-22	Schizophrenia;
LUSC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.47	7.79	0.39	8.53e-14	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs17253792	0.822	rs79483507	chr14:56164718	G/T	cg01858014	chr14:56050164	KTN1	-0.88	-7.08	-0.36	8.38e-12	Putamen volume;
LUSC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.19	-0.8	2.08e-75	Height;
LUSC	cis	rs12286929	0.933	rs11215381	chr11:115022233	T/C	cg04055981	chr11:115044050	NA	0.36	6.29	0.33	1.02e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11997175	0.597	rs6988880	chr8:33594504	C/T	ch.8.33884649F	chr8:33765107	NA	0.42	6.66	0.34	1.15e-10	Body mass index;
LUSC	trans	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.05	-0.31	3.85e-9	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LUSC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12016809	chr21:47604291	C21orf56	0.47	7.03	0.36	1.18e-11	Testicular germ cell tumor;
LUSC	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg11244672	chr19:19639970	YJEFN3	-0.52	-6.68	-0.34	9.85e-11	Bipolar disorder;
LUSC	cis	rs870825	0.616	rs6825561	chr4:185615532	A/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.5	0.59	1.86e-33	Blood protein levels;
LUSC	trans	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.5	0.5	1.77e-22	Mean corpuscular volume;
LUSC	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg02503808	chr4:7069936	GRPEL1	1.07	14.49	0.62	2.9e-37	Monocyte percentage of white cells;
LUSC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg25811766	chr13:21894605	NA	0.79	9.71	0.47	8.23e-20	White matter hyperintensity burden;
LUSC	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-10.7	-0.51	3.65e-23	Heart rate;
LUSC	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg05283184	chr6:79620031	NA	-0.57	-12.18	-0.55	1.73e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg21573476	chr21:45109991	RRP1B	-0.36	-5.7	-0.3	2.66e-8	Mean corpuscular volume;
LUSC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-1.25	-14.0	-0.61	2.4e-35	Diabetic kidney disease;
LUSC	cis	rs790123	1.000	rs790115	chr3:122381117	C/T	cg00926285	chr3:122398533	PARP14	-0.38	-5.83	-0.3	1.33e-8	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs238295	0.805	rs6085211	chr20:5552847	G/C	cg15842884	chr20:5591925	RP5-1022P6.2	-0.44	-5.94	-0.31	7.34e-9	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs1395	0.626	rs72817537	chr2:27497549	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.45	6.34	0.33	7.49e-10	Blood metabolite levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09856410	chr20:34287384	ROMO1;NFS1	-0.41	-6.07	-0.32	3.48e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2625529	0.761	rs972029	chr15:72172986	C/T	cg16672083	chr15:72433130	SENP8	-0.45	-6.61	-0.34	1.53e-10	Red blood cell count;
LUSC	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg12935359	chr14:103987150	CKB	0.54	8.26	0.41	3.46e-15	Body mass index;
LUSC	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg25206134	chr2:45395956	NA	0.52	6.22	0.32	1.52e-9	Bipolar disorder;
LUSC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg10792982	chr14:105748885	BRF1	0.52	9.51	0.46	4.05e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs524023	0.837	rs12362590	chr11:64352540	T/A	cg19131476	chr11:64387923	NRXN2	-0.37	-9.81	-0.47	3.83e-20	Urate levels in obese individuals;
LUSC	cis	rs4253772	0.872	rs45576140	chr22:46638216	C/G	cg09491104	chr22:46646882	C22orf40	-0.59	-6.48	-0.33	3.23e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18099408	chr3:52552593	STAB1	-0.42	-7.28	-0.37	2.44e-12	Electroencephalogram traits;
LUSC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg07395648	chr5:131743802	NA	0.37	5.87	0.31	1.07e-8	Breast cancer;
LUSC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg14343924	chr8:8086146	FLJ10661	0.43	5.93	0.31	7.77e-9	Systolic blood pressure;
LUSC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	10.09	0.48	4.6e-21	Bipolar disorder;
LUSC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg23711669	chr6:146136114	FBXO30	-0.71	-12.27	-0.56	8e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12667521	chr19:29218732	NA	0.62	7.48	0.38	6.7e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.84	0.51	1.15e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.89	0.58	3.95e-31	Bipolar disorder;
LUSC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg27532560	chr4:187881888	NA	-0.43	-6.95	-0.36	1.87e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12760731	0.720	rs12161419	chr1:178379040	A/C	cg00404053	chr1:178313656	RASAL2	0.6	6.25	0.32	1.26e-9	Obesity-related traits;
LUSC	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg12568669	chr8:11666485	FDFT1	0.26	5.78	0.3	1.72e-8	Retinal vascular caliber;
LUSC	trans	rs71435601	0.574	rs522822	chr2:21401851	A/G	cg20757404	chr19:378427	NA	0.38	6.0	0.31	5.1e-9	Cholesterol, total;
LUSC	cis	rs10986311	0.775	rs1007185	chr9:127136644	G/C	cg14243010	chr9:127117328	LOC100129034;PSMB7	-0.44	-7.21	-0.37	3.8e-12	Vitiligo;
LUSC	cis	rs710216	0.957	rs859511	chr1:43430260	C/T	cg03128534	chr1:43423976	SLC2A1	0.47	5.8	0.3	1.54e-8	Red cell distribution width;
LUSC	trans	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg18187862	chr3:45730750	SACM1L	0.53	6.78	0.35	5.31e-11	Primary sclerosing cholangitis;
LUSC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	ch.11.42038R	chr11:967971	AP2A2	0.42	6.28	0.33	1.03e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.58	-9.11	-0.45	7.58e-18	Obesity-related traits;
LUSC	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-7.46	-0.38	7.49e-13	Cognitive test performance;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12728516	chr1:155197152	GBAP1	0.5	5.95	0.31	6.74e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	7.55	0.38	4.18e-13	Height;
LUSC	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg10840412	chr1:235813424	GNG4	0.67	8.97	0.44	2.19e-17	Bipolar disorder;
LUSC	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg05855489	chr10:104503620	C10orf26	0.52	8.08	0.4	1.19e-14	Arsenic metabolism;
LUSC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg12311346	chr5:56204834	C5orf35	-0.63	-9.14	-0.45	6.15e-18	Coronary artery disease;
LUSC	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.45	5.98	0.31	5.64e-9	Renal function-related traits (BUN);
LUSC	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.67	10.29	0.49	9.56e-22	Colorectal cancer;
LUSC	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg23093090	chr10:104574429	C10orf26	0.31	5.65	0.3	3.52e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg18107078	chr1:162760321	HSD17B7	-0.46	-6.6	-0.34	1.61e-10	Breast cancer;
LUSC	cis	rs3105593	0.933	rs7174839	chr15:50889624	G/C	cg08437265	chr15:50716283	USP8	0.4	5.92	0.31	8.09e-9	QT interval;
LUSC	cis	rs9392556	0.829	rs634698	chr6:4114247	T/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.36	-6.2	-0.32	1.71e-9	Blood metabolite levels;
LUSC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg17724175	chr1:150552817	MCL1	0.37	6.7	0.34	8.92e-11	Tonsillectomy;
LUSC	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg18190219	chr22:46762943	CELSR1	-0.48	-5.69	-0.3	2.78e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg25258033	chr6:167368657	RNASET2	0.47	7.85	0.39	5.71e-14	Crohn's disease;
LUSC	cis	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	cis	rs738322	0.719	rs34066050	chr22:38612604	G/A	cg25457927	chr22:38595422	NA	0.45	9.31	0.45	1.8e-18	Cutaneous nevi;
LUSC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21963583	chr11:68658836	MRPL21	-0.57	-8.83	-0.44	5.92e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg19592336	chr6:28129416	ZNF389	-0.51	-6.94	-0.35	2.09e-11	Depression;
LUSC	cis	rs926938	0.520	rs6671984	chr1:115257521	C/T	cg12756093	chr1:115239321	AMPD1	-0.55	-8.04	-0.4	1.57e-14	Autism;
LUSC	cis	rs1595825	1.000	rs1440088	chr2:198871417	A/C	cg00982548	chr2:198649783	BOLL	-0.48	-6.04	-0.31	4.21e-9	Ulcerative colitis;
LUSC	cis	rs6429082	0.738	rs2131921	chr1:235705157	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.71	0.3	2.53e-8	Adiposity;
LUSC	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs193541	0.632	rs6878609	chr5:122095549	C/G	cg19077854	chr5:122220652	SNX24	0.39	7.99	0.4	2.18e-14	Glucose homeostasis traits;
LUSC	trans	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg21659725	chr3:3221576	CRBN	0.71	8.52	0.42	5.73e-16	Menarche (age at onset);
LUSC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.85	15.63	0.65	9.87e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4812048	0.696	rs6070694	chr20:57591126	G/A	cg14073986	chr20:57617431	SLMO2	0.76	6.79	0.35	5.29e-11	Mean platelet volume;
LUSC	cis	rs1113500	0.614	rs12565953	chr1:108607087	C/T	cg06207961	chr1:108661230	NA	0.36	5.74	0.3	2.09e-8	Growth-regulated protein alpha levels;
LUSC	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg06808227	chr14:105710500	BRF1	-0.71	-11.31	-0.53	2.47e-25	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg23029597	chr12:123009494	RSRC2	-0.76	-10.03	-0.48	7.17e-21	Body mass index;
LUSC	cis	rs9815354	0.812	rs73077361	chr3:41850146	G/A	cg03022575	chr3:42003672	ULK4	0.85	8.56	0.42	4.04e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg00310523	chr12:86230176	RASSF9	0.37	6.59	0.34	1.76e-10	Major depressive disorder;
LUSC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg11766577	chr21:47581405	C21orf56	-0.42	-6.16	-0.32	2.15e-9	Testicular germ cell tumor;
LUSC	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg22852734	chr6:133119734	C6orf192	1.22	14.16	0.61	5.69e-36	Type 2 diabetes nephropathy;
LUSC	trans	rs11696501	0.739	rs2281210	chr20:44243172	T/G	cg03272292	chr12:48577362	C12orf68	0.52	6.18	0.32	1.88e-9	Brain structure;
LUSC	cis	rs7177699	0.557	rs7403714	chr15:79118650	C/T	cg15571903	chr15:79123663	NA	-0.33	-6.03	-0.31	4.24e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg00520135	chr15:63333846	TPM1	0.33	6.56	0.34	2e-10	Platelet count;
LUSC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.74	0.84	1.09e-88	Chronic sinus infection;
LUSC	cis	rs3820068	0.608	rs7552400	chr1:16035892	A/G	cg24675056	chr1:15929824	NA	0.4	6.58	0.34	1.87e-10	Systolic blood pressure;
LUSC	cis	rs9399401	0.961	rs1891308	chr6:142648235	G/A	cg03128060	chr6:142623767	GPR126	0.32	5.67	0.3	3.01e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	0.81	14.13	0.61	7.23e-36	Cognitive function;
LUSC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg08742575	chr21:47604166	C21orf56	0.4	6.0	0.31	5.24e-9	Testicular germ cell tumor;
LUSC	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg16339924	chr4:17578868	LAP3	0.48	7.24	0.37	3.13e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1971762	0.583	rs1527068	chr12:54088688	A/G	cg23533419	chr12:54090519	NA	-0.38	-6.23	-0.32	1.41e-9	Height;
LUSC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.92	0.31	7.96e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.8	10.35	0.49	5.79e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg10523679	chr1:76189770	ACADM	-0.49	-7.26	-0.37	2.66e-12	Daytime sleep phenotypes;
LUSC	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.42	6.05	0.31	3.97e-9	Height;
LUSC	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg12002119	chr2:101014098	CHST10	0.35	5.65	0.3	3.35e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.95	0.36	1.97e-11	Cystic fibrosis severity;
LUSC	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.55	-0.38	4.24e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.43	6.66	0.34	1.15e-10	Dupuytren's disease;
LUSC	cis	rs11931598	0.702	rs10937780	chr4:7048842	A/G	cg02503808	chr4:7069936	GRPEL1	-0.42	-6.32	-0.33	8.51e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.47	7.52	0.38	5.07e-13	IgG glycosylation;
LUSC	cis	rs9309473	1.000	rs6707722	chr2:73654363	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-6.54	-0.34	2.34e-10	Metabolite levels;
LUSC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.08	0.44	9.64e-18	Motion sickness;
LUSC	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg25922239	chr6:33757077	LEMD2	0.55	8.38	0.42	1.53e-15	Crohn's disease;
LUSC	cis	rs10779751	0.734	rs2259886	chr1:11137778	C/T	cg04508216	chr1:11107452	MASP2	0.32	5.87	0.31	1.05e-8	Body mass index;
LUSC	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg03983476	chr2:10830698	NOL10	0.37	5.75	0.3	2.05e-8	Prostate cancer;
LUSC	cis	rs8027181	0.839	rs7176235	chr15:72999104	A/G	cg25632853	chr15:73088954	NA	0.32	6.62	0.34	1.47e-10	Triglyceride levels;
LUSC	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg26102564	chr10:131424627	MGMT	-0.37	-5.79	-0.3	1.59e-8	Response to temozolomide;
LUSC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg16624210	chr5:671434	TPPP	0.49	6.27	0.32	1.12e-9	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg05340658	chr4:99064831	C4orf37	0.68	11.4	0.53	1.23e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg04111992	chr7:158790115	NA	-0.44	-6.86	-0.35	3.34e-11	Facial morphology (factor 20);
LUSC	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg12483005	chr1:23474871	LUZP1	0.41	6.15	0.32	2.18e-9	Height;
LUSC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.69	-10.91	-0.51	6.33e-24	Platelet count;
LUSC	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg12163867	chr12:51592794	POU6F1	-0.43	-8.09	-0.4	1.13e-14	Cisplatin-induced ototoxicity;
LUSC	cis	rs36093844	0.752	rs79734467	chr11:85571953	C/T	cg25872744	chr11:85566296	CCDC83	-0.45	-5.78	-0.3	1.69e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg06494592	chr3:125709126	NA	-0.57	-5.83	-0.3	1.34e-8	Blood pressure (smoking interaction);
LUSC	cis	rs17401966	0.593	rs11121523	chr1:10214442	T/A	cg19773385	chr1:10388646	KIF1B	-0.46	-6.59	-0.34	1.77e-10	Hepatocellular carcinoma;
LUSC	cis	rs73206853	0.563	rs10400410	chr12:111193499	C/T	cg12870014	chr12:110450643	ANKRD13A	0.64	6.47	0.33	3.51e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg04944784	chr2:26401820	FAM59B	-0.68	-9.49	-0.46	4.45e-19	Gut microbiome composition (summer);
LUSC	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg24851651	chr11:66362959	CCS	0.55	8.04	0.4	1.57e-14	Airway imaging phenotypes;
LUSC	cis	rs2996428	0.601	rs59414187	chr1:3762815	T/C	cg22529645	chr1:3704559	LRRC47	0.36	6.2	0.32	1.69e-9	Red cell distribution width;
LUSC	cis	rs394563	0.601	rs367133	chr6:149797720	T/G	cg11245181	chr6:149772854	ZC3H12D	-0.3	-6.09	-0.32	3.17e-9	Dupuytren's disease;
LUSC	trans	rs11039798	0.698	rs78553793	chr11:48947336	C/A	cg03929089	chr4:120376271	NA	0.74	6.31	0.33	9.03e-10	Axial length;
LUSC	cis	rs6723108	0.702	rs55920206	chr2:135432066	C/T	cg12500956	chr2:135428796	TMEM163	-0.29	-6.9	-0.35	2.63e-11	Type 2 diabetes;
LUSC	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg21775007	chr8:11205619	TDH	0.44	6.57	0.34	1.96e-10	Mood instability;
LUSC	cis	rs2274273	0.870	rs10145203	chr14:55784458	A/C	cg04306507	chr14:55594613	LGALS3	0.54	11.84	0.54	2.97e-27	Protein biomarker;
LUSC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	7.48	0.38	6.51e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4664308	1.000	rs6759836	chr2:160912802	C/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.38	-0.53	1.38e-25	Idiopathic membranous nephropathy;
LUSC	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg24011408	chr12:48396354	COL2A1	0.39	5.79	0.3	1.59e-8	Glycated hemoglobin levels;
LUSC	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg12559939	chr2:27858050	GPN1	0.4	6.4	0.33	5.28e-10	Oral cavity cancer;
LUSC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	0.96	13.48	0.59	2.28e-33	Vitiligo;
LUSC	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg15001381	chr16:403314	AXIN1	0.35	6.5	0.34	2.94e-10	Bone mineral density (spine);Bone mineral density;
LUSC	trans	rs11949289	1.000	rs58572175	chr5:28343587	A/G	cg18220921	chr1:242687527	PLD5	0.35	5.96	0.31	6.57e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg26335602	chr6:28129616	ZNF389	0.46	6.06	0.31	3.64e-9	Depression;
LUSC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg21782813	chr7:2030301	MAD1L1	0.6	10.42	0.5	3.26e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs7809950	0.678	rs62482507	chr7:107024488	T/G	cg23024343	chr7:107201750	COG5	-0.68	-9.93	-0.48	1.52e-20	Coronary artery disease;
LUSC	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.84	-13.81	-0.6	1.25e-34	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.1	-0.36	7.33e-12	Major depressive disorder;
LUSC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.71	9.96	0.48	1.21e-20	Glomerular filtration rate (creatinine);
LUSC	trans	rs890100	0.902	rs971447	chr2:56737876	T/C	cg08299783	chr2:48920986	GTF2A1L;LHCGR	-0.31	-6.07	-0.32	3.5e-9	Gut microbiome composition (summer);
LUSC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg03909863	chr11:638404	DRD4	-0.41	-6.19	-0.32	1.81e-9	Systemic lupus erythematosus;
LUSC	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg20503657	chr10:835505	NA	0.54	7.17	0.37	4.71e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg04455712	chr21:45112962	RRP1B	-0.45	-8.87	-0.44	4.43e-17	Mean corpuscular volume;
LUSC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg26408565	chr15:76604113	ETFA	-0.53	-8.69	-0.43	1.65e-16	Blood metabolite levels;
LUSC	trans	rs853679	0.599	rs149990	chr6:27998258	G/A	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.14	-0.36	5.94e-12	Depression;
LUSC	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg06740227	chr12:86229804	RASSF9	0.38	6.06	0.31	3.64e-9	Major depressive disorder;
LUSC	cis	rs61931739	0.635	rs1601627	chr12:33962420	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.72	-0.35	7.9e-11	Morning vs. evening chronotype;
LUSC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.22	0.32	1.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13401104	0.796	rs10929168	chr2:237115373	C/T	cg19324714	chr2:237145437	ASB18	-0.42	-5.88	-0.31	9.68e-9	Educational attainment;
LUSC	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.75	12.09	0.55	3.82e-28	Endometrial cancer;
LUSC	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.11	-0.45	7.87e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs11809207	1.000	rs55695238	chr1:26521931	C/G	cg00300879	chr1:26503847	CNKSR1	0.31	5.87	0.31	1.05e-8	Height;
LUSC	cis	rs7923609	1.000	rs10822149	chr10:64987412	G/A	cg01631684	chr10:65280961	REEP3	-0.4	-6.26	-0.32	1.19e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4409675	0.576	rs2078328	chr1:28224976	A/G	cg23691781	chr1:28212827	C1orf38	0.31	7.43	0.38	9.31e-13	Corneal astigmatism;
LUSC	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg17507749	chr15:85114479	UBE2QP1	0.7	8.8	0.43	7.23e-17	Schizophrenia;
LUSC	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg07741184	chr6:167504864	NA	0.33	5.99	0.31	5.45e-9	Crohn's disease;
LUSC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08219700	chr8:58056026	NA	0.66	8.38	0.42	1.46e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6961069	0.585	rs10268404	chr7:80239813	C/T	cg04458919	chr7:80252533	CD36	-0.4	-7.32	-0.37	1.91e-12	Platelet count;
LUSC	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg26395211	chr5:140044315	WDR55	0.46	7.11	0.36	6.88e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg23093090	chr10:104574429	C10orf26	-0.36	-6.75	-0.35	6.6e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs8127571	0.551	rs2838986	chr21:47145374	C/T	cg11214348	chr21:47283868	PCBP3	0.43	6.16	0.32	2.11e-9	Immune reponse to smallpox (secreted IFN-alpha);
LUSC	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg21545522	chr1:205238299	TMCC2	0.46	8.63	0.43	2.61e-16	Red blood cell count;
LUSC	cis	rs932287	0.858	rs7109896	chr11:9054522	A/G	cg12365402	chr11:9010492	NRIP3	0.35	5.98	0.31	5.73e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72781680	0.821	rs55948613	chr2:24094787	A/G	cg08917208	chr2:24149416	ATAD2B	0.6	6.98	0.36	1.59e-11	Lymphocyte counts;
LUSC	cis	rs7808935	0.958	rs17156041	chr7:27975745	C/T	cg22168087	chr7:27702803	HIBADH	0.6	6.86	0.35	3.39e-11	Prostate cancer;
LUSC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg06008330	chr7:65541103	ASL	0.39	6.09	0.32	3.19e-9	Aortic root size;
LUSC	trans	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg06521331	chr12:34319734	NA	-0.42	-6.53	-0.34	2.48e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	1.03	23.14	0.78	2.27e-71	Testicular germ cell tumor;
LUSC	cis	rs41271473	1.000	rs4641285	chr1:228878663	G/A	cg16512390	chr1:228756714	NA	0.5	6.04	0.31	4.05e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg01557791	chr16:72042693	DHODH	-0.49	-7.16	-0.36	5.32e-12	Fibrinogen levels;
LUSC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg15103426	chr22:29168792	CCDC117	0.45	5.87	0.31	1.06e-8	Lymphocyte counts;
LUSC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg03806693	chr22:41940476	POLR3H	-0.72	-9.97	-0.48	1.19e-20	Vitiligo;
LUSC	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg26335602	chr6:28129616	ZNF389	0.43	5.77	0.3	1.79e-8	Depression;
LUSC	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-7.91	-0.4	3.77e-14	Chronic sinus infection;
LUSC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.74	0.35	7.06e-11	Menarche (age at onset);
LUSC	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg00012203	chr2:219082015	ARPC2	-0.77	-13.72	-0.6	2.88e-34	Colorectal cancer;
LUSC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg09365446	chr1:150670422	GOLPH3L	0.45	6.29	0.33	9.89e-10	Tonsillectomy;
LUSC	cis	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.43	-0.42	1.05e-15	Morning vs. evening chronotype;
LUSC	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg14092571	chr14:90743983	NA	0.36	5.77	0.3	1.78e-8	Mortality in heart failure;
LUSC	cis	rs2607426	0.681	rs60533951	chr19:41300484	G/A	cg05508168	chr19:41255947	C19orf54;SNRPA	1.0	6.8	0.35	4.87e-11	Blood protein levels;
LUSC	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg13647721	chr17:30228624	UTP6	0.62	6.05	0.31	3.95e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg09359103	chr1:154839909	KCNN3	-0.69	-15.95	-0.66	5.7e-43	Prostate cancer;
LUSC	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-11.18	-0.52	7.56e-25	Coffee consumption (cups per day);
LUSC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.44	-6.58	-0.34	1.85e-10	Menarche (age at onset);
LUSC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg17541715	chr7:1216824	NA	-0.4	-6.23	-0.32	1.38e-9	Longevity;Endometriosis;
LUSC	cis	rs7246967	0.673	rs118059742	chr19:22819446	T/A	cg23217946	chr19:22817039	ZNF492	0.45	6.44	0.33	4.16e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg06238570	chr21:40685208	BRWD1	-0.6	-9.94	-0.48	1.48e-20	Cognitive function;
LUSC	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-9.34	-0.46	1.36e-18	Mitochondrial DNA levels;
LUSC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	5.7	0.3	2.7e-8	Schizophrenia;
LUSC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg13206674	chr6:150067644	NUP43	0.56	8.63	0.43	2.47e-16	Lung cancer;
LUSC	cis	rs9359856	0.564	rs17228548	chr6:90439164	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.43	-0.42	1.02e-15	Bipolar disorder;
LUSC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg04352962	chr1:209979756	IRF6	0.5	6.74	0.35	7.1e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs926938	0.563	rs360642	chr1:115425429	C/G	cg01522456	chr1:115632236	TSPAN2	-0.4	-6.07	-0.32	3.53e-9	Autism;
LUSC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08704250	chr15:31115839	NA	0.59	9.24	0.45	2.97e-18	Huntington's disease progression;
LUSC	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg06636001	chr8:8085503	FLJ10661	0.61	9.39	0.46	9.56e-19	Mood instability;
LUSC	cis	rs2354432	0.607	rs57078845	chr1:146722222	G/A	cg25205988	chr1:146714368	CHD1L	-1.02	-9.45	-0.46	6.3e-19	Mitochondrial DNA levels;
LUSC	cis	rs7674212	0.570	rs1031804	chr4:104066049	C/T	cg16532752	chr4:104119610	CENPE	-0.48	-6.96	-0.36	1.83e-11	Type 2 diabetes;
LUSC	cis	rs11650494	0.831	rs8065389	chr17:47456064	G/T	cg08112188	chr17:47440006	ZNF652	-1.13	-10.27	-0.49	1.07e-21	Prostate cancer;
LUSC	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg13010199	chr12:38710504	ALG10B	0.45	6.38	0.33	5.74e-10	Morning vs. evening chronotype;
LUSC	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.52	10.42	0.5	3.46e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.78	-0.39	9.36e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18404041	chr3:52824283	ITIH1	-0.5	-9.53	-0.46	3.33e-19	Bipolar disorder;
LUSC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06634786	chr22:41940651	POLR3H	-0.54	-6.33	-0.33	7.84e-10	Vitiligo;
LUSC	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg01620082	chr3:125678407	NA	-0.82	-7.32	-0.37	1.84e-12	Depression;
LUSC	cis	rs7833986	1.000	rs72654002	chr8:57095939	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.63	9.35	0.46	1.28e-18	Height;
LUSC	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.65	-0.43	2.17e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06634786	chr22:41940651	POLR3H	-0.53	-6.5	-0.34	2.86e-10	Vitiligo;
LUSC	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg03878208	chr11:72483293	STARD10	0.46	6.88	0.35	2.9100000000000002e-11	Body mass index;
LUSC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg04518342	chr5:131593106	PDLIM4	0.48	8.82	0.43	6.41e-17	Blood metabolite levels;
LUSC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-0.73	-9.35	-0.46	1.32e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs9443645	0.527	rs949846	chr6:79817596	C/T	cg23262351	chr6:79576851	IRAK1BP1	-0.38	-5.73	-0.3	2.24e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs10085978	0.604	rs10099944	chr8:143234817	A/G	cg10785443	chr2:219827728	NA	0.36	6.15	0.32	2.16e-9	Mosquito bite size;
LUSC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.59	9.19	0.45	4.42e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.97	0.44	2.22e-17	Prudent dietary pattern;
LUSC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg06212747	chr3:49208901	KLHDC8B	0.43	5.81	0.3	1.43e-8	Parkinson's disease;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg01777103	chr8:145550585	DGAT1	0.37	6.21	0.32	1.56e-9	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14498989	chr22:39268205	CBX6	-0.4	-5.98	-0.31	5.63e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.49	0.46	4.39e-19	Bipolar disorder;
LUSC	trans	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg06606381	chr12:133084897	FBRSL1	-0.66	-7.13	-0.36	6.26e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7202877	0.572	rs8051611	chr16:75388933	C/T	cg04384234	chr16:75411784	CFDP1	-0.62	-8.71	-0.43	1.45e-16	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7106204	0.748	rs36092013	chr11:24211987	C/T	ch.11.24196551F	chr11:24239977	NA	1.13	12.76	0.57	1.21e-30	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7200543	1.000	rs4985154	chr16:15131642	G/C	cg03427771	chr16:15082598	PDXDC1	-0.42	-5.88	-0.31	9.86e-9	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
LUSC	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.44	-6.6	-0.34	1.63e-10	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg06002616	chr8:101225028	SPAG1	-0.41	-6.82	-0.35	4.37e-11	Atrioventricular conduction;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12191964	chr2:43823338	THADA	-0.47	-7.83	-0.39	6.42e-14	Electrocardiographic conduction measures;
LUSC	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	0.87	14.49	0.62	2.96e-37	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg11812906	chr14:75593930	NEK9	0.66	11.37	0.53	1.55e-25	Height;
LUSC	trans	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg05059571	chr16:84539110	KIAA1609	-0.47	-9.14	-0.45	6.17e-18	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-0.93	-15.59	-0.65	1.53e-41	Body mass index;
LUSC	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg07978099	chr16:83986941	OSGIN1	-0.43	-6.13	-0.32	2.53e-9	Pursuit maintenance gain;
LUSC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg04850211	chr1:228464232	OBSCN	0.32	5.85	0.3	1.18e-8	Diastolic blood pressure;
LUSC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.67	-9.51	-0.46	3.77e-19	Multiple sclerosis;
LUSC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg00677455	chr12:58241039	CTDSP2	-0.6	-8.68	-0.43	1.77e-16	Multiple sclerosis;
LUSC	cis	rs2219968	0.962	rs13254874	chr8:78944681	T/C	cg00738934	chr8:78996279	NA	0.38	6.81	0.35	4.41e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg18402987	chr7:1209562	NA	0.73	7.92	0.4	3.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg17366294	chr4:99064904	C4orf37	0.56	9.95	0.48	1.33e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg13010199	chr12:38710504	ALG10B	0.65	9.81	0.47	3.95e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg01879757	chr17:41196368	BRCA1	-0.47	-7.58	-0.38	3.45e-13	Menopause (age at onset);
LUSC	cis	rs9462027	0.506	rs6934662	chr6:34759884	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.32	-5.65	-0.3	3.37e-8	Systemic lupus erythematosus;
LUSC	cis	rs12618769	0.656	rs3769735	chr2:99092302	C/T	cg10123293	chr2:99228465	UNC50	0.42	7.0	0.36	1.4e-11	Bipolar disorder;
LUSC	cis	rs7818345	0.613	rs13261732	chr8:19330215	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.04	0.31	4.16e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg10547527	chr2:198650123	BOLL	-0.5	-6.13	-0.32	2.49e-9	Ulcerative colitis;
LUSC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg06238570	chr21:40685208	BRWD1	-0.64	-10.72	-0.51	3.15e-23	Cognitive function;
LUSC	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg03522245	chr20:25566470	NINL	0.35	5.67	0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7605827	0.930	rs2287273	chr2:15658523	T/C	cg19274914	chr2:15703543	NA	0.46	8.83	0.43	6.22e-17	Educational attainment (years of education);
LUSC	trans	rs62238980	0.614	rs17745543	chr22:32475456	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg09165964	chr15:75287851	SCAMP5	-0.92	-8.05	-0.4	1.43e-14	Lung cancer;
LUSC	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-1.16	-18.43	-0.71	8.09e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg15691649	chr6:25882328	NA	0.51	7.58	0.38	3.4e-13	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.05e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-0.81	-11.07	-0.52	1.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg24842967	chr1:156084750	LMNA	0.48	6.0	0.31	5.22e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg17344932	chr17:38183730	MED24;SNORD124	-0.48	-7.79	-0.39	8.35e-14	Asthma;
LUSC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg04369109	chr6:150039330	LATS1	-0.54	-7.97	-0.4	2.56e-14	Lung cancer;
LUSC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg13451222	chr11:65405525	SIPA1	0.45	5.65	0.3	3.35e-8	Blood pressure (age interaction);
LUSC	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg11494091	chr17:61959527	GH2	0.38	6.21	0.32	1.59e-9	Height;
LUSC	cis	rs2445762	0.659	rs17524318	chr15:51663386	G/A	cg07517944	chr15:51633816	GLDN	0.37	6.23	0.32	1.39e-9	Hormone measurements;
LUSC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg00945038	chr17:61921165	SMARCD2	0.54	9.45	0.46	6.03e-19	Prudent dietary pattern;
LUSC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg16479474	chr6:28041457	NA	0.32	5.72	0.3	2.31e-8	Parkinson's disease;
LUSC	cis	rs4766566	0.651	rs933306	chr12:111737985	A/T	cg10833066	chr12:111807467	FAM109A	0.56	10.62	0.5	6.88e-23	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
LUSC	cis	rs12760731	0.720	rs16852801	chr1:178403134	A/T	cg00404053	chr1:178313656	RASAL2	-0.57	-6.21	-0.32	1.53e-9	Obesity-related traits;
LUSC	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg20933634	chr6:27740509	NA	0.42	6.03	0.31	4.38e-9	Parkinson's disease;
LUSC	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.56	-10.78	-0.51	1.85e-23	Educational attainment;
LUSC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg23034840	chr1:205782522	SLC41A1	0.67	9.97	0.48	1.17e-20	Menarche (age at onset);
LUSC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg05623727	chr3:50126028	RBM5	-0.37	-6.86	-0.35	3.31e-11	Body mass index;
LUSC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22433210	chr17:43662623	NA	0.75	10.89	0.51	7.94e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6484504	0.625	rs6484501	chr11:31373100	G/T	cg06552810	chr11:31128660	NA	0.39	6.77	0.35	5.78e-11	Red blood cell count;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08118159	chr19:41055208	SPTBN4	-0.43	-6.41	-0.33	5.1e-10	Electrocardiographic conduction measures;
LUSC	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.88	14.29	0.62	1.69e-36	Coronary artery disease;
LUSC	cis	rs7091068	0.566	rs7098349	chr10:95514907	A/C	cg20715218	chr10:95462985	C10orf4	0.63	6.93	0.35	2.23e-11	Urinary tract infection frequency;
LUSC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.78	14.05	0.61	1.44e-35	Menarche (age at onset);
LUSC	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.7	-11.04	-0.52	2.33e-24	Breast size;
LUSC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg08888203	chr3:10149979	C3orf24	-0.44	-6.87	-0.35	3.15e-11	Alzheimer's disease;
LUSC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg21724239	chr8:58056113	NA	0.55	6.37	0.33	6.1e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8114671	0.933	rs2103971	chr20:33786256	T/C	cg07148914	chr20:33460835	GGT7	-0.44	-6.42	-0.33	4.59e-10	Height;
LUSC	cis	rs9653442	0.527	rs10176782	chr2:100782827	C/A	cg22139774	chr2:100720529	AFF3	-0.41	-7.12	-0.36	6.51e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg24250549	chr1:154909240	PMVK	0.64	10.53	0.5	1.42e-22	Prostate cancer;
LUSC	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.55	-0.42	4.39e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg20701182	chr2:24300061	SF3B14	0.75	7.62	0.38	2.73e-13	Lymphocyte counts;
LUSC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-11.59	-0.54	2.5e-26	Schizophrenia;
LUSC	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg08462924	chr1:41848221	NA	0.49	8.26	0.41	3.52e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg10434728	chr15:90938212	IQGAP1	0.46	9.18	0.45	4.48e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00339695	chr16:24857497	SLC5A11	0.61	9.57	0.46	2.45e-19	Intelligence (multi-trait analysis);
LUSC	trans	rs9944715	0.911	rs12969147	chr18:43806524	G/A	cg01718231	chr17:29326311	RNF135	-0.5	-7.04	-0.36	1.13e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg23950597	chr19:37808831	NA	-0.64	-7.47	-0.38	6.98e-13	Coronary artery calcification;
LUSC	cis	rs17255340	0.581	rs9449616	chr6:84100190	G/A	cg08257003	chr6:84140564	ME1	0.35	8.64	0.43	2.3e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.16	0.32	2.1e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg21775007	chr8:11205619	TDH	-0.42	-6.16	-0.32	2.06e-9	Mood instability;
LUSC	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg16070123	chr10:51489643	NA	-0.5	-7.95	-0.4	2.85e-14	Prostate-specific antigen levels;
LUSC	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg19997662	chr15:101784653	CHSY1	0.41	6.13	0.32	2.43e-9	Corneal structure;
LUSC	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.89	-15.42	-0.64	6.78e-41	Morning vs. evening chronotype;
LUSC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.52	6.51	0.34	2.72e-10	Renal function-related traits (BUN);
LUSC	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg10604040	chr11:65559109	OVOL1	0.32	5.85	0.3	1.18e-8	Acne (severe);
LUSC	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg09904177	chr6:26538194	HMGN4	-0.75	-5.79	-0.3	1.63e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg13010199	chr12:38710504	ALG10B	0.65	10.08	0.48	5.06e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg01097406	chr16:89675127	NA	0.49	9.99	0.48	9.77e-21	Vitiligo;
LUSC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg12560992	chr17:57184187	TRIM37	0.9	17.24	0.69	4.15e-48	Intelligence (multi-trait analysis);
LUSC	cis	rs524023	0.914	rs2666559	chr11:64439227	G/T	cg19131476	chr11:64387923	NRXN2	-0.22	-5.73	-0.3	2.24e-8	Urate levels in obese individuals;
LUSC	cis	rs3820928	0.874	rs10176882	chr2:227896432	A/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-7.09	-0.36	7.98e-12	Pulmonary function;
LUSC	cis	rs9309473	0.607	rs7574291	chr2:73594941	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-8.19	-0.41	5.58e-15	Metabolite levels;
LUSC	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	1.0	18.69	0.72	7.18e-54	Ewing sarcoma;
LUSC	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg02023728	chr11:77925099	USP35	0.49	6.88	0.35	3.02e-11	Testicular germ cell tumor;
LUSC	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.68	-0.43	1.76e-16	Response to antipsychotic treatment;
LUSC	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg08975724	chr8:8085496	FLJ10661	0.48	6.96	0.36	1.79e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	1.0	14.36	0.62	9.12e-37	Eosinophil percentage of granulocytes;
LUSC	trans	rs747782	0.527	rs7129364	chr11:48150576	G/A	cg03929089	chr4:120376271	NA	0.72	6.5	0.34	2.99e-10	Intraocular pressure;
LUSC	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg06462663	chr19:18546047	ISYNA1	0.49	8.25	0.41	3.6e-15	Breast cancer;
LUSC	cis	rs2932538	0.922	rs34531155	chr1:113141550	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	10.02	0.48	8.03e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg21400344	chr1:25870172	LDLRAP1	0.37	6.34	0.33	7.53e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-6.7	-0.34	8.72e-11	Tonsillectomy;
LUSC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg06915202	chr7:98029285	BAIAP2L1	-0.32	-6.32	-0.33	8.51e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg05163923	chr11:71159392	DHCR7	0.74	10.94	0.51	5.38e-24	Vitamin D levels;
LUSC	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg12091567	chr17:66097778	LOC651250	-0.91	-14.61	-0.62	9.66e-38	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs2599510	0.748	rs6718214	chr2:32550485	T/C	cg02381751	chr2:32503542	YIPF4	-0.39	-5.77	-0.3	1.78e-8	Interleukin-18 levels;
LUSC	cis	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg06521331	chr12:34319734	NA	-0.48	-7.72	-0.39	1.33e-13	Morning vs. evening chronotype;
LUSC	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg08873628	chr1:175162347	KIAA0040	0.39	5.75	0.3	2.06e-8	Alcohol dependence;
LUSC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg03732007	chr1:2071316	PRKCZ	-0.6	-11.1	-0.52	1.36e-24	Height;
LUSC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg11766577	chr21:47581405	C21orf56	-0.42	-6.35	-0.33	6.99e-10	Testicular germ cell tumor;
LUSC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg13560548	chr3:10150139	C3orf24	0.49	6.89	0.35	2.82e-11	Alzheimer's disease;
LUSC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg01657329	chr11:68192670	LRP5	-0.45	-7.13	-0.36	6.28e-12	Total body bone mineral density;
LUSC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg03609598	chr5:56110824	MAP3K1	-0.43	-6.3	-0.33	9.51e-10	Initial pursuit acceleration;
LUSC	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg12560992	chr17:57184187	TRIM37	-0.64	-10.63	-0.5	6.36e-23	Testicular germ cell tumor;
LUSC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg13770153	chr20:60521292	NA	-0.45	-6.52	-0.34	2.56e-10	Body mass index;
LUSC	trans	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.44	6.02	0.31	4.68e-9	Corneal astigmatism;
LUSC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.01	13.39	0.59	4.9e-33	Platelet count;
LUSC	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg12639453	chr1:2035780	PRKCZ	0.31	6.71	0.34	8.1e-11	Height;
LUSC	trans	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg00845942	chr12:64062724	DPY19L2	-0.62	-7.87	-0.4	5.15e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs6500395	0.962	rs9937134	chr16:48577683	T/A	cg04672837	chr16:48644449	N4BP1	0.43	6.28	0.32	1.05e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg00852783	chr1:26633632	UBXN11	-0.51	-5.82	-0.3	1.37e-8	Obesity-related traits;
LUSC	cis	rs11997175	0.550	rs7459534	chr8:33836623	G/C	ch.8.33884649F	chr8:33765107	NA	0.38	5.91	0.31	8.51e-9	Body mass index;
LUSC	cis	rs1335645	0.570	rs67493833	chr1:111649241	A/T	cg00321911	chr1:111669324	DRAM2	-0.56	-6.0	-0.31	5.01e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg22681709	chr2:178499509	PDE11A	-0.52	-9.18	-0.45	4.74e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg17127132	chr2:85788382	GGCX	-0.43	-6.7	-0.34	8.95e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	trans	rs867371	0.762	rs12905578	chr15:82581264	T/G	cg18393722	chr15:85113863	UBE2QP1	0.48	7.02	0.36	1.24e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg09904177	chr6:26538194	HMGN4	-0.51	-5.71	-0.3	2.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg05084668	chr3:125655381	ALG1L	-0.83	-11.74	-0.54	6.94e-27	Blood pressure (smoking interaction);
LUSC	trans	rs6828577	0.862	rs298994	chr4:119627253	A/G	cg26518628	chr1:97050305	NA	0.41	5.96	0.31	6.58e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
LUSC	trans	rs1035275	0.507	rs17664296	chr3:64148288	C/T	cg13925011	chr1:111216387	KCNA3	-0.31	-6.13	-0.32	2.45e-9	IgG glycosylation;
LUSC	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg00495681	chr13:53174319	NA	0.79	15.07	0.64	1.65e-39	Lewy body disease;
LUSC	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg26395211	chr5:140044315	WDR55	-0.39	-5.98	-0.31	5.86e-9	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03602528	chr17:19266095	B9D1	-0.4	-5.98	-0.31	5.88e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg23711669	chr6:146136114	FBXO30	0.74	12.93	0.58	2.73e-31	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg07870213	chr5:140052090	DND1	0.79	11.66	0.54	1.33e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03352830	chr11:487213	PTDSS2	0.69	8.67	0.43	1.9e-16	Body mass index;
LUSC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22618164	chr12:122356400	WDR66	0.58	8.71	0.43	1.42e-16	Mean corpuscular volume;
LUSC	cis	rs9650315	0.866	rs34114399	chr8:57166135	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.48	6.83	0.35	3.91e-11	Height;
LUSC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.64	8.6	0.43	3.09e-16	High light scatter reticulocyte count;
LUSC	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg03929089	chr4:120376271	NA	0.66	6.18	0.32	1.86e-9	Axial length;
LUSC	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs7512552	0.773	rs3737240	chr1:150483355	C/T	cg15654264	chr1:150340011	RPRD2	0.61	9.6	0.47	1.98e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.47	-5.7	-0.3	2.59e-8	Body mass index;
LUSC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg16743903	chr16:89593216	SPG7	-0.37	-5.81	-0.3	1.44e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg14631576	chr9:95140430	CENPP	-0.33	-5.94	-0.31	7.09e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg11062466	chr8:58055876	NA	0.53	6.94	0.36	2.01e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.58	-9.29	-0.45	2.05e-18	Lymphocyte counts;
LUSC	trans	rs72792513	1.000	rs58611583	chr2:22881278	A/G	cg05844895	chr16:88969569	CBFA2T3	0.52	6.2	0.32	1.63e-9	Hepatitis B;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00039044	chr4:83351858	ENOPH1;HNRPDL	-0.41	-6.0	-0.31	5.25e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.07	20.81	0.75	2.88e-62	Cognitive ability;
LUSC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.03	-0.36	1.2e-11	Bipolar disorder;
LUSC	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg08798685	chr6:27730294	NA	-0.63	-5.99	-0.31	5.39e-9	Breast cancer;
LUSC	cis	rs7605827	0.897	rs6745621	chr2:15537866	C/A	cg19274914	chr2:15703543	NA	0.46	8.99	0.44	1.88e-17	Educational attainment (years of education);
LUSC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg22638593	chr5:131593259	PDLIM4	0.42	6.09	0.32	3.17e-9	Breast cancer;
LUSC	trans	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg06636001	chr8:8085503	FLJ10661	0.43	6.34	0.33	7.37e-10	Retinal vascular caliber;
LUSC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.54	8.63	0.43	2.52e-16	Longevity;Endometriosis;
LUSC	cis	rs354225	0.544	rs10170355	chr2:54808322	G/A	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg08017756	chr2:100939284	LONRF2	-0.4	-7.4	-0.38	1.1e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs1325195	0.839	rs2816189	chr1:179136269	G/C	cg11624085	chr17:8464688	MYH10	0.41	6.66	0.34	1.1e-10	IgE grass sensitization;
LUSC	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg12365402	chr11:9010492	NRIP3	0.45	8.33	0.41	2.16e-15	Hemoglobin concentration;
LUSC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19346786	chr7:2764209	NA	-0.48	-8.05	-0.4	1.44e-14	Height;
LUSC	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.71	-0.3	2.47e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg27572855	chr1:25598939	RHD	0.46	8.19	0.41	5.51e-15	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	0.94	17.57	0.69	2.11e-49	Headache;
LUSC	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg10172584	chr19:19639581	YJEFN3	-0.48	-5.77	-0.3	1.85e-8	Bipolar disorder;
LUSC	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	8.27	0.41	3.29e-15	Adiposity;
LUSC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg12863693	chr15:85201151	NMB	0.34	6.78	0.35	5.6e-11	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02608231	chr3:47844363	DHX30	-0.44	-6.69	-0.34	9.42e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg06636001	chr8:8085503	FLJ10661	0.58	8.43	0.42	1.02e-15	Mean corpuscular volume;
LUSC	cis	rs7246967	0.673	rs7248107	chr19:22878529	G/T	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	trans	rs62126824	0.570	rs1370692	chr2:23620014	C/T	cg15896939	chr1:156030809	RAB25	0.42	6.07	0.32	3.43e-9	Night sleep phenotypes;
LUSC	cis	rs3741151	1.000	rs112628073	chr11:73013626	C/T	cg17517138	chr11:73019481	ARHGEF17	1.13	9.23	0.45	3.13e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs12519773	0.555	rs2578490	chr5:92389236	C/T	cg18783429	chr5:92414398	NA	0.33	7.1	0.36	7.74e-12	Migraine;
LUSC	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.27	0.41	3.21e-15	Menarche (age at onset);
LUSC	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg12927641	chr6:109611667	NA	-0.35	-5.87	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg02569458	chr12:86230093	RASSF9	0.42	6.86	0.35	3.31e-11	Major depressive disorder;
LUSC	cis	rs983392	0.679	rs611418	chr11:60011013	C/T	cg20284999	chr11:59952153	MS4A6A	0.38	6.33	0.33	7.75e-10	Alzheimer's disease (late onset);
LUSC	cis	rs78663649	1.000	rs78663649	chr19:16489447	C/T	cg05286348	chr19:16641544	CHERP	-0.6	-5.78	-0.3	1.73e-8	White blood cell count;
LUSC	cis	rs354225	0.546	rs10170646	chr2:54799606	T/C	cg26097391	chr2:54893211	SPTBN1	0.39	6.31	0.33	8.74e-10	Schizophrenia;
LUSC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg11871910	chr12:69753446	YEATS4	0.65	10.05	0.48	6e-21	Blood protein levels;
LUSC	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.54	-10.85	-0.51	1.09e-23	Glomerular filtration rate (creatinine);
LUSC	trans	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg02030672	chr11:45687055	CHST1	-0.49	-7.87	-0.4	5.01e-14	Obesity-related traits;
LUSC	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg10426581	chr7:100472382	SRRT	0.86	12.33	0.56	4.67e-29	Resting heart rate;
LUSC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08645402	chr16:4508243	NA	0.56	9.77	0.47	5.45e-20	Schizophrenia;
LUSC	trans	rs2894969	0.664	rs11252703	chr10:4795125	A/T	cg19303637	chr13:24153954	TNFRSF19	0.35	6.06	0.31	3.65e-9	Major depressive disorder;
LUSC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg13119609	chr19:45449297	APOC2	0.47	9.46	0.46	5.65e-19	Blood protein levels;
LUSC	cis	rs7216064	1.000	rs7212293	chr17:65847325	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-9.63	-0.47	1.6e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs6087990	0.735	rs2424928	chr20:31388636	T/C	cg13636640	chr20:31349939	DNMT3B	0.92	18.94	0.72	7.43e-55	Ulcerative colitis;
LUSC	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg15534755	chr11:117069859	TAGLN	0.35	5.74	0.3	2.18e-8	Blood protein levels;
LUSC	cis	rs1178968	0.901	rs799303	chr7:72804412	A/C	cg25889504	chr7:72793014	NA	-0.64	-8.47	-0.42	7.91e-16	Triglyceride levels;
LUSC	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg03538708	chr1:25844672	NA	-0.36	-5.84	-0.3	1.22e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs6967385	0.560	rs34130399	chr7:12356746	T/A	cg06484146	chr7:12443880	VWDE	0.5	7.51	0.38	5.42e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg11062466	chr8:58055876	NA	0.51	6.96	0.36	1.84e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg26769984	chr7:1090371	C7orf50	0.66	8.74	0.43	1.17e-16	Bronchopulmonary dysplasia;
LUSC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg05425664	chr17:57184151	TRIM37	0.54	8.6	0.43	3.07e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs11168618	0.935	rs2114322	chr12:48951607	A/G	cg24011408	chr12:48396354	COL2A1	-0.37	-6.04	-0.31	4.13e-9	Adiponectin levels;
LUSC	cis	rs7264396	0.887	rs224362	chr20:34062642	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-5.93	-0.31	7.69e-9	Total cholesterol levels;
LUSC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.35	5.65	0.3	3.47e-8	Systemic lupus erythematosus;
LUSC	cis	rs477692	0.569	rs10764882	chr10:131306496	C/G	cg05714579	chr10:131428358	MGMT	0.41	5.75	0.3	2.06e-8	Response to temozolomide;
LUSC	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.72	9.39	0.46	9.58e-19	Gastritis;
LUSC	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.46	0.53	7.16e-26	Eye color traits;
LUSC	cis	rs7017697	1.000	rs10092772	chr8:19686385	A/T	cg03894339	chr8:19674705	INTS10	-0.46	-6.72	-0.34	7.99e-11	Breast cancer;
LUSC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg16680214	chr1:154839983	KCNN3	-0.52	-9.76	-0.47	5.77e-20	Prostate cancer;
LUSC	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.34	-0.33	7.25e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg12559939	chr2:27858050	GPN1	-0.41	-6.34	-0.33	7.36e-10	Oral cavity cancer;
LUSC	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg03929089	chr4:120376271	NA	0.69	7.78	0.39	9.14e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg15660573	chr17:549704	VPS53	-0.68	-10.31	-0.49	7.98e-22	Prostate cancer;
LUSC	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg09517075	chr8:22133004	PIWIL2	0.43	8.9	0.44	3.61e-17	Hypertriglyceridemia;
LUSC	cis	rs9361491	0.657	rs9343804	chr6:79468052	G/A	cg05283184	chr6:79620031	NA	-0.31	-5.66	-0.3	3.22e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg00784671	chr22:46762841	CELSR1	-0.49	-6.42	-0.33	4.56e-10	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	0.95	14.3	0.62	1.54e-36	Dupuytren's disease;
LUSC	cis	rs9400467	0.592	rs462493	chr6:111683740	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg04733989	chr22:42467013	NAGA	0.62	9.64	0.47	1.48e-19	Schizophrenia;
LUSC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-1.18	-14.3	-0.62	1.62e-36	Breast cancer;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21099776	chr17:17739742	SREBF1	-0.42	-6.22	-0.32	1.52e-9	Hepatitis;
LUSC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	9.75	0.47	6.45e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs10193935	1.000	rs58962161	chr2:42400278	T/A	cg27598129	chr2:42591480	NA	-0.55	-7.56	-0.38	3.91e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-12.21	-0.56	1.35e-28	Chronic sinus infection;
LUSC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11905131	chr22:24372483	LOC391322	-0.42	-6.89	-0.35	2.75e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.26	-0.32	1.19e-9	Breast cancer;
LUSC	cis	rs1712517	0.503	rs72846198	chr10:105098024	G/A	cg04362960	chr10:104952993	NT5C2	-0.52	-6.95	-0.36	1.89e-11	Migraine;
LUSC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg02931644	chr1:25747376	RHCE	0.38	7.07	0.36	9.08e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg03146154	chr1:46216737	IPP	-0.51	-7.73	-0.39	1.3e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg24642844	chr7:1081250	C7orf50	-0.79	-10.58	-0.5	9.41e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg26695010	chr11:65641043	EFEMP2	-0.46	-7.01	-0.36	1.32e-11	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	trans	rs17169634	1.000	rs6950651	chr7:34076802	A/C	cg18512313	chr14:70700886	NA	0.61	6.25	0.32	1.29e-9	Alzheimer's disease;
LUSC	cis	rs4654899	0.833	rs10916919	chr1:21317524	A/G	cg01072550	chr1:21505969	NA	0.53	8.02	0.4	1.85e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs9467160	0.734	rs9467170	chr6:24452754	G/A	cg20631270	chr6:24437470	GPLD1	0.41	5.66	0.3	3.24e-8	Liver enzyme levels;
LUSC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg10909506	chr17:38081995	ORMDL3	0.35	6.22	0.32	1.45e-9	Self-reported allergy;
LUSC	cis	rs4363385	0.740	rs4845518	chr1:153003903	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-5.71	-0.3	2.45e-8	Inflammatory skin disease;
LUSC	cis	rs75920871	0.528	rs3886960	chr11:116924990	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.42	-0.33	4.69e-10	Subjective well-being;
LUSC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg01802117	chr1:53393560	SCP2	0.39	6.46	0.33	3.72e-10	Monocyte count;
LUSC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg20283391	chr11:68216788	NA	-0.58	-8.17	-0.41	6.64e-15	Total body bone mineral density;
LUSC	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg01420254	chr6:26195488	NA	0.51	6.3	0.33	9.56e-10	Gout;Renal underexcretion gout;
LUSC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03264133	chr6:25882463	NA	0.43	7.49	0.38	6.03e-13	Blood metabolite levels;
LUSC	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg22705602	chr4:152727874	NA	-0.37	-7.97	-0.4	2.51e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs73206853	0.841	rs2339511	chr12:110789372	C/T	cg12870014	chr12:110450643	ANKRD13A	0.59	6.6	0.34	1.58e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	9.47	0.46	5.4e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.04	0.36	1.07e-11	Multiple sclerosis;
LUSC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.45	-7.17	-0.37	4.77e-12	IgG glycosylation;
LUSC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg02782426	chr3:40428986	ENTPD3	-0.32	-5.76	-0.3	1.96e-8	Renal cell carcinoma;
LUSC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg03526776	chr6:41159608	TREML2	0.47	8.71	0.43	1.39e-16	Alzheimer's disease (late onset);
LUSC	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs981844	0.714	rs6853529	chr4:154706267	C/T	cg14289246	chr4:154710475	SFRP2	0.53	7.31	0.37	1.93e-12	Response to statins (LDL cholesterol change);
LUSC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.8	-0.39	8.06e-14	Height;
LUSC	cis	rs7715806	0.500	rs3797581	chr5:75002895	G/T	cg19683494	chr5:74908142	NA	0.55	7.51	0.38	5.54e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3106136	0.546	rs2664880	chr4:95144177	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.59	-0.43	3.3e-16	Capecitabine sensitivity;
LUSC	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg08017756	chr2:100939284	LONRF2	-0.41	-7.64	-0.39	2.38e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1256061	0.603	rs1256039	chr14:64738979	G/C	cg21174375	chr14:64681225	SYNE2	0.35	6.26	0.32	1.19e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs4845459	0.967	rs1886734	chr1:152591142	A/C	cg08895932	chr1:152778580	LCE1C	-0.36	-6.3	-0.33	9.62e-10	Psoriasis;
LUSC	cis	rs7408868	0.656	rs1043997	chr19:15292437	T/C	cg14696996	chr19:15285081	NOTCH3	0.63	6.71	0.34	8.55e-11	Pulse pressure;
LUSC	cis	rs6977660	1.000	rs12666159	chr7:19804199	T/C	cg05791153	chr7:19748676	TWISTNB	0.55	6.19	0.32	1.72e-9	Thyroid stimulating hormone;
LUSC	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg19629631	chr7:2060116	MAD1L1	-0.35	-5.76	-0.3	1.95e-8	Neuroticism;
LUSC	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-0.9	-18.23	-0.71	4.98e-52	Urate levels in lean individuals;
LUSC	trans	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg21775007	chr8:11205619	TDH	0.49	6.84	0.35	3.71e-11	Neuroticism;
LUSC	trans	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.25	-0.32	1.28e-9	Bladder cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07444005	chr13:21678461	NA	0.58	8.24	0.41	3.97e-15	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-7.11	-0.36	7.27e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs60154123	0.772	rs701944	chr1:210417098	G/A	cg22029157	chr1:209979665	IRF6	0.64	6.47	0.33	3.59e-10	Coronary artery disease;
LUSC	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg03585969	chr10:35415529	CREM	0.6	8.98	0.44	1.95e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg13042288	chr15:90349979	ANPEP	-0.46	-6.6	-0.34	1.63e-10	Uric acid levels;
LUSC	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.65	9.84	0.47	3.09e-20	Corneal astigmatism;
LUSC	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	8.8	0.43	7.64e-17	Height;
LUSC	trans	rs12145833	0.596	rs12026068	chr1:243440352	A/G	cg01826367	chr1:224180288	NA	0.63	5.95	0.31	6.62e-9	Obesity (early onset extreme);
LUSC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	7.28	0.37	2.45e-12	Mood instability;
LUSC	cis	rs4919687	0.550	rs11191372	chr10:104462187	T/C	cg05855489	chr10:104503620	C10orf26	0.71	11.56	0.53	3.16e-26	Colorectal cancer;
LUSC	cis	rs7572733	0.534	rs7572123	chr2:198769637	A/G	cg00792783	chr2:198669748	PLCL1	0.46	6.2	0.32	1.68e-9	Dermatomyositis;
LUSC	cis	rs897080	0.552	rs1067320	chr2:44633122	A/G	cg00619915	chr2:44497795	NA	-0.41	-5.8	-0.3	1.54e-8	Height;
LUSC	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg25251562	chr2:3704773	ALLC	-0.49	-7.52	-0.38	5.1e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.09	15.87	0.66	1.14e-42	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19717773	chr7:2847554	GNA12	-0.39	-6.43	-0.33	4.34e-10	Height;
LUSC	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.77	-12.85	-0.58	5.65e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg17757837	chr7:157058334	UBE3C	0.82	13.04	0.58	1.07e-31	Body mass index;
LUSC	cis	rs7590368	0.715	rs72779474	chr2:10965980	G/A	cg15705551	chr2:10952987	PDIA6	0.61	6.68	0.34	1.01e-10	Educational attainment (years of education);
LUSC	cis	rs2692947	0.666	rs7566050	chr2:96626030	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.26	0.32	1.2e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-1.04	-20.21	-0.74	7.12e-60	Height;
LUSC	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg22467129	chr15:76604101	ETFA	-0.44	-7.05	-0.36	1.06e-11	Blood metabolite levels;
LUSC	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg20744362	chr22:50050164	C22orf34	0.36	6.54	0.34	2.33e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2274273	0.870	rs11851169	chr14:55815932	G/A	cg04306507	chr14:55594613	LGALS3	0.53	11.62	0.54	1.95e-26	Protein biomarker;
LUSC	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg06917634	chr15:78832804	PSMA4	0.75	12.65	0.57	3.07e-30	Sudden cardiac arrest;
LUSC	cis	rs9513627	0.915	rs73556174	chr13:100121797	T/C	cg25919922	chr13:100150906	NA	-0.8	-6.96	-0.36	1.83e-11	Obesity-related traits;
LUSC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg17279839	chr7:150038598	RARRES2	0.54	7.89	0.4	4.38e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.42	0.5	3.24e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg05717871	chr11:638507	DRD4	-0.34	-5.9	-0.31	8.74e-9	Systemic lupus erythematosus;
LUSC	cis	rs56283067	0.847	rs1552196	chr6:44698265	A/G	cg20913747	chr6:44695427	NA	0.43	6.87	0.35	3.08e-11	Total body bone mineral density;
LUSC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg18758796	chr5:131593413	PDLIM4	0.38	6.67	0.34	1.06e-10	Blood metabolite levels;
LUSC	trans	rs1532331	0.898	rs10075647	chr5:43149499	C/T	cg17870909	chr21:47566968	FTCD	0.26	6.13	0.32	2.51e-9	Menarche (age at onset);
LUSC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg07414643	chr4:187882934	NA	0.54	9.87	0.48	2.56e-20	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14577476	chr17:49337432	MBTD1;UTP18	-0.37	-6.32	-0.33	8.53e-10	Electrocardiographic conduction measures;
LUSC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.53	6.86	0.35	3.3e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	9.24	0.45	3.06e-18	Response to antipsychotic treatment;
LUSC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	0.9	13.47	0.59	2.53e-33	Menopause (age at onset);
LUSC	trans	rs877282	0.583	rs11253428	chr10:823233	C/T	cg22713356	chr15:30763199	NA	0.75	9.37	0.46	1.12e-18	Uric acid levels;
LUSC	trans	rs953492	0.644	rs3896337	chr1:243414066	C/T	cg25284624	chr1:224180302	NA	-0.44	-6.73	-0.35	7.41e-11	Diastolic blood pressure;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08081407	chr3:57583693	ARF4	0.44	7.05	0.36	1e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg27205649	chr11:78285834	NARS2	0.5	6.09	0.32	3.12e-9	Alzheimer's disease (survival time);
LUSC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg06145435	chr7:1022769	CYP2W1	0.33	5.71	0.3	2.56e-8	Bronchopulmonary dysplasia;
LUSC	trans	rs72674100	1.000	rs72880598	chr4:97988599	A/G	cg16405019	chr1:18959625	PAX7	-0.58	-6.33	-0.33	7.76e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7122539	0.506	rs7944999	chr11:66687863	A/G	cg24851651	chr11:66362959	CCS	0.45	7.82	0.39	7.17e-14	HIV-1 susceptibility;
LUSC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.71	0.47	8.23e-20	Lung cancer;
LUSC	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg15147215	chr3:52552868	STAB1	-0.35	-6.97	-0.36	1.69e-11	Electroencephalogram traits;
LUSC	cis	rs10465746	0.967	rs12757632	chr1:84416408	T/C	cg10977910	chr1:84465055	TTLL7	0.43	6.33	0.33	7.96e-10	Obesity-related traits;
LUSC	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg13615516	chr5:77269221	NA	0.4	6.76	0.35	6.09e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg04450456	chr4:17643702	FAM184B	-0.35	-5.85	-0.3	1.17e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.83	0.3	1.29e-8	Rheumatoid arthritis;
LUSC	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg05775895	chr3:12838266	CAND2	0.5	8.66	0.43	2.11e-16	P wave duration;
LUSC	cis	rs9361491	0.508	rs9343789	chr6:79426581	A/G	cg05283184	chr6:79620031	NA	-0.39	-6.82	-0.35	4.26e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7106204	0.514	rs12789549	chr11:24254726	C/G	ch.11.24196551F	chr11:24239977	NA	0.92	10.14	0.49	3.15e-21	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg21782813	chr7:2030301	MAD1L1	-0.49	-8.28	-0.41	2.99e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg09323728	chr8:95962352	TP53INP1	-0.36	-7.22	-0.37	3.44e-12	Type 2 diabetes;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg00533393	chr11:747458	TALDO1	0.7	6.45	0.33	3.91e-10	Body mass index;
LUSC	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg24296786	chr1:45957014	TESK2	0.45	6.59	0.34	1.71e-10	High light scatter reticulocyte count;
LUSC	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.57	-9.26	-0.45	2.59e-18	Schizophrenia;
LUSC	cis	rs12681287	0.752	rs1436628	chr8:87313345	C/G	cg27223183	chr8:87520930	FAM82B	0.49	6.1	0.32	2.99e-9	Caudate activity during reward;
LUSC	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02018176	chr4:1364513	KIAA1530	0.72	12.87	0.58	4.52e-31	Longevity;
LUSC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg10857441	chr5:6722123	POLS	-0.44	-8.06	-0.4	1.4e-14	Menopause (age at onset);
LUSC	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg16482183	chr6:26056742	HIST1H1C	1.07	13.68	0.6	3.98e-34	Iron status biomarkers;
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg16103275	chr6:290800	DUSP22	-0.42	-7.21	-0.37	3.83e-12	Menopause (age at onset);
LUSC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.19	-13.56	-0.6	1.16e-33	Diabetic kidney disease;
LUSC	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg14092571	chr14:90743983	NA	-0.35	-5.71	-0.3	2.45e-8	Mortality in heart failure;
LUSC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg03146154	chr1:46216737	IPP	0.5	7.41	0.38	1.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg08847533	chr14:75593920	NEK9	0.84	14.69	0.63	4.81e-38	Height;
LUSC	cis	rs7804356	1.000	rs10229837	chr7:26840652	G/A	cg03456212	chr7:26904342	SKAP2	-0.55	-6.47	-0.33	3.54e-10	Type 1 diabetes;
LUSC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	10.67	0.5	4.71e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2109514	0.650	rs12531767	chr7:116129005	T/A	cg12739419	chr7:116140593	CAV2	-0.27	-5.77	-0.3	1.77e-8	Prevalent atrial fibrillation;
LUSC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg12963246	chr6:28129442	ZNF389	0.54	7.47	0.38	7.25e-13	Depression;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13802269	chr4:120133706	USP53	0.77	6.15	0.32	2.16e-9	Cognitive performance;
LUSC	cis	rs1784581	0.588	rs9346894	chr6:162430763	T/C	cg17173639	chr6:162384350	PARK2	0.58	10.02	0.48	7.54e-21	Itch intensity from mosquito bite;
LUSC	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.72	11.13	0.52	1.13e-24	Alcohol dependence;
LUSC	cis	rs34421088	0.532	rs2409754	chr8:11155613	A/G	cg21775007	chr8:11205619	TDH	0.49	7.24	0.37	3.19e-12	Neuroticism;
LUSC	cis	rs965513	1.000	rs7021576	chr9:100540541	C/T	cg13688889	chr9:100608707	NA	-0.56	-8.32	-0.41	2.35e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.13	-0.41	8.59e-15	Chronic sinus infection;
LUSC	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg11645453	chr3:52864694	ITIH4	0.47	10.62	0.5	7.08e-23	Schizophrenia;
LUSC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg24829409	chr8:58192753	C8orf71	0.58	6.33	0.33	7.89e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.17	-0.32	1.98e-9	Resting heart rate;
LUSC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg09021430	chr5:549028	NA	-0.53	-6.97	-0.36	1.7e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs10789491	0.767	rs4660359	chr1:47190019	C/G	cg15501359	chr1:47185051	KIAA0494	0.71	9.19	0.45	4.22e-18	Response to hepatitis C treatment;
LUSC	cis	rs6782228	0.606	rs2712405	chr3:128332082	T/C	cg16766828	chr3:128327626	NA	-0.32	-5.84	-0.3	1.25e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg10857441	chr5:6722123	POLS	-0.44	-8.06	-0.4	1.36e-14	Menopause (age at onset);
LUSC	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	9.73	0.47	7.58e-20	Lung cancer in ever smokers;
LUSC	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg18850127	chr7:39170497	POU6F2	0.62	9.37	0.46	1.12e-18	IgG glycosylation;
LUSC	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg13628971	chr7:2884303	GNA12	0.46	6.79	0.35	5.03e-11	Height;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg26626185	chr16:74808370	FA2H	0.68	6.14	0.32	2.38e-9	Cognitive performance;
LUSC	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.5	-0.46	4.07e-19	Schizophrenia;
LUSC	trans	rs1325195	0.920	rs9726961	chr1:179089475	C/G	cg11624085	chr17:8464688	MYH10	-0.44	-7.38	-0.37	1.25e-12	IgE grass sensitization;
LUSC	cis	rs4845459	0.967	rs4845453	chr1:152591953	C/G	cg08895932	chr1:152778580	LCE1C	-0.35	-6.02	-0.31	4.57e-9	Psoriasis;
LUSC	cis	rs12681287	0.547	rs9297922	chr8:87542317	A/G	cg27223183	chr8:87520930	FAM82B	0.53	6.99	0.36	1.54e-11	Caudate activity during reward;
LUSC	cis	rs2692947	0.567	rs4907276	chr2:96391109	G/T	cg23100626	chr2:96804247	ASTL	-0.25	-5.77	-0.3	1.84e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs72792276	0.818	rs57249773	chr5:127463166	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	7.84	0.39	5.98e-14	Red cell distribution width;
LUSC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-1.03	-20.07	-0.74	2.47e-59	Height;
LUSC	trans	rs2392780	0.536	rs437980	chr8:128335246	A/C	cg10897648	chr18:56338258	MALT1	-0.41	-6.17	-0.32	1.92e-9	Breast cancer (early onset);
LUSC	cis	rs7589342	0.895	rs2033008	chr2:106502585	T/A	cg16077055	chr2:106428750	NCK2	0.34	6.29	0.33	1.02e-9	Addiction;
LUSC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.77	11.09	0.52	1.55e-24	Corneal astigmatism;
LUSC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.75	12.15	0.55	2.24e-28	Cognitive function;
LUSC	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg09184832	chr6:79620586	NA	-0.43	-6.96	-0.36	1.76e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2239815	0.515	rs5762839	chr22:29231447	C/T	cg02153584	chr22:29168773	CCDC117	0.57	6.71	0.34	8.38e-11	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LUSC	cis	rs7131987	0.617	rs3764953	chr12:29502236	T/C	cg09582351	chr12:29534625	ERGIC2	-0.35	-7.15	-0.36	5.49e-12	QT interval;
LUSC	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg22676075	chr6:135203613	NA	-0.62	-10.0	-0.48	8.77e-21	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs57590327	0.503	rs11706976	chr3:81899653	C/T	cg07356753	chr3:81810745	GBE1	-0.65	-10.3	-0.49	8.94e-22	Extraversion;
LUSC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-12.4	-0.56	2.66e-29	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7605827	0.930	rs6708288	chr2:15535477	A/G	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.52	10.42	0.5	3.46e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg05941027	chr17:61774174	LIMD2	0.22	5.72	0.3	2.4e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.93	0.31	7.55e-9	Menopause (age at onset);
LUSC	cis	rs9283706	0.764	rs17218390	chr5:66280426	A/G	cg11590213	chr5:66331682	MAST4	0.41	5.96	0.31	6.27e-9	Coronary artery disease;
LUSC	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg13010199	chr12:38710504	ALG10B	0.61	9.53	0.46	3.47e-19	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-1.03	-9.27	-0.45	2.31e-18	Mitochondrial DNA levels;
LUSC	cis	rs9948	0.786	rs62156225	chr2:97414118	T/C	cg01990225	chr2:97406019	LMAN2L	-0.78	-5.86	-0.31	1.1e-8	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg04036182	chr15:45458818	NA	0.35	5.72	0.3	2.32e-8	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg11663144	chr21:46675770	NA	-0.41	-7.14	-0.36	5.99e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.98	-0.4	2.44e-14	Schizophrenia;
LUSC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10150615	chr22:24372951	LOC391322	-0.43	-7.13	-0.36	6.06e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-0.82	-10.08	-0.48	4.74e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	0.9	13.22	0.59	2.17e-32	Breast cancer;
LUSC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11764359	chr7:65958608	NA	0.68	11.06	0.52	2e-24	Aortic root size;
LUSC	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg18753928	chr3:113234510	CCDC52	-0.52	-8.01	-0.4	1.99e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg06627628	chr2:24431161	ITSN2	0.61	8.89	0.44	3.99e-17	Asthma;
LUSC	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg06740227	chr12:86229804	RASSF9	-0.37	-5.85	-0.3	1.16e-8	Major depressive disorder;
LUSC	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.53	8.01	0.4	1.94e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4363385	0.747	rs1415970	chr1:152965741	G/C	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.66	-0.39	2.08e-13	Inflammatory skin disease;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21439498	chr19:59086698	MGC2752	-0.41	-5.97	-0.31	6.01e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg22920501	chr2:26401640	FAM59B	-0.55	-7.33	-0.37	1.71e-12	Gut microbiome composition (summer);
LUSC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	13.99	0.61	2.45e-35	Total body bone mineral density;
LUSC	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-1.13	-18.15	-0.7	1.04e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg21775007	chr8:11205619	TDH	-0.65	-10.32	-0.49	7.26e-22	Retinal vascular caliber;
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg16132339	chr22:24313637	DDTL;DDT	0.41	6.43	0.33	4.37e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg12267291	chr8:126010467	SQLE	0.35	6.63	0.34	1.32e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg16099169	chr2:106886729	NA	-0.53	-6.54	-0.34	2.25e-10	Facial morphology (factor 23);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09130549	chr8:97247213	UQCRB	0.8	6.21	0.32	1.62e-9	Cognitive performance;
LUSC	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg17507749	chr15:85114479	UBE2QP1	0.58	7.12	0.36	6.59e-12	Schizophrenia;
LUSC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg06600287	chr1:53387719	ECHDC2	-0.28	-6.07	-0.32	3.52e-9	Monocyte count;
LUSC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-7.03	-0.36	1.18e-11	Blood metabolite levels;
LUSC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26314531	chr2:26401878	FAM59B	-0.69	-9.44	-0.46	6.75e-19	Gut microbiome composition (summer);
LUSC	cis	rs7528419	0.617	rs4970834	chr1:109814880	C/T	cg00908766	chr1:109817496	CELSR2	-0.61	-9.22	-0.45	3.53e-18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUSC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg02136620	chr5:178986620	RUFY1	-0.46	-7.12	-0.36	6.68e-12	Lung cancer;
LUSC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs1979679	0.573	rs4930825	chr12:28727107	A/G	cg13890972	chr12:28721907	NA	-0.41	-6.0	-0.31	5.13e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs6574644	1.000	rs6574641	chr14:81774111	T/C	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	0.98	8.12	0.41	9.29e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs59698941	0.882	rs66537260	chr5:132309237	C/T	cg14825688	chr5:132208181	LEAP2	-0.54	-5.75	-0.3	2.01e-8	Apolipoprotein A-IV levels;
LUSC	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.45	-0.42	9.36e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-17.6	-0.69	1.63e-49	Body mass index;
LUSC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg07741184	chr6:167504864	NA	0.39	6.93	0.35	2.12e-11	Primary biliary cholangitis;
LUSC	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg24296786	chr1:45957014	TESK2	0.44	6.06	0.31	3.75e-9	Red blood cell count;Reticulocyte count;
LUSC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	14.13	0.61	7.23e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg09491104	chr22:46646882	C22orf40	-0.7	-6.82	-0.35	4.32e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.86	-0.31	1.08e-8	Total body bone mineral density;
LUSC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.08	-0.32	3.37e-9	Platelet count;
LUSC	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg04374321	chr14:90722782	PSMC1	0.76	12.04	0.55	5.82e-28	Mortality in heart failure;
LUSC	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg20243544	chr17:37824526	PNMT	0.39	5.76	0.3	1.96e-8	Self-reported allergy;
LUSC	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg01620082	chr3:125678407	NA	-0.81	-7.15	-0.36	5.36e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs8022206	0.659	rs986383	chr14:68327447	A/C	cg15809352	chr2:121748218	GLI2	0.45	6.58	0.34	1.8e-10	Platelet count;Mean platelet volume;
LUSC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg22907277	chr7:1156413	C7orf50	0.68	7.36	0.37	1.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs244293	1.000	rs244288	chr17:53231841	G/A	cg19360675	chr17:53046073	COX11;STXBP4	-0.4	-5.71	-0.3	2.52e-8	Menarche (age at onset);
LUSC	trans	rs2700987	0.692	rs6953856	chr7:37386089	T/A	cg26076750	chr5:98105150	RGMB	-0.37	-6.63	-0.34	1.36e-10	Psoriasis vulgaris;Psoriasis;
LUSC	cis	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.88	-0.31	9.71e-9	Eotaxin levels;
LUSC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg10657630	chr21:48055338	PRMT2	0.38	5.84	0.3	1.26e-8	Testicular germ cell tumor;
LUSC	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg11789530	chr4:8429930	ACOX3	-0.41	-6.18	-0.32	1.82e-9	Response to antineoplastic agents;
LUSC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg07424592	chr7:64974309	NA	0.71	6.19	0.32	1.72e-9	Diabetic kidney disease;
LUSC	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg14664628	chr15:75095509	CSK	0.52	6.67	0.34	1.09e-10	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	trans	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07923666	chr12:49932857	KCNH3	-0.53	-6.53	-0.34	2.42e-10	Resting heart rate;
LUSC	cis	rs2637266	0.935	rs4520537	chr10:78392978	C/T	cg18941641	chr10:78392320	NA	0.41	7.45	0.38	8.27e-13	Pulmonary function;
LUSC	trans	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.09	-0.32	3.02e-9	Depression;
LUSC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06634786	chr22:41940651	POLR3H	0.52	6.16	0.32	2.11e-9	Vitiligo;
LUSC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg22907277	chr7:1156413	C7orf50	0.49	7.56	0.38	3.84e-13	Longevity;Endometriosis;
LUSC	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-8.79	-0.43	8.06e-17	Response to antipsychotic treatment;
LUSC	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg13206674	chr6:150067644	NUP43	0.56	8.73	0.43	1.2e-16	Lung cancer;
LUSC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg02038168	chr22:39784481	NA	-0.47	-7.86	-0.4	5.34e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg04455712	chr21:45112962	RRP1B	0.42	7.86	0.39	5.49e-14	Mean corpuscular volume;
LUSC	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.54	8.7	0.43	1.52e-16	Breast cancer;
LUSC	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg25173405	chr17:45401733	C17orf57	0.37	5.75	0.3	2.01e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg16011800	chr17:1958478	HIC1	0.46	6.17	0.32	1.94e-9	Lymphocyte counts;Red cell distribution width;
LUSC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg23625390	chr15:77176239	SCAPER	0.5	7.73	0.39	1.31e-13	Blood metabolite levels;
LUSC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg21733973	chr7:65235735	NA	0.43	6.13	0.32	2.5e-9	Calcium levels;
LUSC	cis	rs9399401	1.000	rs1040525	chr6:142703669	C/T	cg03128060	chr6:142623767	GPR126	0.32	5.94	0.31	7.24e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg23649088	chr2:200775458	C2orf69	-0.54	-6.85	-0.35	3.55e-11	Schizophrenia;
LUSC	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg09526685	chr4:187126073	CYP4V2	0.53	5.72	0.3	2.43e-8	Blood protein levels;
LUSC	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg19920283	chr7:105172520	RINT1	0.57	6.08	0.32	3.34e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg10518543	chr12:38710700	ALG10B	0.41	5.79	0.3	1.62e-8	Morning vs. evening chronotype;
LUSC	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg00012203	chr2:219082015	ARPC2	-0.7	-11.58	-0.54	2.78e-26	Colorectal cancer;
LUSC	cis	rs2279817	1.000	rs4920619	chr1:18023112	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.47	6.54	0.34	2.32e-10	Neuroticism;
LUSC	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.63	-0.39	2.45e-13	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg07701084	chr6:150067640	NUP43	0.49	7.26	0.37	2.69e-12	Lung cancer;
LUSC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg20608306	chr11:116969690	SIK3	0.38	6.33	0.33	8.09e-10	Blood protein levels;
LUSC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	6.74	0.35	7.17e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg13010199	chr12:38710504	ALG10B	-0.49	-7.45	-0.38	8.18e-13	Morning vs. evening chronotype;
LUSC	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg10909506	chr17:38081995	ORMDL3	0.34	6.07	0.32	3.55e-9	Self-reported allergy;
LUSC	trans	rs1864585	0.520	rs17776427	chr8:10672972	G/T	cg26278703	chr11:58910052	FAM111A	0.58	6.3	0.33	9.3e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUSC	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg23711669	chr6:146136114	FBXO30	0.78	12.61	0.57	4.33e-30	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg07414643	chr4:187882934	NA	-0.38	-6.17	-0.32	2.03e-9	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-0.98	-17.61	-0.69	1.49e-49	Height;
LUSC	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	7.42	0.38	9.78e-13	Glomerular filtration rate (creatinine);
LUSC	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg02038168	chr22:39784481	NA	-0.49	-8.02	-0.4	1.78e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg26769984	chr7:1090371	C7orf50	0.57	7.16	0.36	5.3e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05901451	chr6:126070800	HEY2	0.57	8.57	0.42	3.94e-16	Endometrial cancer;
LUSC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	6.07	0.32	3.42e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg02376097	chr19:46275166	DMPK	0.4	6.99	0.36	1.49e-11	Coronary artery disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg10339344	chr11:60674203	PRPF19	0.46	6.35	0.33	6.88e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6961069	0.538	rs3173800	chr7:80289921	A/T	cg04458919	chr7:80252533	CD36	-0.38	-6.52	-0.34	2.58e-10	Platelet count;
LUSC	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.76	0.35	6.2e-11	Corneal astigmatism;
LUSC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06634786	chr22:41940651	POLR3H	0.48	5.68	0.3	2.95e-8	Cannabis dependence symptom count;
LUSC	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg22907277	chr7:1156413	C7orf50	0.72	7.61	0.38	2.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7607369	0.559	rs13002060	chr2:219660394	G/T	cg02176678	chr2:219576539	TTLL4	-0.54	-9.62	-0.47	1.72e-19	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.72	-0.35	7.84e-11	Response to antipsychotic treatment;
LUSC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.98	0.36	1.58e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg16339924	chr4:17578868	LAP3	0.57	8.81	0.43	6.77e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.42	6.17	0.32	2.03e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg13319975	chr6:146136371	FBXO30	0.48	7.25	0.37	3.01e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.59	-8.06	-0.4	1.37e-14	Red cell distribution width;
LUSC	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg06092702	chr1:163392909	NA	-0.44	-7.53	-0.38	4.83e-13	Motion sickness;
LUSC	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-9.3	-0.45	1.86e-18	Morning vs. evening chronotype;
LUSC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg07741184	chr6:167504864	NA	0.37	6.72	0.35	7.82e-11	Crohn's disease;
LUSC	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-6.24	-0.32	1.35e-9	Neutrophil percentage of white cells;
LUSC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg18350739	chr11:68623251	NA	-0.36	-6.35	-0.33	7.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.77	-11.0	-0.52	3.19e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg03585969	chr10:35415529	CREM	0.62	9.08	0.44	9.71e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7180079	0.544	rs4777594	chr15:65076993	A/G	cg08069370	chr15:64387884	SNX1	0.55	5.87	0.31	1.05e-8	Monocyte count;
LUSC	cis	rs4363385	0.510	rs11205182	chr1:153045748	C/T	cg25856811	chr1:152973957	SPRR3	-0.37	-6.16	-0.32	2.04e-9	Inflammatory skin disease;
LUSC	cis	rs4604732	0.536	rs4925674	chr1:247636906	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.45	6.94	0.35	2.11e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.67	-0.39	1.87e-13	Morning vs. evening chronotype;
LUSC	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg27494647	chr7:150038898	RARRES2	0.46	7.21	0.37	3.71e-12	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg05926928	chr17:57297772	GDPD1	0.48	6.94	0.36	2.01e-11	Schizophrenia;
LUSC	trans	rs10851478	0.872	rs11852336	chr15:49948824	T/C	cg23074453	chr15:44487924	FRMD5	-0.33	-6.12	-0.32	2.61e-9	Oral cavity cancer;
LUSC	cis	rs2303282	0.716	rs2241957	chr16:56401294	T/C	cg00500540	chr16:56394104	NA	-0.44	-7.55	-0.38	4.1e-13	Breast cancer;
LUSC	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg08048268	chr3:133502702	NA	-0.38	-6.92	-0.35	2.25e-11	Iron status biomarkers;
LUSC	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.94	-19.67	-0.73	9.36e-58	Ulcerative colitis;
LUSC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg25767906	chr1:53392781	SCP2	-0.54	-10.54	-0.5	1.27e-22	Monocyte count;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg27597084	chr11:124670238	C11orf61	0.39	5.98	0.31	5.73e-9	Asthma;
LUSC	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg01256987	chr12:42539512	GXYLT1	-0.41	-7.47	-0.38	7.03e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg24920358	chr1:40204285	PPIE	-0.59	-10.59	-0.5	8.72e-23	Blood protein levels;
LUSC	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg18200150	chr17:30822561	MYO1D	0.3	5.79	0.3	1.59e-8	Schizophrenia;
LUSC	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-6.68	-0.34	9.79e-11	Monocyte percentage of white cells;
LUSC	cis	rs11031096	0.811	rs4910599	chr11:4156040	T/A	cg18678763	chr11:4115507	RRM1	-0.5	-7.34	-0.37	1.59e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2617583	0.967	rs2617595	chr5:1448246	C/T	cg07148919	chr5:1466943	LPCAT1	0.42	6.32	0.33	8.17e-10	Breast cancer;
LUSC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.13e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2729354	0.502	rs2848641	chr11:57263068	G/C	cg24343310	chr11:57249947	NA	0.42	8.85	0.44	5.35e-17	Blood protein levels;
LUSC	cis	rs867529	0.600	rs335120	chr2:89072731	A/G	cg26627705	chr2:89060884	NA	0.4	5.7	0.3	2.62e-8	Height;
LUSC	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg16434002	chr17:42200994	HDAC5	-0.43	-5.99	-0.31	5.34e-9	Total body bone mineral density;
LUSC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.08	16.47	0.67	4.75e-45	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs714027	0.585	rs41168	chr22:30418161	A/C	cg11564601	chr22:30592435	NA	-0.36	-6.22	-0.32	1.52e-9	Lymphocyte counts;
LUSC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	5.94	0.31	7.17e-9	Menopause (age at onset);
LUSC	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg20701182	chr2:24300061	SF3B14	0.87	11.33	0.53	2.12e-25	Lymphocyte counts;
LUSC	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg09173681	chr1:183549694	NCF2	0.64	11.45	0.53	7.79e-26	Systemic lupus erythematosus;
LUSC	cis	rs1943345	0.642	rs11233500	chr11:82881407	C/T	cg07047830	chr11:82868014	PCF11	-0.7	-10.97	-0.51	3.97e-24	Obesity-related traits;
LUSC	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.63	-8.5	-0.42	6.18e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs11571404	1	rs11571404	chr12:1041450	C/T	cg27417659	chr7:98567827	TRRAP	-0.51	-6.5	-0.34	3e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg14582100	chr15:45693742	SPATA5L1	0.57	10.33	0.49	6.78e-22	Homoarginine levels;
LUSC	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg07332563	chr6:291687	DUSP22	-0.51	-7.86	-0.4	5.2e-14	Menopause (age at onset);
LUSC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg04733989	chr22:42467013	NAGA	-0.63	-9.79	-0.47	4.63e-20	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.7	10.75	0.51	2.35e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.68	12.44	0.56	1.81e-29	Metabolite levels;
LUSC	cis	rs8016982	0.662	rs8014406	chr14:81657760	A/C	cg01989461	chr14:81687754	GTF2A1	0.5	6.63	0.34	1.35e-10	Schizophrenia;
LUSC	trans	rs984440	0.542	rs7815305	chr8:139083637	T/C	cg03334052	chr1:168888044	NA	0.4	6.44	0.33	4.26e-10	Obesity-related traits;
LUSC	cis	rs4478858	0.595	rs4949387	chr1:31803440	T/A	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs10979	1.000	rs13211390	chr6:143888010	A/T	cg25407410	chr6:143891975	LOC285740	-0.74	-11.93	-0.55	1.4e-27	Hypospadias;
LUSC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	0.65	13.71	0.6	3.1e-34	Prudent dietary pattern;
LUSC	cis	rs10186029	0.509	rs1122846	chr2:213939354	C/G	cg08319019	chr2:214017104	IKZF2	0.45	6.63	0.34	1.36e-10	Systemic sclerosis;
LUSC	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.97	-0.36	1.72e-11	Bladder cancer;
LUSC	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-6.01	-0.31	4.73e-9	Total body bone mineral density;
LUSC	cis	rs778371	0.723	rs35491427	chr2:233688542	C/T	cg08000102	chr2:233561755	GIGYF2	-0.77	-12.28	-0.56	7.13e-29	Schizophrenia;
LUSC	cis	rs654950	0.840	rs116241899	chr1:41994546	T/C	cg06885757	chr1:42089581	HIVEP3	-0.34	-6.61	-0.34	1.52e-10	Airway imaging phenotypes;
LUSC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08564027	chr20:61660810	NA	0.91	17.54	0.69	2.68e-49	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.63	0.86	5.12e-99	Chronic sinus infection;
LUSC	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg05360949	chr19:41903737	BCKDHA;EXOSC5	-0.44	-6.33	-0.33	7.79e-10	Height;
LUSC	cis	rs1355223	0.966	rs11602318	chr11:34766983	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.43	6.05	0.31	3.85e-9	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg22920501	chr2:26401640	FAM59B	-0.78	-10.78	-0.51	1.94e-23	Gut microbiome composition (summer);
LUSC	cis	rs4343996	0.566	rs6967278	chr7:3396185	A/G	cg21248987	chr7:3385318	SDK1	-0.35	-5.79	-0.3	1.67e-8	Motion sickness;
LUSC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.38	-0.49	4.47e-22	Platelet count;
LUSC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg01579765	chr21:45077557	HSF2BP	0.5	10.54	0.5	1.31e-22	Mean corpuscular volume;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg23760189	chr11:58910128	FAM111A	0.7	6.01	0.31	4.96e-9	Body mass index;
LUSC	cis	rs778371	0.755	rs778352	chr2:233804330	A/T	cg08000102	chr2:233561755	GIGYF2	-0.5	-6.78	-0.35	5.42e-11	Schizophrenia;
LUSC	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg08017756	chr2:100939284	LONRF2	-0.48	-9.11	-0.45	8.01e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs2041895	0.509	rs1838445	chr12:107314585	T/A	cg13944111	chr12:107296891	NA	0.37	6.5	0.34	2.95e-10	Glaucoma (low intraocular pressure);
LUSC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18876405	chr7:65276391	NA	-0.56	-8.93	-0.44	3e-17	Aortic root size;
LUSC	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg17366294	chr4:99064904	C4orf37	0.54	8.93	0.44	2.96e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg22676075	chr6:135203613	NA	0.46	7.21	0.37	3.84e-12	Red blood cell count;
LUSC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg08000102	chr2:233561755	GIGYF2	-0.7	-11.66	-0.54	1.34e-26	Coronary artery disease;
LUSC	cis	rs6580649	0.941	rs72644842	chr12:48448274	A/G	cg24011408	chr12:48396354	COL2A1	-0.46	-6.13	-0.32	2.43e-9	Lung cancer;
LUSC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18099408	chr3:52552593	STAB1	-0.41	-7.2	-0.37	3.98e-12	Electroencephalogram traits;
LUSC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg19812747	chr11:111475976	SIK2	-0.53	-7.89	-0.4	4.28e-14	Primary sclerosing cholangitis;
LUSC	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg02389323	chr16:88786976	FAM38A	1.16	10.45	0.5	2.67e-22	Plateletcrit;
LUSC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06022373	chr22:39101656	GTPBP1	0.8	13.2	0.59	2.68e-32	Menopause (age at onset);
LUSC	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg18681998	chr4:17616180	MED28	0.8	14.42	0.62	5.52e-37	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.47	7.85	0.39	5.84e-14	Vitiligo;
LUSC	cis	rs790123	0.692	rs790126	chr3:122387655	G/A	cg00926285	chr3:122398533	PARP14	-0.39	-5.66	-0.3	3.3e-8	Response to angiotensin II receptor blocker therapy;
LUSC	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg23711669	chr6:146136114	FBXO30	0.81	13.98	0.61	2.84e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.5	-5.65	-0.3	3.48e-8	Red blood cell traits;
LUSC	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.49	0.5	1.91e-22	Lymphocyte counts;
LUSC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18131467	chr2:239335373	ASB1	-1.05	-25.06	-0.81	1.02e-78	Multiple system atrophy;
LUSC	trans	rs62238980	0.614	rs117629537	chr22:32400579	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs2652834	0.851	rs1007075	chr15:63413501	A/G	cg05507819	chr15:63340323	TPM1	0.44	5.72	0.3	2.35e-8	HDL cholesterol;
LUSC	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg03585969	chr10:35415529	CREM	0.6	8.76	0.43	9.64e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg06606381	chr12:133084897	FBRSL1	-0.56	-6.62	-0.34	1.39e-10	Depression;
LUSC	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg17724175	chr1:150552817	MCL1	-0.45	-7.87	-0.4	4.82e-14	Urate levels;
LUSC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs3026401	0.562	rs2863231	chr11:31796560	C/T	cg06552810	chr11:31128660	NA	-0.35	-5.89	-0.31	9.37e-9	Body mass index;
LUSC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg03676636	chr4:99064102	C4orf37	0.33	7.16	0.36	5.04e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11958404	0.932	rs11950297	chr5:157419938	T/G	cg05962755	chr5:157440814	NA	0.55	6.61	0.34	1.53e-10	IgG glycosylation;
LUSC	cis	rs295140	1.000	rs7584810	chr2:201167772	G/A	cg04283868	chr2:201171347	SPATS2L	0.44	6.61	0.34	1.56e-10	QT interval;
LUSC	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-8.0	-0.4	2.13e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg17507749	chr15:85114479	UBE2QP1	0.69	9.0	0.44	1.76e-17	Schizophrenia;
LUSC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-11.57	-0.53	2.89e-26	Colorectal cancer;
LUSC	cis	rs7575217	0.961	rs7572504	chr2:101779739	C/T	cg23907051	chr2:101730305	TBC1D8	-0.26	-6.69	-0.34	9.44e-11	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg06212747	chr3:49208901	KLHDC8B	0.44	5.93	0.31	7.68e-9	Parkinson's disease;
LUSC	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	6.5	0.33	2.98e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs8032315	0.895	rs4932370	chr15:91404705	A/G	cg05469396	chr15:91419421	FURIN	0.37	6.01	0.31	4.92e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4343996	0.754	rs6461983	chr7:3347339	A/G	cg21248987	chr7:3385318	SDK1	0.37	6.35	0.33	6.83e-10	Motion sickness;
LUSC	cis	rs7605827	0.930	rs2111455	chr2:15549882	C/T	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.08e-17	Educational attainment (years of education);
LUSC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-1.05	-15.37	-0.64	1.09e-40	Vitiligo;
LUSC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg14582100	chr15:45693742	SPATA5L1	0.58	10.56	0.5	1.11e-22	Homoarginine levels;
LUSC	cis	rs9462027	0.628	rs9462015	chr6:34739726	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.91	-0.31	8.62e-9	Systemic lupus erythematosus;
LUSC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg06627628	chr2:24431161	ITSN2	-0.61	-7.32	-0.37	1.88e-12	Lymphocyte counts;
LUSC	cis	rs41271473	0.948	rs11803118	chr1:228826831	A/G	cg10167378	chr1:228756711	NA	0.6	7.07	0.36	9.23e-12	Chronic lymphocytic leukemia;
LUSC	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.54	-0.34	2.36e-10	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg11635098	chr7:100497156	NA	-0.38	-6.09	-0.32	3.08e-9	Monocyte percentage of white cells;
LUSC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg18681998	chr4:17616180	MED28	0.87	16.11	0.66	1.27e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg04460285	chr2:113522412	CKAP2L	0.39	5.95	0.31	6.75e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg07382826	chr16:28625726	SULT1A1	0.27	5.82	0.3	1.4e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg03585969	chr10:35415529	CREM	0.64	9.53	0.46	3.46e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs73228161	1.000	rs73228167	chr12:94663925	C/G	cg27125177	chr10:85956635	PCDH21	-0.5	-6.15	-0.32	2.27e-9	Major depressive disorder;
LUSC	cis	rs4285028	0.699	rs12637968	chr3:121599976	C/T	cg11130432	chr3:121712080	ILDR1	-0.63	-9.44	-0.46	6.61e-19	Multiple sclerosis;
LUSC	cis	rs3743266	0.613	rs1063100	chr15:60734697	A/G	cg21667061	chr15:60772094	NARG2	-0.37	-6.2	-0.32	1.65e-9	Menarche (age at onset);
LUSC	cis	rs250677	0.522	rs10038913	chr5:148354224	A/G	cg18129178	chr5:148520854	ABLIM3	0.53	7.83	0.39	6.34e-14	Breast cancer;
LUSC	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	0.7	11.24	0.52	4.39e-25	Blood metabolite ratios;
LUSC	cis	rs4240897	0.935	rs3766744	chr1:12043717	G/A	cg13216073	chr1:12042593	MFN2	0.36	6.35	0.33	7.14e-10	Tuberculosis;
LUSC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg19592336	chr6:28129416	ZNF389	0.48	6.35	0.33	7.02e-10	Parkinson's disease;
LUSC	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg09509183	chr1:209979624	IRF6	0.49	5.84	0.3	1.25e-8	Cleft lip with or without cleft palate;
LUSC	trans	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg06521331	chr12:34319734	NA	-0.41	-6.35	-0.33	7.23e-10	Bladder cancer;
LUSC	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg26384229	chr12:38710491	ALG10B	0.48	6.94	0.35	2.06e-11	Morning vs. evening chronotype;
LUSC	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg23752985	chr2:85803571	VAMP8	0.33	6.98	0.36	1.57e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.32	6.07	0.32	3.46e-9	Obesity-related traits;
LUSC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.54	-8.33	-0.41	2.1e-15	Tonsillectomy;
LUSC	cis	rs4363385	0.755	rs1933382	chr1:153003295	G/T	cg25856811	chr1:152973957	SPRR3	0.36	5.94	0.31	7.06e-9	Inflammatory skin disease;
LUSC	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg00376283	chr12:123451042	ABCB9	0.65	8.31	0.41	2.45e-15	Neutrophil percentage of white cells;
LUSC	cis	rs62400317	0.859	rs72858511	chr6:45218119	A/G	cg20913747	chr6:44695427	NA	-0.49	-7.8	-0.39	7.8500000000000006e-14	Total body bone mineral density;
LUSC	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg24531977	chr5:56204891	C5orf35	-0.57	-8.31	-0.41	2.5e-15	Coronary artery disease;
LUSC	cis	rs3849570	0.732	rs11715625	chr3:81875938	A/T	cg07356753	chr3:81810745	GBE1	-0.59	-8.81	-0.43	6.92e-17	Waist circumference;Body mass index;
LUSC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.87	-12.39	-0.56	2.84e-29	Ileal carcinoids;
LUSC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20135002	chr11:47629003	NA	-0.49	-7.81	-0.39	7.55e-14	Subjective well-being;
LUSC	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg19622623	chr12:86230825	RASSF9	0.4	5.71	0.3	2.44e-8	Major depressive disorder;
LUSC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.48	-0.33	3.34e-10	Lung cancer;
LUSC	trans	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.77	0.47	5.46e-20	Mean corpuscular volume;
LUSC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg21724239	chr8:58056113	NA	0.61	7.21	0.37	3.7e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs3125734	0.608	rs7905731	chr10:64018472	T/C	cg19640130	chr10:64028056	RTKN2	-0.4	-7.1	-0.36	7.59e-12	Rheumatoid arthritis;
LUSC	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.79	0.3	1.6e-8	Breast cancer;
LUSC	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.93	-0.48	1.55e-20	Platelet count;
LUSC	cis	rs3087591	0.960	rs2905883	chr17:29550141	G/A	cg24425628	chr17:29625626	OMG;NF1	0.54	7.89	0.4	4.46e-14	Hip circumference;
LUSC	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg03676636	chr4:99064102	C4orf37	0.38	7.88	0.4	4.55e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs240764	0.717	rs6904959	chr6:101157916	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-6.07	-0.32	3.52e-9	Neuroticism;
LUSC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg04450456	chr4:17643702	FAM184B	0.37	6.12	0.32	2.66e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg26384229	chr12:38710491	ALG10B	0.6	9.19	0.45	4.24e-18	Morning vs. evening chronotype;
LUSC	cis	rs9463078	0.753	rs1329716	chr6:44953758	C/T	cg25276700	chr6:44698697	NA	-0.28	-5.76	-0.3	1.94e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg24130564	chr14:104152367	KLC1	0.45	6.49	0.33	3.14e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2236918	1.000	rs2526701	chr1:242018427	T/C	cg17736920	chr1:242011382	EXO1	0.45	7.12	0.36	6.71e-12	Menopause (age at onset);
LUSC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg11764359	chr7:65958608	NA	0.54	6.97	0.36	1.75e-11	Aortic root size;
LUSC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-1.08	-16.19	-0.66	6.07e-44	Initial pursuit acceleration;
LUSC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.88	-0.4	4.69e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg18357645	chr12:58087776	OS9	0.56	8.51	0.42	5.79e-16	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg17968037	chr7:100024898	ZCWPW1	-0.39	-6.07	-0.31	3.57e-9	Platelet count;
LUSC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg21724239	chr8:58056113	NA	0.62	7.06	0.36	9.73e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10208940	0.920	rs13422657	chr2:68706989	T/C	cg12452813	chr2:68675892	NA	0.56	5.88	0.31	1.01e-8	Urate levels in lean individuals;
LUSC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg09034736	chr1:150693464	HORMAD1	0.52	7.51	0.38	5.52e-13	Tonsillectomy;
LUSC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg27588902	chr6:42928151	GNMT	-0.29	-6.57	-0.34	1.93e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	10.25	0.49	1.31e-21	Birth weight;
LUSC	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg01881094	chr2:180872142	CWC22	-0.8	-9.94	-0.48	1.5e-20	Schizophrenia;
LUSC	cis	rs61990749	0.544	rs7151211	chr14:78151901	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.61	-6.49	-0.33	3.14e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg13393036	chr8:95962371	TP53INP1	-0.45	-9.58	-0.46	2.21e-19	Type 2 diabetes;
LUSC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-0.88	-18.62	-0.71	1.43e-53	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2629540	0.781	rs2293064	chr10:126396511	C/G	cg08799069	chr10:126477246	METTL10	0.5	7.43	0.38	8.88e-13	Cocaine dependence;
LUSC	cis	rs6084875	0.840	rs6084850	chr20:4725662	G/A	cg26097573	chr20:4721490	PRNT	-0.31	-5.74	-0.3	2.16e-8	Systemic lupus erythematosus;
LUSC	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-7.13	-0.36	6.27e-12	Coronary artery disease;
LUSC	cis	rs240993	0.595	rs1040383	chr6:111902188	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.34	6.06	0.31	3.58e-9	Inflammatory skin disease;Psoriasis;
LUSC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg09365446	chr1:150670422	GOLPH3L	0.55	8.44	0.42	9.59e-16	Tonsillectomy;
LUSC	cis	rs12530845	0.943	rs78188670	chr7:135335163	T/C	cg23117316	chr7:135346802	PL-5283	-0.57	-9.84	-0.47	3.1e-20	Red blood cell traits;
LUSC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg22105103	chr4:187893119	NA	0.72	14.01	0.61	2.12e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6756513	0.520	rs7569566	chr2:70174030	T/C	cg02498382	chr2:70120550	SNRNP27	-0.26	-6.52	-0.34	2.54e-10	Breast cancer;Platelet count;
LUSC	cis	rs1971762	0.583	rs12319789	chr12:54090450	G/C	cg23533419	chr12:54090519	NA	-0.36	-5.76	-0.3	1.88e-8	Height;
LUSC	trans	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.69	-0.43	1.66e-16	Retinal vascular caliber;
LUSC	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg26384229	chr12:38710491	ALG10B	0.74	11.93	0.55	1.42e-27	Morning vs. evening chronotype;
LUSC	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg12564285	chr5:131593104	PDLIM4	0.37	6.8	0.35	4.9e-11	Blood metabolite levels;
LUSC	cis	rs16976116	0.951	rs3759862	chr15:55483104	C/A	cg11288833	chr15:55489084	RSL24D1	0.53	6.35	0.33	7.21e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg06494592	chr3:125709126	NA	-0.5	-5.7	-0.3	2.62e-8	Blood pressure (smoking interaction);
LUSC	cis	rs2348418	0.715	rs10843206	chr12:28722756	C/T	cg13890972	chr12:28721907	NA	-0.39	-6.89	-0.35	2.81e-11	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg08683831	chr4:1404607	NA	0.36	6.02	0.31	4.52e-9	Obesity-related traits;
LUSC	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.82	-0.39	7.05e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg22437258	chr11:111473054	SIK2	0.54	7.6	0.38	3.03e-13	Primary sclerosing cholangitis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24103018	chr19:17420930	DDA1	-0.48	-6.16	-0.32	2.1e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg21890820	chr11:65308645	LTBP3	0.5	7.41	0.38	1.03e-12	Bone mineral density;
LUSC	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg16950941	chr11:66035639	RAB1B	0.54	8.01	0.4	1.97e-14	Gout;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25173401	chr4:53548	ZNF595;ZNF718	0.43	6.64	0.34	1.3e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg06074448	chr4:187884817	NA	-0.41	-6.87	-0.35	3.24e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg13047869	chr3:10149882	C3orf24	0.6	8.12	0.41	9.19e-15	Alzheimer's disease;
LUSC	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg10604040	chr11:65559109	OVOL1	0.31	5.78	0.3	1.72e-8	Eosinophil percentage of white cells;
LUSC	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.53	-10.13	-0.48	3.33e-21	Schizophrenia;
LUSC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	1.03	18.02	0.7	3.34e-51	Parkinson's disease;
LUSC	cis	rs829883	0.659	rs11109521	chr12:98930809	C/A	cg25150519	chr12:98850993	NA	-0.63	-8.71	-0.43	1.47e-16	Colorectal adenoma (advanced);
LUSC	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.86	14.72	0.63	3.93e-38	Bladder cancer;
LUSC	cis	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg17187183	chr4:55093834	PDGFRA	0.39	5.89	0.31	9.61e-9	Corneal astigmatism;
LUSC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg18904891	chr8:8559673	CLDN23	0.56	7.65	0.39	2.14e-13	Obesity-related traits;
LUSC	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03517284	chr6:25882590	NA	-0.42	-6.57	-0.34	1.92e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.65	-10.91	-0.51	6.55e-24	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs7916410	0.512	rs1900003	chr10:70004551	A/C	cg06988349	chr10:69991859	ATOH7	0.33	5.8	0.3	1.56e-8	Optic disc area;
LUSC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.85	15.25	0.64	3.1e-40	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25508527	chr19:7294983	INSR	0.7	6.13	0.32	2.55e-9	Cognitive performance;
LUSC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.92	0.31	7.86e-9	Menopause (age at onset);
LUSC	cis	rs469568	0.935	rs338875	chr5:178669297	A/G	cg08999896	chr5:178685787	ADAMTS2	-0.29	-6.1	-0.32	3.01e-9	Stroke (pediatric);
LUSC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-1.04	-22.89	-0.78	2.15e-70	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6104690	1.000	rs6104690	chr20:10988099	G/A	cg07172334	chr21:31655261	KRTAP24-1	-0.33	-5.94	-0.31	6.99e-9	Bladder cancer;
LUSC	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.63	-0.43	2.52e-16	Rheumatoid arthritis;
LUSC	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg15605315	chr1:45957053	TESK2	-0.44	-6.77	-0.35	5.74e-11	High light scatter reticulocyte count;
LUSC	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.78	-0.47	5.11e-20	Multiple sclerosis;
LUSC	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg06636001	chr8:8085503	FLJ10661	0.48	7.36	0.37	1.44e-12	Joint mobility (Beighton score);
LUSC	cis	rs34375054	0.641	rs34624329	chr12:125608028	T/G	cg09839279	chr12:125627357	AACS	-0.33	-6.09	-0.32	3.03e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7189233	0.531	rs9302648	chr16:53527781	G/T	cg09728985	chr16:53543985	NA	-0.31	-5.8	-0.3	1.55e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg16797656	chr11:68205561	LRP5	0.47	8.38	0.42	1.48e-15	Bone mineral density;
LUSC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.07	-17.63	-0.69	1.25e-49	Primary sclerosing cholangitis;
LUSC	trans	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.54	-8.66	-0.43	2e-16	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg13256891	chr4:100009986	ADH5	0.49	7.3	0.37	2.18e-12	Alcohol dependence;
LUSC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg08968635	chr6:28129556	ZNF389	0.44	5.65	0.3	3.38e-8	Parkinson's disease;
LUSC	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.81	-17.26	-0.69	3.73e-48	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg13206674	chr6:150067644	NUP43	0.41	6.34	0.33	7.49e-10	Testicular germ cell tumor;
LUSC	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg22437258	chr11:111473054	SIK2	0.5	6.89	0.35	2.78e-11	Primary sclerosing cholangitis;
LUSC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg17143192	chr8:8559678	CLDN23	0.64	9.33	0.45	1.54e-18	Obesity-related traits;
LUSC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.69	-13.17	-0.58	3.29e-32	Monocyte count;
LUSC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg07703079	chr11:430292	ANO9	0.63	6.88	0.35	2.92e-11	Body mass index;
LUSC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg14552801	chr7:65878734	NA	0.39	5.97	0.31	6.13e-9	Aortic root size;
LUSC	cis	rs7582720	1.000	rs72934711	chr2:203709997	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.73	8.0	0.4	2.12e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg14769373	chr6:40998127	UNC5CL	-0.56	-8.04	-0.4	1.54e-14	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg22532475	chr10:104410764	TRIM8	-0.36	-7.89	-0.4	4.31e-14	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg02176678	chr2:219576539	TTLL4	-0.57	-10.14	-0.48	3.18e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs807669	0.505	rs8142503	chr22:19166717	G/T	cg02655711	chr22:19163373	SLC25A1	0.53	9.49	0.46	4.4e-19	Metabolite levels;
LUSC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.79	0.35	5.13e-11	Tonsillectomy;
LUSC	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.89	14.86	0.63	1.09e-38	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9420	0.961	rs708228	chr11:57585662	C/T	cg02958346	chr11:57425731	CLP1	-0.43	-6.22	-0.32	1.5e-9	Schizophrenia;
LUSC	cis	rs12973672	1.000	rs12975284	chr19:35770962	G/C	cg12095397	chr19:35769544	USF2	0.44	6.91	0.35	2.42e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg18806716	chr10:30721971	MAP3K8	-0.61	-9.89	-0.48	2.13e-20	Inflammatory bowel disease;
LUSC	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg19875535	chr5:140030758	IK	-0.54	-8.9	-0.44	3.63e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-7.03	-0.36	1.18e-11	Monocyte percentage of white cells;
LUSC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-1.04	-20.21	-0.74	7.12e-60	Height;
LUSC	cis	rs9929218	1.000	rs9929218	chr16:68820946	G/A	cg02972257	chr16:68554789	NA	0.41	5.73	0.3	2.19e-8	Colorectal cancer;
LUSC	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg00376283	chr12:123451042	ABCB9	0.67	8.44	0.42	9.73e-16	Neutrophil percentage of white cells;
LUSC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg13607699	chr17:42295918	UBTF	0.55	8.38	0.42	1.46e-15	Total body bone mineral density;
LUSC	cis	rs17095355	1.000	rs57440982	chr10:111735772	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.58	-7.48	-0.38	6.7e-13	Biliary atresia;
LUSC	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg15423357	chr2:25149977	NA	0.37	7.19	0.37	4.31e-12	Body mass index in non-asthmatics;
LUSC	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg14343924	chr8:8086146	FLJ10661	0.45	6.19	0.32	1.76e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs34638657	0.827	rs2303262	chr16:82203758	C/T	cg09439754	chr16:82129088	HSD17B2	-0.41	-6.28	-0.32	1.06e-9	Lung adenocarcinoma;
LUSC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg21016266	chr12:122356598	WDR66	0.54	7.68	0.39	1.82e-13	Mean corpuscular volume;
LUSC	trans	rs1998174	0.509	rs2901600	chr1:171835654	G/A	cg13482142	chr2:234261155	NA	0.42	6.13	0.32	2.46e-9	Platelet distribution width;
LUSC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg25039879	chr17:56429692	SUPT4H1	0.67	8.85	0.44	5.03e-17	Cognitive test performance;
LUSC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg19622623	chr12:86230825	RASSF9	0.44	6.29	0.33	1.02e-9	Major depressive disorder;
LUSC	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg06671706	chr8:8559999	CLDN23	0.49	6.27	0.32	1.09e-9	Obesity-related traits;
LUSC	cis	rs4462272	0.554	rs2862946	chr10:101862648	G/A	cg02250046	chr10:101825185	CPN1	-0.33	-6.06	-0.31	3.57e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg07741184	chr6:167504864	NA	-0.36	-6.53	-0.34	2.41e-10	Crohn's disease;
LUSC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg03146154	chr1:46216737	IPP	0.5	7.54	0.38	4.48e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21545522	chr1:205238299	TMCC2	0.5	9.45	0.46	5.97e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs7119	0.717	rs12898370	chr15:77808598	A/T	cg27398640	chr15:77910606	LINGO1	-0.29	-6.32	-0.33	8.41e-10	Type 2 diabetes;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18807030	chr7:931980	C7orf20	-0.72	-6.09	-0.32	3.04e-9	Cognitive performance;
LUSC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19717773	chr7:2847554	GNA12	-0.39	-6.2	-0.32	1.69e-9	Height;
LUSC	cis	rs12368653	0.641	rs11172300	chr12:58076515	C/T	cg12615879	chr12:58013172	SLC26A10	0.38	8.71	0.43	1.4e-16	Multiple sclerosis;
LUSC	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg05528280	chr10:464225	DIP2C	0.4	6.19	0.32	1.76e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg11062466	chr8:58055876	NA	0.77	8.64	0.43	2.42e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg00484396	chr16:3507460	NAT15	0.47	7.0	0.36	1.42e-11	Body mass index (adult);
LUSC	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.32	0.49	7.37e-22	Colorectal cancer;
LUSC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg23711669	chr6:146136114	FBXO30	0.88	16.13	0.66	1.12e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg08999081	chr20:33150536	PIGU	0.37	6.67	0.34	1.08e-10	Height;
LUSC	trans	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg06636001	chr8:8085503	FLJ10661	0.46	6.37	0.33	6.32e-10	Monocyte count;
LUSC	cis	rs7011049	0.908	rs72640866	chr8:53843014	C/T	cg26025543	chr8:53854495	NA	0.52	6.3	0.33	9.5e-10	Systolic blood pressure;
LUSC	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg07828340	chr4:882639	GAK	1.05	11.18	0.52	7.56e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs10266483	0.774	rs10949894	chr7:63800521	C/A	cg24201672	chr7:64023550	ZNF680	0.44	5.8	0.3	1.53e-8	Response to statin therapy;
LUSC	cis	rs41271951	0.512	rs12074309	chr1:151087827	T/C	cg11822372	chr1:151115635	SEMA6C	-0.76	-6.95	-0.36	1.98e-11	Blood protein levels;
LUSC	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg24011408	chr12:48396354	COL2A1	0.49	8.14	0.41	8.04e-15	Plateletcrit;
LUSC	cis	rs4363385	0.667	rs11803197	chr1:152934420	G/A	cg07796016	chr1:152779584	LCE1C	-0.43	-6.03	-0.31	4.23e-9	Inflammatory skin disease;
LUSC	cis	rs9921338	0.887	rs9926136	chr16:11437275	A/G	cg00044050	chr16:11439710	C16orf75	-0.51	-6.79	-0.35	5.18e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg16743903	chr16:89593216	SPG7	-0.47	-6.5	-0.34	2.9e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.23	0.32	1.4e-9	Total body bone mineral density;
LUSC	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg15704280	chr7:45808275	SEPT13	0.73	8.39	0.42	1.38e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg05925327	chr15:68127851	NA	-0.43	-6.74	-0.35	7.01e-11	Obesity;
LUSC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.06	20.5	0.75	4.82e-61	Cognitive ability;
LUSC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	12.81	0.57	7.77e-31	Chronic sinus infection;
LUSC	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08219700	chr8:58056026	NA	0.68	8.19	0.41	5.59e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs2414856	0.510	rs72756988	chr15:64597636	C/T	cg08069370	chr15:64387884	SNX1	-0.77	-6.53	-0.34	2.44e-10	Pulse pressure;Systolic blood pressure;
LUSC	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg01528321	chr10:82214614	TSPAN14	0.83	12.44	0.56	1.93e-29	Post bronchodilator FEV1;
LUSC	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg09034736	chr1:150693464	HORMAD1	0.44	6.16	0.32	2.05e-9	Melanoma;
LUSC	cis	rs929596	0.564	rs2741038	chr2:234563998	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-6.03	-0.31	4.27e-9	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs11955175	1.000	rs11956743	chr5:40677593	G/A	cg05478818	chr5:40835740	RPL37	0.7	5.77	0.3	1.81e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.83	0.39	6.38e-14	Parkinson's disease;
LUSC	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg24011408	chr12:48396354	COL2A1	-0.4	-5.73	-0.3	2.26e-8	Glycated hemoglobin levels;
LUSC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg16339924	chr4:17578868	LAP3	0.55	8.41	0.42	1.18e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg00945038	chr17:61921165	SMARCD2	0.55	9.25	0.45	2.73e-18	Prudent dietary pattern;
LUSC	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.2	0.32	1.69e-9	Schizophrenia;
LUSC	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg16386425	chr10:429943	DIP2C	-0.44	-6.97	-0.36	1.65e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-12.37	-0.56	3.29e-29	Platelet count;
LUSC	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg24675056	chr1:15929824	NA	-0.4	-6.75	-0.35	6.71e-11	Systolic blood pressure;
LUSC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg13395646	chr4:1353034	KIAA1530	-0.62	-10.07	-0.48	5.08e-21	Obesity-related traits;
LUSC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-9.68	-0.47	1.06e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg09034736	chr1:150693464	HORMAD1	0.43	6.2	0.32	1.71e-9	Melanoma;
LUSC	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg03585969	chr10:35415529	CREM	0.61	9.08	0.44	9.76e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg02951883	chr7:2050386	MAD1L1	0.55	10.14	0.49	3.12e-21	Bipolar disorder and schizophrenia;
LUSC	cis	rs59698941	0.943	rs66480446	chr5:132274793	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	6.9e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs2303282	0.690	rs869205	chr16:56394035	T/C	cg00500540	chr16:56394104	NA	-0.44	-7.59	-0.38	3.3e-13	Breast cancer;
LUSC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg26587870	chr6:27730563	NA	-0.52	-6.06	-0.31	3.75e-9	Depression;
LUSC	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg13010344	chr12:123464640	ARL6IP4	-0.51	-6.27	-0.32	1.13e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg21285383	chr16:89894308	SPIRE2	0.35	7.45	0.38	8.16e-13	Vitiligo;
LUSC	trans	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg07211511	chr3:129823064	LOC729375	-0.82	-11.83	-0.54	3.19e-27	Blood pressure (smoking interaction);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg00611675	chr8:128748464	MYC	0.49	6.01	0.31	4.82e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.72	13.95	0.61	3.66e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg07741184	chr6:167504864	NA	-0.35	-6.42	-0.33	4.78e-10	Crohn's disease;
LUSC	cis	rs4363385	0.553	rs41263664	chr1:152974063	G/A	cg00922841	chr1:152955080	SPRR1A	-0.38	-6.48	-0.33	3.3e-10	Inflammatory skin disease;
LUSC	trans	rs7922314	1.000	rs61865883	chr10:64572680	A/T	cg00459623	chr2:176936581	NA	-0.48	-6.13	-0.32	2.52e-9	Cutaneous psoriasis;
LUSC	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg26384229	chr12:38710491	ALG10B	0.72	11.29	0.53	3.03e-25	Morning vs. evening chronotype;
LUSC	cis	rs9323205	0.677	rs12587080	chr14:51723079	A/C	cg23942311	chr14:51606299	NA	-0.39	-7.25	-0.37	2.92e-12	Cancer;
LUSC	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg23933602	chr10:16859644	RSU1	0.63	8.74	0.43	1.19e-16	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg13395646	chr4:1353034	KIAA1530	0.55	8.38	0.42	1.54e-15	Obesity-related traits;
LUSC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg12751644	chr20:60527061	NA	-0.34	-6.0	-0.31	5.03e-9	Body mass index;
LUSC	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg21775007	chr8:11205619	TDH	-0.48	-6.68	-0.34	9.82e-11	Systolic blood pressure;
LUSC	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg17252645	chr8:143867129	LY6D	-0.37	-6.4	-0.33	5.13e-10	Urinary tract infection frequency;
LUSC	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg14433983	chr11:636460	DRD4	-0.35	-5.88	-0.31	9.78e-9	Systemic lupus erythematosus;
LUSC	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg07211511	chr3:129823064	LOC729375	-1.24	-20.36	-0.74	1.75e-60	Blood pressure (smoking interaction);
LUSC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg08270630	chr22:50330655	NA	0.41	6.24	0.32	1.34e-9	Schizophrenia;
LUSC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	0.79	13.89	0.6	6.34e-35	Cognitive function;
LUSC	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	6.95	0.36	1.97e-11	Rheumatoid arthritis;
LUSC	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg03929089	chr4:120376271	NA	0.74	6.91	0.35	2.4e-11	Axial length;
LUSC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg17554472	chr22:41940697	POLR3H	0.48	5.91	0.31	8.32e-9	Vitiligo;
LUSC	cis	rs929596	0.501	rs4530361	chr2:234590041	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-6.55	-0.34	2.23e-10	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs9612	1.000	rs58896392	chr19:44269142	G/A	cg08581076	chr19:44259116	C19orf61	0.47	5.7	0.3	2.69e-8	Exhaled nitric oxide output;
LUSC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg13939156	chr17:80058883	NA	0.34	6.57	0.34	1.97e-10	Life satisfaction;
LUSC	cis	rs11645898	0.872	rs34832584	chr16:72162966	G/T	cg14768367	chr16:72042858	DHODH	-0.65	-7.15	-0.36	5.63e-12	Blood protein levels;
LUSC	cis	rs977987	0.778	rs4243112	chr16:75321031	T/C	cg04384234	chr16:75411784	CFDP1	-0.38	-6.0	-0.31	5.04e-9	Dupuytren's disease;
LUSC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg05872129	chr22:39784769	NA	-0.58	-9.83	-0.47	3.47e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs3849570	1.000	rs9818006	chr3:81828230	A/C	cg07356753	chr3:81810745	GBE1	-0.58	-9.2	-0.45	3.93e-18	Waist circumference;Body mass index;
LUSC	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg04450456	chr4:17643702	FAM184B	0.4	6.71	0.34	8.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.69	-10.12	-0.48	3.6e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg01652190	chr22:50026171	C22orf34	-0.28	-5.69	-0.3	2.83e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs708547	0.647	rs6843644	chr4:57891239	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.53	7.66	0.39	1.98e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1507153	0.673	rs9361414	chr6:79345448	G/T	cg05283184	chr6:79620031	NA	-0.42	-7.33	-0.37	1.74e-12	Sjögren's syndrome;
LUSC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-8.17	-0.41	6.51e-15	Chronic sinus infection;
LUSC	cis	rs2742417	0.603	rs2253979	chr3:45773320	A/G	cg10512202	chr3:45649293	LIMD1	0.36	5.94	0.31	7.3e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	1.0	15.0	0.63	3.09e-39	Obesity-related traits;
LUSC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg00012203	chr2:219082015	ARPC2	0.87	16.56	0.67	2.26e-45	Colorectal cancer;
LUSC	cis	rs2274273	0.624	rs12050123	chr14:55840386	G/A	cg04306507	chr14:55594613	LGALS3	0.49	9.94	0.48	1.47e-20	Protein biomarker;
LUSC	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg23601095	chr6:26197514	HIST1H3D	0.7	7.53	0.38	4.89e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs1979679	0.573	rs7316056	chr12:28728676	A/G	cg13890972	chr12:28721907	NA	-0.41	-6.0	-0.31	5.13e-9	Ossification of the posterior longitudinal ligament of the spine;
LUSC	cis	rs9837602	1.000	rs35521705	chr3:99716690	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.17	0.32	1.96e-9	Breast cancer;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg16142952	chr22:24129598	SMARCB1	0.4	6.27	0.32	1.11e-9	Triglycerides;
LUSC	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg05714579	chr10:131428358	MGMT	0.53	8.05	0.4	1.52e-14	Response to temozolomide;
LUSC	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg18753928	chr3:113234510	CCDC52	-0.54	-8.23	-0.41	4.16e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7106204	0.748	rs4636667	chr11:24238615	T/C	ch.11.24196551F	chr11:24239977	NA	1.17	14.66	0.63	6.73e-38	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg05084668	chr3:125655381	ALG1L	-0.52	-7.95	-0.4	2.82e-14	Blood pressure (smoking interaction);
LUSC	cis	rs17227506	0.630	rs67670052	chr8:13443474	G/C	cg03566418	chr8:13424080	C8orf48	0.42	6.34	0.33	7.58e-10	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs7197653	0.519	rs55757091	chr16:68323654	G/A	cg09835421	chr16:68378352	PRMT7	-0.58	-6.69	-0.34	9.26e-11	Magnesium levels;
LUSC	cis	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg27411982	chr8:10470053	RP1L1	-0.49	-7.32	-0.37	1.83e-12	Morning vs. evening chronotype;
LUSC	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-9.54	-0.46	3.15e-19	Bladder cancer;
LUSC	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg19774624	chr17:42201019	HDAC5	-0.81	-13.38	-0.59	5.26e-33	Total body bone mineral density;
LUSC	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.0	0.44	1.79e-17	Menarche (age at onset);
LUSC	cis	rs77633900	0.502	rs116917406	chr15:76922940	T/C	cg21673338	chr15:77095150	SCAPER	-0.71	-5.98	-0.31	5.72e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg07606381	chr6:8435919	SLC35B3	0.72	12.19	0.55	1.55e-28	Motion sickness;
LUSC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-14.31	-0.62	1.5e-36	Dental caries;
LUSC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.64	8.7	0.43	1.51e-16	High light scatter reticulocyte count;
LUSC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg27170947	chr2:26402098	FAM59B	-0.69	-10.55	-0.5	1.2e-22	Gut microbiome composition (summer);
LUSC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs400736	0.894	rs225092	chr1:8036075	G/C	cg25007680	chr1:8021821	PARK7	0.59	9.32	0.45	1.69e-18	Response to antidepressants and depression;
LUSC	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21659725	chr3:3221576	CRBN	-0.49	-7.8	-0.39	8.26e-14	Body mass index;
LUSC	cis	rs6977660	1.000	rs5017194	chr7:19820035	A/T	cg07541023	chr7:19748670	TWISTNB	0.51	5.7	0.3	2.6e-8	Thyroid stimulating hormone;
LUSC	cis	rs4947962	0.525	rs28573307	chr7:55148816	C/T	cg23757825	chr7:55092271	EGFR	-0.46	-5.78	-0.3	1.7e-8	Subjective response to lithium treatment;
LUSC	cis	rs16854884	0.586	rs4616638	chr3:143735423	A/T	cg06585982	chr3:143692056	C3orf58	-0.51	-8.58	-0.42	3.75e-16	Economic and political preferences (feminism/equality);
LUSC	cis	rs4343996	0.521	rs12667184	chr7:3413793	A/G	cg21248987	chr7:3385318	SDK1	0.34	5.75	0.3	1.99e-8	Motion sickness;
LUSC	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg17127132	chr2:85788382	GGCX	0.46	7.42	0.38	9.82e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs6987853	0.931	rs2923444	chr8:42397004	C/T	cg09913449	chr8:42400586	C8orf40	0.49	8.26	0.41	3.35e-15	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15340874	chr1:174969621	CACYBP	-0.42	-6.08	-0.32	3.21e-9	Electrocardiographic conduction measures;
LUSC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.97	0.4	2.6e-14	Prudent dietary pattern;
LUSC	cis	rs968451	0.762	rs5757618	chr22:39724551	A/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	8.7	0.43	1.5e-16	Primary biliary cholangitis;
LUSC	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg00105475	chr2:10696890	NA	0.37	6.12	0.32	2.55e-9	Prostate cancer;
LUSC	cis	rs12946454	0.668	rs4792867	chr17:43249444	C/T	cg10701640	chr17:43249399	NA	0.52	12.37	0.56	3.47e-29	Systolic blood pressure;
LUSC	cis	rs3772130	0.962	rs6784571	chr3:121539991	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.68	10.13	0.48	3.31e-21	Cognitive performance;
LUSC	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-8.91	-0.44	3.4e-17	Morning vs. evening chronotype;
LUSC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg15147215	chr3:52552868	STAB1	-0.33	-6.44	-0.33	4.06e-10	Electroencephalogram traits;
LUSC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg15145296	chr3:125709740	NA	-0.56	-6.21	-0.32	1.58e-9	Blood pressure (smoking interaction);
LUSC	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg11189052	chr15:85197271	WDR73	-0.42	-6.29	-0.33	1.02e-9	P wave terminal force;
LUSC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-7.01	-0.36	1.29e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg22782873	chr19:19639568	YJEFN3	0.5	6.07	0.32	3.52e-9	Bipolar disorder;
LUSC	trans	rs4773505	0.745	rs4988951	chr13:90429775	T/G	cg07142010	chr1:21901166	ALPL	-0.31	-5.95	-0.31	6.9e-9	Loneliness (multivariate analysis);
LUSC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.79	12.96	0.58	2.05e-31	Aortic root size;
LUSC	cis	rs28829049	0.597	rs2313509	chr1:19437860	C/T	cg13387374	chr1:19411106	UBR4	0.42	5.78	0.3	1.71e-8	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg17507749	chr15:85114479	UBE2QP1	0.54	6.66	0.34	1.15e-10	Schizophrenia;
LUSC	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	0.98	14.97	0.63	4.11e-39	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg13047869	chr3:10149882	C3orf24	0.63	9.07	0.44	1.02e-17	Alzheimer's disease;
LUSC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs2639990	1.000	rs609303	chr18:72895242	C/T	cg11568697	chr18:72916393	ZADH2	0.54	6.4	0.33	5.11e-10	Vascular endothelial growth factor levels;
LUSC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.9	14.8	0.63	1.84e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.6	11.62	0.54	1.88e-26	Pulse pressure;
LUSC	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.84	12.34	0.56	4.25e-29	Breast cancer;
LUSC	cis	rs6076065	0.723	rs4815203	chr20:23395633	C/G	cg11657817	chr20:23433608	CST11	0.44	8.22	0.41	4.64e-15	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg26384229	chr12:38710491	ALG10B	0.72	11.37	0.53	1.52e-25	Morning vs. evening chronotype;
LUSC	cis	rs7179456	0.547	rs6494035	chr15:59015888	C/G	cg05156742	chr15:59063176	FAM63B	0.5	7.23	0.37	3.38e-12	Asperger disorder;
LUSC	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.42	5.66	0.3	3.23e-8	Menarche (age at onset);
LUSC	cis	rs9399401	0.884	rs263180	chr6:142862768	C/A	cg03128060	chr6:142623767	GPR126	0.32	6.03	0.31	4.36e-9	Chronic obstructive pulmonary disease;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24465448	chr8:17942444	ASAH1	0.4	5.95	0.31	6.64e-9	Triglycerides;
LUSC	cis	rs17373728	0.710	rs12544686	chr8:76218074	C/T	cg07016329	chr8:76221503	NA	-0.46	-6.69	-0.34	9.27e-11	Diabetic kidney disease;
LUSC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13126279	chr21:47581558	C21orf56	0.52	7.99	0.4	2.26e-14	Testicular germ cell tumor;
LUSC	cis	rs713477	0.967	rs11158039	chr14:55906696	A/T	cg13175173	chr14:55914753	NA	-0.32	-6.72	-0.35	7.95e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	0.85	12.07	0.55	4.45e-28	Eosinophil percentage of granulocytes;
LUSC	trans	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg09050820	chr6:167586206	TCP10L2	0.74	9.61	0.47	1.89e-19	Gastritis;
LUSC	cis	rs6693567	0.565	rs12093148	chr1:150265173	G/A	cg09579323	chr1:150459698	TARS2	-0.43	-6.0	-0.31	5.03e-9	Migraine;
LUSC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	0.97	13.69	0.6	3.61e-34	Vitiligo;
LUSC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.28	-7.29	-0.37	2.21e-12	Lymphocyte counts;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18187865	chr6:34857018	ANKS1A;TAF11	-0.41	-6.3	-0.33	9.63e-10	Electrocardiographic conduction measures;
LUSC	cis	rs6484504	0.576	rs169623	chr11:31184157	T/C	cg26647111	chr11:31128758	NA	-0.41	-6.03	-0.31	4.44e-9	Red blood cell count;
LUSC	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	0.51	7.23	0.37	3.26e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.71	0.57	1.8e-30	Bipolar disorder;
LUSC	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-7.21	-0.37	3.8e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg18681998	chr4:17616180	MED28	0.89	15.6	0.65	1.34e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.46	6.11	0.32	2.79e-9	Renal function-related traits (BUN);
LUSC	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg21252483	chr19:49399788	TULP2	-0.48	-6.77	-0.35	5.81e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.61	10.19	0.49	2.08e-21	Blood metabolite levels;
LUSC	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg12140854	chr5:148520817	ABLIM3	-0.42	-6.14	-0.32	2.38e-9	Breast cancer;
LUSC	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg04455712	chr21:45112962	RRP1B	0.45	8.36	0.42	1.69e-15	Mean corpuscular volume;
LUSC	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg04920474	chr2:44395004	PPM1B	0.66	8.33	0.41	2.1e-15	Height;
LUSC	cis	rs5770917	1.000	rs12627787	chr22:51012381	C/T	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.65	-5.7	-0.3	2.7e-8	Narcolepsy;
LUSC	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.49	-0.42	6.89e-16	Total cholesterol levels;
LUSC	cis	rs6977660	1.000	rs5017196	chr7:19819983	T/C	cg07541023	chr7:19748670	TWISTNB	0.51	5.7	0.3	2.6e-8	Thyroid stimulating hormone;
LUSC	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg11502198	chr6:26597334	ABT1	0.72	12.07	0.55	4.23e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg06784218	chr1:46089804	CCDC17	-0.47	-9.14	-0.45	6.34e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2236918	1.000	rs735943	chr1:242030151	C/T	cg17736920	chr1:242011382	EXO1	-0.43	-6.75	-0.35	6.37e-11	Menopause (age at onset);
LUSC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.5	-11.48	-0.53	6.06e-26	Longevity;
LUSC	trans	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg10756647	chr7:56101905	PSPH	-0.86	-8.46	-0.42	8.51e-16	Diabetic kidney disease;
LUSC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg05347473	chr6:146136440	FBXO30	0.54	9.33	0.45	1.51e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3764563	1.000	rs623675	chr19:15705115	G/A	cg20725493	chr19:15740067	CYP4F8	0.67	6.55	0.34	2.2e-10	Inflammatory biomarkers;
LUSC	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg15704280	chr7:45808275	SEPT13	0.76	8.47	0.42	8.13e-16	Axial length;
LUSC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg06263672	chr7:65235340	NA	-0.44	-6.46	-0.33	3.61e-10	Calcium levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg15878588	chr22:38203858	GCAT	-0.42	-6.42	-0.33	4.76e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3784262	0.607	rs4646576	chr15:58338998	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.0	-0.36	1.39e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs4494114	0.875	rs7518432	chr1:39363522	G/C	cg25970120	chr1:39325951	RRAGC	-0.4	-6.22	-0.32	1.49e-9	Blood protein levels;
LUSC	cis	rs62400317	0.859	rs11965706	chr6:45141441	T/A	cg18551225	chr6:44695536	NA	-0.43	-6.92	-0.35	2.37e-11	Total body bone mineral density;
LUSC	trans	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	7.26	0.37	2.72e-12	Menarche (age at onset);
LUSC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.69	0.83	1.71e-88	Chronic sinus infection;
LUSC	cis	rs721399	0.553	rs10095072	chr8:18244662	G/T	cg18736775	chr8:18248649	NAT2	-0.55	-6.57	-0.34	1.88e-10	Blood metabolite levels;
LUSC	cis	rs7192380	1.000	rs2161630	chr16:69606461	C/T	cg26679644	chr16:69762563	NA	0.36	6.21	0.32	1.61e-9	Sjögren's syndrome;
LUSC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg09904177	chr6:26538194	HMGN4	0.47	7.48	0.38	6.76e-13	Schizophrenia;
LUSC	cis	rs4961252	0.505	rs12680168	chr8:142102522	A/T	cg09914555	chr8:142094789	NA	-0.48	-7.18	-0.37	4.52e-12	Isovolumetric relaxation time;Response to interferon beta therapy;
LUSC	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg00701064	chr4:6280414	WFS1	0.47	8.34	0.42	1.91e-15	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg21724239	chr8:58056113	NA	0.56	6.86	0.35	3.37e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7923837	0.656	rs2497306	chr10:94485211	A/C	cg25093409	chr10:94429542	NA	-0.35	-6.0	-0.31	5.16e-9	Body mass index;Multiple sclerosis;
LUSC	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg08773314	chr2:239334832	ASB1	0.39	8.26	0.41	3.49e-15	Multiple system atrophy;
LUSC	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg22815214	chr1:201083145	CACNA1S	0.6	10.44	0.5	2.77e-22	Permanent tooth development;
LUSC	cis	rs7072216	0.922	rs10786415	chr10:100151266	A/G	cg26618903	chr10:100175079	PYROXD2	-0.3	-5.95	-0.31	6.89e-9	Metabolite levels;
LUSC	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg00071950	chr4:10020882	SLC2A9	0.47	7.69	0.39	1.63e-13	Bone mineral density;
LUSC	cis	rs3820068	0.608	rs12760450	chr1:16037282	G/A	cg24675056	chr1:15929824	NA	0.41	6.83	0.35	4.07e-11	Systolic blood pressure;
LUSC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg27284194	chr4:1044797	NA	0.37	5.98	0.31	5.75e-9	Longevity;
LUSC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg23982607	chr1:1823379	GNB1	0.35	5.85	0.3	1.18e-8	Body mass index;
LUSC	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-8.23	-0.41	4.19e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08859206	chr1:53392774	SCP2	0.5	8.58	0.43	3.56e-16	Monocyte count;
LUSC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.6	-9.93	-0.48	1.56e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.85	-0.58	5.7e-31	Chronic sinus infection;
LUSC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg02475777	chr4:1388615	CRIPAK	0.44	6.58	0.34	1.84e-10	Obesity-related traits;
LUSC	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg24130564	chr14:104152367	KLC1	-0.7	-11.17	-0.52	7.85e-25	Intelligence (multi-trait analysis);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18788872	chr11:32605728	EIF3M	0.46	6.4	0.33	5.35e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg08888203	chr3:10149979	C3orf24	-0.42	-6.44	-0.33	4.12e-10	Alzheimer's disease;
LUSC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg11062466	chr8:58055876	NA	0.76	9.04	0.44	1.31e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg02153584	chr22:29168773	CCDC117	0.58	8.72	0.43	1.35e-16	Lymphocyte counts;
LUSC	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22590775	chr19:49891494	CCDC155	0.57	7.4	0.38	1.09e-12	Multiple sclerosis;
LUSC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg05585544	chr11:47624801	NA	0.41	7.19	0.37	4.39e-12	Subjective well-being;
LUSC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.1	0.52	1.39e-24	Alzheimer's disease;
LUSC	cis	rs116988415	0.584	rs78707026	chr14:65249283	A/G	cg00114569	chr14:65239327	SPTB	0.63	6.92	0.35	2.28e-11	Daytime sleep phenotypes;
LUSC	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03352830	chr11:487213	PTDSS2	0.74	8.84	0.44	5.65e-17	Body mass index;
LUSC	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	0.57	9.07	0.44	1.02e-17	Breast cancer;
LUSC	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg12863693	chr15:85201151	NMB	0.37	6.88	0.35	2.97e-11	Schizophrenia;
LUSC	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg22681709	chr2:178499509	PDE11A	-0.53	-8.28	-0.41	3.04e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg06618935	chr21:46677482	NA	-0.35	-6.79	-0.35	5.25e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg23625390	chr15:77176239	SCAPER	-0.67	-10.37	-0.49	5.18e-22	Blood metabolite levels;
LUSC	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg03929089	chr4:120376271	NA	0.69	7.78	0.39	9.14e-14	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs4845570	1.000	rs6683364	chr1:151746202	T/A	cg07092448	chr1:151763213	TDRKH	-1.27	-14.41	-0.62	5.93e-37	Coronary artery disease;
LUSC	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg03929089	chr4:120376271	NA	-0.45	-6.12	-0.32	2.58e-9	HDL cholesterol;
LUSC	cis	rs500891	1.000	rs36017560	chr6:84181468	T/C	cg08257003	chr6:84140564	ME1	0.34	7.02	0.36	1.26e-11	Platelet-derived growth factor BB levels;
LUSC	trans	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.39	0.42	1.38e-15	Diabetic kidney disease;
LUSC	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg17052675	chr2:3827356	NA	0.63	9.81	0.47	4.08e-20	Type 2 diabetes;
LUSC	cis	rs12618769	0.597	rs72821956	chr2:99159966	G/T	cg10123293	chr2:99228465	UNC50	0.5	8.14	0.41	7.98e-15	Bipolar disorder;
LUSC	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg09835421	chr16:68378352	PRMT7	-0.5	-5.72	-0.3	2.37e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs500891	0.672	rs1418734	chr6:84163888	G/A	cg08257003	chr6:84140564	ME1	0.38	9.07	0.44	1.08e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-11.11	-0.52	1.26e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs57590327	0.504	rs4856349	chr3:81502928	C/T	cg07356753	chr3:81810745	GBE1	0.46	6.15	0.32	2.21e-9	Extraversion;
LUSC	cis	rs9653442	0.863	rs10865035	chr2:100835734	A/G	cg22139774	chr2:100720529	AFF3	-0.44	-7.95	-0.4	2.82e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7119038	0.818	rs4936441	chr11:118725660	C/G	cg19308663	chr11:118741387	NA	-0.36	-6.14	-0.32	2.34e-9	Sjögren's syndrome;
LUSC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	12.24	0.56	1.05e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs11608355	0.515	rs2287191	chr12:109931741	C/T	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs12541635	0.967	rs13256474	chr8:107086419	T/C	cg10147462	chr8:107024639	NA	-0.47	-8.6	-0.43	3.13e-16	Age of smoking initiation;
LUSC	cis	rs10875595	0.836	rs2879202	chr5:140668375	G/T	cg24830062	chr5:140700576	TAF7	-0.52	-6.49	-0.33	3.17e-10	Pulmonary function decline;
LUSC	cis	rs10144321	0.903	rs1212911	chr14:100917372	C/T	cg14882082	chr14:100845427	WDR25	-0.42	-8.03	-0.4	1.67e-14	Menarche (age at onset);
LUSC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.63	-8.13	-0.41	8.49e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs62400317	0.762	rs9367210	chr6:44863395	G/A	cg18551225	chr6:44695536	NA	-0.46	-7.44	-0.38	8.7e-13	Total body bone mineral density;
LUSC	trans	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Depression;
LUSC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg09655341	chr17:79618100	PDE6G	-0.28	-6.31	-0.33	8.88e-10	Eye color traits;
LUSC	cis	rs9920506	0.536	rs11072768	chr15:78929478	A/C	cg04896959	chr15:78267971	NA	0.37	6.59	0.34	1.76e-10	Post bronchodilator FEV1;
LUSC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.56	-0.67	2.25e-45	Monocyte count;
LUSC	cis	rs10170310	0.872	rs62161711	chr2:139259222	A/G	cg03782584	chr2:139258740	SPOPL	0.33	5.89	0.31	9.56e-9	Response to antipsychotic treatment;
LUSC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.24	0.37	3.16e-12	Platelet count;
LUSC	cis	rs3770081	1.000	rs56104203	chr2:86336256	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.04	-7.32	-0.37	1.86e-12	Facial emotion recognition (sad faces);
LUSC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	11.16	0.52	8.78e-25	Prudent dietary pattern;
LUSC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg03732007	chr1:2071316	PRKCZ	-0.54	-9.94	-0.48	1.46e-20	Height;
LUSC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.6	8.63	0.43	2.63e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs17155006	0.746	rs430628	chr7:107746214	T/G	cg05962710	chr7:107745446	LAMB4	-0.36	-6.52	-0.34	2.57e-10	Pneumococcal bacteremia;
LUSC	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.57	-0.34	1.94e-10	Schizophrenia;
LUSC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-17.0	-0.68	3.84e-47	Gut microbiome composition (summer);
LUSC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg25258033	chr6:167368657	RNASET2	0.37	5.83	0.3	1.28e-8	Crohn's disease;
LUSC	trans	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg10756647	chr7:56101905	PSPH	0.84	9.21	0.45	3.82e-18	Diabetic kidney disease;
LUSC	cis	rs55894533	0.597	rs2645408	chr8:11746358	A/G	cg21281001	chr8:11725306	CTSB	0.42	5.76	0.3	1.92e-8	Leprosy;
LUSC	cis	rs9896052	0.649	rs6501801	chr17:73447030	A/G	cg25649188	chr17:73499917	CASKIN2	-0.38	-5.87	-0.31	1.04e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
LUSC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg08859206	chr1:53392774	SCP2	0.49	8.33	0.41	2.13e-15	Monocyte count;
LUSC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg16586182	chr3:47516702	SCAP	0.53	8.62	0.43	2.66e-16	Colorectal cancer;
LUSC	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg11843238	chr5:131593191	PDLIM4	0.33	5.96	0.31	6.53e-9	Blood metabolite levels;
LUSC	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg21100191	chr22:23484243	RTDR1	0.88	15.05	0.64	1.99e-39	Bone mineral density;
LUSC	cis	rs10788264	0.621	rs9633734	chr10:124057667	T/C	cg09507567	chr10:124027408	NA	0.43	7.09	0.36	8e-12	Total body bone mineral density;
LUSC	cis	rs9362426	1.000	rs242271	chr6:88082029	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	5.85	0.31	1.15e-8	Depressive episodes in bipolar disorder;
LUSC	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.69	-0.47	9.86e-20	Multiple sclerosis;
LUSC	cis	rs16937	0.597	rs3862949	chr1:205103070	A/T	cg00857998	chr1:205179979	DSTYK	0.46	6.56	0.34	1.99e-10	Schizophrenia;
LUSC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	0.81	10.84	0.51	1.14e-23	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg03354898	chr7:1950403	MAD1L1	-0.35	-6.6	-0.34	1.59e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4629180	1.000	rs4851457	chr2:102091220	C/T	cg04415270	chr2:102091202	RFX8	0.56	9.07	0.44	1.02e-17	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg22532475	chr10:104410764	TRIM8	-0.25	-6.04	-0.31	4e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg20744362	chr22:50050164	C22orf34	0.38	7.05	0.36	1.03e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg18827107	chr12:86230957	RASSF9	-0.47	-7.06	-0.36	9.99e-12	Major depressive disorder;
LUSC	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.16	-0.36	5.25e-12	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg11062466	chr8:58055876	NA	0.65	8.33	0.41	2.12e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9399401	1.000	rs972982	chr6:142666861	A/G	cg03128060	chr6:142623767	GPR126	0.31	5.68	0.3	2.97e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.52	0.57	9.53e-30	Motion sickness;
LUSC	cis	rs238295	0.846	rs6053528	chr20:5582598	G/T	cg15842884	chr20:5591925	RP5-1022P6.2	-0.44	-5.96	-0.31	6.53e-9	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs6882046	0.513	rs647983	chr5:88048071	T/C	cg22951263	chr5:87985283	NA	-0.47	-7.72	-0.39	1.39e-13	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LUSC	trans	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg18187862	chr3:45730750	SACM1L	0.55	7.09	0.36	8.01e-12	Primary sclerosing cholangitis;
LUSC	cis	rs6546550	0.901	rs6739780	chr2:70138111	G/A	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg16797656	chr11:68205561	LRP5	0.38	6.19	0.32	1.77e-9	Total body bone mineral density;
LUSC	cis	rs9309473	0.607	rs12478346	chr2:73584360	C/T	cg20560298	chr2:73613845	ALMS1	-0.61	-8.96	-0.44	2.37e-17	Metabolite levels;
LUSC	cis	rs36093844	0.698	rs79435802	chr11:85585206	T/C	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.53	-8.59	-0.43	3.48e-16	Height;
LUSC	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg21775007	chr8:11205619	TDH	-0.51	-7.45	-0.38	7.94e-13	Neuroticism;
LUSC	cis	rs10419226	0.540	rs6510995	chr19:18770776	G/A	cg22001208	chr19:18782374	NA	-0.38	-6.39	-0.33	5.73e-10	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-9.3	-0.45	1.91e-18	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25072359	chr17:41440525	NA	0.69	9.65	0.47	1.36e-19	Menopause (age at onset);
LUSC	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs983392	0.709	rs56273223	chr11:59984676	A/C	cg02771260	chr11:59836817	MS4A3	-0.36	-5.92	-0.31	8.12e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.44	6.87	0.35	3.17e-11	Resistin levels;
LUSC	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg05855489	chr10:104503620	C10orf26	-0.48	-7.35	-0.37	1.53e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg12784241	chr6:158402508	SYNJ2	0.36	6.08	0.32	3.3e-9	Educational attainment (years of education);
LUSC	cis	rs887829	0.570	rs10168333	chr2:234596988	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.39	-6.28	-0.33	1.04e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs3087591	0.922	rs2905801	chr17:29524974	C/T	cg24425628	chr17:29625626	OMG;NF1	0.6	8.55	0.42	4.36e-16	Hip circumference;
LUSC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg03684893	chr10:554711	DIP2C	0.35	6.03	0.31	4.24e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg07587117	chr16:2239488	CASKIN1	0.33	6.44	0.33	4.27e-10	Height;
LUSC	trans	rs10511400	0.618	rs923726	chr3:119917879	T/C	cg02809009	chr19:50354510	PTOV1	-0.72	-6.43	-0.33	4.52e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg00343986	chr7:65444356	GUSB	0.44	6.8	0.35	4.95e-11	Aortic root size;
LUSC	cis	rs4343996	0.558	rs10235815	chr7:3413867	T/G	cg21248987	chr7:3385318	SDK1	0.36	6.19	0.32	1.8e-9	Motion sickness;
LUSC	cis	rs422249	0.634	rs174616	chr11:61629122	C/T	cg06860612	chr11:61641270	FADS3	0.28	5.89	0.31	9.66e-9	Trans fatty acid levels;
LUSC	cis	rs4499344	0.556	rs438268	chr19:33109904	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.9	12.49	0.56	1.22e-29	Mean platelet volume;
LUSC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg11871910	chr12:69753446	YEATS4	0.6	8.04	0.4	1.6e-14	Response to diuretic therapy;
LUSC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg00339695	chr16:24857497	SLC5A11	-0.36	-5.98	-0.31	5.69e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-0.85	-14.94	-0.63	5.32e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9463078	0.764	rs6458415	chr6:44881592	G/C	cg25276700	chr6:44698697	NA	-0.28	-5.74	-0.3	2.08e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg10253484	chr15:75165896	SCAMP2	-0.49	-6.48	-0.33	3.26e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg02018176	chr4:1364513	KIAA1530	0.44	6.2	0.32	1.66e-9	Recombination rate (females);
LUSC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24110177	chr3:50126178	RBM5	-0.64	-11.08	-0.52	1.67e-24	Body mass index;
LUSC	cis	rs4077515	0.806	rs3812564	chr9:139271190	A/G	cg14019695	chr9:139328340	INPP5E	0.43	8.25	0.41	3.6e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg24069376	chr3:38537580	EXOG	-0.4	-7.65	-0.39	2.16e-13	Electrocardiographic conduction measures;
LUSC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	1.2	13.92	0.61	4.64e-35	Diabetic kidney disease;
LUSC	cis	rs3849570	0.555	rs4481177	chr3:81996817	A/T	cg07356753	chr3:81810745	GBE1	0.42	6.09	0.32	3.1e-9	Waist circumference;Body mass index;
LUSC	trans	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.64	-10.89	-0.51	7.99e-24	Mean corpuscular volume;
LUSC	cis	rs4629710	0.538	rs11754401	chr6:131582197	G/A	cg12606694	chr6:131520996	AKAP7	0.63	9.65	0.47	1.36e-19	Multiple myeloma (IgH translocation);
LUSC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg06096015	chr1:231504339	EGLN1	0.54	9.38	0.46	1.02e-18	Hemoglobin concentration;
LUSC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg01871581	chr19:12707946	ZNF490	-0.57	-8.85	-0.44	5.04e-17	Bipolar disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg08467185	chr19:12917312	RNASEH2A	0.74	6.19	0.32	1.79e-9	Cognitive performance;
LUSC	cis	rs9549260	0.755	rs9532571	chr13:41218670	C/T	cg21288729	chr13:41239152	FOXO1	0.61	9.47	0.46	5.35e-19	Red blood cell count;
LUSC	cis	rs6554196	0.508	rs999021	chr4:55524533	C/G	cg18836493	chr4:55524333	KIT	-0.43	-7.43	-0.38	9.31e-13	Monocyte count;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg02107564	chr22:41488750	EP300	0.43	6.55	0.34	2.19e-10	Triglycerides;
LUSC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg25036284	chr2:26402008	FAM59B	0.69	9.19	0.45	4.15e-18	Gut microbiome composition (summer);
LUSC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg17971929	chr21:40555470	PSMG1	-0.47	-7.13	-0.36	6.08e-12	Menarche (age at onset);
LUSC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg14895029	chr7:2775587	GNA12	-0.42	-6.48	-0.33	3.37e-10	Height;
LUSC	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	7.09	0.36	8.23e-12	Resting heart rate;
LUSC	cis	rs4400599	0.549	rs12044616	chr1:154189417	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-6.15	-0.32	2.24e-9	Platelet distribution width;
LUSC	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg25428297	chr7:1022841	CYP2W1	0.28	6.01	0.31	4.82e-9	Longevity;Endometriosis;
LUSC	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg25272121	chr1:152190972	HRNR	-0.39	-6.76	-0.35	6.05e-11	Inflammatory skin disease;
LUSC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.87	-12.47	-0.56	1.47e-29	Initial pursuit acceleration;
LUSC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg04727924	chr7:799746	HEATR2	-0.55	-6.67	-0.34	1.07e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9399401	0.961	rs2039986	chr6:142655238	G/A	cg03128060	chr6:142623767	GPR126	0.31	5.68	0.3	3e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-8.81	-0.43	6.75e-17	Schizophrenia;
LUSC	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg00757033	chr12:89920650	WDR51B	0.59	10.34	0.49	6.1e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg27411982	chr8:10470053	RP1L1	-0.38	-5.9	-0.31	8.95e-9	Neuroticism;
LUSC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs3784262	1.000	rs7495968	chr15:58244103	C/G	cg12031962	chr15:58353849	ALDH1A2	0.33	6.19	0.32	1.8e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg01802117	chr1:53393560	SCP2	-0.39	-6.37	-0.33	6.33e-10	Monocyte count;
LUSC	trans	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg26384229	chr12:38710491	ALG10B	0.58	9.51	0.46	4.02e-19	Morning vs. evening chronotype;
LUSC	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg19336497	chr11:14380999	RRAS2	-0.32	-5.68	-0.3	2.96e-8	Mitochondrial DNA levels;
LUSC	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.47	8.77	0.43	9.43e-17	Axial length;
LUSC	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg02696742	chr7:106810147	HBP1	-0.63	-9.54	-0.46	3.16e-19	Coronary artery disease;
LUSC	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg06640241	chr16:89574553	SPG7	0.71	11.32	0.53	2.24e-25	Multiple myeloma (IgH translocation);
LUSC	cis	rs6845621	0.700	rs6839469	chr4:18916269	A/G	cg12196642	chr4:18937545	NA	-0.34	-6.29	-0.33	9.99e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.63	-0.34	1.36e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg21770322	chr7:97807741	LMTK2	0.41	7.21	0.37	3.79e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg15133208	chr4:90757351	SNCA	-0.53	-8.19	-0.41	5.6e-15	Neuroticism;
LUSC	cis	rs17014483	1.000	rs2860528	chr4:89655632	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.68	5.76	0.3	1.93e-8	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	8.74	0.43	1.13e-16	Menarche (age at onset);
LUSC	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg24375607	chr4:120327624	NA	0.78	11.57	0.53	2.96e-26	Corneal astigmatism;
LUSC	cis	rs3857536	0.813	rs9360190	chr6:66942302	T/C	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs56283067	0.887	rs12215095	chr6:44756910	T/C	cg20913747	chr6:44695427	NA	-0.43	-6.69	-0.34	9.17e-11	Total body bone mineral density;
LUSC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg20135002	chr11:47629003	NA	-0.52	-8.15	-0.41	7.6e-15	Subjective well-being;
LUSC	cis	rs9943753	0.508	rs7138357	chr12:109832303	A/G	cg19025524	chr12:109796872	NA	-0.38	-6.98	-0.36	1.59e-11	HDL cholesterol;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01858923	chr14:65569399	MAX	-0.41	-6.0	-0.31	5.09e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg06238570	chr21:40685208	BRWD1	0.48	7.49	0.38	6.36e-13	Cognitive function;
LUSC	cis	rs2479724	1.000	rs2479724	chr6:41890982	T/C	cg17623882	chr6:41773611	USP49	-0.62	-10.15	-0.49	2.91e-21	Menarche (age at onset);
LUSC	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.74	-10.99	-0.52	3.32e-24	Glomerular filtration rate;
LUSC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	6.99	0.36	1.51e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-8.73	-0.43	1.2e-16	Obesity-related traits;
LUSC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg25767906	chr1:53392781	SCP2	-0.51	-9.21	-0.45	3.7e-18	Monocyte count;
LUSC	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg02023728	chr11:77925099	USP35	0.46	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg00012203	chr2:219082015	ARPC2	-0.56	-8.98	-0.44	2.07e-17	Ulcerative colitis;
LUSC	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.13	-0.32	2.47e-9	Neutrophil percentage of white cells;
LUSC	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg25173405	chr17:45401733	C17orf57	-0.4	-6.38	-0.33	5.8e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg03806693	chr22:41940476	POLR3H	0.85	12.22	0.56	1.25e-28	Vitiligo;
LUSC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg24531977	chr5:56204891	C5orf35	-0.72	-10.75	-0.51	2.41e-23	Coronary artery disease;
LUSC	trans	rs750134	0.901	rs12423733	chr12:109117989	C/T	cg23338993	chr2:234600423	UGT1A10;UGT1A6;UGT1A9;UGT1A7;UGT1A8	0.48	6.05	0.31	3.94e-9	Low high density lipoprotein cholesterol levels;
LUSC	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg08000102	chr2:233561755	GIGYF2	0.67	11.12	0.52	1.16e-24	Coronary artery disease;
LUSC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.87	-0.31	1.06e-8	Platelet count;
LUSC	trans	rs564343	0.583	rs571374	chr11:65817592	C/T	cg26701943	chr11:108369231	KDELC2	-0.44	-6.12	-0.32	2.6e-9	Obesity (early onset extreme);
LUSC	cis	rs4654899	0.643	rs589755	chr1:21099846	A/G	cg01072550	chr1:21505969	NA	-0.45	-6.78	-0.35	5.43e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg12935359	chr14:103987150	CKB	-0.61	-9.88	-0.48	2.35e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg06096015	chr1:231504339	EGLN1	0.57	10.12	0.48	3.69e-21	Hemoglobin concentration;
LUSC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-6.96	-0.36	1.84e-11	Bipolar disorder;
LUSC	cis	rs7615316	0.779	rs4441672	chr3:142149212	C/T	cg16271453	chr3:142027066	XRN1	-0.42	-7.15	-0.36	5.43e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg03878208	chr11:72483293	STARD10	0.59	7.71	0.39	1.45e-13	Type 2 diabetes;
LUSC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg18904891	chr8:8559673	CLDN23	0.6	8.32	0.41	2.27e-15	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.41	0.42	1.2e-15	Prudent dietary pattern;
LUSC	cis	rs7577696	0.711	rs385076	chr2:32489851	T/C	cg02381751	chr2:32503542	YIPF4	0.42	6.0	0.31	5.1e-9	Inflammatory biomarkers;
LUSC	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg15704280	chr7:45808275	SEPT13	0.62	7.69	0.39	1.62e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs35883536	0.566	rs12566440	chr1:101095202	A/G	cg06223162	chr1:101003688	GPR88	0.36	6.39	0.33	5.7e-10	Monocyte count;
LUSC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg06221963	chr1:154839813	KCNN3	0.46	9.08	0.44	9.72e-18	Prostate cancer;
LUSC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.74	-11.22	-0.52	5.44e-25	Menarche (age at onset);
LUSC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg08684580	chr7:98029266	BAIAP2L1	0.45	8.35	0.42	1.83e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4664308	0.618	rs35771982	chr2:160885418	G/C	cg03641300	chr2:160917029	PLA2R1	-0.47	-7.74	-0.39	1.15e-13	Idiopathic membranous nephropathy;
LUSC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.01	0.31	4.88e-9	Menopause (age at onset);
LUSC	trans	rs10090774	0.965	rs11780104	chr8:142002107	C/T	cg16477744	chr7:157367142	PTPRN2;MIR153-2	0.28	6.04	0.31	4.13e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs4478037	1.000	rs61433006	chr3:33162363	T/A	cg19404215	chr3:33155277	CRTAP	0.96	10.11	0.48	4.01e-21	Major depressive disorder;
LUSC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg02951883	chr7:2050386	MAD1L1	-0.51	-9.06	-0.44	1.11e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11764359	chr7:65958608	NA	0.63	9.44	0.46	6.47e-19	Aortic root size;
LUSC	cis	rs4253772	0.872	rs78864133	chr22:46638486	C/T	cg24881330	chr22:46731750	TRMU	0.63	5.78	0.3	1.72e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg09904177	chr6:26538194	HMGN4	0.73	13.27	0.59	1.45e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs1864400	0.690	rs2565200	chr10:43622933	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.41	-6.94	-0.35	2.08e-11	Hirschsprung disease;
LUSC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.48	8.42	0.42	1.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg25333225	chr19:40791658	AKT2	-0.55	-6.76	-0.35	6.26e-11	Height;
LUSC	cis	rs12286929	0.780	rs2187986	chr11:115001410	C/T	cg04055981	chr11:115044050	NA	0.33	5.73	0.3	2.19e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	0.98	16.07	0.66	1.85e-43	Testicular germ cell tumor;
LUSC	cis	rs13089785	0.965	rs12493045	chr3:123620718	C/A	cg01860459	chr3:123419554	MYLK	0.35	5.95	0.31	6.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg18240062	chr17:79603768	NPLOC4	0.69	12.86	0.58	4.98e-31	Eye color traits;
LUSC	cis	rs926938	0.527	rs360684	chr1:115499001	A/G	cg12756093	chr1:115239321	AMPD1	0.43	6.51	0.34	2.69e-10	Autism;
LUSC	cis	rs56399783	0.901	rs73049380	chr7:2832845	C/T	cg19731401	chr7:2775893	GNA12	0.69	9.57	0.46	2.53e-19	Childhood ear infection;
LUSC	cis	rs12190007	0.517	rs3006183	chr6:169808263	T/C	cg15038512	chr6:170123185	PHF10	-0.38	-6.14	-0.32	2.34e-9	Obesity-related traits;
LUSC	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg14092571	chr14:90743983	NA	-0.9	-18.67	-0.71	8.83e-54	Gut microbiota (bacterial taxa);
LUSC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg11843238	chr5:131593191	PDLIM4	0.46	7.78	0.39	9.34e-14	Acylcarnitine levels;
LUSC	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	1.01	16.73	0.68	4.65e-46	Gout;Urate levels;Serum uric acid levels;
LUSC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg03676636	chr4:99064102	C4orf37	0.34	7.56	0.38	3.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg09179987	chr1:167433047	CD247	-0.36	-5.94	-0.31	7.26e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.5	-8.85	-0.44	5.33e-17	Menopause (age at onset);
LUSC	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg06637938	chr14:75390232	RPS6KL1	0.53	8.62	0.43	2.76e-16	Height;
LUSC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07677032	chr17:61819896	STRADA	0.49	8.18	0.41	6.14e-15	Prudent dietary pattern;
LUSC	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.12	26.67	0.82	9.47e-85	Schizophrenia;
LUSC	cis	rs983392	0.709	rs4939320	chr11:59981801	T/C	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.07	-0.32	3.51e-9	Alzheimer's disease (late onset);
LUSC	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg11019008	chr10:131425282	MGMT	-0.41	-6.26	-0.32	1.16e-9	Response to temozolomide;
LUSC	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg21231944	chr12:82153410	PPFIA2	-0.4	-5.93	-0.31	7.71e-9	Resting heart rate;
LUSC	trans	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg20935933	chr6:143382018	AIG1	0.5	7.32	0.37	1.92e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs2996428	0.667	rs11578581	chr1:3770642	G/A	cg22529645	chr1:3704559	LRRC47	0.35	6.12	0.32	2.63e-9	Red cell distribution width;
LUSC	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.44	-6.55	-0.34	2.2e-10	Neuroticism;
LUSC	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg20243544	chr17:37824526	PNMT	0.53	7.78	0.39	9.15e-14	Asthma;
LUSC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg22823121	chr1:150693482	HORMAD1	0.59	9.21	0.45	3.57e-18	Tonsillectomy;
LUSC	cis	rs6736093	0.901	rs34875611	chr2:112763025	G/A	cg12686935	chr2:112915763	FBLN7	-0.37	-5.96	-0.31	6.41e-9	Coronary artery disease;
LUSC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg08270630	chr22:50330655	NA	-0.44	-6.61	-0.34	1.48e-10	Schizophrenia;
LUSC	cis	rs3820928	0.874	rs2177594	chr2:227836239	C/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.52	-0.38	5.01e-13	Pulmonary function;
LUSC	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.6e-16	Lung cancer;
LUSC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg05082376	chr22:42548792	NA	0.43	6.55	0.34	2.14e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg17749961	chr2:30669863	LCLAT1	-0.62	-7.67	-0.39	1.96e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.05	0.36	1.03e-11	Bipolar disorder;
LUSC	cis	rs952623	0.649	rs6974522	chr7:39073372	G/C	cg15212455	chr7:39170539	POU6F2	0.36	5.86	0.31	1.09e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg13607699	chr17:42295918	UBTF	0.49	7.63	0.39	2.41e-13	Total body bone mineral density;
LUSC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	-1.18	-21.49	-0.76	6.25e-65	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg24579218	chr15:68104479	NA	-0.37	-6.48	-0.33	3.25e-10	Restless legs syndrome;
LUSC	cis	rs9399401	0.845	rs263186	chr6:142861491	A/G	cg03128060	chr6:142623767	GPR126	0.31	5.86	0.31	1.13e-8	Chronic obstructive pulmonary disease;
LUSC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg07395648	chr5:131743802	NA	-0.38	-5.76	-0.3	1.88e-8	Breast cancer;
LUSC	cis	rs11018904	0.906	rs10501713	chr11:89953013	G/A	cg26028595	chr11:89956573	CHORDC1	-0.52	-6.11	-0.32	2.84e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg10596483	chr8:143751796	JRK	0.52	7.57	0.38	3.79e-13	Schizophrenia;
LUSC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.71	0.6	3.09e-34	Cognitive test performance;
LUSC	trans	rs2262909	1.000	rs2078089	chr19:22209753	A/T	cg17074339	chr11:11642133	GALNTL4	-0.41	-6.2	-0.32	1.68e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs36093844	0.615	rs77258124	chr11:85578081	G/A	cg25872744	chr11:85566296	CCDC83	-0.45	-5.88	-0.31	9.88e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg24642844	chr7:1081250	C7orf50	-0.7	-10.18	-0.49	2.21e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg05784532	chr1:230284198	GALNT2	0.49	7.39	0.38	1.16e-12	Coronary artery disease;
LUSC	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.63	-7.82	-0.39	6.77e-14	Yeast infection;
LUSC	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg13852791	chr20:30311386	BCL2L1	0.79	8.89	0.44	3.84e-17	Mean corpuscular hemoglobin;
LUSC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-7.44	-0.38	8.51e-13	Aortic root size;
LUSC	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg00012203	chr2:219082015	ARPC2	-0.75	-12.9	-0.58	3.64e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs12530845	0.673	rs4073627	chr7:135312572	A/G	cg23117316	chr7:135346802	PL-5283	0.62	9.77	0.47	5.55e-20	Red blood cell traits;
LUSC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7827545	1.000	rs1372662	chr8:135567046	C/G	cg17885191	chr8:135476712	NA	0.58	8.9	0.44	3.71e-17	Hypertension (SNP x SNP interaction);
LUSC	cis	rs1865721	0.682	rs3745082	chr18:73142734	G/T	cg26385618	chr18:73139727	C18orf62	-0.47	-8.83	-0.44	5.92e-17	Intelligence;
LUSC	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg17366294	chr4:99064904	C4orf37	0.5	8.71	0.43	1.48e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg14784868	chr12:69753453	YEATS4	0.54	8.07	0.4	1.27e-14	Response to diuretic therapy;
LUSC	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg08085267	chr17:45401833	C17orf57	0.59	9.85	0.47	2.96e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7112925	0.738	rs11227673	chr11:66832528	C/T	cg24851651	chr11:66362959	CCS	-0.36	-6.05	-0.31	3.83e-9	Height;
LUSC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg19592336	chr6:28129416	ZNF389	0.5	6.6	0.34	1.61e-10	Parkinson's disease;
LUSC	trans	rs140364877	1	rs140364877	chr7:1885178	C/T	cg11244813	chr1:145039882	PDE4DIP	0.38	6.05	0.31	3.88e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg01689657	chr7:91764605	CYP51A1	0.31	5.73	0.3	2.22e-8	Breast cancer;
LUSC	cis	rs10992471	0.603	rs12341817	chr9:95252152	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.77	-0.39	9.98e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs12651329	1.000	rs12651329	chr4:36079594	A/G	cg11850622	chr4:159593397	ETFDH;C4orf46	-0.39	-6.04	-0.31	4.05e-9	Amyotrophic lateral sclerosis (age of onset);
LUSC	cis	rs12928939	0.911	rs11645704	chr16:71826611	G/T	cg03805757	chr16:71968109	PKD1L3	-0.46	-6.65	-0.34	1.23e-10	Post bronchodilator FEV1;
LUSC	cis	rs7605827	0.930	rs4668918	chr2:15661992	A/T	cg19274914	chr2:15703543	NA	0.44	8.22	0.41	4.55e-15	Educational attainment (years of education);
LUSC	cis	rs7523050	0.643	rs17563938	chr1:109401654	C/T	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg19592336	chr6:28129416	ZNF389	0.51	6.58	0.34	1.8e-10	Depression;
LUSC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg01181863	chr3:195395398	SDHAP2	-0.54	-7.48	-0.38	6.51e-13	Pancreatic cancer;
LUSC	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg12935359	chr14:103987150	CKB	-0.57	-8.68	-0.43	1.81e-16	Body mass index;
LUSC	cis	rs4557202	0.509	rs12690576	chr3:160647912	G/A	cg03342759	chr3:160939853	NMD3	-0.44	-6.12	-0.32	2.57e-9	Menarche (age at onset);
LUSC	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg24642439	chr20:33292090	TP53INP2	-0.51	-7.62	-0.38	2.73e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg01879757	chr17:41196368	BRCA1	-0.45	-7.33	-0.37	1.7e-12	Menopause (age at onset);
LUSC	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg12140854	chr5:148520817	ABLIM3	-0.4	-5.86	-0.31	1.1e-8	Breast cancer;
LUSC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg20203395	chr5:56204925	C5orf35	-0.74	-10.01	-0.48	8.49e-21	Initial pursuit acceleration;
LUSC	cis	rs2637266	0.655	rs846628	chr10:78538392	G/A	cg18941641	chr10:78392320	NA	0.39	7.06	0.36	9.84e-12	Pulmonary function;
LUSC	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4964805	0.913	rs7134701	chr12:104202691	C/T	cg02344784	chr12:104178138	NT5DC3	0.44	7.07	0.36	9.28e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg14829155	chr15:31115871	NA	-0.55	-6.72	-0.34	8.01e-11	Huntington's disease progression;
LUSC	cis	rs7605827	0.836	rs9287659	chr2:15595755	C/T	cg19274914	chr2:15703543	NA	0.46	8.76	0.43	1e-16	Educational attainment (years of education);
LUSC	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	9.55	0.46	2.9e-19	Mean platelet volume;
LUSC	cis	rs4812048	0.649	rs6070702	chr20:57621562	G/C	cg14073986	chr20:57617431	SLMO2	0.88	9.5	0.46	4.16e-19	Mean platelet volume;
LUSC	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.71	-12.37	-0.56	3.47e-29	White blood cell count (basophil);
LUSC	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg08501292	chr6:25962987	TRIM38	0.65	5.86	0.31	1.12e-8	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg13010199	chr12:38710504	ALG10B	-0.43	-6.35	-0.33	7.23e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs752010	0.695	rs10890155	chr1:42107843	C/T	cg06885757	chr1:42089581	HIVEP3	0.44	8.51	0.42	6.01e-16	Lupus nephritis in systemic lupus erythematosus;
LUSC	trans	rs7916697	0.593	rs7912895	chr10:70021498	A/G	cg04882175	chr6:131122610	NA	-0.48	-6.46	-0.33	3.68e-10	Optic disc area;
LUSC	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19748678	chr4:122722346	EXOSC9	-0.49	-7.32	-0.37	1.82e-12	Type 2 diabetes;
LUSC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	6.23	0.32	1.44e-9	Personality dimensions;
LUSC	cis	rs1419980	0.673	rs4883421	chr12:7774028	A/G	cg25828445	chr12:7781288	NA	0.58	6.09	0.32	3.03e-9	HDL cholesterol levels;
LUSC	trans	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg13565492	chr6:43139072	SRF	-0.61	-6.4	-0.33	5.21e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.89e-10	Life satisfaction;
LUSC	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg22532475	chr10:104410764	TRIM8	-0.25	-5.99	-0.31	5.4e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg09003973	chr2:102972529	NA	1.22	13.03	0.58	1.2e-31	Gut microbiota (bacterial taxa);
LUSC	trans	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg26043149	chr18:55253948	FECH	-0.46	-7.06	-0.36	9.71e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg15242686	chr22:24348715	GSTTP1	0.48	7.59	0.38	3.24e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg05343316	chr1:45956843	TESK2	0.62	8.63	0.43	2.49e-16	Platelet count;
LUSC	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg01620082	chr3:125678407	NA	-0.8	-7.32	-0.37	1.86e-12	Depression;
LUSC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg11871910	chr12:69753446	YEATS4	0.91	16.98	0.68	4.65e-47	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs12692738	0.526	rs355860	chr2:165629911	T/G	cg26993132	chr16:89239499	CDH15	0.31	6.03	0.31	4.36e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2835872	0.965	rs2835849	chr21:39011524	T/C	cg20424643	chr21:39039972	KCNJ6	0.39	6.05	0.31	3.87e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.44	-5.7	-0.3	2.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg06392426	chr19:10676186	KRI1	-0.48	-5.76	-0.3	1.89e-8	Red cell distribution width;
LUSC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11764359	chr7:65958608	NA	0.62	9.22	0.45	3.55e-18	Aortic root size;
LUSC	trans	rs11723530	0.507	rs4692584	chr4:170814421	C/T	cg14385325	chr17:74564821	ST6GALNAC2	-0.32	-6.28	-0.32	1.03e-9	Myopia (pathological);
LUSC	cis	rs9341808	0.905	rs9343977	chr6:80967001	C/T	cg08355045	chr6:80787529	NA	0.52	9.16	0.45	5.36e-18	Sitting height ratio;
LUSC	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg16342193	chr10:102329863	NA	-0.32	-5.88	-0.31	1.02e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2219968	1.000	rs34130020	chr8:78962583	T/C	cg00738934	chr8:78996279	NA	0.34	6.18	0.32	1.89e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg24531977	chr5:56204891	C5orf35	-0.56	-8.27	-0.41	3.31e-15	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs2073300	1.000	rs6048813	chr20:23448221	G/A	cg09953122	chr20:23471693	CST8	-0.72	-6.61	-0.34	1.54e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-0.84	-10.03	-0.48	7.15e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs853679	1.000	rs853679	chr6:28296863	C/A	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.44	-0.33	4.25e-10	Depression;
LUSC	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg09184832	chr6:79620586	NA	-0.44	-7.0	-0.36	1.39e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10875746	0.859	rs4760680	chr12:48466697	G/T	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs3790645	0.645	rs3790644	chr1:26884676	G/A	cg17456097	chr1:26900765	RPS6KA1	0.52	7.05	0.36	1.03e-11	Glucose homeostasis traits;
LUSC	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg04518342	chr5:131593106	PDLIM4	0.45	8.25	0.41	3.63e-15	Breast cancer;
LUSC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg12310025	chr6:25882481	NA	-0.5	-9.06	-0.44	1.09e-17	Blood metabolite levels;
LUSC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.35	0.37	1.49e-12	Motion sickness;
LUSC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg00376283	chr12:123451042	ABCB9	0.7	9.84	0.47	3.03e-20	Neutrophil percentage of white cells;
LUSC	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg23172400	chr8:95962367	TP53INP1	-0.29	-5.91	-0.31	8.57e-9	Type 2 diabetes;
LUSC	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg20283391	chr11:68216788	NA	-0.6	-8.45	-0.42	9.21e-16	Total body bone mineral density;
LUSC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg23630131	chr7:65973040	NA	0.21	5.66	0.3	3.26e-8	Aortic root size;
LUSC	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg22823121	chr1:150693482	HORMAD1	0.51	7.46	0.38	7.39e-13	Melanoma;
LUSC	cis	rs7202877	0.610	rs11149814	chr16:75332981	T/C	cg04384234	chr16:75411784	CFDP1	-0.63	-8.83	-0.44	6.02e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg25039879	chr17:56429692	SUPT4H1	0.66	9.06	0.44	1.11e-17	Cognitive test performance;
LUSC	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg12935359	chr14:103987150	CKB	0.66	10.79	0.51	1.68e-23	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12881726	chr7:30544409	GGCT	-0.41	-6.06	-0.31	3.61e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg04727924	chr7:799746	HEATR2	0.55	7.13	0.36	6.15e-12	Cerebrospinal P-tau181p levels;
LUSC	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.42	-0.38	1e-12	Neuroticism;
LUSC	cis	rs738322	0.574	rs738323	chr22:38569527	C/T	cg25457927	chr22:38595422	NA	-0.37	-7.21	-0.37	3.8e-12	Cutaneous nevi;
LUSC	cis	rs4132509	0.739	rs10803150	chr1:243822600	C/T	cg21452805	chr1:244014465	NA	0.64	6.87	0.35	3.15e-11	RR interval (heart rate);
LUSC	cis	rs2859741	0.967	rs822854	chr1:37485788	A/G	cg09363841	chr1:37513479	NA	-0.39	-7.78	-0.39	9.37e-14	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg14019146	chr3:50243930	SLC38A3	-0.35	-7.74	-0.39	1.2e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.54	-9.21	-0.45	3.75e-18	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20160885	chr7:5013524	RNF216L	0.4	6.08	0.32	3.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7481584	0.962	rs11024766	chr11:2984645	C/G	cg08508325	chr11:3079039	CARS	0.3	5.84	0.3	1.23e-8	Calcium levels;
LUSC	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg05294307	chr14:35346193	BAZ1A	-0.59	-7.08	-0.36	8.66e-12	Psoriasis;
LUSC	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.62	6.55	0.34	2.16e-10	Schizophrenia;
LUSC	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	1.1	17.07	0.68	1.97e-47	Exhaled nitric oxide output;
LUSC	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg05340658	chr4:99064831	C4orf37	0.69	11.64	0.54	1.62e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg08999081	chr20:33150536	PIGU	-0.41	-7.6	-0.38	3.05e-13	Coronary artery disease;
LUSC	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg25554036	chr4:6271136	WFS1	0.61	12.78	0.57	1.03e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04565464	chr8:145669602	NFKBIL2	0.38	6.08	0.32	3.23e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg04896959	chr15:78267971	NA	0.5	10.42	0.5	3.23e-22	Coronary artery disease or large artery stroke;
LUSC	cis	rs859767	0.679	rs4954158	chr2:135426618	T/C	cg12500956	chr2:135428796	TMEM163	-0.27	-6.22	-0.32	1.51e-9	Neuroticism;
LUSC	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg09479241	chr17:27052676	TLCD1	0.45	6.12	0.32	2.66e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs2806561	0.808	rs4654834	chr1:23364919	T/C	cg19743168	chr1:23544995	NA	-0.39	-8.08	-0.4	1.16e-14	Height;
LUSC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00339695	chr16:24857497	SLC5A11	0.39	6.63	0.34	1.36e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6500395	0.925	rs12920170	chr16:48701530	A/G	cg04672837	chr16:48644449	N4BP1	-0.45	-6.85	-0.35	3.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg26395211	chr5:140044315	WDR55	-0.37	-5.78	-0.3	1.74e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg00599273	chr12:58146742	CDK4	-0.29	-5.73	-0.3	2.19e-8	Multiple sclerosis;
LUSC	cis	rs698813	0.604	rs2340814	chr2:44490977	C/T	cg00619915	chr2:44497795	NA	-0.53	-7.56	-0.38	4.02e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.85	14.82	0.63	1.51e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs11264213	0.686	rs12041193	chr1:36412760	C/T	cg27506609	chr1:36549197	TEKT2	0.5	7.14	0.36	5.68e-12	Schizophrenia;
LUSC	cis	rs68170813	0.617	rs12535761	chr7:107139275	A/C	cg24556660	chr7:106842632	COG5;HBP1	-0.46	-5.7	-0.3	2.7e-8	Coronary artery disease;
LUSC	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg27539214	chr16:67997921	SLC12A4	-0.56	-7.23	-0.37	3.42e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg23306229	chr2:178417860	TTC30B	0.45	5.79	0.3	1.65e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg08132940	chr7:1081526	C7orf50	-0.51	-6.06	-0.31	3.73e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg26338869	chr17:61819248	STRADA	0.4	5.66	0.3	3.19e-8	Prudent dietary pattern;
LUSC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.68	-10.47	-0.5	2.3e-22	Aortic root size;
LUSC	trans	rs7939886	0.920	rs11227145	chr11:55839278	C/A	cg03929089	chr4:120376271	NA	0.73	6.06	0.31	3.74e-9	Myopia (pathological);
LUSC	cis	rs2303282	0.664	rs4784664	chr16:56447286	T/C	cg00500540	chr16:56394104	NA	-0.39	-6.6	-0.34	1.6e-10	Breast cancer;
LUSC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg17143192	chr8:8559678	CLDN23	0.66	9.6	0.46	2e-19	Obesity-related traits;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07752304	chr19:925903	ARID3A	-0.43	-6.49	-0.33	3.02e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg14668632	chr7:2872130	GNA12	-0.43	-6.13	-0.32	2.43e-9	Height;
LUSC	cis	rs3862435	0.831	rs1042538	chr15:91044408	T/A	cg22089800	chr15:90895588	ZNF774	-0.55	-5.85	-0.3	1.16e-8	Response to exercise (triglyceride level interaction);
LUSC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-8.44	-0.42	9.6e-16	Monocyte count;
LUSC	cis	rs12760731	0.516	rs12403484	chr1:178129059	C/A	cg00404053	chr1:178313656	RASAL2	0.59	5.97	0.31	6.14e-9	Obesity-related traits;
LUSC	cis	rs73195822	0.614	rs17683336	chr12:111212712	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	7.04	0.36	1.13e-11	Itch intensity from mosquito bite;
LUSC	trans	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg19694781	chr19:47549865	TMEM160	-0.4	-6.35	-0.33	6.92e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg15556689	chr8:8085844	FLJ10661	0.55	8.43	0.42	1.07e-15	Retinal vascular caliber;
LUSC	cis	rs6785206	0.803	rs6774512	chr3:128415868	C/T	cg16766828	chr3:128327626	NA	-0.69	-7.62	-0.38	2.63e-13	Lymphocyte percentage of white cells;
LUSC	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.87	0.4	5.08e-14	Coffee consumption (cups per day);
LUSC	cis	rs6969780	1.000	rs6969780	chr7:27159136	G/C	cg26364809	chr7:27145159	NA	-0.58	-5.98	-0.31	5.74e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg21361702	chr7:150065534	REPIN1	0.59	8.47	0.42	8.11e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg05347473	chr6:146136440	FBXO30	0.52	8.62	0.43	2.77e-16	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg18825076	chr15:78729989	IREB2	-0.5	-7.84	-0.39	6.17e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-8.11	-0.41	9.66e-15	Personality dimensions;
LUSC	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg18357645	chr12:58087776	OS9	0.59	8.98	0.44	2.06e-17	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg10755058	chr3:40428713	ENTPD3	0.36	5.97	0.31	5.99e-9	Renal cell carcinoma;
LUSC	trans	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg04995722	chr7:26192034	NFE2L3	-0.41	-6.23	-0.32	1.41e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs2887399	0.505	rs10132992	chr14:96225224	C/T	cg20659435	chr10:77156218	NA	-0.58	-6.03	-0.31	4.29e-9	Mosaic loss of chromosome Y;
LUSC	trans	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.47	-0.38	6.98e-13	Menarche (age at onset);
LUSC	cis	rs73200209	0.625	rs11611787	chr12:116644886	G/T	cg01776926	chr12:116560359	MED13L	-0.5	-6.14	-0.32	2.35e-9	Total body bone mineral density;
LUSC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg09359103	chr1:154839909	KCNN3	-0.7	-16.24	-0.66	4.09e-44	Prostate cancer;
LUSC	cis	rs2255336	0.808	rs59611026	chr12:10597986	A/G	cg16084090	chr12:10586130	KLRC2	-0.44	-5.65	-0.3	3.5e-8	Blood protein levels;
LUSC	cis	rs727505	0.954	rs1568883	chr7:124710761	G/A	cg23710748	chr7:124431027	NA	-0.4	-6.98	-0.36	1.63e-11	Lewy body disease;
LUSC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg21970626	chr13:21893289	NA	-0.47	-8.99	-0.44	1.85e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs16854884	0.586	rs7650172	chr3:143729408	G/C	cg01302019	chr3:143689584	C3orf58	-0.34	-5.65	-0.3	3.46e-8	Economic and political preferences (feminism/equality);
LUSC	cis	rs116988415	0.584	rs4902313	chr14:65242164	T/C	cg00114569	chr14:65239327	SPTB	0.65	6.55	0.34	2.18e-10	Daytime sleep phenotypes;
LUSC	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg09044154	chr16:88155775	NA	0.57	7.47	0.38	6.92e-13	Menopause (age at onset);
LUSC	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg18683606	chr7:100471612	SRRT	0.46	6.19	0.32	1.78e-9	Resting heart rate;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg01284702	chr19:11039163	C19orf52;YIPF2	-0.45	-6.35	-0.33	6.89e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg27494647	chr7:150038898	RARRES2	0.52	7.89	0.4	4.43e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs13006833	0.739	rs291429	chr2:191197941	G/A	cg21644426	chr2:191273491	MFSD6	0.43	6.13	0.32	2.52e-9	Urinary metabolites;
LUSC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	6.11	0.32	2.75e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4704187	0.640	rs4704183	chr5:74471048	C/G	cg03227963	chr5:74354835	NA	0.29	6.22	0.32	1.46e-9	Response to amphetamines;
LUSC	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg04607235	chr12:12878440	APOLD1	-0.46	-5.67	-0.3	3.12e-8	Systemic lupus erythematosus;
LUSC	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg01657329	chr11:68192670	LRP5	-0.43	-6.45	-0.33	3.96e-10	Total body bone mineral density;
LUSC	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-6.41	-0.33	5.01e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg26162295	chr17:38119207	GSDMA	-0.24	-5.77	-0.3	1.86e-8	Self-reported allergy;
LUSC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg00509249	chr6:109615579	CCDC162	-0.32	-5.85	-0.3	1.19e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs4280164	0.945	rs11158632	chr14:24769663	A/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.56	-6.63	-0.34	1.36e-10	Parent of origin effect on language impairment (paternal);
LUSC	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg00677455	chr12:58241039	CTDSP2	0.7	10.6	0.5	7.78e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	0.87	14.79	0.63	1.95e-38	Tonsillectomy;
LUSC	cis	rs10186029	0.509	rs62187851	chr2:213940374	T/A	cg08319019	chr2:214017104	IKZF2	-0.41	-5.89	-0.31	9.48e-9	Systemic sclerosis;
LUSC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-0.88	-18.7	-0.72	6.89e-54	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg01579765	chr21:45077557	HSF2BP	0.51	10.41	0.49	3.78e-22	Mean corpuscular volume;
LUSC	cis	rs1178968	0.818	rs6957049	chr7:72754037	G/A	cg25889504	chr7:72793014	NA	0.59	7.96	0.4	2.69e-14	Triglyceride levels;
LUSC	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg17143192	chr8:8559678	CLDN23	0.64	8.85	0.44	5.04e-17	Obesity-related traits;
LUSC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg02018176	chr4:1364513	KIAA1530	0.52	9.06	0.44	1.13e-17	Obesity-related traits;
LUSC	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg12564285	chr5:131593104	PDLIM4	0.42	7.68	0.39	1.74e-13	Breast cancer;
LUSC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg07061783	chr6:25882402	NA	-0.39	-6.06	-0.31	3.75e-9	Blood metabolite levels;
LUSC	cis	rs4698790	0.846	rs11730651	chr4:110718730	T/C	cg07850274	chr4:110748770	RRH	-0.36	-5.7	-0.3	2.6e-8	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
LUSC	cis	rs3771570	0.901	rs4675964	chr2:242324760	A/C	cg21155796	chr2:242212141	HDLBP	0.51	6.25	0.32	1.28e-9	Prostate cancer;
LUSC	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg09307838	chr4:120376055	NA	0.72	10.36	0.49	5.25e-22	Corneal astigmatism;
LUSC	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg03806693	chr22:41940476	POLR3H	-0.54	-7.39	-0.37	1.18e-12	Neuroticism;
LUSC	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.79	11.58	0.54	2.77e-26	Corneal astigmatism;
LUSC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg00509249	chr6:109615579	CCDC162	-0.32	-5.84	-0.3	1.21e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg19920283	chr7:105172520	RINT1	0.5	6.16	0.32	2.07e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2637266	0.935	rs2583059	chr10:78395178	G/C	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.95e-13	Pulmonary function;
LUSC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.51	-7.89	-0.4	4.39e-14	Platelet count;
LUSC	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-9.5	-0.46	4.19e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7759001	0.857	rs6935118	chr6:27354958	T/A	cg18711553	chr6:27366782	ZNF391	0.39	5.74	0.3	2.1e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26314531	chr2:26401878	FAM59B	-0.71	-9.69	-0.47	1.03e-19	Gut microbiome composition (summer);
LUSC	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.35	-6.56	-0.34	2.08e-10	Monocyte percentage of white cells;
LUSC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-7.63	-0.39	2.42e-13	Alzheimer's disease (late onset);
LUSC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.09	0.55	3.77e-28	Motion sickness;
LUSC	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg02796970	chr10:39023768	NA	-0.49	-7.93	-0.4	3.22e-14	Menopause (age at onset);
LUSC	cis	rs968451	0.756	rs1007117	chr22:39675770	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	9.43	0.46	7.29e-19	Primary biliary cholangitis;
LUSC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-0.91	-15.89	-0.66	9.36e-43	Height;
LUSC	trans	rs11696501	0.694	rs2171371	chr20:44273482	T/C	cg03272292	chr12:48577362	C12orf68	0.49	6.08	0.32	3.2e-9	Brain structure;
LUSC	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg06612196	chr6:6737390	NA	-0.56	-11.01	-0.52	2.91e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg02018176	chr4:1364513	KIAA1530	0.51	8.68	0.43	1.74e-16	Obesity-related traits;
LUSC	cis	rs9815354	0.669	rs113059632	chr3:41932858	G/A	cg03022575	chr3:42003672	ULK4	0.82	8.55	0.42	4.49e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg13010199	chr12:38710504	ALG10B	0.67	10.09	0.48	4.43e-21	Bladder cancer;
LUSC	cis	rs9400467	0.528	rs11153291	chr6:111720130	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.98	-0.36	1.57e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.61	-14.0	-0.61	2.23e-35	Sense of smell;
LUSC	cis	rs2425143	1.000	rs12481228	chr20:34218673	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.05	-0.31	3.92e-9	Blood protein levels;
LUSC	cis	rs9309473	0.606	rs77962988	chr2:73886090	T/C	cg20560298	chr2:73613845	ALMS1	-0.5	-5.81	-0.3	1.47e-8	Metabolite levels;
LUSC	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.09	0.74	2.07e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg09365446	chr1:150670422	GOLPH3L	-0.41	-6.05	-0.31	3.97e-9	Tonsillectomy;
LUSC	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg02574844	chr11:5959923	NA	-0.45	-6.31	-0.33	8.71e-10	DNA methylation (variation);
LUSC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg04414720	chr1:150670196	GOLPH3L	0.52	8.33	0.41	2.06e-15	Melanoma;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02767759	chr16:30366751	CD2BP2	0.46	6.66	0.34	1.12e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7587476	0.689	rs10498025	chr2:215749256	A/G	cg04004882	chr2:215674386	BARD1	0.48	6.03	0.31	4.23e-9	Neuroblastoma;
LUSC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg22800045	chr5:56110881	MAP3K1	0.79	10.23	0.49	1.56e-21	Initial pursuit acceleration;
LUSC	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg03563238	chr19:33554763	RHPN2	0.39	6.38	0.33	6.02e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg06001716	chr17:41278141	BRCA1;NBR2	-0.36	-5.74	-0.3	2.12e-8	Menopause (age at onset);
LUSC	trans	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg21775007	chr8:11205619	TDH	0.41	6.26	0.32	1.16e-9	Mood instability;
LUSC	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.47	7.21	0.37	3.81e-12	Asthma (bronchodilator response);
LUSC	cis	rs77741769	0.529	rs2047568	chr12:121243790	A/G	cg02419362	chr12:121203948	SPPL3	-0.45	-8.52	-0.42	5.4e-16	Mean corpuscular volume;
LUSC	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	11.56	0.53	3.25e-26	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2710642	0.566	rs2710651	chr2:63166379	G/A	cg17519650	chr2:63277830	OTX1	0.66	9.61	0.47	1.84e-19	LDL cholesterol levels;LDL cholesterol;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17940190	chr20:49547700	ADNP	0.41	6.02	0.31	4.48e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg26384229	chr12:38710491	ALG10B	-0.81	-13.79	-0.6	1.46e-34	Morning vs. evening chronotype;
LUSC	cis	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg08807101	chr21:30365312	RNF160	0.49	6.33	0.33	8.02e-10	Cognitive test performance;
LUSC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.24	14.24	0.61	2.72e-36	Diabetic kidney disease;
LUSC	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg05373962	chr22:49881684	NA	-0.41	-8.82	-0.43	6.49e-17	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg06951627	chr6:26196580	NA	0.52	5.67	0.3	3.14e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.52e-8	Breast cancer;
LUSC	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg14458575	chr2:238380390	NA	0.66	11.52	0.53	4.53e-26	Prostate cancer;
LUSC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg17143192	chr8:8559678	CLDN23	0.66	9.64	0.47	1.41e-19	Obesity-related traits;
LUSC	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg21064579	chr19:49206444	FUT2	0.47	8.99	0.44	1.94e-17	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
LUSC	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.93	-0.31	7.68e-9	Neutrophil percentage of white cells;
LUSC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg03790207	chr6:42947109	PEX6	-0.45	-6.92	-0.35	2.31e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg00376283	chr12:123451042	ABCB9	0.81	12.43	0.56	2.11e-29	Platelet count;
LUSC	cis	rs7605827	0.897	rs12692271	chr2:15640317	T/C	cg19274914	chr2:15703543	NA	0.46	8.84	0.44	5.74e-17	Educational attainment (years of education);
LUSC	cis	rs6736093	0.966	rs13003919	chr2:112753950	A/G	cg12686935	chr2:112915763	FBLN7	0.38	6.11	0.32	2.73e-9	Coronary artery disease;
LUSC	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.07	0.4	1.29e-14	Breast cancer;
LUSC	cis	rs11229555	0.598	rs4519112	chr11:58176386	C/T	cg15696309	chr11:58395628	NA	-0.61	-7.54	-0.38	4.58e-13	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs31872	0.597	rs31874	chr5:140369318	C/T	cg19650706	chr5:140594406	PCDHB13	0.51	7.08	0.36	8.43e-12	Visceral adipose tissue adjusted for BMI;
LUSC	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg16482183	chr6:26056742	HIST1H1C	0.64	9.08	0.44	9.81e-18	Iron status biomarkers;
LUSC	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg24642844	chr7:1081250	C7orf50	-0.79	-10.46	-0.5	2.44e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.19	-0.32	1.8e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.56	0.38	3.96e-13	Ulcerative colitis;
LUSC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.78	0.35	5.56e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg15649852	chr7:65879115	NA	-0.41	-5.7	-0.3	2.57e-8	Aortic root size;
LUSC	cis	rs7072216	0.922	rs6584191	chr10:100152055	C/G	cg26618903	chr10:100175079	PYROXD2	-0.3	-5.86	-0.31	1.08e-8	Metabolite levels;
LUSC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg26441486	chr22:50317300	CRELD2	0.36	5.87	0.31	1.06e-8	Schizophrenia;
LUSC	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg04362960	chr10:104952993	NT5C2	0.58	9.33	0.45	1.49e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg22709100	chr7:91322751	NA	0.39	5.86	0.31	1.08e-8	Breast cancer;
LUSC	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg24642439	chr20:33292090	TP53INP2	0.47	7.17	0.37	4.84e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg05340658	chr4:99064831	C4orf37	0.42	6.68	0.34	9.87e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9311676	0.656	rs11721168	chr3:58408679	G/A	cg26110898	chr3:58419937	PDHB	0.4	6.5	0.34	2.9e-10	Systemic lupus erythematosus;
LUSC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg13393036	chr8:95962371	TP53INP1	0.44	8.6	0.43	3.05e-16	Type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.23	0.52	4.94e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7804356	0.954	rs10270187	chr7:26885885	C/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg03233332	chr7:66118400	NA	0.41	6.05	0.31	3.95e-9	Aortic root size;
LUSC	cis	rs1443512	0.704	rs4759308	chr12:54329031	A/T	cg17410650	chr12:54324560	NA	-0.58	-10.45	-0.5	2.58e-22	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg15556689	chr8:8085844	FLJ10661	-0.63	-9.76	-0.47	5.99e-20	Neuroticism;
LUSC	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.6	0.38	3.03e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-9.46	-0.46	5.61e-19	Gut microbiome composition (summer);
LUSC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg10130564	chr11:117069849	TAGLN	0.38	6.54	0.34	2.34e-10	Blood protein levels;
LUSC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg23985595	chr17:80112537	CCDC57	0.34	6.49	0.33	3.03e-10	Life satisfaction;
LUSC	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg04545296	chr12:48745243	ZNF641	0.37	6.82	0.35	4.23e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs2012796	0.957	rs8009083	chr14:81818289	A/G	cg02996355	chr14:81879375	NA	0.43	6.38	0.33	5.86e-10	Night sleep phenotypes;
LUSC	trans	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg02800362	chr5:177631904	HNRNPAB	0.88	13.11	0.58	5.56e-32	Obesity-related traits;
LUSC	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg00105475	chr2:10696890	NA	-0.39	-6.5	-0.34	2.88e-10	Prostate cancer;
LUSC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg18477163	chr1:228402036	OBSCN	0.62	12.18	0.55	1.73e-28	Diastolic blood pressure;
LUSC	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg10356904	chr22:49881777	NA	-0.33	-7.52	-0.38	5.26e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg10434728	chr15:90938212	IQGAP1	0.41	8.51	0.42	5.91e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-11.32	-0.53	2.39e-25	Colorectal cancer;
LUSC	trans	rs6030	0.917	rs2301515	chr1:169494196	C/T	cg16792071	chr10:134842795	NA	0.28	6.13	0.32	2.43e-9	Uric acid levels;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg03559043	chr19:58898554	RPS5	0.4	6.03	0.31	4.25e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	27.87	0.84	3.57e-89	Chronic sinus infection;
LUSC	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg15704280	chr7:45808275	SEPT13	-0.71	-10.41	-0.49	3.64e-22	Coronary artery disease;
LUSC	trans	rs853679	0.546	rs483143	chr6:27846744	G/C	cg01620082	chr3:125678407	NA	-0.69	-6.87	-0.35	3.12e-11	Depression;
LUSC	cis	rs9942416	0.660	rs60423072	chr5:75006113	T/A	cg19683494	chr5:74908142	NA	0.44	6.67	0.34	1.05e-10	Age-related disease endophenotypes;
LUSC	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	0.6	9.52	0.46	3.52e-19	Breast cancer;
LUSC	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.31e-41	Bladder cancer;
LUSC	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg23283495	chr1:209979779	IRF6	0.45	7.22	0.37	3.52e-12	Monobrow;
LUSC	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.34	-5.78	-0.3	1.67e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg12863693	chr15:85201151	NMB	0.34	6.78	0.35	5.31e-11	Schizophrenia;
LUSC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	0.83	14.96	0.63	4.36e-39	Sudden cardiac arrest;
LUSC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	9.52	0.46	3.69e-19	Mood instability;
LUSC	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg27489772	chr12:121021490	NA	0.6	7.92	0.4	3.5e-14	Type 1 diabetes nephropathy;
LUSC	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	0.88	13.37	0.59	6.01e-33	Triglycerides;
LUSC	cis	rs7527798	0.592	rs960086	chr1:207827069	A/G	cg09232269	chr1:207846808	CR1L	-0.3	-6.39	-0.33	5.46e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg06740227	chr12:86229804	RASSF9	-0.37	-5.87	-0.31	1.05e-8	Major depressive disorder;
LUSC	cis	rs354225	0.673	rs354232	chr2:54916910	C/A	cg26097391	chr2:54893211	SPTBN1	0.37	6.02	0.31	4.68e-9	Schizophrenia;
LUSC	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg02493740	chr2:85810744	VAMP5	-0.31	-5.68	-0.3	2.94e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs59698941	0.943	rs79586717	chr5:132251790	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs7188861	0.723	rs12599908	chr16:11395915	G/A	cg00044050	chr16:11439710	C16orf75	0.56	6.23	0.32	1.42e-9	HDL cholesterol;
LUSC	cis	rs9503598	0.636	rs7775474	chr6:3468224	T/C	cg00476032	chr6:3446245	SLC22A23	0.31	6.12	0.32	2.59e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LUSC	cis	rs4845459	0.967	rs6693105	chr1:152590663	C/T	cg08895932	chr1:152778580	LCE1C	0.37	6.3	0.33	9.43e-10	Psoriasis;
LUSC	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.57	-0.34	1.93e-10	High light scatter reticulocyte count;
LUSC	cis	rs4919087	1.000	rs4919090	chr10:99088419	C/G	cg25902810	chr10:99078978	FRAT1	-0.46	-6.65	-0.34	1.18e-10	Monocyte count;
LUSC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	trans	rs9650657	0.707	rs7814757	chr8:10675188	T/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.26	-0.32	1.2e-9	Neuroticism;
LUSC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg14668632	chr7:2872130	GNA12	-0.42	-6.12	-0.32	2.67e-9	Height;
LUSC	cis	rs7575217	0.884	rs1192786	chr2:101783556	A/G	cg23907051	chr2:101730305	TBC1D8	-0.27	-6.56	-0.34	2.06e-10	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs12618769	0.597	rs72821920	chr2:99111591	A/G	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg21132104	chr15:45694354	SPATA5L1	0.56	7.75	0.39	1.08e-13	Homoarginine levels;
LUSC	cis	rs4363385	0.693	rs689008	chr1:153047100	G/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.39	-0.37	1.19e-12	Inflammatory skin disease;
LUSC	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.88	0.31	9.77e-9	Schizophrenia;
LUSC	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg09904177	chr6:26538194	HMGN4	-0.7	-6.74	-0.35	7.15e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg19230755	chr7:65878503	NA	0.41	5.82	0.3	1.39e-8	Aortic root size;
LUSC	cis	rs7712401	0.502	rs30066	chr5:122293702	A/G	cg19077854	chr5:122220652	SNX24	0.4	8.56	0.42	4.32e-16	Mean platelet volume;
LUSC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	12.67	0.57	2.52e-30	Alzheimer's disease;
LUSC	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg03676636	chr4:99064102	C4orf37	0.27	5.84	0.3	1.24e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg16240275	chr20:61666158	NCRNA00029	0.42	9.28	0.45	2.13e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4664308	0.967	rs17241973	chr2:160918601	A/G	cg03641300	chr2:160917029	PLA2R1	-0.69	-11.71	-0.54	9.36e-27	Idiopathic membranous nephropathy;
LUSC	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg19743168	chr1:23544995	NA	0.4	7.89	0.4	4.25e-14	Height;
LUSC	cis	rs1975974	0.574	rs17052370	chr17:21736353	A/G	cg18423549	chr17:21743878	NA	0.58	9.18	0.45	4.5e-18	Psoriasis;
LUSC	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.89	15.28	0.64	2.34e-40	Morning vs. evening chronotype;
LUSC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg25258033	chr6:167368657	RNASET2	0.37	5.83	0.3	1.28e-8	Primary biliary cholangitis;
LUSC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-1.03	-25.09	-0.81	7.71e-79	Multiple system atrophy;
LUSC	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg24812749	chr6:127587940	RNF146	0.5	7.22	0.37	3.46e-12	Breast cancer;
LUSC	cis	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05901451	chr6:126070800	HEY2	0.57	8.57	0.42	3.96e-16	Endometrial cancer;
LUSC	cis	rs7582720	1.000	rs72936838	chr2:203772984	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.42	0.42	1.16e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg03161606	chr19:29218774	NA	0.62	8.83	0.44	6.02e-17	Methadone dose in opioid dependence;
LUSC	cis	rs11958404	0.932	rs72816588	chr5:157434390	C/T	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg03585969	chr10:35415529	CREM	0.64	9.51	0.46	4e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3791556	1.000	rs3791562	chr2:240113436	C/T	cg03281426	chr2:240109471	HDAC4	0.51	6.05	0.31	3.98e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg22139774	chr2:100720529	AFF3	-0.5	-8.64	-0.43	2.32e-16	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg11395062	chr17:14139857	CDRT15	-0.41	-5.8	-0.3	1.53e-8	Temperament;
LUSC	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.48	8.51	0.42	6.04e-16	HDL cholesterol;
LUSC	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01341218	chr17:43662625	NA	0.76	11.13	0.52	1.07e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7246967	0.611	rs3853652	chr19:22871913	C/G	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.43	5.96	0.31	6.38e-9	Lung cancer;
LUSC	cis	rs7605827	0.930	rs2111454	chr2:15522331	G/A	cg19274914	chr2:15703543	NA	0.45	8.79	0.43	7.98e-17	Educational attainment (years of education);
LUSC	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg01420254	chr6:26195488	NA	0.56	6.92	0.35	2.32e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7246967	0.611	rs12984903	chr19:22833881	A/G	cg23217946	chr19:22817039	ZNF492	0.49	6.88	0.35	2.88e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg01528321	chr10:82214614	TSPAN14	1.01	15.61	0.65	1.22e-41	Post bronchodilator FEV1;
LUSC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg18357526	chr6:26021779	HIST1H4A	0.43	6.35	0.33	6.93e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg09365446	chr1:150670422	GOLPH3L	0.52	7.46	0.38	7.38e-13	Melanoma;
LUSC	cis	rs4253772	0.938	rs78336060	chr22:46641597	C/T	cg18190219	chr22:46762943	CELSR1	-0.52	-6.02	-0.31	4.71e-9	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08554302	chr11:73308756	FAM168A	0.42	6.12	0.32	2.69e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9399401	0.633	rs6570511	chr6:142757368	G/A	cg03128060	chr6:142623767	GPR126	0.52	8.95	0.44	2.56e-17	Chronic obstructive pulmonary disease;
LUSC	cis	rs477692	0.692	rs7905095	chr10:131448143	C/T	cg05714579	chr10:131428358	MGMT	-0.64	-10.18	-0.49	2.16e-21	Response to temozolomide;
LUSC	cis	rs7809950	1.000	rs987391	chr7:107100794	C/G	cg23024343	chr7:107201750	COG5	-0.54	-8.71	-0.43	1.42e-16	Coronary artery disease;
LUSC	cis	rs7113850	0.541	rs76344090	chr11:24223375	C/G	ch.11.24196551F	chr11:24239977	NA	1.01	8.96	0.44	2.3e-17	Bone fracture in osteoporosis;
LUSC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.6	-5.73	-0.3	2.26e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg21775007	chr8:11205619	TDH	-0.58	-8.49	-0.42	6.96e-16	Neuroticism;
LUSC	cis	rs75229567	0.717	rs77874289	chr12:70234203	A/G	cg10114359	chr12:70132523	RAB3IP	1.19	10.48	0.5	2.14e-22	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs9677476	1.000	rs12621567	chr2:232118813	T/C	cg07929768	chr2:232055508	NA	0.31	5.78	0.3	1.7e-8	Food antigen IgG levels;
LUSC	cis	rs7605827	0.930	rs10207209	chr2:15512701	A/G	cg19274914	chr2:15703543	NA	0.46	8.88	0.44	4.27e-17	Educational attainment (years of education);
LUSC	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.43	-0.42	1.02e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.71	13.23	0.59	2.01e-32	Height;
LUSC	cis	rs2282300	0.739	rs1765139	chr11:30353725	T/C	cg25418670	chr11:30344373	C11orf46	-0.64	-9.29	-0.45	2.08e-18	Morning vs. evening chronotype;
LUSC	cis	rs36093844	0.706	rs75334800	chr11:85586581	A/G	cg25872744	chr11:85566296	CCDC83	-0.46	-5.98	-0.31	5.87e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs11779988	0.629	rs11780813	chr8:17856014	T/C	cg01800426	chr8:17659068	MTUS1	-0.53	-6.72	-0.35	7.95e-11	Breast cancer;
LUSC	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.54	-0.38	4.58e-13	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg08856697	chr17:61627902	DCAF7	-0.57	-6.96	-0.36	1.78e-11	Cognitive function;Information processing speed;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10071973	chr17:16557188	ZNF624	-0.4	-5.97	-0.31	5.99e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6545977	0.527	rs2710647	chr2:63213970	T/C	cg17519650	chr2:63277830	OTX1	0.83	12.66	0.57	2.74e-30	Prostate cancer;
LUSC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.75	0.35	6.74e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs2625529	0.652	rs12148078	chr15:72300471	G/C	cg16672083	chr15:72433130	SENP8	0.51	8.3	0.41	2.58e-15	Red blood cell count;
LUSC	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.43	5.97	0.31	5.9e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg15133208	chr4:90757351	SNCA	-0.54	-8.24	-0.41	3.96e-15	Neuroticism;
LUSC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg08219700	chr8:58056026	NA	0.5	6.59	0.34	1.67e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	0.92	14.77	0.63	2.45e-38	Triglycerides;
LUSC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg26695010	chr11:65641043	EFEMP2	0.42	6.07	0.32	3.38e-9	Breast cancer;
LUSC	cis	rs524023	0.957	rs10792443	chr11:64395252	G/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.21	-0.49	1.79e-21	Urate levels in obese individuals;
LUSC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.14	-0.32	2.38e-9	Neutrophil percentage of white cells;
LUSC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	1.07	17.58	0.69	1.94e-49	Parkinson's disease;
LUSC	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-6.57	-0.34	1.92e-10	Lung cancer;
LUSC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg27588902	chr6:42928151	GNMT	-0.29	-6.49	-0.33	3.11e-10	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg09876464	chr15:85330779	ZNF592	0.36	6.7	0.34	8.83e-11	P wave terminal force;
LUSC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.19	-0.32	1.8e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg05861140	chr6:150128134	PCMT1	-0.39	-5.95	-0.31	6.76e-9	Lung cancer;
LUSC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg06740227	chr12:86229804	RASSF9	0.45	7.26	0.37	2.81e-12	Major depressive disorder;
LUSC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-1.25	-20.35	-0.74	1.98e-60	Blood pressure (smoking interaction);
LUSC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg22166914	chr1:53195759	ZYG11B	0.71	12.47	0.56	1.46e-29	Monocyte count;
LUSC	trans	rs11696501	0.694	rs6073823	chr20:44256910	G/C	cg03272292	chr12:48577362	C12orf68	0.49	6.02	0.31	4.69e-9	Brain structure;
LUSC	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.29	-0.33	1.02e-9	Bipolar disorder;
LUSC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg17724175	chr1:150552817	MCL1	-0.37	-6.74	-0.35	7e-11	Tonsillectomy;
LUSC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.78	-10.93	-0.51	5.6e-24	Alzheimer's disease;
LUSC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07677032	chr17:61819896	STRADA	0.53	8.92	0.44	3.03e-17	Prudent dietary pattern;
LUSC	trans	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg10756647	chr7:56101905	PSPH	0.86	8.36	0.42	1.7e-15	Diabetic kidney disease;
LUSC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg15147215	chr3:52552868	STAB1	-0.29	-5.75	-0.3	2.05e-8	Bipolar disorder;
LUSC	cis	rs17095355	0.901	rs7069128	chr10:111760075	C/T	cg00817464	chr10:111662876	XPNPEP1	0.58	7.24	0.37	3.09e-12	Biliary atresia;
LUSC	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg14196790	chr5:131705035	SLC22A5	0.44	7.02	0.36	1.22e-11	Breast cancer;Mosquito bite size;
LUSC	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg20090143	chr19:45452003	APOC2	0.34	5.81	0.3	1.44e-8	Blood protein levels;
LUSC	cis	rs9815354	0.812	rs73071325	chr3:41809989	T/G	cg03022575	chr3:42003672	ULK4	0.83	8.34	0.41	2.04e-15	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs4499344	0.730	rs10410888	chr19:33103328	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs72772090	0.520	rs56325109	chr5:96112295	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-7.27	-0.37	2.59e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs17030434	0.654	rs1530105	chr4:154646994	C/T	cg14289246	chr4:154710475	SFRP2	0.47	6.45	0.33	3.82e-10	Electrocardiographic conduction measures;
LUSC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg26924012	chr15:45694286	SPATA5L1	1.13	20.89	0.75	1.35e-62	Homoarginine levels;
LUSC	cis	rs67539049	1.000	rs66934548	chr8:11304050	C/A	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.43	-6.57	-0.34	1.98e-10	Itch intensity from mosquito bite;
LUSC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24531977	chr5:56204891	C5orf35	0.87	13.83	0.6	1.01e-34	Initial pursuit acceleration;
LUSC	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg06219351	chr7:158114137	PTPRN2	0.49	8.87	0.44	4.61e-17	Calcium levels;
LUSC	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.44	5.82	0.3	1.41e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	7.61	0.38	2.89e-13	Schizophrenia;
LUSC	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg23752985	chr2:85803571	VAMP8	0.32	6.59	0.34	1.71e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg00857998	chr1:205179979	DSTYK	0.59	9.0	0.44	1.73e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6696846	0.749	rs7515178	chr1:205084120	G/A	cg21643547	chr1:205240462	TMCC2	-0.37	-6.93	-0.35	2.12e-11	Red blood cell count;
LUSC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	29.6	0.85	2.14e-95	Chronic sinus infection;
LUSC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg07741184	chr6:167504864	NA	-0.39	-7.09	-0.36	7.89e-12	Crohn's disease;
LUSC	cis	rs362296	0.698	rs3095072	chr4:3263325	G/A	cg14583973	chr4:3374767	RGS12	-0.32	-6.22	-0.32	1.49e-9	Parental longevity (mother's age at death);
LUSC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.19	0.45	4.24e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7945705	0.818	rs10769948	chr11:8761782	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-11.25	-0.52	3.99e-25	Hemoglobin concentration;
LUSC	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg11887960	chr12:57824829	NA	0.54	6.67	0.34	1.09e-10	Obesity-related traits;
LUSC	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg23093090	chr10:104574429	C10orf26	-0.38	-7.11	-0.36	6.9e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg09835421	chr16:68378352	PRMT7	-0.55	-6.26	-0.32	1.19e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg06521331	chr12:34319734	NA	-0.39	-6.67	-0.34	1.05e-10	Morning vs. evening chronotype;
LUSC	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.46	6.39	0.33	5.52e-10	Renal function-related traits (BUN);
LUSC	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg12179176	chr11:130786555	SNX19	0.64	9.98	0.48	1.08e-20	Schizophrenia;
LUSC	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg20701182	chr2:24300061	SF3B14	0.74	7.33	0.37	1.77e-12	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.34	0.53	1.96e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3820928	1.000	rs59904960	chr2:227761269	T/C	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.96	-0.4	2.72e-14	Pulmonary function;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18796520	chr12:4758272	NDUFA9	-0.38	-6.04	-0.31	4.06e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7903847	0.642	rs11189174	chr10:99139600	C/G	cg20016023	chr10:99160130	RRP12	-0.33	-8.17	-0.41	6.41e-15	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg12615879	chr12:58013172	SLC26A10	-0.27	-5.77	-0.3	1.78e-8	Multiple sclerosis;
LUSC	cis	rs9837602	0.810	rs35885423	chr3:99813218	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.31	0.33	8.81e-10	Breast cancer;
LUSC	cis	rs11809207	0.903	rs17257148	chr1:26526348	G/C	cg00147160	chr1:26503991	CNKSR1	0.39	6.67	0.34	1.07e-10	Height;
LUSC	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg15595755	chr5:1867978	NA	0.47	8.58	0.42	3.71e-16	Cardiovascular disease risk factors;
LUSC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.08	-0.36	8.5e-12	Blood metabolite levels;
LUSC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg08888203	chr3:10149979	C3orf24	-0.61	-8.83	-0.44	5.99e-17	Alzheimer's disease;
LUSC	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg15571903	chr15:79123663	NA	0.32	5.94	0.31	6.97e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.93	0.51	5.67e-24	Hypertriglyceridemia;
LUSC	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg27284194	chr4:1044797	NA	-0.57	-8.22	-0.41	4.41e-15	Recombination rate (females);
LUSC	trans	rs12599106	0.702	rs237997	chr16:34686820	G/A	cg11235426	chr6:292522	DUSP22	0.43	6.48	0.33	3.35e-10	Menopause (age at onset);
LUSC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg00745463	chr17:30367425	LRRC37B	-0.79	-9.11	-0.45	7.81e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg08799069	chr10:126477246	METTL10	0.6	8.26	0.41	3.41e-15	Cocaine dependence;
LUSC	cis	rs9341808	0.667	rs1408292	chr6:80883906	G/T	cg08355045	chr6:80787529	NA	0.49	8.39	0.42	1.38e-15	Sitting height ratio;
LUSC	cis	rs2279817	0.780	rs79136279	chr1:18008121	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.13	-0.32	2.54e-9	Neuroticism;
LUSC	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.72e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	12.72	0.57	1.74e-30	Motion sickness;
LUSC	cis	rs17253792	0.822	rs77033617	chr14:56129746	T/A	cg01858014	chr14:56050164	KTN1	-0.79	-6.68	-0.34	9.73e-11	Putamen volume;
LUSC	cis	rs11112613	0.609	rs11112632	chr12:106041887	A/G	cg03607813	chr12:105948248	NA	-0.63	-8.07	-0.4	1.32e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg00852783	chr1:26633632	UBXN11	-0.5	-5.73	-0.3	2.21e-8	Obesity-related traits;
LUSC	cis	rs4654899	0.758	rs3820326	chr1:21277141	G/A	cg01072550	chr1:21505969	NA	-0.53	-8.03	-0.4	1.67e-14	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6982240	0.514	rs9324543	chr8:142275662	T/C	cg00131261	chr8:142287264	NA	-0.36	-6.05	-0.31	3.99e-9	Tonsillectomy;
LUSC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.91	-15.5	-0.65	3.31e-41	Bladder cancer;
LUSC	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.98	-11.49	-0.53	5.67e-26	Lung cancer in ever smokers;
LUSC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.16	-0.32	2.13e-9	Life satisfaction;
LUSC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-1.02	-16.53	-0.67	2.81e-45	Systemic lupus erythematosus;
LUSC	cis	rs6546537	0.955	rs1396798	chr2:69887837	G/T	cg10773587	chr2:69614142	GFPT1	-0.49	-7.55	-0.38	4.12e-13	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03878208	chr11:72483293	STARD10	0.58	7.57	0.38	3.77e-13	Type 2 diabetes;
LUSC	cis	rs193541	0.632	rs154503	chr5:122204499	G/A	cg19077854	chr5:122220652	SNX24	0.37	7.73	0.39	1.23e-13	Glucose homeostasis traits;
LUSC	cis	rs1113500	0.548	rs11185271	chr1:108659933	A/G	cg06207961	chr1:108661230	NA	0.4	6.64	0.34	1.3e-10	Growth-regulated protein alpha levels;
LUSC	cis	rs6484504	0.779	rs16921914	chr11:31210771	G/A	cg26647111	chr11:31128758	NA	-0.45	-5.83	-0.3	1.3e-8	Red blood cell count;
LUSC	trans	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg07923666	chr12:49932857	KCNH3	-0.48	-5.96	-0.31	6.5e-9	Resting heart rate;
LUSC	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg15423357	chr2:25149977	NA	0.35	6.43	0.33	4.46e-10	Body mass index;
LUSC	cis	rs73198271	0.960	rs73198286	chr8:8612022	C/T	cg01851573	chr8:8652454	MFHAS1	0.59	8.29	0.41	2.75e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg24846343	chr22:24311635	DDTL	0.67	13.9	0.61	5.45e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg05901451	chr6:126070800	HEY2	-0.52	-7.64	-0.39	2.37e-13	High light scatter reticulocyte count;
LUSC	cis	rs2540226	0.935	rs2540228	chr2:39954632	A/C	cg23576258	chr2:39999331	THUMPD2	-0.35	-6.01	-0.31	4.83e-9	Personality dimensions;
LUSC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg02038168	chr22:39784481	NA	-0.42	-6.11	-0.32	2.79e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg10596483	chr8:143751796	JRK	0.52	7.52	0.38	4.98e-13	Schizophrenia;
LUSC	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg00277334	chr10:82204260	NA	-0.52	-7.74	-0.39	1.21e-13	Post bronchodilator FEV1;
LUSC	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg20129853	chr10:51489980	NA	-0.36	-7.64	-0.39	2.33e-13	Prostate-specific antigen levels;
LUSC	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg18681998	chr4:17616180	MED28	0.88	15.6	0.65	1.32e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs4714291	0.862	rs2984445	chr6:40069935	C/T	cg02267698	chr19:7991119	CTXN1	-0.56	-8.45	-0.42	8.83e-16	Strep throat;
LUSC	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.04	0.48	6.92e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs295140	1.000	rs7578220	chr2:201183701	A/G	cg04283868	chr2:201171347	SPATS2L	0.42	6.4	0.33	5.36e-10	QT interval;
LUSC	cis	rs394563	0.602	rs409099	chr6:149766863	T/G	cg03678062	chr6:149772716	ZC3H12D	-0.33	-6.91	-0.35	2.54e-11	Dupuytren's disease;
LUSC	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.2	-0.37	3.99e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.95	-12.41	-0.56	2.52e-29	Exhaled nitric oxide output;
LUSC	cis	rs62400317	0.859	rs62438877	chr6:45089064	A/G	cg20913747	chr6:44695427	NA	-0.46	-7.41	-0.38	1.06e-12	Total body bone mineral density;
LUSC	cis	rs4400599	0.608	rs4845609	chr1:154181954	G/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.99	-0.31	5.4e-9	Platelet distribution width;
LUSC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg19729930	chr2:74357872	NA	0.93	17.79	0.7	2.93e-50	Gestational age at birth (maternal effect);
LUSC	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg23711669	chr6:146136114	FBXO30	0.87	16.25	0.66	3.56e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg23625390	chr15:77176239	SCAPER	-0.6	-9.47	-0.46	5.28e-19	Blood metabolite levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13595813	chr7:86974922	TP53TG1;CROT	0.45	5.99	0.31	5.32e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6591182	0.967	rs11227229	chr11:65354150	C/T	cg05805236	chr11:65401703	PCNXL3	-0.36	-5.69	-0.3	2.73e-8	Non-alcoholic fatty liver disease histology (lobular);
LUSC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg07424592	chr7:64974309	NA	0.71	6.19	0.32	1.72e-9	Diabetic kidney disease;
LUSC	cis	rs17253792	0.822	rs8013831	chr14:56172898	G/A	cg01858014	chr14:56050164	KTN1	-0.73	-6.12	-0.32	2.67e-9	Putamen volume;
LUSC	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg26061582	chr7:22766209	IL6	0.42	6.24	0.32	1.31e-9	Lung cancer;
LUSC	cis	rs7106204	0.609	rs12785699	chr11:24280489	C/T	ch.11.24196551F	chr11:24239977	NA	0.71	6.05	0.31	3.93e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg03806693	chr22:41940476	POLR3H	-0.85	-12.52	-0.57	9.81e-30	Vitiligo;
LUSC	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg16342193	chr10:102329863	NA	-0.35	-6.32	-0.33	8.52e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg21280719	chr6:42927975	GNMT	0.27	6.73	0.35	7.26e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg18681998	chr4:17616180	MED28	0.86	15.53	0.65	2.48e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06634786	chr22:41940651	POLR3H	0.49	5.72	0.3	2.38e-8	Vitiligo;
LUSC	cis	rs6700896	0.931	rs12021623	chr1:66153586	A/C	cg04111102	chr1:66153794	NA	0.33	7.19	0.37	4.18e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg19774624	chr17:42201019	HDAC5	-0.78	-12.05	-0.55	5.39e-28	Total body bone mineral density;
LUSC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-11.9	-0.55	1.77e-27	Extrinsic epigenetic age acceleration;
LUSC	trans	rs6076960	0.713	rs3865568	chr20:6249339	A/G	cg17788362	chr6:86352627	SYNCRIP	0.46	6.55	0.34	2.2e-10	Smooth-surface caries;
LUSC	cis	rs601339	1.000	rs630408	chr12:123172822	C/T	cg11919336	chr12:123188078	GPR109A	0.44	6.58	0.34	1.78e-10	Adiponectin levels;
LUSC	cis	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg00409521	chr11:89956229	CHORDC1	0.4	6.08	0.32	3.33e-9	Asthma;
LUSC	trans	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg06606381	chr12:133084897	FBRSL1	-0.57	-6.81	-0.35	4.67e-11	Depression;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg15271594	chr3:52029932	RPL29	0.45	6.23	0.32	1.44e-9	Mosquito bite size;
LUSC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg08493051	chr2:3487164	NA	-0.56	-8.8	-0.43	7.33e-17	Neurofibrillary tangles;
LUSC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg14582100	chr15:45693742	SPATA5L1	0.41	7.51	0.38	5.61e-13	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg13114125	chr14:105738426	BRF1	-0.94	-15.89	-0.66	9.91e-43	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs295137	0.799	rs4145969	chr2:201139961	C/T	cg04283868	chr2:201171347	SPATS2L	0.41	5.95	0.31	6.88e-9	Asthma (bronchodilator response);
LUSC	trans	rs1532331	0.898	rs13665	chr5:43175953	C/G	cg17870909	chr21:47566968	FTCD	0.26	6.11	0.32	2.73e-9	Menarche (age at onset);
LUSC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.41	-6.17	-0.32	2.02e-9	Platelet count;
LUSC	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.94e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.59	-11.54	-0.53	3.64e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg12560992	chr17:57184187	TRIM37	0.9	17.84	0.7	1.78e-50	Intelligence (multi-trait analysis);
LUSC	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg18352616	chr4:3374830	RGS12	0.3	6.03	0.31	4.45e-9	Serum sulfate level;
LUSC	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.57	-0.6	1.03e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs3126085	0.877	rs12065368	chr1:152253497	C/T	cg26876637	chr1:152193138	HRNR	0.45	6.08	0.32	3.31e-9	Atopic dermatitis;
LUSC	cis	rs354225	0.544	rs12713264	chr2:54805218	A/C	cg26097391	chr2:54893211	SPTBN1	-0.46	-6.96	-0.36	1.84e-11	Schizophrenia;
LUSC	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs644148	0.902	rs12982159	chr19:44964300	C/T	cg15540054	chr19:45004280	ZNF180	-0.58	-8.37	-0.42	1.64e-15	Personality dimensions;
LUSC	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg26924012	chr15:45694286	SPATA5L1	0.73	11.19	0.52	6.75e-25	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs11030122	0.702	rs1452047	chr11:3991648	A/C	cg18678763	chr11:4115507	RRM1	-0.45	-5.77	-0.3	1.82e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	8.12	0.41	9.26e-15	Iron status biomarkers;
LUSC	cis	rs13315871	1.000	rs13317835	chr3:58383275	C/T	cg20936604	chr3:58311152	NA	-0.65	-6.04	-0.31	4.06e-9	Cholesterol, total;
LUSC	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	0.8	13.19	0.59	2.79e-32	Schizophrenia;
LUSC	cis	rs4566357	0.615	rs10174591	chr2:227913140	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-8.27	-0.41	3.17e-15	Coronary artery disease;
LUSC	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.47	-6.49	-0.33	3.08e-10	Reticulocyte count;
LUSC	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg04697454	chr15:93633408	RGMA	0.34	5.94	0.31	7.23e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs7524258	0.867	rs916392	chr1:7271930	T/C	cg07173049	chr1:7289937	CAMTA1	0.36	7.49	0.38	6.4e-13	Tourette's syndrome or obsessive-compulsive disorder;
LUSC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.53	0.38	4.76e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg20406979	chr6:167373233	NA	0.25	5.81	0.3	1.49e-8	Crohn's disease;
LUSC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg27535305	chr1:53392650	SCP2	-0.39	-7.28	-0.37	2.42e-12	Monocyte count;
LUSC	trans	rs156299	0.563	rs198304	chr7:24193423	G/A	cg06529468	chr19:10676722	KRI1	0.38	6.2	0.32	1.7e-9	Vitamin D levels;
LUSC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.85	-0.3	1.19e-8	Platelet count;
LUSC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.56	0.46	2.74e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs9929218	0.748	rs34592833	chr16:68739125	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-12.84	-0.57	6.19e-31	Colorectal cancer;
LUSC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg18240062	chr17:79603768	NPLOC4	0.58	10.1	0.48	4.09e-21	Eye color traits;
LUSC	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg26441486	chr22:50317300	CRELD2	-0.54	-8.25	-0.41	3.75e-15	Schizophrenia;
LUSC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg03233332	chr7:66118400	NA	-0.42	-6.06	-0.31	3.63e-9	Aortic root size;
LUSC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-10.69	-0.5	3.9699999999999997e-23	Schizophrenia;
LUSC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg05535760	chr7:792225	HEATR2	-0.77	-7.64	-0.39	2.36e-13	Cerebrospinal P-tau181p levels;
LUSC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18932078	chr1:2524107	MMEL1	0.29	6.33	0.33	8.05e-10	Ulcerative colitis;
LUSC	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-6.28	-0.32	1.07e-9	Height;
LUSC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.11	16.95	0.68	6.38e-47	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12701220	0.596	rs10274383	chr7:1002013	T/C	cg04102894	chr7:1000210	NA	-0.28	-6.44	-0.33	4.07e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg02997394	chr19:33096574	ANKRD27	0.83	9.48	0.46	4.88e-19	Eosinophilic esophagitis;
LUSC	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg25456477	chr12:86230367	RASSF9	0.39	6.84	0.35	3.72e-11	Major depressive disorder;
LUSC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg23711669	chr6:146136114	FBXO30	0.75	13.4	0.59	4.72e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10992471	0.603	rs10761155	chr9:95153729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.55	-0.38	4.24e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2279817	0.735	rs11203432	chr1:17991196	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.45	-6.01	-0.31	4.88e-9	Neuroticism;
LUSC	cis	rs6772849	0.896	rs4557179	chr3:128366726	A/C	cg16766828	chr3:128327626	NA	-0.3	-5.64	-0.3	3.56e-8	Monocyte percentage of white cells;Monocyte count;
LUSC	cis	rs7246967	0.551	rs8103204	chr19:22936517	T/A	cg23217946	chr19:22817039	ZNF492	0.43	5.87	0.31	1.04e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs7795096	0.806	rs10261999	chr7:151540659	G/T	cg17008978	chr7:151542804	PRKAG2	0.35	6.63	0.34	1.34e-10	Bipolar disorder (age of onset and psychotic symptoms);
LUSC	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg12559939	chr2:27858050	GPN1	0.41	6.34	0.33	7.57e-10	Oral cavity cancer;
LUSC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.19	0.37	4.34e-12	Blood metabolite levels;
LUSC	cis	rs8099014	1.000	rs4940392	chr18:56107146	G/A	cg12907477	chr18:56117327	MIR122	0.41	6.54	0.34	2.25e-10	Platelet count;
LUSC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.64	10.64	0.5	5.62e-23	Bone mineral density;
LUSC	cis	rs3931020	0.688	rs968358	chr1:75193989	G/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.46	5.84	0.3	1.21e-8	Resistin levels;
LUSC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15541040	chr2:3486749	NA	-0.53	-8.42	-0.42	1.14e-15	Neurofibrillary tangles;
LUSC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg07870213	chr5:140052090	DND1	0.78	11.53	0.53	4.14e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	trans	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.97	-0.36	1.71e-11	Retinal vascular caliber;
LUSC	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg04374321	chr14:90722782	PSMC1	-0.66	-9.98	-0.48	1.04e-20	Mortality in heart failure;
LUSC	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg07828340	chr4:882639	GAK	1.07	11.34	0.53	1.99e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg08470875	chr2:26401718	FAM59B	-0.68	-9.16	-0.45	5.53e-18	Gut microbiome composition (summer);
LUSC	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg20628663	chr10:43360327	NA	-0.62	-7.81	-0.39	7.54e-14	Blood protein levels;
LUSC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg04455712	chr21:45112962	RRP1B	0.45	8.58	0.42	3.72e-16	Mean corpuscular volume;
LUSC	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.18	-0.32	1.84e-9	Type 2 diabetes;
LUSC	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg22875332	chr1:76189707	ACADM	-0.68	-9.42	-0.46	7.91e-19	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg13010199	chr12:38710504	ALG10B	-0.4	-6.11	-0.32	2.76e-9	Morning vs. evening chronotype;
LUSC	cis	rs11229555	0.609	rs11229434	chr11:58185501	C/T	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg14196790	chr5:131705035	SLC22A5	0.48	8.06	0.4	1.34e-14	Blood metabolite levels;
LUSC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	16.67	0.67	7.65e-46	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg26958806	chr6:27640298	NA	0.83	6.57	0.34	1.94e-10	Depression;
LUSC	cis	rs7677751	0.806	rs7681399	chr4:55090886	T/G	cg17187183	chr4:55093834	PDGFRA	0.38	5.66	0.3	3.18e-8	Corneal astigmatism;
LUSC	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg00376283	chr12:123451042	ABCB9	0.76	8.36	0.42	1.66e-15	Neutrophil percentage of white cells;
LUSC	cis	rs9677476	0.779	rs10173555	chr2:232108769	C/G	cg07929768	chr2:232055508	NA	0.37	6.21	0.32	1.59e-9	Food antigen IgG levels;
LUSC	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg19773385	chr1:10388646	KIF1B	-0.5	-8.72	-0.43	1.3e-16	Hepatocellular carcinoma;
LUSC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg09877947	chr5:131593287	PDLIM4	0.46	7.25	0.37	2.92e-12	Breast cancer;
LUSC	cis	rs9653442	0.564	rs2309753	chr2:100775920	C/A	cg07810366	chr2:100720526	AFF3	-0.44	-7.6	-0.38	2.92e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs506338	0.517	rs12269736	chr11:64471986	T/C	cg19131476	chr11:64387923	NRXN2	0.36	7.82	0.39	7.2e-14	Body mass index;Urate levels;
LUSC	cis	rs282587	0.569	rs282595	chr13:113379930	A/G	cg07026882	chr13:113417167	ATP11A	0.49	5.73	0.3	2.26e-8	Glycated hemoglobin levels;
LUSC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.96	0.31	6.4e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs858239	0.730	rs858290	chr7:23248036	A/G	cg05407003	chr7:23246146	NA	-0.38	-5.74	-0.3	2.1e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg08557956	chr11:4115526	RRM1	-0.45	-5.69	-0.3	2.81e-8	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs7939886	0.920	rs17150095	chr11:55902900	A/G	cg15704280	chr7:45808275	SEPT13	0.83	6.64	0.34	1.27e-10	Myopia (pathological);
LUSC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.31	-0.53	2.44e-25	Alzheimer's disease;
LUSC	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg22705602	chr4:152727874	NA	-0.33	-6.6	-0.34	1.66e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg04374321	chr14:90722782	PSMC1	0.75	12.08	0.55	4e-28	Mortality in heart failure;
LUSC	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg25208724	chr1:156163844	SLC25A44	1.04	21.93	0.77	1.19e-66	Testicular germ cell tumor;
LUSC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg01017244	chr2:74357527	NA	0.69	13.33	0.59	8.43e-33	Gestational age at birth (maternal effect);
LUSC	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg03676636	chr4:99064102	C4orf37	0.32	7.05	0.36	1.06e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg16006841	chr5:176797999	RGS14	-0.67	-9.33	-0.45	1.46e-18	Urate levels in lean individuals;
LUSC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	1.04	20.04	0.74	3.32e-59	Menopause (age at onset);
LUSC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg16339924	chr4:17578868	LAP3	0.55	8.26	0.41	3.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg00530320	chr1:46809349	NSUN4	0.57	8.71	0.43	1.43e-16	Menopause (age at onset);
LUSC	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg10840412	chr1:235813424	GNG4	0.56	7.28	0.37	2.36e-12	Bipolar disorder;
LUSC	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg21191810	chr6:118973309	C6orf204	0.38	6.75	0.35	6.4e-11	Electrocardiographic conduction measures;
LUSC	cis	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg06521331	chr12:34319734	NA	-0.48	-7.71	-0.39	1.43e-13	Morning vs. evening chronotype;
LUSC	cis	rs1853665	0.721	rs62441761	chr6:150268065	A/G	cg04697775	chr6:150285333	ULBP1	0.56	5.93	0.31	7.43e-9	Radiation response;
LUSC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24110177	chr3:50126178	RBM5	0.57	9.39	0.46	9.37e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg14668632	chr7:2872130	GNA12	-0.45	-6.81	-0.35	4.55e-11	Height;
LUSC	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg27205649	chr11:78285834	NARS2	0.53	6.46	0.33	3.72e-10	Alzheimer's disease (survival time);
LUSC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg24642439	chr20:33292090	TP53INP2	0.64	9.98	0.48	1.09e-20	Coronary artery disease;
LUSC	trans	rs11700980	0.551	rs2832020	chr21:30112231	G/A	cg14791747	chr16:20752902	THUMPD1	0.56	6.14	0.32	2.31e-9	QRS complex (12-leadsum);
LUSC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08677398	chr8:58056175	NA	0.51	6.75	0.35	6.43e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg20744362	chr22:50050164	C22orf34	0.36	6.66	0.34	1.1e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg05347473	chr6:146136440	FBXO30	0.57	9.97	0.48	1.14e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg18753928	chr3:113234510	CCDC52	-0.5	-7.61	-0.38	2.91e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24838063	chr12:130822603	PIWIL1	0.71	11.02	0.52	2.72e-24	Menopause (age at onset);
LUSC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06112835	chr11:68658793	MRPL21	0.51	7.88	0.4	4.58e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.74	-0.51	2.59e-23	Chronic sinus infection;
LUSC	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	5.96	0.31	6.38e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg13531842	chr10:38383804	ZNF37A	-0.46	-7.23	-0.37	3.4e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.43	6.07	0.32	3.4e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7264396	1.000	rs6088881	chr20:34165609	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.52	7.77	0.39	9.46e-14	Total cholesterol levels;
LUSC	cis	rs7923609	0.934	rs10761756	chr10:65172328	C/T	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.01e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg27494647	chr7:150038898	RARRES2	0.45	6.84	0.35	3.69e-11	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg08333703	chr19:35225315	ZNF181	0.31	5.95	0.31	6.7e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs10788264	0.504	rs7069328	chr10:124030741	G/C	cg09507567	chr10:124027408	NA	0.55	9.87	0.48	2.53e-20	Total body bone mineral density;
LUSC	trans	rs4938303	0.587	rs10892017	chr11:116567881	G/C	cg12339133	chr7:1031174	NA	-0.32	-5.98	-0.31	5.64e-9	Triglycerides;
LUSC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg10207240	chr12:122356781	WDR66	0.46	6.57	0.34	1.96e-10	Mean corpuscular volume;
LUSC	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.74	6.97	0.36	1.75e-11	Lung cancer in ever smokers;
LUSC	trans	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg17712092	chr4:129076599	LARP1B	-0.73	-10.24	-0.49	1.38e-21	Breast cancer;
LUSC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	13.5	0.59	1.9e-33	Alzheimer's disease;
LUSC	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg10547527	chr2:198650123	BOLL	-0.5	-5.71	-0.3	2.49e-8	Ulcerative colitis;
LUSC	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg16434002	chr17:42200994	HDAC5	-0.45	-6.42	-0.33	4.81e-10	Total body bone mineral density;
LUSC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg17507749	chr15:85114479	UBE2QP1	0.68	8.55	0.42	4.36e-16	Schizophrenia;
LUSC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-9.85	-0.47	3e-20	Developmental language disorder (linguistic errors);
LUSC	trans	rs724744	0.710	rs1737235	chr6:22351177	C/T	cg13807341	chr11:118445984	ARCN1	-0.36	-6.18	-0.32	1.89e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs7512552	0.839	rs12046446	chr1:150460855	T/G	cg15654264	chr1:150340011	RPRD2	0.63	10.31	0.49	8.08e-22	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg06521331	chr12:34319734	NA	-0.52	-8.62	-0.43	2.69e-16	Morning vs. evening chronotype;
LUSC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg25258033	chr6:167368657	RNASET2	0.46	7.67	0.39	1.91e-13	Crohn's disease;
LUSC	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg18240062	chr17:79603768	NPLOC4	-0.8	-15.5	-0.65	3.45e-41	Eye color traits;
LUSC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.33	0.53	2.21e-25	Menopause (age at onset);
LUSC	cis	rs193541	0.626	rs6898725	chr5:122086938	G/A	cg19077854	chr5:122220652	SNX24	0.27	6.16	0.32	2.12e-9	Glucose homeostasis traits;
LUSC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg23891399	chr17:73824620	UNC13D	0.35	5.68	0.3	2.89e-8	White matter hyperintensity burden;
LUSC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg16447950	chr5:562315	NA	-0.53	-6.97	-0.36	1.69e-11	Obesity-related traits;
LUSC	cis	rs6429082	0.744	rs903347	chr1:235586613	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.56	-7.94	-0.4	3.11e-14	Adiposity;
LUSC	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg26384229	chr12:38710491	ALG10B	0.56	9.0	0.44	1.77e-17	Morning vs. evening chronotype;
LUSC	cis	rs6977660	0.714	rs10276518	chr7:19781325	C/A	cg07541023	chr7:19748670	TWISTNB	0.68	6.79	0.35	5.11e-11	Thyroid stimulating hormone;
LUSC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-1.04	-20.22	-0.74	5.96e-60	Height;
LUSC	cis	rs500891	0.768	rs17255340	chr6:84089191	G/A	cg08257003	chr6:84140564	ME1	0.33	6.91	0.35	2.5e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg03188948	chr7:1209495	NA	0.66	6.93	0.35	2.24e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg21770322	chr7:97807741	LMTK2	0.41	7.05	0.36	1.04e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10754283	0.967	rs2002883	chr1:90105838	A/G	cg21401794	chr1:90099060	LRRC8C	0.65	9.74	0.47	6.91e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg07701084	chr6:150067640	NUP43	0.56	8.54	0.42	4.82e-16	Lung cancer;
LUSC	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg07541023	chr7:19748670	TWISTNB	0.57	6.18	0.32	1.87e-9	Thyroid stimulating hormone;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg16335926	chr5:142784462	NR3C1	0.41	6.28	0.32	1.06e-9	Schizophrenia;
LUSC	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg01620082	chr3:125678407	NA	-0.8	-7.24	-0.37	3.11e-12	Depression;
LUSC	cis	rs6681460	0.932	rs2483705	chr1:67191180	C/G	cg02459107	chr1:67143332	SGIP1	-0.47	-8.71	-0.43	1.46e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg02918577	chr15:93633145	RGMA	0.46	7.75	0.39	1.11e-13	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LUSC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg24829409	chr8:58192753	C8orf71	-0.54	-6.27	-0.32	1.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.73	-8.39	-0.42	1.41e-15	Schizophrenia;
LUSC	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg09092052	chr15:45571596	NA	0.45	6.31	0.33	8.87e-10	Glomerular filtration rate;
LUSC	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg15737290	chr11:93063684	CCDC67	0.63	7.53	0.38	4.63e-13	Pulmonary function decline;
LUSC	trans	rs34816374	1	rs34816374	chr6:26949672	A/G	cg06606381	chr12:133084897	FBRSL1	-0.9	-8.31	-0.41	2.38e-15	Lung cancer in ever smokers;
LUSC	cis	rs4629710	0.592	rs9492865	chr6:131534403	T/A	cg12700074	chr6:131571435	AKAP7	-0.37	-6.22	-0.32	1.48e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	0.83	15.57	0.65	1.71e-41	Dental caries;
LUSC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg05738196	chr6:26577821	NA	-0.83	-16.04	-0.66	2.51e-43	Intelligence (multi-trait analysis);
LUSC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg00745463	chr17:30367425	LRRC37B	-0.79	-9.21	-0.45	3.75e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg11189052	chr15:85197271	WDR73	0.48	5.93	0.31	7.56e-9	Schizophrenia;
LUSC	cis	rs10740039	0.516	rs1348281	chr10:62356233	C/T	cg18175470	chr10:62150864	ANK3	0.47	7.27	0.37	2.5e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg24375607	chr4:120327624	NA	0.75	11.42	0.53	9.94e-26	Corneal astigmatism;
LUSC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg03351412	chr1:154909251	PMVK	0.51	7.98	0.4	2.45e-14	Prostate cancer;
LUSC	cis	rs6696846	0.749	rs7515178	chr1:205084120	G/A	cg21545522	chr1:205238299	TMCC2	0.42	8.08	0.4	1.18e-14	Red blood cell count;
LUSC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg26380479	chr7:97908229	NA	-0.27	-6.06	-0.31	3.67e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg15309053	chr8:964076	NA	0.41	8.19	0.41	5.46e-15	Schizophrenia;
LUSC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24549020	chr5:56110836	MAP3K1	0.49	5.98	0.31	5.58e-9	Initial pursuit acceleration;
LUSC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	6.36	0.33	6.55e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4253772	0.938	rs41329344	chr22:46636930	C/T	cg18190219	chr22:46762943	CELSR1	-0.51	-5.92	-0.31	7.92e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10886558	0.502	rs4428989	chr10:121825969	G/A	cg02041677	chr10:121771263	NA	-0.33	-6.02	-0.31	4.7e-9	Shingles;
LUSC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.52	8.67	0.43	1.9e-16	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg27471124	chr11:109292789	C11orf87	0.43	7.46	0.38	7.48e-13	Schizophrenia;
LUSC	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg25281562	chr12:121454272	C12orf43	0.46	5.86	0.31	1.12e-8	N-glycan levels;
LUSC	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.41	-0.33	4.97e-10	Uric acid levels;
LUSC	trans	rs3857536	0.776	rs2040593	chr6:66944076	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.04	-0.31	4.02e-9	Blood trace element (Cu levels);
LUSC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg17747265	chr1:1875780	NA	0.64	13.68	0.6	3.81e-34	Body mass index;
LUSC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg22823121	chr1:150693482	HORMAD1	0.57	8.78	0.43	8.37e-17	Tonsillectomy;
LUSC	cis	rs2219968	0.962	rs7828745	chr8:78947372	G/A	cg00738934	chr8:78996279	NA	0.37	6.58	0.34	1.77e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.48	0.38	6.51e-13	Bipolar disorder;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg25593729	chr12:122150344	TMEM120B	0.59	7.27	0.37	2.65e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02801482	chr2:159824941	TANC1	-0.42	-6.48	-0.33	3.39e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg03647239	chr10:116582469	FAM160B1	0.47	7.58	0.38	3.42e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.53	-8.92	-0.44	3.2e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.76	12.03	0.55	6.02e-28	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4654899	0.965	rs2873424	chr1:21500701	C/A	cg01072550	chr1:21505969	NA	-0.53	-8.11	-0.41	9.91e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7177699	0.526	rs7182529	chr15:79123631	T/C	cg00540400	chr15:79124168	NA	0.43	7.51	0.38	5.44e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg14438399	chr17:27053147	TLCD1	0.52	5.75	0.3	2.05e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs1712517	0.771	rs61350103	chr10:105069120	A/C	cg05636881	chr10:105038444	INA	0.39	6.39	0.33	5.66e-10	Migraine;
LUSC	cis	rs41271473	1.000	rs11587994	chr1:228860072	A/C	cg10167378	chr1:228756711	NA	0.61	7.28	0.37	2.48e-12	Chronic lymphocytic leukemia;
LUSC	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg22089800	chr15:90895588	ZNF774	0.63	9.5	0.46	4.11e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg01765077	chr12:122356316	WDR66	0.55	8.1	0.41	1.04e-14	Mean platelet volume;
LUSC	cis	rs6741892	0.511	rs35585199	chr2:38923722	C/T	cg23643435	chr2:38893251	GALM	-0.72	-5.7	-0.3	2.6e-8	5-HTT brain serotonin transporter levels;
LUSC	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.78	-11.67	-0.54	1.31e-26	Blood pressure (smoking interaction);
LUSC	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg17366294	chr4:99064904	C4orf37	0.59	10.37	0.49	5.04e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06634786	chr22:41940651	POLR3H	-0.53	-6.06	-0.31	3.76e-9	Vitiligo;
LUSC	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg14061069	chr19:46274453	DMPK	-0.51	-8.65	-0.43	2.17e-16	Coronary artery disease;
LUSC	cis	rs4690686	0.500	rs11728314	chr4:177268373	G/A	cg17059388	chr4:177262070	NA	0.46	8.63	0.43	2.62e-16	Essential tremor;
LUSC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg25258033	chr6:167368657	RNASET2	-0.49	-8.12	-0.41	9.03e-15	Crohn's disease;
LUSC	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg00074818	chr8:8560427	CLDN23	0.59	9.8	0.47	4.21e-20	Obesity-related traits;
LUSC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18357526	chr6:26021779	HIST1H4A	0.45	7.22	0.37	3.63e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg02113368	chr10:135107346	TUBGCP2	-0.34	-6.01	-0.31	4.92e-9	Dementia with Lewy bodies;
LUSC	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg22139774	chr2:100720529	AFF3	-0.53	-9.61	-0.47	1.76e-19	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	trans	rs6851442	0.614	rs28374811	chr4:109038758	G/A	cg24541021	chr2:218896725	NA	0.42	5.95	0.31	6.73e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-1.11	-24.79	-0.8	1.03e-77	Height;
LUSC	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg05738196	chr6:26577821	NA	0.8	15.43	0.65	6.24e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs911119	0.954	rs2424582	chr20:23622550	A/G	cg16589663	chr20:23618590	CST3	0.6	7.51	0.38	5.38e-13	Chronic kidney disease;
LUSC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg02038168	chr22:39784481	NA	-0.5	-8.31	-0.41	2.45e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs11971779	0.666	rs6467847	chr7:139079436	T/C	cg07862535	chr7:139043722	LUC7L2	0.64	7.81	0.39	7.53e-14	Diisocyanate-induced asthma;
LUSC	cis	rs7605827	0.866	rs6745922	chr2:15537931	G/C	cg19274914	chr2:15703543	NA	0.46	8.98	0.44	2e-17	Educational attainment (years of education);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13692001	chr19:40023494	EID2B	0.83	7.18	0.37	4.6e-12	Cognitive performance;
LUSC	cis	rs8064299	0.934	rs895692	chr17:72766252	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.64	10.86	0.51	9.78e-24	Monocyte count;
LUSC	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg16624210	chr5:671434	TPPP	0.47	5.92	0.31	8.21e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-8.33	-0.41	2.12e-15	Body mass index;
LUSC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg12963246	chr6:28129442	ZNF389	0.43	6.0	0.31	5.17e-9	Depression;
LUSC	trans	rs7529925	0.739	rs12239179	chr1:198976492	C/T	cg25702651	chr3:192675515	NA	-0.35	-6.0	-0.31	5.28e-9	Mean corpuscular volume;Red blood cell traits;
LUSC	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg05294307	chr14:35346193	BAZ1A	-0.58	-6.99	-0.36	1.51e-11	Psoriasis;
LUSC	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg10255544	chr17:80519551	FOXK2	0.38	6.24	0.32	1.36e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg22117172	chr7:91764530	CYP51A1	0.33	5.83	0.3	1.34e-8	Breast cancer;
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-8.02	-0.4	1.83e-14	Lymphocyte counts;
LUSC	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.35	-0.46	1.28e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-8.04	-0.4	1.57e-14	Menarche (age at onset);
LUSC	cis	rs1971762	0.561	rs4759288	chr12:54084006	T/A	cg23533419	chr12:54090519	NA	-0.36	-6.04	-0.31	4.21e-9	Height;
LUSC	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg12615879	chr12:58013172	SLC26A10	0.45	10.69	0.5	3.86e-23	Multiple sclerosis;
LUSC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg25174290	chr11:3078921	CARS	-0.41	-6.18	-0.32	1.87e-9	Calcium levels;
LUSC	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06636551	chr8:101224915	SPAG1	-0.45	-8.26	-0.41	3.35e-15	Atrioventricular conduction;
LUSC	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg23649088	chr2:200775458	C2orf69	-0.56	-6.7	-0.34	8.65e-11	Schizophrenia;
LUSC	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg19875535	chr5:140030758	IK	0.5	8.28	0.41	3.06e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.74	12.46	0.56	1.61e-29	Height;
LUSC	trans	rs7739264	0.564	rs760796	chr6:19790387	C/T	cg13431028	chr2:169073609	STK39	0.36	6.05	0.31	3.85e-9	Endometriosis;
LUSC	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg07701084	chr6:150067640	NUP43	0.5	7.43	0.38	8.98e-13	Lung cancer;
LUSC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg04850211	chr1:228464232	OBSCN	-0.33	-6.17	-0.32	2.03e-9	Diastolic blood pressure;
LUSC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg05585544	chr11:47624801	NA	-0.42	-7.31	-0.37	2.04e-12	Subjective well-being;
LUSC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg18357645	chr12:58087776	OS9	0.55	8.21	0.41	4.97e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg05084668	chr3:125655381	ALG1L	-0.77	-11.54	-0.53	3.85e-26	Blood pressure (smoking interaction);
LUSC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.13	17.23	0.69	4.9e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs10761482	1.000	rs10821722	chr10:62081085	A/G	cg18175470	chr10:62150864	ANK3	-0.48	-6.74	-0.35	7.11e-11	Schizophrenia;
LUSC	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg04586622	chr2:25135609	ADCY3	0.42	8.97	0.44	2.22e-17	Body mass index;
LUSC	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg08601574	chr20:25228251	PYGB	-0.42	-6.43	-0.33	4.39e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg23711669	chr6:146136114	FBXO30	-0.82	-14.78	-0.63	2.13e-38	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4478858	0.735	rs11436	chr1:31837320	T/C	cg00250761	chr1:31883323	NA	-0.36	-8.66	-0.43	1.99e-16	Alcohol dependence;
LUSC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-12.84	-0.57	5.91e-31	Alzheimer's disease;
LUSC	cis	rs6714710	0.603	rs11690687	chr2:98461821	C/T	cg26665480	chr2:98280029	ACTR1B	0.56	8.14	0.41	7.74e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg01620082	chr3:125678407	NA	-0.85	-7.28	-0.37	2.42e-12	Lung cancer;
LUSC	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.21	0.61	3.68e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs56283067	0.847	rs12208621	chr6:44752003	G/C	cg20913747	chr6:44695427	NA	-0.5	-8.36	-0.42	1.71e-15	Total body bone mineral density;
LUSC	trans	rs9341835	0.510	rs2622284	chr6:64193572	T/C	cg19533977	chr17:57719682	CLTC	0.33	6.11	0.32	2.8e-9	Schizophrenia;
LUSC	cis	rs7799006	0.582	rs7781284	chr7:2339405	G/T	cg12823233	chr7:2316876	SNX8	-0.35	-5.86	-0.31	1.11e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.62	0.47	1.66e-19	Bipolar disorder;
LUSC	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg01411142	chr8:19674711	INTS10	0.5	5.66	0.3	3.31e-8	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg14582100	chr15:45693742	SPATA5L1	0.44	8.43	0.42	1.07e-15	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs75920871	0.528	rs7109649	chr11:116943544	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.48	-0.33	3.25e-10	Subjective well-being;
LUSC	cis	rs9948	0.655	rs61742095	chr2:97366088	T/C	cg01990225	chr2:97406019	LMAN2L	-1.02	-7.2	-0.37	4.01e-12	Erectile dysfunction and prostate cancer treatment;
LUSC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.24	0.41	3.98e-15	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs2637266	1.000	rs11001835	chr10:78364770	A/G	cg18941641	chr10:78392320	NA	0.39	7.22	0.37	3.61e-12	Pulmonary function;
LUSC	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg16512390	chr1:228756714	NA	0.7	8.89	0.44	4.03e-17	Chronic lymphocytic leukemia;
LUSC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.68	0.34	9.71e-11	Menopause (age at onset);
LUSC	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg05855489	chr10:104503620	C10orf26	-0.71	-10.0	-0.48	8.76e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.11	-0.45	7.95e-18	Monocyte percentage of white cells;
LUSC	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.64e-11	Body mass index;
LUSC	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.21	-15.09	-0.64	1.37e-39	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs2282032	0.527	rs8020828	chr14:90768183	C/T	cg14092571	chr14:90743983	NA	0.48	8.03	0.4	1.67e-14	Longevity;
LUSC	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg22467129	chr15:76604101	ETFA	0.43	6.94	0.35	2.07e-11	Blood metabolite levels;
LUSC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.43	-6.22	-0.32	1.48e-9	Platelet count;
LUSC	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.75	14.7	0.63	4.6e-38	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg22431228	chr1:16359049	CLCNKA	0.44	8.53	0.42	5.02e-16	Dilated cardiomyopathy;
LUSC	cis	rs9378688	0.654	rs2479008	chr6:2347808	C/T	cg12303981	chr6:2244766	GMDS	-0.4	-5.72	-0.3	2.38e-8	Caudate nucleus volume;
LUSC	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg15704280	chr7:45808275	SEPT13	-0.84	-11.72	-0.54	8.17e-27	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.35	0.53	1.87e-25	Menopause (age at onset);
LUSC	cis	rs7923609	0.967	rs10761752	chr10:65160321	T/C	cg01631684	chr10:65280961	REEP3	-0.42	-6.45	-0.33	4.01e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg26395211	chr5:140044315	WDR55	-0.38	-5.74	-0.3	2.14e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9311676	0.632	rs56288363	chr3:58374533	A/T	cg13750441	chr3:58318267	PXK	0.36	6.89	0.35	2.78e-11	Systemic lupus erythematosus;
LUSC	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg16405210	chr4:1374714	KIAA1530	-0.85	-13.81	-0.6	1.26e-34	Longevity;
LUSC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg06064525	chr11:970664	AP2A2	-0.49	-10.7	-0.51	3.73e-23	Alzheimer's disease (late onset);
LUSC	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg15704280	chr7:45808275	SEPT13	-1.03	-19.25	-0.73	4.28e-56	Height;
LUSC	cis	rs6500395	0.962	rs9941275	chr16:48573428	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.57	0.34	1.93e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2004776	0.656	rs11122586	chr1:230866121	G/A	cg07502417	chr1:230849801	AGT	0.25	5.74	0.3	2.12e-8	Diastolic blood pressure;
LUSC	trans	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	10.57	0.5	9.93e-23	Mean corpuscular volume;
LUSC	cis	rs7923609	0.902	rs4633333	chr10:65328539	C/G	cg01631684	chr10:65280961	REEP3	-0.42	-6.59	-0.34	1.77e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg10624161	chr6:107349251	C6orf203	-0.56	-6.99	-0.36	1.48e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs7951105	1.000	rs12282788	chr11:39258863	T/A	cg24085930	chr3:21832523	NA	0.48	6.02	0.31	4.72e-9	Free thyroxine concentration;
LUSC	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.49	0.42	6.73e-16	Response to antipsychotic treatment;
LUSC	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg05802129	chr4:122689817	NA	-0.46	-7.79	-0.39	8.32e-14	Type 2 diabetes;
LUSC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.84	15.34	0.64	1.48e-40	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg21427119	chr20:30132790	HM13	-0.35	-5.67	-0.3	3.08e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg11645453	chr3:52864694	ITIH4	-0.4	-9.2	-0.45	4.07e-18	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg02073558	chr3:44770973	ZNF501	0.59	9.78	0.47	4.98e-20	Depressive symptoms;
LUSC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg16606324	chr3:10149918	C3orf24	0.63	8.77	0.43	8.98e-17	Alzheimer's disease;
LUSC	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg01017244	chr2:74357527	NA	0.65	11.56	0.53	3.04e-26	Gestational age at birth (maternal effect);
LUSC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg04944784	chr2:26401820	FAM59B	-0.7	-9.79	-0.47	4.69e-20	Gut microbiome composition (summer);
LUSC	cis	rs1881396	0.531	rs4665385	chr2:27930837	C/T	cg27432699	chr2:27873401	GPN1	0.63	7.72	0.39	1.34e-13	Nonalcoholic fatty liver disease;
LUSC	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs1927790	0.727	rs12583988	chr13:96991602	G/A	cg03198741	chr6:1003969	LOC285768	-0.4	-5.99	-0.31	5.57e-9	Body mass index;
LUSC	cis	rs6500395	1.000	rs8052073	chr16:48682696	T/C	cg04672837	chr16:48644449	N4BP1	0.45	6.8	0.35	4.69e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13893634	chr17:48229117	PPP1R9B	-0.5	-7.72	-0.39	1.34e-13	Temporomandibular joint disorder;
LUSC	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.72	12.0	0.55	8.08e-28	Height;
LUSC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg19678392	chr7:94953810	PON1	-0.38	-6.12	-0.32	2.65e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg05025164	chr4:1340916	KIAA1530	0.41	6.12	0.32	2.59e-9	Obesity-related traits;
LUSC	cis	rs11608355	0.508	rs2075434	chr12:109797051	G/A	cg19025524	chr12:109796872	NA	-0.47	-8.43	-0.42	1.02e-15	Neuroticism;
LUSC	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.65	-8.03	-0.4	1.69e-14	Yeast infection;
LUSC	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg07636037	chr3:49044803	WDR6	0.67	8.65	0.43	2.22e-16	Menarche (age at onset);
LUSC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg26441486	chr22:50317300	CRELD2	0.49	7.28	0.37	2.45e-12	Schizophrenia;
LUSC	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg22709100	chr7:91322751	NA	-0.41	-6.04	-0.31	4.17e-9	Breast cancer;
LUSC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg23625390	chr15:77176239	SCAPER	0.45	6.9	0.35	2.55e-11	Blood metabolite levels;
LUSC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg23711669	chr6:146136114	FBXO30	-0.89	-17.27	-0.69	3.42e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9807989	0.811	rs11688568	chr2:102969949	C/T	cg03938978	chr2:103052716	IL18RAP	0.31	5.79	0.3	1.58e-8	Asthma;
LUSC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg06784218	chr1:46089804	CCDC17	-0.57	-11.51	-0.53	4.96e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21659725	chr3:3221576	CRBN	0.63	10.43	0.5	3.02e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.03	-0.44	1.38e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg18131467	chr2:239335373	ASB1	-0.74	-6.62	-0.34	1.45e-10	Chronotype;
LUSC	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	1.15	18.46	0.71	6.19e-53	Corneal structure;
LUSC	trans	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg03886242	chr7:26192032	NFE2L3	-0.4	-6.47	-0.33	3.54e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6580649	1.000	rs6580649	chr12:48410517	A/G	cg24011408	chr12:48396354	COL2A1	0.57	7.36	0.37	1.46e-12	Lung cancer;
LUSC	cis	rs7428496	0.528	rs13063075	chr3:142263372	G/A	cg16271453	chr3:142027066	XRN1	-0.5	-8.65	-0.43	2.13e-16	Mean corpuscular hemoglobin;
LUSC	cis	rs7712401	0.601	rs30022	chr5:122285716	T/A	cg19077854	chr5:122220652	SNX24	0.44	9.86	0.47	2.76e-20	Mean platelet volume;
LUSC	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg03570417	chr12:132312461	MMP17	0.43	7.61	0.38	2.85e-13	Migraine;
LUSC	trans	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg07393940	chr7:158741817	NA	0.52	8.6	0.43	3.15e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4629710	0.592	rs13205441	chr6:131575069	G/A	cg12700074	chr6:131571435	AKAP7	-0.35	-5.9	-0.31	8.89e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg03676636	chr4:99064102	C4orf37	0.35	7.56	0.38	3.82e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6429082	0.818	rs291340	chr1:235674379	C/T	cg26050004	chr1:235667680	B3GALNT2	0.62	8.33	0.41	2.17e-15	Adiposity;
LUSC	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg13072238	chr3:49761600	GMPPB	-0.69	-9.06	-0.44	1.08e-17	Menarche (age at onset);
LUSC	trans	rs12310956	0.510	rs7301767	chr12:33886529	A/T	cg13010199	chr12:38710504	ALG10B	0.45	7.0	0.36	1.44e-11	Morning vs. evening chronotype;
LUSC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-8.96	-0.44	2.37e-17	Gut microbiome composition (summer);
LUSC	cis	rs11031096	0.738	rs2923950	chr11:4042069	G/C	cg18678763	chr11:4115507	RRM1	0.39	5.81	0.3	1.47e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg23985595	chr17:80112537	CCDC57	0.33	6.33	0.33	7.82e-10	Life satisfaction;
LUSC	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg11812906	chr14:75593930	NEK9	-0.62	-10.39	-0.49	4.13e-22	Height;
LUSC	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg03859395	chr2:55845619	SMEK2	0.87	16.07	0.66	1.97e-43	Metabolic syndrome;
LUSC	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21659725	chr3:3221576	CRBN	-0.53	-8.41	-0.42	1.23e-15	Body mass index;
LUSC	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg15704280	chr7:45808275	SEPT13	-0.51	-7.26	-0.37	2.79e-12	HDL cholesterol;
LUSC	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg11812906	chr14:75593930	NEK9	-0.64	-10.48	-0.5	2.14e-22	Height;
LUSC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	14.4	0.62	6.64e-37	Platelet count;
LUSC	cis	rs7523050	0.643	rs67567504	chr1:109402580	C/A	cg08274380	chr1:109419600	GPSM2	1.1	10.61	0.5	7.32e-23	Fat distribution (HIV);
LUSC	cis	rs17433780	0.808	rs12125301	chr1:89508501	G/A	cg09516651	chr1:89888402	LOC400759	0.61	11.67	0.54	1.25e-26	Carotid intima media thickness;
LUSC	cis	rs7000551	0.653	rs4872504	chr8:22326717	A/G	cg12081754	chr8:22256438	SLC39A14	0.48	7.25	0.37	2.98e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg13798780	chr7:105162888	PUS7	0.56	6.15	0.32	2.23e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg05738196	chr6:26577821	NA	0.81	15.2	0.64	4.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg11843238	chr5:131593191	PDLIM4	0.45	7.99	0.4	2.15e-14	Blood metabolite levels;
LUSC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.1e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg06640241	chr16:89574553	SPG7	0.89	16.13	0.66	1.07e-43	Multiple myeloma (IgH translocation);
LUSC	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg15819921	chr19:927150	ARID3A	-0.43	-6.37	-0.33	6.25e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs1113500	0.897	rs2336127	chr1:108640870	G/A	cg11967332	chr1:108735228	SLC25A24	0.4	6.07	0.32	3.49e-9	Growth-regulated protein alpha levels;
LUSC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.78	0.3	1.76e-8	Personality dimensions;
LUSC	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg18478394	chr8:109455254	TTC35	0.43	6.79	0.35	5.26e-11	Dupuytren's disease;
LUSC	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.06	-0.31	3.6e-9	Systolic blood pressure;
LUSC	cis	rs722599	0.715	rs11851433	chr14:75339450	C/T	cg06637938	chr14:75390232	RPS6KL1	0.41	6.07	0.32	3.5e-9	IgG glycosylation;
LUSC	cis	rs2637266	0.967	rs12246436	chr10:78352914	C/T	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg16060761	chr17:80687452	NA	0.41	6.31	0.33	8.74e-10	Breast cancer;
LUSC	cis	rs11209185	0.672	rs1926278	chr1:68453859	C/T	cg22082780	chr1:68452167	NA	0.33	6.26	0.32	1.22e-9	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg25237894	chr2:233734115	C2orf82	0.35	6.41	0.33	4.96e-10	Coronary artery disease;
LUSC	cis	rs3820928	0.874	rs13419455	chr2:227850465	C/G	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.63	-0.39	2.44e-13	Pulmonary function;
LUSC	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg22676075	chr6:135203613	NA	0.59	9.41	0.46	8.46e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	8.19e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg04287289	chr16:89883240	FANCA	0.4	5.81	0.3	1.46e-8	Vitiligo;
LUSC	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.49	-6.53	-0.34	2.5e-10	Schizophrenia;
LUSC	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg09307838	chr4:120376055	NA	0.64	9.67	0.47	1.12e-19	Corneal astigmatism;
LUSC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.48	5.88	0.31	1.02e-8	Mean platelet volume;
LUSC	cis	rs2247341	1.000	rs34049648	chr4:1697337	G/A	cg07465881	chr4:1713556	SLBP	-0.38	-5.77	-0.3	1.85e-8	Hip circumference adjusted for BMI;Height;
LUSC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg23172400	chr8:95962367	TP53INP1	-0.39	-7.95	-0.4	2.97e-14	Type 2 diabetes;
LUSC	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.64	0.39	2.25e-13	Iron status biomarkers;
LUSC	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg12002119	chr2:101014098	CHST10	0.36	5.93	0.31	7.72e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg23625390	chr15:77176239	SCAPER	0.48	7.3	0.37	2.18e-12	Blood metabolite levels;
LUSC	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	cis	rs977987	0.836	rs17685540	chr16:75323840	T/C	cg03315344	chr16:75512273	CHST6	0.47	8.63	0.43	2.56e-16	Dupuytren's disease;
LUSC	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	10.1	0.48	4.33e-21	Lymphocyte counts;
LUSC	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg18302933	chr2:88491318	NA	-0.38	-7.51	-0.38	5.31e-13	Response to metformin (IC50);
LUSC	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg21138405	chr5:131827807	IRF1	-0.33	-5.81	-0.3	1.45e-8	Breast cancer;Mosquito bite size;
LUSC	cis	rs116161686	0.500	rs76610459	chr1:210050756	T/G	cg21951975	chr1:209979733	IRF6	0.56	6.8	0.35	4.72e-11	Coronary artery disease;
LUSC	cis	rs2479724	0.870	rs6913232	chr6:41915143	C/T	cg17623882	chr6:41773611	USP49	0.55	8.8	0.43	7.59e-17	Menarche (age at onset);
LUSC	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg17127132	chr2:85788382	GGCX	0.47	7.54	0.38	4.38e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg17507749	chr15:85114479	UBE2QP1	0.56	7.12	0.36	6.7e-12	Schizophrenia;
LUSC	cis	rs17102423	0.731	rs998247	chr14:65546299	C/T	cg11161011	chr14:65562177	MAX	-0.67	-10.17	-0.49	2.42e-21	Obesity-related traits;
LUSC	cis	rs4776059	0.798	rs13329393	chr15:52920505	A/T	cg22715398	chr15:52968154	KIAA1370	0.57	7.39	0.37	1.19e-12	Schizophrenia;
LUSC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg11871910	chr12:69753446	YEATS4	-0.61	-9.0	-0.44	1.68e-17	Blood protein levels;
LUSC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	13.4	0.59	4.48e-33	Alzheimer's disease;
LUSC	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg17470449	chr10:769945	NA	0.5	7.0	0.36	1.41e-11	Uric acid levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20165884	chr8:96281478	C8orf37	0.49	7.31	0.37	1.98e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg00383909	chr3:49044727	WDR6	1.1	9.83	0.47	3.28e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg01579765	chr21:45077557	HSF2BP	-0.5	-10.42	-0.5	3.2800000000000002e-22	Mean corpuscular volume;
LUSC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06850241	chr22:41845214	NA	0.34	6.19	0.32	1.79e-9	Vitiligo;
LUSC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg05738196	chr6:26577821	NA	0.53	8.32	0.41	2.23e-15	Schizophrenia;
LUSC	cis	rs710216	0.917	rs2297977	chr1:43415288	G/T	cg03128534	chr1:43423976	SLC2A1	0.46	5.97	0.31	6.19e-9	Red cell distribution width;
LUSC	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg24375607	chr4:120327624	NA	0.8	12.18	0.55	1.76e-28	Corneal astigmatism;
LUSC	cis	rs981844	0.683	rs1105496	chr4:154756755	T/C	cg14289246	chr4:154710475	SFRP2	-0.47	-6.51	-0.34	2.69e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs9905704	0.846	rs302851	chr17:56685424	G/A	cg12560992	chr17:57184187	TRIM37	0.56	8.07	0.4	1.28e-14	Testicular germ cell tumor;
LUSC	cis	rs2273669	0.667	rs11153139	chr6:109279381	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-6.61	-0.34	1.55e-10	Prostate cancer;
LUSC	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21028142	chr17:79581711	NPLOC4	0.34	8.16	0.41	7.03e-15	Eye color traits;
LUSC	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.32	0.53	2.37e-25	Colorectal cancer;
LUSC	cis	rs34638657	0.732	rs12597534	chr16:82200276	G/T	cg09439754	chr16:82129088	HSD17B2	-0.37	-6.25	-0.32	1.26e-9	Lung adenocarcinoma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26147372	chr3:49130904	QRICH1	-0.42	-6.2	-0.32	1.62e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg16447950	chr5:562315	NA	-0.58	-7.11	-0.36	7.26e-12	Obesity-related traits;
LUSC	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg21770322	chr7:97807741	LMTK2	0.56	10.07	0.48	5.2e-21	Breast cancer;
LUSC	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg24011408	chr12:48396354	COL2A1	0.4	5.8	0.3	1.55e-8	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg13395646	chr4:1353034	KIAA1530	-0.65	-10.25	-0.49	1.32e-21	Obesity-related traits;
LUSC	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg17294928	chr15:75287854	SCAMP5	-0.76	-6.55	-0.34	2.11e-10	Lung cancer;
LUSC	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg05472934	chr7:22766657	IL6	0.52	8.57	0.42	4.03e-16	Lung cancer;
LUSC	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg15445000	chr17:37608096	MED1	0.37	6.35	0.33	7.09e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	7.59	0.38	3.24e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg08847533	chr14:75593920	NEK9	-0.83	-15.44	-0.65	5.91e-41	Height;
LUSC	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg12179176	chr11:130786555	SNX19	0.57	8.58	0.43	3.5e-16	Schizophrenia;
LUSC	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg12935359	chr14:103987150	CKB	0.57	8.62	0.43	2.8e-16	Bone mineral density;
LUSC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg21132104	chr15:45694354	SPATA5L1	0.53	7.09	0.36	7.81e-12	Homoarginine levels;
LUSC	cis	rs2200578	1.000	rs62153845	chr2:99887162	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.57	6.55	0.34	2.16e-10	IgG glycosylation;
LUSC	cis	rs6005807	0.719	rs73430189	chr22:29004881	C/A	cg12565055	chr22:29076175	TTC28	0.54	5.79	0.3	1.62e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs660498	0.507	rs11015783	chr10:27729745	A/G	cg04084786	chr10:27609163	NA	0.39	5.75	0.3	1.99e-8	Asthma (childhood onset);
LUSC	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg04850211	chr1:228464232	OBSCN	0.32	5.7	0.3	2.7e-8	Diastolic blood pressure;
LUSC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg04398451	chr17:18023971	MYO15A	0.57	9.52	0.46	3.67e-19	Total body bone mineral density;
LUSC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-6.96	-0.36	1.81e-11	Bipolar disorder;
LUSC	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg03605463	chr16:89740564	NA	-0.39	-5.65	-0.3	3.51e-8	Vitiligo;
LUSC	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs977987	0.778	rs11862719	chr16:75431708	T/A	cg04384234	chr16:75411784	CFDP1	-0.41	-6.77	-0.35	5.88e-11	Dupuytren's disease;
LUSC	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg11102782	chr19:18549136	ISYNA1	-0.35	-6.54	-0.34	2.3e-10	Breast cancer;
LUSC	cis	rs711245	1.000	rs848602	chr2:36778372	G/A	cg01206211	chr2:36825736	FEZ2	0.37	7.68	0.39	1.78e-13	Height;
LUSC	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg04450456	chr4:17643702	FAM184B	0.38	6.4	0.33	5.4e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg22875332	chr1:76189707	ACADM	-0.42	-6.16	-0.32	2.09e-9	Daytime sleep phenotypes;
LUSC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.59	-8.15	-0.41	7.17e-15	Corneal structure;
LUSC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.2	0.41	5.24e-15	Homoarginine levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03144560	chr20:55043299	C20orf43	-0.51	-6.18	-0.32	1.87e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs506338	0.517	rs530252	chr11:64443465	T/C	cg19395706	chr11:64412079	NRXN2	0.29	5.83	0.3	1.31e-8	Body mass index;Urate levels;
LUSC	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg05784532	chr1:230284198	GALNT2	0.65	9.18	0.45	4.63e-18	Coronary artery disease;
LUSC	trans	rs7976838	0.614	rs17122837	chr12:60073907	C/T	cg04017131	chr8:6419570	ANGPT2;MCPH1	0.66	5.95	0.31	6.71e-9	Response to zileuton treatment in asthma (FEV1 change interaction);
LUSC	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg15557168	chr22:42548783	NA	-0.42	-6.42	-0.33	4.81e-10	Schizophrenia;
LUSC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg23711669	chr6:146136114	FBXO30	0.82	14.52	0.62	2.22e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg12560992	chr17:57184187	TRIM37	0.9	17.24	0.69	4.15e-48	Intelligence (multi-trait analysis);
LUSC	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	6.01	0.31	4.86e-9	Rheumatoid arthritis;
LUSC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg06008330	chr7:65541103	ASL	0.4	6.15	0.32	2.16e-9	Aortic root size;
LUSC	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.62	8.94	0.44	2.76e-17	Body mass index (adult);
LUSC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.73	-0.43	1.28e-16	Response to antipsychotic treatment;
LUSC	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg23435118	chr5:141488016	NDFIP1	-0.57	-8.14	-0.41	8.06e-15	Crohn's disease;
LUSC	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.28	0.53	3.13e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg13010199	chr12:38710504	ALG10B	0.67	10.28	0.49	1.01e-21	Morning vs. evening chronotype;
LUSC	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.83	-15.33	-0.64	1.55e-40	Longevity;
LUSC	cis	rs2303282	0.716	rs2440467	chr16:56417047	C/T	cg00500540	chr16:56394104	NA	0.43	7.34	0.37	1.68e-12	Breast cancer;
LUSC	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.56	-7.09	-0.36	8.08e-12	Schizophrenia;
LUSC	cis	rs2857891	0.817	rs2638101	chr11:6969131	G/A	cg04053776	chr11:6947353	ZNF215	0.41	5.76	0.3	1.87e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs977987	0.778	rs12929908	chr16:75462071	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.56	0.46	2.75e-19	Dupuytren's disease;
LUSC	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg07936489	chr17:37558343	FBXL20	-0.71	-10.01	-0.48	8.51e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs34779708	0.733	rs60553075	chr10:35542462	T/A	cg03585969	chr10:35415529	CREM	0.55	7.63	0.39	2.51e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg05738196	chr6:26577821	NA	-0.58	-6.79	-0.35	5.04e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9653442	0.545	rs11123814	chr2:100767082	A/G	cg22139774	chr2:100720529	AFF3	-0.42	-7.23	-0.37	3.33e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg05256304	chr11:116969870	SIK3	0.29	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	8.52	0.42	5.75e-16	Lymphocyte counts;
LUSC	cis	rs6574644	1.000	rs10149489	chr14:81776403	G/C	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.98	0.31	5.88e-9	Menopause (age at onset);
LUSC	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg04545296	chr12:48745243	ZNF641	0.34	6.27	0.32	1.14e-9	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.25	-0.41	3.75e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs62400317	0.859	rs12193812	chr6:45140761	C/T	cg20913747	chr6:44695427	NA	-0.47	-7.52	-0.38	5.13e-13	Total body bone mineral density;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg26839812	chr6:16129282	MYLIP	0.4	6.09	0.32	3.19e-9	Schizophrenia;
LUSC	cis	rs1461503	0.934	rs7121840	chr11:122845360	A/G	cg27398637	chr11:122830231	C11orf63	-0.41	-6.57	-0.34	1.98e-10	Menarche (age at onset);
LUSC	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	6.92	0.35	2.33e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg16434002	chr17:42200994	HDAC5	-0.46	-6.57	-0.34	1.98e-10	Total body bone mineral density;
LUSC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg13628971	chr7:2884303	GNA12	0.46	6.78	0.35	5.58e-11	Height;
LUSC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	cis	rs4409675	0.576	rs2749119	chr1:28236248	G/A	cg23691781	chr1:28212827	C1orf38	0.33	7.98	0.4	2.3e-14	Corneal astigmatism;
LUSC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	8.32	0.41	2.21e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs7923609	0.967	rs2393966	chr10:65134814	T/G	cg01631684	chr10:65280961	REEP3	-0.38	-5.89	-0.31	9.62e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg06917634	chr15:78832804	PSMA4	-0.44	-5.87	-0.31	1.05e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.26	0.64	2.81e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg23711669	chr6:146136114	FBXO30	0.76	13.72	0.6	2.65e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08219700	chr8:58056026	NA	-0.64	-8.05	-0.4	1.52e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg09201001	chr11:18656081	SPTY2D1	0.89	13.83	0.6	1.06e-34	Breast cancer;
LUSC	cis	rs28785552	0.966	rs7247272	chr19:53236331	C/T	cg10871876	chr19:53194124	ZNF83	-0.56	-8.68	-0.43	1.76e-16	Response to paliperidone in schizophrenia (PANSS score);
LUSC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.67e-8	Aortic root size;
LUSC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg02423579	chr7:2872169	GNA12	-0.48	-6.84	-0.35	3.81e-11	Height;
LUSC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.67	11.9	0.55	1.85e-27	Aortic root size;
LUSC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-7.4	-0.38	1.13e-12	Bipolar disorder;
LUSC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg12463550	chr7:65579703	CRCP	0.46	6.64	0.34	1.27e-10	Aortic root size;
LUSC	trans	rs12412942	1.000	rs12412942	chr10:2357702	C/T	cg06775055	chr4:18023265	LCORL	0.36	6.03	0.31	4.39e-9	Schizophrenia;
LUSC	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg23241863	chr10:102295624	HIF1AN	0.48	5.74	0.3	2.18e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	13.66	0.6	4.5e-34	Platelet count;
LUSC	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.96	-0.4	2.67e-14	Type 2 diabetes;
LUSC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10802521	chr3:52805072	NEK4	-0.48	-7.51	-0.38	5.3e-13	Electroencephalogram traits;
LUSC	cis	rs921665	0.831	rs7566188	chr2:3199057	C/T	cg02624386	chr2:3182749	NA	0.59	6.41	0.33	5.09e-10	World class endurance athleticism;
LUSC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg03676636	chr4:99064102	C4orf37	0.33	7.35	0.37	1.51e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg03342759	chr3:160939853	NMD3	-0.45	-6.3	-0.33	9.2e-10	Parkinson's disease;
LUSC	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg18232548	chr7:50535776	DDC	-0.54	-7.55	-0.38	4.08e-13	Malaria;
LUSC	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg25214090	chr10:38739885	LOC399744	0.52	7.59	0.38	3.33e-13	Corneal astigmatism;
LUSC	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg04369109	chr6:150039330	LATS1	-0.59	-8.63	-0.43	2.61e-16	Lung cancer;
LUSC	cis	rs1982963	1.000	rs3818187	chr14:52509788	A/G	cg10843707	chr14:52510701	NID2	0.42	7.27	0.37	2.59e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg01884057	chr2:25150051	NA	0.49	11.34	0.53	1.91e-25	Body mass index;
LUSC	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg17366294	chr4:99064904	C4orf37	-0.6	-10.88	-0.51	8.36e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.26e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9513627	0.510	rs4365162	chr13:100212614	G/C	cg25919922	chr13:100150906	NA	0.81	6.7	0.34	8.73e-11	Obesity-related traits;
LUSC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg24642439	chr20:33292090	TP53INP2	0.72	10.89	0.51	7.78e-24	Coronary artery disease;
LUSC	cis	rs4443100	0.670	rs13056137	chr22:23407261	C/A	cg14186256	chr22:23484241	RTDR1	0.54	6.98	0.36	1.64e-11	Serum parathyroid hormone levels;
LUSC	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.92	12.13	0.55	2.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg23795048	chr12:9217529	LOC144571	0.34	5.88	0.31	1.02e-8	Sjögren's syndrome;
LUSC	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg17420585	chr12:42539391	GXYLT1	-0.39	-7.85	-0.39	5.79e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg08888203	chr3:10149979	C3orf24	0.6	8.28	0.41	3e-15	Alzheimer's disease;
LUSC	cis	rs2472297	1.000	rs2472297	chr15:75027880	A/G	cg10253484	chr15:75165896	SCAMP2	0.49	5.74	0.3	2.17e-8	Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);Coffee consumption (cups per day);Coffee consumption;Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level);Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LUSC	cis	rs1448094	0.645	rs12301701	chr12:86472798	C/T	cg00310523	chr12:86230176	RASSF9	-0.33	-5.97	-0.31	5.98e-9	Major depressive disorder;
LUSC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.64	-0.54	1.63e-26	Type 2 diabetes;
LUSC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg15556689	chr8:8085844	FLJ10661	0.77	12.42	0.56	2.24e-29	Neuroticism;
LUSC	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-0.78	-12.4	-0.56	2.7e-29	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg26384229	chr12:38710491	ALG10B	0.57	8.9	0.44	3.58e-17	Morning vs. evening chronotype;
LUSC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg18681998	chr4:17616180	MED28	0.85	15.88	0.66	1.1e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.84e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.29	0.53	2.88e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg27494647	chr7:150038898	RARRES2	0.46	6.87	0.35	3.06e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg13319975	chr6:146136371	FBXO30	0.49	7.39	0.37	1.19e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.44	-6.71	-0.34	8.59e-11	Mean platelet volume;
LUSC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.95	0.48	1.3e-20	Personality dimensions;
LUSC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg09998033	chr7:158218633	PTPRN2	-0.61	-9.77	-0.47	5.28e-20	Obesity-related traits;
LUSC	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2346177	0.875	rs2881327	chr2:46641955	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.36	6.2	0.32	1.62e-9	HDL cholesterol;
LUSC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.13	0.41	8.35e-15	Prudent dietary pattern;
LUSC	cis	rs1358748	0.520	rs2093333	chr1:67532103	G/A	cg02640540	chr1:67518911	SLC35D1	0.62	6.52	0.34	2.6e-10	Tuberculosis;
LUSC	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg08213375	chr14:104286397	PPP1R13B	0.4	6.98	0.36	1.6e-11	Reticulocyte count;
LUSC	cis	rs11630290	0.617	rs12440886	chr15:64172899	A/G	cg12036633	chr15:63758958	NA	0.69	7.28	0.37	2.49e-12	Iris characteristics;
LUSC	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg08773314	chr2:239334832	ASB1	0.43	9.26	0.45	2.6e-18	Multiple system atrophy;
LUSC	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg24675056	chr1:15929824	NA	0.44	7.64	0.39	2.28e-13	Systolic blood pressure;
LUSC	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02176678	chr2:219576539	TTLL4	0.61	11.16	0.52	8.41e-25	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg25182066	chr10:30743637	MAP3K8	0.43	6.06	0.31	3.63e-9	Inflammatory bowel disease;
LUSC	trans	rs12639258	0.506	rs6808142	chr3:46556835	C/T	cg00260888	chr20:30865478	KIF3B	0.39	6.06	0.31	3.73e-9	Eotaxin levels;
LUSC	cis	rs8135665	0.600	rs3026682	chr22:38452482	G/A	cg13116946	chr22:38479732	SLC16A8	0.43	6.32	0.33	8.29e-10	Advanced age-related macular degeneration;Age-related macular degeneration;
LUSC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg23815491	chr16:72088622	HP	0.37	6.4	0.33	5.41e-10	Fibrinogen levels;
LUSC	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg17470449	chr10:769945	NA	0.53	7.12	0.36	6.81e-12	Uric acid levels;
LUSC	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg11766577	chr21:47581405	C21orf56	-0.38	-5.71	-0.3	2.54e-8	Testicular germ cell tumor;
LUSC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.45	-7.52	-0.38	5.26e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg13010199	chr12:38710504	ALG10B	-0.64	-10.89	-0.51	7.99e-24	Heart rate;
LUSC	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg13319975	chr6:146136371	FBXO30	-0.47	-7.08	-0.36	8.49e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4812048	0.649	rs116580814	chr20:57618141	G/T	cg14073986	chr20:57617431	SLMO2	0.93	9.65	0.47	1.38e-19	Mean platelet volume;
LUSC	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg06784218	chr1:46089804	CCDC17	0.29	5.83	0.3	1.31e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg02016764	chr4:38805732	TLR1	-0.54	-5.98	-0.31	5.63e-9	Breast cancer;
LUSC	cis	rs7428	0.847	rs1969260	chr2:85568810	C/T	cg24342717	chr2:85555507	TGOLN2	-0.57	-8.36	-0.42	1.71e-15	Ear protrusion;
LUSC	cis	rs11608355	0.545	rs35018715	chr12:109893134	T/C	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.1e-26	Neuroticism;
LUSC	cis	rs56804039	1.000	rs56804039	chr8:8381029	C/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.96	-0.36	1.84e-11	Cervical cancer;
LUSC	cis	rs7178572	0.625	rs12904553	chr15:77845959	G/A	cg22256960	chr15:77711686	NA	-0.44	-7.09	-0.36	7.98e-12	Type 2 diabetes;
LUSC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg26897989	chr16:1907736	C16orf73	-0.45	-7.01	-0.36	1.36e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.88	-0.35	3.05e-11	Mood instability;
LUSC	cis	rs8092503	1.000	rs2871673	chr18:52491427	G/T	cg12377874	chr18:52495404	RAB27B	-0.34	-6.16	-0.32	2.09e-9	Childhood body mass index;
LUSC	cis	rs1018836	0.632	rs1028255	chr8:91485578	A/T	cg16814680	chr8:91681699	NA	-0.65	-9.78	-0.47	4.93e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg04539111	chr16:67997858	SLC12A4	-0.46	-6.27	-0.32	1.1e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg08213375	chr14:104286397	PPP1R13B	0.44	7.58	0.38	3.4e-13	Reticulocyte count;
LUSC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.78	-13.54	-0.6	1.38e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.97	0.55	1.01e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-9.05	-0.44	1.19e-17	Neuroticism;
LUSC	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg13699009	chr12:122356056	WDR66	0.44	6.81	0.35	4.49e-11	Mean corpuscular volume;
LUSC	cis	rs73198271	0.694	rs113694763	chr8:8647076	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	8.12	0.41	9.04e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6845621	0.901	rs1377154	chr4:18924301	A/G	cg12196642	chr4:18937545	NA	-0.36	-6.67	-0.34	1.03e-10	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg07741184	chr6:167504864	NA	0.49	8.55	0.42	4.6e-16	Crohn's disease;
LUSC	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg26373071	chr5:1325741	CLPTM1L	0.4	7.36	0.37	1.48e-12	Lung cancer;
LUSC	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-16.75	-0.68	3.85e-46	Exhaled nitric oxide output;
LUSC	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg15557168	chr22:42548783	NA	-0.43	-7.06	-0.36	9.42e-12	Schizophrenia;
LUSC	cis	rs7560272	0.723	rs7609249	chr2:73813820	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-7.36	-0.37	1.45e-12	Schizophrenia;
LUSC	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg03161606	chr19:29218774	NA	0.51	5.98	0.31	5.58e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs662064	0.962	rs660725	chr1:10557544	A/G	cg20482658	chr1:10539492	PEX14	-0.31	-6.46	-0.33	3.75e-10	Asthma;
LUSC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg17554472	chr22:41940697	POLR3H	-0.48	-5.76	-0.3	1.89e-8	Vitiligo;
LUSC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg13047869	chr3:10149882	C3orf24	0.57	7.9	0.4	4.11e-14	Alzheimer's disease;
LUSC	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.53	-0.34	2.4e-10	Retinal vascular caliber;
LUSC	cis	rs11264213	0.901	rs116757422	chr1:36349560	G/A	cg27506609	chr1:36549197	TEKT2	0.7	8.04	0.4	1.62e-14	Schizophrenia;
LUSC	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg11502198	chr6:26597334	ABT1	0.69	11.09	0.52	1.54e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg21724239	chr8:58056113	NA	0.77	8.37	0.42	1.55e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg06145435	chr7:1022769	CYP2W1	0.32	6.68	0.34	9.72e-11	Longevity;Endometriosis;
LUSC	cis	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg24459738	chr19:57751996	ZNF805	-0.52	-7.69	-0.39	1.66e-13	Hyperactive-impulsive symptoms;
LUSC	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.13	-0.36	6.17e-12	Response to antipsychotic treatment;
LUSC	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg13256891	chr4:100009986	ADH5	0.51	6.96	0.36	1.79e-11	Smoking initiation;
LUSC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.65	0.86	4.24e-99	Chronic sinus infection;
LUSC	cis	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg02972257	chr16:68554789	NA	-0.5	-6.28	-0.32	1.08e-9	Ulcerative colitis;
LUSC	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	6.34	0.33	7.46e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs295140	0.732	rs1367858	chr2:201160771	C/T	cg04283868	chr2:201171347	SPATS2L	0.44	6.3	0.33	9.37e-10	QT interval;
LUSC	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg11812906	chr14:75593930	NEK9	0.66	11.4	0.53	1.23e-25	Height;
LUSC	cis	rs11608355	0.545	rs4766473	chr12:109900596	C/T	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs17401966	0.558	rs6541090	chr1:10402842	A/G	cg19773385	chr1:10388646	KIF1B	-0.34	-5.93	-0.31	7.73e-9	Hepatocellular carcinoma;
LUSC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg16423285	chr20:60520624	NA	0.64	8.08	0.4	1.22e-14	Body mass index;
LUSC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.71	12.72	0.57	1.68e-30	Prudent dietary pattern;
LUSC	cis	rs3768617	0.811	rs12138053	chr1:182979560	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.5	0.42	6.51e-16	Fuchs's corneal dystrophy;
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01516881	chr6:292596	DUSP22	-0.7	-11.32	-0.53	2.39e-25	Menopause (age at onset);
LUSC	cis	rs10887741	0.624	rs7088341	chr10:89427820	C/T	cg13926569	chr10:89418898	PAPSS2	0.32	6.87	0.35	3.08e-11	Exercise (leisure time);
LUSC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg20476274	chr7:133979776	SLC35B4	0.81	14.7	0.63	4.31e-38	Mean platelet volume;
LUSC	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-0.9	-18.17	-0.71	8.55e-52	Metabolite levels;
LUSC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	8.12	0.41	9.02e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs17095355	1.000	rs12267714	chr10:111722052	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.49	-0.38	6.22e-13	Biliary atresia;
LUSC	cis	rs7590368	0.748	rs72779478	chr2:10967124	C/T	cg15705551	chr2:10952987	PDIA6	0.6	6.57	0.34	1.96e-10	Educational attainment (years of education);
LUSC	cis	rs2067615	0.524	rs9971765	chr12:107092299	G/A	cg15890332	chr12:107067104	RFX4	0.35	6.3	0.33	9.61e-10	Heart rate;
LUSC	cis	rs9788682	0.747	rs2869045	chr15:78718899	T/C	cg24631222	chr15:78858424	CHRNA5	-0.7	-9.1	-0.45	8.06e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs668210	0.793	rs522553	chr11:65771669	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.58	7.79	0.39	8.81e-14	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.32	6.1	0.32	2.85e-9	Schizophrenia;
LUSC	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg10426581	chr7:100472382	SRRT	0.86	12.4	0.56	2.74e-29	Resting heart rate;
LUSC	cis	rs7799006	0.929	rs7781856	chr7:2257199	C/T	cg02951883	chr7:2050386	MAD1L1	-0.36	-6.09	-0.32	3.19e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg04414720	chr1:150670196	GOLPH3L	0.51	8.18	0.41	6e-15	Blood protein levels;
LUSC	cis	rs2970818	0.831	rs7958162	chr12:4600634	T/A	cg11146114	chr12:4671731	NA	-0.59	-6.11	-0.32	2.76e-9	Phosphorus levels;
LUSC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg20243544	chr17:37824526	PNMT	0.52	7.41	0.38	1.02e-12	Asthma;
LUSC	cis	rs6750047	0.719	rs1583171	chr2:38270107	G/A	cg07380506	chr2:38303506	CYP1B1	0.41	5.65	0.3	3.36e-8	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg04756594	chr16:24857601	SLC5A11	0.49	6.94	0.35	2.09e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg26876637	chr1:152193138	HRNR	0.45	6.48	0.33	3.21e-10	Atopic dermatitis;
LUSC	cis	rs13418410	0.668	rs4670206	chr2:33796334	T/A	cg04131969	chr2:33951647	MYADML	-0.45	-6.05	-0.31	3.87e-9	Non-response to antidepressants and depression;
LUSC	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg23649088	chr2:200775458	C2orf69	0.59	7.28	0.37	2.36e-12	Schizophrenia;
LUSC	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg26893861	chr17:41843967	DUSP3	1.01	15.04	0.64	2.13e-39	Triglycerides;
LUSC	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg15133208	chr4:90757351	SNCA	-0.34	-5.99	-0.31	5.29e-9	Dementia with Lewy bodies;
LUSC	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg18681998	chr4:17616180	MED28	-0.81	-14.34	-0.62	1.09e-36	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	6.87	0.35	3.09e-11	Parkinson's disease;
LUSC	cis	rs2073300	1.000	rs6137980	chr20:23466726	G/T	cg09953122	chr20:23471693	CST8	-0.87	-6.98	-0.36	1.59e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg14582100	chr15:45693742	SPATA5L1	0.57	10.28	0.49	1.04e-21	Homoarginine levels;
LUSC	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-8.13	-0.41	8.77e-15	Parkinson's disease;
LUSC	cis	rs2857891	0.695	rs2248341	chr11:6984677	A/T	cg04053776	chr11:6947353	ZNF215	0.41	6.06	0.31	3.65e-9	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs6545883	0.503	rs1665272	chr2:61379286	A/C	cg15711740	chr2:61764176	XPO1	-0.39	-6.13	-0.32	2.41e-9	Tuberculosis;
LUSC	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg27124370	chr19:33622961	WDR88	0.52	6.7	0.34	8.63e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg05973401	chr12:123451056	ABCB9	0.52	6.45	0.33	4.04e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg03676636	chr4:99064102	C4orf37	0.28	5.92	0.31	8.19e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg24558204	chr6:135376177	HBS1L	0.68	10.65	0.5	5.53e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	trans	rs3857536	0.813	rs7770349	chr6:66946659	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg11019008	chr10:131425282	MGMT	0.42	5.98	0.31	5.6e-9	Response to temozolomide;
LUSC	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg13939156	chr17:80058883	NA	-0.34	-6.76	-0.35	6.08e-11	Life satisfaction;
LUSC	cis	rs9650315	0.866	rs4629840	chr8:57189267	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	7.01	0.36	1.33e-11	Height;
LUSC	cis	rs2224391	0.628	rs2773311	chr6:5250866	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.49	-6.75	-0.35	6.5500000000000006e-11	Height;
LUSC	trans	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.96	-0.31	6.49e-9	Dementia with Lewy bodies;
LUSC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg13683864	chr3:40499215	RPL14	-1.14	-20.62	-0.75	1.65e-61	Renal cell carcinoma;
LUSC	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.7	-8.52	-0.42	5.55e-16	Body mass index;
LUSC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg06001716	chr17:41278141	BRCA1;NBR2	0.36	5.9	0.31	8.91e-9	Menopause (age at onset);
LUSC	cis	rs6741892	0.793	rs34558770	chr2:38933040	C/T	cg23643435	chr2:38893251	GALM	-0.71	-5.67	-0.3	3.08e-8	5-HTT brain serotonin transporter levels;
LUSC	trans	rs724744	0.741	rs1772080	chr6:22354220	G/A	cg13807341	chr11:118445984	ARCN1	-0.36	-6.19	-0.32	1.77e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg02175503	chr12:58329896	NA	0.48	6.98	0.36	1.57e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg27432699	chr2:27873401	GPN1	0.82	15.39	0.64	8.7e-41	Oral cavity cancer;
LUSC	trans	rs2201841	0.501	rs11209032	chr1:67740092	G/A	cg16262963	chr14:104851903	NA	-0.23	-6.08	-0.32	3.3e-9	Ulcerative colitis;Psoriasis;Crohn's disease;
LUSC	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg09408571	chr1:101003634	GPR88	0.33	6.48	0.33	3.28e-10	Monocyte count;
LUSC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.95e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.33	-7.27	-0.37	2.54e-12	Dupuytren's disease;
LUSC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg05805236	chr11:65401703	PCNXL3	0.56	9.2	0.45	4.04e-18	Acne (severe);
LUSC	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg13010199	chr12:38710504	ALG10B	-0.6	-9.51	-0.46	4e-19	Morning vs. evening chronotype;
LUSC	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.45	-6.89	-0.35	2.81e-11	Menarche (age at onset);
LUSC	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg21699342	chr2:239360505	ASB1	0.43	6.6	0.34	1.65e-10	Multiple system atrophy;
LUSC	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg00898013	chr13:113819073	PROZ	0.53	7.64	0.39	2.28e-13	Platelet distribution width;
LUSC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.78	14.72	0.63	3.88e-38	Longevity;
LUSC	cis	rs7851660	0.809	rs10984253	chr9:100664474	A/G	cg13688889	chr9:100608707	NA	-0.54	-8.43	-0.42	1.05e-15	Strep throat;
LUSC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg23625390	chr15:77176239	SCAPER	0.46	7.0	0.36	1.44e-11	Blood metabolite levels;
LUSC	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.57	9.94	0.48	1.42e-20	Birth weight;
LUSC	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg26102564	chr10:131424627	MGMT	-0.38	-5.94	-0.31	7.31e-9	Response to temozolomide;
LUSC	cis	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg16473166	chr22:50639996	SELO	0.57	7.3	0.37	2.11e-12	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LUSC	cis	rs6012953	1.000	rs932420	chr20:49133069	A/G	cg13958625	chr20:49123093	NA	0.31	6.75	0.35	6.63e-11	Vitiligo;
LUSC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg17971929	chr21:40555470	PSMG1	0.78	13.34	0.59	8.04e-33	Cognitive function;
LUSC	cis	rs4704187	0.687	rs4235683	chr5:74415088	T/C	cg03227963	chr5:74354835	NA	0.32	6.81	0.35	4.62e-11	Response to amphetamines;
LUSC	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg23260525	chr10:116636907	FAM160B1	0.43	9.24	0.45	3.04e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg11247378	chr22:39784982	NA	-0.66	-12.91	-0.58	3.4e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg10657630	chr21:48055338	PRMT2	0.4	6.09	0.32	3.05e-9	Testicular germ cell tumor;
LUSC	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg02175503	chr12:58329896	NA	0.68	10.86	0.51	1.01e-23	Intelligence (multi-trait analysis);
LUSC	trans	rs10221833	0.636	rs355890	chr2:165634976	T/G	cg26993132	chr16:89239499	CDH15	0.31	5.99	0.31	5.47e-9	Response to statin therapy;
LUSC	cis	rs7605827	0.930	rs13015492	chr2:15505716	G/A	cg19274914	chr2:15703543	NA	0.45	8.51	0.42	6.15e-16	Educational attainment (years of education);
LUSC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg15103426	chr22:29168792	CCDC117	0.58	8.09	0.4	1.12e-14	Lymphocyte counts;
LUSC	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg25214090	chr10:38739885	LOC399744	0.53	7.72	0.39	1.33e-13	Corneal astigmatism;
LUSC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.6	0.38	2.95e-13	Obesity-related traits;
LUSC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08470875	chr2:26401718	FAM59B	0.73	9.9	0.48	2.05e-20	Gut microbiome composition (summer);
LUSC	cis	rs6516091	0.640	rs6117070	chr20:6061606	A/G	cg25325723	chr20:6104886	FERMT1	-0.61	-7.07	-0.36	9.14e-12	Abdominal aortic aneurysm;
LUSC	cis	rs11637445	0.677	rs12441598	chr15:68073205	G/A	cg08079166	chr15:68083412	MAP2K5	0.36	7.39	0.37	1.17e-12	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg00078996	chr12:132293329	NA	-0.35	-5.72	-0.3	2.4e-8	Migraine;
LUSC	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg00522288	chr12:125625016	AACS	-0.31	-5.98	-0.31	5.86e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.44	-7.44	-0.38	8.5e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg12927641	chr6:109611667	NA	-0.34	-5.77	-0.3	1.81e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg08219700	chr8:58056026	NA	0.5	6.32	0.33	8.6e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1696756	1.000	rs1696756	chr17:77827973	C/T	cg00646381	chr17:77835854	NA	0.55	9.65	0.47	1.36e-19	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LUSC	cis	rs6433857	0.536	rs1971135	chr2:181351508	G/A	cg23363182	chr2:181467187	NA	-0.45	-7.25	-0.37	2.85e-12	Body mass index;
LUSC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg21475434	chr5:93447410	FAM172A	-0.71	-7.59	-0.38	3.22e-13	Diabetic retinopathy;
LUSC	cis	rs7927771	0.542	rs7108479	chr11:47781460	G/T	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.18e-10	Subjective well-being;
LUSC	cis	rs713477	1.000	rs12893000	chr14:55912280	G/T	cg13175173	chr14:55914753	NA	-0.32	-6.69	-0.34	9.43e-11	Pediatric bone mineral content (femoral neck);
LUSC	trans	rs12340987	0.636	rs12004117	chr9:87764076	C/G	cg01663225	chr11:124492831	TBRG1	-0.68	-5.98	-0.31	5.89e-9	Birth weight;
LUSC	trans	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Depression;
LUSC	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.44	5.97	0.31	6.08e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	11.65	0.54	1.54e-26	Coffee consumption (cups per day);
LUSC	cis	rs28647808	0.786	rs4962135	chr9:136256630	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.6	-8.15	-0.41	7.57e-15	Body mass index (adult);
LUSC	cis	rs6977660	0.714	rs10236607	chr7:19818620	A/G	cg05791153	chr7:19748676	TWISTNB	0.65	6.9	0.35	2.67e-11	Thyroid stimulating hormone;
LUSC	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.6	-8.11	-0.41	9.5e-15	Body mass index (adult);
LUSC	cis	rs8014204	0.550	rs2302832	chr14:75137664	T/C	cg06637938	chr14:75390232	RPS6KL1	0.59	9.27	0.45	2.35e-18	Caffeine consumption;
LUSC	trans	rs76248362	1.000	rs4770509	chr13:24438643	A/G	cg26511321	chr7:27196790	HOXA7	0.53	6.18	0.32	1.91e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.38	5.94	0.31	6.98e-9	Lymphocyte counts;
LUSC	cis	rs9463078	0.683	rs6458412	chr6:44735834	A/G	cg25276700	chr6:44698697	NA	0.32	6.36	0.33	6.8e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2282300	0.739	rs67670125	chr11:30214914	C/T	cg25418670	chr11:30344373	C11orf46	-0.63	-9.01	-0.44	1.61e-17	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11039100	0.850	rs11039116	chr11:5831551	T/A	cg05234568	chr11:5960015	NA	-0.51	-5.82	-0.3	1.36e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs10504073	0.631	rs341813	chr8:50039916	T/C	cg00325661	chr8:49890786	NA	0.59	9.72	0.47	7.68e-20	Blood metabolite ratios;
LUSC	cis	rs1160297	0.609	rs12713232	chr2:53108308	A/T	cg07782112	chr2:53107842	NA	-0.41	-6.93	-0.35	2.13e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg12863693	chr15:85201151	NMB	0.41	8.48	0.42	7.34e-16	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11495060	chr7:100472765	SRRT	-0.42	-6.27	-0.32	1.13e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.9	0.31	8.84e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-0.96	-18.41	-0.71	9.53e-53	Heart rate;
LUSC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg00522288	chr12:125625016	AACS	-0.33	-5.99	-0.31	5.47e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16680214	chr1:154839983	KCNN3	-0.53	-10.03	-0.48	7.38e-21	Prostate cancer;
LUSC	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg20573242	chr4:122745356	CCNA2	-0.45	-6.73	-0.35	7.37e-11	Type 2 diabetes;
LUSC	cis	rs12711979	1.000	rs12711979	chr2:3869559	A/G	cg17052675	chr2:3827356	NA	-0.44	-7.89	-0.4	4.23e-14	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.88	0.6	6.55e-35	Cognitive test performance;
LUSC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11890956	chr21:40555474	PSMG1	-0.7	-10.05	-0.48	6.24e-21	Menarche (age at onset);
LUSC	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg02931644	chr1:25747376	RHCE	0.36	6.45	0.33	3.86e-10	Erythrocyte sedimentation rate;
LUSC	trans	rs78049276	0.512	rs6855875	chr4:148402737	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.55	-6.38	-0.33	6.03e-10	Pulse pressure;
LUSC	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg06134567	chr22:46658398	PKDREJ	-0.55	-6.31	-0.33	8.72e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg17845761	chr1:175162550	KIAA0040	0.31	5.93	0.31	7.53e-9	Alcohol dependence;
LUSC	cis	rs12220238	1.000	rs11000922	chr10:75969305	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.62	6.9	0.35	2.64e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12311346	chr5:56204834	C5orf35	-0.87	-13.56	-0.6	1.12e-33	Initial pursuit acceleration;
LUSC	trans	rs9944715	1.000	rs9963153	chr18:43840064	A/G	cg01718231	chr17:29326311	RNF135	-0.52	-7.22	-0.37	3.43e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg18301423	chr5:131593218	PDLIM4	-0.5	-7.56	-0.38	4.05e-13	Acylcarnitine levels;
LUSC	cis	rs6690583	0.623	rs2083283	chr1:85439996	C/A	cg22153463	chr1:85462885	MCOLN2	0.64	6.15	0.32	2.15e-9	Serum sulfate level;
LUSC	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21171335	chr12:122356390	WDR66	-0.6	-8.94	-0.44	2.79e-17	Mean corpuscular volume;
LUSC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg22166914	chr1:53195759	ZYG11B	0.48	7.61	0.38	2.74e-13	Monocyte count;
LUSC	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg14227996	chr4:17616232	MED28	0.82	7.87	0.4	4.98e-14	Opioid sensitivity;
LUSC	cis	rs714027	1.000	rs4823073	chr22:30512258	G/A	cg11564601	chr22:30592435	NA	-0.37	-6.78	-0.35	5.4e-11	Lymphocyte counts;
LUSC	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg02023728	chr11:77925099	USP35	-0.41	-6.06	-0.31	3.65e-9	Testicular germ cell tumor;
LUSC	cis	rs4629710	0.592	rs3777476	chr6:131533821	A/C	cg12606694	chr6:131520996	AKAP7	0.6	8.97	0.44	2.17e-17	Multiple myeloma (IgH translocation);
LUSC	cis	rs6967385	0.560	rs34130399	chr7:12356746	T/A	cg20607287	chr7:12443886	VWDE	0.49	7.37	0.37	1.37e-12	Response to taxane treatment (placlitaxel);
LUSC	cis	rs259282	0.574	rs4805780	chr19:33114406	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.68	10.0	0.48	8.82e-21	Schizophrenia;
LUSC	cis	rs977987	0.872	rs4887816	chr16:75319716	T/C	cg03315344	chr16:75512273	CHST6	0.47	8.61	0.43	2.88e-16	Dupuytren's disease;
LUSC	cis	rs12712073	0.512	rs6710355	chr2:100699994	T/C	cg22139774	chr2:100720529	AFF3	-0.39	-6.26	-0.32	1.2e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg13699009	chr12:122356056	WDR66	-0.49	-7.89	-0.4	4.26e-14	Mean corpuscular volume;
LUSC	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg04362960	chr10:104952993	NT5C2	0.59	9.44	0.46	6.59e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4654899	0.865	rs12119348	chr1:21484633	C/T	cg01072550	chr1:21505969	NA	-0.49	-7.36	-0.37	1.47e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22496380	chr5:211416	CCDC127	-0.87	-8.93	-0.44	2.83e-17	Breast cancer;
LUSC	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.89	0.31	9.34e-9	Breast cancer;
LUSC	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg10560079	chr2:191398806	TMEM194B	-0.66	-8.31	-0.41	2.44e-15	Diastolic blood pressure;
LUSC	trans	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.65	-0.39	2.2e-13	Menarche (age at onset);
LUSC	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg13010199	chr12:38710504	ALG10B	0.56	8.54	0.42	4.82e-16	Morning vs. evening chronotype;
LUSC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.59	8.87	0.44	4.39e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg23262073	chr20:60523788	NA	-0.42	-6.18	-0.32	1.9e-9	Body mass index;
LUSC	cis	rs977987	0.806	rs7204984	chr16:75475520	G/C	cg03315344	chr16:75512273	CHST6	0.49	9.5	0.46	4.32e-19	Dupuytren's disease;
LUSC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg05347473	chr6:146136440	FBXO30	-0.57	-10.02	-0.48	8.1e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9311676	0.609	rs11925862	chr3:58417927	A/C	cg13750441	chr3:58318267	PXK	0.35	6.83	0.35	4.14e-11	Systemic lupus erythematosus;
LUSC	cis	rs722599	0.639	rs2193596	chr14:75234101	A/C	cg08847533	chr14:75593920	NEK9	0.46	6.29	0.33	9.7e-10	IgG glycosylation;
LUSC	cis	rs6747952	0.899	rs4663856	chr2:239089624	C/A	cg17459225	chr2:239074497	NA	0.34	5.77	0.3	1.86e-8	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg06102403	chr20:30458708	TTLL9;DUSP15	0.43	5.73	0.3	2.21e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg24060327	chr5:131705240	SLC22A5	-0.45	-7.53	-0.38	4.85e-13	Blood metabolite levels;
LUSC	cis	rs1322512	0.677	rs1405692	chr6:152937057	G/A	cg27316956	chr6:152958899	SYNE1	-0.36	-5.94	-0.31	7.06e-9	Tonometry;
LUSC	cis	rs1506636	1.000	rs635072	chr7:123403255	G/A	cg03229431	chr7:123269106	ASB15	0.65	10.7	0.51	3.69e-23	Plateletcrit;Platelet count;
LUSC	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.16	0.32	2.14e-9	Corneal astigmatism;
LUSC	cis	rs3771570	1.000	rs62193221	chr2:242354632	T/C	cg21155796	chr2:242212141	HDLBP	0.62	6.83	0.35	4.12e-11	Prostate cancer;
LUSC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg03676636	chr4:99064102	C4orf37	0.35	7.57	0.38	3.67e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7597155	0.935	rs7563401	chr2:69980193	C/T	cg02498382	chr2:70120550	SNRNP27	-0.25	-5.87	-0.31	1.03e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.89	-0.35	2.79e-11	Systolic blood pressure;
LUSC	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg05861140	chr6:150128134	PCMT1	-0.38	-5.85	-0.3	1.17e-8	Lung cancer;
LUSC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.73	-12.85	-0.58	5.45e-31	White blood cell count (basophil);
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg14668821	chr17:77704760	ENPP7	0.29	6.07	0.32	3.45e-9	Menopause (age at onset);
LUSC	trans	rs2834506	0.521	rs2243982	chr21:35901290	C/T	cg00397714	chr2:192815005	TMEFF2	0.34	6.15	0.32	2.19e-9	Cancer;
LUSC	cis	rs7428496	0.510	rs13093304	chr3:142318911	G/A	cg16271453	chr3:142027066	XRN1	-0.48	-8.1	-0.41	1.07e-14	Mean corpuscular hemoglobin;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17461666	chr22:50946709	NCAPH2;LMF2	-0.44	-6.1	-0.32	2.86e-9	Electrocardiographic conduction measures;
LUSC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg04369109	chr6:150039330	LATS1	-0.57	-8.3	-0.41	2.62e-15	Lung cancer;
LUSC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	10.59	0.5	8.51e-23	Alzheimer's disease;
LUSC	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	6.79	0.35	5.25e-11	Lung cancer in ever smokers;
LUSC	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.88	0.48	2.38e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02176678	chr2:219576539	TTLL4	-0.72	-13.29	-0.59	1.23e-32	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3862435	0.706	rs2589947	chr15:90949177	G/A	cg22089800	chr15:90895588	ZNF774	0.55	5.96	0.31	6.34e-9	Response to exercise (triglyceride level interaction);
LUSC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg20887711	chr4:1340912	KIAA1530	0.41	6.26	0.32	1.18e-9	Obesity-related traits;
LUSC	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.46	7.52	0.38	5.02e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-1.06	-15.45	-0.65	5.36e-41	Vitiligo;
LUSC	cis	rs4704187	0.687	rs1422699	chr5:74442410	G/A	cg03227963	chr5:74354835	NA	0.31	6.77	0.35	5.75e-11	Response to amphetamines;
LUSC	cis	rs7833986	0.534	rs72653928	chr8:56907735	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	10.96	0.51	4.53e-24	Height;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22438603	chr5:127418940	SLC12A2;FLJ33630	-0.37	-6.01	-0.31	4.87e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.59	9.95	0.48	1.3e-20	Type 2 diabetes;
LUSC	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg24375607	chr4:120327624	NA	0.67	10.61	0.5	7.48e-23	Corneal astigmatism;
LUSC	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg17252645	chr8:143867129	LY6D	0.38	6.72	0.34	8.03e-11	Urinary tract infection frequency;
LUSC	trans	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.68	11.89	0.55	1.92e-27	Mean corpuscular volume;
LUSC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg27284194	chr4:1044797	NA	0.34	5.74	0.3	2.17e-8	Obesity-related traits;
LUSC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg00033643	chr7:134001901	SLC35B4	0.46	7.24	0.37	3.13e-12	Mean platelet volume;
LUSC	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-7.94	-0.4	3.03e-14	Morning vs. evening chronotype;
LUSC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg16743903	chr16:89593216	SPG7	-0.41	-5.67	-0.3	3.06e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg19318889	chr4:1322082	MAEA	0.47	7.67	0.39	1.93e-13	Obesity-related traits;
LUSC	cis	rs77633900	0.614	rs2468116	chr15:76870998	G/A	cg21673338	chr15:77095150	SCAPER	-0.74	-7.29	-0.37	2.29e-12	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg17294928	chr15:75287854	SCAMP5	-0.93	-13.54	-0.6	1.36e-33	Blood trace element (Zn levels);
LUSC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg11062466	chr8:58055876	NA	0.71	8.6	0.43	3.25e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg22563815	chr15:78856949	CHRNA5	0.26	6.31	0.33	8.74e-10	Sudden cardiac arrest;
LUSC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.89	-14.15	-0.61	6.29e-36	Systemic lupus erythematosus;
LUSC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	0.62	7.17	0.37	4.99e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1044826	0.642	rs295482	chr3:139229264	A/T	cg00490450	chr3:139108681	COPB2	-0.46	-7.08	-0.36	8.77e-12	Obesity-related traits;
LUSC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg20243544	chr17:37824526	PNMT	-0.38	-5.68	-0.3	2.96e-8	Self-reported allergy;
LUSC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	15.21	0.64	4.56e-40	Total body bone mineral density;
LUSC	cis	rs4654899	0.897	rs6670897	chr1:21066376	T/C	cg01072550	chr1:21505969	NA	-0.47	-7.06	-0.36	9.47e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg13560548	chr3:10150139	C3orf24	0.51	7.32	0.37	1.85e-12	Alzheimer's disease;
LUSC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg22800045	chr5:56110881	MAP3K1	0.82	10.3	0.49	8.69e-22	Type 2 diabetes;
LUSC	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21028142	chr17:79581711	NPLOC4	-0.33	-7.69	-0.39	1.69e-13	Eye color traits;
LUSC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg07936489	chr17:37558343	FBXL20	0.72	10.05	0.48	5.95e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19717773	chr7:2847554	GNA12	-0.41	-6.34	-0.33	7.36e-10	Height;
LUSC	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg03474202	chr17:45855739	NA	-0.29	-6.52	-0.34	2.58e-10	IgG glycosylation;
LUSC	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	9.2	0.45	4.06e-18	Total body bone mineral density;
LUSC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg18306943	chr3:40428807	ENTPD3	0.37	5.76	0.3	1.89e-8	Renal cell carcinoma;
LUSC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.6	-0.38	3.01e-13	Joint mobility (Beighton score);
LUSC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg01125463	chr6:42946178	PEX6	-0.36	-6.14	-0.32	2.39e-9	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05901451	chr6:126070800	HEY2	0.57	8.54	0.42	4.71e-16	Endometrial cancer;
LUSC	cis	rs9534288	0.913	rs9534298	chr13:46625566	C/G	cg15192986	chr13:46630673	CPB2	-0.73	-11.17	-0.52	8.18e-25	Blood protein levels;
LUSC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-8.49	-0.42	6.68e-16	Chronic sinus infection;
LUSC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg11764359	chr7:65958608	NA	0.52	6.7	0.34	8.95e-11	Aortic root size;
LUSC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.25	-14.44	-0.62	4.77e-37	Gout;
LUSC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.53	0.42	5.04e-16	Prudent dietary pattern;
LUSC	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg10523860	chr14:103875565	MARK3	-0.37	-5.68	-0.3	2.93e-8	Body mass index;
LUSC	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.92	12.13	0.55	2.65e-28	Exhaled nitric oxide output;
LUSC	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg00049323	chr5:472564	LOC25845	-0.43	-6.38	-0.33	5.77e-10	Cystic fibrosis severity;
LUSC	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg16797656	chr11:68205561	LRP5	0.45	7.81	0.39	7.47e-14	Total body bone mineral density;
LUSC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.13e-11	Crohn's disease;
LUSC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1298908	0.639	rs2236568	chr10:82035923	C/A	cg01528321	chr10:82214614	TSPAN14	0.59	8.59	0.43	3.43e-16	Diabetic kidney disease;
LUSC	cis	rs7759001	0.803	rs6456775	chr6:27345383	G/T	cg18711553	chr6:27366782	ZNF391	0.41	5.95	0.31	6.67e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	0.92	13.97	0.61	3.03e-35	Breast cancer;
LUSC	cis	rs2067615	0.524	rs1922433	chr12:107077172	A/G	cg15890332	chr12:107067104	RFX4	0.36	6.24	0.32	1.35e-9	Heart rate;
LUSC	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg03929089	chr4:120376271	NA	-0.68	-6.39	-0.33	5.57e-10	Intraocular pressure;
LUSC	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg24450063	chr1:156163899	SLC25A44	1.01	7.93	0.4	3.31e-14	Paclitaxel disposition in epithelial ovarian cancer;
LUSC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	0.93	16.17	0.66	7.55e-44	Menopause (age at onset);
LUSC	cis	rs6484504	0.576	rs158139	chr11:31216076	C/T	cg26647111	chr11:31128758	NA	-0.42	-6.03	-0.31	4.44e-9	Red blood cell count;
LUSC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg15557168	chr22:42548783	NA	-0.46	-7.05	-0.36	1.02e-11	Schizophrenia;
LUSC	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg23625390	chr15:77176239	SCAPER	-0.62	-9.54	-0.46	3.13e-19	Blood metabolite levels;
LUSC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg19774624	chr17:42201019	HDAC5	-0.78	-11.81	-0.54	4.03e-27	Total body bone mineral density;
LUSC	cis	rs72634258	0.838	rs10489450	chr1:8079301	C/T	cg26816564	chr1:7831052	VAMP3	0.48	6.15	0.32	2.2e-9	Inflammatory bowel disease;
LUSC	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg26384229	chr12:38710491	ALG10B	0.79	13.6	0.6	7.86e-34	Morning vs. evening chronotype;
LUSC	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg03585969	chr10:35415529	CREM	0.62	8.95	0.44	2.59e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7727544	0.582	rs3805681	chr5:131537860	T/G	cg14196790	chr5:131705035	SLC22A5	0.42	6.95	0.36	1.87e-11	Blood metabolite levels;
LUSC	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	0.58	9.15	0.45	5.95e-18	Breast cancer;
LUSC	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg20003494	chr4:90757398	SNCA	-0.33	-5.71	-0.3	2.5e-8	Dementia with Lewy bodies;
LUSC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg22166914	chr1:53195759	ZYG11B	-0.41	-6.4	-0.33	5.27e-10	Monocyte count;
LUSC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg07701084	chr6:150067640	NUP43	0.57	8.6	0.43	3.17e-16	Lung cancer;
LUSC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg06462663	chr19:18546047	ISYNA1	0.5	8.49	0.42	6.92e-16	Breast cancer;
LUSC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs4363385	0.510	rs56241316	chr1:152901748	A/G	cg25856811	chr1:152973957	SPRR3	-0.38	-6.16	-0.32	2.04e-9	Inflammatory skin disease;
LUSC	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg12527260	chr11:63683744	RCOR2	0.34	6.85	0.35	3.67e-11	Pulse pressure;
LUSC	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg15744005	chr10:104629667	AS3MT	-0.32	-6.26	-0.32	1.18e-9	Arsenic metabolism;
LUSC	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	1.1	18.43	0.71	8.08e-53	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs2637266	0.626	rs2583066	chr10:78555839	T/C	cg18941641	chr10:78392320	NA	0.38	7.03	0.36	1.19e-11	Pulmonary function;
LUSC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.55	-0.38	4.17e-13	Aortic root size;
LUSC	trans	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg25214090	chr10:38739885	LOC399744	0.47	6.94	0.36	2.11e-11	Corneal astigmatism;
LUSC	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg13072238	chr3:49761600	GMPPB	-0.38	-6.33	-0.33	8.04e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18932078	chr1:2524107	MMEL1	-0.33	-7.17	-0.37	4.82e-12	Ulcerative colitis;
LUSC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	trans	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg10756647	chr7:56101905	PSPH	0.86	8.4	0.42	1.27e-15	Diabetic kidney disease;
LUSC	cis	rs12220238	1.000	rs4320897	chr10:76017732	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.61	7.22	0.37	3.62e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs1163251	0.902	rs483360	chr1:120200606	C/T	cg19096424	chr1:120255104	PHGDH	-0.47	-6.34	-0.33	7.41e-10	Blood metabolite levels;
LUSC	cis	rs9905704	0.918	rs11656666	chr17:56929840	A/G	cg12560992	chr17:57184187	TRIM37	0.57	8.02	0.4	1.79e-14	Testicular germ cell tumor;
LUSC	cis	rs6714710	0.535	rs3192177	chr2:98354511	G/A	cg26665480	chr2:98280029	ACTR1B	0.59	8.05	0.4	1.45e-14	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg14668632	chr7:2872130	GNA12	-0.41	-6.05	-0.31	3.95e-9	Height;
LUSC	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg12559939	chr2:27858050	GPN1	0.39	6.03	0.31	4.3e-9	Oral cavity cancer;
LUSC	cis	rs12575480	0.901	rs6578977	chr11:2101804	C/T	cg15541987	chr11:2077307	NA	-0.43	-6.25	-0.32	1.22e-9	Pursuit maintenance gain;
LUSC	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs713477	0.935	rs12888181	chr14:55906082	A/C	cg04306507	chr14:55594613	LGALS3	-0.29	-5.65	-0.3	3.41e-8	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	14.03	0.61	1.77e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs239198	0.521	rs9377241	chr6:101334265	C/T	cg09795085	chr6:101329169	ASCC3	0.43	6.1	0.32	2.97e-9	Menarche (age at onset);
LUSC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg16680214	chr1:154839983	KCNN3	-0.52	-9.76	-0.47	5.77e-20	Prostate cancer;
LUSC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg19592336	chr6:28129416	ZNF389	0.47	6.2	0.32	1.68e-9	Depression;
LUSC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg07414643	chr4:187882934	NA	0.55	10.47	0.5	2.32e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17030434	1.000	rs10026531	chr4:154727070	C/T	cg14289246	chr4:154710475	SFRP2	-0.49	-6.75	-0.35	6.71e-11	Electrocardiographic conduction measures;
LUSC	trans	rs2229238	0.911	rs59239860	chr1:154492107	G/T	cg25273160	chr11:56955011	LRRC55	0.32	6.1	0.32	2.87e-9	Coronary heart disease;
LUSC	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg07080220	chr10:102295463	HIF1AN	0.6	7.74	0.39	1.19e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg21856205	chr7:94953877	PON1	-0.36	-5.72	-0.3	2.32e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs10754283	0.967	rs10737708	chr1:90119804	A/G	cg21401794	chr1:90099060	LRRC8C	0.61	8.78	0.43	8.66e-17	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	9.41	0.46	8.57e-19	Coronary artery disease;
LUSC	trans	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.62	-0.34	1.42e-10	Endometrial cancer;
LUSC	cis	rs679087	1.000	rs302315	chr12:29919054	G/C	cg14258853	chr12:29935411	TMTC1	-1.0	-17.09	-0.68	1.71e-47	Schizophrenia;
LUSC	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg09184832	chr6:79620586	NA	-0.44	-7.25	-0.37	2.84e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs911555	0.755	rs975892	chr14:103883349	A/T	cg17675199	chr6:35436792	RPL10A	0.44	6.62	0.34	1.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg19318889	chr4:1322082	MAEA	0.44	7.02	0.36	1.24e-11	Obesity-related traits;
LUSC	cis	rs3862435	0.571	rs2589950	chr15:90957179	C/T	cg22089800	chr15:90895588	ZNF774	0.59	6.42	0.33	4.74e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg08601574	chr20:25228251	PYGB	0.46	7.01	0.36	1.29e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.77	9.39	0.46	9.91e-19	Glomerular filtration rate (creatinine);
LUSC	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.73	10.36	0.49	5.62e-22	Corneal astigmatism;
LUSC	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg22705602	chr4:152727874	NA	-0.35	-7.54	-0.38	4.51e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg01444801	chr10:135216882	MTG1	-0.49	-6.54	-0.34	2.27e-10	Systemic lupus erythematosus;
LUSC	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg13010199	chr12:38710504	ALG10B	0.69	10.65	0.5	5.27e-23	Bladder cancer;
LUSC	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg05234568	chr11:5960015	NA	-0.55	-7.91	-0.4	3.9e-14	DNA methylation (variation);
LUSC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg04518342	chr5:131593106	PDLIM4	-0.43	-7.38	-0.37	1.29e-12	Breast cancer;
LUSC	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.99	0.36	1.51e-11	Morning vs. evening chronotype;
LUSC	cis	rs2652834	1.000	rs2729781	chr15:63404265	T/A	cg05507819	chr15:63340323	TPM1	0.67	8.14	0.41	7.84e-15	HDL cholesterol;
LUSC	cis	rs17125944	0.615	rs7151643	chr14:53313661	G/C	cg00686598	chr14:53173677	PSMC6	-0.62	-5.82	-0.3	1.36e-8	Alzheimer's disease (late onset);
LUSC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.76	0.51	2.21e-23	Bone mineral density;
LUSC	cis	rs2857891	0.817	rs2857903	chr11:6979378	G/A	cg04053776	chr11:6947353	ZNF215	0.41	5.74	0.3	2.16e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	trans	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg17830980	chr10:43048298	ZNF37B	-0.53	-6.2	-0.32	1.67e-9	Obesity (extreme);
LUSC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	0.95	19.06	0.72	2.54e-55	Cognitive function;
LUSC	cis	rs11229555	0.645	rs12226725	chr11:58246332	G/A	cg15696309	chr11:58395628	NA	-0.67	-8.1	-0.41	1.02e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.83	-0.43	6.2e-17	Response to antipsychotic treatment;
LUSC	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-9.03	-0.44	1.37e-17	Morning vs. evening chronotype;
LUSC	trans	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04565464	chr8:145669602	NFKBIL2	-0.39	-6.61	-0.34	1.51e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg08684580	chr7:98029266	BAIAP2L1	-0.41	-7.43	-0.38	9.13e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg18904891	chr8:8559673	CLDN23	-0.4	-5.99	-0.31	5.52e-9	Mood instability;
LUSC	trans	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg25214090	chr10:38739885	LOC399744	0.43	6.54	0.34	2.37e-10	Corneal astigmatism;
LUSC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.09	0.48	4.38e-21	Electroencephalogram traits;
LUSC	cis	rs9311676	0.656	rs11915480	chr3:58377159	A/G	cg13750441	chr3:58318267	PXK	0.34	6.76	0.35	5.99e-11	Systemic lupus erythematosus;
LUSC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg18681998	chr4:17616180	MED28	0.81	14.8	0.63	1.84e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10186029	0.676	rs12614406	chr2:213955803	A/G	cg08319019	chr2:214017104	IKZF2	-0.55	-8.02	-0.4	1.82e-14	Systemic sclerosis;
LUSC	cis	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg02972257	chr16:68554789	NA	-0.48	-6.24	-0.32	1.35e-9	Ulcerative colitis;
LUSC	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.3	21.73	0.77	6.94e-66	Type 1 diabetes nephropathy;
LUSC	cis	rs9925964	0.933	rs881929	chr16:31079371	G/T	cg02466173	chr16:30829666	NA	0.35	6.42	0.33	4.65e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.52	8.07	0.4	1.27e-14	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg01884057	chr2:25150051	NA	0.42	9.1	0.45	8.06e-18	Body mass index;
LUSC	cis	rs7582720	1.000	rs72936309	chr2:204040296	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.55	0.42	4.56e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg10840412	chr1:235813424	GNG4	0.47	6.09	0.32	3.02e-9	Bipolar disorder;
LUSC	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg26394196	chr10:1453818	ADARB2	0.38	6.52	0.34	2.66e-10	Radiation response;
LUSC	cis	rs7759001	0.857	rs6915934	chr6:27367887	C/T	cg18711553	chr6:27366782	ZNF391	0.39	5.69	0.3	2.84e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg17366294	chr4:99064904	C4orf37	0.58	9.89	0.48	2.08e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg06784218	chr1:46089804	CCDC17	0.58	11.51	0.53	4.82e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-6.86	-0.35	3.37e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg05519781	chr21:40033154	ERG	0.78	13.39	0.59	4.93e-33	Coronary artery disease;
LUSC	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.73	-10.8	-0.51	1.62e-23	Glomerular filtration rate;
LUSC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.9	-18.4	-0.71	1.05e-52	Intelligence (multi-trait analysis);
LUSC	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.3	-0.37	2.1e-12	Bipolar disorder;
LUSC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg00033643	chr7:134001901	SLC35B4	0.46	7.27	0.37	2.64e-12	Mean platelet volume;
LUSC	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg07382826	chr16:28625726	SULT1A1	0.26	5.69	0.3	2.79e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg06238570	chr21:40685208	BRWD1	0.53	8.43	0.42	1.07e-15	Cognitive function;
LUSC	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg22980127	chr19:33182716	NUDT19	0.95	12.94	0.58	2.44e-31	Red blood cell traits;
LUSC	cis	rs7759001	0.857	rs9468117	chr6:27366862	A/G	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg24642439	chr20:33292090	TP53INP2	0.49	7.34	0.37	1.62e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg00750074	chr16:89608354	SPG7	0.43	7.65	0.39	2.13e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.35	-0.37	1.59e-12	Glomerular filtration rate (creatinine);
LUSC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg16447950	chr5:562315	NA	-0.58	-7.3	-0.37	2.1e-12	Obesity-related traits;
LUSC	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-6.69	-0.34	9.51e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg24375607	chr4:120327624	NA	0.76	11.35	0.53	1.77e-25	Corneal astigmatism;
LUSC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg04369109	chr6:150039330	LATS1	-0.58	-8.62	-0.43	2.74e-16	Lung cancer;
LUSC	cis	rs17102423	0.806	rs4902362	chr14:65582755	G/A	cg11161011	chr14:65562177	MAX	0.59	9.16	0.45	5.35e-18	Obesity-related traits;
LUSC	cis	rs3741151	0.686	rs1938777	chr11:73122340	A/G	cg17517138	chr11:73019481	ARHGEF17	0.79	7.32	0.37	1.86e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	trans	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg13010199	chr12:38710504	ALG10B	0.41	6.49	0.33	3.17e-10	Morning vs. evening chronotype;
LUSC	cis	rs3849570	0.925	rs1464791	chr3:81893929	A/C	cg07356753	chr3:81810745	GBE1	0.64	10.43	0.5	3.08e-22	Waist circumference;Body mass index;
LUSC	trans	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg21775007	chr8:11205619	TDH	0.43	5.98	0.31	5.66e-9	Myopia (pathological);
LUSC	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs136211	0.662	rs9607338	chr22:36759026	C/T	cg16924664	chr22:36878180	TXN2	0.41	6.06	0.31	3.64e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.56	-9.19	-0.45	4.25e-18	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.45	6.68	0.34	9.88e-11	Systemic lupus erythematosus;
LUSC	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg04374321	chr14:90722782	PSMC1	-0.43	-6.49	-0.33	3.11e-10	Mortality in heart failure;
LUSC	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.48	-7.76	-0.39	1.05e-13	Schizophrenia;
LUSC	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg20637307	chr2:213403960	ERBB4	0.44	7.51	0.38	5.38e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg24642439	chr20:33292090	TP53INP2	0.41	6.02	0.31	4.57e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg01879757	chr17:41196368	BRCA1	-0.48	-7.29	-0.37	2.23e-12	Menopause (age at onset);
LUSC	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg21643547	chr1:205240462	TMCC2	-0.38	-7.17	-0.37	4.92e-12	Red blood cell count;
LUSC	cis	rs6977660	0.714	rs12672257	chr7:19813466	C/T	cg07541023	chr7:19748670	TWISTNB	0.65	7.05	0.36	1.02e-11	Thyroid stimulating hormone;
LUSC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg22535103	chr8:58192502	C8orf71	0.59	7.07	0.36	9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs2742417	0.603	rs9826208	chr3:45773991	C/T	cg04837898	chr3:45731254	SACM1L	-0.45	-7.25	-0.37	2.97e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs909002	1.000	rs909002	chr1:32139635	C/T	cg13919466	chr1:32135498	COL16A1	-0.37	-6.9	-0.35	2.57e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs981844	0.712	rs4538465	chr4:154746763	T/C	cg14289246	chr4:154710475	SFRP2	-0.46	-6.32	-0.33	8.22e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.69	11.55	0.53	3.53e-26	Systemic lupus erythematosus;
LUSC	cis	rs2692947	0.644	rs1168974	chr2:96814928	G/A	cg22654517	chr2:96458247	NA	0.32	5.86	0.31	1.08e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9788721	0.967	rs2036527	chr15:78851615	G/A	cg18825076	chr15:78729989	IREB2	-0.47	-7.12	-0.36	6.68e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.61	8.55	0.42	4.57e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8038465	0.615	rs4075802	chr15:73963239	A/G	cg15420318	chr15:73925796	NPTN	0.62	10.76	0.51	2.22e-23	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg22153745	chr1:153894579	GATAD2B	-0.54	-8.2	-0.41	5.23e-15	Total cholesterol levels;
LUSC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.54	-9.3	-0.45	1.92e-18	Prudent dietary pattern;
LUSC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg20607798	chr8:58055168	NA	0.5	6.03	0.31	4.35e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg16393715	chr7:1948819	MAD1L1	0.34	5.82	0.3	1.35e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg17376030	chr22:41985996	PMM1	-0.46	-5.72	-0.3	2.42e-8	Vitiligo;
LUSC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg14784868	chr12:69753453	YEATS4	0.63	9.41	0.46	8.13e-19	Blood protein levels;
LUSC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg04553112	chr3:125709451	NA	-0.5	-5.7	-0.3	2.7e-8	Blood pressure (smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05862135	chr16:3074294	HCFC1R1;THOC6	-0.4	-5.96	-0.31	6.27e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs977987	0.806	rs1109342	chr16:75445675	A/G	cg04384234	chr16:75411784	CFDP1	0.4	6.47	0.33	3.45e-10	Dupuytren's disease;
LUSC	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.72	-0.39	1.35e-13	Type 2 diabetes;
LUSC	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg24375607	chr4:120327624	NA	0.76	11.59	0.54	2.52e-26	Corneal astigmatism;
LUSC	trans	rs9380880	0.826	rs9380882	chr6:39547428	A/T	cg14673904	chr12:46609063	SLC38A1	0.54	5.99	0.31	5.41e-9	Immune response to smallpox vaccine (IL-6);
LUSC	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.7	-0.34	8.71e-11	Inflammatory bowel disease;
LUSC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg15147215	chr3:52552868	STAB1	-0.3	-5.92	-0.31	8e-9	Electroencephalogram traits;
LUSC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.62	8.23	0.41	4.34e-15	High light scatter reticulocyte count;
LUSC	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.55	-0.42	4.59e-16	Intelligence (multi-trait analysis);
LUSC	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg06606381	chr12:133084897	FBRSL1	-0.97	-8.98	-0.44	1.96e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg24375607	chr4:120327624	NA	0.76	11.3	0.53	2.66e-25	Corneal astigmatism;
LUSC	cis	rs6545883	0.759	rs777585	chr2:61412559	A/G	cg15711740	chr2:61764176	XPO1	0.4	6.05	0.31	3.9e-9	Tuberculosis;
LUSC	cis	rs57590327	0.508	rs13093082	chr3:81949958	C/T	cg07356753	chr3:81810745	GBE1	-0.59	-8.68	-0.43	1.79e-16	Extraversion;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg22092082	chr2:191184568	HIBCH	0.41	6.08	0.32	3.24e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg12365402	chr11:9010492	NRIP3	0.43	7.87	0.4	4.92e-14	Hemoglobin concentration;
LUSC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg22834771	chr12:69754056	YEATS4	-0.51	-7.51	-0.38	5.36e-13	Blood protein levels;
LUSC	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg12927641	chr6:109611667	NA	-0.35	-5.87	-0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.71	-9.55	-0.46	2.88e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg13560548	chr3:10150139	C3orf24	0.53	6.84	0.35	3.75e-11	Alzheimer's disease;
LUSC	cis	rs9427116	0.502	rs9427100	chr1:154583762	G/A	cg17218026	chr1:154582156	ADAR	0.56	9.99	0.48	9.98e-21	Blood protein levels;
LUSC	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg24069376	chr3:38537580	EXOG	0.34	6.51	0.34	2.83e-10	Electrocardiographic conduction measures;
LUSC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg17264618	chr3:40429014	ENTPD3	0.34	7.22	0.37	3.62e-12	Renal cell carcinoma;
LUSC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg12463550	chr7:65579703	CRCP	0.46	6.61	0.34	1.5e-10	Aortic root size;
LUSC	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg17757837	chr7:157058334	UBE3C	0.83	13.15	0.58	4.02e-32	Body mass index;
LUSC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg06008330	chr7:65541103	ASL	-0.36	-5.71	-0.3	2.54e-8	Aortic root size;
LUSC	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg19682013	chr15:45996608	NA	0.38	5.75	0.3	2.03e-8	Waist circumference;Weight;
LUSC	cis	rs2692947	0.727	rs749457	chr2:96795944	A/G	cg23100626	chr2:96804247	ASTL	0.26	6.57	0.34	1.96e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs524023	1.000	rs505802	chr11:64357072	T/C	cg07220939	chr11:64358617	SLC22A12	0.23	6.04	0.31	4.18e-9	Urate levels in obese individuals;
LUSC	cis	rs10170846	0.861	rs4674677	chr2:223529658	G/A	cg25565276	chr2:223520875	FARSB	0.66	9.98	0.48	1.05e-20	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg11845111	chr2:191398756	TMEM194B	-0.91	-10.78	-0.51	1.9e-23	Diastolic blood pressure;
LUSC	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg27005118	chr17:13972210	COX10	-0.45	-8.59	-0.43	3.45e-16	Temperament;
LUSC	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.7e-16	Menopause (age at onset);
LUSC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg10978503	chr1:24200527	CNR2	0.53	12.98	0.58	1.85e-31	Immature fraction of reticulocytes;
LUSC	cis	rs12474201	0.862	rs13025595	chr2:46977893	A/G	cg06386533	chr2:46925753	SOCS5	0.66	9.71	0.47	8.4e-20	Height;
LUSC	cis	rs2857891	0.817	rs2638095	chr11:6979915	C/T	cg14883916	chr11:6947541	ZNF215	0.45	5.83	0.3	1.3e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs1775715	0.513	rs2808089	chr10:32145112	A/T	cg03015672	chr10:32216066	ARHGAP12	0.35	6.36	0.33	6.52e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs501916	0.575	rs56345741	chr15:48065010	A/C	cg16110827	chr15:48056943	SEMA6D	-0.39	-6.14	-0.32	2.38e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg12863693	chr15:85201151	NMB	0.34	6.78	0.35	5.49e-11	Schizophrenia;
LUSC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6960043	1.000	rs6972333	chr7:15051643	G/A	cg19272540	chr7:15055459	NA	-0.31	-7.34	-0.37	1.61e-12	Type 2 diabetes;
LUSC	cis	rs3764563	0.935	rs10408443	chr19:15715973	C/T	cg20725493	chr19:15740067	CYP4F8	-0.67	-6.55	-0.34	2.2e-10	Inflammatory biomarkers;
LUSC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg04369109	chr6:150039330	LATS1	-0.53	-7.73	-0.39	1.24e-13	Lung cancer;
LUSC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-7.33	-0.37	1.74e-12	Aortic root size;
LUSC	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg18721089	chr20:30220636	NA	-0.41	-6.76	-0.35	6.18e-11	Mean corpuscular hemoglobin;
LUSC	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg03340356	chr1:67600835	NA	0.42	6.71	0.34	8.14e-11	Psoriasis;
LUSC	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg25566285	chr7:158114605	PTPRN2	-0.33	-6.06	-0.31	3.61e-9	Calcium levels;
LUSC	cis	rs617219	0.889	rs1664551	chr5:78440096	C/T	cg24856658	chr5:78533917	JMY	-0.3	-5.68	-0.3	3e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg03806693	chr22:41940476	POLR3H	1.0	14.26	0.62	2.38e-36	Vitiligo;
LUSC	cis	rs73416724	1.000	rs76658194	chr6:43357601	C/T	cg26312998	chr6:43337775	ZNF318	0.56	6.68	0.34	1.02e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.26e-41	Morning vs. evening chronotype;
LUSC	cis	rs1775715	0.835	rs1419169	chr10:32257204	C/G	cg03015672	chr10:32216066	ARHGAP12	0.33	5.7	0.3	2.58e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg26677194	chr12:130822605	PIWIL1	0.59	8.78	0.43	8.41e-17	Menopause (age at onset);
LUSC	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg23625390	chr15:77176239	SCAPER	-0.65	-9.76	-0.47	6e-20	Blood metabolite levels;
LUSC	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	10.94	0.51	4.98e-24	Ileal carcinoids;
LUSC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.53	-0.42	5.3e-16	Breast cancer;
LUSC	cis	rs10193935	1.000	rs13411405	chr2:42413811	C/A	cg27598129	chr2:42591480	NA	-0.61	-8.05	-0.4	1.48e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17621444	0.522	rs4611122	chr10:121809472	G/A	cg02041677	chr10:121771263	NA	-0.34	-6.31	-0.33	8.87e-10	IgG glycosylation;
LUSC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.67	-11.71	-0.54	8.94e-27	Lung cancer;
LUSC	cis	rs9309473	0.579	rs1852644	chr2:73597718	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-7.81	-0.39	7.72e-14	Metabolite levels;
LUSC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg06784218	chr1:46089804	CCDC17	-0.51	-9.86	-0.47	2.72e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg26380479	chr7:97908229	NA	-0.27	-6.05	-0.31	3.86e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.74	-10.26	-0.49	1.15e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg21775007	chr8:11205619	TDH	0.47	6.67	0.34	1.09e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs12908161	0.515	rs12907646	chr15:85403496	G/A	cg12863693	chr15:85201151	NMB	0.32	5.93	0.31	7.41e-9	Schizophrenia;
LUSC	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-5.77	-0.3	1.79e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg10434728	chr15:90938212	IQGAP1	0.41	8.39	0.42	1.42e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg08470875	chr2:26401718	FAM59B	-0.68	-9.09	-0.45	9.26e-18	Gut microbiome composition (summer);
LUSC	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg05855489	chr10:104503620	C10orf26	0.57	8.5	0.42	6.2e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg13042288	chr15:90349979	ANPEP	-0.47	-6.7	-0.34	8.67e-11	Uric acid levels;
LUSC	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-8.46	-0.42	8.72e-16	Response to antipsychotic treatment;
LUSC	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg04865166	chr7:105162814	PUS7	0.51	5.67	0.3	3.06e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9283706	0.608	rs12523505	chr5:66334631	C/T	cg11590213	chr5:66331682	MAST4	0.44	6.42	0.33	4.75e-10	Coronary artery disease;
LUSC	cis	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg27411982	chr8:10470053	RP1L1	0.41	5.84	0.3	1.25e-8	Neuroticism;
LUSC	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg27489772	chr12:121021490	NA	-0.53	-6.84	-0.35	3.8e-11	Type 1 diabetes nephropathy;
LUSC	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg05234568	chr11:5960015	NA	-0.65	-9.51	-0.46	3.76e-19	DNA methylation (variation);
LUSC	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg02403541	chr12:121454288	C12orf43	0.59	8.45	0.42	8.98e-16	N-glycan levels;
LUSC	cis	rs7043114	0.507	rs7037075	chr9:95216613	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.37	-6.65	-0.34	1.18e-10	Height;
LUSC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg23711669	chr6:146136114	FBXO30	0.84	15.9	0.66	8.58e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg05025164	chr4:1340916	KIAA1530	0.47	7.46	0.38	7.56e-13	Longevity;
LUSC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs72674100	1.000	rs2002117	chr4:97992122	C/T	cg09670535	chr1:18959427	PAX7	-0.63	-6.48	-0.33	3.21e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs12049351	0.774	rs12125125	chr1:229627666	A/T	cg11742688	chr1:229674241	ABCB10	-0.4	-5.68	-0.3	2.96e-8	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg07424592	chr7:64974309	NA	0.63	5.69	0.3	2.81e-8	Diabetic kidney disease;
LUSC	cis	rs6429082	0.668	rs291395	chr1:235652049	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.64	-10.43	-0.5	3.09e-22	Adiposity;
LUSC	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg02574844	chr11:5959923	NA	-0.45	-6.26	-0.32	1.2e-9	DNA methylation (variation);
LUSC	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg09263875	chr16:632152	PIGQ	0.72	13.42	0.59	3.71e-33	Height;
LUSC	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg27068330	chr11:65405492	SIPA1	-0.75	-10.43	-0.5	3.02e-22	Acne (severe);
LUSC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg06001716	chr17:41278141	BRCA1;NBR2	-0.35	-5.79	-0.3	1.62e-8	Menopause (age at onset);
LUSC	trans	rs4618210	0.722	rs1806555	chr3:17016794	G/T	cg26270066	chr15:43941407	CATSPER2	-0.68	-6.12	-0.32	2.57e-9	Myocardial infarction;
LUSC	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg21775007	chr8:11205619	TDH	-0.47	-7.01	-0.36	1.35e-11	Systolic blood pressure;
LUSC	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg07382826	chr16:28625726	SULT1A1	0.28	5.97	0.31	5.93e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs853679	1.000	rs853678	chr6:28297313	T/A	cg06606381	chr12:133084897	FBRSL1	-0.58	-6.44	-0.33	4.25e-10	Depression;
LUSC	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg16524733	chr11:117070046	TAGLN	0.36	5.74	0.3	2.16e-8	Blood protein levels;
LUSC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg18351406	chr4:77819688	ANKRD56	0.58	8.49	0.42	7.11e-16	Emphysema distribution in smoking;
LUSC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.8	12.19	0.55	1.53e-28	Eosinophil percentage of white cells;
LUSC	cis	rs9341808	0.754	rs9352817	chr6:81025879	T/G	cg08355045	chr6:80787529	NA	0.56	9.99	0.48	9.78e-21	Sitting height ratio;
LUSC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg19592336	chr6:28129416	ZNF389	0.47	6.19	0.32	1.75e-9	Depression;
LUSC	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg04362960	chr10:104952993	NT5C2	-0.6	-8.35	-0.42	1.79e-15	Arsenic metabolism;
LUSC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg12257692	chr3:49977190	RBM6	0.26	7.4	0.38	1.1e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg23711669	chr6:146136114	FBXO30	0.9	17.06	0.68	2.3e-47	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9399401	0.601	rs171891	chr6:142850612	G/A	cg03128060	chr6:142623767	GPR126	0.51	8.0	0.4	2.01e-14	Chronic obstructive pulmonary disease;
LUSC	trans	rs1973993	0.745	rs9437743	chr1:96961723	C/T	cg10631902	chr5:14652156	NA	0.44	6.53	0.34	2.43e-10	Weight;
LUSC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10802521	chr3:52805072	NEK4	-0.44	-6.76	-0.35	6.05e-11	Bipolar disorder;
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg04919579	chr3:196230449	RNF168	0.4	6.33	0.33	8.03e-10	Metabolite levels (Pyroglutamine);
LUSC	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg06287003	chr12:125626642	AACS	-0.38	-6.61	-0.34	1.49e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10372701	chr3:142546496	PCOLCE2	-0.36	-6.08	-0.32	3.32e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg19622623	chr12:86230825	RASSF9	-0.44	-6.13	-0.32	2.49e-9	Major depressive disorder;
LUSC	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-5.76	-0.3	1.88e-8	Type 2 diabetes;
LUSC	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.77	-12.95	-0.58	2.23e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg02574844	chr11:5959923	NA	0.46	6.56	0.34	2.09e-10	DNA methylation (variation);
LUSC	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg04508216	chr1:11107452	MASP2	0.31	5.67	0.3	3.17e-8	Body mass index;
LUSC	cis	rs62400317	0.826	rs12205468	chr6:45310285	G/A	cg20913747	chr6:44695427	NA	-0.47	-7.73	-0.39	1.27e-13	Total body bone mineral density;
LUSC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg22166914	chr1:53195759	ZYG11B	-0.55	-9.13	-0.45	6.94e-18	Monocyte count;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg11965913	chr1:205819406	PM20D1	0.92	18.64	0.71	1.16e-53	Menarche (age at onset);
LUSC	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.15	0.32	2.2e-9	Recombination rate (females);
LUSC	cis	rs58785573	0.570	rs1824652	chr4:38644597	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.46	7.1	0.36	7.64e-12	Lymphocyte percentage of white cells;
LUSC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg27535305	chr1:53392650	SCP2	-0.49	-9.55	-0.46	2.99e-19	Monocyte count;
LUSC	cis	rs61990749	0.597	rs10142722	chr14:78275549	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.56	5.97	0.31	6.11e-9	Fibroblast growth factor basic levels;
LUSC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg07507251	chr3:52567010	NT5DC2	0.37	7.59	0.38	3.33e-13	Electroencephalogram traits;
LUSC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg01616529	chr11:638424	DRD4	-0.34	-5.98	-0.31	5.7e-9	Systemic lupus erythematosus;
LUSC	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg15423357	chr2:25149977	NA	-0.37	-7.35	-0.37	1.54e-12	Body mass index in non-asthmatics;
LUSC	cis	rs2879627	0.616	rs1937682	chr10:53678982	A/T	cg06976598	chr10:53639124	PRKG1	0.47	5.88	0.31	9.78e-9	Coronary artery disease;
LUSC	cis	rs722599	0.748	rs59112602	chr14:75358817	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.41	-6.0	-0.31	5.02e-9	IgG glycosylation;
LUSC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	6.36	0.33	6.81e-10	Tonsillectomy;
LUSC	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg21918786	chr6:109611834	NA	0.34	5.87	0.31	1.02e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg08888203	chr3:10149979	C3orf24	0.62	8.51	0.42	5.77e-16	Alzheimer's disease;
LUSC	cis	rs2348418	0.831	rs7296538	chr12:28711783	C/G	cg13890972	chr12:28721907	NA	0.35	5.98	0.31	5.65e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg27539214	chr16:67997921	SLC12A4	-0.5	-6.72	-0.35	7.83e-11	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.07	-0.44	1.06e-17	Monocyte percentage of white cells;
LUSC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg03354898	chr7:1950403	MAD1L1	0.34	6.51	0.34	2.74e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg19468946	chr17:37922297	IKZF3	-0.45	-7.0	-0.36	1.45e-11	Self-reported allergy;
LUSC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.62	-0.43	2.69e-16	Obesity-related traits;
LUSC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg16447950	chr5:562315	NA	-0.53	-6.48	-0.33	3.31e-10	Obesity-related traits;
LUSC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.04	-0.4	1.62e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7143963	1.000	rs7143963	chr14:103304425	C/T	cg21920469	chr14:103375193	NA	-0.43	-5.77	-0.3	1.85e-8	Body mass index;
LUSC	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg24558204	chr6:135376177	HBS1L	0.68	10.65	0.5	5.53e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs10465746	0.967	rs11163879	chr1:84444051	T/C	cg10977910	chr1:84465055	TTLL7	0.42	6.23	0.32	1.42e-9	Obesity-related traits;
LUSC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	18.78	0.72	3.2e-54	Chronic sinus infection;
LUSC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-8.57	-0.42	3.89e-16	Bipolar disorder;
LUSC	cis	rs12532214	0.645	rs6973204	chr7:3178561	C/T	cg19214707	chr7:3157722	NA	0.37	5.66	0.3	3.19e-8	Itch intensity from mosquito bite;
LUSC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	10.53	0.5	1.4e-22	Blood protein levels;
LUSC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.9	-16.15	-0.66	8.73e-44	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg00290607	chr11:67383545	NA	0.36	6.62	0.34	1.41e-10	Mean corpuscular volume;
LUSC	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.44	-6.54	-0.34	2.34e-10	Response to bleomycin (chromatid breaks);
LUSC	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg05729581	chr11:3078854	CARS	0.42	6.22	0.32	1.51e-9	Calcium levels;
LUSC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.0	-0.31	5.02e-9	Bipolar disorder;
LUSC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg23630131	chr7:65973040	NA	0.21	5.78	0.3	1.74e-8	Aortic root size;
LUSC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	8.86	0.44	4.72e-17	Motion sickness;
LUSC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg05941027	chr17:61774174	LIMD2	0.22	5.79	0.3	1.63e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg20295408	chr7:1910781	MAD1L1	-0.52	-7.48	-0.38	6.42e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg06223162	chr1:101003688	GPR88	0.51	9.44	0.46	6.86e-19	Breast cancer;
LUSC	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.74	-0.3	2.14e-8	Educational attainment;
LUSC	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg09904177	chr6:26538194	HMGN4	0.48	7.59	0.38	3.19e-13	Schizophrenia;
LUSC	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07988820	chr12:82153109	PPFIA2	-0.44	-6.2	-0.32	1.7e-9	Resting heart rate;
LUSC	cis	rs1775715	0.644	rs2799022	chr10:32137198	C/T	cg26784012	chr10:32216390	ARHGAP12	0.47	7.91	0.4	3.89e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg04022379	chr5:110408740	TSLP	0.62	9.39	0.46	9.73e-19	Eosinophilic esophagitis;
LUSC	cis	rs10465746	0.935	rs12758441	chr1:84352034	A/G	cg10977910	chr1:84465055	TTLL7	0.44	6.35	0.33	6.92e-10	Obesity-related traits;
LUSC	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg03651054	chr13:50194643	NA	0.36	6.2	0.32	1.71e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs2303282	0.690	rs4783940	chr16:56451482	T/C	cg00500540	chr16:56394104	NA	-0.43	-7.37	-0.37	1.37e-12	Breast cancer;
LUSC	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg11189052	chr15:85197271	WDR73	-0.45	-6.44	-0.33	4.19e-10	P wave terminal force;
LUSC	cis	rs7786877	0.626	rs11983745	chr7:100223678	T/C	cg00334542	chr7:100209784	MOSPD3	-0.67	-7.52	-0.38	5.23e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs926938	0.584	rs360606	chr1:115391769	C/T	cg12756093	chr1:115239321	AMPD1	0.54	8.24	0.41	3.86e-15	Autism;
LUSC	cis	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg02972257	chr16:68554789	NA	0.46	5.99	0.31	5.39e-9	Colorectal cancer;
LUSC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs12618769	0.625	rs4850877	chr2:99112154	C/T	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg18105134	chr13:113819100	PROZ	0.66	9.88	0.48	2.32e-20	Platelet distribution width;
LUSC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	0.92	13.93	0.61	4.14e-35	Breast cancer;
LUSC	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg24687543	chr11:63912206	MACROD1	0.47	5.96	0.31	6.34e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg17541715	chr7:1216824	NA	-0.37	-5.65	-0.3	3.48e-8	Longevity;Endometriosis;
LUSC	cis	rs6500395	1.000	rs12919520	chr16:48705760	G/C	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg09165964	chr15:75287851	SCAMP5	-1.06	-15.86	-0.66	1.22e-42	Blood trace element (Zn levels);
LUSC	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg14196790	chr5:131705035	SLC22A5	0.5	8.31	0.41	2.44e-15	Blood metabolite levels;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg21356179	chr17:73974861	C17orf106;ACOX1	0.47	7.2	0.37	3.98e-12	Schizophrenia;
LUSC	cis	rs2070433	0.500	rs2070435	chr21:47961711	C/T	cg12379764	chr21:47803548	PCNT	0.71	11.01	0.52	3.03e-24	Lymphocyte counts;
LUSC	cis	rs2857891	0.659	rs2262676	chr11:6996609	T/G	cg04053776	chr11:6947353	ZNF215	0.45	6.4	0.33	5.32e-10	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs3812762	0.833	rs10500707	chr11:8817580	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.39	6.48	0.33	3.23e-10	Hypospadias;
LUSC	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21659725	chr3:3221576	CRBN	0.63	10.31	0.49	8.07e-22	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-1.04	-19.93	-0.74	9.13e-59	Height;
LUSC	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg05360949	chr19:41903737	BCKDHA;EXOSC5	0.41	5.71	0.3	2.43e-8	Height;
LUSC	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-7.77	-0.39	1e-13	Blood metabolite levels;
LUSC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg17143192	chr8:8559678	CLDN23	-0.58	-8.02	-0.4	1.82e-14	Obesity-related traits;
LUSC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.57	10.54	0.5	1.3e-22	Homoarginine levels;
LUSC	trans	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg03886242	chr7:26192032	NFE2L3	0.36	5.95	0.31	6.72e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg08999081	chr20:33150536	PIGU	0.33	5.71	0.3	2.54e-8	Height;
LUSC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.73	0.35	7.27e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs981844	0.753	rs1105491	chr4:154726634	A/C	cg14289246	chr4:154710475	SFRP2	0.45	5.96	0.31	6.24e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs62432291	0.681	rs388001	chr6:159658459	C/T	cg14500486	chr6:159655392	FNDC1	-0.54	-6.06	-0.31	3.76e-9	Joint mobility (Beighton score);
LUSC	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg27129171	chr3:47204927	SETD2	0.52	7.52	0.38	4.98e-13	Birth weight;
LUSC	cis	rs4654899	0.865	rs61779120	chr1:21481230	T/C	cg02927042	chr1:21476669	EIF4G3	-0.41	-6.51	-0.34	2.71e-10	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg05340658	chr4:99064831	C4orf37	0.62	9.01	0.44	1.68e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.74	-14.04	-0.61	1.56e-35	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	1.16	15.43	0.65	6.01e-41	Nonalcoholic fatty liver disease;
LUSC	cis	rs41308713	0.681	rs8116426	chr20:37034643	A/C	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.0	6.87	0.35	3.1e-11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05962382	chr2:130345044	NA	-0.35	-6.16	-0.32	2.04e-9	Response to cytidine analogues (gemcitabine);
LUSC	trans	rs330048	0.545	rs11781008	chr8:9153239	G/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.94	0.36	2.11e-11	Systemic lupus erythematosus;
LUSC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg03354898	chr7:1950403	MAD1L1	-0.34	-6.9	-0.35	2.62e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg23029597	chr12:123009494	RSRC2	-0.71	-9.06	-0.44	1.15e-17	Body mass index;
LUSC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg10755058	chr3:40428713	ENTPD3	0.35	5.76	0.3	1.89e-8	Renal cell carcinoma;
LUSC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.98	-0.31	5.61e-9	Tonsillectomy;
LUSC	cis	rs1983891	1.000	rs6458228	chr6:41543793	C/A	cg15051332	chr6:41514432	FOXP4	0.41	5.91	0.31	8.43e-9	Prostate cancer;
LUSC	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.46	-0.42	8.39e-16	Mood instability;
LUSC	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.69	-10.04	-0.48	6.57e-21	Glomerular filtration rate;
LUSC	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg07959070	chr22:50026188	C22orf34	-0.36	-7.39	-0.37	1.18e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg18758796	chr5:131593413	PDLIM4	0.41	6.72	0.34	8.02e-11	Breast cancer;
LUSC	cis	rs62400317	0.859	rs55964727	chr6:45259079	A/C	cg18551225	chr6:44695536	NA	-0.42	-7.08	-0.36	8.7e-12	Total body bone mineral density;
LUSC	cis	rs6489785	0.509	rs3213570	chr12:121222411	C/G	cg02419362	chr12:121203948	SPPL3	0.46	8.48	0.42	7.16e-16	Longevity;Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01447244	chr15:90931524	IQGAP1	-0.4	-6.12	-0.32	2.63e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	8.88	0.44	4.31e-17	Alzheimer's disease;
LUSC	cis	rs2637266	0.783	rs12258504	chr10:78477055	C/T	cg18941641	chr10:78392320	NA	0.34	6.22	0.32	1.52e-9	Pulmonary function;
LUSC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg03188948	chr7:1209495	NA	0.46	6.11	0.32	2.83e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg12463550	chr7:65579703	CRCP	0.43	6.09	0.32	3.08e-9	Aortic root size;
LUSC	cis	rs11169552	0.510	rs4768853	chr12:50981785	A/C	cg12884762	chr12:50931848	DIP2B	-0.32	-5.79	-0.3	1.6e-8	Colorectal cancer;
LUSC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg00310523	chr12:86230176	RASSF9	0.52	9.81	0.47	3.84e-20	Major depressive disorder;
LUSC	cis	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.12	-0.32	2.59e-9	Neuroticism;
LUSC	cis	rs10779751	0.922	rs4845985	chr1:11288618	G/A	cg08854313	chr1:11322531	MTOR	0.89	14.88	0.63	9.08e-39	Body mass index;
LUSC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	6.86	0.35	3.29e-11	Parkinson's disease;
LUSC	cis	rs9612	1.000	rs7246677	chr19:44248625	G/A	cg08581076	chr19:44259116	C19orf61	0.54	6.57	0.34	1.88e-10	Exhaled nitric oxide output;
LUSC	cis	rs243505	0.559	rs10215794	chr7:148478895	C/G	cg09806900	chr7:148480153	CUL1	0.68	10.03	0.48	7.22e-21	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg13902645	chr11:5959945	NA	-0.53	-8.16	-0.41	7.13e-15	DNA methylation (variation);
LUSC	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	9.64	0.47	1.42e-19	Response to bleomycin (chromatid breaks);
LUSC	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.67	-9.95	-0.48	1.33e-20	Tonometry;
LUSC	cis	rs10465746	0.935	rs6692233	chr1:84327214	A/G	cg10977910	chr1:84465055	TTLL7	-0.41	-5.95	-0.31	6.75e-9	Obesity-related traits;
LUSC	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-9.87	-0.48	2.44e-20	Response to antipsychotic treatment;
LUSC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg03146154	chr1:46216737	IPP	-0.5	-7.19	-0.37	4.3e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs713477	0.967	rs61976571	chr14:55908774	T/C	cg13175173	chr14:55914753	NA	-0.32	-6.74	-0.35	7.01e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg17462356	chr17:80056334	FASN	0.46	6.21	0.32	1.56e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2274273	0.624	rs67795323	chr14:55797833	G/A	cg04306507	chr14:55594613	LGALS3	0.48	9.69	0.47	1e-19	Protein biomarker;
LUSC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.64	13.9	0.61	5.59e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22496380	chr5:211416	CCDC127	-0.86	-8.85	-0.44	5.26e-17	Breast cancer;
LUSC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.5	0.46	4.18e-19	Bipolar disorder;
LUSC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-7.99	-0.4	2.25e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15664640	chr17:80829946	TBCD	-0.73	-12.66	-0.57	2.8e-30	Breast cancer;
LUSC	cis	rs1595825	0.735	rs2053394	chr2:198946335	C/T	cg00982548	chr2:198649783	BOLL	-0.54	-6.49	-0.33	3.19e-10	Ulcerative colitis;
LUSC	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg03585969	chr10:35415529	CREM	0.62	9.1	0.45	8.61e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs1493916	0.777	rs1493910	chr18:31318376	A/G	cg27147174	chr7:100797783	AP1S1	-0.54	-8.49	-0.42	6.74e-16	Life satisfaction;
LUSC	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg02569458	chr12:86230093	RASSF9	0.42	6.81	0.35	4.67e-11	Major depressive disorder;
LUSC	cis	rs8032315	0.895	rs4932370	chr15:91404705	A/G	cg05211768	chr15:91427848	FES	-0.32	-6.02	-0.31	4.59e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08677398	chr8:58056175	NA	0.49	7.78	0.39	8.84e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.38	-7.21	-0.37	3.65e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg13939156	chr17:80058883	NA	0.33	6.62	0.34	1.41e-10	Life satisfaction;
LUSC	trans	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg03886242	chr7:26192032	NFE2L3	-0.38	-6.35	-0.33	7.18e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg09307838	chr4:120376055	NA	0.5	7.71	0.39	1.5e-13	Diastolic blood pressure;
LUSC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg19230755	chr7:65878503	NA	-0.41	-5.74	-0.3	2.17e-8	Aortic root size;
LUSC	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg02153584	chr22:29168773	CCDC117	0.51	7.02	0.36	1.22e-11	Lymphocyte counts;
LUSC	cis	rs1107366	1.000	rs1107364	chr3:125904263	G/A	cg08481491	chr3:125900108	ALDH1L1	-0.31	-6.27	-0.32	1.11e-9	Metabolite levels;
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg13453750	chr1:205783389	SLC41A1	-0.33	-6.48	-0.33	3.23e-10	Menarche (age at onset);
LUSC	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg24006582	chr15:45444508	DUOX1	-0.6	-8.73	-0.43	1.24e-16	Uric acid levels;
LUSC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	10.77	0.51	2.12e-23	Hip circumference adjusted for BMI;
LUSC	trans	rs11935423	0.778	rs11933520	chr4:100492189	T/C	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.1	-0.32	3e-9	Gut microbiome composition (summer);
LUSC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg03188948	chr7:1209495	NA	0.61	6.28	0.33	1.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs548181	0.668	rs540555	chr11:125486848	T/C	cg03464685	chr11:125439445	EI24	1.17	14.17	0.61	4.96e-36	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6674970	1.000	rs7546304	chr1:151114484	C/G	cg03258749	chr1:151040405	MLLT11	-0.43	-6.45	-0.33	3.92e-10	Childhood ear infection;
LUSC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.5	-8.4	-0.42	1.27e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg17052675	chr2:3827356	NA	-0.57	-11.28	-0.53	3.32e-25	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.73	14.3	0.62	1.64e-36	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg26043149	chr18:55253948	FECH	0.48	7.22	0.37	3.5e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4919087	1.000	rs11189132	chr10:99086195	G/C	cg25902810	chr10:99078978	FRAT1	-0.47	-6.8	-0.35	4.98e-11	Monocyte count;
LUSC	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg00579484	chr14:23475993	C14orf93	0.39	5.74	0.3	2.12e-8	Cognitive ability (multi-trait analysis);
LUSC	cis	rs12594515	0.935	rs8042519	chr15:45996341	G/C	cg19682013	chr15:45996608	NA	0.39	5.9	0.31	8.69e-9	Waist circumference;Weight;
LUSC	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg18753928	chr3:113234510	CCDC52	-0.51	-7.96	-0.4	2.8e-14	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs977987	0.806	rs4888418	chr16:75460306	C/G	cg03315344	chr16:75512273	CHST6	0.49	9.26	0.45	2.61e-18	Dupuytren's disease;
LUSC	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.93	12.22	0.56	1.2e-28	Exhaled nitric oxide output;
LUSC	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg06092702	chr1:163392909	NA	-0.43	-7.2	-0.37	4.04e-12	Motion sickness;
LUSC	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	8.51	0.42	5.87e-16	Coffee consumption (cups per day);
LUSC	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg11984989	chr7:158649758	WDR60	-1.0	-17.57	-0.69	2.04e-49	Height;
LUSC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.51	0.59	1.8e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs2262909	0.962	rs4932952	chr19:22246788	G/A	cg17074339	chr11:11642133	GALNTL4	0.47	7.17	0.37	4.94e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15369054	chr17:80825471	TBCD	0.7	11.78	0.54	4.96e-27	Breast cancer;
LUSC	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg09479241	chr17:27052676	TLCD1	0.43	5.78	0.3	1.74e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.62	-9.47	-0.46	5.16e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs727505	0.607	rs10464674	chr7:124791551	A/G	cg23710748	chr7:124431027	NA	-0.4	-6.98	-0.36	1.61e-11	Lewy body disease;
LUSC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.38	0.33	5.95e-10	Menopause (age at onset);
LUSC	cis	rs2625529	0.652	rs8040216	chr15:72255249	C/T	cg16672083	chr15:72433130	SENP8	0.49	8.08	0.4	1.2e-14	Red blood cell count;
LUSC	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg00677455	chr12:58241039	CTDSP2	0.64	9.0	0.44	1.69e-17	Multiple sclerosis;
LUSC	trans	rs931812	0.895	rs7831714	chr8:101913987	C/T	cg20993868	chr7:22813445	NA	0.62	11.14	0.52	9.89e-25	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs9372498	0.536	rs62422235	chr6:118971913	G/A	cg18833306	chr6:118973337	C6orf204	-0.46	-5.85	-0.3	1.2e-8	Diastolic blood pressure;
LUSC	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg22491629	chr6:157744540	C6orf35	-0.92	-11.3	-0.53	2.83e-25	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg23625390	chr15:77176239	SCAPER	-0.66	-10.1	-0.48	4.21e-21	Blood metabolite levels;
LUSC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg00509249	chr6:109615579	CCDC162	-0.33	-6.05	-0.31	3.86e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg01475377	chr6:109611718	NA	-0.38	-6.75	-0.35	6.74e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg02389323	chr16:88786976	FAM38A	1.02	10.55	0.5	1.23e-22	Plateletcrit;
LUSC	trans	rs62238980	0.614	rs77112134	chr22:32394449	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	trans	rs6601327	0.602	rs7829463	chr8:9649691	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.38	-0.33	5.92e-10	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg22509179	chr1:25234806	RUNX3	-0.6	-10.09	-0.48	4.48e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1322512	1.000	rs1407488	chr6:152945777	G/T	cg27316956	chr6:152958899	SYNE1	-0.33	-5.65	-0.3	3.45e-8	Tonometry;
LUSC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg23788917	chr6:8435910	SLC35B3	0.51	7.48	0.38	6.55e-13	Motion sickness;
LUSC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-0.75	-13.19	-0.59	2.94e-32	Height;
LUSC	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-0.53	-8.18	-0.41	6.04e-15	Breast cancer;
LUSC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg26338869	chr17:61819248	STRADA	0.41	5.94	0.31	7.17e-9	Prudent dietary pattern;
LUSC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg12463550	chr7:65579703	CRCP	0.55	8.24	0.41	3.89e-15	Aortic root size;
LUSC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg17211192	chr8:82754475	SNX16	-0.81	-11.1	-0.52	1.45e-24	Diastolic blood pressure;
LUSC	cis	rs4588572	0.643	rs7700390	chr5:77789532	T/C	cg11547950	chr5:77652471	NA	-0.61	-8.57	-0.42	3.88e-16	Triglycerides;
LUSC	cis	rs983392	0.679	rs7128450	chr11:60031270	G/C	cg24026212	chr11:59952134	MS4A6A	0.36	6.32	0.33	8.42e-10	Alzheimer's disease (late onset);
LUSC	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.45	0.38	8.31e-13	Colorectal cancer;
LUSC	cis	rs4144027	0.967	rs56126771	chr14:104361143	C/G	cg12183467	chr14:104352244	NA	0.29	5.69	0.3	2.73e-8	Blood metabolite levels;
LUSC	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	0.6	9.35	0.46	1.3e-18	Breast cancer;
LUSC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg16339924	chr4:17578868	LAP3	0.63	9.74	0.47	6.69e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.6	-0.43	3.22e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	13.05	0.58	9.63e-32	Cognitive test performance;
LUSC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.74	-13.08	-0.58	7.37e-32	Personality dimensions;
LUSC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg06238570	chr21:40685208	BRWD1	0.47	7.29	0.37	2.23e-12	Cognitive function;
LUSC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg11102782	chr19:18549136	ISYNA1	0.32	6.09	0.32	3.07e-9	Breast cancer;
LUSC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg18402987	chr7:1209562	NA	0.73	7.84	0.39	5.91e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs59104589	0.550	rs12612038	chr2:242369685	A/G	cg14842376	chr2:242211374	HDLBP	0.52	6.05	0.31	3.97e-9	Fibrinogen levels;
LUSC	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg00484396	chr16:3507460	NAT15	0.49	7.34	0.37	1.6e-12	Body mass index (adult);
LUSC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs12912251	0.947	rs12898460	chr15:38986813	C/T	cg01338139	chr15:38987640	C15orf53	-0.48	-6.45	-0.33	3.95e-10	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LUSC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.59	9.2	0.45	3.9e-18	Iron status biomarkers;
LUSC	cis	rs7759001	0.857	rs6923539	chr6:27362483	C/A	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.46	7.05	0.36	1.01e-11	Endometrial cancer;
LUSC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.59	0.5	8.68e-23	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6977660	0.652	rs10275246	chr7:19851059	G/A	cg11717054	chr11:279423	NLRP6	-0.54	-6.18	-0.32	1.92e-9	Thyroid stimulating hormone;
LUSC	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg24130564	chr14:104152367	KLC1	-0.48	-7.05	-0.36	1.01e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg16240275	chr20:61666158	NCRNA00029	0.42	9.39	0.46	9.76e-19	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg14558114	chr2:88469736	THNSL2	0.8	7.13	0.36	6.19e-12	Plasma clusterin levels;
LUSC	cis	rs970548	0.688	rs2082110	chr10:45931070	A/G	cg23750895	chr10:46321377	AGAP4	-0.55	-5.68	-0.3	2.93e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg13175981	chr1:150552382	MCL1	0.46	6.29	0.33	9.94e-10	Tonsillectomy;
LUSC	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.24	0.32	1.36e-9	Corneal astigmatism;
LUSC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg06096015	chr1:231504339	EGLN1	0.57	10.02	0.48	7.5e-21	Hemoglobin concentration;
LUSC	cis	rs2629540	0.793	rs10794180	chr10:126449306	T/A	cg08799069	chr10:126477246	METTL10	-0.7	-10.56	-0.5	1.12e-22	Cocaine dependence;
LUSC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg22823121	chr1:150693482	HORMAD1	0.49	7.13	0.36	6.37e-12	Melanoma;
LUSC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.06	0.61	1.38e-35	Platelet count;
LUSC	cis	rs2387326	0.717	rs10829343	chr10:129944496	T/C	cg16087940	chr10:129947807	NA	-0.39	-6.0	-0.31	5e-9	Select biomarker traits;
LUSC	trans	rs57046232	0.552	rs4402836	chr20:6338026	G/A	cg17788362	chr6:86352627	SYNCRIP	0.42	5.97	0.31	5.94e-9	Colorectal cancer;
LUSC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg13798912	chr7:905769	UNC84A	-0.58	-5.83	-0.3	1.29e-8	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7615316	0.789	rs2862743	chr3:142112572	C/T	cg16271453	chr3:142027066	XRN1	-0.37	-6.54	-0.34	2.3e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.94	-19.27	-0.73	3.78e-56	Post bronchodilator FEV1;
LUSC	cis	rs9929218	0.954	rs7198799	chr16:68818390	C/T	cg02972257	chr16:68554789	NA	0.42	5.77	0.3	1.86e-8	Colorectal cancer;
LUSC	trans	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg10756647	chr7:56101905	PSPH	0.88	8.91	0.44	3.39e-17	Diabetic kidney disease;
LUSC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg13939156	chr17:80058883	NA	0.34	6.85	0.35	3.54e-11	Life satisfaction;
LUSC	cis	rs968451	0.526	rs5757617	chr22:39722714	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.77	12.43	0.56	2.02e-29	Primary biliary cholangitis;
LUSC	trans	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg26043149	chr18:55253948	FECH	0.46	6.8	0.35	4.9e-11	Bone mineral density;
LUSC	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg15468180	chr1:107600409	PRMT6	-0.39	-6.25	-0.32	1.24e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs6736093	0.966	rs870763	chr2:112745481	C/T	cg12686935	chr2:112915763	FBLN7	0.37	5.96	0.31	6.57e-9	Coronary artery disease;
LUSC	cis	rs7264396	0.836	rs961020	chr20:34182069	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-7.51	-0.38	5.55e-13	Total cholesterol levels;
LUSC	cis	rs7809950	0.678	rs2237661	chr7:106863123	T/C	cg23024343	chr7:107201750	COG5	-0.66	-9.34	-0.46	1.35e-18	Coronary artery disease;
LUSC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg13010199	chr12:38710504	ALG10B	0.67	10.16	0.49	2.56e-21	Bladder cancer;
LUSC	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.4	-0.38	1.14e-12	Neuroticism;
LUSC	cis	rs9297145	0.585	rs13235218	chr7:98785080	C/T	cg05967295	chr7:98741636	SMURF1	-0.61	-9.27	-0.45	2.45e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26314531	chr2:26401878	FAM59B	-0.69	-9.28	-0.45	2.17e-18	Gut microbiome composition (summer);
LUSC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.21	-13.88	-0.6	6.79e-35	Diabetic kidney disease;
LUSC	cis	rs12049330	0.825	rs7536292	chr1:109894693	A/G	cg05049280	chr1:110155535	GNAT2	0.4	5.91	0.31	8.38e-9	Major depressive disorder;
LUSC	cis	rs6977660	0.943	rs10249996	chr7:19844935	G/A	cg05791153	chr7:19748676	TWISTNB	0.55	6.21	0.32	1.6e-9	Thyroid stimulating hormone;
LUSC	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg09835421	chr16:68378352	PRMT7	-0.58	-6.1	-0.32	2.87e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg24006582	chr15:45444508	DUOX1	-0.6	-8.77	-0.43	9.28e-17	Uric acid levels;
LUSC	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg20848291	chr7:100343083	ZAN	0.39	6.14	0.32	2.33e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg01579765	chr21:45077557	HSF2BP	0.53	11.09	0.52	1.49e-24	Mean corpuscular volume;
LUSC	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg13010199	chr12:38710504	ALG10B	0.65	9.84	0.47	3.13e-20	Bladder cancer;
LUSC	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg17509989	chr5:176798049	RGS14	-0.67	-10.62	-0.5	7.02e-23	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg05283184	chr6:79620031	NA	-0.47	-8.98	-0.44	2.04e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs6120849	0.754	rs6088678	chr20:33607551	A/G	cg24642439	chr20:33292090	TP53INP2	-0.6	-6.59	-0.34	1.71e-10	Protein C levels;
LUSC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg19748678	chr4:122722346	EXOSC9	0.48	7.29	0.37	2.21e-12	Type 2 diabetes;
LUSC	cis	rs4964805	0.594	rs751448	chr12:104167185	C/T	cg02344784	chr12:104178138	NT5DC3	0.37	5.94	0.31	7.07e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs136211	0.599	rs9610497	chr22:36767359	C/T	cg16924664	chr22:36878180	TXN2	0.41	6.15	0.32	2.22e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7215564	0.818	rs78905718	chr17:78604278	G/A	cg09596252	chr17:78655493	RPTOR	0.55	6.28	0.32	1.06e-9	Myopia (pathological);
LUSC	trans	rs17683430	0.702	rs61742196	chr22:32369435	C/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs354225	0.615	rs12713274	chr2:54848728	C/T	cg01766943	chr2:54829624	SPTBN1	-0.43	-7.23	-0.37	3.4e-12	Schizophrenia;
LUSC	trans	rs61931739	0.620	rs815052	chr12:33727270	C/A	cg26384229	chr12:38710491	ALG10B	0.42	6.17	0.32	1.97e-9	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08736216	chr1:53307985	ZYG11A	-0.29	-5.93	-0.31	7.48e-9	Monocyte count;
LUSC	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg03465714	chr1:152285911	FLG	-0.42	-5.79	-0.3	1.64e-8	Atopic dermatitis;
LUSC	trans	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-6.46	-0.33	3.74e-10	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-8.73	-0.43	1.28e-16	Obesity-related traits;
LUSC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg06640241	chr16:89574553	SPG7	-0.86	-15.87	-0.66	1.11e-42	Multiple myeloma (IgH translocation);
LUSC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg06454157	chr6:167490870	NA	-0.28	-6.85	-0.35	3.67e-11	Primary biliary cholangitis;
LUSC	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg07636037	chr3:49044803	WDR6	0.55	5.69	0.3	2.82e-8	Menarche (age at onset);
LUSC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03517284	chr6:25882590	NA	0.66	11.45	0.53	7.59e-26	Blood metabolite levels;
LUSC	cis	rs2108225	0.872	rs2051954	chr7:107441097	G/C	cg18560240	chr7:107437656	SLC26A3	-0.44	-6.57	-0.34	1.9e-10	Ulcerative colitis;
LUSC	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.66	-9.39	-0.46	9.8e-19	Metabolic syndrome;
LUSC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg02782426	chr3:40428986	ENTPD3	0.33	6.08	0.32	3.26e-9	Renal cell carcinoma;
LUSC	cis	rs7605827	0.930	rs2380649	chr2:15532612	A/C	cg19274914	chr2:15703543	NA	0.45	8.86	0.44	4.75e-17	Educational attainment (years of education);
LUSC	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.49	7.93	0.4	3.41e-14	Schizophrenia;
LUSC	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg24631222	chr15:78858424	CHRNA5	0.65	8.65	0.43	2.2e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	trans	rs12987465	0.545	rs116021360	chr2:49708739	G/T	cg08691775	chr8:134310658	NDRG1	-0.35	-6.0	-0.31	5.13e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide);
LUSC	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.48	-6.62	-0.34	1.45e-10	Corneal astigmatism;
LUSC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18854424	chr1:2615690	NA	-0.52	-10.59	-0.5	8.5e-23	Ulcerative colitis;
LUSC	cis	rs12348691	0.503	rs1348386	chr9:100612807	A/G	cg13688889	chr9:100608707	NA	-0.75	-11.91	-0.55	1.72e-27	Alopecia areata;
LUSC	trans	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg05839875	chr5:39203190	FYB	-0.32	-6.03	-0.31	4.39e-9	Prostate cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12385672	chr10:18940645	NSUN6	-0.41	-6.03	-0.31	4.25e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg05729581	chr11:3078854	CARS	0.53	8.34	0.41	2.04e-15	Longevity;
LUSC	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72634258	0.519	rs744001	chr1:7934557	G/A	cg26816564	chr1:7831052	VAMP3	0.73	9.49	0.46	4.48e-19	Inflammatory bowel disease;
LUSC	cis	rs6500395	0.775	rs28481630	chr16:48663664	G/C	cg04672837	chr16:48644449	N4BP1	0.47	6.97	0.36	1.73e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg23575115	chr20:49348591	PARD6B	-0.45	-5.97	-0.31	6.05e-9	Hepatitis;
LUSC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21963583	chr11:68658836	MRPL21	0.54	8.24	0.41	4.03e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg14433983	chr11:636460	DRD4	-0.35	-5.88	-0.31	9.78e-9	Systemic lupus erythematosus;
LUSC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	13.56	0.6	1.12e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-9.78	-0.47	4.92e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg26338869	chr17:61819248	STRADA	0.42	6.1	0.32	2.96e-9	Prudent dietary pattern;
LUSC	cis	rs9905704	0.918	rs4132924	chr17:56937653	C/T	cg12560992	chr17:57184187	TRIM37	0.57	8.05	0.4	1.47e-14	Testicular germ cell tumor;
LUSC	cis	rs1881396	0.891	rs62131879	chr2:27755112	T/G	cg27432699	chr2:27873401	GPN1	0.68	9.27	0.45	2.3e-18	Nonalcoholic fatty liver disease;
LUSC	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20135002	chr11:47629003	NA	0.49	7.8	0.39	8.06e-14	Subjective well-being;
LUSC	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg05855489	chr10:104503620	C10orf26	0.52	7.88	0.4	4.72e-14	Arsenic metabolism;
LUSC	cis	rs2742234	0.541	rs7096500	chr10:43712095	C/T	cg15436174	chr10:43711423	RASGEF1A	0.44	7.06	0.36	9.75e-12	Hirschsprung disease;
LUSC	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg07936489	chr17:37558343	FBXL20	0.72	9.96	0.48	1.28e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs926938	0.527	rs7526844	chr1:115543759	T/C	cg01522456	chr1:115632236	TSPAN2	-0.41	-6.35	-0.33	6.93e-10	Autism;
LUSC	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg02466173	chr16:30829666	NA	-0.68	-16.25	-0.66	3.57e-44	Dementia with Lewy bodies;
LUSC	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	ch.11.42038R	chr11:967971	AP2A2	0.5	7.29	0.37	2.22e-12	Alzheimer's disease (late onset);
LUSC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg02782426	chr3:40428986	ENTPD3	-0.31	-6.14	-0.32	2.28e-9	Renal cell carcinoma;
LUSC	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-9.36	-0.46	1.21e-18	Coffee consumption (cups per day);
LUSC	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg14019146	chr3:50243930	SLC38A3	-0.48	-11.09	-0.52	1.5e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.69	-0.34	9.66e-11	Systolic blood pressure;
LUSC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg23711669	chr6:146136114	FBXO30	0.9	16.54	0.67	2.68e-45	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg02269571	chr22:50332266	NA	0.59	7.57	0.38	3.67e-13	Schizophrenia;
LUSC	cis	rs977987	0.815	rs1364078	chr16:75396881	T/C	cg04384234	chr16:75411784	CFDP1	-0.45	-7.5	-0.38	5.83e-13	Dupuytren's disease;
LUSC	cis	rs10186029	0.676	rs35922168	chr2:213949018	T/C	cg08319019	chr2:214017104	IKZF2	0.61	9.03	0.44	1.37e-17	Systemic sclerosis;
LUSC	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg17764715	chr19:33622953	WDR88	0.59	8.01	0.4	1.99e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg21775007	chr8:11205619	TDH	0.42	5.89	0.31	9.33e-9	Neuroticism;
LUSC	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg04362960	chr10:104952993	NT5C2	-0.6	-9.79	-0.47	4.69e-20	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg11317459	chr13:21872234	NA	1.14	15.42	0.64	7.01e-41	White matter hyperintensity burden;
LUSC	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg13390004	chr1:15929781	NA	0.41	6.9	0.35	2.6e-11	Systolic blood pressure;
LUSC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg26924012	chr15:45694286	SPATA5L1	1.14	20.94	0.75	9e-63	Homoarginine levels;
LUSC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg12863693	chr15:85201151	NMB	0.34	6.78	0.35	5.49e-11	Schizophrenia;
LUSC	cis	rs1256061	0.654	rs1256033	chr14:64745399	A/G	cg21174375	chr14:64681225	SYNE2	0.34	6.19	0.32	1.75e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	trans	rs2262909	0.962	rs401424	chr19:22232023	A/G	cg05197062	chr11:11642011	GALNTL4	-0.49	-6.9	-0.35	2.67e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg26408565	chr15:76604113	ETFA	-0.49	-7.88	-0.4	4.81e-14	Blood metabolite levels;
LUSC	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg23241863	chr10:102295624	HIF1AN	0.49	5.7	0.3	2.69e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6066835	1.000	rs6095244	chr20:47318774	T/C	cg18078177	chr20:47281410	PREX1	0.71	5.96	0.31	6.29e-9	Multiple myeloma;
LUSC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg11344533	chr11:111475393	SIK2	0.48	6.45	0.33	3.92e-10	Primary sclerosing cholangitis;
LUSC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg18230493	chr5:56204884	C5orf35	-1.0	-15.35	-0.64	1.32e-40	Initial pursuit acceleration;
LUSC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg07424592	chr7:64974309	NA	0.64	5.73	0.3	2.2e-8	Diabetic kidney disease;
LUSC	cis	rs7072216	0.763	rs10732782	chr10:100166506	C/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-8.99	-0.44	1.93e-17	Metabolite levels;
LUSC	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.69	-0.43	1.64e-16	Uric acid levels;
LUSC	cis	rs2637266	0.935	rs2583050	chr10:78403615	C/T	cg18941641	chr10:78392320	NA	0.42	7.62	0.38	2.67e-13	Pulmonary function;
LUSC	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg16482183	chr6:26056742	HIST1H1C	0.66	9.2	0.45	3.85e-18	Iron status biomarkers;
LUSC	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.61	-9.72	-0.47	7.65e-20	Schizophrenia;
LUSC	cis	rs68170813	0.559	rs3801963	chr7:106898036	C/T	cg02696742	chr7:106810147	HBP1	-0.63	-9.64	-0.47	1.44e-19	Coronary artery disease;
LUSC	cis	rs2835872	0.733	rs2850124	chr21:39036763	T/A	cg20424643	chr21:39039972	KCNJ6	-0.43	-7.24	-0.37	3.08e-12	Electroencephalographic traits in alcoholism;
LUSC	trans	rs10510217	0.872	rs73820109	chr3:1820057	T/C	cg22108469	chr5:174158984	NA	-0.42	-6.03	-0.31	4.42e-9	Total ventricular volume;
LUSC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.44	0.76	1e-64	Prudent dietary pattern;
LUSC	trans	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg25214090	chr10:38739885	LOC399744	0.39	6.05	0.31	3.83e-9	Diastolic blood pressure;
LUSC	cis	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg21775007	chr8:11205619	TDH	0.46	6.55	0.34	2.18e-10	Myopia (pathological);
LUSC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.39	6.34	0.33	7.52e-10	Testicular germ cell tumor;
LUSC	cis	rs4889855	0.530	rs4889863	chr17:78550468	C/T	cg16591659	chr17:78472290	NA	-0.33	-6.11	-0.32	2.75e-9	Fractional excretion of uric acid;
LUSC	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	0.99	14.88	0.63	9.02e-39	Triglycerides;
LUSC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg05738196	chr6:26577821	NA	0.82	15.84	0.66	1.47e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs9341808	0.530	rs3805876	chr6:81031539	C/A	cg08355045	chr6:80787529	NA	0.51	8.89	0.44	3.84e-17	Sitting height ratio;
LUSC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06112835	chr11:68658793	MRPL21	0.51	7.81	0.39	7.61e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg20701182	chr2:24300061	SF3B14	0.6	6.32	0.33	8.22e-10	Lymphocyte counts;
LUSC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.83	13.89	0.61	6.12e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg14789911	chr21:47582049	C21orf56	-0.4	-6.3	-0.33	9.43e-10	Testicular germ cell tumor;
LUSC	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg08085267	chr17:45401833	C17orf57	-0.47	-6.62	-0.34	1.47e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	7.95	0.4	2.86e-14	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs757081	0.667	rs34724588	chr11:17137581	T/C	cg15432903	chr11:17409602	KCNJ11	-0.39	-6.1	-0.32	2.97e-9	Systolic blood pressure;
LUSC	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.84	-0.35	3.68e-11	Monocyte percentage of white cells;
LUSC	cis	rs7944584	0.655	rs2856653	chr11:47361084	T/C	cg20307385	chr11:47447363	PSMC3	-0.71	-10.97	-0.51	4.04e-24	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	trans	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs12220238	0.730	rs10740421	chr10:75941002	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.58	6.79	0.35	5.25e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs654950	0.783	rs668359	chr1:42003425	A/C	cg06885757	chr1:42089581	HIVEP3	-0.41	-8.0	-0.4	2e-14	Airway imaging phenotypes;
LUSC	cis	rs6426558	0.537	rs1320494	chr1:227241300	A/T	cg10327440	chr1:227177885	CDC42BPA	0.55	7.43	0.38	9.42e-13	Neutrophil percentage of white cells;
LUSC	cis	rs6429082	0.764	rs291369	chr1:235691913	T/C	cg26050004	chr1:235667680	B3GALNT2	0.6	7.98	0.4	2.36e-14	Adiposity;
LUSC	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg04896959	chr15:78267971	NA	-0.44	-8.72	-0.43	1.3e-16	Coronary artery disease or large artery stroke;
LUSC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg25019033	chr10:957182	NA	-0.52	-6.58	-0.34	1.82e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs7178572	0.568	rs8037561	chr15:77680462	A/G	cg22256960	chr15:77711686	NA	-0.5	-7.92	-0.4	3.57e-14	Type 2 diabetes;
LUSC	trans	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.21	-0.32	1.59e-9	Bladder cancer;
LUSC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.35	-5.83	-0.3	1.28e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg24060327	chr5:131705240	SLC22A5	-0.51	-8.5	-0.42	6.24e-16	Breast cancer;
LUSC	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg00129232	chr17:37814104	STARD3	-0.43	-6.25	-0.32	1.26e-9	Asthma;
LUSC	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.54	7.33	0.37	1.78e-12	Multiple sclerosis;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg16538604	chr4:2010703	WHSC2	-0.52	-6.41	-0.33	4.88e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs68170813	0.652	rs76742243	chr7:107144202	G/A	cg02696742	chr7:106810147	HBP1	-0.64	-8.62	-0.43	2.79e-16	Coronary artery disease;
LUSC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7916697	0.947	rs56238729	chr10:70001640	T/C	cg06988349	chr10:69991859	ATOH7	0.33	5.81	0.3	1.47e-8	Optic disc area;
LUSC	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.53	-10.56	-0.5	1.14e-22	Glomerular filtration rate (creatinine);
LUSC	trans	rs1864729	1.000	rs2567769	chr8:98297848	G/A	cg08679828	chr8:102218111	ZNF706	-0.8	-6.47	-0.33	3.47e-10	Estradiol plasma levels (breast cancer);
LUSC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg17294928	chr15:75287854	SCAMP5	0.41	5.93	0.31	7.62e-9	Breast cancer;
LUSC	cis	rs10276381	1.000	rs7796417	chr7:28186119	G/C	cg23620719	chr7:28220237	JAZF1	0.59	6.55	0.34	2.15e-10	Crohn's disease;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg04319882	chr16:19535207	CP110	0.44	5.99	0.31	5.57e-9	Neuroticism;
LUSC	trans	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.9	0.48	1.97e-20	Mean corpuscular volume;
LUSC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg09034736	chr1:150693464	HORMAD1	0.45	6.42	0.33	4.74e-10	Melanoma;
LUSC	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.63	10.18	0.49	2.26e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg19318889	chr4:1322082	MAEA	0.47	7.67	0.39	1.93e-13	Obesity-related traits;
LUSC	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg21045802	chr8:109455806	TTC35	0.42	6.58	0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg23791538	chr6:167370224	RNASET2	-0.42	-6.79	-0.35	5.12e-11	Crohn's disease;
LUSC	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.69	-0.43	1.71e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19539318	chr2:172544773	DYNC1I2	-0.44	-6.4	-0.33	5.17e-10	Electrocardiographic conduction measures;
LUSC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10779751	0.879	rs7543400	chr1:11283964	C/G	cg08854313	chr1:11322531	MTOR	0.93	15.93	0.66	6.78e-43	Body mass index;
LUSC	trans	rs931812	0.895	rs4734016	chr8:101910071	C/T	cg20993868	chr7:22813445	NA	0.66	11.99	0.55	8.97e-28	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs983392	0.805	rs11230184	chr11:59965789	G/A	cg24026212	chr11:59952134	MS4A6A	-0.36	-6.16	-0.32	2.09e-9	Alzheimer's disease (late onset);
LUSC	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg16342193	chr10:102329863	NA	-0.35	-6.39	-0.33	5.63e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7605827	0.930	rs7568678	chr2:15596203	C/T	cg19274914	chr2:15703543	NA	0.49	8.7	0.43	1.56e-16	Educational attainment (years of education);
LUSC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg04896959	chr15:78267971	NA	-0.52	-11.52	-0.53	4.38e-26	Diastolic blood pressure;
LUSC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg22535103	chr8:58192502	C8orf71	-0.76	-7.99	-0.4	2.26e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs11209002	0.915	rs6588240	chr1:67577367	A/T	cg02640540	chr1:67518911	SLC35D1	0.69	7.59	0.38	3.25e-13	Crohn's disease;
LUSC	cis	rs6815814	0.861	rs10012017	chr4:38784633	G/T	cg06935464	chr4:38784597	TLR10	0.46	5.87	0.31	1.07e-8	Breast cancer;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg17648537	chr2:86333281	PTCD3;POLR1A	0.42	6.38	0.33	5.88e-10	Asthma;
LUSC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg17376030	chr22:41985996	PMM1	-0.48	-6.04	-0.31	4.06e-9	Vitiligo;
LUSC	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg15212455	chr7:39170539	POU6F2	0.6	9.99	0.48	9.71e-21	IgG glycosylation;
LUSC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18402987	chr7:1209562	NA	0.42	5.65	0.3	3.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.69	10.1	0.48	4.13e-21	Corneal astigmatism;
LUSC	trans	rs984440	0.922	rs7008947	chr8:139075668	G/A	cg03334052	chr1:168888044	NA	-0.44	-6.05	-0.31	3.85e-9	Obesity-related traits;
LUSC	cis	rs418053	0.657	rs204222	chr6:13697476	C/T	cg02206980	chr6:13574034	SIRT5	-0.3	-6.16	-0.32	2.14e-9	Breast cancer;
LUSC	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg04545296	chr12:48745243	ZNF641	-0.33	-6.21	-0.32	1.61e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.01	-0.4	1.95e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg23752985	chr2:85803571	VAMP8	0.33	7.06	0.36	9.68e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06634786	chr22:41940651	POLR3H	0.53	6.3	0.33	9.27e-10	Vitiligo;
LUSC	cis	rs7590720	1.000	rs7590720	chr2:216898658	A/G	cg12620499	chr2:216877984	MREG	-0.92	-14.51	-0.62	2.51e-37	Alcohol dependence;
LUSC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg06784218	chr1:46089804	CCDC17	-0.51	-9.49	-0.46	4.39e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg12748703	chr10:97453984	TCTN3	0.42	6.26	0.32	1.19e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	8.0	0.4	2.06e-14	Joint mobility (Beighton score);
LUSC	cis	rs13315871	1.000	rs13096020	chr3:58367771	G/A	cg20936604	chr3:58311152	NA	-0.63	-5.85	-0.31	1.15e-8	Cholesterol, total;
LUSC	cis	rs789859	1.000	rs789859	chr3:194405888	G/T	cg02072170	chr3:194406190	FAM43A	0.36	7.62	0.38	2.62e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs9303542	0.592	rs34378400	chr17:46589265	A/G	cg09704116	chr17:46666958	LOC404266	-0.37	-6.67	-0.34	1.07e-10	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg00409905	chr10:38381863	ZNF37A	0.35	5.94	0.31	7.29e-9	Extrinsic epigenetic age acceleration;
LUSC	trans	rs4940203	0.625	rs67502388	chr18:50226678	G/C	cg14465628	chr9:98125437	NA	0.3	6.08	0.32	3.25e-9	Obesity-related traits;
LUSC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg16584290	chr5:462447	EXOC3	0.47	8.38	0.42	1.53e-15	Cystic fibrosis severity;
LUSC	trans	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg14791747	chr16:20752902	THUMPD1	0.43	6.13	0.32	2.45e-9	Pancreatic cancer;
LUSC	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.52	3.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12140468	chr1:234509341	C1orf31	-0.4	-6.15	-0.32	2.16e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg14664628	chr15:75095509	CSK	-0.81	-11.95	-0.55	1.18e-27	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	0.86	15.46	0.65	4.6e-41	Bone mineral density;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19701416	chr10:28592092	NA	0.44	6.79	0.35	5.24e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg13535736	chr9:111863775	C9orf5	-0.42	-6.98	-0.36	1.56e-11	Menarche (age at onset);
LUSC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.94	-0.31	7.19e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9400467	0.528	rs17539197	chr6:111769171	C/G	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-7.07	-0.36	9.2e-12	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs9815354	0.680	rs73073294	chr3:42028053	A/G	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9535307	0.615	rs3736830	chr13:50306221	G/C	cg04663916	chr13:50265991	EBPL	0.49	6.14	0.32	2.33e-9	Obesity-related traits;
LUSC	cis	rs4363385	0.818	rs9659389	chr1:152989844	T/C	cg25856811	chr1:152973957	SPRR3	-0.35	-5.75	-0.3	2e-8	Inflammatory skin disease;
LUSC	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg11645453	chr3:52864694	ITIH4	-0.39	-8.95	-0.44	2.56e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-0.8	-15.66	-0.65	7.98e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg09035930	chr12:129282057	SLC15A4	0.76	15.73	0.65	4e-42	Systemic lupus erythematosus;
LUSC	cis	rs354225	0.544	rs3796017	chr2:54807452	T/A	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg22903471	chr2:27725779	GCKR	-0.41	-6.85	-0.35	3.6e-11	Total body bone mineral density;
LUSC	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg00012203	chr2:219082015	ARPC2	0.57	8.66	0.43	2.05e-16	Colorectal cancer;
LUSC	cis	rs10463316	0.894	rs6891252	chr5:150762807	G/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.56	-0.38	3.88e-13	Metabolite levels (Pyroglutamine);
LUSC	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg13010199	chr12:38710504	ALG10B	0.51	7.61	0.38	2.8e-13	Bladder cancer;
LUSC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	13.25	0.59	1.67e-32	Chronic sinus infection;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06808467	chr18:5237767	LOC339290;C18orf18	0.48	8.46	0.42	8.21e-16	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg04155289	chr7:94953770	PON1	-0.34	-5.77	-0.3	1.8e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg24633833	chr3:10029261	TMEM111	0.45	5.89	0.31	9.42e-9	Alzheimer's disease;
LUSC	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg13010199	chr12:38710504	ALG10B	0.65	9.91	0.48	1.78e-20	Bladder cancer;
LUSC	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg26384229	chr12:38710491	ALG10B	0.85	13.47	0.59	2.51e-33	Bladder cancer;
LUSC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18932078	chr1:2524107	MMEL1	0.31	6.93	0.35	2.21e-11	Ulcerative colitis;
LUSC	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22496380	chr5:211416	CCDC127	-0.87	-8.93	-0.44	2.83e-17	Breast cancer;
LUSC	cis	rs7172677	1.000	rs55662404	chr15:75432341	G/A	cg14664628	chr15:75095509	CSK	0.45	5.79	0.3	1.6e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg24375607	chr4:120327624	NA	0.67	10.2	0.49	1.94e-21	Corneal astigmatism;
LUSC	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.48	-7.09	-0.36	8.27e-12	Neutrophil percentage of white cells;
LUSC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg07716408	chr11:68623521	NA	-0.3	-5.78	-0.3	1.75e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs478607	0.748	rs61884413	chr11:64459406	C/T	cg19131476	chr11:64387923	NRXN2	0.33	5.82	0.3	1.35e-8	Urate levels;
LUSC	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg17724175	chr1:150552817	MCL1	-0.35	-6.13	-0.32	2.45e-9	Tonsillectomy;
LUSC	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.41	-6.17	-0.32	2e-9	Depressive symptoms;
LUSC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg18758796	chr5:131593413	PDLIM4	0.41	6.76	0.35	6.13e-11	Breast cancer;
LUSC	trans	rs800082	0.516	rs7611932	chr3:144200593	A/G	cg24215973	chr2:240111563	HDAC4	0.45	6.77	0.35	5.79e-11	Smoking behavior;
LUSC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg06637938	chr14:75390232	RPS6KL1	0.52	8.33	0.41	2.08e-15	Height;
LUSC	cis	rs3092073	0.617	rs8123864	chr20:44598670	T/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.37	-5.86	-0.31	1.12e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-6.14	-0.32	2.39e-9	Crohn's disease;
LUSC	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg27446573	chr6:127587934	RNF146	0.71	10.97	0.51	4.17e-24	Breast cancer;
LUSC	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg10802521	chr3:52805072	NEK4	-0.47	-7.25	-0.37	2.89e-12	Electroencephalogram traits;
LUSC	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg13390004	chr1:15929781	NA	0.41	6.9	0.35	2.66e-11	Systolic blood pressure;
LUSC	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg03929089	chr4:120376271	NA	0.7	7.63	0.39	2.45e-13	Axial length;
LUSC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.88	-0.4	4.66e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs4654899	0.865	rs10916951	chr1:21528835	A/G	cg02927042	chr1:21476669	EIF4G3	0.38	6.13	0.32	2.44e-9	Superior frontal gyrus grey matter volume;
LUSC	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg19046167	chr17:80928561	B3GNTL1	-0.42	-5.93	-0.31	7.39e-9	Breast cancer;
LUSC	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	1.11	24.53	0.8	1.07e-76	Schizophrenia;
LUSC	trans	rs2587949	0.571	rs2600138	chr3:4208596	G/C	cg15139668	chr4:4577005	NA	-0.41	-5.98	-0.31	5.65e-9	Periodontitis (DPAL);
LUSC	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg22532475	chr10:104410764	TRIM8	-0.32	-7.11	-0.36	6.97e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	9.64	0.47	1.44e-19	Personality dimensions;
LUSC	cis	rs6750047	0.567	rs336039	chr2:38258827	C/T	cg07380506	chr2:38303506	CYP1B1	-0.4	-5.78	-0.3	1.67e-8	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs6967385	0.560	rs55794302	chr7:12351495	C/A	cg20607287	chr7:12443886	VWDE	0.5	7.46	0.38	7.34e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg17462356	chr17:80056334	FASN	0.45	5.67	0.3	3.17e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs3755132	0.852	rs60319313	chr2:15792803	C/A	cg12888861	chr2:15731646	DDX1	0.49	7.11	0.36	7.08e-12	Wilms tumor;
LUSC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg06221963	chr1:154839813	KCNN3	-0.44	-8.94	-0.44	2.77e-17	Schizophrenia;
LUSC	cis	rs3812762	0.871	rs11042068	chr11:8815599	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-6.23	-0.32	1.39e-9	Hypospadias;
LUSC	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg07382826	chr16:28625726	SULT1A1	0.28	6.07	0.32	3.47e-9	Body mass index;
LUSC	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.41	-5.64	-0.3	3.56e-8	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg04369109	chr6:150039330	LATS1	-0.56	-8.17	-0.41	6.41e-15	Lung cancer;
LUSC	cis	rs2282300	0.739	rs1765133	chr11:30339400	C/T	cg25418670	chr11:30344373	C11orf46	-0.64	-9.18	-0.45	4.6e-18	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08280861	chr8:58055591	NA	0.52	5.69	0.3	2.76e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2067615	0.579	rs1922435	chr12:107082455	A/G	cg15890332	chr12:107067104	RFX4	0.35	5.91	0.31	8.22e-9	Heart rate;
LUSC	cis	rs6574644	1.000	rs55744181	chr14:81777794	A/G	cg01989461	chr14:81687754	GTF2A1	0.47	5.69	0.3	2.75e-8	Obesity-related traits;
LUSC	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.59	0.43	3.48e-16	Response to antipsychotic treatment;
LUSC	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	cis	rs7586879	0.796	rs916486	chr2:25082629	C/A	cg01884057	chr2:25150051	NA	0.39	7.93	0.4	3.42e-14	Body mass index;
LUSC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg11764359	chr7:65958608	NA	-0.52	-6.81	-0.35	4.44e-11	Aortic root size;
LUSC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg01765077	chr12:122356316	WDR66	0.51	7.44	0.38	8.68e-13	Mean corpuscular volume;
LUSC	cis	rs62408225	1.000	rs2021716	chr6:90941289	C/T	cg06866423	chr6:90926672	BACH2	0.41	5.96	0.31	6.44e-9	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs7939886	0.920	rs7115395	chr11:55877116	G/A	cg03929089	chr4:120376271	NA	0.75	6.12	0.32	2.65e-9	Myopia (pathological);
LUSC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.79	12.72	0.57	1.76e-30	Aortic root size;
LUSC	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	7.08	0.36	8.37e-12	Response to antipsychotic treatment;
LUSC	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg07741184	chr6:167504864	NA	0.45	7.72	0.39	1.38e-13	Crohn's disease;
LUSC	trans	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg19249749	chr1:223853145	CAPN8	-0.49	-6.23	-0.32	1.38e-9	Gut microbiome composition (summer);
LUSC	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg17517138	chr11:73019481	ARHGEF17	1.09	9.0	0.44	1.69e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-0.81	-11.22	-0.52	5.06e-25	Diastolic blood pressure;
LUSC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg12463550	chr7:65579703	CRCP	0.45	6.73	0.35	7.31e-11	Aortic root size;
LUSC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg11247378	chr22:39784982	NA	-0.65	-12.51	-0.56	1.02e-29	Intelligence (multi-trait analysis);
LUSC	cis	rs7759001	0.857	rs1022517	chr6:27365009	G/C	cg18711553	chr6:27366782	ZNF391	0.39	5.71	0.3	2.48e-8	Glomerular filtration rate (creatinine);
LUSC	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg21153622	chr11:89784906	NA	-0.39	-6.04	-0.31	4.09e-9	HDL cholesterol;
LUSC	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.36	-0.42	1.75e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.7	10.89	0.51	7.54e-24	Aortic root size;
LUSC	cis	rs6987853	0.933	rs2923430	chr8:42391195	T/C	cg09913449	chr8:42400586	C8orf40	0.49	8.23	0.41	4.31e-15	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg05650458	chr1:228270764	ARF1	0.41	6.79	0.35	5.14e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs12956009	0.518	rs953291	chr18:44870499	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.41	0.33	5.01e-10	Educational attainment (years of education);
LUSC	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg00310523	chr12:86230176	RASSF9	0.49	9.26	0.45	2.64e-18	Major depressive disorder;
LUSC	trans	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg12856521	chr11:46389249	DGKZ	0.42	6.59	0.34	1.7e-10	Leprosy;
LUSC	cis	rs9905704	0.681	rs4793949	chr17:56571950	C/T	cg12560992	chr17:57184187	TRIM37	0.48	5.86	0.31	1.11e-8	Testicular germ cell tumor;
LUSC	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.78	11.81	0.54	3.85e-27	Heart rate;
LUSC	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.7	-11.75	-0.54	6.61e-27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4917833	0.789	rs10883100	chr10:100219374	T/A	cg19043522	chr10:100227446	HPSE2	0.4	5.71	0.3	2.53e-8	Pediatric bone mineral density (femoral neck);
LUSC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg11062466	chr8:58055876	NA	0.71	8.69	0.43	1.62e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg13699009	chr12:122356056	WDR66	0.49	7.6	0.38	2.95e-13	Mean corpuscular volume;
LUSC	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg00129232	chr17:37814104	STARD3	-0.55	-8.28	-0.41	3.03e-15	Asthma;
LUSC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	10.92	0.51	6.24e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08677398	chr8:58056175	NA	0.5	6.66	0.34	1.13e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg01420254	chr6:26195488	NA	0.66	7.31	0.37	2.05e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs1808579	0.904	rs2960578	chr18:21143739	A/C	cg14672496	chr18:21087552	C18orf8	0.36	6.26	0.32	1.18e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg05025164	chr4:1340916	KIAA1530	0.46	7.06	0.36	9.49e-12	Longevity;
LUSC	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.58	-9.05	-0.44	1.22e-17	Menarche (age at onset);
LUSC	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg26384229	chr12:38710491	ALG10B	0.49	6.98	0.36	1.57e-11	Morning vs. evening chronotype;
LUSC	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.56	0.42	4.16e-16	Response to antipsychotic treatment;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg22463517	chr17:26988906	SDF2;SUPT6H	0.44	6.28	0.32	1.07e-9	Cognitive function;Information processing speed;
LUSC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.46	8.24	0.41	3.92e-15	Coronary artery disease;
LUSC	cis	rs7703051	0.513	rs6895057	chr5:74624234	G/A	cg00601450	chr5:74908170	NA	-0.32	-5.76	-0.3	1.88e-8	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LUSC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg22907277	chr7:1156413	C7orf50	0.71	10.38	0.49	4.75e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg23950597	chr19:37808831	NA	-0.63	-7.8	-0.39	8.08e-14	Coronary artery calcification;
LUSC	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg08601574	chr20:25228251	PYGB	0.42	6.41	0.33	4.9e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.49	7.41	0.38	1.06e-12	Blood metabolite levels;
LUSC	cis	rs1808579	0.904	rs11664076	chr18:21094207	C/T	cg14672496	chr18:21087552	C18orf8	0.36	5.96	0.31	6.34e-9	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg22532475	chr10:104410764	TRIM8	-0.34	-7.54	-0.38	4.58e-13	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg17691542	chr6:26056736	HIST1H1C	0.47	7.32	0.37	1.83e-12	Height;
LUSC	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg23505145	chr19:12996616	KLF1	0.65	11.04	0.52	2.33e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.67	-11.67	-0.54	1.3e-26	Diastolic blood pressure;
LUSC	cis	rs2742417	0.603	rs1019129	chr3:45780780	T/C	cg10512202	chr3:45649293	LIMD1	0.36	6.11	0.32	2.71e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs3755397	1	rs3755397	chr2:242294913	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.65	-5.83	-0.3	1.34e-8	Chronic lymphocytic leukemia;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LUSC	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg07936489	chr17:37558343	FBXL20	-0.8	-10.24	-0.49	1.4e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg06784218	chr1:46089804	CCDC17	0.55	11.09	0.52	1.49e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs1478897	0.804	rs9329246	chr8:11392880	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	6.24	0.32	1.31e-9	Systemic lupus erythematosus;
LUSC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg09165964	chr15:75287851	SCAMP5	0.45	6.76	0.35	6.05e-11	Breast cancer;
LUSC	trans	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-7.01	-0.36	1.29e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.58	-9.33	-0.45	1.49e-18	Body mass index;
LUSC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.51	0.46	3.9e-19	Bipolar disorder;
LUSC	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.52	-7.05	-0.36	1.04e-11	Neutrophil percentage of white cells;
LUSC	cis	rs10782582	0.609	rs78556436	chr1:76352875	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-6.19	-0.32	1.81e-9	Daytime sleep phenotypes;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06463913	chr11:207296	BET1L;RIC8A	-0.49	-6.06	-0.31	3.61e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg20991723	chr1:152506922	NA	0.51	9.74	0.47	6.76e-20	Hair morphology;
LUSC	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg04362960	chr10:104952993	NT5C2	0.62	9.75	0.47	6.31e-20	Arsenic metabolism;
LUSC	cis	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg05299278	chr17:33885742	SLFN14	0.29	6.44	0.33	4.09e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg05340658	chr4:99064831	C4orf37	0.45	7.29	0.37	2.33e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7527798	0.592	rs1323720	chr1:207823161	T/C	cg09232269	chr1:207846808	CR1L	-0.3	-6.46	-0.33	3.78e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg16482183	chr6:26056742	HIST1H1C	0.64	9.14	0.45	6.03e-18	Iron status biomarkers;
LUSC	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg13319975	chr6:146136371	FBXO30	-0.39	-5.93	-0.31	7.4e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg04362960	chr10:104952993	NT5C2	0.6	9.44	0.46	6.82e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg13902645	chr11:5959945	NA	-0.62	-9.31	-0.45	1.76e-18	DNA methylation (variation);
LUSC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.57	-7.0	-0.36	1.43e-11	Lung function (FEV1/FVC);
LUSC	cis	rs68170813	0.522	rs12154818	chr7:107074515	G/C	cg02696742	chr7:106810147	HBP1	-0.46	-6.43	-0.33	4.3e-10	Coronary artery disease;
LUSC	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.6	9.51	0.46	3.96e-19	Morning vs. evening chronotype;
LUSC	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg25214090	chr10:38739885	LOC399744	0.58	8.45	0.42	9.1e-16	Corneal astigmatism;
LUSC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg13699009	chr12:122356056	WDR66	0.49	7.72	0.39	1.37e-13	Mean corpuscular volume;
LUSC	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg17075019	chr10:79541650	NA	-0.76	-12.18	-0.55	1.73e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7178375	0.607	rs12903674	chr15:31194552	G/C	cg01738805	chr15:31195741	MTMR15	0.87	7.07	0.36	9.2e-12	Hypertriglyceridemia;
LUSC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.52	0.34	2.6200000000000003e-10	Bipolar disorder;
LUSC	cis	rs10950821	0.530	rs6950237	chr7:20688135	G/A	cg02470904	chr7:20686108	ABCB5	0.33	5.89	0.31	9.35e-9	Response to statin therapy;
LUSC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg12310025	chr6:25882481	NA	-0.5	-9.07	-0.44	1.03e-17	Blood metabolite levels;
LUSC	cis	rs10489525	0.583	rs12034918	chr1:115626285	C/T	cg01522456	chr1:115632236	TSPAN2	0.62	8.69	0.43	1.6e-16	Autism;
LUSC	cis	rs4704187	0.640	rs74719230	chr5:74431888	G/C	cg03227963	chr5:74354835	NA	0.32	6.89	0.35	2.86e-11	Response to amphetamines;
LUSC	cis	rs11608355	0.545	rs4766474	chr12:109908084	G/C	cg05360138	chr12:110035743	NA	0.89	11.55	0.53	3.47e-26	Neuroticism;
LUSC	cis	rs6906287	0.647	rs11153767	chr6:118960519	C/T	cg21191810	chr6:118973309	C6orf204	0.32	6.01	0.31	4.89e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4474465	0.688	rs7124803	chr11:78280822	T/G	cg27205649	chr11:78285834	NARS2	0.58	7.2	0.37	4.1e-12	Alzheimer's disease (survival time);
LUSC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	trans	rs7951105	1.000	rs1906683	chr11:39254840	C/A	cg24085930	chr3:21832523	NA	0.48	6.02	0.31	4.72e-9	Free thyroxine concentration;
LUSC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg24578937	chr1:2090814	PRKCZ	0.45	10.11	0.48	4e-21	Height;
LUSC	cis	rs3790645	1.000	rs282177	chr1:26899125	C/T	cg17456097	chr1:26900765	RPS6KA1	0.44	6.83	0.35	4.05e-11	Glucose homeostasis traits;
LUSC	trans	rs236907	0.859	rs35674909	chr1:171778147	G/A	cg13482142	chr2:234261155	NA	0.5	6.13	0.32	2.54e-9	Mean platelet volume;
LUSC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.86	14.01	0.61	2.16e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg22777020	chr22:31556080	RNF185	-0.47	-6.06	-0.31	3.64e-9	Colorectal cancer;
LUSC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.73	0.47	7.16e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02034447	chr16:89574710	SPG7	0.44	6.57	0.34	1.95e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs1018836	0.608	rs11997663	chr8:91474484	A/C	cg16814680	chr8:91681699	NA	-0.56	-8.02	-0.4	1.86e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.41	-0.42	1.19e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.51	-5.76	-0.3	1.9e-8	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg24675658	chr1:53192096	ZYG11B	0.61	9.69	0.47	9.89e-20	Monocyte count;
LUSC	cis	rs11997175	0.603	rs6468205	chr8:33778642	T/A	ch.8.33884649F	chr8:33765107	NA	0.41	6.15	0.32	2.21e-9	Body mass index;
LUSC	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg25456477	chr12:86230367	RASSF9	0.35	6.16	0.32	2.14e-9	Major depressive disorder;
LUSC	cis	rs3093024	0.874	rs3093018	chr6:167539805	C/T	cg07741184	chr6:167504864	NA	-0.4	-7.24	-0.37	3.1e-12	Rheumatoid arthritis;
LUSC	trans	rs724744	0.742	rs1008200	chr6:22360741	A/G	cg13807341	chr11:118445984	ARCN1	-0.35	-5.97	-0.31	6.14e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs7804356	0.954	rs3801831	chr7:26853470	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.95e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18252515	chr7:66147081	NA	-0.57	-7.89	-0.4	4.26e-14	Corneal structure;
LUSC	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg08847533	chr14:75593920	NEK9	-0.83	-15.07	-0.64	1.56e-39	Height;
LUSC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.53	8.75	0.43	1.1e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs7215564	0.908	rs7503757	chr17:78685599	A/G	cg04008703	chr7:27280585	NA	-0.39	-5.97	-0.31	6.18e-9	Myopia (pathological);
LUSC	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg23992470	chr4:843637	GAK	0.6	6.4	0.33	5.14e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	7.8	0.39	7.8e-14	Response to antipsychotic treatment;
LUSC	cis	rs13394619	0.565	rs12478958	chr2:11748037	A/G	cg07314298	chr2:11723111	GREB1	-0.39	-6.69	-0.34	9.37e-11	Endometriosis;
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg06877462	chr1:205807181	PM20D1	0.5	8.87	0.44	4.39e-17	Menarche (age at onset);
LUSC	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg02423579	chr7:2872169	GNA12	-0.46	-6.62	-0.34	1.43e-10	Height;
LUSC	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg26384229	chr12:38710491	ALG10B	0.7	10.83	0.51	1.22e-23	Morning vs. evening chronotype;
LUSC	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg11262906	chr1:85462892	MCOLN2	-0.57	-7.31	-0.37	2.01e-12	Serum sulfate level;
LUSC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg08680598	chr22:49984980	NA	-0.33	-6.02	-0.31	4.48e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00754232	chr7:97881723	TECPR1	-0.43	-6.51	-0.34	2.68e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9837602	0.938	rs34922392	chr3:99794730	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	6.32	0.33	8.6e-10	Breast cancer;
LUSC	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.82	-0.43	6.5e-17	Uric acid levels;
LUSC	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg02574844	chr11:5959923	NA	-0.39	-6.13	-0.32	2.42e-9	DNA methylation (variation);
LUSC	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.89	-0.31	9.39e-9	Triglycerides;
LUSC	cis	rs7582720	1.000	rs75324925	chr2:203698300	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.73	0.43	1.22e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.76	13.78	0.6	1.56e-34	Colorectal cancer;
LUSC	trans	rs62238980	0.614	rs76142630	chr22:32392177	A/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	cis	rs11931598	1.000	rs11931598	chr4:7047102	A/G	cg26116260	chr4:7069785	GRPEL1	0.46	6.59	0.34	1.76e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs4843185	0.669	rs4843506	chr16:85715440	T/A	cg05245094	chr16:85669572	KIAA0182	0.39	5.75	0.3	2.07e-8	Platelet distribution width;
LUSC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg05025164	chr4:1340916	KIAA1530	-0.42	-6.39	-0.33	5.73e-10	Obesity-related traits;
LUSC	cis	rs7577851	0.715	rs56175187	chr2:69620650	G/C	cg10773587	chr2:69614142	GFPT1	0.58	6.48	0.33	3.24e-10	Parkinson's disease (age of onset);
LUSC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.76	-0.39	1.08e-13	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.46	-5.75	-0.3	2.02e-8	Schizophrenia;
LUSC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg09034736	chr1:150693464	HORMAD1	0.46	6.7	0.34	8.78e-11	Melanoma;
LUSC	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg01620082	chr3:125678407	NA	-0.81	-7.4	-0.38	1.12e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	0.86	14.3	0.62	1.57e-36	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.47	-8.18	-0.41	6.18e-15	Axial length;
LUSC	cis	rs6545883	0.894	rs9677047	chr2:61585295	C/G	cg15711740	chr2:61764176	XPO1	0.44	6.75	0.35	6.5500000000000006e-11	Tuberculosis;
LUSC	cis	rs394563	0.559	rs7753269	chr6:149671360	G/A	cg03678062	chr6:149772716	ZC3H12D	0.3	6.18	0.32	1.9e-9	Dupuytren's disease;
LUSC	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-8.43	-0.42	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs702885	0.655	rs702907	chr2:65766983	T/C	cg06379192	chr1:3157287	PRDM16	-0.73	-6.18	-0.32	1.92e-9	Electroencephalogram traits;
LUSC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg11663144	chr21:46675770	NA	-0.41	-7.05	-0.36	1.04e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg03233332	chr7:66118400	NA	-0.41	-5.99	-0.31	5.54e-9	Aortic root size;
LUSC	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg06671706	chr8:8559999	CLDN23	0.49	6.57	0.34	1.94e-10	Obesity-related traits;
LUSC	trans	rs2392780	0.536	rs631845	chr8:128338760	G/A	cg10897648	chr18:56338258	MALT1	-0.42	-6.35	-0.33	6.95e-10	Breast cancer (early onset);
LUSC	cis	rs4566357	1.000	rs6721237	chr2:227923357	T/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.75	-0.3	1.97e-8	Coronary artery disease;
LUSC	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg15423357	chr2:25149977	NA	0.3	5.66	0.3	3.24e-8	Body mass index in non-asthmatics;
LUSC	cis	rs807669	0.525	rs9605955	chr22:19181557	C/T	cg02655711	chr22:19163373	SLC25A1	0.5	9.04	0.44	1.32e-17	Metabolite levels;
LUSC	cis	rs2273669	0.667	rs12215736	chr6:109330367	A/G	cg05315195	chr6:109294784	ARMC2	-0.53	-5.89	-0.31	9.28e-9	Prostate cancer;
LUSC	cis	rs941898	0.957	rs3783332	chr14:100586757	A/G	cg26002632	chr14:100625216	DEGS2	-0.36	-6.63	-0.34	1.32e-10	White matter hyperintensity burden;
LUSC	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg04455712	chr21:45112962	RRP1B	0.44	8.38	0.42	1.47e-15	Mean corpuscular volume;
LUSC	cis	rs2124969	0.562	rs6750639	chr2:161066862	T/C	cg03641300	chr2:160917029	PLA2R1	-0.43	-7.03	-0.36	1.17e-11	Waist circumference adjusted for body mass index;
LUSC	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg11161011	chr14:65562177	MAX	-0.71	-10.9	-0.51	7.03e-24	Obesity-related traits;
LUSC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg09796270	chr17:17721594	SREBF1	-0.34	-5.76	-0.3	1.88e-8	Total body bone mineral density;
LUSC	cis	rs2279817	0.863	rs2270976	chr1:18023690	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.46	6.32	0.33	8.57e-10	Neuroticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06258179	chr7:92463261	CDK6	0.42	6.19	0.32	1.81e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7264396	0.887	rs6060434	chr20:34068382	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.26	-0.32	1.19e-9	Total cholesterol levels;
LUSC	cis	rs55728055	0.661	rs62237791	chr22:31973124	A/G	cg01338084	chr22:32026380	PISD	0.93	6.78	0.35	5.4e-11	Age-related hearing impairment;
LUSC	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg09479241	chr17:27052676	TLCD1	0.44	5.89	0.31	9.58e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	6.52	0.34	2.6200000000000003e-10	Menarche (age at onset);
LUSC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	7.43	0.38	9.18e-13	Menarche (age at onset);
LUSC	cis	rs7172677	0.793	rs8029712	chr15:75418170	T/A	cg14664628	chr15:75095509	CSK	-0.45	-5.79	-0.3	1.66e-8	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg01858014	chr14:56050164	KTN1	-0.86	-7.18	-0.37	4.47e-12	Putamen volume;
LUSC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03264133	chr6:25882463	NA	-0.5	-9.15	-0.45	5.74e-18	Blood metabolite levels;
LUSC	cis	rs11637445	0.589	rs4776989	chr15:68130684	T/C	cg08079166	chr15:68083412	MAP2K5	0.35	7.28	0.37	2.37e-12	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg06873352	chr17:61820015	STRADA	-0.6	-10.31	-0.49	8.18e-22	Prudent dietary pattern;
LUSC	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.41	-0.33	4.97e-10	Arsenic metabolism;
LUSC	trans	rs890100	0.800	rs7580549	chr2:56759547	A/G	cg01657744	chr10:88471748	LDB3	0.44	6.11	0.32	2.79e-9	Gut microbiome composition (summer);
LUSC	cis	rs4654899	0.965	rs7525620	chr1:21458392	G/A	cg01072550	chr1:21505969	NA	-0.55	-8.41	-0.42	1.18e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.51	-10.3	-0.49	8.65e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs72772090	0.539	rs13601	chr5:96110596	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.74	-7.49	-0.38	6.25e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg14789911	chr21:47582049	C21orf56	0.42	6.58	0.34	1.8e-10	Testicular germ cell tumor;
LUSC	cis	rs6693567	0.545	rs12049177	chr1:150474337	G/A	cg15654264	chr1:150340011	RPRD2	0.46	7.5	0.38	5.73e-13	Migraine;
LUSC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg17366294	chr4:99064904	C4orf37	0.6	10.61	0.5	7.4e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	1.03	18.02	0.7	3.34e-51	Parkinson's disease;
LUSC	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg03806693	chr22:41940476	POLR3H	-0.54	-7.3	-0.37	2.11e-12	Neuroticism;
LUSC	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg01448562	chr3:133502909	NA	-0.66	-10.57	-0.5	1.03e-22	Iron status biomarkers;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02400128	chr5:114849010	NA	0.48	6.1	0.32	2.99e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg05805236	chr11:65401703	PCNXL3	-0.55	-8.73	-0.43	1.2e-16	Acne (severe);
LUSC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.75	-0.47	6.37e-20	Bipolar disorder;
LUSC	cis	rs9811920	0.690	rs7623587	chr3:99906751	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.35	6.64	0.34	1.26e-10	Axial length;
LUSC	cis	rs597583	0.715	rs7936795	chr11:117391736	A/G	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.45	-0.42	9.26e-16	Putamen volume;
LUSC	cis	rs17401966	0.558	rs17402762	chr1:10414470	T/C	cg17425144	chr1:10567563	PEX14	-0.34	-6.08	-0.32	3.19e-9	Hepatocellular carcinoma;
LUSC	cis	rs7681440	0.626	rs6812593	chr4:90817991	C/T	cg15133208	chr4:90757351	SNCA	-0.35	-5.94	-0.31	7.19e-9	Dementia with Lewy bodies;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12684360	chr13:50367057	KPNA3	0.47	6.33	0.33	8.02e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	17.04	0.68	2.72e-47	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.99	-0.31	5.52e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg17143192	chr8:8559678	CLDN23	0.63	9.28	0.45	2.18e-18	Obesity-related traits;
LUSC	cis	rs73198271	0.563	rs3748143	chr8:8655237	A/G	cg01851573	chr8:8652454	MFHAS1	-0.65	-8.98	-0.44	1.99e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9359856	0.673	rs2039053	chr6:90303760	G/A	cg13799429	chr6:90582589	CASP8AP2	0.75	8.08	0.4	1.19e-14	Bipolar disorder;
LUSC	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg27432699	chr2:27873401	GPN1	0.83	15.57	0.65	1.81e-41	Oral cavity cancer;
LUSC	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.57	8.3	0.41	2.65e-15	Night sleep phenotypes;
LUSC	cis	rs259282	0.519	rs259276	chr19:33160953	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	1.03	14.66	0.63	6.46e-38	Schizophrenia;
LUSC	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg08917208	chr2:24149416	ATAD2B	0.91	10.2	0.49	1.91e-21	Lymphocyte counts;
LUSC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg02807482	chr3:125708958	NA	-0.52	-6.51	-0.34	2.69e-10	Blood pressure (smoking interaction);
LUSC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06022373	chr22:39101656	GTPBP1	0.78	12.16	0.55	2.1e-28	Menopause (age at onset);
LUSC	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-5.97	-0.31	6.08e-9	Ulcerative colitis;
LUSC	cis	rs2970818	0.831	rs2909381	chr12:4606527	T/C	cg11146114	chr12:4671731	NA	-0.58	-5.9	-0.31	9.04e-9	Phosphorus levels;
LUSC	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg17470723	chr8:74884337	TCEB1	0.5	7.38	0.37	1.23e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg26727032	chr16:67993705	SLC12A4	-0.42	-5.79	-0.3	1.62e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.64	0.34	1.28e-10	Intraocular pressure;
LUSC	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg20587970	chr11:113659929	NA	-1.08	-13.25	-0.59	1.76e-32	Hip circumference adjusted for BMI;
LUSC	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg13393036	chr8:95962371	TP53INP1	0.44	8.67	0.43	1.87e-16	Type 2 diabetes;
LUSC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg22029157	chr1:209979665	IRF6	0.81	10.48	0.5	2.07e-22	Cleft lip with or without cleft palate;
LUSC	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.68	-0.43	1.82e-16	Lung cancer;
LUSC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.54	-7.7	-0.39	1.6e-13	Gut microbiome composition (summer);
LUSC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	0.92	19.53	0.73	3.38e-57	Dental caries;
LUSC	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg26876637	chr1:152193138	HRNR	0.45	6.46	0.33	3.74e-10	Atopic dermatitis;
LUSC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg05669848	chr5:237993	SDHA	0.51	5.72	0.3	2.43e-8	Breast cancer;
LUSC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg10351095	chr21:47802916	PCNT	0.42	5.97	0.31	6.16e-9	Testicular germ cell tumor;
LUSC	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-9.64	-0.47	1.4e-19	Body mass index;
LUSC	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.89	14.89	0.63	8.25e-39	Bladder cancer;
LUSC	cis	rs6504340	0.739	rs4793589	chr17:46667863	G/C	cg09704116	chr17:46666958	LOC404266	-0.37	-5.66	-0.3	3.18e-8	Primary tooth development (number of teeth);
LUSC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08219700	chr8:58056026	NA	0.69	8.22	0.41	4.58e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg00945038	chr17:61921165	SMARCD2	0.53	9.35	0.46	1.3e-18	Prudent dietary pattern;
LUSC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg19346786	chr7:2764209	NA	-0.41	-7.3	-0.37	2.1e-12	Height;
LUSC	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg01528321	chr10:82214614	TSPAN14	0.86	13.15	0.58	4.23e-32	Post bronchodilator FEV1;
LUSC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06634786	chr22:41940651	POLR3H	-0.57	-6.86	-0.35	3.34e-11	Vitiligo;
LUSC	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.59	7.87	0.4	4.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9929218	0.954	rs35444713	chr16:68824492	C/T	cg02972257	chr16:68554789	NA	0.42	5.7	0.3	2.62e-8	Colorectal cancer;
LUSC	trans	rs11088226	0.598	rs79634586	chr21:33959363	A/G	cg09050820	chr6:167586206	TCP10L2	0.75	9.54	0.46	3.22e-19	Gastritis;
LUSC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg06238570	chr21:40685208	BRWD1	-0.49	-7.56	-0.38	3.82e-13	Menarche (age at onset);
LUSC	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg03647239	chr10:116582469	FAM160B1	0.47	7.59	0.38	3.26e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg07507251	chr3:52567010	NT5DC2	0.33	6.46	0.33	3.6e-10	Bipolar disorder;
LUSC	trans	rs1997103	0.871	rs9649855	chr7:55410222	T/C	cg20935933	chr6:143382018	AIG1	0.5	7.28	0.37	2.42e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs3733418	0.929	rs12507869	chr4:165895674	T/C	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.49	-5.83	-0.3	1.31e-8	Obesity-related traits;
LUSC	cis	rs1823874	0.581	rs12905599	chr15:100339938	C/T	cg16400843	chr15:100339927	C15orf51	0.4	7.41	0.38	1.07e-12	IgG glycosylation;
LUSC	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg25427524	chr10:38739819	LOC399744	-0.51	-6.84	-0.35	3.76e-11	Obesity (extreme);
LUSC	cis	rs3772130	0.926	rs13072767	chr3:121504098	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.7	10.3	0.49	8.97e-22	Cognitive performance;
LUSC	cis	rs727505	0.721	rs17327715	chr7:124760611	G/C	cg23710748	chr7:124431027	NA	-0.39	-6.93	-0.35	2.19e-11	Lewy body disease;
LUSC	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.7	-11.47	-0.53	6.95e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg05973401	chr12:123451056	ABCB9	0.52	7.1	0.36	7.72e-12	Schizophrenia;
LUSC	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg16359550	chr11:109292809	C11orf87	0.37	6.46	0.33	3.74e-10	Schizophrenia;
LUSC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg15605315	chr1:45957053	TESK2	-0.49	-7.99	-0.4	2.18e-14	High light scatter reticulocyte count;
LUSC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg11235426	chr6:292522	DUSP22	-0.45	-6.73	-0.35	7.19e-11	Menopause (age at onset);
LUSC	cis	rs9942416	0.533	rs12109251	chr5:75024240	C/A	cg19683494	chr5:74908142	NA	0.5	6.82	0.35	4.34e-11	Age-related disease endophenotypes;
LUSC	trans	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg03886242	chr7:26192032	NFE2L3	-0.36	-6.04	-0.31	4.07e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.56	7.48	0.38	6.63e-13	High light scatter reticulocyte count;
LUSC	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg23649088	chr2:200775458	C2orf69	-0.56	-6.67	-0.34	1.07e-10	Schizophrenia;
LUSC	cis	rs41271473	0.898	rs3738073	chr1:228871693	C/T	cg16512390	chr1:228756714	NA	0.5	5.98	0.31	5.73e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs929596	0.603	rs2602363	chr2:234520525	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-6.37	-0.33	6.31e-10	Total bilirubin levels in HIV-1 infection;
LUSC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg06064525	chr11:970664	AP2A2	-0.48	-10.3	-0.49	8.59e-22	Alzheimer's disease (late onset);
LUSC	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.05	12.37	0.56	3.51e-29	Lung cancer in ever smokers;
LUSC	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg27284194	chr4:1044797	NA	0.6	8.85	0.44	5.26e-17	Recombination rate (females);
LUSC	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg22431228	chr1:16359049	CLCNKA	0.32	6.42	0.33	4.6e-10	Dilated cardiomyopathy;
LUSC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg16339924	chr4:17578868	LAP3	0.58	8.86	0.44	4.79e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg11693508	chr17:37793320	STARD3	0.51	6.12	0.32	2.69e-9	Bipolar disorder;
LUSC	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg27068330	chr11:65405492	SIPA1	-0.77	-11.03	-0.52	2.43e-24	Acne (severe);
LUSC	cis	rs1568889	0.667	rs16917914	chr11:28459909	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.47	6.42	0.33	4.81e-10	Bipolar disorder;
LUSC	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-9.72	-0.47	7.91e-20	Hemoglobin concentration;
LUSC	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.5	-0.42	6.35e-16	Retinal vascular caliber;
LUSC	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg08807101	chr21:30365312	RNF160	-0.51	-6.54	-0.34	2.34e-10	Cognitive test performance;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg10024484	chr20:20435885	RALGAPA2	-0.71	-6.64	-0.34	1.24e-10	Cognitive performance;
LUSC	cis	rs9443645	0.507	rs1876389	chr6:79481932	A/T	cg05283184	chr6:79620031	NA	-0.39	-7.25	-0.37	2.83e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.75	14.67	0.63	5.88e-38	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs3768617	0.591	rs9787073	chr1:182974328	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.32	0.41	2.23e-15	Fuchs's corneal dystrophy;
LUSC	cis	rs6686643	0.762	rs6672982	chr1:165612815	T/A	cg16553119	chr1:165599451	MGST3	-0.46	-6.48	-0.33	3.32e-10	Total ventricular volume;
LUSC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg08807101	chr21:30365312	RNF160	0.71	11.23	0.52	4.73e-25	Selective IgA deficiency;
LUSC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	1.05	19.01	0.72	3.89e-55	Parkinson's disease;
LUSC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg17376030	chr22:41985996	PMM1	0.48	6.03	0.31	4.25e-9	Vitiligo;
LUSC	cis	rs4363385	0.693	rs10788849	chr1:152902240	C/A	cg07796016	chr1:152779584	LCE1C	-0.46	-6.57	-0.34	1.98e-10	Inflammatory skin disease;
LUSC	cis	rs12148477	0.787	rs8031311	chr15:51654731	G/T	cg25905881	chr15:51634250	GLDN	0.35	5.74	0.3	2.15e-8	Follicule stimulating hormone;
LUSC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.54e-10	Menopause (age at onset);
LUSC	cis	rs7119	0.700	rs4886883	chr15:77888924	C/T	cg27398640	chr15:77910606	LINGO1	-0.35	-8.26	-0.41	3.56e-15	Type 2 diabetes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03262077	chr1:109505986	CLCC1	0.42	6.4	0.33	5.15e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4285028	0.699	rs2689285	chr3:121586486	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.78	10.73	0.51	2.87e-23	Multiple sclerosis;
LUSC	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.24	0.52	4.47e-25	Eye color traits;
LUSC	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03168497	chr17:48586147	MYCBPAP	0.49	6.55	0.34	2.23e-10	Visceral fat;
LUSC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.67e-12	Motion sickness;
LUSC	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-0.84	-15.5	-0.65	3.28e-41	Height;
LUSC	cis	rs7336332	0.547	rs9581859	chr13:28035147	A/T	cg22138327	chr13:27999177	GTF3A	0.76	7.85	0.39	5.72e-14	Weight;
LUSC	cis	rs11997175	0.583	rs7824990	chr8:33779934	A/G	ch.8.33884649F	chr8:33765107	NA	0.44	6.44	0.33	4.13e-10	Body mass index;
LUSC	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg11645453	chr3:52864694	ITIH4	0.59	14.13	0.61	7.16e-36	Schizophrenia;
LUSC	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.64	0.43	2.37e-16	Menarche (age at onset);
LUSC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg14582100	chr15:45693742	SPATA5L1	0.6	10.95	0.51	4.7e-24	Homoarginine levels;
LUSC	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg16607685	chr5:140181889	PCDHA2;PCDHA1;PCDHA3	-0.3	-5.85	-0.3	1.16e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	0.68	9.2	0.45	4.01e-18	Large artery stroke;
LUSC	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	1.04	16.65	0.67	9.21e-46	Corneal structure;
LUSC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg15704280	chr7:45808275	SEPT13	-1.02	-19.51	-0.73	4.09e-57	Height;
LUSC	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg17127132	chr2:85788382	GGCX	0.5	7.82	0.39	7.15e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg04545296	chr12:48745243	ZNF641	-0.31	-5.97	-0.31	6.13e-9	Obstructive sleep apnea trait (apnea hypopnea index);
LUSC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg20887711	chr4:1340912	KIAA1530	0.51	7.75	0.39	1.09e-13	Obesity-related traits;
LUSC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg20283391	chr11:68216788	NA	-0.58	-8.21	-0.41	4.89e-15	Total body bone mineral density;
LUSC	cis	rs79387448	0.638	rs74731686	chr2:103043981	G/A	cg09003973	chr2:102972529	NA	0.98	9.9	0.48	1.99e-20	Gut microbiota (bacterial taxa);
LUSC	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg27219399	chr15:67835830	MAP2K5	0.35	5.67	0.3	3.11e-8	Restless legs syndrome;
LUSC	trans	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg07211511	chr3:129823064	LOC729375	-0.55	-6.07	-0.32	3.38e-9	Blood pressure (smoking interaction);
LUSC	cis	rs983392	0.679	rs654415	chr11:60013674	G/A	cg20284999	chr11:59952153	MS4A6A	0.38	6.44	0.33	4.23e-10	Alzheimer's disease (late onset);
LUSC	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	14.08	0.61	1.14e-35	Exhaled nitric oxide levels;
LUSC	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg05855489	chr10:104503620	C10orf26	-0.68	-10.15	-0.49	2.8e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg27532560	chr4:187881888	NA	-0.38	-6.1	-0.32	2.99e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11608355	0.545	rs55902232	chr12:109902305	G/A	cg05360138	chr12:110035743	NA	0.91	11.65	0.54	1.48e-26	Neuroticism;
LUSC	cis	rs2692947	0.740	rs60452119	chr2:96420050	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.38	0.33	6.08e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-10.2	-0.49	1.92e-21	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	3.95e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.31	-18.25	-0.71	4.34e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.41	-5.66	-0.3	3.25e-8	Gut microbiome composition (summer);
LUSC	cis	rs3820928	0.935	rs10203363	chr2:227896976	C/T	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.73	-0.39	1.25e-13	Pulmonary function;
LUSC	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg02997394	chr19:33096574	ANKRD27	0.8	9.14	0.45	6.42e-18	Eosinophilic esophagitis;
LUSC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg21361702	chr7:150065534	REPIN1	0.52	6.71	0.34	8.47e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs1395	0.961	rs4665963	chr2:27528692	T/C	cg23587288	chr2:27483067	SLC30A3	-0.3	-5.64	-0.3	3.57e-8	Blood metabolite levels;
LUSC	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.92	15.81	0.65	1.92e-42	Bladder cancer;
LUSC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg06494592	chr3:125709126	NA	-0.5	-6.15	-0.32	2.25e-9	Blood pressure (smoking interaction);
LUSC	trans	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg01620082	chr3:125678407	NA	-0.82	-7.65	-0.39	2.2e-13	Depression;
LUSC	cis	rs1904096	0.506	rs3113863	chr4:95147827	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.37	-0.42	1.57e-15	Type 2 diabetes;
LUSC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg26513180	chr16:89883248	FANCA	0.8	6.4	0.33	5.22e-10	Skin colour saturation;
LUSC	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg24881330	chr22:46731750	TRMU	0.79	7.06	0.36	9.45e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs314370	0.621	rs314312	chr7:100422642	G/C	cg10426581	chr7:100472382	SRRT	0.53	8.13	0.41	8.25e-15	Resting heart rate;
LUSC	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg02023728	chr11:77925099	USP35	0.47	7.06	0.36	9.75e-12	Testicular germ cell tumor;
LUSC	cis	rs4664308	0.618	rs4665139	chr2:160890692	G/T	cg03641300	chr2:160917029	PLA2R1	-0.48	-8.0	-0.4	2.03e-14	Idiopathic membranous nephropathy;
LUSC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg23625390	chr15:77176239	SCAPER	0.45	6.9	0.35	2.55e-11	Blood metabolite levels;
LUSC	trans	rs13424581	1.000	rs10193574	chr2:225741272	C/T	cg12623045	chr10:135067449	NA	-0.49	-6.2	-0.32	1.69e-9	Platelet distribution width;
LUSC	cis	rs6960043	0.714	rs6976086	chr7:15048611	T/G	cg19272540	chr7:15055459	NA	0.35	8.6	0.43	3.07e-16	Type 2 diabetes;
LUSC	cis	rs2354432	0.607	rs6683243	chr1:146733422	A/T	cg25205988	chr1:146714368	CHD1L	-1.0	-9.35	-0.46	1.26e-18	Mitochondrial DNA levels;
LUSC	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.45	6.27	0.32	1.1e-9	Renal function-related traits (BUN);
LUSC	cis	rs9807989	0.773	rs5010059	chr2:102968826	C/G	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.67e-9	Asthma;
LUSC	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg25817165	chr18:72167213	CNDP2	-0.56	-7.53	-0.38	4.66e-13	Mononucleosis;
LUSC	cis	rs6500395	1.000	rs3817029	chr16:48584942	C/T	cg04672837	chr16:48644449	N4BP1	0.44	6.48	0.33	3.31e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs5167	0.533	rs55778858	chr19:45485465	G/A	cg13119609	chr19:45449297	APOC2	0.34	5.67	0.3	3.01e-8	Blood protein levels;
LUSC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.92	-0.48	1.7e-20	Hemoglobin concentration;
LUSC	cis	rs968451	0.789	rs1569500	chr22:39683515	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.71	10.43	0.5	3.2e-22	Primary biliary cholangitis;
LUSC	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg24579218	chr15:68104479	NA	-0.38	-6.55	-0.34	2.21e-10	Obesity;
LUSC	cis	rs9392556	0.829	rs613260	chr6:4120567	C/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.36	-6.16	-0.32	2.06e-9	Blood metabolite levels;
LUSC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg01802117	chr1:53393560	SCP2	-0.37	-6.13	-0.32	2.52e-9	Monocyte count;
LUSC	cis	rs34779708	0.733	rs4007271	chr10:35546611	C/T	cg03585969	chr10:35415529	CREM	0.53	7.38	0.37	1.3e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06481639	chr22:41940642	POLR3H	-0.46	-5.67	-0.3	3.09e-8	Vitiligo;
LUSC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg23985595	chr17:80112537	CCDC57	-0.32	-6.12	-0.32	2.63e-9	Life satisfaction;
LUSC	cis	rs748404	0.697	rs546722	chr15:43580819	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	8.86	0.44	5.01e-17	Lung cancer;
LUSC	trans	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg18187862	chr3:45730750	SACM1L	-0.53	-6.51	-0.34	2.71e-10	Primary sclerosing cholangitis;
LUSC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.97	0.4	2.6e-14	Prudent dietary pattern;
LUSC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	1.1	27.15	0.83	1.64e-86	Testicular germ cell tumor;
LUSC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg22508957	chr16:3507546	NAT15	0.65	10.68	0.5	4.06e-23	Tuberculosis;
LUSC	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	9.46	0.46	5.61e-19	Lung cancer;
LUSC	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.81	-8.62	-0.43	2.7e-16	Lung cancer in ever smokers;
LUSC	trans	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg18187862	chr3:45730750	SACM1L	0.52	6.82	0.35	4.21e-11	Primary sclerosing cholangitis;
LUSC	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	0.96	18.11	0.7	1.53e-51	Bone mineral density;
LUSC	cis	rs7173743	0.756	rs12903613	chr15:79129076	G/T	cg00540400	chr15:79124168	NA	0.35	6.15	0.32	2.17e-9	Coronary artery disease;
LUSC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg00409905	chr10:38381863	ZNF37A	-0.35	-6.16	-0.32	2.04e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.51	-0.34	2.8e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-10.66	-0.5	5.13e-23	Mean corpuscular volume;
LUSC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg02038168	chr22:39784481	NA	-0.48	-8.01	-0.4	1.92e-14	Intelligence (multi-trait analysis);
LUSC	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.87	-0.44	4.49e-17	Triglycerides;
LUSC	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg22709100	chr7:91322751	NA	-0.42	-6.12	-0.32	2.69e-9	Breast cancer;
LUSC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-1.0	-16.81	-0.68	2.25e-46	Body mass index;
LUSC	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg05283184	chr6:79620031	NA	-0.57	-11.99	-0.55	8.43e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08645402	chr16:4508243	NA	0.48	7.52	0.38	5.19e-13	Schizophrenia;
LUSC	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs4356932	0.967	rs4859591	chr4:76948578	G/A	cg00809888	chr4:76862425	NAAA	0.35	5.79	0.3	1.64e-8	Blood protein levels;
LUSC	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg21905437	chr5:178450457	ZNF879	0.43	5.67	0.3	3.1e-8	Pubertal anthropometrics;
LUSC	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg23752985	chr2:85803571	VAMP8	0.33	6.34	0.33	7.49e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.6	-9.47	-0.46	5.4e-19	HDL cholesterol;
LUSC	cis	rs6977660	0.714	rs6976854	chr7:19818311	A/G	cg05791153	chr7:19748676	TWISTNB	0.66	7.0	0.36	1.38e-11	Thyroid stimulating hormone;
LUSC	cis	rs10089	1.000	rs10057122	chr5:127512063	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	10.95	0.51	4.75e-24	Ileal carcinoids;
LUSC	cis	rs7267979	0.668	rs4815398	chr20:25237338	C/T	cg08601574	chr20:25228251	PYGB	-0.46	-6.96	-0.36	1.79e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg04545296	chr12:48745243	ZNF641	0.37	6.72	0.35	7.87e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs679087	0.900	rs12811019	chr12:29935396	C/A	cg14258853	chr12:29935411	TMTC1	0.97	16.92	0.68	8.18e-47	Schizophrenia;
LUSC	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg20991723	chr1:152506922	NA	0.51	9.74	0.47	6.76e-20	Hair morphology;
LUSC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.0	-0.58	1.53e-31	Alzheimer's disease;
LUSC	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.17	0.37	4.75e-12	Blood metabolite levels;
LUSC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06221963	chr1:154839813	KCNN3	-0.59	-13.47	-0.59	2.55e-33	Prostate cancer;
LUSC	cis	rs1595825	0.838	rs16826872	chr2:198898055	T/C	cg00982548	chr2:198649783	BOLL	-0.55	-7.0	-0.36	1.44e-11	Ulcerative colitis;
LUSC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg21644426	chr2:191273491	MFSD6	-0.58	-9.4	-0.46	9.24e-19	Pulse pressure;
LUSC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	0.84	14.22	0.61	3.15e-36	Tonsillectomy;
LUSC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.4	0.33	5.39e-10	Alzheimer's disease (late onset);
LUSC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs295140	1.000	rs13028959	chr2:201185919	C/A	cg04283868	chr2:201171347	SPATS2L	0.42	6.37	0.33	6.12e-10	QT interval;
LUSC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg25767906	chr1:53392781	SCP2	0.53	9.81	0.47	3.97e-20	Monocyte count;
LUSC	cis	rs10208940	0.920	rs10205573	chr2:68829419	A/T	cg12452813	chr2:68675892	NA	0.58	6.05	0.31	3.94e-9	Urate levels in lean individuals;
LUSC	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg05393297	chr12:53359155	NA	-0.35	-6.46	-0.33	3.75e-10	Cancer (pleiotropy);
LUSC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg19592336	chr6:28129416	ZNF389	0.5	6.71	0.34	8.55e-11	Depression;
LUSC	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg13010344	chr12:123464640	ARL6IP4	-0.57	-6.79	-0.35	5.23e-11	Neutrophil percentage of white cells;
LUSC	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg01884057	chr2:25150051	NA	0.48	11.49	0.53	5.56e-26	Body mass index;
LUSC	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg21775007	chr8:11205619	TDH	0.8	13.53	0.6	1.47e-33	Retinal vascular caliber;
LUSC	cis	rs1499972	0.941	rs55779525	chr3:117651483	A/C	cg07612923	chr3:117604196	NA	0.65	5.85	0.3	1.18e-8	Schizophrenia;
LUSC	trans	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.34	-0.33	7.39e-10	Triglycerides;
LUSC	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg05110241	chr16:68378359	PRMT7	-0.57	-6.52	-0.34	2.56e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg02176678	chr2:219576539	TTLL4	0.58	10.59	0.5	8.84e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg18904891	chr8:8559673	CLDN23	0.4	6.36	0.33	6.72e-10	Mood instability;
LUSC	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg10130564	chr11:117069849	TAGLN	-0.37	-6.44	-0.33	4.18e-10	Blood protein levels;
LUSC	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	14.98	0.63	3.73e-39	Mean corpuscular hemoglobin;
LUSC	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg09904177	chr6:26538194	HMGN4	-0.51	-5.71	-0.3	2.54e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg12419862	chr22:24373484	LOC391322	-0.81	-12.03	-0.55	5.99e-28	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	10.89	0.51	7.85e-24	Menopause (age at onset);
LUSC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg02772935	chr3:125709198	NA	-0.47	-5.66	-0.3	3.26e-8	Blood pressure (smoking interaction);
LUSC	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg18478394	chr8:109455254	TTC35	0.42	6.57	0.34	1.93e-10	Dupuytren's disease;
LUSC	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg24375607	chr4:120327624	NA	0.68	10.09	0.48	4.69e-21	Corneal astigmatism;
LUSC	trans	rs9615838	0.579	rs9615822	chr22:48624381	A/G	cg01224366	chr21:45148694	PDXK	-0.65	-6.28	-0.32	1.08e-9	Facial morphology (factor 2, vertical position of orbits relative to midface);
LUSC	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg00105475	chr2:10696890	NA	0.37	6.21	0.32	1.58e-9	Prostate cancer;
LUSC	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.59	8.81	0.43	6.87e-17	Total cholesterol levels;
LUSC	cis	rs16910800	1.000	rs1531808	chr11:23194465	C/A	cg20040320	chr11:23191996	NA	-0.46	-6.62	-0.34	1.42e-10	Cancer;
LUSC	cis	rs6484504	0.600	rs12796587	chr11:31266443	T/C	cg06552810	chr11:31128660	NA	-0.42	-7.4	-0.38	1.09e-12	Red blood cell count;
LUSC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-0.99	-17.49	-0.69	4.35e-49	Coronary artery disease;
LUSC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg20887711	chr4:1340912	KIAA1530	0.7	10.84	0.51	1.2e-23	Longevity;
LUSC	cis	rs698813	0.674	rs4952707	chr2:44500683	G/C	cg00619915	chr2:44497795	NA	-0.53	-7.26	-0.37	2.68e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs9837602	0.872	rs4928234	chr3:99704861	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	5.89	0.31	9.26e-9	Breast cancer;
LUSC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03934478	chr11:495069	RNH1	0.85	9.17	0.45	5.14e-18	Body mass index;
LUSC	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg13206674	chr6:150067644	NUP43	0.42	6.38	0.33	5.88e-10	Testicular germ cell tumor;
LUSC	cis	rs10875746	0.903	rs11168403	chr12:48484958	T/C	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	trans	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg10756647	chr7:56101905	PSPH	0.87	8.4	0.42	1.31e-15	Diabetic kidney disease;
LUSC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg18477163	chr1:228402036	OBSCN	-0.56	-10.21	-0.49	1.83e-21	Diastolic blood pressure;
LUSC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg12257692	chr3:49977190	RBM6	0.24	6.74	0.35	6.86e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg23711669	chr6:146136114	FBXO30	0.74	13.21	0.59	2.48e-32	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2797160	0.967	rs1739358	chr6:126019736	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.94	0.36	2.04e-11	Endometrial cancer;
LUSC	cis	rs7589342	0.831	rs6731173	chr2:106522928	A/G	cg14210321	chr2:106509881	NCK2	-0.61	-9.51	-0.46	3.82e-19	Addiction;
LUSC	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	7.65	0.39	2.14e-13	Height;
LUSC	cis	rs243505	0.528	rs740951	chr7:148470160	C/A	cg09806900	chr7:148480153	CUL1	0.65	9.72	0.47	8.01e-20	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg22782873	chr19:19639568	YJEFN3	-0.49	-6.12	-0.32	2.56e-9	Bipolar disorder;
LUSC	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	6.89	0.35	2.86e-11	Retinal vascular caliber;
LUSC	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg21132104	chr15:45694354	SPATA5L1	0.59	8.31	0.41	2.49e-15	Homoarginine levels;
LUSC	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	12.8	0.57	8.82e-31	Subcortical brain region volumes;Putamen volume;
LUSC	cis	rs1034435	0.755	rs9615336	chr22:48893090	G/C	cg05992904	chr22:48892994	FAM19A5	-0.41	-8.16	-0.41	6.85e-15	Late-onset Alzheimer's disease;
LUSC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg14784868	chr12:69753453	YEATS4	0.61	8.85	0.44	5.33e-17	Blood protein levels;
LUSC	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg26816564	chr1:7831052	VAMP3	0.72	9.63	0.47	1.53e-19	Inflammatory bowel disease;
LUSC	trans	rs2587949	0.615	rs1385486	chr3:4228745	C/T	cg15139668	chr4:4577005	NA	-0.41	-6.08	-0.32	3.23e-9	Periodontitis (DPAL);
LUSC	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.81	13.65	0.6	4.94e-34	Bladder cancer;
LUSC	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.93	15.68	0.65	6.74e-42	Bladder cancer;
LUSC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg03676636	chr4:99064102	C4orf37	0.34	7.49	0.38	6.06e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg11344533	chr11:111475393	SIK2	-0.46	-6.31	-0.33	8.96e-10	Primary sclerosing cholangitis;
LUSC	cis	rs56804039	1.000	rs58361948	chr8:8380995	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.96	-0.36	1.84e-11	Cervical cancer;
LUSC	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	9.22	0.45	3.32e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs11031096	0.738	rs11031070	chr11:4154307	T/C	cg18678763	chr11:4115507	RRM1	0.38	5.77	0.3	1.83e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg23815491	chr16:72088622	HP	0.34	5.97	0.31	6.12e-9	Fibrinogen levels;
LUSC	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.0	-0.48	8.83e-21	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-1.14	-16.68	-0.67	7.08e-46	Breast cancer;
LUSC	cis	rs7771547	0.642	rs12214285	chr6:36434679	C/T	cg07856975	chr6:36356162	ETV7	-0.37	-6.47	-0.33	3.41e-10	Platelet distribution width;
LUSC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-6.41	-0.33	5.01e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.14	-0.32	2.38e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-7.64	-0.39	2.35e-13	Axial length;
LUSC	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg25930673	chr12:123319894	HIP1R	-0.66	-6.52	-0.34	2.53e-10	Schizophrenia;
LUSC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12379764	chr21:47803548	PCNT	0.59	8.15	0.41	7.38e-15	Testicular germ cell tumor;
LUSC	cis	rs1322512	0.917	rs2489545	chr6:153006907	C/T	cg27316956	chr6:152958899	SYNE1	0.34	5.98	0.31	5.72e-9	Tonometry;
LUSC	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg17691542	chr6:26056736	HIST1H1C	0.58	8.03	0.4	1.68e-14	Iron status biomarkers;
LUSC	cis	rs9399401	0.614	rs262125	chr6:142838355	A/T	cg03128060	chr6:142623767	GPR126	0.52	8.39	0.42	1.38e-15	Chronic obstructive pulmonary disease;
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg01238044	chr22:24384105	GSTT1	-0.52	-7.59	-0.38	3.15e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg07395648	chr5:131743802	NA	-0.43	-7.29	-0.37	2.28e-12	Blood metabolite levels;
LUSC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg02807482	chr3:125708958	NA	-0.52	-6.51	-0.34	2.69e-10	Blood pressure (smoking interaction);
LUSC	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.67	-9.98	-0.48	1.06e-20	Corneal astigmatism;
LUSC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	9.3	0.45	1.84e-18	Monocyte percentage of white cells;
LUSC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.88	0.63	8.88e-39	Platelet count;
LUSC	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg10596483	chr8:143751796	JRK	0.52	7.61	0.38	2.9e-13	Schizophrenia;
LUSC	trans	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.41	-0.38	1.04e-12	Neuroticism;
LUSC	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg25214090	chr10:38739885	LOC399744	0.56	8.33	0.41	2.16e-15	Corneal astigmatism;
LUSC	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg13010199	chr12:38710504	ALG10B	0.65	10.2	0.49	1.93e-21	Morning vs. evening chronotype;
LUSC	cis	rs4474465	1.000	rs10899502	chr11:78141021	C/T	cg27205649	chr11:78285834	NARS2	-0.55	-6.33	-0.33	7.7e-10	Alzheimer's disease (survival time);
LUSC	cis	rs2267137	0.843	rs570731	chr22:29758817	A/G	cg07256473	chr22:29710276	RASL10A	-0.38	-7.33	-0.37	1.77e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs791888	0.728	rs2255682	chr10:89419873	C/G	cg13926569	chr10:89418898	PAPSS2	-0.36	-6.89	-0.35	2.75e-11	Magnesium levels;
LUSC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg25124228	chr12:125621409	AACS	-0.45	-6.81	-0.35	4.44e-11	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-9.69	-0.47	9.72e-20	Morning vs. evening chronotype;
LUSC	cis	rs10276381	1.000	rs10276381	chr7:28190121	A/G	cg23620719	chr7:28220237	JAZF1	-0.6	-6.75	-0.35	6.72e-11	Crohn's disease;
LUSC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21518248	chr2:162101506	NA	0.45	6.87	0.35	3.14e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LUSC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg09417038	chr21:47716443	C21orf57	-0.43	-6.73	-0.35	7.5e-11	Testicular germ cell tumor;
LUSC	cis	rs4964805	0.865	rs67825151	chr12:104205444	C/T	cg02344784	chr12:104178138	NT5DC3	0.4	6.37	0.33	6.4e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11060661	chr22:24314208	DDT;DDTL	0.49	7.97	0.4	2.59e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg23601095	chr6:26197514	HIST1H3D	0.68	7.51	0.38	5.59e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.44	0.75	8.43e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg11344533	chr11:111475393	SIK2	-0.49	-6.69	-0.34	9.69e-11	Primary sclerosing cholangitis;
LUSC	cis	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg21775007	chr8:11205619	TDH	0.51	7.31	0.37	2.04e-12	Monocyte count;
LUSC	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg13073564	chr4:8508604	NA	-0.46	-8.74	-0.43	1.17e-16	Response to antineoplastic agents;
LUSC	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg18357645	chr12:58087776	OS9	0.54	8.11	0.41	9.5e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg18904891	chr8:8559673	CLDN23	0.56	7.71	0.39	1.43e-13	Obesity-related traits;
LUSC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.52	-0.42	5.6e-16	Bipolar disorder;
LUSC	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	8.94	0.44	2.78e-17	Lung cancer in ever smokers;
LUSC	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg10130564	chr11:117069849	TAGLN	0.34	5.69	0.3	2.82e-8	Blood protein levels;
LUSC	cis	rs12618769	0.597	rs3769724	chr2:99105981	C/T	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg00484396	chr16:3507460	NAT15	0.71	12.23	0.56	1.09e-28	Tuberculosis;
LUSC	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.88	14.9	0.63	7.45e-39	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg23649088	chr2:200775458	C2orf69	0.49	7.44	0.38	8.65e-13	Osteoporosis;
LUSC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg13319975	chr6:146136371	FBXO30	-0.51	-7.74	-0.39	1.17e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg16482183	chr6:26056742	HIST1H1C	0.63	8.9	0.44	3.71e-17	Iron status biomarkers;
LUSC	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	0.57	8.79	0.43	8.3e-17	Breast cancer;
LUSC	cis	rs9398803	0.830	rs1337735	chr6:126771024	T/A	cg19875578	chr6:126661172	C6orf173	0.42	6.18	0.32	1.9e-9	Male-pattern baldness;
LUSC	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg09835421	chr16:68378352	PRMT7	-0.44	-5.78	-0.3	1.69e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg16482183	chr6:26056742	HIST1H1C	0.56	8.43	0.42	1.01e-15	Height;
LUSC	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.61	-10.38	-0.49	4.47e-22	Lung cancer;
LUSC	cis	rs68170813	0.559	rs74387778	chr7:106963213	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.46	-0.46	5.6e-19	Coronary artery disease;
LUSC	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.84	-15.98	-0.66	4.2e-43	Heart rate;
LUSC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-6.63	-0.34	1.37e-10	Homoarginine levels;
LUSC	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg03433033	chr1:76189801	ACADM	-0.42	-6.21	-0.32	1.57e-9	Daytime sleep phenotypes;
LUSC	cis	rs789859	0.965	rs789858	chr3:194405966	C/T	cg02072170	chr3:194406190	FAM43A	0.36	7.57	0.38	3.65e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-8.65	-0.43	2.26e-16	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg05865280	chr17:75406074	SEPT9	0.47	10.22	0.49	1.65e-21	Airflow obstruction;
LUSC	cis	rs6433857	0.505	rs1542036	chr2:181350009	A/C	cg23363182	chr2:181467187	NA	-0.45	-7.26	-0.37	2.76e-12	Body mass index;
LUSC	cis	rs2219968	0.962	rs10808824	chr8:78926741	G/A	cg00738934	chr8:78996279	NA	0.39	7.06	0.36	9.45e-12	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs4714291	0.832	rs7764688	chr6:40115442	G/T	cg02267698	chr19:7991119	CTXN1	-0.54	-8.08	-0.4	1.18e-14	Strep throat;
LUSC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.43	0.42	1.06e-15	Prudent dietary pattern;
LUSC	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg18827107	chr12:86230957	RASSF9	-0.4	-5.99	-0.31	5.56e-9	Major depressive disorder;
LUSC	trans	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.57	0.38	3.58e-13	Ulcerative colitis;
LUSC	cis	rs11677416	1.000	rs61381693	chr2:113525912	C/A	cg27083787	chr2:113543245	IL1A	0.46	7.05	0.36	1.05e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LUSC	trans	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.18	0.49	2.17e-21	Mean corpuscular volume;
LUSC	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg15383120	chr6:291909	DUSP22	-0.47	-7.18	-0.37	4.56e-12	Menopause (age at onset);
LUSC	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg02423579	chr7:2872169	GNA12	-0.41	-5.95	-0.31	6.71e-9	Height;
LUSC	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-5.97	-0.31	6.04e-9	Recombination measurement;
LUSC	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.88	0.31	1.02e-8	Lung cancer;
LUSC	cis	rs977987	0.750	rs4888414	chr16:75447233	A/G	cg03315344	chr16:75512273	CHST6	0.48	8.92	0.44	3.16e-17	Dupuytren's disease;
LUSC	cis	rs79387448	0.655	rs17639215	chr2:102953444	G/A	cg09003973	chr2:102972529	NA	1.18	12.45	0.56	1.76e-29	Gut microbiota (bacterial taxa);
LUSC	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg12091567	chr17:66097778	LOC651250	-0.74	-9.3	-0.45	1.92e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.56	9.92	0.48	1.71e-20	Birth weight;
LUSC	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg02176678	chr2:219576539	TTLL4	0.59	10.64	0.5	6.05e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg19418458	chr7:158789849	NA	-0.63	-10.4	-0.49	4.1e-22	Facial morphology (factor 20);
LUSC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg22868518	chr11:507468	RNH1	-0.58	-5.76	-0.3	1.95e-8	Body mass index;
LUSC	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg13902645	chr11:5959945	NA	-0.55	-7.7	-0.39	1.54e-13	DNA methylation (variation);
LUSC	cis	rs9677476	0.863	rs10202295	chr2:232084411	T/G	cg07929768	chr2:232055508	NA	0.36	6.76	0.35	6.31e-11	Food antigen IgG levels;
LUSC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.19	0.37	4.36e-12	Cognitive ability;
LUSC	cis	rs7804356	0.954	rs3823929	chr7:26856600	T/C	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.08e-9	Type 1 diabetes;
LUSC	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-6.75	-0.35	6.46e-11	Heart rate;
LUSC	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	11.65	0.54	1.5e-26	Menopause (age at onset);
LUSC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	cis	rs870825	0.616	rs7683615	chr4:185618373	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg16240275	chr20:61666158	NCRNA00029	0.42	9.24	0.45	2.9e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg13902645	chr11:5959945	NA	-0.58	-8.03	-0.4	1.64e-14	DNA methylation (variation);
LUSC	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg13010199	chr12:38710504	ALG10B	0.64	9.79	0.47	4.52e-20	Bladder cancer;
LUSC	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg08017756	chr2:100939284	LONRF2	-0.46	-8.58	-0.42	3.67e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg00701064	chr4:6280414	WFS1	0.58	13.86	0.6	7.78e-35	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13341460	chr6:126307568	TRMT11	0.69	6.33	0.33	7.73e-10	Cognitive performance;
LUSC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08736216	chr1:53307985	ZYG11A	0.3	6.19	0.32	1.78e-9	Monocyte count;
LUSC	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22455342	chr2:225449267	CUL3	0.44	6.02	0.31	4.54e-9	IgE levels in asthmatics (D.p. specific);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02871028	chr19:32896878	DPY19L3	-0.43	-6.61	-0.34	1.54e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2688608	1.000	rs2675680	chr10:75658864	T/C	cg17411546	chr10:75410026	SYNPO2L	-0.45	-6.79	-0.35	5.01e-11	Inflammatory bowel disease;
LUSC	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg14092571	chr14:90743983	NA	-0.35	-5.75	-0.3	2.03e-8	Mortality in heart failure;
LUSC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg16339924	chr4:17578868	LAP3	0.63	9.88	0.48	2.3e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg11645453	chr3:52864694	ITIH4	0.34	8.0	0.4	2.03e-14	Bipolar disorder;
LUSC	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg23387468	chr7:139079360	LUC7L2	-0.41	-6.25	-0.32	1.25e-9	Diisocyanate-induced asthma;
LUSC	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.81	-13.45	-0.59	3.08e-33	Bladder cancer;
LUSC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg09455208	chr3:40491958	NA	0.59	10.22	0.49	1.57e-21	Renal cell carcinoma;
LUSC	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg23601095	chr6:26197514	HIST1H3D	0.66	7.37	0.37	1.39e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24110177	chr3:50126178	RBM5	0.65	11.46	0.53	7.18e-26	Body mass index;
LUSC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06028605	chr16:24865363	SLC5A11	-0.7	-11.23	-0.52	4.7e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13770153	chr20:60521292	NA	-0.62	-8.32	-0.41	2.23e-15	Body mass index;
LUSC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg26513180	chr16:89883248	FANCA	0.79	6.38	0.33	5.97e-10	Skin colour saturation;
LUSC	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg15997130	chr1:24165203	NA	-0.52	-8.24	-0.41	3.91e-15	Immature fraction of reticulocytes;
LUSC	cis	rs4478037	1.000	rs56733391	chr3:33161434	G/A	cg19404215	chr3:33155277	CRTAP	0.96	9.76	0.47	5.72e-20	Major depressive disorder;
LUSC	cis	rs977987	0.843	rs4887820	chr16:75397287	C/T	cg04384234	chr16:75411784	CFDP1	-0.42	-6.91	-0.35	2.52e-11	Dupuytren's disease;
LUSC	cis	rs28647808	0.786	rs4962134	chr9:136256626	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	0.63	13.47	0.59	2.59e-33	Prudent dietary pattern;
LUSC	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.39	6.27	0.32	1.13e-9	Height;
LUSC	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg02275930	chr1:2372054	NA	-0.54	-9.25	-0.45	2.77e-18	Schizophrenia;
LUSC	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg04317338	chr11:64019027	PLCB3	0.57	5.81	0.3	1.48e-8	Mean platelet volume;
LUSC	cis	rs59698941	0.943	rs12519955	chr5:132283095	G/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs2652834	0.718	rs8034945	chr15:63397207	G/A	cg05507819	chr15:63340323	TPM1	0.55	7.07	0.36	8.99e-12	HDL cholesterol;
LUSC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg12386194	chr3:101231763	SENP7	0.48	6.97	0.36	1.67e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.56	8.71	0.43	1.42e-16	Menopause (age at onset);
LUSC	cis	rs524023	1.000	rs559946	chr11:64358605	T/C	cg07220939	chr11:64358617	SLC22A12	0.23	5.99	0.31	5.48e-9	Urate levels in obese individuals;
LUSC	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.54	0.34	2.35e-10	Lung cancer;
LUSC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.38	-0.33	5.86e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	0.9	14.73	0.63	3.34e-38	Breast cancer;
LUSC	trans	rs10949834	0.824	rs3801461	chr7:73536368	C/G	cg08527172	chr7:62560487	NA	0.41	6.03	0.31	4.32e-9	Verbal memory performance (residualized delayed recall change);
LUSC	trans	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.36	-0.33	6.6e-10	Triglycerides;
LUSC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.08	13.44	0.59	3.21e-33	Sexual dysfunction (female);
LUSC	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg24558204	chr6:135376177	HBS1L	0.59	9.07	0.44	1.05e-17	Red blood cell count;
LUSC	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.31	-0.33	8.69e-10	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LUSC	trans	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg26061582	chr7:22766209	IL6	0.51	7.39	0.37	1.17e-12	Lung cancer;
LUSC	cis	rs360798	0.512	rs1420018	chr2:63112500	A/G	cg17519650	chr2:63277830	OTX1	0.5	6.89	0.35	2.8e-11	Coronary artery disease;
LUSC	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	12.04	0.55	5.81e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.82	14.51	0.62	2.39e-37	Metabolic syndrome;
LUSC	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg06937882	chr20:24974362	C20orf3	-0.44	-7.67	-0.39	1.89e-13	Blood protein levels;
LUSC	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg05340658	chr4:99064831	C4orf37	0.58	8.63	0.43	2.47e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg27121462	chr16:89883253	FANCA	0.54	8.4	0.42	1.32e-15	Vitiligo;
LUSC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg20406979	chr6:167373233	NA	0.26	6.29	0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg08270630	chr22:50330655	NA	-0.44	-6.61	-0.34	1.48e-10	Schizophrenia;
LUSC	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.48	-6.48	-0.33	3.22e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg08000102	chr2:233561755	GIGYF2	-0.72	-11.98	-0.55	9.47e-28	Coronary artery disease;
LUSC	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	7.63	0.39	2.45e-13	Response to antipsychotic treatment;
LUSC	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	12.48	0.56	1.29e-29	Primary sclerosing cholangitis;
LUSC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2124969	0.506	rs62175396	chr2:161043603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.46	-5.69	-0.3	2.72e-8	Waist circumference adjusted for body mass index;
LUSC	cis	rs887829	0.569	rs3806596	chr2:234637707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.43	6.59	0.34	1.76e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs16867321	0.694	rs721301	chr2:181387265	A/G	cg23363182	chr2:181467187	NA	0.54	8.43	0.42	1.04e-15	Obesity;
LUSC	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg03806693	chr22:41940476	POLR3H	-0.59	-8.74	-0.43	1.19e-16	Neuroticism;
LUSC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.05e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1775715	0.870	rs3847415	chr10:32219456	G/T	cg26784012	chr10:32216390	ARHGAP12	0.41	6.9	0.35	2.65e-11	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs569214	1.000	rs569214	chr8:27487790	G/T	cg00839333	chr8:27504520	SCARA3	-0.37	-5.75	-0.3	1.99e-8	Alzheimer's disease;
LUSC	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg22705602	chr4:152727874	NA	-0.39	-8.61	-0.43	3.03e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs7851660	0.839	rs2417575	chr9:100628642	G/A	cg13688889	chr9:100608707	NA	-0.56	-8.94	-0.44	2.73e-17	Strep throat;
LUSC	cis	rs911119	0.954	rs2254635	chr20:23622758	G/T	cg16589663	chr20:23618590	CST3	0.62	7.83	0.39	6.44e-14	Chronic kidney disease;
LUSC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.61	12.65	0.57	3.12e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg09021430	chr5:549028	NA	-0.53	-7.49	-0.38	6.08e-13	Lung disease severity in cystic fibrosis;
LUSC	cis	rs17807624	0.702	rs7815172	chr8:11453671	T/C	cg21175976	chr8:11421337	BLK	0.36	6.01	0.31	4.92e-9	Systemic lupus erythematosus;
LUSC	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	8.17	0.41	6.51e-15	Neuroticism;
LUSC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg05776053	chr2:74358815	NA	0.41	6.27	0.32	1.14e-9	Gestational age at birth (maternal effect);
LUSC	cis	rs11229555	0.645	rs12803648	chr11:58177561	G/T	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7683537	0.692	rs56368159	chr4:185654827	T/G	cg04058563	chr4:185651563	MLF1IP	0.78	10.48	0.5	2.13e-22	Systemic lupus erythematosus;
LUSC	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg00745463	chr17:30367425	LRRC37B	0.89	9.03	0.44	1.45e-17	Hip circumference adjusted for BMI;
LUSC	trans	rs9944715	0.954	rs9960378	chr18:43811262	G/A	cg01718231	chr17:29326311	RNF135	-0.54	-7.71	-0.39	1.45e-13	Red cell distribution width;Mean corpuscular volume;
LUSC	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	1.01	14.09	0.61	1.09e-35	Uric acid levels;
LUSC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.17	-0.32	2.02e-9	Platelet count;
LUSC	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.84	-0.44	5.62e-17	Metabolite levels;
LUSC	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg08132940	chr7:1081526	C7orf50	-0.52	-6.17	-0.32	1.98e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg16989719	chr2:238392110	NA	-0.33	-5.93	-0.31	7.74e-9	Prostate cancer;
LUSC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg06627628	chr2:24431161	ITSN2	-0.6	-7.25	-0.37	2.88e-12	Lymphocyte counts;
LUSC	cis	rs8016982	0.632	rs4899786	chr14:81643800	G/T	cg01989461	chr14:81687754	GTF2A1	-0.56	-7.16	-0.36	5.13e-12	Schizophrenia;
LUSC	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg27284194	chr4:1044797	NA	0.57	8.42	0.42	1.12e-15	Recombination rate (females);
LUSC	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.74	12.19	0.55	1.56e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs11622475	1.000	rs11622475	chr14:104509076	C/T	cg12183467	chr14:104352244	NA	-0.4	-7.81	-0.39	7.35e-14	Bipolar disorder;
LUSC	cis	rs11605924	0.792	rs10838524	chr11:45870177	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.56	-8.3	-0.41	2.69e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs76419734	0.510	rs2553446	chr4:106696476	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.57	-6.64	-0.34	1.3e-10	Post bronchodilator FEV1;
LUSC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg20476274	chr7:133979776	SLC35B4	0.81	14.21	0.61	3.62e-36	Mean platelet volume;
LUSC	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg05973401	chr12:123451056	ABCB9	0.52	6.58	0.34	1.85e-10	Neutrophil percentage of white cells;
LUSC	cis	rs73206853	0.620	rs73194023	chr12:111137940	G/A	cg12870014	chr12:110450643	ANKRD13A	0.77	6.83	0.35	4e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg06207120	chr15:45996521	NA	0.4	6.24	0.32	1.31e-9	Waist circumference;Weight;
LUSC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg17211192	chr8:82754475	SNX16	-0.59	-8.75	-0.43	1.07e-16	Diastolic blood pressure;
LUSC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg26566898	chr11:117069891	TAGLN	0.48	8.4	0.42	1.33e-15	Blood protein levels;
LUSC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06221963	chr1:154839813	KCNN3	-0.6	-13.68	-0.6	3.97e-34	Prostate cancer;
LUSC	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg25174290	chr11:3078921	CARS	-0.4	-5.99	-0.31	5.54e-9	Calcium levels;
LUSC	cis	rs12545109	0.800	rs1968551	chr8:57407760	T/C	cg09654669	chr8:57350985	NA	-0.52	-6.61	-0.34	1.5e-10	Obesity-related traits;
LUSC	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg24910161	chr17:38119198	GSDMA	-0.29	-6.46	-0.33	3.76e-10	Asthma and hay fever;
LUSC	cis	rs9420	0.890	rs547891	chr11:57499065	C/T	cg23127183	chr11:57508653	C11orf31	0.53	8.17	0.41	6.49e-15	Schizophrenia;
LUSC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-8.6	-0.43	3.08e-16	Personality dimensions;
LUSC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.68	-10.41	-0.49	3.76e-22	Aortic root size;
LUSC	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.69	0.34	9.17e-11	Intraocular pressure;
LUSC	cis	rs559928	1.000	rs641168	chr11:64146289	C/G	cg24687543	chr11:63912206	MACROD1	-0.41	-5.76	-0.3	1.94e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg26384229	chr12:38710491	ALG10B	0.52	7.33	0.37	1.73e-12	Morning vs. evening chronotype;
LUSC	trans	rs7980799	0.649	rs1601003	chr12:33689436	A/T	cg13010199	chr12:38710504	ALG10B	0.43	6.16	0.32	2.13e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs198426	0.506	rs11230766	chr11:61426582	A/T	cg19838087	chr11:61442541	NA	-0.31	-6.35	-0.33	7.23e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
LUSC	cis	rs9326248	0.769	rs499910	chr11:116763034	G/A	cg26566898	chr11:117069891	TAGLN	0.41	6.95	0.36	1.98e-11	Blood protein levels;
LUSC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.6	-9.53	-0.46	3.44e-19	Pulse pressure;
LUSC	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.26	0.52	3.71e-25	Colorectal cancer;
LUSC	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg18850127	chr7:39170497	POU6F2	0.4	6.0	0.31	5.05e-9	IgG glycosylation;
LUSC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.01	0.31	4.76e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6500395	1.000	rs1558815	chr16:48704869	C/A	cg04672837	chr16:48644449	N4BP1	-0.46	-6.87	-0.35	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.65	9.88	0.48	2.39e-20	Lymphocyte counts;
LUSC	cis	rs6084875	0.812	rs2422938	chr20:4721926	G/C	cg07258627	chr20:4721683	PRNT	-0.34	-6.14	-0.32	2.34e-9	Systemic lupus erythematosus;
LUSC	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	13.61	0.6	7.33e-34	Smoking behavior;
LUSC	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg10434728	chr15:90938212	IQGAP1	0.45	9.09	0.45	9.03e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6700896	0.931	rs79050868	chr1:66120916	G/A	cg04111102	chr1:66153794	NA	0.33	7.34	0.37	1.65e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.81	-12.65	-0.57	3.22e-30	Refractive error;
LUSC	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.28	-0.33	1.04e-9	Total body bone mineral density;
LUSC	cis	rs3105593	0.933	rs11633404	chr15:50899309	C/A	cg08437265	chr15:50716283	USP8	0.4	5.95	0.31	6.6e-9	QT interval;
LUSC	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.87	-14.19	-0.61	4.1e-36	Schizophrenia;
LUSC	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	7.64	0.39	2.28e-13	Iron status biomarkers;
LUSC	cis	rs9443645	0.527	rs9718121	chr6:79729887	T/A	cg05283184	chr6:79620031	NA	-0.36	-6.87	-0.35	3.1e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg18681998	chr4:17616180	MED28	0.91	17.86	0.7	1.55e-50	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg11244672	chr19:19639970	YJEFN3	-0.58	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	cis	rs2019216	0.500	rs7359613	chr17:21944028	T/C	cg22648282	chr17:21454238	C17orf51	-0.5	-6.83	-0.35	4.12e-11	Pelvic organ prolapse;
LUSC	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg22356347	chr1:167427500	CD247	-0.29	-6.61	-0.34	1.54e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
LUSC	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg09184832	chr6:79620586	NA	0.42	6.62	0.34	1.42e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs9311676	0.632	rs56281646	chr3:58424917	G/A	cg26110898	chr3:58419937	PDHB	0.39	6.33	0.33	7.88e-10	Systemic lupus erythematosus;
LUSC	cis	rs9359856	0.600	rs11961825	chr6:90482250	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.51	-0.42	5.78e-16	Bipolar disorder;
LUSC	cis	rs698833	0.501	rs10194161	chr2:44507213	A/G	cg04920474	chr2:44395004	PPM1B	-0.55	-9.28	-0.45	2.24e-18	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg12564285	chr5:131593104	PDLIM4	0.33	6.0	0.31	5.21e-9	Blood metabolite levels;
LUSC	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-11.39	-0.53	1.32e-25	Coronary artery disease;
LUSC	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg05187965	chr10:45406764	TMEM72	-0.37	-8.79	-0.43	7.83e-17	Mean corpuscular volume;
LUSC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg00033643	chr7:134001901	SLC35B4	0.45	6.91	0.35	2.46e-11	Mean platelet volume;
LUSC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10802521	chr3:52805072	NEK4	-0.55	-8.91	-0.44	3.39e-17	Electroencephalogram traits;
LUSC	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg21466736	chr12:48725269	NA	-0.28	-5.68	-0.3	2.89e-8	Platelet count;
LUSC	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg26727032	chr16:67993705	SLC12A4	-0.45	-5.94	-0.31	7.32e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2425143	1.000	rs11699044	chr20:34312713	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	6.2	0.32	1.65e-9	Blood protein levels;
LUSC	cis	rs72781680	0.716	rs2712071	chr2:23990419	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	6.68	0.34	1.02e-10	Lymphocyte counts;
LUSC	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	6.19	0.32	1.76e-9	Height;
LUSC	cis	rs7202877	0.706	rs37602	chr16:75505046	C/T	cg03315344	chr16:75512273	CHST6	-0.4	-5.88	-0.31	1.01e-8	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg24375607	chr4:120327624	NA	0.76	11.41	0.53	1.06e-25	Corneal astigmatism;
LUSC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg06713675	chr4:122721982	EXOSC9	-0.46	-8.06	-0.4	1.39e-14	Type 2 diabetes;
LUSC	cis	rs740160	0.558	rs68164591	chr7:98904440	C/T	cg24650262	chr7:98904301	NA	0.61	6.3	0.33	9.42e-10	Dehydroepiandrosterone sulphate levels;
LUSC	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	11.27	0.52	3.59e-25	Colorectal cancer;
LUSC	cis	rs2708377	0.858	rs2599399	chr12:11283163	G/A	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.76	-7.77	-0.39	9.9e-14	Bitter taste perception;
LUSC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.36	-6.43	-0.33	4.31e-10	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs7189233	0.955	rs60420081	chr16:53520804	A/G	cg04059762	chr16:53544020	NA	-0.32	-5.81	-0.3	1.45e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg09904177	chr6:26538194	HMGN4	0.76	14.14	0.61	6.79e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs9837602	1.000	rs7616988	chr3:99701134	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	5.85	0.3	1.18e-8	Breast cancer;
LUSC	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg00319359	chr11:70116639	PPFIA1	0.58	5.7	0.3	2.65e-8	Coronary artery disease;
LUSC	cis	rs4834770	1.000	rs878374	chr4:120237564	A/G	cg24375607	chr4:120327624	NA	0.4	5.73	0.3	2.28e-8	Blood protein levels;
LUSC	cis	rs6845621	0.866	rs9992468	chr4:18935230	A/G	cg12196642	chr4:18937545	NA	-0.36	-6.76	-0.35	6.14e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs8113142	0.614	rs11083645	chr19:29214000	C/G	cg04546413	chr19:29218101	NA	-0.4	-5.82	-0.3	1.38e-8	Femoral neck bone geometry and menarche (age at onset);
LUSC	cis	rs116988415	0.584	rs747858	chr14:65239772	G/A	cg00114569	chr14:65239327	SPTB	0.7	6.78	0.35	5.46e-11	Daytime sleep phenotypes;
LUSC	cis	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg13609457	chr4:120235615	NA	-0.36	-5.73	-0.3	2.2e-8	Diastolic blood pressure;
LUSC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.74	8.84	0.44	5.49e-17	Body mass index;
LUSC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg07701084	chr6:150067640	NUP43	0.55	8.45	0.42	9.18e-16	Lung cancer;
LUSC	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.76	-12.92	-0.58	2.96e-31	Brugada syndrome;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17524151	chr16:475494	RAB11FIP3	-0.35	-5.98	-0.31	5.67e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs13089785	1.000	rs2332682	chr3:123654633	C/T	cg02012769	chr3:123398346	MYLK	0.34	6.43	0.33	4.44e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4889911	0.544	rs1285271	chr17:77834197	C/T	cg00646381	chr17:77835854	NA	-0.56	-8.33	-0.41	2.17e-15	Electroencephalogram traits;
LUSC	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg05855489	chr10:104503620	C10orf26	0.48	7.37	0.37	1.33e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg08999081	chr20:33150536	PIGU	0.44	8.14	0.41	7.85e-15	Coronary artery disease;
LUSC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.25	-0.49	1.27e-21	Platelet count;
LUSC	trans	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg17675199	chr6:35436792	RPL10A	-0.43	-6.42	-0.33	4.61e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4470077	1.000	rs4470077	chr14:55897538	A/G	cg04306507	chr14:55594613	LGALS3	0.37	5.7	0.3	2.68e-8	Platelet count;
LUSC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	7.59	0.38	3.32e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg07701084	chr6:150067640	NUP43	0.53	7.85	0.39	5.88e-14	Lung cancer;
LUSC	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg09165964	chr15:75287851	SCAMP5	-0.84	-7.69	-0.39	1.67e-13	Lung cancer;
LUSC	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg23711669	chr6:146136114	FBXO30	0.86	15.54	0.65	2.4e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-10.52	-0.5	1.46e-22	Morning vs. evening chronotype;
LUSC	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg17507749	chr15:85114479	UBE2QP1	0.59	7.52	0.38	5.07e-13	Schizophrenia;
LUSC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg23131131	chr22:24373011	LOC391322	0.41	6.0	0.31	5.24e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg08109568	chr15:31115862	NA	-0.58	-7.04	-0.36	1.07e-11	Huntington's disease progression;
LUSC	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg00945038	chr17:61921165	SMARCD2	0.4	6.16	0.32	2.13e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08439880	chr3:133502540	NA	-0.33	-6.02	-0.31	4.66e-9	Iron status biomarkers;
LUSC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	0.65	11.4	0.53	1.23e-25	Blood metabolite levels;
LUSC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11764359	chr7:65958608	NA	0.63	9.49	0.46	4.52e-19	Calcium levels;
LUSC	cis	rs17030434	0.953	rs76442373	chr4:154694783	G/A	cg14289246	chr4:154710475	SFRP2	-0.52	-6.79	-0.35	5.14e-11	Electrocardiographic conduction measures;
LUSC	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg23280166	chr11:118938394	VPS11	0.47	7.25	0.37	2.9e-12	Coronary artery disease;
LUSC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg22907277	chr7:1156413	C7orf50	0.72	7.67	0.39	1.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	6.74	0.35	7.17e-11	Lung cancer in ever smokers;
LUSC	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.61	9.5	0.46	4.31e-19	Blood metabolite ratios;
LUSC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg05623727	chr3:50126028	RBM5	-0.36	-6.85	-0.35	3.61e-11	Body mass index;
LUSC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.53	-0.38	4.77e-13	Personality dimensions;
LUSC	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg21138405	chr5:131827807	IRF1	0.35	6.16	0.32	2.13e-9	Breast cancer;Mosquito bite size;
LUSC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg24375607	chr4:120327624	NA	0.78	11.4	0.53	1.21e-25	Corneal astigmatism;
LUSC	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-8.53	-0.42	5.22e-16	Response to antipsychotic treatment;
LUSC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18404041	chr3:52824283	ITIH1	-0.46	-8.72	-0.43	1.35e-16	Electroencephalogram traits;
LUSC	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg03676636	chr4:99064102	C4orf37	0.35	7.8	0.39	7.75e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9815354	0.812	rs17219090	chr3:42051952	G/C	cg03022575	chr3:42003672	ULK4	0.61	6.48	0.33	3.28e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.55	-8.29	-0.41	2.85e-15	Lymphocyte counts;
LUSC	cis	rs9462027	0.628	rs7739003	chr6:34800329	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.09e-8	Systemic lupus erythematosus;
LUSC	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg24634471	chr8:143751801	JRK	0.5	7.16	0.36	5.23e-12	Schizophrenia;
LUSC	cis	rs6961069	0.935	rs819435	chr7:80224372	T/G	cg04458919	chr7:80252533	CD36	-0.36	-6.67	-0.34	1.09e-10	Platelet count;
LUSC	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	0.82	12.25	0.56	9.46e-29	Blood protein levels;
LUSC	cis	rs2559856	0.967	rs7970837	chr12:102081576	A/G	cg12924262	chr12:102091054	CHPT1	0.42	5.7	0.3	2.67e-8	Blood protein levels;
LUSC	cis	rs4132509	0.793	rs10927046	chr1:243801190	T/C	cg21452805	chr1:244014465	NA	0.58	5.76	0.3	1.94e-8	RR interval (heart rate);
LUSC	cis	rs62400317	0.762	rs756	chr6:44795772	C/T	cg18551225	chr6:44695536	NA	-0.46	-7.37	-0.37	1.34e-12	Total body bone mineral density;
LUSC	cis	rs78663649	0.908	rs79641498	chr19:16521143	C/A	cg05286348	chr19:16641544	CHERP	-0.61	-6.01	-0.31	4.84e-9	White blood cell count;
LUSC	cis	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg06521331	chr12:34319734	NA	-0.45	-7.37	-0.37	1.36e-12	Morning vs. evening chronotype;
LUSC	cis	rs5753037	0.838	rs140145	chr22:30178305	C/T	cg11564601	chr22:30592435	NA	0.34	6.33	0.33	7.78e-10	Type 1 diabetes;
LUSC	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg03433033	chr1:76189801	ACADM	-0.46	-6.93	-0.35	2.12e-11	Daytime sleep phenotypes;
LUSC	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg05925327	chr15:68127851	NA	-0.44	-7.12	-0.36	6.79e-12	Restless legs syndrome;
LUSC	cis	rs1775715	0.966	rs1639132	chr10:32301260	G/A	cg18675610	chr10:32216311	ARHGAP12	-0.29	-6.08	-0.32	3.22e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg02176678	chr2:219576539	TTLL4	0.6	10.84	0.51	1.18e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg13010199	chr12:38710504	ALG10B	0.42	6.1	0.32	2.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg13852791	chr20:30311386	BCL2L1	0.93	14.46	0.62	3.86e-37	Mean corpuscular hemoglobin;
LUSC	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-13.92	-0.61	4.89e-35	Exhaled nitric oxide output;
LUSC	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.56	0.38	3.9e-13	Colorectal cancer;
LUSC	cis	rs10761482	0.500	rs6479716	chr10:62302558	T/C	cg18175470	chr10:62150864	ANK3	-0.47	-6.85	-0.35	3.63e-11	Schizophrenia;
LUSC	cis	rs7712401	0.601	rs185009	chr5:122273767	A/G	cg19077854	chr5:122220652	SNX24	0.42	9.32	0.45	1.68e-18	Mean platelet volume;
LUSC	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg05347473	chr6:146136440	FBXO30	0.45	7.48	0.38	6.47e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg05555928	chr11:63887634	MACROD1	-0.52	-6.35	-0.33	7.06e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg03340356	chr1:67600835	NA	0.39	6.45	0.33	3.81e-10	Psoriasis;
LUSC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg13319975	chr6:146136371	FBXO30	0.54	8.27	0.41	3.17e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7481584	0.962	rs11603638	chr11:2990526	G/A	cg08508325	chr11:3079039	CARS	0.3	5.89	0.31	9.58e-9	Calcium levels;
LUSC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg00012203	chr2:219082015	ARPC2	0.7	11.53	0.53	4.08e-26	Colorectal cancer;
LUSC	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-0.91	-17.35	-0.69	1.58e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7119	0.717	rs12901732	chr15:77818933	G/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.61	-0.34	1.53e-10	Type 2 diabetes;
LUSC	cis	rs6906287	0.647	rs12215793	chr6:118956857	A/T	cg21191810	chr6:118973309	C6orf204	0.32	5.84	0.3	1.24e-8	Electrocardiographic conduction measures;
LUSC	cis	rs2795502	0.564	rs72777187	chr10:43432224	C/T	cg08461752	chr10:43522343	NA	-0.56	-6.67	-0.34	1.06e-10	Blood protein levels;
LUSC	cis	rs4478858	0.684	rs11578407	chr1:31728543	A/G	cg00250761	chr1:31883323	NA	-0.35	-8.43	-0.42	1.09e-15	Alcohol dependence;
LUSC	cis	rs12210905	0.925	rs72838260	chr6:27008168	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-5.73	-0.3	2.24e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg23758822	chr17:41437982	NA	0.98	18.49	0.71	4.55e-53	Menopause (age at onset);
LUSC	cis	rs7264396	0.623	rs11698601	chr20:34205035	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-7.18	-0.37	4.64e-12	Total cholesterol levels;
LUSC	trans	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg20935933	chr6:143382018	AIG1	0.51	7.16	0.36	5.08e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg25456477	chr12:86230367	RASSF9	0.44	7.67	0.39	1.92e-13	Major depressive disorder;
LUSC	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg03585969	chr10:35415529	CREM	0.6	8.84	0.44	5.75e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs28573326	0.629	rs1438119	chr4:166348346	T/C	cg13437084	chr2:26467494	HADHB;HADHA	-0.59	-6.76	-0.35	6.11e-11	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs1403694	0.695	rs11927941	chr3:186433046	A/G	cg12454167	chr3:186435060	KNG1	0.34	8.42	0.42	1.16e-15	Blood protein levels;
LUSC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.19	0.37	4.36e-12	Cognitive ability;
LUSC	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg03676636	chr4:99064102	C4orf37	0.36	8.1	0.41	1.07e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs662064	0.962	rs660725	chr1:10557544	A/G	cg17425144	chr1:10567563	PEX14	0.35	5.69	0.3	2.85e-8	Asthma;
LUSC	cis	rs2219968	0.962	rs9643733	chr8:78950551	G/T	cg00738934	chr8:78996279	NA	0.37	6.65	0.34	1.21e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6693567	0.545	rs1932934	chr1:150449195	G/A	cg15654264	chr1:150340011	RPRD2	0.43	6.85	0.35	3.45e-11	Migraine;
LUSC	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg12856521	chr11:46389249	DGKZ	0.4	6.45	0.33	3.82e-10	Leprosy;
LUSC	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg08668359	chr10:1443807	ADARB2	-0.42	-6.28	-0.32	1.08e-9	Radiation response;
LUSC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12311346	chr5:56204834	C5orf35	-1.09	-16.71	-0.67	5.34e-46	Initial pursuit acceleration;
LUSC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg14582100	chr15:45693742	SPATA5L1	0.57	10.61	0.5	7.49e-23	Homoarginine levels;
LUSC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg12963246	chr6:28129442	ZNF389	0.41	5.74	0.3	2.15e-8	Depression;
LUSC	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg00999904	chr2:3704751	ALLC	-0.34	-6.08	-0.32	3.34e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05794227	chr16:56484937	OGFOD1;NUDT21	-0.41	-6.07	-0.32	3.5e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9309473	0.847	rs13538	chr2:73868328	A/G	cg20560298	chr2:73613845	ALMS1	-0.42	-5.95	-0.31	6.71e-9	Metabolite levels;
LUSC	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg18758796	chr5:131593413	PDLIM4	0.35	6.03	0.31	4.46e-9	Blood metabolite levels;
LUSC	cis	rs3099143	1.000	rs3106378	chr15:77110524	A/C	cg21673338	chr15:77095150	SCAPER	-0.78	-7.37	-0.37	1.33e-12	Recalcitrant atopic dermatitis;
LUSC	cis	rs727505	0.954	rs17327014	chr7:124709349	C/T	cg23710748	chr7:124431027	NA	-0.41	-7.15	-0.36	5.55e-12	Lewy body disease;
LUSC	cis	rs6977660	0.652	rs10274428	chr7:19850592	C/T	cg05791153	chr7:19748676	TWISTNB	0.64	6.74	0.35	7.08e-11	Thyroid stimulating hormone;
LUSC	trans	rs7618314	0.571	rs16854821	chr3:108500645	G/C	cg05749855	chr16:89472771	ANKRD11	0.59	6.0	0.31	5.2e-9	Airway responsiveness in chronic obstructive pulmonary disease;
LUSC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.15	0.32	2.17e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg10729496	chr3:10149963	C3orf24	0.58	7.54	0.38	4.37e-13	Alzheimer's disease;
LUSC	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21659725	chr3:3221576	CRBN	-0.61	-9.07	-0.44	1.05e-17	Resting heart rate;
LUSC	cis	rs909341	0.868	rs2315009	chr20:62344140	C/G	cg09650180	chr20:62225654	GMEB2	-0.44	-5.79	-0.3	1.62e-8	Atopic dermatitis;
LUSC	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg22906224	chr7:99728672	NA	-0.46	-6.5	-0.34	2.92e-10	Coronary artery disease;
LUSC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg17294928	chr15:75287854	SCAMP5	0.41	5.98	0.31	5.88e-9	Breast cancer;
LUSC	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg03859395	chr2:55845619	SMEK2	0.81	14.18	0.61	4.7e-36	Metabolic syndrome;
LUSC	cis	rs377070	0.966	rs309419	chr4:123624001	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.47	6.87	0.35	3.16e-11	Mosquito bite size;
LUSC	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00631329	chr6:26305371	NA	-0.45	-8.62	-0.43	2.78e-16	Educational attainment;
LUSC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg06917634	chr15:78832804	PSMA4	0.83	14.99	0.63	3.39e-39	Sudden cardiac arrest;
LUSC	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg26384229	chr12:38710491	ALG10B	-0.53	-7.82	-0.39	6.96e-14	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg27432699	chr2:27873401	GPN1	0.8	15.0	0.63	3.16e-39	Oral cavity cancer;
LUSC	trans	rs4714291	0.963	rs940352	chr6:40113614	C/T	cg02267698	chr19:7991119	CTXN1	-0.53	-7.38	-0.37	1.26e-12	Strep throat;
LUSC	cis	rs13064411	0.660	rs11916690	chr3:113012343	A/C	cg18753928	chr3:113234510	CCDC52	-0.43	-6.21	-0.32	1.54e-9	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg01881094	chr2:180872142	CWC22	0.81	10.66	0.5	4.83e-23	Schizophrenia;
LUSC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.3	-0.33	9.33e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.77	-12.99	-0.58	1.66e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg13755796	chr4:20253514	NA	-0.39	-6.05	-0.31	3.84e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	1.04	13.36	0.59	6.43e-33	Corneal structure;
LUSC	cis	rs3755132	0.929	rs4668937	chr2:15736029	G/A	cg12888861	chr2:15731646	DDX1	0.5	7.34	0.37	1.68e-12	Wilms tumor;
LUSC	cis	rs9837602	0.938	rs17393059	chr3:99761908	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	6.17	0.32	2.01e-9	Breast cancer;
LUSC	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.9	-0.31	9.01e-9	Resting heart rate;
LUSC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg08917208	chr2:24149416	ATAD2B	0.55	6.16	0.32	2.04e-9	Lymphocyte counts;
LUSC	cis	rs7095944	0.584	rs11245347	chr10:126427037	G/T	cg08799069	chr10:126477246	METTL10	-0.43	-6.67	-0.34	1.09e-10	Asthma;
LUSC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	7.57	0.38	3.58e-13	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.62	9.46	0.46	5.51e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg17633681	chr16:88106987	BANP	0.49	9.04	0.44	1.28e-17	Menopause (age at onset);
LUSC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg05425664	chr17:57184151	TRIM37	-0.55	-8.15	-0.41	7.21e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs3125734	0.633	rs3902162	chr10:64041817	C/T	cg09941381	chr10:64027924	RTKN2	-0.39	-7.13	-0.36	6.25e-12	Rheumatoid arthritis;
LUSC	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg13010199	chr12:38710504	ALG10B	0.64	9.85	0.47	2.98e-20	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg02569458	chr12:86230093	RASSF9	-0.58	-9.78	-0.47	5.09e-20	Major depressive disorder;
LUSC	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg05855489	chr10:104503620	C10orf26	0.73	11.34	0.53	2e-25	Waist circumference;Hip circumference;
LUSC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.55	7.17	0.37	4.87e-12	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs6681460	0.932	rs536410	chr1:67191084	C/T	cg02459107	chr1:67143332	SGIP1	0.46	8.67	0.43	1.89e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg14582100	chr15:45693742	SPATA5L1	0.57	10.33	0.49	6.78e-22	Homoarginine levels;
LUSC	cis	rs708547	0.647	rs1277308	chr4:57897864	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.4	-5.93	-0.31	7.72e-9	Response to bleomycin (chromatid breaks);
LUSC	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	1.05	14.32	0.62	1.33e-36	Exhaled nitric oxide levels;
LUSC	cis	rs1113500	0.933	rs61797345	chr1:108623728	G/A	cg06207961	chr1:108661230	NA	0.4	7.49	0.38	6.17e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs9372498	0.536	rs62422221	chr6:118925581	T/C	cg18833306	chr6:118973337	C6orf204	-0.45	-5.68	-0.3	2.89e-8	Diastolic blood pressure;
LUSC	cis	rs7809950	0.817	rs2712230	chr7:107294151	G/A	cg23024343	chr7:107201750	COG5	0.58	8.2	0.41	5.37e-15	Coronary artery disease;
LUSC	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	12.74	0.57	1.43e-30	Menopause (age at onset);
LUSC	cis	rs926938	0.563	rs360652	chr1:115445478	C/T	cg12756093	chr1:115239321	AMPD1	0.41	6.16	0.32	2.04e-9	Autism;
LUSC	trans	rs11935423	0.778	rs3816873	chr4:100504664	T/C	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.05	-0.31	3.97e-9	Gut microbiome composition (summer);
LUSC	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg06937882	chr20:24974362	C20orf3	-0.41	-6.94	-0.36	2.02e-11	Blood protein levels;
LUSC	cis	rs243505	0.691	rs243480	chr7:148452905	G/T	cg09806900	chr7:148480153	CUL1	-0.52	-6.98	-0.36	1.55e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg08601574	chr20:25228251	PYGB	0.49	7.59	0.38	3.28e-13	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg07362569	chr17:61921086	SMARCD2	-0.3	-6.03	-0.31	4.47e-9	Prudent dietary pattern;
LUSC	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg26727032	chr16:67993705	SLC12A4	-0.42	-6.6	-0.34	1.65e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs8077577	0.895	rs3088233	chr17:18112675	C/T	cg16794390	chr17:18148240	FLII	0.41	5.75	0.3	2.01e-8	Obesity-related traits;
LUSC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.23	-0.56	1.08e-28	Alzheimer's disease;
LUSC	cis	rs2302729	0.858	rs10431348	chr12:2784534	A/G	cg19945202	chr12:2788847	CACNA1C	-0.42	-5.78	-0.3	1.71e-8	Sleep quality;
LUSC	trans	rs11681884	0.786	rs1992761	chr2:113810286	C/T	cg21236845	chr5:98115329	RGMB	0.77	5.96	0.31	6.27e-9	Stroke;
LUSC	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg05973401	chr12:123451056	ABCB9	0.62	8.94	0.44	2.65e-17	Platelet count;
LUSC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.2	0.37	4.05e-12	Motion sickness;
LUSC	cis	rs10465746	0.967	rs6670658	chr1:84461268	A/G	cg10977910	chr1:84465055	TTLL7	0.43	6.35	0.33	6.9e-10	Obesity-related traits;
LUSC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07362569	chr17:61921086	SMARCD2	0.38	7.56	0.38	3.97e-13	Prudent dietary pattern;
LUSC	cis	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg05299278	chr17:33885742	SLFN14	0.29	6.44	0.33	4.11e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs2731664	0.792	rs335435	chr5:176867943	A/G	cg23176889	chr5:176863531	GRK6	-0.65	-12.99	-0.58	1.66e-31	Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9300255	0.664	rs7306755	chr12:123767929	G/A	cg13010344	chr12:123464640	ARL6IP4	0.55	6.69	0.34	9.37e-11	Neutrophil percentage of white cells;
LUSC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg02782426	chr3:40428986	ENTPD3	0.32	6.17	0.32	2.01e-9	Renal cell carcinoma;
LUSC	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg17173187	chr15:85201210	NMB	0.51	9.69	0.47	9.71e-20	Schizophrenia;
LUSC	cis	rs10979	0.964	rs9496682	chr6:143898805	A/G	cg25407410	chr6:143891975	LOC285740	-0.75	-11.97	-0.55	1.06e-27	Hypospadias;
LUSC	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.63	-8.51	-0.42	5.81e-16	Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11079866	chr4:75858172	PARM1	0.43	6.15	0.32	2.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg23711669	chr6:146136114	FBXO30	0.73	11.9	0.55	1.8e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17227506	0.704	rs6530649	chr8:13448112	A/G	cg03566418	chr8:13424080	C8orf48	-0.4	-6.12	-0.32	2.61e-9	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7949030	0.929	rs11231173	chr11:62418921	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.48	8.04	0.4	1.61e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-1.14	-13.32	-0.59	9.63e-33	Arsenic metabolism;
LUSC	cis	rs9311676	0.656	rs11130636	chr3:58380098	C/A	cg13750441	chr3:58318267	PXK	0.36	7.06	0.36	9.88e-12	Systemic lupus erythematosus;
LUSC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg16339924	chr4:17578868	LAP3	-0.56	-8.18	-0.41	5.82e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg11812906	chr14:75593930	NEK9	0.67	11.56	0.53	3.23e-26	Height;
LUSC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg06740227	chr12:86229804	RASSF9	0.44	7.11	0.36	7.2e-12	Major depressive disorder;
LUSC	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg17788362	chr6:86352627	SYNCRIP	0.52	7.62	0.38	2.6e-13	Smooth-surface caries;
LUSC	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21545522	chr1:205238299	TMCC2	0.5	9.45	0.46	5.97e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-6.91	-0.35	2.46e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.6	8.02	0.4	1.85e-14	High light scatter reticulocyte count;
LUSC	cis	rs250677	0.524	rs417413	chr5:148452726	T/C	cg18129178	chr5:148520854	ABLIM3	-0.59	-9.82	-0.47	3.6e-20	Breast cancer;
LUSC	cis	rs4363385	0.626	rs11205192	chr1:153062767	C/T	cg00922841	chr1:152955080	SPRR1A	-0.35	-6.14	-0.32	2.35e-9	Inflammatory skin disease;
LUSC	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg05187965	chr10:45406764	TMEM72	-0.37	-8.79	-0.43	8.33e-17	Mean corpuscular volume;
LUSC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg14019146	chr3:50243930	SLC38A3	-0.33	-7.39	-0.38	1.16e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs747782	0.583	rs11039666	chr11:48324841	C/G	cg15704280	chr7:45808275	SEPT13	0.76	6.49	0.33	3.11e-10	Intraocular pressure;
LUSC	cis	rs2012796	0.957	rs8011477	chr14:81815587	C/T	cg02996355	chr14:81879375	NA	0.46	6.53	0.34	2.48e-10	Night sleep phenotypes;
LUSC	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.65	-8.74	-0.43	1.19e-16	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs28374715	1.000	rs28374715	chr15:41563950	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.83	-14.15	-0.61	6e-36	Ulcerative colitis;
LUSC	cis	rs977987	0.806	rs12448947	chr16:75462954	G/A	cg03315344	chr16:75512273	CHST6	0.5	9.56	0.46	2.75e-19	Dupuytren's disease;
LUSC	cis	rs2455601	0.638	rs3815991	chr11:9007669	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.42	6.74	0.35	6.91e-11	Schizophrenia;
LUSC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.64	10.55	0.5	1.22e-22	Bone mineral density;
LUSC	cis	rs17621444	0.522	rs10736278	chr10:121818149	A/G	cg02041677	chr10:121771263	NA	-0.32	-6.18	-0.32	1.92e-9	IgG glycosylation;
LUSC	trans	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	10.63	0.5	6.47e-23	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg11244672	chr19:19639970	YJEFN3	-0.56	-6.83	-0.35	4.13e-11	Bipolar disorder;
LUSC	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg18105134	chr13:113819100	PROZ	0.65	9.97	0.48	1.14e-20	Platelet distribution width;
LUSC	cis	rs1018836	0.847	rs2285231	chr8:91545387	G/T	cg16814680	chr8:91681699	NA	-0.74	-12.41	-0.56	2.5e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-6.6	-0.34	1.66e-10	Schizophrenia;
LUSC	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg13535736	chr9:111863775	C9orf5	-0.4	-6.6	-0.34	1.59e-10	Menarche (age at onset);
LUSC	trans	rs836788	0.608	rs26784	chr5:80049892	A/G	cg27031367	chr8:145510315	BOP1	-0.37	-6.07	-0.32	3.42e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs7267979	0.545	rs6050426	chr20:25178265	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.59	10.13	0.48	3.21e-21	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg19592336	chr6:28129416	ZNF389	0.45	5.98	0.31	5.78e-9	Depression;
LUSC	cis	rs2729354	0.768	rs2848635	chr11:57253931	T/C	cg24343310	chr11:57249947	NA	0.47	8.64	0.43	2.37e-16	Blood protein levels;
LUSC	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.38	-0.33	6.02e-10	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LUSC	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg18681998	chr4:17616180	MED28	0.84	15.64	0.65	9.43e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg00343986	chr7:65444356	GUSB	0.47	7.0	0.36	1.42e-11	Calcium levels;
LUSC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18404041	chr3:52824283	ITIH1	0.56	10.3	0.49	8.64e-22	Bipolar disorder;
LUSC	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.87	13.64	0.6	5.7e-34	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs9443189	0.570	rs504323	chr6:76294965	A/G	cg01950844	chr6:76311363	SENP6	-0.65	-6.08	-0.32	3.28e-9	Prostate cancer;
LUSC	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.64	8.04	0.4	1.54e-14	Lung function (FEV1/FVC);
LUSC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg04369109	chr6:150039330	LATS1	-0.54	-7.88	-0.4	4.69e-14	Lung cancer;
LUSC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg17279839	chr7:150038598	RARRES2	0.52	7.54	0.38	4.34e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg08859206	chr1:53392774	SCP2	-0.41	-6.72	-0.35	7.81e-11	Monocyte count;
LUSC	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.16	-0.36	5.08e-12	Coronary artery disease;
LUSC	cis	rs9443189	0.570	rs276687	chr6:76429995	G/T	cg01950844	chr6:76311363	SENP6	-0.7	-7.0	-0.36	1.43e-11	Prostate cancer;
LUSC	cis	rs6681460	1.000	rs6697088	chr1:67044724	C/G	cg02459107	chr1:67143332	SGIP1	-0.45	-8.05	-0.4	1.48e-14	Presence of antiphospholipid antibodies;
LUSC	cis	rs3741798	0.614	rs61922044	chr12:12490914	G/A	cg08615371	chr12:12503544	MANSC1	1.1	11.11	0.52	1.31e-24	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg03886242	chr7:26192032	NFE2L3	0.41	6.49	0.33	3.03e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6489882	0.703	rs6489864	chr12:113360025	A/G	cg20102336	chr12:113376681	OAS3	-0.41	-5.75	-0.3	2.02e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg23625390	chr15:77176239	SCAPER	-0.61	-9.56	-0.46	2.6e-19	Blood metabolite levels;
LUSC	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.38	-9.31	-0.45	1.81e-18	Diastolic blood pressure;
LUSC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08109568	chr15:31115862	NA	0.57	8.13	0.41	8.65e-15	Huntington's disease progression;
LUSC	trans	rs9393777	0.778	rs13212921	chr6:27205422	C/T	cg06606381	chr12:133084897	FBRSL1	-0.62	-6.42	-0.33	4.65e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg08917208	chr2:24149416	ATAD2B	0.53	5.88	0.31	1e-8	Lymphocyte counts;
LUSC	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg23260525	chr10:116636907	FAM160B1	0.43	9.24	0.45	3.04e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7575217	0.740	rs13392166	chr2:101768104	T/C	cg23907051	chr2:101730305	TBC1D8	-0.3	-7.85	-0.39	5.65e-14	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	8.23	0.41	4.29e-15	Colorectal or endometrial cancer;
LUSC	cis	rs6594499	0.872	rs7732974	chr5:110455381	T/C	cg04022379	chr5:110408740	TSLP	0.43	6.39	0.33	5.73e-10	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg14895029	chr7:2775587	GNA12	-0.36	-5.66	-0.3	3.31e-8	Height;
LUSC	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg21573476	chr21:45109991	RRP1B	-0.36	-5.79	-0.3	1.6e-8	Mean corpuscular volume;
LUSC	cis	rs6969780	1.000	rs739734	chr7:27159405	C/T	cg26364809	chr7:27145159	NA	-0.61	-6.16	-0.32	2.12e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg20608306	chr11:116969690	SIK3	0.37	6.9	0.35	2.68e-11	Blood protein levels;
LUSC	cis	rs6690583	0.623	rs1371142	chr1:85455373	A/T	cg22153463	chr1:85462885	MCOLN2	0.61	5.91	0.31	8.56e-9	Serum sulfate level;
LUSC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	0.62	13.17	0.58	3.4e-32	Prudent dietary pattern;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22357700	chr19:11805638	NA	0.41	6.47	0.33	3.5e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg09796270	chr17:17721594	SREBF1	0.43	7.63	0.39	2.41e-13	Total body bone mineral density;
LUSC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.34	0.33	7.63e-10	Lung cancer;
LUSC	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.32	0.33	8.55e-10	Corneal astigmatism;
LUSC	cis	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg06521852	chr22:38141419	TRIOBP	0.45	6.73	0.35	7.34e-11	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.5	-7.09	-0.36	8.18e-12	Renal function-related traits (BUN);
LUSC	trans	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg17712092	chr4:129076599	LARP1B	-0.62	-8.3	-0.41	2.68e-15	DNA methylation (variation);
LUSC	cis	rs11945232	1.000	rs28406846	chr4:88343468	C/G	cg23841344	chr4:88312519	HSD17B11	-0.67	-10.33	-0.49	6.62e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs3018712	0.532	rs2513280	chr11:68416907	C/G	cg22747802	chr11:68417633	NA	-0.41	-5.65	-0.3	3.5e-8	Total body bone mineral density;
LUSC	cis	rs721399	0.568	rs34987019	chr8:18274443	T/C	cg18736775	chr8:18248649	NAT2	-0.55	-6.74	-0.35	7.12e-11	Blood metabolite levels;
LUSC	cis	rs8048589	0.604	rs2175020	chr16:12219190	C/T	cg02910054	chr16:12241554	SNX29	0.45	6.15	0.32	2.26e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs1190552	0.841	rs56144019	chr14:102949731	G/A	cg18135206	chr14:102964638	TECPR2	0.47	5.71	0.3	2.56e-8	Blood protein levels;
LUSC	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg21573476	chr21:45109991	RRP1B	-0.37	-6.04	-0.31	4.2e-9	Mean corpuscular volume;
LUSC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg19774624	chr17:42201019	HDAC5	-0.7	-10.65	-0.5	5.47e-23	Total body bone mineral density;
LUSC	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg25214090	chr10:38739885	LOC399744	0.55	8.0	0.4	2.05e-14	Corneal astigmatism;
LUSC	cis	rs7212590	0.748	rs7213697	chr17:57903041	G/C	cg10252138	chr17:58120427	NA	-0.74	-7.0	-0.36	1.37e-11	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.69	-0.34	9.15e-11	Retinal vascular caliber;
LUSC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	17.92	0.7	8.94e-51	Chronic sinus infection;
LUSC	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg11901034	chr3:128598214	ACAD9	-0.41	-6.47	-0.33	3.54e-10	IgG glycosylation;
LUSC	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg03433033	chr1:76189801	ACADM	-0.45	-6.84	-0.35	3.86e-11	Daytime sleep phenotypes;
LUSC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.46	-7.37	-0.37	1.34e-12	Bipolar disorder;
LUSC	cis	rs7119	0.745	rs11632602	chr15:77809764	C/G	cg27398640	chr15:77910606	LINGO1	-0.31	-6.76	-0.35	6.17e-11	Type 2 diabetes;
LUSC	cis	rs7188861	0.597	rs12918017	chr16:11402350	G/A	cg00044050	chr16:11439710	C16orf75	0.59	6.18	0.32	1.84e-9	HDL cholesterol;
LUSC	cis	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.45	3.08e-18	Morning vs. evening chronotype;
LUSC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.95	-13.74	-0.6	2.42e-34	Initial pursuit acceleration;
LUSC	cis	rs701145	0.730	rs701141	chr3:154061053	G/A	cg17054900	chr3:154042577	DHX36	0.8	8.37	0.42	1.56e-15	Coronary artery disease;
LUSC	cis	rs7000551	0.606	rs13256933	chr8:22267199	T/G	cg12081754	chr8:22256438	SLC39A14	0.94	14.61	0.62	9.9e-38	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg06096015	chr1:231504339	EGLN1	0.58	10.37	0.49	5.03e-22	Hemoglobin concentration;
LUSC	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg10978503	chr1:24200527	CNR2	-0.51	-11.53	-0.53	4.09e-26	Immature fraction of reticulocytes;
LUSC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.52	7.54	0.38	4.6e-13	Gut microbiome composition (summer);
LUSC	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg16359550	chr11:109292809	C11orf87	-0.35	-5.92	-0.31	8e-9	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg03146154	chr1:46216737	IPP	0.52	7.7	0.39	1.53e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg04522931	chr7:30324582	ZNRF2	0.38	6.3	0.33	9.26e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	6.91	0.35	2.53e-11	Monocyte percentage of white cells;
LUSC	cis	rs13082711	0.522	rs3103745	chr3:27342927	T/C	cg02860705	chr3:27208620	NA	0.46	8.46	0.42	8.4e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LUSC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg13395646	chr4:1353034	KIAA1530	-0.65	-10.25	-0.49	1.32e-21	Obesity-related traits;
LUSC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg09263875	chr16:632152	PIGQ	0.7	12.63	0.57	3.65e-30	Height;
LUSC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg09033563	chr22:24373618	LOC391322	-0.5	-7.03	-0.36	1.19e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg15744005	chr10:104629667	AS3MT	0.31	6.61	0.34	1.51e-10	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg04287289	chr16:89883240	FANCA	0.78	13.54	0.6	1.38e-33	Vitiligo;
LUSC	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg05791153	chr7:19748676	TWISTNB	0.77	8.33	0.41	2.07e-15	Thyroid stimulating hormone;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21564660	chr12:50236950	BCDIN3D	-0.43	-6.28	-0.32	1.08e-9	Electrocardiographic conduction measures;
LUSC	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg23625390	chr15:77176239	SCAPER	0.6	9.41	0.46	8.06e-19	Blood metabolite levels;
LUSC	cis	rs983392	0.679	rs636317	chr11:60019150	C/T	cg02771260	chr11:59836817	MS4A3	0.38	6.26	0.32	1.17e-9	Alzheimer's disease (late onset);
LUSC	trans	rs2790216	0.526	rs1199093	chr10:59896794	C/G	cg05993363	chr11:15671931	NA	-0.38	-6.03	-0.31	4.38e-9	Inflammatory bowel disease;
LUSC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg08470875	chr2:26401718	FAM59B	-0.69	-9.49	-0.46	4.53e-19	Gut microbiome composition (summer);
LUSC	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	8.36	0.42	1.72e-15	Mean platelet volume;
LUSC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06481639	chr22:41940642	POLR3H	0.5	5.72	0.3	2.42e-8	Vitiligo;
LUSC	trans	rs7567288	0.636	rs7568394	chr2:134462374	G/A	cg12381416	chr3:14359266	NA	0.55	6.1	0.32	3e-9	Height;
LUSC	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg19812747	chr11:111475976	SIK2	-0.53	-7.36	-0.37	1.4e-12	Primary sclerosing cholangitis;
LUSC	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.69	10.56	0.5	1.09e-22	Breast cancer;
LUSC	trans	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg17675199	chr6:35436792	RPL10A	-0.43	-6.32	-0.33	8.21e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg03161606	chr19:29218774	NA	0.61	9.03	0.44	1.38e-17	Methadone dose in opioid dependence;
LUSC	cis	rs11031096	0.677	rs11031043	chr11:4145385	G/T	cg18678763	chr11:4115507	RRM1	0.38	5.77	0.3	1.79e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg18404041	chr3:52824283	ITIH1	0.53	8.86	0.44	4.93e-17	Schizophrenia;
LUSC	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg18850127	chr7:39170497	POU6F2	0.63	9.8	0.47	4.2e-20	IgG glycosylation;
LUSC	cis	rs62400317	0.859	rs10456121	chr6:45092545	G/A	cg18551225	chr6:44695536	NA	-0.42	-6.87	-0.35	3.22e-11	Total body bone mineral density;
LUSC	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg19920283	chr7:105172520	RINT1	0.58	6.25	0.32	1.25e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-9.82	-0.47	3.7e-20	Total cholesterol levels;
LUSC	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	8.12	0.41	9e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg20887711	chr4:1340912	KIAA1530	0.44	6.6	0.34	1.63e-10	Obesity-related traits;
LUSC	cis	rs3784262	0.679	rs4238326	chr15:58336000	C/T	cg12031962	chr15:58353849	ALDH1A2	0.38	6.72	0.35	7.84e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	trans	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg18187862	chr3:45730750	SACM1L	0.54	6.88	0.35	3.03e-11	Primary sclerosing cholangitis;
LUSC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-8.81	-0.43	6.75e-17	Platelet count;
LUSC	trans	rs72674100	1.000	rs77899474	chr4:97952494	C/A	cg09670535	chr1:18959427	PAX7	-0.62	-6.36	-0.33	6.65e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.66	11.29	0.53	3.07e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.67	-10.62	-0.5	6.81e-23	Menarche (age at onset);
LUSC	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg14227996	chr4:17616232	MED28	0.67	7.19	0.37	4.17e-12	Opioid sensitivity;
LUSC	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.7e-32	Blood protein levels;
LUSC	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg03342759	chr3:160939853	NMD3	-0.51	-8.67	-0.43	1.87e-16	Morning vs. evening chronotype;
LUSC	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg10523860	chr14:103875565	MARK3	-0.39	-6.29	-0.33	1.02e-9	Body mass index;
LUSC	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg11645453	chr3:52864694	ITIH4	0.36	7.79	0.39	8.29e-14	Bipolar disorder;
LUSC	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg00262122	chr8:11665843	FDFT1	-0.38	-5.72	-0.3	2.41e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.52	0.38	5.17e-13	Menarche (age at onset);
LUSC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.5	-0.33	3e-10	Life satisfaction;
LUSC	trans	rs7374394	1.000	rs2301052	chr3:184953662	C/T	cg08120831	chr12:122669186	LRRC43	0.3	6.38	0.33	5.81e-10	Cognitive performance;
LUSC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg11189052	chr15:85197271	WDR73	-0.64	-9.98	-0.48	1.08e-20	P wave terminal force;
LUSC	trans	rs731565	1.000	rs1525254	chr7:147406140	C/T	cg20906291	chr6:10382103	NA	-0.56	-6.17	-0.32	1.94e-9	Diabetic kidney disease;
LUSC	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21643547	chr1:205240462	TMCC2	-0.51	-9.5	-0.46	4.34e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-7.13	-0.36	6.32e-12	Cognitive test performance;
LUSC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg26380479	chr7:97908229	NA	-0.28	-6.25	-0.32	1.24e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.91	0.51	6.74e-24	Bladder cancer;
LUSC	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-7.23	-0.37	3.37e-12	Mood instability;
LUSC	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg22705602	chr4:152727874	NA	-0.37	-8.17	-0.41	6.65e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg07414643	chr4:187882934	NA	0.55	10.53	0.5	1.41e-22	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.51	-6.63	-0.34	1.39e-10	Response to bleomycin (chromatid breaks);
LUSC	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.78	11.53	0.53	4.06e-26	Corneal astigmatism;
LUSC	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg12288994	chr5:1860383	NA	0.31	7.02	0.36	1.27e-11	Cardiovascular disease risk factors;
LUSC	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-6.87	-0.35	3.13e-11	Response to antipsychotic treatment;
LUSC	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg26384229	chr12:38710491	ALG10B	0.7	10.96	0.51	4.28e-24	Morning vs. evening chronotype;
LUSC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-1.16	-16.62	-0.67	1.22e-45	Breast cancer;
LUSC	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.84	-0.44	5.51e-17	Retinal vascular caliber;
LUSC	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.69	-0.34	9.49e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2708977	0.637	rs618454	chr2:97080093	C/G	cg01950434	chr2:97203154	ARID5A	-0.44	-6.26	-0.32	1.16e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg03806693	chr22:41940476	POLR3H	0.87	12.97	0.58	2.02e-31	Vitiligo;
LUSC	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg17691542	chr6:26056736	HIST1H1C	0.47	7.1	0.36	7.6e-12	Height;
LUSC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg02153584	chr22:29168773	CCDC117	0.66	10.6	0.5	8e-23	Lymphocyte counts;
LUSC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg15556689	chr8:8085844	FLJ10661	-0.67	-10.88	-0.51	8.4e-24	Mood instability;
LUSC	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.35	-0.53	1.83e-25	Mean corpuscular volume;
LUSC	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg09904177	chr6:26538194	HMGN4	0.76	14.41	0.62	5.82e-37	Intelligence (multi-trait analysis);
LUSC	trans	rs10851478	0.872	rs12591659	chr15:49933823	G/A	cg23074453	chr15:44487924	FRMD5	-0.33	-6.08	-0.32	3.26e-9	Oral cavity cancer;
LUSC	cis	rs7572644	0.723	rs10201105	chr2:28131233	G/C	cg27432699	chr2:27873401	GPN1	-0.52	-6.49	-0.33	3.05e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg06521331	chr12:34319734	NA	-0.48	-7.67	-0.39	1.84e-13	Morning vs. evening chronotype;
LUSC	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.27e-20	Coronary artery disease;
LUSC	cis	rs73198271	0.653	rs10099808	chr8:8659873	A/G	cg01851573	chr8:8652454	MFHAS1	-0.5	-8.58	-0.43	3.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.73	-14.05	-0.61	1.55e-35	Ulcerative colitis;
LUSC	cis	rs4604732	0.642	rs10925048	chr1:247640736	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.36	5.93	0.31	7.62e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg12843872	chr7:90894352	FZD1	0.45	6.33	0.33	7.86e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.4	0.38	1.15e-12	Schizophrenia;
LUSC	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg02176678	chr2:219576539	TTLL4	-0.66	-12.89	-0.58	4.08e-31	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs2932538	0.922	rs12137107	chr1:113127437	A/G	cg22162597	chr1:113214053	CAPZA1	0.7	10.1	0.48	4.1e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.85	-0.54	2.91e-27	Chronic sinus infection;
LUSC	cis	rs1107366	0.722	rs35331719	chr3:125907392	C/A	cg01346077	chr3:125931526	NA	0.34	6.43	0.33	4.32e-10	Metabolite levels;
LUSC	cis	rs7904985	0.889	rs1078789	chr10:88110247	C/T	cg07322936	chr10:88137208	NA	-0.53	-7.14	-0.36	5.69e-12	Barrett's esophagus;
LUSC	cis	rs1030268	0.651	rs12707121	chr7:133496379	A/G	cg10665199	chr7:133106180	EXOC4	0.54	5.84	0.3	1.22e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg03948781	chr1:205179583	DSTYK	0.32	6.21	0.32	1.53e-9	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs3857536	0.611	rs7748258	chr6:66932840	A/G	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.56e-10	Blood trace element (Cu levels);
LUSC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12311346	chr5:56204834	C5orf35	0.83	13.76	0.6	2e-34	Initial pursuit acceleration;
LUSC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg10556349	chr10:835070	NA	0.56	6.44	0.33	4.08e-10	Eosinophil percentage of granulocytes;
LUSC	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06002616	chr8:101225028	SPAG1	-0.44	-7.23	-0.37	3.26e-12	Atrioventricular conduction;
LUSC	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg21699342	chr2:239360505	ASB1	0.53	9.7	0.47	8.96e-20	Multiple system atrophy;
LUSC	cis	rs2996428	0.667	rs61768933	chr1:3766587	G/A	cg22529645	chr1:3704559	LRRC47	0.38	6.77	0.35	5.86e-11	Red cell distribution width;
LUSC	cis	rs4363385	0.643	rs11576457	chr1:152918556	C/T	cg00922841	chr1:152955080	SPRR1A	0.41	6.88	0.35	2.99e-11	Inflammatory skin disease;
LUSC	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-8.65	-0.43	2.18e-16	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg08017756	chr2:100939284	LONRF2	-0.44	-8.21	-0.41	4.95e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg07741184	chr6:167504864	NA	0.51	8.74	0.43	1.15e-16	Crohn's disease;
LUSC	cis	rs68170813	0.559	rs17429118	chr7:106964052	C/T	cg02696742	chr7:106810147	HBP1	-0.64	-9.47	-0.46	5.13e-19	Coronary artery disease;
LUSC	cis	rs9905704	0.914	rs2643120	chr17:56826949	A/T	cg12560992	chr17:57184187	TRIM37	0.56	7.89	0.4	4.39e-14	Testicular germ cell tumor;
LUSC	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg15557168	chr22:42548783	NA	-0.33	-5.66	-0.3	3.18e-8	Cognitive function;
LUSC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9653442	0.628	rs12474386	chr2:100857017	G/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.88	-0.31	9.98e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg05709478	chr1:6581295	PLEKHG5	0.51	5.99	0.31	5.54e-9	Body mass index;
LUSC	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg08601574	chr20:25228251	PYGB	0.45	6.81	0.35	4.56e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg11075029	chr15:45492679	SHF	0.34	6.23	0.32	1.42e-9	Tuberculosis;
LUSC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg05717871	chr11:638507	DRD4	-0.35	-6.08	-0.32	3.37e-9	Systemic lupus erythematosus;
LUSC	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.46	6.75	0.35	6.72e-11	Schizophrenia;
LUSC	cis	rs7707921	0.957	rs2059891	chr5:81508792	G/C	cg15871215	chr5:81402204	ATG10	0.45	6.56	0.34	2.1e-10	Breast cancer;
LUSC	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.58	-0.42	3.71e-16	Rheumatoid arthritis;
LUSC	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg04310649	chr10:35416472	CREM	-0.41	-6.56	-0.34	2.02e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs8114671	0.562	rs2425005	chr20:33407715	C/G	cg07148914	chr20:33460835	GGT7	-0.66	-7.7	-0.39	1.58e-13	Height;
LUSC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg12292205	chr6:26970375	C6orf41	0.66	11.23	0.52	4.99e-25	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03611598	chr17:48586076	MYCBPAP	0.51	6.42	0.33	4.6e-10	Visceral fat;
LUSC	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg10523679	chr1:76189770	ACADM	-0.45	-6.63	-0.34	1.36e-10	Daytime sleep phenotypes;
LUSC	cis	rs360798	0.512	rs9973612	chr2:63019815	G/C	cg17519650	chr2:63277830	OTX1	-0.47	-6.54	-0.34	2.32e-10	Coronary artery disease;
LUSC	cis	rs1997103	0.798	rs12154964	chr7:55414041	G/A	cg17469321	chr7:55412551	NA	0.66	10.64	0.5	6.02e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-9.94	-0.48	1.47e-20	Mood instability;
LUSC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg00530320	chr1:46809349	NSUN4	0.57	8.81	0.43	6.79e-17	Menopause (age at onset);
LUSC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06481639	chr22:41940642	POLR3H	0.49	5.67	0.3	3.04e-8	Vitiligo;
LUSC	trans	rs7178375	1.000	rs4779797	chr15:31208425	C/T	cg04373760	chr16:53404718	NA	-0.63	-8.77	-0.43	9.19e-17	Hypertriglyceridemia;
LUSC	cis	rs34115320	1	rs34115320	chr7:148783936	CT/C	cg23158103	chr7:148848205	ZNF398	-0.4	-6.29	-0.33	9.97e-10	Sum basophil neutrophil counts;Neutrophil count;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg08544746	chr1:3713043	LRRC47	-0.49	-6.03	-0.31	4.38e-9	Neuroticism;
LUSC	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg11812906	chr14:75593930	NEK9	-0.63	-10.52	-0.5	1.56e-22	Height;
LUSC	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.42	-5.69	-0.3	2.73e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-6.4	-0.33	5.11e-10	Major depressive disorder;
LUSC	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg02423579	chr7:2872169	GNA12	-0.36	-5.77	-0.3	1.84e-8	Height;
LUSC	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.76	-12.42	-0.56	2.31e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1577917	0.839	rs1447159	chr6:86609249	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.43	-6.25	-0.32	1.22e-9	Response to antipsychotic treatment;
LUSC	cis	rs7119038	0.774	rs73005423	chr11:118681079	A/G	cg19308663	chr11:118741387	NA	0.36	6.35	0.33	7.15e-10	Sjögren's syndrome;
LUSC	cis	rs12592111	1	rs12592111	chr15:78767346	G/A	cg18825076	chr15:78729989	IREB2	-0.42	-6.72	-0.35	7.89e-11	Parental longevity (combined parental age at death);Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs500891	0.645	rs1180191	chr6:83965006	C/T	cg08257003	chr6:84140564	ME1	0.3	6.66	0.34	1.09e-10	Platelet-derived growth factor BB levels;
LUSC	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg20608306	chr11:116969690	SIK3	0.37	6.78	0.35	5.47e-11	Blood protein levels;
LUSC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg12559939	chr2:27858050	GPN1	0.41	6.4	0.33	5.27e-10	Oral cavity cancer;
LUSC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25067162	chr17:41277974	BRCA1;NBR2	-0.36	-5.87	-0.31	1.05e-8	Menopause (age at onset);
LUSC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11890956	chr21:40555474	PSMG1	-0.68	-9.75	-0.47	6.5e-20	Menarche (age at onset);
LUSC	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg13390004	chr1:15929781	NA	0.41	6.84	0.35	3.85e-11	Systolic blood pressure;
LUSC	cis	rs9902453	0.933	rs1128156	chr17:28513176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.65	0.43	2.28e-16	Coffee consumption (cups per day);
LUSC	cis	rs6542838	0.641	rs883773	chr2:99491635	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.39	-0.33	5.73e-10	Fear of minor pain;
LUSC	cis	rs7527798	0.592	rs2296159	chr1:207851760	G/A	cg09232269	chr1:207846808	CR1L	-0.29	-6.26	-0.32	1.21e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg12432903	chr7:1882776	MAD1L1	-0.49	-6.41	-0.33	4.89e-10	Bipolar disorder;
LUSC	cis	rs921665	0.748	rs1869419	chr2:3202080	C/T	cg02624386	chr2:3182749	NA	0.62	6.61	0.34	1.55e-10	World class endurance athleticism;
LUSC	cis	rs4343996	0.536	rs1554497	chr7:3415446	G/T	cg21248987	chr7:3385318	SDK1	-0.36	-6.14	-0.32	2.31e-9	Motion sickness;
LUSC	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	0.84	13.39	0.59	5.1e-33	Headache;
LUSC	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-16.94	-0.68	6.53e-47	Exhaled nitric oxide output;
LUSC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg06627628	chr2:24431161	ITSN2	-0.6	-7.27	-0.37	2.63e-12	Lymphocyte counts;
LUSC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.77	0.3	1.8e-8	Lung cancer;
LUSC	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.62	9.93	0.48	1.51e-20	Blood metabolite ratios;
LUSC	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg08680598	chr22:49984980	NA	-0.34	-6.32	-0.33	8.22e-10	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg14552801	chr7:65878734	NA	-0.45	-6.48	-0.33	3.2e-10	Aortic root size;
LUSC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg10755058	chr3:40428713	ENTPD3	0.37	5.99	0.31	5.42e-9	Renal cell carcinoma;
LUSC	cis	rs2219968	1.000	rs13276048	chr8:78975258	G/A	cg00738934	chr8:78996279	NA	0.35	6.23	0.32	1.37e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.74	10.06	0.48	5.7e-21	HIV-1 control;
LUSC	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg01620082	chr3:125678407	NA	-0.81	-7.79	-0.39	8.42e-14	Depression;
LUSC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg14993813	chr1:46806288	NSUN4	-0.52	-7.29	-0.37	2.2e-12	Menopause (age at onset);
LUSC	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.53	-14.57	-0.62	1.47e-37	Urate levels in overweight individuals;
LUSC	cis	rs9905704	0.918	rs68139131	chr17:56717249	A/G	cg12560992	chr17:57184187	TRIM37	0.55	7.85	0.39	5.74e-14	Testicular germ cell tumor;
LUSC	cis	rs10979	1.000	rs9484769	chr6:143896719	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs4974559	0.739	rs6845586	chr4:1323070	G/A	cg02980000	chr4:1222292	CTBP1	0.97	9.05	0.44	1.17e-17	Systolic blood pressure;
LUSC	trans	rs1941687	0.764	rs1493918	chr18:31381845	C/G	cg27147174	chr7:100797783	AP1S1	-0.53	-8.13	-0.41	8.21e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.7	-11.39	-0.53	1.32e-25	Colorectal cancer;
LUSC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11645453	chr3:52864694	ITIH4	0.56	13.66	0.6	4.77e-34	Schizophrenia;
LUSC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg25767906	chr1:53392781	SCP2	-0.48	-8.6	-0.43	3.13e-16	Monocyte count;
LUSC	cis	rs9296092	0.560	rs9469511	chr6:33530930	T/G	cg13560919	chr6:33536144	NA	-0.86	-16.35	-0.67	1.43e-44	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs12760731	0.623	rs3791025	chr1:178357907	C/G	cg00404053	chr1:178313656	RASAL2	0.47	5.69	0.3	2.73e-8	Obesity-related traits;
LUSC	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.8	0.43	7.49e-17	Lung cancer in ever smokers;
LUSC	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.69	0.57	2.12e-30	White blood cell count;
LUSC	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg13010199	chr12:38710504	ALG10B	0.65	10.24	0.49	1.4e-21	Bladder cancer;
LUSC	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg03684893	chr10:554711	DIP2C	-0.35	-6.35	-0.33	7.16e-10	Psychosis in Alzheimer's disease;
LUSC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg06064525	chr11:970664	AP2A2	-0.48	-10.38	-0.49	4.55e-22	Alzheimer's disease (late onset);
LUSC	trans	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg25258033	chr6:167368657	RNASET2	-0.47	-7.95	-0.4	2.87e-14	Crohn's disease;
LUSC	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.49	6.72	0.35	8.08e-11	Corneal astigmatism;
LUSC	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg02423579	chr7:2872169	GNA12	-0.41	-6.38	-0.33	5.95e-10	Height;
LUSC	cis	rs7180079	0.925	rs4776447	chr15:64643067	C/T	cg02848875	chr15:64387786	SNX1	0.4	5.64	0.3	3.54e-8	Monocyte count;
LUSC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg18758796	chr5:131593413	PDLIM4	0.35	6.27	0.32	1.1e-9	Blood metabolite levels;
LUSC	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg09835421	chr16:68378352	PRMT7	-0.55	-6.16	-0.32	2.09e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg12935359	chr14:103987150	CKB	-0.52	-7.95	-0.4	2.93e-14	Body mass index;
LUSC	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	7.89	0.4	4.39e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg00376283	chr12:123451042	ABCB9	0.7	7.92	0.4	3.67e-14	Neutrophil percentage of white cells;
LUSC	cis	rs6076065	0.723	rs6083088	chr20:23343793	G/T	cg11657817	chr20:23433608	CST11	0.44	8.23	0.41	4.26e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg22535103	chr8:58192502	C8orf71	-0.68	-7.57	-0.38	3.62e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs9815354	0.767	rs12185934	chr3:41836558	A/C	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg24375607	chr4:120327624	NA	0.79	11.91	0.55	1.72e-27	Corneal astigmatism;
LUSC	cis	rs1595825	0.735	rs6752760	chr2:198918164	G/T	cg00982548	chr2:198649783	BOLL	-0.54	-6.62	-0.34	1.43e-10	Ulcerative colitis;
LUSC	cis	rs2637266	1.000	rs2637264	chr10:78322794	A/C	cg18941641	chr10:78392320	NA	0.37	6.68	0.34	9.86e-11	Pulmonary function;
LUSC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg22920501	chr2:26401640	FAM59B	0.73	9.91	0.48	1.81e-20	Gut microbiome composition (summer);
LUSC	cis	rs17125944	0.686	rs912861	chr14:53333290	C/G	cg00686598	chr14:53173677	PSMC6	-0.59	-5.7	-0.3	2.57e-8	Alzheimer's disease (late onset);
LUSC	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg16339924	chr4:17578868	LAP3	0.49	7.41	0.38	1.02e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs113835537	0.529	rs2279865	chr11:66203025	A/C	cg24851651	chr11:66362959	CCS	0.55	8.35	0.42	1.89e-15	Airway imaging phenotypes;
LUSC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.66	-0.39	2.02e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6546550	0.901	rs4852375	chr2:70125988	C/G	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.37	-0.37	1.32e-12	Prevalent atrial fibrillation;
LUSC	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	0.6	9.45	0.46	6.13e-19	Breast cancer;
LUSC	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg18827107	chr12:86230957	RASSF9	-0.5	-7.48	-0.38	6.66e-13	Major depressive disorder;
LUSC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg04450456	chr4:17643702	FAM184B	0.38	6.5	0.34	2.95e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2425143	1.000	rs10485510	chr20:34445164	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.09	-0.32	3.08e-9	Blood protein levels;
LUSC	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg11130432	chr3:121712080	ILDR1	-0.63	-9.57	-0.46	2.41e-19	Multiple sclerosis;
LUSC	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.73	-0.35	7.32e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	11.25	0.52	4.04e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.66	-8.58	-0.42	3.63e-16	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg16680214	chr1:154839983	KCNN3	-0.51	-9.32	-0.45	1.67e-18	Prostate cancer;
LUSC	cis	rs4654899	0.895	rs10916865	chr1:21136610	C/T	cg01072550	chr1:21505969	NA	0.47	7.0	0.36	1.44e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg00990874	chr7:1149470	C7orf50	-0.46	-5.8	-0.3	1.55e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs354225	0.544	rs10193692	chr2:54808340	A/T	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg25233709	chr10:116636983	FAM160B1	0.37	6.55	0.34	2.13e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg27094323	chr7:1216898	NA	-0.36	-6.12	-0.32	2.65e-9	Longevity;Endometriosis;
LUSC	cis	rs472402	0.560	rs2288447	chr5:6626091	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.5	-7.37	-0.37	1.39e-12	Response to amphetamines;
LUSC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg16031515	chr1:205743344	RAB7L1	-0.27	-5.69	-0.3	2.8e-8	Menarche (age at onset);
LUSC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg15839431	chr19:19639596	YJEFN3	-0.42	-5.98	-0.31	5.61e-9	Tonsillectomy;
LUSC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg06212747	chr3:49208901	KLHDC8B	0.44	6.06	0.31	3.64e-9	Parkinson's disease;
LUSC	cis	rs710216	0.718	rs841852	chr1:43401499	C/T	cg03128534	chr1:43423976	SLC2A1	0.46	5.82	0.3	1.42e-8	Red cell distribution width;
LUSC	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg10645314	chr2:3704589	ALLC	-0.52	-7.77	-0.39	9.84e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg06697600	chr4:7070879	GRPEL1	-0.39	-6.7	-0.34	8.96e-11	Monocyte percentage of white cells;
LUSC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg11812906	chr14:75593930	NEK9	0.39	5.71	0.3	2.53e-8	Caffeine consumption;
LUSC	cis	rs3096299	0.702	rs2086825	chr16:89471542	C/T	cg00750074	chr16:89608354	SPG7	-0.44	-7.64	-0.39	2.26e-13	Multiple myeloma (IgH translocation);
LUSC	cis	rs9814567	0.762	rs13093893	chr3:134292131	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	11.92	0.55	1.51e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs6600671	0.934	rs11249348	chr1:121188302	T/C	cg08727972	chr1:148025634	NBPF14	0.45	6.36	0.33	6.49e-10	Hip geometry;
LUSC	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.63	-10.84	-0.51	1.16e-23	Electrocardiographic conduction measures;
LUSC	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg11984989	chr7:158649758	WDR60	1.12	13.99	0.61	2.61e-35	Height;
LUSC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg25039879	chr17:56429692	SUPT4H1	0.72	9.82	0.47	3.63e-20	Cognitive test performance;
LUSC	cis	rs5758511	0.773	rs9623482	chr22:42360574	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.35	0.37	1.55e-12	Birth weight;
LUSC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg11861562	chr11:117069780	TAGLN	0.44	7.74	0.39	1.21e-13	Blood protein levels;
LUSC	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg22852734	chr6:133119734	C6orf192	1.17	14.03	0.61	1.8e-35	Type 2 diabetes nephropathy;
LUSC	cis	rs12760731	0.668	rs73037529	chr1:178410203	A/T	cg00404053	chr1:178313656	RASAL2	0.59	6.22	0.32	1.46e-9	Obesity-related traits;
LUSC	cis	rs4704187	0.687	rs9654426	chr5:74466737	C/T	cg03227963	chr5:74354835	NA	0.3	6.59	0.34	1.68e-10	Response to amphetamines;
LUSC	trans	rs7944735	0.817	rs747782	chr11:47940925	A/G	cg03929089	chr4:120376271	NA	0.56	6.03	0.31	4.3e-9	Intraocular pressure;
LUSC	cis	rs7804356	1.000	rs12532199	chr7:26854375	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg26587870	chr6:27730563	NA	0.65	6.09	0.32	3.12e-9	Depression;
LUSC	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg09462578	chr12:12878428	APOLD1	-0.68	-7.89	-0.4	4.41e-14	Systemic lupus erythematosus;
LUSC	cis	rs7589342	0.831	rs13429270	chr2:106453060	C/T	cg16077055	chr2:106428750	NCK2	0.37	6.96	0.36	1.76e-11	Addiction;
LUSC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.81	0.54	3.94e-27	Prudent dietary pattern;
LUSC	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-15.15	-0.64	7.76e-40	Exhaled nitric oxide output;
LUSC	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg21798802	chr22:38057573	PDXP	0.32	6.57	0.34	1.89e-10	Fat distribution (HIV);
LUSC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg11764359	chr7:65958608	NA	0.52	6.85	0.35	3.5e-11	Aortic root size;
LUSC	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg08975724	chr8:8085496	FLJ10661	0.46	6.71	0.34	8.31e-11	Retinal vascular caliber;
LUSC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg13114125	chr14:105738426	BRF1	-0.9	-14.91	-0.63	7.09e-39	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg00484396	chr16:3507460	NAT15	0.92	10.5	0.5	1.72e-22	Tuberculosis;
LUSC	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg11498726	chr8:26250323	BNIP3L	-0.43	-6.2	-0.32	1.7e-9	Red cell distribution width;
LUSC	cis	rs7091068	0.616	rs7920366	chr10:95497178	A/T	cg20715218	chr10:95462985	C10orf4	0.62	6.66	0.34	1.12e-10	Urinary tract infection frequency;
LUSC	cis	rs6977660	0.660	rs12531278	chr7:19816439	A/T	cg07541023	chr7:19748670	TWISTNB	0.63	6.84	0.35	3.87e-11	Thyroid stimulating hormone;
LUSC	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg03342759	chr3:160939853	NMD3	-0.43	-6.18	-0.32	1.86e-9	Parkinson's disease;
LUSC	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg21433313	chr16:3507492	NAT15	0.8	10.09	0.48	4.62e-21	Tuberculosis;
LUSC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg05425664	chr17:57184151	TRIM37	0.54	7.95	0.4	2.95e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	9.16	0.45	5.22e-18	Lung cancer in ever smokers;
LUSC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-8.15	-0.41	7.3e-15	Chronic sinus infection;
LUSC	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg24642844	chr7:1081250	C7orf50	-0.68	-6.38	-0.33	5.89e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg06521331	chr12:34319734	NA	0.4	6.22	0.32	1.48e-9	Morning vs. evening chronotype;
LUSC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.79	-13.11	-0.58	5.7e-32	Aortic root size;
LUSC	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg10483660	chr13:112241077	NA	-0.39	-7.2	-0.37	4.13e-12	Menarche (age at onset);
LUSC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.29	0.33	1.01e-9	Menopause (age at onset);
LUSC	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg15744005	chr10:104629667	AS3MT	-0.32	-6.74	-0.35	7.16e-11	Arsenic metabolism;
LUSC	cis	rs9309473	0.500	rs11126402	chr2:73776582	G/C	cg20560298	chr2:73613845	ALMS1	-0.43	-6.64	-0.34	1.26e-10	Metabolite levels;
LUSC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg06008330	chr7:65541103	ASL	0.39	6.15	0.32	2.17e-9	Aortic root size;
LUSC	cis	rs11630290	0.589	rs925250	chr15:64175099	C/A	cg12036633	chr15:63758958	NA	-0.51	-6.45	-0.33	4.03e-10	Iris characteristics;
LUSC	trans	rs9944715	0.954	rs12457740	chr18:43741742	G/A	cg01718231	chr17:29326311	RNF135	0.48	6.82	0.35	4.35e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs290268	1.000	rs290268	chr9:93552450	A/G	cg02608019	chr9:93564028	SYK	0.55	9.13	0.45	6.57e-18	Platelet count;
LUSC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg00945038	chr17:61921165	SMARCD2	0.37	5.66	0.3	3.21e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs6012953	0.874	rs734589	chr20:49178921	G/A	cg13958625	chr20:49123093	NA	-0.26	-5.76	-0.3	1.91e-8	Vitiligo;
LUSC	cis	rs67072384	0.818	rs12287481	chr11:72472336	A/C	cg04827223	chr11:72435913	ARAP1	0.78	6.63	0.34	1.35e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg22089800	chr15:90895588	ZNF774	0.63	10.3	0.49	8.81e-22	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg03676636	chr4:99064102	C4orf37	0.35	7.6	0.38	3.03e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg12850546	chr22:42539477	CYP2D7P1	-0.69	-7.52	-0.38	5.12e-13	Birth weight;
LUSC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg06618935	chr21:46677482	NA	-0.39	-7.74	-0.39	1.18e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18099408	chr3:52552593	STAB1	0.4	6.96	0.36	1.79e-11	Bipolar disorder;
LUSC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-12.01	-0.55	7.21e-28	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	0.9	16.45	0.67	5.98e-45	Cognitive function;
LUSC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12379764	chr21:47803548	PCNT	-0.61	-8.2	-0.41	5.34e-15	Testicular germ cell tumor;
LUSC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg12257692	chr3:49977190	RBM6	-0.25	-6.88	-0.35	2.9e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs754466	1.000	rs67059283	chr10:79683235	C/T	cg17075019	chr10:79541650	NA	-0.64	-8.45	-0.42	9.28e-16	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.19	16.27	0.66	3.11e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.24	30.46	0.86	1.98e-98	Chronic sinus infection;
LUSC	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg27087555	chr16:88793112	FAM38A	-1.38	-13.78	-0.6	1.66e-34	Plateletcrit;
LUSC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-0.85	-11.48	-0.53	5.96e-26	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9443189	0.570	rs72884926	chr6:76266208	T/C	cg01950844	chr6:76311363	SENP6	0.68	6.96	0.36	1.76e-11	Prostate cancer;
LUSC	cis	rs7527798	0.592	rs11118278	chr1:207831357	C/G	cg09232269	chr1:207846808	CR1L	-0.31	-6.32	-0.33	8.26e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs6545883	0.794	rs778152	chr2:61608540	C/A	cg15711740	chr2:61764176	XPO1	0.41	6.42	0.33	4.57e-10	Tuberculosis;
LUSC	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.81	0.3	1.44e-8	Breast cancer;
LUSC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.67	0.57	2.55e-30	Prudent dietary pattern;
LUSC	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg19196401	chr6:110721138	DDO	-0.42	-7.75	-0.39	1.12e-13	Platelet distribution width;
LUSC	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12667521	chr19:29218732	NA	0.63	9.05	0.44	1.24e-17	Methadone dose in opioid dependence;
LUSC	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg24562669	chr7:97807699	LMTK2	0.48	8.64	0.43	2.3e-16	Breast cancer;
LUSC	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg00334542	chr7:100209784	MOSPD3	-0.49	-5.74	-0.3	2.11e-8	Other erythrocyte phenotypes;
LUSC	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg02696742	chr7:106810147	HBP1	-0.61	-9.07	-0.44	1.03e-17	Coronary artery disease;
LUSC	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg17173187	chr15:85201210	NMB	0.49	9.08	0.44	9.81e-18	Schizophrenia;
LUSC	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg04450456	chr4:17643702	FAM184B	-0.4	-6.43	-0.33	4.45e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg18607491	chr14:51706792	TMX1	0.45	6.34	0.33	7.24e-10	Mosquito bite size;
LUSC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	7.99	0.4	2.2e-14	Parkinson's disease;
LUSC	cis	rs17401966	0.522	rs946504	chr1:10308597	T/C	cg17425144	chr1:10567563	PEX14	-0.32	-5.79	-0.3	1.6e-8	Hepatocellular carcinoma;
LUSC	cis	rs752092	1.000	rs11636578	chr15:101787969	T/C	cg19997662	chr15:101784653	CHSY1	-0.43	-6.06	-0.31	3.75e-9	Corneal structure;
LUSC	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg06606381	chr12:133084897	FBRSL1	-1.03	-8.93	-0.44	2.97e-17	Depression;
LUSC	cis	rs2976388	0.669	rs2585135	chr8:143814193	A/G	cg17252645	chr8:143867129	LY6D	-0.38	-6.73	-0.35	7.45e-11	Urinary tract infection frequency;
LUSC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg13175981	chr1:150552382	MCL1	-0.41	-5.68	-0.3	2.92e-8	Tonsillectomy;
LUSC	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.87	16.75	0.68	3.68e-46	Heart rate;
LUSC	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg04218760	chr10:45406644	TMEM72	-0.29	-6.91	-0.35	2.53e-11	Mean corpuscular volume;
LUSC	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg13010199	chr12:38710504	ALG10B	0.52	7.72	0.39	1.34e-13	Morning vs. evening chronotype;
LUSC	cis	rs2354432	0.546	rs11240030	chr1:146882616	G/A	cg25205988	chr1:146714368	CHD1L	0.94	9.13	0.45	6.65e-18	Mitochondrial DNA levels;
LUSC	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg00191853	chr8:101177733	SPAG1	-0.41	-6.53	-0.34	2.46e-10	Atrioventricular conduction;
LUSC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg23985595	chr17:80112537	CCDC57	-0.3	-5.71	-0.3	2.52e-8	Life satisfaction;
LUSC	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg24112000	chr20:60950667	NA	-0.42	-8.23	-0.41	4.32e-15	Colorectal cancer;
LUSC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg05313129	chr8:58192883	C8orf71	-0.49	-6.45	-0.33	3.9e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.15	0.49	2.78e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-1.03	-19.84	-0.74	2.02e-58	Height;
LUSC	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18932078	chr1:2524107	MMEL1	0.3	6.61	0.34	1.55e-10	Ulcerative colitis;
LUSC	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg15423357	chr2:25149977	NA	0.45	9.12	0.45	7e-18	Body mass index;
LUSC	cis	rs7180079	1.000	rs62021592	chr15:64522368	T/G	cg08069370	chr15:64387884	SNX1	-0.54	-5.85	-0.3	1.17e-8	Monocyte count;
LUSC	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg05855489	chr10:104503620	C10orf26	-0.49	-7.46	-0.38	7.74e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	0.87	14.72	0.63	3.76e-38	Tonsillectomy;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg25243455	chr2:114033360	PAX8;LOC440839	-0.34	-7.58	-0.38	3.42e-13	Lymphocyte counts;
LUSC	cis	rs950881	0.932	rs10189526	chr2:102937883	C/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.37	0.33	6.4e-10	Allergy;
LUSC	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg05472934	chr7:22766657	IL6	0.39	6.04	0.31	4.16e-9	Lung cancer;
LUSC	cis	rs7605827	0.704	rs3732001	chr2:15536872	T/C	cg19274914	chr2:15703543	NA	0.46	9.03	0.44	1.45e-17	Educational attainment (years of education);
LUSC	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg20476159	chr18:77451067	CTDP1	-0.31	-5.65	-0.3	3.41e-8	Monocyte count;
LUSC	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg16586182	chr3:47516702	SCAP	-0.5	-7.88	-0.4	4.72e-14	Colorectal cancer;
LUSC	trans	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg06521331	chr12:34319734	NA	-0.41	-6.48	-0.33	3.26e-10	Morning vs. evening chronotype;
LUSC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg20406979	chr6:167373233	NA	0.26	6.21	0.32	1.6e-9	Crohn's disease;
LUSC	cis	rs4494114	1.000	rs4589074	chr1:39354508	T/G	cg25970120	chr1:39325951	RRAGC	-0.4	-6.19	-0.32	1.8e-9	Blood protein levels;
LUSC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-7.19	-0.37	4.24e-12	Alzheimer's disease (late onset);
LUSC	cis	rs2274273	0.840	rs11626751	chr14:55835227	T/C	cg04306507	chr14:55594613	LGALS3	0.54	11.89	0.55	2.08e-27	Protein biomarker;
LUSC	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg24692254	chr21:30365293	RNF160	0.74	11.67	0.54	1.32e-26	Pancreatic cancer;
LUSC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg04518342	chr5:131593106	PDLIM4	-0.43	-6.92	-0.35	2.3e-11	Breast cancer;
LUSC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-10.78	-0.51	1.94e-23	Menarche (age at onset);
LUSC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs4704187	0.687	rs2112871	chr5:74469853	G/A	cg03227963	chr5:74354835	NA	0.29	6.22	0.32	1.46e-9	Response to amphetamines;
LUSC	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.89	0.35	2.84e-11	IgG glycosylation;
LUSC	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg04310649	chr10:35416472	CREM	-0.43	-6.6	-0.34	1.58e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9837602	0.938	rs9828079	chr3:99806645	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.51	6.28	0.32	1.08e-9	Breast cancer;
LUSC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17102423	0.826	rs10873180	chr14:65604361	A/G	cg11161011	chr14:65562177	MAX	0.71	11.12	0.52	1.23e-24	Obesity-related traits;
LUSC	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg18478394	chr8:109455254	TTC35	0.42	6.6	0.34	1.6e-10	Dupuytren's disease;
LUSC	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg00277334	chr10:82204260	NA	-0.56	-7.66	-0.39	2.09e-13	Post bronchodilator FEV1;
LUSC	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg17507749	chr15:85114479	UBE2QP1	0.56	6.91	0.35	2.45e-11	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.61	0.38	2.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-11.86	-0.54	2.59e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2742234	0.590	rs2503848	chr10:43672785	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.43	-7.03	-0.36	1.17e-11	Hirschsprung disease;
LUSC	cis	rs12618769	0.681	rs72823792	chr2:99215142	G/A	cg10123293	chr2:99228465	UNC50	0.47	7.6	0.38	2.98e-13	Bipolar disorder;
LUSC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg08499158	chr17:42289980	UBTF	-0.52	-8.72	-0.43	1.3e-16	Total body bone mineral density;
LUSC	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg16342193	chr10:102329863	NA	-0.39	-6.81	-0.35	4.54e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.07	14.26	0.62	2.27e-36	Uric acid levels;
LUSC	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg11965913	chr1:205819406	PM20D1	-0.48	-6.63	-0.34	1.34e-10	Menarche (age at onset);
LUSC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg04450456	chr4:17643702	FAM184B	-0.42	-6.85	-0.35	3.56e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg08680598	chr22:49984980	NA	-0.32	-5.92	-0.31	8.11e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08677398	chr8:58056175	NA	0.53	7.01	0.36	1.33e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs10419226	0.533	rs6510996	chr19:18788208	A/G	cg22001208	chr19:18782374	NA	-0.37	-6.07	-0.32	3.54e-9	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23158103	chr7:148848205	ZNF398	-0.48	-7.91	-0.4	3.75e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg09877947	chr5:131593287	PDLIM4	0.55	9.03	0.44	1.37e-17	Acylcarnitine levels;
LUSC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.62	6.04	0.31	4.07e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg12463550	chr7:65579703	CRCP	0.51	7.4	0.38	1.13e-12	Aortic root size;
LUSC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg08470875	chr2:26401718	FAM59B	-0.65	-8.64	-0.43	2.33e-16	Gut microbiome composition (summer);
LUSC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	14.23	0.61	2.95e-36	Platelet count;
LUSC	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg18129178	chr5:148520854	ABLIM3	0.56	8.28	0.41	2.97e-15	Breast cancer;
LUSC	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg09835421	chr16:68378352	PRMT7	-0.55	-6.16	-0.32	2.09e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	0.72	11.64	0.54	1.62e-26	Height;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg07902188	chr19:30097207	POP4	0.78	6.19	0.32	1.76e-9	Cognitive performance;
LUSC	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg15839431	chr19:19639596	YJEFN3	-0.56	-6.16	-0.32	2.03e-9	Bipolar disorder;
LUSC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg20476274	chr7:133979776	SLC35B4	0.88	16.95	0.68	6.26e-47	Mean platelet volume;
LUSC	cis	rs10489525	0.528	rs360604	chr1:115390019	G/A	cg12756093	chr1:115239321	AMPD1	0.52	7.01	0.36	1.34e-11	Autism;
LUSC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg05368731	chr17:41323189	NBR1	0.74	12.41	0.56	2.42e-29	Menopause (age at onset);
LUSC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.08	15.39	0.64	8.93e-41	Gut microbiome composition (summer);
LUSC	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg04374321	chr14:90722782	PSMC1	-0.49	-7.48	-0.38	6.74e-13	Mortality in heart failure;
LUSC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.3e-10	Alzheimer's disease (late onset);
LUSC	cis	rs524023	1.000	rs12786214	chr11:64364203	G/A	cg07220939	chr11:64358617	SLC22A12	-0.22	-5.74	-0.3	2.16e-8	Urate levels in obese individuals;
LUSC	trans	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg13010199	chr12:38710504	ALG10B	0.42	6.66	0.34	1.1e-10	Morning vs. evening chronotype;
LUSC	cis	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg00852783	chr1:26633632	UBXN11	-0.48	-5.71	-0.3	2.56e-8	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg09904177	chr6:26538194	HMGN4	-0.71	-6.76	-0.35	6.06e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs57590327	0.504	rs4856348	chr3:81502923	T/G	cg07356753	chr3:81810745	GBE1	0.46	6.12	0.32	2.61e-9	Extraversion;
LUSC	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.13	0.55	2.73e-28	Colorectal cancer;
LUSC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg07424592	chr7:64974309	NA	0.69	6.09	0.32	3.03e-9	Diabetic kidney disease;
LUSC	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.31	-18.31	-0.71	2.43e-52	Hip circumference adjusted for BMI;
LUSC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg02807482	chr3:125708958	NA	-0.52	-6.55	-0.34	2.23e-10	Blood pressure (smoking interaction);
LUSC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.73	0.51	2.84e-23	Hip circumference adjusted for BMI;
LUSC	cis	rs68170813	0.559	rs4730239	chr7:107056960	A/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.32	-0.45	1.62e-18	Coronary artery disease;
LUSC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg05896524	chr21:47604654	C21orf56	-0.53	-8.17	-0.41	6.37e-15	Testicular germ cell tumor;
LUSC	cis	rs9303542	0.559	rs62066693	chr17:46617530	G/C	cg09704116	chr17:46666958	LOC404266	-0.38	-6.69	-0.34	9.51e-11	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-0.93	-15.94	-0.66	6.43e-43	Height;
LUSC	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg08079166	chr15:68083412	MAP2K5	0.41	7.23	0.37	3.29e-12	Restless legs syndrome;
LUSC	cis	rs7000551	0.715	rs1600877	chr8:22378118	C/T	cg12081754	chr8:22256438	SLC39A14	0.45	6.8	0.35	4.81e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs354225	0.544	rs13386146	chr2:54802514	G/C	cg01766943	chr2:54829624	SPTBN1	0.48	7.75	0.39	1.11e-13	Schizophrenia;
LUSC	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg13575925	chr12:9217583	LOC144571	0.35	6.41	0.33	4.82e-10	Sjögren's syndrome;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg00934312	chr7:149570931	ATP6V0E2;LOC401431	0.39	5.94	0.31	6.99e-9	Schizophrenia;
LUSC	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.16	22.2	0.77	9.81e-68	Exhaled nitric oxide output;
LUSC	cis	rs7605827	0.930	rs10203196	chr2:15541154	A/T	cg19274914	chr2:15703543	NA	0.47	9.24	0.45	3.06e-18	Educational attainment (years of education);
LUSC	cis	rs2282300	0.739	rs7942129	chr11:30224692	G/A	cg25418670	chr11:30344373	C11orf46	-0.61	-8.81	-0.43	7.19e-17	Morning vs. evening chronotype;
LUSC	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg00677455	chr12:58241039	CTDSP2	0.61	8.58	0.42	3.64e-16	Multiple sclerosis;
LUSC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.21	-0.37	3.87e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.35	6.72	0.34	8.01e-11	Neutrophil percentage of white cells;
LUSC	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg05738196	chr6:26577821	NA	0.81	15.71	0.65	4.89e-42	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg16325326	chr1:53192061	ZYG11B	0.81	13.96	0.61	3.24e-35	Monocyte count;
LUSC	trans	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-7.89	-0.4	4.31e-14	Morning vs. evening chronotype;
LUSC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg11965913	chr1:205819406	PM20D1	-0.89	-18.14	-0.7	1.16e-51	Menarche (age at onset);
LUSC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.88	20.01	0.74	4.35e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg23172400	chr8:95962367	TP53INP1	-0.43	-8.96	-0.44	2.27e-17	Type 2 diabetes;
LUSC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg00409905	chr10:38381863	ZNF37A	-0.38	-6.44	-0.33	4.21e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07157834	chr1:205819609	PM20D1	0.85	15.33	0.64	1.61e-40	Menarche (age at onset);
LUSC	trans	rs1922233	1.000	rs10013671	chr4:92379974	G/A	cg24250684	chr1:219729030	NA	-0.32	-5.99	-0.31	5.54e-9	Gut microbiome composition (summer and winter);
LUSC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22496380	chr5:211416	CCDC127	-0.7	-8.07	-0.4	1.24e-14	Breast cancer;
LUSC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg11843238	chr5:131593191	PDLIM4	-0.4	-6.55	-0.34	2.18e-10	Blood metabolite levels;
LUSC	cis	rs4776059	1.000	rs4776058	chr15:52880263	A/G	cg22715398	chr15:52968154	KIAA1370	-0.73	-10.48	-0.5	2.05e-22	Schizophrenia;
LUSC	cis	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg05299278	chr17:33885742	SLFN14	-0.31	-6.34	-0.33	7.35e-10	Response to radiotherapy in cancer (late toxicity);
LUSC	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg26668828	chr6:292823	DUSP22	0.75	12.66	0.57	2.8e-30	Menopause (age at onset);
LUSC	cis	rs2046867	0.908	rs1106310	chr3:72818902	A/T	cg25664220	chr3:72788482	NA	0.62	11.12	0.52	1.17e-24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg22903471	chr2:27725779	GCKR	-0.37	-6.41	-0.33	4.92e-10	Total body bone mineral density;
LUSC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg02423579	chr7:2872169	GNA12	-0.44	-6.16	-0.32	2.1e-9	Height;
LUSC	cis	rs7224314	1.000	rs7219229	chr17:65380171	C/T	cg01507342	chr17:65387096	PITPNC1	-0.44	-7.87	-0.4	4.95e-14	Diisocyanate-induced asthma;
LUSC	cis	rs6489882	0.867	rs6489875	chr12:113368030	G/A	cg20102336	chr12:113376681	OAS3	-0.4	-5.74	-0.3	2.17e-8	Chronic lymphocytic leukemia;
LUSC	cis	rs2742234	0.541	rs11528481	chr10:43737767	C/A	cg07801480	chr10:43725741	RASGEF1A	-0.4	-5.88	-0.31	9.77e-9	Hirschsprung disease;
LUSC	cis	rs6987853	0.966	rs2974342	chr8:42436651	A/C	cg09913449	chr8:42400586	C8orf40	0.49	8.35	0.42	1.89e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg06008330	chr7:65541103	ASL	0.4	6.19	0.32	1.77e-9	Aortic root size;
LUSC	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg05791153	chr7:19748676	TWISTNB	0.77	8.32	0.41	2.19e-15	Thyroid stimulating hormone;
LUSC	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg04267008	chr7:1944627	MAD1L1	-0.52	-7.53	-0.38	4.69e-13	Schizophrenia;
LUSC	cis	rs35883536	0.588	rs72977389	chr1:101107053	A/C	cg06223162	chr1:101003688	GPR88	0.35	6.2	0.32	1.68e-9	Monocyte count;
LUSC	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg00376283	chr12:123451042	ABCB9	0.64	8.17	0.41	6.39e-15	Neutrophil percentage of white cells;
LUSC	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg02018176	chr4:1364513	KIAA1530	0.44	6.02	0.31	4.62e-9	Recombination rate (females);
LUSC	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	13.55	0.6	1.27e-33	Exhaled nitric oxide output;
LUSC	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg06623918	chr6:96969491	KIAA0776	0.79	9.69	0.47	9.96e-20	Migraine;Coronary artery disease;
LUSC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg22166914	chr1:53195759	ZYG11B	-0.41	-6.02	-0.31	4.49e-9	Monocyte count;
LUSC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg05623727	chr3:50126028	RBM5	-0.33	-6.11	-0.32	2.72e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg11062466	chr8:58055876	NA	0.65	8.57	0.42	4.03e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.08	0.32	3.3e-9	Mean platelet volume;
LUSC	cis	rs7589342	0.831	rs10169998	chr2:106452253	A/G	cg16077055	chr2:106428750	NCK2	0.37	7.04	0.36	1.12e-11	Addiction;
LUSC	trans	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.6	-0.34	1.61e-10	Life satisfaction;
LUSC	cis	rs4499344	0.730	rs2903755	chr19:33098870	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg25182066	chr10:30743637	MAP3K8	-0.42	-6.15	-0.32	2.19e-9	Inflammatory bowel disease;
LUSC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-8.78	-0.43	8.73e-17	Response to antipsychotic treatment;
LUSC	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg04362960	chr10:104952993	NT5C2	0.53	6.55	0.34	2.22e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg24905901	chr12:53901029	NPFF	0.5	6.04	0.31	4.04e-9	Gut microbiome composition (summer);
LUSC	cis	rs7119167	0.901	rs10898920	chr11:73140138	T/A	cg17517138	chr11:73019481	ARHGEF17	0.52	5.91	0.31	8.53e-9	Blood protein levels;
LUSC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.56	-0.34	2.03e-10	Lung cancer;
LUSC	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg05294307	chr14:35346193	BAZ1A	-0.6	-7.05	-0.36	1.06e-11	Psoriasis;
LUSC	cis	rs1891275	0.515	rs7475294	chr10:93508199	T/C	cg07889827	chr10:93443413	NA	-0.4	-9.29	-0.45	2.06e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg23127183	chr11:57508653	C11orf31	-0.57	-8.86	-0.44	4.99e-17	Schizophrenia;
LUSC	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.54	-0.42	4.85e-16	Body mass index;
LUSC	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg14830002	chr1:247616686	OR2B11	0.65	7.35	0.37	1.49e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9400467	0.528	rs456569	chr6:111674801	T/G	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.67	14.59	0.62	1.18e-37	Hemoglobin concentration;
LUSC	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg27068330	chr11:65405492	SIPA1	0.61	9.26	0.45	2.6e-18	Acne (severe);
LUSC	cis	rs870825	0.616	rs9631783	chr4:185626511	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.77e-32	Blood protein levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17133724	chr18:22932450	ZNF521	-0.44	-7.14	-0.36	5.85e-12	Electrocardiographic conduction measures;
LUSC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg12751644	chr20:60527061	NA	-0.36	-6.32	-0.33	8.56e-10	Body mass index;
LUSC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	1.04	19.19	0.72	7.41e-56	Menopause (age at onset);
LUSC	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg25344623	chr2:136566232	LCT	-0.37	-5.65	-0.3	3.41e-8	Mosquito bite size;
LUSC	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg00540400	chr15:79124168	NA	0.46	8.1	0.41	1.06e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg14809332	chr8:144654887	C8orf73	0.52	6.26	0.32	1.15e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg17691542	chr6:26056736	HIST1H1C	0.56	7.82	0.39	6.84e-14	Iron status biomarkers;
LUSC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.76	12.71	0.57	1.82e-30	Body mass index;
LUSC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg23978390	chr7:1156363	C7orf50	0.45	6.43	0.33	4.3e-10	Longevity;Endometriosis;
LUSC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	1.1	26.31	0.82	2.03e-83	Testicular germ cell tumor;
LUSC	cis	rs12928939	0.517	rs11865456	chr16:71969497	C/T	cg03805757	chr16:71968109	PKD1L3	-0.63	-9.69	-0.47	1.01e-19	Post bronchodilator FEV1;
LUSC	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg07701084	chr6:150067640	NUP43	0.54	8.23	0.41	4.16e-15	Lung cancer;
LUSC	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg19774624	chr17:42201019	HDAC5	-0.8	-13.02	-0.58	1.22e-31	Total body bone mineral density;
LUSC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-1.12	-10.49	-0.5	1.92e-22	Skin colour saturation;
LUSC	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg22676075	chr6:135203613	NA	0.58	9.19	0.45	4.29e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs6960043	0.905	rs11514706	chr7:15059272	A/C	cg19272540	chr7:15055459	NA	-0.31	-7.28	-0.37	2.41e-12	Type 2 diabetes;
LUSC	cis	rs9318086	0.935	rs9652081	chr13:24435510	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.4	-6.14	-0.32	2.3e-9	Myopia (pathological);
LUSC	cis	rs7851660	0.874	rs7037175	chr9:100631662	G/C	cg13688889	chr9:100608707	NA	-0.56	-8.91	-0.44	3.48e-17	Strep throat;
LUSC	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg01475377	chr6:109611718	NA	0.37	6.34	0.33	7.25e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-7.06	-0.36	9.91e-12	Aortic root size;
LUSC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg17264618	chr3:40429014	ENTPD3	0.31	6.33	0.33	7.68e-10	Renal cell carcinoma;
LUSC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg21724239	chr8:58056113	NA	0.56	6.76	0.35	6.29e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3125734	0.660	rs10733769	chr10:63974255	G/T	cg09941381	chr10:64027924	RTKN2	-0.38	-7.09	-0.36	8.05e-12	Rheumatoid arthritis;
LUSC	cis	rs9549260	0.709	rs2721072	chr13:41144919	G/A	cg21288729	chr13:41239152	FOXO1	0.57	8.63	0.43	2.55e-16	Red blood cell count;
LUSC	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg11473876	chr11:109292803	C11orf87	0.42	6.97	0.36	1.69e-11	Schizophrenia;
LUSC	cis	rs6977660	1.000	rs1468288	chr7:19810580	C/G	cg07541023	chr7:19748670	TWISTNB	0.58	6.39	0.33	5.61e-10	Thyroid stimulating hormone;
LUSC	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg24642439	chr20:33292090	TP53INP2	-0.4	-5.76	-0.3	1.92e-8	Height;
LUSC	cis	rs2279817	1.000	rs10788680	chr1:18019454	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.5	7.12	0.36	6.56e-12	Neuroticism;
LUSC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg03929089	chr4:120376271	NA	-0.94	-16.46	-0.67	5.66e-45	Height;
LUSC	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg24558204	chr6:135376177	HBS1L	0.59	9.28	0.45	2.26e-18	Red blood cell count;
LUSC	cis	rs7804356	0.953	rs10227529	chr7:26886309	T/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26314531	chr2:26401878	FAM59B	-0.69	-9.41	-0.46	8.01e-19	Gut microbiome composition (summer);
LUSC	cis	rs7771547	0.607	rs614028	chr6:36484252	G/A	cg07856975	chr6:36356162	ETV7	0.37	6.61	0.34	1.48e-10	Platelet distribution width;
LUSC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.74	10.58	0.5	9.68e-23	Type 2 diabetes;
LUSC	cis	rs8008758	0.517	rs1772028	chr14:101693861	C/G	cg26224664	chr14:101693935	NA	-0.37	-9.49	-0.46	4.7e-19	Body mass index (alcohol intake interaction);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg07990511	chr6:36853609	C6orf89	0.45	7.02	0.36	1.21e-11	Triglycerides;
LUSC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.74	-0.47	6.8e-20	Gut microbiome composition (summer);
LUSC	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.69	-0.39	1.71e-13	Depression;
LUSC	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg04546413	chr19:29218101	NA	0.63	8.3	0.41	2.69e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs17102884	0.600	rs9671386	chr14:75151047	G/A	cg08847533	chr14:75593920	NEK9	0.45	5.84	0.3	1.22e-8	Neuroticism;
LUSC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg02038168	chr22:39784481	NA	-0.47	-7.53	-0.38	4.64e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7707921	0.881	rs111907176	chr5:81312399	A/G	cg15871215	chr5:81402204	ATG10	-0.44	-6.39	-0.33	5.65e-10	Breast cancer;
LUSC	cis	rs4363385	0.647	rs56158137	chr1:152994380	A/T	cg25856811	chr1:152973957	SPRR3	-0.4	-6.45	-0.33	3.88e-10	Inflammatory skin disease;
LUSC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg26335602	chr6:28129616	ZNF389	0.42	5.71	0.3	2.52e-8	Depression;
LUSC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg16316162	chr8:144660157	NAPRT1	-0.68	-7.04	-0.36	1.12e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg00105475	chr2:10696890	NA	0.37	6.1	0.32	2.95e-9	Prostate cancer;
LUSC	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.88	-0.35	3.02e-11	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	1.04	20.11	0.74	1.65e-59	Menopause (age at onset);
LUSC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg07636037	chr3:49044803	WDR6	0.44	6.38	0.33	5.9e-10	Resting heart rate;
LUSC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.77	-12.65	-0.57	3.01e-30	Platelet count;
LUSC	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.82	-0.43	6.25e-17	Response to antipsychotic treatment;
LUSC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg18131467	chr2:239335373	ASB1	1.02	22.98	0.78	9.18e-71	Multiple system atrophy;
LUSC	cis	rs10992471	0.603	rs7850528	chr9:95208992	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.44	-7.85	-0.39	5.82e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg21775007	chr8:11205619	TDH	0.48	6.9	0.35	2.54e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg25344623	chr2:136566232	LCT	0.37	5.68	0.3	2.96e-8	Mosquito bite size;
LUSC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg11494091	chr17:61959527	GH2	0.4	6.91	0.35	2.47e-11	Height;
LUSC	cis	rs4363385	0.626	rs12062770	chr1:153062837	A/C	cg07796016	chr1:152779584	LCE1C	-0.38	-5.73	-0.3	2.27e-8	Inflammatory skin disease;
LUSC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg00033643	chr7:134001901	SLC35B4	0.44	6.55	0.34	2.18e-10	Mean platelet volume;
LUSC	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg21545522	chr1:205238299	TMCC2	0.47	8.71	0.43	1.38e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg23649088	chr2:200775458	C2orf69	0.65	9.42	0.46	7.51e-19	LDL cholesterol to HDL cholesterol ratio;
LUSC	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.0	-0.4	2.03e-14	Body mass index;
LUSC	cis	rs7605827	0.930	rs13024782	chr2:15700715	A/G	cg19274914	chr2:15703543	NA	0.46	8.64	0.43	2.43e-16	Educational attainment (years of education);
LUSC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg08219700	chr8:58056026	NA	0.48	5.88	0.31	1e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg24375607	chr4:120327624	NA	0.77	11.33	0.53	2.17e-25	Corneal astigmatism;
LUSC	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg05110241	chr16:68378359	PRMT7	-0.45	-6.09	-0.32	3.19e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs34734847	0.898	rs696339	chr12:121169436	A/T	cg27246729	chr12:121163418	ACADS	0.41	6.48	0.33	3.29e-10	Mean corpuscular volume;
LUSC	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg12863693	chr15:85201151	NMB	0.42	8.76	0.43	1.02e-16	Schizophrenia;
LUSC	cis	rs11030122	0.702	rs1013351	chr11:3952303	A/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.82	-0.3	1.34e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2976388	0.934	rs2920279	chr8:143762135	A/C	cg17252645	chr8:143867129	LY6D	-0.36	-6.22	-0.32	1.52e-9	Urinary tract infection frequency;
LUSC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.65	12.19	0.55	1.6e-28	Monocyte count;
LUSC	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg01483505	chr11:975446	AP2A2	0.44	6.15	0.32	2.15e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg09034736	chr1:150693464	HORMAD1	0.46	6.74	0.35	6.87e-11	Tonsillectomy;
LUSC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg08999081	chr20:33150536	PIGU	0.38	6.73	0.35	7.25e-11	Coronary artery disease;
LUSC	cis	rs11608355	0.545	rs35422737	chr12:109911456	A/G	cg05360138	chr12:110035743	NA	0.9	11.63	0.54	1.81e-26	Neuroticism;
LUSC	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.68	0.3	2.87e-8	Self-reported allergy;
LUSC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg21862992	chr11:68658383	NA	0.51	8.09	0.4	1.11e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg12432903	chr7:1882776	MAD1L1	-0.38	-6.1	-0.32	2.87e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg22508957	chr16:3507546	NAT15	0.85	11.01	0.52	2.87e-24	Tuberculosis;
LUSC	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg15557168	chr22:42548783	NA	-0.42	-7.11	-0.36	7.28e-12	Cognitive function;
LUSC	trans	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg16724585	chr3:197361211	NA	-0.61	-8.64	-0.43	2.43e-16	Pancreatic cancer;
LUSC	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	9.2	0.45	3.86e-18	Coffee consumption (cups per day);
LUSC	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.12	-0.32	2.61e-9	Resting heart rate;
LUSC	cis	rs713477	1.000	rs7142204	chr14:55908436	G/T	cg04306507	chr14:55594613	LGALS3	0.29	5.7	0.3	2.63e-8	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg17469321	chr7:55412551	NA	0.69	10.95	0.51	4.64e-24	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-6.8	-0.35	4.9e-11	Lung cancer;
LUSC	cis	rs2742234	0.590	rs2435337	chr10:43661836	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.43	-6.96	-0.36	1.78e-11	Hirschsprung disease;
LUSC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06634786	chr22:41940651	POLR3H	0.52	6.16	0.32	2.11e-9	Vitiligo;
LUSC	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	7.22	0.37	3.61e-12	Rheumatoid arthritis;
LUSC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg24562669	chr7:97807699	LMTK2	-0.4	-6.96	-0.36	1.85e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg04756594	chr16:24857601	SLC5A11	0.37	6.1	0.32	2.92e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	14.51	0.62	2.44e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg12365402	chr11:9010492	NRIP3	-0.36	-5.83	-0.3	1.34e-8	Schizophrenia;
LUSC	trans	rs13314892	1.000	rs13318796	chr3:69795183	A/G	cg26149728	chr3:119182545	TMEM39A	-0.44	-5.95	-0.31	6.81e-9	QRS complex (12-leadsum);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06851941	chr3:33319219	FBXL2	-0.36	-6.07	-0.32	3.52e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.68	12.14	0.55	2.36e-28	Prudent dietary pattern;
LUSC	trans	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg07393940	chr7:158741817	NA	0.36	6.56	0.34	2.09e-10	Life satisfaction;
LUSC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg06238570	chr21:40685208	BRWD1	0.48	7.37	0.37	1.34e-12	Cognitive function;
LUSC	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg17168535	chr8:21777572	XPO7	0.65	9.88	0.48	2.34e-20	Mean corpuscular volume;
LUSC	cis	rs12618769	0.625	rs2278207	chr2:99163261	T/A	cg10123293	chr2:99228465	UNC50	0.5	8.21	0.41	4.78e-15	Bipolar disorder;
LUSC	cis	rs9653442	1.000	rs6712515	chr2:100806514	T/C	cg22139774	chr2:100720529	AFF3	-0.44	-7.81	-0.39	7.69e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs7589342	0.566	rs11890447	chr2:106389691	T/C	cg09152813	chr2:106391379	NCK2	-0.38	-6.16	-0.32	2.12e-9	Addiction;
LUSC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg00745463	chr17:30367425	LRRC37B	-0.8	-9.48	-0.46	4.95e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs12620999	0.774	rs13402764	chr2:237951984	C/T	cg23555395	chr2:238036564	NA	-0.37	-6.49	-0.33	3.1e-10	Systemic lupus erythematosus;
LUSC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	16.04	0.66	2.56e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg14416269	chr4:6271139	WFS1	0.36	5.99	0.31	5.56e-9	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg05360949	chr19:41903737	BCKDHA;EXOSC5	0.41	5.76	0.3	1.93e-8	Height;
LUSC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	17.96	0.7	5.97e-51	Chronic sinus infection;
LUSC	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg09365446	chr1:150670422	GOLPH3L	0.47	6.94	0.35	2.07e-11	Melanoma;
LUSC	cis	rs7124681	0.584	rs7950674	chr11:47871017	T/C	cg20307385	chr11:47447363	PSMC3	0.46	6.8	0.35	4.78e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22385477	chr4:186392754	CCDC110	0.41	6.54	0.34	2.34e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg20406979	chr6:167373233	NA	0.26	6.13	0.32	2.5e-9	Crohn's disease;
LUSC	cis	rs7843479	0.965	rs9314269	chr8:21804989	A/G	cg17168535	chr8:21777572	XPO7	0.68	10.58	0.5	9.26e-23	Mean corpuscular volume;
LUSC	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.04	-0.4	1.53e-14	Monocyte count;
LUSC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg25019033	chr10:957182	NA	-0.5	-6.2	-0.32	1.63e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs12900413	0.687	rs72754547	chr15:90308166	A/C	cg24249390	chr15:90295951	MESP1	-0.37	-5.87	-0.31	1.03e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs1322512	0.917	rs2758810	chr6:152963887	G/A	cg27316956	chr6:152958899	SYNE1	-0.37	-6.33	-0.33	7.82e-10	Tonometry;
LUSC	cis	rs281408	0.559	rs204248	chr19:49216224	G/C	cg21064579	chr19:49206444	FUT2	-0.37	-6.37	-0.33	6.09e-10	Urinary metabolites (H-NMR features);
LUSC	cis	rs7804356	1.000	rs3801813	chr7:26887069	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-6.09	-0.32	3.04e-9	Type 1 diabetes;
LUSC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.5	7.26	0.37	2.8e-12	Platelet count;
LUSC	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.69	-10.98	-0.52	3.69e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7712401	0.601	rs246265	chr5:122254950	C/T	cg19077854	chr5:122220652	SNX24	0.42	9.39	0.46	9.57e-19	Mean platelet volume;
LUSC	cis	rs9341808	0.667	rs12209624	chr6:80919133	G/A	cg08355045	chr6:80787529	NA	0.47	8.13	0.41	8.73e-15	Sitting height ratio;
LUSC	cis	rs2463822	0.920	rs7924998	chr11:62073980	C/G	cg06239285	chr11:62104954	ASRGL1	-0.87	-8.55	-0.42	4.36e-16	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg24011408	chr12:48396354	COL2A1	-0.39	-5.67	-0.3	3.16e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs6516091	0.706	rs62199230	chr20:6050124	G/C	cg25325723	chr20:6104886	FERMT1	-0.66	-7.08	-0.36	8.37e-12	Abdominal aortic aneurysm;
LUSC	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg20908204	chr19:46285434	DMPK	-0.38	-6.87	-0.35	3.07e-11	Coronary artery disease;
LUSC	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg13010199	chr12:38710504	ALG10B	0.41	5.93	0.31	7.77e-9	Morning vs. evening chronotype;
LUSC	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg12756686	chr19:29218302	NA	0.54	6.28	0.32	1.08e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	trans	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg15556689	chr8:8085844	FLJ10661	0.47	7.02	0.36	1.27e-11	Retinal vascular caliber;
LUSC	trans	rs890100	0.673	rs11885335	chr2:56679612	C/T	cg01657744	chr10:88471748	LDB3	0.45	6.14	0.32	2.4e-9	Gut microbiome composition (summer);
LUSC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg12564285	chr5:131593104	PDLIM4	0.41	6.42	0.33	4.69e-10	Breast cancer;
LUSC	cis	rs17001868	0.568	rs760700	chr22:40800071	C/T	cg07138101	chr22:40742427	ADSL	-0.64	-7.93	-0.4	3.23e-14	Mammographic density (dense area);
LUSC	cis	rs73198271	0.515	rs78790301	chr8:8625786	G/C	cg01851573	chr8:8652454	MFHAS1	0.62	7.34	0.37	1.61e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08677398	chr8:58056175	NA	0.52	6.4	0.33	5.13e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-1.14	-17.77	-0.7	3.45e-50	Exhaled nitric oxide output;
LUSC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	7.62	0.38	2.64e-13	Height;
LUSC	cis	rs11958404	1.000	rs72816531	chr5:157413079	A/G	cg05962755	chr5:157440814	NA	0.51	6.24	0.32	1.31e-9	IgG glycosylation;
LUSC	cis	rs13401104	0.796	rs72620811	chr2:237118733	C/A	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.41e-8	Educational attainment;
LUSC	cis	rs9815354	0.812	rs73071236	chr3:41992042	A/G	cg03022575	chr3:42003672	ULK4	0.82	8.59	0.43	3.29e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.43	6.14	0.32	2.36e-9	Breast cancer;
LUSC	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg11019008	chr10:131425282	MGMT	-0.45	-6.92	-0.35	2.29e-11	Response to temozolomide;
LUSC	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg08270630	chr22:50330655	NA	-0.42	-6.25	-0.32	1.25e-9	Schizophrenia;
LUSC	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14769373	chr6:40998127	UNC5CL	-0.58	-8.12	-0.41	9e-15	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.55	8.24	0.41	3.88e-15	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg06784218	chr1:46089804	CCDC17	-0.58	-11.5	-0.53	5.39e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg18721089	chr20:30220636	NA	-0.39	-6.12	-0.32	2.66e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg17691542	chr6:26056736	HIST1H1C	0.76	9.71	0.47	8.44e-20	Iron status biomarkers;
LUSC	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg10909506	chr17:38081995	ORMDL3	0.34	6.05	0.31	3.93e-9	Asthma;
LUSC	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01341218	chr17:43662625	NA	0.73	10.62	0.5	6.65e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.66	-9.82	-0.47	3.64e-20	Blood protein levels;
LUSC	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-8.16	-0.41	6.75e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12549902	0.933	rs17659428	chr8:41513809	T/C	cg21772509	chr8:41503840	NKX6-3	0.64	10.42	0.5	3.4e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg16339924	chr4:17578868	LAP3	0.52	7.92	0.4	3.53e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9300255	0.739	rs1879380	chr12:123739111	G/A	cg13010344	chr12:123464640	ARL6IP4	0.47	5.7	0.3	2.6e-8	Neutrophil percentage of white cells;
LUSC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg09365446	chr1:150670422	GOLPH3L	0.54	8.25	0.41	3.72e-15	Tonsillectomy;
LUSC	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg05373962	chr22:49881684	NA	-0.37	-8.79	-0.43	7.76e-17	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.58	9.17	0.45	4.9e-18	Blood protein levels;
LUSC	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg19875535	chr5:140030758	IK	-0.47	-7.7	-0.39	1.55e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7712401	0.601	rs154496	chr5:122221731	A/G	cg19077854	chr5:122220652	SNX24	0.4	9.11	0.45	7.67e-18	Mean platelet volume;
LUSC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg04369109	chr6:150039330	LATS1	-0.57	-8.38	-0.42	1.51e-15	Lung cancer;
LUSC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-6.95	-0.36	1.93e-11	Blood metabolite levels;
LUSC	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg27129171	chr3:47204927	SETD2	0.69	11.48	0.53	6.36e-26	Colorectal cancer;
LUSC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg24733560	chr20:60626293	TAF4	-0.4	-6.31	-0.33	8.85e-10	Body mass index;
LUSC	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg17420585	chr12:42539391	GXYLT1	0.32	5.99	0.31	5.46e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24739457	chr1:205821442	NA	0.41	7.28	0.37	2.46e-12	Menarche (age at onset);
LUSC	cis	rs6545883	0.929	rs6545877	chr2:61741947	T/C	cg15711740	chr2:61764176	XPO1	-0.5	-7.94	-0.4	3.03e-14	Tuberculosis;
LUSC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg00166722	chr3:10149974	C3orf24	0.41	5.87	0.31	1.02e-8	Alzheimer's disease;
LUSC	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.95	-0.4	2.93e-14	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	8.86e-24	Morning vs. evening chronotype;
LUSC	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg13660082	chr14:53194042	PSMC6	0.73	6.82	0.35	4.16e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7432375	0.610	rs56695781	chr3:136510601	G/T	cg15507776	chr3:136538369	TMEM22	0.44	7.3	0.37	2.16e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	6.04	0.31	4.02e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg13319975	chr6:146136371	FBXO30	0.48	7.37	0.37	1.31e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg18721089	chr20:30220636	NA	-0.39	-6.12	-0.32	2.66e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs61931739	0.612	rs2004961	chr12:33994599	A/G	cg06521331	chr12:34319734	NA	-0.42	-7.01	-0.36	1.35e-11	Morning vs. evening chronotype;
LUSC	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg13813247	chr22:41461852	NA	-0.37	-6.68	-0.34	9.83e-11	Neuroticism;
LUSC	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg13206674	chr6:150067644	NUP43	0.58	8.91	0.44	3.38e-17	Lung cancer;
LUSC	cis	rs10072221	0.836	rs7718641	chr5:75708010	T/G	cg03132911	chr5:75698732	IQGAP2	0.36	6.1	0.32	2.88e-9	Mean platelet volume;
LUSC	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg16339924	chr4:17578868	LAP3	0.48	7.21	0.37	3.67e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg22431228	chr1:16359049	CLCNKA	0.4	8.29	0.41	2.78e-15	Systolic blood pressure;
LUSC	cis	rs10779751	1.000	rs4845986	chr1:11288633	G/C	cg08854313	chr1:11322531	MTOR	0.89	14.88	0.63	9.08e-39	Body mass index;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg19823710	chr17:29233276	C17orf42	0.44	6.07	0.32	3.44e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.77	10.28	0.49	1e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9646944	0.501	rs10197310	chr2:103020030	A/T	cg20060108	chr2:102954350	IL1RL1	-0.48	-6.33	-0.33	7.81e-10	Blood protein levels;
LUSC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg24675658	chr1:53192096	ZYG11B	0.59	9.22	0.45	3.51e-18	Monocyte count;
LUSC	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.84	-0.39	6.25e-14	Body mass index;
LUSC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg25344623	chr2:136566232	LCT	0.38	5.75	0.3	2.07e-8	Mosquito bite size;
LUSC	cis	rs6961069	0.560	rs62461673	chr7:80237977	G/T	cg04458919	chr7:80252533	CD36	-0.4	-7.15	-0.36	5.43e-12	Platelet count;
LUSC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg03732007	chr1:2071316	PRKCZ	-0.54	-9.56	-0.46	2.65e-19	Height;
LUSC	cis	rs3818717	0.538	rs12945601	chr17:17653411	C/T	cg09796270	chr17:17721594	SREBF1	0.41	7.33	0.37	1.8e-12	Lymphocyte counts;
LUSC	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg14227996	chr4:17616232	MED28	0.8	8.15	0.41	7.21e-15	Opioid sensitivity;
LUSC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg21782813	chr7:2030301	MAD1L1	0.52	9.32	0.45	1.63e-18	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs911119	1.000	rs3827142	chr20:23617007	G/A	cg16589663	chr20:23618590	CST3	0.6	6.99	0.36	1.48e-11	Chronic kidney disease;
LUSC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg03188948	chr7:1209495	NA	0.62	6.4	0.33	5.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.21	-0.37	3.86e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12760731	0.623	rs12038759	chr1:178262700	A/C	cg00404053	chr1:178313656	RASAL2	0.49	5.92	0.31	7.85e-9	Obesity-related traits;
LUSC	cis	rs7674212	0.541	rs2720460	chr4:104054686	C/T	cg16532752	chr4:104119610	CENPE	0.46	6.62	0.34	1.45e-10	Type 2 diabetes;
LUSC	cis	rs789859	1.000	rs789860	chr3:194405630	A/T	cg02072170	chr3:194406190	FAM43A	0.36	7.59	0.38	3.1400000000000003e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LUSC	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	0.91	17.1	0.68	1.58e-47	Tonsillectomy;
LUSC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg12560992	chr17:57184187	TRIM37	0.77	14.52	0.62	2.32e-37	Intelligence (multi-trait analysis);
LUSC	cis	rs3106136	0.934	rs34145031	chr4:95167123	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.35	-6.02	-0.31	4.68e-9	Capecitabine sensitivity;
LUSC	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	6.81	0.35	4.61e-11	Ovarian reserve;
LUSC	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg07169764	chr2:136633963	MCM6	-0.46	-6.33	-0.33	8.01e-10	Mosquito bite size;
LUSC	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg16339924	chr4:17578868	LAP3	0.55	8.37	0.42	1.57e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg22431228	chr1:16359049	CLCNKA	0.44	8.65	0.43	2.23e-16	Dilated cardiomyopathy;
LUSC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.78	0.35	5.32e-11	Tonsillectomy;
LUSC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11764359	chr7:65958608	NA	-0.58	-8.99	-0.44	1.87e-17	Aortic root size;
LUSC	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.24	0.49	1.34e-21	Bladder cancer;
LUSC	cis	rs9318086	0.935	rs9553083	chr13:24441525	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.39	-5.98	-0.31	5.87e-9	Myopia (pathological);
LUSC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg03461704	chr1:205818484	PM20D1	0.36	5.82	0.3	1.39e-8	Menarche (age at onset);
LUSC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.53	-7.25	-0.37	2.84e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.99	0.36	1.54e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg00310523	chr12:86230176	RASSF9	-0.43	-7.89	-0.4	4.28e-14	Major depressive disorder;
LUSC	trans	rs11935423	0.778	rs28595160	chr4:100502822	G/T	cg02164153	chr5:172068145	NEURL1B	-0.47	-6.05	-0.31	3.97e-9	Gut microbiome composition (summer);
LUSC	cis	rs6939532	0.544	rs10946816	chr6:26361946	C/G	cg09904177	chr6:26538194	HMGN4	-0.46	-6.68	-0.34	9.75e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9323205	0.723	rs61985121	chr14:51705925	A/G	cg23942311	chr14:51606299	NA	-0.44	-8.46	-0.42	8.2e-16	Cancer;
LUSC	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	1.09	17.2	0.69	6.12e-48	Exhaled nitric oxide output;
LUSC	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-10.54	-0.5	1.32e-22	Coffee consumption (cups per day);
LUSC	cis	rs3099143	1.000	rs7178759	chr15:77143513	A/G	cg21673338	chr15:77095150	SCAPER	0.73	7.98	0.4	2.44e-14	Recalcitrant atopic dermatitis;
LUSC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.99	0.48	9.72e-21	Bipolar disorder;
LUSC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg11764359	chr7:65958608	NA	0.54	6.93	0.35	2.14e-11	Aortic root size;
LUSC	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg09754948	chr16:28834200	ATXN2L	0.41	5.87	0.31	1.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.84	0.39	6.07e-14	Prudent dietary pattern;
LUSC	cis	rs701145	0.617	rs9820619	chr3:154028294	G/T	cg10247383	chr3:153839028	SGEF	-0.46	-5.66	-0.3	3.31e-8	Coronary artery disease;
LUSC	trans	rs12153263	0.504	rs10941686	chr5:20284938	C/T	cg07262001	chr22:42734088	NA	-0.31	-6.02	-0.31	4.68e-9	Obstetric antiphospholipid syndrome;
LUSC	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg09835421	chr16:68378352	PRMT7	-0.62	-6.35	-0.33	6.84e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.91	-0.31	8.57e-9	Resting heart rate;
LUSC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	13.79	0.6	1.52e-34	Alzheimer's disease;
LUSC	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg06092702	chr1:163392909	NA	-0.44	-7.45	-0.38	7.89e-13	Motion sickness;
LUSC	cis	rs9311676	0.632	rs11130637	chr3:58405573	C/G	cg13750441	chr3:58318267	PXK	0.34	6.54	0.34	2.3e-10	Systemic lupus erythematosus;
LUSC	cis	rs9796	0.870	rs2925345	chr15:41311799	T/C	cg18705301	chr15:41695430	NDUFAF1	0.45	7.81	0.39	7.44e-14	Menopause (age at onset);
LUSC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg13560548	chr3:10150139	C3orf24	0.5	6.88	0.35	2.95e-11	Alzheimer's disease;
LUSC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg16606324	chr3:10149918	C3orf24	0.64	8.92	0.44	3.07e-17	Alzheimer's disease;
LUSC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg24675658	chr1:53192096	ZYG11B	-0.58	-9.11	-0.45	7.66e-18	Monocyte count;
LUSC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.86	-0.81	6.04e-78	Height;
LUSC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.39	0.33	5.68e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg17554472	chr22:41940697	POLR3H	0.48	5.91	0.31	8.32e-9	Vitiligo;
LUSC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg23262073	chr20:60523788	NA	-0.41	-5.82	-0.3	1.39e-8	Body mass index;
LUSC	cis	rs262150	0.592	rs56062559	chr7:158769109	T/C	cg09640425	chr7:158790006	NA	0.47	5.66	0.3	3.32e-8	Facial morphology (factor 20);
LUSC	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.04	-0.36	1.07e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	ch.11.42038R	chr11:967971	AP2A2	0.42	6.2	0.32	1.62e-9	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg24829409	chr8:58192753	C8orf71	-0.62	-7.59	-0.38	3.17e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-6.97	-0.36	1.71e-11	Height;
LUSC	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg15711740	chr2:61764176	XPO1	-0.5	-7.99	-0.4	2.17e-14	Tuberculosis;
LUSC	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg05855489	chr10:104503620	C10orf26	-0.68	-9.85	-0.47	2.9e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg21775007	chr8:11205619	TDH	-0.51	-7.45	-0.38	8.26e-13	Retinal vascular caliber;
LUSC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11764359	chr7:65958608	NA	-0.62	-9.38	-0.46	1.03e-18	Aortic root size;
LUSC	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg24642844	chr7:1081250	C7orf50	-0.79	-10.39	-0.49	4.39e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	13.94	0.61	3.82e-35	Platelet count;
LUSC	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg13628971	chr7:2884303	GNA12	0.37	5.65	0.3	3.48e-8	Height;
LUSC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg20283391	chr11:68216788	NA	-0.58	-8.31	-0.41	2.5e-15	Total body bone mineral density;
LUSC	cis	rs9815354	1.000	rs13325965	chr3:41914942	G/T	cg03022575	chr3:42003672	ULK4	0.64	6.89	0.35	2.78e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7560272	0.502	rs13013228	chr2:73925216	G/A	cg20560298	chr2:73613845	ALMS1	0.38	5.81	0.3	1.45e-8	Schizophrenia;
LUSC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	29.35	0.85	1.65e-94	Chronic sinus infection;
LUSC	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg08481491	chr3:125900108	ALDH1L1	0.32	6.51	0.34	2.76e-10	Metabolite levels;
LUSC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10150615	chr22:24372951	LOC391322	0.34	5.82	0.3	1.39e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg04939294	chr16:67753445	GFOD2	0.38	6.1	0.32	2.97e-9	Triglycerides;
LUSC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg16049864	chr8:95962084	TP53INP1	-0.58	-10.75	-0.51	2.36e-23	Type 2 diabetes;
LUSC	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg09307838	chr4:120376055	NA	0.75	10.89	0.51	7.5e-24	Corneal astigmatism;
LUSC	cis	rs2996428	0.561	rs12134919	chr1:3744641	G/A	cg13057898	chr1:3703894	LRRC47	0.46	7.92	0.4	3.55e-14	Red cell distribution width;
LUSC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg20406979	chr6:167373233	NA	0.26	6.12	0.32	2.64e-9	Crohn's disease;
LUSC	cis	rs9296092	0.538	rs9469488	chr6:33517117	G/T	cg13560919	chr6:33536144	NA	-0.82	-15.66	-0.65	7.89e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7178375	0.607	rs7171212	chr15:31207711	C/T	cg15020726	chr15:31196382	MTMR15	0.89	7.54	0.38	4.54e-13	Hypertriglyceridemia;
LUSC	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg13010199	chr12:38710504	ALG10B	0.56	8.45	0.42	9.2e-16	Morning vs. evening chronotype;
LUSC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	11.6	0.54	2.27e-26	Menarche (age at onset);
LUSC	trans	rs800082	0.531	rs2204603	chr3:144258720	T/A	cg24215973	chr2:240111563	HDAC4	0.48	7.48	0.38	6.75e-13	Smoking behavior;
LUSC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg21782813	chr7:2030301	MAD1L1	0.58	10.31	0.49	8.12e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg24296786	chr1:45957014	TESK2	-0.52	-7.99	-0.4	2.23e-14	High light scatter reticulocyte count;
LUSC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-12.37	-0.56	3.29e-29	Platelet count;
LUSC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg25072359	chr17:41440525	NA	0.6	7.66	0.39	2.08e-13	Menopause (age at onset);
LUSC	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg01879757	chr17:41196368	BRCA1	-0.5	-8.06	-0.4	1.37e-14	Menopause (age at onset);
LUSC	cis	rs3768617	0.754	rs6673768	chr1:182983396	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	8.48	0.42	7.31e-16	Fuchs's corneal dystrophy;
LUSC	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg23601095	chr6:26197514	HIST1H3D	0.72	7.7	0.39	1.51e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg06008330	chr7:65541103	ASL	0.39	6.03	0.31	4.37e-9	Aortic root size;
LUSC	trans	rs28647808	0.881	rs4962047	chr9:136262916	T/C	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.98	-0.36	1.6e-11	Bladder cancer;
LUSC	cis	rs9296092	0.517	rs55683509	chr6:33471077	A/G	cg13560919	chr6:33536144	NA	-0.78	-13.33	-0.59	8.65e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg13319975	chr6:146136371	FBXO30	-0.53	-7.99	-0.4	2.18e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-14.05	-0.61	1.51e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg01483505	chr11:975446	AP2A2	0.42	5.94	0.31	6.98e-9	Alzheimer's disease (late onset);
LUSC	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg25214090	chr10:38739885	LOC399744	0.53	7.74	0.39	1.2e-13	Corneal astigmatism;
LUSC	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg18795169	chr1:18902165	NA	-1.0	-24.32	-0.8	6.64e-76	Urate levels in lean individuals;
LUSC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg15691649	chr6:25882328	NA	-0.38	-6.22	-0.32	1.49e-9	Blood metabolite levels;
LUSC	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg22283653	chr8:49824208	NA	0.34	6.61	0.34	1.51e-10	Sudden cardiac arrest;
LUSC	cis	rs977987	0.800	rs4888378	chr16:75332041	A/G	cg03315344	chr16:75512273	CHST6	0.47	8.82	0.43	6.26e-17	Dupuytren's disease;
LUSC	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg21972741	chr5:435613	AHRR	0.32	5.82	0.3	1.39e-8	Cystic fibrosis severity;
LUSC	cis	rs6750047	0.546	rs10192788	chr2:38272672	C/T	cg07380506	chr2:38303506	CYP1B1	0.45	6.23	0.32	1.43e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs2692947	0.637	rs1168967	chr2:96826016	A/G	cg23100626	chr2:96804247	ASTL	0.25	6.26	0.32	1.2e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg03676636	chr4:99064102	C4orf37	0.35	7.6	0.38	2.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10193935	1.000	rs13386385	chr2:42436928	G/T	cg27598129	chr2:42591480	NA	-0.63	-8.6	-0.43	3.25e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1113500	0.933	rs4517375	chr1:108638330	A/C	cg06207961	chr1:108661230	NA	-0.41	-7.72	-0.39	1.37e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg04511125	chr2:88470314	THNSL2	-0.44	-6.72	-0.35	7.71e-11	Response to metformin (IC50);
LUSC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02187348	chr16:89574699	SPG7	0.55	8.89	0.44	3.87e-17	Multiple myeloma (IgH translocation);
LUSC	cis	rs983392	0.709	rs4939320	chr11:59981801	T/C	cg02771260	chr11:59836817	MS4A3	-0.36	-5.96	-0.31	6.46e-9	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg19230755	chr7:65878503	NA	-0.39	-5.64	-0.3	3.56e-8	Aortic root size;
LUSC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	0.63	13.39	0.59	4.87e-33	Prudent dietary pattern;
LUSC	cis	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg24692254	chr21:30365293	RNF160	-0.57	-7.14	-0.36	6.03e-12	Cognitive test performance;
LUSC	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg00310523	chr12:86230176	RASSF9	0.45	8.0	0.4	2.1e-14	Major depressive disorder;
LUSC	cis	rs11608355	0.545	rs2302708	chr12:109893726	A/C	cg05360138	chr12:110035743	NA	0.9	11.56	0.53	3.1e-26	Neuroticism;
LUSC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.43	6.88	0.35	3.03e-11	Menopause (age at onset);
LUSC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg05082376	chr22:42548792	NA	0.43	6.53	0.34	2.43e-10	Schizophrenia;
LUSC	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg04106633	chr4:1044584	NA	0.32	5.71	0.3	2.45e-8	Recombination rate (males);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08555112	chr17:48942811	TOB1	0.42	6.24	0.32	1.34e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	7.87	0.4	5.03e-14	Iron status biomarkers;
LUSC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg04369109	chr6:150039330	LATS1	-0.58	-8.58	-0.43	3.55e-16	Lung cancer;
LUSC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.74	7.4	0.38	1.14e-12	Initial pursuit acceleration;
LUSC	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-10.82	-0.51	1.39e-23	Monocyte percentage of white cells;
LUSC	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg24642439	chr20:33292090	TP53INP2	0.71	11.11	0.52	1.31e-24	Coronary artery disease;
LUSC	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg07541023	chr7:19748670	TWISTNB	0.66	7.11	0.36	7.26e-12	Thyroid stimulating hormone;
LUSC	cis	rs9650315	0.810	rs34426788	chr8:57202762	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.27	0.37	2.53e-12	Height;
LUSC	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg07701084	chr6:150067640	NUP43	0.54	8.14	0.41	7.94e-15	Lung cancer;
LUSC	cis	rs7106204	0.513	rs2165784	chr11:24249360	C/A	ch.11.24196551F	chr11:24239977	NA	0.98	11.83	0.54	3.43e-27	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.49	-0.62	2.85e-37	Schizophrenia;
LUSC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	13.34	0.59	8.03e-33	Platelet count;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg24182508	chr19:54672312	TMC4	0.37	5.94	0.31	7.02e-9	Schizophrenia;
LUSC	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg22681709	chr2:178499509	PDE11A	0.4	5.74	0.3	2.1e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2294693	0.685	rs67525613	chr6:41008956	G/T	cg14769373	chr6:40998127	UNC5CL	-0.52	-6.36	-0.33	6.82e-10	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg27129171	chr3:47204927	SETD2	-0.58	-8.28	-0.41	2.99e-15	Birth weight;
LUSC	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.29	6.51	0.34	2.81e-10	Coronary artery disease;
LUSC	cis	rs6558174	0.965	rs4872524	chr8:22489537	A/G	cg03733263	chr8:22462867	KIAA1967	0.45	6.19	0.32	1.76e-9	Breast cancer;
LUSC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.63	-9.63	-0.47	1.53e-19	Intelligence (multi-trait analysis);
LUSC	trans	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.34	0.37	1.69e-12	Neuroticism;
LUSC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg01557791	chr16:72042693	DHODH	-0.51	-7.33	-0.37	1.74e-12	Fibrinogen levels;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg04746587	chr1:44435956	DPH2	0.39	6.01	0.31	4.76e-9	Schizophrenia;
LUSC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg07741184	chr6:167504864	NA	0.38	6.85	0.35	3.46e-11	Crohn's disease;
LUSC	cis	rs2859741	0.528	rs3753776	chr1:37480144	C/T	cg09363841	chr1:37513479	NA	-0.39	-7.47	-0.38	7.2e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	trans	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg07211511	chr3:129823064	LOC729375	-1.23	-21.07	-0.76	2.67e-63	Blood pressure (smoking interaction);
LUSC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg04455712	chr21:45112962	RRP1B	0.45	8.62	0.43	2.66e-16	Mean corpuscular volume;
LUSC	cis	rs2455601	0.638	rs11042148	chr11:9008674	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-6.52	-0.34	2.61e-10	Schizophrenia;
LUSC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg07507251	chr3:52567010	NT5DC2	0.33	6.3	0.33	9.25e-10	Bipolar disorder;
LUSC	cis	rs6429082	0.782	rs704705	chr1:235612320	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.63	-8.55	-0.42	4.59e-16	Adiposity;
LUSC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-1.08	-21.7	-0.76	9.49e-66	Height;
LUSC	cis	rs7804356	0.954	rs3801809	chr7:26895456	G/A	cg03456212	chr7:26904342	SKAP2	-0.52	-6.04	-0.31	4.16e-9	Type 1 diabetes;
LUSC	cis	rs9648716	0.515	rs17695707	chr7:140563901	C/T	cg23214464	chr7:140373596	ADCK2	0.66	5.78	0.3	1.75e-8	Type 2 diabetes;
LUSC	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg17764715	chr19:33622953	WDR88	0.6	8.33	0.41	2.08e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg13010199	chr12:38710504	ALG10B	-0.53	-8.19	-0.41	5.44e-15	Morning vs. evening chronotype;
LUSC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg27535305	chr1:53392650	SCP2	0.4	7.28	0.37	2.39e-12	Monocyte count;
LUSC	cis	rs4499344	0.730	rs7250272	chr19:33100338	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg09491104	chr22:46646882	C22orf40	-0.72	-7.44	-0.38	8.4e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg23229984	chr5:148520753	ABLIM3	0.37	5.97	0.31	6.15e-9	Breast cancer;
LUSC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.45	0.56	1.72e-29	Motion sickness;
LUSC	cis	rs7264396	0.887	rs4911503	chr20:34063095	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-5.99	-0.31	5.46e-9	Total cholesterol levels;
LUSC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg01874867	chr7:94954059	PON1	-0.42	-8.05	-0.4	1.49e-14	Paraoxonase activity;
LUSC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg07835181	chr16:1525278	CLCN7	-0.72	-12.36	-0.56	3.84e-29	Bone mineral density;
LUSC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	0.93	16.17	0.66	7.55e-44	Menopause (age at onset);
LUSC	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg03599575	chr15:90893182	GABARAPL3	0.34	5.8	0.3	1.54e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs9296092	0.538	rs3916674	chr6:33522975	C/T	cg13560919	chr6:33536144	NA	-0.82	-15.68	-0.65	6.77e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs1044826	1.000	rs12695699	chr3:139176109	T/C	cg00490450	chr3:139108681	COPB2	0.5	6.61	0.34	1.5e-10	Obesity-related traits;
LUSC	cis	rs57502260	0.704	rs60538784	chr11:68386735	G/A	cg20283391	chr11:68216788	NA	-0.62	-5.86	-0.31	1.09e-8	Total body bone mineral density (age 45-60);
LUSC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg04317338	chr11:64019027	PLCB3	-0.64	-7.53	-0.38	4.67e-13	Mean platelet volume;
LUSC	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.89	15.25	0.64	3.11e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	0.92	15.13	0.64	9.36e-40	Breast cancer;
LUSC	trans	rs9393777	0.920	rs34071253	chr6:27391802	C/T	cg01620082	chr3:125678407	NA	-0.69	-6.84	-0.35	3.77e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs868036	1.000	rs1026731	chr15:68095018	G/A	cg05925327	chr15:68127851	NA	-0.32	-5.7	-0.3	2.67e-8	Restless legs syndrome;
LUSC	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.89	14.89	0.63	8.55e-39	Tonsillectomy;
LUSC	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg16512390	chr1:228756714	NA	0.49	7.02	0.36	1.23e-11	Chronic lymphocytic leukemia;
LUSC	cis	rs7582720	1.000	rs72934738	chr2:203740861	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.56	0.42	4.25e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg27539214	chr16:67997921	SLC12A4	-0.59	-7.75	-0.39	1.11e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7584330	0.554	rs10178682	chr2:238433818	T/G	cg16989719	chr2:238392110	NA	-0.39	-5.69	-0.3	2.79e-8	Prostate cancer;
LUSC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	0.99	12.9	0.58	3.74e-31	Eosinophil percentage of granulocytes;
LUSC	cis	rs3733418	0.929	rs13149062	chr4:165905360	T/G	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-5.93	-0.31	7.54e-9	Obesity-related traits;
LUSC	cis	rs4604732	0.631	rs4436425	chr1:247632323	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.43	6.64	0.34	1.29e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg00310523	chr12:86230176	RASSF9	0.36	6.5	0.34	2.85e-10	Major depressive disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17213946	chr1:43997516	PTPRF	-0.47	-6.18	-0.32	1.91e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg21775007	chr8:11205619	TDH	-0.53	-7.48	-0.38	6.65e-13	Triglycerides;
LUSC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	5.99	0.31	5.5e-9	Breast cancer;
LUSC	cis	rs4423214	0.547	rs11234030	chr11:71236967	G/A	cg05163923	chr11:71159392	DHCR7	-0.65	-6.82	-0.35	4.23e-11	Vitamin D levels;
LUSC	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.38	-0.33	5.93e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg12454169	chr2:30669597	LCLAT1	0.61	8.2	0.41	5.06e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.7	12.19	0.55	1.6e-28	Prudent dietary pattern;
LUSC	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg17507749	chr15:85114479	UBE2QP1	0.54	6.49	0.33	3.11e-10	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.68	0.43	1.73e-16	Prudent dietary pattern;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19954146	chr6:1312822	FOXQ1	0.39	6.17	0.32	1.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg21724239	chr8:58056113	NA	0.55	6.25	0.32	1.24e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.22	-0.37	3.43e-12	Neuroticism;
LUSC	cis	rs4974559	0.947	rs28509315	chr4:1358107	C/T	cg02980000	chr4:1222292	CTBP1	0.73	7.25	0.37	2.92e-12	Systolic blood pressure;
LUSC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08859206	chr1:53392774	SCP2	-0.66	-12.58	-0.57	5.43e-30	Monocyte count;
LUSC	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg12863693	chr15:85201151	NMB	-0.26	-5.97	-0.31	5.98e-9	P wave terminal force;
LUSC	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg12473912	chr3:136751656	NA	0.39	7.07	0.36	8.96e-12	Neuroticism;
LUSC	cis	rs477692	1.000	rs473073	chr10:131429646	G/T	cg26102564	chr10:131424627	MGMT	0.41	6.41	0.33	4.82e-10	Response to temozolomide;
LUSC	cis	rs2346177	0.875	rs2166745	chr2:46646879	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.37	6.32	0.33	8.45e-10	HDL cholesterol;
LUSC	trans	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg26043149	chr18:55253948	FECH	0.49	7.28	0.37	2.43e-12	Bone mineral density;
LUSC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.25	34.18	0.88	4.53e-111	Chronic sinus infection;
LUSC	cis	rs2274273	0.624	rs68138420	chr14:55777967	G/T	cg04306507	chr14:55594613	LGALS3	0.49	10.11	0.48	3.86e-21	Protein biomarker;
LUSC	trans	rs1325195	0.806	rs2816196	chr1:179103877	G/T	cg11624085	chr17:8464688	MYH10	0.44	7.3	0.37	2.14e-12	IgE grass sensitization;
LUSC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg14773178	chr5:1868261	NA	0.31	5.76	0.3	1.87e-8	Cardiovascular disease risk factors;
LUSC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.58	-8.22	-0.41	4.44e-15	Longevity;Endometriosis;
LUSC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg12292205	chr6:26970375	C6orf41	0.67	11.26	0.52	3.72e-25	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg03609598	chr5:56110824	MAP3K1	-0.38	-5.81	-0.3	1.48e-8	Initial pursuit acceleration;
LUSC	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg06627628	chr2:24431161	ITSN2	-0.6	-7.34	-0.37	1.69e-12	Lymphocyte counts;
LUSC	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13055374	chr1:54872983	SSBP3	0.5	7.73	0.39	1.25e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs897080	0.552	rs1068714	chr2:44634063	T/C	cg00619915	chr2:44497795	NA	-0.41	-5.8	-0.3	1.54e-8	Height;
LUSC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg06238570	chr21:40685208	BRWD1	-0.43	-6.54	-0.34	2.32e-10	Cognitive function;
LUSC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg23788917	chr6:8435910	SLC35B3	-0.51	-7.54	-0.38	4.59e-13	Motion sickness;
LUSC	cis	rs10743315	0.557	rs17343287	chr12:19420064	T/C	cg02471346	chr12:19282374	PLEKHA5	0.81	6.28	0.32	1.07e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg26408565	chr15:76604113	ETFA	-0.45	-7.0	-0.36	1.43e-11	Blood metabolite levels;
LUSC	cis	rs722599	0.683	rs8008475	chr14:75291900	C/T	cg08847533	chr14:75593920	NEK9	0.44	6.21	0.32	1.58e-9	IgG glycosylation;
LUSC	cis	rs2274273	1.000	rs1009977	chr14:55603002	T/G	cg04306507	chr14:55594613	LGALS3	0.57	13.06	0.58	9.13e-32	Protein biomarker;
LUSC	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.74	10.76	0.51	2.3e-23	Corneal astigmatism;
LUSC	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg24069376	chr3:38537580	EXOG	0.39	7.19	0.37	4.27e-12	Electrocardiographic conduction measures;
LUSC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg19812747	chr11:111475976	SIK2	-0.55	-8.2	-0.41	5.19e-15	Primary sclerosing cholangitis;
LUSC	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg23093090	chr10:104574429	C10orf26	-0.38	-7.11	-0.36	6.95e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg23093090	chr10:104574429	C10orf26	-0.36	-6.68	-0.34	1e-10	Arsenic metabolism;
LUSC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	14.06	0.61	1.35e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg03060546	chr3:49711283	APEH	0.55	7.66	0.39	2.07e-13	Resting heart rate;
LUSC	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.89	-0.35	2.83e-11	Joint mobility (Beighton score);
LUSC	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg25237894	chr2:233734115	C2orf82	0.35	6.44	0.33	4.25e-10	Coronary artery disease;
LUSC	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg09365446	chr1:150670422	GOLPH3L	0.48	7.05	0.36	1.05e-11	Melanoma;
LUSC	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg01528321	chr10:82214614	TSPAN14	1.07	12.16	0.55	1.97e-28	Post bronchodilator FEV1;
LUSC	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-1.0	-19.03	-0.72	3.26e-55	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg13607699	chr17:42295918	UBTF	0.5	7.7	0.39	1.52e-13	Total body bone mineral density;
LUSC	cis	rs4789693	0.544	rs4789770	chr17:80376655	C/T	cg04308225	chr17:80449738	NA	0.4	6.13	0.32	2.47e-9	Glucocorticoid-induced osteonecrosis;
LUSC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg04414720	chr1:150670196	GOLPH3L	0.56	9.09	0.45	8.97e-18	Tonsillectomy;
LUSC	cis	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg07988820	chr12:82153109	PPFIA2	-0.42	-6.04	-0.31	4.05e-9	Resting heart rate;
LUSC	cis	rs400736	0.535	rs4418631	chr1:8174197	A/G	cg25007680	chr1:8021821	PARK7	0.44	6.43	0.33	4.45e-10	Response to antidepressants and depression;
LUSC	cis	rs2190422	0.677	rs2382694	chr7:103070983	A/G	cg04218035	chr7:103086829	SLC26A5	0.32	6.29	0.33	1.01e-9	Morning vs. evening chronotype;
LUSC	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg08355456	chr11:67383691	NA	0.37	6.88	0.35	2.97e-11	Mean corpuscular volume;
LUSC	cis	rs6681460	1.000	rs10889634	chr1:67065911	A/G	cg02459107	chr1:67143332	SGIP1	-0.46	-8.54	-0.42	4.68e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg11752832	chr7:134001865	SLC35B4	0.4	5.96	0.31	6.41e-9	Mean platelet volume;
LUSC	trans	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-9.39	-0.46	9.86e-19	Brugada syndrome;
LUSC	cis	rs6460942	0.630	rs1866650	chr7:12396897	C/T	cg06484146	chr7:12443880	VWDE	-0.59	-6.07	-0.32	3.49e-9	Coronary artery disease;
LUSC	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg04117972	chr1:227635322	NA	0.62	7.06	0.36	9.84e-12	Major depressive disorder;
LUSC	trans	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg17712092	chr4:129076599	LARP1B	-0.71	-10.28	-0.49	1.02e-21	Eosinophil percentage of white cells;
LUSC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg04111992	chr7:158790115	NA	0.43	7.04	0.36	1.09e-11	Facial morphology (factor 20);
LUSC	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg24375607	chr4:120327624	NA	0.74	11.16	0.52	8.3e-25	Corneal astigmatism;
LUSC	cis	rs7520050	0.966	rs12021587	chr1:46472759	G/T	cg06784218	chr1:46089804	CCDC17	-0.29	-5.69	-0.3	2.78e-8	Red blood cell count;Reticulocyte count;
LUSC	trans	rs10448080	0.959	rs4732873	chr8:28601554	A/C	cg13109300	chr12:49488587	DHH	0.33	6.14	0.32	2.37e-9	Height;
LUSC	cis	rs3857536	0.813	rs7771716	chr6:66946769	C/T	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	0.88	13.86	0.6	7.72e-35	Blood protein levels;
LUSC	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.21	0.32	1.54e-9	Neuroticism;
LUSC	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	0.98	15.66	0.65	7.7e-42	Dupuytren's disease;
LUSC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg25233709	chr10:116636983	FAM160B1	0.37	6.63	0.34	1.33e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.84	-10.95	-0.51	4.73e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg00990874	chr7:1149470	C7orf50	-0.6	-8.05	-0.4	1.51e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs7191700	0.578	rs243324	chr16:11354970	A/G	cg00044050	chr16:11439710	C16orf75	0.68	12.23	0.56	1.12e-28	Multiple sclerosis;
LUSC	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs6845621	0.689	rs1356464	chr4:18847496	G/A	cg12196642	chr4:18937545	NA	-0.32	-5.84	-0.3	1.24e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg17623882	chr6:41773611	USP49	-0.65	-11.06	-0.52	1.94e-24	Menarche (age at onset);
LUSC	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg23625390	chr15:77176239	SCAPER	-0.64	-9.78	-0.47	4.89e-20	Blood metabolite levels;
LUSC	cis	rs737008	0.922	rs2070923	chr16:11369855	G/T	cg00044050	chr16:11439710	C16orf75	0.57	8.84	0.44	5.52e-17	Obesity-related traits;
LUSC	cis	rs62408225	0.802	rs4997561	chr6:90908057	C/T	cg06866423	chr6:90926672	BACH2	0.44	6.95	0.36	1.88e-11	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg05552183	chr6:42928497	GNMT	0.48	8.21	0.41	4.86e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs9341808	0.754	rs3793000	chr6:80995137	G/A	cg08355045	chr6:80787529	NA	0.56	9.8	0.47	4.14e-20	Sitting height ratio;
LUSC	cis	rs701145	0.585	rs357473	chr3:153895147	C/T	cg17054900	chr3:154042577	DHX36	0.7	7.21	0.37	3.87e-12	Coronary artery disease;
LUSC	cis	rs10754283	0.967	rs6428562	chr1:90102665	G/A	cg21401794	chr1:90099060	LRRC8C	0.65	9.79	0.47	4.51e-20	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.53	7.31	0.37	1.99e-12	IgG glycosylation;
LUSC	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg02493740	chr2:85810744	VAMP5	0.34	5.99	0.31	5.3e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21643547	chr1:205240462	TMCC2	-0.49	-9.3	-0.45	1.88e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg03060546	chr3:49711283	APEH	0.72	12.18	0.55	1.79e-28	Resting heart rate;
LUSC	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg13010199	chr12:38710504	ALG10B	-0.6	-9.09	-0.45	8.66e-18	Bladder cancer;
LUSC	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg24675056	chr1:15929824	NA	0.46	7.96	0.4	2.79e-14	Systolic blood pressure;
LUSC	cis	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg17469321	chr7:55412551	NA	0.65	10.42	0.5	3.41e-22	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg25801113	chr15:45476975	SHF	0.35	7.22	0.37	3.5e-12	Uric acid levels;
LUSC	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg25554036	chr4:6271136	WFS1	0.64	13.57	0.6	1.01e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-17.7	-0.7	6.65e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg21960279	chr19:17905606	B3GNT3	0.39	6.09	0.32	3.14e-9	Tumor biomarkers;
LUSC	cis	rs4629180	0.586	rs1159902	chr2:102133641	G/A	cg04415270	chr2:102091202	RFX8	-0.46	-7.87	-0.4	5.05e-14	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.84	15.14	0.64	8.94e-40	Menarche (age at onset);
LUSC	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg00484396	chr16:3507460	NAT15	0.93	10.74	0.51	2.66e-23	Tuberculosis;
LUSC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs7189233	0.531	rs7194730	chr16:53489190	A/T	cg09728985	chr16:53543985	NA	-0.31	-5.81	-0.3	1.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.66	11.37	0.53	1.54e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg26875233	chr11:93583750	C11orf90	-0.3	-5.86	-0.31	1.13e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg25456477	chr12:86230367	RASSF9	0.43	7.66	0.39	2.03e-13	Major depressive disorder;
LUSC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg11598736	chr3:195384522	SDHAP2	0.6	6.8	0.35	4.77e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.71	-0.34	8.14e-11	Response to antipsychotic treatment;
LUSC	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg16342193	chr10:102329863	NA	-0.38	-6.98	-0.36	1.65e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4917833	0.789	rs11189619	chr10:100220012	C/T	cg19043522	chr10:100227446	HPSE2	0.4	5.71	0.3	2.53e-8	Pediatric bone mineral density (femoral neck);
LUSC	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg13319975	chr6:146136371	FBXO30	0.45	7.02	0.36	1.24e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26384229	chr12:38710491	ALG10B	0.9	15.57	0.65	1.71e-41	Morning vs. evening chronotype;
LUSC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.39	-6.69	-0.34	9.57e-11	High light scatter reticulocyte count;
LUSC	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg17173187	chr15:85201210	NMB	0.49	9.25	0.45	2.65e-18	Schizophrenia;
LUSC	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg07701084	chr6:150067640	NUP43	0.53	7.81	0.39	7.32e-14	Lung cancer;
LUSC	cis	rs4594175	0.926	rs10138345	chr14:51624651	A/G	cg23942311	chr14:51606299	NA	0.31	5.76	0.3	1.87e-8	Cancer;
LUSC	cis	rs939658	0.805	rs12902831	chr15:79433171	G/A	cg17916960	chr15:79447300	NA	-0.52	-10.39	-0.49	4.32e-22	Refractive error;
LUSC	trans	rs10946292	0.656	rs1740	chr6:170441452	C/T	cg17832364	chr10:94847294	NA	0.36	5.99	0.31	5.54e-9	Obesity-related traits;
LUSC	cis	rs2625529	0.689	rs10851847	chr15:72111760	T/C	cg16672083	chr15:72433130	SENP8	-0.46	-7.39	-0.37	1.19e-12	Red blood cell count;
LUSC	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg12745145	chr7:2261452	MAD1L1	-0.3	-5.96	-0.31	6.43e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg27494647	chr7:150038898	RARRES2	0.47	7.29	0.37	2.19e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2292864	0.764	rs2292867	chr17:45357489	C/T	cg18085866	chr17:45331354	ITGB3	-0.65	-5.67	-0.3	3.12e-8	Left atrial antero-posterior diameter;
LUSC	cis	rs9796	0.870	rs7162992	chr15:41290861	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.4	-6.9	-0.35	2.59e-11	Menopause (age at onset);
LUSC	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg03647239	chr10:116582469	FAM160B1	0.48	7.56	0.38	3.94e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg15556689	chr8:8085844	FLJ10661	0.68	10.7	0.51	3.48e-23	Mood instability;
LUSC	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	19.65	0.73	1.08e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.86	-0.81	6.04e-78	Height;
LUSC	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg02753203	chr1:228287806	NA	1.0	19.87	0.74	1.47e-58	Diastolic blood pressure;
LUSC	trans	rs10885582	0.874	rs10885586	chr10:116357563	A/G	cg01002288	chr1:43166549	YBX1	-0.37	-6.35	-0.33	7.06e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.78	0.47	4.96e-20	Bipolar disorder;
LUSC	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-0.93	-15.36	-0.64	1.22e-40	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.52	3.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.72	-0.3	2.41e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg23601095	chr6:26197514	HIST1H3D	0.73	7.46	0.38	7.42e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs7000551	0.689	rs12545909	chr8:22310052	A/G	cg12081754	chr8:22256438	SLC39A14	-0.46	-7.04	-0.36	1.12e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg26875233	chr11:93583750	C11orf90	-0.31	-6.01	-0.31	4.85e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg01774158	chr5:133562094	PPP2CA	0.38	6.37	0.33	6.23e-10	Calcium levels;
LUSC	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg26408565	chr15:76604113	ETFA	-0.48	-7.58	-0.38	3.4e-13	Blood metabolite levels;
LUSC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg07507251	chr3:52567010	NT5DC2	0.31	5.98	0.31	5.63e-9	Bipolar disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg15380588	chr6:144606480	NA	-0.49	-6.12	-0.32	2.61e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg24675658	chr1:53192096	ZYG11B	-0.63	-9.93	-0.48	1.62e-20	Monocyte count;
LUSC	cis	rs735539	0.645	rs6490601	chr13:21245897	G/A	cg04906043	chr13:21280425	IL17D	-0.47	-7.3	-0.37	2.06e-12	Dental caries;
LUSC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg04317338	chr11:64019027	PLCB3	0.69	7.93	0.4	3.42e-14	Mean platelet volume;
LUSC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.9	16.85	0.68	1.6e-46	Menarche (age at onset);
LUSC	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg08085267	chr17:45401833	C17orf57	-0.55	-8.96	-0.44	2.32e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6494488	0.500	rs72742910	chr15:64841834	G/A	cg08069370	chr15:64387884	SNX1	-0.64	-5.65	-0.3	3.48e-8	Coronary artery disease;
LUSC	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg27490568	chr2:178487706	NA	0.59	7.82	0.39	7.04e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg21535247	chr6:8435926	SLC35B3	0.57	8.86	0.44	4.73e-17	Motion sickness;
LUSC	cis	rs7246967	0.673	rs4414616	chr19:22832411	G/A	cg23217946	chr19:22817039	ZNF492	0.49	6.91	0.35	2.52e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs7605827	0.930	rs4668904	chr2:15543642	C/G	cg19274914	chr2:15703543	NA	0.45	8.52	0.42	5.5e-16	Educational attainment (years of education);
LUSC	cis	rs12900413	0.687	rs28752094	chr15:90311645	G/A	cg24249390	chr15:90295951	MESP1	-0.37	-5.85	-0.3	1.17e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs12618769	0.625	rs4850878	chr2:99112180	T/A	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs524023	0.881	rs544838	chr11:64429059	T/C	cg19131476	chr11:64387923	NRXN2	-0.38	-10.5	-0.5	1.79e-22	Urate levels in obese individuals;
LUSC	cis	rs4474465	0.850	rs4441045	chr11:78220436	G/T	cg27205649	chr11:78285834	NARS2	0.49	5.69	0.3	2.74e-8	Alzheimer's disease (survival time);
LUSC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	trans	rs7657257	1.000	rs12643722	chr4:15730103	A/C	cg17675199	chr6:35436792	RPL10A	-0.88	-6.15	-0.32	2.26e-9	Blood protein levels;
LUSC	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.07	14.26	0.62	2.27e-36	Uric acid levels;
LUSC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg11608241	chr8:8085544	FLJ10661	-0.54	-8.08	-0.4	1.18e-14	Neuroticism;
LUSC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03517284	chr6:25882590	NA	-0.46	-8.18	-0.41	6.14e-15	Blood metabolite levels;
LUSC	trans	rs800082	1.000	rs2575194	chr3:144284871	C/T	cg24215973	chr2:240111563	HDAC4	0.47	7.17	0.37	4.98e-12	Smoking behavior;
LUSC	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.56	-8.58	-0.42	3.69e-16	Rheumatoid arthritis;
LUSC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.62	-0.5	6.72e-23	Bipolar disorder and schizophrenia;
LUSC	cis	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg02972257	chr16:68554789	NA	0.43	5.89	0.31	9.18e-9	Colorectal cancer;
LUSC	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg23711669	chr6:146136114	FBXO30	0.87	15.68	0.65	6.49e-42	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12210905	0.688	rs72841376	chr6:27456321	G/A	cg08851530	chr6:28072375	NA	0.97	6.01	0.31	4.99e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg24296786	chr1:45957014	TESK2	0.53	8.37	0.42	1.57e-15	High light scatter reticulocyte count;
LUSC	trans	rs12637928	0.580	rs13075977	chr3:110175685	C/T	cg17371621	chr15:61264283	RORA	0.37	6.25	0.32	1.24e-9	Neuroticism;
LUSC	cis	rs4629180	0.917	rs34217240	chr2:102136682	G/A	cg04415270	chr2:102091202	RFX8	0.53	8.41	0.42	1.2e-15	Chronic rhinosinusitis with nasal polyps;
LUSC	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	trans	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg26043149	chr18:55253948	FECH	-0.55	-8.37	-0.42	1.63e-15	Bone mineral density;
LUSC	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.11	-29.12	-0.85	1.12e-93	Myeloid white cell count;
LUSC	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg25456477	chr12:86230367	RASSF9	0.39	6.88	0.35	2.96e-11	Major depressive disorder;
LUSC	cis	rs1385374	0.858	rs11059926	chr12:129294244	A/T	cg09035930	chr12:129282057	SLC15A4	-0.64	-6.8	-0.35	4.96e-11	Systemic lupus erythematosus;
LUSC	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg01579765	chr21:45077557	HSF2BP	-0.48	-10.08	-0.48	4.95e-21	Mean corpuscular volume;
LUSC	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg06138931	chr13:21896616	NA	0.4	6.74	0.35	6.78e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg06740227	chr12:86229804	RASSF9	0.42	6.71	0.34	8.31e-11	Major depressive disorder;
LUSC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.67	7.14	0.36	5.74e-12	Initial pursuit acceleration;
LUSC	trans	rs1422110	0.879	rs1363268	chr5:85469695	C/T	cg01787110	chr1:109008453	NBPF6	-0.48	-7.95	-0.4	2.86e-14	Attention function in attention deficit hyperactive disorder;
LUSC	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg17168535	chr8:21777572	XPO7	0.69	10.61	0.5	7.14e-23	Mean corpuscular volume;
LUSC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.07	0.44	1.01e-17	Motion sickness;
LUSC	cis	rs7582720	1.000	rs72936834	chr2:203771260	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.66	0.43	2.06e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07677032	chr17:61819896	STRADA	0.52	8.69	0.43	1.68e-16	Prudent dietary pattern;
LUSC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.34	5.85	0.3	1.2e-8	Obesity-related traits;
LUSC	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg22800045	chr5:56110881	MAP3K1	0.43	6.09	0.32	3.19e-9	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg16325326	chr1:53192061	ZYG11B	-0.97	-19.53	-0.73	3.44e-57	Monocyte count;
LUSC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18854424	chr1:2615690	NA	-0.5	-10.04	-0.48	6.48e-21	Multiple sclerosis;
LUSC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg06008330	chr7:65541103	ASL	0.4	6.19	0.32	1.77e-9	Aortic root size;
LUSC	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg11965913	chr1:205819406	PM20D1	-0.48	-6.42	-0.33	4.66e-10	Parkinson's disease;
LUSC	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg19824325	chr16:58548873	SETD6	0.94	9.32	0.45	1.63e-18	Schizophrenia;
LUSC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg27398817	chr8:82754497	SNX16	-0.66	-8.38	-0.42	1.47e-15	Diastolic blood pressure;
LUSC	cis	rs6961069	0.527	rs3212161	chr7:80273358	T/C	cg04458919	chr7:80252533	CD36	0.37	6.45	0.33	3.9e-10	Platelet count;
LUSC	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg00857998	chr1:205179979	DSTYK	0.59	8.82	0.43	6.27e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg07741184	chr6:167504864	NA	0.41	6.61	0.34	1.53e-10	Primary biliary cholangitis;
LUSC	cis	rs2307022	0.586	rs2279539	chr16:68395094	G/A	cg02226672	chr16:68398533	SMPD3	0.3	5.71	0.3	2.54e-8	Body mass index;
LUSC	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.54	-8.54	-0.42	4.83e-16	Schizophrenia;
LUSC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg04450456	chr4:17643702	FAM184B	0.39	6.56	0.34	2.1e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg12564285	chr5:131593104	PDLIM4	0.39	6.91	0.35	2.51e-11	Breast cancer;
LUSC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg05313129	chr8:58192883	C8orf71	-0.5	-6.51	-0.34	2.8e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7582180	0.903	rs7562372	chr2:100906331	T/C	cg08017756	chr2:100939284	LONRF2	-0.35	-5.85	-0.3	1.2e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.57	-10.58	-0.5	9.31e-23	Homoarginine levels;
LUSC	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg01629716	chr15:45996671	NA	0.39	5.88	0.31	9.74e-9	Waist circumference;Weight;
LUSC	cis	rs11018904	0.906	rs17227345	chr11:89954685	A/T	cg26834418	chr11:89957033	CHORDC1	0.48	6.01	0.31	4.96e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7712401	0.601	rs257813	chr5:122217168	G/A	cg19077854	chr5:122220652	SNX24	0.4	9.09	0.45	8.81e-18	Mean platelet volume;
LUSC	trans	rs6858430	0.744	rs2200458	chr4:175741282	C/G	cg23523129	chr19:11457176	TMEM205;CCDC159	0.44	6.47	0.33	3.46e-10	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg24375607	chr4:120327624	NA	-0.71	-11.7	-0.54	9.56e-27	Corneal astigmatism;
LUSC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.77	14.38	0.62	7.9e-37	Longevity;
LUSC	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.93	-0.48	1.54e-20	Migraine;Coronary artery disease;
LUSC	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg15133208	chr4:90757351	SNCA	-0.54	-8.22	-0.41	4.43e-15	Neuroticism;
LUSC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-7.01	-0.36	1.34e-11	Renal function-related traits (BUN);
LUSC	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg17553881	chr5:443987	EXOC3;C5orf55	-0.31	-6.21	-0.32	1.59e-9	Cystic fibrosis severity;
LUSC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg22437258	chr11:111473054	SIK2	0.49	6.63	0.34	1.34e-10	Primary sclerosing cholangitis;
LUSC	cis	rs10484885	0.715	rs2585013	chr6:90553402	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.98	-13.49	-0.59	2.1e-33	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs1957429	0.901	rs1951491	chr14:65346950	G/A	cg23373153	chr14:65346875	NA	1.09	12.86	0.58	4.86e-31	Pediatric areal bone mineral density (radius);
LUSC	cis	rs7254114	0.686	rs7249565	chr19:11302807	C/T	cg02815516	chr19:11306319	KANK2	-0.42	-8.96	-0.44	2.38e-17	Immature fraction of reticulocytes;
LUSC	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg27068330	chr11:65405492	SIPA1	-0.74	-10.3	-0.49	8.46e-22	Acne (severe);
LUSC	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg02023728	chr11:77925099	USP35	0.47	6.76	0.35	6.01e-11	Testicular germ cell tumor;
LUSC	cis	rs2540226	0.874	rs6731026	chr2:39977159	C/T	cg23576258	chr2:39999331	THUMPD2	0.35	5.82	0.3	1.42e-8	Personality dimensions;
LUSC	cis	rs1005224	0.963	rs2302592	chr14:76129287	C/G	cg04684003	chr14:76127793	TTLL5;C14orf1	0.59	8.0	0.4	2.11e-14	Large artery stroke;
LUSC	trans	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg09220050	chr20:48770642	TMEM189;TMEM189-UBE2V1	-0.47	-6.8	-0.35	4.8e-11	Monocyte count;
LUSC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.2	-0.41	5.27e-15	Lung cancer;
LUSC	cis	rs1408224	0.576	rs7335684	chr13:47193696	G/A	cg19833103	chr13:47126551	LRCH1	-0.39	-5.83	-0.3	1.29e-8	QRS complex (12-leadsum);
LUSC	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.61	0.34	1.57e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2354432	0.607	rs3820130	chr1:146724003	A/G	cg25205988	chr1:146714368	CHD1L	-1.0	-9.68	-0.47	1.09e-19	Mitochondrial DNA levels;
LUSC	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-8.16	-0.41	6.75e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	0.99	20.81	0.75	2.8e-62	Platelet distribution width;
LUSC	cis	rs11608355	1.000	rs11608355	chr12:109879292	T/C	cg19025524	chr12:109796872	NA	-0.36	-5.65	-0.3	3.42e-8	Neuroticism;
LUSC	cis	rs2969070	0.831	rs7799266	chr7:2506595	G/A	cg03277898	chr7:2518824	NA	-0.28	-5.92	-0.31	8.09e-9	Diastolic blood pressure;
LUSC	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg01819759	chr13:79234251	RNF219	0.6	8.09	0.4	1.14e-14	Large artery stroke;
LUSC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg15691649	chr6:25882328	NA	-0.37	-5.85	-0.3	1.19e-8	Blood metabolite levels;
LUSC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg11766577	chr21:47581405	C21orf56	-0.42	-6.17	-0.32	1.98e-9	Testicular germ cell tumor;
LUSC	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg18721089	chr20:30220636	NA	-0.37	-5.81	-0.3	1.48e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg24531977	chr5:56204891	C5orf35	-0.58	-8.46	-0.42	8.46e-16	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-7.03	-0.36	1.17e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.56	8.36	0.42	1.68e-15	Total body bone mineral density;
LUSC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.75	13.51	0.59	1.81e-33	Calcium levels;
LUSC	cis	rs6546550	0.935	rs6747542	chr2:70106832	T/C	cg02498382	chr2:70120550	SNRNP27	-0.29	-7.17	-0.37	4.99e-12	Prevalent atrial fibrillation;
LUSC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	6.44	0.33	4.21e-10	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08677398	chr8:58056175	NA	0.52	6.43	0.33	4.33e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.83	-11.43	-0.53	9.54e-26	Ileal carcinoids;
LUSC	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-7.24	-0.37	3.04e-12	Blood metabolite levels;
LUSC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.68	-0.47	1.06e-19	Gut microbiome composition (summer);
LUSC	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg08000102	chr2:233561755	GIGYF2	0.68	11.4	0.53	1.17e-25	Coronary artery disease;
LUSC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	7.36	0.37	1.45e-12	Schizophrenia;
LUSC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg12442385	chr7:1034912	NA	0.36	6.25	0.32	1.23e-9	Longevity;Endometriosis;
LUSC	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg05340658	chr4:99064831	C4orf37	-0.44	-6.93	-0.35	2.19e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs701145	0.585	rs1470664	chr3:153865193	C/T	cg17054900	chr3:154042577	DHX36	0.63	6.19	0.32	1.79e-9	Coronary artery disease;
LUSC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg09359103	chr1:154839909	KCNN3	-0.71	-16.97	-0.68	4.99e-47	Prostate cancer;
LUSC	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg14583973	chr4:3374767	RGS12	0.36	7.51	0.38	5.36e-13	Serum sulfate level;
LUSC	cis	rs2667011	0.512	rs1511217	chr2:160815093	T/C	cg06573604	chr2:160760825	LY75	0.45	6.3	0.33	9.56e-10	Bilirubin levels;
LUSC	cis	rs1577917	0.917	rs1838959	chr6:86556804	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.89	-0.44	3.82e-17	Response to antipsychotic treatment;
LUSC	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg12473912	chr3:136751656	NA	0.39	6.77	0.35	5.97e-11	Neuroticism;
LUSC	trans	rs9409565	0.826	rs9409556	chr9:97239268	T/C	cg05679027	chr9:99775184	HIATL2	-0.45	-6.48	-0.33	3.23e-10	Colorectal cancer (alcohol consumption interaction);
LUSC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25072359	chr17:41440525	NA	0.67	9.62	0.47	1.68e-19	Menopause (age at onset);
LUSC	cis	rs17253792	0.822	rs7145064	chr14:56088860	C/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.54	-0.34	2.24e-10	Putamen volume;
LUSC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg17143192	chr8:8559678	CLDN23	0.62	9.06	0.44	1.12e-17	Obesity-related traits;
LUSC	cis	rs10761482	0.500	rs1938543	chr10:62284660	A/T	cg18175470	chr10:62150864	ANK3	-0.51	-7.4	-0.38	1.12e-12	Schizophrenia;
LUSC	cis	rs12980942	0.630	rs7256856	chr19:41788352	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.59	6.49	0.33	3.13e-10	Coronary artery disease;
LUSC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18404041	chr3:52824283	ITIH1	-0.47	-8.6	-0.43	3.22e-16	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04402350	chr4:146857565	ZNF827	0.39	6.15	0.32	2.25e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg02117656	chr17:79614917	TSPAN10	0.31	5.66	0.3	3.3e-8	Eye color traits;
LUSC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg04756594	chr16:24857601	SLC5A11	-0.48	-7.1	-0.36	7.43e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6546550	0.867	rs6738174	chr2:70150215	A/C	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-9.21	-0.45	3.78e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs3770081	0.793	rs73943946	chr2:86226623	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.06	-6.77	-0.35	5.96e-11	Facial emotion recognition (sad faces);
LUSC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg16606324	chr3:10149918	C3orf24	0.62	9.08	0.44	9.81e-18	Alzheimer's disease;
LUSC	cis	rs9914988	0.537	rs28448745	chr17:27188296	A/C	cg20469991	chr17:27169893	C17orf63	0.55	5.68	0.3	2.9e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg18132916	chr6:79620363	NA	-0.37	-5.74	-0.3	2.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs34779708	0.733	rs12240638	chr10:35542610	G/T	cg03585969	chr10:35415529	CREM	0.55	7.7	0.39	1.55e-13	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg05347473	chr6:146136440	FBXO30	0.52	8.87	0.44	4.42e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4499344	0.664	rs259284	chr19:33163262	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	11.76	0.54	6.07e-27	Mean platelet volume;
LUSC	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg13073564	chr4:8508604	NA	-0.45	-8.63	-0.43	2.47e-16	Response to antineoplastic agents;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16527491	chr14:38065127	FOXA1	0.39	6.04	0.31	4.21e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg22705602	chr4:152727874	NA	-0.34	-6.69	-0.34	9.52e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs793571	0.566	rs610877	chr15:59103328	C/A	cg05156742	chr15:59063176	FAM63B	0.58	8.53	0.42	5.28e-16	Schizophrenia;
LUSC	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg24634471	chr8:143751801	JRK	0.51	7.25	0.37	2.9e-12	Schizophrenia;
LUSC	cis	rs10740039	0.883	rs7088404	chr10:62393078	C/A	cg18175470	chr10:62150864	ANK3	-0.47	-6.91	-0.35	2.46e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	0.67	14.33	0.62	1.28e-36	Prudent dietary pattern;
LUSC	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.68	-10.82	-0.51	1.32e-23	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.18	0.32	1.87e-9	Menopause (age at onset);
LUSC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25072359	chr17:41440525	NA	0.64	9.06	0.44	1.09e-17	Menopause (age at onset);
LUSC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-9.41	-0.46	8.25e-19	Chronic sinus infection;
LUSC	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg00982548	chr2:198649783	BOLL	-0.57	-7.09	-0.36	7.99e-12	Ulcerative colitis;
LUSC	cis	rs9462027	0.628	rs9469859	chr6:34722902	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.75	-0.3	2.01e-8	Systemic lupus erythematosus;
LUSC	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg18105134	chr13:113819100	PROZ	-0.67	-9.99	-0.48	9.94e-21	Platelet distribution width;
LUSC	cis	rs798554	0.686	rs1713920	chr7:2880935	G/C	cg02423579	chr7:2872169	GNA12	-0.44	-6.59	-0.34	1.73e-10	Height;
LUSC	trans	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.44	6.05	0.31	3.98e-9	Corneal astigmatism;
LUSC	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.74	0.65	3.64e-42	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg10560079	chr2:191398806	TMEM194B	-0.72	-8.48	-0.42	7.41e-16	Diastolic blood pressure;
LUSC	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg20302533	chr7:39170763	POU6F2	0.49	8.03	0.4	1.74e-14	IgG glycosylation;
LUSC	cis	rs6700896	0.500	rs4655740	chr1:66084309	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.35	0.33	7.09e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg00277334	chr10:82204260	NA	-0.58	-8.71	-0.43	1.47e-16	Post bronchodilator FEV1;
LUSC	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg15704280	chr7:45808275	SEPT13	0.93	13.42	0.59	3.7e-33	Coronary artery disease;
LUSC	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg06219351	chr7:158114137	PTPRN2	0.49	8.85	0.44	5.12e-17	Calcium levels;
LUSC	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg11344533	chr11:111475393	SIK2	0.48	6.29	0.33	9.78e-10	Primary sclerosing cholangitis;
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.29	6.26	0.32	1.16e-9	Electroencephalogram traits;
LUSC	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg18827107	chr12:86230957	RASSF9	-0.4	-5.99	-0.31	5.31e-9	Major depressive disorder;
LUSC	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg11019008	chr10:131425282	MGMT	0.41	6.36	0.33	6.79e-10	Response to temozolomide;
LUSC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-13.68	-0.6	4.06e-34	Chronic sinus infection;
LUSC	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-10.12	-0.48	3.69e-21	Migraine;Coronary artery disease;
LUSC	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg24397884	chr7:158709396	WDR60	-0.78	-8.98	-0.44	2.02e-17	Height;
LUSC	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.62	11.08	0.52	1.61e-24	Weight;
LUSC	cis	rs17255340	0.520	rs10806258	chr6:84116555	A/G	cg08257003	chr6:84140564	ME1	0.36	8.88	0.44	4.2e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs7084921	0.608	rs11592689	chr10:101865516	A/T	cg02250046	chr10:101825185	CPN1	-0.35	-6.41	-0.33	5.08e-10	Bone mineral density;
LUSC	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg26384229	chr12:38710491	ALG10B	0.49	6.96	0.36	1.77e-11	Morning vs. evening chronotype;
LUSC	cis	rs925255	0.682	rs7590263	chr2:28645802	C/T	cg01273330	chr2:28605224	NA	-0.41	-6.47	-0.33	3.52e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg15704280	chr7:45808275	SEPT13	-0.46	-6.35	-0.33	6.87e-10	HDL cholesterol;
LUSC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg11663144	chr21:46675770	NA	0.41	7.33	0.37	1.77e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	0.59	9.14	0.45	6.14e-18	Breast cancer;
LUSC	cis	rs12681287	0.640	rs7841690	chr8:87365359	T/C	cg27223183	chr8:87520930	FAM82B	0.55	7.37	0.37	1.34e-12	Caudate activity during reward;
LUSC	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg01448562	chr3:133502909	NA	-0.66	-10.83	-0.51	1.27e-23	Iron status biomarkers;
LUSC	cis	rs17001868	0.568	rs2075764	chr22:40758581	C/T	cg07138101	chr22:40742427	ADSL	0.6	7.09	0.36	8.02e-12	Mammographic density (dense area);
LUSC	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg11789530	chr4:8429930	ACOX3	0.64	9.93	0.48	1.56e-20	Response to antineoplastic agents;
LUSC	cis	rs9581857	0.685	rs9319373	chr13:28042835	A/G	cg22138327	chr13:27999177	GTF3A	0.76	8.33	0.41	2.11e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-6.03	-0.31	4.43e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.08	0.55	4.15e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4400599	0.618	rs9803862	chr1:154192143	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.36	6.0	0.31	5.07e-9	Platelet distribution width;
LUSC	cis	rs4619890	0.528	rs62289340	chr4:7879027	C/T	cg24250820	chr4:7887609	AFAP1	0.36	6.11	0.32	2.71e-9	Glaucoma (primary open-angle);
LUSC	cis	rs77861329	1.000	rs876782	chr3:52107909	C/T	cg08692210	chr3:52188851	WDR51A	-0.8	-7.64	-0.39	2.31e-13	Macrophage inflammatory protein 1b levels;
LUSC	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg05738196	chr6:26577821	NA	0.81	15.2	0.64	4.95e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7916697	0.947	rs9783176	chr10:70002393	A/T	cg06988349	chr10:69991859	ATOH7	0.34	5.97	0.31	6.15e-9	Optic disc area;
LUSC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-11.63	-0.54	1.72e-26	Platelet count;
LUSC	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg12863693	chr15:85201151	NMB	0.4	8.44	0.42	9.49e-16	Schizophrenia;
LUSC	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-5.8	-0.3	1.58e-8	Schizophrenia;
LUSC	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg26441486	chr22:50317300	CRELD2	0.45	6.8	0.35	4.81e-11	Schizophrenia;
LUSC	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg14343924	chr8:8086146	FLJ10661	0.44	6.12	0.32	2.66e-9	Neuroticism;
LUSC	cis	rs4356932	0.967	rs4859608	chr4:76991807	G/A	cg00809888	chr4:76862425	NAAA	0.34	5.73	0.3	2.19e-8	Blood protein levels;
LUSC	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg04317338	chr11:64019027	PLCB3	0.55	5.7	0.3	2.62e-8	Mean platelet volume;
LUSC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg02423579	chr7:2872169	GNA12	-0.45	-6.48	-0.33	3.24e-10	Height;
LUSC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.07	0.66	1.96e-43	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg06600287	chr1:53387719	ECHDC2	-0.3	-6.18	-0.32	1.91e-9	Monocyte count;
LUSC	cis	rs1775715	0.966	rs1251386	chr10:32319114	C/T	cg04359828	chr10:32216031	ARHGAP12	-0.34	-5.76	-0.3	1.87e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg12935359	chr14:103987150	CKB	-0.52	-8.07	-0.4	1.26e-14	Body mass index;
LUSC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg16060761	chr17:80687452	NA	-0.52	-7.91	-0.4	3.93e-14	Glycated hemoglobin levels;
LUSC	cis	rs1113500	0.862	rs11185264	chr1:108640506	T/C	cg06207961	chr1:108661230	NA	0.41	7.49	0.38	6.32e-13	Growth-regulated protein alpha levels;
LUSC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg24209194	chr3:40518798	ZNF619	0.49	6.46	0.33	3.75e-10	Renal cell carcinoma;
LUSC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08470875	chr2:26401718	FAM59B	0.72	9.82	0.47	3.79e-20	Gut microbiome composition (summer);
LUSC	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg14438399	chr17:27053147	TLCD1	0.52	5.75	0.3	2.05e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs2040771	0.804	rs1091013	chr22:19248587	C/T	cg02655711	chr22:19163373	SLC25A1	0.47	8.61	0.43	2.93e-16	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.74	19.69	0.73	7.74e-58	Anterior chamber depth;
LUSC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.49	-6.54	-0.34	2.26e-10	Tonsillectomy;
LUSC	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg04450456	chr4:17643702	FAM184B	0.41	6.98	0.36	1.62e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25072359	chr17:41440525	NA	0.66	9.43	0.46	7.13e-19	Menopause (age at onset);
LUSC	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg27068330	chr11:65405492	SIPA1	-0.76	-10.1	-0.48	4.33e-21	Acne (severe);
LUSC	cis	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg06521331	chr12:34319734	NA	-0.4	-5.76	-0.3	1.87e-8	Resting heart rate;
LUSC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg06221963	chr1:154839813	KCNN3	-0.49	-10.21	-0.49	1.74e-21	Prostate cancer;
LUSC	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	7.07	0.36	9.34e-12	Multiple sclerosis;
LUSC	trans	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-8.5	-0.42	6.36e-16	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg13944838	chr5:179740914	GFPT2	-0.59	-9.21	-0.45	3.6e-18	Height;
LUSC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg12963246	chr6:28129442	ZNF389	0.52	7.24	0.37	3.17e-12	Depression;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07252851	chr5:74063056	GFM2;NSA2	-0.51	-6.4	-0.33	5.19e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9308433	0.529	rs9430131	chr1:214481121	C/A	cg06198575	chr1:214491504	SMYD2	0.46	7.14	0.36	5.73e-12	IgG glycosylation;
LUSC	cis	rs10193935	0.901	rs9808509	chr2:42479644	T/C	cg27598129	chr2:42591480	NA	-0.63	-8.25	-0.41	3.58e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-9.32	-0.45	1.63e-18	Gut microbiome composition (summer);
LUSC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg17178900	chr1:205818956	PM20D1	0.74	11.81	0.54	3.83e-27	Menarche (age at onset);
LUSC	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg11993925	chr19:44307056	LYPD5	0.36	7.86	0.4	5.35e-14	Breast cancer (estrogen-receptor negative);Breast cancer;
LUSC	cis	rs10875746	0.903	rs61918806	chr12:48484433	G/A	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.77	-14.09	-0.61	1.05e-35	Obesity-related traits;
LUSC	cis	rs62103177	0.535	rs34299914	chr18:77949236	C/A	cg20368463	chr18:77673604	PQLC1	0.66	6.66	0.34	1.12e-10	Opioid sensitivity;
LUSC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg15556689	chr8:8085844	FLJ10661	0.68	11.38	0.53	1.45e-25	Mood instability;
LUSC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg15691649	chr6:25882328	NA	-0.37	-6.1	-0.32	3e-9	Blood metabolite levels;
LUSC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	6.22	0.32	1.53e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6942756	1.000	rs67997229	chr7:128957366	G/C	cg02491457	chr7:128862824	NA	-0.47	-6.31	-0.33	9.1e-10	White matter hyperintensity burden;
LUSC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg00989853	chr1:209979345	IRF6	0.3	6.6	0.34	1.62e-10	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
LUSC	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg21798802	chr22:38057573	PDXP	0.32	6.64	0.34	1.29e-10	Fat distribution (HIV);
LUSC	cis	rs4774899	0.837	rs11636100	chr15:57414100	T/C	cg21617494	chr15:57618479	NA	-0.36	-6.04	-0.31	4.01e-9	Urinary tract infection frequency;
LUSC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.38	6.11	0.32	2.78e-9	Menopause (age at onset);
LUSC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg18904891	chr8:8559673	CLDN23	-0.37	-5.75	-0.3	1.99e-8	Mood instability;
LUSC	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg13628971	chr7:2884303	GNA12	0.45	6.28	0.32	1.07e-9	Height;
LUSC	cis	rs600231	0.508	rs35292734	chr11:65227700	C/T	cg17120908	chr11:65337727	SSSCA1	-0.65	-9.5	-0.46	4.3e-19	Bone mineral density;
LUSC	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	0.75	12.09	0.55	3.55e-28	Height;
LUSC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg16586182	chr3:47516702	SCAP	0.56	8.79	0.43	8.18e-17	Colorectal cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20598768	chr1:154193039	C1orf43;UBAP2L	0.44	6.68	0.34	1.03e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg06219351	chr7:158114137	PTPRN2	-0.54	-9.85	-0.47	2.89e-20	Calcium levels;
LUSC	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.47	0.5	2.17e-22	Lung cancer in ever smokers;
LUSC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.75	10.04	0.48	6.62e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16218377	chr11:34073324	CAPRIN1	-0.4	-6.1	-0.32	3e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg16797656	chr11:68205561	LRP5	0.37	6.16	0.32	2.13e-9	Total body bone mineral density;
LUSC	trans	rs10221833	0.602	rs355884	chr2:165633933	C/A	cg26993132	chr16:89239499	CDH15	0.31	5.97	0.31	6.09e-9	Response to statin therapy;
LUSC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg13206674	chr6:150067644	NUP43	0.58	9.05	0.44	1.17e-17	Lung cancer;
LUSC	cis	rs11608355	0.515	rs7955932	chr12:109941303	G/A	cg05360138	chr12:110035743	NA	0.93	12.36	0.56	3.76e-29	Neuroticism;
LUSC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg25036284	chr2:26402008	FAM59B	-0.75	-10.82	-0.51	1.4e-23	Gut microbiome composition (summer);
LUSC	cis	rs4842666	0.831	rs12230074	chr12:90090867	A/G	cg00757033	chr12:89920650	WDR51B	0.44	6.12	0.32	2.67e-9	Blood pressure;
LUSC	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg13072238	chr3:49761600	GMPPB	-0.38	-6.32	-0.33	8.2e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg20607798	chr8:58055168	NA	0.52	5.73	0.3	2.29e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg07501729	chr16:846077	CHTF18	0.38	6.31	0.33	9.08e-10	Mean corpuscular volume;
LUSC	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	9.67	0.47	1.16e-19	Coffee consumption (cups per day);
LUSC	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg00677455	chr12:58241039	CTDSP2	0.5	7.63	0.39	2.52e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2625529	0.652	rs3759820	chr15:72300031	A/C	cg16672083	chr15:72433130	SENP8	0.48	8.02	0.4	1.76e-14	Red blood cell count;
LUSC	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg11161011	chr14:65562177	MAX	-0.72	-10.93	-0.51	5.76e-24	Obesity-related traits;
LUSC	trans	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg26384229	chr12:38710491	ALG10B	0.61	8.51	0.42	5.98e-16	Resting heart rate;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05195756	chr6:91296664	MAP3K7	0.73	6.1	0.32	3e-9	Cognitive performance;
LUSC	cis	rs9462027	0.628	rs10947531	chr6:34765118	A/C	cg07306190	chr6:34760872	UHRF1BP1	0.33	5.94	0.31	7.28e-9	Systemic lupus erythematosus;
LUSC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg06454157	chr6:167490870	NA	-0.28	-6.65	-0.34	1.23e-10	Primary biliary cholangitis;
LUSC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg12863693	chr15:85201151	NMB	0.35	7.13	0.36	6.42e-12	Schizophrenia;
LUSC	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg13010199	chr12:38710504	ALG10B	0.52	7.71	0.39	1.5e-13	Morning vs. evening chronotype;
LUSC	cis	rs9900062	1.000	rs2521879	chr17:62742678	A/G	cg02598441	chr17:62777298	LOC146880	-0.62	-6.58	-0.34	1.78e-10	QT interval;
LUSC	cis	rs2414059	0.518	rs56398519	chr15:50773432	A/G	cg08437265	chr15:50716283	USP8	-0.4	-5.83	-0.3	1.27e-8	QT interval;
LUSC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg16262614	chr3:133464971	TF	0.43	7.48	0.38	6.56e-13	Iron status biomarkers (transferrin levels);
LUSC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21963583	chr11:68658836	MRPL21	0.55	8.28	0.41	3.08e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg17757837	chr7:157058334	UBE3C	0.82	13.09	0.58	6.61e-32	Body mass index;
LUSC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg21775007	chr8:11205619	TDH	-0.52	-7.84	-0.39	5.97e-14	Retinal vascular caliber;
LUSC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg14664628	chr15:75095509	CSK	-0.55	-8.25	-0.41	3.67e-15	Breast cancer;
LUSC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07256732	chr16:621771	PIGQ	-0.36	-6.54	-0.34	2.31e-10	Height;
LUSC	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs1775715	0.707	rs2808087	chr10:32146444	C/G	cg04359828	chr10:32216031	ARHGAP12	0.41	7.09	0.36	8.13e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.45	-8.58	-0.42	3.63e-16	Schizophrenia;
LUSC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg17279839	chr7:150038598	RARRES2	-0.45	-6.97	-0.36	1.67e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg19875535	chr5:140030758	IK	0.37	5.73	0.3	2.21e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg23711669	chr6:146136114	FBXO30	0.9	16.35	0.67	1.41e-44	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg06623918	chr6:96969491	KIAA0776	0.73	8.64	0.43	2.33e-16	Migraine;Coronary artery disease;
LUSC	trans	rs1325195	0.920	rs2816206	chr1:179168805	C/G	cg11624085	chr17:8464688	MYH10	0.44	6.91	0.35	2.49e-11	IgE grass sensitization;
LUSC	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	9.44	0.46	6.85e-19	Coffee consumption (cups per day);
LUSC	cis	rs6732160	0.684	rs2043095	chr2:73407442	T/C	cg24220031	chr2:73402428	NA	-0.23	-5.79	-0.3	1.67e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg24006582	chr15:45444508	DUOX1	0.66	9.37	0.46	1.11e-18	Uric acid levels;
LUSC	trans	rs3960554	0.600	rs2302429	chr7:75614777	G/A	cg19862616	chr7:65841803	NCRNA00174	0.77	9.24	0.45	3.07e-18	Eotaxin levels;
LUSC	cis	rs710216	0.917	rs900836	chr1:43412727	T/C	cg03128534	chr1:43423976	SLC2A1	-0.45	-5.9	-0.31	8.85e-9	Red cell distribution width;
LUSC	cis	rs75804782	0.521	rs2117691	chr2:239414734	C/T	cg18131467	chr2:239335373	ASB1	-0.66	-6.01	-0.31	4.97e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg25922239	chr6:33757077	LEMD2	0.45	6.72	0.34	8e-11	Crohn's disease;
LUSC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg14983838	chr19:29218262	NA	0.53	6.29	0.33	9.85e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19626725	chr5:178986131	RUFY1	0.6	11.12	0.52	1.2e-24	Lung cancer;
LUSC	cis	rs981844	0.712	rs897611	chr4:154755519	T/C	cg14289246	chr4:154710475	SFRP2	-0.46	-6.3	-0.33	9.62e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs11229555	0.645	rs12285111	chr11:58208385	T/G	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg01879757	chr17:41196368	BRCA1	-0.43	-6.58	-0.34	1.87e-10	Menopause (age at onset);
LUSC	cis	rs877282	0.797	rs7079164	chr10:756363	A/G	cg17470449	chr10:769945	NA	0.5	6.87	0.35	3.24e-11	Uric acid levels;
LUSC	trans	rs10090774	0.965	rs11780104	chr8:142002107	C/T	cg10310310	chr7:157367150	PTPRN2;MIR153-2	0.29	6.0	0.31	5.25e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11644478	chr21:40555479	PSMG1	-0.63	-9.51	-0.46	3.99e-19	Menarche (age at onset);
LUSC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg23711669	chr6:146136114	FBXO30	0.9	17.22	0.69	5.08e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg11502198	chr6:26597334	ABT1	0.59	9.08	0.44	9.97e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs714027	0.585	rs41173	chr22:30424863	C/G	cg11564601	chr22:30592435	NA	-0.35	-6.02	-0.31	4.6e-9	Lymphocyte counts;
LUSC	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg22676075	chr6:135203613	NA	-0.65	-10.27	-0.49	1.13e-21	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs2282802	0.685	rs7737543	chr5:139646026	A/G	cg26211634	chr5:139558579	C5orf32	0.44	8.32	0.41	2.31e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07677032	chr17:61819896	STRADA	0.53	9.01	0.44	1.62e-17	Prudent dietary pattern;
LUSC	trans	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg04995722	chr7:26192034	NFE2L3	0.38	6.2	0.32	1.67e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3857536	0.776	rs4710316	chr6:66935097	T/A	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs1419980	0.586	rs10845548	chr12:7777657	T/A	cg10578777	chr12:7781093	NA	-0.59	-6.45	-0.33	4e-10	HDL cholesterol levels;
LUSC	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.63	-0.39	2.51e-13	Blood metabolite levels;
LUSC	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg24556660	chr7:106842632	COG5;HBP1	-0.42	-5.83	-0.3	1.32e-8	Coronary artery disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10265308	chr14:21458149	METT11D1	-0.41	-6.01	-0.31	4.8e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21633795	chr20:52824352	PFDN4	0.81	6.47	0.33	3.4e-10	Cognitive performance;
LUSC	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg20701182	chr2:24300061	SF3B14	0.88	11.42	0.53	1.05e-25	Lymphocyte counts;
LUSC	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg07169764	chr2:136633963	MCM6	0.9	12.57	0.57	6.14e-30	Corneal structure;
LUSC	cis	rs2996428	0.667	rs11578070	chr1:3769871	G/C	cg22529645	chr1:3704559	LRRC47	0.36	6.35	0.33	6.86e-10	Red cell distribution width;
LUSC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.06	0.36	9.75e-12	Bipolar disorder;
LUSC	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg17764715	chr19:33622953	WDR88	0.54	7.4	0.38	1.12e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs4794665	0.874	rs963292	chr17:54842555	C/T	cg18503679	chr3:21792543	ZNF385D	0.37	6.02	0.31	4.61e-9	Height;
LUSC	cis	rs10740039	0.768	rs10159993	chr10:62362546	T/A	cg18175470	chr10:62150864	ANK3	-0.46	-6.87	-0.35	3.23e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9815354	0.597	rs79626430	chr3:42023786	A/G	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10740039	0.960	rs10761536	chr10:62404415	A/T	cg18175470	chr10:62150864	ANK3	-0.46	-6.92	-0.35	2.38e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg03929089	chr4:120376271	NA	0.82	11.1	0.52	1.36e-24	Coronary artery disease;
LUSC	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg19773385	chr1:10388646	KIF1B	-0.6	-10.29	-0.49	9.18e-22	Hepatocellular carcinoma;
LUSC	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg15212455	chr7:39170539	POU6F2	0.65	11.25	0.52	3.95e-25	IgG glycosylation;
LUSC	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	0.99	19.5	0.73	4.42e-57	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs6840360	0.642	rs10857260	chr4:152424056	C/G	cg20465933	chr4:152376761	FAM160A1	0.32	5.81	0.3	1.45e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs714027	0.585	rs5763670	chr22:30383758	C/G	cg11564601	chr22:30592435	NA	0.34	5.91	0.31	8.49e-9	Lymphocyte counts;
LUSC	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg18827107	chr12:86230957	RASSF9	-0.4	-5.99	-0.31	5.56e-9	Major depressive disorder;
LUSC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg02503808	chr4:7069936	GRPEL1	0.96	12.41	0.56	2.4e-29	Monocyte percentage of white cells;
LUSC	cis	rs17621444	0.505	rs12359805	chr10:121798593	C/G	cg02041677	chr10:121771263	NA	0.33	6.28	0.32	1.07e-9	IgG glycosylation;
LUSC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.52	7.83	0.39	6.6e-14	Lymphocyte counts;
LUSC	cis	rs11030122	0.661	rs12290747	chr11:3939650	T/C	cg18678763	chr11:4115507	RRM1	-0.45	-5.8	-0.3	1.5e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	7.64	0.39	2.24e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs865483	0.965	rs853199	chr17:35850225	T/C	cg06716730	chr17:35851459	DUSP14	0.29	6.61	0.34	1.53e-10	Monocyte count;
LUSC	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg08048268	chr3:133502702	NA	-0.39	-7.0	-0.36	1.45e-11	Iron status biomarkers;
LUSC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11229555	0.645	rs61889554	chr11:58424081	C/A	cg15696309	chr11:58395628	NA	-0.64	-6.76	-0.35	6.04e-11	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.57	-0.38	3.59e-13	Joint mobility (Beighton score);
LUSC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01341218	chr17:43662625	NA	-0.74	-10.73	-0.51	2.82e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg17366294	chr4:99064904	C4orf37	0.58	10.2	0.49	1.91e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg16325326	chr1:53192061	ZYG11B	-0.82	-14.17	-0.61	5.03e-36	Monocyte count;
LUSC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg07701084	chr6:150067640	NUP43	0.56	8.46	0.42	8.48e-16	Lung cancer;
LUSC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.73	0.35	7.5e-11	Aortic root size;
LUSC	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg13647721	chr17:30228624	UTP6	-0.69	-7.54	-0.38	4.54e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.04	-20.94	-0.75	8.8e-63	Cognitive function;
LUSC	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg21545522	chr1:205238299	TMCC2	0.52	9.91	0.48	1.86e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02463440	chr8:22132932	PIWIL2	0.41	7.43	0.38	8.94e-13	Hypertriglyceridemia;
LUSC	cis	rs667920	0.573	rs9682783	chr3:136539689	T/C	cg15507776	chr3:136538369	TMEM22	0.61	8.47	0.42	8.08e-16	Coronary artery disease;
LUSC	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg17294928	chr15:75287854	SCAMP5	-0.65	-5.94	-0.31	7.12e-9	Lung cancer;
LUSC	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg17143192	chr8:8559678	CLDN23	-0.39	-5.98	-0.31	5.68e-9	Mood instability;
LUSC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg04317338	chr11:64019027	PLCB3	0.54	5.65	0.3	3.4e-8	Mean platelet volume;
LUSC	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg15309053	chr8:964076	NA	0.34	7.11	0.36	7.26e-12	Schizophrenia;
LUSC	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg12310025	chr6:25882481	NA	0.37	6.27	0.32	1.12e-9	Blood metabolite levels;
LUSC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	6.27	0.32	1.13e-9	Tonsillectomy;
LUSC	trans	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg21659725	chr3:3221576	CRBN	-0.72	-8.2	-0.41	5.17e-15	Menarche (age at onset);
LUSC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg11663144	chr21:46675770	NA	-0.42	-7.34	-0.37	1.66e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg07460842	chr6:66804631	NA	0.46	5.69	0.3	2.71e-8	Metabolite levels;
LUSC	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg20991723	chr1:152506922	NA	0.51	9.65	0.47	1.34e-19	Hair morphology;
LUSC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	8.2	0.41	5.32e-15	Height;
LUSC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	1.05	19.12	0.72	1.42e-55	Menopause (age at onset);
LUSC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg12163867	chr12:51592794	POU6F1	-0.6	-10.59	-0.5	8.71e-23	Cisplatin-induced ototoxicity;
LUSC	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg03161606	chr19:29218774	NA	0.54	6.8	0.35	4.87e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs4663866	1.000	rs71426508	chr2:239137767	A/G	cg16914508	chr2:239161102	PER2	0.59	6.22	0.32	1.5e-9	Irritable bowel syndrome;
LUSC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg15782153	chr7:917662	C7orf20	0.42	6.44	0.33	4.07e-10	Perceived unattractiveness to mosquitoes;
LUSC	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg04362960	chr10:104952993	NT5C2	0.59	9.4	0.46	9.13e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.44	-0.33	4.08e-10	Alzheimer's disease (late onset);
LUSC	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg23505145	chr19:12996616	KLF1	0.64	10.74	0.51	2.69e-23	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg07741184	chr6:167504864	NA	0.36	6.49	0.33	3.03e-10	Crohn's disease;
LUSC	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg09754948	chr16:28834200	ATXN2L	0.41	6.12	0.32	2.63e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08677398	chr8:58056175	NA	0.52	6.87	0.35	3.18e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs62400317	0.859	rs4479922	chr6:45248371	T/C	cg20913747	chr6:44695427	NA	-0.48	-7.73	-0.39	1.28e-13	Total body bone mineral density;
LUSC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.52	9.07	0.44	1.05e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg07870213	chr5:140052090	DND1	0.78	11.57	0.53	2.8e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs3936840	0.752	rs2181343	chr14:102993303	A/C	cg18135206	chr14:102964638	TECPR2	-0.55	-8.77	-0.43	9.35e-17	Plateletcrit;
LUSC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg20283391	chr11:68216788	NA	-0.57	-8.14	-0.41	7.95e-15	Total body bone mineral density;
LUSC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-13.14	-0.58	4.53e-32	Alzheimer's disease;
LUSC	cis	rs4654899	0.865	rs12119348	chr1:21484633	C/T	cg02927042	chr1:21476669	EIF4G3	-0.36	-5.69	-0.3	2.82e-8	Superior frontal gyrus grey matter volume;
LUSC	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.14	-20.41	-0.74	1.07e-60	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg16989719	chr2:238392110	NA	-0.48	-7.69	-0.39	1.64e-13	Prostate cancer;
LUSC	cis	rs16912285	0.688	rs12276587	chr11:24280656	C/G	ch.11.24196551F	chr11:24239977	NA	-0.86	-9.31	-0.45	1.7e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg17757837	chr7:157058334	UBE3C	-0.81	-12.97	-0.58	1.95e-31	Body mass index;
LUSC	cis	rs3789045	0.560	rs3747634	chr1:204411063	C/T	cg17419461	chr1:204415978	PIK3C2B	0.49	5.81	0.3	1.44e-8	Educational attainment (college completion);
LUSC	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-6.89	-0.35	2.85e-11	Lung cancer;
LUSC	cis	rs870825	0.616	rs28607131	chr4:185651617	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	12.42	0.56	2.15e-29	Blood protein levels;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02522627	chr10:70715883	DDX21	0.48	6.39	0.33	5.64e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	1.11	15.86	0.66	1.27e-42	Uric acid levels;
LUSC	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg21045802	chr8:109455806	TTC35	-0.43	-6.63	-0.34	1.39e-10	Dupuytren's disease;
LUSC	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg22676075	chr6:135203613	NA	0.49	7.68	0.39	1.72e-13	Red blood cell count;
LUSC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.07	0.4	1.27e-14	Bipolar disorder;
LUSC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2273669	0.667	rs17070136	chr6:109350550	T/C	cg05315195	chr6:109294784	ARMC2	-0.54	-5.9	-0.31	9.1e-9	Prostate cancer;
LUSC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg12963246	chr6:28129442	ZNF389	0.49	6.73	0.35	7.47e-11	Depression;
LUSC	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg20607287	chr7:12443886	VWDE	-0.6	-6.26	-0.32	1.2e-9	Coronary artery disease;
LUSC	cis	rs56399783	0.901	rs56007918	chr7:2826205	A/G	cg19731401	chr7:2775893	GNA12	0.68	9.38	0.46	1.04e-18	Childhood ear infection;
LUSC	cis	rs427941	0.668	rs201438	chr7:101735236	G/A	cg06246474	chr7:101738831	CUX1	0.42	6.82	0.35	4.28e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg23029597	chr12:123009494	RSRC2	-0.75	-9.47	-0.46	5.19e-19	Body mass index;
LUSC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg02269571	chr22:50332266	NA	-0.66	-9.88	-0.48	2.39e-20	Schizophrenia;
LUSC	cis	rs965513	1.000	rs925489	chr9:100546600	C/T	cg13688889	chr9:100608707	NA	-0.56	-8.42	-0.42	1.16e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg00012203	chr2:219082015	ARPC2	-0.58	-9.25	-0.45	2.82e-18	Ulcerative colitis;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg09031657	chr21:48055629	PRMT2	0.71	6.05	0.31	3.98e-9	Body mass index;
LUSC	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg22906224	chr7:99728672	NA	0.46	6.4	0.33	5.29e-10	Coronary artery disease;
LUSC	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.75	10.67	0.5	4.66e-23	Vitiligo;
LUSC	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg03929089	chr4:120376271	NA	0.66	6.15	0.32	2.2e-9	Intraocular pressure;
LUSC	cis	rs2637266	0.935	rs12259550	chr10:78352843	A/G	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg19875535	chr5:140030758	IK	0.51	8.37	0.42	1.55e-15	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg22532475	chr10:104410764	TRIM8	-0.3	-5.74	-0.3	2.16e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9815354	0.812	rs4547673	chr3:41952303	A/C	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.55e-16	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs12210905	1.000	rs72843643	chr6:27211247	G/C	cg11837749	chr1:55047332	ACOT11	0.58	5.98	0.31	5.64e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.86	-12.67	-0.57	2.64e-30	Asthma;
LUSC	cis	rs1775715	0.707	rs2808079	chr10:32167385	C/T	cg03015672	chr10:32216066	ARHGAP12	0.34	6.17	0.32	1.96e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg04362960	chr10:104952993	NT5C2	0.9	11.46	0.53	7.33e-26	Arsenic metabolism;
LUSC	cis	rs2247341	0.577	rs2236995	chr4:1704542	T/G	cg05874882	chr4:1763078	NA	-0.32	-5.99	-0.31	5.3e-9	Hip circumference adjusted for BMI;Height;
LUSC	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg00383909	chr3:49044727	WDR6	1.14	10.32	0.49	7.24e-22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg07424592	chr7:64974309	NA	0.63	5.69	0.3	2.81e-8	Diabetic kidney disease;
LUSC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg11752832	chr7:134001865	SLC35B4	0.55	8.61	0.43	2.94e-16	Mean platelet volume;
LUSC	cis	rs10465746	0.780	rs7551787	chr1:84419297	A/G	cg10977910	chr1:84465055	TTLL7	0.47	6.83	0.35	4.13e-11	Obesity-related traits;
LUSC	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg26384229	chr12:38710491	ALG10B	0.77	13.03	0.58	1.17e-31	Morning vs. evening chronotype;
LUSC	cis	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg06521331	chr12:34319734	NA	-0.35	-6.01	-0.31	4.76e-9	Morning vs. evening chronotype;
LUSC	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	0.57	9.07	0.44	1.02e-17	Breast cancer;
LUSC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg06784218	chr1:46089804	CCDC17	0.49	9.66	0.47	1.26e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9392556	0.829	rs620484	chr6:4114211	G/A	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.37	-6.42	-0.33	4.58e-10	Blood metabolite levels;
LUSC	cis	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg21775007	chr8:11205619	TDH	-0.45	-6.0	-0.31	5.26e-9	Morning vs. evening chronotype;
LUSC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg18512352	chr11:47633146	NA	0.47	9.53	0.46	3.24e-19	Subjective well-being;
LUSC	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.59	-8.81	-0.43	7.11e-17	Response to antineoplastic agents;
LUSC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	13.59	0.6	8.31e-34	Platelet count;
LUSC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg18230493	chr5:56204884	C5orf35	-0.57	-8.9	-0.44	3.61e-17	Coronary artery disease;
LUSC	cis	rs72772090	0.539	rs11750934	chr5:96118487	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-6.58	-0.34	1.83e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.68	0.47	1.06e-19	Lymphocyte counts;
LUSC	cis	rs11779988	0.630	rs17635854	chr8:17895734	A/G	cg01800426	chr8:17659068	MTUS1	-0.42	-5.67	-0.3	3.05e-8	Breast cancer;
LUSC	cis	rs9359856	0.636	rs3748085	chr6:90315789	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.66	-7.18	-0.37	4.61e-12	Bipolar disorder;
LUSC	cis	rs2963155	0.518	rs865482	chr5:142640317	C/A	cg17617527	chr5:142782415	NR3C1	0.71	8.61	0.43	2.97e-16	Breast cancer;
LUSC	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg01884057	chr2:25150051	NA	0.48	11.42	0.53	1e-25	Body mass index;
LUSC	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-8.09	-0.4	1.09e-14	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6977660	0.714	rs10155949	chr7:19834747	T/C	cg07541023	chr7:19748670	TWISTNB	0.59	6.16	0.32	2.05e-9	Thyroid stimulating hormone;
LUSC	trans	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18876405	chr7:65276391	NA	0.49	6.64	0.34	1.24e-10	Corneal structure;
LUSC	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.57	-0.46	2.51e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg25922239	chr6:33757077	LEMD2	0.54	8.11	0.41	9.86e-15	Crohn's disease;
LUSC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg24977027	chr2:88469347	THNSL2	0.57	5.83	0.3	1.3e-8	Plasma clusterin levels;
LUSC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	10.86	0.51	9.65e-24	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg24375607	chr4:120327624	NA	0.49	7.53	0.38	4.7e-13	Diastolic blood pressure;
LUSC	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg12826209	chr6:26865740	GUSBL1	0.51	7.23	0.37	3.29e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs3099143	1.000	rs3110379	chr15:77095175	A/G	cg21673338	chr15:77095150	SCAPER	-0.82	-7.96	-0.4	2.67e-14	Recalcitrant atopic dermatitis;
LUSC	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07636037	chr3:49044803	WDR6	0.7	9.42	0.46	7.44e-19	Menarche (age at onset);
LUSC	cis	rs1185460	0.967	rs1177562	chr11:118949331	C/T	cg01677386	chr11:118938358	VPS11	-0.5	-7.02	-0.36	1.28e-11	Coronary artery disease;
LUSC	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg14604444	chr12:130766091	NA	-0.32	-5.73	-0.3	2.22e-8	Menopause (age at onset);
LUSC	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg25206134	chr2:45395956	NA	-0.61	-7.07	-0.36	8.96e-12	Bipolar disorder;
LUSC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg23711669	chr6:146136114	FBXO30	0.75	13.4	0.59	4.72e-33	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg00990874	chr7:1149470	C7orf50	-0.59	-7.78	-0.39	9.41e-14	Bronchopulmonary dysplasia;
LUSC	cis	rs28647808	0.786	rs4962135	chr9:136256630	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.7	6.9	0.35	2.55e-11	Blood protein levels;
LUSC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg15691649	chr6:25882328	NA	-0.4	-5.74	-0.3	2.15e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.84	15.34	0.64	1.48e-40	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6977660	1.000	rs7791038	chr7:19798833	G/A	cg05791153	chr7:19748676	TWISTNB	0.61	6.72	0.35	7.69e-11	Thyroid stimulating hormone;
LUSC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg17264618	chr3:40429014	ENTPD3	0.29	6.16	0.32	2.07e-9	Renal cell carcinoma;
LUSC	cis	rs56399783	0.808	rs73049331	chr7:2799911	C/T	cg14895029	chr7:2775587	GNA12	0.52	6.17	0.32	1.93e-9	Childhood ear infection;
LUSC	cis	rs7000551	0.751	rs2449341	chr8:22390937	C/A	cg12081754	chr8:22256438	SLC39A14	0.43	6.43	0.33	4.47e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.56	7.79	0.39	8.43e-14	Iron status biomarkers;
LUSC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.58	0.5	9.78e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg03146154	chr1:46216737	IPP	-0.5	-7.23	-0.37	3.29e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs7717823	0.900	rs344515	chr5:35025770	A/G	cg12724942	chr10:75457680	AGAP5	0.28	5.95	0.31	6.88e-9	Urinary metabolites (H-NMR features);
LUSC	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg24060327	chr5:131705240	SLC22A5	-0.48	-6.86	-0.35	3.33e-11	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg26408565	chr15:76604113	ETFA	-0.51	-8.15	-0.41	7.31e-15	Blood metabolite levels;
LUSC	cis	rs11756438	0.572	rs2638551	chr6:118998756	T/C	cg18833306	chr6:118973337	C6orf204	0.36	5.73	0.3	2.2e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs9473147	0.543	rs9369716	chr6:47552180	A/T	cg20196966	chr6:47445060	CD2AP	0.41	5.83	0.3	1.29e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg11645453	chr3:52864694	ITIH4	0.37	9.06	0.44	1.11e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11608355	0.846	rs61934479	chr12:109855111	A/G	cg05360138	chr12:110035743	NA	0.61	8.19	0.41	5.79e-15	Neuroticism;
LUSC	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg07936489	chr17:37558343	FBXL20	0.89	12.28	0.56	7.68e-29	Glomerular filtration rate (creatinine);
LUSC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg09021430	chr5:549028	NA	-0.55	-7.49	-0.38	6.11e-13	Obesity-related traits;
LUSC	cis	rs7202877	0.561	rs2865532	chr16:75350975	A/G	cg03315344	chr16:75512273	CHST6	0.42	5.99	0.31	5.34e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03517284	chr6:25882590	NA	-0.38	-6.8	-0.35	4.88e-11	Height;
LUSC	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	0.36	5.96	0.31	6.55e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs829883	0.639	rs829898	chr12:98857675	A/C	cg25150519	chr12:98850993	NA	0.83	14.26	0.62	2.38e-36	Colorectal adenoma (advanced);
LUSC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg23711669	chr6:146136114	FBXO30	0.73	12.86	0.58	5.2500000000000004e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7119	0.717	rs11634174	chr15:77811232	A/T	cg27398640	chr15:77910606	LINGO1	-0.31	-6.74	-0.35	7.05e-11	Type 2 diabetes;
LUSC	cis	rs11587400	0.634	rs7553926	chr1:115202215	A/G	cg12756093	chr1:115239321	AMPD1	-0.42	-6.4	-0.33	5.12e-10	Autism;
LUSC	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg04310649	chr10:35416472	CREM	-0.39	-5.95	-0.31	6.77e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7246657	0.525	rs10401417	chr19:37467540	C/T	cg23950597	chr19:37808831	NA	-0.51	-5.65	-0.3	3.4e-8	Coronary artery calcification;
LUSC	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg12288994	chr5:1860383	NA	0.3	6.6	0.34	1.63e-10	Cardiovascular disease risk factors;
LUSC	trans	rs12677056	0.651	rs17555872	chr8:113284490	T/C	cg12159992	chr12:102059490	MYBPC1	0.36	6.1	0.32	2.88e-9	Peripheral artery disease;
LUSC	cis	rs7180079	1.000	rs4238425	chr15:64671193	C/A	cg08069370	chr15:64387884	SNX1	0.58	6.18	0.32	1.84e-9	Monocyte count;
LUSC	cis	rs155346	1.000	rs265146	chr5:139398050	C/T	cg01090482	chr5:139365336	NRG2	0.34	5.72	0.3	2.31e-8	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	0.89	16.3	0.67	2.43e-44	Menarche (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26482052	chr2:66660462	NA	0.43	6.3	0.33	9.52e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg18357645	chr12:58087776	OS9	0.51	7.64	0.39	2.33e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.89	0.48	2.14e-20	Bipolar disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06159435	chr11:118966351	H2AFX	-0.55	-6.97	-0.36	1.74e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6496044	0.568	rs10468112	chr15:86073424	G/C	cg13263323	chr15:86062960	AKAP13	-0.37	-6.16	-0.32	2.06e-9	Interstitial lung disease;
LUSC	cis	rs354225	0.819	rs241661	chr2:54924467	G/T	cg26097391	chr2:54893211	SPTBN1	0.37	5.9	0.31	8.71e-9	Schizophrenia;
LUSC	trans	rs12614435	0.512	rs16866420	chr2:179491235	A/C	cg14011486	chr1:26737247	LIN28	0.47	6.52	0.34	2.53e-10	Atrial fibrillation;
LUSC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg02487422	chr3:49467188	NICN1	0.45	7.08	0.36	8.74e-12	Resting heart rate;
LUSC	cis	rs9650657	0.593	rs1968401	chr8:10615383	C/G	cg27411982	chr8:10470053	RP1L1	-0.35	-5.74	-0.3	2.15e-8	Neuroticism;
LUSC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg24881330	chr22:46731750	TRMU	0.89	8.94	0.44	2.7e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg12386194	chr3:101231763	SENP7	0.62	8.52	0.42	5.75e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.22	-0.37	3.48e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg12292205	chr6:26970375	C6orf41	0.51	8.56	0.42	4.13e-16	Schizophrenia;
LUSC	cis	rs11587682	0.760	rs12145082	chr1:150463526	T/C	cg11822372	chr1:151115635	SEMA6C	-0.42	-5.71	-0.3	2.53e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg17031739	chr1:67600172	NA	0.46	6.99	0.36	1.48e-11	Psoriasis;
LUSC	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg13010344	chr12:123464640	ARL6IP4	0.57	6.7	0.34	8.65e-11	Neutrophil percentage of white cells;
LUSC	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18932078	chr1:2524107	MMEL1	0.28	6.16	0.32	2.09e-9	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22590775	chr19:49891494	CCDC155	0.64	9.0	0.44	1.74e-17	Multiple sclerosis;
LUSC	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg16342193	chr10:102329863	NA	0.33	6.31	0.33	8.93e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.46	-6.16	-0.32	2.13e-9	Longevity;Endometriosis;
LUSC	cis	rs7577851	0.715	rs12466680	chr2:69638700	T/G	cg10773587	chr2:69614142	GFPT1	0.56	6.3	0.33	9.29e-10	Parkinson's disease (age of onset);
LUSC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-7.21	-0.37	3.67e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg04362960	chr10:104952993	NT5C2	0.61	8.99	0.44	1.85e-17	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.61	10.54	0.5	1.27e-22	Menopause (age at onset);
LUSC	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg15445000	chr17:37608096	MED1	-0.41	-7.02	-0.36	1.21e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg16586182	chr3:47516702	SCAP	-0.52	-7.99	-0.4	2.25e-14	Colorectal cancer;
LUSC	cis	rs12760731	0.565	rs12044522	chr1:178190180	G/T	cg00404053	chr1:178313656	RASAL2	0.66	6.86	0.35	3.32e-11	Obesity-related traits;
LUSC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg24250549	chr1:154909240	PMVK	-0.58	-9.19	-0.45	4.25e-18	Prostate cancer;
LUSC	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg13010199	chr12:38710504	ALG10B	0.69	10.68	0.5	4.07e-23	Bladder cancer;
LUSC	cis	rs75804782	0.625	rs1039887	chr2:239434892	A/G	cg18131467	chr2:239335373	ASB1	-0.62	-6.79	-0.35	5.29e-11	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs11971779	0.680	rs1133067	chr7:139053069	G/T	cg23387468	chr7:139079360	LUC7L2	0.42	6.43	0.33	4.53e-10	Diisocyanate-induced asthma;
LUSC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.81	-13.75	-0.6	2.17e-34	Hemoglobin concentration;Hematocrit;
LUSC	trans	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.74	-12.79	-0.57	9.1e-31	Brugada syndrome;
LUSC	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg24690094	chr11:67383802	NA	0.44	8.5	0.42	6.36e-16	Mean corpuscular volume;
LUSC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg27494647	chr7:150038898	RARRES2	0.5	7.58	0.38	3.53e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.62	10.03	0.48	7.44e-21	Blood metabolite ratios;
LUSC	cis	rs1107366	0.722	rs10934753	chr3:125906179	G/A	cg01346077	chr3:125931526	NA	0.34	6.44	0.33	4.06e-10	Metabolite levels;
LUSC	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-5.73	-0.3	2.23e-8	Response to antipsychotic treatment;
LUSC	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-7.73	-0.39	1.26e-13	Morning vs. evening chronotype;
LUSC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg14895029	chr7:2775587	GNA12	0.43	6.77	0.35	5.92e-11	Height;
LUSC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.77	-11.95	-0.55	1.19e-27	Tonsillectomy;
LUSC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg04518342	chr5:131593106	PDLIM4	0.55	10.34	0.49	6.47e-22	Acylcarnitine levels;
LUSC	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg26727032	chr16:67993705	SLC12A4	-0.41	-6.43	-0.33	4.34e-10	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09863175	chr15:57618660	NA	0.44	6.34	0.33	7.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13089137	chr2:64068705	UGP2	0.43	6.06	0.31	3.59e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg05855489	chr10:104503620	C10orf26	0.69	10.16	0.49	2.54e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.5	8.44	0.42	9.81e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2048656	0.635	rs7830613	chr8:9649769	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.52	-0.34	2.53e-10	Schizophrenia;
LUSC	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg14906510	chr12:7781169	NA	-0.71	-6.5	-0.33	2.97e-10	HDL cholesterol levels;
LUSC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg26408565	chr15:76604113	ETFA	-0.5	-7.98	-0.4	2.42e-14	Blood metabolite levels;
LUSC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg00701064	chr4:6280414	WFS1	0.59	14.2	0.61	3.93e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg17475774	chr8:145118628	NA	0.48	6.77	0.35	5.73e-11	Blood metabolite levels;
LUSC	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-10.3	-0.49	8.75e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg13798780	chr7:105162888	PUS7	0.57	6.09	0.32	3.04e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.62	-0.34	1.44e-10	Monocyte percentage of white cells;
LUSC	cis	rs2625529	0.824	rs16956452	chr15:72284092	T/C	cg16672083	chr15:72433130	SENP8	-0.51	-7.41	-0.38	1.02e-12	Red blood cell count;
LUSC	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.43	-0.42	1.04e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg21051086	chr3:73046214	PPP4R2	-0.52	-8.0	-0.4	2.13e-14	Pancreatic cancer;
LUSC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg27535305	chr1:53392650	SCP2	0.33	5.97	0.31	6e-9	Monocyte count;
LUSC	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg23422044	chr7:1970798	MAD1L1	0.63	7.26	0.37	2.72e-12	Bipolar disorder;
LUSC	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg06937882	chr20:24974362	C20orf3	-0.41	-6.94	-0.36	2.02e-11	Blood protein levels;
LUSC	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-6.06	-0.31	3.72e-9	IgG glycosylation;
LUSC	cis	rs6087990	0.731	rs2424897	chr20:31338098	A/T	cg13636640	chr20:31349939	DNMT3B	0.99	22.32	0.77	3.51e-68	Ulcerative colitis;
LUSC	cis	rs55871839	0.598	rs4737525	chr8:59799781	G/A	cg07426533	chr8:59803705	TOX	-0.35	-5.67	-0.3	3.07e-8	Pneumonia;
LUSC	cis	rs1107366	0.722	rs750714	chr3:125904688	G/A	cg01346077	chr3:125931526	NA	0.35	6.64	0.34	1.28e-10	Metabolite levels;
LUSC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg13319975	chr6:146136371	FBXO30	0.48	7.25	0.37	3.01e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg00046913	chr16:1877150	HAGH;FAHD1	0.66	6.87	0.35	3.08e-11	Glomerular filtration rate in chronic kidney disease;
LUSC	trans	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg06521331	chr12:34319734	NA	-0.41	-6.13	-0.32	2.49e-9	Bladder cancer;
LUSC	cis	rs9341808	0.690	rs6930534	chr6:80896050	C/T	cg08355045	chr6:80787529	NA	0.59	10.22	0.49	1.58e-21	Sitting height ratio;
LUSC	cis	rs4919087	1.000	rs3740512	chr10:99078745	C/T	cg25902810	chr10:99078978	FRAT1	0.5	7.42	0.38	1.01e-12	Monocyte count;
LUSC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg13047869	chr3:10149882	C3orf24	0.57	7.97	0.4	2.55e-14	Alzheimer's disease;
LUSC	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.62	-0.34	1.46e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg16647868	chr5:131706066	SLC22A5	0.39	5.97	0.31	6e-9	Breast cancer;
LUSC	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg07701084	chr6:150067640	NUP43	-0.54	-8.18	-0.41	5.9e-15	Lung cancer;
LUSC	trans	rs800082	0.516	rs6765790	chr3:144225908	A/G	cg24215973	chr2:240111563	HDAC4	0.45	6.76	0.35	6.03e-11	Smoking behavior;
LUSC	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg08499158	chr17:42289980	UBTF	-0.52	-8.72	-0.43	1.36e-16	Total body bone mineral density;
LUSC	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg01191920	chr7:158217561	PTPRN2	-0.59	-12.01	-0.55	7.1e-28	Obesity-related traits;
LUSC	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg06484146	chr7:12443880	VWDE	-0.66	-8.15	-0.41	7.15e-15	Coronary artery disease;
LUSC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-6.89	-0.35	2.77e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg03522245	chr20:25566470	NINL	-0.36	-5.81	-0.3	1.43e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg05163923	chr11:71159392	DHCR7	0.74	11.0	0.52	3.15e-24	Vitamin D levels;
LUSC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-8.16	-0.41	6.68e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg05855489	chr10:104503620	C10orf26	0.55	6.27	0.32	1.1e-9	Arsenic metabolism;
LUSC	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg01283332	chr5:1856932	NA	-0.33	-6.15	-0.32	2.17e-9	Cardiovascular disease risk factors;
LUSC	cis	rs60154123	0.764	rs1418257	chr1:210452846	G/A	cg22029157	chr1:209979665	IRF6	0.55	5.88	0.31	9.91e-9	Coronary artery disease;
LUSC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.51	-0.46	3.84e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	0.98	14.09	0.61	1.01e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs7561273	0.586	rs11902756	chr2:24300932	A/G	cg06627628	chr2:24431161	ITSN2	-0.51	-6.74	-0.35	6.81e-11	Quantitative traits;
LUSC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg26039829	chr8:22132926	PIWIL2	0.43	7.79	0.39	8.58e-14	Hypertriglyceridemia;
LUSC	trans	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg26043149	chr18:55253948	FECH	0.48	7.22	0.37	3.5e-12	Bone mineral density;
LUSC	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg10556349	chr10:835070	NA	0.44	5.67	0.3	3.02e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs295137	0.725	rs1729413	chr2:201086663	T/G	cg23649088	chr2:200775458	C2orf69	0.45	6.69	0.34	9.57e-11	Asthma (bronchodilator response);
LUSC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg13628971	chr7:2884303	GNA12	0.46	6.31	0.33	8.74e-10	Height;
LUSC	cis	rs2692947	0.727	rs893173	chr2:96789787	T/C	cg22654517	chr2:96458247	NA	0.35	7.04	0.36	1.09e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10992471	0.627	rs10820980	chr9:95253342	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.77	-0.39	9.98e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg01448562	chr3:133502909	NA	0.6	9.64	0.47	1.42e-19	Iron status biomarkers;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25387593	chr11:118927868	HYOU1	0.45	6.58	0.34	1.79e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.65	8.48	0.42	7.57e-16	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg26043149	chr18:55253948	FECH	0.5	7.45	0.38	8.11e-13	Bone mineral density;
LUSC	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg21385522	chr1:16154831	NA	-0.53	-8.1	-0.41	1.03e-14	Systolic blood pressure;
LUSC	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg04414720	chr1:150670196	GOLPH3L	0.51	7.82	0.39	6.99e-14	Melanoma;
LUSC	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg22535103	chr8:58192502	C8orf71	-0.75	-7.79	-0.39	8.27e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg18512352	chr11:47633146	NA	-0.28	-5.82	-0.3	1.4e-8	Subjective well-being;
LUSC	cis	rs2573652	1.000	rs7163481	chr15:100516916	C/G	cg09918751	chr15:100517450	ADAMTS17	0.41	7.87	0.4	5.14e-14	Height;
LUSC	cis	rs6684514	1.000	rs10908499	chr1:156279176	G/C	cg16558208	chr1:156270281	VHLL	0.35	5.67	0.3	3.1e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
LUSC	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg27219399	chr15:67835830	MAP2K5	0.36	5.82	0.3	1.39e-8	Obesity;
LUSC	cis	rs2227631	0.505	rs6955537	chr7:100759727	A/G	cg18465962	chr7:100767262	NA	-0.36	-5.87	-0.31	1.06e-8	Plasminogen activator inhibitor type 1 levels (PAI-1);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09556632	chr1:40839764	SMAP2	-0.51	-6.65	-0.34	1.19e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg06713675	chr4:122721982	EXOSC9	0.49	7.16	0.36	5.26e-12	Type 2 diabetes;
LUSC	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.37	9.12	0.45	7.16e-18	Diastolic blood pressure;
LUSC	cis	rs6722750	0.587	rs1881711	chr2:64416880	T/C	cg22352474	chr2:64371530	PELI1	-0.54	-7.99	-0.4	2.21e-14	Neuroticism;
LUSC	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.47	-0.33	3.47e-10	Retinal vascular caliber;
LUSC	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg02527881	chr3:46936655	PTH1R	0.38	6.89	0.35	2.79e-11	Colorectal cancer;
LUSC	trans	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg13565492	chr6:43139072	SRF	-0.63	-6.57	-0.34	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg20243544	chr17:37824526	PNMT	0.48	6.73	0.35	7.42e-11	Asthma;
LUSC	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg17173187	chr15:85201210	NMB	0.37	6.65	0.34	1.19e-10	Schizophrenia;
LUSC	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg02569458	chr12:86230093	RASSF9	0.52	8.61	0.43	2.94e-16	Major depressive disorder;
LUSC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	16.67	0.67	8.03e-46	Platelet count;
LUSC	cis	rs4988958	0.527	rs6756161	chr2:103048417	C/A	cg03938978	chr2:103052716	IL18RAP	0.37	7.06	0.36	9.98e-12	Asthma (childhood onset);
LUSC	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg08798685	chr6:27730294	NA	-0.68	-6.24	-0.32	1.33e-9	Depression;
LUSC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg22638593	chr5:131593259	PDLIM4	0.39	5.78	0.3	1.71e-8	Blood metabolite levels;
LUSC	trans	rs7792596	0.861	rs6970279	chr7:94014889	A/C	cg25751266	chr3:38495385	LOC100128640;ACVR2B	-0.41	-5.96	-0.31	6.52e-9	Intelligence;
LUSC	cis	rs858239	0.601	rs15775	chr7:23164701	C/T	cg23682824	chr7:23144976	KLHL7	0.4	5.95	0.31	6.59e-9	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs2262909	0.925	rs404822	chr19:22215967	A/C	cg17074339	chr11:11642133	GALNTL4	-0.42	-6.22	-0.32	1.45e-9	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.51	-8.5	-0.42	6.22e-16	Prudent dietary pattern;
LUSC	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg10255544	chr17:80519551	FOXK2	0.41	6.73	0.35	7.32e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs2346177	0.874	rs4953372	chr2:46651624	C/G	cg26688816	chr2:46740690	ATP6V1E2	0.5	7.9	0.4	3.99e-14	HDL cholesterol;
LUSC	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg01256987	chr12:42539512	GXYLT1	-0.41	-7.46	-0.38	7.71e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-10.33	-0.49	7e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs4588572	0.644	rs6882191	chr5:77743098	G/A	cg11547950	chr5:77652471	NA	-0.46	-6.79	-0.35	5.25e-11	Triglycerides;
LUSC	cis	rs9660992	1.000	rs3851296	chr1:205253839	A/C	cg21545522	chr1:205238299	TMCC2	0.41	7.72	0.39	1.36e-13	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg24313572	chr1:56050060	NA	-0.31	-6.32	-0.33	8.32e-10	Morning vs. evening chronotype;
LUSC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	8.55	0.42	4.35e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs61931739	0.635	rs10772122	chr12:33964674	A/C	cg13010199	chr12:38710504	ALG10B	0.4	6.0	0.31	5.01e-9	Morning vs. evening chronotype;
LUSC	cis	rs6076065	0.723	rs6083100	chr20:23358651	G/A	cg11657817	chr20:23433608	CST11	0.42	7.99	0.4	2.19e-14	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg27284194	chr4:1044797	NA	0.52	8.62	0.43	2.77e-16	Recombination rate (males);
LUSC	trans	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	10.67	0.5	4.7e-23	Mean corpuscular volume;
LUSC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg00149659	chr3:10157352	C3orf10	0.61	8.75	0.43	1.07e-16	Alzheimer's disease;
LUSC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg24531977	chr5:56204891	C5orf35	-0.65	-9.75	-0.47	6.24e-20	Coronary artery disease;
LUSC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-0.5	-8.41	-0.42	1.22e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-14.17	-0.61	5.19e-36	Monocyte count;
LUSC	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg00191853	chr8:101177733	SPAG1	-0.41	-6.53	-0.34	2.46e-10	Atrioventricular conduction;
LUSC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg00343986	chr7:65444356	GUSB	-0.44	-6.73	-0.35	7.28e-11	Aortic root size;
LUSC	cis	rs9796	0.674	rs6492978	chr15:41317702	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.44	-7.83	-0.39	6.42e-14	Menopause (age at onset);
LUSC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.46	-0.33	3.78e-10	Joint mobility (Beighton score);
LUSC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg04800585	chr6:26043546	HIST1H2BB	-0.4	-6.08	-0.32	3.3e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10793273	1	rs10793273	chr11:77742595	T/C	cg09721595	chr11:77773924	THRSP	-0.5	-8.99	-0.44	1.83e-17	Pelvic organ prolapse;
LUSC	cis	rs136211	0.577	rs9610498	chr22:36777739	C/T	cg21778268	chr22:36877729	TXN2	-0.41	-6.03	-0.31	4.44e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs1577917	0.629	rs9450285	chr6:86208096	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	6.91	0.35	2.46e-11	Response to antipsychotic treatment;
LUSC	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg00945038	chr17:61921165	SMARCD2	0.4	6.08	0.32	3.27e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs12519773	0.526	rs4264926	chr5:92518686	C/T	cg18783429	chr5:92414398	NA	0.33	7.22	0.37	3.44e-12	Migraine;
LUSC	cis	rs7043114	0.525	rs2516567	chr9:95187418	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.38	-6.88	-0.35	3.04e-11	Height;
LUSC	trans	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg10756647	chr7:56101905	PSPH	0.89	8.61	0.43	2.86e-16	Diabetic kidney disease;
LUSC	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg01879757	chr17:41196368	BRCA1	-0.48	-7.55	-0.38	4.11e-13	Menopause (age at onset);
LUSC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.7	0.47	9.03e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7953508	0.711	rs11611927	chr12:93977591	A/G	cg18151635	chr12:93972918	NA	-0.57	-8.11	-0.41	1e-14	Pubertal anthropometrics;
LUSC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg14416269	chr4:6271139	WFS1	0.54	11.38	0.53	1.35e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg04450456	chr4:17643702	FAM184B	0.36	5.87	0.31	1.04e-8	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg22546130	chr22:19950026	COMT	-0.4	-8.65	-0.43	2.19e-16	Blood metabolite levels;
LUSC	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg20701182	chr2:24300061	SF3B14	0.55	5.7	0.3	2.69e-8	Lymphocyte counts;
LUSC	cis	rs977987	0.742	rs12928898	chr16:75462081	G/A	cg04384234	chr16:75411784	CFDP1	-0.43	-7.0	-0.36	1.39e-11	Dupuytren's disease;
LUSC	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg17724175	chr1:150552817	MCL1	-0.49	-8.75	-0.43	1.1e-16	Urate levels;
LUSC	cis	rs868036	1.000	rs1026733	chr15:68095122	G/A	cg08079166	chr15:68083412	MAP2K5	0.41	8.49	0.42	6.72e-16	Restless legs syndrome;
LUSC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg23985595	chr17:80112537	CCDC57	-0.31	-5.86	-0.31	1.12e-8	Life satisfaction;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00557308	chr15:66274821	MEGF11	0.39	6.04	0.31	4.09e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.34	0.53	1.9e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	9.21	0.45	3.61e-18	Hemoglobin concentration;
LUSC	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg14675211	chr2:100938903	LONRF2	0.37	5.71	0.3	2.46e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg05347473	chr6:146136440	FBXO30	-0.52	-8.89	-0.44	3.85e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2617583	0.967	rs2652510	chr5:1447860	C/T	cg07148919	chr5:1466943	LPCAT1	0.41	6.09	0.32	3.08e-9	Breast cancer;
LUSC	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-6.86	-0.35	3.31e-11	Cognitive test performance;
LUSC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg02569458	chr12:86230093	RASSF9	0.58	9.93	0.48	1.56e-20	Major depressive disorder;
LUSC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg05025164	chr4:1340916	KIAA1530	0.42	6.63	0.34	1.32e-10	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg05347473	chr6:146136440	FBXO30	0.51	8.78	0.43	8.73e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg00745463	chr17:30367425	LRRC37B	0.47	6.47	0.33	3.55e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg15921436	chr17:44337874	NA	-0.72	-10.94	-0.51	5.04e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg04111992	chr7:158790115	NA	-0.44	-7.03	-0.36	1.17e-11	Facial morphology (factor 20);
LUSC	trans	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg07211511	chr3:129823064	LOC729375	-0.76	-10.06	-0.48	5.58e-21	Blood pressure (smoking interaction);
LUSC	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.59	7.61	0.38	2.81e-13	Multiple sclerosis;
LUSC	cis	rs193541	0.626	rs4629596	chr5:122089108	G/A	cg19077854	chr5:122220652	SNX24	0.28	6.31	0.33	8.78e-10	Glucose homeostasis traits;
LUSC	cis	rs7833787	0.929	rs7844317	chr8:18697046	T/A	cg17701159	chr8:18705777	PSD3	-0.37	-5.93	-0.31	7.38e-9	Obesity-related traits;
LUSC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg20406979	chr6:167373233	NA	-0.26	-6.29	-0.33	9.8e-10	Crohn's disease;
LUSC	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg15485101	chr11:133734466	NA	0.38	7.16	0.36	5.15e-12	Childhood ear infection;
LUSC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10802521	chr3:52805072	NEK4	-0.55	-9.0	-0.44	1.75e-17	Electroencephalogram traits;
LUSC	cis	rs62027291	0.654	rs62028181	chr15:77006293	A/G	cg26408565	chr15:76604113	ETFA	0.77	7.01	0.36	1.32e-11	Plateletcrit;
LUSC	cis	rs7582720	0.778	rs6719001	chr2:203777903	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	8.25	0.41	3.69e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg04362960	chr10:104952993	NT5C2	0.61	9.69	0.47	1.01e-19	Arsenic metabolism;
LUSC	trans	rs10016947	1.000	rs28521589	chr4:104252227	G/C	cg02356640	chr11:1501973	HCCA2	0.69	6.07	0.32	3.56e-9	Breast cancer;
LUSC	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg02569458	chr12:86230093	RASSF9	0.48	7.64	0.39	2.37e-13	Major depressive disorder;
LUSC	cis	rs77633900	0.881	rs1875883	chr15:76638231	C/T	cg21673338	chr15:77095150	SCAPER	-0.7	-6.03	-0.31	4.34e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg00944433	chr1:107599041	PRMT6	-0.33	-5.97	-0.31	6.17e-9	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg08017756	chr2:100939284	LONRF2	-0.44	-8.31	-0.41	2.51e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg03633073	chr16:89437518	ANKRD11	-0.36	-5.98	-0.31	5.76e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg06074448	chr4:187884817	NA	-0.39	-6.49	-0.33	3.06e-10	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg22431228	chr1:16359049	CLCNKA	0.35	7.25	0.37	2.84e-12	Dilated cardiomyopathy;
LUSC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-11.65	-0.54	1.5e-26	Total body bone mineral density;
LUSC	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.69	10.72	0.51	3.17e-23	Alcohol dependence;
LUSC	cis	rs10072221	0.836	rs11747990	chr5:75705617	T/C	cg03132911	chr5:75698732	IQGAP2	0.37	6.24	0.32	1.29e-9	Mean platelet volume;
LUSC	cis	rs6942756	1.000	rs7780886	chr7:128879347	G/A	cg02491457	chr7:128862824	NA	-0.53	-7.57	-0.38	3.57e-13	White matter hyperintensity burden;
LUSC	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg17545662	chr6:170176663	C6orf70	0.51	8.24	0.41	4.01e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg02344993	chr17:57696989	CLTC	0.49	7.28	0.37	2.38e-12	Hemoglobin concentration;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14885145	chr10:104262292	SUFU;ACTR1A	-0.46	-6.93	-0.35	2.12e-11	Hepatitis;
LUSC	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg02269571	chr22:50332266	NA	0.59	8.73	0.43	1.21e-16	Schizophrenia;
LUSC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.66	0.47	1.27e-19	Lung cancer;
LUSC	cis	rs4654899	0.802	rs4654724	chr1:21177210	C/T	cg02927042	chr1:21476669	EIF4G3	-0.37	-5.78	-0.3	1.75e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg19318889	chr4:1322082	MAEA	0.48	7.88	0.4	4.54e-14	Obesity-related traits;
LUSC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg08888203	chr3:10149979	C3orf24	0.59	8.11	0.41	9.88e-15	Alzheimer's disease;
LUSC	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.7	10.4	0.49	3.93e-22	Smoking initiation;
LUSC	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg01884057	chr2:25150051	NA	-0.47	-11.47	-0.53	6.9e-26	Body mass index in non-asthmatics;
LUSC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg16606324	chr3:10149918	C3orf24	0.68	10.1	0.48	4.33e-21	Alzheimer's disease;
LUSC	cis	rs10733682	1.000	rs10733682	chr9:129460914	C/T	cg00232160	chr9:129468157	NA	0.32	5.82	0.3	1.39e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1044826	0.692	rs188421	chr3:139234066	A/C	cg00490450	chr3:139108681	COPB2	-0.45	-6.93	-0.35	2.2e-11	Obesity-related traits;
LUSC	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg18225595	chr11:63971243	STIP1	0.44	6.98	0.36	1.64e-11	Platelet count;
LUSC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg23711669	chr6:146136114	FBXO30	0.78	14.05	0.61	1.54e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-6.81	-0.35	4.62e-11	Putamen volume;
LUSC	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg01884057	chr2:25150051	NA	0.45	10.5	0.5	1.77e-22	Body mass index;
LUSC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	9.21	0.45	3.77e-18	Total body bone mineral density;
LUSC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg27398817	chr8:82754497	SNX16	-0.46	-6.2	-0.32	1.7e-9	Diastolic blood pressure;
LUSC	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.59	10.2	0.49	1.89e-21	Itch intensity from mosquito bite;
LUSC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg27398817	chr8:82754497	SNX16	0.66	8.41	0.42	1.18e-15	Diastolic blood pressure;
LUSC	trans	rs800082	1.000	rs12637885	chr3:144291254	G/T	cg24215973	chr2:240111563	HDAC4	-0.46	-6.92	-0.35	2.36e-11	Smoking behavior;
LUSC	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg19653624	chr11:20408972	PRMT3	-0.63	-8.13	-0.41	8.53e-15	Pursuit maintenance gain;
LUSC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.83	0.35	3.97e-11	Tonsillectomy;
LUSC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	cis	rs1775715	0.870	rs1755080	chr10:32255195	G/A	cg18675610	chr10:32216311	ARHGAP12	0.29	6.06	0.31	3.63e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.55	-0.6	1.2e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg17507749	chr15:85114479	UBE2QP1	0.54	6.66	0.34	1.15e-10	Schizophrenia;
LUSC	cis	rs12472274	0.941	rs12616232	chr2:239080093	C/T	cg17459225	chr2:239074497	NA	0.63	9.69	0.47	1.03e-19	Phospholipid levels (plasma);
LUSC	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg10645314	chr2:3704589	ALLC	-0.49	-7.33	-0.37	1.75e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.46	9.62	0.47	1.67e-19	Airflow obstruction;
LUSC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg12963246	chr6:28129442	ZNF389	0.4	6.18	0.32	1.84e-9	Parkinson's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19058453	chr19:9879420	ZNF846	-0.51	-6.08	-0.32	3.22e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs9469578	1.000	rs6942022	chr6:33710284	C/T	cg18708504	chr6:33715942	IP6K3	0.72	9.2	0.45	4.1e-18	Phosphorus levels;
LUSC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.5	0.62	2.75e-37	Platelet count;
LUSC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg15147215	chr3:52552868	STAB1	-0.35	-7.03	-0.36	1.18e-11	Cognitive function;
LUSC	cis	rs4664308	0.875	rs7593593	chr2:160933811	C/T	cg03641300	chr2:160917029	PLA2R1	-0.68	-11.62	-0.54	1.97e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13012494	chr21:47604986	C21orf56	-0.4	-5.7	-0.3	2.58e-8	Testicular germ cell tumor;
LUSC	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg13775593	chr10:823151	NA	0.3	5.71	0.3	2.46e-8	Uric acid levels;
LUSC	cis	rs2677744	0.626	rs2001216	chr15:91498130	T/C	cg23684204	chr15:91497937	RCCD1	0.58	8.01	0.4	1.89e-14	Attention deficit hyperactivity disorder;
LUSC	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.52	0.34	2.64e-10	IgG glycosylation;
LUSC	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-9.62	-0.47	1.71e-19	Neuroticism;
LUSC	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg01528321	chr10:82214614	TSPAN14	-0.95	-10.8	-0.51	1.56e-23	Post bronchodilator FEV1;
LUSC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg26958806	chr6:27640298	NA	0.63	5.65	0.3	3.45e-8	Depression;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11639397	chr19:46010716	VASP	0.42	6.33	0.33	8e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg12751644	chr20:60527061	NA	-0.33	-6.14	-0.32	2.4e-9	Body mass index;
LUSC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-1.19	-12.75	-0.57	1.35e-30	Diabetic kidney disease;
LUSC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg13047869	chr3:10149882	C3orf24	0.6	8.18	0.41	5.93e-15	Alzheimer's disease;
LUSC	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg26384229	chr12:38710491	ALG10B	0.71	10.98	0.51	3.59e-24	Morning vs. evening chronotype;
LUSC	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.59	-6.42	-0.33	4.6e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg08847533	chr14:75593920	NEK9	-0.82	-13.87	-0.6	7.48e-35	Height;
LUSC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.84	11.18	0.52	7.49e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg04369109	chr6:150039330	LATS1	-0.51	-7.22	-0.37	3.59e-12	Lung cancer;
LUSC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg01017244	chr2:74357527	NA	0.73	14.16	0.61	5.37e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs2734839	0.537	rs1554929	chr11:113278764	C/T	cg14159747	chr11:113255604	NA	0.27	7.14	0.36	5.76e-12	Information processing speed;
LUSC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26314531	chr2:26401878	FAM59B	-0.69	-9.21	-0.45	3.67e-18	Gut microbiome composition (summer);
LUSC	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg08493051	chr2:3487164	NA	-0.51	-7.61	-0.38	2.92e-13	Neurofibrillary tangles;
LUSC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	22.14	0.77	1.81e-67	Height;
LUSC	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg22535103	chr8:58192502	C8orf71	-0.75	-7.79	-0.39	8.27e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg10756647	chr7:56101905	PSPH	0.85	8.37	0.42	1.55e-15	Diabetic kidney disease;
LUSC	cis	rs7180079	1.000	rs7180079	chr15:64629873	A/G	cg08069370	chr15:64387884	SNX1	0.57	6.28	0.32	1.05e-9	Monocyte count;
LUSC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg18512352	chr11:47633146	NA	0.47	9.41	0.46	8.08e-19	Subjective well-being;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27614445	chr3:179041226	ZNF639	0.45	7.53	0.38	4.87e-13	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.11	-0.48	3.97e-21	Obesity-related traits;
LUSC	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg17595323	chr11:93583763	C11orf90	-0.31	-5.67	-0.3	3.09e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg03563238	chr19:33554763	RHPN2	0.4	6.33	0.33	7.84e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs13242816	0.881	rs35037267	chr7:116117587	A/T	cg16553024	chr7:116138462	CAV2	-0.52	-5.69	-0.3	2.81e-8	P wave duration;
LUSC	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg03676636	chr4:99064102	C4orf37	0.36	7.65	0.39	2.12e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg24060327	chr5:131705240	SLC22A5	-0.67	-11.6	-0.54	2.19e-26	Breast cancer;
LUSC	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg23752985	chr2:85803571	VAMP8	0.34	7.45	0.38	7.85e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.72	13.55	0.6	1.27e-33	Gestational age at birth (maternal effect);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01435220	chr17:42634155	FZD2	-0.47	-6.13	-0.32	2.55e-9	Hepatitis;
LUSC	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg17462356	chr17:80056334	FASN	0.47	6.04	0.31	4.11e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4776059	1.000	rs12915981	chr15:52901433	C/T	cg25063058	chr15:52860530	ARPP19	0.43	6.07	0.32	3.43e-9	Schizophrenia;
LUSC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06481639	chr22:41940642	POLR3H	-0.53	-6.19	-0.32	1.74e-9	Vitiligo;
LUSC	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg05731713	chr7:157510257	PTPRN2	-0.43	-7.83	-0.39	6.47e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg22823121	chr1:150693482	HORMAD1	0.49	7.11	0.36	6.94e-12	Melanoma;
LUSC	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.22	0.71	5.32e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9807989	0.811	rs11688568	chr2:102969949	C/T	cg09003973	chr2:102972529	NA	0.44	6.04	0.31	4.15e-9	Asthma;
LUSC	cis	rs2051773	0.567	rs12293395	chr11:17047661	C/G	cg15084286	chr11:17036142	PLEKHA7	-0.45	-5.71	-0.3	2.45e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LUSC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08109568	chr15:31115862	NA	-0.72	-10.68	-0.5	4.06e-23	Huntington's disease progression;
LUSC	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg26408565	chr15:76604113	ETFA	-0.47	-7.48	-0.38	6.44e-13	Blood metabolite levels;
LUSC	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg23205692	chr1:25664452	TMEM50A	-0.41	-6.06	-0.31	3.76e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs7809950	1.000	rs2237676	chr7:107198079	C/A	cg23024343	chr7:107201750	COG5	-0.56	-8.88	-0.44	4.33e-17	Coronary artery disease;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg22194305	chr4:2264032	MXD4	0.4	6.35	0.33	6.99e-10	Schizophrenia;
LUSC	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-9.29	-0.45	1.99e-18	Coffee consumption (cups per day);
LUSC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-12.68	-0.57	2.41e-30	Chronic sinus infection;
LUSC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg11752832	chr7:134001865	SLC35B4	0.59	9.24	0.45	2.86e-18	Mean platelet volume;
LUSC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.61	-0.43	2.96e-16	Breast cancer;
LUSC	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg24642439	chr20:33292090	TP53INP2	-0.53	-8.16	-0.41	6.77e-15	Glomerular filtration rate (creatinine);
LUSC	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg04374321	chr14:90722782	PSMC1	0.65	9.96	0.48	1.22e-20	Mortality in heart failure;
LUSC	cis	rs7809950	0.678	rs4730235	chr7:107022506	T/C	cg23024343	chr7:107201750	COG5	-0.68	-9.97	-0.48	1.13e-20	Coronary artery disease;
LUSC	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg02569458	chr12:86230093	RASSF9	0.48	7.66	0.39	2.03e-13	Major depressive disorder;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10507121	chr5:118324332	DTWD2	0.5	7.24	0.37	3.04e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg16339924	chr4:17578868	LAP3	0.58	8.68	0.43	1.74e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg23205692	chr1:25664452	TMEM50A	-0.44	-6.59	-0.34	1.72e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg06640241	chr16:89574553	SPG7	0.74	12.2	0.56	1.45e-28	Multiple myeloma (IgH translocation);
LUSC	trans	rs34421088	0.576	rs2572436	chr8:11099209	C/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.32	-0.33	8.23e-10	Neuroticism;
LUSC	trans	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.62	9.81	0.47	3.97e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg15557168	chr22:42548783	NA	0.46	7.07	0.36	9.14e-12	Schizophrenia;
LUSC	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.94	-0.58	2.45e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg16339924	chr4:17578868	LAP3	0.54	8.15	0.41	7.38e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg22823121	chr1:150693482	HORMAD1	0.48	6.98	0.36	1.63e-11	Melanoma;
LUSC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg22963979	chr7:1858916	MAD1L1	-0.61	-9.72	-0.47	8.03e-20	Bipolar disorder and schizophrenia;
LUSC	cis	rs4959270	0.780	rs4339511	chr6:451895	T/C	cg09757644	chr6:447497	NA	0.28	5.88	0.31	9.96e-9	Limited cutaneous systemic scleroderma;
LUSC	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg11062466	chr8:58055876	NA	0.68	8.11	0.41	9.88e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs12200782	1.000	rs3927423	chr6:26393487	C/T	cg11837749	chr1:55047332	ACOT11	0.59	6.15	0.32	2.19e-9	Small cell lung carcinoma;
LUSC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-9.44	-0.46	6.54e-19	Gut microbiome composition (summer);
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg11905131	chr22:24372483	LOC391322	-0.58	-9.71	-0.47	8.4e-20	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs367943	0.712	rs4331889	chr5:112679795	C/T	cg12552261	chr5:112820674	MCC	0.37	6.15	0.32	2.18e-9	Type 2 diabetes;
LUSC	cis	rs17253792	0.822	rs17253723	chr14:56154015	A/G	cg01858014	chr14:56050164	KTN1	-0.82	-6.77	-0.35	5.9e-11	Putamen volume;
LUSC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg05025164	chr4:1340916	KIAA1530	0.41	6.12	0.32	2.59e-9	Obesity-related traits;
LUSC	trans	rs34421088	0.532	rs1545073	chr8:11167700	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	6.83	0.35	4.11e-11	Neuroticism;
LUSC	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-7.32	-0.37	1.87e-12	Height;
LUSC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg11189052	chr15:85197271	WDR73	0.47	5.65	0.3	3.44e-8	Schizophrenia;
LUSC	cis	rs17818399	0.749	rs4142759	chr2:46783890	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.11	0.32	2.77e-9	Height;
LUSC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.66	-11.04	-0.52	2.35e-24	Diastolic blood pressure;
LUSC	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg26816564	chr1:7831052	VAMP3	0.51	6.28	0.33	1.02e-9	Inflammatory bowel disease;
LUSC	cis	rs7727544	0.582	rs7703009	chr5:131552385	C/G	cg14196790	chr5:131705035	SLC22A5	0.45	7.46	0.38	7.67e-13	Blood metabolite levels;
LUSC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg05552183	chr6:42928497	GNMT	0.47	7.97	0.4	2.48e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg23303369	chr20:44641161	MMP9	0.35	6.09	0.32	3.04e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs8030485	0.536	rs1915724	chr15:79441027	A/G	cg17916960	chr15:79447300	NA	0.39	7.24	0.37	3.09e-12	Left ventricle wall thickness;
LUSC	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg02574844	chr11:5959923	NA	-0.41	-5.74	-0.3	2.15e-8	DNA methylation (variation);
LUSC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg17366294	chr4:99064904	C4orf37	0.58	10.3	0.49	8.56e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg21724239	chr8:58056113	NA	0.55	6.61	0.34	1.48e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs55871839	0.643	rs10105665	chr8:59799367	A/G	cg07426533	chr8:59803705	TOX	-0.36	-5.69	-0.3	2.82e-8	Pneumonia;
LUSC	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.78	-13.83	-0.6	1.08e-34	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-1.13	-19.91	-0.74	1.04e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21552528	chr15:64443755	SNX22	-0.42	-6.13	-0.32	2.44e-9	Electrocardiographic conduction measures;
LUSC	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg00484396	chr16:3507460	NAT15	0.48	7.07	0.36	9.23e-12	Body mass index (adult);
LUSC	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg27411982	chr8:10470053	RP1L1	-0.37	-5.81	-0.3	1.44e-8	Retinal vascular caliber;
LUSC	cis	rs3750965	1.000	rs7937006	chr11:68843932	C/T	cg06818126	chr11:68850279	TPCN2	-0.47	-6.89	-0.35	2.78e-11	Hair color;
LUSC	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg09839279	chr12:125627357	AACS	-0.33	-6.03	-0.31	4.31e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg12935359	chr14:103987150	CKB	0.67	10.87	0.51	9.08e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.17	0.55	1.93e-28	Motion sickness;
LUSC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.2e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.89	-0.31	9.55e-9	Platelet count;
LUSC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg21724239	chr8:58056113	NA	0.82	9.77	0.47	5.51e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg04121214	chr22:50244548	NA	-0.34	-5.74	-0.3	2.14e-8	Schizophrenia;
LUSC	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg16928487	chr17:17741425	SREBF1	-0.43	-8.49	-0.42	6.82e-16	Total body bone mineral density;
LUSC	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg22681709	chr2:178499509	PDE11A	-0.34	-6.3	-0.33	9.46e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.66	-0.47	1.26e-19	Hemoglobin concentration;
LUSC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg13939156	chr17:80058883	NA	0.34	6.53	0.34	2.42e-10	Life satisfaction;
LUSC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.7	0.47	9.08e-20	Bipolar disorder;
LUSC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg16393715	chr7:1948819	MAD1L1	0.35	6.09	0.32	3.17e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs1927790	0.697	rs61966875	chr13:96936525	C/A	cg03198741	chr6:1003969	LOC285768	-0.4	-5.96	-0.31	6.23e-9	Body mass index;
LUSC	cis	rs500891	0.504	rs2152181	chr6:84170615	C/G	cg08257003	chr6:84140564	ME1	0.35	8.67	0.43	1.87e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg23795048	chr12:9217529	LOC144571	0.34	5.85	0.31	1.15e-8	Sjögren's syndrome;
LUSC	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg24558204	chr6:135376177	HBS1L	0.58	9.03	0.44	1.38e-17	Red blood cell count;
LUSC	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg13535736	chr9:111863775	C9orf5	-0.41	-6.85	-0.35	3.66e-11	Menarche (age at onset);
LUSC	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.49	-6.06	-0.31	3.72e-9	Neutrophil percentage of white cells;
LUSC	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg10523679	chr1:76189770	ACADM	-0.49	-7.25	-0.37	2.94e-12	Daytime sleep phenotypes;
LUSC	cis	rs9341808	0.559	rs7762895	chr6:81061431	C/T	cg08355045	chr6:80787529	NA	0.44	7.41	0.38	1.08e-12	Sitting height ratio;
LUSC	cis	rs2074585	0.583	rs28406958	chr15:91069364	C/A	cg10434728	chr15:90938212	IQGAP1	-0.35	-6.44	-0.33	4.17e-10	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.61	7.87	0.4	5.03e-14	Schizophrenia;
LUSC	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.65	8.99	0.44	1.89e-17	Iron status biomarkers;
LUSC	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg25801113	chr15:45476975	SHF	-0.34	-6.71	-0.34	8.19e-11	Uric acid levels;
LUSC	cis	rs7909074	0.509	rs2183994	chr10:45389940	T/C	cg05187965	chr10:45406764	TMEM72	-0.29	-5.81	-0.3	1.49e-8	Mean corpuscular volume;
LUSC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg07636037	chr3:49044803	WDR6	0.43	6.26	0.32	1.21e-9	Resting heart rate;
LUSC	cis	rs7180079	1.000	rs8028184	chr15:64515543	G/A	cg08069370	chr15:64387884	SNX1	-0.54	-5.82	-0.3	1.39e-8	Monocyte count;
LUSC	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg12559939	chr2:27858050	GPN1	0.4	6.32	0.33	8.4e-10	Oral cavity cancer;
LUSC	cis	rs11676348	0.712	rs11687434	chr2:218945143	A/G	cg06547715	chr2:218990976	CXCR2	0.31	5.95	0.31	6.68e-9	Ulcerative colitis;
LUSC	cis	rs7538876	0.935	rs1408420	chr1:17754815	A/G	cg07965774	chr1:17746286	RCC2	-0.32	-5.96	-0.31	6.55e-9	Basal cell carcinoma;
LUSC	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg01416388	chr22:39784598	NA	-0.45	-7.45	-0.38	8.29e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs4889911	0.544	rs2650254	chr17:77833655	A/G	cg00646381	chr17:77835854	NA	0.56	8.74	0.43	1.19e-16	Electroencephalogram traits;
LUSC	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg01689657	chr7:91764605	CYP51A1	0.35	6.3	0.33	9.48e-10	Breast cancer;
LUSC	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg19318889	chr4:1322082	MAEA	-0.53	-8.75	-0.43	1.09e-16	Obesity-related traits;
LUSC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg02873098	chr16:4524103	NMRAL1;HMOX2	0.48	7.04	0.36	1.1e-11	Schizophrenia;
LUSC	cis	rs8133932	0.654	rs375254	chr21:47337151	T/A	cg14185626	chr21:47401492	COL6A1	-0.45	-5.74	-0.3	2.09e-8	Schizophrenia;
LUSC	cis	rs7827545	1.000	rs7008121	chr8:135565904	T/C	cg17885191	chr8:135476712	NA	0.57	8.45	0.42	8.93e-16	Hypertension (SNP x SNP interaction);
LUSC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg15147215	chr3:52552868	STAB1	0.32	6.49	0.33	3.11e-10	Bipolar disorder;
LUSC	cis	rs73206853	0.764	rs28840785	chr12:110844920	C/G	cg12870014	chr12:110450643	ANKRD13A	0.68	7.49	0.38	6.19e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6840360	1.000	rs7669977	chr4:152677527	T/C	cg22705602	chr4:152727874	NA	-0.27	-5.75	-0.3	2.01e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg11766577	chr21:47581405	C21orf56	-0.46	-6.93	-0.35	2.22e-11	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.19	0.37	4.33e-12	Motion sickness;
LUSC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.01e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs656319	0.513	rs17746245	chr8:9981686	A/C	cg27411982	chr8:10470053	RP1L1	0.38	5.64	0.3	3.54e-8	Myopia (pathological);
LUSC	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg18721089	chr20:30220636	NA	-0.32	-5.9	-0.31	8.73e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg16606324	chr3:10149918	C3orf24	0.58	8.23	0.41	4.27e-15	Alzheimer's disease;
LUSC	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg02503808	chr4:7069936	GRPEL1	-1.06	-11.76	-0.54	5.83e-27	Monocyte percentage of white cells;
LUSC	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg14061069	chr19:46274453	DMPK	-0.54	-9.2	-0.45	4.05e-18	Coronary artery disease;
LUSC	cis	rs17824933	0.806	rs11230565	chr11:60776711	A/G	cg16817237	chr11:60793675	NA	0.39	6.09	0.32	3.16e-9	Multiple sclerosis;
LUSC	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.41	-6.62	-0.34	1.42e-10	Homocysteine levels;
LUSC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.6	0.54	2.33e-26	Prudent dietary pattern;
LUSC	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg22676075	chr6:135203613	NA	0.59	9.24	0.45	2.94e-18	Red blood cell count;
LUSC	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg18129178	chr5:148520854	ABLIM3	-0.69	-10.62	-0.5	6.72e-23	Breast cancer;
LUSC	cis	rs977987	0.800	rs12922951	chr16:75355096	C/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.71	-0.34	8.56e-11	Dupuytren's disease;
LUSC	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg21100191	chr22:23484243	RTDR1	0.87	14.61	0.62	1.05e-37	Bone mineral density;
LUSC	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg25427524	chr10:38739819	LOC399744	-0.46	-6.33	-0.33	8.07e-10	Obesity (extreme);
LUSC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.52	0.57	9.28e-30	Motion sickness;
LUSC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.34	5.83	0.3	1.27e-8	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18932078	chr1:2524107	MMEL1	0.31	6.86	0.35	3.42e-11	Ulcerative colitis;
LUSC	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.67	11.4	0.53	1.15e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg06191203	chr2:152266755	RIF1	-0.53	-7.52	-0.38	5.11e-13	Lung cancer;
LUSC	trans	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg13010199	chr12:38710504	ALG10B	0.44	6.85	0.35	3.56e-11	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg12564285	chr5:131593104	PDLIM4	0.46	8.27	0.41	3.17e-15	Breast cancer;
LUSC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.62	8.22	0.41	4.53e-15	Response to diuretic therapy;
LUSC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg20701182	chr2:24300061	SF3B14	0.88	11.18	0.52	7.08e-25	Lymphocyte counts;
LUSC	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg17507749	chr15:85114479	UBE2QP1	0.7	9.24	0.45	3.03e-18	Schizophrenia;
LUSC	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-0.96	-10.25	-0.49	1.29e-21	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	6.04	0.31	4.1e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg06636001	chr8:8085503	FLJ10661	0.75	10.52	0.5	1.54e-22	Red cell distribution width;
LUSC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg12463550	chr7:65579703	CRCP	-0.44	-6.27	-0.32	1.11e-9	Aortic root size;
LUSC	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg05507819	chr15:63340323	TPM1	-0.64	-8.92	-0.44	3.14e-17	Platelet count;
LUSC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg17724175	chr1:150552817	MCL1	0.33	5.66	0.3	3.28e-8	Melanoma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09312254	chr12:112450979	ERP29;TMEM116	-0.4	-6.01	-0.31	4.82e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7189233	0.531	rs1074182	chr16:53471357	T/G	cg09728985	chr16:53543985	NA	-0.31	-5.8	-0.3	1.55e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19717773	chr7:2847554	GNA12	-0.37	-6.19	-0.32	1.75e-9	Height;
LUSC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg22823121	chr1:150693482	HORMAD1	0.49	7.28	0.37	2.48e-12	Melanoma;
LUSC	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg18827107	chr12:86230957	RASSF9	-0.48	-7.13	-0.36	6.22e-12	Major depressive disorder;
LUSC	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-6.85	-0.35	3.57e-11	Monocyte percentage of white cells;
LUSC	cis	rs6500395	0.708	rs9930644	chr16:48555929	G/C	cg04672837	chr16:48644449	N4BP1	0.42	6.12	0.32	2.62e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg19077165	chr18:44547161	KATNAL2	-0.37	-5.69	-0.3	2.8e-8	Personality dimensions;
LUSC	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg24881330	chr22:46731750	TRMU	0.82	7.77	0.39	9.61e-14	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg05985134	chr18:33552581	C18orf21	0.53	7.26	0.37	2.74e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6066835	1.000	rs6125428	chr20:47292823	C/G	cg18078177	chr20:47281410	PREX1	0.77	5.94	0.31	7.31e-9	Multiple myeloma;
LUSC	cis	rs778371	0.676	rs11688166	chr2:233566210	A/G	cg08000102	chr2:233561755	GIGYF2	0.83	13.04	0.58	1.07e-31	Schizophrenia;
LUSC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg14668632	chr7:2872130	GNA12	-0.41	-6.31	-0.33	8.77e-10	Height;
LUSC	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.71	12.47	0.56	1.41e-29	White blood cell count;
LUSC	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.63	9.88	0.48	2.24e-20	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg17366294	chr4:99064904	C4orf37	0.52	9.0	0.44	1.7e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs16957304	1.000	rs16957304	chr16:67334969	C/T	cg01866162	chr16:67596514	CTCF	-0.66	-5.68	-0.3	2.97e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs8048589	0.577	rs8055516	chr16:12180198	A/T	cg02910054	chr16:12241554	SNX29	0.38	5.73	0.3	2.22e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg07701084	chr6:150067640	NUP43	0.54	8.15	0.41	7.58e-15	Lung cancer;
LUSC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg05738196	chr6:26577821	NA	-0.8	-14.96	-0.63	4.5e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11764359	chr7:65958608	NA	0.68	10.89	0.51	7.59e-24	Aortic root size;
LUSC	cis	rs1808579	0.904	rs1652343	chr18:21131929	T/C	cg14672496	chr18:21087552	C18orf8	0.37	6.55	0.34	2.16e-10	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LUSC	cis	rs4363385	0.747	rs10788850	chr1:152963932	A/T	cg00922841	chr1:152955080	SPRR1A	-0.42	-7.29	-0.37	2.26e-12	Inflammatory skin disease;
LUSC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg15103426	chr22:29168792	CCDC117	0.45	5.74	0.3	2.1e-8	Lymphocyte counts;
LUSC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-0.71	-8.95	-0.44	2.5e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg18105134	chr13:113819100	PROZ	-0.68	-9.63	-0.47	1.59e-19	Platelet distribution width;
LUSC	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-6.56	-0.34	2.03e-10	Fear of minor pain;
LUSC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg15704280	chr7:45808275	SEPT13	-1.03	-19.56	-0.73	2.54e-57	Height;
LUSC	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg13385521	chr17:29058706	SUZ12P	0.58	5.98	0.31	5.68e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg05555928	chr11:63887634	MACROD1	-0.45	-5.78	-0.3	1.74e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	1.01	14.57	0.62	1.49e-37	Vitiligo;
LUSC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.49	0.56	1.26e-29	Motion sickness;
LUSC	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg19920283	chr7:105172520	RINT1	0.57	6.19	0.32	1.78e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg00677455	chr12:58241039	CTDSP2	0.49	7.28	0.37	2.45e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg22535103	chr8:58192502	C8orf71	-0.66	-7.38	-0.37	1.25e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg17652424	chr22:38574118	PLA2G6	-0.31	-6.66	-0.34	1.1e-10	Cutaneous nevi;
LUSC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.67	-11.68	-0.54	1.17e-26	Lung cancer;
LUSC	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg23093090	chr10:104574429	C10orf26	-0.36	-6.62	-0.34	1.42e-10	Arsenic metabolism;
LUSC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg08847533	chr14:75593920	NEK9	-0.81	-13.98	-0.61	2.78e-35	Height;
LUSC	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.86	0.51	9.62e-24	Bladder cancer;
LUSC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg13206674	chr6:150067644	NUP43	0.6	9.63	0.47	1.59e-19	Lung cancer;
LUSC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg17724175	chr1:150552817	MCL1	0.37	6.79	0.35	5.02e-11	Tonsillectomy;
LUSC	cis	rs4921915	0.598	rs4646243	chr8:18247609	T/C	cg18736775	chr8:18248649	NAT2	-0.56	-6.13	-0.32	2.5e-9	Iron status biomarkers (transferrin levels);
LUSC	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.13	0.55	2.73e-28	Colorectal cancer;
LUSC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg14092988	chr3:52407081	DNAH1	0.32	6.33	0.33	7.85e-10	Bipolar disorder;
LUSC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-6.05	-0.31	3.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7944735	0.508	rs1872167	chr11:47901269	C/T	cg20307385	chr11:47447363	PSMC3	-0.55	-5.66	-0.3	3.28e-8	Intraocular pressure;
LUSC	cis	rs7084921	0.608	rs11596883	chr10:101861622	T/C	cg02250046	chr10:101825185	CPN1	-0.35	-6.3	-0.33	9.21e-10	Bone mineral density;
LUSC	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.88	17.08	0.68	1.88e-47	Metabolite levels;
LUSC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg27170947	chr2:26402098	FAM59B	0.72	10.79	0.51	1.8e-23	Gut microbiome composition (summer);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24908708	chr8:95835570	INTS8	-0.56	-7.48	-0.38	6.54e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs977987	0.806	rs8051407	chr16:75448659	A/G	cg04384234	chr16:75411784	CFDP1	-0.41	-6.62	-0.34	1.4e-10	Dupuytren's disease;
LUSC	cis	rs9322817	0.691	rs7753202	chr6:105215289	T/C	cg02098413	chr6:105308735	HACE1	-0.28	-5.76	-0.3	1.86e-8	Thyroid stimulating hormone;
LUSC	cis	rs36093844	0.752	rs7121363	chr11:85575110	C/T	cg25872744	chr11:85566296	CCDC83	-0.47	-6.11	-0.32	2.73e-9	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs3741151	0.773	rs73548693	chr11:73286637	G/A	cg17517138	chr11:73019481	ARHGEF17	0.94	8.09	0.4	1.15e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.94	-0.36	2.03e-11	Monocyte percentage of white cells;
LUSC	cis	rs7605827	0.930	rs4668451	chr2:15675285	C/T	cg19274914	chr2:15703543	NA	0.45	8.7	0.43	1.49e-16	Educational attainment (years of education);
LUSC	trans	rs3960554	1.000	rs78663390	chr7:75845837	C/A	cg19862616	chr7:65841803	NCRNA00174	0.84	9.04	0.44	1.28e-17	Eotaxin levels;
LUSC	cis	rs17095355	0.818	rs1009532	chr10:111840725	C/T	cg00817464	chr10:111662876	XPNPEP1	0.53	6.96	0.36	1.81e-11	Biliary atresia;
LUSC	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg18132916	chr6:79620363	NA	-0.39	-6.0	-0.31	5.22e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7851660	0.874	rs2417576	chr9:100628707	C/T	cg13688889	chr9:100608707	NA	-0.56	-8.94	-0.44	2.73e-17	Strep throat;
LUSC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg22532475	chr10:104410764	TRIM8	-0.33	-7.24	-0.37	3.03e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.58	-9.51	-0.46	3.89e-19	Schizophrenia;
LUSC	cis	rs17286411	0.800	rs60740701	chr16:71875515	G/A	cg03805757	chr16:71968109	PKD1L3	0.39	5.72	0.3	2.41e-8	Blood protein levels;
LUSC	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19748678	chr4:122722346	EXOSC9	-0.48	-6.97	-0.36	1.72e-11	Type 2 diabetes;
LUSC	trans	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg27411982	chr8:10470053	RP1L1	-0.36	-6.03	-0.31	4.27e-9	Mood instability;
LUSC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12516959	chr21:47718080	NA	0.45	7.14	0.36	5.9e-12	Testicular germ cell tumor;
LUSC	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg20701182	chr2:24300061	SF3B14	-0.88	-11.33	-0.53	2.16e-25	Lymphocyte counts;
LUSC	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg05283184	chr6:79620031	NA	-0.54	-11.17	-0.52	7.97e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg25019033	chr10:957182	NA	-0.53	-6.03	-0.31	4.37e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg16576597	chr16:28551801	NUPR1	0.33	6.7	0.34	8.61e-11	Body mass index;
LUSC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg07217954	chr7:1067459	C7orf50	0.54	5.71	0.3	2.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg18827107	chr12:86230957	RASSF9	-0.48	-7.08	-0.36	8.62e-12	Major depressive disorder;
LUSC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg15557168	chr22:42548783	NA	-0.45	-6.88	-0.35	2.98e-11	Schizophrenia;
LUSC	trans	rs10097669	0.655	rs2725070	chr8:4439607	G/T	cg16451306	chr5:71475356	MAP1B	0.29	6.0	0.31	5.15e-9	Trans fatty acid levels;
LUSC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg13560548	chr3:10150139	C3orf24	0.48	6.66	0.34	1.14e-10	Alzheimer's disease;
LUSC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg08975724	chr8:8085496	FLJ10661	0.51	7.94	0.4	3.05e-14	Mood instability;
LUSC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05025164	chr4:1340916	KIAA1530	-0.43	-6.55	-0.34	2.14e-10	Obesity-related traits;
LUSC	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg16482183	chr6:26056742	HIST1H1C	0.56	8.34	0.42	2.02e-15	Height;
LUSC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg12560992	chr17:57184187	TRIM37	0.85	15.26	0.64	3e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg08017756	chr2:100939284	LONRF2	-0.46	-8.61	-0.43	3.03e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.26	-0.32	1.2e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-0.81	-16.0	-0.66	3.69e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7113850	0.541	rs74702708	chr11:24226866	T/C	ch.11.24196551F	chr11:24239977	NA	1.01	8.89	0.44	3.79e-17	Bone fracture in osteoporosis;
LUSC	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	13.86	0.6	7.72e-35	Blood protein levels;
LUSC	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg02018176	chr4:1364513	KIAA1530	-0.51	-8.79	-0.43	7.81e-17	Obesity-related traits;
LUSC	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.16	-0.32	2.07e-9	Resting heart rate;
LUSC	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg06618935	chr21:46677482	NA	-0.4	-8.04	-0.4	1.59e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12210905	0.688	rs12209174	chr6:27443952	G/A	cg08851530	chr6:28072375	NA	0.95	5.82	0.3	1.39e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg26876637	chr1:152193138	HRNR	0.42	5.96	0.31	6.41e-9	Atopic dermatitis;
LUSC	cis	rs7923452	0.938	rs67812762	chr10:30759479	G/T	cg18806716	chr10:30721971	MAP3K8	0.58	6.94	0.35	2.06e-11	Itch intensity from mosquito bite;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12926404	chr11:72145533	CLPB	-0.48	-6.2	-0.32	1.71e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg13256891	chr4:100009986	ADH5	-0.43	-5.99	-0.31	5.3300000000000004e-09	Alcohol dependence;
LUSC	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	1.1	15.77	0.65	2.93e-42	Uric acid levels;
LUSC	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg00945038	chr17:61921165	SMARCD2	0.38	5.68	0.3	2.87e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg22906224	chr7:99728672	NA	-0.5	-6.94	-0.35	2.09e-11	Coronary artery disease;
LUSC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08564027	chr20:61660810	NA	0.9	17.09	0.68	1.7e-47	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg16325326	chr1:53192061	ZYG11B	0.81	13.96	0.61	3.24e-35	Monocyte count;
LUSC	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg03859395	chr2:55845619	SMEK2	0.87	16.29	0.67	2.56e-44	Metabolic syndrome;
LUSC	trans	rs12478296	0.748	rs10185596	chr2:243001029	C/A	cg01596870	chr19:55963115	NA	-0.6	-7.55	-0.38	4.09e-13	Obesity-related traits;
LUSC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	0.99	13.78	0.6	1.64e-34	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg22709100	chr7:91322751	NA	0.43	6.26	0.32	1.17e-9	Breast cancer;
LUSC	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg21775007	chr8:11205619	TDH	-0.48	-6.94	-0.36	2.07e-11	Neuroticism;
LUSC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs6005807	0.582	rs8136767	chr22:29008626	G/A	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.13	0.48	3.24e-21	Bipolar disorder;
LUSC	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg05855489	chr10:104503620	C10orf26	-0.69	-8.93	-0.44	2.93e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2882667	0.627	rs1549203	chr5:138468344	A/G	cg04439458	chr5:138467593	SIL1	0.44	9.14	0.45	6.21e-18	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7246657	0.653	rs28701616	chr19:37681098	G/A	cg23950597	chr19:37808831	NA	-0.58	-5.88	-0.31	1.01e-8	Coronary artery calcification;
LUSC	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.93	-0.35	2.22e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg17366294	chr4:99064904	C4orf37	0.59	10.45	0.5	2.62e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs983392	0.805	rs7926729	chr11:59961786	C/T	cg24026212	chr11:59952134	MS4A6A	-0.37	-6.37	-0.33	6.17e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	1.1	17.21	0.69	5.83e-48	Exhaled nitric oxide output;
LUSC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg19592336	chr6:28129416	ZNF389	0.5	6.82	0.35	4.3e-11	Parkinson's disease;
LUSC	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg22823121	chr1:150693482	HORMAD1	0.52	7.57	0.38	3.79e-13	Melanoma;
LUSC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg06453172	chr10:134556979	INPP5A	-0.49	-6.09	-0.32	3.1e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg20243544	chr17:37824526	PNMT	0.47	5.85	0.3	1.18e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg06096015	chr1:231504339	EGLN1	0.54	9.5	0.46	4.17e-19	Hemoglobin concentration;
LUSC	cis	rs2625529	0.652	rs2957361	chr15:72345218	G/A	cg16672083	chr15:72433130	SENP8	0.49	8.14	0.41	8.06e-15	Red blood cell count;
LUSC	cis	rs939658	0.567	rs11631829	chr15:79446529	C/T	cg17916960	chr15:79447300	NA	-0.48	-9.88	-0.48	2.38e-20	Refractive error;
LUSC	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	13.33	0.59	8.18e-33	Blood protein levels;
LUSC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-1.22	-13.52	-0.59	1.63e-33	Diabetic kidney disease;
LUSC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg01689657	chr7:91764605	CYP51A1	0.33	5.99	0.31	5.53e-9	Breast cancer;
LUSC	cis	rs4704187	0.687	rs6862740	chr5:74405749	A/T	cg03227963	chr5:74354835	NA	0.32	6.87	0.35	3.09e-11	Response to amphetamines;
LUSC	cis	rs4917300	0.626	rs28375965	chr8:143103882	A/G	cg25363559	chr8:143086065	NA	-0.32	-7.25	-0.37	2.98e-12	Amyotrophic lateral sclerosis;
LUSC	cis	rs6669072	0.679	rs3845562	chr1:91313811	A/C	cg08895590	chr1:91227319	NA	0.33	7.01	0.36	1.36e-11	Cognitive function;
LUSC	cis	rs2625529	0.761	rs8028532	chr15:72348054	G/A	cg16672083	chr15:72433130	SENP8	-0.51	-7.48	-0.38	6.51e-13	Red blood cell count;
LUSC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg06627628	chr2:24431161	ITSN2	-0.61	-7.32	-0.37	1.88e-12	Lymphocyte counts;
LUSC	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg16850897	chr7:100343110	ZAN	0.38	6.26	0.32	1.17e-9	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LUSC	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	0.6	9.52	0.46	3.55e-19	Breast cancer;
LUSC	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.92	-0.44	3.07e-17	Obesity-related traits;
LUSC	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg10645314	chr2:3704589	ALLC	-0.49	-7.33	-0.37	1.72e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg17376030	chr22:41985996	PMM1	-0.47	-5.99	-0.31	5.3e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4740619	0.619	rs4741557	chr9:16031080	C/T	cg14451791	chr9:16040625	NA	0.33	6.47	0.33	3.49e-10	Body mass index;
LUSC	cis	rs8016982	0.632	rs7142641	chr14:81677454	A/G	cg01989461	chr14:81687754	GTF2A1	0.52	6.96	0.36	1.84e-11	Schizophrenia;
LUSC	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.84	-17.95	-0.7	6.22e-51	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7605827	0.893	rs35123590	chr2:15708639	T/C	cg19274914	chr2:15703543	NA	0.44	8.34	0.41	2.04e-15	Educational attainment (years of education);
LUSC	cis	rs612683	0.735	rs10493923	chr1:100930254	A/G	cg06223162	chr1:101003688	GPR88	-0.49	-9.27	-0.45	2.4e-18	Breast cancer;
LUSC	cis	rs12891047	0.804	rs72723196	chr14:68283697	G/C	cg20999565	chr14:68265668	ZFYVE26	0.38	5.79	0.3	1.58e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.8	0.57	8.38e-31	Prudent dietary pattern;
LUSC	cis	rs7474896	0.526	rs1208716	chr10:38089273	T/A	cg25427524	chr10:38739819	LOC399744	-0.44	-5.66	-0.3	3.31e-8	Obesity (extreme);
LUSC	cis	rs1018697	0.966	rs10748831	chr10:104558743	T/C	cg04362960	chr10:104952993	NT5C2	0.46	6.35	0.33	7.22e-10	Colorectal adenoma (advanced);
LUSC	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	6.45	0.33	3.82e-10	Recombination rate (females);
LUSC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs17102423	0.623	rs4902368	chr14:65612048	A/G	cg11161011	chr14:65562177	MAX	0.62	8.6	0.43	3.05e-16	Obesity-related traits;
LUSC	cis	rs478222	1.000	rs551573	chr2:25305504	A/G	cg01884057	chr2:25150051	NA	0.28	6.12	0.32	2.61e-9	Type 1 diabetes;
LUSC	cis	rs9865818	0.702	rs9834159	chr3:188115232	T/A	cg23651889	chr3:188115336	LPP	-0.38	-5.88	-0.31	1.01e-8	Allergic sensitization;
LUSC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg08470875	chr2:26401718	FAM59B	-0.65	-8.6	-0.43	3.12e-16	Gut microbiome composition (summer);
LUSC	cis	rs9517320	1.000	rs912337	chr13:99141272	A/G	cg07423050	chr13:99094983	FARP1	-0.36	-6.98	-0.36	1.6e-11	Longevity;
LUSC	cis	rs73206853	0.841	rs11065631	chr12:110778383	A/G	cg12870014	chr12:110450643	ANKRD13A	0.67	6.44	0.33	4.25e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.06	-0.36	9.45e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07918776	chr15:49170303	SHC4;EID1	-0.43	-6.65	-0.34	1.17e-10	Electrocardiographic conduction measures;
LUSC	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg17507749	chr15:85114479	UBE2QP1	0.66	8.19	0.41	5.47e-15	Schizophrenia;
LUSC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg20135002	chr11:47629003	NA	0.51	7.99	0.4	2.26e-14	Subjective well-being;
LUSC	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg27411982	chr8:10470053	RP1L1	0.37	5.66	0.3	3.28e-8	Retinal vascular caliber;
LUSC	cis	rs1143633	0.553	rs2723197	chr2:113689747	G/A	cg06156847	chr2:113672199	IL1F7	0.29	6.14	0.32	2.3e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg15147215	chr3:52552868	STAB1	-0.31	-6.13	-0.32	2.47e-9	Bipolar disorder;
LUSC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	1.04	21.65	0.76	1.47e-65	Cognitive function;
LUSC	cis	rs4690686	0.538	rs4690687	chr4:177259635	A/G	cg17059388	chr4:177262070	NA	-0.42	-7.85	-0.39	5.54e-14	Essential tremor;
LUSC	cis	rs11971779	0.680	rs7808740	chr7:139028955	G/T	cg07862535	chr7:139043722	LUC7L2	0.53	6.6	0.34	1.64e-10	Diisocyanate-induced asthma;
LUSC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg03806693	chr22:41940476	POLR3H	0.99	13.85	0.6	9.09e-35	Vitiligo;
LUSC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg25258033	chr6:167368657	RNASET2	0.45	7.08	0.36	8.83e-12	Crohn's disease;
LUSC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg03609598	chr5:56110824	MAP3K1	-0.42	-6.25	-0.32	1.26e-9	Initial pursuit acceleration;
LUSC	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg15962314	chr1:44399869	ARTN	0.29	6.76	0.35	6.16e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	trans	rs953492	0.644	rs10926974	chr1:243396326	C/T	cg25284624	chr1:224180302	NA	-0.44	-6.66	-0.34	1.12e-10	Diastolic blood pressure;
LUSC	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.85	-14.02	-0.61	1.89e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg15848620	chr12:58087721	OS9	-0.57	-8.24	-0.41	4.01e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg07741184	chr6:167504864	NA	0.36	6.53	0.34	2.52e-10	Crohn's disease;
LUSC	cis	rs59698941	0.843	rs61541414	chr5:132226106	G/A	cg14825688	chr5:132208181	LEAP2	-0.51	-6.1	-0.32	2.89e-9	Apolipoprotein A-IV levels;
LUSC	cis	rs1007190	0.881	rs16939676	chr17:42976347	C/A	cg15406952	chr17:42872593	NA	0.56	5.76	0.3	1.88e-8	DNA methylation (variation);
LUSC	cis	rs138491296	1	rs138491296	chr17:27961561	GATTATT/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-9.9	-0.48	2.03e-20	White blood cell count;
LUSC	cis	rs12928939	0.862	rs7197104	chr16:71794061	C/T	cg03805757	chr16:71968109	PKD1L3	-0.43	-6.29	-0.33	1.01e-9	Post bronchodilator FEV1;
LUSC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.4	0.53	1.24e-25	Prudent dietary pattern;
LUSC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg25767906	chr1:53392781	SCP2	-0.53	-10.33	-0.49	7.07e-22	Monocyte count;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg02550027	chr10:102046474	BLOC1S2	0.72	5.98	0.31	5.72e-9	Cognitive performance;
LUSC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg23630131	chr7:65973040	NA	0.21	5.94	0.31	7.16e-9	Aortic root size;
LUSC	cis	rs7605827	0.893	rs7590540	chr2:15719652	A/T	cg19274914	chr2:15703543	NA	0.46	8.75	0.43	1.08e-16	Educational attainment (years of education);
LUSC	cis	rs79220007	1.000	rs79220007	chr6:26098474	T/C	cg17691542	chr6:26056736	HIST1H1C	0.89	5.68	0.3	2.86e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs6961069	0.621	rs2065666	chr7:80230807	G/C	cg04458919	chr7:80252533	CD36	-0.41	-7.17	-0.37	4.95e-12	Platelet count;
LUSC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.48	0.53	6.2e-26	Prudent dietary pattern;
LUSC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06481639	chr22:41940642	POLR3H	-0.55	-6.12	-0.32	2.63e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs4285028	0.696	rs3915060	chr3:121712980	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.56	7.19	0.37	4.19e-12	Multiple sclerosis;
LUSC	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23158103	chr7:148848205	ZNF398	-0.43	-6.77	-0.35	5.95e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg15839431	chr19:19639596	YJEFN3	-0.41	-5.68	-0.3	2.93e-8	Tonsillectomy;
LUSC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg17264618	chr3:40429014	ENTPD3	-0.34	-7.35	-0.37	1.57e-12	Renal cell carcinoma;
LUSC	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg14809332	chr8:144654887	C8orf73	0.54	6.51	0.34	2.83e-10	Attention deficit hyperactivity disorder;
LUSC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05535760	chr7:792225	HEATR2	0.94	9.95	0.48	1.32e-20	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg07936489	chr17:37558343	FBXL20	-0.72	-9.75	-0.47	6.34e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg20607287	chr7:12443886	VWDE	-0.6	-6.2	-0.32	1.65e-9	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg01879757	chr17:41196368	BRCA1	-0.47	-7.16	-0.36	5.11e-12	Menopause (age at onset);
LUSC	cis	rs12900413	0.687	rs28493563	chr15:90309505	C/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.71	-0.3	2.47e-8	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.42	-6.65	-0.34	1.22e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	14.11	0.61	8.6e-36	Monocyte count;
LUSC	cis	rs4566357	1.000	rs3769637	chr2:227922623	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.91	-0.31	8.3e-9	Coronary artery disease;
LUSC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg01483505	chr11:975446	AP2A2	0.4	5.81	0.3	1.44e-8	Alzheimer's disease (late onset);
LUSC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg17747265	chr1:1875780	NA	-0.75	-17.58	-0.69	1.89e-49	Body mass index;
LUSC	cis	rs11997175	1.000	rs7838577	chr8:33760802	A/G	ch.8.33884649F	chr8:33765107	NA	0.52	8.23	0.41	4.15e-15	Body mass index;
LUSC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7786877	0.583	rs41303510	chr7:100226129	C/T	cg16850897	chr7:100343110	ZAN	-0.47	-5.82	-0.3	1.37e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg00784671	chr22:46762841	CELSR1	-0.49	-6.06	-0.31	3.75e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg06636001	chr8:8085503	FLJ10661	0.56	8.51	0.42	6.03e-16	Myopia (pathological);
LUSC	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14169450	chr9:139327907	INPP5E	0.46	8.26	0.41	3.53e-15	Monocyte percentage of white cells;
LUSC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.28	-0.45	2.27e-18	Gut microbiome composition (summer);
LUSC	cis	rs11997175	0.740	rs4733462	chr8:33679904	A/G	ch.8.33884649F	chr8:33765107	NA	0.39	6.04	0.31	4.04e-9	Body mass index;
LUSC	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg05973401	chr12:123451056	ABCB9	0.53	6.59	0.34	1.73e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg25204440	chr1:209979598	IRF6	0.51	5.85	0.3	1.19e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg12559939	chr2:27858050	GPN1	-0.41	-6.4	-0.33	5.37e-10	Oral cavity cancer;
LUSC	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-8.08	-0.4	1.23e-14	Axial length;
LUSC	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg24375607	chr4:120327624	NA	0.72	11.39	0.53	1.28e-25	Corneal astigmatism;
LUSC	cis	rs6580649	0.941	rs7296913	chr12:48488920	G/A	cg24011408	chr12:48396354	COL2A1	-0.45	-6.03	-0.31	4.29e-9	Lung cancer;
LUSC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.74	10.58	0.5	9.68e-23	Type 2 diabetes;
LUSC	cis	rs2248020	0.501	rs2263368	chr11:93264680	A/C	cg15737290	chr11:93063684	CCDC67	0.48	6.87	0.35	3.16e-11	Insulin levels in response to oral glucose tolerance test (30 minutes);
LUSC	cis	rs7241530	0.662	rs6506752	chr18:75904844	C/A	cg14642773	chr18:75888474	NA	0.39	6.02	0.31	4.59e-9	Educational attainment (years of education);
LUSC	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-5.79	-0.3	1.63e-8	Retinal vascular caliber;
LUSC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg08088566	chr11:430123	ANO9	0.64	7.14	0.36	5.87e-12	Body mass index;
LUSC	trans	rs11949289	1.000	rs58116711	chr5:28344497	C/T	cg18220921	chr1:242687527	PLD5	0.35	5.96	0.31	6.57e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	20.89	0.75	1.43e-62	Prudent dietary pattern;
LUSC	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg16928487	chr17:17741425	SREBF1	0.43	8.3	0.41	2.61e-15	Total body bone mineral density;
LUSC	cis	rs1865721	1.000	rs7244787	chr18:73195162	T/C	cg26385618	chr18:73139727	C18orf62	-0.48	-8.0	-0.4	2.12e-14	Intelligence;
LUSC	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg13010199	chr12:38710504	ALG10B	0.48	7.4	0.38	1.13e-12	Morning vs. evening chronotype;
LUSC	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-6.87	-0.35	3.1e-11	Bipolar disorder;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05684569	chr16:81929465	PLCG2	-0.79	-6.56	-0.34	2.01e-10	Cognitive performance;
LUSC	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg00310523	chr12:86230176	RASSF9	0.42	7.57	0.38	3.61e-13	Major depressive disorder;
LUSC	cis	rs6692729	0.966	rs6426547	chr1:227004367	A/G	cg10327440	chr1:227177885	CDC42BPA	0.47	6.72	0.35	7.77e-11	Electrodermal activity;
LUSC	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-9.44	-0.46	6.78e-19	Total cholesterol levels;
LUSC	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg07362569	chr17:61921086	SMARCD2	-0.29	-5.84	-0.3	1.22e-8	Prudent dietary pattern;
LUSC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	6.81	0.35	4.6e-11	Lung cancer in ever smokers;
LUSC	cis	rs7408868	1.000	rs757472	chr19:15273221	T/C	cg14696996	chr19:15285081	NOTCH3	1.01	9.45	0.46	6.13e-19	Pulse pressure;
LUSC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.04	21.28	0.76	3.93e-64	Cognitive function;
LUSC	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg13852791	chr20:30311386	BCL2L1	0.74	8.37	0.42	1.65e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.71	-0.34	8.3e-11	Neutrophil percentage of white cells;
LUSC	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg02018176	chr4:1364513	KIAA1530	0.46	6.51	0.34	2.81e-10	Recombination rate (females);
LUSC	cis	rs12681287	0.640	rs61106663	chr8:87477081	G/C	cg27223183	chr8:87520930	FAM82B	-0.53	-7.16	-0.36	5.04e-12	Caudate activity during reward;
LUSC	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.84	0.44	5.5e-17	Heart rate;
LUSC	cis	rs708547	0.581	rs781661	chr4:57780307	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.47	-6.79	-0.35	5.02e-11	Response to bleomycin (chromatid breaks);
LUSC	cis	rs13089785	1.000	rs13092912	chr3:123604942	C/T	cg02012769	chr3:123398346	MYLK	0.32	5.85	0.3	1.16e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg10729496	chr3:10149963	C3orf24	0.55	7.29	0.37	2.23e-12	Alzheimer's disease;
LUSC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-1.12	-22.64	-0.78	1.96e-69	Coronary artery disease;
LUSC	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg18758796	chr5:131593413	PDLIM4	0.44	7.59	0.38	3.3e-13	Breast cancer;
LUSC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg06008330	chr7:65541103	ASL	-0.4	-6.16	-0.32	2.14e-9	Aortic root size;
LUSC	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg22782873	chr19:19639568	YJEFN3	0.49	6.15	0.32	2.19e-9	Bipolar disorder;
LUSC	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg02023728	chr11:77925099	USP35	0.48	6.76	0.35	6.33e-11	Testicular germ cell tumor;
LUSC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg18225595	chr11:63971243	STIP1	0.63	10.62	0.5	6.96e-23	Platelet count;
LUSC	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg06197492	chr11:2016605	H19	0.41	6.74	0.35	7.07e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs7605827	0.930	rs4668910	chr2:15608013	C/A	cg19274914	chr2:15703543	NA	0.46	8.85	0.44	5.37e-17	Educational attainment (years of education);
LUSC	cis	rs10986311	0.722	rs6478660	chr9:127133920	A/T	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.44	7.22	0.37	3.59e-12	Vitiligo;
LUSC	cis	rs7180079	0.620	rs498806	chr15:64850939	C/T	cg08069370	chr15:64387884	SNX1	0.51	5.74	0.3	2.13e-8	Monocyte count;
LUSC	cis	rs3857536	0.741	rs4710582	chr6:66939984	T/G	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg15147215	chr3:52552868	STAB1	-0.36	-7.33	-0.37	1.74e-12	Electroencephalogram traits;
LUSC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg03563238	chr19:33554763	RHPN2	-0.34	-5.73	-0.3	2.19e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.7	12.06	0.55	4.68e-28	Heart rate;
LUSC	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg18932078	chr1:2524107	MMEL1	0.29	6.41	0.33	4.97e-10	Ulcerative colitis;
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.41	6.28	0.32	1.06e-9	Longevity;Endometriosis;
LUSC	cis	rs2580764	0.515	rs4672005	chr2:55246551	C/T	cg20993754	chr2:55226987	RTN4	0.34	5.71	0.3	2.45e-8	Mean platelet volume;
LUSC	cis	rs7188861	0.681	rs72773819	chr16:11406792	C/A	cg00044050	chr16:11439710	C16orf75	0.57	5.78	0.3	1.74e-8	HDL cholesterol;
LUSC	trans	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg06521331	chr12:34319734	NA	-0.39	-5.96	-0.31	6.34e-9	Bladder cancer;
LUSC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg20406979	chr6:167373233	NA	0.25	5.96	0.31	6.39e-9	Crohn's disease;
LUSC	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg21775007	chr8:11205619	TDH	0.46	6.48	0.33	3.28e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.34e-11	Menopause (age at onset);
LUSC	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	8.11	0.41	9.67e-15	Lung cancer in ever smokers;
LUSC	cis	rs9361491	0.657	rs9343801	chr6:79462275	G/A	cg05283184	chr6:79620031	NA	-0.32	-5.9	-0.31	9.16e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg11663144	chr21:46675770	NA	-0.41	-7.27	-0.37	2.62e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.62	-7.84	-0.39	6.1e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	trans	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg10756647	chr7:56101905	PSPH	0.88	8.95	0.44	2.54e-17	Diabetic kidney disease;
LUSC	cis	rs12940923	1.000	rs12451466	chr17:56378067	G/A	cg19466818	chr17:56409534	MIR142	-0.38	-6.51	-0.34	2.71e-10	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-17.0	-0.68	3.84e-47	Gut microbiome composition (summer);
LUSC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11764359	chr7:65958608	NA	0.63	9.48	0.46	4.74e-19	Aortic root size;
LUSC	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg24154853	chr7:158122151	PTPRN2	0.45	8.86	0.44	4.77e-17	Calcium levels;
LUSC	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.63	-8.32	-0.41	2.28e-15	Huntington's disease progression;
LUSC	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.64	-10.54	-0.5	1.34e-22	Morning vs. evening chronotype;
LUSC	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg23387468	chr7:139079360	LUC7L2	0.42	6.31	0.33	8.87e-10	Diisocyanate-induced asthma;
LUSC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.85	0.3	1.16e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg13628971	chr7:2884303	GNA12	0.43	6.37	0.33	6.31e-10	Height;
LUSC	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg05283184	chr6:79620031	NA	-0.57	-11.77	-0.54	5.31e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs2625529	0.824	rs12903484	chr15:72299481	G/A	cg16672083	chr15:72433130	SENP8	-0.52	-7.58	-0.38	3.51e-13	Red blood cell count;
LUSC	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg24642439	chr20:33292090	TP53INP2	0.39	5.66	0.3	3.3e-8	Height;
LUSC	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg25251562	chr2:3704773	ALLC	-0.4	-7.06	-0.36	9.54e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7246967	0.611	rs2194113	chr19:22958075	C/T	cg23217946	chr19:22817039	ZNF492	0.43	5.86	0.31	1.12e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg26395211	chr5:140044315	WDR55	-0.45	-6.99	-0.36	1.51e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.53	-0.42	5.24e-16	Menopause (age at onset);
LUSC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.57	0.57	6.1e-30	Motion sickness;
LUSC	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg25797454	chr6:150327115	RAET1K	0.35	7.98	0.4	2.34e-14	Alopecia areata;
LUSC	cis	rs10979	1.000	rs9484767	chr6:143887912	C/A	cg25407410	chr6:143891975	LOC285740	-0.75	-12.09	-0.55	3.8e-28	Hypospadias;
LUSC	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg15423357	chr2:25149977	NA	0.46	9.17	0.45	5.08e-18	Body mass index;
LUSC	trans	rs6869502	0.871	rs13354207	chr5:110151791	C/G	cg14733989	chr19:17622331	PGLS	-0.47	-6.25	-0.32	1.25e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6499188	0.522	rs8046299	chr16:68672346	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.21	-0.32	1.61e-9	Ulcerative colitis;
LUSC	cis	rs2040771	0.872	rs12485084	chr22:19162326	A/G	cg02655711	chr22:19163373	SLC25A1	0.52	9.33	0.45	1.51e-18	Metabolite levels (small molecules and protein measures);
LUSC	cis	rs10193935	1.000	rs62144748	chr2:42419468	C/T	cg27598129	chr2:42591480	NA	-0.62	-8.45	-0.42	9.38e-16	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.81	10.26	0.49	1.16e-21	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg15103426	chr22:29168792	CCDC117	0.49	6.25	0.32	1.24e-9	Lymphocyte counts;
LUSC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg16339924	chr4:17578868	LAP3	-0.52	-7.96	-0.4	2.63e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-12.84	-0.57	5.88e-31	Platelet count;
LUSC	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg20129853	chr10:51489980	NA	-0.35	-7.0	-0.36	1.38e-11	Prostate-specific antigen levels;
LUSC	cis	rs524023	0.957	rs12365089	chr11:64364735	A/T	cg19131476	chr11:64387923	NRXN2	-0.38	-10.2	-0.49	1.95e-21	Urate levels in obese individuals;
LUSC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg17541715	chr7:1216824	NA	-0.35	-5.71	-0.3	2.51e-8	Longevity;Endometriosis;
LUSC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg00933542	chr6:150070202	PCMT1	0.32	6.63	0.34	1.34e-10	Lung cancer;
LUSC	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg04111992	chr7:158790115	NA	-0.43	-6.75	-0.35	6.5e-11	Facial morphology (factor 20);
LUSC	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg19628046	chr18:33552617	C18orf21	0.52	6.32	0.33	8.4e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg22676075	chr6:135203613	NA	0.47	7.4	0.38	1.12e-12	Red blood cell count;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg14877820	chr3:16306698	OXNAD1;DPH3	0.68	6.25	0.32	1.26e-9	Body mass index;
LUSC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.05	0.36	1.03e-11	Parkinson's disease;
LUSC	cis	rs2742417	0.565	rs2673031	chr3:45756986	A/G	cg10512202	chr3:45649293	LIMD1	0.36	6.06	0.31	3.65e-9	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.52	-0.46	3.68e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-1.14	-18.49	-0.71	4.69e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg00784671	chr22:46762841	CELSR1	-0.55	-7.0	-0.36	1.41e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	0.5	7.96	0.4	2.68e-14	Uric acid clearance;
LUSC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg18538332	chr22:24372958	LOC391322	-0.42	-7.54	-0.38	4.62e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.67	0.43	1.91e-16	Prudent dietary pattern;
LUSC	cis	rs4073416	0.568	rs12885842	chr14:65918652	C/T	cg03016385	chr14:66212404	NA	-0.42	-6.67	-0.34	1.07e-10	N-glycan levels;
LUSC	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg07157834	chr1:205819609	PM20D1	0.45	5.93	0.31	7.77e-9	Menarche (age at onset);
LUSC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg11645453	chr3:52864694	ITIH4	0.31	7.3	0.37	2.08e-12	Electroencephalogram traits;
LUSC	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg22601191	chr20:60968625	CABLES2	-0.36	-5.77	-0.3	1.81e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg13736514	chr6:26305472	NA	-0.47	-9.45	-0.46	6.09e-19	Educational attainment;
LUSC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg13699009	chr12:122356056	WDR66	0.45	6.81	0.35	4.68e-11	Mean corpuscular volume;
LUSC	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-0.91	-15.86	-0.66	1.23e-42	Height;
LUSC	cis	rs1178968	1.000	rs13240408	chr7:72758023	T/C	cg25889504	chr7:72793014	NA	0.58	7.54	0.38	4.5e-13	Triglyceride levels;
LUSC	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-10.11	-0.48	3.92e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	8.16	0.41	6.75e-15	Lymphocyte counts;
LUSC	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg26102564	chr10:131424627	MGMT	0.43	6.46	0.33	3.73e-10	Response to temozolomide;
LUSC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.86	15.72	0.65	4.61e-42	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs11229555	0.645	rs35279927	chr11:58212129	G/T	cg15696309	chr11:58395628	NA	-0.64	-7.79	-0.39	8.6e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.54e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11214589	0.905	rs2186799	chr11:113242533	G/T	cg14159747	chr11:113255604	NA	0.29	6.97	0.36	1.72e-11	Neuroticism;
LUSC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg12564285	chr5:131593104	PDLIM4	0.44	7.92	0.4	3.48e-14	Breast cancer;
LUSC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	0.91	13.51	0.59	1.7e-33	Breast cancer;
LUSC	cis	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-5.88	-0.31	9.71e-9	Eotaxin levels;
LUSC	cis	rs9296092	0.517	rs3912041	chr6:33521271	T/C	cg13560919	chr6:33536144	NA	-0.82	-15.74	-0.65	3.89e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	0.78	12.11	0.55	3.16e-28	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs6060717	0.536	rs6060704	chr20:34530270	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-5.8	-0.3	1.53e-8	Hip circumference adjusted for BMI;
LUSC	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01585723	chr16:33734837	NA	0.46	7.99	0.4	2.25e-14	Menopause (age at onset);
LUSC	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.4	-5.81	-0.3	1.42e-8	Response to bleomycin (chromatid breaks);
LUSC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.38	5.77	0.3	1.79e-8	Menopause (age at onset);
LUSC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05890377	chr2:74357713	NA	0.73	14.22	0.61	3.3e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg24675658	chr1:53192096	ZYG11B	-0.63	-9.83	-0.47	3.43e-20	Monocyte count;
LUSC	cis	rs7084921	0.608	rs4475856	chr10:101833339	G/T	cg11888571	chr10:102027403	CWF19L1	-0.42	-5.81	-0.3	1.47e-8	Bone mineral density;
LUSC	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg17279839	chr7:150038598	RARRES2	0.42	6.54	0.34	2.36e-10	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg10360139	chr7:1886902	MAD1L1	-0.4	-6.02	-0.31	4.53e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg06002616	chr8:101225028	SPAG1	-0.42	-7.02	-0.36	1.26e-11	Atrioventricular conduction;
LUSC	cis	rs7336332	0.600	rs9579083	chr13:28017270	G/C	cg22138327	chr13:27999177	GTF3A	0.75	9.71	0.47	8.31e-20	Weight;
LUSC	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg23625390	chr15:77176239	SCAPER	0.54	8.49	0.42	6.9e-16	Blood metabolite levels;
LUSC	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg02018176	chr4:1364513	KIAA1530	-0.5	-8.48	-0.42	7.18e-16	Obesity-related traits;
LUSC	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.01	-20.77	-0.75	4.3500000000000004e-62	Ulcerative colitis;
LUSC	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg22732515	chr19:44031385	ETHE1	0.64	10.43	0.5	2.99e-22	Fractional exhaled nitric oxide (childhood);
LUSC	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg10523679	chr1:76189770	ACADM	-0.51	-7.44	-0.38	8.34e-13	Daytime sleep phenotypes;
LUSC	trans	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg10756647	chr7:56101905	PSPH	0.88	8.96	0.44	2.28e-17	Gout;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.68	10.53	0.5	1.37e-22	Lymphocyte counts;
LUSC	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2.04e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg03474202	chr17:45855739	NA	-0.31	-7.07	-0.36	9.11e-12	IgG glycosylation;
LUSC	trans	rs1459104	0.866	rs67929427	chr11:54824182	C/T	cg03929089	chr4:120376271	NA	0.72	6.26	0.32	1.17e-9	Body mass index;
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.68	-10.51	-0.5	1.59e-22	Lymphocyte counts;
LUSC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.61	0.47	1.77e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9807989	0.801	rs6734742	chr2:102967857	C/T	cg09003973	chr2:102972529	NA	0.44	6.05	0.31	3.93e-9	Asthma;
LUSC	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.84	-0.44	5.49e-17	Monocyte percentage of white cells;
LUSC	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-5.85	-0.3	1.16e-8	Cutaneous nevi;
LUSC	cis	rs56283067	0.847	rs10948156	chr6:44689459	G/A	cg18551225	chr6:44695536	NA	-0.5	-8.39	-0.42	1.36e-15	Total body bone mineral density;
LUSC	cis	rs34779708	0.677	rs112355105	chr10:35550294	A/T	cg03585969	chr10:35415529	CREM	0.53	7.3	0.37	2.16e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg04450456	chr4:17643702	FAM184B	0.37	6.17	0.32	1.96e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.73	-8.84	-0.44	5.42e-17	Refractive error;
LUSC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg03188948	chr7:1209495	NA	0.67	7.04	0.36	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg14092988	chr3:52407081	DNAH1	0.3	5.87	0.31	1.06e-8	Bipolar disorder;
LUSC	trans	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.38	-0.33	5.91e-10	Mood instability;
LUSC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.03e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg05347473	chr6:146136440	FBXO30	-0.66	-11.72	-0.54	8.35e-27	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12220238	1.000	rs10824090	chr10:75923446	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.6	7.2	0.37	3.89e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	0.79	13.92	0.61	4.74e-35	Cognitive function;
LUSC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg05347473	chr6:146136440	FBXO30	0.44	7.54	0.38	4.49e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg08017756	chr2:100939284	LONRF2	-0.45	-8.51	-0.42	6.11e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg24675658	chr1:53192096	ZYG11B	0.6	9.33	0.45	1.51e-18	Monocyte count;
LUSC	trans	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg13010199	chr12:38710504	ALG10B	0.47	6.6	0.34	1.61e-10	Resting heart rate;
LUSC	cis	rs2652822	0.935	rs2292038	chr15:63449680	C/G	cg02713581	chr15:63449717	RPS27L	-0.42	-6.72	-0.35	7.65e-11	Metabolic traits;
LUSC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10986311	0.832	rs10119911	chr9:127127172	A/G	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.39	6.27	0.32	1.1e-9	Vitiligo;
LUSC	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.61	-0.34	1.51e-10	Monocyte percentage of white cells;
LUSC	cis	rs41271951	0.512	rs115968379	chr1:151050087	A/C	cg11822372	chr1:151115635	SEMA6C	-0.78	-7.18	-0.37	4.51e-12	Blood protein levels;
LUSC	cis	rs7712401	0.715	rs13163098	chr5:122346536	A/G	cg19077854	chr5:122220652	SNX24	-0.41	-8.85	-0.44	5.29e-17	Mean platelet volume;
LUSC	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg08999081	chr20:33150536	PIGU	-0.41	-7.64	-0.39	2.27e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.83	-0.35	4.04e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	0.57	11.95	0.55	1.26e-27	Obesity-related traits;
LUSC	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.61	0.62	1.05e-37	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg08017756	chr2:100939284	LONRF2	-0.45	-8.35	-0.42	1.82e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.03	0.31	4.27e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg06454157	chr6:167490870	NA	-0.25	-5.96	-0.31	6.44e-9	Crohn's disease;
LUSC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg18225595	chr11:63971243	STIP1	0.65	11.21	0.52	5.79e-25	Platelet count;
LUSC	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg26162295	chr17:38119207	GSDMA	-0.27	-6.52	-0.34	2.53e-10	Lymphocyte percentage of white cells;
LUSC	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg14169450	chr9:139327907	INPP5E	-0.42	-7.4	-0.38	1.09e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg22823121	chr1:150693482	HORMAD1	-0.45	-6.7	-0.34	8.88e-11	Tonsillectomy;
LUSC	cis	rs1568889	1.000	rs16917687	chr11:28062614	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.51	0.46	3.95e-19	Bipolar disorder;
LUSC	cis	rs13006833	0.668	rs291458	chr2:191181481	A/C	cg21644426	chr2:191273491	MFSD6	0.43	6.14	0.32	2.39e-9	Urinary metabolites;
LUSC	cis	rs617219	0.819	rs2607140	chr5:78563227	C/T	cg24856658	chr5:78533917	JMY	-0.31	-6.02	-0.31	4.68e-9	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	trans	rs11700980	0.551	rs2832033	chr21:30114841	C/T	cg14791747	chr16:20752902	THUMPD1	0.55	6.05	0.31	3.8e-9	QRS complex (12-leadsum);
LUSC	trans	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg05926928	chr17:57297772	GDPD1	0.47	6.61	0.34	1.51e-10	Schizophrenia;
LUSC	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg14154082	chr13:112174009	NA	0.38	7.95	0.4	2.97e-14	Menarche (age at onset);
LUSC	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.16	-0.36	5.08e-12	Coronary artery disease;
LUSC	cis	rs654950	0.806	rs941971	chr1:42040893	T/C	cg06885757	chr1:42089581	HIVEP3	-0.43	-8.58	-0.42	3.72e-16	Airway imaging phenotypes;
LUSC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04025307	chr7:1156635	C7orf50	0.43	6.65	0.34	1.22e-10	Longevity;Endometriosis;
LUSC	cis	rs12540874	0.522	rs4947641	chr7:50489038	C/T	cg18232548	chr7:50535776	DDC	-0.61	-9.39	-0.46	9.89e-19	Systemic sclerosis;
LUSC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.65	11.18	0.52	7.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4845570	0.831	rs11588258	chr1:151780728	A/T	cg07092448	chr1:151763213	TDRKH	-1.18	-12.38	-0.56	3.07e-29	Coronary artery disease;
LUSC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg18681998	chr4:17616180	MED28	0.92	18.07	0.7	2.15e-51	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6460942	0.908	rs73677573	chr7:12283598	G/A	cg06484146	chr7:12443880	VWDE	-0.55	-5.85	-0.3	1.18e-8	Coronary artery disease;
LUSC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.67	11.29	0.53	2.84e-25	Blood protein levels;
LUSC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg11062466	chr8:58055876	NA	0.54	7.32	0.37	1.85e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.78	0.35	5.37e-11	Platelet count;
LUSC	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg11812906	chr14:75593930	NEK9	-0.64	-10.98	-0.51	3.89e-24	Height;
LUSC	cis	rs865483	0.861	rs56186148	chr17:35768827	T/A	cg06716730	chr17:35851459	DUSP14	-0.26	-5.67	-0.3	3.15e-8	Monocyte count;
LUSC	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg09904177	chr6:26538194	HMGN4	0.66	11.69	0.54	1.09e-26	Intelligence (multi-trait analysis);
LUSC	trans	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.31	-0.33	8.87e-10	Bladder cancer;
LUSC	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg05110241	chr16:68378359	PRMT7	-0.51	-6.42	-0.33	4.73e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg11812906	chr14:75593930	NEK9	-0.64	-11.2	-0.52	5.95e-25	Height;
LUSC	cis	rs6084875	0.840	rs2077519	chr20:4720750	A/G	cg07258627	chr20:4721683	PRNT	-0.34	-6.2	-0.32	1.69e-9	Systemic lupus erythematosus;
LUSC	cis	rs2820315	1.000	rs2820315	chr1:201872264	A/G	cg10061532	chr1:201886748	LMOD1	-0.26	-5.8	-0.3	1.57e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LUSC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg05973401	chr12:123451056	ABCB9	0.54	6.67	0.34	1.06e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-9.74	-0.47	6.73e-20	Gut microbiome composition (summer);
LUSC	trans	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg25482853	chr8:67687455	SGK3	1.12	15.85	0.66	1.36e-42	Obesity-related traits;
LUSC	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg00049323	chr5:472564	LOC25845	0.52	7.99	0.4	2.28e-14	Cystic fibrosis severity;
LUSC	trans	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg25214090	chr10:38739885	LOC399744	0.49	7.49	0.38	6.22e-13	Corneal astigmatism;
LUSC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg13119609	chr19:45449297	APOC2	0.47	9.46	0.46	5.65e-19	Blood protein levels;
LUSC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-9.06	-0.44	1.11e-17	Monocyte percentage of white cells;
LUSC	cis	rs34891900	0.507	rs2535679	chr22:18202850	A/G	cg08824373	chr22:18117835	NA	-0.41	-6.2	-0.32	1.66e-9	Sum neutrophil eosinophil counts;
LUSC	cis	rs6545883	0.965	rs2305156	chr2:61729268	T/C	cg15711740	chr2:61764176	XPO1	-0.49	-7.72	-0.39	1.34e-13	Tuberculosis;
LUSC	cis	rs12210905	0.925	rs12193463	chr6:26961882	T/G	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-5.93	-0.31	7.67e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg06521331	chr12:34319734	NA	-0.48	-7.71	-0.39	1.43e-13	Morning vs. evening chronotype;
LUSC	cis	rs2639990	1.000	rs2639990	chr18:72915551	T/C	cg02750262	chr18:72916776	ZADH2	0.67	7.45	0.38	7.8e-13	Vascular endothelial growth factor levels;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg17192681	chr2:10953115	PDIA6	0.39	6.22	0.32	1.45e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-1.07	-25.94	-0.82	4.9e-82	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2677744	0.626	rs11854429	chr15:91489685	C/T	cg23684204	chr15:91497937	RCCD1	-0.5	-7.05	-0.36	1.02e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs56146971	0.763	rs2064961	chr14:91868814	A/G	cg10511902	chr14:91842949	CCDC88C	0.44	5.82	0.3	1.37e-8	Alzheimer disease and age of onset;
LUSC	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.72	-11.4	-0.53	1.17e-25	Breast size;
LUSC	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.7	-8.33	-0.41	2.15e-15	Refractive error;
LUSC	cis	rs367615	0.552	rs2115511	chr5:108725403	A/T	cg17395555	chr5:108820864	NA	-0.46	-8.06	-0.4	1.36e-14	Colorectal cancer (SNP x SNP interaction);
LUSC	cis	rs662064	0.889	rs1188526	chr1:10549848	G/C	cg20482658	chr1:10539492	PEX14	-0.34	-6.9	-0.35	2.69e-11	Asthma;
LUSC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg06008330	chr7:65541103	ASL	0.41	6.32	0.33	8.55e-10	Aortic root size;
LUSC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs57590327	0.503	rs13080520	chr3:81850742	T/C	cg07356753	chr3:81810745	GBE1	-0.55	-8.3	-0.41	2.54e-15	Extraversion;
LUSC	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.43	-0.46	7.28e-19	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg09479241	chr17:27052676	TLCD1	0.42	5.71	0.3	2.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs9467773	0.526	rs10946817	chr6:26364056	C/T	cg05738196	chr6:26577821	NA	-0.47	-7.31	-0.37	2.04e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs73193808	0.627	rs73192202	chr21:30520578	A/G	cg24692254	chr21:30365293	RNF160	0.71	6.43	0.33	4.47e-10	Coronary artery disease;
LUSC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	8.73	0.43	1.22e-16	Prudent dietary pattern;
LUSC	cis	rs6681460	0.932	rs2044399	chr1:67054080	T/C	cg02459107	chr1:67143332	SGIP1	0.46	8.43	0.42	1.04e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	6.73	0.35	7.22e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg07701084	chr6:150067640	NUP43	0.51	7.71	0.39	1.45e-13	Lung cancer;
LUSC	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg25251562	chr2:3704773	ALLC	0.52	8.65	0.43	2.23e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	8.07	0.4	1.32e-14	Personality dimensions;
LUSC	cis	rs921968	0.565	rs586194	chr2:219610433	A/G	cg02176678	chr2:219576539	TTLL4	-0.56	-9.9	-0.48	2.05e-20	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg01657329	chr11:68192670	LRP5	-0.4	-5.73	-0.3	2.28e-8	Total body bone mineral density;
LUSC	cis	rs2637266	0.935	rs1907323	chr10:78336015	C/T	cg18941641	chr10:78392320	NA	0.32	5.83	0.3	1.33e-8	Pulmonary function;
LUSC	cis	rs7495132	0.526	rs60433006	chr15:91197475	C/T	cg00756943	chr15:91208460	NA	-0.4	-5.7	-0.3	2.69e-8	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg13334819	chr7:99746414	C7orf59	-0.5	-6.67	-0.34	1.05e-10	Coronary artery disease;
LUSC	cis	rs7584330	0.554	rs74001399	chr2:238445440	G/A	cg16989719	chr2:238392110	NA	-0.41	-5.88	-0.31	9.8e-9	Prostate cancer;
LUSC	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg08499158	chr17:42289980	UBTF	0.38	6.35	0.33	7.23e-10	Total body bone mineral density;
LUSC	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg09904177	chr6:26538194	HMGN4	0.75	14.22	0.61	3.36e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.8	-0.35	4.76e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg06675483	chr6:26987649	LOC100270746;C6orf41	0.29	5.82	0.3	1.37e-8	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs72674100	1.000	rs4434261	chr4:97963014	A/G	cg16405019	chr1:18959625	PAX7	-0.57	-6.11	-0.32	2.78e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg27411982	chr8:10470053	RP1L1	-0.46	-7.08	-0.36	8.74e-12	Neuroticism;
LUSC	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg09640425	chr7:158790006	NA	-0.49	-7.74	-0.39	1.21e-13	Facial morphology (factor 20);
LUSC	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.7	-0.39	1.6e-13	Glomerular filtration rate;
LUSC	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-8.01	-0.4	1.96e-14	Total cholesterol levels;
LUSC	cis	rs7107174	1.000	rs4945261	chr11:77990260	A/G	cg02023728	chr11:77925099	USP35	-0.47	-6.73	-0.35	7.24e-11	Testicular germ cell tumor;
LUSC	cis	rs9326248	0.768	rs4936366	chr11:117026885	G/A	cg16524733	chr11:117070046	TAGLN	0.36	5.71	0.3	2.47e-8	Blood protein levels;
LUSC	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg00376283	chr12:123451042	ABCB9	0.66	8.22	0.41	4.69e-15	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg24006582	chr15:45444508	DUOX1	0.71	10.23	0.49	1.46e-21	Uric acid levels;
LUSC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg25039879	chr17:56429692	SUPT4H1	0.69	9.12	0.45	7.14e-18	Cognitive test performance;
LUSC	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.53	-10.48	-0.5	2.14e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.44	-7.38	-0.37	1.26e-12	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.53e-10	Corneal astigmatism;
LUSC	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg22815214	chr1:201083145	CACNA1S	0.53	9.17	0.45	5.08e-18	Permanent tooth development;
LUSC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg23630131	chr7:65973040	NA	0.21	5.81	0.3	1.42e-8	Aortic root size;
LUSC	cis	rs921665	0.831	rs6548167	chr2:3181062	A/G	cg02624386	chr2:3182749	NA	0.57	6.31	0.33	8.85e-10	World class endurance athleticism;
LUSC	cis	rs6700896	0.522	rs4655778	chr1:66142336	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.51	6.03	0.31	4.25e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.57	-0.42	3.92e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg20307385	chr11:47447363	PSMC3	-0.48	-6.12	-0.32	2.67e-9	Subjective well-being;
LUSC	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg07636037	chr3:49044803	WDR6	0.55	5.69	0.3	2.82e-8	Menarche (age at onset);
LUSC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg16240275	chr20:61666158	NCRNA00029	0.41	9.22	0.45	3.5e-18	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg20203395	chr5:56204925	C5orf35	-0.75	-10.33	-0.49	6.65e-22	Initial pursuit acceleration;
LUSC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg26441486	chr22:50317300	CRELD2	0.52	7.91	0.4	3.74e-14	Schizophrenia;
LUSC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg22823121	chr1:150693482	HORMAD1	0.54	8.44	0.42	9.59e-16	Tonsillectomy;
LUSC	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg24675056	chr1:15929824	NA	0.47	8.23	0.41	4.38e-15	Systolic blood pressure;
LUSC	cis	rs870825	0.616	rs55674580	chr4:185626605	C/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.25	0.59	1.77e-32	Blood protein levels;
LUSC	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.1	0.58	6.37e-32	Total body bone mineral density;
LUSC	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg24687543	chr11:63912206	MACROD1	0.47	5.96	0.31	6.34e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg19468946	chr17:37922297	IKZF3	-0.45	-7.08	-0.36	8.37e-12	Self-reported allergy;
LUSC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00339695	chr16:24857497	SLC5A11	0.6	9.59	0.46	2.1e-19	Intelligence (multi-trait analysis);
LUSC	trans	rs7916697	0.540	rs4551651	chr10:70024529	A/G	cg04882175	chr6:131122610	NA	-0.48	-6.55	-0.34	2.18e-10	Optic disc area;
LUSC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	7.99	0.4	2.24e-14	Prudent dietary pattern;
LUSC	trans	rs7737355	1.000	rs7719126	chr5:130613749	T/C	cg07715041	chr7:99302981	CYP3A7	-0.39	-6.14	-0.32	2.3e-9	Life satisfaction;
LUSC	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg27432699	chr2:27873401	GPN1	-0.57	-8.46	-0.42	8.53e-16	Total body bone mineral density;
LUSC	cis	rs6700896	0.500	rs7549647	chr1:66088184	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	6.31	0.33	8.83e-10	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg13798780	chr7:105162888	PUS7	0.58	6.32	0.33	8.2e-10	Bipolar disorder (body mass index interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09898138	chr12:120426550	CCDC64	0.45	6.02	0.31	4.67e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.19	-0.45	4.18e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg25214090	chr10:38739885	LOC399744	0.55	8.02	0.4	1.87e-14	Corneal astigmatism;
LUSC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15541040	chr2:3486749	NA	-0.56	-9.07	-0.44	1.04e-17	Neurofibrillary tangles;
LUSC	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg01294253	chr9:136912663	BRD3	0.34	6.03	0.31	4.34e-9	Platelet distribution width;
LUSC	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg05861140	chr6:150128134	PCMT1	-0.42	-6.58	-0.34	1.81e-10	Lung cancer;
LUSC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.15	0.32	2.17e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg22676075	chr6:135203613	NA	0.55	8.77	0.43	9.23e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.85	12.22	0.56	1.22e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26994227	chr5:130971071	RAPGEF6	-0.59	-6.97	-0.36	1.67e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-6.93	-0.35	2.12e-11	Prudent dietary pattern;
LUSC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg05084668	chr3:125655381	ALG1L	-0.49	-7.01	-0.36	1.33e-11	Blood pressure (smoking interaction);
LUSC	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg26384229	chr12:38710491	ALG10B	0.5	7.24	0.37	3.16e-12	Morning vs. evening chronotype;
LUSC	cis	rs4843185	0.576	rs380996	chr16:85728813	A/G	cg26571870	chr16:85723150	GINS2	0.34	6.52	0.34	2.57e-10	Platelet distribution width;
LUSC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.41	0.56	2.39e-29	Prudent dietary pattern;
LUSC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25072359	chr17:41440525	NA	0.63	8.9	0.44	3.61e-17	Menopause (age at onset);
LUSC	cis	rs4845875	0.530	rs6667720	chr1:11831615	A/G	cg14194983	chr1:11908298	NPPA	-0.32	-5.73	-0.3	2.19e-8	Midregional pro atrial natriuretic peptide levels;
LUSC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg04518342	chr5:131593106	PDLIM4	0.55	10.41	0.49	3.66e-22	Acylcarnitine levels;
LUSC	cis	rs981844	0.890	rs62325115	chr4:154694847	A/G	cg14289246	chr4:154710475	SFRP2	0.54	6.81	0.35	4.52e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg01420254	chr6:26195488	NA	0.71	7.5	0.38	5.86e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg01879757	chr17:41196368	BRCA1	-0.5	-7.93	-0.4	3.29e-14	Menopause (age at onset);
LUSC	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg12463550	chr7:65579703	CRCP	0.47	6.77	0.35	5.98e-11	Aortic root size;
LUSC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg00409905	chr10:38381863	ZNF37A	-0.36	-6.17	-0.32	2.03e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4776059	0.798	rs4774634	chr15:52872488	G/C	cg22715398	chr15:52968154	KIAA1370	-0.63	-8.48	-0.42	7.43e-16	Schizophrenia;
LUSC	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg09307838	chr4:120376055	NA	0.64	9.64	0.47	1.4e-19	Corneal astigmatism;
LUSC	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg13206674	chr6:150067644	NUP43	0.6	9.38	0.46	1.07e-18	Lung cancer;
LUSC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg24829409	chr8:58192753	C8orf71	-0.58	-6.49	-0.33	3.04e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	11.22	0.52	5.35e-25	Lung cancer in ever smokers;
LUSC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg02153584	chr22:29168773	CCDC117	0.6	8.79	0.43	8.24e-17	Lymphocyte counts;
LUSC	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg27539214	chr16:67997921	SLC12A4	-0.5	-6.72	-0.35	7.83e-11	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg06500355	chr6:111804104	REV3L	0.52	6.26	0.32	1.22e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-9.23	-0.45	3.2e-18	Monocyte count;
LUSC	cis	rs6599077	1.000	rs59425991	chr3:40089986	C/A	cg13683864	chr3:40499215	RPL14	-0.59	-7.63	-0.39	2.51e-13	Sleep-related phenotypes;
LUSC	cis	rs9378688	0.654	rs2505660	chr6:2326441	A/G	cg12303981	chr6:2244766	GMDS	-0.41	-5.79	-0.3	1.63e-8	Caudate nucleus volume;
LUSC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-7.15	-0.36	5.38e-12	Bipolar disorder;
LUSC	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.35	-0.49	5.87e-22	Eye color traits;
LUSC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.87	16.93	0.68	7.19e-47	Mean platelet volume;
LUSC	cis	rs72960926	0.744	rs72952273	chr6:74926284	C/T	cg03266952	chr6:74778945	NA	-0.73	-6.47	-0.33	3.56e-10	Metabolite levels (MHPG);
LUSC	cis	rs11055008	0.620	rs12816452	chr12:12833006	A/T	cg09462578	chr12:12878428	APOLD1	-0.43	-6.58	-0.34	1.78e-10	Pulse pressure;
LUSC	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg09035930	chr12:129282057	SLC15A4	0.52	9.45	0.46	6.29e-19	Systemic lupus erythematosus;
LUSC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.89	0.48	2.14e-20	Bipolar disorder;
LUSC	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg21427119	chr20:30132790	HM13	-0.36	-5.65	-0.3	3.35e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs4663866	0.908	rs2304670	chr2:239165636	C/T	cg16914508	chr2:239161102	PER2	0.67	7.23	0.37	3.26e-12	Irritable bowel syndrome;
LUSC	trans	rs2490361	1.000	rs2490361	chr1:237326974	C/T	cg15653282	chr18:11689218	GNAL	0.39	5.98	0.31	5.86e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	16.07	0.66	1.94e-43	Platelet count;
LUSC	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg10018233	chr7:150070692	REPIN1	0.39	7.1	0.36	7.54e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs7523273	0.606	rs2724380	chr1:207949682	C/T	cg22525895	chr1:207977042	MIR29B2	0.42	6.72	0.35	7.81e-11	Schizophrenia;
LUSC	cis	rs295137	0.799	rs4145969	chr2:201139961	C/T	cg23649088	chr2:200775458	C2orf69	-0.38	-5.9	-0.31	8.78e-9	Asthma (bronchodilator response);
LUSC	cis	rs72960926	0.744	rs1817735	chr6:74980974	T/C	cg03266952	chr6:74778945	NA	-0.87	-7.19	-0.37	4.34e-12	Metabolite levels (MHPG);
LUSC	cis	rs12956009	0.558	rs12960592	chr18:44857203	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.27	0.32	1.09e-9	Educational attainment (years of education);
LUSC	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg01475377	chr6:109611718	NA	-0.39	-7.09	-0.36	7.95e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg11062466	chr8:58055876	NA	0.65	8.48	0.42	7.17e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.86	-15.12	-0.64	1.07e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg07507251	chr3:52567010	NT5DC2	-0.31	-6.39	-0.33	5.66e-10	Electroencephalogram traits;
LUSC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22029157	chr1:209979665	IRF6	0.76	11.32	0.53	2.24e-25	Cleft lip with or without cleft palate;
LUSC	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg21724239	chr8:58056113	NA	0.67	7.43	0.38	9.33e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs240764	0.658	rs9399694	chr6:101257877	A/G	cg09795085	chr6:101329169	ASCC3	-0.46	-6.51	-0.34	2.71e-10	Neuroticism;
LUSC	cis	rs17621444	0.522	rs4752369	chr10:121775790	G/A	cg02041677	chr10:121771263	NA	-0.34	-6.47	-0.33	3.53e-10	IgG glycosylation;
LUSC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg26304593	chr6:42947056	PEX6	-0.52	-7.89	-0.4	4.47e-14	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-1.17	-18.09	-0.7	1.88e-51	Initial pursuit acceleration;
LUSC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg22437258	chr11:111473054	SIK2	0.53	7.53	0.38	4.93e-13	Primary sclerosing cholangitis;
LUSC	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.38	6.49	0.33	3.05e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs12618769	0.597	rs4850874	chr2:99069799	G/A	cg10123293	chr2:99228465	UNC50	0.45	7.58	0.38	3.33e-13	Bipolar disorder;
LUSC	cis	rs4595586	0.679	rs1356264	chr12:39393754	A/T	cg26384229	chr12:38710491	ALG10B	0.43	5.93	0.31	7.46e-9	Morning vs. evening chronotype;
LUSC	cis	rs9472414	0.771	rs562016	chr6:44780978	G/A	cg20913747	chr6:44695427	NA	-0.4	-5.77	-0.3	1.85e-8	Height;
LUSC	cis	rs12760731	0.582	rs9803679	chr1:178410425	T/C	cg00404053	chr1:178313656	RASAL2	0.48	5.76	0.3	1.91e-8	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03517284	chr6:25882590	NA	-0.51	-9.58	-0.46	2.35e-19	Blood metabolite levels;
LUSC	cis	rs12543645	0.598	rs35338507	chr8:10277982	G/A	cg12940923	chr8:10282607	MSRA	0.41	7.12	0.36	6.83e-12	Schizophrenia;
LUSC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg03116740	chr11:841335	TSPAN4;POLR2L	-0.42	-6.7	-0.34	9.03e-11	Mean platelet volume;
LUSC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-10.92	-0.51	6.22e-24	Gut microbiome composition (summer);
LUSC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	6.53	0.34	2.41e-10	Electroencephalogram traits;
LUSC	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-10.64	-0.5	5.77e-23	Coffee consumption (cups per day);
LUSC	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg15921436	chr17:44337874	NA	0.73	11.08	0.52	1.63e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-6.0	-0.31	5.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6546550	0.658	rs10186725	chr2:70015491	A/G	cg02498382	chr2:70120550	SNRNP27	-0.25	-6.1	-0.32	2.93e-9	Prevalent atrial fibrillation;
LUSC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg22143856	chr6:28129313	ZNF389	0.41	5.68	0.3	2.98e-8	Parkinson's disease;
LUSC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg11752832	chr7:134001865	SLC35B4	0.56	8.8	0.43	7.57e-17	Mean platelet volume;
LUSC	cis	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg02751453	chr18:77725136	HSBP1L1	0.41	5.73	0.3	2.25e-8	Opioid sensitivity;
LUSC	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-6.83	-0.35	3.95e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	trans	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg18335740	chr13:41363409	SLC25A15	0.5	7.8	0.39	7.81e-14	Lewy body disease;
LUSC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg22166914	chr1:53195759	ZYG11B	0.7	12.05	0.55	5.41e-28	Monocyte count;
LUSC	cis	rs1865721	0.771	rs4622605	chr18:73139008	T/C	cg26385618	chr18:73139727	C18orf62	-0.55	-10.11	-0.48	3.98e-21	Intelligence;
LUSC	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg01884057	chr2:25150051	NA	0.48	11.42	0.53	1e-25	Body mass index;
LUSC	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg03585969	chr10:35415529	CREM	0.6	8.74	0.43	1.12e-16	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs13401104	0.796	rs10929172	chr2:237116600	C/G	cg19324714	chr2:237145437	ASB18	0.43	5.65	0.3	3.43e-8	Educational attainment;
LUSC	cis	rs3736594	0.513	rs62138968	chr2:27824485	C/G	cg27432699	chr2:27873401	GPN1	0.65	8.74	0.43	1.17e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-1.04	-20.1	-0.74	1.79e-59	Height;
LUSC	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg11502198	chr6:26597334	ABT1	0.72	12.09	0.55	3.67e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	0.97	13.27	0.59	1.45e-32	Eosinophil percentage of granulocytes;
LUSC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	9.9	0.48	1.98e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg24579218	chr15:68104479	NA	-0.39	-6.7	-0.34	8.86e-11	Obesity;
LUSC	cis	rs72772090	0.539	rs11747896	chr5:96113397	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.68	7.04	0.36	1.1e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.42	5.75	0.3	1.98e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg16928487	chr17:17741425	SREBF1	-0.43	-8.55	-0.42	4.5e-16	Total body bone mineral density;
LUSC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg10130564	chr11:117069849	TAGLN	-0.39	-6.64	-0.34	1.24e-10	Blood protein levels;
LUSC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.13	0.36	6.11e-12	Cognitive ability;
LUSC	cis	rs2012796	0.872	rs59397507	chr14:81821334	A/G	cg02996355	chr14:81879375	NA	0.51	7.22	0.37	3.62e-12	Night sleep phenotypes;
LUSC	trans	rs657452	0.722	rs1494461	chr1:49787196	A/G	cg02399189	chr10:45470562	RASSF4	0.42	6.14	0.32	2.31e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg22782873	chr19:19639568	YJEFN3	-0.51	-6.05	-0.31	3.78e-9	Bipolar disorder;
LUSC	cis	rs2324229	0.861	rs1180198	chr6:83959048	C/T	cg08257003	chr6:84140564	ME1	0.27	5.92	0.31	7.93e-9	Platelet-derived growth factor BB levels;
LUSC	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg12863693	chr15:85201151	NMB	0.34	6.82	0.35	4.35e-11	Schizophrenia;
LUSC	cis	rs4474465	0.850	rs4944203	chr11:78220629	A/C	cg27205649	chr11:78285834	NARS2	0.49	5.69	0.3	2.74e-8	Alzheimer's disease (survival time);
LUSC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.84	-15.34	-0.64	1.37e-40	Dental caries;
LUSC	cis	rs2692947	0.770	rs11689832	chr2:96554851	A/C	cg22654517	chr2:96458247	NA	0.37	6.92	0.35	2.38e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2219968	0.676	rs55878309	chr8:78839853	A/G	cg00738934	chr8:78996279	NA	-0.35	-5.94	-0.31	6.98e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg13565492	chr6:43139072	SRF	-0.62	-6.6	-0.34	1.63e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11051970	0.918	rs325417	chr12:32574217	A/G	cg02745156	chr12:32552066	NA	0.43	7.32	0.37	1.84e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg04865166	chr7:105162814	PUS7	0.51	5.69	0.3	2.84e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg08999081	chr20:33150536	PIGU	0.36	6.68	0.34	9.88e-11	Height;
LUSC	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg18721089	chr20:30220636	NA	-0.39	-6.08	-0.32	3.28e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg24642439	chr20:33292090	TP53INP2	0.41	6.0	0.31	5.07e-9	Height;
LUSC	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg06636001	chr8:8085503	FLJ10661	0.67	11.29	0.53	3.02e-25	Mood instability;
LUSC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10802521	chr3:52805072	NEK4	-0.54	-8.63	-0.43	2.6e-16	Bipolar disorder;
LUSC	cis	rs711244	0.748	rs11124555	chr2:37176213	G/A	cg14987922	chr2:37194071	STRN	0.42	6.15	0.32	2.22e-9	Mean platelet volume;
LUSC	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg26102564	chr10:131424627	MGMT	0.42	6.33	0.33	7.79e-10	Response to temozolomide;
LUSC	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg19653624	chr11:20408972	PRMT3	-0.67	-8.44	-0.42	9.97e-16	Pursuit maintenance gain;
LUSC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg00800038	chr16:89945340	TCF25	-0.75	-6.56	-0.34	2.08e-10	Skin colour saturation;
LUSC	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	8.41	0.42	1.25e-15	Menarche (age at onset);
LUSC	cis	rs2299587	0.527	rs7843715	chr8:17733526	C/A	cg01800426	chr8:17659068	MTUS1	-0.39	-5.65	-0.3	3.43e-8	Economic and political preferences;
LUSC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg03146154	chr1:46216737	IPP	-0.57	-8.28	-0.41	3e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs593982	1.000	rs56257941	chr11:65505641	C/T	cg08755490	chr11:65554678	OVOL1	-1.46	-15.35	-0.64	1.35e-40	Atopic dermatitis;
LUSC	trans	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg25214090	chr10:38739885	LOC399744	0.41	6.29	0.33	9.72e-10	Educational attainment;
LUSC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.55	0.57	7.61e-30	Motion sickness;
LUSC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.8	13.66	0.6	4.54e-34	Systolic blood pressure;
LUSC	trans	rs2018683	0.803	rs12700920	chr7:28984924	A/G	cg19402173	chr7:128379420	CALU	-0.54	-8.6	-0.43	3.22e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.81	0.47	4.02e-20	Bipolar disorder;
LUSC	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg25457927	chr22:38595422	NA	-0.42	-8.92	-0.44	3.05e-17	Cutaneous nevi;
LUSC	cis	rs9403521	1.000	rs12528456	chr6:144003706	A/G	cg18240653	chr6:144019428	PHACTR2	-0.51	-6.16	-0.32	2.11e-9	Obesity-related traits;
LUSC	cis	rs9399401	0.633	rs1329705	chr6:142753338	G/A	cg03128060	chr6:142623767	GPR126	0.51	8.35	0.42	1.8e-15	Chronic obstructive pulmonary disease;
LUSC	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg16989719	chr2:238392110	NA	-0.47	-7.19	-0.37	4.33e-12	Prostate cancer;
LUSC	cis	rs6460942	1.000	rs6460942	chr7:12420989	T/C	cg20607287	chr7:12443886	VWDE	-0.62	-6.2	-0.32	1.69e-9	Coronary artery disease;
LUSC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-1.05	-16.06	-0.66	2.08e-43	Initial pursuit acceleration;
LUSC	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.79	11.36	0.53	1.63e-25	Corneal astigmatism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg17144508	chr2:128283727	IWS1	-0.46	-5.98	-0.31	5.72e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg25036284	chr2:26402008	FAM59B	-0.76	-10.98	-0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg25387593	chr11:118927868	HYOU1	0.5	6.0	0.31	5.2e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg21045802	chr8:109455806	TTC35	0.5	7.8	0.39	8.14e-14	Dupuytren's disease;
LUSC	cis	rs1853665	0.669	rs4368824	chr6:150269299	T/A	cg04697775	chr6:150285333	ULBP1	0.52	5.67	0.3	3.11e-8	Radiation response;
LUSC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-7.67	-0.39	1.89e-13	Joint mobility (Beighton score);
LUSC	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-24.66	-0.8	3.21e-77	Myeloid white cell count;
LUSC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	12.98	0.58	1.83e-31	Cognitive test performance;
LUSC	cis	rs11018904	0.861	rs4589254	chr11:89963355	A/C	cg26028595	chr11:89956573	CHORDC1	0.49	5.86	0.31	1.12e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11764359	chr7:65958608	NA	0.68	10.96	0.51	4.39e-24	Aortic root size;
LUSC	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg03647239	chr10:116582469	FAM160B1	0.44	7.15	0.36	5.58e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08219700	chr8:58056026	NA	0.72	8.47	0.42	8.07e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg09754948	chr16:28834200	ATXN2L	0.4	5.66	0.3	3.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg12454169	chr2:30669597	LCLAT1	0.63	8.54	0.42	4.91e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23158103	chr7:148848205	ZNF398	-0.49	-8.02	-0.4	1.74e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6782228	0.606	rs2712417	chr3:128345179	A/G	cg16766828	chr3:128327626	NA	-0.31	-5.66	-0.3	3.3e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
LUSC	cis	rs1160297	0.609	rs10203699	chr2:53105568	A/G	cg07782112	chr2:53107842	NA	0.39	6.62	0.34	1.45e-10	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg17724175	chr1:150552817	MCL1	0.36	6.53	0.34	2.45e-10	Tonsillectomy;
LUSC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.47	-6.74	-0.35	7.05e-11	Platelet count;
LUSC	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg22681709	chr2:178499509	PDE11A	-0.58	-11.37	-0.53	1.48e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	trans	rs61931739	0.620	rs1905241	chr12:33709729	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-6.03	-0.31	4.32e-9	Morning vs. evening chronotype;
LUSC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg02038168	chr22:39784481	NA	-0.44	-6.59	-0.34	1.75e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs3096299	0.702	rs2086825	chr16:89471542	C/T	cg06640241	chr16:89574553	SPG7	0.52	7.85	0.39	5.86e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	0.93	15.97	0.66	4.83e-43	Menopause (age at onset);
LUSC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.64	0.5	5.84e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg21905437	chr5:178450457	ZNF879	0.43	5.67	0.3	3.1e-8	Pubertal anthropometrics;
LUSC	cis	rs2688608	0.967	rs9971040	chr10:75661162	G/C	cg23231163	chr10:75533350	FUT11	-0.37	-5.96	-0.31	6.29e-9	Inflammatory bowel disease;
LUSC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg13010344	chr12:123464640	ARL6IP4	0.41	6.31	0.33	8.93e-10	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg18758796	chr5:131593413	PDLIM4	0.38	6.48	0.33	3.29e-10	Breast cancer;
LUSC	cis	rs7615316	0.528	rs75274088	chr3:142337804	G/A	cg16271453	chr3:142027066	XRN1	-0.45	-7.9	-0.4	4.21e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	7.03	0.36	1.18e-11	Multiple sclerosis;
LUSC	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg01629716	chr15:45996671	NA	0.4	6.09	0.32	3.17e-9	Waist circumference;Weight;
LUSC	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg25214090	chr10:38739885	LOC399744	0.55	8.15	0.41	7.22e-15	Corneal astigmatism;
LUSC	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg04998671	chr14:104000505	TRMT61A	-0.47	-7.29	-0.37	2.23e-12	Coronary artery disease;
LUSC	cis	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg18131467	chr2:239335373	ASB1	-0.73	-6.63	-0.34	1.36e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg23711669	chr6:146136114	FBXO30	0.86	15.52	0.65	2.69e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg04166393	chr7:2884313	GNA12	0.41	5.66	0.3	3.19e-8	Height;
LUSC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg06145435	chr7:1022769	CYP2W1	0.3	6.23	0.32	1.37e-9	Longevity;Endometriosis;
LUSC	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg04155231	chr12:9217510	LOC144571	0.3	5.66	0.3	3.26e-8	Sjögren's syndrome;
LUSC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.86	-11.07	-0.52	1.83e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03934478	chr11:495069	RNH1	0.9	10.35	0.49	5.81e-22	Body mass index;
LUSC	cis	rs4746822	0.954	rs5030937	chr10:70975897	C/T	cg14418922	chr10:70824840	NA	-0.38	-6.22	-0.32	1.47e-9	Glycemic traits (pregnancy);
LUSC	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg01368799	chr11:117014884	PAFAH1B2	0.58	8.88	0.44	4.2e-17	Blood protein levels;
LUSC	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03168497	chr17:48586147	MYCBPAP	-0.48	-6.44	-0.33	4.19e-10	Visceral fat;
LUSC	cis	rs6494488	0.500	rs72742972	chr15:64934117	C/T	cg08069370	chr15:64387884	SNX1	-0.66	-5.78	-0.3	1.7e-8	Coronary artery disease;
LUSC	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg04998671	chr14:104000505	TRMT61A	-0.46	-7.18	-0.37	4.47e-12	Coronary artery disease;
LUSC	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg00750074	chr16:89608354	SPG7	-0.45	-7.86	-0.4	5.41e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	11.49	0.53	5.61e-26	Ileal carcinoids;
LUSC	trans	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.8	-0.43	7.56e-17	Obesity-related traits;
LUSC	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.26	-0.32	1.18e-9	Menopause (age at onset);
LUSC	cis	rs4561483	0.801	rs33649	chr16:11979608	G/C	cg08843971	chr16:11963173	GSPT1	-0.48	-7.13	-0.36	6.06e-12	Testicular germ cell tumor;
LUSC	cis	rs2742540	0.505	rs2742493	chr11:8967592	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.36	6.48	0.33	3.27e-10	Hematocrit;
LUSC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-1.12	-24.88	-0.81	4.68e-78	Height;
LUSC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg01802117	chr1:53393560	SCP2	-0.43	-7.19	-0.37	4.19e-12	Monocyte count;
LUSC	cis	rs1178968	0.901	rs4717752	chr7:72754237	A/T	cg25889504	chr7:72793014	NA	0.59	8.07	0.4	1.24e-14	Triglyceride levels;
LUSC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg02423579	chr7:2872169	GNA12	-0.47	-6.63	-0.34	1.38e-10	Height;
LUSC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg18225595	chr11:63971243	STIP1	-0.46	-5.68	-0.3	2.98e-8	Mean platelet volume;
LUSC	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.86	-15.36	-0.64	1.19e-40	Ulcerative colitis;
LUSC	cis	rs10761482	0.769	rs10740024	chr10:62100840	G/A	cg18175470	chr10:62150864	ANK3	-0.5	-7.15	-0.36	5.53e-12	Schizophrenia;
LUSC	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg13010199	chr12:38710504	ALG10B	0.68	10.53	0.5	1.37e-22	Morning vs. evening chronotype;
LUSC	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg05729581	chr11:3078854	CARS	0.39	5.7	0.3	2.67e-8	Calcium levels;
LUSC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.9	16.2	0.66	5.81e-44	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10489202	1.000	rs275157	chr1:168064178	T/C	cg24449463	chr1:168025552	DCAF6	-0.58	-7.16	-0.36	5.18e-12	Schizophrenia;
LUSC	cis	rs11264213	0.901	rs72661628	chr1:36406547	A/G	cg27506609	chr1:36549197	TEKT2	0.68	7.88	0.4	4.58e-14	Schizophrenia;
LUSC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg08132940	chr7:1081526	C7orf50	-0.52	-6.22	-0.32	1.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg00074818	chr8:8560427	CLDN23	-0.57	-9.65	-0.47	1.39e-19	Obesity-related traits;
LUSC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg21724239	chr8:58056113	NA	0.76	8.2	0.41	5.29e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg06618935	chr21:46677482	NA	-0.39	-7.91	-0.4	3.72e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16405210	chr4:1374714	KIAA1530	-0.65	-10.22	-0.49	1.62e-21	Longevity;
LUSC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.13	16.21	0.66	5.12e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg15145296	chr3:125709740	NA	-0.58	-6.56	-0.34	2.03e-10	Blood pressure (smoking interaction);
LUSC	cis	rs9296092	0.538	rs7761268	chr6:33519300	C/T	cg13560919	chr6:33536144	NA	-0.82	-15.68	-0.65	6.59e-42	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg07393940	chr7:158741817	NA	0.36	6.5	0.34	2.84e-10	Life satisfaction;
LUSC	cis	rs2067615	0.579	rs10861655	chr12:107129419	A/G	cg15890332	chr12:107067104	RFX4	-0.35	-6.3	-0.33	9.66e-10	Heart rate;
LUSC	cis	rs12681287	0.547	rs6471360	chr8:87513469	C/T	cg27223183	chr8:87520930	FAM82B	0.56	7.45	0.38	7.88e-13	Caudate activity during reward;
LUSC	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg14343924	chr8:8086146	FLJ10661	0.45	6.23	0.32	1.39e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg06784218	chr1:46089804	CCDC17	-0.48	-9.23	-0.45	3.17e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg12062639	chr20:23401060	NAPB	0.97	8.29	0.41	2.76e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs6445525	1.000	rs4416407	chr3:65995747	T/C	cg12639933	chr12:57626296	SHMT2	0.34	6.24	0.32	1.3e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg14773178	chr5:1868261	NA	0.32	5.82	0.3	1.4e-8	Cardiovascular disease risk factors;
LUSC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.58	10.66	0.5	4.78e-23	Homoarginine levels;
LUSC	cis	rs9420	0.961	rs12804972	chr11:57463767	T/C	cg02958346	chr11:57425731	CLP1	-0.44	-6.45	-0.33	4.02e-10	Schizophrenia;
LUSC	cis	rs12760731	0.565	rs11583144	chr1:178222070	C/G	cg00404053	chr1:178313656	RASAL2	0.67	6.92	0.35	2.33e-11	Obesity-related traits;
LUSC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg11366901	chr6:160182831	ACAT2	0.96	13.17	0.58	3.4e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.16	0.52	8.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10266483	0.739	rs2692099	chr7:63767762	G/C	cg24201672	chr7:64023550	ZNF680	-0.49	-6.5	-0.34	2.9e-10	Response to statin therapy;
LUSC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg08470875	chr2:26401718	FAM59B	0.63	8.21	0.41	4.98e-15	Gut microbiome composition (summer);
LUSC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.68	11.53	0.53	4.19e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.71	9.13	0.45	6.6e-18	Gut microbiome composition (summer);
LUSC	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg16230307	chr14:35515116	FAM177A1	0.78	9.88	0.48	2.39e-20	Psoriasis;
LUSC	trans	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg09050820	chr6:167586206	TCP10L2	0.74	9.55	0.46	2.82e-19	Gastritis;
LUSC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06634786	chr22:41940651	POLR3H	-0.54	-6.15	-0.32	2.25e-9	Vitiligo;
LUSC	trans	rs59614420	1.000	rs59614420	chr6:161129013	G/A	cg00639886	chr12:54943102	PDE1B	-0.42	-6.17	-0.32	1.99e-9	Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms;
LUSC	cis	rs6977660	0.714	rs12333747	chr7:19814394	G/A	cg05791153	chr7:19748676	TWISTNB	0.7	7.45	0.38	8.29e-13	Thyroid stimulating hormone;
LUSC	cis	rs7106204	0.609	rs16912369	chr11:24297601	C/T	ch.11.24196551F	chr11:24239977	NA	0.69	5.74	0.3	2.14e-8	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs10740039	1.000	rs10994460	chr10:62418791	G/A	cg18175470	chr10:62150864	ANK3	-0.44	-6.94	-0.36	2.02e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6714710	0.580	rs11680018	chr2:98479581	C/A	cg26665480	chr2:98280029	ACTR1B	0.6	8.81	0.43	6.85e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg11244672	chr19:19639970	YJEFN3	0.61	7.56	0.38	4.04e-13	Bipolar disorder;
LUSC	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.4	-6.07	-0.32	3.51e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg13722127	chr7:150037890	RARRES2	0.4	5.96	0.31	6.24e-9	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.8	13.42	0.59	3.9e-33	Menarche (age at onset);
LUSC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	0.92	17.54	0.69	2.67e-49	Cognitive function;
LUSC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg18180107	chr4:99064573	C4orf37	-0.43	-6.12	-0.32	2.59e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7605827	0.791	rs2042146	chr2:15479372	T/A	cg19274914	chr2:15703543	NA	0.44	8.46	0.42	8.7e-16	Educational attainment (years of education);
LUSC	cis	rs35000415	0.938	rs13239597	chr7:128695983	C/A	cg19972273	chr7:128594194	NA	0.63	5.72	0.3	2.34e-8	Systemic lupus erythematosus;
LUSC	trans	rs76248362	0.786	rs9580768	chr13:24436910	T/A	cg26511321	chr7:27196790	HOXA7	0.54	6.24	0.32	1.35e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg18850127	chr7:39170497	POU6F2	0.65	10.27	0.49	1.1e-21	IgG glycosylation;
LUSC	cis	rs10504229	0.516	rs11781671	chr8:57992733	T/C	cg22535103	chr8:58192502	C8orf71	-0.49	-6.43	-0.33	4.5e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg13902645	chr11:5959945	NA	-0.61	-8.48	-0.42	7.35e-16	DNA methylation (variation);
LUSC	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.89	15.05	0.64	2.03e-39	Bladder cancer;
LUSC	trans	rs3857536	0.813	rs7769683	chr6:66946256	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg05855489	chr10:104503620	C10orf26	0.58	9.29	0.45	2.07e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg03929089	chr4:120376271	NA	0.61	6.5	0.34	2.97e-10	Axial length;
LUSC	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-7.44	-0.38	8.55e-13	Putamen volume;
LUSC	trans	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg13565492	chr6:43139072	SRF	-0.63	-6.57	-0.34	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg08807101	chr21:30365312	RNF160	-0.54	-6.85	-0.35	3.48e-11	Cognitive test performance;
LUSC	cis	rs1007190	0.881	rs11079378	chr17:42957462	A/G	cg15406952	chr17:42872593	NA	0.55	5.68	0.3	2.97e-8	DNA methylation (variation);
LUSC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg02079420	chr8:82753780	SNX16	0.39	6.05	0.31	3.83e-9	Diastolic blood pressure;
LUSC	cis	rs1847202	0.859	rs13096870	chr3:72948172	G/A	cg25664220	chr3:72788482	NA	-0.42	-7.5	-0.38	5.69e-13	Motion sickness;
LUSC	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg24342717	chr2:85555507	TGOLN2	-0.74	-11.93	-0.55	1.44e-27	Ear protrusion;
LUSC	cis	rs977987	0.806	rs4888386	chr16:75389740	A/G	cg03315344	chr16:75512273	CHST6	0.54	10.37	0.49	5.04e-22	Dupuytren's disease;
LUSC	cis	rs56399783	0.901	rs73033403	chr7:2877941	G/A	cg14895029	chr7:2775587	GNA12	0.52	6.3	0.33	9.29e-10	Childhood ear infection;
LUSC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.68	0.47	1.11e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg03233332	chr7:66118400	NA	-0.42	-6.04	-0.31	4.06e-9	Aortic root size;
LUSC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24110177	chr3:50126178	RBM5	-0.56	-9.19	-0.45	4.18e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs10740039	0.516	rs2068042	chr10:62320293	C/T	cg18175470	chr10:62150864	ANK3	-0.45	-6.89	-0.35	2.87e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-7.16	-0.36	5.25e-12	Daytime sleep phenotypes;
LUSC	cis	rs7192380	0.895	rs2917671	chr16:69758741	A/T	cg26679644	chr16:69762563	NA	-0.34	-5.74	-0.3	2.09e-8	Sjögren's syndrome;
LUSC	trans	rs2147904	1.000	rs2147904	chr1:42371414	C/T	cg00436174	chr2:128051630	ERCC3	0.35	6.12	0.32	2.63e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
LUSC	cis	rs9341808	0.519	rs684251	chr6:80967337	G/A	cg08355045	chr6:80787529	NA	-0.41	-7.01	-0.36	1.29e-11	Sitting height ratio;
LUSC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-12.92	-0.58	3.12e-31	Chronic sinus infection;
LUSC	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	8.71	0.43	1.44e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs2274273	0.870	rs7153645	chr14:55771518	C/G	cg04306507	chr14:55594613	LGALS3	0.54	12.08	0.55	3.86e-28	Protein biomarker;
LUSC	cis	rs12681287	0.752	rs13262673	chr8:87293600	G/A	cg27223183	chr8:87520930	FAM82B	-0.46	-5.86	-0.31	1.13e-8	Caudate activity during reward;
LUSC	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg16482183	chr6:26056742	HIST1H1C	1.07	13.68	0.6	3.98e-34	Iron status biomarkers;
LUSC	cis	rs7707921	0.881	rs12108833	chr5:81371755	A/G	cg15871215	chr5:81402204	ATG10	-0.44	-6.53	-0.34	2.41e-10	Breast cancer;
LUSC	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg03522245	chr20:25566470	NINL	-0.35	-5.78	-0.3	1.68e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg08085267	chr17:45401833	C17orf57	-0.56	-8.55	-0.42	4.51e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs367943	0.712	rs10042223	chr5:112712832	C/T	cg12552261	chr5:112820674	MCC	0.37	6.18	0.32	1.88e-9	Type 2 diabetes;
LUSC	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg22676075	chr6:135203613	NA	0.46	7.13	0.36	6.1e-12	Red blood cell count;
LUSC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg23172400	chr8:95962367	TP53INP1	-0.4	-8.09	-0.4	1.12e-14	Type 2 diabetes;
LUSC	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg20129853	chr10:51489980	NA	0.36	7.4	0.38	1.14e-12	Prostate-specific antigen levels;
LUSC	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg13042288	chr15:90349979	ANPEP	-0.47	-6.45	-0.33	3.97e-10	Uric acid levels;
LUSC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	12.87	0.58	4.7e-31	Cognitive test performance;
LUSC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.45	0.38	7.82e-13	Motion sickness;
LUSC	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg18512352	chr11:47633146	NA	-0.47	-9.58	-0.46	2.37e-19	Subjective well-being;
LUSC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.58	-0.38	3.42e-13	Aortic root size;
LUSC	cis	rs427941	0.703	rs201451	chr7:101739550	G/A	cg06246474	chr7:101738831	CUX1	0.4	6.64	0.34	1.3100000000000001e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg12463550	chr7:65579703	CRCP	-0.52	-7.62	-0.38	2.63e-13	Aortic root size;
LUSC	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg27068330	chr11:65405492	SIPA1	0.64	9.66	0.47	1.28e-19	Acne (severe);
LUSC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg05347473	chr6:146136440	FBXO30	0.54	9.34	0.45	1.45e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	9.51	0.46	4.03e-19	Lung cancer in ever smokers;
LUSC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg08999081	chr20:33150536	PIGU	0.44	8.06	0.4	1.4e-14	Coronary artery disease;
LUSC	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.85	14.28	0.62	1.95e-36	Bladder cancer;
LUSC	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg05714579	chr10:131428358	MGMT	0.53	8.05	0.4	1.52e-14	Response to temozolomide;
LUSC	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg00129232	chr17:37814104	STARD3	-0.46	-6.9	-0.35	2.69e-11	Asthma;
LUSC	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.48	0.59	2.19e-33	Morning vs. evening chronotype;
LUSC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg26304593	chr6:42947056	PEX6	-0.54	-8.26	-0.41	3.53e-15	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	0.81	13.62	0.6	6.9e-34	Blood protein levels;
LUSC	trans	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.7	-7.45	-0.38	8.27e-13	Menarche (age at onset);
LUSC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg22705602	chr4:152727874	NA	-0.32	-6.54	-0.34	2.28e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg23887609	chr12:130822674	PIWIL1	0.48	6.85	0.35	3.46e-11	Menopause (age at onset);
LUSC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	0.92	13.9	0.61	5.47e-35	Breast cancer;
LUSC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg09165964	chr15:75287851	SCAMP5	0.52	7.59	0.38	3.32e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs742132	0.597	rs35676593	chr6:25596650	T/G	cg03517284	chr6:25882590	NA	0.42	5.72	0.3	2.41e-8	Uric acid levels;
LUSC	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.58	-8.76	-0.43	1.01e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg16647868	chr5:131706066	SLC22A5	-0.41	-5.83	-0.3	1.28e-8	Breast cancer;
LUSC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg04369109	chr6:150039330	LATS1	-0.55	-8.22	-0.41	4.54e-15	Lung cancer;
LUSC	cis	rs8027181	1.000	rs8030477	chr15:73085815	C/T	cg25632853	chr15:73088954	NA	0.35	6.96	0.36	1.86e-11	Triglyceride levels;
LUSC	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg06547715	chr2:218990976	CXCR2	0.33	6.59	0.34	1.76e-10	Ulcerative colitis;
LUSC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg26850624	chr5:429559	AHRR	-0.41	-8.0	-0.4	2.1e-14	Cystic fibrosis severity;
LUSC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.38e-12	Motion sickness;
LUSC	cis	rs12620999	1.000	rs12620999	chr2:238036367	C/T	cg23555395	chr2:238036564	NA	-0.53	-8.94	-0.44	2.77e-17	Systemic lupus erythematosus;
LUSC	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.71	-12.51	-0.56	1.02e-29	White blood cell count (basophil);
LUSC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg23093090	chr10:104574429	C10orf26	0.45	8.43	0.42	1.02e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg17366294	chr4:99064904	C4orf37	0.56	10.05	0.48	5.95e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg04287289	chr16:89883240	FANCA	0.78	13.88	0.6	6.54e-35	Vitiligo;
LUSC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg00933542	chr6:150070202	PCMT1	0.33	6.91	0.35	2.39e-11	Lung cancer;
LUSC	cis	rs7224314	1.000	rs7226214	chr17:65383323	C/T	cg01507342	chr17:65387096	PITPNC1	-0.44	-7.87	-0.4	4.95e-14	Diisocyanate-induced asthma;
LUSC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.83	15.26	0.64	3.02e-40	Dental caries;
LUSC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg10523679	chr1:76189770	ACADM	0.85	11.28	0.53	3.11e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg23093090	chr10:104574429	C10orf26	-0.37	-6.91	-0.35	2.51e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.43	-5.92	-0.31	8.14e-9	Renal function-related traits (BUN);
LUSC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.64	10.78	0.51	1.94e-23	Colorectal cancer;
LUSC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.43	-7.23	-0.37	3.39e-12	Prudent dietary pattern;
LUSC	cis	rs72634258	0.554	rs4562654	chr1:7934423	A/T	cg00042356	chr1:8021962	PARK7	0.63	7.22	0.37	3.51e-12	Inflammatory bowel disease;
LUSC	cis	rs7759001	0.857	rs4504471	chr6:27372242	C/T	cg18711553	chr6:27366782	ZNF391	0.39	5.73	0.3	2.25e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs11208691	0.513	rs60466849	chr1:66107714	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	6.36	0.33	6.62e-10	Lymphocyte percentage of white cells;
LUSC	cis	rs7106204	0.748	rs4360697	chr11:24217160	A/G	ch.11.24196551F	chr11:24239977	NA	1.14	14.08	0.61	1.09e-35	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg13939156	chr17:80058883	NA	0.34	6.54	0.34	2.35e-10	Life satisfaction;
LUSC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg15704280	chr7:45808275	SEPT13	0.78	7.55	0.38	4.31e-13	Axial length;
LUSC	cis	rs72949976	0.606	rs11898263	chr2:214030649	A/G	cg08319019	chr2:214017104	IKZF2	0.67	11.12	0.52	1.15e-24	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg16479474	chr6:28041457	NA	0.32	5.81	0.3	1.47e-8	Parkinson's disease;
LUSC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg00033643	chr7:134001901	SLC35B4	0.42	6.37	0.33	6.41e-10	Mean platelet volume;
LUSC	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.6	-0.43	3.05e-16	Total cholesterol levels;
LUSC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg23262073	chr20:60523788	NA	-0.42	-6.07	-0.32	3.45e-9	Body mass index;
LUSC	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg27246729	chr12:121163418	ACADS	0.47	7.51	0.38	5.56e-13	Mean corpuscular volume;
LUSC	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg20933634	chr6:27740509	NA	0.41	5.83	0.3	1.27e-8	Parkinson's disease;
LUSC	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.82	-0.51	1.41e-23	Alcohol dependence;
LUSC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.74	-12.79	-0.57	9.19e-31	Sudden cardiac arrest;
LUSC	cis	rs983392	0.642	rs636147	chr11:59957092	C/T	cg02771260	chr11:59836817	MS4A3	0.35	5.98	0.31	5.71e-9	Alzheimer's disease (late onset);
LUSC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg06671706	chr8:8559999	CLDN23	-0.49	-6.71	-0.34	8.4e-11	Obesity-related traits;
LUSC	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg12927641	chr6:109611667	NA	-0.38	-6.4	-0.33	5.17e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs5758511	0.773	rs7288749	chr22:42356430	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.38	0.37	1.28e-12	Birth weight;
LUSC	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg20283391	chr11:68216788	NA	-0.6	-8.38	-0.42	1.53e-15	Total body bone mineral density;
LUSC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15369054	chr17:80825471	TBCD	-0.39	-6.46	-0.33	3.74e-10	Breast cancer;
LUSC	cis	rs9323205	0.817	rs56100232	chr14:51699378	A/G	cg23942311	chr14:51606299	NA	-0.45	-8.85	-0.44	5.29e-17	Cancer;
LUSC	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg14689365	chr7:158441557	NCAPG2	0.51	7.32	0.37	1.84e-12	Height;
LUSC	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg04727924	chr7:799746	HEATR2	-0.51	-6.23	-0.32	1.42e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs10465746	0.935	rs942848	chr1:84427707	G/C	cg10977910	chr1:84465055	TTLL7	0.43	6.29	0.33	1.01e-9	Obesity-related traits;
LUSC	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg08219700	chr8:58056026	NA	0.53	6.51	0.34	2.7e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg00376283	chr12:123451042	ABCB9	0.64	8.15	0.41	7.56e-15	Neutrophil percentage of white cells;
LUSC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.32	0.56	5.14e-29	Prudent dietary pattern;
LUSC	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg08000102	chr2:233561755	GIGYF2	-0.48	-7.68	-0.39	1.74e-13	Coronary artery disease;
LUSC	cis	rs6574644	1.000	rs7156251	chr14:81776179	G/A	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg25214090	chr10:38739885	LOC399744	0.53	7.8	0.39	7.74e-14	Corneal astigmatism;
LUSC	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg03948781	chr1:205179583	DSTYK	0.31	5.9	0.31	9.16e-9	Red blood cell count;
LUSC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.42	0.53	9.8e-26	Prudent dietary pattern;
LUSC	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg27446573	chr6:127587934	RNF146	0.62	9.97	0.48	1.19e-20	Breast cancer;
LUSC	cis	rs17621444	0.522	rs4752372	chr10:121808896	T/C	cg02041677	chr10:121771263	NA	-0.33	-6.24	-0.32	1.29e-9	IgG glycosylation;
LUSC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.87	0.51	8.86e-24	Morning vs. evening chronotype;
LUSC	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	6.57	0.34	1.94e-10	Fibroblast growth factor basic levels;
LUSC	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-10.21	-0.49	1.83e-21	Eye color traits;
LUSC	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.54	0.42	4.94e-16	Response to antipsychotic treatment;
LUSC	cis	rs7215564	0.908	rs35821645	chr17:78652479	G/A	cg23238734	chr17:78661607	RPTOR	0.49	6.28	0.32	1.08e-9	Myopia (pathological);
LUSC	cis	rs28830936	0.966	rs8025714	chr15:42120157	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.92	-0.31	7.95e-9	Diastolic blood pressure;
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.84	-13.65	-0.6	5.34e-34	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs897080	0.515	rs1067400	chr2:44677647	G/A	cg00619915	chr2:44497795	NA	-0.43	-6.07	-0.32	3.48e-9	Height;
LUSC	cis	rs3087591	0.919	rs2285892	chr17:29553485	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.57	-8.33	-0.41	2.15e-15	Hip circumference;
LUSC	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.89	-0.31	9.19e-9	Birth weight;
LUSC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg11766577	chr21:47581405	C21orf56	-0.47	-7.11	-0.36	7.3e-12	Testicular germ cell tumor;
LUSC	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg10560079	chr2:191398806	TMEM194B	-0.71	-8.0	-0.4	2.07e-14	Diastolic blood pressure;
LUSC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.68	10.84	0.51	1.21e-23	Heart rate;
LUSC	trans	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22870994	chr11:71340352	NA	-0.41	-6.58	-0.34	1.8e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg18904891	chr8:8559673	CLDN23	0.58	8.07	0.4	1.31e-14	Obesity-related traits;
LUSC	cis	rs4595586	0.655	rs7958206	chr12:39329294	G/A	cg26384229	chr12:38710491	ALG10B	0.46	6.4	0.33	5.41e-10	Morning vs. evening chronotype;
LUSC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg06238570	chr21:40685208	BRWD1	0.47	7.24	0.37	3.13e-12	Cognitive function;
LUSC	trans	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg07393940	chr7:158741817	NA	0.37	6.62	0.34	1.43e-10	Life satisfaction;
LUSC	cis	rs1107366	0.722	rs10934753	chr3:125906179	G/A	cg08481491	chr3:125900108	ALDH1L1	-0.28	-5.69	-0.3	2.85e-8	Metabolite levels;
LUSC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-8.18	-0.41	6.14e-15	Systemic lupus erythematosus;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg26787244	chr11:644011	NA	-0.41	-6.11	-0.32	2.72e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg27539214	chr16:67997921	SLC12A4	-0.46	-5.94	-0.31	7.15e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12681287	0.752	rs6985427	chr8:87302745	C/T	cg27223183	chr8:87520930	FAM82B	-0.46	-5.74	-0.3	2.18e-8	Caudate activity during reward;
LUSC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg05347473	chr6:146136440	FBXO30	-0.58	-10.0	-0.48	9.08e-21	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg24429831	chr19:36120171	RBM42	0.38	6.2	0.32	1.71e-9	Triglycerides;
LUSC	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.44	-6.25	-0.32	1.22e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg19743168	chr1:23544995	NA	0.46	9.11	0.45	8.03e-18	Height;
LUSC	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-6.81	-0.35	4.46e-11	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg23260525	chr10:116636907	FAM160B1	0.47	10.19	0.49	2.13e-21	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.43	0.33	4.44e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs1832871	0.505	rs11757895	chr6:158812456	G/T	cg07165851	chr6:158734300	TULP4	0.44	6.28	0.32	1.08e-9	Height;
LUSC	cis	rs3743266	0.634	rs7165874	chr15:60784609	A/T	cg21667061	chr15:60772094	NARG2	0.38	6.32	0.33	8.55e-10	Menarche (age at onset);
LUSC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.45	-7.12	-0.36	6.52e-12	Alzheimer's disease (late onset);
LUSC	cis	rs1030268	0.608	rs12707106	chr7:133311350	A/T	cg10665199	chr7:133106180	EXOC4	0.6	6.86	0.35	3.34e-11	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg02308097	chr17:79868996	PCYT2	-0.4	-5.97	-0.31	5.9e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.63	8.37	0.42	1.61e-15	High light scatter reticulocyte count;
LUSC	cis	rs874628	0.686	rs885683	chr19:18244690	A/G	cg00493341	chr19:18228948	MAST3	-0.43	-5.94	-0.31	7.11e-9	Multiple sclerosis;
LUSC	cis	rs3768617	0.782	rs12143211	chr1:182990172	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	8.39	0.42	1.42e-15	Fuchs's corneal dystrophy;
LUSC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg24375607	chr4:120327624	NA	0.78	11.4	0.53	1.21e-25	Corneal astigmatism;
LUSC	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-7.83	-0.39	6.66e-14	Chronic sinus infection;
LUSC	cis	rs714027	0.511	rs131274	chr22:30153864	G/A	cg11564601	chr22:30592435	NA	0.32	5.8	0.3	1.58e-8	Lymphocyte counts;
LUSC	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg04369109	chr6:150039330	LATS1	-0.59	-8.69	-0.43	1.64e-16	Lung cancer;
LUSC	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.32	-7.34	-0.37	1.68e-12	Cystic fibrosis severity;
LUSC	cis	rs6076065	0.509	rs2000261	chr20:23311090	G/T	cg11657817	chr20:23433608	CST11	0.39	7.28	0.37	2.4e-12	Facial morphology (factor 15, philtrum width);
LUSC	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg20587970	chr11:113659929	NA	-1.06	-14.45	-0.62	4.35e-37	Hip circumference adjusted for BMI;
LUSC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.86	0.58	5.17e-31	Prudent dietary pattern;
LUSC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg03060546	chr3:49711283	APEH	-0.68	-7.76	-0.39	1.07e-13	Menarche (age at onset);
LUSC	trans	rs12509991	0.847	rs7661885	chr4:126958758	A/G	cg10515953	chr10:61666281	CCDC6	0.46	6.13	0.32	2.46e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg20503657	chr10:835505	NA	0.56	7.31	0.37	2.04e-12	Eosinophil percentage of granulocytes;
LUSC	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg17633681	chr16:88106987	BANP	0.5	9.75	0.47	6.26e-20	Menopause (age at onset);
LUSC	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.67	-10.48	-0.5	2.07e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg13736514	chr6:26305472	NA	-0.38	-7.31	-0.37	1.99e-12	Educational attainment;
LUSC	cis	rs7107174	1.000	rs2511175	chr11:77975081	A/G	cg02023728	chr11:77925099	USP35	0.42	6.01	0.31	4.98e-9	Testicular germ cell tumor;
LUSC	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-8.9	-0.44	3.59e-17	Total cholesterol levels;
LUSC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg18827107	chr12:86230957	RASSF9	0.47	7.04	0.36	1.09e-11	Major depressive disorder;
LUSC	cis	rs2294693	0.945	rs9369260	chr6:41010368	C/G	cg14769373	chr6:40998127	UNC5CL	0.5	6.75	0.35	6.42e-11	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs7202877	0.561	rs7202083	chr16:75383727	G/T	cg03315344	chr16:75512273	CHST6	0.45	5.8	0.3	1.51e-8	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11764359	chr7:65958608	NA	-0.68	-10.93	-0.51	5.47e-24	Aortic root size;
LUSC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg07701084	chr6:150067640	NUP43	0.57	8.86	0.44	4.87e-17	Lung cancer;
LUSC	cis	rs11051970	0.569	rs7298319	chr12:32530385	C/G	cg02745156	chr12:32552066	NA	-0.4	-6.87	-0.35	3.18e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg26566898	chr11:117069891	TAGLN	0.37	7.22	0.37	3.49e-12	Blood protein levels;
LUSC	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg15423357	chr2:25149977	NA	0.44	9.05	0.44	1.19e-17	Body mass index in non-asthmatics;
LUSC	cis	rs10992471	0.603	rs747628	chr9:95289532	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.9	-0.35	2.68e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg01879757	chr17:41196368	BRCA1	-0.46	-7.1	-0.36	7.39e-12	Menopause (age at onset);
LUSC	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg13010199	chr12:38710504	ALG10B	0.7	10.92	0.51	5.95e-24	Bladder cancer;
LUSC	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg12552261	chr5:112820674	MCC	-0.45	-7.2	-0.37	4.07e-12	Type 2 diabetes;
LUSC	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg21053147	chr12:120880522	NA	0.5	6.12	0.32	2.63e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg06462663	chr19:18546047	ISYNA1	0.47	7.93	0.4	3.33e-14	Breast cancer;
LUSC	cis	rs3770081	1.000	rs58381542	chr2:86203685	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.0	-6.54	-0.34	2.36e-10	Facial emotion recognition (sad faces);
LUSC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg13939156	chr17:80058883	NA	0.35	7.07	0.36	8.95e-12	Life satisfaction;
LUSC	trans	rs1941687	0.797	rs8098255	chr18:31401850	A/G	cg27147174	chr7:100797783	AP1S1	0.42	6.33	0.33	7.94e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg05347473	chr6:146136440	FBXO30	0.48	8.08	0.4	1.16e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs500891	0.574	rs12524383	chr6:84136605	T/C	cg08257003	chr6:84140564	ME1	0.37	9.1	0.45	8.48e-18	Platelet-derived growth factor BB levels;
LUSC	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.28	0.53	3.1e-25	Eye color traits;
LUSC	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-1.13	-17.91	-0.7	9.52e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg05340658	chr4:99064831	C4orf37	0.44	6.96	0.36	1.77e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	7.51	0.38	5.43e-13	Retinal vascular caliber;
LUSC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.14	-0.45	6.04e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08645402	chr16:4508243	NA	0.48	7.5	0.38	5.74e-13	Schizophrenia;
LUSC	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg21361702	chr7:150065534	REPIN1	0.45	6.21	0.32	1.56e-9	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg10756647	chr7:56101905	PSPH	0.87	8.55	0.42	4.6e-16	Diabetic kidney disease;
LUSC	trans	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18876405	chr7:65276391	NA	0.49	6.68	0.34	9.84e-11	Corneal structure;
LUSC	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.75	0.35	6.47e-11	Tonsillectomy;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23945789	chr12:111180856	PPP1CC	-0.41	-5.96	-0.31	6.45e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs968451	0.865	rs2076125	chr22:39711351	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.71	9.33	0.45	1.47e-18	Primary biliary cholangitis;
LUSC	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg25281562	chr12:121454272	C12orf43	0.45	5.68	0.3	2.86e-8	N-glycan levels;
LUSC	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg05714579	chr10:131428358	MGMT	0.47	6.86	0.35	3.45e-11	Response to temozolomide;
LUSC	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs41271473	0.607	rs6692032	chr1:228853984	G/C	cg16512390	chr1:228756714	NA	0.49	6.98	0.36	1.55e-11	Chronic lymphocytic leukemia;
LUSC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.31	-0.53	2.52e-25	Bipolar disorder;
LUSC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg15691649	chr6:25882328	NA	-0.35	-5.92	-0.31	8.08e-9	Blood metabolite levels;
LUSC	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg06484146	chr7:12443880	VWDE	-0.68	-7.08	-0.36	8.67e-12	Coronary artery disease;
LUSC	cis	rs2742417	1.000	rs2742369	chr3:45754487	C/A	cg09608765	chr3:45636137	LIMD1	-0.38	-7.53	-0.38	4.87e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.82	0.43	6.27e-17	Motion sickness;
LUSC	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg08975724	chr8:8085496	FLJ10661	0.5	7.31	0.37	1.95e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03517284	chr6:25882590	NA	-0.4	-7.26	-0.37	2.72e-12	Height;
LUSC	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.69	10.61	0.5	7.28e-23	Colorectal cancer;
LUSC	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg02569458	chr12:86230093	RASSF9	0.42	6.71	0.34	8.49e-11	Major depressive disorder;
LUSC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg25039879	chr17:56429692	SUPT4H1	0.68	9.0	0.44	1.72e-17	Cognitive test performance;
LUSC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg09365446	chr1:150670422	GOLPH3L	0.55	8.38	0.42	1.45e-15	Tonsillectomy;
LUSC	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg09021430	chr5:549028	NA	-0.55	-7.17	-0.37	4.85e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg05347473	chr6:146136440	FBXO30	0.46	7.99	0.4	2.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.68	-0.43	1.82e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg26395211	chr5:140044315	WDR55	-0.39	-5.95	-0.31	6.92e-9	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs12524093	0.541	rs74961892	chr6:143041640	A/T	cg22454011	chr18:13611439	C18orf1	0.68	5.96	0.31	6.53e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.82	-11.05	-0.52	2.16e-24	Mean corpuscular hemoglobin;
LUSC	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg16482183	chr6:26056742	HIST1H1C	0.64	9.03	0.44	1.44e-17	Iron status biomarkers;
LUSC	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	8.82	0.43	6.31e-17	Bipolar disorder;
LUSC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg18350739	chr11:68623251	NA	-0.37	-6.31	-0.33	8.85e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg24130564	chr14:104152367	KLC1	-0.54	-7.78	-0.39	9.15e-14	Body mass index;
LUSC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg09877947	chr5:131593287	PDLIM4	-0.45	-6.94	-0.36	2.02e-11	Breast cancer;
LUSC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg04414720	chr1:150670196	GOLPH3L	0.57	9.22	0.45	3.31e-18	Tonsillectomy;
LUSC	cis	rs977987	0.778	rs2113232	chr16:75391185	T/C	cg03315344	chr16:75512273	CHST6	0.5	9.57	0.46	2.41e-19	Dupuytren's disease;
LUSC	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg25801113	chr15:45476975	SHF	0.35	7.37	0.37	1.39e-12	Uric acid levels;
LUSC	cis	rs2708977	0.609	rs611943	chr2:97067074	T/C	cg01950434	chr2:97203154	ARID5A	-0.47	-6.36	-0.33	6.61e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	6.69	0.34	9.66e-11	Tonsillectomy;
LUSC	cis	rs977987	0.806	rs4888383	chr16:75386349	C/T	cg03315344	chr16:75512273	CHST6	0.51	9.67	0.47	1.19e-19	Dupuytren's disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20784733	chr7:66205729	RABGEF1	-0.45	-6.07	-0.32	3.43e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg02574844	chr11:5959923	NA	-0.41	-6.04	-0.31	4e-9	DNA methylation (variation);
LUSC	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg06623918	chr6:96969491	KIAA0776	0.8	9.89	0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15069758	chr1:110198731	GSTM4	0.4	5.97	0.31	6e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg00684032	chr4:1343700	KIAA1530	0.32	5.67	0.3	3.14e-8	Longevity;
LUSC	cis	rs9650657	0.746	rs4841441	chr8:10630898	C/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.51	-0.34	2.79e-10	Neuroticism;
LUSC	cis	rs10489202	0.632	rs3767476	chr1:168066940	C/T	cg24449463	chr1:168025552	DCAF6	-0.73	-11.46	-0.53	7.09e-26	Schizophrenia;
LUSC	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg03929089	chr4:120376271	NA	0.59	6.58	0.34	1.79e-10	Axial length;
LUSC	cis	rs10875746	0.903	rs2158516	chr12:48490834	T/A	cg13454099	chr12:49076203	C12orf41	-0.5	-5.75	-0.3	2.02e-8	Longevity (90 years and older);
LUSC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.75	0.35	6.62e-11	Platelet count;
LUSC	cis	rs11662586	1.000	rs12605316	chr18:77693600	C/T	cg20368463	chr18:77673604	PQLC1	0.61	8.23	0.41	4.32e-15	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LUSC	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.16	0.32	2.14e-9	Corneal astigmatism;
LUSC	cis	rs7224314	1.000	rs62084076	chr17:65383102	G/A	cg01507342	chr17:65387096	PITPNC1	-0.45	-8.03	-0.4	1.67e-14	Diisocyanate-induced asthma;
LUSC	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg27411982	chr8:10470053	RP1L1	0.4	6.39	0.33	5.62e-10	Neuroticism;
LUSC	cis	rs9309473	0.950	rs11689588	chr2:73773691	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-6.98	-0.36	1.57e-11	Metabolite levels;
LUSC	cis	rs62400317	0.762	rs12214794	chr6:44931465	G/A	cg20913747	chr6:44695427	NA	-0.46	-7.27	-0.37	2.59e-12	Total body bone mineral density;
LUSC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg00012203	chr2:219082015	ARPC2	-0.7	-11.59	-0.54	2.53e-26	Colorectal cancer;
LUSC	cis	rs2282300	0.739	rs35229181	chr11:30241698	A/G	cg06241208	chr11:30344200	C11orf46	-0.44	-5.65	-0.3	3.52e-8	Morning vs. evening chronotype;
LUSC	cis	rs4959270	0.874	rs4311550	chr6:451925	A/G	cg09757644	chr6:447497	NA	-0.28	-5.89	-0.31	9.21e-9	Limited cutaneous systemic scleroderma;
LUSC	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg24342717	chr2:85555507	TGOLN2	-0.74	-12.28	-0.56	7.19e-29	Ear protrusion;
LUSC	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg11502198	chr6:26597334	ABT1	-0.69	-11.59	-0.54	2.42e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg17971929	chr21:40555470	PSMG1	0.49	7.16	0.36	5.31e-12	Menarche (age at onset);
LUSC	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg22676075	chr6:135203613	NA	0.58	9.3	0.45	1.96e-18	High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs1595825	1.000	rs59441945	chr2:198879645	T/A	cg00982548	chr2:198649783	BOLL	-0.5	-6.23	-0.32	1.44e-9	Ulcerative colitis;
LUSC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg07507251	chr3:52567010	NT5DC2	0.33	6.54	0.34	2.28e-10	Bipolar disorder;
LUSC	cis	rs932287	1.000	rs932287	chr11:9044767	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-7.35	-0.37	1.56e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg02931644	chr1:25747376	RHCE	0.32	5.82	0.3	1.41e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	0.92	17.57	0.69	2.04e-49	Cognitive function;
LUSC	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg23933602	chr10:16859644	RSU1	0.51	6.21	0.32	1.6e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21385522	chr1:16154831	NA	0.54	8.66	0.43	2.02e-16	Systolic blood pressure;
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg00634984	chr7:65235879	NA	-0.4	-5.83	-0.3	1.32e-8	Calcium levels;
LUSC	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg02023728	chr11:77925099	USP35	-0.43	-6.39	-0.33	5.62e-10	Testicular germ cell tumor;
LUSC	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg15212455	chr7:39170539	POU6F2	0.59	9.46	0.46	5.8e-19	IgG glycosylation;
LUSC	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg08999081	chr20:33150536	PIGU	0.52	10.31	0.49	8.06e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.85	15.63	0.65	1.01e-41	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg18681998	chr4:17616180	MED28	-0.79	-12.75	-0.57	1.28e-30	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.36	0.53	1.64e-25	Eye color traits;
LUSC	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg10523679	chr1:76189770	ACADM	-0.47	-6.77	-0.35	5.77e-11	Daytime sleep phenotypes;
LUSC	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg03948781	chr1:205179583	DSTYK	0.33	6.46	0.33	3.66e-10	Red blood cell count;
LUSC	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg13575925	chr12:9217583	LOC144571	0.34	6.47	0.33	3.55e-10	Sjögren's syndrome;
LUSC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.61	9.55	0.46	2.96e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg24313572	chr1:56050060	NA	-0.29	-5.96	-0.31	6.34e-9	Morning vs. evening chronotype;
LUSC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.35	-5.66	-0.3	3.18e-8	Total body bone mineral density;
LUSC	cis	rs12190007	0.547	rs3006182	chr6:169808323	C/T	cg15038512	chr6:170123185	PHF10	-0.38	-6.14	-0.32	2.34e-9	Obesity-related traits;
LUSC	cis	rs6845621	0.727	rs2215763	chr4:18910559	G/A	cg12196642	chr4:18937545	NA	-0.33	-6.22	-0.32	1.45e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg16228356	chr17:43848958	NA	0.27	6.18	0.32	1.88e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg07926092	chr13:79233506	RNF219	0.49	5.84	0.3	1.24e-8	Large artery stroke;
LUSC	cis	rs4888262	0.545	rs8050624	chr16:74686690	A/G	cg01733217	chr16:74700730	RFWD3	-0.81	-13.55	-0.6	1.24e-33	Testicular germ cell tumor;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg24486960	chr6:44225443	SLC35B2	0.8	6.64	0.34	1.25e-10	Cognitive performance;
LUSC	cis	rs6693567	0.565	rs696617	chr1:150376311	G/T	cg15654264	chr1:150340011	RPRD2	0.45	7.18	0.37	4.49e-12	Migraine;
LUSC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg15691649	chr6:25882328	NA	0.36	5.98	0.31	5.82e-9	Blood metabolite levels;
LUSC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg14582100	chr15:45693742	SPATA5L1	0.58	10.46	0.5	2.44e-22	Homoarginine levels;
LUSC	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.6	9.48	0.46	4.93e-19	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.12	0.36	6.82e-12	Parkinson's disease;
LUSC	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg06808227	chr14:105710500	BRF1	-0.72	-11.65	-0.54	1.49e-26	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg15744005	chr10:104629667	AS3MT	-0.33	-6.79	-0.35	5.08e-11	Arsenic metabolism;
LUSC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg18305652	chr10:134549665	INPP5A	0.45	6.71	0.34	8.4e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg04036182	chr15:45458818	NA	0.35	5.75	0.3	2.01e-8	Response to fenofibrate (adiponectin levels);
LUSC	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.13	-0.41	8.57e-15	Retinal vascular caliber;
LUSC	cis	rs11168618	0.686	rs11168574	chr12:48838969	T/A	cg24011408	chr12:48396354	COL2A1	0.38	6.07	0.32	3.48e-9	Adiponectin levels;
LUSC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13770153	chr20:60521292	NA	-0.62	-8.2	-0.41	5.29e-15	Body mass index;
LUSC	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08109568	chr15:31115862	NA	-0.58	-8.01	-0.4	1.96e-14	Huntington's disease progression;
LUSC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg22437258	chr11:111473054	SIK2	-0.46	-6.31	-0.33	8.62e-10	Primary sclerosing cholangitis;
LUSC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg00339695	chr16:24857497	SLC5A11	-0.36	-6.41	-0.33	4.94e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04597389	chr17:79935740	ASPSCR1	-0.45	-6.86	-0.35	3.37e-11	Electrocardiographic conduction measures;
LUSC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10802521	chr3:52805072	NEK4	0.5	7.96	0.4	2.65e-14	Bipolar disorder;
LUSC	cis	rs2625529	0.503	rs7162299	chr15:72414065	A/G	cg16672083	chr15:72433130	SENP8	0.49	8.05	0.4	1.46e-14	Red blood cell count;
LUSC	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.7	0.34	8.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg13699009	chr12:122356056	WDR66	0.49	7.47	0.38	6.89e-13	Mean corpuscular volume;
LUSC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg06618935	chr21:46677482	NA	-0.41	-8.15	-0.41	7.54e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4654899	1.000	rs7550267	chr1:21448792	T/C	cg01072550	chr1:21505969	NA	-0.53	-8.27	-0.41	3.13e-15	Superior frontal gyrus grey matter volume;
LUSC	cis	rs1983170	0.736	rs4484968	chr1:92012005	C/A	cg25838465	chr1:92012736	NA	0.46	5.73	0.3	2.2e-8	Eosinophil percentage of white cells;
LUSC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg26162295	chr17:38119207	GSDMA	0.24	5.71	0.3	2.56e-8	Self-reported allergy;
LUSC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg09796270	chr17:17721594	SREBF1	-0.4	-6.98	-0.36	1.56e-11	Total body bone mineral density;
LUSC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg13393036	chr8:95962371	TP53INP1	-0.46	-10.25	-0.49	1.3e-21	Type 2 diabetes;
LUSC	trans	rs853679	0.599	rs156743	chr6:27967089	T/C	cg01620082	chr3:125678407	NA	-0.63	-6.89	-0.35	2.83e-11	Depression;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24508409	chr1:112298175	DDX20;C1orf183	-0.4	-6.17	-0.32	1.92e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-7.49	-0.38	6.19e-13	Atrioventricular conduction;
LUSC	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg05110241	chr16:68378359	PRMT7	-0.64	-6.99	-0.36	1.46e-11	Schizophrenia;
LUSC	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-0.75	-11.28	-0.53	3.32e-25	Refractive error;
LUSC	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg07211511	chr3:129823064	LOC729375	-1.24	-20.31	-0.74	2.85e-60	Blood pressure (smoking interaction);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg21219744	chr4:44680344	GUF1	0.47	6.74	0.35	7.13e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg11102782	chr19:18549136	ISYNA1	-0.32	-6.03	-0.31	4.46e-9	Breast cancer;
LUSC	trans	rs629535	0.551	rs62513429	chr8:70149995	A/C	cg21567404	chr3:27674614	NA	-0.93	-13.37	-0.59	5.88e-33	Dupuytren's disease;
LUSC	cis	rs4845459	0.967	rs6700158	chr1:152592828	T/G	cg08895932	chr1:152778580	LCE1C	-0.38	-6.4	-0.33	5.23e-10	Psoriasis;
LUSC	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg15556689	chr8:8085844	FLJ10661	-0.62	-9.94	-0.48	1.46e-20	Joint mobility (Beighton score);
LUSC	cis	rs34734847	0.750	rs3915	chr12:121176679	C/T	cg21892295	chr12:121157589	UNC119B	-0.33	-5.72	-0.3	2.33e-8	Mean corpuscular volume;
LUSC	cis	rs72781680	1.000	rs72781654	chr2:24218099	T/C	cg08917208	chr2:24149416	ATAD2B	0.59	6.76	0.35	6.03e-11	Lymphocyte counts;
LUSC	cis	rs1034435	0.547	rs6008741	chr22:48897881	G/A	cg05992904	chr22:48892994	FAM19A5	-0.39	-6.84	-0.35	3.87e-11	Late-onset Alzheimer's disease;
LUSC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	0.72	13.73	0.6	2.5e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs12220238	0.908	rs10824086	chr10:75912668	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.6	6.92	0.35	2.36e-11	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs7241530	0.636	rs8099795	chr18:75909874	T/G	cg14642773	chr18:75888474	NA	0.39	5.74	0.3	2.17e-8	Educational attainment (years of education);
LUSC	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.83	-0.39	6.55e-14	Body mass index;
LUSC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg26513180	chr16:89883248	FANCA	0.9	17.58	0.69	1.92e-49	Vitiligo;
LUSC	cis	rs1957429	0.901	rs2884308	chr14:65350406	A/T	cg23373153	chr14:65346875	NA	-1.02	-12.58	-0.57	5.57e-30	Pediatric areal bone mineral density (radius);
LUSC	trans	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg20587970	chr11:113659929	NA	-1.04	-12.8	-0.57	8.19e-31	Hip circumference adjusted for BMI;
LUSC	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg09365446	chr1:150670422	GOLPH3L	0.52	7.52	0.38	5.19e-13	Melanoma;
LUSC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg09165964	chr15:75287851	SCAMP5	0.5	7.43	0.38	9.24e-13	Breast cancer;
LUSC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg12751644	chr20:60527061	NA	-0.34	-6.16	-0.32	2.07e-9	Body mass index;
LUSC	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg21573476	chr21:45109991	RRP1B	-0.37	-6.0	-0.31	5.14e-9	Mean corpuscular volume;
LUSC	trans	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-8.31	-0.41	2.44e-15	Obesity-related traits;
LUSC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg14668632	chr7:2872130	GNA12	0.47	7.17	0.37	4.83e-12	Height;
LUSC	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.12	-0.45	7.26e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg09526685	chr4:187126073	CYP4V2	0.62	6.74	0.35	7.18e-11	Blood protein levels;
LUSC	cis	rs2348418	0.831	rs7299042	chr12:28724683	G/T	cg13890972	chr12:28721907	NA	-0.36	-6.2	-0.32	1.69e-9	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs62432291	0.681	rs417719	chr6:159658042	C/T	cg14500486	chr6:159655392	FNDC1	-0.52	-5.7	-0.3	2.67e-8	Joint mobility (Beighton score);
LUSC	cis	rs36093844	0.800	rs17817326	chr11:85595213	C/T	cg16165120	chr11:85566439	CCDC83	-0.39	-5.65	-0.3	3.42e-8	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LUSC	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg22535103	chr8:58192502	C8orf71	-0.57	-6.69	-0.34	9.59e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs834603	0.546	rs1534138	chr7:47482750	T/C	cg09696706	chr7:47479511	TNS3	0.35	6.42	0.33	4.81e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	trans	rs9341835	0.518	rs2622293	chr6:64218491	T/C	cg19533977	chr17:57719682	CLTC	0.33	6.07	0.32	3.53e-9	Schizophrenia;
LUSC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg11494091	chr17:61959527	GH2	0.4	6.91	0.35	2.47e-11	Height;
LUSC	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.22	0.52	5.09e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.14	16.34	0.67	1.63e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg14993813	chr1:46806288	NSUN4	-0.52	-7.24	-0.37	3.02e-12	Menopause (age at onset);
LUSC	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg05343316	chr1:45956843	TESK2	-0.61	-8.75	-0.43	1.06e-16	Platelet count;
LUSC	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	0.83	13.55	0.6	1.22e-33	Blood protein levels;
LUSC	cis	rs9811920	0.809	rs902159	chr3:99747445	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.33	-5.78	-0.3	1.73e-8	Axial length;
LUSC	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.52	-0.42	5.45e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg11494091	chr17:61959527	GH2	-0.71	-16.44	-0.67	6.32e-45	Prudent dietary pattern;
LUSC	trans	rs71435601	0.657	rs4596008	chr2:21417576	C/T	cg20757404	chr19:378427	NA	-0.41	-6.33	-0.33	8.06e-10	Cholesterol, total;
LUSC	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg01689657	chr7:91764605	CYP51A1	0.32	5.84	0.3	1.25e-8	Breast cancer;
LUSC	cis	rs2908296	0.515	rs12673242	chr7:44207494	T/C	cg03639919	chr7:44191311	GCK	0.35	5.66	0.3	3.33e-8	Body mass index;
LUSC	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.64	9.6	0.46	1.99e-19	Schizophrenia;
LUSC	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg25233709	chr10:116636983	FAM160B1	0.37	6.17	0.32	1.93e-9	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7804356	1.000	rs4722644	chr7:26845386	C/A	cg03456212	chr7:26904342	SKAP2	-0.55	-6.48	-0.33	3.36e-10	Type 1 diabetes;
LUSC	cis	rs6967385	0.583	rs7811925	chr7:12351245	C/T	cg06484146	chr7:12443880	VWDE	0.42	6.33	0.33	8e-10	Response to taxane treatment (placlitaxel);
LUSC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg05082376	chr22:42548792	NA	-0.42	-6.29	-0.33	1.01e-9	Schizophrenia;
LUSC	cis	rs3857536	0.706	rs2157963	chr6:66945449	A/T	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs11608355	0.960	rs11066526	chr12:109854476	G/C	cg19025524	chr12:109796872	NA	-0.39	-6.1	-0.32	2.87e-9	Neuroticism;
LUSC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg12463550	chr7:65579703	CRCP	0.43	6.17	0.32	1.96e-9	Aortic root size;
LUSC	trans	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg19402173	chr7:128379420	CALU	-0.57	-9.7	-0.47	9.52e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09861958	chr15:40886425	CASC5	-0.41	-6.11	-0.32	2.85e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12980942	0.935	rs12980480	chr19:41804655	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.62	6.73	0.35	7.24e-11	Coronary artery disease;
LUSC	cis	rs911119	0.908	rs12624424	chr20:23601878	C/T	cg16589663	chr20:23618590	CST3	0.61	7.33	0.37	1.75e-12	Chronic kidney disease;
LUSC	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg23795048	chr12:9217529	LOC144571	0.34	5.94	0.31	7.05e-9	Sjögren's syndrome;
LUSC	cis	rs7091068	0.671	rs620890	chr10:95405424	G/A	cg20715218	chr10:95462985	C10orf4	-0.61	-7.16	-0.36	5.32e-12	Urinary tract infection frequency;
LUSC	cis	rs2932538	0.961	rs4240534	chr1:113175429	T/A	cg22162597	chr1:113214053	CAPZA1	-0.69	-9.87	-0.48	2.41e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg20302342	chr1:156215951	PAQR6	0.33	6.29	0.33	9.79e-10	Tonsillectomy;
LUSC	trans	rs225245	0.782	rs225293	chr17:33925906	A/G	cg19694781	chr19:47549865	TMEM160	-0.42	-6.65	-0.34	1.18e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-9.12	-0.45	6.98e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs4474465	0.688	rs4945302	chr11:78283454	T/C	cg27205649	chr11:78285834	NARS2	0.56	6.83	0.35	4.11e-11	Alzheimer's disease (survival time);
LUSC	cis	rs96067	0.805	rs12033825	chr1:36600311	C/T	cg24686825	chr1:36642396	MAP7D1	-0.68	-9.31	-0.45	1.75e-18	Corneal structure;
LUSC	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg24675056	chr1:15929824	NA	0.48	8.25	0.41	3.58e-15	Systolic blood pressure;
LUSC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg18904891	chr8:8559673	CLDN23	0.61	8.15	0.41	7.22e-15	Obesity-related traits;
LUSC	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg01283332	chr5:1856932	NA	-0.33	-6.23	-0.32	1.39e-9	Cardiovascular disease risk factors;
LUSC	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg18132916	chr6:79620363	NA	-0.38	-5.78	-0.3	1.74e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs243505	0.898	rs243528	chr7:148415740	T/C	cg09806900	chr7:148480153	CUL1	-0.46	-6.63	-0.34	1.3100000000000001e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg21132104	chr15:45694354	SPATA5L1	0.57	7.96	0.4	2.63e-14	Homoarginine levels;
LUSC	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg17173187	chr15:85201210	NMB	0.36	5.96	0.31	6.34e-9	Schizophrenia;
LUSC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg09365446	chr1:150670422	GOLPH3L	0.48	7.06	0.36	9.95e-12	Melanoma;
LUSC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg07424592	chr7:64974309	NA	-0.64	-5.73	-0.3	2.24e-8	Diabetic kidney disease;
LUSC	cis	rs67696533	0.600	rs6141745	chr20:31108805	T/A	cg13636640	chr20:31349939	DNMT3B	0.47	6.25	0.32	1.24e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg22920501	chr2:26401640	FAM59B	0.82	11.98	0.55	9.28e-28	Gut microbiome composition (summer);
LUSC	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.82e-10	Mean corpuscular hemoglobin;
LUSC	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg08219700	chr8:58056026	NA	0.46	6.12	0.32	2.59e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4834770	1.000	rs4834771	chr4:120242772	C/A	cg24375607	chr4:120327624	NA	0.41	5.84	0.3	1.26e-8	Blood protein levels;
LUSC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg14895029	chr7:2775587	GNA12	-0.43	-6.77	-0.35	5.78e-11	Height;
LUSC	cis	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg06521331	chr12:34319734	NA	-0.41	-6.74	-0.35	6.92e-11	Morning vs. evening chronotype;
LUSC	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg02034447	chr16:89574710	SPG7	0.4	5.89	0.31	9.64e-9	Multiple myeloma (IgH translocation);
LUSC	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg24558204	chr6:135376177	HBS1L	0.6	9.57	0.46	2.56e-19	Red blood cell count;
LUSC	cis	rs6669008	1.000	rs55912359	chr1:114167099	C/T	cg26035817	chr1:114414802	PTPN22	0.43	6.66	0.34	1.16e-10	Bacteremia;
LUSC	cis	rs7809950	0.953	rs2520263	chr7:107179119	T/C	cg23024343	chr7:107201750	COG5	-0.56	-8.77	-0.43	9.38e-17	Coronary artery disease;
LUSC	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg22532475	chr10:104410764	TRIM8	-0.25	-5.85	-0.31	1.14e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg15704280	chr7:45808275	SEPT13	0.82	9.19	0.45	4.33e-18	Axial length;
LUSC	cis	rs9296092	0.538	rs62405953	chr6:33524760	C/T	cg13560919	chr6:33536144	NA	-0.84	-16.05	-0.66	2.25e-43	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	12.53	0.57	8.99e-30	Cognitive test performance;
LUSC	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg09904177	chr6:26538194	HMGN4	-0.82	-5.95	-0.31	6.72e-9	Depression;
LUSC	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.59	-0.34	1.74e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg24397884	chr7:158709396	WDR60	0.77	8.8	0.43	7.36e-17	Height;
LUSC	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg22532475	chr10:104410764	TRIM8	0.37	7.86	0.39	5.44e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.86	-15.32	-0.64	1.68e-40	Ulcerative colitis;
LUSC	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.76	-12.51	-0.56	1.02e-29	Endometrial cancer;
LUSC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg05347473	chr6:146136440	FBXO30	-0.49	-8.37	-0.42	1.58e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7712401	0.601	rs34707663	chr5:122320463	A/G	cg19077854	chr5:122220652	SNX24	-0.43	-9.52	-0.46	3.69e-19	Mean platelet volume;
LUSC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.23	0.49	1.53e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg00129232	chr17:37814104	STARD3	-0.49	-7.32	-0.37	1.84e-12	Asthma;
LUSC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg22823121	chr1:150693482	HORMAD1	0.49	7.03	0.36	1.17e-11	Melanoma;
LUSC	trans	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg04995722	chr7:26192034	NFE2L3	0.37	6.15	0.32	2.24e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs3736594	0.546	rs6719960	chr2:27830067	C/T	cg27432699	chr2:27873401	GPN1	-0.62	-8.69	-0.43	1.61e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg26597838	chr10:835615	NA	0.84	11.59	0.54	2.38e-26	Eosinophil percentage of granulocytes;
LUSC	cis	rs4499344	0.696	rs398990	chr19:33104244	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	13.07	0.58	8.21e-32	Mean platelet volume;
LUSC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.48	0.38	6.59e-13	Motion sickness;
LUSC	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.78	11.14	0.52	1.05e-24	Corneal astigmatism;
LUSC	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	8.11	0.41	9.96e-15	Coffee consumption (cups per day);
LUSC	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg26513180	chr16:89883248	FANCA	0.58	8.63	0.43	2.5e-16	Hemoglobin concentration;
LUSC	cis	rs2455601	0.882	rs11042115	chr11:8926679	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.49	-7.8	-0.39	8.18e-14	Schizophrenia;
LUSC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg20887711	chr4:1340912	KIAA1530	0.44	6.64	0.34	1.28e-10	Obesity-related traits;
LUSC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-9.04	-0.44	1.3e-17	Bipolar disorder and schizophrenia;
LUSC	cis	rs7264396	0.887	rs224344	chr20:34036865	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.68	-0.34	9.95e-11	Total cholesterol levels;
LUSC	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg05283184	chr6:79620031	NA	-0.57	-12.2	-0.56	1.41e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	trans	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg25482853	chr8:67687455	SGK3	0.98	15.98	0.66	4.41e-43	Obesity-related traits;
LUSC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg01879757	chr17:41196368	BRCA1	-0.45	-6.84	-0.35	3.68e-11	Menopause (age at onset);
LUSC	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg11189052	chr15:85197271	WDR73	0.47	5.8	0.3	1.54e-8	Schizophrenia;
LUSC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg11752832	chr7:134001865	SLC35B4	0.56	8.78	0.43	8.84e-17	Mean platelet volume;
LUSC	cis	rs4561483	0.767	rs33633	chr16:11994857	A/C	cg08843971	chr16:11963173	GSPT1	-0.46	-6.88	-0.35	2.98e-11	Testicular germ cell tumor;
LUSC	cis	rs9398803	0.966	rs9388487	chr6:126678268	G/T	cg19875578	chr6:126661172	C6orf173	0.41	6.01	0.31	4.82e-9	Male-pattern baldness;
LUSC	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg09034736	chr1:150693464	HORMAD1	0.43	6.01	0.31	4.88e-9	Melanoma;
LUSC	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	7.02	0.36	1.26e-11	Colorectal cancer;
LUSC	cis	rs3849570	1.000	rs13088000	chr3:81839404	T/C	cg07356753	chr3:81810745	GBE1	-0.67	-10.39	-0.49	4.22e-22	Waist circumference;Body mass index;
LUSC	cis	rs17253792	0.822	rs17832371	chr14:56162302	C/A	cg01858014	chr14:56050164	KTN1	-0.85	-6.82	-0.35	4.29e-11	Putamen volume;
LUSC	cis	rs3772130	0.962	rs11707518	chr3:121496568	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	9.88	0.48	2.38e-20	Cognitive performance;
LUSC	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.59	-0.46	2.1e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs738322	0.772	rs9619724	chr22:38517880	T/G	cg25457927	chr22:38595422	NA	-0.35	-6.88	-0.35	3.01e-11	Cutaneous nevi;
LUSC	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg05855489	chr10:104503620	C10orf26	-0.68	-10.15	-0.49	2.8e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.8	-12.57	-0.57	6.25e-30	Pancreatic cancer;
LUSC	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-8.3	-0.41	2.64e-15	Schizophrenia;
LUSC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg06784218	chr1:46089804	CCDC17	0.48	9.58	0.46	2.28e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	8.11	0.41	9.7e-15	Height;
LUSC	cis	rs701145	0.938	rs701131	chr3:154086138	C/G	cg17054900	chr3:154042577	DHX36	0.82	7.89	0.4	4.37e-14	Coronary artery disease;
LUSC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.46	-5.95	-0.31	6.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg20500836	chr17:78818645	RPTOR	-0.39	-6.12	-0.32	2.69e-9	N-glycan levels;
LUSC	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.58	0.34	1.84e-10	Corneal astigmatism;
LUSC	trans	rs2392780	0.536	rs2691039	chr8:128334662	A/G	cg10897648	chr18:56338258	MALT1	-0.4	-6.13	-0.32	2.43e-9	Breast cancer (early onset);
LUSC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.34	-0.42	1.99e-15	Joint mobility (Beighton score);
LUSC	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg05110241	chr16:68378359	PRMT7	-0.56	-6.6	-0.34	1.61e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg02972257	chr16:68554789	NA	0.44	6.03	0.31	4.25e-9	Colorectal cancer;
LUSC	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-8.47	-0.42	7.93e-16	Neuroticism;
LUSC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg26924012	chr15:45694286	SPATA5L1	1.11	20.76	0.75	4.48e-62	Homoarginine levels;
LUSC	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg20243544	chr17:37824526	PNMT	0.49	6.87	0.35	3.19e-11	Asthma;
LUSC	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	10.59	0.5	8.51e-23	Schizophrenia;
LUSC	cis	rs3743104	0.534	rs11854391	chr15:33022582	A/T	cg07179000	chr15:33023586	GREM1	-0.32	-6.17	-0.32	2e-9	Hypospadias;
LUSC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg15147215	chr3:52552868	STAB1	-0.33	-6.59	-0.34	1.67e-10	Electroencephalogram traits;
LUSC	cis	rs1957429	0.901	rs7141985	chr14:65345670	C/T	cg23373153	chr14:65346875	NA	1.08	12.07	0.55	4.21e-28	Pediatric areal bone mineral density (radius);
LUSC	trans	rs76248362	0.748	rs943061	chr13:24431968	C/T	cg26511321	chr7:27196790	HOXA7	-0.67	-7.85	-0.39	5.86e-14	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg04586622	chr2:25135609	ADCY3	0.35	7.3	0.37	2.08e-12	Body mass index in non-asthmatics;
LUSC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.6	0.38	3.11e-13	Prudent dietary pattern;
LUSC	cis	rs10979	1.000	rs34960207	chr6:143886398	C/T	cg25407410	chr6:143891975	LOC285740	-0.74	-11.96	-0.55	1.14e-27	Hypospadias;
LUSC	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21659725	chr3:3221576	CRBN	0.64	10.33	0.49	7e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg17971929	chr21:40555470	PSMG1	-0.48	-7.14	-0.36	5.77e-12	Menarche (age at onset);
LUSC	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg16520312	chr17:43971471	MAPT;LOC100128977	-0.38	-6.43	-0.33	4.29e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg17120908	chr11:65337727	SSSCA1	-0.53	-9.23	-0.45	3.22e-18	Bone mineral density;
LUSC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.79	11.37	0.53	1.56e-25	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7172677	0.768	rs34180494	chr15:75370012	A/C	cg14664628	chr15:75095509	CSK	0.5	6.43	0.33	4.44e-10	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs540254	0.647	rs474918	chr1:160771197	C/T	cg20255094	chr1:160771763	LY9	-0.49	-6.03	-0.31	4.45e-9	Blood protein levels;
LUSC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg12432903	chr7:1882776	MAD1L1	-0.39	-6.26	-0.32	1.16e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg05025164	chr4:1340916	KIAA1530	-0.51	-7.7	-0.39	1.52e-13	Obesity-related traits;
LUSC	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg02023728	chr11:77925099	USP35	0.46	6.67	0.34	1.04e-10	Testicular germ cell tumor;
LUSC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg05347473	chr6:146136440	FBXO30	0.57	9.95	0.48	1.3e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7178572	0.568	rs11072653	chr15:77693934	C/T	cg22256960	chr15:77711686	NA	-0.5	-7.9	-0.4	4.04e-14	Type 2 diabetes;
LUSC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-16.79	-0.68	2.73e-46	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs724744	0.772	rs1737230	chr6:22352366	C/T	cg13807341	chr11:118445984	ARCN1	-0.36	-6.2	-0.32	1.67e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg06238570	chr21:40685208	BRWD1	0.46	7.1	0.36	7.78e-12	Cognitive function;
LUSC	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.33	-0.41	2.08e-15	Acne (severe);
LUSC	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg00792783	chr2:198669748	PLCL1	0.43	5.68	0.3	2.9e-8	Dermatomyositis;
LUSC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.78	-15.03	-0.64	2.36e-39	Longevity;
LUSC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg00933542	chr6:150070202	PCMT1	0.31	6.49	0.33	3.1e-10	Lung cancer;
LUSC	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-7.23	-0.37	3.3e-12	Morning vs. evening chronotype;
LUSC	cis	rs4363385	0.510	rs55959888	chr1:152913490	A/G	cg25856811	chr1:152973957	SPRR3	-0.38	-6.11	-0.32	2.84e-9	Inflammatory skin disease;
LUSC	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg04896959	chr15:78267971	NA	0.52	11.25	0.52	4.02e-25	Coronary artery disease or large artery stroke;
LUSC	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06022373	chr22:39101656	GTPBP1	-0.76	-12.25	-0.56	9.51e-29	Menopause (age at onset);
LUSC	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-10.17	-0.49	2.38e-21	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg20376421	chr12:56546193	MYL6B	-0.52	-6.47	-0.33	3.48e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.71	12.66	0.57	2.79e-30	Prudent dietary pattern;
LUSC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg03929089	chr4:120376271	NA	-0.95	-16.62	-0.67	1.21e-45	Height;
LUSC	cis	rs9487051	0.768	rs2483913	chr6:109521042	G/A	cg00509249	chr6:109615579	CCDC162	-0.33	-5.79	-0.3	1.66e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs12410462	0.581	rs75219436	chr1:227546617	C/T	cg04117972	chr1:227635322	NA	0.6	6.68	0.34	1e-10	Major depressive disorder;
LUSC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg21724239	chr8:58056113	NA	0.58	6.65	0.34	1.21e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2109514	1.000	rs2109514	chr7:116159961	G/A	cg12739419	chr7:116140593	CAV2	-0.28	-6.24	-0.32	1.31e-9	Prevalent atrial fibrillation;
LUSC	cis	rs4722404	0.556	rs765728	chr7:3153564	A/G	cg19214707	chr7:3157722	NA	-0.4	-7.24	-0.37	3.02e-12	Atopic dermatitis;
LUSC	cis	rs2262909	0.962	rs73019889	chr19:22277826	C/G	cg11619707	chr19:22235551	ZNF257	0.39	5.79	0.3	1.63e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2219968	1.000	rs2219968	chr8:78956658	G/A	cg00738934	chr8:78996279	NA	0.35	6.32	0.33	8.23e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg13852791	chr20:30311386	BCL2L1	0.69	7.86	0.4	5.23e-14	Mean corpuscular hemoglobin;
LUSC	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-6.75	-0.35	6.69e-11	Menopause (age at onset);
LUSC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07677032	chr17:61819896	STRADA	0.54	9.03	0.44	1.36e-17	Prudent dietary pattern;
LUSC	cis	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08231603	chr6:135818959	AHI1;C6orf217	-0.42	-6.47	-0.33	3.49e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg03599575	chr15:90893182	GABARAPL3	-0.34	-5.8	-0.3	1.51e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6847149	0.866	rs9918080	chr4:110808051	G/A	cg07850274	chr4:110748770	RRH	0.53	7.5	0.38	5.87e-13	Exercise treadmill test traits;
LUSC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg17764715	chr19:33622953	WDR88	0.61	8.31	0.41	2.45e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1018836	0.700	rs7824376	chr8:91521498	T/C	cg16814680	chr8:91681699	NA	-0.73	-11.41	-0.53	1.05e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg14092988	chr3:52407081	DNAH1	0.3	5.8	0.3	1.53e-8	Bipolar disorder;
LUSC	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg22906224	chr7:99728672	NA	0.52	7.62	0.38	2.71e-13	Coronary artery disease;
LUSC	cis	rs9818941	0.826	rs2673547	chr3:157646627	A/G	cg08654915	chr3:157813417	NA	0.28	6.43	0.33	4.31e-10	Height;
LUSC	trans	rs2797160	0.967	rs80303782	chr6:126004193	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.43	-6.19	-0.32	1.78e-9	Endometrial cancer;
LUSC	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg06671706	chr8:8559999	CLDN23	0.49	6.52	0.34	2.66e-10	Obesity-related traits;
LUSC	cis	rs2625529	0.617	rs8025939	chr15:72460339	T/A	cg16672083	chr15:72433130	SENP8	0.48	7.92	0.4	3.5e-14	Red blood cell count;
LUSC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg05872129	chr22:39784769	NA	0.56	10.15	0.49	2.72e-21	IgG glycosylation;
LUSC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	21.9	0.77	1.58e-66	Prudent dietary pattern;
LUSC	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg07806771	chr7:64541737	NA	0.43	6.03	0.31	4.29e-9	Calcium levels;
LUSC	cis	rs4631830	0.737	rs7071471	chr10:51503335	C/T	cg20129853	chr10:51489980	NA	0.35	6.87	0.35	3.07e-11	Prostate-specific antigen levels;
LUSC	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg00530320	chr1:46809349	NSUN4	0.56	8.7	0.43	1.57e-16	Menopause (age at onset);
LUSC	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg05234568	chr11:5960015	NA	-0.62	-8.78	-0.43	8.47e-17	DNA methylation (variation);
LUSC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11645453	chr3:52864694	ITIH4	0.33	7.81	0.39	7.22e-14	Bipolar disorder;
LUSC	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg07541023	chr7:19748670	TWISTNB	0.66	7.04	0.36	1.11e-11	Thyroid stimulating hormone;
LUSC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg24257776	chr3:47051546	LOC100129354	-0.33	-5.77	-0.3	1.8e-8	Colorectal cancer;
LUSC	cis	rs6543140	0.929	rs7602207	chr2:103032366	C/G	cg09003973	chr2:102972529	NA	0.57	7.44	0.38	8.7e-13	Blood protein levels;
LUSC	cis	rs11809443	0.569	rs11800309	chr1:228391808	G/T	cg18477163	chr1:228402036	OBSCN	0.51	7.21	0.37	3.72e-12	Coronary artery disease;
LUSC	cis	rs8063160	0.756	rs35749174	chr16:89716493	G/A	cg07984980	chr16:89898383	SPIRE2	0.85	6.4	0.33	5.27e-10	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LUSC	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg21775007	chr8:11205619	TDH	0.48	6.86	0.35	3.38e-11	Morning vs. evening chronotype;
LUSC	cis	rs617219	0.726	rs3733893	chr5:78532658	C/T	cg24856658	chr5:78533917	JMY	-0.3	-5.85	-0.3	1.18e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg04545296	chr12:48745243	ZNF641	-0.35	-6.52	-0.34	2.6e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg07424592	chr7:64974309	NA	0.7	6.15	0.32	2.24e-9	Diabetic kidney disease;
LUSC	cis	rs1443512	1.000	rs1443512	chr12:54342684	A/C	cg17410650	chr12:54324560	NA	-0.43	-6.77	-0.35	5.9e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg14416269	chr4:6271139	WFS1	0.45	8.36	0.42	1.78e-15	Cisplatin-induced ototoxicity;
LUSC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg27535305	chr1:53392650	SCP2	0.41	7.87	0.4	5.07e-14	Monocyte count;
LUSC	cis	rs11583043	0.667	rs873760	chr1:101540561	C/A	cg11406453	chr1:101602562	NA	-0.38	-6.33	-0.33	8.05e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg13114125	chr14:105738426	BRF1	-0.92	-15.61	-0.65	1.22e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11031096	0.502	rs7935824	chr11:4046900	C/G	cg08557956	chr11:4115526	RRM1	-0.49	-6.23	-0.32	1.42e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg14004847	chr7:1930337	MAD1L1	-0.46	-6.82	-0.35	4.38e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13412866	chr18:20715409	CABLES1	-0.4	-6.19	-0.32	1.79e-9	Electrocardiographic conduction measures;
LUSC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg27170947	chr2:26402098	FAM59B	0.64	8.17	0.41	6.58e-15	Gut microbiome composition (summer);
LUSC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.43	7.04	0.36	1.1e-11	Blood metabolite levels;
LUSC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.23	0.41	4.34e-15	Prudent dietary pattern;
LUSC	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg11189052	chr15:85197271	WDR73	0.5	6.32	0.33	8.21e-10	Schizophrenia;
LUSC	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	8.09	0.4	1.13e-14	Lung cancer in ever smokers;
LUSC	cis	rs10492096	1.000	rs10492096	chr12:6580582	A/G	cg13857086	chr12:6580257	VAMP1	0.84	9.31	0.45	1.73e-18	Hip geometry;
LUSC	cis	rs13315871	1.000	rs4367085	chr3:58389235	A/G	cg20936604	chr3:58311152	NA	-0.67	-6.29	-0.33	9.73e-10	Cholesterol, total;
LUSC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg06808227	chr14:105710500	BRF1	-0.65	-10.24	-0.49	1.4e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg04944784	chr2:26401820	FAM59B	0.71	10.06	0.48	5.72e-21	Gut microbiome composition (summer);
LUSC	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	9.44	0.46	6.68e-19	Bipolar disorder;
LUSC	cis	rs10740039	0.516	rs6479717	chr10:62319288	G/C	cg18175470	chr10:62150864	ANK3	-0.47	-6.95	-0.36	1.97e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg16099169	chr2:106886729	NA	-0.55	-7.15	-0.36	5.34e-12	Facial morphology (factor 23);
LUSC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	6.82	0.35	4.41e-11	Electroencephalogram traits;
LUSC	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg04117972	chr1:227635322	NA	0.61	6.54	0.34	2.3e-10	Major depressive disorder;
LUSC	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg24468199	chr11:65410028	SIPA1	-0.49	-6.83	-0.35	4.04e-11	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs1007190	0.881	rs8073674	chr17:42969337	A/C	cg15406952	chr17:42872593	NA	0.56	5.76	0.3	1.88e-8	DNA methylation (variation);
LUSC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg11752832	chr7:134001865	SLC35B4	0.56	8.65	0.43	2.2e-16	Mean platelet volume;
LUSC	cis	rs9549260	0.816	rs7324090	chr13:41253958	A/T	cg21288729	chr13:41239152	FOXO1	0.57	8.5	0.42	6.36e-16	Red blood cell count;
LUSC	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg12483005	chr1:23474871	LUZP1	0.41	6.09	0.32	3.03e-9	Height;
LUSC	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.55	11.08	0.52	1.6e-24	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.66	0.5	5.03e-23	Menopause (age at onset);
LUSC	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.46	7.83	0.39	6.4e-14	Lymphocyte counts;
LUSC	cis	rs4253772	0.938	rs41355347	chr22:46637511	G/A	cg18190219	chr22:46762943	CELSR1	-0.52	-5.87	-0.31	1.06e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1044826	1.000	rs9868544	chr3:139163154	C/T	cg00490450	chr3:139108681	COPB2	0.54	7.06	0.36	9.67e-12	Obesity-related traits;
LUSC	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg05855489	chr10:104503620	C10orf26	0.52	7.9	0.4	4.02e-14	Arsenic metabolism;
LUSC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.17	-0.32	2.03e-9	Life satisfaction;
LUSC	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.56	-8.11	-0.41	9.59e-15	Axial length;
LUSC	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	8.2	0.41	5.22e-15	Lung cancer in ever smokers;
LUSC	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg02931644	chr1:25747376	RHCE	0.32	5.76	0.3	1.89e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.86	0.44	4.92e-17	Prudent dietary pattern;
LUSC	cis	rs61869271	0.871	rs6585308	chr10:116727532	G/A	cg23260525	chr10:116636907	FAM160B1	0.31	5.99	0.31	5.58e-9	Tonsillectomy;
LUSC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-10.33	-0.49	7.12e-22	Platelet count;
LUSC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg13072238	chr3:49761600	GMPPB	-0.65	-7.74	-0.39	1.17e-13	Menarche (age at onset);
LUSC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg13453750	chr1:205783389	SLC41A1	-0.32	-6.34	-0.33	7.49e-10	Menarche (age at onset);
LUSC	cis	rs67539049	1.000	rs67684445	chr8:11297327	C/T	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.38	-5.81	-0.3	1.43e-8	Itch intensity from mosquito bite;
LUSC	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.77	-0.39	9.62e-14	Height;
LUSC	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg20243544	chr17:37824526	PNMT	0.4	6.03	0.31	4.26e-9	Self-reported allergy;
LUSC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg05802129	chr4:122689817	NA	-0.34	-6.0	-0.31	5.12e-9	Type 2 diabetes;
LUSC	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.33	0.53	2.17e-25	Eye color traits;
LUSC	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg24468199	chr11:65410028	SIPA1	-0.49	-7.23	-0.37	3.4e-12	Blood pressure (age interaction);
LUSC	cis	rs116988415	1.000	rs116988415	chr14:65292145	C/T	cg25083366	chr14:65239357	SPTB	0.64	6.05	0.31	3.98e-9	Daytime sleep phenotypes;
LUSC	cis	rs7707921	0.767	rs862244	chr5:81586801	G/A	cg15871215	chr5:81402204	ATG10	0.45	7.07	0.36	8.95e-12	Breast cancer;
LUSC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg05623727	chr3:50126028	RBM5	0.32	6.04	0.31	4.04e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs11051970	0.636	rs1045751	chr12:32569496	T/C	cg02745156	chr12:32552066	NA	0.39	7.09	0.36	8.27e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs62400317	0.859	rs62438864	chr6:45041787	G/A	cg18551225	chr6:44695536	NA	-0.42	-6.84	-0.35	3.83e-11	Total body bone mineral density;
LUSC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.72	-0.51	3.15e-23	Bipolar disorder;
LUSC	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.55	-0.42	4.48e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs478607	1.000	rs60159753	chr11:64479112	G/T	cg19131476	chr11:64387923	NRXN2	0.34	6.16	0.32	2.11e-9	Urate levels;
LUSC	trans	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg03929089	chr4:120376271	NA	-0.54	-6.21	-0.32	1.62e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg13206674	chr6:150067644	NUP43	0.56	8.59	0.43	3.41e-16	Lung cancer;
LUSC	trans	rs7980799	0.935	rs1905408	chr12:33516963	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.98	-0.31	5.84e-9	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs67981189	0.613	rs4531677	chr14:71451861	A/G	cg15816911	chr14:71606274	NA	0.35	6.19	0.32	1.75e-9	Schizophrenia;
LUSC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.83	-14.73	-0.63	3.56e-38	Cognitive function;
LUSC	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg12573674	chr2:1569213	NA	-0.55	-7.85	-0.39	5.76e-14	IgG glycosylation;
LUSC	cis	rs6688613	0.694	rs2075946	chr1:166818566	A/G	cg07049167	chr1:166818506	POGK	0.56	8.36	0.42	1.78e-15	Refractive astigmatism;
LUSC	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg11494091	chr17:61959527	GH2	-0.73	-17.44	-0.69	6.96e-49	Prudent dietary pattern;
LUSC	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.17	-0.49	2.38e-21	Obesity-related traits;
LUSC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.28	0.45	2.23e-18	Prudent dietary pattern;
LUSC	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg19773385	chr1:10388646	KIF1B	-0.51	-8.87	-0.44	4.4e-17	Hepatocellular carcinoma;
LUSC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg26897989	chr16:1907736	C16orf73	-0.4	-6.43	-0.33	4.48e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs4363385	0.597	rs55667413	chr1:152976849	G/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.82	-0.39	6.89e-14	Inflammatory skin disease;
LUSC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg08888203	chr3:10149979	C3orf24	0.66	9.07	0.44	1.06e-17	Alzheimer's disease;
LUSC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12310025	chr6:25882481	NA	0.52	9.72	0.47	7.69e-20	Blood metabolite levels;
LUSC	cis	rs7607369	0.536	rs4674344	chr2:219669875	A/T	cg02176678	chr2:219576539	TTLL4	-0.52	-9.15	-0.45	5.72e-18	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.82	14.18	0.61	4.8e-36	Blood protein levels;
LUSC	cis	rs73206853	0.544	rs55752061	chr12:111126096	G/C	cg12870014	chr12:110450643	ANKRD13A	0.7	7.15	0.36	5.53e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg07169764	chr2:136633963	MCM6	1.16	18.64	0.71	1.15e-53	Corneal structure;
LUSC	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg25643088	chr3:52874325	TMEM110	0.38	5.79	0.3	1.6e-8	Schizophrenia;
LUSC	cis	rs7202877	0.610	rs8053632	chr16:75364940	C/T	cg04384234	chr16:75411784	CFDP1	-0.63	-8.88	-0.44	4.22e-17	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg04871131	chr7:94954202	PON1	-0.39	-6.19	-0.32	1.72e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs968451	0.951	rs5757622	chr22:39728861	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	8.74	0.43	1.11e-16	Primary biliary cholangitis;
LUSC	cis	rs6723108	0.651	rs35215000	chr2:135367656	C/A	cg12500956	chr2:135428796	TMEM163	-0.29	-6.86	-0.35	3.28e-11	Type 2 diabetes;
LUSC	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	1.07	14.17	0.61	5.24e-36	Uric acid levels;
LUSC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.41	-0.38	1.06e-12	Blood metabolite levels;
LUSC	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.29	5.79	0.3	1.67e-8	Cognitive function;
LUSC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-9.98	-0.48	1.07e-20	Gut microbiome composition (summer);
LUSC	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg24375607	chr4:120327624	NA	0.76	11.46	0.53	7.46e-26	Corneal astigmatism;
LUSC	trans	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg15556689	chr8:8085844	FLJ10661	0.48	7.21	0.37	3.87e-12	Retinal vascular caliber;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg02765045	chr12:53845774	PCBP2	0.45	6.07	0.32	3.46e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg09021430	chr5:549028	NA	-0.53	-7.49	-0.38	6.08e-13	Lung disease severity in cystic fibrosis;
LUSC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs4478858	0.611	rs1007012	chr1:31710068	G/A	cg00250761	chr1:31883323	NA	-0.35	-8.5	-0.42	6.33e-16	Alcohol dependence;
LUSC	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.62	9.25	0.45	2.65e-18	Superior crus of antihelix expression;
LUSC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg13918804	chr1:2043761	PRKCZ	0.27	5.74	0.3	2.11e-8	Height;
LUSC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.83	-13.37	-0.59	6.03e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20307385	chr11:47447363	PSMC3	-0.45	-5.96	-0.31	6.38e-9	Subjective well-being;
LUSC	cis	rs8092503	1.000	rs12964118	chr18:52495506	A/G	cg12377874	chr18:52495404	RAB27B	0.33	5.99	0.31	5.54e-9	Childhood body mass index;
LUSC	cis	rs983392	0.709	rs11826180	chr11:59991333	T/C	cg20284999	chr11:59952153	MS4A6A	-0.36	-6.09	-0.32	3.14e-9	Alzheimer's disease (late onset);
LUSC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11764359	chr7:65958608	NA	-0.64	-10.54	-0.5	1.27e-22	Aortic root size;
LUSC	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg03651054	chr13:50194643	NA	0.36	6.26	0.32	1.17e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.71	-0.3	2.5e-8	Depression;
LUSC	cis	rs12681287	0.546	rs11539113	chr8:87497176	G/A	cg27223183	chr8:87520930	FAM82B	-0.54	-7.16	-0.36	5.3e-12	Caudate activity during reward;
LUSC	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg02176678	chr2:219576539	TTLL4	0.6	10.72	0.51	3.14e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	7.09	0.36	8.18e-12	HIV-1 control;
LUSC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	5.9	0.31	9.15e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg06637938	chr14:75390232	RPS6KL1	0.53	8.6	0.43	3.04e-16	Height;
LUSC	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg27471124	chr11:109292789	C11orf87	0.43	7.61	0.38	2.85e-13	Schizophrenia;
LUSC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	10.74	0.51	2.66e-23	Coronary artery disease;
LUSC	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg25427524	chr10:38739819	LOC399744	0.47	5.98	0.31	5.83e-9	Obesity (extreme);
LUSC	trans	rs7739264	0.602	rs9350179	chr6:19764095	G/A	cg13431028	chr2:169073609	STK39	0.37	6.23	0.32	1.39e-9	Endometriosis;
LUSC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg03354898	chr7:1950403	MAD1L1	-0.33	-6.43	-0.33	4.53e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4478858	0.709	rs3766296	chr1:31820223	G/A	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.06	0.36	9.75e-12	Bipolar disorder;
LUSC	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg13798780	chr7:105162888	PUS7	0.56	6.19	0.32	1.81e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg06713675	chr4:122721982	EXOSC9	-0.56	-9.62	-0.47	1.74e-19	Type 2 diabetes;
LUSC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg18681998	chr4:17616180	MED28	0.84	15.82	0.65	1.78e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg08270630	chr22:50330655	NA	0.41	6.07	0.32	3.54e-9	Schizophrenia;
LUSC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg26441486	chr22:50317300	CRELD2	0.48	7.11	0.36	7.27e-12	Schizophrenia;
LUSC	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14240646	chr10:27532245	ACBD5	-0.68	-7.86	-0.4	5.19e-14	Breast cancer;
LUSC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-1.04	-18.06	-0.7	2.45e-51	Coronary artery disease;
LUSC	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg26395211	chr5:140044315	WDR55	0.4	6.24	0.32	1.36e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6076065	0.676	rs1419005	chr20:23336432	G/T	cg11657817	chr20:23433608	CST11	-0.44	-8.2	-0.41	5.39e-15	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg25258033	chr6:167368657	RNASET2	0.47	7.91	0.4	3.77e-14	Crohn's disease;
LUSC	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	15.94	0.66	6.17e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg16434002	chr17:42200994	HDAC5	-0.45	-6.44	-0.33	4.13e-10	Total body bone mineral density;
LUSC	cis	rs7605827	0.930	rs2058866	chr2:15519992	G/T	cg19274914	chr2:15703543	NA	0.45	8.78	0.43	8.82e-17	Educational attainment (years of education);
LUSC	cis	rs727505	0.954	rs66526112	chr7:124504074	C/A	cg23710748	chr7:124431027	NA	-0.42	-7.61	-0.38	2.87e-13	Lewy body disease;
LUSC	cis	rs3857536	0.740	rs9360191	chr6:66942454	A/T	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg06008330	chr7:65541103	ASL	-0.4	-6.35	-0.33	6.96e-10	Aortic root size;
LUSC	cis	rs34779708	0.733	rs59287215	chr10:35543994	C/T	cg03585969	chr10:35415529	CREM	0.56	7.79	0.39	8.66e-14	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg09796270	chr17:17721594	SREBF1	0.41	7.2	0.37	4.03e-12	Total body bone mineral density;
LUSC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	7.78	0.39	9.29e-14	Mean platelet volume;
LUSC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.57	-0.34	1.96e-10	Life satisfaction;
LUSC	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg03168497	chr17:48586147	MYCBPAP	0.53	6.98	0.36	1.59e-11	Visceral fat;
LUSC	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.09	0.52	1.54e-24	Fuchs's corneal dystrophy;
LUSC	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg24006582	chr15:45444508	DUOX1	-0.61	-8.95	-0.44	2.44e-17	Uric acid levels;
LUSC	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg21433313	chr16:3507492	NAT15	0.79	9.93	0.48	1.58e-20	Tuberculosis;
LUSC	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.31	-0.33	8.89e-10	Total body bone mineral density;
LUSC	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg00898013	chr13:113819073	PROZ	-0.57	-8.06	-0.4	1.38e-14	Platelet distribution width;
LUSC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg02569458	chr12:86230093	RASSF9	-0.48	-7.95	-0.4	2.87e-14	Major depressive disorder;
LUSC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18876405	chr7:65276391	NA	-0.56	-8.81	-0.43	7.03e-17	Aortic root size;
LUSC	cis	rs2976388	0.692	rs2978983	chr8:143765842	A/G	cg17252645	chr8:143867129	LY6D	0.38	6.65	0.34	1.2e-10	Urinary tract infection frequency;
LUSC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg18190219	chr22:46762943	CELSR1	-0.49	-6.0	-0.31	5.16e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs6504663	0.586	rs60117965	chr17:48569755	G/A	cg03611598	chr17:48586076	MYCBPAP	0.49	6.06	0.31	3.73e-9	Visceral fat;
LUSC	cis	rs6687430	0.514	rs587916	chr1:10545590	G/A	cg20482658	chr1:10539492	PEX14	-0.33	-6.71	-0.34	8.1e-11	Hand grip strength;
LUSC	cis	rs13089785	0.965	rs12488058	chr3:123599681	C/T	cg19611163	chr3:123411211	MYLK	0.35	5.85	0.3	1.15e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg22535103	chr8:58192502	C8orf71	-0.74	-7.67	-0.39	1.95e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg04450456	chr4:17643702	FAM184B	0.41	6.68	0.34	9.96e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06022373	chr22:39101656	GTPBP1	0.74	11.49	0.53	5.61e-26	Menopause (age at onset);
LUSC	cis	rs7707921	0.767	rs178931	chr5:81575601	T/A	cg15871215	chr5:81402204	ATG10	0.46	7.03	0.36	1.19e-11	Breast cancer;
LUSC	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.54	-8.2	-0.41	5.19e-15	Rheumatoid arthritis;
LUSC	cis	rs73195822	0.667	rs7967408	chr12:111164408	A/C	cg12870014	chr12:110450643	ANKRD13A	0.68	7.52	0.38	5.1e-13	Itch intensity from mosquito bite;
LUSC	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg13866156	chr1:1669148	SLC35E2	-0.5	-8.05	-0.4	1.45e-14	Body mass index;
LUSC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06634786	chr22:41940651	POLR3H	-0.58	-6.52	-0.34	2.61e-10	Vitiligo;
LUSC	cis	rs28830936	1.000	rs2577960	chr15:42028354	C/A	cg17847044	chr15:42102381	MAPKBP1	0.27	5.81	0.3	1.45e-8	Diastolic blood pressure;
LUSC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.95	-0.48	1.39e-20	Hemoglobin concentration;
LUSC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg27532560	chr4:187881888	NA	-0.37	-6.07	-0.32	3.5e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9487051	0.768	rs371960	chr6:109525082	A/G	cg01475377	chr6:109611718	NA	-0.35	-5.94	-0.31	7.09e-9	Reticulocyte fraction of red cells;
LUSC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	1.03	17.71	0.7	6.06e-50	Coronary artery disease;
LUSC	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg15704280	chr7:45808275	SEPT13	0.82	7.82	0.39	6.96e-14	Axial length;
LUSC	cis	rs6489882	0.607	rs4767033	chr12:113364382	T/A	cg20102336	chr12:113376681	OAS3	-0.41	-5.89	-0.31	9.59e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg17173187	chr15:85201210	NMB	-0.3	-6.35	-0.33	7.17e-10	Schizophrenia;
LUSC	trans	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.14	-0.41	7.86e-15	Neuroticism;
LUSC	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg25319279	chr11:5960081	NA	-0.41	-5.79	-0.3	1.64e-8	DNA methylation (variation);
LUSC	cis	rs897080	0.515	rs786616	chr2:44592975	C/G	cg00619915	chr2:44497795	NA	-0.41	-5.92	-0.31	8.15e-9	Height;
LUSC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg22800045	chr5:56110881	MAP3K1	-0.63	-7.93	-0.4	3.28e-14	Initial pursuit acceleration;
LUSC	trans	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04565464	chr8:145669602	NFKBIL2	0.39	6.34	0.33	7.57e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg10356904	chr22:49881777	NA	-0.3	-6.01	-0.31	4.92e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.54	-7.83	-0.39	6.64e-14	Breast cancer;
LUSC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg17366294	chr4:99064904	C4orf37	0.56	9.84	0.47	3.25e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg04398451	chr17:18023971	MYO15A	-0.57	-9.22	-0.45	3.34e-18	Total body bone mineral density;
LUSC	cis	rs4363385	0.747	rs1611759	chr1:152957439	T/G	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.51	-0.38	5.5e-13	Inflammatory skin disease;
LUSC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	10.52	0.5	1.55e-22	Bone mineral density;
LUSC	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg06002616	chr8:101225028	SPAG1	-0.45	-7.49	-0.38	6.08e-13	Atrioventricular conduction;
LUSC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg12403142	chr1:92012408	NA	-0.42	-6.77	-0.35	5.91e-11	Breast cancer;
LUSC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.5	-10.92	-0.51	6.08e-24	Type 2 diabetes;
LUSC	cis	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg06521331	chr12:34319734	NA	-0.48	-7.69	-0.39	1.65e-13	Morning vs. evening chronotype;
LUSC	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg23711669	chr6:146136114	FBXO30	0.87	16.0	0.66	3.64e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg03806693	chr22:41940476	POLR3H	-0.54	-7.5	-0.38	5.85e-13	Neuroticism;
LUSC	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg12311346	chr5:56204834	C5orf35	-0.59	-9.39	-0.46	9.9e-19	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs7560272	0.538	rs12619258	chr2:73935915	G/T	cg20560298	chr2:73613845	ALMS1	0.38	5.73	0.3	2.19e-8	Schizophrenia;
LUSC	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg04310649	chr10:35416472	CREM	-0.44	-6.87	-0.35	3.23e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg06606381	chr12:133084897	FBRSL1	-0.72	-6.62	-0.34	1.43e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg19610905	chr11:61596333	FADS2	-0.55	-8.26	-0.41	3.54e-15	LDL cholesterol;
LUSC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.92	0.44	3.02e-17	Motion sickness;
LUSC	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.45	6.48	0.33	3.25e-10	Breast cancer;
LUSC	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg19622623	chr12:86230825	RASSF9	-0.41	-5.73	-0.3	2.26e-8	Major depressive disorder;
LUSC	cis	rs9361491	0.508	rs4706718	chr6:79416883	G/A	cg05283184	chr6:79620031	NA	-0.39	-6.91	-0.35	2.49e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg19773385	chr1:10388646	KIF1B	-0.59	-10.1	-0.48	4.34e-21	Hepatocellular carcinoma;
LUSC	cis	rs75920871	0.588	rs1940626	chr11:116828121	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-6.6	-0.34	1.61e-10	Subjective well-being;
LUSC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	0.89	15.67	0.65	7.27e-42	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg27661571	chr11:113659931	NA	-0.61	-6.87	-0.35	3.09e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.83	14.52	0.62	2.36e-37	Metabolic syndrome;
LUSC	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg23625390	chr15:77176239	SCAPER	-0.64	-9.88	-0.48	2.35e-20	Blood metabolite levels;
LUSC	cis	rs9646944	0.501	rs10181785	chr2:103025274	C/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.6	0.34	1.65e-10	Blood protein levels;
LUSC	cis	rs7572644	0.766	rs7587180	chr2:28176109	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-6.52	-0.34	2.64e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg13010199	chr12:38710504	ALG10B	0.41	5.94	0.31	7.08e-9	Morning vs. evening chronotype;
LUSC	trans	rs10411161	0.721	rs10401778	chr19:52384315	C/T	cg22319618	chr22:45562946	NUP50	-0.49	-5.94	-0.31	6.97e-9	Breast cancer;
LUSC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg13939156	chr17:80058883	NA	-0.33	-6.65	-0.34	1.22e-10	Life satisfaction;
LUSC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-7.38	-0.37	1.25e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg13395646	chr4:1353034	KIAA1530	-0.81	-13.7	-0.6	3.27e-34	Obesity-related traits;
LUSC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg10792982	chr14:105748885	BRF1	0.49	8.35	0.42	1.78e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs7246967	0.673	rs55932152	chr19:22873428	A/T	cg23217946	chr19:22817039	ZNF492	0.49	6.85	0.35	3.48e-11	Bronchopulmonary dysplasia;
LUSC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg01494348	chr8:144660395	NAPRT1	-0.68	-7.03	-0.36	1.19e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg26727032	chr16:67993705	SLC12A4	-0.4	-6.11	-0.32	2.84e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.69	-6.59	-0.34	1.7e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg09184832	chr6:79620586	NA	-0.43	-6.74	-0.35	7.09e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs77633900	0.772	rs2957560	chr15:76700310	A/T	cg21673338	chr15:77095150	SCAPER	-0.7	-5.99	-0.31	5.4e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-6.77	-0.35	5.7e-11	Major depressive disorder;
LUSC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg18490616	chr2:88469792	THNSL2	-0.61	-8.15	-0.41	7.36e-15	Response to metformin (IC50);
LUSC	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	0.86	15.27	0.64	2.74e-40	Prostate cancer;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06804154	chr1:109825675	PSRC1	-0.4	-5.98	-0.31	5.82e-9	Electrocardiographic conduction measures;
LUSC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg10518572	chr11:65560635	OVOL1	-0.27	-6.19	-0.32	1.79e-9	Acne (severe);
LUSC	trans	rs6445975	0.666	rs2070662	chr3:58415590	C/A	cg18950693	chr14:70346909	SMOC1	-0.39	-5.99	-0.31	5.36e-9	Systemic lupus erythematosus;
LUSC	cis	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg20368463	chr18:77673604	PQLC1	-0.67	-6.78	-0.35	5.39e-11	Opioid sensitivity;
LUSC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg12927641	chr6:109611667	NA	-0.4	-6.92	-0.35	2.37e-11	Reticulocyte fraction of red cells;
LUSC	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg24642439	chr20:33292090	TP53INP2	0.41	5.97	0.31	5.95e-9	Height;
LUSC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.88e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9653442	0.900	rs6740838	chr2:100813499	T/G	cg22139774	chr2:100720529	AFF3	-0.45	-7.83	-0.39	6.46e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg13206674	chr6:150067644	NUP43	0.59	9.24	0.45	2.87e-18	Lung cancer;
LUSC	cis	rs4343996	0.754	rs4719883	chr7:3350741	T/A	cg21248987	chr7:3385318	SDK1	-0.36	-6.24	-0.32	1.33e-9	Motion sickness;
LUSC	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg12615879	chr12:58013172	SLC26A10	-0.28	-6.0	-0.31	5.24e-9	Multiple sclerosis;
LUSC	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg11189052	chr15:85197271	WDR73	0.47	5.65	0.3	3.44e-8	Schizophrenia;
LUSC	cis	rs2637266	1.000	rs7897015	chr10:78366566	G/C	cg18941641	chr10:78392320	NA	0.39	7.22	0.37	3.61e-12	Pulmonary function;
LUSC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg20243544	chr17:37824526	PNMT	0.47	5.8	0.3	1.53e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs7968679	1	rs7968679	chr12:9313304	A/G	cg26114124	chr12:9217669	LOC144571	-0.38	-6.97	-0.36	1.66e-11	Myopia;
LUSC	cis	rs12997796	0.556	rs12477737	chr2:86930966	G/T	cg25203885	chr2:87302643	LOC285074	-0.74	-8.05	-0.4	1.51e-14	Schizophrenia;
LUSC	cis	rs12137294	0.866	rs896318	chr1:205205784	A/G	cg21643547	chr1:205240462	TMCC2	-0.36	-6.46	-0.33	3.74e-10	Red cell distribution width;
LUSC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg20406979	chr6:167373233	NA	-0.26	-5.91	-0.31	8.42e-9	Crohn's disease;
LUSC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-8.35	-0.42	1.89e-15	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08677398	chr8:58056175	NA	0.54	6.65	0.34	1.23e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg11752832	chr7:134001865	SLC35B4	-0.61	-9.49	-0.46	4.61e-19	Mean platelet volume;
LUSC	trans	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg13565492	chr6:43139072	SRF	-0.73	-10.92	-0.51	5.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg06714761	chr1:201096289	NA	0.42	7.66	0.39	2.05e-13	Permanent tooth development;
LUSC	cis	rs12940923	1.000	rs34770605	chr17:56376206	C/T	cg19466818	chr17:56409534	MIR142	-0.38	-6.63	-0.34	1.39e-10	Circulating myeloperoxidase levels (plasma);
LUSC	cis	rs10193935	0.901	rs10175378	chr2:42456267	A/C	cg27598129	chr2:42591480	NA	-0.59	-7.84	-0.39	5.91e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg01802117	chr1:53393560	SCP2	0.39	6.36	0.33	6.52e-10	Monocyte count;
LUSC	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg03676636	chr4:99064102	C4orf37	0.34	7.1	0.36	7.58e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-0.91	-17.45	-0.69	6.14e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs3087591	0.922	rs2341348	chr17:29534867	C/T	cg24425628	chr17:29625626	OMG;NF1	0.58	8.32	0.41	2.31e-15	Hip circumference;
LUSC	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg15704280	chr7:45808275	SEPT13	-0.54	-6.2	-0.32	1.67e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs8077577	0.895	rs62072465	chr17:18114494	C/G	cg16794390	chr17:18148240	FLII	0.41	5.75	0.3	2.01e-8	Obesity-related traits;
LUSC	cis	rs4474465	0.850	rs4579956	chr11:78232445	G/C	cg27205649	chr11:78285834	NARS2	0.54	6.12	0.32	2.61e-9	Alzheimer's disease (survival time);
LUSC	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-17.83	-0.7	1.92e-50	Primary sclerosing cholangitis;
LUSC	cis	rs2289328	0.882	rs16970633	chr15:40642877	G/T	cg13931752	chr15:40660718	DISP2	0.45	5.99	0.31	5.35e-9	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs6484504	0.576	rs438578	chr11:31222579	A/G	cg06552810	chr11:31128660	NA	0.39	6.9	0.35	2.62e-11	Red blood cell count;
LUSC	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	13.12	0.58	5.35e-32	Blood protein levels;
LUSC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	16.55	0.67	2.46e-45	Platelet count;
LUSC	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg26587870	chr6:27730563	NA	-0.65	-5.66	-0.3	3.31e-8	Depression;
LUSC	cis	rs11018904	0.906	rs55685917	chr11:89964365	T/C	cg26028595	chr11:89956573	CHORDC1	-0.51	-6.14	-0.32	2.39e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg25206134	chr2:45395956	NA	0.62	7.23	0.37	3.24e-12	Bipolar disorder;
LUSC	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg05925327	chr15:68127851	NA	-0.32	-5.75	-0.3	2.02e-8	Restless legs syndrome;
LUSC	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg07148914	chr20:33460835	GGT7	-0.45	-6.67	-0.34	1.07e-10	Height;
LUSC	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg09835421	chr16:68378352	PRMT7	-0.56	-6.07	-0.32	3.38e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.3	-6.13	-0.32	2.42e-9	Dupuytren's disease;
LUSC	cis	rs5758511	0.514	rs9607885	chr22:42578596	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.55	9.5	0.46	4.19e-19	Birth weight;
LUSC	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	12.54	0.57	7.95e-30	Primary sclerosing cholangitis;
LUSC	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg15309053	chr8:964076	NA	0.42	8.66	0.43	2.11e-16	Schizophrenia;
LUSC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg03060546	chr3:49711283	APEH	0.54	8.33	0.41	2.18e-15	Parkinson's disease;
LUSC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.7	-9.78	-0.47	5e-20	Glomerular filtration rate (creatinine);
LUSC	cis	rs1788820	0.917	rs1788785	chr18:21142340	T/C	cg14672496	chr18:21087552	C18orf8	0.42	6.79	0.35	5.02e-11	Body mass index;
LUSC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg24733560	chr20:60626293	TAF4	0.41	6.73	0.35	7.6e-11	Body mass index;
LUSC	cis	rs6998277	1.000	rs4281092	chr8:103647956	A/G	cg10187029	chr8:103597600	NA	-0.62	-8.06	-0.4	1.36e-14	Migraine;
LUSC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	12.1	0.55	3.42e-28	Personality dimensions;
LUSC	cis	rs3771570	1.000	rs73002111	chr2:242277833	C/T	cg21155796	chr2:242212141	HDLBP	0.63	6.86	0.35	3.32e-11	Prostate cancer;
LUSC	cis	rs9463078	0.727	rs2396371	chr6:44946550	C/T	cg25276700	chr6:44698697	NA	-0.28	-5.88	-0.31	1.02e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2658782	0.789	rs2658776	chr11:93147927	A/G	cg15737290	chr11:93063684	CCDC67	0.64	7.95	0.4	2.91e-14	Pulmonary function decline;
LUSC	cis	rs2742234	0.541	rs4648313	chr10:43716739	G/A	cg15436174	chr10:43711423	RASGEF1A	0.44	7.06	0.36	9.75e-12	Hirschsprung disease;
LUSC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg11871910	chr12:69753446	YEATS4	0.84	15.2	0.64	5.09e-40	Blood protein levels;
LUSC	cis	rs4605213	0.528	rs12951858	chr17:49328627	C/G	cg22932220	chr17:49244634	NME2;NME1-NME2	-0.4	-6.46	-0.33	3.78e-10	Height;
LUSC	cis	rs6087990	0.735	rs6058892	chr20:31388461	C/T	cg13636640	chr20:31349939	DNMT3B	0.91	18.56	0.71	2.37e-53	Ulcerative colitis;
LUSC	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg01475377	chr6:109611718	NA	-0.46	-8.38	-0.42	1.5e-15	Reticulocyte fraction of red cells;
LUSC	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg12615879	chr12:58013172	SLC26A10	-0.3	-6.62	-0.34	1.47e-10	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.21	0.52	5.47e-25	Prudent dietary pattern;
LUSC	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg09796270	chr17:17721594	SREBF1	-0.42	-7.16	-0.36	5.27e-12	Total body bone mineral density;
LUSC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-10.59	-0.5	8.72e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7267979	0.649	rs2500406	chr20:25401862	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.73	-12.96	-0.58	2.19e-31	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg00343986	chr7:65444356	GUSB	0.47	7.02	0.36	1.23e-11	Aortic root size;
LUSC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg00750074	chr16:89608354	SPG7	0.56	10.48	0.5	2.16e-22	Multiple myeloma (IgH translocation);
LUSC	cis	rs6831256	0.583	rs10937929	chr4:3483037	C/T	cg16415104	chr4:3496300	NA	-0.4	-7.34	-0.37	1.6e-12	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LUSC	trans	rs1864585	0.520	rs17718772	chr8:10648056	G/C	cg26278703	chr11:58910052	FAM111A	0.54	6.05	0.31	3.95e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LUSC	cis	rs1014246	0.848	rs10787718	chr10:118467648	A/G	cg14919929	chr10:118506882	NA	-0.44	-6.75	-0.35	6.4e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs4776059	0.550	rs8032394	chr15:52868032	G/A	cg25063058	chr15:52860530	ARPP19	0.53	6.45	0.33	3.82e-10	Schizophrenia;
LUSC	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg23093090	chr10:104574429	C10orf26	-0.45	-8.01	-0.4	1.9e-14	Arsenic metabolism;
LUSC	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg18681998	chr4:17616180	MED28	0.78	13.81	0.6	1.26e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9341835	0.740	rs9294215	chr6:64151771	C/G	cg03326410	chr6:64151739	NA	-0.37	-6.13	-0.32	2.53e-9	Schizophrenia;
LUSC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg16423285	chr20:60520624	NA	-0.47	-5.87	-0.31	1.06e-8	Body mass index;
LUSC	cis	rs16986825	0.570	rs5762879	chr22:29286180	C/T	cg02153584	chr22:29168773	CCDC117	0.57	6.68	0.34	1.02e-10	Pancreatic cancer;
LUSC	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg19628046	chr18:33552617	C18orf21	0.51	6.17	0.32	1.96e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs6516091	0.850	rs75701968	chr20:6049985	C/T	cg25325723	chr20:6104886	FERMT1	-0.65	-7.0	-0.36	1.39e-11	Abdominal aortic aneurysm;
LUSC	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg04546413	chr19:29218101	NA	0.59	7.26	0.37	2.72e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg00012203	chr2:219082015	ARPC2	-0.77	-13.07	-0.58	8.24e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.73	12.84	0.57	6.28e-31	Prudent dietary pattern;
LUSC	cis	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg06521331	chr12:34319734	NA	-0.4	-5.89	-0.31	9.25e-9	Resting heart rate;
LUSC	trans	rs12210905	0.925	rs72838236	chr6:26971202	C/T	cg11837749	chr1:55047332	ACOT11	0.57	6.09	0.32	3.07e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg00484396	chr16:3507460	NAT15	-0.43	-6.91	-0.35	2.47e-11	Body mass index (adult);
LUSC	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg02376097	chr19:46275166	DMPK	0.4	7.0	0.36	1.42e-11	Coronary artery disease;
LUSC	trans	rs77204473	0.744	rs17120293	chr11:116944846	A/G	cg14717557	chr6:100895618	SIM1	-0.54	-6.41	-0.33	5.01e-10	Eosinophil counts;Sum eosinophil basophil counts;
LUSC	cis	rs6977660	1.000	rs7812001	chr7:19803323	A/G	cg05791153	chr7:19748676	TWISTNB	-0.58	-6.63	-0.34	1.33e-10	Thyroid stimulating hormone;
LUSC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21724239	chr8:58056113	NA	0.85	9.05	0.44	1.18e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg22535103	chr8:58192502	C8orf71	-0.75	-9.55	-0.46	2.95e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs4363385	0.818	rs1334849	chr1:153004652	A/G	cg00922841	chr1:152955080	SPRR1A	0.33	5.79	0.3	1.59e-8	Inflammatory skin disease;
LUSC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.66	11.3	0.53	2.82e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18099408	chr3:52552593	STAB1	-0.42	-7.3	-0.37	2.09e-12	Bipolar disorder;
LUSC	cis	rs981844	1.000	rs2606342	chr4:154659980	C/A	cg14289246	chr4:154710475	SFRP2	0.5	6.36	0.33	6.49e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs6977660	1.000	rs13233821	chr7:19813637	A/C	cg05791153	chr7:19748676	TWISTNB	0.56	6.26	0.32	1.17e-9	Thyroid stimulating hormone;
LUSC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.55	10.06	0.48	5.64e-21	Bone mineral density;
LUSC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg15782153	chr7:917662	C7orf20	0.43	6.65	0.34	1.22e-10	Perceived unattractiveness to mosquitoes;
LUSC	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.65	-0.39	2.18e-13	Morning vs. evening chronotype;
LUSC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg10664184	chr19:17420304	DDA1	-0.46	-6.12	-0.32	2.65e-9	Systemic lupus erythematosus;
LUSC	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg19628046	chr18:33552617	C18orf21	0.52	6.29	0.33	9.87e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.85	14.85	0.63	1.22e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs2718058	0.613	rs2718037	chr7:37777846	G/C	cg15028436	chr7:37888078	TXNDC3	0.35	5.77	0.3	1.79e-8	Alzheimer's disease (late onset);
LUSC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg15556689	chr8:8085844	FLJ10661	0.69	11.1	0.52	1.41e-24	Mood instability;
LUSC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg20573242	chr4:122745356	CCNA2	0.64	9.03	0.44	1.36e-17	Type 2 diabetes;
LUSC	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg17462356	chr17:80056334	FASN	-0.46	-6.21	-0.32	1.53e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6500395	1.000	rs12934126	chr16:48705951	C/G	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg18305652	chr10:134549665	INPP5A	0.42	6.62	0.34	1.45e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.19	15.22	0.64	4.13e-40	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7523273	0.606	rs1474742	chr1:207976666	A/C	cg22525895	chr1:207977042	MIR29B2	0.37	5.91	0.31	8.5e-9	Schizophrenia;
LUSC	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg25643088	chr3:52874325	TMEM110	-0.41	-5.95	-0.31	6.88e-9	Schizophrenia;
LUSC	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg27165867	chr14:105738592	BRF1	-0.56	-8.36	-0.42	1.7e-15	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11630290	0.592	rs1912049	chr15:64155606	G/T	cg12036633	chr15:63758958	NA	0.54	6.84	0.35	3.7e-11	Iris characteristics;
LUSC	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.8	-0.39	8.14e-14	Joint mobility (Beighton score);
LUSC	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg13334819	chr7:99746414	C7orf59	-0.5	-6.68	-0.34	1e-10	Coronary artery disease;
LUSC	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.42	-7.5	-0.38	5.66e-13	Glomerular filtration rate;
LUSC	cis	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg06521331	chr12:34319734	NA	-0.42	-6.77	-0.35	5.87e-11	Morning vs. evening chronotype;
LUSC	cis	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg06521331	chr12:34319734	NA	-0.45	-7.33	-0.37	1.79e-12	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg05340658	chr4:99064831	C4orf37	0.59	7.71	0.39	1.48e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27286337	chr10:134555280	INPP5A	0.92	11.97	0.55	1.05e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-8.53	-0.42	5.25e-16	Total cholesterol levels;
LUSC	cis	rs9815354	0.812	rs73077386	chr3:41857652	A/G	cg03022575	chr3:42003672	ULK4	0.83	8.73	0.43	1.28e-16	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12629250	chr15:20149347	NA	0.48	6.42	0.33	4.59e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs939658	0.805	rs36068099	chr15:79438598	G/C	cg17916960	chr15:79447300	NA	-0.52	-10.38	-0.49	4.68e-22	Refractive error;
LUSC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg07157834	chr1:205819609	PM20D1	0.47	6.69	0.34	9.48e-11	Prostate-specific antigen levels;
LUSC	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg02951883	chr7:2050386	MAD1L1	-0.37	-6.11	-0.32	2.7e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs6967385	0.519	rs7795828	chr7:12347689	C/T	cg06484146	chr7:12443880	VWDE	0.52	7.76	0.39	1.07e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg03060546	chr3:49711283	APEH	-0.62	-7.37	-0.37	1.37e-12	Menarche (age at onset);
LUSC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg14440974	chr22:39074834	NA	-0.39	-6.5	-0.34	2.94e-10	Menopause (age at onset);
LUSC	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg14983838	chr19:29218262	NA	0.6	8.66	0.43	2.1e-16	Methadone dose in opioid dependence;
LUSC	cis	rs6960043	0.818	rs2191348	chr7:15064255	G/T	cg19272540	chr7:15055459	NA	-0.32	-7.79	-0.39	8.77e-14	Type 2 diabetes;
LUSC	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.33	-6.45	-0.33	3.84e-10	Total body bone mineral density;
LUSC	cis	rs41271473	1.000	rs4641285	chr1:228878663	G/A	cg10167378	chr1:228756711	NA	0.54	6.59	0.34	1.72e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs2274273	0.615	rs67008693	chr14:55702693	T/C	cg04306507	chr14:55594613	LGALS3	0.48	9.5	0.46	4.1e-19	Protein biomarker;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21313137	chr20:44462302	SNX21	0.37	6.16	0.32	2.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.69	12.61	0.57	4.56e-30	Prudent dietary pattern;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08875078	chr22:50639485	SELO	-0.46	-6.75	-0.35	6.56e-11	Electrocardiographic conduction measures;
LUSC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg01616529	chr11:638424	DRD4	-0.35	-5.79	-0.3	1.65e-8	Systemic lupus erythematosus;
LUSC	cis	rs4363385	0.791	rs10788855	chr1:153002359	A/T	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.09	-0.36	8.12e-12	Inflammatory skin disease;
LUSC	cis	rs4664308	0.875	rs2124969	chr2:160989486	T/C	cg03641300	chr2:160917029	PLA2R1	-0.67	-11.58	-0.54	2.79e-26	Idiopathic membranous nephropathy;
LUSC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-7.76	-0.39	1.07e-13	Total body bone mineral density;
LUSC	cis	rs17255340	0.539	rs9449615	chr6:84089502	G/T	cg08257003	chr6:84140564	ME1	0.35	8.75	0.43	1.1e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03576123	chr11:487126	PTDSS2	-1.1	-11.52	-0.53	4.56e-26	Body mass index;
LUSC	cis	rs3755132	0.929	rs59734551	chr2:15754125	G/A	cg12888861	chr2:15731646	DDX1	0.51	7.3	0.37	2.1e-12	Wilms tumor;
LUSC	cis	rs6580649	0.943	rs9651993	chr12:48404692	G/A	cg24011408	chr12:48396354	COL2A1	0.51	6.84	0.35	3.71e-11	Lung cancer;
LUSC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg18357645	chr12:58087776	OS9	-0.55	-8.29	-0.41	2.71e-15	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg26924012	chr15:45694286	SPATA5L1	1.14	19.88	0.74	1.4e-58	Homoarginine levels;
LUSC	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg24838063	chr12:130822603	PIWIL1	0.67	10.45	0.5	2.57e-22	Menopause (age at onset);
LUSC	cis	rs2766692	1.000	rs2766692	chr14:100684192	C/T	cg14866419	chr14:100704911	YY1	0.46	5.89	0.31	9.28e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg20307385	chr11:47447363	PSMC3	-0.47	-7.02	-0.36	1.24e-11	Subjective well-being;
LUSC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg18230493	chr5:56204884	C5orf35	-0.89	-13.55	-0.6	1.19e-33	Initial pursuit acceleration;
LUSC	cis	rs72627509	0.857	rs2227901	chr4:57798189	A/G	cg26694713	chr4:57773883	REST	-0.5	-6.07	-0.32	3.4e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg12863693	chr15:85201151	NMB	0.36	7.15	0.36	5.61e-12	Schizophrenia;
LUSC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	1.03	19.93	0.74	8.62e-59	Menopause (age at onset);
LUSC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg15445000	chr17:37608096	MED1	-0.38	-6.5	-0.34	2.88e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7189233	0.911	rs8057808	chr16:53520613	G/A	cg09728985	chr16:53543985	NA	-0.38	-6.84	-0.35	3.73e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	6.37	0.33	6.19e-10	Alzheimer's disease (late onset);
LUSC	cis	rs9341808	0.754	rs9352808	chr6:80997342	G/T	cg08355045	chr6:80787529	NA	0.57	9.99	0.48	1e-20	Sitting height ratio;
LUSC	trans	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg25214090	chr10:38739885	LOC399744	0.46	6.81	0.35	4.64e-11	Corneal astigmatism;
LUSC	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg16482183	chr6:26056742	HIST1H1C	0.6	8.21	0.41	4.76e-15	Iron status biomarkers;
LUSC	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg12016809	chr21:47604291	C21orf56	-0.44	-6.61	-0.34	1.53e-10	Testicular germ cell tumor;
LUSC	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg18404041	chr3:52824283	ITIH1	0.53	9.21	0.45	3.64e-18	Schizophrenia;
LUSC	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg05585544	chr11:47624801	NA	-0.4	-6.96	-0.36	1.81e-11	Subjective well-being;
LUSC	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg18721089	chr20:30220636	NA	0.37	5.87	0.31	1.03e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs2273669	0.667	rs9688896	chr6:109364698	T/C	cg05315195	chr6:109294784	ARMC2	-0.54	-5.89	-0.31	9.41e-9	Prostate cancer;
LUSC	cis	rs6060960	0.537	rs6087787	chr20:30452089	G/A	cg06102403	chr20:30458708	TTLL9;DUSP15	0.46	5.68	0.3	2.95e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs3087591	0.708	rs7502834	chr17:29689430	G/A	cg24425628	chr17:29625626	OMG;NF1	0.49	7.18	0.37	4.53e-12	Hip circumference;
LUSC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.84	-0.3	1.22e-8	Platelet count;
LUSC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.49	6.97	0.36	1.74e-11	Osteoporosis;
LUSC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	0.89	16.14	0.66	1.02e-43	Cognitive function;
LUSC	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg24375607	chr4:120327624	NA	0.68	10.98	0.52	3.59e-24	Corneal astigmatism;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg13436085	chr3:183904316	ABCF3	0.38	6.36	0.33	6.52e-10	Triglycerides;
LUSC	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.73	-0.43	1.21e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg22532475	chr10:104410764	TRIM8	-0.28	-5.97	-0.31	6.03e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19626725	chr5:178986131	RUFY1	-0.58	-10.88	-0.51	8.65e-24	Lung cancer;
LUSC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.63	11.24	0.52	4.35e-25	Menopause (age at onset);
LUSC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg17340268	chr14:105411764	AHNAK2	-0.38	-6.07	-0.32	3.41e-9	Rheumatoid arthritis;
LUSC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg23791538	chr6:167370224	RNASET2	-0.42	-6.76	-0.35	6.11e-11	Crohn's disease;
LUSC	cis	rs7605827	0.964	rs6733847	chr2:15564930	G/A	cg19274914	chr2:15703543	NA	0.47	8.97	0.44	2.17e-17	Educational attainment (years of education);
LUSC	cis	rs10779751	0.770	rs6701524	chr1:11198502	A/G	cg08854313	chr1:11322531	MTOR	-0.83	-12.7	-0.57	1.98e-30	Body mass index;
LUSC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg14092988	chr3:52407081	DNAH1	0.33	6.28	0.33	1.04e-9	Bipolar disorder;
LUSC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.62	10.66	0.5	5e-23	Bone mineral density;
LUSC	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg21775007	chr8:11205619	TDH	0.71	11.26	0.52	3.73e-25	Retinal vascular caliber;
LUSC	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-7.74	-0.39	1.2e-13	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-6.07	-0.32	3.54e-9	IgG glycosylation;
LUSC	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg13628971	chr7:2884303	GNA12	-0.4	-6.16	-0.32	2.14e-9	Height;
LUSC	trans	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg20587970	chr11:113659929	NA	0.81	9.8	0.47	4.41e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-1.04	-12.28	-0.56	7.53e-29	Schizophrenia;
LUSC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg25204440	chr1:209979598	IRF6	0.51	6.82	0.35	4.34e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg25457927	chr22:38595422	NA	-0.46	-9.83	-0.47	3.48e-20	Cutaneous nevi;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16303686	chr3:132136102	DNAJC13	-0.43	-6.47	-0.33	3.56e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.5	6.66	0.34	1.15e-10	Corneal astigmatism;
LUSC	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.89	-0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.35	-7.0	-0.36	1.42e-11	Total body bone mineral density;
LUSC	cis	rs77633900	0.772	rs284907	chr15:76741569	A/G	cg21673338	chr15:77095150	SCAPER	-0.7	-6.15	-0.32	2.19e-9	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg00012203	chr2:219082015	ARPC2	0.82	14.08	0.61	1.18e-35	Colorectal cancer;
LUSC	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.83	-9.83	-0.47	3.36e-20	Body mass index;
LUSC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-6.28	-0.33	1.03e-9	Schizophrenia;
LUSC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg04518342	chr5:131593106	PDLIM4	-0.35	-6.48	-0.33	3.33e-10	Blood metabolite levels;
LUSC	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05535760	chr7:792225	HEATR2	0.77	9.24	0.45	2.91e-18	Cerebrospinal P-tau181p levels;
LUSC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08677398	chr8:58056175	NA	0.53	6.45	0.33	3.88e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-7.33	-0.37	1.77e-12	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs9462027	0.606	rs2744959	chr6:34616654	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.34	-5.97	-0.31	6.1e-9	Systemic lupus erythematosus;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg19640263	chr11:62414186	GANAB	-0.5	-6.5	-0.34	2.93e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-1.08	-25.56	-0.81	1.33e-80	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09325506	chr2:243030735	LOC728323	0.41	5.98	0.31	5.76e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg02380750	chr20:61661411	NA	0.33	5.67	0.3	3.02e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	8.61	0.43	2.95e-16	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.77	12.86	0.58	4.88e-31	Cognitive function;
LUSC	cis	rs7267979	0.565	rs6076364	chr20:25556801	T/C	cg03522245	chr20:25566470	NINL	-0.39	-6.0	-0.31	5.18e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg13699009	chr12:122356056	WDR66	0.48	7.55	0.38	4.24e-13	Mean corpuscular volume;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.23	0.41	4.31e-15	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs4561483	0.603	rs11075033	chr16:12006338	C/T	cg08843971	chr16:11963173	GSPT1	0.42	6.45	0.33	3.95e-10	Testicular germ cell tumor;
LUSC	cis	rs7106204	0.620	rs16912295	chr11:24260162	T/C	ch.11.24196551F	chr11:24239977	NA	0.73	6.22	0.32	1.49e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg12062639	chr20:23401060	NAPB	0.78	6.02	0.31	4.61e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg09365446	chr1:150670422	GOLPH3L	0.52	7.88	0.4	4.74e-14	Tonsillectomy;
LUSC	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg19700328	chr14:106028568	NA	-0.41	-6.94	-0.36	1.99e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg13755796	chr4:20253514	NA	-0.41	-6.43	-0.33	4.42e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg24130564	chr14:104152367	KLC1	-0.43	-6.08	-0.32	3.33e-9	Body mass index;
LUSC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs737008	0.960	rs34764020	chr16:11378359	C/T	cg00044050	chr16:11439710	C16orf75	-0.53	-8.13	-0.41	8.61e-15	Obesity-related traits;
LUSC	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg00579200	chr11:133705235	NA	-0.41	-5.86	-0.31	1.14e-8	Childhood ear infection;
LUSC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.54	8.11	0.41	1.01e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LUSC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg17211192	chr8:82754475	SNX16	-0.78	-10.66	-0.5	4.89e-23	Diastolic blood pressure;
LUSC	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg10560079	chr2:191398806	TMEM194B	-0.73	-8.49	-0.42	6.66e-16	Diastolic blood pressure;
LUSC	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	0.57	8.69	0.43	1.66e-16	Breast cancer;
LUSC	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg04310649	chr10:35416472	CREM	-0.44	-6.85	-0.35	3.54e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg23711669	chr6:146136114	FBXO30	0.87	15.58	0.65	1.61e-41	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18876405	chr7:65276391	NA	0.49	6.66	0.34	1.14e-10	Corneal structure;
LUSC	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-0.53	-8.09	-0.4	1.12e-14	Breast cancer;
LUSC	cis	rs62400317	0.826	rs12205642	chr6:45331765	T/C	cg20913747	chr6:44695427	NA	-0.48	-7.8	-0.39	7.82e-14	Total body bone mineral density;
LUSC	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.69	10.1	0.48	4.05e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.27	-0.52	3.43e-25	Mean corpuscular volume;
LUSC	cis	rs6500395	1.000	rs1120276	chr16:48598517	C/G	cg04672837	chr16:48644449	N4BP1	0.43	6.47	0.33	3.44e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.87	0.31	1.06e-8	Morning vs. evening chronotype;
LUSC	cis	rs10743315	0.557	rs80051304	chr12:19286086	G/A	cg02471346	chr12:19282374	PLEKHA5	0.94	6.82	0.35	4.25e-11	Gut microbiota (bacterial taxa);
LUSC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg17554472	chr22:41940697	POLR3H	-0.46	-5.68	-0.3	2.89e-8	Vitiligo;
LUSC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	0.84	11.7	0.54	9.54e-27	Age-related macular degeneration (geographic atrophy);
LUSC	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-8.13	-0.41	8.27e-15	Retinal vascular caliber;
LUSC	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.59	-0.34	1.67e-10	Recombination measurement;
LUSC	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg16797656	chr11:68205561	LRP5	0.38	6.21	0.32	1.58e-9	Total body bone mineral density;
LUSC	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg13607699	chr17:42295918	UBTF	0.75	13.86	0.6	8.11e-35	Red cell distribution width;Reticulocyte count;
LUSC	cis	rs7582720	1.000	rs78907692	chr2:203932176	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.65	0.43	2.2e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-9.48	-0.46	4.78e-19	Intelligence (multi-trait analysis);
LUSC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.85	0.3	1.2e-8	Tonsillectomy;
LUSC	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg21775007	chr8:11205619	TDH	-0.47	-6.82	-0.35	4.37e-11	Triglycerides;
LUSC	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg07701084	chr6:150067640	NUP43	0.54	8.02	0.4	1.82e-14	Lung cancer;
LUSC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.96	-0.36	1.83e-11	Lung cancer;
LUSC	cis	rs2996428	0.667	rs7538067	chr1:3761772	C/T	cg13057898	chr1:3703894	LRRC47	0.52	8.86	0.44	4.96e-17	Red cell distribution width;
LUSC	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg21427119	chr20:30132790	HM13	-0.44	-6.29	-0.33	9.94e-10	Mean corpuscular hemoglobin;
LUSC	cis	rs79387448	0.745	rs76746266	chr2:103124920	C/T	cg09003973	chr2:102972529	NA	0.86	8.52	0.42	5.6e-16	Gut microbiota (bacterial taxa);
LUSC	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg04414720	chr1:150670196	GOLPH3L	0.52	8.25	0.41	3.79e-15	Melanoma;
LUSC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg22920501	chr2:26401640	FAM59B	0.84	12.04	0.55	5.84e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg19046167	chr17:80928561	B3GNTL1	-0.45	-6.66	-0.34	1.1e-10	Breast cancer;
LUSC	cis	rs2425143	0.730	rs6060626	chr20:34415073	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-5.9	-0.31	8.99e-9	Blood protein levels;
LUSC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg11861562	chr11:117069780	TAGLN	0.37	7.18	0.37	4.44e-12	Blood protein levels;
LUSC	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg14664628	chr15:75095509	CSK	0.41	5.83	0.3	1.3e-8	Systemic lupus erythematosus;
LUSC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.02	0.58	1.27e-31	Prudent dietary pattern;
LUSC	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg09479241	chr17:27052676	TLCD1	0.43	5.84	0.3	1.23e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg13939156	chr17:80058883	NA	0.33	6.48	0.33	3.32e-10	Life satisfaction;
LUSC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08280861	chr8:58055591	NA	0.56	5.98	0.31	5.87e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-1.02	-12.08	-0.55	4.03e-28	Mitochondrial DNA levels;
LUSC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-10.92	-0.51	6.1e-24	Mean corpuscular volume;
LUSC	cis	rs829883	0.738	rs249854	chr12:98862772	G/A	cg25150519	chr12:98850993	NA	0.8	13.66	0.6	4.68e-34	Colorectal adenoma (advanced);
LUSC	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07080220	chr10:102295463	HIF1AN	0.68	9.04	0.44	1.34e-17	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.51	-5.82	-0.3	1.41e-8	Yeast infection;
LUSC	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg00012203	chr2:219082015	ARPC2	-0.52	-8.29	-0.41	2.79e-15	Ulcerative colitis;
LUSC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg14664628	chr15:75095509	CSK	-0.56	-8.43	-0.42	1.07e-15	Breast cancer;
LUSC	trans	rs76513454	0.730	rs17571465	chr1:218890658	A/T	cg22737241	chr10:557605	DIP2C	-0.69	-6.17	-0.32	2e-9	Red blood cell density in sickle cell anemia;
LUSC	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	15.36	0.64	1.18e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs151234	0.676	rs508022	chr16:28573963	C/T	cg01378222	chr16:28622494	SULT1A1	-0.62	-8.34	-0.42	1.91e-15	Platelet distribution width;
LUSC	cis	rs9921338	0.886	rs4780363	chr16:11415891	C/T	cg00044050	chr16:11439710	C16orf75	0.48	6.47	0.33	3.57e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg00310523	chr12:86230176	RASSF9	-0.47	-8.97	-0.44	2.22e-17	Major depressive disorder;
LUSC	trans	rs11264799	0.669	rs12082378	chr1:157634567	C/A	cg25498969	chr3:136062740	STAG1	-0.24	-6.25	-0.32	1.23e-9	IgA nephropathy;
LUSC	trans	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg07393940	chr7:158741817	NA	0.36	6.51	0.34	2.79e-10	Life satisfaction;
LUSC	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg05527609	chr1:210001259	C1orf107	-0.89	-11.78	-0.54	5.1e-27	Orofacial clefts;
LUSC	cis	rs4144743	1.000	rs2317385	chr17:45329682	G/A	cg18085866	chr17:45331354	ITGB3	-0.74	-7.72	-0.39	1.38e-13	Body mass index;
LUSC	cis	rs9807989	0.765	rs9807962	chr2:102971664	A/G	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.67e-9	Asthma;
LUSC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	6.06	0.31	3.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-6.88	-0.35	2.89e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg06008330	chr7:65541103	ASL	-0.4	-6.23	-0.32	1.43e-9	Aortic root size;
LUSC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05165339	chr4:1420672	NA	0.28	6.37	0.33	6.16e-10	Obesity-related traits;
LUSC	cis	rs11608355	0.521	rs7972346	chr12:109808771	C/G	cg19025524	chr12:109796872	NA	0.42	7.8	0.39	8.17e-14	Neuroticism;
LUSC	trans	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg27411982	chr8:10470053	RP1L1	0.42	6.33	0.33	7.88e-10	Monocyte count;
LUSC	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg10130564	chr11:117069849	TAGLN	0.31	5.78	0.3	1.71e-8	Blood protein levels;
LUSC	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.71	11.61	0.54	2.1e-26	Eye color traits;
LUSC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg26335602	chr6:28129616	ZNF389	0.44	5.97	0.31	5.91e-9	Depression;
LUSC	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.9	-0.35	2.6e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.91	0.31	8.5e-9	Rheumatoid arthritis;
LUSC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.48	-8.04	-0.4	1.57e-14	Lymphocyte counts;
LUSC	trans	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg07393940	chr7:158741817	NA	0.38	6.74	0.35	6.87e-11	Life satisfaction;
LUSC	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.09	-0.36	8.21e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs16937	0.662	rs12137294	chr1:205182872	A/C	cg21643547	chr1:205240462	TMCC2	-0.36	-6.42	-0.33	4.72e-10	Schizophrenia;
LUSC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg02018176	chr4:1364513	KIAA1530	0.52	8.83	0.43	6.21e-17	Obesity-related traits;
LUSC	cis	rs6906287	0.647	rs34479834	chr6:118826244	T/A	cg21191810	chr6:118973309	C6orf204	0.33	6.03	0.31	4.44e-9	Electrocardiographic conduction measures;
LUSC	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg01028140	chr2:1542097	TPO	-0.62	-8.38	-0.42	1.47e-15	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.73	-0.3	2.22e-8	Total body bone mineral density;
LUSC	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg07080220	chr10:102295463	HIF1AN	0.59	7.72	0.39	1.36e-13	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg22963979	chr7:1858916	MAD1L1	-0.5	-7.7	-0.39	1.53e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs9837602	1.000	rs9878931	chr3:99712634	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.41	-5.89	-0.31	9.26e-9	Breast cancer;
LUSC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg12863693	chr15:85201151	NMB	0.35	6.84	0.35	3.79e-11	Schizophrenia;
LUSC	cis	rs4343996	0.558	rs1554500	chr7:3415864	T/C	cg21248987	chr7:3385318	SDK1	0.36	6.11	0.32	2.8e-9	Motion sickness;
LUSC	trans	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg06636001	chr8:8085503	FLJ10661	0.44	6.47	0.33	3.57e-10	Retinal vascular caliber;
LUSC	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg26102564	chr10:131424627	MGMT	0.39	6.16	0.32	2.05e-9	Response to temozolomide;
LUSC	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg27661571	chr11:113659931	NA	-0.67	-7.7	-0.39	1.56e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.58	-7.25	-0.37	2.99e-12	Body mass index;
LUSC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	0.93	15.95	0.66	5.58e-43	Menopause (age at onset);
LUSC	cis	rs6933660	0.610	rs71549125	chr6:151770796	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	7.62	0.38	2.69e-13	Menarche (age at onset);
LUSC	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg04450456	chr4:17643702	FAM184B	0.37	6.19	0.32	1.81e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs12122100	0.651	rs12129691	chr1:146554147	C/T	cg03526459	chr1:146549940	NA	-0.41	-6.55	-0.34	2.2e-10	HIV-1 control;
LUSC	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg17633681	chr16:88106987	BANP	0.53	10.09	0.48	4.58e-21	Menopause (age at onset);
LUSC	cis	rs13089785	0.965	rs67028142	chr3:123635213	A/G	cg02012769	chr3:123398346	MYLK	0.34	6.26	0.32	1.2e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.94	0.51	5.25e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg04607235	chr12:12878440	APOLD1	-0.56	-6.38	-0.33	5.81e-10	Systemic lupus erythematosus;
LUSC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.72	10.11	0.48	3.92e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg08085267	chr17:45401833	C17orf57	0.54	8.83	0.44	6.01e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	8.71	0.43	1.41e-16	Lung cancer in ever smokers;
LUSC	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg27471124	chr11:109292789	C11orf87	0.42	7.43	0.38	9.39e-13	Schizophrenia;
LUSC	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg05163923	chr11:71159392	DHCR7	-0.71	-10.55	-0.5	1.2e-22	Vitamin D levels;
LUSC	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg11062466	chr8:58055876	NA	0.42	5.66	0.3	3.32e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg03599575	chr15:90893182	GABARAPL3	0.34	5.83	0.3	1.34e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6700896	0.931	rs4655582	chr1:66153363	C/G	cg04111102	chr1:66153794	NA	0.33	7.19	0.37	4.18e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg12935359	chr14:103987150	CKB	-0.65	-10.4	-0.49	3.86e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg20821713	chr7:1055600	C7orf50	-0.38	-5.9	-0.31	9.1e-9	Longevity;Endometriosis;
LUSC	trans	rs984440	0.621	rs1028777	chr8:139077206	G/T	cg03334052	chr1:168888044	NA	0.42	6.54	0.34	2.35e-10	Obesity-related traits;
LUSC	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.77	11.09	0.52	1.49e-24	Corneal astigmatism;
LUSC	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg21724239	chr8:58056113	NA	-0.56	-6.84	-0.35	3.78e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg09165964	chr15:75287851	SCAMP5	-0.97	-11.87	-0.54	2.38e-27	Blood trace element (Zn levels);
LUSC	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg03060546	chr3:49711283	APEH	-0.62	-7.37	-0.37	1.37e-12	Menarche (age at onset);
LUSC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg18132916	chr6:79620363	NA	-0.38	-5.69	-0.3	2.83e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg17042849	chr6:26104293	HIST1H4C	-0.42	-5.88	-0.31	9.82e-9	Height;
LUSC	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg00898013	chr13:113819073	PROZ	-0.61	-9.0	-0.44	1.77e-17	Platelet distribution width;
LUSC	trans	rs4811340	0.600	rs2143941	chr20:51179222	G/A	cg15736553	chr3:11610338	VGLL4	-0.33	-5.95	-0.31	6.7e-9	Thyroid peroxidase antibody positivity;
LUSC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.68	-10.47	-0.5	2.3e-22	Aortic root size;
LUSC	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg03388025	chr16:89894329	SPIRE2	0.31	6.47	0.33	3.52e-10	Vitiligo;
LUSC	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg22705602	chr4:152727874	NA	-0.32	-6.47	-0.33	3.41e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08677398	chr8:58056175	NA	0.49	6.14	0.32	2.31e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-9.68	-0.47	1.1e-19	Brugada syndrome;
LUSC	cis	rs34638657	0.797	rs11645045	chr16:82202137	G/A	cg09439754	chr16:82129088	HSD17B2	-0.4	-6.57	-0.34	1.97e-10	Lung adenocarcinoma;
LUSC	cis	rs11608355	1.000	rs7132057	chr12:109880279	A/C	cg05360138	chr12:110035743	NA	0.45	6.19	0.32	1.74e-9	Neuroticism;
LUSC	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.46	5.86	0.31	1.14e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4660306	0.961	rs11211138	chr1:46015157	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-6.35	-0.33	7.04e-10	Homocysteine levels;
LUSC	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg23601095	chr6:26197514	HIST1H3D	0.73	7.35	0.37	1.52e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08736216	chr1:53307985	ZYG11A	0.29	6.03	0.31	4.36e-9	Monocyte count;
LUSC	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	13.33	0.59	8.64e-33	Mean platelet volume;
LUSC	cis	rs9815354	0.680	rs10510730	chr3:41849013	C/G	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-7.19	-0.37	4.22e-12	Monocyte percentage of white cells;
LUSC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg07424592	chr7:64974309	NA	0.69	6.1	0.32	2.98e-9	Diabetic kidney disease;
LUSC	cis	rs3771570	1.000	rs62190370	chr2:242384194	C/G	cg21155796	chr2:242212141	HDLBP	0.6	6.54	0.34	2.28e-10	Prostate cancer;
LUSC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg24399712	chr22:39784796	NA	-0.63	-11.5	-0.53	5.01e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg15744005	chr10:104629667	AS3MT	-0.27	-5.72	-0.3	2.34e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.7	12.12	0.55	2.81e-28	Age-related hearing impairment;
LUSC	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-8.82	-0.43	6.68e-17	Response to antipsychotic treatment;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02889909	chr14:75760889	NA	-0.52	-6.12	-0.32	2.69e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.69	-0.39	1.62e-13	Glomerular filtration rate;
LUSC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.04	21.37	0.76	1.82e-64	Cognitive function;
LUSC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	0.64	13.34	0.59	7.84e-33	Prudent dietary pattern;
LUSC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg23719950	chr11:63933701	MACROD1	-0.55	-7.62	-0.38	2.63e-13	Mean platelet volume;
LUSC	cis	rs2235544	0.579	rs1537323	chr1:54482523	G/T	cg25741118	chr1:54482237	LDLRAD1	0.33	7.64	0.39	2.27e-13	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
LUSC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg08601574	chr20:25228251	PYGB	0.43	6.6	0.34	1.59e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2275620	0.966	rs6583969	chr10:96826245	G/A	cg09036531	chr10:96991505	NA	-0.41	-5.84	-0.3	1.27e-8	Gout;
LUSC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26769984	chr7:1090371	C7orf50	0.72	10.1	0.48	4.03e-21	Bronchopulmonary dysplasia;
LUSC	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg23978390	chr7:1156363	C7orf50	0.49	6.01	0.31	4.76e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg10018233	chr7:150070692	REPIN1	0.46	9.33	0.45	1.55e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.1	0.41	1.05e-14	Prudent dietary pattern;
LUSC	cis	rs2153904	0.793	rs1891091	chr1:205661418	A/G	cg23034840	chr1:205782522	SLC41A1	0.6	5.71	0.3	2.47e-8	Prostate-specific antigen levels;
LUSC	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg15445000	chr17:37608096	MED1	0.38	6.71	0.34	8.31e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-7.61	-0.38	2.91e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg16797656	chr11:68205561	LRP5	0.37	6.04	0.31	4.2e-9	Total body bone mineral density;
LUSC	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.92	0.31	8.06e-9	Morning vs. evening chronotype;
LUSC	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg20243544	chr17:37824526	PNMT	0.48	6.73	0.35	7.42e-11	Asthma;
LUSC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg08508325	chr11:3079039	CARS	-0.48	-11.12	-0.52	1.16e-24	Type 2 diabetes;
LUSC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg23625390	chr15:77176239	SCAPER	0.5	7.7	0.39	1.52e-13	Blood metabolite levels;
LUSC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	6.53	0.34	2.51e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	7.21	0.37	3.73e-12	Mean platelet volume;
LUSC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	8.1	0.41	1.04e-14	Bipolar disorder;
LUSC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg21724239	chr8:58056113	NA	0.78	8.56	0.42	4.04e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg10909506	chr17:38081995	ORMDL3	0.33	5.87	0.31	1.02e-8	Self-reported allergy;
LUSC	cis	rs3764021	0.840	rs10743823	chr12:9881125	C/T	cg20894963	chr12:9885564	CLECL1	0.33	6.68	0.34	9.93e-11	Type 1 diabetes;
LUSC	cis	rs73198271	0.583	rs11781985	chr8:8589783	C/T	cg01851573	chr8:8652454	MFHAS1	-0.38	-5.75	-0.3	2.03e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9359856	0.564	rs72915903	chr6:90420190	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.87	-8.89	-0.44	4e-17	Bipolar disorder;
LUSC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg03146154	chr1:46216737	IPP	-0.55	-7.94	-0.4	3.11e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs77741769	0.529	rs3213572	chr12:121205078	A/G	cg02419362	chr12:121203948	SPPL3	-0.46	-8.63	-0.43	2.57e-16	Mean corpuscular volume;
LUSC	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.68	9.38	0.46	1.05e-18	Alcohol dependence;
LUSC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.69	-10.12	-0.48	3.6e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg02466173	chr16:30829666	NA	-0.5	-9.55	-0.46	2.91e-19	Dementia with Lewy bodies;
LUSC	cis	rs7084921	0.578	rs7474935	chr10:101875936	G/C	cg11888571	chr10:102027403	CWF19L1	-0.46	-6.34	-0.33	7.53e-10	Bone mineral density;
LUSC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg23711669	chr6:146136114	FBXO30	0.89	16.65	0.67	9.14e-46	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.35	-6.52	-0.34	2.63e-10	Coronary artery disease;
LUSC	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg20988073	chr3:125900093	ALDH1L1	0.3	6.06	0.31	3.59e-9	Metabolite levels;
LUSC	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg21132104	chr15:45694354	SPATA5L1	0.42	6.13	0.32	2.45e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg15445000	chr17:37608096	MED1	-0.39	-6.8	-0.35	4.94e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.59	-9.82	-0.47	3.61e-20	Bone mineral density;
LUSC	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg15704280	chr7:45808275	SEPT13	0.73	8.29	0.41	2.88e-15	Axial length;
LUSC	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg24642439	chr20:33292090	TP53INP2	-0.41	-5.86	-0.31	1.09e-8	Height;
LUSC	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg22705602	chr4:152727874	NA	0.39	8.16	0.41	7.06e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg10909506	chr17:38081995	ORMDL3	0.34	6.09	0.32	3.12e-9	Self-reported allergy;
LUSC	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg05084668	chr3:125655381	ALG1L	0.83	11.42	0.53	9.83e-26	Blood pressure (smoking interaction);
LUSC	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg00784671	chr22:46762841	CELSR1	-0.49	-5.93	-0.31	7.55e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg14196790	chr5:131705035	SLC22A5	0.45	7.57	0.38	3.68e-13	Blood metabolite levels;
LUSC	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg13010199	chr12:38710504	ALG10B	0.61	9.58	0.46	2.34e-19	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg24642439	chr20:33292090	TP53INP2	0.4	5.84	0.3	1.22e-8	Height;
LUSC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-18.06	-0.7	2.45e-51	Coronary artery disease;
LUSC	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23422044	chr7:1970798	MAD1L1	0.58	6.97	0.36	1.72e-11	Bipolar disorder;
LUSC	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg15017067	chr4:17643749	FAM184B	0.36	5.9	0.31	8.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg22676075	chr6:135203613	NA	0.46	7.32	0.37	1.86e-12	Red blood cell count;
LUSC	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.91	-0.35	2.44e-11	Response to antipsychotic treatment;
LUSC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg23711669	chr6:146136114	FBXO30	-0.79	-14.11	-0.61	8.86e-36	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg13866156	chr1:1669148	SLC35E2	-0.49	-7.92	-0.4	3.45e-14	Body mass index;
LUSC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-0.79	-11.08	-0.52	1.62e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg09044154	chr16:88155775	NA	-0.57	-7.58	-0.38	3.43e-13	Menopause (age at onset);
LUSC	cis	rs73195822	0.527	rs73194059	chr12:111221740	G/A	cg12870014	chr12:110450643	ANKRD13A	0.68	7.14	0.36	5.98e-12	Itch intensity from mosquito bite;
LUSC	trans	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04565464	chr8:145669602	NFKBIL2	0.37	6.05	0.31	3.8e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg17187183	chr4:55093834	PDGFRA	0.39	5.74	0.3	2.11e-8	Corneal astigmatism;
LUSC	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.9	11.74	0.54	7.05e-27	Breast cancer;
LUSC	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg02269571	chr22:50332266	NA	-0.54	-8.13	-0.41	8.33e-15	Schizophrenia;
LUSC	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-7.67	-0.39	1.87e-13	Morning vs. evening chronotype;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg21945992	chr3:48956913	ARIH2;C3orf71	-0.42	-6.27	-0.32	1.11e-9	Hepatitis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16515820	chr3:114866447	ZBTB20	0.43	6.54	0.34	2.36e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	1.11	27.04	0.83	3.95e-86	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg23788917	chr6:8435910	SLC35B3	0.51	7.56	0.38	3.86e-13	Motion sickness;
LUSC	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg24578937	chr1:2090814	PRKCZ	0.59	13.12	0.58	5.14e-32	Height;
LUSC	cis	rs4730250	0.654	rs6947857	chr7:106787266	T/G	cg02696742	chr7:106810147	HBP1	0.65	9.18	0.45	4.72e-18	Osteoarthritis;
LUSC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.51	7.24	0.37	3.04e-12	Gut microbiome composition (summer);
LUSC	trans	rs6725041	0.805	rs6745249	chr2:213130571	A/G	cg14430582	chr20:42295543	MYBL2	-0.43	-6.48	-0.33	3.28e-10	QT interval (ambient particulate matter interaction);
LUSC	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg11102782	chr19:18549136	ISYNA1	-0.34	-6.35	-0.33	6.85e-10	Breast cancer;
LUSC	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg14664628	chr15:75095509	CSK	-1.01	-17.39	-0.69	1.06e-48	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg26380479	chr7:97908229	NA	-0.28	-6.21	-0.32	1.56e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg26695010	chr11:65641043	EFEMP2	-0.46	-7.05	-0.36	1.04e-11	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-7.31	-0.37	1.97e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs965469	1.000	rs2236092	chr20:3258188	G/C	cg25506879	chr20:3388711	C20orf194	-0.53	-5.99	-0.31	5.48e-9	IFN-related cytopenia;
LUSC	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg03929089	chr4:120376271	NA	0.72	6.86	0.35	3.37e-11	Axial length;
LUSC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg00684032	chr4:1343700	KIAA1530	0.36	6.06	0.31	3.69e-9	Obesity-related traits;
LUSC	cis	rs10743315	0.557	rs17270134	chr12:19367047	G/A	cg02471346	chr12:19282374	PLEKHA5	0.78	6.28	0.33	1.03e-9	Gut microbiota (bacterial taxa);
LUSC	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg24910161	chr17:38119198	GSDMA	-0.28	-6.07	-0.32	3.49e-9	Asthma;
LUSC	cis	rs6494488	0.500	rs72744723	chr15:65020727	C/A	cg08069370	chr15:64387884	SNX1	-0.65	-5.92	-0.31	7.91e-9	Coronary artery disease;
LUSC	cis	rs394563	0.602	rs409111	chr6:149766860	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.33	-6.91	-0.35	2.53e-11	Dupuytren's disease;
LUSC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg16680214	chr1:154839983	KCNN3	-0.51	-9.33	-0.45	1.56e-18	Prostate cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg10814329	chr22:46692864	CN5H6.4;GTSE1	0.66	6.0	0.31	5.17e-9	Cognitive performance;
LUSC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg12310025	chr6:25882481	NA	-0.5	-9.07	-0.44	1.03e-17	Blood metabolite levels;
LUSC	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg12011299	chr4:100065546	ADH4	0.49	7.94	0.4	3.06e-14	Alcohol dependence;
LUSC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.84	14.86	0.63	1.08e-38	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg05855489	chr10:104503620	C10orf26	-0.65	-8.8	-0.43	7.74e-17	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00339695	chr16:24857497	SLC5A11	0.39	6.79	0.35	5.14e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg26958806	chr6:27640298	NA	0.74	6.04	0.31	4.02e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg24375607	chr4:120327624	NA	0.8	11.68	0.54	1.17e-26	Corneal astigmatism;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg17734135	chr20:3140367	UBOX5;FASTKD5	0.78	6.41	0.33	4.95e-10	Cognitive performance;
LUSC	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.5	7.69	0.39	1.72e-13	Lymphocyte counts;
LUSC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg14196790	chr5:131705035	SLC22A5	0.41	7.0	0.36	1.45e-11	Blood metabolite levels;
LUSC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg07217954	chr7:1067459	C7orf50	0.53	5.71	0.3	2.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg20991723	chr1:152506922	NA	0.5	9.44	0.46	6.55e-19	Hair morphology;
LUSC	trans	rs633715	0.918	rs509325	chr1:177894591	A/C	cg23454797	chr7:27183990	HOXA5	-0.51	-5.98	-0.31	5.79e-9	Body mass index (joint analysis main effects and physical activity interaction);Menarche (age at onset);Body mass index;Body mass index in physically inactive individuals;Obesity;Body mass index in physically active individuals;Waist circumference;
LUSC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg25767906	chr1:53392781	SCP2	-0.64	-12.65	-0.57	3.11e-30	Monocyte count;
LUSC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.84	-0.54	2.94e-27	Chronic sinus infection;
LUSC	cis	rs17604090	0.793	rs66956566	chr7:29688702	A/G	cg19413766	chr7:29689036	LOC646762	-0.56	-7.01	-0.36	1.36e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LUSC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.91	-0.4	3.82e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg00933542	chr6:150070202	PCMT1	0.32	6.58	0.34	1.86e-10	Lung cancer;
LUSC	cis	rs2279817	0.863	rs11203439	chr1:18026328	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.43	5.91	0.31	8.27e-9	Neuroticism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg10572969	chr11:13690188	FAR1	-0.4	-6.14	-0.32	2.31e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg17385448	chr1:15911702	AGMAT	0.38	6.49	0.33	3.03e-10	Systolic blood pressure;
LUSC	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08219700	chr8:58056026	NA	0.67	7.53	0.38	4.78e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg00701064	chr4:6280414	WFS1	0.59	14.2	0.61	3.93e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs45535039	1.000	rs1893032	chr11:119088883	G/A	cg16724696	chr11:118992527	HINFP	0.47	5.78	0.3	1.68e-8	Plateletcrit;
LUSC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg24562669	chr7:97807699	LMTK2	0.34	5.99	0.31	5.42e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg24829409	chr8:58192753	C8orf71	-0.61	-7.49	-0.38	6.09e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.57	9.99	0.48	9.68e-21	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg17691542	chr6:26056736	HIST1H1C	0.45	6.87	0.35	3.11e-11	Height;
LUSC	cis	rs9394152	0.845	rs769051	chr6:33473894	T/G	cg13560919	chr6:33536144	NA	0.59	10.52	0.5	1.57e-22	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg02269571	chr22:50332266	NA	-0.59	-8.83	-0.43	6.16e-17	Schizophrenia;
LUSC	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg14664628	chr15:75095509	CSK	0.45	6.37	0.33	6.15e-10	Systemic lupus erythematosus;
LUSC	cis	rs6844999	0.538	rs6852559	chr4:123591521	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	-0.49	-5.78	-0.3	1.73e-8	Cancer;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg02339392	chr6:28234615	ZNF187	0.33	6.13	0.32	2.51e-9	Tuberculosis;
LUSC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.86	0.6	7.94e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg08017756	chr2:100939284	LONRF2	-0.47	-8.71	-0.43	1.44e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.13	0.32	2.46e-9	Menopause (age at onset);
LUSC	cis	rs11229555	0.645	rs61903159	chr11:58184475	G/A	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg14440974	chr22:39074834	NA	-0.35	-5.91	-0.31	8.52e-9	Menopause (age at onset);
LUSC	cis	rs354225	0.584	rs7586311	chr2:54810762	A/G	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg22777020	chr22:31556080	RNF185	-0.45	-5.74	-0.3	2.18e-8	Colorectal cancer;
LUSC	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-10.41	-0.49	3.65e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05165339	chr4:1420672	NA	-0.29	-6.68	-0.34	9.95e-11	Longevity;
LUSC	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg19418458	chr7:158789849	NA	-0.59	-9.7	-0.47	9.33e-20	Facial morphology (factor 20);
LUSC	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-8.06	-0.4	1.39e-14	Retinal vascular caliber;
LUSC	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg18681998	chr4:17616180	MED28	0.78	13.54	0.6	1.34e-33	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	9.27	0.45	2.37e-18	Motion sickness;
LUSC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg18512352	chr11:47633146	NA	-0.46	-9.19	-0.45	4.42e-18	Subjective well-being;
LUSC	trans	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.77	0.35	5.73e-11	Monocyte count;
LUSC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.95	-12.31	-0.56	5.89e-29	Mean corpuscular hemoglobin;
LUSC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg26338869	chr17:61819248	STRADA	0.4	5.77	0.3	1.81e-8	Prudent dietary pattern;
LUSC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-21.61	-0.76	2.15e-65	Height;
LUSC	cis	rs12986413	0.967	rs1074047	chr19:2158748	A/G	cg09261902	chr19:2140048	AP3D1	0.33	6.13	0.32	2.46e-9	Height;
LUSC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg03289416	chr15:75166202	SCAMP2	0.45	7.04	0.36	1.13e-11	Breast cancer;
LUSC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18404041	chr3:52824283	ITIH1	-0.52	-10.19	-0.49	2.09e-21	Bipolar disorder;
LUSC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg10523860	chr14:103875565	MARK3	-0.38	-6.09	-0.32	3.1e-9	Body mass index;
LUSC	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg00944433	chr1:107599041	PRMT6	-0.38	-7.03	-0.36	1.14e-11	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.95	-20.09	-0.74	2e-59	Post bronchodilator FEV1;
LUSC	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg22963979	chr7:1858916	MAD1L1	0.55	8.62	0.43	2.8e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg07741184	chr6:167504864	NA	-0.47	-8.64	-0.43	2.44e-16	Primary biliary cholangitis;
LUSC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg22823121	chr1:150693482	HORMAD1	0.58	9.08	0.44	9.78e-18	Tonsillectomy;
LUSC	cis	rs10100465	0.961	rs2202793	chr8:118633557	C/T	cg09430518	chr8:118662568	NA	-0.3	-5.78	-0.3	1.73e-8	Leprosy;
LUSC	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg13047869	chr3:10149882	C3orf24	0.65	9.09	0.45	8.75e-18	Alzheimer's disease;
LUSC	trans	rs62055045	0.528	rs57342394	chr16:71562859	G/A	cg21834679	chr15:96891026	NA	-0.39	-6.21	-0.32	1.59e-9	Schizophrenia;
LUSC	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg27284194	chr4:1044797	NA	0.59	8.97	0.44	2.1e-17	Recombination rate (females);
LUSC	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg05855489	chr10:104503620	C10orf26	0.57	9.29	0.45	2.07e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.25	0.56	9.74e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07923666	chr12:49932857	KCNH3	-0.53	-6.56	-0.34	2.05e-10	Resting heart rate;
LUSC	cis	rs9400467	0.508	rs61269242	chr6:111803059	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.67	-0.34	1.04e-10	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg03676636	chr4:99064102	C4orf37	0.33	7.1	0.36	7.64e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25510282	chr3:156544081	LEKR1	-0.41	-6.0	-0.31	5.22e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs4714291	0.963	rs1721409	chr6:40112439	A/T	cg02267698	chr19:7991119	CTXN1	0.53	7.4	0.38	1.09e-12	Strep throat;
LUSC	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg15711740	chr2:61764176	XPO1	-0.46	-6.91	-0.35	2.39e-11	Tuberculosis;
LUSC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.63	7.79	0.39	8.49e-14	Lung function (FEV1/FVC);
LUSC	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	8.02	0.4	1.8e-14	Iron status biomarkers;
LUSC	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg21775007	chr8:11205619	TDH	0.46	6.59	0.34	1.76e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg27170947	chr2:26402098	FAM59B	-0.71	-10.85	-0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	trans	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg02113368	chr10:135107346	TUBGCP2	-0.33	-5.97	-0.31	6.19e-9	Dementia with Lewy bodies;
LUSC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg16325326	chr1:53192061	ZYG11B	-0.89	-16.56	-0.67	2.2e-45	Monocyte count;
LUSC	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.64	-0.39	2.31e-13	Height;
LUSC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06481639	chr22:41940642	POLR3H	-0.46	-5.84	-0.3	1.22e-8	Vitiligo;
LUSC	cis	rs62400317	0.518	rs1321080	chr6:45358323	G/T	cg18551225	chr6:44695536	NA	-0.43	-6.57	-0.34	1.92e-10	Total body bone mineral density;
LUSC	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg05110241	chr16:68378359	PRMT7	-0.49	-6.18	-0.32	1.84e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.43	0.53	9.1e-26	Eye color traits;
LUSC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-11.07	-0.52	1.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg20476274	chr7:133979776	SLC35B4	0.87	17.0	0.68	4.02e-47	Mean platelet volume;
LUSC	cis	rs7590255	1.000	rs13403092	chr2:37987680	C/T	cg23497611	chr2:37985316	NA	0.44	6.42	0.33	4.68e-10	Nonsyndromic cleft lip with cleft palate;
LUSC	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg24692254	chr21:30365293	RNF160	-0.54	-8.01	-0.4	1.87e-14	Dental caries;
LUSC	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg24642439	chr20:33292090	TP53INP2	0.41	5.93	0.31	7.46e-9	Height;
LUSC	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg02415014	chr8:143852576	LYNX1	-0.29	-7.25	-0.37	2.9e-12	Urinary tract infection frequency;
LUSC	trans	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg18187862	chr3:45730750	SACM1L	0.61	7.62	0.38	2.65e-13	Primary sclerosing cholangitis;
LUSC	cis	rs11958404	0.932	rs72816540	chr5:157414500	T/C	cg05962755	chr5:157440814	NA	0.49	6.13	0.32	2.44e-9	IgG glycosylation;
LUSC	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg16579770	chr16:72058938	DHODH	0.34	5.74	0.3	2.08e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LUSC	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.53	-7.85	-0.39	5.81e-14	Lymphocyte percentage of white cells;
LUSC	cis	rs2274273	0.875	rs2075602	chr14:55609774	A/G	cg04306507	chr14:55594613	LGALS3	0.58	13.35	0.59	6.92e-33	Protein biomarker;
LUSC	cis	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg02972257	chr16:68554789	NA	-0.48	-6.21	-0.32	1.56e-9	Ulcerative colitis;
LUSC	cis	rs4285028	0.747	rs1920299	chr3:121593769	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	10.12	0.48	3.63e-21	Multiple sclerosis;
LUSC	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.83	-14.01	-0.61	2.09e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg09184832	chr6:79620586	NA	-0.44	-7.06	-0.36	9.88e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs1832871	0.711	rs9457300	chr6:158714609	G/C	cg07165851	chr6:158734300	TULP4	0.5	7.66	0.39	2.05e-13	Height;
LUSC	cis	rs6967385	0.934	rs3815532	chr7:12371459	C/G	cg06484146	chr7:12443880	VWDE	0.4	5.84	0.3	1.21e-8	Response to taxane treatment (placlitaxel);
LUSC	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-7.92	-0.4	3.51e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	7.64	0.39	2.26e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24904631	chr17:17875305	TOM1L2;LRRC48	-0.39	-6.16	-0.32	2.09e-9	Total body bone mineral density;
LUSC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26314531	chr2:26401878	FAM59B	-0.7	-9.64	-0.47	1.4e-19	Gut microbiome composition (summer);
LUSC	cis	rs11229555	0.598	rs12269888	chr11:58184336	T/C	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg08558340	chr7:100472263	SRRT	0.51	6.26	0.32	1.2e-9	Resting heart rate;
LUSC	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.53	-0.53	3.94e-26	Mean corpuscular volume;
LUSC	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg22467129	chr15:76604101	ETFA	-0.39	-6.03	-0.31	4.33e-9	Blood metabolite levels;
LUSC	trans	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg13010199	chr12:38710504	ALG10B	0.45	6.92	0.35	2.25e-11	Morning vs. evening chronotype;
LUSC	cis	rs12594515	1.000	rs56220882	chr15:45997075	C/G	cg06207120	chr15:45996521	NA	0.39	5.89	0.31	9.46e-9	Waist circumference;Weight;
LUSC	cis	rs6066835	1.000	rs6125439	chr20:47314634	G/A	cg18078177	chr20:47281410	PREX1	0.73	6.18	0.32	1.82e-9	Multiple myeloma;
LUSC	cis	rs4619890	0.528	rs28600706	chr4:7876410	T/C	cg24250820	chr4:7887609	AFAP1	0.36	6.15	0.32	2.16e-9	Glaucoma (primary open-angle);
LUSC	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.81	14.27	0.62	2.1e-36	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7607369	0.559	rs4674341	chr2:219659911	A/G	cg02176678	chr2:219576539	TTLL4	-0.54	-9.62	-0.47	1.72e-19	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs72772090	0.539	rs72773917	chr5:96111302	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.75	-7.79	-0.39	8.5e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs757278	0.552	rs11764070	chr7:117312350	T/G	cg10524701	chr7:117356490	CTTNBP2	0.4	5.69	0.3	2.72e-8	Response to methotrexate in juvenile idiopathic arthritis;
LUSC	cis	rs73198271	0.628	rs11777908	chr8:8590437	C/T	cg01851573	chr8:8652454	MFHAS1	0.46	5.77	0.3	1.83e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg09165964	chr15:75287851	SCAMP5	-1.01	-14.99	-0.63	3.29e-39	Blood trace element (Zn levels);
LUSC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg06096015	chr1:231504339	EGLN1	0.58	10.4	0.49	3.84e-22	Hemoglobin concentration;
LUSC	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg18850127	chr7:39170497	POU6F2	0.66	10.73	0.51	2.8e-23	IgG glycosylation;
LUSC	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-13.32	-0.59	9.64e-33	Total body bone mineral density;
LUSC	cis	rs11676348	0.774	rs4672870	chr2:218941916	C/T	cg00012203	chr2:219082015	ARPC2	-0.46	-6.92	-0.35	2.29e-11	Ulcerative colitis;
LUSC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.13	-0.45	6.78e-18	Gut microbiome composition (summer);
LUSC	cis	rs7903847	0.656	rs12412478	chr10:99134923	C/T	cg08345082	chr10:99160200	RRP12	-0.32	-5.67	-0.3	3.15e-8	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg10909506	chr17:38081995	ORMDL3	0.35	6.29	0.33	9.89e-10	Self-reported allergy;
LUSC	cis	rs7584330	0.554	rs1343768	chr2:238444881	G/A	cg16989719	chr2:238392110	NA	-0.41	-5.91	-0.31	8.32e-9	Prostate cancer;
LUSC	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.6	7.32	0.37	1.9e-12	Inflammatory bowel disease;
LUSC	trans	rs2055729	0.885	rs13268133	chr8:9731470	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.93	0.35	2.21e-11	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg05738196	chr6:26577821	NA	0.56	8.42	0.42	1.15e-15	Schizophrenia;
LUSC	cis	rs4642101	0.561	rs9812144	chr3:12805910	G/A	cg24848339	chr3:12840334	CAND2	0.33	6.48	0.33	3.21e-10	QRS complex (12-leadsum);
LUSC	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg13010199	chr12:38710504	ALG10B	0.54	8.05	0.4	1.48e-14	Morning vs. evening chronotype;
LUSC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg16339924	chr4:17578868	LAP3	0.64	10.13	0.48	3.18e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg13939156	chr17:80058883	NA	0.33	6.51	0.34	2.73e-10	Life satisfaction;
LUSC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.35	5.94	0.31	7.23e-9	Electroencephalogram traits;
LUSC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg00409905	chr10:38381863	ZNF37A	-0.39	-6.61	-0.34	1.52e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4363385	0.818	rs61811863	chr1:152995721	T/C	cg25856811	chr1:152973957	SPRR3	-0.36	-6.0	-0.31	5.1e-9	Inflammatory skin disease;
LUSC	cis	rs6840360	0.642	rs1443090	chr4:152451819	T/C	cg20465933	chr4:152376761	FAM160A1	0.35	6.24	0.32	1.34e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg12863693	chr15:85201151	NMB	-0.34	-6.72	-0.34	8.04e-11	Schizophrenia;
LUSC	trans	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg07923666	chr12:49932857	KCNH3	-0.5	-6.3	-0.33	9.14e-10	Resting heart rate;
LUSC	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg00277334	chr10:82204260	NA	-0.51	-7.41	-0.38	1.05e-12	Post bronchodilator FEV1;
LUSC	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.84	-0.44	5.62e-17	Metabolite levels;
LUSC	cis	rs9326248	0.813	rs474488	chr11:117068977	A/G	cg16524733	chr11:117070046	TAGLN	0.37	5.76	0.3	1.87e-8	Blood protein levels;
LUSC	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg03676636	chr4:99064102	C4orf37	0.35	7.67	0.39	1.9e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1144713	0.606	rs1144718	chr12:32264702	T/C	cg01321189	chr12:32259338	BICD1	0.46	6.83	0.35	4e-11	Obesity-related traits;
LUSC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	0.92	16.14	0.66	1.02e-43	Menopause (age at onset);
LUSC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22590775	chr19:49891494	CCDC155	0.64	9.0	0.44	1.74e-17	Multiple sclerosis;
LUSC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg21770322	chr7:97807741	LMTK2	0.41	7.29	0.37	2.32e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.37	0.37	1.39e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11764359	chr7:65958608	NA	0.79	13.11	0.58	5.75e-32	Aortic root size;
LUSC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg17971929	chr21:40555470	PSMG1	0.74	12.6	0.57	4.88e-30	Cognitive function;
LUSC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg00343986	chr7:65444356	GUSB	0.47	7.12	0.36	6.6e-12	Calcium levels;
LUSC	cis	rs7799006	0.691	rs10447541	chr7:2301578	T/G	cg02951883	chr7:2050386	MAD1L1	-0.37	-6.08	-0.32	3.37e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.98	-0.36	1.64e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2386661	0.547	rs11259742	chr10:5647078	C/T	cg17085576	chr10:5658249	NA	-0.44	-6.58	-0.34	1.8e-10	Breast cancer;
LUSC	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg05347473	chr6:146136440	FBXO30	0.53	8.88	0.44	4.06e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2898681	0.581	rs10003908	chr4:53681089	T/C	cg00338735	chr4:53728038	RASL11B	0.43	5.81	0.3	1.46e-8	Optic nerve measurement (cup area);
LUSC	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-7.59	-0.38	3.16e-13	Glomerular filtration rate;
LUSC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.98	0.31	5.65e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.13	0.36	6.16e-12	IgG glycosylation;
LUSC	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg17640201	chr16:30407289	ZNF48	-0.87	-14.35	-0.62	1.02e-36	Tonsillectomy;
LUSC	cis	rs7189233	0.531	rs8046307	chr16:53518686	G/T	cg09728985	chr16:53543985	NA	-0.3	-5.68	-0.3	2.9e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.59	-9.47	-0.46	5.41e-19	Lymphocyte counts;
LUSC	cis	rs4692589	0.556	rs2279267	chr4:170990053	A/G	cg19918862	chr4:170955249	NA	-0.36	-6.48	-0.33	3.22e-10	Anxiety disorder;
LUSC	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg14210321	chr2:106509881	NCK2	-0.6	-9.17	-0.45	5.11e-18	Addiction;
LUSC	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg21427119	chr20:30132790	HM13	-0.43	-6.1	-0.32	3.01e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg14227996	chr4:17616232	MED28	0.81	8.26	0.41	3.4e-15	Opioid sensitivity;
LUSC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg00074818	chr8:8560427	CLDN23	-0.55	-9.09	-0.45	9.02e-18	Obesity-related traits;
LUSC	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.52	-6.54	-0.34	2.29e-10	Response to bleomycin (chromatid breaks);
LUSC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4499344	0.633	rs259246	chr19:33146154	G/C	cg22980127	chr19:33182716	NUDT19	-0.44	-6.47	-0.33	3.54e-10	Mean platelet volume;
LUSC	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg22601191	chr20:60968625	CABLES2	-0.42	-5.85	-0.3	1.17e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02809009	chr19:50354510	PTOV1	-0.54	-6.73	-0.35	7.6e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg11764359	chr7:65958608	NA	-0.51	-6.63	-0.34	1.36e-10	Aortic root size;
LUSC	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg20333904	chr2:240724165	NA	0.39	7.09	0.36	7.82e-12	Obesity-related traits;
LUSC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg21535247	chr6:8435926	SLC35B3	0.57	8.96	0.44	2.28e-17	Motion sickness;
LUSC	cis	rs6942756	0.715	rs6467242	chr7:129001173	T/A	cg02491457	chr7:128862824	NA	-0.5	-7.24	-0.37	3.05e-12	White matter hyperintensity burden;
LUSC	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg07382826	chr16:28625726	SULT1A1	0.28	6.0	0.31	5.18e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg22681709	chr2:178499509	PDE11A	-0.48	-8.77	-0.43	9.06e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9921338	0.961	rs8056282	chr16:11407236	T/C	cg00044050	chr16:11439710	C16orf75	-0.49	-6.5	-0.34	2.84e-10	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs2652834	1.000	rs2729782	chr15:63403354	G/C	cg05507819	chr15:63340323	TPM1	0.66	8.03	0.4	1.73e-14	HDL cholesterol;
LUSC	cis	rs68092024	0.704	rs792832	chr3:99474862	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.4	-6.18	-0.32	1.86e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg06212747	chr3:49208901	KLHDC8B	0.44	6.12	0.32	2.61e-9	Parkinson's disease;
LUSC	cis	rs9309473	0.950	rs6745480	chr2:73840055	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-6.62	-0.34	1.45e-10	Metabolite levels;
LUSC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	trans	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg10388307	chr1:82828058	NA	0.4	6.14	0.32	2.29e-9	Testicular germ cell tumor;
LUSC	cis	rs12681287	0.511	rs4129535	chr8:87524094	G/T	cg00550725	chr8:87521180	FAM82B	0.43	5.66	0.3	3.21e-8	Caudate activity during reward;
LUSC	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.48	-5.87	-0.31	1.04e-8	Neutrophil percentage of white cells;
LUSC	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg01420254	chr6:26195488	NA	0.65	6.99	0.36	1.54e-11	Gout;Renal underexcretion gout;
LUSC	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	8.33	0.41	2.06e-15	Lung cancer in ever smokers;
LUSC	trans	rs9693857	0.501	rs67985496	chr8:9263128	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.94	-0.31	7.04e-9	Systolic blood pressure;
LUSC	cis	rs11645898	0.810	rs11646364	chr16:72108687	A/T	cg14768367	chr16:72042858	DHODH	-0.68	-7.43	-0.38	9.41e-13	Blood protein levels;
LUSC	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	14.08	0.61	1.14e-35	Exhaled nitric oxide levels;
LUSC	cis	rs11650494	0.831	rs7216993	chr17:47454263	A/G	cg08112188	chr17:47440006	ZNF652	0.96	9.0	0.44	1.74e-17	Prostate cancer;
LUSC	cis	rs4566357	0.964	rs4296416	chr2:227921926	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.74	-0.3	2.09e-8	Coronary artery disease;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01988500	chr16:3030808	PKMYT1	-0.41	-6.19	-0.32	1.73e-9	Hepatitis;
LUSC	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.25	0.56	9.52e-29	Height;
LUSC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18758796	chr5:131593413	PDLIM4	0.53	9.17	0.45	4.88e-18	Acylcarnitine levels;
LUSC	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg03676636	chr4:99064102	C4orf37	0.3	5.97	0.31	6.04e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg22823121	chr1:150693482	HORMAD1	0.51	7.47	0.38	7.01e-13	Melanoma;
LUSC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06544989	chr22:39130855	UNC84B	0.33	5.81	0.3	1.46e-8	Menopause (age at onset);
LUSC	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.29	0.53	3e-25	Eye color traits;
LUSC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg03146154	chr1:46216737	IPP	0.56	8.35	0.42	1.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs9473147	0.516	rs9395279	chr6:47542864	C/T	cg12968598	chr6:47444699	CD2AP	0.52	7.79	0.39	8.3e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	0.97	15.26	0.64	2.88e-40	Body mass index;
LUSC	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg12292205	chr6:26970375	C6orf41	-0.42	-6.32	-0.33	8.26e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg06606381	chr12:133084897	FBRSL1	-0.92	-8.91	-0.44	3.3e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	trans	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg18187862	chr3:45730750	SACM1L	-0.51	-6.18	-0.32	1.83e-9	Primary sclerosing cholangitis;
LUSC	cis	rs11031096	0.782	rs4910904	chr11:4165529	C/T	cg18678763	chr11:4115507	RRM1	0.47	6.7	0.34	9.12e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg26441486	chr22:50317300	CRELD2	0.48	7.13	0.36	6.28e-12	Schizophrenia;
LUSC	trans	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs4589502	0.800	rs4147433	chr15:67201152	G/A	cg09911534	chr15:67153556	NA	0.49	6.37	0.33	6.31e-10	Lung cancer (smoking interaction);
LUSC	cis	rs501916	0.743	rs3743281	chr15:48056958	C/T	cg16110827	chr15:48056943	SEMA6D	-0.49	-7.34	-0.37	1.64e-12	Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg18451016	chr1:38461880	NA	0.5	7.9	0.4	4.12e-14	Coronary artery disease;
LUSC	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg25182066	chr10:30743637	MAP3K8	-0.44	-6.73	-0.35	7.18e-11	Itch intensity from mosquito bite;
LUSC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg26335602	chr6:28129616	ZNF389	0.46	6.34	0.33	7.57e-10	Parkinson's disease;
LUSC	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg00310523	chr12:86230176	RASSF9	0.44	8.25	0.41	3.7e-15	Major depressive disorder;
LUSC	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg13736514	chr6:26305472	NA	-0.44	-8.59	-0.43	3.45e-16	Educational attainment;
LUSC	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg11946769	chr3:48343235	NME6	-0.85	-14.15	-0.61	5.93e-36	Coronary artery disease;
LUSC	trans	rs11039798	0.844	rs41431447	chr11:48983199	A/G	cg15704280	chr7:45808275	SEPT13	0.79	6.87	0.35	3.23e-11	Axial length;
LUSC	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg16329650	chr2:213403929	ERBB4	-0.5	-8.69	-0.43	1.64e-16	Symmetrical dimethylarginine levels;
LUSC	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg01256987	chr12:42539512	GXYLT1	-0.45	-8.48	-0.42	7.32e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.73	12.55	0.57	7.07e-30	Motion sickness;
LUSC	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg21385522	chr1:16154831	NA	-0.55	-8.57	-0.42	3.98e-16	Systolic blood pressure;
LUSC	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg26102564	chr10:131424627	MGMT	0.36	5.69	0.3	2.74e-8	Response to temozolomide;
LUSC	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg17764715	chr19:33622953	WDR88	0.57	7.87	0.4	4.88e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg20608306	chr11:116969690	SIK3	0.36	6.72	0.35	7.68e-11	Blood protein levels;
LUSC	trans	rs4714291	0.963	rs1743973	chr6:40094549	T/G	cg02267698	chr19:7991119	CTXN1	0.54	7.49	0.38	6.01e-13	Strep throat;
LUSC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg05082376	chr22:42548792	NA	0.42	6.39	0.33	5.56e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs722599	0.683	rs10139016	chr14:75274288	T/C	cg06637938	chr14:75390232	RPS6KL1	0.4	5.68	0.3	2.89e-8	IgG glycosylation;
LUSC	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg05368731	chr17:41323189	NBR1	0.78	12.85	0.58	5.65e-31	Menopause (age at onset);
LUSC	cis	rs427941	0.632	rs201507	chr7:101764141	T/C	cg06246474	chr7:101738831	CUX1	0.39	6.39	0.33	5.63e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg06917634	chr15:78832804	PSMA4	-0.48	-5.95	-0.31	6.8e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg07424592	chr7:64974309	NA	0.7	6.05	0.31	3.99e-9	Diabetic kidney disease;
LUSC	cis	rs113835537	0.529	rs7950407	chr11:66258006	A/G	cg24851651	chr11:66362959	CCS	0.55	8.27	0.41	3.16e-15	Airway imaging phenotypes;
LUSC	trans	rs4714291	0.674	rs3008837	chr6:40046725	C/T	cg02267698	chr19:7991119	CTXN1	-0.55	-7.99	-0.4	2.25e-14	Strep throat;
LUSC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	6.31	0.33	8.78e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg15383120	chr6:291909	DUSP22	-0.48	-7.41	-0.38	1.04e-12	Menopause (age at onset);
LUSC	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07080220	chr10:102295463	HIF1AN	0.7	8.65	0.43	2.15e-16	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg22907277	chr7:1156413	C7orf50	0.57	8.87	0.44	4.56e-17	Longevity;Endometriosis;
LUSC	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg11342453	chr6:26196699	NA	0.55	5.78	0.3	1.7e-8	Gout;Renal underexcretion gout;
LUSC	cis	rs3091242	0.967	rs3091240	chr1:25676935	G/T	cg20684491	chr1:25596433	NA	0.41	6.41	0.33	5.09e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-0.78	-11.81	-0.54	4.07e-27	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-6.57	-0.34	1.94e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.82	14.39	0.62	7.5e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg03522245	chr20:25566470	NINL	-0.35	-5.66	-0.3	3.28e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg23711669	chr6:146136114	FBXO30	0.85	15.47	0.65	4.32e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg13385521	chr17:29058706	SUZ12P	0.67	6.62	0.34	1.47e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs2191566	1.000	rs390369	chr19:44506984	C/T	cg03039196	chr19:44506973	ZNF230	-0.36	-6.04	-0.31	4.08e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.64	0.63	8.06e-38	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg12483005	chr1:23474871	LUZP1	0.42	6.62	0.34	1.4e-10	Height;
LUSC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg20203395	chr5:56204925	C5orf35	-0.7	-7.81	-0.39	7.26e-14	Type 2 diabetes;
LUSC	cis	rs6424115	0.557	rs35904775	chr1:24180623	T/C	cg10978503	chr1:24200527	CNR2	-0.52	-12.47	-0.56	1.48e-29	Immature fraction of reticulocytes;
LUSC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	6.91	0.35	2.49e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg05347473	chr6:146136440	FBXO30	0.44	7.64	0.39	2.25e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-6.67	-0.34	1.03e-10	Morning vs. evening chronotype;
LUSC	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg03948781	chr1:205179583	DSTYK	0.33	6.46	0.33	3.66e-10	Red blood cell count;
LUSC	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg27489772	chr12:121021490	NA	0.59	7.79	0.39	8.52e-14	Type 1 diabetes nephropathy;
LUSC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg24829409	chr8:58192753	C8orf71	-0.57	-6.22	-0.32	1.49e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg16339924	chr4:17578868	LAP3	0.54	8.36	0.42	1.69e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06112835	chr11:68658793	MRPL21	0.52	7.92	0.4	3.5e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	trans	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg26043149	chr18:55253948	FECH	-0.46	-7.02	-0.36	1.27e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12936587	0.564	rs7208561	chr17:17615528	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.49	7.58	0.38	3.41e-13	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LUSC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg05861140	chr6:150128134	PCMT1	-0.4	-6.31	-0.33	8.8e-10	Lung cancer;
LUSC	trans	rs62055045	0.528	rs62056191	chr16:71533831	C/T	cg15281710	chr15:96890452	NA	-0.48	-6.85	-0.35	3.55e-11	Schizophrenia;
LUSC	cis	rs11642862	0.901	rs11642733	chr16:30969061	G/A	cg02466173	chr16:30829666	NA	-0.63	-6.45	-0.33	3.9e-10	Tonsillectomy;
LUSC	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg03676636	chr4:99064102	C4orf37	-0.36	-7.66	-0.39	2.04e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.51	0.53	4.82e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg13531842	chr10:38383804	ZNF37A	-0.44	-6.72	-0.35	7.84e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg05347473	chr6:146136440	FBXO30	0.66	11.42	0.53	1.04e-25	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg24768116	chr2:27665128	KRTCAP3	-0.32	-6.35	-0.33	6.97e-10	Total body bone mineral density;
LUSC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg05347473	chr6:146136440	FBXO30	0.66	11.7	0.54	9.84e-27	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg11693508	chr17:37793320	STARD3	0.52	7.13	0.36	6.4e-12	Bipolar disorder;
LUSC	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg05707623	chr12:122985044	ZCCHC8	0.66	8.16	0.41	6.76e-15	Body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20632863	chr12:99038768	APAF1;IKBIP	-0.44	-6.6	-0.34	1.6e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg06521331	chr12:34319734	NA	-0.48	-7.77	-0.39	9.54e-14	Morning vs. evening chronotype;
LUSC	cis	rs6142102	0.961	rs1883524	chr20:32626107	G/A	cg08999081	chr20:33150536	PIGU	0.34	5.85	0.3	1.16e-8	Skin pigmentation;
LUSC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg00825309	chr19:58991885	ZNF446	-0.5	-7.16	-0.36	5.17e-12	Uric acid clearance;
LUSC	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg13615516	chr5:77269221	NA	0.41	6.86	0.35	3.31e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg03929089	chr4:120376271	NA	-0.94	-16.46	-0.67	5.66e-45	Height;
LUSC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18854424	chr1:2615690	NA	-0.49	-9.81	-0.47	3.96e-20	Ulcerative colitis;
LUSC	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg02569458	chr12:86230093	RASSF9	0.37	5.99	0.31	5.44e-9	Major depressive disorder;
LUSC	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg26217441	chr16:89643414	CPNE7	-0.48	-5.69	-0.3	2.71e-8	Plateletcrit;
LUSC	cis	rs2932538	0.922	rs12402469	chr1:113076625	G/A	cg22162597	chr1:113214053	CAPZA1	0.72	10.22	0.49	1.58e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs34779708	0.733	rs3936502	chr10:35549218	C/T	cg03585969	chr10:35415529	CREM	0.52	7.25	0.37	2.96e-12	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs9951602	0.512	rs7237214	chr18:76657394	C/G	cg02800362	chr5:177631904	HNRNPAB	0.88	12.72	0.57	1.72e-30	Obesity-related traits;
LUSC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg04317338	chr11:64019027	PLCB3	0.66	7.51	0.38	5.28e-13	Mean platelet volume;
LUSC	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg24375607	chr4:120327624	NA	0.73	10.98	0.52	3.62e-24	Corneal astigmatism;
LUSC	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg27631724	chr1:11040367	C1orf127	0.54	9.4	0.46	8.69e-19	Ewing sarcoma;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg02562052	chr2:202508330	ALS2CR4	0.35	6.03	0.31	4.44e-9	Tuberculosis;
LUSC	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg23625390	chr15:77176239	SCAPER	0.52	7.98	0.4	2.3e-14	Blood metabolite levels;
LUSC	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg01879757	chr17:41196368	BRCA1	-0.48	-7.66	-0.39	2.04e-13	Menopause (age at onset);
LUSC	cis	rs2235649	0.833	rs9922139	chr16:1848329	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-6.15	-0.32	2.17e-9	Blood metabolite levels;
LUSC	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg05340658	chr4:99064831	C4orf37	0.45	7.2	0.37	3.97e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg02153584	chr22:29168773	CCDC117	0.66	10.72	0.51	3.16e-23	Lymphocyte counts;
LUSC	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg14664628	chr15:75095509	CSK	-0.4	-5.93	-0.31	7.59e-9	Airflow obstruction;
LUSC	cis	rs7178572	1.000	rs6495240	chr15:77766556	T/C	cg22256960	chr15:77711686	NA	-0.55	-9.2	-0.45	4.07e-18	Type 2 diabetes;
LUSC	trans	rs4650994	0.524	rs2761465	chr1:178579404	G/T	cg05059571	chr16:84539110	KIAA1609	0.46	8.67	0.43	1.89e-16	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.6	-8.76	-0.43	1e-16	Response to antineoplastic agents;
LUSC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	14.18	0.61	4.56e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-5.89	-0.31	9.63e-9	Alzheimer's disease (late onset);
LUSC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg07424592	chr7:64974309	NA	0.69	6.08	0.32	3.28e-9	Diabetic kidney disease;
LUSC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg12024160	chr4:1254474	NA	0.32	6.01	0.31	4.98e-9	Obesity-related traits;
LUSC	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg12473912	chr3:136751656	NA	0.39	6.77	0.35	5.97e-11	Neuroticism;
LUSC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06850241	chr22:41845214	NA	0.31	5.72	0.3	2.39e-8	Vitiligo;
LUSC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	12.33	0.56	4.77e-29	Colorectal cancer;
LUSC	cis	rs1775715	0.737	rs55859032	chr10:32213239	C/T	cg03015672	chr10:32216066	ARHGAP12	0.32	5.81	0.3	1.47e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs2835872	0.965	rs857976	chr21:39001177	A/C	cg20424643	chr21:39039972	KCNJ6	0.42	6.33	0.33	7.91e-10	Electroencephalographic traits in alcoholism;
LUSC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.75	0.39	1.1e-13	Electroencephalogram traits;
LUSC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.65	-11.6	-0.54	2.18e-26	Aortic root size;
LUSC	cis	rs1443512	0.812	rs1992563	chr12:54330441	G/T	cg17410650	chr12:54324560	NA	-0.59	-10.58	-0.5	9.56e-23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg24449463	chr1:168025552	DCAF6	0.64	9.77	0.47	5.36e-20	Schizophrenia;
LUSC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-6.99	-0.36	1.49e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-7.59	-0.38	3.21e-13	Personality dimensions;
LUSC	cis	rs2303282	0.716	rs2617847	chr16:56397174	C/G	cg00500540	chr16:56394104	NA	-0.44	-7.55	-0.38	4.1e-13	Breast cancer;
LUSC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08219700	chr8:58056026	NA	0.65	7.22	0.37	3.6e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs652260	1.000	rs604938	chr19:7903484	A/G	cg26014689	chr19:7917955	EVI5L	0.44	7.82	0.39	7.01e-14	Menarche (age at onset);
LUSC	cis	rs73206853	0.841	rs7963504	chr12:110906880	C/A	cg12870014	chr12:110450643	ANKRD13A	0.67	6.47	0.33	3.57e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg21385522	chr1:16154831	NA	0.56	8.46	0.42	8.3e-16	Systolic blood pressure;
LUSC	cis	rs3771570	0.786	rs62186396	chr2:242221219	A/G	cg21155796	chr2:242212141	HDLBP	0.64	6.95	0.36	1.9e-11	Prostate cancer;
LUSC	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.85	12.75	0.57	1.29e-30	Body mass index;
LUSC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.52	0.34	2.67e-10	Lung cancer;
LUSC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg09238746	chr17:78121135	EIF4A3	-0.83	-13.21	-0.59	2.49e-32	Yeast infection;
LUSC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7106204	0.609	rs55751762	chr11:24296146	C/T	ch.11.24196551F	chr11:24239977	NA	0.69	5.68	0.3	2.86e-8	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9283706	0.689	rs10041705	chr5:66317222	C/T	cg11590213	chr5:66331682	MAST4	-0.43	-6.46	-0.33	3.64e-10	Coronary artery disease;
LUSC	cis	rs5758511	0.689	rs11913578	chr22:42347391	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.39	0.37	1.17e-12	Birth weight;
LUSC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg05025164	chr4:1340916	KIAA1530	0.51	8.03	0.4	1.74e-14	Longevity;
LUSC	cis	rs12541635	0.677	rs1006480	chr8:106975524	T/C	cg10147462	chr8:107024639	NA	0.64	12.92	0.58	3.03e-31	Age of smoking initiation;
LUSC	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg05110241	chr16:68378359	PRMT7	-0.52	-6.2	-0.32	1.64e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	0.92	16.31	0.67	2.09e-44	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.61	-0.43	2.98e-16	Lung cancer;
LUSC	cis	rs7267979	0.586	rs6050432	chr20:25184028	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.67	12.48	0.56	1.32e-29	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg08680598	chr22:49984980	NA	0.36	6.88	0.35	2.92e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg24733560	chr20:60626293	TAF4	0.43	7.82	0.39	6.95e-14	Body mass index;
LUSC	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg08917208	chr2:24149416	ATAD2B	0.87	9.99	0.48	9.5e-21	Lymphocyte counts;
LUSC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.07	0.52	1.76e-24	Alzheimer's disease;
LUSC	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg05855489	chr10:104503620	C10orf26	0.52	8.0	0.4	2.12e-14	Arsenic metabolism;
LUSC	cis	rs1178968	0.748	rs10248063	chr7:72776008	T/G	cg25889504	chr7:72793014	NA	0.6	7.8	0.39	7.86e-14	Triglyceride levels;
LUSC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	13.09	0.58	6.8e-32	Cognitive test performance;
LUSC	cis	rs9807989	0.507	rs1592459	chr2:103031569	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.72e-12	Asthma;
LUSC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg03676636	chr4:99064102	C4orf37	0.33	7.26	0.37	2.75e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.84	14.74	0.63	3.18e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg03585969	chr10:35415529	CREM	0.63	9.47	0.46	5.31e-19	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg05872129	chr22:39784769	NA	-0.62	-11.68	-0.54	1.17e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg18681998	chr4:17616180	MED28	0.85	15.41	0.64	7.31e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.74	11.23	0.52	4.98e-25	Type 2 diabetes;
LUSC	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg10356904	chr22:49881777	NA	-0.3	-5.94	-0.31	7.14e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs6772840	1.000	rs17076032	chr3:43822972	A/G	cg11173822	chr5:101925501	NA	0.42	6.26	0.32	1.21e-9	Subjective well-being;
LUSC	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-10.0	-0.48	8.91e-21	Eye color traits;
LUSC	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg01475377	chr6:109611718	NA	-0.37	-6.56	-0.34	2.04e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.11	-0.32	2.81e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg11060661	chr22:24314208	DDT;DDTL	0.5	8.07	0.4	1.27e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12618769	0.570	rs116051325	chr2:99056836	G/A	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.14e-13	Bipolar disorder;
LUSC	cis	rs12474201	0.963	rs3829835	chr2:46925789	C/T	cg06386533	chr2:46925753	SOCS5	0.8	12.28	0.56	7.34e-29	Height;
LUSC	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.91	0.31	8.59e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg23601095	chr6:26197514	HIST1H3D	0.73	7.5	0.38	5.79e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg01765077	chr12:122356316	WDR66	-0.5	-7.22	-0.37	3.47e-12	Mean corpuscular volume;
LUSC	cis	rs6977660	0.714	rs2390156	chr7:19786138	A/T	cg05791153	chr7:19748676	TWISTNB	0.75	7.42	0.38	1.01e-12	Thyroid stimulating hormone;
LUSC	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg05941027	chr17:61774174	LIMD2	0.22	5.88	0.31	9.68e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.79	0.35	5.19e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.79	-0.51	1.67e-23	Chronic sinus infection;
LUSC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg12463550	chr7:65579703	CRCP	0.51	7.34	0.37	1.6e-12	Aortic root size;
LUSC	cis	rs977987	0.843	rs17696749	chr16:75403062	C/G	cg03315344	chr16:75512273	CHST6	0.53	10.36	0.49	5.48e-22	Dupuytren's disease;
LUSC	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg14186256	chr22:23484241	RTDR1	0.91	16.35	0.67	1.52e-44	Bone mineral density;
LUSC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.65	-10.96	-0.51	4.26e-24	Lung cancer;
LUSC	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	0.57	9.06	0.44	1.1e-17	Breast cancer;
LUSC	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg12940439	chr1:67600707	NA	0.37	6.08	0.32	3.2e-9	Psoriasis;
LUSC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-1.25	-13.99	-0.61	2.56e-35	Diabetic kidney disease;
LUSC	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	7.22	0.37	3.5e-12	Retinal vascular caliber;
LUSC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg09365446	chr1:150670422	GOLPH3L	0.54	8.28	0.41	2.91e-15	Tonsillectomy;
LUSC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg21770322	chr7:97807741	LMTK2	0.4	6.91	0.35	2.41e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg08847533	chr14:75593920	NEK9	0.84	15.57	0.65	1.85e-41	Height;
LUSC	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg03474202	chr17:45855739	NA	-0.29	-6.69	-0.34	9.51e-11	IgG glycosylation;
LUSC	cis	rs2901656	0.714	rs10798026	chr1:172453840	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.3	5.94	0.31	7.04e-9	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.35e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs68170813	0.641	rs12534124	chr7:107119047	G/A	cg02696742	chr7:106810147	HBP1	-0.66	-9.82	-0.47	3.6e-20	Coronary artery disease;
LUSC	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg10523679	chr1:76189770	ACADM	-0.47	-6.98	-0.36	1.58e-11	Daytime sleep phenotypes;
LUSC	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21545522	chr1:205238299	TMCC2	0.51	9.51	0.46	3.91e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs4953404	0.613	rs4355163	chr2:46909817	G/C	cg09399716	chr2:46890238	NA	-0.3	-6.63	-0.34	1.34e-10	Pulse pressure (alcohol consumption interaction);
LUSC	cis	rs3125734	0.633	rs1873685	chr10:64032126	C/T	cg09941381	chr10:64027924	RTKN2	-0.4	-7.23	-0.37	3.22e-12	Rheumatoid arthritis;
LUSC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.53	0.6	1.44e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg11645453	chr3:52864694	ITIH4	0.35	8.14	0.41	7.76e-15	Bipolar disorder;
LUSC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg20295408	chr7:1910781	MAD1L1	0.42	5.98	0.31	5.66e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg23229984	chr5:148520753	ABLIM3	0.37	5.66	0.3	3.18e-8	Breast cancer;
LUSC	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg11584989	chr19:19387371	SF4	0.57	6.57	0.34	1.99e-10	Bipolar disorder;
LUSC	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg21053147	chr12:120880522	NA	-0.49	-6.06	-0.31	3.57e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg01884057	chr2:25150051	NA	-0.46	-10.93	-0.51	5.69e-24	Body mass index;
LUSC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.8	-0.35	4.82e-11	Alzheimer's disease (late onset);
LUSC	cis	rs7590368	0.715	rs12475790	chr2:10957907	A/C	cg15705551	chr2:10952987	PDIA6	0.58	6.24	0.32	1.31e-9	Educational attainment (years of education);
LUSC	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.49	6.34	0.33	7.24e-10	Blood protein levels;
LUSC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg09877947	chr5:131593287	PDLIM4	0.49	8.03	0.4	1.68e-14	Breast cancer;
LUSC	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00321850	chr1:175162397	KIAA0040	0.46	7.86	0.4	5.38e-14	Alcohol dependence;
LUSC	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.66	11.35	0.53	1.76e-25	Monocyte count;
LUSC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.78	0.3	1.74e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg18833306	chr6:118973337	C6orf204	-0.46	-5.85	-0.3	1.16e-8	Diastolic blood pressure;
LUSC	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.78	11.25	0.52	4.06e-25	Corneal astigmatism;
LUSC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08219700	chr8:58056026	NA	0.66	7.72	0.39	1.41e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg15997130	chr1:24165203	NA	0.52	8.58	0.43	3.6e-16	Immature fraction of reticulocytes;
LUSC	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg21798802	chr22:38057573	PDXP	0.46	9.76	0.47	5.77e-20	Fat distribution (HIV);
LUSC	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09307838	chr4:120376055	NA	0.75	10.7	0.51	3.49e-23	Corneal astigmatism;
LUSC	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg15848620	chr12:58087721	OS9	-0.54	-7.71	-0.39	1.47e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg15557168	chr22:42548783	NA	-0.33	-5.72	-0.3	2.43e-8	Cognitive function;
LUSC	cis	rs73206853	0.610	rs73194020	chr12:111131366	G/A	cg12870014	chr12:110450643	ANKRD13A	0.69	6.73	0.35	7.61e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg24296786	chr1:45957014	TESK2	-0.41	-5.81	-0.3	1.47e-8	Red blood cell count;Reticulocyte count;
LUSC	cis	rs6693567	0.565	rs1260458	chr1:150347454	C/T	cg15654264	chr1:150340011	RPRD2	0.44	7.04	0.36	1.11e-11	Migraine;
LUSC	cis	rs4664308	0.618	rs17830904	chr2:160891688	C/T	cg03641300	chr2:160917029	PLA2R1	0.47	7.83	0.39	6.58e-14	Idiopathic membranous nephropathy;
LUSC	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.45	0.46	6.17e-19	Blood protein levels;
LUSC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg03146154	chr1:46216737	IPP	0.5	7.41	0.38	1.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg17490921	chr11:116658887	ZNF259	0.36	6.02	0.31	4.63e-9	Triglycerides;
LUSC	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg09491104	chr22:46646882	C22orf40	-0.61	-6.38	-0.33	5.85e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2479724	0.569	rs75720073	chr6:41750301	T/A	cg17623882	chr6:41773611	USP49	0.51	6.77	0.35	5.93e-11	Menarche (age at onset);
LUSC	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	8.18	0.41	6.01e-15	Lymphocyte counts;
LUSC	cis	rs6681460	1.000	rs2031478	chr1:67123742	C/A	cg02459107	chr1:67143332	SGIP1	0.47	8.95	0.44	2.48e-17	Presence of antiphospholipid antibodies;
LUSC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.32	6.51	0.34	2.8e-10	Schizophrenia;
LUSC	cis	rs977987	0.778	rs35415181	chr16:75403124	T/C	cg04384234	chr16:75411784	CFDP1	-0.42	-6.94	-0.36	2e-11	Dupuytren's disease;
LUSC	cis	rs7582180	0.903	rs2309826	chr2:100905274	C/A	cg08017756	chr2:100939284	LONRF2	-0.37	-6.24	-0.32	1.31e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg14552801	chr7:65878734	NA	0.37	5.85	0.3	1.18e-8	Aortic root size;
LUSC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11645453	chr3:52864694	ITIH4	0.33	7.64	0.39	2.35e-13	Bipolar disorder;
LUSC	cis	rs8099014	0.906	rs9953884	chr18:56093448	A/C	cg12907477	chr18:56117327	MIR122	0.43	6.74	0.35	6.92e-11	Platelet count;
LUSC	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg17507749	chr15:85114479	UBE2QP1	0.51	5.89	0.31	9.3e-9	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	9.43	0.46	7.08e-19	Bipolar disorder;
LUSC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.49	8.34	0.42	1.98e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.19	-0.52	6.61e-25	Alzheimer's disease;
LUSC	cis	rs4851254	0.961	rs11692215	chr2:100746573	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-5.69	-0.3	2.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs3213961	0.529	rs6708	chr2:33789534	A/G	cg04131969	chr2:33951647	MYADML	0.48	5.88	0.31	1.01e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs1030268	0.715	rs13235840	chr7:133505091	A/T	cg10665199	chr7:133106180	EXOC4	0.54	5.89	0.31	9.27e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.55	7.59	0.38	3.17e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	0.98	15.66	0.65	7.7e-42	Dupuytren's disease;
LUSC	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg00277334	chr10:82204260	NA	-0.48	-7.41	-0.38	1.06e-12	Sarcoidosis;
LUSC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14829155	chr15:31115871	NA	-0.7	-10.3	-0.49	8.79e-22	Huntington's disease progression;
LUSC	cis	rs6840360	0.642	rs11099819	chr4:152430178	T/C	cg20465933	chr4:152376761	FAM160A1	0.33	5.94	0.31	7.18e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg04827223	chr11:72435913	ARAP1	-0.79	-8.85	-0.44	5.13e-17	Type 2 diabetes;
LUSC	trans	rs62055045	0.528	rs9935288	chr16:71552741	T/C	cg21834679	chr15:96891026	NA	-0.38	-6.18	-0.32	1.89e-9	Schizophrenia;
LUSC	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg08017756	chr2:100939284	LONRF2	-0.33	-5.9	-0.31	8.83e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg08088566	chr11:430123	ANO9	0.59	6.96	0.36	1.76e-11	Body mass index;
LUSC	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.88	-20.56	-0.75	2.74e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7241530	0.717	rs28445036	chr18:75889191	G/A	cg14642773	chr18:75888474	NA	0.36	6.04	0.31	4.18e-9	Educational attainment (years of education);
LUSC	cis	rs9815354	0.812	rs111277902	chr3:41950312	C/T	cg03022575	chr3:42003672	ULK4	0.83	8.63	0.43	2.55e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7178572	0.568	rs28524916	chr15:77599002	T/A	cg22256960	chr15:77711686	NA	0.49	7.8	0.39	7.96e-14	Type 2 diabetes;
LUSC	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg00530320	chr1:46809349	NSUN4	0.55	8.46	0.42	8.29e-16	Menopause (age at onset);
LUSC	cis	rs2625529	0.652	rs28650442	chr15:72155445	A/T	cg16672083	chr15:72433130	SENP8	-0.48	-8.08	-0.4	1.23e-14	Red blood cell count;
LUSC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs6599077	0.950	rs2887954	chr3:40101924	A/G	cg13683864	chr3:40499215	RPL14	-0.59	-7.4	-0.38	1.11e-12	Sleep-related phenotypes;
LUSC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg14403583	chr14:105418241	AHNAK2	-0.57	-9.55	-0.46	2.94e-19	Rheumatoid arthritis;
LUSC	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg17385448	chr1:15911702	AGMAT	0.36	6.09	0.32	3.12e-9	Systolic blood pressure;
LUSC	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.07	0.31	3.56e-9	Schizophrenia;
LUSC	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-6.16	-0.32	2.06e-9	Joint mobility (Beighton score);
LUSC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg23711669	chr6:146136114	FBXO30	0.91	17.59	0.69	1.71e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	7.92	0.4	3.66e-14	Axial length;
LUSC	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg00677455	chr12:58241039	CTDSP2	0.62	8.62	0.43	2.7e-16	Multiple sclerosis;
LUSC	cis	rs6088813	0.883	rs2425061	chr20:33915571	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.37	-5.94	-0.31	7.03e-9	Height;
LUSC	cis	rs8038465	0.638	rs56262972	chr15:73946745	G/A	cg15420318	chr15:73925796	NPTN	0.6	10.15	0.49	2.93e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11060661	chr22:24314208	DDT;DDTL	-0.42	-7.3	-0.37	2.06e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.32	-0.37	1.88e-12	Bipolar disorder;
LUSC	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg16049864	chr8:95962084	TP53INP1	-0.64	-11.85	-0.54	2.72e-27	Type 2 diabetes;
LUSC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.57e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg04267008	chr7:1944627	MAD1L1	-0.51	-7.69	-0.39	1.68e-13	Bipolar disorder and schizophrenia;
LUSC	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.51	-8.28	-0.41	3.03e-15	Schizophrenia;
LUSC	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg10560079	chr2:191398806	TMEM194B	-0.59	-6.88	-0.35	3e-11	Diastolic blood pressure;
LUSC	cis	rs28595532	0.702	rs56217716	chr4:119338490	T/G	cg21605333	chr4:119757512	SEC24D	1.02	8.34	0.42	1.96e-15	Cannabis dependence symptom count;
LUSC	cis	rs68170813	0.617	rs2283041	chr7:107190415	A/G	cg02696742	chr7:106810147	HBP1	-0.64	-8.61	-0.43	2.99e-16	Coronary artery disease;
LUSC	cis	rs10465746	0.967	rs11163876	chr1:84440605	T/C	cg10977910	chr1:84465055	TTLL7	0.42	6.23	0.32	1.42e-9	Obesity-related traits;
LUSC	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg17425144	chr1:10567563	PEX14	0.61	12.48	0.56	1.33e-29	Prostate cancer;
LUSC	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg17470723	chr8:74884337	TCEB1	0.52	8.19	0.41	5.53e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg10167378	chr1:228756711	NA	0.46	6.53	0.34	2.43e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.47	7.7	0.39	1.55e-13	Menarche (age at onset);
LUSC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg22535103	chr8:58192502	C8orf71	-0.78	-7.86	-0.4	5.23e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-0.82	-13.37	-0.59	6.09e-33	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg01528321	chr10:82214614	TSPAN14	1.08	12.25	0.56	9.24e-29	Post bronchodilator FEV1;
LUSC	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.82	-15.37	-0.64	1.05e-40	Heart rate;
LUSC	cis	rs11587400	0.679	rs12090305	chr1:115109441	G/A	cg12756093	chr1:115239321	AMPD1	0.4	5.93	0.31	7.76e-9	Autism;
LUSC	cis	rs11630290	0.774	rs57085979	chr15:64133689	T/C	cg12036633	chr15:63758958	NA	-0.59	-6.67	-0.34	1.03e-10	Iris characteristics;
LUSC	trans	rs9395865	0.501	rs2067833	chr6:53330356	A/G	cg06503243	chr13:42006994	OR7E37P	-0.37	-6.23	-0.32	1.39e-9	Electroencephalographic traits in alcoholism;
LUSC	cis	rs9463078	0.605	rs3799984	chr6:44893640	C/G	cg25276700	chr6:44698697	NA	0.3	6.24	0.32	1.3e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs7681440	0.626	rs2289515	chr4:90816790	T/A	cg15133208	chr4:90757351	SNCA	-0.33	-5.66	-0.3	3.29e-8	Dementia with Lewy bodies;
LUSC	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3771570	0.901	rs4675969	chr2:242217627	C/T	cg21155796	chr2:242212141	HDLBP	0.59	6.92	0.35	2.39e-11	Prostate cancer;
LUSC	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg09307838	chr4:120376055	NA	0.65	9.33	0.45	1.56e-18	Corneal astigmatism;
LUSC	trans	rs7739264	0.602	rs9350179	chr6:19764095	G/A	cg16463452	chr13:29195249	NA	0.3	6.02	0.31	4.56e-9	Endometriosis;
LUSC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg06784218	chr1:46089804	CCDC17	-0.58	-11.55	-0.53	3.58e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.4	-0.33	5.22e-10	Extrinsic epigenetic age acceleration;
LUSC	trans	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-6.87	-0.35	3.11e-11	Menarche (age at onset);
LUSC	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.83	-0.39	6.64e-14	Retinal vascular caliber;
LUSC	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg23950597	chr19:37808831	NA	-0.65	-7.91	-0.4	3.9e-14	Coronary artery calcification;
LUSC	cis	rs11018904	0.906	rs36177012	chr11:89933319	T/C	cg26138821	chr11:89956704	CHORDC1	-0.6	-6.94	-0.35	2.09e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-6.59	-0.34	1.67e-10	Axial length;
LUSC	cis	rs1267303	0.636	rs1267310	chr1:46987307	A/T	cg25110126	chr1:46999211	NA	-0.56	-7.54	-0.38	4.58e-13	Monobrow;
LUSC	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg24675056	chr1:15929824	NA	0.46	7.92	0.4	3.44e-14	Systolic blood pressure;
LUSC	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-0.88	-14.75	-0.63	2.9e-38	Schizophrenia;
LUSC	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg06454157	chr6:167490870	NA	0.26	6.41	0.33	5.05e-10	Primary biliary cholangitis;
LUSC	cis	rs41271951	0.512	rs7537292	chr1:151071038	C/G	cg11822372	chr1:151115635	SEMA6C	-0.76	-6.95	-0.36	1.98e-11	Blood protein levels;
LUSC	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg24848339	chr3:12840334	CAND2	0.35	7.88	0.4	4.52e-14	QRS complex (12-leadsum);
LUSC	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg13628971	chr7:2884303	GNA12	0.47	6.75	0.35	6.68e-11	Height;
LUSC	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg17691542	chr6:26056736	HIST1H1C	0.55	7.79	0.39	8.71e-14	Iron status biomarkers;
LUSC	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg18825076	chr15:78729989	IREB2	0.49	8.04	0.4	1.58e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.4	5.88	0.31	1.02e-8	Lung cancer;
LUSC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg04362960	chr10:104952993	NT5C2	1.15	13.48	0.59	2.28e-33	Arsenic metabolism;
LUSC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.94	0.31	7.2e-9	Menopause (age at onset);
LUSC	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.42	-5.74	-0.3	2.14e-8	Reticulocyte count;
LUSC	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.46	6.15	0.32	2.21e-9	Corneal astigmatism;
LUSC	cis	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.38	-0.37	1.29e-12	Morning vs. evening chronotype;
LUSC	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	0.89	14.56	0.62	1.64e-37	Schizophrenia;
LUSC	cis	rs939574	1.000	rs1024131	chr2:220117458	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.1	8.91	0.44	3.35e-17	Platelet distribution width;
LUSC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg24813613	chr7:1882135	MAD1L1	-0.37	-6.15	-0.32	2.18e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.52	10.36	0.49	5.48e-22	Glomerular filtration rate (creatinine);
LUSC	cis	rs4786125	0.626	rs6500859	chr16:6914358	A/T	cg03623568	chr16:6915990	A2BP1	-0.48	-8.02	-0.4	1.82e-14	Heart rate variability traits (SDNN);
LUSC	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg20744362	chr22:50050164	C22orf34	0.37	7.02	0.36	1.22e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs7119	0.931	rs12901998	chr15:77833524	G/T	cg27398640	chr15:77910606	LINGO1	-0.32	-7.22	-0.37	3.64e-12	Type 2 diabetes;
LUSC	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-12.64	-0.57	3.31e-30	Platelet count;
LUSC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg20090143	chr19:45452003	APOC2	0.47	9.37	0.46	1.08e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs56283067	0.847	rs12215181	chr6:44736076	C/T	cg20913747	chr6:44695427	NA	-0.5	-8.25	-0.41	3.77e-15	Total body bone mineral density;
LUSC	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg17376030	chr22:41985996	PMM1	-0.43	-5.81	-0.3	1.45e-8	Vitiligo;
LUSC	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg09789173	chr7:4769017	FOXK1	0.67	12.59	0.57	5.04e-30	Mosquito bite size;
LUSC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.84	-0.3	1.25e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg02475777	chr4:1388615	CRIPAK	0.4	5.89	0.31	9.36e-9	Obesity-related traits;
LUSC	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg17425144	chr1:10567563	PEX14	0.65	13.6	0.6	7.83e-34	Breast cancer;
LUSC	cis	rs11018904	0.861	rs12787117	chr11:89943681	A/G	cg26834418	chr11:89957033	CHORDC1	-0.52	-6.21	-0.32	1.61e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg03146154	chr1:46216737	IPP	0.51	7.57	0.38	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs156356	0.811	rs552067	chr20:1823326	C/G	cg01434487	chr17:75953891	NA	0.4	6.02	0.31	4.71e-9	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs10193935	1.000	rs57883795	chr2:42387926	C/T	cg27598129	chr2:42591480	NA	-0.63	-8.15	-0.41	7.62e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg05519781	chr21:40033154	ERG	-0.61	-9.86	-0.47	2.63e-20	Coronary artery disease;
LUSC	cis	rs983392	0.680	rs11230201	chr11:59996994	C/G	cg24026212	chr11:59952134	MS4A6A	-0.35	-6.1	-0.32	2.9e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9427116	0.840	rs9427114	chr1:154626705	T/C	cg17218026	chr1:154582156	ADAR	0.5	8.5	0.42	6.3e-16	Blood protein levels;
LUSC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg03233332	chr7:66118400	NA	-0.41	-6.03	-0.31	4.27e-9	Aortic root size;
LUSC	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	0.96	13.3	0.59	1.14e-32	Primary sclerosing cholangitis;
LUSC	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg06156847	chr2:113672199	IL1F7	0.29	6.23	0.32	1.39e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg07393940	chr7:158741817	NA	-0.37	-6.62	-0.34	1.46e-10	Life satisfaction;
LUSC	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	14.64	0.63	8.06e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg14440974	chr22:39074834	NA	-0.36	-5.92	-0.31	7.79e-9	Menopause (age at onset);
LUSC	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg05855489	chr10:104503620	C10orf26	0.61	9.34	0.45	1.45e-18	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg22431228	chr1:16359049	CLCNKA	0.33	6.33	0.33	7.8e-10	Dilated cardiomyopathy;
LUSC	cis	rs7674212	0.537	rs2623060	chr4:104047504	G/A	cg16532752	chr4:104119610	CENPE	-0.49	-6.9	-0.35	2.66e-11	Type 2 diabetes;
LUSC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg06784218	chr1:46089804	CCDC17	0.48	9.48	0.46	4.93e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	10.71	0.51	3.24e-23	Monocyte percentage of white cells;
LUSC	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg15423357	chr2:25149977	NA	0.39	7.7	0.39	1.53e-13	Body mass index in non-asthmatics;
LUSC	cis	rs13315871	0.790	rs13066409	chr3:58428444	A/G	cg20936604	chr3:58311152	NA	-0.71	-6.65	-0.34	1.16e-10	Cholesterol, total;
LUSC	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg03929089	chr4:120376271	NA	0.66	7.34	0.37	1.6e-12	Axial length;
LUSC	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.52	-7.69	-0.39	1.68e-13	Lymphocyte counts;
LUSC	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.65	11.15	0.52	9.29e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	0.97	9.55	0.46	2.87e-19	Plasma clusterin levels;
LUSC	cis	rs8040855	0.579	rs4843029	chr15:85725395	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.87	0.35	3.1e-11	Bulimia nervosa;
LUSC	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg26384229	chr12:38710491	ALG10B	-0.6	-9.21	-0.45	3.72e-18	Morning vs. evening chronotype;
LUSC	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg00310523	chr12:86230176	RASSF9	0.37	6.7	0.34	8.91e-11	Major depressive disorder;
LUSC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs2490361	1.000	rs1024272	chr1:237320224	C/A	cg15653282	chr18:11689218	GNAL	0.39	5.99	0.31	5.46e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6845621	0.811	rs1990495	chr4:18932770	T/G	cg12196642	chr4:18937545	NA	-0.37	-6.88	-0.35	2.92e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-11.16	-0.52	8.49e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg07701084	chr6:150067640	NUP43	0.55	8.55	0.42	4.62e-16	Lung cancer;
LUSC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-6.11	-0.32	2.84e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.58	-8.4	-0.42	1.26e-15	Mean platelet volume;
LUSC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg14668632	chr7:2872130	GNA12	-0.42	-5.95	-0.31	6.81e-9	Height;
LUSC	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg03806693	chr22:41940476	POLR3H	-0.5	-6.8	-0.35	4.74e-11	Neuroticism;
LUSC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.14	-0.32	2.38e-9	Neutrophil percentage of white cells;
LUSC	cis	rs4363385	0.776	rs3170863	chr1:152944594	C/T	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.21	-0.37	3.72e-12	Inflammatory skin disease;
LUSC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs9420	0.754	rs631791	chr11:57675410	A/G	cg23127183	chr11:57508653	C11orf31	0.47	5.68	0.3	2.96e-8	Schizophrenia;
LUSC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.58	9.59	0.46	2.21e-19	Aortic root size;
LUSC	cis	rs829883	0.659	rs11109510	chr12:98911382	A/G	cg25150519	chr12:98850993	NA	-0.63	-8.61	-0.43	2.85e-16	Colorectal adenoma (advanced);
LUSC	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg12615879	chr12:58013172	SLC26A10	-0.26	-5.67	-0.3	3.05e-8	Multiple sclerosis;
LUSC	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg05283184	chr6:79620031	NA	-0.46	-8.75	-0.43	1.09e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12826209	chr6:26865740	GUSBL1	0.74	9.08	0.44	9.64e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg10978503	chr1:24200527	CNR2	-0.44	-9.08	-0.44	9.58e-18	Immature fraction of reticulocytes;
LUSC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg05347473	chr6:146136440	FBXO30	0.58	10.17	0.49	2.47e-21	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg04362960	chr10:104952993	NT5C2	0.91	11.51	0.53	4.9e-26	Arsenic metabolism;
LUSC	cis	rs360798	0.512	rs6739804	chr2:63269604	T/C	cg17519650	chr2:63277830	OTX1	0.58	8.24	0.41	3.87e-15	Coronary artery disease;
LUSC	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg18753928	chr3:113234510	CCDC52	-0.49	-7.39	-0.37	1.2e-12	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-10.43	-0.5	3.05e-22	Heart rate;
LUSC	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg11845111	chr2:191398756	TMEM194B	-0.67	-8.98	-0.44	1.98e-17	Diastolic blood pressure;
LUSC	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg01097406	chr16:89675127	NA	-0.34	-6.58	-0.34	1.79e-10	Vitiligo;
LUSC	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg03676636	chr4:99064102	C4orf37	0.36	8.04	0.4	1.54e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg20135002	chr11:47629003	NA	-0.51	-8.11	-0.41	9.83e-15	Subjective well-being;
LUSC	cis	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg17469321	chr7:55412551	NA	0.66	10.63	0.5	6.09e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg04414720	chr1:150670196	GOLPH3L	0.54	8.42	0.42	1.15e-15	Melanoma;
LUSC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg14019146	chr3:50243930	SLC38A3	0.32	7.08	0.36	8.39e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.65	-0.39	2.1e-13	Height;
LUSC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.64	-8.17	-0.41	6.31e-15	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	12.65	0.57	3.13e-30	Cognitive test performance;
LUSC	cis	rs6005807	0.719	rs7289625	chr22:28896546	G/A	cg12565055	chr22:29076175	TTC28	0.57	5.94	0.31	7.09e-9	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs939658	1.000	rs34286854	chr15:79454374	C/T	cg17916960	chr15:79447300	NA	-0.52	-10.38	-0.49	4.72e-22	Refractive error;
LUSC	cis	rs17621444	0.505	rs10788018	chr10:121805260	T/G	cg02041677	chr10:121771263	NA	-0.34	-6.45	-0.33	3.88e-10	IgG glycosylation;
LUSC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-5.83	-0.3	1.34e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06544989	chr22:39130855	UNC84B	0.35	6.28	0.32	1.06e-9	Menopause (age at onset);
LUSC	cis	rs793571	0.523	rs7161889	chr15:58983425	C/G	cg05156742	chr15:59063176	FAM63B	0.52	7.68	0.39	1.74e-13	Schizophrenia;
LUSC	cis	rs12900413	0.603	rs11629982	chr15:90300272	G/A	cg24249390	chr15:90295951	MESP1	-0.38	-5.96	-0.31	6.56e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs9303542	0.625	rs7222242	chr17:46565486	C/A	cg09704116	chr17:46666958	LOC404266	-0.36	-6.17	-0.32	2.01e-9	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.75	13.18	0.59	3.05e-32	Sudden cardiac arrest;
LUSC	cis	rs6681460	0.966	rs4655506	chr1:67150811	C/T	cg02459107	chr1:67143332	SGIP1	0.46	8.73	0.43	1.21e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg07460842	chr6:66804631	NA	0.49	5.94	0.31	7.24e-9	Metabolite levels;
LUSC	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg05110241	chr16:68378359	PRMT7	-0.57	-6.52	-0.34	2.56e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.48	6.25	0.32	1.23e-9	Huntington's disease progression;
LUSC	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.57	7.78	0.39	9.24e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg08132940	chr7:1081526	C7orf50	-0.51	-5.93	-0.31	7.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg14895029	chr7:2775587	GNA12	-0.42	-6.29	-0.33	1.02e-9	Height;
LUSC	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg13770153	chr20:60521292	NA	-0.4	-5.66	-0.3	3.19e-8	Body mass index;
LUSC	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	6.33	0.33	7.73e-10	Recombination rate (females);
LUSC	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg17623882	chr6:41773611	USP49	-0.63	-10.73	-0.51	2.72e-23	Menarche (age at onset);
LUSC	cis	rs9311676	0.656	rs7642652	chr3:58373667	C/T	cg13750441	chr3:58318267	PXK	0.36	6.93	0.35	2.12e-11	Systemic lupus erythematosus;
LUSC	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg13010199	chr12:38710504	ALG10B	0.43	6.07	0.32	3.39e-9	Morning vs. evening chronotype;
LUSC	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg00376283	chr12:123451042	ABCB9	0.7	9.88	0.48	2.29e-20	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs9341835	0.709	rs4358600	chr6:64153219	G/A	cg03326410	chr6:64151739	NA	-0.38	-6.21	-0.32	1.59e-9	Schizophrenia;
LUSC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg00255919	chr5:131827918	IRF1	0.43	8.28	0.41	3.11e-15	Asthma (sex interaction);
LUSC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg13531842	chr10:38383804	ZNF37A	-0.41	-6.38	-0.33	5.84e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.47	8.03	0.4	1.64e-14	Axial length;
LUSC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg22868518	chr11:507468	RNH1	-0.6	-5.94	-0.31	7.19e-9	Body mass index;
LUSC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06022373	chr22:39101656	GTPBP1	0.76	11.94	0.55	1.35e-27	Menopause (age at onset);
LUSC	cis	rs1172822	0.665	rs897795	chr19:55831577	A/C	cg04391588	chr19:55832610	TMEM150B	0.29	5.79	0.3	1.65e-8	Menarche and menopause (age at onset);Menopause (age at onset);
LUSC	cis	rs7264396	0.832	rs224371	chr20:34074831	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.15	-0.32	2.23e-9	Total cholesterol levels;
LUSC	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg11584989	chr19:19387371	SF4	0.59	7.02	0.36	1.22e-11	Bipolar disorder;
LUSC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07362569	chr17:61921086	SMARCD2	0.38	7.66	0.39	2.06e-13	Prudent dietary pattern;
LUSC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg02527881	chr3:46936655	PTH1R	-0.42	-7.56	-0.38	3.88e-13	Colorectal cancer;
LUSC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg19748678	chr4:122722346	EXOSC9	-0.49	-7.74	-0.39	1.18e-13	Type 2 diabetes;
LUSC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg23985595	chr17:80112537	CCDC57	0.31	5.88	0.31	9.82e-9	Life satisfaction;
LUSC	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-8.03	-0.4	1.67e-14	Lymphocyte counts;
LUSC	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg16624210	chr5:671434	TPPP	0.49	6.1	0.32	2.89e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg04025307	chr7:1156635	C7orf50	0.43	5.92	0.31	8.2e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.7	11.19	0.52	6.48e-25	Prudent dietary pattern;
LUSC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg11608241	chr8:8085544	FLJ10661	0.4	5.74	0.3	2.18e-8	Mood instability;
LUSC	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg06636551	chr8:101224915	SPAG1	0.43	7.81	0.39	7.29e-14	Atrioventricular conduction;
LUSC	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg08601574	chr20:25228251	PYGB	0.42	6.54	0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00881440	chr7:2595255	C7orf27	-0.42	-6.39	-0.33	5.46e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg01620082	chr3:125678407	NA	-0.82	-7.68	-0.39	1.81e-13	Depression;
LUSC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg21963583	chr11:68658836	MRPL21	0.57	8.5	0.42	6.54e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg02018176	chr4:1364513	KIAA1530	0.45	6.4	0.33	5.18e-10	Recombination rate (females);
LUSC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	8.67	0.43	1.92e-16	Cognitive test performance;
LUSC	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg03060546	chr3:49711283	APEH	0.64	7.69	0.39	1.67e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.71	-0.3	2.44e-8	Recombination rate (females);
LUSC	cis	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg06521331	chr12:34319734	NA	0.39	6.49	0.33	3.14e-10	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.37	0.49	4.94e-22	Morning vs. evening chronotype;
LUSC	cis	rs79911532	0.515	rs113244522	chr7:75715307	G/A	cg03592824	chr7:75666768	STYXL1	0.67	6.42	0.33	4.79e-10	Mononucleosis;
LUSC	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg08601574	chr20:25228251	PYGB	0.43	6.6	0.34	1.59e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.85e-20	Coronary artery disease;
LUSC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	12.33	0.56	4.97e-29	Chronic sinus infection;
LUSC	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.52	7.68	0.39	1.83e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg24375607	chr4:120327624	NA	0.74	11.1	0.52	1.45e-24	Corneal astigmatism;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg27096981	chr4:124317819	SPRY1	0.38	6.09	0.32	3.06e-9	Schizophrenia;
LUSC	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.82	-15.9	-0.66	8.61e-43	Inflammatory bowel disease;
LUSC	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.53	8.62	0.43	2.73e-16	Breast cancer;
LUSC	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs77236434	0.826	rs73562565	chr8:13179345	C/T	cg05185040	chr8:41425077	NA	-0.52	-5.95	-0.31	6.7e-9	Familial hepatitis B virus-related hepatocellular carcinoma;
LUSC	cis	rs7809950	0.678	rs12672451	chr7:106853817	C/G	cg23024343	chr7:107201750	COG5	-0.65	-9.08	-0.44	9.69e-18	Coronary artery disease;
LUSC	cis	rs9434723	0.920	rs9434725	chr1:9293861	C/T	cg04199779	chr1:9294473	H6PD	0.59	6.56	0.34	2.01e-10	Height;
LUSC	cis	rs8170	0.603	rs8109328	chr19:17417955	C/T	cg04749549	chr19:17459798	NA	-0.32	-5.84	-0.3	1.24e-8	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LUSC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg07424592	chr7:64974309	NA	0.69	6.07	0.32	3.41e-9	Diabetic kidney disease;
LUSC	trans	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-8.84	-0.44	5.76e-17	Breast cancer;
LUSC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.14	-0.32	2.3e-9	Bipolar disorder;
LUSC	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.93	17.87	0.7	1.36e-50	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs981844	0.714	rs2405202	chr4:154705132	A/G	cg14289246	chr4:154710475	SFRP2	-0.5	-7.04	-0.36	1.12e-11	Response to statins (LDL cholesterol change);
LUSC	cis	rs13089785	1.000	rs2332682	chr3:123654633	C/T	cg03892735	chr3:123506296	MYLK	0.33	5.65	0.3	3.43e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05025164	chr4:1340916	KIAA1530	0.53	8.2	0.41	5.32e-15	Obesity-related traits;
LUSC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.46	-9.49	-0.46	4.58e-19	Type 2 diabetes;
LUSC	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg18232548	chr7:50535776	DDC	-0.4	-5.78	-0.3	1.72e-8	Body mass index;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg10620100	chr15:40714174	NA	0.5	6.43	0.33	4.48e-10	Cognitive function;Information processing speed;
LUSC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg02493740	chr2:85810744	VAMP5	-0.52	-9.04	-0.44	1.34e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg05552183	chr6:42928497	GNMT	0.47	7.67	0.39	1.94e-13	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-8.97	-0.44	2.14e-17	Monocyte percentage of white cells;
LUSC	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg00944433	chr1:107599041	PRMT6	0.35	6.56	0.34	2.03e-10	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs524023	1.000	rs524023	chr11:64358265	C/T	cg07220939	chr11:64358617	SLC22A12	0.23	5.99	0.31	5.48e-9	Urate levels in obese individuals;
LUSC	cis	rs354225	0.544	rs10169954	chr2:54808117	C/G	cg26097391	chr2:54893211	SPTBN1	0.43	6.4	0.33	5.18e-10	Schizophrenia;
LUSC	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.89	20.83	0.75	2.5e-62	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	7.21	0.37	3.73e-12	Mean platelet volume;
LUSC	trans	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg10756647	chr7:56101905	PSPH	0.87	8.43	0.42	1.06e-15	Diabetic kidney disease;
LUSC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	11.44	0.53	8.79e-26	Prudent dietary pattern;
LUSC	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	6.17	0.32	1.93e-9	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs800082	1.000	rs2717391	chr3:144279698	T/C	cg24215973	chr2:240111563	HDAC4	0.47	6.98	0.36	1.59e-11	Smoking behavior;
LUSC	cis	rs35000415	1.000	rs35000415	chr7:128585616	C/T	cg19972273	chr7:128594194	NA	0.68	6.83	0.35	4.05e-11	Systemic lupus erythematosus;
LUSC	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.9	12.12	0.55	2.84e-28	Mean corpuscular hemoglobin;
LUSC	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg19748678	chr4:122722346	EXOSC9	0.47	6.35	0.33	7.21e-10	Type 2 diabetes;
LUSC	cis	rs7607369	0.536	rs13032993	chr2:219666377	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-9.01	-0.44	1.57e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg18827107	chr12:86230957	RASSF9	-0.48	-7.26	-0.37	2.69e-12	Major depressive disorder;
LUSC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg24585782	chr17:78113791	EIF4A3	0.37	5.93	0.31	7.43e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LUSC	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.62	9.47	0.46	5.25e-19	Corneal astigmatism;
LUSC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03934478	chr11:495069	RNH1	0.9	10.31	0.49	8.19e-22	Body mass index;
LUSC	trans	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	9.18	0.45	4.52e-18	Initial pursuit acceleration in psychotic disorders;
LUSC	cis	rs55665837	0.961	rs11023226	chr11:14458817	C/T	cg19336497	chr11:14380999	RRAS2	-0.37	-7.47	-0.38	6.93e-13	Vitamin D levels;
LUSC	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg12310025	chr6:25882481	NA	-0.35	-5.77	-0.3	1.79e-8	Height;
LUSC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg12432903	chr7:1882776	MAD1L1	-0.39	-6.35	-0.33	7.01e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs9831754	0.704	rs1512492	chr3:78471190	A/C	cg06138941	chr3:78371609	NA	-0.5	-6.75	-0.35	6.61e-11	Calcium levels;
LUSC	trans	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.07	-0.32	3.5e-9	Systolic blood pressure;
LUSC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg23630131	chr7:65973040	NA	0.2	5.72	0.3	2.4e-8	Aortic root size;
LUSC	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg11764359	chr7:65958608	NA	0.64	9.66	0.47	1.23e-19	Aortic root size;
LUSC	cis	rs2607426	0.681	rs2545760	chr19:41299824	G/A	cg05508168	chr19:41255947	C19orf54;SNRPA	1.0	6.8	0.35	4.87e-11	Blood protein levels;
LUSC	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg14092571	chr14:90743983	NA	0.37	5.97	0.31	6.09e-9	Mortality in heart failure;
LUSC	cis	rs7927771	0.542	rs7102205	chr11:47745374	C/T	cg20307385	chr11:47447363	PSMC3	0.44	6.32	0.33	8.42e-10	Subjective well-being;
LUSC	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg26536354	chr8:144654954	C8orf73	0.65	7.23	0.37	3.27e-12	Attention deficit hyperactivity disorder;
LUSC	cis	rs11676348	0.935	rs6716276	chr2:218962205	A/G	cg00012203	chr2:219082015	ARPC2	-0.55	-8.54	-0.42	4.89e-16	Ulcerative colitis;
LUSC	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg24692254	chr21:30365293	RNF160	0.52	7.7	0.39	1.6e-13	Pancreatic cancer;
LUSC	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg21053147	chr12:120880522	NA	-0.5	-6.16	-0.32	2.04e-9	Type 1 diabetes nephropathy;
LUSC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18099408	chr3:52552593	STAB1	-0.41	-7.02	-0.36	1.22e-11	Bipolar disorder;
LUSC	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg23711669	chr6:146136114	FBXO30	0.82	14.48	0.62	3.37e-37	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	6.44	0.33	4.18e-10	Tonsillectomy;
LUSC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg02951883	chr7:2050386	MAD1L1	-0.47	-8.18	-0.41	5.88e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg21211680	chr2:198530	NA	-0.58	-7.03	-0.36	1.15e-11	Blood protein levels;
LUSC	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg14433983	chr11:636460	DRD4	-0.37	-6.01	-0.31	4.77e-9	Systemic lupus erythematosus;
LUSC	cis	rs611744	0.806	rs2440387	chr8:109067078	A/G	cg18478394	chr8:109455254	TTC35	0.43	6.32	0.33	8.49e-10	Dupuytren's disease;
LUSC	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg04450456	chr4:17643702	FAM184B	-0.43	-7.03	-0.36	1.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg22823121	chr1:150693482	HORMAD1	0.53	7.92	0.4	3.67e-14	Melanoma;
LUSC	cis	rs977987	0.806	rs4887824	chr16:75441613	T/C	cg04384234	chr16:75411784	CFDP1	-0.41	-6.58	-0.34	1.79e-10	Dupuytren's disease;
LUSC	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg25344623	chr2:136566232	LCT	0.38	5.75	0.3	2e-8	Mosquito bite size;
LUSC	cis	rs9309473	0.848	rs9750915	chr2:73811880	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-6.61	-0.34	1.52e-10	Metabolite levels;
LUSC	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg17425144	chr1:10567563	PEX14	0.62	12.47	0.56	1.51e-29	Prostate cancer;
LUSC	trans	rs895636	1.000	rs895636	chr2:45188353	A/G	cg06568401	chr4:42089384	SLC30A9	0.4	6.04	0.31	4.02e-9	Metabolite levels;Fasting plasma glucose;
LUSC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg24733560	chr20:60626293	TAF4	0.39	6.12	0.32	2.59e-9	Body mass index;
LUSC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.67	11.93	0.55	1.38e-27	Aortic root size;
LUSC	cis	rs7659604	0.540	rs4075065	chr4:122683906	A/G	cg19748678	chr4:122722346	EXOSC9	-0.4	-6.14	-0.32	2.29e-9	Type 2 diabetes;
LUSC	cis	rs1211375	0.606	rs1203977	chr16:256278	A/C	cg00126636	chr16:237282	NA	0.4	6.38	0.33	6.01e-10	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg01528321	chr10:82214614	TSPAN14	0.82	12.33	0.56	4.69e-29	Post bronchodilator FEV1;
LUSC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg09455208	chr3:40491958	NA	0.58	9.9	0.48	2.03e-20	Renal cell carcinoma;
LUSC	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	8.68	0.43	1.82e-16	Height;
LUSC	cis	rs7188861	0.681	rs12598646	chr16:11406519	C/T	cg00044050	chr16:11439710	C16orf75	0.56	6.27	0.32	1.14e-9	HDL cholesterol;
LUSC	cis	rs6500395	0.963	rs12444902	chr16:48667126	G/T	cg04672837	chr16:48644449	N4BP1	0.46	6.9	0.35	2.6e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.63	-9.91	-0.48	1.84e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg21187068	chr8:144659627	NAPRT1	-0.58	-7.59	-0.38	3.18e-13	Attention deficit hyperactivity disorder;
LUSC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg26380479	chr7:97908229	NA	-0.28	-6.26	-0.32	1.19e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg15556689	chr8:8085844	FLJ10661	0.67	11.41	0.53	1.12e-25	Mood instability;
LUSC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.54	8.65	0.43	2.25e-16	Longevity;Endometriosis;
LUSC	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26378065	chr17:18585709	ZNF286B	0.47	6.95	0.36	1.91e-11	Educational attainment (years of education);
LUSC	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.62	10.88	0.51	8.36e-24	Type 2 diabetes;
LUSC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.16	0.76	1.23e-63	Prudent dietary pattern;
LUSC	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg18806716	chr10:30721971	MAP3K8	0.44	7.01	0.36	1.31e-11	Inflammatory bowel disease;
LUSC	cis	rs11586313	1.000	rs11586313	chr1:152890470	C/T	cg07796016	chr1:152779584	LCE1C	-0.55	-8.09	-0.4	1.14e-14	Vitamin D levels;
LUSC	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg06145435	chr7:1022769	CYP2W1	0.31	6.49	0.33	3.12e-10	Longevity;Endometriosis;
LUSC	trans	rs11039798	0.536	rs112223280	chr11:48145077	C/G	cg15704280	chr7:45808275	SEPT13	0.8	6.0	0.31	5.16e-9	Axial length;
LUSC	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg12454169	chr2:30669597	LCLAT1	0.68	8.44	0.42	9.46e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg14993813	chr1:46806288	NSUN4	-0.49	-6.82	-0.35	4.33e-11	Menopause (age at onset);
LUSC	cis	rs3818717	0.538	rs12945601	chr17:17653411	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.45	7.02	0.36	1.28e-11	Lymphocyte counts;
LUSC	cis	rs8038465	1.000	rs8032727	chr15:73977336	A/G	cg15420318	chr15:73925796	NPTN	0.42	6.75	0.35	6.45e-11	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.82	-0.35	4.38e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg25214090	chr10:38739885	LOC399744	0.57	8.4	0.42	1.3e-15	Corneal astigmatism;
LUSC	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02176678	chr2:219576539	TTLL4	0.61	11.19	0.52	6.73e-25	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9905704	0.681	rs7211133	chr17:56558918	G/A	cg19466818	chr17:56409534	MIR142	0.36	6.61	0.34	1.53e-10	Testicular germ cell tumor;
LUSC	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg09904177	chr6:26538194	HMGN4	-0.65	-10.67	-0.5	4.69e-23	Intelligence (multi-trait analysis);
LUSC	cis	rs356992	0.957	rs356993	chr2:60750560	C/T	cg08426369	chr2:60753602	BCL11A	-0.45	-6.25	-0.32	1.26e-9	Educational attainment (years of education);
LUSC	cis	rs7188861	0.768	rs62023605	chr16:11380861	A/C	cg00044050	chr16:11439710	C16orf75	0.56	6.31	0.33	8.71e-10	HDL cholesterol;
LUSC	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg08601574	chr20:25228251	PYGB	0.41	6.21	0.32	1.56e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg17462356	chr17:80056334	FASN	0.46	6.23	0.32	1.4e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs16976116	0.901	rs28433503	chr15:55499857	T/C	cg11288833	chr15:55489084	RSL24D1	0.51	6.1	0.32	2.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs908922	1.000	rs1199150	chr1:152455602	T/C	cg20991723	chr1:152506922	NA	0.5	8.78	0.43	8.68e-17	Hair morphology;
LUSC	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg02466173	chr16:30829666	NA	-0.54	-8.7	-0.43	1.54e-16	Dementia with Lewy bodies;
LUSC	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.52	7.59	0.38	3.12e-13	Night sleep phenotypes;
LUSC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg00814883	chr7:100076585	TSC22D4	-0.76	-9.65	-0.47	1.35e-19	Platelet count;
LUSC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg07716408	chr11:68623521	NA	-0.34	-6.72	-0.35	7.85e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.35	5.71	0.3	2.47e-8	Self-reported allergy;
LUSC	cis	rs1595825	0.891	rs7580003	chr2:198517893	C/T	cg19156104	chr2:198669113	PLCL1	-0.46	-5.75	-0.3	2.02e-8	Ulcerative colitis;
LUSC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg03579872	chr1:53393473	SCP2	-0.39	-5.66	-0.3	3.31e-8	Monocyte count;
LUSC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg01416388	chr22:39784598	NA	-0.45	-6.96	-0.36	1.76e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.88	0.31	9.71e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg20845466	chr8:109260899	EIF3E	0.39	5.95	0.31	6.82e-9	Triglycerides;
LUSC	cis	rs12618769	0.652	rs11896729	chr2:99225645	T/C	cg10123293	chr2:99228465	UNC50	0.47	7.64	0.39	2.27e-13	Bipolar disorder;
LUSC	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg00012203	chr2:219082015	ARPC2	-0.77	-13.07	-0.58	8.08e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LUSC	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg06636001	chr8:8085503	FLJ10661	0.53	7.87	0.4	5.04e-14	Neuroticism;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09975850	chr8:65711396	CYP7B1	0.41	6.23	0.32	1.4e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	12.08	0.55	4.09e-28	Hip circumference adjusted for BMI;
LUSC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.94	0.31	7.28e-9	Menopause (age at onset);
LUSC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.8	-0.3	1.52e-8	Personality dimensions;
LUSC	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg00310523	chr12:86230176	RASSF9	0.4	7.15	0.36	5.68e-12	Major depressive disorder;
LUSC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg09035930	chr12:129282057	SLC15A4	0.66	13.27	0.59	1.4e-32	Systemic lupus erythematosus;
LUSC	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg21573476	chr21:45109991	RRP1B	-0.4	-6.44	-0.33	4.13e-10	Mean corpuscular volume;
LUSC	cis	rs1003719	0.591	rs2040125	chr21:38549236	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.53	7.77	0.39	9.95e-14	Eye color traits;
LUSC	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.35	-0.42	1.89e-15	Morning vs. evening chronotype;
LUSC	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg22117172	chr7:91764530	CYP51A1	-0.32	-5.84	-0.3	1.24e-8	Breast cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02744793	chr10:35378717	CUL2	0.42	6.35	0.33	6.85e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4974559	0.690	rs28641665	chr4:1288781	G/T	cg02980000	chr4:1222292	CTBP1	1.02	9.35	0.46	1.28e-18	Systolic blood pressure;
LUSC	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.59	-0.34	1.75e-10	Myopia (pathological);
LUSC	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg19052272	chr2:3704530	ALLC	0.33	6.22	0.32	1.49e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg20476274	chr7:133979776	SLC35B4	0.88	16.9	0.68	1.01e-46	Mean platelet volume;
LUSC	cis	rs6674970	0.933	rs12134957	chr1:151045419	A/G	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.44	-5.92	-0.31	8.01e-9	Childhood ear infection;
LUSC	cis	rs3087591	0.664	rs2525565	chr17:29666588	T/C	cg24425628	chr17:29625626	OMG;NF1	0.47	7.23	0.37	3.33e-12	Hip circumference;
LUSC	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg02423579	chr7:2872169	GNA12	-0.36	-5.75	-0.3	2.05e-8	Height;
LUSC	trans	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.47	-0.38	6.93e-13	Breast cancer;
LUSC	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.79	11.58	0.54	2.77e-26	Corneal astigmatism;
LUSC	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg26924012	chr15:45694286	SPATA5L1	0.76	11.56	0.53	3.15e-26	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg23630131	chr7:65973040	NA	0.2	5.72	0.3	2.4e-8	Aortic root size;
LUSC	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg17127132	chr2:85788382	GGCX	0.47	7.56	0.38	3.95e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs11051970	0.636	rs2733705	chr12:32561564	T/C	cg02745156	chr12:32552066	NA	0.37	6.82	0.35	4.3e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg15557168	chr22:42548783	NA	-0.42	-7.14	-0.36	5.76e-12	Cognitive function;
LUSC	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg11062466	chr8:58055876	NA	0.68	7.72	0.39	1.33e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg02951883	chr7:2050386	MAD1L1	-0.4	-6.85	-0.35	3.66e-11	Bipolar disorder and schizophrenia;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02732134	chr10:101732382	DNMBP	-0.37	-6.13	-0.32	2.45e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg21385522	chr1:16154831	NA	0.58	8.73	0.43	1.23e-16	Systolic blood pressure;
LUSC	cis	rs9650315	0.530	rs35399441	chr8:57089431	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	8.44	0.42	9.62e-16	Height;
LUSC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg20891558	chr2:74357851	NA	0.79	14.23	0.61	3.02e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs4144743	1.000	rs67923812	chr17:45326151	T/G	cg18085866	chr17:45331354	ITGB3	-0.73	-7.69	-0.39	1.7e-13	Body mass index;
LUSC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg18681998	chr4:17616180	MED28	0.84	15.64	0.65	9.06e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6495367	0.966	rs745029	chr15:79381779	C/T	cg17916960	chr15:79447300	NA	0.36	6.74	0.35	6.95e-11	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg04450456	chr4:17643702	FAM184B	0.36	5.88	0.31	9.97e-9	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	13.83	0.6	1.06e-34	Platelet count;
LUSC	trans	rs7944735	1.000	rs7944735	chr11:47955608	G/C	cg15704280	chr7:45808275	SEPT13	0.64	6.65	0.34	1.18e-10	Intraocular pressure;
LUSC	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg13042288	chr15:90349979	ANPEP	-0.46	-6.42	-0.33	4.66e-10	Uric acid levels;
LUSC	trans	rs6084875	0.840	rs1885357	chr20:4727427	G/A	cg26257163	chr5:25190441	NA	-0.36	-6.06	-0.31	3.62e-9	Systemic lupus erythematosus;
LUSC	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg22532475	chr10:104410764	TRIM8	-0.33	-7.32	-0.37	1.92e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg25801113	chr15:45476975	SHF	0.34	7.11	0.36	6.99e-12	Uric acid levels;
LUSC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08219700	chr8:58056026	NA	0.72	7.79	0.39	8.28e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs9473147	0.516	rs9357546	chr6:47549495	C/T	cg12968598	chr6:47444699	CD2AP	0.51	7.66	0.39	1.99e-13	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs662064	0.962	rs2781230	chr1:10563717	G/A	cg20482658	chr1:10539492	PEX14	0.33	6.64	0.34	1.25e-10	Asthma;
LUSC	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg23649088	chr2:200775458	C2orf69	-0.56	-6.69	-0.34	9.64e-11	Schizophrenia;
LUSC	cis	rs728616	0.681	rs117420340	chr10:82166495	T/C	cg05935833	chr10:81318306	SFTPA2	-0.45	-5.99	-0.31	5.43e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs870825	0.655	rs28555435	chr4:185647300	C/A	cg04058563	chr4:185651563	MLF1IP	0.82	12.65	0.57	2.98e-30	Blood protein levels;
LUSC	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-6.83	-0.35	4.12e-11	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06634786	chr22:41940651	POLR3H	0.52	6.04	0.31	4.17e-9	Vitiligo;
LUSC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg27284194	chr4:1044797	NA	0.37	6.04	0.31	4e-9	Longevity;
LUSC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg24881330	chr22:46731750	TRMU	0.88	8.87	0.44	4.55e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg17366294	chr4:99064904	C4orf37	0.59	10.29	0.49	9.63e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.96	-12.45	-0.56	1.77e-29	Exhaled nitric oxide output;
LUSC	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.53	-6.49	-0.33	3.15e-10	Neutrophil percentage of white cells;
LUSC	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg21064579	chr19:49206444	FUT2	0.46	8.66	0.43	2.07e-16	Dietary macronutrient intake;
LUSC	cis	rs75920871	0.528	rs10466590	chr11:116894413	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.42	-0.33	4.57e-10	Subjective well-being;
LUSC	cis	rs6546550	1.000	rs6546550	chr2:70038232	C/G	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.15	-0.36	5.56e-12	Prevalent atrial fibrillation;
LUSC	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	ch.11.42038R	chr11:967971	AP2A2	0.55	8.31	0.41	2.41e-15	Alzheimer's disease (late onset);
LUSC	cis	rs7582180	0.903	rs13031493	chr2:100896376	G/C	cg08017756	chr2:100939284	LONRF2	-0.36	-6.01	-0.31	4.77e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg25024717	chr12:54324583	NA	-0.35	-5.92	-0.31	7.94e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs77741769	0.571	rs11065284	chr12:121266621	G/A	cg02419362	chr12:121203948	SPPL3	0.45	8.49	0.42	6.8e-16	Mean corpuscular volume;
LUSC	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg05805236	chr11:65401703	PCNXL3	-0.57	-9.25	-0.45	2.79e-18	Acne (severe);
LUSC	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg18721089	chr20:30220636	NA	-0.37	-5.95	-0.31	6.7e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs1348850	0.597	rs13014512	chr2:178470851	T/A	cg22681709	chr2:178499509	PDE11A	-0.55	-8.07	-0.4	1.25e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12756686	chr19:29218302	NA	0.59	6.86	0.35	3.26e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	trans	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg06521331	chr12:34319734	NA	-0.41	-6.43	-0.33	4.33e-10	Bladder cancer;
LUSC	cis	rs67072384	1.000	rs72964185	chr11:72443177	G/A	cg04827223	chr11:72435913	ARAP1	-0.83	-7.37	-0.37	1.38e-12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-1.12	-25.08	-0.81	8.21e-79	Height;
LUSC	cis	rs10864907	0.614	rs7557537	chr2:113702530	T/C	cg06156847	chr2:113672199	IL1F7	-0.28	-5.83	-0.3	1.32e-8	Pulmonary function;
LUSC	cis	rs6733011	0.500	rs10182043	chr2:99417433	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-6.6	-0.34	1.59e-10	Bipolar disorder;
LUSC	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg10765909	chr12:53715428	AAAS	-0.42	-5.98	-0.31	5.77e-9	Platelet distribution width;
LUSC	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg11757124	chr7:157526947	PTPRN2	0.44	6.66	0.34	1.13e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs34779708	0.966	rs1213392	chr10:35430285	C/T	cg03585969	chr10:35415529	CREM	0.59	8.88	0.44	4.28e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg03146154	chr1:46216737	IPP	0.53	7.79	0.39	8.71e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg20135002	chr11:47629003	NA	-0.43	-6.96	-0.36	1.85e-11	Subjective well-being;
LUSC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-6.44	-0.33	4.08e-10	Alzheimer's disease (late onset);
LUSC	cis	rs7615316	0.510	rs7630115	chr3:142210801	C/T	cg16271453	chr3:142027066	XRN1	-0.52	-9.21	-0.45	3.66e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs17767294	0.708	rs72847370	chr6:27849424	A/T	cg23539494	chr17:65276751	NA	0.74	6.11	0.32	2.7e-9	Parkinson's disease;
LUSC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-9.8	-0.47	4.12e-20	Gut microbiome composition (summer);
LUSC	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg18478394	chr8:109455254	TTC35	0.42	6.42	0.33	4.79e-10	Dupuytren's disease;
LUSC	cis	rs6570726	0.526	rs9376934	chr6:145738702	A/G	cg23711669	chr6:146136114	FBXO30	0.55	8.38	0.42	1.45e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg16797656	chr11:68205561	LRP5	0.37	6.09	0.32	3.15e-9	Total body bone mineral density;
LUSC	trans	rs800082	0.501	rs9844730	chr3:144216886	T/G	cg24215973	chr2:240111563	HDAC4	0.49	7.4	0.38	1.12e-12	Smoking behavior;
LUSC	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg05625103	chr10:2543513	NA	0.37	5.78	0.3	1.74e-8	Age-related hearing impairment;
LUSC	trans	rs6601327	0.641	rs4129360	chr8:9573284	T/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-6.29	-0.33	1e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs11971779	0.680	rs4732370	chr7:139077240	A/C	cg23387468	chr7:139079360	LUC7L2	-0.41	-6.25	-0.32	1.25e-9	Diisocyanate-induced asthma;
LUSC	cis	rs6961069	0.585	rs1761663	chr7:80239418	T/C	cg04458919	chr7:80252533	CD36	-0.4	-7.32	-0.37	1.91e-12	Platelet count;
LUSC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg05872129	chr22:39784769	NA	-0.6	-11.01	-0.52	3.01e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs2227564	0.597	rs2271271	chr10:75558867	G/A	cg23231163	chr10:75533350	FUT11	-0.45	-6.57	-0.34	1.91e-10	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg17507749	chr15:85114479	UBE2QP1	0.53	6.54	0.34	2.25e-10	Schizophrenia;
LUSC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg07716408	chr11:68623521	NA	-0.31	-5.96	-0.31	6.55e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs17621444	0.522	rs4322307	chr10:121777328	C/T	cg02041677	chr10:121771263	NA	-0.34	-6.37	-0.33	6.41e-10	IgG glycosylation;
LUSC	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg01028140	chr2:1542097	TPO	-0.61	-8.06	-0.4	1.36e-14	Placebo response in major depressive disorder (% change in symptom score);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09428623	chr2:68480128	PPP3R1	0.5	7.02	0.36	1.27e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4594175	0.926	rs10138269	chr14:51615360	T/C	cg23942311	chr14:51606299	NA	0.31	6.07	0.32	3.39e-9	Cancer;
LUSC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	9.61	0.47	1.81e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-7.08	-0.36	8.71e-12	Colorectal cancer;
LUSC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-9.1	-0.45	8.23e-18	Bipolar disorder;
LUSC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	15.14	0.64	8.96e-40	Platelet count;
LUSC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg16405210	chr4:1374714	KIAA1530	-0.85	-13.94	-0.61	3.89e-35	Longevity;
LUSC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	14.17	0.61	5.3e-36	Tonsillectomy;
LUSC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg13683864	chr3:40499215	RPL14	-1.12	-20.04	-0.74	3.17e-59	Renal cell carcinoma;
LUSC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-5.95	-0.31	6.8e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs62140779	0.778	rs17049584	chr2:58828331	C/G	cg20220755	chr7:142012034	NA	0.39	5.99	0.31	5.43e-9	Neuroticism;
LUSC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18099408	chr3:52552593	STAB1	-0.42	-7.36	-0.37	1.45e-12	Bipolar disorder;
LUSC	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg21972741	chr5:435613	AHRR	0.34	6.35	0.33	7.01e-10	Cystic fibrosis severity;
LUSC	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.77	11.37	0.53	1.57e-25	Corneal astigmatism;
LUSC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.89	0.4	4.28e-14	Bipolar disorder;
LUSC	cis	rs3770081	1.000	rs12622009	chr2:86248325	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.78	-5.68	-0.3	3e-8	Facial emotion recognition (sad faces);
LUSC	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg05973401	chr12:123451056	ABCB9	0.54	7.93	0.4	3.24e-14	Platelet count;
LUSC	cis	rs240764	0.853	rs12206945	chr6:101018032	C/T	cg09795085	chr6:101329169	ASCC3	0.42	6.14	0.32	2.29e-9	Neuroticism;
LUSC	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.77	0.35	5.95e-11	Joint mobility (Beighton score);
LUSC	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	11.91	0.55	1.74e-27	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs11270836	1	rs11270836	chr4:38625915	T/TACATTATGTCATTTCACA	cg18361445	chr4:38666374	KLF3;FLJ13197	0.57	8.4	0.42	1.33e-15	Mumps;
LUSC	cis	rs897984	0.542	rs8061047	chr16:31068960	T/C	cg02466173	chr16:30829666	NA	-0.5	-9.46	-0.46	5.63e-19	Dementia with Lewy bodies;
LUSC	cis	rs6693567	0.526	rs698918	chr1:150319762	A/G	cg15654264	chr1:150340011	RPRD2	0.44	7.02	0.36	1.22e-11	Migraine;
LUSC	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00631329	chr6:26305371	NA	-0.47	-9.48	-0.46	4.98e-19	Educational attainment;
LUSC	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg15468180	chr1:107600409	PRMT6	0.36	5.86	0.31	1.13e-8	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg07716408	chr11:68623521	NA	-0.3	-5.67	-0.3	3.16e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg17507749	chr15:85114479	UBE2QP1	0.53	6.59	0.34	1.71e-10	Schizophrenia;
LUSC	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	7.42	0.38	9.86e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.69	-10.39	-0.49	4.28e-22	Aortic root size;
LUSC	cis	rs1443512	0.588	rs1975473	chr12:54334625	G/A	cg17410650	chr12:54324560	NA	-0.46	-6.16	-0.32	2.12e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg22823121	chr1:150693482	HORMAD1	0.51	7.54	0.38	4.49e-13	Melanoma;
LUSC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg07507251	chr3:52567010	NT5DC2	0.39	7.23	0.37	3.36e-12	Bipolar disorder;
LUSC	cis	rs7617773	0.746	rs4130995	chr3:48358255	C/T	cg11946769	chr3:48343235	NME6	0.76	11.77	0.54	5.7e-27	Coronary artery disease;
LUSC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20135002	chr11:47629003	NA	-0.5	-7.82	-0.39	6.92e-14	Subjective well-being;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21910613	chr1:27191950	NA	0.42	6.1	0.32	2.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg04998671	chr14:104000505	TRMT61A	-0.42	-5.92	-0.31	8.01e-9	Reticulocyte count;
LUSC	trans	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg06606381	chr12:133084897	FBRSL1	-0.66	-6.94	-0.36	2.05e-11	Depression;
LUSC	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg13010199	chr12:38710504	ALG10B	0.66	9.92	0.48	1.69e-20	Bladder cancer;
LUSC	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg16586182	chr3:47516702	SCAP	-0.51	-7.2	-0.37	4.03e-12	Birth weight;
LUSC	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.42	-0.42	1.12e-15	Body mass index;
LUSC	cis	rs4654899	0.802	rs9651021	chr1:21222770	A/C	cg01072550	chr1:21505969	NA	-0.48	-6.94	-0.36	2.04e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg02023728	chr11:77925099	USP35	0.48	6.6	0.34	1.59e-10	Testicular germ cell tumor;
LUSC	cis	rs11630290	0.604	rs17775820	chr15:64168582	G/A	cg12036633	chr15:63758958	NA	-0.64	-7.53	-0.38	4.66e-13	Iris characteristics;
LUSC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.92	0.44	3.19e-17	Prudent dietary pattern;
LUSC	cis	rs11030122	0.702	rs7128762	chr11:3943277	C/G	cg18678763	chr11:4115507	RRM1	-0.45	-5.72	-0.3	2.37e-8	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2046867	0.862	rs11920131	chr3:72858630	C/G	cg25664220	chr3:72788482	NA	-0.71	-12.06	-0.55	4.87e-28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg21862992	chr11:68658383	NA	0.52	8.13	0.41	8.72e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1982963	0.572	rs61971549	chr14:52478541	A/G	cg10843707	chr14:52510701	NID2	0.42	5.93	0.31	7.76e-9	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08219700	chr8:58056026	NA	0.64	8.16	0.41	6.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7605827	0.930	rs1024869	chr2:15549043	G/C	cg19274914	chr2:15703543	NA	0.47	9.12	0.45	7e-18	Educational attainment (years of education);
LUSC	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg17173187	chr15:85201210	NMB	-0.38	-6.89	-0.35	2.87e-11	Schizophrenia;
LUSC	cis	rs72634258	0.786	rs7523335	chr1:8180210	G/A	cg00042356	chr1:8021962	PARK7	0.54	6.59	0.34	1.72e-10	Inflammatory bowel disease;
LUSC	cis	rs80130819	0.748	rs2732440	chr12:48660429	G/A	cg24011408	chr12:48396354	COL2A1	0.46	5.84	0.3	1.22e-8	Prostate cancer;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg16451525	chr16:89167282	ACSF3	-0.38	-6.01	-0.31	4.99e-9	Asthma;
LUSC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.86	0.35	3.37e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4925114	0.568	rs9900803	chr17:17650978	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.5	-7.59	-0.38	3.23e-13	Body mass index;
LUSC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-1.08	-24.85	-0.81	6.31e-78	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg05861140	chr6:150128134	PCMT1	0.42	6.68	0.34	1.01e-10	Lung cancer;
LUSC	cis	rs1832871	0.683	rs56197409	chr6:158684338	A/G	cg07165851	chr6:158734300	TULP4	0.51	7.81	0.39	7.24e-14	Height;
LUSC	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg20790798	chr5:1857306	NA	-0.39	-5.78	-0.3	1.76e-8	Cardiovascular disease risk factors;
LUSC	cis	rs9815354	0.812	rs73830516	chr3:41876056	A/G	cg03022575	chr3:42003672	ULK4	0.85	8.87	0.44	4.46e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg23649088	chr2:200775458	C2orf69	-0.61	-7.08	-0.36	8.8e-12	Schizophrenia;
LUSC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg13770153	chr20:60521292	NA	-0.67	-9.58	-0.46	2.31e-19	Body mass index;
LUSC	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg13319975	chr6:146136371	FBXO30	0.5	7.43	0.38	9e-13	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg09796886	chr4:39640558	C4orf34	-0.46	-6.11	-0.32	2.72e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-11.87	-0.54	2.37e-27	Prudent dietary pattern;
LUSC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00166722	chr3:10149974	C3orf24	0.59	8.16	0.41	6.95e-15	Alzheimer's disease;
LUSC	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg18512352	chr11:47633146	NA	-0.47	-9.32	-0.45	1.62e-18	Subjective well-being;
LUSC	cis	rs4253772	0.872	rs45576140	chr22:46638216	C/G	cg18190219	chr22:46762943	CELSR1	-0.48	-5.81	-0.3	1.45e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs10203711	1.000	rs6707795	chr2:239555580	T/C	cg14580085	chr2:239553406	NA	0.41	6.99	0.36	1.53e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg06521331	chr12:34319734	NA	-0.42	-6.85	-0.35	3.63e-11	Morning vs. evening chronotype;
LUSC	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg06917634	chr15:78832804	PSMA4	-0.59	-7.17	-0.37	4.85e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1865721	0.771	rs6566092	chr18:73136496	C/T	cg26385618	chr18:73139727	C18orf62	-0.55	-10.1	-0.48	4.25e-21	Intelligence;
LUSC	cis	rs10992471	0.603	rs11788523	chr9:95256593	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.77	-0.39	9.98e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02726883	chr17:29421732	NF1	0.44	6.77	0.35	5.91e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12894936	1	rs12894936	chr14:100846991	T/C	cg14882082	chr14:100845427	WDR25	0.39	7.83	0.39	6.61e-14	Menarche (age at onset);
LUSC	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg16414030	chr3:133502952	NA	0.42	6.7	0.34	8.92e-11	Iron status biomarkers;
LUSC	cis	rs7241530	0.662	rs12456683	chr18:75909031	C/T	cg14642773	chr18:75888474	NA	0.39	5.74	0.3	2.17e-8	Educational attainment (years of education);
LUSC	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg18132916	chr6:79620363	NA	-0.37	-5.65	-0.3	3.53e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.88	-12.75	-0.57	1.35e-30	Initial pursuit acceleration;
LUSC	trans	rs931812	0.757	rs4734492	chr8:101901901	C/T	cg20993868	chr7:22813445	NA	-0.5	-9.57	-0.46	2.43e-19	Attention deficit hyperactivity disorder and conduct disorder;
LUSC	cis	rs4891159	0.790	rs4891161	chr18:74142683	A/G	cg24786174	chr18:74118243	ZNF516	-0.91	-18.74	-0.72	4.5e-54	Longevity;
LUSC	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg17127132	chr2:85788382	GGCX	-0.47	-7.61	-0.38	2.77e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg19875535	chr5:140030758	IK	0.47	7.66	0.39	2.01e-13	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18099408	chr3:52552593	STAB1	-0.43	-7.5	-0.38	5.86e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg08975724	chr8:8085496	FLJ10661	0.52	7.92	0.4	3.61e-14	Mood instability;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg20314438	chr6:126661369	C6orf173	0.52	7.23	0.37	3.35e-12	Cognitive function;Information processing speed;
LUSC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg03676636	chr4:99064102	C4orf37	0.34	7.33	0.37	1.8e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12421382	0.683	rs10789735	chr11:109431361	A/T	cg16359550	chr11:109292809	C11orf87	0.41	6.76	0.35	6.24e-11	Schizophrenia;
LUSC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg25258033	chr6:167368657	RNASET2	0.38	5.82	0.3	1.38e-8	Primary biliary cholangitis;
LUSC	cis	rs16910800	1.000	rs16910794	chr11:23202631	A/T	cg20040320	chr11:23191996	NA	-0.44	-6.35	-0.33	6.87e-10	Cancer;
LUSC	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg26677194	chr12:130822605	PIWIL1	0.6	8.96	0.44	2.29e-17	Menopause (age at onset);
LUSC	cis	rs2742234	0.541	rs10793424	chr10:43717116	G/T	cg02780029	chr10:43622663	RET	0.35	5.82	0.3	1.41e-8	Hirschsprung disease;
LUSC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg14552801	chr7:65878734	NA	-0.45	-6.34	-0.33	7.34e-10	Aortic root size;
LUSC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg21433558	chr17:40837037	CNTNAP1	0.36	6.2	0.32	1.69e-9	Colorectal or endometrial cancer;
LUSC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg25036284	chr2:26402008	FAM59B	-0.74	-10.73	-0.51	2.89e-23	Gut microbiome composition (summer);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03648631	chr4:103749307	UBE2D3	0.39	6.06	0.31	3.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg02038168	chr22:39784481	NA	-0.43	-6.47	-0.33	3.47e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LUSC	cis	rs9479482	0.686	rs2184452	chr6:150384827	T/C	cg25797454	chr6:150327115	RAET1K	0.29	6.26	0.32	1.18e-9	Alopecia areata;
LUSC	cis	rs2274273	0.714	rs7154889	chr14:55806885	G/A	cg04306507	chr14:55594613	LGALS3	0.56	13.13	0.58	4.79e-32	Protein biomarker;
LUSC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.56	8.69	0.43	1.68e-16	Menopause (age at onset);
LUSC	cis	rs454953	0.533	rs211436	chr6:133612992	A/G	cg22462983	chr6:133561756	EYA4	-0.41	-5.9	-0.31	8.7e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg08219700	chr8:58056026	NA	0.53	6.83	0.35	4.05e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg09165964	chr15:75287851	SCAMP5	0.52	7.61	0.38	2.87e-13	Breast cancer;
LUSC	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg13010199	chr12:38710504	ALG10B	-0.5	-7.49	-0.38	6.05e-13	Morning vs. evening chronotype;
LUSC	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg03929089	chr4:120376271	NA	-0.78	-12.33	-0.56	4.92e-29	Height;
LUSC	cis	rs243505	0.559	rs1558420	chr7:148480114	G/T	cg09806900	chr7:148480153	CUL1	0.67	9.96	0.48	1.21e-20	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg27411982	chr8:10470053	RP1L1	-0.37	-5.79	-0.3	1.63e-8	Retinal vascular caliber;
LUSC	cis	rs859767	0.741	rs4954159	chr2:135426782	A/G	cg12500956	chr2:135428796	TMEM163	-0.27	-6.04	-0.31	4.1e-9	Neuroticism;
LUSC	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg11812906	chr14:75593930	NEK9	-0.62	-10.32	-0.49	7.47e-22	Height;
LUSC	cis	rs12791968	0.659	rs12808379	chr11:45009273	C/G	cg11846598	chr11:44996168	LOC221122	-0.56	-7.78	-0.39	9.2e-14	Inhibitory control;
LUSC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	12.99	0.58	1.61e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-6.12	-0.32	2.6e-9	Systolic blood pressure;
LUSC	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg23306229	chr2:178417860	TTC30B	0.5	5.82	0.3	1.36e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg09904177	chr6:26538194	HMGN4	-0.42	-6.22	-0.32	1.49e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg01689657	chr7:91764605	CYP51A1	0.32	5.84	0.3	1.27e-8	Breast cancer;
LUSC	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	6.55	0.34	2.18e-10	Iron status biomarkers;
LUSC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08564027	chr20:61660810	NA	0.9	17.3	0.69	2.61e-48	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg21548813	chr6:291882	DUSP22	-0.71	-11.89	-0.55	1.96e-27	Menopause (age at onset);
LUSC	cis	rs889512	0.642	rs3826110	chr16:75277780	G/A	cg04987608	chr16:75300043	BCAR1	-0.49	-5.69	-0.3	2.84e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg20991723	chr1:152506922	NA	0.54	10.18	0.49	2.18e-21	Hair morphology;
LUSC	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg24558204	chr6:135376177	HBS1L	0.59	9.28	0.45	2.26e-18	Red blood cell count;
LUSC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	0.93	18.05	0.7	2.67e-51	Cognitive function;
LUSC	cis	rs16912285	0.688	rs59797575	chr11:24315536	A/T	ch.11.24196551F	chr11:24239977	NA	0.89	9.47	0.46	5.22e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg05855489	chr10:104503620	C10orf26	0.49	7.36	0.37	1.48e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs10170310	1.000	rs10170310	chr2:139278922	C/T	cg10095539	chr2:139258744	SPOPL	0.3	5.81	0.3	1.47e-8	Response to antipsychotic treatment;
LUSC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.49	-8.75	-0.43	1.09e-16	Longevity;Endometriosis;
LUSC	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.87	-0.35	3.22e-11	Monocyte percentage of white cells;
LUSC	cis	rs4713675	0.584	rs3227	chr6:33662295	G/C	cg14003231	chr6:33640908	ITPR3	0.31	6.04	0.31	4.12e-9	Plateletcrit;
LUSC	trans	rs4252134	0.881	rs4252076	chr6:161128922	A/G	cg00639886	chr12:54943102	PDE1B	-0.43	-6.33	-0.33	7.68e-10	Giant cell arteritis;
LUSC	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-5.73	-0.3	2.3e-8	Coronary artery disease;
LUSC	cis	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg05299278	chr17:33885742	SLFN14	0.3	6.55	0.34	2.14e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	trans	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg21775007	chr8:11205619	TDH	-0.42	-6.09	-0.32	3.16e-9	Systolic blood pressure;
LUSC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6960043	0.818	rs10238161	chr7:15053827	A/T	cg19272540	chr7:15055459	NA	0.35	8.69	0.43	1.6e-16	Type 2 diabetes;
LUSC	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg01884057	chr2:25150051	NA	0.48	11.39	0.53	1.29e-25	Body mass index;
LUSC	cis	rs11216435	0.512	rs2276343	chr11:117375596	G/A	cg27161313	chr11:117392002	DSCAML1	-0.41	-7.02	-0.36	1.25e-11	Menarche (age at onset);
LUSC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg13319975	chr6:146136371	FBXO30	-0.37	-5.67	-0.3	3.17e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.61	6.28	0.32	1.08e-9	Initial pursuit acceleration;
LUSC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg03146154	chr1:46216737	IPP	0.56	8.35	0.42	1.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg00353675	chr12:132601362	EP400NL	-0.41	-6.38	-0.33	5.76e-10	N-glycan levels;
LUSC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg13319975	chr6:146136371	FBXO30	-0.37	-5.65	-0.3	3.36e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs78579285	0.583	rs1061238	chr16:88781850	A/G	cg01900006	chr16:88814613	FAM38A	-0.54	-6.12	-0.32	2.69e-9	Joint mobility (Beighton score);
LUSC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-1.15	-16.58	-0.67	1.82e-45	Breast cancer;
LUSC	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07741184	chr6:167504864	NA	-0.35	-6.02	-0.31	4.69e-9	Primary biliary cholangitis;
LUSC	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25072359	chr17:41440525	NA	0.58	8.51	0.42	6.11e-16	Menopause (age at onset);
LUSC	cis	rs977987	0.835	rs11641532	chr16:75329480	T/C	cg04384234	chr16:75411784	CFDP1	-0.4	-6.48	-0.33	3.35e-10	Dupuytren's disease;
LUSC	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg11244672	chr19:19639970	YJEFN3	-0.59	-7.33	-0.37	1.7e-12	Bipolar disorder;
LUSC	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-8.2	-0.41	5.09e-15	Retinal vascular caliber;
LUSC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg07716408	chr11:68623521	NA	-0.32	-6.19	-0.32	1.8e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.01	-0.48	8.51e-21	Platelet count;
LUSC	trans	rs1941687	0.510	rs1452649	chr18:31410858	A/G	cg27147174	chr7:100797783	AP1S1	-0.55	-8.73	-0.43	1.21e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs10779751	0.959	rs2300091	chr1:11266711	C/T	cg08854313	chr1:11322531	MTOR	0.91	16.32	0.67	1.93e-44	Body mass index;
LUSC	cis	rs62400317	0.859	rs12199871	chr6:45307682	C/T	cg18551225	chr6:44695536	NA	-0.45	-7.44	-0.38	8.72e-13	Total body bone mineral density;
LUSC	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs143985986	1	rs143985986	chr3:58399886	TC/T	cg13750441	chr3:58318267	PXK	0.34	6.52	0.34	2.57e-10	Hematocrit;
LUSC	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg13535736	chr9:111863775	C9orf5	-0.38	-5.88	-0.31	1e-8	Menarche (age at onset);
LUSC	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg25382214	chr1:3105252	PRDM16	-0.3	-5.89	-0.31	9.52e-9	Migraine;
LUSC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg13939156	chr17:80058883	NA	-0.33	-6.46	-0.33	3.6e-10	Life satisfaction;
LUSC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.32	0.56	5.33e-29	Cognitive test performance;
LUSC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	0.82	12.42	0.56	2.16e-29	Gut microbiome composition (summer);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22198946	chr2:43454609	ZFP36L2;LOC100129726	-0.41	-6.18	-0.32	1.89e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.3	0.37	2.13e-12	Motion sickness;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16082737	chr14:58711570	PSMA3	-0.44	-6.96	-0.36	1.76e-11	Electrocardiographic conduction measures;
LUSC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.5	6.21	0.32	1.62e-9	Schizophrenia;
LUSC	cis	rs6546550	0.901	rs6716937	chr2:70127229	G/A	cg02498382	chr2:70120550	SNRNP27	-0.3	-7.39	-0.37	1.2e-12	Prevalent atrial fibrillation;
LUSC	cis	rs7953508	0.741	rs1498706	chr12:93996980	C/T	cg18151635	chr12:93972918	NA	-0.41	-5.72	-0.3	2.38e-8	Pubertal anthropometrics;
LUSC	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg03709012	chr19:19516395	GATAD2A	1.02	13.63	0.6	5.9e-34	Nonalcoholic fatty liver disease;
LUSC	cis	rs9309473	0.898	rs10185080	chr2:73797507	C/A	cg20560298	chr2:73613845	ALMS1	-0.47	-6.77	-0.35	5.8200000000000003e-11	Metabolite levels;
LUSC	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg17691542	chr6:26056736	HIST1H1C	0.47	7.04	0.36	1.08e-11	Height;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19432297	chr22:26908626	TFIP11	-0.47	-6.25	-0.32	1.27e-9	Hepatitis;
LUSC	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg13206674	chr6:150067644	NUP43	0.5	7.68	0.39	1.75e-13	Lung cancer;
LUSC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg06784218	chr1:46089804	CCDC17	0.47	9.15	0.45	5.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg13628971	chr7:2884303	GNA12	0.43	6.39	0.33	5.5e-10	Height;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg16944159	chr2:62132759	COMMD1	0.42	6.5	0.34	2.96e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg06521331	chr12:34319734	NA	-0.41	-6.06	-0.31	3.68e-9	Resting heart rate;
LUSC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-1.23	-13.78	-0.6	1.62e-34	Diabetic kidney disease;
LUSC	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg04450456	chr4:17643702	FAM184B	0.41	6.93	0.35	2.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	0.64	13.56	0.6	1.12e-33	Prudent dietary pattern;
LUSC	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg09462578	chr12:12878428	APOLD1	-1.0	-17.09	-0.68	1.76e-47	Lymphocyte counts;
LUSC	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg15556689	chr8:8085844	FLJ10661	0.59	8.38	0.42	1.45e-15	Joint mobility (Beighton score);
LUSC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg19592336	chr6:28129416	ZNF389	0.53	7.05	0.36	1.02e-11	Parkinson's disease;
LUSC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg07701084	chr6:150067640	NUP43	0.58	8.97	0.44	2.22e-17	Lung cancer;
LUSC	cis	rs9815354	1.000	rs28733681	chr3:41863444	C/A	cg03022575	chr3:42003672	ULK4	0.58	6.54	0.34	2.3e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs9653442	0.564	rs11123809	chr2:100758137	C/T	cg07810366	chr2:100720526	AFF3	-0.43	-7.24	-0.37	3.03e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg25251562	chr2:3704773	ALLC	0.63	10.43	0.5	3.16e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.36	-7.5	-0.38	5.64e-13	Hemoglobin concentration;
LUSC	trans	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg07393940	chr7:158741817	NA	0.35	6.28	0.32	1.06e-9	Life satisfaction;
LUSC	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-1.14	-18.19	-0.71	7.14e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-7.95	-0.4	2.82e-14	Renal function-related traits (BUN);
LUSC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.68	10.05	0.48	6.36e-21	Methadone dose in opioid dependence;
LUSC	cis	rs4704187	0.687	rs1422698	chr5:74443132	C/T	cg03227963	chr5:74354835	NA	0.31	6.78	0.35	5.45e-11	Response to amphetamines;
LUSC	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg08755490	chr11:65554678	OVOL1	0.41	5.88	0.31	9.7e-9	Acne (severe);
LUSC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.67	0.43	1.91e-16	Prudent dietary pattern;
LUSC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg09655341	chr17:79618100	PDE6G	-0.29	-6.73	-0.35	7.21e-11	Eye color traits;
LUSC	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg05855489	chr10:104503620	C10orf26	0.54	7.86	0.4	5.41e-14	Arsenic metabolism;
LUSC	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.62	8.91	0.44	3.47e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg21775007	chr8:11205619	TDH	-0.68	-10.92	-0.51	6.24e-24	Retinal vascular caliber;
LUSC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	13.4	0.59	4.43e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.86	-15.14	-0.64	9.02e-40	Ulcerative colitis;
LUSC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg00074818	chr8:8560427	CLDN23	0.58	9.66	0.47	1.23e-19	Obesity-related traits;
LUSC	cis	rs7712401	0.601	rs2910136	chr5:122254017	C/T	cg19077854	chr5:122220652	SNX24	-0.41	-9.16	-0.45	5.32e-18	Mean platelet volume;
LUSC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg23788917	chr6:8435910	SLC35B3	0.49	7.47	0.38	7.01e-13	Motion sickness;
LUSC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg11764359	chr7:65958608	NA	0.52	6.85	0.35	3.5e-11	Aortic root size;
LUSC	cis	rs6736093	1.000	rs34928784	chr2:112657062	G/C	cg12686935	chr2:112915763	FBLN7	-0.4	-6.14	-0.32	2.3e-9	Coronary artery disease;
LUSC	cis	rs1348850	0.757	rs4893954	chr2:178340520	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	7.36	0.37	1.43e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	trans	rs4942242	1.000	rs9533566	chr13:44224691	T/C	cg19169023	chr15:41853346	TYRO3	-0.45	-7.29	-0.37	2.31e-12	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg13042288	chr15:90349979	ANPEP	-0.5	-7.06	-0.36	9.79e-12	Uric acid levels;
LUSC	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg05973401	chr12:123451056	ABCB9	0.64	9.38	0.46	1.04e-18	Platelet count;
LUSC	cis	rs757081	0.702	rs522619	chr11:17204448	A/G	cg15432903	chr11:17409602	KCNJ11	-0.38	-5.85	-0.3	1.18e-8	Systolic blood pressure;
LUSC	cis	rs3741151	0.686	rs7112924	chr11:73106408	C/T	cg17517138	chr11:73019481	ARHGEF17	0.89	8.4	0.42	1.31e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg02569458	chr12:86230093	RASSF9	-0.47	-7.86	-0.4	5.3e-14	Major depressive disorder;
LUSC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18404041	chr3:52824283	ITIH1	-0.62	-12.25	-0.56	9.44e-29	Bipolar disorder;
LUSC	cis	rs6714788	0.523	rs6542905	chr2:100654707	C/G	cg22139774	chr2:100720529	AFF3	-0.38	-6.04	-0.31	4.2e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01585723	chr16:33734837	NA	0.45	7.51	0.38	5.58e-13	Menopause (age at onset);
LUSC	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg21545522	chr1:205238299	TMCC2	0.43	8.2	0.41	5.33e-15	Red blood cell count;
LUSC	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg03563238	chr19:33554763	RHPN2	-0.4	-6.43	-0.33	4.3e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg13565492	chr6:43139072	SRF	-0.72	-10.66	-0.5	4.91e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9318086	0.624	rs9510909	chr13:24436760	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.43	6.41	0.33	5.09e-10	Myopia (pathological);
LUSC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	0.91	12.24	0.56	1.04e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg23887609	chr12:130822674	PIWIL1	0.49	7.26	0.37	2.68e-12	Menopause (age at onset);
LUSC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.68	-8.8	-0.43	7.34e-17	Chronic sinus infection;
LUSC	cis	rs7264396	0.887	rs58458373	chr20:34045611	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.71	-0.34	8.33e-11	Total cholesterol levels;
LUSC	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg06671706	chr8:8559999	CLDN23	0.49	6.57	0.34	1.94e-10	Obesity-related traits;
LUSC	cis	rs4132509	0.793	rs4478795	chr1:243844576	C/T	cg21452805	chr1:244014465	NA	0.65	6.9	0.35	2.64e-11	RR interval (heart rate);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24009358	chr15:66797395	ZWILCH;RPL4	-0.51	-6.95	-0.36	1.94e-11	Hepatitis;
LUSC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg06784218	chr1:46089804	CCDC17	0.55	11.17	0.52	7.69e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.35	-6.38	-0.33	5.75e-10	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg21775007	chr8:11205619	TDH	-0.49	-7.27	-0.37	2.5e-12	Systolic blood pressure;
LUSC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.19	-0.45	4.42e-18	Gut microbiome composition (summer);
LUSC	cis	rs2955259	0.735	rs2955260	chr4:170874986	T/C	cg19918862	chr4:170955249	NA	-0.33	-6.33	-0.33	7.9e-10	Educational attainment;
LUSC	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg05043794	chr9:111880884	C9orf5	-0.34	-7.06	-0.36	9.9e-12	Menarche (age at onset);
LUSC	cis	rs11039100	1.000	rs12798822	chr11:5826711	T/C	cg05234568	chr11:5960015	NA	-0.5	-5.71	-0.3	2.47e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg02508848	chr16:68573721	ZFP90	-0.42	-5.72	-0.3	2.41e-8	Ulcerative colitis;
LUSC	cis	rs7605827	0.930	rs12692260	chr2:15511809	A/G	cg19274914	chr2:15703543	NA	0.46	8.95	0.44	2.45e-17	Educational attainment (years of education);
LUSC	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg21545522	chr1:205238299	TMCC2	0.46	8.38	0.42	1.53e-15	Red blood cell count;
LUSC	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.89	14.17	0.61	5.1e-36	Coronary artery disease;
LUSC	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg15133208	chr4:90757351	SNCA	-0.32	-5.66	-0.3	3.23e-8	Dementia with Lewy bodies;
LUSC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.77	-0.3	1.82e-8	Extrinsic epigenetic age acceleration;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18776286	chr10:52383679	SGMS1	-0.42	-6.36	-0.33	6.76e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs983392	0.642	rs636147	chr11:59957092	C/T	cg20284999	chr11:59952153	MS4A6A	0.36	6.25	0.32	1.28e-9	Alzheimer's disease (late onset);
LUSC	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.83	14.56	0.62	1.62e-37	Metabolic syndrome;
LUSC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg13047869	chr3:10149882	C3orf24	0.66	9.19	0.45	4.17e-18	Alzheimer's disease;
LUSC	cis	rs4356932	0.691	rs7436021	chr4:76905472	A/G	cg00809888	chr4:76862425	NAAA	0.37	5.88	0.31	9.75e-9	Blood protein levels;
LUSC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg18681998	chr4:17616180	MED28	0.85	15.45	0.65	5.32e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.64	11.56	0.53	3.14e-26	Menopause (age at onset);
LUSC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg22800045	chr5:56110881	MAP3K1	0.79	10.53	0.5	1.45e-22	Initial pursuit acceleration;
LUSC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg11764359	chr7:65958608	NA	-0.78	-12.7	-0.57	2.07e-30	Aortic root size;
LUSC	trans	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.61	9.53	0.46	3.28e-19	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg04944784	chr2:26401820	FAM59B	-0.68	-9.42	-0.46	7.58e-19	Gut microbiome composition (summer);
LUSC	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg13010199	chr12:38710504	ALG10B	0.58	9.27	0.45	2.32e-18	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06634786	chr22:41940651	POLR3H	-0.54	-6.63	-0.34	1.34e-10	Vitiligo;
LUSC	cis	rs1858037	0.836	rs17475335	chr2:65605780	G/C	cg08085232	chr2:65598271	SPRED2	-0.43	-6.43	-0.33	4.4e-10	Rheumatoid arthritis;
LUSC	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg24579218	chr15:68104479	NA	0.4	7.01	0.36	1.32e-11	Obesity;
LUSC	cis	rs6424115	1.000	rs12121387	chr1:24166536	T/G	cg15997130	chr1:24165203	NA	-0.52	-8.61	-0.43	2.88e-16	Immature fraction of reticulocytes;
LUSC	cis	rs427943	0.639	rs2838820	chr21:46646005	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.42	6.16	0.32	2.1e-9	Body mass index;
LUSC	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg03859395	chr2:55845619	SMEK2	0.81	14.82	0.63	1.47e-38	Metabolic syndrome;
LUSC	cis	rs11630290	0.736	rs7174738	chr15:64144813	A/T	cg12036633	chr15:63758958	NA	-0.6	-6.92	-0.35	2.37e-11	Iris characteristics;
LUSC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg03526776	chr6:41159608	TREML2	0.33	6.44	0.33	4.24e-10	Alzheimer's disease (late onset);
LUSC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	12.86	0.58	5.11e-31	Chronic sinus infection;
LUSC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg07150166	chr2:30669952	LCLAT1	0.87	7.66	0.39	2.08e-13	Midgestational circulating levels of PBDEs (fetal genetic effect);
LUSC	cis	rs7572644	0.640	rs9678336	chr2:28065404	A/G	cg27432699	chr2:27873401	GPN1	0.52	6.95	0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs5770917	1.000	rs2073605	chr22:51008850	A/G	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.62	-5.72	-0.3	2.42e-8	Narcolepsy;
LUSC	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg06784218	chr1:46089804	CCDC17	-0.33	-6.12	-0.32	2.69e-9	Platelet count;
LUSC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	12.4	0.56	2.61e-29	Prudent dietary pattern;
LUSC	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.68	10.52	0.5	1.49e-22	Colorectal cancer;
LUSC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08219700	chr8:58056026	NA	0.66	8.63	0.43	2.6e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg12927641	chr6:109611667	NA	-0.36	-6.18	-0.32	1.83e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs2762353	0.526	rs12215823	chr6:25726074	G/C	cg16482183	chr6:26056742	HIST1H1C	0.43	6.19	0.32	1.79e-9	Blood metabolite levels;
LUSC	cis	rs939574	0.790	rs72955452	chr2:220101783	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.92	6.33	0.33	7.88e-10	Platelet distribution width;
LUSC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.52	6.75	0.35	6.48e-11	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.51	-0.34	2.75e-10	Calcium levels;
LUSC	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg08085267	chr17:45401833	C17orf57	-0.51	-7.95	-0.4	2.86e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg23950597	chr19:37808831	NA	-0.63	-7.8	-0.39	8.08e-14	Coronary artery calcification;
LUSC	cis	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg24110177	chr3:50126178	RBM5	-0.4	-6.14	-0.32	2.39e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs75229567	0.618	rs11177853	chr12:70184924	A/G	cg10114359	chr12:70132523	RAB3IP	1.46	13.11	0.58	5.71e-32	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs4751006	0.543	rs2890130	chr10:128783848	T/C	cg05702161	chr10:128779687	DOCK1	-0.77	-6.29	-0.33	1.02e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg06636001	chr8:8085503	FLJ10661	0.85	14.88	0.63	8.65e-39	Systolic blood pressure;
LUSC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.84	12.51	0.56	1.01e-29	Cognitive test performance;
LUSC	cis	rs9443189	0.570	rs7765254	chr6:76398143	T/C	cg01950844	chr6:76311363	SENP6	0.64	5.97	0.31	6.19e-9	Prostate cancer;
LUSC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.93	13.17	0.58	3.36e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg05855489	chr10:104503620	C10orf26	-0.67	-9.93	-0.48	1.62e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg05527609	chr1:210001259	C1orf107	0.67	9.88	0.48	2.31e-20	Orofacial clefts;
LUSC	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-17.6	-0.69	1.56e-49	Exhaled nitric oxide output;
LUSC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.28	-0.45	2.26e-18	Gut microbiome composition (summer);
LUSC	cis	rs3772130	0.962	rs4280673	chr3:121526107	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.21	0.49	1.78e-21	Cognitive performance;
LUSC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg25726756	chr21:47582351	C21orf56	-0.34	-5.72	-0.3	2.33e-8	Testicular germ cell tumor;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg19178362	chr17:57233047	PRR11;SKA2	0.4	6.36	0.33	6.49e-10	Schizophrenia;
LUSC	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg08999081	chr20:33150536	PIGU	0.33	5.76	0.3	1.87e-8	Height;
LUSC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	0.91	15.09	0.64	1.31e-39	Breast cancer;
LUSC	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg15556689	chr8:8085844	FLJ10661	0.57	8.64	0.43	2.35e-16	Myopia (pathological);
LUSC	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg25801113	chr15:45476975	SHF	-0.32	-6.45	-0.33	3.89e-10	Uric acid levels;
LUSC	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg08499158	chr17:42289980	UBTF	0.42	6.49	0.33	3.15e-10	Total body bone mineral density;
LUSC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg23711669	chr6:146136114	FBXO30	0.82	14.21	0.61	3.51e-36	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg00033643	chr7:134001901	SLC35B4	0.45	7.02	0.36	1.24e-11	Mean platelet volume;
LUSC	cis	rs6543140	0.964	rs7561351	chr2:103077780	A/G	cg09003973	chr2:102972529	NA	0.55	7.04	0.36	1.09e-11	Blood protein levels;
LUSC	cis	rs12760731	0.669	rs10798609	chr1:178431648	C/T	cg00404053	chr1:178313656	RASAL2	0.55	6.27	0.32	1.13e-9	Obesity-related traits;
LUSC	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg05738196	chr6:26577821	NA	0.64	10.43	0.5	3.19e-22	Intelligence (multi-trait analysis);
LUSC	trans	rs1941687	0.797	rs12963804	chr18:31391208	T/C	cg27147174	chr7:100797783	AP1S1	-0.45	-6.56	-0.34	2.04e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs6693567	0.545	rs4451552	chr1:150455854	C/G	cg15654264	chr1:150340011	RPRD2	0.37	6.0	0.31	5.01e-9	Migraine;
LUSC	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg21100191	chr22:23484243	RTDR1	0.87	14.38	0.62	7.77e-37	Bone mineral density;
LUSC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg08470875	chr2:26401718	FAM59B	-0.67	-8.89	-0.44	3.8e-17	Gut microbiome composition (summer);
LUSC	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg22676075	chr6:135203613	NA	0.48	7.51	0.38	5.47e-13	Red blood cell count;
LUSC	cis	rs1982963	0.572	rs61971550	chr14:52478669	T/G	cg10843707	chr14:52510701	NID2	0.41	5.74	0.3	2.12e-8	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12760731	0.668	rs10913532	chr1:178278692	A/G	cg00404053	chr1:178313656	RASAL2	0.5	6.08	0.32	3.29e-9	Obesity-related traits;
LUSC	trans	rs6600671	1.000	rs6600669	chr1:121213639	G/C	cg00646200	chr1:148855367	NA	0.45	7.05	0.36	1.02e-11	Hip geometry;
LUSC	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.48	8.26	0.41	3.5e-15	Axial length;
LUSC	trans	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg10756647	chr7:56101905	PSPH	0.87	8.67	0.43	1.86e-16	Gout;
LUSC	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00684032	chr4:1343700	KIAA1530	0.37	6.47	0.33	3.48e-10	Obesity-related traits;
LUSC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg16584290	chr5:462447	EXOC3	0.45	8.09	0.4	1.1e-14	Cystic fibrosis severity;
LUSC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg10556349	chr10:835070	NA	0.55	6.21	0.32	1.53e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg17376030	chr22:41985996	PMM1	-0.47	-5.94	-0.31	7.32e-9	Vitiligo;
LUSC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg06808227	chr14:105710500	BRF1	0.66	10.18	0.49	2.25e-21	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg22907277	chr7:1156413	C7orf50	0.72	7.61	0.38	2.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-8.14	-0.41	7.74e-15	Bladder cancer;
LUSC	cis	rs6445967	0.689	rs11714574	chr3:58380465	A/T	cg13750441	chr3:58318267	PXK	-0.29	-5.91	-0.31	8.42e-9	Platelet count;
LUSC	cis	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.3	-0.33	9.13e-10	Morning vs. evening chronotype;
LUSC	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.7	-10.73	-0.51	2.85e-23	Alcohol dependence;
LUSC	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg21573476	chr21:45109991	RRP1B	-0.39	-6.49	-0.33	3.11e-10	Mean corpuscular volume;
LUSC	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg12863693	chr15:85201151	NMB	0.32	6.07	0.32	3.38e-9	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg04455712	chr21:45112962	RRP1B	0.47	9.13	0.45	6.65e-18	Mean corpuscular volume;
LUSC	cis	rs7818345	0.649	rs13250181	chr8:19328766	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.34	6.05	0.31	3.79e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs6977660	1.000	rs5017194	chr7:19820035	A/T	cg05791153	chr7:19748676	TWISTNB	0.53	5.81	0.3	1.42e-8	Thyroid stimulating hormone;
LUSC	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg09184832	chr6:79620586	NA	-0.37	-5.84	-0.3	1.24e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg09238746	chr17:78121135	EIF4A3	-0.6	-8.98	-0.44	1.97e-17	Yeast infection;
LUSC	cis	rs2073300	1.000	rs6114101	chr20:23446322	C/T	cg09953122	chr20:23471693	CST8	-0.79	-6.82	-0.35	4.29e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg21854759	chr1:92012499	NA	0.41	6.59	0.34	1.72e-10	Breast cancer;
LUSC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.28	6.03	0.31	4.33e-9	Electroencephalogram traits;
LUSC	cis	rs7809950	0.954	rs3779494	chr7:107250355	G/A	cg23024343	chr7:107201750	COG5	0.56	8.77	0.43	9.03e-17	Coronary artery disease;
LUSC	cis	rs7605827	0.866	rs2287275	chr2:15658828	C/T	cg19274914	chr2:15703543	NA	0.46	8.86	0.44	4.96e-17	Educational attainment (years of education);
LUSC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.94	0.31	7.2e-9	Menopause (age at onset);
LUSC	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-8.85	-0.44	5.17e-17	Total cholesterol levels;
LUSC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg06784218	chr1:46089804	CCDC17	0.55	11.21	0.52	5.51e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg06627628	chr2:24431161	ITSN2	-0.86	-12.1	-0.55	3.46e-28	Asthma;
LUSC	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-14.52	-0.62	2.16e-37	Ulcerative colitis;
LUSC	trans	rs10098647	0.632	rs72663286	chr8:61106074	T/C	cg09970348	chr3:183978600	ECE2;CAMK2N2	0.44	5.96	0.31	6.54e-9	Obesity-related traits;
LUSC	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg24634471	chr8:143751801	JRK	0.51	7.21	0.37	3.71e-12	Schizophrenia;
LUSC	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg16359550	chr11:109292809	C11orf87	0.48	8.29	0.41	2.75e-15	Schizophrenia;
LUSC	cis	rs4919687	0.550	rs10748828	chr10:104456794	C/T	cg04362960	chr10:104952993	NT5C2	-0.48	-6.88	-0.35	2.9e-11	Colorectal cancer;
LUSC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.51	0.34	2.77e-10	Menopause (age at onset);
LUSC	cis	rs4746818	1.000	rs10998614	chr10:70923347	G/T	cg11621586	chr10:70884670	VPS26A	1.08	13.38	0.59	5.7e-33	Left atrial antero-posterior diameter;
LUSC	cis	rs62400317	0.859	rs10948223	chr6:45273921	A/C	cg20913747	chr6:44695427	NA	-0.45	-7.43	-0.38	9.39e-13	Total body bone mineral density;
LUSC	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg11984989	chr7:158649758	WDR60	-1.08	-13.19	-0.59	2.83e-32	Height;
LUSC	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.75	12.26	0.56	8.64e-29	Lymphocyte percentage of white cells;
LUSC	cis	rs11640436	0.690	rs35010194	chr16:77323769	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.37	5.83	0.3	1.31e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7605827	0.930	rs7578787	chr2:15655119	T/C	cg19274914	chr2:15703543	NA	0.46	8.83	0.43	6.22e-17	Educational attainment (years of education);
LUSC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg23283495	chr1:209979779	IRF6	0.62	9.03	0.44	1.42e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg17264618	chr3:40429014	ENTPD3	0.34	7.25	0.37	2.94e-12	Renal cell carcinoma;
LUSC	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg11473876	chr11:109292803	C11orf87	0.39	6.41	0.33	4.97e-10	Schizophrenia;
LUSC	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg17595323	chr11:93583763	C11orf90	-0.32	-5.84	-0.3	1.26e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg10253484	chr15:75165896	SCAMP2	-0.42	-5.9	-0.31	8.89e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LUSC	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg14696996	chr19:15285081	NOTCH3	1.02	9.37	0.46	1.1e-18	Pulse pressure;
LUSC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	0.92	15.73	0.65	4.08e-42	Menopause (age at onset);
LUSC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg23711669	chr6:146136114	FBXO30	-0.9	-17.4	-0.69	9.72e-49	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2274273	0.870	rs2016931	chr14:55842332	C/G	cg04306507	chr14:55594613	LGALS3	0.53	11.83	0.54	3.33e-27	Protein biomarker;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26233468	chr1:155145786	TRIM46;KRTCAP2	0.44	6.22	0.32	1.5e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.82	13.74	0.6	2.25e-34	Aortic root size;
LUSC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-6.94	-0.36	1.99e-11	Alzheimer's disease (late onset);
LUSC	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.56	-7.27	-0.37	2.52e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg26875233	chr11:93583750	C11orf90	-0.31	-5.95	-0.31	6.81e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg25036284	chr2:26402008	FAM59B	-0.73	-10.8	-0.51	1.54e-23	Gut microbiome composition (summer);
LUSC	cis	rs2303282	0.716	rs8043596	chr16:56419303	T/C	cg00500540	chr16:56394104	NA	-0.42	-7.09	-0.36	7.83e-12	Breast cancer;
LUSC	cis	rs7210086	0.808	rs6501558	chr17:70639488	T/C	cg04206342	chr17:70636940	NA	-0.4	-6.51	-0.34	2.83e-10	Ulcerative colitis;
LUSC	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.82	-12.97	-0.58	1.98e-31	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04925841	chr12:24715491	SOX5	0.41	6.3	0.33	9.55e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg26102564	chr10:131424627	MGMT	0.39	6.16	0.32	2.05e-9	Response to temozolomide;
LUSC	trans	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	9.61	0.47	1.78e-19	Eotaxin levels;
LUSC	trans	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg25214090	chr10:38739885	LOC399744	0.43	6.48	0.33	3.35e-10	Corneal astigmatism;
LUSC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.57	-9.3	-0.45	1.95e-18	Aortic root size;
LUSC	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg26384229	chr12:38710491	ALG10B	0.79	13.4	0.59	4.63e-33	Morning vs. evening chronotype;
LUSC	cis	rs4499344	0.657	rs402862	chr19:33111102	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.82	11.42	0.53	1e-25	Mean platelet volume;
LUSC	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.88	15.08	0.64	1.52e-39	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07362569	chr17:61921086	SMARCD2	0.37	7.66	0.39	2.05e-13	Prudent dietary pattern;
LUSC	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg18827107	chr12:86230957	RASSF9	0.46	6.96	0.36	1.86e-11	Major depressive disorder;
LUSC	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg18196295	chr10:418757	DIP2C	-0.52	-9.09	-0.45	9.21e-18	Psychosis in Alzheimer's disease;
LUSC	cis	rs243505	0.898	rs243539	chr7:148403917	T/C	cg09806900	chr7:148480153	CUL1	-0.49	-7.01	-0.36	1.37e-11	Inflammatory bowel disease;Crohn's disease;
LUSC	trans	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg19894588	chr14:64061835	NA	-0.51	-6.59	-0.34	1.73e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg05784532	chr1:230284198	GALNT2	-0.5	-7.53	-0.38	4.69e-13	Coronary artery disease;
LUSC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.66	0.34	1.15e-10	Intelligence (multi-trait analysis);
LUSC	trans	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.2	-0.32	1.62e-9	Parkinson's disease;
LUSC	cis	rs6906287	0.647	rs11153748	chr6:118773609	A/G	cg21191810	chr6:118973309	C6orf204	0.34	6.21	0.32	1.54e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg19748678	chr4:122722346	EXOSC9	0.49	7.54	0.38	4.58e-13	Type 2 diabetes;
LUSC	trans	rs236907	0.859	rs61807979	chr1:171764281	G/A	cg13482142	chr2:234261155	NA	0.49	6.17	0.32	1.95e-9	Mean platelet volume;
LUSC	cis	rs2806561	1.000	rs1571466	chr1:23449183	T/C	cg19743168	chr1:23544995	NA	0.42	9.05	0.44	1.2e-17	Height;
LUSC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg19318889	chr4:1322082	MAEA	0.4	6.42	0.33	4.64e-10	Longevity;
LUSC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.09	0.32	3.02e-9	Menopause (age at onset);
LUSC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-11.82	-0.54	3.75e-27	Bipolar disorder;
LUSC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg12412775	chr1:25698385	RHCE	-0.3	-6.24	-0.32	1.3e-9	Erythrocyte sedimentation rate;
LUSC	cis	rs6596100	0.538	rs56157864	chr5:132267859	A/T	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Breast cancer;
LUSC	trans	rs41419946	1.000	rs1952179	chr1:165404575	A/G	cg06650914	chr18:74208293	NA	-0.58	-5.97	-0.31	5.97e-9	Gut microbiome composition (winter);
LUSC	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.63	-8.78	-0.43	8.52e-17	Body mass index (adult);
LUSC	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg13114125	chr14:105738426	BRF1	-0.86	-14.36	-0.62	9.79e-37	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.87	0.35	3.17e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.5	7.81	0.39	7.71e-14	Colorectal cancer;
LUSC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.91	17.67	0.7	8.33e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg07507251	chr3:52567010	NT5DC2	0.36	6.91	0.35	2.4e-11	Bipolar disorder;
LUSC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg12564285	chr5:131593104	PDLIM4	0.51	8.97	0.44	2.12e-17	Acylcarnitine levels;
LUSC	cis	rs1160297	0.609	rs10164801	chr2:53096014	C/T	cg07782112	chr2:53107842	NA	0.43	6.99	0.36	1.51e-11	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg21699342	chr2:239360505	ASB1	0.56	10.44	0.5	2.76e-22	Multiple system atrophy;
LUSC	trans	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg12856521	chr11:46389249	DGKZ	0.41	6.52	0.34	2.54e-10	Leprosy;
LUSC	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.12	0.32	2.68e-9	Height;
LUSC	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg05855489	chr10:104503620	C10orf26	0.58	9.23	0.45	3.18e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg20744362	chr22:50050164	C22orf34	0.38	6.98	0.36	1.61e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	7.42	0.38	9.78e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.84	15.06	0.64	1.77e-39	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg14004847	chr7:1930337	MAD1L1	-0.56	-8.49	-0.42	6.7e-16	Schizophrenia;
LUSC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg08132940	chr7:1081526	C7orf50	-0.48	-6.0	-0.31	5.14e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-6.03	-0.31	4.43e-9	Eosinophil percentage of white cells;
LUSC	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg21045802	chr8:109455806	TTC35	0.5	7.73	0.39	1.27e-13	Dupuytren's disease;
LUSC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	0.7	15.03	0.64	2.34e-39	Prudent dietary pattern;
LUSC	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg09904177	chr6:26538194	HMGN4	0.66	11.62	0.54	1.95e-26	Intelligence (multi-trait analysis);
LUSC	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg19920283	chr7:105172520	RINT1	0.58	6.22	0.32	1.48e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.47	7.85	0.39	5.87e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs4253772	0.938	rs10154348	chr22:46638159	C/A	cg09491104	chr22:46646882	C22orf40	-0.59	-6.48	-0.33	3.23e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	7.18	0.37	4.67e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9549260	0.709	rs12585870	chr13:41199487	A/C	cg21288729	chr13:41239152	FOXO1	0.6	9.21	0.45	3.75e-18	Red blood cell count;
LUSC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.75	-12.36	-0.56	3.68e-29	Body mass index;
LUSC	cis	rs9811920	0.695	rs793497	chr3:99505610	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.39	-5.74	-0.3	2.14e-8	Axial length;
LUSC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg06096015	chr1:231504339	EGLN1	0.57	10.02	0.48	7.85e-21	Hemoglobin concentration;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06826115	chr15:67835137	MAP2K5	-0.37	-6.04	-0.31	4.19e-9	Electrocardiographic conduction measures;
LUSC	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.39	-5.92	-0.31	8.08e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19669959	chr18:8706720	NA	-0.39	-6.13	-0.32	2.42e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg16660971	chr17:78860029	RPTOR	0.37	6.06	0.31	3.71e-9	Major depressive disorder;
LUSC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-6.48	-0.33	3.34e-10	Lung cancer;
LUSC	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-9.54	-0.46	3.03e-19	Hemoglobin concentration;
LUSC	cis	rs7561273	0.586	rs13418279	chr2:24349218	G/T	cg06627628	chr2:24431161	ITSN2	-0.51	-6.8	-0.35	4.71e-11	Quantitative traits;
LUSC	cis	rs617219	0.889	rs10044259	chr5:78471854	T/C	cg24856658	chr5:78533917	JMY	-0.29	-5.7	-0.3	2.59e-8	Betaine levels in individuals undergoing cardiac evaluation;
LUSC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	0.66	10.5	0.5	1.83e-22	Height;
LUSC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg03676636	chr4:99064102	C4orf37	0.33	7.2	0.37	4.07e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4704187	0.617	rs4704185	chr5:74471690	G/A	cg03227963	chr5:74354835	NA	0.29	6.22	0.32	1.46e-9	Response to amphetamines;
LUSC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9420	1.000	rs543725	chr11:57483039	A/T	cg23127183	chr11:57508653	C11orf31	-0.53	-8.13	-0.41	8.55e-15	Schizophrenia;
LUSC	trans	rs76248362	1.000	rs9510910	chr13:24437265	C/G	cg26511321	chr7:27196790	HOXA7	0.51	6.29	0.33	1.02e-9	3-hydroxypropylmercapturic acid levels in smokers;
LUSC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.83	14.6	0.62	1.09e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg21231944	chr12:82153410	PPFIA2	-0.37	-5.66	-0.3	3.33e-8	Resting heart rate;
LUSC	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.01	0.48	8.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04521409	chr20:34287082	ROMO1;NFS1	-0.45	-6.75	-0.35	6.64e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.73	12.98	0.58	1.75e-31	Personality dimensions;
LUSC	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg07862535	chr7:139043722	LUC7L2	0.54	6.75	0.35	6.59e-11	Diisocyanate-induced asthma;
LUSC	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg18721089	chr20:30220636	NA	-0.33	-5.78	-0.3	1.73e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.78	11.13	0.52	1.07e-24	Corneal astigmatism;
LUSC	cis	rs9653442	0.545	rs2009094	chr2:100765077	G/A	cg07810366	chr2:100720526	AFF3	-0.45	-7.68	-0.39	1.83e-13	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg10792982	chr14:105748885	BRF1	-0.51	-9.54	-0.46	3.19e-19	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-10.24	-0.49	1.42e-21	Morning vs. evening chronotype;
LUSC	trans	rs12145833	0.538	rs61833885	chr1:243397188	C/A	cg25284624	chr1:224180302	NA	0.7	6.61	0.34	1.48e-10	Obesity (early onset extreme);
LUSC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg17294928	chr15:75287854	SCAMP5	0.43	6.21	0.32	1.57e-9	Breast cancer;
LUSC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.82e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6599077	0.950	rs2371141	chr3:40098918	C/T	cg13683864	chr3:40499215	RPL14	-0.59	-7.4	-0.38	1.11e-12	Sleep-related phenotypes;
LUSC	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg11742103	chr11:62369870	EML3;MTA2	-0.48	-8.28	-0.41	3.04e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg20821713	chr7:1055600	C7orf50	-0.56	-7.39	-0.37	1.2e-12	Bronchopulmonary dysplasia;
LUSC	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-8.67	-0.43	1.86e-16	Neuroticism;
LUSC	cis	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg06521331	chr12:34319734	NA	-0.5	-8.33	-0.41	2.1e-15	Morning vs. evening chronotype;
LUSC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-9.28	-0.45	2.26e-18	Gut microbiome composition (summer);
LUSC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg24060327	chr5:131705240	SLC22A5	-0.53	-8.62	-0.43	2.81e-16	Acylcarnitine levels;
LUSC	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-10.04	-0.48	6.53e-21	Blood metabolite levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08757611	chr17:76250500	NA	-0.41	-6.22	-0.32	1.52e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02176678	chr2:219576539	TTLL4	0.64	11.77	0.54	5.36e-27	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg09281601	chr5:171434020	FBXW11	0.7	6.14	0.32	2.31e-9	Cognitive performance;
LUSC	cis	rs897080	0.515	rs1085495	chr2:44608982	A/G	cg00619915	chr2:44497795	NA	-0.39	-5.75	-0.3	1.97e-8	Height;
LUSC	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg18232548	chr7:50535776	DDC	-0.53	-7.3	-0.37	2.17e-12	Malaria;
LUSC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg24675658	chr1:53192096	ZYG11B	-0.71	-11.73	-0.54	7.4e-27	Monocyte count;
LUSC	trans	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.57	7.57	0.38	3.58e-13	Ulcerative colitis;
LUSC	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg03522245	chr20:25566470	NINL	0.37	5.96	0.31	6.4e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg00012203	chr2:219082015	ARPC2	0.8	14.08	0.61	1.14e-35	Colorectal cancer;
LUSC	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg18681998	chr4:17616180	MED28	0.86	15.49	0.65	3.49e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg09365446	chr1:150670422	GOLPH3L	0.53	8.25	0.41	3.6e-15	Tonsillectomy;
LUSC	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg06636551	chr8:101224915	SPAG1	-0.4	-7.48	-0.38	6.69e-13	Atrioventricular conduction;
LUSC	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg05163923	chr11:71159392	DHCR7	0.74	10.94	0.51	5.36e-24	Vitamin D levels;
LUSC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	5.81	0.3	1.45e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs12681287	0.605	rs6471296	chr8:87374654	A/G	cg27223183	chr8:87520930	FAM82B	0.44	6.21	0.32	1.59e-9	Caudate activity during reward;
LUSC	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg10518543	chr12:38710700	ALG10B	0.42	5.91	0.31	8.54e-9	Morning vs. evening chronotype;
LUSC	cis	rs7572644	0.766	rs13008539	chr2:28174407	A/C	cg27432699	chr2:27873401	GPN1	0.52	6.47	0.33	3.41e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6977660	1.000	rs13233821	chr7:19813637	A/C	cg07541023	chr7:19748670	TWISTNB	0.55	6.34	0.33	7.47e-10	Thyroid stimulating hormone;
LUSC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.99	-14.89	-0.63	8.55e-39	Initial pursuit acceleration;
LUSC	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg00262122	chr8:11665843	FDFT1	-0.42	-6.21	-0.32	1.56e-9	Morning vs. evening chronotype;
LUSC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-1.09	-22.07	-0.77	3.31e-67	Height;
LUSC	cis	rs4478858	0.698	rs6669381	chr1:31833506	A/G	cg00250761	chr1:31883323	NA	-0.36	-8.67	-0.43	1.97e-16	Alcohol dependence;
LUSC	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg09904177	chr6:26538194	HMGN4	0.45	6.47	0.33	3.51e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg27266027	chr21:40555129	PSMG1	-0.4	-5.78	-0.3	1.76e-8	Cognitive function;
LUSC	cis	rs228769	0.562	rs228762	chr17:42138392	C/T	cg19774624	chr17:42201019	HDAC5	0.64	7.41	0.38	1.04e-12	Bone mineral density (hip);Bone mineral density (spine);
LUSC	cis	rs3772130	0.962	rs9883467	chr3:121517833	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.69	10.21	0.49	1.78e-21	Cognitive performance;
LUSC	trans	rs2392780	0.536	rs620808	chr8:128335714	C/T	cg10897648	chr18:56338258	MALT1	-0.41	-6.21	-0.32	1.56e-9	Breast cancer (early onset);
LUSC	cis	rs7589342	0.929	rs13024715	chr2:106433950	A/G	cg16077055	chr2:106428750	NCK2	0.38	7.26	0.37	2.75e-12	Addiction;
LUSC	trans	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg01620082	chr3:125678407	NA	-0.86	-7.5	-0.38	5.97e-13	Depression;
LUSC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg05717871	chr11:638507	DRD4	-0.35	-6.1	-0.32	3.01e-9	Systemic lupus erythematosus;
LUSC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg24154853	chr7:158122151	PTPRN2	0.37	6.84	0.35	3.88e-11	Calcium levels;
LUSC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg13175981	chr1:150552382	MCL1	0.54	7.67	0.39	1.85e-13	Tonsillectomy;
LUSC	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg00376283	chr12:123451042	ABCB9	0.8	12.18	0.55	1.67e-28	Platelet count;
LUSC	cis	rs506338	0.517	rs516117	chr11:64433444	T/C	cg19395706	chr11:64412079	NRXN2	0.29	5.92	0.31	7.91e-9	Body mass index;Urate levels;
LUSC	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg26875233	chr11:93583750	C11orf90	-0.31	-6.06	-0.31	3.76e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg06671706	chr8:8559999	CLDN23	0.5	6.49	0.33	3.11e-10	Obesity-related traits;
LUSC	cis	rs9650657	0.812	rs4240669	chr8:10629987	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.17	-0.32	2.02e-9	Neuroticism;
LUSC	cis	rs6546537	0.550	rs6546531	chr2:69779963	C/A	cg10773587	chr2:69614142	GFPT1	-0.42	-6.66	-0.34	1.14e-10	Serum thyroid-stimulating hormone levels;
LUSC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg04518342	chr5:131593106	PDLIM4	0.45	7.89	0.4	4.38e-14	Breast cancer;
LUSC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg19812747	chr11:111475976	SIK2	0.54	7.67	0.39	1.85e-13	Primary sclerosing cholangitis;
LUSC	trans	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg26384229	chr12:38710491	ALG10B	0.66	10.41	0.49	3.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs4843185	0.731	rs3815795	chr16:85712105	A/G	cg05245094	chr16:85669572	KIAA0182	-0.42	-6.26	-0.32	1.21e-9	Platelet distribution width;
LUSC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.29	6.03	0.31	4.3e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg11861562	chr11:117069780	TAGLN	0.35	6.72	0.35	7.69e-11	Blood protein levels;
LUSC	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.44	6.26	0.32	1.17e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg11130432	chr3:121712080	ILDR1	-0.66	-10.81	-0.51	1.44e-23	Multiple sclerosis;
LUSC	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14893161	chr1:205819251	PM20D1	-0.45	-6.65	-0.34	1.17e-10	Parkinson's disease;
LUSC	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	15.85	0.66	1.36e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.47e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3857536	0.674	rs9345798	chr6:66951331	A/G	cg07460842	chr6:66804631	NA	-0.46	-6.36	-0.33	6.75e-10	Blood trace element (Cu levels);
LUSC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg09455208	chr3:40491958	NA	0.52	8.95	0.44	2.6e-17	Renal cell carcinoma;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27353073	chr11:76092311	PRKRIR	-0.46	-6.82	-0.35	4.25e-11	Electrocardiographic conduction measures;
LUSC	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.9	11.66	0.54	1.37e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2073300	1.000	rs6137971	chr20:23456429	G/T	cg09953122	chr20:23471693	CST8	-0.87	-7.42	-0.38	9.64e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg16989086	chr20:62203971	PRIC285	0.46	6.48	0.33	3.27e-10	Glioblastoma;
LUSC	cis	rs11039100	0.850	rs11039121	chr11:5833161	T/C	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.31	5.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	trans	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.51	8.02	0.4	1.79e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.49	0.56	1.26e-29	Motion sickness;
LUSC	cis	rs7246657	1.000	rs34544865	chr19:37801242	G/C	cg23950597	chr19:37808831	NA	-0.59	-6.5	-0.33	2.99e-10	Coronary artery calcification;
LUSC	trans	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg13010199	chr12:38710504	ALG10B	-0.46	-7.33	-0.37	1.73e-12	Morning vs. evening chronotype;
LUSC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.42	6.68	0.34	9.71e-11	Menopause (age at onset);
LUSC	cis	rs807669	0.525	rs738904	chr22:19167385	C/A	cg02655711	chr22:19163373	SLC25A1	0.52	9.49	0.46	4.61e-19	Metabolite levels;
LUSC	cis	rs12101261	0.556	rs2300516	chr14:81446908	A/G	cg06600135	chr14:81408086	NA	0.46	7.1	0.36	7.47e-12	Graves' disease;
LUSC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg23711669	chr6:146136114	FBXO30	-0.78	-12.87	-0.58	4.79e-31	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg01879757	chr17:41196368	BRCA1	-0.47	-7.16	-0.36	5.11e-12	Menopause (age at onset);
LUSC	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg21918786	chr6:109611834	NA	-0.35	-5.84	-0.3	1.21e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg09904177	chr6:26538194	HMGN4	-0.73	-6.89	-0.35	2.78e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg13939156	chr17:80058883	NA	-0.34	-6.64	-0.34	1.27e-10	Life satisfaction;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00029053	chr2:10830014	NOL10	0.45	6.81	0.35	4.54e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg11057378	chr10:81107060	PPIF	0.37	6.21	0.32	1.57e-9	Height;
LUSC	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.75	12.2	0.56	1.4e-28	Height;
LUSC	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	9.18	0.45	4.55e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg22509179	chr1:25234806	RUNX3	-0.6	-10.08	-0.48	4.72e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg11871910	chr12:69753446	YEATS4	0.82	13.96	0.61	3.16e-35	Blood protein levels;
LUSC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg18305652	chr10:134549665	INPP5A	0.45	6.73	0.35	7.36e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs500891	0.533	rs35156665	chr6:84143765	C/T	cg08257003	chr6:84140564	ME1	0.35	8.52	0.42	5.36e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg24375607	chr4:120327624	NA	0.76	11.87	0.54	2.32e-27	Corneal astigmatism;
LUSC	cis	rs4561483	0.801	rs251723	chr16:11953080	G/C	cg08843971	chr16:11963173	GSPT1	-0.49	-7.22	-0.37	3.56e-12	Testicular germ cell tumor;
LUSC	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg26893861	chr17:41843967	DUSP3	0.98	14.71	0.63	4.09e-38	Triglycerides;
LUSC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg12935359	chr14:103987150	CKB	-0.51	-7.83	-0.39	6.43e-14	Body mass index;
LUSC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26769984	chr7:1090371	C7orf50	0.75	10.55	0.5	1.23e-22	Bronchopulmonary dysplasia;
LUSC	trans	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg24644049	chr4:85504048	CDS1	0.72	7.32	0.37	1.91e-12	Skin colour saturation;
LUSC	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg07959070	chr22:50026188	C22orf34	-0.34	-6.95	-0.36	1.98e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg13683864	chr3:40499215	RPL14	1.06	19.49	0.73	4.7e-57	Renal cell carcinoma;
LUSC	cis	rs1982963	1.000	rs2749876	chr14:52504397	T/G	cg10843707	chr14:52510701	NID2	-0.41	-6.62	-0.34	1.4e-10	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7804356	1.000	rs73067443	chr7:26851074	A/G	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	1.93e-9	Type 1 diabetes;
LUSC	trans	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.72	-0.35	8.01e-11	Depression;
LUSC	trans	rs72674100	1.000	rs2865753	chr4:97992752	A/T	cg16405019	chr1:18959625	PAX7	-0.61	-6.41	-0.33	5.09e-10	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.7	10.91	0.51	6.34e-24	Breast cancer;
LUSC	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04267008	chr7:1944627	MAD1L1	-0.6	-9.21	-0.45	3.82e-18	Bipolar disorder and schizophrenia;
LUSC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg15790184	chr11:494944	RNH1	0.49	7.3	0.37	2.18e-12	Systemic lupus erythematosus;
LUSC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-8.61	-0.43	2.96e-16	Breast cancer;
LUSC	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.07	-0.36	8.88e-12	Alzheimer's disease (late onset);
LUSC	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg19767477	chr5:127420684	SLC12A2	-0.43	-5.77	-0.3	1.86e-8	Ileal carcinoids;
LUSC	trans	rs4650994	0.525	rs4651000	chr1:178532223	A/G	cg05059571	chr16:84539110	KIAA1609	-0.47	-8.98	-0.44	1.96e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg06606381	chr12:133084897	FBRSL1	-0.92	-8.91	-0.44	3.32e-17	Depression;
LUSC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06634786	chr22:41940651	POLR3H	0.52	6.13	0.32	2.43e-9	Vitiligo;
LUSC	cis	rs4363385	0.720	rs6672735	chr1:152981086	A/G	cg25856811	chr1:152973957	SPRR3	-0.34	-5.7	-0.3	2.69e-8	Inflammatory skin disease;
LUSC	cis	rs4285028	0.747	rs9838301	chr3:121375144	G/T	cg11130432	chr3:121712080	ILDR1	-0.58	-8.46	-0.42	8.21e-16	Multiple sclerosis;
LUSC	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg12292205	chr6:26970375	C6orf41	-0.39	-5.8	-0.3	1.55e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01156768	chr18:77439120	CTDP1	-0.43	-6.4	-0.33	5.26e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.51	8.01	0.4	1.94e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.61	9.71	0.47	8.65e-20	Alcohol dependence;
LUSC	cis	rs4363385	0.791	rs512198	chr1:153006245	C/T	cg25856811	chr1:152973957	SPRR3	-0.34	-5.68	-0.3	2.9e-8	Inflammatory skin disease;
LUSC	trans	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	0.96	15.09	0.64	1.41e-39	Dupuytren's disease;
LUSC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11644478	chr21:40555479	PSMG1	-0.65	-9.92	-0.48	1.63e-20	Menarche (age at onset);
LUSC	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg15798862	chr7:76129360	DTX2	-0.51	-8.38	-0.42	1.5e-15	Multiple sclerosis;
LUSC	cis	rs3931020	0.688	rs1051122	chr1:75190452	C/T	cg21906852	chr1:75198582	TYW3;CRYZ	0.45	5.89	0.31	9.55e-9	Resistin levels;
LUSC	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg15423357	chr2:25149977	NA	0.35	6.4	0.33	5.19e-10	Body mass index;
LUSC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-0.98	-14.66	-0.63	6.33e-38	Initial pursuit acceleration;
LUSC	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg13010199	chr12:38710504	ALG10B	0.69	11.78	0.54	5.17e-27	Heart rate;
LUSC	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-12.71	-0.57	1.79e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	7.09	0.36	7.93e-12	Bipolar disorder;
LUSC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.5	-8.78	-0.43	8.74e-17	Menopause (age at onset);
LUSC	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg17507749	chr15:85114479	UBE2QP1	0.57	7.12	0.36	6.66e-12	Schizophrenia;
LUSC	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-7.11	-0.36	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg22491629	chr6:157744540	C6orf35	-0.9	-10.67	-0.5	4.68e-23	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.56	8.63	0.43	2.55e-16	Gestational age at birth (maternal effect);
LUSC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg09640425	chr7:158790006	NA	-0.52	-8.19	-0.41	5.5e-15	Facial morphology (factor 20);
LUSC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.65	11.2	0.52	6.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg26384229	chr12:38710491	ALG10B	0.49	7.06	0.36	9.57e-12	Morning vs. evening chronotype;
LUSC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg07217954	chr7:1067459	C7orf50	0.54	5.71	0.3	2.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs61863818	0.533	rs954148	chr10:99123006	T/C	cg08345082	chr10:99160200	RRP12	-0.29	-5.87	-0.31	1.04e-8	Monocyte percentage of white cells;
LUSC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg05347473	chr6:146136440	FBXO30	0.52	8.79	0.43	8.31e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg11645453	chr3:52864694	ITIH4	0.35	8.16	0.41	6.88e-15	Bipolar disorder;
LUSC	trans	rs2324999	0.607	rs59778458	chr3:86182889	C/G	cg20214535	chr21:43619310	ABCG1	-0.36	-6.19	-0.32	1.79e-9	Subcutaneous adipose tissue;
LUSC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg18758796	chr5:131593413	PDLIM4	0.39	6.58	0.34	1.78e-10	Breast cancer;
LUSC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7572644	0.662	rs12465103	chr2:28199736	G/C	cg27432699	chr2:27873401	GPN1	-0.51	-6.99	-0.36	1.52e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg16339924	chr4:17578868	LAP3	0.59	9.03	0.44	1.38e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg01966878	chr4:90757139	SNCA	-0.42	-5.93	-0.31	7.41e-9	Neuroticism;
LUSC	trans	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg03886242	chr7:26192032	NFE2L3	0.39	6.44	0.33	4.05e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.5	0.38	5.97e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg22437258	chr11:111473054	SIK2	-0.5	-6.84	-0.35	3.88e-11	Primary sclerosing cholangitis;
LUSC	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.6	10.05	0.48	6.31e-21	Birth weight;
LUSC	trans	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg26043149	chr18:55253948	FECH	-0.46	-7.05	-0.36	1.06e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg06360820	chr2:242988706	NA	-0.57	-7.34	-0.37	1.68e-12	Obesity-related traits;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24151027	chr5:77656318	SCAMP1	-0.42	-7.16	-0.36	5.21e-12	Electrocardiographic conduction measures;
LUSC	cis	rs4343996	0.536	rs10228055	chr7:3414750	G/A	cg21248987	chr7:3385318	SDK1	0.34	5.71	0.3	2.44e-8	Motion sickness;
LUSC	cis	rs4356932	1.000	rs6828596	chr4:76961373	A/G	cg00809888	chr4:76862425	NAAA	0.35	5.92	0.31	7.86e-9	Blood protein levels;
LUSC	cis	rs7582720	1.000	rs115654617	chr2:203893999	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	8.79	0.43	7.92e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg09658497	chr7:2847517	GNA12	-0.35	-5.91	-0.31	8.3e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LUSC	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	0.82	12.98	0.58	1.86e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	trans	rs1941687	0.764	rs1493915	chr18:31377582	G/T	cg27147174	chr7:100797783	AP1S1	-0.51	-7.91	-0.4	3.89e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.58	-0.34	1.84e-10	Arsenic metabolism;
LUSC	trans	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg07393940	chr7:158741817	NA	-0.37	-6.56	-0.34	1.99e-10	Life satisfaction;
LUSC	cis	rs4363385	0.510	rs11590369	chr1:152903603	G/C	cg00922841	chr1:152955080	SPRR1A	-0.39	-6.34	-0.33	7.28e-10	Inflammatory skin disease;
LUSC	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.59	-9.45	-0.46	6.32e-19	Body mass index;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04720665	chr1:245028075	HNRNPU	-0.45	-6.11	-0.32	2.72e-9	Hepatitis;
LUSC	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg08017756	chr2:100939284	LONRF2	-0.44	-8.28	-0.41	2.98e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18099408	chr3:52552593	STAB1	-0.39	-6.9	-0.35	2.66e-11	Bipolar disorder;
LUSC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.45	6.98	0.36	1.62e-11	Bipolar disorder;
LUSC	cis	rs10740039	0.842	rs7080024	chr10:62391791	A/G	cg18175470	chr10:62150864	ANK3	0.48	7.43	0.38	9.38e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.89	0.48	2.19e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2932538	0.922	rs12406906	chr1:113117900	G/T	cg22162597	chr1:113214053	CAPZA1	-0.69	-10.07	-0.48	5.3e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs1784581	0.588	rs9295180	chr6:162420579	T/C	cg17173639	chr6:162384350	PARK2	0.57	9.98	0.48	1.06e-20	Itch intensity from mosquito bite;
LUSC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.29	-5.81	-0.3	1.48e-8	Total body bone mineral density;
LUSC	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-0.56	-9.0	-0.44	1.74e-17	Breast cancer;
LUSC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.72	14.09	0.61	1e-35	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg23625390	chr15:77176239	SCAPER	-0.66	-9.93	-0.48	1.55e-20	Blood metabolite levels;
LUSC	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.15	-0.32	2.27e-9	Resting heart rate;
LUSC	cis	rs12760731	0.720	rs12047646	chr1:178274083	G/A	cg00404053	chr1:178313656	RASAL2	0.64	6.76	0.35	6.32e-11	Obesity-related traits;
LUSC	cis	rs9463078	0.683	rs227851	chr6:44699209	A/C	cg25276700	chr6:44698697	NA	0.3	5.85	0.31	1.15e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs11630290	0.639	rs925248	chr15:64167543	G/A	cg12036633	chr15:63758958	NA	0.5	6.1	0.32	2.89e-9	Iris characteristics;
LUSC	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg16228356	chr17:43848958	NA	-0.27	-6.27	-0.32	1.1e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg04310649	chr10:35416472	CREM	-0.42	-6.47	-0.33	3.5e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg21775007	chr8:11205619	TDH	0.45	6.4	0.33	5.13e-10	Neuroticism;
LUSC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.2e-17	Tonsillectomy;
LUSC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg05717871	chr11:638507	DRD4	-0.36	-5.89	-0.31	9.43e-9	Systemic lupus erythematosus;
LUSC	cis	rs952623	0.649	rs12538487	chr7:39075380	A/G	cg15212455	chr7:39170539	POU6F2	0.36	5.96	0.31	6.42e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg08283293	chr5:175964814	RNF44	0.46	6.15	0.32	2.24e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs4619890	0.672	rs6446621	chr4:7810507	A/T	cg00251875	chr4:7801337	AFAP1	-0.41	-5.72	-0.3	2.31e-8	Glaucoma (primary open-angle);
LUSC	trans	rs9393777	0.720	rs56401801	chr6:27301512	T/A	cg01620082	chr3:125678407	NA	-0.75	-6.6	-0.34	1.66e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs601339	1.000	rs7969523	chr12:123168636	T/G	cg11919336	chr12:123188078	GPR109A	0.42	6.23	0.32	1.37e-9	Adiponectin levels;
LUSC	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-8.72	-0.43	1.34e-16	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2274273	0.967	rs8009670	chr14:55583477	G/A	cg04306507	chr14:55594613	LGALS3	0.56	12.84	0.57	6.2e-31	Protein biomarker;
LUSC	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg12927641	chr6:109611667	NA	-0.34	-5.77	-0.3	1.81e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs6834538	0.597	rs2029211	chr4:113488134	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.34	5.72	0.3	2.31e-8	Free thyroxine concentration;
LUSC	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg26384229	chr12:38710491	ALG10B	-0.67	-10.36	-0.49	5.26e-22	Bladder cancer;
LUSC	cis	rs354225	0.544	rs7556752	chr2:54810044	G/C	cg01766943	chr2:54829624	SPTBN1	0.49	7.9	0.4	4.21e-14	Schizophrenia;
LUSC	trans	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg07211511	chr3:129823064	LOC729375	1.02	12.41	0.56	2.46e-29	Blood pressure (smoking interaction);
LUSC	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg00990874	chr7:1149470	C7orf50	-0.48	-6.37	-0.33	6.26e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	13.33	0.59	8.18e-33	Systemic lupus erythematosus;
LUSC	trans	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg14343924	chr8:8086146	FLJ10661	-0.44	-5.98	-0.31	5.87e-9	Monocyte count;
LUSC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26314531	chr2:26401878	FAM59B	0.72	10.07	0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg20243544	chr17:37824526	PNMT	0.57	7.44	0.38	8.51e-13	Glomerular filtration rate (creatinine);
LUSC	cis	rs57590327	0.527	rs11917558	chr3:81610805	G/A	cg07356753	chr3:81810745	GBE1	-0.42	-5.65	-0.3	3.41e-8	Extraversion;
LUSC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-7.46	-0.38	7.55e-13	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs6142102	0.580	rs4911139	chr20:32551535	G/A	cg24642439	chr20:33292090	TP53INP2	0.39	5.65	0.3	3.51e-8	Skin pigmentation;
LUSC	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg17178900	chr1:205818956	PM20D1	-0.41	-5.77	-0.3	1.81e-8	Prostate-specific antigen levels;
LUSC	cis	rs12602901	0.519	rs238238	chr17:4856376	A/G	cg09495303	chr17:4804838	CHRNE;C17orf107	0.38	6.69	0.34	9.4e-11	Blood metabolite levels;
LUSC	cis	rs548181	0.736	rs497344	chr11:125470524	T/C	cg03464685	chr11:125439445	EI24	1.15	14.15	0.61	6.29e-36	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07362569	chr17:61921086	SMARCD2	-0.39	-7.82	-0.39	6.99e-14	Prudent dietary pattern;
LUSC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg02018176	chr4:1364513	KIAA1530	0.5	8.54	0.42	4.76e-16	Obesity-related traits;
LUSC	cis	rs6066835	1.000	rs6066815	chr20:47299870	T/C	cg18078177	chr20:47281410	PREX1	0.76	5.96	0.31	6.36e-9	Multiple myeloma;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg05778415	chr2:75185968	POLE4	-0.44	-5.97	-0.31	5.99e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg14092988	chr3:52407081	DNAH1	0.32	6.24	0.32	1.3e-9	Bipolar disorder;
LUSC	cis	rs10193935	0.901	rs10179237	chr2:42515501	C/T	cg27598129	chr2:42591480	NA	-0.58	-8.0	-0.4	2e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-7.73	-0.39	1.29e-13	Chronic sinus infection;
LUSC	cis	rs4713675	0.584	rs4713666	chr6:33679061	A/G	cg14003231	chr6:33640908	ITPR3	0.29	5.69	0.3	2.82e-8	Plateletcrit;
LUSC	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	11.94	0.55	1.31e-27	Ileal carcinoids;
LUSC	cis	rs909002	0.849	rs2271933	chr1:32092525	C/T	cg01639898	chr1:32083012	HCRTR1	-0.27	-6.4	-0.33	5.39e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg17385448	chr1:15911702	AGMAT	0.38	6.08	0.32	3.19e-9	Systolic blood pressure;
LUSC	cis	rs12464559	0.522	rs4414677	chr2:152624932	A/C	cg01189475	chr2:152685088	ARL5A	-0.63	-6.79	-0.35	5.09e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.06	-0.36	9.78e-12	Coronary artery disease;
LUSC	cis	rs2976388	1.000	rs2294008	chr8:143761931	C/T	cg17252645	chr8:143867129	LY6D	-0.36	-6.2	-0.32	1.67e-9	Urinary tract infection frequency;
LUSC	cis	rs2230307	0.518	rs2810425	chr1:100665072	G/C	cg24955406	chr1:100503596	HIAT1	-0.57	-6.26	-0.32	1.15e-9	Carotid intima media thickness;
LUSC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg12564285	chr5:131593104	PDLIM4	-0.44	-7.54	-0.38	4.45e-13	Breast cancer;
LUSC	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg13575925	chr12:9217583	LOC144571	-0.34	-6.21	-0.32	1.58e-9	Sjögren's syndrome;
LUSC	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg00262122	chr8:11665843	FDFT1	0.44	6.49	0.33	3.13e-10	Myopia (pathological);
LUSC	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg06671706	chr8:8559999	CLDN23	0.49	6.52	0.34	2.66e-10	Obesity-related traits;
LUSC	cis	rs6545883	0.931	rs12713437	chr2:61722904	C/T	cg15711740	chr2:61764176	XPO1	-0.5	-7.85	-0.39	5.89e-14	Tuberculosis;
LUSC	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg17507749	chr15:85114479	UBE2QP1	0.65	8.1	0.41	1.04e-14	Schizophrenia;
LUSC	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg25258033	chr6:167368657	RNASET2	0.39	5.79	0.3	1.66e-8	Primary biliary cholangitis;
LUSC	trans	rs2587949	0.615	rs2600134	chr3:4239099	C/T	cg15139668	chr4:4577005	NA	-0.41	-6.25	-0.32	1.25e-9	Periodontitis (DPAL);
LUSC	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg24768116	chr2:27665128	KRTCAP3	-0.33	-6.36	-0.33	6.46e-10	Total body bone mineral density;
LUSC	cis	rs3862435	0.518	rs2444061	chr15:90909439	T/G	cg22089800	chr15:90895588	ZNF774	0.59	6.5	0.33	2.97e-10	Response to exercise (triglyceride level interaction);
LUSC	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg23093090	chr10:104574429	C10orf26	-0.47	-5.81	-0.3	1.49e-8	Arsenic metabolism;
LUSC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.42	6.51	0.34	2.73e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg07169764	chr2:136633963	MCM6	-1.12	-16.85	-0.68	1.53e-46	Corneal structure;
LUSC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.61	8.09	0.4	1.1e-14	High light scatter reticulocyte count;
LUSC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-17.07	-0.68	2.02e-47	Gut microbiome composition (summer);
LUSC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21862992	chr11:68658383	NA	0.51	7.94	0.4	3.03e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg04414720	chr1:150670196	GOLPH3L	0.55	9.05	0.44	1.23e-17	Tonsillectomy;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg06938235	chr12:56498303	PA2G4	-0.55	-7.24	-0.37	3.03e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs10216189	0.785	rs4352753	chr7:5527223	A/C	cg11800390	chr7:5515995	FBXL18	0.31	6.52	0.34	2.64e-10	Relative hand skill in reading disability;
LUSC	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg09904177	chr6:26538194	HMGN4	-0.8	-6.0	-0.31	5.13e-9	Depression;
LUSC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg03213289	chr20:61660250	NA	0.68	14.09	0.61	1.04e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12618769	0.571	rs72821939	chr2:99138872	T/C	cg10123293	chr2:99228465	UNC50	0.46	7.67	0.39	1.95e-13	Bipolar disorder;
LUSC	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg21775007	chr8:11205619	TDH	-0.5	-7.14	-0.36	5.7e-12	Neuroticism;
LUSC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg11859384	chr17:80120422	CCDC57	0.36	5.7	0.3	2.68e-8	Life satisfaction;
LUSC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06634786	chr22:41940651	POLR3H	0.53	6.15	0.32	2.16e-9	Vitiligo;
LUSC	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.43	5.85	0.3	1.19e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2742234	0.541	rs10793422	chr10:43703874	G/A	cg15436174	chr10:43711423	RASGEF1A	0.44	7.0	0.36	1.43e-11	Hirschsprung disease;
LUSC	cis	rs2731664	0.756	rs335433	chr5:176867207	T/C	cg23176889	chr5:176863531	GRK6	-0.69	-14.34	-0.62	1.11e-36	Intelligence (multi-trait analysis);
LUSC	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	cis	rs977987	0.806	rs12051136	chr16:75435731	G/T	cg03315344	chr16:75512273	CHST6	0.48	8.92	0.44	3.21e-17	Dupuytren's disease;
LUSC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg09035930	chr12:129282057	SLC15A4	0.65	12.82	0.57	6.88e-31	Systemic lupus erythematosus;
LUSC	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg02176678	chr2:219576539	TTLL4	-0.56	-10.03	-0.48	7.4e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7072216	0.881	rs6584192	chr10:100152373	T/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-5.64	-0.3	3.57e-8	Metabolite levels;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01442334	chr4:110481823	CCDC109B	-0.36	-6.25	-0.32	1.23e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.76	-11.74	-0.54	7.26e-27	Menarche (age at onset);
LUSC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg23788917	chr6:8435910	SLC35B3	0.5	7.49	0.38	6.2e-13	Motion sickness;
LUSC	trans	rs6924906	0.529	rs1341224	chr6:82260446	T/C	cg15052890	chr17:4636830	MED11;CXCL16	0.58	6.12	0.32	2.57e-9	Blood pressure;
LUSC	trans	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg26043149	chr18:55253948	FECH	0.49	7.31	0.37	2.03e-12	Bone mineral density;
LUSC	cis	rs1018836	0.632	rs7017295	chr8:91482356	C/T	cg16814680	chr8:91681699	NA	0.66	9.98	0.48	1.03e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-6.01	-0.31	4.81e-9	Height;
LUSC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26314531	chr2:26401878	FAM59B	-0.72	-10.07	-0.48	5.09e-21	Gut microbiome composition (summer);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00622682	chr22:32870857	FBXO7	-0.44	-6.55	-0.34	2.18e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9547692	1.000	rs61950374	chr13:37475485	C/T	cg01493522	chr13:37497338	NA	-0.45	-6.44	-0.33	4.13e-10	Coronary artery disease;
LUSC	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg17173187	chr15:85201210	NMB	0.51	9.66	0.47	1.24e-19	Schizophrenia;
LUSC	cis	rs4499344	0.633	rs411328	chr19:33140178	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.75	11.52	0.53	4.4e-26	Mean platelet volume;
LUSC	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-7.16	-0.36	5.33e-12	Daytime sleep phenotypes;
LUSC	cis	rs2230307	0.572	rs514090	chr1:100563186	C/G	cg24955406	chr1:100503596	HIAT1	0.59	6.36	0.33	6.62e-10	Carotid intima media thickness;
LUSC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-10.51	-0.5	1.67e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg09781936	chr22:19749961	TBX1	-0.33	-5.95	-0.31	6.85e-9	Inflammatory bowel disease;
LUSC	cis	rs7809950	0.678	rs75617662	chr7:107030439	G/A	cg23024343	chr7:107201750	COG5	-0.68	-9.97	-0.48	1.12e-20	Coronary artery disease;
LUSC	cis	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.82	-0.3	1.35e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg11584989	chr19:19387371	SF4	0.57	6.92	0.35	2.31e-11	Bipolar disorder;
LUSC	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg04315214	chr1:2043799	PRKCZ	-0.38	-7.71	-0.39	1.44e-13	Height;
LUSC	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg01765077	chr12:122356316	WDR66	0.54	7.82	0.39	7.14e-14	Mean corpuscular volume;
LUSC	cis	rs3736594	0.765	rs12994085	chr2:27952406	C/T	cg27432699	chr2:27873401	GPN1	-0.64	-8.99	-0.44	1.88e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg01294253	chr9:136912663	BRD3	-0.35	-5.92	-0.31	8.09e-9	Platelet distribution width;
LUSC	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-7.86	-0.4	5.29e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.36	0.49	5.35e-22	Mean corpuscular volume;
LUSC	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-6.84	-0.35	3.75e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.92	-0.31	8.17e-9	Personality dimensions;
LUSC	cis	rs6960043	0.818	rs12699673	chr7:15049604	T/C	cg19272540	chr7:15055459	NA	0.35	8.6	0.43	3.07e-16	Type 2 diabetes;
LUSC	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg02158880	chr13:53174818	NA	0.54	9.28	0.45	2.22e-18	Lewy body disease;
LUSC	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg22508957	chr16:3507546	NAT15	-0.39	-5.81	-0.3	1.46e-8	Body mass index (adult);
LUSC	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	19.52	0.73	3.72e-57	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg12564285	chr5:131593104	PDLIM4	-0.37	-6.71	-0.34	8.43e-11	Breast cancer;
LUSC	cis	rs57590327	0.555	rs3943556	chr3:81738892	G/C	cg07356753	chr3:81810745	GBE1	-0.67	-10.37	-0.49	5.03e-22	Extraversion;
LUSC	cis	rs6840360	1.000	rs3749561	chr4:152610117	C/T	cg22705602	chr4:152727874	NA	0.3	6.31	0.33	8.88e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg09509183	chr1:209979624	IRF6	0.45	6.05	0.31	3.92e-9	Cleft lip with or without cleft palate;
LUSC	cis	rs977987	0.645	rs10871311	chr16:75450912	T/A	cg04384234	chr16:75411784	CFDP1	-0.42	-6.69	-0.34	9.63e-11	Dupuytren's disease;
LUSC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg22800045	chr5:56110881	MAP3K1	0.77	9.51	0.46	3.83e-19	Initial pursuit acceleration;
LUSC	cis	rs16912285	0.748	rs58504811	chr11:24252020	T/G	ch.11.24196551F	chr11:24239977	NA	0.88	8.96	0.44	2.29e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7520050	0.807	rs3013594	chr1:46138000	T/C	cg24296786	chr1:45957014	TESK2	-0.4	-5.73	-0.3	2.26e-8	Red blood cell count;Reticulocyte count;
LUSC	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg15704280	chr7:45808275	SEPT13	0.64	7.26	0.37	2.71e-12	Axial length;
LUSC	cis	rs73206853	0.698	rs59574270	chr12:111112098	A/C	cg12870014	chr12:110450643	ANKRD13A	0.69	7.38	0.37	1.3e-12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-9.45	-0.46	6.1e-19	Type 2 diabetes;
LUSC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08109568	chr15:31115862	NA	0.73	10.96	0.51	4.45e-24	Huntington's disease progression;
LUSC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg15704280	chr7:45808275	SEPT13	-1.01	-18.0	-0.7	4.04e-51	Height;
LUSC	cis	rs16854884	0.657	rs6791078	chr3:143736876	A/G	cg06585982	chr3:143692056	C3orf58	0.5	7.93	0.4	3.36e-14	Economic and political preferences (feminism/equality);
LUSC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.04	0.44	1.31e-17	Motion sickness;
LUSC	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.87	-0.31	1.03e-8	IgG glycosylation;
LUSC	cis	rs67072384	0.818	rs6592483	chr11:72463974	A/G	cg04827223	chr11:72435913	ARAP1	-0.82	-6.66	-0.34	1.15e-10	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs9473147	0.516	rs9395279	chr6:47542864	C/T	cg20196966	chr6:47445060	CD2AP	0.42	5.87	0.31	1.07e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs12541635	0.677	rs4734892	chr8:106990088	G/C	cg10147462	chr8:107024639	NA	0.65	13.51	0.59	1.73e-33	Age of smoking initiation;
LUSC	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg24634471	chr8:143751801	JRK	0.51	7.29	0.37	2.28e-12	Schizophrenia;
LUSC	trans	rs11039798	0.764	rs12418936	chr11:48986418	T/C	cg15704280	chr7:45808275	SEPT13	0.8	6.9	0.35	2.64e-11	Axial length;
LUSC	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg12288994	chr5:1860383	NA	0.3	6.64	0.34	1.28e-10	Cardiovascular disease risk factors;
LUSC	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg08645402	chr16:4508243	NA	0.49	7.64	0.39	2.37e-13	Schizophrenia;
LUSC	cis	rs977987	0.778	rs8057849	chr16:75443816	T/C	cg04384234	chr16:75411784	CFDP1	-0.41	-6.61	-0.34	1.52e-10	Dupuytren's disease;
LUSC	cis	rs11158026	0.574	rs8019390	chr14:55409084	C/G	cg04306507	chr14:55594613	LGALS3	0.36	6.47	0.33	3.44e-10	Parkinson's disease;
LUSC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg01557791	chr16:72042693	DHODH	-0.43	-6.53	-0.34	2.42e-10	Fibrinogen levels;
LUSC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.24	-0.32	1.32e-9	Total body bone mineral density;
LUSC	trans	rs979233	0.502	rs276250	chr5:42062640	G/C	cg07010552	chr17:7358735	CHRNB1	-0.41	-6.02	-0.31	4.72e-9	Systemic lupus erythematosus;
LUSC	cis	rs2996428	0.667	rs10492942	chr1:3764216	C/T	cg22529645	chr1:3704559	LRRC47	0.37	6.43	0.33	4.48e-10	Red cell distribution width;
LUSC	cis	rs12476592	0.714	rs262494	chr2:63845484	C/T	cg10828910	chr2:63850056	LOC388955	0.51	6.31	0.33	8.77e-10	Childhood ear infection;
LUSC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg21535247	chr6:8435926	SLC35B3	0.58	8.94	0.44	2.76e-17	Motion sickness;
LUSC	cis	rs12210905	0.688	rs12215289	chr6:27468705	T/C	cg08851530	chr6:28072375	NA	0.95	6.15	0.32	2.21e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg20019720	chr6:154832845	CNKSR3	0.61	9.42	0.46	7.81e-19	Lipoprotein (a) levels;
LUSC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg25767906	chr1:53392781	SCP2	-0.62	-12.18	-0.55	1.78e-28	Monocyte count;
LUSC	cis	rs68170813	0.599	rs12533516	chr7:106937135	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	4.02e-20	Coronary artery disease;
LUSC	cis	rs1865721	0.728	rs8087297	chr18:73136221	T/A	cg26385618	chr18:73139727	C18orf62	-0.54	-9.86	-0.47	2.71e-20	Intelligence;
LUSC	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.75	-0.3	2.04e-8	Type 2 diabetes;
LUSC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.14	-0.49	3.1e-21	Obesity-related traits;
LUSC	cis	rs3771570	0.901	rs73008106	chr2:242422446	C/T	cg21155796	chr2:242212141	HDLBP	0.61	6.96	0.36	1.76e-11	Prostate cancer;
LUSC	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg04310649	chr10:35416472	CREM	-0.43	-6.59	-0.34	1.73e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg24375607	chr4:120327624	NA	-0.63	-10.05	-0.48	6.3e-21	Corneal astigmatism;
LUSC	cis	rs10992471	0.603	rs4744137	chr9:95288352	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-6.9	-0.35	2.68e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4948275	0.550	rs7904815	chr10:63136612	G/A	cg03237606	chr10:63212265	TMEM26	-0.38	-5.84	-0.3	1.26e-8	Night sleep phenotypes;
LUSC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg20406979	chr6:167373233	NA	-0.26	-5.98	-0.31	5.75e-9	Crohn's disease;
LUSC	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg08048268	chr3:133502702	NA	-0.41	-7.49	-0.38	6.2e-13	Iron status biomarkers;
LUSC	cis	rs7927771	0.524	rs10838758	chr11:47771476	T/C	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.18e-10	Subjective well-being;
LUSC	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg10434728	chr15:90938212	IQGAP1	-0.34	-7.42	-0.38	9.9e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.12	-0.32	2.69e-9	Resting heart rate;
LUSC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg03806693	chr22:41940476	POLR3H	0.97	13.39	0.59	4.91e-33	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-7.35	-0.37	1.51e-12	Schizophrenia;
LUSC	cis	rs2637266	1.000	rs2395388	chr10:78357203	C/T	cg18941641	chr10:78392320	NA	0.39	7.13	0.36	6.4e-12	Pulmonary function;
LUSC	cis	rs117623576	0.941	rs7912584	chr10:32416623	C/T	cg03047570	chr10:32398778	NA	-0.62	-6.63	-0.34	1.36e-10	Anti-saccade response;
LUSC	cis	rs7582720	0.725	rs72934725	chr2:203725983	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	8.17	0.41	6.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg03806693	chr22:41940476	POLR3H	-0.95	-13.44	-0.59	3.25e-33	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25894440	chr7:65020034	NA	0.47	7.05	0.36	1.06e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg05501817	chr11:14380813	RRAS2	-0.55	-9.07	-0.44	1.04e-17	Sense of smell;
LUSC	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg25019033	chr10:957182	NA	-0.46	-5.77	-0.3	1.79e-8	Eosinophil percentage of granulocytes;
LUSC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	0.87	17.96	0.7	6.2e-51	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7246657	0.551	rs12978093	chr19:37584416	C/T	cg23950597	chr19:37808831	NA	-0.55	-6.05	-0.31	3.86e-9	Coronary artery calcification;
LUSC	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.39	5.82	0.3	1.41e-8	Educational attainment;
LUSC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg02551604	chr5:131831745	NA	0.44	6.89	0.35	2.75e-11	Asthma (sex interaction);
LUSC	cis	rs9549260	0.755	rs7989711	chr13:41215696	C/T	cg21288729	chr13:41239152	FOXO1	0.64	9.9	0.48	2.01e-20	Red blood cell count;
LUSC	cis	rs2137920	0.891	rs2254628	chr10:50236631	G/C	cg27141751	chr10:50231850	C10orf72	0.38	5.73	0.3	2.28e-8	Migraine with aura;
LUSC	cis	rs10740039	0.516	rs2154392	chr10:62317486	G/A	cg18175470	chr10:62150864	ANK3	-0.47	-6.94	-0.36	2.01e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6740322	0.748	rs6544635	chr2:43486704	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-6.51	-0.34	2.75e-10	Coronary artery disease;
LUSC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.4	5.65	0.3	3.49e-8	Tonsillectomy;
LUSC	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	8.38	0.42	1.54e-15	Response to antipsychotic treatment;
LUSC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg00409905	chr10:38381863	ZNF37A	-0.35	-6.03	-0.31	4.4e-9	Extrinsic epigenetic age acceleration;
LUSC	cis	rs6815814	0.861	rs73142654	chr4:38785697	T/A	cg06935464	chr4:38784597	TLR10	0.46	5.87	0.31	1.07e-8	Breast cancer;
LUSC	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	1.02	23.02	0.78	6.62e-71	Multiple myeloma;
LUSC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg00431813	chr7:1051703	C7orf50	-0.4	-6.29	-0.33	9.7e-10	Longevity;Endometriosis;
LUSC	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.52	-7.13	-0.36	6.38e-12	Renal function-related traits (BUN);
LUSC	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg05340658	chr4:99064831	C4orf37	0.44	6.81	0.35	4.42e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26401822	chr12:123459832	ABCB9;OGFOD2	-0.41	-5.95	-0.31	6.95e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg16647868	chr5:131706066	SLC22A5	-0.38	-6.11	-0.32	2.78e-9	Breast cancer;
LUSC	cis	rs7804356	0.953	rs10225700	chr7:26869880	C/T	cg03456212	chr7:26904342	SKAP2	-0.56	-6.46	-0.33	3.63e-10	Type 1 diabetes;
LUSC	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	0.48	7.1	0.36	7.45e-12	Breast cancer;
LUSC	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	0.97	10.96	0.51	4.58e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs9693857	0.520	rs4841163	chr8:9366178	C/G	cg15556689	chr8:8085844	FLJ10661	0.46	6.76	0.35	6.25e-11	Systolic blood pressure;
LUSC	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg12386194	chr3:101231763	SENP7	0.56	7.79	0.39	8.41e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg05082376	chr22:42548792	NA	-0.42	-6.29	-0.33	1.01e-9	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25130672	chr12:104850576	CHST11	-0.4	-6.09	-0.32	3.15e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg23788917	chr6:8435910	SLC35B3	0.49	7.22	0.37	3.45e-12	Motion sickness;
LUSC	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.8	0.3	1.57e-8	Breast cancer;
LUSC	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg05472934	chr7:22766657	IL6	0.52	7.92	0.4	3.5e-14	Lung cancer;
LUSC	cis	rs9650315	0.866	rs35835348	chr8:57201435	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	7.31	0.37	1.93e-12	Height;
LUSC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg07061783	chr6:25882402	NA	-0.61	-8.8	-0.43	7.58e-17	Urate levels;
LUSC	trans	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.07	-0.32	3.44e-9	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6539267	0.748	rs1921953	chr12:106721012	C/T	cg00173435	chr12:106696525	TCP11L2	0.47	6.34	0.33	7.48e-10	Tourette syndrome;
LUSC	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg13010199	chr12:38710504	ALG10B	0.4	5.85	0.3	1.16e-8	Morning vs. evening chronotype;
LUSC	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg10434728	chr15:90938212	IQGAP1	0.33	6.25	0.32	1.22e-9	Rheumatoid arthritis;
LUSC	cis	rs13253111	0.583	rs6993376	chr8:28096300	A/C	cg26534493	chr8:28060551	NA	0.37	6.76	0.35	6.2e-11	Childhood body mass index;
LUSC	cis	rs300703	0.810	rs72772835	chr2:134554	C/T	cg21211680	chr2:198530	NA	-0.73	-6.68	-0.34	9.84e-11	Blood protein levels;
LUSC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg14343924	chr8:8086146	FLJ10661	-0.43	-6.04	-0.31	4.1e-9	Mood instability;
LUSC	cis	rs2273669	0.504	rs74421833	chr6:109409274	A/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.8	-0.3	1.57e-8	Prostate cancer;
LUSC	cis	rs6690583	0.623	rs1371143	chr1:85455532	C/T	cg11262906	chr1:85462892	MCOLN2	0.67	6.75	0.35	6.38e-11	Serum sulfate level;
LUSC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg08888203	chr3:10149979	C3orf24	0.62	8.0	0.4	2.09e-14	Alzheimer's disease;
LUSC	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.29	6.51	0.34	2.82e-10	Coronary artery disease;
LUSC	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg04586622	chr2:25135609	ADCY3	0.4	8.36	0.42	1.71e-15	Body mass index;
LUSC	cis	rs4708431	0.540	rs12527674	chr6:168492582	A/G	cg02770688	chr6:168491649	NA	0.34	6.41	0.33	4.9e-10	Attention deficit hyperactivity disorder (combined symptoms);
LUSC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg27535305	chr1:53392650	SCP2	0.36	6.66	0.34	1.13e-10	Monocyte count;
LUSC	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-8.32	-0.41	2.29e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03530756	chr16:3285262	ZNF200	0.46	6.63	0.34	1.3100000000000001e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.17	-0.32	2.02e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg07169764	chr2:136633963	MCM6	-0.59	-7.8	-0.39	8.24e-14	Mosquito bite size;
LUSC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.38	0.33	5.94e-10	Personality dimensions;
LUSC	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg15704280	chr7:45808275	SEPT13	-0.54	-6.18	-0.32	1.87e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg03213289	chr20:61660250	NA	0.67	13.93	0.61	4.17e-35	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg24558204	chr6:135376177	HBS1L	0.58	9.03	0.44	1.38e-17	Red blood cell count;
LUSC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg15790184	chr11:494944	RNH1	-0.52	-5.9	-0.31	8.96e-9	Body mass index;
LUSC	cis	rs4917300	0.647	rs2201176	chr8:143118987	A/G	cg25363559	chr8:143086065	NA	-0.34	-7.25	-0.37	2.83e-12	Amyotrophic lateral sclerosis;
LUSC	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg05283184	chr6:79620031	NA	-0.57	-11.82	-0.54	3.53e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg08824895	chr13:115047677	UPF3A	0.55	8.6	0.43	3.24e-16	Schizophrenia;
LUSC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg04733989	chr22:42467013	NAGA	0.62	9.7	0.47	8.94e-20	Schizophrenia;
LUSC	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg11812906	chr14:75593930	NEK9	-0.65	-11.23	-0.52	4.73e-25	Height;
LUSC	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg22431228	chr1:16359049	CLCNKA	0.41	8.56	0.42	4.09e-16	Systolic blood pressure;
LUSC	trans	rs3756766	0.959	rs4835790	chr5:137744392	T/C	cg21075261	chr7:155633421	NA	-0.35	-5.98	-0.31	5.85e-9	Schizophrenia;
LUSC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-11.59	-0.54	2.48e-26	Systemic lupus erythematosus;
LUSC	cis	rs16910800	0.731	rs7125729	chr11:23181637	A/G	cg20040320	chr11:23191996	NA	-0.59	-7.63	-0.39	2.4e-13	Cancer;
LUSC	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-6.6	-0.34	1.57e-10	Blood metabolite levels;
LUSC	cis	rs1728785	0.892	rs4783648	chr16:68558334	C/T	cg02972257	chr16:68554789	NA	0.57	6.98	0.36	1.57e-11	Ulcerative colitis;
LUSC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg14552801	chr7:65878734	NA	0.4	6.0	0.31	5.21e-9	Aortic root size;
LUSC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.51	7.23	0.37	3.38e-12	Gut microbiome composition (summer);
LUSC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.8	0.35	4.88e-11	Platelet count;
LUSC	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg09654669	chr8:57350985	NA	0.58	8.12	0.41	9.05e-15	Obesity-related traits;
LUSC	trans	rs11039798	0.920	rs12417899	chr11:49017552	G/A	cg03929089	chr4:120376271	NA	0.77	6.33	0.33	7.7e-10	Axial length;
LUSC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg11752832	chr7:134001865	SLC35B4	0.53	8.0	0.4	2.08e-14	Mean platelet volume;
LUSC	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-11.55	-0.53	3.35e-26	Colorectal cancer;
LUSC	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg12863693	chr15:85201151	NMB	0.34	6.15	0.32	2.27e-9	Schizophrenia;
LUSC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.67	0.3	3.04e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg26597838	chr10:835615	NA	0.78	9.46	0.46	5.75e-19	Eosinophil percentage of granulocytes;
LUSC	cis	rs1018836	0.628	rs35816262	chr8:91511017	C/G	cg16814680	chr8:91681699	NA	-0.71	-10.77	-0.51	2.07e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1375194	0.582	rs13391166	chr2:33805314	C/T	cg04131969	chr2:33951647	MYADML	0.64	9.07	0.44	1.03e-17	Response to antidepressants in depression;
LUSC	cis	rs4363385	0.720	rs1134220	chr1:152976306	T/G	cg25856811	chr1:152973957	SPRR3	-0.34	-5.7	-0.3	2.69e-8	Inflammatory skin disease;
LUSC	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-7.06	-0.36	9.51e-12	Height;
LUSC	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.1	0.61	9.67e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg23029597	chr12:123009494	RSRC2	-0.72	-9.72	-0.47	8.1e-20	Body mass index;
LUSC	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg23029597	chr12:123009494	RSRC2	-0.71	-9.04	-0.44	1.28e-17	Body mass index;
LUSC	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg12935359	chr14:103987150	CKB	0.55	8.54	0.42	4.75e-16	Body mass index;
LUSC	cis	rs6500395	1.000	rs4785535	chr16:48707659	A/G	cg04672837	chr16:48644449	N4BP1	-0.46	-6.95	-0.36	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs1335645	0.655	rs61804623	chr1:111650834	T/G	cg00321911	chr1:111669324	DRAM2	-0.59	-6.16	-0.32	2.13e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs6967385	0.560	rs4554369	chr7:12356511	C/T	cg06484146	chr7:12443880	VWDE	0.5	7.51	0.38	5.42e-13	Response to taxane treatment (placlitaxel);
LUSC	cis	rs7715806	0.500	rs17563995	chr5:75007556	A/G	cg19683494	chr5:74908142	NA	0.57	7.76	0.39	1.05e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg08798685	chr6:27730294	NA	-0.64	-6.01	-0.31	4.93e-9	Breast cancer;
LUSC	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg17366294	chr4:99064904	C4orf37	0.57	10.0	0.48	9.46e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg00750074	chr16:89608354	SPG7	-0.56	-9.89	-0.48	2.17e-20	Multiple myeloma (IgH translocation);
LUSC	cis	rs2708377	0.789	rs115164039	chr12:11249393	T/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.78	7.46	0.38	7.47e-13	Bitter taste perception;
LUSC	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg23093090	chr10:104574429	C10orf26	-0.46	-8.24	-0.41	4.04e-15	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg18904891	chr8:8559673	CLDN23	-0.64	-8.57	-0.42	3.92e-16	Obesity-related traits;
LUSC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg22535103	chr8:58192502	C8orf71	0.78	8.3	0.41	2.6e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.43e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7528419	0.895	rs599839	chr1:109822166	A/G	cg00908766	chr1:109817496	CELSR2	-0.74	-11.21	-0.52	5.65e-25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
LUSC	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05901451	chr6:126070800	HEY2	0.89	16.67	0.67	7.72e-46	Brugada syndrome;
LUSC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg06096015	chr1:231504339	EGLN1	0.55	9.57	0.46	2.48e-19	Hemoglobin concentration;
LUSC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg11663144	chr21:46675770	NA	-0.42	-7.24	-0.37	3.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs1775715	0.870	rs1755080	chr10:32255195	G/A	cg03015672	chr10:32216066	ARHGAP12	0.33	5.69	0.3	2.85e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg19773385	chr1:10388646	KIF1B	-0.57	-9.66	-0.47	1.29e-19	Hepatocellular carcinoma;
LUSC	cis	rs77741769	0.529	rs7137504	chr12:121221628	C/T	cg02419362	chr12:121203948	SPPL3	0.46	8.56	0.42	4.27e-16	Mean corpuscular volume;
LUSC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg00745463	chr17:30367425	LRRC37B	0.79	9.27	0.45	2.31e-18	Hip circumference adjusted for BMI;
LUSC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg25726756	chr21:47582351	C21orf56	0.33	5.67	0.3	3.16e-8	Testicular germ cell tumor;
LUSC	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	10.57	0.5	1.01e-22	Prudent dietary pattern;
LUSC	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg12473912	chr3:136751656	NA	0.4	7.28	0.37	2.48e-12	Neuroticism;
LUSC	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25072359	chr17:41440525	NA	0.64	9.05	0.44	1.22e-17	Menopause (age at onset);
LUSC	trans	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg19862616	chr7:65841803	NCRNA00174	0.87	10.19	0.49	2.01e-21	Eotaxin levels;
LUSC	trans	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.14	0.32	2.31e-9	Corneal astigmatism;
LUSC	cis	rs6954274	0.789	rs4725229	chr7:9830571	T/G	cg27477025	chr7:9765726	NA	-0.38	-5.69	-0.3	2.76e-8	Subjective well-being;
LUSC	cis	rs7640424	0.819	rs34937412	chr3:107829484	G/C	cg09227934	chr3:107805635	CD47	-0.44	-6.87	-0.35	3.17e-11	Body mass index;
LUSC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg07703079	chr11:430292	ANO9	0.58	6.41	0.33	4.83e-10	Body mass index;
LUSC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg19592336	chr6:28129416	ZNF389	0.51	6.66	0.34	1.13e-10	Depression;
LUSC	cis	rs11971779	0.838	rs11764161	chr7:139115198	T/C	cg07862535	chr7:139043722	LUC7L2	0.71	8.46	0.42	8.53e-16	Diisocyanate-induced asthma;
LUSC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	0.93	15.79	0.65	2.51e-42	Menopause (age at onset);
LUSC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24110177	chr3:50126178	RBM5	-0.6	-10.08	-0.48	4.76e-21	Body mass index;
LUSC	cis	rs859767	0.741	rs11898084	chr2:135428054	T/C	cg12500956	chr2:135428796	TMEM163	-0.27	-6.04	-0.31	4.1e-9	Neuroticism;
LUSC	cis	rs9648716	0.515	rs62487920	chr7:140491258	C/T	cg23214464	chr7:140373596	ADCK2	0.63	5.66	0.3	3.31e-8	Type 2 diabetes;
LUSC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18404041	chr3:52824283	ITIH1	-0.62	-12.01	-0.55	7.56e-28	Bipolar disorder;
LUSC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg06096015	chr1:231504339	EGLN1	0.56	9.73	0.47	7.59e-20	Hemoglobin concentration;
LUSC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg24829409	chr8:58192753	C8orf71	-0.58	-6.13	-0.32	2.44e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	0.87	14.68	0.63	5.6e-38	Tonsillectomy;
LUSC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	1.06	20.18	0.74	8.67e-60	Menopause (age at onset);
LUSC	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg02569458	chr12:86230093	RASSF9	0.57	9.64	0.47	1.41e-19	Major depressive disorder;
LUSC	cis	rs9534288	0.731	rs2404730	chr13:46617381	G/A	cg15192986	chr13:46630673	CPB2	-0.66	-10.45	-0.5	2.75e-22	Blood protein levels;
LUSC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg19318889	chr4:1322082	MAEA	0.45	7.37	0.37	1.39e-12	Obesity-related traits;
LUSC	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.17	0.49	2.5e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg22029157	chr1:209979665	IRF6	0.51	8.14	0.41	7.85e-15	Monobrow;
LUSC	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg23202291	chr11:1979235	NA	0.39	6.09	0.32	3.14e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23598886	chr18:12777645	NA	-0.6	-5.9	-0.31	8.85e-9	Inflammatory skin disease;
LUSC	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg23172400	chr8:95962367	TP53INP1	-0.38	-7.71	-0.39	1.46e-13	Type 2 diabetes;
LUSC	cis	rs2224391	0.628	rs2773314	chr6:5253800	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-6.76	-0.35	6.08e-11	Height;
LUSC	cis	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg20159608	chr7:32802032	NA	-0.71	-9.2	-0.45	4.05e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	0.97	18.8	0.72	2.73e-54	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.54	-0.6	1.29e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg05861140	chr6:150128134	PCMT1	-0.4	-6.29	-0.33	9.83e-10	Lung cancer;
LUSC	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg19680485	chr15:31195859	MTMR15	0.5	6.58	0.34	1.86e-10	Huntington's disease progression;
LUSC	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg11901034	chr3:128598214	ACAD9	-0.4	-6.11	-0.32	2.74e-9	IgG glycosylation;
LUSC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg23985595	chr17:80112537	CCDC57	0.31	5.82	0.3	1.38e-8	Life satisfaction;
LUSC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg22920501	chr2:26401640	FAM59B	-0.81	-12.43	-0.56	2.09e-29	Gut microbiome composition (summer);
LUSC	cis	rs1451375	0.669	rs4512339	chr7:50646977	C/T	cg18232548	chr7:50535776	DDC	-0.51	-7.61	-0.38	2.85e-13	Malaria;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05926943	chr16:50100517	HEATR3	0.74	6.18	0.32	1.92e-9	Cognitive performance;
LUSC	cis	rs3750965	1.000	rs3750965	chr11:68840160	A/G	cg06818126	chr11:68850279	TPCN2	-0.46	-6.68	-0.34	9.95e-11	Hair color;
LUSC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16680214	chr1:154839983	KCNN3	0.5	9.32	0.45	1.68e-18	Prostate cancer;
LUSC	cis	rs6545883	0.868	rs7608483	chr2:61836235	A/C	cg15711740	chr2:61764176	XPO1	-0.46	-7.37	-0.37	1.33e-12	Tuberculosis;
LUSC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg16479474	chr6:28041457	NA	0.33	5.72	0.3	2.36e-8	Parkinson's disease;
LUSC	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg15001381	chr16:403314	AXIN1	0.34	6.25	0.32	1.24e-9	Bone mineral density (spine);Bone mineral density;
LUSC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg13770153	chr20:60521292	NA	-0.61	-8.39	-0.42	1.43e-15	Body mass index;
LUSC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg24562669	chr7:97807699	LMTK2	0.36	6.29	0.33	9.85e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg11366901	chr6:160182831	ACAT2	0.81	11.23	0.52	4.73e-25	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg03806693	chr22:41940476	POLR3H	0.99	14.04	0.61	1.61e-35	Vitiligo;
LUSC	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg07862535	chr7:139043722	LUC7L2	0.53	6.63	0.34	1.36e-10	Diisocyanate-induced asthma;
LUSC	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg23950597	chr19:37808831	NA	-0.63	-7.34	-0.37	1.66e-12	Coronary artery calcification;
LUSC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	7.5	0.38	5.82e-13	Colorectal cancer;
LUSC	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg25174290	chr11:3078921	CARS	-0.42	-6.28	-0.32	1.06e-9	Calcium levels;
LUSC	cis	rs4654899	1.000	rs7554770	chr1:21481361	A/T	cg01072550	chr1:21505969	NA	-0.55	-8.5	-0.42	6.28e-16	Superior frontal gyrus grey matter volume;
LUSC	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-7.59	-0.38	3.13e-13	Neuroticism;
LUSC	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg00074818	chr8:8560427	CLDN23	0.58	9.88	0.48	2.23e-20	Obesity-related traits;
LUSC	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg20016023	chr10:99160130	RRP12	-0.33	-8.04	-0.4	1.57e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7215564	0.908	rs34932625	chr17:78653155	A/G	cg09596252	chr17:78655493	RPTOR	0.56	6.05	0.31	3.85e-9	Myopia (pathological);
LUSC	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg03315344	chr16:75512273	CHST6	0.5	8.97	0.44	2.2e-17	Dupuytren's disease;
LUSC	cis	rs12618769	0.597	rs3754883	chr2:99129451	T/C	cg10123293	chr2:99228465	UNC50	0.46	7.53	0.38	4.73e-13	Bipolar disorder;
LUSC	cis	rs1044826	1.000	rs1044826	chr3:139073011	A/G	cg00490450	chr3:139108681	COPB2	-0.58	-7.62	-0.38	2.73e-13	Obesity-related traits;
LUSC	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg05313129	chr8:58192883	C8orf71	-0.51	-5.91	-0.31	8.63e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7264396	0.887	rs8116304	chr20:34054409	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-6.65	-0.34	1.18e-10	Total cholesterol levels;
LUSC	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg03647239	chr10:116582469	FAM160B1	0.45	7.21	0.37	3.78e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-10.27	-0.49	1.09e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4243830	1.000	rs11809957	chr1:6584420	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.9	8.76	0.43	9.71e-17	Body mass index;
LUSC	cis	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg20159608	chr7:32802032	NA	-0.71	-9.2	-0.45	4.05e-18	Metabolite levels (HVA/MHPG ratio);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19252529	chr3:170075940	SKIL	-0.41	-6.14	-0.32	2.33e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg18105134	chr13:113819100	PROZ	-0.67	-9.51	-0.46	3.79e-19	Platelet distribution width;
LUSC	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg13010199	chr12:38710504	ALG10B	-0.62	-10.36	-0.49	5.5e-22	Heart rate;
LUSC	cis	rs9463078	0.510	rs4714832	chr6:44978183	T/C	cg25276700	chr6:44698697	NA	0.29	6.03	0.31	4.31e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg21535247	chr6:8435926	SLC35B3	0.57	8.79	0.43	8.02e-17	Motion sickness;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg23296392	chr10:72648329	PCBD1	0.7	6.0	0.31	5.25e-9	Cognitive performance;
LUSC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06656553	chr16:89960601	TCF25	-0.65	-5.7	-0.3	2.63e-8	Skin colour saturation;
LUSC	cis	rs9811920	0.683	rs4928230	chr3:99661963	A/G	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	-0.35	-6.66	-0.34	1.14e-10	Axial length;
LUSC	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	0.84	12.37	0.56	3.44e-29	Inflammatory bowel disease;
LUSC	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.53	-8.54	-0.42	4.95e-16	Height;
LUSC	cis	rs981844	0.683	rs1037655	chr4:154750408	A/G	cg14289246	chr4:154710475	SFRP2	-0.46	-6.32	-0.33	8.22e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs3931020	0.688	rs405445	chr1:75221150	C/T	cg21906852	chr1:75198582	TYW3;CRYZ	-0.43	-5.72	-0.3	2.33e-8	Resistin levels;
LUSC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	1.03	20.55	0.75	2.97e-61	Cognitive function;
LUSC	cis	rs2108225	0.934	rs2190392	chr7:107452685	T/C	cg18560240	chr7:107437656	SLC26A3	-0.43	-6.54	-0.34	2.27e-10	Ulcerative colitis;
LUSC	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg12573674	chr2:1569213	NA	-0.55	-6.16	-0.32	2.15e-9	Placebo response in major depressive disorder (% change in symptom score);
LUSC	cis	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg06521852	chr22:38141419	TRIOBP	0.4	5.91	0.31	8.58e-9	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-6.01	-0.31	4.78e-9	Bipolar disorder;
LUSC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.71	9.37	0.46	1.11e-18	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs4974559	0.793	rs10025954	chr4:1351382	C/T	cg02980000	chr4:1222292	CTBP1	0.7	7.06	0.36	9.72e-12	Systolic blood pressure;
LUSC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg17553881	chr5:443987	EXOC3;C5orf55	-0.37	-8.44	-0.42	9.51e-16	Cystic fibrosis severity;
LUSC	cis	rs4363385	0.782	rs4845515	chr1:153003871	G/T	cg00922841	chr1:152955080	SPRR1A	-0.4	-7.08	-0.36	8.6e-12	Inflammatory skin disease;
LUSC	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	7.12	0.36	6.54e-12	Ovarian reserve;
LUSC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24549020	chr5:56110836	MAP3K1	0.47	5.69	0.3	2.8e-8	Initial pursuit acceleration;
LUSC	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg05714579	chr10:131428358	MGMT	0.53	8.05	0.4	1.43e-14	Response to temozolomide;
LUSC	cis	rs3812762	0.957	rs10160684	chr11:8775419	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.36	6.25	0.32	1.27e-9	Hypospadias;
LUSC	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg16359550	chr11:109292809	C11orf87	0.32	5.78	0.3	1.67e-8	Schizophrenia;
LUSC	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg04851639	chr8:1020857	NA	-0.4	-8.23	-0.41	4.31e-15	Schizophrenia;
LUSC	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg20744362	chr22:50050164	C22orf34	0.28	5.66	0.3	3.18e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg13903809	chr12:93964785	SOCS2	-0.43	-6.43	-0.33	4.29e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg21535247	chr6:8435926	SLC35B3	0.58	8.9	0.44	3.49e-17	Motion sickness;
LUSC	cis	rs2522056	1.000	rs2057655	chr5:131807624	A/G	cg24060327	chr5:131705240	SLC22A5	-0.42	-6.0	-0.31	5.05e-9	Lymphocyte counts;Fibrinogen;
LUSC	cis	rs4948275	0.550	rs10994742	chr10:63132240	A/T	cg26785954	chr10:63212815	TMEM26	-0.37	-5.64	-0.3	3.56e-8	Night sleep phenotypes;
LUSC	cis	rs2692947	0.832	rs2692954	chr2:96683378	T/G	cg22654517	chr2:96458247	NA	0.34	6.43	0.33	4.4e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg03233332	chr7:66118400	NA	-0.4	-5.92	-0.31	8.15e-9	Aortic root size;
LUSC	trans	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg04681394	chr10:134997386	KNDC1	0.28	6.02	0.31	4.57e-9	Mean corpuscular volume;
LUSC	cis	rs9309473	0.660	rs11679594	chr2:73779507	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-6.22	-0.32	1.46e-9	Metabolite levels;
LUSC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.61	8.36	0.42	1.75e-15	High light scatter reticulocyte count;
LUSC	cis	rs9341808	0.718	rs9448899	chr6:80845864	G/A	cg08355045	chr6:80787529	NA	0.57	10.03	0.48	7.17e-21	Sitting height ratio;
LUSC	cis	rs9436747	0.546	rs10749753	chr1:65998467	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.45	-6.19	-0.32	1.73e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LUSC	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg08799069	chr10:126477246	METTL10	-0.6	-8.33	-0.41	2.12e-15	Cocaine dependence;
LUSC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg24562669	chr7:97807699	LMTK2	0.35	6.17	0.32	2.01e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	13.4	0.59	4.48e-33	Alzheimer's disease;
LUSC	cis	rs73198271	0.562	rs964772	chr8:8651306	A/G	cg01851573	chr8:8652454	MFHAS1	0.6	8.29	0.41	2.81e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2124969	0.527	rs56040145	chr2:160983850	A/G	cg03641300	chr2:160917029	PLA2R1	-0.48	-5.79	-0.3	1.6e-8	Waist circumference adjusted for body mass index;
LUSC	cis	rs3126085	0.877	rs2338431	chr1:152169305	A/G	cg26876637	chr1:152193138	HRNR	0.45	6.36	0.33	6.58e-10	Atopic dermatitis;
LUSC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg00677455	chr12:58241039	CTDSP2	-0.71	-10.87	-0.51	8.98e-24	Multiple sclerosis;
LUSC	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg24375607	chr4:120327624	NA	0.76	11.87	0.54	2.32e-27	Corneal astigmatism;
LUSC	cis	rs9549260	0.755	rs17061503	chr13:41246758	A/G	cg21288729	chr13:41239152	FOXO1	-0.63	-9.83	-0.47	3.41e-20	Red blood cell count;
LUSC	cis	rs829880	0.558	rs249821	chr12:98897811	T/C	cg25150519	chr12:98850993	NA	0.44	5.65	0.3	3.52e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-9.71	-0.47	8.8e-20	Hemoglobin concentration;
LUSC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.92	11.97	0.55	1.05e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg11344533	chr11:111475393	SIK2	-0.48	-6.58	-0.34	1.78e-10	Primary sclerosing cholangitis;
LUSC	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg13010344	chr12:123464640	ARL6IP4	0.5	6.37	0.33	6.4e-10	Neutrophil percentage of white cells;
LUSC	cis	rs6960043	1.000	rs6960043	chr7:15052860	C/T	cg19272540	chr7:15055459	NA	0.3	7.22	0.37	3.59e-12	Type 2 diabetes;
LUSC	cis	rs59918340	1.000	rs59918340	chr8:142232256	A/G	cg23750338	chr8:142222470	SLC45A4	0.48	8.75	0.43	1.1e-16	Immature fraction of reticulocytes;
LUSC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	6.49	0.33	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg23505145	chr19:12996616	KLF1	0.64	11.0	0.52	3.08e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg12062639	chr20:23401060	NAPB	0.93	8.13	0.41	8.57e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg13319975	chr6:146136371	FBXO30	-0.47	-7.05	-0.36	1.04e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg05347473	chr6:146136440	FBXO30	0.4	6.91	0.35	2.48e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg27411982	chr8:10470053	RP1L1	0.37	5.86	0.31	1.14e-8	Retinal vascular caliber;
LUSC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.74	-10.84	-0.51	1.12e-23	Multiple sclerosis;
LUSC	cis	rs2274273	0.553	rs56166765	chr14:55738018	T/C	cg04306507	chr14:55594613	LGALS3	0.49	9.81	0.47	4.08e-20	Protein biomarker;
LUSC	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg05887092	chr17:76393375	PGS1	0.53	9.51	0.46	3.84e-19	HDL cholesterol levels;
LUSC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.89	-0.31	9.6e-9	Aortic root size;
LUSC	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-10.3	-0.49	8.54e-22	Morning vs. evening chronotype;
LUSC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg18230493	chr5:56204884	C5orf35	-0.88	-13.27	-0.59	1.44e-32	Initial pursuit acceleration;
LUSC	trans	rs724744	0.742	rs1205944	chr6:22356823	T/C	cg13807341	chr11:118445984	ARCN1	-0.36	-6.07	-0.32	3.5e-9	Basophil percentage of granulocytes;Basophil percentage of white cells;
LUSC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	9.03	0.44	1.43e-17	Motion sickness;
LUSC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.98	-13.22	-0.59	2.24e-32	Alzheimer's disease;
LUSC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.09	-0.48	4.66e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs2559856	1.000	rs2695282	chr12:102089502	A/G	cg12924262	chr12:102091054	CHPT1	-0.44	-6.17	-0.32	2.02e-9	Blood protein levels;
LUSC	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg24060327	chr5:131705240	SLC22A5	-0.38	-6.26	-0.32	1.21e-9	Blood metabolite levels;
LUSC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg15704280	chr7:45808275	SEPT13	-1.01	-18.93	-0.72	8.57e-55	Height;
LUSC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg15839431	chr19:19639596	YJEFN3	0.42	5.73	0.3	2.3e-8	Tonsillectomy;
LUSC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.62	12.64	0.57	3.5e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs17095355	0.748	rs2501577	chr10:111846687	C/T	cg00817464	chr10:111662876	XPNPEP1	0.56	7.23	0.37	3.34e-12	Biliary atresia;
LUSC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	0.99	23.0	0.78	8.03e-71	Menarche (age at onset);
LUSC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg24060327	chr5:131705240	SLC22A5	0.6	9.92	0.48	1.71e-20	Breast cancer;
LUSC	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg08085267	chr17:45401833	C17orf57	0.54	8.85	0.44	5.17e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	10.92	0.51	6.24e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg22705602	chr4:152727874	NA	-0.35	-7.03	-0.36	1.16e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs1775715	0.870	rs7912121	chr10:32228995	T/G	cg18675610	chr10:32216311	ARHGAP12	0.28	6.19	0.32	1.81e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg24375607	chr4:120327624	NA	0.79	11.75	0.54	6.4e-27	Corneal astigmatism;
LUSC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-11.07	-0.52	1.75e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.87	16.06	0.66	2.16e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.73	12.14	0.55	2.48e-28	Motion sickness;
LUSC	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg17652424	chr22:38574118	PLA2G6	-0.27	-5.69	-0.3	2.81e-8	Cutaneous nevi;
LUSC	cis	rs2273669	0.667	rs74582170	chr6:109312689	C/T	cg05315195	chr6:109294784	ARMC2	-0.55	-6.2	-0.32	1.62e-9	Prostate cancer;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg25942484	chr19:4941818	UHRF1	-0.39	-6.12	-0.32	2.65e-9	N-glycan levels;
LUSC	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	7.28	0.37	2.35e-12	Mood instability;
LUSC	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg26408565	chr15:76604113	ETFA	-0.49	-7.88	-0.4	4.81e-14	Blood metabolite levels;
LUSC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23158103	chr7:148848205	ZNF398	-0.4	-6.21	-0.32	1.62e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17467752	chr17:38218738	THRA	-0.5	-7.05	-0.36	1.05e-11	White blood cell count (basophil);White blood cell count;
LUSC	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg16342193	chr10:102329863	NA	-0.33	-6.06	-0.31	3.64e-9	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-9.94	-0.48	1.46e-20	Hemoglobin concentration;
LUSC	trans	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.27	-0.45	2.45e-18	Depression;
LUSC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg13939156	chr17:80058883	NA	-0.32	-6.29	-0.33	1.01e-9	Life satisfaction;
LUSC	cis	rs1018697	0.966	rs6584526	chr10:104566241	G/C	cg04362960	chr10:104952993	NT5C2	0.51	7.07	0.36	9.23e-12	Colorectal adenoma (advanced);
LUSC	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg09491104	chr22:46646882	C22orf40	-0.73	-6.61	-0.34	1.56e-10	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg10756647	chr7:56101905	PSPH	0.85	8.22	0.41	4.44e-15	Diabetic kidney disease;
LUSC	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg25233709	chr10:116636983	FAM160B1	0.37	6.59	0.34	1.69e-10	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs239198	0.578	rs11155708	chr6:101292189	G/A	cg09795085	chr6:101329169	ASCC3	0.44	6.27	0.32	1.13e-9	Menarche (age at onset);
LUSC	trans	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg14791747	chr16:20752902	THUMPD1	-0.43	-6.15	-0.32	2.24e-9	Pancreatic cancer;
LUSC	cis	rs1376303	0.643	rs2060730	chr7:32968342	T/C	cg06627557	chr7:32535165	LSM5;AVL9	-0.66	-5.73	-0.3	2.28e-8	Intelligence (multi-trait analysis);
LUSC	trans	rs11976180	1.000	rs6464574	chr7:143748257	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.13	-0.32	2.43e-9	Obesity-related traits;
LUSC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.4	5.67	0.3	3.1e-8	Schizophrenia;
LUSC	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg20283391	chr11:68216788	NA	-0.5	-7.14	-0.36	5.81e-12	Total body bone mineral density;
LUSC	cis	rs72772090	0.710	rs17400741	chr5:96066576	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.68	-7.43	-0.38	9.39e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg13010199	chr12:38710504	ALG10B	0.7	10.81	0.51	1.44e-23	Bladder cancer;
LUSC	cis	rs13385	0.769	rs7710268	chr5:139576347	T/C	cg26211634	chr5:139558579	C5orf32	0.44	6.59	0.34	1.76e-10	Atrial fibrillation;
LUSC	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg22709100	chr7:91322751	NA	0.39	5.66	0.3	3.25e-8	Breast cancer;
LUSC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	7.18	0.37	4.53e-12	Personality dimensions;
LUSC	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.75	-0.3	2e-8	Testicular germ cell tumor;
LUSC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	12.29	0.56	6.69e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg23711669	chr6:146136114	FBXO30	0.87	16.09	0.66	1.58e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03667269	chr22:22090129	YPEL1	-0.45	-6.52	-0.34	2.61e-10	Electrocardiographic conduction measures;
LUSC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.85	-0.3	1.19e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg05855489	chr10:104503620	C10orf26	0.56	9.02	0.44	1.52e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs4285028	0.948	rs12637351	chr3:121694412	A/G	cg11130432	chr3:121712080	ILDR1	0.66	10.01	0.48	8.2e-21	Multiple sclerosis;
LUSC	cis	rs870825	0.929	rs871254	chr4:185589226	G/C	cg04058563	chr4:185651563	MLF1IP	0.83	10.8	0.51	1.6e-23	Blood protein levels;
LUSC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.55	-0.5	1.19e-22	Bipolar disorder and schizophrenia;
LUSC	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg16989719	chr2:238392110	NA	-0.38	-6.6	-0.34	1.61e-10	Prostate cancer;
LUSC	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00684032	chr4:1343700	KIAA1530	0.37	6.47	0.33	3.48e-10	Obesity-related traits;
LUSC	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg17173187	chr15:85201210	NMB	0.35	6.26	0.32	1.19e-9	Schizophrenia;
LUSC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg10360139	chr7:1886902	MAD1L1	-0.45	-6.94	-0.35	2.08e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.29	6.45	0.33	3.94e-10	Coronary artery disease;
LUSC	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.9	15.61	0.65	1.25e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11645453	chr3:52864694	ITIH4	0.32	7.46	0.38	7.53e-13	Bipolar disorder;
LUSC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.52	0.57	9.53e-30	Motion sickness;
LUSC	cis	rs6940638	1.000	rs12215241	chr6:27023081	G/A	cg09904177	chr6:26538194	HMGN4	-0.5	-5.76	-0.3	1.9e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.67	11.48	0.53	5.96e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.43	6.18	0.32	1.86e-9	Blood metabolite levels;
LUSC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	0.97	17.42	0.69	8.69e-49	Cognitive function;
LUSC	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg16482183	chr6:26056742	HIST1H1C	0.45	6.46	0.33	3.67e-10	Height;
LUSC	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg07167872	chr1:205819463	PM20D1	-0.49	-6.89	-0.35	2.75e-11	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	12.19	0.55	1.59e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg01620082	chr3:125678407	NA	-0.78	-7.21	-0.37	3.82e-12	Breast cancer;
LUSC	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-0.87	-13.31	-0.59	9.83e-33	Prostate cancer;
LUSC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.62	10.63	0.5	6.47e-23	Menopause (age at onset);
LUSC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-7.62	-0.39	2.57e-13	Aortic root size;
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg26354017	chr1:205819088	PM20D1	0.85	15.1	0.64	1.21e-39	Menarche (age at onset);
LUSC	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg19875535	chr5:140030758	IK	-0.54	-8.9	-0.44	3.63e-17	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg08799069	chr10:126477246	METTL10	0.6	8.23	0.41	4.3e-15	Cocaine dependence;
LUSC	cis	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg17420585	chr12:42539391	GXYLT1	-0.33	-6.25	-0.32	1.28e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg01879757	chr17:41196368	BRCA1	-0.46	-6.92	-0.35	2.26e-11	Menopause (age at onset);
LUSC	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg08085267	chr17:45401833	C17orf57	-0.6	-9.97	-0.48	1.12e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg18479299	chr3:125709523	NA	-0.5	-5.79	-0.3	1.6e-8	Blood pressure (smoking interaction);
LUSC	cis	rs41271473	0.948	rs11803118	chr1:228826831	A/G	cg16512390	chr1:228756714	NA	0.53	6.22	0.32	1.49e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs714027	1.000	rs714027	chr22:30577771	A/G	cg11564601	chr22:30592435	NA	0.37	6.86	0.35	3.25e-11	Lymphocyte counts;
LUSC	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg05110241	chr16:68378359	PRMT7	-0.51	-5.98	-0.31	5.8e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs2018683	0.707	rs2391717	chr7:28971162	G/C	cg19402173	chr7:128379420	CALU	-0.46	-7.07	-0.36	9.25e-12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19717773	chr7:2847554	GNA12	-0.35	-5.86	-0.31	1.12e-8	Height;
LUSC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.87	-0.58	4.63e-31	Chronic sinus infection;
LUSC	cis	rs9928842	0.771	rs8059190	chr16:75260797	T/A	cg09066997	chr16:75300724	BCAR1	0.49	6.22	0.32	1.48e-9	Alcoholic chronic pancreatitis;
LUSC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-0.99	-17.57	-0.69	2.14e-49	Coronary artery disease;
LUSC	cis	rs2273669	0.504	rs75555274	chr6:109478385	G/A	cg05315195	chr6:109294784	ARMC2	-0.55	-5.85	-0.3	1.18e-8	Prostate cancer;
LUSC	cis	rs9905704	0.918	rs302858	chr17:56692800	G/T	cg12560992	chr17:57184187	TRIM37	0.55	7.74	0.39	1.19e-13	Testicular germ cell tumor;
LUSC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg13010344	chr12:123464640	ARL6IP4	-0.44	-5.98	-0.31	5.62e-9	Neutrophil percentage of white cells;
LUSC	cis	rs2625529	0.526	rs6494997	chr15:72560642	C/T	cg16672083	chr15:72433130	SENP8	0.47	7.8	0.39	7.96e-14	Red blood cell count;
LUSC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07157834	chr1:205819609	PM20D1	0.53	8.67	0.43	1.91e-16	Menarche (age at onset);
LUSC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg08684580	chr7:98029266	BAIAP2L1	-0.44	-8.01	-0.4	1.96e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6690583	0.623	rs7540706	chr1:85534645	A/G	cg11262906	chr1:85462892	MCOLN2	-0.67	-6.03	-0.31	4.24e-9	Serum sulfate level;
LUSC	cis	rs977987	0.778	rs2865528	chr16:75455942	T/C	cg04384234	chr16:75411784	CFDP1	-0.45	-7.4	-0.38	1.14e-12	Dupuytren's disease;
LUSC	trans	rs1027730	1.000	rs1472747	chr8:94081031	C/T	cg20324262	chr19:12958871	MAST1	-0.56	-5.97	-0.31	6.21e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs9395066	0.545	rs4714828	chr6:44846008	A/G	cg25276700	chr6:44698697	NA	0.3	6.01	0.31	4.92e-9	Height;
LUSC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-9.82	-0.47	3.57e-20	Gut microbiome composition (summer);
LUSC	cis	rs7572644	0.640	rs12464988	chr2:28058226	C/T	cg27432699	chr2:27873401	GPN1	0.52	6.95	0.36	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6692729	0.966	rs6697431	chr1:227015198	C/T	cg10327440	chr1:227177885	CDC42BPA	0.48	6.96	0.36	1.81e-11	Electrodermal activity;
LUSC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	ch.11.42038R	chr11:967971	AP2A2	0.41	6.11	0.32	2.78e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7818345	0.967	rs6992893	chr8:19287504	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.96	0.36	1.8e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00166722	chr3:10149974	C3orf24	0.61	8.64	0.43	2.44e-16	Alzheimer's disease;
LUSC	trans	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05039488	chr6:79577232	IRAK1BP1	0.44	6.6	0.34	1.66e-10	Endometrial cancer;
LUSC	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg23750338	chr8:142222470	SLC45A4	0.58	11.3	0.53	2.65e-25	Immature fraction of reticulocytes;
LUSC	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg06207120	chr15:45996521	NA	-0.4	-6.27	-0.32	1.1e-9	Waist circumference;Weight;
LUSC	cis	rs2857891	0.817	rs2638101	chr11:6969131	G/A	cg14883916	chr11:6947541	ZNF215	0.44	5.86	0.31	1.12e-8	Response to cytadine analogues (cytosine arabinoside);
LUSC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs11112613	0.818	rs117644588	chr12:106022040	G/C	cg03607813	chr12:105948248	NA	0.75	9.13	0.45	6.82e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg21017887	chr14:105400489	NA	0.67	12.39	0.56	2.8e-29	Rheumatoid arthritis;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg03130149	chr11:3819041	PGAP2;NUP98	0.44	6.14	0.32	2.31e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg10150615	chr22:24372951	LOC391322	-0.34	-5.75	-0.3	2.02e-8	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg13010199	chr12:38710504	ALG10B	0.7	10.59	0.5	8.81e-23	Bladder cancer;
LUSC	cis	rs2540226	0.844	rs17478972	chr2:39995172	A/G	cg23576258	chr2:39999331	THUMPD2	0.34	5.78	0.3	1.71e-8	Personality dimensions;
LUSC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.92e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07677032	chr17:61819896	STRADA	0.55	9.11	0.45	8.03e-18	Prudent dietary pattern;
LUSC	cis	rs500891	0.574	rs10943932	chr6:84155957	A/C	cg08257003	chr6:84140564	ME1	0.37	9.02	0.44	1.5e-17	Platelet-derived growth factor BB levels;
LUSC	cis	rs7923609	1.000	rs10761742	chr10:65085048	A/G	cg01631684	chr10:65280961	REEP3	-0.42	-6.42	-0.33	4.62e-10	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg22908266	chr2:27273008	AGBL5	-0.46	-7.05	-0.36	1.06e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	7.72	0.39	1.4e-13	Height;
LUSC	cis	rs1775715	0.644	rs2799022	chr10:32137198	C/T	cg04359828	chr10:32216031	ARHGAP12	0.41	7.07	0.36	9.07e-12	Bipolar disorder with mood-incongruent psychosis;
LUSC	trans	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg26043149	chr18:55253948	FECH	0.44	6.79	0.35	5.22e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg08975724	chr8:8085496	FLJ10661	0.5	7.16	0.36	5.12e-12	Myopia (pathological);
LUSC	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg18131467	chr2:239335373	ASB1	1.04	24.67	0.8	2.93e-77	Multiple system atrophy;
LUSC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.33	5.69	0.3	2.78e-8	Menopause (age at onset);
LUSC	cis	rs10754283	0.967	rs1934044	chr1:90107501	C/T	cg21401794	chr1:90099060	LRRC8C	-0.63	-9.5	-0.46	4.2e-19	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.67	11.27	0.52	3.58e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6977660	0.714	rs6977079	chr7:19818207	G/A	cg05791153	chr7:19748676	TWISTNB	0.66	7.0	0.36	1.38e-11	Thyroid stimulating hormone;
LUSC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.67	-11.62	-0.54	1.86e-26	Lung cancer;
LUSC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20307385	chr11:47447363	PSMC3	-0.46	-6.15	-0.32	2.19e-9	Subjective well-being;
LUSC	trans	rs1459104	0.636	rs559362	chr11:55275456	T/G	cg03929089	chr4:120376271	NA	0.57	6.07	0.32	3.42e-9	Body mass index;
LUSC	cis	rs2348418	0.864	rs7978086	chr12:28715694	G/T	cg13890972	chr12:28721907	NA	-0.34	-5.81	-0.3	1.49e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg02972257	chr16:68554789	NA	-0.53	-6.48	-0.33	3.3e-10	Ulcerative colitis;
LUSC	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-11.82	-0.54	3.71e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg21724239	chr8:58056113	NA	0.8	8.55	0.42	4.58e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2227564	0.700	rs12413039	chr10:75524759	C/G	cg17411546	chr10:75410026	SYNPO2L	0.47	5.91	0.31	8.42e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs416603	0.901	rs149597	chr16:11343942	C/G	cg00044050	chr16:11439710	C16orf75	-0.66	-11.24	-0.52	4.49e-25	Type 1 diabetes;
LUSC	trans	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg10756647	chr7:56101905	PSPH	0.85	8.47	0.42	7.94e-16	Gout;
LUSC	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-7.63	-0.39	2.46e-13	Joint mobility (Beighton score);
LUSC	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg03929089	chr4:120376271	NA	-0.57	-6.85	-0.35	3.59e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs7914558	0.646	rs10883796	chr10:104655315	G/A	cg05855489	chr10:104503620	C10orf26	0.42	5.7	0.3	2.64e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg00757033	chr12:89920650	WDR51B	0.54	9.17	0.45	5.05e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg16606324	chr3:10149918	C3orf24	0.62	9.08	0.44	9.8e-18	Alzheimer's disease;
LUSC	cis	rs2835872	0.863	rs702859	chr21:38997701	G/A	cg20424643	chr21:39039972	KCNJ6	-0.38	-5.86	-0.31	1.1e-8	Electroencephalographic traits in alcoholism;
LUSC	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.24	-18.9	-0.72	1.08e-54	Type 1 diabetes nephropathy;
LUSC	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg23260525	chr10:116636907	FAM160B1	0.47	10.15	0.49	2.82e-21	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs11997175	0.545	rs7818001	chr8:33807682	G/T	ch.8.33884649F	chr8:33765107	NA	0.48	7.23	0.37	3.22e-12	Body mass index;
LUSC	cis	rs6714710	0.603	rs2044459	chr2:98447004	T/C	cg26665480	chr2:98280029	ACTR1B	0.61	8.91	0.44	3.25e-17	Posterior cortical atrophy and Alzheimer's disease;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg20530585	chr3:149376036	WWTR1	0.38	6.22	0.32	1.49e-9	Calcium levels;
LUSC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.52	0.76	4.61e-65	Prudent dietary pattern;
LUSC	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.5	7.21	0.37	3.75e-12	Coronary heart disease;
LUSC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24531977	chr5:56204891	C5orf35	0.86	13.95	0.61	3.69e-35	Initial pursuit acceleration;
LUSC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg11494091	chr17:61959527	GH2	0.4	6.81	0.35	4.47e-11	Height;
LUSC	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg07211511	chr3:129823064	LOC729375	-1.14	-17.6	-0.69	1.62e-49	Blood pressure (smoking interaction);
LUSC	cis	rs62400317	0.762	rs6909047	chr6:44998915	C/G	cg20913747	chr6:44695427	NA	-0.44	-6.88	-0.35	3.03e-11	Total body bone mineral density;
LUSC	cis	rs7605827	0.964	rs6748427	chr2:15564799	T/C	cg19274914	chr2:15703543	NA	0.47	9.02	0.44	1.47e-17	Educational attainment (years of education);
LUSC	cis	rs61931739	0.635	rs4442626	chr12:33912530	C/T	cg06521331	chr12:34319734	NA	-0.41	-6.69	-0.34	9.21e-11	Morning vs. evening chronotype;
LUSC	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg05754148	chr16:3507555	NAT15	0.51	7.54	0.38	4.52e-13	Tuberculosis;
LUSC	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg00857998	chr1:205179979	DSTYK	0.59	8.89	0.44	3.85e-17	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg21880101	chr17:80066754	CCDC57	-0.31	-5.87	-0.31	1.03e-8	Life satisfaction;
LUSC	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.24	0.37	3.05e-12	Educational attainment;
LUSC	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.79	8.11	0.41	9.54e-15	Lung cancer in ever smokers;
LUSC	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg03929089	chr4:120376271	NA	0.68	7.54	0.38	4.38e-13	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs1493916	0.837	rs4997493	chr18:31407302	C/T	cg27147174	chr7:100797783	AP1S1	-0.55	-8.73	-0.43	1.21e-16	Life satisfaction;
LUSC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.91	14.58	0.62	1.3e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg18818563	chr19:9546128	ZNF266	0.4	5.96	0.31	6.54e-9	N-glycan levels;
LUSC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	11.47	0.53	6.92e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-6.63	-0.34	1.35e-10	Response to antipsychotic treatment;
LUSC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg24675658	chr1:53192096	ZYG11B	0.61	9.65	0.47	1.3e-19	Monocyte count;
LUSC	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg17385448	chr1:15911702	AGMAT	0.37	6.29	0.33	9.81e-10	Systolic blood pressure;
LUSC	cis	rs2463822	1.000	rs2513744	chr11:62077785	C/A	cg06239285	chr11:62104954	ASRGL1	0.94	9.3	0.45	1.85e-18	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.62	-13.05	-0.58	9.79e-32	Monocyte percentage of white cells;
LUSC	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg13010199	chr12:38710504	ALG10B	0.41	5.97	0.31	5.93e-9	Morning vs. evening chronotype;
LUSC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg13683864	chr3:40499215	RPL14	-1.14	-21.3	-0.76	3.44e-64	Renal cell carcinoma;
LUSC	cis	rs7178572	0.568	rs12906708	chr15:77681444	A/G	cg22256960	chr15:77711686	NA	-0.5	-7.93	-0.4	3.23e-14	Type 2 diabetes;
LUSC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg09699651	chr6:150184138	LRP11	0.37	5.79	0.3	1.61e-8	Lung cancer;
LUSC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-12.38	-0.56	3.04e-29	Longevity;Endometriosis;
LUSC	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg13010199	chr12:38710504	ALG10B	0.7	10.75	0.51	2.4e-23	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs806215	1.000	rs2106186	chr7:127241352	G/C	cg25922125	chr7:127225783	GCC1	0.59	7.25	0.37	2.98e-12	Type 2 diabetes;
LUSC	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg18681998	chr4:17616180	MED28	0.77	13.86	0.6	7.94e-35	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs67072384	1.000	rs2886367	chr11:72455034	C/T	cg04827223	chr11:72435913	ARAP1	-0.78	-6.8	-0.35	4.98e-11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
LUSC	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg14541582	chr5:601475	NA	-0.38	-5.93	-0.31	7.36e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	6.95	0.36	1.94e-11	Hip circumference adjusted for BMI;
LUSC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	10.66	0.5	4.78e-23	Homoarginine levels;
LUSC	cis	rs11971779	0.680	rs6963867	chr7:139059964	T/G	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg24375607	chr4:120327624	NA	0.69	10.6	0.5	7.74e-23	Corneal astigmatism;
LUSC	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg17173187	chr15:85201210	NMB	0.37	6.37	0.33	6.23e-10	Schizophrenia;
LUSC	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.72	11.05	0.52	2.14e-24	Hypertriglyceridemia;
LUSC	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.68	-12.61	-0.57	4.34e-30	Ulcerative colitis;
LUSC	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg00310523	chr12:86230176	RASSF9	0.52	9.73	0.47	7.31e-20	Major depressive disorder;
LUSC	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-7.68	-0.39	1.83e-13	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-0.98	-14.49	-0.62	2.85e-37	Initial pursuit acceleration;
LUSC	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg13010199	chr12:38710504	ALG10B	0.48	7.43	0.38	8.98e-13	Morning vs. evening chronotype;
LUSC	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg11812906	chr14:75593930	NEK9	0.66	10.87	0.51	9.39e-24	Height;
LUSC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08280861	chr8:58055591	NA	0.54	5.88	0.31	1.02e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg11632617	chr15:75315747	PPCDC	-0.51	-6.6	-0.34	1.66e-10	Blood trace element (Zn levels);
LUSC	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg18478394	chr8:109455254	TTC35	0.45	6.61	0.34	1.51e-10	Dupuytren's disease;
LUSC	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg15704280	chr7:45808275	SEPT13	-0.62	-6.74	-0.35	7.17e-11	Axial length;
LUSC	cis	rs3820068	0.608	rs10927836	chr1:16034368	G/C	cg24675056	chr1:15929824	NA	0.41	6.84	0.35	3.9e-11	Systolic blood pressure;
LUSC	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg05373962	chr22:49881684	NA	-0.46	-11.16	-0.52	8.26e-25	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg26395211	chr5:140044315	WDR55	-0.39	-5.98	-0.31	5.69e-9	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg01475377	chr6:109611718	NA	-0.46	-8.44	-0.42	9.54e-16	Reticulocyte fraction of red cells;
LUSC	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg17757837	chr7:157058334	UBE3C	0.81	12.79	0.57	9.22e-31	Body mass index;
LUSC	trans	rs11165623	0.564	rs7555035	chr1:96996026	T/C	cg10631902	chr5:14652156	NA	-0.41	-6.06	-0.31	3.69e-9	Hip circumference;Waist circumference;
LUSC	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02176678	chr2:219576539	TTLL4	0.58	10.61	0.5	7.11e-23	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11764359	chr7:65958608	NA	0.5	6.36	0.33	6.75e-10	Aortic root size;
LUSC	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	5.73	0.3	2.29e-8	Schizophrenia;
LUSC	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg08999081	chr20:33150536	PIGU	0.37	6.69	0.34	9.61e-11	Height;
LUSC	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg00129232	chr17:37814104	STARD3	-0.47	-7.0	-0.36	1.39e-11	Asthma;
LUSC	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg20933634	chr6:27740509	NA	-0.45	-5.93	-0.31	7.47e-9	Parkinson's disease;
LUSC	cis	rs7712401	0.540	rs416763	chr5:122317241	G/A	cg19077854	chr5:122220652	SNX24	-0.43	-9.53	-0.46	3.35e-19	Mean platelet volume;
LUSC	cis	rs4786125	0.626	rs11077095	chr16:6916451	C/T	cg03623568	chr16:6915990	A2BP1	0.48	8.47	0.42	7.96e-16	Heart rate variability traits (SDNN);
LUSC	cis	rs2282032	1.000	rs17799244	chr14:90760040	C/T	cg14092571	chr14:90743983	NA	0.47	6.29	0.33	9.72e-10	Longevity;
LUSC	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg06917634	chr15:78832804	PSMA4	-0.44	-5.97	-0.31	5.94e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg22907277	chr7:1156413	C7orf50	0.72	10.41	0.49	3.75e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7202877	0.706	rs4888393	chr16:75413673	C/T	cg04384234	chr16:75411784	CFDP1	-0.66	-9.59	-0.46	2.2e-19	Type 2 diabetes;Type 1 diabetes;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg10135520	chr20:47895337	C20orf199;SNORD12C;ZNFX1	0.38	6.08	0.32	3.34e-9	Triglycerides;
LUSC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.57	9.21	0.45	3.66e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.42	-5.76	-0.3	1.95e-8	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs12367572	1.000	rs12367572	chr12:45290466	C/T	cg04608330	chr12:45269318	NELL2	0.55	8.68	0.43	1.77e-16	Gut microbiome composition (summer);
LUSC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg25036284	chr2:26402008	FAM59B	0.76	10.98	0.52	3.69e-24	Gut microbiome composition (summer);
LUSC	cis	rs72781680	0.768	rs56339558	chr2:24125234	G/A	cg08917208	chr2:24149416	ATAD2B	0.59	6.83	0.35	3.96e-11	Lymphocyte counts;
LUSC	cis	rs7572644	0.665	rs12478766	chr2:28041200	T/C	cg27432699	chr2:27873401	GPN1	0.57	7.28	0.37	2.47e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg19920283	chr7:105172520	RINT1	0.6	6.26	0.32	1.15e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-8.61	-0.43	2.98e-16	Lung cancer;
LUSC	cis	rs524023	0.958	rs12802649	chr11:64359627	C/T	cg19131476	chr11:64387923	NRXN2	-0.38	-10.2	-0.49	1.96e-21	Urate levels in obese individuals;
LUSC	cis	rs7246657	0.598	rs10405372	chr19:37668775	A/C	cg23950597	chr19:37808831	NA	-0.57	-5.79	-0.3	1.64e-8	Coronary artery calcification;
LUSC	cis	rs6967385	0.867	rs7808500	chr7:12359042	T/C	cg06484146	chr7:12443880	VWDE	0.38	5.72	0.3	2.41e-8	Response to taxane treatment (placlitaxel);
LUSC	trans	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-5.99	-0.31	5.44e-9	Triglycerides;
LUSC	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg06532163	chr17:45867833	NA	0.34	6.33	0.33	8.02e-10	IgG glycosylation;
LUSC	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.26	0.32	1.21e-9	Platelet count;
LUSC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg14346243	chr4:90757452	SNCA	-0.41	-5.96	-0.31	6.43e-9	Neuroticism;
LUSC	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg18683606	chr7:100471612	SRRT	0.46	6.07	0.32	3.49e-9	Resting heart rate;
LUSC	cis	rs11051970	0.679	rs2733696	chr12:32554635	A/G	cg02745156	chr12:32552066	NA	0.37	6.8	0.35	4.69e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7336332	0.598	rs9581850	chr13:28012265	A/G	cg22138327	chr13:27999177	GTF3A	0.8	9.82	0.47	3.7e-20	Weight;
LUSC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg25427524	chr10:38739819	LOC399744	0.43	5.73	0.3	2.25e-8	Obesity (extreme);
LUSC	cis	rs1832871	0.711	rs9459904	chr6:158700982	C/T	cg07165851	chr6:158734300	TULP4	0.5	7.79	0.39	8.52e-14	Height;
LUSC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg01238044	chr22:24384105	GSTT1	-0.51	-7.36	-0.37	1.47e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg06064525	chr11:970664	AP2A2	-0.34	-6.75	-0.35	6.61e-11	Alzheimer's disease (late onset);
LUSC	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg17462356	chr17:80056334	FASN	-0.43	-5.91	-0.31	8.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs8027181	0.839	rs8025333	chr15:73025121	A/G	cg25632853	chr15:73088954	NA	0.31	6.4	0.33	5.34e-10	Triglyceride levels;
LUSC	cis	rs7503807	0.935	rs9910745	chr17:78610543	C/T	cg09596252	chr17:78655493	RPTOR	0.46	7.82	0.39	7.03e-14	Obesity;
LUSC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg21361702	chr7:150065534	REPIN1	0.5	6.9	0.35	2.62e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-1.07	-25.94	-0.82	4.9e-82	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Body mass index;
LUSC	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg10523679	chr1:76189770	ACADM	-0.48	-6.99	-0.36	1.53e-11	Daytime sleep phenotypes;
LUSC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg17366294	chr4:99064904	C4orf37	0.56	9.8	0.47	4.42e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg11062466	chr8:58055876	NA	0.51	6.59	0.34	1.75e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg14983838	chr19:29218262	NA	0.6	8.71	0.43	1.39e-16	Methadone dose in opioid dependence;
LUSC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	8.98	0.44	2.09e-17	Post bronchodilator FEV1;
LUSC	cis	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg21775007	chr8:11205619	TDH	-0.41	-5.79	-0.3	1.62e-8	Monocyte count;
LUSC	cis	rs55665837	0.922	rs12287212	chr11:14449861	C/A	cg19336497	chr11:14380999	RRAS2	-0.38	-7.69	-0.39	1.63e-13	Vitamin D levels;
LUSC	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	8.63	0.43	2.62e-16	Bipolar disorder;
LUSC	cis	rs1014246	0.813	rs11197805	chr10:118479677	G/A	cg14919929	chr10:118506882	NA	0.45	6.78	0.35	5.34e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs2067615	0.579	rs6539283	chr12:107222989	C/T	cg19260189	chr12:106995001	RFX4	0.22	5.69	0.3	2.81e-8	Heart rate;
LUSC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-6.77	-0.35	5.93e-11	Menopause (age at onset);
LUSC	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-0.85	-14.96	-0.63	4.49e-39	Body mass index;
LUSC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg10523860	chr14:103875565	MARK3	-0.38	-6.16	-0.32	2.15e-9	Body mass index;
LUSC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.58	10.76	0.51	2.21e-23	Bone mineral density;
LUSC	cis	rs722599	0.715	rs61978928	chr14:75321714	T/C	cg08847533	chr14:75593920	NEK9	-0.45	-6.45	-0.33	3.88e-10	IgG glycosylation;
LUSC	trans	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg25214090	chr10:38739885	LOC399744	0.44	6.58	0.34	1.79e-10	Corneal astigmatism;
LUSC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg06640241	chr16:89574553	SPG7	0.91	17.15	0.68	9.99e-48	Multiple myeloma (IgH translocation);
LUSC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg11062466	chr8:58055876	NA	0.51	6.5	0.34	2.9e-10	Developmental language disorder (linguistic errors);
LUSC	trans	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg04938255	chr1:94312360	MIR760	0.37	6.22	0.32	1.45e-9	Metabolite levels (Pyroglutamine);
LUSC	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.07e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.92	-0.35	2.31e-11	Monocyte percentage of white cells;
LUSC	cis	rs10465746	0.905	rs34274953	chr1:84415011	G/A	cg10977910	chr1:84465055	TTLL7	0.43	6.3	0.33	9.21e-10	Obesity-related traits;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg21881034	chr19:18723557	TMEM59L	0.72	6.17	0.32	1.99e-9	Cognitive performance;
LUSC	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg25919922	chr13:100150906	NA	-0.74	-7.84	-0.39	6.07e-14	Obesity-related traits;
LUSC	cis	rs12220238	0.915	rs7922519	chr10:75976573	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.62	7.22	0.37	3.42e-12	Soluble interleukin-2 receptor subunit alpha;
LUSC	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg15704280	chr7:45808275	SEPT13	-0.73	-8.36	-0.42	1.74e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	19.95	0.74	7.16e-59	Height;
LUSC	cis	rs57549656	0.799	rs72980725	chr19:2711083	T/C	cg06609049	chr19:2785107	THOP1	0.49	6.35	0.33	7.09e-10	Schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23029546	chr1:155294555	RUSC1;C1orf104	0.5	6.84	0.35	3.78e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	trans	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg05926928	chr17:57297772	GDPD1	1.11	13.96	0.61	3.39e-35	Opioid sensitivity;
LUSC	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg27539214	chr16:67997921	SLC12A4	-0.58	-6.65	-0.34	1.21e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4953318	0.796	rs10168349	chr2:46360907	G/C	cg12428440	chr2:46370979	PRKCE	0.35	6.21	0.32	1.56e-9	Red blood cell count;Hematocrit;Red blood cell traits;
LUSC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg22920501	chr2:26401640	FAM59B	-0.8	-11.37	-0.53	1.47e-25	Gut microbiome composition (summer);
LUSC	trans	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs662064	0.963	rs10864459	chr1:10563609	C/T	cg20482658	chr1:10539492	PEX14	0.32	7.0	0.36	1.38e-11	Asthma;
LUSC	cis	rs7123876	0.546	rs11604837	chr11:72360007	G/A	cg03713592	chr11:72463424	ARAP1	0.76	7.88	0.4	4.66e-14	Body mass index;
LUSC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg05347473	chr6:146136440	FBXO30	0.56	9.58	0.46	2.29e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg02167203	chr6:41068553	NFYA;LOC221442	-0.39	-5.78	-0.3	1.67e-8	Alzheimer's disease (late onset);
LUSC	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg03585969	chr10:35415529	CREM	0.62	9.27	0.45	2.42e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg13531842	chr10:38383804	ZNF37A	-0.43	-6.71	-0.34	8.54e-11	Extrinsic epigenetic age acceleration;
LUSC	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.7	-10.66	-0.5	5.08e-23	Colorectal cancer;
LUSC	trans	rs12317459	0.591	rs11115433	chr12:83200084	T/A	cg10237817	chr1:154519846	TDRD10	0.31	6.22	0.32	1.46e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg25173405	chr17:45401733	C17orf57	-0.37	-5.73	-0.3	2.21e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg02018176	chr4:1364513	KIAA1530	0.46	6.44	0.33	4.26e-10	Recombination rate (females);
LUSC	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg09904177	chr6:26538194	HMGN4	-0.54	-6.43	-0.33	4.46e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs3791556	1.000	rs3791558	chr2:240113255	G/A	cg03281426	chr2:240109471	HDAC4	0.51	6.05	0.31	3.97e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg01858014	chr14:56050164	KTN1	-0.83	-6.64	-0.34	1.27e-10	Putamen volume;
LUSC	cis	rs2067615	0.579	rs10778506	chr12:107143260	T/C	cg15890332	chr12:107067104	RFX4	0.34	6.27	0.32	1.1e-9	Heart rate;
LUSC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg03146154	chr1:46216737	IPP	0.53	7.89	0.4	4.27e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4356932	1.000	rs4637430	chr4:76962223	G/T	cg00809888	chr4:76862425	NAAA	0.36	5.97	0.31	5.91e-9	Blood protein levels;
LUSC	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg05887092	chr17:76393375	PGS1	0.64	12.37	0.56	3.3e-29	HDL cholesterol levels;
LUSC	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg04362960	chr10:104952993	NT5C2	0.6	9.59	0.46	2.18e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.87	0.31	1.07e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.19e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-10.37	-0.49	5.06e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs7241530	0.662	rs11081528	chr18:75902453	G/A	cg14642773	chr18:75888474	NA	0.41	6.27	0.32	1.14e-9	Educational attainment (years of education);
LUSC	cis	rs7804356	1.000	rs4722647	chr7:26890446	G/C	cg03456212	chr7:26904342	SKAP2	-0.52	-5.95	-0.31	6.64e-9	Type 1 diabetes;
LUSC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-7.64	-0.39	2.29e-13	Personality dimensions;
LUSC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg10523860	chr14:103875565	MARK3	-0.4	-6.4	-0.33	5.28e-10	Body mass index;
LUSC	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19346786	chr7:2764209	NA	-0.48	-8.04	-0.4	1.6e-14	Height;
LUSC	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg15654264	chr1:150340011	RPRD2	0.61	10.04	0.48	6.57e-21	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.73	-0.3	2.24e-8	Ulcerative colitis;
LUSC	cis	rs4474465	0.920	rs12222907	chr11:78219726	C/T	cg27205649	chr11:78285834	NARS2	0.49	5.69	0.3	2.74e-8	Alzheimer's disease (survival time);
LUSC	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg13798780	chr7:105162888	PUS7	0.55	6.01	0.31	4.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.5	8.77	0.43	9.18e-17	HDL cholesterol;
LUSC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-19.39	-0.73	1.25e-56	Height;
LUSC	cis	rs75229567	0.618	rs1599745	chr12:70186029	A/G	cg10114359	chr12:70132523	RAB3IP	1.12	10.43	0.5	3.11e-22	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LUSC	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg04398451	chr17:18023971	MYO15A	0.41	6.26	0.32	1.21e-9	Total body bone mineral density;
LUSC	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg25456477	chr12:86230367	RASSF9	0.39	6.94	0.36	1.99e-11	Major depressive disorder;
LUSC	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg24692254	chr21:30365293	RNF160	0.68	10.88	0.51	8.46e-24	Selective IgA deficiency;
LUSC	trans	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg21775007	chr8:11205619	TDH	-0.43	-6.07	-0.32	3.43e-9	Joint mobility (Beighton score);
LUSC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg09034736	chr1:150693464	HORMAD1	0.5	7.33	0.37	1.76e-12	Tonsillectomy;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20060523	chr4:142557759	IL15	0.41	5.97	0.31	5.91e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg02782426	chr3:40428986	ENTPD3	0.41	7.7	0.39	1.59e-13	Renal cell carcinoma;
LUSC	cis	rs3771570	1.000	rs55645375	chr2:242269024	A/G	cg21155796	chr2:242212141	HDLBP	0.63	6.86	0.35	3.32e-11	Prostate cancer;
LUSC	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg08017756	chr2:100939284	LONRF2	-0.45	-8.35	-0.42	1.82e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs73200209	0.744	rs55643039	chr12:116609355	T/G	cg01776926	chr12:116560359	MED13L	-0.5	-6.12	-0.32	2.66e-9	Total body bone mineral density;
LUSC	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.54	-7.39	-0.37	1.17e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg14530993	chr4:882597	GAK	0.72	7.35	0.37	1.51e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg05343316	chr1:45956843	TESK2	-0.41	-5.83	-0.3	1.34e-8	Homocysteine levels;
LUSC	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg20701182	chr2:24300061	SF3B14	0.77	7.73	0.39	1.25e-13	Lymphocyte counts;
LUSC	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg02238051	chr16:1777708	MAPK8IP3	-0.41	-6.32	-0.33	8.31e-10	Bladder cancer;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg21899138	chr3:52720056	GNL3;PBRM1	0.38	6.14	0.32	2.31e-9	Asthma;
LUSC	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg21951975	chr1:209979733	IRF6	0.55	6.97	0.36	1.74e-11	Cleft lip with or without cleft palate;
LUSC	trans	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.41	-0.33	5.05e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	13.53	0.6	1.44e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg09904177	chr6:26538194	HMGN4	0.75	14.04	0.61	1.66e-35	Intelligence (multi-trait analysis);
LUSC	cis	rs7809950	0.635	rs62483629	chr7:106866178	T/C	cg23024343	chr7:107201750	COG5	-0.66	-9.34	-0.46	1.35e-18	Coronary artery disease;
LUSC	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	1.17	13.66	0.6	4.72e-34	Arsenic metabolism;
LUSC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03517284	chr6:25882590	NA	-0.52	-9.66	-0.47	1.25e-19	Blood metabolite levels;
LUSC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg20628663	chr10:43360327	NA	-0.76	-11.24	-0.52	4.48e-25	Blood protein levels;
LUSC	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21643547	chr1:205240462	TMCC2	-0.53	-10.17	-0.49	2.36e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.47	7.8	0.39	7.86e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg17143192	chr8:8559678	CLDN23	0.59	8.58	0.42	3.71e-16	Obesity-related traits;
LUSC	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg15448220	chr1:150897856	SETDB1	0.44	6.43	0.33	4.41e-10	Melanoma;
LUSC	cis	rs472402	0.560	rs2288444	chr5:6619923	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.4	-5.91	-0.31	8.5e-9	Response to amphetamines;
LUSC	cis	rs1775715	0.870	rs10827003	chr10:32266216	A/G	cg04359828	chr10:32216031	ARHGAP12	0.37	6.09	0.32	3.19e-9	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg02380750	chr20:61661411	NA	0.34	5.93	0.31	7.57e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg00531865	chr16:30841666	NA	-0.34	-6.11	-0.32	2.77e-9	Dementia with Lewy bodies;
LUSC	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg15744005	chr10:104629667	AS3MT	-0.29	-6.26	-0.32	1.2e-9	Reticulocyte count;
LUSC	cis	rs981844	1.000	rs62325085	chr4:154663283	A/G	cg14289246	chr4:154710475	SFRP2	0.5	6.44	0.33	4.05e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs7809950	1.000	rs2520264	chr7:107179344	T/C	cg23024343	chr7:107201750	COG5	-0.55	-8.72	-0.43	1.32e-16	Coronary artery disease;
LUSC	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg00376283	chr12:123451042	ABCB9	-0.7	-10.77	-0.51	2.12e-23	Neutrophil percentage of white cells;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg14642671	chr17:48450604	EME1;MRPL27	0.76	6.23	0.32	1.37e-9	Body mass index;
LUSC	cis	rs9807989	0.765	rs6751967	chr2:102967413	T/C	cg09003973	chr2:102972529	NA	0.45	6.19	0.32	1.8e-9	Asthma;
LUSC	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.89	15.83	0.65	1.63e-42	Metabolic syndrome;
LUSC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.99	-0.48	1.01e-20	Hemoglobin concentration;
LUSC	cis	rs61935443	0.666	rs11107781	chr12:95301086	T/A	cg21533806	chr12:95267307	NA	0.49	5.7	0.3	2.63e-8	Schizophrenia;
LUSC	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg23093090	chr10:104574429	C10orf26	-0.45	-8.54	-0.42	4.97e-16	Immature fraction of reticulocytes;Schizophrenia;
LUSC	cis	rs9814567	0.502	rs12634127	chr3:134256159	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-8.36	-0.42	1.71e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06869160	chr12:89919815	GALNT4;WDR51B	-0.4	-6.02	-0.31	4.66e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10992471	0.603	rs10992349	chr9:95233887	T/C	cg14631576	chr9:95140430	CENPP	-0.34	-6.17	-0.32	1.97e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-1.24	-13.61	-0.6	7.06e-34	Diabetic kidney disease;
LUSC	cis	rs12530845	1.000	rs12540688	chr7:135329690	T/C	cg23117316	chr7:135346802	PL-5283	-0.57	-9.85	-0.47	2.84e-20	Red blood cell traits;
LUSC	cis	rs865483	0.895	rs2107104	chr17:35835031	G/A	cg06716730	chr17:35851459	DUSP14	0.27	6.12	0.32	2.59e-9	Monocyte count;
LUSC	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-6.27	-0.32	1.12e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs632111	0.519	rs281380	chr19:49214470	A/G	cg21064579	chr19:49206444	FUT2	-0.33	-5.97	-0.31	6.2e-9	Serum lipase activity;
LUSC	cis	rs6681460	0.649	rs967322	chr1:67003446	C/T	cg02459107	chr1:67143332	SGIP1	0.37	6.18	0.32	1.92e-9	Presence of antiphospholipid antibodies;
LUSC	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg11984989	chr7:158649758	WDR60	1.12	13.33	0.59	8.35e-33	Height;
LUSC	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14442939	chr10:27389572	ANKRD26	0.49	5.85	0.3	1.17e-8	Breast cancer;
LUSC	cis	rs7106204	0.609	rs34237482	chr11:24295932	G/A	ch.11.24196551F	chr11:24239977	NA	0.69	5.68	0.3	2.86e-8	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg22532475	chr10:104410764	TRIM8	-0.32	-7.11	-0.36	6.97e-12	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.75	-0.35	6.5500000000000006e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9443645	0.611	rs10943616	chr6:79823541	G/A	cg05283184	chr6:79620031	NA	-0.43	-8.08	-0.4	1.19e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs55665837	1.000	rs10832268	chr11:14465068	C/A	cg05501817	chr11:14380813	RRAS2	-0.4	-6.54	-0.34	2.3e-10	Vitamin D levels;
LUSC	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg17691542	chr6:26056736	HIST1H1C	0.53	7.38	0.37	1.26e-12	Iron status biomarkers;
LUSC	cis	rs9372498	0.536	rs72952733	chr6:118834452	A/G	cg18833306	chr6:118973337	C6orf204	-0.45	-5.69	-0.3	2.81e-8	Diastolic blood pressure;
LUSC	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg20026190	chr17:76395443	PGS1	0.45	8.17	0.41	6.52e-15	HDL cholesterol levels;
LUSC	cis	rs9534288	0.742	rs7337140	chr13:46641481	C/T	cg15192986	chr13:46630673	CPB2	0.73	11.23	0.52	4.69e-25	Blood protein levels;
LUSC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg11062466	chr8:58055876	NA	0.64	8.44	0.42	1.01e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.99	-0.36	1.53e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg13010199	chr12:38710504	ALG10B	0.42	6.14	0.32	2.38e-9	Morning vs. evening chronotype;
LUSC	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg23306229	chr2:178417860	TTC30B	-0.53	-6.0	-0.31	5.23e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs1788820	0.917	rs1788825	chr18:21109250	T/C	cg14672496	chr18:21087552	C18orf8	0.43	6.8	0.35	4.81e-11	Body mass index;
LUSC	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg22117172	chr7:91764530	CYP51A1	0.32	5.74	0.3	2.17e-8	Breast cancer;
LUSC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2710642	0.821	rs2710639	chr2:63138963	C/T	cg17519650	chr2:63277830	OTX1	0.44	6.08	0.32	3.26e-9	LDL cholesterol levels;LDL cholesterol;
LUSC	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg00757033	chr12:89920650	WDR51B	0.61	10.77	0.51	2.12e-23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg05425664	chr17:57184151	TRIM37	0.56	7.92	0.4	3.48e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg18904891	chr8:8559673	CLDN23	0.6	7.89	0.4	4.36e-14	Obesity-related traits;
LUSC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg06917634	chr15:78832804	PSMA4	0.83	14.9	0.63	7.48e-39	Sudden cardiac arrest;
LUSC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg04727924	chr7:799746	HEATR2	-0.54	-6.71	-0.34	8.46e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg16447950	chr5:562315	NA	-0.55	-6.78	-0.35	5.34e-11	Obesity-related traits;
LUSC	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.83	13.63	0.6	5.96e-34	Bladder cancer;
LUSC	cis	rs73198271	0.603	rs570364	chr8:8593638	G/T	cg01851573	chr8:8652454	MFHAS1	0.4	6.22	0.32	1.52e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs1160297	0.609	rs78310136	chr2:53093171	G/A	cg07782112	chr2:53107842	NA	0.44	7.18	0.37	4.58e-12	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg24596788	chr1:163392923	NA	-0.4	-6.91	-0.35	2.53e-11	Motion sickness;
LUSC	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg26441486	chr22:50317300	CRELD2	-0.55	-8.23	-0.41	4.11e-15	Schizophrenia;
LUSC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-7.0	-0.36	1.4e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg14983838	chr19:29218262	NA	0.66	9.29	0.45	1.98e-18	Methadone dose in opioid dependence;
LUSC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg13319975	chr6:146136371	FBXO30	0.72	11.07	0.52	1.73e-24	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg15309053	chr8:964076	NA	0.34	6.98	0.36	1.62e-11	Schizophrenia;
LUSC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.66	-0.5	4.97e-23	Monocyte count;
LUSC	cis	rs9814567	0.752	rs4955547	chr3:134334975	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-12.49	-0.56	1.24e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14442939	chr10:27389572	ANKRD26	-0.91	-7.98	-0.4	2.36e-14	Breast cancer;
LUSC	cis	rs3739821	0.841	rs943392	chr9:130725441	A/G	cg21181453	chr9:130700954	DPM2	-0.31	-6.3	-0.33	9.15e-10	Glaucoma (primary angle closure);
LUSC	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg22508957	chr16:3507546	NAT15	-0.66	-10.85	-0.51	1.04e-23	Tuberculosis;
LUSC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-6.32	-0.33	8.19e-10	Lung cancer;
LUSC	cis	rs6977660	1.000	rs10260527	chr7:19801930	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	6.36	0.33	6.55e-10	Thyroid stimulating hormone;
LUSC	cis	rs12618769	0.652	rs7588254	chr2:99217785	G/T	cg10123293	chr2:99228465	UNC50	0.43	6.93	0.35	2.19e-11	Bipolar disorder;
LUSC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.69	-10.41	-0.49	3.64e-22	Lymphocyte counts;
LUSC	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.28	-17.59	-0.69	1.83e-49	Hip circumference adjusted for BMI;
LUSC	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg14019146	chr3:50243930	SLC38A3	-0.44	-10.42	-0.5	3.44e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg24375607	chr4:120327624	NA	0.76	12.22	0.56	1.2e-28	Corneal astigmatism;
LUSC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg13453750	chr1:205783389	SLC41A1	-0.33	-6.41	-0.33	5.09e-10	Menarche (age at onset);
LUSC	cis	rs6845621	0.835	rs9995472	chr4:18935997	A/G	cg12196642	chr4:18937545	NA	-0.36	-6.76	-0.35	6.14e-11	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg12560992	chr17:57184187	TRIM37	0.59	9.44	0.46	6.84e-19	Testicular germ cell tumor;
LUSC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg11663144	chr21:46675770	NA	-0.4	-6.81	-0.35	4.49e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26314531	chr2:26401878	FAM59B	-0.46	-5.89	-0.31	9.19e-9	Gut microbiome composition (summer);
LUSC	cis	rs4363385	0.719	rs6587714	chr1:152933023	T/C	cg07796016	chr1:152779584	LCE1C	-0.47	-6.64	-0.34	1.26e-10	Inflammatory skin disease;
LUSC	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg13010344	chr12:123464640	ARL6IP4	-0.43	-5.88	-0.31	9.74e-9	Neutrophil percentage of white cells;
LUSC	trans	rs7818345	0.649	rs13250181	chr8:19328766	G/A	cg07611933	chr16:2773245	NA	-0.23	-6.07	-0.32	3.49e-9	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg13319975	chr6:146136371	FBXO30	0.49	7.34	0.37	1.69e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs911119	0.909	rs3761279	chr20:23620075	C/G	cg16589663	chr20:23618590	CST3	0.6	7.08	0.36	8.36e-12	Chronic kidney disease;
LUSC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg17971929	chr21:40555470	PSMG1	-0.5	-7.35	-0.37	1.51e-12	Menarche (age at onset);
LUSC	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg24375607	chr4:120327624	NA	0.77	12.25	0.56	9.43e-29	Corneal astigmatism;
LUSC	cis	rs6580649	0.883	rs7967762	chr12:48420214	C/T	cg24011408	chr12:48396354	COL2A1	-0.49	-6.57	-0.34	1.89e-10	Lung cancer;
LUSC	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	12.89	0.58	3.95e-31	Bipolar disorder;
LUSC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg18230493	chr5:56204884	C5orf35	0.76	12.7	0.57	1.93e-30	Initial pursuit acceleration;
LUSC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs1577917	0.883	rs6454505	chr6:86592362	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.42	-6.0	-0.31	5.22e-9	Response to antipsychotic treatment;
LUSC	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-6.58	-0.34	1.77e-10	Schizophrenia;
LUSC	cis	rs7210086	0.808	rs3935122	chr17:70641315	C/T	cg04206342	chr17:70636940	NA	-0.39	-6.42	-0.33	4.57e-10	Ulcerative colitis;
LUSC	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg13010199	chr12:38710504	ALG10B	0.53	8.0	0.4	2.12e-14	Morning vs. evening chronotype;
LUSC	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg16342193	chr10:102329863	NA	-0.35	-6.32	-0.33	8.52e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs2348418	0.966	rs7315631	chr12:28698244	A/G	cg13890972	chr12:28721907	NA	-0.34	-5.75	-0.3	2.06e-8	Lung function (FVC);Lung function (FEV1);
LUSC	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg19875535	chr5:140030758	IK	0.37	5.65	0.3	3.38e-8	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	7.05	0.36	1.06e-11	Endometrial cancer;
LUSC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	6.33	0.33	7.9e-10	Mean platelet volume;
LUSC	cis	rs6577655	0.517	rs4909295	chr8:135588042	G/A	cg17885191	chr8:135476712	NA	0.59	7.75	0.39	1.1e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg27170947	chr2:26402098	FAM59B	0.71	10.85	0.51	1.04e-23	Gut microbiome composition (summer);
LUSC	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg03929089	chr4:120376271	NA	0.68	7.43	0.38	9.31e-13	Axial length;
LUSC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg09267113	chr7:98030324	BAIAP2L1	0.39	5.89	0.31	9.58e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.49	-9.64	-0.47	1.48e-19	Paraoxonase activity;
LUSC	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg16386425	chr10:429943	DIP2C	-0.4	-6.08	-0.32	3.29e-9	Psychosis in Alzheimer's disease;
LUSC	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg10434728	chr15:90938212	IQGAP1	-0.44	-9.06	-0.44	1.15e-17	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg23711669	chr6:146136114	FBXO30	0.76	13.55	0.6	1.27e-33	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs2894969	0.664	rs11252703	chr10:4795125	A/T	cg01633858	chr22:43547540	TSPO	0.4	6.04	0.31	4.14e-9	Major depressive disorder;
LUSC	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.61	10.06	0.48	5.62e-21	Height;
LUSC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg10755058	chr3:40428713	ENTPD3	0.35	5.85	0.3	1.17e-8	Renal cell carcinoma;
LUSC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg24531977	chr5:56204891	C5orf35	-0.69	-10.2	-0.49	1.92e-21	Coronary artery disease;
LUSC	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.18	0.49	2.21e-21	Lymphocyte counts;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg18578119	chr4:1236638	CTBP1	-0.69	-6.73	-0.35	7.52e-11	Cognitive performance;
LUSC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	0.92	17.56	0.69	2.35e-49	Heart rate;
LUSC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg13531842	chr10:38383804	ZNF37A	-0.47	-7.39	-0.37	1.2e-12	Extrinsic epigenetic age acceleration;
LUSC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.7	-10.66	-0.5	5e-23	Aortic root size;
LUSC	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg19773385	chr1:10388646	KIF1B	-0.6	-10.29	-0.49	9.18e-22	Hepatocellular carcinoma;
LUSC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.9	-16.82	-0.68	1.99e-46	Menarche (age at onset);
LUSC	trans	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg18187862	chr3:45730750	SACM1L	-0.53	-6.42	-0.33	4.73e-10	Primary sclerosing cholangitis;
LUSC	cis	rs2637266	0.935	rs2579775	chr10:78401677	G/A	cg18941641	chr10:78392320	NA	0.42	7.67	0.39	1.94e-13	Pulmonary function;
LUSC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg13939156	chr17:80058883	NA	0.33	6.47	0.33	3.45e-10	Life satisfaction;
LUSC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg04775059	chr7:64541387	NA	-0.45	-5.67	-0.3	3.13e-8	Aortic root size;
LUSC	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-6.36	-0.33	6.69e-10	Response to antipsychotic treatment;
LUSC	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg01065977	chr19:18549689	ISYNA1	-0.24	-6.07	-0.32	3.45e-9	Breast cancer;
LUSC	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg00898013	chr13:113819073	PROZ	0.53	7.91	0.4	3.72e-14	Platelet distribution width;
LUSC	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg15704280	chr7:45808275	SEPT13	-0.81	-11.29	-0.53	2.88e-25	Coronary artery disease;
LUSC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18252515	chr7:66147081	NA	0.39	5.66	0.3	3.22e-8	Aortic root size;
LUSC	cis	rs925550	0.932	rs6844999	chr4:123581235	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.57	-5.69	-0.3	2.71e-8	Primary biliary cholangitis;
LUSC	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg10167378	chr1:228756711	NA	0.76	10.12	0.48	3.68e-21	Chronic lymphocytic leukemia;
LUSC	cis	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05901451	chr6:126070800	HEY2	-0.58	-8.78	-0.43	8.6e-17	Endometrial cancer;
LUSC	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg07169764	chr2:136633963	MCM6	1.18	17.35	0.69	1.61e-48	Corneal structure;
LUSC	cis	rs34115320	1	rs34115320	chr7:148783936	CT/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	7.25	0.37	3.01e-12	Sum basophil neutrophil counts;Neutrophil count;
LUSC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg20307385	chr11:47447363	PSMC3	0.45	5.82	0.3	1.37e-8	Subjective well-being;
LUSC	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg04117972	chr1:227635322	NA	0.62	7.06	0.36	9.84e-12	Major depressive disorder;
LUSC	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.6	-0.34	1.59e-10	Retinal vascular caliber;
LUSC	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg24060327	chr5:131705240	SLC22A5	-0.38	-6.22	-0.32	1.49e-9	Blood metabolite levels;
LUSC	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg12863693	chr15:85201151	NMB	0.33	6.28	0.32	1.05e-9	Schizophrenia;
LUSC	cis	rs1707322	0.613	rs1473840	chr1:46601197	A/G	cg06784218	chr1:46089804	CCDC17	-0.39	-7.14	-0.36	5.75e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg11663144	chr21:46675770	NA	-0.41	-7.14	-0.36	5.77e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs6484504	0.532	rs2150212	chr11:31255935	G/A	cg14844989	chr11:31128820	NA	-0.39	-6.02	-0.31	4.6e-9	Red blood cell count;
LUSC	cis	rs9905704	0.671	rs2531737	chr17:56554357	A/G	cg19466818	chr17:56409534	MIR142	0.35	6.5	0.34	2.94e-10	Testicular germ cell tumor;
LUSC	cis	rs35123781	1.000	rs682164	chr5:139058589	A/G	cg10513866	chr5:139070639	NA	0.45	9.05	0.44	1.21e-17	Schizophrenia;
LUSC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	0.99	13.92	0.61	4.89e-35	Vitiligo;
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg02592596	chr15:30919014	ARHGAP11B	0.35	6.14	0.32	2.28e-9	Tuberculosis;
LUSC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.64	-14.98	-0.63	3.73e-39	Prostate cancer;
LUSC	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg27087555	chr16:88793112	FAM38A	-1.47	-14.65	-0.63	7.21e-38	Plateletcrit;
LUSC	cis	rs4566357	1.000	rs6436649	chr2:227923952	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.9	-0.31	8.79e-9	Coronary artery disease;
LUSC	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.2	-0.32	1.63e-9	Resting heart rate;
LUSC	cis	rs7241530	0.662	rs12961616	chr18:75908142	T/G	cg14642773	chr18:75888474	NA	0.39	5.74	0.3	2.17e-8	Educational attainment (years of education);
LUSC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg05347473	chr6:146136440	FBXO30	0.47	7.61	0.38	2.88e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08280861	chr8:58055591	NA	0.55	6.46	0.33	3.69e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs72700829	0.593	rs77209899	chr1:150992019	G/A	cg11822372	chr1:151115635	SEMA6C	-0.74	-6.77	-0.35	5.98e-11	Schizophrenia;
LUSC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	22.79	0.78	5.28e-70	Height;
LUSC	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg03647239	chr10:116582469	FAM160B1	0.45	7.21	0.37	3.81e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-9.43	-0.46	6.88e-19	Gut microbiome composition (summer);
LUSC	cis	rs9815354	0.812	rs73069292	chr3:41973963	T/C	cg03022575	chr3:42003672	ULK4	0.85	8.85	0.44	5.2e-17	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg00564555	chr16:1970112	NA	0.38	6.47	0.33	3.47e-10	Glomerular filtration rate in chronic kidney disease;
LUSC	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg14092571	chr14:90743983	NA	-0.34	-5.66	-0.3	3.19e-8	Mortality in heart failure;
LUSC	cis	rs752010	0.841	rs17363834	chr1:42076607	C/T	cg06885757	chr1:42089581	HIVEP3	0.41	8.4	0.42	1.26e-15	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.03	0.4	1.66e-14	Prudent dietary pattern;
LUSC	cis	rs12519773	0.905	rs13177386	chr5:92443605	A/C	cg18783429	chr5:92414398	NA	0.28	5.95	0.31	6.86e-9	Migraine;
LUSC	cis	rs68170813	0.559	rs7783181	chr7:106977613	A/G	cg02696742	chr7:106810147	HBP1	-0.63	-9.52	-0.46	3.74e-19	Coronary artery disease;
LUSC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg02782426	chr3:40428986	ENTPD3	0.37	7.09	0.36	8.04e-12	Renal cell carcinoma;
LUSC	trans	rs9944715	0.954	rs7231820	chr18:43823431	G/A	cg01718231	chr17:29326311	RNF135	-0.5	-7.07	-0.36	9.28e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg23711669	chr6:146136114	FBXO30	0.88	16.1	0.66	1.48e-43	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg06636001	chr8:8085503	FLJ10661	0.55	8.11	0.41	1e-14	Retinal vascular caliber;
LUSC	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg10978503	chr1:24200527	CNR2	0.54	13.24	0.59	1.85e-32	Immature fraction of reticulocytes;
LUSC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg19678392	chr7:94953810	PON1	-0.36	-5.65	-0.3	3.47e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg06207120	chr15:45996521	NA	0.39	6.04	0.31	4.12e-9	Waist circumference;Weight;
LUSC	cis	rs977987	0.586	rs12920883	chr16:75432681	T/C	cg04384234	chr16:75411784	CFDP1	-0.43	-6.9	-0.35	2.55e-11	Dupuytren's disease;
LUSC	cis	rs10779751	0.762	rs6671083	chr1:11325910	A/G	cg08854313	chr1:11322531	MTOR	-0.69	-11.9	-0.55	1.85e-27	Body mass index;
LUSC	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg24296786	chr1:45957014	TESK2	-0.41	-5.81	-0.3	1.47e-8	Red blood cell count;Reticulocyte count;
LUSC	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg20587970	chr11:113659929	NA	-1.03	-13.81	-0.6	1.22e-34	Hip circumference adjusted for BMI;
LUSC	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg18478394	chr8:109455254	TTC35	0.46	7.12	0.36	6.76e-12	Dupuytren's disease;
LUSC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg23711669	chr6:146136114	FBXO30	0.74	11.45	0.53	7.84e-26	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg07936489	chr17:37558343	FBXL20	0.73	10.27	0.49	1.12e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-0.96	-14.15	-0.61	5.98e-36	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg08975724	chr8:8085496	FLJ10661	-0.39	-5.65	-0.3	3.44e-8	Joint mobility (Beighton score);
LUSC	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg05425664	chr17:57184151	TRIM37	-0.48	-7.14	-0.36	5.87e-12	Testicular germ cell tumor;
LUSC	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg17480646	chr11:65405466	SIPA1	-0.46	-5.94	-0.31	7.01e-9	Acne (severe);
LUSC	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13126279	chr21:47581558	C21orf56	-0.53	-8.1	-0.41	1.03e-14	Testicular germ cell tumor;
LUSC	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg03647239	chr10:116582469	FAM160B1	-0.44	-7.08	-0.36	8.61e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg11344533	chr11:111475393	SIK2	-0.46	-6.35	-0.33	6.87e-10	Primary sclerosing cholangitis;
LUSC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	13.94	0.61	4.03e-35	Platelet count;
LUSC	trans	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.09	-0.36	8.24e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg06521331	chr12:34319734	NA	-0.47	-7.58	-0.38	3.42e-13	Morning vs. evening chronotype;
LUSC	cis	rs10419226	0.541	rs11883401	chr19:18791768	C/G	cg22001208	chr19:18782374	NA	-0.38	-6.45	-0.33	3.85e-10	Barrett's esophagus;Esophageal adenocarcinoma;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg06484146	chr7:12443880	VWDE	-0.68	-7.23	-0.37	3.41e-12	Coronary artery disease;
LUSC	cis	rs662735	0.515	rs686901	chr11:30854334	C/G	cg06552810	chr11:31128660	NA	0.33	5.84	0.3	1.27e-8	Hemoglobin concentration;Hematocrit;
LUSC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg14552801	chr7:65878734	NA	-0.45	-6.34	-0.33	7.34e-10	Aortic root size;
LUSC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24531977	chr5:56204891	C5orf35	0.86	13.85	0.6	8.6e-35	Initial pursuit acceleration;
LUSC	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg01483505	chr11:975446	AP2A2	0.41	5.7	0.3	2.58e-8	Alzheimer's disease (late onset);
LUSC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg26441486	chr22:50317300	CRELD2	-0.47	-7.18	-0.37	4.69e-12	Schizophrenia;
LUSC	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg24375607	chr4:120327624	NA	0.7	11.2	0.52	6.37e-25	Corneal astigmatism;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg20152424	chr11:576455	PHRF1;LOC143666	-0.41	-5.99	-0.31	5.55e-9	Hepatitis;
LUSC	cis	rs11630290	0.592	rs4777332	chr15:64158112	A/G	cg12036633	chr15:63758958	NA	0.53	6.73	0.35	7.35e-11	Iris characteristics;
LUSC	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg22980127	chr19:33182716	NUDT19	0.94	12.81	0.57	7.79e-31	Red blood cell traits;
LUSC	trans	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.78	0.47	4.84e-20	Mean corpuscular volume;
LUSC	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg17845761	chr1:175162550	KIAA0040	-0.31	-6.0	-0.31	5.07e-9	Alcohol dependence;
LUSC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.86	-14.09	-0.61	1.09e-35	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs2172802	0.659	rs4484334	chr4:62499841	C/T	cg04118610	chr4:62707027	LPHN3	0.45	6.17	0.32	1.94e-9	Partial epilepsies;
LUSC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.53	-10.38	-0.49	4.57e-22	Asthma (sex interaction);
LUSC	cis	rs11229555	0.645	rs10896774	chr11:58175837	T/G	cg15696309	chr11:58395628	NA	-0.63	-7.83	-0.39	6.48e-14	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg11965913	chr1:205819406	PM20D1	0.52	8.8	0.43	7.35e-17	Menarche (age at onset);
LUSC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.61	9.92	0.48	1.68e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-0.72	-12.16	-0.55	2e-28	Height;
LUSC	cis	rs9361491	0.510	rs1507151	chr6:79483246	T/C	cg05283184	chr6:79620031	NA	-0.45	-8.15	-0.41	7.42e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg19592336	chr6:28129416	ZNF389	0.53	7.05	0.36	1.02e-11	Parkinson's disease;
LUSC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg12165864	chr7:66369176	NA	-0.51	-6.89	-0.35	2.79e-11	Corneal structure;
LUSC	cis	rs4595586	0.870	rs2388172	chr12:39290539	A/G	cg10518543	chr12:38710700	ALG10B	0.41	5.72	0.3	2.43e-8	Morning vs. evening chronotype;
LUSC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-5.88	-0.31	9.73e-9	Extrinsic epigenetic age acceleration;
LUSC	trans	rs4596713	0.568	rs7850573	chr9:71747260	C/T	cg25283916	chr1:242222868	NA	-0.31	-6.37	-0.33	6.34e-10	Headache;
LUSC	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.67	11.45	0.53	7.91e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg04374321	chr14:90722782	PSMC1	-0.75	-11.86	-0.54	2.48e-27	Mortality in heart failure;
LUSC	cis	rs11051970	0.918	rs76930558	chr12:32538839	A/C	cg24626660	chr12:32551988	NA	0.38	6.07	0.32	3.43e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7119167	0.901	rs73542998	chr11:73148498	A/G	cg17517138	chr11:73019481	ARHGEF17	0.49	5.72	0.3	2.33e-8	Blood protein levels;
LUSC	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg09365446	chr1:150670422	GOLPH3L	0.47	7.01	0.36	1.33e-11	Melanoma;
LUSC	cis	rs1712517	0.904	rs4918007	chr10:105107470	G/A	cg05636881	chr10:105038444	INA	-0.38	-6.35	-0.33	6.94e-10	Migraine;
LUSC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.62	-10.33	-0.49	6.99e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg20368463	chr18:77673604	PQLC1	-0.7	-7.52	-0.38	5.12e-13	Opioid sensitivity;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16322893	chr3:107809956	CD47	-0.46	-6.82	-0.35	4.19e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9392556	0.829	rs660560	chr6:4125941	A/G	cg08342332	chr6:4079704	C6orf201;C6orf146	-0.38	-6.41	-0.33	5.08e-10	Blood metabolite levels;
LUSC	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	0.88	13.06	0.58	9.12e-32	Blood protein levels;
LUSC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.48	7.53	0.38	4.72e-13	Menarche (age at onset);
LUSC	cis	rs16949788	0.793	rs78198355	chr15:66685808	C/T	cg08120210	chr15:66682733	MAP2K1	-0.6	-5.94	-0.31	7.18e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs921665	0.681	rs6548169	chr2:3183752	A/G	cg16434511	chr2:3151078	NA	-0.62	-5.98	-0.31	5.74e-9	World class endurance athleticism;
LUSC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	13.3	0.59	1.08e-32	Multiple sclerosis;
LUSC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07362569	chr17:61921086	SMARCD2	0.38	7.82	0.39	7.02e-14	Prudent dietary pattern;
LUSC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg26380479	chr7:97908229	NA	-0.26	-5.8	-0.3	1.58e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4285028	0.747	rs9852845	chr3:121390618	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.91	-12.81	-0.57	8.07e-31	Multiple sclerosis;
LUSC	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-8.45	-0.42	9.09e-16	Total body bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg26578400	chr12:132413450	PUS1	-0.39	-6.08	-0.32	3.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1395	0.778	rs11693001	chr2:27412744	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.2	0.37	4.12e-12	Blood metabolite levels;
LUSC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.81	13.59	0.6	8.62e-34	Aortic root size;
LUSC	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg22139774	chr2:100720529	AFF3	0.51	9.09	0.45	9.16e-18	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9818941	0.824	rs2712320	chr3:157770116	A/G	cg08654915	chr3:157813417	NA	-0.33	-7.58	-0.38	3.39e-13	Height;
LUSC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg21733973	chr7:65235735	NA	0.4	5.71	0.3	2.45e-8	Calcium levels;
LUSC	trans	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg06606381	chr12:133084897	FBRSL1	-0.51	-5.97	-0.31	5.95e-9	Lung cancer in ever smokers;
LUSC	cis	rs1007190	0.881	rs12937256	chr17:42981499	C/T	cg15406952	chr17:42872593	NA	0.58	5.86	0.31	1.08e-8	DNA methylation (variation);
LUSC	cis	rs870825	0.929	rs10027213	chr4:185579871	C/G	cg04058563	chr4:185651563	MLF1IP	0.82	11.48	0.53	6.36e-26	Blood protein levels;
LUSC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg00343986	chr7:65444356	GUSB	0.45	6.88	0.35	3e-11	Aortic root size;
LUSC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.67	11.41	0.53	1.14e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	6.31	0.33	8.94e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg24675658	chr1:53192096	ZYG11B	0.57	9.15	0.45	5.61e-18	Monocyte count;
LUSC	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-1.03	-14.3	-0.62	1.68e-36	Exhaled nitric oxide output;
LUSC	trans	rs2018683	0.899	rs10269454	chr7:28978400	C/T	cg19402173	chr7:128379420	CALU	-0.55	-8.85	-0.44	5.05e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg20398880	chr6:41068722	NFYA;LOC221442	-0.39	-6.06	-0.31	3.67e-9	Alzheimer's disease (late onset);
LUSC	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg17691542	chr6:26056736	HIST1H1C	0.45	6.85	0.35	3.49e-11	Height;
LUSC	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg11941060	chr3:133502564	NA	0.46	7.25	0.37	2.91e-12	Iron status biomarkers;
LUSC	cis	rs9815354	0.767	rs17281182	chr3:41817263	C/T	cg03022575	chr3:42003672	ULK4	0.85	8.67	0.43	1.87e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg27499820	chr13:21296301	IL17D	-0.3	-5.76	-0.3	1.92e-8	Dental caries;
LUSC	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.99	-0.31	5.56e-9	Type 2 diabetes;
LUSC	cis	rs2274273	1.000	rs61508494	chr14:55587297	T/C	cg04306507	chr14:55594613	LGALS3	0.55	12.78	0.57	1.0500000000000001e-30	Protein biomarker;
LUSC	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.6	13.63	0.6	6e-34	Height;
LUSC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg21890820	chr11:65308645	LTBP3	1.41	9.74	0.47	6.65e-20	Height;
LUSC	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg00750074	chr16:89608354	SPG7	-0.46	-7.87	-0.4	4.95e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.54	8.28	0.41	2.99e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs12410462	0.581	rs75219436	chr1:227546617	C/T	cg23173402	chr1:227635558	NA	0.55	6.39	0.33	5.42e-10	Major depressive disorder;
LUSC	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.45	-6.25	-0.32	1.23e-9	Reticulocyte count;
LUSC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg24375607	chr4:120327624	NA	0.79	11.83	0.54	3.33e-27	Corneal astigmatism;
LUSC	cis	rs60154123	0.772	rs664072	chr1:210422160	G/A	cg22029157	chr1:209979665	IRF6	0.64	6.46	0.33	3.73e-10	Coronary artery disease;
LUSC	trans	rs12478296	0.515	rs13412492	chr2:243000583	T/G	cg01596870	chr19:55963115	NA	-0.53	-6.86	-0.35	3.44e-11	Obesity-related traits;
LUSC	cis	rs13394619	1.000	rs2358040	chr2:11731774	G/T	cg07314298	chr2:11723111	GREB1	0.56	10.07	0.48	5.43e-21	Endometriosis;
LUSC	cis	rs11018904	0.906	rs12793836	chr11:89953493	C/T	cg26028595	chr11:89956573	CHORDC1	-0.52	-6.1	-0.32	2.96e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg03806693	chr22:41940476	POLR3H	0.85	12.22	0.56	1.25e-28	Vitiligo;
LUSC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	0.84	14.22	0.61	3.22e-36	Menopause (age at onset);
LUSC	cis	rs977987	0.872	rs4243111	chr16:75320827	C/T	cg04384234	chr16:75411784	CFDP1	-0.4	-6.52	-0.34	2.56e-10	Dupuytren's disease;
LUSC	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg00677455	chr12:58241039	CTDSP2	0.62	8.72	0.43	1.31e-16	Multiple sclerosis;
LUSC	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg05855489	chr10:104503620	C10orf26	-0.69	-9.87	-0.48	2.54e-20	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg19318889	chr4:1322082	MAEA	0.47	7.67	0.39	1.93e-13	Obesity-related traits;
LUSC	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg24324837	chr19:49891574	CCDC155	0.49	7.03	0.36	1.17e-11	Multiple sclerosis;
LUSC	cis	rs6463523	0.933	rs79984239	chr7:766220	A/G	cg14391382	chr7:866102	UNC84A	0.47	7.15	0.36	5.63e-12	Subjective well-being;
LUSC	cis	rs7178572	0.568	rs1446312	chr15:77412189	G/C	cg22256960	chr15:77711686	NA	-0.52	-8.1	-0.41	1.01e-14	Type 2 diabetes;
LUSC	cis	rs909341	0.710	rs6010998	chr20:62294402	A/T	cg09650180	chr20:62225654	GMEB2	0.45	5.83	0.3	1.33e-8	Atopic dermatitis;
LUSC	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg22491629	chr6:157744540	C6orf35	-0.84	-10.03	-0.48	7.07e-21	Hemostatic factors and hematological phenotypes;
LUSC	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg15704280	chr7:45808275	SEPT13	0.7	6.69	0.34	9.51e-11	Axial length;
LUSC	cis	rs8040855	0.599	rs8037195	chr15:85724686	G/A	cg04831495	chr15:85060580	GOLGA6L5	0.41	6.85	0.35	3.66e-11	Bulimia nervosa;
LUSC	trans	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg21051086	chr3:73046214	PPP4R2	-0.52	-7.95	-0.4	2.84e-14	Pancreatic cancer;
LUSC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06634786	chr22:41940651	POLR3H	0.49	5.76	0.3	1.91e-8	Vitiligo;
LUSC	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg11693508	chr17:37793320	STARD3	0.62	7.62	0.38	2.57e-13	Bipolar disorder;
LUSC	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg24596788	chr1:163392923	NA	-0.45	-7.62	-0.38	2.6e-13	Motion sickness;
LUSC	cis	rs16854884	0.586	rs7634145	chr3:143754150	G/A	cg06585982	chr3:143692056	C3orf58	0.52	8.27	0.41	3.23e-15	Economic and political preferences (feminism/equality);
LUSC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg12257692	chr3:49977190	RBM6	-0.26	-7.34	-0.37	1.68e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg05729581	chr11:3078854	CARS	-0.51	-7.82	-0.39	6.88e-14	Longevity;
LUSC	cis	rs76793172	1.000	rs77461667	chr19:46341177	G/A	cg27118825	chr19:46318748	RSPH6A;SYMPK	0.46	5.83	0.3	1.32e-8	Eosinophil counts;
LUSC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg06387496	chr7:2775674	GNA12	-0.37	-5.71	-0.3	2.52e-8	Height;
LUSC	cis	rs7246967	0.673	rs56725192	chr19:22810938	T/G	cg23217946	chr19:22817039	ZNF492	0.45	6.33	0.33	7.68e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg11764359	chr7:65958608	NA	-0.59	-8.19	-0.41	5.72e-15	Aortic root size;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg02155262	chr4:178363707	AGA	0.41	6.26	0.32	1.18e-9	Schizophrenia;
LUSC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.72	12.12	0.55	2.87e-28	Motion sickness;
LUSC	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-8.98	-0.44	2.04e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg13072238	chr3:49761600	GMPPB	0.36	5.9	0.31	8.96e-9	Body mass index;
LUSC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.09	0.45	8.99e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4845459	0.967	rs4845454	chr1:152592184	C/T	cg08895932	chr1:152778580	LCE1C	-0.38	-6.48	-0.33	3.31e-10	Psoriasis;
LUSC	cis	rs6961069	0.743	rs3211885	chr7:80289402	C/T	cg04458919	chr7:80252533	CD36	-0.33	-5.91	-0.31	8.23e-9	Platelet count;
LUSC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.7	-12.14	-0.55	2.41e-28	Dental caries;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14045140	chr9:95432176	IPPK	-0.5	-6.67	-0.34	1.04e-10	Hepatitis;
LUSC	cis	rs2267681	0.544	rs1990354	chr7:139523858	A/G	cg14116596	chr7:139528673	TBXAS1	0.36	6.38	0.33	5.8e-10	Cervical cancer;
LUSC	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg04374321	chr14:90722782	PSMC1	-0.43	-6.51	-0.34	2.72e-10	Mortality in heart failure;
LUSC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg21782813	chr7:2030301	MAD1L1	0.47	7.89	0.4	4.23e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs2637266	1.000	rs3923670	chr10:78375001	C/G	cg18941641	chr10:78392320	NA	0.38	6.94	0.36	2.04e-11	Pulmonary function;
LUSC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg07777115	chr5:623756	CEP72	-0.44	-5.65	-0.3	3.47e-8	Obesity-related traits;
LUSC	cis	rs1395	0.922	rs6547521	chr2:27488432	G/C	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.39	6.32	0.33	8.22e-10	Blood metabolite levels;
LUSC	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg00376283	chr12:123451042	ABCB9	-0.65	-7.67	-0.39	1.91e-13	Neutrophil percentage of white cells;
LUSC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.74	-13.33	-0.59	8.5e-33	Intelligence (multi-trait analysis);
LUSC	cis	rs1534166	1.000	rs1534166	chr3:133537067	C/T	cg01448562	chr3:133502909	NA	-0.5	-7.28	-0.37	2.4e-12	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg02269571	chr22:50332266	NA	-0.56	-8.36	-0.42	1.72e-15	Schizophrenia;
LUSC	cis	rs259282	0.669	rs731673	chr19:33132295	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.7	11.05	0.52	2.18e-24	Schizophrenia;
LUSC	cis	rs727505	1.000	rs722560	chr7:124488035	T/C	cg23710748	chr7:124431027	NA	-0.42	-7.46	-0.38	7.65e-13	Lewy body disease;
LUSC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg13206674	chr6:150067644	NUP43	0.58	9.49	0.46	4.56e-19	Lung cancer;
LUSC	cis	rs2224391	1.000	rs2753249	chr6:5263475	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.46	-6.61	-0.34	1.55e-10	Height;
LUSC	cis	rs11608355	0.545	rs7316375	chr12:109906998	G/C	cg05360138	chr12:110035743	NA	0.9	11.57	0.53	2.97e-26	Neuroticism;
LUSC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg00310523	chr12:86230176	RASSF9	0.54	10.05	0.48	5.93e-21	Major depressive disorder;
LUSC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg00343986	chr7:65444356	GUSB	0.44	6.68	0.34	9.96e-11	Aortic root size;
LUSC	trans	rs9944715	0.954	rs62096523	chr18:43737966	T/A	cg01718231	chr17:29326311	RNF135	0.48	6.83	0.35	4.1e-11	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg24060327	chr5:131705240	SLC22A5	0.4	6.68	0.34	1.01e-10	Blood metabolite levels;
LUSC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	7.08	0.36	8.46e-12	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg24250549	chr1:154909240	PMVK	0.63	10.14	0.49	3.15e-21	Prostate cancer;
LUSC	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg14993813	chr1:46806288	NSUN4	-0.52	-7.32	-0.37	1.82e-12	Menopause (age at onset);
LUSC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg08888203	chr3:10149979	C3orf24	0.67	9.36	0.46	1.21e-18	Alzheimer's disease;
LUSC	trans	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.08	-0.44	9.93e-18	Depression;
LUSC	cis	rs6543140	0.964	rs4851592	chr2:103087641	C/T	cg09003973	chr2:102972529	NA	0.52	6.57	0.34	1.9e-10	Blood protein levels;
LUSC	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg07148914	chr20:33460835	GGT7	0.56	8.34	0.42	1.99e-15	Height;
LUSC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg23711669	chr6:146136114	FBXO30	0.76	13.58	0.6	9.4e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg25173405	chr17:45401733	C17orf57	0.36	5.73	0.3	2.26e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg14092988	chr3:52407081	DNAH1	0.32	6.25	0.32	1.27e-9	Bipolar disorder;
LUSC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-8.16	-0.41	6.78e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs80130819	0.515	rs7315258	chr12:48572670	T/C	cg24011408	chr12:48396354	COL2A1	0.48	6.57	0.34	1.96e-10	Prostate cancer;
LUSC	cis	rs3126085	0.825	rs7535078	chr1:152222915	T/C	cg03465714	chr1:152285911	FLG	-0.41	-5.79	-0.3	1.64e-8	Atopic dermatitis;
LUSC	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg03676636	chr4:99064102	C4orf37	0.34	7.33	0.37	1.73e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	0.8	14.27	0.62	2.18e-36	Cognitive function;
LUSC	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg08999081	chr20:33150536	PIGU	0.46	8.3	0.41	2.52e-15	Coronary artery disease;
LUSC	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-6.88	-0.35	2.89e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg13939156	chr17:80058883	NA	0.33	6.48	0.33	3.3e-10	Life satisfaction;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06116271	chr12:120906938	DYNLL1;SFRS9	0.42	6.14	0.32	2.39e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17467752	chr17:38218738	THRA	0.75	11.81	0.54	3.96e-27	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-6.45	-0.33	3.97e-10	Recombination measurement;
LUSC	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg03371404	chr2:241525653	CAPN10	-0.41	-5.87	-0.31	1.06e-8	Bipolar disorder;
LUSC	trans	rs7657257	1.000	rs10516290	chr4:15732456	T/C	cg17675199	chr6:35436792	RPL10A	-0.83	-6.11	-0.32	2.84e-9	Blood protein levels;
LUSC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-13.61	-0.6	7.18e-34	Hemoglobin concentration;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10484450	chr14:67982152	TMEM229B	0.44	6.29	0.33	9.77e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.99	0.44	1.84e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs57046232	0.552	rs1998971	chr20:6334912	G/A	cg21095983	chr6:86352623	SYNCRIP	0.47	7.08	0.36	8.33e-12	Colorectal cancer;
LUSC	cis	rs12900413	0.687	rs35562959	chr15:90310537	C/T	cg24249390	chr15:90295951	MESP1	-0.37	-5.91	-0.31	8.6e-9	Coronary artery aneurysm in Kawasaki disease;
LUSC	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg21573476	chr21:45109991	RRP1B	-0.37	-5.97	-0.31	5.94e-9	Mean corpuscular volume;
LUSC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg06454157	chr6:167490870	NA	-0.26	-6.1	-0.32	2.86e-9	Crohn's disease;
LUSC	cis	rs4692589	0.531	rs12650424	chr4:170975204	T/C	cg19918862	chr4:170955249	NA	0.38	6.74	0.35	6.91e-11	Anxiety disorder;
LUSC	cis	rs10266483	0.739	rs679966	chr7:63767066	C/T	cg24201672	chr7:64023550	ZNF680	-0.49	-6.56	-0.34	2.03e-10	Response to statin therapy;
LUSC	cis	rs4253772	0.938	rs45550937	chr22:46638128	C/G	cg09491104	chr22:46646882	C22orf40	-0.59	-6.48	-0.33	3.23e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.72	-0.35	7.84e-11	Response to antipsychotic treatment;
LUSC	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg16342193	chr10:102329863	NA	0.39	6.73	0.35	7.23e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg10434728	chr15:90938212	IQGAP1	-0.4	-8.34	-0.42	1.95e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.71	-0.3	2.47e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10802521	chr3:52805072	NEK4	-0.47	-6.79	-0.35	5.23e-11	Bipolar disorder;
LUSC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24110177	chr3:50126178	RBM5	0.56	9.15	0.45	5.78e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-6.4	-0.33	5.2e-10	Waist circumference;Hip circumference;
LUSC	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg25214090	chr10:38739885	LOC399744	0.56	8.06	0.4	1.33e-14	Corneal astigmatism;
LUSC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg16434002	chr17:42200994	HDAC5	0.44	5.95	0.31	6.85e-9	Total body bone mineral density;
LUSC	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg12292205	chr6:26970375	C6orf41	-0.6	-7.39	-0.37	1.17e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs7588746	0.621	rs10497859	chr2:201144446	G/A	cg23649088	chr2:200775458	C2orf69	-0.41	-5.86	-0.31	1.13e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
LUSC	cis	rs3106136	0.527	rs4693376	chr4:95157240	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.03	-0.4	1.71e-14	Capecitabine sensitivity;
LUSC	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg04691961	chr3:161091175	C3orf57	-0.35	-6.11	-0.32	2.74e-9	Morning vs. evening chronotype;
LUSC	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg25173405	chr17:45401733	C17orf57	-0.38	-6.12	-0.32	2.6e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg08601574	chr20:25228251	PYGB	0.38	5.68	0.3	2.88e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-10.76	-0.51	2.14e-23	Eye color traits;
LUSC	cis	rs28830936	1.000	rs4923905	chr15:41909889	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.28	-6.31	-0.33	8.93e-10	Diastolic blood pressure;
LUSC	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg02569458	chr12:86230093	RASSF9	0.38	6.07	0.32	3.45e-9	Major depressive disorder;
LUSC	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg17788362	chr6:86352627	SYNCRIP	0.45	6.48	0.33	3.31e-10	Smooth-surface caries;
LUSC	cis	rs10979	1.000	rs12215667	chr6:143893213	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-12.13	-0.55	2.58e-28	Hypospadias;
LUSC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg12419862	chr22:24373484	LOC391322	-1.02	-19.51	-0.73	4.07e-57	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg24692254	chr21:30365293	RNF160	-0.72	-11.11	-0.52	1.29e-24	Pancreatic cancer;
LUSC	cis	rs2290159	0.948	rs7956	chr3:12624763	C/T	cg23032965	chr3:12705835	RAF1	-0.54	-7.04	-0.36	1.12e-11	Cholesterol, total;
LUSC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.38	5.83	0.3	1.29e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg00945038	chr17:61921165	SMARCD2	0.39	5.8	0.3	1.56e-8	Hip circumference adjusted for BMI;Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21809942	chr18:45456743	SMAD2	0.47	6.24	0.32	1.35e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.52	-11.46	-0.53	7.4e-26	Height;
LUSC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.6	8.54	0.42	4.71e-16	Diastolic blood pressure;
LUSC	cis	rs981844	0.885	rs62325082	chr4:154661274	A/G	cg14289246	chr4:154710475	SFRP2	0.5	6.44	0.33	4.05e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg03676636	chr4:99064102	C4orf37	0.34	7.46	0.38	7.58e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg01448562	chr3:133502909	NA	0.65	10.41	0.49	3.69e-22	Iron status biomarkers;
LUSC	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	0.48	6.39	0.33	5.42e-10	Corneal astigmatism;
LUSC	trans	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg10756647	chr7:56101905	PSPH	0.87	8.68	0.43	1.74e-16	Diabetic kidney disease;
LUSC	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg11062466	chr8:58055876	NA	0.59	7.34	0.37	1.65e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg13030586	chr4:186347098	UFSP2	0.83	6.75	0.35	6.6e-11	Cognitive performance;
LUSC	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.68	-0.6	3.86e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08470875	chr2:26401718	FAM59B	-0.72	-9.9	-0.48	1.91e-20	Gut microbiome composition (summer);
LUSC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg22166914	chr1:53195759	ZYG11B	-0.4	-5.92	-0.31	8.17e-9	Monocyte count;
LUSC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg25251562	chr2:3704773	ALLC	-0.71	-10.96	-0.51	4.38e-24	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	trans	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg06521331	chr12:34319734	NA	0.41	6.57	0.34	1.99e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg23034840	chr1:205782522	SLC41A1	0.69	9.76	0.47	5.75e-20	Prostate-specific antigen levels;
LUSC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg11062466	chr8:58055876	NA	0.7	8.6	0.43	3.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg07153921	chr17:41440717	NA	-0.39	-5.75	-0.3	2.02e-8	Menopause (age at onset);
LUSC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg25566285	chr7:158114605	PTPRN2	0.31	5.85	0.3	1.2e-8	Calcium levels;
LUSC	trans	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.54	-0.34	2.37e-10	Monocyte count;
LUSC	cis	rs9815354	0.812	rs12108049	chr3:41958161	A/G	cg03022575	chr3:42003672	ULK4	0.83	8.69	0.43	1.66e-16	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg01438892	chr2:61108274	REL	-0.43	-6.58	-0.34	1.83e-10	Monocyte count;
LUSC	cis	rs7617773	0.817	rs11130163	chr3:48312658	T/C	cg11946769	chr3:48343235	NME6	0.75	11.45	0.53	7.65e-26	Coronary artery disease;
LUSC	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.65	11.03	0.52	2.48e-24	Alcohol dependence;
LUSC	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg16339924	chr4:17578868	LAP3	-0.57	-8.22	-0.41	4.6e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg27433088	chr4:174089019	GALNT7	-0.39	-5.67	-0.3	3.14e-8	Dementia and core Alzheimer's disease neuropathologic changes;
LUSC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9287719	0.745	rs4997810	chr2:10755540	T/A	cg00105475	chr2:10696890	NA	0.36	5.81	0.3	1.42e-8	Prostate cancer;
LUSC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	9.09	0.45	8.87e-18	Mean platelet volume;
LUSC	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg24558204	chr6:135376177	HBS1L	0.68	10.41	0.49	3.78e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs2637266	1.000	rs12260379	chr10:78365036	C/T	cg18941641	chr10:78392320	NA	0.39	7.11	0.36	7.28e-12	Pulmonary function;
LUSC	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.53	6.86	0.35	3.43e-11	Multiple sclerosis;
LUSC	trans	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg14791747	chr16:20752902	THUMPD1	-0.42	-5.95	-0.31	6.66e-9	Pancreatic cancer;
LUSC	trans	rs7951105	1.000	rs7937705	chr11:39247947	T/G	cg24085930	chr3:21832523	NA	0.49	6.06	0.31	3.58e-9	Free thyroxine concentration;
LUSC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg02153584	chr22:29168773	CCDC117	-0.64	-9.94	-0.48	1.43e-20	Lymphocyte counts;
LUSC	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg00310523	chr12:86230176	RASSF9	0.43	7.72	0.39	1.38e-13	Major depressive disorder;
LUSC	cis	rs7428496	0.528	rs2227929	chr3:142277536	C/T	cg16271453	chr3:142027066	XRN1	0.47	8.37	0.42	1.57e-15	Mean corpuscular hemoglobin;
LUSC	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg05985134	chr18:33552581	C18orf21	0.5	7.07	0.36	8.86e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg08807101	chr21:30365312	RNF160	-0.67	-10.36	-0.49	5.32e-22	Pancreatic cancer;
LUSC	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg13395646	chr4:1353034	KIAA1530	-0.64	-10.15	-0.49	2.88e-21	Obesity-related traits;
LUSC	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg08270630	chr22:50330655	NA	0.41	6.06	0.31	3.64e-9	Schizophrenia;
LUSC	cis	rs7091068	0.518	rs4144098	chr10:95432600	C/T	cg20715218	chr10:95462985	C10orf4	0.46	5.88	0.31	1.01e-8	Urinary tract infection frequency;
LUSC	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg09934977	chr17:18586148	ZNF286B	0.42	6.65	0.34	1.17e-10	Educational attainment (years of education);
LUSC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11645453	chr3:52864694	ITIH4	0.36	8.37	0.42	1.55e-15	Bipolar disorder;
LUSC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg05729581	chr11:3078854	CARS	-0.57	-8.31	-0.41	2.52e-15	Longevity;
LUSC	cis	rs12956009	0.583	rs919979	chr18:44902739	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.19	0.32	1.74e-9	Educational attainment (years of education);
LUSC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	10.52	0.5	1.53e-22	Hip circumference adjusted for BMI;
LUSC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg14668632	chr7:2872130	GNA12	-0.45	-6.41	-0.33	4.94e-10	Height;
LUSC	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg08392591	chr16:89556376	ANKRD11	0.38	5.67	0.3	3.16e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs11650494	0.516	rs4640235	chr17:47502352	T/C	cg08112188	chr17:47440006	ZNF652	1.07	8.76	0.43	1.01e-16	Prostate cancer;
LUSC	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.43	17.45	0.69	6.4e-49	Opioid sensitivity;
LUSC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg05896524	chr21:47604654	C21orf56	0.53	8.14	0.41	7.98e-15	Testicular germ cell tumor;
LUSC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg24562669	chr7:97807699	LMTK2	0.35	6.17	0.32	2.01e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs832540	0.866	rs252894	chr5:56224339	A/C	cg18230493	chr5:56204884	C5orf35	0.46	6.06	0.31	3.76e-9	Coronary artery disease;
LUSC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg11062466	chr8:58055876	NA	0.64	8.49	0.42	6.73e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs6429082	0.818	rs696248	chr1:235668511	C/A	cg26050004	chr1:235667680	B3GALNT2	0.61	8.06	0.4	1.41e-14	Adiposity;
LUSC	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg05234568	chr11:5960015	NA	-0.57	-8.33	-0.41	2.1e-15	DNA methylation (variation);
LUSC	trans	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg06521331	chr12:34319734	NA	-0.4	-6.19	-0.32	1.74e-9	Bladder cancer;
LUSC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg02269571	chr22:50332266	NA	-0.59	-8.72	-0.43	1.31e-16	Schizophrenia;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg07001414	chr14:21457871	METT11D1	0.5	6.94	0.36	2.04e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00908189	chr16:619842	PIGQ	0.66	10.15	0.49	2.75e-21	Height;
LUSC	trans	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	11.93	0.55	1.4e-27	Exhaled nitric oxide output;
LUSC	cis	rs9650315	0.929	rs35928074	chr8:57168612	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	7.12	0.36	6.82e-12	Height;
LUSC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg21361702	chr7:150065534	REPIN1	0.5	6.87	0.35	3.09e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg25985355	chr7:65971099	NA	-0.36	-5.68	-0.3	2.94e-8	Aortic root size;
LUSC	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21659725	chr3:3221576	CRBN	-0.59	-8.27	-0.41	3.21e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs9400467	0.528	rs455247	chr6:111667799	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-6.94	-0.35	2.09e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg25319279	chr11:5960081	NA	0.38	6.25	0.32	1.27e-9	DNA methylation (variation);
LUSC	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.8	11.48	0.53	6.19e-26	Corneal astigmatism;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg12225893	chr2:86115700	ST3GAL5	0.42	6.08	0.32	3.22e-9	Mosquito bite size;
LUSC	cis	rs60154123	0.772	rs815358	chr1:210430437	A/G	cg22029157	chr1:209979665	IRF6	0.58	5.93	0.31	7.41e-9	Coronary artery disease;
LUSC	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.47	6.08	0.32	3.23e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg27129171	chr3:47204927	SETD2	-0.69	-10.9	-0.51	7.07e-24	QT interval;
LUSC	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg07936489	chr17:37558343	FBXL20	-0.7	-9.54	-0.46	3.03e-19	Glomerular filtration rate (creatinine);
LUSC	trans	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.48	0.46	4.93e-19	Mean corpuscular volume;
LUSC	cis	rs4805834	0.640	rs11671862	chr19:33304298	C/T	cg00891608	chr19:33463040	C19orf40;CCDC123	-0.56	-5.71	-0.3	2.48e-8	Creatinine levels;
LUSC	cis	rs2742417	1.000	rs9829631	chr3:45740558	T/C	cg09608765	chr3:45636137	LIMD1	-0.38	-7.42	-0.38	9.93e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-9.71	-0.47	8.3e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg20283391	chr11:68216788	NA	-0.54	-7.99	-0.4	2.27e-14	Total body bone mineral density;
LUSC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs981844	0.712	rs878911	chr4:154755615	A/G	cg14289246	chr4:154710475	SFRP2	-0.46	-6.41	-0.33	4.85e-10	Response to statins (LDL cholesterol change);
LUSC	trans	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-6.28	-0.32	1.02e-9	Monocyte count;
LUSC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.46	-6.8	-0.35	4.82e-11	Alzheimer's disease (late onset);
LUSC	trans	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-8.8	-0.43	7.56e-17	Obesity-related traits;
LUSC	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg02574844	chr11:5959923	NA	-0.43	-6.14	-0.32	2.37e-9	DNA methylation (variation);
LUSC	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9309473	0.632	rs6706179	chr2:73578577	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-8.1	-0.41	1.05e-14	Metabolite levels;
LUSC	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg23029597	chr12:123009494	RSRC2	-0.72	-9.25	-0.45	2.74e-18	Body mass index;
LUSC	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg20744362	chr22:50050164	C22orf34	0.39	7.15	0.36	5.37e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg13560548	chr3:10150139	C3orf24	0.52	7.46	0.38	7.33e-13	Alzheimer's disease;
LUSC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg12560992	chr17:57184187	TRIM37	0.83	15.44	0.65	5.86e-41	Intelligence (multi-trait analysis);
LUSC	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg06096015	chr1:231504339	EGLN1	0.57	9.93	0.48	1.56e-20	Hemoglobin concentration;
LUSC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg00152838	chr16:24741724	TNRC6A	0.47	5.74	0.3	2.07e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.61	8.55	0.42	4.57e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.42	6.58	0.34	1.79e-10	Bone mineral density (spine);Bone mineral density;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19877581	chr12:62654212	USP15	-0.41	-6.0	-0.31	5.1e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.91	0.61	5.12e-35	Cognitive test performance;
LUSC	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.53	0.53	3.91e-26	Ileal carcinoids;
LUSC	trans	rs75804782	0.641	rs112066551	chr2:239362486	G/A	cg01134436	chr17:81009848	B3GNTL1	0.64	6.16	0.32	2.14e-9	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg08676812	chr11:65308423	LTBP3	1.06	6.8	0.35	4.79e-11	Height;
LUSC	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg12179176	chr11:130786555	SNX19	0.6	8.97	0.44	2.13e-17	Schizophrenia;
LUSC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.17	-0.52	7.89e-25	Mean corpuscular volume;
LUSC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg07424592	chr7:64974309	NA	-0.63	-5.65	-0.3	3.53e-8	Diabetic kidney disease;
LUSC	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg02569458	chr12:86230093	RASSF9	-0.48	-7.95	-0.4	2.87e-14	Major depressive disorder;
LUSC	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg26395211	chr5:140044315	WDR55	0.45	7.01	0.36	1.29e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.41	0.33	5.04e-10	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg17366294	chr4:99064904	C4orf37	0.56	9.83	0.47	3.29e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.14	-0.49	3.1e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs9796	0.636	rs1983400	chr15:41373029	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.29	-0.41	2.84e-15	Menopause (age at onset);
LUSC	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg21798802	chr22:38057573	PDXP	0.32	6.64	0.34	1.24e-10	Fat distribution (HIV);
LUSC	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg19653624	chr11:20408972	PRMT3	-0.67	-8.48	-0.42	7.28e-16	Pursuit maintenance gain;
LUSC	cis	rs67696533	1.000	rs6119893	chr20:31142813	G/T	cg13636640	chr20:31349939	DNMT3B	0.47	6.86	0.35	3.28e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs193541	0.626	rs4835881	chr5:122088040	G/T	cg19077854	chr5:122220652	SNX24	0.27	6.16	0.32	2.12e-9	Glucose homeostasis traits;
LUSC	trans	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.74	-10.08	-0.48	4.95e-21	Blood trace element (Cu levels);
LUSC	cis	rs11153306	0.529	rs11153303	chr6:111937875	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-7.17	-0.37	4.83e-12	Tonsillectomy;
LUSC	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.69	13.22	0.59	2.26e-32	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg17120908	chr11:65337727	SSSCA1	0.55	9.67	0.47	1.17e-19	Bone mineral density;
LUSC	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg12560992	chr17:57184187	TRIM37	-0.71	-12.19	-0.56	1.54e-28	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.74	12.56	0.57	6.56e-30	Motion sickness;
LUSC	cis	rs134594	0.961	rs134604	chr22:29474077	A/G	cg03665785	chr22:29458676	C22orf31	0.28	5.75	0.3	1.96e-8	Birth weight;
LUSC	cis	rs6693567	0.565	rs834237	chr1:150363930	A/G	cg15654264	chr1:150340011	RPRD2	0.45	7.18	0.37	4.62e-12	Migraine;
LUSC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	10.52	0.5	1.5e-22	Monocyte percentage of white cells;
LUSC	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg11473876	chr11:109292803	C11orf87	0.4	6.52	0.34	2.59e-10	Schizophrenia;
LUSC	trans	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg25214090	chr10:38739885	LOC399744	0.52	7.7	0.39	1.51e-13	Corneal astigmatism;
LUSC	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg03474202	chr17:45855739	NA	-0.31	-6.99	-0.36	1.52e-11	IgG glycosylation;
LUSC	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg12257692	chr3:49977190	RBM6	-0.21	-5.7	-0.3	2.69e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.51	6.53	0.34	2.41e-10	Multiple sclerosis;
LUSC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.57	0.38	3.77e-13	Motion sickness;
LUSC	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg10434728	chr15:90938212	IQGAP1	-0.45	-9.3	-0.45	1.9e-18	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg14416269	chr4:6271139	WFS1	0.51	10.61	0.5	7.27e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg15691649	chr6:25882328	NA	-0.51	-7.74	-0.39	1.21e-13	Blood metabolite levels;
LUSC	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg11645453	chr3:52864694	ITIH4	0.36	8.1	0.41	1.03e-14	Bipolar disorder;
LUSC	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg07636037	chr3:49044803	WDR6	0.56	5.73	0.3	2.24e-8	Menarche (age at onset);
LUSC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg14582100	chr15:45693742	SPATA5L1	0.49	8.44	0.42	9.51e-16	Homoarginine levels;
LUSC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg07870213	chr5:140052090	DND1	-0.76	-11.27	-0.52	3.37e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs73198271	1.000	rs55971558	chr8:8614403	G/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-5.81	-0.3	1.42e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg14530993	chr4:882597	GAK	0.76	7.51	0.38	5.35e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.46	7.47	0.38	6.99e-13	Menarche (age at onset);
LUSC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg22638593	chr5:131593259	PDLIM4	0.45	6.77	0.35	5.75e-11	Acylcarnitine levels;
LUSC	cis	rs6546550	0.900	rs2054047	chr2:70117421	A/C	cg02498382	chr2:70120550	SNRNP27	-0.31	-7.58	-0.38	3.55e-13	Prevalent atrial fibrillation;
LUSC	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.91	-0.35	2.41e-11	Lung cancer;
LUSC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg21724239	chr8:58056113	NA	0.58	6.68	0.34	9.96e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg23791538	chr6:167370224	RNASET2	0.36	5.67	0.3	3.14e-8	Crohn's disease;
LUSC	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.34	-6.41	-0.33	4.96e-10	Platelet count;
LUSC	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg09092052	chr15:45571596	NA	0.46	6.41	0.33	5.09e-10	Glomerular filtration rate;
LUSC	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.54	7.09	0.36	8.24e-12	Menarche (age at onset);
LUSC	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg26695010	chr11:65641043	EFEMP2	0.43	6.05	0.31	3.92e-9	Breast cancer;
LUSC	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-18.25	-0.71	4.33e-52	Primary sclerosing cholangitis;
LUSC	cis	rs10986311	0.775	rs7872979	chr9:127104412	G/A	cg14243010	chr9:127117328	LOC100129034;PSMB7	0.43	6.9	0.35	2.59e-11	Vitiligo;
LUSC	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg01420254	chr6:26195488	NA	0.71	7.5	0.38	5.86e-13	Gout;Renal underexcretion gout;
LUSC	trans	rs62238980	0.614	rs118073663	chr22:32397610	A/T	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.53	-6.0	-0.31	5e-9	Childhood ear infection;
LUSC	trans	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg11887960	chr12:57824829	NA	0.54	6.67	0.34	1.08e-10	Obesity-related traits;
LUSC	cis	rs17155006	0.746	rs446800	chr7:107747928	A/C	cg05962710	chr7:107745446	LAMB4	-0.36	-6.52	-0.34	2.57e-10	Pneumococcal bacteremia;
LUSC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg11764359	chr7:65958608	NA	-0.49	-6.24	-0.32	1.32e-9	Aortic root size;
LUSC	cis	rs6700896	0.931	rs10749755	chr1:66129530	C/T	cg04111102	chr1:66153794	NA	0.33	7.26	0.37	2.81e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg27494647	chr7:150038898	RARRES2	0.58	8.54	0.42	4.73e-16	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs72781680	0.665	rs2953028	chr2:24068126	T/C	cg08917208	chr2:24149416	ATAD2B	0.62	7.1	0.36	7.32e-12	Lymphocyte counts;
LUSC	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	9.23	0.45	3.22e-18	Lung cancer;
LUSC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.39	6.19	0.32	1.81e-9	Bipolar disorder;
LUSC	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg23093090	chr10:104574429	C10orf26	0.32	5.87	0.31	1.06e-8	Arsenic metabolism;
LUSC	cis	rs4629180	0.651	rs9653468	chr2:102108403	A/G	cg04415270	chr2:102091202	RFX8	-0.44	-7.6	-0.38	2.94e-13	Chronic rhinosinusitis with nasal polyps;
LUSC	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg15556689	chr8:8085844	FLJ10661	0.55	8.32	0.41	2.32e-15	Retinal vascular caliber;
LUSC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.67	-11.44	-0.53	8.43e-26	IgG glycosylation;
LUSC	cis	rs427941	0.703	rs201455	chr7:101740212	C/T	cg06246474	chr7:101738831	CUX1	0.39	6.34	0.33	7.52e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
LUSC	cis	rs4363385	0.719	rs12748969	chr1:152932654	T/C	cg00922841	chr1:152955080	SPRR1A	-0.4	-6.59	-0.34	1.72e-10	Inflammatory skin disease;
LUSC	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg18165381	chr3:44552316	NA	0.38	6.33	0.33	7.76e-10	Depressive symptoms;
LUSC	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg23029597	chr12:123009494	RSRC2	-0.7	-9.52	-0.46	3.54e-19	Body mass index;
LUSC	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.07	0.48	5.08e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg10356904	chr22:49881777	NA	-0.33	-7.39	-0.37	1.21e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg21880101	chr17:80066754	CCDC57	-0.31	-5.8	-0.3	1.54e-8	Life satisfaction;
LUSC	cis	rs965469	0.843	rs6051842	chr20:3397434	T/C	cg25506879	chr20:3388711	C20orf194	-0.52	-5.64	-0.3	3.57e-8	IFN-related cytopenia;
LUSC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg22963979	chr7:1858916	MAD1L1	-0.56	-8.41	-0.42	1.18e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs6594499	0.778	rs3806932	chr5:110405675	C/T	cg09098825	chr3:47866946	DHX30	0.49	6.0	0.31	5.02e-9	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.76	12.07	0.55	4.41e-28	Colorectal cancer;
LUSC	cis	rs939574	0.656	rs6710315	chr2:220137991	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.79	-6.36	-0.33	6.6e-10	Platelet distribution width;
LUSC	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg19792802	chr11:65647270	CTSW	0.41	6.23	0.32	1.38e-9	Crohn's disease;
LUSC	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg03342759	chr3:160939853	NMD3	-0.42	-6.21	-0.32	1.59e-9	Morning vs. evening chronotype;
LUSC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.51	8.62	0.43	2.69e-16	Prudent dietary pattern;
LUSC	cis	rs4478858	0.839	rs10798834	chr1:31708977	G/A	cg00250761	chr1:31883323	NA	-0.38	-9.89	-0.48	2.13e-20	Alcohol dependence;
LUSC	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.03	0.44	1.35e-17	Lung cancer in ever smokers;
LUSC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	10.88	0.51	8.25e-24	Hip circumference adjusted for BMI;
LUSC	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg00898013	chr13:113819073	PROZ	0.49	7.29	0.37	2.33e-12	Platelet distribution width;
LUSC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08859206	chr1:53392774	SCP2	-0.68	-12.84	-0.58	5.79e-31	Monocyte count;
LUSC	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg13010199	chr12:38710504	ALG10B	-0.62	-9.58	-0.46	2.28e-19	Bladder cancer;
LUSC	trans	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg26647312	chr5:1645268	NA	0.59	5.95	0.31	6.91e-9	Initial pursuit acceleration;
LUSC	cis	rs73416724	1.000	rs73416724	chr6:43337802	A/G	cg26312998	chr6:43337775	ZNF318	0.57	6.62	0.34	1.4e-10	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21659725	chr3:3221576	CRBN	-0.58	-8.34	-0.42	1.92e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg21665744	chr7:39171113	POU6F2	0.44	6.67	0.34	1.08e-10	IgG glycosylation;
LUSC	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg12884169	chr21:40033163	ERG	0.61	12.33	0.56	4.83e-29	Coronary artery disease;
LUSC	trans	rs1362931	0.543	rs17288905	chr6:46683382	A/G	cg01218148	chr9:34523776	ENHO	0.63	6.04	0.31	4.02e-9	Lipoprotein-associated phospholipase A2 activity and mass;
LUSC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg23711669	chr6:146136114	FBXO30	0.87	15.89	0.66	9.56e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg02569458	chr12:86230093	RASSF9	0.48	7.69	0.39	1.65e-13	Major depressive disorder;
LUSC	cis	rs6700896	0.931	rs1938490	chr1:66132800	T/A	cg04111102	chr1:66153794	NA	0.33	7.26	0.37	2.81e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs7939886	0.920	rs17150117	chr11:55941186	T/C	cg15704280	chr7:45808275	SEPT13	0.88	6.69	0.34	9.39e-11	Myopia (pathological);
LUSC	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.88	15.05	0.64	1.94e-39	Bladder cancer;
LUSC	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg24006582	chr15:45444508	DUOX1	0.67	9.67	0.47	1.16e-19	Uric acid levels;
LUSC	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg03806693	chr22:41940476	POLR3H	-0.56	-8.26	-0.41	3.45e-15	Neuroticism;
LUSC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg25039879	chr17:56429692	SUPT4H1	0.72	9.66	0.47	1.21e-19	Cognitive test performance;
LUSC	cis	rs394563	0.663	rs415434	chr6:149772645	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.3	-6.08	-0.32	3.26e-9	Dupuytren's disease;
LUSC	cis	rs7659604	0.502	rs4315813	chr4:122674866	G/A	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.91	-0.31	8.47e-9	Type 2 diabetes;
LUSC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg25428297	chr7:1022841	CYP2W1	0.28	5.74	0.3	2.11e-8	Longevity;Endometriosis;
LUSC	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg24812749	chr6:127587940	RNF146	0.49	7.16	0.36	5.1e-12	Breast cancer;
LUSC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg13560548	chr3:10150139	C3orf24	0.47	6.6	0.34	1.58e-10	Alzheimer's disease;
LUSC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg12935359	chr14:103987150	CKB	-0.52	-8.07	-0.4	1.26e-14	Body mass index;
LUSC	cis	rs6076065	0.510	rs6137899	chr20:23320137	C/T	cg11657817	chr20:23433608	CST11	0.4	7.4	0.38	1.13e-12	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg25174290	chr11:3078921	CARS	0.61	9.53	0.46	3.47e-19	Longevity;
LUSC	cis	rs9837602	1.000	rs4571265	chr3:99705111	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.41	5.89	0.31	9.26e-9	Breast cancer;
LUSC	trans	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg13010199	chr12:38710504	ALG10B	0.43	6.71	0.34	8.6e-11	Morning vs. evening chronotype;
LUSC	cis	rs4654899	0.931	rs3125161	chr1:21126346	A/G	cg01072550	chr1:21505969	NA	0.48	7.14	0.36	5.69e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.93	15.97	0.66	4.9e-43	Morning vs. evening chronotype;
LUSC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-9.96	-0.48	1.22e-20	Platelet count;
LUSC	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg03522245	chr20:25566470	NINL	-0.35	-5.67	-0.3	3.1e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg05973401	chr12:123451056	ABCB9	0.53	6.49	0.33	3.01e-10	Neutrophil percentage of white cells;
LUSC	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg04155289	chr7:94953770	PON1	-0.34	-5.7	-0.3	2.6e-8	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg03676636	chr4:99064102	C4orf37	0.35	7.65	0.39	2.21e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs17253792	0.822	rs9323289	chr14:56106784	G/C	cg01858014	chr14:56050164	KTN1	-0.84	-6.78	-0.35	5.6e-11	Putamen volume;
LUSC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg01802117	chr1:53393560	SCP2	0.46	7.46	0.38	7.38e-13	Monocyte count;
LUSC	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.54	-0.38	4.58e-13	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg03342759	chr3:160939853	NMD3	-0.49	-8.18	-0.41	5.82e-15	Morning vs. evening chronotype;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17680823	chr2:240016541	HDAC4	-0.39	-6.21	-0.32	1.55e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	trans	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-6.41	-0.33	4.96e-10	Blood trace element (Cu levels);
LUSC	trans	rs2262909	1.000	rs2175366	chr19:22128279	C/T	cg05197062	chr11:11642011	GALNTL4	-0.51	-7.02	-0.36	1.27e-11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg05313129	chr8:58192883	C8orf71	-0.5	-5.71	-0.3	2.44e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs3824488	0.920	rs28510415	chr9:98245026	A/G	cg23555120	chr12:106533863	NUAK1	0.57	6.19	0.32	1.81e-9	Neuroticism;
LUSC	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg20607287	chr7:12443886	VWDE	-0.6	-6.26	-0.32	1.2e-9	Coronary artery disease;
LUSC	cis	rs11039100	0.607	rs11038952	chr11:5780354	T/C	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26314531	chr2:26401878	FAM59B	-0.66	-9.13	-0.45	6.46e-18	Gut microbiome composition (summer);
LUSC	cis	rs11018904	0.906	rs55685917	chr11:89964365	T/C	cg26138821	chr11:89956704	CHORDC1	-0.58	-7.18	-0.37	4.67e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs4478858	0.735	rs4949205	chr1:31800579	A/G	cg00250761	chr1:31883323	NA	-0.36	-8.94	-0.44	2.66e-17	Alcohol dependence;
LUSC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg14552801	chr7:65878734	NA	-0.46	-6.53	-0.34	2.45e-10	Aortic root size;
LUSC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-8.18	-0.41	6.14e-15	Systemic lupus erythematosus;
LUSC	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.38	-0.33	5.83e-10	Mood instability;
LUSC	trans	rs4427176	0.507	rs7010270	chr8:9556847	C/T	cg20111118	chr4:148653624	ARHGAP10	0.39	6.32	0.33	8.51e-10	Mosquito bite size;
LUSC	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg13010199	chr12:38710504	ALG10B	0.65	10.16	0.49	2.61e-21	Bladder cancer;
LUSC	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg04691961	chr3:161091175	C3orf57	-0.35	-6.11	-0.32	2.74e-9	Morning vs. evening chronotype;
LUSC	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg14893161	chr1:205819251	PM20D1	0.42	5.77	0.3	1.85e-8	Parkinson's disease;
LUSC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.0	-0.48	9.09e-21	Hemoglobin concentration;
LUSC	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg18105134	chr13:113819100	PROZ	-0.68	-10.19	-0.49	1.99e-21	Platelet distribution width;
LUSC	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg00321850	chr1:175162397	KIAA0040	-0.46	-7.94	-0.4	3.19e-14	Alcohol dependence;
LUSC	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21659725	chr3:3221576	CRBN	-0.64	-10.41	-0.49	3.65e-22	Intelligence (multi-trait analysis);
LUSC	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg03929089	chr4:120376271	NA	0.61	6.59	0.34	1.71e-10	Axial length;
LUSC	trans	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg25214090	chr10:38739885	LOC399744	0.42	6.43	0.33	4.34e-10	Educational attainment;
LUSC	cis	rs7091068	0.662	rs829106	chr10:95441742	G/T	cg20715218	chr10:95462985	C10orf4	0.64	6.89	0.35	2.75e-11	Urinary tract infection frequency;
LUSC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg11189052	chr15:85197271	WDR73	-0.63	-9.89	-0.48	2.09e-20	P wave terminal force;
LUSC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.69	-0.3	2.85e-8	Depression;
LUSC	cis	rs34734847	1.000	rs34734847	chr12:121154221	T/C	cg27246729	chr12:121163418	ACADS	0.47	7.52	0.38	4.94e-13	Mean corpuscular volume;
LUSC	cis	rs7527798	0.592	rs12411037	chr1:207857158	T/C	cg09232269	chr1:207846808	CR1L	-0.32	-6.87	-0.35	3.21e-11	Erythrocyte sedimentation rate;
LUSC	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg05714579	chr10:131428358	MGMT	0.46	6.42	0.33	4.64e-10	Response to temozolomide;
LUSC	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg24130564	chr14:104152367	KLC1	0.45	6.53	0.34	2.43e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg13789015	chr9:136890014	NCRNA00094	0.7	12.41	0.56	2.52e-29	Platelet distribution width;
LUSC	cis	rs55728055	0.661	rs12165609	chr22:32036332	T/C	cg01338084	chr22:32026380	PISD	0.82	6.18	0.32	1.83e-9	Age-related hearing impairment;
LUSC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg00033643	chr7:134001901	SLC35B4	0.46	7.25	0.37	3e-12	Mean platelet volume;
LUSC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-8.56	-0.42	4.27e-16	Bipolar disorder and schizophrenia;
LUSC	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-6.51	-0.34	2.81e-10	Educational attainment;
LUSC	cis	rs2969070	0.763	rs4721714	chr7:2498467	G/A	cg03277898	chr7:2518824	NA	-0.29	-6.06	-0.31	3.77e-9	Diastolic blood pressure;
LUSC	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg08601574	chr20:25228251	PYGB	0.45	6.81	0.35	4.56e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs979233	0.502	rs2202093	chr5:42130945	T/A	cg07010552	chr17:7358735	CHRNB1	-0.42	-6.09	-0.32	3.15e-9	Systemic lupus erythematosus;
LUSC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg23978390	chr7:1156363	C7orf50	0.48	5.84	0.3	1.23e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs672059	1.000	rs672119	chr1:183162506	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.55	8.1	0.41	1.02e-14	Hypertriglyceridemia;
LUSC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg13206674	chr6:150067644	NUP43	0.44	6.72	0.35	7.64e-11	Testicular germ cell tumor;
LUSC	cis	rs59698941	0.943	rs67551921	chr5:132289033	G/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.36	7.1	0.36	7.73e-12	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LUSC	cis	rs9880211	0.898	rs6770476	chr3:136073920	C/T	cg21827317	chr3:136751795	NA	-0.39	-6.1	-0.32	2.9e-9	Body mass index;Height;
LUSC	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg22709100	chr7:91322751	NA	0.39	5.79	0.3	1.67e-8	Breast cancer;
LUSC	cis	rs6669919	0.901	rs7527396	chr1:211667857	C/T	cg25617285	chr1:211431773	RCOR3	-0.36	-6.03	-0.31	4.26e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7590368	1.000	rs2884289	chr2:10959724	G/A	cg15705551	chr2:10952987	PDIA6	0.58	8.0	0.4	2.11e-14	Educational attainment (years of education);
LUSC	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.97	-0.31	6.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.75	0.35	6.53e-11	Height;
LUSC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg18402987	chr7:1209562	NA	0.67	7.1	0.36	7.4e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg06623918	chr6:96969491	KIAA0776	0.8	10.38	0.49	4.79e-22	Migraine;Coronary artery disease;
LUSC	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.74	11.21	0.52	5.88e-25	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg06740227	chr12:86229804	RASSF9	0.37	5.79	0.3	1.59e-8	Major depressive disorder;
LUSC	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.47	8.3	0.41	2.68e-15	HDL cholesterol;
LUSC	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.69	-8.4	-0.42	1.3e-15	Body mass index;
LUSC	cis	rs9815354	0.638	rs73073267	chr3:42021163	A/T	cg03022575	chr3:42003672	ULK4	0.77	7.77	0.39	9.53e-14	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg12463550	chr7:65579703	CRCP	-0.53	-7.73	-0.39	1.24e-13	Aortic root size;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg21137026	chr11:417246	SIGIRR	0.42	6.77	0.35	5.74e-11	Schizophrenia;
LUSC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg24562669	chr7:97807699	LMTK2	0.35	6.16	0.32	2.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs500891	0.693	rs1145914	chr6:83993797	A/G	cg08257003	chr6:84140564	ME1	0.33	7.15	0.36	5.67e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg23950597	chr19:37808831	NA	-0.65	-7.91	-0.4	3.9e-14	Coronary artery calcification;
LUSC	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.4	0.49	3.97e-22	Schizophrenia;
LUSC	cis	rs35079168	0.923	rs10858277	chr9:137287959	G/A	cg13941235	chr9:137270186	RXRA	-0.32	-5.7	-0.3	2.66e-8	Intelligence;
LUSC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg11062466	chr8:58055876	NA	0.67	8.68	0.43	1.72e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9346649	0.933	rs9364398	chr6:168489433	G/T	cg02770688	chr6:168491649	NA	-0.38	-6.99	-0.36	1.52e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LUSC	cis	rs10886558	0.662	rs2151888	chr10:121769435	G/T	cg02041677	chr10:121771263	NA	0.34	5.73	0.3	2.23e-8	Shingles;
LUSC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg13319975	chr6:146136371	FBXO30	0.5	7.52	0.38	5.18e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg13047869	chr3:10149882	C3orf24	0.56	7.73	0.39	1.24e-13	Alzheimer's disease;
LUSC	cis	rs983392	0.805	rs2123314	chr11:59966295	C/T	cg02771260	chr11:59836817	MS4A3	0.36	5.98	0.31	5.8e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4499344	0.604	rs259287	chr19:33164859	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	11.73	0.54	7.5e-27	Mean platelet volume;
LUSC	cis	rs7432375	0.610	rs7621932	chr3:136517016	C/T	cg15507776	chr3:136538369	TMEM22	0.44	7.34	0.37	1.68e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg21890820	chr11:65308645	LTBP3	0.75	7.64	0.39	2.29e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg17385448	chr1:15911702	AGMAT	0.4	6.05	0.31	3.94e-9	Systolic blood pressure;
LUSC	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg04117972	chr1:227635322	NA	0.61	6.73	0.35	7.22e-11	Major depressive disorder;
LUSC	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg01733217	chr16:74700730	RFWD3	0.98	21.95	0.77	9.95e-67	Multiple myeloma;
LUSC	trans	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg26811252	chr16:29126840	RRN3P2	0.58	9.17	0.45	5.08e-18	Menopause (age at onset);
LUSC	cis	rs17095355	1.000	rs7080576	chr10:111710817	C/T	cg00817464	chr10:111662876	XPNPEP1	0.58	7.58	0.38	3.46e-13	Biliary atresia;
LUSC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg14552801	chr7:65878734	NA	-0.38	-5.96	-0.31	6.31e-9	Aortic root size;
LUSC	cis	rs13385	0.769	rs4913074	chr5:139613567	T/C	cg26211634	chr5:139558579	C5orf32	0.46	7.05	0.36	1.04e-11	Atrial fibrillation;
LUSC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.29	6.4	0.33	5.13e-10	Electroencephalogram traits;
LUSC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	11.62	0.54	2e-26	Alzheimer's disease;
LUSC	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23978390	chr7:1156363	C7orf50	0.49	6.76	0.35	6.34e-11	Longevity;Endometriosis;
LUSC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg03146154	chr1:46216737	IPP	0.5	7.36	0.37	1.42e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6700896	0.931	rs12044840	chr1:66115213	C/G	cg04111102	chr1:66153794	NA	0.32	7.1	0.36	7.54e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.39	-0.42	1.4e-15	Total body bone mineral density;
LUSC	cis	rs9815354	1.000	rs6768128	chr3:41865080	G/A	cg03022575	chr3:42003672	ULK4	0.59	6.55	0.34	2.2e-10	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs231513	0.954	rs231508	chr17:41967583	G/A	cg26893861	chr17:41843967	DUSP3	-0.52	-6.23	-0.32	1.37e-9	Cognitive function;
LUSC	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg06636551	chr8:101224915	SPAG1	-0.39	-7.13	-0.36	6.17e-12	Atrioventricular conduction;
LUSC	cis	rs68170813	0.596	rs76888321	chr7:106945926	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-9.87	-0.48	2.57e-20	Coronary artery disease;
LUSC	cis	rs970548	0.688	rs2082111	chr10:45931060	A/C	cg15590007	chr10:45870220	ALOX5	0.58	6.57	0.34	1.92e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LUSC	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg08847533	chr14:75593920	NEK9	-0.39	-5.87	-0.31	1.07e-8	Caffeine consumption;
LUSC	cis	rs860295	0.580	rs7528441	chr1:155843256	T/G	cg08949192	chr1:155289623	RUSC1;FDPS	-0.34	-5.67	-0.3	3.07e-8	Body mass index;
LUSC	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	0.98	10.97	0.51	4.05e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs500891	0.533	rs1932092	chr6:84192944	G/A	cg08257003	chr6:84140564	ME1	-0.33	-8.03	-0.4	1.67e-14	Platelet-derived growth factor BB levels;
LUSC	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.92	-0.35	2.38e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg15691649	chr6:25882328	NA	-0.41	-5.96	-0.31	6.28e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg13385521	chr17:29058706	SUZ12P	0.68	6.67	0.34	1.07e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs7945718	0.934	rs10831909	chr11:12817182	C/G	cg25843174	chr11:12811716	TEAD1	0.33	7.21	0.37	3.75e-12	Educational attainment (years of education);
LUSC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.46	-6.99	-0.36	1.48e-11	Melanoma;
LUSC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	9.96	0.48	1.2e-20	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg14343924	chr8:8086146	FLJ10661	0.41	5.69	0.3	2.82e-8	Mood instability;
LUSC	cis	rs2637266	0.783	rs846640	chr10:78524293	T/C	cg18941641	chr10:78392320	NA	0.39	7.12	0.36	6.86e-12	Pulmonary function;
LUSC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg00343986	chr7:65444356	GUSB	0.43	6.54	0.34	2.29e-10	Aortic root size;
LUSC	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg16070123	chr10:51489643	NA	-0.52	-8.22	-0.41	4.48e-15	Prostate-specific antigen levels;
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg25703541	chr22:24373054	LOC391322	-0.89	-14.49	-0.62	2.87e-37	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg14893161	chr1:205819251	PM20D1	0.42	5.74	0.3	2.09e-8	Parkinson's disease;
LUSC	cis	rs10979	0.782	rs9390108	chr6:143892722	A/T	cg25407410	chr6:143891975	LOC285740	-0.73	-11.58	-0.54	2.64e-26	Hypospadias;
LUSC	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg06740227	chr12:86229804	RASSF9	0.36	5.75	0.3	2.04e-8	Major depressive disorder;
LUSC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg25019033	chr10:957182	NA	-0.53	-6.9	-0.35	2.61e-11	Eosinophil percentage of granulocytes;
LUSC	trans	rs3960554	0.808	rs11983987	chr7:75657850	A/G	cg19862616	chr7:65841803	NCRNA00174	0.66	7.59	0.38	3.15e-13	Eotaxin levels;
LUSC	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	1.23	18.5	0.71	4.35e-53	Corneal structure;
LUSC	cis	rs506338	0.517	rs530775	chr11:64426933	A/G	cg19131476	chr11:64387923	NRXN2	0.36	7.81	0.39	7.34e-14	Body mass index;Urate levels;
LUSC	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg05855489	chr10:104503620	C10orf26	0.52	7.88	0.4	4.72e-14	Arsenic metabolism;
LUSC	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-9.87	-0.48	2.48e-20	Hemoglobin concentration;
LUSC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg19592336	chr6:28129416	ZNF389	0.53	7.23	0.37	3.25e-12	Depression;
LUSC	trans	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-9.22	-0.45	3.34e-18	Depression;
LUSC	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg13699009	chr12:122356056	WDR66	0.5	7.46	0.38	7.33e-13	Mean corpuscular volume;
LUSC	cis	rs3812111	0.510	rs9387390	chr6:116584080	T/C	cg18828861	chr6:116576566	TSPYL4	0.38	6.74	0.35	7e-11	Age-related macular degeneration;
LUSC	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.23	0.32	1.37e-9	Retinal vascular caliber;
LUSC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	14.21	0.61	3.51e-36	Platelet count;
LUSC	cis	rs2502731	0.539	rs3003608	chr9:130984430	C/A	cg13642260	chr9:130955380	CIZ1	0.44	6.97	0.36	1.75e-11	Attention deficit hyperactivity disorder;
LUSC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	9.51	0.46	4.02e-19	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg25258033	chr6:167368657	RNASET2	0.47	7.75	0.39	1.11e-13	Crohn's disease;
LUSC	cis	rs77741769	0.764	rs11065332	chr12:121360959	G/A	cg02403541	chr12:121454288	C12orf43	0.51	7.54	0.38	4.58e-13	Mean corpuscular volume;
LUSC	cis	rs10465746	0.780	rs11163865	chr1:84366917	C/T	cg10977910	chr1:84465055	TTLL7	0.45	6.36	0.33	6.7e-10	Obesity-related traits;
LUSC	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg13615516	chr5:77269221	NA	0.39	6.68	0.34	9.78e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg13010199	chr12:38710504	ALG10B	0.56	8.45	0.42	9.2e-16	Morning vs. evening chronotype;
LUSC	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.48	-7.21	-0.37	3.65e-12	Urate levels;
LUSC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg07701084	chr6:150067640	NUP43	0.57	8.88	0.44	4.29e-17	Lung cancer;
LUSC	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg11060661	chr22:24314208	DDT;DDTL	0.49	8.05	0.4	1.47e-14	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg14993813	chr1:46806288	NSUN4	-0.5	-6.91	-0.35	2.4e-11	Menopause (age at onset);
LUSC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18876405	chr7:65276391	NA	0.55	8.77	0.43	9.27e-17	Aortic root size;
LUSC	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.55	-7.36	-0.37	1.4e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg13073564	chr4:8508604	NA	-0.49	-9.22	-0.45	3.38e-18	Response to antineoplastic agents;
LUSC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.67	0.39	1.89e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg25767906	chr1:53392781	SCP2	0.48	8.71	0.43	1.47e-16	Monocyte count;
LUSC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg22535103	chr8:58192502	C8orf71	-0.65	-7.34	-0.37	1.59e-12	Developmental language disorder (linguistic errors);
LUSC	trans	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg26043149	chr18:55253948	FECH	0.49	7.28	0.37	2.43e-12	Bone mineral density;
LUSC	cis	rs6062509	0.732	rs6062304	chr20:62351539	A/T	cg01176363	chr20:62369445	LIME1	-0.46	-6.98	-0.36	1.63e-11	Prostate cancer;
LUSC	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg00191853	chr8:101177733	SPAG1	-0.41	-6.56	-0.34	2.08e-10	Atrioventricular conduction;
LUSC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg08499158	chr17:42289980	UBTF	-0.52	-8.65	-0.43	2.18e-16	Total body bone mineral density;
LUSC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg21724239	chr8:58056113	NA	0.73	8.03	0.4	1.73e-14	Developmental language disorder (linguistic errors);
LUSC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg16606324	chr3:10149918	C3orf24	0.66	9.6	0.47	1.97e-19	Alzheimer's disease;
LUSC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg11764359	chr7:65958608	NA	-0.69	-10.49	-0.5	1.88e-22	Aortic root size;
LUSC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.73	13.13	0.58	4.77e-32	Prudent dietary pattern;
LUSC	cis	rs7264396	0.778	rs6120959	chr20:34077848	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.41	-0.33	5.1e-10	Total cholesterol levels;
LUSC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25067162	chr17:41277974	BRCA1;NBR2	0.37	6.25	0.32	1.28e-9	Menopause (age at onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17890984	chr13:95248455	TGDS	-0.42	-6.23	-0.32	1.43e-9	Electrocardiographic conduction measures;
LUSC	cis	rs11077998	0.933	rs2291395	chr17:80526139	A/G	cg10255544	chr17:80519551	FOXK2	0.36	5.8	0.3	1.51e-8	Reticulocyte fraction of red cells;
LUSC	cis	rs4631830	0.932	rs4581397	chr10:51532367	A/G	cg10326726	chr10:51549505	MSMB	-0.34	-5.76	-0.3	1.86e-8	Prostate-specific antigen levels;
LUSC	cis	rs2303282	0.665	rs922446	chr16:56393191	T/C	cg00500540	chr16:56394104	NA	-0.44	-7.52	-0.38	5.12e-13	Breast cancer;
LUSC	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26384229	chr12:38710491	ALG10B	0.9	15.54	0.65	2.33e-41	Morning vs. evening chronotype;
LUSC	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg24006582	chr15:45444508	DUOX1	-0.61	-8.95	-0.44	2.44e-17	Uric acid levels;
LUSC	cis	rs2398893	0.889	rs7872984	chr9:96782447	T/C	cg14459158	chr9:96720562	NA	0.3	5.9	0.31	8.96e-9	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.24	0.56	1.01e-28	Motion sickness;
LUSC	trans	rs17039065	0.920	rs12506757	chr4:109411903	G/A	cg07444054	chr2:108107501	NA	0.45	6.29	0.33	1.01e-9	Gut microbiome composition (summer);
LUSC	trans	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg21775007	chr8:11205619	TDH	0.42	6.18	0.32	1.9e-9	Mood instability;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07333738	chr16:765560	METRN	-0.51	-6.32	-0.33	8.48e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg23750338	chr8:142222470	SLC45A4	-0.52	-10.02	-0.48	7.63e-21	Immature fraction of reticulocytes;
LUSC	cis	rs9462027	0.628	rs6919654	chr6:34810739	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.75	-0.3	1.97e-8	Systemic lupus erythematosus;
LUSC	cis	rs4690686	0.534	rs11133147	chr4:177281718	A/G	cg17059388	chr4:177262070	NA	0.32	6.43	0.33	4.46e-10	Essential tremor;
LUSC	cis	rs10992471	0.603	rs13301537	chr9:95229047	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.68	-0.39	1.78e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg05717871	chr11:638507	DRD4	-0.34	-5.9	-0.31	8.74e-9	Systemic lupus erythematosus;
LUSC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.37	6.95	0.36	1.97e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7759001	0.857	rs9468101	chr6:27352938	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.75	0.3	1.97e-8	Glomerular filtration rate (creatinine);
LUSC	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg09044154	chr16:88155775	NA	-0.59	-7.85	-0.39	5.6e-14	Menopause (age at onset);
LUSC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg09699651	chr6:150184138	LRP11	0.37	5.86	0.31	1.12e-8	Lung cancer;
LUSC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	0.98	21.18	0.76	9.77e-64	Menarche (age at onset);
LUSC	cis	rs3741151	1.000	rs75004180	chr11:73024739	A/G	cg17517138	chr11:73019481	ARHGEF17	1.09	9.25	0.45	2.82e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7681440	0.647	rs1372508	chr4:90819786	C/G	cg01966878	chr4:90757139	SNCA	0.34	5.72	0.3	2.34e-8	Dementia with Lewy bodies;
LUSC	cis	rs13089785	1.000	rs35181974	chr3:123607884	C/A	cg19611163	chr3:123411211	MYLK	0.34	5.84	0.3	1.23e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs62400317	0.859	rs12203558	chr6:45244423	C/G	cg20913747	chr6:44695427	NA	-0.47	-7.65	-0.39	2.2e-13	Total body bone mineral density;
LUSC	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.6	-9.23	-0.45	3.26e-18	Morning vs. evening chronotype;
LUSC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.15	-0.32	2.18e-9	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg26043149	chr18:55253948	FECH	0.51	7.52	0.38	4.96e-13	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg07828340	chr4:882639	GAK	0.97	9.67	0.47	1.14e-19	Parkinson's disease;
LUSC	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg12365402	chr11:9010492	NRIP3	0.47	8.39	0.42	1.39e-15	Hemoglobin concentration;
LUSC	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg13010199	chr12:38710504	ALG10B	0.68	10.77	0.51	1.98e-23	Morning vs. evening chronotype;
LUSC	cis	rs9815354	0.812	rs73071352	chr3:41828300	A/G	cg03022575	chr3:42003672	ULK4	0.85	8.62	0.43	2.78e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg26395211	chr5:140044315	WDR55	0.45	7.01	0.36	1.33e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.72	12.79	0.57	9.24e-31	Prudent dietary pattern;
LUSC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg00857998	chr1:205179979	DSTYK	0.63	9.64	0.47	1.41e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs4363385	0.818	rs1890285	chr1:153015396	T/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.53	-0.38	4.68e-13	Inflammatory skin disease;
LUSC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.61	0.43	2.84e-16	Prudent dietary pattern;
LUSC	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-10.14	-0.49	3.06e-21	Bladder cancer;
LUSC	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg07837209	chr13:79184101	NA	-0.5	-7.1	-0.36	7.7e-12	Large artery stroke;
LUSC	trans	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg26811252	chr16:29126840	RRN3P2	0.61	9.7	0.47	9.3e-20	Menopause (age at onset);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06375580	chr12:42538820	GXYLT1	0.42	6.0	0.31	5e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg13010199	chr12:38710504	ALG10B	0.69	10.65	0.5	5.27e-23	Bladder cancer;
LUSC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg22823121	chr1:150693482	HORMAD1	0.6	9.33	0.45	1.46e-18	Tonsillectomy;
LUSC	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg14346243	chr4:90757452	SNCA	-0.39	-5.73	-0.3	2.25e-8	Neuroticism;
LUSC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg13397359	chr6:42928475	GNMT	0.65	11.1	0.52	1.37e-24	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs3790645	1.000	rs1064196	chr1:26887592	C/T	cg17456097	chr1:26900765	RPS6KA1	-0.41	-5.89	-0.31	9.19e-9	Glucose homeostasis traits;
LUSC	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.53	-0.38	4.91e-13	Neuroticism;
LUSC	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg18758796	chr5:131593413	PDLIM4	0.43	7.35	0.37	1.54e-12	Breast cancer;
LUSC	cis	rs9303542	0.527	rs8074125	chr17:46610060	G/T	cg09704116	chr17:46666958	LOC404266	-0.37	-6.52	-0.34	2.56e-10	Ovarian cancer;Epithelial ovarian cancer;
LUSC	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg12935359	chr14:103987150	CKB	-0.53	-8.13	-0.41	8.59e-15	Body mass index;
LUSC	trans	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-8.96	-0.44	2.32e-17	Heart rate;Heart rate variability traits (RMSSD);
LUSC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg12963246	chr6:28129442	ZNF389	0.54	7.74	0.39	1.2e-13	Parkinson's disease;
LUSC	cis	rs1712517	0.844	rs1163087	chr10:105043289	G/A	cg05636881	chr10:105038444	INA	0.39	6.3	0.33	9.24e-10	Migraine;
LUSC	cis	rs9650657	0.644	rs10091386	chr8:10696620	A/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.36	-0.33	6.49e-10	Neuroticism;
LUSC	cis	rs1375194	0.582	rs4670735	chr2:33801456	C/T	cg04131969	chr2:33951647	MYADML	-0.65	-9.01	-0.44	1.66e-17	Response to antidepressants in depression;
LUSC	cis	rs10207060	0.500	rs7566489	chr2:240703985	C/T	cg20333904	chr2:240724165	NA	-0.35	-6.1	-0.32	2.95e-9	Obesity-related traits;
LUSC	cis	rs6460942	0.908	rs6978768	chr7:12232366	G/A	cg06484146	chr7:12443880	VWDE	-0.56	-5.75	-0.3	2.03e-8	Coronary artery disease;
LUSC	trans	rs10208649	1.000	rs6731217	chr2:54131093	A/G	cg07564088	chr5:95170684	NA	0.68	5.97	0.31	6.17e-9	Body mass index;
LUSC	cis	rs7000551	0.751	rs2469768	chr8:22381362	G/A	cg12081754	chr8:22256438	SLC39A14	0.47	7.24	0.37	3.2e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LUSC	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg24642439	chr20:33292090	TP53INP2	0.5	7.43	0.38	8.94e-13	Height;
LUSC	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg07701084	chr6:150067640	NUP43	0.46	6.93	0.35	2.23e-11	Testicular germ cell tumor;
LUSC	cis	rs12824058	0.816	rs1874522	chr12:130816536	C/T	cg24838063	chr12:130822603	PIWIL1	-0.67	-10.75	-0.51	2.43e-23	Menopause (age at onset);
LUSC	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg01765077	chr12:122356316	WDR66	0.51	7.38	0.37	1.25e-12	Mean corpuscular volume;
LUSC	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg27147174	chr7:100797783	AP1S1	0.63	9.62	0.47	1.64e-19	Life satisfaction;
LUSC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.56	0.5	1.12e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs13126513	0.510	rs10516445	chr4:100524679	C/G	cg05468953	chr4:100565104	NA	0.38	7.22	0.37	3.52e-12	Metabolite levels (MHPG);
LUSC	trans	rs16993852	1.000	rs112708439	chr4:37753497	C/A	cg10635443	chr8:23557486	NA	0.53	6.09	0.32	3.05e-9	Staphylococcus aureus nasal carriage (intermittent);
LUSC	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg02158880	chr13:53174818	NA	0.55	9.35	0.46	1.28e-18	Lewy body disease;
LUSC	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg16405210	chr4:1374714	KIAA1530	-0.55	-8.3	-0.41	2.63e-15	Obesity-related traits;
LUSC	cis	rs500891	1.000	rs17256973	chr6:84175967	C/T	cg08257003	chr6:84140564	ME1	0.34	7.12	0.36	6.55e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs6545883	0.525	rs1729662	chr2:61391305	G/A	cg15711740	chr2:61764176	XPO1	-0.41	-6.43	-0.33	4.54e-10	Tuberculosis;
LUSC	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.9	0.31	8.78e-9	Lung cancer;
LUSC	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg25237894	chr2:233734115	C2orf82	-0.37	-6.91	-0.35	2.41e-11	Coronary artery disease;
LUSC	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg10596483	chr8:143751796	JRK	0.53	7.59	0.38	3.17e-13	Schizophrenia;
LUSC	cis	rs11997175	0.583	rs56045827	chr8:33787015	G/A	ch.8.33884649F	chr8:33765107	NA	0.46	6.76	0.35	6.32e-11	Body mass index;
LUSC	cis	rs1832871	0.672	rs6933928	chr6:158747071	C/T	cg07165851	chr6:158734300	TULP4	0.46	6.89	0.35	2.81e-11	Height;
LUSC	cis	rs6840360	0.642	rs11735957	chr4:152427506	G/A	cg20465933	chr4:152376761	FAM160A1	0.33	5.94	0.31	7.18e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg00745463	chr17:30367425	LRRC37B	0.88	8.73	0.43	1.21e-16	Hip circumference adjusted for BMI;
LUSC	trans	rs7944735	0.832	rs7130876	chr11:48050995	A/G	cg15704280	chr7:45808275	SEPT13	0.72	7.28	0.37	2.4e-12	Intraocular pressure;
LUSC	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg20701182	chr2:24300061	SF3B14	0.58	6.19	0.32	1.72e-9	Lymphocyte counts;
LUSC	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg27432699	chr2:27873401	GPN1	0.79	14.36	0.62	9.17e-37	Oral cavity cancer;
LUSC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.67	0.3	3.1e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs7523050	0.643	rs12725689	chr1:109405151	T/C	cg08274380	chr1:109419600	GPSM2	1.12	10.99	0.52	3.4e-24	Fat distribution (HIV);
LUSC	cis	rs6967385	0.604	rs2883866	chr7:12332245	T/A	cg06484146	chr7:12443880	VWDE	0.41	6.54	0.34	2.34e-10	Response to taxane treatment (placlitaxel);
LUSC	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.59	-9.09	-0.45	9.25e-18	Endometrial cancer;
LUSC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg14552801	chr7:65878734	NA	-0.46	-6.47	-0.33	3.44e-10	Aortic root size;
LUSC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-12.64	-0.57	3.3e-30	Chronic sinus infection;
LUSC	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg23093090	chr10:104574429	C10orf26	-0.35	-6.44	-0.33	4.15e-10	Arsenic metabolism;
LUSC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-7.5	-0.38	5.97e-13	Personality dimensions;
LUSC	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg08017756	chr2:100939284	LONRF2	-0.47	-8.64	-0.43	2.36e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	0.94	18.56	0.71	2.36e-53	Cognitive function;
LUSC	cis	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg10840412	chr1:235813424	GNG4	0.55	7.14	0.36	5.8e-12	Bipolar disorder;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg14114326	chr11:63381845	PLA2G16	0.49	6.5	0.34	2.95e-10	Hepatitis;
LUSC	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg02258303	chr16:87377426	FBXO31	0.62	10.26	0.49	1.17e-21	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LUSC	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg22676075	chr6:135203613	NA	0.57	9.0	0.44	1.7e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg16558253	chr16:72132732	DHX38	-0.38	-6.07	-0.32	3.45e-9	Fibrinogen levels;
LUSC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg12463550	chr7:65579703	CRCP	-0.63	-5.68	-0.3	2.92e-8	Diabetic kidney disease;
LUSC	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	11.38	0.53	1.39e-25	Eye color traits;
LUSC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg23985595	chr17:80112537	CCDC57	-0.32	-6.15	-0.32	2.16e-9	Life satisfaction;
LUSC	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.67	10.84	0.51	1.18e-23	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg27426351	chr10:43362370	NA	0.45	6.48	0.33	3.38e-10	Blood protein levels;
LUSC	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg04310649	chr10:35416472	CREM	-0.42	-6.43	-0.33	4.45e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg04310649	chr10:35416472	CREM	0.4	6.27	0.32	1.13e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7107174	0.892	rs4945265	chr11:78027458	G/A	cg02023728	chr11:77925099	USP35	0.48	6.83	0.35	4.04e-11	Testicular germ cell tumor;
LUSC	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg23950597	chr19:37808831	NA	-0.61	-6.99	-0.36	1.53e-11	Coronary artery calcification;
LUSC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg17366294	chr4:99064904	C4orf37	0.56	9.96	0.48	1.27e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.55	-8.28	-0.41	3.02e-15	Gut microbiome composition (summer);
LUSC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg05738196	chr6:26577821	NA	0.79	15.12	0.64	1.04e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg12011299	chr4:100065546	ADH4	-0.72	-10.43	-0.5	3.12e-22	Alcohol dependence;
LUSC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg16339924	chr4:17578868	LAP3	0.55	8.25	0.41	3.68e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs9614461	0.702	rs2294202	chr22:45738327	A/T	cg13318129	chr22:45737514	FAM118A	0.57	6.41	0.33	4.95e-10	Tonsillectomy;
LUSC	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg05340658	chr4:99064831	C4orf37	0.66	10.86	0.51	9.9899999999999993e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs11229555	0.957	rs10896796	chr11:58394256	A/G	cg15696309	chr11:58395628	NA	-0.69	-9.27	-0.45	2.43e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg17187183	chr4:55093834	PDGFRA	0.38	5.72	0.3	2.31e-8	Corneal astigmatism;
LUSC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg24209194	chr3:40518798	ZNF619	0.45	5.92	0.31	7.86e-9	Renal cell carcinoma;
LUSC	trans	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg17675199	chr6:35436792	RPL10A	-0.43	-6.34	-0.33	7.25e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs7804356	1.000	rs7785689	chr7:26861609	G/A	cg03456212	chr7:26904342	SKAP2	-0.52	-6.09	-0.32	3.05e-9	Type 1 diabetes;
LUSC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.55	-8.21	-0.41	4.78e-15	Total body bone mineral density;
LUSC	cis	rs1256061	0.624	rs1256046	chr14:64729356	A/C	cg21174375	chr14:64681225	SYNE2	0.35	6.26	0.32	1.19e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg12311346	chr5:56204834	C5orf35	-0.62	-9.55	-0.46	2.95e-19	Coronary artery disease;
LUSC	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg13010199	chr12:38710504	ALG10B	0.58	9.27	0.45	2.37e-18	Morning vs. evening chronotype;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18479798	chr11:64533623	SF1	0.53	7.4	0.38	1.15e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	7.16	0.36	5.27e-12	Menarche (age at onset);
LUSC	cis	rs6489882	0.902	rs1981556	chr12:113372961	C/G	cg20102336	chr12:113376681	OAS3	-0.42	-6.03	-0.31	4.29e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.91	-16.09	-0.66	1.54e-43	Cognitive function;
LUSC	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg23260525	chr10:116636907	FAM160B1	0.44	9.34	0.46	1.38e-18	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg11530693	chr1:120165357	ZNF697	0.69	10.79	0.51	1.79e-23	Systemic lupus erythematosus;
LUSC	cis	rs12200782	1.000	rs72844496	chr6:26611608	G/A	cg11502198	chr6:26597334	ABT1	-0.76	-5.8	-0.3	1.53e-8	Small cell lung carcinoma;
LUSC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg00857998	chr1:205179979	DSTYK	0.67	10.37	0.49	4.88e-22	White blood cell count (basophil);Basophil percentage of white cells;
LUSC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	13.12	0.58	5.41e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs3768617	0.745	rs4546885	chr1:183025555	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.56	8.09	0.4	1.12e-14	Fuchs's corneal dystrophy;
LUSC	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg26695010	chr11:65641043	EFEMP2	-0.48	-7.24	-0.37	3.07e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs4654899	0.931	rs10799671	chr1:21196764	C/T	cg01072550	chr1:21505969	NA	0.48	7.28	0.37	2.41e-12	Superior frontal gyrus grey matter volume;
LUSC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.05	0.64	1.96e-39	Platelet count;
LUSC	cis	rs977987	0.933	rs1834014	chr16:75501274	G/A	cg04384234	chr16:75411784	CFDP1	-0.48	-7.87	-0.4	4.88e-14	Dupuytren's disease;
LUSC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg23711669	chr6:146136114	FBXO30	0.87	16.53	0.67	2.75e-45	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12286929	0.576	rs2275997	chr11:115100186	A/G	cg04055981	chr11:115044050	NA	0.37	6.5	0.34	2.89e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg23711669	chr6:146136114	FBXO30	-0.92	-17.68	-0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs983392	0.679	rs636317	chr11:60019150	C/T	cg24026212	chr11:59952134	MS4A6A	0.38	6.68	0.34	1.01e-10	Alzheimer's disease (late onset);
LUSC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg04756594	chr16:24857601	SLC5A11	-0.48	-7.02	-0.36	1.25e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg14769373	chr6:40998127	UNC5CL	-0.56	-8.17	-0.41	6.51e-15	Gastric cancer;Non-cardia gastric cancer;
LUSC	trans	rs12902680	0.677	rs1821474	chr15:46543718	A/G	cg04321580	chr8:143696133	ARC	-0.41	-5.96	-0.31	6.39e-9	Neuroticism;
LUSC	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg13607699	chr17:42295918	UBTF	0.53	8.25	0.41	3.6e-15	Total body bone mineral density;
LUSC	cis	rs4792901	0.722	rs8074904	chr17:41571577	G/A	cg22562494	chr17:41607896	ETV4	-0.32	-6.02	-0.31	4.58e-9	Dupuytren's disease;
LUSC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg17376030	chr22:41985996	PMM1	-0.48	-6.04	-0.31	4.06e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6489882	0.872	rs7132797	chr12:113375036	A/C	cg20102336	chr12:113376681	OAS3	-0.41	-5.95	-0.31	6.85e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs7177699	0.557	rs62011002	chr15:79120578	C/T	cg00540400	chr15:79124168	NA	0.45	7.94	0.4	3.17e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	9.98	0.48	1.06e-20	Personality dimensions;
LUSC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg26335602	chr6:28129616	ZNF389	0.45	6.24	0.32	1.33e-9	Depression;
LUSC	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	11.25	0.52	4e-25	Colorectal cancer;
LUSC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg22535103	chr8:58192502	C8orf71	-0.8	-8.61	-0.43	2.94e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	9.62	0.47	1.65e-19	Height;
LUSC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg16405210	chr4:1374714	KIAA1530	-0.56	-9.03	-0.44	1.39e-17	Obesity-related traits;
LUSC	cis	rs11997175	0.679	rs10954935	chr8:33670379	C/G	ch.8.33884649F	chr8:33765107	NA	0.39	6.03	0.31	4.27e-9	Body mass index;
LUSC	cis	rs977987	0.836	rs7200053	chr16:75474618	C/T	cg03315344	chr16:75512273	CHST6	0.49	9.5	0.46	4.32e-19	Dupuytren's disease;
LUSC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	0.65	13.81	0.6	1.25e-34	Prudent dietary pattern;
LUSC	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg21385522	chr1:16154831	NA	-0.99	-18.42	-0.71	8.77e-53	Dilated cardiomyopathy;
LUSC	cis	rs965469	1.000	rs2236089	chr20:3257194	C/A	cg25506879	chr20:3388711	C20orf194	-0.51	-5.82	-0.3	1.39e-8	IFN-related cytopenia;
LUSC	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	14.18	0.61	4.72e-36	Exhaled nitric oxide levels;
LUSC	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg00376283	chr12:123451042	ABCB9	0.71	10.88	0.51	8.26e-24	Platelet count;
LUSC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.6	9.88	0.48	2.28e-20	Blood metabolite levels;
LUSC	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg18002602	chr11:66138449	SLC29A2	0.45	8.12	0.41	8.95e-15	Educational attainment (years of education);
LUSC	cis	rs151234	0.741	rs56236750	chr16:28594711	C/T	cg01378222	chr16:28622494	SULT1A1	-0.63	-8.57	-0.42	3.94e-16	Platelet distribution width;
LUSC	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.83	14.67	0.63	6e-38	Metabolic syndrome;
LUSC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg18758796	chr5:131593413	PDLIM4	0.42	7.12	0.36	6.72e-12	Breast cancer;
LUSC	cis	rs10871290	1.000	rs10871290	chr16:74472696	C/T	cg01733217	chr16:74700730	RFWD3	-0.56	-8.02	-0.4	1.83e-14	Breast cancer;
LUSC	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg18681998	chr4:17616180	MED28	0.87	15.4	0.64	8.33e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg19743168	chr1:23544995	NA	-0.38	-7.45	-0.38	8.14e-13	Height;
LUSC	trans	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.58e-15	Diabetic kidney disease;
LUSC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg27121462	chr16:89883253	FANCA	0.57	8.98	0.44	2e-17	Vitiligo;
LUSC	cis	rs4718428	0.705	rs4718430	chr7:66432024	G/T	cg12165864	chr7:66369176	NA	-0.55	-7.14	-0.36	5.95e-12	Corneal structure;
LUSC	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg25110126	chr1:46999211	NA	0.56	7.55	0.38	4.16e-13	Monobrow;
LUSC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg00409905	chr10:38381863	ZNF37A	-0.37	-6.3	-0.33	9.44e-10	Extrinsic epigenetic age acceleration;
LUSC	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.69	10.34	0.49	6.5e-22	Corneal astigmatism;
LUSC	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg24579218	chr15:68104479	NA	-0.39	-6.74	-0.35	6.88e-11	Obesity;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg04127825	chr1:167503222	NA	0.43	6.15	0.32	2.26e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7818345	0.967	rs4554480	chr8:19284072	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	7.5	0.38	5.68e-13	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg13939156	chr17:80058883	NA	0.33	6.45	0.33	3.87e-10	Life satisfaction;
LUSC	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg08847533	chr14:75593920	NEK9	-0.8	-13.77	-0.6	1.71e-34	Height;
LUSC	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.76	13.41	0.59	4.17e-33	Colorectal cancer;
LUSC	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg19920283	chr7:105172520	RINT1	0.57	6.14	0.32	2.39e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07080220	chr10:102295463	HIF1AN	0.7	9.43	0.46	7.36e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs814295	0.736	rs6744393	chr2:27750139	C/T	cg27432699	chr2:27873401	GPN1	0.5	5.73	0.3	2.26e-8	Triglyceride levels;
LUSC	cis	rs73198271	0.740	rs1039910	chr8:8648066	T/C	cg01851573	chr8:8652454	MFHAS1	0.54	8.75	0.43	1.1e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs7605827	0.930	rs7605730	chr2:15598696	A/G	cg19274914	chr2:15703543	NA	0.47	9.07	0.44	1.06e-17	Educational attainment (years of education);
LUSC	cis	rs7503807	1.000	rs12936076	chr17:78601195	C/T	cg09596252	chr17:78655493	RPTOR	0.44	7.5	0.38	5.93e-13	Obesity;
LUSC	cis	rs9517320	1.000	rs9584856	chr13:99126551	G/T	cg20487152	chr13:99095054	FARP1	0.36	6.7	0.34	8.6e-11	Longevity;
LUSC	cis	rs6969780	0.778	rs2465276	chr7:27145717	G/A	cg26364809	chr7:27145159	NA	-0.61	-6.12	-0.32	2.68e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
LUSC	cis	rs9323205	0.798	rs2999391	chr14:51655109	A/G	cg23942311	chr14:51606299	NA	0.37	7.73	0.39	1.3e-13	Cancer;
LUSC	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.87	-12.7	-0.57	2.01e-30	Asthma;
LUSC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg00684032	chr4:1343700	KIAA1530	0.32	5.84	0.3	1.25e-8	Longevity;
LUSC	cis	rs4964805	0.865	rs3935416	chr12:104206955	C/G	cg02344784	chr12:104178138	NT5DC3	0.49	7.9	0.4	3.97e-14	Attention deficit hyperactivity disorder;
LUSC	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	ch.11.42038R	chr11:967971	AP2A2	0.45	6.58	0.34	1.79e-10	Alzheimer's disease (late onset);
LUSC	trans	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.47	6.96	0.36	1.83e-11	Endometrial cancer;
LUSC	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg13393036	chr8:95962371	TP53INP1	0.44	9.17	0.45	4.87e-18	Type 2 diabetes;
LUSC	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg13010199	chr12:38710504	ALG10B	0.56	8.45	0.42	9.2e-16	Morning vs. evening chronotype;
LUSC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg26335602	chr6:28129616	ZNF389	0.43	5.74	0.3	2.17e-8	Depression;
LUSC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg21132104	chr15:45694354	SPATA5L1	0.58	8.25	0.41	3.64e-15	Homoarginine levels;
LUSC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.49	-7.7	-0.39	1.55e-13	Tonsillectomy;
LUSC	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg22532475	chr10:104410764	TRIM8	0.25	5.87	0.31	1.03e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LUSC	cis	rs7106204	1.000	rs6484025	chr11:24214514	C/G	ch.11.24196551F	chr11:24239977	NA	0.97	9.16	0.45	5.54e-18	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg03605463	chr16:89740564	NA	0.61	9.57	0.46	2.41e-19	Vitiligo;
LUSC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00149659	chr3:10157352	C3orf10	1.01	14.42	0.62	5.3e-37	Alzheimer's disease;
LUSC	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.77	-0.43	8.96e-17	Monocyte percentage of white cells;
LUSC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03264133	chr6:25882463	NA	-0.4	-6.83	-0.35	4.06e-11	Blood metabolite levels;
LUSC	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg13390004	chr1:15929781	NA	0.4	6.69	0.34	9.64e-11	Systolic blood pressure;
LUSC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.74	-0.3	2.14e-8	Depression;
LUSC	cis	rs28829049	0.597	rs12745238	chr1:19393710	C/T	cg13387374	chr1:19411106	UBR4	0.4	5.66	0.3	3.27e-8	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg20307385	chr11:47447363	PSMC3	0.51	5.92	0.31	7.81e-9	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02034447	chr16:89574710	SPG7	-0.42	-6.3	-0.33	9.2e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg00852783	chr1:26633632	UBXN11	-0.48	-5.76	-0.3	1.96e-8	Obesity-related traits;
LUSC	cis	rs3091242	1.000	rs3091242	chr1:25674785	C/T	cg26659404	chr1:25747437	RHCE	-0.28	-5.78	-0.3	1.7e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg04733989	chr22:42467013	NAGA	0.41	6.67	0.34	1.05e-10	Cognitive function;
LUSC	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg24578937	chr1:2090814	PRKCZ	-0.43	-9.19	-0.45	4.33e-18	Height;
LUSC	cis	rs3743266	0.613	rs1869484	chr15:60742063	G/T	cg21667061	chr15:60772094	NARG2	-0.37	-6.27	-0.32	1.09e-9	Menarche (age at onset);
LUSC	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg12002119	chr2:101014098	CHST10	0.36	5.99	0.31	5.44e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg01483505	chr11:975446	AP2A2	0.4	5.81	0.3	1.44e-8	Alzheimer's disease (late onset);
LUSC	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08219700	chr8:58056026	NA	0.67	8.68	0.43	1.75e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg07741184	chr6:167504864	NA	-0.35	-6.41	-0.33	4.84e-10	Crohn's disease;
LUSC	cis	rs7572644	0.699	rs6738887	chr2:28268467	C/T	cg27432699	chr2:27873401	GPN1	-0.53	-7.13	-0.36	6.07e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg06636001	chr8:8085503	FLJ10661	0.65	10.69	0.5	3.96e-23	Mood instability;
LUSC	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg03788504	chr6:150331562	NA	-0.25	-5.74	-0.3	2.12e-8	Alopecia areata;
LUSC	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg16586182	chr3:47516702	SCAP	-0.51	-7.17	-0.37	4.79e-12	Birth weight;
LUSC	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg24675056	chr1:15929824	NA	0.5	8.7	0.43	1.53e-16	Systolic blood pressure;
LUSC	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg07677032	chr17:61819896	STRADA	-0.49	-8.21	-0.41	4.77e-15	Prudent dietary pattern;
LUSC	trans	rs11071559	0.526	rs1963497	chr15:61071791	A/C	cg21548772	chr3:47422338	PTPN23	0.37	6.15	0.32	2.21e-9	Asthma;
LUSC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.87	-0.58	4.63e-31	Chronic sinus infection;
LUSC	trans	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg25214090	chr10:38739885	LOC399744	-0.41	-6.45	-0.33	3.97e-10	Corneal astigmatism;
LUSC	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg08798685	chr6:27730294	NA	-0.42	-5.78	-0.3	1.7e-8	Parkinson's disease;
LUSC	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg03477792	chr4:77819574	ANKRD56	0.61	8.63	0.43	2.59e-16	Emphysema distribution in smoking;
LUSC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-6.96	-0.36	1.77e-11	Obesity-related traits;
LUSC	cis	rs11577318	0.538	rs10902745	chr1:26687070	G/C	cg00852783	chr1:26633632	UBXN11	-0.54	-7.4	-0.38	1.09e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg03676636	chr4:99064102	C4orf37	0.34	7.39	0.37	1.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs10266483	0.739	rs10949900	chr7:63812129	A/G	cg24201672	chr7:64023550	ZNF680	0.48	6.24	0.32	1.35e-9	Response to statin therapy;
LUSC	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	6.41	0.33	5.05e-10	IgG glycosylation;
LUSC	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg01420254	chr6:26195488	NA	0.66	7.31	0.37	2.05e-12	Gout;Renal underexcretion gout;
LUSC	trans	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg19731845	chr4:166199412	KLHL2;GK3P	-0.48	-6.59	-0.34	1.76e-10	Corneal astigmatism;
LUSC	cis	rs4664304	0.772	rs10183731	chr2:160740989	A/G	cg03641300	chr2:160917029	PLA2R1	0.36	5.77	0.3	1.84e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg21153622	chr11:89784906	NA	-0.39	-6.08	-0.32	3.3e-9	Coronary artery disease;
LUSC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18404041	chr3:52824283	ITIH1	-0.54	-10.39	-0.49	4.23e-22	Electroencephalogram traits;
LUSC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg05738196	chr6:26577821	NA	-0.48	-7.11	-0.36	6.88e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg14186256	chr22:23484241	RTDR1	0.93	17.14	0.68	1.12e-47	Bone mineral density;
LUSC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg12963246	chr6:28129442	ZNF389	0.43	6.15	0.32	2.26e-9	Depression;
LUSC	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg02023728	chr11:77925099	USP35	0.46	6.72	0.34	8.05e-11	Testicular germ cell tumor;
LUSC	cis	rs3741151	0.773	rs7950375	chr11:73281345	G/A	cg17517138	chr11:73019481	ARHGEF17	0.98	8.2	0.41	5.31e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.72	11.89	0.55	1.95e-27	Prudent dietary pattern;
LUSC	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg04733989	chr22:42467013	NAGA	-0.47	-7.7	-0.39	1.5700000000000001e-13	Cognitive function;
LUSC	cis	rs611744	0.870	rs635941	chr8:109235457	G/A	cg18478394	chr8:109455254	TTC35	0.4	6.02	0.31	4.67e-9	Dupuytren's disease;
LUSC	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg13256891	chr4:100009986	ADH5	-0.46	-6.12	-0.32	2.58e-9	Alcohol dependence;
LUSC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.67	0.34	1.06e-10	Neutrophil percentage of white cells;
LUSC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25072359	chr17:41440525	NA	0.64	9.02	0.44	1.51e-17	Menopause (age at onset);
LUSC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	6.05	0.31	3.8e-9	Height;
LUSC	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg18252515	chr7:66147081	NA	-0.49	-6.47	-0.33	3.44e-10	Corneal structure;
LUSC	cis	rs7707921	0.767	rs6894520	chr5:81594748	C/T	cg15871215	chr5:81402204	ATG10	-0.42	-6.7	-0.34	8.79e-11	Breast cancer;
LUSC	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg05253716	chr12:129299332	SLC15A4;MGC16384	0.45	6.68	0.34	9.94e-11	Systemic lupus erythematosus;
LUSC	cis	rs9420	0.961	rs11602109	chr11:57435296	G/A	cg02958346	chr11:57425731	CLP1	-0.43	-6.33	-0.33	7.73e-10	Schizophrenia;
LUSC	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg24375607	chr4:120327624	NA	0.78	11.35	0.53	1.82e-25	Corneal astigmatism;
LUSC	cis	rs4499344	0.657	rs259238	chr19:33140381	A/G	cg22980127	chr19:33182716	NUDT19	-0.48	-6.94	-0.35	2.06e-11	Mean platelet volume;
LUSC	cis	rs12425451	0.552	rs10848765	chr12:3141495	C/T	cg05389053	chr12:3131226	TEAD4	0.41	5.87	0.31	1.04e-8	Narcolepsy with cataplexy;
LUSC	cis	rs735539	0.645	rs1411038	chr13:21248431	A/G	cg04906043	chr13:21280425	IL17D	-0.48	-7.76	-0.39	1.03e-13	Dental caries;
LUSC	cis	rs34734847	0.871	rs2239760	chr12:121163518	C/A	cg21892295	chr12:121157589	UNC119B	-0.48	-8.55	-0.42	4.41e-16	Mean corpuscular volume;
LUSC	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg13010199	chr12:38710504	ALG10B	-0.52	-7.74	-0.39	1.16e-13	Bladder cancer;
LUSC	cis	rs6977940	0.818	rs11765386	chr7:2894512	A/G	cg19731401	chr7:2775893	GNA12	-0.58	-6.49	-0.33	3.16e-10	White matter integrity;
LUSC	cis	rs10864907	0.614	rs10199311	chr2:113697961	C/T	cg06156847	chr2:113672199	IL1F7	-0.28	-5.84	-0.3	1.27e-8	Pulmonary function;
LUSC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14893161	chr1:205819251	PM20D1	0.86	15.93	0.66	6.79e-43	Menarche (age at onset);
LUSC	cis	rs6750047	0.605	rs59501228	chr2:38261972	A/C	cg07380506	chr2:38303506	CYP1B1	-0.44	-6.13	-0.32	2.49e-9	Cutaneous malignant melanoma;Melanoma;
LUSC	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.46	8.79	0.43	8.11e-17	Axial length;
LUSC	trans	rs11681884	0.786	rs1992763	chr2:113810736	T/A	cg19632953	chr13:113635898	MCF2L	0.69	6.03	0.31	4.45e-9	Stroke;
LUSC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg13683864	chr3:40499215	RPL14	1.09	21.26	0.76	4.94e-64	Renal cell carcinoma;
LUSC	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg14019695	chr9:139328340	INPP5E	0.44	8.12	0.41	9.39e-15	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg25243455	chr2:114033360	PAX8;LOC440839	-0.34	-7.68	-0.39	1.73e-13	Lymphocyte counts;
LUSC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	9.1	0.45	8.31e-18	Motion sickness;
LUSC	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	8.91	0.44	3.26e-17	Response to bleomycin (chromatid breaks);
LUSC	cis	rs6084875	0.840	rs2422933	chr20:4720035	T/C	cg07258627	chr20:4721683	PRNT	-0.34	-6.14	-0.32	2.32e-9	Systemic lupus erythematosus;
LUSC	cis	rs727505	0.954	rs989177	chr7:124412886	A/G	cg14311320	chr7:124405732	GPR37	-0.33	-5.7	-0.3	2.64e-8	Lewy body disease;
LUSC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg12463550	chr7:65579703	CRCP	0.62	5.67	0.3	3.04e-8	Diabetic kidney disease;
LUSC	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg00745463	chr17:30367425	LRRC37B	0.57	7.2	0.37	4.07e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg26597838	chr10:835615	NA	0.8	9.93	0.48	1.6e-20	Eosinophil percentage of granulocytes;
LUSC	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg10911889	chr6:126070802	HEY2	0.42	6.39	0.33	5.59e-10	Brugada syndrome;
LUSC	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg18132916	chr6:79620363	NA	-0.37	-5.7	-0.3	2.6e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-13.68	-0.6	3.86e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg11344533	chr11:111475393	SIK2	0.46	6.07	0.32	3.56e-9	Primary sclerosing cholangitis;
LUSC	cis	rs77741769	0.571	rs11065282	chr12:121264415	G/T	cg02419362	chr12:121203948	SPPL3	0.45	8.34	0.41	2.04e-15	Mean corpuscular volume;
LUSC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23978390	chr7:1156363	C7orf50	0.5	7.07	0.36	9.07e-12	Longevity;Endometriosis;
LUSC	cis	rs7760949	0.963	rs9475771	chr6:13914869	A/G	cg27413430	chr6:13925136	RNF182	-0.54	-8.23	-0.41	4.34e-15	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs4629710	0.545	rs11154621	chr6:131547341	A/G	cg12606694	chr6:131520996	AKAP7	0.57	8.82	0.43	6.68e-17	Multiple myeloma (IgH translocation);
LUSC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.26	0.37	2.68e-12	Parkinson's disease;
LUSC	cis	rs17286411	0.777	rs4788569	chr16:71914785	A/G	cg03805757	chr16:71968109	PKD1L3	0.42	6.89	0.35	2.72e-11	Blood protein levels;
LUSC	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.92	15.7	0.65	5.59e-42	Bladder cancer;
LUSC	cis	rs9650315	0.929	rs4400356	chr8:57180161	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	6.82	0.35	4.17e-11	Height;
LUSC	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg05340658	chr4:99064831	C4orf37	-0.44	-6.99	-0.36	1.53e-11	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg08847533	chr14:75593920	NEK9	0.85	15.77	0.65	2.82e-42	Height;
LUSC	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg04315214	chr1:2043799	PRKCZ	0.39	7.45	0.38	8.27e-13	Height;
LUSC	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-0.79	-14.15	-0.61	6.28e-36	Brugada syndrome;
LUSC	cis	rs2540226	0.816	rs9309042	chr2:40001889	G/A	cg23576258	chr2:39999331	THUMPD2	0.33	5.69	0.3	2.83e-8	Personality dimensions;
LUSC	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg19629631	chr7:2060116	MAD1L1	-0.35	-5.7	-0.3	2.68e-8	Neuroticism;
LUSC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-1.23	-13.63	-0.6	5.9e-34	Diabetic kidney disease;
LUSC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg11218175	chr11:495084	RNH1	0.54	5.85	0.3	1.19e-8	Body mass index;
LUSC	cis	rs9309473	0.607	rs6740173	chr2:73602266	C/G	cg20560298	chr2:73613845	ALMS1	-0.57	-8.39	-0.42	1.39e-15	Metabolite levels;
LUSC	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.85	-19.39	-0.73	1.19e-56	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg00945038	chr17:61921165	SMARCD2	0.54	9.72	0.47	8.06e-20	Prudent dietary pattern;
LUSC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg11663144	chr21:46675770	NA	-0.41	-7.03	-0.36	1.15e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg07395648	chr5:131743802	NA	0.47	7.62	0.38	2.7e-13	Breast cancer;Mosquito bite size;
LUSC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg26338869	chr17:61819248	STRADA	0.42	6.17	0.32	1.99e-9	Prudent dietary pattern;
LUSC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg13798912	chr7:905769	UNC84A	-0.59	-5.99	-0.31	5.35e-9	Cerebrospinal P-tau181p levels;
LUSC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg08508325	chr11:3079039	CARS	-0.51	-12.75	-0.57	1.35e-30	Longevity;
LUSC	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg03676636	chr4:99064102	C4orf37	0.36	7.93	0.4	3.38e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.5	6.05	0.31	3.86e-9	Mean platelet volume;
LUSC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg02380750	chr20:61661411	NA	0.33	5.83	0.3	1.32e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.75	-13.41	-0.59	4.16e-33	Aortic root size;
LUSC	trans	rs12637928	0.580	rs1533211	chr3:110186311	A/T	cg17371621	chr15:61264283	RORA	0.36	6.07	0.32	3.39e-9	Neuroticism;
LUSC	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-5.85	-0.3	1.18e-8	Recombination rate (females);
LUSC	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-8.44	-0.42	9.55e-16	Response to antipsychotic treatment;
LUSC	cis	rs6845621	0.727	rs6837620	chr4:18898521	A/G	cg12196642	chr4:18937545	NA	-0.33	-6.11	-0.32	2.73e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LUSC	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg15557168	chr22:42548783	NA	-0.4	-6.8	-0.35	4.75e-11	Cognitive function;
LUSC	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.5	6.72	0.35	7.82e-11	Tonsillectomy;
LUSC	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-15.94	-0.66	6.34e-43	Height;
LUSC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-7.07	-0.36	9.2e-12	Alzheimer's disease (late onset);
LUSC	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg19628046	chr18:33552617	C18orf21	0.5	6.39	0.33	5.58e-10	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg17366294	chr4:99064904	C4orf37	0.55	9.01	0.44	1.63e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	cis	rs8016982	0.662	rs1951616	chr14:81671752	T/C	cg01989461	chr14:81687754	GTF2A1	0.51	6.83	0.35	3.91e-11	Schizophrenia;
LUSC	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg04058563	chr4:185651563	MLF1IP	0.41	6.59	0.34	1.72e-10	Kawasaki disease;
LUSC	cis	rs9581857	0.547	rs78273785	chr13:28052884	T/C	cg22138327	chr13:27999177	GTF3A	0.77	8.21	0.41	4.96e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg21724239	chr8:58056113	NA	0.8	8.35	0.42	1.85e-15	Developmental language disorder (linguistic errors);
LUSC	trans	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-6.76	-0.35	6.16e-11	Monocyte count;
LUSC	cis	rs9473147	0.543	rs4711880	chr6:47480676	A/G	cg20196966	chr6:47445060	CD2AP	0.41	5.79	0.3	1.66e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg09165964	chr15:75287851	SCAMP5	-0.92	-8.63	-0.43	2.56e-16	Lung cancer;
LUSC	cis	rs7267979	0.528	rs6076366	chr20:25564626	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.71	-12.72	-0.57	1.74e-30	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.63	0.86	5.12e-99	Chronic sinus infection;
LUSC	trans	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg20935933	chr6:143382018	AIG1	0.5	7.33	0.37	1.71e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06636316	chr19:30303495	CCNE1	-0.42	-6.21	-0.32	1.54e-9	Electrocardiographic conduction measures;
LUSC	cis	rs72781680	0.716	rs2712079	chr2:24082061	G/A	cg08917208	chr2:24149416	ATAD2B	0.6	6.95	0.36	1.97e-11	Lymphocyte counts;
LUSC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	0.95	18.98	0.72	5.3e-55	Cognitive function;
LUSC	cis	rs6982240	0.569	rs6992278	chr8:142279383	C/G	cg00131261	chr8:142287264	NA	-0.38	-6.63	-0.34	1.38e-10	Tonsillectomy;
LUSC	cis	rs3736594	0.513	rs62138965	chr2:27816593	T/C	cg27432699	chr2:27873401	GPN1	0.66	8.73	0.43	1.25e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22307029	chr19:49891270	CCDC155	0.67	8.61	0.43	2.92e-16	Multiple sclerosis;
LUSC	cis	rs1712517	0.873	rs1712510	chr10:105009086	A/G	cg05636881	chr10:105038444	INA	-0.42	-6.91	-0.35	2.4e-11	Migraine;
LUSC	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.31	0.45	1.77e-18	Blood protein levels;
LUSC	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07988820	chr12:82153109	PPFIA2	-0.43	-6.0	-0.31	5.12e-9	Resting heart rate;
LUSC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg23303369	chr20:44641161	MMP9	-0.35	-6.09	-0.32	3.18e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg18721089	chr20:30220636	NA	-0.37	-5.76	-0.3	1.86e-8	Mean corpuscular hemoglobin;
LUSC	cis	rs7833787	1.000	rs17383616	chr8:18704800	A/C	cg17701159	chr8:18705777	PSD3	-0.36	-5.73	-0.3	2.2e-8	Obesity-related traits;
LUSC	cis	rs1950626	0.623	rs61991083	chr14:101436435	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.4	7.47	0.38	7.07e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-6.44	-0.33	4.12e-10	Major depressive disorder;
LUSC	cis	rs12618769	0.652	rs3754871	chr2:99224309	A/T	cg10123293	chr2:99228465	UNC50	0.47	7.71	0.39	1.48e-13	Bipolar disorder;
LUSC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.66	0.83	2.24e-88	Chronic sinus infection;
LUSC	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg27411982	chr8:10470053	RP1L1	0.42	6.72	0.35	7.89e-11	Mood instability;
LUSC	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02176678	chr2:219576539	TTLL4	0.6	10.98	0.52	3.66e-24	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg04310649	chr10:35416472	CREM	-0.4	-6.22	-0.32	1.52e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs9549260	0.755	rs4325426	chr13:41216437	C/A	cg21288729	chr13:41239152	FOXO1	0.64	9.95	0.48	1.29e-20	Red blood cell count;
LUSC	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg20684491	chr1:25596433	NA	0.36	5.65	0.3	3.43e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs117352156	0.943	rs10508740	chr10:29220339	A/T	cg06394621	chr10:29236369	NA	-0.45	-5.91	-0.31	8.29e-9	Aggressiveness in attention deficit hyperactivity disorder;
LUSC	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.5	-5.74	-0.3	2.14e-8	Schizophrenia;
LUSC	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg08017756	chr2:100939284	LONRF2	-0.46	-8.57	-0.42	3.91e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22509189	chr2:225307070	NA	-0.49	-6.24	-0.32	1.33e-9	IgE levels in asthmatics (D.p. specific);
LUSC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg22907277	chr7:1156413	C7orf50	0.68	7.31	0.37	2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs240764	0.853	rs2062634	chr6:101002618	G/C	cg09795085	chr6:101329169	ASCC3	-0.41	-5.9	-0.31	9.04e-9	Neuroticism;
LUSC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	0.83	14.09	0.61	1.01e-35	Tonsillectomy;
LUSC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.67	11.43	0.53	9.5e-26	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12050794	0.671	rs62022788	chr15:72559326	T/G	cg16672083	chr15:72433130	SENP8	0.47	7.8	0.39	7.96e-14	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs2996428	0.629	rs12135894	chr1:3728061	C/T	cg22529645	chr1:3704559	LRRC47	0.35	6.03	0.31	4.36e-9	Red cell distribution width;
LUSC	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg10018233	chr7:150070692	REPIN1	0.36	6.61	0.34	1.48e-10	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg08892416	chr16:89800313	ZNF276	-0.37	-6.32	-0.33	8.39e-10	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs4363385	0.720	rs6680624	chr1:152983872	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.67	-0.39	1.9e-13	Inflammatory skin disease;
LUSC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06850241	chr22:41845214	NA	0.33	5.83	0.3	1.28e-8	Vitiligo;
LUSC	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.8	0.51	1.66e-23	Lung cancer in ever smokers;
LUSC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.39	-5.87	-0.31	1.07e-8	Platelet count;
LUSC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	0.95	16.07	0.66	1.92e-43	Menopause (age at onset);
LUSC	cis	rs7177699	0.550	rs7182716	chr15:79123753	T/C	cg00540400	chr15:79124168	NA	0.43	7.5	0.38	5.63e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg10356904	chr22:49881777	NA	-0.3	-5.94	-0.31	7.14e-9	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs829883	1.000	rs1347956	chr12:98889564	A/G	cg25150519	chr12:98850993	NA	0.64	10.01	0.48	8.48e-21	Colorectal adenoma (advanced);
LUSC	cis	rs9473147	0.543	rs9473126	chr6:47481833	C/G	cg20196966	chr6:47445060	CD2AP	0.41	5.79	0.3	1.66e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7607369	0.536	rs12623007	chr2:219665335	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-8.94	-0.44	2.63e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LUSC	cis	rs295140	0.933	rs10931900	chr2:201177193	T/C	cg04283868	chr2:201171347	SPATS2L	0.43	6.56	0.34	2.08e-10	QT interval;
LUSC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg22920501	chr2:26401640	FAM59B	0.81	12.05	0.55	5.03e-28	Gut microbiome composition (summer);
LUSC	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg06191203	chr2:152266755	RIF1	0.51	6.99	0.36	1.46e-11	Lung cancer;
LUSC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.1	17.14	0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg15790184	chr11:494944	RNH1	0.54	5.99	0.31	5.43e-9	Body mass index;
LUSC	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg15839431	chr19:19639596	YJEFN3	-0.58	-6.41	-0.33	5.02e-10	Bipolar disorder;
LUSC	cis	rs16854884	0.657	rs16854772	chr3:143703890	A/G	cg06585982	chr3:143692056	C3orf58	0.45	6.86	0.35	3.29e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg09184832	chr6:79620586	NA	-0.44	-7.1	-0.36	7.7e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg06600287	chr1:53387719	ECHDC2	-0.32	-6.56	-0.34	2.09e-10	Monocyte count;
LUSC	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-9.32	-0.45	1.66e-18	Extrinsic epigenetic age acceleration;
LUSC	cis	rs738322	0.555	rs5750549	chr22:38547172	C/T	cg25457927	chr22:38595422	NA	-0.4	-7.95	-0.4	2.85e-14	Cutaneous nevi;
LUSC	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg17385448	chr1:15911702	AGMAT	0.38	5.79	0.3	1.61e-8	Systolic blood pressure;
LUSC	cis	rs73206853	0.609	rs7966169	chr12:111045898	T/C	cg12870014	chr12:110450643	ANKRD13A	0.69	7.58	0.38	3.37e-13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-5.97	-0.31	5.95e-9	Huntington's disease progression;
LUSC	cis	rs2548003	0.518	rs967080	chr5:28755831	T/C	cg22863700	chr5:28928346	NA	0.42	6.04	0.31	4.19e-9	Hip geometry;
LUSC	cis	rs1784581	0.894	rs1626020	chr6:162383379	G/A	cg17173639	chr6:162384350	PARK2	-0.8	-15.02	-0.63	2.55e-39	Itch intensity from mosquito bite;
LUSC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg13397359	chr6:42928475	GNMT	0.59	9.78	0.47	5.06e-20	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs1451375	0.959	rs1451373	chr7:50622606	A/G	cg18232548	chr7:50535776	DDC	0.51	7.83	0.39	6.32e-14	Malaria;
LUSC	cis	rs4363385	0.574	rs6683514	chr1:152984397	A/G	cg25856811	chr1:152973957	SPRR3	-0.36	-6.03	-0.31	4.32e-9	Inflammatory skin disease;
LUSC	cis	rs4423214	0.559	rs10898228	chr11:71228358	A/T	cg05163923	chr11:71159392	DHCR7	-0.69	-7.12	-0.36	6.62e-12	Vitamin D levels;
LUSC	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.99	0.4	2.2e-14	Asthma and hay fever;
LUSC	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg21427119	chr20:30132790	HM13	-0.42	-6.27	-0.32	1.1e-9	Mean corpuscular hemoglobin;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg03031660	chr17:73257791	MRPS7;GGA3	0.37	6.62	0.34	1.47e-10	Triglycerides;
LUSC	cis	rs11997175	0.624	rs12677772	chr8:33772521	T/C	ch.8.33884649F	chr8:33765107	NA	0.51	7.8	0.39	7.91e-14	Body mass index;
LUSC	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg09904177	chr6:26538194	HMGN4	0.73	13.27	0.59	1.45e-32	Intelligence (multi-trait analysis);
LUSC	cis	rs3087591	0.960	rs12603885	chr17:29466722	C/T	cg24425628	chr17:29625626	OMG;NF1	0.56	8.03	0.4	1.69e-14	Hip circumference;
LUSC	cis	rs7804356	1.000	rs12536145	chr7:26894860	A/T	cg03456212	chr7:26904342	SKAP2	-0.52	-6.04	-0.31	4.16e-9	Type 1 diabetes;
LUSC	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg19610905	chr11:61596333	FADS2	-0.54	-8.08	-0.4	1.17e-14	Trans fatty acid levels;
LUSC	cis	rs9886651	0.905	rs10110243	chr8:128805020	A/G	cg07795030	chr8:128802207	NA	-0.35	-6.22	-0.32	1.53e-9	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LUSC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg24812749	chr6:127587940	RNF146	0.73	10.48	0.5	2.02e-22	Breast cancer;
LUSC	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg21545522	chr1:205238299	TMCC2	0.47	8.76	0.43	1.02e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg10326726	chr10:51549505	MSMB	0.34	5.77	0.3	1.76e-8	Prostate-specific antigen levels;
LUSC	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg10518543	chr12:38710700	ALG10B	0.4	5.7	0.3	2.68e-8	Morning vs. evening chronotype;
LUSC	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg13010199	chr12:38710504	ALG10B	0.66	10.33	0.49	6.76e-22	Morning vs. evening chronotype;
LUSC	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg13628971	chr7:2884303	GNA12	0.38	5.84	0.3	1.22e-8	Height;
LUSC	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg00484396	chr16:3507460	NAT15	-0.37	-6.21	-0.32	1.53e-9	Body mass index (adult);
LUSC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg02569458	chr12:86230093	RASSF9	0.61	10.31	0.49	8.24e-22	Major depressive disorder;
LUSC	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg24851651	chr11:66362959	CCS	-0.37	-5.92	-0.31	8.01e-9	Educational attainment (years of education);
LUSC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.56e-10	Menopause (age at onset);
LUSC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg19077165	chr18:44547161	KATNAL2	-0.38	-5.75	-0.3	1.98e-8	Personality dimensions;
LUSC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg26924012	chr15:45694286	SPATA5L1	1.12	20.7	0.75	8.1e-62	Homoarginine levels;
LUSC	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg06219351	chr7:158114137	PTPRN2	0.49	7.7	0.39	1.53e-13	Calcium levels;
LUSC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg19592336	chr6:28129416	ZNF389	0.55	7.18	0.37	4.6e-12	Parkinson's disease;
LUSC	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg26408565	chr15:76604113	ETFA	0.47	7.43	0.38	8.89e-13	Blood metabolite levels;
LUSC	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg12927641	chr6:109611667	NA	0.36	6.1	0.32	2.99e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs35883536	0.647	rs12026951	chr1:101046273	C/T	cg06223162	chr1:101003688	GPR88	-0.47	-8.81	-0.43	6.81e-17	Monocyte count;
LUSC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg13319975	chr6:146136371	FBXO30	0.5	7.44	0.38	8.58e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg08085267	chr17:45401833	C17orf57	-0.54	-8.57	-0.42	3.77e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.18	-0.32	1.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs1325195	0.881	rs1173077	chr1:179220878	C/T	cg11624085	chr17:8464688	MYH10	0.43	7.01	0.36	1.33e-11	IgE grass sensitization;
LUSC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06634786	chr22:41940651	POLR3H	0.49	6.12	0.32	2.56e-9	Vitiligo;
LUSC	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg13010199	chr12:38710504	ALG10B	0.57	9.04	0.44	1.26e-17	Morning vs. evening chronotype;
LUSC	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.53	-8.44	-0.42	1e-15	Platelet count;
LUSC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02187348	chr16:89574699	SPG7	0.61	10.03	0.48	7.29e-21	Multiple myeloma (IgH translocation);
LUSC	cis	rs12530845	0.623	rs73721662	chr7:135341314	G/A	cg23117316	chr7:135346802	PL-5283	-0.63	-9.65	-0.47	1.31e-19	Red blood cell traits;
LUSC	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg25566285	chr7:158114605	PTPRN2	0.34	6.53	0.34	2.45e-10	Calcium levels;
LUSC	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-6.36	-0.33	6.74e-10	Fear of minor pain;
LUSC	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg03684893	chr10:554711	DIP2C	-0.37	-6.81	-0.35	4.68e-11	Psychosis in Alzheimer's disease;
LUSC	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg20701182	chr2:24300061	SF3B14	0.74	7.6	0.38	3.07e-13	Lymphocyte counts;
LUSC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.83	0.6	1.04e-34	Platelet count;
LUSC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg03676636	chr4:99064102	C4orf37	0.33	7.17	0.37	4.89e-12	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7760949	0.889	rs9396272	chr6:13938080	C/T	cg27413430	chr6:13925136	RNF182	-0.55	-8.44	-0.42	9.95e-16	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7180079	0.502	rs8033972	chr15:64524980	G/A	cg08069370	chr15:64387884	SNX1	-0.45	-6.52	-0.34	2.57e-10	Monocyte count;
LUSC	cis	rs4343996	0.967	rs34608458	chr7:3357881	G/A	cg21248987	chr7:3385318	SDK1	-0.39	-6.62	-0.34	1.41e-10	Motion sickness;
LUSC	cis	rs988712	0.705	rs10501087	chr11:27670108	C/T	cg10635145	chr11:27742435	BDNF	0.45	5.88	0.31	1.01e-8	Obesity;
LUSC	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg18132916	chr6:79620363	NA	-0.38	-5.85	-0.3	1.17e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	7.62	0.38	2.66e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6543140	0.601	rs78178597	chr2:103023596	G/T	cg09003973	chr2:102972529	NA	0.73	8.63	0.43	2.53e-16	Blood protein levels;
LUSC	trans	rs12210905	0.688	rs78285097	chr6:27374644	G/C	cg14616345	chr9:133901267	LAMC3	-0.65	-5.95	-0.31	6.6e-9	Hip circumference adjusted for BMI;
LUSC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg22638593	chr5:131593259	PDLIM4	0.44	6.28	0.33	1.05e-9	Acylcarnitine levels;
LUSC	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-10.59	-0.5	8.37e-23	Bone mineral density;
LUSC	cis	rs2901656	1.000	rs6691993	chr1:172426998	T/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.3	6.01	0.31	4.78e-9	Red cell distribution width;Platelet distribution width;
LUSC	cis	rs11630290	1.000	rs72750987	chr15:63999112	G/C	cg12036633	chr15:63758958	NA	-0.73	-8.18	-0.41	6.2e-15	Iris characteristics;
LUSC	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg09904177	chr6:26538194	HMGN4	-0.75	-7.04	-0.36	1.12e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.54	-9.1	-0.45	8.12e-18	Homoarginine levels;
LUSC	cis	rs7582720	1.000	rs72936304	chr2:204036357	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.55	0.42	4.56e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7106204	0.534	rs75297923	chr11:24253530	A/G	ch.11.24196551F	chr11:24239977	NA	0.72	6.09	0.32	3.05e-9	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg00024416	chr22:24240387	NA	-0.34	-5.91	-0.31	8.55e-9	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	1.13	19.75	0.73	4.68e-58	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs10740039	1.000	rs10761541	chr10:62415141	C/G	cg18175470	chr10:62150864	ANK3	-0.42	-6.84	-0.35	3.7e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg23795048	chr12:9217529	LOC144571	0.34	5.83	0.3	1.32e-8	Sjögren's syndrome;
LUSC	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.46	9.67	0.47	1.13e-19	Airflow obstruction;
LUSC	cis	rs11645898	0.935	rs3812985	chr16:72187957	A/T	cg14768367	chr16:72042858	DHODH	-0.53	-6.35	-0.33	7.16e-10	Blood protein levels;
LUSC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	12.01	0.55	7.58e-28	Personality dimensions;
LUSC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg06001716	chr17:41278141	BRCA1;NBR2	0.4	6.39	0.33	5.7e-10	Menopause (age at onset);
LUSC	cis	rs4595586	0.525	rs4511319	chr12:39340457	T/C	cg13010199	chr12:38710504	ALG10B	0.42	6.01	0.31	4.75e-9	Morning vs. evening chronotype;
LUSC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg03146154	chr1:46216737	IPP	0.55	8.32	0.41	2.34e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12227505	chr17:78194145	SLC26A11;SGSH	-0.48	-6.99	-0.36	1.47e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	0.93	16.14	0.66	1.04e-43	Menopause (age at onset);
LUSC	cis	rs7264396	0.943	rs1810741	chr20:34109715	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-5.68	-0.3	2.98e-8	Total cholesterol levels;
LUSC	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.14	-0.36	5.7e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7589342	0.894	rs6736932	chr2:106444854	A/G	cg16077055	chr2:106428750	NCK2	0.35	6.77	0.35	5.86e-11	Addiction;
LUSC	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.13	-20.08	-0.74	2.19e-59	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg16405210	chr4:1374714	KIAA1530	-0.54	-8.38	-0.42	1.45e-15	Obesity-related traits;
LUSC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg17724175	chr1:150552817	MCL1	-0.37	-6.81	-0.35	4.57e-11	Tonsillectomy;
LUSC	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg04102894	chr7:1000210	NA	-0.24	-5.81	-0.3	1.47e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg17724175	chr1:150552817	MCL1	0.37	6.6	0.34	1.63e-10	Tonsillectomy;
LUSC	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg01191920	chr7:158217561	PTPRN2	-0.52	-10.81	-0.51	1.5e-23	Obesity-related traits;
LUSC	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23158103	chr7:148848205	ZNF398	-0.5	-8.34	-0.42	1.92e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg07701084	chr6:150067640	NUP43	0.56	8.74	0.43	1.15e-16	Lung cancer;
LUSC	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg27284194	chr4:1044797	NA	0.58	8.7	0.43	1.55e-16	Recombination rate (females);
LUSC	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg03342759	chr3:160939853	NMD3	-0.45	-6.33	-0.33	7.76e-10	Parkinson's disease;
LUSC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.61	0.34	1.54e-10	Menopause (age at onset);
LUSC	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	9.2	0.45	3.94e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg03563238	chr19:33554763	RHPN2	0.39	6.33	0.33	7.88e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	0.91	14.87	0.63	9.5e-39	Breast cancer;
LUSC	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	7.07	0.36	9.19e-12	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg00310523	chr12:86230176	RASSF9	0.52	9.88	0.48	2.27e-20	Major depressive disorder;
LUSC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	1.23	16.83	0.68	1.93e-46	Eosinophil percentage of granulocytes;
LUSC	cis	rs2235649	0.663	rs12596160	chr16:1848784	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.11	-0.32	2.76e-9	Blood metabolite levels;
LUSC	cis	rs9467711	0.516	rs1324088	chr6:25841122	C/T	cg08501292	chr6:25962987	TRIM38	0.57	6.09	0.32	3.19e-9	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2289583	0.642	rs12148697	chr15:75384375	G/T	cg14664628	chr15:75095509	CSK	-0.43	-5.83	-0.3	1.28e-8	Systemic lupus erythematosus;
LUSC	cis	rs4285028	0.699	rs73855465	chr3:121574219	C/T	cg11130432	chr3:121712080	ILDR1	-0.62	-9.38	-0.46	1.03e-18	Multiple sclerosis;
LUSC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.54	8.7	0.43	1.54e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs17155006	0.664	rs402113	chr7:107743664	A/G	cg05962710	chr7:107745446	LAMB4	-0.34	-6.07	-0.32	3.53e-9	Pneumococcal bacteremia;
LUSC	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg04362960	chr10:104952993	NT5C2	0.62	9.84	0.47	3.19e-20	Arsenic metabolism;
LUSC	cis	rs10489202	0.657	rs3767479	chr1:168069840	C/A	cg24449463	chr1:168025552	DCAF6	-0.67	-10.05	-0.48	6.15e-21	Schizophrenia;
LUSC	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg07645718	chr20:61493192	TCFL5	0.73	5.74	0.3	2.11e-8	Obesity-related traits;
LUSC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg23281280	chr6:28129359	ZNF389	-0.46	-6.01	-0.31	4.83e-9	Parkinson's disease;
LUSC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg16584290	chr5:462447	EXOC3	-0.35	-6.16	-0.32	2.13e-9	Cystic fibrosis severity;
LUSC	cis	rs243505	0.660	rs3779038	chr7:148542822	C/T	cg09806900	chr7:148480153	CUL1	0.49	6.45	0.33	3.88e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25072359	chr17:41440525	NA	0.66	9.28	0.45	2.14e-18	Menopause (age at onset);
LUSC	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg23950597	chr19:37808831	NA	-0.62	-7.57	-0.38	3.68e-13	Coronary artery calcification;
LUSC	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg13628971	chr7:2884303	GNA12	-0.45	-6.67	-0.34	1.08e-10	Height;
LUSC	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg14092571	chr14:90743983	NA	0.36	5.78	0.3	1.71e-8	Mortality in heart failure;
LUSC	cis	rs60154123	0.505	rs7540237	chr1:210053325	C/T	cg21951975	chr1:209979733	IRF6	0.58	6.64	0.34	1.24e-10	Coronary artery disease;
LUSC	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.12	-0.45	7.26e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19638132	chr11:59521665	STX3	0.45	6.59	0.34	1.68e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.78	-0.35	5.45e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.44	6.58	0.34	1.77e-10	Height;
LUSC	trans	rs961253	0.522	rs6085496	chr20:6315656	C/T	cg21095983	chr6:86352623	SYNCRIP	0.53	7.78	0.39	9.08e-14	Colorectal cancer;
LUSC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg08975724	chr8:8085496	FLJ10661	0.52	7.54	0.38	4.43e-13	Mood instability;
LUSC	cis	rs4450131	0.902	rs10794174	chr10:126357981	T/C	cg20435097	chr10:126320824	FAM53B	-0.22	-5.79	-0.3	1.63e-8	White blood cell count (basophil);
LUSC	cis	rs7107174	0.901	rs2450139	chr11:77924544	G/A	cg02023728	chr11:77925099	USP35	0.48	7.03	0.36	1.17e-11	Testicular germ cell tumor;
LUSC	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.38	0.33	5.91e-10	Educational attainment (years of education);
LUSC	cis	rs1577917	0.839	rs12055653	chr6:86546663	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-6.47	-0.33	3.55e-10	Response to antipsychotic treatment;
LUSC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26314531	chr2:26401878	FAM59B	-0.69	-9.24	-0.45	3.03e-18	Gut microbiome composition (summer);
LUSC	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg04414720	chr1:150670196	GOLPH3L	0.49	7.78	0.39	9.11e-14	Melanoma;
LUSC	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.77	-13.95	-0.61	3.72e-35	Brugada syndrome;
LUSC	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg03060546	chr3:49711283	APEH	0.56	8.0	0.4	2.14e-14	Resting heart rate;
LUSC	cis	rs3799977	0.531	rs62436031	chr6:44722203	A/G	cg25276700	chr6:44698697	NA	0.3	6.25	0.32	1.24e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg14664628	chr15:75095509	CSK	0.43	6.16	0.32	2.11e-9	Caffeine consumption;
LUSC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.39	-7.31	-0.37	1.98e-12	Platelet count;
LUSC	cis	rs2708977	1.000	rs2708977	chr2:97230074	G/A	cg01950434	chr2:97203154	ARID5A	-0.55	-8.39	-0.42	1.36e-15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs8014204	0.762	rs10139018	chr14:75274292	T/C	cg06637938	chr14:75390232	RPS6KL1	0.52	8.09	0.4	1.08e-14	Caffeine consumption;
LUSC	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.66	11.27	0.53	3.37e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs858239	0.601	rs929508	chr7:23166709	C/A	cg23682824	chr7:23144976	KLHL7	0.4	5.82	0.3	1.4e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	6.38	0.33	6.05e-10	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs2324229	0.828	rs1180204	chr6:83956724	A/G	cg08257003	chr6:84140564	ME1	-0.26	-5.91	-0.31	8.35e-9	Platelet-derived growth factor BB levels;
LUSC	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg00898013	chr13:113819073	PROZ	0.55	8.23	0.41	4.22e-15	Platelet distribution width;
LUSC	cis	rs12681287	0.640	rs6471309	chr8:87387760	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.64e-12	Caudate activity during reward;
LUSC	cis	rs9646944	0.501	rs2293223	chr2:103035468	C/T	cg20060108	chr2:102954350	IL1RL1	0.48	6.51	0.34	2.8e-10	Blood protein levels;
LUSC	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg10645314	chr2:3704589	ALLC	0.37	6.43	0.33	4.49e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs7945718	0.934	rs10831907	chr11:12790875	C/T	cg25843174	chr11:12811716	TEAD1	-0.32	-7.14	-0.36	5.68e-12	Educational attainment (years of education);
LUSC	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg14004847	chr7:1930337	MAD1L1	-0.52	-7.94	-0.4	3.01e-14	Schizophrenia;
LUSC	cis	rs6005807	0.719	rs12167434	chr22:29040821	C/T	cg12565055	chr22:29076175	TTC28	0.54	5.86	0.31	1.12e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.24	0.32	1.34e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg22676075	chr6:135203613	NA	0.47	7.49	0.38	6.25e-13	Red blood cell count;
LUSC	cis	rs13315871	1.000	rs4367085	chr3:58389235	A/G	cg12435725	chr3:58293450	RPP14	-0.73	-7.35	-0.37	1.56e-12	Cholesterol, total;
LUSC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.23	14.12	0.61	8.1e-36	Diabetic kidney disease;
LUSC	cis	rs10761482	0.954	rs10821714	chr10:62065131	T/C	cg18175470	chr10:62150864	ANK3	-0.45	-6.26	-0.32	1.2e-9	Schizophrenia;
LUSC	cis	rs16910800	0.731	rs16910738	chr11:23189455	C/T	cg20040320	chr11:23191996	NA	-0.59	-7.63	-0.39	2.4e-13	Cancer;
LUSC	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.44	-5.78	-0.3	1.7e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Smoking initiation;
LUSC	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg02569458	chr12:86230093	RASSF9	0.58	9.93	0.48	1.56e-20	Major depressive disorder;
LUSC	cis	rs2398893	0.889	rs2039313	chr9:96781684	C/G	cg14459158	chr9:96720562	NA	-0.29	-5.65	-0.3	3.4e-8	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg18827107	chr12:86230957	RASSF9	0.46	6.96	0.36	1.86e-11	Major depressive disorder;
LUSC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	0.76	11.18	0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs12760731	0.565	rs12047117	chr1:178132608	G/A	cg00404053	chr1:178313656	RASAL2	0.66	6.8	0.35	4.85e-11	Obesity-related traits;
LUSC	cis	rs3741151	0.764	rs7101561	chr11:73264219	G/C	cg17517138	chr11:73019481	ARHGEF17	0.98	8.16	0.41	6.67e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg23283495	chr1:209979779	IRF6	0.68	8.38	0.42	1.51e-15	Cleft lip with or without cleft palate;
LUSC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg14019146	chr3:50243930	SLC38A3	0.36	8.02	0.4	1.78e-14	Body mass index;
LUSC	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg10621924	chr7:39171070	POU6F2	0.46	7.25	0.37	2.86e-12	IgG glycosylation;
LUSC	cis	rs9650315	0.866	rs35811702	chr8:57187244	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	6.88	0.35	3.01e-11	Height;
LUSC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg17279839	chr7:150038598	RARRES2	0.52	7.74	0.39	1.23e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg07741184	chr6:167504864	NA	0.39	6.96	0.36	1.85e-11	Crohn's disease;
LUSC	cis	rs1322512	0.713	rs1744390	chr6:152937489	C/T	cg27316956	chr6:152958899	SYNE1	-0.36	-5.94	-0.31	7.06e-9	Tonometry;
LUSC	cis	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg17168535	chr8:21777572	XPO7	0.68	10.16	0.49	2.6e-21	Mean corpuscular volume;
LUSC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg04450456	chr4:17643702	FAM184B	0.39	6.51	0.34	2.77e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-12.84	-0.57	5.91e-31	Alzheimer's disease;
LUSC	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg08854313	chr1:11322531	MTOR	-0.92	-16.84	-0.68	1.64e-46	Body mass index;
LUSC	cis	rs1335645	0.570	rs11805357	chr1:111651660	G/C	cg00321911	chr1:111669324	DRAM2	-0.6	-6.29	-0.33	9.88e-10	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.33	-7.35	-0.37	1.55e-12	Dupuytren's disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19693015	chr17:78965712	CHMP6	-0.43	-6.42	-0.33	4.68e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12618769	0.652	rs3754872	chr2:99223925	A/T	cg10123293	chr2:99228465	UNC50	0.46	7.55	0.38	4.26e-13	Bipolar disorder;
LUSC	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg07959070	chr22:50026188	C22orf34	-0.34	-7.05	-0.36	1.01e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs2708977	0.965	rs2314109	chr2:97243532	A/G	cg01950434	chr2:97203154	ARID5A	-0.56	-8.55	-0.42	4.38e-16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LUSC	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg15848620	chr12:58087721	OS9	-0.53	-7.55	-0.38	4.25e-13	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg06462663	chr19:18546047	ISYNA1	0.48	8.16	0.41	6.81e-15	Breast cancer;
LUSC	cis	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg17469321	chr7:55412551	NA	0.66	10.62	0.5	6.87e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.69	11.38	0.53	1.39e-25	Heart rate;
LUSC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg09034736	chr1:150693464	HORMAD1	0.48	6.98	0.36	1.62e-11	Tonsillectomy;
LUSC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.74	12.48	0.56	1.36e-29	Motion sickness;
LUSC	cis	rs17253792	0.822	rs10151664	chr14:56029533	A/G	cg01858014	chr14:56050164	KTN1	-0.65	-6.12	-0.32	2.68e-9	Putamen volume;
LUSC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.52	9.12	0.45	7.33e-18	Crohn's disease;
LUSC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg14092988	chr3:52407081	DNAH1	0.32	6.15	0.32	2.19e-9	Bipolar disorder;
LUSC	cis	rs72949976	0.864	rs10176806	chr2:214022596	T/G	cg08319019	chr2:214017104	IKZF2	-0.61	-9.2	-0.45	4.12e-18	Lung cancer;Squamous cell lung carcinoma;
LUSC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	0.85	14.66	0.63	6.35e-38	Tonsillectomy;
LUSC	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg09699651	chr6:150184138	LRP11	0.45	7.17	0.37	4.98e-12	Testicular germ cell tumor;
LUSC	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-7.22	-0.37	3.46e-12	Monocyte percentage of white cells;
LUSC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg16797656	chr11:68205561	LRP5	0.49	8.86	0.44	4.76e-17	Total body bone mineral density;
LUSC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.65	8.21	0.41	4.72e-15	Lung function (FEV1/FVC);
LUSC	trans	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg01620082	chr3:125678407	NA	-0.57	-6.28	-0.32	1.05e-9	Depression;
LUSC	cis	rs55883249	0.958	rs113937820	chr2:9746668	A/G	cg23886495	chr2:9695866	ADAM17	0.51	6.03	0.31	4.3e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg20295408	chr7:1910781	MAD1L1	-0.44	-6.28	-0.32	1.07e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg05985134	chr18:33552581	C18orf21	0.51	6.91	0.35	2.5e-11	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg23649088	chr2:200775458	C2orf69	0.52	6.92	0.35	2.3e-11	Schizophrenia;
LUSC	cis	rs4700695	0.719	rs36923	chr5:65464783	G/C	cg21114390	chr5:65439923	SFRS12	-0.65	-9.18	-0.45	4.52e-18	Facial morphology (factor 19);
LUSC	cis	rs9549260	0.753	rs1986649	chr13:41178824	C/T	cg21288729	chr13:41239152	FOXO1	0.53	5.96	0.31	6.31e-9	Red blood cell count;
LUSC	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg14196790	chr5:131705035	SLC22A5	0.43	7.17	0.37	4.74e-12	Blood metabolite levels;
LUSC	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-0.91	-16.24	-0.66	4.18e-44	Height;
LUSC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg02269571	chr22:50332266	NA	-0.57	-8.59	-0.43	3.41e-16	Schizophrenia;
LUSC	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg20587970	chr11:113659929	NA	-1.13	-15.62	-0.65	1.09e-41	Hip circumference adjusted for BMI;
LUSC	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg02696742	chr7:106810147	HBP1	-0.65	-9.83	-0.47	3.27e-20	Coronary artery disease;
LUSC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18099408	chr3:52552593	STAB1	-0.46	-8.18	-0.41	6.16e-15	Bipolar disorder;
LUSC	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg20933634	chr6:27740509	NA	-0.46	-6.25	-0.32	1.27e-9	Parkinson's disease;
LUSC	cis	rs4474465	1.000	rs4944200	chr11:78166930	C/A	cg27205649	chr11:78285834	NARS2	-0.48	-5.74	-0.3	2.12e-8	Alzheimer's disease (survival time);
LUSC	cis	rs41271473	0.687	rs7535661	chr1:228887667	C/T	cg16512390	chr1:228756714	NA	0.49	6.56	0.34	2.03e-10	Chronic lymphocytic leukemia;
LUSC	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg04218760	chr10:45406644	TMEM72	-0.28	-6.76	-0.35	6.15e-11	Mean corpuscular volume;
LUSC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg07701084	chr6:150067640	NUP43	0.54	8.2	0.41	5.08e-15	Lung cancer;
LUSC	trans	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	8.22	0.41	4.57e-15	Ulcerative colitis;
LUSC	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg01528321	chr10:82214614	TSPAN14	0.61	9.07	0.44	1.06e-17	Post bronchodilator FEV1;
LUSC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-0.88	-16.44	-0.67	6.47e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	0.9	12.43	0.56	2.06e-29	Vitiligo;
LUSC	cis	rs10979	1.000	rs12211659	chr6:143898348	G/T	cg25407410	chr6:143891975	LOC285740	-0.74	-12.07	-0.55	4.41e-28	Hypospadias;
LUSC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg27535305	chr1:53392650	SCP2	0.37	6.77	0.35	5.83e-11	Monocyte count;
LUSC	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg10434728	chr15:90938212	IQGAP1	0.39	8.11	0.41	9.52e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs6987853	0.814	rs2923411	chr8:42455206	T/C	cg09913449	chr8:42400586	C8orf40	0.44	7.42	0.38	9.89e-13	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs13223928	0.554	rs13438334	chr7:3156956	G/A	cg19214707	chr7:3157722	NA	-0.53	-9.52	-0.46	3.63e-19	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
LUSC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	1.03	19.24	0.73	4.58e-56	Menopause (age at onset);
LUSC	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg24812749	chr6:127587940	RNF146	0.64	9.54	0.46	3.05e-19	Breast cancer;
LUSC	cis	rs9311676	0.656	rs56232415	chr3:58394850	C/T	cg26110898	chr3:58419937	PDHB	0.4	6.42	0.33	4.6e-10	Systemic lupus erythematosus;
LUSC	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07080220	chr10:102295463	HIF1AN	0.65	8.42	0.42	1.09e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.38	5.72	0.3	2.31e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs2573652	0.722	rs11636084	chr15:100543394	A/G	cg00587665	chr15:100533223	ADAMTS17	-0.36	-6.35	-0.33	6.83e-10	Height;
LUSC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg16374953	chr13:31191680	USPL1	0.4	6.91	0.35	2.47e-11	Breast cancer;
LUSC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.87	10.79	0.51	1.67e-23	Cognitive function;
LUSC	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.5	-5.9	-0.31	8.78e-9	Body mass index;
LUSC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg17178900	chr1:205818956	PM20D1	0.8	13.53	0.6	1.43e-33	Menarche (age at onset);
LUSC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg18827107	chr12:86230957	RASSF9	-0.48	-7.17	-0.37	4.97e-12	Major depressive disorder;
LUSC	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.66	-10.56	-0.5	1.09e-22	Height;
LUSC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19346786	chr7:2764209	NA	-0.49	-8.27	-0.41	3.2e-15	Height;
LUSC	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg16230307	chr14:35515116	FAM177A1	0.8	9.77	0.47	5.46e-20	Psoriasis;
LUSC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg24881330	chr22:46731750	TRMU	0.89	8.94	0.44	2.7e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs13088645	0.532	rs7623580	chr3:134164345	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.47	6.32	0.33	8.13e-10	Coronary artery disease;
LUSC	cis	rs3931020	0.688	rs277396	chr1:75213648	A/C	cg00121533	chr1:75199117	CRYZ;TYW3	-0.48	-6.1	-0.32	2.92e-9	Resistin levels;
LUSC	trans	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg06606381	chr12:133084897	FBRSL1	-0.59	-6.71	-0.34	8.46e-11	Depression;
LUSC	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-1.15	-18.25	-0.71	4.26e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LUSC	cis	rs55665837	1.000	rs12283797	chr11:14442262	C/G	cg05501817	chr11:14380813	RRAS2	-0.41	-6.61	-0.34	1.51e-10	Vitamin D levels;
LUSC	cis	rs3857536	0.785	rs6455089	chr6:66944733	A/C	cg07460842	chr6:66804631	NA	-0.46	-6.42	-0.33	4.59e-10	Blood trace element (Cu levels);
LUSC	cis	rs2797160	0.508	rs9375404	chr6:125927895	G/A	cg05901451	chr6:126070800	HEY2	-0.41	-5.8	-0.3	1.51e-8	Endometrial cancer;
LUSC	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-9.35	-0.46	1.3e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7202877	0.610	rs3844219	chr16:75370230	G/T	cg03315344	chr16:75512273	CHST6	0.42	6.22	0.32	1.49e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	7.25	0.37	2.91e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-7.58	-0.38	3.36e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs3847687	1.000	rs11061303	chr12:131526322	A/G	cg13586425	chr12:131519906	GPR133	-0.25	-5.83	-0.3	1.3e-8	Longevity;
LUSC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg18190219	chr22:46762943	CELSR1	-0.49	-6.08	-0.32	3.25e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs150647904	1	rs150647904	chr1:54839485	T/TCAG	cg17417004	chr1:54819992	SSBP3	0.52	6.3	0.33	9.41e-10	Platelet distribution width;
LUSC	cis	rs4363385	0.740	rs4845518	chr1:153003903	A/G	cg00922841	chr1:152955080	SPRR1A	-0.44	-7.7	-0.39	1.54e-13	Inflammatory skin disease;
LUSC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26314531	chr2:26401878	FAM59B	-0.73	-9.65	-0.47	1.3e-19	Gut microbiome composition (summer);
LUSC	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.7	10.57	0.5	1.06e-22	Corneal astigmatism;
LUSC	trans	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg18187862	chr3:45730750	SACM1L	-0.53	-6.42	-0.33	4.73e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6599077	1.000	rs9873761	chr3:40086208	A/G	cg13683864	chr3:40499215	RPL14	0.55	7.29	0.37	2.28e-12	Sleep-related phenotypes;
LUSC	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg21775007	chr8:11205619	TDH	0.72	11.71	0.54	9.09e-27	Retinal vascular caliber;
LUSC	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg12365402	chr11:9010492	NRIP3	0.48	8.86	0.44	4.68e-17	Hemoglobin concentration;
LUSC	cis	rs500891	0.574	rs13203553	chr6:84121882	A/G	cg08257003	chr6:84140564	ME1	-0.34	-7.61	-0.38	2.91e-13	Platelet-derived growth factor BB levels;
LUSC	cis	rs10779751	0.727	rs4845852	chr1:11233559	C/T	cg08854313	chr1:11322531	MTOR	0.87	13.89	0.61	6.08e-35	Body mass index;
LUSC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.53	-13.12	-0.58	5.14e-32	Longevity;
LUSC	cis	rs7582180	0.903	rs7421891	chr2:100902166	G/A	cg08017756	chr2:100939284	LONRF2	-0.36	-6.16	-0.32	2.12e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	0.58	9.3	0.45	1.96e-18	Breast cancer;
LUSC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg19592336	chr6:28129416	ZNF389	0.44	5.76	0.3	1.92e-8	Parkinson's disease;
LUSC	cis	rs965469	1.000	rs6051838	chr20:3389012	A/C	cg25506879	chr20:3388711	C20orf194	-0.52	-5.76	-0.3	1.93e-8	IFN-related cytopenia;
LUSC	cis	rs4363385	0.530	rs6663448	chr1:152894627	C/T	cg25856811	chr1:152973957	SPRR3	-0.38	-6.16	-0.32	2.15e-9	Inflammatory skin disease;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23894768	chr18:5295771	ZFP161	-0.4	-6.07	-0.32	3.39e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg06784218	chr1:46089804	CCDC17	-0.5	-10.06	-0.48	5.91e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-11.77	-0.54	5.48e-27	Gut microbiome composition (summer);
LUSC	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg09455208	chr3:40491958	NA	-0.43	-7.67	-0.39	1.87e-13	Renal cell carcinoma;
LUSC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg02475777	chr4:1388615	CRIPAK	0.49	7.16	0.36	5.17e-12	Obesity-related traits;
LUSC	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg18478394	chr8:109455254	TTC35	0.41	6.33	0.33	8.11e-10	Dupuytren's disease;
LUSC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg07636037	chr3:49044803	WDR6	0.44	6.38	0.33	5.9e-10	Resting heart rate;
LUSC	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.56	-8.01	-0.4	1.97e-14	Iron status biomarkers;
LUSC	cis	rs3809566	0.710	rs4075583	chr15:63340227	C/T	cg00520135	chr15:63333846	TPM1	-0.27	-5.65	-0.3	3.38e-8	Platelet count;
LUSC	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	0.79	12.29	0.56	6.86e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LUSC	cis	rs1712517	0.771	rs7074749	chr10:105116056	C/T	cg05636881	chr10:105038444	INA	0.41	6.75	0.35	6.73e-11	Migraine;
LUSC	cis	rs2282802	0.651	rs10060071	chr5:139599097	T/C	cg26211634	chr5:139558579	C5orf32	0.42	7.9	0.4	4.06e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs35883536	0.647	rs10875316	chr1:101044150	G/A	cg06223162	chr1:101003688	GPR88	-0.49	-9.24	-0.45	2.89e-18	Monocyte count;
LUSC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25072359	chr17:41440525	NA	0.63	9.17	0.45	4.88e-18	Menopause (age at onset);
LUSC	trans	rs867371	0.502	rs7176926	chr15:82538094	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.32	-0.33	8.38e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
LUSC	cis	rs500891	0.533	rs3798886	chr6:84131526	G/A	cg08257003	chr6:84140564	ME1	0.36	8.73	0.43	1.27e-16	Platelet-derived growth factor BB levels;
LUSC	cis	rs1775715	0.707	rs2799024	chr10:32166922	A/G	cg26784012	chr10:32216390	ARHGAP12	0.47	7.91	0.4	3.91e-14	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg09367891	chr1:107599246	PRMT6	0.52	8.02	0.4	1.81e-14	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.74	-7.55	-0.38	4.3e-13	Initial pursuit acceleration;
LUSC	cis	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg17469321	chr7:55412551	NA	0.68	10.92	0.51	5.92e-24	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.64	0.6	5.79e-34	Cognitive test performance;
LUSC	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg10172584	chr19:19639581	YJEFN3	-0.46	-5.65	-0.3	3.42e-8	Bipolar disorder;
LUSC	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg00677455	chr12:58241039	CTDSP2	-0.69	-10.37	-0.49	4.85e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg11663144	chr21:46675770	NA	-0.41	-7.19	-0.37	4.2e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg26876637	chr1:152193138	HRNR	0.42	5.89	0.31	9.36e-9	Atopic dermatitis;
LUSC	cis	rs9322817	0.691	rs1933804	chr6:105341969	G/C	cg02098413	chr6:105308735	HACE1	0.28	5.96	0.31	6.53e-9	Thyroid stimulating hormone;
LUSC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-20.24	-0.74	5.17e-60	Coronary artery disease;
LUSC	trans	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg15556689	chr8:8085844	FLJ10661	0.47	6.97	0.36	1.72e-11	Retinal vascular caliber;
LUSC	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg21427119	chr20:30132790	HM13	-0.36	-5.66	-0.3	3.29e-8	Mean corpuscular hemoglobin;
LUSC	trans	rs10432489	0.708	rs4315481	chr2:181761394	T/C	cg04744134	chr19:8408128	KANK3	-0.79	-6.36	-0.33	6.73e-10	QT interval;
LUSC	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg25930673	chr12:123319894	HIP1R	-0.65	-6.43	-0.33	4.51e-10	Schizophrenia;
LUSC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.88	-13.99	-0.61	2.57e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg03351412	chr1:154909251	PMVK	0.53	8.21	0.41	4.97e-15	Prostate cancer;
LUSC	cis	rs11958404	0.860	rs6885815	chr5:157437253	C/T	cg05962755	chr5:157440814	NA	0.54	6.37	0.33	6.16e-10	IgG glycosylation;
LUSC	cis	rs6977660	0.714	rs28371050	chr7:19816882	C/T	cg07541023	chr7:19748670	TWISTNB	0.63	6.84	0.35	3.87e-11	Thyroid stimulating hormone;
LUSC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	16.09	0.66	1.51e-43	Platelet count;
LUSC	trans	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg16660971	chr17:78860029	RPTOR	0.37	6.01	0.31	4.78e-9	Major depressive disorder;
LUSC	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.8	0.35	4.9e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	9.59	0.46	2.1e-19	Hip circumference adjusted for BMI;
LUSC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13126279	chr21:47581558	C21orf56	0.56	8.66	0.43	2.02e-16	Testicular germ cell tumor;
LUSC	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg00540400	chr15:79124168	NA	0.46	8.1	0.41	1.06e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg06521331	chr12:34319734	NA	-0.4	-6.52	-0.34	2.55e-10	Morning vs. evening chronotype;
LUSC	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg20607287	chr7:12443886	VWDE	-0.59	-6.14	-0.32	2.35e-9	Coronary artery disease;
LUSC	cis	rs1941023	0.503	rs894591	chr11:60132647	T/C	cg08716584	chr11:60157161	MS4A7	-0.63	-11.86	-0.54	2.53e-27	Congenital heart disease (maternal effect);
LUSC	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg24675056	chr1:15929824	NA	0.46	8.03	0.4	1.69e-14	Systolic blood pressure;
LUSC	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg07382826	chr16:28625726	SULT1A1	0.28	6.08	0.32	3.3e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg00431813	chr7:1051703	C7orf50	-0.44	-7.06	-0.36	9.57e-12	Longevity;Endometriosis;
LUSC	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg27411982	chr8:10470053	RP1L1	-0.49	-7.93	-0.4	3.4e-14	Neuroticism;
LUSC	cis	rs9921338	0.924	rs7204628	chr16:11444572	A/C	cg00044050	chr16:11439710	C16orf75	-0.49	-6.74	-0.35	6.99e-11	Vein graft stenosis in coronary artery bypass grafting;
LUSC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08280861	chr8:58055591	NA	0.54	6.48	0.33	3.2e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs8114671	1.000	rs8114671	chr20:33789142	C/A	cg07148914	chr20:33460835	GGT7	-0.44	-6.58	-0.34	1.82e-10	Height;
LUSC	trans	rs1994089	0.781	rs67486235	chr17:33517652	G/T	cg25602930	chr2:9533887	ASAP2	0.44	6.44	0.33	4.22e-10	Macrophage inflammatory protein 1b levels;
LUSC	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.86	15.47	0.65	4.49e-41	Metabolic syndrome;
LUSC	cis	rs1790761	0.967	rs12573992	chr11:67197757	A/G	cg24690094	chr11:67383802	NA	-0.31	-5.68	-0.3	2.96e-8	Mean corpuscular volume;
LUSC	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg24733560	chr20:60626293	TAF4	0.41	7.64	0.39	2.37e-13	Body mass index;
LUSC	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg23205692	chr1:25664452	TMEM50A	0.4	5.81	0.3	1.46e-8	Erythrocyte sedimentation rate;
LUSC	cis	rs4363385	0.693	rs440598	chr1:153044733	T/C	cg00922841	chr1:152955080	SPRR1A	-0.43	-7.39	-0.37	1.19e-12	Inflammatory skin disease;
LUSC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg12463550	chr7:65579703	CRCP	0.62	5.67	0.3	3.04e-8	Diabetic kidney disease;
LUSC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg13939156	chr17:80058883	NA	-0.33	-6.56	-0.34	2.08e-10	Life satisfaction;
LUSC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20891558	chr2:74357851	NA	0.79	14.33	0.62	1.24e-36	Gestational age at birth (maternal effect);
LUSC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.23	0.52	4.89e-25	Prudent dietary pattern;
LUSC	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg00933542	chr6:150070202	PCMT1	0.29	5.88	0.31	9.93e-9	Lung cancer;
LUSC	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	16.52	0.67	3.11e-45	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg26893861	chr17:41843967	DUSP3	1.01	15.05	0.64	1.87e-39	Triglycerides;
LUSC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06028605	chr16:24865363	SLC5A11	0.69	10.95	0.51	4.74e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg17724175	chr1:150552817	MCL1	-0.47	-8.35	-0.42	1.79e-15	Blood protein levels;
LUSC	cis	rs2742234	0.590	rs2742237	chr10:43621323	C/G	cg15436174	chr10:43711423	RASGEF1A	-0.44	-7.13	-0.36	6.31e-12	Hirschsprung disease;
LUSC	cis	rs72960926	0.744	rs77045321	chr6:74915572	T/C	cg03266952	chr6:74778945	NA	-0.79	-6.42	-0.33	4.66e-10	Metabolite levels (MHPG);
LUSC	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	10.43	0.5	3.03e-22	Coffee consumption (cups per day);
LUSC	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.85	14.34	0.62	1.09e-36	Bladder cancer;
LUSC	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg08017756	chr2:100939284	LONRF2	-0.47	-8.86	-0.44	4.94e-17	Intelligence (multi-trait analysis);
LUSC	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg16989086	chr20:62203971	PRIC285	0.47	6.53	0.34	2.46e-10	Glioblastoma;
LUSC	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg16989086	chr20:62203971	PRIC285	-0.44	-6.34	-0.33	7.58e-10	Glioblastoma;
LUSC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.59	10.66	0.5	4.93e-23	Bone mineral density;
LUSC	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.92	-0.35	2.33e-11	Lung cancer;
LUSC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	11.26	0.52	3.93e-25	Menarche (age at onset);
LUSC	cis	rs12891047	0.804	rs7149482	chr14:68286295	C/T	cg20999565	chr14:68265668	ZFYVE26	0.38	5.79	0.3	1.58e-8	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs12760731	0.720	rs12048790	chr1:178407906	T/C	cg00404053	chr1:178313656	RASAL2	0.59	6.22	0.32	1.46e-9	Obesity-related traits;
LUSC	cis	rs134594	1.000	rs134600	chr22:29472884	T/C	cg03665785	chr22:29458676	C22orf31	0.28	5.75	0.3	1.96e-8	Birth weight;
LUSC	cis	rs28829049	0.597	rs72651403	chr1:19519887	G/C	cg13387374	chr1:19411106	UBR4	0.45	6.3	0.33	9.61e-10	QRS duration in Tripanosoma cruzi seropositivity;
LUSC	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-7.09	-0.36	8.24e-12	Asthma;
LUSC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	0.72	13.8	0.6	1.34e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg11473876	chr11:109292803	C11orf87	0.41	6.58	0.34	1.82e-10	Schizophrenia;
LUSC	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg06740227	chr12:86229804	RASSF9	0.39	6.25	0.32	1.23e-9	Major depressive disorder;
LUSC	cis	rs6982240	0.514	rs10481391	chr8:142277149	A/G	cg27411547	chr8:142287226	NA	-0.49	-8.28	-0.41	3.1e-15	Tonsillectomy;
LUSC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs11051970	0.879	rs2651363	chr12:32587550	G/T	cg02745156	chr12:32552066	NA	-0.39	-6.77	-0.35	5.66e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	trans	rs2786098	0.611	rs4316386	chr1:197515777	A/T	cg16005942	chr6:160526640	IGF2R	-0.48	-5.95	-0.31	6.88e-9	Asthma;
LUSC	cis	rs3857536	0.741	rs2097679	chr6:66937994	T/C	cg07460842	chr6:66804631	NA	-0.47	-6.47	-0.33	3.47e-10	Blood trace element (Cu levels);
LUSC	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg20701182	chr2:24300061	SF3B14	0.55	5.7	0.3	2.69e-8	Lymphocyte counts;
LUSC	cis	rs7084921	0.608	rs12761969	chr10:101832036	G/C	cg02250046	chr10:101825185	CPN1	-0.34	-6.13	-0.32	2.45e-9	Bone mineral density;
LUSC	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg08854313	chr1:11322531	MTOR	0.8	12.45	0.56	1.6800000000000001e-29	Body mass index;
LUSC	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg27661571	chr11:113659931	NA	-0.66	-7.51	-0.38	5.31e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg10360139	chr7:1886902	MAD1L1	-0.45	-6.93	-0.35	2.17e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg12559939	chr2:27858050	GPN1	0.41	6.48	0.33	3.28e-10	Oral cavity cancer;
LUSC	cis	rs9296092	0.517	rs76662639	chr6:33508476	G/A	cg13560919	chr6:33536144	NA	-0.84	-14.68	-0.63	5.34e-38	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg26566898	chr11:117069891	TAGLN	0.37	7.05	0.36	1.03e-11	Blood protein levels;
LUSC	cis	rs6700896	0.500	rs12145237	chr1:66124882	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.93	0.31	7.6e-9	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg07636037	chr3:49044803	WDR6	0.44	6.29	0.33	9.67e-10	Resting heart rate;
LUSC	cis	rs1866706	0.896	rs1866711	chr11:12875301	C/T	cg25843174	chr11:12811716	TEAD1	-0.28	-5.71	-0.3	2.53e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg06784218	chr1:46089804	CCDC17	-0.47	-8.92	-0.44	3.06e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25072359	chr17:41440525	NA	0.6	8.61	0.43	2.86e-16	Menopause (age at onset);
LUSC	cis	rs9309473	1.000	rs10179134	chr2:73637519	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-6.18	-0.32	1.85e-9	Metabolite levels;
LUSC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg26116260	chr4:7069785	GRPEL1	-1.1	-12.83	-0.57	6.3e-31	Monocyte percentage of white cells;
LUSC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg22963979	chr7:1858916	MAD1L1	-0.55	-8.39	-0.42	1.43e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg18187862	chr3:45730750	SACM1L	-0.52	-6.32	-0.33	8.29e-10	Primary sclerosing cholangitis;
LUSC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg12463550	chr7:65579703	CRCP	0.52	7.55	0.38	4.29e-13	Aortic root size;
LUSC	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg12002119	chr2:101014098	CHST10	0.35	5.77	0.3	1.77e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2425143	0.643	rs6058324	chr20:34388789	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.71	-0.3	2.51e-8	Blood protein levels;
LUSC	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg17366294	chr4:99064904	C4orf37	0.61	10.74	0.51	2.7e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4974559	0.947	rs28711287	chr4:1346682	G/C	cg02980000	chr4:1222292	CTBP1	0.74	7.35	0.37	1.54e-12	Systolic blood pressure;
LUSC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg23985595	chr17:80112537	CCDC57	-0.31	-6.03	-0.31	4.41e-9	Life satisfaction;
LUSC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg23711669	chr6:146136114	FBXO30	0.76	13.72	0.6	2.76e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4664304	0.934	rs72957586	chr2:160762687	G/A	cg03641300	chr2:160917029	PLA2R1	-0.41	-6.78	-0.35	5.38e-11	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.43	-6.1	-0.32	3.01e-9	Reticulocyte count;
LUSC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06634786	chr22:41940651	POLR3H	0.52	6.04	0.31	4.17e-9	Vitiligo;
LUSC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-9.58	-0.46	2.34e-19	Chronic sinus infection;
LUSC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24110177	chr3:50126178	RBM5	0.55	9.1	0.45	8.4e-18	Intelligence (multi-trait analysis);
LUSC	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-1.16	-16.04	-0.66	2.41e-43	Hip circumference adjusted for BMI;
LUSC	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.61	-5.67	-0.3	3.03e-8	Narcolepsy;
LUSC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg10523860	chr14:103875565	MARK3	0.39	6.21	0.32	1.55e-9	Body mass index;
LUSC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00290607	chr11:67383545	NA	-0.41	-7.89	-0.4	4.41e-14	Mean corpuscular volume;
LUSC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.75	-0.3	2.04e-8	Personality dimensions;
LUSC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-5.98	-0.31	5.6e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg05717871	chr11:638507	DRD4	-0.34	-5.9	-0.31	8.74e-9	Systemic lupus erythematosus;
LUSC	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg20243544	chr17:37824526	PNMT	0.48	6.1	0.32	2.86e-9	Glomerular filtration rate (creatinine);
LUSC	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg11189052	chr15:85197271	WDR73	0.5	6.34	0.33	7.64e-10	Schizophrenia;
LUSC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.46	7.64	0.39	2.32e-13	Hip circumference adjusted for BMI;
LUSC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	15.51	0.65	3.1e-41	Platelet count;
LUSC	cis	rs11031096	0.502	rs1442726	chr11:4094748	G/C	cg18678763	chr11:4115507	RRM1	-0.47	-6.09	-0.32	3.1e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs870825	0.929	rs72689258	chr4:185590550	G/C	cg04058563	chr4:185651563	MLF1IP	0.83	11.29	0.53	2.87e-25	Blood protein levels;
LUSC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.18	0.37	4.69e-12	Motion sickness;
LUSC	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg08917208	chr2:24149416	ATAD2B	0.87	9.67	0.47	1.19e-19	Lymphocyte counts;
LUSC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg25036284	chr2:26402008	FAM59B	-0.69	-9.73	-0.47	7.08e-20	Gut microbiome composition (summer);
LUSC	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg01629716	chr15:45996671	NA	0.39	5.96	0.31	6.31e-9	Waist circumference;Weight;
LUSC	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg07701084	chr6:150067640	NUP43	0.47	7.11	0.36	7.04e-12	Lung cancer;
LUSC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg06238570	chr21:40685208	BRWD1	0.48	7.49	0.38	6.36e-13	Cognitive function;
LUSC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg01973587	chr1:228161476	NA	0.44	8.04	0.4	1.62e-14	Diastolic blood pressure;
LUSC	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg21724239	chr8:58056113	NA	0.56	6.66	0.34	1.13e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg18758796	chr5:131593413	PDLIM4	0.34	5.83	0.3	1.31e-8	Blood metabolite levels;
LUSC	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.75	13.18	0.59	3.05e-32	Sudden cardiac arrest;
LUSC	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg05343316	chr1:45956843	TESK2	0.65	8.88	0.44	4.17e-17	Platelet count;
LUSC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.4	-5.93	-0.31	7.55e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg01579765	chr21:45077557	HSF2BP	-0.55	-11.46	-0.53	7.13e-26	Mean corpuscular volume;
LUSC	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg01966878	chr4:90757139	SNCA	-0.42	-5.81	-0.3	1.43e-8	Neuroticism;
LUSC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg05623727	chr3:50126028	RBM5	0.32	5.96	0.31	6.38e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07256732	chr16:621771	PIGQ	-0.35	-6.38	-0.33	5.75e-10	Height;
LUSC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg05347473	chr6:146136440	FBXO30	0.54	9.03	0.44	1.44e-17	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7582720	0.943	rs72936839	chr2:203773237	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	8.42	0.42	1.16e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.58	-9.27	-0.45	2.44e-18	Body mass index;
LUSC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06850241	chr22:41845214	NA	0.31	5.65	0.3	3.47e-8	Vitiligo;
LUSC	cis	rs710216	0.957	rs859511	chr1:43430260	C/T	cg22176566	chr1:43424700	SLC2A1	0.46	5.8	0.3	1.56e-8	Red cell distribution width;
LUSC	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg05110241	chr16:68378359	PRMT7	-0.51	-5.99	-0.31	5.5e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs2835872	0.758	rs1709835	chr21:39037636	A/G	cg20424643	chr21:39039972	KCNJ6	-0.44	-7.39	-0.37	1.18e-12	Electroencephalographic traits in alcoholism;
LUSC	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.05	-0.36	1.06e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg21724239	chr8:58056113	NA	0.57	6.58	0.34	1.84e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9467773	0.529	rs7356988	chr6:26396727	G/T	cg09904177	chr6:26538194	HMGN4	-0.53	-7.87	-0.4	4.98e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.6	-9.27	-0.45	2.33e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	trans	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg26043149	chr18:55253948	FECH	-0.46	-7.05	-0.36	1.01e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs2285947	1.000	rs10228845	chr7:21583617	G/A	cg04471919	chr7:21584483	DNAH11	0.34	7.61	0.38	2.86e-13	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LUSC	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.87	-0.4	4.88e-14	Morning vs. evening chronotype;
LUSC	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg26441486	chr22:50317300	CRELD2	-0.54	-8.04	-0.4	1.59e-14	Schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg26494424	chr12:124118326	EIF2B1;GTF2H3	-0.53	-6.76	-0.35	6.3e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg18129178	chr5:148520854	ABLIM3	-0.74	-10.19	-0.49	2.01e-21	Breast cancer;
LUSC	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg07169764	chr2:136633963	MCM6	-0.6	-7.95	-0.4	2.88e-14	Mosquito bite size;
LUSC	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	0.56	8.54	0.42	4.84e-16	Breast cancer;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg12149777	chr4:139937459	CCRN4L	-0.48	-6.55	-0.34	2.22e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs17401966	0.522	rs7368073	chr1:10314962	G/T	cg17425144	chr1:10567563	PEX14	-0.32	-5.67	-0.3	3.15e-8	Hepatocellular carcinoma;
LUSC	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-9.35	-0.46	1.3e-18	Neuroticism;
LUSC	cis	rs2594989	0.943	rs9830784	chr3:11434605	A/G	cg00170343	chr3:11313890	ATG7	0.52	5.88	0.31	9.99e-9	Circulating chemerin levels;
LUSC	cis	rs13089785	0.791	rs16834826	chr3:123584488	C/T	cg02012769	chr3:123398346	MYLK	-0.33	-6.22	-0.32	1.5e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-9.42	-0.46	7.58e-19	Gut microbiome composition (summer);
LUSC	cis	rs977987	0.778	rs7203157	chr16:75417920	T/C	cg04384234	chr16:75411784	CFDP1	-0.43	-7.2	-0.37	4.07e-12	Dupuytren's disease;
LUSC	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	8.97	0.44	2.11e-17	Iron status biomarkers;
LUSC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg11845111	chr2:191398756	TMEM194B	-0.81	-11.01	-0.52	2.86e-24	Diastolic blood pressure;
LUSC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	8.7	0.43	1.59e-16	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7789940	1.000	rs76024966	chr7:75995021	C/T	cg15798862	chr7:76129360	DTX2	-0.52	-8.58	-0.42	3.63e-16	Multiple sclerosis;
LUSC	cis	rs4919087	0.884	rs4917762	chr10:98976471	G/T	cg25902810	chr10:99078978	FRAT1	0.5	7.09	0.36	7.8e-12	Monocyte count;
LUSC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg08859206	chr1:53392774	SCP2	-0.42	-6.76	-0.35	6.07e-11	Monocyte count;
LUSC	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-6.76	-0.35	6.23e-11	Retinal vascular caliber;
LUSC	cis	rs10208940	0.920	rs10211211	chr2:68718191	G/C	cg12452813	chr2:68675892	NA	0.58	5.95	0.31	6.61e-9	Urate levels in lean individuals;
LUSC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg17330251	chr7:94953956	PON1	-0.37	-5.91	-0.31	8.61e-9	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg24130564	chr14:104152367	KLC1	-0.43	-5.78	-0.3	1.68e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.0	-0.48	9.09e-21	Hemoglobin concentration;
LUSC	cis	rs134594	0.569	rs134559	chr22:29458441	C/T	cg13586696	chr22:29458723	C22orf31	-0.39	-6.38	-0.33	5.75e-10	Birth weight;
LUSC	cis	rs12575480	0.637	rs6578975	chr11:2095799	C/T	cg15541987	chr11:2077307	NA	0.41	6.3	0.33	9.52e-10	Pursuit maintenance gain;
LUSC	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg19682013	chr15:45996608	NA	0.39	5.9	0.31	8.82e-9	Waist circumference;Weight;
LUSC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg13939156	chr17:80058883	NA	0.34	6.72	0.35	7.89e-11	Life satisfaction;
LUSC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.28	0.49	1.06e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7582720	1.000	rs4675310	chr2:203880834	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.75	-7.84	-0.39	5.97e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LUSC	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg00945038	chr17:61921165	SMARCD2	0.4	6.09	0.32	3.17e-9	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg04450456	chr4:17643702	FAM184B	0.39	6.45	0.33	3.85e-10	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.05e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg24675658	chr1:53192096	ZYG11B	0.62	9.86	0.47	2.72e-20	Monocyte count;
LUSC	cis	rs698813	0.572	rs12613771	chr2:44490660	C/A	cg00619915	chr2:44497795	NA	-0.53	-7.61	-0.38	2.83e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg08213375	chr14:104286397	PPP1R13B	0.52	10.14	0.49	3.02e-21	Schizophrenia;
LUSC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg22834771	chr12:69754056	YEATS4	-0.49	-7.4	-0.38	1.14e-12	Blood protein levels;
LUSC	cis	rs7929679	0.521	rs11032852	chr11:34788308	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.9	0.31	8.92e-9	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LUSC	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg19116668	chr7:99932089	PMS2L1	0.35	6.12	0.32	2.68e-9	Coronary artery disease;
LUSC	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg09835421	chr16:68378352	PRMT7	-0.45	-5.96	-0.31	6.35e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg26061582	chr7:22766209	IL6	0.48	7.09	0.36	8e-12	Lung cancer;
LUSC	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg06207120	chr15:45996521	NA	0.39	5.99	0.31	5.51e-9	Waist circumference;Weight;
LUSC	cis	rs7605827	0.897	rs1996518	chr2:15517419	A/G	cg19274914	chr2:15703543	NA	0.45	8.73	0.43	1.27e-16	Educational attainment (years of education);
LUSC	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg02023728	chr11:77925099	USP35	0.48	6.81	0.35	4.5e-11	Testicular germ cell tumor;
LUSC	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-7.35	-0.37	1.49e-12	Lung cancer in ever smokers;
LUSC	cis	rs9807841	0.568	rs1560707	chr19:10750738	A/C	cg09936142	chr19:10668400	KRI1	-0.39	-6.18	-0.32	1.84e-9	Inflammatory skin disease;
LUSC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg24879335	chr3:133465180	TF	0.46	7.91	0.4	3.69e-14	Iron status biomarkers (transferrin levels);
LUSC	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-10.83	-0.51	1.24e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg22920501	chr2:26401640	FAM59B	-0.74	-10.51	-0.5	1.71e-22	Gut microbiome composition (summer);
LUSC	cis	rs7089973	0.523	rs7071789	chr10:116735341	T/C	cg23260525	chr10:116636907	FAM160B1	0.29	5.7	0.3	2.64e-8	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs1044826	0.913	rs9860521	chr3:139214559	A/G	cg00490450	chr3:139108681	COPB2	0.51	6.8	0.35	4.8e-11	Obesity-related traits;
LUSC	trans	rs72674100	1.000	rs13353562	chr4:97977235	T/C	cg09670535	chr1:18959427	PAX7	-0.56	-5.98	-0.31	5.64e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs73198271	0.515	rs79282666	chr8:8638225	T/C	cg01851573	chr8:8652454	MFHAS1	0.56	6.24	0.32	1.32e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs17034641	1.000	rs12990867	chr2:46372411	G/A	cg12428440	chr2:46370979	PRKCE	0.44	5.92	0.31	8.03e-9	Hemoglobin;Hematocrit;
LUSC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg06096015	chr1:231504339	EGLN1	0.58	10.29	0.49	9.7e-22	Hemoglobin concentration;
LUSC	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-8.24	-0.41	3.89e-15	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs853679	0.567	rs1005126	chr6:28367623	C/G	cg06606381	chr12:133084897	FBRSL1	-0.43	-6.15	-0.32	2.15e-9	Depression;
LUSC	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg24690094	chr11:67383802	NA	0.42	8.3	0.41	2.7e-15	Mean corpuscular volume;
LUSC	trans	rs6561151	0.681	rs61959998	chr13:44462501	A/T	cg12856521	chr11:46389249	DGKZ	0.78	9.71	0.47	8.39e-20	Crohn's disease;
LUSC	cis	rs686320	1.000	rs3132770	chr11:65251317	G/A	cg21890820	chr11:65308645	LTBP3	0.75	7.37	0.37	1.31e-12	Hip circumference adjusted for BMI;
LUSC	cis	rs2224391	0.534	rs2753229	chr6:5246633	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.49	-6.74	-0.35	7e-11	Height;
LUSC	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-7.04	-0.36	1.08e-11	Monocyte percentage of white cells;
LUSC	cis	rs362296	0.698	rs362283	chr4:3259558	T/C	cg14583973	chr4:3374767	RGS12	-0.31	-5.85	-0.3	1.19e-8	Parental longevity (mother's age at death);
LUSC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg20821713	chr7:1055600	C7orf50	-0.45	-5.65	-0.3	3.52e-8	Bronchopulmonary dysplasia;
LUSC	trans	rs3857536	0.813	rs7771569	chr6:66946717	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-6.06	-0.31	3.62e-9	Blood trace element (Cu levels);
LUSC	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg20583945	chr8:144636462	GSDMD	0.44	5.79	0.3	1.62e-8	Venous thromboembolism (SNP x SNP interaction);
LUSC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg01483505	chr11:975446	AP2A2	0.42	6.01	0.31	4.75e-9	Alzheimer's disease (late onset);
LUSC	cis	rs16910800	0.731	rs59333536	chr11:23191649	G/A	cg20040320	chr11:23191996	NA	-0.59	-7.63	-0.39	2.4e-13	Cancer;
LUSC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg05313129	chr8:58192883	C8orf71	-0.49	-5.67	-0.3	3.14e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg16230307	chr14:35515116	FAM177A1	0.79	10.14	0.49	3.01e-21	Psoriasis;
LUSC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.81	13.64	0.6	5.83e-34	Aortic root size;
LUSC	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg07578070	chr6:150326732	RAET1K	0.41	6.36	0.33	6.56e-10	Alopecia areata;
LUSC	cis	rs73193808	0.614	rs2832251	chr21:30559552	G/C	cg03476357	chr21:30257390	N6AMT1	0.45	6.05	0.31	3.96e-9	Coronary artery disease;
LUSC	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.6	-0.38	2.97e-13	Bone mineral density;
LUSC	cis	rs62400317	0.859	rs12209161	chr6:45104321	G/A	cg20913747	chr6:44695427	NA	-0.47	-7.5	-0.38	5.93e-13	Total body bone mineral density;
LUSC	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg02503808	chr4:7069936	GRPEL1	1.05	14.94	0.63	5.16e-39	Monocyte percentage of white cells;
LUSC	cis	rs897080	0.515	rs698815	chr2:44706974	G/T	cg00619915	chr2:44497795	NA	-0.44	-6.4	-0.33	5.31e-10	Height;
LUSC	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-9.16	-0.45	5.28e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg12463550	chr7:65579703	CRCP	-0.53	-7.73	-0.39	1.31e-13	Aortic root size;
LUSC	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.55	9.71	0.47	8.39e-20	Birth weight;
LUSC	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.75	6.54	0.34	2.31e-10	Lung cancer in ever smokers;
LUSC	cis	rs17253792	0.822	rs75999534	chr14:56036413	A/T	cg01858014	chr14:56050164	KTN1	-0.89	-7.04	-0.36	1.1e-11	Putamen volume;
LUSC	cis	rs7178572	0.568	rs4886866	chr15:77696166	A/T	cg22256960	chr15:77711686	NA	-0.49	-7.81	-0.39	7.66e-14	Type 2 diabetes;
LUSC	cis	rs12681287	0.571	rs10097450	chr8:87358677	G/A	cg27223183	chr8:87520930	FAM82B	0.55	7.37	0.37	1.34e-12	Caudate activity during reward;
LUSC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg05082376	chr22:42548792	NA	-0.42	-6.29	-0.33	1.01e-9	Schizophrenia;
LUSC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-6.5	-0.34	2.87e-10	Lung cancer;
LUSC	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg21132104	chr15:45694354	SPATA5L1	0.42	6.14	0.32	2.4e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19346786	chr7:2764209	NA	-0.38	-6.55	-0.34	2.23e-10	Height;
LUSC	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg04414720	chr1:150670196	GOLPH3L	0.52	8.07	0.4	1.3e-14	Melanoma;
LUSC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.46	0.42	8.63e-16	Prudent dietary pattern;
LUSC	cis	rs4988958	0.548	rs6543127	chr2:103028301	A/C	cg03938978	chr2:103052716	IL18RAP	0.37	7.08	0.36	8.72e-12	Asthma (childhood onset);
LUSC	trans	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg14791747	chr16:20752902	THUMPD1	0.42	6.31	0.33	9e-10	Dental caries;
LUSC	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.99	-0.4	2.16e-14	Morning vs. evening chronotype;
LUSC	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg13852791	chr20:30311386	BCL2L1	0.92	11.23	0.52	5e-25	Mean corpuscular hemoglobin;
LUSC	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	11.17	0.52	7.7e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	8.57	0.42	3.81e-16	Menarche (age at onset);
LUSC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs9473147	0.516	rs1931837	chr6:47442377	C/T	cg20196966	chr6:47445060	CD2AP	0.41	5.66	0.3	3.28e-8	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg05855489	chr10:104503620	C10orf26	0.62	7.86	0.39	5.47e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs1474256	0.630	rs79015977	chr15:79450147	G/A	cg17916960	chr15:79447300	NA	0.37	6.51	0.34	2.7e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg18404041	chr3:52824283	ITIH1	-0.41	-7.45	-0.38	8.01e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4891159	0.790	rs689885	chr18:74110563	T/G	cg24786174	chr18:74118243	ZNF516	0.81	14.91	0.63	6.76e-39	Longevity;
LUSC	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg25173405	chr17:45401733	C17orf57	-0.46	-6.7	-0.34	8.87e-11	Glaucoma (primary open-angle);
LUSC	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21659725	chr3:3221576	CRBN	-0.53	-8.46	-0.42	8.77e-16	Body mass index;
LUSC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.56	8.91	0.44	3.47e-17	Longevity;Endometriosis;
LUSC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg20398880	chr6:41068722	NFYA;LOC221442	-0.37	-5.89	-0.31	9.63e-9	Alzheimer's disease (late onset);
LUSC	cis	rs3018712	0.590	rs4930585	chr11:68411347	T/C	cg20283391	chr11:68216788	NA	0.57	5.69	0.3	2.73e-8	Total body bone mineral density;
LUSC	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg24733560	chr20:60626293	TAF4	0.44	8.09	0.4	1.15e-14	Body mass index;
LUSC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	8.56	0.42	4.29e-16	Motion sickness;
LUSC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.65	0.86	4.24e-99	Chronic sinus infection;
LUSC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00864171	chr11:67383662	NA	0.4	7.15	0.36	5.56e-12	Mean corpuscular volume;
LUSC	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg13852791	chr20:30311386	BCL2L1	0.71	8.05	0.4	1.49e-14	Mean corpuscular hemoglobin;
LUSC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12379764	chr21:47803548	PCNT	-0.64	-8.86	-0.44	4.9e-17	Testicular germ cell tumor;
LUSC	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg06191203	chr2:152266755	RIF1	-0.54	-7.28	-0.37	2.41e-12	Lung cancer;
LUSC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg21918786	chr6:109611834	NA	-0.37	-6.41	-0.33	4.89e-10	Reticulocyte fraction of red cells;
LUSC	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg17764715	chr19:33622953	WDR88	0.58	7.95	0.4	2.98e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg03670158	chr17:41323431	NBR1	-0.44	-6.11	-0.32	2.79e-9	Hepatitis;
LUSC	cis	rs1322512	0.874	rs2038619	chr6:152968787	G/A	cg27316956	chr6:152958899	SYNE1	-0.37	-6.34	-0.33	7.62e-10	Tonometry;
LUSC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg25456477	chr12:86230367	RASSF9	0.44	7.77	0.39	9.69e-14	Major depressive disorder;
LUSC	cis	rs9400467	0.528	rs6933627	chr6:111600809	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.35	-6.43	-0.33	4.38e-10	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg16325326	chr1:53192061	ZYG11B	0.87	15.87	0.66	1.16e-42	Monocyte count;
LUSC	cis	rs11585357	0.689	rs2977293	chr1:17599444	C/T	cg08277548	chr1:17600880	PADI3	-0.45	-5.77	-0.3	1.86e-8	Hair shape;
LUSC	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg04455712	chr21:45112962	RRP1B	0.46	8.62	0.43	2.69e-16	Mean corpuscular volume;
LUSC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg27165867	chr14:105738592	BRF1	-0.53	-7.76	-0.39	1.06e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.69	10.41	0.49	3.68e-22	Corneal astigmatism;
LUSC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.9	15.63	0.65	1e-41	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg03676636	chr4:99064102	C4orf37	0.35	7.68	0.39	1.83e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg11019008	chr10:131425282	MGMT	0.46	6.91	0.35	2.47e-11	Response to temozolomide;
LUSC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.4	6.0	0.31	5.19e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg03526776	chr6:41159608	TREML2	0.33	6.19	0.32	1.74e-9	Alzheimer's disease (late onset);
LUSC	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg13607699	chr17:42295918	UBTF	0.49	7.63	0.39	2.41e-13	Total body bone mineral density;
LUSC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.51	7.17	0.37	4.94e-12	Cognitive ability;
LUSC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.73	12.46	0.56	1.62e-29	Motion sickness;
LUSC	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg08601574	chr20:25228251	PYGB	-0.42	-6.44	-0.33	4.23e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg09491104	chr22:46646882	C22orf40	-0.72	-6.91	-0.35	2.51e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg07549590	chr16:15018862	NA	-0.47	-7.65	-0.39	2.13e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg08017634	chr8:144659831	NAPRT1	0.7	6.06	0.31	3.64e-9	Attention deficit hyperactivity disorder;
LUSC	cis	rs9650315	0.810	rs13279155	chr8:57202446	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	-0.54	-6.72	-0.35	7.8e-11	Height;
LUSC	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg09307838	chr4:120376055	NA	-0.59	-9.17	-0.45	4.95e-18	Corneal astigmatism;
LUSC	cis	rs12681287	0.752	rs10956786	chr8:87301237	T/C	cg27223183	chr8:87520930	FAM82B	-0.45	-5.73	-0.3	2.29e-8	Caudate activity during reward;
LUSC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg23985595	chr17:80112537	CCDC57	-0.32	-6.28	-0.33	1.04e-9	Life satisfaction;
LUSC	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.21	-0.37	3.7e-12	Schizophrenia;
LUSC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.47	9.39	0.46	9.78e-19	Mean corpuscular volume;
LUSC	cis	rs4704187	0.687	rs4345300	chr5:74376571	C/T	cg03227963	chr5:74354835	NA	0.31	6.73	0.35	7.4e-11	Response to amphetamines;
LUSC	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	0.6	9.36	0.46	1.17e-18	Breast cancer;
LUSC	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17467752	chr17:38218738	THRA	0.77	12.59	0.57	5.34e-30	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs2625529	0.617	rs2415120	chr15:72105544	A/G	cg16672083	chr15:72433130	SENP8	-0.47	-7.67	-0.39	1.94e-13	Red blood cell count;
LUSC	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg07701084	chr6:150067640	NUP43	0.51	7.78	0.39	8.9e-14	Lung cancer;
LUSC	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	11.87	0.54	2.31e-27	Ileal carcinoids;
LUSC	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg27068330	chr11:65405492	SIPA1	0.65	9.82	0.47	3.71e-20	Acne (severe);
LUSC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10802521	chr3:52805072	NEK4	-0.56	-8.8	-0.43	7.57e-17	Bipolar disorder;
LUSC	cis	rs6733011	0.582	rs2280256	chr2:99449174	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-6.52	-0.34	2.65e-10	Bipolar disorder;
LUSC	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg20684491	chr1:25596433	NA	0.41	6.66	0.34	1.1e-10	Erythrocyte sedimentation rate;
LUSC	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg01238044	chr22:24384105	GSTT1	0.59	7.23	0.37	3.34e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LUSC	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg05340658	chr4:99064831	C4orf37	0.46	7.28	0.37	2.39e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6977940	0.643	rs73033417	chr7:2882855	C/G	cg19346786	chr7:2764209	NA	0.52	5.73	0.3	2.29e-8	White matter integrity;
LUSC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg20608306	chr11:116969690	SIK3	0.34	6.33	0.33	7.99e-10	Blood protein levels;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20264529	chr10:30638039	MTPAP	-0.44	-6.4	-0.33	5.37e-10	Electrocardiographic conduction measures;
LUSC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg19592336	chr6:28129416	ZNF389	0.47	6.04	0.31	4.21e-9	Depression;
LUSC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg02269571	chr22:50332266	NA	-0.57	-8.51	-0.42	6.17e-16	Schizophrenia;
LUSC	cis	rs9296092	0.560	rs62407569	chr6:33538865	A/G	cg13560919	chr6:33536144	NA	-0.85	-16.25	-0.66	3.53e-44	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg09165964	chr15:75287851	SCAMP5	-0.73	-6.56	-0.34	2.01e-10	Lung cancer;
LUSC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg18681998	chr4:17616180	MED28	0.9	17.84	0.7	1.85e-50	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs11971779	0.680	rs11764236	chr7:139118514	C/T	cg07862535	chr7:139043722	LUC7L2	0.57	7.16	0.36	5.18e-12	Diisocyanate-induced asthma;
LUSC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.86	-0.31	1.14e-8	Vitiligo;
LUSC	cis	rs11785693	0.862	rs73183633	chr8:4994543	G/A	cg26367366	chr8:4980734	NA	0.74	8.82	0.43	6.57e-17	Neuroticism (multi-trait analysis);Neuroticism;
LUSC	cis	rs34638657	0.872	rs2967326	chr16:82188246	A/G	cg09439754	chr16:82129088	HSD17B2	-0.41	-6.62	-0.34	1.47e-10	Lung adenocarcinoma;
LUSC	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg23241863	chr10:102295624	HIF1AN	0.47	5.65	0.3	3.46e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9640161	0.830	rs1051823	chr7:150070814	G/A	cg10018233	chr7:150070692	REPIN1	0.45	9.1	0.45	8.6e-18	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs589691	0.502	rs487662	chr11:64481880	G/A	cg19131476	chr11:64387923	NRXN2	-0.35	-8.3	-0.41	2.63e-15	Urate levels;
LUSC	trans	rs4252134	0.881	rs4252107	chr6:161137518	T/C	cg07697006	chr5:132202367	UQCRQ	-0.42	-5.95	-0.31	6.95e-9	Giant cell arteritis;
LUSC	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg24596788	chr1:163392923	NA	-0.45	-7.49	-0.38	6.31e-13	Motion sickness;
LUSC	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg21535247	chr6:8435926	SLC35B3	-0.46	-6.66	-0.34	1.13e-10	Motion sickness;
LUSC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg27494647	chr7:150038898	RARRES2	-0.45	-6.79	-0.35	5.25e-11	Blood protein levels;Circulating chemerin levels;
LUSC	trans	rs60843830	0.508	rs300750	chr2:208794	T/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.41	6.55	0.34	2.23e-10	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs6700896	0.966	rs7542446	chr1:66091106	G/A	cg04111102	chr1:66153794	NA	0.32	7.02	0.36	1.23e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg26695010	chr11:65641043	EFEMP2	-0.46	-7.05	-0.36	1.04e-11	Sum eosinophil basophil counts;Eosinophil counts;
LUSC	cis	rs7712401	0.562	rs384483	chr5:122261573	G/T	cg19077854	chr5:122220652	SNX24	-0.39	-8.39	-0.42	1.41e-15	Mean platelet volume;
LUSC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-7.63	-0.39	2.52e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg04317338	chr11:64019027	PLCB3	0.66	7.53	0.38	4.65e-13	Mean platelet volume;
LUSC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg23172400	chr8:95962367	TP53INP1	-0.43	-8.96	-0.44	2.27e-17	Type 2 diabetes;
LUSC	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.2	0.37	4.13e-12	Blood metabolite levels;
LUSC	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg19622623	chr12:86230825	RASSF9	0.4	5.75	0.3	2.02e-8	Major depressive disorder;
LUSC	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg02825527	chr7:2087843	MAD1L1	-0.48	-5.87	-0.31	1.07e-8	Bipolar disorder;
LUSC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg06671706	chr8:8559999	CLDN23	0.48	6.52	0.34	2.65e-10	Obesity-related traits;
LUSC	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg24154853	chr7:158122151	PTPRN2	0.44	8.48	0.42	7.5e-16	Calcium levels;
LUSC	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.89	15.26	0.64	2.9e-40	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs7945705	0.818	rs10769948	chr11:8761782	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.37	-7.44	-0.38	8.46e-13	Hemoglobin concentration;
LUSC	cis	rs965513	1.000	rs7030256	chr9:100535203	C/G	cg13688889	chr9:100608707	NA	-0.58	-8.65	-0.43	2.23e-16	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg04398451	chr17:18023971	MYO15A	0.5	8.08	0.4	1.18e-14	Total body bone mineral density;
LUSC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg02503808	chr4:7069936	GRPEL1	-0.99	-11.91	-0.55	1.64e-27	Monocyte percentage of white cells;
LUSC	cis	rs7215564	0.908	rs7501497	chr17:78660738	T/C	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs6494488	0.500	rs66500186	chr15:65002594	A/G	cg08069370	chr15:64387884	SNX1	-0.61	-5.75	-0.3	1.98e-8	Coronary artery disease;
LUSC	cis	rs2952768	0.965	rs2254137	chr2:208444028	C/A	cg22739477	chr2:208394512	CREB1	0.34	5.66	0.3	3.24e-8	Opioid sensitivity;
LUSC	trans	rs2587949	0.593	rs795288	chr3:4204455	T/C	cg15139668	chr4:4577005	NA	-0.41	-6.12	-0.32	2.68e-9	Periodontitis (DPAL);
LUSC	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	9.4	0.46	8.73e-19	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4474465	1.000	rs10899534	chr11:78210502	G/C	cg27205649	chr11:78285834	NARS2	0.49	5.73	0.3	2.29e-8	Alzheimer's disease (survival time);
LUSC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg18306943	chr3:40428807	ENTPD3	0.38	5.74	0.3	2.09e-8	Renal cell carcinoma;
LUSC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg02951883	chr7:2050386	MAD1L1	-0.46	-8.12	-0.41	9.03e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg05623727	chr3:50126028	RBM5	0.34	6.32	0.33	8.47e-10	Body mass index;
LUSC	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-6.95	-0.36	1.96e-11	Blood metabolite levels;
LUSC	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg26566898	chr11:117069891	TAGLN	0.37	7.0	0.36	1.37e-11	Blood protein levels;
LUSC	cis	rs9473147	0.543	rs9369716	chr6:47552180	A/T	cg12968598	chr6:47444699	CD2AP	0.52	7.95	0.4	2.91e-14	Platelet distribution width;Mean platelet volume;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg16845172	chr2:240425983	NA	0.46	6.31	0.33	9.01e-10	Neuroticism;
LUSC	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg06360820	chr2:242988706	NA	-0.89	-10.2	-0.49	1.88e-21	Obesity-related traits;
LUSC	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-7.51	-0.38	5.3e-13	Morning vs. evening chronotype;
LUSC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10862848	chr6:42927986	GNMT	-0.28	-6.73	-0.35	7.35e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09678228	chr12:44230058	TMEM117	-0.4	-6.12	-0.32	2.68e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs926392	0.640	rs62202616	chr20:37692775	G/C	cg16355469	chr20:37678765	NA	0.5	6.58	0.34	1.79e-10	Dialysis-related mortality;
LUSC	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	7.22	0.37	3.53e-12	Blood metabolite levels;
LUSC	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.77	-12.92	-0.58	3.07e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Smoking initiation;
LUSC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-11.9	-0.55	1.77e-27	Extrinsic epigenetic age acceleration;
LUSC	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg22482690	chr17:47019901	SNF8	0.38	7.14	0.36	5.76e-12	Type 2 diabetes;
LUSC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.71	-11.04	-0.52	2.36e-24	Menarche (age at onset);
LUSC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg27170947	chr2:26402098	FAM59B	0.72	10.77	0.51	2.12e-23	Gut microbiome composition (summer);
LUSC	cis	rs9549260	0.712	rs9532564	chr13:41160579	C/G	cg21288729	chr13:41239152	FOXO1	0.57	6.16	0.32	2.14e-9	Red blood cell count;
LUSC	trans	rs3736485	0.903	rs8039835	chr15:51865864	A/G	cg09125779	chr4:57547999	HOPX	0.34	6.01	0.31	4.85e-9	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2455601	0.786	rs10279	chr11:8969309	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.46	-7.81	-0.39	7.69e-14	Schizophrenia;
LUSC	cis	rs4680	0.712	rs740601	chr22:19950763	T/G	cg22546130	chr22:19950026	COMT	-0.39	-8.42	-0.42	1.1e-15	Blood metabolite levels;
LUSC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-1.2	-13.15	-0.58	4.19e-32	Diabetic kidney disease;
LUSC	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg13010199	chr12:38710504	ALG10B	-0.43	-6.32	-0.33	8.6e-10	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-5.99	-0.31	5.55e-9	Fear of minor pain;
LUSC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg06784218	chr1:46089804	CCDC17	0.55	11.09	0.52	1.49e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs13202913	0.837	rs6906678	chr6:151772395	A/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	6.02	0.31	4.71e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LUSC	cis	rs354225	0.544	rs11892443	chr2:54805776	A/G	cg01766943	chr2:54829624	SPTBN1	0.48	7.61	0.38	2.89e-13	Schizophrenia;
LUSC	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.66	11.12	0.52	1.17e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg05294307	chr14:35346193	BAZ1A	-0.59	-7.06	-0.36	9.61e-12	Psoriasis;
LUSC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	13.46	0.59	2.67e-33	Alzheimer's disease;
LUSC	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg24642439	chr20:33292090	TP53INP2	-0.39	-5.67	-0.3	3.12e-8	Height;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12929040	chr8:56792373	LYN	0.43	6.39	0.33	5.47e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.77	12.6	0.57	4.86e-30	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LUSC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.45	7.14	0.36	5.9e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg24562669	chr7:97807699	LMTK2	0.37	6.36	0.33	6.72e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg03351412	chr1:154909251	PMVK	0.48	7.43	0.38	8.96e-13	Prostate cancer;
LUSC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.39	5.78	0.3	1.74e-8	Menopause (age at onset);
LUSC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-9.85	-0.47	2.97e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg13560548	chr3:10150139	C3orf24	0.49	6.89	0.35	2.82e-11	Alzheimer's disease;
LUSC	cis	rs2625529	0.730	rs2957373	chr15:72340929	T/C	cg16672083	chr15:72433130	SENP8	0.5	8.01	0.4	1.87e-14	Red blood cell count;
LUSC	cis	rs2979489	0.891	rs17551512	chr8:30330109	A/G	cg26383811	chr8:30366931	RBPMS	-0.51	-8.08	-0.4	1.23e-14	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
LUSC	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	trans	rs1459104	0.925	rs12577653	chr11:55077102	G/A	cg15704280	chr7:45808275	SEPT13	0.75	6.18	0.32	1.92e-9	Body mass index;
LUSC	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg02023728	chr11:77925099	USP35	0.45	6.83	0.35	4.05e-11	Testicular germ cell tumor;
LUSC	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.1	-17.98	-0.7	4.8e-51	Primary sclerosing cholangitis;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21908638	chr3:101497982	FAM55C	-0.44	-6.45	-0.33	4.04e-10	Electrocardiographic conduction measures;
LUSC	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg12419862	chr22:24373484	LOC391322	-1.04	-21.46	-0.76	8.36e-65	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7953508	0.711	rs3825199	chr12:93976954	A/G	cg18151635	chr12:93972918	NA	-0.56	-7.93	-0.4	3.26e-14	Pubertal anthropometrics;
LUSC	cis	rs59104589	0.521	rs62190414	chr2:242424687	A/G	cg19488206	chr2:242435732	STK25	0.37	5.65	0.3	3.49e-8	Fibrinogen levels;
LUSC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg15848620	chr12:58087721	OS9	-0.54	-7.81	-0.39	7.51e-14	Celiac disease or Rheumatoid arthritis;
LUSC	cis	rs1957429	0.808	rs6573580	chr14:65331766	C/G	cg23373153	chr14:65346875	NA	0.95	10.83	0.51	1.25e-23	Pediatric areal bone mineral density (radius);
LUSC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg03146154	chr1:46216737	IPP	0.5	7.14	0.36	5.83e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs56283067	0.887	rs9472365	chr6:44770214	C/G	cg20913747	chr6:44695427	NA	0.43	6.73	0.35	7.25e-11	Total body bone mineral density;
LUSC	cis	rs2078087	0.522	rs2105160	chr1:183226129	G/C	cg13843938	chr1:183241246	NMNAT2	0.38	6.31	0.33	9e-10	Obesity-related traits;
LUSC	cis	rs6681460	0.800	rs485543	chr1:67194372	C/T	cg02459107	chr1:67143332	SGIP1	-0.46	-8.37	-0.42	1.59e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg19196401	chr6:110721138	DDO	-0.45	-8.46	-0.42	8.59e-16	Platelet distribution width;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg02678013	chr4:25378485	ANAPC4	0.4	6.28	0.32	1.05e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.43	5.99	0.31	5.3e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7927771	0.524	rs7929014	chr11:47776283	C/T	cg20307385	chr11:47447363	PSMC3	0.44	6.44	0.33	4.18e-10	Subjective well-being;
LUSC	trans	rs10982256	0.870	rs1408525	chr9:117274994	C/T	cg03506640	chr14:85997753	FLRT2	-0.35	-5.95	-0.31	6.65e-9	Bipolar disorder;
LUSC	trans	rs6600671	1.000	rs4844380	chr1:121193620	A/T	cg00646200	chr1:148855367	NA	0.47	7.37	0.37	1.34e-12	Hip geometry;
LUSC	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.84	0.51	1.15e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg16482183	chr6:26056742	HIST1H1C	0.44	6.53	0.34	2.43e-10	Height;
LUSC	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg11584989	chr19:19387371	SF4	-0.53	-6.3	-0.33	9.52e-10	Bipolar disorder;
LUSC	cis	rs4363385	0.818	rs3795381	chr1:153004848	T/C	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.22	-0.37	3.42e-12	Inflammatory skin disease;
LUSC	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg13010199	chr12:38710504	ALG10B	0.66	10.18	0.49	2.22e-21	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg14552801	chr7:65878734	NA	-0.46	-6.53	-0.34	2.45e-10	Aortic root size;
LUSC	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	0.96	13.28	0.59	1.29e-32	Primary sclerosing cholangitis;
LUSC	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg27661571	chr11:113659931	NA	-0.71	-8.0	-0.4	2.07e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs12618769	1.000	rs12618769	chr2:99239931	A/G	cg10123293	chr2:99228465	UNC50	-0.41	-5.87	-0.31	1.05e-8	Bipolar disorder;
LUSC	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.29	5.72	0.3	2.33e-8	Lymphocyte counts;
LUSC	cis	rs9283706	0.607	rs10471696	chr5:66304823	T/C	cg11590213	chr5:66331682	MAST4	0.45	6.72	0.34	8.08e-11	Coronary artery disease;
LUSC	cis	rs4363385	0.588	rs11205180	chr1:153022070	A/G	cg25856811	chr1:152973957	SPRR3	-0.36	-6.0	-0.31	5.04e-9	Inflammatory skin disease;
LUSC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25072359	chr17:41440525	NA	0.62	9.36	0.46	1.2e-18	Menopause (age at onset);
LUSC	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	1.12	19.01	0.72	3.91e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg13206674	chr6:150067644	NUP43	0.55	8.04	0.4	1.57e-14	Lung cancer;
LUSC	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg25214090	chr10:38739885	LOC399744	0.57	8.42	0.42	1.1e-15	Corneal astigmatism;
LUSC	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.85	-0.3	1.15e-8	Resting heart rate;
LUSC	cis	rs68170813	0.617	rs117884147	chr7:107177593	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-8.63	-0.43	2.46e-16	Coronary artery disease;
LUSC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.83	0.47	3.46e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg08000102	chr2:233561755	GIGYF2	0.68	11.42	0.53	9.96e-26	Coronary artery disease;
LUSC	trans	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg20935933	chr6:143382018	AIG1	0.51	7.44	0.38	8.66e-13	QRS interval (sulfonylurea treatment interaction);
LUSC	trans	rs6601327	0.898	rs1458942	chr8:9406602	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-6.09	-0.32	3.04e-9	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.39	-5.71	-0.3	2.47e-8	Extrinsic epigenetic age acceleration;
LUSC	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.58	7.13	0.36	6.19e-12	Multiple sclerosis;
LUSC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.53	7.78	0.39	9.04e-14	Gut microbiome composition (summer);
LUSC	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg18806716	chr10:30721971	MAP3K8	0.53	8.74	0.43	1.12e-16	Inflammatory bowel disease;
LUSC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg05347473	chr6:146136440	FBXO30	-0.57	-9.86	-0.47	2.71e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	13.51	0.59	1.77e-33	Total body bone mineral density;
LUSC	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg17968037	chr7:100024898	ZCWPW1	-0.38	-5.79	-0.3	1.64e-8	Platelet count;
LUSC	cis	rs2996428	0.667	rs111640545	chr1:3752792	G/A	cg13057898	chr1:3703894	LRRC47	0.52	9.11	0.45	7.57e-18	Red cell distribution width;
LUSC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg06008330	chr7:65541103	ASL	0.41	6.32	0.33	8.55e-10	Aortic root size;
LUSC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-9.42	-0.46	7.74e-19	Gut microbiome composition (summer);
LUSC	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg23034840	chr1:205782522	SLC41A1	0.51	5.9	0.31	8.76e-9	White blood cell types;
LUSC	cis	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg09307838	chr4:120376055	NA	0.5	7.54	0.38	4.45e-13	Diastolic blood pressure;
LUSC	cis	rs997295	0.520	rs4776971	chr15:68081097	C/A	cg08079166	chr15:68083412	MAP2K5	0.37	7.83	0.39	6.52e-14	Motion sickness;
LUSC	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.84	-0.35	3.74e-11	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg18393173	chr6:34856135	ANKS1A;TAF11	0.37	6.44	0.33	4.23e-10	Tuberculosis;
LUSC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg17971929	chr21:40555470	PSMG1	-0.5	-7.38	-0.37	1.24e-12	Menarche (age at onset);
LUSC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg17800788	chr1:21766015	NBPF3	0.32	6.13	0.32	2.43e-9	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.36	-0.46	1.24e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07425625	chr1:1243562	PUSL1;ACAP3	-0.42	-6.38	-0.33	5.97e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4253772	0.938	rs41378347	chr22:46636976	G/A	cg18190219	chr22:46762943	CELSR1	-0.47	-5.73	-0.3	2.28e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.6	-9.87	-0.48	2.46e-20	Brain structure;
LUSC	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg25828445	chr12:7781288	NA	0.62	6.59	0.34	1.67e-10	HDL cholesterol levels;
LUSC	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.24e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg07507251	chr3:52567010	NT5DC2	0.32	6.16	0.32	2.13e-9	Bipolar disorder;
LUSC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg22920501	chr2:26401640	FAM59B	-0.75	-11.39	-0.53	1.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg10117171	chr1:25599238	RHD	-0.41	-6.22	-0.32	1.47e-9	Erythrocyte sedimentation rate;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18973632	chr17:36886646	CISD3	-0.41	-6.04	-0.31	4.07e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6686643	1.000	rs959617	chr1:165616881	C/G	cg16553119	chr1:165599451	MGST3	-0.44	-6.68	-0.34	9.8e-11	Total ventricular volume;
LUSC	cis	rs77741769	0.534	rs58918988	chr12:121332953	G/A	cg02419362	chr12:121203948	SPPL3	0.46	8.51	0.42	6.09e-16	Mean corpuscular volume;
LUSC	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg22117172	chr7:91764530	CYP51A1	0.32	5.82	0.3	1.36e-8	Breast cancer;
LUSC	cis	rs4478858	0.647	rs10798835	chr1:31709055	T/C	cg00250761	chr1:31883323	NA	-0.34	-8.26	-0.41	3.37e-15	Alcohol dependence;
LUSC	cis	rs2274273	0.662	rs67215571	chr14:55673723	G/A	cg04306507	chr14:55594613	LGALS3	0.47	9.24	0.45	3.04e-18	Protein biomarker;
LUSC	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	0.87	17.46	0.69	6.03e-49	Ulcerative colitis;
LUSC	cis	rs16854884	0.632	rs34038325	chr3:143685097	G/A	cg06585982	chr3:143692056	C3orf58	0.45	6.83	0.35	4.09e-11	Economic and political preferences (feminism/equality);
LUSC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg17507749	chr15:85114479	UBE2QP1	0.67	8.48	0.42	7.14e-16	Schizophrenia;
LUSC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg06064525	chr11:970664	AP2A2	-0.49	-10.82	-0.51	1.42e-23	Alzheimer's disease (late onset);
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24449302	chr15:66679100	MAP2K1	-0.36	-6.65	-0.34	1.18e-10	Electrocardiographic conduction measures;
LUSC	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg23229984	chr5:148520753	ABLIM3	-0.38	-6.1	-0.32	2.88e-9	Breast cancer;
LUSC	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg00784671	chr22:46762841	CELSR1	-0.52	-6.59	-0.34	1.69e-10	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs13315871	0.929	rs35004361	chr3:58313394	T/C	cg12435725	chr3:58293450	RPP14	-0.7	-7.23	-0.37	3.21e-12	Cholesterol, total;
LUSC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg14552801	chr7:65878734	NA	0.37	5.7	0.3	2.7e-8	Aortic root size;
LUSC	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg08027265	chr7:2291960	NA	-0.64	-11.68	-0.54	1.17e-26	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg21293242	chr8:11204541	TDH	0.32	5.85	0.3	1.15e-8	Retinal vascular caliber;
LUSC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03352830	chr11:487213	PTDSS2	0.68	8.57	0.42	3.96e-16	Body mass index;
LUSC	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg16482183	chr6:26056742	HIST1H1C	0.65	9.13	0.45	6.68e-18	Iron status biomarkers;
LUSC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg17757837	chr7:157058334	UBE3C	0.81	13.1	0.58	6.53e-32	Body mass index;
LUSC	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg08508325	chr11:3079039	CARS	0.38	8.45	0.42	9.13e-16	Calcium levels;
LUSC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	0.92	15.51	0.65	2.94e-41	Menopause (age at onset);
LUSC	cis	rs7760949	0.888	rs1966191	chr6:13911961	A/C	cg27413430	chr6:13925136	RNF182	0.48	7.01	0.36	1.31e-11	Mean corpuscular hemoglobin concentration;
LUSC	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg03929089	chr4:120376271	NA	-0.54	-6.21	-0.32	1.58e-9	Acute lymphoblastic leukemia (childhood);
LUSC	trans	rs9929218	0.608	rs35158985	chr16:68796746	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.69	-10.35	-0.49	5.93e-22	Colorectal cancer;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg09131844	chr2:27651398	NRBP1	0.41	6.21	0.32	1.58e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs2932538	0.922	rs2932535	chr1:113201412	G/C	cg22162597	chr1:113214053	CAPZA1	-0.67	-9.72	-0.47	7.69e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12667521	chr19:29218732	NA	0.61	7.51	0.38	5.53e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LUSC	cis	rs7112043	0.778	rs1472975	chr11:34776643	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.4	5.74	0.3	2.08e-8	Lung disease severity in cystic fibrosis;
LUSC	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg24375607	chr4:120327624	NA	0.67	10.54	0.5	1.33e-22	Corneal astigmatism;
LUSC	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg15571903	chr15:79123663	NA	-0.35	-6.4	-0.33	5.3e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg21918786	chr6:109611834	NA	-0.36	-6.25	-0.32	1.25e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.99	-0.36	1.5e-11	Monocyte percentage of white cells;
LUSC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg04369109	chr6:150039330	LATS1	-0.58	-8.43	-0.42	1.02e-15	Lung cancer;
LUSC	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg22823121	chr1:150693482	HORMAD1	0.5	7.32	0.37	1.85e-12	Melanoma;
LUSC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg05084668	chr3:125655381	ALG1L	-0.47	-6.65	-0.34	1.22e-10	Blood pressure (smoking interaction);
LUSC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-9.61	-0.47	1.89e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.4	5.75	0.3	2e-8	Tonsillectomy;
LUSC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.8	13.41	0.59	4.19e-33	Menarche (age at onset);
LUSC	cis	rs751728	0.687	rs943479	chr6:33752013	A/G	cg25922239	chr6:33757077	LEMD2	0.42	6.37	0.33	6.27e-10	Crohn's disease;
LUSC	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	1.13	17.16	0.68	8.74e-48	Corneal structure;
LUSC	cis	rs238295	0.805	rs1056244	chr20:5551034	G/C	cg15842884	chr20:5591925	RP5-1022P6.2	-0.43	-5.87	-0.31	1.07e-8	Occipital cortical area (total cortical area interaction);
LUSC	cis	rs10848704	0.637	rs11062351	chr12:2881763	C/T	cg19995117	chr12:2880862	NA	0.47	8.94	0.44	2.61e-17	Quantitative traits;
LUSC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg18402987	chr7:1209562	NA	0.71	7.71	0.39	1.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg14563129	chr8:141290188	TRAPPC9	-0.71	-5.99	-0.31	5.4e-9	Cognitive performance;
LUSC	cis	rs12210905	0.688	rs12213471	chr6:27406063	C/G	cg08851530	chr6:28072375	NA	0.93	5.77	0.3	1.77e-8	Hip circumference adjusted for BMI;
LUSC	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.84	-20.23	-0.74	5.51e-60	Itch intensity from mosquito bite adjusted by bite size;
LUSC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg04369109	chr6:150039330	LATS1	-0.58	-8.63	-0.43	2.49e-16	Lung cancer;
LUSC	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg22906224	chr7:99728672	NA	0.48	6.68	0.34	1.03e-10	Coronary artery disease;
LUSC	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-9.14	-0.45	6.18e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LUSC	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg14829155	chr15:31115871	NA	-0.71	-10.33	-0.49	6.68e-22	Huntington's disease progression;
LUSC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg05896524	chr21:47604654	C21orf56	0.48	7.31	0.37	1.98e-12	Testicular germ cell tumor;
LUSC	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.62	6.93	0.35	2.17e-11	Crohn's disease;
LUSC	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	0.93	17.19	0.69	6.65e-48	Headache;
LUSC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.58	-10.33	-0.49	6.63e-22	Extrinsic epigenetic age acceleration;
LUSC	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg27432699	chr2:27873401	GPN1	-0.56	-8.37	-0.42	1.57e-15	Total body bone mineral density;
LUSC	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg20701182	chr2:24300061	SF3B14	0.54	5.81	0.3	1.46e-8	Lymphocyte counts;
LUSC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg13206674	chr6:150067644	NUP43	0.63	10.37	0.49	5.14e-22	Lung cancer;
LUSC	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-6.38	-0.33	6.06e-10	Fibrinogen levels;
LUSC	trans	rs9944715	0.954	rs9959905	chr18:43811050	A/G	cg01718231	chr17:29326311	RNF135	-0.53	-7.41	-0.38	1.03e-12	Red cell distribution width;Mean corpuscular volume;
LUSC	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg08601574	chr20:25228251	PYGB	-0.43	-6.6	-0.34	1.62e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg22823121	chr1:150693482	HORMAD1	0.49	7.06	0.36	9.73e-12	Melanoma;
LUSC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg05084668	chr3:125655381	ALG1L	-0.49	-7.01	-0.36	1.33e-11	Blood pressure (smoking interaction);
LUSC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg24675658	chr1:53192096	ZYG11B	-0.67	-10.66	-0.5	4.97e-23	Monocyte count;
LUSC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.5	-6.86	-0.35	3.25e-11	Tonsillectomy;
LUSC	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg20295408	chr7:1910781	MAD1L1	0.41	5.84	0.3	1.26e-8	Schizophrenia;
LUSC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.72	12.86	0.58	5.23e-31	Prudent dietary pattern;
LUSC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.77	13.24	0.59	1.8e-32	Menarche (age at onset);
LUSC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg07741184	chr6:167504864	NA	0.37	6.72	0.35	7.82e-11	Crohn's disease;
LUSC	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg11752832	chr7:134001865	SLC35B4	0.4	5.79	0.3	1.61e-8	Mean platelet volume;
LUSC	cis	rs73198271	0.632	rs570396	chr8:8593652	A/G	cg01851573	chr8:8652454	MFHAS1	0.4	6.22	0.32	1.52e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6681460	0.966	rs11208932	chr1:67097853	T/C	cg02459107	chr1:67143332	SGIP1	0.46	8.55	0.42	4.52e-16	Presence of antiphospholipid antibodies;
LUSC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg00343986	chr7:65444356	GUSB	0.44	6.3	0.33	9.48e-10	Calcium levels;
LUSC	cis	rs4589502	0.800	rs1498499	chr15:67202620	C/T	cg09911534	chr15:67153556	NA	0.5	6.5	0.34	2.92e-10	Lung cancer (smoking interaction);
LUSC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19748678	chr4:122722346	EXOSC9	0.49	7.53	0.38	4.64e-13	Type 2 diabetes;
LUSC	trans	rs488628	0.848	rs1614410	chr3:118138386	A/G	cg06621744	chr14:37052470	NKX2-8	-0.25	-5.96	-0.31	6.42e-9	White matter integrity (bipolar disorder risk interaction);
LUSC	cis	rs7072216	0.666	rs11189592	chr10:100155642	C/A	cg26618903	chr10:100175079	PYROXD2	-0.32	-5.73	-0.3	2.3e-8	Metabolite levels;
LUSC	cis	rs9902453	0.967	rs12602065	chr17:28482488	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	7.95	0.4	2.93e-14	Coffee consumption (cups per day);
LUSC	cis	rs6500395	1.000	rs871902	chr16:48593779	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.51	0.34	2.76e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg22709100	chr7:91322751	NA	0.44	6.44	0.33	4.28e-10	Breast cancer;
LUSC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-12.08	-0.55	3.94e-28	Type 2 diabetes;
LUSC	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg27471124	chr11:109292789	C11orf87	0.48	8.4	0.42	1.33e-15	Schizophrenia;
LUSC	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg16928487	chr17:17741425	SREBF1	-0.44	-8.6	-0.43	3.16e-16	Total body bone mineral density;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16953067	chr3:9005230	RAD18	-0.48	-7.77	-0.39	9.49e-14	Electrocardiographic conduction measures;
LUSC	cis	rs698813	0.674	rs11678787	chr2:44496315	C/T	cg00619915	chr2:44497795	NA	-0.53	-7.17	-0.37	4.86e-12	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs4253772	0.938	rs14842	chr22:46639457	A/T	cg18190219	chr22:46762943	CELSR1	-0.52	-6.02	-0.31	4.71e-9	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg04317338	chr11:64019027	PLCB3	0.63	7.25	0.37	2.91e-12	Mean platelet volume;
LUSC	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg21573476	chr21:45109991	RRP1B	-0.37	-5.88	-0.31	1.02e-8	Mean corpuscular volume;
LUSC	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.95	-12.41	-0.56	2.52e-29	Exhaled nitric oxide output;
LUSC	cis	rs988712	0.705	rs11030104	chr11:27684517	C/T	cg10635145	chr11:27742435	BDNF	0.48	6.26	0.32	1.19e-9	Obesity;
LUSC	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg03676636	chr4:99064102	C4orf37	0.27	5.8	0.3	1.54e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg19230755	chr7:65878503	NA	0.41	6.13	0.32	2.49e-9	Aortic root size;
LUSC	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.82	-17.73	-0.7	4.71e-50	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.95	-0.4	3e-14	Joint mobility (Beighton score);
LUSC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.6	0.38	3.12e-13	Electroencephalogram traits;
LUSC	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.63	8.17	0.41	6.29e-15	Schizophrenia;
LUSC	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg17173187	chr15:85201210	NMB	0.49	9.31	0.45	1.74e-18	Schizophrenia;
LUSC	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg11645453	chr3:52864694	ITIH4	0.34	7.97	0.4	2.49e-14	Body mass index;
LUSC	cis	rs6460942	0.732	rs73677575	chr7:12286532	A/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.11	-0.32	2.71e-9	Coronary artery disease;
LUSC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	0.64	13.56	0.6	1.12e-33	Prudent dietary pattern;
LUSC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg04518342	chr5:131593106	PDLIM4	-0.54	-10.19	-0.49	2.09e-21	Acylcarnitine levels;
LUSC	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg01528321	chr10:82214614	TSPAN14	0.87	13.37	0.59	6.24e-33	Post bronchodilator FEV1;
LUSC	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg00277334	chr10:82204260	NA	-0.5	-6.71	-0.34	8.23e-11	Post bronchodilator FEV1;
LUSC	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg13010199	chr12:38710504	ALG10B	-0.58	-9.09	-0.45	8.82e-18	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg03342759	chr3:160939853	NMD3	-0.42	-6.83	-0.35	3.91e-11	Morning vs. evening chronotype;
LUSC	cis	rs372883	0.935	rs379592	chr21:30706470	A/G	cg24692254	chr21:30365293	RNF160	-0.41	-5.68	-0.3	3e-8	Pancreatic cancer;
LUSC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg17366294	chr4:99064904	C4orf37	0.58	10.23	0.49	1.53e-21	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg11693508	chr17:37793320	STARD3	0.53	6.43	0.33	4.36e-10	Bipolar disorder;
LUSC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	6.93	0.35	2.14e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs2282802	0.660	rs7726176	chr5:139547971	T/A	cg26211634	chr5:139558579	C5orf32	-0.41	-7.59	-0.38	3.12e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg02574844	chr11:5959923	NA	0.42	6.6	0.34	1.59e-10	DNA methylation (variation);
LUSC	cis	rs7408868	1.000	rs6512018	chr19:15282138	T/C	cg14696996	chr19:15285081	NOTCH3	0.96	9.25	0.45	2.67e-18	Pulse pressure;
LUSC	cis	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg06521331	chr12:34319734	NA	0.38	6.22	0.32	1.52e-9	Morning vs. evening chronotype;
LUSC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	6.56	0.34	2.04e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-6.77	-0.35	5.96e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs7113850	0.541	rs76874215	chr11:24235158	G/A	ch.11.24196551F	chr11:24239977	NA	1.0	9.09	0.45	9.2e-18	Bone fracture in osteoporosis;
LUSC	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg05784532	chr1:230284198	GALNT2	0.53	7.97	0.4	2.55e-14	Coronary artery disease;
LUSC	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg08975724	chr8:8085496	FLJ10661	0.43	6.09	0.32	3.06e-9	Systolic blood pressure;
LUSC	trans	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg07393940	chr7:158741817	NA	0.37	6.75	0.35	6.53e-11	Life satisfaction;
LUSC	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg17764715	chr19:33622953	WDR88	0.6	8.34	0.42	2.02e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-0.91	-16.96	-0.68	5.59e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs2455601	1.000	rs2455601	chr11:8899400	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.44	-7.3	-0.37	2.18e-12	Schizophrenia;
LUSC	trans	rs75804782	0.641	rs3769123	chr2:239349328	C/G	cg01134436	chr17:81009848	B3GNTL1	0.66	6.4	0.33	5.11e-10	Morning vs. evening chronotype;Chronotype;
LUSC	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.41	-0.33	5e-10	Cutaneous nevi;
LUSC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg17554472	chr22:41940697	POLR3H	-0.48	-5.84	-0.3	1.22e-8	Vitiligo;
LUSC	cis	rs7973719	0.868	rs6486910	chr12:7356479	G/A	cg07052231	chr12:7363540	PEX5	0.54	9.42	0.46	7.85e-19	IgG glycosylation;
LUSC	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg13206674	chr6:150067644	NUP43	0.46	7.05	0.36	1e-11	Testicular germ cell tumor;
LUSC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.73	-12.61	-0.57	4.3e-30	Sudden cardiac arrest;
LUSC	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg09699651	chr6:150184138	LRP11	0.45	7.17	0.37	4.98e-12	Testicular germ cell tumor;
LUSC	cis	rs6674970	0.932	rs12569193	chr1:151115186	C/T	cg11822372	chr1:151115635	SEMA6C	0.55	8.44	0.42	9.44e-16	Childhood ear infection;
LUSC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	11.07	0.52	1.76e-24	Alzheimer's disease;
LUSC	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg25801113	chr15:45476975	SHF	0.34	7.01	0.36	1.32e-11	Uric acid levels;
LUSC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg16405210	chr4:1374714	KIAA1530	-0.57	-8.8	-0.43	7.35e-17	Obesity-related traits;
LUSC	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg13256891	chr4:100009986	ADH5	-0.43	-5.97	-0.31	5.95e-9	Alcohol dependence;
LUSC	trans	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg26043149	chr18:55253948	FECH	0.51	7.79	0.39	8.56e-14	Bone mineral density;
LUSC	trans	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg24644049	chr4:85504048	CDS1	0.88	7.56	0.38	3.94e-13	Skin colour saturation;
LUSC	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg27411982	chr8:10470053	RP1L1	0.4	6.35	0.33	7.01e-10	Mood instability;
LUSC	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg13390004	chr1:15929781	NA	0.42	6.98	0.36	1.61e-11	Systolic blood pressure;
LUSC	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg08847533	chr14:75593920	NEK9	-0.8	-13.94	-0.61	4e-35	Height;
LUSC	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg02466173	chr16:30829666	NA	-0.69	-16.1	-0.66	1.5e-43	Dementia with Lewy bodies;
LUSC	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	8.81	0.43	7.06e-17	Lung cancer;
LUSC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.61	7.59	0.38	3.31e-13	Lung function (FEV1/FVC);
LUSC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.78	-0.3	1.74e-8	Depression;
LUSC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21545522	chr1:205238299	TMCC2	0.5	9.34	0.45	1.45e-18	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg06454157	chr6:167490870	NA	-0.23	-5.8	-0.3	1.51e-8	Crohn's disease;
LUSC	cis	rs5758511	0.689	rs62240864	chr22:42563889	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.54	8.21	0.41	4.97e-15	Birth weight;
LUSC	cis	rs11587400	0.679	rs6537836	chr1:115108923	T/C	cg12756093	chr1:115239321	AMPD1	0.4	5.93	0.31	7.76e-9	Autism;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00357593	chr19:14530417	DDX39	-0.49	-6.09	-0.32	3.08e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11945232	1.000	rs4314250	chr4:88340969	A/G	cg23841344	chr4:88312519	HSD17B11	0.64	9.8	0.47	4.34e-20	Intelligence (multi-trait analysis);
LUSC	trans	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg19676328	chr12:49525230	TUBA1B	-0.51	-7.33	-0.37	1.71e-12	Total cholesterol levels;
LUSC	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg10326726	chr10:51549505	MSMB	-0.37	-6.36	-0.33	6.63e-10	Prostate-specific antigen levels;
LUSC	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg27129171	chr3:47204927	SETD2	-0.68	-11.05	-0.52	2.16e-24	Colorectal cancer;
LUSC	cis	rs4654899	0.865	rs6665549	chr1:21475884	G/C	cg02927042	chr1:21476669	EIF4G3	-0.36	-5.8	-0.3	1.51e-8	Superior frontal gyrus grey matter volume;
LUSC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06544989	chr22:39130855	UNC84B	0.36	6.28	0.33	1.04e-9	Menopause (age at onset);
LUSC	cis	rs9487051	0.735	rs380774	chr6:109519623	C/T	cg01475377	chr6:109611718	NA	-0.36	-6.11	-0.32	2.72e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg03676636	chr4:99064102	C4orf37	0.34	7.52	0.38	5.05e-13	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.48	6.47	0.33	3.4e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs72960926	0.744	rs72950548	chr6:74907794	T/C	cg03266952	chr6:74778945	NA	-0.78	-6.3	-0.33	9.2e-10	Metabolite levels (MHPG);
LUSC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	8.79	0.43	8.13e-17	Prudent dietary pattern;
LUSC	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11635524	chr19:46850777	PPP5C	-0.43	-6.12	-0.32	2.56e-9	Electrocardiographic conduction measures;
LUSC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg20295408	chr7:1910781	MAD1L1	-0.51	-7.09	-0.36	8.15e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs6977660	0.714	rs4719586	chr7:19825548	T/C	cg07541023	chr7:19748670	TWISTNB	0.6	6.3	0.33	9.45e-10	Thyroid stimulating hormone;
LUSC	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg18904891	chr8:8559673	CLDN23	0.56	7.23	0.37	3.32e-12	Obesity-related traits;
LUSC	cis	rs7236492	0.872	rs78226032	chr18:77230822	G/A	cg15644404	chr18:77186268	NFATC1	-0.56	-5.94	-0.31	7.35e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	8.55	0.42	4.63e-16	Menarche (age at onset);
LUSC	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg15073853	chr19:18549131	ISYNA1	-0.31	-5.76	-0.3	1.93e-8	Breast cancer;
LUSC	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg04414720	chr1:150670196	GOLPH3L	0.52	8.02	0.4	1.75e-14	Melanoma;
LUSC	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg22139774	chr2:100720529	AFF3	0.46	8.26	0.41	3.47e-15	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.75e-10	Crohn's disease;
LUSC	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg10523679	chr1:76189770	ACADM	-0.49	-7.06	-0.36	9.81e-12	Daytime sleep phenotypes;
LUSC	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg02176678	chr2:219576539	TTLL4	0.58	10.24	0.49	1.41e-21	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs10193935	0.792	rs72794590	chr2:42378392	G/A	cg27598129	chr2:42591480	NA	-0.57	-7.6	-0.38	3.06e-13	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg26384229	chr12:38710491	ALG10B	0.71	11.72	0.54	8.1e-27	Morning vs. evening chronotype;
LUSC	cis	rs59698941	0.882	rs4705977	chr5:132245114	C/A	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.07	16.31	0.67	2.14e-44	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.73	12.17	0.55	1.86e-28	Motion sickness;
LUSC	cis	rs12760731	0.565	rs12028023	chr1:178087408	G/A	cg00404053	chr1:178313656	RASAL2	0.67	6.7	0.34	8.81e-11	Obesity-related traits;
LUSC	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg00484396	chr16:3507460	NAT15	0.48	7.87	0.4	4.89e-14	Body mass index (adult);
LUSC	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg26102564	chr10:131424627	MGMT	0.39	6.09	0.32	3.08e-9	Response to temozolomide;
LUSC	cis	rs12530845	0.887	rs61360007	chr7:135316879	G/A	cg23117316	chr7:135346802	PL-5283	-0.58	-9.31	-0.45	1.82e-18	Red blood cell traits;
LUSC	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg12292205	chr6:26970375	C6orf41	-0.63	-7.57	-0.38	3.72e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg25182066	chr10:30743637	MAP3K8	-0.46	-6.5	-0.34	2.92e-10	Inflammatory bowel disease;
LUSC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg23262073	chr20:60523788	NA	-0.4	-5.93	-0.31	7.71e-9	Body mass index;
LUSC	cis	rs7617773	0.963	rs6766754	chr3:48182589	T/C	cg11946769	chr3:48343235	NME6	-0.62	-9.45	-0.46	6.24e-19	Coronary artery disease;
LUSC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg26924012	chr15:45694286	SPATA5L1	1.12	20.31	0.74	2.75e-60	Homoarginine levels;
LUSC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg12292205	chr6:26970375	C6orf41	0.68	11.53	0.53	4.12e-26	Schizophrenia;
LUSC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg04944784	chr2:26401820	FAM59B	-0.75	-10.94	-0.51	5.29e-24	Gut microbiome composition (summer);
LUSC	cis	rs11031096	0.782	rs7130580	chr11:4169301	G/A	cg18678763	chr11:4115507	RRM1	-0.55	-7.99	-0.4	2.22e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg08888203	chr3:10149979	C3orf24	0.66	9.26	0.45	2.47e-18	Alzheimer's disease;
LUSC	cis	rs72627509	0.857	rs56155140	chr4:57824451	G/A	cg26694713	chr4:57773883	REST	0.48	5.71	0.3	2.49e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-10.56	-0.5	1.06e-22	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08677398	chr8:58056175	NA	0.52	6.99	0.36	1.46e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg00343986	chr7:65444356	GUSB	-0.42	-6.45	-0.33	3.89e-10	Aortic root size;
LUSC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg19622623	chr12:86230825	RASSF9	0.44	6.17	0.32	1.97e-9	Major depressive disorder;
LUSC	cis	rs559928	0.847	rs11601738	chr11:64159307	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	6.68	0.34	1.02e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LUSC	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.59	9.48	0.46	4.74e-19	Body mass index;
LUSC	cis	rs7584330	0.628	rs73098849	chr2:238389739	G/A	cg14458575	chr2:238380390	NA	0.56	6.92	0.35	2.31e-11	Prostate cancer;
LUSC	cis	rs10733682	0.659	rs3906146	chr9:129463613	C/T	cg00232160	chr9:129468157	NA	0.38	6.63	0.34	1.36e-10	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg04518342	chr5:131593106	PDLIM4	-0.44	-7.68	-0.39	1.83e-13	Breast cancer;
LUSC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg03146154	chr1:46216737	IPP	0.54	8.3	0.41	2.66e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg15212455	chr7:39170539	POU6F2	0.54	8.97	0.44	2.18e-17	IgG glycosylation;
LUSC	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg17366294	chr4:99064904	C4orf37	0.57	10.18	0.49	2.27e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg07636037	chr3:49044803	WDR6	0.92	12.02	0.55	6.95e-28	Menarche (age at onset);
LUSC	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.85	0.51	1.05e-23	Colorectal cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15401922	chr6:157802439	ZDHHC14	0.41	6.42	0.33	4.65e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs3960554	0.932	rs11975745	chr7:75843524	T/C	cg19862616	chr7:65841803	NCRNA00174	0.89	9.56	0.46	2.71e-19	Eotaxin levels;
LUSC	cis	rs1358748	0.522	rs11209001	chr1:67587723	C/T	cg02640540	chr1:67518911	SLC35D1	0.67	6.55	0.34	2.15e-10	Tuberculosis;
LUSC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg17968037	chr7:100024898	ZCWPW1	-0.4	-6.02	-0.31	4.51e-9	Platelet count;
LUSC	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg04155231	chr12:9217510	LOC144571	0.3	5.66	0.3	3.26e-8	Sjögren's syndrome;
LUSC	cis	rs193541	0.507	rs1466370	chr5:122083780	A/G	cg19077854	chr5:122220652	SNX24	0.26	5.64	0.3	3.56e-8	Glucose homeostasis traits;
LUSC	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.27	-0.45	2.33e-18	Bone mineral density;
LUSC	cis	rs240764	0.853	rs2001102	chr6:100978351	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-5.91	-0.31	8.42e-9	Neuroticism;
LUSC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg14440974	chr22:39074834	NA	-0.37	-6.14	-0.32	2.34e-9	Menopause (age at onset);
LUSC	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg21293242	chr8:11204541	TDH	0.33	6.3	0.33	9.54e-10	Retinal vascular caliber;
LUSC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg24675658	chr1:53192096	ZYG11B	0.75	12.91	0.58	3.37e-31	Monocyte count;
LUSC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg21770322	chr7:97807741	LMTK2	0.41	7.02	0.36	1.27e-11	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg19773385	chr1:10388646	KIF1B	-0.54	-8.42	-0.42	1.11e-15	Hepatocellular carcinoma;
LUSC	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg04586622	chr2:25135609	ADCY3	0.42	8.98	0.44	1.97e-17	Body mass index;
LUSC	cis	rs62458065	0.640	rs28587905	chr7:32533054	C/T	cg20159608	chr7:32802032	NA	-0.75	-9.41	-0.46	8.26e-19	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg06671706	chr8:8559999	CLDN23	0.49	6.43	0.33	4.36e-10	Obesity-related traits;
LUSC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs28595532	0.800	rs114321375	chr4:119341663	G/A	cg21605333	chr4:119757512	SEC24D	1.02	8.31	0.41	2.41e-15	Cannabis dependence symptom count;
LUSC	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	6.0	0.31	5.06e-9	IgG glycosylation;
LUSC	cis	rs6500395	0.926	rs1039343	chr16:48577507	T/G	cg04672837	chr16:48644449	N4BP1	0.44	6.58	0.34	1.77e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7590368	0.715	rs56321198	chr2:10959292	C/A	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg00191853	chr8:101177733	SPAG1	0.34	5.78	0.3	1.74e-8	Atrioventricular conduction;
LUSC	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.42	0.33	4.58e-10	Height;
LUSC	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg09365446	chr1:150670422	GOLPH3L	0.49	7.18	0.37	4.54e-12	Melanoma;
LUSC	cis	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg06521852	chr22:38141419	TRIOBP	0.44	6.58	0.34	1.79e-10	Optic cup area;Vertical cup-disc ratio;
LUSC	cis	rs240764	0.621	rs12175456	chr6:101219511	A/T	cg09795085	chr6:101329169	ASCC3	-0.44	-6.26	-0.32	1.19e-9	Neuroticism;
LUSC	cis	rs67539049	1.000	rs56388647	chr8:11295084	T/C	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.4	-6.2	-0.32	1.69e-9	Itch intensity from mosquito bite;
LUSC	cis	rs8018808	0.875	rs11159258	chr14:77880593	T/C	cg20045696	chr14:77926864	AHSA1	0.35	5.75	0.3	2.01e-8	Myeloid white cell count;
LUSC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg21285383	chr16:89894308	SPIRE2	0.31	6.64	0.34	1.24e-10	Vitiligo;
LUSC	cis	rs2274273	0.563	rs79163357	chr14:55738449	G/A	cg04306507	chr14:55594613	LGALS3	0.49	9.77	0.47	5.27e-20	Protein biomarker;
LUSC	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.7	10.51	0.5	1.69e-22	Blood pressure (smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19307233	chr1:231377017	C1orf131;GNPAT	-0.41	-6.2	-0.32	1.69e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg08916839	chr5:415575	AHRR	0.75	7.1	0.36	7.63e-12	Fat distribution (HIV);
LUSC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.23	0.49	1.55e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.77	0.35	5.7e-11	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs28647808	0.881	rs41316984	chr9:136259231	T/C	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg25237894	chr2:233734115	C2orf82	0.34	6.32	0.33	8.31e-10	Coronary artery disease;
LUSC	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg02403541	chr12:121454288	C12orf43	-0.7	-10.16	-0.49	2.71e-21	N-glycan levels;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg21638108	chr19:19431283	KIAA0892;SF4	-0.46	-6.15	-0.32	2.2e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs3741798	1.000	rs2160588	chr12:12487447	C/T	cg08615371	chr12:12503544	MANSC1	1.07	11.68	0.54	1.13e-26	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg11859384	chr17:80120422	CCDC57	0.36	5.65	0.3	3.43e-8	Life satisfaction;
LUSC	cis	rs4356932	0.871	rs4859606	chr4:76965879	C/T	cg00809888	chr4:76862425	NAAA	0.34	5.68	0.3	2.94e-8	Blood protein levels;
LUSC	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.97	-0.31	6.07e-9	Resting heart rate;
LUSC	cis	rs965469	1.000	rs2236107	chr20:3285821	C/T	cg25506879	chr20:3388711	C20orf194	-0.55	-5.99	-0.31	5.36e-9	IFN-related cytopenia;
LUSC	cis	rs6537837	1.000	rs3768486	chr1:110123971	A/G	cg05049280	chr1:110155535	GNAT2	0.51	6.91	0.35	2.43e-11	Major depressive disorder;
LUSC	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	8.51	0.42	6.02e-16	Coffee consumption (cups per day);
LUSC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	7.71	0.39	1.41e-13	Menarche (age at onset);
LUSC	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.32	5.66	0.3	3.28e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg23422044	chr7:1970798	MAD1L1	-0.61	-7.18	-0.37	4.64e-12	Bipolar disorder;
LUSC	cis	rs433852	1.000	rs433852	chr19:49117104	C/T	cg06677660	chr19:49140777	SEC1;DBP	-0.58	-6.96	-0.36	1.85e-11	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg00277334	chr10:82204260	NA	0.49	7.7	0.39	1.59e-13	Sarcoidosis;
LUSC	cis	rs2324229	0.828	rs1180230	chr6:83949261	T/C	cg08257003	chr6:84140564	ME1	0.28	6.78	0.35	5.51e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg13047869	chr3:10149882	C3orf24	0.57	7.98	0.4	2.42e-14	Alzheimer's disease;
LUSC	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg18758796	chr5:131593413	PDLIM4	0.35	5.96	0.31	6.44e-9	Blood metabolite levels;
LUSC	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg11645453	chr3:52864694	ITIH4	-0.35	-8.14	-0.41	8.17e-15	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg11645453	chr3:52864694	ITIH4	-0.39	-8.79	-0.43	8.09e-17	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs9394438	0.628	rs2153947	chr6:37544930	A/G	cg00985040	chr6:37553208	NA	-0.38	-7.98	-0.4	2.39e-14	IgG glycosylation;
LUSC	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	15.26	0.64	3.04e-40	Lymphocyte percentage of white cells;
LUSC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg02018176	chr4:1364513	KIAA1530	0.55	9.76	0.47	5.74e-20	Longevity;
LUSC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg05425664	chr17:57184151	TRIM37	0.55	8.65	0.43	2.26e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg14552801	chr7:65878734	NA	-0.36	-5.74	-0.3	2.15e-8	Aortic root size;
LUSC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg23796481	chr11:64053134	BAD;GPR137	0.52	8.27	0.41	3.16e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LUSC	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.84	18.2	0.71	6.88e-52	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1395	0.677	rs113353646	chr2:27492674	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.52	7.69	0.39	1.68e-13	Blood metabolite levels;
LUSC	cis	rs12704876	0.509	rs1464808	chr7:96363633	A/T	cg03808172	chr7:96339361	SHFM1	0.5	7.73	0.39	1.24e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.82	-10.56	-0.5	1.14e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs939658	0.935	rs12903747	chr15:79449627	A/C	cg17916960	chr15:79447300	NA	0.47	9.56	0.46	2.65e-19	Refractive error;
LUSC	cis	rs2070997	0.667	rs10901291	chr9:133717881	C/T	cg11464064	chr9:133710261	ABL1	0.48	5.65	0.3	3.47e-8	Response to amphetamines;
LUSC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	1.19	16.28	0.67	2.87e-44	Eosinophil percentage of granulocytes;
LUSC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg04518342	chr5:131593106	PDLIM4	0.36	6.85	0.35	3.62e-11	Blood metabolite levels;
LUSC	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	7.04	0.36	1.07e-11	Schizophrenia;
LUSC	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	6.78	0.35	5.42e-11	Height;
LUSC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg06096015	chr1:231504339	EGLN1	0.58	10.39	0.49	4.18e-22	Hemoglobin concentration;
LUSC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18099408	chr3:52552593	STAB1	-0.43	-7.53	-0.38	4.66e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg06740227	chr12:86229804	RASSF9	0.37	5.82	0.3	1.39e-8	Major depressive disorder;
LUSC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.45	-8.65	-0.43	2.26e-16	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg21772509	chr8:41503840	NKX6-3	0.65	10.6	0.5	7.91e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LUSC	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.74	-11.82	-0.54	3.48e-27	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg07741184	chr6:167504864	NA	0.32	5.89	0.31	9.43e-9	Crohn's disease;
LUSC	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg22705602	chr4:152727874	NA	-0.34	-6.86	-0.35	3.31e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs11679564	0.714	rs4016031	chr2:37184754	C/T	cg14987922	chr2:37194071	STRN	0.63	9.39	0.46	9.32e-19	Immature fraction of reticulocytes;
LUSC	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg15997130	chr1:24165203	NA	0.53	8.71	0.43	1.39e-16	Immature fraction of reticulocytes;
LUSC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg24813613	chr7:1882135	MAD1L1	0.42	7.17	0.37	4.96e-12	Bipolar disorder and schizophrenia;
LUSC	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg16339924	chr4:17578868	LAP3	0.5	7.35	0.37	1.54e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg25456477	chr12:86230367	RASSF9	0.33	5.8	0.3	1.55e-8	Major depressive disorder;
LUSC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg20891283	chr12:69753455	YEATS4	0.73	11.62	0.54	1.99e-26	Cerebrospinal fluid biomarker levels;
LUSC	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-8.13	-0.41	8.56e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2227564	0.729	rs2688617	chr10:75646147	A/T	cg23231163	chr10:75533350	FUT11	-0.43	-5.94	-0.31	7.3e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg23711669	chr6:146136114	FBXO30	0.74	13.27	0.59	1.41e-32	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-7.24	-0.37	3.03e-12	Morning vs. evening chronotype;
LUSC	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg02023728	chr11:77925099	USP35	0.52	7.15	0.36	5.64e-12	Testicular germ cell tumor;
LUSC	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg01620082	chr3:125678407	NA	-0.75	-7.36	-0.37	1.43e-12	Depression;
LUSC	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg17757837	chr7:157058334	UBE3C	-0.82	-13.31	-0.59	1.01e-32	Body mass index;
LUSC	cis	rs9341808	0.718	rs10943699	chr6:80940541	G/A	cg08355045	chr6:80787529	NA	0.56	9.69	0.47	1e-19	Sitting height ratio;
LUSC	cis	rs9815354	0.812	rs17282671	chr3:41887455	T/C	cg03022575	chr3:42003672	ULK4	0.84	8.73	0.43	1.2e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs7577696	0.785	rs7592356	chr2:32370344	C/T	cg02381751	chr2:32503542	YIPF4	-0.44	-6.12	-0.32	2.59e-9	Inflammatory biomarkers;
LUSC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg04906043	chr13:21280425	IL17D	0.48	9.06	0.44	1.12e-17	Dental caries;
LUSC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg17420585	chr12:42539391	GXYLT1	-0.37	-7.38	-0.37	1.27e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg24562669	chr7:97807699	LMTK2	0.36	6.29	0.33	9.85e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg17507749	chr15:85114479	UBE2QP1	0.65	8.1	0.41	1.04e-14	Schizophrenia;
LUSC	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg04851639	chr8:1020857	NA	-0.39	-7.94	-0.4	3.19e-14	Schizophrenia;
LUSC	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg24558204	chr6:135376177	HBS1L	0.58	8.88	0.44	4.14e-17	Red blood cell count;
LUSC	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg01677386	chr11:118938358	VPS11	-0.48	-6.86	-0.35	3.37e-11	Coronary artery disease;
LUSC	cis	rs6693567	0.586	rs4970979	chr1:150483840	C/T	cg15654264	chr1:150340011	RPRD2	0.45	7.32	0.37	1.89e-12	Migraine;
LUSC	cis	rs4356932	0.967	rs28642977	chr4:76972731	C/T	cg00809888	chr4:76862425	NAAA	0.34	5.78	0.3	1.75e-8	Blood protein levels;
LUSC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg26380479	chr7:97908229	NA	0.26	5.94	0.31	7.33e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22496380	chr5:211416	CCDC127	-0.78	-9.4	-0.46	8.9e-19	Breast cancer;
LUSC	cis	rs7106204	0.620	rs12805125	chr11:24258967	A/T	ch.11.24196551F	chr11:24239977	NA	-0.72	-6.66	-0.34	1.14e-10	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs1950626	0.671	rs34675695	chr14:101447913	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.7	0.39	1.51e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs3733418	0.799	rs13110766	chr4:165956628	C/T	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.45	-5.91	-0.31	8.6e-9	Obesity-related traits;
LUSC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-8.07	-0.4	1.29e-14	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg06636001	chr8:8085503	FLJ10661	0.55	8.13	0.41	8.74e-15	Myopia (pathological);
LUSC	cis	rs6693567	0.507	rs9436120	chr1:150473084	T/C	cg15654264	chr1:150340011	RPRD2	0.45	7.21	0.37	3.83e-12	Migraine;
LUSC	cis	rs2625529	0.590	rs7183196	chr15:72544401	A/G	cg16672083	chr15:72433130	SENP8	-0.49	-7.59	-0.38	3.13e-13	Red blood cell count;
LUSC	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg22732515	chr19:44031385	ETHE1	0.64	10.42	0.5	3.27e-22	Fractional exhaled nitric oxide (childhood);
LUSC	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg17470723	chr8:74884337	TCEB1	0.52	8.06	0.4	1.33e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg03676636	chr4:99064102	C4orf37	0.36	7.89	0.4	4.25e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg23985595	chr17:80112537	CCDC57	0.31	5.84	0.3	1.23e-8	Life satisfaction;
LUSC	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.86	14.9	0.63	7.55e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LUSC	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-38.91	-0.91	3.99e-126	Myeloid white cell count;
LUSC	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg24631222	chr15:78858424	CHRNA5	-0.64	-8.55	-0.42	4.48e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.69	-10.57	-0.5	9.97e-23	Aortic root size;
LUSC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.32	-6.25	-0.32	1.27e-9	Total body bone mineral density;
LUSC	cis	rs1113500	0.933	rs10881497	chr1:108634515	A/G	cg11967332	chr1:108735228	SLC25A24	-0.42	-6.43	-0.33	4.34e-10	Growth-regulated protein alpha levels;
LUSC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-11.17	-0.52	8.01e-25	Mean corpuscular volume;
LUSC	cis	rs747782	0.639	rs61649224	chr11:48057640	G/A	cg20307385	chr11:47447363	PSMC3	-0.64	-5.83	-0.3	1.33e-8	Intraocular pressure;
LUSC	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.57	-8.55	-0.42	4.34e-16	Metabolite levels;
LUSC	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg27165867	chr14:105738592	BRF1	-0.53	-7.72	-0.39	1.36e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg24631222	chr15:78858424	CHRNA5	0.64	8.59	0.43	3.36e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg04369109	chr6:150039330	LATS1	-0.55	-8.09	-0.4	1.1e-14	Lung cancer;
LUSC	cis	rs8099014	0.861	rs4940705	chr18:56120155	G/A	cg12907477	chr18:56117327	MIR122	0.45	7.01	0.36	1.33e-11	Platelet count;
LUSC	cis	rs2734839	0.964	rs2234690	chr11:113291748	T/A	cg14159747	chr11:113255604	NA	0.23	5.78	0.3	1.69e-8	Information processing speed;
LUSC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.16	-0.32	2.09e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs9815354	1.000	rs9876960	chr3:41985812	C/T	cg03022575	chr3:42003672	ULK4	-0.51	-5.74	-0.3	2.11e-8	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03264133	chr6:25882463	NA	0.47	7.65	0.39	2.11e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs72781680	0.716	rs2712086	chr2:24004739	G/C	cg08917208	chr2:24149416	ATAD2B	0.6	6.91	0.35	2.44e-11	Lymphocyte counts;
LUSC	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.36	-5.81	-0.3	1.45e-8	Response to antipsychotic treatment;
LUSC	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg13607699	chr17:42295918	UBTF	-0.54	-8.47	-0.42	7.71e-16	Total body bone mineral density;
LUSC	cis	rs7119	0.717	rs12899390	chr15:77815238	A/C	cg27398640	chr15:77910606	LINGO1	-0.3	-6.49	-0.33	3.14e-10	Type 2 diabetes;
LUSC	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg05340658	chr4:99064831	C4orf37	0.58	8.82	0.43	6.37e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs710216	0.843	rs710214	chr1:43439282	C/T	cg22176566	chr1:43424700	SLC2A1	0.47	5.79	0.3	1.59e-8	Red cell distribution width;
LUSC	cis	rs4619890	0.528	rs62289359	chr4:7897168	C/T	cg24250820	chr4:7887609	AFAP1	0.36	6.13	0.32	2.44e-9	Glaucoma (primary open-angle);
LUSC	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg18681998	chr4:17616180	MED28	0.77	13.73	0.6	2.53e-34	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg14004847	chr7:1930337	MAD1L1	0.52	8.18	0.41	6.08e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs11166629	1.000	rs4909330	chr8:135644369	T/C	cg27224718	chr8:135614730	ZFAT	0.64	10.62	0.5	7.01e-23	Smoking quantity;
LUSC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg26338869	chr17:61819248	STRADA	0.42	6.18	0.32	1.88e-9	Prudent dietary pattern;
LUSC	cis	rs11690935	0.655	rs17614941	chr2:172541378	A/G	cg13550731	chr2:172543902	DYNC1I2	0.48	7.33	0.37	1.74e-12	Schizophrenia;
LUSC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.43	7.07	0.36	9.1e-12	Platelet count;
LUSC	cis	rs79247733	0.786	rs2286442	chr22:30772686	C/T	cg03868770	chr22:30783737	RNF215	-0.58	-6.9	-0.35	2.54e-11	Tonsillectomy;
LUSC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg14092988	chr3:52407081	DNAH1	0.31	5.94	0.31	7.06e-9	Bipolar disorder;
LUSC	cis	rs6693567	0.565	rs2264417	chr1:150368501	C/T	cg15654264	chr1:150340011	RPRD2	0.45	7.19	0.37	4.39e-12	Migraine;
LUSC	trans	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	12.45	0.56	1.72e-29	Eotaxin levels;
LUSC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	10.8	0.51	1.66e-23	Bone mineral density;
LUSC	cis	rs2692947	0.770	rs2315417	chr2:96500289	T/C	cg22654517	chr2:96458247	NA	0.39	7.7	0.39	1.52e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs11945232	1.000	rs11945232	chr4:88342369	A/G	cg23841344	chr4:88312519	HSD17B11	-0.66	-10.54	-0.5	1.27e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg13736514	chr6:26305472	NA	-0.49	-9.71	-0.47	8.44e-20	Educational attainment;
LUSC	cis	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg02508848	chr16:68573721	ZFP90	-0.43	-5.77	-0.3	1.84e-8	Ulcerative colitis;
LUSC	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg13042288	chr15:90349979	ANPEP	-0.49	-6.9	-0.35	2.7e-11	Uric acid levels;
LUSC	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-6.03	-0.31	4.43e-9	Eosinophil percentage of white cells;
LUSC	cis	rs1983891	1.000	rs4714485	chr6:41536587	T/G	cg15051332	chr6:41514432	FOXP4	0.39	5.69	0.3	2.84e-8	Prostate cancer;
LUSC	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg12365402	chr11:9010492	NRIP3	-0.49	-9.32	-0.45	1.63e-18	Hemoglobin concentration;
LUSC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg23788917	chr6:8435910	SLC35B3	0.49	7.28	0.37	2.36e-12	Motion sickness;
LUSC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.85	15.3	0.64	2.01e-40	Menarche (age at onset);
LUSC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.28	-5.81	-0.3	1.47e-8	Lung cancer;
LUSC	cis	rs151234	0.741	rs3194168	chr16:28603012	A/G	cg01378222	chr16:28622494	SULT1A1	-0.64	-8.55	-0.42	4.58e-16	Platelet distribution width;
LUSC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg06740227	chr12:86229804	RASSF9	0.45	7.19	0.37	4.37e-12	Major depressive disorder;
LUSC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg16647868	chr5:131706066	SLC22A5	-0.4	-6.04	-0.31	4.03e-9	Breast cancer;
LUSC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg16524733	chr11:117070046	TAGLN	0.42	7.31	0.37	2.02e-12	Blood protein levels;
LUSC	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg11062466	chr8:58055876	NA	0.61	7.52	0.38	5.24e-13	Developmental language disorder (linguistic errors);
LUSC	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg02574844	chr11:5959923	NA	-0.39	-5.98	-0.31	5.89e-9	DNA methylation (variation);
LUSC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08219700	chr8:58056026	NA	0.67	8.55	0.42	4.48e-16	Developmental language disorder (linguistic errors);
LUSC	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg25482853	chr8:67687455	SGK3	1.18	16.97	0.68	5.1e-47	Lung disease severity in cystic fibrosis;
LUSC	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.15	0.49	2.74e-21	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs3126085	0.935	rs12742573	chr1:152260103	A/C	cg26876637	chr1:152193138	HRNR	-0.44	-5.83	-0.3	1.3e-8	Atopic dermatitis;
LUSC	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-10.88	-0.51	8.68e-24	Body mass index (adult);
LUSC	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.52	8.56	0.42	4.14e-16	Immature fraction of reticulocytes;
LUSC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07677032	chr17:61819896	STRADA	0.52	8.7	0.43	1.53e-16	Prudent dietary pattern;
LUSC	cis	rs12618769	0.597	rs3729568	chr2:99100196	T/G	cg10123293	chr2:99228465	UNC50	0.43	6.97	0.36	1.73e-11	Bipolar disorder;
LUSC	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.31	21.86	0.77	2.15e-66	Type 1 diabetes nephropathy;
LUSC	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg01620082	chr3:125678407	NA	-0.85	-7.63	-0.39	2.53e-13	Depression;
LUSC	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg20573242	chr4:122745356	CCNA2	-0.46	-6.85	-0.35	3.61e-11	Type 2 diabetes;
LUSC	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg21361702	chr7:150065534	REPIN1	0.46	6.69	0.34	9.53e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-1.02	-24.68	-0.8	2.72e-77	Urate levels in lean individuals;
LUSC	trans	rs2262909	0.893	rs4244912	chr19:22203237	T/A	cg05197062	chr11:11642011	GALNTL4	-0.51	-7.08	-0.36	8.34e-12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-0.84	-14.65	-0.63	7.06e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg23840854	chr1:161414152	NA	-0.92	-11.12	-0.52	1.22e-24	Rheumatoid arthritis;
LUSC	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg16386425	chr10:429943	DIP2C	0.37	5.75	0.3	2.06e-8	Psychosis in Alzheimer's disease;
LUSC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg14004847	chr7:1930337	MAD1L1	-0.51	-7.79	-0.39	8.73e-14	Bipolar disorder and schizophrenia;
LUSC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-0.79	-9.93	-0.48	1.55e-20	Developmental language disorder (linguistic errors);
LUSC	cis	rs16976116	0.851	rs28393427	chr15:55490981	A/G	cg11288833	chr15:55489084	RSL24D1	0.5	5.98	0.31	5.65e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg26043149	chr18:55253948	FECH	-0.45	-6.97	-0.36	1.7e-11	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg00495681	chr13:53174319	NA	-0.51	-7.92	-0.4	3.59e-14	Lewy body disease;
LUSC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.57	8.78	0.43	8.67e-17	Menopause (age at onset);
LUSC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18876405	chr7:65276391	NA	-0.54	-8.47	-0.42	7.77e-16	Aortic root size;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01191584	chr2:27594002	SNX17;EIF2B4	0.44	6.31	0.33	8.62e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg24130564	chr14:104152367	KLC1	-0.7	-11.11	-0.52	1.29e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs7091068	0.566	rs1326220	chr10:95486155	G/A	cg20715218	chr10:95462985	C10orf4	0.67	7.26	0.37	2.66e-12	Urinary tract infection frequency;
LUSC	cis	rs71335811	1	rs71335811	chr19:49130070	TC/T	cg06530960	chr19:49140787	SEC1;DBP	-0.57	-7.85	-0.39	5.7e-14	Myeloid white cell count;
LUSC	cis	rs9928842	0.941	rs8057145	chr16:75256251	A/G	cg09066997	chr16:75300724	BCAR1	0.51	6.33	0.33	7.71e-10	Alcoholic chronic pancreatitis;
LUSC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.89	18.15	0.7	1.07e-51	Intelligence (multi-trait analysis);
LUSC	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-8.17	-0.41	6.35e-15	Morning vs. evening chronotype;
LUSC	cis	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg07460842	chr6:66804631	NA	0.88	8.93	0.44	2.87e-17	Exhaled nitric oxide output;
LUSC	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg21970626	chr13:21893289	NA	-0.52	-9.55	-0.46	2.91e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LUSC	cis	rs7113850	0.541	rs76671714	chr11:24231278	C/G	ch.11.24196551F	chr11:24239977	NA	1.01	9.09	0.45	8.71e-18	Bone fracture in osteoporosis;
LUSC	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg05985134	chr18:33552581	C18orf21	0.52	7.09	0.36	8.03e-12	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs227833	0.826	rs227854	chr6:44701035	C/T	cg20913747	chr6:44695427	NA	-0.37	-5.65	-0.3	3.44e-8	Monobrow;
LUSC	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg00677455	chr12:58241039	CTDSP2	0.73	11.38	0.53	1.43e-25	Intelligence (multi-trait analysis);
LUSC	trans	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg11244813	chr1:145039882	PDE4DIP	0.36	5.96	0.31	6.51e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg24375607	chr4:120327624	NA	0.76	12.21	0.56	1.33e-28	Corneal astigmatism;
LUSC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.59	9.61	0.47	1.82e-19	Aortic root size;
LUSC	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg22532475	chr10:104410764	TRIM8	-0.25	-6.0	-0.31	5.11e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg04056025	chr13:45694609	GTF2F2	0.78	6.21	0.32	1.62e-9	Cognitive performance;
LUSC	trans	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	8.94	0.44	2.64e-17	Mean corpuscular volume;
LUSC	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-11.67	-0.54	1.26e-26	Coffee consumption (cups per day);
LUSC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.7	-12.17	-0.55	1.85e-28	Dental caries;
LUSC	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	14.61	0.62	1.05e-37	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg13902645	chr11:5959945	NA	-0.58	-8.23	-0.41	4.32e-15	DNA methylation (variation);
LUSC	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg05110241	chr16:68378359	PRMT7	-0.83	-8.92	-0.44	3.09e-17	Schizophrenia;
LUSC	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg09307838	chr4:120376055	NA	-0.62	-9.26	-0.45	2.57e-18	Corneal astigmatism;
LUSC	trans	rs1973993	0.689	rs17375929	chr1:96962246	A/T	cg10631902	chr5:14652156	NA	-0.41	-6.03	-0.31	4.46e-9	Weight;
LUSC	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg09835421	chr16:68378352	PRMT7	-0.55	-6.16	-0.32	2.09e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg06636001	chr8:8085503	FLJ10661	0.6	9.19	0.45	4.37e-18	Mood instability;
LUSC	cis	rs3087591	0.639	rs2342052	chr17:29721011	T/C	cg24425628	chr17:29625626	OMG;NF1	0.49	7.49	0.38	6.29e-13	Hip circumference;
LUSC	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.66	-11.76	-0.54	6.01e-27	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg00509249	chr6:109615579	CCDC162	-0.34	-6.12	-0.32	2.66e-9	Reticulocyte fraction of red cells;
LUSC	cis	rs2692947	0.655	rs60090597	chr2:96406266	G/A	cg23100626	chr2:96804247	ASTL	0.29	6.92	0.35	2.33e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg06784218	chr1:46089804	CCDC17	0.53	11.14	0.52	1.05e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs3847687	1.000	rs78233646	chr12:131520170	G/T	cg13586425	chr12:131519906	GPR133	-0.27	-6.32	-0.33	8.31e-10	Longevity;
LUSC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg06238570	chr21:40685208	BRWD1	-0.58	-9.27	-0.45	2.36e-18	Menarche (age at onset);
LUSC	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15369054	chr17:80825471	TBCD	0.68	10.73	0.51	2.72e-23	Breast cancer;
LUSC	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg03732007	chr1:2071316	PRKCZ	0.49	7.79	0.39	8.55e-14	Height;
LUSC	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg03676636	chr4:99064102	C4orf37	-0.28	-5.82	-0.3	1.37e-8	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.41	-0.42	1.21e-15	Lymphocyte counts;
LUSC	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg21573476	chr21:45109991	RRP1B	-0.4	-6.36	-0.33	6.52e-10	Mean corpuscular volume;
LUSC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg14343924	chr8:8086146	FLJ10661	-0.42	-5.91	-0.31	8.23e-9	Mood instability;
LUSC	cis	rs3820928	0.839	rs12470666	chr2:227876525	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.51	-0.38	5.59e-13	Pulmonary function;
LUSC	cis	rs1957429	0.522	rs76721513	chr14:65403891	C/G	cg23373153	chr14:65346875	NA	-0.98	-7.73	-0.39	1.3e-13	Pediatric areal bone mineral density (radius);
LUSC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg12463550	chr7:65579703	CRCP	0.62	5.69	0.3	2.77e-8	Diabetic kidney disease;
LUSC	cis	rs11608355	0.545	rs11613023	chr12:109898047	T/C	cg05360138	chr12:110035743	NA	0.9	11.49	0.53	5.61e-26	Neuroticism;
LUSC	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg00982548	chr2:198649783	BOLL	-0.57	-7.34	-0.37	1.65e-12	Ulcerative colitis;
LUSC	cis	rs7605827	0.930	rs2111448	chr2:15599073	T/G	cg19274914	chr2:15703543	NA	0.47	9.08	0.45	9.55e-18	Educational attainment (years of education);
LUSC	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg13393036	chr8:95962371	TP53INP1	-0.35	-6.76	-0.35	6.01e-11	Type 2 diabetes;
LUSC	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg13010344	chr12:123464640	ARL6IP4	-0.47	-5.92	-0.31	8.19e-9	Neutrophil percentage of white cells;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg09683566	chr17:21002807	NA	-0.4	-5.95	-0.31	6.72e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg24006582	chr15:45444508	DUOX1	-0.6	-8.93	-0.44	2.94e-17	Uric acid levels;
LUSC	cis	rs4954585	0.659	rs4072435	chr2:137013901	C/T	cg05194412	chr2:137003533	NA	0.41	7.57	0.38	3.79e-13	Colorectal cancer;
LUSC	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg17764715	chr19:33622953	WDR88	0.58	7.88	0.4	4.62e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg18105134	chr13:113819100	PROZ	-0.68	-9.6	-0.47	1.9e-19	Platelet distribution width;
LUSC	cis	rs1185460	0.967	rs2509121	chr11:118928253	C/T	cg01677386	chr11:118938358	VPS11	-0.5	-7.0	-0.36	1.4e-11	Coronary artery disease;
LUSC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg06637938	chr14:75390232	RPS6KL1	0.55	8.62	0.43	2.67e-16	Height;
LUSC	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg07870213	chr5:140052090	DND1	-0.74	-10.99	-0.52	3.51e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg24634471	chr8:143751801	JRK	-0.59	-8.91	-0.44	3.48e-17	Schizophrenia;
LUSC	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.9	15.55	0.65	2.12e-41	Bladder cancer;
LUSC	cis	rs9807989	0.839	rs1420099	chr2:102980543	C/G	cg09003973	chr2:102972529	NA	0.44	6.02	0.31	4.5e-9	Asthma;
LUSC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg04025307	chr7:1156635	C7orf50	0.42	5.88	0.31	9.84e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-9.13	-0.45	6.87e-18	Gut microbiome composition (summer);
LUSC	cis	rs7597155	1.000	rs6727897	chr2:69987384	A/G	cg02498382	chr2:70120550	SNRNP27	-0.24	-5.83	-0.3	1.34e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	0.67	6.73	0.35	7.37e-11	Prostate cancer;
LUSC	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg00852783	chr1:26633632	UBXN11	0.6	9.63	0.47	1.59e-19	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18099408	chr3:52552593	STAB1	-0.41	-6.96	-0.36	1.84e-11	Bipolar disorder;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg18831827	chr4:95373876	PDLIM5	-0.41	-5.97	-0.31	6.21e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-6.25	-0.32	1.27e-9	Triglycerides;
LUSC	cis	rs9311676	0.632	rs7643057	chr3:58374015	C/T	cg26110898	chr3:58419937	PDHB	0.42	6.75	0.35	6.62e-11	Systemic lupus erythematosus;
LUSC	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg22153463	chr1:85462885	MCOLN2	-0.68	-8.21	-0.41	4.76e-15	Serum sulfate level;
LUSC	cis	rs12791968	0.527	rs4755300	chr11:45013421	C/T	cg11846598	chr11:44996168	LOC221122	0.58	7.13	0.36	6.33e-12	Inhibitory control;
LUSC	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg04492858	chr10:133558786	NA	0.43	7.19	0.37	4.2e-12	Survival in rectal cancer;
LUSC	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg22906224	chr7:99728672	NA	-0.5	-6.99	-0.36	1.49e-11	Coronary artery disease;
LUSC	cis	rs4409675	0.576	rs2474470	chr1:28234999	C/T	cg23691781	chr1:28212827	C1orf38	0.33	7.96	0.4	2.68e-14	Corneal astigmatism;
LUSC	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	0.79	11.12	0.52	1.2e-24	Blood protein levels;
LUSC	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg04455712	chr21:45112962	RRP1B	0.45	8.49	0.42	6.82e-16	Mean corpuscular volume;
LUSC	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg17644776	chr2:200775616	C2orf69	0.37	5.78	0.3	1.75e-8	Osteoporosis;
LUSC	cis	rs13006833	0.739	rs12693568	chr2:191202637	A/G	cg21644426	chr2:191273491	MFSD6	0.45	6.3	0.33	9.61e-10	Urinary metabolites;
LUSC	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06028605	chr16:24865363	SLC5A11	0.68	10.29	0.49	9.04e-22	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.7	-10.79	-0.51	1.7e-23	Aortic root size;
LUSC	cis	rs16949788	1.000	rs80298548	chr15:66690448	A/G	cg08120210	chr15:66682733	MAP2K1	-0.6	-5.96	-0.31	6.36e-9	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg12863693	chr15:85201151	NMB	0.36	7.35	0.37	1.56e-12	Schizophrenia;
LUSC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17410650	chr12:54324560	NA	-0.6	-11.03	-0.52	2.55e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LUSC	cis	rs858239	0.600	rs7776644	chr7:23119307	C/T	cg23682824	chr7:23144976	KLHL7	0.4	5.86	0.31	1.13e-8	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.43	-7.9	-0.4	4.03e-14	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg19812747	chr11:111475976	SIK2	-0.51	-7.24	-0.37	3.02e-12	Primary sclerosing cholangitis;
LUSC	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg02574844	chr11:5959923	NA	-0.45	-6.32	-0.33	8.49e-10	DNA methylation (variation);
LUSC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg03060546	chr3:49711283	APEH	0.71	11.95	0.55	1.23e-27	Resting heart rate;
LUSC	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg09044154	chr16:88155775	NA	-0.55	-7.27	-0.37	2.52e-12	Menopause (age at onset);
LUSC	cis	rs977987	0.741	rs10514393	chr16:75344476	C/T	cg04384234	chr16:75411784	CFDP1	-0.42	-6.79	-0.35	5.19e-11	Dupuytren's disease;
LUSC	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg23093090	chr10:104574429	C10orf26	-0.37	-6.84	-0.35	3.81e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg14458575	chr2:238380390	NA	0.58	6.82	0.35	4.36e-11	Prostate cancer;
LUSC	cis	rs7923609	0.967	rs10740134	chr10:65315433	T/C	cg01631684	chr10:65280961	REEP3	-0.43	-6.71	-0.34	8.47e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06376129	chr1:205180539	DSTYK	-0.42	-6.29	-0.33	1.01e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs10207060	0.500	rs6731870	chr2:240708096	C/A	cg07506560	chr2:240697449	NA	0.44	6.86	0.35	3.26e-11	Obesity-related traits;
LUSC	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg23625390	chr15:77176239	SCAPER	-0.65	-9.97	-0.48	1.18e-20	Blood metabolite levels;
LUSC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00166722	chr3:10149974	C3orf24	0.55	7.51	0.38	5.38e-13	Alzheimer's disease;
LUSC	trans	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg10756647	chr7:56101905	PSPH	0.87	8.46	0.42	8.32e-16	Diabetic kidney disease;
LUSC	cis	rs2354432	0.607	rs2353999	chr1:146830686	T/C	cg25205988	chr1:146714368	CHD1L	-0.95	-8.76	-0.43	9.97e-17	Mitochondrial DNA levels;
LUSC	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg10356904	chr22:49881777	NA	-0.29	-5.78	-0.3	1.75e-8	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs1775715	0.737	rs2778661	chr10:32159191	C/T	cg18675610	chr10:32216311	ARHGAP12	0.3	6.61	0.34	1.51e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.43	8.33	0.41	2.19e-15	Monocyte percentage of white cells;
LUSC	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg21211680	chr2:198530	NA	0.66	7.8	0.39	8e-14	Blood protein levels;
LUSC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.65	11.03	0.52	2.39e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1832871	0.965	rs2105333	chr6:158755437	T/G	cg07165851	chr6:158734300	TULP4	-0.35	-5.92	-0.31	8.13e-9	Height;
LUSC	trans	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg24644049	chr4:85504048	CDS1	0.69	7.03	0.36	1.15e-11	Skin colour saturation;
LUSC	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg06484146	chr7:12443880	VWDE	-0.74	-7.41	-0.38	1.02e-12	Coronary artery disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg00699235	chr12:49962218	MCRS1	0.41	6.17	0.32	1.96e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg02034447	chr16:89574710	SPG7	0.44	6.53	0.34	2.4e-10	Multiple myeloma (IgH translocation);
LUSC	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg20283391	chr11:68216788	NA	-0.5	-7.04	-0.36	1.09e-11	Bone mineral density;
LUSC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg16928487	chr17:17741425	SREBF1	-0.45	-8.72	-0.43	1.34e-16	Total body bone mineral density;
LUSC	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg15485101	chr11:133734466	NA	0.39	7.02	0.36	1.27e-11	Childhood ear infection;
LUSC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg24829409	chr8:58192753	C8orf71	-0.52	-6.15	-0.32	2.21e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs4631830	0.863	rs3123078	chr10:51524971	A/G	cg20129853	chr10:51489980	NA	0.33	6.75	0.35	6.65e-11	Prostate-specific antigen levels;
LUSC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18099408	chr3:52552593	STAB1	-0.4	-6.96	-0.36	1.81e-11	Bipolar disorder;
LUSC	cis	rs460214	0.576	rs2836604	chr21:40041295	A/C	cg21578987	chr21:40029669	ERG	0.42	6.51	0.34	2.74e-10	Response to cognitive-behavioural therapy in anxiety disorder;
LUSC	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg07741184	chr6:167504864	NA	0.4	7.08	0.36	8.76e-12	Primary biliary cholangitis;
LUSC	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.74	-14.38	-0.62	8.22e-37	Ulcerative colitis;
LUSC	cis	rs3007168	0.794	rs10138053	chr14:51615152	T/C	cg23942311	chr14:51606299	NA	-0.35	-6.61	-0.34	1.49e-10	Cancer;
LUSC	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg08179530	chr6:36648295	CDKN1A	-0.7	-10.66	-0.5	4.81e-23	QRS duration;
LUSC	trans	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg05059571	chr16:84539110	KIAA1609	-0.47	-8.95	-0.44	2.49e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg11812906	chr14:75593930	NEK9	0.54	8.22	0.41	4.57e-15	Height;
LUSC	cis	rs10761482	0.906	rs7911934	chr10:62092090	A/G	cg18175470	chr10:62150864	ANK3	-0.47	-6.74	-0.35	6.97e-11	Schizophrenia;
LUSC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg20406979	chr6:167373233	NA	0.25	5.75	0.3	2.01e-8	Crohn's disease;
LUSC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg22903471	chr2:27725779	GCKR	-0.4	-6.82	-0.35	4.31e-11	Total body bone mineral density;
LUSC	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg17507749	chr15:85114479	UBE2QP1	0.57	7.32	0.37	1.88e-12	Schizophrenia;
LUSC	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg04117972	chr1:227635322	NA	0.57	6.58	0.34	1.78e-10	Major depressive disorder;
LUSC	trans	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg13010199	chr12:38710504	ALG10B	0.52	7.91	0.4	3.72e-14	Morning vs. evening chronotype;
LUSC	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg25643088	chr3:52874325	TMEM110	0.4	6.24	0.32	1.32e-9	Schizophrenia;
LUSC	cis	rs12681287	0.547	rs4961197	chr8:87512436	T/C	cg27223183	chr8:87520930	FAM82B	-0.55	-7.34	-0.37	1.65e-12	Caudate activity during reward;
LUSC	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg12311346	chr5:56204834	C5orf35	-0.57	-8.85	-0.44	5.02e-17	Coronary artery disease;
LUSC	cis	rs870825	0.616	rs10013562	chr4:185610486	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	13.34	0.59	7.69e-33	Blood protein levels;
LUSC	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02463440	chr8:22132932	PIWIL2	0.44	7.96	0.4	2.65e-14	Hypertriglyceridemia;
LUSC	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-7.0	-0.36	1.41e-11	Alzheimer's disease (late onset);
LUSC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg06640241	chr16:89574553	SPG7	0.85	15.13	0.64	9.2e-40	Multiple myeloma (IgH translocation);
LUSC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.85	15.85	0.66	1.39e-42	Mean platelet volume;
LUSC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-13.29	-0.59	1.26e-32	Alzheimer's disease;
LUSC	cis	rs9311676	0.656	rs62258120	chr3:58391128	G/A	cg13750441	chr3:58318267	PXK	0.35	6.84	0.35	3.85e-11	Systemic lupus erythematosus;
LUSC	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg25072359	chr17:41440525	NA	0.62	8.91	0.44	3.42e-17	Menopause (age at onset);
LUSC	cis	rs3847687	0.869	rs11061300	chr12:131523261	G/A	cg25772418	chr12:131519998	GPR133	-0.27	-5.69	-0.3	2.82e-8	Longevity;
LUSC	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.67	-8.67	-0.43	1.96e-16	Schizophrenia;
LUSC	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg13798780	chr7:105162888	PUS7	0.55	5.95	0.31	6.83e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.69	-9.16	-0.45	5.21e-18	Schizophrenia;
LUSC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg04553112	chr3:125709451	NA	-0.5	-5.7	-0.3	2.7e-8	Blood pressure (smoking interaction);
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg02405530	chr4:926135	TMEM175;GAK	-0.48	-6.21	-0.32	1.57e-9	Cognitive function;Information processing speed;
LUSC	cis	rs4380275	1.000	rs4380275	chr2:773278	C/T	cg21665850	chr2:731073	NA	0.42	6.75	0.35	6.49e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LUSC	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg10356904	chr22:49881777	NA	-0.32	-7.08	-0.36	8.77e-12	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg18306943	chr3:40428807	ENTPD3	0.39	5.99	0.31	5.41e-9	Renal cell carcinoma;
LUSC	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg03676636	chr4:99064102	C4orf37	0.33	7.19	0.37	4.22e-12	Colonoscopy-negative controls vs population controls;
LUSC	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg11887960	chr12:57824829	NA	0.55	6.69	0.34	9.64e-11	Lung disease severity in cystic fibrosis;
LUSC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg20887711	chr4:1340912	KIAA1530	0.51	7.86	0.4	5.26e-14	Obesity-related traits;
LUSC	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg11102782	chr19:18549136	ISYNA1	0.32	6.2	0.32	1.67e-9	Breast cancer;
LUSC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg11752832	chr7:134001865	SLC35B4	0.56	8.78	0.43	8.5e-17	Mean platelet volume;
LUSC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg07636037	chr3:49044803	WDR6	0.44	6.28	0.32	1.07e-9	Resting heart rate;
LUSC	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg04998671	chr14:104000505	TRMT61A	-0.39	-5.83	-0.3	1.28e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	trans	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg01620082	chr3:125678407	NA	-0.6	-6.09	-0.32	3.15e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	6.83	0.35	3.91e-11	Neuroticism;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg25091458	chr3:190232250	IL1RAP	0.46	6.55	0.34	2.17e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg12454169	chr2:30669597	LCLAT1	0.6	8.0	0.4	2.12e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LUSC	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg06462663	chr19:18546047	ISYNA1	0.42	6.97	0.36	1.65e-11	Breast cancer;
LUSC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg14552801	chr7:65878734	NA	-0.38	-5.9	-0.31	9.08e-9	Aortic root size;
LUSC	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg19784903	chr17:45786737	TBKBP1	-0.42	-6.04	-0.31	4.11e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs73416724	0.841	rs78415183	chr6:43394041	T/G	cg26312998	chr6:43337775	ZNF318	0.55	6.39	0.33	5.45e-10	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs10761482	0.861	rs4948410	chr10:62116047	G/A	cg18175470	chr10:62150864	ANK3	-0.51	-7.25	-0.37	2.99e-12	Schizophrenia;
LUSC	cis	rs7818345	0.967	rs11204040	chr8:19288525	T/A	cg11303988	chr8:19266685	CSGALNACT1	0.36	6.96	0.36	1.8e-11	Language performance in older adults (adjusted for episodic memory);
LUSC	trans	rs7572263	0.528	rs13025862	chr2:209072106	C/T	cg15570148	chr3:61235985	FHIT	0.49	6.11	0.32	2.85e-9	Glioma;Non-glioblastoma glioma;
LUSC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	13.0	0.58	1.55e-31	Chronic sinus infection;
LUSC	cis	rs977987	0.806	rs4993969	chr16:75411521	A/T	cg04384234	chr16:75411784	CFDP1	-0.42	-7.23	-0.37	3.31e-12	Dupuytren's disease;
LUSC	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.51	-7.81	-0.39	7.37e-14	Lymphocyte counts;
LUSC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg17376030	chr22:41985996	PMM1	0.48	5.93	0.31	7.5e-9	Vitiligo;
LUSC	cis	rs12541635	0.677	rs1817939	chr8:107029820	A/G	cg10147462	chr8:107024639	NA	0.67	14.15	0.61	6.05e-36	Age of smoking initiation;
LUSC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg27165867	chr14:105738592	BRF1	-0.51	-7.25	-0.37	2.86e-12	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg17279839	chr7:150038598	RARRES2	0.49	7.44	0.38	8.59e-13	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-9.26	-0.45	2.58e-18	Gut microbiome composition (summer);
LUSC	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg23950597	chr19:37808831	NA	-0.64	-7.6	-0.38	3.03e-13	Coronary artery calcification;
LUSC	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06636551	chr8:101224915	SPAG1	-0.44	-8.03	-0.4	1.63e-14	Atrioventricular conduction;
LUSC	cis	rs524023	0.957	rs552307	chr11:64357539	G/A	cg19131476	chr11:64387923	NRXN2	0.37	9.88	0.48	2.27e-20	Urate levels in obese individuals;
LUSC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg07741184	chr6:167504864	NA	0.36	6.59	0.34	1.73e-10	Crohn's disease;
LUSC	cis	rs2296342	0.652	rs2296338	chr6:33630816	G/A	cg14003231	chr6:33640908	ITPR3	0.36	7.01	0.36	1.35e-11	Schizophrenia;
LUSC	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg24642439	chr20:33292090	TP53INP2	0.5	7.57	0.38	3.67e-13	Height;
LUSC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg07507251	chr3:52567010	NT5DC2	0.33	6.42	0.33	4.6e-10	Bipolar disorder;
LUSC	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	6.95	0.36	1.9e-11	Tonsillectomy;
LUSC	cis	rs4654899	0.802	rs4654724	chr1:21177210	C/T	cg01072550	chr1:21505969	NA	-0.52	-7.65	-0.39	2.22e-13	Superior frontal gyrus grey matter volume;
LUSC	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg04998671	chr14:104000505	TRMT61A	-0.45	-7.15	-0.36	5.46e-12	Coronary artery disease;
LUSC	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.86	13.69	0.6	3.62e-34	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06481639	chr22:41940642	POLR3H	-0.51	-5.91	-0.31	8.64e-9	Vitiligo;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00682015	chr13:76111918	COMMD6	-0.35	-6.02	-0.31	4.6e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs2274273	0.686	rs17253695	chr14:55574610	A/T	cg04306507	chr14:55594613	LGALS3	-0.46	-9.14	-0.45	6.05e-18	Protein biomarker;
LUSC	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg11693508	chr17:37793320	STARD3	0.66	8.2	0.41	5.26e-15	Bipolar disorder;
LUSC	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	7.99	0.4	2.17e-14	Iron status biomarkers;
LUSC	cis	rs9399401	0.667	rs11155242	chr6:142691549	A/C	cg04461802	chr6:142623433	GPR126	0.48	5.96	0.31	6.25e-9	Chronic obstructive pulmonary disease;
LUSC	cis	rs75920871	0.528	rs7941428	chr11:116903384	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-6.42	-0.33	4.68e-10	Subjective well-being;
LUSC	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.55	11.25	0.52	4.09e-25	Coronary artery disease;
LUSC	cis	rs16917546	1.000	rs10995250	chr10:64396921	G/A	cg03961010	chr10:64397487	ZNF365	-0.41	-6.53	-0.34	2.45e-10	Basal cell carcinoma;
LUSC	cis	rs6500395	1.000	rs6500397	chr16:48642235	T/C	cg04672837	chr16:48644449	N4BP1	0.46	6.7	0.34	8.81e-11	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg14343924	chr8:8086146	FLJ10661	0.39	5.7	0.3	2.68e-8	Mood instability;
LUSC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05025164	chr4:1340916	KIAA1530	-0.43	-6.82	-0.35	4.18e-11	Obesity-related traits;
LUSC	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg06207120	chr15:45996521	NA	0.4	6.07	0.32	3.54e-9	Waist circumference;Weight;
LUSC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18758796	chr5:131593413	PDLIM4	-0.53	-9.19	-0.45	4.18e-18	Acylcarnitine levels;
LUSC	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg13798780	chr7:105162888	PUS7	0.56	6.04	0.31	4.04e-9	Bipolar disorder (body mass index interaction);
LUSC	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg09197432	chr4:183729176	NA	0.69	9.18	0.45	4.55e-18	Pediatric autoimmune diseases;
LUSC	cis	rs1322512	0.713	rs1744385	chr6:152940466	A/G	cg27316956	chr6:152958899	SYNE1	-0.34	-5.71	-0.3	2.51e-8	Tonometry;
LUSC	cis	rs11608355	0.846	rs4766472	chr12:109853602	C/G	cg05360138	chr12:110035743	NA	0.61	8.19	0.41	5.79e-15	Neuroticism;
LUSC	trans	rs11700980	0.551	rs2832041	chr21:30116018	C/A	cg14791747	chr16:20752902	THUMPD1	0.55	6.01	0.31	4.94e-9	QRS complex (12-leadsum);
LUSC	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg21211680	chr2:198530	NA	0.73	7.58	0.38	3.37e-13	Blood protein levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20065718	chr12:133430224	CHFR	0.48	6.59	0.34	1.75e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1190552	0.846	rs3783382	chr14:102965437	A/T	cg18135206	chr14:102964638	TECPR2	0.48	5.89	0.31	9.54e-9	Blood protein levels;
LUSC	cis	rs909002	0.849	rs10798881	chr1:32101775	G/C	cg01639898	chr1:32083012	HCRTR1	0.26	6.02	0.31	4.59e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg14458575	chr2:238380390	NA	0.55	6.43	0.33	4.33e-10	Prostate cancer;
LUSC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg07169764	chr2:136633963	MCM6	-0.58	-7.55	-0.38	4.27e-13	Mosquito bite size;
LUSC	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg25456477	chr12:86230367	RASSF9	0.44	7.86	0.4	5.41e-14	Major depressive disorder;
LUSC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg22166914	chr1:53195759	ZYG11B	-0.49	-7.65	-0.39	2.23e-13	Monocyte count;
LUSC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg27572855	chr1:25598939	RHD	0.46	8.38	0.42	1.52e-15	Erythrocyte sedimentation rate;
LUSC	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg23649088	chr2:200775458	C2orf69	-0.54	-6.53	-0.34	2.39e-10	Schizophrenia;
LUSC	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg16228356	chr17:43848958	NA	0.26	5.89	0.31	9.38e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.39	0.46	9.85e-19	Prudent dietary pattern;
LUSC	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg13263323	chr15:86062960	AKAP13	-0.35	-5.66	-0.3	3.34e-8	Coronary artery disease;
LUSC	trans	rs28647808	0.786	rs28649804	chr9:136257709	C/T	cg12569217	chr2:109379859	RANBP2	0.61	6.01	0.31	4.92e-9	Blood protein levels;
LUSC	trans	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg20935933	chr6:143382018	AIG1	0.51	7.34	0.37	1.65e-12	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg14458575	chr2:238380390	NA	0.76	8.83	0.44	5.94e-17	Prostate cancer;
LUSC	cis	rs911119	0.837	rs2208289	chr20:23579526	A/G	cg16589663	chr20:23618590	CST3	-0.58	-7.23	-0.37	3.22e-12	Chronic kidney disease;
LUSC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	1.06	20.07	0.74	2.54e-59	Menopause (age at onset);
LUSC	cis	rs3820928	0.874	rs1949807	chr2:227891861	A/G	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.62	-0.38	2.63e-13	Pulmonary function;
LUSC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.47	0.46	5.29e-19	Prudent dietary pattern;
LUSC	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	18.97	0.72	5.86e-55	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	11.21	0.52	5.47e-25	Prudent dietary pattern;
LUSC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg00814883	chr7:100076585	TSC22D4	-0.66	-8.42	-0.42	1.16e-15	Platelet count;
LUSC	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08645402	chr16:4508243	NA	-0.52	-8.77	-0.43	9.02e-17	Schizophrenia;
LUSC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg12310025	chr6:25882481	NA	-0.5	-9.07	-0.44	1.03e-17	Blood metabolite levels;
LUSC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.64	10.59	0.5	8.35e-23	Lymphocyte counts;
LUSC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg17366294	chr4:99064904	C4orf37	0.58	10.27	0.49	1.12e-21	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7119	0.651	rs12904200	chr15:77845902	C/G	cg27398640	chr15:77910606	LINGO1	-0.32	-6.92	-0.35	2.32e-11	Type 2 diabetes;
LUSC	trans	rs2587949	0.615	rs2120512	chr3:4211943	T/G	cg15139668	chr4:4577005	NA	-0.41	-6.03	-0.31	4.44e-9	Periodontitis (DPAL);
LUSC	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.13	-0.32	2.47e-9	Neutrophil percentage of white cells;
LUSC	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg11502198	chr6:26597334	ABT1	0.71	11.81	0.54	3.94e-27	Intelligence (multi-trait analysis);
LUSC	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.5	6.28	0.32	1.05e-9	Renal function-related traits (BUN);
LUSC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.58	9.01	0.44	1.62e-17	Longevity;
LUSC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg22903657	chr4:1355424	KIAA1530	-0.35	-5.78	-0.3	1.73e-8	Longevity;
LUSC	cis	rs12891047	0.865	rs8011120	chr14:68258238	A/G	cg20999565	chr14:68265668	ZFYVE26	-0.39	-6.01	-0.31	4.78e-9	Amyotrophic lateral sclerosis (sporadic);
LUSC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18932078	chr1:2524107	MMEL1	-0.33	-7.21	-0.37	3.77e-12	Ulcerative colitis;
LUSC	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-6.19	-0.32	1.78e-9	Self-reported allergy;
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg27340350	chr19:49559583	CGB7	0.38	6.12	0.32	2.65e-9	Risky sexual behaviors in alcohol dependence;
LUSC	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.48	0.33	3.38e-10	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg21016266	chr12:122356598	WDR66	0.59	8.88	0.44	4.28e-17	Mean corpuscular volume;
LUSC	cis	rs4654899	0.802	rs12127519	chr1:21247365	C/T	cg01072550	chr1:21505969	NA	-0.48	-6.91	-0.35	2.4e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.85	11.1	0.52	1.38e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs1595825	0.838	rs73058878	chr2:198895078	T/G	cg10547527	chr2:198650123	BOLL	-0.52	-6.25	-0.32	1.23e-9	Ulcerative colitis;
LUSC	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg07952391	chr2:88470173	THNSL2	-0.4	-5.7	-0.3	2.68e-8	Response to metformin (IC50);
LUSC	cis	rs61897795	0.657	rs174590	chr11:61616977	G/C	cg21709803	chr11:61594965	FADS2	-0.37	-5.65	-0.3	3.52e-8	Neutrophil count;Sum basophil neutrophil counts;
LUSC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-0.92	-13.6	-0.6	7.64e-34	Initial pursuit acceleration;
LUSC	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg00745463	chr17:30367425	LRRC37B	-0.68	-7.84	-0.39	6.14e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs597583	0.806	rs12224853	chr11:117394822	A/G	cg27161313	chr11:117392002	DSCAML1	0.4	6.77	0.35	5.93e-11	Putamen volume;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11698548	chr7:43769233	C7orf44	-0.4	-5.96	-0.31	6.3e-9	Hepatitis;
LUSC	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.17	0.55	1.95e-28	Colorectal cancer;
LUSC	cis	rs7590368	0.715	rs56025654	chr2:10960952	G/A	cg15705551	chr2:10952987	PDIA6	0.57	6.2	0.32	1.62e-9	Educational attainment (years of education);
LUSC	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg18904891	chr8:8559673	CLDN23	-0.51	-6.63	-0.34	1.34e-10	Obesity-related traits;
LUSC	cis	rs4700695	0.668	rs166180	chr5:65499225	C/T	cg21114390	chr5:65439923	SFRS12	-0.5	-6.96	-0.36	1.81e-11	Facial morphology (factor 19);
LUSC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.03	-0.31	4.45e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg24110177	chr3:50126178	RBM5	0.51	8.21	0.41	4.74e-15	Intelligence (multi-trait analysis);
LUSC	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg23505145	chr19:12996616	KLF1	0.65	11.05	0.52	2.17e-24	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg20203395	chr5:56204925	C5orf35	-0.87	-11.96	-0.55	1.11e-27	Initial pursuit acceleration;
LUSC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10802521	chr3:52805072	NEK4	-0.55	-8.82	-0.43	6.3e-17	Bipolar disorder;
LUSC	trans	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg26043149	chr18:55253948	FECH	-0.46	-7.09	-0.36	7.93e-12	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg15147215	chr3:52552868	STAB1	-0.31	-6.2	-0.32	1.65e-9	Bipolar disorder;
LUSC	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg13010199	chr12:38710504	ALG10B	0.69	10.64	0.5	6.03e-23	Bladder cancer;
LUSC	cis	rs2012796	1.000	rs8008024	chr14:81818492	A/G	cg02996355	chr14:81879375	NA	0.5	7.17	0.37	4.89e-12	Night sleep phenotypes;
LUSC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.77	12.33	0.56	4.77e-29	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6496044	0.568	rs11855789	chr15:86066403	G/A	cg13263323	chr15:86062960	AKAP13	-0.38	-6.27	-0.32	1.12e-9	Interstitial lung disease;
LUSC	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-7.47	-0.38	7.15e-13	Fear of minor pain;
LUSC	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg06145435	chr7:1022769	CYP2W1	0.33	7.05	0.36	1.01e-11	Longevity;Endometriosis;
LUSC	trans	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg10756647	chr7:56101905	PSPH	0.86	8.37	0.42	1.59e-15	Diabetic kidney disease;
LUSC	cis	rs138918	0.967	rs105585	chr22:43557492	G/A	cg08909806	chr22:43548696	TSPO	0.39	6.99	0.36	1.48e-11	Monocyte count;
LUSC	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.33	-5.89	-0.31	9.37e-9	IgG glycosylation;
LUSC	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg08085267	chr17:45401833	C17orf57	0.52	8.51	0.42	5.97e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg00310523	chr12:86230176	RASSF9	0.46	8.5	0.42	6.35e-16	Major depressive disorder;
LUSC	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg22535103	chr8:58192502	C8orf71	-0.55	-6.04	-0.31	4.05e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg26876637	chr1:152193138	HRNR	-0.41	-6.16	-0.32	2.1e-9	Atopic dermatitis;
LUSC	cis	rs1461503	0.809	rs7121955	chr11:122845478	A/T	cg27398637	chr11:122830231	C11orf63	-0.41	-6.57	-0.34	1.98e-10	Menarche (age at onset);
LUSC	cis	rs12410462	0.581	rs7543931	chr1:227550976	A/T	cg23173402	chr1:227635558	NA	0.55	6.22	0.32	1.49e-9	Major depressive disorder;
LUSC	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg11871910	chr12:69753446	YEATS4	0.45	5.83	0.3	1.29e-8	Response to diuretic therapy;
LUSC	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg08854313	chr1:11322531	MTOR	0.87	14.82	0.63	1.52e-38	Body mass index;
LUSC	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg22139774	chr2:100720529	AFF3	-0.46	-7.98	-0.4	2.34e-14	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
LUSC	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg19700328	chr14:106028568	NA	-0.42	-7.0	-0.36	1.45e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LUSC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg23788917	chr6:8435910	SLC35B3	0.5	7.41	0.38	1.02e-12	Motion sickness;
LUSC	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg08807101	chr21:30365312	RNF160	-0.53	-7.9	-0.4	4.17e-14	Dental caries;
LUSC	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.8	0.3	1.56e-8	Lymphocyte counts;
LUSC	cis	rs9581857	0.685	rs10467687	chr13:28036516	G/A	cg22138327	chr13:27999177	GTF3A	0.75	7.8	0.39	7.94e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LUSC	cis	rs4604732	0.527	rs60444724	chr1:247623164	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.42	6.18	0.32	1.88e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs907683	0.570	rs3755056	chr2:220281016	T/A	cg15015639	chr2:220282977	DES	0.29	6.76	0.35	6.04e-11	Resting heart rate;
LUSC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg25767906	chr1:53392781	SCP2	-0.53	-9.47	-0.46	5.38e-19	Monocyte count;
LUSC	cis	rs12618769	0.625	rs3820945	chr2:99105156	G/A	cg10123293	chr2:99228465	UNC50	0.46	7.63	0.39	2.49e-13	Bipolar disorder;
LUSC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg06600287	chr1:53387719	ECHDC2	-0.29	-6.24	-0.32	1.33e-9	Monocyte count;
LUSC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg18825119	chr6:163149453	PACRG;PARK2	-0.35	-6.26	-0.32	1.16e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4704187	0.687	rs10462512	chr5:74387317	C/G	cg03227963	chr5:74354835	NA	0.32	6.8	0.35	4.75e-11	Response to amphetamines;
LUSC	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg18681998	chr4:17616180	MED28	-0.8	-14.2	-0.61	4.08e-36	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg12935359	chr14:103987150	CKB	-0.52	-8.14	-0.41	7.69e-15	Body mass index;
LUSC	cis	rs4343996	0.869	rs10266047	chr7:3476501	C/G	cg21248987	chr7:3385318	SDK1	0.36	5.98	0.31	5.69e-9	Motion sickness;
LUSC	cis	rs1178968	0.818	rs4717086	chr7:72777049	A/G	cg25889504	chr7:72793014	NA	0.6	7.8	0.39	7.86e-14	Triglyceride levels;
LUSC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg05844789	chr1:228464394	OBSCN	-0.3	-5.71	-0.3	2.54e-8	Diastolic blood pressure;
LUSC	cis	rs7106204	0.590	rs7114724	chr11:24239976	A/G	ch.11.24196551F	chr11:24239977	NA	1.14	14.62	0.62	9.32e-38	Response to Homoharringtonine (cytotoxicity);
LUSC	trans	rs6600671	0.934	rs11249431	chr1:121286203	A/G	cg00646200	chr1:148855367	NA	-0.51	-8.05	-0.4	1.46e-14	Hip geometry;
LUSC	cis	rs9925964	0.967	rs749767	chr16:31124407	C/T	cg03418659	chr16:31128414	MYST1	-0.42	-6.78	-0.35	5.45e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg21231944	chr12:82153410	PPFIA2	-0.41	-6.22	-0.32	1.52e-9	Resting heart rate;
LUSC	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg03929089	chr4:120376271	NA	0.6	6.55	0.34	2.18e-10	Axial length;
LUSC	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.87	-20.34	-0.74	2.17e-60	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7605827	0.930	rs1990755	chr2:15616013	C/G	cg19274914	chr2:15703543	NA	0.47	9.13	0.45	6.85e-18	Educational attainment (years of education);
LUSC	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg24812749	chr6:127587940	RNF146	0.73	10.48	0.5	2.02e-22	Breast cancer;
LUSC	cis	rs9837602	1.000	rs923470	chr3:99757792	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.09	-0.32	3.14e-9	Breast cancer;
LUSC	cis	rs859767	0.709	rs4954154	chr2:135370656	G/A	cg12500956	chr2:135428796	TMEM163	-0.28	-6.21	-0.32	1.61e-9	Neuroticism;
LUSC	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg27572855	chr1:25598939	RHD	0.43	7.75	0.39	1.12e-13	Erythrocyte sedimentation rate;
LUSC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.75	-13.62	-0.6	6.9e-34	Intelligence (multi-trait analysis);
LUSC	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg26875233	chr11:93583750	C11orf90	-0.31	-6.06	-0.31	3.76e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
LUSC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26314531	chr2:26401878	FAM59B	-0.68	-9.2	-0.45	3.91e-18	Gut microbiome composition (summer);
LUSC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg18827107	chr12:86230957	RASSF9	-0.47	-6.97	-0.36	1.71e-11	Major depressive disorder;
LUSC	cis	rs2219968	0.962	rs4573260	chr8:78942894	T/C	cg00738934	chr8:78996279	NA	0.38	6.77	0.35	5.66e-11	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs12145833	0.538	rs10926977	chr1:243411367	T/G	cg25284624	chr1:224180302	NA	0.68	6.29	0.33	1.01e-9	Obesity (early onset extreme);
LUSC	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg23625390	chr15:77176239	SCAPER	-0.62	-9.49	-0.46	4.49e-19	Blood metabolite levels;
LUSC	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg13263323	chr15:86062960	AKAP13	-0.35	-5.72	-0.3	2.38e-8	Coronary artery disease;
LUSC	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.88	12.75	0.57	1.33e-30	Lymphocyte percentage of white cells;
LUSC	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.81	-0.47	3.86e-20	Osteoarthritis;
LUSC	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg24578937	chr1:2090814	PRKCZ	0.46	10.15	0.49	2.73e-21	Height;
LUSC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg06915202	chr7:98029285	BAIAP2L1	-0.3	-6.04	-0.31	4.05e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.64	13.49	0.59	2.18e-33	Monocyte percentage of white cells;
LUSC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.46	-8.71	-0.43	1.4e-16	Monocyte percentage of white cells;
LUSC	cis	rs7215564	0.908	rs34785514	chr17:78661166	A/G	cg09596252	chr17:78655493	RPTOR	0.55	6.07	0.32	3.4e-9	Myopia (pathological);
LUSC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.44	-8.63	-0.43	2.45e-16	Colorectal cancer;
LUSC	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.53	-10.58	-0.5	9.77e-23	Glomerular filtration rate (creatinine);
LUSC	cis	rs1506636	0.720	rs633590	chr7:123442156	G/A	cg03229431	chr7:123269106	ASB15	0.48	7.69	0.39	1.61e-13	Plateletcrit;Platelet count;
LUSC	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg11057378	chr10:81107060	PPIF	0.39	6.46	0.33	3.69e-10	Height;
LUSC	cis	rs9905704	0.633	rs2632523	chr17:56506634	G/A	cg19466818	chr17:56409534	MIR142	-0.32	-6.08	-0.32	3.26e-9	Testicular germ cell tumor;
LUSC	cis	rs4746818	0.793	rs2805914	chr10:70859291	A/G	cg11621586	chr10:70884670	VPS26A	0.97	9.56	0.46	2.73e-19	Left atrial antero-posterior diameter;
LUSC	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	9.96	0.48	1.27e-20	Bone mineral density;
LUSC	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.76	7.4	0.38	1.11e-12	Lung cancer in ever smokers;
LUSC	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21028142	chr17:79581711	NPLOC4	0.32	7.61	0.38	2.77e-13	Eye color traits;
LUSC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg06096015	chr1:231504339	EGLN1	0.56	10.02	0.48	8.05e-21	Hemoglobin concentration;
LUSC	trans	rs4650994	0.524	rs2209170	chr1:178607388	C/A	cg05059571	chr16:84539110	KIAA1609	0.47	8.88	0.44	4.24e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg25214090	chr10:38739885	LOC399744	0.54	7.96	0.4	2.73e-14	Corneal astigmatism;
LUSC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg09509183	chr1:209979624	IRF6	0.42	5.64	0.3	3.57e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs8179	0.761	rs42032	chr7:92237426	G/A	cg15732164	chr7:92237376	CDK6	-0.46	-6.87	-0.35	3.09e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LUSC	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.55	8.49	0.42	6.99e-16	Schizophrenia;
LUSC	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg11244672	chr19:19639970	YJEFN3	0.6	7.33	0.37	1.72e-12	Bipolar disorder;
LUSC	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23598886	chr18:12777645	NA	0.67	6.37	0.33	6.38e-10	Inflammatory skin disease;
LUSC	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.91	15.66	0.65	7.95e-42	Bladder cancer;
LUSC	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg19468946	chr17:37922297	IKZF3	-0.44	-6.87	-0.35	3.1e-11	Self-reported allergy;
LUSC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	1.02	17.62	0.69	1.38e-49	Coronary artery disease;
LUSC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.44	6.76	0.35	6.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13770153	chr20:60521292	NA	-0.62	-8.86	-0.44	4.82e-17	Body mass index;
LUSC	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg00750074	chr16:89608354	SPG7	-0.47	-8.01	-0.4	1.87e-14	Multiple myeloma (IgH translocation);
LUSC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12292205	chr6:26970375	C6orf41	-0.58	-7.15	-0.36	5.62e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs11168618	0.967	rs11168619	chr12:48933605	G/C	cg24011408	chr12:48396354	COL2A1	0.41	6.57	0.34	1.96e-10	Adiponectin levels;
LUSC	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-7.89	-0.4	4.45e-14	Chronic sinus infection;
LUSC	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.65	-0.43	2.18e-16	Total cholesterol levels;
LUSC	cis	rs4690686	0.500	rs11725547	chr4:177268444	T/C	cg17059388	chr4:177262070	NA	0.46	8.59	0.43	3.28e-16	Essential tremor;
LUSC	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-5.83	-0.3	1.28e-8	Menopause (age at onset);
LUSC	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.62	-10.39	-0.49	4.16e-22	Schizophrenia;
LUSC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.74	10.58	0.5	9.68e-23	Type 2 diabetes;
LUSC	cis	rs7577851	0.514	rs12466648	chr2:69560024	A/G	cg10773587	chr2:69614142	GFPT1	0.56	6.06	0.31	3.78e-9	Parkinson's disease (age of onset);
LUSC	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg00277334	chr10:82204260	NA	-0.45	-6.28	-0.32	1.07e-9	Post bronchodilator FEV1;
LUSC	cis	rs7605827	0.897	rs1468912	chr2:15662922	A/G	cg19274914	chr2:15703543	NA	0.47	9.19	0.45	4.44e-18	Educational attainment (years of education);
LUSC	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg17366294	chr4:99064904	C4orf37	0.51	8.12	0.41	9.3e-15	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg22166914	chr1:53195759	ZYG11B	-0.48	-7.62	-0.38	2.6e-13	Monocyte count;
LUSC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg00945038	chr17:61921165	SMARCD2	0.53	9.54	0.46	3.22e-19	Prudent dietary pattern;
LUSC	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.37	8.83	0.44	6.01e-17	Diastolic blood pressure;
LUSC	cis	rs6500395	0.926	rs9936446	chr16:48645807	G/C	cg04672837	chr16:48644449	N4BP1	0.47	6.66	0.34	1.16e-10	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg08798685	chr6:27730294	NA	-0.41	-5.77	-0.3	1.76e-8	Parkinson's disease;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27622405	chr5:54830971	PPAP2A;RNF138P1	0.45	6.38	0.33	5.78e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg23298862	chr7:158159286	PTPRN2	0.32	5.66	0.3	3.27e-8	Response to amphetamines;
LUSC	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg24596788	chr1:163392923	NA	-0.41	-6.98	-0.36	1.6e-11	Motion sickness;
LUSC	cis	rs977987	0.898	rs12918974	chr16:75493943	T/A	cg03315344	chr16:75512273	CHST6	0.53	9.98	0.48	1.07e-20	Dupuytren's disease;
LUSC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg13114125	chr14:105738426	BRF1	-0.92	-15.88	-0.66	1.09e-42	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.4	-0.42	1.28e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg26395211	chr5:140044315	WDR55	0.45	6.91	0.35	2.5e-11	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06028605	chr16:24865363	SLC5A11	0.61	9.46	0.46	5.74e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-0.87	-16.13	-0.66	1.07e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs7119	0.679	rs12909808	chr15:77816944	A/G	cg27398640	chr15:77910606	LINGO1	-0.31	-6.57	-0.34	1.96e-10	Type 2 diabetes;
LUSC	cis	rs965513	1.000	rs1561962	chr9:100546219	C/T	cg13688889	chr9:100608707	NA	-0.55	-8.17	-0.41	6.46e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LUSC	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-8.26	-0.41	3.48e-15	Neuroticism;
LUSC	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	0.87	12.66	0.57	2.75e-30	Blood protein levels;
LUSC	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.99	-0.36	1.5e-11	Monocyte percentage of white cells;
LUSC	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg09654669	chr8:57350985	NA	-0.61	-8.16	-0.41	7.11e-15	Obesity-related traits;
LUSC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg06096015	chr1:231504339	EGLN1	-0.53	-9.18	-0.45	4.66e-18	Hemoglobin concentration;
LUSC	cis	rs9309473	0.519	rs7598901	chr2:73675844	C/T	cg20560298	chr2:73613845	ALMS1	0.47	7.37	0.37	1.36e-12	Metabolite levels;
LUSC	cis	rs9612	1.000	rs9612	chr19:44235517	A/G	cg08581076	chr19:44259116	C19orf61	0.51	6.17	0.32	1.99e-9	Exhaled nitric oxide output;
LUSC	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	10.72	0.51	3e-23	Mean corpuscular hemoglobin;
LUSC	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg20503657	chr10:835505	NA	0.6	7.76	0.39	1.06e-13	Eosinophil percentage of granulocytes;
LUSC	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg02176678	chr2:219576539	TTLL4	-0.58	-10.33	-0.49	6.84e-22	Mean corpuscular hemoglobin concentration;
LUSC	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg18232548	chr7:50535776	DDC	0.54	7.58	0.38	3.45e-13	Malaria;
LUSC	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg15133208	chr4:90757351	SNCA	-0.53	-8.13	-0.41	8.37e-15	Neuroticism;
LUSC	cis	rs977987	0.815	rs11149818	chr16:75419373	G/A	cg03315344	chr16:75512273	CHST6	0.53	10.24	0.49	1.39e-21	Dupuytren's disease;
LUSC	cis	rs4908769	0.660	rs302714	chr1:8486131	A/C	cg00546117	chr1:8445545	RERE	-0.28	-5.71	-0.3	2.46e-8	Allergy;
LUSC	cis	rs3849570	1.000	rs4411908	chr3:81802418	A/C	cg07356753	chr3:81810745	GBE1	-0.59	-9.61	-0.47	1.77e-19	Waist circumference;Body mass index;
LUSC	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg05234568	chr11:5960015	NA	-0.62	-8.82	-0.43	6.48e-17	DNA methylation (variation);
LUSC	cis	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg06521331	chr12:34319734	NA	-0.4	-6.16	-0.32	2.13e-9	Morning vs. evening chronotype;
LUSC	cis	rs6494488	0.500	rs76625439	chr15:65018904	G/C	cg08069370	chr15:64387884	SNX1	-0.65	-5.72	-0.3	2.33e-8	Coronary artery disease;
LUSC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.58	-10.82	-0.51	1.42e-23	Longevity;Endometriosis;
LUSC	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg13206674	chr6:150067644	NUP43	0.43	6.45	0.33	4.02e-10	Testicular germ cell tumor;
LUSC	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg23601095	chr6:26197514	HIST1H3D	0.7	7.53	0.38	4.89e-13	Gout;Renal underexcretion gout;
LUSC	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg08601574	chr20:25228251	PYGB	-0.43	-6.61	-0.34	1.55e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg02493740	chr2:85810744	VAMP5	-0.51	-8.8	-0.43	7.35e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17916960	chr15:79447300	NA	-0.53	-10.49	-0.5	2e-22	Refractive error;
LUSC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg12963246	chr6:28129442	ZNF389	0.38	5.97	0.31	6.22e-9	Cardiac Troponin-T levels;
LUSC	cis	rs9399401	0.667	rs1329707	chr6:142724439	T/C	cg03128060	chr6:142623767	GPR126	0.58	9.64	0.47	1.45e-19	Chronic obstructive pulmonary disease;
LUSC	cis	rs372883	0.869	rs2027605	chr21:30726773	A/G	cg24692254	chr21:30365293	RNF160	0.39	5.68	0.3	2.88e-8	Pancreatic cancer;
LUSC	cis	rs2235649	0.833	rs9926962	chr16:1851826	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.42	-6.14	-0.32	2.32e-9	Blood metabolite levels;
LUSC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.74	12.46	0.56	1.65e-29	Motion sickness;
LUSC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	0.89	13.12	0.58	5.18e-32	Breast cancer;
LUSC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	0.64	13.72	0.6	2.8e-34	Prudent dietary pattern;
LUSC	cis	rs3806933	0.522	rs11241100	chr5:110460958	C/T	cg04022379	chr5:110408740	TSLP	0.65	9.42	0.46	7.84e-19	Eosinophilic esophagitis;
LUSC	cis	rs11809207	0.951	rs111772533	chr1:26523404	C/G	cg00147160	chr1:26503991	CNKSR1	0.42	6.88	0.35	2.93e-11	Height;
LUSC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg03929089	chr4:120376271	NA	-0.93	-15.96	-0.66	5.16e-43	Height;
LUSC	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg22709100	chr7:91322751	NA	0.39	5.75	0.3	1.98e-8	Breast cancer;
LUSC	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg23205692	chr1:25664452	TMEM50A	0.39	5.76	0.3	1.94e-8	Plateletcrit;Mean corpuscular volume;
LUSC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.93	-14.5	-0.62	2.71e-37	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg15468180	chr1:107600409	PRMT6	-0.36	-5.83	-0.3	1.29e-8	Facial morphology (factor 21, depth of nasal alae);
LUSC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg25258033	chr6:167368657	RNASET2	0.46	7.49	0.38	6.24e-13	Crohn's disease;
LUSC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg03233332	chr7:66118400	NA	-0.42	-6.09	-0.32	3.05e-9	Aortic root size;
LUSC	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.73	-0.39	1.27e-13	Morning vs. evening chronotype;
LUSC	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg26769984	chr7:1090371	C7orf50	0.68	10.3	0.49	8.39e-22	Bronchopulmonary dysplasia;
LUSC	cis	rs2742234	0.541	rs10899786	chr10:43744583	G/A	cg02780029	chr10:43622663	RET	0.35	5.71	0.3	2.56e-8	Hirschsprung disease;
LUSC	cis	rs9463078	0.683	rs227847	chr6:44695493	A/G	cg25276700	chr6:44698697	NA	0.31	6.08	0.32	3.22e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LUSC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg13683864	chr3:40499215	RPL14	-1.11	-21.6	-0.76	2.22e-65	Renal cell carcinoma;
LUSC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14159672	chr1:205819179	PM20D1	-0.77	-14.8	-0.63	1.83e-38	Monocyte percentage of white cells;
LUSC	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg05925327	chr15:68127851	NA	-0.47	-6.83	-0.35	4.1e-11	Restless legs syndrome;
LUSC	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.69	11.33	0.53	2.21e-25	Eye color traits;
LUSC	cis	rs12136530	0.774	rs4912097	chr1:19784410	C/G	cg01832549	chr1:19774989	CAPZB	-0.31	-5.68	-0.3	2.89e-8	Lead levels in blood;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25248346	chr19:41869851	B9D2;TMEM91	-0.43	-6.48	-0.33	3.22e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs1950626	0.750	rs72700530	chr14:101429459	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.44	7.75	0.39	1.08e-13	Pelvic organ prolapse (moderate/severe);
LUSC	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	0.37	5.75	0.3	2.07e-8	Lymphocyte counts;
LUSC	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg03585969	chr10:35415529	CREM	0.62	9.1	0.45	8.41e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-10.71	-0.51	3.24e-23	Body mass index;
LUSC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg00745463	chr17:30367425	LRRC37B	-0.66	-8.09	-0.4	1.14e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs7827545	1.000	rs7832857	chr8:135565477	A/G	cg17885191	chr8:135476712	NA	0.56	8.35	0.42	1.87e-15	Hypertension (SNP x SNP interaction);
LUSC	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg25797454	chr6:150327115	RAET1K	0.34	7.8	0.39	8.18e-14	Alopecia areata;
LUSC	cis	rs7804356	0.861	rs111373218	chr7:26859152	G/A	cg03456212	chr7:26904342	SKAP2	-0.53	-6.17	-0.32	2.01e-9	Type 1 diabetes;
LUSC	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.31	-6.44	-0.33	4.26e-10	Dupuytren's disease;
LUSC	cis	rs4363385	0.550	rs2050673	chr1:152923698	C/T	cg25856811	chr1:152973957	SPRR3	-0.36	-5.9	-0.31	9.03e-9	Inflammatory skin disease;
LUSC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	21.13	0.76	1.58e-63	Prudent dietary pattern;
LUSC	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg11584989	chr19:19387371	SF4	-0.6	-7.08	-0.36	8.81e-12	Bipolar disorder;
LUSC	cis	rs7246967	0.673	rs3853650	chr19:22880490	A/G	cg23217946	chr19:22817039	ZNF492	0.42	5.95	0.31	6.66e-9	Bronchopulmonary dysplasia;
LUSC	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg13813247	chr22:41461852	NA	-0.37	-6.77	-0.35	5.91e-11	Neuroticism;
LUSC	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-8.86	-0.44	4.84e-17	Monocyte percentage of white cells;
LUSC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg06640241	chr16:89574553	SPG7	0.83	14.56	0.62	1.53e-37	Multiple myeloma (IgH translocation);
LUSC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg20283391	chr11:68216788	NA	-0.5	-7.23	-0.37	3.42e-12	Total body bone mineral density;
LUSC	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	8.8	0.43	7.56e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-9.7	-0.47	9.52e-20	Morning vs. evening chronotype;
LUSC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg22535103	chr8:58192502	C8orf71	-0.64	-7.32	-0.37	1.9e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg17366294	chr4:99064904	C4orf37	0.55	9.6	0.47	1.98e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.6	8.66	0.43	2.08e-16	Bipolar disorder;
LUSC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-6.65	-0.34	1.21e-10	Lung cancer;
LUSC	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg24375607	chr4:120327624	NA	-0.69	-10.81	-0.51	1.47e-23	Corneal astigmatism;
LUSC	cis	rs6489882	0.934	rs1859331	chr12:113376331	C/A	cg20102336	chr12:113376681	OAS3	-0.41	-6.05	-0.31	3.9e-9	Chronic lymphocytic leukemia;
LUSC	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg09479241	chr17:27052676	TLCD1	0.42	5.86	0.31	1.09e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs11209002	0.567	rs2224501	chr1:67532526	G/T	cg02640540	chr1:67518911	SLC35D1	0.6	8.17	0.41	6.36e-15	Crohn's disease;
LUSC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.58	0.46	2.25e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.13	-0.36	6.26e-12	Schizophrenia;
LUSC	cis	rs72627509	1.000	rs57265257	chr4:57839280	A/T	cg26694713	chr4:57773883	REST	0.5	5.87	0.31	1.05e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg17644776	chr2:200775616	C2orf69	0.43	6.54	0.34	2.27e-10	Schizophrenia;
LUSC	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg15432903	chr11:17409602	KCNJ11	0.62	10.61	0.5	7.42e-23	Type 2 diabetes;
LUSC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-6.08	-0.32	3.35e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg20887711	chr4:1340912	KIAA1530	0.53	8.04	0.4	1.59e-14	Obesity-related traits;
LUSC	cis	rs9341835	0.741	rs6929702	chr6:64144114	T/C	cg03326410	chr6:64151739	NA	-0.36	-6.02	-0.31	4.53e-9	Schizophrenia;
LUSC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg18827107	chr12:86230957	RASSF9	-0.49	-7.12	-0.36	6.8e-12	Major depressive disorder;
LUSC	cis	rs500891	1.000	rs13207536	chr6:84188476	A/G	cg08257003	chr6:84140564	ME1	0.33	6.93	0.35	2.16e-11	Platelet-derived growth factor BB levels;
LUSC	cis	rs239198	0.521	rs13198473	chr6:101337779	C/T	cg09795085	chr6:101329169	ASCC3	0.41	5.87	0.31	1.07e-8	Menarche (age at onset);
LUSC	cis	rs4664304	0.802	rs3749114	chr2:160832996	A/T	cg23995753	chr2:160760732	LY75	-0.33	-6.13	-0.32	2.41e-9	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg24812749	chr6:127587940	RNF146	0.5	7.19	0.37	4.2e-12	Breast cancer;
LUSC	cis	rs9788721	0.967	rs55853698	chr15:78857939	T/G	cg18825076	chr15:78729989	IREB2	-0.5	-7.52	-0.38	5.05e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg02153584	chr22:29168773	CCDC117	0.59	8.92	0.44	3.16e-17	Lymphocyte counts;
LUSC	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg17168535	chr8:21777572	XPO7	0.87	16.11	0.66	1.29e-43	Mean corpuscular volume;
LUSC	cis	rs2573652	1.000	rs12441080	chr15:100516968	A/G	cg09918751	chr15:100517450	ADAMTS17	0.42	7.93	0.4	3.34e-14	Height;
LUSC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg23788917	chr6:8435910	SLC35B3	0.48	7.14	0.36	5.95e-12	Motion sickness;
LUSC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg13114125	chr14:105738426	BRF1	-0.9	-15.44	-0.65	5.97e-41	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-8.43	-0.42	1.07e-15	Morning vs. evening chronotype;
LUSC	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg09509183	chr1:209979624	IRF6	0.43	5.73	0.3	2.25e-8	Cleft lip with or without cleft palate;
LUSC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	10.16	0.49	2.69e-21	Electroencephalogram traits;
LUSC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00166722	chr3:10149974	C3orf24	-0.53	-7.64	-0.39	2.3e-13	Alzheimer's disease;
LUSC	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg04121214	chr22:50244548	NA	0.34	5.75	0.3	2.02e-8	Schizophrenia;
LUSC	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg27494647	chr7:150038898	RARRES2	0.46	7.19	0.37	4.31e-12	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs2281845	0.859	rs1325312	chr1:201079021	A/G	cg22815214	chr1:201083145	CACNA1S	0.54	9.27	0.45	2.42e-18	Permanent tooth development;
LUSC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg20203395	chr5:56204925	C5orf35	-0.77	-10.24	-0.49	1.4e-21	Initial pursuit acceleration;
LUSC	trans	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg03886242	chr7:26192032	NFE2L3	0.38	6.29	0.33	9.81e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg22823121	chr1:150693482	HORMAD1	0.61	9.34	0.45	1.45e-18	Tonsillectomy;
LUSC	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg23093090	chr10:104574429	C10orf26	-0.34	-6.26	-0.32	1.19e-9	Arsenic metabolism;
LUSC	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg20991723	chr1:152506922	NA	0.51	9.74	0.47	6.76e-20	Hair morphology;
LUSC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.37	-6.06	-0.31	3.72e-9	Neutrophil percentage of white cells;
LUSC	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg00792783	chr2:198669748	PLCL1	0.43	5.86	0.31	1.12e-8	Dermatomyositis;
LUSC	cis	rs4974559	0.790	rs5019560	chr4:1324793	G/A	cg02980000	chr4:1222292	CTBP1	0.85	9.71	0.47	8.27e-20	Systolic blood pressure;
LUSC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg00701064	chr4:6280414	WFS1	-0.58	-14.33	-0.62	1.28e-36	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20418281	chr17:27717751	TAOK1	-0.44	-6.63	-0.34	1.34e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.71	10.76	0.51	2.23e-23	Smoking initiation;
LUSC	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg03859395	chr2:55845619	SMEK2	0.85	15.18	0.64	5.99e-40	Metabolic syndrome;
LUSC	cis	rs1775715	0.835	rs113450267	chr10:32223728	G/A	cg03015672	chr10:32216066	ARHGAP12	0.32	5.72	0.3	2.31e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.62	-8.12	-0.41	9.35e-15	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LUSC	cis	rs2227564	0.729	rs2688615	chr10:75651499	C/G	cg23231163	chr10:75533350	FUT11	-0.43	-5.85	-0.31	1.14e-8	Crohn's disease;Inflammatory bowel disease;
LUSC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg23630131	chr7:65973040	NA	-0.21	-5.81	-0.3	1.42e-8	Aortic root size;
LUSC	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg08677398	chr8:58056175	NA	0.43	5.99	0.31	5.47e-9	Developmental language disorder (linguistic errors);
LUSC	cis	rs907612	0.638	rs907613	chr11:1874292	G/A	cg07277017	chr11:1874093	LSP1	0.34	6.0	0.31	5.23e-9	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LUSC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg19130645	chr7:65235666	NA	-0.38	-5.89	-0.31	9.67e-9	Calcium levels;
LUSC	cis	rs654950	0.806	rs7550496	chr1:42043834	G/A	cg06885757	chr1:42089581	HIVEP3	0.44	8.98	0.44	2e-17	Airway imaging phenotypes;
LUSC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg05025164	chr4:1340916	KIAA1530	0.49	7.58	0.38	3.34e-13	Obesity-related traits;
LUSC	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg09509183	chr1:209979624	IRF6	0.41	6.28	0.33	1.02e-9	Monobrow;
LUSC	cis	rs4253772	0.872	rs45528736	chr22:46638312	A/G	cg24881330	chr22:46731750	TRMU	0.63	5.85	0.31	1.15e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg02972257	chr16:68554789	NA	0.45	5.81	0.3	1.46e-8	Colorectal cancer;
LUSC	cis	rs7177699	0.557	rs7164479	chr15:79123054	C/T	cg00540400	chr15:79124168	NA	0.43	7.55	0.38	4.3e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.1	-17.14	-0.68	1.07e-47	Gut microbiome composition (summer);
LUSC	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg05283184	chr6:79620031	NA	-0.45	-8.61	-0.43	2.94e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg01475377	chr6:109611718	NA	-0.41	-7.26	-0.37	2.69e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg15448220	chr1:150897856	SETDB1	-0.4	-5.8	-0.3	1.54e-8	Melanoma;
LUSC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg13126279	chr21:47581558	C21orf56	-0.43	-6.34	-0.33	7.62e-10	Testicular germ cell tumor;
LUSC	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg02454025	chr1:11042201	C1orf127	1.02	18.51	0.71	3.88e-53	Ewing sarcoma;
LUSC	cis	rs9807989	0.507	rs6745614	chr2:102991213	A/G	cg03938978	chr2:103052716	IL18RAP	0.37	7.1	0.36	7.4e-12	Asthma;
LUSC	trans	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg07817883	chr1:32538562	TMEM39B	-0.54	-6.28	-0.32	1.08e-9	Monocyte percentage of white cells;
LUSC	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.77	11.52	0.53	4.56e-26	Cognitive ability;
LUSC	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg05110241	chr16:68378359	PRMT7	-0.57	-6.38	-0.33	5.93e-10	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs6906287	0.647	rs10457330	chr6:118731468	A/T	cg21191810	chr6:118973309	C6orf204	0.33	6.14	0.32	2.39e-9	Electrocardiographic conduction measures;
LUSC	cis	rs7246967	0.551	rs8112442	chr19:22893369	C/T	cg23217946	chr19:22817039	ZNF492	0.41	5.7	0.3	2.67e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg01733217	chr16:74700730	RFWD3	0.97	22.15	0.77	1.61e-67	Multiple myeloma;
LUSC	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg10518543	chr12:38710700	ALG10B	0.41	5.79	0.3	1.62e-8	Morning vs. evening chronotype;
LUSC	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-5.92	-0.31	7.78e-9	Height;
LUSC	trans	rs13390641	0.614	rs111831581	chr2:104095920	C/A	cg03260781	chr1:16346299	HSPB7	-0.46	-6.09	-0.32	3.14e-9	Blood pressure;Blood pressure (anthropometric measures interaction);
LUSC	cis	rs7615316	0.934	rs1129393	chr3:142283813	A/G	cg16271453	chr3:142027066	XRN1	-0.36	-6.25	-0.32	1.29e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg08579753	chr1:39174525	NA	0.51	6.19	0.32	1.72e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-9.99	-0.48	9.49e-21	Hemoglobin concentration;
LUSC	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-9.89	-0.48	2.15e-20	Migraine;Coronary artery disease;
LUSC	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.71	10.83	0.51	1.26e-23	Fuchs's corneal dystrophy;
LUSC	cis	rs5766691	0.644	rs6007607	chr22:47529288	C/G	cg15757745	chr22:47558489	TBC1D22A	-0.63	-10.03	-0.48	7.27e-21	Longevity;
LUSC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.83	-12.5	-0.56	1.12e-29	Motion sickness;
LUSC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg22166914	chr1:53195759	ZYG11B	-0.4	-5.96	-0.31	6.31e-9	Monocyte count;
LUSC	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.64	-0.3	3.57e-8	Breast cancer;
LUSC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg23711669	chr6:146136114	FBXO30	0.78	13.66	0.6	4.51e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg05973401	chr12:123451056	ABCB9	0.52	6.53	0.34	2.39e-10	Neutrophil percentage of white cells;
LUSC	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg14092571	chr14:90743983	NA	-0.36	-5.86	-0.31	1.11e-8	Mortality in heart failure;
LUSC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.5	8.69	0.43	1.66e-16	Prudent dietary pattern;
LUSC	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg05855489	chr10:104503620	C10orf26	0.59	9.52	0.46	3.66e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg15605315	chr1:45957053	TESK2	0.46	7.33	0.37	1.78e-12	High light scatter reticulocyte count;
LUSC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	1.11	9.74	0.47	6.79e-20	Skin colour saturation;
LUSC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg05863683	chr7:1912471	MAD1L1	0.3	5.77	0.3	1.8e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg25173405	chr17:45401733	C17orf57	0.39	6.2	0.32	1.65e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg16482183	chr6:26056742	HIST1H1C	0.56	8.47	0.42	7.76e-16	Height;
LUSC	cis	rs7945718	0.967	rs4757945	chr11:12808718	A/G	cg25843174	chr11:12811716	TEAD1	-0.35	-7.76	-0.39	1.05e-13	Educational attainment (years of education);
LUSC	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg26727032	chr16:67993705	SLC12A4	-0.43	-5.8	-0.3	1.5e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg07636037	chr3:49044803	WDR6	0.79	10.27	0.49	1.12e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.95	-13.54	-0.6	1.33e-33	Initial pursuit acceleration;
LUSC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg03146154	chr1:46216737	IPP	0.56	8.35	0.42	1.84e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg06484146	chr7:12443880	VWDE	-0.74	-7.61	-0.38	2.77e-13	Coronary artery disease;
LUSC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg05347473	chr6:146136440	FBXO30	0.53	9.11	0.45	7.97e-18	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-0.64	-11.21	-0.52	5.94e-25	Blood metabolite levels;
LUSC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-0.93	-15.59	-0.65	1.53e-41	Body mass index;
LUSC	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg13010199	chr12:38710504	ALG10B	0.69	10.65	0.5	5.27e-23	Bladder cancer;
LUSC	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg26354017	chr1:205819088	PM20D1	-0.41	-5.95	-0.31	6.93e-9	Prostate-specific antigen levels;
LUSC	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg20302533	chr7:39170763	POU6F2	0.57	9.46	0.46	5.77e-19	IgG glycosylation;
LUSC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.19	-0.49	2.11e-21	Developmental language disorder (linguistic errors);
LUSC	cis	rs1256061	0.624	rs1256046	chr14:64729356	A/C	cg23250157	chr14:64679961	SYNE2	0.32	5.7	0.3	2.68e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
LUSC	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg21573476	chr21:45109991	RRP1B	0.39	6.4	0.33	5.37e-10	Mean corpuscular volume;
LUSC	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg10547527	chr2:198650123	BOLL	-0.52	-5.97	-0.31	5.91e-9	Ulcerative colitis;
LUSC	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg22437258	chr11:111473054	SIK2	0.49	6.33	0.33	8.08e-10	Primary sclerosing cholangitis;
LUSC	cis	rs6693567	0.565	rs471738	chr1:150276429	G/A	cg15654264	chr1:150340011	RPRD2	-0.45	-7.44	-0.38	8.42e-13	Migraine;
LUSC	cis	rs9309473	0.607	rs6716776	chr2:73587713	T/C	cg20560298	chr2:73613845	ALMS1	-0.55	-8.24	-0.41	3.84e-15	Metabolite levels;
LUSC	trans	rs7838490	0.780	rs35716194	chr8:89678635	C/T	cg24558378	chr1:183589673	NA	0.34	6.17	0.32	2e-9	Body mass index and cholesterol (psychopharmacological treatment);
LUSC	cis	rs6484504	0.576	rs2756191	chr11:31135882	A/T	cg06552810	chr11:31128660	NA	0.4	7.16	0.36	5.04e-12	Red blood cell count;
LUSC	cis	rs9296092	0.538	rs62405943	chr6:33517359	A/G	cg13560919	chr6:33536144	NA	-0.81	-15.57	-0.65	1.72e-41	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg11887960	chr12:57824829	NA	0.55	7.24	0.37	3.18e-12	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	6.83	0.35	4.07e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg21770322	chr7:97807741	LMTK2	0.4	7.06	0.36	9.83e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg24675658	chr1:53192096	ZYG11B	0.6	9.4	0.46	9.2e-19	Monocyte count;
LUSC	cis	rs7561273	0.545	rs10865262	chr2:24337594	A/G	cg08063864	chr2:24346004	PFN4;LOC375190	0.42	6.02	0.31	4.54e-9	Quantitative traits;
LUSC	cis	rs6939532	0.544	rs10946816	chr6:26361946	C/G	cg05738196	chr6:26577821	NA	-0.41	-5.66	-0.3	3.19e-8	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg08601574	chr20:25228251	PYGB	-0.45	-6.89	-0.35	2.73e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg20573242	chr4:122745356	CCNA2	-0.46	-6.75	-0.35	6.61e-11	Type 2 diabetes;
LUSC	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg17366294	chr4:99064904	C4orf37	0.56	9.77	0.47	5.22e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1018836	0.608	rs10094978	chr8:91509054	C/T	cg16814680	chr8:91681699	NA	-0.63	-9.42	-0.46	7.95e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg26597838	chr10:835615	NA	0.83	11.57	0.54	2.8e-26	Eosinophil percentage of granulocytes;
LUSC	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-1.15	-18.29	-0.71	2.9e-52	Exhaled nitric oxide output;
LUSC	cis	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg17469321	chr7:55412551	NA	0.65	10.6	0.5	7.9399999999999994e-23	QRS interval (sulfonylurea treatment interaction);
LUSC	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg18478394	chr8:109455254	TTC35	0.42	6.53	0.34	2.38e-10	Dupuytren's disease;
LUSC	cis	rs73200209	0.744	rs61937384	chr12:116698606	G/C	cg01776926	chr12:116560359	MED13L	-0.48	-5.88	-0.31	1.01e-8	Total body bone mineral density;
LUSC	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg27471124	chr11:109292789	C11orf87	0.41	7.22	0.37	3.52e-12	Schizophrenia;
LUSC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	11.19	0.52	6.57e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg09034736	chr1:150693464	HORMAD1	0.5	7.3	0.37	2.18e-12	Tonsillectomy;
LUSC	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg27129171	chr3:47204927	SETD2	0.7	11.65	0.54	1.47e-26	Colorectal cancer;
LUSC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg18758796	chr5:131593413	PDLIM4	0.43	6.93	0.35	2.22e-11	Breast cancer;
LUSC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg09436375	chr6:42928200	GNMT	-0.29	-6.73	-0.35	7.54e-11	Alzheimer's disease in APOE e4+ carriers;
LUSC	cis	rs6939532	0.597	rs2273558	chr6:26466035	A/C	cg05738196	chr6:26577821	NA	-0.5	-7.11	-0.36	7.18e-12	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	11.3	0.53	2.63e-25	Lung cancer in ever smokers;
LUSC	cis	rs1044826	0.642	rs4607068	chr3:139162994	A/G	cg15131784	chr3:139108705	COPB2	0.42	6.85	0.35	3.55e-11	Obesity-related traits;
LUSC	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg11245181	chr6:149772854	ZC3H12D	-0.33	-7.09	-0.36	7.79e-12	Dupuytren's disease;
LUSC	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Smoking initiation;
LUSC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg13395646	chr4:1353034	KIAA1530	0.49	7.0	0.36	1.44e-11	Obesity-related traits;
LUSC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	10.87	0.51	8.89e-24	Hip circumference adjusted for BMI;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24465448	chr8:17942444	ASAH1	-0.41	-6.31	-0.33	9.02e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg03929089	chr4:120376271	NA	0.82	11.17	0.52	7.89e-25	Height;
LUSC	trans	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg12856521	chr11:46389249	DGKZ	0.42	6.69	0.34	9.32e-11	Leprosy;
LUSC	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg22705602	chr4:152727874	NA	-0.38	-7.88	-0.4	4.71e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs4363385	0.818	rs2152994	chr1:152991060	C/T	cg00922841	chr1:152955080	SPRR1A	0.44	7.68	0.39	1.82e-13	Inflammatory skin disease;
LUSC	cis	rs7202877	0.706	rs8054586	chr16:75410705	G/C	cg03315344	chr16:75512273	CHST6	0.42	6.18	0.32	1.87e-9	Type 2 diabetes;Type 1 diabetes;
LUSC	cis	rs10788972	0.873	rs4926619	chr1:54558101	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.27	-5.89	-0.31	9.58e-9	Parkinson disease and lewy body pathology;
LUSC	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg01420254	chr6:26195488	NA	0.64	7.05	0.36	1.01e-11	Gout;Renal underexcretion gout;
LUSC	trans	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.9	0.35	2.57e-11	Endometrial cancer;
LUSC	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07080220	chr10:102295463	HIF1AN	0.67	9.26	0.45	2.5e-18	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs12760731	0.641	rs11590951	chr1:178322757	C/T	cg00404053	chr1:178313656	RASAL2	0.57	6.04	0.31	4.13e-9	Obesity-related traits;
LUSC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg00343986	chr7:65444356	GUSB	0.43	6.56	0.34	2.07e-10	Aortic root size;
LUSC	cis	rs41271951	0.512	rs6664387	chr1:151021509	A/G	cg11822372	chr1:151115635	SEMA6C	-0.78	-7.16	-0.36	5.06e-12	Blood protein levels;
LUSC	cis	rs1018836	0.631	rs2205157	chr8:91472384	C/T	cg16814680	chr8:91681699	NA	-0.56	-8.24	-0.41	4.09e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LUSC	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg18825076	chr15:78729989	IREB2	-0.54	-8.58	-0.42	3.62e-16	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg24550644	chr17:30846204	MYO1D	-0.37	-5.81	-0.3	1.49e-8	Schizophrenia;
LUSC	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg11693508	chr17:37793320	STARD3	0.66	7.61	0.38	2.78e-13	Bipolar disorder;
LUSC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.8	10.96	0.51	4.41e-24	IgE levels in asthmatics (D.p. specific);
LUSC	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.71	-0.39	1.47e-13	Neuroticism;
LUSC	cis	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg24375607	chr4:120327624	NA	0.49	7.56	0.38	3.87e-13	Diastolic blood pressure;
LUSC	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg07169764	chr2:136633963	MCM6	0.57	7.71	0.39	1.49e-13	Mosquito bite size;
LUSC	cis	rs9811920	0.809	rs6440967	chr3:99722396	G/T	cg06077670	chr3:99629837	C3orf26;FILIP1L;MIR548G	0.36	6.61	0.34	1.54e-10	Axial length;
LUSC	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg21960279	chr19:17905606	B3GNT3	0.38	5.78	0.3	1.71e-8	Tumor biomarkers;
LUSC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg23172400	chr8:95962367	TP53INP1	-0.45	-9.48	-0.46	4.92e-19	Type 2 diabetes;
LUSC	cis	rs2580764	0.624	rs12713284	chr2:55228861	G/A	cg09592903	chr2:55203963	RTN4	-0.49	-10.09	-0.48	4.58e-21	Mean platelet volume;
LUSC	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.83	-0.3	1.33e-8	Testicular germ cell tumor;
LUSC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.89	0.4	4.26e-14	Bipolar disorder;
LUSC	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg06671660	chr6:41068741	NFYA;LOC221442	-0.4	-5.65	-0.3	3.4e-8	Alzheimer's disease (late onset);
LUSC	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	11.46	0.53	7.03e-26	Lung cancer in ever smokers;
LUSC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg07507251	chr3:52567010	NT5DC2	0.32	6.13	0.32	2.44e-9	Bipolar disorder;
LUSC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg02580895	chr19:2754563	NA	-0.46	-6.79	-0.35	5.11e-11	Total cholesterol levels;
LUSC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg07716408	chr11:68623521	NA	0.32	6.33	0.33	7.67e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19346786	chr7:2764209	NA	-0.5	-8.63	-0.43	2.62e-16	Height;
LUSC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.34	-7.21	-0.37	3.68e-12	Longevity;Endometriosis;
LUSC	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.37	6.13	0.32	2.41e-9	Ovarian reserve;
LUSC	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg13010199	chr12:38710504	ALG10B	0.67	10.52	0.5	1.56e-22	Morning vs. evening chronotype;
LUSC	cis	rs983392	0.667	rs634475	chr11:59942081	G/A	cg02771260	chr11:59836817	MS4A3	0.37	6.28	0.33	1.03e-9	Alzheimer's disease (late onset);
LUSC	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg14416269	chr4:6271139	WFS1	0.54	11.65	0.54	1.5e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg17968037	chr7:100024898	ZCWPW1	-0.42	-6.1	-0.32	2.9e-9	Platelet count;
LUSC	cis	rs9311676	0.656	rs4681682	chr3:58337833	A/G	cg26110898	chr3:58419937	PDHB	-0.43	-6.95	-0.36	1.91e-11	Systemic lupus erythematosus;
LUSC	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg09835421	chr16:68378352	PRMT7	-0.56	-6.23	-0.32	1.39e-9	HDL cholesterol;
LUSC	cis	rs870825	0.932	rs28702958	chr4:185575562	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	11.24	0.52	4.52e-25	Blood protein levels;
LUSC	cis	rs12980942	0.872	rs12985339	chr19:41801756	A/T	cg25627403	chr19:41769009	HNRNPUL1	-0.61	-6.58	-0.34	1.79e-10	Coronary artery disease;
LUSC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	1.05	19.04	0.72	3.07e-55	Menopause (age at onset);
LUSC	cis	rs7572733	0.555	rs7561950	chr2:198754244	C/T	cg00792783	chr2:198669748	PLCL1	0.45	6.1	0.32	2.89e-9	Dermatomyositis;
LUSC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg22532475	chr10:104410764	TRIM8	0.28	5.71	0.3	2.49e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg08470875	chr2:26401718	FAM59B	0.7	9.08	0.44	9.74e-18	Gut microbiome composition (summer);
LUSC	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg23625390	chr15:77176239	SCAPER	-0.65	-9.99	-0.48	9.5e-21	Blood metabolite levels;
LUSC	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg07701084	chr6:150067640	NUP43	0.52	7.58	0.38	3.51e-13	Lung cancer;
LUSC	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg21231944	chr12:82153410	PPFIA2	-0.4	-6.2	-0.32	1.63e-9	Resting heart rate;
LUSC	cis	rs7589342	0.839	rs12997003	chr2:106436413	C/T	cg14210321	chr2:106509881	NCK2	-0.53	-7.94	-0.4	3.11e-14	Addiction;
LUSC	cis	rs7613051	0.580	rs11720449	chr3:33066467	C/T	cg19000631	chr3:33138515	GLB1;TMPPE	0.61	6.43	0.33	4.31e-10	Atopic dermatitis;
LUSC	cis	rs12776158	0.901	rs57677741	chr10:71217131	G/A	cg12610070	chr10:71211762	TSPAN15	-0.46	-5.91	-0.31	8.46e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg01733217	chr16:74700730	RFWD3	0.88	15.49	0.65	3.75e-41	Multiple myeloma;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg12328890	chr11:706098	EPS8L2	-0.45	-7.27	-0.37	2.63e-12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	trans	rs72674100	1.000	rs10027971	chr4:97967340	T/C	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs16854884	0.741	rs55909524	chr3:143794734	T/C	cg06585982	chr3:143692056	C3orf58	0.44	6.47	0.33	3.44e-10	Economic and political preferences (feminism/equality);
LUSC	cis	rs897080	0.553	rs1067338	chr2:44624708	G/A	cg00619915	chr2:44497795	NA	-0.39	-5.65	-0.3	3.45e-8	Height;
LUSC	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg05855489	chr10:104503620	C10orf26	-0.68	-10.23	-0.49	1.51e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg25214090	chr10:38739885	LOC399744	0.57	8.42	0.42	1.14e-15	Corneal astigmatism;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg23883215	chr8:26240324	BNIP3L	-0.42	-5.99	-0.31	5.3e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg05855489	chr10:104503620	C10orf26	-0.64	-7.79	-0.39	8.46e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-6.23	-0.32	1.44e-9	IgG glycosylation;
LUSC	cis	rs10493773	0.618	rs34746573	chr1:86075360	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.39	-7.65	-0.39	2.24e-13	Urate levels in overweight individuals;
LUSC	cis	rs2455601	0.786	rs2568068	chr11:8977830	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-6.08	-0.32	3.22e-9	Schizophrenia;
LUSC	cis	rs73206853	0.563	rs9300316	chr12:111196204	T/C	cg12870014	chr12:110450643	ANKRD13A	0.67	6.98	0.36	1.56e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.74	-0.39	1.19e-13	Blood metabolite levels;
LUSC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg16099169	chr2:106886729	NA	-0.45	-6.64	-0.34	1.24e-10	Facial morphology (factor 23);
LUSC	cis	rs6066835	0.867	rs11698214	chr20:47359603	G/A	cg18078177	chr20:47281410	PREX1	0.65	5.76	0.3	1.93e-8	Multiple myeloma;
LUSC	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg17757837	chr7:157058334	UBE3C	0.82	12.98	0.58	1.8e-31	Body mass index;
LUSC	cis	rs7818345	1.000	rs7818345	chr8:19306618	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.35	6.48	0.33	3.34e-10	Language performance in older adults (adjusted for episodic memory);
LUSC	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg10523860	chr14:103875565	MARK3	-0.4	-6.44	-0.33	4.18e-10	Body mass index;
LUSC	cis	rs500891	0.547	rs2152183	chr6:84102879	A/C	cg08257003	chr6:84140564	ME1	-0.32	-7.21	-0.37	3.7e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg04607235	chr12:12878440	APOLD1	-0.53	-6.0	-0.31	5.17e-9	Systemic lupus erythematosus;
LUSC	cis	rs6558174	0.965	rs2003908	chr8:22491518	T/C	cg03733263	chr8:22462867	KIAA1967	0.46	6.08	0.32	3.27e-9	Breast cancer;
LUSC	trans	rs6924906	0.655	rs74548211	chr6:82238149	C/A	cg15052890	chr17:4636830	MED11;CXCL16	-0.58	-6.12	-0.32	2.57e-9	Blood pressure;
LUSC	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg25174290	chr11:3078921	CARS	-0.41	-6.14	-0.32	2.33e-9	Calcium levels;
LUSC	cis	rs4363385	0.765	rs3806221	chr1:153002555	G/T	cg00922841	chr1:152955080	SPRR1A	-0.45	-7.9	-0.4	4e-14	Inflammatory skin disease;
LUSC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	6.17	0.32	2.03e-9	Height;
LUSC	cis	rs155346	1.000	rs265152	chr5:139379707	C/T	cg01090482	chr5:139365336	NRG2	-0.36	-6.08	-0.32	3.2e-9	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
LUSC	trans	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg13010199	chr12:38710504	ALG10B	-0.46	-7.18	-0.37	4.69e-12	Morning vs. evening chronotype;
LUSC	cis	rs2282300	0.739	rs16920406	chr11:30216158	A/C	cg25418670	chr11:30344373	C11orf46	-0.62	-9.01	-0.44	1.56e-17	Morning vs. evening chronotype;
LUSC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg23985595	chr17:80112537	CCDC57	0.31	5.9	0.31	8.94e-9	Life satisfaction;
LUSC	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg11262906	chr1:85462892	MCOLN2	0.53	6.79	0.35	5.16e-11	Serum sulfate level;
LUSC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg21361702	chr7:150065534	REPIN1	0.5	6.7	0.34	8.83e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.57	-6.98	-0.36	1.57e-11	Body mass index;
LUSC	cis	rs4285028	0.747	rs4048699	chr3:121404483	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.88	12.83	0.57	6.63e-31	Multiple sclerosis;
LUSC	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.06	0.36	9.43e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg05347473	chr6:146136440	FBXO30	0.56	9.55	0.46	2.83e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg05855489	chr10:104503620	C10orf26	-0.48	-7.35	-0.37	1.53e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs4077468	1.000	rs11801695	chr1:205916175	A/C	cg14893161	chr1:205819251	PM20D1	0.42	6.15	0.32	2.23e-9	Cystic fibrosis-related diabetes;
LUSC	cis	rs7192380	1.000	rs8049728	chr16:69654790	G/T	cg26679644	chr16:69762563	NA	0.34	6.14	0.32	2.41e-9	Sjögren's syndrome;
LUSC	cis	rs6076065	1.000	rs2424538	chr20:23382076	A/G	cg11657817	chr20:23433608	CST11	0.44	8.66	0.43	2.12e-16	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg15445000	chr17:37608096	MED1	0.39	6.68	0.34	9.76e-11	Glomerular filtration rate (creatinine);
LUSC	trans	rs2840044	1.000	rs8073935	chr17:33985849	C/T	cg19694781	chr19:47549865	TMEM160	-0.56	-8.93	-0.44	2.8e-17	Response to radiotherapy in cancer (late toxicity);
LUSC	cis	rs394563	0.810	rs480870	chr6:149784818	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.37	-7.87	-0.4	4.99e-14	Dupuytren's disease;
LUSC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg05785598	chr3:49045655	WDR6	0.34	5.7	0.3	2.68e-8	Parkinson's disease;
LUSC	cis	rs1163251	0.837	rs595283	chr1:120247887	C/G	cg19096424	chr1:120255104	PHGDH	-0.46	-6.18	-0.32	1.86e-9	Blood metabolite levels;
LUSC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.89	12.84	0.57	5.85e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11048434	0.736	rs2377672	chr12:9112414	A/G	cg23795048	chr12:9217529	LOC144571	0.34	5.88	0.31	1.02e-8	Sjögren's syndrome;
LUSC	trans	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.17	-0.37	4.79e-12	Depression;
LUSC	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.73	11.25	0.52	4.16e-25	Fuchs's corneal dystrophy;
LUSC	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg08270630	chr22:50330655	NA	0.4	5.89	0.31	9.67e-9	Schizophrenia;
LUSC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg24675658	chr1:53192096	ZYG11B	0.73	12.09	0.55	3.83e-28	Monocyte count;
LUSC	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.46	-0.42	8.3e-16	Retinal vascular caliber;
LUSC	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.77	11.21	0.52	5.88e-25	Corneal astigmatism;
LUSC	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.64	9.32	0.45	1.59e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs1595825	0.891	rs16866940	chr2:198509058	C/T	cg19156104	chr2:198669113	PLCL1	-0.46	-5.78	-0.3	1.69e-8	Ulcerative colitis;
LUSC	cis	rs1124376	1.000	rs4417886	chr3:20108511	C/T	cg05072819	chr3:20081367	KAT2B	0.61	6.63	0.34	1.37e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.47	-5.97	-0.31	6.04e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg03465714	chr1:152285911	FLG	-0.36	-6.27	-0.32	1.13e-9	Inflammatory skin disease;
LUSC	cis	rs10276381	0.786	rs28430601	chr7:28238811	A/G	cg23620719	chr7:28220237	JAZF1	0.67	6.87	0.35	3.25e-11	Crohn's disease;
LUSC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26314531	chr2:26401878	FAM59B	-0.67	-9.12	-0.45	7.08e-18	Gut microbiome composition (summer);
LUSC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11645453	chr3:52864694	ITIH4	0.34	7.8	0.39	8.14e-14	Bipolar disorder;
LUSC	trans	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg03926050	chr12:111020225	PPTC7	0.4	6.4	0.33	5.3e-10	Schizophrenia (age at onset);
LUSC	trans	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg15556689	chr8:8085844	FLJ10661	0.55	7.97	0.4	2.54e-14	Retinal vascular caliber;
LUSC	trans	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.22	-0.32	1.5e-9	Parkinson's disease;
LUSC	trans	rs9929218	0.906	rs33965787	chr16:68828173	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-10.8	-0.51	1.57e-23	Colorectal cancer;
LUSC	cis	rs7523273	0.606	rs2724398	chr1:207993699	A/G	cg22525895	chr1:207977042	MIR29B2	-0.41	-6.56	-0.34	2.01e-10	Schizophrenia;
LUSC	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg26353448	chr1:248524236	OR2T4	-0.3	-5.66	-0.3	3.32e-8	Common traits (Other);
LUSC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02359409	chr6:42947317	PEX6	-0.37	-5.73	-0.3	2.22e-8	Alzheimer's disease in APOE e4+ carriers;
LUSC	trans	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.9	0.35	2.57e-11	Endometrial cancer;
LUSC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg06212747	chr3:49208901	KLHDC8B	0.43	5.79	0.3	1.65e-8	Parkinson's disease;
LUSC	cis	rs4780355	0.918	rs243318	chr16:11358018	G/A	cg00044050	chr16:11439710	C16orf75	0.57	8.55	0.42	4.38e-16	Crohn's disease and psoriasis;
LUSC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg18681998	chr4:17616180	MED28	0.86	15.71	0.65	4.78e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	cis	rs6912958	0.677	rs111990232	chr6:88022240	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	8.48	0.42	7.35e-16	Monocyte percentage of white cells;
LUSC	trans	rs429017	0.541	rs432902	chr5:41273953	A/G	cg17064250	chr6:45388500	RUNX2	0.32	6.15	0.32	2.23e-9	Blood protein levels;
LUSC	cis	rs7809950	0.678	rs62483640	chr7:106900214	T/G	cg23024343	chr7:107201750	COG5	-0.66	-10.02	-0.48	7.73e-21	Coronary artery disease;
LUSC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-8.32	-0.41	2.23e-15	Hemoglobin concentration;
LUSC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.98	-14.54	-0.62	1.92e-37	Initial pursuit acceleration;
LUSC	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg10911889	chr6:126070802	HEY2	0.43	6.62	0.34	1.47e-10	Brugada syndrome;
LUSC	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg14690467	chr7:148917905	ZNF282	-0.26	-5.7	-0.3	2.69e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg01483505	chr11:975446	AP2A2	0.42	5.89	0.31	9.68e-9	Alzheimer's disease (late onset);
LUSC	trans	rs225245	0.782	rs178649	chr17:33908197	C/G	cg19694781	chr19:47549865	TMEM160	-0.42	-6.65	-0.34	1.18e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LUSC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg16325326	chr1:53192061	ZYG11B	0.81	14.13	0.61	7.58e-36	Monocyte count;
LUSC	trans	rs4650994	0.544	rs2811306	chr1:178599248	C/G	cg05059571	chr16:84539110	KIAA1609	0.47	8.85	0.44	5.31e-17	HDL cholesterol levels;HDL cholesterol;
LUSC	cis	rs7834588	0.526	rs7008796	chr8:63866789	C/A	cg20602954	chr8:63776762	NKAIN3	0.37	5.67	0.3	3.07e-8	Response to Vitamin E supplementation;
LUSC	cis	rs6840360	0.539	rs1443087	chr4:152450095	C/A	cg20465933	chr4:152376761	FAM160A1	0.32	5.77	0.3	1.85e-8	Intelligence (multi-trait analysis);
LUSC	cis	rs9650315	0.514	rs13258040	chr8:57207208	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.71	0.39	1.44e-13	Height;
LUSC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg06815965	chr1:205818668	PM20D1	0.39	5.96	0.31	6.47e-9	Menarche (age at onset);
LUSC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.74	12.27	0.56	8.2e-29	Cognitive function;
LUSC	trans	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.72	-12.18	-0.55	1.65e-28	Platelet distribution width;
LUSC	cis	rs6723108	0.651	rs6724774	chr2:135407285	C/T	cg12500956	chr2:135428796	TMEM163	-0.27	-6.29	-0.33	9.76e-10	Type 2 diabetes;
LUSC	cis	rs59698941	0.943	rs57045911	chr5:132272311	T/C	cg02081065	chr5:132209139	LEAP2	-0.63	-6.35	-0.33	7.02e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg19622623	chr12:86230825	RASSF9	-0.41	-5.8	-0.3	1.51e-8	Major depressive disorder;
LUSC	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg13010199	chr12:38710504	ALG10B	0.48	7.4	0.38	1.13e-12	Morning vs. evening chronotype;
LUSC	cis	rs2932538	0.961	rs4838960	chr1:113163632	G/T	cg22162597	chr1:113214053	CAPZA1	-0.53	-7.56	-0.38	3.8e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LUSC	trans	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg10756647	chr7:56101905	PSPH	-0.95	-8.91	-0.44	3.32e-17	Diabetic kidney disease;
LUSC	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-0.85	-16.4	-0.67	9.02e-45	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	cis	rs11608355	0.521	rs6606706	chr12:109830173	C/T	cg19025524	chr12:109796872	NA	-0.4	-7.5	-0.38	6e-13	Neuroticism;
LUSC	trans	rs12637928	0.560	rs35372780	chr3:110154651	A/T	cg17371621	chr15:61264283	RORA	0.38	6.45	0.33	3.84e-10	Neuroticism;
LUSC	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg20219074	chr11:18656078	SPTY2D1	0.73	10.97	0.51	3.96e-24	Breast cancer;
LUSC	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg03676636	chr4:99064102	C4orf37	0.31	6.25	0.32	1.27e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-1.13	-17.93	-0.7	7.53e-51	Exhaled nitric oxide output;
LUSC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-1.24	-13.9	-0.61	5.54e-35	Diabetic kidney disease;
LUSC	cis	rs34638657	0.872	rs2967350	chr16:82196130	T/C	cg09439754	chr16:82129088	HSD17B2	-0.39	-6.36	-0.33	6.64e-10	Lung adenocarcinoma;
LUSC	cis	rs6714710	0.627	rs6748124	chr2:98519014	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	8.56	0.42	4.18e-16	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg22963979	chr7:1858916	MAD1L1	0.54	8.15	0.41	7.55e-15	Bipolar disorder and schizophrenia;
LUSC	trans	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg04995722	chr7:26192034	NFE2L3	-0.43	-6.59	-0.34	1.68e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg20203395	chr5:56204925	C5orf35	-0.45	-6.67	-0.34	1.09e-10	Coronary artery disease;
LUSC	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg05768032	chr16:30646687	NA	0.4	5.96	0.31	6.32e-9	Multiple myeloma;
LUSC	cis	rs6714710	0.603	rs10432626	chr2:98561153	C/A	cg26665480	chr2:98280029	ACTR1B	0.58	8.43	0.42	1.04e-15	Posterior cortical atrophy and Alzheimer's disease;
LUSC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg10729496	chr3:10149963	C3orf24	0.58	7.45	0.38	7.84e-13	Alzheimer's disease;
LUSC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19748678	chr4:122722346	EXOSC9	0.49	7.53	0.38	4.64e-13	Type 2 diabetes;
LUSC	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg16989719	chr2:238392110	NA	-0.36	-6.26	-0.32	1.16e-9	Prostate cancer;
LUSC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg06064525	chr11:970664	AP2A2	-0.49	-10.73	-0.51	2.85e-23	Alzheimer's disease (late onset);
LUSC	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-8.27	-0.41	3.22e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2692947	0.860	rs2579520	chr2:96660300	C/T	cg23100626	chr2:96804247	ASTL	-0.22	-5.67	-0.3	3.06e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	trans	rs2018683	0.624	rs2286219	chr7:28998663	G/A	cg19402173	chr7:128379420	CALU	-0.51	-7.55	-0.38	4.11e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LUSC	cis	rs17253792	0.822	rs2296181	chr14:56107051	G/A	cg01858014	chr14:56050164	KTN1	-0.84	-6.78	-0.35	5.6e-11	Putamen volume;
LUSC	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg14993813	chr1:46806288	NSUN4	-0.51	-7.01	-0.36	1.32e-11	Menopause (age at onset);
LUSC	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-8.0	-0.4	2.01e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs6495367	0.898	rs2049176	chr15:79392548	A/C	cg17916960	chr15:79447300	NA	0.41	7.64	0.39	2.38e-13	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.71	12.66	0.57	2.84e-30	Prudent dietary pattern;
LUSC	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg23093090	chr10:104574429	C10orf26	-0.45	-7.94	-0.4	3.09e-14	Arsenic metabolism;
LUSC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg04756594	chr16:24857601	SLC5A11	-0.49	-6.88	-0.35	2.92e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs6574644	1.000	rs28501387	chr14:81772667	G/A	cg01989461	chr14:81687754	GTF2A1	0.47	5.72	0.3	2.41e-8	Obesity-related traits;
LUSC	trans	rs2236293	0.755	rs10758324	chr9:35799078	C/G	cg11239633	chr3:37903682	CTDSPL	-0.36	-6.51	-0.34	2.8e-10	Blood protein levels;
LUSC	cis	rs4363385	0.818	rs678960	chr1:153011621	G/A	cg00922841	chr1:152955080	SPRR1A	-0.41	-7.21	-0.37	3.65e-12	Inflammatory skin disease;
LUSC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.62	8.23	0.41	4.34e-15	High light scatter reticulocyte count;
LUSC	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	6.82	0.35	4.18e-11	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.67	10.55	0.5	1.21e-22	Body mass index (adult);
LUSC	cis	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg07460842	chr6:66804631	NA	-0.73	-9.77	-0.47	5.46e-20	Blood trace element (Cu levels);
LUSC	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg01528321	chr10:82214614	TSPAN14	0.6	9.02	0.44	1.51e-17	Post bronchodilator FEV1;
LUSC	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg24006582	chr15:45444508	DUOX1	-0.6	-8.77	-0.43	9.28e-17	Uric acid levels;
LUSC	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg04352962	chr1:209979756	IRF6	0.55	6.3	0.33	9.18e-10	Cleft lip with or without cleft palate;
LUSC	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg10130564	chr11:117069849	TAGLN	0.31	5.8	0.3	1.58e-8	Blood protein levels;
LUSC	cis	rs4930561	0.765	rs7931502	chr11:67959607	A/C	cg16338278	chr11:67432957	ALDH3B2	-0.39	-6.87	-0.35	3.14e-11	Breast cancer in childhood cancer survivors;IgG glycosylation;
LUSC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg12963246	chr6:28129442	ZNF389	0.48	6.71	0.34	8.34e-11	Depression;
LUSC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	8.95	0.44	2.49e-17	Motion sickness;
LUSC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg20607798	chr8:58055168	NA	0.51	5.7	0.3	2.6e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg22535103	chr8:58192502	C8orf71	-0.79	-9.0	-0.44	1.69e-17	Developmental language disorder (linguistic errors);
LUSC	trans	rs1864729	1.000	rs2853312	chr8:98281319	T/C	cg08679828	chr8:102218111	ZNF706	-0.81	-7.39	-0.37	1.16e-12	Estradiol plasma levels (breast cancer);
LUSC	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06636551	chr8:101224915	SPAG1	-0.45	-8.26	-0.41	3.54e-15	Atrioventricular conduction;
LUSC	cis	rs6540559	0.673	rs7525951	chr1:210018306	C/T	cg23283495	chr1:209979779	IRF6	-0.63	-7.71	-0.39	1.49e-13	Cleft lip with or without cleft palate;
LUSC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg23490090	chr17:78081364	GAA	0.36	5.67	0.3	3.16e-8	Yeast infection;
LUSC	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg17173187	chr15:85201210	NMB	0.4	6.53	0.34	2.43e-10	Schizophrenia;
LUSC	cis	rs934734	0.563	rs955903	chr2:65575553	A/G	cg08085232	chr2:65598271	SPRED2	-0.43	-6.73	-0.35	7.36e-11	Rheumatoid arthritis;
LUSC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg09877947	chr5:131593287	PDLIM4	0.45	7.08	0.36	8.79e-12	Breast cancer;
LUSC	cis	rs4947962	0.585	rs17172440	chr7:55156010	G/T	cg23757825	chr7:55092271	EGFR	-0.46	-5.67	-0.3	3.08e-8	Subjective response to lithium treatment;
LUSC	cis	rs13064411	0.696	rs6786974	chr3:113190149	T/A	cg18753928	chr3:113234510	CCDC52	-0.51	-7.65	-0.39	2.1e-13	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-8.94	-0.44	2.7e-17	Total cholesterol levels;
LUSC	cis	rs4919687	0.550	rs7907503	chr10:104440050	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.0	-0.31	5.27e-9	Colorectal cancer;
LUSC	cis	rs4363385	0.510	rs11488175	chr1:153039778	A/G	cg25856811	chr1:152973957	SPRR3	0.35	5.85	0.3	1.17e-8	Inflammatory skin disease;
LUSC	cis	rs9815354	0.812	rs17283243	chr3:41914792	C/T	cg03022575	chr3:42003672	ULK4	0.83	8.67	0.43	1.88e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg02466173	chr16:30829666	NA	-0.6	-11.0	-0.52	3.27e-24	Multiple myeloma;
LUSC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg18512352	chr11:47633146	NA	0.47	9.53	0.46	3.24e-19	Subjective well-being;
LUSC	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg08048268	chr3:133502702	NA	0.35	6.37	0.33	6.28e-10	Alcohol consumption (transferrin glycosylation);
LUSC	cis	rs6076065	0.676	rs6083084	chr20:23335582	A/G	cg11657817	chr20:23433608	CST11	-0.46	-8.52	-0.42	5.39e-16	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs6484504	0.817	rs67707190	chr11:31210500	A/G	cg26647111	chr11:31128758	NA	-0.45	-5.83	-0.3	1.3e-8	Red blood cell count;
LUSC	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	8.44	0.42	9.83e-16	Menarche (age at onset);
LUSC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg20203395	chr5:56204925	C5orf35	-0.74	-10.17	-0.49	2.47e-21	Initial pursuit acceleration;
LUSC	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.78	11.26	0.52	3.82e-25	Corneal astigmatism;
LUSC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg01657329	chr11:68192670	LRP5	-0.44	-6.52	-0.34	2.57e-10	Total body bone mineral density;
LUSC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg12463550	chr7:65579703	CRCP	0.52	7.58	0.38	3.51e-13	Aortic root size;
LUSC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg00031303	chr3:195681400	NA	0.7	10.07	0.48	5.22e-21	Pancreatic cancer;
LUSC	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-6.05	-0.31	3.92e-9	Huntington's disease progression;
LUSC	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-9.46	-0.46	5.87e-19	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg23029597	chr12:123009494	RSRC2	-0.69	-9.04	-0.44	1.26e-17	Body mass index;
LUSC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg22166914	chr1:53195759	ZYG11B	0.6	10.15	0.49	2.86e-21	Monocyte count;
LUSC	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-0.56	-9.06	-0.44	1.13e-17	Breast cancer;
LUSC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg16240275	chr20:61666158	NCRNA00029	0.42	9.24	0.45	2.9e-18	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.47	6.45	0.33	4.01e-10	Corneal astigmatism;
LUSC	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg24579218	chr15:68104479	NA	-0.38	-6.55	-0.34	2.21e-10	Obesity;
LUSC	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-13.67	-0.6	4.42e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.78	16.08	0.66	1.78e-43	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	11.89	0.55	2.04e-27	Personality dimensions;
LUSC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	1.03	17.93	0.7	7.68e-51	Parkinson's disease;
LUSC	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg17470723	chr8:74884337	TCEB1	0.53	8.24	0.41	4.02e-15	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	1.08	17.87	0.7	1.37e-50	Coffee consumption;Coffee consumption (cups per day);
LUSC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg04287289	chr16:89883240	FANCA	0.79	13.99	0.61	2.45e-35	Vitiligo;
LUSC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.65	11.17	0.52	7.64e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7615316	0.934	rs2227930	chr3:142277575	A/T	cg16271453	chr3:142027066	XRN1	-0.37	-6.39	-0.33	5.59e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9420	0.961	rs12807250	chr11:57600285	C/T	cg02958346	chr11:57425731	CLP1	-0.44	-6.31	-0.33	8.67e-10	Schizophrenia;
LUSC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.83	-0.54	3.21e-27	Type 2 diabetes;
LUSC	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg04865166	chr7:105162814	PUS7	0.51	5.73	0.3	2.27e-8	Bipolar disorder (body mass index interaction);
LUSC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg18240062	chr17:79603768	NPLOC4	0.7	12.82	0.57	7.47e-31	Eye color traits;
LUSC	cis	rs295137	0.798	rs295142	chr2:201211716	C/T	cg23649088	chr2:200775458	C2orf69	-0.39	-6.02	-0.31	4.72e-9	Asthma (bronchodilator response);
LUSC	cis	rs73198271	0.515	rs76620708	chr8:8619083	C/T	cg01851573	chr8:8652454	MFHAS1	0.63	7.22	0.37	3.47e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs3125734	0.633	rs4979774	chr10:63967795	A/T	cg09941381	chr10:64027924	RTKN2	-0.38	-7.14	-0.36	6.02e-12	Rheumatoid arthritis;
LUSC	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg23750338	chr8:142222470	SLC45A4	0.58	11.26	0.52	3.76e-25	Immature fraction of reticulocytes;
LUSC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg27165867	chr14:105738592	BRF1	-0.53	-7.76	-0.39	1.06e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.03	20.38	0.74	1.47e-60	Cognitive function;
LUSC	cis	rs722599	0.562	rs2287400	chr14:75182937	G/A	cg08847533	chr14:75593920	NEK9	0.43	6.27	0.32	1.09e-9	IgG glycosylation;
LUSC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.21	-0.37	3.87e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs7560272	0.723	rs1052161	chr2:73828538	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.18	-0.37	4.58e-12	Schizophrenia;
LUSC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08736216	chr1:53307985	ZYG11A	-0.28	-5.83	-0.3	1.33e-8	Monocyte count;
LUSC	cis	rs911119	1.000	rs13038305	chr20:23610262	C/T	cg16589663	chr20:23618590	CST3	0.59	6.95	0.36	1.88e-11	Chronic kidney disease;
LUSC	cis	rs3784262	1.000	rs4369598	chr15:58318603	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-5.98	-0.31	5.59e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LUSC	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	9.48	0.46	4.84e-19	Bipolar disorder;
LUSC	cis	rs35995292	0.963	rs2392609	chr7:38952595	C/T	cg19327137	chr7:38886074	VPS41	0.37	6.04	0.31	4.14e-9	Subjective well-being (multi-trait analysis);
LUSC	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.72	0.43	1.33e-16	Menopause (age at onset);
LUSC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg05802129	chr4:122689817	NA	-0.5	-8.12	-0.41	9.17e-15	Type 2 diabetes;
LUSC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08704250	chr15:31115839	NA	-0.47	-6.94	-0.35	2.08e-11	Huntington's disease progression;
LUSC	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-8.19	-0.41	5.44e-15	Neuroticism;
LUSC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	1.04	19.44	0.73	7.67e-57	Menopause (age at onset);
LUSC	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg26384229	chr12:38710491	ALG10B	-0.56	-8.39	-0.42	1.4e-15	Drug-induced liver injury (flucloxacillin);
LUSC	trans	rs9392918	0.967	rs9405351	chr6:7712582	A/G	cg12631351	chr5:80256738	RASGRF2	0.37	6.35	0.33	7.11e-10	Height;
LUSC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg13560548	chr3:10150139	C3orf24	0.47	6.6	0.34	1.58e-10	Alzheimer's disease;
LUSC	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23248424	chr5:179741104	GFPT2	-0.48	-7.26	-0.37	2.8e-12	Height;
LUSC	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg17127132	chr2:85788382	GGCX	0.47	7.45	0.38	8.14e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg23202291	chr11:1979235	NA	0.39	6.04	0.31	4.01e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs2279817	0.735	rs75044419	chr1:18008241	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.5	-6.13	-0.32	2.54e-9	Neuroticism;
LUSC	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.67	-9.15	-0.45	5.86e-18	Schizophrenia;
LUSC	cis	rs751728	0.664	rs9394167	chr6:33754396	A/G	cg25922239	chr6:33757077	LEMD2	0.42	6.37	0.33	6.27e-10	Crohn's disease;
LUSC	cis	rs4690686	0.554	rs13141274	chr4:177285027	C/T	cg17059388	chr4:177262070	NA	0.31	6.2	0.32	1.67e-9	Essential tremor;
LUSC	cis	rs2734839	0.964	rs2587548	chr11:113292212	G/C	cg14159747	chr11:113255604	NA	0.23	5.78	0.3	1.69e-8	Information processing speed;
LUSC	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg05855489	chr10:104503620	C10orf26	-0.71	-11.55	-0.53	3.32e-26	Waist circumference;Hip circumference;
LUSC	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg00999904	chr2:3704751	ALLC	-0.33	-5.9	-0.31	8.91e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg24375607	chr4:120327624	NA	0.77	11.43	0.53	9.27e-26	Corneal astigmatism;
LUSC	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-7.13	-0.36	6.36e-12	Homocysteine levels;
LUSC	trans	rs2926702	0.810	rs726285	chr8:71071187	A/C	cg16517358	chr11:46164796	NA	-0.37	-5.98	-0.31	5.84e-9	Non-small cell lung cancer;
LUSC	cis	rs500891	0.570	rs13208458	chr6:84093204	C/A	cg08257003	chr6:84140564	ME1	0.32	7.29	0.37	2.29e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg23711669	chr6:146136114	FBXO30	0.86	16.1	0.66	1.47e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	1.07	18.35	0.71	1.71e-52	Parkinson's disease;
LUSC	cis	rs977987	0.806	rs11643410	chr16:75428306	C/T	cg03315344	chr16:75512273	CHST6	0.49	9.2	0.45	3.88e-18	Dupuytren's disease;
LUSC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08045932	chr20:61659980	NA	0.58	10.25	0.49	1.33e-21	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg02807482	chr3:125708958	NA	-0.51	-6.33	-0.33	8.01e-10	Blood pressure (smoking interaction);
LUSC	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg02167203	chr6:41068553	NFYA;LOC221442	0.42	5.93	0.31	7.38e-9	Alzheimer's disease (late onset);
LUSC	cis	rs12410462	0.581	rs4329477	chr1:227552494	A/G	cg23173402	chr1:227635558	NA	-0.53	-6.55	-0.34	2.21e-10	Major depressive disorder;
LUSC	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg27411982	chr8:10470053	RP1L1	0.42	6.58	0.34	1.78e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
LUSC	cis	rs3736594	0.546	rs965813	chr2:27789861	T/A	cg27432699	chr2:27873401	GPN1	0.66	8.89	0.44	4.02e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LUSC	cis	rs3771570	0.901	rs55764424	chr2:242407467	C/T	cg21155796	chr2:242212141	HDLBP	0.54	6.26	0.32	1.2e-9	Prostate cancer;
LUSC	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	8.55	0.42	4.46e-16	Response to antipsychotic treatment;
LUSC	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg15309053	chr8:964076	NA	0.42	8.42	0.42	1.11e-15	Schizophrenia;
LUSC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10802521	chr3:52805072	NEK4	-0.54	-8.63	-0.43	2.6e-16	Bipolar disorder;
LUSC	cis	rs8092503	1.000	rs6566871	chr18:52475904	T/C	cg12377874	chr18:52495404	RAB27B	-0.32	-5.65	-0.3	3.43e-8	Childhood body mass index;
LUSC	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg21231944	chr12:82153410	PPFIA2	-0.38	-5.88	-0.31	9.83e-9	Resting heart rate;
LUSC	cis	rs2219968	0.961	rs2200014	chr8:78956394	A/T	cg00738934	chr8:78996279	NA	-0.33	-6.0	-0.31	5.1e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg20713898	chr8:124780851	FAM91A1	-0.55	-7.61	-0.38	2.87e-13	Pancreatic cancer;
LUSC	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg18854424	chr1:2615690	NA	0.47	9.77	0.47	5.59e-20	Ulcerative colitis;
LUSC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg00310523	chr12:86230176	RASSF9	0.53	9.79	0.47	4.69e-20	Major depressive disorder;
LUSC	cis	rs10843647	0.967	rs1948033	chr12:30329005	T/C	cg12718339	chr12:29936407	TMTC1	-0.35	-5.87	-0.31	1.07e-8	Glucose homeostasis traits;
LUSC	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg15485101	chr11:133734466	NA	0.39	7.28	0.37	2.35e-12	Childhood ear infection;
LUSC	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg06197492	chr11:2016605	H19	0.42	6.94	0.35	2.08e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LUSC	cis	rs2742417	1.000	rs938363	chr3:45746364	T/G	cg09608765	chr3:45636137	LIMD1	-0.38	-7.51	-0.38	5.48e-13	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs2219968	0.700	rs10088166	chr8:78867175	T/C	cg00738934	chr8:78996279	NA	-0.36	-6.1	-0.32	3.01e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg21724239	chr8:58056113	NA	0.6	6.93	0.35	2.19e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs7113850	0.541	rs74708033	chr11:24223512	C/T	ch.11.24196551F	chr11:24239977	NA	0.99	9.06	0.44	1.09e-17	Bone fracture in osteoporosis;
LUSC	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg03647239	chr10:116582469	FAM160B1	0.45	7.13	0.36	6.13e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg05855489	chr10:104503620	C10orf26	-0.48	-7.35	-0.37	1.53e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.7	12.45	0.56	1.71e-29	Diastolic blood pressure;
LUSC	cis	rs12824058	0.737	rs873663	chr12:130816316	C/T	cg26677194	chr12:130822605	PIWIL1	0.59	8.45	0.42	8.85e-16	Menopause (age at onset);
LUSC	cis	rs7312774	0.618	rs4964510	chr12:107357251	A/G	cg16260113	chr12:107380972	MTERFD3	0.97	7.2	0.37	4.04e-12	Severe influenza A (H1N1) infection;
LUSC	cis	rs116988415	0.584	rs1875054	chr14:65255066	G/A	cg25083366	chr14:65239357	SPTB	0.65	6.69	0.34	9.18e-11	Daytime sleep phenotypes;
LUSC	cis	rs9473147	0.516	rs9395283	chr6:47551444	T/C	cg20196966	chr6:47445060	CD2AP	0.42	5.91	0.31	8.6e-9	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg11494091	chr17:61959527	GH2	0.38	6.56	0.34	2.1e-10	Height;
LUSC	cis	rs2652834	0.861	rs4774472	chr15:63353760	C/A	cg05507819	chr15:63340323	TPM1	0.71	9.19	0.45	4.19e-18	HDL cholesterol;
LUSC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-7.36	-0.37	1.47e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.43	-6.04	-0.31	4.15e-9	IgG glycosylation;
LUSC	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg18753928	chr3:113234510	CCDC52	-0.54	-8.23	-0.41	4.16e-15	Response to simvastatin treatment (PCSK9 protein level change);
LUSC	cis	rs17597773	0.527	rs2484699	chr1:221083752	C/T	cg16008148	chr1:221062819	NA	0.42	8.1	0.41	1.02e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.5	8.23	0.41	4.21e-15	Immature fraction of reticulocytes;
LUSC	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg00990874	chr7:1149470	C7orf50	-0.49	-5.75	-0.3	2.05e-8	Bronchopulmonary dysplasia;
LUSC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg23711669	chr6:146136114	FBXO30	0.88	16.1	0.66	1.48e-43	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs62400317	0.893	rs62436782	chr6:45143118	T/A	cg18551225	chr6:44695536	NA	-0.42	-6.96	-0.36	1.84e-11	Total body bone mineral density;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg06527865	chr1:234746497	IRF2BP2	0.39	6.02	0.31	4.65e-9	Triglycerides;
LUSC	cis	rs9815354	1.000	rs9824731	chr3:41889698	G/T	cg03022575	chr3:42003672	ULK4	0.63	6.85	0.35	3.49e-11	Pulse pressure;Diastolic blood pressure;
LUSC	trans	rs6773957	1.000	rs1063538	chr3:186574183	T/C	cg01963189	chr4:121613795	NA	-0.33	-6.07	-0.32	3.48e-9	Adiponectin levels;
LUSC	cis	rs71386933	0.543	rs36114735	chr16:72017683	C/T	cg08717414	chr16:71523259	ZNF19	-0.69	-5.87	-0.31	1.05e-8	Post bronchodilator FEV1;
LUSC	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg06671706	chr8:8559999	CLDN23	0.51	6.63	0.34	1.3100000000000001e-10	Obesity-related traits;
LUSC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.36	0.59	6.67e-33	Cognitive test performance;
LUSC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg07952391	chr2:88470173	THNSL2	0.76	6.71	0.34	8.32e-11	Plasma clusterin levels;
LUSC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	16.21	0.66	5.15e-44	Platelet count;
LUSC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg20203395	chr5:56204925	C5orf35	-0.74	-9.97	-0.48	1.14e-20	Initial pursuit acceleration;
LUSC	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg23093090	chr10:104574429	C10orf26	-0.37	-7.06	-0.36	9.95e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs1775715	0.677	rs2799034	chr10:32175896	A/G	cg18675610	chr10:32216311	ARHGAP12	0.3	6.65	0.34	1.19e-10	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg05729581	chr11:3078854	CARS	-0.53	-8.18	-0.41	5.98e-15	Longevity;
LUSC	cis	rs4423214	0.879	rs1792283	chr11:71135136	T/C	cg05163923	chr11:71159392	DHCR7	-0.66	-8.63	-0.43	2.56e-16	Vitamin D levels;
LUSC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-19.2	-0.72	6.74e-56	Height;
LUSC	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg19622623	chr12:86230825	RASSF9	-0.43	-6.18	-0.32	1.86e-9	Major depressive disorder;
LUSC	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.62	-0.38	2.67e-13	Type 2 diabetes;
LUSC	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg12564285	chr5:131593104	PDLIM4	0.35	6.3	0.33	9.49e-10	Blood metabolite levels;
LUSC	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg24881330	chr22:46731750	TRMU	0.87	7.07	0.36	8.96e-12	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs679087	0.606	rs167318	chr12:29943124	T/C	cg14258853	chr12:29935411	TMTC1	-0.64	-7.81	-0.39	7.64e-14	Schizophrenia;
LUSC	cis	rs7113850	0.541	rs74832028	chr11:24232359	A/T	ch.11.24196551F	chr11:24239977	NA	1.0	9.14	0.45	6e-18	Bone fracture in osteoporosis;
LUSC	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg01858014	chr14:56050164	KTN1	-0.89	-7.33	-0.37	1.76e-12	Putamen volume;
LUSC	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg00071950	chr4:10020882	SLC2A9	-0.51	-8.41	-0.42	1.23e-15	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs1014246	0.541	rs2011695	chr10:118507219	A/C	cg14919929	chr10:118506882	NA	-0.48	-7.97	-0.4	2.55e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg14702927	chr19:46366445	FOXA3;SYMPK	-0.47	-5.99	-0.31	5.42e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13126279	chr21:47581558	C21orf56	0.47	7.05	0.36	1e-11	Testicular germ cell tumor;
LUSC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.72	12.12	0.55	2.79e-28	Motion sickness;
LUSC	cis	rs2455601	1.000	rs2455601	chr11:8899400	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.95	-0.36	1.98e-11	Schizophrenia;
LUSC	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg06606381	chr12:133084897	FBRSL1	-0.94	-8.61	-0.43	2.86e-16	Breast cancer;
LUSC	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg23093090	chr10:104574429	C10orf26	-0.37	-6.94	-0.35	2.06e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs9309473	0.607	rs6720094	chr2:73588076	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-7.47	-0.38	7.23e-13	Metabolite levels;
LUSC	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg00677455	chr12:58241039	CTDSP2	0.71	11.07	0.52	1.83e-24	Intelligence (multi-trait analysis);
LUSC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg02487422	chr3:49467188	NICN1	0.45	7.08	0.36	8.66e-12	Resting heart rate;
LUSC	cis	rs1557765	0.527	rs4756887	chr11:17394597	T/G	cg15432903	chr11:17409602	KCNJ11	0.43	7.6	0.38	2.96e-13	Body mass index;Social communication problems;
LUSC	trans	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg17712092	chr4:129076599	LARP1B	0.57	6.82	0.35	4.24e-11	Glomerular filtration rate (creatinine);Chronic kidney disease;
LUSC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg11764359	chr7:65958608	NA	-0.53	-7.03	-0.36	1.18e-11	Aortic root size;
LUSC	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg13010199	chr12:38710504	ALG10B	0.67	10.23	0.49	1.56e-21	Bladder cancer;
LUSC	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-0.56	-9.0	-0.44	1.74e-17	Breast cancer;
LUSC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg05347473	chr6:146136440	FBXO30	-0.58	-9.74	-0.47	6.76e-20	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21963583	chr11:68658836	MRPL21	0.56	8.33	0.41	2.15e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg00310523	chr12:86230176	RASSF9	-0.35	-6.35	-0.33	6.92e-10	Major depressive disorder;
LUSC	cis	rs1403694	0.515	rs1624569	chr3:186450069	A/G	cg12454167	chr3:186435060	KNG1	0.28	7.38	0.37	1.25e-12	Blood protein levels;
LUSC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg24881330	chr22:46731750	TRMU	0.88	8.84	0.44	5.52e-17	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg00149659	chr3:10157352	C3orf10	0.62	8.93	0.44	2.82e-17	Alzheimer's disease;
LUSC	cis	rs11871801	0.517	rs665268	chr17:40722029	A/G	cg16308533	chr17:40838983	CNTNAP1	0.4	5.88	0.31	1e-8	Crohn's disease;
LUSC	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg22482690	chr17:47019901	SNF8	0.4	7.53	0.38	4.81e-13	Type 2 diabetes;
LUSC	cis	rs77633900	0.614	rs1443110	chr15:76928322	C/T	cg21673338	chr15:77095150	SCAPER	0.74	7.41	0.38	1.06e-12	Non-glioblastoma glioma;Glioma;
LUSC	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	ch.11.42038R	chr11:967971	AP2A2	0.47	6.99	0.36	1.49e-11	Alzheimer's disease (late onset);
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00679716	chr14:23067188	ABHD4	-0.45	-6.09	-0.32	3.05e-9	Hepatitis;
LUSC	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg14809332	chr8:144654887	C8orf73	0.54	6.53	0.34	2.41e-10	Attention deficit hyperactivity disorder;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg00929878	chr9:95087334	NOL8;CENPP	0.46	7.5	0.38	5.68e-13	Triglycerides;
LUSC	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	0.99	17.86	0.7	1.52e-50	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LUSC	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg00484396	chr16:3507460	NAT15	0.69	12.06	0.55	4.78e-28	Tuberculosis;
LUSC	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.82	-13.55	-0.6	1.28e-33	Morning vs. evening chronotype;
LUSC	cis	rs3812762	0.879	rs10743088	chr11:8787620	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.38	6.62	0.34	1.42e-10	Hypospadias;
LUSC	cis	rs77216612	0.877	rs66561220	chr12:12878765	T/C	cg04607235	chr12:12878440	APOLD1	-0.96	-15.77	-0.65	2.85e-42	Lymphocyte counts;
LUSC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg26441486	chr22:50317300	CRELD2	0.48	7.17	0.37	4.93e-12	Schizophrenia;
LUSC	trans	rs877282	0.583	rs12358255	chr10:828626	C/T	cg22713356	chr15:30763199	NA	0.78	9.99	0.48	9.81e-21	Uric acid levels;
LUSC	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.35	-7.49	-0.38	6.15e-13	Hemoglobin concentration;
LUSC	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg15704280	chr7:45808275	SEPT13	-0.57	-7.07	-0.36	8.93e-12	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	0.87	11.66	0.54	1.4e-26	Eosinophil percentage of granulocytes;
LUSC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	0.92	13.16	0.58	3.76e-32	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7264396	0.887	rs4911510	chr20:34093153	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-6.39	-0.33	5.72e-10	Total cholesterol levels;
LUSC	cis	rs73206853	0.764	rs3026468	chr12:110758081	T/A	cg12870014	chr12:110450643	ANKRD13A	0.68	6.44	0.33	4.21e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	8.16	0.41	6.81e-15	Coronary artery disease;
LUSC	cis	rs2354432	0.607	rs7545467	chr1:146746248	A/G	cg25205988	chr1:146714368	CHD1L	-0.99	-9.33	-0.45	1.49e-18	Mitochondrial DNA levels;
LUSC	cis	rs4946717	0.716	rs4478446	chr6:106472120	T/A	cg02270332	chr6:106475062	NA	0.46	9.45	0.46	6.05e-19	Inflammatory bowel disease;
LUSC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg01483505	chr11:975446	AP2A2	0.42	5.9	0.31	9.15e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18099408	chr3:52552593	STAB1	-0.41	-7.03	-0.36	1.2e-11	Bipolar disorder;
LUSC	cis	rs9400467	0.528	rs4276544	chr6:111759699	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.36	-6.73	-0.35	7.4e-11	Blood metabolite levels;Amino acid levels;
LUSC	cis	rs1044826	0.623	rs4383548	chr3:139040515	C/T	cg00490450	chr3:139108681	COPB2	0.53	6.6	0.34	1.6e-10	Obesity-related traits;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02567981	chr12:50101354	FMNL3	0.5	7.37	0.37	1.36e-12	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs7939886	0.764	rs79601668	chr11:55753767	G/C	cg03929089	chr4:120376271	NA	0.79	6.5	0.34	2.94e-10	Myopia (pathological);
LUSC	cis	rs113835537	0.559	rs11227498	chr11:66269714	A/G	cg24851651	chr11:66362959	CCS	0.54	8.06	0.4	1.38e-14	Airway imaging phenotypes;
LUSC	cis	rs11577318	0.537	rs12030833	chr1:26689220	A/G	cg00852783	chr1:26633632	UBXN11	-0.53	-7.33	-0.37	1.78e-12	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg07148914	chr20:33460835	GGT7	0.53	8.16	0.41	7.08e-15	Height;
LUSC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.66	11.29	0.53	2.88e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs4253772	0.938	rs41371446	chr22:46637272	T/C	cg18190219	chr22:46762943	CELSR1	-0.51	-5.92	-0.31	7.92e-9	LDL cholesterol;Cholesterol, total;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08181751	chr6:24646551	KIAA0319	0.45	6.05	0.31	3.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg27124370	chr19:33622961	WDR88	0.57	7.46	0.38	7.64e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg04398451	chr17:18023971	MYO15A	-0.54	-9.06	-0.44	1.13e-17	Total body bone mineral density;
LUSC	cis	rs11039100	1.000	rs11039110	chr11:5829111	A/G	cg05234568	chr11:5960015	NA	-0.5	-5.7	-0.3	2.64e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg22709100	chr7:91322751	NA	-0.38	-5.72	-0.3	2.37e-8	Breast cancer;
LUSC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg06001716	chr17:41278141	BRCA1;NBR2	0.41	6.55	0.34	2.2e-10	Menopause (age at onset);
LUSC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg09491104	chr22:46646882	C22orf40	-0.64	-7.45	-0.38	8e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg03983476	chr2:10830698	NOL10	-0.38	-5.76	-0.3	1.88e-8	Prostate cancer;
LUSC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg22834771	chr12:69754056	YEATS4	-0.49	-7.37	-0.37	1.31e-12	Blood protein levels;
LUSC	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.07	13.25	0.59	1.75e-32	Lung cancer in ever smokers;
LUSC	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg26384229	chr12:38710491	ALG10B	-0.55	-8.19	-0.41	5.5e-15	Drug-induced liver injury (flucloxacillin);
LUSC	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg22782873	chr19:19639568	YJEFN3	-0.53	-6.17	-0.32	1.95e-9	Bipolar disorder;
LUSC	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.77	11.04	0.52	2.25e-24	Corneal astigmatism;
LUSC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	0.64	13.79	0.6	1.46e-34	Prudent dietary pattern;
LUSC	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg24503407	chr1:205819492	PM20D1	0.48	6.91	0.35	2.5e-11	Menarche (age at onset);
LUSC	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg13390004	chr1:15929781	NA	0.42	7.0	0.36	1.43e-11	Systolic blood pressure;
LUSC	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg18850127	chr7:39170497	POU6F2	0.41	5.98	0.31	5.62e-9	IgG glycosylation;
LUSC	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg24556660	chr7:106842632	COG5;HBP1	-0.43	-5.83	-0.3	1.29e-8	Coronary artery disease;
LUSC	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg09491104	chr22:46646882	C22orf40	-0.72	-7.44	-0.38	8.4e-13	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs2652834	1.000	rs2729783	chr15:63403316	C/T	cg05507819	chr15:63340323	TPM1	0.54	6.38	0.33	5.82e-10	HDL cholesterol;
LUSC	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-12.24	-0.56	1.05e-28	Chronic sinus infection;
LUSC	cis	rs4629710	0.563	rs9483238	chr6:131567196	A/T	cg12700074	chr6:131571435	AKAP7	-0.35	-5.85	-0.31	1.15e-8	Multiple myeloma (IgH translocation);
LUSC	cis	rs1030877	1.000	rs2576737	chr2:105891510	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.78	14.95	0.63	4.61e-39	Obesity-related traits;
LUSC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg11645453	chr3:52864694	ITIH4	0.36	7.92	0.4	3.64e-14	Bipolar disorder;
LUSC	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg08355456	chr11:67383691	NA	-0.32	-5.91	-0.31	8.51e-9	Mean corpuscular volume;
LUSC	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	cis	rs75920871	0.528	rs7108912	chr11:116925996	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-6.42	-0.33	4.69e-10	Subjective well-being;
LUSC	trans	rs9341835	0.511	rs1744146	chr6:64221869	A/C	cg19533977	chr17:57719682	CLTC	0.33	6.07	0.32	3.53e-9	Schizophrenia;
LUSC	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	0.88	13.86	0.6	7.72e-35	Blood protein levels;
LUSC	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg11062466	chr8:58055876	NA	0.57	7.22	0.37	3.61e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg03676636	chr4:99064102	C4orf37	0.35	7.85	0.39	5.8e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg03609598	chr5:56110824	MAP3K1	-0.39	-5.88	-0.31	1.01e-8	Initial pursuit acceleration;
LUSC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.29	-7.38	-0.37	1.27e-12	Lymphocyte counts;
LUSC	cis	rs713477	1.000	rs12887846	chr14:55911139	T/C	cg13175173	chr14:55914753	NA	-0.32	-6.74	-0.35	7.01e-11	Pediatric bone mineral content (femoral neck);
LUSC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	20.8	0.75	3.31e-62	Prudent dietary pattern;
LUSC	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21643547	chr1:205240462	TMCC2	-0.5	-9.45	-0.46	6e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20600053	chr18:56806937	SEC11C	0.41	6.04	0.31	4.14e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-7.4	-0.38	1.13e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.76	11.3	0.53	2.82e-25	Corneal astigmatism;
LUSC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08280861	chr8:58055591	NA	0.55	6.49	0.33	3.02e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg13010344	chr12:123464640	ARL6IP4	-0.5	-7.55	-0.38	4.09e-13	Height;Educational attainment;Head circumference (infant);
LUSC	cis	rs9462027	0.628	rs9462019	chr6:34748730	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.33	-5.86	-0.31	1.1e-8	Systemic lupus erythematosus;
LUSC	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg00857998	chr1:205179979	DSTYK	0.64	10.09	0.48	4.63e-21	Red blood cell count;
LUSC	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg26384229	chr12:38710491	ALG10B	0.49	7.03	0.36	1.14e-11	Morning vs. evening chronotype;
LUSC	cis	rs7599312	0.532	rs7564590	chr2:213387900	C/T	cg16329650	chr2:213403929	ERBB4	0.48	7.1	0.36	7.54e-12	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg24375607	chr4:120327624	NA	0.76	12.17	0.55	1.85e-28	Corneal astigmatism;
LUSC	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg25124228	chr12:125621409	AACS	-0.58	-9.55	-0.46	2.95e-19	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	cis	rs13242816	1.000	rs62471202	chr7:116112562	G/A	cg16553024	chr7:116138462	CAV2	-0.52	-5.71	-0.3	2.44e-8	P wave duration;
LUSC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-6.46	-0.33	3.76e-10	Aortic root size;
LUSC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08219700	chr8:58056026	NA	0.65	7.17	0.37	4.83e-12	Developmental language disorder (linguistic errors);
LUSC	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg20701182	chr2:24300061	SF3B14	0.73	7.39	0.37	1.2e-12	Lymphocyte counts;
LUSC	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg24579218	chr15:68104479	NA	-0.41	-6.49	-0.33	3.09e-10	Restless legs syndrome;
LUSC	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-9.26	-0.45	2.59e-18	Cleft plate (environmental tobacco smoke interaction);
LUSC	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg22823121	chr1:150693482	HORMAD1	-0.51	-7.56	-0.38	3.98e-13	Melanoma;
LUSC	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	cis	rs9395066	0.545	rs4711805	chr6:44870102	T/C	cg25276700	chr6:44698697	NA	0.3	5.96	0.31	6.26e-9	Height;
LUSC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03264133	chr6:25882463	NA	-0.44	-7.61	-0.38	2.76e-13	Blood metabolite levels;
LUSC	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg22709100	chr7:91322751	NA	0.39	5.73	0.3	2.27e-8	Breast cancer;
LUSC	cis	rs259282	0.538	rs8100917	chr19:33114702	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.68	10.0	0.48	8.82e-21	Schizophrenia;
LUSC	trans	rs4605213	0.528	rs12951858	chr17:49328627	C/G	cg26211529	chr7:79554138	NA	0.32	6.06	0.31	3.58e-9	Height;
LUSC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg06134567	chr22:46658398	PKDREJ	-0.46	-5.65	-0.3	3.44e-8	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg06096015	chr1:231504339	EGLN1	0.56	10.0	0.48	9.18e-21	Hemoglobin concentration;
LUSC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg02221750	chr19:17393354	ANKLE1	0.9	14.42	0.62	5.31e-37	Systemic lupus erythematosus;
LUSC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg25204440	chr1:209979598	IRF6	0.51	6.73	0.35	7.43e-11	Cleft lip with or without cleft palate;
LUSC	cis	rs9837602	1.000	rs7616988	chr3:99701134	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-6.22	-0.32	1.47e-9	Breast cancer;
LUSC	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-8.04	-0.4	1.62e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs4700695	0.719	rs27077	chr5:65445342	C/T	cg21114390	chr5:65439923	SFRS12	0.62	9.31	0.45	1.78e-18	Facial morphology (factor 19);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg01867433	chr22:38966164	DMC1	-0.39	-6.11	-0.32	2.71e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg19875535	chr5:140030758	IK	0.5	8.24	0.41	3.98e-15	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs62103177	0.564	rs3930042	chr18:77723843	G/A	cg14227996	chr4:17616232	MED28	0.64	6.85	0.35	3.62e-11	Opioid sensitivity;
LUSC	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg03676636	chr4:99064102	C4orf37	0.36	7.85	0.39	5.64e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1178968	0.591	rs10440929	chr7:72786770	A/C	cg25889504	chr7:72793014	NA	0.61	7.85	0.39	5.62e-14	Triglyceride levels;
LUSC	cis	rs8038465	0.615	rs11637315	chr15:73944068	G/C	cg15420318	chr15:73925796	NPTN	0.6	10.26	0.49	1.16e-21	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs68170813	0.641	rs12538848	chr7:106984569	G/T	cg02696742	chr7:106810147	HBP1	-0.6	-9.08	-0.45	9.51e-18	Coronary artery disease;
LUSC	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.41	-0.38	1.04e-12	Morning vs. evening chronotype;
LUSC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg20608306	chr11:116969690	SIK3	0.36	6.7	0.34	9.04e-11	Blood protein levels;
LUSC	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.95	-20.29	-0.74	3.18e-60	Ulcerative colitis;
LUSC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg22963979	chr7:1858916	MAD1L1	-0.62	-9.86	-0.47	2.63e-20	Bipolar disorder and schizophrenia;
LUSC	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20307385	chr11:47447363	PSMC3	0.45	5.9	0.31	8.99e-9	Subjective well-being;
LUSC	cis	rs7771547	0.519	rs6928287	chr6:36375438	G/A	cg07856975	chr6:36356162	ETV7	0.44	6.54	0.34	2.34e-10	Platelet distribution width;
LUSC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11764359	chr7:65958608	NA	-0.68	-10.88	-0.51	8.08e-24	Aortic root size;
LUSC	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg26408565	chr15:76604113	ETFA	-0.48	-7.63	-0.39	2.46e-13	Blood metabolite levels;
LUSC	cis	rs7512552	0.582	rs834233	chr1:150354276	G/A	cg15654264	chr1:150340011	RPRD2	0.6	9.39	0.46	9.44e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs11239930	0.934	rs10900313	chr1:146560747	T/A	cg02487331	chr1:146550467	NA	-0.31	-5.71	-0.3	2.47e-8	AIDS progression;
LUSC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg22166914	chr1:53195759	ZYG11B	-0.59	-9.78	-0.47	4.95e-20	Monocyte count;
LUSC	cis	rs698813	0.573	rs6544750	chr2:44490780	T/C	cg00619915	chr2:44497795	NA	-0.55	-7.7	-0.39	1.56e-13	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LUSC	cis	rs2617583	0.967	rs2617594	chr5:1448288	A/G	cg07148919	chr5:1466943	LPCAT1	0.42	6.29	0.33	1.02e-9	Breast cancer;
LUSC	cis	rs9815354	0.812	rs17215589	chr3:41831203	C/T	cg03022575	chr3:42003672	ULK4	0.86	8.63	0.43	2.54e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs2262909	0.962	rs55735642	chr19:22241176	C/T	cg11619707	chr19:22235551	ZNF257	0.39	5.83	0.3	1.29e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LUSC	cis	rs4691139	0.903	rs10434177	chr4:165915531	A/T	cg25904183	chr4:165877875	C4orf39;TRIM61	-0.45	-6.04	-0.31	4.04e-9	Ovarian cancer in BRCA1 mutation carriers;
LUSC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg24675658	chr1:53192096	ZYG11B	0.72	12.03	0.55	6.08e-28	Monocyte count;
LUSC	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg25251562	chr2:3704773	ALLC	-0.49	-7.44	-0.38	8.43e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LUSC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23161317	chr6:28129485	ZNF389	-0.42	-5.66	-0.3	3.21e-8	Depression;
LUSC	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg18964960	chr10:1102726	WDR37	0.65	6.38	0.33	5.96e-10	Glomerular filtration rate (creatinine);
LUSC	cis	rs7719624	0.870	rs1990199	chr5:135395543	G/C	cg12897067	chr5:135418308	NA	0.42	6.05	0.31	3.94e-9	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg23649088	chr2:200775458	C2orf69	-0.54	-6.35	-0.33	7.07e-10	Schizophrenia;
LUSC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg19912559	chr1:40204330	PPIE	0.51	7.8	0.39	7.84e-14	Blood protein levels;
LUSC	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg04837898	chr3:45731254	SACM1L	-0.45	-7.22	-0.37	3.57e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg01448562	chr3:133502909	NA	-0.65	-10.61	-0.5	7.25e-23	Iron status biomarkers;
LUSC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.71	-12.59	-0.57	5.02e-30	Prudent dietary pattern;
LUSC	cis	rs2235649	0.798	rs9932983	chr16:1848184	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.45	-6.06	-0.31	3.72e-9	Blood metabolite levels;
LUSC	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg21665744	chr7:39171113	POU6F2	0.4	6.31	0.33	8.91e-10	IgG glycosylation;
LUSC	trans	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg04995722	chr7:26192034	NFE2L3	-0.36	-5.97	-0.31	6.03e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7809950	1.000	rs2712215	chr7:107188207	A/G	cg23024343	chr7:107201750	COG5	-0.57	-8.96	-0.44	2.29e-17	Coronary artery disease;
LUSC	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg04998671	chr14:104000505	TRMT61A	-0.47	-6.68	-0.34	9.96e-11	Reticulocyte count;
LUSC	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-6.85	-0.35	3.59e-11	Response to antipsychotic treatment;
LUSC	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg20503657	chr10:835505	NA	0.63	7.93	0.4	3.38e-14	Eosinophil percentage of granulocytes;
LUSC	cis	rs1403694	0.695	rs11924390	chr3:186433099	T/C	cg12454167	chr3:186435060	KNG1	0.34	8.42	0.42	1.1e-15	Blood protein levels;
LUSC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-6.34	-0.33	7.63e-10	Longevity;Endometriosis;
LUSC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg10729496	chr3:10149963	C3orf24	0.54	7.15	0.36	5.48e-12	Alzheimer's disease;
LUSC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg25019033	chr10:957182	NA	-0.51	-6.26	-0.32	1.19e-9	Eosinophil percentage of granulocytes;
LUSC	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg25024717	chr12:54324583	NA	-0.38	-6.42	-0.33	4.58e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LUSC	cis	rs73206853	0.841	rs56065235	chr12:111016287	C/T	cg12870014	chr12:110450643	ANKRD13A	0.69	6.51	0.34	2.76e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LUSC	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg11879182	chr18:77439856	CTDP1	0.73	11.81	0.54	3.76e-27	Monocyte count;
LUSC	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.93	15.88	0.66	1.04e-42	Bladder cancer;
LUSC	cis	rs16867321	0.950	rs4667223	chr2:181498302	C/G	cg23363182	chr2:181467187	NA	-0.44	-5.7	-0.3	2.69e-8	Obesity;
LUSC	cis	rs6087990	0.842	rs4911105	chr20:31330413	G/A	cg13636640	chr20:31349939	DNMT3B	0.98	21.42	0.76	1.15e-64	Ulcerative colitis;
LUSC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg11062466	chr8:58055876	NA	0.43	5.77	0.3	1.81e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg05855489	chr10:104503620	C10orf26	-0.68	-10.09	-0.48	4.41e-21	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs6429082	0.585	rs7524848	chr1:235711688	G/C	cg26050004	chr1:235667680	B3GALNT2	-0.45	-5.92	-0.31	8e-9	Adiposity;
LUSC	cis	rs2235649	0.828	rs9936486	chr16:1849888	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-6.18	-0.32	1.84e-9	Blood metabolite levels;
LUSC	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg24578937	chr1:2090814	PRKCZ	-0.45	-10.12	-0.48	3.61e-21	Height;
LUSC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.6	9.19	0.45	4.24e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs500891	0.859	rs62419327	chr6:84154298	C/T	cg08257003	chr6:84140564	ME1	0.35	7.26	0.37	2.71e-12	Platelet-derived growth factor BB levels;
LUSC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.96	-17.13	-0.68	1.22e-47	Body mass index;
LUSC	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	7.52	0.38	5.06e-13	Coffee consumption (cups per day);
LUSC	cis	rs4889855	0.505	rs12952775	chr17:78607820	A/G	cg16591659	chr17:78472290	NA	-0.33	-5.82	-0.3	1.37e-8	Fractional excretion of uric acid;
LUSC	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg27572855	chr1:25598939	RHD	0.42	7.36	0.37	1.4e-12	Erythrocyte sedimentation rate;
LUSC	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg06096015	chr1:231504339	EGLN1	0.46	8.12	0.41	9.39e-15	Hemoglobin concentration;
LUSC	cis	rs17102423	0.558	rs11628664	chr14:65615651	C/T	cg11161011	chr14:65562177	MAX	-0.63	-8.44	-0.42	1e-15	Obesity-related traits;
LUSC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg03579872	chr1:53393473	SCP2	-0.39	-5.87	-0.31	1.05e-8	Monocyte count;
LUSC	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg27446573	chr6:127587934	RNF146	0.62	9.97	0.48	1.19e-20	Breast cancer;
LUSC	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg10253484	chr15:75165896	SCAMP2	0.46	6.39	0.33	5.49e-10	Systemic lupus erythematosus;
LUSC	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg17385448	chr1:15911702	AGMAT	0.36	6.18	0.32	1.82e-9	Systolic blood pressure;
LUSC	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17507749	chr15:85114479	UBE2QP1	0.56	7.08	0.36	8.46e-12	Schizophrenia;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11965880	chr10:23003653	PIP4K2A	-0.41	-5.96	-0.31	6.33e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6460942	0.505	rs73290446	chr7:12358133	T/G	cg06484146	chr7:12443880	VWDE	-0.58	-6.11	-0.32	2.85e-9	Coronary artery disease;
LUSC	cis	rs2952156	0.916	rs903506	chr17:37879762	G/A	cg20243544	chr17:37824526	PNMT	0.49	6.97	0.36	1.7e-11	Asthma;
LUSC	cis	rs829883	0.872	rs1641641	chr12:98896018	A/C	cg25150519	chr12:98850993	NA	0.63	9.43	0.46	7.25e-19	Colorectal adenoma (advanced);
LUSC	cis	rs17034641	0.938	rs12990701	chr2:46372472	C/G	cg12428440	chr2:46370979	PRKCE	0.44	6.09	0.32	3.03e-9	Hemoglobin;Hematocrit;
LUSC	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg20283391	chr11:68216788	NA	-0.59	-8.29	-0.41	2.76e-15	Total body bone mineral density;
LUSC	cis	rs9788721	0.836	rs17483686	chr15:78733390	A/T	cg18825076	chr15:78729989	IREB2	-0.59	-9.76	-0.47	5.72e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04219446	chr17:73629082	RECQL5;LOC643008	0.41	6.58	0.34	1.79e-10	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.66	11.03	0.52	2.58e-24	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg00857998	chr1:205179979	DSTYK	0.56	8.45	0.42	9.41e-16	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs506338	0.517	rs471618	chr11:64465403	T/C	cg19395706	chr11:64412079	NRXN2	0.28	5.73	0.3	2.18e-8	Body mass index;Urate levels;
LUSC	cis	rs2445762	0.642	rs72729210	chr15:51633629	G/A	cg07517944	chr15:51633816	GLDN	0.41	6.78	0.35	5.32e-11	Hormone measurements;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	ch.8.34907260F	chr8:34787718	NA	-0.45	-6.14	-0.32	2.33e-9	Hepatitis;
LUSC	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg05621596	chr22:47072043	GRAMD4	-0.4	-6.72	-0.35	7.78e-11	Urate levels in obese individuals;
LUSC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.6	-11.4	-0.53	1.15e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg06002616	chr8:101225028	SPAG1	-0.41	-6.82	-0.35	4.37e-11	Atrioventricular conduction;
LUSC	cis	rs28647808	0.881	rs28622217	chr9:136267323	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-0.6	-5.97	-0.31	6.15e-9	Blood protein levels;
LUSC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg25258033	chr6:167368657	RNASET2	0.47	7.88	0.4	4.71e-14	Crohn's disease;
LUSC	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.56	10.93	0.51	5.54e-24	Hemoglobin concentration;
LUSC	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.32	-6.35	-0.33	7.21e-10	Hemoglobin concentration;
LUSC	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg13206674	chr6:150067644	NUP43	0.58	9.08	0.45	9.37e-18	Lung cancer;
LUSC	cis	rs7572644	0.664	rs4313931	chr2:28074701	C/T	cg27432699	chr2:27873401	GPN1	0.52	6.62	0.34	1.45e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.73	12.43	0.56	2.07e-29	Prudent dietary pattern;
LUSC	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg07856975	chr6:36356162	ETV7	0.34	6.21	0.32	1.61e-9	Platelet distribution width;
LUSC	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-13.81	-0.6	1.24e-34	Coronary artery disease;
LUSC	cis	rs7215564	0.908	rs756077	chr17:78663071	A/G	cg23238734	chr17:78661607	RPTOR	0.48	6.07	0.32	3.39e-9	Myopia (pathological);
LUSC	trans	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg15556689	chr8:8085844	FLJ10661	0.48	6.81	0.35	4.53e-11	Monocyte count;
LUSC	cis	rs7561273	0.609	rs1056122	chr2:24342505	C/T	cg06627628	chr2:24431161	ITSN2	0.51	6.99	0.36	1.5e-11	Quantitative traits;
LUSC	cis	rs9309473	0.528	rs2091022	chr2:73564570	G/A	cg20560298	chr2:73613845	ALMS1	-0.56	-8.2	-0.41	5.09e-15	Metabolite levels;
LUSC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg01802117	chr1:53393560	SCP2	-0.39	-6.44	-0.33	4.23e-10	Monocyte count;
LUSC	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg09184832	chr6:79620586	NA	-0.44	-7.18	-0.37	4.46e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg22535103	chr8:58192502	C8orf71	-0.58	-6.91	-0.35	2.45e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	1.04	17.84	0.7	1.71e-50	Testicular germ cell tumor;
LUSC	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-8.89	-0.44	3.82e-17	Metabolite levels;
LUSC	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg07606381	chr6:8435919	SLC35B3	-0.52	-7.77	-0.39	9.97e-14	Motion sickness;
LUSC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-12.99	-0.58	1.64e-31	Hemoglobin concentration;
LUSC	cis	rs4460629	0.521	rs12039316	chr1:155073221	C/T	cg23973274	chr1:155060172	NA	-0.32	-6.27	-0.32	1.13e-9	Serum magnesium levels;
LUSC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.97	16.54	0.67	2.5e-45	Cognitive ability;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09687332	chr3:49977370	RBM6	0.46	6.15	0.32	2.27e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs9815354	1.000	rs9823254	chr3:41894768	G/C	cg03022575	chr3:42003672	ULK4	0.63	6.9	0.35	2.57e-11	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14159672	chr1:205819179	PM20D1	0.79	13.28	0.59	1.3e-32	Menarche (age at onset);
LUSC	trans	rs72674100	1.000	rs17026330	chr4:97969873	G/A	cg09670535	chr1:18959427	PAX7	-0.56	-5.97	-0.31	6.09e-9	Post bronchodilator FEV1/FVC ratio;
LUSC	cis	rs2147959	0.824	rs10916313	chr1:228625882	C/G	cg18477163	chr1:228402036	OBSCN	-0.43	-6.04	-0.31	4.16e-9	Adult asthma;
LUSC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06221963	chr1:154839813	KCNN3	-0.64	-14.82	-0.63	1.54e-38	Prostate cancer;
LUSC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.12	0.41	9.02e-15	Prudent dietary pattern;
LUSC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13770153	chr20:60521292	NA	-0.63	-8.55	-0.42	4.57e-16	Body mass index;
LUSC	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	0.98	7.88	0.4	4.66e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs77741769	0.571	rs12371178	chr12:121309129	T/C	cg02419362	chr12:121203948	SPPL3	0.46	8.56	0.42	4.08e-16	Mean corpuscular volume;
LUSC	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg26384229	chr12:38710491	ALG10B	0.72	11.71	0.54	9.17e-27	Morning vs. evening chronotype;
LUSC	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg15596816	chr17:45501030	LOC100272146;C17orf57	-0.41	-6.47	-0.33	3.53e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs7119	0.931	rs11630540	chr15:77833625	G/A	cg27398640	chr15:77910606	LINGO1	-0.32	-7.16	-0.36	5.07e-12	Type 2 diabetes;
LUSC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.05e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg24006582	chr15:45444508	DUOX1	0.59	8.3	0.41	2.6e-15	Uric acid levels;
LUSC	cis	rs12594515	1.000	rs7162201	chr15:45992658	A/C	cg01629716	chr15:45996671	NA	0.39	5.89	0.31	9.44e-9	Waist circumference;Weight;
LUSC	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg03585969	chr10:35415529	CREM	0.63	9.08	0.44	9.93e-18	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg04920474	chr2:44395004	PPM1B	0.67	8.63	0.43	2.62e-16	Height;
LUSC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg01181863	chr3:195395398	SDHAP2	-0.59	-8.04	-0.4	1.53e-14	Pancreatic cancer;
LUSC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg01802117	chr1:53393560	SCP2	-0.43	-7.19	-0.37	4.19e-12	Monocyte count;
LUSC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26314531	chr2:26401878	FAM59B	0.73	10.21	0.49	1.79e-21	Gut microbiome composition (summer);
LUSC	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg21132104	chr15:45694354	SPATA5L1	0.41	6.02	0.31	4.69e-9	Response to fenofibrate (adiponectin levels);
LUSC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	0.92	14.01	0.61	2.1e-35	Breast cancer;
LUSC	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg00129232	chr17:37814104	STARD3	-0.52	-8.06	-0.4	1.38e-14	Asthma;
LUSC	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg24881330	chr22:46731750	TRMU	0.8	6.72	0.35	7.8e-11	LDL cholesterol;Cholesterol, total;
LUSC	cis	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.55	-5.98	-0.31	5.87e-9	Metabolite levels (HVA/MHPG ratio);
LUSC	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg19628046	chr18:33552617	C18orf21	0.5	6.03	0.31	4.41e-9	Endometriosis;Drug-induced torsades de pointes;
LUSC	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg05340658	chr4:99064831	C4orf37	0.62	9.96	0.48	1.26e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.42	6.04	0.31	4.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs859767	0.501	rs6742638	chr2:135407360	T/G	cg12500956	chr2:135428796	TMEM163	-0.27	-6.29	-0.33	9.76e-10	Neuroticism;
LUSC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg21724239	chr8:58056113	NA	0.57	6.61	0.34	1.56e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-1.02	-16.11	-0.66	1.34e-43	Exhaled nitric oxide output;
LUSC	cis	rs4919087	0.962	rs10882889	chr10:99045890	A/G	cg25902810	chr10:99078978	FRAT1	0.47	6.61	0.34	1.56e-10	Monocyte count;
LUSC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg23711669	chr6:146136114	FBXO30	0.76	13.58	0.6	9.51e-34	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.84	12.74	0.57	1.41e-30	Cognitive ability;
LUSC	cis	rs28595532	0.546	rs36058627	chr4:119233201	G/T	cg21605333	chr4:119757512	SEC24D	0.73	6.2	0.32	1.67e-9	Cannabis dependence symptom count;
LUSC	trans	rs12599106	0.679	rs34584967	chr16:34475725	T/G	cg01171360	chr6:293285	DUSP22	-0.51	-7.62	-0.38	2.57e-13	Menopause (age at onset);
LUSC	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg04310649	chr10:35416472	CREM	-0.43	-6.38	-0.33	5.76e-10	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.96	-12.45	-0.56	1.77e-29	Exhaled nitric oxide output;
LUSC	cis	rs708547	0.957	rs1623306	chr4:57773595	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.52	6.28	0.33	1.04e-9	Response to bleomycin (chromatid breaks);
LUSC	cis	rs9650315	0.586	rs56042981	chr8:57207813	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.8	0.39	7.83e-14	Height;
LUSC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg00945038	chr17:61921165	SMARCD2	0.53	9.23	0.45	3.27e-18	Prudent dietary pattern;
LUSC	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg11789530	chr4:8429930	ACOX3	-0.59	-9.08	-0.44	9.65e-18	Response to antineoplastic agents;
LUSC	cis	rs12618769	0.597	rs3769713	chr2:99151434	A/G	cg10123293	chr2:99228465	UNC50	0.5	8.12	0.41	9.36e-15	Bipolar disorder;
LUSC	cis	rs67366981	0.925	rs66846709	chr14:77692812	G/A	cg22824376	chr14:77648248	TMEM63C	0.75	6.95	0.36	1.89e-11	Obsessive-compulsive symptoms;
LUSC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg02079420	chr8:82753780	SNX16	0.41	7.01	0.36	1.29e-11	Diastolic blood pressure;
LUSC	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-8.44	-0.42	1.01e-15	Hepatocellular carcinoma;
LUSC	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	13.49	0.59	2.03e-33	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg21775007	chr8:11205619	TDH	-0.63	-9.91	-0.48	1.84e-20	Retinal vascular caliber;
LUSC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.86	-0.81	6.04e-78	Height;
LUSC	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg15704280	chr7:45808275	SEPT13	0.58	7.29	0.37	2.3e-12	Intraocular pressure;
LUSC	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg05163923	chr11:71159392	DHCR7	-0.66	-9.07	-0.44	1.06e-17	Vitamin D levels;
LUSC	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg05738196	chr6:26577821	NA	0.79	14.91	0.63	6.82e-39	Intelligence (multi-trait analysis);
LUSC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	1.03	17.81	0.7	2.29e-50	Parkinson's disease;
LUSC	cis	rs6599077	1.000	rs113909479	chr3:40097967	C/G	cg13683864	chr3:40499215	RPL14	-0.61	-7.25	-0.37	2.94e-12	Sleep-related phenotypes;
LUSC	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg09654669	chr8:57350985	NA	-0.55	-7.77	-0.39	9.95e-14	Obesity-related traits;
LUSC	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg13256891	chr4:100009986	ADH5	0.5	6.92	0.35	2.31e-11	Smoking initiation;
LUSC	cis	rs6460942	1.000	rs6948314	chr7:12418363	T/A	cg06484146	chr7:12443880	VWDE	-0.7	-6.98	-0.36	1.62e-11	Coronary artery disease;
LUSC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg22166914	chr1:53195759	ZYG11B	0.68	11.57	0.53	2.95e-26	Monocyte count;
LUSC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03576123	chr11:487126	PTDSS2	0.96	10.56	0.5	1.08e-22	Body mass index;
LUSC	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg24550644	chr17:30846204	MYO1D	-0.38	-6.14	-0.32	2.38e-9	Schizophrenia;
LUSC	cis	rs4499344	0.730	rs410616	chr19:33106109	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	12.93	0.58	2.86e-31	Mean platelet volume;
LUSC	cis	rs2274273	0.870	rs10139083	chr14:55782735	C/A	cg04306507	chr14:55594613	LGALS3	0.54	11.84	0.54	2.97e-27	Protein biomarker;
LUSC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg21770322	chr7:97807741	LMTK2	0.41	7.06	0.36	9.5e-12	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs62408225	0.963	rs62408211	chr6:90902808	A/T	cg06866423	chr6:90926672	BACH2	0.38	5.7	0.3	2.7e-8	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg14993813	chr1:46806288	NSUN4	-0.51	-7.21	-0.37	3.84e-12	Menopause (age at onset);
LUSC	cis	rs11264799	0.716	rs1113662	chr1:157635825	T/C	cg18268488	chr1:157545234	FCRL4	0.33	5.75	0.3	2.02e-8	IgA nephropathy;
LUSC	cis	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg17187183	chr4:55093834	PDGFRA	0.38	5.83	0.3	1.3e-8	Corneal astigmatism;
LUSC	cis	rs12618769	0.625	rs72819970	chr2:99034554	C/G	cg10123293	chr2:99228465	UNC50	0.46	7.75	0.39	1.09e-13	Bipolar disorder;
LUSC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg05313129	chr8:58192883	C8orf71	-0.5	-5.78	-0.3	1.69e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg22705602	chr4:152727874	NA	-0.32	-6.41	-0.33	4.85e-10	Intelligence (multi-trait analysis);
LUSC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.46	7.88	0.4	4.78e-14	Intelligence (multi-trait analysis);
LUSC	cis	rs1775715	0.966	rs1755066	chr10:32309160	C/G	cg04359828	chr10:32216031	ARHGAP12	-0.35	-5.84	-0.3	1.21e-8	Bipolar disorder with mood-incongruent psychosis;
LUSC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg27494647	chr7:150038898	RARRES2	0.52	7.89	0.4	4.43e-14	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21643547	chr1:205240462	TMCC2	-0.53	-10.19	-0.49	2.1e-21	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs4499344	0.730	rs7246338	chr19:33099504	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.83	12.73	0.57	1.49e-30	Mean platelet volume;
LUSC	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg05347473	chr6:146136440	FBXO30	-0.38	-6.23	-0.32	1.38e-9	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9395066	0.525	rs1971482	chr6:44991113	C/T	cg25276700	chr6:44698697	NA	0.29	6.01	0.31	4.91e-9	Height;
LUSC	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg07862535	chr7:139043722	LUC7L2	-0.57	-7.17	-0.37	4.9e-12	Diisocyanate-induced asthma;
LUSC	cis	rs2996428	0.667	rs72640928	chr1:3768568	T/C	cg17848003	chr1:3704513	LRRC47	0.33	6.25	0.32	1.24e-9	Red cell distribution width;
LUSC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg19812747	chr11:111475976	SIK2	-0.55	-8.18	-0.41	5.88e-15	Primary sclerosing cholangitis;
LUSC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	7.61	0.38	2.91e-13	Initial pursuit acceleration;
LUSC	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg05294307	chr14:35346193	BAZ1A	-0.57	-7.1	-0.36	7.76e-12	Psoriasis;
LUSC	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg17145862	chr1:211918768	LPGAT1	0.23	6.1	0.32	2.97e-9	Leprosy;
LUSC	cis	rs6681460	0.932	rs524114	chr1:67188335	C/T	cg02459107	chr1:67143332	SGIP1	-0.44	-7.89	-0.4	4.37e-14	Presence of antiphospholipid antibodies;
LUSC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.41	-0.38	1.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg05585544	chr11:47624801	NA	-0.4	-6.89	-0.35	2.75e-11	Subjective well-being;
LUSC	cis	rs78579285	0.589	rs113010486	chr16:88798398	A/G	cg01900006	chr16:88814613	FAM38A	0.6	6.66	0.34	1.13e-10	Joint mobility (Beighton score);
LUSC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg18681998	chr4:17616180	MED28	0.88	16.23	0.66	4.22e-44	Parasitemia in Tripanosoma cruzi seropositivity;
LUSC	trans	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg05065690	chr12:49246007	DDX23	0.4	6.37	0.33	6.3e-10	Schizophrenia;
LUSC	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	5.82	0.3	1.36e-8	Schizophrenia;
LUSC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-9.02	-0.44	1.51e-17	Platelet count;
LUSC	trans	rs57046232	0.552	rs6038449	chr20:6337980	C/T	cg21095983	chr6:86352623	SYNCRIP	0.47	7.04	0.36	1.11e-11	Colorectal cancer;
LUSC	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg14228332	chr4:119757509	SEC24D	-0.8	-6.12	-0.32	2.64e-9	Cannabis dependence symptom count;
LUSC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.79	12.3	0.56	6.25e-29	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg22166914	chr1:53195759	ZYG11B	0.54	8.61	0.43	2.83e-16	Monocyte count;
LUSC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-0.76	-11.18	-0.52	7.33e-25	Gut microbiome composition (summer);
LUSC	cis	rs7681440	0.605	rs1372509	chr4:90817311	A/G	cg15133208	chr4:90757351	SNCA	-0.33	-5.69	-0.3	2.75e-8	Dementia with Lewy bodies;
LUSC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.78	-0.3	1.71e-8	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs3791556	0.898	rs3828222	chr2:240109568	A/G	cg03281426	chr2:240109471	HDAC4	-0.54	-7.72	-0.39	1.34e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg22549504	chr19:17448937	GTPBP3	0.55	7.2	0.37	4.1e-12	Systemic lupus erythematosus;
LUSC	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg22618164	chr12:122356400	WDR66	0.59	8.47	0.42	7.74e-16	Mean corpuscular volume;
LUSC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg06784218	chr1:46089804	CCDC17	0.54	11.04	0.52	2.29e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	trans	rs4942242	1.000	rs1105856	chr13:44227067	G/T	cg19169023	chr15:41853346	TYRO3	0.47	7.58	0.38	3.34e-13	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	1.07	14.1	0.61	9.68e-36	Diabetic retinopathy;
LUSC	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg09365446	chr1:150670422	GOLPH3L	0.47	7.01	0.36	1.33e-11	Tonsillectomy;
LUSC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.86	-0.4	5.29e-14	Developmental language disorder (linguistic errors);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg06564803	chr16:70100193	PDXDC2	-0.39	-5.97	-0.31	5.96e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg22709100	chr7:91322751	NA	0.39	5.86	0.31	1.08e-8	Breast cancer;
LUSC	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	5.76	0.3	1.93e-8	Schizophrenia;
LUSC	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.86	14.0	0.61	2.4e-35	Bladder cancer;
LUSC	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	6.96	0.36	1.75e-11	Red blood cell count;
LUSC	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg19875535	chr5:140030758	IK	-0.53	-8.69	-0.43	1.61e-16	Depressive symptoms (multi-trait analysis);
LUSC	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	6.63	0.34	1.34e-10	Retinal vascular caliber;
LUSC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	1.04	25.83	0.82	1.25e-81	Multiple system atrophy;
LUSC	cis	rs3820928	0.934	rs60141402	chr2:227761445	A/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.74	-0.39	1.21e-13	Pulmonary function;
LUSC	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.87	20.03	0.74	3.52e-59	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg22508957	chr16:3507546	NAT15	-0.41	-6.47	-0.33	3.49e-10	Body mass index (adult);
LUSC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg15242686	chr22:24348715	GSTTP1	0.48	7.66	0.39	2.02e-13	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	trans	rs12554020	0.582	rs2001609	chr9:96395363	C/T	cg03862290	chr14:101515739	MIR655	0.48	6.08	0.32	3.32e-9	Schizophrenia;
LUSC	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg18404041	chr3:52824283	ITIH1	0.41	7.12	0.36	6.57e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg22189786	chr22:42395067	WBP2NL	0.43	5.75	0.3	2.06e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LUSC	cis	rs7315438	0.600	rs12367485	chr12:115885910	G/A	cg24172291	chr12:115889509	NA	-0.36	-6.15	-0.32	2.18e-9	Colorectal cancer;
LUSC	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg05347473	chr6:146136440	FBXO30	0.56	9.54	0.46	3.02e-19	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg25036284	chr2:26402008	FAM59B	0.66	8.7	0.43	1.55e-16	Gut microbiome composition (summer);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00023492	chr1:19970710	NBL1	-0.49	-6.04	-0.31	4.1e-9	Bipolar disorder and schizophrenia;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg24752028	chr2:30369779	YPEL5	-0.51	-6.12	-0.32	2.61e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg24879335	chr3:133465180	TF	0.45	7.82	0.39	7.1e-14	Iron status biomarkers (transferrin levels);
LUSC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg01416388	chr22:39784598	NA	-0.43	-6.93	-0.35	2.21e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs9925964	0.869	rs2288004	chr16:31054040	G/C	cg02466173	chr16:30829666	NA	0.35	6.44	0.33	4.18e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg09835421	chr16:68378352	PRMT7	-0.54	-5.92	-0.31	7.97e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.82	-15.9	-0.66	8.57e-43	Inflammatory bowel disease;
LUSC	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.69	0.39	1.61e-13	Height;
LUSC	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg08601574	chr20:25228251	PYGB	0.45	6.81	0.35	4.56e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.87	-0.31	1.04e-8	Bipolar disorder;
LUSC	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg23691090	chr22:46449981	C22orf26;LOC150381	0.43	6.94	0.35	2.06e-11	Dupuytren's disease;Subjective well-being;
LUSC	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg07080220	chr10:102295463	HIF1AN	0.62	8.27	0.41	3.32e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.54	-7.33	-0.37	1.76e-12	Mean platelet volume;
LUSC	cis	rs7940866	0.774	rs10466547	chr11:130823576	T/C	cg12179176	chr11:130786555	SNX19	0.61	9.17	0.45	4.96e-18	Schizophrenia;
LUSC	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg10253484	chr15:75165896	SCAMP2	-0.53	-7.16	-0.36	5.24e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.69	8.83	0.44	5.91e-17	Schizophrenia;
LUSC	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-0.98	-11.14	-0.52	9.91e-25	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	0.93	13.79	0.6	1.44e-34	Cannabis dependence symptom count;
LUSC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg12463550	chr7:65579703	CRCP	0.45	6.17	0.32	1.99e-9	Aortic root size;
LUSC	trans	rs6445525	1.000	rs6805139	chr3:66005660	G/A	cg12639933	chr12:57626296	SHMT2	0.34	6.1	0.32	3e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg05717871	chr11:638507	DRD4	-0.37	-6.39	-0.33	5.7e-10	Systemic lupus erythematosus;
LUSC	cis	rs9837602	1.000	rs4075038	chr3:99680086	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.39	5.77	0.3	1.84e-8	Breast cancer;
LUSC	cis	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.43	-0.42	1.09e-15	Morning vs. evening chronotype;
LUSC	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg11502198	chr6:26597334	ABT1	0.59	9.3	0.45	1.84e-18	Intelligence (multi-trait analysis);
LUSC	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs12042107	0.656	rs1342780	chr1:91198676	A/C	cg13456504	chr1:91191583	NA	0.39	6.38	0.33	5.8e-10	Educational attainment;
LUSC	cis	rs4285028	0.948	rs35902163	chr3:121649526	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.71	-0.47	8.51e-20	Multiple sclerosis;
LUSC	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg18232548	chr7:50535776	DDC	-0.61	-9.43	-0.46	6.97e-19	Malaria;
LUSC	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg21252483	chr19:49399788	TULP2	-0.48	-6.76	-0.35	6.21e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LUSC	cis	rs4713675	0.584	rs9380375	chr6:33682391	G/A	cg14003231	chr6:33640908	ITPR3	0.29	5.75	0.3	2.02e-8	Plateletcrit;
LUSC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	11.39	0.53	1.32e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg05110241	chr16:68378359	PRMT7	-0.51	-6.12	-0.32	2.69e-9	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg04310649	chr10:35416472	CREM	-0.4	-6.07	-0.32	3.51e-9	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg13010199	chr12:38710504	ALG10B	0.67	10.31	0.49	8.3e-22	Bladder cancer;
LUSC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg06742321	chr12:123595122	PITPNM2	0.38	5.79	0.3	1.59e-8	Platelet count;
LUSC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg25258033	chr6:167368657	RNASET2	0.45	6.81	0.35	4.5e-11	Crohn's disease;
LUSC	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.98	-0.31	5.72e-9	IgG glycosylation;
LUSC	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg10253484	chr15:75165896	SCAMP2	-0.49	-6.45	-0.33	4.04e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LUSC	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.09	0.36	7.86e-12	Blood metabolite levels;
LUSC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06112835	chr11:68658793	MRPL21	0.5	7.65	0.39	2.23e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.5	-11.89	-0.55	2.01e-27	Longevity;
LUSC	trans	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.36	-0.33	6.45e-10	Triglycerides;
LUSC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg02380750	chr20:61661411	NA	0.34	6.01	0.31	4.97e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs11112613	0.818	rs73184099	chr12:106018143	A/G	cg03607813	chr12:105948248	NA	0.73	9.06	0.44	1.14e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LUSC	cis	rs977987	0.736	rs11865296	chr16:75473693	C/T	cg03315344	chr16:75512273	CHST6	0.48	9.4	0.46	8.91e-19	Dupuytren's disease;
LUSC	trans	rs12571093	0.656	rs3858147	chr10:70013264	A/G	cg04882175	chr6:131122610	NA	-0.52	-5.97	-0.31	6.17e-9	Optic nerve measurement (disc area);
LUSC	cis	rs62400317	0.859	rs28583363	chr6:45231336	T/A	cg18551225	chr6:44695536	NA	-0.44	-7.28	-0.37	2.46e-12	Total body bone mineral density;
LUSC	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg03676636	chr4:99064102	C4orf37	0.36	7.94	0.4	3.15e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg21890820	chr11:65308645	LTBP3	1.39	9.51	0.46	3.82e-19	Height;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg03395546	chr19:41222599	ADCK4;ITPKC	-0.56	-6.88	-0.35	3.05e-11	Bipolar disorder and schizophrenia;
LUSC	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg22676075	chr6:135203613	NA	0.58	9.08	0.44	9.79e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LUSC	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg25173405	chr17:45401733	C17orf57	-0.4	-6.49	-0.33	3.06e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg16606324	chr3:10149918	C3orf24	0.64	9.55	0.46	2.89e-19	Alzheimer's disease;
LUSC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg03351412	chr1:154909251	PMVK	0.42	6.42	0.33	4.69e-10	Prostate cancer;
LUSC	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg01851573	chr8:8652454	MFHAS1	0.55	9.14	0.45	6.38e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg21775007	chr8:11205619	TDH	-0.54	-7.87	-0.4	5.07e-14	Neuroticism;
LUSC	cis	rs877282	0.945	rs11599043	chr10:777972	C/T	cg17470449	chr10:769945	NA	0.52	7.42	0.38	9.92e-13	Uric acid levels;
LUSC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg08219700	chr8:58056026	NA	0.5	6.22	0.32	1.51e-9	Developmental language disorder (linguistic errors);
LUSC	trans	rs17236969	0.557	rs72887143	chr2:156597056	A/T	cg04365699	chr3:177320997	NA	-0.26	-5.97	-0.31	5.97e-9	Menarche (age at onset);
LUSC	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg00191853	chr8:101177733	SPAG1	-0.41	-6.56	-0.34	2.08e-10	Atrioventricular conduction;
LUSC	cis	rs3741151	1.000	rs74795285	chr11:73033387	A/G	cg17517138	chr11:73019481	ARHGEF17	1.14	9.76	0.47	5.59e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LUSC	cis	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg21775007	chr8:11205619	TDH	0.46	7.01	0.36	1.31e-11	Retinal vascular caliber;
LUSC	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg23992470	chr4:843637	GAK	0.59	6.21	0.32	1.61e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg14664628	chr15:75095509	CSK	-0.39	-5.82	-0.3	1.4e-8	Airflow obstruction;
LUSC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg22920501	chr2:26401640	FAM59B	0.83	11.99	0.55	8.76e-28	Gut microbiome composition (summer);
LUSC	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-7.9	-0.4	4.2e-14	Schizophrenia;
LUSC	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg08601574	chr20:25228251	PYGB	-0.44	-6.8	-0.35	4.76e-11	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	0.92	17.63	0.69	1.17e-49	Heart rate;
LUSC	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg16512390	chr1:228756714	NA	0.71	8.99	0.44	1.81e-17	Chronic lymphocytic leukemia;
LUSC	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg25174290	chr11:3078921	CARS	-0.41	-6.22	-0.32	1.49e-9	Calcium levels;
LUSC	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	13.19	0.59	2.83e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	17.3	0.69	2.6e-48	Chronic sinus infection;
LUSC	cis	rs12367572	0.965	rs7952764	chr12:45246211	C/A	cg04608330	chr12:45269318	NELL2	-0.58	-9.26	-0.45	2.51e-18	Gut microbiome composition (summer);
LUSC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg04553112	chr3:125709451	NA	-0.51	-5.75	-0.3	2.06e-8	Blood pressure (smoking interaction);
LUSC	cis	rs6906287	0.647	rs7773274	chr6:118934740	C/G	cg21191810	chr6:118973309	C6orf204	0.32	5.91	0.31	8.23e-9	Electrocardiographic conduction measures;
LUSC	trans	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.32	-0.33	8.19e-10	Bladder cancer;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05984044	chr4:47034181	GABRB1	0.45	7.01	0.36	1.33e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg07862535	chr7:139043722	LUC7L2	0.56	7.05	0.36	1.04e-11	Diisocyanate-induced asthma;
LUSC	cis	rs977987	0.836	rs35209155	chr16:75470496	G/A	cg03315344	chr16:75512273	CHST6	0.5	9.66	0.47	1.22e-19	Dupuytren's disease;
LUSC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg16405210	chr4:1374714	KIAA1530	-0.56	-8.52	-0.42	5.41e-16	Obesity-related traits;
LUSC	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg04362960	chr10:104952993	NT5C2	0.61	9.53	0.46	3.35e-19	Arsenic metabolism;
LUSC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	5.91	0.31	8.46e-9	Tonsillectomy;
LUSC	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg05340658	chr4:99064831	C4orf37	0.64	10.77	0.51	2.06e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.05	-0.36	1.05e-11	Reticulocyte fraction of red cells;
LUSC	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg03929089	chr4:120376271	NA	-0.56	-6.82	-0.35	4.18e-11	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08677398	chr8:58056175	NA	0.52	6.67	0.34	1.04e-10	Developmental language disorder (linguistic errors);
LUSC	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg23093090	chr10:104574429	C10orf26	-0.35	-6.36	-0.33	6.67e-10	Arsenic metabolism;
LUSC	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg07080220	chr10:102295463	HIF1AN	0.61	8.14	0.41	8.11e-15	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg21100191	chr22:23484243	RTDR1	0.91	15.61	0.65	1.22e-41	Bone mineral density;
LUSC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg04727924	chr7:799746	HEATR2	-0.55	-6.71	-0.34	8.58e-11	Cerebrospinal P-tau181p levels;
LUSC	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21643547	chr1:205240462	TMCC2	-0.5	-9.46	-0.46	5.79e-19	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-1.13	-17.64	-0.69	1.06e-49	Exhaled nitric oxide output;
LUSC	cis	rs7572644	0.712	rs10204832	chr2:28228408	T/A	cg27432699	chr2:27873401	GPN1	-0.52	-6.45	-0.33	3.97e-10	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LUSC	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.62	10.4	0.49	3.96e-22	Blood metabolite ratios;
LUSC	cis	rs10887741	0.690	rs12772633	chr10:89442492	G/A	cg13926569	chr10:89418898	PAPSS2	0.32	6.83	0.35	4.13e-11	Exercise (leisure time);
LUSC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg03354898	chr7:1950403	MAD1L1	-0.41	-8.39	-0.42	1.39e-15	Bipolar disorder and schizophrenia;
LUSC	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-8.17	-0.41	6.41e-15	Response to antipsychotic treatment;
LUSC	cis	rs1385374	0.858	rs3741615	chr12:129298848	G/A	cg09035930	chr12:129282057	SLC15A4	-0.62	-6.65	-0.34	1.2e-10	Systemic lupus erythematosus;
LUSC	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg11189052	chr15:85197271	WDR73	-0.42	-6.02	-0.31	4.6e-9	P wave terminal force;
LUSC	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg15485101	chr11:133734466	NA	-0.43	-7.93	-0.4	3.28e-14	Childhood ear infection;
LUSC	trans	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg13010199	chr12:38710504	ALG10B	0.46	7.1	0.36	7.36e-12	Morning vs. evening chronotype;
LUSC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg03806693	chr22:41940476	POLR3H	1.03	14.3	0.62	1.55e-36	Vitiligo;
LUSC	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg20026190	chr17:76395443	PGS1	0.46	8.16	0.41	6.75e-15	HDL cholesterol levels;
LUSC	cis	rs7605827	0.930	rs6431712	chr2:15691292	C/T	cg19274914	chr2:15703543	NA	0.46	8.83	0.44	5.83e-17	Educational attainment (years of education);
LUSC	cis	rs7580658	0.963	rs12991768	chr2:128146245	A/G	cg09760422	chr2:128146352	NA	-0.34	-7.35	-0.37	1.59e-12	Protein C levels;
LUSC	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg15556689	chr8:8085844	FLJ10661	0.69	11.63	0.54	1.71e-26	Parkinson's disease;
LUSC	trans	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg06521331	chr12:34319734	NA	-0.39	-5.98	-0.31	5.82e-9	Bladder cancer;
LUSC	cis	rs4889855	0.545	rs61171555	chr17:78465975	T/G	cg16591659	chr17:78472290	NA	-0.48	-8.16	-0.41	6.76e-15	Fractional excretion of uric acid;
LUSC	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg19676328	chr12:49525230	TUBA1B	-0.52	-8.42	-0.42	1.13e-15	Total cholesterol levels;
LUSC	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg12011299	chr4:100065546	ADH4	-0.73	-10.73	-0.51	2.92e-23	Alcohol dependence;
LUSC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg08470875	chr2:26401718	FAM59B	-0.65	-8.92	-0.44	3.02e-17	Gut microbiome composition (summer);
LUSC	trans	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.53	-0.38	4.74e-13	Neuroticism;
LUSC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg23630131	chr7:65973040	NA	0.21	5.81	0.3	1.42e-8	Aortic root size;
LUSC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg25039879	chr17:56429692	SUPT4H1	0.67	8.85	0.44	5.03e-17	Cognitive test performance;
LUSC	cis	rs2842992	0.747	rs4709379	chr6:160227530	A/G	cg11366901	chr6:160182831	ACAT2	0.96	12.23	0.56	1.11e-28	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg09998033	chr7:158218633	PTPRN2	-0.54	-8.62	-0.43	2.78e-16	Obesity-related traits;
LUSC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08045932	chr20:61659980	NA	0.59	10.5	0.5	1.76e-22	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs10203711	0.966	rs4605316	chr2:239595344	C/T	cg14580085	chr2:239553406	NA	0.42	7.07	0.36	9.07e-12	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg00908189	chr16:619842	PIGQ	0.72	11.22	0.52	5.11e-25	Height;
LUSC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06634786	chr22:41940651	POLR3H	0.51	6.15	0.32	2.18e-9	Vitiligo;
LUSC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg04017836	chr7:65315216	NA	-0.38	-6.01	-0.31	4.99e-9	Height;
LUSC	trans	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-6.26	-0.32	1.19e-9	Blood trace element (Cu levels);
LUSC	trans	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg05926928	chr17:57297772	GDPD1	-0.44	-6.36	-0.33	6.65e-10	Schizophrenia;
LUSC	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg19773385	chr1:10388646	KIF1B	-0.56	-8.93	-0.44	2.96e-17	Hepatocellular carcinoma;
LUSC	trans	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg10756647	chr7:56101905	PSPH	0.9	9.03	0.44	1.4e-17	Diabetic kidney disease;
LUSC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.82	13.78	0.6	1.59e-34	Aortic root size;
LUSC	cis	rs9341835	0.772	rs6919709	chr6:64139856	C/T	cg03326410	chr6:64151739	NA	-0.37	-6.01	-0.31	4.72e-9	Schizophrenia;
LUSC	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	10.51	0.5	1.69e-22	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	0.9	18.81	0.72	2.35e-54	Urate levels in lean individuals;
LUSC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23158103	chr7:148848205	ZNF398	-0.43	-6.72	-0.35	7.94e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	trans	rs11039798	0.841	rs7294179	chr11:48765408	G/A	cg03929089	chr4:120376271	NA	0.76	6.37	0.33	6.29e-10	Axial length;
LUSC	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.82	-11.86	-0.54	2.49e-27	Lymphocyte percentage of white cells;
LUSC	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg04362960	chr10:104952993	NT5C2	-1.02	-11.67	-0.54	1.24e-26	Arsenic metabolism;
LUSC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.51	8.61	0.43	2.91e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg23625390	chr15:77176239	SCAPER	0.47	7.13	0.36	6.25e-12	Blood metabolite levels;
LUSC	cis	rs908922	0.651	rs1885531	chr1:152480233	T/G	cg20991723	chr1:152506922	NA	0.51	9.05	0.44	1.22e-17	Hair morphology;
LUSC	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg14830002	chr1:247616686	OR2B11	-0.55	-8.13	-0.41	8.32e-15	Acute lymphoblastic leukemia (childhood);
LUSC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg07424592	chr7:64974309	NA	0.67	5.88	0.31	9.86e-9	Diabetic kidney disease;
LUSC	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg27572855	chr1:25598939	RHD	0.45	8.07	0.4	1.26e-14	Erythrocyte sedimentation rate;
LUSC	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg16031515	chr1:205743344	RAB7L1	-0.27	-5.68	-0.3	2.9e-8	Menarche (age at onset);
LUSC	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-6.75	-0.35	6.71e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LUSC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg18196295	chr10:418757	DIP2C	0.49	8.17	0.41	6.45e-15	Psychosis in Alzheimer's disease;
LUSC	cis	rs2559856	0.935	rs2559864	chr12:102084710	C/G	cg12924262	chr12:102091054	CHPT1	0.43	5.99	0.31	5.47e-9	Blood protein levels;
LUSC	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg00129232	chr17:37814104	STARD3	-0.43	-6.34	-0.33	7.36e-10	Asthma;
LUSC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg06600287	chr1:53387719	ECHDC2	-0.3	-6.23	-0.32	1.43e-9	Monocyte count;
LUSC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg16434002	chr17:42200994	HDAC5	0.45	6.0	0.31	5.13e-9	Total body bone mineral density;
LUSC	cis	rs877282	0.898	rs11253353	chr10:766862	C/A	cg17470449	chr10:769945	NA	0.5	6.42	0.33	4.68e-10	Uric acid levels;
LUSC	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.93	17.34	0.69	1.67e-48	Diastolic blood pressure;Systolic blood pressure;
LUSC	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg10356904	chr22:49881777	NA	-0.34	-7.53	-0.38	4.85e-13	Monocyte count;Monocyte percentage of white cells;
LUSC	trans	rs2587949	0.615	rs1087727	chr3:4204974	A/G	cg15139668	chr4:4577005	NA	-0.41	-6.08	-0.32	3.33e-9	Periodontitis (DPAL);
LUSC	cis	rs10875746	0.951	rs8804	chr12:48541757	A/G	cg13454099	chr12:49076203	C12orf41	-0.51	-6.02	-0.31	4.61e-9	Longevity (90 years and older);
LUSC	cis	rs11756438	0.572	rs1844964	chr6:119002528	C/T	cg18833306	chr6:118973337	C6orf204	0.36	5.75	0.3	2.05e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs7615316	1.000	rs2177396	chr3:142343401	A/G	cg16271453	chr3:142027066	XRN1	-0.36	-6.07	-0.32	3.52e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs9905704	0.681	rs4793948	chr17:56562062	G/A	cg19466818	chr17:56409534	MIR142	0.35	6.5	0.34	2.94e-10	Testicular germ cell tumor;
LUSC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18758796	chr5:131593413	PDLIM4	0.47	7.59	0.38	3.13e-13	Acylcarnitine levels;
LUSC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg03060546	chr3:49711283	APEH	0.49	6.59	0.34	1.68e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LUSC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg17330251	chr7:94953956	PON1	-0.41	-6.63	-0.34	1.35e-10	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs56399783	0.901	rs11971014	chr7:2778444	C/T	cg14895029	chr7:2775587	GNA12	0.51	5.73	0.3	2.22e-8	Childhood ear infection;
LUSC	cis	rs7945718	0.781	rs11022505	chr11:12822366	A/G	cg25843174	chr11:12811716	TEAD1	-0.31	-7.09	-0.36	7.98e-12	Educational attainment (years of education);
LUSC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg06008330	chr7:65541103	ASL	-0.4	-6.16	-0.32	2.14e-9	Aortic root size;
LUSC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg03240473	chr21:43526662	UMODL1;C21orf128	-0.59	-9.57	-0.46	2.41e-19	IgG glycosylation;
LUSC	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg03676636	chr4:99064102	C4orf37	0.38	7.96	0.4	2.68e-14	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20135002	chr11:47629003	NA	0.49	7.8	0.39	8.06e-14	Subjective well-being;
LUSC	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.27	0.32	1.13e-9	Diisocyanate-induced asthma;
LUSC	cis	rs3812111	0.510	rs4946151	chr6:116595289	G/C	cg18828861	chr6:116576566	TSPYL4	0.38	6.57	0.34	1.96e-10	Age-related macular degeneration;
LUSC	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17467752	chr17:38218738	THRA	-0.82	-13.57	-0.6	1.05e-33	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg02753203	chr1:228287806	NA	1.0	19.9	0.74	1.12e-58	Diastolic blood pressure;
LUSC	trans	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	12.22	0.56	1.23e-28	Exhaled nitric oxide output;
LUSC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-0.99	-14.45	-0.62	4.26e-37	Initial pursuit acceleration;
LUSC	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg19773385	chr1:10388646	KIF1B	-0.51	-8.81	-0.43	6.93e-17	Hepatocellular carcinoma;
LUSC	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg20283391	chr11:68216788	NA	-0.5	-6.99	-0.36	1.46e-11	Total body bone mineral density;
LUSC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06850241	chr22:41845214	NA	0.34	6.37	0.33	6.21e-10	Vitiligo;
LUSC	trans	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg26384229	chr12:38710491	ALG10B	0.6	8.41	0.42	1.2e-15	Resting heart rate;
LUSC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg22638593	chr5:131593259	PDLIM4	-0.45	-6.52	-0.34	2.61e-10	Acylcarnitine levels;
LUSC	cis	rs17102423	0.731	rs10143198	chr14:65555471	C/T	cg11161011	chr14:65562177	MAX	-0.67	-10.17	-0.49	2.43e-21	Obesity-related traits;
LUSC	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg15654264	chr1:150340011	RPRD2	0.47	7.49	0.38	6.37e-13	Migraine;
LUSC	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	0.59	9.25	0.45	2.65e-18	Breast cancer;
LUSC	trans	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg05926928	chr17:57297772	GDPD1	-0.85	-9.8	-0.47	4.43e-20	Opioid sensitivity;
LUSC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.86	-0.54	2.57e-27	Chronic sinus infection;
LUSC	cis	rs4845459	1.000	rs6702463	chr1:152598711	A/T	cg08895932	chr1:152778580	LCE1C	-0.36	-6.04	-0.31	4.12e-9	Psoriasis;
LUSC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21862992	chr11:68658383	NA	0.52	8.08	0.4	1.23e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs8056893	0.842	rs3785114	chr16:68372323	C/G	cg02226672	chr16:68398533	SMPD3	0.32	5.84	0.3	1.23e-8	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LUSC	trans	rs4252134	0.959	rs4252096	chr6:161134273	C/G	cg00639886	chr12:54943102	PDE1B	-0.44	-6.33	-0.33	7.8e-10	Giant cell arteritis;
LUSC	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg08807101	chr21:30365312	RNF160	-0.49	-6.49	-0.33	3.01e-10	Cognitive test performance;
LUSC	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg27411982	chr8:10470053	RP1L1	0.38	5.89	0.31	9.35e-9	Retinal vascular caliber;
LUSC	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg15571903	chr15:79123663	NA	-0.33	-6.16	-0.32	2.06e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LUSC	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg21433313	chr16:3507492	NAT15	0.4	5.69	0.3	2.81e-8	Body mass index (adult);
LUSC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15556689	chr8:8085844	FLJ10661	0.78	13.27	0.59	1.4e-32	Systolic blood pressure;
LUSC	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg26441486	chr22:50317300	CRELD2	-0.53	-7.92	-0.4	3.57e-14	Schizophrenia;
LUSC	cis	rs10170846	0.893	rs1447108	chr2:223542231	A/G	cg25565276	chr2:223520875	FARSB	0.62	9.38	0.46	1.02e-18	Schizophrenia (inflammation and infection response interaction);
LUSC	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg21573476	chr21:45109991	RRP1B	0.44	7.11	0.36	7.27e-12	Mean corpuscular volume;
LUSC	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-5.8	-0.3	1.57e-8	Joint mobility (Beighton score);
LUSC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg13560548	chr3:10150139	C3orf24	0.5	7.05	0.36	1.01e-11	Alzheimer's disease;
LUSC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	0.99	18.65	0.71	1.02e-53	Menopause (age at onset);
LUSC	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg16928487	chr17:17741425	SREBF1	0.45	8.81	0.43	6.79e-17	Total body bone mineral density;
LUSC	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg03806693	chr22:41940476	POLR3H	-0.5	-6.91	-0.35	2.45e-11	Neuroticism;
LUSC	cis	rs76878669	0.561	rs7940980	chr11:66172910	C/T	cg24851651	chr11:66362959	CCS	0.39	5.95	0.31	6.77e-9	Educational attainment (years of education);
LUSC	cis	rs2303282	0.716	rs2432538	chr16:56421427	A/G	cg00500540	chr16:56394104	NA	-0.43	-7.32	-0.37	1.84e-12	Breast cancer;
LUSC	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg23958373	chr8:599963	NA	0.83	8.86	0.44	4.77e-17	IgG glycosylation;
LUSC	trans	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-6.57	-0.34	1.98e-10	Neuroticism;
LUSC	cis	rs17095355	0.901	rs28365866	chr10:111767214	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.61	-6.84	-0.35	3.8e-11	Biliary atresia;
LUSC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	12.32	0.56	5.38e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.72	-0.35	7.86e-11	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs9378688	0.654	rs2450307	chr6:2324639	A/G	cg12303981	chr6:2244766	GMDS	-0.41	-5.77	-0.3	1.84e-8	Caudate nucleus volume;
LUSC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg27165867	chr14:105738592	BRF1	-0.55	-8.17	-0.41	6.52e-15	Mean platelet volume;Platelet distribution width;
LUSC	trans	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.38	0.33	5.85e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs12220238	0.908	rs10824077	chr10:75887038	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.63	-7.75	-0.39	1.14e-13	Soluble interleukin-2 receptor subunit alpha;
LUSC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-9.63	-0.47	1.61e-19	Gut microbiome composition (summer);
LUSC	trans	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg01134436	chr17:81009848	B3GNTL1	0.66	6.28	0.32	1.02e-9	Morning vs. evening chronotype;Chronotype;
LUSC	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-8.14	-0.41	7.68e-15	Retinal vascular caliber;
LUSC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg26338869	chr17:61819248	STRADA	0.42	6.08	0.32	3.25e-9	Prudent dietary pattern;
LUSC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.01	0.55	7.43e-28	Colorectal cancer;
LUSC	cis	rs939574	0.818	rs6744146	chr2:220070597	T/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.95	-8.17	-0.41	6.53e-15	Platelet distribution width;
LUSC	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg11062466	chr8:58055876	NA	0.48	5.68	0.3	2.93e-8	Developmental language disorder (linguistic errors);
LUSC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-18.93	-0.72	8.57e-55	Height;
LUSC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	12.7	0.57	2.07e-30	Platelet count;
LUSC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	6.04	0.31	4.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg19875535	chr5:140030758	IK	0.45	7.17	0.37	4.9e-12	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg07169764	chr2:136633963	MCM6	1.18	17.48	0.69	4.99e-49	Corneal structure;
LUSC	cis	rs10465746	0.780	rs12139191	chr1:84387871	A/C	cg10977910	chr1:84465055	TTLL7	0.44	6.36	0.33	6.81e-10	Obesity-related traits;
LUSC	trans	rs13011075	0.881	rs7597167	chr2:68612946	C/T	cg14221825	chr19:46271408	SIX5	0.43	6.17	0.32	1.95e-9	Mean corpuscular volume;
LUSC	cis	rs6541297	0.699	rs12065546	chr1:230295245	C/T	cg05784532	chr1:230284198	GALNT2	0.55	6.3	0.33	9.26e-10	Coronary artery disease;
LUSC	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg26384229	chr12:38710491	ALG10B	0.78	13.3	0.59	1.11e-32	Morning vs. evening chronotype;
LUSC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.66	11.23	0.52	4.91e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs6960043	0.818	rs10807778	chr7:15054190	C/G	cg19272540	chr7:15055459	NA	0.33	8.13	0.41	8.38e-15	Type 2 diabetes;
LUSC	trans	rs6561151	0.957	rs2121034	chr13:44473866	G/T	cg12856521	chr11:46389249	DGKZ	0.57	7.44	0.38	8.69e-13	Crohn's disease;
LUSC	cis	rs10782582	0.609	rs78776851	chr1:76424845	T/C	cg10523679	chr1:76189770	ACADM	-0.43	-6.04	-0.31	4.17e-9	Daytime sleep phenotypes;
LUSC	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg24375607	chr4:120327624	NA	0.75	10.76	0.51	2.15e-23	Corneal astigmatism;
LUSC	trans	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg25214090	chr10:38739885	LOC399744	0.48	6.87	0.35	3.07e-11	Corneal astigmatism;
LUSC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg25838465	chr1:92012736	NA	0.7	13.6	0.6	8.17e-34	Breast cancer;
LUSC	cis	rs9640161	0.783	rs2021871	chr7:150071156	T/C	cg27494647	chr7:150038898	RARRES2	0.36	5.8	0.3	1.52e-8	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg21361702	chr7:150065534	REPIN1	0.52	6.74	0.35	6.77e-11	Blood protein levels;Circulating chemerin levels;
LUSC	cis	rs11809207	1.000	rs34587428	chr1:26522392	C/T	cg00147160	chr1:26503991	CNKSR1	0.42	6.96	0.36	1.8e-11	Height;
LUSC	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08439880	chr3:133502540	NA	0.32	5.76	0.3	1.88e-8	Iron status biomarkers;
LUSC	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg18721089	chr20:30220636	NA	-0.39	-6.15	-0.32	2.2e-9	Mean corpuscular hemoglobin;
LUSC	cis	rs2249625	0.545	rs2249021	chr6:72889472	A/G	cg18830697	chr6:72922368	RIMS1	-0.37	-7.38	-0.37	1.25e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LUSC	cis	rs6494488	0.500	rs72744730	chr15:65040065	C/G	cg08069370	chr15:64387884	SNX1	-0.66	-5.76	-0.3	1.89e-8	Coronary artery disease;
LUSC	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	7.39	0.38	1.16e-12	Response to antipsychotic treatment;
LUSC	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg12823233	chr7:2316876	SNX8	-0.36	-6.01	-0.31	4.92e-9	Schizophrenia, schizoaffective disorder or bipolar disorder;
LUSC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg04944784	chr2:26401820	FAM59B	-0.68	-9.49	-0.46	4.49e-19	Gut microbiome composition (summer);
LUSC	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.63	9.57	0.46	2.57e-19	Retinal vascular caliber;
LUSC	cis	rs2282802	0.685	rs2337081	chr5:139642414	A/C	cg26211634	chr5:139558579	C5orf32	0.44	8.3	0.41	2.59e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg26395211	chr5:140044315	WDR55	-0.37	-5.72	-0.3	2.37e-8	Depressive symptoms (multi-trait analysis);
LUSC	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	7.77	0.39	9.78e-14	Spherical equivalent (joint analysis main effects and education interaction);
LUSC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg15704280	chr7:45808275	SEPT13	-1.12	-24.13	-0.8	3.54e-75	Height;
LUSC	trans	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	10.6	0.5	8.29e-23	Mean corpuscular volume;
LUSC	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg00745463	chr17:30367425	LRRC37B	-0.7	-8.52	-0.42	5.45e-16	Hip circumference adjusted for BMI;
LUSC	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg06547715	chr2:218990976	CXCR2	0.33	6.45	0.33	3.93e-10	Ulcerative colitis;
LUSC	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	6.3	0.33	9.48e-10	Breast cancer;
LUSC	cis	rs6681460	0.932	rs2044400	chr1:67054081	T/A	cg02459107	chr1:67143332	SGIP1	0.46	8.43	0.42	1.04e-15	Presence of antiphospholipid antibodies;
LUSC	cis	rs1957429	0.901	rs1957434	chr14:65349909	C/T	cg23373153	chr14:65346875	NA	1.07	12.89	0.58	3.85e-31	Pediatric areal bone mineral density (radius);
LUSC	trans	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg26811252	chr16:29126840	RRN3P2	0.6	9.61	0.47	1.78e-19	Menopause (age at onset);
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg19302295	chr19:14228590	PRKACA	0.64	5.99	0.31	5.39e-9	Cognitive performance;
LUSC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg03351412	chr1:154909251	PMVK	0.55	8.7	0.43	1.52e-16	Prostate cancer;
LUSC	trans	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	6.89	0.35	2.74e-11	Menarche (age at onset);
LUSC	cis	rs17253792	0.822	rs10129890	chr14:56040413	A/T	cg01858014	chr14:56050164	KTN1	-0.76	-6.24	-0.32	1.32e-9	Putamen volume;
LUSC	trans	rs2055729	0.645	rs7828229	chr8:9742841	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.92	-0.35	2.38e-11	Multiple myeloma (hyperdiploidy);
LUSC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	13.61	0.6	7.09e-34	Cognitive test performance;
LUSC	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg23950597	chr19:37808831	NA	-0.63	-7.6	-0.38	2.95e-13	Coronary artery calcification;
LUSC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.93	15.96	0.66	5.05e-43	Morning vs. evening chronotype;
LUSC	cis	rs72634258	0.786	rs6577468	chr1:8183921	T/C	cg00042356	chr1:8021962	PARK7	0.61	7.42	0.38	9.56e-13	Inflammatory bowel disease;
LUSC	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg13852791	chr20:30311386	BCL2L1	0.93	14.41	0.62	5.98e-37	Mean corpuscular hemoglobin;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg11242200	chr8:22857399	RHOBTB2	-0.42	-6.43	-0.33	4.43e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.44	6.78	0.35	5.42e-11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LUSC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.79	-14.52	-0.62	2.23e-37	Total body bone mineral density;
LUSC	cis	rs6723226	0.767	rs10172308	chr2:32555760	G/A	cg02381751	chr2:32503542	YIPF4	-0.63	-9.7	-0.47	9.04e-20	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg06008330	chr7:65541103	ASL	0.41	6.31	0.33	8.79e-10	Aortic root size;
LUSC	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-13.74	-0.6	2.39e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LUSC	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg26408565	chr15:76604113	ETFA	-0.43	-6.85	-0.35	3.64e-11	Blood metabolite levels;
LUSC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg05084668	chr3:125655381	ALG1L	-0.49	-6.89	-0.35	2.86e-11	Blood pressure (smoking interaction);
LUSC	cis	rs7241530	0.662	rs35308826	chr18:75903736	T/C	cg14642773	chr18:75888474	NA	0.39	6.02	0.31	4.59e-9	Educational attainment (years of education);
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg02205746	chr16:2732724	KCTD5	-0.5	-6.6	-0.34	1.62e-10	Bipolar disorder and schizophrenia;
LUSC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-7.98	-0.4	2.29e-14	Hemoglobin concentration;
LUSC	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg20019720	chr6:154832845	CNKSR3	0.63	8.56	0.42	4.17e-16	Lipoprotein (a) levels;
LUSC	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg18904891	chr8:8559673	CLDN23	0.54	7.48	0.38	6.58e-13	Obesity-related traits;
LUSC	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg24634471	chr8:143751801	JRK	0.51	7.21	0.37	3.71e-12	Schizophrenia;
LUSC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg21724239	chr8:58056113	NA	0.78	9.44	0.46	6.76e-19	Developmental language disorder (linguistic errors);
LUSC	trans	rs10211296	0.584	rs13389345	chr2:166455078	A/G	cg01325958	chr17:37793326	STARD3	0.41	5.94	0.31	6.99e-9	Risky sexual behaviors in alcohol dependence;
LUSC	trans	rs4714291	0.832	rs761798	chr6:40087514	C/T	cg02267698	chr19:7991119	CTXN1	0.57	8.8	0.43	7.51e-17	Strep throat;
LUSC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.91	17.28	0.69	3e-48	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg09034736	chr1:150693464	HORMAD1	0.45	6.25	0.32	1.25e-9	Melanoma;
LUSC	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg04896959	chr15:78267971	NA	0.52	11.03	0.52	2.56e-24	Coronary artery disease or large artery stroke;
LUSC	cis	rs7113850	0.541	rs75893426	chr11:24210429	T/C	ch.11.24196551F	chr11:24239977	NA	0.98	7.5	0.38	5.69e-13	Bone fracture in osteoporosis;
LUSC	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg09904177	chr6:26538194	HMGN4	0.48	7.01	0.36	1.37e-11	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.29	6.54	0.34	2.27e-10	Coronary artery disease;
LUSC	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08645402	chr16:4508243	NA	0.53	8.98	0.44	2.03e-17	Schizophrenia;
LUSC	cis	rs6543140	0.572	rs17027173	chr2:103057043	G/A	cg09003973	chr2:102972529	NA	0.71	8.24	0.41	3.86e-15	Blood protein levels;
LUSC	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	0.49	7.75	0.39	1.11e-13	Uric acid clearance;
LUSC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.62	10.66	0.5	5e-23	Bone mineral density;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg01573445	chr19:45927190	ERCC1	-0.47	-6.21	-0.32	1.57e-9	Hepatitis;
LUSC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-13.0	-0.58	1.52e-31	Platelet count;
LUSC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg19046167	chr17:80928561	B3GNTL1	0.44	7.07	0.36	9.38e-12	Breast cancer;
LUSC	cis	rs722599	0.748	rs2300599	chr14:75359441	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.4	-5.77	-0.3	1.77e-8	IgG glycosylation;
LUSC	cis	rs2346177	0.811	rs4953373	chr2:46652145	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-8.9	-0.44	3.63e-17	HDL cholesterol;
LUSC	cis	rs804280	1.000	rs804280	chr8:11612698	G/T	cg21775007	chr8:11205619	TDH	0.43	6.16	0.32	2.1e-9	Myopia (pathological);
LUSC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg08493051	chr2:3487164	NA	-0.56	-8.66	-0.43	2.12e-16	Neurofibrillary tangles;
LUSC	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg01420254	chr6:26195488	NA	0.69	7.35	0.37	1.53e-12	Gout;Renal underexcretion gout;
LUSC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	0.93	18.29	0.71	2.88e-52	Cognitive function;
LUSC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	6.92	0.35	2.32e-11	Intelligence (multi-trait analysis);
LUSC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.7	10.66	0.5	5e-23	Aortic root size;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19560692	chr2:20646664	RHOB	-0.44	-6.41	-0.33	4.97e-10	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg05340658	chr4:99064831	C4orf37	0.64	10.53	0.5	1.4e-22	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg06521331	chr12:34319734	NA	-0.46	-7.69	-0.39	1.71e-13	Morning vs. evening chronotype;
LUSC	cis	rs7615316	0.751	rs9289647	chr3:142032483	G/A	cg16271453	chr3:142027066	XRN1	-0.4	-6.94	-0.36	2.04e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	0.91	17.45	0.69	6.11e-49	Cerebrospinal fluid biomarker levels;
LUSC	cis	rs11039100	0.607	rs11038944	chr11:5778930	C/T	cg05234568	chr11:5960015	NA	-0.42	-5.67	-0.3	3.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs4654899	0.643	rs12145181	chr1:21086046	C/A	cg01072550	chr1:21505969	NA	-0.47	-7.04	-0.36	1.07e-11	Superior frontal gyrus grey matter volume;
LUSC	cis	rs2219968	1.000	rs7003907	chr8:78976336	A/G	cg00738934	chr8:78996279	NA	0.35	6.3	0.33	9.41e-10	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg05340658	chr4:99064831	C4orf37	-0.46	-7.3	-0.37	2.1e-12	Waist-to-hip ratio adjusted for body mass index;
LUSC	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg22709100	chr7:91322751	NA	0.39	5.86	0.31	1.13e-8	Breast cancer;
LUSC	cis	rs12618769	1.000	rs72825720	chr2:99247508	T/C	cg10123293	chr2:99228465	UNC50	0.42	5.75	0.3	1.96e-8	Bipolar disorder;
LUSC	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-8.59	-0.43	3.46e-16	Body mass index;
LUSC	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg27539214	chr16:67997921	SLC12A4	-0.57	-7.21	-0.37	3.78e-12	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg09365446	chr1:150670422	GOLPH3L	0.55	7.87	0.4	5.01e-14	Urate levels;
LUSC	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg17633681	chr16:88106987	BANP	0.53	10.18	0.49	2.24e-21	Menopause (age at onset);
LUSC	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg22029157	chr1:209979665	IRF6	0.73	8.96	0.44	2.42e-17	Cleft lip with or without cleft palate;
LUSC	cis	rs7315438	0.600	rs1874893	chr12:115886473	A/G	cg24172291	chr12:115889509	NA	0.35	5.99	0.31	5.34e-9	Colorectal cancer;
LUSC	cis	rs9905704	0.881	rs695137	chr17:56776663	G/A	cg12560992	chr17:57184187	TRIM37	0.56	8.01	0.4	1.92e-14	Testicular germ cell tumor;
LUSC	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg19622623	chr12:86230825	RASSF9	0.43	5.99	0.31	5.39e-9	Major depressive disorder;
LUSC	cis	rs5769707	0.681	rs1107514	chr22:50042383	T/C	cg20744362	chr22:50050164	C22orf34	0.37	6.85	0.35	3.55e-11	Monocyte count;Monocyte percentage of white cells;
LUSC	cis	rs4474465	0.915	rs7123060	chr11:78208634	A/G	cg27205649	chr11:78285834	NARS2	0.51	5.89	0.31	9.2e-9	Alzheimer's disease (survival time);
LUSC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.38	0.42	1.54e-15	Prudent dietary pattern;
LUSC	cis	rs10979	1.000	rs6905264	chr6:143894378	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-12.25	-0.56	9.15e-29	Hypospadias;
LUSC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	13.8	0.6	1.34e-34	Alzheimer's disease;
LUSC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-11.06	-0.52	1.96e-24	Alzheimer's disease;
LUSC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg22907277	chr7:1156413	C7orf50	0.7	7.6	0.38	3.08e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg11161011	chr14:65562177	MAX	0.77	12.18	0.55	1.76e-28	Obesity-related traits;
LUSC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg23985595	chr17:80112537	CCDC57	-0.33	-6.52	-0.34	2.6e-10	Life satisfaction;
LUSC	cis	rs10887741	0.690	rs12772633	chr10:89442492	G/A	cg24243914	chr10:89418206	PAPSS2	0.32	6.14	0.32	2.39e-9	Exercise (leisure time);
LUSC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg20203395	chr5:56204925	C5orf35	-0.76	-10.12	-0.48	3.5e-21	Initial pursuit acceleration;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg09060823	chr12:56862504	SPRYD4	0.42	5.98	0.31	5.67e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.79	16.21	0.66	5.1e-44	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.64	6.3	0.33	9.2e-10	Cerebrospinal P-tau181p levels;
LUSC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg04756594	chr16:24857601	SLC5A11	-0.37	-6.21	-0.32	1.61e-9	Intelligence (multi-trait analysis);
LUSC	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-11.9	-0.55	1.77e-27	Hemoglobin concentration;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg23260799	chr11:451101	PTDSS2	0.47	6.62	0.34	1.39e-10	Cognitive function;Information processing speed;
LUSC	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg03342759	chr3:160939853	NMD3	-0.53	-7.56	-0.38	3.97e-13	Parkinson's disease;
LUSC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25067162	chr17:41277974	BRCA1;NBR2	0.36	6.05	0.31	3.95e-9	Menopause (age at onset);
LUSC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg25258033	chr6:167368657	RNASET2	-0.47	-7.78	-0.39	9.43e-14	Crohn's disease;
LUSC	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-7.28	-0.37	2.49e-12	Educational attainment;
LUSC	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.86	-0.4	5.34e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg06637938	chr14:75390232	RPS6KL1	0.51	7.81	0.39	7.28e-14	Height;
LUSC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10802521	chr3:52805072	NEK4	-0.57	-9.3	-0.45	1.87e-18	Electroencephalogram traits;
LUSC	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg23795048	chr12:9217529	LOC144571	0.34	5.88	0.31	9.84e-9	Sjögren's syndrome;
LUSC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg12292205	chr6:26970375	C6orf41	0.66	11.24	0.52	4.54e-25	Autism spectrum disorder or schizophrenia;
LUSC	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg13256891	chr4:100009986	ADH5	-0.5	-6.47	-0.33	3.53e-10	Alcohol dependence;
LUSC	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg20701182	chr2:24300061	SF3B14	0.54	5.78	0.3	1.75e-8	Lymphocyte counts;
LUSC	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg15445000	chr17:37608096	MED1	0.4	6.72	0.35	7.92e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg11344533	chr11:111475393	SIK2	-0.48	-6.58	-0.34	1.78e-10	Primary sclerosing cholangitis;
LUSC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-0.82	-14.34	-0.62	1.15e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg02376097	chr19:46275166	DMPK	0.4	7.15	0.36	5.51e-12	Coronary artery disease;
LUSC	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg17178900	chr1:205818956	PM20D1	0.47	7.26	0.37	2.73e-12	Menarche (age at onset);
LUSC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg24250549	chr1:154909240	PMVK	-0.57	-9.14	-0.45	6.2e-18	Prostate cancer;
LUSC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.62	8.31	0.41	2.42e-15	High light scatter reticulocyte count;
LUSC	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg02569458	chr12:86230093	RASSF9	0.59	9.97	0.48	1.15e-20	Major depressive disorder;
LUSC	trans	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg06762398	chr15:78372177	NA	0.49	6.02	0.31	4.52e-9	Prostate cancer;
LUSC	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	11.84	0.54	3.07e-27	Platelet count;
LUSC	cis	rs72634258	0.786	rs9434991	chr1:8178708	G/C	cg00042356	chr1:8021962	PARK7	0.54	6.61	0.34	1.55e-10	Inflammatory bowel disease;
LUSC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg12751644	chr20:60527061	NA	-0.34	-6.32	-0.33	8.23e-10	Body mass index;
LUSC	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg13010199	chr12:38710504	ALG10B	0.56	8.59	0.43	3.45e-16	Morning vs. evening chronotype;
LUSC	cis	rs9837602	1.000	rs9837602	chr3:99824685	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-6.11	-0.32	2.78e-9	Breast cancer;
LUSC	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg01966878	chr4:90757139	SNCA	-0.36	-6.22	-0.32	1.52e-9	Dementia with Lewy bodies;
LUSC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08847533	chr14:75593920	NEK9	0.69	10.66	0.5	5.01e-23	Height;
LUSC	cis	rs4474465	1.000	rs7935292	chr11:78169885	C/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.74	-0.3	2.12e-8	Alzheimer's disease (survival time);
LUSC	cis	rs9341808	0.935	rs2298307	chr6:80816296	A/G	cg08355045	chr6:80787529	NA	0.51	8.94	0.44	2.68e-17	Sitting height ratio;
LUSC	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg25214090	chr10:38739885	LOC399744	0.5	7.39	0.37	1.19e-12	Corneal astigmatism;
LUSC	cis	rs897080	0.514	rs1067376	chr2:44648361	A/G	cg00619915	chr2:44497795	NA	-0.42	-6.0	-0.31	5.23e-9	Height;
LUSC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg23172400	chr8:95962367	TP53INP1	-0.43	-8.97	-0.44	2.21e-17	Type 2 diabetes;
LUSC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg00012203	chr2:219082015	ARPC2	0.71	11.8	0.54	4.15e-27	Colorectal cancer;
LUSC	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg12620499	chr2:216877984	MREG	0.93	13.93	0.61	4.15e-35	Alcohol dependence;
LUSC	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg20734569	chr3:48348370	SPINK8	-0.46	-7.81	-0.39	7.43e-14	Coronary artery disease;
LUSC	cis	rs11690935	0.959	rs6738445	chr2:172599615	T/C	cg13550731	chr2:172543902	DYNC1I2	0.83	13.25	0.59	1.66e-32	Schizophrenia;
LUSC	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg20016023	chr10:99160130	RRP12	-0.32	-7.99	-0.4	2.16e-14	Granulocyte percentage of myeloid white cells;
LUSC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg18827107	chr12:86230957	RASSF9	-0.48	-7.18	-0.37	4.63e-12	Major depressive disorder;
LUSC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg08200582	chr11:442649	ANO9	-0.55	-5.86	-0.31	1.13e-8	Body mass index;
LUSC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.37	6.16	0.32	2.14e-9	Electroencephalogram traits;
LUSC	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg07701084	chr6:150067640	NUP43	0.5	7.09	0.36	8.1e-12	Lung cancer;
LUSC	trans	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg05943368	chr17:21179232	NA	0.76	6.66	0.34	1.16e-10	Cognitive performance;
LUSC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg26408565	chr15:76604113	ETFA	-0.52	-8.3	-0.41	2.6e-15	Blood metabolite levels;
LUSC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15541040	chr2:3486749	NA	-0.58	-9.21	-0.45	3.59e-18	Neurofibrillary tangles;
LUSC	cis	rs6060717	0.528	rs73905955	chr20:34332938	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.25	-0.32	1.24e-9	Hip circumference adjusted for BMI;
LUSC	trans	rs17518584	0.934	rs1991872	chr3:85443793	C/T	cg13236679	chr6:37467396	C6orf129	0.46	6.23	0.32	1.41e-9	Cognitive function;Information processing speed;
LUSC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg01879757	chr17:41196368	BRCA1	-0.48	-7.4	-0.38	1.12e-12	Menopause (age at onset);
LUSC	cis	rs7131987	0.834	rs7139273	chr12:29434650	T/C	cg09582351	chr12:29534625	ERGIC2	-0.3	-6.35	-0.33	7.2e-10	QT interval;
LUSC	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	1.23	19.68	0.73	8.47e-58	Corneal structure;
LUSC	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg05966235	chr16:28915196	ATP2A1	-0.33	-5.77	-0.3	1.81e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
LUSC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg26441486	chr22:50317300	CRELD2	0.48	7.1	0.36	7.5e-12	Schizophrenia;
LUSC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg07741184	chr6:167504864	NA	0.37	6.59	0.34	1.7e-10	Crohn's disease;
LUSC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg12560992	chr17:57184187	TRIM37	0.71	12.56	0.57	6.54e-30	Intelligence (multi-trait analysis);
LUSC	cis	rs9420	0.961	rs10896647	chr11:57571883	C/T	cg23127183	chr11:57508653	C11orf31	-0.58	-8.84	-0.44	5.64e-17	Schizophrenia;
LUSC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg12560992	chr17:57184187	TRIM37	0.84	15.27	0.64	2.55e-40	Intelligence (multi-trait analysis);
LUSC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.57	8.86	0.44	4.69e-17	Menopause (age at onset);
LUSC	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg02018176	chr4:1364513	KIAA1530	0.44	6.02	0.31	4.62e-9	Recombination rate (females);
LUSC	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg02269571	chr22:50332266	NA	-0.55	-8.2	-0.41	5.16e-15	Schizophrenia;
LUSC	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg02016764	chr4:38805732	TLR1	-0.53	-5.74	-0.3	2.16e-8	Breast cancer;
LUSC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg00074818	chr8:8560427	CLDN23	0.57	9.83	0.47	3.43e-20	Obesity-related traits;
LUSC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg20573242	chr4:122745356	CCNA2	0.44	6.77	0.35	5.65e-11	Type 2 diabetes;
LUSC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg15103426	chr22:29168792	CCDC117	-0.44	-5.7	-0.3	2.69e-8	Lymphocyte counts;
LUSC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06656553	chr16:89960601	TCF25	-0.64	-5.66	-0.3	3.2e-8	Skin colour saturation;
LUSC	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg09835421	chr16:68378352	PRMT7	-0.54	-6.08	-0.32	3.32e-9	HDL cholesterol;Metabolic syndrome;
LUSC	trans	rs7819412	0.635	rs2409716	chr8:11010748	C/T	cg03826601	chr12:9102508	M6PR	0.4	6.42	0.33	4.78e-10	Triglycerides;
LUSC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.83	14.99	0.63	3.44e-39	Mean platelet volume;
LUSC	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg12940439	chr1:67600707	NA	0.38	6.54	0.34	2.33e-10	Psoriasis;
LUSC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03934478	chr11:495069	RNH1	0.82	9.82	0.47	3.7799999999999997e-20	Body mass index;
LUSC	trans	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg25482853	chr8:67687455	SGK3	1.04	15.58	0.65	1.6e-41	Obesity-related traits;
LUSC	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.85	-0.35	3.47e-11	Monocyte percentage of white cells;
LUSC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	13.78	0.6	1.67e-34	Chronic sinus infection;
LUSC	cis	rs983392	0.709	rs2081547	chr11:59989430	C/T	cg20284999	chr11:59952153	MS4A6A	-0.37	-6.12	-0.32	2.57e-9	Alzheimer's disease (late onset);
LUSC	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-6.9	-0.35	2.57e-11	Monocyte percentage of white cells;
LUSC	cis	rs11605275	0.892	rs16937352	chr11:20032010	G/C	cg14835545	chr11:20032148	NAV2	-0.86	-6.53	-0.34	2.43e-10	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg21231944	chr12:82153410	PPFIA2	-0.39	-5.8	-0.3	1.5e-8	Resting heart rate;
LUSC	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg02475777	chr4:1388615	CRIPAK	0.45	6.69	0.34	9.62e-11	Obesity-related traits;
LUSC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	10.42	0.5	3.24e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg15819921	chr19:927150	ARID3A	-0.43	-6.37	-0.33	6.16e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
LUSC	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg08601574	chr20:25228251	PYGB	-0.42	-6.54	-0.34	2.29e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.61	8.55	0.42	4.57e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg24896692	chr6:18387562	RNF144B	-0.42	-6.06	-0.31	3.65e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg27121462	chr16:89883253	FANCA	0.55	9.02	0.44	1.52e-17	Vitiligo;
LUSC	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.59	-9.48	-0.46	4.76e-19	Body mass index;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15585372	chr7:97910571	BRI3	0.44	5.97	0.31	6.03e-9	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.45	-7.07	-0.36	9.2e-12	Parkinson's disease;
LUSC	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	0.91	11.94	0.55	1.33e-27	Uric acid levels;
LUSC	cis	rs2742234	0.955	rs2435385	chr10:43665750	A/G	cg02780029	chr10:43622663	RET	-0.33	-5.92	-0.31	7.93e-9	Hirschsprung disease;
LUSC	trans	rs12439619	0.846	rs28470877	chr15:82538138	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.47	-6.13	-0.32	2.44e-9	Intelligence (multi-trait analysis);
LUSC	trans	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.37	-0.33	6.25e-10	Monocyte count;
LUSC	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg22431228	chr1:16359049	CLCNKA	-0.57	-12.77	-0.57	1.15e-30	Systolic blood pressure;
LUSC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg09626299	chr10:82213104	TSPAN14	-0.2	-5.92	-0.31	8.16e-9	Post bronchodilator FEV1;
LUSC	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg25019033	chr10:957182	NA	-0.58	-7.75	-0.39	1.14e-13	Eosinophil percentage of granulocytes;
LUSC	cis	rs7605827	0.930	rs2277916	chr2:15494152	C/G	cg19274914	chr2:15703543	NA	0.45	8.59	0.43	3.33e-16	Educational attainment (years of education);
LUSC	cis	rs11195062	0.766	rs7897645	chr10:112006669	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.92	-0.31	8e-9	Multiple myeloma;
LUSC	cis	rs6076065	0.963	rs6048777	chr20:23373302	C/T	cg11657817	chr20:23433608	CST11	0.43	8.68	0.43	1.77e-16	Facial morphology (factor 15, philtrum width);
LUSC	cis	rs2692947	0.763	rs7570074	chr2:96407037	T/C	cg23100626	chr2:96804247	ASTL	0.26	6.38	0.33	6.08e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg07701084	chr6:150067640	NUP43	0.56	8.55	0.42	4.49e-16	Lung cancer;
LUSC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg19592336	chr6:28129416	ZNF389	0.5	6.75	0.35	6.37e-11	Depression;
LUSC	cis	rs1160297	0.609	rs1451455	chr2:53101529	T/C	cg07782112	chr2:53107842	NA	0.43	7.14	0.36	5.76e-12	Hemostatic factors and hematological phenotypes;
LUSC	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg15744005	chr10:104629667	AS3MT	-0.33	-6.78	-0.35	5.33e-11	Arsenic metabolism;
LUSC	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg19554555	chr3:13937349	NA	-0.41	-6.08	-0.32	3.37e-9	Ovarian reserve;
LUSC	cis	rs9297145	0.509	rs13222381	chr7:98785024	T/G	cg05967295	chr7:98741636	SMURF1	-0.6	-9.17	-0.45	4.92e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LUSC	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg17507749	chr15:85114479	UBE2QP1	0.54	6.74	0.35	7.17e-11	Schizophrenia;
LUSC	cis	rs2294693	0.947	rs10456496	chr6:40988840	A/G	cg14769373	chr6:40998127	UNC5CL	0.55	8.21	0.41	4.93e-15	Gastric cancer;Non-cardia gastric cancer;
LUSC	cis	rs9815354	0.812	rs10510733	chr3:42009192	T/C	cg03022575	chr3:42003672	ULK4	0.82	8.57	0.42	3.93e-16	Pulse pressure;Diastolic blood pressure;
LUSC	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg08270630	chr22:50330655	NA	-0.38	-5.64	-0.3	3.58e-8	Schizophrenia;
LUSC	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.61	-8.65	-0.43	2.13e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LUSC	cis	rs11158026	0.757	rs8018800	chr14:55453306	C/T	cg04306507	chr14:55594613	LGALS3	-0.38	-7.55	-0.38	4.21e-13	Parkinson's disease;
LUSC	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg18123596	chr17:36956264	PIP4K2B	0.47	6.34	0.33	7.61e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LUSC	cis	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg26958806	chr6:27640298	NA	0.74	6.04	0.31	4.02e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg05163923	chr11:71159392	DHCR7	-0.77	-10.02	-0.48	7.56e-21	Vitamin D levels;
LUSC	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg15133208	chr4:90757351	SNCA	-0.52	-7.97	-0.4	2.52e-14	Neuroticism;
LUSC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	0.92	15.2	0.64	4.85e-40	Breast cancer;
LUSC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.68	11.66	0.54	1.38e-26	Aortic root size;
LUSC	cis	rs34421088	0.586	rs2272594	chr8:11142625	T/C	cg21775007	chr8:11205619	TDH	0.5	7.15	0.36	5.55e-12	Neuroticism;
LUSC	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22307029	chr19:49891270	CCDC155	0.52	7.0	0.36	1.41e-11	Multiple sclerosis;
LUSC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg17143192	chr8:8559678	CLDN23	0.66	9.26	0.45	2.46e-18	Obesity-related traits;
LUSC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg17366294	chr4:99064904	C4orf37	0.59	10.6	0.5	8.31e-23	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs16912285	0.636	rs7114960	chr11:24310828	G/A	ch.11.24196551F	chr11:24239977	NA	0.85	8.87	0.44	4.55e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	trans	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg14791747	chr16:20752902	THUMPD1	-0.4	-6.16	-0.32	2.09e-9	Dental caries;
LUSC	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg24060327	chr5:131705240	SLC22A5	-0.48	-7.76	-0.39	1.04e-13	Breast cancer;
LUSC	cis	rs2282300	0.653	rs12800124	chr11:30239865	A/G	cg25418670	chr11:30344373	C11orf46	-0.66	-9.53	-0.46	3.4e-19	Morning vs. evening chronotype;
LUSC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.58	-8.22	-0.41	4.44e-15	Longevity;Endometriosis;
LUSC	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg07169764	chr2:136633963	MCM6	-0.62	-8.08	-0.4	1.22e-14	Mosquito bite size;
LUSC	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg18301423	chr5:131593218	PDLIM4	0.45	6.84	0.35	3.85e-11	Acylcarnitine levels;
LUSC	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg12091567	chr17:66097778	LOC651250	-0.73	-9.54	-0.46	3.03e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs13385	0.769	rs6871511	chr5:139592314	G/A	cg26211634	chr5:139558579	C5orf32	0.45	6.48	0.33	3.27e-10	Atrial fibrillation;
LUSC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg27165867	chr14:105738592	BRF1	-0.51	-7.45	-0.38	7.86e-13	Mean platelet volume;Platelet distribution width;
LUSC	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg24733560	chr20:60626293	TAF4	0.36	5.84	0.3	1.21e-8	Body mass index;
LUSC	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg17724175	chr1:150552817	MCL1	0.43	7.43	0.38	9.32e-13	Urate levels;
LUSC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12379764	chr21:47803548	PCNT	-0.42	-5.97	-0.31	5.91e-9	Testicular germ cell tumor;
LUSC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	12.38	0.56	3.16e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs752010	0.619	rs6703992	chr1:42115888	G/A	cg06885757	chr1:42089581	HIVEP3	0.57	11.47	0.53	6.46e-26	Lupus nephritis in systemic lupus erythematosus;
LUSC	trans	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg19862616	chr7:65841803	NCRNA00174	0.84	9.49	0.46	4.52e-19	Eotaxin levels;
LUSC	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-10.15	-0.49	2.72e-21	Migraine;Coronary artery disease;
LUSC	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg03647239	chr10:116582469	FAM160B1	0.41	6.23	0.32	1.41e-9	Bipolar disorder or attention deficit hyperactivity disorder;
LUSC	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg04117972	chr1:227635322	NA	0.57	6.73	0.35	7.56e-11	Major depressive disorder;
LUSC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	11.37	0.53	1.56e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LUSC	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg11019008	chr10:131425282	MGMT	-0.39	-5.7	-0.3	2.7e-8	Response to temozolomide;
LUSC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg07741184	chr6:167504864	NA	0.35	6.23	0.32	1.41e-9	Crohn's disease;
LUSC	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-24.41	-0.8	2.87e-76	Exhaled nitric oxide levels;
LUSC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg12463550	chr7:65579703	CRCP	-0.55	-8.35	-0.42	1.82e-15	Aortic root size;
LUSC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.2	13.62	0.6	6.4e-34	Diabetic kidney disease;
LUSC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.82	-0.39	7.17e-14	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21028142	chr17:79581711	NPLOC4	0.32	7.79	0.39	8.41e-14	Eye color traits;
LUSC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-1.12	-24.92	-0.81	3.6e-78	Height;
LUSC	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg01677386	chr11:118938358	VPS11	-0.48	-6.8	-0.35	4.93e-11	Coronary artery disease;
LUSC	cis	rs13401104	0.796	rs72620806	chr2:237113736	C/T	cg19324714	chr2:237145437	ASB18	0.43	5.72	0.3	2.35e-8	Educational attainment;
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02351056	chr10:126480372	METTL10	-0.39	-6.03	-0.31	4.41e-9	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg13395646	chr4:1353034	KIAA1530	0.6	9.08	0.44	9.58e-18	Obesity-related traits;
LUSC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10802521	chr3:52805072	NEK4	-0.55	-8.77	-0.43	9.4e-17	Bipolar disorder;
LUSC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg06784218	chr1:46089804	CCDC17	0.48	9.5	0.46	4.15e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LUSC	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg01017244	chr2:74357527	NA	0.71	13.71	0.6	3.06e-34	Gestational age at birth (maternal effect);
LUSC	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-13.47	-0.59	2.41e-33	Electrocardiographic conduction measures;
LUSC	cis	rs4566357	0.930	rs13424003	chr2:227926860	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.89	-0.31	9.43e-9	Coronary artery disease;
LUSC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.66	11.19	0.52	6.63e-25	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg23711669	chr6:146136114	FBXO30	-0.82	-14.69	-0.63	4.91e-38	Lobe attachment (rater-scored or self-reported);
LUSC	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22050897	chr2:236840170	AGAP1	-0.37	-6.34	-0.33	7.29e-10	Age-related hearing impairment (SNP x SNP interaction);
LUSC	cis	rs1405069	0.809	rs1063021	chr6:36932327	A/G	cg26433444	chr6:36932349	PI16	0.29	7.03	0.36	1.16e-11	Chemerin levels;
LUSC	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg27219399	chr15:67835830	MAP2K5	0.36	5.74	0.3	2.17e-8	Obesity;
LUSC	cis	rs981844	0.857	rs56198877	chr4:154718970	A/G	cg14289246	chr4:154710475	SFRP2	0.47	5.94	0.31	7e-9	Response to statins (LDL cholesterol change);
LUSC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg06238570	chr21:40685208	BRWD1	-0.58	-8.76	-0.43	1.02e-16	Menarche (age at onset);
LUSC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.65	-10.53	-0.5	1.44e-22	Longevity;Endometriosis;
LUSC	cis	rs2742417	0.587	rs2742375	chr3:45784602	G/A	cg04837898	chr3:45731254	SACM1L	-0.45	-7.35	-0.37	1.55e-12	Response to anti-depressant treatment in major depressive disorder;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg07364676	chr22:29137974	CHEK2;HSCB	-0.46	-5.96	-0.31	6.37e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-17.84	-0.7	1.73e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg11502198	chr6:26597334	ABT1	-0.69	-11.17	-0.52	7.75e-25	Intelligence (multi-trait analysis);
LUSC	cis	rs6424115	0.546	rs35993651	chr1:24180613	C/G	cg15997130	chr1:24165203	NA	-0.49	-8.05	-0.4	1.42e-14	Immature fraction of reticulocytes;
LUSC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.84	-13.0	-0.58	1.57e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LUSC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg25036284	chr2:26402008	FAM59B	-0.71	-10.02	-0.48	7.79e-21	Gut microbiome composition (summer);
LUSC	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	6.85	0.35	3.59e-11	Ulcerative colitis;Inflammatory bowel disease;
LUSC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06634786	chr22:41940651	POLR3H	0.53	6.15	0.32	2.2e-9	Vitiligo;
LUSC	cis	rs72781680	0.706	rs72794290	chr2:23896106	A/T	cg08917208	chr2:24149416	ATAD2B	0.98	9.61	0.47	1.76e-19	Lymphocyte counts;
LUSC	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.75	6.61	0.34	1.5e-10	Schizophrenia;
LUSC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	13.69	0.6	3.61e-34	Platelet count;
LUSC	cis	rs73195822	0.614	rs73194057	chr12:111216913	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	7.73	0.39	1.28e-13	Itch intensity from mosquito bite;
LUSC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.6	8.06	0.4	1.39e-14	High light scatter reticulocyte count;
LUSC	trans	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg10756647	chr7:56101905	PSPH	0.85	8.28	0.41	3.01e-15	Diabetic kidney disease;
LUSC	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg17830980	chr10:43048298	ZNF37B	0.57	8.43	0.42	1.05e-15	Extrinsic epigenetic age acceleration;
LUSC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg08888203	chr3:10149979	C3orf24	0.64	8.54	0.42	4.67e-16	Alzheimer's disease;
LUSC	cis	rs3820928	0.874	rs1996998	chr2:227840294	C/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-7.51	-0.38	5.57e-13	Pulmonary function;
LUSC	cis	rs752010	0.619	rs1123483	chr1:42114198	C/T	cg06885757	chr1:42089581	HIVEP3	-0.59	-12.11	-0.55	3.21e-28	Lupus nephritis in systemic lupus erythematosus;
LUSC	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.52	-7.69	-0.39	1.67e-13	Renal function-related traits (BUN);
LUSC	cis	rs7597155	0.935	rs7589995	chr2:69980427	A/G	cg02498382	chr2:70120550	SNRNP27	-0.24	-5.77	-0.3	1.77e-8	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg01966878	chr4:90757139	SNCA	-0.34	-5.9	-0.31	8.95e-9	Dementia with Lewy bodies;
LUSC	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg10621924	chr7:39171070	POU6F2	0.42	6.26	0.32	1.17e-9	IgG glycosylation;
LUSC	cis	rs360798	0.512	rs360801	chr2:62955387	C/T	cg17519650	chr2:63277830	OTX1	0.42	5.91	0.31	8.42e-9	Coronary artery disease;
LUSC	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg18806716	chr10:30721971	MAP3K8	-0.62	-9.92	-0.48	1.7e-20	Inflammatory bowel disease;
LUSC	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg03060546	chr3:49711283	APEH	0.65	7.67	0.39	1.84e-13	Menarche (age at onset);
LUSC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.52	8.72	0.43	1.37e-16	Immature fraction of reticulocytes;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg08475257	chr11:65819627	SF3B2	-0.41	-6.26	-0.32	1.19e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs62400317	0.614	rs12210292	chr6:44925293	A/G	cg18551225	chr6:44695536	NA	-0.39	-5.77	-0.3	1.79e-8	Total body bone mineral density;
LUSC	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg01689657	chr7:91764605	CYP51A1	0.32	5.78	0.3	1.69e-8	Breast cancer;
LUSC	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg16342193	chr10:102329863	NA	-0.37	-6.64	-0.34	1.26e-10	Palmitoleic acid (16:1n-7) levels;
LUSC	cis	rs35883536	0.647	rs2783693	chr1:101045040	C/T	cg06223162	chr1:101003688	GPR88	0.49	9.15	0.45	5.99e-18	Monocyte count;
LUSC	cis	rs7267979	0.586	rs6050431	chr20:25183908	C/T	cg08601574	chr20:25228251	PYGB	0.44	6.68	0.34	1e-10	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg05313129	chr8:58192883	C8orf71	-0.51	-5.79	-0.3	1.64e-8	Developmental language disorder (linguistic errors);
LUSC	cis	rs259282	0.514	rs10420153	chr19:33112957	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.74	10.78	0.51	1.92e-23	Schizophrenia;
LUSC	cis	rs7633857	0.512	rs10936215	chr3:160652271	A/G	cg03342759	chr3:160939853	NMD3	-0.41	-5.98	-0.31	5.76e-9	Educational attainment (years of education);
LUSC	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg02493740	chr2:85810744	VAMP5	-0.53	-9.37	-0.46	1.14e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LUSC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.73	-10.19	-0.49	2.06e-21	Glomerular filtration rate (creatinine);
LUSC	cis	rs10489202	0.683	rs4657730	chr1:168072738	A/T	cg24449463	chr1:168025552	DCAF6	-0.66	-9.84	-0.47	3.03e-20	Schizophrenia;
LUSC	cis	rs11779988	0.545	rs454692	chr8:17789298	T/C	cg01800426	chr8:17659068	MTUS1	-0.5	-6.12	-0.32	2.61e-9	Breast cancer;
LUSC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg11062466	chr8:58055876	NA	0.76	9.09	0.45	9.22e-18	Developmental language disorder (linguistic errors);
LUSC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg13010199	chr12:38710504	ALG10B	0.69	11.27	0.52	3.59e-25	Heart rate;
LUSC	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg14733031	chr19:17904427	B3GNT3	-0.4	-6.52	-0.34	2.61e-10	Calcium levels;
LUSC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg20406979	chr6:167373233	NA	0.27	6.21	0.32	1.61e-9	Crohn's disease;
LUSC	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg22815214	chr1:201083145	CACNA1S	0.43	5.9	0.31	8.71e-9	Permanent tooth development;
LUSC	cis	rs9308433	0.529	rs904321	chr1:214506550	G/C	cg06198575	chr1:214491504	SMYD2	0.46	7.19	0.37	4.33e-12	IgG glycosylation;
LUSC	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.86	-19.8	-0.73	2.78e-58	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs965469	0.895	rs12626130	chr20:3393192	G/T	cg25506879	chr20:3388711	C20orf194	-0.55	-5.77	-0.3	1.84e-8	IFN-related cytopenia;
LUSC	trans	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg21659725	chr3:3221576	CRBN	-0.71	-7.82	-0.39	7.08e-14	Menarche (age at onset);
LUSC	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-8.86	-0.44	4.7e-17	Response to antipsychotic treatment;
LUSC	cis	rs5770917	1.000	rs2269384	chr22:51011115	C/T	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.61	-5.7	-0.3	2.69e-8	Narcolepsy;
LUSC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg23711669	chr6:146136114	FBXO30	0.92	17.68	0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg03563238	chr19:33554763	RHPN2	-0.39	-6.24	-0.32	1.3e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
LUSC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg13939156	chr17:80058883	NA	0.34	6.73	0.35	7.56e-11	Life satisfaction;
LUSC	cis	rs9473147	0.516	rs1485780	chr6:47556630	A/C	cg12968598	chr6:47444699	CD2AP	0.52	7.93	0.4	3.32e-14	Platelet distribution width;Mean platelet volume;
LUSC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg13319975	chr6:146136371	FBXO30	0.5	7.48	0.38	6.6e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.78	11.27	0.52	3.47e-25	Corneal astigmatism;
LUSC	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-10.13	-0.48	3.26e-21	Platelet distribution width;
LUSC	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg11693508	chr17:37793320	STARD3	0.51	6.12	0.32	2.69e-9	Bipolar disorder;
LUSC	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.99	0.36	1.51e-11	Morning vs. evening chronotype;
LUSC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg01238044	chr22:24384105	GSTT1	-0.51	-7.36	-0.37	1.47e-12	Liver enzyme levels (gamma-glutamyl transferase);
LUSC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.58	9.48	0.46	4.76e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LUSC	trans	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg21775007	chr8:11205619	TDH	0.45	6.36	0.33	6.62e-10	Systolic blood pressure;
LUSC	cis	rs6060717	0.653	rs2590962	chr20:34615363	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-6.37	-0.33	6.14e-10	Hip circumference adjusted for BMI;
LUSC	cis	rs11158026	0.603	rs67571433	chr14:55447982	A/G	cg04306507	chr14:55594613	LGALS3	0.4	7.42	0.38	9.78e-13	Parkinson's disease;
LUSC	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg15605315	chr1:45957053	TESK2	0.49	8.02	0.4	1.74e-14	High light scatter reticulocyte count;
LUSC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg23630131	chr7:65973040	NA	-0.21	-5.93	-0.31	7.77e-9	Aortic root size;
LUSC	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.01	-0.36	1.3e-11	Colorectal cancer;
LUSC	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg26408565	chr15:76604113	ETFA	-0.44	-6.92	-0.35	2.36e-11	Blood metabolite levels;
LUSC	cis	rs62400317	0.859	rs6919873	chr6:45159336	A/G	cg18551225	chr6:44695536	NA	-0.44	-7.26	-0.37	2.76e-12	Total body bone mineral density;
LUSC	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg22089800	chr15:90895588	ZNF774	-0.64	-9.66	-0.47	1.27e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LUSC	cis	rs3931020	0.688	rs277396	chr1:75213648	A/C	cg26855724	chr1:75198818	TYW3;CRYZ	-0.46	-5.84	-0.3	1.24e-8	Resistin levels;
LUSC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg14668632	chr7:2872130	GNA12	-0.4	-5.68	-0.3	2.96e-8	Height;
LUSC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg12432903	chr7:1882776	MAD1L1	-0.36	-5.82	-0.3	1.41e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg23262073	chr20:60523788	NA	-0.39	-6.24	-0.32	1.36e-9	Body mass index;
LUSC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-8.28	-0.41	3.03e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.54	-8.08	-0.4	1.17e-14	Menarche (age at onset);
LUSC	cis	rs6546537	1.000	rs3899666	chr2:69867871	A/G	cg10773587	chr2:69614142	GFPT1	0.42	6.48	0.33	3.29e-10	Serum thyroid-stimulating hormone levels;
LUSC	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg21548813	chr6:291882	DUSP22	-0.7	-11.49	-0.53	5.74e-26	Menopause (age at onset);
LUSC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.8	-11.76	-0.54	6.2e-27	Multiple sclerosis;
LUSC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.84	13.87	0.6	7.3e-35	Blood metabolite levels;Acylcarnitine levels;
LUSC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg05347473	chr6:146136440	FBXO30	0.49	8.22	0.41	4.64e-15	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg14019146	chr3:50243930	SLC38A3	-0.32	-7.09	-0.36	8.22e-12	Intelligence (multi-trait analysis);
LUSC	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg17757837	chr7:157058334	UBE3C	-0.91	-15.03	-0.64	2.3e-39	Body mass index;
LUSC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23158103	chr7:148848205	ZNF398	-0.47	-7.71	-0.39	1.5e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LUSC	cis	rs6693567	0.565	rs698913	chr1:150299145	G/A	cg15654264	chr1:150340011	RPRD2	0.44	7.02	0.36	1.22e-11	Migraine;
LUSC	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg05527609	chr1:210001259	C1orf107	0.94	12.02	0.55	6.49e-28	Orofacial clefts;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04279164	chr11:106698694	GUCY1A2	0.42	6.7	0.34	8.61e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs2303282	0.716	rs2587869	chr16:56406926	G/A	cg00500540	chr16:56394104	NA	-0.44	-7.6	-0.38	3.04e-13	Breast cancer;
LUSC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	0.99	13.85	0.6	9.05e-35	Eosinophil percentage of granulocytes;
LUSC	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.89	-20.57	-0.75	2.54e-61	Liver enzyme levels (alkaline phosphatase);
LUSC	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg19731845	chr4:166199412	KLHL2;GK3P	0.45	6.07	0.32	3.38e-9	Corneal astigmatism;
LUSC	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg22906224	chr7:99728672	NA	-0.5	-6.94	-0.35	2.09e-11	Coronary artery disease;
LUSC	cis	rs686320	1.000	rs2957267	chr11:65235792	C/T	cg21890820	chr11:65308645	LTBP3	0.79	7.96	0.4	2.74e-14	Hip circumference adjusted for BMI;
LUSC	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-8.54	-0.42	4.85e-16	Joint mobility (Beighton score);
LUSC	trans	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg06753689	chr10:1034030	GTPBP4	-0.6	-5.97	-0.31	6.09e-9	Autism spectrum disorder or schizophrenia;
LUSC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-0.99	-17.56	-0.69	2.27e-49	Height;
LUSC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg21132104	chr15:45694354	SPATA5L1	0.57	7.97	0.4	2.54e-14	Homoarginine levels;
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17074213	chr1:92351695	TGFBR3	0.53	9.13	0.45	6.75e-18	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg22789318	chr17:981643	ABR	0.47	6.33	0.33	7.98e-10	Neuroticism;
LUSC	cis	rs1003719	0.679	rs2246285	chr21:38582431	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-9.86	-0.47	2.79e-20	Eye color traits;
LUSC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg15534755	chr11:117069859	TAGLN	0.34	5.88	0.31	1.01e-8	Blood protein levels;
LUSC	cis	rs701145	0.938	rs355768	chr3:154045001	A/G	cg17054900	chr3:154042577	DHX36	0.82	8.64	0.43	2.31e-16	Coronary artery disease;
LUSC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg05861140	chr6:150128134	PCMT1	-0.38	-6.04	-0.31	4.07e-9	Lung cancer;
LUSC	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.82	-0.3	1.36e-8	Testicular germ cell tumor;
LUSC	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg16989719	chr2:238392110	NA	-0.36	-6.2	-0.32	1.64e-9	Prostate cancer;
LUSC	cis	rs4343996	0.870	rs7780027	chr7:3386228	T/C	cg21248987	chr7:3385318	SDK1	-0.4	-6.63	-0.34	1.33e-10	Motion sickness;
LUSC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18404041	chr3:52824283	ITIH1	-0.57	-11.2	-0.52	5.98e-25	Bipolar disorder;
LUSC	cis	rs2692947	0.832	rs62153679	chr2:96558400	C/T	cg23100626	chr2:96804247	ASTL	0.26	6.36	0.33	6.62e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LUSC	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	14.33	0.62	1.18e-36	Allergic disease (asthma, hay fever or eczema);
LUSC	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg05425664	chr17:57184151	TRIM37	-0.49	-7.41	-0.38	1.03e-12	Testicular germ cell tumor;
LUSC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.69	-11.64	-0.54	1.59e-26	Cognitive function;
LUSC	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg02891314	chr5:179741120	GFPT2	-0.58	-9.17	-0.45	4.95e-18	Height;
LUSC	cis	rs4737010	0.578	rs4466386	chr8:41679853	A/G	cg08923054	chr8:41654455	ANK1	0.35	6.9	0.35	2.59e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LUSC	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.19	-0.49	2.13e-21	Platelet count;
LUSC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	0.91	18.43	0.71	7.95e-53	Dental caries;
LUSC	cis	rs6942756	0.774	rs2694574	chr7:128908963	A/G	cg02491457	chr7:128862824	NA	0.51	7.71	0.39	1.5e-13	White matter hyperintensity burden;
LUSC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg26587870	chr6:27730563	NA	-0.64	-6.03	-0.31	4.37e-9	Depression;
LUSC	cis	rs4919694	1.000	rs77969925	chr10:104649357	C/T	cg04362960	chr10:104952993	NT5C2	1.14	13.06	0.58	9.2e-32	Arsenic metabolism;
LUSC	cis	rs3767633	0.502	rs2499845	chr1:161933066	G/C	cg27519958	chr1:161735129	ATF6	-0.38	-5.9	-0.31	8.79e-9	IgG glycosylation;
LUSC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg26924012	chr15:45694286	SPATA5L1	1.12	20.85	0.75	2.06e-62	Homoarginine levels;
LUSC	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg05025164	chr4:1340916	KIAA1530	0.43	6.42	0.33	4.66e-10	Obesity-related traits;
LUSC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg20283391	chr11:68216788	NA	0.59	8.32	0.41	2.25e-15	Total body bone mineral density;
LUSC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg25767906	chr1:53392781	SCP2	0.53	9.69	0.47	9.78e-20	Monocyte count;
LUSC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg01256987	chr12:42539512	GXYLT1	-0.44	-8.5	-0.42	6.62e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LUSC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg04944784	chr2:26401820	FAM59B	-0.77	-11.31	-0.53	2.54e-25	Gut microbiome composition (summer);
LUSC	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-6.06	-0.31	3.6e-9	Ulcerative colitis;
LUSC	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-9.86	-0.47	2.69e-20	Migraine;Coronary artery disease;
LUSC	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg16586182	chr3:47516702	SCAP	0.51	7.29	0.37	2.31e-12	Colorectal cancer;
LUSC	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.42	5.93	0.31	7.51e-9	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg02018176	chr4:1364513	KIAA1530	0.46	6.45	0.33	3.83e-10	Recombination rate (females);
LUSC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg21724239	chr8:58056113	NA	0.77	8.35	0.42	1.81e-15	Developmental language disorder (linguistic errors);
LUSC	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg22823121	chr1:150693482	HORMAD1	-0.46	-6.76	-0.35	6.28e-11	Melanoma;
LUSC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg21535247	chr6:8435926	SLC35B3	0.59	9.24	0.45	3.06e-18	Motion sickness;
LUSC	cis	rs7804356	1.000	rs3801834	chr7:26852062	T/C	cg03456212	chr7:26904342	SKAP2	-0.54	-6.25	-0.32	1.24e-9	Type 1 diabetes;
LUSC	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg20908204	chr19:46285434	DMPK	-0.46	-8.74	-0.43	1.19e-16	Coronary artery disease;
LUSC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21545522	chr1:205238299	TMCC2	0.51	9.82	0.47	3.72e-20	Mean corpuscular volume;Mean platelet volume;
LUSC	trans	rs17075286	1	rs17075286	chr3:43230723	C/G	cg00455883	chr3:73046007	PPP4R2	-0.47	-6.29	-0.33	1.01e-9	Bipolar disorder and schizophrenia;
LUSC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg09877947	chr5:131593287	PDLIM4	0.47	7.28	0.37	2.35e-12	Breast cancer;
LUSC	cis	rs7584330	0.554	rs6736468	chr2:238422228	A/G	cg14458575	chr2:238380390	NA	0.47	6.21	0.32	1.54e-9	Prostate cancer;
LUSC	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg20368463	chr18:77673604	PQLC1	-0.59	-9.06	-0.44	1.11e-17	Schizophrenia;
LUSC	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg20203395	chr5:56204925	C5orf35	-0.46	-6.93	-0.35	2.18e-11	Breast cancer;Breast cancer (early onset);
LUSC	cis	rs714027	0.566	rs4820827	chr22:30477589	T/C	cg11564601	chr22:30592435	NA	-0.33	-5.71	-0.3	2.52e-8	Lymphocyte counts;
LUSC	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg23985595	chr17:80112537	CCDC57	-0.33	-6.38	-0.33	6.07e-10	Life satisfaction;
LUSC	cis	rs3087591	1.000	rs9904169	chr17:29572518	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.56	-8.19	-0.41	5.62e-15	Hip circumference;
LUSC	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg03948781	chr1:205179583	DSTYK	0.3	5.8	0.3	1.54e-8	Mean corpuscular volume;Mean platelet volume;
LUSC	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg26695010	chr11:65641043	EFEMP2	0.55	8.47	0.42	7.65e-16	Eosinophil percentage of white cells;
LUSC	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg17810781	chr1:201082982	CACNA1S	0.34	6.46	0.33	3.65e-10	Permanent tooth development;
LUSC	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg11189052	chr15:85197271	WDR73	0.54	6.13	0.32	2.42e-9	Schizophrenia;
LUSC	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg13073564	chr4:8508604	NA	0.45	8.45	0.42	8.87e-16	Response to antineoplastic agents;
LUSC	cis	rs12681287	0.752	rs10435563	chr8:87266060	C/T	cg27223183	chr8:87520930	FAM82B	-0.45	-5.72	-0.3	2.33e-8	Caudate activity during reward;
LUSC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.48	-6.19	-0.32	1.79e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
LUSC	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg11845111	chr2:191398756	TMEM194B	-0.86	-10.83	-0.51	1.25e-23	Diastolic blood pressure;
LUSC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.72	12.76	0.57	1.22e-30	Prudent dietary pattern;
LUSC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.46	-8.24	-0.41	4.06e-15	Intelligence (multi-trait analysis);
LUSC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg10729496	chr3:10149963	C3orf24	0.53	7.17	0.37	4.94e-12	Alzheimer's disease;
LUSC	cis	rs7712401	0.601	rs36099390	chr5:122317719	G/A	cg19077854	chr5:122220652	SNX24	-0.43	-9.53	-0.46	3.35e-19	Mean platelet volume;
LUSC	cis	rs17407555	0.601	rs73229828	chr4:10026833	A/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-6.25	-0.32	1.24e-9	Schizophrenia (age at onset);
LUSC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg20203395	chr5:56204925	C5orf35	-0.75	-10.33	-0.49	6.65e-22	Initial pursuit acceleration;
LUSC	trans	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg10536369	chr2:170335894	BBS5	0.33	6.1	0.32	2.89e-9	Height;
LUSC	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.75	8.76	0.43	9.89e-17	Schizophrenia;
LUSC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.42	0.38	9.97e-13	Bipolar disorder;
LUSC	trans	rs561341	0.609	rs739800	chr17:30190083	T/A	cg20587970	chr11:113659929	NA	0.81	9.8	0.47	4.41e-20	Hip circumference adjusted for BMI;
LUSC	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	6.17	0.32	1.95e-9	Tonsillectomy;
LUSC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-13.32	-0.59	9.34e-33	Extrinsic epigenetic age acceleration;
LUSC	cis	rs4730250	0.707	rs257378	chr7:106801395	C/G	cg02696742	chr7:106810147	HBP1	-0.64	-8.94	-0.44	2.63e-17	Osteoarthritis;
LUSC	cis	rs3764021	0.870	rs10844597	chr12:9874899	G/A	cg20894963	chr12:9885564	CLECL1	0.35	7.13	0.36	6.24e-12	Type 1 diabetes;
LUSC	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17344932	chr17:38183730	MED24;SNORD124	-0.43	-6.82	-0.35	4.38e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LUSC	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg19789473	chr17:27170043	C17orf63	-0.3	-5.67	-0.3	3.08e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LUSC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-7.39	-0.37	1.19e-12	Mood instability;
LUSC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13126279	chr21:47581558	C21orf56	-0.46	-6.82	-0.35	4.19e-11	Testicular germ cell tumor;
LUSC	cis	rs1595825	0.891	rs4491721	chr2:198521407	C/G	cg19156104	chr2:198669113	PLCL1	-0.45	-5.69	-0.3	2.74e-8	Ulcerative colitis;
LUSC	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg26727032	chr16:67993705	SLC12A4	-0.44	-5.87	-0.31	1.05e-8	HDL cholesterol;Metabolic syndrome;
LUSC	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg12863693	chr15:85201151	NMB	0.42	8.65	0.43	2.14e-16	Schizophrenia;
LUSC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg16325326	chr1:53192061	ZYG11B	0.94	18.87	0.72	1.39e-54	Monocyte count;
LUSC	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-7.78	-0.39	9.19e-14	Retinal vascular caliber;
LUSC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.75	12.78	0.57	1.01e-30	Motion sickness;
LUSC	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	0.97	10.96	0.51	4.58e-24	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg27170947	chr2:26402098	FAM59B	-0.69	-10.28	-0.49	1e-21	Gut microbiome composition (summer);
LUSC	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.49	6.96	0.36	1.79e-11	Iron status biomarkers;
LUSC	cis	rs7507204	0.723	rs12982194	chr19:3411947	G/A	cg08380311	chr19:3435252	NFIC	0.7	9.63	0.47	1.59e-19	Height;
LUSC	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.55	-8.48	-0.42	7.32e-16	Lymphocyte counts;
LUSC	cis	rs10740039	0.883	rs34168977	chr10:62392674	A/C	cg18175470	chr10:62150864	ANK3	-0.46	-6.93	-0.35	2.19e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LUSC	cis	rs939574	1.000	rs6712442	chr2:220117333	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.02	-8.86	-0.44	4.81e-17	Platelet distribution width;
LUSC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg14552801	chr7:65878734	NA	0.38	5.79	0.3	1.65e-8	Aortic root size;
LUSC	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg12552261	chr5:112820674	MCC	-0.44	-7.04	-0.36	1.07e-11	Type 2 diabetes;
LUSC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.88	12.56	0.57	6.71e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	1.03	18.02	0.7	3.55e-51	Coronary artery disease;
LUSC	cis	rs11676348	0.808	rs61700947	chr2:219046171	C/G	cg18102446	chr2:218934044	RUFY4	-0.35	-5.7	-0.3	2.65e-8	Ulcerative colitis;
LUSC	cis	rs721399	0.614	rs4646246	chr8:18248661	A/G	cg18736775	chr8:18248649	NAT2	-0.61	-7.48	-0.38	6.67e-13	Blood metabolite levels;
LUSC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg14416269	chr4:6271139	WFS1	0.53	11.1	0.52	1.38e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LUSC	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg13064429	chr11:112161200	NA	-0.49	-6.28	-0.32	1.06e-9	Hepatitis;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg20804199	chr2:157189308	NR4A2	-0.45	-6.96	-0.36	1.86e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.37	-6.32	-0.33	8.53e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LUSC	trans	rs877282	0.898	rs11253356	chr10:768604	G/A	cg22713356	chr15:30763199	NA	0.98	13.6	0.6	7.66e-34	Uric acid levels;
LUSC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg13256891	chr4:100009986	ADH5	0.47	7.17	0.37	4.93e-12	Alcohol dependence;
LUSC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.14	17.39	0.69	1.1e-48	Age-related macular degeneration (geographic atrophy);
LUSC	cis	rs701145	0.556	rs357502	chr3:153955950	C/T	cg17054900	chr3:154042577	DHX36	0.45	5.88	0.31	9.8e-9	Coronary artery disease;
LUSC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.59	-9.31	-0.45	1.72e-18	Longevity;
LUSC	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg03585969	chr10:35415529	CREM	0.6	8.96	0.44	2.37e-17	Inflammatory bowel disease;Crohn's disease;
LUSC	cis	rs7605827	0.930	rs11889160	chr2:15605509	C/T	cg19274914	chr2:15703543	NA	0.46	8.74	0.43	1.16e-16	Educational attainment (years of education);
LUSC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg13319975	chr6:146136371	FBXO30	0.51	7.62	0.39	2.57e-13	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg06671706	chr8:8559999	CLDN23	0.48	6.58	0.34	1.86e-10	Obesity-related traits;
LUSC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg01802117	chr1:53393560	SCP2	0.41	6.71	0.34	8.26e-11	Monocyte count;
LUSC	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-7.0	-0.36	1.43e-11	Blood metabolite levels;
LUSC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11645453	chr3:52864694	ITIH4	0.33	7.6	0.38	3.08e-13	Bipolar disorder;
LUSC	cis	rs981844	0.712	rs11099914	chr4:154743519	C/T	cg14289246	chr4:154710475	SFRP2	-0.47	-6.38	-0.33	6.04e-10	Response to statins (LDL cholesterol change);
LUSC	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-9.0	-0.44	1.74e-17	Cleft plate (environmental tobacco smoke interaction);
LUSC	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14582970	chr9:125676085	ZBTB6	0.45	6.8	0.35	4.72e-11	Chronic obstructive pulmonary disease-related biomarkers;
LUSC	cis	rs7719624	0.811	rs13159365	chr5:135389433	C/T	cg12897067	chr5:135418308	NA	-0.44	-6.42	-0.33	4.75e-10	Response to cytidine analogues (gemcitabine);
LUSC	cis	rs870825	0.616	rs6552801	chr4:185620623	G/A	cg04058563	chr4:185651563	MLF1IP	0.87	13.38	0.59	5.39e-33	Blood protein levels;
LUSC	cis	rs714027	0.585	rs5752978	chr22:30300586	C/G	cg11564601	chr22:30592435	NA	0.34	5.87	0.31	1.02e-8	Lymphocyte counts;
LUSC	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg07895657	chr22:50616420	PANX2	-0.34	-5.96	-0.31	6.37e-9	Obesity-related traits;
LUSC	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg00074818	chr8:8560427	CLDN23	0.6	9.65	0.47	1.36e-19	Obesity-related traits;
LUSC	cis	rs4343996	0.934	rs4495320	chr7:3369936	G/A	cg21248987	chr7:3385318	SDK1	-0.4	-6.78	-0.35	5.55e-11	Motion sickness;
LUSC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg19230755	chr7:65878503	NA	0.41	5.75	0.3	2e-8	Aortic root size;
LUSC	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg24313572	chr1:56050060	NA	-0.31	-6.47	-0.33	3.4e-10	Morning vs. evening chronotype;
LUSC	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg09953122	chr20:23471693	CST8	-0.87	-7.32	-0.37	1.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LUSC	cis	rs887829	0.570	rs6753320	chr2:234595615	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.36	5.74	0.3	2.09e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LUSC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.36	-5.81	-0.3	1.42e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
LUSC	cis	rs12545109	0.800	rs2609978	chr8:57394467	T/C	cg09654669	chr8:57350985	NA	-0.51	-6.78	-0.35	5.55e-11	Obesity-related traits;
LUSC	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg23711669	chr6:146136114	FBXO30	0.86	15.52	0.65	2.69e-41	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg17366294	chr4:99064904	C4orf37	0.56	9.97	0.48	1.15e-20	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg04369109	chr6:150039330	LATS1	-0.56	-8.28	-0.41	2.93e-15	Lung cancer;
LUSC	trans	rs10411161	0.702	rs8110073	chr19:52383123	C/A	cg22319618	chr22:45562946	NUP50	-0.5	-5.96	-0.31	6.24e-9	Breast cancer;
LUSC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg03579872	chr1:53393473	SCP2	0.4	5.73	0.3	2.29e-8	Monocyte count;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19959648	chr3:197687180	LMLN;IQCG	-0.39	-6.07	-0.32	3.38e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs12681287	0.640	rs7832493	chr8:87371533	A/C	cg00550725	chr8:87521180	FAM82B	-0.43	-5.7	-0.3	2.65e-8	Caudate activity during reward;
LUSC	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg08557956	chr11:4115526	RRM1	-0.44	-5.79	-0.3	1.62e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
LUSC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.55	10.64	0.5	5.75e-23	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg24578937	chr1:2090814	PRKCZ	-0.41	-8.94	-0.44	2.71e-17	Height;
LUSC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg23281280	chr6:28129359	ZNF389	0.44	5.73	0.3	2.24e-8	Parkinson's disease;
LUSC	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg17376030	chr22:41985996	PMM1	-0.42	-5.71	-0.3	2.56e-8	Vitiligo;
LUSC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07362569	chr17:61921086	SMARCD2	0.37	7.61	0.38	2.83e-13	Prudent dietary pattern;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05851844	chr12:16035312	STRAP	-0.41	-6.05	-0.31	3.79e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs17095355	1.000	rs12259261	chr10:111725145	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.59	-7.54	-0.38	4.55e-13	Biliary atresia;
LUSC	cis	rs11622475	1.000	rs12889168	chr14:104481957	A/T	cg12183467	chr14:104352244	NA	-0.45	-8.19	-0.41	5.66e-15	Bipolar disorder;
LUSC	cis	rs56399783	0.901	rs17241904	chr7:2875574	C/T	cg14895029	chr7:2775587	GNA12	0.5	6.11	0.32	2.74e-9	Childhood ear infection;
LUSC	cis	rs2652834	0.851	rs10851724	chr15:63416702	A/T	cg05507819	chr15:63340323	TPM1	-0.45	-5.76	-0.3	1.86e-8	HDL cholesterol;
LUSC	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.44	-7.9	-0.4	4.09e-14	Glomerular filtration rate;
LUSC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg19318889	chr4:1322082	MAEA	0.49	8.06	0.4	1.36e-14	Obesity-related traits;
LUSC	trans	rs7178375	1.000	rs11070678	chr15:31219764	A/G	cg04373760	chr16:53404718	NA	0.64	8.74	0.43	1.14e-16	Hypertriglyceridemia;
LUSC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg05347473	chr6:146136440	FBXO30	0.4	6.78	0.35	5.4e-11	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	12.22	0.56	1.2e-28	Menopause (age at onset);
LUSC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg21535247	chr6:8435926	SLC35B3	0.57	8.78	0.43	8.88e-17	Motion sickness;
LUSC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg00814883	chr7:100076585	TSC22D4	-0.73	-9.85	-0.47	2.85e-20	Platelet count;
LUSC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg06096015	chr1:231504339	EGLN1	0.56	10.05	0.48	6.32e-21	Hemoglobin concentration;
LUSC	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg01509843	chr8:143695822	ARC	0.38	5.73	0.3	2.19e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs3857536	0.813	rs1029401	chr6:66952268	A/G	cg07460842	chr6:66804631	NA	-0.46	-6.36	-0.33	6.75e-10	Blood trace element (Cu levels);
LUSC	cis	rs701145	0.585	rs1727954	chr3:153871272	T/A	cg17054900	chr3:154042577	DHX36	0.69	6.76	0.35	6.15e-11	Coronary artery disease;
LUSC	cis	rs1178968	0.901	rs7795782	chr7:72766817	T/G	cg25889504	chr7:72793014	NA	0.6	7.8	0.39	7.86e-14	Triglyceride levels;
LUSC	cis	rs2282802	0.685	rs6893253	chr5:139661279	T/C	cg26211634	chr5:139558579	C5orf32	0.45	8.47	0.42	7.7e-16	Intelligence (multi-trait analysis);
LUSC	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-6.95	-0.36	1.9e-11	Systemic lupus erythematosus and Systemic sclerosis;
LUSC	trans	rs6561151	0.681	rs61209988	chr13:44416335	G/C	cg12856521	chr11:46389249	DGKZ	0.75	9.64	0.47	1.45e-19	Crohn's disease;
LUSC	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg27411982	chr8:10470053	RP1L1	0.37	5.84	0.3	1.26e-8	Retinal vascular caliber;
LUSC	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg12564285	chr5:131593104	PDLIM4	0.35	6.42	0.33	4.67e-10	Blood metabolite levels;
LUSC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05535760	chr7:792225	HEATR2	0.95	9.8	0.47	4.32e-20	Cerebrospinal P-tau181p levels;
LUSC	trans	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.68	-7.47	-0.38	6.98e-13	Menarche (age at onset);
LUSC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg21724239	chr8:58056113	NA	0.69	8.86	0.44	4.77e-17	Developmental language disorder (linguistic errors);
LUSC	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.01	14.21	0.61	3.55e-36	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LUSC	cis	rs59698941	0.527	rs11742089	chr5:132178930	G/A	cg14825688	chr5:132208181	LEAP2	-0.44	-6.49	-0.33	3.17e-10	Apolipoprotein A-IV levels;
LUSC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg02380750	chr20:61661411	NA	0.33	5.83	0.3	1.32e-8	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs4731207	0.967	rs2267708	chr7:124392512	C/T	cg14311320	chr7:124405732	GPR37	0.32	6.11	0.32	2.72e-9	Cutaneous malignant melanoma;
LUSC	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg11130432	chr3:121712080	ILDR1	-0.63	-9.59	-0.46	2.19e-19	Multiple sclerosis;
LUSC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18404041	chr3:52824283	ITIH1	-0.58	-11.15	-0.52	9.53e-25	Bipolar disorder;
LUSC	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg24006582	chr15:45444508	DUOX1	-0.62	-9.03	-0.44	1.35e-17	Uric acid levels;
LUSC	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	12.93	0.58	2.87e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LUSC	trans	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg25214090	chr10:38739885	LOC399744	0.47	6.82	0.35	4.32e-11	Corneal astigmatism;
LUSC	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg01689657	chr7:91764605	CYP51A1	-0.34	-6.16	-0.32	2.11e-9	Breast cancer;
LUSC	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.75	12.2	0.56	1.5e-28	Colorectal cancer;
LUSC	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.77	-10.41	-0.49	3.56e-22	Coronary artery disease;
LUSC	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.82	10.73	0.51	2.72e-23	Schizophrenia;
LUSC	trans	rs56116032	0.521	rs10738245	chr9:11711490	A/T	cg14090374	chr1:85667233	SYDE2	-0.51	-6.65	-0.34	1.19e-10	Neuroticism;
LUSC	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21016266	chr12:122356598	WDR66	-0.52	-7.81	-0.39	7.41e-14	Mean corpuscular volume;
LUSC	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00631329	chr6:26305371	NA	-0.46	-9.18	-0.45	4.58e-18	Educational attainment;
LUSC	cis	rs4746822	0.559	rs4746826	chr10:70985650	G/A	cg14418922	chr10:70824840	NA	-0.38	-6.61	-0.34	1.49e-10	Glycemic traits (pregnancy);
LUSC	cis	rs7106204	0.748	rs4598670	chr11:24236524	G/A	ch.11.24196551F	chr11:24239977	NA	1.14	14.86	0.63	1.1e-38	Response to Homoharringtonine (cytotoxicity);
LUSC	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	0.99	12.09	0.55	3.56e-28	Nonalcoholic fatty liver disease;
LUSC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg06915202	chr7:98029285	BAIAP2L1	-0.31	-6.15	-0.32	2.18e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs1413885	0.516	rs7537733	chr1:65838229	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.48	7.18	0.37	4.6e-12	Anticoagulant levels;
LUSC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	10.4	0.49	3.84e-22	Cognitive test performance;
LUSC	cis	rs6012953	0.654	rs6020566	chr20:49123032	A/G	cg13958625	chr20:49123093	NA	0.28	5.8	0.3	1.52e-8	Vitiligo;
LUSC	trans	rs4729127	1.000	rs4729127	chr7:94008535	A/G	cg14660007	chr13:78271894	SLAIN1	0.5	6.45	0.33	3.88e-10	Intelligence;
LUSC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	16.33	0.67	1.77e-44	Platelet count;
LUSC	cis	rs8048589	0.604	rs11642033	chr16:12207990	A/G	cg02910054	chr16:12241554	SNX29	0.47	6.1	0.32	3.01e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LUSC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg18904891	chr8:8559673	CLDN23	0.53	7.22	0.37	3.57e-12	Obesity-related traits;
LUSC	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg20991723	chr1:152506922	NA	0.52	9.73	0.47	7.34e-20	Hair morphology;
LUSC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg18512352	chr11:47633146	NA	-0.43	-9.01	-0.44	1.59e-17	Subjective well-being;
LUSC	cis	rs7216064	1.000	rs9912770	chr17:65868233	C/T	cg12091567	chr17:66097778	LOC651250	-0.73	-9.37	-0.46	1.13e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LUSC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg18758796	chr5:131593413	PDLIM4	0.38	6.67	0.34	1.06e-10	Blood metabolite levels;
LUSC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg08365687	chr3:52569147	NT5DC2;LOC440957	0.27	5.71	0.3	2.45e-8	Electroencephalogram traits;
LUSC	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-6.11	-0.32	2.77e-9	Neuroticism;
LUSC	trans	rs13314892	1.000	rs13318796	chr3:69795183	A/G	cg24703757	chr4:183838736	DCTD	-0.46	-6.31	-0.33	8.76e-10	QRS complex (12-leadsum);
LUSC	cis	rs7809950	0.678	rs17153981	chr7:106922106	A/G	cg23024343	chr7:107201750	COG5	-0.67	-10.18	-0.49	2.15e-21	Coronary artery disease;
LUSC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg18240062	chr17:79603768	NPLOC4	-0.57	-9.84	-0.47	3.25e-20	Eye color traits;
LUSC	cis	rs9807841	0.592	rs10401513	chr19:10778763	A/T	cg09936142	chr19:10668400	KRI1	-0.42	-6.78	-0.35	5.46e-11	Inflammatory skin disease;
LUSC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.71	0.47	8.56e-20	Bipolar disorder;
LUSC	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-9.77	-0.47	5.45e-20	Multiple sclerosis;
LUSC	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg09467607	chr2:36825704	FEZ2	0.58	13.84	0.6	9.87e-35	Height;
LUSC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg11062466	chr8:58055876	NA	0.64	8.5	0.42	6.22e-16	Developmental language disorder (linguistic errors);
LUSC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg17971929	chr21:40555470	PSMG1	0.79	13.69	0.6	3.66e-34	Cognitive function;
LUSC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg00945038	chr17:61921165	SMARCD2	0.54	9.54	0.46	3.18e-19	Prudent dietary pattern;
LUSC	cis	rs6977660	1.000	rs10240227	chr7:19823188	T/C	cg05791153	chr7:19748676	TWISTNB	0.53	5.82	0.3	1.37e-8	Thyroid stimulating hormone;
LUSC	cis	rs281408	0.559	rs281386	chr19:49217305	A/G	cg21064579	chr19:49206444	FUT2	-0.37	-6.27	-0.32	1.14e-9	Urinary metabolites (H-NMR features);
LUSC	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg17376030	chr22:41985996	PMM1	-0.42	-5.71	-0.3	2.53e-8	Vitiligo;
LUSC	cis	rs3924048	0.559	rs6541037	chr1:12626155	A/G	cg00291366	chr1:12616550	NA	0.32	7.32	0.37	1.83e-12	Optic cup area;
LUSC	cis	rs7916697	0.891	rs7897809	chr10:70000293	A/G	cg06988349	chr10:69991859	ATOH7	0.34	6.06	0.31	3.66e-9	Optic disc area;
LUSC	cis	rs829883	0.724	rs11109508	chr12:98905985	T/C	cg25150519	chr12:98850993	NA	-0.64	-8.7	-0.43	1.53e-16	Colorectal adenoma (advanced);
LUSC	cis	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg23950597	chr19:37808831	NA	-0.58	-7.02	-0.36	1.23e-11	Coronary artery calcification;
LUSC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg20476274	chr7:133979776	SLC35B4	0.81	14.94	0.63	5.36e-39	Mean platelet volume;
LUSC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg01879757	chr17:41196368	BRCA1	-0.46	-7.04	-0.36	1.1e-11	Menopause (age at onset);
LUSC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg15445000	chr17:37608096	MED1	-0.4	-6.81	-0.35	4.56e-11	Glomerular filtration rate (creatinine);
LUSC	cis	rs11779988	0.528	rs376771	chr8:17864985	G/A	cg01800426	chr8:17659068	MTUS1	-0.53	-6.35	-0.33	6.95e-10	Breast cancer;
LUSC	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-8.2	-0.41	5.36e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LUSC	cis	rs7575217	0.697	rs2582930	chr2:101721369	T/A	cg23907051	chr2:101730305	TBC1D8	-0.29	-7.68	-0.39	1.76e-13	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
LUSC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.44	-6.35	-0.33	6.91e-10	Bronchopulmonary dysplasia;
LUSC	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-7.55	-0.38	4.32e-13	Response to bleomycin (chromatid breaks);
LUSC	cis	rs6496667	0.532	rs2601207	chr15:90963542	C/G	cg10434728	chr15:90938212	IQGAP1	-0.32	-6.34	-0.33	7.44e-10	Rheumatoid arthritis;
LUSC	cis	rs11051970	0.918	rs73084099	chr12:32539751	C/T	cg24626660	chr12:32551988	NA	0.38	6.07	0.32	3.43e-9	Response to tocilizumab in rheumatoid arthritis;
LUSC	cis	rs9326248	0.813	rs7115562	chr11:117020470	A/G	cg26566898	chr11:117069891	TAGLN	0.39	6.12	0.32	2.55e-9	Blood protein levels;
LUSC	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17957827	chr17:79895524	PYCR1	-0.45	-7.02	-0.36	1.22e-11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
LUSC	cis	rs7760535	0.764	rs240994	chr6:111675757	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.37	-7.01	-0.36	1.36e-11	Metabolic traits;
LUSC	trans	rs13376197	1.000	rs4657785	chr1:194691336	A/G	cg05738240	chr12:114337927	RBM19	0.43	5.99	0.31	5.4e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;Cerebrospinal fluid t-tau levels;
LUSC	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg15448220	chr1:150897856	SETDB1	0.44	6.42	0.33	4.75e-10	Melanoma;
LUSC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg20295408	chr7:1910781	MAD1L1	0.41	5.82	0.3	1.41e-8	Bipolar disorder and schizophrenia;
LUSC	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg17366294	chr4:99064904	C4orf37	0.55	9.63	0.47	1.62e-19	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg15839431	chr19:19639596	YJEFN3	-0.65	-7.26	-0.37	2.65e-12	Bipolar disorder;
LUSC	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22307029	chr19:49891270	CCDC155	0.61	7.78	0.39	9.21e-14	Multiple sclerosis;
LUSC	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.58	9.17	0.45	4.9e-18	Blood protein levels;
LUSC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	0.93	18.29	0.71	2.88e-52	Cognitive function;
LUSC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08564027	chr20:61660810	NA	0.91	17.49	0.69	4.57e-49	Prostate cancer (SNP x SNP interaction);
LUSC	trans	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.69	0.47	9.76e-20	Mean corpuscular volume;
LUSC	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01341218	chr17:43662625	NA	-0.77	-11.3	-0.53	2.68e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LUSC	cis	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg01251360	chr16:68772225	CDH1	-0.24	-5.69	-0.3	2.79e-8	Colorectal cancer;
LUSC	cis	rs6736093	1.000	rs6755101	chr2:112658964	T/C	cg12686935	chr2:112915763	FBLN7	-0.39	-5.99	-0.31	5.37e-9	Coronary artery disease;
LUSC	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.59	-7.21	-0.37	3.78e-12	Lung function (FEV1/FVC);
LUSC	cis	rs7586879	0.639	rs6722022	chr2:25098859	A/G	cg15423357	chr2:25149977	NA	0.44	8.71	0.43	1.44e-16	Body mass index;
LUSC	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg04362960	chr10:104952993	NT5C2	0.59	9.34	0.45	1.43e-18	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LUSC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg23630131	chr7:65973040	NA	0.2	5.7	0.3	2.57e-8	Aortic root size;
LUSC	cis	rs10489202	0.612	rs3820401	chr1:168074753	T/C	cg24449463	chr1:168025552	DCAF6	-0.64	-9.84	-0.47	3.23e-20	Schizophrenia;
LUSC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg05313129	chr8:58192883	C8orf71	-0.52	-6.73	-0.35	7.36e-11	Developmental language disorder (linguistic errors);
LUSC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	30.63	0.86	5.12e-99	Chronic sinus infection;
LUSC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg12927641	chr6:109611667	NA	-0.43	-7.47	-0.38	7.04e-13	Reticulocyte fraction of red cells;
LUSC	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.48	6.74	0.35	6.99e-11	Hip circumference adjusted for BMI;Body mass index;
LUSC	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg00495681	chr13:53174319	NA	0.79	15.67	0.65	7.42e-42	Lewy body disease;
LUSC	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-6.24	-0.32	1.32e-9	Alzheimer's disease (late onset);
LUSC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg23711669	chr6:146136114	FBXO30	0.92	17.68	0.7	7.53e-50	Lobe attachment (rater-scored or self-reported);
LUSC	cis	rs11997175	0.624	rs7819074	chr8:33682472	C/T	ch.8.33884649F	chr8:33765107	NA	0.48	7.11	0.36	7.29e-12	Body mass index;
LUSC	cis	rs6961069	0.585	rs12706916	chr7:80257032	A/G	cg04458919	chr7:80252533	CD36	-0.41	-7.28	-0.37	2.49e-12	Platelet count;
LUSC	cis	rs7814319	0.966	rs10095443	chr8:97269738	C/T	cg20787634	chr8:97240163	UQCRB	-0.35	-6.12	-0.32	2.62e-9	Lung function (FVC);
LUSC	cis	rs258324	0.790	rs8062346	chr16:89732668	G/A	cg26513180	chr16:89883248	FANCA	0.75	6.67	0.34	1.08e-10	Height;
LUSC	cis	rs4700695	0.545	rs29441	chr5:65509116	G/T	cg21114390	chr5:65439923	SFRS12	-0.51	-7.1	-0.36	7.59e-12	Facial morphology (factor 19);
LUSC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg17330251	chr7:94953956	PON1	-0.39	-6.47	-0.33	3.59e-10	Yu-Zhi constitution type in type 2 diabetes;
LUSC	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	6.52	0.34	2.52e-10	Lung cancer in ever smokers;
LUSC	trans	rs62238980	0.614	rs1547411	chr22:32443590	T/C	cg26675682	chr22:29834657	RFPL1S;RFPL1	-0.51	-6.04	-0.31	4.04e-9	Childhood ear infection;
LUSC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg06238570	chr21:40685208	BRWD1	0.47	7.24	0.37	3.13e-12	Cognitive function;
LUSC	cis	rs7674212	0.570	rs2126470	chr4:104061762	T/C	cg16532752	chr4:104119610	CENPE	-0.5	-7.23	-0.37	3.37e-12	Type 2 diabetes;
LUSC	cis	rs12101261	0.580	rs4411444	chr14:81445108	A/G	cg06600135	chr14:81408086	NA	0.47	7.3	0.37	2.12e-12	Graves' disease;
LUSC	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg10909506	chr17:38081995	ORMDL3	0.34	6.17	0.32	1.97e-9	Self-reported allergy;
LUSC	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg02403541	chr12:121454288	C12orf43	0.72	10.41	0.5	3.5e-22	N-glycan levels;
LUSC	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg17366294	chr4:99064904	C4orf37	0.55	9.03	0.44	1.42e-17	Colonoscopy-negative controls vs population controls;
LUSC	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg00071950	chr4:10020882	SLC2A9	0.52	8.38	0.42	1.47e-15	Bone mineral density;
LUSC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg12751644	chr20:60527061	NA	-0.38	-6.52	-0.34	2.56e-10	Obesity-related traits;
LUSC	cis	rs7590368	0.926	rs12623588	chr2:10957612	C/G	cg15705551	chr2:10952987	PDIA6	-0.53	-7.45	-0.38	8.05e-13	Educational attainment (years of education);
LUSC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	11.99	0.55	8.55e-28	Chronic sinus infection;
LUSC	cis	rs6005807	0.640	rs7289534	chr22:29016057	C/T	cg12565055	chr22:29076175	TTC28	0.53	5.77	0.3	1.76e-8	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
LUSC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.92	-13.47	-0.59	2.58e-33	Initial pursuit acceleration;
LUSC	cis	rs7809950	1.000	rs7793613	chr7:107250484	C/T	cg23024343	chr7:107201750	COG5	-0.55	-8.69	-0.43	1.62e-16	Coronary artery disease;
LUSC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg01475377	chr6:109611718	NA	-0.41	-7.26	-0.37	2.7e-12	Reticulocyte fraction of red cells;
LUSC	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg17385448	chr1:15911702	AGMAT	0.36	6.2	0.32	1.69e-9	Systolic blood pressure;
LUSC	cis	rs7843479	0.965	rs11135741	chr8:21801091	C/T	cg17168535	chr8:21777572	XPO7	0.68	10.58	0.5	9.65e-23	Mean corpuscular volume;
LUSC	trans	rs12145833	0.596	rs61833906	chr1:243419706	T/C	cg01826367	chr1:224180288	NA	0.67	6.03	0.31	4.42e-9	Obesity (early onset extreme);
LUSC	cis	rs6484504	0.600	rs7122895	chr11:31346620	G/C	cg06552810	chr11:31128660	NA	0.39	6.87	0.35	3.24e-11	Red blood cell count;
LUSC	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg11584989	chr19:19387371	SF4	0.67	8.2	0.41	5.3e-15	Bipolar disorder;
LUSC	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg05025164	chr4:1340916	KIAA1530	0.43	6.56	0.34	2.02e-10	Obesity-related traits;
LUSC	cis	rs11971779	0.680	rs10271297	chr7:139052310	A/T	cg23387468	chr7:139079360	LUC7L2	0.41	6.22	0.32	1.5e-9	Diisocyanate-induced asthma;
LUSC	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg18002602	chr11:66138449	SLC29A2	0.46	8.31	0.41	2.46e-15	Educational attainment (years of education);
LUSC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04398451	chr17:18023971	MYO15A	-0.68	-11.78	-0.54	5.18e-27	Total body bone mineral density;
LUSC	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg05855489	chr10:104503620	C10orf26	0.53	8.11	0.41	9.87e-15	Arsenic metabolism;
LUSC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.62	-12.62	-0.57	3.87e-30	Longevity;Endometriosis;
LUSC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg25039879	chr17:56429692	SUPT4H1	0.66	8.81	0.43	6.99e-17	Cognitive test performance;
LUSC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.4	6.07	0.32	3.42e-9	Prostate cancer (SNP x SNP interaction);
LUSC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	0.65	13.71	0.6	2.93e-34	Prudent dietary pattern;
LUSC	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.92	11.99	0.55	8.47e-28	Exhaled nitric oxide output;
LUSC	cis	rs3733606	1.000	rs3733606	chr4:6883012	A/G	cg05012661	chr4:6891264	NA	-0.46	-6.94	-0.36	1.99e-11	Platelet count;
LUSC	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg02454025	chr1:11042201	C1orf127	0.94	17.91	0.7	9.78e-51	Ewing sarcoma;
LUSC	cis	rs2012796	0.913	rs8010181	chr14:81820125	T/C	cg02996355	chr14:81879375	NA	0.46	6.72	0.35	7.88e-11	Night sleep phenotypes;
LUSC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg09655341	chr17:79618100	PDE6G	-0.28	-6.53	-0.34	2.42e-10	Eye color traits;
LUSC	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.51	0.56	1.06e-29	Ileal carcinoids;
LUSC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg13560548	chr3:10150139	C3orf24	0.52	7.16	0.36	5.13e-12	Alzheimer's disease;
LUSC	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg10596483	chr8:143751796	JRK	0.53	7.59	0.38	3.17e-13	Schizophrenia;
LUSC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg06453172	chr10:134556979	INPP5A	-0.49	-6.13	-0.32	2.51e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LUSC	cis	rs2282300	0.696	rs12578061	chr11:30249365	T/A	cg25418670	chr11:30344373	C11orf46	-0.66	-9.53	-0.46	3.4e-19	Morning vs. evening chronotype;
LUSC	cis	rs2273669	0.667	rs12214121	chr6:109322554	A/G	cg05315195	chr6:109294784	ARMC2	0.53	5.94	0.31	7.18e-9	Prostate cancer;
LUSC	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg27411982	chr8:10470053	RP1L1	-0.49	-8.04	-0.4	1.55e-14	Neuroticism;
LUSC	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg08313168	chr12:7315531	NA	0.46	5.98	0.31	5.65e-9	Lung disease severity in cystic fibrosis;
LUSC	cis	rs9467773	0.550	rs9379874	chr6:26440429	A/T	cg05738196	chr6:26577821	NA	-0.52	-7.72	-0.39	1.37e-13	Intelligence (multi-trait analysis);
LUSC	cis	rs7605827	0.930	rs12692273	chr2:15688834	G/C	cg19274914	chr2:15703543	NA	0.45	8.68	0.43	1.82e-16	Educational attainment (years of education);
LUSC	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg03522245	chr20:25566470	NINL	-0.35	-5.76	-0.3	1.94e-8	Liver enzyme levels (alkaline phosphatase);
LUSC	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg24558204	chr6:135376177	HBS1L	0.58	8.84	0.44	5.6e-17	Red blood cell count;
LUSC	cis	rs12760731	0.720	rs12072124	chr1:178366990	G/A	cg00404053	chr1:178313656	RASAL2	0.57	6.1	0.32	2.87e-9	Obesity-related traits;
LUSC	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg13010199	chr12:38710504	ALG10B	0.64	9.96	0.48	1.23e-20	Bladder cancer;
LUSC	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.65	-8.41	-0.42	1.22e-15	Schizophrenia;
LUSC	cis	rs911119	0.955	rs1555355	chr20:23594580	T/C	cg16589663	chr20:23618590	CST3	0.56	6.76	0.35	6.19e-11	Chronic kidney disease;
LUSC	cis	rs1507153	0.812	rs9359337	chr6:79389316	C/T	cg05283184	chr6:79620031	NA	-0.39	-6.82	-0.35	4.3e-11	Sjögren's syndrome;